id|nct_id|group_type|title|description
16241944|NCT05080569|Experimental|MOH/IUI treatment with LPS|(Mild) Ovarian stimulating treatment and insemination are according to regular treatment protocol. Females assigned to the treatment group start LPS, applying 3dd200mg Utrogestan in vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation
16241945|NCT05080569|Placebo Comparator|MOH/IUI treatment with placebo|"Females will receive regular MOH/IUI treatment. The female cycle is mildly stimulated and monitored until the desired amount of ripe follicles is achieved. In the absence of other reasons to cancel the treatment, ovulation is triggered and subsequently pre-washed semen is inseminated into the uterus.
~Females assigned to the placebo group start placebo, applying 3dd1 vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation"
16241946|NCT05080556|Active Comparator|Arm 1 (control) - standard dosing carboplatin|Arm 1 (Standard Dosing): Carboplatin AUC5 based on EDTA renal clearance.
16241947|NCT05080556|Experimental|Arm 2 (experimental) - adaptive therapy carboplatin according to CA125|Arm 2 (Adaptive Therapy): Carboplatin dose will be calculated according to the CA125 value.
16241948|NCT05080543|Active Comparator|Group AT|will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
16241949|NCT05080543|Placebo Comparator|Controlled|will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
16241950|NCT05080530|No Intervention|1. Normal Vit D (> 30ng/mL)|Follow-up after 3 months with standard treatment
16241951|NCT05080530|Experimental|2. Insufficient Vit D (20-30ng/mL)|single oral dose capsule 200,000 IU of Cholecalciferol
16241952|NCT05080530|No Intervention|3. Insufficient Vit D (20-30ng/mL)|Follow-up after 3 months with standard treatment
16241953|NCT05080530|Experimental|4. Deficient Vit D|single oral dose capsule 200,000 IU of Cholecalciferol
16241955|NCT05080491|Experimental|Determination of thyroid profile and neuropsychological assessment|
16241956|NCT05080478||Group A|patients receiving ticagrelor 90mg bid
16241957|NCT05080478||Group B|patients receiving clopidogrel 75mg qd
16241958|NCT05080465|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
16241959|NCT05080452||ACNES patients|Patients referred to ultrasound-guided treatment for abdominal wall pain caused by ACNES
16241960|NCT05080452||LUCNES patients|Patients referred to ultrasound-guided treatment for lower back pain caused by LUCNES
16241964|NCT05080426|Experimental|Intervention Group|"Mangers in the intervention group will be asked to:
~1. Complete an online survey. 2. Take the Family Supportive Supervisor Training online (FSST). 3. Take the Supervisor Support for Leave Use module 4. Track their behaviors for two weeks 5. Participate in a webinar 7. Complete a post-training survey. 8. 8-10 managers will participate in the focus group.
~Employees in the intervention group will be asked to:
~1. Complete an online survey twice over the course of 6 months."
16241965|NCT05080426|No Intervention|Control Group|"Managers and employees in the control group will be asked to:
~1. Complete an online survey twice over the course of 6 months."
16241966|NCT05080413|Experimental|Parkinson disease group|A total of 10 patients in this group will walk under the same conditions (off- state of antiparkinson drugs). Participants will be instructed to walk three laps on a 10-meter track under each of the following three conditions : 1) without stimulation, 2) with visual cues using a laser shoe, 3) with auditory cues using a metronome.
16241967|NCT05080400|Experimental|Gellan gum|White rice cooked with gellan gum
16241968|NCT05080400|Placebo Comparator|Control|White rice cooked without gellan gum
16241969|NCT05080374|Experimental|HVLA + exercise Group|Spinal manipulation (HVLA) + trunk exercise program
16241970|NCT05080374|Experimental|HVLA + kinesiotaping group|Spinal manipulation (HVLA) + Kinesiotaping (lumbar)
16241971|NCT05080374|Experimental|HVLA + Respiratory exercise group|Spinal manipulation (HVLA) + respiratory exercise program
16241972|NCT05080361||Reports of adverse events associated with the use of BRAF +/- MEK inhibitors|"Reports of adverse event (individual case safety reports) from Vigibase, the World Health Organization pharmacovigilance database related to the use of BRAF +/- MEK inhibitors from inception (1986) until March, 1, 2021 will be extracted.
~Cases concurrently reporting on immune checkpoint inhibitor therapies will be excluded."
16241973|NCT05080348|Active Comparator|Ropivacaine iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.25% Ropivacaine with 1:400,000 epinephrine in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
16241974|NCT05080348|Sham Comparator|Normal Saline iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.9% Normal Saline in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
16241975|NCT05080335|Active Comparator|TRANS-gender female instructor, with videos (TV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
16241976|NCT05080335|Active Comparator|CIS-gender female instructor, with videos (CV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
16241977|NCT05080335|Active Comparator|TRANS-gender female, with NO videos (TN)|Didactic materials do NOT use short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
16241978|NCT05080335|Active Comparator|CIS-gender female, with NO videos (CN)|Didactic materials do NOT use short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
16244068|NCT05065541|Experimental|Part 3|
16241979|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS) plus antihistamines (AH1)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) plus antihistamines (AH1) for 4 weeks
16241980|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) for 4 weeks
16241981|NCT05080322|Active Comparator|maintenance intranasal corticosteroid (INS)|the patients will be treated with intra-nasal corticosteroid(INS) maintenance therapy for 4 weeks
16241982|NCT05080309|Sham Comparator|Control|During labor the women will have free access to water only but not fruit juice or other calory source.
16241983|NCT05080309|Experimental|Carbohydrate|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
16241984|NCT05080296||All patients underwent DaTSCAN SPECT scans|
16241985|NCT05080283|Experimental|CP1110 Sound Processor System with ForwardFocus On (SCAN)|
16241986|NCT05080283|Experimental|CP1110 Sound Processor System with ForwardFocus Off (SCAN)|
16241987|NCT05080283|Active Comparator|Nucleus 7 Sound Processor (model: CP1000) system|
16242001|NCT05080205|Experimental|Morbidly obese subjects|Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)
16242002|NCT05080205|No Intervention|Control subjects|Non-obese controls are only studied at baseline
16242003|NCT05080192||Fenofibrate recipients|Approximately 20 subjects who were randomized to the Fenofibrate arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
16242004|NCT05080192||Placebo recipients|Approximately 20 subjects who were randomized to the placebo arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
16242005|NCT05080179|Experimental|Self-Benefit/Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
16242006|NCT05080179|Experimental|Self-Benefit/No Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. They did not read any information about the number of Pennsylvanians who downloaded the app."
16242007|NCT05080179|Experimental|Other Benefit/Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
16242008|NCT05080179|Experimental|Other Benefit/No Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They did not read any information about the number of Pennsylvanians who downloaded the app."
16242009|NCT05080166|Experimental|Clinicians Interviews|Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
16242010|NCT05080166|Experimental|Lymphoma Survivors Field Test|A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
16242011|NCT05080166|Experimental|UPLYFT Pilot|Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.
16242012|NCT05080140||Simvastatin|
16242013|NCT05080140||Ezetimibe|
16242014|NCT05080140||Omega -3 fatty acids-|
16242015|NCT05080140||Simvastatin+ Ezetimibe|
16242016|NCT05080140||Simvastain + ezetimibe + omega|
16242052|NCT05079854|Active Comparator|TOPICAL MOXIFLOXACIN|After the surgery, the antibiotic is topical administered, Moxifloxacin 0.5% 0.1mL.
16242375|NCT05077592|Active Comparator|Intervention|The use of 10% surgical povidone iodine to wash the wound directly after fascial closure and before wound closure
16242020|NCT05080114|Experimental|Modified technique (MT)|All the steps of the laparoscopic hysterectomy were performed according to conventional standard technique until the colpotomy step. Instead, the modified Bakay technique was used for later on.
16242021|NCT05080114|Active Comparator|Standard technique (ST)|The conventional standard total laparoscopic hysterectomy technique was used in this control group.
16242022|NCT05080101|Active Comparator|Conventional Physiotherapy Group|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
16242023|NCT05080101|Experimental|Basic Body Awareness Therapy Group|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
16242024|NCT05080088||Colonoscopy Only Group|
16242025|NCT05080088||Artificial intelligence GI GENIUS ™ only Group|
16242026|NCT05080088||Endoscopic Cap and Artificial Intelligence GI GENIUS ™ Group|
16242027|NCT05080075|Experimental|Participants receiving a platelet rich plasma injection|All patients in the study will be receiving a platelet rich plasma injection, and we will be following their clinical outcomes
16242028|NCT05080062|Experimental|Intervention|Will receive pain-rehabilitation and the intervention ( an interview called Requirements and functional Schedule, with the patients employer and an occupational therapist)
16242029|NCT05080062|Active Comparator|No intervention|Will receive pain-rehabilitation
16242030|NCT05080049|Experimental|erythropoietin|
16242031|NCT05080049|Placebo Comparator|Placebo|
16242032|NCT05080036|Experimental|Unbalanced healthy subjects|
16242033|NCT05080010|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
16242034|NCT05079984|No Intervention|Focus Groups|Utilizing the mHealth Agile Development & Evaluation Lifestyle model, Aim 1 will focus on collecting stakeholder feedback (youth with chronic pain and their parents) to inform an iterative, user-centered development process of a digital graded exposure intervention, to be trialed in Aim 2 (Arm 2).
16242035|NCT05079984|Experimental|Graded Exposure Intervention|For Aim 2, adolescents with chronic pain will be enrolled in a single-arm feasibility trial examining acceptability, feasibility, and preliminary effectiveness of a novel, digitally delivered, graded exposure treatment.
16242036|NCT05079971|Active Comparator|Group A is a control group with aEEG monitoring only, and with retrospective cEEG review|
16242037|NCT05079971|Experimental|Group B is undergoing aEEG monitoring with concurrent full EEG review|
16242038|NCT05079958|Experimental|Stage2 - cognitive-behavioral education|A quasi-experimental design will be used to determine the effects of a four-week cognitive-behavioral education course related to smoking cessation on the participants' smoking cessation behavior, smoking decision-making, and self-efficacy in smoking cessation.
16242039|NCT05079958|Experimental|Stage 3- 12-week brisk walking|"Subjects who are at the preparation  and action stage will be recruited and randomly divided into experimental or control group to identify the effect of a 12-week brisk walking on improving the participants' immediate (short-term), three-month, and six month (long-term) health status."
16242040|NCT05079945|Experimental|Spinal cord Tractography|Healthy volunteer having the tractography exam
16242043|NCT05079906|Other|Main study arm|All subjects will have their SFA lesion assessed with FFR measurement.
16242044|NCT05079906|Other|Sub-study|Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
16242045|NCT05079893||Cases|The cases will be the patients suffering from low back pain for at least three months and referred by an orthopedic doctor or general physician.
16242046|NCT05079893||Controls|The controls will be the patients matched for age, sex, handedness who had no complaints of lower back pain
16242047|NCT05079880|Experimental|GC group|received 300 mg of caffeine citrate infusion
16242048|NCT05079880|Placebo Comparator|GS group|Equivalent saline infusion
16242049|NCT05079867||Perimodiolar (PM)|Patients to be implanted with: Mid Scala or CI532 / 632 (Slim modiolar) electrode
16242050|NCT05079867||Lateral wall (PL)|Patients to be implanted with: Slim J or CI522 / 622 (Slim Lateral) electrode
16242051|NCT05079854|Active Comparator|INTRACAMERAL MOXIFLOXACIN|After the surgery, the antibiotic is intracameral administered, Moxifloxacin 0.5% 0.1mL.
16242053|NCT05079841|Experimental|Intrapartum nipple stimulation|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or stimulate by hand (intervention) to induce labor.
16242054|NCT05079841|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor.
16242055|NCT05079828|Active Comparator|Arm 1|Patients receive first a PET/CT with 68Ga-PSMA-11 and a second PET/CT with 18F-PSMA-1007
16242056|NCT05079828|Active Comparator|Arm 2|Patients receive first a PET/CT with 18F-PSMA-1007 and a second with 68Ga-PSMA-11
16242057|NCT05079802|Experimental|Group 1|study group
16242058|NCT05079802|Other|Group 2|control group
16242059|NCT05079789|Experimental|Amiloride|Treatment wirh Amiloride, start dose 5 mg
16242060|NCT05079789|Active Comparator|Furosemide|Treatment with Furosemide, start dose 40 mg
16242062|NCT05079763|Experimental|Experimental arm|Application of bacterial cellulose-monolaurin hydrogel in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
16242063|NCT05079763|Placebo Comparator|Placebo Arm|Application of placebo cream in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
16242064|NCT05079750|Experimental|Group 1: Low Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10^9 vp
16242065|NCT05079750|Experimental|Group 2: Mid Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5x10^10 vp Note: may be increased to n=9 following interim safety reviews
16242066|NCT05079750|Experimental|Group 3: High Dose|n=14 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10^10 vp Note: will be decreased to n=11 if Group 2 is increased to n=9
16242067|NCT05079737||Subjects with Fitzpatrick Skin Type I-III|Subjects 21 years of age or older with Fitzpatrick Skin Type I-III will be enrolled and analyzed by age.
16242068|NCT05079737||Subjects with Fitzpatrick Skin Type IV-VII|Subjects 21 years of age or older with Fitzpatrick Skin Type IV-VII will be enrolled and analyzed by age.
16242069|NCT05079711||Symptomatic for vaginal yeast|Women presenting to the clinic with symptoms of vulvovaginal candidiasis.
16242070|NCT05079711||Asymptomatic for vaginal yeast|Women presenting to the clinic with no symptoms of vulvovaginal candidiasis.
16242071|NCT05079698|Experimental|Stereotactic Body Radiotherapy and 177Lu-PSMA-617|
16242072|NCT05079685||Cases-Control|Women aged 18-39 years, with BMI <30 and good ovarian reserve, undergoing study for primary sterility, subsidiary of conducting tubal patency studies to rule out pathology of the same and thus be able to perform Spousal or Donor IA.
16242075|NCT05079646|No Intervention|Group 1, subgroup A (blue color coded)|Normal teeth with no cavity preparation and no endodontic procedure.
16242076|NCT05079646|Experimental|Group 1, subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu).
16242077|NCT05079646|Experimental|Group 1, subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent)
16242078|NCT05079646|Active Comparator|Group 1, subgroup D (black color coded) positive control group|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson)
16242079|NCT05079646|No Intervention|Group 2, Subgroup A (Blue color coded) negative control group|Normal teeth with no cavity preparation and no endodontic procedure.
16242080|NCT05079646|Experimental|Group 2, Subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu) by using tofflemire retainer and matrix band.
16242081|NCT05079646|Experimental|Group 2, Subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent) by using tofflemire retainer and matrix band.
16242082|NCT05079646|Active Comparator|Group 2, Subgroup D (black color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson) by using tofflemire retainer and matrix band.
16242083|NCT05079633|Active Comparator|Moderna COVID-19 vaccine (mRNA 1273)|110 participants will be randomly assigned to Moderna COVID 19
16242084|NCT05079633|Experimental|Medigen COVID-19 vaccine (MVC COV1901)|110 participants will be randomly assigned to Medigen COVID 19 vaccine
16242085|NCT05079620|Experimental|Antibiotics|"5 days of empiric antibiotics selected from a guideline-appropriate regimen. Alternate agents may be selected by the treating team if allergies or other patient factors mandate, but are still recommended for a 5 day course. Supportive care including oxygen and ventilation can be offered ad libitum.
~Options include ceftriaxone, Augmentin, cefepime, vancomycin, levofloxacin."
16242086|NCT05079620|No Intervention|Control|No initial antibiotic therapy unless clinical picture changes or worsens. Supportive care including oxygen and ventilation can be offered ad libitum.
16242087|NCT05079607|Experimental|Mitopure Topical Formula|
16242088|NCT05079594|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, when the baby starts to cry, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
16242376|NCT05077579||metabolically abnormal overweight & obese|
16242089|NCT05079594|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb. It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvey Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies. In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position.
16242090|NCT05079594|Experimental|Mother Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks. Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks. The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it. It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements.
16242093|NCT05079568|Experimental|Active VR Group|"Subjects will be provided an Oculus Go VR headset pre-loaded with a menu of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes."
16242094|NCT05079568|Sham Comparator|Sham VR Group|Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. ubjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
16242095|NCT05079555|No Intervention|Control group|The control group consisted of patients who followed conventional therapy.
16242096|NCT05079555|Experimental|Intervention group|The intervention group consisted of patients rehabilitated using the robotic platform.
16242097|NCT05079542|Experimental|Immediate implant placement|Implant is placed immediately after tooth extraction.
16242098|NCT05079542|Active Comparator|Delayed implant placement|Implant is placed 8 weeks after tooth extraction.
16242099|NCT05079542|Experimental|Lithium disilicate crown|Crown out of Lithiumdisilicate is inserted onto the implant.
16242100|NCT05079542|Active Comparator|Zirconia Crown|Crown out of Zirconia is inserted onto the implant.
16242101|NCT05079529|Experimental|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|This group will receive capsule contains 180 mg of β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma lucidum which will be taken 3 times daily for 90 days
16242102|NCT05079529|Placebo Comparator|Placebo Group|This group will receive empty capsule which will be taken 3 times daily for 90 days
16242103|NCT05079516|Experimental|Primary motor cortex|Theta burst transcranial magnetic stimulation (cTBS) will be applied over primary motor cortex.
16242104|NCT05079516|Experimental|Somatosensory cortex|Theta burst transcranial magnetic stimulation (cTBS) will be applied over primary somatosensory cortex.
16242105|NCT05079516|Sham Comparator|Vertex sham|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
16242106|NCT05079516|Experimental|Visual cortex|Theta burst transcranial magnetic stimulation (cTBS) will be applied over visual cortex.
16242107|NCT05079516|Sham Comparator|Visual cortex sham|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over visual cortex.
16242108|NCT05079503|Experimental|TNT plus GEN-001|Total neoadjuvant therapy (TNT) includes short-course radiotherapy (25 Gy/5fx), followed by systemic chemotherapy with FOLFOX regimen for 3-6 months. GEN-001 is orally administered once daily during total TNT periods and surgery will be performed 1 month after systemic chemotherapy.
16242109|NCT05079490|No Intervention|Baseline|All children will receive outcome measures.
16242110|NCT05079490|Experimental|Intervention phase|Children in the experimental group will receive intervention for 12 weeks while children in the control group remain their regular activities.
16242111|NCT05079490|No Intervention|Follow up phase|All children will be followed after the end of intervention phase and receive outcome measures at 3- and 6-month after the completion of intervention.
16242112|NCT05079477|Active Comparator|Calorie label|"Calorie label (control) will display a calories per package label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels. Additionally, all snack items will have a calories per serving label."
16242113|NCT05079477|Experimental|Sugar graphic warning label|"All products in this arm will also have calorie labels. Beverages with added sugar will also have sugar graphic warning labels with the text: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay along with graphics depicting the amount of sugar in the beverage."
16242114|NCT05079464|Experimental|Exercise primed tDCS|Individuals randomized to this group will receive exercise at University Health Network-Toronto Rehabilitation Institute followed by active tDCS.
16242115|NCT05079464|Other|Exercise primed Sham stimulation|Individuals randomized to this group will receive exercise at University Health Network-Toronto Rehabilitation Institute followed by sham tDCS.
16242116|NCT05079464|Other|Treatment as usual (exercise education) & tDCS|Individuals randomized to this group will receive routine advice about physical activity, and active tDCS.
16242117|NCT05079464|Other|Treatment as usual (exercise education) & sham stimulation|Individuals randomized to this group will receive routine advice about physical activity, and sham tDCS.
16242295|NCT05078086||Patients undergoing cardiac surgery with CPB|>18 y/o patients who undergo cardiac surgery with cardiopulmonary bypass and with a preoperative additive EuroSCORE I≥ 6
16242377|NCT05077579||metabolically normal overweight|
16242378|NCT05077579||obese and metabolically normal lean|
16242119|NCT05079438|Experimental|CRT with Dendrobium huoshanense Suppository|"Dendrobium huoshanense Suppository: 1.7g rectal administration per day for 5 weeks
~Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
16242120|NCT05079438|No Intervention|CRT with Placebo|"Placebo: 1.7g rectal administration per day for 5 weeks
~Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
16242121|NCT05079425|Experimental|Part A: Fasting|Single ascending dose (SAD).
16242122|NCT05079425|Experimental|Part A: Fed|Single ascending dose (SAD).
16242123|NCT05079425|Experimental|Part B: Fasting|Multiple Ascending Dose (MAD)
16242124|NCT05079412||NIV-NAVA group|Premature infants (22 0/7 to 31 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIV-NAVA for at least 24 hours are enrolled in this arm after obtaining parents' consent.
16242125|NCT05079412||NIPPV group|Premature infants (22 0/7 to 31 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIPPV for at least 24 hours are enrolled in this arm after obtaining parents' consent.
16242126|NCT05079399||Healthy Control|
16242127|NCT05079399||Diabetes but no retinopathy|
16242128|NCT05079399||Mild non proliferative diabetic retinopathy|
16242129|NCT05079399||Moderate non proliferative diabetic retinopathy|
16242130|NCT05079399||Severe non proliferative diabetic retinopathy|
16242131|NCT05079399||Proliferative diabetic retinopathy|
16242132|NCT05079386|Experimental|New Voice Prosthesis|Patients will use the New Voice Prosthesis for two weeks to investigate short term feasibility and explore limitations and advantages. If the patient wishes to leave the New Voice Prosthesis in situ, this will be allowed under the condition that the subject agrees to remain in the study and report (adverse) events on an ongoing basis, until the device is removed after a maximum of 12 months.
16242133|NCT05079360|Experimental|Sabizabulin Treatment Group|Subjects in the Sabizabulin Treatment Group will receive sabizabulin 32mg each day by mouth until disease progression is observed and confirmed by BICR.
16242134|NCT05079360|Active Comparator|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
16242135|NCT05079347|Experimental|Healer led HIV testing|"Traditional healers will offer HIV testing to their patients. They will provide the test result to patients. If the patient is positive they will refer their patients to the health facility via referral form and/or walk them to the clinic (based on patient preference). If the patient is negative, the healer will encourage them to re-test at the health facility in 6 months during an open house event where healers will attend to try and de-stigmatize going to the health facility."
16242136|NCT05079321|Experimental|Coated Scleral Lens|Participants wear a lens coated with Hydra-PEG.
16242137|NCT05079321|Placebo Comparator|Uncoated Scleral Lens|Participants wear an uncoated (control) lens.
16242145|NCT05079282|Experimental|ONO-4685 monotherapy|Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy
16242146|NCT05079269|Experimental|Intervention|The investigators will start a balanced crystalloid solution (in detail we will administer 500ml if the actual body weight is ≤80 kg: the investigators will administer 1000 ml if the actual body weight is >80 kg:) within 20 to 40 minutes before induction of anesthesia in the pre-operative area or at the ward, as appropriate.
16242147|NCT05079269|No Intervention|Control|Patients will receive the balanced crystalloid solution according to the current clinical standard of care.
16242148|NCT05079256|Experimental|Laser therapy|595 nm Pulsed dye laser (PDL) therapy for psoriasis
16242149|NCT05079256|No Intervention|deferred treatment|Untreated lesion
16242150|NCT05079243|Experimental|Scaffold and adipose-derived stromal cell enriched fat grafts|Randomized and paired injections. Each participant will receive all 11 solutions.
16242151|NCT05079243|No Intervention|Controls samples|Control samples of untreated skin
16242152|NCT05079230|Experimental|Magrolimab + Venetoclax + Azacitidine|"Participants will receive
~magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter
~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter
~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle
~Each cycle is 28 days."
16242153|NCT05079230|Placebo Comparator|Magrolimab Placebo + Venetoclax + Azacitidine|"Participants will receive
~magrolimab placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter
~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter
~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle
~Each cycle is 28 days."
16242158|NCT05079152|Experimental|Experimental group|Experimental Group (468 subjects) will receive: 1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
16242159|NCT05079152|Active Comparator|Control group A|Control Group A (468 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
16242160|NCT05079152|Active Comparator|Control group B|Control Group B (468 subjects) will receive: 1st dose: PPV23 only; 2nd dose: IIV4 only
16242161|NCT05079139|Other|surgical technique of Musset|
16242164|NCT05079100|Active Comparator|group of intervention (counseling)|the group will receive the contraception counseling
16242165|NCT05079100|No Intervention|group of control (no counseling)|this group will not receive any counseling
16242166|NCT05079087|Experimental|PENG BLOCK arm|The first arm will consist of patients that undergo PENG block administering a mixture of Ropivacaine 0.5% + Dexamethasone 4 mg in a volume of 20 ml before performing the spinal anaesthesia.
16242167|NCT05079087|Active Comparator|Ketamine- Midazolam arm|The second arm consist in Patients that will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
16242170|NCT05079061|Active Comparator|Misoprostol group|At delivery of baby, routine uterotonics (syntometrine 1ml intramuscular or syntocinon 5 units intravenous bolus followed by 40 units in 500ml normal saline infusion over 4 hours in women contraindicated for syntometrine) will be given as routine practice, and sublingual misoprostol will be given to women in misoprostol group.
16242171|NCT05079061|No Intervention|Control group|At delivery of baby, routine uterotonics (syntometrine 1ml intramuscular or syntocinon 5 units intravenous bolus followed by 40 units in 500ml normal saline infusion over 4 hours in women contraindicated for syntometrine) will be given as routine practice, and no additional sublingual misoprostol will be given to women in control group.
16242172|NCT05079048|Active Comparator|conventional retentive element|The conventional group received implant-supported mandibular overdentures retained by metal housings and nylon retentive elements,
16242173|NCT05079048|Experimental|PEEK retentive element|PEEK group received implant-supported mandibular overdentures retained by PEEK housings ,
16242174|NCT05079035|Experimental|Experimental: TTAX03|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is suspended in a volume of 2.0mL of sterile, preservative free 0.9% NaCl.
16242175|NCT05079035|Placebo Comparator|Control: Saline|2.0mL of sterile, preservative free 0.9% NaCl alone
16242176|NCT05079022|Experimental|Furmonertinib|ctDNA-MRD positive participants received 3 years of furmonertinib once daily as adjuvant therapy after radical surgery until disease progression or unacceptable toxicity occurs.
16242177|NCT05079009|Experimental|ECCO2R pulsatile configuration|Adult patients hospitalized in the medical ICU for whom a treatment by ECCO2R has been indicated.
16242180|NCT05078970|No Intervention|Treatment As Usual (TAU)|Participants in this group will be studied as they proceed through treatment in the acute care setting and follow the intervention plan laid out in the discharge summary, per usual protocols at each facility. In both settings, the elements of typical care include crisis prevention planning, which outlines potential triggers, skills to use, and people and places to call in crisis, as well as referral to ongoing behavioral health treatment. We will not alter usual care but track recommendations, contacts and care through questionnaires the family completes as well as medical record review in order to understand the impact of the experimental conditions in relation to typical services.
16242181|NCT05078970|Active Comparator|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
16242182|NCT05078970|Active Comparator|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and a maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
16242296|NCT05078073|Experimental|aGVHD-HBOT|Patients after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
16242383|NCT05077553|Experimental|TCI999 probiotic sachet|
16242186|NCT05078944|Experimental|Active acupuncture + Donepezil|Active acupuncture treatment is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Acupuncture + Drug: Donepezil hydrochloride
16242187|NCT05078944|Sham Comparator|Sham acupuncture + Donepezil|Sham acupuncture treatment with no skin penetration and no current output on sham acupoints is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Sham acupuncture + Drug: Donepezil hydrochloride
16242189|NCT05078918|Experimental|Comprehensive care program|Intervention group receiving newly developed comprehensive care program pre- and post-operatively.
16242190|NCT05078918|Active Comparator|Usual care|Control group receiving usual care
16242196|NCT05078866|Experimental|Prevention (Nous-209 vaccine)|Patients receive GAd20-209-FSPs IM on day 1 and MVA-209-FSPs IM at week 8.
16242197|NCT05078853||Formal/standard evaluation of a suspected cervical lymph node|"Patient with cervical lymph node suspected as differentiated thyroid carcinoma metastasis will be evaluated according to the current accepted American Thyroid Association Guidelines.
~Two clinical scenarios, for each one of them the formal evaluation is described below:
~Fine needle aspiration Clinic (a patient with known or suspected differentiated thyroid carcinoma is evaluation for suspicious cervical lymph node): the formal evaluation will include cytology and formal thyroglobulin measurement from the needle washout.
~Operating room (evaluation of suspicious cervical lymph node found during partial or complete thyroidectomy in patient with known or suspected differentiated thyroid carcinoma): the formal evaluation will include frozen section and/or final histology."
16242198|NCT05078853||Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"Patient with cervical lymph node suspected as differentiated thyroid carcinoma metastasis will be evaluated using the study kit: Novel rapid POC-Tg.
~Two clinical scenarios, for each one of them the performance of the study kit (POC-Tg) will be valuated in parallel to the formal evaluation:
~Fine needle aspiration Clinic (a patient with known or suspected differentiated thyroid carcinoma is evaluation for suspicious cervical lymph node): the suspected cervical lymph node will be evaluated using the POC-Tg in parallel to the formal evaluation.
~Operating room (evaluation of suspicious cervical lymph node found during partial or complete thyroidectomy in patient with known or suspected differentiated thyroid carcinoma): the suspected cervical lymph node will be evaluated using the POC-Tg in parallel to the formal evaluation."
16242199|NCT05078840||Patients with DLBCL limited stages and without risk factors|Patients with DLBCL in limited stages and without risk factors that will receive standard chemoimmunotherapy and their treatment will be adapted according to PET response after 3 cycles.
16242200|NCT05078827|Active Comparator|Comparator Arm|Reference Product (B): EFUDEX® (Fluorouracil 5%) Topical Cream of Bausch Health US, LLC, USA
16242201|NCT05078827|Experimental|Arms and Interventions|Test Product (A): Fluorouracil Cream, 5% of Encube Ethicals Pvt. Ltd., India
16242202|NCT05078827|Placebo Comparator|Placebo Arm|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
16242203|NCT05078801||Endoscopic drainage|All patients with perihilar malignant biliary obstruction treated with endoscopic drainage. This drainage can be multimodal using endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS)-guided biliary drainage.
16242204|NCT05078801||Radiologic percutaneous drainage|All patients with perihilar malignant biliary obstruction treated with percutaneous drainage
16242205|NCT05078788|Experimental|Laser uretherotomy|Using Holmium laser uretherotomy only in the treatment of bulbar uretheral stricture
16242206|NCT05078788|Experimental|Laser uretherotomy with intralesional steroids|Using holmium laser uretherotomy with injection of 80 mg of triamcinolone (diluted with normal saline to 10 ml) in the treatment of bulbar uretheral stricture
16242207|NCT05078775|Experimental|Nonessential Amino Acid Restriction (NEAAR) Medical Food|This is a single arm study in which all subjects will receive NEAAR medical food and standard of care FDA approved chemotherapy. Each week NEAAR medical food will be consumed 5 consecutive days followed by 2 days of habitual food.
16242208|NCT05078762|Experimental|iVR|The intervention group will train on a bronchoscopy simulator in an iVR environment with Virtual Reality Goggles (HTC IVE Pro Eye, HTC corporation, Taiwan) while using the bronchoscopy simulator.
16242209|NCT05078762|No Intervention|Non iVR|The control group will train on a bronchoscopy simulator without VR goggles.
16242210|NCT05078749|Active Comparator|Exercise training group|Continuous progressive exercise training will be applied to the treatment group. The exercises will be performed every day, twice a day, for an average of 10 minutes/session, for eight weeks. Exercise training will be updated regularly at two-week intervals. A different and progressive new exercise will be sent to the patients as a Youtube link. The patients will be interviewed by video every week.
16242211|NCT05078749|Sham Comparator|Control training group|The control group will be followed up as a home program by explaining the exercises and giving a brochure. They will be asked to do the exercises regularly for 7 days/week, 2 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
16242212|NCT05078736|Experimental|moderate intensity intermittent training|baseline physical therapy treatment along with moderate intensity intermittent training
16242213|NCT05078736|Experimental|moderate intensity continuous training|baseline physical therapy treatment along with moderate intensity continuous training
16242297|NCT05078073|No Intervention|aGVHD-HBOT free|Patients after allo-HSCT will NOT receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
16242214|NCT05078723|Experimental|CYP2C19*2 and CYP2C19*3 Variants|The group of participants has been genotyped to have the CYP2C19*2 and/or CYP2C19*3 variant during the first part of the study. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the wild-type CYP2C19 study subjects.
16242215|NCT05078723|Experimental|Wildtype CYP2C19|The group of participants has been genotyped to have wild-type CYP2C19. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the CYP2C19*2 and/or CYP2C19*3 study subjects.
16242216|NCT05078710|Experimental|Telitacicept arm|Telitacicept 160mg once a week for 24 week as an add-on treatment regimen.
16242217|NCT05078697||early pregnancy women|According to the 2020 high-risk population score model, participants with high risks for GDM and normal health participants will be enrolled into the study.
16242220|NCT05078671|Active Comparator|Standard olaparib|Olaparib 300mg twice daily
16242221|NCT05078671|Experimental|Boosted olaparib|Olaparib 100mg twice daily + cobicistat 150mg twice daily
16242222|NCT05078658|Experimental|Low-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
16242223|NCT05078658|Active Comparator|Recommended carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with 50% (+/- 5%) of the recommended energy from carbohydrates.
16242224|NCT05078645|Other|Group 1: Maya use on 1st, 3th and 5th day|Group 1 uses the Maya on the 1st, 3th and 5th day and not on the 2nd, 4th and 6th day of their admission to either the ICU, MC or CCU.
16242225|NCT05078645|Other|Group 2: Maya use on the 2nd, 4th, and 6th day|Group 2 uses the Maya on the 2nd, 4th and 6th day and not on the 1st, 3th, and 5th day of their admission to either the ICU, MC or CCU.
16242226|NCT05078632||Healthy volunteers|healthy volunteers
16242227|NCT05078632||intensive care patient|patient hospitalized in intensive care unit
16242228|NCT05078619|Experimental|TAVI only|Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation without preceding PCI of significant coronary artery disease
16242229|NCT05078619|No Intervention|TAVI with preceding PCI|Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation with preceding PCI of significant coronary artery disease which is currently the standard of care.
16242231|NCT05078580|Experimental|Healthy participants|Matched healthy participants with normal hepatic function
16242232|NCT05078580|Experimental|Mild hepatic impairment patients|Mild hepatic impaired participants with Child-Pugh score of 5 to 6
16242233|NCT05078580|Experimental|Moderate hepatic impairment patients|Moderate hepatic impaired participants with Child-Pugh score of 7 to 9
16242234|NCT05078580|Experimental|Severe hepatic impairment patients|Severe hepatic impaired participants with Child-Pugh score of 10 to 15
16242235|NCT05078567|Experimental|Single arm open label study|Topical used natural lactic acid-enriched cream twice daily.
16242236|NCT05078541|Experimental|RFA Warthins Tumor Group|Group of patients who will under RFA for Warthin's tumor.
16242237|NCT05078528|Experimental|Experimental group - MMC|Imaging of study participants will be performed during the colposcopy examination. The mobile colposcope and the confocal imaging probe, together referred to as the Multimodal Mobile Colposcope (MMC), will be used to image and/or record videos the cervix. Cervical biopsies will be performed using biopsy forceps per standard protocols.
16242238|NCT05078515||Patients with recurrence after TME|Patients who developed local recurrence after TME of rectal cancer
16242239|NCT05078515||Patients without recurrence after TME|Patients who did not develop local recurrence after TME of rectal cancer
16242242|NCT05078489|Experimental|Action-observation arm|Participants will be asked to watch videos of neck exercises without performing any exercise. The intervention will take approximately 15 minutes.
16242243|NCT05078489|Placebo Comparator|Placebo intervention|Participants will be asked to watch videos of landscapes. The intervention will take approximately 15 minutes.
16242244|NCT05078476|Active Comparator|Manchester Short Splint|Dorsal splint ending shortly behind the wrist. The splint will be worn for 6 weeks after surgery and the patient will perform active and passive exercises in the splint.
16242245|NCT05078476|Experimental|Relative Motion Flexion|In the relative motion splint the injured finger is positioned in relative flexion in the MCP joint to the adjacent fingers. Additionally to the relative motion flexion splint a wrist orthosis is adapted. Passive and active exercises will be performed out of the splint.
16242298|NCT05078060||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
16242299|NCT05078060||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
16242379|NCT05077566|Active Comparator|Exercise at 60% vo2|This arm will receive 15 minutes of exercise at 60% VO2 max.
16242246|NCT05078463|Experimental|Intervention A: Microneedle with 2 Finger Tip Units (FTUs) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 10 mm x 10 mm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. Two (2) Finger Tip Units (FTUs) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 1.15g/4cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
16242247|NCT05078463|Experimental|Intervention B: Microneedle with 1 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 10 mm x 10 mm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5% (dose: approximately 0.61 g/4cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
16242248|NCT05078463|Experimental|Intervention C: Microneedle with 2 Finger Tip Units (FTUs) EMLA for 15 minutes|A Maltose Microneedle array patch (size: 10 mm x 10 mm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. Two (2) Finger Tip Units (FTUs) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 1.15g/4cm2) will then be topically applied for 15 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
16242249|NCT05078463|Sham Comparator|Intervention D: 2 Finger Tip Units (FTUs) EMLA only and PVA-containing PET Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. Two (2) Finger Tip Units (FTUs) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 1.15g/4cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
16242254|NCT05078424|Experimental|CBT Treatment group|This group receives CBT interventions that aim to improve mental well-being, depressive and anxiety symptoms in young people.
16242255|NCT05078424|No Intervention|Wait-list Control group|This group does not receive CBT intervention but will receive appropriate intervention after the CBT treatment group and follow-up phases complete.
16242258|NCT05078398|Experimental|POINT-B|Patients will receive perioperative counseling on opioid consumption following breast surgery, both preoperatively and postoperatively. Upon discharge, patients will be asked whether they would like to be discharged with narcotic pain medication or not.
16242259|NCT05078398|Active Comparator|Usual Care|Patients will receive equivalent of 5 tabs of Norco 5/325 mg upon discharge routinely
16242260|NCT05078385|Experimental|AGLE-102|The study is designed to examine the safety of administering EVs derived from allogeneic MSCs to 2nd degree burn wounds of less than 20% TBSA. The study will consist of a single dose level which will evaluate the safety of administering allogeneic Extracellular Vesicles-with a total of 10 patients. The chosen dosage will correlate to a dose of MSCs administered under another protocol (IND 14810). The dose level delivered will be EVs derived from approximately 1 X 104 MSCs for each cm2 treated area not to exceed 20% TBSA in total (cumulative, if more than one area is treated). The limitation in wound sizes to be treated will not change throughout the study. Up to 2 additional administrations of EVs will be given over a period of no more than 8 weeks. The first treatment will be administered within 48 hours of the burn injury. The subsequent treatments will be administered no less than 7 days and no more than 6 weeks apart.
16242261|NCT05078372|Active Comparator|Ropivacaine and midazolam epidural administration|"An elastomeric pump was prepared for epidural infusion. This was prepared with 150 mg (20 ml) of 0.75% ropivacaine plus midazolam at 50 mcg / kg / 12 hrs. The solution was made up to 125 ml with physiological solution.
~And 20 ml of physiological solution, was intraarticular administered as placebo."
16242262|NCT05078372|Active Comparator|Ropivacaine and midazolam intraarticular administration|"Ropivacaine 0.75% at 1.5 mg / kg was used with midazolam at 50 mcg / kg, to complete 20 ml of solution and was administrated on the knee articulation after tourniquet release.
~And an elastomeric pump was prepared for epidural infusion, with 150 ml of physiological solution as placebo."
16242300|NCT05078047|Experimental|Experimental arm|"Reduced dose intensity of IO:
~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision"
16242380|NCT05077566|Experimental|Exercise at 90% vo2|This arm will receive 15 minutes of exercise at 90% VO2 max.
16242266|NCT05078320|Experimental|Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder|Cognitive-behaviour therapy, Exposure and response prevention (ERP)
16242267|NCT05078307|Active Comparator|OHR System|Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.
16242268|NCT05078307|Experimental|OHV System|Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.
16242269|NCT05078294||Cases|Patients treated as monotherapy with phototherapy, cyclosporine, methotrexate, azathioprine, mycophenolate, dupilumab, baricitinib, upadacitinib, or tralokilumab for the treatment of moderate to severe atopic dermatitis.
16242270|NCT05078281||Cases|Patients with severe eosinophilic asthma receiving benralizumab.
16242273|NCT05078255|Placebo Comparator|placebo injections + placebo infusion|
16242274|NCT05078255|Experimental|Semaglutide 1.34 mg/ml injections + GIP infusion|
16242275|NCT05078255|Experimental|placebo injections + GIP infusion|
16242276|NCT05078255|Experimental|Semaglutide 1.34 mg/ml injections + placebo infusion|
16242277|NCT05078242|Experimental|Experimental: EaseVRx sessions|This is a study of patients with chronic pain to assess usability of a VR device at home. The main goals are 1) to collect data on feasibility of recruitment, 2) to collect data on daily adherence to therapy, and 3) to collect preliminary effectiveness data on pain and mood outcomes. There will be 7 sessions over one week, with each session lasting about 2-16 minutes. All patients recruited will be in the active arm; this is not a randomized pilot study.
16242278|NCT05078229|Experimental|FOCUS|Focusing On mindfulness for Caregivers Under Stress (FOCUS)will consist of six one-on-one, 45-60 minute sessions delivered either in-person (sessions 1-3) or via video conference (sessions 4-6). The first few sessions will primarily focus on how to direct attention to the breath or some object of attention (e.g., parts of the body). As the program progresses, participants are asked to apply these skills to thoughts and emotions. Throughout the treatment, caregivers are reminded to utilize existing coping skills, as well as how to integrate the new skills learned throughout this program for managing stress. Formal mindfulness meditations are conducted within each session, lasting from 7-20 minutes; participants will be asked to practice mindfulness exercises daily.
16242279|NCT05078229|Active Comparator|Healthy Living|Healthy Living (HL) will consist of six, 45-60 minute sessions delivered one-on-one; sessions 1-3 in-person on HCT unit and sessions 4-6 via video conference. HL will be based on the American Cancer Society's (ACS) Caregiver Resource Guide.
16242280|NCT05078229|No Intervention|Standard of Care - Enhanced Care|Participants in Enhanced Care will receive treatment consistent with what is offered to all caregivers of allogeneic HCT patients. This entails the option of attending weekly support groups and meeting with social workers as needed. At the baseline session, participants randomized to Enhanced Care will be provided with a modified version of the ACS Caregiver Resource Guide.
16242281|NCT05078216||Cancer patients|"The exercise program consisted of a 12-week supervised intervention, with twice per week sessions of 90 minutes, and was developed in a friendly and close environment, which promoted social interaction between participants. Apart from the twice-weekly supervised sessions, as early as the fifth week, one or two individualized home-based sessions were established for each patient in order to achieve his/her specific objectives with the help of any required supporting material such as documents and video references with exercise examples.
~All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR)"
16242282|NCT05078203|Experimental|Exercise|Individuals will warm up for 3 minutes before exercising for 30 minutes at an intensity derived from their graded exercise test before cooling down for 3 minutes (36 minutes).
16242283|NCT05078203|Placebo Comparator|Rest|Individuals will be placed on seated rest for the equivalent amount of time (36 minutes)
16242287|NCT05078177|Experimental|AHSCT + intrathecal Rituximab|AHSCT with reduced intensity condition regimen (RIC). Lumbar puncture with intrathecal injection of 25 mg Rituximab will be performed once from about D+12 to D+14 AHSCT, depending on the duration of cytopenia.
16242288|NCT05078164|No Intervention|Treatment as Usual|Youth who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
16242289|NCT05078164|Experimental|Bridging the Gap (BTG)|Youth randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 3-months of community case management and a firearm counseling program.
16242290|NCT05078151|Other|Metastatic prostate cancer|Patients will receive whole-body MRI with diffusion-weighted imaging at baseline and after 4 and 8 weeks of treatment.
16242291|NCT05078138|Experimental|Exogenous Erythropoietin|Recombinant human Erythropoietin subcutaneous injection of 50 IU/kg body mass 3 times per week for 4 week
16242292|NCT05078138|Placebo Comparator|Placebo|Saline subcutaneous injection 3 times per week for 4 week
16242293|NCT05078112|Experimental|Sleep Device intervention|Infants will utilize the sleep device during sleep for 20 days
16242294|NCT05078099|Experimental|Study arm - Binocular CureSight|Using binocular treatment device 90 min a day 5 times a week for 12 weeks following by 90 min a day 3 times a week for additional 12 weeks
16242301|NCT05078047|No Intervention|Control arm|"Standard IO:
~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice."
16242304|NCT05078021||Normal control|Healthy, non-asthmatic control subjects
16242305|NCT05078021||Mild asthma|Requiring low dose inhaled corticosteroid (ICS) plus as needed short acting beta-agonist (SABA) or as needed ICS-Formoterol.
16242306|NCT05078021||Moderate asthma|Low dose ICS-Long acting beta-agonist (LABA) maintenance + ICS-LABA reliever or SABA reliever
16242307|NCT05078021||Severe asthma|Medium to high dose ICS-LABA maintenance + as needed SABA or ICS-formoterol
16242308|NCT05078008|Placebo Comparator|Group 1 - Physiotherapy modalities|
16242309|NCT05078008|Experimental|Group 2 - Physiotherapy modalities + Balneotherapy modalities|
16242310|NCT05077995|Experimental|Group 1|Sixty healthy adults, aged 18-65 years, will be included following written informed consent.
16242311|NCT05077969|Experimental|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
16242312|NCT05077969|Placebo Comparator|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.
16242317|NCT05077943|Active Comparator|No Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time, in 3 months without being supervised
16242318|NCT05077943|Experimental|With Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time and breathing and chest mobilization exercise for 3 times per week. They will be supervised through online meetings.
16242319|NCT05077930|Experimental|Convalescent Plasma|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Centro de Hematologia e Hemoterapia do Paraná - Hemepar following national blood donation guidelines and Brazilian Health Regulatory Agency (ANVISA) criteria. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined. Participants will receive the standard of care treatment and a single unit of convalescent plasma (volume=200 mL or 400 mL).
16242320|NCT05077930|Active Comparator|Standard of care|Standard of care treatment according to the institutional protocol.
16242323|NCT05077904|Experimental|Staccato alprazolam Arm|Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
16242324|NCT05077904|Placebo Comparator|Placebo Arm|Participants randomized to this arm will receive a single dose of placebo by inhalation.
16242325|NCT05077878||normal|Patients with non-orthodontic treatment and have no root resorption
16242326|NCT05077878||mild to moderate|Patients with orthodontic treatment and have mild to moderate root resorption
16242327|NCT05077878||severe|Child patients with non-orthodontic treatment and have severe root resorption
16258697|NCT04965389|Experimental|Sequence 3|
16242339|NCT05077826|Experimental|Full Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of up to 4 mA, delivered for up to 40 minutes.
16242340|NCT05077826|Placebo Comparator|Partial Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of 0.1 mA, delivered for up to 40 minutes.
16242341|NCT05077813|Active Comparator|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
16242342|NCT05077813|Active Comparator|9 cis retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
16242343|NCT05077813|Active Comparator|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
16242344|NCT05077813|Active Comparator|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
16242345|NCT05077813|Active Comparator|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
16242346|NCT05077813|Placebo Comparator|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days 50- 50-
16242347|NCT05077800|Experimental|Safety Run-In: FOLFIRINOX + 9-ING-41 + Losartan|"The study will begin with a Safety Run-In phase to establish the side effects from the study treatment to its safety before beginning the main part of the study, six (6) participants will receive 1-2 cycles of:
~FOLFIRINOX
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle
~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle
~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle
~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle
~9-ING-41 on days on days 1, 3, 8, and 11 of every 14-day cycle
~Losartan daily of every 14-day cycle."
16242368|NCT05077644|Other|Participants who use Stella App|Participant experience in using the mobile application and EPDS results
16242369|NCT05077631|Experimental|ACD856|
16242370|NCT05077631|Placebo Comparator|Placebo|
16242371|NCT05077618||patients with Alzheimer's disease|47 cases (patients with Alzheimer's disease)
16242372|NCT05077618||patients without Alzheimer's disease|47 patients without Alzheimer's disease
16242374|NCT05077592|No Intervention|Control|Direct Wound closure
16242381|NCT05077566|No Intervention|No intervention|No intervention
16242348|NCT05077800|Experimental|FOLFIRNINOX|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.
~For initial complete therapy, participants will receive FOLFIRINOX as follows:
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)
~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~For Maintenance therapy, participants will receive FOLFIRINOX as follows:
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression
~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX until further disease progression"
16242349|NCT05077800|Experimental|FOLFIRINOX + Losartan|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.
~For initial complete therapy:
~FOLFIRINOX
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)
~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Losartan daily up to 12 cycles (24 weeks)
~For Maintenance therapy:
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression
~Losartan daily until disease progression
~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + Losartan until further disease progression"
16242350|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.
~For initial complete therapy:
~FOLFIRINOX
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)
~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)
~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle up to 12 cycles (24 weeks)
~For Maintenance therapy:
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression
~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression
~For Complete Therapy Round 2, repeat of initial complete therapy until further disease progression"
16242351|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41 + Losartan|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.
~For initial complete therapy:
~FOLFIRINOX
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle
~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle
~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle
~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle
~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle
~Losartan daily
~For Maintenance therapy:
~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression
~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression
~Losartan daily until disease progression
~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + 9-ING-41+ Losartan until further disease progression"
16242352|NCT05077787|Experimental|Experimental Group|Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.
16242353|NCT05077787|No Intervention|Control Group|Neonates recruited in control group will receive phototherapy alone along with regular care
16242354|NCT05077774|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System
16242355|NCT05077761|Experimental|High-intensity laser therapy|77 participants will receive active high-intensity laser therapy interventions on hamstring muscle to improve the flexibility of muscle
16242356|NCT05077761|Sham Comparator|Sham High-intensity laser therapy|77 participants will receive sham high-intensity laser therapy on hamstring muscle
16242357|NCT05077735|Experimental|Treatment (hypofractionated RT)|Patients undergo hypofractionated RT over 10 fractions. Patients who achieve progression undergo up to 2 retreatment courses.
16242358|NCT05077722|Experimental|AI Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy (PCIT) will wear a Garmin smartwatch that will provided targeted messages during tantrums picked up by the Garmin devices that will instruct them on how to deescalate their child.
16242359|NCT05077722|Sham Comparator|Sham Biometric - Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy will wear Garmin smartwatch and will receive only random messages throughout the day with various relaxation strategies such as reminders to practice deep breathing with their child.
16242363|NCT05077696||Patients with progressive motor neuron disease without definite diagnosis|Patients with progressive motor neuron disease without definite diagnosis
16242366|NCT05077670||Study group|"LAA + LA Map in AF
~Identify LAA connections and detect rotors with CartoFinder
~Electrical cardioversion. Sinus rhythm restoration
~Pacing from the coronary sinus at 300 and 600ms periods
~Analyze COHERENT activation maps in sinus rhythm
~Ablation as suggested by current clinical guidelines and the characteristics of the patient"
16242367|NCT05077657||Single-Arm|This is a multi-center, single arm, open-label study to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).
16242382|NCT05077553|Placebo Comparator|Placebo sachet|
16242386|NCT05077527|Experimental|Treatment (conditioning, axicabtagene ciloleucel)|Patients receive fludarabine IV over 30 minutes and cyclophosphamide IV over 1 hour on days -5, -4, and -3. Patients then receive axicabtagene ciloleucel IV over 30 minutes on day 0.
16242391|NCT05077488|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Intradermal injection (deep dermis) in marionettes lines and/or forehead by a specialist injector
16242392|NCT05077475|Experimental|Sequence A|Period 1: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
16242393|NCT05077475|Experimental|Sequence B|Period 1: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
16242394|NCT05077462|Experimental|Sequence A|Period 1: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
16242395|NCT05077462|Experimental|Sequence B|Period 1: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
16242396|NCT05077449|Experimental|XZP-3287+Fulvestrant|
16242397|NCT05077449|Placebo Comparator|Placebo + Fulvestrant|
16242398|NCT05077436|Experimental|Sequence 1|"Participants receive a single dose of study drug, every 4 days:
~Day 1: Participants in fasted state receive Vamifeport Formulation 1
~Day 5: Participants in fed state receive Vamifeport Formulation 1
~Day 9: Participants in fed state receive Vamifeport Formulation 2
~Day 13: Participants in fasted state receive Vamifeport Formulation 2"
16242399|NCT05077436|Experimental|Sequence 2|"Participants receive a single dose of study drug, every 4 days:
~Day 1: Participants in fed state receive Vamifeport Formulation 1
~Day 5: Participants in fasted state receive Vamifeport Formulation 2
~Day 9: Participants in fasted state receive Vamifeport Formulation 1
~Day 13: Participants in fed state receive Vamifeport Formulation 2"
16242400|NCT05077436|Experimental|Sequence 3|"Participants receive a single dose of study drug, every 4 days:
~Day 1: Participants in fasted state receive Vamifeport Formulation 2
~Day 5: Participants in fed state receive Vamifeport Formulation 2
~Day 9: Participants in fed state receive Vamifeport Formulation 1
~Day 13: Participants in fasted state receive Vamifeport Formulation 1"
16242401|NCT05077436|Experimental|Sequence 4|"Participants receive a single dose of study drug, every 4 days:
~Day 1: Participants in fed state receive Vamifeport Formulation 2
~Day 5: Participants in fasted state receive Vamifeport Formulation 1
~Day 9: Participants in fasted state receive Vamifeport Formulation 2
~Day 13: Participants in fed state receive Vamifeport Formulation 1"
16242403|NCT05077397|Active Comparator|Group 1|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.
~Patients of Group 1 will be monitored by the InSpectra Tissue Spectrometer, StO2, added to standard ASA monitorisation."
16242404|NCT05077397|Active Comparator|Group 2|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.
~Patients of Group 2 will be monitored by O3TM Regional Oximeter System, added to standard ASA monitorisation."
16242405|NCT05077397|No Intervention|Group 3|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.
~Patients of Group 2 will be monitored by standard ASA monitorisation."
16242407|NCT05077371|Experimental|Experimental group 1|newly diagnosed breast cancer patients receiving the peer support program at the beginning of their medical treatment.
16242408|NCT05077371|Experimental|Experimental group 2|newly diagnosed breast cancer patients receiving the social peer support program at the end of their medical treatment.
16242409|NCT05077358|Experimental|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
16242410|NCT05077358|Active Comparator|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
16242411|NCT05077345||1/Venous blood sampling|The vessel was determined for cannulation and an anatomical tourniquet was applied. Skin antiseptic was prepared. The plastic wings of the winged angioket were held open. The skin over the vein to be accessed was stretched with the fingers of the free hand. The needle was inserted into the skin a few millimeters distal to the point to be inserted, and the blood was vascularized until the education. The cannula was advanced by retracting the stylet. The tourniquet was removed and the cannula was fixed.
16242412|NCT05077345||2/Heel puncture|The skin was prepared with an antiseptic. The baby's heel was placed at an angle between the thumb and forefinger, with the other fingers grasping the ankle from behind. Pressure was applied to the back of the ankle with the other fingers by taking support against the thumb. The first drop of blood was wiped with sterile gauze by inserting the needle, and the next drops of blood were absorbed into the paper by touching the middle of the ring on the filter paper. An adhesive bandage was applied by applying pressure to the puncture site.
16242413|NCT05077345||3:Orogastric Catheter insertion|The head of the bed was raised and the newborn was placed on his back. The midpoint distance from the tip of the nose to the ear, xiphoid and umbilicus was measured to determine the insertion length. With one hand, the infant's mouth was opened while his head was stabilized. With the other hand, the MV probe was advanced to the specified depth. The position of the OG probe was confirmed and fixed.
16258698|NCT04965389|Experimental|Sequence 4|
16242414|NCT05077345||4:Umbilical Catheter insertion|The system was filled with liquid by connecting the tap to the UK. The faucet was turned off, sterile gauze was placed around the umbilical clamp and lifted out of the sterile area. The other assistant held the cord with a clamp and lifted it vertically up and away from the sterile field. The cord and its surroundings were prepared with an antiseptic solution and covered. The umbilicus was tied with a single knot and the cord was cut horizontally with a scalpel. Bleeding on the surface of the cord was wiped with sterile gauze. The cord stump was grasped with toothed forceps close to the vessel to be catheterized. The catheter was placed in the lumen of the vessel and advanced in the vessel. When the catheter exceeded 5 cm, it was aspirated to confirm the intraluminal position. The blood that came with an average of 0.5 ml bolus solution was cleaned and the catheter was fixed.
16242415|NCT05077345||5:Tracheal Intubation|The head of the infant was positioned in the midline, slightly extended, with the chin up. The head was stabilized with the right hand by turning on the light of the laryngoscope. The blade of the laryngoscope was inserted by sliding the blade over the tongue until the tip of the blade rested on the Vallecula. The blade of the laryngoscope was slid up to open the mouth even more. The other assistant gently dipped it into the suprasternal notch. The concave edge of the tube was held with the right hand, and it was advanced approximately 2 cm, passing it between the vocal cords when the vocal cords and trachea were seen.
16242416|NCT05077332|Experimental|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
16242417|NCT05077332|Placebo Comparator|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
16242418|NCT05077306|Experimental|music therapy group|Patients receive an individual single session of receptive music therapy in presence.
16242419|NCT05077306|No Intervention|Control group|Patients receive standard care
16242430|NCT05077241|Experimental|Experimental group - inspiratory muscle training group with load|Experimental group: Inspiratory muscle training with POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) with 30% of Pimax. with weekly load increment of 10% of the Pimax value. initial. The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication.
16242431|NCT05077241|Placebo Comparator|Control group - inspiratory muscle training group without load|Subjects will use a IMT POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) device without any load and will receive the same guidelines as experimental group (The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication). At the end of the research, the control group will have the right to experimental treatment with the IMT protocol, if this is effective.
16242432|NCT05077215|Experimental|Arm 1: EG-007+ Len+Pem Regimen|
16242433|NCT05077215|Active Comparator|Arm 2: Len+Pem Regimen|
16242434|NCT05077202||ultra sound|lung ultrasound
16242435|NCT05077202||ct chest|patients had done CT chest already and we receive it from hospital files
16244069|NCT05065528|Placebo Comparator|Control|
16242440|NCT05077150||PCP cases|"Any allogeneic HSCT recipient who, during the 1-year study period, underwent a BAL from the day of transplant, and whose BAL fluid was positive for PcP: either by qPCR alone, or positive cytology or IF, irrespectively of clinical presentation, imaging, co-infection and PcP treatment. Only first episode of PcP will be included (incident cases).
~Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP."
16242441|NCT05077150||Controls|Controls are matched to case on Centre and HSCT date and if possible on gender and date of birth.
16242442|NCT05077137|Experimental|Td Vaccine|The first 15 subjects enrolled will receive the Td (tetanus diphtheria) vaccine at cycle 4 of IO therapy. The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.
16242443|NCT05077137|Experimental|IPOL Vaccine|Subjects 16 through 25 will receive the IPOL (polio booster) vaccine at cycle 4 of IO therapy. The IPOL vaccine is administered as 0.5 mL intramuscular or subcutaneous injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor
16242444|NCT05077111|Experimental|Group A|sole Thoracic Epidural Anesthesia
16242445|NCT05077111|Active Comparator|Group B|General Anesthesia with One Lung Ventilation
16242446|NCT05077098|Experimental|ADXS-504|Subjects with Biochemically Recurrent Prostate Cancer will receive ADXS-504 with dose escalation schema
16242452|NCT05077046|Experimental|Intervention first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the intervention first arm participants will be asked to execute the assessment trial / test battery with the intervention pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the control pen."
16242453|NCT05077046|Experimental|Control first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the control first arm participants will be asked to execute the assessment trial / test battery with the control pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the intervention pen."
16242454|NCT05077033|Experimental|Intratumoral phIL12 gene electrotransfer|
16242455|NCT05077007|Active Comparator|Percutaneous nephrolithotomy|patients suffering of pelvic renal stones underwent Percutaneous nephrolithotomy
16242456|NCT05077007|Active Comparator|Extracorporeal Shock Wave Lithotripsy|patients suffering of pelvic renal stones underwent Extracorporeal Shock Wave Lithotripsy
16242457|NCT05077007|No Intervention|control group|Healthy volunteers with negative history of renal stones or renal impairment to measure the level of urinary markers in their urine samples
16242458|NCT05076994|Experimental|Patient Education Tool|
16242459|NCT05076994|Active Comparator|Standard Care|
16242460|NCT05076981||Pure Natural Cycle|"Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)
~TVUS day 9-10 of cycle to identify dominant follicle.
~Blood test for IVF1 every 24h until identification of the LH surge.
~The LH surge will be diagnosed when the concentration rises by 180% above the latest serum value available in that patient and continued to rise thereafter (Fatemi et al, 2010).
~Once the LH rise is detected, blood test for IVF1 to be performed after 2h, and then every 12h after LH rise for 2 days.
~During luteal phase, IVF1 day 7 after LH rise and day 14 after LH rise."
16242461|NCT05076981||Modified Natural Cycle|"Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)
~TVUS day 9-10 of cycle to identify dominant follicle.
~Once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously. IVF1 to be performed just before the rhCG-administration.
~IVF1 2h after rhCG.
~IVF1 every 12h for 2 days after rhCG.
~During luteal phase, IVF1 day 7 after rhCG and day 14 after rhCG."
16242462|NCT05076968||Complete dentures fabricated by undergraduate students|
16242463|NCT05076968||Complete dentures fabricated by prosthodontists|
16242464|NCT05076955|Experimental|Treatment of Diabetic Foot Ulcer|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
16242465|NCT05076942|Experimental|Chemoradiation|Inguinofemoral radiotherapy (48-50 Gy in 1.8 Gy daily fractions, with a boost dose to the involved inguinal site for a total equivalent dose of 56 Gy over 5-6 weeks, preferably with simultaneous integrated boost technique) combined with weekly cisplatin 40 mg/m2 intravenously on days 1, 8, 15, 22 and 29
16242524|NCT05076487||African American Women with Food Security|30 African American women with obesity who are food secure
16242525|NCT05076487||African American Women with Food Insecurity|30 African American women with obesity who are food insecure
16242526|NCT05076474|Experimental|TR1R2|T(Orlistat 60-mg) R1(Alli 60-mg) R2（Alli 60-mg×2）
16242527|NCT05076474|Experimental|R2TR1|R2（Alli 60-mg×2） T(Orlistat 60-mg) R1(Alli 60-mg)
16242466|NCT05076916|Experimental|Intervention group|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. During the follow-up period, the patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the intervention group who came to the hospital for follow-up or treatment.
16242467|NCT05076916|No Intervention|Control group|The control group received routine patient education and routine hospital follow-ups given by Oncology Education Nurses during the three-month follow-up period. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the control group who came to the hospital for follow-up or treatment.
16242468|NCT05076903|Experimental|OFA group|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
16242469|NCT05076903|Active Comparator|Control group|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
16242470|NCT05076890|Experimental|15 mg/g Full Spectrum Hemp Extract|A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.
16242471|NCT05076890|Experimental|50 mg/g Full Spectrum Hemp Extract|A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.
16242472|NCT05076877|Experimental|Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin|Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.
16242473|NCT05076851|Placebo Comparator|placebo group|placebo+ADT
16242474|NCT05076851|Experimental|Proxalutamide|Proxalutamide +ADT
16242475|NCT05076838|Experimental|Valtoco In Pediatric Subjects with Epilepsy|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
16242476|NCT05076825|Experimental|Neurodynamic Sliding|participents receive routine physical therapy along with TENS, Hot pack and Neurodynamic Stretching. (For 30 seconds, 3 times per session for 3 alternative days a week & duration of 4 weeks).
16242477|NCT05076825|Active Comparator|Static Streching|Participent receive the routine physical therapy treatment that will include TENS, Hot pack and static stretching for 30 seconds and 3 times per session for 3 alternative days a week (duration of 4 weeks).
16242482|NCT05076799|Active Comparator|3 L Polyethylene glycol solution group|The participants were instructed to consume 3000 mL of PEG solution
16242483|NCT05076799|Experimental|100 ml lactulose combined with 1 L PEG group|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
16242484|NCT05076799|Experimental|100 ml lactulose combined with 2 L PEG group|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
16242485|NCT05076799|Experimental|200 ml lactulose group|the participants were instructed to consume 200 ml lactulose
16242486|NCT05076786|Experimental|Chidamide + Etoposide + Cisplatin/Carboplatin|Experimental arm will be treated by chidamide combined with etoposide and cisplatin/carboplatin regimen for 4-6 cycles.
16242487|NCT05076773|Placebo Comparator|Control Group (D)|Patient will receive opioid only for management of their perioperative pain
16242488|NCT05076773|Active Comparator|Paravertebral block Group (A)|Will receive thoracic paravertebral block
16242489|NCT05076773|Active Comparator|Pectoral block Group (B)|Will receive pectoral 1 and 2 block
16242490|NCT05076773|Active Comparator|Erector spinae block Group (C)|Will receive erector spinae block
16242491|NCT05076760|Experimental|MEM-288 Intratumoral Injection|"Patients with accessible, subcutaneous, or superficial lymph node lesion ≥ 1 cm3 that is palpable will receive intratumoral injection of MEM-288 once every 3 week (planned 2 doses, maximum 6 doses) at one of three dose cohort levels.
~Dose cohort level 1 (1 x 10^10 viral particles)
~Dose cohort level 2 (3.3 x 10^10 viral particles)
~Dose cohort level 3 (1 x 10^11 viral particles)"
16242528|NCT05076474|Experimental|R1R2T|R1(Alli 60-mg) R2（Alli 60-mg×2） T(Orlistat 60-mg)
16242529|NCT05076461|Experimental|ondansetron group|Children in ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
16242530|NCT05076461|Experimental|Domperidone group|Children in domperidone group, oral suspension of domperidone was given as 0.5 mg per kg body weight
16242492|NCT05076747|Experimental|Cardiovascular training|Cardiovascular training will comprise 4 weeks of moderate-to-vigorous continuous training followed by 4 weeks of progressive high-intensity interval training (HIIT) performed on recumbent steppers. This intervention will be performed in addition to the conventional standard therapy sessions. We will start with very moderate intensities and prepare participants for higher intensities. Introducing HIIT will allow us to use higher intensities over short bursts of exercise interspersed with periods of active rest. HIIT is more effective than continuous training to increase BDNF and we have shown that even a single bout of HIIT reduces interhemispheric imbalances in excitability and improves motor learning in chronic stroke.
16242493|NCT05076747|Active Comparator|Standard Therapy|Will comprise 8 weeks of the control protocol that includes regular sessions of physiotherapy, occupational therapy, and speech therapy.
16242494|NCT05076734|Other|Analysis of blood samples from healthy pregnant women|A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
16242495|NCT05076721|Experimental|Simulation group|The simulation training group will receive a simulation training of a sepsis case which will see the participants implementing one-hour bundle sepsis with a high-fidelity manikin.
16242496|NCT05076721|Experimental|Conventional group|The conventional training group will receive a case-based discussion of a sepsis case which will see the participants implementing one-hour bundle sepsis.
16242498|NCT05076695|Experimental|TPPF group|Patients will be treated with Trastuzumab, Pyrotinib, Palbociclib plus Fulvestrant(TPPF).
16242499|NCT05076682|Experimental|choline|choline with anti-PD-1 and chemo ( exactly same regimen in previous treatment)
16242500|NCT05076682|Experimental|sodium cromoglicate|sodium cromoglicate with anti-PD-1 and chemo ( exactly same regimen in previous treatment)
16242501|NCT05076669|Active Comparator|Control|The control group will receive the routine care prescribed by the sites and will be provided with ostomy equipment by FSK.
16242502|NCT05076669|Experimental|interventional group|The interventional group will benefit from delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites.
16242503|NCT05076656|Experimental|Probiotics arm|Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)
16242504|NCT05076656|Experimental|FMT arm|Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.
16242505|NCT05076656|Placebo Comparator|Control arm|Individuals who receive a probiotics pill daily of placebo (milk powder)
16242506|NCT05076643||University students|University students in Universiti Tunku Abdul Rahman Sungai Long Campus
16242507|NCT05076617|Experimental|Staccato alprazolam|Participants will receive Staccato alprazolam by inhalation.
16242508|NCT05076604|Active Comparator|Cardioplegia|4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.
16242509|NCT05076604|Active Comparator|Microplegia|Nondiluted microplegia consists of all parts human blood.
16242510|NCT05076591|Experimental|IMM2902|IMM2902 Dose escalation: 0.03, 0.1, 0.25, 0.5, 1.0, 1.5, and 2.0 mg/kg through intravenous administration weekly up to 48 weeks.
16242511|NCT05076578|Experimental|Evaluate the harvesting of micografts in healthy and patients with chronic wounds|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
16242512|NCT05076552|Experimental|Phase 1: Dose Escalation|In Phase 1, participants will receive TACH101 in a 48 hour single-dose lead-in period followed by repeated dosing on a 3-day on/4-day off schedule in each 28 day cycle.
16242513|NCT05076552|Experimental|Phase 1b: Dose Expansion|"In Phase 1b, participants will receive TACH101 at the RP2D identified in Phase 1 on a 3-day on/4-day off schedule. Two cohorts of participants will be enrolled:
~Participants with gastrointestinal cancers
~Participants with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC)."
16242514|NCT05076539|Other|Geospatial|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery)
16242515|NCT05076526|Active Comparator|HA|Patients will receive 2 intra-articular injections of 2mL Synolis VA (20 mg/mL HA and 40 mg/mL sorbitol), with an interval of 1 month between both injections.
16242516|NCT05076526|Experimental|PRP-HA|Patients will receive 2 intra-articular injections of 5mL CM-PRP-HA combination (3mL of autologous PRP, 2mL of 16mg/mL HA), with an interval of 1 month between both injections.
16242517|NCT05076513|Experimental|Arm A: Presumed Newly-Diagnosed glioblastoma|Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with radiation (60 Gy over 6-7 weeks, as per standard of care). Following radiotherapy, eligible study participants may receive niraparib maintenance treatment.
16242518|NCT05076513|Experimental|Arm B: Recurrent Glioma (Grades II-IV)|Participants undergoing resection of a recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss will be treated with niraparib for 4 days prior to a planned surgical resection. Participants who proceed to the Expansion cohort will receive niraparib in 28d cycles after surgery.
16242519|NCT05076500||Cervical cancer|Cervical cancer patients receiving standard of care radiotherapy
16242520|NCT05076500||Rectal cancer|Rectal cancer patients receiving standard of care radiotherapy
16242521|NCT05076500||Head and neck cancer|Head and neck cancer patients receiving standard of care radiotherapy
16242522|NCT05076500||nodal non-Hodgkin lymphoma|Patients with nodal NHL receiving standard of care radiotherapy
16242523|NCT05076500||cutaneous lymphoma|Patients with cutaneous lymphoma receiving standard of care radiotherapy
16242534|NCT05076435|Experimental|Restrictive fluid administration|"No IV fluids unless one of the extenuating circumstances occur;
~In case of severe hypoperfusion or severe circulatory impairment defined by either: 1) Lactate≥4 mmol/L, 2) Hypotension (systolic BP < 90 mmHg), 3) Mottling beyond the kneecap (mottling score >2) OR 4) Urinary output<0.1 mL/kg bodyweight/h (only in the first 4hrs after randomization) then a bolus of 250 ml of IV crystalloid solution may be given followed by re-evaluation
~In case of overt fluid losses (e.g. vomiting, large aspirates,) IV fluid may be given to correct for the loss, but not above the volume lost.
~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:
~Correct dehydration or electrolyte deficiencies Ensure a total fluid input of 1 L in 24hrs
~IV fluids may be given as carrier for medication, but with lowest possible volume"
16242535|NCT05076435|Active Comparator|Usual care (standard care)|"There will be no upper limit for the use of either IV or oral/enteral fluids
~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.
~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid
~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
16242540|NCT05076383|Experimental|Motor relearning program (MRP)|
16242541|NCT05076383|Active Comparator|Conventional physical therapy program (CPT)|
16242542|NCT05076370|Active Comparator|CBD 400mg|CBD 400mg
16242543|NCT05076370|Active Comparator|CBD 800mg|CBD 800mg
16242544|NCT05076370|Active Comparator|CBD 1200mg|CBD 1200mg
16242545|NCT05076357|Experimental|Only diet group|Dietary energy prescription at -30% of Energy requirements (55% carbohydrate; 27% fat; 18% protein) during 8 weeks. Follow up with a registered dietitian.
16242546|NCT05076357|Experimental|Only cold exposure group|No dietary intervention. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 16 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during 90 min.
16242547|NCT05076357|Experimental|Combined diet + cold exposure group|Dietary energy prescription at -30% of Energy requirements (55% carbohydrate; 27% fat; 18% protein). Follow up with a registered dietitian. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 16 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during during 90 min.
16242548|NCT05076344||Group 1: young adults|50 adults aged 18-19 years, with low lifetime noise exposure and audiometric thresholds in the normal range for their age.
16242549|NCT05076344||Group 2: older adults with low noise exposure|50 adults aged 30-50 years, with low lifetime noise exposure and audiometric thresholds in the normal range for their age.
16242550|NCT05076344||Group 3: older adults with high noise exposure|50 adults aged 30-50 years, with high lifetime noise exposure and audiometric thresholds in the normal range for their age.
16242551|NCT05076344||Group 4: older adults with suspected noise-induced hearing loss|50 adults aged 30-50 years, with high lifetime noise exposure and audiometric thresholds above the normal range for their age.
16242552|NCT05076331||Health and Aging Brain Study Cohort|Health and Aging Brain Study participants age 50 and older.
16242553|NCT05076318|Experimental|Alanine-infusion|Alanine infusion taking place over a 3 hour period while monitorering metabolic changes in blood samples before and after dialysis
16242554|NCT05076292|Experimental|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise and placebo will be administered after exercise.
16242555|NCT05076292|Experimental|2*75 ug glucagon before exercise and after exercise|75 ug glucagon will be administered subcutaneously just before exercise and another 75 ug of glucagon will be administered immediately after exercise.
16242556|NCT05076292|Active Comparator|Saline as placebo|Saline as placebo will be administered in the same amount as glucagon before and after exercise.
16242557|NCT05076279|Experimental|Single port or reduced ports|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
16242558|NCT05076266||Women Who Decline TMIST|Women who decline TMIST will be asked to fill out a survey with questions about demographics, income and employment, attitudes and experiences about COVID-19, and emotional well-being.
16242559|NCT05076253|Active Comparator|Ivermectin|Ivermectin 12 mg per day for 5 plus standard care
16242560|NCT05076253|Placebo Comparator|Placebo|Placebo plus standard care
16242561|NCT05076240||Adults with ventilator associated pneumonia in COVID-19 ARDS|Patient hospitalized in intensive care unit for acute respiratory distress related to a Sars-Cov2 infection having contracted ventilator associated pneumonia. The diagnosis was made by culture but also with a FilmArray® multiplex PCR analysis.
16242562|NCT05076227||BNT162b2/BNT162b2 - 3 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 3 weeks as boost vaccination
16242563|NCT05076227||ChAdOx1/ChAdOx1 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and also receiving AstraZeneca as boost vaccination after 12 weeks
16242564|NCT05076227||ChAdOx1/BNT162b2 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and receiving BioNTech as boost vaccination after 12 weeks
16242565|NCT05076227||BNT162b2/BNT162b2 - 6 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 6 weeks as boost vaccination
16263902|NCT04928547||U.S.|
16242568|NCT05076201|Experimental|Patients with completed rehab|The aim of this research is to follow-up a cohort of patients at the end of their detoxification cure (cocaïne).
16242569|NCT05076175|Experimental|Ozanimod High Dose|
16242570|NCT05076175|Experimental|Ozanimod Low Dose|
16242571|NCT05076162||Group 1|Serum 25(OH)D levels <12 ng/ml
16242572|NCT05076162||Group 2|Serum 25(OH)D levels ≥12 ng/ml
16242573|NCT05076149|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
16242574|NCT05076149|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
16242575|NCT05076136|Experimental|Regional treatment|Group A was given regional treatment with baseline treatment protocol
16242576|NCT05076136|Active Comparator|Standard physiotherapy treatment|Group B was given standard physiotherapy treatment with baseline protocol
16242577|NCT05076123|Experimental|Experimental group-1 (M-CIMT group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) in addition to conventional therapy. M-CIMT is shorter versions of CIMT. The original CIMT devotes six or more hours for therapy and constraining of the intact arm for 90% of waking hours per day and over a period of two weeks. Researchers have observed that such a schedule of CIMT is exhaustive and possibly resulting in non-compliance. Because of this reason,s Modified shorter versions of CIMT (mCIMT) have been designed by researchers. Duration of M-CIMT interventions varies from 2 to 10 weeks and the treatment time also varies from as short as 30 minutes to three hours per day in various studies. Nevertheless both CIMT and mCIMT have shown promising success. M-CIMT emphasizes massed practice with the affected upper limb.
16242578|NCT05076123|Experimental|Experimental group-2 (M-CIMT+TES group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) and threshold electrical stimulation (TES) in addition to conventional therapy. TES is based on low-intensity (<100 Hz) and long-duration current and is applied with superficial electrodes. TES provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction. TES can improve motor learning and motor performance by improving connections between sensory-motor cortical association regions in the brain.
16242579|NCT05076123|No Intervention|Control group|participants in this group will be trained with conventional therapy. Conventional therapy consists of strength training, stretching exercises and functional activity training.
16242580|NCT05076110|Active Comparator|Standard of Care Group|Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure
16242581|NCT05076110|Experimental|Non-Opiate Pain Control Group|Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.
16242582|NCT05076097|Experimental|Orelatinib in combination of rituximab and lenalidomide(OLR) Arm|Induction phase of mantle cell L lymphoma: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1
16242584|NCT05076058|Experimental|Treatment group|"Tablet name: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza;
~Dosage: 1g/tablet, 3 tablets/time；
~Frequency: 2 times/day;
~Duration: 6 months"
16242585|NCT05076058|Placebo Comparator|Control group|"Tablet name: Placebo;
~Dosage: 1g/tablet, 3 tablets/time；
~Frequency: 2 times/day;
~Duration: 6 months"
16242586|NCT05076045|Experimental|Personal sound amplification products|Speech perception will be evaluated using personal sound amplification products.
16242587|NCT05076045|No Intervention|Control|Speech perception will be evaluated without using hearing devices.
16242588|NCT05076032|Experimental|OXO-001 200 mg|Two tablets of 100 mg have to be taken once daily in the early morning.
16242589|NCT05076032|Experimental|OXO-001 300 mg|Two tablets of 150 mg have to be taken once daily in the early morning.
16242590|NCT05076032|Placebo Comparator|Placebo|Two tablets have to be taken once daily in the early morning.
16242591|NCT05076019|Experimental|Atorvastatin 80 mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
16242592|NCT05076019|Placebo Comparator|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
16242593|NCT05076006|Placebo Comparator|Placebo|Tablets without active ingredients
16242594|NCT05076006|Experimental|PF-06700841|tablets containing active drug (a combined TYK/JAK inhibitor)
16242595|NCT05075993|Experimental|Regimen A: LVGN3616 + LVGN6051 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
16242596|NCT05075993|Experimental|Regimen B: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
16242597|NCT05075993|Experimental|Regimen C: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
16242598|NCT05075993|Experimental|Regimen D: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
16242599|NCT05075980|Experimental|Arm A (IMPT, cisplatin)|Patients who already underwent surgical resection undergo IMPT for 18 sessions (Monday-Friday) over 24 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care.
16242600|NCT05075980|Experimental|Arm B (IMPT, cisplatin)|Patients undergo surgical resection and then IMPT for 15 sessions (Monday-Friday) over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care.
16242601|NCT05075967|Experimental|Integrated Strategy|"Black MSM living in intervention communities will have access to the HPTN 096 integrated strategy in addition to standard HIV prevention and care services available in their communities.
~The integrated strategy includes a combination of four community-, organizational-, and interpersonal-level components designed to impact individual-level outcomes."
16242602|NCT05075967|Other|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
16242608|NCT05075902|Experimental|Multimorbidity Group (MULTI)|Multimorbidity group is composed of post menopausal women with two or more chronic diseases cardiometabolic (Hypertension, diabetes, dislipidemias, obesity).
16242609|NCT05075902|Experimental|Morbidity Group (MORB)|Morbidity group is composed of postmenopausal women with one or no chronic cardiometabolic disease (Hypertension, diabetes, dislipidemias, obesity)
16242610|NCT05075889|Experimental|Benign Bone patients|Patients with Benign Bone tumors requiring intralesional operative management will be administered immunofluorescent indocyanine green 24 hours prior to surgery, imaging of perfused tissues will be performed at the time of tumor removal.
16242613|NCT05075863|Experimental|Clomiphene Citrate|A total of 39 women were given clomiphene citrate, 100mg from 3 to 7 days of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of >2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
16242614|NCT05075863|Experimental|Letrozole|A total of 39 women were given letrozole, 5mg from day 3 to 7 of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of >2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
16242615|NCT05075837|Experimental|Virus-specific T cells for the treatment of active viral infections following allogeneic HSCT.|Virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus (EBV), Cytomegalovirus (CMV) that developed in young patients (age between 0 and 21 years) after allogeneic hematopoietic cell transplantation (allo-HSCT)
16242616|NCT05075824|Experimental|Crovalimab|Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.
16242617|NCT05075824|Placebo Comparator|Placebo|Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.
16242618|NCT05075811|Experimental|Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC)|Direct injection of vertebral bone marrow derived mesenchymal stem cells at a dose of 100 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
16242619|NCT05075811|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of vertebral allogeneic bone marrow derived mesenchymal stem cells at a dose of 100 million cells into ileal pouch fistula(s).
16242621|NCT05075772|Experimental|BI 765080 - Administration mode 1 (T)|Subcutaneous (SC) injection (Test, T)
16242622|NCT05075772|Experimental|BI 765080 - Administration mode 2 (R)|Intravenous (IV) infusion (Reference, R)
16242660|NCT05075499|Active Comparator|MS Alemtuzumab treatment|MS patients under treatment with Alemtuzumab
16242661|NCT05075486|Experimental|Intervention group|Group who recieve collaborative quality improvement during study period.
16263903|NCT04928547||MRI|
16242629|NCT05075720|Experimental|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with sodium nitrate as an additive.
16242630|NCT05075720|Experimental|Meat without added nitrate|Pork sausages, prepared by a commercial butcher, equivalent in weight to the meat plus nitrate intervention. Nitrate is not an allowed additive in sausages.
16242631|NCT05075707|No Intervention|control group|Participants will receive the descriptive medication by neurologist
16242632|NCT05075707|Experimental|electromagnetic group|Participants will receive the descriptive medication by neurologist in addition to electromagnetic therapy. Electromagnetic therapy will be applied for 20 min/session for three days each week for two months.
16242633|NCT05075707|Experimental|low laser therapy group|Participants will receive the descriptive medication by neurologist in addition to low laser therapy. Low laser therapy will be applied for 20 min/session for three days each week for two months.
16242636|NCT05075681|Experimental|Ruxolitinib combined with Chidamide|All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
16242637|NCT05075668|Active Comparator|OSA support via CPAP face mask|Auto-titrated according to the settings made by sleep physicians, FiO2 0.21
16242638|NCT05075668|Active Comparator|OSA support via HFNC at 20 L/min|High flow nasal insufflation of air (FiO2 0.21) at 20 L/min
16242639|NCT05075668|Active Comparator|OSA support via HFNC at 30 L/min|High flow nasal insufflation of air (FiO2 0.21) at 30 L/min
16242640|NCT05075668|Active Comparator|OSA support via HFNC at 40 L/min|High flow nasal insufflation of air (FiO2 0.21) at 40 L/min
16242641|NCT05075655|Experimental|EBUS-MFB and EBUS-TBNA|patient will have both TBNA and MFB in the same operating time
16242650|NCT05075564|Experimental|Part 1 dose escalation|ES002023 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
16242651|NCT05075564|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
16242654|NCT05075525|Experimental|High Intensity Laser Therapy Group|Patients underwent High Intensity Laser Therapy (HILT) and exercise for 10 sessions
16242655|NCT05075525|Experimental|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Patients will be treated by transcutaneous electrical nerve stimulation(TENS), ultrasound (US) and exercise for 10 sessions
16242656|NCT05075525|Experimental|Ultrasound and Interferential Current Stimulation Group|Patients will be treated with ultrasound (US) ,interferential current stimulation and exercise for 10 sessions
16242657|NCT05075512|Experimental|experimental group|anlotinib combined with fulvestrant
16242658|NCT05075499|Active Comparator|MS no immunomodulatory treatment|MS patients receiving no immunomodulatory treatment
16242659|NCT05075499|Active Comparator|MS Teriflunomide treatment|MS patients under treatment with Teriflunomide
16242662|NCT05075473|Experimental|Segmental Stabilization|Segmental control over the primary stabilizers (TrA, deep multifidus, pelvic floor and diaphram) is maintained. Weight of body is minimized by using drawing in maneuver. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
16242663|NCT05075473|Active Comparator|General lumber stabilization exercises|It includes exercises in closed chain with low velocity as well as low load. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for about 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
16242664|NCT05075460|Experimental|Tucidinostat, Azacitidine combined with CHOP|Tucidinostat, Azacitidine combined with CHOP
16242665|NCT05075460|Active Comparator|CHOP|CHOP
16242666|NCT05075447|Experimental|ADHD group|Child diagnosed with ADHD
16242667|NCT05075447|No Intervention|control group|Children without any diagnosis
16242668|NCT05075447|Experimental|ADHD+ODD/CD group|Child diagnosed with ADHD+ODD/CD
16242669|NCT05075434|Experimental|Intervention Group|This group will receive the protocol prescribed by the health centre (calf stretching exercises, plantar fascia, proprioception exercises, ultrasound, magnet therapy and gait re-education and proprioceptive exercises for 40-45 minutes). In addition, you will receive 15 minutes of the instrumental technique of diacutaneous fibrolysis. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
16242670|NCT05075434|Active Comparator|Control Group|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
16242671|NCT05075421||Group 1 (high marker)|Patients with elevated serum markers
16242672|NCT05075421||Group 2 (normal marker)|Patients with normal value of serum markers
16242673|NCT05075408|Experimental|Nemolizumab 30 mg|
16242674|NCT05075408|Experimental|Nemolizumab 60 mg|
16242675|NCT05075408|Placebo Comparator|Placebo|
16242676|NCT05075395|Experimental|Intervention|The PT/OT provider will assess whether the patient meets eligibility criteria. If the patient is eligible to participate, they will then introduce the study to the patient and their parent or guardian. If the patient is interested in participating, the PI or PIs research assistant (RA) will seek written informed consent. After informed consent is obtained, the PI or RA will begin pretest data collection. Then, the PT/OT provider will begin the therapy session with Paro. The PI or RA will remain in the room during therapy session to record field notes. When the therapy session is complete, the PI or RA will begin posttest data collection. The patient will remain in the study for up to 7 PT/OT sessions or until they are discharged from the PICU. The PT/OT providers will coordinate all subsequent therapy sessions with the PI/RA while the patient remains on the study protocol.
16242677|NCT05075382||Pilot group|Group of 40 patients that will act as observationnal group for this study
16242678|NCT05075369|No Intervention|baseline Intraocular pressure|The participants will have their intraocular pressure measured with Goldmann Application Tonometry immediately prior to beginning the water drinking test.
16242679|NCT05075369|Active Comparator|Change in Intraocular pressure with Water drinking test|The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
16242680|NCT05075356|Experimental|Single participant arm|"The iToBoS intervention is a total body imaging device, to image the total skin surface in order to detect and monitor for signs of skin cancer.
~The imaging process involves laying down on a bed that has a framework of cameras arched over it. The imaging process takes less then 10 minutes, and requires the participant to lay in two different positions (face-up and face-down).
~The study visit also includes individual dermoscopic images taken of certain moles on the skin. This is done in combination with a clinical skin examination. Participants are given the option of providing a saliva sample for genetic research. Participants are then asked to complete a series of questionnaires.
~There a three visits in total (month 0, 6 and 12), in which these procedures are repeated (except for saliva sample)."
16242681|NCT05075343|Experimental|Custom foot orthoses (CFO)|Participants with a confirmed diagnosis of PsA and foot pain received and wore custom foot orthoses (CFO).
16242682|NCT05075330|Experimental|Intervention|Participants who live in the Orange Mound community of Memphis. Billboards targeting stigma reduction were posted in the community for one month.
16242683|NCT05075330|No Intervention|Control|Participants who live in the Frayser community of Memphis. No billboards (intervention) were placed here.
16242684|NCT05075317|Active Comparator|Standard cardiac rehabilitation|The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
16242685|NCT05075317|Experimental|Standard cardiac rehabilitation + TRE|Participants in this group will receive the same standard assessment and individualized recommendations as the comparator group, but will also be counseled to restrict their eating to between 11 am and 7 pm during the program starting the evening of the consultation. They will also be advised to perform their home-based exercise sessions during the fasting period in the morning.
16242686|NCT05075304|Experimental|A low dose of BDB-001|6 patients administered low dose of BDB-001 injection
16242687|NCT05075304|Experimental|A intermediate dose of BDB-001|6 patients administered intermediate dose of BDB-001 injection
16242688|NCT05075304|Experimental|A high dose of BDB-001|3-6 patients administered high dose of BDB-001 injection
16327521|NCT04486976|Experimental|Glaucoma|
16242691|NCT05075265||Methadone Group|adult patients undergoing cardiac surgery with extracorporeal circulation
16242695|NCT05075200|Experimental|Group I|Participants with glomerular filtration rate (GFR) < 60 mL/min/1.73m2 (and dialysis)
16242696|NCT05075200|Experimental|Group II|Participants with GFR ≥ 60 mL/min/1.73m2
16242697|NCT05075187||Participants diagnosed with Frontotemporal Dementia|Participants diagnosed with Frontotemporal Dementia
16242698|NCT05075161|Experimental|Pirfenidone|Patients randomized to Pirfernidone Group will receive tables of 267 mg
16242699|NCT05075161|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive 5 ml of Water
16242700|NCT05075148||Aneurysmal bone cyst|Patient aging from 0 to 30 years with diagnosis of aneurysmal bone cyst treated by percutaneous alcolisation or endovascular embolization.
16242701|NCT05075135|Experimental|3D-splint group|Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
16242702|NCT05075135|Active Comparator|Plaster cast group|"The control intervention is the same as the study intervention, but the participants wear the gold-standard plaster cast instead of the newly designed Swibrace 3D-splint."
16242703|NCT05075122|Experimental|Vaccination arm|Pembrolizumab flat dose iv every 3 weeks + UV1 vaccination (UV1 plus GM-CSF/Sargramostim as adjuvant per vaccination)
16242704|NCT05075122|Other|Calibration arm|Pembrolizumab flat dose iv every 3 weeks
16242705|NCT05075109|Experimental|High Frequency TENS|high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
16242706|NCT05075109|Experimental|Low Frequency TENS|low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks with task related training.
16242707|NCT05075109|Active Comparator|Task Related Training|postural control, shoulder mobilization, weight bearing exercises, functional activities that will comprise of simple tasks to more advanced movement patterns
16242708|NCT05075096||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
16242709|NCT05075096||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
16242710|NCT05075096||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
16242715|NCT05075031||300 Newborn feeding on Breast Milk or Artificial Milk Formula rom birth to about 2 months of age|The electronic patient record of 300 Newborn feeding on Breast Milk or Artificial Milk Formula from birth to about 2 months of age would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
16242716|NCT05075031||300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year|The electronic patient record of 300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
16327522|NCT04486976|Experimental|Cataract|
16242717|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year|The electronic patient record of 300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
16242718|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 5 year up to 15 year|The electronic patient record of 300 child feeding on Artificial Milk Formula or any source of DHA from 5 year up to 15 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
16242719|NCT05075031||Control Group|"The electronic patient record of 150 infant and child patients who feed on only cow's milk which does not provide a rich source of DHA and did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the cohorts that feed on Breast Milk or Artificial Milk Formula
~The electronic patient record of 150 adult patients from 15 years to 25 years who did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021"
16242720|NCT05075018||Healthcare Workers with COVID-19 Infection|Healthcare workers who have been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
16242721|NCT05075018||Healthcare Workers without COVID-19 Infection|Healthcare workers who have not been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
16242722|NCT05075005|Active Comparator|Treatment Cohort|Treatment Cohort: Will utilize a minimalist shoe (Vibram® Fivefingers) and follow the training protocol described below for training on natural terrain.
16242723|NCT05075005|Experimental|Control Cohort|Control Cohort: Will utilize the same minimalist shoe and follow the same training schedule as the treatment group, with the modification of training on hardscapes.
16242724|NCT05074992|Experimental|Ipilimumab|3mg/kg Ipilimumab IV infusion (day 1) given as a 21 day cycle for 2 cycles.
16242725|NCT05074979|Other|control group|While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
16242726|NCT05074979|Experimental|home exercise program group|this group will implement COVID 19 home exercise program.
16242727|NCT05074979|Experimental|telerehabilitation group|this group will implement COVID 19 telerehabilitation program.
16242728|NCT05074966|Experimental|mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;
~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
16242729|NCT05074966|Active Comparator|FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
~Cetuximab：500 mg/m2, IV, d1, q2w Oxaliplatin： 85 mg/m2, IV d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w;
~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
16242732|NCT05074940|Experimental|Amivantamab|Amivantamab weekly for the first cycle and biweekly thereafter.
16242733|NCT05074927|Other|Cohort|All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
16242734|NCT05074914|Experimental|Adenocarcinoma of the oesophagus|curative oesophagectomy
16242735|NCT05074914|No Intervention|Barrett's oesophagus|Weight stable patient under survelliance with Barrett's oespophagus
16242736|NCT05074901|Experimental|digital behavioral intervention|Digital behavioral interventions to improve mood and decrease fatigue, sleep complaints and substance usage.
16242737|NCT05074901|No Intervention|e-diaries|Ecological momentary assessment based on e-diaries on a weekly basis to evaluate sleep/wake schedules, physical activity, substance usage and nutrition.
16242740|NCT05074875||Cohort 1|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.
~Cohort 1 subjects will undergo Visit 0 after informed consent is obtained. Eligible subjects will return for follow-up at Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks"
16242741|NCT05074875||Cohort 2|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.
~Cohort 2 subjects will undergo Visit 1, within 4 (+/- 2) weeks of hospital discharge or outpatient infection, after informed consent is obtained. Eligible subjects will return for follow-up Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks."
16242742|NCT05074875||Cohort 3a|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.
~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.
~Subjects enrolled within ≤ 12 weeks of hospital discharge or outpatient COVID- 19 infection will undergo their first study visit at Visit 1 (Weeks 6-12)."
16242743|NCT05074875||Cohort 3b|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.
~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.
~Subjects enrolled ≥ 12 weeks from hospital discharge or outpatient COVID- 19 infection will undergo their first visit within 4 weeks before week 24. Subjects that are enrolled into Cohort 3 will be followed until Week 72."
16242744|NCT05074862|Experimental|Ketone monoester (3-OHB)|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 200 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 150 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.
16242745|NCT05074862|Placebo Comparator|Placebo Treatment|Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.
16242746|NCT05074849|Experimental|Smart insoles + Education|Participants in this group will receive a 90-minute group session education on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch)
16242747|NCT05074849|No Intervention|Smart Insoles|Participants in this group will not receive a 90-minute group session education on foot self-care, but will receive foot care supplies, insoles and smart watch
16242748|NCT05074849|No Intervention|Usual Care|Participants will not receive foot self-care education or the use of insoles and smart watch.
16242749|NCT05074836|Experimental|Formula Milk|"Formula milk designed for young children aged over 3 years;
~Dosage: 195 ml/time;
~Frequence: 2 times /day;
~Duration: 12 months"
16242750|NCT05074836|Active Comparator|Regular milk|"Regular milk (pure milk);
~Dosage: 195 ml/time;
~Frequence: 2 times /day;
~Duration: 12 months"
16242751|NCT05074836|Other|Control foods|"Grain foods: e.g., bread;
~Dosage: 20-40 g/time;
~Frequence: 2 times /day;
~Duration: 12 months"
16242758|NCT05074797||covid not diabetic with AKI|AKI in pt with covid_19 not diabetic
16242759|NCT05074797||AKI in covid_19 in diabetic|AKI in covid_19 in diabetic pt
16242760|NCT05074797||covid_19 in diabetic|covid_19 in diabetic without AKI
16242761|NCT05074784|Active Comparator|Control Group|Tongue depressor exercise protocol for tongue strengthening for control group. Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
16242762|NCT05074784|Experimental|Intervention Group|IOPI exercise protocol for tongue strengthening for intervention group. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
16242767|NCT05074693|Experimental|EASE App|800 participants (i.e. 200 White, 200 Black/African American, 200 Hispanic/Latinx, and 200 Native American/Indigenous individuals) with elevated anxiety sensitivity will be enrolled and randomly assigned to either 1) the EASE app developed by our team targeting sensitivity to interoceptive stress, or 2) a series of educational videos covering topics such as meditation, mindfulness, and stress reduction.
16242768|NCT05074693|Other|Educational Videos|800 participants (i.e. 200 White, 200 Black/African American, 200 Hispanic/Latinx, and 200 Native American/Indigenous individuals) with elevated anxiety sensitivity will be enrolled and randomly assigned to either 1) the EASE app developed by our team targeting sensitivity to interoceptive stress, or 2) a series of educational videos covering topics such as meditation, mindfulness, and stress reduction.
16242770|NCT05074641|Experimental|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
16242771|NCT05074641|Active Comparator|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
16242772|NCT05074628|Experimental|Nitrofurantion|is the drug of choice for the treatment of infections caused by multidrug resistant pathogens.
16242773|NCT05074628|Active Comparator|Calcium Hydroxide|Most commonly used intracanal medicaments . Antimicrobial activity of calcium hydroxide is related to the release of hydroxyl ions in an aqueous environment.
16242774|NCT05074615|Experimental|Cranio-Cervical Flexion Training Group|"Participants of this group will receive conventional training along with cranio-cervical flexion training and home plan.
~Cranio-cervical flexion training will be given with the help of pressure biofeedback unit. the cuff will be inflated at a specific pressure level and patient will be asked to maintain that pressure and gradually increase it."
16242775|NCT05074615|Active Comparator|Conventional Therapy Group|Participants of this group will receive only conventional therapy and home plan will be given which includes; hot pack, TENS, neck isometrics and passive stretching of neck musculature. Home plan will include self-stretches and neck isometrics.
16242776|NCT05074602|Experimental|SHR8008|
16242777|NCT05074602|Active Comparator|Fluconazole|
16242778|NCT05074589|Experimental|Treatment group A|Irinotecan liposome plus 5-fluorouracil, Leucovorin
16242779|NCT05074589|Active Comparator|Treatment group B|Placebo plus 5-fluorouracil, Leucovorin
16242780|NCT05074576|Experimental|Mulligan group|In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied.
16242781|NCT05074576|Other|Control group|Electroterapy agents are applied in the contro group
16242782|NCT05074563|Active Comparator|Online REsOluTioN training|The active comparator arm will receive access to online REsOluTioN training to enhance resilience.
16242783|NCT05074563|Other|Control|The control arm will have no access to the online training.
16242784|NCT05074550|Experimental|PPMX-T003|This drug should be administered within 48 hours after the phlebotomy. In addition, as a dose escalation design, 4 doses of 0.25 mg/kg, 0.4 mg/kg, 0.64 mg/kg, and 1 mg/kg are administered to the same subject, when the next phlebotomy required during observation period after the 1st administration.
16242785|NCT05074537||MRI Participants|
16242786|NCT05074537||PET/CT Participants|
16242787|NCT05074537||CT Participants|
16242788|NCT05074524|Experimental|rTMS group|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
16242789|NCT05074524|Sham Comparator|Placebo Group|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
16242790|NCT05074511||healthy|Children in this group will be healthy category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 5th to 85th percentiles
16242791|NCT05074511||overweight|Children in this group will be overweight category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 85th to 95th percentiles .
16242792|NCT05074511||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
16242793|NCT05074511||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
16242794|NCT05074498|Experimental|Part 1: TB006|Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.
16242795|NCT05074498|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive 5 once-weekly doses of matching placebo.
16242796|NCT05074498|Experimental|Part 2: TB006|Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
16242797|NCT05074498|Placebo Comparator|Part 2: Placebo|Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
16242798|NCT05074485|Experimental|Placebo plus nociceptive pain challenge, then anakinra plus nociceptive pain challenge|Pharmacological challenge (with placebo) plus nociceptive pain challenge, then pharmacological challenge (with anakinra) plus nociceptive pain challenge
16242799|NCT05074485|Experimental|Anakinra plus nociceptive pain challenge, then placebo plus nociceptive pain challenge|Pharmacological challenge (with anakinra) plus nociceptive pain challenge, then pharmacological challenge (with placebo) plus nociceptive pain challenge
16242800|NCT05074472|Experimental|Active Treatment: ZB131|During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.
16242803|NCT05074446|Experimental|Stereotype Threat Group|Stereotype threat manipulation will be performed on the participants in the experimental group just before they are taken into the testing room.
16242804|NCT05074446|No Intervention|Control Group|The other group (Control Group) will not be given any prior information.
16242805|NCT05074433|Experimental|casirivimab+imdevimab Initial + Q4W|Initial subcutaneous (SC) dose, then SC dose every 4 weeks (Q4W)
16242806|NCT05074433|Experimental|casirivimab+imdevimab Q4W|SC dose Q4W
16242807|NCT05074433|Experimental|casirivimab+imdevimab Q12W|SC dose every 12 weeks (Q12W)
16242808|NCT05074433|Placebo Comparator|Placebo|SC dose Q4W
16244070|NCT05065528|Experimental|Intervention|
16242810|NCT05074394|Experimental|COVI-DROPS|40 mg of COVI-DROPS administered intranasally
16242811|NCT05074394|Placebo Comparator|Placebo|2 mL placebo administered intranasally
16242812|NCT05074381|Experimental|Dry needling|A single dry needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into skin surface, fascia,into the muscle tissue at the MTrP location of the M. Obliquus Capitis Inferior, and will move the needle up and down to elicit local twitch responses.In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
16242813|NCT05074381|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
16242814|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart|Astra-Zeneca vaccine 0.5 mL/dose
16242815|NCT05074368|Active Comparator|mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
16242816|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
16242817|NCT05074368|Active Comparator|The mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose
16242818|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
16242819|NCT05074355|Experimental|Azacitidine and Venetoclax|"A treatment cycle is 28 days long.
~Azacitidine will be given by injection under the skin, once a day, for the first 6 days of every cycle.
~Venetoclax will be given orally, once a day, as follows at the discretion of their study doctors:
~Cycle 1:
~Day 1 - 100 mg
~Day 2 - 200 mg
~Days 3 to 28 - 400 mg
~Cycle 2:
~Participants with a response to the study drugs will continue taking 400 mg from Days 1 to 21, with no study drug from Days 22 to 28 during Cycle 2.
~Participants who have not yet responded to the study drugs will continue taking 400 mg from Days 1 to 28 during Cycle 2.
~Cycle 3 and subsequent cycles:
~Participants with a response to the study drugs will continue to take 400 mg from Days 1 to 21, with no study drug from Days 22 to 28.
~Participants whose disease has not worsened will continue taking 400 mg from Days 1 to 28.
~Participants have not responded to the study drugs will be withdrawn from the study."
16242820|NCT05074329|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
16242821|NCT05074329|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
16242822|NCT05074303|Experimental|Beta-glucan|500 mg/day beta-glucan
16242823|NCT05074303|Placebo Comparator|Placebo|500 mg/day cellulose
16242824|NCT05074290|Experimental|Epidiferphane + taxane chemotherapy|
16242831|NCT05074238|Experimental|Sunscreen Application|The study participant will be instructed to start applying the sunscreen provided to them to the randomly assigned half of the wound (A or B).
16242832|NCT05074238|Experimental|No Suncreen Application|The study participant will be instructed to not apply the sunscreen provided to them to the randomly assigned half of the wound (A or B).
16242833|NCT05074225|Experimental|ED&C|The ED&C arm will receive the standard ED&C care.
16242834|NCT05074225|Experimental|Excision|The excision arm will undergo standard excision with repair by complex linear closure.
16242835|NCT05074212|Experimental|Complex Linear Closure|The study participant will receive two layers of sutures to close the wound.
16242836|NCT05074212|Experimental|Second Intention Healing|The study participant will not have any sutures placed.
16242837|NCT05074199|Active Comparator|W-plasty|"The cosmetic appearance of scars closed in a in a zig-zag  fashion (W-plasty)."
16242838|NCT05074199|Active Comparator|Linear closure|"The cosmetic appearance of scars closed in a standard straight line fashion (linear closure)."
16242839|NCT05074186|Experimental|neurological thrombectomy device|Revascularization device is an investigational device.
16244668|NCT05061446|Experimental|Etrasimod Dose 2|
16244669|NCT05061446|Placebo Comparator|Placebo|
16242841|NCT05074160||OLP Registry primary analysis population|Adult primary liver transplant recipients who are transplanted with an OCS perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
16242842|NCT05074147|Experimental|3 weeks antibiotherapy|Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.
16242843|NCT05074147|Experimental|6 weeks antibiotherapy|Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.
16242844|NCT05074134|Experimental|[14C]-TNP-2092|
16242847|NCT05074108|Experimental|Pilot study|Adapt and pilot a nutrition-based intervention. The program will take a holistic approach to educate participants about basic nutrition and cooking skills, sleep, and mindfulness strategies to enhance mental health.
16242848|NCT05074095||1|Patients with urogenital injuries
16242849|NCT05074095||2|Patients without urogenital injuries
16242850|NCT05074082||Flap reconstruction|Patients who had a flap formation as part of a multi-visceral extended resection for advanced pelvic (rectal, urological, gynaecological, sarcomatous origin) malignancy
16242853|NCT05074043||covid19|covid 19 proven by clinical, PCR. not associated with mucor
16242854|NCT05074043||covid19 associated with mucor|covid19 associated with mucor proven by clinical, histopathological
16242855|NCT05074030|Active Comparator|PNF|Participants in the PNF condition will receive normative feedback only on their alcohol use.
16242856|NCT05074030|Experimental|PFIcope+EMI|The 6-week PFIcope+EMI includes: 1) an in-person personalized feedback session to present feedback on problems with drinking to cope, discuss the individual's use of alcohol to cope, and generate coping skills messages to be used in the EMI intervention; 2) EMA to monitor affect, intention to drink, coping skills usage, alcohol use, drinking to cope post-discharge; 3) tailored text messages (EMI) based on EMA (individualized coping skills messages when NA and intention to drink are reported).
16242857|NCT05074004|No Intervention|control group|"No intervention was applied to the control group in this process.
~be receiving treatment in Clinic Day Hospital
~Volunteering to participate in research"
16242858|NCT05074004|Experimental|Psychoeducation|"be receiving treatment in Clinic Day Hospital
~Volunteering to participate in research"
16242859|NCT05073991||Lung surgery|Patients underwent lung surgery.
16242860|NCT05073991||Open aortic suregry|Patients underwent open aortic surgery.
16242861|NCT05073991||Thoracic endovascular aortic repair (TEVAR)|Patients underwent TEVAR.
16242862|NCT05073991||Endovascular aneurysm repair (EVAR)|Patients underwent EVAR.
16242863|NCT05073978||Case group|Case group with certain pregnancy outcome, e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
16242864|NCT05073978||Control group|Control group without certain pregnancy outcome,e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
16242865|NCT05073965|Experimental|Intervention Group|Subject receive a 1000IU vitamin D supplement dose daily for 6 months
16242866|NCT05073965|Placebo Comparator|Placebo group|Subject receive a placebo daily for 6 months
16242867|NCT05073952|Active Comparator|Connective tissue graft|patient in this group will be treated with a flap and a connective tissue graft at the moment of implant placement.
16242868|NCT05073952|Active Comparator|Flapess|patient in this group will be treated with a flapless approach at the moment of implant placement.
16242871|NCT05073926||Persons with latent tuberculosis treated with 4 months rifampicin|Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months
16242872|NCT05073926||Persons with latent tuberculosis treated with 6-9 months isoniazide|Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6-9 months
16242873|NCT05073913|Other|Living kidney donors|complete vascular exploration before and one year after nephrectomy
16242874|NCT05073900|Experimental|Rhomboid intercostal block|Ultrasound guided rhomboid intercostal block
16242875|NCT05073900|Active Comparator|Erector spinae plane block|Ultrasound guided erector spinae plane block
16242876|NCT05073887|Experimental|3 nerve|3 genicular nerve blockade and radio frequency ablation
16242877|NCT05073887|Active Comparator|5 nerve|3 genicular nerve blockade and radio frequency ablation 2 genicular nerve blockade and pulse radio frequency
16242878|NCT05073874|Other|Functional Near-Infrared Spectroscopy (fNIRS)|"Subjects will be guided to walk at a normal pace while maintaining the required attentional focus:
~no instructions about the attentional focus
~internal focus on their feet movements,
~external focus on two lines drawn on the floor,
~divided attention (walking while performing an arithmetic task).
~A fNIRS system will be used for the prefrontal cortex activation evaluation and connected soles for gait analyses."
16242879|NCT05073861|Experimental|App-based STEM online learning group|Participants in the experimental group will receive a 2.5-month intervention with the blended STEM learning app.
16242880|NCT05073861|Active Comparator|E-book learning group|The control group receive e-book chapters about STEM for learning for the same period of 2.5-month as the experimental group.
16243058|NCT05072769|Experimental|Experimental group|After the fetus and placenta are born, feeding 100 gr (5-6 pieces) dates to the experimental group
16352746|NCT04309175|Experimental|Slow-Fast|
16242882|NCT05073835|Experimental|Intervention|Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.
16242883|NCT05073835|Placebo Comparator|Control|Placebo administration, once weekly, subcutaneous injection.
16242886|NCT05073809||Group 1|Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
16242887|NCT05073809||Group 2|Proven or suspected oral cavity cancer, amenable to intraoral examination
16242888|NCT05073796|Experimental|Interventional arm|Participants will receive the intervention as descibed in the respective section.
16242889|NCT05073783||Cohort A|Pompe disease patients receiving Myozyme® (alglucosidase alfa) in a home-care setting.
16242890|NCT05073783||Cohort B|MPS I patients receiving Aldurazyme® (laronidase) in a home-care setting.
16242891|NCT05073770|Experimental|N64|"Based on the penis girth measurements, eligible participants will be assigned to two groups:
~Group 1: The couples who will test the 64 mm plain condom (n=25).
~The test condom has the following specifications throughout the study:
~The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm."
16242892|NCT05073770|Experimental|N69|"Based on the penis girth measurements, eligible participants will be assigned to two groups:
~Group 2: The couples who will test the 69 mm plain condom (n=25).
~The test condom has the following specifications throughout the study:
~The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
16242893|NCT05073757||Orthognatic surgery|Orthognathic surgery patients, adults or minors whose bone maturity is sufficient according to the investigator.
16242894|NCT05073744|Experimental|Tumor ablation using nalbuphine for pain control and anaesthesia|Nalbuphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
16242895|NCT05073744|Active Comparator|Tumor ablation using morphine for pain control and anaesthesia|Morphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
16242896|NCT05073731|Experimental|Synchronized Telerehabilitation|Physical activity training aiming to increase hand/arm function and fine motor function will be applied via videoconference for 8 weeks, 2 days a week, in 45-60 minute sessions.
16242897|NCT05073731|Active Comparator|Asynchronous Telerehabilitation|Exercise videos and exercise tracking form will be sent.
16242898|NCT05073718|Experimental|LDASA + prophylactic doses of LMWH (n=199)|
16242899|NCT05073718|Placebo Comparator|Placebo + prophylactic doses of LMWH (n=199)|
16242902|NCT05073679|Experimental|Intervention|Oral naltrexone, to start as 25mg for three days then 50mg a day thereafter for up to nine weeks or completion of higher level of care, whichever haver happens first. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler
16242903|NCT05073679|Placebo Comparator|Control|Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for nine weeks or until completion of higher level of care, whichever happens first
16242904|NCT05073666||pulmonary embolism|Patients with a recent pulmonary embolism event will be followed for 6 months and will benefit of routine tests (Lung scintigraphy, venous echo doppler, d- dimers measurement) in order to determine chronic thrombo-embolic disease prevalence and its risk factors.
16242906|NCT05073640|Active Comparator|Pentoxifylline|Pentoxifylline (Oxopurin 400 mg)
16242907|NCT05073640|Placebo Comparator|Placebo|Placebo (105 mg Lactose and 510 mg Dextrose)
16242910|NCT05073614|Other|patients with chronic gastritis|patients with symptomatic chronic gastritis will undergo upper endoscopy, gastric biopsies will be obtained to establish giagnosis of chronic gastritis, detection of h.pylori and assessment of heparanase expression.
16242915|NCT05073575|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied to exposed dental roots surfaces, after scaling and root planing therapy
16242916|NCT05073575|Active Comparator|No-hyaluronic acid Group|Only scaling and root planning will be performed on the exposed dental roots surfaces
16242917|NCT05073562|Experimental|Nutrition+ Intervention|This group will receive a structured nutrition education package provided by Community Health Assistants (CHAs) based on a handbook on nutrition education developed by UNICEF with collaboration from the Liberia Ministry of Health. The structured nutrition education package will focus on four key areas: causes and prevention of anemia, healthy eating and food choices, hand washing, and physical exercise. Participants in the intervention group will also receive IFA supplementation on a weekly basis for the duration of the study, and a one-time oral deworming treatment (mebendazole), which will be administered once at the beginning of the study.
16242918|NCT05073562|Active Comparator|Control group - standard services only|This group will receive only the current package of basic nutrition services provided at the health facility and at community level by health workers and CHAs, respectively.
16242922|NCT05073523|Other|Meal A|Diet: meal proportion 1
16242923|NCT05073523|Other|Meal B|Diet: meal proportion 2
16242924|NCT05073523|Other|Meal C|Diet: meal proportion 3
16242928|NCT05073484|Experimental|10 mg of BAT6021|BAT6021 100mg/vial，10mg Ⅳ infusions
16242929|NCT05073484|Experimental|30 mg of BAT6021|BAT6021 100mg/vial，30mg Ⅳ infusions
16242930|NCT05073484|Experimental|100 mg of BAT6021|BAT6021 100mg/vial，100mg Ⅳ infusions
16242931|NCT05073484|Experimental|300 mg of BAT6021|BAT6021 100mg/vial，300mg Ⅳ infusions
16242932|NCT05073484|Experimental|600 mg of BAT6021|BAT6021 100mg/vial，600mg Ⅳ infusions
16242933|NCT05073484|Experimental|900 mg of BAT6021|BAT6021 100mg/vial，900mg Ⅳ infusions
16242934|NCT05073484|Experimental|100mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions
16242935|NCT05073484|Experimental|300mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions
16242936|NCT05073484|Experimental|600mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions
16242937|NCT05073471|Experimental|PSE Only|Participants will exercise their hands, arms, shoulders, and torso with musical cues provided by neurologic music therapist. A simple gross/fine movements and emotional level will be assessed before and after each session. During the session, participants will be measured their brainwaves using electroencephalography (EEG) to understand their neurophysiological responses. Participant's motion will be also captured to acquire kinematic quantities.
16242938|NCT05073471|Experimental|PSE+tDCS|Participants in this group will proceed with the same procedure as PSE only group, but tDCS modulation will be additionally provided.
16242939|NCT05073458|Experimental|Group A: Parsaclisib|Participants will receive parsaclisib for 24 weeks (double-blind period). Participant who completed the double-blind period and tolerating the study treatment upon investigator's opinion will continue into open-label extension period for an additional 24 weeks. starting from Day 1 for 24 weeks.
16242940|NCT05073458|Placebo Comparator|Group B: Placebo followed by Parsaclisib|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive parsaclisib in the 24 week open-label extension period.
16242942|NCT05073419|Active Comparator|Control|Post-AMI patients in this arm will receive standard of care
16242943|NCT05073419|Experimental|ICM|Post-AMI patients in this arm will receive standard of care and an ICM
16242944|NCT05073406|Experimental|Hypobaric normoxia|Altitude exposure in hypobaric normoxic condition
16242945|NCT05073406|Sham Comparator|Hypobaric hypoxia|Altitude exposure in hypobaric hypoxic condition
16242946|NCT05073393|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
16242947|NCT05073393|Placebo Comparator|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
16242948|NCT05073380|Experimental|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the YMCA early childhood education centres (ECECs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
16243056|NCT05072782|Other|Status quo arm|"If the patient received no prophylactic therapy after resection, no treatments will be started.
~If the patient received a prophylactic therapy after resection, the same will be continued at the same dose."
16245054|NCT05058716||COVID-19 negative patients|
16242949|NCT05073380|Sham Comparator|Intervention|"The PRO-ECO intervention to increase the quality of outdoor play involves four primary components:
~Modifying YMCA GV's outdoor play policies The ECEC policy on outdoor play requirements and procedures will be modified in conjunction with YMCA management..
~ECE training ECEs will undergo training delivered by YMCA of Southwestern Ontario that includes the importance of outdoor risky play, along with other online training tools along with resources on supporting outdoor play. There will also be ongoing as-needed supportive training and mentorship provided by YMCA senior managers and research team, along with peer mentorship and support.
~ECEC outdoor space modification This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.
~Parent engagement We will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
16242954|NCT05073341|Experimental|experimental and control group and intervention is given in the experimental group|Nurse-led family intervention is given in the experimental group having three components i.e infarmation about the patient condition , guidance, and emotional support
16242955|NCT05073341|Other|control group|No intervention will be given in the control group
16242961|NCT05073302|Experimental|Treatment Group|Implantation of the Device-Less sentinel units. Ultrasound Monitoring. Islet Transplantation. Explantation of Device-Less Sentinels. Standard of Care. Concomitant Care. Post Transplant Testing and Visits. Participant Retention (nine month follow up assessment).
16242962|NCT05073289|Experimental|SAPC|SAPC is a acronmy that defines Sandplay activity in psychiatry clinic
16242963|NCT05073289|Active Comparator|Control Group|
16242964|NCT05073276|Active Comparator|Non-weightbearing for the first six weeks after surgery|Not weightbearing after surgery
16242965|NCT05073276|Experimental|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
16242966|NCT05073263|Active Comparator|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
16242967|NCT05073263|Experimental|Full weight -bearing for the first six weeks after surgery|If the patient is randomized to the full weightbearing group, the patient will be instructed about acceptable exercises and activities.
16242968|NCT05073250|Experimental|Experimental arm|Enrolled patients will be administered IBI376 plus rituximab, induction therapy for 6 cycles (28-day cycle). Patients assessed as partial response (PR) after 6 cycles of induction therapy will receive another 6 cycles of IBI376 combined with rituximab induction therapy.
16242969|NCT05073237|Experimental|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. Recommended and only FDA approved dosage is one CE/BZA tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications.
16242970|NCT05073237|Placebo Comparator|Placebo|Participants assigned to placebo will receive a daily tablet. To assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication. Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about CE/BZA and its potential side effects and contraindications, again to maintain the blind.
16243059|NCT05072769|No Intervention|Control group|The group that was not attempted any intervention in the postpartum period
16245251|NCT05057273|Active Comparator|adalimumab|
16242973|NCT05073211|Experimental|SJW-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
16242974|NCT05073211|Active Comparator|IAA-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
16242975|NCT05073198|Experimental|Experiment|Giving educational brochures about testicular cancer and Testicular Self-Examination to the students in the experimental group
16242976|NCT05073198|No Intervention|Control|No intervention
16242977|NCT05073185||High Obesity Risk|Half of the children (35 boys and 35 girls) will be healthy weight, but at high-risk for obesity (defined as having both biological mother with a body mass index ≥ 30 kg/m2 and father with a body mass index ≥ 25 kg/m2.
16242978|NCT05073185||Low Obesity Risk|Half (35 boys and 35 girls) will be healthy weight, but at low-risk for obesity (defined as having both biological mother and father with a body mass index < 25 kg/m2).
16242979|NCT05073172|Experimental|Arm I (StrataXRT)|Patients apply StrataXRT topically to the affected area once or twice daily starting from the fist dose of radiation therapy until dermatitis has returned to grade =< 1.
16242980|NCT05073172|Active Comparator|Arm II (standard of care)|Patients receive standard of care including calendula and/or aquaphor applied 2-6 times daily plus hydrogel or silver silvadene or topical corticosteroids applied twice daily starting from the fist dose of radiation therapy until dermatitis has returned to grade =< 1.
16242981|NCT05073159|Active Comparator|0 degree Head-of-Bed (HOB) position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
16242982|NCT05073159|Active Comparator|Elevated (30-degree or more) head-of-bed|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
16242983|NCT05073133|Experimental|OAV101|A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes
16242984|NCT05073120||Piqray Prescriber's/HCP receiving the guide for hyperglycemia|HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).
16242985|NCT05073107|Experimental|Test: With Dental Monitoring|"Dental Monitoring (DM) Kit + 2-month DM subscription
~Required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:
~Day 0 (To be taken at the clinic)
~Day 7 (To be taken in the evening after brushing teeth)
~Day 14 (To be taken in the evening after brushing teeth)
~Day 21(To be taken in the evening after brushing teeth)
~Day 28 (To be taken before study Visit 2)
~There is a window period of +1 day for the intra-oral videos."
16242986|NCT05073107|No Intervention|Control: Without Dental Monitoring|No DM Kit
16242987|NCT05073094|Experimental|Esmolol|1 mg/kg (max. 100 mg) as a bolus before aortic cross-clamping and 2 mg/kg (max. 200 mg) in the cardioplegia solution
16242988|NCT05073094|Placebo Comparator|Placebo|Equivalent volume of saline as a bolus before aortic cross-clamping and in the cardioplegic solution
16242989|NCT05073081|Experimental|Prehabilitation|The 8-week prehabilitation program will be delivered online using synchronous and asynchronous sessions delivered by either a physiotherapist, chiropractor or kinesiologist. There will be 4 individual exercises sessions delivered synchronously using Zoom or Physitrack in which motivational interviewing and graded activity exercises will be conducted. Participants will also be asked to exercise at least 3 times a week using the asynchronous exercise videos. The exercises will be individualized on participants functional ability and personal goals identified at baseline, with a focus on muscle strengthening, stretching, improving spinal flexibility and stability. There will be a booster session at 6-weeks post-op. Participants will also undergo 5 group educational sessions, which will provide information regarding: goal setting, pain education, self-management, pacing, post-operative expectations, exercise recommendations, and information regarding their upcoming surgery.
16242990|NCT05073081|Active Comparator|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice. This generally consists of one session with an anesthesiologist, a nurse and access to our online videos.
16242991|NCT05073068|Experimental|AM exercise|
16242992|NCT05073068|Experimental|PM exercise|
16242993|NCT05073068|Active Comparator|Control|
16242994|NCT05073055|Active Comparator|Group SA|Group 1 (SE) (n = 35): patients undergoing spinal anesthesia of patients in our hospital to do unilateral inguinal hernia operation. Block application and the times when the sensory block reaches the T10 level are recorded. Surgery is allowed in patients who develop sensory block at the T10 level. During our study, no changes will be made to the procedure described above, which is standardized during our study, only patient data will be recorded observationally. Patients who do not have sufficient sensory block to start the procedure despite waiting 10 minutes will be registered and excluded from the study and additional anesthesia will be applied.
16243057|NCT05072782|Experimental|Therapy escalation arm|Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
16352747|NCT04309175|Experimental|Fast-Slow|
16242995|NCT05073055|Active Comparator|Group ESP+TA|Group 2 (Errector spina block + TA) (n = 35): 2% lidocaine hydrochloride (10 mg / ml) 15 ml, 0.5% bupivacaine hydrochloride (20 mg / ml) 15 ml, serum 8.4% Sodium Bicarbonate 5 ml to be used for each patient before the operation in order to apply the erectile spina block block with tumescent anesthesia. Adding adrenaline tartrate (5 μg / mL) to 5 ml with saline, a total of 40 ml of mixture was prepared. Hydrodissection was achieved using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle on the Transverse Process of L1. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
16242996|NCT05073042|Experimental|Morning exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
16242997|NCT05073042|Experimental|Evening exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
16242998|NCT05073042|Active Comparator|Time of choice exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
16242999|NCT05073042|No Intervention|No exercise period|"During the two-week washout (i.e., break) periods between the exercise interventions, participants will not have an exercise goal. Participants will continue to receive weekly emails and wear a physical activity sensor daily."
16243000|NCT05073029|Active Comparator|standard care group|3-month course of individually selected nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
16243001|NCT05073029|Experimental|intervention group|additionally to previous group recieved treatment with synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103) and vitamin D3 - 2000 IU. The students were instructed to take vitamin D3 and synbiotic sachets twice a day for 3 months.
16243054|NCT05072808|No Intervention|Control Group|ED providers randomized to the Control Group will neither receive the results of the parent-completed PACCI-ED or specific recommendations for outpatient referrals. Patients randomized to the control group will receive usual care.
16243030|NCT05072938|Active Comparator|Nizatidine Monotherapy|Nizatidine Monotherapy
16243031|NCT05072938|Experimental|Rebamipide/Nizatidine Combination Therapy|Rebamipide/Nizatidine Combination Therapy
16243032|NCT05072925|Active Comparator|Combustible Cigarette|The usual brand of combustible cigarette smoked by study subjects, with a minimum Federal Trade Commission tar yield of 8mg
16243033|NCT05072925|Experimental|BIDI Stick ENDS Arctic flavor|BIDI Stick ENDS containing 6% nicotine and Arctic flavor
16243034|NCT05072925|Experimental|BIDI Stick ENDS Classic flavor|BIDI Stick ENDS containing 6% nicotine and Classic flavor
16243035|NCT05072925|Experimental|BIDI Stick ENDS Zest flavor|BIDI Stick ENDS containing 6% nicotine and Zest flavor
16243036|NCT05072925|Experimental|BIDI Stick ENDS Regal flavour|BIDI Stick ENDS containing 6% nicotine and Regal flavor
16243037|NCT05072925|Experimental|BIDI Stick ENDS Winter flavour|BIDI Stick ENDS containing 6% nicotine and Winter flavor
16243038|NCT05072925|Experimental|BIDI Stick ENDS Solar flavor|BIDI Stick ENDS containing 6% nicotine and Solar flavor
16243039|NCT05072925|Active Comparator|JUUL ENDS Virginia Tobacco flavor|JUUL ENDS containing 5% nicotine and Virginia Tobacco flavor
16243040|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with platelet rich plasm|patients with chronic shoulder pain injected with platelet rich plasm ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
16243041|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with Hyaluronic acid|patients with chronic shoulder pain injected with Hyaluronic acid ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
16243042|NCT05072886|Experimental|AT193|Topical applied daily
16243043|NCT05072886|Placebo Comparator|Placebo|Topical applied daily
16243044|NCT05072873|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
16243045|NCT05072873|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
16243046|NCT05072860|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid or placebo
16243047|NCT05072860|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
16243048|NCT05072847||ADAPT|The ADAPT system by Striker
16243049|NCT05072834||Cohort A|children with chronic malnutrition who do not respond to adequate supplemental feeding will undergo Upper Gastrointestinal Endoscopy
16243050|NCT05072834||Cohort B|Children 6 months to 24 months old who are undergoing Upper Gastrointestinal endoscopy for any appropriate indication
16243051|NCT05072821|Experimental|Botulinum Toxin type A injection side|The Botulinum Toxin type A will be injected into the dermal layer before skin closure in keloid excision surgery. The concentration of Botulinum Toxin type A is 100 units in 2 mL and dosage is 8 units/cm. The maximal dose is 100 units for each participant.
16243052|NCT05072821|Placebo Comparator|0.9% saline injection side|The 0.9% saline will be injected into the dermal layer before skin closure in keloid excision surgery. The dosage is 0.16 mL/cm.
16243053|NCT05072808|Active Comparator|Intervention Group|ED Providers randomized to the Intervention Group will be able to view the results of the parent-completed questionnaire, the Pediatric Asthma Control and Communication Instrument for the Emergency Department (PACCI-ED), and outpatient referral recommendations aligned with asthma severity.
16243055|NCT05072795|Experimental|Stress Induction|
16249830|NCT05026190|Other|azoospermic patients|
16243060|NCT05072756||Gynecologists|Brazilian gynecologists who agreed to participate and answered the questionnaire
16243062|NCT05072730|Experimental|Super high-pressure balloon (OPN NC)|Patients will be treated with a Super high-pressure percutaneous transluminal coronary angioplasty (PTCA) balloon (OPN NC).
16243063|NCT05072730|Experimental|Intravascular lithotripsy (IVL)|Patients will be treated with intravascular lithotripsy (IVL).
16243064|NCT05072717|Experimental|Patients with a meniscal tear requiring surgery|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an arthroscopic imaging system.
16243065|NCT05072704|Active Comparator|Control group|Sufentanil IV injection
16243066|NCT05072704|Experimental|OFA group|Dexmedetomidine IV infusion
16243067|NCT05072691||Patients with Multiple sclerosis and Optic Neuritis|Patients ≥ 18 year-old at the time of enrollment, with newly diagnosed multiple sclerosis according to 2017 McDonald diagnostic criteria Patients ≥ 18 year-old at the time of enrollment with first episode of optic neuritis, fulfilling or not (i.e. CIS, clinically isolated syndrome) 2017 McDonald diagnostic criteria for multiple sclerosis
16243068|NCT05072691||Patients with non-inflammatory neurologic diseases (NIND)|Patients ≥ 18 year-old with suspected non-inflammatory neurologic diseases (such as Alzheimer disease, intracranial hypertension, etc) receiving routine diagnostic lumbar puncture
16243069|NCT05072691||Patients with other inflammatory neurologic diseases (IND)|Patients ≥ 18 year-old with suspected inflammatory neurologic diseases other than multiple sclerosis (such as inflammatory peripheral neuropathies, meningitis, neuromyelitis optica spectrum disorders, etc) receiving routine diagnostic lumbar puncture
16243070|NCT05072665|Experimental|PATIENT WITH Irritable Bowel Syndrome|"2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection.
~A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped"
16243071|NCT05072652|Experimental|Immobilization|Participants in the immobilization groups will undergo one week of unilateral knee joint immobilization of the left leg.
16243072|NCT05072652|No Intervention|Control|The control group will not undergo any intervention.
16243075|NCT05072626|Active Comparator|high MCT formula with breast milk (or infant formula)|high MCT formula with breast milk（or infant formula）: Patients will be enrolled from 4 to 5 days after the Kasai operation. Daily dose: according to the amount of enteral nutrition, q2h, q3h, or tube feeding.
16243076|NCT05072626|Experimental|MCT powder with breast milk (or infant formula)|Patients will be enrolled from 4 to 5 days after the Kasai operation. Daily dose: according to the amount of enteral nutrition, q2h, q3h, or tube feeding.
16243077|NCT05072613||Pregnant women|Pregnant women attending Antenatal Care Services
16243078|NCT05072613||School children|Children attending Primary Schools
16243079|NCT05072600|Experimental|arm 1|All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
16243080|NCT05072587|Active Comparator|Group A - Standard ADA dietary guidelines (SADA)|Participants in this group will be given prepared meals based on standard ADA dietary guidelines for 12 weeks.
16243081|NCT05072587|Experimental|Group B - Plant Based ADA diet with no oxysterols (PB-ADAØ).|Participants in this group will be given prepared meals based on ADA guidelines but with no dietary cholesterol oxides/oxysterols - Plant-based ADA diet
16243084|NCT05072561|Experimental|Experimental|
16243085|NCT05072548|Experimental|Intervention|The intervention arm will receive access to the ABCs of SLEEPING Intervention.
16243086|NCT05072548|No Intervention|Control group|The control group arm does not receive the ABCs of SLEEPING intervention. This arm is free to access other resources while enrolled in the study. After the post-test follow up time point, the control group arm will be able to access the intervention.
16243087|NCT05072535|Experimental|Part 1-Group A|Subjects will receive 200 mg HA121-28 tablet A on Day 1 of the first cycle, followed by tablet B on Day 36 of the second cycle, in the fasted state.
16243088|NCT05072535|Experimental|Part 1-Group B|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle, followed by tablet A on Day 36 of the second cycle, in the fasted state.
16243089|NCT05072535|Experimental|Part 2-Group C|Subjects will receive 200 mg HA121-28 tablet B on Day1 of the first cycle in fasted state, followed by tablet B on Day 36 of the second cycle in the fed state.
16243090|NCT05072535|Experimental|Part 2-Group D|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle in the fed state, followed by tablet B on Day 36 of the second cycle in fasted state.
16243091|NCT05072522|Experimental|SKLB1028|"Dose-escalation stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles, in three doses beginning at 200 mg and rising to 400 mg.
~Cohort-expansion stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles at selected dose as per the results of dose-escalation stage."
16243094|NCT05072470|Experimental|Roger Microphone|Participants will be using a Roger microphone transmitter and hearing aid receiver to complete speech in noise task
16243095|NCT05072457|Experimental|Experimental|The Roger microphone will be used in conjunction with Audeo P hearing aid to test localization
16243098|NCT05072431|Experimental|Experimental group|The participants in the experimental group received the 3D VR training program.
16243099|NCT05072431|No Intervention|Control group|The control group did not receive any intervention.
16243100|NCT05072418||Children with dyslexia|
16243101|NCT05072418||Non-dyslexic children|
16243102|NCT05072405|Other|simvastatin 20 mg (Zocor®, MSD)|simvastatin 20 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases.
16243103|NCT05072405|Other|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases
16243104|NCT05072392|Experimental|Foley-assisted|"The tip of the nasal endotracheal tube will be telescoped onto a 16g Foley catheter. If a ballooned catheter is used then the inflation port may be cut off prior to use. The catheter tip is then fed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. The catheter is then removed from the tip of the nasal endotracheal tube through the mouth and disposed of. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may opt to use the other side nare.
~Following this, the anesthetist will complete the rest of the intubation as usual."
16243105|NCT05072392|No Intervention|Control|"The endotracheal tube is passed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may choose to use the other side nare.
~Following this, the anesthetist will complete the rest of the intubation as usual."
16243106|NCT05072379|Experimental|Mobile health app group|routine care and mobile health app
16243107|NCT05072379|No Intervention|control group|routine care
16243108|NCT05072353|Experimental|Treatment|DFU Patients are subjected to digital or transmetatarsal amputation. The treatment is provided during the amputation surgical session according to the SEFFI technique. The SEFFICARE® system (SEFFILINE S.r.l., Via delle Lame, 98, 40122 Bologna, Italy) is a disposable commercially available device. The device is provided in a sterile bag without any drugs. The SEFFI is a 5-step technique meaning preparation, anesthesia, harvesting, washing, and fluidification. The resulting tissue (2.5 mL per syringe) is ready for grafting. The stumps are closed by primary intention following adipose tissue injection.
16243109|NCT05072340|Experimental|RISE (Blended learning)|"Students will undergo a training that comprises of six sessions: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.
~RISE training will be hosted via the NUS' online learning platform, LumiNUS and virtual face-to-face platform, Zoom. Each session will take approximately one to two hours per week. One session is made available each week to encourage completion before moving onto the next session. Students will be provided with materials in the form of interactive videos. Virtual face-to-face sessions, online forum, quizzes and homework will be additionally available to students."
16243110|NCT05072340|Active Comparator|RISE (Asynchronous learning)|"Students will also undergo a six-session training comprising of: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.
~RISE training will be hosted via the NUS' online learning platform, LumiNUS. One session is made available each week to encourage completion before moving onto the next session. Participants will be reminded via emails and short message service (SMS) to complete the intervention. Students will be provided with materials in the form of interactive videos in LumiNUS."
16243111|NCT05072327|Experimental|Mohs surgery conbind with cryotherapy|patients in this group received both Mohs surgery and cryotherapy.
16243112|NCT05072327|Active Comparator|Mohs surgery|patients in this group received only Mohs surgery.
16243113|NCT05072314|Active Comparator|Lidocaine|2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative.
16243114|NCT05072314|Placebo Comparator|Placebo|0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative.
16243115|NCT05072301|Experimental|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
16243116|NCT05072301|Placebo Comparator|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
16244670|NCT05061433|No Intervention|Usual Care|Participants receive standard of care.
16243117|NCT05072288|Experimental|Remote activity program|Activity program based on objective evaluation. Possibility of 35 different programs primarily targeting impairments (lower limb, upper limb or balanced)
16243118|NCT05072275||Subjects receiving care from Scripps Health physicians in Cardiology and Primary Care|A confidential data request will be submitted to screen the Scripps Health EHR system for individuals meeting study inclusion criteria and having seen a participating study physician in the past two years.
16243119|NCT05072262|Active Comparator|Control (dexamethasone only)|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
16243120|NCT05072262|Experimental|Study group (NSAIDs and dexamethasone)|Topical nepafenac (Nevanac) 3 mg/ml and dexamethasone 1 mg/ml (Spersadex) started the day after surgery.
16243121|NCT05072249||lay person provided with take home naloxone|Naloxone all forms
16243122|NCT05072236|Placebo Comparator|normal saline|intravenous 5 mL normal saline 1 minute before bronchoscopic insertion
16243123|NCT05072236|Experimental|etomidate|intravenous etomidate 0.15 mg/kg 1 minute before bronchoscopic insertion
16243124|NCT05072236|Active Comparator|lidocaine|intravenous lidocaine 1.5 mg/kg 1 minute before bronchoscopic insertion
16243125|NCT05072223|Experimental|Group A|
16243126|NCT05072223|Active Comparator|Group B|
16243129|NCT05072197|Experimental|Mobile device application group|routine care and mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment
16243130|NCT05072197|No Intervention|control group|routine care for breast cancer women during their chemotherapy treatment
16243131|NCT05072184|Active Comparator|ESP block|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
16243132|NCT05072184|Sham Comparator|Control|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of saline on each side
16243137|NCT05072145||Non-tele-ED hospital|Patients receiving care in an ED that does not provide any tele-ED service
16243138|NCT05072145||Tele-ED hospital|Patients receiving care in an ED that uses tele-ED services, but patient care did NOT utilize this service
16243139|NCT05072145||Tele-ED used|Patient care was provided through tele-ED services
16243143|NCT05072119||Patients with PM|All patients underwent PM implantation
16243144|NCT05072119||Patients with ICD|All patients undeerwent ICD implantation
16243145|NCT05072119||Patients with ILR|All patients underwent ILR implantation
16243146|NCT05072106|Active Comparator|Single agent lurbinectedin cycle|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
16243147|NCT05072106|Active Comparator|Bosentan co-administration cycle|"Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
~Lurbinectedin: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1 in first three patients. Dose for remaining five patients will depend on PK and safety outcomes in first three patients."
16243153|NCT05072067|Experimental|OBESE PATIENT|OverStitch™ Sx with a Single channel endoscop CO2 Insufflation, patient on decubitus dorsal, with intubate 3 to 7 sutures, from the antral ogiv to the cardia are done
16243157|NCT05072028|Experimental|[14C]DBPR108|Subjects will receive a single oral 100 mg (radioactivity of 150 µCi) dose of [14C]DBPR108 on Day 1.
16243158|NCT05072002||pregnant women with low back pain|
16243159|NCT05071989|Experimental|Sleep education group do not supported with social media reminders|Sleep education do not supported with social media reminders
16243160|NCT05071989|Experimental|Sleep education group supported with social media reminders|Sleep education group supported with social media reminders
16243161|NCT05071989|No Intervention|Control group|No intervention was made in the control group.
16243163|NCT05071950|Other|14 days continuous glucose monitoring|The participants started and completed the control period for continuous 7 days and followed with D-allulose period for 7 days
16243164|NCT05071937|Experimental|ZEN003694 + Talazoparib|"ZEN003694: 48.0 mg daily (oral) in 28-day cycles
~Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694"
16243165|NCT05071924|Experimental|PLH Teens Original|The original in-person PLH programme is delivered by community-based workers in low-resource settings. Implementation occurs in a group-based format with both joint parent and teen sessions (10 sessions) and separate parent and teen sessions (4 sessions).
16243166|NCT05071924|Experimental|PLH Teens Hybrid|The hybrid delivery of PLH Teens consists of 8 sessions delivered to parents via WhatsApp (ParentChat-Teens) and 4 sessions delivered to parents and adolescents in person.
16243167|NCT05071898|Experimental|Open label administration of semaglutide|Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
16243168|NCT05071885|Experimental|Game-based Exercise program|"Each exercise session would last 45 minutes and supervised by study staff at First Step Wellness center you will be shown how to handle and move the joystick and how to play a group of computer games. The game activities will require you to move the joystick at various speeds, movement' amplitudes and in different directions. Each game will be played for 2-3 minutes.
~A variety of therapy handles of different shapes and sizes have been produced that Snap-On to joystick handle. These are designed to practice a broad range of manual dexterity skills involving the thumb, fingers, wrist and elbow, o Different games will also be used to vary the movement types and precision levels. To note you will be able to choose the types of movement exercises and games to use."
16243169|NCT05071885|Active Comparator|Range of motion and Strength Exercise program.|"This will involve stretching, range of motion and strength exercises as set out by training staff at the First Step Wellness center.
~On completion of the ten week exercise program, you will be invited to take part in a 30-minute interview to discuss the experiences you had on receiving the specific hand exercise program. The whole interview session will be audio taped. Your identity will be protected and your privacy will be maintained. All the information discussed and shared during the interview will be kept confidential and safely protected."
16243170|NCT05071872||Rotarex®S|Treatment performed with Rotarex®S
16243171|NCT05071872||Aspirex®S|Treatment performed with Aspirex®S
16243172|NCT05071859||GOBACK|The patient must have been diagnosed with cancer at ≤25 years of age and have been diagnosed with one or more congenital anomalies reported through the APEC14B1 registry intake data. For all patients in APEC14B1 with self-reported congenital anomalies we will: 1) recruit cases; 2) administer the GOBACK Study questionnaire; 3) collect biological samples for sequencing; and 4) obtain medical records to verify anomalies. Medical records will be used to validate self-reported congenital anomalies and is a crucial step prior to sequencing. Additionally, we will be able to identify those with well-established cancer predisposition syndromes that involve congenital anomalies, such as WAGR syndrome.
16243173|NCT05071846|Experimental|MVX-ONCO-2|
16243174|NCT05071833|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
16243175|NCT05071833|Experimental|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
16243176|NCT05071820|Experimental|Mobile application program|
16243177|NCT05071820|Active Comparator|Traditional program|
16243180|NCT05071794|Active Comparator|Group A|Subhypnotic dose of propofol, 0.5mg/kg, 10 - 15 min before end of surgery
16243181|NCT05071794|Placebo Comparator|Group B|Normal saline 0.9%, 10 mL , 10 - 15 min before end of surgery
16243182|NCT05071781|Active Comparator|Cortisol releasing hormone group|HVs will start with CRH infusion.
16243183|NCT05071781|Placebo Comparator|Placebo (sodium choride) group|HVs will start with NaCl 0.9% (placebo) infusion
16243184|NCT05071768|Experimental|ACT|Focused ACT Group Treatment
16243185|NCT05071742||IBD group|According to the consensus opinions on diagnosis and Treatment of Inflammatory Bowel Disease (Beijing, 2018) formulated by Chinese Society of Gastroenterology, Chinese Medical Association The diagnosis of IBD was confirmed by clinical, laboratory, radiographic, digestive endoscopy and histopathological examination.
16243186|NCT05071742||control group|During the same period, healthy subjects were collected from the physical examination center of our hospital as subjects of the normal control group. Infectious diarrhea, ischemic bowel disease, radiation enteritis, gastrointestinal tumor, diabetes, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroiditis were excluded from all clinical examinations before inclusion.
16243190|NCT05071716|Experimental|Rifaximin SSD-40mg IR|
16243191|NCT05071716|Placebo Comparator|Placebo|
16243192|NCT05071703|Experimental|Trilaciclib, carboplatin, etoposide, Topotecan|Trilaciclib plus Carboplatin combined with Etoposide OR Topotecan (ES-SCLC patients)
16243375|NCT05070364|Experimental|Peginterferon Lambda for 48 weeks|Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up
16243195|NCT05071677||Observational (survey, interview)|Patients participate in a standard of care treatment planning meeting over 3 hours with members of the multidisciplinary treatment team including, the oncologist, radiologist, oncology surgeon, and social worker. Patients then complete surveys over 20 minutes and within 30 days later. Some patients may participate in interviews over 30 minutes.
16243196|NCT05071664|Experimental|Group 1: Guselkumab and Golimumab|Participants will receive subcutaneous (SC) guselkumab and golimumab.
16243197|NCT05071664|Active Comparator|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab and placebo.
16243198|NCT05071638|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion. Cell dose for all patients was targeted at 5×107 cells per kilogram.
16243199|NCT05071638|No Intervention|control group|The control group received standardized treatment without special treatment.
16243200|NCT05071612|Experimental|AD109 Dose 1|
16243201|NCT05071612|Experimental|AD109 Dose 2|
16243202|NCT05071612|Experimental|AD504 Dose 1|
16243203|NCT05071612|Experimental|AD504 Dose 2|
16243204|NCT05071612|Active Comparator|Atomoxetine 1|
16243205|NCT05071612|Active Comparator|Atomoxetine 2|
16243206|NCT05071612|Placebo Comparator|Placebo 1|
16243207|NCT05071612|Placebo Comparator|Placebo 2|
16243211|NCT05071573|Experimental|Intervention arm|"Quality improvement package Identification of a viral load champion whose role will include tracing and recalling patients who need further assessments of their VL or switch to second-line regimen.
~QIP to address process and clinic impediments to VLM as well as training in antiretroviral treatment monitoring guidelines Training in the use of enhanced TIER.Net technology developed as part of the trial and how to access reports on the dashboard system.
~Augmentation of TIER.Net with a dashboard system VL results will be imported into TIER.Net daily from the National Health Laboratory Service which will be linked to patients in TIER.Net based on multiple exclusive and linked deterministic rules using a combination of variables such as name, surname, sex, date of birth, date of visit, NHLS lab number, facility and folder number. The information contained in TIER.Net will be used to develop a dashboard which summarises viral load data at individual and clinic level."
16243212|NCT05071573|No Intervention|Control arm|Viral load results are manually captured on to the TIER.Net system with filing of the paper results in patients' clinical notes for nurses' review during routine appointments. This is used to produce a monthly enrolment and quarterly cohort reports for the central monitoring of the ART programme.
16243213|NCT05071560|Active Comparator|Face-to-Face Group|This arm will have a 3 day per week face-to-face participant-tailored combined exercise program, with 2 supervised sessions and 1 non supervised aerobic session, for 8 weeks
16243214|NCT05071560|Experimental|Home-Based Group|This arm will have a 3 day per week home-based participant-tailored combined exercise program, with 2 remotely supervised sessions (online) and 1 non supervised aerobic session, for 8 weeks
16243215|NCT05071547|Experimental|Internet-delivered acceptance and commitment therapy addition|The IACT addition supplies participants with weekly educational material and additional exercises in line with live IRPR, although enriched with multimedia. Participants will have access to their rehabilitation content via the web-site and can practice in their homes in-between live sessions of IRPR.
16243216|NCT05071547|Active Comparator|Interdisciplinary pain rehabilitation program|A 6-week long multimodal treatment including approximately 108 hours on site, focusing on return to work. Psychologists, physicians, physiotherapists (PT) and occupational therapists (OT) give synchronized treatments with a CBT/ACT approach.
16243217|NCT05071521|Active Comparator|Eating disorders prevention|"The Body Project. The Body Project is a dissonance-based eating disorders prevention programme. It is a manualised evidence-based programme that targets eating pathology and body image dissatisfaction in young women. The objective of the programme is to create cognitive dissonance to encourage participants to decrease pursuing ideal-thinness. It includes group discussion, written and behavioural exercises and role-play to achieve cognitive dissonance (Stice, Rohde, & Shaw, 2013). It involves four group sessions for an hour each in consecutive weeks. At the beginning of each meeting, the facilitator reinforces voluntary commitment. Homework is explained and given at the end of each meeting and reviewed at the beginning of the following meeting.
~References:
~Stice, E., Rohde, P., Shaw, H. (2013). The body project a dissonance-based eating disorders prevention intervention (updated edition). New York: Oxford University Press."
16243218|NCT05071521|Sham Comparator|Healthy eating education|"The control group were asked to read educational material in Arabic about healthy nutrition and active lifestyle from the Saudi branch of the World Obesity Federation (Kayl Association for Combatting Obesity, 2021). The material includes information about body mass index; easy ways to measure food units without a scale; benefits of working out; means to adopt healthier daily habits; and healthier food alternatives. The material was chosen because it was designed to be easy to understand by any individual.
~References:
~Kayl Association for Combatting Obesity. (2021). Kayl association for combatting obesity. Retrieved from https://www.kayl.org.sa"
16243219|NCT05071508||Preterm Infants|Premature infants (born between 25 and 34 + 6 weeks gestational age) admitted to the University of Minnesota Masonic Children's Hospital NICU
16243220|NCT05071495|Experimental|Intervention group|
16243221|NCT05071495|No Intervention|Control group|
16243222|NCT05071482|Experimental|flumatinib arm|600 mg QD oral administration, fasting (2 hours before administration and 1 hour after administration).
16243223|NCT05071482|Active Comparator|imatinib arm|600 mg QD oral administration, with a meal
16243224|NCT05071469|No Intervention|Control Group (CG)|Patients in the control group which waiting an appointment for the physiotherapy program received no intervention.
16243251|NCT05071248|No Intervention|patients with conventional early mobilization (historic group)|All patients fulfill the same criteria like the intervention group and receive conventional early mobilization.
16251967|NCT05011630||Non-IAA group|No IAA formation
16243225|NCT05071469|Experimental|Kinesiotaping Group (KG)|The first strip was a Y-strip for inhibition of the supraspinatus and was applied from its insertion to origo with paper-off tension. This strip was applied with the patient in a position of combining contra-lateral cervical side bending and the arm reaching behind the back. The second strip was an I-strip with Y shape at the end of tape. It was applied from the coracoid process around the posterior deltoid with approximately 50% to 75% tension and downward pressure applied for a mechanical correction.
16243226|NCT05071469|Experimental|Mulligan Mobilization Technique Group (MG)|The physiotherapist glided the humeral head in a postero-lateral-inferior direction with thenar eminence. The patient performed the offending movement while the glide was sustained. This movement should now become pain-free. Passive overpressure could be given by the patient at the end of the newly available range using his/her other hand. The hand of the physiotherapist should also move along with the movement in order to sustain the glide along the treatment plane. When the patient moved his/her shoulder, rotation of the scapula allowed upward. MT was applied 10 repetitions for each session, 30 sec rest period between sets, 4 sessions with 24 hours between 2 treatment seasons.
16243230|NCT05071443|Experimental|Negative pressure wound therapy (NPWT)|Negative pressure wound therapy (NPWT): an NPWT device will be applied hermetically from randomization to skin grafting.
16243231|NCT05071443|Active Comparator|Conventional dressing|Conventional dressing will be performed from randomization to skin grafting. The dressings will be performed following usual procedures of investigating centers
16243232|NCT05071430|Active Comparator|Active Treatment (HB-01)|Approximately 40 patients will receive HB-01 active study drug.
16243233|NCT05071430|Placebo Comparator|Placebo Treatment|Approximately 40 patients will receive a matched placebo.
16243234|NCT05071417|Experimental|Semaglutide|Patients on semaglutide
16243236|NCT05071391||Obese|Obese patients undergoing Roux-en-Y gastric bypass
16243237|NCT05071378|Experimental|Intervention Group|This arm will be enrolled in the intervention prior to any data collection
16243238|NCT05071378|No Intervention|Wait listed control|This arm will receive the intervention after all study data is collected
16243239|NCT05071365|Experimental|Videos|"Single Arm study: All participants recruited to the study will be allocated to a single arm- videos in which participants will be able to access self help videos for plantar fasciitis"
16243240|NCT05071352|Experimental|Nefopam group|"Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium.
~Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours."
16243241|NCT05071352|Placebo Comparator|Control group|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
16243242|NCT05071339|Experimental|Participants|"Patients treated at the IVF unit at Shamir Medical Center planned for an antagonist cycle will undergo blood test and US exam at day 2-3 of their menstrual cycle. Patients will be recruited if a leading follicle 10-13 is shown in the presence of E2 > 200-350 pmol/L.
~Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-5 days intervention."
16243243|NCT05071326|Experimental|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
16243246|NCT05071300|Experimental|ION-682884|ION-682884 will be administered by subcutaneous (SC) injection once every 4 weeks for up to 3 years (157 weeks).
16243247|NCT05071287|Placebo Comparator|Control Group (mHealth+low-fat diet group)|The low-fat group will be asked to restrict total calorie and total fat consumption according to the Look AHEAD intervention and MyPlate guidelines, with 26-44% carbs, 10-30% protein, and less than 30% fat.
16243248|NCT05071287|Experimental|Intervention Group (mHealth + low-carbohydrate/ketogenic diet group)|Total calories will be set according to Look AHEAD intervention, and carbohydrate consumption restriction will be set based on recommendations from American Diabetic Association, National Kidney Foundation, and other evidence-based resources. Participants in this group will be asked to consume a low-carb/ketogenic diet. Specially, participants will receive a carbohydrate, protein, and fat intake goal based on 1.5 : 1 ratio (1.5 grams of fat to 1 gram of carbohydrate and protein combined). Daily macronutrient and calorie consumption will be individualized for each participant using ideal body weight as inferred from wrist circumference and activity level. Carbohydrate consumption will be less than 10% (20~50 g), protein 10-20% (1.0~1.2g/kg ideal body weight), and fat 70-80% of total daily energy, respectively. Nutritional ketosis will be reached by consuming such diet (0.5 mmol/L).
16243249|NCT05071274|Experimental|SkinPen Precision System|"After a 15-minute acclimation to ambient temperature and humidity conditions, subjects will participate in bio instrumentation to assess for erythema and will participate in standard photography.
~The Investigator will treat each subject's face from hairline to jawline with the SkinPen Precision System following instructions in the SKINPEN PRECISION SYSTEM INSTRUCTIONS with the following treatment of the face at depths of up to 1.5mm. Treatment depth will be recorded for each subject at every visit. Subjects will be dispensed a study provided diary and trained on compliance."
16243250|NCT05071248|Active Comparator|patients with robot-assisted early mobilization|All patients will receive a physical examination at various time points to assess physical functionality and muscle strength, as well as a sonographic examination of leg muscles, diaphragm, and lungs. These examinations should be performed on day -1 (preoperatively), on postoperative days 1,2,3, then once a week if the patient remains in the ICU, on day 28, on the day of discharge from the ICU, and on a follow-up examination approximately 3 months after discharge from the ICU.The follow-up examination should only take place if the patients present themselves at the hospital anyway due to medically indicated follow-up examinations (not study-related). Alternatively, patients can be asked about their condition by telephone.
16243252|NCT05071235|Placebo Comparator|CG (control group) + dressing|The group will receive placebo LLLT (low-level laser therapy) application associated with Helianthus annuus oil dressing.
16243253|NCT05071235|Active Comparator|LG1 (LLLT group 1) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
16243254|NCT05071235|Active Comparator|LG2 (LLLT group 2) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
16243255|NCT05071235|Active Comparator|LG3 (LLLT group 3) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
16243256|NCT05071222|Experimental|ARTEGENE drug product|Autologous purified CD34+ cells transduced with a self-inactivated lentiviral vector, expressing the DCLRE1C gene (alias Artemis)
16243257|NCT05071209|Experimental|Treatment (elimusertib)|Patients receive elimusertib PO BID on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for 26 cycles in the absence of disease progression or unacceptable toxicity.
16243260|NCT05071183|Experimental|TPX-0005 + Trametinib|"TPX-0005 + Trametinib Dose Escalation and Dose Expansion
~Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC"
16243261|NCT05071170||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification
~Soft and hard foods manipulated by cooking method"
16243262|NCT05071157||anorexia nervosa|girls between 12 and 18 years old with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
16243263|NCT05071157||obesity|girls between 12 and 18 years old with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30).
16243264|NCT05071157||normal weight|girls between 12 and 18 years old without BMI abnormality, without eating disorders, without serious medical pathology
16243265|NCT05071144||Pediatric Spine Deformity Patients|Standard of care surgery using robotics coupled with navigation
16243266|NCT05071131|Active Comparator|Inulin|30 grams inulin per day for 28 days
16243267|NCT05071131|Placebo Comparator|Placebo|30 grams maltodextrin per day for 28 days
16243268|NCT05071118|Active Comparator|pregabalin group|Two hours before surgery, the pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery.
16243269|NCT05071118|Active Comparator|placebo group|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
16243270|NCT05071105|Experimental|40Gy/5fx|The starting dose level will be 8Gy x 5 fractions, i.e., 40 Gy/5 nonconsecutive once-daily fractions.
16243271|NCT05071105|Experimental|42.5Gy/5fx|The intermediate dose level will be 8.5Gy x 5 fractions, i.e. 42.5Gy/5 nonconsecutive once-daily fractions.
16243272|NCT05071105|Experimental|45Gy/5fx|The higher dose level will be 9Gy x 5 fractions, i.e. 45Gy/5 nonconsecutive once-daily fractions
16243273|NCT05071092|Experimental|Intervention group|The intervention will consist of personalized guidance from a dietician focussing on improving adherence to the Dutch dietary guidelines.
16243274|NCT05071092|No Intervention|Usual care group|The usual care group will not receive any special guidance regarding healthy nutrition, but will have access to their care team as usual.
16243275|NCT05071079|Experimental|Challenge with whole dose blood-stage inoculum (neat)|Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL
16243276|NCT05071079|Experimental|Challenge with 1:5 dilution blood-stage inoculum|1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
16243277|NCT05071079|Experimental|Challenge with 1:10 dilution blood-stage inoculum|1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
16243278|NCT05071079|Experimental|Challenge with 1:20 dilution blood-stage inoculum|1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
16243279|NCT05071066|Experimental|Group-based ADHD+ Treatment|"This randomized controlled trial (RCT) will run in multi-sites including 5 non-governmental organizations (NGOs) in Hong Kong. Core treatment components are developed by an expert group comprised of psychiatrists and clinical psychologists including internet use/addiction intervention, cognitive training, etc.
~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months."
16243280|NCT05071066|Other|wait-list control group|For participants in the waiting list control group, they will receive 1-3 hours psychoeducation during the 3 months wait period. Appropriate intervention will be offered after the treatment group.
16243281|NCT05071053|Experimental|Tusamitamab ravtansine+Ramucirumab|"Part 1: participants to receive an intravenous (IV) dose of tusamitamab ravtansine in combination with an IV dose of ramucirumab on Day 1 of Cycle 1 followed by an additional IV dose of tusamitamab in combination with IV dose of ramucirumab at Day 1 Cycle 2 of 14-day cycle in all subsequent cycles.
~Part 2: participants to receive the recommended dose of tusamitamab ravtansine established in the Part 1 in combination with IV dose of ramucirumab on Day 1 of Cycle 1 followed by IV dose of tusamitamab in combination with IV dose of ramucirumab at Day 1 Cycle 2 of 14-day cycle in all subsequent cycles."
16243282|NCT05071040|Experimental|Exercise group|Participants will follow a strength exercise program monitored through the use of a specifically designed smartphone application.
16243283|NCT05071040|No Intervention|Control group|Continue their daily routine without exercise prescription.
16243284|NCT05071027|Experimental|App Medication Reminder Group|Patients in this group will receive dual antiplatelet medication reminders.
16243285|NCT05071027|No Intervention|Non-app Using Group|Patients in this group receive the same standard of care [i.e. endovascular stent-based treatment of unruptured aneurysms] as the other group, but do not receive app dual antiplatelet reminders.
16243287|NCT05071001|Experimental|A|
16243288|NCT05071001|Experimental|B|
16243289|NCT05070988||Rare diseases|Children and adult patients with rare diseases and followed at the Necker Enfant Malades Hospital, Paris
16243290|NCT05070975||Twins|Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin hospitalized for an acute RSV-infection
16243291|NCT05070962||Clinical population|having experienced repeated and prolonged traumatic exposure
16243292|NCT05070962||General population|Student volunteers from the University of Lille
16243295|NCT05070936|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backwards both open and closed eyes, and walking on tandem both open and closed eyes. Exercise program was applied for 8 weeks. Patients were observed in the hospital every two weeks. The exercises given in the session were given as home exercises, 3 times a day, for 10 repetitions.
16243296|NCT05070923|Experimental|HealthyLifetime Group|"HL is an 8-week, personalized health coaching program that includes a comprehensive assessment made through a survey and a virtual' home visit (via video), a goal-directed strengthening action plan developed by the participant with the guidance of the nurse, a tailored daily planning guide to enhance action steps and goal attainment, and six weekly 30 minute nurse coaching sessions with participants the Healthie application technology via their personal home computer, Tablet or Smartphone device. If a participant does not use a personal device or the device cannot support the Healthie platform, the HL program will provide a Tablet to them for their use during the program. All video sessions ( ie, home visit, strengthening plan, and weekly coaching sessions will use a two-way video but only the audio portions of the sessions will be recorded. The HL program, tailored to each participant's need for strong and resilient function, encompasses the following key elements:"
16243297|NCT05070923|No Intervention|Usual Care Group|Participants randomized to the usual care group will be given information about when to expect reminders on the Healthie platform to complete future surveys at the end of week 8, and after three months that will be available on the Healthie Platform for them to fill out and save on the platform. They will also be reminded how to contact the study coordinator if they should have questions. Participants in this group will have the view to other functions on the platform turned off. They will only be able to view documents as the reminders appear for them to complete.
16243298|NCT05070910|Experimental|NDT|Therapy will be provided 2 days to 4 days per week for one-hour sessions
16243299|NCT05070897||Population A|18 to 64 years old
16243300|NCT05070897||Population B|65 years old and more
16243301|NCT05070884||non respondants of neo treatment|those patients with no response or partial response when administered with Chemotherapy prior to sugery
16243302|NCT05070871|Active Comparator|Hydrolyzed Collagen type II|10 capsules daily of hydrolyzed collagen (CH) type II is taken per orally. Each capsule contains ~500 mg of CH. Once or twice daily dosing. Duration: 6 months.
16243303|NCT05070871|Placebo Comparator|Maltodextrin|10 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once or twice daily dosing. Duration: 6 months.
16243304|NCT05070871|Experimental|Unhydrolyzed Collagen type II (Salmon bone meal)|10 capsules daily of salmon bone meal enriched with vitamin D3 is taken per orally. Each capsule contains 300 mg of maltodextrin, 200 mg of salmon bone meal (10 capsules = 2000 mg salmon bone meal = 340 mg elemental calcium in the form of microcrystalline hydroxyapatite), and 4 micrograms of vitamin D3 (10 capsules = 40 micrograms of vitamin D3 = 1600 IU).
16243305|NCT05070858|Experimental|Group 1|Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP and OLTP
16243306|NCT05070858|Experimental|Group 2|Combination regimen throughout the study
16243307|NCT05070858|Experimental|Group 3|Cemdisiran throughout the study
16243308|NCT05070845|Experimental|Open Label PF-06835375 Treatment|subcutaneous injection 25 milligram once monthly for 3 months
16243309|NCT05070832|Experimental|Hyperthermia Group|The neoadjuvant therapy is hyperthermia combined with concurrent radiochemotherapy for this group.
16243310|NCT05070832|No Intervention|Non-hyperthermia group|The neoadjuvant treatment is concurrent radiochemotherapy, which is standard treatment for LARC according to the guidelines.
16243311|NCT05070819|Experimental|Cardiac surgery patients|"After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.
~After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained
~At the end of Teboul' test when lower limbs are lifted
~30 minutes of CPB
~End of CPB
~End of volume transtion from CPB circuit to patient
~Before Teboul' test at the end of surgery
~End of Teboul' test when lower limbs are lifted"
16243312|NCT05070793|Other|Culturally adapted interpersonal psychotherapy|Individual psychotherapy intervention based on Brief Interpersonal Psychotherapy (IPT-B) with additional cultural adaptation for transgender and nonbinary individuals.
16243344|NCT05070559|Experimental|Active Release Technique Group|Patients in this group will receive Active Release Technique along with conventional therapy
16243345|NCT05070559|Experimental|Graston Technique Group|Patients in this group will receive Instrumental Assisted Soft Tissue Mobilization along with conventional therapy
16243318|NCT05070754|Experimental|Cold Atmospheric Plasma (CAP)|We are proposing a clinical trial of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.
16243319|NCT05070754|Active Comparator|Cryotherapy|Current standard of care (SOC) for treating Verruca Vulgaris in Children is cryotherapy. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
16243320|NCT05070754|Active Comparator|Cantharidin|SOC for treatment of Molluscum Contagiosum is cantharidin. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
16243321|NCT05070741|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm). Subjects will complete 12 heat therapy treatments over the course of 4 weeks. Within 24-48 hours after the last heat therapy experience, post-treatment laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm) will be performed.
16243322|NCT05070728|Sham Comparator|Sham Comparator|sham injection
16243323|NCT05070728|Active Comparator|FAI insert (0.05 mg fluocinolone acetonide)|FAI insert (0.05 mg fluocinolone acetonide)
16243324|NCT05070715||Group 1: FGR group|Estimated fetal weight <10th percentile
16243325|NCT05070715||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
16243326|NCT05070702|Experimental|CT-1500 Active (SAD)|6 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of CT-1500 between 5 mg and 120 mg
16243327|NCT05070702|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of matching placebo
16243328|NCT05070702|Experimental|CT-1500 Active (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of CT-1500 between 5 and 45 mg
16243329|NCT05070702|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of matching placebo
16243330|NCT05070689|Experimental|Single Group|A. Chohan Continuous squeezing Suture (ACCSS): An obstetrical procedure using half circle 40mm round body polyglactin 910 suture # 1 (Vicryl plus by Ethicon ®) for control of haemorrhage from the lower segment, in patients with Placenta Accreta for the prevention of hysterectomy at caesarean section
16243331|NCT05070676|Experimental|Lateral cephalometric radiographs of pre-adolescent patients (8-13) years old.|
16243332|NCT05070663||Participants with severe asthma|Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study.
16243333|NCT05070650|Experimental|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
16243334|NCT05070650|Active Comparator|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day
16243335|NCT05070637|Experimental|No-touch laparoscopic radical nephrectomy|Group A patients will undergo a no-touch laparoscopic radical nephrectomy, with the dissection being done through the Gerota's fascia plane until exposure of the corresponding great vessel (vena cava on the right side, and aorta on the left side) is obtained. The renal pedicle will be directly isolated, and ligated using Weck® clips with no kidney manipulation.
16243336|NCT05070637|Active Comparator|Conventional laparoscopic radical nephrectomy|Group B patients will undergo a conventional laparoscopic radical nephrectomy approach, starting with opening of the Gerota's fascia, identification of the ureter, traction on the peri-renal fat below the ureter while dissecting cephalad until the renal pedicle is reached. The renal pedicle will then be isolated while maintaining traction on the kidney, and peri-renal fat, and ligated using Weck® clips.
16243337|NCT05070637|Other|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in patients with hypo-functioning kidneys, and no renal cell carcinoma.
16243338|NCT05070624|Experimental|Intervention|"After informed consent, we will assign participants in a 1:1 ratio to the intervention or control group using Randomize.net.
~Participants randomized to intervention group will get access to the Virtual Peer Support Program."
16243339|NCT05070624|No Intervention|Control|Control group: Those randomized to the waitlist control will be given access to the peer support intervention on completion of the first 12-week program. A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions 21. will have access to informational resources via the aTouchAway™ App and will also receive the intervention at the end of the trial.
16243340|NCT05070611|Experimental|Recurrent chalazia with IPL-MGX|The patients whose lesions had failed to respond to warm compresses and antibiotic and steroid treatment underwent incision and curettage. One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid. After removal of the ultrasound gel, meibomian gland expression (MGX) was performed with forceps-shaped meibomian gland compressor.
16243341|NCT05070598|Experimental|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab Q3W d1 Pyrotinib d1-21 Nab-paclitaxel Q3W d1 Tegafur d1-14
16244983|NCT05059223|Experimental|AXS-12 (reboxetine)|Up to 5 weeks
16243352|NCT05070533|Active Comparator|Individual treatment|The strength and balance activities of the LiFE program will be carried out. Participants will receive 7 home visits and will be given the support material for the manual (diptychs, pictures, etc.).
16243353|NCT05070533|Experimental|Groupal treatment|The strength and balance activities of the LiFE program will be carried out. Participants will be invited to participate in groups of about 8 - 12 people in community venues.
16243354|NCT05070507|Experimental|Enzyme containing lozenge|
16243355|NCT05070507|Placebo Comparator|Placebo lozenge|
16243356|NCT05070494|Other|้healthy subject with standard dose trivalent influenza vaccine|้healthy volunteer that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)
16243357|NCT05070494|Active Comparator|ESRD patient with standard dose trivalent influenza vaccine|ESRD patient that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)
16243358|NCT05070494|Experimental|ESRD patient with double dose trivalent influenza vaccine|ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) total 1 ml ( 1 ml /(30 mcg/strain)
16243359|NCT05070494|Experimental|ESRD patient with double dose - booster trivalent influenza vaccine|ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) and booster with Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) at next 6 months after first dose
16243360|NCT05070468|Active Comparator|Group A|Prescribing Vaginally Dexamethasone tablets to the Group A
16243361|NCT05070468|Placebo Comparator|Group B|Prescribing Vaginally placebo tablets to the Group B
16243362|NCT05070455|Experimental|Asceniv|Asceniv™ will be given as an intravenous infusion at the same dose, or higher dose where medically appropriate, as the subject's previous IV Immunoglobulin G treatment (300-800 mg/kg) every 21 or 28 days.
16243363|NCT05070442|No Intervention|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart which replicates the traditional shopping experience of online grocery stores.
16243364|NCT05070442|Experimental|Norms Arm (Arm 2)|Participants will experience a modified version of NUSMart with norm-based messaging and peer comparison features enabled. Nutri-Score labels will be enabled and displayed on all products within the store. A floating side panel will provide a visual indicator of the participants' average weighted Nutri-Score.
16243365|NCT05070442|Experimental|Norms and Incentive Arm (Arm 3)|Same as Arm 2, except participants are notified that they have been awarded an additional $5 towards their participation reimbursement. However, this additional $5 will be forfeited if their basket average weighted Nutri-Score falls below the average of their peers'. (Financial incentive leveraging on loss aversion).
16243366|NCT05070429|Other|Conventional hearing healthcare group|The conventional hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. During Year 1, this group will receive clinic-based audiological rehabilitative service delivery and be able to use conventional options to address any unanticipated needs that arise, and then during Year 2, this group will also receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise.
16243367|NCT05070429|Other|Telehealth hearing healthcare group|The telehealth hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. This group will receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise during both years of the study.
16243368|NCT05070416|Experimental|Crowns self-adhesively cemented|Group 1 receives crowns with an occlusal thickness of 1.5 mm and luted with a self-adhesive, self-curing resin cement (SpeedCem Plus, Ivoclar Vivadent AG).
16243369|NCT05070416|Experimental|Crowns adhesively luted|Group 2 receives crowns with an occlusal thickness of 1.2 mm delivered with a dual-curing resin cement (Variolink Esthetic (DC),Ivoclar Vivadent AG).
16243370|NCT05070403|Experimental|Afatinib Intervention|Participants will receive afatinib 40 mg once a day. Each cycle is 4 weeks. They will have CT imaging (and/or digital photography) done at baseline and every 8 weeks while on treatment. Participants will have a baseline and on-treatment (at 4 weeks) tumor biopsy, and a biopsy at disease progression if feasible. Patients may remain on treatment as long as they are deriving clinical benefit, until disease progression or intolerable toxicity.
16243371|NCT05070390|Experimental|Panel A- Moderate RI|Single dose of MK-0616 10 mg
16243372|NCT05070390|Experimental|Panel B- Healthy Controls|Single dose of MK-0616 10 mg
16243373|NCT05070377|Experimental|Intervention|The ActTeens Program will include interventions in three different context: (1) structured physical activity sessions by physical education (school), (2) self-monitoring plus goal setting by pedometer (out-of-school), and (3) healthy lifestyle guidance (social support). The structured PA will be developed in PE lessons, twice a week, with twenty-minute each lesson (40 min·week) To promote active behavior out-of-school will be used a pedometer plus goals setting where each adolescent of the intervention group will receive their own goal (based on the number of steps measured in the baseline week) outlining the goals to achieve weekly. To improve healthy behavior will be sent by WhatsApp® messages about healthy eating and regular PA for the intervention and parents groups.
16243374|NCT05070377|No Intervention|Control|The control group participated in usual practice (regularly scheduled PE and postcurricular school sport) for the duration of the intervention .
16243376|NCT05070364|No Intervention|No treatment for 12 weeks|No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up
16243377|NCT05070351|Experimental|PPI deprescribing arm|Patients taking a PPI (at least 20 mg omeprazole equivalent daily) will be instructed to stop taking their PPI.
16243378|NCT05070351|No Intervention|PPI continuation arm|Patients will be instructed to continue taking their PPI (at least 20 mg omeprazole equivalent daily) as usual.
16243379|NCT05070338|Experimental|Guideline-Based Nudges|
16243380|NCT05070338|Experimental|Peer-Based Nudges|
16243381|NCT05070338|No Intervention|Control|
16243382|NCT05070325|Experimental|Cold application group (Group 1)|In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
16243383|NCT05070325|Experimental|Shotblocker group (Group 2)|The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
16243384|NCT05070325|Experimental|Control Group (Group 3)|The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
16243385|NCT05070312|Experimental|MEDI3506 dose 1|MEDI3506 dose1
16243386|NCT05070312|Experimental|MEDI3506 dose 2|MEDI3506 dose 2
16243387|NCT05070312|Placebo Comparator|Placebo|Placebo 2 mL and 4 mL
16243393|NCT05070260|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
16243394|NCT05070260|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
16243395|NCT05070247|Experimental|Dose Escalation: TAK-500 Single Agent (SA) (dosed Q3W)|TAK-500 dose escalation starting at 8 microgram per kilogram (mcg/kg), infusion, intravenously, once on Day 1 of each 21-days treatment cycle, once every 3 weeks (Q3W), for up to 1 year.
16243396|NCT05070247|Experimental|Dose Escalation: TAK-500 (dosed Q3W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Day 1 of each 21-days treatment cycle (Q3W), along with pembrolizumab 200 milligram (mg) infusion, intravenously, once on Day 1 of each 21-days treatment cycle (Q3W), for up to 1 year. The exact starting dose of TAK-500 will be determined from the results of the TAK-500 SA arm dose escalation.
16243397|NCT05070247|Experimental|Dose Expansion: TAK-500 (dosed Q3W and/or Q2W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Days 1 and 22 (Q3W), and/or once on Days 1, 15, and 29, once every 2 weeks (Q2W), in a 42-days treatment cycle with pembrolizumab 200 mg infusion, intravenously, once on Days 1 and 22 (Q3W), in a 42-days treatment cycle for up to 1 year. The dose of TAK-500 for the Dose Expansion arm will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
16243398|NCT05070234||short stature children born small for gestational age|This group was defined as a group of children whose birth weight and/or birth length equal or less than -2 SD for sex and gestational age, and who had failed to catch up in growth, remaining short after 2 years old.
16243399|NCT05070221|Experimental|Arm A|Patients histologically confirmed mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
16243400|NCT05070221|Experimental|Arm B|Patients histologically confirmed non-mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
16243401|NCT05070195|Experimental|The DDI of SKLB1028 and Midazolam|Eligible subjects received a single dose of Midazolam 15 mg on Day 1, and took a single dose of Midazolam 15 mg and a single dose of SKLB1028 150 mg with dosing interval of 0.5 h on Day 3.
16243402|NCT05070182||Patients with brain damage|"ICU patients with brain damage (due to cardiac arrest, intracranial hemorrhage or traumatic brain injury). and GCS upon entry <=8.
~All patients will be examined with a transcranial doppler (TCD) and a metabolic computer (for the measurements of REE) After the final diagnosis the patients' characteristics will be compared according to if they were brain dead or not"
16243403|NCT05070169||Early Surgical Fixation|Prospective cohort of patients with intertrochanteric fractures with DOAC (direct oral anticoagulation) therapy undergoing early surgical fixation (within 24 hours).
16243404|NCT05070169||Delayed Surgical Fixation|Retrospective control group of patients with intertrochanteric fractures with DOAC medication who underwent delayed surgical fixation (≥48 hours) from January 2014 to December 2018.
16243405|NCT05070156|Experimental|Experimental: B010-A injection for patient with GPC3 Positive Hepatocellular Carcinoma|
16243406|NCT05070143|Experimental|Brief education|"Participants will be randomly allocated to the Brief Education condition or one of the five treatment conditions (see below).
~In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time."
16243407|NCT05070143|Experimental|Treatment condition|All participants will receive the Brief Education intervention described above. Then, participants will be randomly allocated to one of the following conditions for habit formation.
16243408|NCT05070130||dPR and FFR|Subjects with aortic stenosis who are considered for TAVR will undergo a physiological assessment and prediction of ischemic coronary lesions pre- and post-TAVR by using Opsens non-hyperemic dPR and/or Opsens FFR
16243410|NCT05070104|Experimental|Single Arm|CPI-613 mFFX Bevacizumab
16243413|NCT05070052|Experimental|Group CBT|9 group sessions lasting 75-90 minutes each. CBT starts with psychoeducation about emotions, their primary functions, and how our emotions can affect the way we think and behave. They next learn about behavioral strategies that can help them manage or overcome difficult emotions. Group members also complete gradual exposure exercises, which involve engaging with activities that elicit negative emotions. Finally, group members are taught cognitive skills to help them cope with difficult/stressful thoughts.
16243414|NCT05070052|Experimental|Group MBCT|9 group sessions lasting 75-90 minutes each. The focus of sessions 1 through 4 will be learning to bring greater awareness to the present moment, on purpose, and nonjudgmentally. Appropriate responding is the focus of sessions 5 through 8. All skills are reviewed in session 9.
16243415|NCT05070039|Other|patients with invasive and non invasive urothelial carcinoma|patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.
16243416|NCT05070026|Experimental|uni-portal VATS group|
16243417|NCT05070026|Experimental|three port VATS group|
16243418|NCT05070013|Experimental|Adaptive DBS stimulation|Subjects experience adaptive stimulation during one week of at-home night sleep.
16243419|NCT05070013|Active Comparator|Open-loop DBS stimulation|Subjects experience open-loop stimulation (standard clinical stimulation therapy based on DBS programming for the treatment of motor symptoms) during one week of at-home night sleep.
16243420|NCT05070013|No Intervention|No DBS Stimulation|DBS stimulation is turned off (control) during one week of at-home night sleep.
16243421|NCT05070000||US|Ultrasound
16243422|NCT05070000||CT|Computed tomography
16243423|NCT05070000||US after CT|Ultrasound after Computed tomography
16243424|NCT05069987|Experimental|VR-immersion|
16243425|NCT05069987|No Intervention|Non-VR control|
16243428|NCT05069961|Active Comparator|ESPB Group|20ml Ropivacaine is injected near the nerves in the back and then continued using an infusion pump.
16243429|NCT05069961|Active Comparator|TEA Group|5ml Bupivacaine is injected into the space around the spinal cord and then continued using an infusion pump.
16243430|NCT05069948|Experimental|HeadOn intervention|Participants are given access to HeadOn - a web application that delivers a CBT programme to patients following concussion.
16243431|NCT05069935|Experimental|Dose Escalation|"Cohort A: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved
~Cohort B: FT538 plus trastuzumab in subjects with advanced documented HER2+ tumors
~Cohort C: FT538 plus cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell carcinoma (HNSCC)"
16243432|NCT05069935|Experimental|Dose Expansion|"Cohort A, Arm 1: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved (except urothelial carcinoma (UC))
~Cohort A, Arm 2: FT538 plus an anti-PD-1 antibody (nivolumab or pembrolizumab) in subjects with solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved (except UC)
~Cohort B, Arm 1: FT538 plus trastuzumab in subjects with HER2+ tumors
~Cohort C, Arm 1: FT538 plus cetuximab in subjects with advanced CRC or HNSCC
~Subjects with UC may be enrolled in the randomized expansion cohorts as follows:
~Cohort A, Arm R1: FT538 plus avelumab
~Cohort A, Arm R2: FT538 plus atezolizumab"
16243433|NCT05069922|Active Comparator|Fresh Frozen Plasma|At 6-8 hours, Initiate FFP infusion
16243434|NCT05069922|Active Comparator|Albumin|At 7 hours, Initiate 5% Albumin infusion
16243435|NCT05069909|Active Comparator|Conventional technique|The group of patients who received dentures fabricated with conventional technique first
16243436|NCT05069909|Active Comparator|Simplified technique|The group of patients who received dentures fabricated with simplified technique first
16243439|NCT05069883|Experimental|Oral Steroid|In this group oral steroids were given after Direct vision internal urethrotomy
16243440|NCT05069883|Placebo Comparator|No Oral Steroids|In this group no oral steroids were given after Direct vision internal urethrotomy
16243441|NCT05069870|Experimental|The DDI of SKLB1028 and Itraconazole|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Itraconazole 200 mg twice-daily on Day 8 and 200 mg once-daily on Day 9 through Day 18, and took a single dose of SKLB1028 100 mg on Day 11.
16243442|NCT05069870|Experimental|The DDI of SKLB1028 and Gemfibrozil|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Gemfibrozil 600 mg twice-daily on Day 8 through Day 19, and took a single dose of SKLB1028 100 mg on Day 12.
16243443|NCT05069870|Experimental|The DDI of SKLB1028 and Rifampicin|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1, then took Rifampicin 600 mg once-daily on Day 8 through Day22, and took a single dose of SKLB1028 150 mg on Day 15.
16243444|NCT05069857|Experimental|Neoadjuvant arm|The patients received three cycles of neoadjuvant therapy, with 14 days each. Dosage and administration: 200mg Carrelizumab intravenously on the first day of each cycle; Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle. Then the patients received the standard treatment of surgery and postoperative adjuvant therapy of radiotherapy or chemoradiotherapy.
16243445|NCT05069857|No Intervention|Control arm|The patients received the standard treatment of surgery and postoperative adjuvant therapy of radiotherapy or chemoradiotherapy.
16243449|NCT05069831|Active Comparator|Abrocitinib 100mg|This arm will receive 100mg of the study drug
16243450|NCT05069831|Active Comparator|Abrocitinib 200mg|This arm will receive 200mg of the study drug
16243451|NCT05069805|Active Comparator|PECS II block group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
16243452|NCT05069805|Active Comparator|ESP block group|Patients in ESP group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
16243453|NCT05069779|Experimental|Diazepam|Oral
16243454|NCT05069779|Placebo Comparator|Placebo|Oral
16243455|NCT05069766|Experimental|BioXmark™|
16243458|NCT05069740|Experimental|Salsalate|3000 mg/day salsalate (1500 mg twice daily) for 5 days
16243459|NCT05069740|Placebo Comparator|Placebo|1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days
16243460|NCT05069727|Active Comparator|Group 1, Regular Protocol|Participants will bolus (insulin), based on carbohydrate content in each meal
16243461|NCT05069727|Experimental|Group 2, Simplified protocol|Participants will bolus (insulin), based on three sets of meal set of meals announcement
16243462|NCT05069714|Experimental|MTX 1 week hold|Patients who will hold MTX for 1 week after an influenza vaccine.
16243463|NCT05069714|Active Comparator|MTX 2 week hold|Patients who will hold MTX for 2 weeks after an influenza vaccine.
16243465|NCT05069688|Experimental|Dolutegravir PK during standard and high-dose rifampicin|This is a single arm study: all patients are started on HIV/TB cotreatment considered standard of care and then for two weeks (study weeks 20-21) high-dose rifampicin is given during which safety and pharmacokinetics are examined.
16243466|NCT05069662||Patients treated with oral anticancer drugs|Patients treated with oral anticancer drugs followed in the Oncoral program
16243467|NCT05069649|Experimental|Ergoferon|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15-30 minutes before meals), keep the tablets in the mouth, without swallowing, until completely dissolved.
16243468|NCT05069649|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Ergoferon scheme.
16243469|NCT05069636|Experimental|Lymphatic OMM plus Moderna COVID-19 Vaccine regimen|Patients receive OMM treatments that will include thoracic inlet and outlet myofascial release, pectoral traction myofascial release, and Miller Thoracic Lymphatic Pump technique plus the Moderna COVID-19 Vaccine regimen.
16243470|NCT05069636|Sham Comparator|Light Touch plus Moderna COVID-19 Vaccine regimen|Patients receive a series of light touch techniques plus the Moderna COVID-19 Vaccine regimen.
16243475|NCT05069610|Experimental|Standard of care + AD17002 (3 doses)|Received 3 weekly doses of AD17002 20μg/dose of AD17002 by intranasal route
16243476|NCT05069610|Placebo Comparator|Standard of care + Placebo (3 doses)|Received 3 weekly doses of Placebo 20μg/dose of formulation buffer by intranasal route
16243477|NCT05069610|Experimental|Standard of care + AD17002 (5 doses)|Received 5 doses of AD17002 in 15 days 20μg/dose of AD17002 by intranasal route
16243478|NCT05069610|Placebo Comparator|Standard of care + Placebo (5 doses)|Received 5 doses of Placebo in 15 days 20μg/dose of formulation buffer by intranasal route
16243481|NCT05069584|Experimental|transperineal biopsy|The strategy evaluated is based on performing targeted and systematized prostate biopsies performed by the transperineal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
16243482|NCT05069584|Active Comparator|transrectal biopsy|The comparison strategy is based on performing targeted and systematized prostate biopsies performed by the transrectal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
16243483|NCT05069558|Experimental|Investigational PFO Closure Device|PFO closure with the study Occlutech Flex II PFO device.
16243484|NCT05069558|Active Comparator|Standard of Care PFO Closure Device|PFO closure with either of the standard of care PFO occlusion devices; Amplatzer PFO Occluder or the Gore Cardioform PFO Occluder.
16243485|NCT05069545||Tresiba + Fiasp using NovoPen 6 per local label|Participants will use Tresiba® and Fiasp® in NovoPen® 6 as prescribed to participants by the study doctor
16243486|NCT05069519|Experimental|Facebook Condition|Participants assigned to this intervention will take part in personalized Facebook health education, receive a smartwatch, receive weekly health education, share sentiments on Facebook, and receive personalized feedback.
16243487|NCT05069519|Experimental|Smartwatch Condition|Participants assigned to this intervention will use a Fitbit to track daily physical activity (PA), share PA data remotely, and receive personalized feedback.
16243488|NCT05069519|Experimental|Combined Condition|Participants assigned to this condition will receive both Fitbit and Facebook health education programs, (The Smartwatch and Facebook Conditions). The investigators will also provide weekly personalized feedback, based on PA data and sentiment analysis, that have been developed in prior pilot studies.
16243505|NCT05069454|Active Comparator|Control group|Have not received any doses of any form of COVID-19 vaccine
16244984|NCT05059223|Placebo Comparator|Placebo|Up to 5 weeks
16243489|NCT05069519|No Intervention|Attention Control|Participants assigned to the control condition will not receive any intervention. They will receive a Fitbit smartwatch, and continue with their standard care currently done in their life during the intervention period.
16243490|NCT05069506|Experimental|Glucose as reference food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16243491|NCT05069506|Experimental|Goat milk as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16243492|NCT05069506|Experimental|Goat milk and currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16243493|NCT05069506|Experimental|Currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16243494|NCT05069506|Experimental|Sultanina raisins as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16243495|NCT05069506|Experimental|Goat milk as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
16243496|NCT05069506|Experimental|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
16243497|NCT05069493||Tension-free|Hiatal hernia repair by tension-free mesh closure
16243498|NCT05069493||Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
16243499|NCT05069480|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was one hour and few minutes rest in between. The first part included: reflex inhibiting patterns, strengthening activities, stretching exercises, and postural reactions exercises. The second part included: arm-reaching tasks, arm-hand tasks, hand manipulative tasks for the more affected upper limb through performing functional tasks of daily living activities.
~The traditional intervention was carried out three sessions per week for twelve successive weeks."
16243500|NCT05069480|Experimental|Experimental Group|"Participants of the experimental group have received two hours treatment program that included three parts, the first and the second parts were similar to that applied for participants in the control group for one hour followed by few minutes rest, then the third part was applied for one hour. The third part included a virtual reality intervention program by using virtual reality equipment to simulate a range of upper limb tasks related to arm-hand activities and hand manipulative tasks through using different games and soft-wares.
~The treatment program for the experimental group was carried out three sessions per week for twelve successive weeks."
16243501|NCT05069467|Experimental|Acupuncture|Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
16243502|NCT05069467|Sham Comparator|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
16243503|NCT05069467|No Intervention|Usual Care|Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.
16243504|NCT05069454|Active Comparator|Exposure group|Healthcare workers vaccinated by any of the available COVID19 vaccine;
16243506|NCT05069441||Patients with extubation after a weaning trial|Patients who sucessfully complete a spontaneous breathing trial are enrolled in this group.
16243507|NCT05069428|Experimental|ramelteon|ramelteon 8 mg crushed tablet daily at 20:30
16243508|NCT05069428|Placebo Comparator|placebo|placebo powder equivalent grams at 20:30
16243509|NCT05069415|Active Comparator|Emmetropia|The target refraction for both eyes will be emmetropia (± 0.25 D).
16243510|NCT05069415|Experimental|Mini monovision|The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.
16243511|NCT05069402|Experimental|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
16243512|NCT05069402|Active Comparator|High-protein diet|Oral nutrition with high-protein content
16243513|NCT05069402|Active Comparator|Standard nutrition|Oral nutrition with standard components
16243516|NCT05069363|Experimental|Intervention Group|All participants in this feasibility trial will receive a course of whole-body photobiomodulation therapy (18 sessions over 6 weeks)
16243517|NCT05069350|Experimental|bupivacaine 0.5%|
16243518|NCT05069350|Experimental|oxybuprocaine|
16243519|NCT05069324||Acromegaly patients not adequately controlled by any kind of SSAs monotherapy|Acromegaly patients not adequately controlled by any kind of SSAs monotherapy, requiring PEG in combination with SSAs or PEG monotherapy
16243520|NCT05069324||Acromegaly patients adequately controlled by medical treatment|Acromegaly patients adequately controlled by medical treatment, by any kind of SSAs or by PEG
16243521|NCT05069311|Experimental|Hysterectomy|Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
16243522|NCT05069298|Experimental|INTERVENTION|Silibinin (A) for three months, with an administration regimen of 3 oral doses of 300 mg per day, before each main meal.
16243523|NCT05069298|Placebo Comparator|CONTROL|Similar treatment regimen, but with a placebo.
16243524|NCT05069285|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian)
16243525|NCT05069285|Active Comparator|Sleep hygiene advice|A sheet of paper with standard sleep hygiene advice
16243526|NCT05069272|Active Comparator|Intervention|Synergistic combination of Bakuchiol and Ethyl Linoleate
16243527|NCT05069272|Placebo Comparator|Vehicle|No active ingredients
16243529|NCT05069246|Experimental|Group 1 / Nigella Sativa oil / NS|"Group 1- Nigella Sativa (NS) N. sativa oil (Al-Hussan Food Products Factory, Riyadh, Kingdom of Saudi Arabia), which was brought from the local market in Riyadh.
~Each participant was given a 3 weeks supply of oil, and a sterile plastic 15ml graduated measuring cap. They were asked to measure 5ml of oil into the cap and add 5ml of normal drinking water to this and rinse their mouth for 3mins with this solution and spit it out at the end. This was done morning and evening for 14 days.
~Group 1: Maintained adequate plaque control levels using mechanical methods + N.sativa oil (5ml oil + 5ml water) pulling for 3 mins twice daily in the morning and at night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).
~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
16243530|NCT05069246|Active Comparator|Group 2 / Chlorohexidine / CHX|"Group 2- Chlorohexidine (CHX).
~Chlorohexidine (Middle East Pharmaceutical Industries Ltd, Riyadh, Kingdom of Saudi Arabia).
~Each participant was given a 3 week supply of chlorohexidine. They were asked to use 10ml of CHX morning and evening, rinsing their mouth for 3 mins and then spit it out at the end. This was done morning and evening for 14 days.
~Group2: maintained adequate plaque control levels using mechanical methods + chlorohexidine rinse twice daily 10ml in the morning and at the night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).
~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
16243531|NCT05069233||UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
16243532|NCT05069220|Experimental|18F-MFBG PET/CT in neuroendocrine malignancies|Each patient receive a single intravenous injection of 18F-MFBG 148-444 MBq (4- 12mCi) and undergo PET/CT scan at 60-90 min post-injection. All patients should have a routine clinical 131I-MIBG scintigraphy (planar and/or SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.
16243533|NCT05069207||Monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
16243534|NCT05069207||Non-monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
16243535|NCT05069207||Daytime Urinary Incontinence|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
16243536|NCT05069207||Control Group Healthy Individuals|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
16243537|NCT05069194||COPD|Patients with chronic obstructive pulmonary disease
16243538|NCT05069194||High Risk|People who do not suffer from COPD, but have high risk factor for COPD.
16243539|NCT05069194||Health|People who do not suffer from COPD and do not have a high risk factor for COPD either.
16243540|NCT05069181|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
16243541|NCT05069181|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
16244985|NCT05059210|No Intervention|Control|Coach McLungs not yet implemented in practice
16243542|NCT05069181|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
16243543|NCT05069168||LVEFrecovery|patient who shows improvement of left ventricular systolic function
16243544|NCT05069168||Non LVEF recovery|patient who don't show improvement of left ventricular systolic function
16243545|NCT05069155|No Intervention|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design.
16243546|NCT05069155|Experimental|Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 12-week intervention period.
~At the end of the 12 week intervention period, participants will enter a 6 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design."
16243547|NCT05069142|Experimental|Intervention group|15 participants will be randomly selected to the intervention group. These individuals will receive six weeks of pre-operative exercise instruction and education, as well as six weeks of graduated post-operative exercise instruction, beginning at three weeks post-op with the surgeons clearance.
16243548|NCT05069142|No Intervention|Control group|15 participants will be randomly selected to the control group. This group will receive pre-operative education in the form of videos regarding the procedure and pain. They will not receive exercise instruction.
16243555|NCT05069103|Experimental|Intervention|"Similar to the original TWIST trial, patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:
~A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).
~At least one image of their surgical wound(s).
~Patients will receive automated requests via notifications asking to complete the online tool over the 30-day period (every 3 days +/- 1 day), however they may also complete the online form whenever wished."
16243556|NCT05069090||Students and academics Universidad La Frontera|The intervention consists of social distancing measures to curb the viral transmission of SARS-CoV-2. The Araucanía region was subject to lockdown in a different moment than the Coquimbo region, creating exogenous variation.
16243557|NCT05069090||Students and academics Universidad Católica del Norte|The intervention consists of social distancing measures to curb the viral transmission of SARS-CoV-2. The Coquimbo region was subject to lockdown in a different moment than the Araucanía region, creating exogenous variation.
16243558|NCT05069077|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
16243559|NCT05069077|Other|non-music group|Participants in the non-music group will undergo diagnostic outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
16243560|NCT05069064|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
16243561|NCT05069064|Other|non-music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
16243562|NCT05069051|Experimental|Belimumab|Patients obtain belimumab in combination with rituximab/venetoclax
16243563|NCT05069051|Active Comparator|Standard of Care|Patients obtain the combination rituximab/venetoclax
16243564|NCT05069038|Experimental|Treatment|"The following drugs will be taken for six cycles:
~Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days and 7 days off schedule (meaning: on Days 1-21 of each 28-day cycle).
~Letrozole should be taken daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
~Goserelin is given as subcutaneous injection every 28 days at a dose of 3.6 mg. It is to be given on Day 1 of each cycle. Goserelin will only be administered to pre-menopausal subjects."
16243565|NCT05069025|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
16243566|NCT05069025|Other|non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
16243567|NCT05069012|Active Comparator|50 micrograms|Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
16243568|NCT05069012|Active Comparator|150 micrograms|Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
16243738|NCT05067920||Symptomatic patients|60 patients with COVID-19 symptoms related at the time of diagnosis.
16243569|NCT05069012|Active Comparator|250 micrograms|Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
16243570|NCT05068986|Other|single arm intervention|
16243571|NCT05068973|Experimental|Luciola|Bronchoscopic implantation of the fiducial marker NOVATECH® LUCIOLA™ EB prior to radiotherapy treatment.
16243572|NCT05068960|Experimental|Study group|The study group will receive an interscalene block consisting of 10 mL 0.5% bupivacaine and 10 mL of liposomal bupivacaine [133mg].
16243573|NCT05068960|Active Comparator|Control group|The control group will receive an interscalene block consisting of 20 mL of 0.5%bupivacaine alone.
16243574|NCT05068947|Experimental|Study drug: GV101|50 mg or 200 mg tablets totaling to 50mg, 100 mg, 200 mg, 400 mg tablets will be administered once orally to subjects in the treatment group, cohort 1 to 4. 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the treatment group, cohort 5 to 7.
16243575|NCT05068947|Placebo Comparator|Placebo|Matched placebo control 50 mg or 200 mg tablets totaling to 50mg, 100 mg, 200 mg, 400 mg tablets will be administered once orally to subjects in the control group, cohort 1 to 4. Matched placebo control 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the control group, cohort 5 to 7.
16243580|NCT05068895||Group1|Volunteers with normal glucose tolerance.
16243581|NCT05068895||Group2|type 2 diabetic patients without microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or lower extremity arterial disease) complications.
16243582|NCT05068895||Group3|type 2 diabetic patients with lower extremity artery disease diagnosed through the measurement of ABI (the ratio of ankle-to-brachial systolic blood pressure).
16243583|NCT05068882|Experimental|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
16243584|NCT05068882|Active Comparator|High-protein diet|Oral nutrition with high-protein content
16243585|NCT05068882|Active Comparator|Standard nutrition|Oral nutrition with standard ingredients
16243586|NCT05068882|No Intervention|No intervention|No intervention
16243587|NCT05068869|Other|Dignio Digital Remote Care intervention group|Participants will receive the MyDignio app for individualized follow-up for 12 months.
16243588|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
16243589|NCT05068856|Experimental|HRS2543|
16243590|NCT05068843|Active Comparator|Arthroscopic partial meniscectomy|"In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy (APM) within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
~Other Names:
~APM meniscal surgery surgery"
16243591|NCT05068843|Other|Physical therapy|The physical therapy program consisted of a physical therapist-led incremental exercise program containing of coordination/balance, closed kinetic chain strengths and cardiovascular exercises (see Appendix 1). The program was designed for 8 weeks with a total of 16 treatment sessions, each with a duration of 30 minutes. All 16 sessions were reimbursed. If knee symptoms persisted following the physical therapy program (e.g., knee pain, limitations in daily activities or mechanical dysfunction ), the patient could attend additional physical therapy sessions (not reimbursed by the study) or have meniscal surgery, depending on a shared decision after consultation with their orthopaedic surgeon.
16243592|NCT05068830|Experimental|Exercised plasma (ExPlas)|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
16243593|NCT05068830|Active Comparator|Octaplasma|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
16243594|NCT05068830|Placebo Comparator|Saline|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)
16243595|NCT05068817|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
16243596|NCT05068817|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
16243597|NCT05068817|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
16244986|NCT05059210|Active Comparator|Intervention|Coach McLungs Implemented in Practice
16243598|NCT05068804|Experimental|cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
16243599|NCT05068804|Placebo Comparator|Control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
16243602|NCT05068765|No Intervention|control group|Once enrolled and consent is documented, eligible subject's will participate in the study for approximately six months.
16243603|NCT05068765|Experimental|communication skills psychoeducation|Communication skills focused psychoeducation group will be given a communication skills-focused psychoeducation program for eight weeks, one session per week, for a total of eight sessions. The number of sessions was planned with reference to the study in which the effect of the psychoeducation program on general health and communication skills in caregivers of individuals with schizophrenia was investigated.Session groups will be formed from a single session of 60-90 minutes for each topic.
16243604|NCT05068765|Experimental|general psychoeducation|General psychoeducation group will be given a general psychoeducation program for four weeks, one session per week, in total. Session groups will be formed from a single session of 60-90 minutes for each topic.
16243605|NCT05068752|Experimental|Vemurafenib in Combination with Sorafenib|
16243606|NCT05068739|Experimental|PA-EMR (Partial ampullary endoscopic mucosal resection)|Partial ampullary endoscopic mucosal resection
16243607|NCT05068739|Active Comparator|NKF(Needle knife fistulotomy)|Needle knife fistulotomy
16243608|NCT05068713|Experimental|Hihg Target Mean Arterial Pressure|Target of mean arterial pressure of 85-90 mmHg in ther first 24h after liver transplant.
16243609|NCT05068713|Active Comparator|Low Target Mean Arterial Pressure|Target of mean arterial pressure of 65-70 mmHg in ther first 24h after liver transplant.
16243610|NCT05068700|Active Comparator|Integrated Pulmonary Index disabled|Nurses randomized to the experimental arm will be asked to disable the Integrated Pulmonary Index feature of the Medtronic Capnostream 35p monitor when monitoring sedated patients with capnography.
16243611|NCT05068700|Experimental|Integrated Pulmonary Index enabled|Nurses randomized to the experimental arm will be asked to enable the Integrated Pulmonary Index feature of the Medtronic Capnostream 35p monitor when monitoring sedated patients with capnography.
16243612|NCT05068687|Experimental|intraoperative high-resolution PET-CT imaging of resected malignancy|
16243613|NCT05068674|Active Comparator|Cohort 1|Low dose (50M cells)
16243614|NCT05068674|Active Comparator|Cohort 2|Medium dose (150M cells)
16243615|NCT05068674|Active Comparator|Cohort 3|High dose (300M cells)
16243616|NCT05068661|Active Comparator|Combined Spinal Epidural|10 mcg of preservative-free fentanyl and 2 mg of preservative-free isobaric 0.25% bupivacaine will be administered into the intrathecal space to initiate analgesia. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
16243617|NCT05068661|Active Comparator|Dural Puncture Epidural|A 25-G Whitacre needle will be used to puncture the dura. An initiation dose of 20 mL of ropivacaine 0.1% with fentanyl (2 mcg/mL) will be administered. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
16243618|NCT05068648|Active Comparator|MWC Configuration 1|"standard upholstery back that promotes posterior pelvic tilt set at or below cushion level and 1 above inferior angle"
16243619|NCT05068648|Active Comparator|MWC Configuration 2|active contour back positioned with seat gap and with free scapulae
16243620|NCT05068648|Active Comparator|MWC Configuration 3|active contour back positioned with seat gap and with blocked scapulae
16243621|NCT05068648|Active Comparator|MWC Configuration 4|deep contour back positioned with seat gap and with free scapulae
16243622|NCT05068648|Active Comparator|MWC Configuration 5|deep contour back positioned without seat gap and with free scapulae
16243623|NCT05068622||patients with nasogastric tube before surgery|
16243624|NCT05068622||patients without nasogastric tube before surgery|
16243625|NCT05068609||Cohort 1|Participants with squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab
16243626|NCT05068596|Experimental|study groip|received the designed physical therapy program as the control group. In addition, they received progressive resistive functional strength training in the plantigrade foot position.
16243627|NCT05068596|Other|control group|received a designed physical therapy program
16243628|NCT05068583||Osteosarcoma|
16243629|NCT05068583||Ewing Sarcoma|
16243630|NCT05068583||Rhabdomyosarcoma|
16243631|NCT05068583||Synovial Sarcoma|
16243632|NCT05068583||Non-Rhabdomyosarcoma Soft Tissue Sarcoma|
16243633|NCT05068583||Hepatic Tumors|
16243634|NCT05068583||Renal Tumors|
16243635|NCT05068583||Thyroid Tumors|
16243636|NCT05068583||Germ Cell Tumors|
16243637|NCT05068583||Healthy Volunteers|
16243638|NCT05068570|Experimental|EXPERMINTAL GROUP|start with cycle at a pace of 15-25 cycles per minute without resistance and end with cycle 45cycles per minute
16243639|NCT05068570|No Intervention|CONTROL GROUP|selected respiratory exercise program
16243640|NCT05068557|Active Comparator|Intervention group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with fish oil (3 capsules daily. Containing EPA+DHA: 1.8 g). (n=40)
16243641|NCT05068557|Placebo Comparator|Control group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with chia/linseed oil (3 capsules daily. Containing ALA 1.6 g). (n=40)
16243642|NCT05068531||Observational|We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.
16243643|NCT05068505|Experimental|Community health worker delivered multicomponent intervention|The study will employ a closed cohort stepped wedge cluster randomized design. There will be a sequential crossover of clusters from the control to the intervention arms and the order of the cross over will be randomly determined. This study will be conducted in 21 clusters within Nakaseke district. Each cluster will consist of 4-5 villages. We plan to rollout the intervention in two clusters per month and one cluster in the final month.
16243644|NCT05068505|No Intervention|Control|All clusters will be observed under both the intervention and control arm through sequential crossover.
16243645|NCT05068492||Training cohort|
16243646|NCT05068492||Validation cohort|
16243647|NCT05068492||Test cohort|
16243648|NCT05068479|Experimental|Natural Emmetropic Presbyopes|Patients that did not undergo any vision correcting surgery or implantation of an intraocular lens but suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
16243649|NCT05068479|Experimental|Post Laser Vision Correction (LVC) Emmetropic Presbyopes|Patients that underwent laser vision correction procedure (e.g. LASIK) in the past and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
16243650|NCT05068466|Experimental|INCB054707 (Dose A)|Participants will be administered single-dose INCB054707 on Day 1 followed by once daily dose of INCB054707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
16243651|NCT05068466|Experimental|INCB054707 (Dose B)|Participants will be administered a single-dose INCB054707 on Day 1 followed by once daily dose of INCB54707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours.
16243652|NCT05068466|Placebo Comparator|Placebo (Dose A)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
16243653|NCT05068466|Placebo Comparator|Placebo (Dose B)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
16243654|NCT05068453|Experimental|OH2+HX-008+RT|Patients will get OH2 （once every two weeks）and HX-008 (once every three weeks)and radiotherapy (totally 3 times).
16243655|NCT05068440|Experimental|Zanubrutinib|administered orally
16243656|NCT05068427|Experimental|Chidamide + Envafolimab|Patients receive Chidamide 20mg or 30mg orally twice per week and Envafolimab 400mg subcutaneous infusions every 4 weeks untile disease progression or unacceptable toxicity.
16243657|NCT05068414||Patients with atrial fibrillation|
16243658|NCT05068401|Experimental|Regimen A (RIC)|"Fludarabine 30 mg/m2/day intravenously (IV) on Days -6, -5, -4, - 3, -2
~Cy 14.5 mg/kg/day IV on Days -6, -5
~Total body irradiation (TBI) 200 centigray (cGy) on Day -1
~Day 0 will be the day of infusion of non-T-cell depleted bone marrow"
16243659|NCT05068401|Experimental|Regimen B (FIC)|1. Busulfan ≥ 9mg/kg total dose (IV or oral (PO)) on Days -6, -5, -4, -3 2a. Cy 50mg/kg/day IV on Days -2, -1 OR 2b. Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2 3. Day 0 will be the day of infusion of non T-cell depleted bone marrow
16243660|NCT05068401|Experimental|Regimen C (FIC)|"Cy 50mg/kg/day IV on Days -5, -4
~TBI 200cGy twice a day on Days -3, -2, -1
~Day 0 will be the day of infusion of non- T-cell depleted bone marrow"
16243661|NCT05068388|Placebo Comparator|Placebo|oral capsule
16243662|NCT05068388|Experimental|1 mg (Z)-endoxifen|oral capsule
16243663|NCT05068388|Experimental|2 mg (Z)-endoxifen|oral capsule
16243664|NCT05068375||Thrombotic group|Non-critically COVID-19 patients with unusual thrombotic events
16243665|NCT05068375||Non-thrombotic group|Non-critically COVID-19 patients without thrombotic events
16243666|NCT05068362|Other|Implant|Use of Medpor implant in auricle reconstruction in microtia
16243667|NCT05068349|Experimental|A group of patients with ischemic stroke were treated with butylphthalide injection and capsules|Patients eligible for inclusion and exclusion are only divided into one group, no controls or other.
16243668|NCT05068336||desflurane|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
16243669|NCT05068336||sevoflurane|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
16243670|NCT05068323|Other|Epilepsy|Newly diagnosed epileptic patients
16243671|NCT05068323|Sham Comparator|Control|healthy subjects
16243672|NCT05068310||Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors|Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors who are scheduled for skin biopsy or excision
16243675|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose A|Varying doses of ABBV-154 as described in the protocol.
16243676|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose B|Varying doses of ABBV-154 as described in the protocol.
16243677|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose C|Varying doses of ABBV-154 as described in the protocol.
16243678|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose D|Varying doses of ABBV-154 as described in the protocol.
16243679|NCT05068284|Placebo Comparator|Induction Phase: Randomized Placebo|Fixed dose placebo as described in the protocol.
16243680|NCT05068284|Experimental|Re-Induction Phase: ABBV-154 Randomized Dose A|Varying doses of ABBV-154 as described in the protocol.
16243681|NCT05068284|Experimental|Re-Induction Phase: ABBV-154 Randomized Dose B|Varying doses of ABBV-154 as described in the protocol.
16243682|NCT05068284|Experimental|Maintenance Phase: ABBV-154 Randomized Dose A|Fixed dose ABBV-154 every other week.
16243683|NCT05068284|Experimental|Maintenance Phase: ABBV-154 Randomized Dose B|Fixed dose ABBV-154 every other week.
16243684|NCT05068284|Placebo Comparator|Maintenance Phase: Randomized Placebo|Fixed dose placebo every other week.
16243685|NCT05068271|Experimental|Multi-Domain Exercise Program|"Time: 6 months, total of 180 min of exercise per week.
~Intervention: aerobic training, muscular fitness training, balance, flexibility, meditation and social interaction."
16243686|NCT05068271|Active Comparator|Active Control Group|"Time: 6 months, total of 180 min of online educational course per week.
~Intervention: educational materials relating to the effects of exercise on cognitive function and aging-related cognitive decline."
16243688|NCT05068245|No Intervention|Routine pain control|The routine pain control group will receive instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants.
16243689|NCT05068245|Experimental|Routine pain control plus music|Patients randomized to receive music in addition to routine pain control measures, will be instructed to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants. Preselected classical music will be played for this group throughout the procedure.
16243690|NCT05068232|Experimental|Participants With Extensive Small Cell Lung Cancer (All Participants)|"This arm will involve all participants in the study who have extensive small cell lung cancer that has not responded to previous treatments. All participants will receive the same treatment of study drugs and radiation treatment in cycles (a specific window of time).
~You will receive up to four 21-day cycles of chemotherapy using carboplatin, etoposide and durvalumab (immunotherapy) as part of a standard care treatment plan recommended by your doctor. These drugs will be combined with ablative radiation treatment during the second cycle of chemotherapy.
~After completing these four cycles of chemotherapy (with radiation treatment added in cycle 2), you will continue to receive a fixed dose of durvalumab until your cancer progresses, you experience serious side effects, you decide to no longer be part of the study or the study doctor request to take you off the study for medical reasons."
16243691|NCT05068219|Active Comparator|Usual technique|Standard rehabilitation
16243692|NCT05068219|Experimental|CR technique|Standard rehabilitation + 3 CR
16243696|NCT05068193|Other|Sequence 1|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.
~*Sequence 1
~[Period I] Administration of BR2008-1 (single dose)
~- Wash out for 2 weeks
~[Period II] Administration of BR2008 (single dose)"
16243697|NCT05068193|Other|Sequence 2|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.
~*Sequence 2
~[Period I] Administration of BR2008 (single dose)
~Wash out for 2 weeks
~[Period II] Administration of BR2008-1 (single dose)"
16243698|NCT05068180|Experimental|Neuroleptanalgesia group|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
16243699|NCT05068180|Placebo Comparator|Control group|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
16243700|NCT05068141|Experimental|SG001 plus Nab-Paclitaxel|Patients will receive SG001 intravenously at a dose of 240 mg on Days 1 and 15 of every 4-week cycle in combination with nab-paclitaxel at a dose of 100 mg/m^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or unacceptable toxicity, or other discontinuation or termination criteria are met.
16243701|NCT05068115||1|Young breast cancer patients in China from 2000 to 2015, of whom the clinical features, diagnosis and treatment models and survival status are described.
16243704|NCT05068076|Experimental|Patients undergoing ablation for HCC|Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment
16243705|NCT05068063|Experimental|Femoral Triangle + IPACK block|Patients randomized to receive a combination of femoral triangle block and active IPACK block
16243706|NCT05068063|Active Comparator|Femoral Triangle block|Patients randomized to receive a combination of femoral triangle block and sham IPACK block
16243707|NCT05068050|Experimental|Experimental group|This arm will be provided by horse-assisted therapy interventions.
16243708|NCT05068050|Active Comparator|Control group|This arm will be provided by the physical exercise interventions.
16243736|NCT05067933|Placebo Comparator|Part 2 Healthy Adults: Placebo control|Repeat dose administration with matching placebo tablets in healthy male and female adult volunteers 18 to 75 years old
16243737|NCT05067920||Asymptomatic patients|60 patients without COVID-19 symptoms related at the time of diagnosis.
16243709|NCT05068037|Active Comparator|STANDARD|"TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Patients will receive an antiemetic (ondansetron 4 mg). The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.
~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g.
~PACU:
~Analgesia in VAS> 3: piritramide 3 mg p.p. Antiemetic for POSB: metoclopramide 10 mg"
16243710|NCT05068037|Active Comparator|CONTROL|"TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Group does not receive neither acupuncture nor antiemetics. The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.
~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g.
~PACU:
~Analgesia in VAS> 3: piritramide 3 mg p.p. Antiemetic for POSB: ondansetron 4 mg."
16243711|NCT05068037|Active Comparator|STUDY|"Before surgery, one of the team members will talk to the patient and perform brief medical hypnosis to gain the patient's confidence in the method and teach him the method of relaxing and building an imaginary safe place where he feels comfortable and safe. Therapeutic communication through hypnosis will be used as an additional method in order to improve the well-being and comfort of the patient, reduce stress and use sedatives.
~TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Patients will receive acupuncture (PC6 and LI4 bilaterally) and no antiemetic The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.
~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g. Removal of acupuncture needles at the end of operation
~PACU:
~Analgesia in VAS> 3: piritramide 3 mg p.p. Antiemetic for POSB: ondansetron 4 mg"
16243712|NCT05068024|Experimental|Treatment of NSCLC patients with EGFR genetic alterations|
16243713|NCT05068011||Spinal cord stimulation|Patients will receive differential target multiplexed spinal cord stimulation
16243714|NCT05067998||IV Vitamin Therapy Treatments|IV vitamin infusion therapy involves inserting an IV line into a vein in your arm to administer a high concentration of liquid vitamins, antioxidants, amino acids, and minerals into your bloodstream. The therapy may be for only one vitamin or a cocktail of nutrients.
16243715|NCT05067998||Herbal Medicine, Vitamins|Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort. Herbal Medicine is type of medicine that uses roots, stems, leaves, flowers, or seeds of plants to improve health, prevent disease, and treat illness.
16243716|NCT05067998||Supplements|Dietary supplements are substances you might use to add nutrients to your diet or to lower your risk of health problems such as osteoporosis or arthritis. Dietary supplements come in the form of pills, capsules, powders, gel capsules and tablets, extracts, or liquids. Dietary supplements come in a variety of forms, including tablets, capsules, gummies, and powders, as well as drinks and energy bars. Popular supplements include vitamins D and B12; minerals like calcium and iron; herbs such as echinacea and garlic; and products like glucosamine, probiotics, and fish oils.
16243717|NCT05067998||Vitamins (Orally)|Vitamins are substances that our bodies need to develop and function normally. They include vitamins A, C, D, E, and K, choline, and the B vitamins (thiamin, riboflavin, niacin, pantothenic acid, biotin, vitamin B6, vitamin B12, and folate/folic acid). Vitamins are essential nutrients that enable your body to work properly and to stay healthy. Most vitamins can be found in the food that we eat or from vitamin supplements.
16243723|NCT05067959||IBD patients|patients with IBD (Chron's disease, Ulcerative colitis, IBD-Unspecify). patients will be divided into two sub-groups: IBD patients on anti-TNF therapy IBD patients on any other therapy
16243724|NCT05067959||Controls|healthy volunteers
16243725|NCT05067946|Experimental|GX-19N|GX-19N will be intramusculary administered via EP on day 1 and day 29.
16243726|NCT05067946|Placebo Comparator|Placebo|Placebo will be intramusculary administered via EP on day 1 and day 29
16243727|NCT05067933|Experimental|Part 1 Cohort 1a (Naïve, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
16243728|NCT05067933|Experimental|Part 1 Cohort 1b (Naïve, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
16243729|NCT05067933|Experimental|Part 1 Cohort 1c (Naïve, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
16243730|NCT05067933|Experimental|Part 1 Cohort 1d (Naïve, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
16243731|NCT05067933|Experimental|Part 1 Cohort 2a (Prior vaccinated, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
16243732|NCT05067933|Experimental|Part 1 Cohort 2b (Prior vaccinated, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
16243733|NCT05067933|Experimental|Part 1 Cohort 2c (Prior vaccinated, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
16243734|NCT05067933|Experimental|Part 1 Cohort 2d (Prior vaccinated, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
16243735|NCT05067933|Experimental|Part 2 Healthy Adults: Active vaccine|Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 in healthy male and female adult volunteers 18 to 75 years old
16243739|NCT05067907||Control|COVID-19 ICU-admitted patients that did not received physiotherapy interventions during ICU stay.
16243740|NCT05067907||Physiotherapy|COVID-19 ICU-admitted patients that received physiotherapy interventions during ICU stay.
16243741|NCT05067894|Experimental|Adult - Medium dose|25 µg dose, adult group (18-59 years)
16243742|NCT05067894|Experimental|Adult - High Dose|50 µg dose, adult group (18-59 years)
16243743|NCT05067894|Active Comparator|Adult - Control|SARS-CoV-2 inactivated vaccine, adult group (18-59 years)
16243744|NCT05067894|Experimental|Elderly - Medium dose|25 µg dose, elderly group (> 60 years)
16243745|NCT05067894|Experimental|Elderly - High dose|50 µg dose, elderly group (> 60 years)
16243746|NCT05067894|Active Comparator|Elderly - Control|SARS-CoV-2 inactivated vaccine, elderly group (> 60 years)
16243747|NCT05067881||Pneumohematocele|Patients with SARS CoV-2 diagnosis and PHC on imaging studies
16243748|NCT05067868|Experimental|Replagal|Participants with fabry disease will receive Replagal 0.2 milligram per kilogram (mg/kg) intravenous infusion on Day 1 and every 2 weeks up to Week 51.
16243749|NCT05067855|Experimental|Pilates exercise program group|The pilates exercise program group will perform five exercises
16243750|NCT05067842||Locally advanced esophageal or gastroesophageal adenocarcinoma|Subjects with diagnosed locally advanced esophageal or gastroesophageal adenocarcinoma.
16243751|NCT05067829|Active Comparator|Ideal Body weight|ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR IDEAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR IDEAL BODY WEIGHT WILL BE GIVEN. INTUBATION WILL BE DONE AT 45.SECONDS.LATER ON, INTUBATION CONDITIONS, TOF VALUE DURING INTUBATION PROCEDURE,TIME OF TOF ZERO,TIME OF TOF C 1 WILL BE EVALUATED.
16243752|NCT05067829|Active Comparator|Total Body Weight|ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR TOTAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR TOTAL BODY WEIGHT WILL BE GIVEN. INTUBATION WILL BE DONE AT 45.SECONDS.LATER ON, INTUBATION CONDITIONS, TOF VALUE DURING INTUBATION PROCEDURE,TIME OF TOF ZERO,TIME OF TOF C 1 WILL BE EVALUATED.
16243753|NCT05067829|Active Comparator|Corrected Body Weight|ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR CORRECTED BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR CORRECTED BODY WEIGHT WILL BE GIVEN. INTUBATION WILL BE DONE AT 45.SECONDS.LATER ON, INTUBATION CONDITIONS,TOF VALUE DURING INTUBATION PROCEDURE,TIME OF TOF ZERO,TIME OF TOF C 1 WILL BE EVALUATED.
16243754|NCT05067816|Active Comparator|Distance Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a distance scale-up format where each site implementation team will receive technical assistance individually. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
16243755|NCT05067816|Experimental|Quality Improvement Collaborative Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a quality improvement collaborative scale-up format where implementation teams will work collaboratively during training and implementation. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
16243756|NCT05067790|Experimental|Higher Dose Nusinersen|There will be two groups of participants previously treated with risdiplam in the study (nusinersen-naive group and nusinersen-experienced group), who will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months.
16243757|NCT05067777|Experimental|Arm I (SMT)|Patients receive SMT over 45 minutes once weekly for 6 weeks.
16243758|NCT05067777|Sham Comparator|Arm II (LT)|Patients receive LT over 45 minutes once weekly for 6 weeks.
16243759|NCT05067777|Active Comparator|Arm III (waitlist)|Patients receive no intervention for 6 weeks.
16243760|NCT05067764|Experimental|Aponeurectomy with grafting|The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.
16243761|NCT05067764|Active Comparator|Aponeurectomy alone|The control group evaluates the aponeurectomy alone.
16243762|NCT05067738|Other|Discharge|Phase 1-Patients will continue to be admitted after their surgery as is the current practice. Phase 2-Patients will have their chest tube removed once they meet chest tube removal criteria and will be discharged home once they meet discharge criteria.
16243763|NCT05067725|No Intervention|Control|Standard of practice
16243764|NCT05067725|Experimental|CarePath Intervention|Clinician decision support computer tool that consists of a best practice alert (BPA) embedded with a headache questionnaire, Medication Express Lane (for medication ordering), and Ask-a-doc button (for prompt virtual consultation with a neurologist)
16243765|NCT05067712|Active Comparator|Open Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposed with the Open Technique followed by the Orthodontic Treatment phase
16243766|NCT05067712|Active Comparator|Closed Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposure with the Closed technique followed by the Orthodontic Treatment phase.
16243767|NCT05067699||Patients|recurrent pityriasis versicolor
16243768|NCT05067699||Controls|Healthy age and sex matched
16243769|NCT05067686||Mental Health Professionals|
16243770|NCT05067686||Non Mental Health Professionals|
16243771|NCT05067673|Placebo Comparator|Control group|Placebo dry needling
16243772|NCT05067673|Experimental|Experimental group|Dry needling
16243773|NCT05067660|Active Comparator|Cohort A - Standard-of-care template-based salvage radiotherapy|Study participants in cohort A undergo template-based salvage radiotherapy according to current standard-of-care protocol. Dose fractionations include dose of 70/2 Gy in the prostatic bed, 50/2 Gy in the pelvic lymph node area and 45/1,8 Gy in the para-aortic lymph node. To the PSMA PET-CT positive lymph nodes, a boost dose will be considered depending on the anatomic site and will be delivered with a simultaneous integrated boost technique (SIB). The typical boost dose to PSMA PET-CT positive lymph nodes is 57,5/2,3 Gy, respecting normal tissue constraints. The dose to PSMA PET-CT positive areas in the prostatic bed is 74-78/2 Gy.
16243806|NCT05067465|Experimental|Whole-grain products (rich in soluble fibers)|"Standardized diet over five days (n = 40) - composed of oatmeal, oat bran, oat milk, whole wheat pasta, whole wheat bread, hummus
~Test meal on day 6 (n = 12) - composed of oatmeal, oat bran, oat milk"
16245242|NCT05057312|Experimental|Experimental arm 1|Video narrative persuasion
16243774|NCT05067660|Experimental|Cohort B - PSMA PET CT-targeted stereotactic ablative radiotherapy|Study participants in cohort B undergo stereotactic ablative radiotherapy, targeted only to PSMA PET-CT-positive areas judged to be suspicious of prostate cancer metastasis by nuclear medicine physician. Dose fractionations in the experimental arm vary from 24/8 Gy to 30/10 Gy in PSMA PET-CT positive lymph nodes in pelvic or para-aortic areas. PSMA PET-CT positive areas in the prostatic bed receive a dose of 35/7 Gy.
16243775|NCT05067647|Experimental|Thoracic, Urologic, Ear, Nose and Throat (ENT) Procedures|Any thoracic, urologic, or ENT procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use. Participants will be considered enrolled when the ENSEAL X1 device has been attempted to be used for a vessel transection during thoracic, urologic, or ENT procedures.
16243776|NCT05067634|Experimental|12 to < 18 year olds|
16243777|NCT05067634|Experimental|6 to <12 years old|
16243778|NCT05067634|Experimental|4 to <6 years old|
16243779|NCT05067634|Experimental|2 to <4 years old|
16243780|NCT05067621|Experimental|Receive treatment|Liraglutide (Victoza) pen is a subcutaneous injection
16243781|NCT05067621|Placebo Comparator|Placebo|The placebo pen is almost exactly the same as the Victoza subcutaneous injection except it does not contain the active ingredient, Liraglutide.
16243782|NCT05067608|Active Comparator|Control arm|"Subjects in the control arm will receive normal pooled platelets for all of their transfusion within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
16243783|NCT05067608|Experimental|Treatment arm|"Subjects in the treatment arm will receive thawed cryopreserved pooled platelets for all of their transfusions (except for unplanned or urgent platelet transfusions outside stipulated periods when thawed cryopreserved platelets are unavailable) within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
16243784|NCT05067595|Experimental|Arm I (lower FMT, fiber supplementation)|Patients undergo lower FMT via colonoscopy on day 0, and receive upper FMT capsules PO over 2 days. Patients also receive fiber supplementation PO daily on days 1-42.
16243785|NCT05067595|Experimental|Arm II (lower FMT)|Patients undergo lower FMT via colonoscopy on day 0, and receive upper FMT capsules PO over 2 days.
16243786|NCT05067595|Experimental|Arm III (upper FMT, fiber supplementation)|Patients receive upper FMT capsules PO over 2 days. Patients also receive fiber supplementation PO daily on days 0-41.
16243787|NCT05067595|Experimental|Arm IV (upper FMT)|Patients receive upper FMT capsules PO over 2 days.
16243788|NCT05067582|Placebo Comparator|Placebo Capsules|1 capsule twice daily
16243789|NCT05067582|Experimental|L1-79 200 mg or 300 mg Capsules|1 capsule twice daily
16243790|NCT05067569|Experimental|Digital brief behavioural therapy for insomnia|Participants randomised to the digital brief behavioural therapy for insomnia (SleepFix app) will be provided an unique access code to download the app. The intervention uses sleep retraining therapy to reduce excess time spent in bed and retrain sleep by matching time in bed (minimum of five and a half hours) to total sleep time. All participants in the intervention arm will also be provided a sleep-tracking wearable device (Fitbit) which will synchronised bed times (going to bed and rising) and are synchronised with the SleepFix app. Participants wil complete a daily sleep diary, rate sleep quality and mood. The intervention is provided for 6 weeks.
16243791|NCT05067569|Active Comparator|Sleep Health Education wait-list control|"Participants randomised to the control group will gain access to the first Sleep Health Education module immediately following completion of baseline questionnaires. There are three modules provided bi-weekly with information about sleep health and broad details about managing sleep disturbances. Participants will receive a link to this information as each module is made available.
~Upon completion of the study (week 26), the control group will receive free access to the SleepFix mobile application."
16243792|NCT05067556|Experimental|Intervention|Acceptance and Commitment Therapy for Chronic Pain (ACT-CP)
16243793|NCT05067543||Tornier Perform Humeral System - Stem|Partial or total shoulder arthroplasty using the Tornier Perform Humeral Stem.
16243794|NCT05067530|Experimental|CDK4/6 inhibitor alone: Palbociclib (IMP)|Palbociclib alone (125 mg orally (PO) per day, days 1-14)
16243795|NCT05067530|Active Comparator|Chemotherapy alone: Paclitaxel|Paclitaxel alone (80 mg/m^2 intravenously (IV), day 1, 8, 15 and 22)
16243796|NCT05067530|Experimental|CDK4/6 inhibitor + chemotherapy: Paclitaxel + Palbociclib|Paclitaxel (80 mg/m^2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
16243797|NCT05067530|Active Comparator|Chemotherapy alone: Carboplatin|Carboplatin alone (area under the curve (AUC) 2 IV, day 1, 8, 15 and 22)
16243798|NCT05067530|Experimental|CDK4/6 inhibitor + chemotherapy: Carboplatin + Palbociclib|Carboplatin (AUC 2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
16243799|NCT05067517|Active Comparator|Nintedanib|Nintedanib 150 mg administered PO twice daily
16243800|NCT05067517|Placebo Comparator|Placebo|Placebo administered PO twice daily
16243801|NCT05067491|Experimental|Intervention|The experimental group will go through an exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable.
16243802|NCT05067491|No Intervention|Non-intervention|The control group will not go through an exposure therapy session using an augmented reality headset device. This will be a no-intervention control group that can have some form of exposure therapy following the conclusion of the treatment/research period.
16243803|NCT05067478|Experimental|Cohort A Vibegron|Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
16243804|NCT05067478|Experimental|Cohort B Vibegron|Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or mirabegron and anticholinergic therapy experience will receive vibegron as per the U.S. label.
16243805|NCT05067465|Experimental|Milk and dairy products|"Standardized diet over five days (n = 40) - composed of cow milk, cheese, cream cheese, cream, valess milk schnitzel
~Test meal on day 6 (n = 12) - composed of milk, cheese, cream cheese, cream"
16254020|NCT04997668|Active Comparator|Ho:YAG Laser group|Ho:YAG Laser group
16243807|NCT05067465|Experimental|Sausage and processed meat (pork)|"Standardized diet over five days (n = 40) - composed of Lyoner (pig), Viennese (pig), minced meat (pig)
~Test meal on day 6 (n = 12) - composed of Lyoner (pig), Viennese (pig)"
16243808|NCT05067465|Experimental|Meat-free sausage and meat alternatives (based on egg, pea, soy)|"Standardized diet over five days (n = 40) - composed of Mortadella (egg-based), Viennese (egg-based), vegan mince (soy-based)
~Test meal on day 6 (n = 12) - composed of Mortadella (egg-based), Viennese (egg-based)"
16243809|NCT05067452|No Intervention|Standard of care including diabetes self-management education|"Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. Control participants will participate in the Diabetes Self-Management Program, an evidence-based program that takes place over 6 weeks that meets the standard of care for diabetes education.
~At the end of follow up, the control arm will receive three months diabetes-tailored food support consisting of diabetes-tailored grocery boxes and nutrition case-management."
16243810|NCT05067452|Experimental|Diabetes-tailored food support plus diabetes self-management education|"The intervention has two components: 1) diabetes-tailored food support that consists of weekly, home-delivered medically tailored meals, and monthly home-delivered healthy groceries, from baseline to 24 weeks, and 2) three case-management sessions with client services staff from the partnering nutrition agency over the 12 weeks of intervention.
~The intervention will be delivered in addition to a base condition consisting of remote participation in the Diabetes Self-Management Program, an evidence-based diabetes education program that takes place over 6 weeks also received by the control group as part of the standard of care."
16243813|NCT05067426|Experimental|HIIT-HV|"HIIT-HV - high intensity interval training high volume
~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period. Each training session is followed by 30 minutes of low-intensity training (total of 300 minutes of additional low-intensity training during this period)."
16243814|NCT05067426|Experimental|HIIT-LV|"HIIT- LV - high intensity interval training low volume
~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period."
16243815|NCT05067426|No Intervention|Control group|Participants continue with their regular training program.
16243816|NCT05067413|Sham Comparator|Total mesorectal excision approach|Patients of the control group who are to receive the traditional approach-- total mesorectal excision approach to transect the distal rectum are assigned into this arm.
16243817|NCT05067413|Experimental|Transanterior obturator nerve gateway approach|Patients of the experimental group who are to receive the novel approach-- transanterior obturator nerve gateway approach to transect the distal rectum are assigned into this arm.
16243818|NCT05067387|Placebo Comparator|Placebo|Oral placebo; sesame and MCT oil
16243819|NCT05067387|Experimental|20 mg THC|THC suspended in sesame oil
16243820|NCT05067387|Experimental|20 mg CBD|CBD suspended in MCT oil
16243821|NCT05067387|Experimental|20 mg THC + 20 mg CBD|THC and CBD in sesame and MCT oil
16243822|NCT05067361|Experimental|Experimental Group|
16243823|NCT05067361|Active Comparator|Active control Group|
16243824|NCT05067348|Experimental|Tocilizumab|Participants will receive tocilizumab administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
16243825|NCT05067348|Placebo Comparator|Placebo|Participants will receive placebo administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
16243826|NCT05067335|Experimental|Romosozumab|Subjects randomized to this arm will receive romosozumab during all treatment Periods.
16243827|NCT05067335|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind-Placebo controlled Period and romosozumab during the Open-Label treatment Period
16243828|NCT05067322|Experimental|Minecraft|This group played the video game under development in Minecraft
16243829|NCT05067322|Placebo Comparator|Control|This group played another game.
16243830|NCT05067309||Missed abortion received letrozole then misoprostol|
16243831|NCT05067309||Missed abortion received misoprostol alone|
16243832|NCT05067296||Cesarean section niche and patients with abnormal uterine bleeding|Observation by Tvs
16243833|NCT05067296||Abnormal uterine bleeding in patients without Cesarean section niche|Observation by Tvs
16243834|NCT05067283|Experimental|MK-1084|Participants will receive MK-1084 daily oral escalating doses of 25 mg, 50 mg, 100 mg and 200 mg until progressive disease or discontinuation.
16243835|NCT05067283|Experimental|Pembrolizumab plus MK-1084|Participants will receive MK-1084 daily oral escalating dose of 25 mg, 50 mg, 100 mg, and 200 mg plus pembrolizumab given as a 200 mg intravenous infusion once every 21-day cycle up to a total of 35 cycles (up to ~24 months). Treatment with MK-1084 will continue until progressive disease or discontinuation.
16243841|NCT05067257|Experimental|Resiniferatoxin|15 mcg, 20 mcg, or 25 mcg in 2mL injected once into the epidural space
16243842|NCT05067257|Placebo Comparator|Placebo|2mL injected once into the epidural space
16243843|NCT05067257|No Intervention|Concurrent Control|No intervention
16243844|NCT05067244|Experimental|MDMA assisted psychotherapy|Participants will undergo a 2-month course of CPT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered ini two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
16243845|NCT05067218|Active Comparator|buzzy device (intervention)|The wings of buzzy device will be kept frozen and once the child is ready, the frozen wing will be attached to the device and Buzzy will be placed extra-orally above the area/cheek where local anesthetic is to be delivered.
16243846|NCT05067218|Experimental|Conventinal anasthesia ( control )|"The site of injection will be dried then topical anesthetic gel of 20% benzocaine (Dharma Ophal-S) will be applied. The duration of application of gel will be 1 minute.
~Local anesthetic solution will be delivered using a standard aspirating syringe with 27-gauge, 21 mm short needles."
16243847|NCT05067205|Sham Comparator|open release|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using open carpal tunnel release method with duration of 6 months estimated.
16243848|NCT05067205|Experimental|mini CTS releaser|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using mini CTS releaser method with duration of 6 months estimated.
16243849|NCT05067192||Parkinson's Disease|Patients with Parkinson's Disease. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
16243850|NCT05067192||Dementia with Lewy Bodies|Patients with Dementia with Lewy Bodies. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
16243851|NCT05067192||Multiple System Atrophy|Patients with Multiple System Atrophy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
16243852|NCT05067192||Corticobasal Syndrome|Patients with Corticobasal Syndrome. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
16243853|NCT05067192||Progressive Supranuclear Palsy|Patients with Progressive Supranuclear Palsy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
16243854|NCT05067192||Healthy controls|Healthy contols. Contols will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
16243855|NCT05067153|Experimental|Intervention|Intervention group (n=50, anticipated) receives 30 days postoperative treatment with 5000 IE LMWH daily.
16243856|NCT05067153|Active Comparator|Control|Control group (n=50, anticipated) receives standard 10 days postoperative treatment with 5000 IE LMWH daily.
16243857|NCT05067140|Experimental|ARV-766|Oral tablet(s), once or twice daily in 28 day cycles
16243858|NCT05067127|Experimental|Group 1: Pegcetacoplan administration|Subcutaneous infusion of 20mL (1080 mg), twice weekly (for adults or adolescents >50kg), and the three other weight-based doses either of 10mL (540mg), 12mL (648mg), or 15mL (810mg)
16243859|NCT05067127|Placebo Comparator|Group 2: Placebo administration|Subcutaneous infusion of either 10mL, 12mL, 15mL, or 20mL, twice weekly
16243860|NCT05067114||Observational Cohort|Screening, detection, and referral for atrial fibrillation
16243861|NCT05067101|Experimental|Capsule Sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before laparoscopic cystectomy
16243862|NCT05067101|Placebo Comparator|Conventional Radical Cystoprostatectomy|Patients undergoing conventional radical cystoprostatectomy
16243863|NCT05067075|Experimental|Blinded CGM|Blinded continuous glucose monitor Dexcom G6Pro
16243864|NCT05067062|Active Comparator|new zealand blackcurrant extract|Capsules will be take daily or every other day.
16243865|NCT05067062|Placebo Comparator|control|no capsules will be provided.
16243866|NCT05067049|Experimental|Connected EORTC-C30 arm (quality of life questionnaires on pad, phone,...)|The patients in this arm will have connected mobile app at home and they will regularly fill questionnaires. There are two different questionnaires : one with 14 questions about patient's quality of life and about the evolution of his surgical scar. One with 9 questions only about quality of life. They will also have meetings with physicians.
16243867|NCT05067049|Other|No QoL online follow-up arm|The patient haven't any questionnaires to fill at home. This is the normal management of the pathology. They only have different meeting with the specialist,as usual.
16243868|NCT05067023|Experimental|MRI scan|All participants will undergo 1 DCE-MRI scan before surgery or puncture.
16243869|NCT05066997|Experimental|Active treatment arm: OCS-01|"In Stage 1: Active treatment arm: OCS-01 - 6 times a day dosing for 6 weeks followed by TID dosing for 6 weeks.
~. In Stage 2, subjects will receive the dosing regimen from Stage 1 for OCS-01 for 52 weeks."
16243870|NCT05066997|Placebo Comparator|Vehicle placebo arm|"In stage 1: Vehicle: 6 times a day dosing for 6 weeks followed by TID dosing for 6 weeks.
~In Stage 2, subjects will receive the matched dosing regimen for Vehicle for 52 weeks."
16243871|NCT05066984|Experimental|structured, multidisciplinary and personalized post-ICU care|structured, multidisciplinary and personalized post-ICU care
16243872|NCT05066984|No Intervention|Ususal care|Usual care
16243873|NCT05066971|Experimental|Participants in gradual self-adjustment rate control medication|Patients receive a weekly simplified version of the information transmitted by the HM system. In the first 3 months, using that information, the physician changes or not the rate control medication posology (i.e. if the mean heart rate is 60bpm, betablocker dose is cut to half, and another heart rate evaluation is done a week later, and if heart rate is now 120bpm the dose is increased to a 3/4 of the initial dose, and so on). After those three initial months where physician guide titration, the patient is allowed to make self-adjustment of their medication accordingly to the information received (i.e. increasing or decreasing their rate control medication depending on heart rates and activity hours per day.
16243874|NCT05066958|Experimental|boost anti-viral immunity after T-cell depleted HSCT|
16243875|NCT05066932||Familial Hypercholesterolemia and hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and hyperTriglyceridemia
16243876|NCT05066932||Familial Hypercholesterolemia without hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and without hyperTriglyceridemia
16243879|NCT05066906|Experimental|Use of Identifor and Companion+referral to employment agencies|This group will use the Identifor tool and Companion app for a period of 6 months. They will also receive standard referral to employment agencies.
16243880|NCT05066906|Active Comparator|Referral to employment agencies|This group will not use the Identifor tool and Companion app. They will only receive standard referral to employment agencies.
16243881|NCT05066893|Active Comparator|standard of care|standard of care will be given as per usual care
16243882|NCT05066893|Experimental|intensive monitoring|intensive monitoring every week will be given to participants
16243883|NCT05066880|Experimental|Yoga|Participants allocated to the yoga group will receive the yoga-based intervention through an internet-based video conference remotely in real-time. Each class will accommodate a maximum of 5 subjects. A qualified physiotherapist who was a certificated yoga instructor will teach in these classrooms. The 8-week exercise intervention consists of three times per week sessions of yoga.
16243884|NCT05066880|Experimental|Aerobic exercise|Participants of the aerobic exercise group will be requested to perform unsupervised aerobic training in the home environment (e.g., at home, park, backyard, or in the local gym). The 8-week exercise intervention consists of three times per week sessions of aerobic exercise. Training will consist of a 10-min warm-up period, aerobic activity, and 5-min cool-down period.
16243885|NCT05066880|No Intervention|Wait-list|Participants in the wait-list group will be advised to continue their habitual physical activity next to usual medical care. A yoga or aerobic exercise program of 8 weeks will be offered after the ending of the study period.
16243886|NCT05066854|Experimental|Integron research|"Empirical antibiotic treatment chosen based on the results of the integron search:
~when PCR is negative, patients will receive SXT (30 mg/kg/j of sulfamethoxazole and 6 mg/kg/j of trimethoprim)
~when PCR is positive or uninterpretable for integrons, patients will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
16243887|NCT05066854|Other|Usual practice|Empirical antibiotic treatment based on the usual practice of each center according to the GPIG guidelines.
16243888|NCT05066841|Experimental|CM group|
16243889|NCT05066841|Placebo Comparator|placebo group|
16243890|NCT05066828|Active Comparator|conventional obturator|Participants received conventional obturator one piece
16243891|NCT05066828|Experimental|sectional obturator|two pieces obturators connected by magnet attachments
16243892|NCT05066815|Experimental|Hybrid superstructure|Vita Enamic is a Hybrid ceramic consists of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
16243893|NCT05066815|Active Comparator|Ceramic superstructure|IPS Emax is the mostly used ceramic superstructures in implant supported restorations.
16243894|NCT05066802|Experimental|modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42~46h continuous infusion, every other week for 6 cycles (12 weeks).
16243895|NCT05066789|Active Comparator|Biodegradable Polymer DES|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.
~This group will use Orsiro Mission stent during the index procedure."
16243896|NCT05066789|Active Comparator|12-month DAPT|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.
~This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily)."
16243897|NCT05066789|Experimental|Polymer-free DCS|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.
~This group will use BioFreedom Ultra stent during the index procedure."
16243898|NCT05066789|Experimental|Prasugrel monotherapy|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.
~This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone."
16243899|NCT05066776||Patients with Pulmonary Nodule|Patients at high-risk of lung cancer found to have a pulmonary nodule 6-20 mm in size.
16243900|NCT05066763||People with Parkinson's disease|
16243901|NCT05066750|Experimental|Mindful breathing video|Participants watch a 10 minute mindful breathing video
16243902|NCT05066750|Active Comparator|Control video|Participants watch a 10 minute control video
16243903|NCT05066737|Experimental|patients who has pelvic organ prolapse and underwent lateral suspension via V-notes surgery|
16243904|NCT05066724|Experimental|Centanafadine|400 mg total daily dose Centanafadine Sustained Release (SR)
16243905|NCT05066711||ACP System|
16243906|NCT05066698|Experimental|ST266|Topical ocular application: one drop in the study eye four times a day for 8 weeks
16243907|NCT05066698|Placebo Comparator|Placebo|Topical ocular application: one drop in the study eye four times a day for 8 weeks
16243908|NCT05066685||All Participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
16243909|NCT05066672|Experimental|NV-5138 400 mg oral capsules|Either 2 or 4 400 mg oral capsules administered once daily
16243910|NCT05066672|Placebo Comparator|matched placebo|2 or 4 oral capsules administered once daily
16243911|NCT05066646|Experimental|CT103A in relapsed and refractory multiple myeloma patients|CT103A autologous CAR-T cells will be infused at RP2D of 1.0 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
16244071|NCT05065502|Active Comparator|Academic Detailing (AD) Only|One-on-one educational outreach to employees and providers.
16243912|NCT05066633|Placebo Comparator|Control Group|Matching placebo will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
16243913|NCT05066633|Experimental|Treatment Group|Metoprolol succinate will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
16243914|NCT05066620|Experimental|Intervention group|Chinese herbal medicine FYTF-919: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
16243915|NCT05066620|Placebo Comparator|Control group|Placebo treatment: Oral liquid 33ml TID (or patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
16243916|NCT05066607|Experimental|Single-stage|"Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and Dexamethasone 10-20 mg weekly on days 1, 8, 15 and 22.
~Each cycle will be of 28 days duration. During cycle 1, Isatuximab will be administered weekly on days 1, 8, 15, and 22 then days 1 and 15 in subsequent cycles from cycle 2 to 9 or 12.
~For each individual patient, the treatment period will be 12 months, unless CR at the completion of 9 cycles, disease progression or unacceptable toxicity occurs. The duration of follow-up for overall survival will be 1 year after the last patient enters overall survival follow-up."
16243917|NCT05066594||Transoral incisionless fundoplication with EsophyX device (EndoGastric Solutions)|Patients treated by transoral incisionless fundoplication (TIF) using the EsophyX device (EndoGastric Solutions) for gastro-esophageal reflux disease will be enrolled in the registry and clinically followed-up for 5 years from the date of TIF procedure.
16243918|NCT05066581|No Intervention|Philips band|It is a medical device that collects, among other things, movement data by means of an accelerometer, from which it accelerometer, from which it estimates the total time of sleep (TTS) and wakefulness, and waking time, also offering the efficiency of the same (time asleep in relation to time in bed). time in bed). In addition, it collects data not related to sleep, such as energy expenditure (in kilocalories), energy expenditure (in kilocalories) (in kilocalories), heart rate, and daily activity (in steps), among others.
16243919|NCT05066581|Active Comparator|Philips Band + Live chat|In the Intervention group, in addition to having the philips band, the subjects will interact through the live chat system that they will have to download to their mobile phones. This live chat offers the possibility to consult in real time, thus initiating a process of relationship between researcher/subject.
16243920|NCT05066568|Other|Sequence of interventions starting with tDCS as the first intervention|"Week 1 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min
~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.
~Week 3 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.
~Intervention time: 20 minutes
~Week 4 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes.
~Week 5 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.
~Intervention time: 20 minutes"
16243921|NCT05066568|Other|Sequence of interventions starting with Hypnosis as the first intervention|"Week 1 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.
~Intervention time: 20 minutes
~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.
~Week 3 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min
~Week 4 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.
~Intervention time: 20 minutes
~Week 5 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes."
16243922|NCT05066555||Advanced-stage Hodgkin Lymphoma patients (1)|All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Comparator arm).
16243923|NCT05066555||Advanced-stage Hodgkin Lymphoma patients (2)|All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Experimental arm).
16243924|NCT05066542|Active Comparator|NDPP Standard of Care SOC|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
16244022|NCT05065866|Experimental|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of CC-486 in combination with Duvelisib in patients with lymphoid malignancy. Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 6 dose levels will be used.
16244023|NCT05065840|Experimental|4 Pillars Program|Patients at study clinics who consent to have their HPV vaccination history verified with the Georgia Registry of Immunization Transactions and Services (GRITS).
16243925|NCT05066542|Experimental|NDPP + Basketball (BB)|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30-minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and bi-weekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
16243926|NCT05066529|Experimental|dry-needling group|"32 participants in this group Dry-needling treatment will be applied once a week for three weeks. Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)
~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
16243927|NCT05066529|Other|exercise group|"32 participants in this group Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)
~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
16243928|NCT05066516|Experimental|Period 1: Individual components (ICs), period 2: FCDP|Period 1: Individual components (ICs), period 2: FCDP
16243929|NCT05066516|Experimental|Period 1: FCDP, period 2: ICs|Period 1: FCDP, period 2: ICs
16243930|NCT05066503|Active Comparator|Delirious subjects receiving active study product|Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 7 days.
16243931|NCT05066503|Placebo Comparator|Delirious subjects receiving placebo|Subjects will ingest a flavored, sweetened, inactive drink twice daily for up to 7 days.
16243932|NCT05066503|No Intervention|Non-delirious control subjects who receive no intervention|Subjects receive no intervention and are observed for 2-3 days.
16243933|NCT05066490|Experimental|GroupI|This group received endurance exercises only.
16243934|NCT05066490|Experimental|Group II|This group received resistance exercises followed by endurance exercises.
16243935|NCT05066477|Active Comparator|CalGo (Salmon bone meal)|4 capsules daily of CalGo (salmon bone meal enriched with Vitamin D3) is taken per orally. Each capsule contains ~500 mg of salmon bone meal (380 mg calcium, 200 mg phosphorus, 500 mg native collagen type 2), and 10 micrograms of vitamin D3 (400 IU). Once daily dosing. Duration: 2 years.
16243936|NCT05066477|Placebo Comparator|Maltodextrin|4 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once daily dosing. Duration: 2 years.
16243937|NCT05066451|Experimental|%5 dextrose prolotherapy|A total of 3 sessions of prolotherapy solution containing 5% dextrose will be applied at the beginning, 3rd week, and the 6th week.
16243938|NCT05066451|Active Comparator|%15 dextrose prolotherapy|A total of 3 sessions of prolotherapy solution containing 15% dextrose will be applied at the beginning, 3rd week, and the 6th week.
16243939|NCT05066438||Antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed AND must have received standardized counselling on and practiced antenatal hand expression for a minimum of 10 days beginning no earlier than 36 weeks gestational age.
16243940|NCT05066438||No antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed but have NOT received any standardized counselling on antenatal hand expression and have not practiced antenatal hand expression OR have practiced antenatal hand expression but for less than 10 days.
16243941|NCT05066425|Experimental|Soluble Corn Fiber|22g Soluble Corn Fiber/day for 4 weeks
16243942|NCT05066425|Placebo Comparator|Maltodextrin|22g Maltodextrin/day for 4 weeks
16243943|NCT05066412|Experimental|Arm 1|Prophylactic CD45RA-depleted DLI
16243944|NCT05066373|Experimental|EDP1815 capsule A (fasted)|In part 1 period 1, 12 healthy volunteers will receive a single dose of EDP1815 capsule A, dosed in the fasted state
16243945|NCT05066373|Experimental|EDP1815 capsule B (fasted)|In part 1 period 2, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fasted state
16243946|NCT05066373|Experimental|EDP1815 tablet (fasted)|In part 1 period 3, 12 healthy volunteers will receive a single dose of EDP1815 tablet, dosed in the fasted state
16243947|NCT05066373|Experimental|EDP1815 capsule B (fed)|In part 1 period 4, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fed state
16243948|NCT05066360|Other|participants with epilepsy|healthy, menstruating females between 12-18 ages
16243949|NCT05066360|Other|healthy participants|epileptic, menstruating females between 12-18 ages
16243950|NCT05066347|No Intervention|Usual care|Patients randomized to usual care will receive all care as prescribed by the discharging physician and there will be no study specific interventions. The current usual care varies from no outpatient monitoring to short-term Holter monitoring (24 hours to 72 hours).
16243951|NCT05066347|Experimental|Prolonged 24/7 live outpatient cardiac rhythm monitoring|Patients randomized to the intervention arm will receive 24/7 live cardiac rhythm monitoring for 15 days. If a patient is randomized to the intervention arm and was prescribed outpatient cardiac monitoring such as Holter monitor, this will be replaced by the 24/7 live monitoring and will be applied either prior or within 24 hours of discharge from the ED.
16243952|NCT05066334|Experimental|Active Arm|"Two procedures:
~Bone marrow harvesting from the posterior superior iliac crest region
~Single injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control"
16243953|NCT05066334|Sham Comparator|Sham Procedure|"Two sham procedures:
~Simulated bone marrow harvesting without insertion into the posterior iliac crest region
~Simulated injection under only local anaesthesia without disc injection and without placebo injection."
16244024|NCT05065840|No Intervention|Adjacent time-period Control Group|The background HPV update rate among PLWH will be obtained by using the electronic medical record (EMR) and GRITS to identify HPV vaccination uptake 18 months prior to the intervention. These data are collected retrospectively and no study participants are prospectively assigned to this study arm.
16243954|NCT05066321|Experimental|Mindfulness Oriented Recovery Enhancement (MORE) Arm|During hospitalization, participants will receive brief mindfulness training individually in person and complete a series of quantitative baseline questionnaires. Participants will complete 1 MORE session weekly for 8 sessions delivered in small groups of up to 5 people. These sessions will be delivered by a social worker in-person at baseline, and via telehealth after discharge. Follow-up surveys will be conducted at 3-, 6-. 9-, and 12- weeks, and an audio-recorded qualitative exit interview (45-60 minutes) will be completed upon completion of the intervention and the 12-week follow-up survey.
16243955|NCT05066308|Experimental|Cannabidiol (CBD)|The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). We will follow the titration schedule recommended in the EPIDIOLEX label with 5 mg/kg/d in week 1, 10 mg/kg/d in week 2, 15 mg/kg/d in week 3, and 20 mg/kg/d in week 4 with the second PET scan conducted after one week at the maximum labeled dose. Any participant not tolerating a given dose can either go back down to the next lowest dose or delay uptitration at any week in the protocol. We will instruct patients to take Epidiolex with a meal rather than in a fasted state. Participants will be treated for 4 weeks in total.
16243956|NCT05066308|Placebo Comparator|Placebo|The placebo will be taken at identical doses to the active drug condition.
16243957|NCT05066282||Participants with past PTSD who received IMP in the main study|
16243958|NCT05066256|Experimental|Fluid responsive test|Measure cardiac output, inferior vena cava (IVC) diameter variation and LV diastolic function (E/e') baseline Fluid challenge Measure cardiac output, IVC diameter variation and LV diastolic function (E/e') after fluid challenge
16243959|NCT05066243||focus group|15 service users for focus group
16243960|NCT05066243||questionnaire|150 patients to test questionnaire
16243961|NCT05066230|Experimental|KSI-301 - Treatment Group A|Intravitreal injection of KSI-301 (5 mg): three initiating doses, and then every 24 weeks through Week 92
16243962|NCT05066230|Sham Comparator|Treatment Group B|Sham injection on the same schedule as Treatment Group A
16243963|NCT05066217|Placebo Comparator|Placebo|Placebo (Drug Product Oral Solution) to match active
16243964|NCT05066217|Experimental|Active|Drug Product Oral Solution
16243965|NCT05066204|Other|Sequence: self-study, then teaching video|Participants first do self-study, then right afterwards watch a teaching video, then become tested on a simulator and are videorecorded for evaluation
16243966|NCT05066204|Other|Sequence: teaching video, then self study|Participants first watch a teaching video, then do self-study, then become tested on a simulator and are videorecorded for evaluation
16243967|NCT05066178|Experimental|CAS Treatment for MV ASD|Participants will receive CAS treatment, modified for minimally verbal children with autism
16243968|NCT05066165|Experimental|Arm 1: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count <5%, administered by IV infusion following lymphodepleting chemotherapy.
16243969|NCT05066165|Experimental|Arm 2: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count ≥5%, administered by IV infusion following lymphodepleting chemotherapy.
16243970|NCT05066152|Experimental|Probiotic|For 8 weeks of interventional period, the patient received 10 probiotic drops (1x1010 Cfu LGG) once daily at breakfast.
16243971|NCT05066152|Placebo Comparator|Placebo|For 8 weeks of interventional period, the patient received 10 probiotic drops (placebo) once daily at breakfast.
16243972|NCT05066139|No Intervention|Arm A Standard of care|"Patients will receive standard care before treatment initiation (i.e. geriatric assessment only).
~Geriatric assessment includes: Mini Mental State Examination ; mini-Geriatric Depression Scale (mini-GDS) ; Body Mass Index (BMI) calculation ; Mini Nutritional Assessment (MNA) ; Time up and Go ; Cumulative Illness Rating Scale - Geriatric (CIRS-G) ; Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) questionnaires."
16243973|NCT05066139|Experimental|Arm B Multidisciplinary EPODIG program|Patients will undergo the same geriatric assessment as in Arm A plus EPODIG-G program before treatment initiation.
16243974|NCT05066126|Experimental|High-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a high-mixed presentation of content.
16243975|NCT05066126|Experimental|Low-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a low-mixed presentation of content.
16243976|NCT05066126|Experimental|High-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a high-mixed presentation of content.
16243977|NCT05066126|Experimental|Low-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a low-mixed presentation of content.
16243978|NCT05066113|Experimental|Healthy Participants|Electrothermolysis treatment using varying levels of RF energies
16243979|NCT05066100|Experimental|Pregnant women with FIRN|Women desiring to breastfeed and identified during their pregnancy as having flat, inverted or retracted nipples
16243980|NCT05066087|Experimental|DAHLIA treatment|6 weeks of online behavioural treatment; mainly self-guided and weekly contact with their therapist
16243981|NCT05066087|Other|Treatment as usual|receive usual treatment at their rehabilitation centre; detailed information will be collected to define what treatment as usual means in clinical settings.
16243982|NCT05066074|Experimental|Distal Radial Access|Distal Radial (Anatomical Snuffbox) Vascular Access prior to catheterization
16243983|NCT05066074|Active Comparator|Proximal Radial Access|Proximal Radial Vascular Access prior to catheterization
16243984|NCT05066061|Active Comparator|standard|Only use local anesthetic cream
16243985|NCT05066061|Experimental|anxiolytic gas|Use local anesthetic cream and anesthetic and anxiolytic gas
16243986|NCT05066061|Experimental|virtual reality|Use local anesthetic cream and virtual reality mask
16243987|NCT05066048||The appendectomy group|
16243988|NCT05066048||Colorectal cancer group|
16243989|NCT05066048||Normal group|
16244176|NCT05064696|Experimental|Group 2 (Treatment group)|Surgical wound will be covered with the PICO dressing.
16243990|NCT05066035|Active Comparator|Neostigmine|"The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation.
~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
16243991|NCT05066035|Active Comparator|Neostigmine and Sugammadex|"In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose.
~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
16243992|NCT05066022|Experimental|Experimental: CT0590 CAR T cells|Dose-escalated CAR T cells infusion
16243995|NCT05065996||Different 4D flow MRI parameters in aortic dilatation and controls|Patients with aortic dilatation (n=20) scheduled for aortic MRI and healthy controls (n=20) without aortic dilatation. One time aortic MRI with 4D flow imaging.
16243996|NCT05065996||Value of aortic 4D flow MRI parameters to predict aortic dilatation in 5 years follow up|Patients with aortic dilatation (n=100) scheduled for aortic MRI follow up in Kuopio University Hospital. Aortic 4D flow MRI will be done yearly for 5 years and flow parameters predicting aortic dilatation will be analysed.
16243997|NCT05065996||Histology, molecular biology and genetics behind aortic dilatation|Patients scheduled for aortic operation (n=20+100) in Kuopio University Hospital. Aortic tissue samples and blood will be collected for analysis and compared to 4D flow MRI parameters. Control samples will be collected from healthy organ donors (n=5+5) operated in Kuopio University Hospital.
16243998|NCT05065983|Experimental|PXVX0317 (CHIKV VLP, alum-adjuvanted) vaccine|All study participants will receive the same Investigational Product (40 µg CHIKV VLP, alum-adjuvanted according to the same single dose schedule on Day 1).
16243999|NCT05065970|Placebo Comparator|Placebo|
16244000|NCT05065970|Experimental|Felzartamab Arm #1|
16244001|NCT05065970|Experimental|Felzartamab Arm #2|
16244002|NCT05065970|Experimental|Felzartamab Arm #3|
16244003|NCT05065957|Experimental|Phase IIa:Dose-Finding Stage|"Level -4: 20 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).
~Level -3: 40 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).
~Level -2: 60 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).
~Level -1: 80 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).
~Level 1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).
~Level 2: 100 mg D07001-softgel capsules plus 800 mg/m^2 Xeloda (or 30/40/50 mg/m^2 TS-1).
~Level 3: 100 mg D07001-softgel capsules plus 1000 mg/m^2 Xeloda (or 40/50/60 mg/m^2 TS-1)."
16244004|NCT05065957|Active Comparator|Phase IIb/III: Dose Expansion Stage|"ASC+ D07001-softgel capsules plus Xeloda (or TS-1)
~ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)"
16244005|NCT05065944||Pre-Anesthesia Evaluation: Telemedicine|Pre-Anesthesia evaluation conducted remotely via video conferencing
16244006|NCT05065944||Pre-Anesthesia Evaluation: In person|Pre-Anesthesia evaluation conducted in person
16244007|NCT05065931||Before|before CDSS on-line
16244008|NCT05065931||After|after CDSS on-line
16244009|NCT05065918|Active Comparator|Control - alcohol use reduction content|Alcohol use reduction content
16244010|NCT05065918|Experimental|Intervention - sexual violence and alcohol use harm reduction content|sexual violence and alcohol use harm reduction content
16244011|NCT05065905|Experimental|Interferon|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day
~Interventions:
~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
16244012|NCT05065905|Experimental|Interferon daily|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU given with Interal® (interferon alpha) 3,000,000 IU every day
~Interventions:
~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
16244013|NCT05065905|No Intervention|Control|"All participants receive only basic antimicrobial treatment
~Interventions:
~Drug: Antituberculosis complex therapy"
16244029|NCT05065814|Other|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus patients who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
16244030|NCT05065814|Other|Systemic sclerosis group|Demographic information of systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
16244031|NCT05065814|Other|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
16244032|NCT05065801|Experimental|GABRINOX|"D1, D8 and D15 GEMBRAX: Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest
~D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over 46h at 2400mg / m² followed by 2 weeks of rest"
16244033|NCT05065801|Active Comparator|FOLFIRINOX|D1, D15, D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400mg / m², 5-fluorouracil 400mg / m² as a bolus followed by continuous administration over 46h at 2.400mg / m² followed by 2 weeks of rest.
16244034|NCT05065788||2020 Lockdown period|Patients who access to Ophthalmological emergency service during lockdown period in 2020
16244035|NCT05065788||2019|Patients who access to Ophthalmological emergency service in 2019 definite periods
16244036|NCT05065775|Experimental|Dexmedetomidine|Single intranasal 100 µg bolus dose of dexmedetomidine
16244037|NCT05065762||Phase 1|Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria
16244038|NCT05065762||Phase 2|Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan
16244039|NCT05065736|Experimental|18F-Clofarabine|18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy
16244041|NCT05065697||TAVR arm|Symptomatic severe aortic stenosis undergoing transfemoral TAVR of any devices
16244042|NCT05065697||SAVR arm|Symptomatic severe aortic stenosis undergoing isolated bioprosthetic surgical aortic valve replacement
16244043|NCT05065684||rhBMP-2 and rhBMP-7|patients who have been treated with rhBMP-2 or rhBMP-7 for long bone non-union or acute fractures
16244044|NCT05065684||No-BMP|patients who have been treated with standart care, i.e. non-union resection and autologous bone graft
16244045|NCT05065671|Experimental|Tolcapone|Tolcapone 100 mg by mouth once
16244046|NCT05065671|Experimental|Duloxetine|Duloxetine 30 mg by mouth once
16244047|NCT05065658||Critically-ill COVID-19 patients receiving posaconazole prophylaxis|
16244048|NCT05065658||Critically-ill COVID-19 patients without antifungal prophylaxis|
16244049|NCT05065645|Active Comparator|APN01|Angiotensin Converting Enzyme 2: 1.25 mg/ml, 2.5 mg/ml or 5 mg/ml
16244050|NCT05065645|Placebo Comparator|NaCl|Sodium Chloride: 0.9% NaCl solution
16244051|NCT05065632||Groupe 1|[1-15[
16244052|NCT05065632||Group 2|[15- 30[
16244053|NCT05065632||Group 3|[30-45[
16244054|NCT05065632||Group 4|[45-60[
16244055|NCT05065632||Group 5|60+
16244056|NCT05065619|Experimental|MT-2766 High dose|
16244057|NCT05065619|Placebo Comparator|Placebo|
16244058|NCT05065619|Experimental|MT-2766 Low dose|
16244059|NCT05065593|Experimental|Face-to-Face Training Group|"After completing all assessments, the intervention group will participate in face-to-face exercise training with a physiotherapist for 3 days for 4 months.
~In the first week, patients will be taught body awareness; parameters of correct loading on the muscle will be explained and the limits of safe exercise will be drawn. At the beginning and end of all exercises, there will be short-term active stretching and relaxation exercises performed by the patient as a warm-up and cool-down period. In the first 4 weeks, it is planned to increase the physical fitness levels of individuals with progressive resistance exercises and to make them suitable for aerobic loading. For each patient, the PRE, resistance will be increased from 60% to 80% for as long as the person can. At the end of the 1st month, the time allocated to resistance exercise training will be reduced and until the end of the 4th month, an increasing intensity aerobic exercise training will be given on the stationary bike."
16244060|NCT05065593|Active Comparator|Home-Based Control Group|After the patients assigned to the control group are evaluated by the physiotherapist with field tests and scales for physical functions, the patients will be informed about the importance of lifestyle changes in disease management, gait training will be given to increase their physical activity level and participants will be asked to follow a 45-minute walking program every day within their own means. All patients in the control group will be followed up regularly and their activity levels will be questioned in interim evaluations by asking them to keep a weekly physical activity diary.
16244061|NCT05065580|Active Comparator|Pre test|
16244062|NCT05065580|Active Comparator|Post test|
16244063|NCT05065567|Active Comparator|haloperidol|
16244064|NCT05065567|Active Comparator|droperidol|
16244065|NCT05065554|Experimental|ACALABRUTINIB + RITUXIMAB/BIOSIMILAR|"Acalabrutinib and rituximab (or biosimilar) with be contained in the treatment regimen.
~Acalabrutinib will be administered twice daily, with 28 consecutive days defined as a treatment cycle. Acalabrutinib will be administered for 48 cycles or until disease progression or unacceptable toxicity.
~Rituximab will be administered on Days 1, 8, 15, and 22 of Cycles 1 and 4. Participants will have study visits every cycle for cycles 1-6, then every 3 cycles, with the next visit at Cycle 9, then C12, C15, etc.
~Participants will continue acalabrutinib until disease progression or intolerable adverse effect develops. They will be followed for up to 2 years after completion of 48 cycles of treatment or until death"
16244066|NCT05065541|Experimental|Part 1|
16244067|NCT05065541|Experimental|Part 2|
16244072|NCT05065502|Experimental|AD + LEAP Combined|This arm combines use of AD plus the Learn. Engage. Act. Process (LEAP) program. LEAP is a 6-month quality improvement coaching program plus a 6-month monthly follow-up.
16244073|NCT05065489||Schizophrenia patients|patients who diagnosed with schizophrenia in accordance with DSM-5 criteria
16244074|NCT05065489||Bipolar disorder patients|patients who diagnosed with bipolar disorder in accordance with DSM-5 criteria
16244075|NCT05065489||Depression patients|patients who diagnosed with major depression disorder in accordance with DSM-5 criteria
16244076|NCT05065489||Health control|health participants who have not diagnosed with any psychological or psychiatric disease.
16244077|NCT05065476||Study Group|"Participants signed up for the webinar will be learning and practicing the Isha Kriya practice (meditation for beginners) taught by the Isha Foundation."
16244078|NCT05065463|Experimental|Cohort 1|Participants with severe renal impairment will receive a single dose of AZD8233 on Day 1.
16244079|NCT05065463|Experimental|Cohort 2|Participants who are healthy will receive a single dose of AZD8233 on Day 1.
16244080|NCT05065463|Experimental|Cohort 3|Participants with ESRD on dialysis will receive a single dose of AZD8233. Cohort 3a, participants will receive AZD8233 the day after haemodialysis and Cohort 3b participants will receive AZD8233 1 hour before the start of the haemodialysis respectively.
16244082|NCT05065437|Experimental|Virtual reality and spinal stimulation|Safety and feasibility of a virtual reality and spinal stimulation intervention will be tested.
16244083|NCT05065424|Experimental|IV Atropine and Fentanyl Premedication Arm|Participants will receive premedication regimen of 20 micrograms/kilogram intravenous atropine and 0.5 micrograms/kilogram intravenous fentanyl prior to performance of LISA.
16244084|NCT05065424|Placebo Comparator|IV Normal Saline Placebo Arm|Participants will receive two intravenous Normal Saline infusions in quantities equivalent to the calculated volumes of atropine and fentanyl for participant's weight prior to performance of LISA.
16244085|NCT05065411|Experimental|Enobosarm Combination Group|Enobosarm Combination Group will receive enobosarm 9 mg each day by mouth (QD), and abemaciclib (a CDK 4/6 inhibitor) will administered 150 mg BID
16244086|NCT05065411|Active Comparator|Control Treated Group|Control Treated Group will receive a non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant which is standard of care after the patient has experienced disease progression on an estrogen blocking agent + CDK 4/6 inhibitor. The decision of which comparator treatment will be used will be made prior to randomization.
16244087|NCT05065398|Experimental|HLX208|
16244091|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Japanese subjects|
16244092|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects|
16244093|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Caucasian subjects|
16244094|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects|
16244095|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Japanese subjects|
16244096|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects|
16244097|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Caucasian subjects|
16244098|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects|
16244099|NCT05065346|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16244100|NCT05065333|Experimental|Septic Shock Clinical Decision Support|Emergency Department sites in this arm will have Clinical Decision Support (CDS) alerts active in the Electronic Health Record during clinical ED care of patients with suspected sepsis, in addition to following usual institutional standard of care for sepsis. The CDS will alert providers to patients at high risk for developing septic shock.
16244101|NCT05065333|Active Comparator|Clinical Diagnosis Only|Emergency Department sites in this arm will follow the institutional standard for sepsis care without Clinical Decision Support. Standard care includes clinical diagnosis of sepsis supported by institutional sepsis education, a sepsis pathway and orderset.
16244102|NCT05065307|Experimental|Video game in Virtual reality|The study subject will be playing a video game during the venipuncture, in virtual reality
16244103|NCT05065307|Active Comparator|Video game on a tablet|The study subject will be playing a video game during the venipuncture, on a tablet
16244210|NCT05064462||All the patients included in the study|50 patients, at least 18 years old, first heart transplant
16244104|NCT05065294|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.
16244105|NCT05065281|Experimental|Education|Participants that have undergone the educational intervention
16244106|NCT05065281|No Intervention|Waitlist|Participants still waiting to cross over to intervention arm
16244108|NCT05065255||Patients|Adult subjects with neurogenic or non-neurogenic urinary tract disorders, newly initiated to ASI, and users of the SpeediCath line of catheters.
16244109|NCT05065242|Experimental|Cognitive Behavioural Therapy|Cognitive Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles and to a lesser extent some cognitive exercises. focused on handling sleep disturbing thought activities.
16244110|NCT05065242|No Intervention|Waitlist|The waitlist serves as a passive control which will receive the same measures as the cognitive behaviour therapy group.
16244111|NCT05065229|Experimental|A|Right foot no.520 Left foot no.521
16244112|NCT05065229|Experimental|B|Right foot no.521 Left foot no.520
16244115|NCT05065203||Postpartum patients|Women booked and have delivery of their child(ren) at Lucile Packard Children's Hospital
16244116|NCT05065190|Experimental|nintedanib|
16244117|NCT05065190|Placebo Comparator|Placebo|
16244118|NCT05065177|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated mumps vaccine;"
16244119|NCT05065177|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;
~Intervention: control live attenuated mumps vaccine;"
16244120|NCT05065164|Experimental|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
16244121|NCT05065164|Placebo Comparator|placebo control|Placebo subcutaneous injection /6 months, twice a year
16244122|NCT05065151|Experimental|Stimulation|Patients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept PC device.
16244123|NCT05065151|Experimental|No Stimulation|Patients will have stimulation turned off through their Medtronic Percept PC device.
16244124|NCT05065138|Experimental|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
16244125|NCT05065138|No Intervention|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
16244127|NCT05065112|Active Comparator|PVI only|Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.
16244128|NCT05065112|Experimental|PVI + IM|Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.
16244129|NCT05065099|Experimental|OnTRACK Intervention|"In the intervention condition, HCPs will be trained in the usage of the OnTRACK system.
~They will be oriented to the educational videos, the symptom tracking, and the interpretation of the data that is provided by the patients and families, and the associated management strategies based on that data. Additionally, patients and parents will be trained to use the OnTRACK smartphone app on their phone from diagnosis to recovery (or 12 weeks if not recovered), including daily exertional monitoring symptom ratings and use of the educational videos. School personnel will be introduced to the OnTRACK app and the data summary features in the school dashboard and the associated supports that can be provided to the student based on that data."
16244130|NCT05065099|No Intervention|Treatment as Usual|"In the control condition, the HCP provides usual/standard care to the patients and parents as is the practice within the specific clinic. The OnTRACK app and the educational modules are not provided."
16244133|NCT05065047|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30 minutes every 8 weeks
16244134|NCT05065021|Experimental|Initial/Cohort C|Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
16244135|NCT05065021|Experimental|Cohort A|"Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
16244136|NCT05065021|Experimental|Cohort B|"Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
16244139|NCT05064995||Patients|Patients with the Diagnosis of a Bipolar Disorder
16244140|NCT05064995||Healthy Controls|Individuals with no diagnosis of Bipolar Disorder
16244141|NCT05064969|Experimental|Single-arm non-randomised|This study includes a baseline assessment, a 9-week (with the possibility of extension to 12 weeks) blended intervention period, a post-intervention assessment, and two follow-ups at 3 and 6 months. Informal caregivers of people with dementia (with at least 18-year-old) with no restriction in terms of sex, educational level, or ethnic background will be included.
16244142|NCT05064956|Experimental|Ad26.ZEBOV|Ad26.ZEBOV will be given as a booster dose to all participants approximately 4 years after administration of the 2-dose Ebola regimen, Ad26.ZEBOV/MVA-BN-Filo, as part of the parent trial VAC52150EBL2002.
16244143|NCT05064943||Total Knee Replacement|Patients who have undergone total knee replacement
16244144|NCT05064930|Active Comparator|Bifidobacterium lactis|Probiotic formula contains 5x109 Bifidobacterium lactis Nordbiotic™ BI040 colony forming units (CFU)/capsule
16244145|NCT05064930|Active Comparator|Bacillus coagulans|Probiotic formula contains 2x109 Bacillus coagulans Nordbiotic™BC300 colony forming units (CFU)/capsule
16244146|NCT05064930|Placebo Comparator|Maltodextrin|Maltodextrin (starch hydrolisate) as a compound presents in probiotic formula.
16244147|NCT05064917||Children with suspected cow's milk allergy|
16244148|NCT05064904|Active Comparator|never received RAAS blockers or multidiscipline consultation before AKI.|The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.
16244149|NCT05064904|Active Comparator|had received RAAS blockers and multidiscipline consultation before AKI.|"All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.
~Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D)."
16244150|NCT05064891||Stroke patients|
16244151|NCT05064891||Participants without stroke|
16244155|NCT05064865|Experimental|Freeze-dried table grape powder|The intervention group will consume 46 g/day of a freeze-dried table grape powder.
16244156|NCT05064865|Placebo Comparator|Placebo grape powder|The control group will consume the same amount of a placebo with a similar taste to the table grape powder.
16244157|NCT05064852||Surufatinib|Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.
16244158|NCT05064839|Experimental|Bony scintigraphy|Bony scintigraphy within 1 to 4 months after inclusion
16244159|NCT05064826||Standard visit|Participants will have standard Emergency Department visit as per standard operating procedures which should last approximately 3 -5 hours.
16244160|NCT05064826||Extended visit with Observation|Participants will have extended Emergency Department visit by having an observation (which could be up to 23 hours) time in addition to the standard ED visit. In addition, information will be gathered about about the participants, use of opioids, healthcare visits, the quality of health, life, and treatment, and other topics. Urine or saliva or both may also be collected.
16244161|NCT05064813|Experimental|Mindfulness Based Stress Reduction Group|8 weeks of Mindfulness Based Stress Reduction Group (MBSR).
16244162|NCT05064813|Active Comparator|Stress Education Group|8 weeks of Stress Education Group (SE).
16244166|NCT05064787|Other|Single Arm Cohort Receiving Digital Health Coaching|All study participants will be enrolled in a 6-month digital health coaching program.
16244169|NCT05064761|Experimental|Treatment group|PLLA new dilution for treatment to improve appearance of cellulite.
16244170|NCT05064748|Experimental|Treatment Cohort|
16244173|NCT05064709|Experimental|Treatment (CCM ON)|CCM therapy will be turned on for the entire duration of the study.
16244174|NCT05064709|Sham Comparator|Sham (CCM OFF)|CCM therapy will be turned off for the first 18 months of the study. After 18 months, CCM therapy will be turned on for the rest of the study duration.
16244175|NCT05064696|Active Comparator|Group 1 (Control group)|Surgical wound will be covered with the standard non-stick gauze dressing.
16245243|NCT05057312|Experimental|Experimental arm 2|Written narrative Persuasion
16244177|NCT05064683|Experimental|white noise|The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
16244178|NCT05064683|Experimental|facilitated tucking|The newborns in the facilitated tucking were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.
16244179|NCT05064683|No Intervention|control|Newborns in the control group did not receive any treatment other than routine applications while receiving Nasal CPAP support in the neonatal intensive care unit.
16244180|NCT05064670|Experimental|Exercise|The intervention group will, in addition to routine clinical care according to (inter-) national guidelines, receive an exercise program of resistance and aerobic exercise delivered online in group exercise classes twice weekly, behaviour change counselling sessions and exercise maintenance phone calls.
16244181|NCT05064670|No Intervention|Control|The control group will receive routine clinical care according to (inter-) national guidelines
16244185|NCT05064644|Active Comparator|Plant stanol ester comparator|Product that contains plant stanol ester
16244186|NCT05064644|Placebo Comparator|Placebo comparator|Placebo product
16244187|NCT05064631|Experimental|Active intervention|Oral Broncho-Vaxom (3.5mg) administered daily for 10 days per month for 24 months
16244188|NCT05064631|Placebo Comparator|Placebo control|Matched placebo administered daily for 10 days per month for 24 months
16244189|NCT05064618|Experimental|Phase I study; 3+3 Design|"Phase I study; single-center, open-label, uncontrolled, dose-finding study
~MIKE-1 (AM80, Tamibarotene) After the DLT assessment period, if there is no evidence of disease progression or unacceptable toxicity to the patient according to RECIST v1.1, the investigational drug in each dose group will continue to be administered orally twice daily after breakfast and dinner for up to 24 weeks.The dose of the study drug will not be reduced or increased in the same subject.
~6 mg dose group (level 1).
~8 mg dose group (level 2).
~4 mg group (level 0). To be considered when two or more cases of DLT occur at level 1.
~GEM/nab-PTX (Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) will be administered intravenously."
16244190|NCT05064618|Experimental|Phase II study; Single-centre, open-label, single arm, uncontrolled study.|The dose of MIKE-1 will be fixed at the clinically recommended dose determined in Phase I. MIKE-1 will be administered orally twice daily after breakfast and dinner, and treatment will be continued until the occurrence of intolerable toxicity or disease progression, up to a maximum of six courses, to confirm efficacy and safety (tolerability).
16244192|NCT05064579||Patients with asthma|Children and adolescents aged 8 to 17 years old with a doctor's diagnosis of asthma and controller asthma treatment
16244193|NCT05064579||Holders of parental authority|Holders of parental authority of patients with asthma described in group A
16244194|NCT05064579||Doctors|Doctors caring for patients with asthma described in group A
16244195|NCT05064566||caries diagnosis|diagnostic accuracy of clinical visual examination (ICDAS II), digital intraoral radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), by examining third molar teeth in comparison to gold standard micro-CT images.
16244196|NCT05064553||Ultrasound Surveillance Group|Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.
16244197|NCT05064553||CT/MRI Surveillance Group|Subjects will undergo standard of care CT/MRI surveillance imaging.
16244198|NCT05064540|Experimental|Alto Abdominal Stent Graft System|Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
16244199|NCT05064540|Active Comparator|Comparators|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
16244200|NCT05064527||Patients|"OCD (ICD-10 F42) as the primary or secondary diagnosis, verified with a semi-structured psychopathological interview using Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-PL).
~CY-BOCS > 7: mild (8-15), moderate (16-23), severe (24-31), extreme (32-40)
~A psychiatrist determined that the child is eligible for care within psychiatry for their primary diagnosis.
~Patient is age 8 through 17 years (both inclusive)."
16244201|NCT05064527||Controls|"Ages 8 through 17 years (both inclusive).
~Sex and age (+/- 3months) matched to an included patient."
16244202|NCT05064527||Caregivers of Patients|Parent or guardian of patient with OCD
16244203|NCT05064527||Caregivers of Controls|Parent or guardian of control participant
16244204|NCT05064514|Experimental|Transcatheter Tricuspid Valved Stent Graft intervention|Participants who have carcinoid heart disease with severe symptomatic tricuspid regurgitation and with a significant backflow in the caval and hepatic veins will be treated with the implantation of the Transcatheter Tricuspid Valved Stent Graft
16244205|NCT05064501||Asthma and COVID19 infection|Asthma and COVID19 infection
16244206|NCT05064501||Asthma without COVID19 infection|Asthma and COVID19 infection
16244207|NCT05064488|Experimental|Part-1: Evobrutinib + Digoxin + Metformin + Rosuvastatin|
16244208|NCT05064488|Experimental|Part-2: Evobrutinib + Sumatriptan|
16244209|NCT05064475||Recurrent breast cancer patients with elevated tumor markers|PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer cells by using 18F-FDG. Its ability to identify tumor recurrence before detection of morphologic changes in conventional imaging reflecting its importance in detecting BC recurrence in asymptomatic patients with high tumor markers and negative results of radiological imaging. 18F-FDG PET/CT is frequently used for BC evaluation. However, data on its value in evaluating BC recurrence in patients with elevated tumor markers are limited and unclear
16244213|NCT05064436|Experimental|Part A - Healthy Participants|
16244214|NCT05064436|Experimental|Part B - Participants with MS|
16244215|NCT05064423|Experimental|Clinical Trials Education|Community Health Educators (CHE) will provide Clinical Trial Education to increase knowledge of Clinical Trials and the importance of Clinical Trial participation.
16244216|NCT05064410|Experimental|Educational Intervention and Referral for Fecal Immunochemical Test (FIT) Kit or Colonoscopy|The Community Health Educator (CHE) will provide online colorectal cancer (CRC) early detection, prevention, and screening education to increase knowledge of CRC and the importance of screening. These sessions will be conducted virtually within a group format or one-on-one via phone. Additionally, the CHE will provide information regarding FIT kit and colonoscopy screening and the screening process for attendees. The CHE and research assistant will be prepared to provide access to screening resources and services through participants' existing coverage. Those participants who do not have a primary care provider will be provided information on obtaining FIT kits through the mechanisms of the Federally Qualified Health Center (FQHC) and/or a colonoscopy through the cancer center on a case by case basis.
16244219|NCT05064358|Experimental|Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1|
16244220|NCT05064358|Experimental|Cohort 2: Participants receiving belantamab mafodotin at DL 2|
16244221|NCT05064358|Experimental|Cohort 3: Participants receiving belantamab mafodotin at DL 3|
16244222|NCT05064358|Experimental|Cohort 4: Participants receiving belantamab mafodotin at DL 4|
16244223|NCT05064358|Experimental|Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification|
16244224|NCT05064345|Active Comparator|HB0034 dose group 1|HB0034 single dose
16244225|NCT05064345|Active Comparator|HB0034 dose group 2|HB0034 single dose
16244226|NCT05064345|Active Comparator|HB0034 dose group 3|HB0034 single dose
16244227|NCT05064345|Active Comparator|HB0034 dose group 4|HB0034 single dose
16244228|NCT05064345|Active Comparator|HB0034 dose group 5|HB0034 single dose
16244229|NCT05064345|Active Comparator|HB0034 dose group 6|HB0034 single dose
16244230|NCT05064345|Active Comparator|HB0034 dose group 7|HB0034 single dose
16244231|NCT05064345|Placebo Comparator|Matching placebo for each dose group|placebo, single dose
16244232|NCT05064332|Experimental|OC only|Subjects will receive a single dose of an oral contraceptive during the first period of the study
16244233|NCT05064332|Experimental|PF-06650833 + OC|Subjects will receive PF-06650833 every day for 11 days and a single dose of an oral contraceptive on day 10.
16244236|NCT05064293|Other|Control Arm|"Data will be collected at baseline and 6-month follow-up from the standardized instruments and automated sources for all eligible subjects randomized to the control arm.
~Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider.
~Study clinicians will document clinically relevant information from their assessment in a telephone encounter and route these to the child's KP primary care provider in Epic as well as the site navigator.
~Control arm participants do not receive navigation."
16244237|NCT05064293|Experimental|Navigation Arm|"6-months of telephonic support from a mental health (MH) navigator to promote early access, engagement, coordination, and personalization of mental health treatment and services as soon as early symptoms of mental health problems are detected in children.
~The navigator model and implementation to be tested include:
~Automated identification of early symptoms for children
~Virtual collection of self-reported, standardized assessment scores
~Psychologists interpreting assessment scores and providing feedback to families and PCPs
~Trained clinicians serving as MH navigators to conduct family outreach, engage them in MH care, and coordinate with and between clinicians for up to 6-months
~Up to 4 video-based behavioral health sessions with the MH navigator, as needed, while barriers to initiation of ongoing mental health services can be explored and addressed over the 6-month period."
16244238|NCT05064280|Experimental|Pembrolizumab|Pembrolizumab is FDA approved and commercially available for the treatment of many types of cancer, but it may not be approved for the type of cancer that you have.
16244239|NCT05064280|Experimental|Lenvatinib|Lenvatinib in combination with pembrolizumab is FDA approved for the treatment of patients with certain types of endometrial cancer.
16244240|NCT05064267||CKD stage 3|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 3 from a non-inflammatory etiology.
16244241|NCT05064267||CKD stage 4|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 4 from a non-inflammatory etiology.
16244242|NCT05064267||CKD stage 5|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 5 from a non-inflammatory etiology.
16244243|NCT05064254|Active Comparator|Treatment as usual|All participants allocated to the control group will have access to standard care.
16244244|NCT05064254|Experimental|Mindful Adaptive Practice in Pregnancy Therapy|"Participants allocated to the intervention group will have access to treatment as usual in addition to synchronous virtual MAPP.
~MAPP draws upon existing integrative principles of structured psychotherapies (mindfulness-based, cognitive, behavioural and relational psychotherapy)"
16244245|NCT05064241|Experimental|Virtual Advisory Board|Participants have access to a genetic counselor to answer their questions on accessing genetic medicine.
16244246|NCT05064241|No Intervention|Virtual Peer-to-Peer Discussion Board|Participants answer each others' questions on the topic of accessing genetic medicine.
16244247|NCT05064228|Experimental|m-ReACT app condition|Participants will download the m-ReACT app on their mobile phones and will be asked to engage with the app for a period of 12 weeks.
16244248|NCT05064228|Active Comparator|Brief Advice|Participants will be given a one time brief informational session on the importance of engaging in substance-free activity while in AUD treatment.
16244249|NCT05064215||injection behind NAC|in 7 breasts dye was injected behind the nipple areola complex before breast reduction
16244250|NCT05064215||Injection into lateral upper quadrant|in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction
16244251|NCT05064215||injection into medial upper quadrant|in 2 breasts dye was injected into upper medial glandular tissue before breast reduction
16244252|NCT05064202|Experimental|Impella CP|ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the experimental arm will be treated with an Impella CP (+/- standard of care)
16244253|NCT05064202|Other|Standard of care|ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the control arm will be treated with inotropes (standard of care)
16244254|NCT05064189|No Intervention|Group 1|15 patients will be included in group 1 (no additional treatment)
16244255|NCT05064189|Experimental|Group 2|15 patients will be in group 2 (treatment directly after cataract surgery in the surgical theatre)
16244256|NCT05064189|Experimental|Group 3|15 patients will receive treatment after local anaesthesia (pre-operatively) and directly after cataract surgery (group 3)
16244257|NCT05064176|Experimental|Reconstructive lymphatic surgery|"The intervention treatment is reconstructive lymphatic surgery and consists of the application of lymphovenous anastomosis (LVA), lymph node transfer (LNT) or a combination of both. The choice of reconstructive technique(s) is determined by the surgeon and is based on the algorithm for reconstructive lymphatic surgery of lymphoedema.
~Additionally, all patients receive usual care (i.e. maintenance decongestive lymphatic therapy)"
16244258|NCT05064176|Active Comparator|No surgery|All patients receive usual care (i.e. maintenance decongestive lymphatic therapy)
16244259|NCT05064150||NET patient observational cohort|Patients diagnosed with lung or gastrointestinal neuroendocrine tumors
16244260|NCT05064137|Experimental|Curodont Repair® ( monomeric self - assembling peptide P11-4 )|Self assembling peptide P11-4 as Curodont Repair® can remineralize WSLs in a deeper manner than fluoride by guided enamel regeneration by forming a three-dimensional matrix within the subsurface body of an initial carious lesion to which calcium and phosphate ions found in natural saliva can bind and build de novo hydroxyapatite crystals.
16244261|NCT05064137|Active Comparator|Clinpro white varnish® ( Tricalcium Phosphate Fluoride Varnish, 5% F- )|Fluoride varnish is the gold standard for treating WSLs.
16244262|NCT05064124||CADDIE|Participants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system
16244263|NCT05064124||Control group|Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system
16244264|NCT05064111||All subjects|The experimental conditions will include a standard prostate biopsy using an FDA-approved ultrasound machine with application of the experimental (non-FDA approved) image fusion software.
16244265|NCT05064098||Pre-Surgical Breast Cancer Patients|Adult female patients newly diagnosed with stage 0-III breast cancer seen as a surgical consultation from 06/01/2019 to present.
16244266|NCT05064098||Breast Cancer Survivors|Breast Cancer Survivors
16244267|NCT05064085|Experimental|Dose Level 1|Cemiplimab 350mg + Capecitabine 800 mg/m^2
16244268|NCT05064085|Experimental|Dose Level 2|Cemiplimab 350mg + Capecitabine 1000 mg/m^2
16244269|NCT05064072|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
16244270|NCT05064072|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube
16244271|NCT05064072|Active Comparator|Silk plaster|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube
16244272|NCT05064059|Experimental|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
16244273|NCT05064059|Active Comparator|Standard of Care (Regorafenib or TAS-102)|Participants will receive 160 mg regorafenib orally daily on Days 1-21 of each 28-day cycle. Participants will also receive 35 mg/m^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day treatment cycle.
16244274|NCT05064046|Experimental|LuCa + Health Disparity module|"Participants will be asked to complete the Health Disparities module that is an interactive CME/CE online course which offers 0.5 continuing education credit hours.
~The will also be asked to complete the LuCa course."
16244275|NCT05064046|Active Comparator|LuCa only module|"LuCa is a free interactive CME/CE online course entitled, Lung Cancer and the Primary Care Provider. For the purpose of this study, participants will be asked to complete session 1 which offers 1.0 continuing education credit hours, including AMA PRA Category 1 credits, AANP, and AAFP Prescribed credits."
16244276|NCT05064033|Experimental|GROUP A|Pragmatic Set of intervention and posterior capsular stretch
16244277|NCT05064033|Active Comparator|GROUP B|Pragmatic Set of intervention and Sleeper Stretch
16244278|NCT05064020||Polypharmacy|"Polypharmacy: patient is using five or more medications will be considered polypharmacy.
~Subjects having polypharmacy condition with taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
16255899|NCT04984577|Experimental|Compound Edaravone Injection-High dose|
16244279|NCT05064020||Nonpolypharmacy|"Nonpolypharmacy: patient is using less than five medications will be considered nonpolypharmacy
~Nonpolypharmacy Subjects taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
16244280|NCT05064007|Experimental|1|this group will be exposed to condition A first, then B, and C
16244281|NCT05064007|Experimental|2|this group will be exposed to condition B first, then C, and A
16244282|NCT05064007|Experimental|3|this group will be exposed to condition C first, then A, and B
16244283|NCT05063994|Experimental|Chronocort|Hydrocortisone modified-release capsule - Chronocort®. 63 subjects will be randomised to this group using an interactive response technology (IRT).
16244284|NCT05063994|Active Comparator|Cortef|Immediate-release hydrocortisone capsule (IRHC) - Cortef. 63 subjects will be randomised to this group using an interactive response technology (IRT).
16244285|NCT05063981||CRSwNP|10 patients with severe refractory eosinophilic asthma plus CRSwNP
16244286|NCT05063981||No CRSwNP|10 patients with severe refractory eosinophilic asthma and no CRSwNP
16244287|NCT05063968|Experimental|Part A - Single Ascending Dose (SAD) phase: Experimental|
16244288|NCT05063968|Placebo Comparator|Part A - Single Ascending Dose (SAD) phase:Placebo|
16244289|NCT05063968|Experimental|Part B - Food Effect (FE) phase: Experimental 1|
16244290|NCT05063968|Experimental|Part B - Food Effect (FE) phase: Experimental 2|
16244291|NCT05063968|Experimental|Part C - multiple ascending dose (MAD) phase: Experimental|
16244292|NCT05063968|Placebo Comparator|Part C - multiple ascending dose (MAD) phase:Placebo|
16244293|NCT05063955||Chronic Heart Failure|Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
16244294|NCT05063955||Controls|Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.
16244295|NCT05063929|Experimental|Fruits|Participants will receive 2 cup eq fruits per day
16244296|NCT05063929|Other|Fruit restriction|Participants will receive 1/2 cup eq fruits per day
16244297|NCT05063916|Experimental|AK104|cadonilimab) can help to control neuroendocrine cervical cancer that is recurrent (has come back after treatment) or metastatic (has spread).
16244298|NCT05063903||Fontan Group|"Fontan Group Inclusion Criteria
~be between the ages of 8-50 Having undergone Fontan operation in our hospital or another center Clinical stability of the patients (preserved ventricular function), No change in ongoing drug therapy that adversely affects clinical stability, At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital
~Fontan Group Exclusion Criteria:
~Inability to access the patient's medical data Neurological and/or genetic musculoskeletal disease Having orthopedic and cognitive problems that prevent testing The patient's and/or family's unwillingness to participate in the study"
16244299|NCT05063903||Control Group|"Control Group Inclusion Criteria:
~Not have cardiovascular, neurological and/or genetic musculoskeletal disease Not having orthopedic and cognitive problems that prevent testing The patient's and/or family's willingness to participate in the study"
16244300|NCT05063890|Experimental|Muscle Specific MET|
16244301|NCT05063890|Experimental|Movement specific MET|
16244302|NCT05063877|Placebo Comparator|Placebo|"Matched placebo control 10 mg capsule or 20 mg capsules totaling to 10 mg, 20 mg, 40mg or 60 mg will be administered once daily orally for 12 weeks with the option for open-label extension.
~Intervention: Drug: Placebo"
16244303|NCT05063877|Experimental|Study drug EQU-001|"10mg capsules or 20 mg EQU-001 capsules totally 10 mg, 20 mg, 40 mg, 60 mg will be administered once orally daily to active-treatment subjects for 12-weeks with the option for open-label extension.
~Intervention: Drug : EQU-001"
16244304|NCT05063864|Experimental|Nursing Support Program|the group that applied the nursing support program
16244305|NCT05063864|No Intervention|No Nursing Support Program|the group that did not receive a nursing support program
16244306|NCT05063851|Experimental|Memantine hydrochloride|
16244307|NCT05063851|Placebo Comparator|Placebo|
16244308|NCT05063838|Experimental|Pharmacogenomic group|The perioperative (anesthetic and postoperative pain management) plan for each patient will be determined preoperatively by the treating anesthesia team. Thereafter, the pharmacogenomic results of the patient will be released and a personalised anesthetic plan formulated based on international pharmacogenomic guidelines. The treating anesthesia team will then modify the perioperative care plan based on the patients' pharmacogenomic results and the international pharmacogenomic guidelines.
16244309|NCT05063838|No Intervention|Control group|Perioperative care will be managed according to current 'standard care' practice at Peter MacCallum Cancer Centre.
16244310|NCT05063825|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
16244311|NCT05063825|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
16244312|NCT05063799|Experimental|a case included pulmonary rehabilitation program|
16244313|NCT05063786|Experimental|Experimental Arm (Arm A) Cohort 1 (HER2+/HR-)|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 8 mg/kg IV loading dose, followed by 6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2 mg/kg IV weekly (weekly schedule), or 600 mg SC every 3 weeks.
~Alpelisib 300 mg oral once daily."
16244314|NCT05063786|Experimental|Experimental Arm (Arm A) Cohort 2 (HER2+/HR+)|"Trastuzumab either IV or SC: 8 mg/kg IV loading dose, followed by 6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2 mg/kg IV weekly (weekly schedule), or 600mg SC every 3 weeks.
~Alpelisib 300 mg oral once daily. Fulvestrant 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
~Males and females who are not post-menopausal must have been on a gonadotropin-releasing hormone (GnRH) agonist (e.g. goserelin or leuprorelin) for at least 28 days prior to starting study treatment, and should continue with this therapy."
16244315|NCT05063786|Active Comparator|Control Arm (Arm B ) Cohorts 1 and 2|"Trastuzumab either IV or SC: 8 mg/kg IV loading dose, followed by 6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule), or 600 mg SC every 3 weeks.
~Chemotherapy (CT): vinorelbine, capecitabine or eribulin (according to investigator preference):
~Vinorelbine either oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
~Capecitabine: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
~Eribulin: 1.23 mg/m2 IV on days 1 and 8, every 3 weeks."
16244316|NCT05063773|Experimental|Group 1|
16244317|NCT05063773|No Intervention|Group 2|
16244318|NCT05063760|Experimental|TGCT patients - exercise|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
16244319|NCT05063760|No Intervention|TGCT patients - nonexercising controls|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
16244320|NCT05063747||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 is defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis U07.1 in the nationwide Swedish intensive care registry.
16244321|NCT05063747||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up not including patients in the COVID-19 ICU cohort. COVID-19 is defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
16244322|NCT05063747||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. ICU and hospital admitted COVID-19 patients are not included.
16244323|NCT05063734|Experimental|Part A, THR-687 dose level 1|
16244324|NCT05063734|Experimental|Part A, THR-687 dose level 2|
16244325|NCT05063734|Experimental|Part B, treatment naïve subjects, THR-687 selected dose level|
16244326|NCT05063734|Active Comparator|Part B, treatment naïve subjects, aflibercept|
16244327|NCT05063734|Experimental|Part B, previously treated subjects, THR-687 selected dose level|
16244328|NCT05063734|Active Comparator|Part B, previously treated subjects, aflibercept|
16244329|NCT05063721|Experimental|Intra-arterial delivery of autologous MABs|Autologous mesoangioblasts (MABs) will be intra-arterially delivered to lower leg of participant
16244330|NCT05063721|No Intervention|No intervention|intra-subject control
16244331|NCT05063708|Sham Comparator|Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|"Traditional dysphagia therapy (TDT) involved orofacial, lingual, and laryngeal motor exercises and compensatory swallowing strategies included various modifications of head, neck, and body postures and adjustment of food/liquid temperature, viscosity, and volume. The choice of specific strategies was based on the FEES findings and the clinical swallowing examination. The rehabilitative treatment will be administered in the 8 centers taking part to the study. The electrodes in this sham group will be placed in the same positions as the active treatment, with a current between 3 and 5 mA (average of 3.5 mA) current unable to perform muscle contraction. Every MS patient will be received 16 sessions of TDT according to their degree of dysphagia, contemporary associated with Sham neuromuscular electrostimulation two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks"
16244332|NCT05063708|Experimental|traditional dysphagia therapy plus Neuromuscular electrostimulation|Every MS patient will be treated with traditional dysphagia therapy, associated with an active neuromuscular electrostimulation. The amplitude will be increased until the subject will feel a 'grabbing sensation' which corresponded to muscular contraction. This will be the amplitude used for the therapy. This process will be repeated for the second channel of the stimulator. The typical electrical stimulus is at 80 Hz and at 300 microsec, and it will be adapted to avoid annoying stimulus to the patients. During therapy, both channels will be active. Every MS patient will be received 16 sessions of traditional dysphagia therapy according to their degree of dysphagia, contemporary associated with neuromuscular electrostimulation , according to our previous experiences, two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks.
16244333|NCT05063695||Epidural|Patients who underwent Nuss procedure under epidural protocol (between January and December of 2019)
16244334|NCT05063695||ESP|Patients who underwent Nuss procedure using ESP catheter protocol (June 2020 to April 2021)
16244335|NCT05063682|Experimental|Treatment|Patients receive EGFRvIII -CAR T cells intracerebroventricular over 15 minutes on day 1. Patients may receive additional cycles based on the persistence of the cells.
16244336|NCT05063669|Experimental|Cognitive Occupational Therapy|Occupational therapy applications were carried out 40 minutes, twice a week (one individual session and one group intervention session) and total of 8 weeks. In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
16244337|NCT05063669|No Intervention|Control|No intervention was performed in this group.
16244338|NCT05063656|Experimental|Gabapentin Open-label treatment|8-week treatment with gabapentin
16244339|NCT05063630|Experimental|Medical treatment plus intracranial stenting (MT plus IS)|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
16244340|NCT05063630|Active Comparator|Medical treatment alone (MT)|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
16244396|NCT05063279|No Intervention|Negative control group|A negative control group is included in the study which will not receive any resistance training.
16244397|NCT05063266|Active Comparator|Group A|Deep Breathing exercise
16244343|NCT05063604|Experimental|Citalopram 20-40 mg|Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.
16244344|NCT05063604|Experimental|Psychotherapy|Participants received one psychotherapy session weekly for 12 weeks.
16244345|NCT05063591|Experimental|Intervention arm|Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment.
16244346|NCT05063578|Experimental|Participant|
16244347|NCT05063565|Active Comparator|TheraSphere alone|Treatment with TheraSphere
16244348|NCT05063565|Experimental|TheraSphere followed by Durvalumab and Tremelimumab|TheraSphere followed by Tremelimumab plus Durvalumab administered once, then repeated administration of Durvalumab monthly up 18 months post randomization
16244349|NCT05063552|Experimental|Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)|Patients receive cetuximab intravenously (IV) over 30-60 minutes on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16244350|NCT05063552|Experimental|Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)|Patients receive bevacizumab IV over 30-90 on day 1, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16244351|NCT05063552|Experimental|Phase II, Arm C (Bevacizumab, Atezolizumab)|Patients receive bevacizumab IV over 30-90 on day 1 and atezolizumab over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16244352|NCT05063552|Experimental|Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)|Patients receive cetuximab IV over 30-60 minutes on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16244353|NCT05063552|Experimental|Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)|Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
16244357|NCT05063526||Group B|"40 patients who are mechanically ventilated due to pulmonary disease at respiratory ICU had their diagnosis as follows: 21 (53%) had COPD, 8 (20%) had asthma, 5 (13%) had bronchiectasis, 5 (13%) had pneumonia and
~1 (3%) had viral influenza H1N1. Out of group B patients, 11 patients (13.75%) had failed weaning, of which 6 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 3 patients were re-intubated and 2 patients died."
16244358|NCT05063526||Group A|40 patients on mechanical ventilation due to non-pulmonary disease at respiratory ICU had their diagnosis as follows: 24 (60%) had congestive heart failure, 4 (10%) had diabetes mellitus, 4 (10%) had sepsis other than pneumonia, 2 (5%) had epilepsy, 2 (5%) had embolic hemiplegia, and 4 (10%) had chronic renal failure. Out of group A patient, 9 patients (11.25%) had failed weaning of which 4 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 2 patients were reintubated and 3 patients died.
16244359|NCT05063526||control group.|40 patients Chronic obstructive pulmonary disease (COPD) from Outpatient Clinic
16244360|NCT05063513|Experimental|Transplant arm|Experimental arm will undergo mobilisation with cyclophosphamide (CY) 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
16244361|NCT05063513|Active Comparator|Rituximab arm|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
16244362|NCT05063500|Experimental|Experimental group|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
16244363|NCT05063500|Active Comparator|Control group|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
16244364|NCT05063487||Recent HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test recent on the rapid test for recent infection (RTRI).
16244365|NCT05063487||Long-Term HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test long-term on the rapid test for recent infection (RTRI).
16244366|NCT05063474||PAD: Peripheral Artery Disease|People with Peripheral Artery Disease (PAD). No intervention given, observation and assessment only
16244367|NCT05063474||PLL+PAD: People with Limb Loss and Peripheral Artery Disease|People with Lower-Limb Loss (PLL) and Peripheral Artery Disease (PAD) No intervention given, observation and assessment only
16244368|NCT05063461||sevoflurane with remifentanil|patients receive standardized sevoflurane with different concentrations of remifentanil
16244398|NCT05063266|Experimental|Group B|Inspiratory Muscle Training
16244399|NCT05063253|Experimental|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once weekly.
16244400|NCT05063253|Experimental|TG103, 22.5 mg|TG103 (22.5 mg) will be administered via subcutaneous injection once weekly.
16244401|NCT05063253|Experimental|TG103, 30 mg|TG103 (30 mg) will be administered via subcutaneous injection once weekly.
16244369|NCT05063448|Experimental|DadSpace Intervention|Participants will take part in a 12-hour educational discussion-based mentoring program intervention over 8 weeks. The intervention will be facilitated by a trained father facilitator and will include education and support on topics relevant to perinatal fathers. Topics include father identity, stress management, infant development, co-parenting, masculinity and caregiving, healthy communication, and work-life balance. Participants will additionally have access to a brief educational podcast series on related topics. Participants will also be invited to monthly follow-up daddy/baby drop-in groups.
16244370|NCT05063422|Experimental|Mild Resorption of mandibular ridge|Loss of upto 1/3 of original vertical height
16244371|NCT05063422|Experimental|Moderate Resorption of mandibular ridge|2. Moderate Resorption: Loss of upto 1/3 to 2/3 of original vertical height
16244372|NCT05063422|Experimental|Severe Resorption of mandibular ridge|3. Severe Resorption: Loss of 2/3 or more of original vertical height
16244373|NCT05063409|Active Comparator|1:1 Ratio of FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:1 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
16244374|NCT05063409|Active Comparator|1:4 Ratio FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
16244375|NCT05063396|Active Comparator|opioid free anesthesia|opioid free anesthesia
16244376|NCT05063396|Placebo Comparator|Opioid-sparing anesthesia|Opioid-sparing anesthesia
16244377|NCT05063383||PCOS|"Oligomenorrhea/amenorrhea
~Clinical androgen excess or biochemical androgen excess
~Polycystic ovary showed by gynecological ultrasound"
16244378|NCT05063383||NOPCOS|not meet Rotterdam standards
16244381|NCT05063357|Other|Radioactive iodine-labeled monoclonal antibody omburtamab|Single arm
16244382|NCT05063344||Sexually active persons who self-select for syphilis testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
16244383|NCT05063344||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
16244384|NCT05063344||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior
16244387|NCT05063318|Active Comparator|Sequence TR|"Sequence 1 (TR)
~Cycle 1: Itraconazole + lurbinectedin 0.8 mg/m²
~Cycle 2: Lurbinectedin alone 3.2 mg/m²
~Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)
~PART A The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m². In Part A, all patients will receive itraconazole plus lurbinectedin in Cycle 1 and lurbinectedin alone in Cycles 2 and 3 (this last cycle being optional).
~PART B Randomization will apply for study Part B only. In Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A. In Part B, patients will be randomly assigned to the corresponding sequences."
16244388|NCT05063318|Active Comparator|Sequence RT|"Sequence 2 (RT):
~Cycle 1: Lurbinectedin alone 3.2 mg/m²
~Cycle 2: Itraconazole + lurbinectedin 0.8 mg/m²
~Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)"
16244393|NCT05063292|No Intervention|Control group|Patients covered with a 41 centigrade degrees double layered cotton cloth
16244394|NCT05063292|Experimental|Prewarmed group|Patients receive active prewarming with an air forced blanket ( full body blanket) 30 minutes prior to the operation
16244395|NCT05063279|Experimental|Resistance training group|Participants in two age groups will receive moderate (three sets of per exercise per session) and low-volume (one set of resistance per session) training allocated to either right or left upper- and lower extremities. A total of 24 sessions will be performed over 10-12 weeks.
16244402|NCT05063253|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly.
16244403|NCT05063240|Experimental|Mobile phone text messaging plus prospective motivational interviewing|Experimental: Text messaging-motivational interviewing. Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding the infants. Participants will be asked to respond within 48 hours, indicating no problem or a problem with breastfeeding that requires help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, and 10. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
16244404|NCT05063240|Active Comparator|Standard infant feeding counselling|Standard infant feeding counselling as part of routine primary healthcare practice
16244405|NCT05063227||Study group|As this is a single-group, observational study all patients will be monitored with all three nociception monitoring systems (the Surgical Pleth Index (SPI), the Pupillary Pain Index (PPI) and the Nociception Level (NOL)) and data on heart rate changes as a variable used in current clinical practice to choose the opioid dosage during general anesthesia will be obtained additionally.
16244406|NCT05063214||Ultrasound assessment|Muscle ultrasound evaluation
16244407|NCT05063201|Experimental|Cariprazine|
16244408|NCT05063201|Placebo Comparator|Placebo|
16244409|NCT05063188|Active Comparator|Control group|
16244410|NCT05063188|Experimental|Intervention group|
16244411|NCT05063175|Active Comparator|Control Group|Children in the control group received the conventional physical therapy protocol which was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking.
16244412|NCT05063175|Experimental|Experimental Group|The children in the experimental group received the conventional protocol applied to the control group. Further, they wore TheraTog orthotic undergarment with its strapping system for 8 hours daily for 12 successive weeks.
16244413|NCT05063162|Experimental|Rozanolixizumab Arm|Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.
16244414|NCT05063162|Placebo Comparator|Placebo Arm|Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding.
16244415|NCT05063149|Active Comparator|Broncho-Vaxom treatment|Infants in this arm will be given 3,5mg bacterial lysate (OM-85) 10 days per month from 6 weeks after birth until 12 months of age.
16244416|NCT05063149|Placebo Comparator|Placebo|Infants in this arm will be given a placebo powder from a capsule that will be indistinguishable from the active study drug.
16244417|NCT05063136|Experimental|Capecitabine+endocrine therapy|capecitabine (500mg, tid) (for 1 year)+standard endocrine therapy (at least 5 years)
16244418|NCT05063136|Placebo Comparator|Placebo+endocrine therapy|oral placebo (tid) (for 1 year) + standard endocrine therapy (at least 5 years)
16244419|NCT05063123|Other|Single arm - Flotetuzumab|1 - 3 cycles of Flotetuzumab. Flotetuzumab will be administered intravenously via continuous (pump) administration. At least for the first 7 days of cycle 1, the drug will be administered in an inpatient hospital setting, but afterwards may be administered in an outpatient setting using an ambulatory pump configuration. Flotetuzumab will be dosed using multi-step increments in dosing over the first week as follows: 30, 60, 100, 200, 300, and 400 ng/kg/day each for 24 hours. On day 7, the dose will be increased to 500 ng/kg/day and administered as a continuous infusion for the remainder of cycle 1. After 1 cycle of flotetuzumab patients will proceed with alloHCT. However if there is a delay in access to transplantation, patients are allowed to receive up to 2 additional cycles flotetuzumab provided all non-hematologic toxicities have resolved to Grade <2.
16244420|NCT05063110|Experimental|Treatment arm|300 mg of ITACITINIB will be administrated per os every day for 30 days, dose with reduction to 200 mg per safety is allowed if AEs are observed or if co-administered a strong CYP3A inhibitor
16244421|NCT05063097||CCU patients|All consecutive patients over 18 years admitted to the CCU.
16244422|NCT05063084|Experimental|OHD (HFNO)|High flow nasal oxygen
16244423|NCT05063084|Other|Control|Classic pre-oxygenation with facemask
16244424|NCT05063071|Experimental|TAF monotherapy without HBIG|The standard dose of TAF 25mg daily was used. TAF can be used on the first day after orthotopic liver transplantation. No HBIG was used before, during, or after transplantation; and therapeutic vaccination was not routinely used.
16244425|NCT05063058|Experimental|Molecular guided therapy|
16244426|NCT05063045|Experimental|smart-cloth|Participants receive smart-cloth assisted home nursing care
16244427|NCT05063045|No Intervention|routine care|This group receive routine care
16244428|NCT05063032|Experimental|High-density mapping guided ablation|High-density map and return-cycles map in order to localize the protected isthmus with precision for focal/minimal ablation.
16244429|NCT05063032|Active Comparator|Empirical linear ablation|Empirical predefined set of linear ablation.
16244433|NCT05062993|Experimental|study group|Patients with chronic radicular pain will be included in this study. Ultrasound guided caudal epidural pulse radiofrequency technique will be applied to the study group.
16244434|NCT05062980|Experimental|Phase 1|"Up to 3 sequential dose escalation cohorts will be treated with GPX-001 intravenously on Day 1 in addition to pembrolizumab 200 mg fixed dose infusion every 21-days until progression or unacceptable toxicity.
~The first group will receive GPX-001 IV infusion at 0.06 mg/kg, the next group 0.09 mg/kg and the third group will receive 0.12 mg/kg. An expansion cohort of 12 patients will receive the MTD to confirm RP2D for Phase 2 portion."
16244435|NCT05062980|Experimental|Phase 2 Combination|Patients will receive the RP2D of GXP-001 intravenously on Day 1 in addition to pembrolizumab 200 mg fixed dose infusion every 21-days until progression or unacceptable toxicity.
16244436|NCT05062980|Active Comparator|Phase 2 Active Comparator|Patients will receive docetaxel 75 mg/m2 infusion with or without ramucirumab 10 mg/kg infusion every 21 days until progression or unacceptable toxicity.
16244492|NCT05062486|Experimental|Resveratrol, Quercetin, Curcumin (RQC)|Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
16244493|NCT05062486|Active Comparator|Curcumin|Curcumin (1000mg BID); 24 months
16244437|NCT05062967||HAOD Cohort|"This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide.
~The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection"
16244438|NCT05062967||OrthoC-Tx Cohort|This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection
16244439|NCT05062967||Ortho-CoRIS Cohort|"This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research.
~The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection."
16244440|NCT05062967||TrazHE Cohort|"This cohort includes patients whose clinical picture is compatible with HAE infection.
~The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE."
16244441|NCT05062967||Ortho-C-Rodent Cohort|This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).
16244442|NCT05062967||Ortho-C-Domestic Rodent Cohort|This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.
16244443|NCT05062967||Ortho-C-Carnivore Cohort|"This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over.
~Feces, liver and serum samples will be taken to study the transmission of Ortho-C."
16244444|NCT05062954|Experimental|Polyphenol-rich cranberry extract supplement standardized in PACs|Supplementation with polyphenol-rich cranberry extract standardized in PACs (1 capsule / day)
16244445|NCT05062954|Placebo Comparator|Placebo supplement|Supplementation with placebo (1 capsule / day)
16244446|NCT05062941|Active Comparator|Control group|Conventional therapy (CT) was applied to all participants. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS) in conventional mode, 5 minutes of ultrasound (1.5 W/cm2, 1 MHz), 20 minutes of interference current with vacuum electrodes (80 Hz pulse frequency, 1/1 rectangular spectrum), and exercises (all exercises were applied as 1 set of 10 repetitions in each direction: Codman exercises (3-directions), wand exercises (4-directions), exercises using the shoulder wheel (2-directions), exercises with exercise band (5-directions), exercises on the finger ladder (1 set of 10 repetitions in both directions); and shoulder capsule stretching exercises performed (1 set of 12 repetitions) by asking the subjects to wait 20 seconds where the tension was felt).
16244447|NCT05062941|Active Comparator|Study group|"Same conventional therapy (CT) that was applied to control group was also applied to all participants in this group. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and the same exercises.
~In addition to the CT program, only study group has received HILT (BTL 6000, BTL Industries, Inc., USA) application to the shoulder area (analgesic mode, 25 Hz,10 W, 12 j/cm2) for 2 minutes."
16244450|NCT05062915|No Intervention|Baseline population|Historic cohorte for comparisson in study 1. Baseline population 1 all patients with AVS. Baseline 2 population part of baseline 1 but with peripheral cause of AVS. Are offered late onset vestibular rehabilitaion if they have balance deficit.
16244451|NCT05062915|Active Comparator|Study population|"The study population is divided into 2 groups, based on the findings in the clinical investigation.
~study population 1: all patients with acute Vestibular syndrome (AVS) Study population 2: all patients from study group 1, with vestibular/peripheral cause of AVS. They are offered early onset rehabilitation.
~Arm 1 and 2 are compared for cost-effectiveness and compared to the costs of the diagnosis."
16244452|NCT05062902|Active Comparator|Template Injection|For the standard template injection, 200 units of BoNT diluted in 6mL of preservative saline will be prepared. 1/4 of the prepared BoNT solution will be administered to each of the pubococcygeus and puborectalis muscle at 5 and 7 o'clock position, respectively. The index finger will be used for palpation as the 20-gauge spinal needle with a trumpet guide (i.e. paracervical block kit) piercing through the vaginal mucosa to the intended muscle groups. The syringe will be withdrawn before each injection to avoid intravascular injection.
16244453|NCT05062902|Experimental|Guided Injection|For the guided injection, pelvic floor injections (total of 4) will be made to the pubococcygeus and puborectalis muscles each, at NMJ locations (1.5 ml per site), at patient-specific locations and depths identified from vaginal HD-sEMG recordings. NMJ mappings will be generated for each participant. The channel locations will provide angle measurements for each NMJ. The device will calculate these parameters based on acquired HD-sEMG. The index finger will be used for palpation and guidance of injection needle through the vaginal mucosa to the defined injection sites. The BoNT dosage with respect to the total 200 units administered to each site will be patient specific, determined as the ratio of the resting average resting root-mean square (RMS) value of a specific region divided by the total average resting RMS.
16244454|NCT05062889|Experimental|Arm B FOLFOXIRI, part 1 (adjuvant)|FOLFOXIRI Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluoruracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. In the case of oxaliplatin and/or irinotecan interruption because of adverse events, patient's refusal or investigator's choice, the continuation of the other drugs until 12 cycles is recommended.
16244455|NCT05062889|Active Comparator|Arm A mFOLFOX6 or CAPOX (at investigator's choice), part 1 (adjuvant)|"mFOLFOX6 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. The continuation of 5FU/leucovorin until 12 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.
~CAPOX Oxaliplatin 130 mg/sqm iv over 2 hours, day 1; Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14; to be repeated every 3 weeks until 8 cycles. The continuation of Capecitabine until 8 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.
~Pending the results of ct-DNA analysis, up to 2 cycles of FOLFOX/CAPOX before randomization are allowed to start the adjuvant treatment within 8-10 weeks after surgery"
16244456|NCT05062889|Experimental|Arm B Trifluridine/Tipiracil, part 2 (post-adjuvant)|Trifluridine/Tipiracil: 35 mg/ m2/bid per os days 1-5 and 8-12 to be repeated every 4 weeks until 6 cycles.
16244457|NCT05062889|No Intervention|Arm A Observation, part 2 (post-adjuvant)|Follow-up
16244460|NCT05062837|Experimental|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
16244461|NCT05062824|Experimental|Intervention|Participants in the intervention will have access to Baby Feed
16244462|NCT05062824|No Intervention|Standard Care|Participants in the standard care group will NOT have access to Baby Feed
16244465|NCT05062785|Experimental|Intranasal insulin|A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin.
16244466|NCT05062772||Glioblastoma|
16244467|NCT05062759|Experimental|Tezepelumab|Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
16244468|NCT05062759|Placebo Comparator|Placebo to Tezepelumab|Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
16244469|NCT05062746|Experimental|MRT group|One session Matrix-Rhythm Therapy
16244470|NCT05062746|Other|Control group|One session routine, conventional physiotherapy and rehabilitation
16244471|NCT05062720|Experimental|Local consolidative therapy (LCT) + systemic therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
16244472|NCT05062720|Active Comparator|Systemic therapy alone|Appropriate second-line systemic therapy, as defined in the NCCN guidelines will be used during study treatment (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). The choice of specific regimen will be left to the discretion of the treating oncologist but cannot include other experimental or investigational treatment. Sample appropriate systemic therapies include FOLFOX or FOLFIRI with a biologic agent such as an anti-angiogenic antibody or anti-EGFR antibody.
16244473|NCT05062707||AYA cancer patients|Patients aged 18-39 years, with a first histological and/or cytological diagnosis of a haematological or solid malignancy, scheduled to start systemic therapy with curative intent.
16244474|NCT05062681|Active Comparator|Dexamethasone group|Patients will receive dexamethasone 8 mg q12hours
16244475|NCT05062681|Experimental|methylprednisolone group|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
16244476|NCT05062668||iStent|POAG patient operated at the CHU of Amiens or the CH of Saint-Quentin of a combined cataract and iStent inject or inject W surgery from January 2018 to September 2020.
16244477|NCT05062668||cataract only|POAG patients operated only on cataract from January 2018 to September 2020.
16244478|NCT05062655|Experimental|Drug reconciliation|Drug reconciliation and transmission to pharmacist
16244479|NCT05062655|No Intervention|standard|
16244480|NCT05062590|Experimental|Group Intervention|Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
16244481|NCT05062590|No Intervention|Group control|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations
16244482|NCT05062577|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants will receive ASP8062 once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
16244483|NCT05062577|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive matching placebo once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
16244484|NCT05062564|Experimental|LipiFlow group|Single preoperative treatment with the thermal pulsation system LipiFlow within two months before cataract surgery
16244485|NCT05062564|Active Comparator|Control group|Eyelid warm compresses plus eyelid massage twice a day for the preoperative month
16244486|NCT05062551|Experimental|intervetion group|50 patients complained of post-menstrual bleeding with confirmed presence of isthmocele. After written consent, the patient will be subjected to three steps hysteroscopic resection of an isthmocele by removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
16244487|NCT05062525||Immunotherapy|
16244488|NCT05062525||Non-Immunotherapy|
16244489|NCT05062512||Participants living with and without neurodegenerative diseases|No intervention
16244490|NCT05062499|Active Comparator|Active TENS|electrical stimulation
16244491|NCT05062499|Sham Comparator|Sham TENS|no stimulation
16244535|NCT05062226|Experimental|GMP-based products|GMP-based nutritional protein substitutes for the dietary management of PKU and TYR
16244501|NCT05062434|Experimental|Intervention Arm|VA cardiac electrophysiologists receiving the intervention
16244502|NCT05062421||Cases 1|Patients treated with JAK-type kinase inhibitors.
16244503|NCT05062421||Cases 2|Patients treated with monoclonal antibodies against TNF.
16244504|NCT05062421||Cases 3|Patients treated with soluble receptor against TNF.
16244505|NCT05062421||Cases 4|Patients treated with FAME group biosimilars.
16244506|NCT05062421||Cases 5|Patients treated with rituximab.
16244507|NCT05062421||Cases 6|Patients treated with abatacept.
16244508|NCT05062421||Cases 7|Patients treated with drugs that block the IL6.
16244509|NCT05062408||cases|Patients treated with direct-acting antivirals.
16244510|NCT05062395||Observational (diet, FDG PET CT)|Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive FDG then undergo PET CT.
16244511|NCT05062382|Experimental|Complementary feeding program|Promotion of two main products: 1) Cerifam, a fortified complementary food popular in Ethiopia, and 2) eggs.
16244512|NCT05062382|No Intervention|Comparison|Comparison arm with no program
16244513|NCT05062369|Experimental|Participants receiving active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of active transcranial direct current stimulation (tDCS) to dorsolateral prefrontal cortex (DLPFC) while in the Lodging Plus treatment program and then 5 remote sessions of active tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
16244514|NCT05062369|Sham Comparator|Participants receiving active and sham active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of sham-tDCS sessions while in the Lodging Plus treatment program and then 5 remote sessions of active-tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
16244515|NCT05062356|Experimental|Suprainguinal fascia iliaca compartment block (FICB)|Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve.
16244516|NCT05062356|Active Comparator|Pericapsular nerve group block (PENG)|The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus.
16244517|NCT05062356|Sham Comparator|Local analgesia infiltration (LAI)|local anesthetic infiltration (LAI) into the anterior pericapsular tissues
16244518|NCT05062356|Sham Comparator|No adjunct: spinal anaesthesia (control)|Standard spinal anesthesia technique
16244519|NCT05062343|Active Comparator|Dilapan-S|After randomization, the patient will have Dilapan-S placed via sterile speculum exam with placement of 3-5 rods. The rods will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the rods will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
16244520|NCT05062343|Active Comparator|Cook Catheter|After randomization, the patient will have the Cook catheter placed via sterile vaginal or speculum exam with the uterine component of the balloon inflated to maximum 60mL. The balloon will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the Cook catheter will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
16244521|NCT05062330|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days|
16244522|NCT05062330|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days|
16244523|NCT05062317|Experimental|ctDNA (Low Risk)|Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.
16244524|NCT05062317|Experimental|ctDNA (High Risk)|Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX [5-fluorouracil, leucovorin and oxaliplatin] or FOLFIRI [5-fluorouracil, leucovorin and irinotecan] with or without bevacizumab)
16244525|NCT05062304||Fluticasone furoate-vilanterol|Reference group
16244526|NCT05062304||Fluticasone furoate-umeclidinium-vilanterol|Exposure group
16244529|NCT05062265|Active Comparator|Tight Rope Fixation|
16244530|NCT05062265|Active Comparator|tight rope fixation w/ AITFL repair augmentation with an internal brace|
16244531|NCT05062252|Experimental|Mirror group|Mirror Medacta Shoulder System
16244532|NCT05062252|Active Comparator|Historical Control group|Total shoulder arthroplasty system
16244533|NCT05062239|Active Comparator|Continuance|Continuance prior statin therapy.
16244534|NCT05062239|Experimental|Discontinuance|Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
16244536|NCT05062213|Experimental|Moisturizer Body Lotion|All participants will receive the product and use it at home.
16244537|NCT05062200|Experimental|Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])|Japanese participants will receive single oral dose 1 of JNJ-77242113 or matching placebo on Day 1 in Cohort 1 of Part 1.
16244538|NCT05062200|Experimental|Cohort 2: JNJ-77242113 or Placebo (SAD)|Japanese participants will receive single oral dose 2 of JNJ-77242113 or matching placebo on Day 1 in Cohort 2 of Part 1.
16244539|NCT05062200|Experimental|Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])|Chinese participants will receive single oral dose 2 of JNJ-77242113 or matching placebo on Day 1 in Cohort 3 of Part 2.
16244540|NCT05062187||Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
16244541|NCT05062187||Healthy Individual|Proprioception on balance and gait functions in healthy individuals
16244542|NCT05062174||mifepristone + surgery|Mifepristone is taken orally as a one-time only dose between 48 and 56 hours before your planned prophylactic mastectomy surgery
16244543|NCT05062161|Experimental|Sleep Hygiene/Extension Intervention|Participants with short sleep duration will receive a 60-minute educational session on sleep hygiene/extension. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts and/or complete questionnaires about sleep. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
16244544|NCT05062161|Active Comparator|Control Condition|Participants with short sleep duration will receive a 60-minute educational session on sleep physiology. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
16244545|NCT05062148|No Intervention|Standard of Care|Subjects will follow the standard of care, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
16244546|NCT05062148|Active Comparator|Float-REST|Subjects will do Flotation Restricted Environmental Stimulation Therapy, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
16244547|NCT05062148|Active Comparator|Photobiomodulation|Subjects will do photobiomodulation, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
16244548|NCT05062135|Experimental|Morphological analysis of endometrium|"PCOS: Seventeen PCOS subjects underwent two endometrial biopsies after the first P4-treated cycle, the first between days 5-9 of the cycle and the other between days 20-22 (i.e., under P4 treatment) of the cycle.
~Controls: Thirteen ovulatory control women under two endometrial biopsies, performed after the first month of luteal P4 treatment, the first between days 5-9 and the second between days 20-22 of the cycle To quantify the parameters of interest, images were captured using a high-resolution camera (AxioCam-MCR, Carl Zeiss) adapted to a light microscope (Axiolab, Carl Zeiss) and adjusted with 40× objective lenses. The images were transmitted to a computer with AxioVision Rel 4.2 software (Carl Zeiss). For assessment of glandular and surface epithelial thickness, cell count, and counting newly formed blood vessels, ten images of each endometrial sample were made for each patient. For VEGF-C determination, the numerical density of blood vessels per mm2 was established"
16244549|NCT05062122||vibration group|Hand skills will be evaluated before and after the 10-minute vibration application.
16244550|NCT05062122||kinesiology tape group|Manual dexterity will be evaluated before and after kinesiology tape application.
16244551|NCT05062122||control group|Manual dexterity will be evaluated before and after conventional physiotherapy.
16244552|NCT05062109|Experimental|Multimodal geriatric prehabilitation|
16244553|NCT05062096|Other|Group 1: BRAF-mutated metastatic patients treated with 1st line targeted therapy|BRAF-mutated metastatic patients treated with 1st line targeted therapy
16244554|NCT05062096|Other|Group 2: Metastatic patients treated with 1st line immunotherapy|Metastatic patients treated with 1st line immunotherapy
16244555|NCT05062096|Other|Group 3: BRAF-mutated patients treated with adjuvant targeted therapy|BRAF-mutated patients treated with adjuvant targeted therapy
16244556|NCT05062096|Other|Group 4: Patients treated with adjuvant immunotherapy|Patients treated with adjuvant immunotherapy
16244558|NCT05062070|Active Comparator|5 Percent TolaSure Topical Gel|5% (w/w) TolaSure Gel
16244559|NCT05062070|Placebo Comparator|Topical Vehicle Gel|TolaSure Vehicle Gel
16244567|NCT05062005|Other|Induction Chemotherapy+Chemoradiotherapy|
16244568|NCT05062005|Other|Chemoradiotherapy|
16244574|NCT05061966|Active Comparator|Online Resource website|The comparator is a website that includes a list of freely available web-based resources for sexual and gender minority youth.
16245244|NCT05057312|Experimental|Experimental arm 3|Enhanced Access to HPV vaccines
16244575|NCT05061966|Experimental|immi|The intervention is a novel and scalable web application designed to provide sexual and gender minority youth with tools for affirming their identity and coping with minority stress.
16244576|NCT05061953||EDSS 0-2.0|Diagnosis of Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS) or Primary Progressive MS (PPMS). An EDSS score between 0 and 2.0.
16244577|NCT05061953||EDSS 2.5-4.0|Diagnosis of Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS) or Primary Progressive MS (PPMS). An EDSS score between 2.5 and 4.0.
16244578|NCT05061953||EDSS 4.5-6.0|Diagnosis of Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS) or Primary Progressive MS (PPMS). An EDSS score between 4.5 and 6.0.
16244579|NCT05061953||EDSS 6.5-8.0|Diagnosis of Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS) or Primary Progressive MS (PPMS). An EDSS score between 6.5 and 8.0.
16244580|NCT05061953||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
16244583|NCT05061914|Active Comparator|pericardiocentesis|vitally unstable patients with tamponading pericardial effusion undergone percutaneous gradual drainage by a central venous catheter
16244584|NCT05061914|Active Comparator|subxiphoiodal drainage|drainage of the pericardial effusion through a subxiphoidal midline incision
16244585|NCT05061914|Active Comparator|thoracotomy|encysted and undiagnosed pericardial effusion drainage through anterior thoracotomy performing a pericardiopleural window and take a pericardial biopsy
16244586|NCT05061914|Active Comparator|VATS drainage|encysted and undiagnosed pericardial effusion drainage through VATS that permits performing a pericardiopleural window and take a pericardial biopsy with minimal incisions
16244587|NCT05061901|Other|Sequence TR|19 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16244588|NCT05061901|Other|Sequence RT|19 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16244589|NCT05061888|Active Comparator|Food Waste Intervention Group|This group will receive an intervention on food waste management and fruit and vegetable replacement to increase diet quality while avoiding an increase in calories. Both groups will obtain free fruit and vegetable boxes and will use the FoodImage app to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
16244590|NCT05061888|Placebo Comparator|Stress Management Control Group|This group will receive an intervention on Stress Management and will be intensity matched to the treatment group. Both groups will obtain free fruit and vegetable boxes and will use FoodImage to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
16244591|NCT05061875||Cases|Patients treated with ceftriaxone doses equal to or higher 4 grams / day.
16244592|NCT05061862||CIED Indicated Subjects|Subjects indicated to receive a cardiac implantable electronic devices (CIEDs)
16244593|NCT05061836|Experimental|Dextrose0|Acetate Ringer's solution
16244594|NCT05061836|Experimental|Dextrose1|1.25%dextrose equivalence
16244595|NCT05061836|Experimental|Dextrose2|2.5%dextrose equivalence
16244596|NCT05061836|Active Comparator|Dextrose5|5%dextrose
16244597|NCT05061823|Experimental|Bintrafusp alfa|
16244740|NCT05061017|Experimental|Pixatimod (PG545) + Nivolumab|"Pixatimod : 25 mg IV, weekly
~Nivolumab: 480 mg IV, Q4 weeks"
16244601|NCT05061797|Active Comparator|Active Study Product|An energy beverage formulated to improve the thermogenic (calorie burning) impact in humans via caffeine and ingredients for overall metabolic wellness.
16244602|NCT05061797|Placebo Comparator|Placebo|A carbonated soft-drink with the same appearance, aroma, and flavor as the active study product
16244603|NCT05061784||MEN-1 patients who underwent routine thymectomy during parathyroidecotmy|A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.
16244604|NCT05061771|Active Comparator|nomacopan (rVA576)|"PART A:
~High dose nomacopan (standard complement ablating doses on Day 1 followed by 45 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd
~or
~Low dose nomacopan (standard complement ablating doses on Day 1 followed by 15 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS
~PART B:
~Nomacopan (standard complement ablating doses on Day 1 followed by to be confirmed mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd"
16244605|NCT05061771|Placebo Comparator|Placebo|"PART A:
~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 45mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd
~or
~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 15mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd
~PART B:
~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of active dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd"
16244606|NCT05061758|Experimental|Four injections of 250µg LY3056480|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.
~Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11
~Group 2 - Regimen 2. Weekly
~Group 3 - Regimen 3. Every two weeks"
16244607|NCT05061758|Placebo Comparator|Four injections of placebo|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.
~Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11
~Group 2 - Regimen 2. Weekly
~Group 3 - Regimen 3. Every two weeks"
16244608|NCT05061745|Active Comparator|Guided Meditation VR for Wellness|Selected modules of commercially available meditation VR
16244609|NCT05061745|Active Comparator|Accelerated Transcranial Magnetic Stimulation: Treatment A|Intermittent theta-burst over dlPFC
16244610|NCT05061745|Active Comparator|Accelerated Transcranial Magnetic Stimulation: Treatment B|Intermittent theta-primed 10Hz over mPFC
16244611|NCT05061732|Experimental|RBCL|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levofloxacin 0.5 g qd for 14 days
16244612|NCT05061732|Experimental|RBLM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levofloxacin 0.5 g bid for 14 days
16244613|NCT05061732|Experimental|RBCM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
16244614|NCT05061732|Experimental|RA|Rabeprazole 20 mg bid, and Amoxicillin 1.0 g tid for 14 days
16244615|NCT05061732|Experimental|RAB|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, and Amoxicillin 1.0 g tid for 14 days
16244616|NCT05061732|Experimental|RAM|Rabeprazole 20 mg bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
16244617|NCT05061732|Experimental|RBAM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
16244618|NCT05061732|Experimental|RBAM4|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g tid for 14 days
16244619|NCT05061732|Experimental|RBDM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
16244620|NCT05061732|Active Comparator|RBTM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and tetracycline 0.5 g qid for 14 days
16244621|NCT05061719|Experimental|Lumateperone 42 mg|
16244622|NCT05061706|Experimental|Lumateperone 42 mg|
16244623|NCT05061706|Placebo Comparator|Placebo|
16244631|NCT05061667|Active Comparator|Group I|Group I will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve paravertebral block which is already proven to be effective in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, paravertebral block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the paravertebral space at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
16244664|NCT05061472||LNG-IUD|Pre-menopausal women with overweight or obesity who are newly initiating a levonorgestrel-containing intrauterine device, either Mirena or Lilleta (Levonorgestrel 52mg/device)
16244665|NCT05061459||Group1:|28 control
16244666|NCT05061459||Group 2:|68 T2DM patients
16244667|NCT05061446|Experimental|Etrasimod Dose 1|
16244632|NCT05061667|Experimental|Group II|Group II will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve rhomboid block which is being experimented for its efficacy in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, rhomboid block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the plane between rhomboid muscle and intercostal muscles, medial to scapula at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
16244633|NCT05061654|Experimental|Treatment arm|Eligible patients will be started on empiric ceftolozane-tazobactam in addition to standard care.
16244634|NCT05061641|Active Comparator|progesterone 200mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg
16244635|NCT05061641|Experimental|progesterone 400mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg
16244636|NCT05061641|Experimental|progesterone 600mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg
16244637|NCT05061628|Experimental|JS006 as Monotherapy|"JS006 as Monotherapy dose-escalation：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1800mg).
~JS006 as Monotherapy dose-extension：1 or 2 proposed dose levels, to be determined."
16244638|NCT05061628|Experimental|JS006 in combination with Toripalimab|"JS006 in combination with Toripalimab dose-escalation：2 or 3 proposed dose levels, to be determined.
~JS006 in combination with Toripalimab dose-extension：1 or 2 proposed dose levels, to be determined.
~JS006 in combination with Toripalimab indications expansion: 2 to 4 specific tumor types are selected for indication expansion after the combination dose-expansion is completed."
16244639|NCT05061615||acne vulgaris patients|
16244640|NCT05061602||Diabetic Group|The patients were included if they were of 18 years or older, with a diagnosis of diabetes mellitus for more than three years.
16244641|NCT05061602||NonDiabetic Group|The healthy age-matched control group was included.
16244642|NCT05061576|Active Comparator|Standard of care|Oral advice on exercise from a physician.
16244643|NCT05061576|Experimental|Active intervention|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
16244644|NCT05061563|Experimental|Period 1|A single dose of elinzanetant and an additional IV (microtracer dose) of [13C5]BAY 3427080 will be administered.
16244645|NCT05061563|Experimental|Period 2|Once daily oral dose of esomeprazole and a single oral dose of elinzanetant will be administered.
16244646|NCT05061550|Experimental|Durvalumab and Oleclumab|Participants will receive Durvalumab + Oleclumab + chemotherapy (every 3 weeks [Q3W]) followed by surgery. Post-surgery, participants will receive Durvalumab + Oleclumab (every 4 weeks [Q4W]), unless progression of disease (PD) or any withdrawal criteria are met.
16244647|NCT05061550|Experimental|Durvalumab and Monalizumab|Participants will receive Durvalumab + Monalizumab + chemotherapy (Q3W) followed by surgery. Post-surgery, participants will receive Durvalumab + Monalizumab (Q4W), unless PD or any withdrawal criteria are met.
16244653|NCT05061524|Experimental|YH35324|"Part A: A single dose of the YH35324 will be administered subcutaneously in 5 dose groups (0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses
~Part B: A single dose of the YH35324 will be administered subcutaneously. The dose of YH35324 will be determined after the safety, tolerability, PK, and PD data in Part A are reviewed"
16244654|NCT05061524|Placebo Comparator|Placebo|"Part A: A single dose of the Placebo will be administered subcutaneously in 5 Cohorts(Dose groups=0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses
~Part B: Placebo is not administered in Part B"
16244655|NCT05061524|Active Comparator|Xolair® for injection (Omalizumab)|"Part A: A single fixed dose of the Omalizumab 300mg will be administered subcutaneously in 4 Cohorts(Dose groups of YH35324=1, 3, 6, and 9 mg/kg)
~Part B: A single dose of the Omalizumab 300mg will be administered subcutaneously."
16244656|NCT05061511||Healthy gingival tissue|healthy patients with absence of gingivitis (full-mouth bleeding score <10%), no history of periodontal disease, having ≥20 teeth, and ≤1 tooth with interdental clinical attachment loss.
16244657|NCT05061511||Periodontitis patients|patients with stage III or IV periodontitis, which means that these patients would have deep periodontal lesions that extend at least to the mid portion of the roots and whose management is complicated by the presence of intrabony defects, furcation involvement, history of periodontal tooth loss and localized ridge defects.
16244658|NCT05061511||Peri-implantitis patients|patients affected by peri-implantitis, defined as radiographic evidence of bone loss ≥3 mm and probing pocket depth ≥6 mm around implants in conjunction with bleeding on probing; or defined as bleeding and/or suppuration on probing, increased probing pocket depth from a previous examination and loss of peri-implant bone.
16244659|NCT05061498|Other|Additional Pacing maneuvers|In all study participants additional pacing maneuvers (cycle lenght and output) are performed
16244660|NCT05061485|Experimental|Sucrose|The participants will be served a test drink with 75g sucrose dissolved in water
16244661|NCT05061485|Experimental|Sucrose + protein|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal protein (whey protein)
16244662|NCT05061485|Experimental|Sucrose + fat|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal fat (cream)
16244663|NCT05061472||COC|Pre-menopausal women with overweight or obesity who are newly initiating the combined oral contraceptive, Sprintec (norgestimate/ethinyl estradiol 0.25mg/35mcg)
16244671|NCT05061433|Experimental|Intervention|"Initial Home Visit: MIH/CP provider team will visit the patient's home at the scheduled time following a specific General Followup Protocol involving 1. Assessment of patient understanding of recent illness and medical therapy including reinforcement of medical adherence, 2. Any other disease-specific concerns, 3. Performance of a home safety evaluation, 4. If patients have concerns relating to their ability to manage their disease process at home, 5. MIH/CP providers and an on-call social worker will provide assistance in the form of on-site, telephone, and electronic referrals or provision of appointments with appropriate services.
~Subsequent visits: The MIH/CP team will decide in conjunction with Medical Control and the PMD if further followup is needed, and the most appropriate followup interval., At 30 days from initial hospital discharge, the patient will be discharged from the MIH/CP program in conjunction with the PMD."
16244676|NCT05061407||Paediatric surgical patients|All patients < 18 years old, admitted to participating hospitals during the study period who undergo elective and non-elective surgery
16244677|NCT05061394||Second division football players|Players competing in the third best league in Denmark
16244678|NCT05061394||"Danmarkserien football players"|Players competing in the fourth best league in Denmark
16244679|NCT05061381|Experimental|A Lust for Life Schools Programme Group|A Lust for Life programme will be delivered to primary school pupils by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
16244680|NCT05061381|No Intervention|Waiting list control group|Participants will be placed on a sixteen-week waiting list for the programme.
16244681|NCT05061368|Experimental|Sildenafil|Participants will be administered a 25 mg oral dose of sildenafil.
16244682|NCT05061368|Placebo Comparator|Placebo|Participants will be administered an oral placebo indistinguishable from the sildenafil pill.
16244683|NCT05061355|Experimental|Surgery plus medical therapy|Heart valve surgery will be performed as soon as possible and preferably within 48 hours of randomization in addition to standard medical care for IE.
16244684|NCT05061355|No Intervention|Medical therapy|Only standard medical care for IE.
16244685|NCT05061342||Cancer Patients|Those with cancer.
16244686|NCT05061342||Normal (non cancer) controls|Those without cancer.
16244687|NCT05061329||Normal individuals|no sino-nasal disease - no upper airway allergies - no intra nasal medication - normal sense of smell
16244688|NCT05061329||COVID-19 positive patient|
16244689|NCT05061329||Post-COVID-19 patients|Previous COVID-19 positive patients with prolonged olfactory dysfunction
16244690|NCT05061329||Patients with chronic rhinosinusitis with and without nasal polyps|
16244691|NCT05061329||Patients with smell loss|
16244692|NCT05061316|Experimental|Nutrition intervention group|Participants will receive Nestlé Impact Advanced Recovery Immunonutrition two times daily for 5 days leading up to the date of surgery. Nestlé Impact Advanced Recovery will be administered either orally or through a feeding tube.
16244693|NCT05061303||Group Omperazole|Patients will receive p.o. the standard, most commonly used triple immunosuppression regimen: tacrolimus, mycophenolate mofetil, prednisone and p.o. omeprazole 20 mg (group Omeprazole).
16244694|NCT05061303||Group Famotidine|Patients will receive p.o. the standard, most commonly used triple immunosuppression regimen: tacrolimus, mycophenolate mofetil, prednisone and p.o. famotidine 20 mg (group Famotidine).
16244695|NCT05061290|Experimental|Control Porridge|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
16244696|NCT05061290|Experimental|Reference Porride A|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Ascorbic acid, Corn starch
16244697|NCT05061290|Experimental|Test Porridge B|Wholegrain maize flour, Moringa leaf powder, Mango powder, Carrot powder, Corn starch
16244698|NCT05061290|Experimental|Test Porridge C|Wholegrain maize flour, Baobab fruit powder, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
16244699|NCT05061290|Experimental|Test Porridge D|Wholegrain maize flour, Baobab fruit powder, Moringa leaf powder, Mango powder, Carrot powder
16244700|NCT05061277|Experimental|Recifercept|A 300 mg single subcutaneous (SC) dose of recifercept for the treatment phase of study
16244701|NCT05061264|Experimental|Active infection group|A cohort of 38 patients carrying an active infection (mesh sinus, exposed mesh or enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with PVDF mesh.
16244702|NCT05061264|Active Comparator|Clean control group|A cohort of 38 patients with ventral hernias, and submitted to clean ventral hernia repair with PVDF mesh.
16244818|NCT05060380|No Intervention|Control|The control group will be asked to maintain their normal lifestyle and will be advised to continue their standard care of treatment.
16244703|NCT05061251|Experimental|BAY 2402234|Patients will receive 1 dose (5mg) orally, per day of BAY 2402234 for the 2 days prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery, for a total of 3 administered doses.
16244704|NCT05061238|Other|Vibrating Device|you will be asked to walk up and down a hallway 5 times with the vibrating device strapped to different parts of your leg.
16244705|NCT05061225|Experimental|Intervention|Participants invited to the private Facebook group
16244706|NCT05061225|No Intervention|Waiting list|Waiting list. Will be invited to Facebook group after finalising the study and will receive same intervention.
16244707|NCT05061199||ECA group|TCC with extracorporeal anastomosis (ECA)
16244708|NCT05061199||ICA group|TCC with intracorporeal anastomosis (ICA).
16244709|NCT05061186|Experimental|Resistive Expiratory muscle Training Group|Mild Resistive Expiratory muscle Training Group
16244710|NCT05061186|Active Comparator|Conventional Breathing Exercise Group|Breathing Ex: Pursed lip Breathing, Diaphragmatic breathing ex, incentive spirometer
16244714|NCT05061160|Experimental|Interval Aerobic Exercise training Group|
16244715|NCT05061160|Active Comparator|Continuous Aerobic Exercise training Group|
16244716|NCT05061147|Experimental|Max-40279-01 in combination with Azacitidine (AZA)|"This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts:
~Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules.
~Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group.
~All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA)."
16244721|NCT05061121|Experimental|sustained natural apophyseal glides|Investigate the short- and mid-term effects of Mulligan's SNAGs on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
16244722|NCT05061121|Experimental|Myofascial release|Investigate the short- and mid-term effects of Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
16244723|NCT05061121|Experimental|sustained natural apophyseal glides in addition to myofascial release|Investigate the short- and mid-term effects of Mulligan's SNAGs combined with Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
16244724|NCT05061108|Experimental|Intervention|Randomized selection of recruited participants that will receive intervention
16244725|NCT05061108|No Intervention|Control|Randomized selection of recruited participants that will not receive intervention
16244731|NCT05061069|Experimental|Infants with permanent hearing loss|Each infant with permanent hearing loss in Flanders will be offered a vestibular screening by means of the cVEMP (cervical vestibular evoked myogenic potentials) test to screen for vestibular deficits.
16244732|NCT05061056|Experimental|Russian current 10%|Subjects will receive a interventions (Russian Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
16244733|NCT05061056|Experimental|Russian current 20%|Subjects will receive a interventions (Russian Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
16244734|NCT05061056|Experimental|Aussie current 10%|Subjects will receive a interventions (Aussie Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
16244735|NCT05061056|Experimental|Aussie current 20%|Subjects will receive a interventions (Aussie Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
16244736|NCT05061043|Active Comparator|Group A|Routine physical therapy treatment
16244737|NCT05061043|Experimental|Group B:|Routine physical therapy along with orofacial therapy
16244738|NCT05061030|Active Comparator|Wharton's jelly derived mesenchymal stromal cells (Protrans)|Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).
16244739|NCT05061030|Placebo Comparator|Placebo|Placebo (saline) is given intravenously over a period of 20-40 min.
16244741|NCT05061017|Experimental|Pixatimod (PG545) + Nivolumab + cyclophosphamide|"Pixatimod : 25 mg IV, weekly
~Nivolumab: 480 mg IV, Q4 weeks
~cyclophosphamide: 50 mg PO twice daily (Day 1-Day 7; Day 15-Day 21) with a 7-day drug free interval (Day 8-Day 14 and Day 22-Day 28)"
16244742|NCT05060991|Experimental|Immunosuppression reduction|Reduction of immunosuppression before and after administration of a third dose of SARS-CoV-2 mRNA vaccine
16244743|NCT05060991|No Intervention|Standard of care|No change to immunosuppression before or after receipt of a third dose of SARS-Co-2 mRNA vaccine
16244744|NCT05060978|Active Comparator|Watch your Weight During the Holidays Program|
16244745|NCT05060978|Active Comparator|Relative 5:2 Fasting|
16244746|NCT05060978|Placebo Comparator|Control Group|
16244747|NCT05060965|Experimental|Cessation intervention|"All participants will receive nicotine replacement therapy and a referral to both Maryland Quitline and Johns Hopkins Tobacco Treatment Clinic for continued cessation care.
~Nicotine replacement therapy: Nicoderm patches, gum, lozenges
~Low nicotine dependence: Lozenge (2 mg) or Gum (2 mg) or Patch (7 mg)
~Moderate nicotine dependence: Patch (14 mg) and Lozenge (2 mg) or Gum (2 mg)
~High nicotine dependence: Patch (21 mg) and Lozenge (4 mg) or Gum (4 mg)
~Regardless of the level of nicotine addiction and subsequent dose of nicotine replacement therapy (NRT), participants of this trials are described as recipients of NRT products."
16244748|NCT05060952||PJI|Patients with septic arthroplasty failure
16244749|NCT05060952||Aseptic|Patients with aseptic causes of arthroplasty failure
16244752|NCT05060900|Experimental|Hand and Wrist Ligament Reconstruction with Allograft Ligament|Participants will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
16244753|NCT05060887|Experimental|OVX836 - 180µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180μg dose on Day 1.
16244754|NCT05060887|Experimental|OVX836 - 300µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 300μg dose on Day 1.
16244755|NCT05060887|Experimental|OVX836 - 480µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 480μg dose on Day 1.
16244756|NCT05060887|Placebo Comparator|Saline solution (B. Braun Ecoflac® Plus)|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day 1.
16244757|NCT05060874||single group|gripwise or jamar will be randomly assessed first
16244758|NCT05060848||ADRD|"Participants in the ADRD group will have a score of greater than or equal to 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory.
~Subgroups based on sex and race categories will also be examined."
16244759|NCT05060848||Control|Participants in the control group will have a score of less than 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory
16244762|NCT05060822|Experimental|HEC585 dose A|Drug: HEC585 dose A once daily, up to 24 weeks
16244763|NCT05060822|Experimental|HEC585 dose B|Drug: HEC585 dose B once daily, up to 24 weeks
16244764|NCT05060822|Experimental|HEC585 dose C|Drug: HEC585 dose C once daily, up to 24 weeks
16244765|NCT05060822|Active Comparator|pirfenidone|Drug: pirfenidone three times a day (target dose), up to 24 weeks
16244766|NCT05060822|Placebo Comparator|placebo|Drug: placebo once daily, up to 24 weeks
16244767|NCT05060809|Experimental|Hemodialysis patient with high level of dp uc-MGP|one hundred and twenty hemodialysis patients with high level of dephosphorylated uc-MGP received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by Kauppila score.In addition, study patients were subjected to an echocardiography at baseline as well as 6 months post vitamin K1 supplementation. Echocardiography was performed by the same operator.
16244768|NCT05060796|Experimental|EGFR CAR-T|Group: 3 dose levels
16244769|NCT05060783||Renal Call Carcinoma|Patrients with renal cancer
16244770|NCT05060783||Oncocytoma|Patients with oncocytoma
16244771|NCT05060783||Healthy persons|Patients with CT scan shows no renal cancer
16244772|NCT05060757|Experimental|colonoscopy|Participants will be patients undergoing colonoscopy
16244773|NCT05060744|Active Comparator|Intervention (Antacid)|"An Antacid, a CE marked medical device under normal conditions of use.
~Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet)
~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
16244774|NCT05060744|Placebo Comparator|Control|"The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers.
~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
16244775|NCT05060731|Active Comparator|Oral iron supplementation|Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.
16244776|NCT05060731|Active Comparator|Intravenous iron supplementation|Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.
16244777|NCT05060705|Experimental|Efesovir|The patients of experimental arm take study drug Efesovir twice a day as an antiviral therapy in dose 0.125 ml / kg. Daily dose of Efesovir: 0.250 ml / kg. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
16244778|NCT05060705|Active Comparator|Remdesivir|"The patients are treated with the antiviral drug Remdesivir in dose 200 mg intravenously on the 1st day, then by 100 mg intravenously daily for 5 - 10 days, depending on the severity of the disease."
16244779|NCT05060692||LONGCOVID|Patient with Long-COVID Syndrom
16244780|NCT05060692||CONTROLS|Healthy individials
16244781|NCT05060679||Systemic inflammatory response syndrome (SIRS)|Patients receive SIRS therapy.
16244782|NCT05060679||Sepsis|Patients receive sepsis therapy.
16244783|NCT05060679||Sepsis-related acute kidney injury|Patients receive sepsis and sepsis-related acute kidney injury therapy.
16244784|NCT05060666|Experimental|Ivermectin|2 doses of ivermectin at day 0 and day 2
16244785|NCT05060666|Placebo Comparator|Placebo|2 doses of placebo at day 0 and day 2
16244786|NCT05060653|Experimental|SBRT followed by surgical stabilization within 48 hours|SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.
16244788|NCT05060601|Experimental|Gracey micro-curettes|Subgingival mechanical debridement will be performed using an ultrasonic scaler with specific thin tips and Gracey micro-curette.
16244789|NCT05060601|Active Comparator|Standard Gracey curettes|Subgingival mechanical debridement will be performed using a conventional ultrasonic scaler and standard Gracey curettes.
16244790|NCT05060588|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
16244791|NCT05060588|Active Comparator|Valsartan|1 tablet of Valsartan every 24 hours for 6 months
16244792|NCT05060575|Experimental|EDUTC|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.
~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
16244793|NCT05060575|Active Comparator|Control Group|Routine hospital care.
16244796|NCT05060549|Experimental|Cariprazine 1.5 mg|Participants will receive 1.5 mg daily of cariprazine (Vraylar) for six weeks
16244797|NCT05060549|Experimental|Cariprazine 3 mg|Participants will receive 3 mg daily of cariprazine (Vraylar) for six weeks
16244798|NCT05060536|Active Comparator|Removal of infrapatellar fat pad|When patients will have their fat pad removed.
16244799|NCT05060536|Placebo Comparator|No removal of infrapatellar fat pad|When patients will not have their fat pad removed.
16244800|NCT05060523|Experimental|Tolvaptan with Midodrine|
16244801|NCT05060523|Active Comparator|Tolvaptan with Placebo|
16244802|NCT05060510|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
16244803|NCT05060510|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
16244804|NCT05060497||Covid patients|Participants who were treated in hospital with laboratory diagnosed Covid-19 requiring high flow oxygen, non invasive ventilation or intubation and have now recovered. They will be recruited 5-7 months post discharge from their local hospital Trust
16244805|NCT05060497||Healthy control volunteers|Participants who are otherwise healthy, who have not had Covid-19 infection and are age, gender, BMI and ethnicity matched to patients
16244808|NCT05060471|Experimental|Intervetional group|Neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and concurrent toripalimab
16244809|NCT05060432|Experimental|Part 1A - EOS-448 + anti-PD1|Participants will receive EOS-448 and anti-PD1 at every cycle
16244810|NCT05060432|Experimental|Part 1B - EOS-448 + inupadenant|Participants will receive EOS-448 at every cycle and inupadenant on a ongoing basis
16244811|NCT05060419|Experimental|Meropenem-FL058 (180min infusion)|
16244812|NCT05060419|Active Comparator|Piperacillin-Tazobactan (30min infusion)|
16244813|NCT05060406|Experimental|LY06006 60mg|"injection
~Interventions:
~Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
16244814|NCT05060406|Placebo Comparator|Placebo|"injection
~Interventions:
~Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
16244815|NCT05060393|Experimental|Intervention group|Daily use of mindfulness-based mobile application for 30 days.
16244816|NCT05060393|No Intervention|Control group|Treatment as usual
16244817|NCT05060380|Experimental|Exercise training|The exercise training group will receive progressive muscle resistive exercise, 10 sets of exercises for 2 times per week for a total of 6 months.
16244819|NCT05060367|Experimental|Liposomal multivitamin/mineral condition|Ingestion of novel, liposomal multivitamin/mineral.
16244820|NCT05060367|Active Comparator|Standard multivitamin/mineral condition|Ingestion of standard multivitamin/mineral.
16244821|NCT05060354||MS Kesimpta (ofatumumab)|MS patients treated with Kesimpta (ofatumumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
16244822|NCT05060354||MS Ocrevus (ocrelizumab)|MS patients treated with Ocrevus (ocrelizumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
16244823|NCT05060354||MS Gilenya (fingolimod) and Mayzent (siponimod)|MS patients treated with Gilenya (fingolimod) or Mayzent (siponimod) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
16244824|NCT05060354||Healthy Control|Individuals with major autoimmune disorders or current treatment with immunosuppressive or immunomodulatory drugs Received SARS-CoV2 vaccination (completed regimen) within 2-6 months of enrollment Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
16244825|NCT05060328||Health services research (Google Translate Conversation Mode)|"Patients use Google Translate Conversation Mode translation application before and after surgery. Patients also complete survey over 10 minutes."
16244826|NCT05060315||De Novo Cohort|Patients new to parenteral prostacyclin-class therapy.
16244827|NCT05060315||Transition Cohort|Patients who are currently receiving SC Remodulin therapy via a previous generation infusion pump.
16244828|NCT05060289||Modeling group|The data of modeling group is used to construct a predictive model of DILI endpoint events.
16244829|NCT05060289||Validation group|Validation group is used to validate the predictive model externally.
16244830|NCT05060276|Experimental|STI-3258|Intravenous infusion to be given with prophylaxis for infusion reactions, evaluating up to five dose cohorts including: 8 mg/kg, 12 mg/kg, 16 mg/kg, 20 mg/kg, and 24 mg/kg.
16244831|NCT05060263|Experimental|Cohort 1|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244832|NCT05060263|Experimental|Cohort 2|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244833|NCT05060263|Experimental|Cohort 3|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244834|NCT05060263|Experimental|Cohort 4|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244835|NCT05060263|Experimental|Cohort 5|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244836|NCT05060263|Experimental|Cohort 6|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244837|NCT05060263|Experimental|Cohort 7|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
16244838|NCT05060237|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).
~One single photodynamic therapy (PDT)."
16244839|NCT05060224|Experimental|Low Level Laser|EasyLaser: Low Level Laser 808 nm and 500 mW. The first four treatments where planned as two treatments per week. The remaining six treatments where planned as once a week.
16244840|NCT05060198|Active Comparator|Artemether-lumefantrine (AL)|Participants will be randomized to receive a standard weight-based regimen of artemether-lumefantrine (Coartem®, Novartis Pharmaceuticals Corporation, Missouri, USA). Children in the AL arm received two daily doses (morning and evening) orally, over 3 days (6 doses total at 0, 8, 24, 36, 48, and 60 hours post initial dose, administered with food or milk at the clinic and at home). To promote and evaluate adherence, study staff called parents in the evening to remind them to give the AL dose to the child and to bring the blister pack to the clinic the next day for confirmation.
16244841|NCT05060198|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Participants will be randomized to receive a standard weight-based regimen of dihydroartemisinin-piperaquine (DuoCotexin®; Holley-Cotec Pharmaceuticals, Beijing, China). DP was administered once a day for three days (at 0, 24, and 48 hours, orally).
16244842|NCT05060185|Other|single arm|the patients will be treated by the trial device
16244843|NCT05060172|Experimental|Bloomlife NST|
16244844|NCT05060159|No Intervention|Hemodialysis|Conventional hemodialysis
16244845|NCT05060159|Experimental|Hemofiltration|Postdilutional hemofiltration
16244846|NCT05060146|No Intervention|Standard care|
16244847|NCT05060146|Experimental|Structured medico-pharmaceutical collaboration|
16244848|NCT05060120||confirmed ovarian torsion|immediately before laparoscopy and 1 day post- operation and four weeks after laparoscopy a panel of serum biomarkers will be tested
16244849|NCT05060120||confirmed non ovarian torsion|immediately before laparoscopy
16244850|NCT05060120||control group|match control Compare healthy controls with patients with or without ovarian torsion as confirmed by laparoscopy
16244851|NCT05060107|Experimental|Experimental group - sEVs|Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
16244852|NCT05060081|Experimental|Pilates exercise program group|Pilates exercise program group will perform five exercises.
16244853|NCT05060081|Active Comparator|Traditional plank exercise program group|Traditional plank exercise program group will perform five exercises.
16244854|NCT05060068|Placebo Comparator|Placebo group|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
16244855|NCT05060068|Experimental|Low-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
16244856|NCT05060068|Experimental|High-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
16244857|NCT05060055|Experimental|Test Group|Customized healing abutment inserted in immediate implant placement in association with the use of a connective tissue graft.
16244858|NCT05060055|Active Comparator|Control Group|Customized healing abutment inserted in immediate implant placement.
16244863|NCT05060016|Experimental|Part 1: AMG 757 Low Dose|Participants will receive the low dose of AMG 757.
16244864|NCT05060016|Experimental|Part 1: AMG 757 High Dose|Participants will receive the high dose of AMG 757.
16244865|NCT05060016|Experimental|Part 2: Dose Expansion|Participants will receive the selected target dose of AMG 757 based on findings in Part 1.
16244866|NCT05060003|Experimental|Arm 1: Atezolizumab + Tiragolumab|"Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).
~Tiragolumab is given as an IV infusion every 4 weeks at a dose of 840 mg over 60 minutes (+/- 15 minutes).
~Treatment can continue for up to 13 cycles."
16244867|NCT05060003|Active Comparator|Arm 2: Atezolizumab|"Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).
~Treatment can continue for up to 13 cycles."
16244868|NCT05059990|Experimental|Low Intensity Aerobic Exercises Group|stationary cycle for aerobic exercise
16244869|NCT05059990|Active Comparator|Active Exercises Group|Upper and lower limb range of Motion (ROM) & stretching exercises uses in active exercise group
16244870|NCT05059977|Experimental|TAK-881 0.4 g/kg (in-line warmed)|Participants will receive a single dose of TAK-881 comprising of 0.4 gram per kilogram (g/kg) (in-line warmed) Immune Globulin Subcutaneous (IGSC), 20 percent (%) at progressively increased infusion rates and Recombinant Human Hyaluronidase (rHuPH20) dose of 80 unit per gram (U/g) immunoglobulin G (IgG) on Day 1 of the study treatment period.
16244871|NCT05059977|Experimental|TAK-881 1.0 g/kg (in-line warmed)|Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
16244872|NCT05059977|Experimental|TAK-881 1.0 g/kg (un-warmed)|Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (un-warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
16244873|NCT05059964|Experimental|Circuit Training program|
16244874|NCT05059964|Active Comparator|Continuous aerobic exercise Group|
16244875|NCT05059938|Experimental|MyFitnessPal user|Patients will be shown how to download and use MyFitnessPal onto the patient's smartphone. The patient will be asked to use the application to aid in the patient's weight loss plan over up to six months.
16244876|NCT05059938|No Intervention|Traditional Weight Loss Counseling|Patients will be given traditional weight loss counseling from the physician and monitored over up to six months.
16244877|NCT05059925|Experimental|Structured gym activities|
16244878|NCT05059925|Active Comparator|Traditional aerobic activities|
16244879|NCT05059912|Experimental|CD7 positive relapsed or refractory T cell lymphoma|Humanized CD7 CAR-T cells intravenously infused to patient with R/R T-NHL[ at a dose of (0.5- 5)x10^6 CD7 CAR-T cells/kg
16244882|NCT05059886||lower limb amputee|No intervention, pure observational study
16244885|NCT05059847|No Intervention|Standard Care Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus the World Health Organization recommendation that indicates at least 150 min a week of moderate physical activity, equivalent to walking 30 minutes a day for 5 days at an intensity between 60 and 70% of your maximum heart rate.
16244886|NCT05059847|Active Comparator|Resistance Training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a resistance exercise routine using weights. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
16244887|NCT05059847|Experimental|Cross-training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a cross-training routine using implements without any extra weight to improve stability, joint mobility and general strength of the body. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
16244890|NCT05059821|Experimental|Experimental Personalized Cancer Vaccine|Patients with recurrent HCC after surgical resection and refractory to available line of treatment will receive Personalized peptide based vaccine with autologous heat shock protein 70 and autologous activated monocytes
16244891|NCT05059782|Active Comparator|Group A (drug treatment group)|Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
16244892|NCT05059782|Experimental|Group B (radiotherapy group)|IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.
16244893|NCT05059782|Experimental|Group C (radiotherapy + drug group)|Drug therapy is the same as group A; IFRT is the same as group B.
16244894|NCT05059756|Experimental|Treatment group|PTNS and PFR (twice daily)
16244895|NCT05059756|Experimental|Control group|Sham PTNS and PFR (twice daily)
16244896|NCT05059743|Experimental|[14C]-Larotinib|Patients will receive single dose of [14C]-Larotinib (Suspension, 350mg/100μCi).
16244897|NCT05059730|Active Comparator|Men|Men will belong to one arm
16244898|NCT05059730|Active Comparator|Women (follicular phase)|Women will be allocated in this group during the follicular phase of their menstrual cycle.
16244899|NCT05059730|Active Comparator|women (luteal phase)|Women will be allocated in this group during the luteal phase of their menstrual cycle.
16244900|NCT05059717|Experimental|Diagnostic (standard of care MRI, MR DENSE MRI)|Patients undergo standard of care MRI and then undergo an MRI of the liver using MR DENSE imaging sequences over 60-90 minutes. Healthy volunteers undergo MRI of the liver using DENSE imaging sequences.
16244901|NCT05059704|Experimental|Circuit Class Training|Patients will participate in a total of 1.5hour/day for 8 weeks with a 1:3 (therapist to patient). The circuit will be divided into 5 specific stations, 5 to 10 minutes for warm-up tasks and 15 to 20 minutes on each station as tailored to the patient's activity level
16244902|NCT05059704|Active Comparator|Individual Task specific training|Patients will participate in a total of 1.5hour/day for 8 weeks with 1:1 (therapist to patient) ratio. During each session, all patients will perform 5 to 10 minutes warm-up tasks, then practiced the selected tasks for the rest of the time.
16244903|NCT05059691||Observational (transbronchial cryobiopsy)|Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.
16244904|NCT05059678|Experimental|Group I (education material, videoconference session)|Participants receive education materials (brochure and a video) and attend 2 weekly videoconference intervention sessions over 45 minutes each. Caregivers attend 2 additional weekly intervention sessions over 45 minutes each.
16244905|NCT05059678|Active Comparator|Group II (waitlist control)|Participants receive standard of care.
16244908|NCT05059652|Experimental|Ischemic Preconditioning (n= 22)|"The IPC protocol will be applied in the proximal region of the thigh of the limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain.
~Participants will be relaxed and comfortably seated. The same cuff used to determine the total occlusion pressure (TOP) will be used and the protocol will consist of four cycles of total ischemia (according to the TOP value determined individually) of five minutes, followed immediately by four cycles of five minutes of vascular reperfusion (0 mmHg ), totaling 40 minutes."
16244909|NCT05059652|Placebo Comparator|Placebo (n= 22)|The placebo protocol will be performed on the lower limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain. Participants will perform a protocol similar to the IPC, but during the four cycles of five minutes of occlusion, the cuffs will only be inflated with 10mmHg so as not to cause arterial or venous occlusion, alternating with four cycles of five minutes of reperfusion (0 mmHg).
16244910|NCT05059639|Experimental|Almond (2 ounces)|Consume 2 ounces almond daily for 8 weeks
16244911|NCT05059639|Active Comparator|Pretzel|Consume comparative amount of pretzel for 8 weeks
16244912|NCT05059626|Experimental|Simvastatin|30 days of Simvastatin (10mg/day)
16244913|NCT05059626|Experimental|bazedoxifene + conjugated estrogen|30 days of bazedoxifene + conjugated estrogen (0.45mg/20mg/day)
16244914|NCT05059626|Placebo Comparator|Placebo|30 days of placebo (microcrystalline cellulose filler capsule; 1 pill/day)
16244915|NCT05059613|Experimental|probiotics group|Use thalidomide in combination with probiotics during radiotherapy and chemotherapy
16244916|NCT05059613|No Intervention|thalidomide group|Thalidomide is used only during radiotherapy and chemotherapy
16244917|NCT05059613|No Intervention|healthy control group|healthy control group
16244918|NCT05059600|Experimental|ZULRESSO®|Participants will administer ZULRESSO® in a home setting as a single, continuous, intravenous (IV) infusion for 60-hours (hrs) starting on Day 1.
16244919|NCT05059587|Experimental|MBA-P01|MBA-P01 will be injected into the GL: initial double-blind treatment on Day 1.
16244920|NCT05059587|Active Comparator|BOTOX®|BOTOX® will be injected into the GL: initial double-blind treatment on Day 1.
16244921|NCT05059574|Experimental|Experimental group|Mothers in this group will begin their baby's first breastfeeding by crawling to the breast.
16244922|NCT05059574|No Intervention|Control group|Mothers in this group will begin their baby's first breastfeeding with biological breastfeeding.
16244987|NCT05059197|Experimental|AP collagen peptide|Each subject takes one active bottle per day for 12 weeks. Each bottle contains AP collagen 1000 mg
16244988|NCT05059197|Placebo Comparator|Placebo|Each subject takes one active bottle per day for 12 weeks.
16255900|NCT04984577|Active Comparator|Edaravone Injection|
16244923|NCT05059561||Patients group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. According to the Cobb method, individuals with a Cobb angle greater than 10° were diagnosed with Idiopathic Scoliosis. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the study and control groups completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
16244924|NCT05059561||Control group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. Healthy individuals who applied for the same examination and met the inclusion criteria were determined as the control group by random sampling method. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the control group completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
16244925|NCT05059548||Male Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
16244926|NCT05059548||Female Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
16244927|NCT05059535|Experimental|cryoneurolysis of the saphenous nerve|A cryoneurolysis of the saphenous nerve will be performed between 7 days and 5 days before the knee arthroplasty
16244928|NCT05059535|Experimental|cryoneurolysis of geniculate nerves|A cryoneurolysis of geniculate nerves will be performed between 7 days and 5 days before the knee arthroplasty
16244929|NCT05059535|Placebo Comparator|control|No cryoneurolysis will be performed before the knee arthroplasty
16244930|NCT05059522|Experimental|Arm 1|Avelumab monotherapy as specified by sub-study protocol B9991001C
16244931|NCT05059522|Experimental|Arm 2|Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
16244932|NCT05059522|Experimental|Arm 3|Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
16244933|NCT05059522|Experimental|Arm 4|Avelumab monotherapy as specified by sub-study protocol B9991009C
16244934|NCT05059522|Experimental|Arm 5|Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
16244935|NCT05059522|Experimental|Arm 6|Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
16244936|NCT05059522|Experimental|Arm 7|Avelumab in combination with Axitinib as specified by sub-study B9991027C.
16244937|NCT05059522|Experimental|Arm 8|Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
16244938|NCT05059509|Experimental|FB825|One dose FB825, 5mg/kg, by 1 hour IV infusion on Day 1
16244939|NCT05059496|Experimental|Hamstring stretching with Pressure Biofeedback Unit|Hot pack, Hamstring stretching with Biofeedback unit, TENS
16244940|NCT05059496|Active Comparator|Hamstring stretching with out Pressure Biofeedback Unit|Hot pack, Hamstring stretching without Biofeedback unit, TENS
16244941|NCT05059470|Experimental|Pembrolizumab|The infusions are given every 6 weeks
16244942|NCT05059457||Controlled setting: single capillary and pooled capillary and venous blood|Single drop capillary blood, pooled capillary blood, and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a controlled setting.
16244943|NCT05059457||Field setting: single capillary and venous blood|Single drop capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
16244944|NCT05059457||Field setting: pooled capillary and venous blood|Pooled capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
16244945|NCT05059444||Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III)|
16244946|NCT05059444||Cohort 2: Non-small cell lung cancer (stage II-III)|
16244947|NCT05059444||Cohort 3: Invasive breast carcinoma with all of the following:|"Clinical stage T1-4/N0-3/M0 at presentation AND
~Completed preoperative systemic chemotherapy-containing regimen AND
~Underwent definitive surgical resection of the primary tumor AND
~Has pathological evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes AND
~Hormone receptor and HER2 status are known"
16244948|NCT05059444||Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma|
16244949|NCT05059444||Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III)|
16244950|NCT05059444||Cohort 6: Gastric adenocarcinoma (stage II-III)|
16244951|NCT05059444||Cohort 7: Surgically resected pancreatic adenocarcinoma|
16244952|NCT05059444||Cohort 8: Invasive squamous cell carcinoma of the head and neck|Includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers.
16244953|NCT05059444||Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma|Defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology).
16244954|NCT05059444||Cohort 10: High-risk endometrial carcinoma|Defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology).
16244955|NCT05059444||Cohort 11: High-risk renal cell carcinoma|Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent.
16244956|NCT05059418|Active Comparator|Clonazepam|Topical treatment of oral mucosa with a 3-min lozenge tablet with clonazepam (0.5 mg), three times a day.
16244957|NCT05059418|Active Comparator|Capsaicin|Topical treatment of oral mucosa with capsaicin rinsing solution (XXXX IE) for three min three times a day.
16244958|NCT05059418|Placebo Comparator|Placebo|Topical treatment of oral mucosa with rinsing solution without capsaicin for three min three times a day.
16245026|NCT05058924|Experimental|Prophylactic Low Molecular Weight Heparin (LMWH) + Low Dose Aspirin|Prophylactic LMWH for 3 weeks followed by low dose Aspirin for 3 weeks.
16244959|NCT05059392|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly sessions, each 90 minutes, up to 14 participants/group. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
16244962|NCT05059366|Experimental|Expert participants randomized to MVG followed by 2VE|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the Manual ventilation grip device (MVG) first followed by the standard 2VE technique alone.
16244963|NCT05059366|Experimental|Expert participants randomized to 2VE followed by MVG|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG).
16244964|NCT05059366|Experimental|Novice participants randomized to MVG followed by 2VE|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) first followed by the standard technique (2VE) alone
16244965|NCT05059366|Experimental|Novice participants randomized to 2VE followed by MVG|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG)
16244966|NCT05059353|Experimental|Patients with MCI|Subjects will be provided with a digital tablet and a wearable device. The digital tablet will be pre-loaded with 10 modules, 1 module per week (1 hour) for 10 weeks to be completed at home. The modules comprises of Education, Physical Activity, Reminiscence Therapy and Cognitive Games. The wearable device will be use to track and collect physiological data. Subjects will be instructed to wear the wearable device during the therapy session and during sleep, and as much as possible for the duration of the study. Exceptions for wearing the wearable device include water-related activities such as swimming or bathing.
16244967|NCT05059353|Experimental|Cognitively Normal Subjects|Subjects will be provided with a digital tablet and a wearable device. The digital tablet will be pre-loaded with 10 modules, 1 module per week (1 hour) for 10 weeks to be completed at home. The modules comprises of Education, Physical Activity, Reminiscence Therapy and Cognitive Games. The wearable device will be use to track and collect physiological data. Subjects will be instructed to wear the wearable device during the therapy session and during sleep, and as much as possible for the duration of the study. Exceptions for wearing the wearable device include water-related activities such as swimming or bathing.
16244968|NCT05059353|No Intervention|Caregivers of Patients with MCI|Subjects will be asked to complete a questionnaire during screening visit and follow-up visit. This is an exploratory cohort with the objective to explore whether the improvement (if any) in patients with MCI after using the study intervention could ease caregiver burden.
16244969|NCT05059327|Experimental|Arm A (Basimglurant to Placebo)|Basimglurant to Placebo
16244970|NCT05059327|Placebo Comparator|Arm B (Placebo to Basimglurant)|Placebo to Basimglurant
16244971|NCT05059314|Experimental|Interventional group|"Warm up and cool down
~Brisk walk (30 mintues each session per week 5 days)
~Week 1 to 6"
16244972|NCT05059314|No Intervention|Control group|Routine activity
16244976|NCT05059288|Experimental|Investigation Mask|Non invasive ventilation mask
16244977|NCT05059275|Experimental|Modified operation group|Undergo the modified ostium obstruction surgery due to symptomatic TCs.
16244978|NCT05059262|Experimental|Part 1/Part 2 - vimseltinib/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) vimseltinib for 24 weeks in Part 1 and continue on 30 mg biw vimseltinib in Part 2
16244979|NCT05059262|Placebo Comparator|Part 1/Part 2 - placebo/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) matching placebo for 24 weeks in Part 1 and have option to receive 30 mg biw vimseltinib in Part 2
16244980|NCT05059249|Experimental|Manual Traction|Moist heat packs & TENS for ten minutes followed by Manual Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient.
16244981|NCT05059249|Experimental|Mechanical traction|Moist heat packs & TENS for ten minutes followed by Mechanical Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient
16244989|NCT05059171|Active Comparator|Rotary motion using OneShape single file|File size 25 with a taper of 0.06 was mounted to a 6:1 speed-reduction headpiece powered by X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). The speed and torque were set to 400 rpm and 1 N.cm torque, respectively. In a picking motion without pressure, mechanical preparation began with the first RC two-thirds followed by the next 3 mm followed by the full WL.
16244990|NCT05059171|Active Comparator|Reciprocating motion using WaveOne Gold single file|A Primary file size 25 a taper of 0.07 was installed to pre-programmed reciprocation angles and speed for the WaveOne system handpiece of an endomotor (X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). After ensuring a passive fit of the hand file along the predetermined WL, the RC coronal two-thirds was initially instrumented then followed by the full WL.
16244991|NCT05059158||Alzheimer's Disease|Patients with a Alzheimer's Disease diagnosis
16244992|NCT05059158||Mild Cognitive Impairment|Patients with a mild cognitive impairment diagnosis
16244993|NCT05059158||Subjective Cognitive Decline|Patients with a subjective cognitive decline diagnosis
16244994|NCT05059145|Experimental|Chlorhexidine gluconate, 1% vaginal cream|8 ml vaginal cream every night for a week and then prophylactic treatment with 8 ml/week for another 11 weeks
16244995|NCT05059145|Active Comparator|Fluconazole, 150 mg oral capsule|Fluconazole150 mg (oral capsule) every 3 days for the first 3 doses, then prophylactic treatment with 150 mg/week for another 11 weeks
16244996|NCT05059132|Experimental|Tele-rehabilitation|Participants in the tele-rehabilitation arm will receive a home-based, remotely delivered rehabilitation program.
16244997|NCT05059132|Active Comparator|Education only|Participants in the education arm will receive educational materials only, delivered through telecommunication messages.
16244998|NCT05059106|Experimental|Group 1|Half dose of ChAdOx1 nCoV-19 (AZD1222) ) in a 2-dose schedule with an interval of 8 weeks.
16244999|NCT05059106|Active Comparator|Group 2|Standad dose of ChAdOx1 nCoV-19 (AZD1222) in a 2-dose schedule with an interval of 8 weeks.
16245000|NCT05059080||Participants Diagnosed with COVID-19|Participants were previously enrolled in a RO7496998 (AT-527) study
16245001|NCT05059067||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
16245002|NCT05059067||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
16245003|NCT05059054|Experimental|Strengthening group|Strengthening exercise
16245004|NCT05059054|Active Comparator|Insole group|Insole application
16245005|NCT05059041|Experimental|Dilated first, non-dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained after dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained before dilation.
16245006|NCT05059041|Experimental|Non-dilated first, dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained before dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained after dilation.
16245007|NCT05059028|Active Comparator|Oxytocin massage|
16245008|NCT05059028|Active Comparator|music therapy|
16245009|NCT05059028|No Intervention|control group|
16245010|NCT05059015|Active Comparator|CERVICAL HPV|Routine screening procedure based on HPV tests with cervical sampling by a health personnel
16245011|NCT05059015|Experimental|SELF SAMPLING HPV ARM 2|Screening based on HPV self-testing and colposcopic evaluation
16245012|NCT05059015|Experimental|SELF SAMPLING HPV ARM 3|Arm 3: screening based only on HPV self-testing
16245013|NCT05058989||Pregnant women who are aged between 18 to 47 years old (childbearing age).|These patients must be willing to be followed up for 1 year and agreeing to give the informed consent. Recruitment period will take up to three months. Follow up period will be conducted at the end of first, second and third trimester and three months after giving birth.
16245014|NCT05058976|Experimental|Romosozumab, then Zoledronic Acid|Monthly dose: 210 mg Romosozumab subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
16245015|NCT05058976|Placebo Comparator|Placebo, then Zoledronic Acid|Monthly dose: placebo saline subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
16245016|NCT05058963|Experimental|Mantram repetition program|Weekly 90 minute virtual group therapy sessions for 8 weeks run by two faciliators and will consist of 5-8 participants.
16245017|NCT05058950||Aging Across Adulthood: Cognitively Normal|Participants with age 21 to 59 years will be enrolled virtually from the community.
16245018|NCT05058950||Aging Across Adulthood: Aging Cohort With Low Risk for Decline|Participants with age ≥60 years having missing descriptor of minimal risk factors for cognitive decline will be enrolled virtually from the community.
16245019|NCT05058950||Aging Across Adulthood: Aging Cohort With High Risk for Decline|Participants with age ≥60 years and self-reported history of a minimum of 2-4 risk factors for cognitive decline will be enrolled virtually from the community.
16245020|NCT05058950||Aging Across Adulthood Arm: Subjective Cognitive Complaint|Participants with age ≥50 years and positive screen result from Cognitive Function Instrument (CFI) will be enrolled virtually from the community.
16245021|NCT05058950||Aging Across Adulthood: MCI|Participants with a diagnosis of MCI, mild neurocognitive disorder (MND), or cognitively impaired, not demented (CIND) will be enrolled virtually from the community.
16245022|NCT05058950||Phenotyped in Research Objectively: Cognitively Normal|"Participants with age ≥50 years and with a label of cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
16245023|NCT05058950||Phenotyped in Research Objectively: Exploratory Biomarker|"Participants with age >=50 years, with documented positive result for an Alzheimer's disease biomarker, and with a label of subjective cognitive complaints or cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
16245024|NCT05058950||Phenotyped in Research Objectively: MCI|"Participants with a label of MCI or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
16245025|NCT05058924|Active Comparator|Prophylactic Low Molecular Weight Heparin (LMWH)|Prophylactic LMWH for 6 weeks postpartum
16245029|NCT05058898||Risk factors transmission cases|Human cases of monkeypox confirmed by PCR
16245030|NCT05058898||Risk factors transmission contacts and co-exposures|Human contact of confirmed monkeypox cases
16245031|NCT05058898||Serological follow up cases|Human cases of monkeypox confirmed by PCR from Lobaye region
16245032|NCT05058898||Serological follow up contacts and co-exposures|Human contact of confirmed monkeypox cases from Lobaye region adjusted for age, month of the year and village of origin
16245035|NCT05058859|Experimental|Study Drug|The study drug is Dapagliflozin
16245038|NCT05058833||Patients with cardiac diastolic dysfunction|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
16245039|NCT05058833||Patients with coronary microcirculatory dysfunction|Patients with coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
16245046|NCT05058768||control group|Healthy people served as the control group
16245047|NCT05058768||experimental group|Patients with acute lung injury were treated as the experimental group.
16245048|NCT05058755|Experimental|TALE regimen|tislelizumab plus azacytidine and lenalidomide
16245049|NCT05058755|Experimental|TEPA regimen|tislelizumab plus etoposide and pegaspargase
16245050|NCT05058742|Experimental|Nervus vagus stimulation|Non-invasive Nervus vagus stimulation called AuriStim Intermittent stimluation cycle of three hours of activity and three hours of rest, equating to four cycles of three hours of Stimulation in 24 hours) is performed. The stimulation is performed until the patient's condition is better and he or she isdischarged from OCU or transferred to normal ward or dies.
16245051|NCT05058742|No Intervention|Control|There is no Nervus vagus stimulation.
16245052|NCT05058729||Cohort 1|Participants with multiple sclerosis (MS) or clinically isolated syndrome (CIS) who are enrolled in MS PATHS under Study 888MS001 and have completed at least one COVID-19 questionnaire administered by a participating healthcare institution.
16245053|NCT05058716||COVID-19 positive patients|
16245055|NCT05058690|Experimental|Individuals who had a CCTA as part of their clinical care|Approximately 90 individuals who had a CCTA as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable;
16245056|NCT05058690|Experimental|Individuals who had a chest CT as part of their clinical care|Approximately 90 individuals who had a chest CT as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable.
16245057|NCT05058677|Experimental|aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution|Treatment will be performed before the endotracheal suctioning
16245058|NCT05058677|Experimental|aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
16245059|NCT05058677|Experimental|Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution|Treatment will be performed before the endotracheal suctioning
16245060|NCT05058677|Experimental|Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
16245061|NCT05058677|Experimental|Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
16245062|NCT05058677|Experimental|Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
16245070|NCT05058625|Experimental|Needly Group|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
16245071|NCT05058625|Active Comparator|Control Group|Normal volleyball training
16245072|NCT05058612|Experimental|Midodrine|Midodrine 10 mg PO/NG q8h
16245073|NCT05058612|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
16245074|NCT05058599||facial videos dataset|facial videos collected from Zhongshan Ophthalmic Center of Sun Yat-sen University.
16245075|NCT05058586|Active Comparator|Conventional theraphy group|13 patients received twenty sessions of conventional therapy for four weeks
16245076|NCT05058586|Active Comparator|Anti gravity treadmill training|13 patients received twenty sessions of conventional therapy for four weeks and Alter-G training was performed 3 days/week for 4 weeks, with up to 30 min. of training per session.
16245077|NCT05058586|Active Comparator|Underwater walking therapy group|13 patients received twenty sessions of conventional therapy for four weeks and three sessions of aerobic exercise treatment of 45 minutes per week underwater
16245078|NCT05058573|Experimental|Myofascial relaxation technique + Temporomandibular joint release techniques group (n=22)|medical treatment + temporomandibular joint relaxation (temporalis, masseter, and suboccipital muscles) + myofasial release/trigger points (trapezius, rhomboideus, and levator scapulae, sternocleidomastoideus muscles),
16245079|NCT05058573|Experimental|Temporomandibular joint release techniques group (n=22)|only temporomandibular joint relaxation will be performed in this group (temporalis, masseter, and suboccipital muscles).
16245080|NCT05058573|Experimental|Control group (n=22)|only medication treatment will be applied
16245081|NCT05058560|Experimental|BACE+Tislelizumab|BACE was performed on the first day of the first cycle, and the first 200 mg of tislelizumab was given 3-5 days later.
16245082|NCT05058547|Experimental|SWEPPE|Participants will receive the smartphone application SWEPPE.
16245083|NCT05058547|No Intervention|Control|Participants randomized to the control group will not receive any active intervention for return to work after completing an Interdisciplinary Pain Rehabilitation Program .
16245084|NCT05058534||Very preterm infants born between November 30, 2018 and November 30, 2019|Infants born between November 30, 2018 - November 30, 2019, before implementation of the new multiperfusion neonatal system
16245085|NCT05058534||Very preterm infants born between December 1st, 2019 and December 31st, 2022|Infants born between January 1rst, 2019 - December 31st, 2022, after implementation of the new multiperfusion neonatal system
16245086|NCT05058521||In-hospital VTE group|In-hospital VTE group includes patients who were with a hospital stay over 3 days and new-onset of VTE during their stay. Patients who presented for VTE were excluded.
16245087|NCT05058521||Negative group|Negative group includes patients who were with a hospital stay over 3 days and did not have a VTE during their hospital stay.
16245088|NCT05058508|Experimental|EXER|"Just Move exercises"
16245089|NCT05058508|Experimental|SOC EXER|Standard of Care Exercise
16245090|NCT05058495|Experimental|mobile programme users|Patients will receive and use Mobile Lymphedema Self-Care Support Program application and will receive standart lymphedema education.
16245091|NCT05058495|Active Comparator|control group|Patients who will receive standart lymphedema education
16245092|NCT05058482|Experimental|Non-adhesive Liquid Embolic System(NALES)|
16245093|NCT05058482|Active Comparator|Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter|
16245094|NCT05058469||Tracheotomy without antiplatelet therapy+technique 1|
16245095|NCT05058469||Tracheotomy under antiplatelet therapy+technique 1|
16245096|NCT05058469||Tracheotomy without antiplatelet therapy+technique 2|
16245097|NCT05058469||Tracheotomy under antiplatelet therapy+technique 2|
16245098|NCT05058456|Experimental|Single-arm|
16245099|NCT05058443|Experimental|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
16245100|NCT05058443|Placebo Comparator|placebo control|Placebo subcutaneously /6 months, twice a year
16245101|NCT05058430|Experimental|Human Factors|"The primary objective of this research is to assess the human factors in relabeling the SaliPen from a prescription-based device to an OTC.
~Primary performance endpoints:
~The user can select the device properly.
~The user can use the device as instructed in the IFU."
16245102|NCT05058417|Experimental|Empagliflozin group|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
16245103|NCT05058417|Placebo Comparator|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
16245104|NCT05058404|Experimental|Standard arm (A)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
~Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
~After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
16245105|NCT05058404|Experimental|Experimental arm (B)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
~Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:
~Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;
~In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.
~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
16245106|NCT05058391|Experimental|Elaprase 0.5 mg/kg|Participants will receive a single dose of Elaprase 0.5 milligrams per kilogram (mg/kg) body weight, intravenous infusion on Day 1, Week 1 followed by every week up to end of treatment (EOT) (Day 358, Week 52).
16245107|NCT05058365|Experimental|Intervention group|
16245108|NCT05058365|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
16245109|NCT05058352|Experimental|HS269|Multiple doses of HS269 tablets
16245111|NCT05058326||TEST GROUP|Women with fecal incontinence referred to outpatients clinic.
16245112|NCT05058313|Experimental|Postmenopausal patients|
16245113|NCT05058300||Patients with Chest Pain|An unselected patient-population with chest pain in emergency department
16245114|NCT05058287|Experimental|Group 1: Topical Steroid|
16245115|NCT05058287|Placebo Comparator|Group 2: Topical Normal Saline|
16245116|NCT05058274||Single arm|All participants
16245117|NCT05058248|Active Comparator|Pudendal block|Ultrasound-guided bilateral pudendal block at the start of surgery, in gynecological position: injection of 15 mL of 0.475% Naropein in each ischiorectal fossa.
16245118|NCT05058248|Other|the standard method|Operated and anesthetized patients according to the standard method within the department
16245119|NCT05058235|Experimental|Active Release Technique|Hot pack, TENS, Quadriceps Isometric strengthening, Active Release Technique
16245120|NCT05058235|Active Comparator|Bent leg raise|Hot pack, TENS, Quadriceps Isometric strengthening, Bent leg raise
16245121|NCT05058222|Active Comparator|Deep breathing ex (10 reps) Group|The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
16245122|NCT05058222|Experimental|Deep breathing ex (30 reps) Group|The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
16245123|NCT05058209|Active Comparator|Arm 1|Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous.
16245124|NCT05058209|Active Comparator|Arm 2|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only.
16245128|NCT05058183|Experimental|All participants|All participants
16245129|NCT05058170||Renal transplant patients|
16245134|NCT05058144|Experimental|novel alpha glucan|50g novel alpha glucan dissolved in 300ml water
16245135|NCT05058144|Active Comparator|glucose syrup|50g dissolved in 300ml water
16245136|NCT05058144|Active Comparator|Inulin|15g Inulin dissolved in 300ml water
16245137|NCT05058131|Active Comparator|Dietary fibre|Butyrate-promoting dietary fibre
16245138|NCT05058131|Placebo Comparator|Placebo compound|Placebo compound
16245139|NCT05058118|Experimental|FL058|a single ascending dose (SAD) of intravenous (IV) FL058(50mg~2000mg)
16245140|NCT05058118|Placebo Comparator|Placebo|FL058 Placebo
16245141|NCT05058105|Experimental|FL058 500mg and Meropenem 1000mg|"FL058 500mg and Meropenem 1000mg (8 subjects);
~FL058 Placebo and Meropenem 1000mg(2 subjects)"
16245142|NCT05058105|Experimental|FL058 1000mg and Meropenem 1000mg|"D1
~FL058 1000mg(8 subjects) and FL058 Placebo(2 subjects);
~D4
~Meropenem 1000mg(8 subjects) and Meropenem Placebo(2 subjects);
~D7~ D15
~FL058 1000mg and Meropenem 1000mg (8 subjects);
~FL058 Placebo and Meropenem 1000mg(2 subjects)"
16245143|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 120min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);
~FL058 Placebo and Meropenem 2000mg(2 subjects)"
16245144|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 180min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);
~FL058 Placebo and Meropenem 2000mg(2 subjects)"
16245145|NCT05058105|Experimental|FL058 2000mg and Meropenem 2000mg|"FL058 2000mg and Meropenem 2000mg (8 subjects);
~FL058 Placebo and Meropenem 2000mg(2 subjects)"
16245148|NCT05058079|Active Comparator|Hand-held group|Patients hand will be held by the anesthesia provider during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will have their hand under the folded blanket holding the patient's hand.
16245149|NCT05058079|No Intervention|No hand holding group|No physical contact for comfort or reassurance during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will be next to the patient's hand.
16245150|NCT05058066|Active Comparator|Control implant loaded at 6 weeks post-surgery|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
16245151|NCT05058066|Experimental|Test implant loaded at 6 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
16245152|NCT05058066|Experimental|Test implant loaded at 3 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
16245153|NCT05058053|Experimental|Cold application group|"After starting amiodarone treatment, cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals. At all stages of the study, the researcher closely monitored the patients. During the treatment, the development of phlebitis after cold application during the 24-hour infusion was evaluated every 2 hours by the researcher using the Visual Infusion Phlebitis Scale and recorded. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
16245154|NCT05058053|No Intervention|Control group|"the patients who were started on amiodarone infusion were observed for the development of phlebitis, receiving no intervention. During the treatment, phlebitis development was evaluated and recorded by the researcher using the Visual Infusion Phlebitis Scale every 2 hours during the 24-hour infusion. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
16245155|NCT05058040|Experimental|GV-971|The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening
16245156|NCT05058027|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 6g prefilled syringe after surgery
16245157|NCT05058027|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
16245158|NCT05057988|Experimental|Empowered Relief|
16245159|NCT05057975|Experimental|Sunrise|Home Sleep Test, OSA diagnosis based on mandibular movements recording
16245160|NCT05057975|Active Comparator|PSG|Polysomnography, OSA diagnosis based on local scoring by center
16245163|NCT05057936||Control|Healthy healthcare workers
16245164|NCT05057936||Chronic kidney disease (CKD)|CKD stage 3-5 (eGFR < 60 mL/min/1.73m3)
16245165|NCT05057936||Dialysis patients|CKD stage 5 requiring HD
16245166|NCT05057936||kidney transplant patients|patients receiving kidney transplantation for more than 3 months
16245167|NCT05057936||dialysis patients|CKD patients requring continuos ambulatory peritoneal dialysis
16245168|NCT05057923|Experimental|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
16245169|NCT05057923|Experimental|neutralizing antibody booster for vaccinated participants|participants after 4-month vaccinated with Sinovac received 1 capsule of 1×10^11 CFU of B. subtilis spore
16245170|NCT05057897|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose administered on Day 1 and second dose on Day 29.
16245171|NCT05057884|Experimental|Breathing training|The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogramme (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold.
16245172|NCT05057884|No Intervention|Control|The control group receives standard of care. They perform the study measurements before and after the intervention period of 12 weeks. They are offered to perfom the breathing training after study completion.
16245173|NCT05057871|Experimental|PEMF+exercise|A total of 20 sessions of pulse electromagnetic field therapy using an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, Italia), five times a week and once a day for four weeks, were applied to the patients. The patients were then given a daily exercise program once a day by a physiotherapist.
16245174|NCT05057871|Sham Comparator|Sham PEMF+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
16245175|NCT05057858|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
16245176|NCT05057858|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
16245177|NCT05057858|Experimental|Poor Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
16245178|NCT05057845|Experimental|Cryoablation in combination with Tislelizumab plus lenvatinib|
16245179|NCT05057832||Cases|Patients treated with Ustekinumab.
16245180|NCT05057819|Experimental|Empagliflozin first, Placebo second|Oral empagliflozin 25 mg daily in the morning for 20 days, followed by oral placebo (daily in the morning) for 20 days after a wash-out period of 2-6 weeks
16245181|NCT05057819|Placebo Comparator|Placebo first, Empagliflozin second|Oral placebo (daily in the morning) for 20 days, followed by oral empagliflozin 25 mg daily in the morning for 20 days after a wash-out period of 2-6 weeks
16245182|NCT05057806|Experimental|Empagliflozin Group|Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months
16245183|NCT05057806|Placebo Comparator|Placebo group|Subjects will be randomized to receive the empagliflozin placebo for 3 months
16245184|NCT05057793|No Intervention|Standard of care|Multilayer, multicomponent compression intended for the treatment of VLU
16245185|NCT05057793|Active Comparator|Standard of care + geko 12h|Multilayer multicomponent compression intended for the treatment of VLU in conjuction with geko™ therapy 12 hours daily
16245186|NCT05057780|Experimental|Intervention Curriculum|The intervention course consisted of 3 hour-long sessions on communication delivered over a 4-month period. It differed from the control course in subject matter and pedagogy. Subject matter focused on specific skills used in communication: reflective listening, responding to emotion, and providing information within a broad range of communication scenarios. In terms of pedagogy, the intervention course was interactive with a focus on skills practice, communication drills, and improvisation to engage learners. The sessions consisted of fifteen minutes of lecture and 45 minutes of skills practice.
16245187|NCT05057780|Active Comparator|Control (Standard) Curriculum|The control course consisted of three hour-long didactic lectures on delivering bad news, discussing prognosis, and talking to patients about pain. The majority of time in these lectures was spent on didactic material. Little, if any, time was spent practicing skills or on interactive skill building. The three parts of the course were delivered over a 4-month period.
16245188|NCT05057767|Experimental|Pre-induction Group (I)|will receive intravenous midazolam premedication 2mg in a volume of 3 ml, 15 minutes before induction of anesthesia
16245189|NCT05057767|Experimental|Pre-extubation Group (II)|will receive intravenous midazolam 2mg in a volume of 3 ml 30 minutes before extubation at the end of surgery
16245190|NCT05057767|Placebo Comparator|Control Group (III)|will receive 3 ml normal saline 15 minutes before induction of anesthesia plus 3 ml normal saline 30 minutes before extubation at the end of surgery.
16245191|NCT05057754|Experimental|Experimental Group|A total of 50 participants are estimated to be recruited, each completing six conditions in the following order: 1) wrist cooling, 2) wrist heating, 3) exercising, 4) typing, 5) using a mouse, 6) cooking, with an observation of intraneural blood flow assessed with Doppler sonography before and after each condition.
16245192|NCT05057741|Experimental|B-17E|Multimodal prehabilitation: exercise, nutrition and relaxation
16245193|NCT05057741|No Intervention|B-17C|Usual care group: advice of surgeons about self care
16245194|NCT05057728|Experimental|Intervention group (SEP+)|SEP+ is designed as a multi-focused (child, teacher, parent) school-based intervention, which can be employed as either a universal (i.e. targeting all children) or an indicated prevention program (i.e. targeting specifically children at risk for behavior problems). The SEP+ intervention comprises three types of intervention: 1) the classroom-based intervention in the form of a curriculum of 43 activities (2-3 activities/week) delivered over 4-months aimed at developing social-emotional skills; 2) a 6-sessions (2-2.5h/session) teacher training focused on increasing the use of positive discipline strategies and developing coaching skills for supporting children's social-emotional learning; and 3) a 6 sessions parent training (1.5.-2h/session) aiming to teach ways to manage parenting stress, to increase parent-child quality time, support children's emotion regulation and problem-solving, as well as increase positive discipline strategies.
16245195|NCT05057715|Active Comparator|Cohort 1|Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
16245196|NCT05057715|Active Comparator|Cohort 2|Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
16245197|NCT05057715|Active Comparator|Cohort -1|In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
16245198|NCT05057702|Experimental|Individualized Treatment Recommendation|Participants will receive an individualized treatment recommendation including a combination of up to four FDA-approved drugs within 21 business days of tissue acquisition using the results of real-time high-throughput drug screening, whole exome sequencing (WES), and RNA sequencing.
16245199|NCT05057689|Experimental|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 200 mcg.
16245200|NCT05057689|Experimental|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 100 mcg.
16245201|NCT05057689|Experimental|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart. The maximum dose will be 10 mg
16245202|NCT05057676|Experimental|Intervention Autoimmune Intervention Mastery Course (AIM) online course|This arm will begin the intervention immediately after randomization
16245203|NCT05057676|Other|Delayed Autoimmune Intervention Mastery Course|This is the control arm.
16245204|NCT05057663|Active Comparator|Bleomycin group|
16245205|NCT05057663|Active Comparator|5-Fluorouracil group|
16245206|NCT05057650|Experimental|Intervention|Vegan food for 5 weeks: approximately 50 participants volunteered for the intervention.
16245207|NCT05057637||Complete cohort|In all patients included in the study subsequent optical coherence tomography (OCT) measurements will be performed pre and post stent placement.
16245208|NCT05057624|Placebo Comparator|non-GC-MRT|Placebo- music will play at all times during the trials.
16245209|NCT05057624|Active Comparator|GC-MRT|Music will only play when participants view angry faces and will stop when they look at neutral faces.
16245210|NCT05057624|Experimental|GC-MRT-exp|Music will only play when participants look at neutral faces and will stop when they view angry faces.
16245211|NCT05057611|Active Comparator|Usual Care Group (UC)|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, HR (heart rate) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
16245212|NCT05057611|Experimental|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If <40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If <50 mmHg NE will be increased for MAP >65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.
~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.
~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
16245213|NCT05057598|Experimental|Intervention group on diet and lifestyles|The arm consists to provide survivors with evidence-based recommendations and to promote improved nutrition and physical activity through videos and lectures available on the website (theoretical lectures on preventive strategies, and practical videos on cooking techniques and specific physical exercises).
16245214|NCT05057585|Experimental|Exercise group|"Routine preoperative care of the clinic was performed in both groups. Turning in bed, arm and leg exercises were applied to only the experimental group for 15 minutes and 12-24 hours prior to surgery. Later, both groups were provided to fill in the Anxiety Specific to Surgery Questionnaire (ASSQ). After interventions for postoperative pain by clinical nurses in both groups during the postoperative period, nurses waited until oral feeding and patients' general condition to stabilize. Afterwards, turning in bed, arm and leg exercises were applied to the experimental group patients for the second time for 15 minutes. Later, both groups took a few steps in front of their bed as part of the early ambulation procedure."
16245245|NCT05057312|Experimental|Experimental arm 4|Video narrative persuasion; Enhanced Access to HPV vaccines
16245246|NCT05057312|Experimental|Experimental arm 5|Written narrative Persuasion
16245247|NCT05057312|No Intervention|Control/ active comparator Arm 6|CDC information
16245248|NCT05057299||Patients with extramedullary leukemia(eAML) with myeloid neoplasms|
16245249|NCT05057286|Experimental|Subjects with gummy smile|The study procedure consisted of recruitment, pre&post-operative photography, gingivoplasty, BTX-A injection, recall visits, and data collecting.
16245215|NCT05057585|No Intervention|No treatment group|"Routine preoperative care of the clinic was performed in both groups. Later, both groups were provided to fill in the Anxiety Specific to Surgery Questionnaire (ASSQ). After interventions for postoperative pain by clinical nurses in both groups during the postoperative period, nurses waited until oral feeding and patients' general condition to stabilize. Afterwards, turning in bed, arm and leg exercises were applied to the experimental group patients for the second time for 15 minutes. Later, both groups took a few steps in front of their bed as part of the early ambulation procedure. The patients who tolerate early ambulation were mobilized by allowing them to walk in the clinical corridor, walk around in a social space specially designed for patients and spend time. In the two days following surgery, 15-minute exercise was applied once to the experimental group."
16245219|NCT05057507||Atrial fibrillation patients undergoing radiofrequency catheter ablation|Up to 115 patients undergoing radiofrequency catheter ablation will be enrolled.
16245220|NCT05057494|Experimental|Arm A: Acalabrutinib plus Venetoclax (AV)|Participants will receive acalabrutinib and venetoclax orally.
16245221|NCT05057494|Experimental|Arm B: Venetoclax plus Obinutuzumab (VO)|Participants will receive Venetoclax orally and Obinutuzumab via IV infusion.
16245226|NCT05057455||ICU patients diagnosed with sepsis or septic shock|compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
16245228|NCT05057429|Experimental|Bioelectric Dressing on the Right Armpit and Standard Gauze Dressing on the Left Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the right armpit and will receive the standard gauze dressing for up to 8 weeks on the left armpit.
16245229|NCT05057429|Experimental|Bioelectric Dressing on the Left Armpit and Standard Gauze Dressing on the Right Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the left armpit and will receive the standard gauze dressing for up to 8 weeks on the right armpit.
16245230|NCT05057416|Experimental|High Intensity Interval Training (HIIT) Protocol|Participants in the HIIT group will start with a 2.5-minute warm-up at about 30% VO2 max. The participants will then complete 3 running bouts at 80-90% VO2 max. Each running bout will be separated by 2 minutes of active rest where the participants will walk at 50% VO2 max. The total exercise time of this protocol will be 15 minutes. Finally, the participants will finish with a 2.5 min cool-down where they will walk at a light intensity of 30% VO2 max, for a total exercise duration of 20 minutes.
16245231|NCT05057416|Experimental|Sprint Interval Training (SIT) Protocol|Participants in the Sprint Interval Training group will perform a 2.5-minute warm up at a VO2 max of 30%. Next, the participants will perform 6 all-out sprints at 150-200% of VO2 max, separated by 2-minute active rests at 50% VO2 max. The total exercise time of the SIT protocol is about 14 minutes. Finally, the participants will perform a walking cool-down of 3.5 minutes at 30% VO2 max, for a total exercise duration of 20 minutes.
16245232|NCT05057416|Experimental|Moderate Intensity Continuous Training (MICT)Protocol|Participants in the Moderate Intensity Continuous Training group will first be warming up for 2.5 minutes at a VO2 max of 30%. After the warm up, participants will be running for 15 minutes at 45-60% of VO2 max. Finally, the participants will perform a 2.5-minute cool-down at 30% VO2 max, for a total exercise duration of 20 minutes.
16245233|NCT05057390|Experimental|New Human Milk Fortifier|From the Baseline (start of intervention) each patient will receive the case study product for at least 4 weeks (28 days), with at least 1-week administration in the community.
16245234|NCT05057377||Post-TBI Participants|Over a 2-day period post-TBI adults age 18 years and older, will undergo overground assessments with a questionnaire regarding motivation during day 1, followed by robotic safety-environment assessments during day 2.
16245235|NCT05057364|Experimental|Heart Smart Group|Receives Heart Smart Intervention
16245236|NCT05057351|Experimental|Active ingredient|Isopentenyltheophylline 0.44% + Glycerin 4.56%
16245237|NCT05057351|Placebo Comparator|Placebo|Glycerin 4.56%
16245238|NCT05057338|Experimental|CoreDISTparticipation|"a) at the MS-OP clinic, in addition to the regular consultations, the patient will have a structured digital conversation with the MS-nurse addressing work related issues and a session with a physiotherapist exploring possibilities for change in balance and walking; b) in the municipality, a physiotherapist will continue exploration of improvements, followed by four weeks of GroupCoreDIST focusing on balance, walking and physical activity and conducted in groups of 3-5 individuals with MS and led by a physiotherapist.
~To promote participation in employment, a structured digital meeting between each patient, the MS-nurse, the patient's employer, and the physiotherapist will take place; followed by c) four weeks of outdoor group based exercises and physical activity led by a physiotherapist, complemented with an evaluation form regarding employment and physical activity."
16245239|NCT05057338|Active Comparator|Standard care|The control group will receive the usual consultations at the MS-OP clinic including exploration of possibilities for change in balance and walking together with physiotherapist at the MS-OP clinic. The control group will furthermore follow standard care (their usual follow-up) in the municipality.
16245240|NCT05057325|Experimental|Wave One Gold|Receporcating single file used for preparation of root canals in primary molars
16245241|NCT05057325|Experimental|One shape|Rotation single file used for preparation of root canals in primary molars
16245250|NCT05057273|Experimental|omilancor (BT-11) 1,000mg|
16245252|NCT05057260||Long Covid cohort|Long Covid patients managed in the 10 participating sites
16245253|NCT05057247|Experimental|Duvelisib plus Docetaxel chemotherapy|"Participants will receive duvelisib by mouth twice daily,dosage per protocol continuously (days 1-21 of a 21-day cycle) with a 7-day lead-in planned prior to the start of taxane therapy.
~Docetaxel at via IV will be delivered on day 1 of each 21-day cycle.
~Treatment will continue for 24-months or until unacceptable toxicity, progression, or death."
16245254|NCT05057234|Experimental|Simultaneous - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx while tissued-based NGS panel is in progress
16245255|NCT05057234|Experimental|Simultaneous - no additional testing|Patients undergoing no additional testing while tissue-based NGS panel is in progress
16245256|NCT05057234|Experimental|Sequential - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx if standard tissue based NGS oncopanel testing identifies no somatic tier 1 variant of strong clinical significance
16245257|NCT05057221|Experimental|Uproleselan|Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
16245258|NCT05057208||Vaccinated|COVID Vaccinated
16245259|NCT05057208||Non-vaccinated|COVID Non-vaccinated
16245260|NCT05057195|Experimental|Interstitial radiation therapy|Duration: 11 days
16245261|NCT05057195|Active Comparator|Postoperative external beam therapy, on the bed of the removed tumor|Duration: 4 weeks
16245262|NCT05057182|Experimental|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
16245263|NCT05057169|Experimental|BNT162b2 third dose after two doses of BNT162b2|
16245264|NCT05057169|Experimental|CoronaVac third dose after two doses of BNT162b2|
16245265|NCT05057169|Experimental|BNT162b2 third dose after two doses of CoronaVac|
16245266|NCT05057169|Experimental|CoronaVac third dose after two doses of CoronaVac|
16245267|NCT05057156|Experimental|"application supervised by a psychologist via teleconsultations"|patient have app, and teleconsultation with psychologist
16245268|NCT05057156|Placebo Comparator|"application in total autonomy"|patients have app, they play when they want
16245269|NCT05057156|No Intervention|"control group without using the application"|patients haven't app
16245270|NCT05057143|Experimental|Replacement of a defect in the chest wall with an individual implant|A patient with a tumor lesion of the chest wall undergoes СT scan with a step width of less than 1 mm, then engineers design an individual model to replace the defect. Using a 3D printer, a model is made based on the patient's anthropometric data.
16245271|NCT05057143|Active Comparator|Replacement of a defect in the chest wall with titanium plates|The use of standard titanium plates to replace the chest defect. These plates must be modeled and modified using special equipment intraoperatively, based on the characteristics of the defect after resection.
16245272|NCT05057130|Experimental|Three-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28 and 35 days IV with leucovorin 60 mg / m2 in the first 5 days after each administration of methotrexate. The interval between cycles is 42 days
16245273|NCT05057130|Active Comparator|Two-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. The interval between cycles is 28 days
16245274|NCT05057117|Active Comparator|Botulinum toxin A|One treatment with standard dosage (50-100 units) of botulinum toxin A in one axilla
16245275|NCT05057117|Active Comparator|Microwave thermolysis|One standard treatment (energy level 5) with microwave thermolysis in one axilla
16245276|NCT05057104||CK-SBRT with TACE group|
16245277|NCT05057104||Conversion hepatectomy after CK-SBRT plus TACE|
16245278|NCT05057091|Experimental|Lomber Roll techniques group|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
16245279|NCT05057091|Experimental|Posterior- anterior central vertebral manipulation techniques group|Another technique that we will use as a specific vertebral manipulation technique will be Maitland's posterior-anterior central vertebral manipulation and posterior - anterior unilateral central vertebral mobilization technique.
16245280|NCT05057078|Experimental|Intervention group|A mindfulness-based stress reduction program will be done once a week for eight weeks
16245281|NCT05057078|No Intervention|Control group|During study process, no application will be made to the control group.
16245282|NCT05057065||Hyperlipidemia|"HBsAg(+) patients
~TC>5.17mmol/L（200mg/dl）and（or）TG>2.3mmol/L（200mg/dl）"
16245283|NCT05057065||diabetes|"HBsAg(+) patients
~FPG>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h."
16245284|NCT05057065||CHB without metabolic disease|"HBsAg(+) patients
~without diabetes/ obesity/hyperlipidemia"
16245285|NCT05057052|Experimental|Cryoablation in combination with Sintilimab plus regorafenib|
16245286|NCT05057039||hypertensive group|SBP >=140mmHg, DBP >=90mmHg, or use of antihypertensive drug
16245287|NCT05057039||normotensive group|SBP <=140mmHg and DBP <=90mmHg without use of antihypertensive drug
16245288|NCT05057026||Adult mental health support program|We will evaluate the Impact of an Adult mental health support program on stigmatization and confidence of medical residents working with people with mental health concerns. The intervention will be delivered to approximately 30 residents from the University of Dalhousie family medicine residency program from the 2021-2022 academic year. The training will be delivered by resident groups. The first group will receive the PSP training October - November 2022. The second will receive the training November 2021 to February 2022. The third will take the training March to May 2022. Each group will include approximately 10 residents.
16245291|NCT05057000|Experimental|Group A|DIET PROGRAM IN ADDITION TO AEROBIC EXRCISES
16245292|NCT05057000|Other|Group B|DIET PROGRAM
16245293|NCT05056987|Other|TOTAL30, then AOHP|Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
16245294|NCT05056987|Other|AOHP, then TOTAL30|Senofilcon A contact lenses worn first, with lehfilcon A contact lenses worn second, as randomized. The senofilcon A contact lenses will be worn for approximately 14 days. The lehfilcon A contact lenses will be worn for approximately 28 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
16245295|NCT05056974|Experimental|UB-421 + chidamide|UB-421 + chidamide combination therapy
16245296|NCT05056961|Other|Large tidal volumes without respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, without respiratory distress symptoms
16245297|NCT05056961|Other|Large tidal volumes with respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, with respiratory distress symptoms (for example, supra-clavicular and thoracic-abdominal asynchronies...)
16245298|NCT05056948||Control|Original 3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria
16245299|NCT05056948||Test|"3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria.
~The right first molar (FDI number 16) will be removed in the computer and then designed by artificial intelligence (AI) system
~AI system will be trained by
~different algorithms such as Group 1) Voxel-based; Group 2) View-based; Group 3) Point-based; and Group 4) Fusion methods
~Group i) maxillary model only and Group ii) with antagonist model"
16245300|NCT05056935|Experimental|LB1148|active
16245301|NCT05056935|Placebo Comparator|Placebo|placebo
16245302|NCT05056922|Experimental|Tele-PCIT (Parent-Child Interaction Therapy)|
16245303|NCT05056922|Active Comparator|Treatment as Usual|
16245304|NCT05056909|Active Comparator|Standard of care|CKD care, as routinely provided in the respective nephrology outpatient clinic.
16245305|NCT05056909|Experimental|Intervention|standard of care + Kidney ACTion AI-supported software for chronic kidney disease care.
16245306|NCT05056896|Experimental|Low Dose Aspirin|Participants will be randomly assigned to aspirin group and receive a daily low dose aspirin (81 mg) for the duration of the study up to 12 weeks.
16245307|NCT05056896|Experimental|Placebo|Participants will be randomly assigned to placebo group and receive a daily placebo capsule for the duration of the study up to 12 weeks.
16245308|NCT05056883|Experimental|Treatment A|K-237 0.3-0.4mg/kg (once daily)
16245309|NCT05056883|Placebo Comparator|Control A|Placebo (once daily)
16245310|NCT05056870|Experimental|Test/Control|Eligible subjects will be randomized to the sequence, Test/Control
16245311|NCT05056870|Experimental|Control/Test|Eligible subjects will be randomized to the sequence, Control/Test
16245312|NCT05056857||Observational (biospecimen collection, medical chart review)|Patients undergo collection of blood samples and their medical charts are reviewed.
16245313|NCT05056844|Experimental|Diagnostic (CESM, DBT)|Patients receive iodine-based contrast agent IV then undergo CESM over 10-15 minutes. Patients who have not undergone standard of care DBT within 3 months from the study, also undergo DBT.
16245314|NCT05056831|Other|In-Depth Interviews-First|The first interviews with health care providers and clinical stakeholders
16245315|NCT05056831|Other|In Depth Interviews-Second|The second interview guide for interviews with rural cancer survivors
16245316|NCT05056818||Observational (medical records)|Patients' medical records and past imaging examinations are reviewed.
16245317|NCT05056805|Active Comparator|Arm A (aerobic exercise, nutritional recommendation)|Patients are encouraged to complete at least 30 minutes of moderate intensity aerobic exercise, at least 3 times per week. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Aerobic exercises and nutrition are tracked in the Pt Pal app
16245318|NCT05056805|Experimental|Arm B (aerobic, strength exercise, nutritional recommendation)|Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
16245319|NCT05056792|Experimental|Participants in this group will receive NMES guided strength training.|NMES guided strength training of the quadriceps femoris muscle for 8 weeks.
16245320|NCT05056792|Sham Comparator|Participants in this group will receive Sham NMES.|Participants in this group will receive Sham NMES guided strength training of the quadriceps femoris muscle for 8 weeks.
16245321|NCT05056779|Experimental|Nemolizumab|
16245322|NCT05056779|Experimental|Placebo|
16245324|NCT05056753|Active Comparator|Investigational Device|The HWBV chair consists of a custom-made saddle-seat type of chair. The vibration actuators are embedded into the underside design of the chair. The base contains two vibrators, one for each side of the chair, and the chair is split in half vertically so that the vibrating actuators are able to send a harmonic vibration at alternating frequencies, upwards through each side of the chair. The HWBV system is considered a non-significant and non-substantial risk device.
16245325|NCT05056753|Sham Comparator|Control Device|The Control device is identical in construction to the Active device. The vibration mode, however, is a significantly different setting than that used by the Active version, so that the mechanoreceptors in the cervical spine are not effectively stimulated.
16245326|NCT05056740||MS|Patients with a definite MS diagnosis according to the 2017 McDonald criteria
16245327|NCT05056740||Red-flag MS|Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS
16245328|NCT05056740||Other CNS autoimmune diseases|Patients with a definite diagnostic of CNS autoimmune disease that is not MS
16245329|NCT05056740||Controls|Patients with a definite diagnostic of non-inflammatory CNS disorder
16245332|NCT05056714||patients with Nasosinus Polyposis|patients with Nasosinus Polyposis included in the study
16245333|NCT05056701|Experimental|patient with preeclampsia|Patient meeting preeclampsia criteria according to International Society for the Study of Hypertension in Pregnancy (ISSHP) 2018 definitions
16245334|NCT05056688|Experimental|Application of training set to experimental group|Testicular Model BSE/TSE Training Set
16245335|NCT05056688|No Intervention|Control Group|
16245336|NCT05056675|Experimental|PENG block for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of 0.5% ropivacaine iv is injected.
16245337|NCT05056675|Placebo Comparator|Placebo for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of NaCL 0.9% is injected.
16245338|NCT05056662||Group 1|Patients with negative invasive functional evaluation
16245339|NCT05056662||Group 2|Patients with positive invasive functional evaluation undergoing PCI
16245340|NCT05056662||Group 3|Patients with positive invasive functional evaluation undergoing PCI and subsequent retest of functional indexes
16245341|NCT05056649||Heart Failure Patients with impaired ejection fraction|
16245342|NCT05056623|Experimental|Dyadic pain management program|The DPM is an 8-week group-based program. The DPM included 4 weeks of center-based, face-to-face activities and 4 weeks digital-based activities delivered via a WhatsApp group.
16245343|NCT05056623|Other|Usual care and pain management pamphlet|The participants in the control group will receive the usual care and a pain management pamphlet.
16245344|NCT05056610|Experimental|Patients with IBS or FI|Food antigens are added to duodenal mucosa during CLE
16245345|NCT05056610|Experimental|healthy controls|Food antigens are added to duodenal mucosa during CLE
16245346|NCT05056597||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
16245347|NCT05056597||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype
16245348|NCT05056597||BN|Participants that meet DSM-V criteria for Bulimia Nervosa.
16245349|NCT05056597||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
16245350|NCT05056584|Experimental|Healthy control subjects|Healthy control subjects, matched for age, sex and BMI
16245351|NCT05056584|Experimental|Patients with End-stage Renal Disease|Patients with hemodialysis-treated ESRD.
16245352|NCT05056584|Experimental|Patients with liver cirrhosis|Patients with Child-Pugh A or B Cirrhosis
16245353|NCT05056571|Experimental|Relaxation exercise|Intensive care nurses will apply 20 minutes of online (zoom meeting) progressive muscle relaxation exercise twice a week, for 8 weeks, for a total of 16 group sessions. In order to support nurses' adaptation to the research, the group counselor will remind the nurses by phone twice a week during the implementation process, and their regular participation in online sessions will be supported.
16245354|NCT05056571|No Intervention|Control|No attempt will be made during the research.
16245355|NCT05056558|Experimental|Baricitinib|Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14
16245356|NCT05056558|Placebo Comparator|Placebo|Continued SOC according as mentioned in operational definition in the protocol
16245357|NCT05056545|Experimental|PPFP Intervention|The study team will train government clinic staff in ANC, L&D, IV, or postpartum services to promote and provide the PPFP intervention at the selected facilities. Community Health Workers (CHW) and 'Happy Clients' will be trained as PPFP promotional agents. Video-based PPFP promotions will be shown at the intervention facilities. If interested in PPFP, women will be referred to the facility by their CHW.
16245358|NCT05056545|No Intervention|Standard of Care|Currently, no systematic PPFP training, promotional, or service delivery activities are regularly taking place at the selected facilities. The team will compare the intervention with historical records from the facilities applying intervention and compare
16245359|NCT05056532||patients|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
16245360|NCT05056532||Control group|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
16245361|NCT05056519|Experimental|Experimental group|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine
16245362|NCT05056519|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
16245363|NCT05056506|Active Comparator|Endoscopic papillary large balloon dilation group|Endoscopic papillary large balloon dilation to extract bile duct stones
16245364|NCT05056506|Experimental|Endoscopic papillary Large balloon dilation combined with limited endoscopic sphincterotomy group|Endoscopic papillary large balloon dilation combined with limited endoscopic sphincterotomy to extract bile duct stones
16245365|NCT05056493|Experimental|Clinical Providers|Clinical provider site champions will be invited to participate in web-based quantitative surveys and a semi-structured interview
16245485|NCT05055674|Active Comparator|COMVC App|Participants in this arm will have access to COMVC, a smartphone app designed to deliver only psychoeducational content and mental health monitoring.
16246233|NCT05050500|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 6 months
16245366|NCT05056493|Experimental|Parent/Caregivers|Patient and parent/caregiver subjects from the participating clinic sites will be enrolled. These participants are all adults - parents or caregivers of children and youth with special health care needs (CYSHCN) and adult patients with multiple chronic conditions (MCC) who are already receiving care at Duke Health.
16245367|NCT05056480||Parents/caregivers|Parents/caregivers of children <20 years old who received interdisciplinary care coordination within the Pediatric Complex Care Integration (PCCI) program
16245368|NCT05056480||Clinical staff|PCCI care management staff participating in implementation of the PCCI program
16245369|NCT05056467|Experimental|IOL|Preeclampsia High-risk Women schedule labor induction at 39 weeks of gestation
16245370|NCT05056467|No Intervention|Expectant Management|Preeclampsia High-risk Women under expectant management
16245371|NCT05056454|No Intervention|Treatment as usual (TAU, a.k.a. Perinatal Psychiatric Care)|This treatment condition is modelled after the psychiatry-delivered treatment usually provided at the Maternal Outpatient Mental Health Services (MOMS) Clinic associated with the UCLA Westwood OB-GYN Clinic and Department of Psychiatry.
16245372|NCT05056454|Experimental|Screening and Treatment of Anxiety and Depression (STAND)|This treatment condition provides access to a system of care, in which type of treatment is allocated based on presenting symptomatology. Participants will learn their allocation from study staff or participants will create a secure account through STAND to learn about their allocation through the STAND online dashboard. Through their STAND online dashboard, they could also have access to a) their CAT-MH results over time from the start of treatment, b) assessment of their current diet/nutrition and psychoeducation about the relationship between diet/nutrition and mental health, and c) list of additional resources available to them.
16245375|NCT05056428|Experimental|Intervention group|8-week mindfulness program
16245376|NCT05056428|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after experimental group completed the intervention.
16245377|NCT05056415|Active Comparator|Treatment as Usual (TAU)|"In the involved municipalities, TAU mainly consists of short-term efforts, such as Occupational Therapist (OT) prescribing technical aids, often initiated by the housing staff (HS). Daily support provided by HS varies, depending on the approach and commitment of individual staff and the norms that prevail in different housing units, as well as variations between municipalities. Co-planning on long-term rehabilitation efforts does not exist or is weak, and collaboration between OT and HS is, as described by staff from both parties, difficult to achieve.
~After a control-period of 6 month, house facilities within the TAU-group will also be offered ELR."
16245378|NCT05056415|Experimental|Everyday Life Rehabilitation (ELR) plus TAU|"ELR is a model for long-term, outreach, and personalized rehabilitation for persons with SPD living in sheltered or supported housing facilities, in close collaboration between resident, OT, and HS.
~ELR includes personcentred, motivational-, recovery- and activity-based methods, built on certain process steps. The focus is to promote personal recovery, while targeting meaningful daily activities, through person-driven goals, negotiated expectations, exploration and activity-training in real-life situations, and a maintenance phase. ELR includes a web-based educational package, and devices for reflective collaborative learning.
~ELR consists of a weekly session with an OT, followed by regular collaboration with HS, who support the resident on a daily basis, in line with guidance given by the OT and input shared from the HS. The intervention period will last for 6 months.
~Prior to the intervention, OT, HS, and HM will partake in web-based training, with associated manuals, and tools."
16245379|NCT05056402|Experimental|9-17y (0,6m)|Subjects who aged 9-17 years old would receive 2 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
16245380|NCT05056402|Experimental|9-17y (0,1,6m)|Subjects who aged 9-17 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
16245381|NCT05056402|Experimental|18-26y (0,1,6m)|Subjects who aged 18-26 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
16245382|NCT05056389|Experimental|NIPEX-OXA arm|20 patients treated with NIPEC-OXA after CRS and HIPEC.
16245385|NCT05056363|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
16245386|NCT05056363|Experimental|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
16245387|NCT05056350|Other|Assessment of the feasibility and impact of a back-to-work support program|questionnaires, back to work coaching
16245425|NCT05056077|Experimental|Condition II (text, health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
16245388|NCT05056337|Experimental|Treatment group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with lenvatinib(8mg/d for BW<60kg and 12mg for BW≥60kg) in combination with toripalimab(240mg iv Q3W) and TACE (on demand). Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the conversion resection rate will be calculated, and patient survival will be assessed.
16245389|NCT05056337|Active Comparator|Control group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with TACE alone. Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the translational resection rate will be calculated, and patient survival will be assessed.
16245390|NCT05056324|Experimental|Intervention group|
16245391|NCT05056324|Active Comparator|Control group|
16245392|NCT05056311|Experimental|Parent Utilization of Decision Aid Website|All enrolled parents will view the decision aid website for as long and as frequently as they wish before the initial visit to the urologist.
16245393|NCT05056298|Experimental|Insole and Exercise group|will contain 17 patients, they will receive the custom made arch support insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
16245394|NCT05056298|Active Comparator|Exercise group|will contain 17 patients, they will receive the standard insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
16245395|NCT05056285||Down syndrome less than four years Group|
16245398|NCT05056246|Experimental|Group 1: Japanese participants - AMG 133 low dose|Japanese participants will receive the low dose of AMG 133 administered via subcutaneous injection.
16245399|NCT05056246|Experimental|Group 2: Japanese participants - AMG 133 medium dose|Japanese participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
16245400|NCT05056246|Experimental|Group 3: Japanese participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
16245401|NCT05056246|Experimental|Group 4: Caucasian participants - AMG 133 medium dose|Caucasian participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
16245402|NCT05056246|Experimental|Group 5: Caucasian participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
16245403|NCT05056233|Experimental|Systane Hydration|Systane Hydration lubricant eye drops dosed 4 times a day for 6 weeks (2 weeks prior to surgery and 4 weeks post surgery), with investigator defined post-operative standard of care
16245404|NCT05056233|No Intervention|No Treatment|Investigator defined post-operative standard of care
16245405|NCT05056220|Active Comparator|High expected effect: Human Albumin 20% + Standard Medical Treatment|
16245406|NCT05056220|Placebo Comparator|High expected effect: NaCl 0.9% + Standard Medical Treatment|
16245407|NCT05056220|Active Comparator|Low expected effect: Human Albumin 20% + Standard Medical Treatment|
16245408|NCT05056220|Placebo Comparator|Low expected effect: NaCl 0.9% + Standard Medical Treatment|
16245409|NCT05056207|Other|Cohort I (patients receiving annual lymphedema screening)|We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.
16245410|NCT05056207|Other|Cohort II (patients followed intensively for lymphedema)|We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.
16245411|NCT05056194|Experimental|Valiloxybate|XW10172 Modified Release (MR) Granules for Oral Suspension
16245412|NCT05056194|Placebo Comparator|Placebo|Placebo Granules for Oral Suspension
16245413|NCT05056181|Experimental|PAI|Participants assigned to the PAI arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will receive conventional medical treatment. They will also participate in 2 weeks of training (12 sessions), plus telematic assistance of a specialized practitioner who will follow them during the post-discharge training sessions for a period of 12 weeks, with 3 workouts per week.
16245414|NCT05056181|No Intervention|TAU|Participants assigned to the TAU arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will also receive conventional medical treatment.
16245415|NCT05056155|Experimental|Systane Complete|First dose of Systane Complete in both eyes on Day 0, followed by Systane Complete self-administered 4 times daily for 28 days
16245416|NCT05056142|Active Comparator|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL
16245417|NCT05056142|Active Comparator|Spinal Anesthesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
16245418|NCT05056129|Experimental|Sensor-controlled digital game (SCDG)|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
16245419|NCT05056129|Active Comparator|Sensors-only|The control group will receive only the weight monitoring and physical activity sensors
16245420|NCT05056116|Experimental|Biliary Tract Cancer|Surufatinib 250mg/Toripalimab 240mg
16245421|NCT05056103|Other|TrachFlush|
16245422|NCT05056090|Experimental|Patients will receive MV in PP|Patients assigned to the intervention group will be turned in PP within the two hours after randomization for at least 16 consecutive hours. Then, patients will be turned in SP. Then, PP sessions are repeated as long as stopping criteria for PP are not met
16245423|NCT05056090|No Intervention|Patients will receive MV in SP|
16245424|NCT05056077|Experimental|Condition I (text, health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16255901|NCT04984577|Placebo Comparator|Placebo Injection|
16245426|NCT05056077|Experimental|Condition III (text, health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245427|NCT05056077|Experimental|Condition IV (text, health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages and use digital health tool kit for 48 weeks.
16245428|NCT05056077|Experimental|Condition IX (health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245429|NCT05056077|Experimental|Condition V (text, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245430|NCT05056077|Experimental|Condition VI (text, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
16245431|NCT05056077|Experimental|Condition VII (text, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245432|NCT05056077|Experimental|Condition VIII (text)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive text messages for 48 weeks.
16245433|NCT05056077|Experimental|Condition X (health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
16245434|NCT05056077|Experimental|Condition XI (health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245435|NCT05056077|Experimental|Condition XII (health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients use digital health tool kit for 48 weeks.
16245436|NCT05056077|Experimental|Condition XIII (health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245437|NCT05056077|Experimental|Condition XIV (health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
16245438|NCT05056077|Experimental|Condition XV (support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
16245439|NCT05056077|Experimental|Condition XVI (study booklet)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with colon or rectal cancer.
16245440|NCT05056064|Experimental|CA oral cavity|Standard Treatment+Oral exercise
16245441|NCT05056064|No Intervention|control|Standard treatment
16245442|NCT05056051|Active Comparator|Post-EET Surveillance Group: WATS-3D samples followed by Forceps biopsies|Sampling will occur with WATS-3D followed by forceps biopsies. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
16245443|NCT05056051|Active Comparator|Post-EET Surveillance Group: Forceps biopsies followed by WATS-3D samples|Sampling will occur with forceps biopsies followed by WATS-3D. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
16245444|NCT05056038|Active Comparator|Lateral Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
16256003|NCT04983758||Severe PCP|
16245445|NCT05056038|Active Comparator|Posterior Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the posterior border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
16245446|NCT05056025|Experimental|postbiotics with vitamins|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
16245447|NCT05056025|Placebo Comparator|vitamins|vitamins (AREDS formulation and recommended daily dose)
16245448|NCT05055986||CBCT Dicom files of patients|CBCT Dicom files of patients will be used for measurements of mandibular bone volume by open-source software.
16245449|NCT05055934|Experimental|SHR-1314 injection|
16245450|NCT05055934|Placebo Comparator|placebo|
16245451|NCT05055921|Experimental|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
16245452|NCT05055895||early onset deliryum on dementia|It was earlier than The median time of onset of delirium superimposed dementia
16245453|NCT05055895||Delirium on dementia (normal)|It was equal or later than The median time of onset of delirium superimposed dementia
16245454|NCT05055882||children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
16245455|NCT05055856|Active Comparator|Frailty or more|patients with the geriatric syndrome who will be recruited at the geriatric out patient clinic
16245456|NCT05055856|Placebo Comparator|healthy|healthy aged people defined as in the modified SENIEUR protocol who will be recruited by an extern call thanks UZ Brussel website of thanks to staff's knowledge
16245457|NCT05055843|Experimental|Screening (3D MRI)|Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate time.
16245459|NCT05055817||bloody stool group|bloody stool appear in the hospitalized neonate
16245460|NCT05055817||non-bloody stool group|bloody stool do not appear in the hospitalized neonate
16245461|NCT05055804|Experimental|ELG Device Comparison to Whole Blood Testing|Participant will place thumb in the ELG device for scan. Scan generally takes between 1-2 minutes. ELG then displays a readout of both a glucose and A1C reading on the screen of the ELG device.
16245462|NCT05055791|Experimental|Arm 1|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
16245463|NCT05055791|Experimental|Arm 2|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
16245464|NCT05055778|Experimental|SmokfreeTXT|Research version of the publicly available SmokefreeTXT program
16245465|NCT05055765|Active Comparator|TEST GROUP I|Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
16245466|NCT05055765|Active Comparator|TEST GROUP II|Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
16245467|NCT05055752|Other|PL-ASA capsule, then IR-ASA tablet|
16245468|NCT05055752|Other|IR-ASA tablet, then PL-ASA capsule|
16245469|NCT05055739|Experimental|SW|Patients undergoing sternal closure with steel wires
16245470|NCT05055739|Experimental|RP|Patients undergoing sternal closure with a rigid plate
16245471|NCT05055726|Experimental|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|"Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis.
~The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC.
~In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day.
~In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds."
16245478|NCT05055700|Experimental|Intervention group|This arm will review a mobile app to learn information about prenatal genetic testing before their appointment with maternal-fetal medicine specialists.
16245479|NCT05055700|No Intervention|Control group|This arm will only receive usual care - visit maternal-fetal medicine specialists.
16245480|NCT05055687|Experimental|Part A：FL058|a single ascending dose (SAD) of intravenous (IV) FL058(2500mg~3000mg)
16245481|NCT05055687|Placebo Comparator|Part A：Placebo|FL058 Placebo
16245482|NCT05055687|Experimental|Part B：FL058|a multiple ascending dose (MAD) of intravenous (IV) FL058(500mg~2000mg)
16245483|NCT05055687|Placebo Comparator|Part B：Placebo|FL058 Placebo
16245484|NCT05055674|Experimental|Motherly App|Participants in this arm will have access to Motherly, a smartphone app that is designed to promote life habits that have been shown to improve depression and mental health in mothers.
16246234|NCT05050500|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 6 months
16245486|NCT05055661|No Intervention|The control group|Patients randomized to the control group will receive conventional service at the reference Basic Health Unit and be contacted throughout the six months to collect the study variables, by telephone contact.
16245487|NCT05055661|Experimental|The intervention group|Patients randomized to the intervention grop will receive the same conventional service as the control group at the reference Basic Health Unit and also will be carried, once a month, the pharmaceutical teleconsultation during six months, by video call. The study variables will be collected in the same periods as the control group patients, by telephone contact.
16245488|NCT05055648|Active Comparator|Photon Arm|Standard arm with neoadjuvant chemoradiotherapy (nCXT) with photons
16245489|NCT05055648|Experimental|Proton Arm|Experimental arm with neoadjuvant chemoradiotherapy (nCPT) with protons
16245490|NCT05055635|Experimental|Doseescalated pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day.
16245491|NCT05055609|Experimental|Open Label|In the dose escalation portion, it is estimated that approximately 12-24 subjects will be enrolled in four dose cohorts. The dose expansion portion will enroll 6-12 subjects.
16245492|NCT05055596|Experimental|Gentle Movement|
16245493|NCT05055596|Active Comparator|Health Coaching|
16245494|NCT05055583|Experimental|Toripalimab in Combination With Platinum-based Chemotherapy|Participants receive totally 3-4 cycles of toripalimab combined with platinum-based chemotherapy neoadjuvant treatment during preoperative period. After the last treatment (Day 21 of Cycle 4), surgery will be performed within 4-6 weeks. Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention was to receive maintenance therapy within 6-12 weeks of the MDT assessment.
16245495|NCT05055570||The group with postoperative pulmonary complications|
16245496|NCT05055570||The group without postoperative pulmonary complications|
16245497|NCT05055557||ARDS group|"1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).
~3.Diagnosis of ARDS less than 72 hours. 4.Just observation"
16245498|NCT05055557||Critically ill patients without ARDS group|Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.
16245499|NCT05055557||healthy adult group|Healthy adults, voluntarily join the study.
16245500|NCT05055544|Active Comparator|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A)
16245501|NCT05055544|Active Comparator|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
16245502|NCT05055518|Experimental|A Phase I, open-labeled multicenter study|APL-102 Capsules
16245503|NCT05055505|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
16245504|NCT05055505|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
16245505|NCT05055492|No Intervention|Control period|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
16245506|NCT05055492|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
16245507|NCT05055453|Experimental|Experimental Study Group|"It is a prospective study to investigate whether the MyPhonak Junior app can improve speech understanding in children with hearing aids, by evaluating the use of the volume, noise reduction and directional microphone using the MyPhonak Junior App.. The study is linked to randomized patient and test allocation carried out.
~Introduction to the MyPhonak Junior app. There are measurements of speech understanding of sentences Carried out in background noise with the Oldenburg sentence test (OLSA). The language test is hard of hearing children and adolescents known from routine clinical practice. Various everyday situations / noise scenarios are played out. Questionnaire (E-HAK, also known from routine) and interview of the children regarding the use of the app in everyday life."
16245508|NCT05055440||Mechanically ventilated patients with COVID-19 in the ICU|Mechanically ventilated patients with COVID-19 admitted to the intensive care unit using sedation and neuromuscular blocker
16245509|NCT05055427|Experimental|• Experimental: Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) and the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.
16245510|NCT05055427|Active Comparator|• Active Comparator: Controlled arm|Patients receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline
16245511|NCT05055414|Experimental|UI030|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
16245512|NCT05055414|Placebo Comparator|Placebo|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
16245514|NCT05055388||Group with sepsis complicated with multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with multidrug-resistant bacteria if microbial culture results showed multidrug-resistance.
16246235|NCT05050487|Experimental|treatment|patient will recieve pericapsular nerve group block
16245515|NCT05055388||Group with sepsis complicated with none multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with none multidrug-resistant bacteria if microbial culture results showed none-multidrug-resistance or no positive result of microbial culture.
16245516|NCT05055362|Experimental|Honey Spice Group|The dietary intervention will be a 10-day feasibility trial, using a honey, spice infused baked good. The participants will receive the baked good on day 1 and will be asked to consume a 50-gram baked good daily for 10 days with or without their meals. The honey, spice infused baked good will contain 15g honey and 3g of spice blend (turmeric and cinnamon). A saliva sample will be taken at the start of the intervention (day 1) before consumption of the baked good and after the intervention ends (day 10), 2 hours after consuming the final baked good. Additionally, participants will provide a urine sample to determine microalbuminuria level, complete a spice-consumption survey and a semi-quantitative food frequency questionnaire (day 1). At day 10, participants will indicate if their spice consumption and dietary intake has changed over the past 10 days. Each day, they will tick off the amount of baked good consumed (100%, 75%, 50%, 25%, 0%).
16245517|NCT05055349|Active Comparator|corneal collagen cross linking and intrastromal corneal keraring segments.|20 eyes will undergo corneal collagen cross linking (epithelium off) 1 month after Femtosecond laser assisted intrastromal corneal keraring segments
16245518|NCT05055349|Active Comparator|toric phakic posterior IOL implantation and corneal collagen cross linking|20 eyes will undergo toric phakic posterior IOL implantation 1 year after corneal collagen cross linking (epithelium off).
16245519|NCT05055336|Experimental|Gastroparesis|Participants in this group are children diagnosed with gastroparesis per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
16245520|NCT05055336|Experimental|Dyspepsia|Participants in this group are children diagnosed with functional dyspepsia per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
16245521|NCT05055336|Experimental|Healthy Controls|Participants in this group are children that do not have gastroparesis, functional dyspepsia, or any other gastroenterology condition. Participants will be getting an ultrasound once.
16245522|NCT05055323|Experimental|Treatment (pyrvinium pamoate)|Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
16245523|NCT05055310||Normal elderly|normal cognitive group
16245524|NCT05055310||aMCI|amnestic mild cognitive impairment
16245525|NCT05055310||AD|Alzhiemer's disease
16245526|NCT05055297|Experimental|SELUTION SLR™ DEB 014|
16245527|NCT05055297|Active Comparator|Plain (Uncoated) Balloon Angioplasty (PTA)|
16245528|NCT05055284|Experimental|Experimental group|Experimental: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training along with patellar taping
16245529|NCT05055284|Sham Comparator|Control group|No Intervention: Control: Participants in this group will receive Sham EMG-BF guided strength training without patellar taping
16245530|NCT05055271||Delphi panel|The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.
16245535|NCT05055245||Patients undergoing assisted reproductive technology|Patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
16245536|NCT05055232|Experimental|XZP-3621|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
16245537|NCT05055219||Group 1: Overweight or Obese Group (visits #1-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight. Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
16245538|NCT05055219||Group 2: Overweight or Obese Group (visits #3-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight, or children and young adults who previously participated in the study (completed visits #1-2 in previous study phase). Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
16245539|NCT05055219||Group 3: Normal Weight Control Group|Children and adolescents who are 8 to 17 years of age, who have do not have risk factors for diabetes such as being overweight or a history of type 2 diabetes in the family. Healthy weight, as defined by a BMI ≥ 5th percentile & < 85th percentile. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
16245540|NCT05055206|Experimental|Lymphatic drainage mapping in patients with oropharynx cancer|"Participants will be given 4 to 6 injections of the radiotracer 99m-Technetium Sulfur Colloid by a needle into one of the veins of the radiotracer around the tumour.
~Participants will then have at least 1 or possibly 2 SPECT-CT scans (a special x-ray scan of the body from many angles that are turned into 3-dimensional pictures on a screen)."
16245541|NCT05055193||Preterm infants who received postnatal corticosteroid for bronchopulmonary dysplasia|Corticosteroids used are hydrocortisone (as first-line therapy) and betamethasone (in situations of particular severity)
16245542|NCT05055193||Preterm infants who did not receive postnatal corticosteroid for bronchopulmonary dysplasia|No corticosteroids
16245543|NCT05055180||HFpEF with pulmonary hypertension|Invasively diagnosed HFpEF and pulmonary hypertension according to current guidelines
16245544|NCT05055180||HFpEF without pulmonary hypertension|Invasively diagnosed HFpEF without pulmonary hypertension according to current guidelines
16245545|NCT05055180||Patients without HFpEF|Patients without invasive evidence of HFpEF
16245546|NCT05055167|Experimental|Envafolimab|Elderly NSCLC Patients with high PD-L1 expression
16245547|NCT05055154|Experimental|Very low calorie diet|Use of very low calorie diet prepared in the hospital
16245548|NCT05055141|Experimental|Care to Share Poster|"The intervention was an 18x18 poster board with a large blank surface for patients to share information about who they are as people and what is important to them. The Care to Share poster was co-designed with ten medicine inpatients during pilot testing. The goal of the poster was to equip Caregivers with humanizing information about their patients, thereby provoking more genuine empathetic interactions. Based on input from pilot testing, the researcher wrote on the poster for the patient to ensure ease of completion and legibility. The posters were displayed on the wall behind patients' beds, so Caregivers entering the room could easily see the information when facing the patient."
16245549|NCT05055141|No Intervention|Control|Study participants hospitalized on the two control units had no Care to Share poster.
16245550|NCT05055128|Experimental|X842 25 mg BID|Patients will receive 2 tablets (X842 25mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 25 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
16245551|NCT05055128|Experimental|X842 50 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
16245552|NCT05055128|Experimental|X842 75 mg BID|Patients will receive 2 tablets (X842 50 mg×2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
16245553|NCT05055128|Experimental|X842 100 mg BID|Patients will receive 2 tablets (X842 50 mg×2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
16245554|NCT05055128|Active Comparator|Lansoprazole|Patients will receive 2 tablets (X842 dummy×2) and 1 capsule (Lansoprazole 30 mg) in the morning, and 2 tablets (X842 dummy×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
16245555|NCT05055115|Experimental|Balloon Eustachian Tuboplasty|Patients with long-lasting symptoms of ETD, who benefits from tympanostomy tube insertion, will be offered Balloon Eustachian Tuboplasty (BET) of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
16245556|NCT05055102||Patient with WOVEX bifurcated prosthesis|"Patients who have undergone open abdominal aortic surgery between January 1st, 2013 and December 31, 2017 in Burgundy Dijon Hospital.
~Patients who have been treated with a WOVEX bifurcated prosthesis (Wovex® Polyester Vascular Protheses)"
16245557|NCT05055089||new-generation bioprostheses|Patients undergoing surgical aortic valve replacement with new-generation bioprostheses
16245558|NCT05055089||traditional bioprosthesis|patients who received a traditional bioprosthesis
16245559|NCT05055076||PODEYE TORIC|Adult patients who have undergone cataract surgery with mono- or bilateral implantation of POD EYE TORIC IOL (POD T 49P) and who meet all the inclusion and exclusion criteria will be invited to participate in the study.
16245560|NCT05055063|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
16245561|NCT05055050|Experimental|UGN-201 Pre Radical Cystectomy|UGN-201 200 mg/50ml
16245562|NCT05055024|Experimental|NLS-2 (mazindol extended release)|NLS-2 (mazindol extended release) administered once a day.
16245563|NCT05055011||Observational (survey, medical record review)|Parents complete survey over 20 minutes. Patients' medical records are reviewed.
16245564|NCT05054998|Experimental|Diagnostic (fludeoxyglucose F-18, PET/MRI)|Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.
16245565|NCT05054985|Experimental|Intervention arm|Patients with thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
16245566|NCT05054972||A|Group of patients in whom the left renal vein was divided for exposure of the aorta.
16245567|NCT05054972||A+|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was present.
16245568|NCT05054972||A-|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was not present.
16245569|NCT05054972||B|Group of patients in whom the left renal vein was mobilized but not divided for exposure of the aorta.
16245570|NCT05054959|Experimental|consolidation chemotherapy|"chemoradiation: intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).
~6 cycles of CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1."
16245571|NCT05054959|Active Comparator|induction chemotherapy|"4 cycles of induction CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1.
~Chemoradiation:intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).
~2 cycles of consolidation CAPOX chemotherapy."
16245572|NCT05054946|Active Comparator|Endometrioma|Participants who will have endometrioma after histopathological evaluation.
16245573|NCT05054946|Active Comparator|Mature cystic teratoma (dermoid cyst)|Participants who will have mature cystic teratoma (dermoid cyst) after histopathological evaluation.
16245574|NCT05054946|Active Comparator|Serous or mucinous cystadenoma|Participants who will have serous or mucinous cystadenoma after histopathological evaluation.
16245575|NCT05054933|Other|ultrasound capsule endoscopy examination|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
16245578|NCT05054907||Wearable devices + Smartphone|The only arm in the study.
16245579|NCT05054881|Other|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
16245580|NCT05054881|Other|Sciatic nerve block under ultrasound control without a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
16245581|NCT05054868|Active Comparator|Group 1 (Control group) - Oxycodone only|Subjects randomized to this group will receive oxycodone for postop pain management (standard of care).
16245582|NCT05054868|Experimental|Group 2 (Treatment group) - Oxycodone and Ketorolac|Subjects randomized to this group will receive oxycodone and ketorolac for postop pain management.
16245583|NCT05054855|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention.
16245584|NCT05054855|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an inperson session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
16245585|NCT05054842|Experimental|treatment group A|
16245586|NCT05054842|Placebo Comparator|treatment group B|
16245587|NCT05054829|Experimental|PEERS|
16245588|NCT05054829|Other|Controls|
16245589|NCT05054816|Experimental|Investigational adaptive directional microphone strategy|Receiver-in-canal hearing aid with an investigational adaptive directional microphone strategy.
16245590|NCT05054816|Active Comparator|Comparator adaptive directional microphone strategy 1|Receiver-in-canal hearing aid with a comparator adaptive directional microphone strategy 1.
16245591|NCT05054816|Active Comparator|Comparator adaptive directional microphone strategy 2|Receiver-in-canal hearing aid with a comparator adaptive directional microphone strategy 2.
16245592|NCT05054816|Active Comparator|Comparator fixed directional microphone strategy|Receiver-in-canal hearing aid with a comparator fixed directional microphone strategy.
16245593|NCT05054803|Experimental|WJ-MSC (XCEL-UMC-BETA)|Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.
16245594|NCT05054803|Placebo Comparator|Placebo|Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin
16245595|NCT05054790|Experimental|"Autologous Neo-Bladder Construct"|All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
16245596|NCT05054777||oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques
16245597|NCT05054777||conventional breast-conserving surgery|The conventional breast-conserving surgery were performed without any oncoplastic operations
16245598|NCT05054764||Participants with CLTI and BTK lesions planned for revascularization|The study population will be CLTI patients presenting with lower limb tissue loss (ulcer or gangrene) and BTK lesions who are candidates for revascularization for limb salvage.
16245599|NCT05054751|Experimental|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.
~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side.The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
16245661|NCT05054257|Experimental|Autologous CAR19 T lymphocytes|Human Autologous T Lymphocytes Expressing the Chimeric Antigen Receptor Specific to CD19
16245690|NCT05054023|Active Comparator|Soulagel®; Belpharma Tunisia|100g tubes that contained extracts of cinnamon, cloves, cypress, lavender, thyme, peppermint, rosemary, arnica, and camphor. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
16245600|NCT05054751|Placebo Comparator|Placebo+Fulvestrant|"Placebo: The dose of placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.
~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
16245601|NCT05054738|Experimental|Combined Recovery Program (CRP)+Treatment-as-usual (TAU)|Combined Recovery Program (CRP) is a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit. Attendance of CRP will be in addition to Treatment as Usual (TAU), that is, standard inpatient programming.
16245602|NCT05054738|Active Comparator|CRP+ Stable & Able (S&A)+TAU|Combined Recovery Program (CRP) a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit, plus a home telehealth program (Stable & Able) which begins on day 1 of hospital discharge. Attendance of CRP and S&A will be in addition to TAU, that is, standard inpatient programming.
16245603|NCT05054738|No Intervention|Treatment-as-usual only (TAU):|TAU will only receive the usual care on the inpatient unit including medical and medication management.
16245604|NCT05054725|Experimental|RMC-4630 and sotorasib, Safety Run-in|"Safety Run-In:
~RMC-4630 and sotorasib"
16245605|NCT05054725|Experimental|RMC-4630 and sotorasib, Expansion|"Dose Expansion:
~RMC-4630 and sotorasib"
16245606|NCT05054699|Experimental|MST|Subjects will receive 12-18 sessions of frontal Magnetic Seizure Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
16245607|NCT05054699|Active Comparator|ECT|Subjects will receive 12-18 sessions of bilateral Electroconvulsive Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
16245608|NCT05054686|Experimental|Combination of Strengthening and Aerobic Exercises at Clinic|Combination of Strengthening and Aerobic Exercises at Clinic and Stretching and Aerobic Exercises at Home
16245609|NCT05054686|Active Comparator|Combination of Stretching and Aerobic Exercises at Clinic|Combination of Stretching and Aerobic Exercises at Clinic and Strengthening and Aerobic Exercises at Home
16245610|NCT05054686|Active Comparator|Combination of Strengthening, Stretching and Aerobic Exercises at Clinic|Combination of Strengthening, Stretching and Aerobic Exercises at Clinic and Aerobic Exercises at Home
16245611|NCT05054673|Experimental|intervention|PALFIQUE universal adhesive (Tokuyama self-cure universal adhesive)
16245612|NCT05054673|Active Comparator|control|3M™ ESPE™ single bond Universal Adhesive
16245613|NCT05054660|Experimental|caring chatbot|The investigators will enroll participants aged over 55 in the psychiatric outpatient department. The participants will get a one-month caring chatbot and can interact with the chatbot freely.
16245614|NCT05054647||family caregivers of palliative patients|psychometric questionnaires
16245615|NCT05054634||Experimental Group (EG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
16245616|NCT05054634||Control Group (CG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
16245619|NCT05054608||COVID-19 ICU cohort|All patients, 18 to 63 years old, admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
16245620|NCT05054608||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
16245621|NCT05054608||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
16245622|NCT05054595|Active Comparator|Standard Pain Psychoeducation|
16245623|NCT05054595|Active Comparator|Audio-Recorded Mindfulness-Based Intervention|
16245624|NCT05054595|Experimental|Nurse-Led Mindfulness-Based Intervention|
16245625|NCT05054569|Experimental|10-week eHealth intervention|Weekly video conference groups led by a trained facilitator
16245626|NCT05054543|Experimental|Uproleselan|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation
16245627|NCT05054543|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation
16245628|NCT05054530|Experimental|GMA106|6 different dosages will be subcutaneously injected into the abdomen.
16245629|NCT05054530|Placebo Comparator|Matching placebo|6 different dosages will be subcutaneously injected into the abdomen.
16245630|NCT05054504|Other|Intervention|The primary intervention is a multi-phase, mixed methods, implementation research study that will investigate the feasibility and acceptability of the limited introduction of ultrasound via the Butterfly iQ device into routine ANC service delivery at health center level in Blantyre, Malawi. The study will occur in three phases: 1) Training, 2) Iterative Service Delivery, and 3) Final Evaluation.
16245633|NCT05054478|Experimental|Experimental Arm|"4 days of dexamethasone. According to local practice, one dose of doxorubicine (30 mg/m2 IV) or cyclophosphamide (750 mg/m2 IV) may also be added
~Induction Treatment (4 months): Subject will receive 4 x 28 days cycles of Dara-VRD induction:
~Daratumumab sc 1800 mg on D1 D8 D15 D22 for cycle1 & 2 and D1 D15 for cycle 3 & 4 Bortezomib sc 1.3 mg/m2 on D1 D4 D8 D11 for each cycle Lenalidomide po 25 mg on D1 to D21 for each cycle Dexamethasone po 20 mg on D1 D2 D8 D9 D15 D16 D22 D23 for each cycle
~High dose melphalan 200mg/m2 as conditioning therapy and first ASCT
~First consolidation : 2 cycles of Dara-VRd
~Daratumumab 1800 mg s.c D1 D15
~Bortezomib 1.3 mg/m2 s.c D1 D8 D15 D22
~Lenalidomide 25 mg p.o from D1 to D21
~Dexa 20 mg p.o D1 D8 D15 D22
~High dose melphalan 200mg/m2 as conditioning therapy and second ASCT Second consolidation : 6 cycles of Dara-VRd (every 2 months for 2 years) Then maintenance: Lenalidomide every 28 days (25 mg from D1 to D21) for 1 year"
16245634|NCT05054465|Experimental|Pre-transplant consolidation and post-transplant maintnance with navitoclax and venetoclax.|Patients will be treated with VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al. (doi: 10.1158/2159-8290.CD-20-1465) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging will be followed by alloSCT according to local protocol.Within 90 days from alloSCT patients will be started on VEN and NAV maintenance. For post-alloSCT maintenance a dose escalation scheme based on the BOIN design will be applied with a maximal dose of VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al.
16245635|NCT05054452|Experimental|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
16245636|NCT05054439|Experimental|SI-B001 combined with paclitaxel|Administration by intravenous infusion. SI-B001 was administered intravenously once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction is tolerable during the first administration, the subsequent administration can be completed in 60-120 min. Paclitaxel dose was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After the infusion of SI-B001, paclitaxel pretreatment and paclitaxel infusion were performed for no less than 3 hours. The 4-week cycle of the study was maintained until disease progression or cessation due to intolerable toxicity or other reasons
16245637|NCT05054426|Experimental|intravenous MTX|intravenous methotrexate at a dose of 1g/m2 for 4 courses
16245638|NCT05054426|Experimental|intrathecal MTX|intrathecal methotrexate 10mg at a time for 4 courses
16245640|NCT05054400|Other|F18 Fluciclovine|"radioactive imaging agent help researchers better see how the disease is responding to laser interstitial thermal therapy (LITT)"
16245641|NCT05054387|Experimental|Agalsidase beta|Agalsidase beta treatment at approved dose and regimen, administered once every 2 weeks as an IV infusion
16245642|NCT05054374|Experimental|Arm 1, Part 1 - mirdametinib in combination with fulvestrant|"Postmenopausal patients with estrogen receptor positive metastatic breast cancer harboring NF1 loss of function or another alteration of the MAPK pathway.
~Part 1: safety run-in (confirmation of the RP2D for mirdametinib in combination with the standard recommended dose of fulvestrant). This part may include the mirdametinib dose de-escalation according to the 3+3 design if necessary"
16245643|NCT05054374|Experimental|Arm 1, Part 2 - mirdametinib in combination with fulvestrant|"Postmenopausal patients with estrogen receptor positive metastatic breast cancer harboring NF1 loss of function or another alteration of the MAPK pathway.
~Part 2: dose expansion cohorts where the mirdametinib RP2D will be administered in combination with the standard recommended dose of fulvestrant"
16245644|NCT05054374|Experimental|Arm 2, Part 1 - mirdametinib as single agent|"Adult patients with advanced solid cancers driven by the alteration of the MAPK pathway
~Part 1: mirdametinib dose escalation to MTD or RP2D according to the 3+3 design"
16245645|NCT05054374|Experimental|Arm 2, Part 2 - mirdametinib as single agent|"Adult patients with advanced solid cancers driven by the alteration of the MAPK pathway
~Part 2: dose expansion cohorts"
16245646|NCT05054361||recent onset patients|patients with recently diagnosed type 1 diabetes
16245647|NCT05054361||at risk patients|patients with a high genetic risk type 1 diabetes
16245648|NCT05054361||control subjects|control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)
16245649|NCT05054361||control subjects for endoscopy|patients without type 1 diabetes requiring UGI endoscopy for any medical reason
16245650|NCT05054348|Experimental|IO-108 Monotherapy|increasing dose levels of IO-108
16245651|NCT05054348|Experimental|IO-108 + pembrolizumab combination therapy|increasing dose levels of IO-108 in combination with a fixed dose of pembrolizumab
16245652|NCT05054335|Experimental|Supportive care (walking function test, X-ray)|Patients undergo walking function assessment using optical motion capture and bi-plane dynamic X-ray imaging pre- and post-hemipelvectomy.
16245653|NCT05054322|No Intervention|Standard Care|Participants will be monitored via video call twice a day without any specific drugs.
16245654|NCT05054322|Experimental|Fluticasone propionate with spacer|Fluticasone propionate 125 mcg with spacer, 4 puffs, twice a day, added to standard care
16245657|NCT05054296|Active Comparator|Group I (education exercise packet, FitBit)|Patients receive general education exercise packet with instruction to exercise regularly for up to 150 minutes weekly. Patients also wear a FitBit daily over 16 weeks.
16245658|NCT05054296|Experimental|Group II (exercise program FitBit)|Patients participate in supervised and self-directed exercise sessions over 60 minutes BIW for up to 16 weeks. Patients also wear a FitBit daily over 16 weeks.
16245659|NCT05054283||Length of hospital Stay (normal)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
16245660|NCT05054283||Length of hospital Stay (prolonged)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
16245662|NCT05054244||control group|The patients in control group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires: visual analogue scale, McGill Pain questionnaire, Wound Quality of Life Index, Health Quality of Life Questionnaire, Beck depression and Beck anxiety inventory.
16245663|NCT05054244||HBOT group|"The patients in HBOT group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue.
~The HBOT sessions will be performed 5 days a week in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires as in control group."
16245664|NCT05054231|Experimental|Patient treated with CAR-T cells|
16245665|NCT05054218||Participants who receive 3rd dose of mRNA-1273 SARS-CoV-2 vaccine|Cancer patients who have already received their 1st and 2nd doses of mRNA-1273 SARS-CoV-2 vaccine will receive a 3rd dose of the vaccine. The volume of vaccine injected will be 0.5 mL, containing a 100-μg dose of mRNA-1273.
16245666|NCT05054205|Experimental|Experimental group|To the experimental group; motivational interview based self-management education was given for 30-45 minutes with groups of 5-8 people, COPD education guide was given, questions were shared with the question-answer method and group interaction was provided. After the self-management education, 3 motivational interviews were conducted 3 days apart with 30-45 minutes.The data were collected in three stages as pre-test, post-test and follow-up (after 30 day).
16245667|NCT05054205|No Intervention|Control group|Normal care was continued in the control group.
16245668|NCT05054179|Experimental|Ropivacaine Group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side during Sternotomy, followed by infusion of 3 mL/h for 48 hours.
16245669|NCT05054179|Placebo Comparator|Placebo group|The participants of this group will receive 20 mL of saline via parasternal multi-orifice catheters on each side during Sternotomy, followed by infusion of 3 mL/h for 48 hours.
16245675|NCT05054114|Experimental|Drug: Interferon Gamma|IFN-G administered for 2 10-day courses with a 1-week pause between the courses.
16245676|NCT05054114|No Intervention|Control: No intervention|Any preventive method including a variety of pharmacologic therapies against COVID-19, alongside the use of antiviral and immunomodulating agents, with the exception of drugs prescribed off-label or for research purposes, and IFN-G as well.
16245677|NCT05054101|Experimental|VieCovid2020 smartphone application|The VieCovid2020 smartphone application in add-on to usual psychiatric intervention
16245678|NCT05054101|Placebo Comparator|Usual psychiatric intervention|Usual psychiatric intervention alone
16245681|NCT05054075|Experimental|Vaccinated|Subjects that received a vaccine against COVID-19 lineage virus
16245682|NCT05054075|Experimental|Non-vaccinated|Subjects that did not receive a vaccine against COVID-19 lineage virus
16245683|NCT05054075|Experimental|Infected|Subjects that are infected with a COVID-19 lineage virus
16245684|NCT05054062|Experimental|Healthy participants|
16245685|NCT05054049|Experimental|Abbott i-stat Allinity|Randomised patients to this arm receive the application of the point of care testing device to provide further diagnostic information to assist clinical decision making.
16245686|NCT05054049|Placebo Comparator|Usual Care|Randomised patients to this arm receive usual care.
16245687|NCT05054036|Experimental|MoviPrep|"For MoviPrep, the dose, schedule, and route of administration are as follows:
~On the evening prior to the colonoscopy, mix the powder with lukewarm water to a total volume of 32 oz. Drink 8 oz. every 15 minutes until the solution is finished. Drink 16 oz. of clear liquids before bed.
~On the morning of the procedure, repeat the above steps and make sure all fluids are consumed at least 2 hours prior to colonoscopy.
~Limit food intake to a regular breakfast, light lunch and clear soup or plain yogurt for dinner on the day prior to the colonoscopy (completed at least 1 hour prior to the first MoviPrep dose.
~Consume only clear liquids from the start of MoviPrep until after the colonoscopy."
16245688|NCT05054036|Active Comparator|GoLYTELY|"For GoLYTELY, the dose, schedule, and route of administrate are as follows:
~On the evening prior to the colonoscopy, mix powder with lukewarm water to a total volume of 4 liters. Drink 2 liters of the solution and store the rest in the refrigerator.
~Drink the remaining 2 liters on the morning of the procedure.
~Limit food intake to a light breakfast on the day prior to the colonoscopy, followed by only clear liquids until the procedure is complete.
~Avoid red and purple liquids."
16245689|NCT05054023|Active Comparator|Piroxicam gel|50g tubes that contained 0.5% piroxicam. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
16245994|NCT05052164|Experimental|Gluten-free nutrition plan + exercise group|Celiac women who perform a physical exercise program 3/4 times per week and a gluten-free isocaloric dietary plan.
16245694|NCT05053997|Experimental|NAVIGATE intervention arm|Nurse navigation
16245695|NCT05053997|No Intervention|Navigate control arm|Standard treatment and care
16245696|NCT05053984|Experimental|Neuromodulation|This study has only 1 arm and the control group is their baseline data
16245697|NCT05053971|Experimental|Treatment (entinostat, ZEN003694)|"RUN-IN PHASE: Patients receive ZEN003694 PO QD or entinostat PO QW during days -14 to 1.
~PHASE 2: Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16245698|NCT05053958|No Intervention|using conventional protocol|Patients will receive a pre-operative CBCT examination. Implants will be inserted using freehand drilling protocol. The implants will be placed using flapless technique with the reference of neighboring teeth and 3D radiographic information.
16245699|NCT05053958|Active Comparator|using digital protocol|Patients will receive a pre-operative CBCT examination and optical scan of the oral tissues by intra-oral scanner. Digital Imaging and Communications in Medicine (DICOM) file from the CBCT examination and the Standard Tessellation Language (STL) file from the optical scan will be imported and merged in implant planning software. The virtual implant planning will be performed. The surgical guide and prosthesis are designed according to the virtual plan.
16245700|NCT05053932||Patients included in Drepagreffe 1 study (NCT01340404)|biological collection
16245701|NCT05053919|Experimental|SR device group|
16245702|NCT05053919|Placebo Comparator|placebo device group|
16245703|NCT05053893|Experimental|New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)|Roxadustat(FibroGen, China), 100mg (45-60kg) or 120mg (≥ 60kg) each time, three times a week, orally on an empty stomach in the morning. The initial dose of Sacubitril Valsartan Sodium Tablets(Novartis, China) is 50mg, once a day, taken on an empty stomach in the morning, and gradually titrated from the minimum dose to the maximum tolerated dose.
16245704|NCT05053893|Experimental|Traditional treatment group(EPO combined with ACEI or ARB )|Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week; Perindopril tablets (Servier, China), taken on an empty stomach, gradually titrated from the minimum dose to the maximum tolerated dose.
16245709|NCT05053854|Experimental|177Lu-DOTA-Octreotate + talazoparib|Patients will receive 4 cycles of 177Lu-DOTA-Octreotate every 8 weeks, the last 3 cycles combined with talazoparib on days 2-6 of each cycle.
16245710|NCT05053841|No Intervention|Control group|fifteen obese females who received letrozole only
16245711|NCT05053841|Active Comparator|metformin group|fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily
16245712|NCT05053841|No Intervention|lean group|fifteen non- obese breast cancer females who received letozole for six months, treatment period
16245713|NCT05053828||Non-diabetic controls on clopidogrel|Non-diabetic patients prescribed clopidogrel
16245714|NCT05053828||Diabetic patients on clopidogrel|Diabetic patients on clopidogrel
16245715|NCT05053828||Diabetic patients on antiplatelet drugs other than clopidogrel|Diabetic patients on antiplatelet drugs other than clopidogrel
16245716|NCT05053802|Experimental|Microwave ablation plus Camrelizumab|Microwave ablation plus Camrelizumab (no more than 16 cycles)
16245717|NCT05053802|Other|Microwave ablation|Microwave ablation
16245718|NCT05053789|Experimental|Group 1|After enrolment into the study and randomization to the study group (V0) and baseline examinations (V1), patients will receive 1 drop of Lacrimera at the study site and will be instructed to apply one drop of C-NAC into both eyes before bedtime for the following 5 consecutive days and return for a follow-up visit after 7±1 days (V2). Patients will complete a diary describing symptoms during the day, use of Lacrimera and potential side effects until the next visit. If the NEI grading is ≤1 OR the OSDI score <20 at the next visit, treatment with Lacrimera will be discontinued and one further physical follow-up appointment will be arranged, which will take place 28±2 days after the last physical visit.
16245719|NCT05053789|Active Comparator|Group 2|The study days are conducted in the same way as for the study group. Patients of the control group will receive preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine) for 4 times a day as control.
16245720|NCT05053763|Other|Experimental: age<65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
16245721|NCT05053763|Other|Active Comparator:age ≥65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
16245722|NCT05053750|Experimental|Paclitaxel|
16245723|NCT05053750|Experimental|Bevacizumab|
16245724|NCT05053737|Experimental|SBRT with Neoadjuvant Atezolizumab|Patients will undergo SBRT with atezolizumab neoadjuvantly followed by surgery and strictly risk-adjusted adjuvant treatment with radiation with or without chemotherapy according to national guidelines.
16246236|NCT05050487|Experimental|treatement|patient will receive lumbar paravertebral nerve block
16245725|NCT05053724|Experimental|Start to move group|In the Start to move group, physical therapy was included according to the Gosselink protocol, which establishes 6 levels of care divided according to system stability and state of consciousness. At level 0, no physical mobilization therapy was applied due to systemic lability. From level 1 to 5, passive mobilizations, use of muscle electrostimulation, active mobilizations and exercises against resistance, application of conventional cycloergometer, up to walking with assistance if the subject is able to perform it.
16245726|NCT05053724|Active Comparator|Conventional treatment group|In the conventional treatment group, passive mobilization, active-assisted mobilization and exercises against resistance, facilitation of high functional positions such as sedentary, bipedal and walking were applied, according to conventional treatment protocol.
16245733|NCT05053698||Initial gas tamponade|Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade
16245734|NCT05053698||Initial silicone oil tamponade|Primary vitrectomy and fluid-air exchange with silicone oil tamponade
16245735|NCT05053698||Relapse treated with gas tamponade|Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade
16245736|NCT05053698||Relapse treated with silicone oil tamponade|Secondary vitrectomy and fluid-air exchange with silicone oil tamponade
16245737|NCT05053685||Obstructive Sleep Apnoea (OSA)|Subjects with OSA
16245738|NCT05053685||Elevated Urine Metanephrines|Subjects with elevated metanephrines
16245739|NCT05053672|No Intervention|Conventional therapy back pain treatment|Participants randomized to сonventional therapy group will receive complex rehabilitation program including physical exercise, phonophoresis with hydrocortisone, lumbar region massage, acupuncture within 2 weeks.
16245740|NCT05053672|Active Comparator|Conventional physiotherapy therapy back pain treatment + ReOxy-therapy|Participants randomized to Active Comparator group will receive complex rehabilitation program and 10 ReOxy-therapy sessions within 2 weeks (5 sessions per week).
16245741|NCT05053672|Placebo Comparator|Conventional physiotherapy therapy + Sham ReOxy-therapy|Participants randomized to Placebo Comparator group will receive complex rehabilitation program and 10 sham ReOxy-therapy sessions within 2 weeks (5 sessions per week).
16245742|NCT05053659|Experimental|Loncastuximab tesirine & venetoclax|"Participants will receive a baseline disease assessment via PET/CT in FDG avid lymphomas; CT scan (chest, abdomen, pelvis; inclusion of neck in selected cases). Bome marrow biopsy in selected cases.
~Premedication includes:
~Allopurinol (to reduce uric acid) 300mg orally daily starting day -1 and continuing at least until day 7 of each cycle.
~Dexamethasone (steroid pre-medication) 4mg orally twice daily on day -1, day 1 and day 2 of each cycle.
~Adequate oral hydration starting on day -1 or -2, defined as 1 - 2 liters of oral intake of liquids in 24 hours
~Study treatment to be given every 21 days.
~Loncastuximab tesirine (50 - 150 μg/kg) intravenously (IV) on day 1 of each 21-day cycle
~Venetoclax (400 - 800 mg) orally, every day on days 1 - 5 of each 21-day cycle. Dose ramp-up on cycle 1 (over days 1 - 5 for target dose 400mg, 1 - 6 for target dose 600mg and 1 - 7 for target dose 800mg"
16245743|NCT05053646|Experimental|Marrow venting arm|Meniscal suture associated with marrow venting procedure
16245744|NCT05053646|Active Comparator|Control arm|Meniscal suture alone, without marrow venting procedure
16245745|NCT05053633||Combined spinal epidural anesthesia|Apply combined spinal epidural anesthesia
16245746|NCT05053620||Single arm|All patients.
16245747|NCT05053607|Other|1. Single Arm Cohort Receiving Digital Health Coaching|"All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.
~Participants have the option to participate in a one time interview about their treatment experience."
16245748|NCT05053594|Experimental|Group N10|Reversal with neostigmine 10 mcg/kg and atropine 5 mcg/kg
16245749|NCT05053594|Experimental|Group N20|Reversal with neostigmine 20 mcg/kg and atropine 10 mcg/kg
16245750|NCT05053594|Experimental|Group N30|Reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
16245751|NCT05053594|Placebo Comparator|Group P|Spontaneous reversal (placebo)
16245752|NCT05053581||Patient|
16245753|NCT05053568|Experimental|Intervention group|Live visualised, fluoroscopy-fused, image-guided, left ventricular lead placement on the basis of avoiding scar and targeting late mechanically activated segments.
16245754|NCT05053568|No Intervention|Control group|Empirical standard-of-care left ventricular lead placement, in line with current CRT implantation guidelines with electrical guiding on the basis of Q-LV sense.
16245755|NCT05053555|Experimental|Group A (Prospective cohort )|20 patients, will undergo initial diagnostic workup, staging and treatment per institutional standard of care. Intervention: High dose rate brachytherapy (HDRBT)
16245756|NCT05053555|Experimental|Group B( Retrospective chart review )|40 patients who meet same eligibility criteria, but did not receive HDRBT between 1/1/2000 and 1/1/2021.
16245757|NCT05053542||With or without enema before operation|Patients who had received pre-operative bowel preparation(PBP) were identified using electronic medical records. Patients prescribed an enema solution (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before surgery were allocated to the PBP group. Patients who received no PBP were allocated to none PBP group.
16245758|NCT05053529|Experimental|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
16245995|NCT05052164|Experimental|Gluten-free nutrition plan group|Women with celiac disease following a gluten-free isocaloric dietary plan.
16245759|NCT05053529|Experimental|Constrained induced movement therapy (CIMT)|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
16245760|NCT05053516|Other|the intervention group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
16245761|NCT05053516|Other|the control group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
16245762|NCT05053503|Placebo Comparator|Active tAN + placebo|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive a placebo pill that will appear similar to lofexidine in size, shape, color, and smell.
16245763|NCT05053503|Active Comparator|Active tAN + lofexidine|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive lofexidine based on the clinical site's standard of care.
16245764|NCT05053503|No Intervention|Sham tAN + placebo|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive a placebo pill that will appear similar to lofexidine in size, shape, color, and smell.
16245765|NCT05053503|Sham Comparator|Sham tAN + lofexidine|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive lofexidine based on the clinical site's standard of care.
16245766|NCT05053503|Active Comparator|depot naltrexone|Naltrexone treatment will be administered according to the clinical site's standard of care.
16245767|NCT05053503|Experimental|Active tAN + depot naltrexone|Participants will be provided with a Spark Sparrow Therapy System and instructed to administer therapy for a minimum of two hours a day until the Day 28 visit. Naltrexone treatment will be administered according to the clinical site's standard of care.
16245770|NCT05053477|Active Comparator|Control Group|Patients will receive median nerve perineural injection of bupivacaine with mehylprednisolone under ultrasound guidance
16245771|NCT05053477|Active Comparator|PRF Group|Patients will receive median nerve pulsed radiofrequency (PRF) and median nerve perineural injection of bupivacaine under ultrasound guidance
16245772|NCT05053477|Active Comparator|PRP Group|Patients will receive median nerve perineural injection of platelet-rich plasma (PRP) under ultrasound guidance
16245773|NCT05053451|Experimental|dlPFC/TPJ Stimulation + Rest|20 minutes of 2 mA direct current stimulation during rest.
16245774|NCT05053438|Active Comparator|Intensive Multidisciplinary Intervention (Standard Care)|Children with a history of chronic food refusal will be randomized to receive the standard of care. The standard of care for tube wean is to accomplish the balance between enteral supplementation and oral intake, the tube feeding regimen will follow the schedule of therapeutic meals (e.g., mid-day supplementation occurs after morning therapeutic meals).
16245775|NCT05053438|Experimental|Intensive Multidisciplinary Intervention (Standard Care) + Hunger provocation (Rapid Tube Wean)|"Children with a history of chronic food refusal will be randomized to receive the experimental arm that combines standard care with rapid tube wean.
~All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use regular tube wean sheet to provide credit for oral intake for remainder of admission."
16245776|NCT05053425|Experimental|Venetoclax group|"Induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7, sc.
~Consolidation therapy: Regimen A or B was chosen according to the wishes of the patients. In addition, venetoclax was used for 14 days for positive minimal residual disease(MRD) and 7 days for MRD negative.
~regimen A: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3, ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen B: the first two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; If the patient's ECOG performance status ≥2,the reduction of regimen IA(cytarabine+idarubicin)was 5+2.
~Maintenance therapy: azacytidine 75mg/m2, d1-7, sc."
16245777|NCT05053412||HCC diagnosed Stage 1 (both A and B)|200 stage 1 (A and B) HCC diagnosed patients
16245778|NCT05053412||HCC diagnosed Stage 2|150 stage 2 HCC diagnosed patients
16245779|NCT05053412||HCC diagnosed Stage 3|100 stage 3 HCC diagnosed patients
16245780|NCT05053412||HCC diagnosed Stage 4|50 stage 4 HCC diagnosed patients
16245781|NCT05053412||Control liver cancer surveillance subjects|500 patients total: 250 Subjects with liver cirrhosis, 250 subjects without liver cirrhosis
16245782|NCT05053399|Experimental|TECNIS Symfony Toric IOL|Model Series ZXT
16245783|NCT05053386|Experimental|Idarubicin|10mg idarubicin is dissolved in 5ml water for injection, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
16245784|NCT05053386|Active Comparator|Epirubicin|50mg epirubicin is dissolved in 5ml 5% glucose solution, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
16245785|NCT05053373|Experimental|Electroacupuncture Added to Pelvic Floor Muscle Training|Patients will be in a prone position. Bilateral Zhongliao (BL33) and Huiyangacupoint (BL35) will be identified and punctured by an acupuncturist. The electrodes will be placed on the needle handles, and stimulate for 30 minutes at 50 Hz with a current intensity between 1 to 5 mA. PFMT will be performed 3 sets a day (morning, around noon, and night).
16245996|NCT05052164|Active Comparator|Celiac controls group|Women with celiac disease in whom all variables are measured but no intervention is performed.
16245786|NCT05053373|Experimental|Sham Electroacupuncture Added to Pelvic Floor Muscle Training|The preparation for the patients will be the same as that for the patients who will receive EA. Whereas, instead of using real acupuncture needles, special designed placebo needles (size 0.30 × 25 mm) with the blunt-head will be used in the PFMT+sham EA group to penetrate the fixed pad to the skin surface but without skin penetration. The same procedure for deqi will be performed as in the PFMT+EA group. A special-designed cable (the intermediate wire of the cable is cut off but the appearance is normal) will be used to connect the electrodes to the electroacupuncture machine. Therefore, the electroacupuncture machine appears to work, but does not actually stimulated acupoints. The sham EA treatment will also be maintained for 30 minutes. PFMT will be performed 3 sets a day (morning, around noon, and night),
16245787|NCT05053360|Experimental|Healing Touch|Subjects in this arm get a HT session post cesarean
16245788|NCT05053360|Active Comparator|Control|Subjects in this arm get a control activity of equal duration
16245789|NCT05053347|Experimental|intervention group|
16245790|NCT05053347|Placebo Comparator|placebo group|
16245791|NCT05053334|Experimental|BP11 (Proposed biosimilar)|Subcutaneous injection of Omalizumab developed by CuraTeQ.
16245792|NCT05053334|Active Comparator|US-Xolair|Subcutaneous injection of Omalizumab licensed for use in USA
16245793|NCT05053334|Active Comparator|EU-Xolair|Subcutaneous injection of Omalizumab approved for use in Europe.
16245794|NCT05053321|Experimental|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
16245795|NCT05053308|Active Comparator|IV PCA (proportional dosage)|Breakthrough pain control by bolus based IV patient-controlled anagesia Fentanyl bolus = MME * 15%
16245796|NCT05053308|Experimental|SL-FTN (equivalent dose for PCA bolus)|Breakthrough pain control by sublingual fentanyl Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
16245797|NCT05053295|Experimental|Immuncell-LC/Nivolumab group|Patients will receive nivolumab once a day at 4-week intervals and Immuncell-LC 12 times (3 treatments once a week, followed by 5 treatments every other week, and finally 4 treatments every 4 weeks).
16245798|NCT05053282||master endurance athletes|men aged 65 to 75 with more than 150 minutes of running activity per week at least 15 years history of running
16245799|NCT05053282||elderly sedentary|men aged 65 to 75 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
16245800|NCT05053282||young endurance athletes|men aged 20 to 30 with more than 150 minutes of running activity per week at least 3 years history of running
16245801|NCT05053282||young sedentary|men aged 20 to 30 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
16245802|NCT05053269||good body weight growth|body weight growth after birth is consistent with the growth curve
16245803|NCT05053269||poor body weight growth|body weight growth after birth is inconsistent with the growth curve
16245804|NCT05053256||HFpEF|Heart failure with preserved ejection fraction
16245805|NCT05053256||HFrEF|Heart failure with reduced ejection fraction
16245806|NCT05053230|Experimental|IM@Home|Participants with head and neck tumors, thoracic tumors, gynecological tumors, or melanoma
16245807|NCT05053230|Placebo Comparator|Enhanced usual care|Participants with head and neck tumors, thoracic tumors, gynecological tumors, or melanoma
16245808|NCT05053217|Active Comparator|Patients diagnosed with fibromyalgia|
16245809|NCT05053217|Active Comparator|Patients without a diagnosis of fibromyalgia|
16245813|NCT05053191|Experimental|Nurses|MSKCC day-shift nurses (Clinical Nurse I to IV) assigned to the GI inpatient unit (MH16) at the time of study, all of whom provide initial and ongoing assessment of patients' physical, psychosocial, cultural and informational needs
16245814|NCT05053178|Experimental|Intervention group|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented.
16245815|NCT05053178|No Intervention|Control group|For the students in the control group, the standard support program given by the school administration and course instructors will be applied for clinical problems. At the end of the study, it is planned to apply mandala activities among the students in the control group
16245816|NCT05053165|Experimental|A (LB-P6)|Healthy volunteers will be administered once daily orally
16245817|NCT05053165|Experimental|B (LB-P8)|Healthy volunteers will be administered once daily orally
16245818|NCT05053165|Experimental|C (Placebo)|Healthy volunteers will be administered once daily orally
16245819|NCT05053152|Placebo Comparator|Arm I (placebo, SABR)|Patients receive placebo PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
16245820|NCT05053152|Experimental|Arm II (relugolix, SABR)|Patients receive relugolix PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
16245930|NCT05052528|Experimental|Dose level 3 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.
16245825|NCT05053126|Experimental|Lyrica 300 mg|Single Dose
16245826|NCT05053126|Experimental|Lyrica 450 mg|Single Dose
16245827|NCT05053126|Experimental|Lyrica 300mg with Oxycodone 20 mg|Single Dose
16245828|NCT05053126|Experimental|Lyrica 450 mg with Oxycodone 20 mg|Single Dose
16245829|NCT05053126|Active Comparator|Oxycodone 20 mg|Single Dose
16245830|NCT05053126|Placebo Comparator|Placebo|Single Dose
16245831|NCT05053113|Experimental|Group 1 (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls over 30-45 minutes each from a health coach weekly during month 1, twice monthly during months 2-4, and monthly during months 5-6 for a total of 12 phone calls that focus on identifying needs, practicing autonomy supportive behaviors, and the development of a mutual support plan. Participants also engage in at least one physical activity per week with their partner and monitor their own and each other's activity using a FitBit. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days. Participants also receive an electronic newsletter twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity.
16245832|NCT05053113|Active Comparator|Group 2A (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls from a health coach as in Intervention I that focus on providing support for behavioral skills, including monitoring physical activity, goal-setting, and problem-solving to overcome barriers to physical activity. Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
16245833|NCT05053113|Active Comparator|Group 2B (FitBit, newsletter, accelerometer)|Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 to share basic health education related to physical activity and provide support for engagement. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
16245834|NCT05053100||Observational (record review, blood collection)|Patients' electronic health record are reviewed for 12 months and/or undergo collection of blood at pretreatment and on days 7, 28, 90, and 180.
16245838|NCT05053074|Experimental|Group A|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) alone, then NHF (30l/min) plus 1% CO2.
16245839|NCT05053074|Experimental|Group B|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) plus 1% CO2 , then NHF (30l/min) alone.
16245840|NCT05053061|Experimental|Telerehabilitation Arm|
16245841|NCT05053048|Experimental|STD-SL-PLUS stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The control stem (STD-SL-PLUS stem) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron.
16245842|NCT05053048|Active Comparator|NT-SL-PLUS Stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The experimental stem (NT SL-PLUS) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron. The surface of the NT SL-PLUS stem was thereafter additionally treated chemically by short-acid etching with HF and mechanically by dry ice blasting in order to loosen and remove the residual alumina particles up to 96% without changing the existing surface microtopography.
16245843|NCT05053035|Experimental|AL001|AL001 every 4 weeks
16245844|NCT05053035|Placebo Comparator|Placebo|Placebo every 4 weeks
16245845|NCT05053022|Experimental|Microneedling with Skinpen Precision System|"Skinpen precision system will be used in accordance with the instructions in the IFU on the treatment area. A numbing cream will be applied at least 20-30 minutes before the Skinpen Precision system treatment is done. The affected areas will be treated at depths of up to 2.50mm. Treatment depth will be recorded for each treatment at every visit.
~Subjects will be dispensed with the Blue Lizard sunscreen and trained on proper use."
16245846|NCT05053009|Experimental|Ibuprofen sustained release|Single dose of 800 mg Brufen Retard oral premedication will be administered 1 hour before local anesthesia
16245847|NCT05053009|Placebo Comparator|Placebo|1 capsule of 500 mg of glucose oral premedication will be adminstered 1 hour before local anesthesia
16245931|NCT05052528|Experimental|Dose level 4 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.
16256004|NCT04983745|Experimental|Experimental|niraparib and dostarlimab
16245850|NCT05052983|Experimental|Nemolizumab|
16245851|NCT05052983|Placebo Comparator|Placebo|
16245852|NCT05052970|Experimental|12 mg/m ^ 2 dose group (ArmA)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2
16245853|NCT05052970|Experimental|16 mg/m ^ 2 dose group (ArmB)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2
16245854|NCT05052970|Experimental|20 mg/m ^ 2 dose group (ArmC)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2
16245855|NCT05052957|Experimental|stem cell mobilization after radiation therapy|Participants at University Hospitals-Seidman Cancer Center (UH-SCC) will receive stem cell mobilization after 6 weeks of standard of care (SOC) radiotherapy. Followed by SOC chemotherapy.
16245856|NCT05052957|Active Comparator|stem cell mobilization after surgery|Participants at the NIH Cancer Center (NIH-CC) will receive stem cell mobilization following SOC surgery prior to SOC radiotherapy. Followed by SOC chemotherapy.
16245857|NCT05052944||Cochlear implant recipients|Patients with single-sided deafness undergoing cochlear implantation
16245858|NCT05052931|Experimental|treatment group|Nab-paclitaxel combined with oxaliplatin and S-1
16245859|NCT05052918|Active Comparator|Exercise|"Patients with prediabetes undergoing a 12-week exercise program
~(1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks)"
16245860|NCT05052918|No Intervention|Control|Patients with prediabetes with no intervention
16245861|NCT05052918|No Intervention|Metformin|Patients with prediabetes using metformin
16245862|NCT05052905|Experimental|Study|Exercises
16245863|NCT05052892||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
16245864|NCT05052892||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
16245865|NCT05052879|Experimental|TORONTO 20 + 30/60|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:
~1 tablet of Toronto association, oral;
~1 tablet of tadalafil placebo, oral."
16245866|NCT05052879|Active Comparator|TADALAFIL|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:
~1 tablet of tadalafil , oral;
~1 tablet of Toronto association placebo, oral."
16245867|NCT05052866|Experimental|Robot Intervetnion|Participants in this Arm will interact with Ryan Companionbot.
16245868|NCT05052853|Experimental|NMDAE|An NMDA enhancer
16245869|NCT05052853|Placebo Comparator|Placebo|Placebo
16245870|NCT05052840|Experimental|Muscle endurance training (MET)|
16245871|NCT05052840|Active Comparator|Conventional Treatment|
16245872|NCT05052827|Active Comparator|Children|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
16245873|NCT05052827|Active Comparator|Adolescent Females|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
16245874|NCT05052827|Active Comparator|Adolescent Males|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
16245875|NCT05052814|Experimental|Calcium hydroxide ( Ca(OH)2 )|Root canal medicament which was placed into root canals with a lentulo spiral.
16245876|NCT05052814|Experimental|Chlorhexidine gel (CHX gel)|Root canal medicament which was placed into root canals with a lentulo spiral.
16245877|NCT05052814|Experimental|Calcium hydroxide+ CHX gel|Root canal medicament which was placed into root canals with a lentulo spiral.
16245880|NCT05052788||Case group|40 patients according to inclusion criteria .
16245881|NCT05052788||Control group|20 normal people with no history of previous brain insult and with free neurological examination .
16245882|NCT05052775|Active Comparator|Chlorhexidine Group|These patients were control group given chlorhexidine mouthwash 2 times per day for 15 days
16245883|NCT05052775|Experimental|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
16245884|NCT05052775|Experimental|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
16245885|NCT05052762|Experimental|Group A: Elastic resisted training for Gluteus Maximus strength.|bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped and weight-bearing hip extension are added.
16245886|NCT05052762|Experimental|Group B: Weight resisted training for Gluteus Maximus strength|Prone hip extension with knee flexion against weighted resistance
16245887|NCT05052749|Experimental|High Intensity Resistance Training (HIRT)|In this HIRT group, participants will perform warm-up activity for 15 minutes then high intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
16245888|NCT05052749|Active Comparator|Low-moderate Resistance Exercise Training|In this low-moderate resistance training group, participants will perform warm-up activity for 15 minutes then low-moderate intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
16245891|NCT05052723|Experimental|Cabozantinib and pembrolizumab|
16245893|NCT05052697|Experimental|mIRV A strain, 3.75 micrograms (ug) dose|
16245894|NCT05052697|Experimental|mIRV A strain, 7.5ug dose|
16245895|NCT05052697|Experimental|mIRV A strain, 15ug dose|
16245896|NCT05052697|Experimental|mIRV A strain, 30ug dose|
16245897|NCT05052697|Experimental|mIRV B strain, 3.75ug dose|
16245898|NCT05052697|Experimental|mIRV B strain, 7.5ug dose|
16245899|NCT05052697|Experimental|mIRV B strain, 15ug dose|
16245900|NCT05052697|Experimental|mIRV B strain, 30ug dose|
16245901|NCT05052697|Experimental|bIRV 15ug + 15ug dose|
16245902|NCT05052697|Experimental|bIRV 7.5ug + 7.5ug dose|
16245903|NCT05052697|Experimental|bIRV 7.5ug + 15ug dose|
16245904|NCT05052697|Experimental|bIRV 3.75ug + 15ug dose|
16245905|NCT05052697|Active Comparator|QIV|
16245906|NCT05052697|Experimental|qIRV|
16245907|NCT05052684|Experimental|Leaflex™ Performer|
16245910|NCT05052645|No Intervention|Standard of Care Group|Subjects will receive standard of care neuropathic pain treatment without acupuncture.
16245911|NCT05052645|Experimental|Acupuncture Treatment Group|Subjects will receive acupuncture treatment in addition to to the standard of care neuropathic pain treatment.
16245912|NCT05052619|Experimental|Preventive use of advanced antibiotics group|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
16245913|NCT05052619|Other|Routine group|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
16245914|NCT05052593|Experimental|Compressive myofascial release|". patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. with pressure directed from distal to proximal.
~Conventional treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)"
16245915|NCT05052593|Active Comparator|Conventional treatment|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
16245916|NCT05052580|Other|COVID-19 Exposure Testing|
16245917|NCT05052567|Experimental|CEND-1|CEND-1+paclitaxel (albumin-bound type)+gemcitabine
16245918|NCT05052554|Experimental|30 µg cohort|Open label single dose cohort: Dose level 1
16245919|NCT05052554|Experimental|60 µg cohort|Open label single dose cohort: Dose level 2
16245920|NCT05052541|Experimental|Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
16245921|NCT05052541|Experimental|Analgesia Arm: THC, then Placebo, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
16245922|NCT05052541|Experimental|Analgesia Arm: THC/CBD, then THC, then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
16245923|NCT05052541|Experimental|Analgesia Arm: THC/CBD, then Placebo, then THC|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
16245924|NCT05052541|Experimental|Analgesia Arm: Placebo, then THC, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
16245925|NCT05052541|Experimental|Analgesia Arm: Placebo, then THC/CBD, then THC|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
16245926|NCT05052541|Experimental|Reduction Arm: THC/CBD|Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
16245927|NCT05052541|Placebo Comparator|Reduction Arm: Placebo|Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
16245928|NCT05052528|Experimental|Dose level 1 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
16245929|NCT05052528|Experimental|Dose level 2 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
16245932|NCT05052528|Experimental|Dose level 5 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
16245933|NCT05052528|Experimental|Dose level 6 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
16245934|NCT05052515|Placebo Comparator|Placebo|Oral treatment Two tablets twice a day for one year
16245935|NCT05052515|Experimental|Nutritional Supplementation|Oral treatment Two tablets twice a day for one year
16245936|NCT05052502|Experimental|reactive focal mass drug administration (rfMDA)|Reactive FMDA (rfMDA) led by VMVs in response to cases in study area sub-district, in both villages and forest workers; quantitative G6PD testing for all individuals and 14-day PQ for G6PD non-deficient.
16245937|NCT05052502|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMVs; village-based RACD conducted by district staff in some areas.
16245938|NCT05052476|Experimental|Open label Bactecal® D Liquid 1 dose|Patients will receive 1 dose of Bactecal® D Liquid by day which corresponds to 2 ml of product
16245939|NCT05052476|Experimental|Open label Bactecal® D Liquid 2 doses|Patients will receive 2 doses of Bactecal® D Liquid by day which correspond to 4 ml of product.
16245940|NCT05052463||sodium (hypo-hyper-normonatremia)|
16245941|NCT05052463||potassium (hypo-hyper-normokalemia)|
16245942|NCT05052463||calcium (hyper-hypo-normocalcemia)|
16245943|NCT05052463||magnesium (hyper-hypo-normocalcemia)|
16245944|NCT05052463||phosphor (hypo-hyper-normophosphatemia)|
16245945|NCT05052450||Dementia with Alzheimer|Patients previously diagnosed with Alzheimer disease would be included
16245946|NCT05052450||Dementia with Lewy Body Dementia|Patients previously diagnosed with Lewy Body Dementia would be included
16245947|NCT05052450||Dementia with Fronto-Temporal Dementia|Patients previously diagnosed with Fronto-Temporal Dementia would be included
16245948|NCT05052450||Dementia with Vascular Disease|Patients previously diagnosed with Dementia with Vascular Disease would be included
16245949|NCT05052450||Dementia with Parkinson Disease|Patients previously diagnosed with Dementia with Parkinson Disease would be included
16245950|NCT05052437|Experimental|Utidelone|
16245951|NCT05052437|Experimental|Utidelone plus capecitabine|
16245952|NCT05052424||Children with MIS-C|"Children (age <18 years) hospitalized in the Children´s University Hospital of Cologne diagnosed with MIS-C (WHO criteria)
~Assessment of clinical data
~Blood samples are taken before therapy and on days 1,2,5,7 und 9.
~RNA and protein expression of cytokines and immune cell-related markers will be determined via multiplex ELISA, FACS, quantitative PCR, RNAseq, and Western blot."
16245953|NCT05052411|Experimental|Expanded beta testing of the JomPrEP app|App usage assessments and analytics over a 3-month period.
16245954|NCT05052398|Experimental|Part 1: PSP NEURO SERUM|The first part, will consist of a single arm in which all patients will receive PSP NEURO SERUM in their hands three times a day for 28 days. Each application will consist of 1 g of PSP NEURO SERUM.
16245955|NCT05052385||ECP only (aGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
16245956|NCT05052385||ECP and Ruxolitinib (aGVHD patients)|Patients treated with ECP and Ruxolitinib
16245957|NCT05052385||Ruxolitinib only (aGVHD patients)|Patients treated with Ruxolitinib and other Standard Of Care treatments (SOC)
16245958|NCT05052385||ECP only (cGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
16245959|NCT05052385||ECP and treatment combination (cGVHD patients)|Patients treated with ECP and Ruxolitinib or Ibrutinib
16245960|NCT05052385||Treatment combination only (cGVHD patients)|Patients treated with Ibrutinib and/or Ruxolitinib and other Standard Of Care treatments (SOC)
16245961|NCT05052333||Examining the psychosocial impacts of Covid-19 in Pakistan.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Urdu-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245962|NCT05052333||Examining the psychosocial impacts of Covid-19 in Iraq.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Arabic-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245963|NCT05052333||Examining the psychosocial impacts of Covid-19 in Turkey.|This is exploratory research and data will be obtained on a set of measures (N=500) using a unilingual (Turkish) survey with longitudinal assessment after 12 months of the initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245964|NCT05052333||Examining the psychosocial impacts of Covid-19 in USA.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245965|NCT05052333||Examining the psychosocial impacts of Covid-19 in Bangladesh.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Bangla) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245966|NCT05052333||Examining the psychosocial impacts of Covid-19 in Malaysia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Malay-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245967|NCT05052333||Examining the psychosocial impacts of Covid-19 in Indonesia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Indonesian) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16245968|NCT05052333||Examining the psychosocial impacts of Covid-19 in Somalia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Somalia-English) survey with longitudinal assessment after 12 months of the initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
16257294|NCT04974983||A|Treatment without bevacizumab
16245969|NCT05052307||Fully vaccinated with BNT162b2 COVID-19 vaccine|Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
16245970|NCT05052307||Ever vaccinated with BNT162b2 COVID-19 vaccine|defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
16245971|NCT05052307||Partially vaccinated with BNT162b2 COVID-19 vaccine|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
16245972|NCT05052307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
16245973|NCT05052307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
16245974|NCT05052281|Experimental|Intervention group|"The first MB course session and technology training will take place in-person, prior to 23 weeks gestation. The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress. Sessions are delivered 1-on-1 with a trained facilitator and are based on principles of cognitive-behavioral therapy (CBT) and attachment theory. The MB course is divided into 3 sections: 1) Pleasant Activities; 2) Thoughts; 3) Contact with Others. Throughout each module, mindfulness skills training will be integrated as a strategy to help center participants. All participants will receive a Participant Manual for Families, containing worksheets that correspond to the 12 sessions."
16245975|NCT05052281|Active Comparator|Stress monitoring (control) group|This group will not receive any additional intervention but will engage in stress monitoring via biosensors and EMA text messages through the 14 week period
16245976|NCT05052268|Experimental|Phase 1 XTX202 Dose Escalation|Phase 1 Dose Escalation of XTX202 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
16245977|NCT05052268|Experimental|Phase 2 XTX202 Dose Expansion|"Part 2A will enroll patients with metastatic renal cell carcinoma who have progressed following standard-of-care treatment.
~Part 2B will enroll patients with melanoma who have progressed following standard-of-care treatment."
16245978|NCT05052255|Experimental|Part 1: Dose Escalation / Part 2: Cohort Expansion|"Part 1-Dose Escalation: Escalating doses of RVU120, in patients who have progressed from previous therapy.
~Part 2-Cohort Expansion: Recommended dose in patients with tumor types selected from part 1."
16245979|NCT05052242||one group compared two measurement methods|one group compared two measurement methods
16245980|NCT05052229|Placebo Comparator|Placebo|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquide Healthcare, Montreal, Quebec, Canada).
16245981|NCT05052229|Active Comparator|Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; DIN 02451328).
16245984|NCT05052190|Active Comparator|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
16245985|NCT05052190|Active Comparator|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text with no link to schedule an appointment.
16245986|NCT05052190|Active Comparator|Text Message R/R with Direct Appointment Schedule Link + text Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
16245987|NCT05052190|Active Comparator|Text Message R/R without Direct Appointment Schedule Link + Text Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
16245988|NCT05052190|Active Comparator|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
16245989|NCT05052190|Active Comparator|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
16245990|NCT05052190|Active Comparator|Portal Message R/R with Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
16245991|NCT05052190|Active Comparator|Portal Message R/R without Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
16245992|NCT05052190|No Intervention|No R/R Message or Pre-Appointment Reminder|Participants do not receive any flu vaccine R/R message or Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment during the specified flu season.
16245993|NCT05052177||Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk|"inclusion criteria:
~> 18-years-old
~Right systemic ventricle
~Severe tricuspid regurgitation
~Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy
~High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and thus having underwent a percutaneous treatment of tricuspid regurgitation
~exclusion criteria - pregnant ou breastfeeding women"
16245997|NCT05052164|No Intervention|Non-celiac controls group|Non celiac menopausal or post-menopausal in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
16245998|NCT05052151|Active Comparator|Low temperature|Dialysate temperature
16245999|NCT05052151|Active Comparator|High temperature|Dialysate temperature
16246000|NCT05052151|Active Comparator|Low bicarbonate|Dialysate bicarbonate concentration
16246001|NCT05052151|Active Comparator|High bicarbonate|Dialysate bicarbonate concentration
16246002|NCT05052138|Experimental|Tactile massage 1|Tactile massage 1 will receive one 15-min tactile massages (hand massage) per week for 6 weeks
16246003|NCT05052138|Experimental|Tactile massage 2|Tactile massage 2 will receive five 15-min tactile massages(hand massage) per week for 6 weeks
16246004|NCT05052138|No Intervention|comparison group|The comparison group will receive regular care and activities.
16246005|NCT05052125|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94% Intervention: Drug: Oxygen gas
16246006|NCT05052125|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas
16246007|NCT05052112|Active Comparator|E-PR-01 200mg|Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to 7 days
16246008|NCT05052112|Placebo Comparator|E-PR-02 200mg|Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to7 days
16246009|NCT05052099|Experimental|mFOLFOX6 combined with Atezolizumab and Bevacizumab|"Patients will receive mFOLFOX6 combined with Atezolizumab 840 mg and Bevacizumab 10 mg/kg in 14-day cycles.
~Treatment will be continued until disease progression, unacceptable toxicity or voluntary withdrawal."
16246010|NCT05052086|Experimental|Magnetomotoric ultrasound|Magnetomotoric ultrasound in addition to MRI.
16246011|NCT05052073||MD patients|"patients with different forms of muscle dystrophy, for example
~facioscapulohumeral dystrophy
~dysferlinopathy
~caveolinopathy"
16246012|NCT05052073||Controls|- healthy age- and sex-matched controls (10 men, 10 women)
16246015|NCT05052047|Experimental|Brisk Walking Group|
16246016|NCT05052047|Active Comparator|Conventional Breathing Exercise Group|
16246017|NCT05052034||BAROQUE MUSIC|This group would listen to baroque music to control their anxiety level during their oral surgeries.
16246018|NCT05052034||CLASSICISM MUSIC|this group would listen to classical music to control their anxiety level during their oral surgeries.
16246019|NCT05052034||CONTROL GROUP|This group would not listen to music during their oral intervention, acting as a control group.
16246020|NCT05052021||Perioperative or Recent Covid19 Infection|"Patients will be classified as having Perioperative Covid19 Infection if they test positive for SARS-CoV-2 within 7 days before and 30 days after surgery.
~Patients will be classified as having Recent Covid19 infection if they tested positive for Covid19 within 1-6 weeks before surgery.
~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
16246021|NCT05052021||No or Previous Covid19 Infection|"Patients will be classified as having No Covid19 Infection if they have never tested positive for Covid19.
~Patients will be classified as having Previous Covid19 Infection when they tested positive for Covid19 infection 7 weeks or more before surgery.
~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
16246024|NCT05051982|Experimental|Study Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the study group, the monitor will be in full view of the anesthesiologist administering the anesthetic.
16246025|NCT05051982|No Intervention|Control Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the control group, an apparatus will be placed over the monitor will not be in view of the anesthesiologist. The
16246026|NCT05051969|Experimental|Remote Mindfulness-Based Stress Reduction Program|Mindfulness- Based Stress Reduction classes
16246027|NCT05051956||CDK4/6 inhibitors|The patient who is started on one of the CDK 4/6 inhibitors (palbociclib 125 mg 3 weeks on 1 week off) or ribociclib 600 mg 3 weeks on 1 week off) will be followed up for adverse events.
16246033|NCT05051891|Experimental|the experimental group|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
16246034|NCT05051891|Experimental|The control group|R-CHOP
16246035|NCT05051878|Experimental|articulating paper occlusal adjustment|occlusal adjustments of implant supported prosthesis according to articulating paper occlusal analysis
16246237|NCT05050474|Experimental|V-01 COVID-19 Vaccine|One dose administrated by intramuscular injection
16246036|NCT05051878|Experimental|T-scan occlusal analysis|occlusal adjustments of implant supported prosthesis according to T-scan occlusal analysis
16246037|NCT05051865|Experimental|Camrelizumab Combined With SHR1020|Camrelizumab combined with SHR1020 for advanced melanoma.
16246038|NCT05051852||Women with low-grade squamous intraepithelial lesion (LSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as low-grade squamous intraepithelial lesion (LSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
16246039|NCT05051839|Experimental|Radiographic bone level|
16246040|NCT05051839|Experimental|Peri implant soft tissue volume|
16246041|NCT05051826|Experimental|1.Drag Umbrella 2. Hand Resistance 3.Resistance Suit|"In the water, a small umbrella is attached to the athlete to increase resistance.
~In the water, increase resistance by increasing the area of the hand.
~In the water, use swim shorts that increase resistance"
16246042|NCT05051826|Experimental|1 Resistance 2 Bands Swiss Ball 3 Medicine Ball 4 Pulley Pull|"On land, use a stretch rope to increase resistance.
~On land, inflatable bouncy balls are used to increase strength.
~On land, solid balls are used to increase strength.
~On land, pulleys are used to increase resistance."
16246043|NCT05051800|Experimental|Early Intervention|Families will receive the online program to support coping and communication near the time of a child's cancer diagnosis
16246044|NCT05051800|Active Comparator|Delayed Intervention|Families will receive the online program to support coping and communication approximately 6 months after a child's cancer diagnosis
16246045|NCT05051787|Experimental|Breastfeeding women|Mothers over 18, treated with amoxicillin alone or associated with clavulanic acid for at least 2 days, breastfeeding their child.
16246046|NCT05051774|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the 12 weeks intervention consists of three monthly group education and center-based group exercise followed by 20 minutes of individualized telephone follow-up at weeks 3, 7, and 11.
16246047|NCT05051774|No Intervention|Control Group|The control group will receive the usual care provided in the study hospital included an unstructured health education conducted by a nurse on healthy lifestyle and health assessment and brief unstructured health education on their conditions, focusing on the risk factors management and stress management by the cardiologist.
16246048|NCT05051761|Experimental|Jaktinib 50mg BID|Jaktinib administered orally. Placebo administered orally to maintain the blind.
16246049|NCT05051761|Experimental|Jaktinib 75mg BID|Jaktinib administered orally. Placebo administered orally to maintain the blind.
16246050|NCT05051761|Placebo Comparator|placebo|Placebo administered orally.
16246051|NCT05051748|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
16246052|NCT05051748|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA).
16246053|NCT05051748|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
16246054|NCT05051748|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
16246055|NCT05051748|Active Comparator|In-office bleaching + Remineralization|n-office bleaching was applied followed by MI-Paste Plus®
16246056|NCT05051748|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
16246057|NCT05051748|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by in-office bleaching and lastly MI-Paste Plus®
16246058|NCT05051748|No Intervention|Control|no treatment (control).
16246061|NCT05051722||Cohort 1 - AUB / PMB|Women ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
16246062|NCT05051722||Cohort 2 - Biopsy-provend EC or AEH or EIN|Women ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
16246063|NCT05051722||Cohort 3 - Cervix pathology|Women ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
16246064|NCT05051722||Cohort 4 - Benign Uterine Pathology|Women with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All women enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
16246065|NCT05051722||Cohort 5 - Healthy Control Women|Healthy women ≥45 years of age presenting for well-woman exams to serve as a control group. These women will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These women will not have known or clinically-suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
16246066|NCT05051709|Active Comparator|Foot with no fusion|
16246067|NCT05051709|Active Comparator|Foot with fusion|
16246129|NCT05051306|Experimental|High-load resistance exercise|4 high-load resistance exercises that target all major muscle groups.
16246130|NCT05051306|Experimental|Low-load resistance exercise|4 low-load resistance exercises that target all major muscle groups.
16246131|NCT05051306|No Intervention|Sedentary control|Subjects in control trial stayed sedentary during the period.
16246068|NCT05051696|Experimental|Oncorine (H101) with or without radiotherapy|The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.
16246069|NCT05051683|Active Comparator|group (1)|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer
16246070|NCT05051683|No Intervention|group (2)|surgical management of acute perforated peptic ulcer
16246071|NCT05051670|Experimental|SP group|patients group underwent gastrectomy using da vinci SP
16246072|NCT05051657|Experimental|PKU express pus|PKU express plus to be transitioned onto over a maximum of 6 weeks and then incorporated into each participants usual diet for 28 days. Amount taken and frequency to be determined by dietitian.
16246075|NCT05051631|Experimental|Intervention plus 12 months maintenance|Clinics in this group will be in the control phase for 2 months, receive the 4 month intervention, and be in the maintenance phase for 12 months.
16246076|NCT05051631|Experimental|Intervention plus 10 months maintenance|Clinics in this group will be in the control phase for 4 months, receive the 4 month intervention, and be in the maintenance phase for 10 months.
16246077|NCT05051631|Experimental|Intervention plus 8 months maintenance|Clinics in this group will be in the control phase for 6 months, receive the 4 month intervention, and be in the maintenance phase for 8 months.
16246078|NCT05051631|Experimental|Intervention plus 6 months maintenance|Clinics in this group will be in the control phase for 8 months, receive the 4 month intervention, and be in the maintenance phase for 6 months.
16246079|NCT05051631|Experimental|Intervention plus 4 months maintenance|Clinics in this group will be in the control phase for 10 months, receive the 4 month intervention, and be in the maintenance phase for 4 months.
16246080|NCT05051618|Experimental|POWER-MS|The POWER-MS condition will deliver the Guidelines for Exercise in MS (GEMS) program with a remotely coached/guided, home-based setting using telerehabilitation. GEMS recommends 30 minutes of moderate intensity aerobic activity, 3x/week AND strength training exercises for major muscle groups, 3x/week.
16246081|NCT05051618|Active Comparator|FLEX-MS|The FLEX-MS condition will primarily focus on flexibility as the applicable exercise modality. As such, the program will emphasize that flexibility is an important component of fitness. The goal would be for each participant to enhance their flexibility by engaging in a titrated exercise prescription where the number of sets and time to hold per set will increase throughout the 16-week program.
16246082|NCT05051605||Vaccinated group|Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.
16246093|NCT05051553|Experimental|Treatment 1A|
16246094|NCT05051553|Experimental|Treatment 1B|
16246095|NCT05051553|Experimental|Treatment 2A|
16246096|NCT05051553|Experimental|Treatment 2B|
16246097|NCT05051553|Experimental|Treatment 2C|
16246098|NCT05051540|Experimental|Inelastic Compression System Group|Participants in this group will receive the inelastic compression wrap for daily use on their legs for 6 consecutive weeks.
16246100|NCT05051514||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
16246101|NCT05051514||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
16246102|NCT05051514||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour.
16246103|NCT05051501|Experimental|Probiotics C2P/Placebo|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
16246104|NCT05051501|Experimental|Placebo/Probiotics C2P|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
16246132|NCT05051293||male cirrhotic with hypotension|
16246133|NCT05051293||male cirrhotic without hypotension|
16246134|NCT05051280|Experimental|CBCT guidance group|Left atrial appendage occlusion under cone-beam computed tomography fusion image guidance
16246105|NCT05051475|Active Comparator|radiofrequency ablation|Circumferential ablation with radiofrequency ablation will be performed for each segment of the BE starting from the proximal end with one ablation at 12J/cm2, followed by cleaning of mucosal slough with esophageal cap, patient extubation, cleaning of ablation device with wet gauze, and finally a second ablation at 12 J/cm2 (1 × 12J/cm2-clean-1 × 12 J/cm2). Focal ablations will be performed with three consecutive ablations at 12 J/cm2 without cleaning (simplified protocol).
16246106|NCT05051475|Active Comparator|hybrid argon plasma coagulation|Patients in the Hybrid argon plasma coagulation group will be treated with a single ablation per session with a power limitation of 60 W (pulsed mode (VIO® 300 D & APC 2, PULSED APC®, Effect 2). No scraping with the endoscope cap and second ablation will be performed.
16246107|NCT05051462|Experimental|Intervention group|Study participants participating in family constellation therapy between assessment 1 and 2.
16246108|NCT05051462|No Intervention|Wait-list control group|Study participants participating in family constellation therapy only after all 3 assessment points.
16246109|NCT05051449|Experimental|Ketamine|
16246110|NCT05051436|Experimental|Mirabegron (M)|Drug will be administered for 12 weeks after baseline procedures.
16246111|NCT05051436|Experimental|Tadalafil (T)|Drug will be administered for 12 weeks after baseline procedures.
16246112|NCT05051436|Experimental|Mirabegron and Tadalafil (MT)|Both drugs will be administered for 12 weeks after baseline procedures.
16246113|NCT05051436|Placebo Comparator|Placebo (P)|
16246114|NCT05051423||Patients diagnosed with primary gastric tumors referred to our department for EUS local staging.|"Patients will be included or excluded according to the following criteria used throughout the study:
~Inclusion criteria: Patients diagnosed with primary gastric tumors referred for local staging by EUS (n=40); Age 18 to 90 years old, men or women; Signed informed consent for EUS with contrast-enhancement and tissue sampling
~Exclusion criteria: Prior treatment with chemo-radiotherapy; Failure to provide informed consent; severe coagulopathy.
~Data collected for each participant will include: Personal data (name, surname, age, sex); results from previous investigations (blood count, liver and renal function tests, tumoral markers, gastroscopy, computed tomography), EUS variables (including CEH-EUS), histological and immunohistochemical findings, TNM and pTNM status (if possible), molecular analysis findings."
16246115|NCT05051410|No Intervention|control|single visit root canal treatment will be performed with no additional irrigation.
16246116|NCT05051410|Experimental|intracanal cryotherapy with needle irrigation|single visit root canal treatment will be performed with additional irrigation with cold saline using needle irrigation.
16246117|NCT05051410|Experimental|intracanal cryotherapy using Endovac system|single visit root canal treatment will be performed with additional irrigation with cold saline using EndoVac system.
16246118|NCT05051397|Experimental|HYPERCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=50mmHg will be targeted
16246119|NCT05051397|Active Comparator|NORMOCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=40mmHg will be targeted
16246120|NCT05051384|Experimental|Intraocular tumor|New sonographic software technique on ultrasonography to detect low-vascular flow inside intraocular tumors
16246121|NCT05051358||Subjects undergoing Therapeutic Endoscopic Ultrasound|"Procedures that will be captured include:
~EUS- ERCP, Endoscopic Hepatology - EUS, EUS-Coils placement, EUS Glue injection, EUS-Fiducial placement, EUS-Neurolysis, EUS-Stent placement, EUS-alcohol injection, EUS-guided Ablation, EUS-guided anastomosis, EUS Guided ERCP for gallbladder, pancreatic duct or biliary duct drainage, EUS guided - Hemostasis, EUS guided- Therapy for cancer or premalignant lesion (Injection, neurolysis, fiducial, aspiration, RFA ), EUS - Fluid Collection, abscess or cavity drainage, EUS - Guided Ductal Drainage, EUS - Guided Anastomosis"
16246122|NCT05051345|Experimental|Goal 1 (Wellness app)|Participants download and use the Wellness app onto their smartphones. Participants also receive information on the services provided for pregnant women and smoking cessation.
16246123|NCT05051345|Experimental|Goal 2 (counseling, Wellness app, self-help)|Participants receive telephone counseling sessions over 30-45 minutes for a minimum of 6 sessions in the prenatal period and about 4-6 postpartum period. Participants who start counseling after birth, may receive 6-8 sessions up to 4 months postpartum. Participants may also use the Pregnancy and Wellness smartphone app that provides wellness messages, smoking cessation information, relapse prevention tips, and tips to create a smoke-free home. Participants also receive tobacco cessation self-help materials including National Partnership for Smoke Free Families and Forever Free Baby and Me.
16246124|NCT05051345|Experimental|Goal 3 (Smoke-free Homes)|Participants receive the Smoke-Free Homes kit providing guidance for how to talk with household members and visitors about not smoking inside the home. Participants may also receive 3 separate Smoke-Free Homes mailings over 6 weeks, and a coaching call from a Baby Steps for Health counselor to help follow the steps described in the mailed materials in order to set up a smoke-free home.
16246125|NCT05051345|Experimental|Goal 4 (counseling)|Non-pregnant participants receive telephone counseling sessions over 30 minutes for 6-8 sessions over a 3 month period.
16246126|NCT05051332|Experimental|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
16246127|NCT05051332|Active Comparator|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.
16246128|NCT05051319||Elderly participants living at home|Participants over the age of 65, living at home, not having mental and communication problems that would prevent the evaluations, and volunteering to participate in the study. The sociodemographic information of the participants such as gender, duration of education, living environment and people with whom they live were recorded. In addition, information about the medical condition of geriatric individuals, such as body mass indexes and the number of drugs used, was also recorded in the form. In order to evaluate the cognitive status of the participants, the Standardized or Standardized Mini-Mental Test for the Uneducated was used according to their educational status. The Center for Disease Control Health-Related Quality of Life-4 Scale (CDC HRQoL-4) was used to assess quality of life, and the Geriatric Depression Scale was used to assess emotional status. In addition, the presence of pain and pain levels according to body regions were determined with a 6-point Likert-type scale.
16246232|NCT05050513||control group|kident graft preserved in standard condition (without M101)
16246135|NCT05051267|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, when the baby starts to cry, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
16246136|NCT05051267|Experimental|Mothers Embrace|A mothers embrace is one of the earliest and most common care events that mothers offer to their babies. Close physical contact between mother and baby during hugs can reduce stress by facilitating co-regulation of mother and baby. In a study conducted in Turkey, it was stated that holding the baby on the lap for pain relief in painful interventions is a practical and easy method.
16246137|NCT05051267|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb (Balci, 2006). It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvery Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies (Karp, 2015). In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position (Karakoç, & Türker, 2014).
16246138|NCT05051267|Experimental|Mother's Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks (Eskandari, Keshavarz, & Jahdi, 2010). Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks (Djordjevic, 2010 ). The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it (Arabin, 2002). It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements (Campbell-Yeo, Fernandes, & Johnston, 2011).
16246139|NCT05051267|Experimental|Mothers Embrace and White Noise Applied Group|One minute after the procedure, the baby's pain score will be evaluated. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the white noise will continue to be listened to. The crying time of the baby after the procedure will be noted. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to pre-procedural basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
16246140|NCT05051267|Experimental|Mothers Embrace and Mother's Voice Group|After the procedure, the baby will continue to listen to the baby who is in the mother's arms. One minute after the procedure, the baby's pain score will be evaluated and the HR and O2 values will be noted. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the mother's voice will continue to be listened to. The crying time of the baby after the procedure will be noted. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
16246141|NCT05051254|Experimental|Respiratory muscle impairment|Minor patients with primary or secondary impairment of respiratory muscles and followed at Necker Hospital
16246142|NCT05051241|Experimental|GFH018|"The duration of the first cycle is 31 days and the subsequent periods are 28 days.
~Subjects will receive treatment with GFH018 until disease progression (clinically- or radiologically-confirmed), occurrence of intolerable toxicity, or subjects discontinue from the study treatment for other reasons."
16246143|NCT05051228||GEAR cohort|This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.
16246144|NCT05051215||Control group|40 healthy volunteers were included in the healthy control group
16246145|NCT05051215||NPM group|60 patients of NPM (30 PCM and 30 GM)were included
16246146|NCT05051202|Experimental|25g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 25 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
16246147|NCT05051202|Active Comparator|25g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 25 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
16246148|NCT05051202|Experimental|35g Sugars From Fiber per day|Administered in 50 g Flapjack containing 35 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
16246149|NCT05051202|Active Comparator|35g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 35 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
16246150|NCT05051202|Experimental|45g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 45 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
16246151|NCT05051202|Active Comparator|45g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 45 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
16246152|NCT05051189|Active Comparator|Patients with sleep apnea having oxygen Saturation >85%|Children with OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
16246153|NCT05051189|Active Comparator|Patients with sleep apnea having oxygen Saturation <85%|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
16246154|NCT05051163|Experimental|Ceftriaxone|Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily
16246155|NCT05051163|Active Comparator|Ampicillin and Gentamicin|"Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly
~Gentamicin will be administered intravenously at a dose 5mg/kg once daily"
16246156|NCT05051150|Active Comparator|epinephrine 0.03 mcg|
16246157|NCT05051150|Active Comparator|epinephrine 0.05 mcg|
16246158|NCT05051150|Active Comparator|epinephrine 0.07 mcg|
16246159|NCT05051137||Infliximab initiators|Rheumatoid arthritis patients initiating infliximab after treatment with methotrexate for a minimum of 30 days.
16246160|NCT05051137||Sulfasalazine + Hydroxychloroquine initiators|Rheumatoid arthritis patients initiating sulfasalazine and hydroxychloroquine after treatment with methotrexate for a minimum of 30 days.
16246161|NCT05051124|Experimental|Sub-Aim 2.2 Participants|
16246162|NCT05051098||TherVacB Subgroup|"No interventions. The participating study centers of the EU funded project TherVacB recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort."
16246163|NCT05051085|Experimental|"Internet-delivered treatment: SpilleFri."|"All participants receive the internet-delivered therapist-assisted 8-modules treatment program SpilleFri."
16246164|NCT05051072|Other|MRI in morphological sequence, diffusion tensor and resting functional|"standard anatomical sequences T1, FLAIR (Fluid Attenuated Inversion Recovery), TOF(Time-of-flight MR angiography) , DRIVE, sequence centered on the V after injection of gadolinated contrast product as part of routine care,
~diffusion tensor sequence (DTI)"
16246167|NCT05051046|Experimental|Hypnosis|
16246168|NCT05051046|No Intervention|General anesthesia|Common practice
16246169|NCT05051033|Active Comparator|Surgical mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery.
16246170|NCT05051033|Active Comparator|Transcatheter edge-to-edge repair|In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
16246171|NCT05051020|Active Comparator|Conventional Method|Placement of peripheral venous catheter using conventional methods
16246172|NCT05051020|Experimental|VeinViewer Visualization Only|Use of a VeinViewer to visualize the most suitable target. Once the target has been identified and marked, the device will be placed aside and the peripheral venous catheter will be placed using conventional methods
16246173|NCT05051020|Experimental|Constant Imaging with VeinViewer|Identification of the most suitable target and placement of a peripheral venous catheter under constant imaging with a VeinViewer
16246174|NCT05051007|Active Comparator|fentanyl group|
16246175|NCT05051007|Active Comparator|lidocaine group|
16246176|NCT05050994|Experimental|Microwave ablation|Patients receiving microwave ablation of splenomegaly
16246177|NCT05050981||HT|Women using hormone replacement therapy (estrogen only or oestrogen and progestin) for treating climacteric symptoms.
16246178|NCT05050981||SSRI|Women using selective serotonin reuptake inhibitors for treating climacteric symptoms.
16246179|NCT05050981||Control group|Women not using hormone replacement therapy or selective serotonin reuptake inhibitors
16246180|NCT05050968|Experimental|Adapted Physical Activity Group|Patients will follow a 3-month physical activity program 3 times a week between V1 and V2. Then, between V2 and V3, no APA program will be offered to both groups.
16246181|NCT05050968|No Intervention|Control group|Patients will receive standard hospital management
16246182|NCT05050955||LungCare Surveillance (1000 Cases)|
16246183|NCT05050955||Control Group (500 Controls)|
16246186|NCT05050929|Active Comparator|20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases|Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
16246187|NCT05050929|Experimental|8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases|A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
16246191|NCT05050903||Asthma|
16246192|NCT05050903||Healthy controls|
16246193|NCT05050890||Breast cancer|Breast cancer patients who are currently receiving neoadjuvant therapy
16246194|NCT05050877||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
16246195|NCT05050864|Active Comparator|internal ventricular shunt (neurosurgery)|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
16246196|NCT05050864|Active Comparator|endovacascular stenting (interventional neuroradiology)|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid.
16246199|NCT05050812|Experimental|Grounded|All participants will sleep on a grounding mat for at least six hours per 24-hour period.
16246200|NCT05050786|Active Comparator|Standard wound dressing|
16246201|NCT05050786|Experimental|Negative Pressure Wound Therapy (NPWT)|
16246202|NCT05050773||Nicorandil group|Patients who are prescribed with Nicorandil with or without other concomitant medication
16246203|NCT05050773||Non-Nicorandil group|Patients who are prescribed with antianginal drugs except Nicorandil
16246204|NCT05050760|Experimental|The experimental group|Drug：DCF+Camrelizumab Camrelizumab:200mg/time,IV,Q3W
16246205|NCT05050747||Arm 1|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger
16246206|NCT05050747||Arm 2|Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
16246207|NCT05050747||Arm 3|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger
16246208|NCT05050734|Experimental|CBIT-E|For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
16246209|NCT05050734|No Intervention|Waitlist Control (WLC)|These participants will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. The final assessment will be approximately 11 weeks after baseline.
16246213|NCT05050656|Active Comparator|Group D (duloxetine group)|Two hours before surgery, participants received oral duloxetine 60 mg tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
16246214|NCT05050656|Placebo Comparator|Group C (control group)|Two hours before surgery, participants received oral placebo tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
16246215|NCT05050643|Active Comparator|CACP-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
16246216|NCT05050643|Active Comparator|CACP-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
16246217|NCT05050643|Active Comparator|HCMA-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
16246218|NCT05050643|Active Comparator|HCMA-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
16246219|NCT05050630|Experimental|TR2-ICE|All patients eligible for inclusion were treated with TR2-ICE, and the first efficacy evaluation was conducted after the second course of treatment. If the patient can achieve complete response (CR), partial response (PR), and disease stability (SD), the clinical benefit is considered, and the TR2-ICE treatment regimen is continued. The second efficacy assessment was performed after the 4th course of treatment. If patients achieved complete response (CR) or partial response (PR) compared to baseline, the clinical treatment was considered effective and the TR2-ICE treatment regimen was continued. After the completion of six courses of induction chemotherapy, an end-of-course assessment was performed. Patients with CR and PR can choose to undergo autologous hematopoietic stem cell transplantation consolidation therapy, or lenalidomide or Tirelarizin monotherapy or both combination maintenance therapy.
16246220|NCT05050617||Acute Pulmonary Embolism|Subjects in this single cohort will undergo point-of-care echocardiography at the time of presentation and subsequent follow up to assess for short term adverse events or complications.
16246221|NCT05050604|Experimental|Choline Alfoscerate|
16246222|NCT05050604|Placebo Comparator|Placebo of Choline Alfoscerate|
16246223|NCT05050591|Experimental|Single-Arm Study|This is a prospective trial of the clinical utility of a patient-specific silicone stent implant for patients with complex airway disease, requiring an airway stent. The aim of this study is to observe the outcomes associated with the implants. Current stents have been suboptimal for treating benign stenosis of the airway and we are seeking to create a better treatment option. We hypothesize, based on the previous compassionate-use cases, that placing a patient-specific silicone stent will effectively alleviate symptoms associated with stenosis of the airway. The main measure of effectiveness will be patient-reported outcomes.
16246224|NCT05050578|Other|LID018869, then AOHP|Lehfilcon A contact lenses worn first, followed by senofilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day over a 30-day wear period per study lens type. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
16246225|NCT05050578|Other|AOHP, then LID018869|Lehfilcon A contact lenses worn first, followed by senofilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day over a 30-day wear period per study lens type. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
16246226|NCT05050539|Active Comparator|Early Responders to Low Intensity|Early responders will include those with targeted levels of fidelity by the October assessment. They will continue to receive low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
16246227|NCT05050539|Active Comparator|Non-Responders Continue Low Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to continue receiving low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
16246228|NCT05050539|Experimental|Non-Responders Increasing to High Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to have high intensity support added (low intensity + holistic individualized facilitation, tailored educational materials).
16246229|NCT05050526|Experimental|Exercise program|Participants in the experimental group will take part in a 12-week exercise program.
16246230|NCT05050526|No Intervention|Control|Participants in the control group will not receive any intervention.
16246231|NCT05050513||interventional group|kidney graft preserved with M101
16246238|NCT05050461|Active Comparator|Cases|Patients with a history of B-NHL
16246239|NCT05050461|Other|Controls|Spouses of cases
16246240|NCT05050448|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
16246241|NCT05050448|Experimental|SAM2 Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wireless SAM Ultrasonic Diathermy Device for 1 hour at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
16246242|NCT05050448|Placebo Comparator|Topical Pain-Relief Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
16246243|NCT05050435||Early extubated (in operating room) patients after valvular cardiac surgery|
16246244|NCT05050435||Later extubated (in ICU) patients after valvular cardiac surgery|
16246245|NCT05050422|Placebo Comparator|Control|
16246246|NCT05050422|Active Comparator|Study|
16246247|NCT05050409|Experimental|Brief mindfulness followed by brief mindfulness for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive another single session of brief mindfulness. Responders will continue to receive standard of care.
16246248|NCT05050409|Experimental|Standard care followed by brief mindfulness for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive one session of brief mindfulness. Responders will continue to receive standard of care.
16246249|NCT05050409|Experimental|Brief mindfulness followed by MORE for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
16246250|NCT05050409|Experimental|Standard care followed by MORE for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
16246251|NCT05050396|Experimental|Cooled radio frequency|In CRF, water circulates inside the probe to remove heat, modulating the thermal heat in the tissue to around 60°C, and alters the overall size, shape, and projections of lesions compared to conventional RFA. It is postulated that the greater sized CRF lesions may reduce the number of technical failures in the setting of a complex and variable neuronal innervation to the knee. The ability to target a greater amount of neuronal tissue is believed to produce long-term pain relief at least to the duration of relief produced by conventional RFA [27]
16246252|NCT05050396|Experimental|Thermocoagulant radio frequency|Conventional radiofrequency Ablation RFA of the knee can be performed under fluoroscopic, or other imaging, guidance, with a cannula advanced into the joint towards the area connecting the shaft to the epicondyle. The area is stimulated to identify the nerve position and to ensure that no motor nerves are activated, as evidenced by absence of fasciculations. The RF electrode is then advanced through the cannula to the target area [18] The electrode tip heats up targeted local tissue within a few millimeters to a temperature typically greater than 47°C (ranging from 70°C to 90°C) for 120 130 seconds, generated through an electromagnetic field with a frequency of 250 kHz . [15,18] The ablative heat is provided via flow of electrical current, generating a well-delineated lesion [24]
16246253|NCT05050383|Other|Drug-Induced Sleep Endoscopy|Drug-Induced Sleep Endoscopy
16246254|NCT05050370|Experimental|Lifestyle-integrated exercise and care support|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and cancer-related information with personalized support.
16246255|NCT05050357|Active Comparator|hormonal intrauterine device arm|
16246256|NCT05050357|Active Comparator|progestin arm|
16246257|NCT05050331|Experimental|Muscle Energy Technique (MET) Group|Post-isometric relaxation was given as the form of MET. It was applied to gastrocnemius and soleus with patient supine and foot extended, knee was flexed for soleus and extended for gastrocnemius muscle. The patient ankle was dorsiflexed by the therapist until the point of discomfort or resistance, and the patient was instructed to exert pressure using 20% force for 5-7 seconds toward plantar flexion. Relaxation was given for 5 seconds and the therapist passively dorsiflex the ankle to a new barrier. Gastrocnemius and soleus both received a single set of 5 repetitions separately. Treatment was given for 4 weeks, 3 sessions per week.
16246258|NCT05050331|Experimental|Trigger Point Release Group|Trigger points of gastrocnemius muscle was released. The patient in prone lying with legs extended and the therapist in walk standing position, applied vertical downward pressure toward the trigger points for 90 seconds with the therapist's thumb. Three repetitions was given with 30 seconds relaxation time. After that, 3 longitudinal strokes in caudal to cranial direction was given by the therapist's thumb over the taut band. Treatment was provided for 4 weeks, 3 sessions per week.
16246259|NCT05050318|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to < 36 months|0.5-mL dose of Fluzone Quadrivalent vaccine single injection at Day 01. For participants for whom 2 doses of influenza vaccine are recommended as per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose will be administered at Day 28 (window, 28-35 days).
16246260|NCT05050318|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to < 9 years|0.5-mL dose of Fluzone Quadrivalent vaccine single injection at Day 01. For participants for whom 2 doses of influenza vaccine are recommended as per ACIP guidance, a second dose will be administered at Day 28 (window, 28-35 days).
16246261|NCT05050318|Experimental|Fluzone High-Dose vaccine Group 3: adults ≥ 65 years|0.7-mL dose of Fluzone High-Dose vaccine single injection at Day 01.
16246295|NCT05050110|Other|chronic kidney disease patients|Evaluation of Increased fruits and vegetables consumption in chronic kidney disease patients maintaining normokalemia with patiromer
16246296|NCT05050097|Experimental|Treatment Regimen A: Talquetamab + Carfilzomib|Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
16246297|NCT05050097|Experimental|Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib|Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
16246262|NCT05050305|Experimental|Marizomib plus pomalidomide and dexamethasone|"A safety run-in using a modified 3+3 dose de-escalation design with relapsed/refractory multiple myeloma (RRMM) cohort, expanded to a total of 16 participants once recommended phase 2 does (RP2D) has been identified.
~Marizomib (MRZ) at a pre-determined dose on Days 1, 8, 15, 22 of a 28 day study cycle
~Pomalidomide (POM) at a daily predetermined dose on Days 1-21 of a 28 day study cycle
~Dexamethasone (DEX) at a daily predetermined dose on Days 1, 2, 8, 9, 15, 16, 22, 23 of a 28 day study cycle
~Simultaneously, relapsed/refractory multiple myeloma (RRMM) with central nervous system (CNS) involvement cohort will receive an identical modified 3+3 dose de-escalation design and expanded to an efficacy-evaluable total of 30 patients once recommended phase 2 does (RP2D has been identified"
16246263|NCT05050292|Experimental|Experimental Group|An internal algorithm of the cognitive stimulation platform will adjust the activities' difficulty depending on the participant's performance, always demanding a maximum cognitive effort.
16246264|NCT05050292|Active Comparator|Control Group|The internal algorithm will be deactivated, so the cognitive stimulation activities will be of constant difficulty throughout the intervention.
16246265|NCT05050279|Placebo Comparator|Placebo|Delgocitinib placebo capsule
16246266|NCT05050279|Experimental|Active dose 1|Delgocitinib capsule (Dose 1)
16246267|NCT05050279|Experimental|Active dose 2|Delgocitinib capsule (Dose 2)
16246268|NCT05050279|Experimental|Active dose 3|Delgocitinib capsule (Dose 3)
16246269|NCT05050279|Experimental|Active dose 4|Delgocitinib capsule (Dose 4)
16246270|NCT05050266|Experimental|REP|Replicating Effective Practices (REP)
16246271|NCT05050266|Experimental|EBQI|Evidence-Based Quality Improvement (EBQI)
16246272|NCT05050253|Experimental|SOS group|Peritoneal lavage with super-oxidized solution (SOS)
16246273|NCT05050253|Active Comparator|Control group|Peritoneal lavage with Ringer's lactate
16246274|NCT05050240|Experimental|Cold Exposure|The cold vest procedure: The first blood draw will be taken from participants before the cooling procedure (time 0, 30mL blood). Participants will then be requested to put on hospital scrubs and the cooling vest will be placed on them. Since muscle shivering is an alternative way of heat production (skeletal thermogenesis), we will first determine individual 'shivering threshold' for each participant (coldest tolerable temperature; typically 14°C / 57.2F), based on participant-report and direct observation. The cold vest will then be kept on for 3 hours with a temp set to the coldest tolerable temperature (shivering threshold +2°C (~16-17°C / 60.8F-62.6F) and body temperature will be monitored by a tympanic thermometer. Following 3 hours, 30mL of blood will be drawn (Time 180min). All participants will be re-warmed with blankets after cooling has been completed, and offered a warm drink and a snack.
16246275|NCT05050227|Experimental|cCBT Enhanced Collaborative Care|Participants in the intervention arm will receive computerized cognitive behavioral therapy (cCBT) supported by a depression care manager in addition to the usual care provided.
16246276|NCT05050227|Active Comparator|Usual Care|Participants in the usual care arm will receive the usual care provided as described below.
16246277|NCT05050214|Experimental|Experimental: GAZYVA, GAZYVARO(Obinutuzumab)|Participants will receive Obinutuzumab 1000 mg solution for infusion (total dose of 3000 mg in 30 days).
16246278|NCT05050201|Experimental|Sleepio Intervention|Participants using the Sleepio application - access for 6 sessions, over 10 weeks
16246279|NCT05050188|Experimental|cohort 1: H008 20mg|H008 20mg tablets, orally, once, daily, for 7 days
16246280|NCT05050188|Experimental|cohort 1: H008 placebo 20mg|H008 placebo 20mg tablets, orally, once, daily, for 7 days
16246281|NCT05050188|Experimental|cohort 1: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
16246282|NCT05050188|Experimental|cohort 2: H008 40mg|H008 40mg tablets, orally, once, daily, for 7 days
16246283|NCT05050188|Experimental|cohort 2: H008 placebo 40mg|H008 placebo 40mg tablets, orally, once, daily, for 7 days
16246284|NCT05050188|Experimental|cohort 2: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
16246285|NCT05050162|Experimental|ARM I (high-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
16246286|NCT05050162|Experimental|Arm II (low-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
16246287|NCT05050162|Experimental|Arm III (high-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
16246288|NCT05050162|Experimental|Arm IV (low-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
16246289|NCT05050149|Experimental|Experimental: PTX-022|PTX-022 QTORIN
16246290|NCT05050136|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
16246291|NCT05050136|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
16246292|NCT05050136|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
16246298|NCT05050097|Experimental|Treatment Regimen C: Talquetamab + Lenalidomide|Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
16246299|NCT05050097|Experimental|Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide|Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
16246300|NCT05050097|Experimental|Treatment Regimen E: Talquetamab + Pomalidomide|Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.
16246301|NCT05050084|Experimental|Arm I (RT)|Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity.
16246302|NCT05050084|Experimental|Arm II (RT, ADT)|Patients undergo RT as Arm I. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days.
16246303|NCT05050084|Experimental|Arm III (RT, ADT)|Patients receive treatment as in Arm II.
16246304|NCT05050084|Experimental|Arm IV (RT, ADT, darolutamide)|Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
16246305|NCT05050071|Active Comparator|Calcium hydroxide (7 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
16246306|NCT05050071|Experimental|Allium sativum (7 days)|is a species of bulbous flowering plant in the onion genus Allium
16246307|NCT05050071|Experimental|Combination (7 days)|combination between Calcium hydroxide and Allium sativum
16246308|NCT05050071|Active Comparator|Calcium hydroxide (14 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
16246309|NCT05050071|Experimental|Allium sativum (14 days)|is a species of bulbous flowering plant in the onion genus Allium
16246310|NCT05050071|Experimental|Combination (14 days)|combination between Calcium hydroxide and Allium sativum
16246311|NCT05050058||Neonates born to diabetic mothers|
16246312|NCT05050058||Neonates born to non-diabetic mothers (control)|
16246313|NCT05050006|Experimental|Cohort 1|Patients who relapsed after or were refractory to at least 1 prior line of systemic therapy including a PD-1 inhibitor.
16246314|NCT05050006|Experimental|Cohort 2|Patients who were intolerant to a PD-1 inhibitor and have persistent disease after stopping PD-1 therapy.
16246315|NCT05050006|Experimental|Cohort 3|Patients who had a best response of stable disease despite being treated with at least 4 doses of a PD-1 inhibitor in the previous line of therapy.
16246316|NCT05049980|Experimental|Medical treatment|Patients choosing medical treatment with Mifégyne® and MisoOne®
16246317|NCT05049980|Active Comparator|Surgical treatment|Patients choosing surgical treatment by endo-uterine aspiration.
16246318|NCT05049954|Experimental|Healthy Ketogenic Diet (HKD)|"Participants in the HKD group will be advised to follow a calorie-restricted healthy ketogenic diet (n=35), with a maximum of 50g net carbohydrate intake daily, with calorie prescriptions calculated based on the Schofield equation, adjusted with a deficit of 500 kcal daily to promote weight loss.
~Participants will attend group workshops conducted by dietitians at weeks 1, 3, 5, 7, and thereafter at 6-week intervals over the course of a 6-month period (total of 7 workshops). Participants will also be recommended to use the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, steps count and to aid in their adherence to the diet and physical activity recommendations during the 6 months period. The participants will be recommended to achieve their incremental daily step count goal from 3,000, 7,000 to 10,000 to promote increased physical activity, as per their tolerance."
16246319|NCT05049954|Active Comparator|Low Fat caloric-restricted Diet (LFD)|"Participants in the reference group will be instructed to follow a calorie-restricted low fat diet (LFD) (n=35), with calorie prescriptions calculated based on the Schofield equation, adjusted with a deficit of 500 kcal daily to promote weight loss.
~Similar to the experimental group, participants will attend group workshops conducted by dietitians at weeks 1, 3, 5, 7, and thereafter at 6-week intervals over the course of a 6-month period (total of 7 workshops). Participants will also be recommended to use the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, steps count and to aid in their adherence to the diet and physical activity recommendations during the 6 months period. The participants will be recommended to achieve their incremental daily step count goal from 3,000, 7,000 to 10,000 to promote increased physical activity, as per their tolerance."
16246320|NCT05049941||group1|Group (1): veno-arterial carbon dioxide tension / arteriovenous oxygen content P(v-a)CO2/C(a-v)O2 ratio group.
16246321|NCT05049941||group 2|Group (2): Lactate clearance (LC) group; Lactate level was measured then LC rate was calculated by the equation [(lactate(T0)- lactate(T8))/lactate(T0)] × 100%.
16246322|NCT05049941||group 3|"Group (3):
~veno-arterial carbon dioxide tension group; P(v-a)co2 difference"
16246323|NCT05049928|Experimental|Experimental arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.
16246324|NCT05049928|No Intervention|Control arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.
16246325|NCT05049915|Experimental|Masquelet technique: bioactive glass|
16246326|NCT05049915|Active Comparator|Masquelet technique: RIA + TCP|
16247128|NCT05044364|Experimental|China clevidipine butyrate injection|Yangtze River Pharmaceutical Group Co., Ltd.
16246329|NCT05049889|Active Comparator|History of Immersion Pulmonary Edema|"The participants will have 2 visits:
~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.
~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
16246330|NCT05049889|Active Comparator|No history of Immersion Pulmonary Edema|"The participants will have 2 visits:
~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.
~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
16246331|NCT05049863|Experimental|Phase I Dose Level 0: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
16246332|NCT05049863|Experimental|Phase I Dose Level 1: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
16246333|NCT05049863|Experimental|Phase II: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
16246334|NCT05049850|Experimental|Imlifidase|Imlifidase is administered intravenously as one dose of 0.25 mg/kg over 15 minutes within the 24-hour period prior to transplantation. (A second dose may be given if the crossmatch test at 4 hours after the first dose remains positive.)
16246335|NCT05049837||Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
16246336|NCT05049837||Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
16246337|NCT05049837||Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.
16246338|NCT05049837||Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
16246339|NCT05049837||Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
16246340|NCT05049837||Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
16246341|NCT05049824|Experimental|SFM Treatment Arm|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion
16246342|NCT05049811|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
16246343|NCT05049811|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
16246346|NCT05049785|Active Comparator|Arm I (counseling)|Patients attend 13 nutrition counseling sessions over 45 minutes each for 1 year. Patients may receive nutrition handouts.
16246347|NCT05049785|Experimental|Arm II (nutrition and PA intervention)|Patients attend 2 tasting sessions for low-fat and low-sugar recipes and complete 2 PA sessions over 1 hour for each session.
16246348|NCT05049772|Experimental|Telerehabilitation-based motor imagery group|Behavioral: Telerehabilitation-based motor imagery group Participants in the Telerehabilitation-based motor imagery group will imagine for the lumbar region exercises (e.g. bridges, knee-to-chest stretches, pelvic tilts) in the sessions in home using the study audio-video motor imagery script for 2 times per week; 30 min per day for 10 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week). In addition, the participants will be given stabilization exercises In addition, the participants will be given stabilization exercises for 10 weeks for 40 minutes, 2 days a week.
16246406|NCT05049382|Experimental|Horizontal|Classified as horizontal according to winter classification
16247815|NCT05039736|Experimental|nivolumab|nivolumab by vein every 4 weeks for up to 2 years
16246349|NCT05049772|Active Comparator|Stabilization Exercises group|Behavioral: Stabilization Exercises group An exercise program consisting of lumbar stabilization exercises for the participants will be planned for the pelvic ring muscles to develop the neutral lumbar spine. Co-contraction of the transversus abdominus muscle and the multifidus muscle will form the basis of the exercises. Stabilization exercises will be given for 10 weeks for 40 minutes, 2 days a week.
16246350|NCT05049772|No Intervention|Healthy control group|no specific intervention
16246351|NCT05049759|Experimental|Feasibility testing|The feasibility trial, aims to assess the feasibility of the intervention, including assessment of acceptability and outcome measures. Twenty youths with anxiety and/or depressive symptoms will be recruited to the intervention. Physical activity will be measured using the Actigraph GT3X+ monitor at baseline and post-intervention. Outcome measures concerning symptom change will be assessed (anxiety and depression). Semi-structured qualitative interview with participants, caregivers and referring specialists will help identify possible contextual and practical factors associated with delivery of the intervention and explore acceptability of assessment procedures, the intervention, and perceived benefits and barriers to participation.
16246352|NCT05049746||Ancillary-Correlative (interview, questionnaire, discussion)|Patients undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes. Subsequently, a decision support tool will be developed consistent with standards for content development and evaluation from the IPDAS Collaboration and implemented through an iterative process of design, development and evaluation to engage end users in its development. Once developed, field testing of the decision tool will be conducted to demonstrate feasibility and acceptability in real-world clinical setting, followed by pilot testing to evaluate the efficacy of the decision support tool.
16246353|NCT05049733|Experimental|Arm 1|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 1 mg/kg and then switch to other doses after washout periods.
16246354|NCT05049733|Experimental|Arm 2|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 2 mg/kg and then switch to other doses after washout periods.
16246355|NCT05049733|Experimental|Arm 3|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 4 mg/kg and then switch to other doses after washout periods.
16246356|NCT05049733|Placebo Comparator|Arm 4|Participants will begin with ingestion of placebo soft gel tablets that do not contain cannabinoids and then switch to other doses after washout periods.
16246357|NCT05049720|Experimental|Experimental|Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.
16246358|NCT05049707|Placebo Comparator|Control|The control arm will receive an equivalent volume of normal saline as the treatment group
16246359|NCT05049707|Experimental|IV magnesium|We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.
16246360|NCT05049694|Experimental|zirconia crowns|esthetic crowns for capping permanent molars with caries
16246361|NCT05049694|Experimental|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
16246362|NCT05049681|Experimental|SHR-1210（Camrelizumab）+Apatinib|Apatinib 250mg, q.d.po; SHR-1210（Camrelizumab） 200 mg，Intravenous injection,q2W ,A course of treatment need 28 days.
16246363|NCT05049681|Active Comparator|SHR-1210（Camrelizumab）|SHR-1210（Camrelizumab） 200 mg，Intravenous injection. q2W ,A course of treatment need 28 days.
16246364|NCT05049668||RACE 1 patients|After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study
16246365|NCT05049655||Study Formula|New infant formula fed ad lib
16246366|NCT05049655||Comparator Formula|Commercially available infant formula fed ad lib
16246367|NCT05049655||Human Milk Reference Group|Human milk
16246368|NCT05049642|Experimental|Group 1|Patients will either be randomized to group 1 (instillation of 1 drop of C-NAC) or group 2 (no instillation of C-NAC) in a 1:1 fashion. Afterwards one drop of C-NAC will be instilled into the study eye of group 1. 1 hour after treatment VAS and the symptom questionnaire will be performed repeatedly in both groups. Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days. Patients assigned to group 1 will receive Lacrimera® for home treatment over the following 5 days. 1 drop of Lacrimera® is supposed to be installed into the eye 20 minutes prior to installation of the respective antibiotic eye drops or ointments.
16246369|NCT05049642|No Intervention|Group 2|Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days.
16246370|NCT05049629|Experimental|Eye 1|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
16246371|NCT05049629|Active Comparator|Eye 2|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
16246374|NCT05049603|Experimental|Atorvastatin|Atorvastatin 20 mg/day (the experimental treatment), one tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks, associated with intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks
16246375|NCT05049603|Placebo Comparator|Placebo|Intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks, and placebo (one tablet/day, given approximately at 10 pm, after dinner and before going to bed) for 24 weeks
16246459|NCT05049044||Cohort 10: BSC|Best supportive care only (BSC)
16246378|NCT05049577|Placebo Comparator|Control group|To maintain blinding, in the control group, the remifentanil infusion was replaced with 50 ml of normal saline in 50 ml syringe. The remifentanil (or saline) infusion was run until the pump indicated the target Ce had been achieved. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia in all patients was induced using 2 mg/kg of 2% propofol. The attending anesthesiologist asked the patients how they felt pain to evaluate pain severity of PIP while half -dose of propofol was administered. After the rest of the propofol was administered, the attending anesthesiologists asked the same question.
16246379|NCT05049577|Experimental|Remifentanil group|Remifentanil 1 mg was diluted into 50 ml of normal saline. A commercial TCI pump (Orchestra Base Primea, Fresenius Vial, France) was used for the effect-site TCI of remifentanil. The study groups received remifentanil to a target Ce of 4 ng/ ml. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia induction and the evaluation of pain were same as control group
16246380|NCT05049564|Experimental|keyhole group|patient harbored aneurysm who was treated by microsurgical clipping via keyhole approach.
16246381|NCT05049564|Experimental|conventional group|patient harbored aneurysm who was treated by microsurgical clipping via conventional craniotomy.
16246382|NCT05049564|Experimental|endovascular group|patient harbored aneurysm who was treated by endovascular coiling via femoral approach.
16246383|NCT05049538||Observational (biospecimen collection, Pap smear)|Patients undergo collection of blood samples for liquid biopsy during pre-treatment consultation before hysterectomy, after hysterectomy but before starting any chemotherapy, and at the end of last chemotherapy cycle. Patients also undergo collection of tissue samples during hysterectomy. Patients may also undergo Pap smears before and after hysterectomy.
16246384|NCT05049525|Active Comparator|Itraconazole and Terbinafine|During the first 4 weeks itraconazole will be administered alone at 200 mg twice daily, followed by itraconazole 200 mg twice daily and terbinafine 250 mg twice daily for the remaining 16 weeks. Both drugs will be administered orally.
16246385|NCT05049525|Placebo Comparator|Placebo|During the first 4 weeks a placebo will be administered alone at 200 mg twice daily, followed by placebo 200 mg twice daily and another placebo 250 mg twice daily for the remaining 16 weeks. Both placebos will be administered orally.
16246386|NCT05049512|Experimental|Multi-nut OIT|Participants will have a personalised combination of two nuts they are allergic to for their multi-nut OIT (a. peanut, b. almond, c. cashew, d. hazelnut, e. walnut). In the escalation visit, participants will receive 5 increasing doses of personalised multi-nut OIT in clinic at 20-minute intervals: 1 mg, 3 mg, 6 mg, 12 mg, 24 mg total nut protein, 12 mg/nut. The build-up phase will consist of daily home doses of multi-nut OIT and clinic visits every 2 weeks for up-dosing, up to a maintenance dose of 600 mg total protein, 300 mg/nut, over 3-8 months. In the maintenance phase, participants will continue to take their multi-nut OIT dose of 600 mg total protein each day at home for the remainder of the 18 months, with visits to the clinic every 3 months.
16246387|NCT05049512|No Intervention|Standard Care|Strict avoidance of the 2 study nuts the participants are allergic to over 18 months - a. peanut, b. almond, c. cashew, d. hazelnut, e. walnut, as per standard care instructions for children with allergies in Australia.
16246388|NCT05049486|No Intervention|MRI sequences and (DTI)|The aim of this study is to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high resolution anatomical MRI sequences and diffusion tensor imaging (DTI). To do so, the patient will undergo a MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing.
16246389|NCT05049486|Active Comparator|CT scan|Three to 4 weeks after the procedure the patient will undergo a limited CT scan of the pelvis to visualise the position of the SNS lead. The scan will focus only on the sacrum, implanted lead, and rectum and will not be extended beyond this area. Imaging from this CT will be superimposed to the MRI imaging the patient had pre-operatively, and a computational simulation will be performed.
16246390|NCT05049473|Experimental|Chemotherapy|"Pts with biological age up to 55 y with advanced stage will receive 6 cycles of intensive treatment: blocks (A1-B1-C1-A2-B2-C2). If after A1 and B1 cycles CR is observed, the rest of the cycles will be administered with reduced doses.
~In pts with biological age >55 y with advanced stage block will receive A and B with attenuated doses (A1*-B1*-A2*-B2*-A3*-B3*).
~Pts with biological age up to 55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 blocks. If CR is not reached, patients will complete the 6 treatment cycles.
~Pts with a biological age >55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 attenuated blocks (A1*-B1*-A2*-B2*). If CR is not reached, patients will complete the 6 cycles of treatment."
16246393|NCT05049447|Active Comparator|Verum arm|Intervention: Drug: Verum (Pascoflair)
16246394|NCT05049447|Placebo Comparator|Placebo arm|Intervention: Drug: Placebo
16246395|NCT05049434|Experimental|Medicurtain®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
16246396|NCT05049434|Active Comparator|GUARDIX-SG®|Treat Medicurtain® 5ml prefilled syringe after surgery
16246397|NCT05049421|Other|Patients following CABG|Recruitment amongst patients enrolled in SWEDEGRAFT RCT at Aarhus University Hospital scheduled for follow-up
16246398|NCT05049408||Group OSCC|Patients with Oral Squamous Cell Carcinoma (OSCC)
16246399|NCT05049408||Group OPMD|Patients with oral potentially malignant disorders (OPMD)
16246400|NCT05049408||Group HC|Healthy Control
16246401|NCT05049395|Active Comparator|Control group|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
16246402|NCT05049395|Experimental|HFNO group|The patients are administered oxygen of 30L-60L/min until the end of the hysteroscopy operation.
16246403|NCT05049382|Experimental|Mesioangular|Classified as mesioangular according to winter classification
16246404|NCT05049382|Experimental|Vertical|Classified as vertical according to winter classification
16246405|NCT05049382|Experimental|Distoangular|Classified as distoangular according to winter classification
16246408|NCT05049356||Children referred to outpatient clinic|Diagnostic interview (Schedule for Affective Disorders and Schizophrenia (K-SADS) cf. Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) with parents. Diagnostic groups/cohorts (e.g., DMDD, ADHD, Oppositional Defiant Disorder) will be based on the diagnoses given cf. K-SADS.
16246409|NCT05049356||Typical developing children and their parent(s)|Norm values on hair cortisol data will be obtained from typical developing children and their parent(s) by the same procedure as described under Outcome measure(s), 21. Stress Response by Cortisol levels.
16246412|NCT05049330||Derivation Cohort|The derivation cohort collected data to derive the clinical decision rule.
16246413|NCT05049330||Validation Cohort|The validation cohort collected data to validate the clinical decision rule
16246414|NCT05049317|Experimental|FTME group|Participants will undergo laparoscopic FTME surgery.
16246415|NCT05049304|Experimental|OA-enriched functional olive oil|
16246416|NCT05049304|Active Comparator|Olive oil not enriched in OA|
16246417|NCT05049291|Experimental|Intervention|One time receipt and review of an information sheet
16246418|NCT05049291|No Intervention|Non-Intervention|Usual care will be delivered per standards of care.
16246419|NCT05049278|Active Comparator|Norepinephrine|Norepinephrine Bitartrate Hydrate : 4 mg/4 mL
16246420|NCT05049278|Active Comparator|Phenylephrine|Phenylephrine hydrochloride : 10 mg/1 mL
16246421|NCT05049265|Experimental|JS007|
16246422|NCT05049239|Experimental|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.
16246423|NCT05049239|Active Comparator|Physical training combined with cognitive support|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.
~The cognitive support consists of person centred individual occupational therapy."
16246424|NCT05049239|No Intervention|Control group|The control group receive no intervention.
16246425|NCT05049226|Experimental|Two doses of SV at interval 60 to less than 90 days|Participants who have received two doses of SV at interval 60 to less than 90 days
16246426|NCT05049226|Experimental|Two doses of SV at interval 90 to less than 120 days|Participants who have received two doses of SV at interval 90 to less than 120 days
16246427|NCT05049226|Experimental|Two doses of SV at interval 120 to 180 days|Participants who have received two doses of SV at interval 120 to 180 days
16246428|NCT05049213|Experimental|Topical medical treatment|Intranasal spray and oral gargling
16246429|NCT05049213|No Intervention|Standard of care|no intervention
16246430|NCT05049187||Group 1 COVISHIELD|Participants will receive one dose of COVID-19 vaccine (Covishield) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
16246431|NCT05049187||Group 2 COVAXIN|Participants will receive one dose of COVID-19 vaccine (Covaxin) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
16246432|NCT05049174|Experimental|Intensive intervention|
16246433|NCT05049174|Active Comparator|Low-threshold intervention|
16246434|NCT05049161|Experimental|Temelimab 18 mg/kg|Monthly IV repeated dose
16246435|NCT05049161|Experimental|Temelimab 36 mg/kg|Monthly IV repeated dose
16246436|NCT05049161|Experimental|Temelimab 54 mg/kg|Monthly IV repeated dose
16246437|NCT05049148|Other|Patients requirering brain/medullary tumors excision|All patients requirering a surgery for brain or medullar excision
16246438|NCT05049135||Sleep apnea group|Patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
16246439|NCT05049135||Control group|partners of patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
16246440|NCT05049122|Experimental|Dupilumab|Dupilumab every 2 weeks (q2w). Dosing interval may be changed from q2w to q4w at week 24
16246441|NCT05049109|Experimental|Group X|Patients who have had stroke and high blood pressure will participate in 5 telehealth visits, which will take place over 3 months. In addition, remote BP monitoring will be given.
16246442|NCT05049109|Active Comparator|Group Y|Patients who have had stroke and high blood pressure will participate in 3 visits with primary care and stroke practitioner.
16246443|NCT05049096|Experimental|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
16246444|NCT05049096|Sham Comparator|sham-control group|In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
16246445|NCT05049083|Experimental|Treatment group A|
16246446|NCT05049083|Experimental|Treatment group B|
16246447|NCT05049070|Experimental|GoEyes|GoEyes Self administered refraction test + Standard of care refraction test
16246448|NCT05049057|Experimental|Active Drug|Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.
16246449|NCT05049057|Placebo Comparator|Placebo|Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.
16246450|NCT05049044||Cohort 1: cRT-CT+IO|Concomitant radio-chemotherapy and consolidation immunotherapy (cRT-CT+IO)
16246451|NCT05049044||Cohort 2: sRT-CT+IO|Sequential radio-chemotherapy and consolidation immunotherapy (sRT-CT+IO)
16246452|NCT05049044||Cohort 3: cRT-CT|Concomitant radio-chemotherapy (cRT-CT)
16246453|NCT05049044||Cohort 4: sRT-CT|Sequential radio-chemotherapy (sRT-CT)
16246454|NCT05049044||Cohort 5: CT|Chemotherapy only (CT)
16246455|NCT05049044||Cohort 6: CT+IO|Chemotherapy plus immunotherapy (CT+IO)
16246456|NCT05049044||Cohort 7: RT|Radiation therapy only (RT)
16246457|NCT05049044||Cohort 8: IO|Immunotherapy only (IO)
16246458|NCT05049044||Cohort 9: TT|Targeted therapy only (TT)
16246460|NCT05049031|Experimental|Breast cancer treated with hormone therapy|Adult patients with T1-T3, N0-N2, M0 breast cancer and referred to the Menopause Center of Toulouse Hospital for their breast cancer
16246461|NCT05049018|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was for one hour and 15 minutes rest in between. The first part included: muscle strengthening and facilitation exercises, stretching exercises, and postural reactions exercises. The second part included: functional exercise for facilitation of arm-reaching and arm-hand skills, manipulative tasks (grasping and release activities), and daily living activities for the affected upper limb.
~The traditional treatment program was applied for both groups by therapists, experienced in stroke rehabilitation. It was carried out three sessions per week for twelve successive weeks."
16246462|NCT05049018|Experimental|Experimental Group|"Participants in the experimental group received two hours treatment program that included three parts, the first and the second parts (similar to that were applied for participants in the control group). These two parts were applied for one hour followed by 15 minutes rest, then the third part was applied for one hour. The third part of the program was a one-hour virtual reality intervention program by using (ArmeoSpring) virtual reality equipment to simulate a range of upper limb tasks that facilitate arm activities, manipulative skills, and daily living tasks through using different interactive games and soft-wares.
~The traditional treatment part of the program was applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program was applied by other experienced physiotherapists, who were well trained in using the (ArmeoSpring) System. All three parts of the program were carried out three sessions per week for twelve successive weeks."
16246463|NCT05049005|Active Comparator|RED FOOD Intervention Group|Participants in the RED FOOD group will be taught a simplified way of identifying high-calorie foods (red foods) and reducing them using the Traffic Light Diet. Limiting the number of red foods consumed is a simple way to reduce calories without having to track calories. Participants in this group will use the study website to track their red foods and will be given a daily red food limit base on their baseline weight and will track their red foods on the study website daily. Participants will be recommended to enter their red foods at least once per day (at which time they would enter all red foods for the day), but ideally multiple times per day to reduce errors associated with recall.
16246464|NCT05049005|Experimental|GREEN FOOD Intervention Group|Participants in the GREEN FOOD group will be taught a simplified way of identifying low-calorie foods (green foods) and maximizing them using the Traffic Light Diet. Maximizing the number of green foods consumed is a simple way to reduce dietary energy density while allowing for consumption of a satisfying amount (i.e. weight and volume) of food. Maximizing green food consumption may simultaneously reduce red food consumption, thereby reducing calorie intake and promoting greater diet quality than red food reduction alone. Participants in this group will also use the study website to track their green foods and will be given a daily green food goal based on their baseline weight and will track their green foods on the study website daily. Participants will be recommended to enter their green foods at least once per day (at which time they would enter all green foods for the day), but ideally multiple times per day to reduce errors associated with recall.
16246469|NCT05048966|Experimental|Group Wellness Class 1|
16246470|NCT05048966|Active Comparator|Group Wellness Class 2|
16246471|NCT05048953||MRC GROUP|All newly admitted patients (shifted to ICU within 48 h of hospital admission), aged ≥ 16 years and expected to stay in ICU or critical care areas for 7 days will be included in the study after excluding those who fulfill excluding criterial. In all the participants, muscle strength will be assessed at day 1, day 4 and day 7, if the patients are awake as assessed by Richmond Agitation Sedation Scale (RASS) (19) between -1 and 1, and cooperative (20) assessed by being able to follow at least 3 out of 5 verbal commands with facial muscles (scored by the Score of 5 Questions). Assessment will be done by an ICU physician blinded to the result of ultrasound. The MRC score will be used for assessment of strength in the following six muscle groups bilaterally: wrist dorsiflexors, elbow flexors, shoulder abductors, hip flexors, knee extensors and ankle dorsiflexors. ICU-AW will be defined as MRC sum score < 48, in accordance with the international consensus statement.(1)
16246472|NCT05048953||Muscle ultrasound measurements (the index test)|"Muscle ultrasound will be performed by an ICU faculty or a DM resident of Critical care medicine (who has an experience of at least 25 muscle ultrasonography with at least 10 muscle ultrasonography performed under supervision) (21) and will be blinded to the result of MRC score of the patient. Muscle ultrasound images on day 1, day 4 and day 7 will be obtained in the participants.
~The following parameters will be measured by muscle ultrasound
~Muscle thickness
~Muscle echogenicity
~Muscle fasciculations Muscle thick"
16246473|NCT05048940|Experimental|HETEROLOGOUS VACCINE|COVID-19 Vaccine Janssen, injectable suspension
16246474|NCT05048940|Active Comparator|HOMOLOGOUS VACCINE|Spikevax (Moderna), injectable dispersion
16246475|NCT05048901|Experimental|Cabozantinib and Lanreotide|Oral cabozantinib 40-60 mg/day and lanreotide 120mg deep subcutaneous injection (SC) in day 1 every 4 weeks.
16246478|NCT05048862||Neuromuscular disorder|Patients age at least 20 years, and have been diagnosed as neuromuscular disorders by the neurologist. Patients who are unable to read the questionnaire, fail to accept all the examinations, and refuse to provide inform consent are excluded from this study.
16246479|NCT05048862||Normal group|The normal group (age at least 20 years) who had no neurological symptoms or signs were also recruited. The neurological examination performed by the board neurologist must be normal in the normal group.
16246480|NCT05048849|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16246481|NCT05048836|Experimental|Food subsidy, no lifestyle support, 6 months|Participant will receive $40 healthy food subsidy for 6 months.
16246482|NCT05048836|Experimental|Food delivery, no lifestyle support, 6 months|Participant will receive twice monthly healthy food delivery for 6 months.
16246483|NCT05048836|Experimental|Food subsidy, with lifestyle support, 6 months|Participants will receive food subsidy and healthy lifestyle support for 6 months.
16246484|NCT05048836|Experimental|Food delivery, with lifestyle support, 6 months|Participants will receive twice monthly food box deliveries and lifestyle support for 6 months.
16246485|NCT05048836|Experimental|Food subsidy, no lifestyle support, 12 months|Participants will receive food subsidy for 12 months.
16246486|NCT05048836|Experimental|Food delivery, no lifestyle support, 12 months|Participants will receive twice monthly food box deliveries for 12 months.
16246487|NCT05048836|Experimental|Food subsidy, with lifestyle support, 12 months|Participant will receive food subsidy and lifestyle support for 12 months.
16246488|NCT05048836|Experimental|Food delivery, with lifestyle support, 12 months|Participants will receive twice monthly food box deliveries and lifestyle support for 12 months.
16246489|NCT05048823|Experimental|Intervention Protocol|Visceral techniques for the gastrointestinal system
16246490|NCT05048823|Sham Comparator|Placebo Protocol|simulated visceral techniques in the region of the gastrointestinal system, without therapeutic intent
16246491|NCT05048810|Experimental|68Ga-DOTA-NT-20.3|Subjects will undergo PET imaging using 68Ga-DOTA-NT-20.3.
16246492|NCT05048797|Experimental|Arm 1|Trastuzumab Deruxtecan (T-DXd)
16246493|NCT05048797|Active Comparator|Arm 2|Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)
16246496|NCT05048771||FERTITOP|300 patients (15-25 years) from 5 different hospitals (University Hospitals of Nancy, Strasbourg, Reims, Besançon, Dijon (France)) who have finished all cancer treatments for at least 2 years.
16246497|NCT05048758||Individuals with AUD + moderate to severe ACE|Individuals with alcohol use disorder (AUD) and moderate to severe adverse childhood experiences (ACE)
16246498|NCT05048758||Individuals with AUD + no or mild ACE|Individuals with alcohol use disorder (AUD) and no or mild adverse childhood experiences (ACE)
16246511|NCT05048706|Experimental|Super Pulse Thulium fiber Laser|
16246512|NCT05048706|Active Comparator|Holmium: Yttrium-Aluminium-Garnet Laser|
16246513|NCT05048680|Experimental|Hypoxia - Rest|Sessions of intermittent hypoxia at rest; 3 sessions/week; 8 weeks. To be compared with the placebo (normoxia) group at rest.
16246514|NCT05048680|Placebo Comparator|Normoxia - Rest|Sessions of normoxia at rest; 3 sessions/week; 8 weeks.
16246515|NCT05048680|Experimental|Hypoxia - Exercise|Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks. To be compared with the placebo (exercise under normoxia) group.
16246516|NCT05048680|Active Comparator|Normoxia - Exercise|Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks.
16246517|NCT05048667|Experimental|SWT plus PRP Group|Participants will receive weekly Shock Wave Therapy (SWT) and Platelet Rich Plasma (PRP) for 4 weeks. SWT will be administered weekly on Day 1 and Weeks 1, 2, 3 and 4. PRP will be administered on Day 1 and Week 4.
16246518|NCT05048667|Placebo Comparator|Sham SWT plus Placebo Saline Group|Participants will receive weekly Sham Shock Wave Therapy (SWT) and Placebo Saline Intracavernosal Injection (ICI) for 4 weeks. Sham SWT will be administered weekly on Day 1 and Weeks 1, 2, 3 and 4. Placebo Saline ICI will be administered on Day 1 and Week 4.
16257295|NCT04974983||B|Treatment with bevacizumab
16246519|NCT05048654||Group A: Retrospective|Retrospectively, there will be an abstract of AMH and FSH from survivors seen at CHCO and UCH from October 1st, 2016 to September 31st, 2019 and assess time points.
16246520|NCT05048654||Group B: Prospective|Prospectively, survivors will be evaluated by a member of the FPRLE team in the outpatient clinic at 12 months post-therapy completion and every 6 months to 36 months as part of clinical care. Per standard of care AMH and FSH will be drawn at each time point.
16246521|NCT05048641|Experimental|WhatsApp Reminder group|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
16246522|NCT05048641|No Intervention|No Reminder (NR) group|Subjects who are allocated to the NR group received standard-of-care service which is no reminder text messages via WhatsApp Messenger prior to their scheduled repeat mammography and no follow up phone reminder until the completion of the outcome measurement period.
16246523|NCT05048628|Active Comparator|İce Pieces İmpregnated Group|Impregnation of pieces of ice was delivered to us; one ice cube is planned after wearing and movements automatically by the throat purchase to exit use and sound program, and move with one ice cube after movement. It can be used after extubation. It is in sound class with Visual Analogue Scale (VAS) for the use of customers before and after the application. Extubation is in the last 0. hours, no small application is made, only in sound class with VAS. Evaluated by Stout's Hoarseness Scale
16246524|NCT05048628|Active Comparator|Green Tea Gargle Solution Group|To the patients included in the gargle group with green tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of green tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0. th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.0
16246525|NCT05048628|Active Comparator|Arnica Montana Tea Gargle Solution Group|To the patients included in the gargle group with arnica montana tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of arnica montana tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.
16246526|NCT05048628|No Intervention|Control Group|Patients in the control group; sore throat and hoarseness scores at 0 hour immediately after extubation,to collect at 4, 6 and 8 hours after extubation, sore throat (Visual Analogue Scale) VAS; Stout s Voice if hoarseness It is evaluated with the Slightness Scale.
16246527|NCT05048615|Experimental|Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine|Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.
16246528|NCT05048589|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
16246529|NCT05048589|Experimental|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
16246530|NCT05048576|Experimental|Positive auditory cues|Participants will listen to the following auditory cues ~30 seconds apart Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.
16246531|NCT05048576|Experimental|Negative auditory cues|Participants will listen to the following auditory cues ~30 seconds apart You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.
16246532|NCT05048576|Experimental|Music|Participants will be allowed to select a streaming music station of their choice.
16246533|NCT05048576|Active Comparator|Silence|Participants will walk in silence while wearing noise cancelling headphones.
16246534|NCT05048550|No Intervention|A (control)|First visit assessments at 8 weeks corrected gestational age. No glasses prescribed.
16246535|NCT05048550|Experimental|B1 (intervention)|First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed.
16246536|NCT05048550|Experimental|B2 (intervention)|First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed.
16246537|NCT05048537|Other|18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.|
16246538|NCT05048524|Experimental|SLOG|
16246539|NCT05048511||Normal|Women with sufficient vitamin D level, when 25(OH)D >20 ng/ml
16246540|NCT05048511||Deficient|women deficiency vitamin D level, when 25(OH)D <20 ng/ml
16246541|NCT05048498|Active Comparator|Azacitidine|"Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days.
~Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days."
16246542|NCT05048498|Experimental|NEX-18a|"Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a
~Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a"
16246543|NCT05048485||LEOPARD Cohort 1|"Control group: The study will enroll 50 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are not receiving nutritional supplementation.
~TB LION group: The study will enroll 50 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are receiving nutritional supplementation."
16246544|NCT05048485||LEOPARD Cohort 2|The study will enroll 300 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are not enrolled in the TB-LION study.
16246545|NCT05048472|Experimental|Intervention|Use of point of care viral load monitoring (Abbott PoC devices)
16246546|NCT05048472|No Intervention|Control|Use of the standard of care viral load monitoring (centralized viral load monitoring)
16246791|NCT05046665|Other|Metastatic cohort|Eligible participants recruited from the metastatic cohort
16246547|NCT05048459|Active Comparator|Standard surveillance|This surveillance approach involves the participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
16246548|NCT05048459|Experimental|Telemedicine surveillance (tele-surveillance)|Tele-surveillance involves the participant staying at home while their healthcare providers follow their condition and give them the care they need. They can communicate with their healthcare team through face-to-face video conferencing on their desktop computer, laptop, smart phone, or tablet. They can also communicate with their healthcare team by phone.
16246549|NCT05048433|Experimental|implementation strategy for active learning to promote physical activity|
16246550|NCT05048433|Active Comparator|Usual Implementation support|
16246551|NCT05048420|Experimental|Ramp lesion repair|
16246552|NCT05048420|Experimental|Anterior cruriciate ligament reconstruction|
16246553|NCT05048407|Experimental|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
16246554|NCT05048394|Experimental|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand
16246555|NCT05048394|Experimental|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
16246556|NCT05048368|Experimental|Cohort A-Larotinib|Cohort A:Healthy participants with normal hepatic function （match to subjects with mild hepatic impairment_cohort B）
16246557|NCT05048368|Experimental|Cohort B-Larotinib|Subjects with mild hepatic impairment
16246558|NCT05048368|Experimental|Cohort C-Larotinib|Healthy participants with normal hepatic function （match to subjects with moderate hepatic impairment_cohort D）
16246559|NCT05048368|Experimental|Cohort D-Larotinib|Subjects with moderate hepatic impairment.
16246560|NCT05048355|Experimental|Power Knee Mainstream Dynamic|
16246561|NCT05048355|Active Comparator|Passive MPK|
16246562|NCT05048342|Experimental|Arm 1|LOU064 open-label treatment taken orally for 52 weeks.
16246563|NCT05048329|Experimental|Soft Launch|We will include five eligible patients into the soft launch to test and reconfigure workflow, protocol, alerting structure and other operation related factors.
16246564|NCT05048329|Experimental|Pilot|After the soft launch, we will include 45 eligible patients into the pilot to conduct the rest of the study
16246565|NCT05048316|Experimental|eHealth|Weekly video conference groups led by a trained facilitator
16246566|NCT05048303|Experimental|Individualized Lutajet operative group|Arthroscopic modified individualized flexible Latarjet procedure with preservation of the coracoacromial arch. During the procedure, we perform coracoid osteotomy with preservation of coracoacromial arch, then split subscapular tendon, transfer the bone graft and fix it with double button under arthroscopy.
16246567|NCT05048290|Experimental|Group I (communication workshops, video, surveys)|Participants complete 2 communication workshops about conversational skills and development of a video about the summer student's research experience over 3 hours each during the second week of the summer research experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
16246568|NCT05048290|Active Comparator|Group II (generic communication workshops, surveys)|Participants complete 2 generic communication workshops about networking and presentation skills over 3 hours each during the second week of the summer experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
16246569|NCT05048277|Experimental|Single Arm Study|"The intervention will consist of one 60-minute long session conducted through NYU ZOOM. Each session will be between one parent and one study consultant. The session is goal-oriented and solution-focused. During the SSC, consultants will identify the participant's hope for the session and a specific modifiable goal. From this, the consultant will discuss the smallest-possible step participants can take toward overcoming their identified problem and work together in creating an Action Plan, which will present three specific actions the participant can take to accomplishing the session's established goals. Following completion of the two-week follow-up assessment, additional resources personalized to participants will also be provided (i.e., referrals for further services and online resources for parents/children). Ultimately, this intervention is a way to potentially jumpstart progress and facilitate hope and agency."
16246570|NCT05048264|Active Comparator|Kenalog 40 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Kenalog in the index shoulder.
16246571|NCT05048264|Active Comparator|Dexamethasone 4 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 4 mg corticosteroid injection of Dexamethasone in the index shoulder.
16246572|NCT05048264|Active Comparator|Celestone 6 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 6 mg corticosteroid injection of Celestone in the index shoulder.
16246573|NCT05048264|Active Comparator|Depo-medrol 40 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Depo-Medrol in the index shoulder.
16246574|NCT05048251|Experimental|cTBS|continuous TBS to right MFG
16246575|NCT05048251|Experimental|iTBS|intermittent TBS to right MFG
16246576|NCT05048251|Sham Comparator|sham|sham stimulation to right MFG
16246577|NCT05048238|Experimental|tofacitinib XR|"Participants will take one 11 mg tablet by mouth every morning. The treatment period will be 25 days.
~Tofacitinib tablets should be swallowed whole and intact, do not crush, split or chew."
16246578|NCT05048225||Low-salt (LS) group|intake of < 5 g of salt per day
16246579|NCT05048225||Normal-salt (NS) group|intake of 5 - 7.5 g of salt per day
16246580|NCT05048225||High-salt (HS) group|intake of 7.5 - 10 g of salt per day
16246581|NCT05048225||Very high-salt (VHS) group|intake of > 10 g of salt per day
16246585|NCT05048199|Experimental|pressure regulated volume-controlled mode of ventilation (PRVC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
16246586|NCT05048199|Active Comparator|volume-controlled mode of ventilation (VC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
16246587|NCT05048186||Decision Aid Arm|Participants in this arm will review educational material from the ADHD Decision Aid developed by the Cincinnati Children's Hospital Medical Center.
16246588|NCT05048186||Control Arm|Participants in this group will not receive any educational materials.
16246589|NCT05048173||Sentinel lymph node group|woman who had sentinel lymph node mapping and biopsy
16246590|NCT05048173||Lymphadenectomy group|woman who underwent traditional pelvic lymphadenectomy without sentinel lymph node mapping
16246591|NCT05048160|Experimental|6MW3211|"Dosage form: injection
~Specification: 240 mg / 8 ml/Vial"
16246592|NCT05048147|Experimental|CM Intervention Group|Cluster. RCT of 16 urban and rural communities. CHEWs will facilitate use of CF-CS and educate households on HAP exposure throughout the intervention period
16246593|NCT05048147|No Intervention|Self-Directed Group|Receive information on CFCS use and education on HAP in 16 urban and rural communities; will not receive the CM intervention
16246594|NCT05048134|Experimental|Treatment group A|
16246595|NCT05048134|Experimental|Treatment group B|
16246596|NCT05048134|Experimental|Treatment group C|
16246597|NCT05048134|Experimental|Treatment group D|
16246598|NCT05048134|Experimental|Treatment group E|
16246599|NCT05048121|Experimental|CLS02021 - Investigational Product arm|Cosmetic cream with proprietary cosmetic ingredient CLS02021.
16246600|NCT05048121|Placebo Comparator|PLC01021 - Placebo Control arm|Cosmetic cream, identical to the studied product but without cosmetic ingredient. Color, texture, scent and the packaging are identical as a IP.
16246602|NCT05048082|Experimental|Fluorescence imaging with pegsitacianine|Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
16246603|NCT05048056|Experimental|AK120 Regimen 1|AK120 Regimen 1- subcutaneous injection every 2 weeks for 30 weeks.
16246604|NCT05048056|Experimental|AK120 Regimen 2|AK120 Regimen 2- subcutaneous injection every 2 weeks for 30 weeks.
16246605|NCT05048056|Experimental|Placebo to AK120|Placebo subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 1, subcutaneous injection at Week16, after primary endpoint evaluation
16246606|NCT05048043|Experimental|Computer-assisted Behavior Intervention|A serious game paired with teacher consultation to address common needs related to ADHD in the classroom.
16246607|NCT05048043|Active Comparator|Challenging Horizons Program, School Consultation|An established teacher consultation program to help teachers address ADHD in the classroom.
16246608|NCT05048017|Experimental|Regorafenib plus PD-1 inhibitor|"Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF).
~Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.
~Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers.
~Pembrolizumab (Keytruda) the programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells."
16246609|NCT05048004||periprocedural oral anticoagulation|Oral anticoagulation will be continued without a periprocedural pause
16246610|NCT05048004||no periprocedural oral anticoagulation|Pause of oral anticoagulation on the day of the intervention
16246611|NCT05047991|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV + Oxaliplatin|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin(LV) and oxaliplatin intravenously on day 1 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
16246612|NCT05047991|Active Comparator|Cohort 2: Nab-paclitaxel + Gemcitabine|The patients in cohort 2 will receive nab-paclitaxel and gemcitabine intravenously on day 1、day 8 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
16246613|NCT05047978|Active Comparator|A routine cow's milk-based infant formula|A routine cow's milk-based infant formula
16246614|NCT05047978|Experimental|A partially hydrolyzed cow's milk protein (PHP) infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
16246615|NCT05047965|Experimental|Diagnostic (standard MRI, Dixon MRI)|Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
16246616|NCT05047952|Experimental|Vortioxetine|Start at 10 mg vortioxetine once daily (OD) for the first 2 weeks, then dosed up to 20 mg vortioxetine OD for weeks 2-8.
16246617|NCT05047952|Placebo Comparator|Placebo|Placebo capsule taken OD for weeks 0-8.
16246618|NCT05047939|Experimental|remimazolam group|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery. In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
16247816|NCT05039723|Experimental|Treatment|Treatment with Xeomin, Radiesse, and/or Belotero
16246619|NCT05047939|Active Comparator|propofol group|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
16246620|NCT05047926|No Intervention|Primary Cytoreductive Surgery|Women diagnosed with or having a high suspicion for ovarian cancer and undergoing primary surgical intervention for debulking of tumor.
16246621|NCT05047926|Experimental|Neoadjuvant Chemotherapy prior to Cytoreductive Surgery|Women diagnosed with or having a high suspicion for ovarian cancer and recommended to have Neoadjuvant Chemotherapy (NACT) prior to undergoing an interval debulking surgical intervention.
16246622|NCT05047913|Experimental|18F-FTX|The radioactive tracer (FAZA)
16246626|NCT05047887|Experimental|Study group|Modified socket shield technique with autogenous dentin graft
16246627|NCT05047887|Active Comparator|Control group|Modified socket shield technique with alloplast
16246628|NCT05047874||short-term (3 days) high-dose (1000 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone
16246629|NCT05047874||low-dose long-term (2x 40 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone
16246630|NCT05047861|Experimental|Study group|patients will receive the implant in the previously preserved socket using Socket shield technique with Alloplastic graft material
16246631|NCT05047861|Active Comparator|Control group|patients will receive the implant in the previously preserved socket shield with Autogenous dentin graft
16246632|NCT05047848|Experimental|chidamide + fulvestrant|
16246633|NCT05047822||Historical Controls|
16246634|NCT05047822||Concurrent Controls|
16246635|NCT05047822||Vaccinated Cohort|
16246636|NCT05047809|Experimental|"Jingchuang Ointment(JCO) group"|"Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration. Besides, JCO was applied once a day on the wounds, last 3 months.
~Jingchuang Ointment (JCO) is made by Chuang Song Zong Pharmaceutical Co., Ltd. (Taiwan)"
16246637|NCT05047809|Other|Regular treatment group|Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration.
16246638|NCT05047796|Experimental|Intervention Protocol|Visceral osteopathic techniques
16246639|NCT05047796|Sham Comparator|Sham Protocol|Simulated visceral osteopathic techniques
16246640|NCT05047783|Experimental|Masitinib 3.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)
16246641|NCT05047783|Experimental|Masitinib 4.5 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)
16246642|NCT05047783|Experimental|Masitinib 6.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)
16246643|NCT05047783|Placebo Comparator|Placebo|Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis
16246648|NCT05047757|Experimental|Fava bean|The intervention consists in a test meal containing 250 g of cooked and peeled favabean, to provide 20 g protein. Fava bean are intrinsically labelled with 15N.
16246649|NCT05047744|Experimental|Prosthesis Cohort|Surgery dual mobility Prosthesis
16246652|NCT05047718|Experimental|convalescent participants PFIZER|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Pfizer vaccine
16246653|NCT05047718|Experimental|Naive participants PFIZER|Participant without past history of COVID-19 and vaccinated by anti-covid19 Pfizer vaccine
16246654|NCT05047718|Experimental|convalescent participants MODERNA|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Moderna vaccine
16246655|NCT05047718|Experimental|Naive participants MODERNA|Participant without past history of COVID-19 and vaccinated by anti-covid19 Moderna vaccine
16257447|NCT04973982|Active Comparator|ENVARSUS|ENVARSUS used as per licence
16246657|NCT05047692|Experimental|Group 1: Low dose|The subject will receive a single dose of AdCLD-CoV19-1(5.0x10^10VP) as an intramuscular injection.
16246658|NCT05047692|Experimental|Group 2: High dose|The subject will receive a single dose of AdCLD-CoV19-1(1.0x10^11VP) as an intramuscular injection.
16246659|NCT05047679|Experimental|Perioperative Pain Neuroscience Education|Patients in the experimental treatment group will receive Perioperative Pain Neuroscience Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
16246660|NCT05047679|Active Comparator|Perioperative Biomedical Education|Patients in the control treatment group will receive Perioperative Biomedical Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
16246661|NCT05047666||Cases Group|Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).
16246662|NCT05047666||Symptomatic Control Group|Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.
16246663|NCT05047666||Healthy Control Group|At the community.
16246664|NCT05047640|Experimental|BNT162b2 vaccine|Participants in this arm will receive one booster dose of the BNT162b2.
16246665|NCT05047640|Experimental|JNJ-78436735 vaccine|Participants in this arm will receive one booster dose of the JNJ-78436735
16246666|NCT05047627|Experimental|Smartphone Digital Intervention Group|The Smartphone Digital Intervention Group is the experimental group. Participants randomized to this group will download the smartphone intervention and be asked to use the intervention four times per week for four weeks ( 16 digital sessions). The smartphone digital intervention will also continuously collect passive sensing data. The smartphone digital intervention will be designed to treat anxiety and depression by providing informational videos to help participants treat these symptoms. These videos include information about physical activity, muscle relaxation, and other proven helpful interventions to help with anxiety and depression.
16246667|NCT05047627|No Intervention|Wait list Control Condition|The wait list control condition will not receive the digital intervention treatment for the duration of the study. They will still provide urine samples during the study. Participants assigned to this condition will be able to access the digital intervention after their participation in the study.
16246668|NCT05047614|Experimental|Study 1|Twelve patients in study group 1 receiving lumbar repositioning feedback training
16246669|NCT05047614|Experimental|Study 2|Twelve patients in study group 2 receiving transverses abdominis training
16246670|NCT05047614|Experimental|Study 3|Twelve patients in study group 3 receiving both lumbar repositioning feedback training and tranversus abdominis training
16246671|NCT05047614|Experimental|Control|Twelve patients in control group receiving conventional lumbar propriception physical therapy program .
16246675|NCT05047575|Experimental|REASSURE|6 months following enrollment, survivors enrolled in REASSURE will take a Patient Reported Outcomes (PRO) survey. PRO survey will be scored and a referral recommendation will be determined. The Medical Oncologist will make their own referral assessment and will take precedent during this pilot study. Primary Care Physicians (PCPs) will be notified of survivor participation at the time of enrollment.
16246676|NCT05047575|No Intervention|Pre-REASSURE|This is an observational arm.
16246677|NCT05047562|Active Comparator|Pilates Group|Participants will undergo 16 sessions, twice a week on alternate days through the following Pilates Method exercises: Pelvic Curl, Leg lift Supine, One leg circle modified and Hundred modified. There will be 4 sets of 5 repetitions in the first week, 6 repetitions in the second week, 7 repetitions in the third week, 8 repetitions in the fourth week, 9 repetitions in the fifth week, 10 repetitions in the sixth to eighth week.
16246678|NCT05047562|Active Comparator|Segmental Stabilization Group|Participants will undergo 16 consultations, twice a week on alternate days through the following Segmental Stabilization exercises: multifidus in prone position, transverse abdomen in four supports, transverse abdomen in dorsal decubitus and transverse abdomen associated with multifidus in position orthostatic. There will be 4 sets of 10 repetitions of 10 seconds in all appointments.
16246679|NCT05047536|Experimental|KZR-261 with standard therapy: open-label|"Part 1 (Dose Escalation)
~The initial dose cohort of the Dose Escalation will receive 1.8 mg/m2 of KZR-261. Subjects will receive 3 doses in a 28-day cycle.
~___________________________________________
~Part 2 (Dose Expansion)
~Following safety review of all Dose Escalation cohorts and determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), KZR-261 will be evaluated for safety and preliminary efficacy in 4 tumor-specific cohorts and 1 all-tumor cohort to determine the recommended phase 2 dose (RP2D). The 4 tumor-specific cohorts will include:
~melanoma (including uveal melanoma)
~colorectal cancer
~prostate cancer
~mesothelioma"
16246680|NCT05047523|Experimental|ALXN1840|ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.
16246681|NCT05047523|Active Comparator|Standard of Care|Participants will receive their current therapy or initiate Standard of Care therapy.
16246682|NCT05047510|Experimental|Anti-GPC3-IRDye800CW Intraoperative Fluorescence|The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
16246683|NCT05047497||less than 10 years working|workers who work in cement factories in a period of time less than 10 years
16246684|NCT05047497||from 10-15 years working|workers who work in cement factories in a period of time from 10-15 years
16246685|NCT05047497||more than 15 years working|workers who work in cement factories in a period of time more than 15 years
16246686|NCT05047484|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo twice daily (BID) on Day 1 through Day 14 in a fasted state.
16246687|NCT05047484|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
16246688|NCT05047484|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
16246689|NCT05047484|Experimental|Cohort 4: 200 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
16246690|NCT05047484|Experimental|Cohort 5: 120 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fed state.
16246691|NCT05047484|Experimental|Cohort 6: 240 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fasted state.
16246692|NCT05047458|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
16246693|NCT05047458|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
16246694|NCT05047458|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
16246695|NCT05047445|Experimental|COVIDITY administered via needle-free injection (intradermal).|
16246696|NCT05047445|Experimental|COVIDITY administered via needle-free injection (intramuscular).|
16246697|NCT05047419||Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 6 weeks post due date and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
16246698|NCT05047419||Not Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 9 months and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
16246699|NCT05047406|Experimental|Probiotic|2 oral mini-bottles daily of Bacillus clausii probiotic liquid containing 2 billion spores/bottle for 2 weeks before living donor liver transplantation surgery In addition, patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
16246700|NCT05047406|No Intervention|Control (No Probiotic)|patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
16246701|NCT05047393||Coccygodynia group|51 patients with a diagnosis of coccygodynia will be included in the study.
16246702|NCT05047380||coccycodinia group|A total of 54 patients diagnosed with coccycodinia
16246703|NCT05047367||single-group studies|A total of 149 patients diagnosed with CTS, 126 female and 23 male, were included in the study
16246706|NCT05047341|Experimental|Single arm|
16246707|NCT05047302|Experimental|Treatment|The goal of the BlueLeaf System is to percutaneously form one or more functional, autogenous deep venous valves and restore venous competence.
16246708|NCT05047276|Experimental|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
16246709|NCT05047263|Experimental|Finerenone (BAY94-8862)|Participants will receive finerenone.
16246710|NCT05047263|Placebo Comparator|Placebo|Participants will receive placebo.
16246713|NCT05047237|No Intervention|Control|Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up.
16246714|NCT05047237|No Intervention|Active Decliners|Subjects who decline intervention. Standard of care treatment with month 6 follow up.
16246715|NCT05047237|Experimental|Active Intervention|Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face [F2F] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up.
16246716|NCT05047224|Experimental|Tele-assessment + in-person assessment|Participants in this group will receive a tele-assessment using the TAP and will attend a traditional, in-person evaluation for autism spectrum disorder in a clinic setting.
16246717|NCT05047224|Active Comparator|Tele-assessment only|Participants in this group will receive a tele-assessment using the TAP, followed by a second, shorter tele-assessment.
16246718|NCT05047211|Active Comparator|Oral Iron group|"Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks three times daily.
~Intravenous placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride."
16246719|NCT05047211|Experimental|IV Iron group|"Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.
~Oral placebo will be given by mouth for a total of 6 weeks TID."
16246720|NCT05047198|Active Comparator|Control|Catheter Ablation using invasive mapping
16246721|NCT05047198|Experimental|Treatment|Radio-ablation using non-invasive mapping
16246722|NCT05047185|Other|Low dose|BID low dose of PHA-022121
16246723|NCT05047185|Other|High dose|BID high dose of PHA-022121
16246724|NCT05047185|Other|Placebo|BID placebo
16246725|NCT05047172|Experimental|Experimental Arm: Ticagrelor and Aspirin|Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
16246726|NCT05047172|Active Comparator|Standard of Care Arm: Clopidogrel and Aspirin|Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)
16246727|NCT05047172|Experimental|Experimental Arm: Rivaroxaban and Aspirin|Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
16246728|NCT05047159|Experimental|drug therapy group|Drug: drug therapy There is no restriction on the choice of therapeutic drugs.
16246729|NCT05047159|Experimental|drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group|"Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.
~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.
~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
16246730|NCT05047159|Experimental|drug therapy combined with light therapy group|"Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
16246731|NCT05047159|Experimental|drug therapy combined with electroconvulsive therapy (ECT) group|"Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
16246732|NCT05047159|Experimental|drug therapy combined with magnetic seizure therapy (MST) group|"Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
16246733|NCT05047133|Experimental|Early Adminstration of TXA + Intraoperative TXA|This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
16246734|NCT05047133|Other|Intraoperative only TXA|This group will only receive the intraoperative TXA.
16246735|NCT05047120|Experimental|Intervention group|HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT to identify adaptive cognitions and make adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). Participants will undergo 4 sessions during inpatient rehabilitation admission, each lasting 30-60 minutes. Sessions will include brief assessments of pain intensity, adverse events, and between session practice. Participants in this group will also complete baseline, follow-up, and post-discharge assessments.
16246736|NCT05047120|No Intervention|Measures only|People who consent to the measures only and usual care group will be encouraged to continue using the health care services available to them to address their pain. This includes a Rehabilitation Psychologist who can offer nonpharmacological pain management strategies. Participants in this group will baseline, follow-up, and post-discharge assessments.
16246738|NCT05047081|Experimental|College Workshop Arm|Intervention
16246739|NCT05047081|Placebo Comparator|Placebo|Placebo
16246740|NCT05047055||Single Group - 4 months moxifloxacin group|"Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Moxifloxacin (M)
~Isoniazid, rifampicin, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by isoniazid, rifampicin, ethambutol and moxifloxacin daily for 2 months (2 HRZEM daily / 2HREM daily) - Duration 4 months
~Drug dosages The Fixed-dose Combination (FDC) for HRZE(75/150/400/275mg) used under NTEP according to weight category will be used.
~The patients enrolled in the study will receive an additional tablet of moxifloxacin(M) 400mg (body weight <64 Kg) / 600mg (body weight >65 Kg) along with the FDC both in the intensive and continuation phase."
16246741|NCT05047042|Experimental|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The intervention will take place in participants' homes, at times convenient for the participant. Programming will be administered virtually through the University of Alberta's Cancer Rehabilitation Clinic, which is fully equipped for virtual delivery of services. The study intervention will be tailored to the individual with respect to their baseline strength, symptom profile and prior experience with exercise. Pre- and post-testing will be done virtually. The mode, intensity and duration of each exercise session will be based on the participant's baseline fitness and status that day. Variations on each exercise will be provided to ensure an appropriate movement and intensity and to allow for individual prescription. Resistance bands will be used to provide resistance during strengthening and balance retraining exercises. The interactive group class will be led virtually by an exercise or rehabilitation specialist.
16246742|NCT05047029||Patients with cirrhosis|Patients with cirrhosis and transjugular intrahepatic portosystemic shunt implantation.
16246743|NCT05047016|Other|Dynamic consent arm|Subjects will receive a virtual investigational product once daily. Subjects also need to measure their body temperature once daily at the scheduled timepoint.
16246744|NCT05047003||Patients under evaluation for Suspected Concussion|Device: EyeBOX Model EBX-4 (Portable version)
16246745|NCT05046990||RAC evaluation|Patients older than 18 years without previous history of Hp infection or eradication undergoing a gastroscopy
16246746|NCT05046977|Active Comparator|Single tibial osteotomy|Single tibial osteotomy done to achieve correction
16246747|NCT05046977|Active Comparator|Double tibial osteotomy|Double tibial osteotomy done to achieve correction
16246748|NCT05046951|Active Comparator|Web arm|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
16246792|NCT05046652||One bag of convalescent plasma therapy|Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.
16246793|NCT05046652||Two bags of convalescent plasma therapy|Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.
16246794|NCT05046639|Experimental|Treatment group 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
16246749|NCT05046951|Active Comparator|Print Arm|The Should I Screen print-based education (included with this IRB protocol) will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
16246750|NCT05046938|Experimental|intervention group|It was planned to apply 5 sessions of MI to the intervention group, and to follow-up 2 months after the interviews were completed.
16246751|NCT05046938|No Intervention|control group|No application will be made to the students in the control group, and at the end of the study, a seminar on food addiction and quality of life will be given to the students.
16246752|NCT05046925||24-hour PACU group|closely monitor in post-anesthetic unit (PACU) and the stay time is less than 24 hours, then patients can be discharged to floor
16246753|NCT05046925||24-hour ICU group|closely monitor in intensive care unit (ICU) and the stay time is less than 24 hours, even patients die within 24 hours in ICU
16246754|NCT05046912|Experimental|Clinical|Clinical participants with a primary diagnosis of psychosis or related disorder.
16246755|NCT05046912|Active Comparator|Non-clinical|Non-clinical participants with no mental health diagnoses.
16246756|NCT05046899|Experimental|BIOpH+ Psoriasis Medical Bath|BIOpH+ Psoriasis Medical Bath is bath. Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.
16246757|NCT05046899|Active Comparator|Comparative device|Comparative device is Cetaphil Moisturizing Lotion. The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
16246758|NCT05046886|Active Comparator|Usual Care Control (UCC)|
16246759|NCT05046886|Active Comparator|Standardized|
16246760|NCT05046886|Active Comparator|Personalized|
16246763|NCT05046860|Experimental|Dalbavancine + Rifampicine|
16246764|NCT05046847|Experimental|TQB3811|The initial dose is 2.5mg, once a day (QD), and the medication stage is divided into single administration and continuous administration. The single administration is given once a day, and the continuous administration is entered 4 days after drug withdrawal. The drug is administered continuously until the disease progresses.
16246765|NCT05046834|Experimental|cold application Group|a cold gel pack will be wrapped in gauze and placed directly on the skin in an area with a radius of about 5 cm to cover the chest tube. The cold gel package will remain on the skin surface for about 20 minutes.
16246766|NCT05046834|Experimental|Cold Application Group with Thermometer|10 of cold application. After a minute, the skin temperature will be measured with an infrared thermometer if the temperature has dropped below 13.6 o C, the procedure will be terminated. If the skin temperature has not decreased below 13.6 0 C, the application will be continued, the application will be terminated when the temperature drops below the specified temperature.
16246767|NCT05046834|No Intervention|control Group|standard pain procedure.
16246773|NCT05046795|Experimental|Revefenacin inhalation solution 175 mcg QD.|Revefenacin inhalation solution 175 mcg QD.
16246774|NCT05046795|Placebo Comparator|Placebo inhalation solution QD.|Placebo inhalation solution QD.
16246775|NCT05046782|Experimental|MRI technique|restriction spectrum imaging (RSI) can detect prostate cancer better than a standard-of-care MRI.
16246776|NCT05046756|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
16246777|NCT05046756|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
16246778|NCT05046743|Experimental|Colonic gas load|
16246779|NCT05046743|Sham Comparator|Sham|
16246780|NCT05046730|Experimental|Prospective Evaluation of the SFM Device|This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
16246781|NCT05046730|Active Comparator|Retrospective Chart Review of Historical Controls|In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
16246782|NCT05046691|Experimental|Intervention group|8-week .b Foundations course
16246783|NCT05046691|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
16246784|NCT05046678||Control|Periodontally healthy, non-smoking
16246785|NCT05046678||Smokers with periodontally healthy|Periodontally healthy, smoking
16246786|NCT05046678||Non-smokers with gingivitis|Gingivitis, non-smoking
16246787|NCT05046678||Smokers with gingivitis|Gingivitis, smoking
16246788|NCT05046678||Non-smokers with periodontitis|Periodontitis, non-smoking
16246789|NCT05046678||Smokers with periodontitis|Periodontitis, smoking
16246790|NCT05046665|Other|Staging cohort|Eligible participants recruited to the staging cohort
16246924|NCT05045677|Active Comparator|Standard care|Standard care alone
16246795|NCT05046639|Placebo Comparator|Sham preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
16246796|NCT05046626|Experimental|nutritional counseling|Arm with intervention
16246797|NCT05046613||Pregnant women with migraine exposed to Rimegepant|
16246798|NCT05046613||Pregnant women with migraine not exposed to Rimegepant|
16246799|NCT05046574|Experimental|Therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have a therapy dog present during their stroke rehabilitative therapy sessions.
16246800|NCT05046574|No Intervention|No therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have stroke rehabilitative therapy sessions per standard of care with no therapy dog present.
16246801|NCT05046561|Active Comparator|STRI Formula|STRI Formula 3 capsules by mouth twice daily for 10 days
16246802|NCT05046561|Placebo Comparator|Placebo|Placebo 3 capsules by mouth twice daily for 10 days
16246803|NCT05046548|Experimental|Vaccine|"At Stage I:
~Group 1 - 10 volunteers, Vaccine 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.
~At Stage II:
~Group 1 - 140 volunteers,Vaccine0.5 ml, 14 days interval, post-vaccination observation period of 28 days.
~At Stage III:
~Group 3 - 150 volunteers, Vaccine 0.5 ml, 14 days interval, post-vaccination observation for 6 months."
16246804|NCT05046548|Placebo Comparator|Placebo|"No active ingredient in the placebo
~At Stage I:
~Group 2 - 5 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.
~At Stage II:
~Group 2 - 45 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.
~At Stage III:
~Group 4 - 50 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 6 months."
16246805|NCT05046535||Smokers|Individuals with MS who are current tobacco smokers: Either cigarettes, hookah pipe, E-cigarettes or other forms of tobacco. This group will perform all the assessments including surveys about nicotine dependence and smoking behavior.
16246806|NCT05046535||Non-smokers|Individuals with MS who are non-smokers of any form of tobacco. This group will perform all the assessments except for the surveys related to nicotine dependence and smoking behavior.
16246807|NCT05046522|Experimental|Palmitoylethanolamide sold as Levagen +|Palmitoylethanolamide in capsule form - taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
16246808|NCT05046522|Placebo Comparator|A comparator placebo capsule - Maltodextrin and microcrystalline cellulose mix|A comparator capsule taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
16246809|NCT05046509||COVID_Patients|"Patient has been confirmed diagnosis Covid-19 disease by PCR
~Patient aged 18 years and above"
16246810|NCT05046496|No Intervention|Observational arm|Patients recruited to this arm will undergo no intervention.
16246811|NCT05046496|Active Comparator|Interventional arm|Patients recruited to this arm will undergo intra-arterial digital subtraction angiography, with or without intra-arterial stent placement
16246812|NCT05046483||Diabetes Cohort|Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and diabetes mellitus type 1 or type 2 according to criteria of the German Diabetes Society (DDG) (HbA1c ≥ 6.5 % or orale glucose tolerance test), aged 18-80 years at inclusion into the study
16246813|NCT05046483||Normal Glucose Tolerance (NGT) Cohort|Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and normal glucose tolerance (HbA1c < 5.9 % and normal oral glucose tolerance test), aged 18-80 years at inclusion into the study
16246814|NCT05046457|Experimental|3mg BCX supplement|One 3mg BCX capsule + one placebo capsule to be taken once per day for 8 weeks
16246815|NCT05046457|Experimental|6mg BCX supplement|Two 3mg BCX capsules to be taken once per day for 8 weeks
16246816|NCT05046457|Placebo Comparator|0mg BCX supplementation|Two placebo capsules to be taken once per day for 8 weeks
16246817|NCT05046444||Unclear diagnosis via conventional methods|The study population consists of carefully chosen patients with potential hematological malignancy, for which current diagnostic methods were not sufficient to provide clear-cut diagnosis and definitive clinical guidance. SIRIUS will be conducted for a total number of 110 patients with inconclusive diagnosis by gold standard techniques for a total of up to nine months after the first enrollment.
16246818|NCT05046431|Active Comparator|EU Simponi|
16246819|NCT05046431|Experimental|BAT2506|
16246820|NCT05046418||Hypoallergenic formula containing synbiotics|Infants (aged <13 months) with cow's milk allergy (CMA) who are prescribed a hypoallergenic formula containing synbiotics as part of usual clinical practice for the dietary management of CMA.
16246821|NCT05046405|Experimental|home-based remotely supervised tDCS|The intervention combines home-based tDCS (1 or 2 cycles of 15 daily sessions for 3 weeks/cycle at 2 mA for 30 minutes) with tele-health for remote supervision and e-health for self-monitoring of depressive symptoms.
16246826|NCT05046366||Lung cancer group|Participants with lung cancer/pulmonary nodules
16246827|NCT05046366||Pulmonary tuberculosis group|Participants with pulmonary tuberculosis
16246828|NCT05046366||COIVD-19 group|Participants with COIVD-19
16246829|NCT05046353|Experimental|D-serine|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
16246830|NCT05046353|Placebo Comparator|placebo|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
16246832|NCT05046314|Experimental|TK216+Vincristin|
16246833|NCT05046301||Diagnostic (contrast-enhanced mammography)|Patients complete a questionnaire and undergo collection of a blood sample. Patients undergo CEM.
16246834|NCT05046288|Experimental|Group 1|Participants will participate to the 3-month cycle of virtual guided tour of the MMFA and will complete assessments at M0 and at M3
16248334|NCT05036447|No Intervention|DM-Rest|Control leg (i.e. no exercise) in DM1-patients
16246835|NCT05046288|No Intervention|Group 2|Participants will not participate to the 3-month cycle of virtual guided tour of the MMFA but will complete assessments at M0 and at M3
16246836|NCT05046275||MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
16246837|NCT05046275||Non MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
16246838|NCT05046249||Chiropractic clinicians|Swiss chiropractic clinicians
16246839|NCT05046236|Experimental|Interactive POWER rehabilitation|Participants in this group would be treated with POWER for twice a week, total 12 weeks.
16246840|NCT05046236|Active Comparator|Conventical physical training Group|Participants in this group would be treated with traditional exercise rehabilitation for twice a week, total 12 weeks.
16246841|NCT05046236|No Intervention|Control group|Usual care
16246842|NCT05046223|Experimental|high-flow nasal oxygen|THRIVE( Transnasal humidified rapid-insufflation ventilatory exchange), a method of high-flow nasal oxygen (HFNO), is planned to applied for bronchoscopic interventions
16246843|NCT05046223|Active Comparator|supraglottic devise|iGel, a supraglottic devise with tip in upper esophagus, is planned to applied for bronchoscopic interventions
16246844|NCT05046210|Experimental|LHA group (EG)|"Behavioral: LHA intervention
~Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day, whereas the participants in the EG also received 4 lessons from a LHA over 4 weeks."
16246845|NCT05046210|Placebo Comparator|Leaflet group (CG)|"Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
~The participants in the CG received oral exercise intervention and leaflets only."
16246846|NCT05046197||Work Package 1 - patients and carers|"Qualitative interview of 48 Patients, or their carers where the patient lacks capacity, who have had a ReSPECT form completed in the previous 6 months. To include:
~12 patients living in care homes 12 patients living at home (nearing the end of their life) 12 patients living at home (not nearing the end of their life)"
16246847|NCT05046197||Work Package 1 - GPs|Qualitative interview of 30 General Practitioners who are involved in the ReSPECT process
16246848|NCT05046197||Work Package 1 - Care home managers|Qualitative interview of 24 care home managers.
16246849|NCT05046197||Work Package 2 - Focus groups/interviews (Members of the Public)|Qualitative interview of 30 members of the public with an interest in healthcare regarding attitudes to the ReSPECT process.
16246850|NCT05046197||Work Package 2 - Focus groups/interviews (Health and Social Care Professionals)|Qualitative interview of 30 Non-GP Health and Social Care Professionals regarding attitudes to the ReSPECT process.
16246851|NCT05046197||Work Package 2 - Focus groups/interviews (Faith Leaders)|Qualitative interview of 8 faith leaders regarding attitudes to the ReSPECT process.
16246852|NCT05046197||Work Package 2 - Survey (Members of the Public)|Survey of 1000 members of the public to measure public awareness and acceptability of emergency care treatment plans
16246853|NCT05046197||Work Package 2 - Survey (GPs)|Survey of 1000 GPs to measure the views of GPs nationally regarding the use of emergency care treatment plans including ReSPECT, in primary care.
16246854|NCT05046197||Work Package 3 - Patient records|Patient records of 413 patients within 12 CCGs in England who have had a ReSPECT form completed in the previous 12 months
16246855|NCT05046184|No Intervention|Healthy Controls|Healthy controls will undergo clinician assessments and fMRI to compare to MDD group.
16246856|NCT05046184|Active Comparator|MDD - Ketamine|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four ketamine infusions.
16246857|NCT05046184|Placebo Comparator|MDD - Midazolam|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four midazolam infusions.
16246858|NCT05046171|Experimental|Arm 1: Pharmacist-led deprescribing intervention|Pharmacists will complete a comprehensive medication assessment with the participant via telemedicine and discuss tailored recommendations for discontinuations of potentially inappropriate medications. The pharmacist will document the evaluation and recommendations and communicate to the participant and care team members. The pharmacist will telephone each participant at least one time after the initial intervention to assess adherence to instructions and recommendations, and to assess any symptoms potentially related to medication discontinuation.
16246859|NCT05046171|Active Comparator|Arm 2: Patient education brochure|Participants will receive a brochure discussing medication appropriateness and deprescribing in general terms
16246925|NCT05045664|Active Comparator|Standard|Standard dose (24 Gy) involved site radiotherapy plus Rituximab
16246926|NCT05045664|Experimental|Experimental|ow-dose (4 Gy) involved site radiotherapy in combination with Obinutuzumab
16246860|NCT05046158|Active Comparator|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.
16246861|NCT05046158|Active Comparator|Standard of Care Dressing|Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.
16246862|NCT05046145|Experimental|tDCS + speech therapy+ sham|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
16246863|NCT05046145|Experimental|sham + tDCS + speech therapy|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
16246867|NCT05046106|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks.
16246868|NCT05046106|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
16246869|NCT05046106|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
16246870|NCT05046093|Experimental|Single intervention arm - transbronchial cryobiopsy|Patients enrolled in this single arm will have lung nodules biopsied by transbronchial cryobiopsy.
16246871|NCT05046080||Observational (medical record review)|Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
16246872|NCT05046067|Experimental|Diagnostic (CT)|Patients undergo 4 CT scans during standard of care surgery.
16246875|NCT05046041|Experimental|Mifepristone + Misoprostol|200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
16246876|NCT05046028|Experimental|Test|50 patients with squamous cell head cancer over 18 years of age, receiving chemoradiation therapy, receiving 3 bottles (х 200 ml) of ONS with Protein Oncosensation with a neutral taste throughout the course of treatment.
16246877|NCT05046028|Active Comparator|Prospective Control group|50 patients over 18 years of age with squamous cell carcinoma of the head and neck, receiving chemoradiation therapy, receiving standard nutritional therapy with a neutral taste throughout the course of treatment.
16246878|NCT05046028|Sham Comparator|Retrospective Control group|60 patients who received chemoradiotherapy earlier with standard nutritional support.
16246879|NCT05046015|No Intervention|non diabetic|Control Group of 20 non-diabetics. Skin measurements, evaluation of skin dryness and sampling of skin particles will be performed
16246880|NCT05046015|Experimental|moderate dryness-diabetic|"Experimental: Diabetics with moderate dryness. Intervention Group of 20 diabetics with moderate dryness
~10% Urea foot lotion During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
16246881|NCT05046015|Experimental|severe dryness- diabetic|"Intervention Group of 20 diabetics with severe dryness 10% Urea foot ointment During the course of the study participants cleanse their feet once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® Fuss Salbe 10% Urea on both feet once daily in the evening by themselves."
16246882|NCT05046002||Research Prospective|Patients who develop new symptoms of suspected myocarditis/pericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath, or pain with breathing; palpitations; or syncope.
16246883|NCT05046002||Control Positive|first-degree family member who also had similar reactions
16246884|NCT05046002||Control Negative|"first-degree family member who has been vaccinated in a similar timeframe with the participants but did not experience myocarditis side-effects.
~If a first-degree relative is not available, then a voluntary control who has received the same COVID-19 vaccine in a similar time frame can be recruited."
16246885|NCT05046002||Research Retrospective|identified patients previously diagnosed with the condition, at participating centers
16246927|NCT05045651|Experimental|patient specific knee prosthesis|TKA with Gender Solution® posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
16246928|NCT05045651|Experimental|Unisex knee prosthesis|TKA with posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
16246886|NCT05045989|Experimental|Residence-based asymptomatic SARS-CoV-2 testing|The aim of the RB-TPP was to increase and maintain participation of students in regular COVID-19 testing in university residences. The R-TPP was delivered over 4 weeks in April-May 2021 and required asymptomatic students to take a saliva test for COVID-19, twice weekly for four weeks. This was combined with relaxed social restrictions within the residence during the study period (i.e., removing the need for 2 metre distancing between students living in the same residence), surge testing and enhanced support for students who were required to self-isolate (i.e., welfare and financial support).
16246887|NCT05045976|Experimental|Experimental group|The experimental group will receive the web-based interactive self-management support intervention.
16246888|NCT05045976|No Intervention|Control group|The control group will receive usual care and regular patients education.
16246889|NCT05045963||Observational (medical record review)|Patients' medical charts are reviewed retrospectively.
16246890|NCT05045950|Experimental|WBRT-PRDR plus memantine.|Study patients will receive WBRT-PRDR within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique. Memantine should ideally start two days (or one day) prior to WBRT PRDR and must start no later than the fourth WBRT PRDR treatment and will continue for a maximum of 24 weeks (≈six months). Memantine will be administered as per standard institutional guidelines.
16246891|NCT05045937||COVID-19 patients treated with Ivermectin|This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
16246892|NCT05045937||COVID-19 patients declining Ivermectin and wanting traditional treatment|This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
16246893|NCT05045924||Intervention group|20 patients with decompensated liver cirrhosis monitored using a wrist-watch wearable device, with associated smart weighing scales and blood pressure cuff, along with a smartphone application (including economic smartphone in those patients if not available), to facilitate home monitoring.
16246894|NCT05045924||Control group|20 patients with decompensated liver cirrhosis receiving standard quality of care.
16246895|NCT05045911|Experimental|Endoscopic Barbed-clips Suturing|Patients will be closed the mucosal defect after colorectal ESD using Endoscopic Barbed-clips Suturing.
16246896|NCT05045898|Experimental|Control group|plantar massage
16246897|NCT05045898|Experimental|Intervention group|plantar massage and textured insoles
16246898|NCT05045872|Experimental|EMRA|Patients will receive contrast-enhanced renal artery magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography.
16246899|NCT05045859|Experimental|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning.
16246900|NCT05045859|No Intervention|No Intervention: Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 15-weeks waiting period. At the end of that period received the exact intervention as the study group.
16246906|NCT05045820|Active Comparator|Treatment|
16246907|NCT05045820|Sham Comparator|Sham|
16246908|NCT05045807|Experimental|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with sodium nitrate as an additive.
16246909|NCT05045807|Experimental|Meat with added nitrate plus vegetables|"The same intervention as of Arm meat with added nitrate consumed together with mixed vegetables."
16246910|NCT05045794|Experimental|Hypothermic oxygenated perfusion (HOPE)|Ex-vivo donor liver preservation using static cold storage followed by HOPE using the VitaSmart Liver Machine
16246911|NCT05045794|Other|Static cold storage|Ex-vivo donor liver preservation using static cold storage only
16246912|NCT05045781|Experimental|Eptinezumab 100 mg|
16246913|NCT05045781|Experimental|Eptinezumab 300 mg|
16246914|NCT05045768|Experimental|Postinfectious ibs and diarrhea predominant classical IBS|Capsule containing Xyloglucan Tamarindus indica seed standardized extract, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec sagl) twice daily
16246915|NCT05045755||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
16246916|NCT05045755||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
16246917|NCT05045742||Training|A subset of patients that are used to train the machine learning algorithm.
16246918|NCT05045742||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
16246919|NCT05045729||OHCA SPORTS|All OHCA, where the patient was engaged in sports at the time of the event
16246920|NCT05045716|Experimental|Lecanemab 10 mg/kg|Participants will receive lecanemab 10 milligram per kilogram (mg/kg), as single dose IV infusion over approximately 1 hour on Day 1.
16246921|NCT05045716|Experimental|Lecanemab 700 mg|Participants will receive lecanemab 700 milligram (mg), as single fixed dose SC injection in the abdomen on Day 1.
16246922|NCT05045703|Experimental|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
16246923|NCT05045677|Experimental|Digital DBT intervention group|Digital intervention group plus standard care
16246931|NCT05045625||Study Group|Twelve patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
16246932|NCT05045612|Experimental|Intervention|Stop antibiotic therapy as instituted by admitting physician
16246933|NCT05045612|No Intervention|Control|Continue antibiotic therapy at the discretion of the treating physician (no change in ongoing treatment)
16246934|NCT05045599|Experimental|Integration of Family planning in Maternal, Newborn and Child Health|Strengthening of capacity of LHWs and Health care provider in providing integrated services Ensure Sustained supplies are available Community Mobilization Infrastructure support to ensure privacy and confidentiality Improvement of data recording, reporting and use
16246935|NCT05045599|Active Comparator|Standard of care|
16246936|NCT05045586|Experimental|Modified Coronally Advanced Tunnel With Connective Tissue Graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
16246937|NCT05045586|Active Comparator|MCAT With Cross-linked Hyaluronic Acid in Addition to CTG|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with cross-linked hyaluronic acid. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
16246938|NCT05045560||antenatal diagnosis of anorectal malformation|Groupe 1 : antenatal diagnosis of anorectal malformation
16246939|NCT05045560||postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound|Groupe 2 : postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound
16246940|NCT05045560||postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound|Groupe 3 : postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound
16246941|NCT05045547||Patients with febrile illness|Febrile patients attending village malaria workers (VMWs)
16246942|NCT05045547||Health centre staffs|Health centre staffs from 12 rural health centres
16246943|NCT05045547||Key stakeholders|"Key stakeholders , for example health managers and health professionals:
~the director, deputy-directors, and technical officers at the National Malaria Control Program;
~the directors and deputy-directors of the Provincial Health Departments in Battambang and Pailin province;
~health officers actively involved in community-based (malaria) programmes at the district levels in Battambang and Pailin provinces;
~health workers (i.e., nurses or doctors) actively involved in community-based (malaria) programmes in Battambang and Pailin provinces;
~community representatives and village malaria workers from villages in both Battambang Pailin province."
16246944|NCT05045534|Experimental|Cohort 1 Single Dose SD1 (first dose)|Group SD1 a first single dose of TB-840(n=6) or placebo(n=2)
16246945|NCT05045534|Experimental|Cohort 2 Single Dose SD2 (second dose)|Group SD2 a first single dose of TB-840(n=6) or placebo(n=2)
16246946|NCT05045534|Experimental|Cohort 3 Single Dose SD3 (third dose)|Group SD3 a first single dose of TB-840(n=6) or placebo(n=2)
16246947|NCT05045534|Experimental|Cohort 4 Single Dose SD4 (fourth dose)|Group SD4 a first single dose of TB-840(n=6) or placebo(n=2)
16246948|NCT05045534|Experimental|Cohort 5 Single Dose SD5 (fifth dose)|Group SD5 a first single dose of TB-840(n=6) or placebo(n=2)
16246949|NCT05045534|Experimental|Cohort 6 Single Dose SD6 (sixth dose)|Group SD6 a first single dose of TB-840(n=6) or placebo(n=2)
16246950|NCT05045534|Experimental|Cohort 7 Single Dose SD7 (seventh dose)|Group SD7 a first single dose of TB-840(n=6) or placebo(n=2)
16246951|NCT05045534|Experimental|Cohort 8 Single Dose SD8 (eighth dose)|Group SD8 a first single dose of TB-840(n=6) or placebo(n=2)
16246952|NCT05045534|Experimental|Cohort 9 : Mutiple Dose MD1|Group MD1 a first multiple dose of TB-840(n=6) or placebo(n=2)
16246953|NCT05045534|Experimental|Cohort 10 : Mutiple Dose MD2|Group MD2 a first multiple dose of TB-840(n=6) or placebo(n=2)
16246954|NCT05045534|Experimental|Cohort 11 : Mutiple Dose MD3|Group MD3 a first multiple dose of TB-840(n=6) or placebo(n=2)
16246955|NCT05045521|Experimental|plyometric warm up group|set of active exercises used as warm up protocol.
16246956|NCT05045521|Experimental|resistance warm up group|warm up protocol on treadmill wearing weighted jacket
16246957|NCT05045521|Active Comparator|control|warm up protocol on treadmill without weights
16246958|NCT05045508|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|
16246959|NCT05045508|Placebo Comparator|Placebo (vehicle) nasal spray|
16246960|NCT05045495||Healthy Volunteer|120 Healthy Volunteers will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
16246961|NCT05045495||CSID Case|50 CSID cases defined by being on Sucraid for at least 12 months will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
16246962|NCT05045482|Experimental|Saroglitazar Magnesium 1 mg|"The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.
~Study drug -Saroglitazar Magnesium tablets; Dosage form- Tablets (immediate release); Dose- 1 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration of treatment- 28 consecutive days"
16246963|NCT05045482|Experimental|Saroglitazar Magnesium 2 mg|"The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.
~Study drug -Saroglitazar Magnesium tablets: Dosage form- Tablets (immediate release); Dose- 2 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration- 28 consecutive days"
16246964|NCT05045469|Active Comparator|group A (dian dao san group)|Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
16246965|NCT05045469|Placebo Comparator|group B( topical medicine without therapeutic effects)|Placebo (topical medicine without therapeutic effects) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
16246966|NCT05045443|Active Comparator|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea
16246967|NCT05045443|Placebo Comparator|Standard of nutritional care|Standard of nutritional support care
16246968|NCT05045430|Experimental|Assigned Intervention|Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silver II Non-Woven Dressing
16246969|NCT05045417||Cases with SLE|"110 patients with SLE will be divided to :
~40 patients with lupus nephritis
~40 patients interstitial lung disease
~30 SLE patients without internal organ affection)"
16246970|NCT05045417||control group|30 sex and age matched healthy individuals as a control group
16246971|NCT05045404|Experimental|Treatment (poziotinib hydrochloride, ramucirumab)|Patients receive poziotinib hydrochloride PO BID on day 1 and ramucirumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16246972|NCT05045391||pulmonary tuberculosis (smear-positive) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-positive)
16246973|NCT05045391||pulmonary tuberculosis (smear-negative) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-negative)
16246977|NCT05045352|Active Comparator|Echogenic needle|venous access performed under ultrasound guidance with echogenic needles
16246978|NCT05045352|No Intervention|Non-Echogenic needles|venous access performed under ultrasound guidance with non-echogenic needles
16246979|NCT05045339|Experimental|Exercise Group|Five different ball exercises were implemented for 35 minutes, 3 sessions per week for 2 months.
16246980|NCT05045339|No Intervention|Control Group|No exercises were performed in control group
16246981|NCT05045326|Experimental|Experimental: Intervention Group|Participants in the intervention group will receive an intensive motivational intervention with individual and group treatment for smoking cessation. The treatment, provided by trained professionals, will include psychological, psycho-educational support and pharmacological treatment advice.
16246982|NCT05045326|Placebo Comparator|Placebo Comparator: Brief Counselling|Participants in the placebo group will receive a brief intervention for smoking cessation.
16246983|NCT05045313|Experimental|The DDI of DBPR108 and Warfarin Sodium Tablets|Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.
16246984|NCT05045313|Experimental|The DDI of DBPR108 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.
16246985|NCT05045313|Experimental|The DDI of DBPR108 and Probenecid Tablets|Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.
16246986|NCT05045287|Experimental|hypofractionated radiation therapy|receive chest wall and nodal irradiation at a dose of 43.5 Gy in 15 fractions over 3 weeks
16246987|NCT05045274|Active Comparator|dapagliflozin|(a) Dapagliflozin 10 mg once daily within 24 hours after PPCI for 3 month
16246988|NCT05045274|Placebo Comparator|conventional therapy|"Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.
~Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.
~Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
16246989|NCT05045261|No Intervention|A - Standard of care NUC|Patients will continue their standard of care NUC treatment
16246990|NCT05045261|Experimental|B - NUC discontinuation|Patients will stop their NUC treatment 28 weeks after enrolment
16246991|NCT05045261|Experimental|C - NUC discontinuation after SLGN treatment|"Patients will take from enrolment
~their standard of care NUC treatment for 28 weeks then stop
~3mg SLGN weekly for 24 weeks then stop"
16246992|NCT05045248|Experimental|Patients|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.
16246993|NCT05045209|Experimental|Virtual rehabilitation|Virtual pulmonary rehabilitation will be provided by a tablet with connection to a physiotherapist for monitored exercise sessions with educational videos provided on the tablet.
16246994|NCT05045196|Experimental|Patient and family member of patient undergoing elective open heart surgery- Intervention|Family randomized to the intervention group receiving Health-promoting conversation intervention
16246995|NCT05045196|No Intervention|Patient and family member of patient undergoing elective open heart surgery- Control|Family of a patient undergoing elective open-heart surgery randomized to the intervention group receiving standard care
16246996|NCT05045183|No Intervention|Treatment A: Uncovered Wound (Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as a negative control.
16247094|NCT05044637|Active Comparator|Primaquine (7.0mg x 14d)|Primaquine 14 days Standard blood schizontocidal therapy plus 14 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (0.5 mg/kg).
16246997|NCT05045183|Active Comparator|Treatment B: Standard of Care (SoC) Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, SoC adhesive bandage will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
16246998|NCT05045183|Experimental|Treatment C: Antibiotic Ointment|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment will be applied. This treatment will be applied daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
16246999|NCT05045183|Experimental|Treatment D: Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
16247000|NCT05045183|Experimental|Treatment E: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 0 through Day 2 and all wound sites will be uncovered after Day 3 to Day 16 for assessments.
16247001|NCT05045183|Experimental|Treatment F: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
16247002|NCT05045183|Experimental|Treatment G: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
16247003|NCT05045183|Experimental|Treatment H: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
16247004|NCT05045170|Experimental|propofol group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with propofol sedation
16247005|NCT05045170|Experimental|dexmedetomidine group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with dexmedetomidine sedation
16247006|NCT05045170|Placebo Comparator|control group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia without sedation
16247007|NCT05045157|Experimental|percutaneous A1 pulley release with corticosteroid injection|
16247008|NCT05045157|Active Comparator|corticosteroid injection alone|
16247016|NCT05045131|Experimental|PVI+PWI, 6 months reassessment procedure, 3 year continued rhythm monitoring|Single arm experimental, observational study: All participants receive a single-procedure combined PVI + posterior wall isolation (PVI+PWI), loop recorder implantation, esophagoscopy, a mandated interventional reassessment /reablation procedure at six months and continuous rhythm monitoring for three years
16247017|NCT05045118|Experimental|Intervention arm|Single-arm prospective, multiple assessment intervention study. Participants will receive a digital structured patient education material
16247018|NCT05045105||ICU physicians|Intensive Care physicians who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
16247019|NCT05045105||Neurosurgeons|Neurosurgeons who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
16247020|NCT05045079|Other|Severe tricuspid regurgitation due to atrial fibrillation|Subjects will receive standard of care procedure right heart catheterization with a inferior vena caval (IVC) occlusion maneuver.
16247021|NCT05045066|Experimental|Treatment (cholecalciferol)|Patients with low vitamin D3 levels receive cholecalciferol PO daily for 8 weeks in the absence of unacceptable toxicity.
16247022|NCT05045053|Experimental|xiidra group|patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking
16247023|NCT05045053|No Intervention|control group|patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups
16247095|NCT05044624|Other|Margin, Tumor-Free|
16247096|NCT05044611|Experimental|Amiloride|the experimental arm will receive 5mg of amiloride twice daily during 2 months
16247024|NCT05045040|Experimental|Mobile-based empathic communication support program group|Patients will be provided an mobile-based empathic communication support program to promote ACP discussion for advanced cancer patients and physicians. The experimental group will also receive the usual care as is standard practice.
16247025|NCT05045040|No Intervention|Usual care group|Patients will receive the usual care. The usual care includes routine medical treatment and care by physicians, nurses, pharmacists, and others as well as support from the palliative care team and others as per the patient's situation.
16247026|NCT05045027|Experimental|Basic science (MRI, metabolic imaging, tissue collection)|"AIM 1: Previous scan data from healthy subjects is collected and analyzed.
~AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.
~AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection."
16247027|NCT05045014||Patient group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task. In addition, X-ray images taken during routine follow-ups will be used to determine the location, type of curvature and Cobb angle of the scoliosis. The degree of rotation will be measured with a mobile application called Scoliodetector. Quality of life is planned to be evaluated with the Scoliosis Research Society-22 questionnaire.
16247028|NCT05045014||Control group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task.
16247029|NCT05044988|Experimental|HS-10342|Each subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
16247030|NCT05044975|Experimental|Sleep restriction, Stimulus control, and Systematic light exposure|
16247031|NCT05044975|Experimental|Sleep restriction and Stimulus control|
16247032|NCT05044975|Experimental|Sleep restriction and Systematic light exposure|
16247033|NCT05044975|Experimental|Stimulus control and Systematic light exposure|
16247034|NCT05044975|Experimental|Sleep Restriction|
16247035|NCT05044975|Experimental|Stimulus control|
16247036|NCT05044975|Experimental|Systematic light exposure|
16247037|NCT05044975|No Intervention|Sleep tracking|
16247038|NCT05044962|Experimental|Aim 1a (PK study group 1)|Initiating injectable cabotegravir/rilpivirine (LA ART) and DMPA
16247039|NCT05044962|Experimental|Aim 1a (PK study group 2)|Initiating injectable cabotegravir/rilpivirine (LA ART) and and etonogestrel implant
16247040|NCT05044962|Experimental|Aim 1a (PK study group 3)|Initiating injectable cabotegravir/rilpivirine (LA ART) and levonorgestrel implant.
16247041|NCT05044962|Active Comparator|Aim 1a (PK study group 4)|Receiving injectable cabotegravir/ rilpivirine (LA ART) and not using any hormonal contraceptive method (e.g. copper IUD)
16247042|NCT05044962|Active Comparator|Aim 1a (PK study group 5)|AGYW without HIV and not exposed to antiretrovirals (e.g., for PrEP) initiating DMPA
16247043|NCT05044962|Experimental|Aim 2a (Hybrid trial intervention group)|AGYW with viral suppression on their current ART regimen to switch to cabotegravir/ rilpivirine.
16247044|NCT05044962|Active Comparator|Aim 2a (Hybrid trial comparator group)|AGYW with viral suppression to continue their oral ART regimen.
16247045|NCT05044949|Active Comparator|Low dose L reuteri capsules|Subjects will be asked to consume 2 capsules with high dose L reuteri per day in 28 days.
16247046|NCT05044949|Active Comparator|High dose L reuteri capsules|Subjects will be asked to consume 2 capsules with a low dose L reuteri per day in 28 days.
16247047|NCT05044949|Placebo Comparator|Placebo capsules|Subjects will be asked to consume 2 capsules with placebo powder per day in 28 days.
16247048|NCT05044936|Experimental|Training|Visit 1: sign consent form, pregnancy tests for females, resting blood pressure, height/weight, body composition, and VO2max test. Visit 2: 1-repetition maximum (RM) test and protocol familiarization. Visit 3: perform a muscle-damaging exercise protocol. Pre-exercise soreness and blood samples will be collected. After, they will perform the pre-exercise testing to assess baselines levels of power and sprint times. Upon completion, they will undergo the muscle-damaging exercise protocol. Post-exercise blood samples and soreness will be collected. The participant will then be given either placebo or CBD cream to rub into their quadriceps. Visit 4 & 5: collect blood samples and soreness scale measurements. Participants will then be given the same treatment (placebo or CBD cream) as they had on visit 3. Visit 6 will be similar to visit 3, except the participant will be given the opposite treatment (placebo or CBD cream). Visits 7 & 8 will be similar to visits 4 & 5, respectively.
16247049|NCT05044923|Experimental|Targeted Epidural Spinal Stimulation|Participants will undergo surgery to implant devices that will be used for Targeted Epidural Spinal Stimulation (TESS).
16247050|NCT05044910||MAM children with TB disease|
16247051|NCT05044910||Wellnourished children with TB disease|
16247052|NCT05044910||MAM children with latent TB infection|
16247053|NCT05044910||Well-nourished children with latent TB infection|
16247054|NCT05044897|Experimental|Study treatment|SI-B001 was administered weekly by intravenous infusion（QW）. The 4-week cycle was maintained until disease progression or cessation due to intolerable toxicity or other reasons (e.g., withdrawal of informed consent or death). From C1D1, efficacy was evaluated every 8 weeks ±7 days in the first year and every 12 weeks ±7 days in the second year.
16247097|NCT05044611|Placebo Comparator|Placebo|the control arm will receive a placebo twice daily during 2 months
16248360|NCT05036226|Experimental|Dose level 1|
16247057|NCT05044871|Experimental|Arm 1: Pamiparib+ Bevacizumab|Arm1 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 mutant): Pamiparib 40mg PO. bid. plus Bevacizumab 7.5mg/kg IV. D1 (q3w.).
16247058|NCT05044871|Experimental|Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm2 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and ≥3 CD8+ TILs count): Tislelizumab 200mg IV. D1 + Bevacizumab 7.5mg/kg IV. D1 + Nab-paclitaxel 125mg / m2 IV. D1, 8 (q3w).
16247059|NCT05044871|Experimental|Arm 3: Bevacizumab + Nab-paclitaxel|Arm3 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and <3 CD8+ TILs count): Bevacizumab 7.5mg/kg IV D1, 15 + Nab-paclitaxel 100mg / m2 IV D1, 8, 15 (Q4w).
16247060|NCT05044871|Experimental|Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm4 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: ≥3 CD8+ TILs count): Tislelizumab 200mg IV D1 + Bevacizumab 7.5mg/kg IV D1 + Nab-paclitaxel 125mg / m2 IV D1, 8 (q3w).
16247061|NCT05044871|Experimental|Arm 5: Bevacizumab + Nab-paclitaxel|Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: <3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
16247062|NCT05044858|Experimental|Midpoint transverse process block group|Patients will receive midpoint transverse process block after induction of general anesthesia and before surgical incision
16247063|NCT05044858|Sham Comparator|Sham group|Patients will receive general anesthesia and the same intervention steps will be performed i.e., the block under investigation but instead of local anesthetic a placebo (2ml normal saline) will be injected (sham block)
16247067|NCT05044832|Experimental|Personalized Music|Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit in addition to standard care.
16247068|NCT05044832|No Intervention|Standard of Care|Those assigned to the Standard of Care arm will only receive standard of care in the preoperative holding area as well as in the post-operative care unit
16247069|NCT05044819|Experimental|Cannabidiol|Cannabidiol solution 100 milligrams per milliliter (mg/mL) will be administered orally at a dose level of 5 mg/kg/day for 1 week, then increase to 10 mg/kg/day by the participant or their caregiver twice each day (morning and evening).
16247070|NCT05044806|Experimental|Ultrasound-guided-RIC group|Patients in the ultrasound-guided-RIC group will receive percutaneous coronary intervention (PCI), usual pharmacotherapy and pre-, per-, and post-operative ultrasound-guided remote ischemic conditioning (RIC). The pressure applied during cuff inflation is total occlusion pressure (TOP) determined with ultrasound measurement.
16247071|NCT05044806|Experimental|Traditional RIC group|Patients in the traditional RIC group will receive PCI, usual pharmacotherapy and pre-, per-, and post-operative traditional RIC. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
16247072|NCT05044806|Other|Control group|Patients in the control group will receive PCI and usual pharmacotherapy.
16247076|NCT05044754||SCAP|Patients with recurrent prostate cancer undergoing SCAP
16247077|NCT05044754||HIFU|Patients with recurrent prostate cancer undergoing HIFU
16247078|NCT05044741||Perforated group|
16247079|NCT05044741||Controlled group|
16247080|NCT05044728|Experimental|Neoadjuvant Chemotherapy Immunotherapy stage|Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
16247081|NCT05044715|Experimental|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) as an intervention.
16247082|NCT05044715|Experimental|Compassion-Focused Therapy|Participants in this arm will be enrolled in a CFT group intervention.
16247083|NCT05044702|Experimental|Retro walking|Retro walking
16247084|NCT05044702|Active Comparator|conventional physical therapy|Conventional Physical therapy
16247085|NCT05044689||Colorectal Cancer (Cases)|Based on the existing ARGO (African Colorectal Cancer Group) platform where a current colorectal cancer study is going on, 400 patients with a prior diagnosis and a new diagnosis will be recruited into this study.
16247086|NCT05044689||Controls|We will select our 400 controls from two groups of participants who are free of cancer and gastrointestinal diseases. First, we will leverage community mobilization groups to identify and recruit a target group of 200 community-based population controls. Second, we will identify and recruit the remaining 200 controls from those seeking care in the Outpatient Health Center at OAU, which sees ~50-60 patients per day as part of routine care.
16247087|NCT05044676||patients with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
16247088|NCT05044663||NASH related cACLD|NASH related cACLD (Liver Stiffness ≥10 kPa).
16247089|NCT05044663||Viral hepatitis (HBV / HCV) related cACLD|Viral hepatitis (HBV / HCV) related cACLD
16247090|NCT05044650|Experimental|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days combined with background treatment
16247091|NCT05044650|No Intervention|NON-KOVIR|Only background treatment
16247092|NCT05044637|Experimental|Primaquine (3.5mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
16247093|NCT05044637|Active Comparator|Primaquine (7.0mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
16247098|NCT05044585|Experimental|Remote Automated Monitoring System|Two MultiSense® patches will be placed on each volunteer. The monitoring will last no more than 3 hours, during an induced and controlled hypoxia.
16247099|NCT05044572|Experimental|Open chain kinetic exercises|
16247100|NCT05044572|Experimental|Forward head posture correction exercises|
16247101|NCT05044559|Experimental|Continuous Positive Air Way Group|"Day 1: Use of CPAP between 10 and 12 cmH2O according to tolerance for 20 minutes two time a day at first day of post surgery bed mobility chest physiotherapy ,active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise. and vital was record after exercise.
~Day 2: Active ROM exercise progress of 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time was increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
16247102|NCT05044559|Active Comparator|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.
~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
16247103|NCT05044546|Experimental|Aim 1 and secondary aim 2 (focus group)|Participants participate in focus group over 60-90 minutes. Participants who completed and dropped out of postpartum treatment also participate in a focus group.
16247104|NCT05044546|Experimental|Aim 3 Group I (BA)|Participants participate in smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
16247105|NCT05044546|Experimental|Aim 3 Group II (HW)|Participants participate in smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
16247106|NCT05044546|Experimental|Aim 4 Group III (BA)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
16247107|NCT05044546|Experimental|Aim 4 Group IV (HW)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
16247108|NCT05044533||Cohort 1|Participants with atrial fibrillation (AF) experiencing a bleed
16247111|NCT05044494||study group|non-prompt surgery after acute type a aortic dissection occurred
16247112|NCT05044494||control group|prompt surgery after acute type a aortic dissection occurred
16247113|NCT05044468|Experimental|Group A (liposomal bupivacaine)|Patients receive liposomal bupivacaine via injection into the intercostal nerve block.
16247114|NCT05044468|Active Comparator|Group B (lidocaine)|Patients receive lidocaine via injection into the pleuroscopy port incision sites and indwelling pleural catheter site.
16247115|NCT05044455|Experimental|Arm 1: Immediate Treatment|The immediate treatment group will receive an online 9 week CBT intervention led by trained peers who have themselves recovered from postpartum depression. The CBT group will be two hours long, weekly and involves teaching and practice of core CBT skills. Core cognitive skills including thought records and cognitive restructuring are introduced and practiced from week 1. Behavioural techniques are introduced at week 2 and continue throughout the group, including behavioural activation, relaxation techniques, sleep strategies, exercise and goal setting. Each participant will receive a professionally design CBT manual to facilitate learning. Participants in the treatment group may also receive typical care or treatment as usual for new mothers.
16247116|NCT05044455|No Intervention|Arm 2: Control Group|The control group will receive treatment as usual (TAU) or typical care available for postpartum depression in participant's home communities, via participant's family doctor, mental health services, midwifery services, etc. Subjects in the control group will receive a list of resources where participants may seek treatment and will receive a monthly email encouraging them to seek treatment if symptoms worsen, including thoughts of self harm or harm to participant's child. Participants will also receive a copy of the Canadian Practice Guidelines for the treatment of PPD.
16247117|NCT05044442|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
16247118|NCT05044442|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
16247119|NCT05044442|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
16247120|NCT05044429|Experimental|Intravenous Lidocaine|
16247121|NCT05044429|Active Comparator|Transversus abdominis plane (TAP) block|
16247122|NCT05044429|Active Comparator|Quadratus Lumborum (QL) Block|
16247123|NCT05044416|Experimental|VieScope|intubation with the VieScope laryngoscope
16247124|NCT05044416|Active Comparator|Videolaryngoscopy|intubation with videolaryngoscope
16247125|NCT05044403|Active Comparator|Conventional treatment|Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
16247126|NCT05044403|Experimental|Extracorporeal support with haemoperfusion treatment|Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
16247127|NCT05044390||lung transplantation|Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.
16247129|NCT05044364|Active Comparator|Original research clevidipine butyrate injection|Fresenius Kabi Austria Gmb H (Austria)
16247130|NCT05044351|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted thyroid lobectomy
16247131|NCT05044351|Active Comparator|(B): Conventional surgery|Patients undergoing conventional thyroid surgery without NIRAF-assistance
16247138|NCT05044312|Other|Sleep Disturbances|Difficulty Sleeping
16247139|NCT05044299|Active Comparator|Isoped mobilization with resistance load|Use of Isoped with movement at 3 levels of resistance load: zero, low, high, each condition lasts 3 minutes at 9 minutes total work
16247140|NCT05044299|Active Comparator|Isoped mobilization without resistance load|Use of Isoped with movement at zero resistance load lasts 9 minutes of work
16247141|NCT05044286||40 Transgender and Gender Diverse for World Café Conversation|We will host two world cafe conversations. The first (n = 20) will be specifically or black transgender and gender diverse adults (18+), who are HIV-negative, and have indications for PrEP. The second (n = 20) will be open to transgender and gender diverse adults, who are HIV-negative, and have indication for PrEP.
16247142|NCT05044286||20 Other Key stakeholders for World Café Conversation|We will interview 20 other key stakeholders including medical providers, HIV prevention specialists, outreach workers, PrEP navigators/educators.
16247143|NCT05044286||500 Transgender and Gender Diverse for Survey|We will survey 500 TGD adults (18+), who are HIV negative, and have indications for PrEP.
16247144|NCT05044273||Coronary Artery Disease|
16247145|NCT05044260|Experimental|Direct Sinus elevation using SLA Kit|
16247146|NCT05044247|Experimental|ESP block|ESP block under mixed local anesthetics, betamethasone agent
16247147|NCT05044234|Experimental|Arm 1: Cedirogant|Participants will receive cedirogant Dose A once daily.
16247148|NCT05044234|Experimental|Arm 2: Cedirogant|Participants will receive cedirogant Dose B once daily.
16247149|NCT05044234|Experimental|Arm 3: Cedirogant|Participants will receive cedirogant Dose C once daily.
16247150|NCT05044234|Placebo Comparator|Arm 4: Placebo|Participants will receive placebo once daily.
16247153|NCT05044208||No atrial fibrillation detected|In this cohort, AF is not detected in 7-day ECG monitoring or 2-years follow-up period
16247154|NCT05044208||Atrial fibrillation detected|In this cohort, AF is detected in 7-day ECG monitoring or 2-years follow-up period
16247157|NCT05044182|Experimental|Decompression and drainage seton|Decompress the pressure in intersphincteric space,and drainage seton will be put around the external anal sphincter.
16247158|NCT05044182|Experimental|Cutting seton|Cutting seton will be put around the internal and external anal sphincter.
16247159|NCT05044169|Experimental|Broncho-Vaxom|Intervention
16247160|NCT05044156||Case group|
16247161|NCT05044156||Control group|
16247162|NCT05044143||Women who remained undelivered after their first episode of threatened preterm labor|Women admitted to the hospital due to their first episode of threatened preterm labor (i.e onset of spontaneous labor < 34 weeks gestation), who did not deliver prematurely as labor stopped (with or without interventions such as tocolysis). Those with a cervical length < 25 mm at the time of hospital discharge are eligible to participate in the study
16247163|NCT05044130|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD
~MR spectroscopy verified steatosis"
16247164|NCT05044130|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD
~MR spectroscopy verified no steatosis"
16248361|NCT05036226|Experimental|Dose level 2a|
16247167|NCT05044104|Experimental|Wearable technology in endoscopic gastrointestinal procedures with sedation|Subjects undergoing a endoscopic gastrointestinal procedure with sedation as part of standard of care will wear a consumer-facing wearable smart watch for the duration of the procedure.
16247168|NCT05044091||ovarian/fallopian tube/primary peritoneal cancer patients|ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks
16247169|NCT05044078|Experimental|Group 1 (Autogenic Inhibition)|Autogenic Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the Conventional therapy including neck Isometric strengthening exercise (Neck Flexion, Extension, Both sides Rotation, and Neck Bending with each 5 rep, 10-sec hold, 1 set, in all sessions), Maitland Central posterio-anterior glide (Grade 1 and 2, 30 rep, 3 sets, in all sessions) and hot pack (10 minutes in all sessions on the back of the neck)
16247170|NCT05044078|Active Comparator|Group 2 (Reciprocal Inhibition)|Reciprocal Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the with same Conventional therapy as in group 1 .
16247171|NCT05044065|Experimental|Exercise group|The experimental group will in addition to standard care receive supervised and home-based exercise training program with a specific focus to induce metabolic stress, and protein supplementation to ensure adequate protein intake.
16247172|NCT05044065|No Intervention|Usual care|The control group will in addition to standard care receive protein supplementation to ensure adequate protein intake.
16247173|NCT05044052|Experimental|Intervention Group - Viral prescription pad + emphasis|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. As part of the intervention, these physicians will also receive additional emphasis on the viral prescription pad by 1) encouraging it in the dissemination email of the MyPractice feedback report, and (2) mailing a paper version of the viral prescription pad with instructions on embedding the viral prescription pad into the recipient's EMR.
16247174|NCT05044052|No Intervention|Control group|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. This group will not receive any additional emphasis on the viral prescription pad and will not receive a paper copy in the mail.
16247175|NCT05044039|Experimental|Dose Escalation Stage: Duvelisib|"Duvelisib is an oral medication taken on a twice daily basis on all dosing days. Doses being explored in this study are 15 mg BID (starting dose), 25 mg BID, 50 mg BID, and 15 mg QD. In the dose escalation stage, patients will receive duvelisib from Day -2 through Day 28.
~CAR T-cells will be given per standard of care."
16247176|NCT05044039|Experimental|Cohort A Dose Expansion Stage: Duvelisib|"Patients in Cohort A will receive duvelisib from Day -2 to Day 28. The dose that will be given will be determined in the dose escalation stage.
~CAR T-cells will be given per standard of care."
16247177|NCT05044039|Experimental|Cohort B Dose Expansion Stage: Duvelisib|"Patients in Cohort B will receive duvelisib from Day -2 to Day 180. The dose that will be given will be determined in the dose escalation stage.
~CAR T-cells will be given per standard of care."
16247178|NCT05044026||JAK inhibitor naive|JAK-inhibitor-naive patients
16247179|NCT05044026||Pretreated patients|Patients pretreated for at least 8 weeks with one or more JAK-inhibitors (Jakavi® or otherwise)
16247180|NCT05044013|Experimental|JomPrEP App Group|Participants in the JomPrEP group will be provided with full app access and will be encouraged to use all features of the app.
16247181|NCT05044013|Active Comparator|Control Group|Participants in the control group will receive the JomPrEP app with major intervention features inactivated.
16247182|NCT05044000|Experimental|Heavy blanket|Patients will start with heavy blanket during 15 days
16247183|NCT05044000|Placebo Comparator|Non-heavy blanket|Patients will start with non-heavy blanket during 15 days
16247184|NCT05043987|Experimental|Part A|"Part A will follow the standard 3+3 dose-escalation design and will be enrolled at dose levels of CPO102 at (0.5, 1, 1.8, 2.5, 3.5, 4.5, 5.5 mg/kg).
~Each subject group will receive one dose of CPO-102 every 3 weeks (1 cycle=21 days=1 treatment). For each cohort, the decision whether to dose-escalate will be made once all patients have been enrolled into the cohort and the last patient enrolled has been followed for 21 days (3-week DLT observation period)."
16247185|NCT05043987|Experimental|Part B-Arm 1|Upon attaining a RP2D, Part B-Arm 1 will include approximately 15 patients with pancreatic cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
16247186|NCT05043987|Experimental|Part B-Arm 2|Upon attaining a RP2D, Part B-Arm 2 will include approximately 15 gastric (including gastric esophageal junction) cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
16247187|NCT05043974|Experimental|Dry immersion|5 days of dry-immersion.
16247188|NCT05043961||study group|"Patients who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study.
~Intervention:
~Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles"
16247189|NCT05043948||Coronary Artery Disease_collateral flow grade 2|
16247190|NCT05043948||Coronary Artery Disease_collateral flow grade 0|
16247191|NCT05043948||Peripheral Artery Disease_collateral flow grade 2|
16247192|NCT05043948||Peripheral Artery Disease_collateral flow grade 0|
16247193|NCT05043935|Experimental|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
16247194|NCT05043935|Active Comparator|antimicrobial photodynamic therapy|Application antimicrobial photodynamic therapy in the defect
16247195|NCT05043922|Experimental|CYH33|40mg daily
16247228|NCT05043688|Other|Neoadjuvant Radiochemotherapy Without SHR-1210|"Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29， 5 cycles.
~Radio therapy d1-23. Postoperative adjuvant treatment：according to the recommendations of the guidelines and the investigators"
16247229|NCT05043675|Experimental|[18F]APN-1607|For the injection, subjects will receive a target dose of 0.1~0.15mCi/Kg [18F]APN-1607 as a bolus injection.
16247196|NCT05043909|Experimental|Experimental Group (EG)|The students in EG received VR-based training for elderly oral health care at 2-week (Time 2), 4-week (Time 3), and 6-week (Time 4) follow-ups. The learning module was divided into three sessions according to the physical condition (1) Mild disability, (2) Semi-disability, (3) Total disability and oral condition, (1) wearing dentures, (2) missing teeth of the elderly. Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
16247197|NCT05043909|No Intervention|Control Group (CG)|The students in CG do not receive any of the interventions. However, the same VR-based curriculum of oral health care on dependency elderly were provided at the end of the study.
16247198|NCT05043896|Experimental|Combination therapy|Li-ESWT + tadalafil
16247199|NCT05043896|Sham Comparator|Single Therapy|tadalafil only
16247201|NCT05043870|Experimental|infliximab and immunosuppressives therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1.5-2.5mg/kg per day or methotrexate 10-25 mg/m2 week
16247202|NCT05043870|Active Comparator|infliximab therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
16247203|NCT05043844|No Intervention|Control|In the control group, an investigator performed only a pulmonary recruitment maneuver on the Trendelenburg position before the emergence of anesthesia.
16247204|NCT05043844|Experimental|Abdominal binder|In the abdominal binder group, a pulmonary recruitment maneuver was performed on the Trendelenburg position and the abdominal binder which had a standard height of 22 cm was placed on the abdomen of the patient before the emergence of anesthesia.
16247205|NCT05043831|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Subjects will be treated with DSLT
16247206|NCT05043831|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects will be treated with SLT
16247207|NCT05043818||IBD patients with depression|IBD patients with depression
16247208|NCT05043818||IBD patients without depression|IBD patients without depression
16247209|NCT05043805|Active Comparator|Dextromethorphan|add on therapy
16247210|NCT05043805|Placebo Comparator|placebo|add on therapy
16247211|NCT05043792|Experimental|Dose 1 (Low dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
16247212|NCT05043792|Experimental|Dose 2 (Middle dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
16247213|NCT05043792|Experimental|Dose 3 (High dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
16247214|NCT05043792|Placebo Comparator|Placebo|TT-00920 Placebo, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
16247215|NCT05043779|Other|Preoperative Awake Airway Nasoendoscopy|only one arm
16247216|NCT05043766|Experimental|PF614|Part A will utilize a randomized, open-label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects. Within each dose group, subjects will be randomized to receive repeated BID doses, planned to be 12 hours apart over a 5 day period, for a total of 9 doses. Dose escalation to Dose Groups 2 and 3 will follow a review of pharmacokinetic, safety and tolerability data up to Day 10 of the preceding group. The doses or dosing regimen for Dose groups 2 and 3 may be modified based on a review of the data.
16247217|NCT05043766|Active Comparator|Part B Compare Bioavailability and Bioequivalence|"Part B will utilize an open-label, single-dose, randomized, 4-way crossover design. Following confirmation of eligibility, subjects will be randomized to receive each of the single oral doses of study drugs (one at each treatment period).
~PF614 100 mg administered under fasted conditions; PF614 100 mg administered under fed conditions; OxyContin 40 mg administered under fasted conditions; OxyContin 40 mg administered under fed conditions"
16247218|NCT05043753|No Intervention|Control group: Symphysis fundal height measurement|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNMs) using symphysis fundal height (SFH)
16247219|NCT05043753|Experimental|intervention group: Symphysis fundal height measurement and point of care ultrasound.|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNM) using symphysis fundal height (SFH) and point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
16247220|NCT05043740|No Intervention|Control|Standard of care: management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
16247221|NCT05043740|Experimental|treatment|On top of Standard of care, Evolocumab (Repatha®) 140 mg or Alirocumab(Praluent) 75mg every two weeks: first subcutaneous injection at the time of randomization, followings during 12 months.
16247222|NCT05043727|Experimental|Exer gaming treatment plan|Exer gaming treatment plan
16247223|NCT05043727|Active Comparator|conventional treatment plan|conventional treatment plan
16247224|NCT05043714|Experimental|Intravenous|Patients will receive a first study treatment cycle consisting of one IV infusion of NG-641 on Days 1, 3 and 5 and one IV infusion of nivolumab on Day 15. Patients will then receive nivolumab monotherapy given once every four weeks (on Day 15 of each 28-day cycle), until progression, unacceptable toxicity, withdrawal of consent, completion of 8 cycles of treatment, or the study ends, whichever occurs first.
16247225|NCT05043701|Experimental|Treatment|Patients will be treated with drugs based on functional profiling of autologous tumor cells in vitro
16247226|NCT05043688|Experimental|Neoadjuvant Chemotherapy With SHR-1210|"Neoadjuvant Chemotherapy： Paclitaxel（Albumin Bound）100mg/m2, Day 1,8,15，Carboplatin AUC=5mg/ml/min，Day 1，SHR-1210 200mg，Day 1，every 3 weeks, 2 cycles.
~Postoperative adjuvant treatment：SHR-1210 maintenance"
16247227|NCT05043688|Experimental|Neoadjuvant Radiochemotherapy With SHR-1210|"Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29，SHR-1210 200mg，Day 1,22, 5 cycles.
~Radio therapy d1-23. Postoperative adjuvant treatment：SHR-1210 maintenance"
16247230|NCT05043662||Urothelial carcinoma group|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice (N=80).
16247231|NCT05043662||Control group|Patients need to undergo CTU examination and being treated for benign diseases with ureteroscopy, but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD, CTU and cytology assay (N=30).
16247232|NCT05043649|Experimental|Camsirubicin + pegfilgrastim|Camsirubicin phase 1b dose escalating to determine MTD
16247233|NCT05043610|Experimental|Cohort 1|In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.
16247234|NCT05043610|Active Comparator|Cohort 2 (Control Group)|In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment.
16247235|NCT05043597|Experimental|Thrombus aspiration|
16247236|NCT05043597|No Intervention|control group|
16247237|NCT05043584|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted total thyroidectomy
16247238|NCT05043571|Experimental|Single arm|Single arm Phase I Clinical Trial
16247239|NCT05043558|Experimental|beprostaglandin sodium|
16247240|NCT05043558|No Intervention|control group|
16247241|NCT05043532|Active Comparator|Two passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of two passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
16247242|NCT05043532|Active Comparator|Three passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of three passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
16247243|NCT05043519|Experimental|FAM-NP41 Fluorescence Imaging|The patients will be injected with FAM-NP41 preoperatively, and fluorescence imaging of cranial nerves will be evaluated after the craniotomy.
16247244|NCT05043506||Palbociclib + aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between September 1, 2016, and July 31, 2020.
16247245|NCT05043506||Aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated an aromatase inhibitor as first line therapy between January 1, 2010,, and July 31, 2020
16247246|NCT05043493|Active Comparator|Injection (study) group|This group will receive platelet rich plasma (PRP) injection
16247247|NCT05043493|Placebo Comparator|Control group|This group will receive normal saline (NS) injection
16247248|NCT05043480|Experimental|PEMF arm|In this single-arm study, all participants will be assigned to the intervention arm.
16247249|NCT05043467||Duvie(Lobeglitazone)|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
16247250|NCT05043454|Experimental|Vascular Density Improvement in Hypertensive Participants|Participants will undergo baseline visits and follow-up visits to include neurocognitive testing, VO2 max testing (graded exercise test), blood draws, and retinal scans. Potential subjects must pass an exercise stress test with 12-lead ECG, and training sessions (exercise protocol). Standardized neurocognitive tests assessing functions such as memory and attention will be administered and retinal scans will be conducted. The at-home exercise intervention will be supervised via the Polar beat/flow applications by study personnel. Subjects will engage in cardiovascular exercise with heart rate monitoring on 4 days per week for a total of 10 weeks.
16247251|NCT05043441|Experimental|Acceptance and commitment therapy (ACT) group|10 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
16247252|NCT05043441|Sham Comparator|Psychoeducation control group|Care as usual with psychoeducation materials provided
16247253|NCT05043428|Experimental|Intervention Group|Those randomized to the intervention group will be asked to attend 16 online sessions (2 session/week). Each session will last one hour (total time: 16 hours. The exercise portion will be approximately 30 minutes of each session and led by a certified kinesiologist. These exercises are based on activities related to your daily life. As well, they will take part in peer support sessions. The peer support session will be approximately 30 minutes and be moderated by a behaviour change specialist who will also provide strategies to be active. In this peer support group, particpants will share and learn from other individuals living with COPD to help you stay active during and after the intervention. The online sessions will be video recorded to make sure that the program is delivered as designed.
16247254|NCT05043428|Active Comparator|Control Group|Those randomized to the control group will be asked to participate in an 8-week exercise program based on the exercise component of a standard home-based pulmonary rehabilitation program. During week 1 of the program, participants will receive a videocall via Microsoft Teams from the certified kinesiologist who will prescribe an exercise program, supervise the first exercise session, and provide a copy of Living Well with COPD, a list of strength exercises, and a home exercise diary. In weeks 2-8, participant exercises will be performed offline, on their own. Participants will be encouraged to engage in two or more exercise sessions per week, targeting both aerobic capacity and muscular strength, and document their exercise using a home diary. They will also receive a phone call once a week from the certified kinesiologist to discuss their exercise progress.
16247255|NCT05043415|Active Comparator|Immediate endoscopic necrosectomy|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Then in this group, endoscopic necrosectomy will be performed immediately following index EUS-guided drainage of the necrotic collection, during the same session
16247256|NCT05043415|Active Comparator|Step-up endoscopic intervention|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. In this group, only EUS-guided drainage of the necrotic collection will be performed, and endoscopic necrosectomy will be performed at a separate session at a later time as needed.
16247257|NCT05043402|Experimental|Combination navicixizumab + paclitaxel|Combination navicixizumab + paclitaxel: navicixizumab 3 mg/kg Q2W of a 28 day cycle (i.e., Days 1 and 15); paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28 day cycle
16247258|NCT05043402|Active Comparator|Paclitaxel monotherapy|Paclitaxel monotherapy: paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
16248362|NCT05036226|Experimental|Dose level 2b|
16248363|NCT05036226|Experimental|Dose level 3a|
16247259|NCT05043402|Experimental|Navicixizumab monotherapy|Navicixizumab monotherapy: navicixizumab 3 mg/kg Q2W of a 28-day cycle (i.e., Days 1 and 15)
16247260|NCT05043389|Experimental|Obstructive sleep apnea|myofunctional therapy program
16247261|NCT05043389|No Intervention|control|standard treatment
16247262|NCT05043376|Active Comparator|Standard of care|In this arm patients will receive the standard COVID-19 care as per the hospital guidelines.
16247263|NCT05043376|Experimental|BLIS K12|In this arm patients will receive the BLIS K12 as add-on to the standard COVID-19 care
16247264|NCT05043363||Observational cohort|"Patients with an established diagnosis of inflammatory bowel disease who have been identified as being 'at risk' by either their secondary care doctor or GP and now require endoscopic assessment for ongoing disease symptoms but are unable to access endoscopy services urgently.
~Patients presenting directly to their GP practice with symptoms of anorectal disease (e.g. rectal bleeding or pain) or symptoms that would warrant referral to a hospital under a 2WW appointment according to NICE criteria
~Recruited patients will undergo rectal examination in primary care with the LumenEye X1 with either contemporaneous or retrospective image review by a secondary care clinician. This will require a glycerine suppository to be administered. Patient feedback will be sought with a post-procedural questionnaire."
16247265|NCT05043350|Experimental|Interventional group|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to oral famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
16247266|NCT05043350|Active Comparator|Control group|107 patients will receive standard drug therapy according to the treatment protocols of the National Committee of COVID-19 in addition to oral famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company)
16247267|NCT05043337|Experimental|Maternal voice|Recording the maternal voice in reading children's books, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored maternal voice, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
16247268|NCT05043337|Experimental|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Brahms Lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
16247269|NCT05043337|Experimental|Maternal voice combined with lullaby|Recording the maternal voice in reading children's books and giving mother listening to the lullaby at the same time, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Maternal voice combined with Brahms lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
16247270|NCT05043337|No Intervention|Control group|When the premature infants undergoing heel lance procedure , the control group was under routine care . Measuring with the Respiration , heart rate , oxygen saturation , and neonatal infant pain scale (NIPS ) were recorded 3 minutes before , during , 1st , 3rd , and 10th minutes after the heel lance puncture .
16247271|NCT05043324|Experimental|AIDS, HIV, HBV, HCV, co-infections.|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes.
16247272|NCT05043324|Experimental|"stable cancer, acquired or congenital immunodeficiency."|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes.
16247273|NCT05043311|Experimental|Experimental: 20 µg dose, 18-59 years of age (phase 1/2)|
16247274|NCT05043311|Experimental|Experimental: 20 µg dose, ≥60 years of age (phase 1/2)|
16247275|NCT05043311|Experimental|Experimental: 40 µg dose, 18-59 years of age (phase 1/2)|
16247276|NCT05043311|Experimental|Experimental: 40 µg dose, ≥60 years of age (phase 1/2)|
16247277|NCT05043311|Placebo Comparator|Placebo Comparator: Placebo, 18-59 years of age (phase 1/2)|
16247278|NCT05043311|Placebo Comparator|Placebo Comparator: Placebo, ≥60 years of age (phase 1/2)|
16247279|NCT05043311|Experimental|Vaccination of phase 3 participants (≥18 years of age) with SCTV01C|
16247280|NCT05043311|Placebo Comparator|Vaccination of phase 3 participants (≥18 years of age) with placebo|
16247281|NCT05043298|Experimental|IBI360|
16247282|NCT05043285|Experimental|20 µg dose, 18-59 years of age (phase 1/2)|
16247283|NCT05043285|Experimental|20 µg dose, ≥60 years of age (phase 1/2)|
16247284|NCT05043285|Experimental|40 µg dose, 18-59 years of age (phase 1/2)|
16247285|NCT05043285|Experimental|40 µg dose, ≥60 years of age (phase 1/2)|
16247286|NCT05043285|Placebo Comparator|Placebo, 18-55 years of age (phase 1/2)|
16247287|NCT05043285|Placebo Comparator|Placebo, ≥60 years of age (phase 1/2)|
16247288|NCT05043285|Experimental|Vaccination of phase 3 participants (≥18 years of age) with SCTV01C|
16247289|NCT05043285|Placebo Comparator|Vaccination of phase 3 participants (≥18 years of age) with placebo|
16247290|NCT05043272||Overweight population with basic diseases|Basic diseases include diabetes, hypertension.
16247291|NCT05043272||Overweight population with chronic liver diseases|Chronic liver diseases include chronic hepatitis ,liver cirrhosis, primary hepatocellular carcinoma.
16247292|NCT05043272||Healthy population|Control group
16247293|NCT05043259|Active Comparator|Inactivated vaccine group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of inactivated SARS-CoV-2 vaccine
16247294|NCT05043259|Experimental|Low dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the low dose of aerosolized Ad5-nCoV.
16247295|NCT05043259|Experimental|High dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the high dose of aerosolized Ad5-nCoV.
16247296|NCT05043246||Basic diseases Patients/Healthy People|Hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease,Chronic Liver Diseases Patients
16247366|NCT05042687|Experimental|Tc99m sestamibi|MBI uses an injection of a small amount of radioactive material called technetium99m (Tc99m) sestamibi
16248364|NCT05036226|Experimental|Dose level 3b|
16247297|NCT05043233||Patients with Graves' disease|Graves' disease was diagnosed based on clinical symptoms and laboratory findings. The clinical symptoms included heat intolerance, fatigue, increased appetite, increased sweating, weight loss, muscle weakness, tremors, and diffusely enlarged thyroid glands. The laboratory results included increased serum concentrations of free thyroxine (FT4) and/ or free triiodothyronine (FT3), decreased basal thyroid-stimulating hormone (TSH) level, and TRAb positivity. All participants in this study would be treated with anti-thyroid drugs(MMI: methimazole) according to the 2016 ATA guildline.
16247298|NCT05043220|Experimental|Telemedicine|Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
16247299|NCT05043207|Experimental|uAud|Patients which hearing aid is fitted based on the audiometry obtained with user-operated automated audiometry.
16247300|NCT05043207|Active Comparator|control|Patients which hearing aid is fitted based on the audiometry obtained with traditional audiometry.
16247301|NCT05043194|Experimental|ursodeoxycholic acid arm|Premature infants who meet the inclusion criteria take preventive oral ursodeoxycholic acid on the 7th day after birth. ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
16247302|NCT05043194|Sham Comparator|the control arm|The control group was treated with UDCA after the occurrence of cholestasis.ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
16247303|NCT05043181|Experimental|Homozygous Familial Hypercholesterolemia|
16247304|NCT05043168||Patients with COVID-19|Polymerase Chain Reaction-positive SARS-CoV-2 infection
16247305|NCT05043168||Patients post-SARS-CoV-2 vaccination|Onset of kidney disease potentially relatable to SARS-CoV-2 vaccination based on clinical grounds
16247306|NCT05043129||HIV infenction/AIDS|experimental group
16247307|NCT05043129||Healthy population|Control group
16247308|NCT05043116|Active Comparator|Vitamin D|Dietary supplement: 2000 IU Vitamin D3 daily dose (oral suspension) for one year.
16247309|NCT05043116|Placebo Comparator|Placebo|Oral suspension with no active substance, identical to the active suspension for one year.
16247310|NCT05043090|Experimental|Arm A|savolitinib 600mg plus durvalumab 1500mg
16247311|NCT05043090|Active Comparator|Arm B|sunitinib 50mg
16247312|NCT05043090|Experimental|Arm C|durvalumab 1500mg
16247315|NCT05043064|Active Comparator|Experienced robotic cardiac surgeons|
16247316|NCT05043064|Active Comparator|Cardiac surgeons with limited robotic experience|
16247317|NCT05043064|Active Comparator|Non-cardiac surgeons with limited robotic experience|
16247318|NCT05043051|Active Comparator|Vagal stimulation|Vagal stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the tragus for 2 months.
16247319|NCT05043051|Sham Comparator|Sham stimulation|Sham stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the earlobe for 2 months.
16247320|NCT05043038||General Anesthesia Night Float|The residents will be followed over a three week period - one week prior to night float (baseline), the week of night float, and one week after night float (recovery).
16247321|NCT05043038||Obstetric Anesthesia Call|The residents will be on their four week Obstetric anesthesia rotation. On this rotation, rather than a night float, they are scheduled for 16 hour overnight call approximately every 3-4 days.
16247322|NCT05043025|Active Comparator|Neck extension group|The cricothyroid membrane is identified in a neck extended position.
16247323|NCT05043025|Experimental|Modified ramped position group|The cricothyroid membrane is identified in a modified ramped position.
16247324|NCT05043012|Experimental|Group 1|will have an mpMRI scan with a flexible AIR coil.
16247325|NCT05043012|Experimental|Group 2|will have an mpMRI scan with an endorectal coil
16247326|NCT05042999|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
16247327|NCT05042999|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
16247328|NCT05042986|Experimental|Single Dose Capsule|Single oral dose of 200 mg (100 μCi in 200 mg salt [0.5 μCi/mg as salt], equivalent to 100 μCi in 142 mg active [0.7 μCi/mg as active]) of [14C]-SKI-O-703 containing approximately 100 μCi of [14C]-SKI-O-703 per capsule after an overnight fast.
16247329|NCT05042973|Active Comparator|Active drug (Empagliflozin)|Empagliflozin 10 mg, 1 capsule per day
16247330|NCT05042973|Placebo Comparator|Inactive drug (placebo)|Placebo, 1 capsule per day
16247331|NCT05042960|Experimental|50% brightness group|Participants will be using a computer screen reducing screen brightness 50%.
16247332|NCT05042960|Experimental|Light App group|Participants in this group will use a modulating computer screen tone with flux or night shift app.
16247333|NCT05042960|No Intervention|Control group|Participants in this group will be a control with no change in screen features
16247334|NCT05042947|Experimental|DLCT|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences, and the experimental group used double-loop coil clamp technology to treat the wound.
16247335|NCT05042947|Active Comparator|Traditional technology|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences.The control group used the traditional hemostatic clip technique to treat the wound
16247363|NCT05042713|Active Comparator|One Curve with One Flare|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
16247364|NCT05042700|Experimental|Melatonin-Placebo sequence|50% of the included patients will receive 4 weeks of treatment with melatonin, followed by a 4 week wash out period, and then 4 weeks of treatment with placebo. The treatments are blinded.
16247584|NCT05041322|Placebo Comparator|Placebo|Subjects take Placebo pills (twice a day) for 14 Days.
16247336|NCT05042934|Experimental|Treatment (lurbinectedin, fine-needle aspiration, irinotecan)|Patients receive lurbinectedin IV over 60 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo fine-needle aspiration on days 2-6 of cycle 1. Beginning in cycle 2, if the biopsy shows suppression of NR0B1, then patients receive irinotecan IV over 1 hour on the day of maximum NR0B1 suppression on cycle 2. If the duration of NR0B1 suppression from lurbinectedin alone exceeds 48 hours, or if the duration of NR0B1 suppression from lurbinectedin and irinotecan exceeds 48 hours and is longer than that seen with lurbinectedin alone, then patients may receive a second dose of irinotecan during the extended period of NR0B1 suppression.
16247337|NCT05042921||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 21 months and the available data is collected retrospectively.
16247338|NCT05042921||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 21 months.
16247339|NCT05042908|Experimental|A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid tumors|Drug: LBL-003Injection The test drugLBL-003will be preset with 6 escalation dose levels: dose A, dose B, dose C, dose D and dose E, dose F , administered twice a week.
16247340|NCT05042895|Active Comparator|PCO women|Group A will consist of 100 PCO infertile women
16247341|NCT05042895|Active Comparator|unexplained infertile cases|group B will consist of 50-unexplained infertility.
16247342|NCT05042882|Experimental|Early enteral nutrition|Intervention group: enteral nutrition from the first postoperative night until 50% of caloric requirements are covered by oral nutrition. Enteral nutrition will start at a flow of 250 ml/12h. If tolerated, enteral nutrition will be increased to 500 ml/12h on postoperative day 1, 750 ml/12h on postoperative day 2, and 1000 ml/12h on postoperative day 3. A hypercaloric enteral nutrition will be used (Isosource Energy Fibre or similar).
16247343|NCT05042882|No Intervention|Oral nutrition|Control group: patients will receive standardized oral nutrition. The night after the operation, patients will be allowed to have free drinks. On postoperative day 1, they will receive bouillons, creams, yogurts, and drinks >2 l. On postoperative day 2, they will receive a light diet. On postoperative day 3, they will receive half portion of normal diet and on postoperative day 4 normal diet.
16247344|NCT05042856|Experimental|PanOptix|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
16247345|NCT05042830|Active Comparator|Active group|Birch allergic subjects receiving birch pollen extract challenge
16247346|NCT05042830|Placebo Comparator|Control group|Birch allergic subjects receiving saline
16247347|NCT05042817|Active Comparator|Morphine|50 mg prilocaine + 2.5 mcg sufentanil + 100 mcg morphine (0.1ml)
16247348|NCT05042817|Placebo Comparator|NaCl 0.9%|50 mg prilocaine + 2.5 mcg sufentanil + 0.1 ml saline
16247349|NCT05042804|Experimental|Machine Learning Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, and they will also view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
16247350|NCT05042804|No Intervention|No Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, but they will not view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
16247351|NCT05042791|Experimental|SRT combined with pyrotinib and capecitabine|"SRT: SRT needs to be comprehensively considered based on the size, number, and location of the lesion, and SRS and FSRT are performed according to clinical needs.
~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
16247352|NCT05042791|Active Comparator|WBRT combined with pyrotinib and capecitabine|"WBRT: WBRT need to be considered based on the size, number, and location of the lesion.
~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
16247353|NCT05042778|Experimental|Auricular branch of the vagus nerve|Indwelling fixed semipermanent needles embedded in a skin-colored adhesive tape will be used in active points around the vagus nerve stimulation area.
16247354|NCT05042778|Active Comparator|Lesser occipital nerve|Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used in active points around the lesser occipital nerve stimulation area.
16247355|NCT05042778|No Intervention|No intervention|No auriculotherapy will be applied.
16247356|NCT05042752|No Intervention|No intervention arm|Standard care of AHF on a patient admitted on a HAH unit consists in physical examination and basic complementary tests
16247357|NCT05042752|Experimental|Experimental arm|Clinical ultrasound on HAH admitted patient. Clinical handheld Ultrasound consists of inferior vena cava diameter measurement and lung ultrasound protocol in order to guided Diuretic Therapy
16247358|NCT05042726|Experimental|cTBS First|The first course of treatment, participants are treated with cTBS for 2 weeks, a total of 10 times, then followed up for 8 weeks. The first course of treatment, participants are treated with pseudo-stimulation for 2 weeks, a total of 10 times, then followed up for 8 weeks.
16247359|NCT05042726|Experimental|Pseudo-stimulation First|The first course of treatment, participants are treated with pseudo-stimulation for 2 weeks, a total of 10 times, then followed up for 8 weeks. The first course of treatment, participants are treated with cTBS for 2 weeks, a total of 10 times, then followed up for 8 weeks.
16247360|NCT05042713|Active Comparator|Wave One Gold|The Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
16247361|NCT05042713|Active Comparator|One Flare and Wave One Gold file system|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
16247362|NCT05042713|Active Comparator|One Curve|The One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
16247365|NCT05042700|Experimental|Placebo-Melatonin sequence|50% of the included patients will receive 4 weeks of treatment with placebo, followed by a 4 week wash out period, and then 4 weeks of treatment with melatonin. The treatments are blinded.
16247367|NCT05042674|Other|Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily|Participants will consume placebo on first study day, consume 25mg of ergothioneine on second study day, then consume 25mg of ergothioneine daily for 1 week
16247368|NCT05042661|Experimental|acupuncture-like transcutaneous electrical nerve stimulation|"The experimental group received acupuncture-like transcutaneous electrical nerve stimulation three times a week for 4 weeks.
~Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment"
16247369|NCT05042661|No Intervention|Control group:conventional therapy|The control group will receive routine care.
16247370|NCT05042648|No Intervention|Control group (Group A)|Group A will receive no intervention
16247371|NCT05042648|Experimental|Buprenorphine group (Group B)|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
16247372|NCT05042635|Experimental|Ixekizumab (4 weeks) + Jueyin Granules (12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin Granules was used in the 12-week traditional Chinese medicine treatment period.
16247373|NCT05042635|Placebo Comparator|Ixekizumab (4 weeks) + Jueyin placebo Granules(12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin placebo Granules was used in the 12-week traditional Chinese medicine treatment period.
16247374|NCT05042622|Experimental|Cytokine adsorber patients on ECMO|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
16247375|NCT05042622|Experimental|Cytokine adsorber patients with sepsis|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
16247376|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients on ECMO|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
16247377|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients with sepsis|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
16247378|NCT05042622|No Intervention|Control (subgroups)1|No filter will be installed into the ECMO in this study group (15 patients)
16247379|NCT05042622|No Intervention|Control (subgroups) 2|No filter will be installed into the patient with sepsis (15 patients)
16247384|NCT05042570|Experimental|Instrument Assisted Soft Tissue Mobilization|Group 1 (n=13): Each session will consist of 40 minutes. An additional 10 minutes of IASTM will be performed to the 30-minute NDT program.
16247385|NCT05042570|Experimental|Stretching Exercises|Group 2 (n=13): Each session will consist of 40 minutes. In addition to the NDT program applied for 30 minutes, 10 minutes of Stretching Exercises will be performed.
16247386|NCT05042570|Active Comparator|Control|Group 3 (n=13): Each session will consist of 40 minutes. There will be no additional application to the NDT program, which is applied for 40 minutes, and it will be included as a control group in the study.
16247387|NCT05042557||Sun Yat-sen University Cancer Center|
16247388|NCT05042557||hanghai Chest Hospital|
16247389|NCT05042557||Tianjin Cancer Hospital|
16247390|NCT05042557||Fudan University Shanghai Cancer Center|
16247391|NCT05042557||Anhui Cancer Hospital|
16247392|NCT05042557||Shandong Cancer Hospital|
16247393|NCT05042557||Hunan Cancer Hospital|
16247394|NCT05042557||Yunnan Cancer Hospital|
16247395|NCT05042557||Chinese Academy of Medical Sciences|
16247396|NCT05042544||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. In settings with high anticipated HCV antibody prevalence (>15%; e.g. drug treatment, prisons, needle and syringe programs), people who have previously been told they have HCV infection, or people who have previously received HCV treatment, testing will be performed using point-of-care HCV RNA testing. In settings with a low anticipated HCV antibody prevalence (<15%; e.g. mental health, homelessness), testing will be performed using point-of-care HCV antibody testing and if positive, point-of-care HCV RNA testing will be performed.
16247397|NCT05042531|Experimental|experimental group|Patients with intermediate and high risk AML were negative for minimal residual disease after intensive induction and consolidation chemotherapy,the patients were randomly divided into two groups, and one group was given azacitidine(75mg/m2, per day on day 1-7]. Dasatinib 100 mg p.o. qd was administered on days 1-28 of each consolidation cycle.
16247398|NCT05042531|Active Comparator|control group|Patients with intermediate and high risk AML were negative for minimal residual disease after intensive induction and consolidation chemotherapy,the patients were randomly divided into two groups, and the other group was given azacitidine(75mg/m2, per day on day 1-7)on days 1-28 of each consolidation cycle.
16247399|NCT05042518|Experimental|Intervention group|The participant in the intervention group will practice breathing control and self-talk with objectives for relaxation. The duration of training is 4-5 minutes in each session, 4 sessions per week for 1 month.
16247400|NCT05042518|Placebo Comparator|Control group|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month).
16247401|NCT05042505|Active Comparator|Dapa Group|Patients with diabetes mellitus will receive dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
16247402|NCT05042505|Active Comparator|Sita Group|Patients with diabetes mellitus will receive sitagliptin 100 mg once daily.Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
16247403|NCT05042492|No Intervention|Group 1: SC (moveUP)|In group 1: moveUP (class 1, CE-marked, medical device) is being used as the rehabilitation solution after TKA. It has become a valid digital rehabilitation solution and is recognised by the Belgian government as mobile health application in rehabilitation of hip and knee arthroplasty surgeries. It's a full service with daily personalized and individualized follow up by certified physical therapists and certified health care providers. The use of tele-rehabilitation for TKA patients has been internationally recognized with the 2018 John N. Insall Award during the American Knee Society Meeting
16247404|NCT05042492|Experimental|Group 2: SC (moveUP) with 10 days of geko|In group 2: Next to SC (moveUP), the application of a single gekoTM device is used on the operated leg after surgery (day 0). This device will be worn for 24 hours and at least 8 hours from day 1 until day 10.
16247405|NCT05042479|Experimental|Standard treatment then virtual reality then choice between the two|"Efficiency of VR will be evaluated for each patient across 3 potentially painful care-procedures :
~For the first treatment, the child will benefit usual distraction and pain prevention techniques.
~For the 2nd, the child will use a VR headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age and parental agreement.
~For the 3rd treatment, the child will choose his/her favorite technique."
16247406|NCT05042466|Experimental|Plant Medicine On Boarding|The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every other day dose of 1 gram to 1.5 grams .Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
16247407|NCT05042466|Experimental|Participant|1gram to 1.5 grams psilocybin
16247408|NCT05042466|Experimental|Psychiatrist|Psychiatrist QC scaling back SSRI's replacing with psilocybin.
16247409|NCT05042466|Experimental|On-Boarding Plant Medicine Specialist|The On-Boarding Provider will control dosage of the plant medicine.
16247410|NCT05042453||Hysteropexy using Splentis via vaginal route|Non-fertile women ≥ 18 years with uterine descent (POP-Q ≥ 2) which are study-independently scheduled for hysteropexy with Splentis
16247411|NCT05042440|Experimental|efanesoctocog alfa (BIVV001)|Each participant will be sequentially dosed with three single intravenous (IV) doses of first rFVIII (Advate®), second Polyethylene Glycol (PEG)-rFVIII (Adynovi® or Adynovate®), and lastly, BIVV001
16247412|NCT05042427||primigravida women|Weight management health literacy of primigravida women.
16247413|NCT05042414|Experimental|Breastmilk|Randomized intervention order.
16247414|NCT05042401|Experimental|Treatment group A|
16247415|NCT05042401|Experimental|Treatment group B|
16247416|NCT05042388|Experimental|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Group intervention comprised of didactics and trainings in cognitive behavioral therapy relapse prevention skills and mindfulness meditation.
16247417|NCT05042388|Active Comparator|Treatment-As-Usual (TAU)|Standard procedure for residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on issues related to mental health and substance use disorders; and medication counseling. No aspect of the treatment-as-usual services provided entails mindfulness training or components of mindfulness training.
16247418|NCT05042375|Experimental|camrelizumab + famitinib|
16247419|NCT05042375|Experimental|pembrolizumab|
16247420|NCT05042375|Experimental|camrelizumab|
16247421|NCT05042362|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
16247422|NCT05042362|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
16247423|NCT05042349||Elite athletes|Pregnant female elite athletes
16247424|NCT05042349||Controls|Moderately physical active pregnant females
16247425|NCT05042349||Sponsors|Sponsors of the athletes
16247426|NCT05042349||Coaches/tema leaders|Coaches or team leaders of the atheltes
16247427|NCT05042336|Experimental|camrelizumab/lenvatinib combined with TACE|"Phase Ib trial： Ib-A group [camrelizumab q3w group]: TACE d1, camrelizumab 200mg, d1, 22, 43; Lenvatinib d7-43; Surgery d50; Group Ib-B [camrelizumab q2w group]: TACE d1, camrelizumab 200mg, d1, 15, 29; Lenvatinib d7-43; Surgery d50.
~Phase II trial： The enrolled patients received camrelizumab/lenvatinib combined with TACE treatment (a relatively safer treatment plan based on phase Ib), and the first imaging efficacy evaluation was performed at 6-8 weeks to evaluate surgical resection"
16247428|NCT05042323|Experimental|TF-CBT-Skills|Step 1: 4-5 sessions with stabilization/skill building Step 2: 4-5 sessions with narrative and cognitive processing
16247429|NCT05042323|Active Comparator|TF-CBT-Narr|Step 1: 4-5 sessions with narrative and cognitive processing Step 2: 4-5 sessions with stabilization/skill building
16247434|NCT05042297|Active Comparator|Combined Posterior and anterior ring fixation|Posterior ring fixation via a single posterior Sacroiliac screw or two Iliac wing plates. While anterior ring fixation was via a single para-symphyseal plate in Tile B2 injuries. Meanwhile, we used double superior and anterior symphyseal plates in Tile C1 injuries.
16247435|NCT05042297|Experimental|Isolated Posterior ring fixation|We used either two Sacroiliac screws in S1 and S2, or two Iliac wing plates.
16247436|NCT05042284|Experimental|NE PERT|Non-enteric coated pancreatic enzyme preparation containing 30,000U of protease.
16247437|NCT05042284|Placebo Comparator|Placebo|Similar appearing glucose capsules.
16247438|NCT05042271||Meropenem: Patients who underwent TPE (Phase 1)|In phase 1, each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first therapeutic plasma exchange (TPE) and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
16248365|NCT05036226|Experimental|Dose level 4|
16247439|NCT05042271||Meropenem: after TPE (Phase 2)|was similar to phase 1 except that the meropenem administration and PK studies were conducted >6 hours apart from the next TPE
16247440|NCT05042258|Experimental|Dupilumab administration|dupilumab administered in weight based dosage for 12 weeks. The drug will be administered once a week during this time through a subcutaneous injection.
16247441|NCT05042245|Experimental|ornithine aspartate granule group|Patients in this group will be given aspartate ornithine granules (3 g po tid, after three meals) and silymarin capsule simulant (140 mg po bid, before breakfast and dinner).
16247442|NCT05042245|Active Comparator|silymarin capsule group|Patients in this group will be given silymarin capsule (140 mg po bid, before breakfast and dinner) and aspartate ornithine granules simulant (3 g po tid, after three meals) .
16247443|NCT05042219||COPD (ICS)|COPD before initiation of inhaled corticosteroid therapy
16247444|NCT05042219||COPD (LTOT-NIV)|COPD before initiation of long term oxygen therapy or domiciliary long-term non-invasive ventilation
16247445|NCT05042219||COPD (Roflumilast )|COPD before initiation of Roflumilast therapy
16247446|NCT05042219||Bronchial asthma (antibody)|Bronchial asthma before initiation of antibody therapy
16247447|NCT05042219||Bronchial asthma (ICS)|Bronchial asthma before initiation of inhaled corticosteroid therapy
16247448|NCT05042219||Pulmonary fibrosis|Pulmonary fibrosis before initiation of antifibrotic therapy
16247450|NCT05042193||Unvaccinated SARS-CoV-2 positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated
16247451|NCT05042193||Vaccinated|Participants who were vaccinated against SARS-CoV-2
16247452|NCT05042180|Experimental|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
16247453|NCT05042180|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
16247454|NCT05042167|Experimental|High-load resistance exercise|Subjects in high-load trial performed 3 sets per exercise, 8 repetitions with load of 70%-1RM with 90 sec of rest between sets, followed by a fourth set to voluntary failure.
16247455|NCT05042167|No Intervention|Sedentary control|Subjects in control trial stayed sedentary during the period.
16247456|NCT05042154|No Intervention|Standard of Care Cohort for COPD|Standard care patients will receive routine clinical management as per their treating physicians based on the GOLD Criteria.
16247457|NCT05042154|Active Comparator|WatchPAT Cohort|Consented patients will undergo group randomization to either standard AECOPD care or to the WatchPAT One cohort (WPC). The WPC will undergo a single night of in-hospital sleep apnea testing from 2200 to 0600 using the WatchPAT One, a portable and disposable home sleep apnea testing device (Itamar Medical, Israel [WPAT]).
16247460|NCT05042128|Experimental|Standard Care + CEND1|Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
16247461|NCT05042128|Placebo Comparator|Standard Care + Placebo|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
16247462|NCT05042115|Experimental|Education in pain neurosciences and clinical hypnosis|Pain neuroscience education and clinical hypnosis
16247463|NCT05042115|Active Comparator|Education in pain neurosciences and clinical hypnosis plus Osteopathic manipulative treatment|Pain neuroscience education and clinical hypnosis, associated with osteopathic manipulative treatment
16247464|NCT05042102|Experimental|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
16247465|NCT05042102|Experimental|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
16247466|NCT05042102|Experimental|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
16247467|NCT05042102|Experimental|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
16247468|NCT05042089||pathological tumor stage 1-2 (pT1-2)|Stage pT1 and pT2 according to pathology results of patients who underwent partial or radical nephrectomy.
16247469|NCT05042089||pathological tumor stage ≥pT3a|Stage ≥pT3a according to pathology results of patients who underwent partial or radical nephrectomy.
16247470|NCT05042076|Experimental|BK with VST|Adult patients with BKV infection and nephropathy (BKN) following kidney transplantation. Consented patients who lack a donor or have a cell manufacturing failure will be entered into an observational group and will be replaced, if they do not become eligible during the study period
16247471|NCT05042063||Participants with cough as a symptom|This group will be composed of patients at the Clínica Universidad de Navarra that complain of having cough as a remarkable symptom.
16247472|NCT05042063||Validation subgroup|This subgroup will be composed by both, patients belonging to the main study group, as well as voluntaries, who will be asked to provide a series of elicited cough and non-cough sounds for validation purposes.
16248401|NCT05036031||Non-ACLF patients|
16247473|NCT05042050|Experimental|A-iMAPS Intervention|Participants will receive six sessions of Attachment-focused iMAgery therapy for PSychosis. They will be randomised to different baseline lengths (two to five assessment sessions)
16247474|NCT05042037|Active Comparator|Double-blind, placebo-controlled interventional study|Active treatment group will receive a 3-gram sachet of probiotics containing multi-strain of lactobacillus and Bifidobacterium 30 Colony Forming Unit x 109 to be taken twice daily for 12 weeks.
16247475|NCT05042037|Placebo Comparator|Placebo|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 12 weeks.
16247476|NCT05042024|Active Comparator|the SRP Group|Patients received conventional periodontal therapy including scaling and root planing as a full-mouth procedure, n=25.
16247477|NCT05042024|Experimental|the Arg Group|Patients received oral L-arginine aspartate (Yuria-Pharm, Ukraine) at a dose of 1 g t.i.d. for 10 days after conventional periodontal therapy, n=25.
16247478|NCT05042024|Experimental|the Orn Group|Patients received oral L-ornithine aspartate (Farmak, Ukraine) at a dose of 3 g t.i.d. for 15 days after conventional periodontal therapy, n=25.
16247479|NCT05041998|Experimental|Unmodified Socket + 8 Socket Modifications in Random Order|The sequence of the 9 different interventions (original socket and 8 versions derived from it) is randomized for each participant. The number of participants is smaller than the number of possible permutations. Therefore the enacted ordering is randomly selected from the pool of possible orderings. Participants walk for less than 10 minutes with every socket type while data is being collected.
16247480|NCT05041985|Experimental|group A (the Test group)|arm which received Diazepam 5 mg therapy for 7 days after whiplash
16247481|NCT05041985|No Intervention|group B (the control group)|a group which did not receive Diazepam 5 mg therapy
16247482|NCT05041972|Experimental|Cohort 1: HER2 Mutated Non-Small Cell Lung Cancer (NSCLC)|Intervention: Drug: ARX788
16247483|NCT05041972|Experimental|Cohort 2: HER2 Mutation Breast Cancer|Intervention: Drug: ARX788
16247484|NCT05041972|Experimental|Exploratory Cohort A: Other HER2-Mutated tumors|Intervention: Drug: ARX788
16247485|NCT05041972|Experimental|Cohort 3: HER2 Amplification Biliary Tract Cancer (BTC)|Intervention: Drug: ARX788
16247486|NCT05041972|Experimental|Cohort 4 HER2 Amplification Colorectal (CRC), Ovarian Endometrial, NSCLC, and other solid tumors|Intervention: Drug: ARX788
16247487|NCT05041972|Experimental|Cohort 5: HER2 Mutation or HER2 Amplification Solid Tumors|Intervention: Drug: ARX788
16247488|NCT05041959|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
16247489|NCT05041959|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
16247490|NCT05041946|Experimental|Methylphenidate|treatment of attention deficit disorder and narcolepsy (sleep disorder)
16247491|NCT05041946|Experimental|Placebo|Sugar pill
16247492|NCT05041920|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design.
16247493|NCT05041907|Active Comparator|Positive control (monoclonals)|
16247494|NCT05041907|Experimental|Favipiravir|
16247495|NCT05041907|Experimental|Ivermectin|
16247496|NCT05041907|Experimental|Remdesivir|
16247497|NCT05041907|Other|Negative control group|
16247498|NCT05041881|Active Comparator|Trifocal IOL group|Patients implanted during cataract or refractive surgery with trifocal lens, which allowed to see for far, intermediate and near distance, but due to optic design having unwanted effect like optical phenomena and lower contrast sensitivity
16247499|NCT05041881|Active Comparator|Accommodating IOL group|Patients implanted during cataract or refractive surgery with accommodating lens, which allowed to see for far and should improve intermediate distance better than monofocal lens do.
16247500|NCT05041881|Active Comparator|Monofocal IOL group|Patients implanted during cataract or refractive surgery with standard monofocal lens, which allowed to see for far but patients do not experiences optical phenomena or low contrast sensitivity.
16247501|NCT05041868|Experimental|Study group|The program comprises the practice of warm-up, muscle strengthening with free weights and with their own body weight against the action of gravity for the main muscular groups, balance control training, aerobic training, and relaxation exercises. The proposal consists of 3 weekly sessions, for 12 consecutive weeks.
16247502|NCT05041855|Experimental|Community based childhood obesity intervention|A novel family-inclusive childhood obesity treatment program consisting of 12 family group sessions delivered in English and Spanish by health educators at community recreation centers, followed by three group booster sessions occurring every 6 months.
16247503|NCT05041855|Active Comparator|Primary care based childhood obesity intervention|A healthy lifestyle counseling intervention delivered by trained primary care providers and health educators at visits occurring every 3 months.
16247504|NCT05041842|Experimental|Tucatinib plus systemic treatment with or without hormone therapy|Addition of tucatinib (300 mg orally twice daily) to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy
16247505|NCT05041829|Experimental|lowsodium|Participants in this arm will be guided to have low dietary sodium intake of <2.3 g/day (<100 mmol/day) for 4 weeks.
16247506|NCT05041829|Active Comparator|highsodium|Participants in this arm will be guided to have low dietary sodium intake of ≥4 - <6 g/day (≥174 - <261 mmo/day) for 4 weeks.
16247507|NCT05041816|Experimental|Focal vibration group|The Myovolt device used in our previous study will be used for focal vibration delivery during week three to six. Participants will wear Myovolt secured by an elastic band, at a location based on therapist and participants preference. During the four weeks of the FV therapy, participants will be asked to use the Myovolt device for up to 0.5-hour per session (each site 10 minutes per session, with one-minute intersession between sites), once in the morning and once in the evening each day, for five days a week. The dosing paradigm was chosen based on the safety and potential effectiveness of the FV therapy, and our preliminary study.
16247509|NCT05041790|Experimental|Choline Alfoscerate|
16247510|NCT05041790|Placebo Comparator|Placebo|
16248702|NCT05033821|Experimental|Intervention|Participants who receive the FOY+ImPACT intervention
16247511|NCT05041777||Prospective data collection, retrospective OCT image evaluation|From February 2017-June 2017 patients were included prospectively. OCT images were evaluated retrospectively in conjunction with clinical images. A deep learning algorithm is developed with use of this dataset including 676 OCT images.
16247512|NCT05041777||Prospective data collection and OCT image evaluation|From January 2021-April 2021 patients were included prospectively. OCT images were evaluated prospectively in a clinical setting. The deep learning algorithm will be prospectively validated with use of this dataset including 287 OCT images.
16247513|NCT05041764||PCR positive|samples that are positive for the detection of SARS-CoV2. The SARS-CoV2 sequence of positive samples is provided, together with an indication about patient's neigborhood, corresponding to one of the 21 different spots which wastewater was analyzed
16247514|NCT05041764||PCR negative|samples that are p negative for the detection of SARS-CoV2. T
16247515|NCT05041751|Active Comparator|Arm I (trigger point injections)|Patients receive standard of care trigger point injections at baseline
16247516|NCT05041751|Experimental|Arm II (myofascial release)|Patients perform myofascial release for 10 minutes each day.
16247517|NCT05041738|Experimental|Intraoral Cryotherapy|
16247518|NCT05041738|Active Comparator|Intracanal Cryotherapy|
16247519|NCT05041725|Experimental|remimazolam infusion|Intraoperative remimazolam infusion for postoperative sedation
16247520|NCT05041712||Case cohort|Observational study of children between the ages of 2 days to < 18 years who are cannulated onto ECMO at participating sites
16247521|NCT05041712||Control cohort|Observational study of children between the ages of 2 days to < 18 years admitted to the Johns Hopkins Pediatric Intensive Care Unit (PICU) or Pediatric Cardiac Intensive Care Unit (PCICU) for any reason.
16247522|NCT05041699|Experimental|IPM Ring-105|Ring-105 (xx mg dapivirine + xxx mg levonorgestrel)
16247523|NCT05041699|Active Comparator|IPM Ring-106.|Ring-106 (xx mg dapivirine + xxx mg levonorgestrel)
16247524|NCT05041686|Experimental|CADISS® System|
16247525|NCT05041673|Active Comparator|Group 1|metformin +/- insulin +/- sulfonylurea
16247526|NCT05041673|Experimental|Group 2|Metformin plus vildagliptin +/- insulin +/- sulfonylurea
16247527|NCT05041673|Experimental|Group 3|Metformin plus liraglutide +/- insulin+/- sulfonylurea
16247528|NCT05041673|Experimental|Group 4|Metformin plus empagliflozin +/- insulin +/- sulfonylurea
16247529|NCT05041660|Experimental|VR ICT|Virtual-reality-based inhibitory control training done daily at home for 6 weeks.
16247530|NCT05041660|Sham Comparator|VR Sham ICT|"Virtual-reality-based sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
16247531|NCT05041660|Active Comparator|Non-VR ICT|Computerized inhibitory control training done daily at home for 6 weeks.
16247532|NCT05041660|Sham Comparator|Non-VR Sham ICT|"Computerized sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
16247533|NCT05041647|Experimental|High CBD [25:1]|"1 dose (1 mL) of HIGH CBD
~50 mg/ml CBD and 2 mg/ ml THC"
16247534|NCT05041647|Experimental|Low CBD [5:1]|"1 dose (1 mL) of LOW CBD
~10 mg/ml CBD and 2 mg/ ml THC"
16247535|NCT05041647|Placebo Comparator|Placebo|"1 dose (1 mL) of PLACEBO
~No active ingredients"
16247536|NCT05041634|Experimental|Single Group Pilot study pre/post|One group of 8 participants receiving 14 week intervention
16247537|NCT05041621|Experimental|Sensor augmented MDI therapy plus mobile application with reinforcement learning algorithm|Participants with type 1 diabetes will undergo sensor-augmented MDI therapy for 4 months using a freestyle libre glucose sensor (Abbott Diabetes Care) and a mobile application integrated with the reinforcement learning algorithm.
16247538|NCT05041608||Subjects undergoing Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
16247539|NCT05041595||Sick Cohort|Borreliosis Subjects - established diagnosis of early Borreliosis expressing EM Rash Borreliosis Subjects - expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease
16247540|NCT05041595||Apparently Healthy|Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease
16247541|NCT05041582|Experimental|Real tDCS + Citalopram + Rehabilitation|"Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks
~Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
16247542|NCT05041582|Sham Comparator|Sham tDCS + Citalopram + Rehabilitation|"Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks
~Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
16247543|NCT05041582|Placebo Comparator|Real tDCS + Placebo + Rehabilitation|"Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks
~Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
16247544|NCT05041582|Placebo Comparator|Sham tDCS + Placebo + Rehabilitation|"Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks
~Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
16247545|NCT05041556||Case-control study of clinical outcomes|These are children who live in RTS,S implementation areas aged less than 5 years and who were eligible to have received RTS,S based on their date or birth and age, will be eligible to be recruited into the study. Cases will be recruited in sentinel hospitals of the ongoing malaria Vaccine Pilot Evaluation (MVPE). Control for a case will be a child who lives outside a 100-metre radius from the case, matched on date of birth (+/- 1 month of date of birth of the case)
16247546|NCT05041556||Case-control study of mortality outcome|These will be children who died of any cause excluding accidents or trauma, who are eligible to have received the RTS,S vaccine based on their date of birth and age. Cases will be recruited from the community-based mortality surveillance of MVPE. Control for a mortality case will be a live child who lives outside a 100 metre radius from the case with date of birth +/- 1 month of the date of birth of the case who are eligible to have received the RTS,S vaccine.
16247547|NCT05041543|Experimental|NTX-101 Group A|Day 1: One time administration, single drop. 4 subjects randomized 3:1 to NTX-101 or placebo.
16247548|NCT05041543|Experimental|NTX-101 Group B|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
16247549|NCT05041543|Experimental|NTX-101 Group C|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
16247550|NCT05041543|Experimental|NTX-101 Group D|Day 1: One time administration, two drops. Day 3-7: Two time administration, two drops each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
16247551|NCT05041543|Experimental|NTX-101 Group E|Day 1: One time administration, four drops. Day 3-7: Two time administration, four drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
16247552|NCT05041517|No Intervention|Control|No intervention
16247553|NCT05041517|Experimental|BOLT + 1 PTC|BOLT Training + 1 PTC Call
16247554|NCT05041517|Experimental|BOLT + 2 PTC|BOLT Training + 2 PTC Calls
16247555|NCT05041517|Experimental|BOLT + 4 PTC|BOLT Training + 4 PTC Calls
16247556|NCT05041504|Experimental|Intervention|Participants assigned to the intervention arm will receive the True North Peer Navigation intervention.
16247557|NCT05041504|Other|Active Waitlist Control|Participants assigned to the control arm will receive usual care and access to an online health resource library. After completion of the study, they will receive the True North Peer Navigation intervention.
16247558|NCT05041491|Experimental|BREAK Intervention|Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.
16247559|NCT05041491|Active Comparator|ONE Intervention|Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.
16247560|NCT05041478|Experimental|Cold EMR with adjuvant STSC to margins|Standard cold EMR technique with adjuvant snare tip soft coagulation to defect margins
16247561|NCT05041478|Active Comparator|Cold EMR|Standard Cold EMR resection technique
16247562|NCT05041465|Experimental|French Green Clay Mask|
16247563|NCT05041465|Experimental|Rhassoul Clay Mask|
16247564|NCT05041465|Experimental|Bentonite Clay Mask|
16247565|NCT05041452||Noncirrhotic portal hypertension (NCPH)|Patients with non-cirrhotic portal hypertension (NCPH) with pre-sinusoidal (e.g., porto-sinusoidal vascular disease, portal vein obstruction, congenital hepatic fibrosis, biliary diseases,), sinusoidal (e.g., sinusoidal destruction in the setting of acute hepatic injury, inflammatory or toxic fibrosis, non-alcoholic steatohepatitis), or post-sinusoidal causes (Budd-Chiari syndrome, sinusoidal obstruction syndrome).
16247566|NCT05041452||Cirrhotic portal hypertension|Patients with cirrhosis and portal hypertension.
16247567|NCT05041439|Experimental|Community health worker (CHW) group|Participants in the intervention arm will receive 5 one-on-one sessions over 6 months with a CHW, as well as a manual and written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
16247568|NCT05041439|No Intervention|Enhanced care condition (ECC)|Participants in this arm will receive 5 outreach calls at the same interval as the intervention arm, as well as written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
16247569|NCT05041426|Experimental|Letermovir|Participants who are CMV seropositive (CMV R+) will receive letermovir prophylaxis for 6 months, and participants who are CMV donor seropositive/recipient seronegative (CMV D+/R-) will receive letermovir prophylaxis for 12 months. Letermovir will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If letermovir is co-administered with cyclosporine A, the dosage of letermovir will be decreased to 240 mg once daily.
16247570|NCT05041426|Active Comparator|Valganciclovir|Historical controls will be lung transplant recipients for idiopathic pulmonary fibrosis from 2010-2019 who are CMV R+ or CMV D+/R-. CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
16247571|NCT05041413|Experimental|Moms Quit Intervention|12 weeks of the Moms Quit text message intervention
16247572|NCT05041413|Active Comparator|Text4Baby|12 weeks of Text4Baby messages
16247573|NCT05041400|Other|Healthy subjects|"Evaluation carried out on a BIODEX S4 Pro isokinetic dynamometer after a standardised 10-minute warm-up on this same dynamometer .
~The measurement range will be from 0° (full extension) to 90° of flexion for each knee, providing 91 degrees of measurement."
16247576|NCT05041361|Experimental|Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH)|Participants receive up to 8 weekly whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions. Each WBH session (including preparation and cool down) is up to approximately 2.5 hours, and each CBT session is approximately 50 minutes.
16247577|NCT05041348||liver cirrhosis with sarcopenia|In order to diagnosis sarcopenia, patients' muscle strength and physical function will be measured. Patients with sarcopenia will show the decrease of muscle strength and physical function.
16247578|NCT05041348||liver cirrhosis without sarcopenia|The decrease of muscle strength and physical function will not appear in patients.
16247579|NCT05041348||healthy group|No related diseases
16247580|NCT05041335|Experimental|Heparin and microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve
16247581|NCT05041335|Experimental|Heparin and no microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin
16247582|NCT05041335|Experimental|No heparin and microsieve|The needle not be prepped. The provider will expel the tissue onto the microsieve
16247583|NCT05041335|Active Comparator|No heparina nd no microsieve|The needle not be prepped. The provider will expel the tissue into formalin
16257448|NCT04973982|Active Comparator|ADOPORT|ADOPTION used as per licence
16247585|NCT05041322|Active Comparator|Buspirone|"Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
~Other Names:
~Buspar"
16247586|NCT05041309|Experimental|Axicabtagene Ciloleucel|"All participants who previously received axicabtagene ciloleucel in the parent study will be enrolled in this arm for long-term follow-up.
~In certain circumstances, participants may be eligible to receive a second course of axicabtagene ciloleucel treatment after enrolling in this long-term follow-up (LTFU) study at the same dose level that was administered in the completed parent study."
16247587|NCT05041309|Experimental|Brexucabtagene Autoleucel (KTE-X19)|"All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this arm for long-term follow-up.
~In certain circumstances, participants may be eligible to receive a second course of brexucabtagene autoleucel treatment after enrolling in this LTFU study at the same dose level that was administered in the completed parent study."
16247588|NCT05041309|No Intervention|KITE-585|All participants who previously received KITE-585 in the parent study will be enrolled in this arm for long-term follow-up.
16247589|NCT05041309|No Intervention|KITE-718|All participants who previously received KITE-718 in the parent study will be enrolled in this arm for long-term follow-up.
16247590|NCT05041309|No Intervention|KITE-439|All participants who previously received KITE-439 in the parent study will be enrolled in this arm for long-term follow-up.
16247591|NCT05041309|No Intervention|KITE-222|All participants who previously received KITE-222 in the parent study will be enrolled in this arm for long-term follow-up.
16247592|NCT05041296||Chronic group|Chronic epilepsy with recurrent seizures
16247593|NCT05041296||Acute group|Epilepsy and short-term history of seizures
16247594|NCT05041296||Control group|Healthy participants
16247595|NCT05041283|No Intervention|Standard Preparation|Control arm; patients receive a standard support for bowel preparation consisting of a explanatory dialogue with a gastroenterologist and a brochure with a structurated description of bowel preparation and colonoscopy conduct
16247596|NCT05041283|Active Comparator|Phone-call Supported Preparation|In addition to standard preparation, patients receive a phone call every day starting at 3 days before colonoscopy in which a investigator explains key points of bowel preparation and patients can ask questions concerning bowel preparation and colonoscopy conduct.
16247597|NCT05041283|Experimental|Chatbot Supported Preparation|In addition to standard preparation, patients receive an access to a chatbot which can be contacted via Whats App starting at 3 days before colonoscopy. The chatbot is programed to answer questions concerning bowel preparation and colonoscopy conduct.
16247598|NCT05041270|Placebo Comparator|control group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
16247599|NCT05041270|Active Comparator|dexmedetomidine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)
16247600|NCT05041270|Active Comparator|nalbuphine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)
16247601|NCT05041257|Experimental|Mirvetuximab Soravtansine|Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
16247602|NCT05041244|Experimental|Interventional arm|NPWT will be delivered through devices (ActiVac and InfoVac) according to FDA protocol in conjunction with the polyurethane foams. Dressing changed will be on a weekly basis.
16247603|NCT05041244|Other|Control|Standard of care Participants will be given the standard care provided in specialist foot care clinics or in-patients.
16247604|NCT05041231|Sham Comparator|Sham (group A)|Treatment procedure performed with the device that will not provide the bioactive light (laser)
16247605|NCT05041231|Experimental|PBT (group B)|Treatment procedure performed with the device that will provide the bioactive light (laser)
16247606|NCT05041218||Patients undergoing coronary artery angiography and/or percutaneous coronary intervention|Consecutive patients with indication to perform coronary artery angiography and/or percutaneous coronary intervention at Ferrara University Hospital
16247607|NCT05041205|Placebo Comparator|Placebo control group|placebo drink powder without active ingredients, 1 sachet per day with 50 ml water for 12 weeks
16247608|NCT05041205|Experimental|Beauty drink powder group|Beauty drink powder is the test article provide to participants, 1 sachet per day with 50 ml water for 12 weeks
16247609|NCT05041205|Placebo Comparator|cosmetic apparatus group|This group is designed for a cosmetic apparatus control group without consumption of placebo or test article. Together with the specified cleanser, the apparatus is used for daily facial cleaning, two times in the morning and evening for 12 weeks.
16247610|NCT05041205|Experimental|Beauty drink powder + cosmetic apparatus group|In this group, Beauty drink powder is consumed 1 sachet daily with 50 ml water and the cosmetic apparatus is used together with the specified cleanser for daily facial cleaning, two times in the morning and evening for 12 weeks.
16247611|NCT05041192|Experimental|Synaquell Group|Subjects will receive the dietary supplement, Synaquell, twice-daily during the hockey season.
16247612|NCT05041192|Placebo Comparator|Placebo Group|Subjects will receive the placebo twice-daily, during the hockey season.
16247613|NCT05041179|Active Comparator|7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)|"First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning
~Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening"
16247614|NCT05041179|Active Comparator|4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)|"First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning
~Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening"
16247615|NCT05041179|Active Comparator|2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)|"First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning
~Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening"
16247616|NCT05041179|Placebo Comparator|Placebo control (7.2 g isomaltulose)(arm D)|"First dose (3.6 g isomaltulose) consumed in the morning
~Second dose (3.6 g isomaltulose) taken in the evening"
16247656|NCT05040841|Experimental|Condition 7|"Includes 3 interventions:
~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support."
16247617|NCT05041166|Experimental|Protocol optimization cohort|Following the [13C]pyruvate injection, dynamic imaging and 3D volumetric imaging of volunteers in the first cohort (HP MRI protocol optimization, Aim 1) will be performed on the 3-T MRI scanner, using different [13C] RF excitation/detection coils.
16247618|NCT05041166|Experimental|Tissue reference cohort|The optimal setup will then be used for HP MRI of the second cohort.
16247619|NCT05041153|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO QD, Treatment repeats every 42 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
16247620|NCT05041127|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.
16247621|NCT05041114|Other|Single|Implantation of motor neuroprosthesis medical device.
16247622|NCT05041101|Experimental|Treatment (grapiprant, eribulin mesylate)|Patients receive grapiprant PO BID on day 1-21 and eribulin mesylate IV over 5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16247623|NCT05041075|Active Comparator|WB:UC|Weighted Blanket 2nd infusion Usual Care 3rd infusion
16247624|NCT05041075|Active Comparator|UC:WB|Usual Care 2nd infusion Weighted Blanket 3rd infusion
16247625|NCT05041062|Experimental|All Participants in Study Who Have Mesothelioma|Individuals in this group will receive a combination of two immunotherapy drugs (nivolumumab and ipilimumab) before and after surgery to remove their cancer. There will also be a follow up period to determine how well the drugs and surgery worked to get rid of your cancer. Your overall participation in this study (including drug treatment, surgery and follow up visits) will last for roughly one and a half years. All eligible participant who enroll in the study will participate in this group.
16247626|NCT05041023||Relative volunteers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been discussed with the relatives, a relative can be included after information and acceptance of the study. One relative per situation can be included : the most involved personn in the relationship with the resuscitation team.
16247627|NCT05041023||Caregivers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been considered, 2 to 3 caregivers who are present at the time the WLST is initiated can be included (1 physician and 1 or 2 paramedics).
16247628|NCT05041010|Experimental|Neu2000KWL|
16247629|NCT05041010|Placebo Comparator|Placebo|
16247630|NCT05040984||solifenacin|
16247631|NCT05040984||mirabegron|
16247634|NCT05040945|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy
16247635|NCT05040945|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy
16247636|NCT05040932|Experimental|YH004|The dose escalation phase includes 7 dose levels of YH004, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 16 cycles if patients receive benefits.
16247637|NCT05040919||with an arrythmia|patient suffering from STEMI and presenting an arrythmia
16247638|NCT05040919||without an arrythmia|patient suffering from STEMI and not presenting an arrythmia
16247639|NCT05040906|Experimental|H02+ Chemotherapy|Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
16247640|NCT05040906|Active Comparator|Rituxan+Chemotherapy|Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
16247641|NCT05040893|Experimental|Outpatient Physiotherapy Intervention|POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals. The intervention consists of eight one-on-one, supervised sessions delivered over 8 to 10 weeks, approximately one week apart. Each session will be approximately one hour long.
16247642|NCT05040880|Experimental|Sequence A|TRTR
16247643|NCT05040880|Experimental|Sequence B|RTRT
16247644|NCT05040867|No Intervention|Control group (CG)|Participants will continue with their daily life and usual care.
16247645|NCT05040867|Experimental|Traditional periodization exercise group (TEG)|Participants will participate in a physical exercise program with a preplanned intensity progression.
16247646|NCT05040867|Experimental|Heart Rate Variability exercise group (HRVG)|Participants will participate in a physical exercise program guide by participants' daily heart rate variability to plan the intensity progression.
16247647|NCT05040854||Healthy Subjects|Blood donors
16247648|NCT05040854||IBD patients - under biological therapy|Patients with IBD followed up in consultation on biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23.
16247649|NCT05040854||IBD patients - naive|Patients newly diagnosed with IBD and need for biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23,
16247650|NCT05040841|Experimental|Condition 1|"Includes 1 intervention:
~S2/Peer: Enhanced peer group support."
16247651|NCT05040841|Experimental|Condition 2|"Includes 1 intervention:
~S1/Text: Weekly check-in text messages."
16247652|NCT05040841|Experimental|Condition 3|"Includes 1 intervention:
~M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
16247653|NCT05040841|Experimental|Condition 4|"Includes 3 interventions:
~M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
16247654|NCT05040841|Experimental|Condition 5|"Includes 1 intervention:
~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient."
16247655|NCT05040841|Experimental|Condition 6|"Includes 3 interventions:
~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
16247710|NCT05040503|Active Comparator|Patients without sepsis|patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
16247657|NCT05040841|Experimental|Condition 8|"Includes 3 interventions:
~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages."
16247658|NCT05040841|Experimental|Condition 9|"Includes 1 intervention:
~M1/OTR: Outreach (OTR) to patient due to unsuppressed VL test result."
16247659|NCT05040841|Experimental|Condition 10|"Includes 3 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
16247660|NCT05040841|Experimental|Condition 11|"Includes 3 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support."
16247661|NCT05040841|Experimental|Condition 12|"Includes 3 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages."
16247662|NCT05040841|Experimental|Condition 13|"Includes 3 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support."
16247663|NCT05040841|Experimental|Condition 14|"Includes 3 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages."
16247664|NCT05040841|Experimental|Condition 15|"Includes 3 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
16247665|NCT05040841|Experimental|Condition 16|"Includes 5 interventions:
~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
16247666|NCT05040828|Experimental|Early interventional treatment group|The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
16247667|NCT05040828|Active Comparator|Post-onset treatment group|The patients in this group: oral drug therapy after the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020.). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
16247668|NCT05040828|Active Comparator|Control group|The patients in this group:Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
16247669|NCT05040815|Experimental|chemo-radiation treatment|"Radiotherapy with concurrent 5-fluorouracil and mitomycin-C combination treatment.
~Radiotherapy consists of 5400 cGy delivered in 30 fractions over 6 weeks. The investigators will be using the current standard regimen for the study or no change in the current CCI treatment regimen. However, the radiotherapy target will be smaller than current practice since the investigators will be omitting prophylactic inguinal irradiation."
16247670|NCT05040802||Pertussis Case Group|"Infants between 2 days to less than 2 months of age for whom a case of pertussis was reported (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case and/or clinically compatible illness) and who met case inclusion criteria.
~This post-hoc analysis was limited to infants born of mothers vaccinated with Adacel or who did not receive any tetanus, diphtheria, and acellular pertussis (Tdap) vaccine."
16247671|NCT05040802||Control Group|"Infants born at the same hospital as the case-infant who were less than 2 months old on the case-infant's cough onset date, and who met control inclusion criteria.
~This post-hoc analysis was limited to infants born of mothers vaccinated with Adacel or who did not receive any Tdap vaccine."
16247672|NCT05040789|Experimental|Group 1|CoVLP Lot 1
16247673|NCT05040789|Experimental|Group 2|CoVLP Lot 2
16247674|NCT05040789|Experimental|Group 3|CoVLP Lot 3
16247675|NCT05040776|Other|Active|EP-7041 infusion 0.6 mg/kg/hr or 1 mg/kg/hr
16247676|NCT05040763|Experimental|COVID-19 Swab Collection|All participants will receive standard of care COVID-19 testing in addition to buccal swab COVID-19 testing
16247677|NCT05040750||moderate to severe COVID 19 patients|moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed
16247678|NCT05040737|Experimental|Study Arm|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
16247679|NCT05040724|Experimental|Ivermectin|Ivermectin 3mg, on tablet. As a single dose of 400 µg / kg orally (rounded down to the nearest unit). T+ usual care
16247680|NCT05040724|Placebo Comparator|control|placebo of ivermectin administered in the same manner as the active drug in experimental arm + usual care
16247681|NCT05040711|Experimental|mindfulness coach|"Mindfulness coach is an app that provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. . To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
16247709|NCT05040516||Group 1|"The planned procedures include: medical interview, physical examination with basic anthropometric measurements (age, height, body weight); biochemical tests including blood selenium, selenoproteins, renalase and creatinine levels; total antioxidant status (TAS), 24-hour Holter electrocardiography, polysomnography and echocardiography.
~A 10 ml of venous blood sample will be collected by venopuncture. Laboratory tests will be performed using commercially available standardized tests."
16247682|NCT05040711|Active Comparator|control - web MD|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
16247683|NCT05040698|Experimental|Open Label Fostamatinib|Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1
16247684|NCT05040685|Experimental|Axillary mapping reverse|Application of axillary mapping reverse technique
16247685|NCT05040672||Group I|All volunteer male employees of Libbs Pharmaceuticals residing in all Brazilian regions will participate in this research.An online questionnaire will be applied to assess research subjects understanding of prostate cancer and health habits.
16247686|NCT05040659||Anosmic patients|Anosmic patients will be recruited from Dr. Albers Smell Clinic at MGH and through past participation in research with known anosmia and permission to recontact. All consent and testing will occur on a phone/tablet app in the participant's home.
16247687|NCT05040659||Asymptomatic participants / Healthy participants|Asymptomatic participants recruited in a hospital setting (eg. healthcare workers and household members of symptomatic patients who are potentially COVID positive). No symptoms of COVID infection at the time of enrollment. Potential or definite exposure to SARS-CoV-2 virus without symptoms of upper respiratory infection (smell loss, taste loss, fever, myalgia, cough, nasal congestion, runny nose, shortness of breath). All consent and testing will occur on a phone/tablet app in the participant's home.
16247688|NCT05040659||College Students|Asymptomatic college students recruited at the University of Maryland. No symptoms of COVID infection at the time of enrollment. Potential or definite exposure to SARS-CoV-2 virus without symptoms of upper respiratory infection (smell loss, taste loss, fever, myalgia, cough, nasal congestion, runny nose, shortness of breath). All consent and testing will occur on a phone/tablet app in the participant's home.
16247689|NCT05040659||Symptomatic participants|Symptomatic individuals will be recruited from respiratory illness clinics to evaluate smell function in patients with either SARS-CoV2, Influenza, or Adenovirus infection. All consent and testing will occur on a phone/tablet app in the participant's home.
16247690|NCT05040646||Patients|Patients who follow the watch-and-wait program for rectal cancer.
16247691|NCT05040646||Experts|Surgeons, radiotherapists, medical oncologist and other medical personnel who are involved in the treatment of rectal cancer and the watch-and-wait program.
16247692|NCT05040633|Experimental|Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by the Low Lever Laser Therapy.
16247693|NCT05040633|Sham Comparator|Sham Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by a sham Low Level Laser Therapy (LLLT). The laser equipment will be deactivated and not switched on.
16247694|NCT05040633|Active Comparator|Standard Exercise Therapy|Trial participants in this group will only receive the standard exercise therapy. The exercise therapy will consist of strengthening and stretching exercises.
16247695|NCT05040620|No Intervention|Placebo|controlling group who will receive traditional orthodontic treatment.
16247696|NCT05040620|Experimental|Olive Oil|experimental group who will receive the local application of Olive Oil five times daily after teeth brushing
16247697|NCT05040607||Primary Ciliary Dyskinesia (PCD)|"The first stage of the study:
~Data of 20 PCD patients from the database recorded between 10 July 2015 and 10 January 2017.
~The second stage of the study:
~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent supervised inspiratory muscle training (IMT) at our research unit and airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017.
~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017."
16247698|NCT05040607||Healthy Group|Data of 20 healthy subjects from the database recorded between 10 July 2015 and 10 January 2017.
16247699|NCT05040594|Experimental|Treatment A (right) B (left)|Subjects will receive PavéDerm J-Fill Soft Dermal Filler and Restylane® Lyft Lidocaine. One product will be randomized, per NLF.
16247700|NCT05040594|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane® Lyft Lidocaine and PavéDerm J-Fill Soft Dermal Filler. One product will be randomized, per NLF.
16247701|NCT05040581|Experimental|Experimental Group - 1 Day CBT|"The intervention is a 6-hour long CBT-based workshop. Cognitive behavioural therapy is a structured psychotherapy based on the cognitive theory of depression that posits that negative thoughts about the self, others and the future can lead to and perpetuate depressed mood states. CBT equips participants with skills that enable them to identify and modify distortions in their thinking that lead to depressed mood and maladaptive behavioural responses.
~The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning."
16247702|NCT05040581|Other|Control Group - 90-minute Information Session|Participants in the control group will be invited to participate in a 90-minute information session that will contain information about PPD.
16247703|NCT05040568|Experimental|Cetuximab|given to patients with high-risk colorectal cancer
16247704|NCT05040555|Experimental|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1~5.
16247705|NCT05040542||Infant Cohort|Healthy infants aged from 0-36 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
16247706|NCT05040542||Preschooler Cohort|Healthy preschooler aged from 37-72 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
16247707|NCT05040529||PLDRH|patients who underwent pure laparoscopic donor right hepatectomy
16247708|NCT05040529||ODRH|patients who underwent conventaional open donor right hepatectomy
16247711|NCT05040503|Experimental|Patients with sepsis|Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
16247712|NCT05040503|Experimental|Patients with septic shock|Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
16247713|NCT05040503|Active Comparator|Healthy volunteers|
16247714|NCT05040490|Experimental|SUG group|sugammadex as reversal drugs
16247715|NCT05040490|No Intervention|NEO group|neostigmine as reversal drugs
16247716|NCT05040477|Experimental|Experimental Group (1): Muscle energy techniques,Moist Hot pack and TENS.|"Experimental group included Moist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45C.Conventional TENS applied for 10 mins.
~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle.These pre and post intervention values were mentioned in questionnaire. The participants were administered with muscle energy technique (PIR) and data was collected again 2 and 4 weeks after the interventions."
16247717|NCT05040477|Experimental|Experimental Group (2): Facets joint mobilizations, Moist Hot pack and TENS.|"Experimental group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.
~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Facet joint mobilization (UPA & SNAGS) and data was collected again 2 and 4 weeks after the interventions."
16247718|NCT05040477|Active Comparator|Control Group:Conventional Therapy (Stretching, strengthening , Moist Hot pack and TENS)|"Control group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.
~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Conventional (sustained stretching and isometric strengthening) physical therapy and data was collected again 2 and 4 weeks after the interventions."
16247719|NCT05040464|Experimental|AZA group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg(W0)-80mg(W2)-40mg(W6) and then 40mg EOW and oral AZA capsules at a daily dose of 2.5 mg/kg
16247720|NCT05040464|Experimental|MTX group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg (week (W) 0)-80mg(W2)-40mg(W6) and then 40mg EOW and sub-cutaneous MTX 25mg once a week
16247721|NCT05040438|Experimental|Autologous NK cell infusion combined with HAIC|HAIC of 5-FU (500 mg/m2, Q4W) and cisplatin (15 mg/m2, Q4W) will be administered for up to 4 cycles to patients with locally advanced HCC. Subjects who achieved sustained SD or better based on the mRECIST criteria after 2nd cycle of HAIC will be enrolled to receive 1x10^9 cells VAX-NK/HCC infusion.
16247722|NCT05040425|Experimental|Chinese herbal medicine treatment|
16247723|NCT05040425|No Intervention|Non-Chinese herbal medicine treatment|
16247724|NCT05040412|Experimental|Diabetic mellitus patients using insulin|The trachea will be intubated by direct laryngoscopy.
16247725|NCT05040412|Experimental|Diabetic patients using oral antidiabetic drug|The trachea will be intubated by direct laryngoscopy.
16247726|NCT05040399|Other|Locking Compression Plates|Patients in whom we used Locking compression plates for sternal fixation
16247727|NCT05040399|Other|Wires|Patients in whom we used Sternal Wires for sternal fixation
16247728|NCT05040386|Active Comparator|Usual COPD Care|Participants randomized to this arm will receive the standard of care for COPD.
16247729|NCT05040386|Experimental|Intervention (ENABLE-COPD plus Usual COPD Care)|Participants randomized to this arm will receive the experimental treatment for COPD (i.e. ENABLE-COPD plus usual COPD care).
16247731|NCT05040360|Experimental|Arm I (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO once QD on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16247732|NCT05040360|No Intervention|Arm II (surveillance)|Patients undergo surveillance with no active treatment.
16247733|NCT05040347||PVTT group|The diagnosis of portal vein tumor thrombosis was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
16247734|NCT05040347||HCC group|The diagnosis of HCC was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
16247735|NCT05040347||control group|The presence of PVTT or HCC was confirmed by medical record review and all the recorded events were confirmed by a radiologist using imaging studies, ultrasound, contrast-enhanced, or MR.
16247736|NCT05040334|Active Comparator|group(1)|69 patients receiving a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)tablets
16247737|NCT05040334|Placebo Comparator|Group (2)|69 patients receiving placebo
16247738|NCT05040321|Experimental|MIB-626|Subjects will either take MIB-626 or placebo tablet twice a day for 90 days. For those who receive MIB-626, we plan on giving subjects 1000mg of the drug, twice a day for 90 days. MIB-626 will be in two 500mg tablets.
16247739|NCT05040321|Placebo Comparator|Placebo Tablet|Subjects will be randomized to receive either the placebo or MIB-626 tablets twice a day orally.
16247742|NCT05040295|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
16247743|NCT05040295|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
16247744|NCT05040282|Other|Etonogestrel 68 mg implant|Women will be subjected to etonogestrel 68 mg implant insertion (Implanon NXT; Organon, USA Inc) according to manufacture instructions. The insertion will be within the first 5 days of the menstrual cycle
16247745|NCT05040243|Experimental|Treatment Group|"On the basis of conventional acupuncture treatment combined with acupoint application of Yanqing Zhitong Ointment.
~Acupuncture point:Weizhong,Shenshu,Dachangshu,Jaji,Ashi Acupoint application:Pain in the lumbar spine, Mingmen, Yaoyangguan, Shenshu (double), Ashi (6 points in total); Within 3 inches beside the spine on both sides of the waist, Shenshu (double), Dachangshu (double), Ashi (6 points in total); 3 inches away from the sides of the spine on both sides of the waist, Shenshu (double), Zhishi (double), Ashi (6 points in total).
~Stick to each point for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.
~Three times a week( Monday, Wednesday, and Friday). Course of treatment: each course lasts for 2 weeks, a total of 2 courses of continuous treatment."
16247746|NCT05040243|Sham Comparator|Control Group|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.
~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
16247747|NCT05040217|Experimental|Gene transfer of AAV2-BDNF|Up to 12 subjects will receive open-label AAV2-BDNF
16247748|NCT05040204|Experimental|Experimental Supplement 1|6 subjects will consume 12 grams of dietary supplement 1 daily for 4 weeks
16247749|NCT05040204|Experimental|Experimental Supplement 2|6 subjects will consume 12 grams of dietary supplement 2 daily for 4 weeks
16247750|NCT05040204|Experimental|Experimental Supplement 3|20 subjects will consume 50 grams of dietary supplement 3 daily for 4 weeks
16247751|NCT05040204|Placebo Comparator|Placebo Comparator 1|6 subjects will consume 12 grams of placebo dietary supplement daily for 4 weeks
16247752|NCT05040204|Placebo Comparator|Placebo Comparator 2|6 subjects will consume 50 grams of placebo dietary supplement daily for 4 weeks
16247753|NCT05040191|Experimental|Control Group|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Nursing Fundamentals Skills Laboratory. The laboratory consists of 3 practice rooms, 1 control room and 1 analysis room. A video prepared by the researcher on the Simple Nasogastric Tube Application Model in line with the steps of Checklist for Teaching Nasogastric Tube Application Skills was watched and preliminary information was given. The questions were answered by allowing the students to ask questions."
16247754|NCT05040191|Experimental|Haptic Interactive Virtual Reality Simulation(Experiment 1 group)|Application in the Experiment-1 Group: After the theoretical lesson, the students in the Experiment-1 group were taken to the computer laboratory room where the haptic interactive virtual reality application was installed. The Nasogastric Tube Application with Haptic Interactive Virtual Reality Simulation was applied and explained by the researcher and preliminary information was given. The questions were answered by allowing the students to ask questions.
16247755|NCT05040191|Experimental|Haptic Interactive Computer Based Simulation(Experiment 2 group)|Application in the Experiment-2 Group: After the theoretical lesson, the students in the Experiment-2 group were taken to the laboratory room where the haptic interactive computer-based simulation was located. This computer-assisted simulation allows us to see the application on the computer screen while performing an application with a haptic arm. It gives feedback on hand manipulations similar to reality. It was explained by the researcher by applying the nasogastric tube application skill with haptic interactive computer-based simulation and preliminary information was given. The questions were answered by allowing the students to ask questions.
16247756|NCT05040178||Male and Female Adult and Pediatric Participants|Patients treated with carglumic acid for the treatment for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
16247757|NCT05040165|Experimental|Failure time analysis|"The primary objective is to evaluate the durability of the investigational device over its intended use lifetime (i.e. warranty period), specifically relating to any defect in the TPE material. Additionally, to gather information on the rate of side-effects, i.e. skin rashes, sores, etc.
~Secondary objectives relate to gather information on how amputees use the liner, specifically:
~Intensity of use (days/week and hours/day)
~Alternation; i.e. switching every other day between liners
~Use of personal hygiene or cosmetic products
~The following performance and safety aspects are to be verified:
~• The ICEFORM line of devices are durable over their intended use lifetime."
16247758|NCT05040152|Experimental|Arm I (telephone-based intervention)|Participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes.
16247759|NCT05040152|Active Comparator|Arm II (education brochures)|Participants receive education brochures describing the American Institute for Cancer Research physical activity and dietary guidelines.
16247760|NCT05040139||Malone procedure|The percutaneous caecal access is performed surgically
16247761|NCT05040139||Percutaneous Endoscopic Caecostomy|The percutaneous caecal acces is performed endoscopically.
16247762|NCT05040126|Active Comparator|Arm 1 - 26 weeks of BDQ +Pa + LZD (600mg)|"26 wks. of BDQ +Pa + LZD (600mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.
~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in Arm1.
~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
16247763|NCT05040126|Experimental|Arm 2 - 9 weeks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg)|"9 wks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.
~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 2 and ½ tablet of 600 mg once daily in CP of Arm 2 .
~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
16247813|NCT05039749|No Intervention|Standard Hospital Lighting (SL) Room|The lighting in this room was standard florescent hospital lighting. The only changes in the lighting was the on/off settings normally associated with lighting.
16247764|NCT05040126|Experimental|Arm 3 -13 weeks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg)|"13 wks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.
~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 3 and ½ tablet of 600 mg once daily in CP of Arm 3.
~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
16247765|NCT05040113|Experimental|CBP-307|Take CBP-307orally at 30 min ± 2 min after the start of high-fat breakfast intake
16247766|NCT05040100|No Intervention|Textbook Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images.
16247767|NCT05040100|Experimental|3D Model Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images. Upon completion of the didactic session, the 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
16247768|NCT05040087|Active Comparator|USE OF DIABETES Rx GUIDED LARGELY BY HbA1c LEVELS|Extended-release [ER] metformin will be added if HbA1c is ≥7.0% after 3 months; if already used and maximized, pioglitazone will be begun. Other Rx will be added each time HbA1c reaches ≥7.5%. The sequence of Rx will be the same as in intensive Rx subjects; those using insulin will also do prebreakfast SMBG, aiming for glucose <100 mg/dl.
16247769|NCT05040087|Experimental|USE OF DIABETES Rx GUIDED BY SELF-MONITORED BLOOD GLUCOSE (SMBG)|"Guidance by SMBG:
~Glucose goals: We will aim for <100 mg/dl premeal (2), <130 postmeal.
~Monitoring will include pre-breakfast 2x/wk, and a 5-point profile 1x/wk (before and 1.5-2.5 hr after breakfast, before lunch, before supper, and bedtime).
~Added Rx will be used if SMBG is >goal ≥3x in 2 consecutive weeks after ≥4 weeks of MOVE! and/or the previous Rx [e.g., any 3 of the 7 goals (<100 mg/dl premeal, <130 post)]. Metformin ER will be given first (if not already on it), and increased to 2000 mg/day if there are no side effects. (If metformin is not tolerated, it will be stopped and the second Rx will become the first Rx and given instead. If other Rx are not tolerated, the next Rx will be used. The second Rx will be the TZD pioglitazone, followed by the GLP-1 RA semaglutide, then the SGLT-2 inhibitor empagliflozin. If still above goal, glargine insulin will be added, titrated to keep fasting glucose <100 mg/dl."
16247770|NCT05040074|Experimental|SQ-Kyrin TMVr Feasibility Study|Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.
16247771|NCT05040061|Experimental|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
16247772|NCT05040061|Active Comparator|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices. These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
16247773|NCT05040048||Parkinson's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Motor and non motor assessments for Parkinson's disease group only.
16247774|NCT05040048||Alzheimer's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Brain MRI for Alzheimer's disease group only.
16247775|NCT05040022|Active Comparator|Group pneumoperitoneum pressure 10|Pneumoperitoneum pressure at 10 mmHg
16247776|NCT05040022|Placebo Comparator|Group neumoperitoneum pressure 14|Pneumoperitoneum pressure at 10 mmHg
16247777|NCT05040009|Active Comparator|moderate and high risk patient with integrated foot care program|"Integrated foot care program will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months
~Regular foot care and examination by an adequately trained professional: -
~Structured education
~Adequate footwear
~Foot-related exercises and weight-bearing activity.
~Foot examination and screening every 4 months in moderate risk and 2 months in high-risk patient for diabetic foot.
~Instructions about foot self-management"
16247778|NCT05040009|No Intervention|moderate and high risk patient with conventional treatment|conventional treatment will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months.
16247779|NCT05039996|Active Comparator|Intervention group|"Educational and training part. The educational part will be done once in the first visit in about 30 minutes Information and skills will be demonstrated and applied in the session through power point presentation, educational brochures, and video lessons and guided home-based practice.
~Appropriate relaxation training Program
~Relaxation training comprises deep breathing exercises and progressive muscle relaxation, to perform them daily and to keep a record of them.
~Group meeting sessions for training will be held every week for the 1st 4 weeks
~Video programs will be used as relaxation facilitators.
~Patient will try these exercises for the first time in front of the researcher.
~Patients will be advised to perform them daily for 8 weeks to achieve 60 sessions and to keep a record of them.
~Follow up of the intervention group adherence to instructions will be done weekly by Telephone."
16247780|NCT05039996|Placebo Comparator|Control group|The control group will be advised to be adherent to the prescribed medications only and try not to change the treatment plan during the study period.
16247781|NCT05039983|Experimental|EGCG application|We have chosen a dose of 880 umol/L as the lower limit for this phase I study by referring to previous studies. Six dose levels for EGCG were defined as following: 880, 1760, 2640, 3430, and 4400 umol/L per dose. Dose escalation proceeded according to a standard phase I design with three patients initially treated on each tier. If, on any dose tier of EGCG, two of three patients or two of six patients experienced a grade III or IV toxicity due to EGCG, dose escalation of EGCG would cease. The maximally tolerated dose (MTD) was defined as the highest dose with fewer than one-third of patients experiencing a dose-limiting toxicity (DLT) due to EGCG. EGCG solution was given continuously for 8 days before anti-tumor treatment.
16247782|NCT05039970|Experimental|Experimental Arm - WellQuest™ Users|Participants in National DPP groups randomized to the experimental arm will be instructed by lifestyle coaches to download the WellQuest™ game application and will receive instructions on how to use the game throughout the LCP.
16247783|NCT05039970|No Intervention|Control Arm|Participants in National DPP groups randomized to the control arm will proceed with their routine National DPP participation.
16247784|NCT05039957|Active Comparator|A|
16247785|NCT05039957|Experimental|B|
16247786|NCT05039944|Experimental|SI-B001_A|Patients with unresectable or metastatic gastric cancer, HER2-negative and without standard treatment were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16247787|NCT05039944|Experimental|SI-B001_B|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed conventional chemotherapy combined with EGFR mab were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16247788|NCT05039944|Experimental|SI-B001_C|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed multiple lines of conventional chemotherapy (excluding EGFR monoclonal antibody) were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16247789|NCT05039944|Experimental|SI-B001 combined with irinetecan_D|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16247790|NCT05039944|Experimental|SI-B001 combined with FOLFIRI or FOLFOX_E|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16247791|NCT05039944|Experimental|SI-B001 combined with irinetecan_F|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16247792|NCT05039931|Experimental|GNC-035|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
16247793|NCT05039918|Experimental|Intervention|"Following randomisation, infants will receive CT-optimal stimulation (gentle stroking) at a velocity of 3cm/s over the area which the infant will be stroked (10cm) for a duration of 10s applied proximally to the pain site prior to the heel prick. Location of the heel prick will be based on clinical judgement. There will be an inter-stimulus interval of approximately 1 second between the end of the touch and heel prick, and touch stimulation will be applied to the lower leg ipsilateral to the heel receiving the noxious stimuli. All infants will have cardio-respiratory monitoring during the intervention. All other environmental factors will be as standard care (e.g., temperature, lighting and sounds).
~The heel prick will be performed by a member of the infants designated clinical team who have performed the procedures in a standardised manner according to the institutional and unit policy."
16247794|NCT05039918|No Intervention|Control|Infants who are randomised to the control group will receive standard care consistent with neonatal policy. The infant will undergo a heel prick in the incubator or crib in an identical fashion to the infants in the intervention group.
16247795|NCT05039905|Experimental|99mTc-MSA-ICG injection|"99mTc-MSA-ICG injection
~1mCi of 99mTc
~1mg of MSA 0.1mg of ICG Total 1cc injection volume at 2 hours before the surgery"
16247796|NCT05039892|Experimental|All eligible subjects|
16247797|NCT05039866||Subjects who received ST-920|Subjects who received ST-920 in clinical study ST-920-201
16247798|NCT05039853|Experimental|A brief cognitive task-based based intervention|Participants will engage in a brief cognitive task including: a memory reminder procedure, playing the computer game, Tetris, on a smart-device using mental rotation.
16247799|NCT05039853|Placebo Comparator|Placebo activity|Participants will engage with a placebo activity: listening to a pod-cast for approximately 15 minutes on a smart-device.
16247802|NCT05039827|Experimental|MWM GROUP|Mobilization with movement with wrist extension
16247803|NCT05039827|Active Comparator|SOFT TISSUE MOBILIZATION GROUP|Parallel and perpendicular soft tissue massage at common extensor origin
16247804|NCT05039814||AKI|patients suffered postoperative acute kidney injury
16247805|NCT05039814||Non-AKI|patients did not suffer postoperative acute kidney injury
16247806|NCT05039801|Experimental|Part A (IACS-6274)|Patients receive IACS-6274 PO BID on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16247807|NCT05039801|Experimental|Part B (IACS-6274, pembrolizumab)|Patients receive IACS-6274 PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16247810|NCT05039762|Active Comparator|Extracorporeal anastomosis|Laparoscopic right hemicolectomy with Extracorporeal anastomosis in patients with colon cancer.
16247811|NCT05039762|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy with Intracorporeal anastomosis in patients with colon cancer.
16247812|NCT05039749|Experimental|Human Central Lighting (HCL) Room|This inpatient room was outfitted with lights that mimic the day/night cycle, thereby supporting circadian rhythm. Day time lights were automatically on during 0600 to 1900 and in use any time the patients would normally utilize their lights, with a goal of three hours of light exposure per day. The lights automatically transitioned to warmer toned evening lighting at 1900.
16247814|NCT05039736|Experimental|cabozantinib|cabozantinib by mouth every day for 6 weeks
16247819|NCT05039697|Experimental|NBO group Normobaric Hyperoxia combined with endovascular mechanical thrombectomy|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30minutes after admission) at a ventilation rate of 10L/min using a sealed non-ventilating oxygen storagemask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
16247820|NCT05039697|Placebo Comparator|Control group Inhale air placebo plus endovascular mechanical thrombectomy|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%
16247821|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan|Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan
16247822|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost|Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost
16247823|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan|Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan
16247824|NCT05039684||Ocular hypertension - No treatment|Patients ocular hypertension untreated
16247825|NCT05039671||Measurement-based care|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
16247826|NCT05039658|Experimental|Single agent treatment arm with IBI110|IBI110 administered at RP2D
16247827|NCT05039658|Experimental|Combination treatment arm with IBI10 and sintilimab|IBI110 and sintilimab administered at RP2D
16247828|NCT05039645|Other|Open Arm Study - All participants|"Study is open arm with no blinding or randomisation. Patients will receive standard care including frequent clinical visits, education, and preventative foot care/podiatry as required. Patients will also be given a DFS thermovisual scanner device. Patients will be instructed to use the DFS on a daily basis, at home, to record thermovisual data about the soles of their feet.
~Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of >2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment)."
16247829|NCT05039632|Experimental|Cohort I (NBTXR3, Abscopal, ipilimumab, ipilimumab)|Patients receive NBTXR3 intratumorally on day 1. Patients also receive ipilimumab IV over 90 minutes on day 8. Beginning day 15, patients undergo Abscopal radiation therapy over 1-2 weeks. Patients then receive ipilimumab IV over 90 minutes and ipilimumab IV over 30 minutes on day 29. Cycles with nivolumab repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16247830|NCT05039632|Experimental|Cohort II (NBTXR3, RadScopal, ipilimumab, nivolumab)|Patients receive NBTXR3 intratumorally on day 1. Patients also receive ipilimumab IV over 90 minutes on day 8. Beginning day 15, patients undergo RadScopal radiation therapy over 1-2 weeks. Patients then receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 29. Cycles with nivolumab repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16247833|NCT05039606|Experimental|the treatment group|Nedplatin combined with intensive radiotherapy group
16247834|NCT05039606|Active Comparator|the control group|Cisplatin was combined with the IMRT group
16247835|NCT05039593|Experimental|first group|The patients in the first group will be given oral care with 0.12% chlorhexidine twice a day.
16247836|NCT05039593|Experimental|second group|The patients in the second group will be given oral care with 0.12% chlorhexidine 3 times a day.
16247837|NCT05039593|Experimental|third group|The patients in the third group will be given oral care with 0.12% chlorhexidine 4 times a day.
16247838|NCT05039580|Experimental|PD-1 monoclonal antibody group|PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age >=18 years, or age <18 years but weight >=40kg. While for patients age <18 years, the dose of PD-1 monoclonal antibody is 3mg/kg.
16247839|NCT05039567|Experimental|optimal heart team group|Heart teams in this group will be established according to the optimal heart team protocol. Each team consists of two interventional cardiologists and two cardiac surgeons. Team members will be trained systematically before the heart team meeting.
16247840|NCT05039567|No Intervention|conventional heart team group|Heart teams in this group will be established according to the basic elements recommended by guidelines. Each team consists of an interventional cardiologist, a cardiac surgeon, and a non-interventional cardiologist. No team training will be held before the heart team meeting.
16248201|NCT05037370|Experimental|PRK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
16247846|NCT05039528|Experimental|Intervention|Participants will receive the personalized OSA messages.
16247847|NCT05039528|Placebo Comparator|Control|Placebo participants will receive no treatment during the experiment.
16247848|NCT05039515|Experimental|IPN60130 high dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
16247849|NCT05039515|Experimental|IPN60130 low dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
16247850|NCT05039515|Placebo Comparator|Placebo|Oral capsule, swallowed whole or sprinkled onto food, once daily
16247851|NCT05039502|Experimental|Retreatment system using in rotational motion|Previous root canal filling materials were removed with D1-D2-D3 retreatment files with using an endodontic motor in rotational motion
16247852|NCT05039502|Experimental|Retreatment system using in reciprocal motion|Previous root canal filling materials were removed with Reciproc 25 file with using an endodontic motor in reciprocal motion
16247853|NCT05039502|Experimental|Retreatment system using in additional rotational motion|Previous root canal filling materials were removed with XP-endo finisher r file with using an endodontic motor in rotational motion
16247854|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
16247855|NCT05039489|Active Comparator|The schizophrenia patients with general auditory hallucinations|Drug intervention
16247856|NCT05039489|No Intervention|The healthy controls|MRI scan at baseline and no drugs treatment
16247857|NCT05039489|Experimental|Drug + cTBS intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug + cTBS intervention (the left temporoparietal cortex as the stimulation target)
16247858|NCT05039489|Active Comparator|Drug intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug intervention
16247859|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations from the fourth arm|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
16247860|NCT05039476|Active Comparator|Retinol face cream|Retinol face cream on one half of the participant's face
16247861|NCT05039476|Placebo Comparator|Placebo face cream|Placebo face cream on one half of the participant's face
16247862|NCT05039463||PRP + HA|two injections of PRP (plasma rich in platelets ), in combination with HA (hyaluronic acid)
16247863|NCT05039463||HA alone|HA (hyaluronic acid)
16247864|NCT05039450|Experimental|EFX 28 mg|
16247865|NCT05039450|Experimental|EFX 50 mg|
16247866|NCT05039450|Placebo Comparator|Placebo|
16247867|NCT05039437|Experimental|MGF-4|Take two MGF-4 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-4 and other excipients.
16247868|NCT05039437|Experimental|MGF-7|Take two MGF-7 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-7 and other excipients.
16247871|NCT05039411|Experimental|Human umbilical cord mesenchymal stem cells (UC-MSCs)|All patients to receive allogeneic UC-MSCs via intralesional injection
16247872|NCT05039398|Active Comparator|Comparison group|
16247873|NCT05039398|Experimental|Telephone D&G|
16247874|NCT05039398|Experimental|Physical meeting D&G|
16247875|NCT05039385|Experimental|ESATRAL Group|They will perform the supervised physical exercise program. The supervised exercise program (ESATRAL) will last 24 weeks with 2-3 non-consecutive weekly sessions. The duration of each session will be 30 minutes and will progressively increase depending on the phase in which we are until reaching 60 minutes.
16247876|NCT05039385|No Intervention|Control Group|They will follow their daily treatment without added exercise
16247877|NCT05039372|Experimental|training and consultancy|"Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered to the patients in this group at the first interview. Individual training will be given to the patient in line with the training guide prepared for the rheumatoid arthritis patient, and the guide will be shared after the training. In line with the theory of planned behavior in patients with rheumatoid arthritis, counseling service will be provided by the researcher to the extent of the training plan prepared for symptom management. At the end of the 3rd month, the patients will be interviewed face to face and the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered again."
16247878|NCT05039372|No Intervention|control|"After obtaining written consent from the patients who agreed to participate in the study, the patients included in the control group were asked to continue their rheumatologist follow-up and their normal lives (hospital routine, daily life). Patients in this group will fill out the Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Evaluation Questionnaire at the first interview. After 3 months, data collection tools other than the Patient Identification Form will be applied to the patients and the training guide to be prepared for rheumatoid arthritis patients will be given."
16247879|NCT05039359|Active Comparator|FlecIH-103 (flecainide acetate inhalation solution)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.
16247880|NCT05039359|Placebo Comparator|Vehicle-matched inhalation solution (placebo)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.
16247881|NCT05039346||Brain Tumor|Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
16248202|NCT05037357||nasopharyngeal carcinoma patients|Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.
16247882|NCT05039346||Care Giver|"Should a patient be unable to answer, the care giver will step in and provide surrogate answers.
~Additionally, at four weeks following the patient's death, the patient's care giver will be interviewed by utilizing a validated questionnaire."
16247883|NCT05039333||RUS (Surgical navigation, anatomy 3D-reconstruction)|single-arm study : prospective observational 1-arm (RUS group)
16247884|NCT05039320|Experimental|Group 1 - probiotic|"The use of Streptococcus salivarius K12 containing tablets (Bactoblis, registration number: AM.01.06.01.003.Е.000024.07.18; 20.07.18, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).
~Ingredients: basic active ingredient - Streptococcus salivarius K12 (≥1×109 CFU in 1 tablet), excipients - fructose (sweetener), maltodextrin, silicon dioxide, magnesium stearate (vegetable), strawberry flavouring."
16247885|NCT05039320|Placebo Comparator|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).
~Ingredients: fructose (sweetener), maltodextrin, silicon dioxide, magnesium stearate (vegetable), flavouring (strawberry)."
16247886|NCT05039307|Experimental|Intervention group (Educational and motivational strategy)|The intervention group will be provided with a multi-component intervention entailing the following components distributed over the 24-months study: 4 individualized education sessions at the household, 4 group activities (2 group education sessions and 2 physical activity sessions) at the healthcare center, and 4 focus groups at the healthcare center as well. The motivational components of goal setting and the use of a pedometer will be incorporated in the individualized education sessions. Moreover, community activities will be incorporated in the second year of the study after exploring whether the activities are feasible and acceptable by the community. The topics covered by the intervention are healthy diet, physical activity, weight control strategies and knowledge and awareness of T2DM and GDM. Additionally, at baseline participants will be provided with a healthy lifestyle brochure with general recommendations.
16247887|NCT05039307|No Intervention|Comparison group (Basic educational strategy)|The comparison group will be limited to receive the healthy lifestyle brochure with general recommendations at baseline only.
16247888|NCT05039294|Experimental|intervention|provided the educational programs with all contents, and follow up after one month
16247889|NCT05039294|No Intervention|control|received no intervention, but assessed pre-post
16247890|NCT05039281|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16247891|NCT05039268|Active Comparator|15mg Dose Group|Participants will receive a fixed dose regimen of five doses of 15mg.
16247892|NCT05039268|Active Comparator|30mg Dose Group|Participants will receive a fixed dose regimen of five doses of 30mg.
16247893|NCT05039242|Active Comparator|Control Group A(Conventional Physical Therapy)|Balanced resistive hand exercise with use of physio hand ball squeezes
16247894|NCT05039242|Experimental|Experimental Interventional Group B (I-Band Application of Kinesiotaping)|Participants will receive exercise interventions as group A along with that the Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm.
16247895|NCT05039242|Experimental|Experimental Interventional Group C (fan shaped Application of Kinesiotaping)|Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects
16247896|NCT05039229|Experimental|Nozzles (NZ)|Intervention with the aim of reducing bioaerosol exposure for the employees, targeting alteration of nozzles or nozzle function along the production line.
16247897|NCT05039229|Experimental|Cleaning of surfaces (CS)|Intervention with the aim of reducing bioaerosol exposure for the employees while cleaning their personal operating areas (work benches and part of production lines) during work operations or while cleaning floor areas.
16247898|NCT05039229|No Intervention|Control (CTR)|Work is to be carried out as usual without any intervention measures. Follow-up according to the same schedule as for the other intervention groups.
16247899|NCT05039216||patients initiating a biotherapy or a target treatment|Blood sampling
16247900|NCT05039216||patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology|Blood sampling
16247901|NCT05039203||Intervention group|Inpatients with an indwelling urinary catheter (IUC) at admission to a rehabilitation clinic for persons ≥65 years in Sweden. Intervention is removal of the IUC.
16247902|NCT05039203||Control group|Inpatients without an IUC at admission to a rehabilitation clinic for persons ≥65 years in Sweden
16247903|NCT05039190|Active Comparator|Experimental: HBM9161 (680mg )|HBM9161 680mg; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
16247904|NCT05039190|Placebo Comparator|Placebo Comparator: Placebo|Placebo; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
16247905|NCT05039177|Experimental|Dose Escalation (Part 1): ERAS-007 in combination with encorafenib and cetuximab|ERAS-007 will be orally administered in combination with encorafenib and cetuximab to study participants with BRAFm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
16247906|NCT05039177|Experimental|Dose Escalation (Part 2): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered in combination with palbociclib to study participants with KRASm or NRASm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
16247907|NCT05039177|Experimental|Dose Expansion (Part 3): ERAS-007 in combination with encorafenib and cetuximab|ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with encorafenib and cetuximab to study participants with BRAFm CRC.
16247908|NCT05039177|Experimental|Dose Expansion (Part 4): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 2) in combination with palbociclib to study participants with KRASm or NRASm CRC.
16247935|NCT05038982|Experimental|Prurigo Nodularis|Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
16248203|NCT05037344|Experimental|Internet-based psychotherapy|16 weeks of internet-based cognitive behavioral therapy
16247909|NCT05039164|Experimental|Remote Training Strategy (RTS)|The RTS will be developed during Phase 1 of this 5-year project using an iterative process (Rapid Prototyping) to develop an online training platform. Investigators will train school staff from both conditions remotely on providing a brief in-service training to teachers on recognizing warning signs of excessive anxiety, depression, and disruptive behavior problems in children. Teachers will nominate students who might need Tier 2 services. Investigators will offer protected access to asynchronous training materials to school behavioral health staff (BHS). The materials will include didactic content, audio and visual examples, as well as treatment materials and resources. The RTS will also allow synchronous training and consultation for the implementation of EBPs by BHS supported by expert consultants and school personnel to coordinate services in a child-centered approach for students already receiving other services at school.
16247910|NCT05039164|Active Comparator|Control Condition (CC)|School behavioral health staff (BHS) in the CC will be trained remotely on providing a brief in-service training to teachers tasked with nominating students on recognizing warning signs of excessive anxiety, depression, and disruptive behavior problems in children. Investigators will offer protected access to asynchronous training materials such as training modules that include didactic content, audio and visual examples, as well as treatment materials and resources, all of which can be viewed at the trainee's individual pace and convenience.
16247911|NCT05039151||septic shock|50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas
16247912|NCT05039151||control|35 non-septic patients with oedema from another cause
16247913|NCT05039138|Experimental|Group I (control)|: it includes 17 patients who will receive traditional strength training program.
16247914|NCT05039138|Experimental|Group II (experimental):|it includes 17 patients who will receive upper extremity neuromuscular training exercises
16247915|NCT05039125|Active Comparator|40000HZ ultrasound cavitation|group A (n=15) received 40000HZ ultrasound cavitation, Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
16247916|NCT05039125|Active Comparator|2600HZ ultrasound cavitation|group B (n=15) received 2600HZ ultrasound cavitation. Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
16247917|NCT05039112|Other|P1fA, then MyDay Toric|Verofilcon A toric contact lenses worn first, with stenfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
16247918|NCT05039112|Other|MyDay Toric, then P1fA|Stenfilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
16247919|NCT05039099|Experimental|AP-101|AP-101 is administered by IV.
16247920|NCT05039099|Placebo Comparator|Placebo|Placebo is administered by IV.
16247921|NCT05039086||PDE5 inhibitors|Exposure group
16247922|NCT05039086||Endothelin receptor antagonists|Reference group
16247924|NCT05039060|Active Comparator|Group 1|Group 1: Modified MAC diet (first 3-weeks) followed by conventional diet (second 3-weeks)
16247925|NCT05039060|Placebo Comparator|Group 2|Group 2: Conventional diet (first 3-weeks) followed by modified MAC diet (second 3-weeks)
16247927|NCT05039034||Low-risk Group|Low-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but without chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
16247928|NCT05039034||Mediate-risk Group|Mediate-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but meanwhile suffer from chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
16247929|NCT05039034||High-risk Group|High-risk Group is defined as the population with ≥3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), or population with history of stroke or/and transient ischemic attack.
16247933|NCT05038995||Cow milk elimination group|The CME children will be eligible for the study if they (1) had a diagnosis of CMA by OFC, except children with known anaphylaxis (2) those on a CME diet or a specialized infant formula for at least three months (3) had reintroduced cow's milk for at least three months ago. Children who excluded other foods in addition to cows' milk in the first four years of life for ≥ three months and who currently introduced these foods for at least ≥ three months will be also enrolled in the CME group.
16247934|NCT05038995||Healthy group|Healthy children will ve eligible for the study if they (1) did not have CMA and other allergic diseases (2) who had never been on a diet throughout their lives.
16247936|NCT05038982|Experimental|Chronic Pruritus of Unknown Origin|Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
16247937|NCT05038969|Experimental|A test|Test drug (Stomopral) 1 capsule contains 40 mg Enteric Coated Pellets of Esomeprazole
16247938|NCT05038969|Active Comparator|B reference|Reference drug (Nexium) 1 capsule contains 40 mg Esomeprazole
16247939|NCT05038943|Experimental|SherpaPak|cardiac allografts recovered from donors after circulatory determined death using thoracoabdominal normothermic regional perfusion will be transported to the recipient center in Paragonix SherpaPak Cardiac Transport System
16247940|NCT05038930|Experimental|Intervention protocol|"Phase 1. The patient will be positioned in a supine position for 20 minutes on the Sara Combilizer®. When necessary, the head of the patient can be elevated to a maximum of 30 degrees during the 20 minutes baseline measurements.
~Phase 2. The patient will be positioned in a seated position for 10 minutes with the trunk and head elevated to at least 70 degrees.
~Phase 3. The patient will be moved to the standing position for 20 minutes with an elevation angle of the Sara Combilizer of at least 70 degrees. If patients become haemodynamically unstable during the seated or standing position, they will be returned to the supine position, and the intervention will be terminated.
~Phase 4. The patient is returned to the phase 1 position (supine). Further measurements are made for at least 20 minutes."
16247941|NCT05038930|No Intervention|Sedentary protocol|The sedentary protocol will follow the same four phases as the intervention protocol only the patient will remain in the supine position on the Sara Combilizer®. Ideally, no interventions will occur during the 70-minute protocol. If medications are given or other interventions are necessary, this will be registered.
16247942|NCT05038904|Experimental|Acalabrutinib|Participants will be given acalabrutinib (four doses of 100 mg of acalabrutinib to be taken orally twice daily).
16247943|NCT05038891||Digital Cervical Assessment performed first|A digital cervical exam will be performed by an experienced senior obstetrics and gynecology resident, using index finger and middle finger to measure the dilation and thickness of the cervix. This is the gold standard measurement utilized to assess the labor course. In this group, the digital cervical exam is done first, followed by a participant-performed ultrasound imaging assessment of the cervix.
16247944|NCT05038891||Ultrasound Assessment performed first|Ultrasound imaging will be first taught by an experienced RN, then self-performed by the participant in the presence of junior obstetrics and gynecology resident and the RN. The junior resident will ensure the ultrasound device is functioning properly and the images are saved. In this group, the participant-performed imaging assessment is done first, followed by a digital cervical exam performed by an experienced senior obstetrics and gynecology resident.
16247945|NCT05038878|Experimental|GnRH antagonist (Elagolix)|Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression
16247946|NCT05038865||Malocclusion group|500 12-19 year olds with malocclusion, defined as IOTN-DHC grade 3, 4 or 5. The adolescents are consecutively recruited new patients at three orthodontic centers; Center for Orthodontics and Pediatric Dentistry, Norrköping, Public Dental Service Östergötland; Department of Orthodontics, Folktandvården Stockholms län AB, Folktandvården Eastmaninstitutet, Stockholm, Sweden and Department of Orthodontics, Malmö University, Malmö, Sweden. Patients are examined at the first visit at the orthodontic department, before any orthodontic treatment is begun.
16247947|NCT05038865||No malocclusion group|175 12-19 year olds without malocclusion, defined as IOTN-DHC grade 1 or 2. Patients are consectively recruited adolescents examined at their general dentistry clinic.
16247948|NCT05038852|Other|Group 1 smartphone applications|app is designed to help you learn relaxation skills
16247949|NCT05038852|Other|Group 2 smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
16247950|NCT05038839|Experimental|Treatment (cabozantinib, pamiparib)|Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16247951|NCT05038826||trial 1|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
16247952|NCT05038826||trial 2|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
16247953|NCT05038826||trial 3|RNA-polymerase-II inhibitor
16247954|NCT05038826||trial 4|Tyrosine kinases inhibitor
16247955|NCT05038826||trial 5|Tyrosine kinases inhibitor
16247956|NCT05038826||trial 6|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
16247957|NCT05038813|Experimental|Anlotinib combined with TQB2450|Anlotinib: 12mg, capsule, once a day. TQB2450: 1200mg, Injection, Once every three weeks.
16247961|NCT05038774|Experimental|Interventional group|GPs of the Interventional group will receive (1 day) face to face education with structured educational material on strategies of hypertension management by a senior cardiologist.
16247962|NCT05038774|Active Comparator|Control group|GPs of the Control group will receive print version of education material (Structured educational material) on strategies of structured hypertension management.
16247963|NCT05038761||Type 1 or type 2 diabetes mellitus participants|Participants will be enrolled after the decision to initiate venous blood glucose testing and Cascade Continuous Glucose Monitoring (CGM) system as per investigator's routine treatment practice.
16247964|NCT05038748||ASD group|80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
16247965|NCT05038748||Sibling group|30 unaffected siblings of ASD youths
16247966|NCT05038748||TD group|40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007
16247967|NCT05038735|Experimental|Alpelisib plus fulvestrant|Alpelisib 300 mg orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15, and on Day 1 on every Cycle thereafter, in a 28 days cycle.
16247968|NCT05038735|Placebo Comparator|Alpelisib-matching placebo plus fulvestrant|Alpelisib-matching placebo orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15 and on Day 1 on every Cycle thereafter, in a 28 days cycle. Participants who have disease progression per RECIST v1.1 as assessed by BIRC will have the option to crossover to be treated with alpelisib plus fulvestrant
16247969|NCT05038709|Experimental|Pink Pad|Hip arthroscopy using The Pink Pad Hip Kit Patient Positioning System (Xodus Medical, New Kensington, PA). The pad is placed between the patient and the traction table, using a perineal post.
16247970|NCT05038709|No Intervention|Control (No pad)|Hip arthroscopy in the usual fashion, no pad, using traction table with perineal post.
16247971|NCT05038696|Experimental|Single arm|Single arm Phase I Clinical Trial
16247972|NCT05038683|Experimental|HOT|Holbæk Obesity Treament
16247973|NCT05038683|Active Comparator|COT|Conventional Obesity Treatment
16247974|NCT05038670|Active Comparator|PERSONA|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet PERSONA system
16247975|NCT05038670|Active Comparator|Journey II|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Smith&Nephew Journey II system
16247976|NCT05038657|Experimental|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
16247977|NCT05038644|Experimental|Arm Z: Dose Level -1 for Group A (T-ALL, T-LBL)|0.1 mg intravenous (IV) Cycle (C) 1 Day (D) 1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
16247978|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) for Group A (T-ALL, T-LBL)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
16247979|NCT05038644|Experimental|Arm B: Dose Level 1 for Group A (T-ALL, T-LBL)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
16247980|NCT05038644|Experimental|Arm C: Dose Level 2 Group A (T-ALL, T-LBL)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
16247981|NCT05038644|Experimental|Arm D: Dose Level 3 Group A (T-ALL, T-LBL)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
16247982|NCT05038644|Experimental|Arm Z: Dose Level -1 Group B (AML)|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
16247983|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) Group B (AML)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
16247984|NCT05038644|Experimental|Arm B: Dose Level 1 Group B (AML)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
16247985|NCT05038644|Experimental|Arm C: Dose Level 2 Group B (AML)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
16247986|NCT05038644|Experimental|Arm D: Dose Level 3 Group B (AML)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
16247987|NCT05038618|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16247988|NCT05038605|Active Comparator|Topical metronidazole|Topical application of metronidazole cream on the anal verge after surgery
16247989|NCT05038605|Active Comparator|Oral metronidazole|oral metronidazole 500 mg tablets after surgery
16247990|NCT05038605|No Intervention|Control|No metronidazole was received
16247991|NCT05038592|Experimental|Treatment (decitabine, tagraxofusp-erzs)|Patients receive decitabine IV over 60 minutes on days 1-5, and tagraxofusp-erzs IV over 15 minutes on days 1-3. Cycles of decitabine repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment with tagraxofusp-erzs repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
16247992|NCT05038579|Experimental|Musiquence|Dementia group was involved in a 14-session customized cognitive stimulation program, using Musiquence.
16247993|NCT05038566|No Intervention|Comparator Baseline|The subject wears their usual partial hand prosthesis while performing functional outcome measures.
16247994|NCT05038566|Experimental|Pointdexter|The subject wears a modified version of their usual partial hand prosthesis. The modification replaces the usual index finger of the partial hand prosthesis with the investigational Pointdexter device. Subjects will either test out this hand configuration in the lab while performing functional outcome measures or at home in their daily lives for approximately four weeks.
16247995|NCT05038553||Patients with early rheumatoid arthritis|
16247996|NCT05038540|Experimental|Virtual reality application|Application of virtual reality glasses during scaling and root planning to a quadrant.
16247997|NCT05038540|Active Comparator|No application|No application of virtual reality glasses during scaling and root planning to a quadrant.
16247998|NCT05038527|Experimental|ABM/P-15 bone graft|Group A: Bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15)
16247999|NCT05038527|No Intervention|Standard treatment|Group B: Standard bone graft which is a mix of locally harvested bone and a morselized femoral head (allogenic)
16248000|NCT05038514|Experimental|music therapy|Music therapy intervention, bluetooth headphones will be applied in the intensive care unit and will be disinfected after the application. The intervention consists of a 30-minute, single-session, nature-based music concert. the music concert is calibrated by the audiologist (60 decibels). During nature-based music listening, patients will be asked to close their eyes, rest and follow the sound flow.
16248001|NCT05038514|No Intervention|control|The control group will be given the prone position and music therapy will not be applied.
16248002|NCT05038501||Comorbidities in Oncosurgery patients|Prevalence of comorbidities as Coronary artery disease, Hypertension , Diabetes Mellitus,Hypothyroidism and Corona Virus Infection will be studied in patients undergoing Oncosurgeries.
16248003|NCT05038488|Experimental|MIB-626|Oral administration of MIB-626 substantially raises the intracellular NAD+ levels and activates signaling mechanisms that regulate inflammation and cell survival, downregulates the NLRP3 inflammasome, and attenuates the inflammatory response in a number of experimental models, and protects against tissue damage induced by pro-inflammatory cytokines.
16248004|NCT05038488|Placebo Comparator|Placebo Tablet|"A placebo control will be supplied. Participants randomized to placebo will receive matching tablet.
~Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC."
16248005|NCT05038488|Other|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
16248006|NCT05038475||Mild group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.
~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).
~Intervention:
~COVID-19 Antibody testing at different time points"
16248007|NCT05038475||Moderately-severe group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.
~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).
~Intervention:
~COVID-19 Antibody testing at different time points"
16248008|NCT05038462|Active Comparator|Maternal supplementation with Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
16248009|NCT05038462|Placebo Comparator|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
16248010|NCT05038449|Experimental|Colchicine group|"The colchicine treatment includes an initial dose of 1 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 6 days and 0.5 mg every 24 hours until the completion of 10 days of total treatment.
~+ standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)."
16248011|NCT05038449|Placebo Comparator|Standard therapy group|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).
16248012|NCT05038436|Experimental|Polyglucosamine L112|composed of (beta-1.4 polymer of D-glucosamine and N-acetyl-D-glucosamine)
16248013|NCT05038436|Placebo Comparator|Placebo|Dicalcium phosphate, cellulose
16248014|NCT05038423|Active Comparator|A structured 12-week group walking program|Participants engaged in an evidence-based 12-week walking program.
16248015|NCT05038423|Experimental|A structured 12-week group walking program + 5RS|In addition to the 12-week group walking program, participants engaged in the 5R Shared Leadership Program, which implements a structure of shared leadership and strengthens the identity leadership skills of the appointed peer leaders.
16248016|NCT05038410|Active Comparator|Wobenzym®|Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).
16248017|NCT05038410|Placebo Comparator|PLACEBO|No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.
16248018|NCT05038397|Experimental|Therasphere|
16248019|NCT05038384||Observational (survey)|Participants complete a survey over 20 minutes.
16248020|NCT05038371||Patients with neovascular age-related macular degeneration|This will include 10 subjects with a diagnosis of age-related macular degeneration.
16248021|NCT05038371||Controls|This group will comprise 10 participants who plan to undergo vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring.
16248022|NCT05038332|Active Comparator|Moderately Hypo-fractionated Radiation Therapy|20 fractions of moderately hypofractionated radiation therapy over no more than 5-6 weeks.
16248023|NCT05038332|Experimental|Ultra-Hypofractionated Radiation Therapy|5 fractions of ultra-hypofractionated radiation therapy with at least one day between each treatment over the course of no more than 3-4 weeks
16248024|NCT05038319|Active Comparator|Cyanoacrylate injection and EUS guided coil and glue injection|The procedure would be performed under conscious sedation.The endoscope would be used to reach the site of Varices. In Conventional technique treatment with cyanoacrylate the injection was performed using a 23-G sclerotherapy needle catheter . One vial of N-butyl-2-cyanoacrylate (0.5 mL) was mixed with Lipiodol) in a 1:1 ratio, and injected intravesically as a 1 mL bolus. The injection was repeated until total hardening of the varix. In treatment with coil and cyanoacrylate once the gastric varix was identified, the total diameter of the vascular pseudotumor was measured and the puncture was made at the site of the widest varix. The puncture was performed using a 19 G needle . the size of the coil after release should not be greater than the caliber of the vessel. Following coil deployment, 2 mL of distilled water was injected, followed by one vial (0.5 mL) of N-butyl-2-cyanoacrylate mixed with Lipiodol in 1:1 ratio.
16248025|NCT05038319|Placebo Comparator|COIL and GLUE|"Cyanoacrylate injection, first published by Soehendra in 1986, remains the conventional treatment method.
~Since coils were first used to treat ectopic varices by Levy in 2008(6), this technique has been increasingly implemented into clinical practice. However, its higher cost has been a limiting factor in more widespread use.
~Depending on the ectasia of the varix the following coil was deployed: 8 mm x 20 cm, 10 mm x 20 cm, or 10 mm x 30 cm (Interlock-18 Fibered IDC Occlusion System,Cook)."
16248028|NCT05038293|Experimental|Automated mouthpiece-based toothbrush|Under observation of study staff, participants assigned to the automated mouthpiece-based toothbrush will insert a properly fitted mouthpiece and use the automated device directly over the sink.
16248029|NCT05038293|Active Comparator|Manual toothbrush|Under observation of study staff, participants assigned to the manual toothbrush will be timed brushing their teeth directly over the sink using a pre-dispensed quantity of toothpaste on bristles dampened with water.
16248030|NCT05038280|Experimental|Let's Talk about Children intervention|Teachers, students, and parents in Finland, that take part in the LTC -intervention.
16248031|NCT05038280|No Intervention|Control group|The control group includes teachers who do not use the method in their work and students and parents who do not participate in the discussions.
16248032|NCT05038267||Femous patients|Adults undergoing general anesthesia for an elective cardiac surgery requiring cardiopulmonary bypass
16248033|NCT05038254|Active Comparator|Arm I (standard of care)|Patients receive standard of care consisting of oncology care provided via telemedicine.
16248034|NCT05038254|Experimental|Arm II (standard of care, remote monitoring)|Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
16248170|NCT05037591|Experimental|sea grape extract Q|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16257564|NCT04973189|Placebo Comparator|placebo in healthy young adults.|
16248035|NCT05038241||Active VKC|All females and males of pubertal age with active VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
16248036|NCT05038241||Previous active VKC|All females and males of pubertal age who suffered of VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
16248037|NCT05038228||NVAF High GI bleed risk|NVAF patients with a high risk of gastrointestinal bleeding
16248038|NCT05038215|Experimental|multifactor intervention|The experimental group will receive adherence promotion techniques in addition to routine care.
16248039|NCT05038215|Active Comparator|Control|The control group will receive routine care
16248040|NCT05038202|Experimental|Bencycloquidium Bromide|Bencycloquidium Bromide Nasal Spray (90μg per spray)：1 spray on each nostril, 4times per day, continuous treatment for 4 weeks (28days).
16248041|NCT05038202|Active Comparator|Mometasone Furoate Aqueous|Mometasone Furoate Aqueous Nasal Spray (50μg per spray)：2 sprays on each nostril, 1 time per day, continuous treatment for 4 weeks (28days).
16248042|NCT05038202|Experimental|Bencycloquidium Bromide with Mometasone Furoate Aqueous|Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray: For Bencycloquidium Bromide Nasal Spray(90μg per spray), 1 spray on each nostril, 4times per day. For Mometasone Furoate Aqueous Nasal Spray (50μg per spray), 2 sprays on each nostril, 1 time per day. If there is an overlap between the two drugs, use Bencycloquidium Bromide Nasal Spray first, and then mometasone furoate nasal spray should be used after an interval of more than 30 minutes.
16248043|NCT05038189|Experimental|Ankylosing Spondylitis|Study group
16248044|NCT05038189|Experimental|Non-radiographic Axial Spondyloarthritis|Study group
16248045|NCT05038189|Experimental|Healthy individuals|Control group
16248046|NCT05038176|Experimental|Active intervention group (AI)|The active intervention group (AI) receiving the active treatment (MANUP intervention) which include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
16248047|NCT05038176|Active Comparator|Delayed intervention group (DI)|"DI participants will only receive motivational text-messages. They will then flip and receive full intervention after the AI group has completed the program."
16248048|NCT05038163|No Intervention|Control Arm|In Part II of the experiment, subjects are not presented with nutrition or warning labels when choosing between beverages.
16248049|NCT05038163|Experimental|Nutrition Labels Arm|In Part II of the experiment, subjects are shown enlarged nutrition labels when choosing between beverages.
16248050|NCT05038163|Experimental|Text Warning Labels Arm|In Part II of the experiment, subjects are shown a warning message about the health risks of sugary beverages when choosing between beverages.
16248051|NCT05038163|Experimental|Graphic Warning Labels Arm|In Part II of the experiment, subjects are shown a graphic warning message about the health risks of sugary beverages when choosing between beverages. The message, for example, could include photos of tooth decay and other negative health outcomes.
16248052|NCT05038150|Experimental|one arm|Cohorts of 3 participants will be enrolled, admitted to an infusion unit, and treated with a single IV infusion of SGN1 over 2 hours and closely evaluated for DLTs for 28 days after the infusion unit. Up to 5 cohorts will be evaluated.
16248053|NCT05038137|Experimental|Time restricted feeding|
16248054|NCT05038137|Active Comparator|Control|
16248055|NCT05038124|Experimental|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction. Active sparing of the intended surgical approach will be incorporated into the radiation plan by creating an avoidance structure. Surgical stabilization will proceed within 1 week of completion of radiotherapy. Pathologic specimens will be obtained intraoperatively via existing surgical access for histologic and molecular analysis.
16248056|NCT05038111||Dex|Dexmedetomidine infusion during the perioperative period
16248057|NCT05038111||Non-Dex|Did not have dexmedetomidine infusion during the perioperative period
16248058|NCT05038098|Experimental|Cohort I (preoperative injection)|Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.
16248059|NCT05038098|Experimental|Cohort II (intraoperative)|Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
16248060|NCT05038085|Experimental|experimental group application|progressive muscle relaxation exercise health education
16248061|NCT05038085|No Intervention|control group application|No intervention will be made in the control group.
16248062|NCT05038072|Experimental|4 mg Triamcinolone Acetonide (TA)/ Suprachoriodal Injection|Suprachoroidal injection of 4 mg in 100 μL of TA was administered as a single injection.
16248063|NCT05038059|Active Comparator|1. Ethylene diammine tetra acetic acid group|samples will be rinsed with ethylene diamine tetra acetic acid group, which is the gold standard for final rinse and compares with the experimental group.
16248064|NCT05038059|No Intervention|2. Control group|no final irrigant will be used and evaluate the outcomes
16248065|NCT05038059|Experimental|3. Experimental group|final irrigation of root canal will be done with ethanolic extract of sapindus mukorossi
16248066|NCT05038046|Experimental|TCM daycare model|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
16248067|NCT05038046|No Intervention|Control group|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
16248171|NCT05037591|Experimental|sea grape extract R|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248068|NCT05038033|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy program adapted for the prevention of excessive weight gain. Involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
16248069|NCT05038033|Active Comparator|Cognitive-Behavioral Therapy (CBT)|The CBT program will match the delivery format and dose of the IPT program. There will be one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
16248072|NCT05038007|Active Comparator|Control|Bupivacaine Hydrochloride in perioperative intercostal blockades
16248073|NCT05038007|Experimental|Intervention|Liposomal bupivacaine in perioperative intercostal blockades
16248074|NCT05037994|Placebo Comparator|Control Group (C Group)|Patients will receive continuous US suprascapular nerve block only.
16248075|NCT05037994|Experimental|Gabapentin Group (G Group)|Patients will receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.
16248076|NCT05037968|Experimental|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side
16248077|NCT05037968|Active Comparator|Trinity Evolution|Trinity Evolution is a cryopreserved, viable cellular allograft containing cancellous bone and demineralized cortical bone designed for surgical use, applied per spine level at the contralateral side.
16248078|NCT05037955||ILIT from trial NCT00470457|Patients who received ILIT in the original trial in 2005
16248079|NCT05037955||SCIT from trial NCT00470457|Patients who received SCIT in the original trial in 2005
16248080|NCT05037955||SCIT outpatient control|Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years
16248081|NCT05037942|Experimental|Blood flow-restricted exercise at 40% limb occlusion pressure (BFR-40)|Participants in BFR-40 will perform a lower-body exercise protocol under BFR set to 40% of the participants' relative limb occlusion pressure.
16248082|NCT05037942|Experimental|Blood flow-restricted exercise at 80% limb occlusion pressure (BFR-80)|Participants in BFR-80 will perform the same lower-body BFR exercise protocol as BFR-40; however, the occlusion pressure will be set to 80% of the participants' relative limb occlusion pressure.
16248083|NCT05037942|No Intervention|Control for BFR-40|Participants randomised to BFR-40 will perform the same exercise protocol without BFR with the contralateral leg.
16248084|NCT05037942|No Intervention|Control for BFR-80|Participants randomised to BFR-80 will perform the same exercise protocol without BFR with the contralateral leg.
16248085|NCT05037929|Experimental|Astegolimab Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).
16248086|NCT05037929|Experimental|Astegolimab Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).
16248087|NCT05037929|Placebo Comparator|Placebo|Participants will receive SC placebo Q2W.
16248088|NCT05037903|Experimental|Cognitive-behavioral therapy|Cognitive-behavioral therapy, including behavioral exercises and homework assignments.
16248089|NCT05037890|Active Comparator|Plant sterol enriched margarine|20 grams plant sterol enriched margarine on a daily basis for a period of 6 months.
16248090|NCT05037890|Active Comparator|Plant stanol enriched margarine|20 grams plant stanol enriched margarine on a daily basis for a period of 6 months.
16248091|NCT05037890|Placebo Comparator|Control margarine|20 grams control margarine on a daily basis for a period of 6 months.
16248092|NCT05037877|Active Comparator|Intervention group|HUM supplement - 1 capsule per day
16248093|NCT05037877|Placebo Comparator|Placebo group|Placebo supplement - 1 capsule per day
16248094|NCT05037864||Ballet Dancer Group (Adolescent Ballet Dancers)|Adolescent ballet dancer student aged 7-17 years who have been actively attending a ballet dance school for at least 1 year will be form ballet dancer group. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, ballet duration(min/day), frequency (times/week) and continuity (year) will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
16248095|NCT05037864||Control Group (Sedentary Adolescents)|The control group (Sedentary Adolescent) of the study, are not ballet dance students who aged 7-17 years and have not experience in competitive sport or activity. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
16248096|NCT05037851|Experimental|PC945|14.8 mg PC945 administered twice daily for 12 weeks
16248097|NCT05037851|Active Comparator|Standard of Care (SoC)|Mold-active SoC prophylaxis/pre-emptive therapy
16248098|NCT05037838||Patient undergoing a liver transplantation|Patients undergoing a liver transplantation and able to have a transesopahageal ultrasound
16248099|NCT05037812|Placebo Comparator|Injection|Saline
16248100|NCT05037812|Experimental|Injections|"Superficial multimodal analgesia composition includes 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline.
~Deep medial multimodal analgesia composition includes 2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline."
16248101|NCT05037799||Group 1|body-weight < 50kg
16248102|NCT05037799||Group 2|50 kg ≤ body-weight < 100 kg
16248103|NCT05037799||Group 3|100 kg ≤ body-weight < 150 kg
16248104|NCT05037799||Group 4|150 kg ≤ body-weight < 200 kg
16248172|NCT05037591|Experimental|sea grape extract S|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248105|NCT05037786|Active Comparator|Powerpoint group|In the control group, there will be a face-to-face intervention of 15 minutes of education on pain explained by Verbal form with supporting Powerpoint presentation. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
16248106|NCT05037786|Experimental|Infographic group|In the intervention group, the same pain education will be carried out, explained verbally but with the support of an infographic instead of a Powerpoint. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
16248107|NCT05037773|Experimental|Group 1|In this condition, the intervention is administered immediately after the baseline.
16248108|NCT05037773|Experimental|Group 2 (waiting-list group)|This group is both a control and an experimental group. Indeed, the intervention (i.e., the same as for group 1) is administered but after a second baseline which is held after the completion of the Group 1. This condition will allow to check the specific efficiency of the intervention.
16248109|NCT05037760|Experimental|Arm 1a|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) monotherapy
16248110|NCT05037760|Experimental|Arm 1b|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
16248111|NCT05037760|Experimental|Arm 2a|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) monotherapy
16248112|NCT05037760|Experimental|Arm 2b|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
16248113|NCT05037747|Experimental|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
16248114|NCT05037747|No Intervention|Control|The control group was asked to continue their usual low-protein diet eating schedule and pattern.
16248115|NCT05037734|Active Comparator|Robotic-Assisted UKA|Randomized participant will receive UKA via the ROSA Partial Knee System.
16248116|NCT05037734|Active Comparator|Traditional/Conventional UKA|Randomized participant will receive the UKA via Conventional/Traditional UKA Methods.
16248117|NCT05037721|Experimental|gargling with green tea of stroke patients|Use fresh green tea (package date less than one month) sourced from the local market and serve in the form of soaked tea bags. 0.5% green tea refers to a tea bag soaked in 0.5g green tea, soaked in 100ml warm water for 5 minutes and let cool. Then, put each bottle of 15ml mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
16248118|NCT05037721|Active Comparator|gargling with water of stroke patients|Use water 15ml of mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
16248119|NCT05037708|Experimental|Group 1|Group 1 receives treatment A for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B was applied to group 1.
16248120|NCT05037708|Active Comparator|Group 2|Group 2 receives treatment B for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A was applied to group 2 .
16248121|NCT05037695|Experimental|empagliflozin + OMT|empagliflozin 25mg - Daily - at least 15 days before the PCI procedure OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
16248122|NCT05037695|No Intervention|OMT|OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
16248123|NCT05037682|Other|Primary Care Practices|Dissemination and Implementation Research
16248124|NCT05037669|Experimental|Cohort A: Acute Lymphoblastic Leukemia (ALL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Acute Lymphoblastic Leukemia (ALL)
16248125|NCT05037669|Experimental|Cohort B: Chronic Lymphocytic Leukemia (CLL) + Non-Hodgkin's Lymphoma (NHL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL).
16248126|NCT05037656|No Intervention|Control|Students in the control group will receive the standard health education curriculum.
16248127|NCT05037656|Experimental|Experimental|Students in the treatment group will receive the school-based classroom curriculum.
16248173|NCT05037591|Experimental|sea grape extract T|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248204|NCT05037344|Active Comparator|Internet-based psychotherapy waiting group|16 weeks of internet-based cognitive bahavioral therapy after waiting of 16 weeks
16248205|NCT05037318|Experimental|Stress arousal reappraisal|
16248206|NCT05037318|Experimental|Worked examples|
16248207|NCT05037318|Experimental|Stress arousal reappraisal + Worked examples|
16248128|NCT05037643|Experimental|Pre-emptive TIPS in Cystic Fibrosis Related Liver Disease and non-cirrhotic portal hypertension|"Patients with CFLD without cirrhosis were eligible for a pre-emptive TIPS, when early (asymptomatic) signs of portal hypertension. All procedures were performed under general anaesthesia by an experienced interventional radiologist. Depending on the patient's age and physiognomy, TIPS was created following a conventional transjugular technique as for adults or by a dedicated combined percutaneous transhepatic-transjugular (PIPS) approach for small children. Routinely, an expanded polytetrafluoroethylene-covered endoprosthesis was used for shunt creation. If the sheath could not be negotiated into the main portal vein, a self-expandable, non-covered stent was placed. We did not pursue a minimum gradient reduction.
~Percutaneous liver biopsy was performed during TIPS procedure to confirm the diagnosis of fibrosis or cirrhosis."
16248132|NCT05037604||Cases|Patients diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
16248133|NCT05037604||Control|Patients not diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
16248134|NCT05037591|Placebo Comparator|placebo A|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248135|NCT05037591|Placebo Comparator|placebo B|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248136|NCT05037591|Placebo Comparator|placebo C|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248137|NCT05037591|Placebo Comparator|placebo D|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248138|NCT05037591|Placebo Comparator|placebo E|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248139|NCT05037591|Placebo Comparator|placebo F|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248140|NCT05037591|Placebo Comparator|placebo G|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248141|NCT05037591|Placebo Comparator|placebo H|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248142|NCT05037591|Placebo Comparator|placebo I|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248143|NCT05037591|Placebo Comparator|placebo J|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248144|NCT05037591|Placebo Comparator|placebo K|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248145|NCT05037591|Placebo Comparator|placebo L|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248146|NCT05037591|Placebo Comparator|placebo M|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248147|NCT05037591|Placebo Comparator|placebo N|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248148|NCT05037591|Placebo Comparator|placebo O|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248149|NCT05037591|Placebo Comparator|placebo P|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248150|NCT05037591|Placebo Comparator|placebo Q|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248151|NCT05037591|Placebo Comparator|placebo R|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248152|NCT05037591|Placebo Comparator|placebo S|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248153|NCT05037591|Placebo Comparator|placebo T|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
16248154|NCT05037591|Experimental|sea grape extract A|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248155|NCT05037591|Experimental|sea grape extract B|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248156|NCT05037591|Experimental|sea grape extract C|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248157|NCT05037591|Experimental|sea grape extract D|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248158|NCT05037591|Experimental|sea grape extract E|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248159|NCT05037591|Experimental|sea grape extract F|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248160|NCT05037591|Experimental|sea grape extract G|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248161|NCT05037591|Experimental|sea grape extract H|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248162|NCT05037591|Experimental|sea grape extract I|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248163|NCT05037591|Experimental|sea grape extract J|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248164|NCT05037591|Experimental|sea grape extract K|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248165|NCT05037591|Experimental|sea grape extract L|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248166|NCT05037591|Experimental|sea grape extract M|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248167|NCT05037591|Experimental|sea grape extract N|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248168|NCT05037591|Experimental|sea grape extract O|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248169|NCT05037591|Experimental|sea grape extract P|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
16248174|NCT05037578|Experimental|Project Grace|This intervention will be delivered through church-based multilevel activities by trained church leaders using religiously/ culturally-tailored study materials (sermon guides, responsive readings, educational games, brochures, educational/testimonial videos) packaged in a culturally-tailored. Intervention churches will receive the Project Grace Tool Kit and intervention implementation directions to seek cognitive screening. These churches will hold a Project Grace Kickoff event, where a sermon, and other tool kit materials will be distributed. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities over 4 months. Delivery of intervention components will coincide with existing, multilevel activities that occur in churches through: a) churchwide services, b) outreach ministry groups; and c) individual level activities (e.g., text/voice/email health promotion messages from church) over 4 months.
16248175|NCT05037578|Active Comparator|Standard Control|Standard information churches will receive standard dementia education information. These churches will receive: a) non-tailored project materials collected from mental health organizations and b) standard community-based mental health screening events) coordinated by their Community Health Liaisons. These churches will receive all Project Grace Tool Kit materials and implementation training after the completion of assessments.
16248176|NCT05037565|Experimental|Treatment group|One group receive PHGG following study protocol (treatment group).
16248177|NCT05037565|No Intervention|Control group|This group will not receive PHGG
16248178|NCT05037552|Active Comparator|BIPOLAR FORCEPS|The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room.
16248179|NCT05037552|Experimental|FLOSEAL|"FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective.
~During this study, it will be used in 1st intention."
16248180|NCT05037539|Experimental|Injectable Fentanyl in Sublingual Route|Injectable Fentanyl in Sublingual Route that given after the first time Breakthrough Pain is occurred 50 mcg in sublingual route
16248181|NCT05037539|Active Comparator|Oral Morphine Syrup|Oral Morphine Syrup 2.5 ml ( 5 mg) in oral router that first time given after Breakthrough Pain is occurred
16248182|NCT05037526|Active Comparator|Dexcom G System|The Dexcom G6 or current version intended use is for the management of diabetes. It is a small flexible device that records interstitial glucose levels every 5 min and is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 or current version System results should be based on the glucose trends and several sequential readings over time. The system consists of a sensor, transmitter, receiver and mobile app.
16248183|NCT05037526|Active Comparator|Standard care of gestational diabetes with self monitoring blood glucose (SMBG)|SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily.
16248184|NCT05037513|Active Comparator|CDC-PrEP|1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
16248185|NCT05037513|Experimental|SBCM-PrEP|Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
16248187|NCT05037487|Placebo Comparator|Placebo|Smoked placebo cannabis
16248188|NCT05037487|Experimental|20 mg CBD|Smoked cannabis with CBD
16248189|NCT05037487|Experimental|20 mg CBD + 20 mg THC|Smoked cannabis with CBD and THC
16248190|NCT05037487|Experimental|20 mg THC|Smoked cannabis with THC
16248191|NCT05037461|Experimental|High-dose-high precision MR-guided radiotherapy|"Radiotherapy for pancreatic NET will be delivered in an image-guided, hypofractionated scheme of 5 fractions of 8 Gy, prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days 2 or 3 times a week with a maximum overall treatment time of 14 days on the 1.5T MR-Linac (Elekta Unity MR-Linac).
~The Gross Tumor Volume (GTV) is defines as the pNET visible on pre-treatment CT and MRI scan. No clinical target volume (CTV) is used. The PTV is made by adding a 3mm margin to the GTV.
~The treatment plan is a 9-14 field intensity modulated radiotherapy (IMRT) plan with dose prescribed to 95% of the PTV. While respecting the dose constraints to adjacent tissues"
16248192|NCT05037448|Other|Telehealth|Me & My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me & My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
16248193|NCT05037435|Experimental|The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
16248194|NCT05037435|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
16248198|NCT05037396||Brolucizumab|Participants received brolucizumab injection during the index period
16248199|NCT05037383|Other|Study group|Each participant will be part of the same group, since the study is focusing on the motion and viewing of the operating staff. There are no patient records collected.
16248200|NCT05037370|Experimental|LASIK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
16248208|NCT05037318|No Intervention|Control|
16248209|NCT05037305|Other|Arm One Pharmacogenetic Testing Cohort|"All individuals in the Arm One Pharmacogenetic Testing Cohort will be undergo pharmacogenomic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center."
16248210|NCT05037292|Experimental|PAUSE|"Surgical specialty clinics that completed an onboarding training for team members to use the standardized frailty screening incorporated in Veterans' medical records. Veterans identified as frail upon screening will be referred to a multidisciplinary PAUSE Board comprised of members from surgery, anesthesia, geriatrics, palliative care, case management, rehabilitation, nutrition."
16248211|NCT05037292|No Intervention|Usual Care|Surgical specialty clinics that have not yet implemented the PAUSE Intervention. Veterans at these clinics will receive usual perioperative assessment and management by the clinical team.
16248212|NCT05037279|Experimental|Verity-BCG|"Bacillus Calmette-Guérin (BCG): Strain Russian BCG-I
~Freeze-dried powder for bladder instillation"
16248213|NCT05037279|Active Comparator|OncoTICE|"Standard of Care
~Bacillus Calmette-Guérin (BCG): Strain TICE
~Freeze-dried powder for bladder instillation"
16248214|NCT05037266|Experimental|55 - 64 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1
16248215|NCT05037266|Experimental|At least 65 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1
16248216|NCT05037253|Active Comparator|high dose|Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months.
16248217|NCT05037253|Active Comparator|Low dose:|Vitamin D therapy will prescribe for 3 months at a dosage of 2,000 IU/day.
16248218|NCT05037240|Active Comparator|Intervention Group|
16248219|NCT05037240|Placebo Comparator|Placebo|
16248222|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) low dose|The participants will receive the low dose of BCD-250
16248223|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) high dose|The participants will receive the high dose of BCD-250
16248224|NCT05037188|Experimental|Cohort 1/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
16248225|NCT05037188|Placebo Comparator|Cohort 1/Placebo|The participants will receive placebo
16248226|NCT05037188|Experimental|Cohort 2/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
16248227|NCT05037188|Placebo Comparator|Cohort 2/Placebo|The participants will receive placebo
16248228|NCT05037175|Experimental|CPT-Text + Incentive|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.
~Retention Incentive (RI). Participants will be told at baseline that they can retain their discount in subsequent months if they message with their therapist regularly."
16248229|NCT05037175|Experimental|CPT-Text + Reminder As Usual|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.
~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
16248230|NCT05037175|Active Comparator|Texting as Usual + Incentive|TAU. TAU will be conducted by Talkspace therapists with a specialty in PTSD. Retention Incentive (RI). Participants will be told at baseline that they can retain their discount in subsequent months if they message with their therapist regularly.
16248231|NCT05037175|Active Comparator|Texting as Usual + Reminder as Usual|TAU. TAU will be conducted by Talkspace therapists with a specialty in PTSD. Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
16248232|NCT05037162|Experimental|Arm 1 - CimetrA-1|CimetrA-1, with a total dose containing a combination of Curcumin 40 mg, Boswellia 30 mg and Vitamin C 120 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
16248233|NCT05037162|Experimental|Arm 2 - CimetrA-2|CimetrA-2, with a total dose containing a combination of Curcumin 28 mg, Boswellia 21 mg and Vitamin C 84 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
16248234|NCT05037162|Placebo Comparator|Arm 3 - Placebo|Placebo, composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
16248329|NCT05036473|Experimental|2x25/100mg treatment group|2x25/100mg WD-1603
16258939|NCT04963777|Experimental|Prebiotic|Oligofructose-enriched inulin
16248240|NCT05037136||Ablation|Participants recruited from the LoTO_CASA_AF trial (ClinicalTrials.gov Identifier: NCT04280042) who underwent either conventional catheter ablation or thoracoscopic surgical ablation to treat their long standing persistent AF with be asked to continue downloading data from their implanted loop recorder and monitor their heart rate and physical activity level (step count) using a wrist worn activity tracker.
16248241|NCT05037123|Active Comparator|Arm 1|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.3 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
16248242|NCT05037123|Active Comparator|Arm 2|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
16248243|NCT05037123|Placebo Comparator|Arm 3|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
16248244|NCT05037110|Experimental|Physical activity group|
16248245|NCT05037110|Experimental|Chemosensory training group|
16248246|NCT05037110|No Intervention|Control group|For 12 weeks, continue the participant's routine (no intervention). This is done remotely. Then, every two weeks, complete an online follow-up questionnaire (15 minutes each).
16248247|NCT05037097|Experimental|Study Group 1, Adult Participants Not Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29
16248248|NCT05037097|Experimental|Study Group 2, Adult Participants Not Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
16248249|NCT05037097|Experimental|Study Group 3, Adult Participants Not Previously Vaccinated to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
16248250|NCT05037097|Experimental|Study Group 4, Adult Participants Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1
16248251|NCT05037097|Experimental|Study Group 5, Adult Participants Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1
16248252|NCT05037097|Experimental|Study Group 6, Adult Participants Previously Vaccinated randomized to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1
16248253|NCT05037071|Experimental|Upper body compression|An arm compression sleeve with a graduated compression between 18-25 mmHg will be worn on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy.
16248254|NCT05037071|No Intervention|No compression|Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. .
16248255|NCT05037045|Experimental|GLP-1 RA therapy|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months.
16248256|NCT05037032|Active Comparator|Study drug naltrexone hydrochloride|50 mg Naltrexone PO
16248257|NCT05037032|Placebo Comparator|Matching placebo for naltrexone hydrochloride|Matching placebo for Study Drug Naltrexone
16248258|NCT05037019|Experimental|Single fraction radiotherapy|Single fraction of 21 Gy stereotactic radiation therapy delivered to a single malignant lesion of the breast prior to any other treatment for breast cancer.
16248259|NCT05037006|Experimental|Group I-30|Inhalational anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
16248260|NCT05037006|Experimental|Group I-50|Inhalational anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
16248261|NCT05037006|Experimental|Group I-70|Inhalational anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
16248262|NCT05037006|Experimental|Group V-30|Intravenous anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
16248263|NCT05037006|Experimental|Group V-50|Intravenous anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
16248264|NCT05037006|Experimental|Group V-70|Intravenous anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
16248265|NCT05036993|Experimental|Intervention|Coaching
16248266|NCT05036993|Experimental|Control|Control, Coaching later
16248267|NCT05036980|Experimental|0.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
16248268|NCT05036980|Experimental|1.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
16248269|NCT05036980|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
16248271|NCT05036954||no arm|
16248272|NCT05036941|Experimental|Arm 1|Acteev™ system (Acteev™ N95 masks YQD8008 during shifts+ Acteev™ fabric masks in community)
16248273|NCT05036941|Active Comparator|Arm 2|Standard system (standard N95 masks during shifts+ fabric masks in community)
16248274|NCT05036928||HIV infection group|
16248277|NCT05036889|Experimental|MND|Subject's physician in this group will be using the Mind.Px report as a treatment reference for prescribing the subject's biologic.
16248330|NCT05036473|Placebo Comparator|placebo group|placebo are tablets-matching with the same active groups.
16258940|NCT04963777|Placebo Comparator|Placebo|Maltodextrin
16248278|NCT05036889|No Intervention|TAU|Treatment as usual. This group will have the biologic prescribed with results given to the physician at the end of the subject's participation and will not be used as a reference for the subject's treatment.
16248281|NCT05036863||Patients with multiple myeloma|
16248282|NCT05036850||Incident and Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
16248283|NCT05036837|Experimental|OZOPROMAF_SEQ1|"OZOPROMAF consists of: local superficial anesthesia by application of EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (O2O3) mixture by 26Gx 1⁄2 - 0.45x13mm needle into mucosal margin surrounding bone exposure or around situs evidenced by CT scans.
~Pain intensity and/or other symptoms are assessed at each visit and the day after by a questionnaire (numerical rating scale).
~OZOPROMAF is applied on 7-15 days, depending on patient compliance, until the resolution (i.e. formation of sequestrum and clinical healing -T1).
~Follow-up visits are scheduled to confirm healing at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3/ T4/T5.
~Positive outcomes
~at T1/T2 clinical healing (no signs of acute phlogosis and no symptoms compatible with MRONJ);
~at T3/ T4/T5 clinical healing and no radiological signs of MRONJ."
16248284|NCT05036824||COVID-19 patients|"Patients admitted to hospital with COVID-19, PCR+ SARS-CoV-2 infection administered thromboprophylaxis with tinzaparin.
~Dosage: intermediate or therapeutic dose Frequency of tinzaparin administration: once daily Duration: Unknown"
16248285|NCT05036798|Experimental|Tislelizumab combined with Lenvatinib and GEMOX|"Chemotherapy regimen(GEMOX):
~Gemcitabine 1g/m2,Oxaliplatin 100mg/m, D1, Q3W Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD
~Receive at least 3 cycles of combined treatment, and perform imaging evaluation after 3 cycles of treatment. If surgical treatment is not possible, imaging evaluation will be performed every two cycles thereafter until surgical treatment is feasible. If more than 7 cycles are still not possible for surgical resection, enter Tislelizumab + Lenvatinib maintenance treatment until the disease progresses or the toxicity cannot be tolerated.
~If patients undergoing R0 resection, start to receive Tislelizumab + Lenvatinib+Gemox regimen in 4-8 weeks after surgery for 7 cycles, and then entered Tislelizumab+Lenvatinib for 1 year or disease progression or toxicity cannot be tolerated"
16248286|NCT05036785|Active Comparator|Suture removal at 7 days|Suture removal at 7 days post skin surgery
16248287|NCT05036785|Active Comparator|Suture removal at 10 days|Suture removal at 10 days post skin surgery
16248288|NCT05036772|No Intervention|Standard Practice|The control arm is supported according to the usual practice. The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography
16248289|NCT05036772|Experimental|Interventionnal|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
16248290|NCT05036759|Experimental|68Ga-FAPI, PET/MR|inject 68Ga-FAPI，and then perform PET/MR
16248291|NCT05036733|Experimental|Dupilumab|
16248292|NCT05036720|Experimental|LTP+Dads|Participants in this arm will be offered the LTP+Dads intervention. The intervention will be delivered by trained Community Health Workers (CHWs). This will be co-facilitated by LTP+ master trainers.
16248293|NCT05036720|Other|Wait-list control:|Participants in this arm will be offered the intervention once the LTP+ arm have completed their outcome assessment. For example, in each Union Council (UC) once the LTP+ arm has completed the intervention and 4th month outcome assessment the wait-list control group in the same UC will be offered the intervention.
16248294|NCT05036720|Other|Optional mothers component|To facilitate changes in co-parenting and optimize impact on child development, the partners of fathers who participate will be offered optional LTP+ group sessions running parallel to LTP+Dads.
16248295|NCT05036707|Active Comparator|1|Healthy Volunteer
16248296|NCT05036694|Other|Ambulatory HIV positive patients|Ambulatory HIV positive patients with signs and symptoms of TB, and Ambulatory HIV positive patients with advanced disease and CD4 less than 200 cell.
16248297|NCT05036681|Experimental|futibatini|
16248298|NCT05036681|Experimental|pembrolizumab|
16248299|NCT05036668|Experimental|ABO809|Participants will receive ABO809 at a single oral dose of 1x10^4 oocysts. Other doses such as 1x10^6 oocysts may be considered to optimize the model
16248300|NCT05036655|Active Comparator|Intervention: PGMP|Sites will implement a perioperative glycemic management pathway based on national guidelines and current evidence, with support of an implementation scientist team.
16248301|NCT05036655|Active Comparator|Non-intervention: usual care|Sites will perform usual perioperative glycemic management.
16248302|NCT05036642|Experimental|Stroke Survivors|Stroke survivors with upper extremity motor impairments
16248303|NCT05036629|Experimental|MRI protocol|Feasibility and use of methods developed in clinical research protocols or cognitive: the reproducibility of the parameters of acquisition, of the design of the activation paradigms development and results according to people will be an important element for the future integration of these methods in clinical or cognitive research protocols.
16248304|NCT05036616||Separation technique|
16248305|NCT05036616||Integration technique|
16248306|NCT05036603|No Intervention|1/routin medical care and neonatal intensive care unit's daily care|Group 1 (n=20) routine medical treatment for newborns on mechanical ventilator respiratory support and CPAP; Appropriate antibiotics given according to the needs of the baby, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care will be provided.
16248331|NCT05036460|Active Comparator|Ultrasonography + direct visualization|To detect using ultrasonography assisted direct visualization.
16248332|NCT05036460|Experimental|Direct visualization|To detect using direct visualization.
16248333|NCT05036447|Experimental|DM1-Ex|Moderate-heavy resistance exercise of one leg in DM1-patients
16248307|NCT05036603|Experimental|2/active chest physiotherapy in modified drainage positions|Group 2 (n=20) newborns on mechanical ventilator respiratory support and CPAP; A single session of active chest physiotherapy (CP) will be applied using modified drainage positions (avoiding the trendelenburg position, excessive position change and avoiding hand contact in babies younger than 30 weeks or who are sensitive to position change). Active CP in various modified drainage positions; It will consist of percussion and vibration methods with proprioceptive replacement stimulations. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
16248308|NCT05036603|Experimental|3/active chest physiotherapy in prone positions|Group 3 (n=20) newborns on mechanical ventilator respiratory support and CPAP; a single session of active chest physiotherapy treatment to be applied only in the prone position; Starting with proprioceptive stimulation, percussion and vibration methods will be applied. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
16248309|NCT05036590|Active Comparator|Control group|"The design is a stepped-wedge cluster randomized controlled trial. The study will be conducted in 9 centers (clusters) and will be conducted in 6 successive phases of 4 months each.
~During the first period, groups will be in the control period, then sequentially and according to a randomly defined order, at each time, one group will go into the intervention period after a transition period of 4 months allowing the intervention to be deployed (training of three health professionals for each center and then implementation of the BREF program).
~Thus, each cluster will belong successively to the control group and the intervention group. During the control period, caregivers will be supported according to the usual practices of each center. During the intervention period, the BREF program will be offered to all eligible caregivers."
16248310|NCT05036590|Experimental|intervention group|Thus, each cluster will belong successively to the control group and the intervention group. During the intervention period, the BREF program will be offered to all eligible caregivers.
16248312|NCT05036564|Experimental|Study population - PCNSL|"Patients (pts) with clinical and radiological suspicion of PCNSL or with confirmed diagnosis of PCNSL will be enrolled to the protocol. They will represent the Study population"
16248313|NCT05036564|Other|Control|"Pts with suspicion of secondary CNS lymphoma, that includes subjects with DLBCL and involvement of the CNS at presentation in association with systemic disease, or subjects with systemic DLBCL and CNS relapse during or after primary therapy.
~Pts with histological diagnosis of systemic DLBCL at high risk of CNS relapse according to Institutional guidelines and patients with histological diagnosis of systemic high grade B cell lymphoma, according to 2017 WHO classification;
~pts affected by neurological disorders that are usually differential diagnosis of PCNSL (i.e. neurodegenerative and neuroinflammatory disorders, toxic or infective encephalitis, other primary CNS tumors)."
16248314|NCT05036551||Stage 2 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
16248315|NCT05036551||Stage 3 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
16248316|NCT05036538|Experimental|Relaxation intervention with natural sounds|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
16248317|NCT05036538|Experimental|Relaxation intervention with natural sounds and binaural beats|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
16248318|NCT05036538|Experimental|Relaxation intervention with natural sounds and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
16248319|NCT05036538|Experimental|Relaxation intervention with natural sounds, binaural beats and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
16248320|NCT05036538|No Intervention|Control without Intervention|
16248321|NCT05036525|Experimental|use HANBIO BarriGel|
16248322|NCT05036525|No Intervention|No anti-adhesive product|
16248323|NCT05036512|Placebo Comparator|Placebo|Placebo as a tablet or capsule with dose based off of preceding cohort's data.
16248324|NCT05036512|Experimental|GBT021601|GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.
16248325|NCT05036499|Experimental|Personalized Feedback Intervention (PFI)|Personalized Feedback Intervention targeting pain-related anxiety for hazardous drinkers with chronic pain
16248326|NCT05036499|No Intervention|Assessment Only|Assessment only, no active treatment elements
16248327|NCT05036473|Experimental|25/100mg treatment group|25/100mg WD-1603
16248328|NCT05036473|Experimental|25/150mg treatment group|25/150mg WD-1603
16248335|NCT05036447|Experimental|Ctrl-Ex|Moderate-heavy resistance exercise of one leg in healthy participants
16248336|NCT05036447|No Intervention|Ctrl-Rest|Control leg (i.e. no exercise) in healthy participants
16248337|NCT05036434|Experimental|Treatment arm|Pembrolizumab 200mg q 3wks IV / Lenvatinib 20mg daily once PO q 3wks
16248338|NCT05036421|Experimental|Study Group|Empagliflozin
16248340|NCT05036395|Experimental|The neonates evaluated by the routine assessment protocol and AI-assisted cEEG Diagnostic tool|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol and AI assisted cEEG diagnostic tool in real time during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.
~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
16248341|NCT05036395|Active Comparator|The neonates evaluated by the routine assessment protocol|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.
~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
16248342|NCT05036382||Experimental Group|A group that receives an incentive message one month after the start of the experiment
16248343|NCT05036382||Control Group|A group that does not receive an incentive message (for equity, incentive messages will be sent in the last month of the experiment)
16248344|NCT05036369|Experimental|Active capsule|The Vibrant non-biodegradable capsule administrated twice a week
16248345|NCT05036369|Placebo Comparator|Placebo|The placebo capsule is a white colored, softgel biodegradable capsule filled with soybean oil, beeswax and Calcium Carbonate, Gelatin, Glycerin or Titanium dioxide which is visually similar to the Vibrant active capsule
16248346|NCT05036356|Experimental|Controlled App Group|"Subjects will receive access to the Headspace app and will receive weekly reminders to complete activities from the Inspiration, Ideation, Implementation block model of human-centered design in the app."
16248347|NCT05036356|Experimental|Ad lib App Group|Subjects will receive access to the Headspace app and be encouraged to use it ad lib.
16248350|NCT05036330||Observational (evaluation, examination, questionnaire)|Patients undergo speech and swallow evaluation by speech pathologist or study staff member and examination of TEP and laryngectomy stoma. Patients also complete questionnaires over 30 minutes about use the ProvoxLife HME system, symptoms, ability to communicate, exercise and physical activity levels, and quality of life at baseline and 3 months post-ProvoxLife.
16248351|NCT05036317|Experimental|Empagliflozin|Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.
16248352|NCT05036317|Placebo Comparator|Placebo|Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.
16248353|NCT05036304|Active Comparator|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
16248354|NCT05036304|Experimental|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park).
16248356|NCT05036278|Experimental|Damoctocog alfa-pegol prophylaxis regimens|"Prophylaxis regimens:
~Participants with a high risk score (> 4) continue on prophylaxis 2x/week (40 IU/kg/dose).
~Participants with a medium risk score (2 to 4) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose).
~Participants with a low risk score (< 2) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose) and then after 4 weeks to a less frequent (e.g. Q7D) regimen (60 IU/kg/dose)."
16248357|NCT05036252||Participants with HER2-positive breast cancer|Participants with HER2-positive breast cancer who have developed mild cardiotoxicity during HER2-targeted therapy, defined by a decline in LVEF > 10% to < 53% without symptoms of clinical heart failure (NYHA class III or IV), will be eligible for participation in this study.
16248358|NCT05036239|Experimental|Exercised|One bout of 50 eccentric biceps curls
16248359|NCT05036239|No Intervention|Control|No eccentric biceps curls
16248366|NCT05036213|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
16248367|NCT05036213|Placebo Comparator|concentrated beet root juice with depleted nitrate content|The placebo treatment is also beetroot juice provide by the same company (BEET IT, James White Drinks, Ipswich, UK), but it does not contain any inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
16248368|NCT05036200|Experimental|four pulsed dye laser sessions were administered every eight weeks in the 21 patients|
16248369|NCT05036187|Experimental|Weight Loss Program Only|Participants complete an online behavioral weight loss program.
16248370|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss.
16248371|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
16248372|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (4) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
16248373|NCT05036187|Experimental|Weight Loss Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
16248374|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Social Support Program|Participants complete a (1) online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
16248375|NCT05036187|Experimental|Weight Loss Program + Body Image Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
16248376|NCT05036187|Experimental|Weight Loss Program + Social Support Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
16248377|NCT05036174|Experimental|Diphenhydramine|Topical 5% diphenhydramine ointment applied at knee joint at a dose of 2 g three times a day for 7 days
16248378|NCT05036174|Placebo Comparator|Placebo|Vehicle (placebo) ointment applied at knee joint at a dose of 2 g three times a day for 7 days
16248379|NCT05036161||Predicting treatment failure of Nasal High Flow in newborns|newborns with respiratory distress treated with NHF
16248380|NCT05036161||Predicting treatment failure of Continuous Positive Airway Pressure in newborns|newborns with respiratory distress treated with CPAP
16248381|NCT05036148||Patients indicated for MH screening|Patients referred to MH center for MH diagnostic
16248382|NCT05036135|Experimental|Phase 2b low dose AV-101|
16248383|NCT05036135|Experimental|Phase 2b medium dose AV-101|
16248384|NCT05036135|Experimental|Phase 2b high dose AV-101|
16248385|NCT05036135|Placebo Comparator|Phase 2b Placebo|
16248386|NCT05036135|Experimental|Phase 3 dose AV-101 (Optimal dose selected in Phase 2b)|
16248387|NCT05036135|Placebo Comparator|Phase 3 Placebo|
16248388|NCT05036122|Experimental|Whole-body exercise in healthy adults (Aim 1)|Subjects will have blood [lactate] measurement obtained with the LabClasp device while completing an exercise stress test on a treadmill or bicycle.
16248389|NCT05036122|Experimental|ICU patients susceptible to developing sepsis (Aim 2)|Subjects will have blood [lactate] measurement obtained with the LabClasp device as frequently as required for clinical purposes
16248390|NCT05036109|Other|Aspirin, Vitamin D|by mouth every day for up to 90 days
16248393|NCT05036083|Experimental|Diagnostic (CEM, DBT, medical record)|Patient receive iodinated contrast agent IV and undergo CEM. Patients who have not undergone DBT as part of their screening or diagnostic imaging within 3 month, undergo DBT. Patients medical records are reviewed.
16248394|NCT05036070|Experimental|Study Lens|Model C0001
16248395|NCT05036070|Active Comparator|Control Lens|Model ZCB00
16248396|NCT05036057||COPD patients and their proxies|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.
~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
16248397|NCT05036044||With moderate or severe carotid-cerebral artery disease|moderate (stenosis 50-69%) or severe (stenosis 70-100%) carotid-cerebral artery disease
16248398|NCT05036044||Without moderate or severe carotid-cerebral artery disease|mild (stenosis 30-49%) or no (stenosis 0-29%) carotid-cerebral artery disease
16248399|NCT05036031||EASL-CLIF ACLF patients|
16248400|NCT05036031||APASL ACLF patients|
16248402|NCT05036018|Active Comparator|Group 1|Patients treated with the ACURATE neo2 valve under isolated local anesthesia
16248403|NCT05036018|Active Comparator|Group 2|Patients treated with the ACURATE neo2 valve under local anesthesia with conscious sedation (CS)
16248404|NCT05036018|Active Comparator|Group 3|Patients treated with the Evolut Pro or Pro+ valve under isolated local anesthesia
16248405|NCT05036018|Active Comparator|Group 4|Patients treated with the Evolut Pro or Pro+ valve under local anesthesia with conscious sedation (CS)
16248406|NCT05036005|Experimental|Ontruzant + Pertuzumab (optional) + Chemotherapy|"All patients will receive 6 cycles of Ontruzant® i.v. q21d in combination with standard chemotherapy with or without pertuzumab, at the discretion of investigator's decision. Initial dose of Ontruzant® i.v. will be 8 mg/kg b.w. followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d. Clinical and bioptic tumor assessment will be performed during baseline and during surgery.
~Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned for 30 days after the last administration of study medication."
16248407|NCT05035979|Experimental|TCM comprehensive treatment group|Participants in the TCM treatment group will receive BaiDi Quzhi granule two times daily after meals, Ju Yin cream therapy three times per week for 8 weeks.
16248408|NCT05035979|Active Comparator|TCM internal treatment group|Participants in the TCM internal treatment group will receive Baidi Quzhi granule two times daily after meals and Ju Yin placebo therapy three times per week for 8 weeks.
16248409|NCT05035979|Active Comparator|TCM external treatment group|Participants in the TCM external treatment group will receive Baidi Quzhi placebo granule two times daily after meals and Ju Yin cream therapy three times per week for 8 weeks.
16248410|NCT05035979|Placebo Comparator|Placebo group|Participants in the placebo group will receive Baidi Quzhi placebo granule two times daily after meals, Ju Yin placebo therapy three times per week for 8 weeks.
16248411|NCT05035966||Prediabetes|In the case-control study, prediabetes was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. Prediabetes was defined as impaired fasting glucose (FPG ≥6.1 mmol/L and <7.0 mmol/L, and 2-h post-glucose load <7.8 mmol/L) and/or impaired glucose tolerance (FPG <6.1 mmol/L, and 2-h post-glucose load ≥7.8 mmol/L and <11.1 mmol/L). In the nested case-control study, new-onset prediabetes was defined as FPG ≥6.1 mmol/L and <7.0 mmol/L.
16248412|NCT05035966||Healthy control|In the case-control study, healthy control was defined as FPG <6.1 mmol/L and 2-h post-glucose load <7.8 mmol/L. In the nested case-control study, healthy control was defined as FPG <6.1 mmol/L.
16248413|NCT05035953|Experimental|Edaravone|Edaravone Dexborneol injection
16248414|NCT05035953|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
16248415|NCT05035927|Experimental|Open Label Oral Psilocybin|
16248416|NCT05035914|Experimental|Experimental: anlotinib+mXELIRI|"Dose-escalation phase:
~A: anlotinib 8 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;
~B: anlotinib 10 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;
~C: anlotinib 12 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;
~Dose-expansion phase:
~anlotinib RP2D, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;"
16248417|NCT05035901|Experimental|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
16248418|NCT05035888|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
16248419|NCT05035888|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
16248420|NCT05035875||40 COPD patients|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
16248421|NCT05035875||40 healthy individuals|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
16248422|NCT05035862|Experimental|Infusion of γMSCs|Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of γMSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of γMSCs at 5x106 cells/kg.
16248423|NCT05035849|Active Comparator|Group A|Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.
16248424|NCT05035849|Active Comparator|Group B|Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.
16248425|NCT05035836|Experimental|Zanidatamab|zanidatamab by vein every 2 weeks (+/- 3 days) for up to 6 doses (3 study cycles
16248426|NCT05035823|Other|Single|Implantation of the motor neuroprosthesis medical device.
16248427|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
16248428|NCT05035810|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.
~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
16248429|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
16248430|NCT05035810|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.
~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
16248431|NCT05035797|Active Comparator|CaRe-ECMO group|Patients in the CaRe-ECMO group will be treated with usual care, ECMO therapy, and cardiopulmonary rehabilitation program.
16248432|NCT05035797|Placebo Comparator|Control group|Usual care and ECMO therapy
16248433|NCT05035784|Active Comparator|Fecal supernatant|Fecal supernatant is used for treatment of childhood Constipation
16248434|NCT05035784|Placebo Comparator|non-Fecal supernatant|Placebo is used for treatment of childhood Constipation
16248435|NCT05035771|Experimental|Pressure wire measurements|
16248436|NCT05035758|No Intervention|Control Goups|The control group (A) receives standard exercise therapy that is part of the rehabilitation at the center and no additional intervention
16248437|NCT05035758|Experimental|Transcendental Meditation|The intervention group (B) receives transcendental meditation sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
16248438|NCT05035758|Experimental|Yoga|The intervention group (C) receives yoga sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
16248439|NCT05035745|Experimental|Patients with refractory solid tumors|Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.
16248440|NCT05035732|Experimental|18F-ACBC|
16248441|NCT05035719||Group 1|Cardiac patients
16248442|NCT05035706|Experimental|Treatment (biopsy, biospecimen collection)|Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.
16248443|NCT05035693|Experimental|PMCF MOVE-C|PMCF MOVE®_C is a single arm observational study with 170 patients.
16248444|NCT05035680|Active Comparator|Arm i - Seasonal influenza vaccine|Single 0.5 mL intramuscular (IM) injection of an unadjuvanted seasonal influenza vaccine
16248445|NCT05035680|Experimental|Arm ii - SWE and unadjuvanted seasonal influenza vaccine|Single 0.8 mL IM injection of SWE mixed with unadjuvanted seasonal influenza vaccine
16248446|NCT05035680|Active Comparator|Arm iii - MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
16248447|NCT05035667||Observational (questionnaires)|Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.
16248448|NCT05035654|Experimental|Treatment Arm A: LYR-220 Design 1|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
16248449|NCT05035654|Experimental|Treatment Arm B: LYR-220 Design 2|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
16248450|NCT05035641|Experimental|AND017 Dose A|AND017 will be administrated orally at dose A
16248451|NCT05035641|Experimental|AND017 Dose B|AND017 will be administrated orally at dose B
16248452|NCT05035641|Experimental|AND017 Dose C|AND017 will be administrated orally at dose C
16248453|NCT05035641|Placebo Comparator|Placebo|Placebo will be administrated orally
16248454|NCT05035628|Experimental|Cardiopulmonary exercise training group|Cardiopulmonary exercise intervention will include aerobic exercise, resistance and respiratory exercises, three sessions per week for 2 months
16248455|NCT05035628|No Intervention|control group|Control group with no intervention.
16248457|NCT05035602||Oesophagectomy|Patients who have undergone oesophageal cancer resection.
16248458|NCT05035602||Gastrectomy|Patients who have undergone gastric cancer resection.
16248459|NCT05035602||Control group|A cohort consisting of healthy controls who have not been diagnosed with, or have undergone treatment for oesophageal or gastric cancer.
16248460|NCT05035589||TCZ|The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
16248461|NCT05035589||Control|50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
16248462|NCT05035576|Active Comparator|400 mg OPN-019|
16248463|NCT05035576|No Intervention|Standard of Care (SOC)|
16248464|NCT05035563|No Intervention|Traditional communication management (Pre-intervention)|"Traditional communication practices are maintained, which consists of reporting the patient's medical conditions or specific requirements of the case, between the health team and the family.
~According to the social and administrative conditions of each centers, medical telephone information is provided on the conditions of the patients."
16248465|NCT05035563|Experimental|Early and integral communication strategy (EICS) (Post-intervention)|"EICS that includes a bundle of various strategies that allow to favor communication and contact between family members, patients and health team.
~That considers the delivery of: (1) Receive timely and understandable information; (2) Receive visits, companionship, and spiritual assistance"
16248466|NCT05035550|Experimental|Non-Deceptive Placebo|The NDP group was informed that the purpose of the study was to test a mind-body intervention that might help participants deal with the stress and anxiety that they are feeling during the pandemic. The intervention included two videos that introduced the effects of non-deceptive placebos, followed by a presentation on up-to-date non-deceptive placebo research. The participants then received instruction on how they would take their non-deceptive placebos for the next two weeks. Participants were asked to complete daily pill-taking adherence surveys (~5 min) and weekly at midpoint (1-week) and endpoint (2-week).
16248467|NCT05035550|No Intervention|No-Treatment Control|The Control group did not receive an intervention. Instead, participants were informed that the purpose of the study was to track individual psychological and physical health over longer time periods in the context of the pandemic. Participants were asked to complete weekly questionnaires at midpoint (1-week) and endpoint (2-week).
16248468|NCT05035537|Experimental|Group 1 (PGDT)|Group 1(PGDT, intervention group) where minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide a goal directed fluid administration protocol
16248469|NCT05035537|No Intervention|Group 2 (control)|Group 2 (control) managed according to local and international best practice guidelines using standard hemodynamic monitoring
16248470|NCT05035524|Active Comparator|Sodium Bicarbonate|Adjuvant SB treatment Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group
16248471|NCT05035524|Placebo Comparator|Placebo|Placebo
16248472|NCT05035511|Experimental|Responders vs Non-responders|After the tDCS outcome recorded immediately after tDCS treatment, participants will be categorized into responders and non-responders based on the percentage of change in the total SRS score (primary outcome). Participants that show reductions of at least 10% in the total SRS scores as compared to baseline scores will be considered responders.
16248473|NCT05035498|Active Comparator|Phenylephrine group|Phenylephrine infusion simultaneous with spinal anesthesia
16248474|NCT05035498|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with spinal anesthesia
16248475|NCT05035485|Active Comparator|Phenylephrine group|Rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred
16248476|NCT05035485|Experimental|Norepinephrine group|Rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred
16248477|NCT05035472|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
16248478|NCT05035472|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
16248483|NCT05035446|Experimental|single-incision plus one-port laparoscopic surgery(SILS + 1)|It requires an auxiliary small incision and one more port to perform laparoscopic gastrectomy
16248484|NCT05035446|Other|conventional laparoscopic surgery(CLS)|It requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy
16248485|NCT05035433|Experimental|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
16248486|NCT05035433|Experimental|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
16248489|NCT05035394|Active Comparator|Cataract|Cataract surgery as stand alone. Cataract surgery will be performed in a standardized fashion.
16248490|NCT05035394|Active Comparator|KDB|Cataract surgery combined with Kahook Dual Blade Glide goniotomy. The goniotomy will be performed at the end of cataract surgery through the temporal cataract incision.
16248491|NCT05035394|Active Comparator|Istent|Cataract surgery combined with iStent Inject W. The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.
16248492|NCT05035381|Experimental|Experiment Group|
16248493|NCT05035368|Experimental|Ladarixin - placebo|"In this arm the treatment sequence is ladarixin 400 mg twice-a-day, followed by placebo, as adjunctive therapy to insulin in overweight, IR, T1D patients.
~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Ladarixin 24 weeks, washout 21 days, Placebo 24 weeks)."
16248494|NCT05035368|Experimental|Placebo - Ladarixin|"In this arm the treatment sequence is placebo followed by ladarixin 400 mg twice-a-day, as adjunctive therapy to insulin in overweight, IR, T1D patients.
~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Placebo 24 weeks, washout 21 days, Ladarixin 24 weeks)."
16248495|NCT05035355|Experimental|weaning protocol group|spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula group
16248496|NCT05035355|No Intervention|routine SBT weaning group|
16248497|NCT05035342|Experimental|Fecal microbiota Transplant (FMT)|Fecal microbiota Transplant (FMT) prepared from the stools of healthy donors diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min) and manufactured in capsules (n=50 capsules corresponding to approximately 50 grams of stool; 25 two days in a row).
16248498|NCT05035342|Placebo Comparator|Placebo of FMT|FMT vehicle (solution of saline (NaCl 0.9%)) with 80% glycerol (storage in the same conditions as preparation for FMT experimental group) administered at the same volume and same time point as the experimental group.
16248499|NCT05035316|Placebo Comparator|Placebo|125 BD participants will receive placebo. Patients, clinicians and researchers will be blinded for the intervention
16248500|NCT05035316|Active Comparator|Active|125 BD participants will receive active treatment. Patients, clinicians and researchers will be blinded for the intervention
16248501|NCT05035303|Active Comparator|Nor-Epinephrine (NE)-Group|The PCNL tract is infiltrated by Nor-Epinephrine before its dilatation.
16248502|NCT05035303|Placebo Comparator|S-Group|The PCNL tract is infiltrated by Normal Saline before its dilatation.
16248503|NCT05035290|Experimental|Negative pressure ventilation|Negative pressure application after extubation
16248504|NCT05035290|No Intervention|Standard approach|Standard approach - oxygentherapy based on patients need
16248505|NCT05035277|Active Comparator|Acetylsalicylic acid|Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
16248506|NCT05035277|Experimental|Direct oral anticoagulation (DOAC)|Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
16248507|NCT05035264|Active Comparator|Neutral head position|Laryngeal mask will be inserted after anaesthesia induction in neutral head position
16248508|NCT05035264|Active Comparator|Sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
16248509|NCT05035264|Experimental|Beyond sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
16248510|NCT05035251||experimental|patients with a condition
16248511|NCT05035251||control|patients without condition
16248512|NCT05035238|Active Comparator|Arm 1|3 μg / 0.5 mL
16248513|NCT05035238|Active Comparator|Arm 2|4,5 μg / 0.5 mL
16248517|NCT05035199||Patients with psychiatric disorders|Patients with psychiatric disorders of the affective spectrum.
16248518|NCT05035186|Experimental|Group 1|Clarithromycin based
16248519|NCT05035186|Experimental|Group 2|Levofloxacin based
16248522|NCT05035160||Group 1|Pregnant and postpartum birthing persons with perinatal pathology.
16248523|NCT05035160||Group 2|Healthy pregnant and postpartum birthing persons.
16248524|NCT05035160||Group 3|Healthy non-pregnant persons (healthy volunteers).
16248525|NCT05035147|Experimental|Low dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8 q3w
16248526|NCT05035147|Active Comparator|High dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8,15 q4w
16248527|NCT05035121|Experimental|milk supplement|The milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
16248528|NCT05035121|Experimental|soy milk supplement|The soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
16248529|NCT05035121|Placebo Comparator|control|The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
16248530|NCT05035108|Experimental|extensive hepatectomy patient|hiHep bioartificial liver therapy
16248535|NCT05035069|Experimental|Ciprofol|
16248536|NCT05035069|Active Comparator|Propofol|
16248537|NCT05035056|Other|CT Coronary Angiogram with quantitative characterization of plaque|
16248538|NCT05035043|Experimental|NAFLD patients|Non-Alcoholic Fatty Liver Disease patients
16248539|NCT05035030|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 72 weeks.
16248540|NCT05035004|Experimental|Post exercise hot water immersion|Moderate intensity cycling for 30 minutes, followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion.
16248541|NCT05035004|Active Comparator|Exercise|Moderate intensity cycling for 30 minutes.
16248542|NCT05035004|Active Comparator|Hot water immersion|Whole-body hot water immersion for 30 minutes, followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion.
16248543|NCT05034965|Active Comparator|deep injection of hyaluronic acid fillers|Each female will receive filler injection deep to the muscle (supraperiosteal) on one side of the face.
16248544|NCT05034965|Active Comparator|superficial injection of hyaluronic acid fillers|Each female will receive filler injection at superficial level to the muscle (subcutaneous) on the contralateral side(same dose and same site).
16248548|NCT05034939|Active Comparator|FLEX Vessel Prep System followed with PTA (TEST arm)|FLEX Vessel Prep System is used to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion. Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
16248549|NCT05034939|Active Comparator|PTA only (CONTROL arm)|Standard Balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
16248550|NCT05034926||Cohort 1|Participants with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer (NSCLC)
16248551|NCT05034913|Experimental|Photography to Measure Children's Height, Wrist Circumference, and Abdominal Circumference|Subjects will be given instructions on how to take two photographs at home and submit them securely. Subjects will also be given instructions on how to measure height, wrist circumference, and waist circumference and submit this data to the research team.
16248552|NCT05034900|Active Comparator|Chest Physiotherapy Group|Patients in this group will perform comprehensive chest physiotherapy program two times a day, 7 days a week for 8 weeks at their homes.
16248553|NCT05034900|Experimental|OPEP device + Chest Physiotherapy Group|In addition to the same physiotherapy program applied to the controls, patients in this group will also use OPEP device two times a day, 7 days a week for 8 weeks at their homes.
16248554|NCT05034887|Experimental|Trastuzumab Deruxtecan (T-DXd)|One cycle is 21 days, with T-DXd repeated 3 cycles before surgery as the neo adjuvant treatment.
16248557|NCT05034861|Experimental|cCTG|cCTG group, that will undergo a following process: EFW and Doppler assessment biweekly, and instead of additional weekly Doppler-only assessment, the patients will be provided with an electronic cCTG device at no cost (Carebits). Women will be asked to apply Carebits device at least twice weekly for at least 30 minutes (e.g. Mondays-Thursdays) with minimum 72 hours interval in case of 2 sessions per week. The trace will be examined by an independent centre, available 24 hours daily. The person examining the trace is trained or already specialized in Obs&Gynae. In case of situation requiring medical intervention, the patient will be immediately contacted by phone and advised to self-refer to the nearest Antenatal Unit. In case of normal trace, a full report will follow within 30 minutes after last reading of the trace.
16248558|NCT05034861|Active Comparator|Doppler|Doppler group, that will undergo a standard process of antenatal care in case of FGR. The EFW will be assessed biweekly. In case of positive end-diastolic flow in UA, Doppler assessment (MCA PI, UA PI, DV PI, Ut PI) will be provided on a weekly basis. In case of deterioration to AEDF/REDF, further management will depend on clinical situation and the patient will be excluded from the study group (applies to both arms).
16248559|NCT05034848|Other|PAD group|PAD patients, diagnosis after undergoing an echo-doppler in the Vascular Medicine Department of Orleans regional Hospital
16248563|NCT05034809|Experimental|Treatment Group|Other than the guided management of Dengue Fever with warning signs, the treatment group will receive a standard dose of 20mg/day of melatonin20-21 for 5 days. The dosing was based on the study by Leiberman et al and Malhotra et al. If a patient is unable to tolerate the whole or punctured tablet, it will be given with milk or water. There is no known interaction between melatonin and milk known to date. Daily complete blood count will be done and be recording in an electronic record using Microsoft Excel.
16248564|NCT05034809|No Intervention|Control Group|Other than the guided management of Dengue Fever with warning signs, the control group will be manage according the Department of Health Dengue Management Guideline. No placebo will be given.
16248565|NCT05034783|Experimental|[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan|Patients of Insulinoma PET/CT imaging: In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4, respectively.
16248566|NCT05034757|Experimental|Hyaluronate|HA injection
16248567|NCT05034757|Experimental|HA + ESWT|HA + ESWT
16248568|NCT05034718|Active Comparator|Control Arm|Completion of nurse powerform and data collection only.
16248569|NCT05034718|Experimental|Intervention Arm|Completion of nurse powerform, data collection and physician alert/powerform with score calculation and recommendations.
16248570|NCT05034705|Active Comparator|Active comparator: Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
16248571|NCT05034705|Experimental|Experimental: Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
16248572|NCT05034692|Experimental|Overlap group|Total laparoscopic with intracorporeal anastomosis by overlap method
16248573|NCT05034692|Active Comparator|Traditional group|Laparoscopic-assisted colectomy with extracorporeal anastomosis
16248574|NCT05034679||Vaciinated|First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination.
16248575|NCT05034679||Infected patients by covid-19 and not vacinated|Second group patients who were infected by Covid-19 ant therefor were not vaccinated
16248576|NCT05034679||Not infected nor vacinated|Ptients who who were not infected nor vacinated by Covid-19.
16248705|NCT05033808|Experimental|Epirubicin Phase I|Administration of epirubicin i.v. 3.75 mg/m2 once.
16248577|NCT05034666|Active Comparator|Before education|"Before alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.
~This is before applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
16248578|NCT05034666|Active Comparator|After education|"After alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.
~This is after applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
16248579|NCT05034653|Experimental|Intermittent Fasting Healthy Plate (IFHP)|Dry fasting from dawn to dusk for two days a week (Monday and Thursday) and Healthy Plate for the rest of the week. Female participants were discouraged from fasting during their menstruation period.
16248580|NCT05034653|Active Comparator|Healthy Plate|Practice the Healthy Plate concept in at least one meal every day
16248581|NCT05034640||Conventional Multiport Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had multiport video assisted thoracoscopic surgery for pediatric pneumothorax.
16248582|NCT05034640||Single Port Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had single port video assisted thoracoscopic surgery for pediatric pneumothorax.
16248583|NCT05034627|Experimental|Treatment (calaspargase pegol-mknl, cobimetinib)|Patients receive calaspargase pegol-mknl IV over 1 hour on day 1 and cobimetinib PO QD on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16248588|NCT05034588||Intensiv care patients after acute kidney injury|Patients with condition after intensive care stay and acute kidney injury and subsequent convalescence (without preexisting underlying cardiac disease or other disease with potential cardiac involvement).
16248589|NCT05034588||Intensiv care patients without kidney injury|Patients with condition after intensive care stay and subsequent convalescence (without kidney injury and preexisting underlying cardiac disease or other disease with potential cardiac involvement).
16248590|NCT05034575|Experimental|Novice and experienced medical personnel|Participants will be asked to complete two tasks each taking approximately 10 minutes while wearing eye-tracking technology to understand focus of gaze during laryngeal endoscopy and stroboscopy interpretation.
16248591|NCT05034562|Experimental|Diagnostic (gallium Ga 68-labeled PSMA-11, PET/CT, PET/MRI)|Patients receive gallium Ga 68-labeled PSMA-11 IV. 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.
16248592|NCT05034549|No Intervention|Control|
16248593|NCT05034549|Experimental|Noninvasive ventilation|
16248594|NCT05034536|Experimental|Pembrolizumab + Infliximab|"Participants will be randomly assigned to receive pembrolizumab and infliximab.
~Pembrolizumab will be administered every 3 weeks for up to 2 years
~Infliximab will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
16248595|NCT05034536|Experimental|Pembrolizumab + Placebo|"Participants will be randomly assigned to receive pembrolizumab and placebo.
~Pembrolizumab will be administered every 3 weeks for up to 2 years
~Placebo. will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
16248596|NCT05034510|Active Comparator|Low frequency 80 Hz then short pulse width 30 usec stimulation|Each participant will undergo to low frequency stimulation for 4 weeks, then will switch to short pulse width stimulation paradigm for 4 weeks according to the crossover design.
16248597|NCT05034510|Active Comparator|Short pulse width 30 usec then low frequency 80 Hz stimulation|Each participant will undergo to short pulse width stimulation paradigm for 4 weeks, then will switch to low frequency for 4 weeks according to the crossover design.
16248598|NCT05034497|Experimental|Dose Escalation for Cohorts 1-3|"Each participant will receive a single 5cc administration of 186RNL.
~At each dose level, a minimum of three to a maximum of six participants will be enrolled.
~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.
~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:
~COHORT ACTIVITY Cohort 1 (6.6 mCi) Cohort 2 (13.2 mCi) Cohort 3 (26.4 mCi)"
16248599|NCT05034484|Experimental|ALPN-303 Regimen A|
16248600|NCT05034484|Placebo Comparator|Placebo Regimen A|
16248601|NCT05034484|Experimental|ALPN-303 Regimen B|
16248602|NCT05034484|Placebo Comparator|Placebo Regimen B|
16248603|NCT05034458|Experimental|Diet|Patients will do biologic treatment and will do Crohns Disease Exclusion Diet for 12 weeks.They will be monitored periodically by interview and physical examination by physician and nutritionist, laboratory, fecal calprotectin.
16248604|NCT05034458|No Intervention|Control|Patients with normal treatment
16248605|NCT05034445||Sputum group|Sputum samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (sputum 1000X)
16248606|NCT05034445||Tissue group|Clinical data review to obtain corresponding tissue samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (tissue 1000X)
16248607|NCT05034445||Plasma group|Clinical data review to obtain corresponding plasma samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (plasma 10000X)
16248608|NCT05034432|Experimental|Intra-Op Prophylactic VT ablation|Subjects will get ablation procedure as needed if they were determined to be refractory to medical antiarrhythmic control should undergo catheter-based electrophysiology study and ablation on LVAD support
16248609|NCT05034432|Active Comparator|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
16248610|NCT05034419|Experimental|Active stimulation|Patients undergoing cardiac surgery will be randomized to active low level tragus stimulation for 30 min (pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz). Stimulation will be provided using the Parasym device.
16248611|NCT05034419|Sham Comparator|Sham stimulation|Patients undergoing cardiac surgery will be randomized to sham stimulation for 30 min. The Parasym device will be placed on the patient's tragus, but no current will be delivered.
16248612|NCT05034406|Experimental|Lidocaine group|A total amount of 6 mL of 2% lidocaine was injected at the three trocar insertion sites (2 mL at each insertion site) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
16248613|NCT05034406|Experimental|Levobupivacaine|Total amount of 6 mL of 0.5% levobupivacaine was injected at the three trocar insertion sites (2 mL at each) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
16248614|NCT05034406|No Intervention|Control group|No local or peritoneal administration of any local anesthetic prior, during and after the surgical procedure
16248615|NCT05034393||Patients with de novo or recurrent HR-positive HER2-negative mBC|Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020
16248616|NCT05034380|Active Comparator|Lean|males aged 18-30 years with BMI < 25
16248617|NCT05034380|Experimental|Overweight/Obese|males aged 18-30 years with BMI >= 25
16248618|NCT05034367|Experimental|Healthy persons|The responses of the healthy subjects are utilized to create reference ranges for a normal cough response to mannitol
16248619|NCT05034354|Experimental|Infant remote physiological monitoring|Infants <12 months of age with single ventricle physiology or biventricular cyanotic congenital heart disease. Patients will be recruited from inpatient and outpatient cardiology service at the Stollery Children's Hospital will be purposively selected, with 50% of the patients living at least 100km from the Stollery.
16248620|NCT05034354|Experimental|Pediatric remote physiological monitoring|Patients aged 5-17 with heart failure, listed for transplant, or within 1 year of transplant. Patients will be recruited from inpatient and outpatient cardiology service at the Stollery Children's Hospital will be purposively selected, with 50% of the patients living at least 100km from the Stollery.
16248621|NCT05034341|Experimental|Multimodal Prehabilitation Arm|"The Multimodal Prehabilitation group will receive:
~An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to a home exercise program. Patients' compliance will be monitored by phone each week.
~Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar-free.
~Pain and Neuroscience Education: Per University of Florida Health Pain and Neuroscience program at Shands hospital.
~Standard Clinical Care: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with a focus on preoperative cognitive assessment."
16248622|NCT05034341|Active Comparator|Standard Clinical Care Comparison Arm|"The Standard Clinical Care Comparison group will receive:
~Education related to preoperative activity and home based exercise program.
~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.
~A final preoperative visit before surgery where a second set of functional assessment will be implemented"
16248623|NCT05034328||Healsea® Children: isotonic seawater based nasal spray supplemented with natural Symbiofilm® extract|Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed.
16248624|NCT05034328||Conventional therapies|Children will receive conventional therapies for common cold as needed, nasal irrigation excluded
16248625|NCT05034315|Experimental|Whole egg consumption|
16248626|NCT05034315|No Intervention|No egg control|
16248627|NCT05034302||Recordings|Selection criteria include individuals between the ages of 18-85 years, no major chronic illness that impair mobility and able to complete activities of daily living without assistance. We will recruit approximately equal number of men and women and 30% of the sample will be racial or ethnic minorities.
16248628|NCT05034276|Experimental|MORE-VR|Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.
16248629|NCT05034250||Women with infertility|The patient suffers from primary or secondary infertility, defined as the inability to conceive despite frequent unprotected sexual intercourse for at least 12 months.
16248630|NCT05034250||Women with recurrent miscarriage|The patient suffers from recurrent miscarriage, defined as three or more consecutive miscarriages before the 20th gestation week with the same partner.
16248631|NCT05034250||Healthy controls|The woman does neither suffer from infertility/sterility nor from recurrent miscarriage and is also otherwise healthy with regular cycles.
16248632|NCT05034237|Experimental|ND;YAG 1064 NM LASER|monthly sessions of laser hair removal
16248633|NCT05034224|Sham Comparator|Sham|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is kept deflated.
16248634|NCT05034224|Active Comparator|Coronary sinus occlusion|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is inflated.
16248635|NCT05034211|Active Comparator|Programmed intermittent Bolus Epidural technique|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered every 60 minutes via an epidural catheter placed for labor analgesia on L2-L3/L3-L4 level
16248636|NCT05034211|Active Comparator|Provider administered bolus epidural technique on patient request|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered by the provider on patient request
16248637|NCT05034198|No Intervention|Stakeholder Input|Behavioral health staff (BHS) will be asked to complete two semi-structured qualitative interviews and a set of surveys. The first interview will be about perceived barriers and facilitators on utilizing a remote training platform. The second interview will cover perceived feasibility and acceptability of the proposed training, consultation, and the implementation of evidence-based practices. The surveys will ask about the perceived acceptability, appropriateness, and feasibility of the remote training platform.
16248703|NCT05033821|No Intervention|Control|Participants who receive standard library programing, but not the FOY+ImPACT intervention.
16248704|NCT05033808|Placebo Comparator|Placebo|Administration of NaCl i.v. as placebo once.
16248638|NCT05034198|No Intervention|Asynchronous Training|Mental health trainers with expertise in the treatment of externalizing and internalizing behavior disorders will video-record the training modules and produce them using lecture capture technology (i.e., showing speaker and Power Point slides on a split screen). Each training module will be approximately 45 minutes long. BHS will be given a procedures manual with instructions on how to access the video-recorded training modules on-demand.
16248639|NCT05034198|Experimental|Synchronous Training|After completing the first mini-trial, Investigators will develop manuals and procedures for the synchronous (interactive) portion of the training. The specific components of the synchronous remote training, as well as session length and frequency, will be determined by the results of preliminary studies and Aim 1 of the proposed study. Research team consultants will provide remote consultation to BHS. The synchronous consultation will be conducted using a video-conferencing platform, and will have two main components: didactics and coaching.
16248640|NCT05034185||Patients with one or more polyps detected|"During colonoscopy, the Clinician inspect for the presence of polyps as per routine clinical practice with the CAD EYE function turned off. When a polyp is encountered, the Clinician will make a prediction on the histology based on the white light and BLI features of the polyp with and without optical magnification, as per routine clinical practice. Following this, the CAD EYE function will be switched on and the Clinician will take note of the CADx prediction for the same polyp, which will be either neoplastic or hyperplastic.
~In addition, other polyp features such as the size and location will be recorded, which is similar to what is performed in routine clinical practice. The polyp will be resected and sent for pathological examination, which will form the gold standard for the diagnosis of polyp histology."
16248643|NCT05034146|Experimental|68Ga-FAPI PET/CT in malignant tumors|Investigators select subjects from patients who have underwent whole-body 18F-FDG PET/CT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET/CT scan with time interval of one to four week.
16248644|NCT05034133|Experimental|Study arm|Patients with limited stage small cell lung cancer receive durvalumab with chemotherapy (Etoposide and Cisplatin) for receive 6 cycles, and then receive thoracic radiotherapy.
16248645|NCT05034120|Experimental|MB:Single arm|10 subjects will be enrolled in this arm. The subjects will take a single dose XZP-3621 tablet after a low-fat meal and perform excretion collection consistently.
16248646|NCT05034120|Experimental|FE:Arm A|Cycle1 Day1: fasting; Cycle2 Day10: High-fat meal; Cycle3 Day19: Low-fat meal
16248647|NCT05034120|Experimental|FE:Arm B|Cycle1 Day1: High-fat meal; Cycle2 Day10: Low-fat meal; Cycle3 Day19: fasting
16248648|NCT05034120|Experimental|FE:Arm C|Cycle1 Day1: Low-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: High-fat meal
16248649|NCT05034120|Experimental|FE:Arm D|Cycle1 Day1: fasting; Cycle2 Day10: Low-fat meal; Cycle3 Day19: High-fat meal
16248650|NCT05034120|Experimental|FE:Arm E|Cycle1 Day1: High-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: Low-fat meal
16248651|NCT05034120|Experimental|FE:Arm F|Cycle1 Day1: Low-fat meal; Cycle2 Day10: High-fat meal; Cycle3 Day19:fasting
16248652|NCT05034107|Experimental|Persons with dementia|Persons who have been diagnosed with dementia by their physicians and in nursing homes. Persons with dementia who have at least one symptom of BPSD and willing to participate in this study. These participants will be exposed to diffused Ylang-Ylang aromatherapy.
16248653|NCT05034081|Experimental|group A|to know the effect of post-bariatric body contouring surgery on weight loss and metabolism
16248654|NCT05034081|No Intervention|group B|compare this group of patients with group A to detect weight changes and metabolic changes without any post-bariatric intervention
16248655|NCT05034068|No Intervention|control|the patients will be treated by using oral care only and evaluation will be done before cancer treatment and weekly till the treatment completed. In each weekly visit, oral sites will be examined, and a score was given to each site based on the degree of mucositis.
16248656|NCT05034068|Active Comparator|bezaydamine hydrochloride.|All patients were advised to rinse 15 mL of the solution benzydamine for 2 min, four to eight times daily before and during, and for 2 weeks after completion of cancer therapy. In case of any problem (e.g. burning or stinging), patients will be allowed to dilute the solution with water in the ratio 1:1 or 1:2. Study evaluations will be conducted before cancer treatment and weekly thereafter until 2 weeks after completion of the therapy .In each weekly visit, oral sites were examined and a score was given to each site based on the degree of mucositis.
16248657|NCT05034068|Active Comparator|low-level laser therapy|the patients will be treated by using a low-level laser therapy, the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2. The irradiations will be done intra-orally avoiding the tumor site, oral examinations will be recorded at each irradiation session and the degree of mucositis will be recorded.
16248658|NCT05034055|Experimental|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
16248662|NCT05034029|Experimental|Metformin|Metformin hydrochloride sustained release tablet will administer orally in escalating doses to reduce side-effects and maintain masking: 0.5 g/dag for the first two weeks, 1 g/dag for the next 2 weeks, and then 2 g/dag until the end of the study if tolerated. If the subject cannot tolerate the maximum dose (2 g/day), take their maximum tolerable dose. In case of adverse reaction, the researcher can judge whether the subject needs to reduce or stop the drug according to the specific situation.
16248663|NCT05034029|Placebo Comparator|Placebo|Placebo will administer the same as the experimental drug.
16248664|NCT05034016|Experimental|HM experimental group|Intraocular implant test product
16248665|NCT05034016|No Intervention|Natural observation control group|Natural observation of the disease changes, no surgical intervention
16248666|NCT05034003|Experimental|zirconia crowns|Zirconia crowns placed on primary incisor teeth
16248667|NCT05034003|Experimental|composite strip crowns|composite strip crowns placed on primary incisor teeth
16248668|NCT05034003|No Intervention|Control tooth|Caries-free primary incisor tooth
16248669|NCT05033990||Healthy Controls|Participants with no smoking history (< 100 cigarettes in lifetime); post-bronchodilator FEV1/FVC > 0.70; post-bronchodilator FEV1 > 80% predicted; post-bronchodilator FVC > 80% predicted; Chronic Airway Assessment Test (CAAT) score < 10
16248670|NCT05033990||Gold 0|"Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 > 80% predicted; and Chronic Airway Assessment Test (CAAT) score ≥ 10.
~GOLD stands for the Global initiative for Chronic Obstructive Lung Disease. The Gold"
16248671|NCT05033990||Preserved Ratio Impaired Spirometry (PRISm)|Participants with with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 < 80% predicted.
16248672|NCT05033990||Gold 1 - 2|Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-80% predicted.
16248673|NCT05033977|Experimental|Center-based Exercise|"patients did exercises with a physical therapist in a clinic 3 days and 45 minute in a week for 6 weeks.
~The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings."
16248674|NCT05033977|Experimental|Home-based exercise|Patients did exercises at home every day and 3 times per day. The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings.
16248675|NCT05033964|Experimental|DESyne BDS Plus Drug Eluting Coronary Stent Arm|DESyne BDS Plus is loaded with Sirolimus, Rivaroxaban and Agratroban
16248676|NCT05033964|Active Comparator|DEsyne X2 Novolimus Eluting Coronary Stent|The DESyne X2 NECSS is loaded with Novolimus (metabolite of sirolimus)
16248677|NCT05033951||Cohort 1|Patients who start NIV in the first two months after the first visit to the HMV
16248678|NCT05033951||Cohort 2|Patients who do not start NIV in the first two months after the first visit to the HMV.
16248679|NCT05033938|Active Comparator|Early Mobilization|Post-operatively subjects receive a removable wrist splint that can be taken off for early wrist mobilization
16248680|NCT05033938|Active Comparator|Late Mobilization|Post-operatively subjects receive a splint and are not instructed to not move their wrist till the 2 week follow up visit.
16248681|NCT05033925|Placebo Comparator|Placebo|receive a plasebo capsule 2 doses per day
16248682|NCT05033925|Experimental|FADA 800 mg/day|receive FADA capsules twice a day (each 400 mg)
16248683|NCT05033925|Experimental|FADA 2000 mg/day|receive FADA capsules twice a day (each 1000 mg)
16248688|NCT05033899|Experimental|group E: ERAS group|36 non-insulin dependent diabetic patients will undergo lumbar decompression surgery following ERAS protocol.
16248689|NCT05033899|No Intervention|group C: conventional group|conventional perioperative care.
16248692|NCT05033873|Experimental|Group A: Universal Exercise Unit Therapy (UEU)|This experimental group will be given universal exercise unit therapy.
16248693|NCT05033873|Experimental|Group B: Sling Exercise Therapy (SET)|This experimental group will be given sling exercise therapy
16248694|NCT05033873|Other|Group C: Control Group|Control group will be given routine physical therapy
16248695|NCT05033860|Experimental|Intervention group|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and questionnaire surveys were conducted afterwards.
16248696|NCT05033860|No Intervention|Control group|Questionnaire surveys were conducted without leaflets distribution.
16248697|NCT05033847|Experimental|Subject last vaccination time is within 30-90 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
16248698|NCT05033847|Experimental|Subject last vaccination time is within 91-180 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
16248699|NCT05033847|Experimental|Subject last vaccination time more than 181 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
16248700|NCT05033834||Group A|People received any registered COVID-19 vaccination
16248701|NCT05033834||Group B|People developed COVID-19 infection after partial or full vaccination with any registered COVID-19 vaccine
16248706|NCT05033808|Experimental|Epirubicin Phase II|Administration of epirubicin i.v. 7.5 mg/m2 once.
16248707|NCT05033808|Experimental|Epirubicin Phase III|Administration of epirubicin i.v. 15 mg/m2 once.
16248708|NCT05033795|Experimental|Water A|2 L of water A per day
16248709|NCT05033795|Other|Water B|2 L of water B per day
16248710|NCT05033782||MS patients|"This group includes patients living in Ile de France, followed in the neurology department of the Pitié Salpêtrière Hospital in Paris for relapsing-remitting MS.
~Clinical examination will be performed to evaluate the disability (EDSS scale), as part of the care (systematic for all MS consultations)
~- A paper questionnaire is given to the patient during the consultation. The patient will be contacted by telephone within 15 days after the consultation by a health care staff to collect the answers to the questionnaire."
16248711|NCT05033769|Experimental|Eribulin|Arm A. Eribulin 1.23 mg/m^2, administered as an injection on day 1 and 8 q 21d for a maximum of 4 therapy cycles
16248712|NCT05033769|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m^2, administered as an injection on day 1, 8 and 15 q21d for a maximum of 4 therapy cycles
16248713|NCT05033756|Experimental|Pembrolizumab / Olaparib|All eligible participants according to the definition of cohorts 1-3 will receive pembrolizumab i.v. 200 mg q3w in combination with olaparib tablets 300 mg twice daily (total dose 600 mg per day).
16248714|NCT05033743|Experimental|Treatment Group|Secnidazole treatment
16248715|NCT05033730|No Intervention|Standard care: Control (Group A)|Patients who are scheduled for elective surgical upper airway surgery will be given General Anesthesia by an anesthesiologist who is the principal investigator and the surgical procedures will be done by the same ENT surgeon. IV Induction of Anesthesia with Propofol Target controlled infusion (TCI), Remifentanil Target controlled infusion (TCI) and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed endotracheal tube after direct laryngoscopy. After intubation by a Suitable size Endotracheal tube, they will be mechanically ventilated using Volume Controlled Ventilation (VCV) with 40% Oxygen and minute ventilation adjusted to keep ETCO2 of 40 mmHg or less, and a PEEP of 5 cmH2O.
16248716|NCT05033730|Experimental|Intervention Group: (Group B)|General Anesthesia will be induced with IV Induction of Anesthesia by an anesthesiologist with Propofol (Target controlled infusion), Remifentanil (Target controlled infusion), and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed Tritube after direct laryngoscopy. They will be mechanically ventilated using Flow Controlled Ventilation (FCV) with 40% Oxygen, Flow rate:13L/Min., Peak Airway Pressure (15 cmH2O), and a PEEP of (5 cmH2O) to keep ETCO2 of 40 mmHg or less. The anesthesia will be maintained with Intravenous Infusion of Propofol, Remifentanil (TCI) to keep BIS 40-60.
16248717|NCT05033717|Experimental|Group A|Tissue Flossing Technique
16248718|NCT05033717|Active Comparator|Group B|Static Stretching exercises
16248719|NCT05033704|Experimental|(Group A)|"Twenty-four of the 48 patients will receive an intraoperative intravenous infusion of 5% human plasma protein fraction PPF, (A group). PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).
~Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl."
16248720|NCT05033704|No Intervention|(Group RS)|24 patients will receive an intraoperative intravenous infusion of crystalloids (0.9 % normal saline and/ or Lactated Ringer's solution) (RS group). Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl.
16248721|NCT05033691|Experimental|Early SRS treatment with SoC|Stereotactic surgery (SRS) to the brain metastases and continuation of Osimertinib, at 2 month (8 weeks) post Osimertinib start
16248722|NCT05033691|Active Comparator|SoC Tagrisso treatment only|continuation of osimertinib alone
16248723|NCT05033665|Active Comparator|Euhydrated|Afternoon urine osmolality < 800 mmol/kg or urine specific gravity < 1.020.
16248724|NCT05033665|Experimental|Underhydrated|Afternoon urine osmolality ≥ 800 mmol/kg or urine specific gravity ≥ 1.020.
16248725|NCT05033652|No Intervention|Standard strategy|
16248726|NCT05033652|Experimental|Warning KD strategy|
16248732|NCT05033587|Experimental|AK105 injection with anlotinib and radiotherapy|"AK105 200mg intravenously (IV) on day 1 of each 21-day cycle until disease progression or treatment intolerance, the dose can not be adjusted.
~Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
~The conventional radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy."
16248733|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa simplex|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.
~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
16248734|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of junctional epidermolysis bullosa|"Female patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.
~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
16248803|NCT05033093|Active Comparator|I Root SP|All samples will be filled with I Root SP root canal sealer and gutta percha
16248735|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa dystrophic|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.
~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
16248736|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of Kindler syndrome|Female patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
16248737|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa simplex|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.
~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
16248738|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of junctional epidermolysis bullosa|"Male patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.
~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
16248739|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa dystrophic|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.
~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
16248740|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of Kindler epidermolysis bullosa|Male patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
16248741|NCT05033561|Experimental|2 doses, 1 week apart|Administration of 2 doses of nOPV2, 1 week apart
16248742|NCT05033561|Experimental|2 doses, 2 week apart|Administration of 2 doses of nOPV2, 2 weeks apart
16248743|NCT05033561|Active Comparator|2 doses, 4 week apart|Administration of 2 doses of nOPV2, 4 weeks apart
16248744|NCT05033548||Managed with AlloCare Monitoring|
16248745|NCT05033548||Managed with Standard of Care|
16248746|NCT05033535|Experimental|S086|
16248747|NCT05033535|Placebo Comparator|Olmesartan medoxomil|S086 PLCEBO
16248748|NCT05033522|Experimental|AlloStim®|AlloStim® is a formulation of living allogeneic Th1-like cells with anti-CD3/CD28 microbeads attached derived from precursors purified from healthy screened blood donors that are differentiated and expanded ex-vivo. AlloStim® is formulated at 10-7 cells/ml in 0.5ml for ID administration and 3ml for IV administration
16248749|NCT05033522|Active Comparator|Physician's Choice|Physician's Choice is either palliative FOLFOX4 chemotherapy plus best supportive care or best supportive care alone.
16248750|NCT05033509||ECMO and AKI|
16248751|NCT05033496||Newborn infants|Newborn infants born in our medical center
16248752|NCT05033483|Experimental|Iron Supplement|65.7 mg of iron as ferrous fumarate
16248753|NCT05033483|Active Comparator|Placebo|0 mg of iron
16248754|NCT05033470|Experimental|Dabir Surface Mattress Overlay System|Eligible patients are treated with a mattress overlay system and standard of care (debridement, proper moisture balance, reduction of bacterial burden and nutritional counseling). Subjects will be seen weekly for 4 weeks. Patients who respond to the offloading device, may use the overlay for an additional 12 weeks with monthly follow-up visits in the clinic or their home. Subjects undergo study procedures on a weekly basis.
16248755|NCT05033457||unilateral biportal endoscopy technique group|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group
16248756|NCT05033457||percutaneous endoscopic transforaminal discectomy group|Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group
16248757|NCT05033444|Experimental|PRV-002|"A single dose of PRV-002 will be administered to each study participant in this arm on study Day 1 at the following dose levels:
~Cohort 1: 9.66 mg
~Cohort 2: 19.38 mg
~Cohort 3: 38.7 mg."
16248758|NCT05033444|Placebo Comparator|Placebo comparator|A single dose of placebo comparator will be administered to each study participant in this arm on study Day 1. Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
16248765|NCT05033418|Experimental|IPRP + CBT-I|Interdisciplinary Pain Rehabilitation Program + Cognitive Behavioral Therapy for Insomnia (IPRP + CBT-I)
16248766|NCT05033418|Active Comparator|IPRP-UC|Interdisciplinary Pain Rehabilitation Program Usual Care (IPRP-UC)
16248767|NCT05033405|Experimental|Experimental:Neuro Linguistic Programming|One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field.
16248768|NCT05033405|No Intervention|control group|No NLP was applied on the control group patients.
16248769|NCT05033392|Experimental|Toripalimab group|Toripalimab is administrated with160mg and repeated every 2 weeks.
16248770|NCT05033379|Experimental|Control Arm|Instruction about importance of sleep.
16248771|NCT05033379|Experimental|Coaching|Undergo resilience coaching
16248804|NCT05033093|Active Comparator|GuttaFlow Bioseal|All samples will be filled with GuttaFlow Bioseal canal sealer and gutta percha
16248805|NCT05033080|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
16248772|NCT05033366||Proov test strip users that record results with the Proov app|Participants using Proov test strips along with the Proov app who have logged at least one complete cycle will be asked to complete an online survey about fertility test results and current/previous pregnancy status. They will also be asked cycle history (irregular vs regular, cycle length), fertility testing (partners semen analysis results, AMH level, HSG results), possible fertility medications taken or prescribed, age, race, smoking status, and BMI.
16248773|NCT05033353|Active Comparator|Group I|Mechanical ventilation was adjusted to maintain an EtCO2 of 33-38 mm Hg in group I regional cerebral oxygen monitoring
16248774|NCT05033353|Active Comparator|Group II|Mechanical ventilation was adjusted to maintain an EtCO2 of 39-45 mm Hg in group II regional cerebral oxygen monitoring
16248775|NCT05033340|Placebo Comparator|SS1-P2b|"Primary efficacy endpoint:
~• Proportion of subjects with endoscopic response at Week 14
~Secondary efficacy endpoint:
~• Proportion of subjects with clinical remission CDAI at Week 14"
16248776|NCT05033340|Placebo Comparator|SS2-I|"Primary efficacy endpoints:
~Proportion of subjects with endoscopic response at Week 14
~Proportion of subjects with clinical remission CDAI at Week 14
~Secondary efficacy endpoints:
~Proportion of subjects with clinical remission PRO2 at Week 14
~Proportion of subjects with clinical response CDAI at Week 14
~Proportion of subjects with endoscopic response and clinical remission CDAI at Week 14
~Proportion of subjects with endoscopic remission at Week 14"
16248777|NCT05033340|Active Comparator|SS3-M|"Primary efficacy endpoints:
~Proportion of subjects with clinical remission CDAI at Week 52
~Proportion of subjects with endoscopic response at Week 52
~Secondary efficacy endpoints:
~Proportion of subjects with clinical remission CDAI at Week 52 among subjects in clinical remission CDAI at SS3-M baseline (defined as Week 14 or EI-Week 6 Visit)
~Proportion of subjects with endoscopic response at Week 52 among subjects in endoscopic response at SS3-M baseline
~Proportion of subjects with corticosteroid-free clinical remission CDAI at Week 52 among subjects receiving corticosteroids at SS3-M baseline
~Proportion of subjects with endoscopic remission at Week 52
~Proportion of subjects with clinical remission PRO2 at Week 52"
16248778|NCT05033327|Other|Nutrition and Exercise App|The exercise and nutrition app intervention will be provided to study participants. The app offers self-directed and supervised (virtual) programming to support nutrition and exercise self-management. Each participant follows a program that has been tailored to their overall health, physical function, and needs.
16248779|NCT05033314|Experimental|Rivaroxaban thromboprophylaxis|
16248780|NCT05033314|Placebo Comparator|Placebo|
16248781|NCT05033301|No Intervention|Specialist-led Ned Clinic|Participants enrolled in specialist-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist for one year.
16248782|NCT05033301|Experimental|Nurse-led Ned Clinic|Participants enrolled in the nurse-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist. In addition, men will be asked to complete another set of PROs that will be monitored by a trained oncology nurse, in between their specialist visits.
16248783|NCT05033288||Observational (questionnaires, medical record review)|Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed.
16248784|NCT05033262|No Intervention|Control|
16248785|NCT05033262|Experimental|Intervention|
16248786|NCT05033249||Normal|Alvarado Score 4 - 7 Normal according to the initial computed tomographic evaluation
16248787|NCT05033249||Patient|Alvarado Score 4 - 7 Acute appendicitis according to the initial computed tomographic evaluation
16248788|NCT05033223|Other|Follow-up|
16248789|NCT05033210|Other|Control Group|The control group will receive Psychological First Aid (PFA) and Care as Usual (CAU)
16248790|NCT05033210|Experimental|Treatment Group|The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2), in addition to Psychological First Aid (PFA) and care as usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress (K10 > 15.9) at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.
16248791|NCT05033197|Experimental|CBBS intervention group|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
16248794|NCT05033171|Experimental|Study group|"Patients with scoliosis induced surgical indication (Cobb-degree>45).
~Posterior screw-rod fixation segmentdesis
~Before the implantation, right after the implantation and after the in situ bending 3D scanning of the rod using Artec Eva Spider type manual 3D scanner will be performed. Scanning is possible from a more than 60 cm distance, so that means the operational area stays sterile.
~EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery (as in the actual clinical protocal)."
16248795|NCT05033158|Other|Cancer patients|Level of antibodies against SARS-CoV-2 will be measured in these patients
16248796|NCT05033145|Experimental|AZVUDINE|"Experimental:
~AZVUDINE 1mg tablet
~Interventions:
~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days"
16248797|NCT05033145|Placebo Comparator|AZVUDINE placebo|"Control:
~AZVUDINE placebo
~Intervention:
~AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days"
16248800|NCT05033106|Active Comparator|Eyes with IVI bevacizumab|0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye
16248801|NCT05033106|Active Comparator|Eyes with IVI ranibizumab|A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant
16248802|NCT05033093|Active Comparator|Ah Plus|All samples will be filled with Ah Plus root canal sealer and gutta percha
16249975|NCT05025163|No Intervention|control group|no intervention in the control group
16248806|NCT05033080|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
16248807|NCT05033067|No Intervention|Usual Care|
16248808|NCT05033067|Experimental|Intervention (P3-BC) Usual Care|intervention + usual care group. In addition to receiving usual care, patients will have access to the aid and related materials before consultation with the physician about cystectomy and urinary diversion.
16248814|NCT05033028|No Intervention|Treatment-as-Usual|Participants will receive the same treatment as if they had not joined the study
16248815|NCT05033028|Experimental|Smartphone with dose changes after using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days play a 2-4 minute game.
16248816|NCT05033028|Experimental|Smartphone with dose changes before using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days to play a 2-4 minute game.
16248817|NCT05033028|Experimental|Focus group with Study Physicans|Study physicians asked to participate in a focus group session or 1:1 interviews if unable to attend the focus group during year one of the study and once annually towards the end of years 2, 3, 4, and 5 of the study
16248818|NCT05033028|Experimental|Focus group with Clinicians|Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.
16248819|NCT05033015|Experimental|Test|Mouth rinse containing enzymes
16248820|NCT05033015|Active Comparator|Placebo|Control, same content as test, without enzymes
16248821|NCT05033002|No Intervention|Treatment as Usual Group|This group will receive treatment as usual which means that no formal stigma reduction intervention will be provided. At the end of the follow-up period, this group will be invited to view the Labda Siku Moja stigma reduction intervention without follow-up.
16248822|NCT05033002|Experimental|Stigma Intervention Group|This group will participate in a 5 week intervention. Each week, intervention group participants will watch one ethnodrama segment of the Labda Siku Moja stigma reduction intervention followed by a guided debrief using motivational interviewing.
16248823|NCT05032989|Experimental|Extraction of distoangular and vertically positioned 3rd molar using cowhorn forcep|Extraction with new technique
16248824|NCT05032989|Active Comparator|Extraction of distoangular and vertically positioned 3rd molar via conventional method|Extraction with the conventional technique
16248825|NCT05032976||Comirnaty|Subjects aged 12 years and older who are scheduled for Comirnaty vaccination
16248826|NCT05032963|Active Comparator|Undisturbed Sleep|8 hours sleep - Subjects randomized to the undisturbed sleep will be instructed to go to sleep at 11pm, and awoken at 7am.
16248827|NCT05032963|Experimental|Restricted Sleep|4 hours sleep - Subjects randomized to the restricted sleep will be instructed to go to sleep at 3am and awoken at 7am.
16248831|NCT05032937|Experimental|ECMR|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.
16248832|NCT05032924|Experimental|PPR group|Receive PRP injection only (PRP form Regen Kit BCT 1)
16248833|NCT05032924|Placebo Comparator|HA group|Receive HA injection only (HYAJOINT Synovial Fluid Supplement, active ingredient: Sodium Hyaluronate 25 mg, package: 2.5 mL per syringe)
16248834|NCT05032911||Asymptomatic participants|Asymptomatic subjects should not present any pain in the cervical region during the last 3 months and no previous treatment for neck pain in order to be included in the study.
16248835|NCT05032911||Neck pain patients|Patients with neck pain should have an intensity of pain of at least 3 points out of 10 on a Visual Analog Scale and a neck pain duration of at least 3 months of evolution. Neck pain could be from nonspecific mechanical origin, associated with whiplash or with a previous medical diagnosis of degenerative or inflammatory alterations of the cervical spine, associated or not with headache and pain in the shoulder region or the upper limb.
16248836|NCT05032885|Experimental|A|48-72 hours after hospital admission, following the baseline assessment of the patient, they will begin to receive physiotherapy treatment with respiratory techniques and motor training, adapted at all times to the clinical situation of the patient, until hospital discharge. If the patient's clinical condition worsens, treatment will be temporarily suspended until the patient improves to allow resumption of treatment.
16248837|NCT05032885|No Intervention|B|48-72 hours after admission to the hospital, after the patient's baseline assessment, the patient will not receive physiotherapy and the usual referral to the Rehabilitation Service for physiotherapy treatment of hospitalized patients will be followed, if the patient's physician considers it necessary and requests it.
16248838|NCT05032872|Experimental|Social Exergame Treatment Group|The treatment group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the full version of the Go&Grow fitness app for 6 weeks.
16248839|NCT05032872|Active Comparator|Control Group|The control group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the Go&Grow fitness app without the social features for 6 weeks.
16248840|NCT05032859|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
16248841|NCT05032859|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
16251284|NCT05016427|Experimental|VT301(high dose)|VT301 high dose: 1.7x10^5 cells/kg
16248842|NCT05032846|Experimental|Ultrasound Guided Laparoscopic Ovarian Cystectomy|During surgical resection of the ovarian cyst, a clinician with experience of ultrasound and laparoscopy will perform an ultrasound scan during surgery to resect cyst tissue only and preserve healthy ovarian tissue.
16248843|NCT05032846|Active Comparator|Laparoscopic Ovarian Cystectomy|A laparoscopic ovarian cystectomy will be performed without ultrasound guidance. This is currently standard clinical practice.
16248844|NCT05032833|Experimental|5-MeO-DMT arm|
16248845|NCT05032833|Placebo Comparator|Placebo arm|
16248847|NCT05032807|Experimental|Novel lipid formulation cannabidiol|
16248848|NCT05032807|Active Comparator|Standard formulation cannabidiol|
16248851|NCT05032781|Experimental|Intra-arterial neuroprotective substances|"Cold saline, minocycline, and magnesium sulfate to be infused intra-arterially immediately after thrombectomy via the internal carotid artery. A dose escalation design will be used, as described above in Study Description."
16248852|NCT05032768||Severe radiation dermatitis|RTOG/EORTC grade 2 and above
16248853|NCT05032768||No or mild radiation dermatitis|RTOG/EORTC grade 0 or 1
16248854|NCT05032755|Experimental|VLNC Group|Participants in this condition will be provided with Spectrum NRC102/103 (nonmenthol/menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco with reported nicotine yield (ISO) of 0.03 +/- 0.01 mg and a tar yield of 9 +/- 1.5. Participants will be asked to smoke only study cigarettes for 4 weeks.
16248855|NCT05032755|Active Comparator|NNC Group|Participants in this condition will be provided with Spectrum NRC600/601 (non-menthol/menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco with reported nicotine yield (ISO) of 0.8 +/- 0.15 mg and a tar yield of 10.5 +/- 1.5.
16248856|NCT05032742|Experimental|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
16248857|NCT05032742|No Intervention|Standard of care|Caregiver participants will receive an informational brochure describing ways to support one's adolescent during detention and community reentry and any other usual care.
16248858|NCT05032729|Placebo Comparator|Placebo beverage|"Flavor
~Non-nutritive sweetener
~Color added to match whey appearance"
16248859|NCT05032729|Experimental|Higher tryptophan beverage|"2.7g high Glycemic Index Carbohydrate
~40g whey
~0.855g tryptophan
~660mg theanine
~53mcg 5'AMP
~Non-nutritive sweetener
~Flavor"
16248860|NCT05032729|Experimental|Lower tryptophan beverage|"2.7g high Glycemic Index Carbohydrate
~30g whey
~0.641g tryptophan
~660mg theanine
~53mcg 5'AMP
~Non-nutritive sweetener
~Flavor"
16248861|NCT05032716|Active Comparator|Balance exersices group|
16248862|NCT05032716|Active Comparator|Balance exersices and treadmill group|
16248869|NCT05032677|Experimental|Conventional Epidural Technique|
16248870|NCT05032677|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
16248871|NCT05032664|Experimental|Intervention Group|Home-based aromatherapy programme
16248872|NCT05032664|Other|Control Group|Wait-list control
16248873|NCT05032651|Experimental|GROUP A-AI (model) Arm Description:|Artificial intelligence assisted platform supported system for the clinical physicians to prescribe ESA dose to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
16248874|NCT05032651|Experimental|GROUP B-AI (model) Arm Description:|ESA dose prescribed by clinical physicians as regular care to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
16248875|NCT05032638|Experimental|Experimental Group|Subjects with motor impairment will work closely with an occupational therapist to identify a goal and select activities that they will work on at home to improve the function of their affected arm.
16248876|NCT05032612|Experimental|PBM Therapy|
16248877|NCT05032612|Sham Comparator|PBM Sham|
16248878|NCT05032599|Experimental|CD5 CART|All patients who receive CD5 CART cell infusion
16248904|NCT05032456|No Intervention|Control Group|For participants randomized to the control group, virtual reality headsets were not used and the clinic's standard of care in laboring women was followed. Participants in this group filled out a visual pain rating scale both in the latent and active phases of labor.
16248905|NCT05032430|Experimental|ATIENDE|Mindfulness-based parental stress reduction intervention
16248906|NCT05032430|Active Comparator|Modified Health Enhancement Program|Attention-matched comparator group designed to influence health and well-being that does not include mindfulness as an active ingredient
16248879|NCT05032586|No Intervention|control groups: without wearing virtual reality headsets|"Before dressing, the child was given paracetamol, which is routinely used to prevent pain. The child was reminded that they would be with their family during the procedure, and either the mother or father was taken to the dressing room during dressing. After the standard burn dressing was applied to the patient by the healthcare personnel in the burn center treatment room, oxygen saturation and heart rate measurements were made again after the procedure and recorded in the Application Registration Form. Before and after the procedure, the patients were asked about the pain and anxiety levels felt during dressing and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
16248880|NCT05032586|Experimental|experimental groups|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
16248881|NCT05032573|Experimental|Olive Oil|Incorporating 60 mL of olive oil into usual diet and Dietary Guidelines recommendations
16248882|NCT05032573|Active Comparator|Control|Dietary Guidelines recommendations
16248887|NCT05032547|Experimental|Primary Care Online Emotion-Regulation Treatment|The youth component in the experimental condition will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as mindfulness practice and acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective responding to their children's and their own emotions.
16248888|NCT05032547|Active Comparator|Supportive Treatment|The intervention will be delivered in a blended treatment format combining asynchronous therapist-guided online modules (text/videos/audio/messaging function) with a synchronous session delivered over video-link.
16248889|NCT05032534|Active Comparator|Newly developed cone for 6 weeks the currently used cone for 6 weeks|Starts off with treatment with the newly developed cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
16248890|NCT05032534|Active Comparator|Currently used cone for 6 weeks the newly developed cone for 6 weeks|Starts off with treatment with the currently used cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
16248891|NCT05032521|Active Comparator|standard practice|
16248892|NCT05032521|Experimental|algorithm|
16248893|NCT05032508|Experimental|xylocaine|
16248894|NCT05032508|Placebo Comparator|Placebo|
16248895|NCT05032495||Heart patients who experienced a cardiac arrhythmia while in hospital|Heart patients who experienced a cardiac arrhythmia while in hospital
16248896|NCT05032495||Heart patients who did not experience a cardiac arrhythmia while in hospital|Heart patients who did not experience a cardiac arrhythmia while in hospital
16248897|NCT05032495||Heart patients with an upcoming procedure that have not had a cardiac arrhythmia|Heart patients with an upcoming procedure that have not had a cardiac arrhythmia
16248898|NCT05032495||Members of the general public|Members of the general public
16248899|NCT05032482|Other|Investigational Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
16248900|NCT05032482|Other|Investigational Treatment 2|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
16248901|NCT05032469|Experimental|Refloxology Intervention|The first foot reflexology was applied to the intervention group for 30 min (20 min on the right foot, 10 min on the left foot) on the first postoperative day (24 h after the surgery). On the second postoperative day, 30 min of foot reflexology was applied to the patients who decided to chest tube removal (CTR). After the foot reflexology applied by the researcher, CTR was performed by the doctor within 10 min. Immediately after CTR, the patient's pain and anxiety level during CTR was measured. At the 15th minute after CTR, the pain and anxiety level of the patients was measured, their satisfaction with the reflexology application was measured. Then, the patients were asked to describe the pain and feelings and thoughts during CTR, 1 hr after CTR, pain level was measured, and they were asked to express their feelings and thoughts about the reflexology application.
16248902|NCT05032469|No Intervention|Standart Care|Participants in the control group will receive standart postoperative care.
16248903|NCT05032456|Experimental|Virtual Reality Group|Investigators used Oculus Quest All-in-one Virtual Reality Gaming Headset (128 GB) VR system. Before the intervention, the investigators introduced the equipment and instructed study participants on how to wear and activate the headsets. The laboring women who enrolled in the virtual reality group first wore the headsets in early labor (Cervical dilation 3 cm) for 20 minutes. The patients were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the images of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance. The second implementation of virtual reality headsets was after the epidural analgesia in the active phase of labor for another 20 minutes (Cervical dilation 6-7cm).
16248945|NCT05032144|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10mg/kg of STSA-1002 as a single dose or dose-matched placebo.
16248907|NCT05032417|Active Comparator|EBNPG knowledge-focused training (knowledge-only group)|The knowledge-focused training includes didactic information about the content of the EBNPG related to nutrition care for individuals on dialysis. This training contains information that is typically shared with RDNs when an EBNPG is released, and in this instance, includes a free webinar developed by the Academy and NKF that provides an overview of EBNPGs, as well as a presentation of the specific EBNPG developed.
16248908|NCT05032417|Experimental|EBNPG knowledge-focused training plus an implementation toolkit (comprehensive group)|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
16248909|NCT05032404|Experimental|BNT103|All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.
16248910|NCT05032391|Experimental|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
16248911|NCT05032391|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
16248912|NCT05032378||People with movement disorders|Adults with acquired movement disorders secondary to neurological injury.
16248913|NCT05032378||Professionals|Professionals providing physical or occupational therapy to participants with acquired movements disorders.
16248914|NCT05032365|Experimental|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
16248915|NCT05032365|Active Comparator|Conventional|Two hours period where the FiO2 delivered will be conventionally adjusted by the healthcare personnel based on SpO2 values obtained from the patient.
16248916|NCT05032352||Treatment Arm|"Treatment Arm 1: 4 cycles of adjuvant treatment with a standard NSCLC cisplatin-based doublet regimen or carboplatin-based regimen if physician choice.
~Treatment 1A: other adjuvant therapy or combination of adjuvant therapies (targeted therapy, immunotherapy, or other)"
16248917|NCT05032352||Observation only|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
16248918|NCT05032339||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for plasma cell disorders
16248919|NCT05032326|Other|OXYTOCIN Treated cohort|babies treated with Oxytocin during the OTBB3 study
16248920|NCT05032326|Other|Untreated cohort|babies not included in the OTBB3 study and therefore never treated with Oxytocin
16248921|NCT05032313||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders.
16248922|NCT05032300|Active Comparator|focused shockwave therapy|Patients will receive 6 sessions of focused shockwave therapy.
16248923|NCT05032300|Active Comparator|control|Patients in the control group will be treated using the home therapy protocol only.
16248924|NCT05032287|Active Comparator|tamsulosin|tamsulosin 0.4 mg once daily
16248925|NCT05032287|Placebo Comparator|Placeb|Placebo once daily
16248926|NCT05032274|Experimental|Single group|The study will include one group and each participant will perform home-based exercise for 8-weeks.
16248927|NCT05032261||Group 1: surviving Patients|Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
16248928|NCT05032261||Group 2: Deceased patients|Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
16248929|NCT05032248|Experimental|tacrolimus|group I (Colchicine and topically applied Tacrolimus),
16248930|NCT05032248|Placebo Comparator|placebo|group II (Colchicine and topically applied Placebo),
16248931|NCT05032235|Experimental|Group A|
16248932|NCT05032235|Experimental|Group B|
16248933|NCT05032235|Experimental|Group C|
16248934|NCT05032196|Experimental|WVE-003 (Dose A) or placebo|
16248935|NCT05032196|Experimental|WVE-003 (Dose B) or placebo|
16248936|NCT05032196|Experimental|WVE-003 (Dose C) or placebo|
16248937|NCT05032196|Experimental|WVE-003 (Dose D) or placebo|
16248938|NCT05032183|Experimental|Treatment (tagraxofusp, chemotherapy)|See Detailed Description
16248939|NCT05032170||Locator Group|The participant has a mandibular overdenture supported by two implants with locator attachments. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
16248940|NCT05032170||Bar Group|The participant has a mandibular overdenture supported by two implants with a dolder bar attachment. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
16248941|NCT05032157|Experimental|Arm 1: LOU064 (blinded)|LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
16248942|NCT05032157|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
16248943|NCT05032144|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2mg/kg of STSA-1002 as a single dose or dose-matched placebo.
16248944|NCT05032144|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5mg/kg of STSA-1002 as a single dose or dose-matched placebo.
16248946|NCT05032144|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20mg/kg of STSA-1002 as a single dose or dose-matched placebo.
16248947|NCT05032144|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30mg/kg of STSA-1002 as a single dose or dose-matched placebo.
16248948|NCT05032131|Experimental|Experimental|"Group 1:
~Patients treated by sirolimus since at least 6 months (but still disabled)
~Group 2:
~Patients currently (for at least 3 months) without specific treatment for inclusion myositis"
16248949|NCT05032118|Experimental|Ketamine|Intravenous ketamine will be initiated following aneurysm securement at 0.5mg/kg/h and will be titratable by 0.2mg/kg/h every 20min to a Richmond Agitation Sedation Scale (RASS) goal of 0 to -1 (or as otherwise clinically indicated). Ketamine boluses will be available at 0.5mg/kg every 1hr as needed for inadequate sedation or breakthrough agitation. An additional 0.5mg/kg bolus may be utilized prior to initiating the ketamine infusion, or as needed at the discretion of the clinician. The maximum ketamine infusion dose will be limited to 4mg/kg/h. A fixed-dose propofol infusion at 10mcg/kg/min will simultaneously be administered to minimize the potential psychomimetic side effects of ketamine. This sedation paradigm will continue for up to 10 days post-bleed or until the study participant no longer requires sedation, whichever occurs earlier. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
16248950|NCT05032118|Active Comparator|Standard of Care|Intravenous titratable propofol will be initiated as needed per current standard of care, which generally consists of initiating the infusion at 10-20mcg/kg/min with titration parameters of 5-10mcg/kg/min every 5-10min for a RASS goal of 0 to -1 (or as otherwise clinically indicated). Propofol boluses are available at 10-20mg (or higher dosages if clinically required) every 15min as needed for inadequate sedation or breakthrough agitation. The maximum infusion dose is generally limited to 50mcg/kg/min. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
16248951|NCT05032105|Experimental|Intervention|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
16248952|NCT05032092|Experimental|Adult patients with locally advanced and/or metastasized carcinoma|"Liquid biopsies of all 200 study patients will be analysed with FoundationOne®Liquid CDx.
~Tissue biopsies from all study patients for whom a tissue biopsy is available will be analysed with FoundationOne® CDx and IHC (approximately 50% of the enrolled patients).
~Biomarker Monitoring of study patients receiving matched therapy with AVENIO ctDNA Surveillance Kit."
16248953|NCT05032066|Experimental|HZN-825 300 mg once daily (QD)|Two 150 mg oral tablets given in the morning with a meal and two matching placebo tablets given in the evening with a meal, total daily dose 300 mg HZN-825
16248954|NCT05032066|Experimental|HZN-825-300 mg twice daily (BID)|Two 150 mg oral tablets given in the morning with a meal and two 150 mg oral tablets given in the evening with a meal, total daily dose 600 mg HZN-825
16248955|NCT05032066|Placebo Comparator|Placebo BID|Matching placebo tablets (2) given in the morning with a meal and matching placebo tablets (2) given in the evening with a meal, total daily dose 4 placebo tablets
16248956|NCT05032040|Experimental|XmAb20717|
16248957|NCT05032027|Experimental|Probiotic group|Probiotic( recieving Probiotic at the first day of chemoradiotherapy daily)with radiotherapy and Chemotherapy Intervention
16248958|NCT05032027|No Intervention|placebo group|placebo( one times a day)with radiotherapy and Chemotherapy Intervention
16248959|NCT05032027|No Intervention|healthy control group|healthy control group
16248963|NCT05032001|Experimental|Metformin|Metformin 1.7-2.5mg per day during twelve weeks
16248964|NCT05032001|Experimental|Metformina + IDDP-4|Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day
16248965|NCT05032001|Experimental|Metformina + ISGLT-2|Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day
16248966|NCT05031988||University Students|To assess the effect of determinants of physical activity and mental health among university students during Covid-19 movement restriction order.
16248967|NCT05031975|Experimental|TEMIRI|"Irinotecan intravenous infusion (IV) given every 14 days in combination with oral (PO) temozolomide over days 1-5 every 28 days.
~The treatment will consist of six 28-days cycles of TEMIRI."
16248968|NCT05031962||CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Implant-based breast reconstruction following mastectomy using the CELLIS Breast matrix
16248969|NCT05031949|Experimental|Hyperbaric oxygen therapy plus Camrelizumab|Subjects receive Camrelizumab intravenous at the dose 3mg/kg on Day 1 every 3 weeks, and breath pressurized (0.25 MPa) 100% oxygen (O2) indirectly by a head hood or mask for 60 minutes in multiplace chambers at Day 1 of every week.
16248970|NCT05031936|Active Comparator|Touhy needle group|cervical medial branch block using touhy needle
16248971|NCT05031936|Placebo Comparator|Quincke needle group|cervical medial branch block using quincke needle
16248972|NCT05031923|Experimental|SMV and antimicrobial photodynamic therapy|Application SMV and antimicrobial photodynamic therapy in intrabony defect
16248973|NCT05031923|Active Comparator|SMV application|Application SMV in intrabony defect
16248974|NCT05031910|Experimental|Arm I (VR/3D-CEPs, standard treatment)|Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.
16248975|NCT05031910|Active Comparator|Arm II (standard treatment)|Prior to surgery (day 0-13), patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29.
16249069|NCT05031377|Experimental|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
16249070|NCT05031377|Sham Comparator|Control|Receive usual care
16248976|NCT05031897|Experimental|Radiation-Based Cohort (fludarabine, TBI, infusion)|Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
16248977|NCT05031897|Experimental|Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)|Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0.
16248978|NCT05031884||MGIR3-US group|using MGIR3-US to do ultrasonic examinations.
16248979|NCT05031884||control group|using conventional B-mode ultrasound to do ultrasonic examinations.
16248980|NCT05031871|Experimental|Treatment group A|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
16248981|NCT05031871|Experimental|Treatment group B|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
16248982|NCT05031871|Experimental|Treatment group C|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
16248983|NCT05031871|Experimental|Treatment group D|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
16248984|NCT05031858|Experimental|Vojta Therapy|Reflex turn first phase: Patient positioned supine with legs flexed 30º-45º. The pectoral area is stimulated for five minutes on each side x 2 consecutive times. Total 20 minutes per session.
16248985|NCT05031858|Active Comparator|Control Group|.Inspiratory techniques, mucociliary clearance techniques (expiratory). Use of inspiratory and expiratory incentives. Employment of mechanical assistants
16248986|NCT05031845||COVID-19 positive, Hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.
~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
16248987|NCT05031845||COVID-19 positive, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.
~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
16248988|NCT05031845||COVID-19 negative, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.
~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
16248989|NCT05031832||HIV-negative|
16248990|NCT05031832||HIV-positive|
16248991|NCT05031819|Experimental|Practice Facilitation to support TASSH integration (group A).|Components of the PF strategy include: (a) establishment of a steering committee of key stakeholders (ministry of health, state primary care agency, AIDS control agency, patient advocates) to provide leadership and guide integration of TASSH into HIV care platform; (b) training of the HIV nurses on TASSH protocol; and (c) training of practice facilitators, who will serve as coaches, provide support, and performance feedback to the PHC nurses on TASSH implementation.
16248992|NCT05031819|Sham Comparator|TASSH only (group B)|HIV nurses based at Group B facilities will be trained on the 5As counseling approach strategy (Ask, Assess, Advise, Assist, and Arrange) and referral for the participants to the health center. However, they will not receive practice facilitation from the POFs. Participants attending PHC randomized to Group B will receive standard care offered by the facility.
16248997|NCT05031793|Experimental|Collaborative Care of TCM and Western Medicine|
16248998|NCT05031793|Active Comparator|Western medicine|
16248999|NCT05031780|Experimental|Phase 2: Mitapivat 50 mg BID|Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.
16249000|NCT05031780|Experimental|Phase 2: Mitapivat 100 mg BID|Double-blind Period: Mitapivat 100 mg BID for 12 weeks.
16249001|NCT05031780|Placebo Comparator|Phase 2: Placebo|Double-blind Period: Mitapivat-matching placebo for 12 weeks.
16249002|NCT05031780|Experimental|Phase 2: Open-Label Extension Period|"Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after.
~Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after.
~Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after."
16249003|NCT05031780|Experimental|Phase 3: Mitapivat selected Phase 3 dose|Double-blind Period: Mitapivat selected Phase 3 dose (50 mg or 100 mg BID) for 52 weeks.
16249004|NCT05031780|Placebo Comparator|Phase 3: Placebo|Double-blind Period: Mitapivat-matching placebo selected Phase 3 dose (which can be either 50 mg or 100 mg BID based on the phase 2 results) for 52 weeks.
16249005|NCT05031780|Experimental|Phase 3: Open-Label Extension Period|Participants may choose to receive the selected Phase 3 mitapivat dose (which can be either 50 mg or 100 mg BID based on the phase 2 results) for 216 weeks after the Double-blind Period.
16249006|NCT05031767|Active Comparator|Usual care|Conventional current follow-up strategy
16249007|NCT05031767|Experimental|Remote monitoring|Remote monitoring by health professionals at the hospital
16249008|NCT05031767|Experimental|Patient-initiated care|No pre-scheduled visits or remote monitoring.
16249009|NCT05031754||Infants with atopic dermatitis|Infants with atopic dermatitis
16249010|NCT05031754||Infants without atopic dermatitis|Infants without atopic dermatitis
16249011|NCT05031741|Experimental|Telemedicine|Teens who are randomly assigned a telemedicine card will have exposure to a pretend telemedicine visit equipped with an iPad and telehealth provider on the other end. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care through telemedicine from their own home or private space.
16249012|NCT05031741|Experimental|In-person Mobile Unit|Teens who are randomly assigned a in-person mobile unit card will have exposure to a pretend mobile unit visit equipped with a healthcare provider. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care on the mobile unit.
16249013|NCT05031728|Experimental|CPT Group|Cognitive Processing Therapy (CPT) is employed. Each patient will attend 12 individual sessions with the therapist. The sessions will be on the weekly basis. The standard manual of CPT (Resick et al., 2016) is going to be employed.
16249014|NCT05031715|Experimental|Dietary supplement|Berberine Phytosome
16249015|NCT05031702|Active Comparator|Dietary supplement|Extract from Camellia Sinensis leaf
16249016|NCT05031702|Placebo Comparator|Placebo|Tablets of the same size as the active component
16249017|NCT05031689|Placebo Comparator|SPF 30 and Placebo|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
16249018|NCT05031689|Active Comparator|SPF 30 and pharmaceutical formulation with green banana peel|In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.
16249019|NCT05031676|Experimental|group 1|Intervention consists at induction : direct intravenous lidocaine 1.5 mg/kg; clonidine 2 μg/kg in 250 ml of isotonic saline, started as soon as the venous route is taken and over a period of approximately 15 minutes; magnesium sulfate 50 mg/kg in the same isotonic saline as clonidine.
16249020|NCT05031676|No Intervention|group 2|In classic induction: fentanyl at a dose of 2 µg/kg. Following induction in all patients consisted of the administration of propofol 2-3 mg/kg in titration, rocuronium 0.6 mg/kg, ketamine 0.5 mg/kg, methylprednisolone 120 mg.
16249021|NCT05031663|Experimental|Almonds|The almond group will receive 15% of their daily energy intake in the form of almonds
16249022|NCT05031663|Placebo Comparator|Pretzel|The placebo group will receive an isocaloric carbohydrate based pretzel snack
16249023|NCT05031650|Active Comparator|openCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with a T-piece resuscitator with 8 cm H2O pressure and 0.30 fiO2. The heart rate (HR) and preductal saturation (SpO2) will be evaluated every 30 seconds. Individually, the following steps will be done according to the situation:
~If the HR > 120 / min and SpO2 not measured yet or be in the target range: The pressure will be continue as 8 cmH2O.
~If the HR between 100-120 but SpO2 below the target range or not measured yet : First the pressure will be increased to 10 cm H2O; than fiO2 will be increased gradually if the patient will not respond to 10 cmH2O pressure. Pressure will be reduced to 8 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
16249024|NCT05031650|Active Comparator|standardCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with T-piece resuscitator at 6 cmH2O pressure and 0.30 fiO2. HR and preductal saturation will be evaluated every 30 seconds. The following steps will be performed according to the situation:
~If the HR > 120 / min and SpO2 be in the target range or not measurable yet: The pressure will be continue as 6 cmH2O.
~If the HR between 100-120 but SpO2 below the target range or not measured yet : The pressure will increased up to 8 cm H2O. FiO2 will be increased gradually if the patient will not respond to 8 cmH2O pressure. Pressure will be reduced to 6 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
16249025|NCT05031637|Experimental|treatment by night-time BP|titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of <120 mmHg; intervention group)
16249026|NCT05031637|Other|treatment by daytime BP|Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of <135 mmHg; control group)
16249027|NCT05031624|Experimental|CDX-0159|Subjects will receive a single dose of CDX-0159
16249028|NCT05031624|Placebo Comparator|Normal Saline|Subjects will receive a single dose of normal saline
16249029|NCT05031611|Experimental|Intuitive Eating Treatment|"The intervention was a novel 10-week program aimed at promoting IE through pre-recorded videos, reading material, and bi-weekly discussion sessions. The intervention introduced the following modules sequentially: Unconditional Permission to Eat, Reliance to Hunger and Fullness Cues, Body-Food Choice Congruence, Gentle Nutrition, and Joyful Movement.
~Every other week, a new module was introduced. Participants were taught the concept of this module through video and reading, then prompted to practice it over the week. On opposite weeks, the module last introduced was discussed in greater detail through video, and participants were given the opportunity to discuss amongst one another and have all questions answered by the researchers."
16249099|NCT05031195||2nd tertile|
16249100|NCT05031195||3rd tertile|
16251285|NCT05016414|No Intervention|Control|4 days of strict bed rest
16249030|NCT05031611|No Intervention|Waitlist Control|Waitlist control group participants completed a series of questionnaires at the beginning and end of a 10-week interval, to compare changes in those who completed the intervention versus those who did not. This group was subsequently invited to participate in the intervention after their time on the wait-list.
16249031|NCT05031598|Experimental|Long-term fasting|The participants will undergo 6-12 fasting days according to the Buchinger Wilhelmi fasting program
16249032|NCT05031585|Experimental|Intervention Group|Nasal lubricant spray
16249033|NCT05031585|Placebo Comparator|Placebo|Placebo spray
16249034|NCT05031572|Other|conventional caloric restriction diet|(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet
16249035|NCT05031572|Other|Intermitent fasting|Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.
16249036|NCT05031559|Experimental|Episodic Future Thinking|
16249037|NCT05031559|Experimental|Compassion|
16249038|NCT05031559|Sham Comparator|Control|
16249039|NCT05031533|Experimental|Assigned Interventions|"Radiation therapy: Dose-painting radiation
~Systemic treatment: Choose a systemic treatment plan according to the patient's genetic testing status
~(1) Chemotherapy
~Squamous cell carcinoma: Paclitaxel 135mg/m2 D1 + Cisplatin 25mg/m2 D1-3, every 21 days, a total of 2-4 cycles.
~Non-squamous cell carcinoma (adenocarcinoma, large cell carcinoma): Pemetrexed 500mg/m2 d1 + Cisplatin 75 mg/m2 d1-3, a total of 2-4 cycles.
~(2) Targeted therapy: According to the patient's genetic testing status, molecular targeted therapy such as EGFR-TKI and ALK inhibitors can be selected; (3) Immunotherapy: According to the patient's genetic testing status, immunotherapy such as PD1/PD-L1 inhibitors can be selected;"
16249040|NCT05031520|Experimental|Intervention group|Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator. Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.
16249042|NCT05031494|Experimental|YH003 with Toripalimab in subjects with unresectable /metastatic melanoma|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment;
16249043|NCT05031494|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment;
16249044|NCT05031494|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment;
16249045|NCT05031481|Experimental|VENUS 20 + 0,064|Venus association vaginal cream, single dose.
16249046|NCT05031481|Experimental|VENUS 20 + 1|Venus association vaginal cream, single dose.
16249047|NCT05031481|Experimental|VENUS 20 + 4|Venus association vaginal cream, single dose.
16249048|NCT05031481|Active Comparator|Butoconazole nitrate 100 mg|Butoconazole nitrate vaginal cream, single-dose containing 100 mg.
16249049|NCT05031468||Group 1: Individuals vaccinated during pregnancy|Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)
16249050|NCT05031468||Group 2: Individuals vaccinated postpartum|Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)
16249051|NCT05031468||Group 3: Infants of individuals vaccinated during pregnancy|Infants of individuals who receive vaccine during pregnancy (approximately 200 infants per vaccine type)
16249052|NCT05031468||Group 4: Infants of individuals vaccinated postpartum|Infants of individuals who receive vaccine postpartum (approximately 65 infants per vaccine type)
16249053|NCT05031455|Experimental|Dupilumab|Time 0 - 600mg subcutaneous Week 1 - 300mg subcutaneous Week 3 - 300mg subcutaneous Week 5 - 300mg subcutaneous
16249054|NCT05031455|Placebo Comparator|Placebo|Time 0 - 600mg subcutaneous Week 1 - 300mg subcutaneous Week 3 - 300mg subcutaneous Week 5 - 300mg subcutaneous
16249061|NCT05031416|Experimental|Consumers who smoke at outpatient community mental health clinic|Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy
16249062|NCT05031403|Experimental|Stroke (Telerehabilitation)|Exercise therapy with telerehabilitation system
16249063|NCT05031403|Other|Stroke (Home Exercise)|Exercise therapy with brochure
16249064|NCT05031403|Experimental|Multiple Sclerosis (Telerehabilitation)|Exercise therapy with telerehabilitation system
16249065|NCT05031403|Other|Multiple Sclerosis (Home Exercise)|Exercise therapy with brochure
16249066|NCT05031403|Experimental|Parkinson Disease (Telerehabilitation)|Exercise therapy with telerehabilitation system
16249067|NCT05031403|Other|Parkinson Disease (Home Exercise)|Exercise therapy with brochure
16249068|NCT05031390|Experimental|Physiotherapist-led training|Physiotherapy-led training of patients with FAIS
16259268|NCT04961476||GrM1|GrM1 - with 1-MNA supplementation
16249071|NCT05031364|Experimental|Consultation-Based Training on BIACA|Community mental health clinicians will be given online one-on-one training and consultation in the BIACA (Behavioral Interventions for Anxiety in Children with Autism; e.g., Wood et al., 2020) CBT program. Clinicians will be provided with weekly 30-minute video-conference-based consultation sessions with an expert in BIACA. These consultation sessions are manual-driven and utilize a Practice-Based Coaching format, in which a trained consultant meets weekly with clinicians to provide practice-based feedback (cf. McLeod et al., 2018). Consultation meetings include agenda setting, case material review, planning for the next treatment session, and a meeting summary. Relevant online training materials (e.g., demonstration videos of CBT sessions; corresponding written session materials) developed in the context of a NIMH R34 grant available on meya.ucla.edu (1R34MH110591) will also be provided to clinicians for each upcoming therapy session.
16249072|NCT05031364|Active Comparator|Usual Care Augmented by Self-Instruction Resources for CBT for Autism|Community mental health clinicians in this arm will provide any therapy, counseling, and/or behavioral treatment procedures they deem appropriate for each participating child. Clinicians randomized to this arm will be given immediate access to CBT-for-autism self-instruction materials that are already freely available to any clinician at meya.ucla.edu (see Consultation-Based Training on BIACA arm, above), to supplement their usual clinical care, if they so choose, until they complete their Usual Care/Self-Instruction participation and are offered direct training and weekly consultation in BIACA.
16249073|NCT05031351|Experimental|High dosage Withania somnifera|544mg oral twice a day
16249074|NCT05031351|Experimental|Medium dosage Withania somnifera|272mg oral twice a day
16249075|NCT05031351|Placebo Comparator|Placebo|Matched capsules twice a day
16249076|NCT05031338||SX-One MicroKnife with ultrasound guidance|Carpal Tunnel Release using the SX-One MicroKnife with ultrasound guidance
16249077|NCT05031338||Traditional mini-open technique without ultrasound guidance|Carpal Tunnel Release using the traditional mini-open technique without ultrasound guidance
16249078|NCT05031325|Experimental|Endoscopic submucosal dissection with Purastat|To compare of the risk of bleeding after endoscopic submucosal dissection, after ESD, application of Purastat gel (not a drug but a device with CE mark) with a catheter of a gel on the resected area to cover the whole surface of mucosal resection.
16249079|NCT05031325|No Intervention|Comparative arm without Purastat|After endoscopic submucosal dissection (ESD) and hemostasis, if the patient is randomized in the comparative group, no gel will be applied on the resected area that will remain like this without intervention (common practice)
16249080|NCT05031312|Active Comparator|inferior oblique anterior nasal transposition|Group A for inferior oblique anterior nasal transposition 2mmx2mm posterior and nasal to inferior rectus insertion to control vertical deviation especially large angle vertical deviation and V pattern with more potent postoperative effect in unilateral and bilateral cases
16249081|NCT05031312|Active Comparator|inferior oblique myectomy|Group B for inferior oblique myectomy to control vertical deviation but not of large angle which lead to residual inferior oblique overaction
16249082|NCT05031299|Active Comparator|Control group (Standard care)|Participants in the control group will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors for 3 months.
16249083|NCT05031299|Experimental|Intervention group 1 (Application)|Participants will will be additionally provided with a health-promotion application for self-management for 3 months.
16249084|NCT05031299|Experimental|Intervention group 2 (Devices)|"Participants will be additionally provided with wearables and devices for 3 months including:
~A weighing scale (assessing also body composition) device
~A smartwatch/wristband to assess physical activity but also sleep pattern."
16249085|NCT05031286|Experimental|Experimental Arm|
16249086|NCT05031273|Experimental|Residents moving into a congregate-living development with more features that support healthy living|Residents moving into a congregate-living development designed for older adults with more design and amenities features in the building, site, and/or neighbourhood that support physical activity, healthy eating, and social connections.
16249087|NCT05031273|No Intervention|Residents living in a standard congregate-living development|Residents living in a standard community-based congregate-living development designed for older adults.
16249088|NCT05031260|No Intervention|Control group|The individuals in the control group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum.
16249089|NCT05031260|Experimental|Experimental group|The individuals in this group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum. Instead, they will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
16249090|NCT05031247|Experimental|Community Navigator Social Support|More intensive case management and weekly check-ins with older adults. The Community Navigator will be focused on increasing social contact and connection for older adult refugees and immigrants. Those who receive the intervention will be offered up to ten (30-minute-long) meetings with a Community Navigator and access to up to three group sessions over a 3-month period, alongside the standard services they receive for enrollment with the organization.
16249091|NCT05031247|No Intervention|Program Support as Usual|Standard program support will be provided to participants enrolled. These services are offered to all enrolled in the program and may include, but is not limited to the following: financial assistance services, case management, healthcare access services, employment and tax services, education services, citizenship and immigration services, community services and civic engagement, and refugee services.
16249092|NCT05031234|Active Comparator|Group with morphine|conventional general anaesthesia with morphine
16249093|NCT05031234|Experimental|Group without opiates|general anaesthesia without opiates
16249094|NCT05031221|Experimental|Yoga + behavioral weight loss|In person and virtual yoga + 150 minutes of moderate-to-vigorous physical activity/week + weekly instruction on dietary strategies for weight loss
16249095|NCT05031208|Experimental|Vagus nerve stimulation|Invasive vagus nerve stimulation
16249096|NCT05031208|Experimental|Transcutaneous vagus nerve stimulation|Cymba concha stimulation
16249097|NCT05031208|Sham Comparator|Sham vagus nerve stimulation|No vagus nerve stimulation
16249098|NCT05031195||1st tertile|
16249103|NCT05031169|Experimental|A-PRF|Surgical treatment A-PRF membrane
16249104|NCT05031169|Active Comparator|SCTG|Surgical treatment with SCTG
16249105|NCT05031156|Active Comparator|non-splinting of OT Bridge system|Leaving the dental implants abutments solitary followed by denture pick up
16249106|NCT05031156|Experimental|splinting of OT Bridge|Splinting of implants abutments using titanium wire then followed by denture pick up
16249107|NCT05031143|Active Comparator|SCTA injection (n=6 eyes)|Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.
16249108|NCT05031143|No Intervention|Non-injected eyes (Standard Treatment) (n=6 eyes)|Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months
16249109|NCT05031130|No Intervention|Control Group|For the control group, the researcher will provide routine care to pregnant adolescents.
16249110|NCT05031130|Experimental|Experimental group|For the experimental group, the researcher will provide the empowered program integrated with family support plus routine care.
16249111|NCT05031117|Experimental|Conventional Epidural Technique|
16249112|NCT05031117|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
16249113|NCT05031104|Active Comparator|Control group|Patients in this group undergone a standard exercise program.
16249114|NCT05031104|Experimental|LLT group|Patients in this group undergone a standard exercise program as the control group in addition to the LLT.
16249115|NCT05031091||Case: patients with confirmed leprosy|diagnosed or followed up in French Guiana between the beginning of 2006 and the end of 2022
16249116|NCT05031091||Control: patient with a dermatological condition not clinically suspicious of leprosy|Any patient, of any age, consulting for a dermatological pathology not clinically suspicious of leprosy during a dermatological consultation by a practitioner of the Cayenne Hospital
16249117|NCT05031078|Experimental|Group 1: Lymph node sampling at D-30, D14 and D30|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.
~Group 1 will have lymph node sampling done D-30, D14 and D30 after the first dose.
~Bone marrow sampling will be done for all groups at D730."
16249118|NCT05031078|Experimental|Group 2: Lymph node sampling at D-30, D74 and D90|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.
~Group 2 will have lymph node sampling doneD-30, D74 and D90. Bone marrow sampling will be done for all groups at D730."
16249119|NCT05031078|Experimental|Group 3: Lymph node sampling at D-30, D194 and D210|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.
~Group 3 will have lymph node sampling D-30, D194 and D210. Bone marrow sampling will be done for all groups at D730."
16249120|NCT05031065||Women undergoing radiation treatment after lumpectomy for breast cancer.|There is no specific study intervention being used. Samples will be collected from participants undergoing standard of care radiotherapy at pre-specified timepoints.
16249121|NCT05031052|Experimental|Normothermic machine perfusion (NMP)|End-ischemic NMP will be performed immediately after arrival of the allocated and static cold stored ECD kidney graft. The study protocol aims a duration of 4 hours. Machine perfusion will be performed with a combination of patient's blood group matched packed red blood cells (RBC) and a special manufactured solution with the currently only certified device in Europe (XVIVO - KidneyAssist®). After 4 hours of perfusion and viability assessment, the kidney allograft will be disconnected from the device immediately prior to transplantation and flushed with three litres of Custodiol HTK solution via the renal artery. Then transplantation will be performed in typical method.
16249122|NCT05031052|Active Comparator|Statical cold storage (SCS)|Conventional method kidney transplantation of statical cold stored and transported ECD kidney allograft. The allocated kidney allograft will be flushed with Custodiol HTK solution during back table preparation with the aim of immediate implantation into recipient.
16249123|NCT05031039||Female Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians females that have unilateral or bilateral cleft lip and palate deformity
16249124|NCT05031039||Male Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians males that have unilateral or bilateral cleft lip and palate deformity
16249125|NCT05031026|Active Comparator|donor group|where donors only will receive dexmedetomidine
16249126|NCT05031026|Active Comparator|recpient group|where recepients only will receive dexmedetomidine
16249127|NCT05031026|Placebo Comparator|control group|both donors and recipients will receive a placebo
16249128|NCT05031013||Dialysis patients|Dialysis patients
16249129|NCT05031000|Experimental|Subject POCT glucometer measurement|Blood glucose measurement POCT glucometer
16249130|NCT05030987|Experimental|RDN|Renal Denervation
16249131|NCT05030987|Sham Comparator|Sham|Sham Procedure
16249132|NCT05030974|Active Comparator|stratum A1 - 3rd dose of mRNA-1273|Patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
16249133|NCT05030974|Active Comparator|stratum A2 - 3rd dose of mRNA-1273 with discontinuation of MMF/MPA|patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the 3rd dose
16249134|NCT05030974|Active Comparator|stratum B1 - 3rd dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
16249135|NCT05030974|Active Comparator|statum B2 - 3rd double dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms
16249136|NCT05030974|Active Comparator|stratum B3 - Ad26.COV2.S vaccine|patients treated with any combination of immunosuppressive drugs, receiving a 3rd COVID vaccination with Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)
16249137|NCT05030961|Experimental|Pediatric Cochlear Implant Candidate Group|Participants who are in the process of receiving standard of care cochlear implant evaluation. Participants will receive a virtual team-based clinic as a part of the candidacy evaluation process for one year.
16249138|NCT05030961|Experimental|Established Cochlear Implant Recipient Group|Participants who are established cochlear implant recipients. Participants will receive a virtual team-based clinic, including remote cochlear implant programming, for one year.
16249139|NCT05030948|Experimental|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. They will take place at community partner sites during times when all participants can attend. In case of adverse weather, indoor locations are available through community partners. Walks will reflect participant goals and abilities, initially lasting 10 minutes, with 5-minute stretching warm-up and 5-minute cool down exercises, for a total of 20 minutes. Walk duration will increase by 5 minutes/week to at least 30 minutes with program content delivery time decreasing to accommodate increased walk times within the 1-hour session. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
16249140|NCT05030948|No Intervention|Attention Control|"If assigned to this group, participants will take part in 1-hour group (5-6 participants) sessions delivered twice a week for 3 months. The sessions will be with a trained Community Health Worker or qualified staff that will involve reviewing education topics in Spanish related to adult health. They will take place at community partner sites or remotely during times when all participants can attend. In case of adverse weather, indoor locations, or remote options will be available. Upon completing the 3 months of education sessions, for the next 3 months, they will receive educational booster sessions delivered every other week via phone calls/text messaging."
16249141|NCT05030935|Experimental|Intervention Group|This group will be able to use the mHealth App.
16249142|NCT05030935|No Intervention|Control group|The Instructions Manual consists of a hard copy of the mHealth App bibliographical content. In addition, a calendar that can be used as a reminder for patient position switching is present and a hard copy explanation of the scale which can be used by the caregiver and through handwriting, determine the need for support surfaces.
16249143|NCT05030922|Experimental|Diet intervention|Follow up of both mother and offspring 20 years after allocation to an antiatherogenic diet during pregnancy.
16249144|NCT05030922|No Intervention|Control|Follow up of both mother and offspring 20 years after allocation to control group during pregnancy.
16249145|NCT05030909|Experimental|transdiagnostic group protocol|The study will run two gender-specific treatment groups (8 participants each) recruited from the community, with one individual session (for information, consent and initial data collection) and 5 group sessions. Both groups will receive the same intervention.
16249146|NCT05030896|Experimental|Experimental group|Participants will receive EPM and they will perform exercise program during 1 month.
16249147|NCT05030896|Experimental|Control group|Participants will receive needling puncture and they will perform exercise program during 1 month.
16249148|NCT05030883|Experimental|unreliable source|In this condition participants receive a news message from an unreliable source
16249149|NCT05030883|Experimental|reliable source|In this condition participants receive a news message from an reliable source
16249150|NCT05030883|Experimental|no source|In this condition participants receive a news message without a source
16249151|NCT05030870|Experimental|Capnographic monitoring group|In this group, in addition to the standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients, the capnographic is also monitored. The capnographic data of the patients are available for additional noninvasive assessment of ventilation.
16249152|NCT05030870|Active Comparator|Standard monitoring group|In this group, standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients. Capnographic data are not visible by closing the CO2 sampling line till the endoscopy end.
16249153|NCT05030857|Experimental|GLPG4716 and Midazolam|
16249156|NCT05030831|Experimental|INZ-701|The study design is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.
16249157|NCT05030818|Experimental|Polypill|Patients will be receiving the polypill at the adequate doses during 3 months
16249158|NCT05030818|Active Comparator|Drugs taken separately|Patients will be receiving during 3 months the same components and at the same doses than with the polypill
16249161|NCT05030779|Experimental|Treatment of SLE|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
16249162|NCT05030766|Experimental|MT plus NRT Group|Participants who receive the Mindfulness Training (MT) intervention for 4 weeks in addition to 6 weeks of Nicotine Replacement Therapy (NRT).These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
16249163|NCT05030766|Experimental|CM plus NRT Group|Participants who receive the Contingency Management (CM) intervention for 4 weeks in addition to 6 weeks of NRT. These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
16249164|NCT05030766|Experimental|MT plus NRT with additional CM Group|Participants who received the MT intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional CM intervention for another 4 weeks.
16249669|NCT05027269|Experimental|Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2-4|AOC 1001 will be administered three times.
16249165|NCT05030766|Experimental|CM plus NRT with additional MT Group|Participants who received the CM intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional MT intervention for another 4 weeks.
16249166|NCT05030753|Experimental|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
16249167|NCT05030753|Active Comparator|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
16249168|NCT05030727|Other|Evaluation of intraoperative NGAL levels in terms of acute kidney injury in geriatric patients|only one group
16249169|NCT05030714|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.
16249170|NCT05030701||cancerous patients|
16249171|NCT05030701||non cancerous patients|
16249172|NCT05030688|Active Comparator|Group FICB = Fascia iliaca compartment block|FICB will be performed with a suprainguinal approach under US guidance. The probe will be placed sagittally to view the ilium and iliacus muscle. The probe will be moved medially and inferiorly along the inguinal ligament to view the femoral artery. The probe will then be moved superiorly and laterally along the inguinal ligament towards the anterior superior iliac crest to reach the lateral aspect of the femoral nerve. The deep circumflex artery will be visualized 1-2 cm cephalad to the inguinal ligament and superficial to the iliac fascia. The needle will be inserted with in-plane method 2-4 cm caudal to the inguinal ligament to reach below the fascia ilica. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
16249173|NCT05030688|Active Comparator|Group PENG|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
16249174|NCT05030675|Experimental|Treatment (fostamatinib)|Patients receive fostamatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles (week 24) in the absence of disease progression or unacceptable toxicity.
16249175|NCT05030662|Experimental|Experimental:Walking stick exercise|"The experimental:Walking stick exercise
~Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)
~The video clip of walking stick exercise is available to the patients.
~The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
16249176|NCT05030662|No Intervention|Control group: conventional physical therapy.|"Perform bed mobility and transfers with the least amount of assistance while maintaining appropriate weight bearing (WB) precautions.
~Ambulate with an assistive device for 25-100 feet and ascend/descend stairs to allow for independence with household activities while maintaining appropriate WB.
~Verbalize understanding of post-operative activity recommendations/precautions including use of proper positioning of the lower extremity, range of motion and strengthening exercises."
16249177|NCT05030649|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
16249178|NCT05030649|Active Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
16249179|NCT05030636|Experimental|EX starts at 9:30 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 9:30 am.
16249180|NCT05030636|Experimental|EX starts at 11:00 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 11:00 am.
16249181|NCT05030636|No Intervention|No EX|Control condition. A choice of 30 minutes sedentary activities.
16249182|NCT05030623|Experimental|Tadalafil|
16249183|NCT05030623|Placebo Comparator|Placebo|
16249184|NCT05030610|Experimental|Intervention Group|Participants, along with a support person, will complete 12 weekly sessions of the BeatIt-ASD intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
16249185|NCT05030597|Experimental|68Ga-DOTA-FAPI and 18F-FDG PET/CT|Investigators recruit patients whom are clinically highly suspected oral cancer or recurrence after treatment. Patients undergo 68Ga-DOTA-FAPI and 18F-FDG PET/CT imaging within one week.
16249186|NCT05030584|Active Comparator|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
16249187|NCT05030584|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
16249188|NCT05030571|Experimental|Intervention|Intervention group will receive DPMAS extracorporeal treatment one session per day for 3 consecutive days plus standard therapy. We plan to use blood flow rate of 100-120 ml/hour with filtration fraction for plasma separation of 25-30%. DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China) We do not use any anticoagulant.
16249189|NCT05030571|Active Comparator|Standard care|Standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017
16249213|NCT05030389|Active Comparator|Health Education program (HE)|Participants receive a web-based health education program (HE) during 14 weeks, on the basis of one at-home session a week
16249190|NCT05030558|Experimental|Interventional group|The web-supported interactive nursing program intervention will last 4 weeks. In the first week of the training, the identity and causes of the disease, which is one of the sub-dimensions of the perception of illness, will be emphasized, and the themes of misperception determined in this field through qualitative study will be emphasized. In the second week, they will be asked to look at training sessions that discuss perceptions of the illness's timeline and consequences. In the last two weeks of the training, they will be asked to attend the trainings for the control of Fibromyalgia symptoms. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times). Data collection forms will be applied to the intervention group 3 times before starting the web-based interactive nurse program, at the end of the program (in the 1st month) and then at the end of the 2nd month.
16249191|NCT05030558|Active Comparator|Control Group|"The Fibromyalgia patient booklet of the Turkish Physical Medicine and Rehabilitation Association will be available in pdf format on the website of the participants assigned to the control group. Participants in this group will be able to access other trainings after the end of the study, if they wish.
~Data collection forms will be applied to the control group 3 times in total, before the start of the study, in the 1st month and the 2nd month of the study."
16249192|NCT05030545|Experimental|Eplerenone Treatment|Eplerenone (50-100mg daily, as tolerated by blood pressure and potassium) for 6 months
16249193|NCT05030532|Experimental|EVERYbody Project: Expert facilitator version|"This gender inclusive, dissonance-based body image program was created from focus group feedback. Based on the Body Project, the program retains key dissonance activities while expanding the inclusivity focus (e.g., expanding the gender focus, exploring diversity within appearance ideals, critically discussing the impact of limited diversity representation in cultural appearance norms).
~Around 10% of content from the previous trial was modified to form the current intervention. Changes focused on enhancing diversity-focused content. College students with body image content interest completed two days (16 hours) of training on the program manual, group management, and conducting inclusive conversations. Post training, students self-assessed their facilitation readiness and were evaluated by two trainers on facilitation expertise. Peer leaders with sufficient expertise were invited to facilitate EVERYbody Project groups."
16249194|NCT05030532|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists, and (2) The Mask You Live In. Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.
~Peer facilitators received brief (1 hour) training on the video group manual."
16249195|NCT05030506|Experimental|Belzutifan + Lenvatinib|Participants will receive a daily oral dose of 120 mg of belzutifan monotherapy for 3 weeks, followed by a combination of a daily oral dose of 120 mg of belzutifan with a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
16249196|NCT05030506|Experimental|Belzutifan + Lenvatinib + Pembrolizumab|Participants will receive an intravenous dose of 400 mg of pembrolizumab once every six weeks for up to 18 infusions (up to 2 years) in combination with a daily oral dose of 120 mg of belzutifan and a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
16249197|NCT05030493||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
16249198|NCT05030493||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg mFOLFOX6 + bevacizumab combination therapy, once every two weeks
16249199|NCT05030480||Chronic kidney disease|eGFR values of less than 60 mL/min/1.73 m2
16249200|NCT05030480||Non-Chronic kidney disease|eGFR values more than 60 mL/min/1.73 m2
16249201|NCT05030467|Experimental|Intervention Arm|Providers within the clinics randomized to the intervention arm will receive a variety of EHR-based tools for eligible patients with uncontrolled hypertension.
16249202|NCT05030467|No Intervention|Control Arm|Providers within the clinics randomized to usual care will receive no EHR tools, except those currently available in clinical practice.
16249204|NCT05030441|Experimental|Ivosidenib|-Ivosidenib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg daily for up to 18 months (approximately 20 28-day cycles), with each cycle being 28 days.
16249205|NCT05030428|Experimental|Inclisiran sodium|Subcutaneous injection
16249206|NCT05030428|Placebo Comparator|Placebo|Subcutaneous injection
16249207|NCT05030415|Experimental|Ixekizumab|ixekizumab 80 mg injection, 160 mgs injected subcutaneously on week 0, 80 mgs injected subcutaneously every two weeks
16249208|NCT05030402|Experimental|Maitland group|44 patients receives tens, SW, Maitland, and exercises. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
16249209|NCT05030402|Active Comparator|Control group|44 receives tens, SW, conventional physiotherapy and exercises as treatment. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
16249210|NCT05030389|Experimental|Adapted Physical Activity (APA)|Participants receive a web-based adapted physical activity (APA) during 12 weeks, on the basis of three at-home sessions a week
16249211|NCT05030389|Experimental|Adapted Physical Activity + Bright Light Exposure (APA + BLE)|Participants receive a web-based APA program during 12 weeks on the basis of three at-home sessions a week, supplemented by a bright light exposure (BLE) during 12 weeks, on the basis of five at-home sessions a week
16249212|NCT05030389|Experimental|Galvanic Vestibular Stimulation (GVS)|Participants receive Galvanic Vestibular Stimulation (GVS) during two weeks, on the basis of five at-home sessions a week
16260739|NCT04950907|Active Comparator|control|CT-guided fine needle biopsy
16249216|NCT05030363|Experimental|Upfront ALDH enzyme supplement|Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal. Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
16249217|NCT05030363|Other|Delayed ALDH enzyme supplement|Delayed ALDH enzyme supplement; patients will not take ALDH enzyme supplement during chemotherapy after randomization on day 1 to day 14 (period 1). On day 15, Patients will visit for subsequent chemotherapy and start ALDH enzyme supplement twice a day for 14 consecutive days during chemotherapy (period 2; day 15 to day 29).
16249218|NCT05030350|Experimental|PH94B 3.2 micrograms|100 microliter nasal spray to each nostril up to four times a day as needed for acute anxiety
16249219|NCT05030337|No Intervention|Manual oxygen control|Standard ventilation with inspired oxygen concentration adjusted manually as per unit's protocol.
16249220|NCT05030337|Other|Closed-loop automated oxygen control|Ventilation with Oxygenie software (closed-loop automated oxygen control system), adjusted by clinical staff as necessary
16249221|NCT05030324|Experimental|XC221 100 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally in the morning (between 7:00 and 11:00) and 1 tablet of placebo in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
16249222|NCT05030324|Experimental|XC221 200 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally twice daily, in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
16249223|NCT05030324|Placebo Comparator|Placebo|Subjects will receive 1 tablet of placebo orally twice daily in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
16249224|NCT05030311|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
16249225|NCT05030311|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
16249226|NCT05030298|Experimental|Cohort A (stereotactic biopsy, radiosurgery, surgery)|Patients undergo MRI-guided stereotactic biopsy. Patients then undergo radiosurgery over 1 fraction. Within 14 days, patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
16249227|NCT05030298|Active Comparator|Cohort B (surgery, radiation therapy, chemotherapy)|Patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
16249228|NCT05030285|Experimental|Intervention|People who are randomised into the intervention arm will undergo 6 weekly psychotherapy sessions
16249229|NCT05030285|No Intervention|Control|People who are randomised into the control arm will undergo usual care
16249232|NCT05030259||patients with fasciotomy|
16249233|NCT05030259||patients without fasciotomy|
16249234|NCT05030246|Experimental|Surufatinib 250mg/Toripalimab 240mg|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody（Toripalimab） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
16249235|NCT05030233|Experimental|Nurse-Administered Touch Intervention|Preterm infants will receive the nurse-administered touch intervention during one episode of essential nursing care.
16249236|NCT05030233|No Intervention|Standard Care|Preterm infants will receive one episode of essential nursing care delivered as standard care.
16249237|NCT05030220||Phase 1|51 subjects with serum levels of testosterone, free testosterone, and sex hormone binding globulin as well as the SpCuV from the cultures obtained in clinic, immediately pre-operative skin cultures, and incised wound cultures.
16249238|NCT05030220||Phase 2|Subjects enrolled to help determine if preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty and if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.
16249240|NCT05030194|Experimental|Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes|Participants will use each product for up to a 30 minute interval But will also be permitted to stop use before the end of the 30-minute ad lib use period
16249241|NCT05030194|Experimental|Order 2 - Electronic Cigarettes and Oral Nicotine product|Participants will use each prodcut for up to 30 minutes but will also be permitted to stop use before the end of the 30-minute ad lib use period
16249242|NCT05030181|Active Comparator|kinesiotaping and exercise|'I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
16249243|NCT05030181|Active Comparator|exercise|1-month home exercise program.
16249244|NCT05030168|No Intervention|Placebo|Twice weekly hemodialysis program plus regular protein diet (1.0 g/kg/day) every day
16249665|NCT05027295|Active Comparator|Pulsed UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of pulsed UVA light for 15 minute exposure time
16249245|NCT05030168|Experimental|Ketosteril|Incremental hemodialysis program, starting from once weekly hemodialysis/hemodialysis filtration(HDF) plus low protein diet (0.6 g/kg/day) and ketoanologues 0.12g/kg/day supplementation on non-dialysis days and regular protein diet (1.0-1.2 g/kg/day) on dialysis day
16249246|NCT05030155|Experimental|Patients with FFS=0 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336
16249247|NCT05030155|Placebo Comparator|Patients with FFS=0 - Placebo|Placebo of Mepolizumab every 4 weeks until D336
16249248|NCT05030155|Experimental|Patients with FFS≥1 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336 and placebo of Azathioprine 1mg/kg/day from D126 until D360 and placebo of cyclophosphamide/mesna at D1, D15, D28, D56, D84 and D112
16249249|NCT05030155|Placebo Comparator|Patients with FFS≥1 - Placebo|Placebo of Mepolizumab every 4 weeks until D336, cyclophosphamide and mesna at D1, D15, D28, D56, D84 and D112 and Azathioprine 1mg/kg/day from D126 until D360
16249250|NCT05030142|Experimental|Mechanical thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
16249251|NCT05030142|Active Comparator|Active Comparator|Best medical treatment alone (usual care)
16249252|NCT05030129|Experimental|Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP)|Ergoloid mesylates (EM) 1 mg three times daily and 5-hydroxytryptophan (5-HTP) 100 mg three times daily for 4 weeks
16249253|NCT05030129|Placebo Comparator|Placebo|2 placebo capsules three times daily for 4 weeks
16249254|NCT05030129|Experimental|Ergoloid mesylates (EM) and placebo|Ergoloid mesylates (EM) 1 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
16249255|NCT05030129|Experimental|5-hydroxytryptophan (5-HTP) and placebo|5-hydroxytryptophan (5-HTP) 100 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
16249256|NCT05030116|Experimental|Experimental group|
16249257|NCT05030116|Active Comparator|Control Group|
16249258|NCT05030103|Active Comparator|Glasses|The participants are asked to wear reading glasses during near-work. The reading glasses have a lenspower of +2.0 diopters.
16249259|NCT05030103|No Intervention|Control|Age matched children and adolescents, no intervention.
16249260|NCT05030090|Active Comparator|Control group|"Consulted by the dietitian using communication software (Line) or telephone.
~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.
~The nutrition care plan period will be three months."
16249261|NCT05030090|Experimental|Nutrition care plan group A|"Consulted by the dietitian using communication software (Line) or telephone.
~Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement
~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.
~3.The nutrition care plan period will be three months."
16249262|NCT05030090|Experimental|Nutrition care plan group B|"Consulted by the dietitian using communication software (Line) or telephone.
~Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement and powdered supplement 1 and nutritional products and powdered supplement 2
~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.
~The nutrition care plan period will be three months."
16249263|NCT05030064|Experimental|Intestinal flora capsule(FMT)|The group includes 27patients.They will receive 16 capsules of intestinal bacteria each time, once a week, 4 times in a row.Each capsule contains 200mg of fecal bacteria.
16249264|NCT05030064|Placebo Comparator|Placebo group|The group includes 27patients.They will receive 16 Placebo capsules each time, once a week, 4 times in a row.
16249265|NCT05030051|Experimental|SkinPen Precision System|This proof of concept study is being conducted over the course of 60 days followed by a 3-month post-treatment visit to assess the efficacy and tolerability of the Sponsor's SkinPen device when used to treat men and women with signs of aging on the dorsum of the hands. Overall assessment of clinical outcome and safety will be based on the evaluation of pre- and post-treatment photos comparing baseline to final visit. The subject's assessment of satisfaction will also be evaluated at Visit 3 and Visit 4. Finally, both the clinician's and subject's assessment will be characterized using a clinician assessment scale at the 3 month post-treatment visit.
16249267|NCT05030025|Experimental|Test|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets,60mg/5 mg/30 mg
16249268|NCT05030025|Experimental|Reference|Triumeq Dispersible Tablets, 5 mg/60 mg/30 mg
16249269|NCT05030012|Experimental|Automated Control (OAM)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
16249270|NCT05030012|Active Comparator|Manual Control (Manual)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.
16249271|NCT05029999|Experimental|Cohort A|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.
~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.
~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
16249272|NCT05029999|Experimental|Cohort B|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle starting on cycle 2 until toxicity or progression.
~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.
~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
16249273|NCT05029999|Experimental|Cohort C|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.
~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle starting on cycle 2 until toxicity or progression for up to 24 months.
~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 2 and 3 only."
16249666|NCT05027282|Experimental|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces|
16249274|NCT05029986|Experimental|All participants|This is a single-arm trial. All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks). Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
16249275|NCT05029973|Experimental|Treatment Group|HAIC Combined With Sintilimab and Bevacizumab Biosimilar
16249276|NCT05029960|Experimental|Experimental|Brivaracetam at a dose of 50 mg twice daily for 6 months
16249277|NCT05029934|Active Comparator|EndoClot group|patients who are being provided with EndoClot adhesive spray after polyp resection
16249278|NCT05029934|Sham Comparator|Conrol group|no further prophylactic bleeding prevention after polyp resection
16249280|NCT05029908||TMD disorders|"75 patients with temporomandibular disorder (TMD) who will apply to the outpatient clinic of Istanbul Physical Therapy and Rehabilitation Training and Research Hospital will be included in our study. Ethics Committee approval was obtained from Bakırköy Sadi Konuk Training and Research Hospital before starting the study and a voluntary consent form will be signed by the patients before the evaluation.
~In this cross-sectional study; 75 participants aged 18-65 years who has temporomandibular joint (TMJ) complaints for more than 3 months and has the cognitive ability to understand test instructions will be included. Patients with a history of previous TMJ operation, muscle, neurological or rheumatic disease that may affect TMJ, and a history of facial/cervical trauma or neoplasia will excluded from the study."
16249285|NCT05029856|Experimental|Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
16249286|NCT05029856|Experimental|Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
16249287|NCT05029856|Experimental|Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
16249288|NCT05029856|Experimental|Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 5 μg SII B.1.351 Vaccine + 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
16249289|NCT05029856|Experimental|Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 6 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
16249290|NCT05029856|Experimental|Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 10 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
16249291|NCT05029856|Experimental|Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
16249292|NCT05029856|Experimental|Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|1 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose on Days 0.
16249293|NCT05029804|Experimental|Intervention Group|"After the initial assessment, patients in this group will be educated by the researcher on walking exercise by using the transtheoritical model. The data will be collected from the patients in the experimental group at baseline, 1st, 3rd, and 6th months of the programme.
~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains include questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
16249294|NCT05029804|No Intervention|Control|"No intervention will be applied to this group. The data will be collected from the patients in the control group at baseline, 1st, 3rd, and 6th months.
~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains included questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
16249295|NCT05029791|Other|Metastatic melanoma|Patients with stage III or IV melanoma eligible for an immunotherapy or targeted therapy
16249296|NCT05029778|Experimental|Experimental L-arginine 3 g and L-citruline 2 g|Drug: L-arginine 3g and L-citruline 2g, Food supplement, PO , for 24 h, until birth
16249297|NCT05029778|Experimental|placebo|Placebo 3g ( starch ) PO for 24 h. until birth
16249298|NCT05029765|Placebo Comparator|Healthy diet Arm|Healthy diet (WHO recommendations) + placebo
16249299|NCT05029765|Placebo Comparator|Mediterranean diet Arm|Mediterranean diet + placebo
16249300|NCT05029765|Active Comparator|"Mediterranean diet plus Arm"|Mediterranean diet + Biopolis-MIX42 (1 capsule per day containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium long).
16249301|NCT05029752|Other|Vendys II Device|Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device
16249302|NCT05029739|Experimental|E-intervention group|Participants will be instructed to download a life-style-changing mobile app to which they will have access for 12 weeks. After the first week of the program, participants who smoke will be offered to incorporate smoking cessation support into their PAD program. These changes are minor and not intended to divide the intervention group in two but instead to personalize the study experience. The program aims to empower positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
16249303|NCT05029739|Active Comparator|Standard of care - control group.|All patients in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, smoking cessation advise and advise on modifiable risk factors. The control arm will also receive an information leaflet about relevant lifestyle modifications for PAD. After the baseline measurements and data collection, there will be no scheduled visits to a health care provider until week 12.
16249304|NCT05029726|Experimental|Investigational|Patients will undergo regional ESPB with bupivacaine plus clonidine in the holding area of the OR immediately prior to surgery. 30mL of 0.25% bupivacaine/1:200,000 epinephrine/50mcg clonidine will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
16249305|NCT05029726|Placebo Comparator|Control|Patients will receive a placebo injection of normal saline via the same ESPB technique. 30ml of normal saline will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
16249306|NCT05029713||liver transplanted patients without sarcopenic obesity (controls)|All liver transplanted patients followed as outpatients at out clinic, which lack at least one of the two conditions (muscle strenght and muscle mass) used to identify sarcopenic obesity.
16249307|NCT05029713||liver transplanted patients with sarcopenic obesity (cases)|All liver transplanted patients followed as outpatients at out clinic, with both muscle strenght and muscle mass.
16249308|NCT05029700|Experimental|Combined exercise group|Combined training consists of trunk stabilization training and aerobic training.
16249309|NCT05029700|Active Comparator|Control group|Aerobic training was given to the control group.
16249312|NCT05029661||No intervention|No intervention
16249313|NCT05029648||Cohort|Simple cohort
16249314|NCT05029635|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 300 mg HMPL-523 once daily for 24 weeks
16249315|NCT05029635|Placebo Comparator|placebo arm|Drug: Placebo HMPL-523 matching placebo will be oral administrated once daily for 24 weeks.
16249316|NCT05029622|Experimental|Triptorelin formulation for Intramuscular injection (IM).|
16249317|NCT05029609|Other|Group A|Group A will receive nasal Foralumab Dose 1 daily for 14 days (n=9) or placebo (n=3)
16249318|NCT05029609|Other|Group B|Group B will receive nasal Foralumab Dose 2 tiw for 14 days (n=9) or placebo (n=3)
16249319|NCT05029609|Other|Group C|Group C will receive nasal Foralumab Dose 3 daily for 14 days (n=9) or placebo (n=3)
16249320|NCT05029609|Other|Group D|Group D will receive nasal Foralumab Dose 4 daily for 14 days (n=9) or placebo (n=3)
16249321|NCT05029596|Active Comparator|Heparin Group|"Participants will receive the UTSW standard of of care for PICC line maintenance.
~All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws."
16249322|NCT05029596|Experimental|Normal Saline Group|Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
16249323|NCT05029583|Experimental|routine screening group|consists of 4 clusters randomized into Group 1 (includes different clinic sites from Group 2)
16249324|NCT05029583|Active Comparator|physician-driven screening group|consists of 4 clusters randomized into Group 2 (includes different clinic sites from Group 1)
16249325|NCT05029570|Experimental|Conduction System Pacing and AV node ablation|Atrioventricular node ablation and subsequent conduction system pacing
16249326|NCT05029570|No Intervention|Medical treatment for rate control of AF|Pharmacological rate control based on clinical practice guidelines
16249327|NCT05029557|No Intervention|Control group patients|The patients in the Control Group will continue their routine procedures.
16249328|NCT05029557|Experimental|Education and telephone follow ups based on the Chronic Care Model|Intervention Group will be given training during their hospital stays (0 months) with the training booklet, which is prepared by the researcher based on the Chronic Care Model, and which includes information and suggestions about self-management strategies. The training will be organized in one single session and in the patient room, in a way not to exceed approximately 45-50 minutes. The dietitian and physiotherapist, who are the team members of the patients, will conduct interviews before the patients are discharged from the ward, and the information obtained will be registered in the hospital clinical information system. The patients, who will be included in the Intervention Group, will be followed up by phone every two weeks after their discharge. Also, reminders and informative information based on the training booklet will be sent to patients every week in the form of a short message.
16249329|NCT05029544|Active Comparator|intervention group 1|dynamic taping and standard rehabilitation program
16249330|NCT05029544|Active Comparator|intervention group 2|Kinesio taping and standard rehabilitation program
16249331|NCT05029544|Other|Control group|No taping on shoulder, only standard rehabilitation program
16249332|NCT05029531|Experimental|intervention/treatment|
16249333|NCT05029518|Experimental|Treatment A: SMP-100 dissolved in water administered under fasting conditions|12 subjects，For Treatment A, SMP-100 will be dissolved in a total of 240 mL of water and administered orally to each subjects, and a hand and mouth check will be performed to ensure consumption of the medication. Subjects will be required not to wear dentures or mouth piercing at the time of dosing. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
16249396|NCT05029102|Experimental|TAS-102 and Anlotinib|TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
16249334|NCT05029518|Experimental|Treatment B: SMP-100 tablets administered under fasting conditions|12 subjects，For Treatment B, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
16249335|NCT05029518|Experimental|Treatment C: SMP-100 tablets administered under fed conditions|"12 subjects，For Treatment C, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL.
~After a supervised fast of at least 10 hours, subjects will be served a high-fat, high-calorie meal of approximately 800 to 1000 calories (approximately 50% of total caloric content of the meal derived from fat). This test meal should derive approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. Subjects should start the meal approximately 30 minutes prior to drug administration. Subjects will be required to completely eat the meal in 30 minutes or less. No food will be allowed until at least 4 hours post-dose."
16249336|NCT05029492|Active Comparator|Diet group|Giving a low caloric diet
16249337|NCT05029492|Experimental|Visceral manipulation with diet group|Giving visceral manipulation added to a low-calorie diet
16249338|NCT05029479|Experimental|Yamakin TMR-Aquabond0|Novel Moisture Resistant, M-TEG-P Phosphate Monomer Based Universal Adhesive (YAMAKIN TMR-Aquabond0)
16249339|NCT05029479|Active Comparator|3m ESPE Single Bond Universal Adhesive|Conventional Universal Adhesive
16249342|NCT05029453|Experimental|Experimental Group|apatinib combine with chemotherapy. Apatinib: initial dose: 500mg,oral,once a day, after meal ( try to take the medicine at the same time each day) Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
16249343|NCT05029453|No Intervention|Control Gtoup|chemotherapy Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
16249344|NCT05029440|Experimental|Electromagnetic and Exercise Group|Pulsed Electromagnetic Field (PEMF) PEMF was administered to the whole body using a 1.8×0.6m mat Exercise Program Exercise program to facilitate bone health
16249345|NCT05029440|Active Comparator|Laser and Exercise Group|Pulsed High Intensity Laser Therapy (HILT) HILT was administered to lumbar region and femoral head using Exercise Program Exercise program to facilitate bone health
16249346|NCT05029440|Active Comparator|Exercise Group|Exercise Program Exercise program to facilitate bone health
16249351|NCT05029401|Experimental|Single dose IMP (DMX-1002)|"Stage 1 (open label): treatment at one of 4 ascending dose levels (3, 6, 9 or 12 mg/kg)
~Stage 2 (blinded): MTD/TTD established in Stage 1 vs placebo (proof of concept)"
16249352|NCT05029401|Placebo Comparator|Matching Placebo|Placebo using capsules identical to the IMP (DMX-1002)
16249353|NCT05029388|Experimental|Aerobic Exercise|This experimental group will receive aerobic exericse. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The aerobic exercise training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
16249354|NCT05029388|Experimental|High Intensity Interval Training|This experimental group will receive high intensity interval training. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The HIIT training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
16249355|NCT05029388|No Intervention|Control Group|This group will not take part in aerobic exercise and HIIT training programme. Participants will be given an exercise diary or logbook to keep track of their exercise habits (i.e., record the type of exercise/activity, hours, and intensity of exercise/activity every day) throughout the intervention periods.
16249356|NCT05029375|Experimental|immediate parental involvement|Parental involvement in training is parallel to children's training
16249357|NCT05029375|Experimental|delayed parental involvement|Parental involvement in training will be given at the end of the children's training
16249358|NCT05029362|Other|Beta testing group|
16249359|NCT05029349|Other|VOC analysis|VOC analysis in exhaled air in patients hospitalised for stable severe COPD
16249360|NCT05029336|Experimental|CD3/CD19 depleted ASCT|The test article is autologous stem cell transplant with a CD3/CD19-depleted stem cell product.
16249361|NCT05029323|Active Comparator|Conventional HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to conventional HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray."
16249362|NCT05029323|Experimental|Fast HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to fast HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray."
16249363|NCT05029310|Experimental|All patients use both patiromer and tacrolimus|Pharmacokinetic investigation of tacrolimus performed in bothe the presence and absence of patiromer for all patients.
16249364|NCT05029297|Experimental|CAPSAICIN 0.75 mg/g topical solution applicable in roll-on|CAPSAICIN 0.75 mg / g topical solution applicable in roll-on: 4 applications per day for 8 weeks.
16249365|NCT05029297|Active Comparator|CAPSAICIN 0.075% cream|CAPSAICIN 0.075% cream (ARAFARMADOL® 0.075% cream): 4 applications per day for 8 weeks.
16249366|NCT05029284|Experimental|teleABLE|Participants will complete 12 teleABLE sessions via videoconferencing, guided by an intervention therapist and participant workbook.
16249367|NCT05029271|Other|InPen with Guardian 4 System Arm|"All subjects will move from phase 1 to phase 4 of the study.
~Phase 1:
~Blinded Continuous Glucose Monitoring (CGM) will be utilized while subjects are on their current MDI therapy.
~Phase 2:
~All subjects will utilize a smart bolus insulin pen injector (InPen™) and app with dose calculator (InPen™ Diabetes Management App).
~Phase 3:
~Subjects will continue on the InPen and InPen App utilizing the HCP insights gained during the titration follow-up visit.
~Phase 4:
~All subjects will utilize the InPen™ with the Guardian™ 4 system."
16249368|NCT05029258||Locally advanced cervical cancer patients treated with standard of care chemoradiation|
16249369|NCT05029245|Experimental|Sinovac 2 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
16249370|NCT05029245|Active Comparator|Sinovac 2 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
16249371|NCT05029245|Experimental|Aztrazeneca 1 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
16249372|NCT05029245|Active Comparator|Aztrazeneca 1 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
16249373|NCT05029245|Experimental|Naive vaccine followed by Comirnaty® 6 microgram Intradermal|Patients who had no history SAR-CoV vaccine before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
16249374|NCT05029245|Active Comparator|Naive vaccine followed by Comirnaty® 30 microgram Intramuscular|Patients who had no history SAR-CoV vaccine before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
16249375|NCT05029245|Experimental|Any history of vaccination with Anti-RBD< 650AU/ml followed by Comirnaty® 6 microgram Intradermal|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
16249376|NCT05029245|Active Comparator|Any history of vaccination with Anti-RBD <650AU/ml followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
16249377|NCT05029232|Active Comparator|ambulant patient with DMD|patient that walk alone or with minor assist
16249378|NCT05029232|Active Comparator|non ambulant patient with DMD|patient need wheel chair
16249379|NCT05029219|Experimental|Virtual reality group|To become proficient in lumbar transforaminal epidural blocks, participants receive additional training using virtual reality programs after audiovisual education.
16249380|NCT05029219|Active Comparator|Self study group|In order to become proficient in lumbar transforaminal epidural block, participants have self-study time using books and videos after audiovisual education.
16249381|NCT05029193|Experimental|Stroke survivors - Mindfulness intervention|Participants who have had a stroke who are receiving the mindfulness intervention immediately after enrollment (no wait period).
16249382|NCT05029193|No Intervention|Stroke survivors - Waitlist control|Participants who have had a stroke who are assigned to the waitlist.
16249383|NCT05029193|Experimental|Caregivers - Mindfulness intervention|Participants caring for someone who have had a stroke and receiving the mindfulness intervention immediately after enrollment (no wait period).
16249384|NCT05029193|No Intervention|Caregivers - Waitlist control|Participants caring for someone who have had a stroke assigned to the waitlist.
16249385|NCT05029167|Active Comparator|Restrictive PaO2 and low normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
16249386|NCT05029167|Active Comparator|Restrictive PaO2 and high normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
16249387|NCT05029167|Active Comparator|Liberal PaO2 and low normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
16249388|NCT05029167|Active Comparator|Liberal PaO2 and high normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
16249389|NCT05029154|Experimental|Exercise|Patients in the exercise group will perform interval training 3 days per week.
16249390|NCT05029154|Placebo Comparator|Attention Control|Physical activity education and physical activity monitoring.
16249391|NCT05029141|Experimental|Chidamide+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.
16249392|NCT05029141|Placebo Comparator|Placebo+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group.
16249393|NCT05029128|Other|Exercise|All participants engage in exercise training
16249394|NCT05029115||SGLT-2 inhibitor administration group|The group who administrated SGLT-2 inhibitor for hypoglycemic medication
16249395|NCT05029115||control|The group who are not administrated SGLT-2 inhibitor
16249397|NCT05029089|Experimental|Experimental: Entire Papilla Preservation Modified Technique (EPPMT)|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated (subperiosteal tunnel). Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. Microsurgical suturing technique with 7-0 materials was performed. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
16249398|NCT05029089|Active Comparator|Entire Papilla Preservation Modified Technique + EMD|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. 24%EDTA was applied on the exposed root surface for 2 minutes, than rinsed and EMD was applied. Vertical incision was closed with simple single sutures(7-0),whereas due to modification of the original technique additional sling suture was applied.
16249399|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft|Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
16249400|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft+sCTG|Procedure: After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. sCTG taken form palate was sutured to the inner part of mucosa flap. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
16249401|NCT05029076|Experimental|Liraglutide injection + Victoza|Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
16249402|NCT05029076|Experimental|Victoza +Liraglutide injection|Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
16249403|NCT05029063|Experimental|Experimental|Rivaroxaban 10mg OD
16249404|NCT05029063|Placebo Comparator|Control|Identical Placebo 10mg OD
16249405|NCT05029050|Experimental|Dexmedetomidine (D)|Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
16249406|NCT05029050|Experimental|Clonidine (C)|Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
16249407|NCT05029050|Placebo Comparator|Placebo (P)|Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
16249408|NCT05029037|Experimental|Group A|80 patients randomized to group A will receive two doses (High) of vitamin C intravenously, twice a day for seven days.
16249409|NCT05029037|Placebo Comparator|Group B|80 patients assigned to group B will receive two doses of Dextrose 500 mL, twice a day for seven days.
16249410|NCT05029024|Active Comparator|Intervention group|Patients allocated to the intervention group received standard care plus a guided 30-minute mindful breathing session which consisted of four breathing exercises done consecutively in one-to-one manner. The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes. Guidance was given by one of the two research assistants, who were medical doctors. They were trained by one of the co-investigators, who was a palliative care physician, certified in mindfulness training.
16249411|NCT05029024|Placebo Comparator|Control group|Patients in the control group received standard care alone.
16249412|NCT05029011||Patients of the Sleep Disorders Laboratory|Monitoring vital signs
16249413|NCT05028998||Veterans with Opioid Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.
~Additionally, we will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews."
16249414|NCT05028998||Veterans with Alcohol Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.
~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
16251901|NCT05012007|Experimental|Text reminder|Standard reminder via text (VEText)
16249415|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.
~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
16249416|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.
~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
16249417|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Commercial Insurance Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.
~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
16249418|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Commercial Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.
~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
16249419|NCT05028998||Patients with Opioid Use Disorder receiving care outside of Veterans Health Administration|We will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews.
16249420|NCT05028998||Opioid Use Disorder Treatment Providers who provide treatment in the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
16249421|NCT05028998||Opioid Use Disorder Providers who treat outside the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
16249422|NCT05028998||Opioid Use Disorder Treatment and Policy Decision Makers|We will be recruiting 20 of these individuals to participate in our Aim 3 qualitative interviews.
16249423|NCT05028985||early COPD patients|younger than 50 years with 10 or more pack-years smoking history and any of these abnormalities: 1) early airflow limitation (post-bronchodilator forced expiratory volume in the first second(FEV1)/forced vital capacity(FVC) < lower limit of normal), 2) compatible CT abnormalities, 3) rapid decline in FEV1 (≥60 ml/yr).
16249424|NCT05028985||Healthy people|healthy without any disabling, physical, neurological, or mental disease and were excluded living in a nursing home.
16249425|NCT05028972|Experimental|Intervention: Personal Amplifier|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
16249426|NCT05028972|Other|Control: No Personal Amplifier|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
16249427|NCT05028959|Experimental|Female athletes|highly trained subjects
16249428|NCT05028959|Experimental|Leisure sport women|recreational sportswomen practicing regular physical activity
16249429|NCT05028946|Experimental|Cohort 1: Foralumab Dose Level 1|Participants will receive foralumab enteric coated capsules at dose level 1, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
16249430|NCT05028946|Experimental|Cohort 2: Foralumab Dose Level 2|Participants will receive foralumab enteric coated capsules at dose level 2, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
16249431|NCT05028946|Experimental|Cohort 3: Foralumab Dose Level 3|Participants will receive foralumab enteric coated capsules at dose level 3, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
16249432|NCT05028946|Experimental|Cohort 4: Foralumab Dose Level 4|Participants will receive foralumab enteric coated capsules at dose level 4, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
16249433|NCT05028933|Experimental|EPCAM CAR-T|"The first stage: single dose escalation The classic 3+3 dose escalation test. The starting dose refers to the results of the previous test of subsequent subjects. In this study, 3 increasing dose levels were set up, with 3 to 6 cases per dose.
~The first dose group is 3×10^5/kg, allowing 10% dose error.
~The second dose group is 1×10^6/kg, allowing 10% dose error.
~The third dose group is 3×10^6/kg, allowing 10% dose error. Each dose group must complete the DLT observation before entering the next dose group; when the first subject in the same dose group has no DLT observed for at least 14 days after cell infusion, the subsequent subjects can receive cell infusion.
~The second stage: combined radiofrequency/microwave ablation for the treatment of advanced digestive system malignant tumors with liver metastases"
16249434|NCT05028907|Experimental|group one (cases with inflamatory punctal stenosis treated with steroids and antibiotics)|patients with inflammatory punctal stenosis were treated by steroids and antibiotics and evaluated by anterior segment optical coherence tomography before and after treatment
16249435|NCT05028907|Placebo Comparator|control group|patients with inflammatory punctal stenosis received only preservative free tear substitutes
16249436|NCT05028894||IPF|Participants diagnosed with idiopathic pulmonary fibrosis
16249437|NCT05028881||HIV positive|No interventions
16249438|NCT05028881||HIV uninfected|No interventions
16249439|NCT05028868||Large artery atherosclerosis(LAA)|
16249440|NCT05028868||Cardiogenic stroke(CS)|
16249441|NCT05028868||Penetrating artery disease(PAD)|
16249442|NCT05028868||Other etiology(OE)|
16249443|NCT05028868||undetermined etiology(UE)|
16249444|NCT05028855||sCAS patients|Investigators plan to enroll 850 patients of symptomatic cerebral atherosclerotic stenosis (sCAS) for cerebral autoregulation assessment to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
16249445|NCT05028842||Non Cirrhotic|Non Cirrhotic
16249446|NCT05028842||Compensated Cirrhotics|Compensated Cirrhotics
16249447|NCT05028842||Decompensated Cirrhotics|Decompensated Cirrhotics
16249448|NCT05028829|Experimental|Group A: Atorvastatin 20 mg|Atorvastatin 20mg will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
16249449|NCT05028829|Placebo Comparator|Group B: Placebo to Match (PTM)|PTM will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
16249667|NCT05027269|Experimental|Part A Single Dose: AOC 1001 Dose Level 1|AOC 1001 will be administered once.
16249452|NCT05028803|Experimental|Phenylbutyrate|Volunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day.
16249453|NCT05028790|Other|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
16249454|NCT05028790|Other|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
16249455|NCT05028777||Patients diagnosed with left ventricular thrombus|All patients diagnosed with left ventricular thrombus through different imaging modalities (echocardiography, CT or MRI) and who have been diagnosed and/or treated at the Inselspital or another site of the Insel Gruppe.
16249456|NCT05028764||18 to 30 years of age group|Consisting of at least 13 males and 13 females
16249457|NCT05028764||31 to 50 years of age group|Consisting of at least 13 males and 13 females
16249458|NCT05028751|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of lanraplenib (LANRA) once daily (QD) + gilteritinib QD in each 28 day cycle for determination of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of LANRA in combination with gilteritinib.
16249459|NCT05028751|Experimental|Part 2: Expansion Cohort|Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of lanraplenib (LANRA) in combination with gilteritinib in Part 1, an expansion cohort will enroll. The expansion cohort will receive LANRA in combination with gilteritinib at the MTD / RP2D once daily (QD) in each 28 day cycle.
16249460|NCT05028738|Active Comparator|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
16249461|NCT05028738|Active Comparator|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
16249462|NCT05028725|Experimental|Esophageal Squamous Cell Carcinoma (ESCC) Cases|Each study participant will undergo esophageal sponge sampling using the 'EsophaCap' sponge device. Group 1 will include a safety-phase, which will consist of a lead-in cohort of 8 patients with ESCC. Subsequent recruitment of ESCC Cases (Group 1) will not commence until the Data Safety Monitoring Board (DSMB) has deemed the safety lead-in data appropriate for continuation. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
16249463|NCT05028725|Experimental|Non-ESCC, Esophageal squamous dysplasia (ESD) Cases|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
16249464|NCT05028725|Experimental|Non-ESCC, Control Group|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
16249465|NCT05028712|Experimental|Visual Information Training|
16249466|NCT05028712|Experimental|Multimodal Training|
16249467|NCT05028699|Experimental|Snack|32 g of a common bean baked snack per day for 28 days.
16249468|NCT05028699|No Intervention|Control|
16249469|NCT05028686||Hospitalized heart failure cohort|Patients hospitalized with heart failure
16249470|NCT05028673|Experimental|Lu AG06466 Capsule, Fasted State|Participants will receive 1 capsule of Lu AG06466 in a fasted state.
16249471|NCT05028673|Experimental|Lu AG06466 Tablet, Fasted State|Participants will receive 1 tablet of Lu AG06466 in a fasted state.
16249472|NCT05028673|Experimental|Lu AG06466 Tablet, Fed State|Participants will receive 1 tablet of Lu AG06466 in a fed state (high-fat meal).
16249473|NCT05028673|Experimental|Lu AG06466 Tablet + Antacid, Fasted State|Participants will receive 1 tablet of Lu AG06466 dosed in combination with antacid in a fasted state.
16249474|NCT05028660||Cohort 1|At least 76 patients with MIBC and elected for NAC
16249475|NCT05028647|Active Comparator|VR treatment|5 subjects per country aged 13-16 treated with VR supported (Oculos) program, one hour a day for 5 days
16249476|NCT05028647|Active Comparator|AR treatment|5 subjects per country aged 10-13 treated with AR supported (tablet) program, one hour a day for 5 days
16249477|NCT05028647|No Intervention|control age 13-16|dyslexic subjects aged 13-16 not randomized to active treatment
16249478|NCT05028647|No Intervention|Control age 10-12|dyslexic subjects aged 10-12 not randomized to active treatment
16249479|NCT05028634|Experimental|Cohort 1 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine.
16249480|NCT05028634|Experimental|Cohort 1 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), Pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine.
16249481|NCT05028634|Experimental|Cohort 2 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), and pneumococcal polysaccharide vaccine (PPSV23).
16249536|NCT05028192||Control group|Patients who will undergo programmed abdominal surgery through any approach type for no neoplastic or inflammatory disease.
16249482|NCT05028634|Experimental|Cohort 2 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap) and Pneumococcal polysaccharide vaccine (PPSV23).
16249483|NCT05028621|Experimental|Genomic analysis|When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
16249484|NCT05028608|Experimental|Period 1|Fixed treatment sequence starting with 2 single oral doses of midazolam and a single dose of elinzanetant.
16249485|NCT05028608|Experimental|Period 2|Up titration of carbamazepine over 4 days (dose 1, 2, 3) continued by fixed dose 3 of carbamazepine prior to administration of midazolam / elinzanetant, followed by carbamazepine administration.
16249486|NCT05028582|Active Comparator|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
16249487|NCT05028582|Placebo Comparator|ARQ-154 Vehicle|ARQ-154 Vehicle
16249491|NCT05028556|Experimental|Y101D|Y101D in subjects with Metastatic or Locally Advanced Solid Tumors
16249492|NCT05028543|Placebo Comparator|conventional TLH|women that will be subjected to conventional Total laparoscopic hysterectomy
16249493|NCT05028543|Experimental|TLH with prior uterine artery clipping at its origin|women that will be subjected to TLH with prior uterine artery clipping at its origin
16249494|NCT05028517|Experimental|FMF Connect Intervention + Coaching|Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
16249495|NCT05028517|Experimental|FMF Connect Intervention (no coaching)|Participants receive the FMF Connect mobile health app. They do not receive coaching.
16249496|NCT05028517|No Intervention|Waitlist comparison group|Participants receive the FMF Connect mobile health app at the conclusion of the study.
16249497|NCT05028504|Experimental|Penpulimab+Anlotinib|Penpulimab 200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16249498|NCT05028478|Experimental|Single Arm|"Four planned CN202 dose level of 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
~Subjects will receive CN202 by intravenous infusion (IV) on Day 1 of each cycle (once every 2 weeks) for up to 24 months"
16249499|NCT05028465|Experimental|EP combined with RFA|Endoscopic Papillectomy Combined with Endobiliary Radiofrequency Ablation
16249500|NCT05028452|Other|Internet based support|Internet based support for informal caregivers to individuals who are undergoing treatment for head and neck cancer.
16249501|NCT05028439|Experimental|RAF combined with gemcitabine and S-1 group|Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with gemcitabine and S-1 within 1 month after RFA.
16249502|NCT05028439|Placebo Comparator|RFA-only gruop|Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
16249503|NCT05028426||Traditional method of care|Patients managed according to the traditional care protocol without an enhanced recovery program
16249504|NCT05028426||Some elements of a fast-track program|operative and postoperative techniques were modified according to a fast-track program
16249505|NCT05028426||Full enhanced recovery program|Patients were managed in an enhanced recovery program (elements of the previous fast-track program were modified and preoperative education was added)
16249506|NCT05028413|No Intervention|Participants Blinded to BrAC reading (Control)|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will complete a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive and be blinded to their breath alcohol readings with the BACtrack Mobile Pro device.
16249507|NCT05028413|Experimental|Participants Aware of their BrAC reading|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will be shown their breath alcohol readings with the BACtrack Mobile Pro device before completing a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
16249508|NCT05028400|Experimental|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
16249509|NCT05028374|Other|"A single booster dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly"|The dose of Moderna mRNA vaccine to be administered is the same for all patients in all enrollment cohorts: 0.5 mL administered intramuscularly as a single dose, according to the manufacturer's package insert.
16249512|NCT05028348|Experimental|Selinexor, pomalidomide and dexamethasone (SPd)|"Selinexor will be given as an oral dose 60 mg (3 20 mg tablets) once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
~Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
~Patients ≤75 years:
~o Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.
~Patients > 75 years:
~Dexamethasone will be given as an oral 20 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion."
16261226|NCT04947436|Active Comparator|Mechanical insufflation/ exsufflation|
16249513|NCT05028348|Active Comparator|Elotuzumab, Pomalidomide and Dexamethasone (EloPd)|"Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
~Pomalidomide will be given as an oral 4 mg dose once a day (QD) on Days 1 to 21 of each 28-day cycle.
~Patients ≤75 years:
~Dexamethasone 28 mg PO + 8 mg IV on days of elotuzumab dosing
~Dexamethasone 40 mg PO on non-elotuzumab days (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.
~Patients >75 years:
~Dexamethasone 8 mg PO + 8 mg IV on days of elotuzumab dosing
~Dexamethasone 20 mg PO on non-elotuzumab dosing weeks (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion."
16249514|NCT05028335|Other|Group G1|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + placebo gel
16249515|NCT05028335|Experimental|Group G2|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + 1.5% Potassium Oxalate gel
16249516|NCT05028322|Active Comparator|Intra-muscular vaccination (Group 1)|This group corresponds to the use of the vaccine as used in the current recommendations.
16249517|NCT05028322|Active Comparator|Intra-dermal vaccination group without application of IMIQUIMOD cream (Group 2)|Administration mode change for Intra-dermal vaccination. ( Instead of Intra-musculaire ) , to have a comparative with the experimental group.
16249518|NCT05028322|Experimental|Intra-dermal vaccination group with application of IMIQUIMOD cream (Group 3)|"Intra-dermal vaccin administration, with an immunity booster few minutes before by IMIQUIMOD application cream.
~Experimental group."
16249525|NCT05028296|Experimental|Patients Scheduled for Standard of Care Upper Endoscopy|
16249526|NCT05028283|Experimental|participants|patients with atrophic acne scars on the cheeks who will reviewing the dermatological clinics at the Dermatology and Venereology Hospital at least 69 patients they will be undergo fat grafting for one session and will be follow up for 6 months after the procedure
16249527|NCT05028270||Balloon technology|The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. The common carotid artery and internal carotid artery will be received laterally. After whole-body heparinization, micro-catheter and guide wire technology are used. In the figure below, the proximal end of the 4mm super-form occlusion ball is marked far away from the eye, plugged and sealed, and the guide tube is pushed around in the internal carotid artery. When the occlusion is finished, the internal carotid artery and the ophthalmic artery are not accompanied far away, and the plot is good. The guiding catheter drives the injection of drugs, topotecar, and topotecan for 5 minutes (the suction balloon is opened and blocked, and the infusion is continuous) to complete the infusion.
16249528|NCT05028270||Microcatheter technology|The tip of the Marathon microcatheter is placed at the opening of the ophthalmic artery. After the contrast agent is confirmed by hand, the chemotherapeutic drugs The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. Maphalan, carboplatin, and topotecan are injected sequentially for 30 minutes. Make sure that the tip position of the catheter is not maintained during the injection process. verb: move. After the operation is completed, the blocking balloon is pulled out under the guidance of the guide wire, the arterial sheath is removed, and the femoral artery puncture point is pressed to stop bleeding.
16249530|NCT05028244|Experimental|Intervention group|Selected patients undego lower extremity ultrasound for diagnosis of deep vein thrombosis 2 times per week (mondays and thursdays) in a period of 3 weeks (21 days) of follow up
16249531|NCT05028244|No Intervention|control group|This group only undergo the first ultrasound assesment to discard previos thrombosis not detected during hospitalization or ambulatory
16249532|NCT05028231||Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|
16249533|NCT05028218|Experimental|TQB3824 tablets|TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle. Dose escalation of TQB3824 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
16249534|NCT05028205|Experimental|Prevention Plus|Child's energy balance behavioral goals will be to consume < 3 sugar-sweetened beverages (e.g., regular carbonated soft drinks, sports drinks, lemonades, ice teas, flavored milk, juice drinks < 100% juice, and punches) servings /wk, ≥1 1 2 cups/day of whole vegetables and ≥ 1 cup/day of whole fruit, engage in ≥ 60 minutes/day of moderate- to vigorous-intensity physical activity, and reduce TV viewing to < 2 hours/day. The caregiver's energy balance behavioral goals will be to consume < 3 sugar-sweetened beverage servings/wk, ≥ 2 1 2 cups/day of whole vegetables and ≥ 1 1 2 cups/day of whole fruit, engage in ≥ 150 minutes of moderate- to vigorous-intensity physical activity per week and reduce TV viewing to < 10 hours/wk.
16249535|NCT05028192||Rectal cancer after neoadjuvant treatment|Rectal cancer patients, ycTNM stage II, III, and IV (AJCC 8th), clinically stratified in the pre-cachectic or cachectic stage according to Fearon K et al. definition. That will be subject to curative intent resection or palliative surgery through any approach (open, laparoscopic, or robotic).
16249537|NCT05028179|No Intervention|Standard Care (comparator)|Patients will receive standard care
16249538|NCT05028179|Experimental|Standard Care plus AI platform (EchoGo)|Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.
16249539|NCT05028153|Active Comparator|Antibiotics|Azithromycin (10mg/kg) administered via oral suspension for 3 consecutive days
16249540|NCT05028153|Placebo Comparator|Placebo|Placebo with no active substance administered via oral suspension for 3 consecutive days
16249541|NCT05028140|Experimental|Piemonte association|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:
~1 tablet Piemonte, oral;
~1 placebo tablet of empagliflozin, oral;
~1 placebo tablet of piglitazone, oral."
16249542|NCT05028140|Active Comparator|Empagliflozin|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:
~1 placebo tablet of Piemonte, oral;
~1 tablet of empagliflozin, oral;
~1 placebo tablet of piglitazone, oral."
16249543|NCT05028140|Active Comparator|Pioglitazone|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:
~1 placebo tablet of Piemonte, oral;
~1 placebo tablet of empagliflozin, oral;
~1 tablet of piglitazone, oral."
16249544|NCT05028127|Experimental|Bimekizumab dosage regimen 1|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.
16249545|NCT05028127|Experimental|Bimekizumab dosage regimen 2|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.
16249546|NCT05028114|Experimental|Part 1 (Formulation Optimisation)|Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided 30 minutes after study drug administration. There will be 4 different formulations of the study drug and participants will be randomised to one of 4 sequences. There will be a washout of 2 days between each administration.
16249547|NCT05028114|Experimental|Part 2 (Placebo Assessment)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.
~Participants are randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods."
16249548|NCT05028114|Experimental|Part 3 (Titration Tolerability)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.
~Participants will be randomised to either study drug or the matching placebo."
16249549|NCT05028101|Active Comparator|Control (Standard of Care (SOC))|Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.
16249550|NCT05028101|Experimental|SOC + Functional Medicine|"Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.
~Perioperative nutrition and lifestyle-based interventions along with select dietary supplements."
16249551|NCT05028088|Experimental|Child-Pugh A|"Diaphragm ultrasound scan before induction of anesthesia.
~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.
~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).
~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
16249552|NCT05028088|Experimental|Child-Pugh B|"Diaphragm ultrasound scan before induction of anesthesia.
~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.
~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).
~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
16249553|NCT05028088|Experimental|Child-Pugh C|"Diaphragm ultrasound scan before induction of anesthesia.
~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.
~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).
~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
16249554|NCT05028075|No Intervention|Usual Care|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity, hours of direct patient care, percent of time providing care for patients with COVID-19) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation.
16249583|NCT05027893|Placebo Comparator|Placebo Comparator: The control group|One third of patients received placebo-tablets containing indifferent substances with no antimicrobial action (99% microcrystalline cellulose, 0.5% silicon dioxide and 0.5% magnesium stearate, which were of the same colour and overall appearance as the used antibiotics. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
16249555|NCT05028075|Experimental|Intervention|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an opt-out appointment based on their results. For the monthly automated text messaging reminders, we will assess how well these are delivered by assessing how often: links are clicked on, text messages receive a response, and participants request to stop receiving texts. For the opt out appointments, we will assess how often appointments are fulfilled or cancelled.
16249556|NCT05028062|Active Comparator|XR-NTX 380 mg, intramuscular injection|Subjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks.
16249557|NCT05028062|Placebo Comparator|Inactive placebo intramuscular injection|Subjects will receive a placebo injection repeated once after 4 weeks.
16249558|NCT05028049||Sufentanil-analgesia in plain area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plain area patients.
16249559|NCT05028049||Remifentanil-analgesia in plain area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plain area patients.
16249560|NCT05028049||Sufentanil-analgesia in plateau area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
16249561|NCT05028049||Remifentanil-analgesia in plateau area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
16249562|NCT05028036|Experimental|Personalized lifestyle intervention|The intervention consists of a personalized lifestyle treatment program to address specific lifestyle issues.
16249563|NCT05028023|Experimental|Pediatric patients with tracheal stenosis undergoing tracheal balloon dilatation|Pediatric patients with severe to median acquired tracheal stenosis undergoing tracheal balloon dilatation, and the effects of apneic oxygenation on regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, and arterial oxygen partial pressure PaO2
16249564|NCT05028010|Experimental|Training|There will be one arm, intervention group.
16249565|NCT05027997|Experimental|Dipraglurant 50 mg|
16249566|NCT05027997|Experimental|Dipraglurant 100 mg|
16249567|NCT05027997|Placebo Comparator|Placebo|
16249568|NCT05027984|Experimental|Intermediate lesion OCT-based management|"At OCT analysis, lesion features prompting intervention instead of conservative approach will be the following:
~FCT <75 µm, plus at least 2 of 3 other OCT criteria of plaque vulnerability (i.e., MLA <3.5 mm2, lipid arc with circumferential extension >180°, and the presence of macrophages).
~The presence of intracoronary thrombus at a non-culprit site, irrespective of the presence of other vulnerability criteria, may prompt treatment with DES, at the operator's discretion.
~All lesions fulfilling these interventional criteria will be treated with an OCT guided DES implantation in order to achieve an optimal stent implantation.
~In presence of a MLA <2.0 mm2, best cut-off showing correlation with fractional-flow reserve positive functional (FFR) assessment, clinical decision whether to treat the lesion will be based on FFR assessment irrespective of the presence of other criteria of vulnerability. Alternatively authors will have the option to treat the lesion with a DES."
16249569|NCT05027984|Active Comparator|Intermediate lesion physiology-based management|The iFR/FFR/RFR measurements will be obtained using a coronary-pressure guidewire. For FFR, hyperemia will be induced with the administration of intravenous adenosine, in accordance with the clinical practice at each participating center. Lesion features prompting intervention instead of conservative medical approach will be the following: iFR ≤0.89, or FFR ≤0.80.(32) All lesions fulfilling these interventional criteria will be treated with an FFR guided DES implantation. PCI will be performed with the aim of achieving a post-stenting FFR ≥0.90 (i.e. optimal FFR result). If post-stenting FFR was <0.90 a further post-dilation of the stent could be performed and if FFR remained at <0.90, a pullback of the wire to identify another possible pressure drop and/or a subsequent stent implantation at least 5 mm from the stent will be performed according to physician's preference.
16249570|NCT05027971||Lithotripsy Cohort|Subjects in this cohort will undergo lithotripsy procedure for the treatment of urinary calculi.
16249571|NCT05027971||Benign Prostatic Hyperplasia (BPH) Cohort|Subjects in this cohort will undergo Holmium Laser Enucleation of the Prostate (HoLEP) procedure for the treatment of BPH.
16249580|NCT05027906|Experimental|AT-1501 Single Arm|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
16249581|NCT05027893|Active Comparator|Active Comparator: The first tested group|Patients orally received film-coated tablets with either 400 mg of moxifloxacin. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
16249582|NCT05027893|Active Comparator|Active Comparator: The second tested group|Patients orally received film-coated tablets with either 400 mg of cefixime. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
16249663|NCT05027308|Experimental|Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive teduglutide 0.05 mg/kg (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous (SC) injection once daily for 24 weeks followed by no treatment period for 4 weeks.
16249584|NCT05027880|Experimental|Single-session Intervention of Growth Mindset for Anxiety (SIGMA)|The SIGMA intervention group will adapt the SSI-GP protocol in two ways: (a) by introducing the growth mindset of emotions rather than personality and (b) providing an experiential process of negative emotion change. SIGMA also consists of five components: (a) an introduction to emotions and the brain for conveying a scientific understanding of emotion and growth mindset of negative emotions; (b) stories and testimonials from high-school-aged youths who described their beliefs that people's negative emotion states (e.g., anxiety, depression, and stress) are malleable, and how these mindsets influence their coping with anxiety; (c) emotion changing experience induced by short videos; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to younger students about the growth mindset of emotion.
16249585|NCT05027880|Experimental|Single session on growth mindset of personality (SSI-GP)|The SSI-GP intervention group will use the intervention protocol of Project Personality (https://osf.io/a9uv2/). The investigators will translate it into Chinese using bilingual native English and Chinese speakers. The key potent elements of SSI-GP consist of five components [17, 40, 41]: (a) an introduction to the brain about the potential of neuroplasticity and behavioural change; (b) written testimonials from older, high-school-aged youths of their belief in change of personality; (c) additional vignettes written by older youths about how growth mindset of personality helped them succeed following setbacks; (d) overview of common questions and misconceptions about growth mindset; and (e) an exercise of writing notes to younger students about the malleability of people's personality traits.
16249586|NCT05027880|Active Comparator|Active control group: Support therapy (ST)|The control condition will be a structurally similar web-based session of supportive therapy. The goals of supportive therapy are to encourage the client to identify and express feelings and to share their emotions-both positive and negative-with close others. ST group does not teach or emphasize specific skills or beliefs. The active control group includes the same number of reading and writing activities as do the SIGMA and SSI-GP interventions. Also, to mirror the intervention groups as closely as possible, supportive therapy will include vignettes written by older, high-school-aged youths, who describe times when they benefited from sharing their feelings with friends or family members.
16249587|NCT05027867|Experimental|Arm 1|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
16249588|NCT05027867|Experimental|Arm 2|KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
16249589|NCT05027854|Experimental|Stimulation|TMS or tES, depending on experiment
16249590|NCT05027854|Sham Comparator|Sham|Corresponding sham TMS or tES
16249591|NCT05027828||patients using olaparib only|
16249592|NCT05027828||patients using olaparib combined with bevacizumab|
16249596|NCT05027802|Experimental|Palovarotene Chronic/Flare-Up Regimen|"Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment.
~Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days."
16249599|NCT05027776|Experimental|Experimental: 2-doses Group|Subjects aged 9-14 years, received 2 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 6-month schedule.
16249600|NCT05027776|Experimental|Experimental: 3-doses Group|Subjects aged 9-19 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
16249601|NCT05027776|Active Comparator|Acitve Group|Subjects aged 20-26 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
16249602|NCT05027763|No Intervention|Control Arm|Standard care - patients will not receive specific dietary advice.
16249603|NCT05027763|Experimental|High Fiber/low fat|Patients will receive sample meals and education/support, will be asked to follow this diet for 10 days.
16249604|NCT05027763|Experimental|Fermented|Patients will receive sample meals and education/support, will be asked to follow this diet for 10 days.
16249605|NCT05027750|Experimental|Intervention|The selected womens were associated with obesity risk factors about obesity (overweight) or obese and between 18-49 years old) and randomly assigned to the experimental group. Obesity training consisting of a total of five sessions structured according to Theory of Planned Behavior was scheduled for the intervention group. Each session lasted for approximately 30 minutes.
16249606|NCT05027750|No Intervention|Control|The control group of the Randomized Controlled Trial (RCT) was composed of 39 womens (between 18-49 years old) randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between ≥30.0 according to the risk rating scales. A standard obesity training consisting of a single session was scheduled for the control group.
16249668|NCT05027269|Placebo Comparator|Part A Single Dose: Placebo|Saline will be administered once.
16249607|NCT05027737|Experimental|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
16249608|NCT05027737|No Intervention|Traditional closure (control)|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo a standardized reversal of their diverting loop ileostomy. The latter will be performed with a stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia and will be performed no earlier than 12 weeks following their index surgery.
16249609|NCT05027711|Experimental|A|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
16249610|NCT05027711|Experimental|B|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
16249611|NCT05027711|Experimental|C|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT). If a BED of ≥ 100 Gy cannot be achieved using an ITV concept (e.g. due to OAR constraints), patients will be treated in arm C using MRgSBRT with the highest achievable dose as deemed appropriate by the treating radiation oncologist
16249612|NCT05027685||Renal Denervation Treatment|Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.
16249613|NCT05027672|Active Comparator|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|At the time of randomisation, patients in this arm receive a second dose of Sputnik V (rAd5) vaccine component two.
16249614|NCT05027672|Experimental|Gam-COVID-Vac / ChAdOx1 nCoV-19|At the time of randomisation, patients in this arm receive Astra Zeneca's vaccine (ChAdOx1 nCoV-19) as a second dose.
16249615|NCT05027672|Experimental|Gam-COVID-Vac / Gam-COVID-Vac (rAd26)|At the time of randomisation, patients in this arm receive a second dose of a repeat of the first component of the Sputnik V vaccine (rAd26) as a second dose.
16249616|NCT05027672|Experimental|Gam-COVID-Vac / mARN-1273|At the time of randomisation, patients in this arm receive as a second dose the vaccine produced by Moderna (mRNA-1273).
16249617|NCT05027659|Experimental|intervention|This study was carried out with two groups. Virtual reality glasses were used for the intervention group.
16249618|NCT05027659|No Intervention|control|No application was made to the control group, standard procedure was followed.
16249619|NCT05027646|Experimental|Part 1 - Bioequivalence|Bioequivalence will be measured in approximately 42 healthy male and female subjects at a single center in the US to achieve at least 33 completers.
16249620|NCT05027646|Experimental|Part 2 - Adhesion|Adhesion will be measured in approximately 90 healthy male and female subjects are planned to be enrolled at a single center in the US.
16249621|NCT05027633|Other|pembrolizumab, docetaxel, and cisplatin or carboplatin|IV
16249622|NCT05027620|Experimental|Home training|Participants train 3 times weekly in their home environment with help of a digital training app, over a 10-week period.
16249623|NCT05027594|Experimental|Dose Escalation Part|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
16249624|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 single agent|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
16249625|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 in combination with dexamethasone|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
16249626|NCT05027581|Experimental|Chondrochymal® group|Subjects will be IA injected at the target knee with 3 mL of Chondrochymal® containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.
16249627|NCT05027581|Active Comparator|Hya-Joint Plus Synovial Fluid Supplement|Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1.
16249628|NCT05027568|Experimental|Drug: IOA-289 single dose|Single oral dose of IOA-289 liquid filled capsule formulation - ascending doses
16249629|NCT05027568|Placebo Comparator|Placebo single dose|Single oral dose of placebo liquid filled caspule formulation
16249630|NCT05027555|Experimental|Multisensory training group|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
16249631|NCT05027555|Active Comparator|Conventional training group.|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
16249632|NCT05027529|Experimental|VA-ECMO and CytoSorb|standard ICU care WITH CytoSorb
16249633|NCT05027529|Placebo Comparator|VA-ECMO only|standard ICU care WITHOUT CytoSorb
16249634|NCT05027516|Active Comparator|Rocephine®|ceftriaxone 1g + lidocaine 35mg; intramuscular injection
16249635|NCT05027516|Active Comparator|Rocephine® + Azithromycin|ceftriaxone 1g + lidocaine 35mg intramuscular injection + azithromycin 2g orally
16249640|NCT05027477|Active Comparator|Radical Prostatectomy|Patients in this group will undergo Radical prostatectomy. There will be about 67 people in this group.
16249641|NCT05027477|Experimental|TULSA Procedure|Patients in this group will undergo TULSA Procedure. There will be about 134 people in this group.
16249644|NCT05027451|Experimental|IXT-m200|3 g of IXT-m200 given once by 30-min intravenous infusion
16249645|NCT05027451|Placebo Comparator|Placebo|Normal saline
16249646|NCT05027438|Experimental|COAST + Deprescribing|CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
16249647|NCT05027425|Experimental|Durvalumab + Tremelimumab + Liver Transplant|Patients will be treated with the immunotherapy combination for up to 4 months. After a minimum 28 day washout, they will undergo locoregional therapy per institutional standards. Eventually, after a minimum 72-day washout from the end of immunotherapy, they will undergo liver transplant.
16249648|NCT05027412|Experimental|En Bloc TURBT with Collins Loop|"If the patient is randomized to the TURB group, it will be carried out with a Collins loop, with bipolar energy.
~After randomization, demographic data (age, sex, exposure to tobacco, occupational risk), symptoms prior to randomization (micro or macrohematuria, LUTS) and laboratory data (urinary cytology, hemoglobin and serum creatinine) will be collected. Finally, the physical characteristics of the lesion will be noted in the cystoscopy immediately prior to the intervention: size, location (s) and appearance of the tumor. After the intervention, the type of procedure (TURB / TUB), the duration of the procedure from when the resector is inserted until the urinary catheter is placed, and complications according to the Clavien-Dindo scale will be recorded. In your first post-surgical check-up, the days of hospital stay and the time of bladder catheterization will be collected."
16249649|NCT05027412|Active Comparator|Conventional TURBT|The TURB will be carried out with bipolar current according to the traditional technique.
16249650|NCT05027399|Active Comparator|Intervention Group|Consultations will be carried out via video call, every 15 days for a period of 3 months, with a total of 6 telephone consultations that will have in order to clarify doubts about the CI, the monitoring of possible clinical signs of instability and help in adapting or creating strategies for better adherence to therapy.
16249651|NCT05027399|No Intervention|Control Group|Will be composed by the participants who will have no intervention and will continue to monitor according to the institution's routine.
16249652|NCT05027386|Experimental|Apatinib Mesylate combined with IT Regimen|"The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
~Combination therapy phase: Apatinib (orally once daily continuously in a 21-day cycle) was combined with IT regimen (repeated every 3 weeks) for up to 6 courses of treatment.
~Apatinib:
~<25Kg：0.25g，po，qd； 25Kg≤wight<40Kg：0.425g，po，qd； 40Kg≤wight<50Kg：0.5g，po，qd.
~IT regimen:
~Temozolomde：150mg/m2，iv 90min，d1-5，（1h before irinotecan）； Irinotecan: 50mg/m2，iv 90min，d1-5.
~Monotherapy maintenance phase: Apatinib is administered as a monotherapy until tumor progression, patient withdrawal, or toxicity becomes intolerable."
16249653|NCT05027373|Experimental|SSGJ-613|
16249654|NCT05027373|Placebo Comparator|Placebo|
16249655|NCT05027360||Acute heart Failure AHF|AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF
16249656|NCT05027347||100 healthy people|10 ml blood and tissue biopsy were collected from each patient
16249657|NCT05027347||100 gastric cancer patients|10 ml blood and tissue biopsy were collected from each patient
16249658|NCT05027334|Experimental|Interventional arm|Participants will be asked to use a designed mobile app to monitor their blood sugar levels
16249659|NCT05027321|No Intervention|Control|control
16249660|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring|1-hour consultation with a hypnopractor just before the examination
16249661|NCT05027321|Experimental|Conversational Hypnosis|conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
16249662|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|1-hour consultation with a hypnopractor just before the examination and conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
16249664|NCT05027295|Active Comparator|Continuous UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of continuous UVA light for 7.5 minute exposure time
16249670|NCT05027269|Placebo Comparator|Part B Multiple Ascending Dose: Placebo|Saline will be administered three times.
16249671|NCT05027243|Experimental|bilateral temporomandibular joint arthroscopy|
16249674|NCT05027217||Standard ICU Arm (Main study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU prior to the COVID-19 surge in the country, who are invasively mechanically ventilated for more than 12 hours. We will include medical, surgical, trauma and neurological/neurosurgical patients who are COVID-19 negative.
16249675|NCT05027217||COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from patients admitted with a confirmed diagnosis of acute respiratory failure due to COVID-19 infection.
16249676|NCT05027217||Non-COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from medical, surgical, trauma and neurological/neurosurgical patients who are not admitted for COVID-19.
16249677|NCT05027204|Experimental|Docetaxel combined with Nivolumab|"Phase Ib: The eligible patients with SCCHN will received Docetaxel for Injection (Albumin-bound) 75 mg/m^2 or 100 mg/m^2 sequentially in combination with Nivolumab 360 mg to evaluate safety and efficacy and explore RP2D.
~Phase II: According to the RP2D determined in the phase Ib study, patients will be treated with Docetaxel for Injection (Albumin-bound) combined with Nivolumab until participants meet the criteria for termination or withdrawal criteria, for a maximum of 2 years."
16249678|NCT05027191||Sevoflurane|This group will receive sevoflurane as the maintenance inhalational anesthetic.
16249679|NCT05027191||Desflurane|This group will receive desflurane as the maintenance inhalational anesthetic.
16249680|NCT05027178|Experimental|Chiropractic care for Ischemic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
16249681|NCT05027178|Experimental|Chiropractic care for Hemorrhagic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
16249682|NCT05027165||Observational group|"In this cohort, 40 NSCLC patients with indication for chemoradiotherapy followed by durvalumab maintenance treatment (standard of care) will be consecutively recruited.
~Comprehensive characterization of all patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as gut/saliva microbiome analyses and will be performed before, after 15 fractions of radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months after start of durvalumab.
~18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12 and 24 months after the end of radiochemotherapy. Lung function will be asssed before start of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18, 24months after start of durvalumab."
16249683|NCT05027152|Experimental|traditional resistance exercises|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise.
16249684|NCT05027152|Experimental|repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
16249685|NCT05027139|Experimental|Zanidatamab plus evorpacept (ALX148)|
16249686|NCT05027126|Active Comparator|Group A: Dexketoprofen (Stadium®)|Reference Drug Pharmaceutical Form: Tablets Dosage: 25 mg Administration way: oral
16249687|NCT05027126|Experimental|Group B: Fixed dose Dexketoprofen-Vitamin B Complex|Fixed dose combination: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin, Thiamine,and Pyridoxine. Administration way: oral
16249690|NCT05027100|Experimental|exploratory research|Anlotinib 10mg QD with 2W stop 1W tiselizumab injection 200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
16249691|NCT05027087|Experimental|Treatment|Participants receive the blueberry gummy supplement
16249692|NCT05027087|Placebo Comparator|Placebo|Participant receive the placebo gummy supplement
16249696|NCT05027061||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Warfarin
16249697|NCT05027061||Cohort 2|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Apixaban
16249698|NCT05027061||Cohort 3|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Dabigatran
16249699|NCT05027061||Cohort 4|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Edoxaban
16249700|NCT05027061||Cohort 5|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Rivaroxaban
16249701|NCT05027061||Cohort 6|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulants
16249702|NCT05027048|Experimental|Calcium chloride|"1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
16249703|NCT05027048|Placebo Comparator|Saline placebo|"60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
16249704|NCT05027035|Active Comparator|Surgical plication|Surgical plication of the diaphragm
16249705|NCT05027035|Active Comparator|Mechanical ventilation|Non-invasive ventiatilatory support
16249706|NCT05027009|Experimental|Group I (low dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 3 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
16249707|NCT05027009|Experimental|Group II (middle dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 4 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
16249708|NCT05027009|Experimental|Group III (high dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 6 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
16249709|NCT05026996|Experimental|Mild hepatic impairment patients|Participants with mild hepatic impairment
16249710|NCT05026996|Experimental|Healthy participants|Matched healthy participants with normal hepatic function
16249711|NCT05026983|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on day 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16249712|NCT05026970|Active Comparator|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
16249713|NCT05026970|Active Comparator|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
16249714|NCT05026970|Active Comparator|Biofeedback+Kegel|Biofeedback (6 sessions) Kegel exercises (twice daily)
16249715|NCT05026957|Active Comparator|Control group|Participating in regular cardiac rehabilitation
16249716|NCT05026957|Experimental|Intervention|Participating in regular cardiac rehabilitation + using the shared-decision making application
16249717|NCT05026944|Experimental|Group A|Percussive massage and static stretching exercises
16249718|NCT05026944|Other|Group B|Static stretching exercises
16249719|NCT05026931|Experimental|Group A|Foam Rolling
16249720|NCT05026931|Active Comparator|Group B|Stretching exercises
16249721|NCT05026918|Active Comparator|Group A|all the components of Manual Chest Physiotherapy wer performed on the patients of this group. MCPT was done few hours before meals and it was made sure that nothing was in patient's mouth while doing chest physiotherapy. MCPT includes postural drainage, percussion and vibrations. Chest Physiotherapy was done thrice a day for 30 minutes and there were 21 sessions a week.
16249722|NCT05026918|Experimental|Group B|all the components of Active Cycle of Breathing techniques (ACBT) were performed on the patients of this group. ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique. These were performed thrice a day for 30 minutes and for 21 sessions a week.
16249723|NCT05026905|Other|GASL arm|"eligible patients will receive gemcitabine 800 mg/m2 on day 1, nab-paclitaxel 125 mg/m2 on day 1, S-1 orally 60-100 mg/day [depending on patient's baseline body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:
~BSA < 1.25 m2: 60 mg/day
~1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day
~BSA ≥ 1.5 m2: 100 mg/day"
16249724|NCT05026905|Other|GAP arm|eligible patients will receive gemcitabine 800 mg/m2, nab-paclitaxel 125 mg/m2 and oxaliplatin 75mg/m2 on day 1 in a 2-week cycle.
16249725|NCT05026892||moderate to severe|patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with moderate to severe or severe form of covid-19
16249726|NCT05026892||begining to moderate|Patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with begnin to moderate or moderate form of covid-19
16249729|NCT05026853|Experimental|PRO Integration into Clinical Practice|PRO scores will be shared with patients and healthcare providers (HCPs) via an emailed report card
16249730|NCT05026853|No Intervention|Usual Care|Patients and HCPs will not receive an emailed PROMIS score report. PROMIS scores, however, will be available in the EMR as usual.
16249731|NCT05026840||IADPSG|
16249732|NCT05026840||WHO '99|
16249733|NCT05026827|Experimental|Iyengar Yoga|Participants will engage in 10 weekly IY classes
16249734|NCT05026827|Active Comparator|Socialization Control|Participants will engage in 10 weekly socialization control group sessions
16249735|NCT05026827|No Intervention|Healthy Comparison Group|A group of participants will also be followed for 10 weeks
16249736|NCT05026814||Women with FGM/C|Women who requested clitoral reconstruction after FGM/C between 01/2013 until 04/2021 and underwent multidisciplinary care consisting of psychosexual care (PC) with or without CR. To be included the women had to attend at least one session with the psychologist as part of psychosexual care.
16261229|NCT04947423|Placebo Comparator|Placebo|Placebo Nasal Gel (0.12 g)
16249741|NCT05026775|Experimental|Initial Medication Adherence (IMA) intervention|General practitioners (GP) will apply the IMA intervention to all patients receiving a new prescription for treatment of cardiovascular disease or diabetes. Following the IMA intervention, nurses and community pharmacists will offer information support in line with the information provided by the GP.
16249742|NCT05026775|Active Comparator|Usual care|Patients will receive the usual care when being prescribed a new prescription for treatment of cardiovascular disease or diabetes. Nurses and community pharmacists will be asked to also provide usual care to those patients.
16249743|NCT05026762|Experimental|Treatment|
16249744|NCT05026749|Placebo Comparator|Control Group|
16249745|NCT05026749|Active Comparator|AZM 20mg/kg Treatment Group|
16249746|NCT05026736|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue to receive treatment at the discretion of the treating physician.
16249747|NCT05026723|Experimental|Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)|The Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
16249748|NCT05026723|Active Comparator|Standard MTM|The Standard Medically Tailored Meal (MTM) intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian.
16249749|NCT05026710|Experimental|Silicone (Coloplast Imajin Hydro) ureteral stent|
16249750|NCT05026710|Experimental|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).|
16249751|NCT05026684|Experimental|Experimental group|Personalized cost information group.
16249752|NCT05026671|Active Comparator|Group DL|The control group consists of intubating the trachea with an endotracheal tube alone (without stylet).
16249753|NCT05026671|Experimental|Group DLS|The Experimental group consists of intubating the trachea with an endotracheal tube + stylet.
16249754|NCT05026671|Experimental|Group VL|The Experimental consists of intubating the trachea with an endotracheal tube + Video-laryngoscope
16249755|NCT05026671|Experimental|Group VLS|The Experimental consists of intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
16249756|NCT05026658|Experimental|Visibly Digital Acuity Product|
16249757|NCT05026658|Experimental|ETDRS Visual Acuity Lane Test|
16249758|NCT05026645||adult inflicted by a chemical weapon|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system.
16249759|NCT05026645||Infant inflicted by a chemical weapon|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system.
16249760|NCT05026645||Women inflicted by a chemical weapon|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system.
16249761|NCT05026645||Men inflicted by a chemical weapon|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system.
16249762|NCT05026645||Elderly inflicted by a chemical weapon|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system.
16249763|NCT05026645||Diagnosed with chronic disease(s) inflicted by a chemical weapon|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system.
16249764|NCT05026645||Clinician (adult) whom performs his/her clinical interventions|Clinician (adult) whom performs his/her clinical interventions while integrating competences in protections and decontamination. Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system. This is the case of when the clinician is required to ensure safety toward his/her patient while performing his/her interventions & procedures.
16249765|NCT05026645||Clinician (adult) injured by duties circumstances|Part of the Population is being studied includes any individual who was affected by chemical attacks and was needed an intervention of the healthcare system. This is the case of when the clinician becomes inflicted by the chemical while intervening toward contaminated patient due to any failure in protection and decontamination.
16249766|NCT05026632|Experimental|Single NPI-002 Intravitreal Implant|
16249767|NCT05026632|Experimental|Double NPI-002 Intravitreal Implant|
16249768|NCT05026632|No Intervention|Control|
16249769|NCT05026619|Placebo Comparator|Control|Receives a fact sheet on diabetes in Singapore
16249770|NCT05026619|Experimental|Fertility-related information|Receives accurate information on age-related fertility
16249771|NCT05026619|Experimental|Policy-related information|Receives accurate information on local policy initiatives related to age at marriage and childbearing
16249772|NCT05026606|Experimental|Treatment (etigilimab, nivolumab)|Patients receive etigilimab IV over 30-90 minutes on days 1 and 15 and nivolumab IV over 30 minutes on days 2 and 15 of cycle 1 and days 1 and 15 of subsequent cycles. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16249773|NCT05026593|Active Comparator|Sintilimab+EP|During each 21-day cycle, participants receive Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
16249826|NCT05026229|Experimental|Dasatinib, Methotrexate and Cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
16249827|NCT05026216|Experimental|Single-arm study|Using CCH-ases on bilateral buttocks and thigh injections. No placebo being used.
16249774|NCT05026593|Experimental|IBI110+Sintilimab+EP|During each 21-day cycle, participants receive IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
16249775|NCT05026567|Active Comparator|Reference Product A|Reference Product A
16249776|NCT05026567|Experimental|Experimental B|Experimental B
16249777|NCT05026567|Experimental|Experimental C|Experimental C
16249778|NCT05026567|Experimental|Experiment D|Experiment D
16249779|NCT05026554||CHE|Adults with moderate to severe chronic hand eczema
16249780|NCT05026554||Healthy Volunteers|Healthy adults
16249781|NCT05026541|Sham Comparator|Nap Practitioners|This is an observational arm of regular nappers. Individuals that take naps at least three times a week will be invited to undergo all of the study procedures for one weekend of data collection.
16249782|NCT05026541|Active Comparator|Shoonya Meditators|This is intervention arm. Participants will learn and practice the fifteen minute shoonya meditation - described as a process of conscious non-doing- and shakti chalana kriya, which is a set of breathing exercises designed as a preparatory practice to shoonya meditation. Participants will practice shoonya meditation twice a day for two months. A weekend of data collection will happen at baseline and two months after they learn the practice.
16249783|NCT05026541|Placebo Comparator|Control Meditators|This is the waitlisted control arm. Participants will practice alternate nostril breathing (sukha kriya) for two months, then will learn shoonya meditation and practice for two months. A weekend of data collection will happen at baseline, two months, and four months.
16249784|NCT05026528|Experimental|Digital DSME/S|Ten-week intervention during which the participant uses a digital diabetes self management education and support system together with the diabetes nurse.
16249785|NCT05026528|No Intervention|Standard care|Control group continuing with regular standardized care.
16249786|NCT05026515||4 years and under|Children coming at dental appointment, aged 4 years and under
16249787|NCT05026515||5 to 6 years|Children coming at dental appointment, aged 5 to 6 years
16249788|NCT05026515||7 years and over|Children coming at dental appointment, aged 7 years and over
16249789|NCT05026502||Participants Being Treated With Elagolix + E2/NETA|Participants will receive Elagolix with Estradiol/Norethindrone Acetate per Standard of Care, as prescribed by their physicians.
16249790|NCT05026489||G6PD Deficiency|In the laboratory of the First Affiliated Hospital of Xi 'an Jiaotong University, tetrazolazole-blue quantitative method will be used to detect G6PD. According to the normal range of the tetrazole-blue quantitative method (6.8-20.5NBT), adults with G6PD activity < 6.8NBT were positive, and G6PD deficiency is confirmed.
16249791|NCT05026489||Normal|The G6PD activity ranged from 6.8 to 20.5 NBT and the G6PD activity is normal.
16249792|NCT05026463|Experimental|Inspiratory support level with PMI equal to -2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
16249793|NCT05026463|Experimental|Inspiratory support level with PMI equal to 0|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
16249794|NCT05026463|Experimental|Inspiratory support level with PMI equal to +2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
16249797|NCT05026411|Other|Orthodontic patients|Magnetic resonance images will be taken from 20 individuals with eating disorders before fixed orthodontic treatment, 12 months of orthodontic treatment and 6 months after orthodontic treatment finished
16249798|NCT05026398|Experimental|Fenfluramine|Drug: Fenfluramine - 15mg twice daily oral solution for seven days
16249799|NCT05026398|Placebo Comparator|Placebo|Placebo - 15mg twice daily oral solution for seven days
16249800|NCT05026385|Experimental|Intervention|"The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing.
~After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase."
16249801|NCT05026385|No Intervention|Usual Care|The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.
16249802|NCT05026372|Experimental|Mindfulness + Compassion (MC)|For participants randomized to the MC condition will focus on compassion and creating positive emotions. This session will include techniques such as guided visualizations and a loving kindness meditation that are intended to facilitate connection with their partners. During this session, couples will also learn the ground rules of mindful and compassionate listening and sharing, as they will be asked to engage in an emotional disclosure task. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
16249828|NCT05026203|Experimental|Ketamine|
16249829|NCT05026203|Placebo Comparator|Midazolam|
16249803|NCT05026372|Experimental|Mindfulness + Gratitude (MG)|Session 2 for participants randomized to group MG will focus on gratitude. Participants will be taught to reflect on things, events, and people which they are grateful for via a gratitude meditation. Couples will share their experiences of practicing gratitude. The instructor will remind the couple of ground rules prior to the emotional disclosure exercise and facilitate if necessary during the sharing. Each member of the couple will take turn in sharing with and listening to their partner. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
16249804|NCT05026372|Experimental|Mindfulness + Value-Based Living (MV)|Session 2 for participants randomized to group MV will focus on learning strategies to live life according to their values. They will first engage in a reflection exercise to help identify their values, and then complete a worksheet. Couples will brain storm together strategies to ensure that their lives reflect their self-identified values. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
16249805|NCT05026372|No Intervention|Attention Control (AC)|For participants randomized to the AC condition, both sessions will focus on discussing issues and themes that emerge for couples, such as communication and perceived supportiveness. Utilizing a reflective listening approach, the interventionist will focus on encouraging participants to share concerns related to their daily experiences. Unlike in the MC, MG, and MV groups, the interventionist will not offer advice, support (other than reflective listening) or any other tools to participants. Additionally, the interventionist will not probe for deep emotional disclosure. Please see the appendix for the session outline. We believe a control group that discusses daily relationship-related concerns serves as an excellent comparison condition in this study since it is viewed as credible by participants and equates for time and attention as well as nonspecific treatment effects such as those provided through social interactions.
16249806|NCT05026359|Experimental|Bilateral ankle coordination training group|Exercise training of bilateral ankle coordination training group consisted of 30 minutes of bilateral ankle coordination training 3 days per week for 4 weeks (total 12 sessions)
16249807|NCT05026359|No Intervention|General rehabilitation intervention group|Exercise training of walking and balance training consisted of 30 minutes of general rehabilitation intervention group 3 days per week for 4 weeks (total 12 sessions)
16249808|NCT05026346||Healthy|Healthy subjects, wothout shoulder pathology
16249809|NCT05026346||Rotator cuff tears|Patients after arthroscopic reconstruction of rotator cuff
16249810|NCT05026333|Experimental|High Stress Group|Group of high stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
16249811|NCT05026333|Experimental|Low Stress Group|Group of low stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
16249812|NCT05026320|Experimental|Naproxen Topical Gel (BAYH006689)|UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
16249813|NCT05026320|Active Comparator|Diclofenac Diethylamine Gel|UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
16249814|NCT05026320|Placebo Comparator|Placebo Gel|UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
16249815|NCT05026307|Experimental|Pterygium|Simple surgical excision of pterygium withe bare sclera
16249816|NCT05026294|Experimental|Experimental group I|The experimental group received plyometric training
16249817|NCT05026294|Experimental|Experimental group II|The experimental group received flat feet rehabilitation training
16249818|NCT05026294|No Intervention|Control group|The Control group didn't receive intervention
16249819|NCT05026281|Experimental|Group 1|at H0 and H0+30min = blood sample taken
16249820|NCT05026268|Experimental|Intracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice with the intracorporeal anastomosis performing.
16249821|NCT05026268|No Intervention|extracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice.
16249822|NCT05026255|Experimental|mechanically ventilated intensive care patients.|Observational data collected for patients in intensive care under mechanical ventilation.
16249823|NCT05026242|Experimental|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
16249824|NCT05026242|Active Comparator|Control|Participants will be provided with isocaloric snacks
16249825|NCT05026229|Experimental|Dasatinib, Vincristine and Prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
16249831|NCT05026177|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks
16249832|NCT05026177|Experimental|Simufilam 50 mg|Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
16249833|NCT05026177|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
16249834|NCT05026164|Active Comparator|Active|CHI-202. Participants will drink one 7.0g CHI-202 powder sachet mixed into 16oz of water twice daily.
16249835|NCT05026164|Placebo Comparator|Placebo|CHI-101. Participants will drink one 7.0g CHI-101 powder sachet mixed into 16oz of water twice daily.
16249836|NCT05026151||non-CO|Consecutive persistent critically ill patients requiring more than 10 days of mechanical ventilation, admitted just before the first COVID-19 wave
16249837|NCT05026151||COVID|Consecutive persistent critically ill COVID-19 patients requiring more than 10 days of mechanical ventilation, admitted during the first COVID-19 wave
16249840|NCT05026125|Active Comparator|Group 1|3 μg/kg (Ideal Body Weight) of Remifentanil
16249841|NCT05026125|Experimental|Group 2|3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil
16249842|NCT05026112||DCM with MSF (MSF+)|Patients with dilated cardiomyopathy and midwall septal fibrosis identified in a previous cardiac MRI scan
16249843|NCT05026112||DCM without MSF (MSF-)|Patients with dilated cardiomyopathy but without midwall septal fibrosis on previous cardiac MRI scan
16249844|NCT05026112||Control - MSF+|Control healthy volunteers (HV) to the MSF+ cohort
16249845|NCT05026112||Control - MSF-|Control healthy volunteers (HV) to the MSF- cohort
16249846|NCT05026099|Experimental|Boxing training program|The program will start with a warm-up session involving breathing and stretching of the trunk and limbs for 5 minutes. The program will include mitt hitting and sand bag hitting for 10 minutes, with a 2-minute rest period. Thereafter, stretching of the trunk and limbs will be performed for 5minutes, similar to the warm-up
16249847|NCT05026099|Active Comparator|Task Oriented Training Program|Upper limb Exercises: Sitting position: open covered pots of different sizes and transfer the flour to a cup with a spoon, then close the pot.Sitting position: pick up coins and cards on the table and put the coins in a pot and gather the cards.Sitting position: write and/or draw pictures on a piece of paper.Sitting position: open a safe box with a key, pick up small objects inside the box, and transfer them to a pot, then lock the safe box Sitting position: pick up and transfer jars, bottles, and glasses of different sizes and weights located on a table. Transfer the liquid contents from jars and bottles to glasses Sitting position: throw and catch balls (in pairs)
16249848|NCT05026086|Experimental|biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
16249849|NCT05026086|Active Comparator|isometric exercises|10 patients will be treated with isometric exercises without pressure biofeedback.
16249850|NCT05026073||Group 1 Endometrial Cancer:|Women with histological diagnosis of cancer of the endometrium (any type) undergoing hysterectomy
16249851|NCT05026073||Group 2 Endometrial Hyperplasia:|Women with histological diagnosis of endometrial hyperplasia (with or without atypia) undergoing hysterectomy
16249852|NCT05026073||Group 3 Controls:|Healthy women undergoing hysterectomy for a benign reason
16249853|NCT05026060||Patients with arterial disease|Minor patients with acute or chronic arterial disease: diagnosis of Moyamoya, diagnosis of sickle cell disease, acute or chronic arterial infarction.
16249854|NCT05026047|Experimental|patients consulting in an infectious disease department|no comparator
16249855|NCT05026034||Training Cohort|Inpatients with HF requiring >24 hours IV diuretics
16249856|NCT05026034||Cohort A|Patients undergoing serial, clinically indicated RHC. To investigate if measures derived by the CPM wearable device correlate with invasive measures of cardiopulmonary haemodynamics (PCWP).
16249857|NCT05026034||Cohort B|Patients receiving haemodialysis. To investigate if changes in measures derived by the CPM wearable device correlate with B-lines on LUS and changes in B-lines before and after haemodialysis and with volume of fluid removed during haemodialysis
16249858|NCT05026034||Cohort C|Patients receiving inpatient intravenous diuretic treatment for heart failure. To investigate if changes in measures derived by the CPM wearable device system correlate with B-lines on lung ultrasound and weight before and after treatment for HF.
16249861|NCT05025995|Experimental|Serious health game|Children played a serious health game with Garfield promoting health behavior, such as less intake of energy dense snacks, drink more water, and exercise more often.
16249862|NCT05025995|Experimental|control|Children in this condition did not play a serious health game and were in control condition.
16249863|NCT05025982||Group of partecipants|we combined two surgical techniques in the same group of patients
16249864|NCT05025969||Glioma|(20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas)
16249865|NCT05025969||Brain metastasis|"The brain metastasis cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available"
16249866|NCT05025956|Experimental|Fisetin group (investigational group)|"20mg/kg of Fisetin per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.
~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
16249867|NCT05025956|Placebo Comparator|Placebo group (control group)|"20mg/kg of Placebo per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.
~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
16249868|NCT05025943|Experimental|Standard lifestyle intervention + omega-3 fatty acid enriched diet|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods
16249869|NCT05025943|Active Comparator|Standard lifestyle intervention|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)
16249870|NCT05025930|Experimental|endoscopic surgical instrument control system (SP1000: single- port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (SP1000)
16249871|NCT05025930|Active Comparator|Comparator: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (IS3000)
16249872|NCT05025917|Experimental|Shatavari|1000 mg per day shatavari root powder (2 x 500 mg opaque capsules; equivalent to 26,500 mg fresh weight shatavari). Ingested in the morning, daily for 6 weeks.
16249873|NCT05025917|Placebo Comparator|Placebo|1000 mg per day magnesium stearate powder (2 x 500 mg opaque capsules). Ingested in the morning, daily for 6 weeks.
16249874|NCT05025904|Experimental|Real-time fMRI neurofeedback (rt-fMRI NFB)|The duration of a session was approximately a half-hour. The course duration was 8 sessions. The preferred frequency was once a week, however, the schedule was flexibly adjusted for patients' convenience.
16249875|NCT05025904|Active Comparator|Сognitive behavioral therapy (CBT)|The duration of a session was approximately an hour/hour and a half. The course duration was 8 individual and 8 group sessions and included home assignments. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience and for improving benefits of the treatment.
16249876|NCT05025904|Active Comparator|EEG neurofeedback (EEG NFB)|"The duration of a session was approximately a half-hour. The course duration was 16 sessions. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience.
~Group was preliminarily aborted for lack of time and participants in order to assign more patients to the abovementioned arms."
16249877|NCT05025891|No Intervention|Arm 1: control|Patients continue consultations as usual in HDJA or at UMIT.
16249878|NCT05025891|Experimental|Arm 2: teleconsultation alone|Patients are directed to the tele-monitoring platform without specific accompaniment.
16249879|NCT05025891|Experimental|Arm 3: teleconsultation and mediation|Patients are referred to the tele-monitoring platform with specific support with mediation.
16249880|NCT05025878||[U-13C]glucose|All participants consented to the study will receive the [U-13C]glucose infusion and collection of ascites for research.
16249881|NCT05025865|Placebo Comparator|HA35 Placebo Group|12 study participants will be given a placebo capsule to take once per day in the morning with breakfast for 3 days.
16249882|NCT05025865|Active Comparator|HA35 Treatment Group|12 study participants will be given an HA35 capsule to take once per day in the morning with breakfast for 3 days.
16249883|NCT05025852||Metformin exposed in utero|Offspring of mothers who were exposed to metformin during pregnancy in the MiTy trial.
16249884|NCT05025852||Placebo exposed in utero|Offspring of mothers who were not exposed to metformin during pregnancy in the MiTy trial.
16249885|NCT05025839||C healthy|Healthy control group
16249886|NCT05025839||C pneum|Control group of patients who were hospitalised and diagnosed with pneumonia ( COVID-19 pneumonia excluded)
16249887|NCT05025839||Mild|Outpatients presenting to the hospital with COVID-19
16249888|NCT05025839||Moderate|In-patients with COVID-19 not requiring ICU admission
16249889|NCT05025839||Severe|Patients with COVID-19 admitted to the ICU
16249890|NCT05025826|Experimental|Phycocare|PHYCOCARE during 12 cycles of 14 days from day -3 before oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months) From D-3 to D14 before cycle 1 chemotherapy: patient will take Phycocare From D1 to D14 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Phycocare On days of chemotherapy the patient does not take Phycocare
16249891|NCT05025826|Placebo Comparator|Placebo|"Placebo during 12 cycles of 13 days from day -3 before cycle 1 of oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months).
~From D-3 to D13 before cycle 1 chemotherapy: patient will take Placebo From D1 to D13 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Placebo.
~On days of chemotherapy the patient does not take Placebo"
16249892|NCT05025813|Experimental|Arm A|"Neoadjuvant Pembrolizumab 4 cycles, 200mg IV Q3W followed by interval restaging:
~If restaging imaging positive will have Radical Neck Resection followed by Pembrolizumab 17 cycles, 200mg IV Q3W +/- External Beam Radiotherapy (if >10% viable tumour cells at resection) If restaging imaging negative will have Mapping biopsy. If biopsy positive will proceed to Radical Neck dissection followed by Pembrolizumab 17 cycles 200mg IV, Q3W If biopsy negative will proceed to Pembrolizumab 17 cycles 200mg IV, Q3W"
16249893|NCT05025800|Experimental|Treatment (ALX148, rituximab, lenalidomide)|Patients receive ALX148 IV over 1 hour once on days 1, 8, 15 and 22, or days 1 and 15, or day 1 depending on dose level. Patients also receive rituximab IV over 4-6 hours on days 1, 8, 15 and 22 of cycle 1, then on day 1 of cycles 2-6, and lenalidomide PO QD on days 1-21 of cycles 1-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16249898|NCT05025774||Case|Adolescent or young adult acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant
16249899|NCT05025774||Control|14-25 years old healthy individuals who are ambulatory without assistance. We may enroll younger subjects but we wish to subjects to match our patient population
16249900|NCT05025761|Experimental|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN),insect repellent (DEET), Insecticide-treated clothes (ITC), and mobile and migrant population-tailored behavioural change communication (BCC) package
16249901|NCT05025761|No Intervention|Control|No personal protection package
16249976|NCT05025163|Experimental|fluoride foam group|intervention; fluoride foam application (with 1.23% fluoride foam application on teeth )
16249902|NCT05025748|Experimental|Health services research (ASQ brochure)|Patients receive ASQ brochure and complete questionnaires over 30 minutes at baseline, over 10 minutes pre-clinic visit, and over 30 minutes post-clinic visit.
16249904|NCT05025722||Confirmed PXE participants|Participants who have index PXE/proband with established PXE and ABCC6 mutations identified.
16249905|NCT05025722||PXE carrier participants|Participants who are biological siblings of the PXE index case and confirmed as PXE carrier.
16249906|NCT05025722||Non-PXE normal participants|Participants who are biological siblings of PXE index case and confirmed as non-PXE normal.
16249907|NCT05025696|Experimental|Intervention|Blacksoap(R) applied whole body twice daily
16249908|NCT05025696|Placebo Comparator|Control|Johnson and Johnsons Baby Soap applied whole body twice daily
16249909|NCT05025657|Experimental|Program|
16249910|NCT05025657|Placebo Comparator|Control|
16249911|NCT05025644|Experimental|Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)|"Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded.
~Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded.
~If LVOT PG post myectomy are >16 mmHg, the surgeon will be advised, for surgical management considerations."
16249912|NCT05025644|Experimental|Preoperative PG under anesthesia ≥ 50mmHg (Group B)|"Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded.
~Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is >16 mmHg will be recorded."
16249913|NCT05025605|Experimental|80 Micrograms|Sublingual film containing 80 micrograms Dexmedetomidine
16249914|NCT05025605|Experimental|120 Micrograms|Sublingual film containing 120 micrograms Dexmedetomidine
16249915|NCT05025605|Placebo Comparator|Placebo|Sublingual Placebo film
16249916|NCT05025592||cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody|patients will receive the combination treatment of cTACE/DEB-TACE plus HAIC and combined with regorafenib and anti-PD1 antibody or not. The anti-PD-1 antibody will be used depended on the contraindications or wishes of patients.
16249917|NCT05025579|Experimental|Exercise group|Considering the protocol suggested in the literature and by examining exercise samples for geriatric individuals, an exercise protocol was created. The first week started with aerobic exercises with a total of 120 minutes, and the next week increased to 160 minutes . A 6-week exercise program was planned and applied 4 days a week in which the intensity was increased gradually. People 's heart rate, blood pressure and respiratory frequency exercise program implementation before and after was recorded in the evaluation form.
16249918|NCT05025566||Psychotic disorders|
16249919|NCT05025566||Depressive disorders|
16249920|NCT05025566||Bipolar disorders|
16249921|NCT05025566||Anxiety disorders|
16249922|NCT05025566||Autism spectrum disorders|
16249923|NCT05025566||Eating disorders|
16249924|NCT05025566||Healthy volunteers|
16249925|NCT05025553|Other|Gut mobilization|Polyethylene Glycol (PEG) at the dose of 6.9 g/d once a day for 6 months.
16249926|NCT05025540||Experimental group|"patients with diabetes
~patients with diabetic kidney disease"
16249927|NCT05025540||Control group|"patients with diabetes
~patients without diabetic kidney disease"
16249928|NCT05025527|Experimental|bpMRI|Man receive the bpMRI for Prostate cancer screening
16249929|NCT05025527|Active Comparator|PSA|Man receive the PSA blood test for Prostate cancer screening
16249931|NCT05025501|Experimental|Intervention group|"Subjects in this group will receive the Famliy based Executive Function Training  program in aiming to reduce ADHD symptoms and improve the executive function."
16249932|NCT05025501|No Intervention|Waiting group|"Subjects in this group will not receive the Famliy based Executive Function Training  program during the study period."
16249933|NCT05025488|Experimental|CALR mutated|peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations
16249934|NCT05025475|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), transseptal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present), and rate of a recurrent neurologic embolic event in patients with cryptogenic stroke and PFO.
16249935|NCT05025475|Active Comparator|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials
16249936|NCT05025462|Experimental|SPF|Salmon peptide fraction supplement: powder mixed in water
16249937|NCT05025462|Active Comparator|Comparator|Casein peptide fraction supplement: powder mixed in water
16249939|NCT05025436|Experimental|Acupoint Laser Group|Each subject in the experimental group was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/- 10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, pause 2 After two weeks, the two groups crossed over and carried out 4 weeks of intervention.
16249977|NCT05025163|Experimental|fluoride varnish group|intervention; fluoride varnish application (with 2.26% fluoride varnish application on teeth)
16249940|NCT05025436|No Intervention|Control Group|Each subject in the control group was given the same main acupoints (5 acupoints) and constitution matching acupoints (1-2 acupoints) without energy acupoint care (therapeutic dose is 0 joules per acupoint), three times a week, after 4 weeks After a two-week suspension, the two groups crossed over for another four-week intervention.
16249942|NCT05025410||General anesthesia using remimazolam and remifentanil|Adult female patients scheduled for gynecological surgery under general anesthesia using remimazolam and remifentanil
16249949|NCT05025358|Experimental|LP-118|"An accelerated titration for the first two dose cohorts (50mg and 100mg) followed by classic 3+3 design for the rest of dose cohorts (200mg, 300mg, 400mg and 500mg) will be used in this study."
16249950|NCT05025345|Experimental|Study Lens|Tecnis Eyhance
16249951|NCT05025345|Active Comparator|Control Lens|Tecnis 1 piece IOL (Intraocular lens)
16249952|NCT05025332|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.
16249953|NCT05025319||Taditional Grid|Patients imaged with traditional grid
16249954|NCT05025319||Virtual Grid|Patients imaged with virtual grid
16249955|NCT05025306|No Intervention|control group|only atraumatic extractions were done, honey was not applied
16249956|NCT05025306|Experimental|experimental group|ziziphus honey was applied into the sockets after tooth extractions in experimental group
16249957|NCT05025293|Experimental|ZOLearly|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 5mg zoledronate (Aclasta) will be administered intravenously.
~The ZOLearly group will have no further infusions during the study period."
16249958|NCT05025293|Placebo Comparator|ZOLlate|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 100ml NaCl 9mg/ml (placebo) will be administered intravenously.
~3 months after hip fracture surgery (at the out-patient clinic): A single dose of 100 ml containing 5mg zoledronate (Aclasta) will administered intravenously."
16249962|NCT05025254||PD patients|This is an observational study. The PD patient group will consist of participants who self-report that they have a diagnosis of Parkinson's disease
16249963|NCT05025254||Healthy controls|This is an observational study. The healthy control group will consist of participants who self-report that they do not have a diagnosis of Parkinson's disease
16249964|NCT05025241|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.
16249965|NCT05025228||Paracetamol IV|Patients with femur fracture that received an initial analgesic treatment with paracetamol intravenously (IV).
16249966|NCT05025228||Paracetamol OR|Patients with femur fracture that received an initial analgesic treatment with paracetamol orally (OR).
16249967|NCT05025215|Experimental|Group A： Precise|The experimental group accepts improved precise aerosol inhalation nursing program，which was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc. This group is planned to enroll 100 patients.
16249968|NCT05025215|Experimental|Group B：Traditional|The control group accepts traditional aerosol inhalation nursing method. This group is planned to enroll 100 patients.
16249969|NCT05025202|Experimental|IET|Participants allocated to this arm performed 4 weeks of isometric wall squat exercise training, 3 times per week.
16249970|NCT05025202|Sham Comparator|Sham|Participants allocated to this arm performed 4 weeks of isometric wall squat training, but the training prescription was intentionally provided at an insufficient intensity to achieve any physiology stimulus.
16249971|NCT05025202|No Intervention|No intervention control|Participants allocated to this arm did not perform any exercise and were required to maintain usual daily habits.
16249972|NCT05025189|Active Comparator|Table Grape|Subjects will consume 4 weeks of (two servings) of standardized Freeze-Dried Whole Table Grape Powder
16249973|NCT05025189|Placebo Comparator|Beige Diet|Subjects will consume 4 weeks of a beige diet (low in fiber and low in polyphenols)
16249974|NCT05025176||Surgery requiring Invasive arterial pressure monitoring|Patients undergoing elective surgery that requires Invasive arterial pressure monitoring as standard of care.
16249978|NCT05025137|Experimental|Flexi-Bar group|Participants in the Flexi-Bar group performed a 60-minute Flexi-Bar exercise every week for 12 consecutive weeks.
16249979|NCT05025137|Experimental|Multi-Component exercise group|Participants in the Multi-Component exercise group performed a 60-minute Multi-Component exercise every week for 12 consecutive weeks.
16249980|NCT05025124||Method comparison|400 samples to be compared directly against the reference method. This is to get the bias estimate.
16249981|NCT05025124||Precision|30 samples will be each split into 10 individual samples to evaluate the precision of the Entia Liberty devices.
16249982|NCT05025098|Active Comparator|Standard therapy|"This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined).
~Standard treatment for AML patients is Azacitidine + Venetoclax.*
~*Only if venetoclax is available to the study at the time-point of study start. If venetoclax is not available AML patients will receive Azacitidine alone similar to MDS patients.
~Standard treatment for MDS is Azacitidine."
16249983|NCT05025098|Experimental|Precision therapy|This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined). The precision therapy arm will receive standard therapy + tumor board decided precision therapy. The tumor board decided precision therapy can in principle be any therapy with marketing authorization in Norway.
16249986|NCT05025072|Experimental|Test IMP|Hydroxycarbamide dispersible tablets (20 x 50 mg)
16249987|NCT05025072|Active Comparator|Reference IMP|Hydroxycarbamide film-coated tablet (1000 mg)
16249988|NCT05025059|Experimental|Supportive care (coaching, exercise, questionnaire)|Patients participate in one-on-one coaching sessions with a health coach QW to discuss the content offered in the program, and challenges they are currently facing in achieving their exercise goals. Patients receive a copy of the WWE workbook, wear a fitness tracker and are encouraged to achieve 150 minutes of walking per week during chemotherapy and up to 1 month after chemotherapy. Patients also participate in the Growing Stronger Strength Training Program and receive instruction manuals. They perform the initial 2 exercises 2 days per week for 4 weeks, and subsequent 2 exercises 2 days per week for the remainder of the chemotherapy course. Patients maintain exercise logs and complete questionnaires over 30-45 minutes at baseline, end of chemotherapy and at 1 month after chemotherapy.
16249989|NCT05025046||Ultrasound findings of thyroid nodules classified as type 3 and 4a of TIRADS|
16249990|NCT05025033|Experimental|PD-1 antibody combined with apatinib and chemotherapy|PD-1 antibody: 200mg intravenous drip every 3 weeks; Apatinib: 250mg/day; Chemotherapy: Irinotecan: 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel: 150mg/m2, intravenous drip once every 3 weeks.
16249991|NCT05025020|Experimental|Standard consultation with interactive 3D visualization|Participants in this group will use the interactive 3D tool in addition to receiving the standard surgical consultation before their breast reconstruction procedure.
16249992|NCT05025020|Active Comparator|Standard consultation|Participants in this group will receive a standard surgical consultation before their breast reconstruction procedure.
16249993|NCT05025007||Cohort 1|The study cohort will consist of patients with spastic diplegic cerebral palsy who were admitted to our outpatient and inpatient clinics of the Physical Medicine and Rehabilitation Department.
16249994|NCT05024994|Experimental|E7820|Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
16249995|NCT05024981|Active Comparator|Classic reeducation|
16249996|NCT05024981|Experimental|Classic reeducation + videographic feedback|
16249997|NCT05024968|Experimental|Treatment (sintilimab)|The study drug is sintilimab. The first dose of study treatment should start on Day 1 of Cycle 1. For the rest of the treatment cycles, the study treatment can be administered 3 day before or 3 days after the scheduled day of administration. Treatment can be delayed for up to 1 week if the administration day is on a holiday or if the subject is otherwise unavailable.
16249998|NCT05024955||Observational (interview, discussion)|Participants attend an interview over 45-60 minutes and/or a focus group over 1.5 to 2 hours.
16249999|NCT05024942||Severe aortic stenosis patients undergoing TAVR|Severe aortic stenosis patients undergoing TAVR will be stratified according to LUS evaluated pulmonary congestion before and after TAVR
16250000|NCT05024916|Experimental|Intervention|Participants will receive the dietary intervention. Participants will take 1 serving of blueberries/day.
16250001|NCT05024916|Active Comparator|Control|Participants will receive a placebo. Participants will take 1 serving of placebo/day.
16250002|NCT05024903|Active Comparator|Control Group: (PWG 1.0)|Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection
16250003|NCT05024903|Active Comparator|Intervention group: PWG 2.0|Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead
16250004|NCT05024890|Experimental|WASH in Schools programme|Schools in the intervention group will receive the Splash WASH in Schools programme (Project WISE) during the study period (2021/2022 academic year), including sanitation, water storage and filtration, drinking water and handwashing stations, and hygiene and menstrual health education.
16250005|NCT05024890|No Intervention|Control|Schools in the control group will receive no intervention during the study period (2021/2022 academic year), but will be on a waitlist to receive the Project WISE intervention after the end of the study period (2022/2023 academic year or later).
16250006|NCT05024877|Experimental|Hetrombopag treatment group|stanozolol 2mg tid + Hetrombopag (started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
16250082|NCT05024357|Experimental|Dasatinib for 6 months|After the allo-HSCT treatment, the patients in this group will receive dasatinib for 6 months.
16250083|NCT05024344|Active Comparator|ESP Group|One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-
16250007|NCT05024864|Active Comparator|Helicobacter pylori screening|At centers randomized to screening, all patients with confirmed MI will be tested H. pylori infection with a bedside UBT incorporated into MI routine care during the hospitalization period. In patients tested H. pylori positive, standard triple eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.
16250008|NCT05024864|No Intervention|Usual care without Helicobacter pylori screening|At centers randomized to no screening, all MI patients will receive usual care and will be followed in national registries. Concerning the use of eradication therapy and other relevant medication), follow-up is performed in the National Drug Prescription Registry.
16250009|NCT05024851||Patients with Psychogenic pruritus|
16250010|NCT05024851||Patients with Neuropathic Pruritus|
16250011|NCT05024838||Spinal anesthesia|The investigators retrospectively collected the electronic medical record of patients receiving spinal anesthesia from July 1, 2018, to Dec 31, 2018. Patients less than 18 years old were excluded from this study.
16250012|NCT05024825|Experimental|Gabapentin|Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
16250013|NCT05024825|Active Comparator|Hydrocodone|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
16250014|NCT05024812|Experimental|Experimental|fruquintinib + toripalimab + SOX
16250015|NCT05024799|Experimental|F-P group|the combination of fentanyl and propofol
16250016|NCT05024799|Experimental|F-D group|the combination of fentanyl and dexmedetomidine
16250017|NCT05024799|Experimental|B-P group|the combination of butorphanol and propofol
16250018|NCT05024799|Experimental|B-D group|the combination of butorphanol and dexmedetomidine
16250019|NCT05024786||control group|
16250020|NCT05024786||CQI group|
16250021|NCT05024773|Experimental|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|
16250022|NCT05024760|No Intervention|Control|This arm will receive standard of care during dental implant insertion.
16250023|NCT05024760|Experimental|Chlorhexidine|Chlorhexidine treatment.
16250024|NCT05024760|Experimental|Hydrogen Peroxide|Hydrogen Peroxide treatment.
16250025|NCT05024747|Experimental|Test Product|Participants will receive a single NicoDerm CQ patch (GSK Dungarvan) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
16250026|NCT05024747|Active Comparator|Reference Product|Participants will receive a single NicoDerm CQ patch (Alza) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
16250027|NCT05024734|Experimental|Epirubicin|"Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.
~If no significant drug selection can be performed in-vitro, Epirubicin will be the default for instillation."
16250028|NCT05024734|Experimental|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
16250029|NCT05024734|Experimental|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
16250030|NCT05024734|Experimental|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
16250031|NCT05024721|Experimental|HIP2101|Taking HIP2101+HPP2102 once daily for 2 weeks.
16250032|NCT05024721|Active Comparator|RLD2101|Taking RLD21012101+HPP2101 once daily for 2 weeks.
16250033|NCT05024708|Experimental|ARVC patients|
16250034|NCT05024708|Active Comparator|Endurance athletes with a dilated RV|
16250035|NCT05024708|Active Comparator|Endurance athletes with normal RV|
16250036|NCT05024708|Experimental|Untrained subject with normal RV|
16250037|NCT05024695|Experimental|Implant Group|
16250038|NCT05024682|Experimental|conventional pulsed radiofrequency|
16250039|NCT05024682|Experimental|pulse dosed pulsed radiofrequency|
16250040|NCT05024669|No Intervention|Control Group|where no desensitizer application was done,
16250041|NCT05024669|Experimental|Group GL|applied with Gluma dentin desensitizer
16250042|NCT05024669|Experimental|Group SF|applied with Shieldforce desensitizer
16250043|NCT05024669|Experimental|Group TC|applied with Telio CS desensitizer
16250044|NCT05024656|Experimental|AmnioExcel Plus Amniotic Membrane + Standard of Care|"AmnioExcel Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering in the homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AmnioExcel Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271.
~Standard of care includes the following:
~Coban™
~Conforming gauze
~Optifoam® non-adhesive dressing
~Xtrasorb® for highly exudated wounds
~Cotton Gauze
~Normal saline (liquid or gel)
~Non-adhering dressings
~Steristrips
~Offloading boot, as appropriate"
16250045|NCT05024656|Active Comparator|Standard of Care|"Coban™
~Conforming gauze
~Optifoam® non-adhesive dressing
~Xtrasorb® for highly exudated wounds
~Cotton Gauze
~Normal saline (liquid or gel)
~Steristrips
~Offloading boot, as appropriate"
16250046|NCT05024630|Experimental|RDN+PVI group|The experimental group received renal artery cryoablation and pulmonary vein cryoablation. Pulmonary vein cryoablation was first followed by renal artery cryoablation.
16250047|NCT05024630|Sham Comparator|PVI only group|The control group received pulmonary vein cryoablation alone. To ensure single blindness, the control group received femoral artery puncture and renal arteriography after cryoablation.
16250084|NCT05024344|Sham Comparator|Sham Group|One 30mL syringe containing 30mL of preservative free normal saline
16262149|NCT04940923||Patients|Patients within 4 weeks of a whiplash injury.
16250048|NCT05024617||trigger finger stage 1-2-3|Volunteer patients between 35-65 years old diagnosed with Stage 1, Stage 2 and Stage 3 trigger finger based on the Froimson Classification were included in the study. Exclusion criteria include paediatric trigger finger, trigger thumb, concomitant de'Quervain tenosynovitis, carpal tunnel syndrome, or Dupuytren's contracture, neurological or rheumatological diseases, chronic pain syndromes, pregnancy and patients with treatment history of related finger/fingers
16250049|NCT05024604||study group|women receiving mini pills as a method of contraception with symptoms not diagnosed with us
16250050|NCT05024604||Control group|women attending to office hysteroscopy unit and not taking hormonal therapy
16250051|NCT05024591||same as study population|Use of AI-based CADe/x by breast radiologists
16250052|NCT05024578|Sham Comparator|Sham|In the sham condition, participants will wear the EEG headband monitor (DREEM2, Dreem, Paris, France) for 1 week, but the sound stimulation feature will be deactivated.
16250053|NCT05024578|Experimental|Auditory Stimulation|In the active experimental condition, participants will complete 1 week of slow oscillation (SO) stimulation with the EEG headband monitor (DREEM2, Dreem, Paris, France) in the form of auditory stimuli (100ms pink noise pulses, i.e., below the waking threshold as established in prior work) sent on the ascending phase of the SO during N3 sleep.
16250054|NCT05024565|Experimental|prolonged intravenous infusion of β-lactams Antibiotics|Administer according to the PK/PD optimized regimen with the goal of increasing T>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
16250055|NCT05024565|No Intervention|short-term intravenous infusion of β-lactams Antibiotics|The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes.
16250056|NCT05024552|Experimental|Dose Escalation Arm|"Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy. The induction and reinduction dose of Vyxeos is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.
~Dose level 1: Vyxeos + 120 mg Gilertinib
~In the event of a dose-limiting toxicity (DLT) at the initial dose level, a dose level minus (-) 1 is permitted Dose Level -1: Vyxeos + 80 mg Gilertinib"
16250057|NCT05024552|Experimental|Dose Expansion Arm|Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy in the dose determined in the dose escalation arm.
16250058|NCT05024539||Regorafenib group|Patients were given only regorafenib orally
16250059|NCT05024539||Joint group|The patient was treated with regorafenib orally and in combination with other medications
16250060|NCT05024526|Experimental|edaravone dexborneol group|
16250061|NCT05024526|Active Comparator|edaravone group|
16250062|NCT05024513|Experimental|BD-HAIC (Biliary drainage & HAIC)|The patients enrolled in this arm would receive external percutaneous biliary drainage plus 3Cir-OFF hepatic arterial infusion chemotherapy （HAIC）with oxaliplatin and 5-fluorouracil.
16250063|NCT05024513|Active Comparator|BD-BSC (Biliary Drainage & Best supportive care)|The patients enrolled in this arm would receive biliary drainage, biliary stents,or biliary stents with Iodine-125 seed strands, plus best supportive care.
16250064|NCT05024500|Experimental|ADRSNet protocol|ARDSnet protocol is the current, standard of care for ARDS. Its used by setting PEEP and the fraction of inspired oxygen (FiO2) to achieve the oxygenation goal (SpO2 ≥ 93% - accepting the range of 90-96%)
16250065|NCT05024500|Experimental|Driving Pressure (DP)|setting PEEP after performing a modified alveolar recruitment maneuver followed by a decremental PEEP titration electing the level correspondent to the lowest driving pressure.
16250066|NCT05024500|Experimental|Electrical Impedance Tomography (EIT)|After performing a modified alveolar recruitment maneuver, the PEEP decremental titration guided by the EIT will be set at the level above the intersection of the curves representing relative alveolar overdistention and collapse.
16250067|NCT05024487|Experimental|Experimental group|The correlation between blood pressure level, dermal resistance level, and subjective symptoms caused by triggered AD below the level of the lesion will be performed in a group of SCI people.
16250068|NCT05024474|Experimental|Intervention: inspiratory muscle training + physical exercise|Inspiratory muscle training (IMT) twice a day for 8 weeks combined with a physical exercise program at least two times a week for 8 weeks.
16250069|NCT05024474|Active Comparator|Active control: physical exercise|A physical exercise program at least two times a week for 8 weeks.
16250070|NCT05024461|Experimental|Patient with an indication for a COVID19 test|The persons included will be those who have an indication for a COVID 19 test and who present themselves at the Cayenne hospital and during the screening missions organised by the Red Cross and Médecin du Monde during the COVID 19 epidemic in the territory
16250071|NCT05024448|Active Comparator|Prednisone|Prednisone, 60mg/d, for 10 days
16250072|NCT05024448|Placebo Comparator|Placebo|
16250073|NCT05024435|Experimental|Nasogastric Tube|
16250074|NCT05024435|Experimental|Lisacath|
16250075|NCT05024422|Active Comparator|Administration of Cabergoline|one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days
16250076|NCT05024422|Active Comparator|Administration of Vitamin B6|200 mg X 3 per day for a week
16250077|NCT05024409|Experimental|Orthotic + Occupational Therapy|
16250078|NCT05024409|Active Comparator|Occupational Therapy alone|
16250079|NCT05024396|Experimental|maximum jump height|Two visits will take place 1-2 weeks apart. At the first visit, participants will complete 2x3 single-leg countermovement jumps measured by two subjects each. At the second visit, three jumps are completed measured by the first test subject.
16250080|NCT05024370||Multiparas, planned cesarean section|Multiparas having a planned cesarean section at the departement of Obstetrics and Gynecology in Herning Hospital. Uncomplicated pregnancy that makes early discharge possible.
16250081|NCT05024357|Experimental|Dasatinib for 1 year|After the allo-HSCT treatment, the patients in this group will continue to take dasatinib orally for 1 year.
16250085|NCT05024331||Pediatric physicians|"Assigned Interventions
~Prediction of the first date of recovery period with given data about chemotherapy of pediatric patients who diagnosed solid tumor at Samsung medical center during 2010-2018
~Sees the result of the prediction algorithm.
~Change or maintain their prediction values.
~Participate in the usability questionnaires."
16250086|NCT05024318|Active Comparator|SABR plus nephrectomy|Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
16250087|NCT05024318|Experimental|Pembrolizumab followed by SABR after cycle 1 plus nephrectomy|Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.
16250088|NCT05024305|Experimental|Dose Escalation Cohort|Four dose levels of TWP-102 injection will be tested by BOIN study design.
16250089|NCT05024305|Experimental|Dose Expansion Cohort|Once the effective doses have been determined, two expansion cohorts will be opened to evaluate the efficacy and safety in one or two tumors.
16250090|NCT05024292||Anterior circulation cerebral infarction|
16250091|NCT05024292||Posterior circulation cerebral infarction|
16250092|NCT05024279|Experimental|Intervention Arm|Patients are randomized to receive left bundle branch are pacing due to higher degree AV block
16250093|NCT05024279|Active Comparator|Control Arm|Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.
16250094|NCT05024266|Experimental|Tislelizumab + Albumin Paclitaxel + Carboplatin|Tislelizumab 200mg d1, Albumin Paclitaxel 260mg/m2 d1, Carboplatin AUC5 d1, Q3W
16250095|NCT05024253|Experimental|patient is receiving Tranexemic acid (TXA )|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare TXA injection at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).
~Maintenance dose: Throughout surgery, continuous infusion at a dose of 5mg/kg/hour will be given until wound closure."
16250096|NCT05024253|Placebo Comparator|standard treatment (saline)|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare 50 ml of 0.9% saline or TXA at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).
~Maintenance dose: Throughout surgery, continuous infusion of saline will be given until wound closure."
16250097|NCT05024240|Experimental|Patient group|20 patients with cerebellum disorders, who suffer from stability disorders and with specific 3 Hz tremor
16250098|NCT05024240|Active Comparator|Control group|20 healthy age-matching probands without any neurological disorders and stability issues
16250099|NCT05024227|Experimental|Experimental: nursing education interventions|nursing education interventions (including e-health platform assistance)
16250100|NCT05024227|No Intervention|No Intervention: Routine care|Only the original form of nursing education leaflets are given
16250107|NCT05024201|Experimental|experimental group for effect of therapeutic touch|Therapeutic touch was applied to the experimental group for three days every other day.
16250108|NCT05024201|No Intervention|control group for effect of therapeutic touch|No application was applied to the control group. Only pretest and posttest were done.
16250109|NCT05024188|Experimental|Antibiotics + FMT|7 days of antibiotics- Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 10 aFMT capsules for three consecutive days (a total of 30 capsules).
16250110|NCT05024188|Placebo Comparator|Placebo|7 days of cellules pills. After cellules pills administration, participants will receive 10 agarose capsules for three consecutive days (a total of 30 capsules).
16250111|NCT05024175||CARv3-TEAM-E T cells|"Eligibility to participate on this study if enrolled on study 20-532 and received infusion of CARv3-TEAM-E T
~The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol
~Medical History/Physical Exam
~Blood Test
~Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.
~Tumor biopsy.
~Data Collection
~Biobanking"
16250112|NCT05024162|Experimental|Prospective Cohort|Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).
16250113|NCT05024149|Experimental|Healthy group|Subjects in this group will not undergo acupuncture intervention. For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s. In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment). At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.
16250114|NCT05024149|Experimental|MDD electroacupuncture intervention group|
16250160|NCT05023941|Experimental|Combined Group|Medicine + Rapid RIPC
16263270|NCT04932876||KTR|Kidney Transplant Recipient
16250115|NCT05024149|Experimental|MDD waiting-list group|In this study, we used a waiting list control group. During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention. After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.
16250116|NCT05024136|Active Comparator|Placebo|Subjects take 30 mins aromatherapy of Limon essential oil per time, a total of 3 times for the month.
16250117|NCT05024136|Experimental|Experimental|Subjects take 30 mins aromatherapy of vetiver essential oil per time, a total of 3 times for the month.
16250118|NCT05024123|Placebo Comparator|Placebo|
16250119|NCT05024123|Experimental|Experimental|
16250120|NCT05024110|Experimental|Group I|GI received high-intensity exercise training.
16250121|NCT05024110|Experimental|Group II|GII received moderate-intensity exercise training.
16250122|NCT05024097|Experimental|Radiation therapy and etrumadenant (AB928)|Enrolled patients will receive Radiation therapy of 25 Gy in 5 fractions along with etrumadenant 150mg oral drug taken once daily. this will then be followed by 9 cycles of FOLFOX in combination of etrumadenant and zimberelimab investigational drugs.
16250123|NCT05024084|Active Comparator|Group Sevoflurane|The patients in this arm will be given Sevoflurane (2-3%) as volatile anesthetic throughout the duration of anesthesia.
16250124|NCT05024084|Active Comparator|Group Desflurane|The patients in this arm will be given Desflurane (7-8%) as volatile anesthetic throughout the duration of anesthesia.
16250125|NCT05024071|Experimental|Swiss Ball|Swiss ball practice can create an unstable environment, promote the recovery of muscle function and develop joint stability. It can train the muscle groups in chest, abdomen, back, buttocks and legs, which play an important role in maintaining body balance and improving athletes' body.
16250126|NCT05024071|Experimental|Balance Plate|The balance board can exercise athletes' waist explosive force and body balance ability in an unstable state.
16250127|NCT05024058|Experimental|Ligelizumab low dose, symptomatic dermographism group|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
16250128|NCT05024058|Experimental|Ligelizumab high dose, symptomatic dermographism|Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
16250129|NCT05024058|Placebo Comparator|Placebo SC q4W, symptomatic dermographism|Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism
16250130|NCT05024058|Experimental|Ligelizumab low dose, cold urticaria|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria
16250131|NCT05024058|Experimental|Ligelizumab high dose, cold urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria
16250132|NCT05024058|Placebo Comparator|Placebo SC q4w, cold urticaria|Placebo subcutaneous injection every 4 weeks in participants with cold urticaria
16250133|NCT05024058|Experimental|Ligelizumab high dose, cholinergic urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria
16250134|NCT05024058|Placebo Comparator|Placebo SC q4w, cholinergic urticaria|Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria
16250140|NCT05024019|Experimental|Study group|The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.
16250141|NCT05024019|No Intervention|Control group|The control group received radiotherapy alone.
16250142|NCT05024006|No Intervention|LSoC|Local Standard of Care
16250143|NCT05024006|Experimental|Rem+LSoC|Remdesivir with Local Standard of Care
16250144|NCT05024006|Experimental|HCQ+LSoC|Hydroxychloroquine with Local Standard of Care
16250145|NCT05024006|Experimental|Lopi/Rito+LSoC|Lopinavir/Ritonavir with Local Standard of Care
16250146|NCT05024006|Experimental|Lopi/Rito+IFN+LSoC|Lopinavir/Ritonavir and Interferon Beta 1a with Local Standard of Care
16250147|NCT05024006|Experimental|IFN+LSoC|Interferon Beta 1a with Local Standard of Care
16250148|NCT05024006|Experimental|ACB+LSoC|Acalabrutinib with Local Standard of Care
16250155|NCT05023954||A|A longitudinal observational study looking at the pregnancy journey of 200 women Bloods taken for sepsis biomarkers including a genomic sepsis-test throughout the pregnancy journey
16250156|NCT05023954||B|A consecutive collection of data from 100 pregnant women with suspected sepsis Bloods taken for Sepsis Biomarkers including a genomic sepsis-test throughout the sepsis episode
16250157|NCT05023941|Active Comparator|Medicine Group|Start orally take Acetazolamide 2 days before entering the hypoxic room.
16250158|NCT05023941|Active Comparator|RIPC Group|Start RIPC training twice daily, 6 days before entering the hypoxic room.
16250159|NCT05023941|Experimental|Rapid RIPC Group|Start RIPC training forth daily, 3 days before entering the hypoxic room.
16250161|NCT05023941|No Intervention|Control Group|Subjects do not receive specific interventions before entering the hypoxic room.
16250162|NCT05023928|Experimental|Tumor antigen-sensitized DC vaccine|"Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.
~2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times."
16250163|NCT05023915|Active Comparator|diammonium glycyrrhizinate enteric-coated capsule + high-dose dexamethasone|Diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months, combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
16250164|NCT05023915|Active Comparator|High-dose dexamethasone|Dexamethasone orally at a dose of 40 mg qd for 4 days. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
16250165|NCT05023902|Active Comparator|Pilates|The Pilates Mat exercise group followed an eight-week exercise program. The exercise protocol of this study was designed by the researchers (Table I). According to previous reports, 6 to 8 weeks of Pilates training has positive effects on physical and psychological health (Akbas, Unver, 2021; Bavli & Koybasi, 2016; Pourvaghar, Bahram, Sharif & Sayyah, 2014; Rogers & Gibson, 2009). As the program advanced, 20-cm diameter mini soft balls, Pilates rings, 65 cm diameter soft gymnastic balls, and rubber bands were used in this order as materials in Pilates exercises. After an initial warm-up exercises at a slow pace for 10 minutes, Pilates exercises with and without equipment were performed for 40 minutes. The exercises ended with a 10- minute recovery and stretching exercises for relaxation of all muscle groups
16250166|NCT05023902|Experimental|NIA Dance|NIA includes nine basic movement forms, 13 principles, and 52 basic moves. The nine movement forms were derived from martial arts, dance arts, and the healing arts of the Alexander Technique, Feldenkrais Method, and Yoga (Rosas & Rosas, 2004). The 13 principles specify areas related to fitness, personal growth, and lifestyle. Centered on the joy of movement, they focus on, for example, being sensitive to personal rhythms, making the correct movement choices, and experiencing positive changes in daily life. The moves of NIA are used to engage all body areas, improve fitness, and facilitate self-healing.
16250167|NCT05023889|Other|open label|single open arm label
16250168|NCT05023876|Experimental|IASTM group|
16250169|NCT05023876|Experimental|Control Group|
16250170|NCT05023863|Active Comparator|Alpha Lipoic Acid Group (intervention group)|35 patients will receive radiation therapy with or without platinum-based chemotherapy in addition to alpha lipoic acid 600 mg tablets twice daily (throughout the radiotherapy period). .
16250171|NCT05023863|Placebo Comparator|Control Group|35 Patients will receive radiation therapy with or without platinum-based chemotherapy in addition to placebo tablets twice daily (throughout the radiotherapy period)
16250172|NCT05023850|Active Comparator|Group TLIP|"Patients will receive a Thoracolumbar Plane Block (TLIPB) under ultrasound guidance while under general anesthesia.
~Intervention: Patients will receive a TLIPB with 20mls 0.25% Bupivicaine bilaterally."
16250173|NCT05023850|Experimental|Group ESP|"Patients will receive an Erector Spinae Plane Block (ESPB) under ultrasound guidance while under general anesthesia.
~Intervention: Procedure: Patients will receive an ESPB with 20 ml 0.25% Bupivacaine bilaterally."
16250174|NCT05023824|Experimental|alpha-blocker withdrawal|receives 5-ARI monotherapy
16250175|NCT05023824|Experimental|5-ARI withdrawal|receives alpha-blocker monotherapy
16250176|NCT05023824|Active Comparator|combination therapy|receives alpha-blocker and 5-ARI
16250177|NCT05023811|Experimental|[14C]RIST4721|[14C]RIST4721 oral solution
16250178|NCT05023798||ATD Cohort 1|The first iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment.
16250179|NCT05023798||ATD Cohort 2|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250180|NCT05023798||ATD Cohort 3|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250181|NCT05023798||ATD Cohort 4|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250182|NCT05023798||ATD Cohort 5|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250183|NCT05023798||ATD Cohort 6|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250184|NCT05023798||ATD Cohort 7|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250185|NCT05023798||ATD Cohort 8|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250186|NCT05023798||ATD Cohort 9|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250187|NCT05023798||ATD Cohort 10|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
16250188|NCT05023785|Experimental|Cardio-Oncology Rehabilitation (CORE)|Participants in the CORE group will have (1) 2 HIIT sessions (1 facility- and 1 home-based) and 1 home-based MICT session, (2) CV risk factor management, and (3) behavioural support for the first 6 months. The behavioural support will continue for CORE participants from months 7-24. Behavioural support includes professionally guided and peer-enhanced exercise behavioural support based on behaviour change stage theories. CORE participants will be provided a wrist-worn heart and physical activity monitor to use throughout the 24-month observation period. After the supervised 6 month exercise period, participants will be asked to maintain a PAI Score of ≥100 for the remainder of the study period via the PAI Health App.
16250189|NCT05023785|No Intervention|Standard of Care 1 (CON1)|Participants in the CON1 group will receive standard medical care only.
16250301|NCT05022927|Experimental|Concomitant use part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab and to determine the MTD.
16250190|NCT05023785|Active Comparator|PAI Group (PAI)|Participants in the PAI group will be asked to download the same PAI Health application as CORE participants and be challenged to meet and maintain a weekly PAI Score ≥100 throughout the 24-month follow-up period.
16250191|NCT05023785|Active Comparator|Exercise Guidelines for Cancer Survivors (ExGL)|Participants in the ExGL group will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated weekly physical activity guidelines for cancer survivors (i.e. 90-150 minutes of moderate to vigorous-intensity physical activity).
16250192|NCT05023785|No Intervention|Standard of Care 2 (CON2)|Participants in the CON2 group will receive standard medical care only.
16250193|NCT05023772|Experimental|Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery|Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.
16250194|NCT05023746||Clinically diagnosed as non-small cell lung cancer samples|
16250195|NCT05023733||1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1|One to two contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1 whose condition requires the use of interbody fusion.
16250196|NCT05023720||Regorafenib group|Patients were given only regorafenib orally
16250197|NCT05023720||Joint group|The patient was treated with regorafenib orally and in combination with other medications
16250199|NCT05023694||Newborn reanimated video recordings|Newborns, requiring stabilization at birth in Delivery Room, prior authorization by verbal and written informed consent
16250200|NCT05023681|Experimental|r-SAK treatment group|intravenous injection of single bolus 5 mg r-SAK in 3min
16250201|NCT05023681|Placebo Comparator|saline control group|intravenous injection of 10ml saline in 3min,r-SAK and saline are the same in appearance
16250202|NCT05023668||Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy|Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy
16250203|NCT05023655|Experimental|Tazemetostat|tazemetostat 800 mg po twice daily in continuous 28- day cycles
16250204|NCT05023642|Experimental|resistance training|"Participants will not be offered the exercise program in the three months before data collection.
~From then on, participants will perform exercises during the resistance training protocol intervention."
16250205|NCT05023642|No Intervention|control group|Individuals in the control group will not be offered the exercise program in the three months before data collection and during the entire period corresponding to the 12-week intervention.
16250207|NCT05023616|Experimental|Real-time home CPR training|Online real-time home CPR(cardiopulmonary resuscitation) training will be provided to participants
16250208|NCT05023616|Active Comparator|Conventional CPR training|Conventional CPR training will be provided to participants
16250209|NCT05023590|Active Comparator|cryo ablation|cryo ablation of left atrium during mitral valve open chest intervention
16250210|NCT05023590|Active Comparator|radio frequency ablation|radio frequency ablation of left atrium during mitral valve open chest intervention
16250211|NCT05023577|Experimental|CL group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levoflaxacin 0.5 g qd for 14 days
16250212|NCT05023577|Experimental|LM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levoflaxacin 0.5 g bid for 14 days
16250213|NCT05023577|Active Comparator|CM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
16250214|NCT05023564||Early onset dementia|Dementia patients with onset age lower than 65y/o
16250215|NCT05023564||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
16250216|NCT05023564||Oldest old dementia|Dementia patients with onset age older than 85y/o
16250217|NCT05023564||Cognitive normal control|Normal Aging with normal cognitive function
16250218|NCT05023551|Experimental|Single arm DSP-0390|Arm Description [*] DSP-0390 by oral administration
16250219|NCT05023538|No Intervention|Usual care|No intervention
16250220|NCT05023538|Experimental|Low-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-30min/training session, 3x/week, 6 months
16250221|NCT05023538|Experimental|High-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-50min/training session, 3x/week, 6 months
16250222|NCT05023538|Experimental|Low-volume high-intense exercise|exercise at 50-85%VO2peak; 20-30min/training session, 3x/week, 6 months
16250225|NCT05023512|Experimental|Message 1|Participants will be randomized to receive version #1 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
16250226|NCT05023512|Experimental|Message 2|Participants will be randomized to receive version #2 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
16250227|NCT05023499||With glutamine supplementation|perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
16250228|NCT05023499||Without glutamine supplementation|no glutamine use
16250229|NCT05023486|Experimental|NP-G2-044 Monotherapy|NP-G2-044 capsule PO QD for each 28-day cycle
16250230|NCT05023486|Experimental|NP-G2-044 Combination Therapy With Anti-PD-(L)1 Therapy|NP-G2-044 capsule PO QD for each 28-day cycle, Anti-PD-(L)1 Therapy per standard of care, at a dose and frequency in accordance with the package insert
16250231|NCT05023473|Active Comparator|PENG block+ morhine|the participants will receive PENG block before being attached to morphine PCA
16250232|NCT05023473|Active Comparator|MORPHINE|The participants will be given morphine PCA without PENG block
16250582|NCT05021081|Experimental|TEST/CONTROL|For Phase 2, eligible subjects that are enrolled will be randomized to the Test/Control contralateral sequence.
16250233|NCT05023460|Active Comparator|Paresthesia-free (burst) ONS|"Implanted lead and impulse generator (IPG), paresthesia-free (burst) active stimulation.
~Lead implanted subcutaneously over greater occipital nerves. Implanted IPG capable of providing paresthesia-free stimulation continuously."
16250234|NCT05023460|Placebo Comparator|Placebo|Implanted lead and IPG, deactivated.
16250235|NCT05023447|Experimental|BRIDGE Intervention (+Service as Usual)|The brief, intensive assessment and integrated formulation (BRIDGE) intervention is delivered over 3-6 months and has a three-fold focus: Firstly, an intensive (post-randomisation) assessment, taking up to two sessions, including BPD symptoms, co-presenting difficulties, neurodevelopmental profile, life events history and psychosocial functional impact. Secondly, up to 16 sessions of Cognitive Analytic Therapy (CAT). Thirdly, development of a shared formulation with a multi-agency group; further development of the shared formulation with the young person, using CAT principles (Reformulation, Recognition and Revision) and, where clinically applicable, their family and service-providers.
16250236|NCT05023447|Active Comparator|Service as Usual|For participants randomised to Service-As-Usual (SAU), a routine letter of their participation will be shared with their service provider(s), including the GP. SAU, likely to range from social services, mentalhealth services, forensic services to no intervention will be mapped and described for each participant. Treatment fidelity to SAU will therefore not be assessed, but the nature and intensity of SAU in different contexts will be described in detail through the qualitative process evaluation.
16250237|NCT05023434||Awake Craniotomy|
16250238|NCT05023434||Healthy Volunteers|
16250239|NCT05023421||Problematic media use of children with CP|The participants in the current study were parents of children with CP aged 4-18 years. They were recruited at the Hacettepe University Physical Therapy and Rehabilitation Faculty Cerebral Palsy and Pediatric Rehabilitation Unit and Special Education and Rehabilitation Centers. The inclusion criteria were having a child with CP aged 2-18 years without severe cognitive problems, being a primary caregiver.
16250240|NCT05023408|Experimental|Intralesional Bleomycin|Intralesional Bleomycin has been given to palmo plantar warts. Generic name: Bleomycin Dose: 1mg/1ml (0.1%) Frequency: every 2 weekly for 6 weeks.
16250241|NCT05023408|Experimental|Cryotherapy|Cryotherapy has been given to palmo plantar warts. Frequency: every 2 weekly for 6 weeks
16250243|NCT05023382||Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily.
16250246|NCT05023356||Contact vital signs monitoring|Routine monitors with cables
16250247|NCT05023356||Non-contact vital signs monitoring|Camera
16250248|NCT05023343|Active Comparator|Active|Unilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine
16250249|NCT05023343|Placebo Comparator|Placebo|Unilateral transmuscular quadratus lumborum block using 30 mL isotonic saline
16250250|NCT05023317|Experimental|Strengths-based linkage to alcohol care (SLAC)|SLAC is a behavioral intervention designed to link persons with substance use/misuse to a care or help option
16250251|NCT05023317|Active Comparator|Usual care|Usual care consists of brief intervention in primary care and/or standard referral to more intensive alcohol care (e.g., outpatient/inpatient, pharmacotherapy)
16250252|NCT05023304|Experimental|Group A Dextenza|
16250253|NCT05023304|Active Comparator|Group B Topical Prednisolone|
16250254|NCT05023291|Other|test group|All patients who give their consent for this study will participate in the test group and will therefore receive the injection with 18F-FDG and images (PET / CT) will be made of the resection piece.
16250255|NCT05023278|Placebo Comparator|Placebo|Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.
16250256|NCT05023278|Experimental|Venlafaxine|Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.
16250257|NCT05023265|Experimental|SBRT for Medically Inoperable RCC|35-40 Gy in five fractions (7-8 Gy/day)
16250258|NCT05023252|Experimental|mobile application|Participants use a mobile application on their smartphone
16250259|NCT05023239|Sham Comparator|control group|patients will receive sham block by 10 ml of normal saline (5 mL in each side) as a control.
16250260|NCT05023239|Experimental|UG-SZM Group|The patients will be receive bilateral Ultrasound-Guided Suprazygomatic Maxillary (UG-SZM) Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine
16250261|NCT05023226|Placebo Comparator|LPVS group|The general ventilator setting.
16250262|NCT05023226|Experimental|LPVS + RM group|Recruitment maneuver.
16250263|NCT05023213|Experimental|Warna-Warni Waktu intervention|Participants in this condition will be asked to view six, approximately five minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
16250264|NCT05023213|No Intervention|Waitlist control condition|These participants will no be contacted during the intervention timeframe.
16250265|NCT05023200||Population|Adults (age ≥18 years) identified by their treating clinician as having lower limb cellulitis that requires intravenous or oral antibiotic treatment either from the hospital or another service based outside of the hospital, which will conduct ongoing follow-up regardless of location.
16250302|NCT05022927|Experimental|Biomarker part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to evaluate the biomarkers.
16250266|NCT05023187|Experimental|Social and Cognitive Online Training Group (SCOT)|A group of participants randomly assigned to a social-cognitive online training through individual cognitive training sessions and group sessions to improve social functioning.
16250267|NCT05023187|Active Comparator|Control Group (CON)|A group of participants randomly assigned to receive an active control intervention to compare performances with the experimental group.
16250270|NCT05023161||Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile|
16250271|NCT05023148|Active Comparator|Electroacupuncture with dietary intervention|"Acupoints stimulation with an electric stimulator on CV12 Zhongwan, CV9 Shuifen, CV6 Qihai, CV4 Guanyuan, ST25 Tianshu bilateral, SP15 Daheng bilateral, ST40 Fenglong bilateral using continuous 2 Hz for 30 minutes. Therapy sessions are three times a week for four weeks (total 12 times).
~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
16250272|NCT05023148|Active Comparator|Thread embedded acupuncture with dietary intervention|"Acupoints stimulation by embedding PDO thread in CV12 Zhongwan penetrating to CV9 Shuifen using 27G x 60 mm, CV4 Guanyuan penetrating to CV6 Qihai using 27G x 40 mm, ST25 Tianshu penetrating to SP15 Daheng using 27G x 40 mm, and perpendicular in ST40 Fenglong bilateral using 31G x 25 mm. Therapy will be done only once.
~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
16250273|NCT05023135||Subjects with Thermal Burn Injury|An initial imaging with the DV-SSP would be completed at the Study Site within 72 hours of suffering a thermal burn injury.
16250274|NCT05023122|Experimental|vitamin D3 + calcium|vitamin D3 (cholecalciferol) 800 IU QD and calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
16250275|NCT05023122|Active Comparator|calcium only|only calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
16250276|NCT05023109|Experimental|GP+PD-1+Tight|"Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.
~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
16250277|NCT05023096|Active Comparator|Menthol+Tobacco|Menthol+Tobacco - where both menthol and tobacco flavored liquids for electronic nicotine delivery systems are available to choose from
16250278|NCT05023096|Experimental|Tobacco|Tobacco - where only tobacco flavored liquid is available for electronic nicotine delivery systems
16250279|NCT05023096|Experimental|Unflavored|Unflavored - where only unflavored liquid is available for electronic nicotine delivery systems
16250280|NCT05023083||diseased individuals|post CABG patients will be included in the study to fill the tool
16250281|NCT05023083||healthy individuals|20 healthy individual will be included to solve questionnaire
16250282|NCT05023070|Experimental|Test condition 1|Nanoemulsion Cannabidiol 200 mg with standard meal
16250283|NCT05023070|Experimental|Test condition 2|Nanoemulsion Cannabidiol 400 mg with standard meal
16250284|NCT05023070|Experimental|Test condition 3|Epidiolex 400 mg with standard meal
16250285|NCT05023070|Experimental|Test condition 4|Nanoemulsion Cannabidiol 400 mg with high fat meal
16250286|NCT05023057|Experimental|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training and social activity; (3) physical exercise; (4) nutritional guidance; and (5) motivational training.
16250287|NCT05023057|No Intervention|Control|At baseline, the participants in the control group will meet a study doctor, be prescribed medication when necessary, and receive educational booklets corresponding to their risk factors and a booklet on lifestyle guidelines to prevent dementia. They will receive usual care during the study period and be informed that they could participate in the multidomain intervention program after this study end.
16250288|NCT05023031|Experimental|NVP-2102|NVP-2102
16250289|NCT05023031|Active Comparator|NVP-2102-R|NVP-2102-R
16250290|NCT05023018|Experimental|Patients with high-grade meningioma|30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma
16250291|NCT05023005|Experimental|Piriformis Strain-Counterstrain|The treatment group will receive strain-counterstrain for the piriformis muscle.
16250292|NCT05023005|Sham Comparator|Hamstring Strain-Counterstrain|The sham group will receive strain-counterstrain treatment for the hamstring muscle.
16250293|NCT05022992|Experimental|Resistance Training Session|Resistance training. Heavy resistance training. 10 reps x 3 set of upper- and lower-body resistance exercises
16250294|NCT05022992|No Intervention|Control|Control activity. None-exercising. 30 min of rest
16250295|NCT05022966||Older people|
16250296|NCT05022953|Experimental|Digital Story Group|"Digital Story Group: One of the researchers gave the experimental group participants a 15-minute briefing on how to perform digital storytelling. She also told them not to talk to the control group participants about the content of the briefing. She created a Pixton account (https://edu.pixton.com/educators/) and a class named Isolation. She sent the link (https://join.pixton.com/x5xb6) to the experimental group participants. She asked them to click on the link and make stories out of their knowledge of isolation in four weeks."
16250297|NCT05022953|No Intervention|Control Group|Control group participants did not go through any training in isolation.
16250298|NCT05022940||TBI rehabilitation|All individuals with mild, moderate or severe TBI registered into rehabilitation.
16250299|NCT05022927|Experimental|Dose escalation part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
16250300|NCT05022927|Experimental|Expansion part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent To evaluate the anti-tumor effect.
16250303|NCT05022914||1|Patients affected by biochemical relapse after radical prostatectomy undergoing staging PSMA-PET/CT and baseline blood sample for miRNA panel assessment.
16250304|NCT05022888|Active Comparator|myofascial pain syndrome|Patients diagnosed with myofascial pain syndrome Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
16250305|NCT05022888|Active Comparator|Healthy volunteers|Healthy volunteers Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
16250306|NCT05022875|Experimental|Experimental app intervention|The complete Healthcare CEO app will be used for intervention in the experimental group.
16250307|NCT05022875|Sham Comparator|Control app intervention|"Participants in the control group will only install the CEO's Profile and Health Tracking interfaces of the Healthcare CEO app."
16250308|NCT05022862|Active Comparator|Usual Care|Participants will receive routine (non-study directed) medical care for latent tuberculosis infection according to published guidelines, including medication, nurse case management, Tuberculosis health education, and toxicity assessments.
16250309|NCT05022862|Active Comparator|Video Directly Observed Therapy alone|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, however treatment will be viewed by video directly observed therapy (video-DOT)
16250310|NCT05022862|Experimental|Video Directly Observed Therapy plus Financial Incentives|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, as well as treatment viewed by video DOT. This arm will also earn financial contingent incentives. Participants will receive incentive payments when a submitted video is monitored by a staff member and deemed valid. If a participant fails to submit a video on a medication day or if a submitted video is deemed invalid (i.e., not the correct person or no appropriate ingestion of medication), the participant will not receive the scheduled incentive amount that day and the daily incentive value will be decreased.The participant will have opportunities the next day to again resume adherence. After taking the medication again for one week, participants will earn a reduced incentive until they adhere to the medication schedule for a week.
16250311|NCT05022849|Experimental|Part 1: Dose Escalation|Participants will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by JNJ-75229414 IV infusion escalated sequentially with a targeted dose consistent with the dose required by the cohort being enrolled to determine recommended Phase 2 dose (RP2D) regimen(s). Additional, intermediate dose levels may be implemented based on the review of all available data including, but not limited to, safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) by the study evaluation team (SET). Participants may receive bridging therapy (anti-androgen receptor agents [example, abiraterone, enzalutamide] and radiotherapy, or chemotherapy [example, docetaxel]) if clinically indicated to maintain disease stability.
16250312|NCT05022849|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-75229414 for each RP2D regimen determined in Part 1.
16250313|NCT05022823|Active Comparator|Standard of Care|Group A (Control). Home decongestive exercise regimen + daytime use of a compression sleeve (12 hours per day)
16250314|NCT05022823|Experimental|DPRE + compression sleeve during exercise|Group B. Decongestive Progressive Resistance Exercise + compression sleeve use during exercise + daytime use of a compression sleeve (12 hours per day)
16250315|NCT05022823|Experimental|DPRE + AC garment during exercise|Group C. Decongestive Progressive Resistance Exercise + Adjustable Compression (AC) garment use during exercise + daytime use of a compression sleeve (12 hours per day).
16250318|NCT05022797|Experimental|Glucarpidase, methotrexate, R-CHOP|Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.
16250319|NCT05022784||Idiopathic Pulmonary Fibrosis Patients|Medicare beneficiaries with IPF who newly initiated treatment with nintedanib
16250320|NCT05022771|Experimental|Single Ascending Doses Cohort 1a|Subjects will receive either Dose level 1 of PMG1015 or Placebo
16250321|NCT05022771|Experimental|Single Ascending Doses Cohort 1b|Subjects will receive either Dose level 2 of PMG1015 or Placebo
16250322|NCT05022771|Experimental|Single Ascending Doses Cohort 1c|Subjects will receive either Dose level 3 of PMG1015 or Placebo
16250323|NCT05022771|Experimental|Single Ascending Doses Cohort 1d|Subjects will receive either Dose level 4 of PMG1015 or Placebo
16250324|NCT05022771|Experimental|Single Ascending Doses Cohort 1e|Subjects will receive either Dose level 5 of PMG1015 or Placebo
16250325|NCT05022771|Experimental|Single Ascending Doses Cohort 1f|Subjects will receive either Dose level 6 of PMG1015 or Placebo
16250326|NCT05022758||Participants treated with rivaroxaban|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on rivaroxaban (defined as the index date) during the enrollment period from January 2015 to December 2017.
16250327|NCT05022758||Participants treated with warfarin|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on warfarin (defined as the index date) during the enrollment period from January 2015 to December 2017.
16250328|NCT05022745|Experimental|ERAS group|Posterior lumbar interbody fusion Multimodal, multidisciplinary patient care.
16250329|NCT05022745|Active Comparator|Standard group|Posterior lumbar interbody fusion Standard treatment pre-, per-, and post-operative
16250330|NCT05022732|Placebo Comparator|Control formula|Excipients and gum arabic in tablet
16250331|NCT05022732|Active Comparator|Experimental formula|Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)
16250332|NCT05022719|Experimental|PillCam Colon2 procedure with MB-MMX|PillCam Colon2 procedure with MB-MMX
16250333|NCT05022706|Experimental|Adolescents living with HIV|"cART directly observed therapy (DOT) for participants at risk of or with a history of non-adherence
~monthly home visits by trained health promoters
~ongoing support in navigating the health system, including accompaniment to appointments and assistance enrolling in public health insurance
~monthly peer support groups"
16250334|NCT05022693|Experimental|BIO89-100 30 mg, Open Lable, Single Dose|
16250335|NCT05022680|Experimental|Participants were used app to record their diet and steps every day|Experimental group was the mHealth with peer led to improved their physical activity during pregnancy. Participants received app to record and monitor their physical activity every days and using it until childbirth.
16250336|NCT05022680|No Intervention|non-mhealth|control group was the traditional prenatal care during pregnancy.
16250337|NCT05022667|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the total thyroidectomy procedure.
16250338|NCT05022667|No Intervention|Standard of Care|The surgeon will not use the PTeye and will proceed with the total thyroidectomy as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
16250339|NCT05022654|Experimental|Cohort_A|Patients with recurrent and metastatic esophageal squamous cell carcinoma who failed pD-1 (L1) -containing mab in the first line were treated with SI-B001 in combination with irinotecan in the second line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16250340|NCT05022654|Experimental|Cohort_B|Patients with recurrent and metastatic ESOPHAGEAL squamous cell carcinoma who failed pD-1 (L1) -containing mab in the second line were treated with SI-B001 combined with irinotecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
16250341|NCT05022641|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
16250342|NCT05022641|No Intervention|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
16250343|NCT05022628|Experimental|Therapy arm|donafenib
16250348|NCT05022602|Experimental|Imagio|Imagio Grayscale only probe and Imagio Duplex probe in ultrasound only and OA modes
16250349|NCT05022589|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-4 sessions per week, ~30 minutes per session.
16250350|NCT05022576|Experimental|PSMA PET/CT guided biopsy arm|Ga-68 PSMA PET/CT imaging is now routinely done in patients with prostate cancer with biochemical recurrence, response evaluation and even in patients with clinical suspicion of prostate cancer. In the present study, we aim to plan robotic arm-assisted Ga-68 PSMA guided transgluteal prostatic biopsies.
16250351|NCT05022563||Parenteral anticoagulant only|LMWH, UFH
16250352|NCT05022563||Warfarin-based|Warfarin only + parenteral anticoagulant bridged warfarin
16250353|NCT05022563||Parenteral anticoagulant / NOAC|NOAC: apixaban, rivaroxban, dabigatran, edoxaban
16250354|NCT05022563||NOAC only|NOAC: apixaban, rivaroxban, dabigatran, edoxaban
16250355|NCT05022550|Experimental|DEEPVR Experiment Group|Youth will be asked to experience an immersive virtual-reality simulation. Youth will wear a lightweight, ultra-high-resolution, wireless, head-mounted VR display (HTC Vive Pro Eye; HTC Corp., Taiwan). Each session will proceed through a series of three stages. First, participants will begin with a 5-min. acclimation period inside a demo VR environment. Second, baseline levels of physiological arousal will be captured over a 5 min. resting period where participants will be asked to sit quietly in a serene virtual environment. Physiological data will be collected using disposable gel-pad electrodes placed on the fingers (galvanic skin response) and torso (electrocardiography). Third, youth will progress through the DEEP VR experience for 15 minutes (see Behavioral Task), an underwater navigation video game wherein regularized, diaphragmatic breathing facilitates movement.
16250356|NCT05022537|Experimental|Treatment (retrograde nephrostomy)|
16250357|NCT05022537|Active Comparator|Control Group ( antegrade nephrostomy)|
16250358|NCT05022524|Experimental|Transition-Age Adults|16-25 year old patients on stable dose of antipsychotic medication for treatment of depression or anxiety.
16250359|NCT05022511|Experimental|Intervention group, women not up to date in CCU screening|Women aged 50-64 years, who have not had a cervical cytology sample taken within 5 years and 6 months will be offered to receive a self-sample device for high risk human papilloma virus (hrHPV) screening by mail, or reminded to see her general practitioner (GP) to have a conventional cervical cytology sample taken.
16250360|NCT05022511|Experimental|Intervention group, women not up to date in CRC screening|Women aged 50-69 years, who have not had a Faecal Immunochemical Test (FIT) within 2 years and 4.5 months will be offered to receive a new self-sampling kit for FIT.
16250361|NCT05022511|No Intervention|Control group|Women in the control group will receive standard screening offers according to the national screening programme.
16250362|NCT05022498|No Intervention|Control 1|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
16250363|NCT05022498|No Intervention|Control 2|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
16250364|NCT05022498|Experimental|Exercise 1|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
16250365|NCT05022498|Experimental|Exercise 2|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
16250366|NCT05022485||Investigational group|Subjects that will be implanted with the ZNN Bactiguard tibia device.
16250367|NCT05022485||Control group|Subjects that have received an uncoated titanium-alloy tibia nail in the past (data collection is retrospective; patients will not have to undergo any study-related procedure).
16250368|NCT05022472|Experimental|Intervention|We will use a 2-armed randomized controlled trial (RCT) where Latino and AA adults >18 years or older from six participating communities and surrounding community health centers (CHC) will be assigned to the 2 VIDA! intervention (n=3 CHC; N=500 participants) or to the control site (e.g., standard of care) (n=3 CHC; N=500 participants). The two major components of the 2VIDA! intervention are: COVID-19 Individual Awareness and Education, COVID-19 Community Outreach and Health Promotion, COVID-19 Individual Health Education and Linkages to Medical and Supportive Services, and pop-up vaccination stations in Latino and AA communities.
16250369|NCT05022472|No Intervention|Standard of care|The standard of care for vaccine delivery at the control sites. This includes individuals who make an appointment on their own or receive the vaccine at a health center and may receive information about the vaccine from their primary healthcare provider.
16250370|NCT05022459||Emicizumab Prophylaxis|This group will include patients on standard of care Emicizumab prophylaxis for Hemophilia A
16250371|NCT05022459||FVIII Prophylaxis|This group will include patients on standard of care FVIII prophylaxis for Hemophilia A
16250372|NCT05022446||Observational (survey)|Participants complete survey over 5-10 minutes.
16250373|NCT05022433||Shukla|Shukla is a birth weight based formula to determine the insertional depth of the UVC
16250374|NCT05022433||UN-1|UN-1 is a body surface based formula to determine the insertional depth of the UVC
16250375|NCT05022420||Salivary gland biospy,|100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.
16250376|NCT05022420||muscular biopsy,|muscular biospy use for the diagnosis of muscular auto-immune disease.
16250377|NCT05022420||neuro muscular biospy|neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease
16250378|NCT05022420||temporal arteries biospy|temporal arteries biospy uses for the diagnosis of giant cell arteritis
16250379|NCT05022407||Cohort 1 (SARS-CoV-2 uninfected)|Participants who test negative on the SARS-CoV-2 rapid test and are not considered at risk of COVID-19 or who have a negative RNA-PCR SARS-CoV-2 test result at baseline.
16250380|NCT05022407||Cohort 2 (SARS-CoV-2 infected)|Participants who test positive on RNA-PCR SARS-CoV-2.
16250381|NCT05022407||Cohort 3 (SARS-CoV-2 exposed)|Participants who have a positive SARS-CoV-2 rapid test result and are not considered to be at risk of active COVID-19 infection or have a negative RNA-PCR SARS-CoV-2 test.
16250382|NCT05022394|Experimental|Treatment (sapanisertib, nivolumab)|Patients receive PO QD on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16250383|NCT05022381|Other|Preoperative and Postoperative Pain Level|The preoperative pain level, hip function and quality of life of patients who underwent radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerve in chronic hip pain will be compared with the postoperative pain level, hip function and quality of life of these patients.
16250384|NCT05022368|Experimental|Oral Safety Device|"patients on which the device LabraGuard is used."
16250389|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine, Arm 1|
16250390|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 2|
16250391|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3|
16250392|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 4|
16250393|NCT05022316|No Intervention|Control Arm|Control clinics will not receive an intervention.
16250394|NCT05022316|Experimental|Intervention Arm|Intervention clinics will have the CDS tools turned on in their EHR.
16250395|NCT05022303|Placebo Comparator|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
16250396|NCT05022303|Experimental|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
16250397|NCT05022290|Experimental|Single-syringe technique|Patients in this arm will receive adenosine in a single syringe, diluted with normal saline up to 20 ml. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
16250398|NCT05022290|Active Comparator|Double-synring technique|Patients in this arm will receive adenosine using a double syringe, the first syringe contains only adenosine and the second syringe contains only normal saline 20 ml. Both syringes are connected to each other, and to the patient's IV portal with a stopcock. The administration must be done by two nurses one after another, adenosine syringe is injected first, then follow by normal saline. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
16250399|NCT05022277|Experimental|Phone-based intervention Plus SMS messages|
16250400|NCT05022277|Experimental|SMS messages only|
16250401|NCT05022277|No Intervention|Control|
16250470|NCT05021783||Patients|Patients with Axial SpondyloArthritis
16250402|NCT05022264||Participants|All participants will have their vital signs measured with conventional techniques as well as with the new experimental medical device (labelled RIA-VS)
16250403|NCT05022251||Lumbar radiculopathy|Lumbar radiculopathy patients (n=122), classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy.
16250404|NCT05022251||Healthy controls|Sex, age, and BMI-matched healthy, pain-free control subjects (n=122) will be recruited for study participation.
16250405|NCT05022212|Active Comparator|LACTIN-V|"LACTIN-V contains a naturally occurring human vaginal strain of Lactobacillus (L.) crispatus CTV- 05. At a potency of 2 x 109 cfu/dose, it is preserved in powder formulation, and applied by a vaginal applicator.
~Women will receive the study product for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
16250406|NCT05022212|Placebo Comparator|Placebo|"A matching placebo formulation without L. crispatus CTV-05 is supplied in an identical applicator containing just the powder formulation.
~Women will receive the placebo for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
16250407|NCT05022199|Experimental|Study Arm: SPY fluorescent angiography|
16250408|NCT05022199|No Intervention|Historic Control Arm: Urinary diversion without the use of SPY|This arm consists of 215 historic controls who have undergone urinary diversion at UVA from 2015-2020 without the use of SPY fluorescent angiography
16250409|NCT05022186|Experimental|Group receiving Cannabidiol|These patients will receive cannabidiol 5% without other medication for cognition and depression
16250410|NCT05022186|Experimental|Group receiving Homotaurine|These patients will receive Vivimind (homotaurine) without other medication for memory and depression
16250411|NCT05022186|No Intervention|Control group|These patients will not receive treatment
16250412|NCT05022173|Experimental|Helmet NIV|Patients randomized to the intervention arm will receive NIV through a phthalate free helmet (CaStar, STARMED) via an ICU ventilator in pressure support (PS) mode.
16250413|NCT05022173|Active Comparator|Facemask NIV|Patients in the control arm will be randomized to the traditional facemask interface. The facemask group will use the same ICU ventilator being used for the helmet group.
16250414|NCT05022160|Experimental|Group P|Patients in this group will receive bilateral pudendal nerve block after spinal anesthesia- before starting the surgery
16250415|NCT05022160|Placebo Comparator|Group C|Patients in this group will only receive spinal anesthesia before starting the surgery
16250416|NCT05022147|Experimental|Alternating-Frequency DBS|In this single-arm study, all participants will receive all interventions in a crossover fashion.
16250417|NCT05022134|Experimental|Intervention (CHOICE-AYA)|The impact of CHOICE-AYA contraceptive counseling on contraceptive use, satisfaction, and continuation will be assessed.
16250420|NCT05022108|Experimental|Antihistamine test|The forearm was sensitized at four points (A, B, C and D). Point A: positive control sensitized with a drop of histamine at a concentration of 10 mg / Ml. Point B: histamine was applied and immediately after, the alpha bisabolol gel with a concentration of 0.5%. Point C: histamine and gel with 2.5% alpha-bisabolol were applied. Point D was sensitized with a drop of histamine and 5.0% alpha-bisabolol gel. The test reading at each point occurred 15 minutes after the procedure.
16250421|NCT05022095||SCI Patients with ongoing spasticity|SCI Patients that are either seen in clinical routine due to fillings or controls of their intrathecal injection pumps or stationary patients will be informed about the project, they are granted with enough time to decide whether they want participate or not. After giving Informed Consent they will be administered a set of questionnaires including SCI-SETde, PSFS (adapted to german), SCIM-SR in german as well as self-evaluation of spasticity severity and intensity. The SCI-SETde will be filled in again one week later to evaluate test-retest reliability. Overall, the burden for the patients is kept at minimum. There are no expected risks or harm to the patients.
16250422|NCT05022082|Experimental|Chest Physiotherapy- Aspiration- Inhaler drugs group|The study group (n=26) will first receive chest physiotherapy (tapotement or vibration) and aspiration, followed by inhaler drug therapy.
16250423|NCT05022082|Other|Inhaler drugs- Chest Physiotherapy- Aspiration group|The control group (n=26) will be administered the inhaler drug routinely administered in the intensive care unit where the study is conducted and then receive chest physiotherapy (tapotement or vibration), then nasopharyngeal and oropharyngeal aspiration
16250424|NCT05022043|Active Comparator|EOS|
16250425|NCT05022043|No Intervention|NO-EOS|
16250426|NCT05022030|Experimental|Arm A|mCapOX (capecitabine+oxaliplatin) plus cetuximab
16250427|NCT05022030|Active Comparator|Arm B|mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab
16250428|NCT05022004|Experimental|BRIN-20-01|
16250429|NCT05022004|Active Comparator|Azopt®|
16250430|NCT05021991|Experimental|PRAX-944 (120 mg)|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
16250431|NCT05021991|Experimental|PRAX-944 (60 mg)|Once daily, oral dosing with titration to 60 mg: 3 days of 20 mg, 4 days of 40 mg, 49 days of 60 mg
16250432|NCT05021991|Experimental|PRAX-944 (20 mg)|Once daily, oral dosing: 56 days of 20 mg
16250433|NCT05021991|Placebo Comparator|Placebo|Once daily, oral dosing: 56 days of placebo
16250434|NCT05021978|Experimental|Part A: Open-label 20 and 40 mg PRAX-944|Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg
16250435|NCT05021978|Experimental|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
16250436|NCT05021978|Active Comparator|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo
16250437|NCT05021965|Experimental|group 1: have two weeks of at-home tooth bleaching|Participants will receive two weeks of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) for the maxillary anterior teeth.
16250438|NCT05021965|Experimental|group 2 : have two sessions of in-office tooth bleaching|Participants will receive two sessions（with a 1- week interval ） of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
16250439|NCT05021965|Experimental|group 3 : one week of at-home and then have one session of in-office tooth bleaching|Participants will receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) and then receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
16250440|NCT05021965|Experimental|group 4 : one week of in-office and then have one session of at-home tooth bleaching|Participants will receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) and a week later receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%)for the maxillary anterior teeth.
16250441|NCT05021952|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
16250442|NCT05021952|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
16250443|NCT05021939|No Intervention|Control Group|No treatment will be given to the control group. Evaluation will be done at the at the baseline and 8th week.
16250444|NCT05021939|Experimental|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
16250445|NCT05021939|Experimental|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
16250446|NCT05021926|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 26
16250447|NCT05021926|Experimental|Comparator product|Juvéderm Voluma™ with lidocaine (Allergan, Inc)
16250448|NCT05021913|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 23
16250449|NCT05021913|Active Comparator|Comparator product|Juvéderm Volift™ with lidocaine (Allergan, Inc)
16250450|NCT05021900|Experimental|Tenalisib 800 mg BID|
16250451|NCT05021900|Experimental|Tenalisib 1200 mg BID|
16250452|NCT05021887|Experimental|Test Product|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
16250453|NCT05021887|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK
16250454|NCT05021874|Active Comparator|Physiotherapeutic procedures: magnetotherapy|Magnetotherapy is a pulsating, non-homogeneous magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) will be applied using an elliptical applicator with a beam width of approx. 5 cm. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
16250455|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-led therapy|Magneto-led therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and LED diodes with the wavelength of 860 nm were applied using an elliptic magnetic-light (IR) applicator with a diameter of 5 [cm] containing 47 infrared diodes. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
16250456|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-laser therapy|Magneto-laser therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and a low-energy laser with infrared wavelength of 808 [nm] (max. power 300 mW) was applied. The dose was set to increase from 3,0 J/cm2 to 5,0 J/cm2 and the total dose applied per each patient from this subgroup was 40 J/cm2. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
16250457|NCT05021874|Active Comparator|Physiotherapeutic procedures: manual therapy of soft tissues|Manual therapy of soft tissues will include: post-isometric relaxation of the masseter, cellular and tissue mobilization with Kibler fold, masseter trigger point therapy. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
16250458|NCT05021861||Test group 1|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS.
16250459|NCT05021861||Test group 2|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
16250460|NCT05021861||Control group|SYSTEMICALLY HEALTHY FEMALES
16250461|NCT05021848|Experimental|Experimental group|The experimental group (N=14) received a 90-minute partnered multicomponent exercises intervention once weekly for 12 weeks
16250462|NCT05021848|No Intervention|control group|The control group (N=14) carried out the usual activities without intervention. (After 12-wk, multicomponent exercises intervention will be given)
16250465|NCT05021822|Active Comparator|Block Group|
16250466|NCT05021822|No Intervention|Control Group|
16250467|NCT05021809|Active Comparator|Group A|Calcium hydroxide intracanal medication without iodoform (Metapaste )
16250468|NCT05021809|Active Comparator|Group B|Calcium hydroxide intracanal medication with iodoform (Metapex)
16250469|NCT05021796||Nurses|"Including criteria: (1) registered nurses, (2) nurses undergoing a training for asthma telecounseling, (3) age 21 or more.
~Excluding criteria: (1) nurses with previous training for asthma counseling, (2) nurses who do not take care of patients with asthma, (3) Pregnant women"
16250471|NCT05021770|Experimental|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined with thiotepa, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 200mg will be used for phase II trial (RP2D).
~Orelabrutinib: 150mg or 200mg orally daily. Thiotepa: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
16250472|NCT05021770|Experimental|Phase II|"Participants will receive orelabrutinib and thiotepa at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.
~Orelabrutinib: RP2D (150 mg or 200 mg qd) Thiotepa:Sintilimab: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
16250473|NCT05021757||Disrupt CAD III PAS Cohort|Patients in the CathPCI Registry who undergo a PCI procedure using a Shockwave C2 Coronary IVL catheter and meeting the eligibility criteria will be included in the PAS cohort. A minimum of 150 patients with 30-day follow-up will be included in the PAS cohort.
16250474|NCT05021731|Active Comparator|3-month Isoniazid plus Rifampicin|Daily isoniazid 300 mg plus rifampicin 600 mg for three months
16250475|NCT05021731|Experimental|3-month Isoniazid plus Rifapentine|Weekly isoniazid 900 mg plus rifapentine 900 mg for 12 weeks
16250476|NCT05021731|Experimental|4-month Rifampicin|Daily rifampicin 600 mg for four months
16250477|NCT05021718|Experimental|Intervention group (IG)|A total of 35 patients in IG received different back and hip strengthening exercises five times a week for six weeks. They were also instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
16250478|NCT05021718|Active Comparator|Control group (CG)|The remaining 35 patients were allocated to CG. The patients in CG were treated with Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks, followed by hot moist compression for the next three weeks. Moreover, they were instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
16250479|NCT05021692|Experimental|Intervention|Intervention group: Pregnant women with preeclampsia who receive a web-based support program based on the Health Promotion Model in addition to routine clinical care will form the intervention group.
16250480|NCT05021692|No Intervention|Control|Pregnant women who receive routine clinical care applied to pregnant women with preeclampsia will constitute the control group.
16250481|NCT05021679|Experimental|AMP Implementation|
16250482|NCT05021666|Experimental|Group A1|PB-718 vs placebo
16250483|NCT05021666|Experimental|Group A2|PB-718 vs placebo
16250484|NCT05021666|Experimental|Group A3|PB-718 vs placebo
16250485|NCT05021666|Experimental|Group A4|PB-718 vs placebo
16250486|NCT05021666|Experimental|Group A5|PB-718 vs placebo
16250487|NCT05021666|Experimental|Group A6|PB-718 vs placebo
16250488|NCT05021666|Experimental|Group B1|PB-718 vs placebo
16250489|NCT05021666|Experimental|Group B2|PB-718 vs placebo
16250490|NCT05021666|Experimental|Group B3|PB-718 vs placebo
16250491|NCT05021666|Experimental|Group B4|PB-718 vs placebo
16250492|NCT05021653||Men who have sex with men (MSM)|Chinese men who have sex with men living with HIV infection and attending the service of HIV specialist service in Hong Kong
16250493|NCT05021653||non-MSM|Chinese heterosexual men and women living with HIV infection and attending the service of HIV specialist service in Hong Kong
16250494|NCT05021640|Experimental|Cohort 1 DCR-AUD|Single dose, subcutaneous administration of 80 mg of DCR-AUD (HV)
16250495|NCT05021640|Placebo Comparator|Cohort 1 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
16250496|NCT05021640|Experimental|Cohort 2 DCR-AUD|Single dose, subcutaneous administration of 240 mg of DCR-AUD (HV)
16250497|NCT05021640|Placebo Comparator|Cohort 2 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
16250498|NCT05021640|Experimental|Cohort 3 DCR-AUD|Single dose, subcutaneous administration of 480 mg of DCR-AUD (HV)
16250499|NCT05021640|Placebo Comparator|Cohort 3 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
16250500|NCT05021640|Experimental|Cohort 4 (OPTIONAL) DCR-AUD|Single dose, subcutaneous administration of 960 mg of DCR-AUD (HV)
16250501|NCT05021640|Placebo Comparator|Cohort 4 (OPTIONAL) DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
16250502|NCT05021627|Experimental|Cardiac autonomic nerve modification|
16250503|NCT05021627|Active Comparator|Pacemaker|
16250504|NCT05021614|Experimental|Treatment|Transcatheter Mitral Valve Repair with Valveclip®
16250505|NCT05021601|Experimental|Bi-atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with bi-atrial ablation procedure.
16250506|NCT05021601|Active Comparator|Left atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with left atrial ablation procedure.
16250507|NCT05021588|Experimental|Group A:dexamethasone|
16250508|NCT05021588|Experimental|Group B: prednisolone or methyl prednisolone according to D-dimer levels.|
16250509|NCT05021588|Experimental|Group C: prednisolone or methylprednisolone and anticoagulants according to the flexible protocol.|
16250510|NCT05021575||2020|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2020.
16250511|NCT05021575||2019|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2019.
16250512|NCT05021562||Niraparib 200-300 milligrams (mg)|Arm description: Niraparib 200 mg, capsules, orally, once daily. For adult participants weighing 77 kilograms (kg) or more and with platelet count 150,000/mcrL or higher before the first dose of this drug, niraparib 300 mg, capsules, orally, once daily.
16250513|NCT05021549|Active Comparator|nasal prong.|the apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong.
16250514|NCT05021549|No Intervention|conventional|the conventional preoxygenation group (30 patients)
16250544|NCT05021341|Active Comparator|Dihydroberberine 100|100 mg of Dihydroberberine
16250545|NCT05021341|Placebo Comparator|Placebo|Maltodextrin
16250515|NCT05021536|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
16250516|NCT05021536|Experimental|AMX0035|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
16250517|NCT05021523|Experimental|HEAT group|Participants are doing passive and active heat exposures
16250518|NCT05021523|Sham Comparator|CON group|Participants are doing sham altitude exposures
16250519|NCT05021510|Experimental|Simultaneous Cervical Traction & Neural Mobilization|Traction is a maneuver of distracting force to the cervical spine to cervical segments/grants decompression of nerve roots. For traction, 10% of the total body weight would be taken. Previous researches that investigated cervical traction found adequate effectiveness on pain reduction in neck and arm as well as improvement in nerve function parameters, and enhancement in neck mobility. The patient would be placed in a supine lying position with the cervical spine placed at 15º of flexion. The head strap will be fitted under the patient's occiput and chin. A safety switch will be given to the patient and ask him to press it if he would feel any kind of discomfort.
16250520|NCT05021510|Active Comparator|consecutive Cervical Traction & Neural Mobilization|the same description is for active comparator except for treatment mode to consecutive.
16250521|NCT05021497|Experimental|Global Positional Re-education|Global Positional Re-education
16250522|NCT05021497|Active Comparator|Conventional Physical Therapy Program|Conventional therapy will consist of a combination of manual techniques
16250523|NCT05021484|Active Comparator|Felzartamab|9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
16250524|NCT05021484|Placebo Comparator|Placebo|9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
16250525|NCT05021471|Experimental|Group A|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
16250526|NCT05021471|Active Comparator|Group B|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
16250527|NCT05021458|Experimental|Group A|Ten patients will be treated with Gong's mobilization.
16250528|NCT05021458|Active Comparator|Group B|Ten patients will be treated with SNAGs
16250529|NCT05021445|Experimental|plates based exercise|This will consists of 12 elderly participants who receive intervention protocol of Plates- based exercises program in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
16250530|NCT05021445|Active Comparator|conventional treatment|this will consists of 12 elderly participants who will receive intervention protocol of Conventional balance training exercises in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
16250531|NCT05021432|Experimental|Virtual Reality Group|Virtual Reality group will receive video based games training.
16250532|NCT05021432|Active Comparator|Circuit Training Group|They will receive Task-oriented Circuit training exercise program
16250533|NCT05021419|Active Comparator|Standard Arm|"Active Comparator: Standard Arm
~Both the current the European society of cardiology guidelines and National Institute of Health and Care Excellence currently advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:
~Visit 1: ACEi/ARB and Low Betablocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Switch ACEi/ARB to Entresto 100mg Visit 5: Modify Entresto dose to 200mg Visit 6: MRA Added Visit 7: MRA up-titrated Visit 8: SGLT2i started"
16250534|NCT05021419|Experimental|Streamlined protocol arm|"Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)
~Visit 1: Low Dose Beta Blocker started, SGLT2i started + Entresto 100 mg bd started
~Visit 2: MRA Added if renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)
~Visit 3: MRA up-titrated if BP and renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)
~Visit 4+: Betablocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of betablockers."
16250535|NCT05021406|Experimental|Carvedilol+ NUCs therapy|Patients randomized to Carvedilol combined with NUCs group during the previous 2-year treatment of RCT study; Patients showed the progression of esophageal varices in NUCs group during the 2-year treatment of RCT study. Based on nucleoside analogue (NUCs), carvedilol will be added to the patients. Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
16250536|NCT05021406|No Intervention|NUCs therapy|Continuing take single or combined nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
16250537|NCT05021393|Experimental|Intervention Group|The intervention group will receive the services from a clinical pharmacist and the existing standard care available in the medical oncology ward.
16250538|NCT05021393|No Intervention|Control Group|The standard care includes the current existing care provided to patients in the hospital. In addition, it includes all the available medical and non-medical services except the service provided by the clinical pharmacist.
16250539|NCT05021380||Group|50 generally healthy children diagnosed with dental pain as symptomatic irreversible pulpitis (SIP) or symptomatic apical periodontitis (SAP) aged from 6 to 12 years old will be included to the GROUP.
16250540|NCT05021367|Experimental|TQB3823 tablets|Subjects receive TQB3823 in the first cycle for a total of 28 days , a single dose on Day 1. Day 2 to Day 7 are the elution period, and the continuous doses are from Day 8 to Day 21. From the second cycle, continuous treatment for 28 days is as a treatment cycle.
16250541|NCT05021354|Experimental|Lateral epicondylalgia|It is established a plan of treatment base on the evidence for dry needling, stretching and eccentric exercise in the patient with lateral epicondylalgia. This is done in two sessions, one session every 10 days and with a duration of about 45 minutes.
16250542|NCT05021341|Active Comparator|Berberine|500 mg of Berberine
16250543|NCT05021341|Active Comparator|Dihydroberberine 200|200 mg of Dihydroberberine
16250546|NCT05021328|Experimental|Anlotinib combined with SBRT|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Toripalimab 240mg iv drip D1 + Anlotinib 12mg, QD, PO, D1-D14；
~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
16250547|NCT05021328|Experimental|Anlotinib combined with SBRT and Toripalimab|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Anlotinib 12mg, QD, PO, D1-D14；
~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
16250548|NCT05021315|Experimental|Iodine group|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
16250549|NCT05021315|No Intervention|Control group|50 women who did not receive preoperative vaginal cleansing even with tap water.
16250550|NCT05021302|Placebo Comparator|Kegel exercises group|20 women in this group
16250551|NCT05021302|Experimental|Electromagnetic stimulation group|20 women in this group
16250552|NCT05021289|Experimental|Guided İmagery|• participants were given one session of guided imagery.
16250553|NCT05021289|No Intervention|control group|No intervention was applied on the control group patients.
16250554|NCT05021276|Experimental|ruxolitinib+basiliximab|Patients with grade 3-4 steroid-refractory aGVHD receive combined therapy of basiliximab and ruxolitinib.
16250555|NCT05021263|Experimental|Magnesium Group|The magnesium group (Mg) will receive a bolus of 50 mg/kg of IV magnesium prior to incision and an infusion of 15 mg/kg/hr, with no preoperative oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
16250556|NCT05021263|Active Comparator|Pregabalin Group|The pregabalin group (Pb) will receive preoperative pregabalin and no IV magnesium bolus and infusion. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
16250557|NCT05021263|Placebo Comparator|Control Group|The control group (Ct) will receive saline solution and no IV magnesium or oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
16250558|NCT05021250|Experimental|Lipiodol marking|HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH.
16250559|NCT05021237|Experimental|Safety Lead In|Six patients with will be enrolled as first dose of 8.5Gy. If 0 or 1 patient experiences dose-limiting toxicity (DLT) out of six patients, then study will move on to expansion phase. If two or more patients experience DLT out of six patients, 6 additional patients will be recruited to lower dose level of 8Gy
16250560|NCT05021224|Other|Engagement strategy groups|We anticipate that approximately 25 patients will receive an engagement strategy (~5 patients per strategy; only 1 strategy per patient). The exact strategies will be developed during the course of this R21 and cannot yet be specified. This is a non-control, pilot feasibility trial.
16250561|NCT05021211||Low Egg Consumers|Participants who consume fewer than 1 whole egg per week
16250562|NCT05021211||Moderate Egg Consumers|Participants who consume 5-9 whole eggs per week
16250563|NCT05021211||High Egg Consumers|Participants who consumes great than or equal to 14 whole eggs per week
16250566|NCT05021172|Experimental|Arm I (Passport to Health booklet, ePrognosis)|Participants receive Passport to Health booklet and complete ePrognosis before scheduled primary care visit.
16250567|NCT05021172|Active Comparator|Arm II (usual care)|Participants receive usual care before scheduled primary care visit.
16250568|NCT05021159||Methotrexate Group|20 acute lymphocytic leukemia patients receiving MTX treatment (3- 5 mg/ cm2)
16250569|NCT05021159||Healthy control group|20 healthy pediatric subjects not receiving any treatment
16250570|NCT05021146|Experimental|Standard care and CEO treatment with standard 20% concentration Copaiba oil|
16250571|NCT05021146|Experimental|Standard care and CEO treatment with 40% concentration Copaiba oil|
16250572|NCT05021146|Placebo Comparator|standard care and placebo treatment with coconut oil|
16250573|NCT05021146|Active Comparator|Standard care|
16250574|NCT05021133|Other|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
16250575|NCT05021120|Experimental|Intervention/treatment|Experimental
16250576|NCT05021107|Experimental|Group A|Fascial Distortion Model with neck isometrics
16250577|NCT05021107|Active Comparator|Group B|Fascial Distortion Model with neck isometrics
16250578|NCT05021094|Experimental|POI patients who taking Kuntai capsule|Patients in this group will take Kuntai capsule orally, 4 capsules each time, 3 times a day, and take the medicine for 3 months.
16250579|NCT05021094|Active Comparator|POI patients who accepting hormone therapy|The estrogen and progesterone sequential regimen was adopted. The drug was estradiol tablets/estradiol didroxyprogesterone tablets (Femoston). Red tablets (estradiol, 1 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 1 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken.
16250580|NCT05021094|Experimental|POI patients who taking Kuntai capsule combined with hormone therapy|Kuntai capsule was taken at the same dose as Kuntai group on the basis of hormone therapy for 3 months.
16250581|NCT05021094|Experimental|Subclinical POI patients who taking Kuntai capsule|Subclinical POI patients in this group which with Kuntai capsule intervention. This group is a self-controlled experiment before and after treatment
16251774|NCT05012930|Experimental|Study Provided Diet - Plant|A group of complementary foods provided to participants by researchers.
16250583|NCT05021081|Experimental|CONTROL/TEST|For Phase 2, eligible subjects that are enrolled will be randomized to the Control/Test contralateral sequence.
16250584|NCT05021068||COPD Patients|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.
~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.
~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
16250585|NCT05021068||Control Group|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.
~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.
~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
16250586|NCT05021042||Acute mastitis (MA)|Lactating women with confirmed acute mastitis
16250587|NCT05021042||Subacute mastitis (SAM)|Lactating women with confirmed subacute mastitis
16250588|NCT05021042||Control (CT)|Lactating women with the absence of acute or subacute mastitis symptomatology.
16250589|NCT05021016|Experimental|"Group 1: Vaccine"|150 volunteers who will be vaccinated with the EpiVacCorona vaccine with two doses spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16250590|NCT05021003|Experimental|Group A|: Core stabilization training with pressure biofeedback unit
16250591|NCT05021003|Active Comparator|Group B|: Core stabilization training without pressure biofeedback unit
16250592|NCT05020990|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (Test) toric lens for one week.
16250593|NCT05020990|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) toric lens for one week.
16250594|NCT05020964|Experimental|Experimental Arm|Trastuzumab and Pyrotinib
16250595|NCT05020951||Laboratory Data|Electronic transfer of laboratory data from participating institutions' local electronic health records to the Medidata/RAVE
16250596|NCT05020925|Experimental|SHR-1701 plus Famitinib|SHR-1701+Famitinib for R/M NPC failure after platinum-based chemotherapy and anti PD-1/PD-L1 antibody therapy
16250597|NCT05020912|Experimental|Photodynamic therapy (PDT)|"Each participant will serve as their own control, receiving PDT for one tumor, no PDT for the second tumor (untreated control).
~Visit 1:
~Informed consent
~Blood draw
~Lesion(s) Photographed
~(ALA) applied for4 hours
~PpIX measured in lesions (PpIX buildup monitored every 30 minutes over a 4 h period)
~PDT with blue light
~Visit 2 (scheduled for within one of the following time intervals: 1-3 days, 4-7 days, or 8-14 days post-PDT):
~Blood draw
~Lesion(s) Photographed
~Mohs surgery
~After procedure, excess frozen BCC tissue will be saved for analysis"
16250598|NCT05020899|Experimental|Quit for Life group|Participants randomized to this arm will receive a 8 week quit smoking program delivered by trained counselors and messages to their cell phones. Participants will also be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
16250599|NCT05020899|Active Comparator|Control group|Participants randomized to this arm will be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
16250600|NCT05020886||Healthy|
16250601|NCT05020886||Stroke|
16250602|NCT05020873||Crizanlizumab|Patients initiated on treatment with commercially available crizanlizumab
16250603|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors > 5 cm)|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
16250604|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors < 5 cm)|Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
16250605|NCT05020860|Active Comparator|HER2-Positive Breast Cancer|Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)
16250606|NCT05020860|Active Comparator|Hormone Receptor Positive Breast Cancer|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
16250607|NCT05020847|Active Comparator|Standard F75|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.
~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
16250608|NCT05020847|Experimental|Alternative F75 with CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.
~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
16250609|NCT05020847|Experimental|Alternative F75 without CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.
~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
16250610|NCT05020834|Experimental|Functional Electrical Stimulation Group|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
16250611|NCT05020834|Experimental|TheraTogs Group|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
16250612|NCT05020821|Active Comparator|Single-shot interscalene block with intravenous dexmedetomidine|participants receiving single-shot interscalene block with intravenous dexmedetomidine
16250613|NCT05020821|Experimental|Continuous interscalene brachial plexus block|participants receiving continuous interscalene brachial plexus block
16250614|NCT05020808|Sham Comparator|Nonessential amino acid formulation (NEAA)|"Novel non-essential amino acid blend dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.
~Product Number: NEAA56812"
16250615|NCT05020808|Active Comparator|Plant Protein Isolate (PPI)|"Plant protein isolate (Fava bean) dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.
~Product Number: FP2011273"
16250618|NCT05020782|Experimental|Intervention Arm|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
16250619|NCT05020769|Experimental|SI-B001 combined with osimertinib|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended)
16250620|NCT05020743||Patients with ALSP|
16250621|NCT05020743||Asymptomatic carriers of the CSF1R gene mutation|
16250622|NCT05020730|Experimental|PTM-001 400 mg daily for 12 weeks|
16250623|NCT05020730|Placebo Comparator|Placebo daily for 12 weeks|
16250624|NCT05020704|Experimental|empagliflozin|empagliflozin 10mg once daily
16250625|NCT05020704|Placebo Comparator|Placebo|matched placebo
16250626|NCT05020678|Experimental|NKX019 - CAR NK cell therapy|All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX019 on Day 0, 7, and 14 of a 28-day cycle.
16250627|NCT05020665|Experimental|Intensive Chemotherapy + Entospletinib (ENTO)|Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with entospletinib (ENTO).
16250628|NCT05020665|Placebo Comparator|Intensive Chemotherapy + Placebo|Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with the matching placebo.
16250629|NCT05020652|Experimental|TQ05105 tablets + Hydroxyurea blank tablets|Take TQ05105 Tablets + Hydroxyurea blank tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration
16250630|NCT05020652|Active Comparator|TQ05105 blank tablets + Hydroxyurea tablets|Take TQ05105 blank tablets + Hydroxyurea tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration
16250631|NCT05020639|Experimental|TQB3820 tablets|TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle. Dose escalation of TQB3820 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data.
16250632|NCT05020626||Controls|
16250633|NCT05020626||Mild cognitive impairment|
16250634|NCT05020626||AD dementia|
16250635|NCT05020613|Other|Early group|Patients whose catheters are removed within the first 48 hours after surgery will form the early group.
16250636|NCT05020613|Other|Late group|Patients whose catheters are removed after the first 48 hours of surgery will form the early group.
16250637|NCT05020600||Patients with fibromyalgia|Patients diagnosed with fibromyalgia according to American College of Rheumatology 2016 criteria
16250639|NCT05020574|Experimental|Cohort A: Standard antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - Prescribed standard postoperative antibiotics to take for at least 7 days post-operatively
16250640|NCT05020574|No Intervention|Cohort B: No antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - No antibiotics post-operatively, unless patient develops clinical evidence of infection
16250641|NCT05020561|Experimental|Arm 1 - Group and Individual|Participants in this experimental Arm 1 will receive the 3 group sessions followed by 4 to 5 individual coaching sessions via phone calls that last 60 minutes each.
16250642|NCT05020561|Experimental|Arm 2 - Group only|Arm 2 will receive only the first 3 Life coach sessions (group session).
16250643|NCT05020561|No Intervention|Arm 3 - Routine care|Arm 3 will receive routine care by the Breast clinic team for the entire course of the study.
16250644|NCT05020548|Active Comparator|pressure 10|mask ventilation with peak inspiratory pressure of 10 cmH2O
16250645|NCT05020548|Active Comparator|pressure 15|mask ventilation with peak inspiratory pressure of 15 cmH2O
16250646|NCT05020548|Active Comparator|pressure 20|mask ventilation with peak inspiratory pressure of 20 cmH2O
16250647|NCT05020535|Experimental|Experimental|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
16250648|NCT05020535|Placebo Comparator|Control|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
16250649|NCT05020522|Other|MRI scan|Mp-MRI, LI-MRI, plasma DNA methylation signature (optional)
16250650|NCT05020509|Active Comparator|Touhy needle group|medial branch block with touhy needle
16250651|NCT05020509|Placebo Comparator|Quincke needle group|medial branch block with Quincke needle
16250781|NCT05019755|Experimental|B(First period) to A(Second period) order|"B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet
~A: Oral Administration of IN-A002(IN-115314) in fasting status
~There will be a wash out period of 7days between period"
16250655|NCT05020483|Experimental|FEIBA Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive activated prothrombin complex concentrate (aPCC) FEIBA to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
16250656|NCT05020483|Placebo Comparator|Placebo Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive a placebo to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
16250657|NCT05020470|Experimental|Self-guided mAPA (S-mAPA)|S-mAPA group will be provided with instructions so that participants can learn to self-administer APA weekly for four weeks and then followed by weekly telecommunication for Q & As.
16250658|NCT05020470|Experimental|In-Person Training + mAPA (IP-mAPA)|Participants will receive one in-person training after baseline data is collected and then will self-administer APA on the same schedule with weekly telecommunication as those in the mAPA group.
16250659|NCT05020470|Active Comparator|Usual Care Control (UC)|"Participants will receive usual care only for their pain; after enrolled, patients will receive weekly telecommunication to control for attention and time. The content of the phone/video call will focus on the pain problem they have and the investigators will provide additional information published by the National Center for Complementary and Integrative Health Chronic Pain: In-Depth (https://www.nccih.nih.gov/health/chronic-pain-in-depth) which the investigators used in the R01 study for participants enrolled in the control group"
16250660|NCT05020457|Experimental|SI-B001 combined with chemotherapy|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion
16250661|NCT05020444|Experimental|TriPRIL CAR T Cells-Dose Escalation|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:
~Leukapheresis: On day -8 white blood cells will be collected.
~Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes
~TriPRIL CAR T Cells will be administered intravenously on day 0 using a 3+3 dose escalation design"
16250662|NCT05020444|Experimental|TriPRIL CAR T Cells-Dose Expansion|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:
~Leukapheresis: On day -8 white blood cells will be collected.
~Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes
~TriPRIL CAR T Cells will be administered intravenously on day 0 using the respective dose (at or below the Maximum Tolerated Dose-MTD), as determined during the dose escalation part."
16250663|NCT05020431|Experimental|One arm|One arm nonrandomized clinical trial
16250664|NCT05020418|Experimental|Cardiac Device Cohort|This study is open to any adult VA patient with data about a cardiac device procedure performed in the electrophysiology laboratory entered into the national VA EHR. During FY 20-FY 24, we anticipate that this will include approximately 9,000 patients per year, or a total of 50,000 patients. In addition, cases that were previously accessed and used to develop the infection monitoring system, and the quality metric monitoring system, may also be included. This includes all patients entered in the VA Clinical Assessment Reporting and Tracking - Electrophysiology Cohort (CART-EP) database during the period from 2006-2016, and all VA patients who received a cardiac device procedure during the period from 2010-2019. This includes another approximately 50,000 patients, for a total of 100,000 patients.
16250665|NCT05020405|Experimental|ARS with GBR and SMV|alveolar ridge splitting in combination with the use of GBR with SMV with immediate implant placement
16250666|NCT05020405|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without SMV with immediate implant placement
16252047|NCT05010941||Hypotension prediction index|prediction of hypotension events
16250669|NCT05020379|Sham Comparator|Group N|"The patients in Group N will not receive any intervention. Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol. The pain intensity will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS are the simple and most commonly used scales.11 The numerical scale is most commonly 0 to 10, with 0 being no pain and 10 being the worst pain imaginable."
16250670|NCT05020379|Experimental|Group ESPB|The patients in the group ESPB will be placed in sitting pozition. A convex probe ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS)
16250671|NCT05020366|Experimental|PrO-PEAR|This group will receive the optimized PrO-PEAR intervention (in addition to usual care).
16250672|NCT05020366|Active Comparator|Enhanced Usual Care|This group will serve as the control group and only receive a report of their child's performance and adherence to World Health Organization recommendations based on baseline data.
16250673|NCT05020340|Experimental|Intervention|External cephalic version
16250674|NCT05020340|No Intervention|Control|ECV will not be performed.
16250675|NCT05020327|Experimental|Low Risk Patients|This is the group of patients who will undergo the graded oral amoxicillin challenge testing. Total dose of the amoxicillin will be 45 mg/kg (maximum of 1000 mg). 10 % of this dose will be given first followed by 90 % of the dose 30 minutes after. Each dose will be given only once.
16250676|NCT05020327|Other|No Risk Patients|Patients in the group will be de-labeled in the electronic medical record for No Risk for allergic reaction to amoxicillin based on screening questionnaire.
16250677|NCT05020327|Other|High Risk|Patients in this group are deemed high risk for allergic reaction to penicillin based on screening questionnaire and will remain labeled with allergy in the electronic medical record. They will be referred as outpatient to allergy-immunology for further evaluation.
16250678|NCT05020314|Experimental|Clinically Based: Healthy Weight Clinic|
16250679|NCT05020301|Experimental|Control group|Participants who have never practiced mindfulness
16250680|NCT05020301|Experimental|Beginner Practitioner|Participants with less than two years of mindfulness practice
16250681|NCT05020301|Experimental|Advanced Practitioner|Participants with more than two years of mindfulness practice
16250682|NCT05020288|Experimental|Orelabrutinib|Orelabrutinib 50mg po qd
16250683|NCT05020275||Blood samples|Blood samples for further assays
16250684|NCT05020262||Test Group|Using PI/PC reconstruct raw data
16250685|NCT05020262||Control Group|Using Idose4/Cardiac Image reconstruct raw data
16250686|NCT05020249|Experimental|Bimekizumab arm|Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
16250687|NCT05020249|Placebo Comparator|Placebo arm|Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.
16250692|NCT05020223|Experimental|MTA pulpotomy|Usuing MTA as capping material for cervical pulpotomy as a treatment option for deep carious primary teeth with signs and symptoms of reversible pulpitis in presence of pulp exposure
16250693|NCT05020223|Experimental|MTA direct pulp capping|Using MTA as capping material in case of trearment of deep carious primary teeth with signs and symptoms of reversible pulpitis with presence of pulp exposure
16250694|NCT05020223|Experimental|MTA indirect pulp capping|Using MTA as indirect capping material for treatment of deep carious primary teeth with signs and symptoms of reversible pulpitis
16250695|NCT05020210||Sivelestat Sodium group|Patients treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
16250696|NCT05020210||Conventional treatment group|Patients not treated with Sivelestat Sodium/Normal Saline after the diagnosis of ARDS
16250697|NCT05020184|Active Comparator|Cimetidine|Cimetidine 800mg orally twice daily
16250698|NCT05020184|Placebo Comparator|Placebo|Placebo capsule orally twice daily
16250699|NCT05020171|Experimental|intervention group|group focus on lower limb strength training with a seated robotic device
16250700|NCT05020171|Active Comparator|control group|physiotherapy group as usual, not focused on strength training
16250730|NCT05020002||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
16250731|NCT05020002||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
16250779|NCT05019768|Experimental|aCFXL|"Accelerated custom fast CXL protocol. The protocol has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin con-sumption rate and the corneal thickness at its thinnest point.
~Riboflavin-VEPTGS solution: Epithelial lavage before UV UVA fluence of 1.8 ±0.9 mW/cm2 UVA Irradiation time 10 ± 1.5 minutes"
16250701|NCT05020158|Experimental|Family Talk intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
16250702|NCT05020145||Immunocompromised|Vaccinated Subject with 1 or >1 immunocompromising conditions.
16250703|NCT05020145||Non-Immunocompromised|Vaccinated subjects without evidence of immunocompromising condition.
16250704|NCT05020145||Total Population (immunocompromised and non)|Vaccinated Subjects with or without 1 or >1 immunocompromising conditions.
16250705|NCT05020119|Experimental|Low dose of neoantigen-based cell therapy (N=3+3)|(1±20%) × 109cells/200 mL every 14 days for 10 doses
16250706|NCT05020119|Experimental|Medium dose of neoantigen-based cell therapy (N=3+3)|(3±20%) × 109cells/200 mL every 14 days for 10 doses
16250707|NCT05020119|Experimental|High dose of neoantigen-based cell therapy (N=3+3)|(9±20%) ×109cells/400 mL every 14 days for 10 doses
16250708|NCT05020106||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
16250709|NCT05020106||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
16250710|NCT05020106||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
16250711|NCT05020106||Cognitively normal controls|Individuals with normal cognitive function
16250712|NCT05020093|Experimental|Injection molding|cavity design, packing technique, bonding technique
16250713|NCT05020093|Active Comparator|Incremental packing|cavity design, packing technique, bonding technique
16250714|NCT05020080|Experimental|ECR MEP conditioning - Stroke|MEP operant conditioning of ECR in stroke survivors
16250715|NCT05020067|Experimental|SPLS-IMRT|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%
16250716|NCT05020067|No Intervention|C-IMRT|The entire parotid gland was delineated as an OAR, and V36 (the percentage volume receiving 36 Gy or more) in the entire parotid gland was constrained to be less than 40%
16250717|NCT05020054|Active Comparator|Intervention Tecartherapy|"The procedures will be performed with Tecartherapy equipment, with the equipment Nèartek®- IBRAMED- Industria Brasileira de Equipamentos Eletromédicos.
~The treatment will be carried out once a week, totaling 10 sessions, by two dermato-functional physiotherapists. During the sessions, all volunteers will be positioned in dorsal decubitus and the applicator positioned in the abdominal region, the therapy will be dynamic and simultaneously the professional must assess the local temperature.
~The parameters used will be:
~Area of 300cm², 1MHz, Capacitive Mode: 60mm Disc: Default 100W Time of 10 minutes, keeping temperature at 42°C Resistive Mode: 60mm Disc: Default 110W Time of 10 minutes, keeping temperature at 42ºC. The total treatment time is 20 minutes."
16250718|NCT05020054|Placebo Comparator|Placebo Tecartherapy|the therapy took place with the equipment turned off
16250719|NCT05020041|Experimental|Intervention|"The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers, or manipulation of objects to maintain COVID-19 sanitary and safety protocols.
~The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers."
16250720|NCT05020041|No Intervention|Control|The schools participating in the control group will receive an online educational talk aimed at promoting healthy habits and the benefits of physical activity inside and outside the school environment.
16250721|NCT05020028|Experimental|CBD Group|The first cohort will receive 50mg cannabidiol Orally Disintegrating Tablets (CBD ODT), three times daily.
16250722|NCT05020028|Placebo Comparator|Placebo Group|Cohort 2 will receive the same instructions, but with the placebo Orally Disintegrating Tablets (ODT) instead.
16250723|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 200×10^6 anti-CD19 chimeric antigen receptor (CD19-CAR+) viable natural killer (NK) cells, single-dose, intravenously, once on Day 0.
16250724|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0.
16250725|NCT05020015|Experimental|Part 1: Dose Expansion: LBCL: TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0 to determine RP2D.
16250726|NCT05020015|Experimental|Part 1: Dose Expansion: iNHL: TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Indolent Non-Hodgkin Lymphoma (iNHL) will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0 to determine RP2D.
16250727|NCT05020015|Experimental|Part 2: Cohort 1- LBCL|Participants with LBCL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 at RP2D, intravenously, once on Day 0.
16250728|NCT05020015|Experimental|Part 2: Cohort 2- iNHL|Participants with iNHL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 at RP2D, intravenously, once on Day 0.
16250729|NCT05020002||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
16250776|NCT05019781|Placebo Comparator|Placebo group|Participants were received single session placebo tape application for one week.
16250777|NCT05019781|No Intervention|Control group|No intervention.
16250732|NCT05019989|Experimental|Intervention group: on diet and physical activity|"Individual advice on diet and on physical activity Kitchen courses to teach basic Mediterranean and macrobiotic recipes (two 1-day course plus ten 3-h courses associated with common dinner) (15-20 participants at a time) Fortnightly common lunch or dinner (50-60 participant at a time) Basic gymnastic course (twelve - monthly- 2-hour courses)
~Study newsletter, with scientific information, kitchen recipes, study facilities
~Periodic conferences on diet and health
~Periodic reinforcement meetings with common meals, gymnastic sessions, and dancing, after the first year
~Periodic body weight assessment (weekly self-measurement and monthly measurement at the study center)
~Discounted rate for advanced kitchen courses
~Psychological support groups"
16250733|NCT05019989|Experimental|Control group: only public recommendations on lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.
~Dissemination of the information on the study by media
~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
16250734|NCT05019976|Experimental|Dose-Finding Group 0 - Dose Level 0|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.
~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.
~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
16250735|NCT05019976|Experimental|Dose-Finding Group 1 - Dose Level 1|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.
~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.
~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
16250736|NCT05019976|Experimental|Dose-Finding Group 2 - Dose Level 2|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.
~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.
~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
16250737|NCT05019976|Experimental|Dose-Finding Group 3 - Dose Level 3|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.
~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.
~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
16250738|NCT05019976|Experimental|Dose-Finding Group 4 - Dose Level 4|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.
~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.
~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
16250778|NCT05019768|Active Comparator|sCXL|Standard protocol of Dresden Riboflavin-VEPTGS solution applied every 2 mins during UV UVA fluence of 3mW/cm2 UVA Irradiation time 30 minutes
16250780|NCT05019755|Experimental|A(First period) to B(Second period) order|"A: Oral Administration of IN-A002(IN-115314) in fasting status
~B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet
~There will be a wash out period of 7days between period"
16252048|NCT05010928|Experimental|Tea mouthwash group|
16250741|NCT05019950|Experimental|LABP-104 250mg|"Dose escalation in the SAD part of the study (Part A) will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either LABP-104 or placebo (ratio 5:2). LABP-104 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort (500 mg, 750 mg, 1000 mg, 1500 mg).
~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either LABP-104 or placebo (ratio 5:2), once daily for seven days. LABP-104 dose levels to be evaluated in Part B will be 250 mg, 500 mg, and 1500 mg."
16250742|NCT05019950|Placebo Comparator|Placebo|"Dose escalation in the SAD part of the study (Part A) will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either LABP-104 or placebo (ratio 5:2). LABP-104 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort (500 mg, 750 mg, 1000 mg, 1500 mg).
~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either LABP-104 or placebo (ratio 5:2), once daily for seven days. LABP-104 dose levels to be evaluated in Part B will be 250 mg, 500 mg, and 1500 mg."
16250743|NCT05019937|Experimental|Multifaceted implementation strategy|Schools randomized to this arm will be exposed to a multifaceted implementation strategy, which contains five implementation components
16250744|NCT05019937|Active Comparator|Single implementation strategy|Schools randomized to this arm will be exposed to a single implementation strategy, which contains one implementation component
16250745|NCT05019924|Active Comparator|Intervention arm|Dietary supplement
16250746|NCT05019924|No Intervention|Control arm|No intervention given
16250747|NCT05019911||Patients with COPD alone|In the cross-sectional part, the group of patients with COPD alone will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
16250748|NCT05019911||Patients with COPD combined with sleep apnea hypopnea syndrome|In the cross-sectional part, the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
16250749|NCT05019898|Experimental|Diagnostic Test: pupillometry|
16250763|NCT05019859|Active Comparator|Intervention|low carb diet
16250764|NCT05019859|No Intervention|Control|traditional low fat diet
16250765|NCT05019846|Experimental|SRT+ADT|Patients in ARM A will be treated with SRT on the prostate (consecutive days or at alternate days to a total dose of 36.25 Gy administered in 5 fraction (7.25 Gy/fraction) + LHRH analogue (Triptoreline 22.5 mg). An anti-androgen drug (es. Bicalutamide 50 mg) must be administered daily starting from 7 days before LHRH analogue administration to 10 days after to prevent the flare effect
16250766|NCT05019846|No Intervention|SRT alone|Patients in ARM B will be treated with SRT on prostate alone at a total dose of 36.25 Gy administered daily or on alternate days in 5 fraction (7.25 Gy/fraction).
16250767|NCT05019833|Experimental|Signals collection|Collection of sensors signals by the implanted device.
16250768|NCT05019820|Active Comparator|Sarcopenia and osteoarthritis group|Women aged 45-65 years diagnosed with sarcopenia and knee osteoarthritis
16250769|NCT05019820|Other|Without osteoarthritis and sarcopenia group|Women aged 45-65 years without a diagnosis of knee osteoarthritis and sarcopenia
16250770|NCT05019807|Other|WhatsApp group|The arm receives education information about diabetes and its complications, diet and physical activities through WhatsApp.
16250771|NCT05019807|Other|Control group|The arm does not received any education information.
16250772|NCT05019794|Experimental|Gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with FGFR2 amplification|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
16250773|NCT05019794|Experimental|GC or GEJ with FGFR1/FGFR2/FGFR3 fusions/rearrangements and activating mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
16250774|NCT05019794|Experimental|Solid tumors[Exclude GC,GEJ,CHOL,UC]with FGFR1/FGFR2/FGFR3 fusions/rearrangements and mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
16250775|NCT05019781|Experimental|KT group|Participants were received single session therapeutic tape application for one week.
16252049|NCT05010928|No Intervention|Control group|
16250782|NCT05019742|Experimental|Placebo|2 placebo tablets, 1 in the morning and 1 in the evening, daily for 8 weeks. After 8 weeks, optional randomization to 1 of 2 SPH3127 daily treatment arms for an additional 10 months
16250783|NCT05019742|Experimental|SPH3127 50 mg|"1 50 mg SPH3127 tablet in the morning and 1 placebo tablet in the evening daily for 8 weeks.
~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
16250784|NCT05019742|Experimental|SPH3127 100 mg|"1 50 mg SPH3127 tablet in the morning and 1 50 mg SPH3127 tablet in the evening daily for 8 weeks.
~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
16250790|NCT05019716|Experimental|Treatment (ZEN-3694, etoposide, cisplatin)|Patients receive ZEN003694 PO QD on days 1-14 during dose escalation and dose expansion cohort or PO QD on days 1-21 for the non-thoracic, non-BRD4 exploratory cohort. All patients may receive ZEN003694 PO QD on days 1-21 starting cycle 5 at the discretion of treating investigator. Patients also receive etoposide IV over 60 minutes on days 1-3 for cycles 1-4 or up to 8 cycles, and cisplatin IV over 60 minutes on day 1 of cycles 1-4 or up to 8 cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16250791|NCT05019703|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16250792|NCT05019690|Experimental|Apatinib Combined With Albumin-Bound Paclitaxel|Participants will receive apatinib combined with albumin-bound paclitaxel until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16250793|NCT05019677|Experimental|GP+PD-1+Tight|"Experimental: Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.
~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
16250794|NCT05019651|Experimental|Single Arm- Apollo Wearable System|Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
16250795|NCT05019638|Active Comparator|Regional anesthesia group|Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.
16250796|NCT05019638|Experimental|Local multimodal analgesia group|Local multimodal analgesia composition will include 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
16250797|NCT05019625||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
16250798|NCT05019625||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
16250799|NCT05019625||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
16250800|NCT05019625||Ultrasound and myography testing|We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.
16250801|NCT05019612||single-group/one cohort|Women with endometriosis, having the clinical indication for laparoscopic endometriosis excision
16250802|NCT05019599|No Intervention|normal controls|subjects with normal renal function
16250803|NCT05019599|Experimental|CKD_Low protein diet|CKD patient with low protein diet (<0.8g/kg/BW)
16250804|NCT05019599|Active Comparator|CKD_normal protein diet|CKD patient with normal protein diet
16250805|NCT05019586||Helicobacter pylori resistance|Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days
16250806|NCT05019586||Newly diagnosed Helicobacter pylori|Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days
16250807|NCT05019586||Previously eradicated Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
16250808|NCT05019586||Never Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
16250809|NCT05019573|Experimental|Black tea group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.
16250810|NCT05019573|Placebo Comparator|Placebo group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.
16250811|NCT05019560|Active Comparator|Group A|"In group A:
~The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.
~Patients received inhalation induction using sevoflurane 8% and fentanyl 2 µg/kg was administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated then atracurium 0.5 mg/kg was given intravenously and sevoflurane reduced to 2%, then laryngoscopy and intubation were done when action of neuromuscular blocker (NMB) was confirmed by the disappearance of T3,T4. During this time, mask assisted ventilation with 100% oxygen was used to achieve normocapnia"
16250833|NCT05019404|Experimental|Functional temporal lobectomy (FTL)|FTL via minicraniotomy is a new surgical approach, consisting of amygdalohippocampectomy and the lateral temporal lobotomy.
16250812|NCT05019560|Active Comparator|Group B|"In group B:
~The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.
~In group B: propofol 1.5 mg/kg and fentanyl 2 µg/kg were administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated and then atracurium 0.5 mg/kg was given intravenously. Propofol infusion 6 mg/kg/hr was started, until action of neuromuscular blocker (NMB) was confirmed by disappearance of T3,T4, then laryngoscopy and intubation were done. The used dosing regimen is according to previous guidelines [8] [9].No inhalational agent was used. Mask assisted ventilation was used to achieve normocapnia."
16250813|NCT05019547||Ankylosing Spondylitis|Participants with Ankylosing Spondylitis
16250814|NCT05019534|Experimental|Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)|Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
16250815|NCT05019521|Experimental|Danicopan: 100 mg|Participants will receive danicopan 100 mg bid during the masked Treatment Period.
16250816|NCT05019521|Experimental|Danicopan: 200 mg|Participants will receive danicopan 200 mg bid during the masked Treatment Period.
16250817|NCT05019521|Experimental|Danicopan: 400 mg|Participants will receive danicopan 400 mg qd during the masked Treatment Period.
16250818|NCT05019521|Placebo Comparator|Placebo|Participants will receive matching placebo for 52 weeks during the masked Treatment Period.
16250819|NCT05019508||High Risk for Gestational Diabetes Mellitus (GDM)|"High risk women screened with HbA1c at initiation of prenatal care who were not diagnosed with Type 2 Diabetes Mellitus or Early GDM.
~These women will have Fetal Cardiac Function Parameters at their 20 week anatomy scan (E/A ratio, IVS, MPI). At their 24-28 week routine GDM screening, we will repeat the HbA1c and will repeat the E/A ratio, IVS, MPI. If women have a growth scan for any reason between 32 and 36 weeks, E/A ratio, IVS, and MPI will be repeated at those times."
16250822|NCT05019482|Experimental|University-based 8-weeks intervention to promote Physical Activity (PA)|Experimental group: 8-weeks program of Physical Activity constructed by users during a design-based innovative workshops before the beginning of the interventions .
16250823|NCT05019482|No Intervention|Control Group|Control group: No intervention, only two measurement times
16250824|NCT05019469|Experimental|Single arm of study|Single Arm. During each study session the participant undertakes 4 walking/activity circuits. During each circuit the participant receives either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. The ordering of the interventions/circuits are systematically alternated for each participant.
16250825|NCT05019456|Experimental|Vaccine|Participants who elect to receive the vaccine
16250826|NCT05019443|Active Comparator|Conventional balloon predilation|the target lesion can be prepared according to standard clinical practice using SC balloons sized 0.8-1:1. Stenting using a drug-eluting stent (DES) is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
16250827|NCT05019443|Experimental|Scoring balloon predilation|the target lesion must be prepared with a scoring balloon (SC) inflated 3 times at nominal pressure. To allow the scoring balloon to cross the lesion, it might be necessary to predilate with a small compliant balloon. The size of the scoring balloon to be used for is based on the size of the vessel. Stenting using a DES is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
16250832|NCT05019417|Experimental|Glycerol phenylbutyrate treatment|"Name of the Investigational Medicinal product: Glycerol phenylbutyrate [GPB] (Ravicti oral liquid 1.1 gr/1 ml; manufacturer Horizon Pharma USA).
~Dosage of GPB will follow the dosage in use for children with urea cycle disorder.
~Initial dose: 5.0 gr (4.5 ml)/ meter square divided by three time a day. An escalating schedule dose of GPB will be used until normal serum T3 levels are reached.
~Initial dose: 5 gr/square meter body surface area (BSA). Second visit: 10 gr/square meter BSA
~The dose raising will be stopped if one of the following condition is reaches:
~Clinically significant side effects
~Reaching the PAA serum toxic threshold of 500 µg/ml
~Reaching the maximal dose of GPB that is in use in urea cycle disorder: 12.4 gr (11.2 ml)/ meter square BSA divided by three times a day.
~Duration of study: 4 months"
16264263|NCT04925934|Placebo Comparator|Placebo SC (dosing interval 3)|
16250834|NCT05019404|Active Comparator|Anterior temporal lobectomy (ATL)|ATL via large frontotemporal craniotomy is a conventional surgical approach, consisting of amygdalohippocampectomy and en bloc resection of the lateral temporal lobe.
16250835|NCT05019378|Experimental|autologous SVF treatment|Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint
16250836|NCT05019378|No Intervention|Placebo group|No treatment
16250837|NCT05019365||Participants with previous HER2 breast cancer|
16250838|NCT05019365||Healthy Volunteers|
16250839|NCT05019352|Experimental|CRRT with cytokine adsorption|Patients will be treated with CRRT and extracorporeal hemoadsorption for 72 hours
16250840|NCT05019352|Experimental|CRRT without cytokine adsorption|Patients will be treated with CRRT without extracorporeal hemoadsorption for 72 hours
16250841|NCT05019352|No Intervention|no CRRT, no cytokine adsorption|Patients will not receive CRRT, nor extracorporeal hemoadsorption. CRRT will only be initiated in case of severe electrolyte disorders or unmanageable fluid overload
16250842|NCT05019339|Experimental|Healthy HomeStyles|Six-week virtual, group nutrition education series using the HomeStyles-2 experimental curriculum administered through SNAP-Ed. This curriculum addresses factors affecting school-aged children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, and irregular breakfast consumption.
16250843|NCT05019339|Active Comparator|Eat Healthy Be Active|Six-week virtual, group nutrition education series using the Eat Healthy Be Active attention control curriculum administered through SNAP-Ed. This curriculum addresses factors affecting overall health and nutritional status: limiting nutrients of concern (saturated fat, sodium, and added sugars), eating healthy while dining out, eating healthy on a budget, losing weight and keeping it off, understanding nutrition facts labels, and being physically active.
16250844|NCT05019326|Experimental|Andrographis extract|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
16250845|NCT05019326|Experimental|Boesenbergia extract|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
16250846|NCT05019326|Other|Standard supportive treatment|Standard supportive treatment, as recommended by guideline from Ministry of Public Health, Thailand, there will be no antivirus given in this asymptomatic group
16250847|NCT05019313||COVID 19 positive patients|"COVID19 positive patients with hypoxemic acute respiratory failure hospitalized in intensive care unit.
~This study evaluates diaphragmatic contractility with ultrasound, blood gas analytical parameters during weaning from invasive mechanical ventilation"
16250848|NCT05019300||COVID-19 patients discharged from critical care units|Adults over 18 years of age who have been hospitalized after COVID-19 diagnosis in the critical care units of Red Salud UC Christus who have been cognitively evaluated with Montreal Cognitive Assessment (MoCA) days prior to their discharge. All patients with a previous history of confirmed neurocognitive or psychotic disorders, prior to hospital admission, were excluded.
16250849|NCT05019287|Experimental|Menstrual blood stem cell secretome group|Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
16250850|NCT05019287|Placebo Comparator|Control group|Intravenous saline injection (Placebo)+Routine treatment
16250851|NCT05019274|Experimental|Culinary Medicine|Series of 6 virtual group Culinary Medicine sessions delivered monthly for 6 months
16250852|NCT05019274|Active Comparator|Nutrition Education|Series of 6 standard of care nutrition visits delivered by clinic dieticians. These are a mix of individual and group sessions.
16250853|NCT05019261|Experimental|Intervention|Multi-component Family Support Intervention
16250854|NCT05019261|No Intervention|Control|Usual ICU care
16250855|NCT05019248||vaccination prior to first cladribine exposition|
16250856|NCT05019248||vaccination shortly after first cladribine exposition|
16250857|NCT05019248||vaccination prior to second cladribine exposition|
16250858|NCT05019248||vaccination following completion of cladribine treatment|
16250859|NCT05019248||vaccination in patients with RRMS not subjected to cladribine|
16250860|NCT05019222|Experimental|Arm 1) Sevoflurane group|Sevoflurane based inhalation anesthesia
16250861|NCT05019222|Active Comparator|Arm 2) Remimazolam group|Remimazolam based total intravenous anesthesia
16250862|NCT05019209|Experimental|Exposure to saline-dissolved house dust mite allergen and allergen-free air|Subjects are blinded to the sequence of interventions in the allergen challenge chamber (ACC). Overall, subjects will be in the ACC 4 times during the study. Of those, exposure to allergen-free air and HDM is allocated in a 2:2 ratio.
16250863|NCT05019196||fMRI，functional reorganization, functional connectivity, functional rating scale|low-grade glioma patients healthy controls
16250864|NCT05019183|Experimental|Experimental arm|Patients in the experimental arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) during which they will be able to move freely in a virtual environment.
16250865|NCT05019183|Other|Control arm|Patients in the control arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) without being exposed to a virtual environment.
16250866|NCT05019170|Experimental|Best Practices + Incentives group|Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
16250867|NCT05019170|Active Comparator|Best Practices|Participants assigned to this condition will receive the best practices treatment alone.
16250868|NCT05019157|Experimental|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic under the supervision of the specialized staff for familiarization with the intervention. and then the participants will proceed with the telerehabilitation program at their homes. Participants will undergo an exercise - based program 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down, with the use of wearable sensors.
16250887|NCT05019040|Experimental|PA1010 10 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 10 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
16250888|NCT05019040|Experimental|PA1010 20 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 20 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
16250869|NCT05019157|Active Comparator|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down.
16250870|NCT05019157|No Intervention|Usual care group|Patients will not undertake any exercise based intervention and will only follow their usual medication treatment .The patients will wear the accelerometer for the 12 week study duration and visit the corresponding outpatient cardiac clinic every 4 weeks to upload the recorded data. The patients will also receive educational phone videoconference sessions every week for physical activity, diet/nutritional and smoking cessation counseling.
16250871|NCT05019144|Active Comparator|Face-to-face arm|Standard face-to-face burn care.
16250872|NCT05019144|Experimental|TOBI arm|A novel smartphone application for burn wound care, called the Telemedicine Optimized Burn Intervention (TOBI), was recently developed to enable burn experts to direct burn wound care while the patient and caregiver are home through text messaging and video-conferencing. The app was designed to bring expert wound care directly to the patient's home to address barriers to healthcare, including high cost burden and time commitment (e.g., geographic limitations, transportation to burn centers, parking, lodging, meals, time away from school and work), particularly for patients/families in rural and medically underserved communities. TOBI is synced with a portal used by providers, as an adjunct to standard therapy. This burn app provides education through frequently asked questions, instructional burn dressing change videos in addition to direct communication between patient and burn expert through store-and-forward pictures and videoconferencing.
16250873|NCT05019131|Experimental|Intervention arm|"Training: The investigators will develop a training for providers that addresses the following topics: Stress & positive coping mechanisms; Unconscious bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication;
~Peer support and mentorship: The investigators will identify what works best for these groups in terms of group composition, size, and how the groups want to interact.
~Leadership engagement: To ensure leadership buy in, support and sustainability of the intervention, the investigators will engage leadership of the County.
~Embedded champions: To facilitate ongoing engagement, the investigators will identify local leaders, and invite them to training where they will be taught how to facilitate peer support groups and serve as champions."
16250874|NCT05019131|No Intervention|Control arm|Will not receive any training during the intervention period
16250875|NCT05019118|Experimental|Intervention/treatment|"Dairy foods made with UNICLA milk Participants (n = 45) ingested UNICLA milk and dairy products (yogurt and cheese) for three months.
~UNICLA milk is characterised by an improved nutritional composition, obtained by modifying cow's diet, feeeding the dairy cows with a sufficient and balanced ration, which recreates the fatty acid profile of the spring.
~This ration includes pastures, high-quality forages and, among other components, a significant amount of flax seeds, which constitute a source of unsaturated fatty acids such as omega-3 and selenised yeast, as a source of organic selenium.
~Consequently, UNICLA milk and dairy products are naturally enriched in selenium and ω-3 PUFA.
~The daily intake reflects the usual consumption habits, being the recommended amounts of 200 ml of milk and 125 g of yogurt per day and 400g of fresh cheese per week"
16250876|NCT05019118|Placebo Comparator|Conventional milk|"Participants (n = 45) ingest milk and conventional dairy products daily for 3 months.
~Daily intake reflects usual dairy consumption habits in real life conditions, without forcing or inducing increased consumption. Therefore, the recommended amounts are 200 ml of milk and 125 g of yogurt per day and 400 g of fresh cheese per week"
16250879|NCT05019092|Experimental|Screening|Ultrasound (US) examination of lower limbs 48 hours after admission and again after 3-5 days (5-7 days after the admission)
16250880|NCT05019092|No Intervention|Control|Ultrasound (US) examination according to the clinical evaluation of risk factors for deep vein thrombosis (DVT) and life-threatening bleeding, based on the standard of care (SOC) of the enrolling institution.
16250881|NCT05019079|Experimental|electroacupuncture group|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation was stopped 30min later.
16250882|NCT05019079|No Intervention|control group|The patient underwent routine anesthesia without acupuncture treatment
16250885|NCT05019053|Experimental|Coping Crew Intervention|Interested participants who meet the screening criteria will be assigned to receive COPING CREW. First, following informed consent, eligible participants will complete a baseline assessment appointment in the week prior to the group beginning. During the baseline appointment, participants will provide informed consent, be instructed in the use of Microsoft Teams, complete a battery of self-report measures, be given a semi-structured diagnostic interview, and follow instructions to install a mobile app that will be used to track their mood and homework. Then, 4 groups of COPING CREW, with 6 participants per group, will be run. Participants will complete four weekly 60-minute virtual intervention sessions followed by a booster session two weeks later. Participants will complete daily surveys and homework assignments on their mobile devices. Links to follow-up surveys will be sent to participants at 1- and 3-month follow-ups.
16250886|NCT05019040|Experimental|PA1010 5 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 5 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
16250889|NCT05019027|Other|Off On Off On Sequence|This arm will follow an Off On Off On sequence. This is the only arm in the study. Subjects will begin in the Off phase (Period 1), downtitrating their beta-blocker by 50% each week until they are completely off the drug for a total of two weeks. At the end of Period 1, Subjects will have the opportunity to crossover into Period 2, where they will begin the On phase. Subjects will restart their beta-blocker by starting a low dose and then doubling this dose every week until reaching their original dose. They will then have the opportunity to continue to Period 3 (Off phase) and Period 4 (On phase).
16250890|NCT05019014||Neurodegenerative disease|Participants with a diagnosis of Probable Alzheimer's Disease, prodromal Alzheimer's Disease, Frontotemporal Dementia, Mild Cognitive Impairment, Dementia with Lewy Bodies, mild and moderate/severe TBI, and familial or sporadic ALS per El Escorial Criteria or individuals with known gene mutations associated with ALS.
16250891|NCT05019014||Age-matched controls|Healthy participants with no diagnosis.
16250892|NCT05019001|Other|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
16250893|NCT05019001|Other|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
16250894|NCT05018988|Experimental|Oral vitamin D3 spray|10µg/day for 12 weeks (BetterYou ltd.)
16250895|NCT05018988|Placebo Comparator|Placebo Comparator|Xylitol (BetterYou ltd.)
16250896|NCT05018975|Experimental|Tazemetostat|Subjects will receive tazemetostat 800mg BID for 15 days in addition to standard of care treatment. The duration of the interventional part of the study will last 15 days.
16250897|NCT05018975|No Intervention|Control|Subjects receiving standard of care treatment
16250898|NCT05018962|Experimental|Cutting balloon followed by paclitaxel coated balloon|
16250899|NCT05018949||Patients who have undergone LL angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
16250900|NCT05018936|Experimental|treatment group|Hetrombopag would be started with 5mg/day. The dosage would be increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.
16250901|NCT05018923|Experimental|RBMD group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
16250902|NCT05018923|Active Comparator|RAMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and tetracycline 0.5 g qid for 14 days
16250903|NCT05018897|Experimental|To Share or Not to Share|"Manualized, peer-led, strategic disclosure program to guide participants in disclosing suicidality, held in group format, consisting of six sessions, each one hour in duration, once per week.
~Pre-survey, post-survey, and 3-month follow-up survey"
16250904|NCT05018897|Active Comparator|Peer Support|"Peer-led support group, held in group format, consisting of six sessions, each one hour in duration, once per week.
~Pre-survey, post-survey, and 3-month follow-up survey"
16250905|NCT05018884||Patients without SSI|Patients who underwent surgery and who developed a surgical site infection (SSI) during 30 days after surgery
16250906|NCT05018884||Patients with SSI|Patients who underwent surgery and who didn't develop a surgical site infection (SSI) during 30 days after surgery
16250907|NCT05018871|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16250908|NCT05018858|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
16250909|NCT05018845|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
16250910|NCT05018832|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
16250911|NCT05018819|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16250912|NCT05018806|Experimental|Rilzabrutinib|Rilzabrutinib 400 mg BID
16250913|NCT05018806|Placebo Comparator|Placebo|Placebo BID
16250914|NCT05018793|Experimental|Treatment Group|Single intrathecal injection of 100 million cells
16250915|NCT05018780|Experimental|Muscle Energy Technique|"Post isometric relaxation: Patient will perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds and than participants will be asked to relax the contraction with an exhalation. This will be repeated five times in one session.
~- Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
16250916|NCT05018780|Experimental|Sacral Manipulation|"To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.
~To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.
~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
16250917|NCT05018767|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16250918|NCT05018741||Liver transplant|
16250919|NCT05018728|Experimental|Voxelotor|Children with sickle cell anemia taking voxelotor for 12 weeks.
16250920|NCT05018715||coronary heart disease|A total of 300 patients with CHD WHO were hospitalized in the First Affiliated Hospital of Xinjiang Medical University from August 2021 to February 2022 were selected, all of whom met the DIAGNOSTIC criteria of CHD formulated by the World Health Organization (WHO) and excluded diseases such as highly severe valvular disease and congenital heart disease
16250921|NCT05018715||Healthy person|.A total of 300 healthy subjects from the First Affiliated Hospital of Xinjiang Medical University during the same period were selected as controls.
16250922|NCT05018702|Experimental|ARX788|
16250923|NCT05018689|Active Comparator|Aevidum curriculum|Curriculum: Aevidum has developed a 5-lesson 3-hour mental health curriculum that can be broken up and integrated into existing school health curricula. The study team in partnership with the Executive Director of Aevidum will collaborate with schools to implement the curriculum to their 9th grade students.
16250924|NCT05018689|Active Comparator|Aevidum curriculum + club|Curriculum + club. Schools assigned to the curriculum plus club will also start an Aevidum club at their school. Club basic processes and ideas for events are housed on the Aevidum website. Schools will select faculty and student leaders who will participate in a kickoff web-based training at the start of the academic year. The training is led by current Aevidum student leaders at schools with successful clubs. This is a standard orientation process that Aevidum has run for many years in-person, but has been adapted to a virtual format with the COVID-19 pandemic.
16250925|NCT05018676|Experimental|ARX788|
16250926|NCT05018663||Prospective enrollment|All subjects will be enrolled prospectively. Subjects will be included in the study after eligibility is assessed and informed consent is obtained. The slide scanner will scan the slides on site and the images will be securely saved and sent for interpretation by the AI software at a different location. The results of the AI interpretation of the slides will be blinded to the on-site procedure team including the endoscopist and cytopathologist until the final pathology report is complete.
16250927|NCT05018637|Experimental|WJ-MSC group|intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
16250928|NCT05018637|Active Comparator|Teriparatide group|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
16250929|NCT05018624|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
16250930|NCT05018624|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through IM Apps
16250931|NCT05018611|Experimental|LifeSkills Mobile|Access to LifeSkills Mobile app. Participants will complete 4 modules with 20 activities across 6 months. Participants can log in at their convenience but will not be able to access the next module until the previous module is completed.
16250932|NCT05018611|No Intervention|Standard of Care|HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP and referrals to the local PrEP clinics, and sexually transmitted infection testing via an on-line location findings app.
16250933|NCT05018598|Experimental|CHF5993|2 inhalations BID, Daily dose is 400/24/50 μg
16250934|NCT05018598|Active Comparator|CHF1535|2 inhalations BID, Daily dose is 800/24 μg
16250935|NCT05018585|Experimental|Diamyd|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
16250936|NCT05018585|Placebo Comparator|Placebo|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
16250937|NCT05018572|Experimental|"Personalised internet-based treatment I am"|"Personalised internet-based treatment I am."
16250938|NCT05018572|No Intervention|Treatment As Usual|Treatment in primary care / Treatment As Usual (TAU), which is medical treatment
16250939|NCT05018559|Experimental|Intervention group nursing care|Participants receive a co-created physical activity intervention called BuG lesson (German: 'Bewegt und Gesund'-Stunde; English: PA and health lesson).
16250940|NCT05018559|No Intervention|Control group nursing care|Participants do not receive any treatment in addition to their vocational education and training curriculum.
16250941|NCT05018559|Experimental|Intervention group automotive mechatronics|Participants receive a co-created physical activity intervention called tutoring system.
16250942|NCT05018559|No Intervention|Control group automotive mechatronics|Participants do not receive any treatment in addition to their vocational education and training curriculum.
16250943|NCT05018546|Experimental|Gravity Irrigation|RIRS under Gravity irrigation
16250944|NCT05018546|Experimental|Pressure Irrigation|RIRS under Pressure irrigation.
16250945|NCT05018533|Experimental|Cohort 1|TAKC-02 0.15mg Single dose
16250946|NCT05018533|Placebo Comparator|Placebo (to Cohort 1)|
16250947|NCT05018533|Experimental|Cohort 2|TAKC-02 0.5mg Single dose
16250948|NCT05018533|Placebo Comparator|Placebo (to Cohort 2)|
16250949|NCT05018533|Experimental|Cohort 3|TAKC-02 1.5mg Single dose
16250950|NCT05018533|Placebo Comparator|Placebo (to Cohort 3)|
16250951|NCT05018533|Experimental|Cohort 4|TAKC-02 5mg Single dose
16250952|NCT05018533|Placebo Comparator|Placebo (to Cohort 4)|
16250953|NCT05018533|Experimental|Cohort 4.5 *optional|TAKC-02 10mg Single dose
16250954|NCT05018533|Placebo Comparator|Placebo (to Cohort 4.5) *optional|
16250955|NCT05018533|Experimental|Cohort 5|TAKC-02 15mg Single dose
16250956|NCT05018533|Placebo Comparator|Placebo (to Cohort 5)|
16250957|NCT05018533|Experimental|Cohort 6|TAKC-02 Multiple dose (low)
16250958|NCT05018533|Placebo Comparator|Placebo (to Cohort 6)|
16250959|NCT05018533|Experimental|Cohort 7|TAKC-02 Multiple dose (high)
16250960|NCT05018533|Placebo Comparator|Placebo (to Cohort 7)|
16250961|NCT05018520|Experimental|4RCHOP+4R|Four Courses of R-CHOP Plus Four Courses of Rituximab
16250962|NCT05018520|Experimental|6RCHOP+2R|Six Courses of R-CHOP Plus Two Courses of Rituximab
16250963|NCT05018507||total knee arthroplasty patients|data collection only
16250964|NCT05018494|Experimental|Group A|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
16250965|NCT05018494|Active Comparator|Group B|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
16250966|NCT05018481|Placebo Comparator|HA35 Placebo Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.
16250967|NCT05018481|Active Comparator|HA35 Treatment Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.
16251030|NCT05018065|Active Comparator|51 women having no Covid-19 history|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
16250968|NCT05018468|Experimental|ventilation with an anatomical facial mask|Intervention group 1: Patients in this group undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
16250969|NCT05018468|Experimental|ventilation with a nasal mask|Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. Ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
16250970|NCT05018455|Experimental|Fall prevention intervention program conducted through telehealth|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. Each participant will practice from home, using a zoom system. The duration of each training will be one hour, the frequency of training will be twice a week for three months.
16250971|NCT05018455|Active Comparator|Similar fall prevention intervention program conducted through face to face group training|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. The training sessions will be delivered at the local community center, twice a week for one hour for three months.
16250972|NCT05018429||nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
16250973|NCT05018429||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles) during the operation.
16250974|NCT05018416|Experimental|2 REACT injections|Cohort 1 subjects will receive 2 REACT injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
16250975|NCT05018416|Experimental|1 REACT Injections|Cohort 2 subjects will receive 1 REACT injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT injection into the contralateral kidney.
16250976|NCT05018403|Experimental|AON-D21|Single ascending doses by iv infusion.
16250977|NCT05018403|Placebo Comparator|Placebo|Placebo medication identical in appearance to active.
16250978|NCT05018390|Experimental|OMT|Osteopathic manipulative treatment : participants will receive low-amplitude tissue mobilizations on peripheral, vertebral, cranial and/or visceral articular systems.
16250979|NCT05018390|Sham Comparator|Sham|Participants will be applied gestures that look like actual osteopathic manipulations but are not therapeutic.
16250980|NCT05018390|No Intervention|Test-retest|Participants will undergo the two eye movement measurements, but will not receive any (actual or sham) treatment. 30 minutes will elapse between the two measurements.
16250981|NCT05018377|Active Comparator|Raj'z catheter|
16250982|NCT05018377|Active Comparator|NAVI catheter|
16250983|NCT05018364||cases|measure serum erythropoietin level
16250984|NCT05018364||controls|measure serum erythropoietin level
16250985|NCT05018351|Active Comparator|Treatment as Usual-Integrated Care (TAU-IC)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-half of research participants will be randomized to integrated care alone.
16250986|NCT05018351|Experimental|Peer Navigator Program (PNP)|"Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:
~scheduling and attending healthcare appointments;
~partnering with participant on tasks that arise from appointments;
~health-related goal setting; and
~taking action-steps toward health-related goals."
16250987|NCT05018338||The study cohort|The study will enroll 10 subjects meeting the eligibility criteria, with the expectation to obtain complete data from at least 6 subjects.
16250988|NCT05018325|Active Comparator|Arm 1: Colonoscopy 6 minute withdrawal time|-Undergo colonoscopy with the standard 6-minute withdrawal time followed by a tandem colonoscopy of at least another 6-minute withdrawal time.
16250989|NCT05018325|Experimental|Arm 2: Colonoscopy 9 minute withdrawal time|-Undergo a 9-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time.
16250990|NCT05018325|Experimental|Arm 3: Colonoscopy 12 minute withdrawal time|-Undergo colonoscopy with a 12-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time
16250991|NCT05018312|Experimental|Modified Collaborative Assessment (MCA)|The patients allocated to this arm will receive assessment inspired by therapeutic/collaborative assessment, as a pre-treatment to the standard psychotherapeutic treatment they will receive in the clinic.
16250992|NCT05018312|Active Comparator|Assessment as usual (AAU)|The patients allocated to this arm will receive standard assessment offered in the clinic, before proceeding to the standard psychotherapeutic treatment they will receive in the clinic.
16250993|NCT05018299|Placebo Comparator|FB704A placebo|placebo
16250994|NCT05018299|Experimental|FB704A|Anti-IL6 antibody
16250995|NCT05018286|Experimental|Apraglutide subcutaneous (SC) injections, once weekly|Peptide analogue of Glucagon-like Peptide 2 (GLP-2)
16250996|NCT05018273|Experimental|VB10.NEO 3 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 3 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).
~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
16250997|NCT05018273|Experimental|VB10.NEO 6 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 6 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).
~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
16250998|NCT05018260|Experimental|GCMRT|Attention bias modification: participants will receive gaze-contingent feedback according to their viewing patterns on disgusted and neutral faces
16251286|NCT05016414|Experimental|Lower body negative pressure|4 days of strict bed rest with nightly lower body negative pressure at -20mmHg
16250999|NCT05018260|Experimental|attention control|Attention control modification: participants will receive gaze-contingent feedback according to their viewing patterns on rounded and sharp geometric shapes
16251000|NCT05018247|Active Comparator|Urgent revascularization with Optimal Medical Therapy|Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
16251001|NCT05018247|Other|Optimal Medical Treatment with delayed revascularization|OMT without revascularization for a minimum of approximately 105 days if clinically stable. At their first follow-up visit (Day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter and will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
16251002|NCT05018234|Experimental|Treatment|
16251009|NCT05018208||Arm 1 (wearable device[s], smartphone app)|Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks.
16251010|NCT05018208||Arm 2 (wearable device[s], smartphone app, questionnaires)|Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
16251011|NCT05018195|Active Comparator|Benign|Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
16251012|NCT05018195|Experimental|Endometrial cancer|Women who receive surgery(staging or cytoreductive surgery) for endometrial cancer. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
16251013|NCT05018182|Experimental|Neoadjuvant chemotherapy|4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX
16251014|NCT05018169|Experimental|BA-A|Teens will participate in BA-A. BA-A is a 12-session manualized treatment that utilizes established BA strategies and incorporates common mental health treatment adaptations for young people with ASD.
16251015|NCT05018156|Experimental|Default Genetics Referral Process|
16251016|NCT05018143|Experimental|STARS|The investigators will deliver an online intervention focused on safety planning (STARS). The intervention content includes life skills interactive modules across 14 domains, a goal tracker, referral to community resources, and scheduling of peer mentoring sessions.
16251017|NCT05018143|Active Comparator|Control Condition|The investigators will deliver an in-person therapeutic session where participants can develop an individualized safety plan for use during a suicidal crisis, focusing on adaptive coping, addressing barriers or ambivalence, and strengthening their self-efficacy.
16251018|NCT05018130|Experimental|Bio-integrative|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.
16251019|NCT05018130|Active Comparator|Metallic|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm metallic cannulated screws.
16251020|NCT05018117|Experimental|Young (18-28 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
16251021|NCT05018117|Experimental|Old (60-85 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
16251022|NCT05018117|Placebo Comparator|Young (18-28 years) participants - placebo gum|placebo gum, one time before fMRI measurements
16251023|NCT05018117|Placebo Comparator|Old (60-85 years) participants - placebo gum|placebo gum, one time before fMRI measurements
16251024|NCT05018104||Lower Limb Orthopedic Surgery Patients who Received Popliteal Sciatic Nerve Blocks|All patients undergoing lower limb surgery who received popliteal sciatic nerve blocks (with or without other peripheral nerve blocks) at St. Paul's Hospital from January 4, 2016 to November 1, 2019
16251028|NCT05018078|Experimental|Coronavirus vaccination|Patients in the experimental need to accept the coronavirus vaccination
16251029|NCT05018065|Active Comparator|50 women previously diagnosed with mild - medium Covid-19 and had ambulatory care|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
16252153|NCT05010213|No Intervention|Control group|There will be no intervention to the control group.
16251031|NCT05018039|Experimental|Collaborative care model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider (psychologist or psychiatrist) and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.
~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments with the physiotherapist and/or occupational therapist (usual care)."
16251032|NCT05018039|No Intervention|Usal Care|"Current usual care within musculoskeletal outpatients involves an initial patient assessment by a physiotherapist or occupational therapist (or both) to determine the needs and goals of the patient in relation to their musculoskeletal condition. Clinicians also help to inform, educate, and empower patients to self-manage their rehabilitation where possible.
~Following this initial assessment, patients are provided with a plan of their therapy treatment. The therapist(s) progress patients exercise, as appropriate. Therapy is most often a 1:1 session but can also include group classes. Physical therapy involves exercise and education, while occupational therapy focuses on practical strategies to perform daily tasks.
~If the therapists feel that patients require additional support for their mental health problems, they can request this support via the General Practitioner or the hospital mental health services."
16251033|NCT05018026|No Intervention|Arm 1 (Control Arm)|A default NUSMart that mirrors a conventional web-grocery store in Singapore where some healthier products are displayed with Singapore's Healthier Choice Symbol (HCS) logos (Control).
16251034|NCT05018026|Experimental|Arm 2 (Nutri-Grade Arm)|Similar to Arm 1 except that beverages will be displayed with a color-coded and graded Nutri-Grade label.
16251035|NCT05018013|Active Comparator|Duloxetine group|The eligible subjects will receive duloxetine hydrochloride enteric-coated capsules plus placebo to Ammoxetine.
16251036|NCT05018013|Placebo Comparator|Placebo group|The eligible subjects will receive placebo to Ammoxetine and placebo to Duloxetine.
16251037|NCT05018013|Experimental|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
16251038|NCT05018013|Experimental|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
16251039|NCT05018013|Experimental|Ammoxetine group-cohort 3|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
16251040|NCT05018013|Experimental|Ammoxetine group-cohort 4|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
16251041|NCT05018000|Active Comparator|Arm 1: Enhanced usual care|Participants in this arm will receive their usual care plus a Financial Resource Sheet. The financial resource sheet lists and describes existing organization and community resources available to KP members.
16251042|NCT05018000|Experimental|Arm 2: Brief financial navigation intervention|Participants in this arm will receive their usual care, and the Financial Resource Sheet described in Arm 1, plus one (1) cycle of financial navigation (total cycles: 1; total length: 6 months). In each intervention cycle participants will get at least one (1) phone call with a CAFÉ Financial Navigator, the navigator will talk with participants to identify financial questions or concerns. The navigator will create a personalized plan for each participant. Participants can request extra support from the navigator for up to 6 months.
16251043|NCT05018000|Experimental|Arm 3: Extended financial navigation intervention|Participants in this arm will receive their usual care, a Financial Resource Sheet and the brief intervention described in Arm 2 (i.e., one (1) cycle of financial navigation). Plus, they will receive two (2) additional cycles of financial navigation (total cycles: 3; total length: 6 months).
16251044|NCT05017987|Active Comparator|Sequence A=Reference-Test|"T(Test drug): ATB-101 R1(Reference drug1): ATB-1011 R2(Reference drug2): ATB-1012
~First stage: co-administration of R1 and R2, single dose and then Washout: 7days and then Second stage: administration of T, single dose"
16251045|NCT05017987|Active Comparator|Sequence B=Test-Reference|First stage: administration of T, single dose and then Washout: 7days and then Second stage: co-administration of R1 and R2, single dose
16251046|NCT05017974|Experimental|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement (MBSR+PS)|The study intervention is standard mindfulness-based stress reduction (MBSR), which will be delivered through 8 weekly 2.5-hour sessions via video conferencing to groups of 20-30 pregnant and non-pregnant people. MBSR also consists of a 2.5-hour orientation session, a 30-minute private interview with the instructor, and an all-day retreat, all conducted via video conferencing. The supplemental prenatal sleep content will be delivered through 6-8 30-minute sessions via video conferencing either individually or to small groups, and draws material from mindfulness-based therapy for insomnia, mindfulness-based childbirth and parenting program, and cognitive behavior therapy for prenatal insomnia.
16251047|NCT05017974|Other|Treatment as Usual|The control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy, with the exception of asking participants to refrain from participating in non-study mindfulness practice. Use of non-study treatment will be tracked.
16251048|NCT05017961|Active Comparator|Autograft|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group an autograft will be used to fill the void. For the purpose of autologous grafting, cancellous strips of bone will be harvested from the posterior superior iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s). This will be the control arm.
16251049|NCT05017961|Other|Allograft only|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) will be used to fill the void. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
16251216|NCT05016856|Active Comparator|Reminder Only Condition|To promote adherence, participants will receive generic reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone.
16251050|NCT05017961|Other|Allograft combined with BMAC|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) combined with BMAC will be used to fill the void. For the purpose of BMAC preparation, bone marrow will be collected from iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
16251053|NCT05017935|Experimental|Renal Denervation|
16251056|NCT05017909|Experimental|Experimental Group 1|3-week web-based education group
16251057|NCT05017909|Experimental|Experimental Group 2|3-week face to face education group
16251058|NCT05017909|Active Comparator|Control Group|Uneducated group
16251059|NCT05017896||Normal Perfusion|
16251060|NCT05017896||Low Perfusion|
16251061|NCT05017883|Experimental|TAA05 cell injection|TAA6 cell injection#Targeting FLT3 autologous chimeric antigen receptor T cells#
16251062|NCT05017870|Experimental|KSR-001-01|Participants received KSR-001-01 for 6 days.
16251063|NCT05017870|Experimental|KSR-001-02|Participants received KSR-001-02 for 6 days.
16251064|NCT05017870|Experimental|KSR-001-03|Participants received KSR-001-03 for 6 days.
16251065|NCT05017870|Placebo Comparator|KSR-001-04|Participants received KSR-001-04 for 6 days.
16251068|NCT05017844|Placebo Comparator|KSR-001-04|KSR-001-04 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
16251069|NCT05017844|Experimental|KSR-001-02|KSR-001-02 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
16251070|NCT05017844|Experimental|KSR-001-03|KSR-001-03 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
16251071|NCT05017831|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
16251072|NCT05017831|Experimental|FBT w/ Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of FBT over six months. The first 9 sessions of FBT will be preceded by adolescent-focused CRT.
16251073|NCT05017818||Treated and untreated subjects with TK2 deficiency|Two TK2 deficiency groups. (1) Subjects treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study. (2) Subjects not treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study.
16251074|NCT05017805|Experimental|COVID-19 Vaccines|One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
16251075|NCT05017792|Other|1- Before vaccination:|"To detect:
~COVID-19 IgG/IgM Rapid Test
~COVID-19 IgG/IgM by quantitative method(ELISA).
~D-dimer"
16251076|NCT05017792|Other|2-7 days after the first dose|Measuring D-dimer
16251077|NCT05017792|Other|3-Before the second dose:|To detect IgG and IgM To detect the level of Covid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
16251078|NCT05017792|Other|4-After 3 months from the second dose:|To detect the level ofCovid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
16251079|NCT05017792|Other|5-After 6 months from the second dose:|To detect the level ofCovid 19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
16251082|NCT05017766||A) Urinary tract infection|Processing of residual urine for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS), immunophenotyping. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties (Highly sensitive mass spectrometry, whole genome sequencing), expression of virulence factors, genomic alterations of bacterial species, metabolism, surface molecule expression, gene expression levels, cytokine levels, immune cell biology, antibiotic concentration (chromatography/mass spectrometry). Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included. First, a pilot study from randomly selected patients within each bacterial species group (n=50, each) is done.
16251083|NCT05017766||B) Pneumonia|Processing of residual samples (tracheal secretion, bronchioalveolar lavage (BAL)) for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
16251084|NCT05017766||C) Deep-seated infections|Processing of intraoperative material residual samples for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
16251085|NCT05017766||D) Controls for A), B) and C)|Control samples result from patients with a suspected infection (infection sites A), B) or C), in which no microbiological confirmed infection has been diagnosed. Storage at biobank
16251086|NCT05017766||E) Clinical controls for A), B) and C) without obtained samples|For clinical controls, clinical characteristics of patients with detection of target pathogens in their routine samples (but which could not be included for sample analysis in this study) will be assessed.
16251087|NCT05017766||F) Cohort with analysis whether the application of Article (Art) 34 HFV can avoid a bias|Since part of the data and samples in this study are collected with the representative consent of the ethics committees, it is investigated whether the application of Art. 34 HFV prevents selection bias with respect to the study population. For this purpose, differences between the actual study population using Art. 34 HFV and the study population with provided research consent will be descriptively investigated in terms of the prevalence of multi-resistant germs and other available population characteristics.
16251088|NCT05017753|Active Comparator|Control group|Standard-of-care medical treatment.
16251089|NCT05017753|Experimental|Intervention group|Thoracentesis in addition to standard-of-care medical treatment.
16251090|NCT05017740|Active Comparator|ICSI|
16251091|NCT05017740|Active Comparator|PICSI|
16251092|NCT05017714|Experimental|Active plus SOC|
16251093|NCT05017714|Placebo Comparator|Placebo plus SOC|
16251094|NCT05017688|Other|Patient population|"The population of the study will be adult patients with GI-aGVHD grade III to IV undergoing MaaT013 treatment through named-patient use program ATUn (Early Access Program).
~Blood and stool samples will be collected at each visit to analyse the gut microbiota and the immune cells."
16251095|NCT05017675|Experimental|High fructose diet|Participants will receive dietary products high in fructose for 4 weeks.
16251096|NCT05017675|Experimental|High saturated fat diet|Participants will receive dietary products high in saturated fat for 4 weeks.
16251098|NCT05017649|Other|Healthy volunteers|volunteers showing no hypercholesterolemia
16251099|NCT05017649|Experimental|Patients with untreated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia with no treatment at the time of inclusion
16251100|NCT05017649|Experimental|Patients with treated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia and treated at the time of inclusion
16251101|NCT05017636|Active Comparator|Treatment groupThorck Shock Wave Ibramed (terapia ESWT)- fat cell death|The shock wave treatment was performed on the left side of the abdomen
16251102|NCT05017636|No Intervention|Without intervention.|no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group without intervention.
16251103|NCT05017623|Experimental|Intervention/treatment|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
16251104|NCT05017610|Experimental|Treatment (methimazole, lomustine, liothyronine)|See Outline in Detailed Description.
16251105|NCT05017597|Experimental|Fatigue management|"Prescribed exercises by Physical Therapy Problem-Solving Sessions to resume activities that ther person needs to do, wants to do or is expected to do.
~Four online educational modules: What is Cancer-Related Fatigue? Nutrition, Sleep Hygiene and Exercise"
16251106|NCT05017584|Experimental|Hyperbaric bupivacaine 10.5mg|
16251107|NCT05017584|Experimental|Hyperbaric bupivacaine 12mg|
16251108|NCT05017584|Experimental|Hyperbaric bupivacaine 13.5mg|
16251109|NCT05017584|Experimental|Hyperbaric bupivacaine 15mg|
16251116|NCT05017558||intervention|Measurement of viral load in HIV-1 infected mothers at delivery by POC to optimise post-natal prophylaxis and neonatal diagnosis of children according to the estimated risk of MTCT (high risk:VL at delivery ≥ 1000 copies/mL, low risk: VL at delivery < 1000 copies/mL) in Conakry, Guinea.
16251148|NCT05017311|Active Comparator|Random Allocation; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
16251279|NCT05016466||Group I. Patients with DLCO <80%.|Patients with DLCO <80% will be followed at baseline and once a year during the study
16264264|NCT04925921|Experimental|Treatment|Treatment with the SR-1 Laser
16251119|NCT05017532|Experimental|Intervention|Intervention with RC2S+ that consists of 24 biweekly sessions
16251120|NCT05017519||Nuclear family type|The husband and wife with baby (aged less than 5 months) and with or without children (2-5)
16251121|NCT05017519||Extended family type (three-generation family)|The husband and wife with baby (aged less than 5 months), children (2-5), and grandparents aged > 65 years old
16251122|NCT05017493|Experimental|Treatment arm|Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.
16251123|NCT05017493|No Intervention|Control arm|Patients in the Control arm received the standard of care for Covid19.
16251124|NCT05017480|Experimental|CBP-201 Dose|CBP-201 Dose subcutaneous (SC) injection
16251125|NCT05017480|Placebo Comparator|Placebo|subcutaneous (SC) injection
16251126|NCT05017467|Experimental|vss|Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery
16251127|NCT05017467|Experimental|QuickDASH , VAS|, Quick Disabilities of Arm Shoulder and Hand functional score (QuickDASH) and Visual Analogue Scale (VAS) test was used to determine overall hand function, activities of daily living, work performance, pain, aesthetics, and satisfaction with hand function
16251128|NCT05017454|Experimental|sodium valproate group|Group 1 will be treated with the optimized sodium valproate-loaded nanospanlastic dispersion, twice daily on the affected areas of the scalp for 3 months
16251129|NCT05017454|Active Comparator|topical steroid group|Group 2 will be treated with the marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
16251130|NCT05017428|Experimental|Low Dose|The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.
16251131|NCT05017428|Experimental|Medium Dose|The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.
16251132|NCT05017428|Experimental|High Dose|The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.
16251133|NCT05017428|Placebo Comparator|Placebo|In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.
16251136|NCT05017376||group A|small optical zone
16251137|NCT05017376||group B|large optical zone
16251138|NCT05017363|Experimental|Intervention Group (ENGAGE)|Therapists will consist of pairs within sites providing similar interventions to similar children so that treatment and child characteristics other than the goal-setting intervention will be similar within each site. Therapists will use principles-based goal-setting approaches and strategies in the goal-setting toolbox. It is anticipated that treatment block lengths will vary from 3-8 sessions over 2-8 weeks, representing typical clinical variation.
16251139|NCT05017363|No Intervention|Usual Care Group (Control)|The control group will comprise usual care.
16251140|NCT05017350|Experimental|Radiofrequency ablation group|hemostasis using radiofrequency ablation for track bleeding
16251141|NCT05017337||BASILICA-A|"Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) patients recruited both retrospectively and prospectively.
~Pre- and post-operative (4 w and 12 m) blood samples taken from prospectively recruited patients. Post-operative pathological FFPE tissue samples obtained from all recruited patients."
16251142|NCT05017337||BASILICA-C|"Patients undergoing capsule related surgery (any-grade of capsular contracture, irradiated and unirradiated capsules) recruited prospectively.
~Pre- and post-operative (4 w) blood samples taken from all patients. Intra-operative tissue sampling (capsular washings, 2 samples of ADM and 2 samples of non-ADM capsule) from all patients."
16251143|NCT05017337||BASILICA-N|"Implant naive patients undergoing implant insertion surgery recruited prospectively.
~Pre- and post-operative (4 w and 12 m) blood samples taken from all patients."
16251144|NCT05017324|Experimental|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an individualised RR-TB treatment recommendation
16251145|NCT05017324|No Intervention|Standard of Care|Standard of care diagnosis of the drug resistance profile and individualised treatment
16251146|NCT05017311|Active Comparator|Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted as non-responders to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
16251147|NCT05017311|Placebo Comparator|Allocation by Predictive Biomarker Algorithm; Placebo|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted to respond to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
16251149|NCT05017311|Placebo Comparator|Random Allocation; Placebo|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
16251150|NCT05017298|Experimental|Study Group|Each subject receives three separate doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion on day 0 , 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.
16251151|NCT05017298|Placebo Comparator|Control Group|The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.
16251152|NCT05017285|Other|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
16251153|NCT05017285|Experimental|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum.
16251154|NCT05017272|Active Comparator|Opioid Addiction Recovery Support (OARS)|Data collected post-implementation of OARS in conjunction with medication for opioid use disorder (MOUD) at study sites.
16251155|NCT05017272|No Intervention|Treatment as Usual|Data collected at baseline before OARS in conjunction with MOUD is implemented at study sites.
16251156|NCT05017259|Experimental|low carbohydrate trial|The energy distribution was carbohydrate 10%, protein 40-50%, fat 40-50% in the LC trial.
16251157|NCT05017259|Active Comparator|high carbohydrate trial|The energy distribution was carbohydrate 60-65%, protein 30-40%, fat 5-10% in the HC trial.
16251158|NCT05017246|Active Comparator|Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)|"Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital
~Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.
~Intraoperative: dexamethasone and epidural bupivacaine
~Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine
~Postoperative: hydromorphone PCA, ibuprofen, oxycodone"
16251159|NCT05017246|Experimental|Intrathecal morphine with intraoperative lidocaine infusion|"Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)
~Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight
~Day of surgery postoperative: toradol, ibuprofen, tylenol
~Postoperative: ibuprofen, oxycodone, and hydromorphone prn"
16251160|NCT05017220|Experimental|Nature-based stimulation program|Participants will receive a single intervention with a duration of 30 minutes based on a multisensorial nature-based stimulation
16251161|NCT05017220|Other|Control intervention|Participants will be involved in a placebo task for 30 minutes
16251162|NCT05017207||Patient with periampullary cancer and pancreaticoduodenectomy|Only one group of patient with periampullary cancer
16251163|NCT05017194|Experimental|Emodepside 5 mg|
16251164|NCT05017194|Experimental|Emodepside 10 mg|
16251165|NCT05017194|Experimental|Emodepside 15 mg|
16251166|NCT05017194|Experimental|Emodepside 20 mg|
16251167|NCT05017194|Experimental|Emodepside 25 mg|
16251168|NCT05017194|Experimental|Emodepside 30 mg|
16251169|NCT05017194|Active Comparator|Albendazole|
16251170|NCT05017194|Placebo Comparator|Placebo|
16251171|NCT05017181||BioVal|BioVal is a single site validation study to determine the histological correlates underpinning signals derived from 13C-pyruvate HYP-MRI in men with known prostate cancer scheduled for prostatectomy.
16251172|NCT05017181||ProVal|ProVal is a single site, prospective, longitudinal observational cohort study to determine the prognostic value of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known early prostate cancer on active surveillance.
16251173|NCT05017181||TecVal|TecVal is a multi-site validation study to determine the inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.
16251174|NCT05017168|Experimental|CT-P63|Single Ascending Dose
16251175|NCT05017168|Placebo Comparator|Placebo|Single Ascending Dose
16251176|NCT05017155|Active Comparator|Lamotrigine|When on the lamotrigine treatment arm, the participant will commence at lamotrigine 25mg (milligram) daily for two weeks; then increase to 25mg twice daily for two weeks; then increase to 50mg daily for one week; then increase to 100mg in the morning, 50mg at midday and 50mg at night for one week; then increase to 100mg in the morning, 50mg at midday and 100mg at night for two weeks.
16251177|NCT05017155|Active Comparator|Mexiletine|When on the mexiletine treatment arm, the participant will commence at mexiletine 100mg daily for two weeks; then increase to 200mg daily for two weeks; then increase to 200mg twice daily for one week; then increase to 200mg three times a day for one week; then remain on 200mg three times a day for two weeks.
16251178|NCT05017142||Patient population|Children, adolescents and adults diagnosed with an IBrainD before age 18, who are born, treated or living in Switzerland
16251179|NCT05017129|Experimental|Inmates Care modules|This is a within-subjects, pre-post design with a single intervention. The intervention is a 6 module computer-based learning program for training peer caregivers in end-of-life care.
16251180|NCT05017116|Experimental|Part A，single dose group|Subjects will receive single dose RBD1016/placebo on D1 combined with antiviral drugs during the study period.
16251181|NCT05017116|Experimental|Part B, multiple dose group|Subjects will receive two doses of RBD1016/placebo on D1 and D29 combined with antiviral drugs during the study period.
16251182|NCT05017103|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16251183|NCT05017090|Sham Comparator|Group N|The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
16251184|NCT05017090|Experimental|Group M-TAPA|After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
16251185|NCT05017077|Experimental|Telemonitoring|To evaluate the feasibility and efficacy of a new model of tele monitoring in pediatric population in advanced heart failure, we will enroll 20 patients in advanced NYHA/Ross class in waiting list for Heart Transplant. An home telemonitoring capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients
16251186|NCT05017064|Experimental|Cryotherapy group|An intraoral ice pack will be placed on the mucosal groove during root canal treatment.
16251187|NCT05017064|Placebo Comparator|Control group|No ice pack will be used.
16251188|NCT05017051||Dysexecutive patients|Patients with dysexecutive syndrome
16251189|NCT05017051||Healthy subjects|Healthy subjects to be used as control group
16251190|NCT05017025|Experimental|Treatment (osimertinib, aurora A kinase inhibitor LY3295668)|Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
16251193|NCT05016999|No Intervention|Control|Volunteers in this group will not take any products.
16251194|NCT05016999|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
16251195|NCT05016973|Experimental|RC48-ADC+ Triplizumab|RC48-ADC on days 1 every 21 days plus triplizumab on days 1 every 21 days
16251196|NCT05016960|Experimental|Sleep-SMART|Sleep-SMART intervention
16251198|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 10mcg|Two applications of 10mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
16251199|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 25mcg|Two applications of a vaccine composed of a recombinant S1 antigen 28 days apart
16251200|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 50mcg|Two applications of 50mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
16251201|NCT05016934|Placebo Comparator|Placebo|Two applications of placebo 28 days apart
16251202|NCT05016921|Experimental|Transcutaneous magnetic stimulation|Transcutaneous magnetic stimulation targeting the stellate ganglion
16251203|NCT05016908||Biofluid collection|Eligible volunteers will be asked to provide a single urine sample and undergo a single blood draw.
16251204|NCT05016895|Experimental|Bi-annual single dose azithromycin|Mass, community-based distribution of single dose azithromycin solution (200 mg/5ml) dosed at 20 mg/kg weight to all eligible infants ages 1 to 11 months twice yearly (approximately 6 months apart)
16251215|NCT05016869|Experimental|Experimental|fruquintinib plus capecitabine
16251217|NCT05016856|Experimental|Smart Adherence Support Condition|To promote adherence, participants will receive reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone. In this condition, participants will receive adaptive and tailored reminders based on dynamic algorithms that deploy reminders in a way that considers participant preferences, days and times of previous successful assessments, the success of previous reminder attempts, and answers to brief questions contained within reminder prompts. Parameter weights for these variables will be adjusted dynamically over a 6-month assessment period to ensure that reminders are deployed when they are most likely to be acted upon.
16251218|NCT05016843|Experimental|CBT, 8 weeks and access to forum.|
16251219|NCT05016843|Experimental|CBT, 16 weeks and access to forum.|
16251220|NCT05016843|Experimental|CBT, 8 weeks and no access to forum.|
16251221|NCT05016843|Experimental|CBT, 16 weeks and no access to forum.|
16251222|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and access to forum.|
16251223|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and access to forum.|
16251224|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and no access to forum.|
16251225|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and no access to forum.|
16251226|NCT05016843|Experimental|Waitlist, 8 weeks and access to forum.|
16251227|NCT05016843|Experimental|Waitlist, 16 weeks and access to forum.|
16251228|NCT05016843|Experimental|Waitlist, 8 weeks and no access to forum.|
16251229|NCT05016843|Experimental|Waitlist, 16 weeks and no access to forum.|
16251230|NCT05016830|Sham Comparator|Sham bilateral transcranial direct current stimulation|Sham bilateral transcranial direct current stimulation consisted of 2 milliamperes (mA) of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex, but the stimulation was turned off after 30 seconds. On Sham Stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
16251231|NCT05016830|Experimental|Bilateral transcranial direct current stimulation|Bilateral transcranial direct current stimulation consisted of 2 mA of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex and the stimulation was on for 20 minutes. On stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
16251232|NCT05016817|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16251233|NCT05016804|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16251234|NCT05016791|Active Comparator|Active|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider. In addition, participants in this arm shall be loaned an Apple Watch device and undergo an education session to familiarise themselves with the study recording schedule and how to perform recordings.
16251235|NCT05016791|No Intervention|Control|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider.
16251236|NCT05016778|Experimental|Treatment Group|This is a open label, single arm clinical trial.
16251238|NCT05016739|Experimental|CADISS System|
16251239|NCT05016713|Active Comparator|Intervention group 1|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
16251240|NCT05016713|Active Comparator|Intervention group 2|Chlorhexidine mouthwash is added to the previous oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.
16251241|NCT05016713|Placebo Comparator|Control group|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
16251242|NCT05016687|Experimental|Experimental Part I Cohort 1-5: CUR-N399|Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.
16251243|NCT05016687|Placebo Comparator|Experimental Part I Cohort 1-5: Placebo|Healthy subjects will receive Placebo to match treatment of CUR-N399.
16251244|NCT05016687|Experimental|Experimental Part IIa Cohort 1-3: CUR-N399|Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.
16251245|NCT05016687|Placebo Comparator|Experimental Part IIa Cohort 1-3: Placebo|Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
16251246|NCT05016687|Experimental|Experimental Part IIb: CUR-N399|Healthy subjects >/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.
16251247|NCT05016687|Placebo Comparator|Experimental Part IIb: Placebo|Healthy subjects >/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
16251248|NCT05016674|Experimental|Laser-assisted liposuction|Laser-Assisted Liposuction with the LipoLife system.
16251249|NCT05016661|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
16251250|NCT05016661|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles
16251251|NCT05016648||PEARS patients|Patients who underwent the personalized external aortic root support procedure at the AMC. Cerebral monitoring measurements (NIRS, EEG, TCD and blood pressure) are used for the study.
16251252|NCT05016635||Sub-arachnoid Hemorrhage Patients|
16251253|NCT05016622|Experimental|Booster dose|
16251280|NCT05016466||Group II. Patients with DLCO ≥ 80%.|Patients with DLCO ≥80% only will be followed at baseline and year 5.
16251281|NCT05016440|Active Comparator|Lisinopril|10mg Lisinopril tablets
16251282|NCT05016440|Placebo Comparator|Sugar pill|sugar pill
16251254|NCT05016609|Experimental|POC HCV antibody group (Arm A)|This group will receive POC HCV antibody testing via fingerprick using the OraQuick HCV antibody test (OraSure) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
16251255|NCT05016609|Experimental|POC HCV RNA group (Arm B)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will receive POC HCV viral load testing via fingerstick using the Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
16251256|NCT05016609|Experimental|Test and treat group (ArmC)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will be provided a starter pack of HCV treatment (epclusa). POC tests results will be confirmed through standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. HCV RNA positive participants will continue treatment. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
16251257|NCT05016609|No Intervention|Control|This group will receive the standard of care for HCV testing and treatment. Participants in this group will fill out a short behavioural questionnaire and a clinical questionnaire.
16251258|NCT05016596|Placebo Comparator|placebo|Acacia gum
16251259|NCT05016596|Experimental|turmeric|High bioavailable turmeric extract
16251260|NCT05016583|Experimental|Paula Method|
16251264|NCT05016557|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g protein
16251265|NCT05016557|Experimental|Spirulina|Bolus ingestion of spirulina providing 25g protein
16251266|NCT05016557|Experimental|Chlorella|Bolus ingestion of chlorella providing 25g protein
16251267|NCT05016544|Experimental|Inetetamab+Pyrotinib|Dose Escalation and Dose Expansion: Inetetamab in combination with Pyrotinib in HER2 mutant or amplified participants with advanced or metastatic NSCLC
16251268|NCT05016531|Experimental|Low Intensity Focused Ultrasonic Stimulation|There are different combinations of intensity and frequency with LIFUS
16251269|NCT05016518|Experimental|Propofol group|Propofol based total intravenous anesthesia
16251270|NCT05016518|Active Comparator|Remimazolam group|Remimazolam based total intravenous anesthesia
16251271|NCT05016505|Experimental|Compliance through relocation and cessation|Smokers will be referred by the survey team to Community Outreach Workers (COWs) trained to address the heath care needs of underserved populations providing medical care and services, including tobacco cessation. The COW will coordinate smoking cessation support, including serving as a liaison between participant and research team, providing information regarding the smoke-free policy and opportunities for relocation, and connecting participant to access to tobacco replacement therapy and/or physician support if deemed appropriate.
16251272|NCT05016505|Experimental|Compliance through resident endorsement|Buildings assigned will be targeted for a series of 2 in-residence programs that involve community forums and the creative arts to garner resident endorsements of smoke-free living environments. Premised on resident engagement, this arm seeks to impact social and physical dimensions of the residential environment to achieve compliance. The sessions will: 1) inform residents of risks associated with smoking and secondhand smoke; 2) identify reasons to have a smoke-free home, 3) ask residents to sign a pledge on paper and/or virtually; 4) display smoke-free signage on doors and/or social media pages with an original hashtag (#Smokefree[building address]); and 5) refer residents to the Smoke-free NYCHA website for information on the policy and existing cessation resources.
16251273|NCT05016505|Experimental|Compliance through relocation/cessation plus resident endorsement (combined)|The combined intervention will be carried out in the buildings assigned to this RCT arm, which will provide in-residence programs based on the resident endorsement treatment and the smoking relocation/cessation treatment. Both will occur simultaneously with one geared toward all building residents (resident endorsement) and the other targeting smokers (smoking relocation/cessation) with the goal of reducing both personal smoking and secondhand smoke exposure.
16251274|NCT05016505|No Intervention|Standard NYCHA approach (control)|Buildings and study participants assigned to this arm will be recruited and followed over a 12-month period to assess outcomes. No additional programs or services will be delivered to the buildings or residents assigned to this arm beyond standard programs that NYCHA may provide to support the smoke-free mandate. Field staff will document any policy-related signage, activities or information to which these participants are exposed.
16251275|NCT05016492|Experimental|Digital game group|The digital game group received the standard 4-week course of rehabilitation but with an additional 30-min interactive digital game training session per week.
16251276|NCT05016492|Active Comparator|Standard rehab group|The standard rehab group received the standard 4-week course of rehabilitation delivered in one 30-min session per week.
16251283|NCT05016427|Experimental|VT301(low dose)|VT301 low dose: 8.5x10^4 cells/kg
16251287|NCT05016388|Experimental|Collaborative Multidimensional Model (CMD)|The teams in the CMD group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the CMD training and the CMD will be installed in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
16251288|NCT05016388|Other|Standard Model (SM)|The teams in the SM group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the SM training and the SM will be set in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
16251289|NCT05016375||T2DM|Individuals with T2DM.
16251290|NCT05016362||Group A|blepharoplasty with repositioning of the nasal fat pad to the central arcus marginalis of the superior orbital rim during surgery.
16251291|NCT05016362||Group B|blepharoplasty with repositioning of the nasal fat pad to orbitoglabellar groove during surgery.
16251292|NCT05016349|Experimental|All trans-retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral All trans-retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251293|NCT05016349|Experimental|Mifepristone, Cannabidiol (Epidiolex) , All trans-retinoic acid and tamoxifen|Patients will receive oral Mifepristone daily for 4 weeks ,after which daily oral All trans-retinoic acid, tamoxifen and Cannabidiol (Epidiolex) is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251294|NCT05016349|Experimental|Mifepristone , All trans-retinoic acid, Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, All trans-retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251295|NCT05016349|Experimental|9 cis retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 9 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251296|NCT05016349|Experimental|Mifepristone, 13 cis retinoic acid , Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251297|NCT05016349|Experimental|9 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral 9 cis retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251298|NCT05016349|Experimental|13 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
16251299|NCT05016349|Sham Comparator|Standard therapy|Patients will receive the approved standard therapy
16251300|NCT05016336|Experimental|strategy-based cognitive training + social interaction|The experimental group received twelve 60 minutes sessions of strategy-based cognitive training. (i.e., training in mnemonic memory strategies). We chose to train multiple strategies instead of a single one in effort to reach larger training gains. each session began with engaging conversations between the researcher and participants. After each practice trial, participants were encouraged to share their ideas/stories/associations or visual images (mnemonic uses) in turn. All other participants were allowed to give feedback relating to what can be learned from each mnemonic use or give their own ideas on how they think it can be improved.
16251301|NCT05016336|Active Comparator|social interaction|The social interaction control group received the same number of group meetings but without the strategy training. Meetings content consisted of providing tools for making social connections, providing tools for interpersonal communication and raising the participant's sense of personal well-being through group contact.
16251302|NCT05016323|Experimental|HR19042 Capsules|
16251303|NCT05016323|Placebo Comparator|Placebo|
16251304|NCT05016310|Experimental|High Vit D|High Dose Vitamin D
16251305|NCT05016310|Active Comparator|SOC Vit D|Standard of Care Vitamin D
16251306|NCT05016297|Experimental|baricitinib 4mg per day + HCQ 200mg twice a day|On the basis of the HCQ treatment before, patients in this group will be added on baricitinib 4mg once a day.
16251307|NCT05016297|Active Comparator|HCQ 200mg twice a day|Patients in this group will be given HCQ 200mg twice a day for 12 weeks. Patients who has no response to HCQ treatment alone at week 12 will be switched to baricitinib + HCQ group and added on baricitinib 4mg per day until the end of the study (week 24).
16251310|NCT05016271|Experimental|True air purifier group|Children in this group will receive an intervention of air purifiers with high-efficiency particulate air (HEPA) filters.
16251311|NCT05016271|Sham Comparator|Sham air purifier group|Children in this group will receive an intervention of air purifiers without high-efficiency particulate air (HEPA) filters.
16251312|NCT05016258||KONTACT MB|Adult patients needed one or multiple implant-supported fixed restoration(s)
16251315|NCT05016232|Experimental|Strength Based Case Management (SBCM)|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
16251316|NCT05016232|Experimental|PrEP adherence training and counseling|"Stage 2: Stepped Intervention:
~Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and
~Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
16251317|NCT05016232|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to local PrEP clinic
16251318|NCT05016232|No Intervention|Standard of Care: Stage 2|Stage 2: Standard clinical PrEP care: Doctor visit every three months to assess for side effects, do blood work, and receive a HIV test.
16251319|NCT05016219|Active Comparator|Active Intervention plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
16251320|NCT05016219|Active Comparator|Active Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
16251321|NCT05016219|Active Comparator|Placebo Light plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
16251322|NCT05016219|Placebo Comparator|Placebo Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
16251323|NCT05016206|Experimental|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants received all 3 doses of danicopan in ascending fashion over 3 periods:
~Treatment A (Period 1): Danicopan 400 milligrams (mg) and moxifloxacin-matching placebo.
~Treatment B (Period 2): Danicopan 800 mg and moxifloxacin-matching placebo.
~Treatment C (Period 3): Danicopan 1200 mg and moxifloxacin-matching placebo."
16251324|NCT05016206|Placebo Comparator|Control Arm (EFG and IJK)|"Participants received 1 of 2 treatment sequences (Treatment Sequence EFG or Treatment Sequence IJK) over 3 periods:
~Treatment E (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin-matching placebo.
~Treatment F (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin 400 mg.
~Treatment G (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin-matching placebo.
~Treatment I (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin 400 mg.
~Treatment J (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin-matching placebo.
~Treatment K (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin 400 mg."
16251325|NCT05016193|Experimental|Intervention Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.
~Participants will be asked to wear the Axem Home prototype headband when doing their daily upper-extremity rehabilitation exercises at home.
~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once per week."
16251326|NCT05016193|Active Comparator|Control Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.
~Participants will be asked to keep track of how many minutes of rehabilitation they have completed as per standard care.
~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once at the beginning of the study and again at the end of the study during the clinical assessment sessions."
16251327|NCT05016180|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
16251328|NCT05016180|Experimental|Ropivacaine|Before the induction of anesthesia, Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
16251331|NCT05016154|Experimental|Online group CBT intervention|Online group CBT delivered via Microsoft Teams (a secure web-based video conferencing platform) in 10 weekly workshops of 60-75 minutes.
16251332|NCT05016154|Active Comparator|SilverCloud guided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are also contacted by the SilverCloud support team which offers them guidance and support while using the app.
~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
16251333|NCT05016154|Active Comparator|SilverCloud unguided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.
~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
16251334|NCT05016154|Active Comparator|Mood Flow|The Moodflow app is a mood tracker and journal that helps students figure out what changes their mood. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.
16251335|NCT05016141|No Intervention|no intervention|Participants will be observed for 12 months. Participants will use the Health in Motion app to set goals and keep track of their health and health events, including falls. These participants will NOT receive the education modules or the exercise program.
16251775|NCT05012930|Experimental|Study Provided Diet - Dairy|A group of complementary foods provided to participants by researchers.
16251336|NCT05016141|Experimental|digital fall prevention program|Participants will complete the Health in Motion digital fall prevention program for 12 months. This program consists of education modules (modified from the Matter of Balance Program) and exercises based on a digital translation of the Otago Exercise Program.
16251337|NCT05016128|Experimental|S-ketamine|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
16251338|NCT05016128|Placebo Comparator|Saline|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
16251339|NCT05016115||physiotherapy students|Totally 120 physiotherapy students at a non-governmental university in Istanbul participated in this study.
16251340|NCT05016102|Other|Control condition|30 min to watching exercise-related video
16251341|NCT05016102|Other|Aerobic exercise condition|20 minutes of moderate-intensity exercise on treadmill
16251342|NCT05016102|Other|Resistance exercise condition|One set of 15 repetition 9 muscle exercises dumbbell squat with chair, dumbbell right/left foot lunge, sit-up, push-up, back muscle with superman, dumbbell right/left bicep curl, dumbbell calf raise.
16251343|NCT05016089|Experimental|Simplified Pilates exercise group (SPEG)|The participants in the SPEG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks. Each participant will undertake a total of 24 exercise sessions.
16251344|NCT05016089|Other|Wait-list control group (WLCG)|The participants in the WLCG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks after two scheduled assessment sessions and a waiting period of 12 weeks in between. Each participant will undertake a total of 24 exercise sessions.
16251345|NCT05016076|Active Comparator|Dexamethasone|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
16251346|NCT05016076|Placebo Comparator|Placebo (0.9% sodium chloride)|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
16251347|NCT05016076|Active Comparator|Inspiratory pressure (10 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
16251348|NCT05016076|Active Comparator|Inspiratory pressure (15 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
16251349|NCT05016076|Active Comparator|Inspiratory pressure (20 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
16251350|NCT05016076|Active Comparator|Inspiratory pressure (25 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
16251351|NCT05016076|Active Comparator|Video intubating stylet|A tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved.
16251352|NCT05016076|Active Comparator|Video laryngoscopy|A tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients.
16251353|NCT05016076|Active Comparator|Direct laryngoscopy|Tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
16251354|NCT05016076|Active Comparator|Goal-directed hemodynamic therapy|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2.61 In brief, if cardiac index < 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is < 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
16266396|NCT04910867|Experimental|Intervention Arm|APOL1 testing program
16251355|NCT05016076|No Intervention|Usual care (control)|Subjects allocated to the control group are hemodynamically managed as per anesthesiologist preference. Typically, isolated hypotension (20% decrease in mean arterial pressure below baseline or < 60 mmHg) is treated by single or consecutive boluses of norepinephrine 5 or 10 μg. If hypotension persists, repeat boluses of ephedrine 4 mg will be administered until mean arterial pressure is above 60 mmHg. If hypotension is accompanied by signs of hypovolemia (urine output < 0.5 ml·kg-1·hr-1 and/or an increase in heart rate > 20% above baseline), crystalloid or colloid fluids will be given until urine output and/or heart rate are normalized. If hypotension persists despite volume challenge, norepinephrine will be used.
16251356|NCT05016063|Experimental|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR T cells
16251357|NCT05016050|Experimental|Digital therapeutic|Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.
16251358|NCT05016037|Other|Lexically Based Speech Intelligibility Recast|Speech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study phonological, acoustic and suprasegmental sequelae of improvements in speech.
16251359|NCT05016024|Other|Colilen IBS + Placebo|First Period: Colilen IBS Second Period: Placebo
16251360|NCT05016024|Other|Placebo + Colilen IBS|First Period: Placebo Second Period: Colilen IBS
16251361|NCT05016011|Experimental|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.
16251362|NCT05016011|Active Comparator|Marrow cellution (standard treatment)|Patients will undergo marrow cellution surgical procedure.
16251364|NCT05015985|Active Comparator|MUSIC-CARE Group|"In the Music-Care group, a program of music therapy was administered through a hardware and software provided to the investigative team by the Music-Care Company. The standardized techniques include three sequences in which the relaxing, maintenance and simulating times differ.
~Music-Care utilizes the U technique designed to gradually relax the listener. In the current study, music sequences during patients' sessions were based on the mount U, and instrumental musical works were selected for a varying numbers styles (classical, jazz, world music, etc.) and adapted to the patient's style via patient request."
16251365|NCT05015985|Sham Comparator|CONTROL group|In the control group, a music program from an established playlist with various instrumental music is chosen by the patient and delivered by the same tablet.
16251366|NCT05015972|Experimental|CTA30X UCAR-T treatment|CD19+ R/R B Hematologic Malignancies patients be treated with a single dose of CTA30X UCAR-T cells. Total dose of(5-30)*10E6/kg cells will be administered at Day 0
16251367|NCT05015959||mortality outcomes|mortality classification into preventable, potentially preventable and non-prevenatable
16251368|NCT05015946|Experimental|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
16251369|NCT05015933|Experimental|Refill at home|Patients will have one pump refill at home instead of at the hospital.
16251370|NCT05015920|Experimental|Mobilization,harvest,transduction,conditioning,treatment,engraftment|Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
16251371|NCT05015907|Experimental|Selective supraclavicular nerve block|After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
16251372|NCT05015907|Active Comparator|Control|The nerve block is not performed in the control group.
16251373|NCT05015894|Experimental|NNC0480-0389|All participants will be administered a single s.c. dose of 18 mg NNC0480-0389
16251374|NCT05015881|Active Comparator|Ketone ester + echocardiogram + PET FDG scanning visit.|"Subjects will drink single dose of ketone ester 1.9 kcal/kg + echocardiogram + PET scanning visit. Dietary Supplement: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (R)-3-hydroxybutyrate (commercially available as DeltaG, (TdeltaS, Orlando, FL). 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan."
16251375|NCT05015881|Other|Echocardiogram + PET FDG scanning visit.|Subjects will complete a echocardiogram + PET scanning visit. 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.
16251376|NCT05015868|Experimental|IDENTIFICATION OF THE CAUSE OF THE EPILEPSY AND OF THE EPILEPTOGENIC ZONE (sequential approach)|"Step1: standard of care.
~acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data
~complete neuropsychological assessment
~genetic tests through Next generation sequencing epilepsies panel, or exome
~Step 2: experimental
~- combined Electroencephalogram-Functional brain magnetic resonance imaging registration.
~Step 3: experimental
~In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:
~execution of High Density-Electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;
~7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone(PI, Italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
16251377|NCT05015855|Placebo Comparator|OBGYN-PrEP|OBGYN-PrEP has 4 parts: (1) prioritize PrEP; (2) train providers in PrEP and intervention; (3) identify PrEP-appropriate women through a risk screen; and (4) monitor progress and fidelity to protocol.
16251469|NCT05015257|Experimental|Alternative F75 without CMV +Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Alternative F75 without CMV during the stabilization phase
16251378|NCT05015855|Experimental|NP-PC PrEP|NP-PC PrEP incorporates the standard of care and practices in OBGYN-PrEP but enhances access to additional skilled providers, as the PrEP provider burden is shifted to a Nurse Practitioner (NP) who will use a sexpositive approach to deliver PrEP services via telemedicine
16251379|NCT05015842|Experimental|Kinesio Tapping plus Conventional Physical Therapy - Experimental Group|"Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).
~The KT was applied to the back once a week with a treatment duration of 2 weeks. Each KT was applied for continuous three days and the next KT was applied after a break of two days. Each participant in the experimental group was assessed for any allergy reaction of the skin to KT."
16251380|NCT05015842|Other|Conventional Physical Therapy alone - Control Group|Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).
16251381|NCT05015829||Classical low-flow low-gradient aortic stenosis|LVEF<50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
16251382|NCT05015829||Paradoxical low-flow low-gradient aortic stenosis|LVEF>50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
16251383|NCT05015816|Experimental|Group A: Time series|Individuals at high risk of developing melanoma will be invited to attend for sequential TBP imaging, full body skin examination by a Dermatologist and completion of a case report form (CRF) every three months for two years. At the end of the study participants will also be invited to complete a feasibility questionnaire
16251384|NCT05015816|No Intervention|Group B: Baseline cohort|All patients who undergo standard care and are selected for total body photography (TBP) imaging will be invited to consent to this group. Any individuals who have had previous TBP imaging will also be eligible to enter Group B of this study. A baseline CRF will be completed and a participant feasibility questionnaire. There will be no additional images taken for the purposes of the study and no additional clinic visits in relation to this part of the study. However, individuals who consent to Group B will also agree to share any future TBP images taken in the department over the next two years so that any sequential images can also be included in the analysis
16251385|NCT05015803|Experimental|CBTi Intervention with sleep diary app/dashboard + IoT|Device-based intervention facilitation and clinician interfacing for Cognitive Behavioral Therapy for Insomnia (CBTi). An electronic sleep diary and app/dashboard will permit clinician interfacing, supplemented with environmental cues that are programmed to remind patients of their behavioral prescription. Ambulatory devices collect objective and subjective data, providing direct feedback to the clinician to inform the therapeutic approach.
16251386|NCT05015803|Active Comparator|CBTi (Active Control)|Standard CBTi delivered via video conferencing [Zoom Health], without electronic sleep diary app/dashboard [traditional pencil-and-paper diary instead], environmental cues, or live ambulatory device feedback to the clinician.
16251387|NCT05015803|Placebo Comparator|Passive Control|Sleep hygiene education and training, without CBTi.
16251388|NCT05015790|Experimental|use of virtual reality Bliss Solution|in the experimental arm the patient will receive the usual practice associated with a virtual reality session (20 minutes renewable) in a world chosen with the patient beforehand
16251389|NCT05015790|No Intervention|current practice, without Bliss Solution|patient will receive the usual practice, local anesthesia
16251390|NCT05015777|Experimental|Intervention Group|Participated in the exercise programme
16251391|NCT05015777|No Intervention|Control Group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
16251392|NCT05015764|Experimental|Reprieve Cardiovascular System|
16251393|NCT05015764|Active Comparator|Standard of Care|
16251394|NCT05015751||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
16251395|NCT05015738|Other|Traditional diabetes education|"The subjects and activities were applied to the control group, who received traditional diabetes education, between 8:00 and 10:00 with the classical method, which lasted 2 hours, for 10 weeks. The training was completed by the researcher with the verbal narration method. Diabetes Achievement Assessment Test with question and answer method was administered to the students at the beginning and end of the application. These questions were the same questions asked to the experimental group. Interaction of groups with each other was limited. Students were informed about this and their consent was taken.At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels."
16251396|NCT05015738|Experimental|Diabetes Education supported by digital tools|The subjects included in the course content were given between 10:00-12:00 with the animation supported method, which lasted for 2 hours. The animations were created by the researchers to reflect all guidelines for diabetes. The scenario of the animation video was prepared in line with the training content. Storyboards in videos and animations were created with the collaboration of researchers and experts in their fields (software specialists, computer programmers). The animation video was voiced in Turkish by a professional actor. Animations are 2 minutes each and a total of 18 minutes long. The 'Kahoot' application, a Web 2.0 tool, was used to apply Diabetes Achievement Evaluation Test. At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels.
16251397|NCT05015725||Treated hypothyroidism|Patients with treated hypothyroidism
16251398|NCT05015712|Experimental|moderate intensity continuous training|
16251399|NCT05015712|No Intervention|guideline control|Patients assigned to the guideline control just received 1-time advice on training according to guidelines.
16251400|NCT05015699|Experimental|HT Supreme|Device: HT Supreme ( R&D by Sinomed, Tianjin, China) Drug: 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system interventions
16251401|NCT05015686|Experimental|Experimental Group with the immunization course of 0,28 days, 0,42 days or 0,56 days|960 subjects (including 480 children aged 13-17 years and 480 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days.
16251402|NCT05015686|Active Comparator|Control Group|960 subjects (including 480 children aged 13-17 years and 480 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days.
16251403|NCT05015686|Experimental|Experimental Group with the immunization course of 0, 70 days|320 subjects (including 160 children aged 13-17 years and 160 adults aged 18 years and older) will receive two doses of the experimental vaccine with the immunization course of 0, 70 days.
16251404|NCT05015686|Placebo Comparator|Placebo group|160 subjects (including 80children aged 13-17 years and 80 adults aged 18 years and older) will receive two doses of the placebo with the immunization course of 0, 70 days.
16251405|NCT05015673|Experimental|SEP-363856 25mg|SEP-363856 25 mg given orally
16251406|NCT05015673|Experimental|SEP-363856 50mg|SEP-363856 50mg given orally
16251407|NCT05015673|Placebo Comparator|Placebo|Placebo given orally
16251408|NCT05015660|Experimental|left bundle branch pacing|
16251409|NCT05015660|Active Comparator|Right ventricular pacing|
16251410|NCT05015647|Experimental|LP group|LP group (n=17) was prescribed high calories/low proteins diet (30 Kcal/kg and 0.6-0.7gr/kg respectively) supplemented with commercial protein free products (protein content <2%).
16251411|NCT05015647|Active Comparator|NP group|NP group (n=18) was prescribed high calories/normal proteins diet (30 kcal/kg and 0.8 gr/kg respectively)
16251412|NCT05015634|Active Comparator|Active Arm|Patients will be discharged from the hospital with the telemedicine package. If the patient develops possible cardiac symptoms and seeks medical attention, the data provided by the telemedicine package will be acted upon, as appropriate, by the trial cardiology team. With remote follow up over the phone at 3, 6 and 9 months.
16251413|NCT05015634|Placebo Comparator|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
16251414|NCT05015621|Active Comparator|study group|all subjects will receive study treatment in 21-day cycle, Surufatinib 250mg, QD and Toripalimab, 240mg, IV drip, Q3W, D1, the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first
16251415|NCT05015621|Other|control group|FOLFIRI group subjects will receive study treatment in 14- day cycle, Irinotecan: 180 mg/m^2, iv drip over 30～90 minutes, on Day 1; Calcium folinate: 400 mg/m^2, iv drip for about 2 hours, given upon completion of infusion of Irinotecan on Day 1; 5-FU: 400 mg/m^2, iv bolus, given upon completion of infusion of Calcium folinate on Day 1, followed by 2400 mg/m^2 continuously iv drip for 46～48 hours.
16251416|NCT05015608|Experimental|Savolitinib + Osimertinib|Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks)
16251417|NCT05015608|Active Comparator|Pemetrexed combined with platinum|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
16251418|NCT05015595|Active Comparator|Memantine|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of Memantine up to 20mg/day.
~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Memantine will be reduced at 10mg/day due to safety reasons before the end of treatment (T5)."
16251419|NCT05015595|Placebo Comparator|Placebo|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of placebo 20 mg/day.
~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Placebo will be reduced at 10mg/day, following the study protocol, before the end of treatment (T5)."
16251420|NCT05015582|Experimental|Treatment|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C
~Intraop: Use of upper body and lower forced air warming intra-operative at 32 and 42˚C respectively and IV fluids with hotline fluid warmer set at 42˚C"
16251421|NCT05015582|Active Comparator|Control Group|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C
~Intraop: Use of upper body forced air warming intra-operative at ambient (32˚C) and IV fluids at room temperature"
16251422|NCT05015569|Active Comparator|Patient Gown + COVR garment|Patients will receive the standard of care patient gown and a COVR garment. Patients undergoing unilateral lower extremity surgery will receive a half short. Patients undergoing upper extremity or spine surgery will receive the brief (bilateral) style COVR garment.
16251423|NCT05015569|Active Comparator|Patient Gown|Patient will receive the standard of care patient gown only without undergarments.
16251424|NCT05015556|No Intervention|Casting|Casting of the distal radius for 6 weeks
16251425|NCT05015556|Active Comparator|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
16251426|NCT05015543|Experimental|Patients paticipating in the Personal Training Program|The study patients complete two training sessions per week (60 minutes each) under supervision (16 weeks)
16251427|NCT05015530||Test Medical Device|Healsea Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
16251428|NCT05015517|Active Comparator|ESPB Group|This group will receive ultrasound-guided erector spinae plane block and subarachnoid block.
16251429|NCT05015517|Active Comparator|FIB Group|This group will receive supra-inguinal fascia iliaca block and subarachnoid block .
16251430|NCT05015504|Experimental|Time restricted feeding|The study will consist of three phases. In phase I all study subjects will be in the ad libitum feeding phase for one week followed by Phase II. In Phase II the subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week. For phase III (final week), patients will be returned to an ad libitum feeding. The first and third phases will serve as control phases, and the second phase will be the experimental phase
16251470|NCT05015244|Experimental|Von Willebrand Disease Type 2B patient with neurological symptoms|evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.
16266397|NCT04910841|Experimental|Connect|
16251431|NCT05015491|Experimental|Noom Healthy Weight Program|"The Noom platform uses a cognitive behavioral approach to weight loss that integrates set content with interaction with live coaches to support client efforts at behavior change. The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. It has 52 weeks of curriculum with 1-3 articles to read per day (Reading level: Grade 6-8)."
16251432|NCT05015478|Active Comparator|Active Tailored Rhythmic Lighting|1 hour intervention period where active lighting is experienced by participants.
16251433|NCT05015478|Placebo Comparator|Inactive Placebo Rhythmic Lighting|1 hour intervention period where an inactive, placebo lighting condition is experienced by participants.
16251434|NCT05015465||70 patients with juvenile SLE.|Anterior segment OCT for juvenile SLE patients.
16251435|NCT05015465||70 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
16251436|NCT05015439|Experimental|Cannabidiol|Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.
16251437|NCT05015439|Placebo Comparator|Placebo|Participants will receive six weeks of placebo.
16251438|NCT05015426|Experimental|Dose Level -1|"Dose Level -1 may be used as a de-escalation dose level due to Dose Limiting Toxicities (DLTs) from Dose Level 1
~Participants will receive 1.0 x 106 cells/kg (0.75-1.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion"
16251439|NCT05015426|Experimental|Dose Level 1|Participants will receive 5.0 x 106 cells/kg (3.75-6.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
16251440|NCT05015426|Experimental|Dose Level 2|Participants will receive 2.5 x 107 cells/kg (1.875-3.125 x 107 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
16251441|NCT05015426|Experimental|Dose Level 3|Participants will receive 1.0 x 108 cells/kg (0.75-1.25 x 108 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
16251442|NCT05015426|Experimental|Treatment at Maximum Tolerated Dose|Participants will receive Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells at the dose determined to be the Maximum Tolerated Dose, administered as a single infusion
16251443|NCT05015413|Experimental|shock wave group|Group A will receive shockwave therapy 2 session per week for 6 weeks
16251444|NCT05015413|Experimental|low level laser group|Group B will receive low level laser therapy 2 session per week for 6 weeks
16251445|NCT05015400|Experimental|Fluid Increase|The increased fluid intervention arm will begin on day 2 after the onset of bleeding (day 1) of their phase 1 menses through day 5. For the increased fluid intake intervention, participants will a) consume an additional 64 oz (1.89 L) of plain water only on top of habitual fluid intake and b) aim to at least urinate 5 times per day.
16251446|NCT05015400|No Intervention|Fluid Habitual|The fluid habitual non-intervention arm will a) maintain normal fluid intake volume and beverage choices and a) urination frequency.
16251447|NCT05015387|Active Comparator|SI group|Patients with periodontitis received subgingival instrumentation.
16251448|NCT05015387|Experimental|SI+PACNs group|Patients with periodontitis received subgingival instrumentation and subgingival application of collagen hydrogels with proanthocyanidins.
16251449|NCT05015387|No Intervention|Healthy controls|The no-treatment control group consisted of systemically healthy individuals with healthy periodontal state.
16251450|NCT05015374|Placebo Comparator|placebo|Compared the difference of changes in psychometrics between Astaxanthin users and placebo group.
16251451|NCT05015374|Active Comparator|Astaxanthin|Compared the difference in adverse effects between Astaxanthin users and placebo group.
16251452|NCT05015361|Experimental|Treatment group A/B|Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate
16251453|NCT05015361|Active Comparator|Treatment group C|Treatment group C: Propofol Injection.
16251454|NCT05015348|Experimental|O3A arm|participants of this arm will be provided with omega-3 PUFA
16251455|NCT05015348|Placebo Comparator|placebo arm|participants of this arm will be provided with same amount of palm oil as placebo
16251458|NCT05015322|Active Comparator|subacromial injection|ultrasound (US)-guided subacromial injection
16251459|NCT05015322|Active Comparator|acromioclavicular joint and subacromial injection|ultrasound (US)-guided acromioclavicular joint and subacromial injection
16251460|NCT05015322|Active Comparator|suprascapular nerve block|ultrasound (US)-guided suprascapular nerve block
16251461|NCT05015309|Experimental|SH3765 tablet|Daily oral administration of SH3765 tablet
16251462|NCT05015283|Experimental|Laparoscopic One-anastomosis gastric bypass|In this group, the bariatric procedure is laparoscopic one-anastomosis gastric bypass, all operations follow the same standard operating procedure.
16251463|NCT05015283|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass, all operations follow the same standard operating procedure.
16251464|NCT05015270||Less disease group|"Patients with coronary artery diameter stenosis <70% confirmed by coronary angiography;
~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
16251465|NCT05015270||Severe disease group|"Patients with coronary artery stenosis ≥70% confirmed by coronary angiography;
~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
16251466|NCT05015257|Active Comparator|Standard F100|If the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
16251467|NCT05015257|Experimental|Standard F75+Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Standard F75 during the stabilization phase
16251468|NCT05015257|Experimental|Alternative F75 with CMV +Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Alternative F75 with CMV during the stabilization phase
16251471|NCT05015205|Experimental|MET Group|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The exercises were performed 3 times per week for 4 weeks.
16251472|NCT05015205|Experimental|Control Group|Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. The exercises were performed 3 times per week for 4 weeks.
16251473|NCT05015192|Experimental|NH102 3mg|NH102 3mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16251474|NCT05015192|Experimental|NH102 9mg|NH102 9mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16251475|NCT05015192|Experimental|NH102 20mg|NH102 20mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16251476|NCT05015192|Experimental|NH102 40mg|NH102 40mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16251477|NCT05015192|Experimental|NH102 60mg|NH102 60mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16251478|NCT05015192|Experimental|NH102 80mg|NH102 80mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16251479|NCT05015179|No Intervention|Control|Laparoscopic partial nephrectomy is performed with an intraoperative ultrasound (US) control
16251480|NCT05015179|Experimental|Experimental|Underwent Laparoscopic partial nephrectomy with the aid of the mixed reality model
16251481|NCT05015166|Experimental|Internet delivered self-help program with therapist support|"The intervention consists of 8 therapist-supported self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which they send to their therapist and receive feedback within a few days.
~The treatment is based on principles from affect-focused psychodynamic psychotherapy."
16251482|NCT05015166|Active Comparator|Internet delivered self-help program without therapist support|The intervention consists of 8 self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which the participants are encouraged to try. The treatment is based on principles from affect-focused psychodynamic psychotherapy.
16251483|NCT05015166|No Intervention|Waitlist|Participants will receive no intervention for 8 weeks.
16251484|NCT05015153|Experimental|Intervention group|20 sessions of Pulmonary rehabilitation will be performed over a period of 3 months
16251485|NCT05015153|No Intervention|Control group|No Pulmonary rehabilitation
16251486|NCT05015140|Experimental|experiment group|"The first day before the application of music to each of the 15 patients in the experimental group (D-1) 'Patient Identification First evaluation will be made by filling the form and then the Richard Campbell Sleep Questionnaire . The day before transplant (D-1) Starting from 10 days, calm music including nature sounds determined by the music therapist will be played using mp3 player. The Richard Campbell Sleep questionnaire will be filled again on the 10th day (D + 10) after the transplant."
16251487|NCT05015140|No Intervention|control group|"- The day before the transplant (D-1) for each of the 15 patients in the control group, first 'Patient Identification Form' and then 'Richard The first evaluations will be made by filling the Campbell Sleep Questionnaire, and standard treatment and care interventions will be given to the patients in this group.
~The sleep questionnaire was filled out again on the tenth day (D + 10) after the transplant without any intervention."
16251488|NCT05015127|Experimental|HBM9161 680 mg qw|Subcutaneous injection; HBM9161 680 mg qw
16251489|NCT05015127|Experimental|HBM9161 680 mg qw by q2w|Subcutaneous injection; HBM9161 680 mg qw by q2w
16251490|NCT05015127|Experimental|Placebo|Subcutaneous injection; Placebo
16251491|NCT05015114||Primary Sjogren's Syndrome|Participants with Primary Sjogren's Syndrome
16251492|NCT05015088||Gastrocnemius Stretching Group|The study will enroll 20 healthy subjects between the ages of 18 to 65 years old. Individuals will be recruited from multiple locations. Exclusion criteria include: any boney or tendinous foot/ankle operative procedure, diagnosis of neuromuscular disorder, any previous ankle fracture or degenerative changes that would limit dorsiflexion range of motion. Participants must have no obvious gait asymmetries demonstrated through observation. In addition, participants who are pregnant will be excluded from participation in the study.
16251493|NCT05015075|Experimental|CR group|participants who have exercise-based cardiac rehabilitation program after PM.
16251494|NCT05015075|Placebo Comparator|non-CR group|participants who have only routine regular follow-up after PM instead of CR program
16251495|NCT05015062|Experimental|Mobile-based intervention with standardized incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive standardized compensation for performing the work.
16251496|NCT05015062|Experimental|Mobile-based intervention with performance-based incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive performance-based compensation for performing the work.
16251497|NCT05015062|No Intervention|Control without intervention|Participants will not receive the mobile-based intervention
16251498|NCT05015049||Neonatal population - hypertensive disorder of pregnancy|All babies born to a woman with a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
16251499|NCT05015049||Neonatal population - no hypertensive disorder of pregnancy|All babies born to a woman without a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
16251500|NCT05015036||Minimally invasive surgery of the lumbar spine with ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
16251501|NCT05015036||Minimally invasive surgery of the lumbar spine|Minimally invasive surgery of the lumbar spine
16251633|NCT05013996|Active Comparator|Control|Patients randomized to the control group will be treated according to the usual methods of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
16251502|NCT05015023|Experimental|Intervention|The behavioral intervention will be conducted on the experimental group for consecutive six months. The components of the intervention will be group health education, phone counseling, and home visits.
16251503|NCT05015023|No Intervention|Control|The routine care will be continued in the control group.
16251504|NCT05015010|Experimental|Alectinib|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 96 weeks. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
16251505|NCT05014997||Patient|30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.
16251506|NCT05014997||Control|30 healthy control subject without diagnosis of any chronic disease
16251507|NCT05014984|Active Comparator|Telephone Delivered MOVE!|During the baseline visit, Veterans randomized to the control arm will receive only the standard information about MOVE!, diet, and physical activity delivered by the same lay educators. They will not learn the WOOP technique nor receive telephone follow up as detailed below. While we considered having an attention control with the same amount of contact, we decided that the study would be more pragmatic and findings would be more relevant to real-world practice if the control arm followed standard patient education and referral strategies. Data collection during study visits will be at the same timepoints in both arms.
16251508|NCT05014984|Experimental|Mental Contrasting with Implementation Intentions (WOOP) plus MOVE!|At the baseline visit, a lay educator will teach the WOOP technique in-person using protocols adapted from our prior work.12 After, to support WOOP practice, the lay educator will schedule and provide 3 follow-up telephone check-ins with the Veteran
16251509|NCT05014971|Experimental|Tele-neurohub|This group will receive the tele-neurohub intervention which includes telemedicine appointments with the neurologist, speech therapist, social worker, and nutritionist at baseline, 3 months and 6 months, and PT and OT every 2 weeks for maintenance neuro-rehabilitation.
16251510|NCT05014971|Active Comparator|Usual care group|Receive usual care but will have study visit assessments at baseline and 6 months.
16251511|NCT05014958|Experimental|40 hz frequency exercise group|Individuals in this study group will receive exercise training at 40 hz frequency on whole body vibration device.
16251512|NCT05014958|Experimental|25 hz frequency exercise group|Individuals in this study group will receive exercise training at 25 hz frequency on whole body vibration device.
16251513|NCT05014958|Active Comparator|0 hz frequency exercise group|Individuals in this study group will receive exercise training at 0 hz frequency on whole body vibration device.
16251514|NCT05014945|Experimental|Atelocollagen group|After obtaining informed consent for the study, epidural nerve block was performed. The patient is asked to return to the outpatient clinic of the pain center after 2 weeks. At this time, when the NRS of back pain does not improve by more than 50% compared to before the epidural nerve block and the cross-sectional area of the multifidus muscle using ultrasound is 5 cm2 or less, final enrollment is decided. The evaluation of the cross-sectional area and thickness of the multifidus muscle using ultrasound is performed with the patient prone, and the cross-sectional area of the multifidus muscle is measured at the same position as the level of the lesion on MRI.
16251518|NCT05014906|Active Comparator|minocycline, azelaic acid|minocycline vs minocycline in comination with 15% azelaic acid for treatment of rosacea
16251519|NCT05014906|Experimental|azelaic acid|45 mg oral minocycline vs 45 mg oral minocycline plus 15% azelaic acid in the treatment of facial rosacea
16251520|NCT05014893|No Intervention|Control|Control group, without specific treatments
16251521|NCT05014893|Experimental|Cognitive training|This group receives treatments to improve cognitive function.
16251522|NCT05014880|Placebo Comparator|ICR (Intensive Cardiac Rehabilitation)|"20 patients will be randomly assigned to the standard of care group, which will receive the standard health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR group."
16251523|NCT05014880|Experimental|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|"20 patients will be randomly assigned to the Time-Restricted Eating (TRE) group which will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR x TRE group."
16251524|NCT05014867||Arm 1|Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5
16251525|NCT05014867||Arm 2|Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5
16251526|NCT05014867||Arm 3|Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after performing PGS
16251527|NCT05014867||Arm 4|Poor responders women undergoing conventional frozen embryo transfer on Day 5
16251528|NCT05014854|Other|Intervention|"Finger and tip pressures are assessed in two phases (A/B). Baseline measurements (A) are collected in the 1st and 2nd therapy session after inclusion. First, data is collected via SEMS (from 2nd grade) or via a sheet with standard forms (1st grade), followed by the recording of a standard sentence (from SEMS) or a standard form at the end of the session. The 2nd session is started and ended with the writing of the chosen standard set. Phase-A-measurements are recorded without feedback.
~From the 3rd therapy session on SensoGrip is used with activated feedback (B). At the end of each session, the same standard set used in Phase A is written twice - once with and once without feedback. This order changes each time to minimize possible bias due to habitation to writing with SensoGrip. Data is recorded in both forms. Children can take SensoGrip home from the 4th session on and use it in daily life.
~In the last session, SEMS or the standard forms are re-executed as initially applied."
16251634|NCT05013983|Experimental|Low-dose vaccine (6-11 years)|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
16251529|NCT05014841|Experimental|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 20-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
16251530|NCT05014828|Experimental|Safety Run in Stage and Combination Assessment|lenvatinib + tislelizumab
16251533|NCT05014789|Experimental|Control-IQ 2.0 technology 2.0 on the t:slim X2 insulin pump|"Each subject will use different combinations of new features of the system each week, in random order, over the next 4 weeks, using the t:slim X2 insulin pump with Control-IQ technology 2.0.
~The first 5 subjects in the study will complete a 48 hour session with multiple challenges during use of Control-IQ technology 2.0, before moving on the outpatient portion of the trial."
16251534|NCT05014776|Experimental|Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207|
16251535|NCT05014763|Active Comparator|CTG from deep palate|The connective tissue graft harvested from the deep palate during flap elevation for implant placement
16251536|NCT05014763|Experimental|CTG from tuberosity|The connective tissue graft harvested from the tuberosity
16251537|NCT05014737||Patients with low risk of PONV|
16251538|NCT05014737||Patients with high risk of PONV|
16251539|NCT05014711|Experimental|remifentanil group|After enrollment, remifentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
16251540|NCT05014711|Active Comparator|fentanil group|After enrollment, fentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
16251541|NCT05014698|Experimental|WGS|"at inclusion visit :
~- Blood collection for whole Genome sequencing will be performed
~At final visit :
~the results of the WGS will be delivered to patients"
16251542|NCT05014685|Experimental|RA group|
16251543|NCT05014685|Experimental|RAM group|
16251544|NCT05014685|Experimental|RAB group|
16251545|NCT05014685|Active Comparator|RABM group|
16251549|NCT05014659|Experimental|Creatine monohydrate|Participants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days.
16251550|NCT05014659|Placebo Comparator|Placebo|Participants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days.
16251551|NCT05014646|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16251552|NCT05014633|Experimental|EI skills training|Individuals in the intervention group received the pertinent training. The duration of the training for the intervention group was 16 hours (four four-hour sessions). The whole training process lasted for one month. EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
16251553|NCT05014633|No Intervention|Control|Individuals in the control group did not receive any training
16251554|NCT05014594|Active Comparator|Group A (Dapaglifozin)|Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
16251555|NCT05014594|Placebo Comparator|Group B (Placebo)|Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
16251556|NCT05014581|Experimental|Pre-emptive vasopressor|Pre-emptive continuous infusion of norepinephrine during intubation
16251557|NCT05014581|No Intervention|No vasopressor|No pre-emptive administration of vasopressors
16251558|NCT05014568|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
16251559|NCT05014568|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
16251560|NCT05014555||Group A Non-biologic Group|Participants on treatment regimen of mesalamine monotherapy or thiopurine monotherapy, or corticosteroids.
16251561|NCT05014555||Group B Anti-TNF Group|Participants on treatment regimen of maintenance montherapy of infliximab (at least 8 every 8 weeks), golilumamb (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly), or combination therapy of anti-TNF therapy as described above along with either 15mg of methotrexate or azathiprine at least 1.0mg/kg or 6MP 0.5mg/kg.
16251562|NCT05014555||Group C Ustekinumab Group|Participants on treatment regimen of ustekinumab monotherapy or combination therapy with methotrexate or azathioprine.
16251563|NCT05014555||Group D Vedolizumab Group|Participants on vedolizumab monotherapy or combination therapy with methotrexate or azathioprine.
16251564|NCT05014542|Experimental|Acupuncture Group|Participants in Acupuncture group will get acupuncture treatments to their symptomatic knee/knees according to the study protocol. Acupuncture will be provided to participants in three cycles, each three weeks duration, with frequency three times weekly. Period between the cycles is three weeks long. Participants will get acupuncture as adjunctive therapy to conventional medical treatment (analgesic therapy) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
16251565|NCT05014542|Active Comparator|Control Group|Participants in Control group will get their standard conventional treatment (analgesics) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
16251566|NCT05014529||Control group|Polysomography show AHI less than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
16251567|NCT05014529||OSA without CPAP group|Polysomography show AHI greater than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
16251568|NCT05014529||OSA with CPAP group|Polysomography show AHI greater than 15 events/h and participants receive CPAP more than 6 months.
16251569|NCT05014516||Single arm|Those participants who have experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery
16251570|NCT05014503|Experimental|Adaptive version of the therapeutic game|The adaptive therapeutic game will use a game-entry level that is based on the individual visual perceptual profile of the child. Children with higher visual perceptual capacities will be able to start the game at a higher entry level compared to children with lower visual perceptual capacities. Thereby, the entry level will also be different for the different games. In addition, the adaptive game uses an in-game adaptivity system that has been developed using artificial intelligence (more specifically, reinforcement learning): this means that the game can adjust the difficulty automatically, based on the game-behaviour and success of the child. Children learning fast, will more quickly move to higher difficulty levels compared to children learning slower. Thereby, this in-game adaptivity also enables children to return to lower difficulty levels when a difficulty level is too high.
16251571|NCT05014503|Active Comparator|Non-adaptive version of the therapeutic game|The non-adaptive therapeutic game will use the same, lowest entry level for all children. During game play, a fixed stepwise increase in difficulty will be built in, not adjusted to the gaming behaviour or success of the child. All children will follow the same, gradual approach in difficulty and a fixed number of trials is set for each difficulty level. To prevent extreme frustration however, a safety margin is integrated by preventing the difficulty level to increase further when a child has more than a predefined number of unsuccessful trials. Likewise, the stepwise increase in difficulty level will only continue after a fixed, predefined number of successful trials. A child will also never return to a lower difficulty level, once a difficulty level is reached.
16251572|NCT05014490|Experimental|Exib (Test)|A single oral dose of the test product Exib 120 mg etoricoxib film-coated tablets.
16251573|NCT05014490|Active Comparator|Arcoxia® (Reference)|A single oral dose of the reference product Arcoxia® 120 mg etoricoxib film-coated tablets.
16251574|NCT05014477||Patients experiencing device embolization after left atrial appendage occlusion|Device embolization following either surgical or interventional left atrial appendage occlusion
16251575|NCT05014438|Placebo Comparator|Placebo|
16251576|NCT05014438|Experimental|Treatment BMS-986166 Dose 1|
16251577|NCT05014438|Experimental|Treatment BMS-986166 Dose 2|
16251578|NCT05014438|Experimental|Treatment BMS-986166 Dose 3|
16251579|NCT05014438|Experimental|Treatment Branebrutinib|
16251584|NCT05014386|Active Comparator|Ahmed Glaucoma Valve Implantation|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
16251585|NCT05014386|Active Comparator|Ologen augmentation group|In addition to what is planned for the other Arm;, a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure.
16251586|NCT05014373|Active Comparator|Experimental: Favipiravir + Best supportive Care|Favipiravir (or Avigan) 1800 mg tablet 2x a day on Day 1 then 800 mg 2x a day from Day 2 to maximum of Day 14
16251587|NCT05014373|Placebo Comparator|Comparator: Best Supportive Care|Best supportive care or Standard Treatment includes oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases
16251588|NCT05014360|Experimental|JNJ-64251330|Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
16251589|NCT05014347||Health Care Professionals|Health Care Professionals (HCP) working in PancreatoBiliary Endoscopy and EUS Division of IRCCS San Raffaele (both endoscopists and nurses)
16251590|NCT05014347||"Expert patients"|a set of at least 30 outpatients undergoing EUS, who already underwent this procedure at least once
16251591|NCT05014347||Patients|100 consecutive patients undergoing EUS
16251592|NCT05014334|Experimental|Berberine-containing triple therapy|vonoprazan 20 mg , amoxicillin 1000 mg , and berberine 500 mg by mouth,twice daily for 14 days.
16251593|NCT05014334|Active Comparator|Bismuth-containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16251594|NCT05014334|Active Comparator|vonoprazan-containing quadruple therapy|Bismuth potassium citrate 220 mg, vonoprazan 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16251595|NCT05014308|Experimental|piezocision group|piezocision surgical procedure was done according to Dibart's et al,
16251596|NCT05014308|Experimental|fiberotomy group|the fiberotomy procedure followed Edward's et al
16251597|NCT05014308|No Intervention|control group|no intervention
16251598|NCT05014295|No Intervention|Control Group|Survey questions at baseline and at one week. The control group will have had one week to reflect on the questions, and investigators anticipate some influence of this on responses.
16251599|NCT05014295|Active Comparator|Intervention Group|The intervention group will be prompted about accessing their medical records from the major local health systems online, with links to directions provided by each hospital system. They will then be asked to fill out the same questionnaire.
16251602|NCT05014256|Experimental|STEPS Health System Surveillance and Outreach intervention|
16251603|NCT05014256|No Intervention|Usual Kidney Care|
16251604|NCT05014230|Other|Treatment as Usual|Opioid medication, as prescribed in routine care
16251605|NCT05014230|Experimental|Open Label Placebo + Treatment as Usual|Opioid medication, as prescribed in routine care + Honest placebos
16251606|NCT05014217||Mentalization-based Treatment|Participants who have been oriented to the mentalization-based treatment among the clinical adult population with a cluster B personality disorder.
16251607|NCT05014217||Dialectical Behavior Therapy-inspired Treatment|Participants who have been oriented to the dialectical behavior therapy-inspired treatment among the clinical adult population with a cluster B personality disorder.
16251608|NCT05014191||Radiation therapy in frog leg position|
16251609|NCT05014191||Radiation therapy in straight leg position|
16251610|NCT05014178||Adult CKD stage 1-5 participants|"Age greater than or equal to 18 years
~Estimated GFR < 90 mL/min/1.73m²"
16251611|NCT05014178||Adult transplanted participants|• Age greater than or equal to 18 years
16251612|NCT05014178||Adult dialysis participants|"Age greater than or equal to 18 years
~More than 3 months duration of therapy"
16251613|NCT05014178||Adult ADPKD|• Age greater than or equal to 18 years
16251614|NCT05014178||Adults treated for nephrolithiasis|• Age greater than or equal to 18 years
16251615|NCT05014178||Adult healthy controls including kidney donors|"Age greater than or equal to 18 years
~Lack of kidney disease, heart failure, liver cirrhosis and peripheral"
16251616|NCT05014165||Ancillary-Correlative (Cord Blood collection)|Accrue patients with ALL and AML who indicate having banked cord blood at birth through the COG Project:EveryChild (APEC14B1)
16251617|NCT05014152|Experimental|Single group|"This study is specially designed according to its age range and customized/non-customized range, and meets the requirements of ISO 80601-2-56 test population (table). Comply with the age range and population requirements of ISO 80601-2-56, as well as clinical and subject trials, including news to the population over five years old, and hopefuls must account for at least 30% of the total and less than 50% of the total.
~Each subject uses Q-temp-w1 to measure axillary temperature and obtains 3 temperature values, and at the same time uses a reference body temperature patch (Omron thermometer MC-171W) to measure the other side axillary temperature, and 1 is measured Temperature value data. Perform clinical efficacy analysis based on the measurement results. The main evaluation indicators of the trial include clinical bias, limits of agreement, and clinical repeatability."
16251618|NCT05014139|Experimental|Enfortumab vedotin: Dose escalation cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
16251619|NCT05014139|Experimental|Enfortumab vedotin: Dose expansion cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
16251620|NCT05014126|Experimental|Pain, Stress, & Emotions Class|No active or placebo comparator will be used. This is a single-arm study design.
16251621|NCT05014100|Experimental|The treatment group|Orelabrutinib 150mg once daily in a 28-day cycle. Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days
16251622|NCT05014087|Experimental|Arm A: Digoxin|In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.
16251623|NCT05014087|No Intervention|Arm B: No Digoxin|In the no digoxin arm, no study drug or placebo will be administered.
16251624|NCT05014074|Experimental|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
16251625|NCT05014061|Experimental|Adenosine|Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
16251626|NCT05014061|No Intervention|Controll|Standard of care
16251627|NCT05014048|Active Comparator|vitamin D3|20 mikrog vitamin D3 daily, 3 months
16251628|NCT05014048|Placebo Comparator|Placebo|Placebo
16251629|NCT05014035|Experimental|Exercise Intervention|
16251630|NCT05014009|Experimental|FIFA11+ and multidirectional training (MD)|Participants in the MD group will take part in an 8-week NMT intervention known to reduce the risk of sports injury and expected to improve COD movement strategies.
16251631|NCT05014009|Active Comparator|FIFA11+ and linear sprint training (LS)|Participants in the LS group will take part in an 8-week NMT intervention, which is known to reduce the risk of sports injury but is unlikely to improve COD movement strategies and is expected to improve linear sprint performance.
16251632|NCT05013996|Experimental|Intervention|Patients randomized to the experimental (MIDSA groupe) will be treated according to the usual methods of each of the centers (CMP / CRIAVS / private practitioners, etc.) completed with the Multidimensional Inventory of Development, Sex, and Aggression-MIDSA groupe Multidimensional Inventory of Development, Sex, and Aggression-inventory tool.
16251635|NCT05013983|Experimental|Medium-dose vaccine (6-11 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
16251636|NCT05013983|Experimental|Medium-dose vaccine (12-17 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
16251637|NCT05013983|Experimental|High-dose vaccine (12-17 years)|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
16251638|NCT05013983|Placebo Comparator|Low-dose placebo (6-11 years)|three doses of low-dose placebo at the schedule of day 0, 21，42.
16251639|NCT05013983|Placebo Comparator|Medium-dose placebo (6-11 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
16251640|NCT05013983|Placebo Comparator|Medium-dose placebo (12-17 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
16251641|NCT05013983|Placebo Comparator|High-dose placebo (12-17 years)|three doses of high-dose placebo at the schedule of day 0, 21，42.
16251642|NCT05013970|Other|Knee osteoarthritis|Patients with mild to moderate osteoarthritis who suffer from persistent knee pain treated with catheter-directed geniculate artery embolization
16251643|NCT05013957||Retrospective analysis|Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated
16251644|NCT05013957||Prospective analysis|Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated
16251645|NCT05013918||Hospitalized people in Nursing Home|
16251646|NCT05013905|Experimental|PRA023|Participants to receive PRA023 administered by intravenous (IV) infusion.
16251647|NCT05013892|Experimental|NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine|"Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive:
~NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.
~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
16251648|NCT05013892|Experimental|HA-WBRT (hippocampal avoidance whole brain radiation Therapy) + Memantine|"Participants will be randomly assigned to HA-WBRT (hippocampal avoidance whole brain radiation Therapy) administration group and receive:
~HA-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.
~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
16251651|NCT05013866|Active Comparator|Repair of resin Z350|Repair with Z350 on resin composite proximal
16251652|NCT05013866|Experimental|Repair of Tetric Evo Ceram Bulkfill|Repair with Tetric Evo Ceram on resin composite proximal
16251653|NCT05013853|Active Comparator|Resin Z350 of proximal posterior teeth|Restorative with Z350 composite of proximal caries lesions or restorations replacement
16251654|NCT05013853|Active Comparator|Resin Tetric N Ceram Bulkfill of proximal posterior teeth|Restorative with Tetric N Ceram Bulkfill composite of proximal caries lesions or restorations replacement
16251655|NCT05013853|Experimental|Resin Fill Up! of proximal posterior teeth|Restorative with Fill Up! composite of proximal caries lesions or restorations replacement
16251656|NCT05013840||Physicians using neuromodulation|
16251657|NCT05013827||Company representatives|
16251658|NCT05013814||Children with unilateral cerebral palsy|
16251659|NCT05013814||Typically developed children|
16251660|NCT05013801|Experimental|Cosmetic Facial Serum Q69|Cosmetic facial serum. To be used twice daily on lesional areas of the face for 12 weeks.
16251661|NCT05013801|Other|2% Hydroquinone|2% hydroquinone cream to be used twice daily on lesional areas of the face as directed by the dermatologist for no longer than 8 weeks.
16251662|NCT05013788|Experimental|Treatment|
16251663|NCT05013788|Active Comparator|Control Group|
16251664|NCT05013762|Active Comparator|Speed-biased complex motor skill training|"Participants will perform 400 complex movements per day over 4 days over a one-week period. The task requires participants to navigate their hand through a track projected on the surface of a table with a width of 5cm. Participants receive adaptive score based on their movement time. ."
16251665|NCT05013762|Other|Accuracy-biased complex motor skill training|The accuracy-biased group receives a dose equivalent intervention with a emphasize on accuracy. The width of the track projected on the table is narrower (less than 2cm) and the adaptive score received are based on their accuracy to say within the boundary of the track.
16251666|NCT05013749|Active Comparator|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
16251667|NCT05013749|Active Comparator|Partial myometrial resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesicouterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
16251669|NCT05013723||Intervention|Patients who received casirivimab-imdevimab antibody infusion
16251670|NCT05013723||Control|Matched control group who did not receive MAb, matched on diagnosis date, age, gender and Utah COVID-19 Risk Score
16251671|NCT05013710||Plan A Health|Founded in 2018, Plan A Health, Inc seeks to address health care disparities in rural communities by improving access to reproductive and sexual care. Beginning April 2021, the first Plan A mobile health clinic opened, serving five counties in the Mississippi Delta. The care team in the clinic includes a community health worker, nurse practitioner, volunteer providers, residents, and a collaborating physician.
16251672|NCT05013710||Just the Pill|Just The Pill offers telemedicine appointments by phone or online for sexual and reproductive health needs that is delivered to the patient's home. The organization is also opening a mobile health clinic that will deliver care directly to communities.
16251673|NCT05013697|Experimental|Experimental group 1|"Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib (4-6 cycles).
~Maintenance treatment: TQB2450 injection+Anlotinib."
16251674|NCT05013697|Experimental|Experimental group 2|Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection (4-6 cycles). Maintenance treatment: TQB2450 injection.
16251675|NCT05013684|Active Comparator|Older adults with BPPV|
16251676|NCT05013684|No Intervention|Older adults without BPPV|
16251677|NCT05013671|Active Comparator|residents with BPPV|
16251678|NCT05013671|Other|residents without BPPV|
16251679|NCT05013658|Active Comparator|junior|their anesthesia experiences are between 1 months and 1 year,
16251680|NCT05013658|Active Comparator|senior|Their anesthesia experiences are more than 4 years
16251681|NCT05013645|Experimental|Sterilized probiotic (LfQi601)|Sterilized probiotic topically administered.
16251682|NCT05013645|Placebo Comparator|Gel control product|Inactive placebo.
16251683|NCT05013632||Exposed pregnant women|Pregnant women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 at any time during pregnancy or within 90 days prior to the first day of the LMP
16251684|NCT05013632||Active comparator pregnant women|Pregnant women treated with another therapy for mild to severe COVID-19
16251685|NCT05013632||Unexposed pregnant women|Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild to severe COVID-19
16251686|NCT05013619||adolescent cerebral palsy|Demographical data, the subtypes of CP, Gross Motor Functional Classification System level, circumstances of pain, pain questionnaire will be analyzed.
16251687|NCT05013619||adolescent cerebral palsy's mother|pain questionnaire will be analyzed.
16251688|NCT05013606|Experimental|Active Treatment: Hydrogen water|Hydrogen pills mixed in a water glass that is ingested up to five time a day for 30 days.
16251689|NCT05013606|Placebo Comparator|Placebo: Inactive pill|Inactive pills mixed in a water glass that is ingested up to five time a day for 30 days.
16251690|NCT05013593|Experimental|Symptomatic RCE|Bladder symptomatic group receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
16251691|NCT05013593|Experimental|Healthy RCE|Healthy group without bladder symptoms receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
16251692|NCT05013593|Placebo Comparator|Symptomatic PL|Bladder symptomatic group receiving placebo
16251693|NCT05013593|Placebo Comparator|Healthy PL|Healthy group without bladder symptoms receiving placebo
16251694|NCT05013580|Experimental|Open Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with a type of tissue (the amnion-chorion membrane) taken from a placenta and will be left partially open to heal.
16251695|NCT05013580|Active Comparator|Closed Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with collagen tissue and stitched closed while it heals.
16251696|NCT05013567|Experimental|Ibuprofen gel 5%|
16251697|NCT05013567|Placebo Comparator|Placebo|
16251698|NCT05013554|Experimental|SAR443216-Dose Escalation|Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive an IV infusion administration of SAR443216
16251699|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort A|Participants with metastatic breast cancers with HER2 high expression will receive an IV infusion administration of SAR443216
16251700|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort B|Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive an IV infusion administration of SAR443216
16251701|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort C|Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive an IV infusion administration of SAR443216
16251702|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort D|Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive an IV infusion administration of SAR443216
16251703|NCT05013541||Patients included|"Patients with lower urinary tract disorders assessed with multichannel cystometry and presence of rectal contractions.
~Measure of amplitude and frequency of rectal contractions function of the bladder sensation and volume of bladder filling."
16251704|NCT05013528|Experimental|Bal-A-Vis-X training Group|Bal-A-Vis-X training Group
16251705|NCT05013528|Active Comparator|Aerobic Training Group|Aerobic Training Group
16251706|NCT05013515|Experimental|Salivary Gland Carcinomas|Patients with Salivary Gland Carcinomas were given Surufatinib .
16251707|NCT05013502|Experimental|Empagliflozin 10mg daily, 12 weeks|Single arm trial
16251708|NCT05013489|Experimental|Mindfulness, compassion and intercare based Intervention|An Eight week mindfulness and intercare group online program.
16251709|NCT05013489|No Intervention|Waiting list|Psychological support if needed. No other intervention.
16251710|NCT05013476|Active Comparator|In-Person ultrasound participants|In-Person ultrasound participant's will receive ultrasound training that is guided by online modules (identical to virtual) with trained faculty in the same room with a ration of 4 students to 1 instructor.
16251835|NCT05012553|Experimental|education of self and peer assesment|Stoma care skills of the group who received self and peer assessment training will be evaluated.
16251711|NCT05013476|Active Comparator|Virtual ultrasound participants|Virtual ultrasound participants will receive ultrasound training that is guided by online modules (identical to in-person) with trained faculty present in a private zoom classroom. Faculty will be rotating between breakout rooms and will share the same ratio of participants to staff.
16251712|NCT05013450|Experimental|Dupilumab + anti-PD-1/PD-L1 (SOC)|Patients will continue SOC immunotherapy with PD-1/PD-L1 blockade following progression of disease, and three q3w cycles of dupilumab will be administered
16251713|NCT05013437|Experimental|Evomela (Melphalan)|Participants will receive Evomela 16 mg/m2 on day 1 of the study only. Evomela will be given as IV infusion over 30 minutes after administration of 500 cc normal saline as pre-hydration and pre-medications Prochlorperazine, Acetaminophen, and Diphenhydramine.
16251714|NCT05013424|Experimental|OnabotulinumtoxinA|Participants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.
16251715|NCT05013411||Healthcare workers|Healthcare workers with patient care experience and are willing to share their experience of current practices of obtaining patient observations.
16251716|NCT05013398|Experimental|The Together Webinar Programme (TTP-Webinar)|Participants receive the six weekly session TTP-Webinar intervention.
16251717|NCT05013398|No Intervention|Waitlist condition|Participants do not receive any intervention as part of waitlist condition. Note: Following the collection of measures at the follow-up time point, participants assigned to the waitlist condition were offered four TTP-Webinar groups to sign up to.
16251718|NCT05013385|Experimental|Spesolimab|
16251719|NCT05013385|Placebo Comparator|Placebo|
16251720|NCT05013372|Other|Dose-escalation|Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg
16251721|NCT05013359||Adolescents Living with Obesity (ALwO)|Recruited from online, general population consumer panels
16251722|NCT05013359||Health Care Providers (HCPs)|HCPs treating adolescents who have obesity
16251723|NCT05013359||Caregivers|A parent or legal guardian of an adolescent with obesity
16251724|NCT05013333|Other|AED 3 with Uni-padz|
16251725|NCT05013320|Active Comparator|Dexmedetomidine only|dexmedetomidine is administered during the surgery
16251726|NCT05013320|Experimental|Combined dexmedetomidine and glycopyrrolate|glycopyrrolate and dexmedetomidine are administered during the surgery
16251727|NCT05013307|Experimental|CASE|In this prospective study the investigators aim to quantify participants' responses to physical activity and cognitive testing. Participants will be asked to undergo cognitive testing prior to engaging in physical activity, to identify any provocation of symptoms in adolescents ranging from ages 10 to 22 years. Responses to physical activity will be measured through metabolic testing (heart rate reserve and relative VO2 max) and physiologic markers (e.g., blood pressure, heart rate, oxygen saturation, rate of perceived exertion, dyspnea). Additionally, participants will be monitored for any changes in symptoms that occur during or after physical activity as measured by the modified PCSS symptom inventory.
16251728|NCT05013294|Experimental|Intervention|The intervention group will receive a total of 43 text messages. Text messages were developed using the Behavior Chang Wheel (BCW) through a systematic process linked to specific behavior change techniques. The text messages will provide practical information or guidance to influence selection and eating healthy diet for type 2 diabetes care. The text messages were either loss- or gain-framed to increase influence on behavioral decisions. Additionally, the participants will receive a text message to rate their ability on selection of food and eating of healthy diet based on the messages received in the month. The combination of the one-way and two-way messages in this group are designed to increase engagement of the participants.
16251729|NCT05013294|Placebo Comparator|Control Arm|The control group will continue receiving standard care in the hospitals. The control group shall also receive a reminder text messages one day prior the routine clinic appointment. The clinic appointment dates shall be derived from the hospital where the participant receives routine diabetes care.
16251730|NCT05013268|Experimental|Tislelizumab plus TP regimen as neoadjuvant therapy for local advanced cervical carcinoma|"Experimental:
~Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin The subjects enrolled in this trial will receive tislelizumab 200mg ivgtt d1, paclitaxel (175mg/m2 ivgtt d1) or docetaxel (75mg/m2 ivgtt d1), cisplatin (75mg/m2 ivgtt d1) or carboplatin (AUC=5 ivgtt d1). The regimen will be repeated every 3 weeks for 3 cycles. Chemotherapy regimen will be selected by investigators.
~Subjects will be enrolled serially."
16251731|NCT05013255|Active Comparator|Pioglitazone 15mg Dose|Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
16251732|NCT05013255|Active Comparator|Pioglitazone 30mg Dose|Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
16251733|NCT05013255|No Intervention|No Drug|Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
16251738|NCT05013216|Experimental|KRAS peptide vaccine|
16251739|NCT05013203||Aseptic (uninfected) Revision Spine Surgery|Aseptic revision for indications including but not limited to hardware failure, adjacent segment pathology, radiculopathy, instability, cord compression.
16251740|NCT05013203||Spine Surgery for Degenerative Disease|Primary degenerative pathology surgery where a disc sample is extracted to enable spinal decompression or fusion. The potential primary surgeries include but are not limited to microdiscectomy, laminectomy, and lumbar and cervical fusion
16251741|NCT05013203||Septic (infected) Revision Spine Surgery|Spine surgery for known infection specifically: epidural abscess or septic revision. Epidural abscess must be managed surgically for inclusion. Septic revision cases include any surgery to address infected hardware from a previous spinal surgery.
16251742|NCT05013190||Participants With Multiple Myeloma (MM)|Participants diagnosed with MM (Newly Diagnosed Multiple Myeloma [NDMM]) using IMWG criteria and received a bortezomib-based triple-drug regimens for more than 2 cycles as initial therapy will be treated with ixazomib based regimens strictly following NINLARO® label will be observed prospectively for 24 months.
16251743|NCT05013164|Experimental|Folinic Acid + Behavioral Therapy|Children receiving folinic acid and behavioral therapy. Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks.
16251744|NCT05013164|No Intervention|Behavioral Therapy|Children received only behavioral therapy for 12 weeks.
16251745|NCT05013151|Experimental|Date consumption|Consumption of 6 dates a day until 41 weeks of gestation
16251746|NCT05013151|Experimental|Castor oil consumption|One time consumption of 60 CC of Castor oil
16251747|NCT05013151|No Intervention|Control Group|
16251748|NCT05013138|Active Comparator|Standard of Care Arm|During the study period, standard of care providers will continue to provide standard of care treatment(s); however, families receiving care from the standard of care providers will complete all study surveys. Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination. However, standard of care providers will still be able to provide resources to the families as part of standard of care.
16251749|NCT05013138|Experimental|Intervention Arm|Intervention providers will undergo training for ACEs screening and discussion. Eligible families will be enrolled into the study at the intake of their child's 4-month, 6-month, 9-month, 15-month, or 18-month well child check. Caregivers will complete the intake surveys including demographics, caregiver ACEs, resilience, warmth, PTSD, and depression. The providers will lead a discussion regarding the impact of caregiver ACEs. Patients will be contacted 1-week, 6-months, and 18-months following their enrollment to obtain repeat measures of the survey instruments. At the 18-month time point, the electronic medical record (EMR) will be queried to obtain outcome measures.
16251750|NCT05013125|No Intervention|Conventional Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo usual colonoscopy as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
16251751|NCT05013125|Active Comparator|ENDO-AID assisted Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo ENDO-AID assisted colonoscopy with all polyps treated as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
16251752|NCT05013112|Placebo Comparator|Placebo group|Patients receive no additional therapy.
16251753|NCT05013112|Experimental|Metformin group|Patients receive metformin 500mg twice daily from discharge.
16251754|NCT05013112|Experimental|Empagliflozin|Patients receive Empagliflozin once daily from discharge.
16251755|NCT05013099|Experimental|Subjects with melanoma, Merkel cell, renal cell, or NSCLC|Eligible subjects will receive up to three 89Zr-Df-crefmirlimab PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion as follows: First scan within 14 days prior to the onset of IOT, and a second scan 4 to 6 weeks after start of immunotherapy. The second 89Zr-Df-crefmirlimab infusion and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third 89Zr-Df-crefmirlimab PET scan at the principal investigator's (PI's) discretion.
16251757|NCT05013073|Experimental|Experimental Arm|All patients will be enrolled in a single arm and download the mobile application ASTHMAxcel ED to their smartphones.
16251758|NCT05013060|Active Comparator|The mixture of probiotics and microcapsulated sodium butyrate|One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides
16251759|NCT05013060|Placebo Comparator|Placebo|Maltodextrin
16251760|NCT05013034|Placebo Comparator|Placebo (Current Standard of Care)|Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
16251761|NCT05013034|Experimental|Basiliximab|Basiliximab in addition to Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
16251762|NCT05013021|Other|Sedentary participants|"Series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT).
~These measurements consist of physiological measurements (VO2max), neuromuscular capacities (force-speed profile), autonomic nervous system responses (heart rate variability) and blood markers (lactate, CK, cytokinases, µRNA)."
16251763|NCT05013008|Experimental|Finerenone (BAY94-8862)|Finerenone tablet
16251764|NCT05013008|Placebo Comparator|Placebo|Matching placebo
16251765|NCT05012982|Experimental|AirBand followed by uninflated AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
16251766|NCT05012982|Experimental|Uninflated Airbnd followed by AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
16251767|NCT05012969|Experimental|intervention|HipStop bandage for 12 weeks to prevent dislocation of the hip
16251768|NCT05012969|No Intervention|control|normal procedure after dislocation of hip which is information on movement restrictions
16251769|NCT05012956|Active Comparator|POP group|Pelvic organ prolapse patients enrolled for sacrocolpopexy surgery at UZ Leuven.
16251770|NCT05012956|Active Comparator|Control group|Patients assigned to gynecologic laparoscopic surgery, other than sacrocolpopexy, at UZ Leuven.
16251773|NCT05012930|Experimental|Study Provided Diet - Meat|A group of complementary foods provided to participants by researchers.
16251776|NCT05012930|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
16251777|NCT05012917|Other|Patient/Proxy-SSPedi Administered First|"Parent/child dyads will complete self-report SSPedi/mini-SSPedi and proxy-SSPedi as the first period and then co-SSPedi as a second period."
16251778|NCT05012917|Other|Co-SSPedi Administered First|"Parent/child dyads will complete co-SSPedi as the first period and then self-report SSPedi/mini-SSPedi and proxy-SSPedi as a second period."
16251779|NCT05012904|Experimental|Parent Support Group|From 10 minutes before the procedure until 10 minutes after the procedure, a parent provided support to their child. To provide support, parents held children on their laps, holding the extremity from which the blood was drawn, holding the children's hands, and communicating with their children during the process in the child's room. The parent support intervention was coordinated by the nurse involved in conducting the study.
16251780|NCT05012904|No Intervention|Control Group|Routine venipuncture procedure was performed on the control group. From 10 minutes before the procedure until 10 minutes after the procedure, the parent was present in their child's room but did not participate in the procedure. The standard parent presence procedure was coordinated by the nurse involved in conducting the study.
16251781|NCT05012891||Study Population|Fifty (n=50) consecutive patients with lower-extremity disability or chronic pain (unilateral or bilateral), undergoing a rehabilitation course in a Day-Care Center setting.
16251782|NCT05012878|Experimental|Cardiac rehabilitation - High intensity interval training (HIIT)|Patients attending cardiac rehabilitation randomized to HIIT.
16251783|NCT05012878|Active Comparator|Cardiac rehabilitation - Moderate intensity continuous training (MICT)|Patients attending cardiac rehabilitation randomized to MICT.
16251784|NCT05012878|Placebo Comparator|Cardiac rehabilitation - control|The control group (12 week period) will include participants who have declined cardiac rehabilitation.
16251785|NCT05012878|No Intervention|Healthy control group|Healthy age-matched adults without cardiovascular disease, who will complete baseline assessments only. No intervention period.
16251786|NCT05012865||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
16251787|NCT05012852|Experimental|VagiVitalAC|
16251788|NCT05012852|No Intervention|No treatment|
16251789|NCT05012839||Complicated appendicitis|The development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
16251790|NCT05012839||Non-complicated appendicitis|No development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
16251791|NCT05012826|Experimental|Osteopathic Manipulative Treatment (OMT)+ Physiotherapy (PT) Group|Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
16251792|NCT05012826|Active Comparator|Physiotherapy Group (PT)|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
16251793|NCT05012813|Experimental|Supportive care (SFIT, biospecimen, interview)|Patients participate in SFIT, using VR pictures of forest and greenspace, and humidified wood and fragrance oils, over 1 hour. Patients also undergo blood sample collection at baseline and on day 3 or 4 and participate in interviews at baseline and post-treatment.
16251794|NCT05012800|Experimental|COVID-19 Vaccines in older adults|Healthy people between the ages of 60 and 80 inoculated coronavirus vaccine on day 0 and day 21, respectively.
16251795|NCT05012800|Experimental|COVID-19 Vaccines in young adults|Healthy people between the ages of 20 and 59 inoculated coronavirus vaccine on day 0 and day 21, respectively.
16251796|NCT05012787|Experimental|SCB-2019 Group|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
16251797|NCT05012787|Placebo Comparator|Control Group|Havrix and Placebo
16251798|NCT05012774|Experimental|Aim 1, Sentence Training: Sentence Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.
~This arm gives printed whole sentence feedback following an attempt to lipread each sentence.
~Participants receive pre- and post-training tests."
16251799|NCT05012774|Experimental|Aim 1, Sentence Training: Word Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.
~This arm gives printed whole word feedback following an attempt to lipread each sentence. Word feedback is for correct words and words that are perceptually similar but incorrect responses.
~Participants receive pre- and post-training tests."
16251800|NCT05012774|Experimental|Aim 1, Sentence Training: Consonant Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.
~This arm gives printed consonant word feedback following an attempt to lipread each sentence. Word feedback is for correct words, but only the consonants are given as feedback for words that are perceptually similar but incorrect responses.
~Participants receive pre- and post-training tests."
16251801|NCT05012774|No Intervention|Aim 1, Sentence Training: No Training Control|Participants receive only the pre- and post-training tests.
16251802|NCT05012774|Experimental|Aim 2, Nonsense Word Training|Participants train to lipread nonsense words that name nonsense pictures. Participants receive pre- and post-training tests.
16252911|NCT05005156|Active Comparator|Active vaccine Ad5-nCoV|two dose of active vaccine Ad5-nCoV
16251803|NCT05012774|Experimental|Aim 3, Audiovisual Nonsense Word Training|"Participants train to recognize audiovisual spoken nonsense words that name nonsense pictures and are presented in speech-shaped noise. The paradigm is the same as in Aim 2.
~Participants receive pre- and post-training tests."
16251804|NCT05012774|Experimental|Aim 3, Audiovisual Sentence Training|"Participants receive the same training paradigm from Aim 1 with the most effective feedback type from Aim 1. But the sentences are audiovisual and in speech-shaped noise.
~Participants receive pre- and post-training tests."
16251805|NCT05012761|Experimental|SR419 capsules|Ascending single and multiple doses of SR419 orally
16251806|NCT05012761|Placebo Comparator|Placebo|Ascending single and multiple doses of SR419 placebo orally
16251807|NCT05012748|Experimental|Ketogenic diet|The participants are instructed to follow a ketogenic diet consisting of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant.
16251808|NCT05012748|No Intervention|Normal western diet|The participants are instructed to follow a normal western diet without emphasising any particular macronutrient.
16251809|NCT05012735|Experimental|Treatment Group: Prototype Ultrathin Hydrocolloid Bandage and Study Cleanser|Participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the evening prior to bandage application and in the morning after removing the bandage(s) on Days 0 through 7. On Days 7 through 14, no bandages will be worn and participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the morning and evening. Participants will cover their closed and popped pimples in the evening with 1 or 2 bandages on Days 0 through 6.
16251810|NCT05012735|Active Comparator|Control Group: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face twice daily using the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
16251811|NCT05012722||Decompensated Heart Failure with reduced ejection fraction (HFrEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFrEF)
16251812|NCT05012722||Decompensated Heart Failure with Preserved ejection fraction (HFpEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFpEF)
16251813|NCT05012722||Acute Kidney Injury in patients with Chronic Kidney Disease stage 3a,3b or 4|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e. stable Chronic Kidney Disease stage 3a, 3b and 4
16251814|NCT05012709|Experimental|intervention group|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
16251815|NCT05012709|No Intervention|control group|The TAU group received usual routine care.
16251816|NCT05012696|Experimental|Sequence A: Non-invasive ventilation - High flow nasal cannula|Once participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.
16251817|NCT05012696|Experimental|Sequence B: High flow nasal cannula - Non-invasive ventilation|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation
16251818|NCT05012683|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
16251819|NCT05012683|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
16251820|NCT05012670|Experimental|[14C]-Paxalisib Capsule|Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).
16251821|NCT05012657|Experimental|Prosthesis|Patient is temporarily fit with Point Partial partial finger prosthetic system
16251822|NCT05012644||Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
16251823|NCT05012644||Aromatase inhibitor alone|Aromatase inhibitor alone
16251824|NCT05012631|Experimental|Losartan|Participants will receive oral losartan as tablets or oral solution one time daily. The dosing will depend on age and will be based on drug label and dosing used in studies on patients with SCD.
16251825|NCT05012618|Experimental|Dose escalation part (Part A)|Patients will receive LUNA18 capsule(s) at escalated doses
16251826|NCT05012618|Experimental|Biomarker part (Part B)|Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
16251827|NCT05012618|Experimental|Cohort expansion part (Part C)|Patients will receive LUNA18 capsule(s) at the recommended dose
16251828|NCT05012605||SLEEPR cohort|Individuals within first 3 months following stroke who did not have obstructive sleep apnea within the first 15 days following stroke
16251829|NCT05012592|Active Comparator|Intervention Group|Health Awareness Program To Reduce Malnutrition and Helminth Infestation Among Primary School children
16251830|NCT05012592|No Intervention|Comparison group|No Intervention during intervention period
16251831|NCT05012579|Experimental|TAPS delivered by Cala device|Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.
16251832|NCT05012566|Experimental|Hyaluronic Acid filler and Botulinum Toxin group|"Hyaluronic Acid filler:
~Juvederm Volbella: it will be used in the softer soft tissue, beacuse its reology is the softest
~Juvederm Volift: it will be used in malar area, because its reology is intermediate between the three products
~Juvederm Voluma: il will be used unstructured area bacause it has the best rheologic characteristics in the reintegration of loss of tissue.
~The differents products are going to use in different areas, depending on the area of the paralysis.
~Botulinum Toxin:
~Vistabex (50U/vial): it is going to be used in the controlateral area of the paralysed face, in order to relax muscle hyper-tonicity.
~Dosage and administration steps will be selected according to the clinical situation."
16251833|NCT05012566|No Intervention|Control group|The control group will undergo at the same examinations of the treated group but it will not be subjected to any treatment.
16251834|NCT05012553|No Intervention|no education about self and peer assesment|Stoma care skills of the group who did not receive self- and peer-assessment training will be evaluated.
16251836|NCT05012514|No Intervention|Control- Without intervention|The participants have the right side of the abdomen as a control without inversion
16251837|NCT05012514|Active Comparator|LLLT- With intervention|The participants received the LED PBMT treatment with associated red and infrared wavelengths sequentially on the left side of the abdomen
16251838|NCT05012501||PVT group|（1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2) In accordance with the diagnostic criteria of portal vein thrombosis in the 2015 European Society of Hepatology Clinical Practice Guidelines: Hepatic Vascular Diseases. Color ultrasound, CT, MRI, and other imaging studies confirmed the presence of portal vein thrombosis and the specific location of the thrombosis.
16251839|NCT05012501||without PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
16251842|NCT05012475|Experimental|Participants|The study involves a pre-intervention phase (4 weeks long), followed by a cause and effect training phase (1 week long), followed by an intervention phase (12 weeks long), and ending with a post-intervention phase (4-weeks long) for a total of 5-6 months from start to finish.
16251843|NCT05012449|Experimental|Arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with the arthrography-assisted joystick technology.
16251844|NCT05012449|No Intervention|No arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with open or close reduction .
16251845|NCT05012436|Experimental|YHD1119 75mg, 150mg NF|CLcr (mL/min/1.73m2) >= 60 Period 1 : YHD1119 75 mg Period 2 : YHD1119 150 mg NF
16251846|NCT05012436|Experimental|YHD1119 75mg|60 > CLcr (mL/min/1.73m2) >= 30 Period 1 : YHD1119 75 mg Period 2 : NA
16251847|NCT05012423|Placebo Comparator|SAD Cohorts 1 to 7: Participants Receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
16251848|NCT05012423|Experimental|SAD Cohorts 1 to 7: Participants receiving ECC0509|Participants in each SAD cohort will be randomized to receive 1 of 7 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg).
16251849|NCT05012423|Placebo Comparator|MAD Cohorts 1 to 3: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
16251850|NCT05012423|Experimental|MAD Cohorts 1 to 3: Participants receiving ECC0509|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (8 mg, 20 mg, or 40 mg) for 14 days.
16251851|NCT05012410|Experimental|Immediate treatment group with High-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive telephone and email prompts.
16251852|NCT05012410|Experimental|Immediate treatment group with Low-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive email prompts only.
16251853|NCT05012410|Experimental|Waitlist Control after three months with high-Intensity prompts|After three months, caregivers will receive WeCareAdvisor and telephone and email prompts.
16251854|NCT05012410|Experimental|Waitlist Control after three months with Low-Intensity Prompts|After three months, caregivers will receive WeCareAdvisor and email prompts only.
16251855|NCT05012397|Experimental|Milademetan (RAIN-32)|260 mg once dailly orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
16251856|NCT05012384|Experimental|Vergence exercises|Orthoptic vergence exercises
16251857|NCT05012384|Placebo Comparator|Generic treatment|
16251858|NCT05012371|Experimental|Arm A (lenvatinib, everolimus)|Patients receive lenvatinib PO QD and everolimus PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
16251859|NCT05012371|Active Comparator|Arm B (cabozantinib)|Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
16251860|NCT05012358||Observational Cohort|no intervention
16251861|NCT05012345|Experimental|4 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 4 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
16251862|NCT05012345|Experimental|6 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 6 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
16251898|NCT05012020|Experimental|mHealth Remote Monitoring|Use of the Clinic Portal by Healthcare professionals and use of the Mobile App by patients/caregivers
16251899|NCT05012007|No Intervention|Control arm: No Reminder|Usual care
16251900|NCT05012007|Experimental|Automated phone reminder|Standard reminder via phone (audiocare)
16251863|NCT05012332|Other|Erector Spinae Plane Block|All volunteers will be given the choice of procedural pain relief in the form of rapifen 0,5-1 mg. All volunteers included will receive an unilateral ESPB at the T7 level with 30 ml of 2,5 mg/ml ropivacaine and a total of 0,3 mmol gadolinium. The intervention will be performed by the PhD candidate connected to the study. The ESPB will be performed under ultrasound guidance, where the needle target is the transverse process of the Th7 vertebra, under the musculus (m.) erector spinae. All volunteers will be tested for cold and pinprick sensation 30 minutes after block completion, and the results plotted on a dermatome map before they undergo an MRI.
16251864|NCT05012319|Experimental|treatment arm|"Nitric Oxide Nasal Spray Enovid"
16251865|NCT05012319|Placebo Comparator|Placebo|Placebo
16251866|NCT05012293|Experimental|Experimental: Fatigue Manipulation|
16251869|NCT05012254|Experimental|Induction treatment + Maintenance|"Induction: 2 cycles of platinum-based chemotherapy plus (Nivolumab + Ipilimumab):
~- Non-squamous NSCLC patients: Pemetrexed: 500 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6 or Cisplatin: 75 mg/m2 IV, Q3W Nivolumab: 360 mg IV Q3W Ipilimumab: 1mg/kg IV Q6W
~2 cycles will be administered at 21-day intervals (Q3W) for Pemetrexed, Carboplatin/Cisplatin and Nivolumab. Ipilimumab will be administered at 42 days interval (Q6W).
~- Squamous NSCLC patients: Paclitaxel: 200 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6, Q3W Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W
~Maintenance: following two cycles of chemo-immunotherapy the patients will receive:
~Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W
~Immunotherapy will be administered until disease progression, unacceptable toxicity, loss of clinical benefit or up to a maximum of 2 years of treatment."
16251870|NCT05012241||Czech patients with multiple sclerosis|Czech patients with multiple sclerosis will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test. Video of their performance will be obtained.
16251871|NCT05012215|Experimental|Paravertebral|Ultrasound-guided thoracic paravertebral block
16251872|NCT05012215|Active Comparator|Caudal|Caudal block
16251873|NCT05012189|Active Comparator|Oseltamivir|Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza.
16251874|NCT05012189|Experimental|Baloxavir|Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza.
16251875|NCT05012176|Experimental|Arm I (EFT)|Patients participate in EFT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in EFT in their daily lives. Patients are asked to recall future positive experiences to create text cues which vividly describes these experiences.
16251876|NCT05012176|Active Comparator|Arm II (ERT)|Patients participate in ERT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in ERT in their daily lives. Patients are asked to recall past positive experiences to create text cues which vividly describes these experiences.
16251877|NCT05012163|Experimental|Pennsylvania (PA) Lottery Scratch-Off Financial Incentive|"Participants in this arm will receive a message stating that they will receive a PA lottery $1 scratch-off ticket if they get a flu shot at an upcoming appointment. The message will mention that they could win $5,000 (the top prize for the scratch-off game).
~Note: $1 scratch-off products vary over time; at study implementation, an active game with top prize of $5,000 (or the next-highest top prize) will be selected and will define the prize in the raffle absent upfront odds"
16251878|NCT05012163|Experimental|Certain Cash Payout Financial Incentive|Participants in this arm will receive a message stating that they will receive $1 in cash if they get a flu shot at an upcoming appointment.
16251879|NCT05012163|Experimental|Reminder / Active Control (No Financial Incentive)|Participants in this arm will receive a message stating that they can get a flu shot at an upcoming appointment. These participants will not be offered a financial incentive for getting a flu shot.
16251880|NCT05012163|No Intervention|No Treatment Control|No additional contact beyond standard Geisinger flu shot communications
16251881|NCT05012137|Experimental|SASIS-FICB|All subjects will be enrolled in the experimental group and receive an Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
16251882|NCT05012124|Experimental|Arm I (t-CoCM)|Patients use the t-CoCM digital app platform and clinic care managers use the t-CoCM web-based registry platform to support delivery of collaborative care. Patient's complete surveys at baseline, 3, 6 and 9 months. Some patients also participate in an interview about their user experience with the t-CoCM digital platform. Care managers also participate in interviews regarding their experience with CoCM and the newly developed web-based platform.
16251883|NCT05012124|Active Comparator|Arm II (u-CoCM)|Patients receive usual care and clinic care managers deliver usual CoCM. Patients complete surveys at baseline, 3, 6 and 9 months.
16251890|NCT05012072|Experimental|MLI Experimental group|6 group sessions over 6 weeks with pregnant Latinas starting at 14-20 weeks to 20-26 weeks in their prenatal care setting.
16251891|NCT05012072|No Intervention|Control usual prenatal care|Only data collection but no intervention
16251895|NCT05012033||Group A|Patients started acutely on high dose prednisolone (>30mg for any inflammatory condition)
16251896|NCT05012033||Group B|Patients on longer term anti-inflammatory doses of prednisolone to treat any medical condition warranting their use, including post COVID.
16251897|NCT05012033||Group C|Patients receiving multiple high doses of methylprednisolone or dexamethasone in association with oral prednisolone.
16252046|NCT05010954|Active Comparator|Lansoprazole 30mg group (n=200)|
16251902|NCT05011994|Experimental|Maintenance intervention|Participants will receive a 12-week mobile health (mHealth) intervention that consists of action planning, text messages, and coordinator support.
16251903|NCT05011968|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce (soil, water, harvesting time)
16251904|NCT05011968|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Iodine crop lettuce.
16251905|NCT05011955|Experimental|Mindfulness, compassion and intercare based Intervention|Four week, one hour peer week, online group intervention plus home work based on mindfulness, compassion and intercare based programs.
16251906|NCT05011955|Active Comparator|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work based on psychoeducation about stress, anxiety, selfcare and effective communication.
16251907|NCT05011955|Other|General curricular intervention|All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.
16251908|NCT05011942|Placebo Comparator|normal saline control arm|ii. normal saline used after initial skin incision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point.
16251909|NCT05011942|Active Comparator|Irrisept irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects
16251910|NCT05011929|Experimental|online CBT-I with support (individualized feedback and reminders)|The mobile-APP based CBT-I consists of 6 weekly session. The treatment is structured and based on the well-established CBT elements for treating insomnia. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention. reminders and individualized feedback regarding the behavioral strategies will be sent to the participant every week.
16251911|NCT05011929|Active Comparator|online CBT-I without support|same as the experimental arm but without reminders and individualized feedback
16251912|NCT05011916|No Intervention|Control group|Patients in the control group received 0.1% fluorometholone eye drops (0.1% fluorometholone + 0.05% tacrolimus eye drops for patients after corneal transplantation). The patients applied 0.1% fluorometholone eye drops 4 times daily for 10 weeks. Patients were instructed to continue with their usual ophthalmic medication regimens, such as topical antibacterial and antiviral drugs.
16251913|NCT05011916|Experimental|Low-concentration group|Patients in the low-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
16251914|NCT05011916|Experimental|Medium-concentration group|Patients in the medium-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
16251915|NCT05011916|Experimental|High-concentration group|Patients in the High-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
16251916|NCT05011903|Experimental|PFI+CDF with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) and Cross-tailored Dynamic Feedback (CDF) related to alcohol use and related sexual behavior. They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
16251917|NCT05011903|Experimental|PFI+GHI with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior, and generic health information (GHI). They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
16251918|NCT05011903|Experimental|PFI-only with no diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior. They do not complete weekend diary surveys.
16251919|NCT05011903|No Intervention|Control|Participants in this condition get no intervention and do not complete weekend diary surveys.
16251920|NCT05011890|Other|Single-arm|Participants will be assigned to the single-arm involving weekly monitoring of their patient-reported outcomes using Moovcare®.
16251921|NCT05011877||Acute Hypercapnic Respiratory Failure patients with Sleep Disorders|Acute Hypercapnic Respiratory Failure patients with Sleep Disorders
16251922|NCT05011877||Acute Hypercapnic Respiratory Failure patients without Sleep Disorders|Acute Hypercapnic Respiratory Failure patients without Sleep Disorders
16251923|NCT05011864|Experimental|Tele-Behavioral Activation and Fall Prevention|Each subject will participate in five 1-hour, weekly Tele-BA sessions followed by four 1-1.5 hour, weekly in-home FP sessions with the same provider
16251924|NCT05011864|Experimental|Tele-Behavioral Activation|Each subject in this arm will participate in five 1-hour, weekly Tele-BA sessions followed by four weekly check-in (booster) calls of up to 30 minutes each.
16251925|NCT05011864|Experimental|Fall Prevention|Each subject will participate in four 1-1.5 hour, weekly in-home (or tele, if COVID continues) FP sessions followed by four weekly check-in (booster) calls of up to 30 minutes each.
16251926|NCT05011864|Active Comparator|Attention Control (Telephone Support Call)|AC participants in this study will receive five weekly telephone calls of up to 45 minutes each and four weekly check-in calls of up to 30 minutes each from a research assistant (RA) who will employ genuine regard and attentive listening and provide nonspecific support.
16251927|NCT05011851|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.
16251966|NCT05011630||IAA group|Intraabdominal abscess (IAA) is defined as either a turbid discharge from the intraoperatively placed drain or a postoperative fluid collection managed by CT-guided placement of drains with documental bacteriological culture.
16251928|NCT05011838|Experimental|A multi-component intervention to improve hypertension care and control|The intervention will be implemented in Commune 2. It will integrate activities related to 1) Health services redesign, 2) Clinical staff training and 3) Patient and community engagement. The intervention activities will be implemented by health services staff with technical assistance from the investigation team.
16251929|NCT05011838|No Intervention|Routine Care|The Commune 6 was selected as control area, where routine care will be delivered.
16251930|NCT05011825|Experimental|Pregnant Moms' Empowerment Program|The PMEP is a 5-session program, delivered prenatally. The first three sessions address violence and mental health and the final two sessions address labor/delivery, infant health and early parenting.
16251931|NCT05011825|No Intervention|Control|Control group participants received information about community resources, but did not receive any study-related intervention.
16251932|NCT05011812|Experimental|Part 1, Treatment A|Dose level 1 of PBI-0451
16251933|NCT05011812|Experimental|Part 1, Treatment B|Dose level 2 of PBI-0451
16251934|NCT05011812|Experimental|Part 1, Treatment C|Dose level 3 of PBI-0451
16251935|NCT05011812|Experimental|Part 1, Treatment D|Dose level 4 of PBI-0451
16251936|NCT05011812|Experimental|Part 2, Treatment E|PBI-0451 =/< Dose level 1
16251937|NCT05011812|Experimental|Part 2, Treatment F|PBI-0451 =/< Dose level 2
16251938|NCT05011812|Experimental|Part 2, Treatment G|PBI-0451 =/< Dose level 3
16251939|NCT05011812|Experimental|Part 2, Treatment H|PBI-0451 =/< Dose level 4
16251940|NCT05011812|Experimental|Part 3, Treatment J|PBI-0451 + ritonavir (a CYP450 3A inhibitor)
16251941|NCT05011812|Experimental|Part 3, Treatment K|PBI-0451 + ritonavir
16251942|NCT05011812|Experimental|Part 3, Treatment L|"PBI-0451 dose TBD
~+ midazolam (a sensitive CYP450 3A substrate)"
16251943|NCT05011812|Experimental|Part 1, Treatment M|Dose level 2 of PBI-0451 with food
16251944|NCT05011799|Experimental|Arm I (health education)|Participants attend 1-2 monthly peer educator-led education sessions about PCA genetic testing over 3 hours each for 18 months.
16251945|NCT05011799|Active Comparator|Arm II (cancer educational materials)|Participants receive mailed informational materials about PCA risk, family history, and genetic testing.
16251946|NCT05011786||Open repair group|children with inguinal hernia who were repaired with open high ligation of the hernia sac through an inguinal incision.
16251947|NCT05011786||Laparoscopic repair group|children with inguinal hernia who were repaired laparoscopically by closing the the PPV at the level of internal ring with a purse string suture
16251948|NCT05011773|Experimental|Deep brain stimulation|"All patients have already undergone deep brain stimulation. Results compared on and off stimulation."
16251949|NCT05011760|Experimental|PET|[C-11]NPA PET Scan
16251950|NCT05011747|Active Comparator|single-site VT group|Viscotrabeculotomy is performed through a superonasal triangular scleral flap.
16251951|NCT05011747|Active Comparator|two-site VT group|Viscotrabeculotomy is performed through a superonasal and an inferotemporal triangular scleral flap.
16251952|NCT05011721|Experimental|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
16251953|NCT05011708|Experimental|Test (I-DROP MGD)|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.
~Part II, patients shall receive either only I-DROP MGD"
16251954|NCT05011708|Active Comparator|Control - Thealoz Duo|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.
~Part II, patients shall receive either only I-DROP MGD"
16251955|NCT05011695|Active Comparator|1. Group ESWT treatment|"6000 SWT Easy device will be used for ESWT treatment. The plantar fascia of the patients will be applied once a week for 3 weeks. In each application, 2400 beats, 2.0 bar pressure and 12 frequency doses of ESWT will be applied"
16251956|NCT05011695|Active Comparator|2. Group transverse friction massage|Transverse friction massage will be applied to the plantar fascia of the patients for 3 weeks, 3 days a week, on Mondays, Wednesdays, and Fridays, with a break for 1 day and 15 minutes each. Transverse friction massage, when the patient is in the supine semi-lying position, the big toe will be dorsiflexed and in this position, it will be applied in the direction that will be transverse to the plantar fascia.
16251957|NCT05011695|Active Comparator|3. Group exercise group|Stretching the plantar fascia and gastrocsoleus muscles of the patients, towel picking exercises with the foot intrinsic muscles, heel drop exercises will be given. All stretching and exercises will be applied once a day, 5 days a week, for 3 weeks. Plantar fascia stretching exercises will be performed with a physiotherapist; While the patient is lying in the supine position, 30 seconds of stretching will be performed using the windlass (windlass) mechanism (toes are brought to dorsi flexion). This stretch will be repeated 3 times. Gastrocsoleus stretching exercises will be studied with a physiotherapist. In the supine position, the gastrocsoleus muscles will be stretched for 10 seconds and stretching will be performed with 10 repetitions. Towel collection exercises for the foot intrinsic muscles will be practiced in 3 sets, 15 repetitions per day. Heel drop exercise will be applied in 3 sets of 15 repetitions per day.
16251958|NCT05011682|Experimental|Joslin Diabetes Senter nutrition|all participants will first follow their own usual diet (2 weeks) and then the Joslin Diabetes Senter nutrition plan (2 weeks)
16251959|NCT05011669|Experimental|Latuda® 40mg/d|
16251960|NCT05011669|Experimental|Latuda® 80mg/d|
16251961|NCT05011656|Experimental|1- Seraph-100 plus State of the Art Care|The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.
16251962|NCT05011656|Active Comparator|2 - State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
16251963|NCT05011643||Symptomatic statin users|Statin users with self-reported muscle symptoms
16251964|NCT05011643||Asymptomatic statin users|Statin users without muscle symptoms
16251965|NCT05011643||Non-statin using controls|Participants not using statins
16251968|NCT05011617|Experimental|MAC group|Electroacupuncture was performed for two consecutive days before surgery (2 daily 30-min sessions) by a licensed acupuncturist at 4.0 mA using an alternating frequency of 2 and 100 Hz (every 1.5 seconds) (LH-202, Huawei, Beijing, China). Acupoints included bilateral Yunmen (LU2), Zhongfu (LU1), Lieque (LU7), and Neiguan (PC6). On the day of surgery, electroacupuncture started upon the completion of a loading dose of dexmedetomidine, was suspended when CPB started (to avoid interference with electrocardiogram recording) and continued until the end of surgery.
16251969|NCT05011617|No Intervention|IGA group|Anesthesia was induced with propofol (2.0-3.5 μg/mL) by target control infusion and 0.3-0.5 μg/kg sufentanil. Tracheal intubation was facilitated by rocuronium (1.0 mg/kg). Anesthesia was maintained using isoflurane at 0.7-1.0 minimal alveolar concentration in a gas mixture of oxygen and air and remifentanil (0.05-0.2 μg·kg-1·min-1) by intravenous injection pump. Sufentanil dose was totally 2.5-4.0 μg/kg. Muscle relaxation was achieved using 1/3-1/4 of the induction dose every 40-60 min based on a train of four. Mechanical ventilation with 80% O2 in air was used. Tidal volume (7-8 mL/kg) and respiratory rate (10-12/min) were adjusted according to PETCO2 to achieve normal ventilation (PETCO2 35-45 mmHg).
16251970|NCT05011604|Other|Implant Failure|Early peri-implantitis and failed osseointegration.
16251971|NCT05011591|Experimental|swimming economy|This is a study based on a comparative clinical trial (effect of an imposed V and/or SR on the swimming economy of swimmers or para-swimmers). This longitudinal study is carried out on a representative sample of swimmers and para-swimmers selected for their potential at the Paris 2024 Olympic and Paralympian Games. Following a standardized warm-up, all swimmers will perform intermittent swimming tests of progressive velocity in a 50 m indoor pool in their swimming specialty with or without an imposition of the SR to adopt. During the trials, the swimmers and para-swimmers will be equipped with inertial measurement units, as well as a heart rate monitor and tissue oximeters. The swimming and non-swimming phases will also be filmed continuously. Gas exchanges will be recorded 2 minutes after the warm-up and during the 7 minutes of passive recovery. Micro blood samples will be taken from the earlobe at the end of the warm-up and at 1, 3, 5 and 7 minutes of recovery between each trial.
16251972|NCT05011578|Experimental|clinical and radiographic findings after surgical treatment for radiocapitellar fracture|30 patients will be included in a interventional study for an evaluation of the clinical and radiographic finding after at least 10 years after radiocapitellar surgery
16251973|NCT05011565||Fontan Group|"Fontan Group Inclusion Criteria
~be between the ages of 8-50
~Having undergone Fontan operation in our hospital or another center
~Clinical stability of the patients (preserved ventricular function),
~No change in ongoing drug therapy that adversely affects clinical stability,
~At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital
~Fontan Group Exclusion Criteria:
~Inability to access the patient's medical data
~Neurological and/or genetic musculoskeletal disease
~Having orthopedic and cognitive problems that prevent testing
~The patient's and/or family's unwillingness to participate in the study"
16251974|NCT05011565||Control Group|"Control Group Inclusion Criteria:
~Not have cardiovascular, neurological and/or genetic musculoskeletal disease
~Not having orthopedic and cognitive problems that prevent testing
~The patient's and/or family's willingness to participate in the study"
16251975|NCT05011552|Experimental|The intervention group|
16251976|NCT05011552|Placebo Comparator|The control group|
16251977|NCT05011539||Ovarian cancer|The patients with ovarian cancer
16251978|NCT05011539||Control group|
16251979|NCT05011526|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16251980|NCT05011526|Experimental|AZD1222|ChAdOx1 nCoV-19 vaccine
16251981|NCT05011513|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
16251982|NCT05011513|Placebo Comparator|Placebo|Orally administered Placebo
16251983|NCT05011500|Experimental|Starting with closed mask|Patient 1-8, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using a closed mask. For the next 5 fractions these patients will receive radiotherapy using an open mask. For the 5 fractions after that these patients will receive radiotherapy using no mask. This schedule repeats for the rest of their treatment.
16251984|NCT05011500|Experimental|Starting with open mask|Patient 9-16, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using an open mask. For the next 5 fractions these patients will receive radiotherapy using no mask. For the 5 fractions after that these patients will receive radiotherapy using a closed mask. This schedule repeats for the rest of their treatment.
16251985|NCT05011500|Experimental|Starting with no mask|Patient 17-24, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using no mask. For the next 5 fractions these patients will receive radiotherapy using a closed mask. For the 5 fractions after that these patients will receive radiotherapy using an open mask. This schedule repeats for the rest of their treatment.
16251986|NCT05011487|Experimental|osimertinib plus chemotherapy|Osimertinib (80mg/qd) po. for 60 days with two cycles of Pemetrexed (500 mg/m2) to be administered with cisplatin (75mg/m2) on Day 1 of every 3-week cycle for 2 cycles
16251987|NCT05011461|Experimental|Almond Oil|Almond Oil Pressed Cold
16251988|NCT05011461|Active Comparator|Topical Retinol|Retinol Lotion 0.5%
16251989|NCT05011448|Other|Single arm study with two interventions|Single arm where each participant will undergo two interventions in the following order: Verbal Interaction and Music Therapeutic Interaction. Both interactions will be conducted by the same music therapist.
16251990|NCT05011435||Users|users of the web-application
16251991|NCT05011422|Experimental|ex vivo αβ-TCR/CD19 depleted haplo-hematopoietic stem cell infusion (HSCT)|"Patients will undergo standard of care conditioning regiment prior to HSCT
~On Day 0, patients will undergo infusion of the ex vivo αβ-TCR/CD19 depleted haplo-HSCT from a stimulated peripheral stem cell source per institutional standard of care. Patients whose graft has a residual CD20+ count > 1.0 x 105 will receive a single infusion of rituximab on Day +1 at a dose of 375 mg/m2."
16251992|NCT05011409||Newly diagnosed breast cancer patients|Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.
16267992|NCT04899960|No Intervention|Control (Validation) Group|
16251995|NCT05011383|Experimental|ATM|Patients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone
16251996|NCT05011383|Experimental|CDK12|Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone
16251997|NCT05011383|Experimental|CHEK2|Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone
16252000|NCT05011344|Experimental|Exposed hospital staff|"Hospital health care or non-health care staff willing to participate in the study:
~Healthcare personnel (physician, nurse, caregiver) who have worked for a minimum of 2 weeks since March 1, 2020 in a care unit dedicated to the management of patients confirmed or suspected of COVID-19 infection, in the participating centers: intensive care units, emergency rooms, radiology, COVID-19 units;
~Staff (physician, technician) who have worked for a minimum of 2 weeks since March 1, 2020 in the AP-HM laboratories handling samples from patients confirmed or suspected of having COVID-19 infection."
16252001|NCT05011344|Other|'Non-exposed' hospital workers|Hospital health care worker (physician, nurse, caregiver) willing to participate in the study who has not worked since March 1, 2020 in an intensive care unit or emergency department or other department dedicated to the management of patients confirmed or suspected of having COVID-19 infection.
16252002|NCT05011331|Experimental|MedCline Shoulder Relief System|Patients who will receive the MedCline Shoulder Relief System pillow
16252003|NCT05011331|Active Comparator|Control|Patients who will not receive the MedCline Shoulder Relief System pillow
16252004|NCT05011318|Experimental|Fatigue Manipulation|
16252005|NCT05011305|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
16252006|NCT05011305|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
16252007|NCT05011305|Placebo Comparator|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
16252008|NCT05011292|Active Comparator|Control Group|The control group includes parents that will view an educational video about a topic other than infant SCB consumption.
16252009|NCT05011292|Experimental|Intervention Group|The intervention group will include those parents who participate in the study after the control data has been collected and two SCB reduction-related videos have been introduced (one for showing at the 4-month visit and one for the 12-month visit).
16252011|NCT05011266|Experimental|Buprenorphine-naloxone|Buprenorphine/naloxone 4/1 mg/day sub-lingual tablets
16252012|NCT05011266|Placebo Comparator|Placebo|placebo sub-lingual tablet
16252013|NCT05011253||Intervention|The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.
16252014|NCT05011253||Control|The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)
16252015|NCT05011240|Experimental|Paediatric Autism Communication Therapy (PACT) Intervention plus Community Assistance as Usual|Participants will receive 12 sessions over 5 months of Paediatric Autism Communication Therapy (PACT).
16252016|NCT05011240|Active Comparator|Community support as usual plus psychoeducation (Control)|Participants in the Control group will receive psycho-educational support via monthly sessions led by researchers with experience in child development. In each session, a presentation will be delivered to provide parents with information about child development and environmental factors that contribute to healthy child development, including sensitive parenting styles, frequent positive social interactions between parents and children and cognitive stimulation. The presentations will be followed by group discussions. Children will also continue to receive Community Assistance as Usual via their normal early education centers. These centers offer daily activities designed to promote children's learning, autonomy, movement, integration and socialization. Children attend their educational center five days per week between the hours of 8am and 5pm.
16252017|NCT05011227|Experimental|Camrelizumab and chemotherapy combined with endoscopic surgery|Camrelizumab and chemotherapy combined with endoscopic surgery
16252018|NCT05011214|Active Comparator|group S|patients were anesthetized by face mask with 8 vol% sevoflurane with total 5 L/min-1 fresh gas flow . Anaesthesia was maintained by continuously using 3.5-4% sevoflurane. The end tidal anaesthetic concentration was mantained betweent 1.3 and 1.4 MAC.
16252019|NCT05011214|Experimental|group E|patients received 0.5mg/kg IV esketamine at first,after surgical field disinfection, another 0.25mg/kg IV esketamine was administered. Then 1mg/kg propofol was administered every 5 minutes after intubation.
16252020|NCT05011201|Experimental|Experimental Group|Participants will undergo a single testing session of gait retraining using two variants of the dual joint visual feedback system (DJVF). The DJVF system uses IMU sensors to measure knee and hip joint motions and calculates the users foot position, relative to their pelvis. The relative foot position is represented in real time on a screen in front of the user with feedback designed to elicit increases in anteriorly located foot positions.
16252021|NCT05011188|Experimental|Does Escalation|Up to two dose levels of FOR46 will be evaluated. Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required.
16252022|NCT05011188|Experimental|Dose Expansion|Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1, at the maximum tolerated dose (MTD) as determined in Phase 1b. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required.
16267993|NCT04899960|Experimental|İnterventional Group|
16252023|NCT05011175||Individuals with Parkinson's Disease|Individuals that have been diagnosed with Parkinson's Disease will be enrolled to participant in the survey research.
16252025|NCT05011149|Experimental|Selective early medical treatment (SMART) strategy|"Infants who are randomized to experimental group will follow the SMART treatment protocol, which includes echocardiographic screening every 72 hours to categorize PDA disease severity by combining clinical and echocardiographic features. At any evaluation if patients are found to have a severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness, they will receive pharmacotherapy aimed at PDA closure (The PDA severity has been divided into mild, moderate or severe based on pre-defined clinical and echocardiographic criteria)."
16252026|NCT05011149|No Intervention|Early conservative management strategy|Infants randomized to this arm will not undergo any further echocardiographic assessment or pharmacological treatment of the PDA regardless of the clinical signs. If the infant gets an echocardiographic assessment for a reason different than PDA assessment (such as hypotension or oxygenation failure) and a PDA is incidentally noted that fits the treatment criteria, the infant will not be initiated on pharmacotherapy. After 7 days of age, decision on PDA assessment and treatment will be at the discretion of the treating physician.
16252027|NCT05011123|Experimental|Group 1|1 injection of vYF vaccine at Day 1
16252028|NCT05011123|Active Comparator|Group 2|1 injection of Stamaril vaccine at Day 1
16252029|NCT05011110|Experimental|GraduSOX (left leg) & Sigvaris (right leg)|Half of participants will wear a GraduSOX compression stocking on their left leg whilst wearing a Sigvaris compression stocking on their right leg.
16252030|NCT05011110|Experimental|GraduSOX (right leg) & Sigvaris (left leg)|Half of participants will wear a GraduSOX compression stocking on their right leg whilst wearing a Sigvaris compression stocking on their left leg.
16252031|NCT05011097|Experimental|Y150|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with Y150 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
16252032|NCT05011084|Experimental|Game Ready Cryotherapy with Compression Group|Post-operative treatment will involve using a Game Ready ® unit
16252033|NCT05011084|Active Comparator|Control Cryotherapy Group|Post-operative treatment will involve using the standard of care cryotherapy (i.e., traditional ice packs without compression).
16252034|NCT05011058|Experimental|Nanatinostat with Valganciclovir|"Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.
~Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week."
16252035|NCT05011045||Observational (neurocognitive assessment, questionnaires, MRI)|Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.
16252036|NCT05011032|Other|Control Group|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
16252037|NCT05011032|Experimental|Non-diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
16252038|NCT05011032|Experimental|Diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
16252039|NCT05011019|Experimental|AL2846 Capsules|"During the dose escalation phase, patients enrolled in the group will first receive a single fasting administration（AL2846 capsules 120-150mg，oral）. The observation period is 3 days. If dose-limited toxity (DLT) does not occur, they will continue to receive multiple consecutive fasting administrations (120mg-150mg，once a day，oral ),every 28 days as a treatment cycle.
~During the dose expansion phase, patients will receive multiple consecutive fasting administrations (AL2846 capsules，120mg-150mg, oral ), every 28 days as a treatment cycle."
16252041|NCT05010980||retrospective|For the retrospective part of the study, the existing echocardiographic database will be used to retrieve data. The database query includes the last 2 years.
16252042|NCT05010980||prospective|For the prospective part of the study, patients will be included who have the clinical indication for cmr and scintigraphy due to suspected cardiac amyloidosis and fulfill the inclusion criteria.
16252043|NCT05010967|Experimental|High intensity interval training|High intensity interval training will be administered three days a week for 8 weeks. six series with 3 minutes rest period between series. For first 4 weeks the series would consist of 30 seconds of exercise and 30 seconds rest. exercises will consist of burpees, skipping, lunges, 1-legged squat, leg lever, push ups. for next four weeks the duration of exercise will be 45 seconds followed by 30 seconds recovery.
16252044|NCT05010967|Active Comparator|Yoga Training|Yoga will be administered 3 days a week for 8 weeks. the session would be of 30-50 minutes with 5 minutes breathing followed by 15-35 minutes yoga and 10 minutes supine meditation. cat-cow stretch, child's pose, downward dog, plank, cobra pose will be used.
16252045|NCT05010954|Experimental|LXI-15028 50mg group(n=200)|
16252050|NCT05010915|Experimental|dorsolateral prefrontal cortex|"Age > 50 years.
~Major depressive disorder (MDD).
~Right handiness
~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
16252051|NCT05010915|Experimental|ventrolateral prefrontal cortex|"Age > 50 years.
~Major depressive disorder (MDD).
~Right handiness
~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
16252052|NCT05010915|Placebo Comparator|sham comparator|"Age > 50 years.
~Major depressive disorder (MDD).
~Right handiness
~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
16252053|NCT05010902||Multiple sclerosis|Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis
16252054|NCT05010889||Achalasia patients|Patients schedule to undergo POEM for treatment of symptomatic achalasia. The diagnosis of achalasia was based on high resolution manometry, barium esophagram, and upper endoscopy.
16252055|NCT05010876|Experimental|standard care + C1 inhibitor|The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.
16252056|NCT05010876|Experimental|standard care + Icatibant + C1 inhibitor|"The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.
~The icatibant will be used in a single injection of 30 mg subcutaneously, preferably in the abdominal region. These doses correspond to the doses usually used in the treatment of conditions in which icatibant is indicated."
16252057|NCT05010876|Placebo Comparator|standard care + placebo|
16252058|NCT05010863||Patients with early gastric cancer|
16252059|NCT05010863||Patients with advanced gastric cancer|
16252060|NCT05010863||healthy person|
16252061|NCT05010863||Patients with colorectal cancer|
16252062|NCT05010863||Liver cancer patients|
16252063|NCT05010863||Breast cancer patient|
16252064|NCT05010863||Patients with atrophic gastritis|
16252065|NCT05010837|Experimental|Kinesio taping with abdominal exercises|Kinesio taping will be applied along with abdominal exercises.
16252066|NCT05010837|Active Comparator|Abdominal Exercises|Only abdominal exercises will be administered to the participants.
16252067|NCT05010824|Experimental|Intervention group|The intervention will involve three consultation sessions and four follow-up phone calls with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
16252068|NCT05010824|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
16252069|NCT05010785|Experimental|alveolar ridge splitting with GBR and i-PRF|alveolar ridge splitting in combination with the use of GBR with i-PRF (sticky bone) with immediate implant placement
16252070|NCT05010785|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without i-PRF (sticky bone) with immediate implant placement
16252071|NCT05010772|Experimental|Arm A (decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
16252072|NCT05010772|Experimental|Arm B (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16252073|NCT05010772|Experimental|Arm C (decitabine and cedazuridine, gilteritinib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16252074|NCT05010772|Experimental|Arm D (decitabine and cedazuridine, enasidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16252075|NCT05010772|Experimental|Arm E (decitabine and cedazuridine, ivosidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16252076|NCT05010759|Experimental|Ablation Arm|Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
16252077|NCT05010746|Experimental|MV replacement with Innovalve MR system|MV replacement with Innovalve MR system
16252078|NCT05010733|Experimental|Thick-Layer Technique|Total hip arthroplasty using the Exeter V40 cemented femoral stem [Stryker Orthopaedics, Mahwah, New Jersey].
16252079|NCT05010733|Active Comparator|Thin-Layer Technique (French Paradox)|Total hip arthroplasty using the Müller Straight Stem [Zimmer, Winterthur, Switzerland].
16252080|NCT05010707|Active Comparator|Transdermal estradiol plus spironolactone|"Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose."
16252081|NCT05010707|Active Comparator|Daily sublingual estradiol plus spironolactone|"Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels.
~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
~Spironolactone will be started at 50 mg daily and will increase to standard dose."
16252082|NCT05010707|Active Comparator|Twice daily sublingual estradiol plus spironolactone|"Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels
~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
~Spironolactone will be started at 50 mg daily and will increase to standard dose."
16252083|NCT05010694|Experimental|Monotherapy Dose Escalation.|Treatment with GH35 alone, conducted until disease progression, intolerance or end of study.
16252084|NCT05010681|Experimental|Lenvatinib plus Sintilimab|
16252085|NCT05010668|Experimental|Cryoablation in combination with Sintilimab plus lenvatinib|
16252087|NCT05010616|Experimental|Three-dimensional digital simulation with fixed appliance|The records will be obtained at the first visit, which will be one week before placing brackets. At the second visit, the orthodontic appliances will be applied; then assessments will be taken after 15 minutes of showing the patient the digital simulation of their teeth alignment at the end of orthodontic treatment.
16252088|NCT05010603||Families with a history of Alzheimer's Disease|Families with two or more family members affected with Alzheimer's Disease
16252089|NCT05010603||Un-related, non-demented controls|Un-related, non-demented healthy controls over age 55
16252090|NCT05010603||Individuals with Dementia (Alzheimer's Disease)|Individuals with dementia over the age of 65
16252091|NCT05010590|Active Comparator|Romosozumab and denosumab|
16252092|NCT05010590|Active Comparator|Romosozumab|
16252093|NCT05010577|Experimental|BX004-A|Participants will be randomized to receive standard dose of nebulized bacteriophage
16252094|NCT05010577|Placebo Comparator|Placebo|Participants will be randomized to receive nebulized placebo
16252095|NCT05010564|Experimental|Autologous TriCAR T-Cells and lymphodepletion chemotherapy|Three dose levels will be evaluated. The TriCAR T-cells will be administered after lymphodepletion chemotherapy with Cyclophosphamide and fludarabine.
16252096|NCT05010538||Sarecycline|Eligible patients will be prescribed with commercially available sarecycline at a dosage of 1.5 mg/kg/day and followed for 12 weeks post initiation of treatment.
16252097|NCT05010525|Experimental|ATG-016-20mg|20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
16252098|NCT05010525|Experimental|ATG-016-35mg|35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
16252099|NCT05010525|Experimental|ATG-016-50mg|50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
16252100|NCT05010525|Experimental|ATG-016-65mg|65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
16252103|NCT05010499|Active Comparator|Femoral nerve block|Patients will receive femoral nerve block (20 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
16252104|NCT05010499|Active Comparator|Fascia iliaca block|Patients will receive fascia iliaca block (40 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
16252105|NCT05010473|Experimental|Neurotypical Human Participants|Native speakers of Chinese and native speakers of English
16252106|NCT05010460|Experimental|Roxadustat|Roxadustat
16252107|NCT05010460|Placebo Comparator|placebo|Placebo has the same appearance with the experimental drug (Roxadustat).
16252108|NCT05010447|Experimental|Study Group|Participants receive the Virtual Coach App for one week at the beginning of their therapy and one week towards the end of their therapy.
16252109|NCT05010434|Experimental|Sintilimab and Bevacizumab Combined with Radiotherapy|
16252112|NCT05010408|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort|Full sweetness (sugar) for 6 months
16252113|NCT05010408|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
16252114|NCT05010408|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort|Reduced sweetness (moderate sugar level) for 6 months
16252115|NCT05010408|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
16252116|NCT05010408|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
16252117|NCT05010408|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
16252118|NCT05010395|No Intervention|Control|Individuals in this arm did not receive a letter.
16252119|NCT05010395|Experimental|Arm 1: Basic Letter|Individuals received a letter with information about the benefits of enrolling, the February 15th sign-up deadline, the HealthCare.gov website, and the call center phone number.
16252120|NCT05010395|Experimental|Arm 2: Action|"Individuals in this arm received a letter that emphasized only minimal marginal effort is required; and used adjectives and verbs connoting action (e.g., almost done, quick, act now, and fast)."
16252154|NCT05010213|Experimental|Experimental group|The experimental group will be given training based on the roy adaptation model.
16252121|NCT05010395|Experimental|Arm 3: Action, Implementation|Individuals in this arm received a letter similar to Arm 2, but with the addition of a calendar that draws attention to the February 15th deadline; and provided fill-in blanks in which the recipient can write the planned month, day, and time when they intend to enroll.
16252122|NCT05010395|Experimental|Arm 4: Action, Implementation, Picture|Individuals in this arm received a letter similar to Arms 2 and 3, but with the addition of an image of then HealthCare.gov Chief Executive Officer Kevin Counihan
16252123|NCT05010395|Experimental|Arm 5: Norm|"Individuals in this arm received a letter that included the following social norm sentence: Americans are enrolling but you haven't joined them."
16252124|NCT05010395|Experimental|Arm 6: Norm, Pledge|"Individuals in this arm received a letter that included a statement, to be checked in agreement, that I pledge to Get Covered at Healthcare.gov."
16252125|NCT05010395|Experimental|Arm 7: Loss Aversion|"Individuals in this arm received a letter that warned You risk paying a fee of $325 or 2% of your income-whichever is higher."
16252126|NCT05010395|Experimental|Arm 8: Kitchen Sink|Individuals in this arm received a letter that includes all behavioral dynamics except for the pledge (due to space limitations).
16252127|NCT05010382|Experimental|Test group|Hybrid surface dental implant
16252128|NCT05010382|Experimental|Control group|moderately rough surface implant
16252129|NCT05010369|Experimental|non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
16252130|NCT05010369|Experimental|hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
16252131|NCT05010369|Experimental|squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
16252132|NCT05010369|Experimental|reactive|patients diagnosed with a reactive (non-cancerous) lymph node
16252133|NCT05010369|Experimental|other|none of the above. Other cancer and non-cancer conditions
16252134|NCT05010356|Experimental|Healthy control subjects|Healthy control subjects undergoing a hyperinsulinemic euglycemic clamp
16252135|NCT05010356|Experimental|Breast cancer survivors|Breast cancer survivors undergoing a hyperinsulinemic euglycemic clamp
16252136|NCT05010343|Active Comparator|carbon ion irradation group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
16252137|NCT05010343|Active Comparator|Carbon Ion Irradiation With SIB group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
16252138|NCT05010330||healthy control|healthy people
16252139|NCT05010330||lung cancer|patients diagnosed with lung cancer
16252140|NCT05010317|Experimental|Group receiving the mindfulness and acceptance intervention|This group will under go six sessions of the mindfulness and acceptance based therapy. These sessions will be delivered in six weeks, utilizing 2 hours every week. This will be in addition to the standard of care (clinic based counselling).
16252141|NCT05010317|Active Comparator|Control group|This group will continue receiving the usual clinic based care (counselling) only.
16252143|NCT05010291|Experimental|Standard of Care (SOC) messaging|Participants randomized into this arm will receive standard voice call reminders + the Standard of Care (SOC) text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include the SOC text
16252144|NCT05010291|Experimental|Loss aversion messaging|Participants randomized into this arm will receive standard voice call reminders + loss aversion text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include loss aversion framing.
16252145|NCT05010291|Experimental|Social norms messaging|Participants randomized into this arm will receive standard voice call reminders + social norms text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include social norms framing.
16252146|NCT05010291|Experimental|Altruism messaging|Participants randomized into this arm will receive standard voice call reminders + altruism text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include altruism framing.
16252147|NCT05010278||Latarjet|Patients followed up 6 months after a Latarjet procedure
16252148|NCT05010265||Use of advanced neurotechnologies to detect consciousness and predict recovery|Treating clinicians, family members (caregivers) and patients recovering from a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
16252149|NCT05010252|Experimental|Cycled Light|It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies over 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
16252150|NCT05010252|No Intervention|Dim light|no intervention
16252151|NCT05010239|Active Comparator|Intervention group|Patients in the intervention group will receive a 30-minute MBST session by a palliative care physician trained in mindfulness practice. The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing. Outcomes will be measured at baseline and at minute 30.
16252152|NCT05010239|Placebo Comparator|Control group|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
16252197|NCT05009875|Experimental|SBD111|
16252155|NCT05010200|Experimental|Cohort 1 - Primary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC.
16252156|NCT05010200|Experimental|Cohort 2 - Secondary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC, and CDX-301
16252157|NCT05010200|Experimental|Cohort 3 - Expansion treatment cohort|An expansion cohort if the treatment of all 3 together has not triggered a safety stopping event.
16252158|NCT05010187|Experimental|Behavioral: Motivational Interview (MI)|Participants will complete a brief motivational interview focusing on determinants of women's alcohol use, including a focus on normative perceptions as well as motives for drinking.
16252159|NCT05010187|Active Comparator|Behavioral: Health Coaching (HC)|Participants will complete a brief health coaching interview and session focusing on educational modules.
16252160|NCT05010148|Placebo Comparator|Placebo|Patients will be administered D5 water intravenously at the same infusion rate (ml/hr) as the intervention group for 48 hours after major spinal surgery.
16252161|NCT05010148|Experimental|Intervention-Intravenous Lidocaine Infusion|Will be administered intravenous lidocaine at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery.
16252162|NCT05010135||Healthy Subject|Aged 60 and over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.
16252163|NCT05010135||Vertebral fracture subjects|"Aged 60 or over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.
~Have been diagnosed by doctors to have the vertebral fracture"
16252164|NCT05010122|Experimental|Treatment (decitabine, cedazuridine, venetoclax, gilteritib)|"INDUCTION (CYCLE 1): Patients receive decitabine and cedazuridine PO QD on days 1-5, venetoclax PO QD on days 1-28, and gilteritinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity
~CONSOLIDATION (CYCLES 2-24): Patients receive decitabine and cedazuridine PO QD on days 1-5, gilteritinib PO QD on days 1-28, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE (CYCLES 24+): Patients receive gilteritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16252165|NCT05010109||Ancillary-Correlative (SPECT/CT, stress test, biospecimen)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
16252166|NCT05010096|Experimental|Arm I (elimusertib, copanlisib)|Patients receive Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 4 and 18. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
16252167|NCT05010096|Experimental|Arm II (elimusertib, copanlisib)|Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
16252168|NCT05010083|Experimental|diet and lifestyle program|
16252169|NCT05010070|Experimental|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindful eating.
16252170|NCT05010057|Experimental|New Zealand blackcurrants (NZBC)|1 NZBC capsule (containing 300 mg active cassis containing 105 mg of anthocyanins, i.e. 35-50 % delphinidin-3-rutinoside, 5-20 % delphinidin-3-glucoside, 30-45 % cyanidin-3-rutinoside, 3-10 % cyanidin-3-glucoside), consumed in the morning, for 12 days.
16252171|NCT05010057|Placebo Comparator|Placebo (PLA)|1 placebo capsule (containing 300 mg microcrystalline cellulose M102), consumed in the morning, for 12 days.
16252172|NCT05010044|Experimental|Participants received MBCT once a week for 8 weeks|Participants received MBCT once a week for 8 weeks. At the same time, the drug therapy for psoriasis was used .
16252173|NCT05010044|Active Comparator|Active comparator|Only the drug therapy for psoriasis was used .
16252174|NCT05010031|Experimental|radiation|Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).
16252175|NCT05010018|Experimental|Intervention|We will pilot the BUD app in 19 intervention corner stores over an 8-month period in East Baltimore. During this time, we will collect data from corner store owners, producers, whole salers, and consumers.
16252176|NCT05010018|No Intervention|Control|We will collect data from 19 control corner stores over the same 8-month period. They will not receive any form of intervention or delay intervention.
16252177|NCT05010005|Experimental|Ruxolitinib and Duvelisib|Ruxolitinib 20mg BID plus Duvelisib 25mg, 50mg, or 75mg BID. Patients will be instructed to take duvelisib and ruxolitinib by mouth every 12 hours, the same time each day, +/- 2 hours. Duvelisib and ruxolitinib will be provided via the institutional investigational pharmacy. Dose escalation. The researchers will utilize a dose-escalation standard 3+3 design in which we evaluate 3 doses of duvelisib (25mg BID, 50mg BID, and 75mg BID) in combination with ruxolitinib 20mg BID. A minus-1 dose level of duvelisib (15mg BID) can be used if de-escalation is needed. The cohort expansion phase will have two treatment groups JAK/STAT activation or mutation present or JAK/STAT activation or mutation absent or unknown.
16252198|NCT05009875|Placebo Comparator|Placebo|
16252199|NCT05009862|Placebo Comparator|Control|Participants will receive 81mg daily of aspirin + placebo for 30 days.
16252186|NCT05009953|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.
16252187|NCT05009953|Experimental|Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.
16252188|NCT05009940|Experimental|Gradusox then Sigvaris compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Gradusox compression stockings applied to both legs.
~After a washout period, the second intervention received are Sigvaris compression stockings applied to both legs."
16252189|NCT05009940|Experimental|Sigvaris then Gradusox compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Sigvaris compression stockings applied to both legs.
~After a washout period, the second intervention received are Gradusox compression stockings applied to both legs."
16252190|NCT05009927|Experimental|Imatinib interruption|Immediate interruption of imatinib until progressive disease. In case of 1st relapse, imatinib will be reintroduced at 400mg/d and further increased at 800mg/d in case of 2nd relapse after re-introduction.
16252191|NCT05009927|No Intervention|Imatinib maintenancce|Maintenance of imatinib at the last dose routinely taken by the patient in the 10-year period prior to randomization (either 300 or 400 mg once daily). In case of progressive disease imatinib will be increased up to 800mg/day.
16252192|NCT05009914|Experimental|cardiac denervation group|In this group, patients undergoing CABG will receive the procedure of our new way of cardiac denervation, excision of Marshall ligament and Waterstone fat pad.
16252193|NCT05009914|No Intervention|controlled group|In this group ,patients undergoing CABG will not receive the procedure of cardiac denervation.
16252194|NCT05009901|Experimental|Alpha Lipoic Acid|alpha lipoic acid PO 600 mg daily for 8 weeks
16252195|NCT05009901|Placebo Comparator|Placebo|placebo PO daily for 8 weeks
16252196|NCT05009888||Adult KCL IoPPN Staff|Freely consenting Adult KCL Staff attending King's College London, IoPPN, Denmark Hill site will all have an antibody test on finger prick blood. The antibody test will give a rapid result for the presence of IgG or IgM antibodies to COVID-19
16252200|NCT05009862|Experimental|Intervention|Participants will receive 81mg of aspirin + rivaroxaban 2.5mg twice daily for 30 days.
16252201|NCT05009849|Experimental|Exercise I|Yogic and Routine Exercises (referred to as exercise I) Phase I: 1-7 days (Minimum attendance 4 days), Phase II: 8 - 14 days (Minimum attendance 4 days), Phase III: at 6-9 months or 12-15 months 1 year up gradation of exercises at 6-9 month or 12-15 months 1 year (Depending upon compliance to phase II exercises) Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months Exercise evaluation will be done at 6-9, 12-15, 30-33, 48-51 and 66-69 months
16252202|NCT05009849|Active Comparator|Exercise II|Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months
16252203|NCT05009836|Experimental|Savolitinib|Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)
16252204|NCT05009836|Placebo Comparator|placebo|placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
16252205|NCT05009823||Stabilization phase|"The dietetic treatment is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.
~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
16252206|NCT05009823||Transition phase|The child is assigned to one the therapeutic regimen depending on the treatment received during the stabilization phase and the results of the appetite test.
16252207|NCT05009810|Experimental|astaxanthin 4 mg|The astaxanthin 4 mg will be taken 1 capsule once daily for 2 months.
16252208|NCT05009810|Experimental|astaxanthin 6 mg|The astaxanthin 6 mg will be taken 1 capsule once daily for 2 months.
16252209|NCT05009810|Placebo Comparator|Placebo|The placebo will be taken 1 capsule once daily for 2 months.
16252210|NCT05009797||Patients undergoing atrial fibrillation catheter ablation|Patients undergoing scheduled atrial fibrillation catheter ablation.
16252211|NCT05009784|Active Comparator|Short Traffic Sound|100 seconds of traffic sound
16252212|NCT05009784|Active Comparator|Medium Traffic Sound|200 seconds of traffic sound
16252213|NCT05009784|Active Comparator|Long Traffic Sound|300 seconds of traffic sound
16252214|NCT05009784|Experimental|Short Traffic and Bird Sound|100 seconds of traffic and bird sound
16252215|NCT05009784|Experimental|Medium Traffic and Bird Sound|200 seconds of traffic and bird sound
16252216|NCT05009784|Experimental|Long Traffic and Bird Sound|300 seconds of traffic and bird sound
16252217|NCT05009784|Experimental|Short Traffic and Water Sound|100 seconds of traffic and water sound
16252218|NCT05009784|Experimental|Medium Traffic and Water Sound|200 seconds of traffic and water sound
16252219|NCT05009784|Experimental|Long Traffic and Water Sound|300 seconds of traffic and water sound
16252220|NCT05009771||IV-PCA group|Patients receiving intravenous patient-controlled analgesia (IV-PCA) will be allocated to IV-PCA group.
16252221|NCT05009771||IV-PCA + NALDEBAIN group|Patients treated with the combination of IV-PCA and intramuscular injection of dinalbuphine sebacate will be allocated to IV-PCA + NALDEBAIN group.
16252222|NCT05009771||NALDEBAIN group|Patients injected with dinalbuphine sebacate intramuscularly will be allocated to NALDEBAIN group.
16252223|NCT05009758|Active Comparator|T2-high asthma with nasal polyps|"FeNO > 25 ppB
~Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months
~Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)
~Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
16252224|NCT05009758|Active Comparator|T2-high asthma without nasal polyps|"FeNO > 25 ppB
~Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months
~Absence of NP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)
~Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
16252225|NCT05009758|Active Comparator|CRSwNP in absence of asthma|"Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines26
~Evidence of Type 2 inflammation: blood eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L26 at the screening visit
~Absence of asthma and N-ERD
~Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
16252226|NCT05009745|Experimental|Intervention|"The intervention will be PGT-A strategy involving trophectoderm biopsy and comprehensive chromosome screening (CCS) using Next Generation Sequencing (NGS). All embryos will be frozen after the biopsy procedure and transferred in a subsequent frozen-thawed embryo transfer. Embryo selection for transfer will be based on morphological criteria and the genetic screening result.
~Only euploid embryos or mosaic euploid embryos deemed suitable to be transferred will be replaced into the uterus in a subsequent frozen-thawed embryo transfer cycles."
16252227|NCT05009745|No Intervention|Control arm|Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.
16252228|NCT05009732|Experimental|Proxalutamide (GT0918) plus standard of care|Participants receive 300mg once daily orally plus standard of care for 14days
16252229|NCT05009732|Placebo Comparator|Placebo plus standard of care|Participants will receive placebo tablets matching Proxalutamide (GT0918) orally plus standard of care for 14 days
16252230|NCT05009719|Experimental|Prophylactic|The patients with high risk of relapse of disease and full donor chimerism after allo-HSCT without signs of the disease will be include in this group.
16252231|NCT05009719|Experimental|Preventive|The patients with persisted minimal residual disease or cytogenetic relapse after allo-HSCT will be include in this group.
16252476|NCT05008003|Experimental|Investigational treatment|Combination of dietary supplements Curcumin + Quercetin + Vitamin D
16252232|NCT05009706|Experimental|Self Care group|Patients who are randomized to the intervention Self Care group will get advice and support on physical excercise, nutrition and symptom management to perform at home for 12 weeks. Once a week, patients will come to the hospital for follow-up and to exercise with a physiotherapist.
16252233|NCT05009706|No Intervention|Control group|Patients who are randomized to the Control group will receive ordinary health care (from an outpatient clinic), but will also be encouraged to follow recommendation of 150 minutes/week of moderate physical activity (12 weeks). To compensate for the extra attention received by the intervention group by the advice/support, the patients in the control group will be dialed with a nurse at 3, 6 and 9 weeks to discuss their current activity.
16252234|NCT05009693|Experimental|white light intervention group|Between the second and the eighth days of the application phase, the patients in the intervention group were administered a standard white light at 10,000 Lux intensity by an independent nurse (RA1) in their home environment using a Litebook Elite light source (The Litebook Company Ltd., Medicine Hat, AB). The distance between the light source and the patient's face was set at 50 cm, and the intensity of the light for each patient was checked using a Lux Meter. The intervention was applied between 07:00 and 10:00 in the morning for 30 minutes without interruption, and it was continued for seven successive days. The light application procedure was followed based on the previous studies on oncology patients. The second and third evaluations of the fatigue status of patients were completed on the 9th and 21st days.
16252235|NCT05009693|No Intervention|Control group|
16252236|NCT05009680|Experimental|Part 1 GB1211, Single Dose (Child Pugh B)|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
16252237|NCT05009680|Experimental|Part 1 GB1211 Healthy Matched Participants, Single Dose|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
16252238|NCT05009680|Experimental|Part 2 GB1211 Multiple Dose, Twice a day (Child Pugh B)|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
16252239|NCT05009680|Placebo Comparator|Part 2 Placebo, Twice a day (Child Pugh B)|Placebo is administered twice daily
16252240|NCT05009680|Experimental|Part 1 GB1211, Single Dose (Child Pugh C)|Part 1 GB1211 Healthy Matched Participants, Single Dose
16252241|NCT05009680|Experimental|Part 3 GB1211 Healthy Matched Participants, Single Dose|Part 1 GB1211 Healthy Matched Participants, Single Dose
16252242|NCT05009667||IMR first group|In this group, IMR based on pressure wire and arterial physiological detector will be measured first, and then caIMR base on angiography images and pressure sensor will be measured secondly.
16252243|NCT05009667||caIMR first group|In this group, caIMR based on angiography images and pressure sensor will be measured first, and then IMR based on pressure wire and arterial physiological detector will be measured secondly.
16252244|NCT05009654|Experimental|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
16252245|NCT05009654|Placebo Comparator|leucine|4000 mg L-leucine per day for 24 weeks
16252246|NCT05009641|Experimental|carnitine2|2000 mg L-carnitine per day for 24 weeks
16252247|NCT05009641|Active Comparator|carnitine|1000 mg L-carnitine per day for 24 weeks
16252248|NCT05009641|No Intervention|control|no supplementation
16252249|NCT05009628|Experimental|automated oxygenation with a sitting patient position in the ICU|
16252250|NCT05009628|No Intervention|controlled oxygenation with a lying patient position in the ICU|
16252251|NCT05009628|Experimental|automated oxygenation with the patient lying down in the ICU|
16252252|NCT05009628|Experimental|control oxygenation with the patient in a sitting position in the ICU|
16252253|NCT05009615|Experimental|Green coffee extract|Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks
16252254|NCT05009615|Experimental|Beta-glucan|Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks
16252255|NCT05009615|Experimental|Green coffee + Beta-glucan|Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks
16252256|NCT05009602||Participating Centre|To complete all index tests and reference scan
16252257|NCT05009576|Active Comparator|vac with silver|wounds of patients will be covered with a vac dressing with single layer of Ag+ hydrocolloid dressings. Such pattern of dressing will be followed in every change of dressing in 48 hours.
16252258|NCT05009576|Active Comparator|simple VAC without silver alginate|wounds of patients will be covered with VAC dressings only. Such pattern of dressing will be followed in every change of dressing in 48 hours.
16252259|NCT05009563|Experimental|Inpatients with RT-PCR proven SARS-CoV-2 infection|Inpatients with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection of the Department of Pulmonology of Semmelweis University who will undergo whole-body FDG-PET/CT
16252260|NCT05009563|Active Comparator|patients undergoing FDG-PET/CT for oncological indication|Age- and gender-matched group of patients undergoing FDG-PET/CT for oncological indication in the same time period
16252261|NCT05009550|Active Comparator|Erector spinae plane block group (ESP)|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group. Then standard sedation method is applied to all patients.
16252262|NCT05009550|Other|Control Group|This Group was received no intervention.Standard sedation method is applied to all patients.
16252263|NCT05009524|Experimental|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES (interactive Physical and Cognitive Exercise System) involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
16252264|NCT05009524|Active Comparator|PACE (physical and cognitive exercise)|"PACE (Physical and Cognitive Exercise) involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
16252265|NCT05009511|Experimental|Traumatic Brain Injury (TBI)|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13.
16252266|NCT05009511|Experimental|Traumatic Brain Injury (TBI) with MDD|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13. In addition, individuals will have a diagnosis of major depressive disorder (MDD) as per DSM-5.
16252267|NCT05009511|Experimental|Major Depressive Disorder (MDD)|Individuals meeting criteria for major depressive disorder (MDD) including qualifiers 'in partial remission' or 'in full remission' if they are actively in treatment for the condition and still carry the depression diagnosis.
16252268|NCT05009511|Experimental|Healthy Individuals|Healthy individuals without psychiatric and neurological conditions.
16252269|NCT05009498|Placebo Comparator|Placebo group|Patient will receive a placebo dosing, identical in appearance and at the same intervals as the interventional dose
16252270|NCT05009498|Active Comparator|Vitamin D3 supplementation group|Patient will receive high-dose Vitamin D3 supplementation in capsule form, identical in appearance and at the same intervals as the placebo dose
16252271|NCT05009485|Experimental|Intervention|Participants will be remotely monitored with the Current Health platform, respond to daily respiratory surveys, receive daily medication reminders and an action plan. Daily dashboard rounds and vital sign alarms from the continuously collected vital signs will be used to identify changes in health and escalated accordingly.
16252272|NCT05009472|Experimental|Cleft Lip and Palate Patient|Cleft patient with transverse maxillary constriction and anteroposterior deficiency
16252275|NCT05009446|Experimental|Preoperative radiotherapy and chemotherapy|Preoperative radiotherapy and chemotherapy plus endoscopic surgery
16252276|NCT05009433|Experimental|Pregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). The program will be also based on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise."
16252277|NCT05009433|Active Comparator|Pregnant MICT group|The moderate intensity continuous training (MICT) program will be implemented based on the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the MICT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise.
16252278|NCT05009433|Sham Comparator|Pregnant standard care group|During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to taking part in the study tests.
16252279|NCT05009433|Experimental|Nonpregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019).
~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
16252280|NCT05009433|Active Comparator|Nonpregnant MICT group|"The moderate intensity continuous training program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020).
~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
16252281|NCT05009433|Sham Comparator|Nonpregnant standard care group|During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests.
16252282|NCT05009420|Experimental|Avocado|Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
16252283|NCT05009407||HOSTS|patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
16252284|NCT05009407||DONORS|grafts from donors that would be analyzed
16252313|NCT05009199|Experimental|[18F]MNI-444|After a wash-out of caffeine of at least 24 hours, each participant will receive a single injection of [18F]MNI-444 followed by brain PET imaging of up to 90 minutes to establish baseline A2A receptor binding.
16252314|NCT05009186|Other|Covid-19 group|We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test
16252285|NCT05009394|Active Comparator|Targeted Muscle Reinnervation (TMR)|In this surgical procedure, the residual peripheral nerve is transferred to an available muscle in the stump that has been deinnervated from its native nerve. The surgical procedure includes three core steps: preparation of the residual nerve; motor nerve identification from the targeted muscle; and coaptation. To prepare the residual nerve, the surgeon identifies the injured nerve that has developed a painful neuroma and cuts the nerve back to healthy fascicles. Next, the surgeon dissects the motor nerve to a nearby target and thereby denervates a native muscle. Lastly, the injured nerve where the neuroma was excised is transferred and coapted to the newly severed motor nerve stump innervating the targe muscle. The surgery time is approximately 2-3 hours and it takes place in the hospital. The patient can leave the hospital the same day.
16252286|NCT05009394|Active Comparator|Regenerative Peripheral Nerve Interface (RPNI)|The RPNI procedure involves construction of a residual peripheral nerve split into several nerve fascicles and implanted into free skeletal muscle grafts. The surgeon first identifies the injured nerve and excises the terminal neuroma. Then, this peripheral nerve is transected into several intraneural fascicles. Next, autologous muscle grafts are harvested from a healthy donor site and the transected nerve endings are placed in the middle part of each muscle graft, in parallel to the muscle fibres. The muscle graft is wrapped around the distal transected nerve ending and anchored by epimysial sutures, and an RPNI is created. This is repeated for each group of fascicles obtained from splitting a transected nerve. The surgery time is approximately 2-3 hours and it takes place in the hospital. The patient can leave the hospital the same day.
16252287|NCT05009394|Active Comparator|Standard neuroma treatment, neuroma excision and muscle burying|The standard neuroma treatment includes excision of the terminal neuroma and burying the nerve into an adjacent deep muscle. As in the TMR and RPNI procedure, the surgeon starts with finding the injured nerve and excises the terminal neuroma into healthy fascicles. Next, the surgeon identifies a deep nearby muscle which is away from joint motion and has limited output opportunities for the nerve. The nerve is then channelled inside to the deep muscle without applying any tension on it and secured by sutures. The surgery time is approximately 1-2 hours and it takes place in the hospital. The patient can leave the hospital the same day.
16252288|NCT05009381|Experimental|Treatment group|Treatment group will receive STYLAGE® XXL at enrollment with an optional touch up injection 30 days later
16252289|NCT05009381|Experimental|control group|Control group will not be treated at enrollment visit. Subjects will receive STYLAGE® XXL at visit 6 months after randomization, if they are still eligible for chin augmentation with an optional touch up injection 30 days later.
16252290|NCT05009368|Experimental|Arm A - Sequence AC|Treatment A in Period 1 and Treatment C in Period 2
16252291|NCT05009368|Experimental|Arm B - Sequence BC|Treatment B in Period 1 and Treatment C in Period 2
16252292|NCT05009355|Experimental|experimental|A Group: Consisted of 20 patients who were treated with scaling and root planing in conjunction with 2g antioxidant Vit (C)
16252293|NCT05009355|No Intervention|Control|A Group: consisted of 20 patients who were treated with scaling and root planing.
16252294|NCT05009342|Experimental|Below-knee soft resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts three layers of jersey supplemented by strips of soft resins to be unrolled along the leg after immersion in warm water
~Duration to ankle immobilization with soft resin boot : 21 days."
16252295|NCT05009342|Other|Below-knee rigid resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts one layer of jersey and then one layer of foam composed by strips of cotton wool to be unrolled supplemented by strips of rigid resins to be unrolled along the leg after immersion in warm water.
~Duration to ankle immobilization with soft resin boot : 21 days."
16252296|NCT05009329|Experimental|Phase 1 Dose Exploration|Dose escalation of JAB-21822 to determine maximum tolerated dose
16252297|NCT05009329|Experimental|Phase 1 Dose Expansion|Conditionally required
16252298|NCT05009316|Experimental|Questionnaires|Patients will answer online surveys containing different questionnaires that will evaluate psychosocial variables as well as pain variables.
16252299|NCT05009303||Participants|Thirty healthy individuals and seventy patients suffering from chronic pain or disability in one or both of their lower extremities
16252300|NCT05009290|Experimental|Treatment group：SHR3680 + ADT|
16252301|NCT05009290|Placebo Comparator|Treatment group : Placebo + ADT|
16252302|NCT05009264||OMT Group|This group will receive OMT muscle energy as treatment for myofascial pain syndrome
16252303|NCT05009264||Injection Group|This group will receive lidocaine injections for myofascial pain syndrome
16252304|NCT05009251|No Intervention|No-Contact Control|Subjects in the no-contact control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
16252305|NCT05009251|Experimental|Reminder Control|Subjects in the reminder control arm will receive messages reminding them to get the flu shot without being advised of their risk status.
16252306|NCT05009251|Experimental|High Risk Only|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
16252307|NCT05009251|Experimental|High Risk with Explanation Based on Medical Records|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
16252308|NCT05009251|Experimental|High Risk with Explanation Based on Algorithm|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
16252309|NCT05009238|Experimental|Group (A)|Group (A): will receive lumbar stabilization exercises
16252310|NCT05009238|No Intervention|Group (B)|Group (B): will be control group.
16252311|NCT05009212|Experimental|ESt group|Endoscopic stricturotomy
16252312|NCT05009212|Active Comparator|EBD group|Endoscopic balloon dilatation
16268203|NCT04898322|Experimental|2.5mg SY-005|
16252315|NCT05009173|Active Comparator|Stylet-in|Lumbar puncture performed keeping the stylet inside the needle until the practitioner reaches the appropriate location.
16252316|NCT05009173|Active Comparator|Stylet-out|The practitioner remove the stylet once he/she has passed the skin and moves the needle forward with the stylet.
16252317|NCT05009160||Patients with Multiple Sclerosis (PwMS)|PwMS will download the dreaMS App and will follow the study schedule.
16252318|NCT05009160||Healthy Control Persons (HC)|HC will download the dreaMS App and will follow the same study schedule as PwMS.
16252319|NCT05009147|Experimental|experimental group|receive whole body manual massage
16252320|NCT05009147|No Intervention|control group|After experiment, receive whole body manual massage
16252321|NCT05009134||Control|18-55 years, healthy
16252322|NCT05009134||Allergic rhinitis|patients with AR without AIT
16252323|NCT05009134||Allergen immunotherapy|patients with AR with AIT for more than 1 year
16252324|NCT05009121||Czech adult people after stroke|Czech adult people after stroke will be asked basic questions about present feelings according to their condition using a questionnaire. Then they will be tested by the Box and Block Test in only one session. Video of their performance will be obtained. The Box and Block Test will be done during their regular rehabilitation by occupational therapist.
16252325|NCT05009108||Czech adult patients after a stroke|Czech adults patients after a stroke will be asked to fill in a informed agreement and as well to answer short questionnaire. Then they will be tested by the Purdue Pegboard Test in only one session. Video of their performance will be obtained as well.
16252326|NCT05009095|Experimental|The Listening Program® with bone conduction headphones|"The Listening Program ® Spectrum music requires a person listen to psycho-acoustically modified classical music online using specialized Waves ™ headphones. The headphones transmit sound through bone conduction which provides another mode of perceiving sound (https://advancedbrain.com). The Listening Program ® can be carried out in the home environment with either the base schedule, two fifteen minute sessions at least 30 minutes apart, or a condensed schedule for 30 minutes.
~Bone conduction allows the listening experience to go deeper into the vestibular system which is purported to reduce stress, help regulate the fight or flight response, and allow the listener to achieve a state of calm and relaxed alertness. This theory is based on the function of the vagus nerve, the 10th cranial nerve, which has branches that extend to the eardrum. Stimulation of the vagus nerve stimulates the parasympathetic nervous system (Allen, 2008)."
16252327|NCT05009082|Active Comparator|Arm 1|Chemotherapy followed by maintenance with niraparib
16252328|NCT05009082|Active Comparator|Arm 2|Chemotherapy in combination with bevacizumab followed by maintenance with bevacizumab and niraparib
16252331|NCT05009056|Experimental|postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
16252332|NCT05009056|Active Comparator|Presurgical computer guided functional appliance|Using the software, 3D digitized mandible will be virtually repositioned in ideal centric relation through accurate adjustment of the condyle in its glenoid fossa. Patients' dental casts will be scanned, and digitized into a virtual 3D model and superimposed to the CT cuts into the virtual plan software environment in order to produce preoperative CAD/CAM splint on the adjusted centric occlusion. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
16252333|NCT05009030||Study group|Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
16252334|NCT05009017||Biosimilar group|
16252335|NCT05009017||Originator group|
16252336|NCT05008991||Study group|The study group will consist of (20) obese menopausal women whom are recently recovered from mild-moderate COVID-19 after one month.
16252337|NCT05008991||Control group|The control group will consist of (20) obese menopausal women; whom are not be affected by COVID-19.
16252338|NCT05008978|Experimental|Test 1|
16252339|NCT05008978|Experimental|Test 2|
16252340|NCT05008978|Experimental|Test 3|
16252341|NCT05008978|Experimental|Test 4|
16252342|NCT05008978|Experimental|Test 5|
16252343|NCT05008965|Experimental|FB825|"FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.
~FB825 will be administered as 1-hour IV- infusions every 4 weeks."
16252344|NCT05008965|Placebo Comparator|Placebo|"Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.
~Placebo will be administered as 1-hour IV- infusions every 4 weeks."
16252345|NCT05008952|Active Comparator|Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
16252346|NCT05008952|Experimental|Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent > 25% (male) or > 35% (female).
16252347|NCT05008952|Active Comparator|Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( > 30 kg/m2) and 2 or more of the following risk factors: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
16252348|NCT05008939|Experimental|sevoflurane|Those with 1-hour inhalation of 1% sevoflurane/30% oxygen
16252349|NCT05008939|Placebo Comparator|placebo|Those with 1-hour inhalation of 30% oxygen
16268204|NCT04898322|Experimental|5mg SY-005|
16252350|NCT05008926|Experimental|Naloxegol|"Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
~Management of constipation and gastroparesis according to the recommendations."
16252351|NCT05008926|Placebo Comparator|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
16252353|NCT05008900|Experimental|Surveillance|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will go on surveillance. Routine PSA will be conducted and a repeat PSMA PET/CT imaging will be conducted when the PSA rises to greater than 0.5 to less than 1.0 ng/mL.
16252354|NCT05008900|No Intervention|Salvage radiotherapy|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA of greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will receive salvage radiotherapy to the prostate bed. This radiotherapy may or may not include the pelvic lymph nodes.
16252355|NCT05008887|Experimental|Fractional CO2 laser and topical methotrexate solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.
~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of methotrexate solution (2.5% concentration vial 50mg/2ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.
~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
16252356|NCT05008887|Active Comparator|Fractional CO2 laser and topical 5-fluorouracil solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.
~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of 5-fluorouracil solution 5% concentration vial 250mg/5ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.
~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
16252357|NCT05008874||Males with AMN|Adult males with confirmed diagnosis of ALD and symptoms of AMN.
16252358|NCT05008861|Experimental|FMT with anti-PD-1/PD-L1 treatment|
16252359|NCT05008848|Experimental|Group I (SGR program, text messages)|Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks.
16252360|NCT05008848|Active Comparator|Group II (booklet)|Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking.
16252361|NCT05008835|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
16252362|NCT05008835|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
16252363|NCT05008835|Placebo Comparator|Placebo|Placebo
16252364|NCT05008822|Experimental|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
16252365|NCT05008822|Active Comparator|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
16252368|NCT05008783|Experimental|AK104 + Oxaliplatin + Capecitabine|AK104 in combination with Oxaliplatin and Capecitabine
16252369|NCT05008783|Placebo Comparator|Placebo + Oxaliplatin + Capecitabine|Placebo in combination with Oxaliplatin and Capecitabine
16252370|NCT05008770||Older adults without sarcopenia|Healthy volunteers aged 65+ years who do not fulfill diagnostic criteria for sarcopenia, according to the revised European Working Group on Sarcopenia in Older People (EWGSOP2)
16252371|NCT05008744||Patients presenting with TTTS|Pregnant persons between 16 and 36 weeks of pregnancy with a diagnosis of twin to twin transfusion syndrome
16252372|NCT05008731|Experimental|Group 1|botulinum toxin: 100 units (0.5ml) in 1 injection
16252373|NCT05008731|Placebo Comparator|Group 2|Placebo: 0.5 ml in 1 injection
16252374|NCT05008718|Active Comparator|38% SDF group|38% silver diamine fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
16252375|NCT05008718|Placebo Comparator|5% NaF group|5% sodium fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
16252376|NCT05008705|Experimental|Intervention|Patients allocated to this arm will be submitted to intervention (protein supplementation plus neuromuscular electrostimulation).
16252377|NCT05008705|Placebo Comparator|Placebo|Patients allocated to this arm will be submitted to a placebo intervention (isocaloric supplement plus sham for neuromuscular electrostimulation).
16252378|NCT05008679|No Intervention|Control|patients with heart failure to receive standard HF therapy
16252379|NCT05008679|Experimental|Oseltamivir|patients with heart failure to receive oseltamivir (at a dose of 75 mg twice daily) for 1 month in addition to standard HF therapy
16252405|NCT05008471|Experimental|Intervention group|The recommended target energy for NPC radiotherapy patients is 25-30kcal/(kg·d), in addition，the intervention group begins with an additional 50% daily energy increase during the peri-radiotherapy.
16252380|NCT05008666|Experimental|L-DEP, Sintinimab+Chidamide, Sintinimab+Azacitidine|"【L-DEP】
~L-asparaginase: 2000U/m2 d5, im
~Doxorubicin liposome: 25mg/m2 d1, ivd
~Etoposide: 100mg/m2 d1, d8, d15, ivd
~Methylprednisolone: 15mg/kg/day d1-3, 0.75mg/kg/day, d4-7, 0.25mg/kg/day, d8-14, ivd
~【Sintinimab+Chidamide】
~Sintinimab: 200mg，d1,ivd,q21d Chidamide：30mg biw, continued oral
~【Sintinimab+Azacitidine】
~Sintinimab:200mg，d1, ivd, q21d Azacitidine:75mg/m2, d1-d7, ih, q28d"
16252381|NCT05008640||Study group (all subjects)|All subjects belonged to the same study group, regardless of symptoms, disease diagnosis or state. Furthermore, there was no stratification of the population by sex, age, race or disease severity.
16252382|NCT05008627||Doffing PPE with verbal instructions and monitor|The subject will remove the PPE according to verbal instructions by a monitor
16252383|NCT05008627||Doffing PPE without verbal instructions|The subject will remove the PPE independently without a monitor
16252384|NCT05008614|Experimental|Erector spinae plane block group (ESP group)|"Patients receiving continuous unilateral ESP block.
~Interventions:
~Procedure: Ultrasound-guided unilateral ESP block via catheter placement for continuous infusion Drug: Ropivacaine 0.75% Injectable Solution Device: 21-gauge 85 mm perineural catheter, 18-gauge 100 mm stimulator needle (Silverstim, Vygon, Ecouen, France)"
16252385|NCT05008614|Active Comparator|Thoracic epidural analgesia group (TEA group)|"Patients receiving thoracic epidural analgesia.
~Interventions:
~Procedure: Fluoroscopy-guided thoracic epidural analgesia Drug: Ropivacaine 0.75% Injectable Solution Device: 17-gauge Tuohy needle (FlexTip Plus®, Teleflex Medical, USA)"
16252386|NCT05008588|Experimental|Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment|Intranasal of 160 μl of conditioned medium
16252387|NCT05008588|Experimental|Umbilical cord mesenchymal stem cells treatment|Intra-parenchymal transplantation of 1-2x10^6 UC-MSCs
16252388|NCT05008588|Active Comparator|Standard treatment (control)|Neurologic and Neutrophic Drugs
16252389|NCT05008575|Experimental|antiCD33 CAR NK cells|After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated
16252390|NCT05008562||COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|"Patients over the age of 18 who are hospitalized in our intensive care unit with a diagnosis of COVID-19 will be included in the study.
~The day the patients are admitted to the intensive care unit will be considered the 1st day of the study. SOFA, qSOFA, APACHE II, CRP, procalcitonin values will be recorded on the first day. On the first day of our patients, rectus femoris muscle thickness measurement will be done ultrasonographically (bilateral). In addition, bilateral thigh circumference will be measured anthropometrically (with a tape measure). It is planned to evaluate the muscle strength of the patients according to the MRC (Medical Research Council) scoring.
~In addition to these measurements, the creatine kinase values in the routine clinical follow-up of the patients, the differences between the fluid intake and output values, inotropic supplements used in their treatment, diuretic needs, and neuromuscular blocker use will also be noted."
16252391|NCT05008549|Experimental|First Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.
16252392|NCT05008549|Experimental|Second Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
16252393|NCT05008549|Experimental|Third Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
16252394|NCT05008549|Experimental|Fourth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
16252395|NCT05008549|Experimental|Fifth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
16252396|NCT05008549|Experimental|Sixth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
16252397|NCT05008536|Experimental|Anti-BCMA CAR-NK Cells|After preconditioning with chemotherapy, the Anti-BCMA CAR-NK Cells will be evaluated
16252398|NCT05008523|Experimental|Opioids and Police Safety Occupational Risk Reduction Training|Provides occupational risk reduction training for police in 49 slides including 8 filmed videos (police officers, MDs, SSP staff, a person in recovery). The training is delivered online with secure access only for enrolled study participants.
16252399|NCT05008523|Active Comparator|COVID Occupational Risk Reduction Training|The COVID-19 and Police Safety training (Control only) includes 22 slides, also narrated by a professional voice narrator.
16252403|NCT05008484|Experimental|NMES Plus Vitamin D|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach and 2000IU oral vitamin D supplementation daily for 9 months.
16252404|NCT05008484|Experimental|Passive movement plus vitamin D|Subjects will undergo 9 months of simple passive movement exercise at home and 2000IU oral vitamin D supplementation daily for 9 months.
16252475|NCT05008003|Active Comparator|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
16252406|NCT05008471|No Intervention|Conventional group|Unlike the intervention group,conventional group should be treated according to the consensus of experts on standardized nutrition management.
16252407|NCT05008458||children with febrile seizures|
16252408|NCT05008458||febrile children without seizures|
16252409|NCT05008458||healthy control children|
16252410|NCT05008445|Experimental|LM-102 Dose Escalation Level 1, 3mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~first dose: 3mg/kg, Q3W;"
16252411|NCT05008445|Experimental|LM-102 Dose Escalation Level 2, 10mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~Second dose: 10mg/kg, Q3W;"
16252412|NCT05008445|Experimental|LM-102 Dose Escalation Level 3, 20mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~Third dose: 20mg/kg, Q3W;"
16252413|NCT05008445|Experimental|LM-102 Dose Escalation Level 4, 30mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~Four dose: 30mg/kg, Q3W;"
16252414|NCT05008445|Experimental|LM-102 Dose Escalation Level 5, 40mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~Five dose: 40mg/kg, Q3W;"
16252415|NCT05008445|Experimental|LM-102 (RP2D-1) combined with SOC Dose Escalation|During the dose escalation of LM-102 combined with SOC,the next lower dose groups (RP2D-1) of LM-102 monotherapy's RP2D will be adopted as the starting dose.
16252416|NCT05008445|Experimental|LM-102 (RP2D) combined with SOC Dose Escalation|During the dose escalation of LM-102 combined with SOC,(If applicable) LM-102 monotherapy's RP2D will be adopted as the starting dose.
16252417|NCT05008432||HFpEF Patients Diagnosed with Obstructive Sleep Apnea|Right heart cath patients who are diagnosed with HFpEF will undergo a home sleep apnea test
16252418|NCT05008419|Experimental|Discourse Treatment|Biweekly discourse treatment sessions.
16252419|NCT05008419|No Intervention|Treatment as Usual|No treatment. Participants will engage in their usual care.
16252420|NCT05008406||Preclinical medical students|
16252421|NCT05008406||Clinical medical students|
16252422|NCT05008393|Placebo Comparator|Placebo|Patients will receive placebo orally once daily for 10 days.
16252423|NCT05008393|Experimental|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 orally once daily for 10 days.
16252424|NCT05008393|Experimental|PJS-539 Dose 2|Patients will receive PJS-539 dose 2 orally once daily for 10 days.
16252425|NCT05008380|Experimental|Standard of care + prone positioning|Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
16252426|NCT05008380|No Intervention|Standard of care|Standard of care
16252427|NCT05008367|Active Comparator|Treatment A|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
16252428|NCT05008367|Active Comparator|Treatment B|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
16252429|NCT05008367|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
16252430|NCT05008354|Active Comparator|Pyridoxine|
16252431|NCT05008354|Placebo Comparator|Placebo|
16252432|NCT05008341|Experimental|Solriamfetol|Participants will receive a single oral dose of solriamfetol 150 mg with 240 mL water at 0 hour on the morning of Day 1, 2 hours after completion of a light breakfast.
16252433|NCT05008328|Experimental|Music Therapy plus Standard Care|Music therapy intervention in addition to standard hospital care during an SBT.
16252434|NCT05008328|Active Comparator|Standard Care|Standard hospital care during an SBT.
16252435|NCT05008315|Experimental|deep and superficial tissue mobilization group|include deep and superficial tissue mobilization
16252436|NCT05008315|Active Comparator|superficial tissue mobilization group|superficial tissue mobilization
16252437|NCT05008315|Placebo Comparator|control group|Sham (very light hand touch on the same location as the other two groups but without any treatment intention)
16252438|NCT05008315|Other|vaginal delivery group|education session
16252439|NCT05008302|Experimental|To improve the coordination of the wrist and hand after stroke in three age groups.|The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
16252440|NCT05008289|Active Comparator|ACTIVE|Magnetic transcutaneous spinal cord stimulation
16252441|NCT05008289|Sham Comparator|PLACEBO|
16252442|NCT05008276||Youth with obesity and elevated HbA1c|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
16252443|NCT05008276||Healthy normal-weight controls|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
16252444|NCT05008263||Patients with viral chronic liver disease at primary diagnosis|Patients with primary diagnosis of viral hepatitis B and hepatitis C who was referred for liver biopsy. All patients underwent liver shear wave elastography and dynamic liver scintigraphy evaluating liver physical and functional changes shortly prior to liver biopsy procedure.
16252445|NCT05008250|Experimental|study group|Metoprolol tartrate (25 mg twice per day, orally) plus TMYXP (40 pills twice per day, orally). the treatment duration is 8 weeks.
16252446|NCT05008250|Placebo Comparator|control group|Metoprolol tartrate (25 mg twice per day, orally) plus placebo (40 simulated pills twice per day, orally). The treatment is 8 weeks.
16252447|NCT05008237|Experimental|Cisplatin plus docetaxel|"D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks
~Treatment will be continued until disease progression or unacceptable toxic effects."
16252449|NCT05008211|Experimental|Intervention|"There will be a respiratory team, same as the usual care, responsible for patients requiring domiciliary NIV in the intervention group.
~The IMB model-based intervention of this study is a six-week program consisted of a one-hour face-to-face home visit in the first week, two 20-minute telephone follow-ups in the second and fourth weeks, and a half-hour face-to-face follow-up at hospital in the sixth week, and a telephone consultation hotline during office hours.
~There are three major components including information, motivation and behavioral skill interventions as proposed by the IMB model and will be deliberately arranged in the different sessions."
16252450|NCT05008211|Placebo Comparator|Control - usual care|There is a respiratory team of health care professionals responsible for patients requiring domiciliary NIV. The team is led by a Medical Consultant and with respiratory nurse(s) as team members who are responsible for assisting patients or their family to initiate domiciliary NIV and teaching the relevant technical skills. The nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems such as leakage and pressure sore in hospital before discharge. Commercial leaflet or booklet according to the choice of ventilator with information of the ventilator, interface, accessories and the ventilator company will be provided to the patient.
16252451|NCT05008198||Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
16252454|NCT05008172|Experimental|Splenic Artery Embolization (SAE)|If a patient is randomized to the SAE arm, the Interventional Radiology (IR) team will be notified of the patient's enrollment. The timing of embolization is left to the IR team but will occur within 6-12 hours of enrollment.
16252455|NCT05008172|No Intervention|Observation|Patients assigned to the observation arm will be transferred from the trauma bay to floor or the ICU for monitoring and continuous care under the Trauma team.
16252456|NCT05008159|Experimental|The EMBOLDEN program|3 month community-based mobility and healthy aging intervention
16252457|NCT05008159|No Intervention|Usual care|
16252458|NCT05008146|Experimental|PET|[C-11]NOP-1A
16252459|NCT05008120||MDD + RBD|"Clinical diagnosis of lifetime major depressive disorder, based on the M.I.N.I.;
~RBD diagnosis according to the International classification of sleep disorder (ICSD) 3rd edition, fulfilling both the clinical and video-polysomnography (vPSG) criteria;
~Depressive symptoms onset before RBD onset"
16252460|NCT05008120||MDD|"Age-and sex-matched with MDD+RBD probands;
~Lifetime diagnosis of MDD based on M.I.N.I.;
~Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)
~Free of RBD symptoms or other hallmark features of RBD (e.g. REM Sleep Without Atonia, RWSA) by vPSG"
16252461|NCT05008120||Health control|"Age-and sex-matched with MDD+RBD subjects;
~Free of psychiatric disorders based on M.I.N.I.;
~Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)
~Free of RBD symptoms or RWSA by vPSG"
16252462|NCT05008107|Experimental|Virtual Reality|Virtual reality (VR) will be provided to families of patients undergoing ambulatory pediatric surgery. VR will provide personalized education to patients and their families about the entire continuum of the child's surgical experience. This will range from the hospital registration, the peri-operative experience, including the separation of the child from the parent in the pre-operative area and the anesthetic induction process, and the post-operative hospital ward.
16252463|NCT05008107|No Intervention|Control|Families will receive standard pre-operative instructions.
16252464|NCT05008094||Genetic testing cohort (Phase 1)|Group of Croatian Parkinson's disease patients who will be tested with whole-exome sequencing in target Parkinson's genes.
16252465|NCT05008094||Drug-naive Parkinson's disease patients (Phase 2)|Drug-naive Parkinson's disease patients that will be prospectively followed in the two-year period for each patient.
16252466|NCT05008094||Control group (Phase 2)|Control patients who do not have neurodegenerative diseases. The control group will perform the same measurement as the drug-naive Parkinson's disease patients.
16252467|NCT05008068|Experimental|PRF alone|
16252468|NCT05008068|Active Comparator|PRF in addition to Simvastatin|
16252469|NCT05008055|Experimental|Capivasertib monotherapy|Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
16252470|NCT05008042|Active Comparator|Mecobalamine 5 mg/ml|The active substance of vitamin B12 given in the study is Mecobalamin 5mg / ml 2 ml ie 10 mg and is given intramuscularly.
16252471|NCT05008042|Placebo Comparator|NaCl 9mg/ml|Placebo substance given in the study is Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) given intramuscularly.
16252472|NCT05008029|Experimental|In situ immobilization|Immobilization without reducing the radius fracture and above-elbow casting.
16252473|NCT05008029|Active Comparator|Reduction under general anesthesia|Radius closed reduction under general anesthesia and above-elbow casting. Percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block if needed.
16252474|NCT05008016||Procalcitonine analysed|The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement
16252479|NCT05007977|Experimental|Treatment order: placebo, low dose, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
16252480|NCT05007977|Experimental|Treatment order: placebo, high dose, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
16252481|NCT05007977|Experimental|Treatment order: low dose, placebo, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
16252482|NCT05007977|Experimental|Treatment order: low dose, high dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
16252483|NCT05007977|Experimental|Treatment order: high dose, placebo, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
16252484|NCT05007977|Experimental|Treatment order: high dose, low dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
16252485|NCT05007964|Experimental|Spatz4 subjects|Subjects will be studied in an open label multi-center center study which will examine the usability of the adjustment process and success of the process. .
16252490|NCT05007938|Experimental|Icotinib + Befotertinib|"Icotinib（125 mg orally, three times daily）
~Befotertinib（25 mg orally, three times daily）"
16252491|NCT05007925|Experimental|Single-arm|
16252492|NCT05007912||Orvil Group|Group that used the Orvil (circular stapler) for esophagojejunostomy
16252493|NCT05007912||Linear Group|Group that used the linear stapler for esophagojejunostomy
16252494|NCT05007899|Active Comparator|Daily|Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
16252495|NCT05007899|Experimental|Alternate Day|Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
16252496|NCT05007873|Experimental|Treatment (dasatinib, decitabine and cedazuridine)|"Patients receive dasatinib PO QD on days 1-28. Beginning cycle 4, patients also receive decitabine and cedazuridine PO QD on days 1-3. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days for up to 12 years in the absence of disease progression or unacceptable toxicity."
16252497|NCT05007860||No active therapy|Age ≥18 years and CLL/SLL (WHO criteria). We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, active therapy, treating physician intent to initiate CLL/SLL therapy within ≤2 months, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
16252498|NCT05007860||BTK inhibitor therapy (continued)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is continued through vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
16252499|NCT05007860||BTK inhibitor therapy (interrupted)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is interrupted at time of vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
16252500|NCT05007847|Active Comparator|Active|Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. They shall undergo an education and training session to ensure technical competency of heart rhythm recording and familiarity with the recommended recording schedule for the duration of the study. Participants will also be given the contact details for a dedicated email mailbox for the duration of the study through which they can submit remote transmissions of ECG data.
16252501|NCT05007847|No Intervention|Control|Participants in the control arm will be advised to continue with the standard of care and advised to contact their direct clinical team or primary care physician should they experience any symptoms of concern (palpitations, dizziness, collapse). They will be contacted by the study team at 6 and 12 months for clinical assessment (symptoms, hospitalisation data, further stroke events, mortality).
16252502|NCT05007821|Experimental|Arm A|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm A participants will take linezolid (LZD) once a day for the entire treatment period.
~Weeks 1-26: LZD 600 mg once daily (QD)
~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD
~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD
~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
16252503|NCT05007821|Experimental|Arm B|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm B participants will take a higher dose of linezolid (LZD) once a day for 4 weeks and then continue taking that higher dose of LZD just three times a week for the rest of the treatment period.
~Weeks 1-4: LZD 1200 mg once daily (QD)
~Weeks 5-26: LZD 1200 mg three times per week (TIW)
~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD
~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD
~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
16252504|NCT05007808|Experimental|G001 Topical Gel|G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
16268205|NCT04898322|Experimental|10mg SY-005|
16252505|NCT05007808|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
16252506|NCT05007795|No Intervention|Programmatic MDR TB treatment regimen|Conventional MDR-TB laboratory tests. Sputum culture (and smear microscopy) will be evaluated monthly during the treatment period (and 6 monthly during the follow-up period) for the conventional arm.
16252507|NCT05007795|Experimental|Sequence based resistance testing and individualized treatment|Sputum extracted for targeted sequencing and drug resistance profile provided to clinician for individualized treatment.
16252508|NCT05007782|Experimental|Phase 1a, Part A - GS-1811 Dose Escalation|Participants will receive escalating dose levels of GS-1811 for up to 12 months to determine maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of GS-1811.
16252509|NCT05007782|Experimental|Phase 1a, Part B - Mandatory Paired Tumor Biopsy|Participants with select tumor types will receive GS-1811 at the dose deemed safe in Part A for up to 12 months.
16252510|NCT05007782|Experimental|Phase 1b, Part C: GS-1811 + Pembrolizumab|Participants will receive GS-1811 at dose levels deemed safe in Part A in combination with pembrolizumab for up to 24 months.
16252511|NCT05007769|Experimental|Ramucirumab + Atezolizumab + N-803|-Ramucirumab intravenously (IV) on Day 1, atezolizumab IV on Day 1, and N-803 subcutaneous (SC) on Day 1 of each cycle. Cycles are 21 days.
16252513|NCT05007743|Active Comparator|Stimulation of inner tragus|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
16252514|NCT05007743|Sham Comparator|Stimulation of ear lobe|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
16252515|NCT05007730|Experimental|Intervention Arm|
16252516|NCT05007717|Experimental|Data-informed Stepped Care (DiSC) arm|At intervention sites, HCW will assign ALHIV to different levels or intensity of HIV services depending on their current and anticipated health care needs. The stepped care framework is designed to be flexible, to accommodate variable individual and social support services available at each facility.
16252517|NCT05007717|No Intervention|Standard of care|Sites randomized to the control arm will continue with standard of care approaches for adolescent clinic visits (usually 1-3 monthly visits) regardless of health care needs and additional support as needed.
16252518|NCT05007704||Anesthesiologists for preliminary survey|Anesthesiologists who have completed their training within the last three years to identify preliminary competencies for Delphi round one survey.
16252519|NCT05007704||Global Experts in Anesthesiology and Critical Care Medicine|Anesthesiologist (a medical graduate who has completed a nationally recognized Anesthesiology training programme) involved in the management of critically ill patients in ICU and have more than ten years of experience in teaching and training in Critical Care. They will be involved in the Delphi process to generate expert consensus on the additional competencies (mandatory desirable and optional) required for Anesthesiologists to practice Critical Care in the Intensive Care Unit (ICU).
16252520|NCT05007691|Experimental|Occlusal splints|"In a clinical setting, participants test the closure of the occlusal splint with the antagonistic dentition.
~Only one of the two occlusal splints (mandibular splint and maxillary splint) is used at a time. Occlusal splints are applied separately and alternately."
16252521|NCT05007678|No Intervention|Standard of Care|The usual care will be offered as per current advice on management of hospitalised patients.
16252522|NCT05007678|Active Comparator|leflunomide|Patients admitted to the hospital COVID-19 positive and within 2 weeks of symptoms' onset will be treated with loading dose of 100 mg leflunomide for 3 days, followed by 20 mg once daily. Participants with ALT/AST levels 2 times above upper limits of normal reference range will receive 10mg instead of 20mg.
16252523|NCT05007665||Chronic Liver Diseases Patients/Healthy People|Chronic hepatitis (B OR C) , autoimmune hepatitis, liver cirrhosis, primary hepatocellular carcinoma
16252524|NCT05007652|Experimental|multiple myeloma cohort (KRN125)|
16252525|NCT05007652|Active Comparator|multiple myeloma cohort (KRN8601)|
16252526|NCT05007652|Experimental|malignant lymphoma cohort|
16252527|NCT05007639||Patients diagnosed BEFORE implementation of the public health intervention program|All adult patients (≥18 years old) diagnosed between 1 November 2006 and 31 December 2007 in the Aquitaine and Midi-Pyrénées administrative districts in South-West France (6 million inhabitants, 10% of the French population) with primary STS of any stage were included. Patients with visceral, bone, uterus or Kaposi's sarcoma, gastrointestinal stromal tumors, or mesotheliomas were not included. Patients being treated for recurrence, and patients diagnosed outside of the administrative districts were not eligible. STS diagnoses were made in public or private pathology laboratories. Data were collected from all relevant sources: pathology reports, medical records from private and public centers,
16252528|NCT05007639||Patients diagnosed DURING implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 january 2008 and 31 october 2008.
~The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3)."
16252529|NCT05007639||Patients diagnosed AFTER implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 November 2008 and 31 December 2009."
16252530|NCT05007626||zero to six Exo|
16252531|NCT05007613|Experimental|cabozantinib plus atezolizumab|cabozantinib 40mg PO QD atezolizumab 1200mg IVD 30-60mins Q3W
16252532|NCT05007600|Experimental|trial group|Participants in the experimental group received an 8-week intensive (Monday to Friday) online interactive course.
16252533|NCT05007600|No Intervention|Control group|Participants in the control group consumed 8 weeks of unidirectional online video and audio programs (such as from YouTube).
16252534|NCT05007587|Experimental|Lenvatinib，Then HAIC of mFOLFOX regimen|Cohort1：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.
16252535|NCT05007587|Experimental|Lenvatinib，Then HAIC of ROX regimen|Cohort2：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
16252536|NCT05007561|Experimental|Naltrexone|50mg naltrexone HCL once daily for seven days by mouth
16252537|NCT05007561|Placebo Comparator|placebo|sugar pill once daily for seven days by mouth
16252538|NCT05007548|Experimental|Ga68-Dolacga Injection|Ga68-Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
16252539|NCT05007535||HD-IVUS-guided primary PCI|Prospective, single arm, observational
16252540|NCT05007522|Experimental|Study Drug|Ketotifen 2 mg administered in tablet form twice a day (every 12 hr). Indomethacin sustained-release (SR) 75 mg, twice a day (every 12 hr). Patients will be administered 28 doses in total of ketotifen/indomethacin combination.
16252541|NCT05007522|Placebo Comparator|Placebo|Placebo pills matching in appearance to study drug twice a day for 28 doses total.
16252542|NCT05007509|Experimental|COVID-19 vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
16252543|NCT05007509|Active Comparator|Commercial COVID-19 vaccine|Subjects will receive 2 injections of commercial COVID-19 vaccine administered 21 days apart.
16252544|NCT05007496|Experimental|AV-COVID-19 (0.1 mcg S-protein)|DCL previously incubated with 0.1 mcg spike protein
16252545|NCT05007496|Experimental|AV-COVID-19 (0.33 mcg S-protein)|DCL previously incubated with 0.33 mcg spike protein
16252546|NCT05007496|Experimental|AV-COVID-19 (1.0 mcg S-protein)|DCL previously incubated with 1.0 mcg spike protein
16252547|NCT05007483|Experimental|Group 1 (Modified paleolithic elimination diet).|Modified paleolithic elimination diet.
16252548|NCT05007483|Experimental|Group 2 (TROO)|Time Restricted Olive Oil Based (TROO) Ketogenic Diet
16252549|NCT05007483|Placebo Comparator|Group 3 Control|Dietary Guidelines for Americans Diet
16252550|NCT05007470|Experimental|Probiotic|VSL#3
16252551|NCT05007470|Placebo Comparator|Pacebo|
16252552|NCT05007457|Experimental|Experimental Group|telerehabilitation
16252553|NCT05007457|Active Comparator|Control group|Standard treatment
16252554|NCT05007444|Placebo Comparator|Placebo comparator|Patients in the placebo group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
16252555|NCT05007444|Active Comparator|Active comparator P2Et|Patients in the P2Et group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
16252556|NCT05007431||Women asylum seekers|
16252557|NCT05007418|Experimental|STI-1492|Four dosing cohorts will be evaluated: Cohort 1 (1 × 10^5 donor DAR-T cells/kg); Cohort 2 (5 × 10^5 donor DAR-T cells/kg); Cohort 3 (1 × 10^6 donor DAR-T cells/kg); Cohort 4 (3 × 10^6 donor DAR-T cells/kg) where STI-1492 will be administered intravenously once.
16252558|NCT05007405||Osteoarticular infections|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
16252559|NCT05007392|Experimental|Drug: Dotinurad + Febuxostat Matched Placebo|Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
16252560|NCT05007392|Active Comparator|Drug: Febuxostat + Dotinurad Matched Placebo|Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
16252561|NCT05007366|Active Comparator|Real-time gait biofeedback (RTGBF)|The RTGBF regimen delivers biofeedback that cues a personalized target to normalize vertical ground reaction force (vGRF) of each limb.
16252562|NCT05007366|Sham Comparator|Sham real-time gait biofeedback (Sham RTGBF)|The Sham RTGBF regimen will receive biofeedback that cues their habitual step length determined during the accommodation period on the first session of treadmill walking.
16252563|NCT05007353|Experimental|Structured Lifestyle Intervention|Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation.
16252564|NCT05007353|Experimental|Self-Guided Intervention|General health information provided to participants.
16252565|NCT05007314|Experimental|Human Science|Arm 1 will include university graduates that hold at least a science undergraduate degree (or equivalent) in human science, including psychology, neuroscience, human biology, or medicine.
16252566|NCT05007314|Active Comparator|Natural or non-science|Arm 2 will include university graduates from non-human or non-scientific fields such as engineering, history, language studies, or law.
16252567|NCT05007288|Experimental|RET Treated Eye Plus INhance Group|Participants randomized to receive the restorative eye treatment (RET) intervention on either the left or right eyelid will administer the RET cream on the eyelid daily for 4 consecutive weeks prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
16252568|NCT05007288|Experimental|RET Untreated eye Plus INhance Group|Participants randomized to not receive the RET intervention will not receive any intervention prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
16252569|NCT05007275|Experimental|Single arm, dose escalation|Experimental: Healthy Volunteers Biological/Vaccine: AZD1222 (1x10^9 vp, 5x10^9 vp and 1x10^10 vp)
16252570|NCT05007262|Experimental|Tangningtongluo tablets|Tangningtongluo tablets, 4 tablets one time,tid,po, taken after meals.The patients will receive drugs for 24 weeks continuously. After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI） and Angiotensin Receptor Blocker（ARB） drugs will be continued to use as the original treatment protocol.
16252571|NCT05007262|Active Comparator|Calcium dobesilate capsules|Calcium dobesilate capsules, 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI ）and Angiotensin Receptor Blocker （ARB） drugs will be continued to use as the original treatment protocol.
16252572|NCT05007249|Other|Overweight or obese minors with intellectual disability|
16252573|NCT05007236|Experimental|RP7214 + Standard of care (SOC)|
16252574|NCT05007236|Placebo Comparator|Placebo + Standard of care (SOC)|
16252575|NCT05007223||1. Experimental: doxycycline|Given doxycycline and assessment of skin
16252576|NCT05007223||2. No Intervention: Healthy Controls|Control subjects to assess if there is baseline difference in the skin microbiome
16252577|NCT05007210|Experimental|Prenatal massage therapy group|Prenatal massage therapy for prenatal attachment, physiological and psychological distress, maternal and fetal well-being.
16252578|NCT05007210|No Intervention|Control group|Pregnant women in the control group were interviewed twice (once a week for 30th and 34th week) by the same massaging midwife. No additional attempt was made except for filling out the forms and evaluating the biophysical profile by the obstetrician in these interviews. The massaging midwife's phone number was given to the pregnant women in both groups if they want to reach anytime. A phone number was set for the study, and this phone number was used by the massaging midwife. This service has been provided for pregnant women to reach her whenever they want.
16252579|NCT05007197|Experimental|Intervention Group|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people.
~Group-specific diabetes trainings were completed in two training sessions. Each training session lasted an average of one and a half hours and a fifteen minute break was given.
~The auditory group in the intervention group, calling by phone; visual group by SMS and WhatsApp tactile group, reminder alerts were made by phone+SMS+WhatsApp."
16252580|NCT05007197|No Intervention|Control Group|The learning modality of the control group were determined and standard group training was provided with the education booklet.
16252581|NCT05007184|No Intervention|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart, which replicates the traditional shopping experience of online grocery stores.
16252582|NCT05007184|Experimental|Warning Label Arm (Arm 2)|Similar to Arm 1 except that products are labeled with Chilean warning FOP labels.
16252583|NCT05007184|Experimental|Nutri-Score Arm (Arm 3)|Similar to Arm 1 except that products are labeled with NutriScore FOP labels.
16252584|NCT05007171|Experimental|Very low calorie diet|Use of very low calorie diet in hospital for 3 weeks
16252585|NCT05007158||pocket infection|Patients with isolated pocket infection were diagnosed in the presence of local signs of inflammation (one or more of erythema, pain, warmth, swelling, induration, tenderness, or fluctuation), wound dehiscence, hardware protrusion or pus discharge at the pocket in the absence of systemic findings.
16252586|NCT05007158||CIED systemic infection|Patient s with a CIED systemic infection, diagnosed as the presence of pocket infection accompanied by bacteraemia or echocardiographic finding suggestive of infective endocarditis, but not fulfilling the Duke criteria.
16252587|NCT05007158||Lead-associated infective endocarditis|Patients with infective endocarditis, diagnosed according to modified Duke criteria
16252588|NCT05007158||control group|CIED Patients presenting for elective device exchange or planned lead revision between without local or systemic infections were selected as controls
16252589|NCT05007145|Experimental|PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin|Participants receive PD-1 Inhibitor 200mg on Day 1 every 3 weeks (Q3W), albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2-4 cycles，followed by surgery.
16252590|NCT05007145|Active Comparator|Albumin-bound paclitaxel+cisplatin+radiotherapy|Participants receive albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2 cycles combined with radiotherapy(40Gy/2Gy),followed by surgery.
16252591|NCT05007132|Experimental|Arm A|Trifluridine/tipiracil, 35 mg/m² body surface area (BSA), twice daily, orally on days 1-5 and 8-12 Panitumumab at 6 mg/kg bodyweight, intravenous infusion on days 1 and 15
16252592|NCT05007132|Active Comparator|Arm B|Trifluridine/tipiracil, 35 mg/m² body surface area, twice daily, orally on days 1-5 and 8-12 Bevacizumab at 5 mg/kg bodyweight, intravenous infusion on days 1 and 15
16252593|NCT05007119|Active Comparator|Control Group|"It includes participants receiving conventional physical therapy for low back pain female patients for a period of 6 months.
~McKenzie extension exercise Protocol Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence
~Static:
~Lying Prone
~Lying prone in extension
~Sustained extension
~Posture correction
~Dynamic:
~Extension in lying
~Extension in lying with clinician overpressure
~Extension mobilization
~Extension in standing"
16252594|NCT05007119|Experimental|Experimental Group|"Group (A) Involves participants receiving cupping therapy along with conventional physicla therapy for a period of 6 months .
~Moist Heat Pack for 10 mins McKenzie Extension Exercise Protocol"
16252601|NCT05007093|Experimental|Anlotinib hydrochloride|
16252602|NCT05007080|Experimental|Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 1 [Standard Volume])|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (standard volume) on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.
16252603|NCT05007080|Experimental|Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 1 [Lower Volume])|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (lower volume) on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.
16252604|NCT05007080|Experimental|Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.
16252605|NCT05007080|Experimental|Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.
16252606|NCT05007080|Experimental|Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. Participants who received active vaccine may receive 1 or 2 doses of selected formulation.
16252607|NCT05007080|Experimental|Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. Participants who received active vaccine may receive 1 or 2 doses of selected formulation.
16252608|NCT05007080|Placebo Comparator|Part 1 (Dose Selection Cohort): Placebo|Participants will receive 2 doses of placebo on Day 1 and Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner at a selected dose level.
16252609|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 1 [Standard or Lower Volume])|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (standard or lower volume) on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252610|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252611|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252612|NCT05007080|Placebo Comparator|Part 2 (Dose Expansion Cohort): Placebo: 1-Dose Regimen|Participants will receive 1-dose of placebo on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16253079|NCT05003882||Arm F|Commercially available, orally ingestible CBD product F
16252613|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252614|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252615|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Selected dose level [SDL])|Participants will receive 2 doses of SDL on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252616|NCT05007080|Placebo Comparator|Part 2 (Dose Expansion Cohort): Placebo: 2-Doses Regimen|Participants will receive 2 doses of placebo on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
16252617|NCT05007054||Percutaneous coronary intervention|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months.
16252618|NCT05007054||Coronary artery bypass grafting|The left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. Te procedure was performed by surgeons experienced in onpump or of-pump surgery at the operator's discretion.
16252619|NCT05007054||Medical therapy|Patients with neither PCI nor CABG treatment were allocated to the MT alone group. For medical therapy, antiplatelet medication, statins, renin-angiotensin system blockade, β-blockers, and nitrate were used.
16252620|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and Quadrivalent adjuvanted influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the quadrivalent adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
16252621|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and high-dose quadrivalent influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
16252622|NCT05007028|Experimental|Nitrous Oxide|Active Drug: EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)
16252623|NCT05007028|Placebo Comparator|Medical air|Control Drug: Medical air : 78% N2 / 22% O2
16252624|NCT05007015|Experimental|Transanal Irrigation|This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm
16252625|NCT05007015|No Intervention|Tradition care Control arm|This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.
16252626|NCT05007002|Experimental|Robot-based therapy|Chronic stroke patients receiving robot-based therapy
16252627|NCT05006989|Experimental|Intervention Group|Participants will be provided pre-made whole blueberry freeze-dried powder to be consumed.
16252628|NCT05006989|Placebo Comparator|Placebo Group|Participants will be provided placebo powder to be consumed.
16252629|NCT05006976|Active Comparator|NSAC health only|Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.
16252630|NCT05006976|Experimental|NSAC health + MBW|Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.
16252631|NCT05006963|Experimental|face-to-face group|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, totaling 24 face-to-face consultations lasting 40 minutes each. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms.Techniques of manual therapy and therapy by exercise. In general, extra-oral and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will be mouth opening exercise will be also performed with the tongue on the palate, proprioceptive exercises with hyperboloid. In addition to these, additional exercises may be performed, according to the patient's need. The conducts will be adapted according to the needs of each patient. The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene.
16252632|NCT05006963|Active Comparator|telerehabilitation|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, by telerehabilitation lasting 40 minutes each.A physiotherapist through video call via WhatsApp application. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms. Patients will be instructed to perform extra-oral and intra-oral self-massage and in the cranio-cervical musculature, bone mobilization hyoid, which would replace the mobilization unspecific articulation performed in person.Exercise will also be carried out mouth opening with tongue on the palate, exercises proprioceptives with hyperboloid. The conducts will be adapted according to the needs of each patient.The conducts will be adapted according to the needs of each patient.The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene
16252633|NCT05006937|Active Comparator|laser dusting|"In the dusting arm, the ureteroscope will be advanced into the kidney or ureter over an access wire without an access sheath in place. The identified stone will be dusted using a 200 micron Moses laser fiber at a setting of 0.3-0.6 J and 50-120 Hz using the Moses 2.0 laser system. Stone dusting will continue until the surgeon feels the fragments are all negligible in size and would be able to pass. One small piece will be extracted for analysis and the remainder will be left to pass spontaneously. If there is no evidence of injury or swelling of the ureter at the conclusion of the case a stent will be omitted."
16252671|NCT05006781|Experimental|tDCS+Dose B|Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
16252634|NCT05006937|Active Comparator|basketing|In the Basketing arm, a ureteral access sheath (UAS) will be placed per standard fashion. The ureteroscope will be introduced into the kidney and the stone fragmented at a setting of 0.8-1.0 J and 6-15 Hz. The resultant fragments will be basket extracted through the sheath for analysis. All fragments will be removed until no residual stone remains. At the time of UAS removal the ureter will be inspected. If there is no evidence of ureteral injury or swelling then a stent will be omitted.
16252635|NCT05006911|Experimental|PBOHB|Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients
16252636|NCT05006898|Experimental|PBO Investigational drug|Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
16252637|NCT05006898|Active Comparator|Pilocarpine|Pilocarpine was instilled in the other oye.
16252638|NCT05006898|Active Comparator|Brimonidine|Brimonidine was instilled in the other eye.
16252639|NCT05006885|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
16252640|NCT05006885|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
16252641|NCT05006885|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
16252642|NCT05006885|Placebo Comparator|Placebo|Administered once a week for 12 weeks
16252643|NCT05006872|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
16252644|NCT05006872|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
16252645|NCT05006846||Cohort 1|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between February 18, 2020, to May 25, 2020.
16252646|NCT05006846||Cohort 2|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between July 17, 2020, to August 31, 2020.
16252647|NCT05006833|Experimental|Bundled clinician training and bundled text messages|Clinicians will receive bundled approach training and parents will receive bundled text messages.
16252648|NCT05006833|Experimental|Bundled clinician training and benefits text messages|Clinicians will receive bundled approach training and parents will receive benefits text messages.
16252649|NCT05006833|Experimental|Bundled clinician training and no text messages|Clinicians will receive bundled approach training and parents will not receive any intervention text messages.
16252650|NCT05006833|Experimental|Benefits clinician training and bundled text messages|Clinicians will receive benefits approach training and parents will receive bundled text messages.
16252651|NCT05006833|Experimental|Benefits clinician training and benefits text messages|Clinicians will receive benefits approach training and parents will receive benefits text messages.
16252652|NCT05006833|Experimental|Benefits clinician training and no text messages|Clinicians will receive benefits approach training and parents will not receive any intervention text messages.
16252653|NCT05006833|Experimental|Deferred-clinician training and bundled text messages|Clinicians will receive training after the study and parents will receive bundled text messages.
16252654|NCT05006833|Experimental|Deferred-clinician training and benefits text messages|Clinicians will receive training after the study and parents will receive benefits text messages.
16252655|NCT05006833|No Intervention|Deferred-clinician training and no text messages|Clinicians will receive training after the study and parents will not receive intervention text messages.
16252656|NCT05006820||No intervention|
16252657|NCT05006807||Twitch Monitoring|Patients undergoing surgery with general anesthesia requiring neuromuscular blockade.
16252658|NCT05006794|Experimental|Part A: GS-9716 Dose-Escalation|Participants will receive escalating doses of GS-9716 to establish MTD.
16252659|NCT05006794|Experimental|Part A: GS-9716 Dose-Expansion|Participants will receive the MTD or below MTD of GS-9716.
16252660|NCT05006794|Experimental|Part B (Cohort B1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
16252661|NCT05006794|Experimental|Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
16252662|NCT05006794|Experimental|Part B (Cohort B3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
16252663|NCT05006794|Experimental|Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
16252664|NCT05006794|Experimental|Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
16252665|NCT05006794|Experimental|Part C (Cohort C1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
16252666|NCT05006794|Experimental|Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
16252667|NCT05006794|Experimental|Part C (Cohort C3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
16252668|NCT05006794|Experimental|Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
16252669|NCT05006794|Experimental|Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
16252670|NCT05006781|Experimental|tDCS+Dose A|Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
16253080|NCT05003882||Arm G|Commercially available, orally ingestible CBD product G
16252672|NCT05006781|Experimental|tDCS+Dose C|Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
16252673|NCT05006781|Placebo Comparator|tDCS+placebo|Drug: Placebo Placebo Device: tDCS tDCS
16252674|NCT05006768|Experimental|T test|Test drug (Barcimiant) 1 tablet contains 4 mg Baricitinib
16252675|NCT05006768|Active Comparator|B reference (first dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
16252676|NCT05006768|Active Comparator|B reference (second dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
16252677|NCT05006755|Experimental|control group|the group of primary molar teeth that will be treated in furcal perforation with Mineral Trioxide Aggregate
16252678|NCT05006755|Experimental|experimental group|the group of primary molar teeth that will be treated in furcal perforation with Biodentine
16252679|NCT05006742|Active Comparator|CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
16252680|NCT05006742|Active Comparator|FB-CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
16252681|NCT05006729||RURAL cohort study|A longitudinal research project in ten rural counties in Alabama, Kentucky, Louisiana, and Mississippi enrolling approximately 4,600 participants from these communities, examining several different aspects of their health, including heart and lung function.
16252684|NCT05006703|Experimental|Intervention group|Access to digital intervention
16252685|NCT05006703|No Intervention|Control group|Usual care group
16252686|NCT05006690|Experimental|Telerehabilitation Training Group|"In the telerehabilitation group, an individualized rehabilitation program according to the principles of spinal stabilization exercises will be applied via video conference, 3 days a week, 1 hour, online in real-time, accompanied by a physiotherapist, for 8 weeks.
~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
16252687|NCT05006690|Experimental|Face-to-Face Training Group|"In the face-to-face training group, an individualized rehabilitation program according to the principles of spinal stabilization exercises will be applied in the clinic under the supervision of a physiotherapist for 1 hour, 3 days a week, for 8 weeks.
~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
16252688|NCT05006690|Experimental|Home-Based Training Group|"In the home exercise group, patients will be asked to perform individualized spinal stabilization exercises at home, 3 days a week, for 8 weeks.
~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
16252689|NCT05006677||non-vitamin K antagonist oral anticoagulants (NOACs)|
16252690|NCT05006677||vitamin K antagonists (VKAs)|
16252691|NCT05006677||antiplatelet agents|
16252692|NCT05006677||non-antithrombotic therapy|
16252693|NCT05006664|Experimental|Brentuximab Vedotin (Adcetris) in Combination with CHEP|Single arm, open label, Brentuximab Vedotin (Adcetris) in Combination with CHEP
16252694|NCT05006651|No Intervention|Laryngoscope|Intubation with traditional laryngoscope
16252695|NCT05006651|Active Comparator|McGrath MAC|Intubation with video laryngoscope
16252696|NCT05006651|Active Comparator|Trachway|Intubation with video stylet
16252697|NCT05006638|Placebo Comparator|control group|will receive the traditional supportive treatment according to (PCC-ASUH) protocol
16252698|NCT05006638|Active Comparator|case group|will receive the traditional supportive treatment plus administration of ILE (20%) 1.5 ml/kg as a bolus over 2-3 minutes. Followed immediately by an infusion of 20 % lipid emulsion at a rate of 0.25 mL/kg/min. After 3 minutes of this infusion rate, response to the bolus and initial infusion should be assessed. If there has been a significant response, the infusion rate can be adjusted to 0.025 mL/kg/min with monitoring of blood pressure, heart rate, and other available hemodynamic parameters during the infusion with a maximum dose of 10 mL/kg
16252699|NCT05006625||Adolescents and Young Adults|Adolescents and Young Adults Seeking HIV Treatment and Prevention
16252700|NCT05006625||Service Providers|Service Providers for Adolescents and Young Adults Seeking HIV Treatment and Prevention
16252701|NCT05006612|Active Comparator|Group 1 ((Serratus Anterior Plane Block SAPB)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%.
16252702|NCT05006612|Active Comparator|Group 2 ((Serratus Anterior Plane Block SAPB combined with Modified Pectoral Nerve Block)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 20 ml levobupivacaine 0.25%and Modified Pectoral Nerve Block with injection of 10 ml levobupivacaine 0.25%between the two pectoralis muscles, after that, the probe was turned toward the axilla, and as the serratus anterior muscle was recognized above the third and fourth ribs, 10 mL of levobupivacaine 0.25% was injected above this muscle
16252703|NCT05006599|Experimental|Humulin® R U-100|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin® R U-100 (40 IU) four times daily for 3 weeks.
16252704|NCT05006599|Placebo Comparator|Placebo|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.
16252705|NCT05006586||RVF|All patients having undergone repair for rectovaginal fistula
16252708|NCT05006560|Experimental|Usual care rehabilitation and aftercare|Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.
16252709|NCT05006560|Experimental|Rehabilitation and aftercare (aligned)|"Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.
~During rehabilitation, participants already get familiarized with components of the after care program."
16252710|NCT05006547||Young adults|18<age<35
16252711|NCT05006547||Middle aged adults|50<age<65
16252712|NCT05006521|Experimental|KN-002 for SAD (Part 1)|Up to 6 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
16252713|NCT05006521|Placebo Comparator|Placebo for SAD (Part 1)|Up to 6 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
16252714|NCT05006521|Experimental|KN-002 for MAD (Part 2)|Up to 4 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
16252715|NCT05006521|Experimental|Placebo for MAD (Part 2)|Up to 4 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
16252716|NCT05006508|Experimental|Usage of tool|Participants get access to the tool and use it regularly
16252717|NCT05006508|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.
16252718|NCT05006495|Experimental|C3 laminectomy with C4-6 laminoplasty|Cervical myelopathy patients who underwent C3 laminectomy with laminoplasty.
16252719|NCT05006495|Active Comparator|C3-6 laminoplasty|Cervical myelopathy patients who underwent C3-6 laminoplasty.
16252720|NCT05006482|Active Comparator|Arm I (usual care)|Patients and caregivers receive routine survivorship follow-up care at their doctor's office for 5 visits over 12 months.
16252721|NCT05006482|Experimental|Arm II (GEMS intervention)|Patients and caregivers participate in GEMS consultation over 1 hour that includes discussion of results and recommendations from geriatric assessment. Patients also participate in survivorship health education sessions over 75 minutes twice weekly for 4 weeks. Patients also participate in EXCAP program, which includes daily walking and resistance exercises.
16252722|NCT05006469|Experimental|BAd treatment|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, >70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
16252723|NCT05006456||Cohort 1|Cohort 1 consists of 2000 subjects undergoing catheter ablation with STSF catheter, in which AI is used to guide the ablation lesion creation.
16252724|NCT05006456||Cohort 2|Cohort 2 consists of 2000 subjects who undergoing catheter ablation using QDOT or HELIOSTAR catheter.
16252725|NCT05006443|Other|Moderate or severe tricuspid regurgitation|40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
16252726|NCT05006430|Active Comparator|Intervention Arm|"Subjects will receive Standard of Care (SOC), based on AASLD/EASL guidelines and one dose of PRIM-DJ2727 (30 grams of stool/dose ~ 3 capsules) every day for a week followed by once weekly for 3 weeks, amounting to total 10 doses.
~PRIM-DJ2727 (microbiota suspension) is an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors. It will be provided by University of Texas School of Public Health."
16252727|NCT05006430|Placebo Comparator|Placebo Arm|"Subjects will receive Standard of Care (SOC), based on AASLD/EASL guidelines and one dose of Placebo every day for a week followed by once weekly for 3 weeks, amounting to total 10 doses.
~Placebo will be identical to the investigational product but will not contain active PRIM-DJ2727."
16252728|NCT05006417|Experimental|Participants with R-CECS|Botox to be injected under standard palpatory technique into the affected lower leg compartment.
16252729|NCT05006404|Experimental|Autus Valve Arm|Pulmonary Valve Replacement Surgery with the Autus Valve
16252730|NCT05006391|Experimental|Tele-Coaching (Online) Community-Based Exercise|This study involves two phases: a six month online Community-Based Exercise Intervention (Phase 1), followed by a six month Follow-Up Monitoring Phase (Phase 2).
16252731|NCT05006378|Placebo Comparator|Placebo Capsule|
16252732|NCT05006378|Experimental|Chamomile Tea|Subjects will consume three servings of chamomile tea throughout the day for the one-week treatment period. Each tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
16252733|NCT05006378|Experimental|Chamomile Extract Capsule|Subjects will consume three chamomile capsules throughout the day for the one-week treatment period. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
16252734|NCT05006365|Experimental|Transcranial Pulse Stimulation|Investigators will use a single-blind randomized controlled trial design with two-armed repeated measures. The trial design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement. The first arm is the Intervention Group (Transcranial Pulse Stimulation) (TPS group)
16252735|NCT05006365|Active Comparator|Waitlist Control Group|Second arm is the waitlist control group.
16252736|NCT05006352|Experimental|DNL343 (High Dose)|
16252737|NCT05006352|Experimental|DNL343 (Low Dose)|
16252738|NCT05006352|Placebo Comparator|Placebo|
16252739|NCT05006339|Experimental|Dental Monitoring|Orthodontic retention review via dental monitoring only
16252740|NCT05006339|Active Comparator|Clinic Review|Orthodontic retention review via in-office visits as per routine care
16252741|NCT05006326|Experimental|68Ga-PSMA PET/MR|The investigators selected patients with a high clinical suspicion of HCC, or patients with confirmed HCC without tumour-related treatment who were to be biopsied or surgically resected to obtain pathological results. Patients signed an informed consent form and underwent 68Ga-PSMA PET/MR imaging (or PET/CT imaging if the patient had a contraindication to MR imaging).
16252775|NCT05006079|Active Comparator|Morphine alone|15mg immediate-release oral morphine, administered both at 9:30 am and 12:00 pm
16253081|NCT05003882||Arm H|Commercially available, orally ingestible CBD product H
16252742|NCT05006313|Experimental|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.
16252743|NCT05006300|Experimental|Group 1|One application of Topialyse Baume Barrière per day
16252744|NCT05006300|Experimental|Group 2|Two applications of Topialyse Baume Barrière per day
16252745|NCT05006287|Experimental|Non-Vitamin K Oral Anticoagulant (NOAC) Group|Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)
16252746|NCT05006287|Active Comparator|Warfarin Group|Anticoagulation with warfarin to target INR 2.5
16252747|NCT05006274||Group 1-Traditional soft tissue balance|Patients in group 1 will receive traditional, manual soft-tissue balancing during surgery. For the purpose of the study, the balance will be quantitatively assessed at the end of the case, by means of surgeon-blinded VERASENSE measurements before and after cementation.
16252748|NCT05006274||Group 2-Soft tissue balance using VERASENSE|For the patients in Group 2, intra-operative sensor feedback will be used in creating a quantitatively balanced knee (VERASENSE, OrthoSensor Inc.). Thereby, a quantitatively balanced knee is characterized by a mediolateral load differential below 15lbs at 10-45-90 degrees of flexion.
16252749|NCT05006261|Experimental|Tele-Tai Chi|Tele-Tai Chi intervention
16252753|NCT05006235|Active Comparator|Salbutamol Group|included babies who had received nebulized B2 agonist salbutamol (0.15 mg/kg) + 4ml normal saline
16252754|NCT05006235|Active Comparator|Epinephrine Group|included babies who had received nebulized epinephrine (0, 05 ml/Kg) + 4ml normal saline
16252755|NCT05006235|Placebo Comparator|Saline Group|include babies who had received nebulized 0.9% saline
16252756|NCT05006222|Active Comparator|ERT group|The participants are enrolled in this group whose get enzyme replacement therapy
16252757|NCT05006222|No Intervention|non-ERT group|The participants are enrolled in this group whose not get enzyme replacement therapy
16252758|NCT05006209|Active Comparator|One visit root canal treatment with CHX|The teeth were treated in one-visit (OV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
16252759|NCT05006209|Active Comparator|Two visit root canal treatment with CH|The teeth were treated in two visit (TV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
16252760|NCT05006183|Experimental|iFR-guided|One-stage, virtually planned, iFR-guided and optimized PCI.
16252761|NCT05006183|Active Comparator|Angiography-guided|Standard practice staged angiography-guided PCI
16252762|NCT05006170||6 to below 10 kg weight band|Children with perinatal HIV infection whose weight from 6 kg to below 10 kg
16252763|NCT05006170||10 to below 14 kg weight band|Children with perinatal HIV infection whose weight from 10 kg to below 14 kg
16252764|NCT05006170||14 to below 20 kg weight band|Children with perinatal HIV infection whose weight from 14 kg to below 20 kg
16252765|NCT05006157|Experimental|ViaOne device|ViaOne device will be used for percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac
16252768|NCT05006131||Patients who are at high-risk for pancreatic cancer|Patients that meet the eligibility criteria based on CAPS3 or updated national pancreatic cancer screening guidelines
16252769|NCT05006118|Experimental|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
16252770|NCT05006105|Experimental|PPG-based mHealth on smartphone|Participants used PPG-based mHealth on a smartphone for 6 months. Participants were asked to perform two spot-check measurements and additional measurements in case of symptoms. The use of PPG-based mHealth on a smartphone was initiated on the day of insertable loop recorder insertion.
16252771|NCT05006105|Experimental|PPG-based mHealth on smartwatch|Participants used PPG-based mHealth on a smartwatch for 6 months. Participants were asked to wear the smartwatch continuously (except during battery charging). The use of PPG-based mHealth on a smartwatch was initiated on the day of insertable loop recorder insertion.
16252772|NCT05006092|Experimental|surveillance endoscopy with CADe support|
16252773|NCT05006092|No Intervention|conventional surveillance endoscopy|
16252774|NCT05006079|Placebo Comparator|Placebo drug|Lactose, administered both at 9:30 am and 12:00 pm
16252776|NCT05006079|Active Comparator|Alprazolam alone|0.25mg oral alprazolam, administered at both 9:30 am and 12:00 pm
16252777|NCT05006079|Active Comparator|Morphine then alprazolam|15mg oral morphine administered at 9:30 am, then 0.25mg oral alprazolam administered at 12:00 pm
16252778|NCT05006079|Active Comparator|Alprazolam then morphine|0.25mg oral alprazolam administered at 9:30 am, then 15mg oral morphine administered at 12:00 pm
16252779|NCT05006079|Active Comparator|Morphine+alprazolam simultaneously|morphine 15mg + 0.25mg alprazolam at 9:30 am, then morphine 15mg + 0.25mg alprazolam at 12:00 pm
16252780|NCT05006066||Healthy volunteers - Pain-Free|"Each participant will be stimulated with 4 temporal summation stimulation conditions:
~continuous thermal (1 stimulation of two minutes)
~repetitive thermal (30 stimulations of 1 second)
~continuous mechanical (1 stimulation of two minutes)
~repetitive mechanical (30 stimulation of 1 second)"
16252781|NCT05006053||Qualitative study with healthcare professionals|Healthcare professionals working in Child and Adolescent Mental Health Services, Sexual Assault Referral Centres or with e-therapy providers
16252782|NCT05006040|Experimental|Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase|Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.
16252783|NCT05006027||Percutaneous coronary intervention using a 7-Fr thin wall sheath via the snuffbox approach|patients with coronary artery disease who planned to perform PCI using 7-Fr thin wall sheath via the snuffbox approach
16252784|NCT05006014||Patient with non restorable teeth|Patient with non restorable teeth located in smile line needs extraction with immediate implantation and immediate provisionalization to improve psychiatric effect of tooth loss
16252785|NCT05006001||Case|Cases were defined as patients with an event of renal impairment during follow-up, such as acute kidney injury.
16252786|NCT05006001||Control|Cases were defined as patients without an event of renal impairment during follow-up, such as acute kidney injury.
16252787|NCT05006001||Exposure|Exposure was defined as patients with colchicine and NSAIDs combination therapy.
16252788|NCT05006001||Non-Exposure|Non-Exposure was defined as patients with other gout therapy.
16252789|NCT05005988|Experimental|Empowerment educational intervention|Three 30-minute sessions will be conducted with each mother in the intervention group, the first during the first week after admission, the second session within 7 days after the second session, and the third 3 to 2 days before discharge. An induction to the out-of-hospital kangaroo program will also take place on the day of admission to the program. Mothers will receive a booklet with general care contents and empowerment information.
16252790|NCT05005988|No Intervention|Usual intervention|Mothers receive information for home infant care, no theoretical perspective and no empowerment approach is considered
16252791|NCT05005975|Experimental|Dersimelagon 100mg|
16252792|NCT05005962||Acute ischemic patients suffering with stroke|Acute ischemic patients treated with commercially available neurothrombectomy devices in India. The device can be either a stent retriever or aspiration catheter to treat the stroke as per the labeling indications of the products.
16252793|NCT05005936||Ancillary-Correlative (ABUS, WBUS)|Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).
16252794|NCT05005923|No Intervention|Periodontal healthy|
16252795|NCT05005923|Active Comparator|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
16252796|NCT05005923|Active Comparator|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
16252797|NCT05005910|Experimental|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
16252798|NCT05005910|Active Comparator|PPIs|PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days
16252799|NCT05005897|Experimental|Screening - treatment|From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).
16252800|NCT05005897|No Intervention|Control|The control-group sample will be stored and analyzed when the child is 12 months old. Those with elevated tHcy will contribute to the control group.
16252801|NCT05005884|Active Comparator|oral phenolics intake|Prescription of oral phenolics 250 mg two times daily
16252802|NCT05005884|Placebo Comparator|placebo caplet intake|Prescription of oral phenolics 250 mg two times daily
16252805|NCT05005858|Experimental|Autograft|"The filler used in ridge splitting is autologous bone block harvested from mandible
~Interventions:
~Procedure: ridge splitting
~Procedure: bone core biopsy
~Device: dental implant placement
~Measurement: clinical measurement with Williams probe
~Micro-CT analysis
~Histomorphometric measurements"
16252806|NCT05005845|Active Comparator|0.5% NFX-179 gel|Topical gel applied once daily to target cNFs
16252807|NCT05005845|Active Comparator|1.5% NFX-179 gel|Topical gel applied once daily to target cNFs
16252808|NCT05005845|Placebo Comparator|Vehicle gel|Topical gel applied once daily to target cNFs
16252885|NCT05005338|Experimental|Cohort A|
16252810|NCT05005819|Experimental|[18F]APN-1607|Participants will receive an IV bolus injection of [18F]APN-1607, followed by PET brain imaging.
16252811|NCT05005806|Active Comparator|Omega 3 soft gel|participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
16252812|NCT05005806|Placebo Comparator|placebo|placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
16252813|NCT05005793|Experimental|Sodium bicarbonate|Oral sodium bicarbonate at a dose of 0.5 mEq/kg-lean body weight/day
16252814|NCT05005793|Placebo Comparator|Placebo|Oral placebo at a dose of 0.5 mEq/kg-lean body weight/day
16252815|NCT05005780|Experimental|µ-alpha oscillation coupled ipsilesional 100 Hz triplet bursts|µ-rhythm (The µ rhythm frequency band is defined by activity falling between 8 and 13 Hz and recorded by scalp electrodes over the sensorimotor cortex during waking neural activity) negative peak triggered TMS of ipsilesional primary motor cortex, consisting of 400 triple pulses at 100 Hz, delivered at a mean inter-triple pulse interval of 3.0 s. Stimulation intensity: 100% resting motor threshold.
16252816|NCT05005780|Active Comparator|contralesional 1 Hz rTMS|1200 stimuli to the contralesional primary motor cortex at 1 Hz. Stimulation intensity: 115% resting motor threshold.
16252817|NCT05005767|Placebo Comparator|Placebo group|ten patients with sites suffering from mild chronic periodontitis sites will be treated with scaling and root planing (SRP) only
16252818|NCT05005767|Active Comparator|test group|Ten patients with sites suffering from mild chronic periodontitis. sites will be treated with scaling and root planing (SRP) and subgingival application of Frankincense extract gel
16252819|NCT05005754|Experimental|Probiotics|Subjects are instructed to take one capsule of probiotics daily for a total of 3 months
16252820|NCT05005754|Placebo Comparator|Placebo Control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
16252821|NCT05005741|Experimental|Beinaglutide|
16252822|NCT05005741|Active Comparator|Dulaglutide|
16252823|NCT05005728|Experimental|Cohort A - AVPCa|XmAb20717 + carboplatin + cabazitaxel
16252824|NCT05005728|Experimental|Cohort B - HRD/CDK12 PARP - Progressors|XmAb20717 + carboplatin + cabazitaxel
16252825|NCT05005728|Experimental|Cohort C - HRD/CDK12 PARP Naïve|XmAb20717 + olaparib
16252826|NCT05005728|Experimental|Cohort D - MSI-H or MMRD|XmAb20717 monotherapy
16252827|NCT05005728|Experimental|Cohort E - No Targetable Mutations|XmAb20717 + carboplatin + cabazitaxel
16252828|NCT05005715|Active Comparator|Dexmedetomidine group|After the induction of anesthesia, the dexmedetomidine group received intravenous dexmedetomidine at a loading dose of 1µg/kg for 10 min, followed by a maintenance dose of 0.5µg/kg/h until the end of surgery.
16252829|NCT05005715|Placebo Comparator|Control group|After the induction of anesthesia, the control group received intravenous normal saline at the same loading volume for 10 min, followed by the same volume until the end of surgery.
16252830|NCT05005702|Experimental|study group|Patients were assigned to inspiratory muscle training (IMT) for 6 weeks. During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training. The inspiratory load was set at 40% of maximal inspiratory pressure. The training session was supervised at the hospital.
16252831|NCT05005689|Active Comparator|Mouthwash|Fluoride mouthwash (0.05%; 225ppm) 10ml for 1 minute daily
16252832|NCT05005689|Experimental|Tooth Mousse|"Tooth Mousse Plus (Recaldent™ CPP-ACP [casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)] and Sodium Fluoride 0.2% w/w; 900 ppm).
~Tooth creme; 2ml smear daily"
16252833|NCT05005676|Experimental|adductor pollicis AP|Measurement site: M.adductor pollicis of both arms.
16252834|NCT05005676|Experimental|Corrugator supercilii CS|Measurement site: M. corrugator supercilii at both sides
16252835|NCT05005663|Active Comparator|group A|patients younger than 2 years
16252836|NCT05005663|Active Comparator|group B|patients older than 2 years
16252837|NCT05005637|Experimental|Anti Tuberculosis Therapy|"Dosage form: ATT fixed-dose combination (FDC). FDC intensive phase containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), while FDC continuation phase containing rifampicin-isoniazid.
~Dosage: according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets.
~Frequency: Intensive phase: once daily. Continuation phase: 3 times/week. Duration: 6 months (2 months of FDC intensive phase + 4 months of FDC continuation phase)"
16252838|NCT05005637|Active Comparator|Oral Steroid|Dosage form: Oral prednisone Dosage: 1 mg/kgBW/day (max 60 mg/day) Duration: until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
16252839|NCT05005624||Validation group 1 (VG-1)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.1 logMAR (Snellen 20/25)
16252840|NCT05005624||Validation group 2 (VG-2)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.4 logMAR (Snellen 20/50)
16252841|NCT05005624||Validation group 3 (VG-3)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.7 logMAR (Snellen 20/100)
16252842|NCT05005611|Placebo Comparator|Placebo|
16252843|NCT05005611|Experimental|Probiotics-1|
16252844|NCT05005611|Experimental|Probiotics-2|
16252845|NCT05005611|Experimental|Probiotics-3|
16252846|NCT05005598||pediatric population|pediatric population of CHU of Nancy, France.
16252847|NCT05005585|Experimental|vestibuler socket therapy|immediate implant placement in esthatic zone with final crown placement after 2 months with VST technique
16252848|NCT05005585|Experimental|contour augmentation|Early implant placement in esthatic zone with contour augmentation and final crown after 3 months of implant placement
16252849|NCT05005572|Experimental|Treatment|
16252850|NCT05005572|No Intervention|Control|
16252851|NCT05005559|Experimental|Vaccine candidate|
16252852|NCT05005559|Placebo Comparator|Saline placebo|
16252853|NCT05005546|Experimental|Experimental: Yoga|
16252854|NCT05005546|Experimental|Experimental: Laughter Yoga|
16252855|NCT05005546|No Intervention|Control|
16252856|NCT05005533||Mild and Moderate Severe Group|Individuals with Chronic Obstructive Pulmonary Disease with a Forced Expiratory Volume greater than 50% of the expected value
16252857|NCT05005533||Severe and Very Severe Group|Individuals with Chronic Obstructive Pulmonary Disease whose Forced Expiratory Volume is less than 50% of the expected value
16252858|NCT05005520|Active Comparator|Active Comparator: Single ascending dose DTRI-031|Drug: DTRI-031 Single doses of DTRI-031 delivered via intravenous injection. Ascending dose levels will be evaluated.
16252859|NCT05005520|Placebo Comparator|Placebo Comparator: Single Dose Placebo|Drug: Placebo Single doses of placebo delivered via intravenous injection, matched to DTRI-031 cohorts
16252860|NCT05005507|Experimental|Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks for 24 weeks plus NA treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly for 24 weeks.
16252861|NCT05005507|Experimental|Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil, or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from Week 12 till Week 24.
16252862|NCT05005507|Experimental|Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from baseline till Week 12.
16252863|NCT05005494|Active Comparator|Magnesium sulfate IV|10 patients scheduled for thyroidectomy
16252864|NCT05005494|Placebo Comparator|Placebo|10 patients scheduled for thyroidectomy
16252865|NCT05005468|Experimental|Camrelizumab Combined With Famitinib|Drug: Camrelizumab Drug: Famitinib
16252866|NCT05005468|No Intervention|Observation|Observation
16252867|NCT05005455|Active Comparator|bevacizumab with old manufacturing process.|
16252868|NCT05005455|Experimental|bevacizumab with new manufacturing process.|
16252870|NCT05005429|Experimental|Experimental: Bintrafusp alfa (M7824)|"Bintrafusp alfa (M7824): 1200mg, over 60 minutes IV infusion The treatment will start within 1-5 days from enrollment. The treatment will be administered at day 1 of 14-day intervals .
~Treatment will be administered until unacceptable toxicity, loss of clinical benefit, disease progression or completion of 2 years of therapy. If the patient has benefit after 2 years, the trial chair and the sponsor must be consulted to evaluate how to continue with the treatment."
16252871|NCT05005416|Experimental|GOALS Intervention|The experimental arm is an 8-week cognitive-behavioral based physical therapy (PT) intervention for chronic spine pain. The manualized intervention utilizes a hybrid tele-rehabilitation delivery model. GOALS comprises an initial in-person evaluation (60 min) by a research physical therapist, followed by 6 remote treatment sessions (30-45 min each) conducted by the same physical therapist once a week by telephone. A second in-person evaluation is conducted at the midpoint of the GOALS intervention to assess progress and advance the participant's home exercise program.
16252872|NCT05005416|Active Comparator|Usual Care Physical Therapy|The control arm is Usual Care physical therapy (PT) at a local Federally Qualified Health Center (FQHC), which offers PT services at 4 outpatient clinics across San Diego county. Participants in the Usual Care group attend an initial PT evaluation at a FQHC Physical Rehabilitation Clinic. The frequency and type of PT intervention are then determined by the treating physical therapist in accordance with standard clinical practice at the FQHC.
16252873|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514|Participants will receive ABBV-514.
16252874|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514 + Pembrolizumab|Participants will receive ABBV-514 in combination with pembrolizumab.
16252875|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion.
16252876|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Pembrolizumab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with pembrolizumab
16252877|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Budigalimab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with budigalimab.
16252878|NCT05005390|Experimental|Group A (TTIP ventilation then mask ventilation )|Subjects will first be ventilated with the TTIP technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1).Subjects will then be ventilated with mask ventilation (Step 2).In Step 1, if ventilation fails with the TTIP technique for all of the first three consecutive breaths, the subject will be crossed over to the mask ventilation. If ventilation fails again with all the first three consecutive breaths after crossover,the study will be terminated.The routine care is resumed including tracheal intubation or laryngeal mask airway (LMA) insertion.
16252879|NCT05005390|Active Comparator|Group B (mask ventilation, then TTIP ventilation)|Subjects will first be ventilated with the mask technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1).Subjects will then be ventilated with TTIP technique (Step 2).In Step 1, if ventilation fails for all of the first three consecutive breaths, the subject will be crossed over to the TTIP ventilation. If ventilation fails again with all the first three consecutive breaths after crossover,the study will be terminated.The routine care is resumed including tracheal intubation or LMA insertion.
16252880|NCT05005377|Experimental|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
16252881|NCT05005377|Experimental|Socket Preservation with Freeze-Dried Bone Allograft|the extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
16252886|NCT05005325|Active Comparator|Experimental group(Male)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
16252887|NCT05005325|Experimental|Experimental group(Female)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
16252890|NCT05005299|Experimental|Dose Level A|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose: 600mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
16252891|NCT05005299|Experimental|Dose Level B|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 to -6 (total venetoclax dose: 1100mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
16252892|NCT05005299|Experimental|Dose Level C|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on day -8 to -6 (total venetoclax dose: 2500mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
16252893|NCT05005299|Experimental|Dose Level B'|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose: 1900mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
16252894|NCT05005286||Group A|Lactating women with vaginal infection during pregnancy as confirmed by past medical records
16252895|NCT05005286||Group B|Lactating women without any vaginal infection during pregnancy
16252896|NCT05005273|Experimental|Part 1|
16252897|NCT05005273|Experimental|Part 2: Arm A|
16252898|NCT05005273|Experimental|Part 2: Arm B|
16252899|NCT05005260|Active Comparator|liposomal bupivacaine single-shot interscalene blockade|Subjects will receive a preoperative single-injection interscalene nerve block with long-acting numbing medicine, liposomal bupivacaine
16252900|NCT05005260|Active Comparator|continuous interscalene nerve blockade|Subjects will receive a preoperative interscalene nerve block with a continuous catheter device which provides local anesthetic, bupivacaine, for up to 3 days.
16252901|NCT05005247|Experimental|GBS-NN/NN2|Single dose 0.5 millilitre (mL) intramuscular injection of GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
16252902|NCT05005234|Experimental|GFH925|"Phase I Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design.
~Phase I Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently.
~Phase 2 Subjects with advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy."
16252903|NCT05005221|Active Comparator|Unidirectional Text Reminders|"Participants in the unidirectional text reminder arm will receive automated text messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection.
~N=15"
16252904|NCT05005221|Experimental|Bidirectional Text Communication|"Participants in the bidirectional text communication arm will also receive automated messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection but they will be asked to confirm the planned day or reschedule. On the day of sample collection participants will also reply with the time the samples are collected to trigger future reminder messages for each of the 4 samples.
~N=30"
16252905|NCT05005208|Experimental|Rehabilitation Group|PD subjects will be going through a rehabilitation program based on an Irish dance with the support of the technological platform SI-ROBOTICS
16252906|NCT05005195|Other|Abdominal CT Scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer.
16252907|NCT05005182|Experimental|Cohort A (luspatercept)|Patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
16252908|NCT05005182|Experimental|Cohort A (luspatercept, hydroxyurea)|Patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
16252909|NCT05005169|Experimental|intrapartum streptococcal B detection by PCR|The automatons will be installed by the laboratory in the delivery rooms and used delocalized by the obstetrical teams. Verification and validation of results will be ensured by the microbiology laboratory team, according to the recommendations and procedures already in use for off-site biology.
16252910|NCT05005169|Active Comparator|"intrapartum streptococcal B detection by SGB culture strategy"|
16252912|NCT05005156|Placebo Comparator|Placebo for Ad5-nCoV vaccine|one dose of placebo for Ad5-nCoV vaccine
16252913|NCT05005143||Paroxysmal AF ablation|Patients with standard indications to paroxysmal AF ablation
16252914|NCT05005130|Experimental|TASKPEN|a package of integrated HIV/NCD services
16252915|NCT05005117|Experimental|Laparoscopic operation|Laparoscopic emergency colon resection
16252916|NCT05005117|Active Comparator|Open operation|Open emergency colon resection
16252917|NCT05005091|Active Comparator|oral carbohydrate|the patients drunk oral carbohydrate two hours ago preoperatively
16252918|NCT05005091|No Intervention|no oral carbohydrate|the patients did not drink oral carbohydrate preoperatively
16252919|NCT05005078|Placebo Comparator|Placebo|WST-057 Matching placebo
16252920|NCT05005078|Experimental|WST-057 active|WST-057 topical solution
16252921|NCT05005065|Experimental|Treatment AB|Participants will be randomized to receive IN-C005 Y mg (Treatment A) and IN-A001 Y mg (Treatment B) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
16252922|NCT05005065|Experimental|Treatment BA|Participants will be randomized to receive IN-A001 Y mg and IN-C005 Y mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
16252923|NCT05005065|Experimental|Treatment CD|Participants will be randomized to receive IN-C005 Z mg (Treatment C) and IN-C005 X mg (Treatment D) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
16252924|NCT05005065|Experimental|Treatment DC|Participants will be randomized to receive IN-C005 X mg and IN-C005 Z mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
16252925|NCT05005052|Experimental|Sulodexide arm|Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks
16252926|NCT05005052|Placebo Comparator|Placebo arm|Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks
16252927|NCT05005039||Obese postmenopausal women who will undergo RYGB|
16252928|NCT05005039||Obese postmenopausal women who will undergo SG|
16252931|NCT05005013|Experimental|Active tDCS + Mindfulness|
16252932|NCT05005013|Sham Comparator|Sham tDCS + Mindfulness|
16252933|NCT05005000|Experimental|MFAT|
16252934|NCT05005000|Active Comparator|Steroid (Control)|
16252935|NCT05004987|Active Comparator|Escitalopram (ESC)|
16252936|NCT05004987|Placebo Comparator|Placebo (PBO)|
16252937|NCT05004974|Experimental|Sintilimab with Pemigatinib|Sintilimab combined with Pemigatinib every 3 weeks (Q3W): Sintilimab is administered every 3 weeks (200mg, IV), Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
16252938|NCT05004948|Active Comparator|Resistance exercise group|This group has conducted a resistance exercise program (50-60% of 1RM, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
16252939|NCT05004948|Active Comparator|Aerobic exercise program|This group has conducted an aerobic exercise program ( 50-70% maxHR, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
16252940|NCT05004948|No Intervention|Metformin group|This group received only metformin without any exercise intervention.
16252941|NCT05004935|Experimental|beetroot juice|single intake of beetroot juice containing 800mg nitrates
16252942|NCT05004935|Active Comparator|nitrates|single intake of 800mg nitrates (NaNO3)
16252943|NCT05004922||ICSI in upper cavity|Embryo transfer into the upper cavity
16252944|NCT05004922||ICSI in midcavity|Embryo transfer into the midcavity
16252945|NCT05004909|Active Comparator|1 Fingertip Unit 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
16252946|NCT05004909|Experimental|2 Fingertip Units 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
16252949|NCT05004883|Experimental|Regulation of Cues Enhanced Treatment|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning, and it will be combined with aspects of BWL to capitalize on the strengths of both treatments.
16252950|NCT05004883|Active Comparator|Behavioral Weight Loss|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
16252951|NCT05004883|Active Comparator|Nutrition, Stress Management, and Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
16252952|NCT05004870|Experimental|Women with a known history of submucosal fibroids (that have not been surgically removed)|
16268206|NCT04898322|Placebo Comparator|Placebo|
16252955|NCT05004818|Sham Comparator|sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
16252956|NCT05004818|Experimental|GVS stimulation coupled with inverse phase rotatory chair stimulation|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. The rotatory chair was activated in sinusoidal harmonic acceleration protocol in inverse phase to galvanic vestibular stimulation.
16252957|NCT05004805|Experimental|Methylene blue Arm|The intervention is carried out in addition to the standard treatment. Administered Intervention is topical application of 0.02% Methylene blue solution in the form of repeated nasopharyngeal irrigation. The investigational drug is equipped with a spray nozzle to perform three administrations into both lower nasal passages. After three administrations on each side, it is recommended to take a deep breath so that the injected solution is distributed along the nasopharynx and oropharynx every 4 hours (5-6 times a day with a break for sleep). Duration is the period of stay of the subject, as long as there is no need for non-invasive or invasive mechanical ventilation. If the subject refuses further treatment in a hospital but does not withdraw consent to participate in the study, they should continue to take study drug after discharge from hospital, but not later than the date of the follow-up visit.
16252958|NCT05004805|Placebo Comparator|Saline solution Arm|The intervention is carried out in addition to the standard treatment. Adminestered Intervention is saline solution in the form of repeated nasopharyngeal irrigation. Dosage form, dosage, frequency and duration of intervention are the same.
16252959|NCT05004792|Active Comparator|Intervention|Access to DermLoop Learn IT platform
16252960|NCT05004792|No Intervention|Control group|No access to DermLoop Learn
16252961|NCT05004779|Experimental|human stem cell media apply lesion|human media apply after non ablative laser treatment
16252962|NCT05004779|Sham Comparator|control condition lesion|normal saline apply after non ablative laser treatment
16252963|NCT05004766|Experimental|virtual reality apply|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
16252964|NCT05004766|No Intervention|control condition|Each patient participated in the control condition, during which he or she performed RAGT with no distraction for the same amount of time spent doing therapy in VR.
16252965|NCT05004753|Experimental|Artemisinin 500mg|The dose regimen will be in cycles. In a cycle a subject will receive Artemisinin 500 mg capsule once daily plus SOC on Day 1 to Day 5 followed by 5 days off (no dosing of Artemisinin) or SOC alone. A subject can have a total of consecutive 3 cycles maximum. Here SOC is Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division)
16252966|NCT05004753|Active Comparator|Standard of Care|Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Mild Patients: HYDROXYCHLOROQUINE Moderate Patients: Dexamethasone - OD for 05
16252967|NCT05004740||Lactating birthing persons delivering at Sinai Health System or from the general population|
16252971|NCT05004714||Head Start Staff|Head Start staff including teachers, family advocates, directors, and others
16252972|NCT05004714||Head Start Children with Asthma|Children enrolled in Head Start program with physician diagnosed asthma
16252975|NCT05004675|Experimental|lerodalcibep|300 mg SC dosed monthly
16252976|NCT05004675|Active Comparator|inclisiran|284 mg SC dosed Day 1 and Day 90
16252979|NCT05004636|No Intervention|No_Mg|Ctrl Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will not receive Mg (the intervention) in the block; instead they will receive 0.3mL of sterile saline.
16252980|NCT05004636|Experimental|Mg|Treatment Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will receive 150 mg Mg (0.3 mL-the intervention) in the block.
16252981|NCT05004623|Other|Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device. Lymph node dissection in each hemipelvis should be performed as standard if no sentinel lymph node is detected. Decision of proceeding with complementary lymph node dissection after sentinel lymph node detection is a surgeon decision, according to his/her usual practice.
16252982|NCT05004610|No Intervention|standard of care|Patients will receive the standard of care infusion (balanced crystalloids)
16252983|NCT05004610|Experimental|treatement group|half molar sodium lactate infusion 15 µmol/Kg/min
16253082|NCT05003882||Arm I|Commercially available, orally ingestible CBD product I
16252984|NCT05004597|Experimental|infants longitudinally received three dimensional photo|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months
16252985|NCT05004584|Experimental|Wheat home-based|
16252986|NCT05004584|Experimental|Rye home-based|
16252987|NCT05004584|Experimental|Rye clinic-based|
16252988|NCT05004584|Experimental|Wheat clinic-based|
16252989|NCT05004584|Experimental|Wheat/Rye clinic-based with blood sampling|
16252990|NCT05004571|Placebo Comparator|Placebo|"Matched placebo control 10 mg capsules or 20 mg capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once orally to placebo subjects in the SAD portion of the study.
~10 mg capsules or 20 mg capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once daily for 14 days orally to placebo subjects in the SAD portion of the study."
16252991|NCT05004571|Experimental|Study drug EQU-001|"10 mg capsules or 20 mg EQU-001 capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once orally to active-treatment subjects in the SAD portion of the study.
~10 mg capsules or 20 mg EQU-001 capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once daily for 14 days orally to active treatment subjects in the SAD portion of the study."
16252992|NCT05004558|Experimental|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
16252993|NCT05004545|Experimental|group 1 Profol Infusion to CABG patients to check lactate level|Propofol infusion according to bodyweight will be given to check lactate level on CPB
16252994|NCT05004545|Active Comparator|sevoflurane will be given to group 2 to check lacate level|Sevoflurane MAC % will be given to CABG patients to check lactate level
16252995|NCT05004519|Experimental|Opioid free anesthesia|"Dexmedetomidine 0,5 microgrammes/kg of ideal body weight (IBW) + magnesium 40 mg/kg of total body weight (TBW) in 10 minutes
~Dexmedetomidine 0,4- 0,8 microgrammes/kg of IBW/h;Lidocaine 2% 49ml+ Ketamine 50mg: 1ml/10kg of IBW/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ KgTBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;dexmedetomidine: 0,4-0,8 microgramme/kg/h;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence
~Stop dexmedetomidine;Stop sevorane;1 ml of NaCL 0,9%;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Lidocaïne 2% 49ml + Ketamine 50 mg: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
16252996|NCT05004519|Experimental|Multimodal anesthesia|"magnesium 40 mg/kg of total body weight (TBW) in 10 minutes
~Remifentanil 0,2-0,4 microgrammes/kg/min of ideal body weight; Saline 0,9%: Infusion at 1ml/10kg of ideal body weight/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ Kg TBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;remifentanil 0,2-0,4 microgrammes/kg/min;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence
~Stop remifentanil;Stop sevorane;1 ml of morphine 10mg/ml;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Salne 50ml: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
16252997|NCT05004506|Experimental|Group A|"Group A patients will receive their treatment at the completion of the case while under general anesthesia. The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
~Group A patients will receive placebo intra-articular and arthroscopic portal site saline injections equal in volume and procedure time point as the treatment in Group B.
~At the completion of the case, the patient will be extubated and transferred to the PACU."
16252998|NCT05004506|Active Comparator|Group B|"Group B will receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection. At the completion of the arthroscopic procedure the patient will receive an additional 20ccs of 0.5% marcaine with epinephrine intra-articular injection.
~Group B patients will also receive 10ccs of 2% lidocaine with epinephrine injected superficially into each of the arthroscopic portal sites. Group B patients will receive a 15cc saline injection around the saphenous nerve under the same procedure as the adductor canal block for Group A.
~At the completion of the case, the patient will be extubated and transferred to the PACU."
16252999|NCT05004493||Plasma arm|Patients receiving plasma as one of the main replacement fluids
16253000|NCT05004493||No Plasma|Patients receiving saline and/or 5% albumin as the replacement fluid.
16253001|NCT05004480|Experimental|Surgical Mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill while wearing surgical mask
16253002|NCT05004480|Experimental|Non mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill without wearing surgical mask
16253003|NCT05004467|Experimental|Mobilization with movement technique|"The therapist applies supported pressure on right and left side and articular planes. Meanwhile, the patient executes active movements and the therapist is trying to find the specifies cervical joint to get partial or total painful relief or movements with restrictions.
~If the therapist couldn´t relief or remove pain or restriction with the pressure permorfem, he will readjust pressure and slide in differents planes of motion. It is necessary achieve that aim.
~After that, the patient stay in sit down raised position on a stool, with his back in contact with the wall.
~Hip, knee and ankle of the patient suppor a certain position: 90º of flexion which will be checked with a conventional goniometer. His hands are on the thighs. The treatment lasts 5 minutes."
16253004|NCT05004467|Sham Comparator|Placebo technique|Placebo manual technique is performed similar to experimental group technique but no slides are performed. The therapist simply embraces cervical region with boths hands, avoiding any pressure or any painfully caoture.
16253005|NCT05004454|Experimental|Bacillus subtilis BS50|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
16253006|NCT05004454|Placebo Comparator|Placebo|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
16253083|NCT05003882||Arm J|Commercially available, orally ingestible CBD product J
16253084|NCT05003882||Arm K|Commercially available, orally ingestible CBD product K
16253007|NCT05004441|Experimental|First-line treatment|"First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for twelve cycles.
~Maintenance treatment: Fruquintinib and Capecitabine"
16253008|NCT05004428||Type 2 Diabetes Mellitus patients with Chronic Kidney Disease|Canadian patients medical history data will be collected retrospectively.
16253009|NCT05004415|Experimental|AT-527 550 mg (R07496998)|
16253010|NCT05004402||Primiparous women|Primiparous women after vaginal delivery
16253011|NCT05004389||Acute Stroke|Persons ≥18 years of age with acute (≤3 days) ischemic or intracerebral hemorrhagic stroke.
16253012|NCT05004376|No Intervention|Non-adherent control|Control subjects will receive no text intervention and a 150 day follow-up phone call.
16253013|NCT05004376|Experimental|Non-adherent intervention|Intervention subjects will receive the text messaging intervention and a 150 day follow-up phone call.
16253014|NCT05004363|Active Comparator|Lokelma|Lokelma therapy
16253015|NCT05004363|Placebo Comparator|Control|Placebo
16253016|NCT05004350|Experimental|Encorafenib and cetuximab|"Safety Lead-in (SLI) phase:
~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly
~Randomized (Phase II) phase:
~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
16253017|NCT05004350|Experimental|Irinotecan and cetuximab or FOLFIRI and cetuximab|"Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles.
~Irinotecan and cetuximab:
~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and
~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly
~OR
~FOLFIRI and cetuximab:
~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks
~Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks
~5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and
~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
16253018|NCT05004324|Experimental|Furestem-AD Inj.|"Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
~baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).
~After 12 weeks, Experimental group will receive placebo."
16253019|NCT05004324|Placebo Comparator|Placebo|"Placebo
~baseline (0week) Placebo comparator group will receive placebo.
~After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL)."
16253020|NCT05004311|Experimental|Group A (severe renal function impairment)|Eight (8) participants with severe renal impairment.
16253021|NCT05004311|Experimental|Group B (healthy)|Eight (8) control participants, matched to the 8 severe renal impaired participants enrolled in Group A.
16253022|NCT05004298|Other|Animal assisted terapy|The program structure will aim to influence the 6 specific factors, described in the Multifactorial Model of Positive Mental Health of Dr. Lluch, which are: F1-Personal Satisfaction, F2-Prosocial Attitude, F3-Self-control, F4-Autonomy, F5- Problem Solving and Self-actualization and F6 Interpersonal Relationship Skills. For this reason, direct contact exercises with the dog will be designed and defined to work on them.
16253023|NCT05004285|Other|MRI / [F-18]Florastamin|MRI and [F-18]Florastamin PET/CT are performed for each subject.
16253024|NCT05004272|Active Comparator|Massage|
16253025|NCT05004272|Active Comparator|Gymnastics|
16253026|NCT05004272|Placebo Comparator|Lecture|
16253027|NCT05004259|Experimental|Arm 1|Six weekly doses of subcutaneous daratumumab 1,800mg and hyaluronidase 30,000U.
16253028|NCT05004233|Experimental|Ischemic stroke patients|Patients hospitalized for an ischemic stroke.
16253029|NCT05004220||Group 1|Group 1 consists of first time donors undergoing all 8 tracked plasmaphereses.
16253030|NCT05004220||Group 2|Group 2 consists of first time donors undergoing only last 4 plasmaphereses, serving as control for the first 4 donations.
16253031|NCT05004194|Experimental|Cold water caloric stimulation|50 cc of ice-cold water irrigation into the right ear at 1-2 cc/second, once per participant.
16253032|NCT05004181|Experimental|Part A - Cohort 1: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
16253033|NCT05004181|Experimental|Part A - Cohort 2: 18 to 55 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
16253034|NCT05004181|Experimental|Part A - Cohort 3: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7) of 30 µg.
16253035|NCT05004181|Experimental|Part A - Cohort 4: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
16253036|NCT05004181|Experimental|Part A - Cohort 5: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 of 30 µg.
16253037|NCT05004181|Experimental|Part A - Cohort 6: 18 to 55 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
16253038|NCT05004181|Experimental|Part B - Cohort 1: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
16253039|NCT05004181|Experimental|Part B - Cohort 4: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
16253040|NCT05004181|Experimental|Part B - Cohort 6: 18 to 85 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
16253041|NCT05004168|Experimental|SPF evaluation|Healthy male or female subjects with Fitzpatrick Skin Type of II-IV were included in the SPF study
16253042|NCT05004142|Experimental|FCN-437c with Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
16253043|NCT05004142|Experimental|FCN-437c in combination with Letrozole + Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
16253044|NCT05004129|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
16253085|NCT05003882||Arm L|Commercially available, orally ingestible CBD product L
16253045|NCT05004116|Experimental|Repotrectinib|"Phase 1:
~Part A (patients 12-25 years old, >50kg): TPX-0005 (Repotrectinib) will be given orally (without regard to food) once daily for 14 days, then increased to twice daily for remainder of cycles and concurrently administered with chemotherapy backbone described below. Approximately 4-24 pediatric subjects will be enrolled into 2-4 dose levels (pending if DL-1 or DL-1b are utilized), with maximum of 6 subjects per dose level according to the 'rolling 6' design. Starting dose of TPX-0005 (Repotrectinib) will begin at dose level (DL) 1. Part B (combination therapy; patients less than 12 years old or ≤ 50kg): For 6 additional patients, a safety run-in will be conducted with TPX-0005 (Repotrectinib) and chemotherapy."
16253046|NCT05004103|Experimental|Skin microbiome evaluation|Female healthy volunteers applied cosmetic products (cleanser and moisturizer cream), the diversity of skin microbiome will be examined before and after using the products
16253047|NCT05004090||children with ND|children with neurodevelopmental disabilities (ND) age between 3 and 24 months (chronologically or corrected in the case of children born preterm).
16253048|NCT05004090||Typical developed children (TD)|children with typical development age between 3 and 24 months (chronological).
16253049|NCT05004077|Active Comparator|Conventional amiodarone dosing regimen (CDR)|Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
16253050|NCT05004077|Active Comparator|Repeated amiodarone bolus dosing regimen (RBDR)|Initial amiodarone bolus of 150 mg IV over 10 minutes, then 1.0 mg/min IV amiodarone infusion for 6 hours, then a 0.5 mg/min IV amiodarone infusion for 18 hours, followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. In addition, patients in the RBDR will receive an additional 150 mg IV amiodarone bolus whenever the patient develops tachycardia (Heart Rate (HR) = 110 beats per minute) lasting more than 10 minutes. This bolus may be repeated up to a total of 5 times (6 total boluses) over the first 24 hours. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
16253051|NCT05004064|Experimental|Acalabrutinib and rituximab|Patients with untreated mantle cell lymphoma will receive acalabrutinib and rituximab for up to six cycles. Each cycle will comprise of acalabrutinib 100mg twice daily orally for 28 days and rituximab 375mg/m2 IV on day 1 (+/1 3 days) of every cycle.
16253052|NCT05004051||Patients who are booked for and then subsequently have undergone endovascular repair.|
16253053|NCT05004051||Patients with infrarenal AA without indications for repair undergoing serial monitoring|
16253054|NCT05004038|Active Comparator|Early Group|We will conduct a randomized, double-blind trial using a stepped-wedge design and involving a total of 60 patients with stable treated HIV and suppressed viral load who will all receive the BCG vaccine during the course of the study. Patients will be divided into two groups of equal size (early and late groups regarding administration of the BCG verum). The trial will be placebo-controlled and double-blind. Patients in the early group will receive the BCG verum at the beginning of Treatment Phase 1, and then the placebo at the beginning of Treatment Phase 2.
16253055|NCT05004038|Active Comparator|Late Group|Patients in the late group will receive placebo at the beginning of Treatment Phase 1 and then the BCG verum at the beginning of Treatment Phase 2.
16253056|NCT05004025|Experimental|TTF Plus Chemotherapy|Novacure Optune with Opdivo and Yervoy
16253057|NCT05004012|Other|Control|No diagnosis of gastroparesis, functional dyspepsia, or prior G-POEM
16253058|NCT05004012|Other|Gastroparesis|Patients with a diagnosis of gastroparesis meeting the inclusion criteria
16253059|NCT05004012|Other|Functional Dyspepsia|Patients with a diagnosis of functional dyspepsia meeting the inclusion criteria
16253060|NCT05004012|Other|G-POEM|Patients who received a G-POEM procedure meeting the inclusion criteria
16253061|NCT05003999|Experimental|Intermittent catheterization starting with a hydrophilic catheter (HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter i.e. SpeediCath ® (Coloplast A/S, Humlebæk, Denmark)
16253062|NCT05003999|Active Comparator|Intermittent catheterization starting with a non-hydrophilic catheter (non-HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter i.e. Self-Cath ® (Coloplast A/S, Humlebæk, Denmark); Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
16253063|NCT05003986|Experimental|Population 1: FSGS and/or MCD|Subjects with selected proteinuric glomerular diseases associated with FSGS and MCD histological patterns
16253064|NCT05003986|Experimental|Population 2: IgAN, IgAV, or AS|Subjects with biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or subjects with Alport syndrome (AS)
16253065|NCT05003973|Experimental|home-based anti-resistance exercise|
16253066|NCT05003973|Experimental|usually care|
16253067|NCT05003960|Experimental|Treatment Group|One intravenous infusion of 100 million cells
16253068|NCT05003947|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16253069|NCT05003934|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16253070|NCT05003921|Experimental|Treatment Group|three intrathecal injections of 50 million cells at two-month intervals.
16253071|NCT05003908|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16253074|NCT05003882||Arm A|Commercially available, orally ingestible CBD product A
16253075|NCT05003882||Arm B|Commercially available, orally ingestible CBD product B
16253076|NCT05003882||Arm C|Commercially available, orally ingestible CBD product C
16253077|NCT05003882||Arm D|Commercially available, orally ingestible CBD product D
16253078|NCT05003882||Arm E|Commercially available, orally ingestible CBD product E
16253086|NCT05003882||Arm M|Commercially available, orally ingestible CBD product M
16253087|NCT05003882||Control|Waitlist control
16253088|NCT05003869|Experimental|Intraoperative resection of intrauterine scar tissue by TCRA|Study group: patients took the bladder lithotomy position, routinely disinfected vulva and vagina, and laid sterile towel and sheet.pliers Clamp the front lip of the cervix, explore the depth of the uterine cavity, dilate the cervical canal one by one, place the endoscopy, and examine the uterine cavity.After the scar tissue contracted on one side, the scar tissue was disintegrated at the boundary between the intima and scar tissue. The scar tissue was removed with the annular electrode, and a balloon was placed after surgery to prevent re-adhesion.Complete adhesion release is defined as a return to normal shape of the uterine cavity with bilateral uterine angles exposed.
16253089|NCT05003869|No Intervention|No scar tissue resection group|During the operation, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips with needle-like electrodes, and scar tissue was not excised.
16253090|NCT05003856|Experimental|Treatment (RFA)|Patients undergo ultrasound guided RFA over 1-2 hours.
16253091|NCT05003843|Other|Single Arm|Use of Indigo Aspiration System in patients with obstruction due to DVT
16253092|NCT05003830||AD group|Patients who meet the core clinical diagnostic criteria for Alzheimer's disease as defined by NIA-AA for mild cognitive decline or probable Alzheimer's disease.
16253093|NCT05003830||Healthy control group|Age-matched subjects, who are healthy and have no clinically significant related abnormalities in their physical examinations, laboratory tests, vital signs, or ECG. In addition, no first-degree family history of early-onset AD or other neurodegenerative diseases related to dementia.
16253094|NCT05003817|Experimental|LV-unloading|Participants in the elective unloading (intervention) group will have a percutaneous left ventricular unloading device (pLVAD) inserted at the start of the procedure, before the coronary intervention. Maximal support will be provided throughout the procedure, following which support will be weaned and the device removed should the patient remain haemodynamically stable.
16253095|NCT05003817|No Intervention|Standard of Care|Participants in the control arm will receive the planned high-risk percutaneous coronary intervention as is the current standard of care without elective left ventricular unloading. Alternative mechanical circulatory support devices (such as the intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) will only be permitted in case of complications.
16253102|NCT05003778|Active Comparator|Traditional equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using traditional equipment (i.e., power racks, barbells, dumbbells, etc.)
16253103|NCT05003778|Experimental|Minimal equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.)
16253104|NCT05003778|Experimental|Minimal equipment resistance and endurance training with blood flow restriction|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.) while wearing upper- and lower-body blood-flow restriction cuffs
16253105|NCT05003765|No Intervention|Saline injection (CTRL)|Arm 1- 50 Patients-Control Group (CTRL): No Block (Saline) Post-operatively patients will receive 20 mL of Saline (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
16253106|NCT05003765|Experimental|SPIP Block|Arm 2-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
16253107|NCT05003765|Experimental|SPIP Block + Magnesium|Arm 3-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine + 200mg of magnesium sulfate (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
16253108|NCT05003765|Experimental|SPIP Block + Magnesium + Buprenorphine|Arm 4-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine+ 200mg of magnesium sulfate + buprenorphine (300mcg) (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
16253109|NCT05003739|Experimental|Logica Mirror|Since the trial is not comparative, the only arm implies the use of the investigational device (Logica Mirror femoral stem)
16253110|NCT05003726|Experimental|Non-pharmacological group including KM|Non-pharmacological treatment including Korean medicine will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
16253111|NCT05003726|Active Comparator|Pharmacological group|Pharmacological treatment will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
16253161|NCT05003518|Experimental|Condition 16: Low Personalisation+Low Frequency+Gamification|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
16253112|NCT05003713|Experimental|Part 1: SAD Cohorts A through F CORT125236|Cohorts will receive a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 20-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose level and dose regimen (whether to split the dose) will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT125236 dose from the previous cohort in a fasted or fed state; the dose level, dose regimen, and prandial state will be determined after evaluation of safety and PK data from previous cohorts.
16253113|NCT05003713|Placebo Comparator|Part 1: SAD Cohorts A through F Placebo|Cohorts will receive a single dose of placebo matching CORT125236 lipid capsule formulation by mouth on Day 1. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
16253114|NCT05003713|Experimental|Part 2: MAD Cohorts A through D CORT125236|Cohorts will receive once- or twice-daily doses of CORT125236 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose level, dose schedule, and prandial state for each cohort will be determined after evaluation of safety and PK data from Part 1 and preceding Part 2 cohorts.
16253115|NCT05003713|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT125236 lipid capsule formulation by mouth for 14 days. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
16253116|NCT05003713|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg (20 mg + 5 mg) tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT125236 and the prandial state will be determined after evaluation of safety and PK data from Part 1. Part 3 of the study is optional.
16253117|NCT05003700|Experimental|HAIC(RALOX) plus Lenvatinib and Camrelizumab|Hepatic arterial infusion of oxaliplatin and raltitrexed every 3 weeks. Lenvatinib 8 mg once daily (QD) oral dosing. Camrelizumab 200mg intravenously every 3 weeks.
16253118|NCT05003687|Experimental|Part A: Single Dose of Lu AG06474 or Placebo|Participants will receive single oral dose of Lu AG06474 or placebo.
16253119|NCT05003687|Experimental|Part B: Repeated Dose of Lu AG06474 and Food Interaction|"Participants will receive a single oral dose of Lu AG06474 in each dosing period (Period 1, 2, and 3) in the following sequence:
~Sequence B1: Fed - Fasting- Fasting
~Sequence B2: Fasting- Fed - Fasting
~Sequence B3: Fasting- Fasting - Fed"
16253120|NCT05003674|Experimental|Adults cochlear implant recipients receiving alternative stimulation strategy|ACE strategy, 8 maxima, alternative mode
16253121|NCT05003674|Active Comparator|Adults cochlear implant recipients receiving Standard-of-Care stimulation strategy.|ACE strategy, 8 maxima, monopolar mode.
16253122|NCT05003661|Experimental|Mother's voice|Neonates receive the intervention that recording of mother's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
16253123|NCT05003661|Experimental|Father's voice|Neonates receive the intervention that recording of father's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
16253124|NCT05003661|No Intervention|control group|When the infants undergoing heel puncture procedure, the control group were under routine care. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
16253125|NCT05003648|Placebo Comparator|Placebo|Participants will be on the placebo arm for 2 months and will then cross over to the pramipexole arm for 2 months
16253126|NCT05003648|Active Comparator|Pramipexole|Participants will be on the pramipexole arm for 2 months and will then cross over to the placebo arm for 2 months
16253127|NCT05003635|Active Comparator|AFT+ EVEBRA device (intervention arm)|"Before and after the AFT surgery, patients are required to wear the EVEBRA expansion device for a total duration of 4 weeks. Thereafter patients will receive a PexyBra over the reconstructed breast.
~Pre-operatively patients are required to wear the device for a total of 200 hours."
16253128|NCT05003635|No Intervention|AFT without EVEBRA device (control arm)|Patients will receive the AFT treatment for total reconstruction without the requirement of wearing the EVEBRA device.
16253129|NCT05003622|Experimental|encorafenib|Encorafenib hard capsule will be orally self-administered. A fixed-flat dose of 300 mg (4 x 75 mg) Per Oral (PO) encorafenib will be administered once-daily (QD).
16253132|NCT05003596|Experimental|Steroid Group|Patients receive 21 tablets of 4 mg methylprednisolone to be taken by mouth over a 6 week taper. Patients will be advised to not take other anti-inflammatory medications like NSAIDs.
16253133|NCT05003596|Active Comparator|Control Group|Patients will recieve standard treatment that focuses on mobilization and stabilization using common techniques like buddy taping and splinting. Pain control will be managed using non-NSAID medications like Tylenol or opioid narcotics when deemed medically necessary.
16253134|NCT05003583||Children who stutter|Children who are diagnosed with developmental stuttering.
16253135|NCT05003583||Children who do not stutter|Children who are typically fluent (do not have a diagnosis of stuttering).
16254139|NCT04996693|Other|Scanner 1|Imaging performed on scanner 1: Photon-Counting Detector CT
16253136|NCT05003570|Experimental|Remifentanil|Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).
16253137|NCT05003570|Active Comparator|Fentanyl|Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).
16253138|NCT05003544|Active Comparator|PENG BLOCK ( Group A)|A regional block will be applied while the patient is in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) will initially be placed in a transverse plane on the AIIS and then rotate the probe approximately 45 degrees counterclockwise to align with the pubic ramus. In this view, IPE, iliopsoas muscle and tendon, femoral artery and pectineus muscle will be observed. A 22 gauge, 80 mm needle will be inserted from lateral to medial in an in-plane approach to place the psoas tendon anteriorly and posteriorly in the musculofacial plane between the pubic ramus. Following negative aspiration, a local anesthetic solution (20ml bupivacaine 0.5%) will be injected.
16253139|NCT05003544|Active Comparator|Intra-articular( Group B)|It will be applied to the intra-articular region by the surgeon at the end of the operation. A volume of 90 ml (30 ml of 0.5% bupivacaine and 60 ml of 0.9% NaCl)
16253140|NCT05003544|Active Comparator|Quadratus lumborum block ( Group C)|The patient will be in the lateral position. A low-frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in-plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.5 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
16253141|NCT05003531|Experimental|IBI112 dose 1|Participants will receive IBI112 dose 1 subcutaneous injection(SC)
16253142|NCT05003531|Experimental|IBI112 dose 4|Participants will receive IBI112 dose 4 subcutaneous injection(SC)
16253143|NCT05003531|Experimental|IBI112 dose 2|Participants will receive IBI112 dose 2 subcutaneous injection(SC)
16253144|NCT05003531|Experimental|IBI112 dose 3|Participants will receive IBI112 dose 3 subcutaneous injection(SC)
16253145|NCT05003531|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection(SC)
16253146|NCT05003518|Experimental|Condition 1: Low Personalisation+Low Frequency|The intervention will have low levels of personalisation and one message a day will be sent to participants.
16253147|NCT05003518|Experimental|Condition 2: High Personalisation+Low Frequency|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname) and one message a day will be sent to participants.
16253148|NCT05003518|Experimental|Condition 3: Low Personalisation+High Frequency|The intervention will have low levels of personalisation and three messages a day will be sent to participants.
16253149|NCT05003518|Experimental|Condition 4: High Personalisation+High Frequency|The intervention will have high levels of personalisation and three messages a day will be sent to participants.
16253150|NCT05003518|Experimental|Condition 5: High Personalisation+Low Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
16253151|NCT05003518|Experimental|Condition 6: Low Personalisation+High Frequency+Gamification|The intervention will have low levels of personalisation, contains gamified progress updates, and three messages a day will be sent to participants.
16253152|NCT05003518|Experimental|Condition 7: High Personalisation+High Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and three message a day will be sent to participants.
16253153|NCT05003518|Experimental|Condition 8: Low Personalisation+Low Frequency+Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and one message a day will be sent to participants.
16253154|NCT05003518|Experimental|Condition 9: High Personalisation+Low Frequency+Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and one message a day will be sent to participants.
16253155|NCT05003518|Experimental|Condition 10: Low Personalisation + High Frequency + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and three message a day will be sent to participants.
16253156|NCT05003518|Experimental|Condition 11: High Personalisation + High Frequency + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and three message a day will be sent to participants.
16253157|NCT05003518|Experimental|Condition 12: Low Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
16253158|NCT05003518|Experimental|Condition 13: High Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
16253159|NCT05003518|Experimental|Condition 14: Low Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three message a day.
16253160|NCT05003518|Experimental|Condition 15: High Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three messages a day.
16253162|NCT05003505||Women with cervical cytology (TCT) abnormalities|In the enrollment, women who have undergone cervical cytology (TCT) examination for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months, 12 months and 24 months.
16253163|NCT05003492|Active Comparator|Combination Therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose will be performed.
~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
16253164|NCT05003492|Sham Comparator|Standard Therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
16253165|NCT05003479|Experimental|candidate vaccine|
16253166|NCT05003479|Placebo Comparator|Placebo|
16253167|NCT05003466|Experimental|candidate vaccine|
16253168|NCT05003466|Placebo Comparator|Placebo|
16253169|NCT05003453|Experimental|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2-3 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
16253170|NCT05003453|Placebo Comparator|Placebo comparator|A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2-3 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
16253171|NCT05003440|Experimental|NNC0385-0434 15 mg|15 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
16253172|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 15 mg)|Oral placebo will be administered once-daily over 10 consecutive days
16253173|NCT05003440|Experimental|NNC0385-0434 40 mg|40 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
16253174|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 40 mg)|Oral placebo will be administered once-daily over 10 consecutive days
16253175|NCT05003440|Experimental|NNC0385-0434 100 mg|100 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
16253176|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 100 mg)|Oral placebo will be administered once-daily over 10 consecutive days
16253177|NCT05003427|Experimental|68Ga-FAPI-04 PET/CT|The patients were injected with 55.5-148 MBq (1.5-4mCi) of 68Ga-FAPI-04 in one dose intravenously and underwent SPECT/CT scan 30-90 min later.
16253179|NCT05003388|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
16253180|NCT05003375||Multiple Sclerosis (MS)|People with MS diagnosis, aged 18-55 years, Relapsing Remitting type, EDSS < 6.0, normal vision (if necessary corrected), Dutch speaking.
16253181|NCT05003375||Healthy Controls (HC)|Healthy controls without relevant health conditions (diabetes, thyroid diseases, neurological disorders), non-pregnant, aged 18-55 years, normal vision (if necessary corrected), Dutch speaking.
16253182|NCT05003362|No Intervention|usual care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician.
16253183|NCT05003362|Active Comparator|ACT|An 8-week mindfulness-based group therapy.
16253186|NCT05003336|Experimental|Xiangshao Granules|dissolve 1 sachet (4 g) of Xiangshao Granules in water to be drank 3 times a day after meal for 8 weeks
16253187|NCT05003336|Placebo Comparator|Xiangshao Granules Placebo|dissolve 1 sachet (4 g) of Xiangshao Granules placebo in water to be drank 3 times a day after meal for 8 weeks
16253461|NCT05001347|Experimental|TJ004309 and Atezolizumab|TJ004309 20 mg/kg Q3W in combination with atezolizumab 1200 mg Q3W
16253198|NCT05003297||patients whom were hospitalized for 3 days or less|
16253199|NCT05003297||patients hospitalized for more than 3 days|
16253200|NCT05003284|Experimental|acupressure wristband|On the day before the surgery, the patients in the experimental groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the experimental group patients went to surgery, the PC6 acupressure point was determined for the patients. Immediately after the experimental group patients were taken to the wards after surgery, wristbands were placed on both wrists. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
16253201|NCT05003284|Placebo Comparator|placebo wristband|On the day before the surgery, the patients in the placebo groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the placebo group patients went to surgery, the PC6 acupressure point was determined for the patients. Right after their surgery, patients in the placebo group were fitted with a wristband that looked the same as the acupressure wristband but did not have an acupressure application head. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
16253202|NCT05003271|Experimental|Small group zoom meeting|Group one: will be asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants e.g. questions, perceptions, etc.).
16253203|NCT05003271|Experimental|YouTube pre-recorded video|Group two: will be asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
16253204|NCT05003258|Other|Patients with RVO|Dexamethasone Intravitreal Implant is used in patients with Macular ar edema due to retinal vein occlusion either from the start or after unsatisfactory response to anti - VEGF
16253205|NCT05003245|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
16253206|NCT05003245|Active Comparator|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
16253207|NCT05003232|No Intervention|Control group|
16253208|NCT05003232|Experimental|Optimal MAP group|
16253209|NCT05003219||ERAS group|patients received posterior cervical open-door laminoplasty under ERAS mode
16253210|NCT05003219||Conventional group|patients received posterior cervical open-door laminoplasty under routine perioperative management mode
16253211|NCT05003206|Experimental|PD,DBS|Patients with idiopathic PD before and after DBS surgery
16253212|NCT05003193|Experimental|Using a pedometer|The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
16253213|NCT05003193|No Intervention|Not using a pedometer|The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.
16253214|NCT05003180|Active Comparator|Surgical|"Surgical stabilization with posterior fixation. Brace treatment will not be used postoperative. Early ambulation after surgery is encouraged. Surgery is to be performed within 2 weeks from the injury. The choice of supplier and brand of implants are based on the preference of each participating center.
~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
16253215|NCT05003180|No Intervention|Non-surgical treatment|"No surgical stabilization is performed. Early ambulation after treatment randomization is encouraged. Brace treatment is not required, but a standard three-point hyperextension brace may be offered up to 3 months for pain relief. The choice of supplier and brand of brace are based on the preference of each participating center. The brace will only be used upon mobilization. Brace use will be estimated by the patient at the 3-4 months follow-up.
~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
16253216|NCT05003167|Experimental|Expiratory Muscle Strength Training|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
16253217|NCT05003154|No Intervention|Conventional management group|Received conventional management based on Guidelines for GDM in China
16253218|NCT05003154|Experimental|Digitalized management group|Reveived conventional management and digitalized management
16253219|NCT05003141|Experimental|Single-arm, escalating dose levels|3 + 3 Phase 1 dose escalation design; sequential ascending dose levels.
16253220|NCT05003128|Experimental|LED screen|
16253223|NCT05003102|Experimental|Dexmedetomidine cycling then Standard Pediatric Intensive Care Unit (PICU) sedation protocol|One the first night, participants receive a dexmedetomidine bolus of 0.5 mcg/kg which is then titrated at an increased drip rate of 0.3 mcg/kg/hr until a.) a targeted Richmond Agitation-Sedation Scale (RASS) state that is one level deeper than what was targeted during the day is achieved or b.) infusion is at max drip rate (dexmedetomidine 2 mcg/kg/hr). On the second night, participants receive the standard PICU Sedation Protocol of fentanyl infusion at 1 mcg/kg/hr and dexmedetomidine infusion at 0.3 mcg/kg/hr with no modifications made until goal RASS reached or at max infusion drips achieved (fentanyl 5 mcg/kg/hr and dexmedetomidine 2 mcg/kg/hr).
16253261|NCT05002842|Experimental|Delayed Intervention|Those in the deferred intervention arm will commence the LovingKindness Meditation practice intervention approximately 3 weeks (post 3 -week survey) after enrollment and participate three weeks thereafter.
16268988|NCT04892537|Placebo Comparator|Placebo|Placebo procedure
16253224|NCT05003102|Active Comparator|Standard Pediatric Intensive Care Unit (PICU) sedation protocol then Dexmedetomidine cycling|On the first night, participants will receive the standard PICU Sedation Protocol of fentanyl infusion at 1 mcg/kg/hr and dexmedetomidine infusion at 0.3 mcg/kg/hr with no modifications made until goal RASS reached or at max infusion drips achieved (fentanyl 5 mcg/kg/hr and dexmedetomidine 2 mcg/kg/hr). On the second night, participants receive a dexmedetomidine bolus of 0.5 mcg/kg which is then titrated at an increased drip rate of 0.3 mcg/kg/hr until a.) a targeted Richmond Agitation-Sedation Scale (RASS) state that is one level deeper than what was targeted during the day is achieved or b.) infusion is at max drip rate (dexmedetomidine 2 mcg/kg/hr).
16253225|NCT05003089|Experimental|BAY1834845 arm|BAY1834845 will be administered twice daily for 7 consecutive days (Days 1 - 7).
16253226|NCT05003089|Experimental|BAY1830839 arm|BAY1830839 will be administered twice daily for 7 consecutive days (Days 1 - 7).
16253227|NCT05003089|Active Comparator|Prednisolone arm|Prednisolone will be administered twice daily for 7 consecutive days (Days 1 - 7).
16253228|NCT05003089|Placebo Comparator|Placebo arm|Placebo will be administered twice daily for 7 consecutive days (Days 1 - 7).
16253229|NCT05003076|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
16253230|NCT05003076|Experimental|Methamphetamine Then Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
16253231|NCT05003063|Active Comparator|Donepezil|5mg Donepezil will be administered in pill form.
16253232|NCT05003063|Placebo Comparator|Placebo|5mg placebo will be administered in pill form.
16253233|NCT05003050|Experimental|Meditation Based Group|8 sessions weekly for 8 weeks Each session for 1hour Sessions on line (virtual) Self-care tools and techniques, mindfulness and meditation
16253234|NCT05003050|Experimental|Energy Therapy (Pranic Healing)|8 Sessions Weekly sessions for 8 weeks Each session 1 hour Pranic Healing (Energy Therapy)
16253235|NCT05003050|No Intervention|Stanrd of Care Group|Routine medical care and appointments
16253236|NCT05003037|Experimental|Wild-type Genotype|
16253237|NCT05003037|Experimental|EGFR mutation|
16253238|NCT05003024|Active Comparator|TOF scan train of four ratio monitoring|Recovery of train of four ratio after sugammadex administration
16253239|NCT05003024|Experimental|ITF device tetanus stimulation monitoring|Recovery of tetanus 100 Hz ratio after sugamamdex administration
16253240|NCT05002998|Other|Teprotumumab 4 Infusions|"• 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:
~Placebo if a participant is a treatment responder at Week 12 or
~Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12"
16253241|NCT05002998|Other|Teprotumumab 8 Infusions|8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)
16253242|NCT05002998|Other|Teprotumumab 16 Infusions|16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)
16253243|NCT05002985|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
16253244|NCT05002972|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
16253245|NCT05002959||TESS Anatomic|Subjects who received the Anatomic T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
16253246|NCT05002959||TESS Reverse|Subjects who received the Reverse T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
16253247|NCT05002946|Experimental|A: SP-104 Fasting|Oral administration of SP-104 under fasting conditions
16253248|NCT05002946|Experimental|B: SP-104 Under Fed Conditions|Oral administration of SP-104 under fed conditions
16253249|NCT05002946|Active Comparator|Naltrexone Hydrochloride Tablets Fasting|Oral administration of Naltrexone Hydrochloride Tablets, 50 mg USP under fasting
16253250|NCT05002933|Experimental|Insulin glargine 300 U/ml|Insulin glargine 300 U/ml once daily for 24 weeks. Participants may continue for an additional 12 week extension period or switch to other anti-diabetic treatment, insulin dose will be adjusted according to the recommended dose titration algorithm
16253251|NCT05002920||cleft patients received alveolar bone grafting|alveolar bone grafting was performed when the cleft patients were aged around 9 years old. CBCT was used to analyze the bone mineral density of grafted tissue.
16253252|NCT05002907||General adult population living along the Maroni River in French Guiana and Suriname|General adult population living along the Maroni River in French Guiana and Suriname, upstream from Apatou. All adults (men and women) 18 years or older of both sexes will be able to participate in the study, in French Guiana and Suriname. Participation will be based on volunteering and signing informed consent. The acceptability and diversity of recruitment will be improved by seeking community support through community leaders and local associations and through appropriate communication (radio spots, posters in health centers and public establishments) before the survey .
16253253|NCT05002894|Experimental|exercise group|This group included twenty six post-menopausal women. They will participate in Pilates exercise, medical standard care for fatigue and advices to deal with fatigue. The Pilates exercises consisted of a set of 10 movements: bridging; hundred; roll up; one leg circle (both ways); single straight leg stretch; single leg kick; side kick up and down; side kick circles; rest position (stretch and relaxation); and curling ,women were instructed to perform 30 min per session, 3 sessions per week, for 8 weeks.
16253254|NCT05002894|Experimental|standard care group|Each post-menopausal woman in both groups will receive a medical standard care for post-menopausal fatigue.
16253257|NCT05002868|Experimental|RP12146|RP12146 will be administered orally daily (QD or BID)
16253258|NCT05002855||Enhanced Recovery After Surgery (ERAS)|
16253259|NCT05002855||Conventional Recovery Strategy (pre-ERAS)|
16253260|NCT05002842|Experimental|Immediate Intervention|Those in the immediate intervention arm will begin the LovingKindess Meditation practice upon enrollment.
16253262|NCT05002829|Experimental|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.
~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
16253263|NCT05002829|Active Comparator|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics
~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
16253265|NCT05002803|Experimental|Otago Exercise Program|Older adults will receive the Arabic Otago Exercise Program for 8 weeks plus health awareness videos.
16253266|NCT05002803|No Intervention|Control group|Older adults will receive only health awareness videos every 2 weeks.
16253267|NCT05002790|Experimental|Data collection|All 20 anticipated subjects to be scanned under MRI, with data collected and analysed together
16253268|NCT05002777|Experimental|Rilzabrutinib|Oral rilzabrutinib 400 mg BID
16253269|NCT05002751||Cohort 1|1. Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes (PALN). Pelvic or PALN nodal status confirmed by PET/CT scan or fine needle biopsy or extra peritoneal biopsy or laparoscopic biopsy. The PALN must be inferior to the T12/L1 interspace.
16253270|NCT05002738|Experimental|Overall Cohort|Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days
16253271|NCT05002725|Experimental|PENG|An ultrasound guided PENG catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
16253272|NCT05002725|Active Comparator|Femoral Block|An ultrasound guided Femoral Nerve catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
16253273|NCT05002712|Experimental|Heavy resistance training|Group A
16253274|NCT05002712|Experimental|Contrast strength training|Group B
16253275|NCT05002712|Active Comparator|Elastic resistance training|Group C
16253276|NCT05002686|Experimental|Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection|
16253277|NCT05002673|Experimental|SLEEPERONE|
16253278|NCT05002673|Experimental|COMFORTIN|
16253279|NCT05002660|Experimental|Group 1 (Intervention)|"For Change Club members (CCM) only: CCM will participate in meetings of the Change Club weekly for six months and continue implementation of a change to the community environment for up to an additional 24 months. Change Club members will also be asked to recruit 10 or more friends and family members (FFM) to participate in the research study.
~In addition, 100 community residents (CR) will be recruited into the study. Family members, friends and community residents do not participate in the Change Club, but may hear about Change Club activities in their community."
16253280|NCT05002660|Experimental|Group 2 (Control)|Control group participants will participate in no intervention activities during the 4-year research study.
16253281|NCT05002647||exposure group|Data from electronic clinical pharmacist records of two infectious disease hospitals
16253282|NCT05002647||Non-exposure group A|Data from medical records of the hospital with no clinical pharmacy.
16253283|NCT05002647||Non-exposure group B|Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
16253284|NCT05002634|Experimental|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
16253285|NCT05002608|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
16253286|NCT05002608|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
16253287|NCT05002595||Modified quadruple therapy|pantoprazole 40mg bid, amoxicillin 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 14 days
16253288|NCT05002595||Tailored eradication|pantoprazole 40mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid or pantoprazole 40mg bid, tetracycline 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 7 days
16253289|NCT05002582||patients with hematological diseases|to clarify the intestinal carriage rate of carbapenem-resistant Organisms (CRO) in patients with hematological diseases
16253290|NCT05002569|Experimental|Arm A: Relatlimab + Nivolumab|Combination
16253291|NCT05002569|Experimental|Arm B: Nivolumab|Monotherapy
16253292|NCT05002543||MANTRA Aortic Sub-study|"Subjects diagnosed with aortic valve disease who are considered suitable to undergo aortic valve replacement with a CORCYM device can be included in this study.
~The following devices can be entered in the study:
~Tissue Valve:
~Perceval® PLUS SUTURELESS AORTIC HEART VALVE
~Perceval® S SUTURELESS AORTIC HEART VALVE
~Mechanical Valves:
~Bicarbon™ Bileaflet Heart Valve Prostheses Models:
~Bicarbon Fitline Aortic (LFA)
~Bicarbon Slimline Aortic (LSA)
~Bicarbon Overline Aortic (LOV)
~Carbomedics Prosthetic Heart Valve Models:
~Standard Aortic Valve
~Reduced Aortic Valve
~Supra-Annular Aortic Valve (Top Hat)
~Orbis™ Aortic Valve
~Ascending Aorta Prostheses
~CARBOMEDICS-CARBO-SEAL™
~CARBOMEDICS CARBO-SEAL™ VALSALVA"
16253323|NCT05002270|Experimental|Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-21822 will be administered alone to determine the MTD and RP2D
16253324|NCT05002270|Experimental|Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion|JAB-21822 will be administered alone at RP2D in selected cancer type patients to evaluate the preliminary antitumor activity.
16253611|NCT05000463|Active Comparator|ozone group|Ozone injection under ultrasound guidance in addition to the medical treatment
16253293|NCT05002543||MANTRA Mitral/Tricuspid Sub-study|"Subjects diagnosed with mitral and/or tricuspid valve disease who are considered suitable to undergo mitral valve repair/replacement and/or tricuspid valve repair with a CORCYM device can be included in this study.
~The following devices can be entered in the study:
~Annuloplasty Rings:
~SOVERING™ ANNULOPLASTY DEVICE models
~annuloplasty ring, mitral model
~annuloplasty band, mitral and tricuspid models
~Carbomedics Annuloplasty Ring models:
~CARBOMEDICS ANNULOFLO®
~CARBOMEDICS ANNULOFLEX®
~Memo Annuloplasty Ring o MEMO 3D™ SEMIRIGID ANNULOPLASTY RING
~Mitral Valves:
~Bicarbon™ Bileaflet Heart Valve Prostheses Models:
~o Bicarbon Fitline Mitral (LFM)
~Carbomedics Prosthetic Heart Valve Models:
~Standard Mitral Valve
~Orbis™ Mitral Valve
~OptiForm® Mitral Valve"
16253294|NCT05002543||MANTRA Memo 4D Sub-study|Subjects diagnosed with mitral valve disease who are considered suitable to undergo mitral valve repair with a CORCYM Memo 4D annuloplasty ring can be included in this study.
16253295|NCT05002530|Experimental|Aerosolized All trans retinoic acid|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 3 weeks.
16253296|NCT05002530|Sham Comparator|Placebo/Control|1 vitamin A softgels per day for3 weeks
16253297|NCT05002517|Experimental|Tociliziumab group|Patients assigned to this arm will receive an intravenous dose of tocilizumab. Patients weighing 75 kg or more will receive 600 mg. Those weighing less than 75 kg will receive 400 mg.
16253298|NCT05002517|Active Comparator|Metilprednisolone group|Patients in this arm will receive a daily intravenous dose of 250 mg methylprednisolone for 3 days.
16253299|NCT05002504|Experimental|Patients receiving craniosacral therapy|30 children without previous pathology receiving craniosacral therapy
16253300|NCT05002504|Active Comparator|Patients receiving balance and coordination therapy|31 patients without previous pathology receiving balance and coordination therapy
16253301|NCT05002504|Placebo Comparator|Patients receiving placebo|25 patients without previous pathology receiving placebo
16253302|NCT05002491|Experimental|High protein feeding|Two isocaloric feeding phases of 2 weeks followed by an ad-libitum feeding phase of 3 months
16253303|NCT05002478|Experimental|Prone Group|Turn patient in prone position after surfactant administration. After 6 hours turn patient in supine position and perform EIT and LUS.
16253304|NCT05002478|No Intervention|Supine Group|Leave patient in supine position after surfactant administration. After 6 hours perform EIT and LUS.
16253305|NCT05002452||Locally Advanced HCC Patients|Patients which are diagnosed with locally advanced hepatocellular carcinoma (HCC) will receive standard HAIC treatment.
16253308|NCT05002426||The type and orientation of Rouviere sulcus|"open type, fused type or absent type"
16253309|NCT05002387|Experimental|Unicompartmental OA or equivocal findings in XR|After obtaining informed consent, patients will undergo needle arthroscopy, performed in the operating room prior to undergoing arthroplasty
16253310|NCT05002374|Experimental|Experimental Group|
16253311|NCT05002374|Active Comparator|Control Group|
16253312|NCT05002361|Active Comparator|Treatment A+B|24 mg dexamethasone i.v. perioperatively
16253313|NCT05002361|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively
16253314|NCT05002348|Experimental|Acupoint Laser Group|In the experimental group, the laser pen was turned on, and the acupoint stimulation was performed for about 3-5 minutes. Each acupoint was performed once a day. The patient wore goggles and observed the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
16253315|NCT05002348|No Intervention|control group|In the control group, the laser pen does not turn on the energy. The acupoint stimulation is performed for about 3-5 minutes, and each acupoint is performed once a day. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
16253316|NCT05002322|Experimental|intervention health facilities|Health facilities implement the optimization of the cascade under research team support and continuous supervision
16253317|NCT05002322|No Intervention|Control|Health facilities implement the optimization of the cascade and maintain supervision without research team support
16253318|NCT05002309|Experimental|Psychotherapy|Cognitive-behavioural therapy
16253319|NCT05002309|Experimental|Pharmacotherapy|Antidepressant medication
16253320|NCT05002296|Active Comparator|traditional physical therapy program|
16253321|NCT05002296|Experimental|rotatory upper cervical manipulation to both sides|
16253322|NCT05002283|Experimental|Study group|the patients undergo free gingival graft harvest from the palate using a patient specific guide
16253325|NCT05002270|Experimental|Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion|JAB-21822 will be administered together with Cetuximab in mCRC patients to evaluate the preliminary antitumor activity.
16253326|NCT05002257|Experimental|Experimental Arm|
16253327|NCT05002257|Active Comparator|Control arm|
16253328|NCT05002244|Experimental|Arm A|CTL0801 (Azilsartan) QD, 4days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days
16253329|NCT05002244|Experimental|Arm B|CTL0802 (Rosuvasatin) QD, 7days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days
16253330|NCT05002231|Experimental|Losmapimod 15 mg oral tablet in healthy subjects (Treatment Regimen A)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
16253331|NCT05002231|Experimental|Losmapimod two 7.5 mg oral tablets in healthy subjects (Treatment Regimen B)|Subjects will be randomized to 1 of 6 treatment sequences to receive two 7.5 mg tablets of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
16253332|NCT05002231|Experimental|Losmapimod one 15 mg oral tablet in healthy subjects (Treatment Regimen C)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fed conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before breakfast and will receive a high-fat breakfast approximately 30 minutes before dose administration. Subjects must consume the meal within 25 minutes or less. Washout period of 48 hours between dosing.
16253333|NCT05002218|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
16253334|NCT05002218|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
16253335|NCT05002205||COVID-19|exposed cohort with a diagnosis of COVID-19 in the last 6 months
16253336|NCT05002205||no history of COVID-19|non-exposed cohort without a diagnosis of COVID-19. Tested for COVID-19 because of symptoms at the same time (+/- 1 month) as the exposed cohort.
16253337|NCT05002192||ELP_ONLY|Patients who were diagnosed with community-acquired pneumonia and were treated with Eucalyptol, Limonene and Pinene Enteric Soft Capsules, not treated with other oral mucolytics.
16253338|NCT05002192||EXP_ONLY|Patients diagnosed with community-acquired pneumonia and treated with an oral mucolytic drug other than Eucalyptol, Limonene and Pinene Enteric Soft Capsules.
16253339|NCT05002192||ELP+AMB|Patients diagnosed with community-acquired pneumonia and treated with Eucalyptol, Limonene and Pinene Enteric Soft Capsules and ambroxol injection.
16253340|NCT05002192||EXP+AMB|Patients diagnosed with community-acquired pneumonia and treated with oral mucolytics and ambroxol injection other than Eucalyptol, Limonene and Pinene Enteric Soft Capsules.
16253341|NCT05002192||AMB_ONLY|Patients diagnosed with community-acquired pneumonia and treated with ambroxol injection alone.
16253342|NCT05002179|Experimental|Treatment group|"Treatment group, 3 x 2 Echinaforce chewable tablets (EC, 3x800mg) daily during prevention and 5 x 2 EC (5x800mg) during acute viral Respiratory tract infection vRTIs"
16253343|NCT05002179|No Intervention|Control Group|"No treatment Comparison group. Participants are free to take none or any preventive measure. Participants are requested not to take any Echinacea products"
16253344|NCT05002166||Children aged less than 18 years with a confirmed diagnosis of IBD.|"All patients admitted with inflammatory bowel disease will be subjected to:
~History: including name, age ,sex ,family history, consanguinity, history of rectal bleeding, mucus or blood in the stool, diarrhea, abdominal pain ,vomiting ,nausea and loss of appetite.
~Examination: including general examination, chest, cardiac, abdominal and neurological examination
~Investigation:including labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope."
16253345|NCT05002153|Experimental|Fecal Microbiota Transplantation (FMT)|FMT capsules administration - intervention arm
16253346|NCT05002153|Placebo Comparator|Placebo|Placebo capsules administration
16253347|NCT05002140|Experimental|XRD-0394 40 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
16253348|NCT05002140|Experimental|XRD-0394 80 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
16253349|NCT05002140|Experimental|XRD-0394 160 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
16253350|NCT05002140|Experimental|XRD-0394 (Dose TBD)|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT. A single biopsy will be performed in each subject (either after RT alone or after XRD-0394 and RT).
16253351|NCT05002127|Experimental|Phase 2 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
16253352|NCT05002127|Active Comparator|Phase 2 - Arm B|Trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
16253353|NCT05002127|Experimental|Phase 3 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
16253354|NCT05002127|Active Comparator|Phase 3 - Arm B|Ramucirumab 8 mg/kg Q2W IV and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
16253355|NCT05002114|Placebo Comparator|Placebo Group|Does not get active topical CBD. Instead, gets an identical placebo-containing topical agent.
16253356|NCT05002114|Experimental|Active Group|Does get active topic CBD.
16253357|NCT05002101|Active Comparator|zinc group|The children were randomized to receive daily zinc sulphate. The elemental zinc dose was 3 mg/ day to children whose weight is less than 10 kg and 7 mg/ day to children whose weight is 10 kg or more.
16253358|NCT05002101|Placebo Comparator|placebo group|The placebo was non-nutritious and vitamin-free, designed to be identical to the zinc syrup in colour, odour, consistency and taste. Zinc and placebo syrups were packaged in similar bottles.
16253361|NCT05002075|No Intervention|Usual care arm|Participants in the usual control group will receive standard of care per their providers' discretion.
16253362|NCT05002075|Experimental|m-health cardiac rehabilitation intervention arm|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program
16253363|NCT05002062|Sham Comparator|G1 ( Conventional Physical Therapy Program group)|"Patients in G1 underwent conventional physical therapy program continued for 3 months, included (aerobic training 20 minutes, resistive training for 15 minutes and flexibility program for 15 minutes).
~The whole treatment session lasted from 50 minutes to one hour, 3 times per week for 3 consecutive months."
16253364|NCT05002062|Active Comparator|G2 ( Computer-based Cognitive Therapy group)|"Patients in G2 underwent Computer-based cognitive training continued for 3 months, included (attention/concentration, memory and reaction behavior training).
~The whole treatment session timing lasted 50 minutes to one hour, 3 times per week for 3 consecutive months."
16253365|NCT05002049|Experimental|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the SEEDS project, and participants will be assessed at baseline and end-of-study.
16253366|NCT05002049|No Intervention|Control Group (No intervention)|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
16253367|NCT05002036|Active Comparator|HA-GB|eyedrop containing hyaluronic acid and gingko biloba (Trium eyedrops, Sooft srl)
16253368|NCT05002036|No Intervention|No treatment|no treatment for iatrogenic dry-eye
16253369|NCT05001997|Active Comparator|Diet A - Lactose free probiotic yogurt|Plain flavoured lactose free probiotic yogurt (contains Lactobacillus acidophilus and Bifidobacterium lactis)
16253370|NCT05001997|Placebo Comparator|Diet B - Lactose free yogurt (non-probiotic)|Plain flavoured lactose free yogurt (contains only starter cultures)
16253371|NCT05001984|Active Comparator|Intervention group|In addition to high-intensity statin and antiplatelet treatment, patients will receive treatment of alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks
16253372|NCT05001984|No Intervention|Control group|Patient will have high-intensity statin and antiplatelet treatment.
16253373|NCT05001971|Experimental|Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
16253374|NCT05001958|Experimental|Action observation|
16253375|NCT05001945|Placebo Comparator|Placebo|Placebo tablet(s) by mouth once or twice daily.
16253376|NCT05001945|Experimental|Dose 1|MLS-101 tablet(s) by mouth once or twice daily.
16253377|NCT05001945|Experimental|Dose 2|MLS-101 tablet(s) by mouth once or twice daily.
16253378|NCT05001945|Experimental|Dose 3|MLS-101 tablet(s) by mouth once or twice daily.
16253379|NCT05001945|Experimental|Dose 4|MLS-101 tablet(s) by mouth once or twice daily.
16253380|NCT05001945|Experimental|Dose 5|MLS-101 tablet(s) by mouth once or twice daily.
16253381|NCT05001932|Active Comparator|Multifocal|Patients will receive a multifocal lens bilateral (Alcon Vivity).
16253382|NCT05001932|Active Comparator|Mono-vision|Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant myopia of -2.50D.
16253383|NCT05001932|Active Comparator|Minimono-vision|Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant -1.25D.
16253384|NCT05001932|Active Comparator|Monofocal|Patients will receive a monofocal lens bilateral. Target refraction will be -0.25D.
16253385|NCT05001919|Placebo Comparator|collagen membrane|10 sites treated with surgery and bone graft and collagen membrane as GTR
16253386|NCT05001919|Experimental|Concentrated growth factor membrane|10 sites treated by surgery +bone graft and concentrated growth factor membrane as GTR
16253387|NCT05001906|No Intervention|Control group|The control group (CG) will consist of pregnant women with standard prenatal care, who attending theoretical classes on childbirth (CG, n = 35). The control group will not exercise. The sedentary participants will continue their regular daily activities and life habits.
16253388|NCT05001906|Experimental|Exercise group|The exercise group (EG) will consist of pregnant women who will attend theoretical classes and prenatal exercises in the program of psychophysical preparation for childbirth (EG, n = 35). The experimental group will exercise for 45 minutes, three times a week.
16253389|NCT05001893||The use of a mixture of BonAlive® putty and autologous bone|A retrospective case-controlled study will be created to compare the use of a mixture of BonAlive® putty and autologous bone to autologous bone alone for clinical safety and efficacy.
16253424|NCT05001607|Other|Study trial|All participants will perform pulmonary blockade on an intubating manikin using 4 different methods: Endobronchial intubation with an endotracheal tube; Bronchial blocker attached to the outside of an endotracheal tube; Double lumen endotracheal tube; and Intraluminal placement of bronchial blocker.
16253392|NCT05001854|Experimental|Fludrocortisone|"100 μg every 6 hours of fludrocortisone per os
~A pharmacokinetic study is performed in this arm"
16253393|NCT05001854|Placebo Comparator|Control|100 μg every 6 hours of placebo per os
16253394|NCT05001828|Experimental|Previously Treated AML|Previously treated AML based on the revised 2017 European LeukemiaNet (ELN) criteria with age at least 18 years, and having ≥10% blasts in bone marrow or peripheral blood
16253395|NCT05001828|Experimental|Untreated AML With High Risk Features|Untreated AML per ELN criteria with high risk features, or age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75 years, cardiac disease or prior anthracycline use or high probability of treatment-related mortality
16253396|NCT05001815|Experimental|Continuous subcutaneous insulin infusion (CSII)|Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices.
16253397|NCT05001815|Active Comparator|Multiple daily insulin injection (MDI)|Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment.
16253398|NCT05001802|Active Comparator|transverse quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
16253399|NCT05001802|Experimental|longitudinal quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
16253400|NCT05001789|Experimental|Active|Working memory training with task-difficulty increasing across sessions
16253401|NCT05001789|Active Comparator|Sham|Working memory training with task-difficulty remaining constant across sessions.
16253402|NCT05001776|Active Comparator|Endovenous laser ablation without anticoagulants|Endovenous laser ablation without using of any anticoagulant
16253403|NCT05001776|Active Comparator|Endovenous laser ablation with short-term anticoagulant|Endovenous laser ablation and subsequent 7 days of subcutaneous fondaparinux sodium
16253404|NCT05001776|Active Comparator|Medical treatment|45 days of subcutaneous fondaparinux sodium
16253405|NCT05001763|Placebo Comparator|Placebo|Glucose, 2mg, tablet.
16253406|NCT05001763|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment.
16253407|NCT05001750|Experimental|continuous antibiotic use until the EVD is removed|continuous antibiotic use until the EVD is removed. Nafcillin 1-2 grams every 6 hours (depending on weight) until the EVD is removed. If penicillin allergic Doxycycline 100mg every 12 hours until the EVD is removed.
16253408|NCT05001750|No Intervention|antibiotics for a total of twenty-four hours|antibiotics for a total of twenty-four hours Nafcillin 1-2 grams every 6 hours (depending on weight) for a total of 24 hours. If penicillin allergic Doxycycline 100mg every 12 hours for a total of 24 hours.
16253409|NCT05001737|Experimental|Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)|MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
16253410|NCT05001724|Experimental|Cohort 1: KN046 plus Lenvatinib RP3D.|Experimental arm: Cohort 1: KN046 5mg/kg every 2 weeks + lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
16253411|NCT05001724|Experimental|Cohort 2: Lenvatinib RP3D|Cohort 2 lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
16253412|NCT05001724|Active Comparator|Docetaxel|Active Comparator: docetaxel 75 mg/m² every 3 weeks until progressive disease or unacceptable toxicity.
16253413|NCT05001711|Experimental|WHO Group 2|
16253414|NCT05001711|Experimental|WHO Group 3|
16253415|NCT05001698|Experimental|Anifrolumab|All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.
16253416|NCT05001672|Experimental|TAF arm|"54 patients will be randomized into TAF arm*. TAF 25 mg QD will be initiated 7 days before bDMARDs, and continued for up to 144-weeks.
~*for patients received rituximab (anti-CD20 monoclonal antibody) will be enrolled into TAF arm, and TAF 25 mg QD will be initiated 7 days before rituximab, and continued for up to 144-weeks. Max 20 rituximab patients will be recruited."
16253417|NCT05001672|Other|Observation arm|54 patients will be randomized into observation arm initially. These patients will be closely monitored their HBV status (including qHBsAg and HBV DNA) for 48 weeks. TAF 25 mg QD will be initiated for 144 weeks in the presence of HBV reactivation, or after 48 weeks of observation.
16253418|NCT05001659|Other|computer simulator|training students ACLS by one computer simulator
16253419|NCT05001659|Other|mannequin simulator|training students ACLS by one mannequin simulator
16253420|NCT05001646|Experimental|In-home EMF protection device|
16253421|NCT05001633|Experimental|Intervention|modified media content experience
16253422|NCT05001633|Active Comparator|Control|media content experience
16253423|NCT05001620|Experimental|Palliative Care Consultation in Post-Acute Care|Subjects will receive usual care plus a telehealth palliative care consultation by specialty providers who will document their findings in the Electronic Health Record (EHR), and communicate their findings and recommendations to the clinical team.
16253425|NCT05001594|No Intervention|Usual care|Each participant will go through the normal rehabilitation process that follows ACL reconstruction
16253736|NCT04999618||Group with Haemoblock (A)|
16253426|NCT05001594|Experimental|Usual care+ knee vibratory device|Each participant will go through the normal rehabilitation process that follows ACL reconstruction. Additionally, each participant will receive the active device that applies non-invasive vibrational stimulation to the leg for two months, and will be asked to wear it during ambulation for at least an hour per day.
16253427|NCT05001581|Active Comparator|Treatment with biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps augmentation after its tenodesis
16253428|NCT05001581|Active Comparator|Treatment without biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps tenotomy
16253429|NCT05001568|Experimental|Optimized Providence brace|The braces will be designed using optimization and finite element analysis.
16253430|NCT05001568|Active Comparator|Conventional Providence brace|The braces will be designed by an orthotist using the conventional design method.
16253431|NCT05001555|Experimental|Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)|"Group A:
~Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days."
16253432|NCT05001555|Active Comparator|Group B: Dexketoprofen|Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
16253433|NCT05001542|Experimental|Experimental Arm|VR simulation exercise with a digital follow-up component to help assess the physiological and psychological indicators of moral distress
16253434|NCT05001529|Experimental|Group A|Subject with severe asthma, treated with anti IL5R antibodies
16253435|NCT05001529|No Intervention|Group B|Subject with severe asthma, treated with conventional therapy
16253442|NCT05001503|Experimental|Intervention Group|The clinical team has access to the Stability UO software. All other care is given as standard.
16253443|NCT05001503|No Intervention|Control Group|Standard care given.
16253444|NCT05001490|Experimental|Experimental group|
16253445|NCT05001490|No Intervention|Control group|
16253446|NCT05001464||Reflectance Pulse Oximeter|The participants wear reflectance pulse oximeter for continuous monitoring when carrying out PSG . Oxygen desaturation index (ODI), average blood oxygen saturation, minimum blood oxygen saturation, percentage of blood oxygen saturation less than 90% in the whole recording time (TS90%), fastest heart rate, slowest heart rate and average heart rate are recorded by reflectance pulse oximeter.
16253448|NCT05001438|Active Comparator|Hidro alone|The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
16253449|NCT05001438|Experimental|Hidro + MUA|"The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
~After the Hidrodilatation the patient is sedated and then a Movilization of the glenohumeral joint is performed."
16253450|NCT05001412|Experimental|Cohort one|Extensive SCLC patients who are Peripheral type or tumor vascular invasion grade one or less.
16253451|NCT05001412|Experimental|Cohort two|Extensive SCLC patients who are central type or tumor vascular invasion grade two to three.
16253452|NCT05001399|Experimental|Holographic Memory Resolution® (HMR) Intervention|Intervention will be comprised of 4 sessions lasting approximately 90 minutes at one of two sites, Billings Clinic in Billings, Montana or Healing Dimensions AAC in Tucson, Arizona. The 4 sessions will be completed in approximately 9 weeks.
16253453|NCT05001386|Experimental|Lymphoproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .
16253454|NCT05001386|Sham Comparator|Control group|Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)
16253455|NCT05001386|Experimental|Myeloproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).
16253456|NCT05001373|Experimental|Study Group 1|eOD-GT8 60mer mRNA Vaccine (100µg)
16253457|NCT05001373|Experimental|Study Group 2|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
16253458|NCT05001373|Experimental|Study Group 3|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
16253459|NCT05001373|Experimental|Study Group 4|Core-g28v2 60mer mRNA Vaccine (100µg)
16253462|NCT05001334|Experimental|Kangaroo care|The mothers of the experimental group who accept to participate in the research are given training on how to make kangaroo care and what to pay attention to.
16253463|NCT05001334|No Intervention|Control group|The mothers of the control group who accept to participate in the research are NOT given any extra training other than routine breastfeeding and care of a newborn.
16253464|NCT05001321||Training Group|Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.
16253465|NCT05001321||Internal Validation Group|Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
16253466|NCT05001321||External Validation Group|Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
16253467|NCT05001295|Experimental|Physical Activity|
16253468|NCT05001295|Placebo Comparator|Daily Live|
16253469|NCT05001282|Experimental|ELU001|Dose Escalation: Escalating doses of ELU001 Dose Expansion: Recommended Dose for Expansion (or RP2D)
16253470|NCT05001269|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
16253472|NCT05001243|Experimental|Experimental PBOHB|Pilocarpine, brimonidine, Oxymetazoline combined with Hyaluronic Acid and Bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
16253473|NCT05001243|Active Comparator|Pilocarpine 5 mgs|Pilocarpine was instilled in the other oye.
16253474|NCT05001243|Active Comparator|Brimonidine 0.5 mgs|Brimonidine was instilled in the other eye.
16253475|NCT05001217|Experimental|Chinese herbal medicine treatment plus conventional medication|"Participants will receive integrated medicine treatment combining Chinese herbal treatment, given in the form of granules, and conventional medication for 32 weeks. Patients will be differentiated into 4 subgroups based on their Chinese medicine pattern, and receive herbal treatment accordingly. An existing clinical pathway will guide the diagnosis and treatment of the Chinese medicine patterns. The four pattern subgroups are as follows:
~1) the Phlegm-heat stirring Wind subgroup; 2) the Spleen-and Kidney-Yang subgroup; 3) the deficiency of Liver- and Kidney-Yin subgroup; and 4) the Qi deficiency and stasis of Blood subgroup
~To resemble actual clinical practice, minor adjustment of herbal treatment will be possible and also adhere to the mentioned clinical guideline. The dosage of each herbal drug will follow the instructions of China Pharmacopeia."
16253476|NCT05001217|Active Comparator|Conventional medication|Conventional medication for Parkinson's disease include levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
16253477|NCT05001204|Experimental|68Ga-NOTA-RM26 PET/CT|Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.
16253478|NCT05001191|Experimental|Gentle Human Touch Group|
16253479|NCT05001191|No Intervention|Control group|
16253480|NCT05001178||Class I horizontal grower|
16253481|NCT05001178||Class I normal grower|
16253482|NCT05001178||Class I vertical grower|
16253483|NCT05001178||Class II horizontal grower|
16253484|NCT05001178||Class II normal grower|
16253485|NCT05001178||Class II vertical grower|
16253486|NCT05001178||Class III horizontal grower|
16253487|NCT05001178||Class III normal grower|
16253488|NCT05001178||Class III vertical grower|
16253489|NCT05001165|Experimental|Intervention|Patients with perceived gaps in performance measures for guideline-directed medical therapies for heart failure with reduced ejection fraction will be chart-reviewed and called impromptu to receive point of care medication titration or reintegration into routine heart failure clinic. Patients lost to follow-up may be better identified using the HFrEF panel management tools.
16253490|NCT05001165|No Intervention|Usual Care|A control group of patients with HFrEF will receive routine primary and cardiology care as currently indicated in routine scheduled clinic grids. Patients are at the discretion of their primary care and cardiology clinicians regarding whether further HFrEF optimization is warranted. While panel management data is available to all clinicians, clinical workflows and responsibilities do not encourage the use of panel data or response to performance measurement for HFrEF.
16253491|NCT05001152|Experimental|Ozanimod|A maximum of 10 healthy adult participants (i.e., sensory panelists) will complete a maximum of 20 taste assessment days, with at least 4 panelists required to evaluate the taste characteristics of ozanimod on each taste assessment day.
16253493|NCT05001126|Experimental|HIFT 1x/week|HIFT exercise performed one time per week.
16253494|NCT05001126|Experimental|HIFT 2x/week|HIFT exercise performed two times per week.
16253495|NCT05001126|Experimental|HIFT 3x/week|HIFT exercise performed three times per week.
16253496|NCT05001113|Experimental|the subxiphoid approach thoracoscopic thymectomy|The subxiphoid approach thoracoscopic thymectomy is performed in enrolled patients.
16253497|NCT05001113|Active Comparator|the lateral intercostal approach thoracoscopic thymectomy|The lateral intercostal approach thoracoscopic thymectomy is performed in enrolled patients.
16253498|NCT05001100|Active Comparator|Traditional rehabilitation|32 subjects will undergo a virtual motor-reality training during the post-surgical rehabilitation period with VRSS
16253499|NCT05001100|Experimental|Rehabilitation with virtual reality|32 subjects with demographic characteristics similar to the subjects of the Vrrs arm will undergo the habitual rehabilitative physiotherapy.
16253612|NCT05000463|Other|control group|receive the medical treatment only. The medical treatment includes optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin
16253500|NCT05001087||Patients registry|"Non-interventional, multicentre, retrospective and prospective registry. In order to increase the sample size and the validity of the Registry, patients who were diagnosed with myeloma since 1st January 2019 will also be included retrospectively, once their informed consent has been obtained by the enrolling centre. Being a registry, patients will be enrolled consecutively according to their appointments at the centre, at the discretion of their doctor and only once the patient has signed the informed consent form.
~Also patients participating in interventional or other observational studies can be enrolled. In case of patients enrolled in interventional trials, only baseline and survival data can be collected for the period in with the patient is in interventional trial.
~The data will be collected using an electronic data capture (EDC) platform. Hospital visits are planned every 6 months."
16253501|NCT05001074|Experimental|de novo cohort, extended release tacrolimus|de novo cohort, extended release tacrolimus
16253502|NCT05001074|Active Comparator|de novo cohort, immediate release tacrolimus|de novo cohort, immediate release tacrolimus
16253503|NCT05001074|Experimental|conversion cohort, extended release tacrolimus|conversion cohort, extended release tacrolimus
16253504|NCT05001074|Active Comparator|conversion cohort, immediate release tacrolimus|conversion cohort, immediate release tacrolimus
16253505|NCT05001061|Active Comparator|Sublingual Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses
16253506|NCT05001061|Active Comparator|Vaginal Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses
16253507|NCT05001048|Experimental|Low Altitude|Participants will be assessed at an altitude of <1050m.
16253508|NCT05001048|Experimental|Early Acclimatization to High Altitude|Participants will be assessed on day 2 or 3 of a high-altitude expedition at 3,800m.
16253509|NCT05001048|Experimental|Late Acclimatization to High Altitude|Participants will be assessed on day 9 or 10 of a high-altitude expedition at 3,800m.
16253510|NCT05001035|Experimental|Zinc carbonated hydroxy apatite|Toothpaste to be added on white spot lesions in dental enamel
16253511|NCT05001035|Experimental|Bioactive glass|Toothpaste to be added on white spot lesions in dental enamel
16253512|NCT05001035|Experimental|Poly amido amine|Resinous material to be painted on white spot lesions in dental enamel
16253513|NCT05001035|No Intervention|Control|No material to be added
16253514|NCT05001022|Experimental|ALG-020572|Subcutaneous injections of ALG-020572 in HV or CHB subjects, up to 7 injections over the course of up to 29 days
16253515|NCT05001022|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 7 injections over the course of up to 29 days
16253516|NCT05001009|Active Comparator|No then high patient engagement|First stage: No patient engagement Second stage: High patient engagement
16253517|NCT05001009|Active Comparator|No then low patient engagement|First stage: No patient engagement Second stage: Low patient engagement
16253518|NCT05001009|Active Comparator|No then no patient engagement|First stage: No patient engagement Second stage: No patient engagement
16253519|NCT05001009|Active Comparator|Low then high patient engagement|First stage: Low patient engagement Second stage: High patient engagement
16253520|NCT05001009|Active Comparator|Low then low patient engagement|First stage: Low patient engagement Second stage: Low patient engagement
16253521|NCT05001009|Active Comparator|Low then no patient engagement|First stage: Low patient engagement Second stage: No patient engagement
16253522|NCT05000983|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
16253523|NCT05000983|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
16253524|NCT05000970|Experimental|TRIO PLUS tablet and nurse at day 3|Virtual nurse encounter at 3 days
16253525|NCT05000970|Experimental|TRIO PLUS Tablet and nurse at day 3 and 7|Virtual nurse encounter at 3 days and 7 days
16253526|NCT05000970|Placebo Comparator|TRIO PLUS Group|No encounter
16253530|NCT05000944|Experimental|breakfast omission (BO)|No breakfast will be provided until the lunch time at ~12:30. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
16253531|NCT05000944|Experimental|early-morning breakfast consumption (EM-BC)|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at ~08:30 for EM-BC. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
16253532|NCT05000944|Experimental|mid-morning breakfast consumption (MM-BC).|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at ~10:30 for MM-BC (i.e., two hours after EM-BC). Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
16253533|NCT05000931|Experimental|To demonstrate the safety of the Osia 2 System in a pediatric population aged 5 - 11 years.|
16253534|NCT05000918|Experimental|OPH group|Participants should eat a pack of OPH once a day for 28 days. The dosage of the OPH is 11.74 g/day.
16253613|NCT05000450|Experimental|ALLO-605, ALLO-647|
16253535|NCT05000905|Experimental|Adaptive Attention Training|Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.
16253536|NCT05000905|Active Comparator|Low-dose Adaptive Attention Training|Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.
16253537|NCT05000892|Experimental|Sintilimab + Carboplatin + Nab-paclitaxel|"Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days.
~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.
~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
16253538|NCT05000879|Experimental|MMB for Moms|Subjects will receive digital delivery of Mindful Mood Balance for Moms for 12 weeks. Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
16253539|NCT05000879|No Intervention|Waitlist Control|Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
16253540|NCT05000866|No Intervention|CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
16253541|NCT05000866|Active Comparator|CHTC and communications skills training video|Participants complete the standard Couples HIV Testing and Counseling session and also watch a communication skills training video together.
16253542|NCT05000866|Active Comparator|CHTC and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and also complete a substance use module together.
16253543|NCT05000866|Active Comparator|CHTC, communications skills training and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and watch a communication skills training video and complete a substance use module together.
16253544|NCT05000853||Patients with iron deficiency|
16253545|NCT05000853||Patients without iron deficiency|
16253548|NCT05000827|Experimental|PSMA PET/CT based indication for ePLND:|"Node-negative PSMA PET/CT [N0] and M0: do not perform ePLND
~Node-positive PSMA PET/CT [N1] and M0: perform ePLND"
16253549|NCT05000827|Active Comparator|Nomogram-based indication for ePLND (standard of care)|Nomogram-based indication for ePLND (conform current EAU guidelines)
16253550|NCT05000814||cDLT|patients using conventional double lumen tube
16253551|NCT05000814||VDLT|patients using Vivasight DLT
16253552|NCT05000801|Experimental|DC vaccine|Vaccination with autologous or HLA-matched donors' WT1/TERT/survivin loaded DCs plus follow-up care.
16253553|NCT05000788|Experimental|Qigong Group|
16253554|NCT05000788|Active Comparator|Exercise Group|
16253555|NCT05000775|Experimental|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
16253556|NCT05000775|Placebo Comparator|Placebo|Placebo
16253557|NCT05000762||Patients with diabetes mellitus|Patients with type 2 diabetes mellitus
16253558|NCT05000749|Experimental|DBT-SG plus VHA treatment as usual|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
16253559|NCT05000749|Active Comparator|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
16253560|NCT05000736||palbociclib + aromatase inhibitor|Adult patients with HR+/HER2- advanced breast cancer who received the initial endocrine therapy of palbociclib plus aromatase inhibitor at the Cancer Hospital Chinese Academy of Medical Sciences from August 1, 2018 to December 31, 2020.
16253561|NCT05000736||fulvestrant|Adult patients with HR+/HER2- advanced breast cancer who received the initial endocrine therapy of fulvestrant monotherapy at the Cancer Hospital Chinese Academy of Medical Sciences from August 1, 2018 to December 31, 2020.
16253562|NCT05000723||PJI patients|"Patients (older than 18 years) with PJI of a total hip replacement treated at University Hospitals Leuven.
~Diagnosis of PJI of the hip is made based on the EBJIS 2021 criteria. Patients will receive standard of care."
16253563|NCT05000710|Experimental|study arm|"Study treatments include:
~Durvalumab at D1 and q4w + Tremelimumab at C1D1 and C4D1. Radiotherapy 11 fractions (start at D21)."
16253564|NCT05000697|Experimental|Arm 1 - 5FU + Oxaliplatin|1) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by mFOLFOX6 or XELOX for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
16253565|NCT05000697|Active Comparator|Arm 2 - 5FU Only|2) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by capecitabine 2000mg/m2/day for 14 days in a 21 days cycle for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
16253566|NCT05000684|Experimental|JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned|
16253567|NCT05000671|Experimental|Cohort 1|Drug: STC314/Placebo injection Continuous infusion at rate 58.3mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
16253568|NCT05000671|Experimental|Cohort 2|Drug: STC314/Placebo injection Continuous infusion at rate 87.5mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
16253569|NCT05000658|Experimental|group A|HSC one injection of 4 mL soluble Dexamethasone phosphate (16 mg) (equivalent to 100 mg Prednisone), followed by up to 16 mL saline (depending on tolerance)
16253570|NCT05000658|Placebo Comparator|group B|HSC one injection of 4mL of saline and then up to 16 mL of saline (depending on tolerance)
16253571|NCT05000645|No Intervention|Women, Infants, and Children (WIC)|Usual WIC counseling and food benefits for use in person at approved grocery stores.
16253572|NCT05000645|Experimental|WIC + grocery delivery|Usual WIC counseling and food benefits, as well as twice-monthly home deliveries of WIC-approved foods.
16253614|NCT05000437|Experimental|High Intensity Interval Training|single arm intervention, with high intensity interval training
16253573|NCT05000645|Experimental|WIC + grocery delivery + unsweetened beverage delivery|Usual WIC counseling and food benefits as well as twice-monthly home deliveries of WIC-approved foods PLUS unsweetened beverages to replace their current sugar-sweetened beverages (SSB) intake.
16253574|NCT05000632|Experimental|Smoke Free SafeCare (SFSC)|Providers randomized to this group will receive additional SFSC training and will disseminate SFSC program to families who report having a smoker in the home.
16253575|NCT05000632|Active Comparator|Standard SafeCare|Providers randomized to this group will disseminate the Standard SafeCare program to families who report having a smoker in the home.
16253576|NCT05000619|Experimental|Outreach Postcard|This group receives a postcard with a stock image on the front and a message encouraging regular visits to manage health on the back.
16253577|NCT05000619|Experimental|Humorous Postcard|This group receives a postcard with with a cartoon image and a visit-related joke on the front and a humorous message on the back, with additional information about why visits are important, and what to expect at the appointment.
16253578|NCT05000619|Experimental|Physician Letter|This group receives a personalized letter signed by a physician with information about why visits are important, and what to expect at the appointment.
16253579|NCT05000619|No Intervention|No-contact Control|This group will not receive a study mailer during the trial.
16253580|NCT05000606|Experimental|A home visit program|A home visit program including five visits over three months were performed.
16253581|NCT05000606|Other|Control|No other intervention was applied to the control group other than the standard education given in the outpatient clinic
16253582|NCT05000593|Experimental|stem cell treating group|Intra-articular injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 1 week for a total of 3 times.
16253583|NCT05000593|Sham Comparator|control group|Intra-articular injection of normal saline was performed once every 1 week for a total of 3 times.
16253584|NCT05000567|No Intervention|Control Group|No intervention.
16253585|NCT05000567|Experimental|Experimental Older group|12 week strength training program: Nordic Hamstring Exercise
16253586|NCT05000567|Experimental|Experimental Younger group|12 week strength training program: Nordic Hamstring Exercise
16253587|NCT05000554|Experimental|Locally advanced gastric cancer|Patients with locally advanced gastric cancer who can receive PD-1 monoclonal antibody combined with neoadjuvant chemotherapy
16253588|NCT05000541||Armolipid-L/Armolipid Plus-L|Armolipid-L used for participants in Germany and Poland Armolipid Plus-L used for participants in Austria
16253589|NCT05000528|Experimental|Therapeutic education|
16253590|NCT05000528|Active Comparator|Individualized consultation|
16253595|NCT05000489||Minors 1|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
16253596|NCT05000489||Minor 2|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
16253597|NCT05000489||Spina Bifida|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Spina Bifida clinic
16253598|NCT05000489||Pulmonology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the pulmonology clinic
16253599|NCT05000489||Endocrinology 1|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type I Diabetes
16253600|NCT05000489||Endocrinology 2|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type II Diabetes
16253601|NCT05000489||Rheumatology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Rheumatology clinic
16253602|NCT05000489||Gastroenterology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Gastroenterology clinic
16253603|NCT05000489||Neurology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Neurology clinic
16253604|NCT05000489||Cardiology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Cardiology clinic
16253605|NCT05000489||Hematology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Hematology clinic
16253606|NCT05000489||Nephrology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Nephrology clinic
16253607|NCT05000489||Oncology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Oncology clinic
16253608|NCT05000476|Other|Nurse Education and Environmental Regulation|Clinical nurses will be given training on delirium risks, diagnosis, prevention and management. In order to implement the interventions, environmental arrangements will be made in the intensive care units in the light of the training given, and the nurses will record which attempts are made during the day with the daily follow-up form.
16253609|NCT05000476|Experimental|Eye mask and earplugs|"Patients will be monitored for 3 days starting from their hospitalization.
~Along with the regulations, each patient will be assisted by the intensive care nurses for 3 days between 23:00 p.m. - 06:00 a.m. for the use of eye mask and earplugs."
16253610|NCT05000476|No Intervention|Control|With the adjustments made, theywill receive the usual care for 3 days.
16253615|NCT05000424|Experimental|Intervention|Participants in this group will receive a fragrant plant based massage oil with the addition of clary sage essential oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
16253616|NCT05000424|Placebo Comparator|Control|Participants in this group will receive a fragrant plant based massage oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
16253617|NCT05000411|Experimental|Experimental group|
16253618|NCT05000411|Placebo Comparator|Control group|
16253619|NCT05000398|Active Comparator|exercise with a physiotherapist|Participants will exercise with a physiotherapist. 4 times a week for 8 weeks
16253620|NCT05000398|Experimental|home program|The same exercises will be given to the participants as brochures. 4 times a week for 8 weeks
16253621|NCT05000385||Healthy|healthy complete dentition
16253622|NCT05000385||Dental caries|complete dentition with bilateral dental caries (ICDAS 4,5 or 6)
16253623|NCT05000385||Occlusal contacts|occlusal contacts are lost bilaterally due to extraction, changing dentition or orthodontic anomalies; no dental caries
16253624|NCT05000385||Dentures|patients with dentures, no caries and/or missing occlusal contacts on remaining teeth
16253625|NCT05000372|Experimental|68Ga-grazytracer PET/CT in participants before immunotherapy|Participants who have not undergone immunotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 1 h.
16253626|NCT05000372|Experimental|68Ga-grazytracer PET/CT in participants after immunotherapy|Participants post-immunotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 1 h.
16253627|NCT05000359|Other|AYA Text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
16253628|NCT05000346|Experimental|Experimental AQ001S 0.125 mg/mL quarter in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation 4 times a day
16253629|NCT05000346|Experimental|Experimental AQ001S 0.125 mg/mL bis in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation twice a day + placebo by inhalation twice a day
16253630|NCT05000346|Placebo Comparator|Comparator: placebo|No active drug - administered by inhalation 4 times a day
16253631|NCT05000320||Vigabatrin-naive|Adults 18 - 80 years of age suffering from post anoxic status epilepticus (PASE) who have not received vigabatrin.
16253632|NCT05000307|Experimental|Volunteers, infected with COVID-19|
16253633|NCT05000294|Experimental|Atezolizumab + Tivozanib|
16253634|NCT05000281|Experimental|NSAID|Standard of care pain medication regimen with NSAIDs.
16253635|NCT05000281|No Intervention|No NSAIDs|Standard of care pain medication regiment with no NSAIDs
16253636|NCT05000268|Active Comparator|Painful Healthcare Workers with COVID-19|Healthcare workers who have had COVID-19 infection in the past and are now in pain without COVID-19 infection
16253637|NCT05000268|Active Comparator|Painful Health Care Workers without COVID-19|Healthcare workers with past and present pain without COVID-19 infection
16253638|NCT05000255|Experimental|Intervention 1: According to DGP|For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of post-COVID-19 patients (DGP, 2020). The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients)
16253639|NCT05000255|Active Comparator|"Intervention 2: According to Cacioppo E.A.S.E."|The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients), too. The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions.
16253640|NCT05000255|No Intervention|Care as Usual; Standard psychological Support|The patients receive standard care from the psychologists, as is usual in this unit. No intervention is carried out.
16253730|NCT04999644|Experimental|Reduced Nicotine, Full Expectancy|Receive reduced nicotine cigarette expecting full
16253731|NCT04999644|Experimental|Full Nicotine, Full Expectancy|Receive full nicotine cigarette expecting full
16253656|NCT05000203|Experimental|Specific intervention for fear of childbirth|"Online education intervention Participants randomly assigned to the experimental group will be informed by telephone call of their inclusion in the first phase of the trial.
~Participants in the intervention group will be encouraged to attend routine consultations with their midwife and obstetrician, as well as to take advantage of the group maternal education that participants usually develop in their health center.
~Specific intranatal support
~An experimental group will be carried out with a specific support intervention in the obstetric-gynecological emergency area that will supplement the one usually provided to all pregnant women.
~At the end of the participant's stay within the emergency area due to hospital discharge, admission to the ward, or the end of the pregnancy, the collaborating midwife will fill out an online form designed to monitor the care offered. Said form will also be completed at the end of the work shift if the participant's care continues."
16253657|NCT05000203|Active Comparator|Routine intervention for fear of childbirth|"Usual care
~Participants randomly assigned to the control group will be informed by telephone call of their inclusion in the first phase of the trial. The process under study will be explained in detail, resolving any doubts at that time.
~Regular intranatal support
~The participants in the control group will not be identified as pregnant women with fear of childbirth, and will receive the usual care in the obstetric-gynecological emergency area."
16253658|NCT05000190|Experimental|250 mg citicoline|Opaque capsule
16253659|NCT05000190|Placebo Comparator|0 mg citicoline|Opaque capsule matched in appearance to the active capsule
16253660|NCT05000177|Other|Experimental group: Non-specific chronic neck pain group|Subjects with non-specific chronic neck pain will be included to perform 30-minute computer typing task and assess neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation.
16253661|NCT05000177|Other|Control group: Healthy subjects group|Healthy subjects will be included to compare the differences in neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with non-specific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
16253662|NCT05000177|Other|Pilot study: Healthy subjects group|Healthy subjects will be included to test reliability of single-pulse and paired-pulse TMS, including its associated neurophysiological measurements, and also to test reliability of Liberty electromagnetic tracing system and surface electromyography. Subjects in this group will received the same assessment as the NCNP group.
16253663|NCT05000164|Experimental|Market Product|Eligible subjects will be dispensed the study lenses in a bilateral fashion and will be in the treatment for approximately 5 weeks.
16253664|NCT05000151||Patients|Hypermobile Ehlers-Danlos patients (n=21)
16253665|NCT05000151||Healthy subjects|Healthy subjects recruited from the clinic's staff (n=21) Age, Gender and BMI matched with hEDS patients
16253732|NCT04999644|Experimental|Full Nicotine, Reduced Expectancy|Receive full nicotine cigarette expecting reduced
16253733|NCT04999644|Experimental|Reduced Nicotine, Reduced Expectancy|Receive reduced nicotine cigarette expecting reduced
16253666|NCT05000125||Slides from the German Co-Screening program|From 32506 LBC slides (ThinPrep, Hologic Inc., USA) from the German Co-screening program measured in 2020 with the TIS all abnormal findings according to Munich III groups (II-p - V) and 3% of normal slides (Munich III groups (I+II-a)) will be selected for the additional measurement with the Genius Digital cytology system.
16253667|NCT05000112||Patients with mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is seen on surface of the vaginal mucosa, the patient is diagnosed with mesh exposure.
16253668|NCT05000112||Patients without mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is not seen on surface of the vaginal mucosa, bimanual examination will be performed to confirm no foreign body can be feeled on surface of the vaginal mucosa. Then the patient belong to this group.
16253669|NCT05000099||phone calls|patients choosing phone calls as preferred communication technique
16253670|NCT05000099||video call|patients choosing video calls as preferred communication technique
16253671|NCT05000086|Experimental|99Tc methylene diphosphonate|99Tc-MDP was applied as follows: for each course of treatment, 99Tc-MDP 22 mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.
16253672|NCT05000073|Experimental|Experimental Arm|
16253673|NCT05000073|Active Comparator|Control arm|
16253674|NCT05000060|Experimental|1 week restart|Restart of mono or dual antiplatelet therapy one week post injury in TICrH patients
16253675|NCT05000060|Active Comparator|3 week restart|Usual Care for restart of mono or dual antiplatelet therapy after TICrH at clinician's discretion
16253676|NCT05000047||All participants|All participants will have bilateral impressions taken with both methodologies.
16253677|NCT05000034|Experimental|Patients|
16253678|NCT05000021|Experimental|Treatment Group|We will directly test whether targeting diabetes distress and glycemic control in YA with T1D with a time-limited cognitive behavioral intervention can result in clinically significant improvements, over those achieved with standard of medical care CGM alone. Our design is scientifically rigorous and our results will have a significant impact on our scientific understanding of the relationship between diabetes distress and glycemic levels and variability. We will use a secure web-based videoconferencing intervention delivery platform as an innovation that is responsive to the clear efficacy of remotely delivered CBT, CGM initiation and support, and currently covered in telemedicine diabetes care in T1D.
16253679|NCT05000021|No Intervention|Control Group|Control arm participants will also wear CGM throughout the first 6 months, during the 2-week run-in, 12-week CBT intervention, and 2-week post-intervention period. Control arm participants will answer EMA surveys as in the intervention arm to enable paired analysis of responses between arms. Participants can initiate CGM review from their healthcare providers if desired. By allowing control arm participants to have access to CGM and to use CGM data for change in self-management behaviors, we will be able to control for CGM effect on diabetes distress levels in the intervention. We will also provide written materials for recognizing and managing diabetes distress and online resources
16253680|NCT05000008|Experimental|Aerobic Exercise Group|Moderate Intensity Aerobic Exercises
16253681|NCT05000008|Experimental|Resistance Exercise Group|Moderate Intensity Resistance Exercises
16253682|NCT04999995||HFrEF|Patients admitted with acutely decompensated HFrEF without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
16253683|NCT04999995||HFpEF|Patients admitted with acutely decompensated HFpEF without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
16253684|NCT04999995||Non-HF Dyspnea|Patients admitted with acute dyspnea without evidence of HF and without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
16253685|NCT04999982|Experimental|Intervention group- PRE-CARE|Participants will receive the 1:1 PRE-CARE social needs navigation intervention with specific content and delivery strategy which was developed based on 1) quantitative analyses of the association between unmet social needs and ADHD symptoms in a large-scale nationally representative sample of children age 3-5, and 2) in-depth qualitative interviews with parents/guardians of preschoolers with inattention and/or hyperactivity symptoms to identify mechanisms by which unmet social needs exacerbate ADHD symptoms and functioning.
16253686|NCT04999982|Active Comparator|Control group- Care as Usual|Families randomly assigned to the control condition will continue to receive care as usual, which includes screening for social needs annually at well-child visits as recommended by the American Academy of Pediatrics (AAP), followed by provision of information as needed by the family. Families will also be offered the opportunity to make research assessments available to their primary care physician for best continuity of care.
16253687|NCT04999969|Experimental|AZD0171 + Durvalumab + chemotherapy|Participants will receive AZD0171 (intravenous [IV]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel).
16253688|NCT04999956|Experimental|dynamic navigation|
16253689|NCT04999956|Sham Comparator|freehand|
16253690|NCT04999943|Active Comparator|Hypomemylating agent monotherapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle)
16253691|NCT04999943|Experimental|Combined cellular immunotherapy（eDC）with Hypomemylating agent therapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle) with Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin
16253692|NCT04999930|Experimental|Group A|with aerochamber
16253693|NCT04999930|Experimental|Group B|without aerochamber
16253694|NCT04999917|Experimental|intraoperative high-resolution PET-CT imaging of resected breast tumor.|
16253695|NCT04999904|Experimental|Uneven Treadmill Arm|Uneven Treadmill Intervention with up to twelve sessions over approximately six weeks and Standard of Care Physical Therapy with an 18 month follow-up period
16253696|NCT04999904|Active Comparator|Control Arm|Standard of Care Physical Therapy over approximately six weeks with an 18 month follow-up period
16253697|NCT04999891||Surgical Cohort|Elderly patients aged 65 and above who are planned for hip fracture surgery.
16253737|NCT04999618||Group without Haemoblock (B)|
16253698|NCT04999878|Experimental|treatment group|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:
~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.
~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
16253705|NCT04999826||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10 minutes and undergo blood, urine, saliva, and fecal samples collection.
16253706|NCT04999813|Experimental|Comprehensive intensive intervention|On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability.
16253707|NCT04999813|No Intervention|Routine management|Only routine management was carried out for the subjects without special intervention.
16253708|NCT04999800|Experimental|Pembrolizumab combined with Anlotinib|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week, combined with Pembrolizumab 200 mg iv on day 1, and every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated
16253709|NCT04999787|Experimental|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
16253710|NCT04999787|Placebo Comparator|Placebo|
16253711|NCT04999774||School-age children|"Each SAC will be asked to supply fecal and blood samples for testing with:
~Stool microscopy
~Baermann method
~Real-time PCR for S. stercoralis
~Lateral flow rapid test
~ELISA serology (NIE/SsIR and IgG Ratti)"
16253712|NCT04999761|Experimental|Cohort A-1|AB122 will be given in participants with advanced or metastatic solid tumor.
16253713|NCT04999761|Experimental|Cohort A-2|AB122 will be given in participants with advanced or metastatic solid tumor.
16253714|NCT04999761|Experimental|Cohort B-1|AB122 will be given in combination with TAS-116 in participants with pancreatic ductal adenocarcinoma.
16253715|NCT04999761|Experimental|Cohort B-2|AB122 will be given in combination with TAS-116 in participants with colorectal cancer.
16253716|NCT04999735||Patients with FSHD|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
16253717|NCT04999735||Healthy controls|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
16253718|NCT04999722|Active Comparator|APP group|Participants with diabetes who had access to a mobile APP
16253719|NCT04999722|Placebo Comparator|Control Group|Diabetes participants who accepted the traditional management model
16253720|NCT04999709|Active Comparator|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
16253721|NCT04999709|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
16253722|NCT04999696|Experimental|Laparoscopic radical hysterectomy|
16253723|NCT04999696|Active Comparator|Laparotomic radical hysterectomy|
16253724|NCT04999683|Experimental|ITIS diet|anti-inflammatory (ITIS) diet for 14 days
16253725|NCT04999670|Active Comparator|Single suture, knot above fascia|Fascia sutured with #1 polysorb braided absorbable suture, with the knot being superficial to the fascia, starting at the left angle of the fascial incision and closed in a continuous fashion. The contralateral angle is grasped with a kocher clamp and the suture is then tied behind the angle ensuring adequate closure.
16253726|NCT04999670|Active Comparator|Two sutures, knot above fascia|Fascia sutured using #1 polysorb braided absorbable suture with a superficial knot, starting at the left angle and closed in a continuous fashion until the suture is above the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is tied behind the right angle with a superficial knot and run across in a continuous fashion to meet the opposing suture which are then tied together.
16253727|NCT04999670|Active Comparator|Two sutures, buried knots below fascia|Fascia sutured using #1 polysorb braided absorbable suture with a buried knot below the fascia starting at the left angle and closed in a continuous fashion until the suture overlies the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is then tied behind the right angle with a buried knot below the fascia and run across in a continuous fashion to meet the opposing suture which are then tied together.
16253728|NCT04999657|Active Comparator|Active|Device: Non-invasive low-frequency tibial nerve stimulator
16253729|NCT04999657|Sham Comparator|Sham|Device: Non-invasive low-frequency tibial nerve stimulator (same device operation without real current output)
16253738|NCT04999605|Experimental|AK112|AK112 injection
16253739|NCT04999592|Active Comparator|No prophylaxis (placebo)|"Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted.
~Administer antibiotics in response to infection."
16253740|NCT04999592|Experimental|Prophylaxis|Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
16253741|NCT04999579|Active Comparator|Complete denture|Conventional complete denture without supporting devices
16253742|NCT04999579|Experimental|Ultra suction retained complete denture|Conventional complete denture with ultra suction device
16253743|NCT04999553|Active Comparator|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
16253744|NCT04999553|Active Comparator|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
16253745|NCT04999540|Experimental|Tucidinostat + Fulvestrant|"Patients receive 30 mg Chidamide twice per week. Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only.
~Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
16253748|NCT04999514|Experimental|Mindful Parenting Program|The Mindful Parenting program as developed by Bögels and Restifo (2013), is selected as one of the parenting intervention programs in this study. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in parenting context.
16253749|NCT04999514|Experimental|Tuning in to Kids Program|The Tuning in to Kids program as developed by Havighurst and colleagues (2010), is selected as one of the parenting intervention programs in this study. It will be extended to 8-week program that aims at equipping parents with emotion coaching skills.
16253750|NCT04999514|No Intervention|Waitlist Control Group|The waitlist control group will not receive any intervention until the intervention arms complete their training. Depending on the availability of the program instructor, either the Mindful Parenting or Tuning in to Kids program will be offered to this group.
16253751|NCT04999501|Experimental|65 - 75 years|All volunteers aged 65 - 75 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
16253752|NCT04999501|Experimental|85 years and over|All volunteers over the age of 85 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
16253753|NCT04999488|Placebo Comparator|Older adults with sarcopenia (placebo)|
16253754|NCT04999488|Active Comparator|Older adults with sarcopenia (drug)|
16253755|NCT04999462|Experimental|Full-fat fermented dairy|1 serving per day of full-fat yogurt and full-fat fermented cheese
16253756|NCT04999462|Active Comparator|Low-fat fermented dairy|1 serving per day of low-fat yogurt and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
16253757|NCT04999462|Placebo Comparator|Non-dairy, non-fermented foods|2 servings per day of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
16253758|NCT04999449|Experimental|Pharmacokinetic|Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.
16253759|NCT04999449|Experimental|Chair|Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.
16253760|NCT04999436|Experimental|Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
16253761|NCT04999410|Experimental|Long-HITT|Long work bout durations (4 minutes) on cycle ergometers or home trainers
16253762|NCT04999410|Active Comparator|Medium HIIT-L|Medium duration work bouts (2 minutes) with intensity matched to the Long-HITT intensity
16253763|NCT04999410|Active Comparator|Medium HIIT-H|Medium duration work bouts (2 minutes) with intensity at 30% of the difference between Wmax and mean TT power outputs
16253764|NCT04999410|Active Comparator|Short HIIT|Short duration work bouts (30 seconds) with intensity at 50% of the difference between Wmax and mean TT power outputs
16253917|NCT04998357|Experimental|Transplantation|Endovascular infusion
16253771|NCT04999371|No Intervention|Control without intervention|No information or cash incentives are provided to the participants in the control group, but it is also necessary to collect the information of the participants in the control group and perform an alcohol test. Therefore, the project team will provide a certain degree of compensation for participants in the control group (participants of the intervention group also will receive this part of compensation).
16253772|NCT04999371|Active Comparator|Mobile-based information intervention|The participants in this group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.
16253773|NCT04999371|Active Comparator|Mobile-based information intervention with performance-based incentive|The participants in this group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
16253774|NCT04999358|Experimental|Protein group|Participants in the protein group will receive three education sessions. The first two education sessions will be the same for both study arms and will align with the two dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. The content and materials for these sessions will be pre-recorded by the researchers and accessed by participants via the internet or DVD. For the third education session, participants in the protein group will be provided with targeted protein education, which will aim to increase the amount of foods eaten with protein in them (≥1.2 g/kg protein/day) and improve the quality of protein sources that are eaten.
16253775|NCT04999358|Placebo Comparator|Control group|Participants in the control group will receive three education sessions. The first two education sessions will be the same for both study arms and will align with the two dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. The content and materials for these sessions will be pre-recorded by the researchers and accessed by participants via the internet or DVD. Participants in the control group will receive a third dietary education session that is similar to the first two sessions, containing only information that is usually provided in the cardiac rehabilitation programme.
16253776|NCT04999345|Experimental|Experimental Group|Provide resistance and aerobic exercise
16253777|NCT04999345|Placebo Comparator|Control Group|Health education and gross range of motion exercise for upper and lower extremities
16253778|NCT04999332|Experimental|Perioperative chemotherapy with LOTS|"LOTS as one cycle:
~Leucovorin (30 mg) twice daily per oral, day 1 to 7; Oxaliplatin (85 mg per square meter) intravenously, day 1; Docetaxel (40 mg per square meter) intravenously, day 1; S-1 (35 mg per square meter) twice daily per oral, day 1 to 7
~Pre-operative part:
~Four cycles of LOTS every two weeks
~Operative part:
~Curative gastrectomy or gastroesophagectomy plus D2 lymphadenectomy
~Post-operative part:
~Four cycles of LOTS every two weeks"
16253779|NCT04999319|Active Comparator|PVB Group|Paravertebral block administered group
16253780|NCT04999319|Active Comparator|ESPB group|Erector spinae plane block administered group
16253781|NCT04999306|Experimental|Hypnosis group|"the sessions will be conducted following the same dynamics and the same exercises (safe place, reification, anchoring): introduction of the session (conversational hypnosis in order to probe the patient's perceptions of his or her illness and fatigue, discussion of myths and realities); induction with the creation of a safe place that will be used for each session; visualization; deepening of the trance with work on metaphors (reification technique); making specific suggestions on sensations of fatigue, on regaining energy; then instruction for self-hypnosis or anchoring."
16253782|NCT04999306|Experimental|CBT group|"This program will work specifically on the psychosocial determinants of fatigue.
~The first session will be patient education on cancer-related fatigue. S2 will address the concept of perceived control and allow the patient to understand what factors accentuate this condition. S3 will allow the patient to work on the emotions associated with cancer and will be complemented by a hypnosis audio. S4 will address the notion of social support and how the patient can learn to delegate or ask for help. S5 will address the notion of coping strategies, the patient will then be able to identify what he/she puts in place, what is productive and what is not. Finally, the S6 will be a synthesis session that will allow to come back to the points that deserve to be deepened."
16253783|NCT04999293||The Elderly Undergoing Percutaneous Coronary Intervention|Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
16253784|NCT04999280|Experimental|Fiber Croissant (FIBCRO) Group|Daily consumption at breakfast for 2 weeks of a fiber-enriched croissant
16253785|NCT04999280|Active Comparator|Control Croissant (CONCRO) Group|Daily consumption at breakfast for 2 weeks of a control croissant
16253786|NCT04999267|Experimental|INVEST Intervention|
16253787|NCT04999267|No Intervention|Control|The control arm will not receive the INVEST Intervention and will receive the usual vaccine information materials by the schools.
16253788|NCT04999254|Experimental|Osteopathic treatment / Usual care|osteopathic treatment will be applied in this intervention group.
16253789|NCT04999254|Active Comparator|Usual care|Classic medical treatment
16253790|NCT04999241|Experimental|EEN combined therapy group|in the induction of remission phase, EEN will be used combine with corticosteroids or infliximab
16253791|NCT04999241|Active Comparator|Non EEN combination group|in the induction of remission phase, corticosteroids or infliximab will be used without EEN
16253792|NCT04999228|Experimental|Infliximab treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, infliximab will be used as first-line treatment
16253793|NCT04999228|Active Comparator|Corticosteroid treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, corticosteroids will be used as first-line treatment
16253794|NCT04999215|Experimental|Main arm|F-choline intravenous injection
16253795|NCT04999202|Experimental|Dose escalation of BAY2416964|Two dose levels of BAY2416964 are determined in the another BAY2416964 monotherapy study.
16253796|NCT04999202|Experimental|Dose expansion of BAY2416964 in tumor type specific cohort|To determine the RP2D of BAY2416964 in combination therapy with pembrolizumab. Participants will be enrolled in up to 3 tumor type-specific cohorts including relapsed/refractory non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial cancer.
16253797|NCT04999189|Experimental|Patients using mobile applications|Patients diagnosed with type 2 diabetes will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
16253798|NCT04999189|No Intervention|Control group|Patients will receive treatment from medical staff (as usual).
16253799|NCT04999176|Experimental|Rivaroxaban|Oral Rivaroxaban (10 mg once daily) for 30 days post-operative
16253800|NCT04999176|Active Comparator|Enoxaparin|Subcutaneous Enoxaparin (40 mg once daily) for 30 days post-operative
16253801|NCT04999150|Active Comparator|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected.
~Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed . The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex until bone marrow was exposed.
~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.
~The mini-screws were placed.
~A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)."
16253802|NCT04999150|Experimental|Micro-Osteoperforation|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).
~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced ~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.
~The mini-screws were placed.
~A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)."
16253803|NCT04999137|Experimental|Intravenous vitamin C 1.5g + intravenous vitamin B1|intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
16253804|NCT04999137|Experimental|Intravenous Vitamin C 3g + intravenous vitamin B1|Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
16253805|NCT04999137|No Intervention|Usual Care|Usual care
16253806|NCT04999124|Other|Type 2 Diabetes Mellitus patients|
16253813|NCT04999098|Active Comparator|treatment group 1: Echinaforce Forte (EFF) Tablets (chewed)|"1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets."
16253814|NCT04999098|Active Comparator|treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed)|"2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 & 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets."
16253815|NCT04999098|Active Comparator|treatment group 3: Echinaforce Tincture (EFT, gargling)|"3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture."
16253817|NCT04999059||Participants with Fabry Disease|This is a long-term follow-up study of participants who previously received AVR-RD-01 (single dose administration) in the AVRO-RD-01-201 treatment study. No investigational product will be administered in this study.
16253818|NCT04999046|Experimental|FUS treatment|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals. The FUS exposure area will be the epileptogenic focus which is individually different and determined by standard clinical practice previously.
16253819|NCT04999046|Sham Comparator|Sham treatment|Sham treatment is to mimic the FUS treatment procedure but without any energy. The ISPTA will be 0 W/cm2, duration: three repeating 5-minute sham exposures with two 5-minute intermission intervals.
16253820|NCT04999033||Inpatient|This study is a cross-sectional study and no intervention will be involved
16253821|NCT04999020|Experimental|Ravulizumab|Participants will receive ravulizumab in both Parts A and B.
16253822|NCT04999020|Placebo Comparator|Placebo|Participants will receive placebo in both Parts A and B.
16253823|NCT04999007|No Intervention|Control|Whether the patients in the control arm will receive a temporary ileostomy depends on surgeons' experience.
16253824|NCT04999007|Experimental|Intervention|Whether the patients in the intervention arm will receive a temporary ileostomy depends on the risk of anastomotic leakage calculated by the artificial intelligence algorithm.
16253825|NCT04998981|Experimental|K-877 0.1 mg BID|K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
16253826|NCT04998981|Experimental|K-877 0.2 mg BID|K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
16253827|NCT04998981|Active Comparator|Fenofibrate 200 mg QD|Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
16253828|NCT04998981|Placebo Comparator|Placebo|Placcebo tablet x 2 twice daily, Placebo capsule once daily
16253829|NCT04998968||Patients with permanent hypoparathyroidism after total thyroidectomy|Patients with permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region. Permanent hypoparathyroidism is defined as treatment with Calcium and/or vitamin D more than 12 months after surgery.
16253830|NCT04998968||Patients without permanent hypoparathyroidism after total thyroidectomy|Patients without permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region.
16253831|NCT04998955|Experimental|MST group|Exercise intervention, 20 supervised MST sessions
16253832|NCT04998955|No Intervention|Control group|IRD patient controls
16253833|NCT04998942|Experimental|Experimental|
16253834|NCT04998942|Placebo Comparator|Placebo comparator|
16253835|NCT04998916|Experimental|Real TBS to the mPFC|For continuous theta burst stimulation (cTBS), participants will receive 3 sessions of stimulation per visit over the left medial prefrontal cortex (mPFC) (each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec, 600 pulses/session, 60 sec intertrain interval; 120% RMT, MagPro; 10-15 min inter session interval) using a figure 8 coil (Coil Cool-B65 A/P).
16253836|NCT04998916|Sham Comparator|Sham TBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
16253837|NCT04998903||Stem cell transplant with Graft versus host disease|Patients who following hematopoietic stem cell transplant suffered from graft versus host disease and presented with pulmonary infiltrates.
16253838|NCT04998890|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program A 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure training (one adventure day camp (2 sessions) and adventure activities in the beginning of each workshop). One session per week, 3 hours for each session. A variety of cognitive behavioral skills were taught in lectures and these skills were practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework were used in the intervention program.
16253839|NCT04998890|No Intervention|Control group|No intervention of the adventure-based cognitive behavioral program
16253840|NCT04998877||Heart Failure with Preserved Ejection Fraction|
16253841|NCT04998877||Healthy Volunteers|
16253842|NCT04998864||Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
16253844|NCT04998838|Experimental|Tenofovir Disoproxil Fumerate|Pregnant women (&gt;=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible). Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.
16253845|NCT04998825|Experimental|Proteoglycan F group|"Taking Proteoglycan F
~Dosage of Proteoglycan F: 50mg/day
~Used time: 24 weeks"
16253846|NCT04998825|Placebo Comparator|Control group|"Taking Placebo (Dextrin)
~Dosage of Placebo: 50mg/day
~Used time: 24 weeks"
16253847|NCT04998812|Experimental|Women with CIS or MS|Women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.
16253848|NCT04998786|Experimental|assessment of treatment Ixazomib, dexamethasone, iberdomide|Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression
16253849|NCT04998773|Active Comparator|Group Bilateral|32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC
16253850|NCT04998773|Active Comparator|Group Unilateral|32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
16253851|NCT04998773|Placebo Comparator|Group Placebo|32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
16253852|NCT04998760|Experimental|ATG-008 + Chemotherapeutics|ATG-008: Oral, 30 mg QD+Paclitaxel: 175 mg/m2, intravenous infusion >3 h, Day 1, Q3W; ATG-008: Oral, 30 mg QD+Carboplatin: AUC = 5, intravenous infusion >1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion >1h, Day 2, Q3W ; ATG-008: Oral, 30 mg QD+Doxorubicin hydrochloride liposome, 40 mg/m2, Day 1; Q4W;
16253996|NCT04997811|Experimental|VBaP|Combination of sodium valproate, bezafibrate, medroxyprogesterone
16253853|NCT04998760|Experimental|ATG-010 + Chemotherapeutics|"perimental: ATG-010 + Chemotherapeutics ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Paclitaxel: 175 mg/m2, intravenous infusion >3 h, Day 1, Q3W; ATG-010: Oral, 80 mg QW, Day
~1/week of treatment cycles +Carboplatin: AUC = 5, intravenous infusion >1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion >1h, Day 2, Q3W ; ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Doxorubicin hydrochloride liposome, 40 mg/ m2, Day 1; Q4W;"
16253856|NCT04998734||Chronic pain|Patients with chronic non-cancer pain referred to secondary and tertiary care
16253857|NCT04998721|Experimental|Maternal Infant Dyadic Care|Perinatal collaborative care and Promoting First Relationships-Brief
16253858|NCT04998721|Active Comparator|Control|Perinatal collaborative care only
16253859|NCT04998708|Experimental|Intervention|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM). We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
16253860|NCT04998708|No Intervention|Control|
16253861|NCT04998695|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
16253862|NCT04998695|Active Comparator|Sunflower oil|Intake of 45 g/d of sunflower oil as the only source of oil in the diet
16253863|NCT04998682|Experimental|Targeted Axillary Dissection (TAD)|During standard of care (SoC) surgery to remove breast cancer, study participants will undergo a sampling of lymph nodes in the axilla first and then complete removal of axillary lymph nodes under the arm.
16253864|NCT04998669|Experimental|Loncastuximab tesirine + Rituximab|"During the 12-week Induction Phase (Cycles 1 to 4), participants will receive loncastuximab tesirine on days 1 of each 3-week cycle for Cycles 1 through 4; and rituximab on days 1, 8, 15 of Cycle 1 and day 1 of Cycle 2.
~Maintenance Phase 1 (Cycle 5) is 8 weeks: Participants achieving complete response (CR) or partial response (PR) during the Induction Phase will receive loncastuximab tesirine once every 3-weeks; and rituximab once during week 7 or 8. Participants achieving a response of Stable Disease (SD) or Progressive Disease (PD) will be taken off treatment.
~Maintenance Phase 2 (Cycles 6 and 7) is 16 weeks:
~Participants achieving CR during Maintenance Phase 1 receive rituximab once during week 7 or 8 of Cycles 6 and 7.
~Participants achieving PR during Maintenance Phase 1 receive loncastuximab tesirine once every 3-weeks over each 8 week cycle; and rituximab once during week 7 or 8 of Cycles 6 and 7.
~Participants achieving SD or PD will be taken off treatment."
16253865|NCT04998656|Active Comparator|Werewolf FLOW 50 Group|The Werewolf FLOW 50 electrocautery device will be used during surgical treatment for patients assigned to this group.
16253866|NCT04998656|Placebo Comparator|Control Group|No electrocautery device will be used during surgical treatment for patients assigned to this group.
16253867|NCT04998630|Experimental|A (4Hz)|ESWT frequency 4Hz washout period: 1 week
16253868|NCT04998630|Experimental|B (8Hz)|ESWT frequency 8Hz washout period: 1 week
16253869|NCT04998617|Experimental|Toothpaste Containing Curcumin|After screening, participants will be randomly assigned to receive toothpaste that contains 0.5% curcumin.
16253870|NCT04998617|Placebo Comparator|Toothpaste Without Curcumin|After screening, participants will be randomly assigned to receive toothpaste that does not contain curcumin.
16253871|NCT04998604|Experimental|Dupilumab|Dosing every 2 weeks (Q2W)
16253872|NCT04998604|Experimental|Omalizumab|Dosing Q2W or every 4 weeks (Q4W)
16253873|NCT04998591|Experimental|Fasting group|Participants will be councelled and accompanied to follow a fasting regime of 7 days in an outpatient setting under medical supervision.
16253874|NCT04998591|No Intervention|Waiting list|This group maintains their individual diet during the whole time of the study. In case that the first cycle of In-Vitro-Fertilization fails, they are offered a fasting intervention before a next cycle.
16253875|NCT04998578|Active Comparator|Microneedling- Group A|Participants will only perform microneedling
16253876|NCT04998578|Active Comparator|Microneedling and outpatient Cosmetics- Group B|Microneedling associated with the use of outpatient cosmetics
16253877|NCT04998578|Active Comparator|microneedling and home use cosmetics - Group C|Microneedling associated with home use cosmetics
16253878|NCT04998578|Active Comparator|Non-ablative radiofrequency - Group D|Participants will perform only non-ablative radiofrequency
16253879|NCT04998565|Experimental|Routine care|Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
16253880|NCT04998565|Experimental|Routine care plus EA|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
~plus: Electrical acupuncture on body acupoints"
16253881|NCT04998565|Experimental|Routine care plus TENS|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
~plus: Transcutaneous electrical nerve stimulation on breasts"
16253882|NCT04998552|Experimental|SBRT (Cyberknife)|5-10 Gy/fraction. Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
16253883|NCT04998552|Active Comparator|IMRT|1.2-3 Gy/fraction up to 40 fractions. 15 mins daily (M-F) for a total of 28 sessions (5.5 weeks).
16253884|NCT04998539|Experimental|Upright wheelchair forward and occupant upright|Participant will push an upright wheelchair forward over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
16253885|NCT04998539|Experimental|Upright wheelchair backward and occupant upright|Participant will pull an upright wheelchair backwards over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
16253997|NCT04997811|Experimental|Danzol|Single agent
16269196|NCT04891185|Experimental|Primary Debulking Surgery|
16253886|NCT04998539|Experimental|Upright wheelchair forward and occupant leaning forward|Participant will push an upright wheelchair forward over a 5 m soft surface with the wheelchair occupant in the leaning forward body position.The participant will perform the task once.
16253887|NCT04998539|Experimental|Upright wheelchair backward and occupant leaning forward|Participant will pull an upright wheelchair backwards over a 5 m soft surface with the wheelchair occupant in the leaning forward body position.The participant will perform the task once.
16253888|NCT04998539|Experimental|Wheelie wheelchair forward and occupant upright|Participant will push a wheelchair using the wheelie technique forward over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
16253889|NCT04998539|Experimental|Wheelie wheelchair backward and occupant upright|Participant will pull a wheelchair using the wheelie technique backwards over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
16253890|NCT04998526|Experimental|Experimental group|After routine drug treatment is given to hypertension patients, the cold gel pack will be applied to the nape for 3 minutes.
16253891|NCT04998526|Placebo Comparator|Placebo group|After routine drug therapy is given to hypertension patients, the gel pack kept at room temperature will be applied to the nape for 3 minutes.
16253892|NCT04998526|No Intervention|Control group|Routine drug treatment will be given to hypertension patients and no application will be made.
16253893|NCT04998513|Active Comparator|Medical Management Alone Arm|Antibiotics, steroids, fluids
16253894|NCT04998513|Active Comparator|Surgical Arm|Incision and drainage
16253895|NCT04998500|Experimental|GH intervention - control intervention|Participants will receive daily subcutaneous injections of growth hormone for 7 days. Approximately 1-4 months later, the participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant).
16253896|NCT04998500|Experimental|Control intervention - GH intervention|Participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant). Approximately 1-4 months later, the participants will receive daily subcutaneous injections of growth hormone for 7 days.
16253897|NCT04998487|Experimental|LY3471851 (Abdomen)|LY3471851 administered subcutaneously (SC) into the abdomen.
16253898|NCT04998487|Experimental|LY3471851 (Thigh)|LY3471851 administered SC into the thigh.
16253899|NCT04998474|Experimental|FRAME-001 personalized vaccine|"Prospective, single arm, multi center, open-label, phase II clinical trial.
~Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs."
16253900|NCT04998461||Obese patients with normal renal function|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2
~Body Mass Index (BMI) > 30 kg/m2
~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
16253901|NCT04998461||Obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2
~Body Mass Index (BMI) > 30 kg/m2
~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
16253902|NCT04998461||Non-obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2
~Body Mass Index (BMI) between 18 and 30 kg/m2
~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
16253903|NCT04998461||Non-obese patients with normal renal function (control group)|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2
~Body Mass Index (BMI) between 18 and 30 kg/m2
~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
16253904|NCT04998448||Cases|women aged 18 to 50 years, premenopausal, with polycystic ovary syndrome
16253905|NCT04998448||Controls|women aged 18 to 50 years, premenopausal, without polycystic ovary syndrome.
16253906|NCT04998435|Active Comparator|ESPB group|Erector Spinae Plain Block
16253907|NCT04998435|Active Comparator|PV group|Paravertebral Block
16253908|NCT04998422|Experimental|Part A: HG381 Monotherapy Dose Escalation Cohort|Subjects will receive HG381 IV at every one week intervals (Q1W). Escalating doses of HG381 will be evaluated by the traditional 3+3 design.
16253909|NCT04998422|Experimental|Part B: HG381 Monotherapy Dose Expansion Cohort|Subjects will be administered the recommended Phase 2 dose of HG381 IV Q1W established in Part A of the study.
16253910|NCT04998409||Monofocal IOL|
16253911|NCT04998396|Experimental|Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)|Participants will receive a single intravenous (IV) infusion of low-dose BBP-812 on Day 0 in the dose-finding phase of the study.
16253912|NCT04998396|Experimental|Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)|Participants will receive a single IV infusion of high-dose BBP-812 on Day 0 in the dose-finding phase of the study.
16253913|NCT04998396|Experimental|Enrollment Expansion Phase: BBP-812|Participants will receive a single IV infusion of BBP-812 at a selected dose from the dose-finding phase on Day 0 in expansion phase of the study.
16253914|NCT04998383|Experimental|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort
16253915|NCT04998383|Experimental|Noninvasive ventilation|Respiratory assistance is provided by a NIV either Puritan Bennet 840 (Covidien, U.S.A.), EngströmCarestation (GE Healthcare, Finland) or Hamilton-G5 (Hamilton Medical, Germany), will be used for conventional non-invasive ventilation via an oronasal mask that helps patients to cope with their Breathlessness. Settings will be adjusted based on the clinical assessment of the respiratory therapist as per standard practice.
16253916|NCT04998370||Study cohort|The study population consists of patients admitted to an academic tertiary care center due to an aneurysmal subarachnoid hemorrhage. The primary objective of the study focuses on patients included with external ventricular drain (EVD), while secondary objectives consider patients with both EVD and lumbar drain (LD) as well as patients without any drainage system.
16253918|NCT04998344|Experimental|Inactivated influenza vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
16253919|NCT04998344|Active Comparator|Inactivated polio vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
16253920|NCT04998331||Participants With CD30-positive Lymphoma|All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides [MF] and cutaneous anaplastic large cell lymphoma [pcALCL]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse or participants who have a high risk of relapse post autologous stem cell transplantation (ASCT) and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.
16253921|NCT04998318|Active Comparator|Standard of Care|"Visual Inspection with Acetic Acid (VIA): First, the cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied to the cervix using a spray bottle or fox swab. After approximately 1-minute, any changes to the cervix using the naked eye will be noted. Acetic acid may be reapplied if acetowhitening diminishes during visual inspection.
~Visual Inspection with Lugol's Iodine (VILI): After imaging with Acetic acid, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Lesion location(s) will be noted on a clock-face diagram and used to direct biopsy if a lesion is present or random biopsies will be obtained from two quadrants in the absence of a visible lesion."
16253922|NCT04998318|Experimental|Pocket Colposcope|"Pocket-Assisted Visual Inspection with Acetic Acid (PA-VIA): The cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied using a spray bottle or fox swab. After approximately 1-minute, using the Pocket Colposcope any changes to the cervix will be noted. Using the Calla Health image acquisition software, both white and green images of the cervix will be captured at low-resolution. High-resolution green light images will be obtained at the provider's discretion. Acetic acid may be reapplied between white and green imaging at the provider's discretion if acetowhitening diminishes.
~Pocket-Assisted Visual Inspection with Lugol's Iodine (PA-VILI): After imaging with AA, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Images will be acquired. A biopsy will be obtained using the pocket. Random biopsies will be obtained from 2 quadrants in the absence of a visible lesion."
16253923|NCT04998305|Experimental|Treatment sequence TJ-68-Placebo-Placebo-TJ-68|"Employing an N-of-1, crossover design, each participant in the TJ-68 clinical trial will serve as his/her control. The participation will last for 11 weeks - four, 2-week treatment periods with 1-week washout (WO) period between each treatment period. Participants (n=13) will be randomized to the following treatment sequences:
~TJ-68, placebo, placebo, TJ-68 (1 week WO between each treatment period)"
16253924|NCT04998305|Experimental|Treatment sequence Placebo-TJ-68-TJ-68-Placebo|"Employing an N-of-1, crossover design, each participant in the TJ-68 clinical trial will serve as his/her control. The participation will last for 11 weeks - four, 2-week treatment periods with 1-week washout (WO) period between each treatment period. Participants (n=13) will be randomized to the following treatment sequences:
~placebo, TJ-68, TJ-68, placebo (1 week WO between each treatment period)"
16253925|NCT04998292|Experimental|Low level laser therapy|
16253926|NCT04998292|Active Comparator|Control|
16253927|NCT04998279|Experimental|Intervention group|
16253928|NCT04998279|Placebo Comparator|Control group|
16253929|NCT04998266|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
16253930|NCT04998266|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
16253931|NCT04998253|Experimental|Group 1: Sevofruorane (Svofast)|"Experimental group: will receive sedation with sevoflurane with an infusion rate to maintain MAC of 0.7 and fentanyl 1mcg /kg/hour.
~Inhalation sedation The AnaConda device (Sedana Medical, Ireland) is placed between the endotracheal tube and the ventilator circuit. The anesthetic infusion line is attached to a syringe, from where the anesthetic (sevoflurane) will be delivered to said device. The sample line will be taken to the anesthetic gas analyzer whit the Carescape B450 multiparametric monitors (General Electric, Finland) for MAC control. The anesthetic gas outlet port will be attached to the absorbent material container."
16253932|NCT04998253|Active Comparator|Group 2: Propofol (Diprivant)|"Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.
~For both groups, the doses will be titrated to maintain a RASS score between -3 to -4 in both groups.
~Both groups will receive cisatracurium (Nimbex) as a continuous infusion of 3 to 5mcg / kg/min for 48 hours. We will maintain sedation for both groups with the same scheme for 48 hours, after which the drugs used for sedation will be modified at the discretion of the intensive care physicians."
16253933|NCT04998240|Experimental|Prime BBIBP-CorV, Boost AZD1222 (GA1)|In general cohort (N=260), the randomization of study participants will be stratified into two cohorts in which the first arm will receive Prime BBIBP-CorV vaccine followed by Booster dose of AZD1222 vaccine (GA1)
16253934|NCT04998240|Experimental|Prime BBIBP-CorV, Boost BBIBP-CorV (GA2)|In general cohort (N=260), the randomization of study participants will be stratified into two cohorts in which the second arm will receive Prime BBIBP-CorV vaccine followed by Booster dose of BBIBP-CorV vaccine (GA2)
16253935|NCT04998240|Experimental|Prime AZD1222, Boost BBIBP-CorV (GB1)|In general cohort (N=260), the randomization of study participants will be stratified into two cohorts in which the third arm will receive Prime AZD1222 vaccine followed by Booster dose of BBIBP-CorV vaccine (GB1)
16253936|NCT04998240|Experimental|Prime AZD1222, Boost AZD1222 (GB2)|In general cohort (N=260), the randomization of study participants will be stratified into two cohorts in which the fourth arm will receive Prime AZD1222 vaccine followed by Booster dose of AZD1222 vaccine (GB2)
16253937|NCT04998240|Experimental|Prime BBIBP-CorV, Boost AZD1222 (SA1)|In the immunology subset cohort (n=100), participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of AZD1222 vaccine (SA1)
16254827|NCT04992117||Unplanned-extubation in the ICU|Patients with unplanned extubation in the ICU
16253938|NCT04998240|Experimental|Prime BBIBP-CorV, Boost BBIBP-CorV (SA2)|In the immunology subset cohort (n=100), participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of BBIBP-CorV vaccine (SA2)
16253939|NCT04998240|Experimental|Prime AZD1222, Boost BBIBP-CorV (SB1)|In the immunology subset cohort (n=100), participants will receive Prime AZD1222 vaccine followed by Booster dose of BBIBP-CorV vaccine (SB1)
16253940|NCT04998240|Experimental|Prime AZD1222, Boost AZD1222 (SB2)|In the immunology subset cohort (n=100), participants will receive Prime AZD1222 vaccine followed by Booster dose of Boost AZD1222 vaccine (SB2)
16253941|NCT04998227||suspect acute coronary syndrome|"Subjects with the diagnosis of suspected acute coronary syndrome (ACS), age between 20 to 80.
~Exclusion criteria: pregnant women, patients with end-stage renal disease (eGFR <15 mL/min/1.73 m2), cardiogenic shock."
16253942|NCT04998214||control group non cirrhotic|compare liver function 1m after COVID-19 and that at beginning of infection
16253943|NCT04998214||cirrhotic patients|compare liver function 1m after COVID-19 and that at beginning of infection
16253944|NCT04998201|Experimental|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
16253945|NCT04998201|Placebo Comparator|Placebo|calculated volume to match active treatment by sc injection
16253946|NCT04998188|Experimental|Collagen Injection|This group of patients will be treated with single intra-articular injection of collagen.
16253947|NCT04998188|Placebo Comparator|Placebo (saline solution)|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
16253948|NCT04998175|Experimental|iNPH cohort|The patients diagnosed of iNPH.
16253949|NCT04998162|Experimental|SVF injection|All patients with ankle osteoarthritis will be treated with a single injection of SVF, obtained from the patient's abdominal adipose tissue. All patients will be examined with a baseline clinical visit and will be followed-up with clinical evaluation at 1, 3, 6, 12 and 24 months.
16253950|NCT04998149|No Intervention|standard care|The control group subjects will receive standard of care during labor using pillows and wedges as positional devices.
16253951|NCT04998149|Experimental|Peanut ball intervention|The experimental group will receive peanut ball as positioning device during labor
16253952|NCT04998136|Experimental|Semaglutide 2.4 mg|
16253953|NCT04998136|Placebo Comparator|Placebo|
16253954|NCT04998123|Sham Comparator|Sham Stimulation|
16253955|NCT04998123|Experimental|ISP Stimulation|
16253956|NCT04998123|No Intervention|Perpheral Stimulation|
16253957|NCT04998110|Experimental|Supportive Care Intervention|The supportive care intervention arm will receive their usual ambulatory longitudinal nephrology care integrated with ambulatory supportive care through monthly supportive care visits over six months.
16253958|NCT04998110|No Intervention|Usual Care Control|The usual care control arm will be seen at the discretion of their nephrologist, or receive their usual dialysis if on dialysis.
16253959|NCT04998097|Experimental|experimental (iTBS group)|device: Magstim Rapid2 Stimulator
16253960|NCT04998097|Sham Comparator|sham group|device shame Magstim Rapid2 Stimulator
16253961|NCT04998071|Active Comparator|ROUTINE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.25% bupivacaine 0.4 ml/kg. in each side.
16253962|NCT04998071|Active Comparator|ALTERNATIVE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.125% bupivacaine 0.4 ml/kg. in each side.
16253963|NCT04998058|Placebo Comparator|Control (conventional graft procedure), bone substitute and saline solution.|one randomly assigned maxillary sinus grafted internally defined as control (bone substitute + saline solution) per subject.
16253964|NCT04998058|Experimental|Test (modified graft), bone substitute and concentrated culture medium (CM)|one randomly assigned maxillary sinus grafted internally defined as test (bone substitute + concentrated culture medium) per subject.
16253965|NCT04998045|Experimental|Intervention arm|Youth aged 15-24 years Intervention: screening and brief intervention for substance use
16253966|NCT04998032|Experimental|supaglutide RP3D dose+metformin|Supaglutide Subcutaneous injection once a week for 52weeks,combined with metformin
16253967|NCT04998032|Placebo Comparator|placebo+metformin|Placebo Subcutaneous injection once a week for 52weeks,,combined with metformin
16253968|NCT04998019|Experimental|PositiveLinks|Participants from clinics randomized to PL will get the patient smartphone app; clinic staff will receive the provider portal and provider smartphone app, the provider online LMS (learning management system), and the research assistant will use the administrative website to enroll participants. Patients randomized to PL will use it for 12 months or more; they can opt to use it as long as it is available during the study(access depending on enrollment date).
16253969|NCT04998019|No Intervention|Usual Care|Participants from clinics randomized to Usual Care (UC) will receive usual clinic retention and medication adherence support services for 12M. Based on site assessments, and descriptions from the clinics, the UC condition ranges from having no ancillary support to only case management, to Ryan White funding and comprehensive services (adherence support, patient navigation, mental health, substance abuse, dental services and food banks)
16253971|NCT04997980||Amiodarone group|Patients who did receive amiodarone during the attempt of resuscitation
16253972|NCT04997980||NO Amiodarone|Patients who did receive amiodarone during the attempt of resuscitation
16253973|NCT04997967|Experimental|Ketofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Will receive Ketofol (ketamine: propofol concentration 1:4) prepared in 50 ml syringe containing dextrose 5% (each ml contained 8 mg propofol and 2 mg ketamine), administered as following; 5 ml of ketofol as loading then infusion titrated till targeted RSS score.
16253974|NCT04997967|Active Comparator|Propofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
16254018|NCT04997681|Placebo Comparator|Control Exercise Training and Control Cognitive Training|Control Balance and Toning Exercise Training (BAT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
16253975|NCT04997954|Experimental|MediCabilis CBD Oil|MediCabilis CBD Oil to be taken no more than 7ml/day orally based from participants' individual 14 day titration period completed at the beginning of the trial. The frequency of the drug intake can range between once and three times a day depending on the outcome of the 14 day titration period. Titration period allows participants to gradually increase study drug intake in order to find appropriate dose for participants without or with minimal undesired side effects. The treatment will last no more than 6 months.
16253976|NCT04997941|Experimental|Tamoxifen 40mg|Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.
16253977|NCT04997941|Active Comparator|Tamoxifen 20mg|Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.
16253978|NCT04997928||Group 1 (n=20; with mild symptoms)|"Group 1 (n=20; with mild symptoms)
~Covid positive patients with mild symptoms who required to be hospitalized,
~Symptomatic (fever, cough, weakness, joint pain, etc.) new patients who apply to the Covid clinic for the first time,
~Patients with stable vital signs and/or SpO2 ≥92% in room air, no radiological signs of lung involvement or mild pneumonia,
~Patients who have not been started on steroid therapy and who have not yet received anticoagulant therapy."
16253979|NCT04997928||Group 2 (n=20; with moderate symptoms)|"Group 2 (n=20; with moderate symptoms)
~Patients who are positive for Covid 19 and admitted to the covid clinic for the first time;
~Radiologically moderate pneumonia findings and/or SpO2=88-92% in room air,
~Patients who have not been started antiviral, steroid, and anticoagulant treatment."
16253980|NCT04997928||Group 3 (n=20; with severe symptoms)|"Group 3 (n=20; with severe symptoms)
~Patients who are currently hospitalized in the Covid clinic,
~Patients with radiological findings of severe pneumonia or ARDS and/or high FiO2 requirement due to respiratory failure.
~Patients of this group may have received antiviral, anticoagulant, and/or steroid and/or biologic agent treatment."
16253981|NCT04997928||Group 4 (n=20; Control group)|"Group 4 (n=20; Control group)
~The control group will be composed of healthy adult individuals applying to adult allergy outpatient clinics on a voluntary basis.
~Patients who have not been previously diagnosed with Covid-19 and have not vaccinated against Covid-19,
~The control patients will be matched with the study groups according to age, gender, and BMI."
16253982|NCT04997915||Critical COVID-19|Critical COVID-19 patients admitted to the ICU
16253983|NCT04997902|Experimental|PIK3CA-dependent (Cohort 1)|Adult participants with R/M HNSCC whose tumors harbor PI3KCA (activating) mutations and/or amplifications
16253984|NCT04997902|Experimental|HRAS-dependent (Cohort 2)|Adult participants with R/M HNSCC whose tumors have increased HRAS dependency, defined as HRAS overexpression
16253985|NCT04997889|Experimental|artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
16253986|NCT04997889|Active Comparator|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
16253987|NCT04997876||Study Group|Biomarkers from presurgical OCTs are diagnosed
16253988|NCT04997863|Experimental|Sericin hydrogel sheet impregnated with EBN extract|Apply sericin hydrogel sheet impregnated with EBN extract on one-half of the donor site once daily for 8-12 hours per day for 6 months.
16253989|NCT04997863|Placebo Comparator|Placebo hydrogel sheet|Apply placebo hydrogel sheet on another half of the donor site once daily for 8-12 hours per day for 6 months.
16253990|NCT04997850|Experimental|TACE + lenvastinib + sindilimab/carrelizumab|The patients with body weight ≥ 60kg were treated with oral lenvastinib within 3 days (the initial dose was 12mg QD for patients with body weight < 60kg, the initial dose was 8mg QD for patients with body weight < 60kg). After 1-2 weeks of treatment, the patients received the first TACE treatment (3 days before TACE), and continued to take oral lunvastinib 3 days after TACE. Within one week after TACE treatment, 200 mg of sindilimab was given intravenously once every three weeks (every 21 days as a cycle) or 200 mg of carrelizumab was given intravenously once every three weeks (every 21 days as a cycle).
16253991|NCT04997850|Active Comparator|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).
~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
16253992|NCT04997837|Experimental|PD-1 inhibitor and chemoradiotherapy|"PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy.
~PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
~Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.
~Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy."
16253993|NCT04997837|Active Comparator|Chemotherapy|"Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.
~CapeOX:
~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.
~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
~SOX:
~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off.
~FOLFOX:
~Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.
~5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W."
16253994|NCT04997824|Experimental|Artificial Intelligence-based atrial fibrillation catheter ablation|catheter ablation
16253995|NCT04997824|Active Comparator|typical atrial fibrillation catheter ablation|catheter ablation
16253998|NCT04997798|Experimental|Dalpiciclib in combination with letrozole and trastuzumab plus pyrotinib|Receiving intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) and oral pyrotinib (400 mg po QD, Q3W) for six cycles plus oral Dalpiciclib (150 mg QD x 21 Q4W) and oral Letrozole (2.5 mg po QD for 20 weeks)
16253999|NCT04997785|Experimental|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
16254000|NCT04997785|Active Comparator|Intravenous Morphine|Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request.
16254001|NCT04997772||1|Gaucher disease patients > 18 years old.
16254002|NCT04997759|Experimental|Neostigmine group|This group will administered neostigmine for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
16254003|NCT04997759|Experimental|Sugammadex group|This group will administered Sugammadex for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
16254004|NCT04997746||educational pharmaceutical guidelines|Qualified listening of participants; General pharmaceutical educational guidelines on the use of medicines; Manufacture and supply of medicine organizer boxes.
16254005|NCT04997746||Nursing Educational Guidelines|"Nursing educational guidelines; Qualified listening to participants to resolve doubts related to their comorbidities and aging, bringing comfort in relation to their anxieties.
~Nursing interventions will occur through verbal educational guidelines given individually and according to the reality of each participant assessed by the research, based on the nursing diagnoses obtained from the North American Nursing Diagnosis Association - NANDA-I (definitions and classification 2018- 2020) 11th edition."
16254006|NCT04997746||Nutritional Educational Guidelines|Obtaining anthropometric measurements (weight, in kilograms, height (in meters), knee height, arm and calf circumference (in centimeters) to trace the participant's nutritional profile and, subsequently, personalized and appropriate nutritional guidelines will be carried out for each situation The calculation of the Body Mass Index (BMI) must be performed by dividing the weight (W) in kilograms (kg) by the square of the height (H) in meters (m) and indicates the individual's nutritional status. The BMI for the elderly (LIPSCHITZ, 1994 apud TAVARES et al., 2015) determines underweight less than or equal to 22kg / m2, adequate or eutrophic weight between 22 and 27kg / m2 and overweight result greater than or equal to 27kg / m2 .
16254009|NCT04997720|Other|Training|The course will be theoretical-practical, lasting eight hours, divided into two meetings with a theoretical class and practical exercises in microsurgery of increasing complexity. The course will also have an initial and final evaluation.
16254010|NCT04997707|Active Comparator|P group|75-100 µg/kg/min propofol
16254011|NCT04997707|Active Comparator|BA group|25ug/kg/min propofol and 0.2% below corrected-to-age- half MAC of sevoflurane
16254012|NCT04997694|Experimental|Active Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form, Temperature Comfort Perception Scale- The form was recorded in the Shivering Level Diagnosis Form Filling.Before anesthesia was given, heating was performed with the 3M Bair Hugger Model 775 Heating Unit, which has an active heating system, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
16254013|NCT04997694|Experimental|Pasive Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form ,Vital Signs Follow-up Form, Temperature Comfort Perception Scale. The form was recorded in the Shivering Level Diagnosis Form . Before anesthesia was given, heating was performed with a wool blanket, which is a passive heating method, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
16254014|NCT04997694|No Intervention|Control Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form , Temperature Comfort Perception Scale The form was recorded in the Shivering Level Diagnosis Form the participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form , Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
16254015|NCT04997681|Experimental|Exercise Intervention Training and Cognitive Intervention Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Cognitive Training (NeuropeakTM)
16254016|NCT04997681|Active Comparator|Exercise Intervention Training and Control Cognitive Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
16254017|NCT04997681|Active Comparator|Control Exercise Training and Cognitive Intervention Training|Control Balance and Toning Exercise Training (BAT) + Cognitive Training (NeuropeakTM)
16254019|NCT04997668|Active Comparator|SOLTIVE Thulium Fiber Laser group|SOLTIVE Thulium Fiber Laser group
16254021|NCT04997655||Upper Transabdominal Plain Block|All patients in this group are routinely administered general anesthesia. After extubation, the subcostal transverse abdominis area block was directed laterally along the rectus abdominis muscle by finding the linea alba under the xiphoid region under ultrasound guidance with a 22G echogenic block needle, and 20 ml (8 ml 0.5% bupivacaine, 7 ml prilocaine) into the fascia between the rectus abdominis and transverse abdominis muscles. , 5 ml of saline) drug mixture will be performed by the anesthesiologist in charge of that day, who is not aware of the observational measurement to be made, if there is an indication, as a blind practitioner.
16254022|NCT04997655||Opioid analgesia|All patients in this group are routinely administered general anesthesia. Apart from this, in the other group, which does not have peripheral nerve block and only routine opioid analgesia is considered sufficient, only routine peroperative USG diaphragm measurements will be recorded observationally.
16254023|NCT04997616|Experimental|25 mg/day dose of Happy Lane CBD (Lower Dose)|One 25 mg Happy Lane CBD gel capsule per day (25 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days.
16254024|NCT04997616|Experimental|50 mg/day dose of Happy Lane CBD (Larger Dose)|Two 25 mg Happy Lane CBD gel capsules per day (50 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days. Both capsules will be taken at the same time as each other.
16254025|NCT04997603|Other|Athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
16254026|NCT04997603|Other|Non-athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
16254027|NCT04997590|Experimental|Umbilical cord blood mononuclear cells group|Umbilical cord blood mononuclear cells (cell number 1×108/2mL), once every two weeks, 3 times in total.
16254028|NCT04997590|Active Comparator|Staphylococcal Enterotoxin C group|Staphylococcal enterotoxin C (2mL), once every two weeks, 3 times in total.
16254029|NCT04997577|Experimental|Auditory training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios.
16254030|NCT04997577|Experimental|Auditory-cognitive training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios. A short-term memory component is added to the training paradigm to make the task more engaging and challenging.
16254031|NCT04997577|Sham Comparator|Active control of informational videos|Individuals are asked to watch informational videos.
16254032|NCT04997564|Experimental|non-cirrhotic patients|patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment
16254033|NCT04997564|Other|cirrhotic patients|patients will be received TAF once daily for 64 weeks. In this study, after week 64, and patients will continue NUC treatment but pay by themselves.
16254034|NCT04997551|Active Comparator|Colchicine|EC Experimental group: colchicine for 2 weeks orally added to standard treatment.
16254035|NCT04997551|Placebo Comparator|Placebo|Control group: placebo for 2 weeks added to standard treatment.
16254036|NCT04997525|Active Comparator|Natural cycle|These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer
16254037|NCT04997525|Active Comparator|Estradiol and progesterone|These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6
16254038|NCT04997525|Active Comparator|Gonadotropin|These women will receive daily gonadotropin injection before embryo tranfer. Ovulation will be stimulated using hCG injection.
16254039|NCT04997512|No Intervention|Standard of care|Participants are returned to the care of their usual diabetes care provider following randomisation. They will donate blood and urine samples as well as completing diabetes specific questionnaires at 0 and 6 months. They will also wear a blinded glucose sensor (freestyle Libre PRO) for a two week period at month 6.
16254040|NCT04997512|Experimental|Intervention arm|Participants will be randomised at baseline. They will provide blood and urine samples at months 0 and 6 as well as fill in diabetes specific questionnaires. They will receive education surrounding hypoglycaemia at baseline from a diabetes specialist nurse. They will wear a freestyle libre device which is changed every two weeks for a period of 6 months. At weeks 2,4,12 and 24 they will have their diabetes medication adjusted by the diabetes specialist nurse/diabetes doctor according to their blood glucose profiles, analysed from the data generated by freestyle libre.
16254041|NCT04997499|Experimental|Teaching video|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by watching the teaching video and then will be asked to self inject subcutaneous depot-medroxyprogesterone as per the protocol. All participants will then be asked to answer survey questions. All health care providers that participate in the study will likewise be asked to answer survey questions.
16254042|NCT04997486|No Intervention|Control|Subjects will consume all meals/snacks during a ~15-h daily eating period (~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
16254043|NCT04997486|Experimental|TRE isocaloric|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
16254044|NCT04997486|Experimental|TRE ad libitum|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting) without any other dietary advice.
16254045|NCT04997473|Experimental|App Group|Participants will be receiving an addiction model based mobile health (mHealth) weight loss intervention with coaching for a total of 4 months duration
16254046|NCT04997447|Experimental|Intervention group|Two weeks of daily step reduction (limited to 2000 steps per day) followed by four weeks of supervised gym-based exercise rehabilitation (twice per week strength training and twice per week cycle endurance training)
16254047|NCT04997447|No Intervention|Control group|Continued monitoring of habitual daily step count without structured intervention. Classic control.
16254048|NCT04997434|Experimental|Intervention|After 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. The patient will have 15 to 20 minutes to carry out an artistic activity, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session.
16254049|NCT04997434|No Intervention|Control|The questionnaires and VAS will be offered to the control group at the beginning of the wait, then after 30 minutes of waiting under usual conditions.
16254050|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane|Control arm
16254051|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane + Hemoadsorption using HA380|Intervention arm
16254052|NCT04997408|Active Comparator|Study Arm|Mobile device-assisted rehabilitation
16254053|NCT04997408|Active Comparator|Control Arm|In-person therapist-supervised rehabilitation
16254054|NCT04997395|Experimental|CBD|Full spectrum cannabidiol dominant medicinal cannabis
16254056|NCT04997356|Experimental|Hostile Bias Modification (HBM) Training plus Unambiguous Feedback|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They are instructed not to respond if only an aggressive word can be formed. They will receive unambiguously hostile feedback to an essay.
16254057|NCT04997356|Placebo Comparator|Other training plus Unambiguous Feedback|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words. They will receive unambiguously hostile feedback to an essay.
16254058|NCT04997356|Experimental|Hostile Bias Modification (HBM) Training plus Ambiguous Feedback|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They are instructed not to respond if only an aggressive word can be formed. They will receive ambiguously hostile feedback to an essay.
16254059|NCT04997356|Placebo Comparator|Other training plus Ambiguous Feedback|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words. They will receive ambiguously hostile feedback to an essay.
16254060|NCT04997343|Experimental|MS patients|All MS patients will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity obtained from the most recently performed MRI according to clinical practice. These evaluations will be repeated according to clinical practice in patients taking DMT or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline.
16254061|NCT04997343|Other|Healthy controls|Healthy subjects will undergo only the neurophysiological evaluation at baseline.
16254062|NCT04997330|Experimental|Active rTMS|Bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
16254063|NCT04997330|Placebo Comparator|Sham rTMS|Sham bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
16254064|NCT04997317|Active Comparator|Phase 0: Group A|"Cycle 1: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously.
~Cycle 2: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously (following a cross-over design).
~Cycle 3 and Cycle 4 will be performed for group A patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
16254065|NCT04997317|Active Comparator|Phase 0: Group B|"Cycle 1: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously.
~Cycle 2: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously (following a cross-over design).
~Cycle 3 and Cycle 4 will be performed for group B patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
16254066|NCT04997317|Active Comparator|Phase I/II|3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
16254067|NCT04997304|Experimental|AirDuo and ProAir|This trial includes using the inhaler (AirDuo®) Digihaler™ and rescue inhalers (ProAir®) Digihaler™.
16254068|NCT04997291|Experimental|Dexrazoxane|
16254069|NCT04997278|Experimental|Coordinated Reset- Spinal Cord Stimulation|All subjects will undergo spinal cord stimulation (SCS) implantation and will be optimized on standard SCS (sSCS) settings using the standard clinical protocol, including paresthesia mapping, threshold finding, and adjustment of stimulation parameters to provide reduction in pain. Therapeutic sSCS will be maintained for a minimum of one month prior to baseline assessment. Following a washout period of three hours assessments will be performed and Coordinated Reset- spinal cord stimulation (CR-SCS) will be enabled by means of a firmware upgrade. Personnel from Boston Scientific will perform this upgrade. The simulator will then be programmed to deliver CR-SCS. At the end of one month of CR-SCS (with stimulation parameters similarly held constant for the last 7 days), baseline assessment will be repeated after a three hour washout period. Finally, a firmware downgrade will be performed by Boston Scientific Personnel, and patients will be treated with sSCS at their previous settings.
16254070|NCT04997265|Experimental|Low Intensity Anticoagulation|For patients assigned to the low intensity anticoagulation strategy, clinical teams will be instructed to initiate low intensity anticoagulation at doses and frequencies commonly used for deep vein thrombosis (DVT) prophylaxis. The choice of anticoagulant, dose, and frequency of administration will be deferred to treating clinicians.
16254071|NCT04997265|Active Comparator|Moderate Intensity Anticoagulation|For patients assigned to the moderate intensity anticoagulation group, clinical teams will be instructed to initiate a continuous infusion of moderate intensity anticoagulation targeting either a partial thromboplastin time (PTT) of 40-60 seconds or an Anti-Xa level of 0.2 to 0.3 IU/mL. The choice of anticoagulant and approach to dosing will be deferred to treating clinicians.
16254072|NCT04997252|Experimental|high-risk and oligometastatic prostate cance|Neoadjuvant therapy with apalutamide in combination with luteinizing hormone-releasing hormone analogues
16254076|NCT04997226|Active Comparator|tDCS over the left DLPFC with adaptive memory game|The stimulation will be carried out using a battery-powered mobile device made by Neurocon with two 5 x 5 cm electrodes The anodal electrode will be positioned above the F3 region of a standard EEG cap that is parallel to the cortical DLPFC region. The return electrode will be placed over the right eyebrow. The electrodes will remain on the subjects head for 50 minutes - the entire duration of the session. 1mA stimulation will be given for 15 minutes, then a 20-minute break and again 15 minutes of 1 mA stimulation. This protocol has been shown to improve the duration of the stimulus effect (Monte-Silva et al., 2013).
16254077|NCT04997226|Placebo Comparator|Sham tDCS over the left DLPFC with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 50 minutes, similar to the active tDCS arm.
16254078|NCT04997226|Active Comparator|tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but stimulation method will be employed at 2mA intensity for 20 minutes at theta-gamma coupling using a laplacian montage (Alekseichuk et al., 2016).
16254079|NCT04997226|Placebo Comparator|Sham tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 20 minutes, similar to the active tACS arm.
16254080|NCT04997213|Experimental|Interventional group|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and were individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
16254081|NCT04997213|Active Comparator|Control group|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first were commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
16254082|NCT04997200|Experimental|Intervention: One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
16254083|NCT04997200|No Intervention|Control: One night's normal sleep|A normal night's sleep (at least six hours) in the patient's home.
16254089|NCT04997161|Experimental|SZC arm with enhanced dietary advice|Participants will continue taking Sodium Zirconium Cyclosilicate (SZC), which can be titrated up or down to maintain S-K+ in the range 3.5-5.5 mmol/L; participants will also receive enhanced nutritional advice to consume fruit and vegetables. Advice will be provided by dietitians at study visits and by Noom app between visits.
16254090|NCT04997161|Other|SoC arm with standard dietary advice|SZC will be withdrawn and participants will receive SoC as per site practice, including dietary K+ restriction. Dietary advice will be given by dietitians at study visits and by Noom app between study visits.
16254091|NCT04997148||Cladribine|No intervention will be administered as a part of this study. Participants with Highly-active Disease Relapsing-remitting Multiple Sclerosis (HDA-RRMS), who completed at least Year 1 of treatment with cladribine tablets in routine clinical practice will be enrolled into this study and assessed up to maximum 5 years after cladribine tablets initiation.
16254092|NCT04997135||Meibography Subjects|Eligible subjects will undergo testing to evaluate the Meibomian gland appearance
16254093|NCT04997122|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
16254094|NCT04997122|Active Comparator|High-oleic sunflower oil|Intake of 45 g/d of high-oleic sunflower oil as the only source of oil in the diet
16254095|NCT04997109|Experimental|APPLES-tele first, then PCA|Participants receiving the APPLES-tele intervention for 6 weeks followed by the PCA intervention for 6 weeks.
16254096|NCT04997109|Experimental|PCA first, then APPLES-tele|Participants receiving the PCA intervention for 6 weeks followed by the APPLES-tele intervention for 6 weeks.
16254097|NCT04997109|Other|Standard of Care Control Arm|Participants receiving the standard of care for 6 weeks.
16254098|NCT04997096|Experimental|Exercise|"Participants randomized to one of two groups with 2:1 ratio: exercise (n=20)
~- Aerobic and Resistance Exercise for 16 weeks"
16254099|NCT04997096|Active Comparator|Attention Control|"Participants randomized to one of two groups with attention control (n=10).
~-Attention Control for 16 weeks home-based stretching"
16254100|NCT04997083|Experimental|cleft lip and palate patients|Cleft patients with transverse maxillary constriction and anteroposterior deficiency
16254101|NCT04997057|Other|Probiotics mixture|Daily supplementation with a mixture of probiotics for 12 weeks
16254104|NCT04997031||Latinx Adults 18 - 65 y|
16254105|NCT04997018|Experimental|Prostate cancer patients|"Intermediate-risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines. Intermediate-risk patients will be defined as:
~PSA 10-20 ng/ml or
~Gleason score = 7
~Clinical stage T2b/T2c"
16254106|NCT04996992||Parkinson's disease|The cohort includes patients with Parkinson's disease who underwent MRgFUS pallidothalamic tractotomy (PTT).
16254107|NCT04996979|Placebo Comparator|Control|Only standard care
16254828|NCT04992091|Experimental|CONSTRUCTIVE DEBRIEFING|interventional group
16254108|NCT04996979|Experimental|Intervention group|The PENG block was performed for intervention group with local anaesthetic solution composed of 20 ml of ropivacaine 0.5%.
16254109|NCT04996966|Placebo Comparator|control|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
16254110|NCT04996966|Experimental|MSCs injection|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
16254111|NCT04996953||165 patients with insomnia|
16254112|NCT04996940|Experimental|Tobacco then Menthol|Current menthol smokers will be randomized to session order and complete a 30 minute ad libitum session with each product (tobacco e-cigarette and menthol e-cigarette).
16254113|NCT04996940|Experimental|Menthol then tobacco|Current menthol smokers will be randomized to session order and complete a 30 minute ad libitum session with each product (menthol e-cigarette and tobacco e-cigarette).
16254114|NCT04996914|Experimental|TACE+SBRT.|If a patient is eligible to participate in the project according to the in- and exclusion criteria, the patient will assigned to 1-2 sessions of TACE followed by SBRT within one month from last TACE session .
16254115|NCT04996901||derivation cohort|Data from Renmin Hospital of Wuhan University will be used as a derivation cohort.
16254116|NCT04996901||validation cohort|Data from Yichang Central People's Hospital will be used as a derivation cohort.
16254117|NCT04996888|Experimental|with AI preoperative automatic reminder system|After receiving regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions, the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time.
16254118|NCT04996888|No Intervention|without AI preoperative automatic reminder system|The patients in the control group accept colonoscopy routinely without AI based preoperative automatic reminder system. All patients will receive regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions.
16254119|NCT04996875|Experimental|CGT9486|
16254120|NCT04996849||Observational (data collection)|Patients undergo data collection every 6 months for up to 15 years.
16254121|NCT04996836|Experimental|BC diagnosis and Omics|"Participants will be offered:
~Liquid biopsy of ctDNA and targeted NGS (BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, NF1, EPCAM, SMARCA4, CDK12);
~Whole-genome RRBS"
16254122|NCT04996836|No Intervention|BC diagnosis and standard of the care|Participants will not be offered targeted NGS or whole-genome RRBS but will receive their usual clinical care
16254123|NCT04996823|Experimental|Ipilimumab + Axtinib|Participants will receive treatment with ipilimumab 3 mg/kg IV q3 weeks x 4 doses and axitinib at 5 mg by mouth twice daily. Each cycle is 3 weeks/21 days
16254124|NCT04996810|Experimental|PROTOXIN (Phase I/II)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
16254125|NCT04996810|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
16254126|NCT04996797|Experimental|Cohort 1 PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
16254127|NCT04996797|Placebo Comparator|Cohort 1 Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
16254128|NCT04996797|Experimental|CDx+ Expansion Cohort PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
16254129|NCT04996797|Placebo Comparator|CDx+ Expansion Cohort Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
16254130|NCT04996784||Normal weight|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI).The normal weight group will contain 15 patients with a 18.5 ≤ BMI ≤ 25 kg/m2.
~Each group will be divided in two subgroups (female/ male)"
16254131|NCT04996784||Obese|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI). The obese group will contain 15 patients with a BMI ≥ 30 kg/m2.
~Each group will be divided in two subgroups (female/ male)"
16254132|NCT04996771|Experimental|Surufatinib Combined With Toripalimab and Chemotherapy|
16254133|NCT04996771|Experimental|Surufatinib Combined With Chemotherapy|
16254134|NCT04996758|Experimental|Toripalimab and Anlotinib Combination Treatment|Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity
16254135|NCT04996745|Experimental|Intervention Group|Patients randomized to the intervention group of the RCT will be given tablet-based education. The first clinic follow-up visit will consist of screening for consent, providing a QR code for Orthokids, and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will be provided with the tablet for repeat education, with Orthokids and the post-intervention questionnaire will be distributed. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care.
16254136|NCT04996745|No Intervention|Control Group|"Patients randomized to the control group of the RCT will receive the standard clinic experience. This group will not be exposed to any education enrichment about their child's fracture except for the physician's explanation within the exam room.
~The first clinic follow-up visit will consist of screening for consent and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will consist of conducting the post-intervention questionnaire. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care."
16254137|NCT04996732||All Cancers|subgroups according to cancer sites
16269197|NCT04891185|Experimental|Interval Debulking Surgery|
16254140|NCT04996693|Other|Scanner 2|Imaging performed on scanner 2: Energy-Integrating Detector CT (128-slice)
16254141|NCT04996693|Other|Scanner 3|Imaging performed on scanner 3: Energy-Integrating Detector CT (20-slice)
16254142|NCT04996680|Experimental|Blood flow restriction group|patients in this group will undergo a standard strength training program combined with an occlusion cuff. The cuff will reduce the amount of blood flow and therefore increase the metabolic stimulus. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
16254143|NCT04996680|Sham Comparator|Sham group|patients in this group will undergo the same standard strength training program as the BFR-group, combined with an occlusion cuff but pressurized so there is no significant effect on the lower limb blood flow. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
16254144|NCT04996680|Active Comparator|Control group|patients in this group will undergo the same standard strength training program as the BFR-group and placebo-group, but without a tourniquet.
16254145|NCT04996667|Active Comparator|Interventional Radiology Arm (Invasive Cohort)|"Interventional radiology (IR) will perform a right heart catheterization (RHC) as part of a planned IR procedure.
~Bedside apical 4 chamber view (RV:LV ratio) will be recorded using an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform.
~The Butterfly iQ+ (one possible ultrasound device which may be used) is a single-probe, whole-body ultrasound device.
~After initial measurements, inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The same measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
16254146|NCT04996667|Active Comparator|Non-intervention Arm (Non-invasive Cohort)|Vitals including O2 amount and modality, blood pressure, pressor name, dose, and rate will be recorded. If the patient is intubated, the name, dose, and rate of sedation and analgesia will be recorded. If the patient is not intubated, name and dose amount of sedation will be recorded. Arterial blood gas will be obtained if an A-line is placed. Bedside apical 4 chamber view will be recorded (RV:LV ratio) with an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. This data will be obtained before, during iNO administration, and after iNO has been withheld for 2 minutes.
16254147|NCT04996654|Experimental|Exergame|Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
16254148|NCT04996654|Active Comparator|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
16254150|NCT04996628|Experimental|Pancreatic Quantitative Sensory Testing (P-QST)|Definite Chronic Pancreatitis patients undergoing decompressive invasive treatments (endoscopic therapy or surgery) to relieve main pancreatic duct obstruction due to stones and/or stricture for management of pain will undergo P-QST prior to clinically-indicated invasive treatment.
16254151|NCT04996615||high risk population|women at high risk of breast cancer undergoing enhanced MRI
16254152|NCT04996602|Experimental|1.85GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
16254153|NCT04996602|Experimental|7.40GBq of 177Lu-PSMA-617|The patients were intravenously injected with the dose about 7.40GBq (200 mCi) of 177Lu-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
16254154|NCT04996589||Lean subjects|BMI 18.5-22
16254155|NCT04996589||Obese subjects|BMI>30
16254156|NCT04996576|Active Comparator|intranasal injection approach sphinopalatine ganglion block|Then in one nasal side (intranasal injection group) will be chosen randomly (right or left) by closed envelopes method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia and 2 ml saline will be injected in the same place in the other nasal side (to prevent surgeon expectation of intra nasal group by seeing injection site in one side only) by surgeon assistant who will be blind for the injection content.
16254157|NCT04996576|Active Comparator|infrazygomatic approach sphinopalatine ganglion block|"In the side saline only given by the intranasal injection A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.
~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
16254158|NCT04996563|Experimental|Video|A brief educational video on POP will be sent electronically to participants randomized to the video group. Participants will view the video within one week prior to their consultation visit.
16254159|NCT04996563|No Intervention|No video|Participants assigned to this group will not be sent the educational video to view.
16254160|NCT04996550||Carvedilol group|Treated with Carvedilol
16254161|NCT04996550||Metoprolol succinate group|Treated with Metoprolol succinate
16254162|NCT04996537|Experimental|Micro-video with pressure injury(PI) education|"The experimental group's flipped education and training courses adopt a digital learning method and provide a digital learning platform. Log in according to personal account and password, and learn the curriculum units planned by the researcher in order: Prevention and management of stressful injury care as the main axis, enter the digital platform The provided video audio-visual digital teaching materials, combined with clinical situational learning, are equipped with basic knowledge learning, in-class test questions, and unit review, and can open courses for self-study anytime and anywhere, regardless of time and space constraints."
16254197|NCT04996277|Experimental|angiography|Appropriate treatment (implantation of stents) will be given according to the evaluation of the physician.
16254298|NCT04995523|Experimental|Dose Expansion Part D: To be confirmed through a protocol amendment|AZD2936 IV monotherapy
16254163|NCT04996537|Active Comparator|NIS with PI education|At the login interface of the Nursing Information System (NIS) used by the nursing staff daily, a link to the lecture notes (PDF file) of the course on prevention of stress injury is attached, and the nursing staff can view or download them according to their needs. Learn. At the same time, it provides a digital learning platform to download the self-study course handouts (PDF files) and complete the basic demography, pre-test, and post-test data on the platform.
16254164|NCT04996524|Experimental|epidural analgesia group|
16254165|NCT04996524|No Intervention|systemic analgesia group|
16254166|NCT04996511|Experimental|Colorectal Surgery Patients|
16254167|NCT04996498|Active Comparator|Group A (Oxytocin group):|30 women will undergo a hysteroscopic myomectomy with the use of 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine ).
16254168|NCT04996498|Placebo Comparator|Group B (Placebo group):|30 women will undergo hysteroscopic myomectomy with the use of a sterile bacteriostatic water ampule in the distending medium (1,5% glycine).
16254169|NCT04996485|Experimental|Experimental group №1 (Secukinumab )|Secukinumab - subcutaneous injections into the shoulder according to the schedule of 0,1,2,3 weeks, then injections 1 time in 3 months up to 52 weeks of therapy.
16254170|NCT04996485|Experimental|Experimental group №2 (Ustekinumab)|Ustekinumab - subcutaneous injections in the shoulder on schedule 0; 1 month, then every 2 months up to 52 weeks of therapy.
16254171|NCT04996485|Experimental|Experimental group №3 (Dupilumab)|"Dupilumab - subcutaneous injections in the shoulder:
~for patients weighing from 15 to <30 kg: initial dose - 600 mg (2 injections of 300 mg), then 300 mg every 4 weeks; for patients weighing from 30 to <60 kg: initial dose - 400 mg (2 injections of 200 mg), then 200 mg every 2 weeks; for patients weighing 60 kg or more: the initial dose is 600 mg (2 injections of 300 mg), then 300 mg every 2 weeks."
16254172|NCT04996485|Active Comparator|Control group (Symptomatic therapy)|symptomatic therapy with emollients + systemic retinoids
16254173|NCT04996472|Experimental|Sensitivity to phonological rules: Adults|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern
16254174|NCT04996472|Experimental|Sensitivity to semantic category cues: Adults|Arm 1. Referential cue during OR learning.
16254175|NCT04996459||Tislelizumab group|
16254176|NCT04996446|Experimental|Alpps plus Tislelizumab group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
16254177|NCT04996446|Active Comparator|Alpps group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
16254178|NCT04996433|Experimental|Cognitive Behavioral Analysis System of Psychotherapy (CBASP)|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
16254179|NCT04996433|Active Comparator|Behavioral Activation (BA)|Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
16254180|NCT04996420|Experimental|Clearsight|hemodynamic monitoring and goal directed fluid therapy guided by clearsight
16254181|NCT04996420|Other|Control|hemodynamic monitoring blinded and silenced, no goal directed fluid therapy. Fluid therapy based on clinical evaluation and mean arterial pressure by non-invasive monitoring
16254182|NCT04996407|Active Comparator|survival thermal blanket|Patient will be using survival thermal blanket as substitute for perforated blanket with forced air warmer during anesthesia
16254183|NCT04996407|Active Comparator|draping fabric|Patient will be using draping fabrics as substitute for perforated blanket with forced air warmer during anesthesia
16254184|NCT04996394||NMBAs|
16254185|NCT04996368|Active Comparator|low dose (10mg/kg)|The dose of tranexamic acid varies widely ranging from 10mg/kg to 100mg/kg. We are comparing 10mg/kg to conventional 30mg/kg dose. The result of this study will help us to review our current practice.
16254186|NCT04996368|Active Comparator|high dose or conventional group (30mg/kg)|dose 30mg/kg regularly use in our center as a prophylaxis for prevention of bleeding before open heart surgery
16254187|NCT04996329|Experimental|comprehensive smoking cessation intervention group|Early health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
16254188|NCT04996329|Active Comparator|brief smoking cessation intervention group|brief smoking cessation intervention only
16254189|NCT04996316||Clinical staff (interview, training, survey)|Before implementation, some participants will complete usability testing of the interface in the electronic health record and MammoScreen. Participants participate in interviews over 30 minutes at baseline, then undergo training sessions over 20 minutes monthly prior to MammoScreen launch. Clinical staff also participate in interviews over 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the first month of the maintenance phase.
16254190|NCT04996316||Patients (interview, MammoScreen)|Patients participate in interviews over 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.
16254191|NCT04996303|Other|Routine|Routine steroid administration group
16254192|NCT04996303|Other|Pulse|Steroid pulse therapy group
16254193|NCT04996290|Active Comparator|PENG + LFCN block|"The participants in this group received a combined regional technique just before surgery:
~Pericapsular nerve group (PENG) block
~Lateral femoral cutaneus nerve (LFCN) block"
16254194|NCT04996290|No Intervention|No regional anesthesia|Control group
16254195|NCT04996277|Experimental|Fractional Flow Reserve|Patients with FFR ≤ 0.8 will undergo PCI Patients with FFR > 0.8 will be treated with medication For study purposes, all patients will undergo OCT (subject's treatment strategy will be based on FFR results, e.g., stent-implanted OCT).
16254196|NCT04996277|Experimental|Optical CoherenceTomography|Patients with MLA < 4.5mm² will undergo PCI Other patients will be treated with medication For study purposes, all patients will undergo FFR (subject's treatment strategy is based on OCT results; reference to FFR results is not recommended)
16254398|NCT04994756||Stroke|
16254399|NCT04994756||Thrombectomy|
16254198|NCT04996264|Experimental|Varespladib-methyl|"Varespladib-methyl is an immediate-release (IR), oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
~Scaled pediatric doses of varespladib-methyl are supplied as 50 mg IR capsules for oral administration.
~Adult subjects will receive an initial loading dose of 500 mg (2 × 250 mg oral tablet) varespladib-methyl upon randomization, followed by dosing with 250 mg varespladib-methyl (1 × 250 mg oral tablet) approximately 12 hours later, and subsequent twice daily (BID) dosing with 1 × 250 mg varespladib-methyl oral tablets for the remainder of the 7-day treatment period. Tablets may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation.
~Pediatric subjects (5 to < 18 years) will be administered doses of varespladib-methyl determined by allometric scaling, provided as 50 mg capsules. Age-appropriate capsules may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation."
16254199|NCT04996264|Placebo Comparator|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.
~Placebo for scaled pediatric dosing is supplied as an immediate-release capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.
~The dosing of placebo will match that of varespladib-methyl."
16254200|NCT04996251|Experimental|subcutaneous infiltration pre-incision|Marcaine (bupivacaine) injected in the umbilical port site subcutaneously, while in the other 4 sites injection under direct visualization
16254201|NCT04996251|Experimental|subcutaneous infiltration post-incision|local anesthetic infiltrated subcutaneously at the end of the procedure after trocar removal and after skin closure with suture
16254202|NCT04996238|Other|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid will be collected just before the first vaccination (T1: pre-vaccination) and between 14 and 30 days after the second vaccination (T2: post-vaccination)
16254203|NCT04996225|Experimental|Group (A): (study group)|Group (A): (study group) 15 patients received aerobics exercises and balancing exercises in addition to relaxation exercises for 4 weeks, 3sessions/week.
16254204|NCT04996225|Placebo Comparator|Group (B): (Control group)|2-Group (B): (Control group) 15 patients received relaxation exercises in the form of physical relaxation exercise for 4 weeks, 3 sessions/week. the participants who received aerobics exercises and balancing exercises in addition to relaxation exercises (experimental group A), showed significant decrease in anxiety and dizziness more than (placebo group B)
16254205|NCT04996212|Placebo Comparator|Educational Group|
16254206|NCT04996212|Experimental|Respiratory Physiotherapy Group|
16254207|NCT04996212|Experimental|Walking Group|
16254208|NCT04996212|Experimental|Functional Exercise Group|
16254209|NCT04996199|Experimental|Oxcarbazepine GROUP|Oxcarabazepine 150mg BD starting dose & will be increased if the patient is not relieved
16254210|NCT04996199|Active Comparator|Carbamzepine GROUP|carbamazepine 100mg BD initial dose & will be increased if the patient is not relieved
16254211|NCT04996186||Patients enrolled|Patients with Multiple sclerosis, with an age older than 18 years old and symptoms of fecal incontinence or chronic constipation
16254212|NCT04996173|Placebo Comparator|Control|Bronchoscopic Balloon Dilation with Radial Cuts
16254213|NCT04996173|Active Comparator|Intervention|Bronchoscopic Balloon Dilation with Radial Cuts & truFreeze Spray Cryotherapy
16254214|NCT04996160|Experimental|Cohort 1 -(without Ph+ / Ph like mutation)|Dose expansion phase-10 subjects in Cohort 1, 100 mg/m2/daily palbociclib on Days 1 to 5; 11 to 15; and 21 to 30, in combination with chemotherapy. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17.
16254215|NCT04996160|Experimental|Cohort 2-(Ph+ / Ph like ALL subtypes):|Dose escalation phase- 12 subjects in Cohort 2, Palbociclib dose escalation will begin at 75 mg/m2/day, on Days 1 to 5; 11 to 15; and 21 to 30, and escalate or de escalate. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17. Subjects with Ph+ / Ph-like mutation will receive a tyrosine kinase inhibitor (TKI or KI, either dasatinib or ruxolitinib).3 on 3 dose escalation with 2 dose levels.
16254216|NCT04996121|Experimental|XZP-5955 tablets|XZP-5955 tablets
16254217|NCT04996108||Participants with recurrent pericarditis (RP)|Patients aged 16 or over with (1) RP, diagnosed by a clinician, meeting the European Society of Cardiology (ESC) diagnostic criteria, and (2) where the aetiology of the RP is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease).
16254218|NCT04996108||Participants with systemic auto-inflammatory diseases (disease controls)|Patients aged 16 or over with a systemic auto-inflammatory disease, diagnosed by a trained specialist.
16254219|NCT04996108||Healthy volunteers (healthy controls)|Sex, ethnicity and aged matched healthy individuals who do not have a personal history of pericarditis or systemic auto-inflammatory disease.
16254220|NCT04996108||Relatives of individuals with recurrent pericarditis (familial controls)|First degree relatives of participants meeting the criteria for, and included in the study as, RP cases, who are aged 16 or over.
16254221|NCT04996082||Systemic sclerosis group|Patients with systemic sclerosis
16254222|NCT04996082||No Systemic sclerosis group|Patients without systemic sclerosis
16254224|NCT04996056|Experimental|TNX-1300|TNX-1300 Intravenous injection 200 mg once over 2 mins
16254225|NCT04996056|Other|Usual Care|Usual Care per the Emergency Department protocol for treating Cocaine Intoxication
16254226|NCT04996043|Placebo Comparator|Placebo drink|
16254227|NCT04996043|Experimental|Collagen Peptide Drink|
16254228|NCT04996030|Experimental|Single-Dose PK Module: Sequence 1|Participants will receive ATO as IV infusion in fasted state on Day 1, SY-2101 administered orally in fed state on Day 8, and SY-2101 administered orally in fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle
16254229|NCT04996030|Experimental|Single-Dose PK Module: Sequence 2|Participants will receive ATO as IV infusion in fasted state on Day 1, SY-2101 administered orally in fed state on Day 8, and SY-2101 administered orally in fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
16254230|NCT04996030|Experimental|Multiple-Dose IV Module|Participants will receive IV infusion of ATO, once daily (QD), 5 days/week for 28 days as a part of at least 1 cycle (Weeks 1 through 4) of SOC treatment consolidation.
16254231|NCT04996030|Experimental|Multiple-Dose Oral Module|Participants will receive SY-2101, orally, QD, 5 days/week for 28 days as a part of 1 cycle (Cycle 4; Weeks 1 through 4) of SOC treatment consolidation.
16254232|NCT04996017|Experimental|Arm A|atezolizumab 1200mg every 21 days
16254233|NCT04996017|Placebo Comparator|Arm B|Placebo will be supplied by the sponsor and will be identical in appearance to atezolizumab and will comprise the same excipients but without atezolizumab every 21 days
16254234|NCT04996004|Experimental|Dose Escalation|
16254235|NCT04996004|Experimental|Dose Expansion Low Dose (Cohort A)|
16254236|NCT04996004|Experimental|Dose Expansion High Dose (Cohort B)|
16254237|NCT04995991|Experimental|RRT rhythm only|10 RRT rhythm only sessions of 60 minutes, twice a week under the supervision of a trainer
16254238|NCT04995991|Experimental|RRT rhythm + visual cue|10 RRT rhythm + visual cue sessions of 60 minutes, twice a week under the supervision of a trainer
16254239|NCT04995991|No Intervention|No intervention|5 weeks no intervention period
16254240|NCT04995978|Experimental|Pioglitazone|
16254241|NCT04995978|Placebo Comparator|placebo|
16254242|NCT04995952|Experimental|Gross motor training activity|Gross motor training activity It includes training of motor components of child grossly
16254243|NCT04995952|Experimental|Trunk targeted training|In this training group the particpiants were given the exercises that were focused the truck muscles
16254244|NCT04995926|Experimental|Labial mucosa epithelium grafting for corneal limbus substitution.|Surgery for treating limbal stem cell deficiency using a strip of the lip oral mucosa with trimmed off the substantia propria and grafted as a circular corneal limbus substitute.
16254245|NCT04995913|Experimental|Computer-based (PC) online CBT program (Web version of the EASE Online Program)|The Web version of the EASE Online Program delivers the online CBT program through the Program website. It includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy.
16254246|NCT04995913|Experimental|Smartphone-based (App) online CBT program (App version of the EASE Online Program)|The App version of the EASE Online Program delivers the online CBT program through a smartphone application. The program content and system functions are the same as those of the Web version.
16254247|NCT04995913|Other|Waitlist control group|The Waitlist control group will receive the service of the Web version of the EASE Online Program after the two experimental groups completed the service.
16254248|NCT04995900|Experimental|Intervention|Intervention period with active Heart Matters education delivered
16254249|NCT04995900|No Intervention|Control|Control period with no Heart Matters education delivered.
16254250|NCT04995887||C-Section Delivery with EBL ≥ 1500 mL|Patients with ≥ 1500 mL estimated blood loss (EBL) at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
16254251|NCT04995887||C-Section Delivery with EBL < 1500 mL|Patients with < 1500 mL EBL at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
16254252|NCT04995887||Vaginal Delivery with EBL ≥ 1000 mL|Patients with ≥ 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
16254253|NCT04995887||Vaginal Delivery with EBL < 1000 mL|Patients with < 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
16254254|NCT04995874|Experimental|Intervention|KOKOPlus protein and micronutrient powder , a complementary food supplement containing soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix was formulated. Two weeks' supply of KOKOPlus sachets will be given to intervention arm participants every fortnight for 6 months to be mixed into any cereal, soup, stew, or other food given to the children.
16254255|NCT04995874|No Intervention|Control|This arm will not receive the Kokoplus Supplement for the duration of the study.
16254256|NCT04995861|Active Comparator|Group A (adductor canal only)|Will recieve adductor canal block only
16254257|NCT04995861|Active Comparator|Group AB (adductor canal + IPACK)|Will recieve both adductor canal block and IPACK
16254258|NCT04995848|Experimental|Telepalliation group|"The intervention group will participate in the telepalliation program. The patients will lent a tablet during the RCT study to access the TelePal.dk platform an video consultations. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:
~They stop being followed by the Palliative Team due to lack of symptoms
~They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:
~The project nurse or the clinical responsible doctor at the patients' home OR
~A district nurse under video supervision by the project nurse or the clinical responsible doctor
~Death of the patient"
16254294|NCT04995536|Experimental|Treatment (radiation therapy, CAS3/SS3)|Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
16254295|NCT04995523|Experimental|Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced NSCLC|AZD2936 Intravenous (IV) monotherapy
16254296|NCT04995523|Experimental|Dose Expansion Part B: CPI experienced NSCLC|AZD2936 IV monotherapy
16254400|NCT04994756||Aneurysm|
16254259|NCT04995848|No Intervention|Conventional palliation program|"The control group will follow a conventional palliation program. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:
~They stop being followed by the Palliative Team due to lack of symptoms
~They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:
~The project nurse or the clinical responsible doctor at the patients' home OR
~A district nurse under video supervision by the project nurse or the clinical responsible doctor
~Death of the patient"
16254260|NCT04995835|Experimental|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.
16254261|NCT04995822||EUROSTEM femoral stem|All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
16254262|NCT04995809||EPRIMM study participants|
16254263|NCT04995796|Experimental|Enrolled Participants|Study participation will involve 2 visits. The first visit will take approximately 90 minutes, but may be longer if participant desires longer interaction with the DSI/DA. The second visit will take approximately 5 minutes.
16254264|NCT04995783||Ulcerative Colitis|
16254265|NCT04995783||Crohn's Disease|
16254266|NCT04995783||Rheumatoid Arthritis|
16254267|NCT04995783||Psoriasis|
16254268|NCT04995783||Control|
16254269|NCT04995770|Experimental|Praise Text Messages|"The text message praise intervention lasted for 6 months. Each week, transplant coordinators, masked from who enrolled in the study or to which condition participants were randomized, prepared a list of all patients in the study age group whose laboratory blood tests indicated that immunosuppressant medications were within the expected range. A researcher reviewed the list to identify whether any of patients were currently assigned to the intervention, and if so, sent text message praise via REDCap's text message function. We rotated through 14 standardized text messages each week. Examples of messages included: Your labs look very good. Super job taking your meds! and Your labs look great! Thanks for putting in the effort to take care of your health!."
16254270|NCT04995770|No Intervention|Usual Care|Participants in the usual care arm did not receive any praise text messages. All participants continued to receive usual care from the multidisciplinary liver transplant team, including phone calls and follow-up care when laboratory blood tests indicated that immunosuppressant medications were outside of the expected range.
16254271|NCT04995757|Experimental|MicroPort NeuroTech Stentretriever|
16254272|NCT04995757|Active Comparator|Solitaire FR|
16254273|NCT04995744|Other|Patients with closed Neer type 4 proximal humerus fractures|patients aged 50-75 years with closed Neer type 4 proximal humerus fractures
16254274|NCT04995731||Women with pre or peri-menopausal abnormal uterine bleeding or post menopausal bleeding|Eligible women presenting to Women's Health hospital with pre or peri-menopausal AUB or PMB will be prospectively enrolled after obtaining their informed consent. AUB will be deﬁned by symptoms of heavy menstrual bleeding, inter-menstrual bleeding, meno-metrorrhagia, irregular menses, or other AUB among women aged ≥40 years who are not in menopause. Peri-menopausal bleeding will be defined as vaginal bleeding after 6 months of menopause after the age of 40 years. Postmenopausal status will be defined as the absence of menstruation for at least 12 months after the age of 40 years, where any pathological condition of amenorrhea is excluded.
16254275|NCT04995718|Experimental|IPET: Intelligent physical exercise training during working hours|Workplace physical exercise
16254276|NCT04995705|Experimental|Experimental Group Based ACT|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. This consisted of 2.5 hour sessions over 5 consecutive weeks.
16254277|NCT04995705|Active Comparator|Waitlist Control Group -|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. Participants within the waitlist control arm of the study had to wait six weeks before they were offered the same intervention as the intervention arm. They received treatment as usual.
16254278|NCT04995692|Experimental|Telehealth Education for Asthma Connecting Hospital and Home (TEACHH)|New model of patient-centered asthma education
16254279|NCT04995692|Active Comparator|Standard Care (SC) Comparison Group|Standard inpatient asthma education per hospital protocol.
16254280|NCT04995679|Other|Patient whit osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery with metaphyseal sleeves
16254281|NCT04995666|Experimental|Hearing Aid|Participants will wear Phonak rechargeable Audeo hearing aids
16254282|NCT04995653|Experimental|Cohort 1 - Open Label Study|Vancomycin & SER-155
16254283|NCT04995653|Experimental|Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study|Vancomycin & SER-155 OR Vancomycin placebo & SER-155 placebo
16254284|NCT04995640||CILCA patients|Subject with a CILCA and a thoracic cardiovascular disease requiring treatment. Both open cardiovascular repair and endovascular treatment (TEVAR) will be included.
16254285|NCT04995627|Active Comparator|Salt (NaCl)|"12 grams (12 capsules) of NaCl per day
~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
16254286|NCT04995627|Placebo Comparator|Placebo|"12 capsules of placebo per day
~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
16254287|NCT04995601|No Intervention|Standard of Care|Participants will receive DVT prophylaxis using standard intermittent pneumatic compression during postoperative care after total joint replacement.
16254288|NCT04995601|Experimental|Recovery Force MAC|Participants will receive DVT prophylaxis using the RF Health MAC during postoperative care after total joint replacement.
16254289|NCT04995588|Other|Blood test|Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
16254290|NCT04995575||all MINDACT patients who relapse|
16254291|NCT04995562|Experimental|Oxygen with nasal cannula|6 infants on oxygen with nasal cannula
16254292|NCT04995562|Experimental|HFNC, CPAP, or RAM cannula|6 infants currently requiring respiratory support with high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) or RAM cannula
16254293|NCT04995549|Experimental|Measures using Cutiscan® CS 100|
16254297|NCT04995523|Experimental|Dose Expansion Part C: CPI Naive NSCLC|AZD2936 IV monotherapy
16269303|NCT04890535|Placebo Comparator|Part 2 Dose Level 1: placebo|placebo
16254299|NCT04995510||Chronic Obstructive Pulmonary Disease Group|Individuals diagnosed with chronic obstructive pulmonary disease by ''Bolu Abant Izzet Baysal University'' Faculty of Medicine, Department of Chest Diseases and referred to the Physiotherapy and Rehabilitation Department of Bolu Abant Izzet Baysal University Health Sciences Faculty
16254300|NCT04995510||Healthy Group|Volunteer healthy individuals with similar demographic characteristics and without any diagnosed disease will be recruited
16254301|NCT04995497|Experimental|Erector Spinae Plane Block-Administration of Lidocaine|Bilateral ultrasound guided erector spinae plane catheter placement for the administration of lidocaine. Dose will be 2 mg/kg ideal body weight. Bolus will be divided equally between the two ESP catheters. This is followed by lidocaine infusion via ESP catheter at 2 mg/kg/hr for 48 hours after catheter placement.
16254302|NCT04995497|Active Comparator|Intravenous-Administration of Lidocaine|Sham block procedure (catheter will be taped to subjects skin). Subject will receive a bolus of lidocaine at 2 mg/kg ideal body weight. This is followed by lidocaine infusion via intravenous route at 2 mg/kg/hr for 48 hours after sham catheter placement.
16254303|NCT04995484|Experimental|Belzutifan in participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single oral 120 mg dose of belzutifan.
16254304|NCT04995484|Experimental|Belzutifan in participants with normal hepatic function|Participants with normal hepatic function will receive a single oral 120 mg dose of belzutifan.
16254305|NCT04995471|Experimental|In presence RRT - prototype software|10 biweekly in presence sessions of 45 minutes supervised by a trainer
16254306|NCT04995471|Experimental|In presence RRT - online platform|10 biweekly in presence sessions of 45 minutes supervised by a trainer
16254307|NCT04995471|Experimental|Tele-RRT - prototype software|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
16254308|NCT04995471|Experimental|Tele-RRT - online platform|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
16254309|NCT04995471|No Intervention|No intervention|5 weeks no intervention period
16254310|NCT04995458|Experimental|Composite-ceramic|To assess the clinical performance and survival of posterior composite-ceramic implant-supported crowns
16254311|NCT04995458|Active Comparator|Monolithic zirconia|To assess the clinical performance and survival of posterior monolitihic zirconia implant-supported crowns
16254312|NCT04995419|Experimental|Enfortumab vedotin|Participants will receive enfortumab vedotin on Days 1, 8 and 15 of every 4-week (28 days) cycle.
16254313|NCT04995406||Active TB ATB|Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity
16254314|NCT04995406||Latent Tuberculosis Infections LTBI|Participants with presumed latent TB infection
16254315|NCT04995406||Healthy controls HC|Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study
16254316|NCT04995406||Non-tuberculous symptomatic participants|This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.
16254317|NCT04995393|Active Comparator|Glove|A heated glove containing water.
16254318|NCT04995393|Active Comparator|Blanket|A heated blanket.
16254319|NCT04995393|Active Comparator|Gel pack|A heated gel pack.
16254320|NCT04995367|Experimental|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke|The participants will carry out tests for the evaluation of the functionality of the BCI system integrated to the T-FLEX device. The test consists of 1 session that includes four conditional experiments. Real Movement, Continuous Stationary Therapy, Motor Imagery Detection with Visual Stimulation, and Motor Imagery Detection with Tactile Stimulation.
16254321|NCT04995354|Experimental|EGF loaded Hydrogel (Gp I)|30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.
16254322|NCT04995354|Active Comparator|Hydrogel alone ( Gp II)|30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.
16254323|NCT04995354|No Intervention|Control (Gp III)|30 patients will receive the standard of care treatment (Control) which includes benzydamine mouthwash, increased hydration, topical analgesics and antifungals.
16254324|NCT04995341|Experimental|Cohort 1: Functional and structural outcomes in children after bedside OCT imaging in infancy|80 pediatric participants who were previously enrolled in BabySTEPS1 from July 22, 2016 - December 30, 2020 will be enrolled for follow-up neurodevelopmental testing, visual acuity, visual function testing and investigational retinal imaging
16254325|NCT04995341|Experimental|Cohort 2: Test of bedside OCT imaging data to predict RW-ROP or ROP progression|250 infants at risk for retinopathy of prematurity: 132 will be enrolled and have investigational bedside OCT retinal imaging, and their data will be combined with that from 118 infants who had similar imaging in BabySTEPS1 for analysis of the total group versus the indirect ophthalmoscopic clinical exam data.
16254326|NCT04995341|Experimental|Cohort 3: Comparison of ROP imaging with investigational OCT versus retinal camera|102 infants, who are a sub-group of the 132 enrolled in Cohort 2, will also have imaging with a conventional, commercially available, retinal camera system to compare utility, stress, and prediction and documentation of referral-warranted ROP between the camera images and those from investigational OCT.
16254327|NCT04995341|Experimental|Cohort 4: Adult and pediatric participants enrolled for imaging during system development|12 awake healthy adult controls and 12 pediatric participants undergoing examination under anesthesia in the operating room will be imaged with the investigational bedside OCT for the purpose of technological development.
16254328|NCT04995328|Experimental|Radiation Care Gel application|Radiation Care® gel is instructed to use on the target skin area accepted radiation therapy twice daily.
16254330|NCT04995302|Active Comparator|Microneedling and Amnion Bilayer|Microneedling is a dermaroller procedure that uses small needles to prick the skin. Amnion bilayer is used as an additional therapy after microneedling therapy.
16254331|NCT04995302|Placebo Comparator|Microneedling|Microneedling is a dermaroller procedure that uses small needles to prick the skin.
16254332|NCT04995263|No Intervention|Pre-intervention, control group|A basal measurement of primary and secondary outcomes of the target population, prior to the implementation the intervention. Estimated duration 3 months, n = 30.
16254333|NCT04995263|Experimental|Post-intervention, SUEÑA half bundle, active group 1|"Post-intervention, environmental and behavioral modifications in patient care interventions.
~Implementation of components 1 through 4 of SUEÑA intervention in the entire PICU unit. All participants will be exposed to the intervention. Estimated duration: 3 months, n = 30."
16254334|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA half bundle plus, active group 2|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment.
~Participants will be randomized to receive SUEÑA components 1 through 5 Estimated duration: 6 months, n = 30"
16254335|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA full bundle, active group 3|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment and personalized psychoeducation.
~. Participants will be randomized to receive SUEÑA components 1 through 6. Estimated duration: 6 months, n = 30"
16254336|NCT04995250|Experimental|Corrective exercise training for knee Osteoarthritis|
16254338|NCT04995224||Study 1A|Prospective cohort study with 150 newly diagnosed patients with inflammatory bowel disease
16254339|NCT04995224||Study 1B|Prospective cohort study with 450 newly diagnosed patients with IBD
16254340|NCT04995224||Study 2|Cross-sectional study with 10,000 patients in IBD Boost study
16254341|NCT04995224||Study 3|Cross-sectional study with 15,000 patients in IBD BioResource
16254342|NCT04995198||Participants with at least one germline pathogenic/likely pathogenic variant|
16254343|NCT04995198||Participants with at least one variant of uncertain significance|
16254344|NCT04995185|Experimental|PET/CT imaging|Intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole
16254345|NCT04995172||Observational (CT-assisted bronchoscopy, chart review)|Patients undergo RP-EBUS bronchoscopy per standard of care. If the study staff cannot reach the target lesion or is unable to determine a diagnosis, patients undergo bronchoscopy using mobile CT imaging. Patients' medical records are also reviewed for up to 6 months.
16254346|NCT04995159|Experimental|Poststent SAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy
16254347|NCT04995159|Active Comparator|Poststent DAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy
16254348|NCT04995146||Retrospective 3 months cohort (admitted stroke patients)|
16254349|NCT04995146||"Prospective pre-implementation standard of core care quality measures cohort"|
16254350|NCT04995146||"Prospective post-implementation standard of core care quality measures cohort"|
16254351|NCT04995133|Experimental|Colistin Arm|Intravenous administration of 6.75 x 106 Units Colistin for 30 minutes
16254352|NCT04995120|Experimental|Induction chemotherapy and Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.
~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If ORR of primary tumor is CR/PR, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 1year. Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 1year."
16254353|NCT04995107|Experimental|Electro-Press Needle group|Body acupoints of Yintang (GV29), Dazhui (GV14), Guanyuan (CV4), bilateral Zigong (EX-CA1), and bilateral Sanyinjiao (SP6) and auricular acupoints of Heart (CO15), Chuiqian (LO4) and Shenmen (TF4) will be selected for treatment. Auricular acupoints on right and left ear will be stimulated alternatively, one side on each time.The treatment will last 40mins for each session, 3 sessions a week (ideally every other day) for a succession of 6 weeks.
16254354|NCT04995107|No Intervention|Waiting-list group|Participants in the waiting-list group will receive no intervention for 6 weeks and be followed up till weeks 30.
16254355|NCT04995094|Experimental|Imprime PGG + Pembrolizumab (Investigational ARM)|Imprime PGG + Pembrolizumab (Investigational ARM)
16254356|NCT04995094|Active Comparator|Pembrolizumab (Control ARM)|Pembrolizumab (Control ARM)
16254357|NCT04995081|Active Comparator|Allogeneic HB-adMSCs.|"Biological/Vaccine: Allogeneic HB-adMSCs
~Allogeneic HB-adMSCs will be administered intravenously to study participants who qualify.
~Other Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells."
16254358|NCT04995081|Placebo Comparator|Placebo|"Placebo will be administered intravenously to study participants who qualify.
~Other Names: Sterile Saline Solution 0.9%"
16254359|NCT04995068||Included patients|See inclusion and exclusion criteria
16254360|NCT04995042|Experimental|SHR7280 Does Escalation and Expansion|
16254365|NCT04995016|Experimental|Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma|Neoadjuvant pembrolizumab plus axitinib
16254366|NCT04995003|Experimental|Arm A|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody pembrolizumab
16269508|NCT04889157|Placebo Comparator|Placebo|Placebo
16254367|NCT04995003|Experimental|Arm 2|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody nivolumab
16254368|NCT04994990|Experimental|Left Side of Face Receiving Double Dose|
16254369|NCT04994990|Experimental|Right Side of Face Receiving Double Dose|
16254370|NCT04994977|Experimental|Intra-arterial Chemotherapy|Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.
16254371|NCT04994951|Experimental|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
16254372|NCT04994951|Active Comparator|control group|Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
16254373|NCT04994938|Experimental|Peer led diet and exercise intervention|participation in two-times per week diet and exercise peer led interventions.
16254374|NCT04994925|Active Comparator|Control ready meal|Control supermarket brand ready meal with high energy density
16254375|NCT04994925|Experimental|Test ready meal with low energy density|Slimming world test ready meal with low energy density
16254376|NCT04994912|Experimental|EI-001|IV infusion
16254377|NCT04994912|Placebo Comparator|Placebo|IV infusion
16254378|NCT04994899||Interview & Depression Screening|
16254379|NCT04994886|Experimental|Targeted Epidural Spinal Stimulation|"Participants will undergo a surgery for Targeted Epidural Spinal Stimulation (TESS). The neurostimulation system will be used to manage blood pressure instability.
~Patients will then proceed to one month of an intensive device configuration protocol to configure the TESS settings of their investigational device to regain hemodynamic stability. After the intensive device configuration phase, daily supervised at-home hemodynamic TESS will be tested for 5 sessions per week for two weeks. Thereafter, and up to 10 months post-implant, patients will have a minimum of 5 TESS supported at-home sessions per week and one laboratory visit per month during a long-term at-home hemodynamic TESS phase. Finally, patients will have to undergo additional testing during a configuration of additional TESS programs phase. During this phase TESS configurations for hemodynamic stability, respiratory function, trunk stability and spasticity will be tested."
16254380|NCT04994873|Experimental|STEP: Positivity skill enhancement|This intervention includes the Enhanced TAU described below plus it entails 4 in-person sessions delivered during an inpatient psychiatric admission, followed by mood monitoring and skills messages delivered post-discharge via app, to promote the practice of increasing attention to positive affect and experiences as a means of reducing risk for suicidal behavior.
16254381|NCT04994873|Active Comparator|Enhanced TAU|his comparison intervention involves regular programming of the inpatient psychiatric unit, followed by safety plan and resources loaded onto an app that the participant has access to post-discharge.
16254382|NCT04994860|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
16254383|NCT04994860|Active Comparator|Sildenafil|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple three times a day (t.i.d.) oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 2 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
16254384|NCT04994860|Experimental|BIA 5-1058 and Sildenafil|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple t.i.d. oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
16254385|NCT04994847||APOE Unimpaired Observational Trial|300 participants who are cognitively unimpaired; Yearly procedures: blood draw Every Two Year Procedures: cognitive and clinical assessments, CSF collection, MRI, and Tau and Amyloid PET scans
16254386|NCT04994834|Experimental|Intervention|Probiotics
16254387|NCT04994821|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), (Soterix Medical mini-CT tDCS stimulator)
16254388|NCT04994821|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
16254389|NCT04994821|Experimental|Active tDCS with Cognitive Reappraisal (CR)|Active Transcranial Direct Current Stimulation (tDCS) (Soterix Medical mini-CT tDCS stimulator), and Cognitive Reappraisal (CR)
16254390|NCT04994808|Experimental|Arm A (treosulfan, fludarabine, TBI, HCT)|Patients receive treosulfan IV over 2 hours on days -6 to -4 and fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.
16254391|NCT04994808|Experimental|Arm B (clofarabine, TBI, HCT)|Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.
16254392|NCT04994795||Pembrolizumab monotherapy|
16254393|NCT04994795||Chemotherapy and pembrolizumab combination therapy|
16254394|NCT04994795||Chemotherapy doublet|
16254395|NCT04994782|No Intervention|Usual care recipients|Participant dyads in this group will receive usual care (standard clinical education materials)
16254396|NCT04994782|Experimental|Usual care plus GAME-EOL intervention|Participant dyads in this group will receive usual care (standard clinical education materials) plus the GAME-EOL intervention.
16254397|NCT04994769|Experimental|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling
16254401|NCT04994743|Experimental|Cohort 1: CORT113176 150 mg|Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.
16254402|NCT04994743|Placebo Comparator|Cohort 1: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
16254403|NCT04994743|Experimental|Cohort 2: CORT113176 300 mg|Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.
16254404|NCT04994743|Placebo Comparator|Cohort 2: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
16254405|NCT04994743|Experimental|Cohort 3: CORT113176 ≥300 mg|Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.
16254406|NCT04994743|Placebo Comparator|Cohort 3: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
16254410|NCT04994704|Experimental|Propofol group|Propofol based total intravenous anesthesia
16254411|NCT04994704|Active Comparator|Remimazolam group|Remimazolam based total intravenous anesthesia
16254412|NCT04994691|Placebo Comparator|No message|No message sent
16254413|NCT04994691|Active Comparator|Standard message|2 MyChart reminders that child is overdue for well child check visit
16254414|NCT04994691|Active Comparator|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
16254415|NCT04994678|Experimental|Virtual Reality Training Group|VR training system will be setup in multidisciplinary lab of Foundation University Institute of Rehabilitation Sciences Foundation University Islamabad. Display will be provided on 55 inch LED TV with audio feedback. Display will be at height of 5 feet from floor and at distance of 6 feet from Subject. The Virtual reality based training group will receive a game based virtual reality training via XBOX 360 or wii fit balance games. Particiapants will be required to physically move to move avatar on screen to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week for 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
16254416|NCT04994678|Active Comparator|Moderate Aerobic Exercise Training Group|Moderate aerobic exercise training will be provided using motorized tread mill and stationary/recombinent cycle. Treatment will be provided for 30-50 minutes 3 times a week for 6 weeks.
16254417|NCT04994665|Active Comparator|Sleeve gastrectomy|realization of a sleeve gastrectomy alone
16254418|NCT04994665|Experimental|sleeve gastrectomy with omentopexy|realization of a sleeve gastrectomy followed by an omentopexy
16254419|NCT04994652|Experimental|Videolaryngoscope|Intubation attempted with C-MAC videolaryngoscope
16254420|NCT04994652|Active Comparator|Standard laryngoscope|Intubation attempted with standard laryngoscope
16254421|NCT04994639|Experimental|HPI group|Managing intraoperative hemodynamic condition under the HPI guidance
16254422|NCT04994639|No Intervention|Standard care group|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
16254423|NCT04994626|Experimental|Ibrutinib Combined With Rituximab|"Induction therapy: Ibrutinib 560mg administered oral once a day of each 21-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.
~Maintenance therapy: Ibrutinib 560mg administered oral once a day of each 56-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 56-day cycle for 6 cycles."
16254424|NCT04994613|No Intervention|Control Group|The patient will be reserved a standard room in the preoperative area of main campus. This room will not include any additional sensory equipment. The child will be allowed to use any comfort items the family brought with them or offered a hospital iPad, as is current practice for all outpatient surgery patients.
16254425|NCT04994613|Experimental|Sensory Adaptive Environment Group|One of the three dedicated adaptive sensory rooms in the preoperative area of main campus will be set up by nursing and child life staff in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli. The equipment may include a portable popcorn tube with fiberoptic cart, handheld marble panel, color changing floor tiles, other sensory friendly objects, and individual sensory toys. This room will be set up prior to the patient's arrival the day of surgery and reserved for their use.
16254426|NCT04994600||EFA_1st_phase|Exploratory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of Charite intensive care units
16254427|NCT04994600||CFA_2nd_phase|Confirmatory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of collaborating intensive care units.
16254428|NCT04994574|Experimental|tiotropium/olodaterol|
16254429|NCT04994561|Experimental|Subjects receiving study drugs and nutritional supplements|All eligible and consented subjects will receive study drugs and nutritional supplements as described in the intervention.
16254430|NCT04994548||Cirrhotic patients or with portal hypertension|Patients with early esophageal cancer
16254431|NCT04994535|Experimental|BOTOX|BOTOX will be injected into the platysma muscle on Day 1
16254432|NCT04994535|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1
16269687|NCT04887792|Active Comparator|Acetazolamide|acetazolamide capsules
16254433|NCT04994522|Experimental|Belzutifan in Participants with ESRD|Participants with ESRD will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1), followed by a ≥7 day washout period. Participants receive another single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 2).
16254434|NCT04994522|Experimental|Belzutifan in Healthy Participants|Participants in the healthy matched control group will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1).
16254441|NCT04994496|Experimental|Web-based intervention group|Two-week web-based intervention group
16254442|NCT04994496|Sham Comparator|Web-based control group|Two-week web-based sham comparator
16254445|NCT04994470|Experimental|Web-based intervention group|Two-week web-based intervention
16254446|NCT04994470|Sham Comparator|Web-based control group|Two-week web-based sham comparator
16254447|NCT04994457||Adults with Glaucoma or Suspected Glaucoma|Adults with Glaucoma or Suspected Glaucoma, who have previously had standard automated perimetry (SAP) and will receive virtual reality visual field (VRVF) as part of the standard of care
16254448|NCT04994457||Visual Field Naive Adults|Visual Field Naive Adults will receive SAP and VRVF
16254449|NCT04994457||Children with Glaucoma or Suspected Glaucoma|Children with Glaucoma or Suspected Glaucoma, who have previously had SAP and will receive VRVF as part of the standard of care
16254450|NCT04994457||Visual Field Naive Children|Visual Field Naive Children will receive SAP and VRVF
16254451|NCT04994457||Remote Care Arm|Glaucoma or Suspected Glaucoma participants, who have previously had SAP and will receive VRVF at their home
16254452|NCT04994444|Experimental|Preloading|Participants will be started on nicotine patch 3 weeks prior to quit date. At quit date they will use patch and lozenge or gum for 8 weeks.
16254453|NCT04994444|Active Comparator|Standard treatment|Participants will start combination nicotine replacement therapy (patch/gum or patch/lozenge) on their assigned quit date. NRT will be provided for 8 weeks.
16254454|NCT04994431|Experimental|Perioperative Tamsulosin Hydrochloride|Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.
16254455|NCT04994431|No Intervention|Historical Comparator|Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.
16254456|NCT04994418|Experimental|Arm 1. Recommended sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300mg) from whole food while consuming placebo from pills
16254457|NCT04994418|Experimental|Arm 2. High sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300 mg) from whole food while consuming high sodium from pills (3400 mg)
16254458|NCT04994418|Experimental|Arm 3. High sodium and high fructose diet|7 day consumption of high fructose drink (200g) and recommended sodium (2300 mg)from whole food while consuming high sodium pills from pills (3400 mg)
16254459|NCT04994405|No Intervention|Standard Pressure|The extremity tourniquet used during hand surgery for these participants will be the standard pressure of 250 mmHg.
16254460|NCT04994405|Experimental|Lower Tiered Pressures|The study intervention is the inflation of the extremity tourniquet to a pressure lower than the standard pressure of 250 mmHg during hand surgery for these participants determined by tiered guidelines based on systolic blood pressure (SBP).
16254461|NCT04994379|Experimental|1 mA tDCS|Participants receive the stimulation with an intensity of 1 mA.
16254462|NCT04994379|Experimental|1.5 mA tDCS|Participants receive the stimulation with an intensity of 1.5 mA.
16254463|NCT04994379|Sham Comparator|Sham tDCS|Participants receive the sham stimulation (zero electric current after a short initial increase).
16254464|NCT04994366||Intervention Group|The cohort receiving Thank you cards during their stay.
16254465|NCT04994366||Control Group|The cohort not receiving thank you cards during their stay.
16254485|NCT04994197||Diagnosis group of patients with benign urinary diseases|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as benign urinary diseases in this study will be assigned to this group
16254598|NCT04993573||Caregivers|Caregivers who work with older patients will be included. They will have a questionnaire
16254466|NCT04994353|Experimental|Supplementation|"Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA) .For the first week, we measured blood glucose to a meal without any intervention and use those data as a baseline. After that, blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. After intervention, the subjects maintain daily predefined ready-meal (470 kcal). The supplementation formulas are food grade, purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia)."
16254467|NCT04994340||Children|From a cross-sectional perspective, children will fill out questionnaires related to their subjective physical activity levels (PAQ-C), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of children through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
16254468|NCT04994340||Adolescents|From a cross-sectional perspective, adolescents will fill out questionnaires related to their subjective physical activity levels (PAQ-A), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of adolescents through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
16254469|NCT04994327|Experimental|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
16254470|NCT04994327|Placebo Comparator|Control bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
16254471|NCT04994314|Active Comparator|orthodontic primer containing calcium fluoride nanoparticles|Fixed appliance for ten maxillary teeth and the contralateral mandibular teeth will be bonded using orthodontic primer containing calcium fluoride nanoparticles
16254472|NCT04994314|Placebo Comparator|Control primer|Fixed appliance for ten maxillary teeth (contralateral to experimental ten side)and the contralateral mandibular teeth will be bonded using conventional primer (TransbondTM XT orthodontic primers (3M-Unitek, Monrovia, USA)
16254473|NCT04994301||Patient with Cystic Fibrosis|Patients (male, female) age 5-11 with confirmed diagnosis of Cystic Fibrosis. These patients will begin clinically prescribed FDA-approved Trikafta therapy.
16254474|NCT04994288|Experimental|Supaglutide RP3D high dose|during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made andRP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3 , subjets will be assigned to RP3D hign dose, RP3D low dose and placebo
16254475|NCT04994288|Experimental|supaglutide RD3D Low dose|during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made and RP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3, subjets will be assigned to RP3D hign dose, RP3D low dose and placebo
16254476|NCT04994288|Placebo Comparator|placebo|placebo injection
16254477|NCT04994275||Patients admitted to undergo a major elective surgery|
16254478|NCT04994262|Experimental|Intervention Group|"Patients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time.
~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes.
~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded.
~Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form."
16254479|NCT04994262|No Intervention|Control Group|"Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time.
~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded.
~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly.
~Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form."
16254480|NCT04994236|Experimental|Hepatic Artery Infusion Chemotherapy|Subjects assigned to this arm will receive chemotherapy via catheterizations placed into the hepatic artery.
16254481|NCT04994223|Experimental|Group A(combined anticoagulation plus antithrombotic therapy group)|group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.
16254482|NCT04994223|Active Comparator|Group B( antithrombotic therapy alone group)|group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.
16254483|NCT04994210|Experimental|Sintilimab+Chidamide|Sintilimab：200mg(fixed dosage), ivd, qd, q21d Chidamide: 30mg,biw,continued oral
16254484|NCT04994197||Diagnosis group of patients with urothelial cancer|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as urothelial carcinoma in this study will be assigned to this group
16254486|NCT04994197||Recurrence diagnosis group with urothelial cancer|Patients who were diagnosed with non-muscle invasive urothelial carcinoma within two years and diagnose as recurrent urothelial carcinoma in this study will be assigned to this group
16254487|NCT04994197||Recurrence diagnosis group with benign urinary diseases|Patients who were diagnosed with non-muscle invasive urothelial carcinoma within two years and diagnose as benign urinary diseases in this study will be assigned to this group
16254488|NCT04994184||Perforated duodenal ulcer|MORBIDITY AND MORTALITY
16254491|NCT04994119|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5-1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
16254492|NCT04994119|Experimental|Warfarin|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received a single dose of racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
16254493|NCT04994119|Experimental|BIA 5-1058 and Warfarin|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
16254494|NCT04994106|Experimental|Cohort A1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
16254495|NCT04994106|Experimental|Cohort A2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
16254496|NCT04994106|Experimental|Cohort A3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
16254497|NCT04994106|Experimental|Cohort A4 Japanese descent: AZD5462 Dose 3|Randomized participants of Japanese descent will receive Dose 3 of AZD5462.
16254498|NCT04994106|Experimental|Cohort A5: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
16254499|NCT04994106|Experimental|Cohort A6 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
16254500|NCT04994106|Experimental|Cohort A7: AZD5462 Dose 5|Randomized healthy participants will receive Dose 5 of AZD5462.
16254501|NCT04994106|Experimental|Cohort A8 Japanese descent: AZD5462 Dose 5|Randomized participants of Japanese descent will receive Dose 5 of AZD5462.
16254502|NCT04994106|Placebo Comparator|Part A: Placebo (Healthy Participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
16254503|NCT04994106|Placebo Comparator|Part A: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
16254504|NCT04994106|Experimental|Cohort B1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
16254505|NCT04994106|Experimental|Cohort B2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
16254506|NCT04994106|Experimental|Cohort B3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
16254507|NCT04994106|Experimental|Cohort B4: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
16254508|NCT04994106|Experimental|Cohort B5 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
16254509|NCT04994106|Placebo Comparator|Part B: Placebo (Healthy participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
16254510|NCT04994106|Placebo Comparator|Part B: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
16254511|NCT04994093||COLON CANCER|This cohort will consist of 100 patients with Colon Cancer.
16254512|NCT04994080|Experimental|Treatment group A/B|
16254513|NCT04994080|Placebo Comparator|Treatment group C|
16254514|NCT04994054|Experimental|silkworms (Bombyx mori L.) pupae extracts group|This group takes silkworms (Bombyx mori L.) pupae extracts for 12 weeks.
16254515|NCT04994054|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
16254516|NCT04994041|Experimental|Pelvic floor muscle plus adductor strengthening|pelvic floor muscle plus adductor strengthening
16254517|NCT04994041|Active Comparator|Pelvic floor muscle exercises|pelvic floor muscle exercises
16254518|NCT04994028|Active Comparator|Conventional treatment|Conventional treatment that include behavioral and life style modification and dyspnea prevention education
16254519|NCT04994028|Experimental|conventional treatment with volume Spirometry and deep breathing|Conventional treatment along with volume Spirometry and deep breathing exercise
16254520|NCT04994002|Experimental|Cohort 1: CERC-006 (0.5 mg)|Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
16254595|NCT04993586|Experimental|Group C|
16254596|NCT04993586|Experimental|Group D|
16254597|NCT04993586|Experimental|Group E|
16254521|NCT04994002|Experimental|Cohort 2: CERC-006 (1 mg)|Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
16254522|NCT04993989||Pharmacy based survey|Patients received a questionnaire, which was filled out and returned to the Contract Research Organization (CRO) or, alternatively to the pharmacy.
16254523|NCT04993976|Experimental|Prehabilitation group|Strength training along with warm-up and cool down for 8 weeks
16254524|NCT04993976|Active Comparator|Control group|Supervised Standard care plan for 8 weeks
16254525|NCT04993963|Experimental|Cycle Ergometery Training (Prehabilitation)|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown) Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale
16254526|NCT04993963|Active Comparator|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
16254527|NCT04993950|Experimental|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
16254528|NCT04993950|Active Comparator|SNAGS with thoracic postural correction techniques|active as well as therapist-facilitated stretches.thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
16254529|NCT04993937|Active Comparator|Control group|Control group will follow their daily routine activities.
16254530|NCT04993937|Experimental|Experimental group|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
16254531|NCT04993924|Experimental|Participants|Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-6 days
16254536|NCT04993885|Experimental|Treatment group|Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
16254537|NCT04993872|Experimental|BIC/FTC/TAF|Development phase 4: Biktarvy®
16254538|NCT04993859||Male Cancer Survivors with DVSS Score ≥ 9|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
16254539|NCT04993859||Female Cancer Survivors with DVSS Score ≥ 6|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
16254540|NCT04993859||Male Cancer Survivors with DVSS Score < 9|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
16254541|NCT04993859||Female Cancer Survivors with DVSS Score < 6|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
16254542|NCT04993846||Pancreatic cancer patients - Explorative phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments. An oral microbiota (dental plaque) sample will be collected and a periodontal and dental assessment will be performed, before any therapeutic procedure, together with orthopantomography
16254543|NCT04993846||Healthy controls - Explorative phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
16254544|NCT04993846||Pancreatic cancer patients - Validation phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments.
16254545|NCT04993846||Healthy controls - Validation phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
16254546|NCT04993846||IPMN patients controls - Validation phase|Patients suffering from IPMNs evaluated at outpatients clinics or scheduled for surgery.
16254547|NCT04993833||Patients|Patients with risk of cerebral edema.
16254548|NCT04993833||Healthy Control|Staff/Faculty who interact with patients at the enrolling site.
16254549|NCT04993820|Experimental|Physical Activity (PA)|Combination of aerobic exercise and muscle strengthening exercise.
16254550|NCT04993820|Active Comparator|Education Control (CON)|No exercise group.
16254551|NCT04993807|Experimental|Shared decision-making tool|Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.
16254829|NCT04992091|No Intervention|traditional debriefing|noninterventional group
16254552|NCT04993794|Active Comparator|XueBiJing|XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group, Tianjin, China, batch No. 1603231) 100ml Xuebijing injection every 12 h (q12h) for 60 min
16254553|NCT04993794|Placebo Comparator|Normal saline|0.9% saline every 12 h (q12h) for 60 min
16254554|NCT04993781|Experimental|eSTEPS Clinical Decision Support|Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
16254555|NCT04993781|No Intervention|Usual Care|Usual primary care practices regarding exercise-related fall prevention planning
16254556|NCT04993768|Experimental|TPN-101, Dose A|
16254557|NCT04993768|Experimental|TPN-101, Dose B|
16254558|NCT04993768|Experimental|TPN-101, Dose C|
16254559|NCT04993768|Placebo Comparator|Placebo|
16254560|NCT04993755|Experimental|TPN-101, 400 mg/day|
16254561|NCT04993755|Placebo Comparator|Placebo|
16254562|NCT04993742|Experimental|MOMS Intervention|"Women that are currently in the Mentors Offering Maternal Support (M-O-M-S) research program as well as pregnant women entering prenatal care in the first trimester, who are not in the M-O-M-S program may participate in the study.
~Arms Assigned Interventions Experimental: M-O-M-S Intervention M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
~No Intervention: Routine Prenatal Care Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines"
16254563|NCT04993729|Experimental|T89 low-dose group|Subjects in this group will take three T89 capsules and one Placebo capsule each time by oral administration three times daily for 5 days.
16254564|NCT04993729|Experimental|T89 high-dose group|Subjects in this group will take four T89 capsules each time by oral administration three times daily for 5 days.
16254565|NCT04993729|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will take four placebo capsules each time by oral administration three times daily for 5 days.
16254566|NCT04993716||Cohort|Patient present in the SAU after an extra-hospital cardiac arrest
16254567|NCT04993703|Experimental|Kinesiotaping|"A total of 21 sessions physiotherapy sessions including hot pack, ultrasound therapy, transcutaneous electrical nerve stimulation (TENS) and a home exercise program (tendon and nerve gliding, hand and wrist exercises=2 times per day 3sets of ten repetitions) will be applied.
~Additionally for this group, kinesiotaping will be applied by using carpal tunnel technique including button hole and I band technique of space correction; and with 25-50% tension in center of tape over dorsal carpal tunnel at the end of the each session. Patients will request to keep kinesiotaping at nights throughout the study."
16254568|NCT04993703|Experimental|Night splinting|"A total of 21 sessions physiotherapy sessions including hot pack, ultrasound therapy, transcutaneous electrical nerve stimulation (TENS) and a home exercise program (tendon and nerve gliding, hand and wrist exercises=2 times per day 3sets of ten repetitions) will be applied.
~Additionally, night splinting will be advised. Patients will request to keep their splints at nights throughout the study."
16254569|NCT04993703|Experimental|Control group|A total of 21 sessions physiotherapy sessions including hot pack, ultrasound therapy, transcutaneous electrical nerve stimulation (TENS) and a home exercise program (tendon and nerve gliding, hand and wrist exercises=2 times per day 3sets of ten repetitions) will be applied.
16254570|NCT04993690|Experimental|Phase I Dose Escalation|Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated
16254571|NCT04993690|Experimental|Phase I Dose Expansion A|CLL/SLL patients treated with prior regimens.
16254572|NCT04993690|Experimental|Phase I Dose Expansion B|CLL/SLL patients with no prior therapy.
16254573|NCT04993690|Experimental|Phase I Dose Expansion C|MCL patients treated with prior regimens.
16254574|NCT04993690|Experimental|Phase I Dose Expansion D|WM patients treated with prior regimens.
16254575|NCT04993690|Experimental|Phase I Dose Expansion E|MZL patients treated with prior regimens.
16254578|NCT04993664|Experimental|Pelacarsen group (TQJ230)|The first group will receive 80 mg of pelacarsen every month subcutaneously for 6 months.
16254579|NCT04993664|Placebo Comparator|Placebo group|The first group will receive 80 mg of placebo every month subcutaneously for 6 months.
16254580|NCT04993651|Experimental|Continuous Positive Airway Pressure|Those randomized to CPAP will be fitted with CPAP face mask or nasal device by the respiratory therapist and permitted to trial the machine to ensure proper use and fit. CPAP settings: CPAP AUTO 5-20 cm H20 will be utilized. The CPAP device will then be removed. The subject will then be placed in the supine position with a standard roll placed under the right maternal hip. Those randomized to CPAP will have the device applied and machine turned on. For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 > 95%. End tidal CO2 monitors will be applied to both patient groups.
16254581|NCT04993651|No Intervention|Nasal Cannula|For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 > 95%. End tidal CO2 monitors will be applied to both patient groups.
16254582|NCT04993638||EUROSCUP MOBILE cementless|107 who received cementless version of EUROSCUP MOBILE
16254583|NCT04993638||EUROSCUP MOBILE cemented|40 who received cemented version of EUROSCUP MOBILE
16254584|NCT04993625|Experimental|Avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|
16254585|NCT04993612||No pulmonary Hypertension|
16254586|NCT04993612||pulmonary Hypertension Group 1|
16254587|NCT04993612||pulmonary Hypertension Group 2|
16254588|NCT04993612||pulmonary Hypertension Group 3|
16254589|NCT04993612||pulmonary Hypertension Group 4|
16254590|NCT04993612||pulmonary Hypertension Group 5|
16254591|NCT04993599|Experimental|Pediatric patients|<Intervention> The participants(Pediatric patients) mainly interact with the social robot which is controlled by the researcher behind the scene
16254592|NCT04993599|Experimental|Carers|<Intervention> The participants(Carers) interact with the social robot and watch how their child interact with the robot which is controlled by the researcher behind the scene
16254593|NCT04993586|Experimental|Group A|
16254594|NCT04993586|Experimental|Group B|
16254599|NCT04993573||Older|Older 65 people who live alone in their house will be included. They will have Individual interviews.
16254602|NCT04993547|Experimental|Parents present, peers present|The children are accompanied by their parents during the COVID-19 testing, and a visible covid-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
16254603|NCT04993547|Active Comparator|Parent present, peers absent|The children are also accompanied by their parents, but a covered COVID-19 swab test waiting line is set-up whereby the children are unable to observe their peers being tested.
16254604|NCT04993547|Active Comparator|Parents absent, peers present|Parents are absent during the COVID-19 testing, and a visible COVID-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
16254605|NCT04993547|Active Comparator|Parents absent, peers absent|Parents are absent, and a covered COVID-19 swab test waiting line is set-up whereby the children are not able to observe their peers being tested.
16254606|NCT04993534|Experimental|Psychological First Aid + Stepped-care intervention (DWM/PM+)|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.
~The treatment group will receive the stepped-care program consisting of DWM (step 1) and Problem Management Plus (PM+).
~The DWM program has been developed by WHO and collaborators working in the humanitarian field. DWM was designed to be relevant for large segments of adversity-affected populations: it is intended to be transdiagnostic, and easily adaptable to different cultures and languages.
~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques that are empirically supported."
16254607|NCT04993534|Other|Psychological First Aid + usual care|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.
~In addition, both the groups will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation."
16254608|NCT04993521|Active Comparator|bilateral superficial cervical plexus block (BSCPB)|Analgesia obtained by a ultrasound guided cervical plexus block using lidocain
16254609|NCT04993521|Active Comparator|local wound infiltration (LWI)|Analgesia obtained by local wound infiltration of lidocain
16254610|NCT04993508|Experimental|Arm A|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm A will undergo only targeted MRI/US fusion-guided biopsies. Men with PI-RADS 3 and PSAD > 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
16254611|NCT04993508|Active Comparator|Arm B|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm B will undergo targeted MRI/US fusion-guided biopsies and systematic biopsies (standard of care). Men with PI-RADS 3 and PSAD > 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
16254612|NCT04993508|Other|Arm C|Men with PI-RADS 3 in conjunction with PSAD < 0.15 will not be biopsied, but followed-up with MRI annually and PSA every 6 months for 3 years.
16254613|NCT04993508|Other|Arm D|Men with PI-RADS 1 or 2 will not be biopsied, but followed-up with PSA every 6 months for 3 years. A control MRI will be performed after 3 years. At any time, a follow-up can be performed in case of clinical suspicion of PCa or a relevant PSA increase (> 1.0 ng/ml/a).
16254614|NCT04993482||type 2 diabetes mellitus group|124 adults with type 2 diabetes mellitus will be included
16254615|NCT04993482||control group|124 control adults will be included
16254616|NCT04993469|Experimental|Genital sensation and sexual functioning assessment|"Genital sensation testing with clinical assessment and self-examination questionnaire.
~Sexual functioning testing with questionnaires."
16254617|NCT04993456||POAF group|the patients will have atrial fibrillation following the cardiac surgery
16254618|NCT04993456||non-POAF group|the patients will have no atrial fibrillation following the cardiac surgery
16254619|NCT04993443|Experimental|Active Comparator: Drug :LQ036|Experimental, Single and Multiple Oral escalating dose
16254620|NCT04993443|Placebo Comparator|Placebo Comparator: Matching Placebo for LQ036|Matching Placebo for LQ036: Matching Placebo
16254621|NCT04993430|Experimental|Group A|HRS8807 monotherapy dose escalation
16254622|NCT04993430|Experimental|Group B|HRS8807 monotherapy dose expansion
16254623|NCT04993430|Experimental|Group C|HRS8807 in combination with SHR6390 dose escalation
16254624|NCT04993430|Experimental|Group D|HRS8807 in combination with SHR6390 dose expansion
16254625|NCT04993417|Experimental|Mime Therapy along with EMS|MT Group: Mime Therapy along with EMS
16254626|NCT04993417|Experimental|Motor imagery technique along with EMS|MIT Group: Motor imagery technique along with EMS
16254627|NCT04993404|Experimental|Cohort A：Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
16254628|NCT04993404|Experimental|Cohort B：Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
16254629|NCT04993404|Experimental|Cohort C：Normal Hepatic Function|Participants with normal hepatic function matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index) will be administered a single oral dose of Jaktinib Hydrochloride Tablets.
16256005|NCT04983732|Experimental|FL-101-IV|FL-101 single IV infusion over 60-minutes
16254630|NCT04993404|Experimental|Cohort D：Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 11, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
16254631|NCT04993391|Experimental|40mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
16254632|NCT04993391|Experimental|80mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
16254633|NCT04993391|Experimental|160mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
16254634|NCT04993391|Experimental|240mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
16254635|NCT04993391|Experimental|320mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
16254636|NCT04993378||GC patients receiving immunotherapy|
16254637|NCT04993365|Experimental|Experimental Group1|440 participants (including 220 subjects aged 18~59 years and 220 subjects aged 59 years and above ) will receive the first dose of COVID-19 vaccine and quadrivalent influenza vaccine on day 0, and the second dose of COVID-19 vaccine and PPV23 on day 28.
16254638|NCT04993365|Experimental|Experimental Group 2|440 participants (including 220 subjects aged 18~59 years and 220 subjects aged 59 years and above ) will receive the first dose of COVID-19 vaccine on day 0 and the second dose of COVID-19 vaccine on day 28.
16254639|NCT04993365|Experimental|Experimental Group 3|440 participants (including 220 subjects aged 18~59 years and 220 subjects aged 59 years and above ) will receive quadrivalent influenza vaccine on day 0 and PPV23 on day 28.
16254640|NCT04993352|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody.
16254641|NCT04993339|No Intervention|Standard Surgery|Participants in this group undergoing standard of care reparative surgery will not receive additional intervention
16254642|NCT04993339|Experimental|Standard Surgery with OOC|Participants in this group undergoing standard of care reparative surgery will receive OOC as an additional intervention
16254643|NCT04993326|Other|Intervention|"emPOWERed to Change
~Online Courses:
~4 Critical Step to Manage Diabetes modules
~Step 1 Learn about diabetes
~Step 2 Know your diabetes ABCs
~Step 3 Learn how to live with diabetes
~Step 4 Get routine care to stay healthy Diabetes + COVID-19 Protection and Prevention modules
~Introduction to understanding COVID-19 and the risks specific to T2DM
~Learn preventive and protective measures to avoid COVID-19
~COVID-19 Vaccine education and Discussion guide
~Community resource guide to access COVID-19 testing and vaccination Stress Management modules
~Understanding of the relationship between diabetes and stress
~Learn stress management techniques for diabetes Ongoing Program Support: Motivation for participation, medication adherence, accountability and peer-to-peer interaction and support (bi-weekly text messages & private and closed Facebook community support group with peers and professionals)"
16254644|NCT04993326|No Intervention|Control|Usual Standard of Care as deemed by participants provider(s)
16254645|NCT04993313|Experimental|Arm I (counseling, photo guide)|Patients undergo verbal counseling and view a photo guide. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
16254646|NCT04993313|Active Comparator|Arm II (counseling)|Patients undergo verbal counseling. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
16254647|NCT04993300|Experimental|transcranial magnetic stimulation (TMS)|This arm constitute of methamphetamine users who undergone abstinent period
16254648|NCT04993287|Experimental|Soft Launch|5 eligible HF patients enrolled to finetine process and protocol
16254649|NCT04993287|Experimental|Pilot|45 eligible HF patients
16254650|NCT04993261|Experimental|Diagnostic (dual energy CT scan)|Patients undergo one dual energy CT scan during scheduled CT scan.
16254651|NCT04993248|Experimental|Intervention|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.
~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
16254652|NCT04993248|No Intervention|Control|Usual intervention
16254653|NCT04993235||Sotos Syndrome|Children and adolescents with Sotos Syndrome
16254654|NCT04993235||Beckwith-Wiedemann Syndrome|Children and adolescents with Beckwith-Wiedemann Syndrome
16254655|NCT04993235||Control group|Adolescents with typical development
16254656|NCT04993222|Experimental|Sequence TR|6 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2.
16254657|NCT04993222|Experimental|Sequence RT|6 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2.
16254658|NCT04993209|Experimental|NDV-HXP-S 1μg (Stage A)|"Stage A:
~Stage A will be the first use of the product in humans. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β.The scientific justification for these decisions will be approved by the regulatory agency before choosing Alternative (A) 1 or 2 and progression to the next stage, either B1 or B2."
16254678|NCT04993209|Experimental|NDV-HXP-S variant γ vaccine (Stage B) - Group B2a|"Stage B2 (Group B2a) aims to assess the homotypic and heterotypic response induced by each of the vaccines based on variants.
~Participants of this group B2a: 18-59 years old, with prior exposure to SARS-CoV-2."
16254830|NCT04992078|Experimental|Robotic-Unicompartmental Knee Replacement (R-UKR)|NAVIO/CORI Surgical System
16254659|NCT04993209|Experimental|NDV-HXP-S 3μg (Stage A)|"Stage A:
~Stage A will be the first use of the product in humans. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β.The scientific justification for these decisions will be approved by the regulatory agency before choosing Alternative (A) 1 or 2 and progression to the next stage, either B1 or B2."
16254660|NCT04993209|Experimental|NDV-HXP-S 10μg (Stage A)|"Stage A:
~Stage A will be the first use of the product in humans. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β.The scientific justification for these decisions will be approved by the regulatory agency before choosing Alternative (A) 1 or 2 and progression to the next stage, either B1 or B2."
16254661|NCT04993209|Placebo Comparator|Placebo (Stage A)|The stage A is designed as a non-inferiority test comparing the three different doses and using placebo as a control.
16254662|NCT04993209|Experimental|NDV-HXP-S parental vaccine in 3 consecutive lots (Stage B) - Group B1a|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 18-59 years old, no prior exposure to SARS-CoV-2."
16254663|NCT04993209|Active Comparator|Active Vaccine Control (Stage B) - Group B1a|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 18-59 years old, no prior exposure to SARS-CoV-2."
16254664|NCT04993209|Experimental|NDV-HXP-S parental vaccine (Stage B) - Group B1b|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 18-59 years old, with or without prior exposure to prior exposure to SARS-CoV-2."
16254665|NCT04993209|Active Comparator|Active Vaccine Control (Stage B) - Group B1b|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 18-59 years old, with or without prior exposure to SARS-CoV-2."
16254666|NCT04993209|Experimental|NDV-HXP-S parental vaccine (Stage B) - Group B1c|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1c: 18-59 years old, with prior exposure to SARS-CoV-2."
16254667|NCT04993209|Active Comparator|Active Vaccine Control (Stage B) - Group B1c|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1c: 18-59 years old, with prior exposure to SARS-CoV-2."
16254668|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage B) - Group B1d|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 18-59 years old, vaccinated more than 6 months ago."
16254669|NCT04993209|Active Comparator|Active Vaccine Control simple dose (Stage B) - Group B1d|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 18-59 years old, vaccinated more than 6 months ago."
16254670|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage B) - Group B1d (60 years or more)|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 60 years or more, vaccinated more than 6 months ago."
16254671|NCT04993209|Active Comparator|Active Vaccine Control simple dose (Stage B) - Group B1d (60 years or more)|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1d: 60 years or more, vaccinated more than 6 months ago."
16254672|NCT04993209|Experimental|NDV-HXP-S variant γ vaccine (Stage B) - Group B1e|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1e: 18-59 years old, without prior exposure to SARS-CoV-2."
16254673|NCT04993209|Experimental|NDV-HXP-S variant β vaccine (Stage B) - Group B1e|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.
~Participants of this group B1e: 18-59 years old, without prior exposure to SARS-CoV-2."
16254674|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants in 3 consecutive lots (Stage C) - Group C1a|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).
~Participants of this group C1a: 18-59 years old, without prior exposure to SARS-CoV-2."
16254675|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C1b|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).
~Participants of this group C1b: 18-59 years old, with prior exposure to SARS-CoV-2."
16254676|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C1c|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).
~Participants of this group C1c: 18-59 years old"
16254677|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C1c (60 years or more)|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).
~Participants of this group C1c: 60 years or more"
16254823|NCT04992156||Patients cohort|Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FES PET/CT before the initiation of Palbociclib was included.
16254679|NCT04993209|Experimental|NDV-HXP-S variant β vaccine (Stage B) - Group B2a|"Stage B2 (Group B2a) aims to assess the homotypic and heterotypic response induced by each of the vaccines based on variants.
~Participants of this group B2a: 18-59 years old, with prior exposure to SARS-CoV-2."
16254680|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants in 3 consecutive lots (Stage C) - Group C2a|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2a: 18-59 years old, no prior exposure to SARS-CoV-2."
16254681|NCT04993209|Active Comparator|Active Vaccine Control (Stage C) - Group C2a|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2a: 18-59 years old, no prior exposure to SARS-CoV-2."
16254682|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C2b|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2b: 18-59 years old, with or without prior exposure to SARS-CoV-2."
16254683|NCT04993209|Experimental|Active Vaccine Control (Stage C) - Group C2b|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2b: 18-59 years old, with or without prior exposure to SARS-CoV-2."
16254684|NCT04993209|Experimental|NDV-HXP-S parental vaccine (Stage C) - Group C2c|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2c: 18-59 years old, with prior exposure to SARS-CoV-2."
16254685|NCT04993209|Active Comparator|Active Vaccine Control (Stage C) - Group C2c|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2c: 18-59 years old, with prior exposure to SARS-CoV-2."
16254686|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage C) - Group C2d|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2c: 18-59 years old, with prior exposure to SARS-CoV-2."
16254687|NCT04993209|Experimental|Active Vaccine Control simple dose (Stage C) - Group C2d|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2c: 18-59 years old, vaccinated more than 6 months."
16254688|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage C) - Group C2d (60 years or more)|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2c: 60 years old or more, vaccinated more than 6 months."
16254689|NCT04993209|Experimental|Active Vaccine Control simple dose (Stage C) - Group C2d (60 years or more)|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.
~Participants of this group C2c: 60 years old or more, vaccinated more than 6 months."
16254690|NCT04993196|Experimental|T1rho MRI|
16254691|NCT04993183|Experimental|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, service-learning seminar, disability simulation workshop, and two community contact sessions.
16254692|NCT04993157|Experimental|Group 1: Healthy participants with normal hepatic function|Each participant will receive a single dose of FIA586
16254693|NCT04993157|Experimental|Group 2: Participants with mild hepatic impairment|Each participant will receive a single dose of FIA586
16254694|NCT04993157|Experimental|Group 3: Participants with moderate hepatic impairment|Each participant will receive a single dose of FIA586
16254695|NCT04993144|Active Comparator|Active|"Participants received the real intervention of TBS (cTBS 600) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).
~*cTBS = continuous theta burst stimulation"
16254696|NCT04993144|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).
16254697|NCT04993144|No Intervention|Normal control|No intervention.
16254698|NCT04993131|Experimental|Liver transplant|The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
16254699|NCT04993118|Experimental|Integrated Neuromuscular inhibition technique|Experimental group received Integrated neuromuscular inhibition technique. At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. M If pain was reproduced the pressure was maintained over the active trigger point as the position of ease was identiﬁed. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of iINIT.Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
16254727|NCT04992897||REN-Medication combinations|"all evaluable treatments.
~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).
~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
16254824|NCT04992143|Experimental|TACE combined Tilelizumab and Sorafenib|TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)
16256006|NCT04983732|Experimental|FL-101-SC|FL-101 single SC injection
16254700|NCT04993118|Active Comparator|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
16254701|NCT04993105|Experimental|B (exercise + graston):|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surf and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restriction was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.
~."
16254702|NCT04993105|Active Comparator|A (exercise only)|Exercises only. Patients will be given gastrocnemius stretching, plantar fascia stretching, myofascial release and then graston will be given as sham treatment for 10 minutes after applying cream (applying graston on skin but not giving enough pressure).
16254703|NCT04993092|Experimental|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
16254704|NCT04993092|Active Comparator|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
16254705|NCT04993079|Experimental|Clotild®|"Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 100 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study.
~Sixty clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire."
16254706|NCT04993066|Experimental|Treatment Arm|All study subjects are to receive treatment with GentleMax Pro Plus device. Subjects will be scheduled to receive as little as one (1) and up to eight (8) treatments with the GentleMax Pro Plus™ Laser System. Up to 2 follow-ups will occur.
16254707|NCT04993040|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
16254708|NCT04993027|Experimental|Vancomycin Group:|patients will have single dose of 1g vancomycin powder placed on their incision during surgery in addition to standard infection prophylaxis clinical care.
16254709|NCT04993027|Active Comparator|Control Group|Patients will receive all standard infection prophylaxis clinical care.
16254710|NCT04993014|Active Comparator|Cohort 1, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline
16254711|NCT04993014|Experimental|Cohort 1, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline
16254712|NCT04993014|Active Comparator|Cohort 2, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline
16254713|NCT04993014|Experimental|Cohort 2, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline
16254716|NCT04992988|Experimental|Toripalimab+CCRT|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy.
~Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 3 weeks after CCRT"
16254717|NCT04992975||Alzheimer's disease|"Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.
~Repeat neuroimaging and neurocognitive tests after one year."
16254718|NCT04992975||Control group|"Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.
~Repeat neuroimaging, neurocognitive tests after one year."
16254719|NCT04992962|Experimental|CBD/CBN|Participants will receive a 28-day supply of CBD/CBN sublingual tablets to be taken 3 times a day for 28 days.
16254720|NCT04992962|Experimental|CBD/THC|Participants will receive a 28-day supply of CBD/THC sublingual tablets to be taken 3 times a day for 28 days.
16254721|NCT04992962|Placebo Comparator|Placebo|A placebo sublingual tablet to be taken three times a day for 28 days
16254722|NCT04992949|Experimental|CPX351|Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of CONSOLIDATION therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.
16254723|NCT04992936|Experimental|Dry wine from the lees of Cabernet variety (VLC)|Participants will consume a total of 3 g per day of the product that will contain 1.4 g of VLC and 1.6 g of maltodextrin, with 3 g/kg of red fruit flavor and 900 mg/kg of Red TN9014, for 5 weeks.
16254724|NCT04992936|Placebo Comparator|Placebo|Participants will consume a total of 3 g per day of maltodextrin, with 3 g/kg of red fruit flavor and 900 mg/kg of Red TN9014, for 5 weeks.
16254725|NCT04992910|Experimental|Functional Electrical Stimulation|
16254726|NCT04992910|Active Comparator|Standard Therapy|
16254825|NCT04992130|Experimental|Intervention cohort|Pre-season supplementary neurologic training program
16254826|NCT04992130|No Intervention|Control cohort|Usual pre-season training program
16254728|NCT04992897||Consistent efficacy|"all users that performed at least 2 evaluable treatments. In order to isolate the effect of REN treatments, this dataset considered only treatments where REN was used as a standalone treatment.
~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).
~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
16254729|NCT04992897||Treatment intensity distribution|"all treatments.
~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes)."
16254730|NCT04992897||Safety|all reported treatment/device-related adverse events (AEs) within the time period.
16254731|NCT04992871||Patient population|Children, adolescents and adults diagnosed with cerebral palsy who are born, treated or living in Switzerland
16254732|NCT04992858|Experimental|CT053PTSA|60 mg/d, starting on the first day
16254733|NCT04992845|Experimental|Intervention|Vertebral Body Tethering surgery
16254734|NCT04992832|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0*10^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.
16254735|NCT04992832|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
16254736|NCT04992819|No Intervention|Control Group|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. Experiment is about labeling breast milk by time of day before giving it to babies. There is no extra intervention during feeding. The breastmilk of the control group patients will be given without matching according to the clinical routine practice.
~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
16254737|NCT04992819|Experimental|Chronobiological Approach Nutrition Model|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. The milk of the intervention group patients will be matched circadian and given to the babies. Intervention group's breast milk is labeling by time of day before the each feeding. In the intervention group, a label containing the time of expressed breastmilk will be affixed. Circadian matched milk will be provided at each feeding.
~intervention is;n the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
16254738|NCT04992806||patients accepted hip arthroscopy|patients with hip diseases and accepted hip arthroscopy in Peking University Third Hospital
16254739|NCT04992780|Experimental|Hypo-Fractionation|Participants will receive one fraction of radiation therapy a day for 5 days each week for 5 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin area under the curve (AUC) 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
16254740|NCT04992780|Active Comparator|Standard-Fractionation|Participants will receive one fraction of radiation therapy a day for 5 days each week for 6 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin AUC 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
16254741|NCT04992767|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
16254742|NCT04992767|Experimental|Sunnyside Flex|An online intervention to treat symptoms of PTSD and better manage mood during and after pregnancy.
16254743|NCT04992754||Pregnant women over 18 years old coming to consult at the gynecology department|Pregnant women over 18 years old coming to consult at the gynecology department in the Montpellier's hospital
16254744|NCT04992741|Experimental|Experimental|Health Belief Model Based Motivational Interview Group The application will be made by the researcher who has been trained in motivational interviewing techniques. Motivational interviews based on Health Belief Model will be made by telephone to mothers who have daughters studying in high school. There will be 3 interviews with mothers based on the benefits, barriers, sensitivity and severity perception structures of the Health Belief Model regarding HPV infection and vaccination, and each interview will last 15-20 minutes. One week after each interview, the questionnaire/scale forms will be sent via whatsapp and applied.
16254745|NCT04992741|No Intervention|other|The control group will remain subject to the routine process without any intervention.
16254746|NCT04992728||Male Prostate Patients|Adult male patients with fair to good performance status and who (1) have undergone an MRI of the prostate for suspected or known prostate cancer and/or (2) are planning to undergo radical prostatectomy for prostate cancer.
16254747|NCT04992715|Experimental|Metastatic Non-Small Cell Lung Cancer|"Subjects with metastatic non-small cell lung cancer will be recruited as per protocol inclusion/exclusion criteria and will undergo [99mTc]-anti-PDL1 single-domain antibody ([99mTc]-NM-01) SPECT/CT imaging.
~[99mTc]-NM-01 SPECT/CT images will be compared to immunohistochemistry PD-L1 expression results."
16254748|NCT04992702|Experimental|Animated Video|The information in the ACL animated video (https://vimeo.com/281721823) was displayed as a story of a typical athlete who sustained an injury and how this could be prevented through evidence-based prevention strategies.
16254749|NCT04992702|Active Comparator|Web-based Article|The active control group received commonly accessed information from a WebMD web-based article on ACL injury prevention.
16254750|NCT04992702|Placebo Comparator|Placebo control|The placebo control group intervention received an educational video from the CDC about concussions that is comparable in duration to that of the ACL video (https://youtu.be/fSRWF44wgn8).
16254785|NCT04992481|Experimental|4. PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy were performed.
16254786|NCT04992481|No Intervention|Control group|Control group not subjected to any prophylactic program constituted of randomly selected 30 participants.
16254787|NCT04992468|Experimental|GnRH-a+rhCG|Ovulation triggering with GnRH-a+rhCG
16254788|NCT04992468|Active Comparator|GnRH-a|Ovulation triggering with GnRH-a
16254751|NCT04992663|Experimental|Intervention group (VR-group)|"The participants randomised into this group are offered the BirthVR intervention during Labour.
~The VR group receives a VR information moment during labour and the possibility to exercise with the VR glasses and they receive VR during labour from the moment they are in active labour and use VR as much as they prefer. After labour, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated and participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5).
~As soon as VR does not serve as adequate pain relief during labour and a women requests additional pain medication this will be offered according to local protocol."
16254752|NCT04992663|No Intervention|Care as usual group|Patients randomised to the care as usual group will be offered pain medication during labour according to the local protocol, and on maternal request only. Postpartum participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5)
16254753|NCT04992650|Experimental|Breast reconstruction with fat grafting|fat grafting
16254754|NCT04992650|No Intervention|breast reconstruction without fat grafting|No Fat grafting
16254755|NCT04992637|Experimental|ClockWork|Participants who are randomized to treatment will receive the ClockWork intervention
16254756|NCT04992637|Active Comparator|Usual Care|Participants will receive usual care during the postpartum period.
16254757|NCT04992624|Placebo Comparator|Placebo|
16254758|NCT04992624|Experimental|Cannabidiol (CBD)|Up to 150 mg/day.
16254759|NCT04992624|Experimental|Tetrahydrocannabinol (THC)|Up to 10 mg/day.
16254760|NCT04992624|Experimental|CBD plus THC|Up to 150 mg/day CBD plus up to 10 mg/day THC.
16254761|NCT04992611|Experimental|Circadian-Aligned Sleep Extension|A sleep extension period that roughly conforms to a given participant's circadian phase (i.e., fits the schedule of a Morning Lark vs. Night Owl).
16254762|NCT04992611|Experimental|Circadian-Misaligned Sleep Extension|A sleep extension period that does not conform to a given participant's circadian phase. In other words, this condition asks Morning Larks to extend their sleep by sleeping in later, or asks Night Owls to extend their sleep by going to bed earlier.
16254765|NCT04992585|Experimental|PTBD with primary metal stent implantation|PTBD with primary metal stent implantation is performed in the same session as a one step-procedure
16254766|NCT04992585|Active Comparator|PTBD with secondary metal stent implantation|PTBD with secondary metal stent implantation is performed as a two step-procedure with metal stent implantation 3 to 7 days after previous percutaneous transhepatic biliary drainage and insertion of a plastic catheter
16254767|NCT04992572|Active Comparator|General anesthesia|"Patients under this group will be undergoing lumbar decompression surgery with general anesthesia:
~General Anesthesia: Medically induced unconsciousness that suppresses reflexes and requires intubation (a tube inserted through the mouth and into the airway) to assist in breathing."
16254768|NCT04992572|Active Comparator|Monitored Anesthetic Care (MAC)/Local|"Patients under this group wil be undergoing limbar decompression surgery with Monitored Anesthetic care, (MAC)/Local.
~Local + MAC: Local anesthetic (lidocaine) injected into the site of the incision/dissection with additional IV medication (Propofol) to achieve a state in which the patient is generally aware, but relaxed."
16254769|NCT04992559|Experimental|Toripalimab Arm|Toripalimab consolidation therapy
16254770|NCT04992546|Experimental|PRN473 (SAR444727)|Multiple topical doses of PRN473 (SAR444727) for 42 days
16254771|NCT04992546|Placebo Comparator|Placebo|Multiple topical doses of placebo for 14 days, and PRN473 (SAR444727) for 28 days
16254772|NCT04992533|Active Comparator|Long-duration tourniquet|Tourniquets inflated before arthroscopic exploration and deflated after high tibial osteotomy
16254773|NCT04992533|Experimental|Short-duration tourniquet|Tourniquet should be inflated before arthroscopic exploration and deflated immediately after the exploration
16254774|NCT04992520|Experimental|Group 1A: S. sonnei 53G|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
16254775|NCT04992520|Experimental|Group 1B: S. flexneri 2a 2457T|"At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
16254776|NCT04992520|Experimental|Group 2A: S. flexneri 2a 2457T (1500 cfu)|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
16254777|NCT04992520|Experimental|Group 2B: S. sonnei 53G|"At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
16254778|NCT04992507|Experimental|Arm I (surgical resection with TIVA)|Patients undergo surgical resection with TIVA.
16254779|NCT04992507|Active Comparator|Arm II (surgical resection with inhaled volatile anesthetics)|Patients undergo surgical resection with inhaled volatile anesthetics.
16254780|NCT04992494|Experimental|MBCT-T|Mindfulness-based cognitive therapy delivered by Telephone
16254781|NCT04992494|Experimental|MBCT-V|Mindfulness-based cognitive therapy delivered by Video
16254782|NCT04992481|Experimental|1. professional mechanical tooth cleaning (PMTC)+fluoride varnish|This arm constituted of randomly selected 30 participants. In this group professional mechanical tooth cleaning (PMTC)+fluoride varnish were performed.
16254783|NCT04992481|Experimental|2. PMTC+fluoride varnish+gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+gaseous ozone therapy were performed.
16254784|NCT04992481|Experimental|3. PMTC+fluoride varnish+domestic octenidin mouth rinse|This arm contituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse were applied.
16256007|NCT04983706|Experimental|MRI/Ultrasound Fusion Saturation Biopsy|
16254789|NCT04992442|Experimental|TAK-935 300 mg + [14C]TAK-935 50 μg + [14C]TAK-935 300 mg|TAK-935 3×100 mg, tablets, orally, once on Day 1, followed by [14C]TAK-935 50 micrograms (μg) [approximately 1 μCi], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]TAK-935 300 mg (approximately 100 μCi) solution, orally, once on Day 1 of Treatment Period 2.
16254790|NCT04992416|Experimental|SMV with ATBG around implant|SMV mixed with ATBG around immediately placed dental implants in the extraction sockets
16254791|NCT04992416|Active Comparator|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
16254792|NCT04992390|Experimental|Immediate intervention arm|Immediate access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome).
16254793|NCT04992390|Experimental|Delayed intervention arm|Usual care for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome), followed by access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks.
16254794|NCT04992377|Experimental|R-EPOCH plus IBR for RT|
16254795|NCT04992364||Positive Clinical Performances|Subjects show positive clinical performances regarding burnout syndrome
16254796|NCT04992364||Negative Clinical Performances|Subjects show negative clinical performances regarding burnout syndrome
16254797|NCT04992351||WALANT group|WALANT was used exclusively as anesthesia method for the operation
16254798|NCT04992351||control|tourniquet with regional or general anesthesia was used for the operation
16254799|NCT04992338|Experimental|Intervention group - CarpeDiem app|Participants will receive at their home the activity tracker of Fitbit brand, model Inspire HR 2, as well as instructions to download and use the CarpeDiem application and the Fitbit application in their mobile phones and synchronize the bracelet. The intervention consists of detecting unhealthy user behaviors and, through contextualized and personalized recommendations and strategies based on gamification, modifying said behaviors and motivating individuals to maintain this modification over time in order to prevent illnesses associated with bad habits. The intervention is performed through the CarpeDiem application, participants will be able to answer follow-up questionnaires, carry out missions designed to improve their eating habits, monitor their physical activity and sleep.
16254800|NCT04992338|No Intervention|Control group - Activity tracker + general recommendations|"Participants will receive the Fitbit activity tracker, model Inspire HR 2. They will also receive instructions to download the Fitbit application from their mobile phone and synchronize the bracelet. Additionally, this group will receive general recommendations on healthy lifestyle habits through standardized documents that contain general guidelines, such as: Get in the habit of going to sleep and always waking up at the same time, even on weekends."
16254801|NCT04992325||Patients with type 2 diabetes mellitus|The patients with previous diagnosis of type 2 diabetes mellitus, without signs of diabetic retinopathy
16254802|NCT04992325||Healthy subjects|Healthy subjects without actual and previous ocular diseases
16254804|NCT04992299|Experimental|Mindfulness-Based Intervention|6-week group intervention, Learning to BREATHE, an adolescent mindfulness-based intervention derived from mindfulness-based stress reduction
16254805|NCT04992299|Active Comparator|Cognitive-Behavioral Therapy|6-week group intervention, the Blues Program, a cognitive-behavioral intervention for adolescents with elevated symptoms of depression
16254806|NCT04992299|Other|Health Education|6-week group program providing didactic information on adolescent health topics
16254807|NCT04992286|Experimental|people aged 65 years or more|men or women, age Superior to 65 years
16254810|NCT04992260|Experimental|Experimental Group|7000 subjects (including 100 participants aged 6-35 months ,1900 participants aged 3-5 years ,2500 participants aged 6-11 years and 2500 aged 12-17 years )will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28.
16254811|NCT04992260|Placebo Comparator|Control Group|7000 subjects (including 100 participants aged 6-35 months ,1900 participants aged 3-5 years ,2500 participants aged 6-11 years and 2500 aged 12-17 years )will receive two doses of placebo on day 0 and day 28.
16254812|NCT04992247|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
16254813|NCT04992247|Placebo Comparator|Placebo|Excipient
16254815|NCT04992195||Vaccination Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and received COVID-19 vaccination (SinoVac or BioNTech).
16254816|NCT04992195||Control Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and have not received any COVID-19 vaccines nor clinically/serologically evident SARS-CoV-2 infection.
16254817|NCT04992182|Experimental|Inactivated vaccine booster|One standard IM CoronaVac dose (0.5 mL)
16254818|NCT04992182|Experimental|mRNA vaccine booster|One standard IM BNT162b2 dose (0.3 mL)
16254819|NCT04992182|Experimental|Viral vector vaccine booster|One standard IM ChAdOx1 dose (0.5 mL)
16254820|NCT04992182|Placebo Comparator|Placebo|Saline solution IM (0.3 mL)
16254821|NCT04992169|Experimental|Smartphone App with Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their video and are taught to score their own performance/fidelity through question prompts built into the app. When they are finished, the app will offer feedback and follow-up lessons based on the PRT strategies they have not demonstrated consistently.
16254822|NCT04992169|Experimental|Smartphone App without Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their own video but do not score their performance.
16269688|NCT04887792|Active Comparator|Placebo|Identical gelatin capsules
16254831|NCT04992078|Active Comparator|Conventional-Unicompartmental Knee Replacement (C-UKR)|Non-robotic conventional instrumentation
16254839|NCT04992052|Active Comparator|Treatment arm|This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
16254840|NCT04992052|No Intervention|Control Arm|This arm will serve as the control group. Bone wax will not be used in this group.
16254841|NCT04992039|No Intervention|Control Arm|Participants of this arm will not receive the total WHO HEARTS package as an intervention. These participants will be screened in the designated area for universal BP screening via A&D arm-in device. Their diagnosis will be confirmed by measuring their BP by a Medical Officer via an Omron desktop oscillometer. The Medical Officers and UHC nurses of the control sites will be trained up on BP measurement using standard techniques, patient registration, data collection, etc.
16254842|NCT04992039|Experimental|Intervention Arm|Participants of this arm will receive all the components of WHO HEARTS technical package components as an intervention.
16254843|NCT04992026|Experimental|ADT plus abiraterone + surgery|After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.
16254844|NCT04992026|Active Comparator|ADT plus abiraterone|Patients will be only treated with Androgen deprivation therapy + abiraterone acetate along with prednisone. Prostatectomy won't be performed.
16254845|NCT04992013|Experimental|Niraparib|Participants will receive niraparib 1x daily for each 28 day study treatment cycle up to 2 years or until disease worsens or unacceptable side effects occur.
16254846|NCT04992000|Experimental|4-free app + PHN intervention|"The intervention group was received initial education, 4-free apps, and followed by PHN interventions.
~Education, app, and PHN intervention"
16254847|NCT04992000|Experimental|4-free app alone|The apps alone group received the initial education and the 4-free Apps.
16254848|NCT04992000|No Intervention|education|Standard care group received just the initial education.
16254849|NCT04991974|No Intervention|Usual Care (UC)|The UC Arm will include standard services from the sexual health clinic / city health department [at the time of the study, no standardized intervention for opioid use disorder treatment linkage].
16254850|NCT04991974|Active Comparator|Patient Navigation (PN)|The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
16254851|NCT04991974|Experimental|Patient Navigation + Buprenorphine Initiation (PN+BUP)|The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community. The standard buprenorphine bridge prescription will be for buprenorphine/naloxone film: 8/2mg, up to 16mg per day, 7 day supply.
16254852|NCT04991948|Experimental|CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab|
16254853|NCT04991935|Experimental|Administration of CC-93538|Participants are administered CC-93538 dose subcutaneously once weekly
16254854|NCT04991909|Experimental|Treatment group A|
16254855|NCT04991909|Placebo Comparator|Treatment group B|
16254856|NCT04991870|Experimental|Group 1 (CB-NK-TGF-betaR2-/NR3C1- )|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 8 doses in the absence of disease progression or unacceptable toxicity.
16254857|NCT04991870|Experimental|Group 2 (CB-NK-TGF-betaR2-/NR3C1-, resection)|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes on days 0, 7, and 14. Patients undergo standard of care surgical resection on day 15. Beginning 2 weeks after surgery, patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 5 doses (total of 8 doses) in the absence of disease progression or unacceptable toxicity.
16254858|NCT04991857|Experimental|The technology-based family-centered empowerment program for heart failure (T-FAME-HF)|The T-FAME-HF is a 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits. The Program includes 3 four-week phases, which followed by 2 bi-weekly telephone visits. Each phase is designated with a specified goal of care to guide the disease management activities. Commenced with the home visit by the team nurse for each phase, patients' condition and self-care will be assessed. A goal-setting approach will be used to enhance disease monitoring, symptom recognition and response, and treatment compliance. A mobile apps (T-FAME) will be installed in participants' smart-phone and supports the prescribed actions for goal attainment.
16254859|NCT04991857|Active Comparator|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by another team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
16254860|NCT04991844|No Intervention|Control group|The control group did not receive any intervention, but met at three timepoints to complete study questionnaires and provide anthropometric measurements,
16254861|NCT04991844|Experimental|Intervention Group|This group received the study intervention protocol.
16270592|NCT04881435|Active Comparator|Standard steroid treatment|
16254862|NCT04991831||Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease|This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.
16254867|NCT04991792|Experimental|Standard Infant Formula with synbiotics (CS-born)|CS born infants, randomized to receive infant formula with synbiotics
16254868|NCT04991792|Experimental|Standard Infant Formula with prebiotics (CS-born)|CS born infants, randomized to receive infant formula with prebiotics
16254869|NCT04991792|Active Comparator|Control Group 1: Standard Infant Formula (CS-born)|CS born infants, randomized to receive standard infant formula without synbiotics
16254870|NCT04991792|Active Comparator|Control Group 2 : Standard Infant Formula (VD-born)|VD born infants, receiving standard infant formula without synbiotics (self-selected for formula-feeding = non-randomized)
16254871|NCT04991792|No Intervention|Reference Group 1: Breastfed (CS-born)|CS-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
16254872|NCT04991792|No Intervention|Reference Group 2: Breastfed (VD-born)|VD-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
16254873|NCT04991779||The neonates with suspected seizures or high risk of seizures|The neonates with suspected seizures or high risk of seizures are monitored by continuous electroencephalogram (cEEG) at least 12 hours since admission. The cEEG will be interpreted by AI-assisted cEEG diagnostic tool at the end of cEEG monitoring. At the same time, the same cEEG will be manually reported according the reference standard.
16254874|NCT04991766|Experimental|[¹⁴C]-LY3484356 (Part 1)|Single dose of [¹⁴C]-LY3484356 administered orally.
16254875|NCT04991766|Experimental|LY3484356 + [¹⁴C]-LY3484356 (Part 2)|Single dose of LY3484356 administered orally followed by Single dose of [¹⁴C]-LY3484356 administered intravenously (IV).
16254878|NCT04991740|Experimental|Part 1: Dose Escalation|Participants with renal cell carcinoma (RCC), ovarian cancer, colorectal cancer (CRC), and other tumor types with sponsor approval will receive JNJ-78306358. The dose will be escalated sequentially based on the decisions of the study evaluation team until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
16254879|NCT04991740|Experimental|Part 2: Dose Expansion|Participants with RCC, ovarian cancer, CRC and other types of tumors will receive JNJ-78306358 at the RP2D regimen(s) determined in Part 1.
16254880|NCT04991727||PEEP|The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway.Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed.Pulmonary ultrasound was performed. The PEEPgroup was given the first RM (pulmonary retraction) with pressure maintained at 40cmH2O for 30s, followed by a 7cmH2O PEEP to maintain mechanical ventilation, and the RMS was repeated every 30 minutes until the end of surgery
16254881|NCT04991727||ZEEP|"The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway. Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed
~On pulmonary ultrasound, patients in the ZEEP group maintained normal mechanical ventilation throughout the operation without PEEP or RMS"
16254882|NCT04991714|Experimental|Sucrose|10% solution in water
16254883|NCT04991714|Experimental|Sucrose + Reb M|10% sucrose + 60 mg/L Rebaudioside M
16254884|NCT04991714|Experimental|Sucrose + Lactisole|10% sucrose + 30 mg/ L Lactisole
16254885|NCT04991714|Experimental|Sucrose + Reb M + Lactisole|10% sucrose + 60 mg/L Rebaudioside M + 30 mg/ L Lactisole
16254886|NCT04991688|Experimental|BOTOX-A|
16254887|NCT04991675|Active Comparator|pelvic floor muscle exercises|Exercises were taught in the supine position, as described by Kegel (1948), and it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
16254888|NCT04991675|Active Comparator|diaphragmatic breathing exercises|Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
16254889|NCT04991662|Experimental|metaraminol group|During the cesarean section, metaraminol 2ug/kg/min is preventively infused after anesthesia to prevent and treat hypotension.
16254890|NCT04991662|Experimental|phenylephrine group|During cesarean section, preventive infusion of phenylephrine 0.54ug/kg/min after anesthesia to prevent and treat hypotension.
16254891|NCT04991662|Experimental|norepinephrine group|During cesarean section, preventive infusion of norepinephrine 0.08ug/kg/min after anesthesia to prevent and treat hypotension.
16254892|NCT04991649|Experimental|ACT Group|One two-weekly 2-hour of positive parenting program plus a four-weekly 2-hour group ACT program and routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
16256215|NCT04982263||Mild cases|Patients with confirmed COVID-19 and with mild disease
16254893|NCT04991649|Other|Treatment-as-usual (TAU) Group|Routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
16254894|NCT04991636|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
16254895|NCT04991623|Experimental|Kinesiology taping|Apply a kinesiology taping on the abdominal muscles plus conventional physiotherapy
16254896|NCT04991623|Active Comparator|Physiotherapy Group|Apply a conventional physiotherapy
16254897|NCT04991610|Active Comparator|Adult male|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
16254898|NCT04991610|Active Comparator|Adult female|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
16254899|NCT04991597|Experimental|Left Forearm Injection Sites Cooled, Right Forearm Injection Sites at Room Temperature|Palmar aspect of participants left forearm will have a cold compress pack placed on it. The palmar aspect of the right forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
16254900|NCT04991597|Experimental|Right Forearm Injection Sites Cooled, Left Forearm Injection Sites at Room Temperature|Palmar aspect of participants right forearm will have a cold compress pack placed on it. The palmar aspect of the left forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
16254901|NCT04991584|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy Option 1:Amoxicillin+Tetracycline+Furazolidone+Vonoprazan fumarate or Esomeprazole Option 2: Amoxicillin+Furazolidone+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 3: Amoxicillin+Tetracycline+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 4: Amoxicillin+Clarithromycin+Levofloxacin+Vonoprazan fumarate or Esomeprazole Three options are selected according to the actual situation.
16254902|NCT04991571|Experimental|Part 1|Participants will be administered with zibotentan once daily for 5 days.
16254903|NCT04991571|Experimental|Part 2: Treatment Sequence ABC|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment A; Treatment B; Treatment C) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
16254904|NCT04991571|Experimental|Part 2: Treatment Sequence BCA|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment B; Treatment C; Treatment A) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
16254905|NCT04991571|Experimental|Part 2: Treatment Sequence CAB|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment C; Treatment A; Treatment B) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
16254906|NCT04991545|No Intervention|Group A: control group (intubation without IRD/IRRIS device)|Group A = control group (intubation without IRD/IRRIS device) (15 subjects) The first operator experienced with video-laryngoscopy intubation will do the endotracheal intubation after induction of anesthesia.
16254907|NCT04991545|Experimental|Intervention group using Infrared (Active IRD/ IRRIS) device|Group B = intervention group using Infrared active IRD/IRRIS device (15 subjects) Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients. After confirming lack of discomfort during application of the IRRIS/IRD device, anesthesia will be induced
16254908|NCT04991532||Dasatinib group|the CML patient treated with dasatinib
16254909|NCT04991532||Imatinib group|the CML patient treated with imatinib
16254910|NCT04991519||Stroke Survivors|Participants have had a left-hemisphere stroke with or without aphasia, or a stroke elsewhere in the brain causing aphasia. They are given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
16254911|NCT04991519||Controls|Participants are matched to aphasia cohort in age, educational background, race, and gender but have no history of brain injury. They are also given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
16254914|NCT04991493|Placebo Comparator|Placebo group|5ml normal saline was injected intravenously 15 minutes before anesthesia and 5ml normal saline was injected intravenously when the incision was washed and sutured.
16254915|NCT04991493|Experimental|pre-tramadol group|5ml of tramadol containing 1mg / kg was injected intravenously 15 minutes before anesthesia and 5ml of normal saline was injected intravenously when the incision was washed and sutured.
16254916|NCT04991493|Active Comparator|post-tramadol group|5ml of normal saline was injected intravenously 15 minutes before anesthesia and 5ml of tramadol containing 1mg / kg was injected intravenously when the incision was washed and sutured.
16254917|NCT04991480|Experimental|Part A1|Part A1 will evaluate ART4215 monotherapy administered in 21 day cycles. Up to 36 participants will participate in this dose escalation arm.
16254918|NCT04991480|Experimental|Part A2|Part A2 will evaluate ART4215 given in combination with talazoparib in 21 day cycles. Up to 30 participants will participate in this dose escalation arm.
16254919|NCT04991480|Experimental|Part B1|In Part B1 dose expansion, up to 30 participants with solid cancers that have been treated with a PARP inhibitor for an approved indication will receive ART4215.
16254920|NCT04991480|Experimental|Part B2|In Part B2 dose expansion, up to 20 participants with solid cancers with characteristics indicative of sensitivity to pol theta inhibition will receive ART4215.
16254921|NCT04991480|Experimental|Part B3|In Part B3, approximately 90 participants with HER2 negative BRCA breast cancers will be randomized 1:1 to either ART4215 in combination with talazoparib or talazoparib alone.
16254922|NCT04991467|Experimental|Parents of children receiving mental health treatment at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app .
16254923|NCT04991467|Experimental|Parents of children being treated for autoimmune disorders at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
16254924|NCT04991467|Experimental|Healthcare workers at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
16254925|NCT04991454|Other|end-stage pulmonary arterial hypertension .|subjects with end-stage PAH that currently on the waitlist for lung transplant
16254926|NCT04991454|Other|following pulmonary arterial hypertension subjects|Following pulmonary arterial hypertension subjects upto 24 months
16254927|NCT04991441|Experimental|Control|Participants will follow their usual or normal diet for 5 months (CON) followed by an Controlled Dietary Sodium Restriction (INT) diet for 2 months. During the sodium restricted diet, participants will be provided with 2 meals and snacks daily, for 30 days (Month 5 - days 1-30) and 1 meal and snacks daily, for 30 days (Month 6 - days 31-60). These meals should meet the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
16254928|NCT04991441|Experimental|Intervention|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
16254929|NCT04991428|Experimental|Active trancranial direct current stimulation|Active stimulation for 15 minutes
16254930|NCT04991428|Sham Comparator|Sham stimulation|Similar set-up but no actual stimulation
16254931|NCT04991415|Experimental|Treatment|30 minutes of manual therapy three times a week for two weeks (six total sessions).
16254932|NCT04991415|No Intervention|Control|No intervention
16254933|NCT04991402||Pregnant women living with HIV initiating Dolutegravir (DTG) in pregnancy (iDTG)|Pregnant women living with HIV not on antiretroviral therapy (ART) at their 1st antenatal care visit and initiating DTG-based ART in pregnancy.
16254934|NCT04991402||Pregnant women living with HIV already on DTG-based ART prior to pregnancy (cDTG)|Pregnant women living with HIV already on DTG-based ART prior to pregnancy and continuing DTG use through pregnancy.
16254935|NCT04991402||HIV uninfected pregnant women|Pregnant women not living with HIV
16254936|NCT04991389|Experimental|Phase 1 - Contrast 129Xe MRI ages 5-18|The research team will collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Phase contrast MRI of inhaled gas. (4) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
16254937|NCT04991389|Experimental|Phase 2 - Contrast 129Xe MRI ages 3-18|The research team plans to collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
16254938|NCT04991376||Vancomycin|Critically ill patients who suffered from sepsis, treated with vancomycin.
16254939|NCT04991376||Gentamicin|Critically ill patients who suffered from sepsis, treated with gentamicin.
16254940|NCT04991376||Other antibiotic groups|Critically ill patients who suffered from sepsis, treated by other antibiotic groups except for vancomycin or aminoglycoside (gentamicin).
16254941|NCT04991363|Experimental|Patients|
16254942|NCT04991350|Active Comparator|Ranibizumab Group|Patients will receive monthly ranibizumab injections for 3 months.
16254943|NCT04991350|Active Comparator|Bevacizumab Group|Patients will receive monthly bevacizumab injections for 3 months.
16254944|NCT04991337|Experimental|Detraining group|: Will be instructed to avoid high-intensity exercise corresponding to a heart rate (HR) above 75% of maximum heart rate (HRmax) for a period of 16 week
16254945|NCT04991337|Experimental|Control group|Will be instructed to perform at least three weekly sessions of high intensity training, corresponding to a HR above 85% of HRmax, and otherwise continue endurance exercise as usual.
16254946|NCT04991324|Experimental|weekly supplementation|Weekly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 3500 IU per day, as comedication to the usual treatment during 6 months.
16254947|NCT04991324|Active Comparator|monthly supplementation|Monthly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 800 IU per day, as comedication to the usual treatment during 6 months.
16254948|NCT04991324|No Intervention|control group|Usual treatment without vitamin D supplementation.
16254949|NCT04991311|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
16254950|NCT04991298|Active Comparator|Group M|patients will be premedicated with the undiluted IV formulation of Midazolam
16254951|NCT04991298|Active Comparator|Group F|patients will be premedicated with the undiluted IV formulation of fentanyl citrate
16255018|NCT04990830|Experimental|Inhalation Treatment|"Treatment: Inhaled Low molecular weight heparin + Standard COVID-19 treatment,
~Inhaled Low molecular weight heparin (4000 IU given twice a day for 10 days)"
16255019|NCT04990830|Other|Control Group|Treatment: Standard COVID-19 treatment
16256216|NCT04982263||Severe cases|Patients with confirmed COVID-19 and with severe disease
16254952|NCT04991272|Active Comparator|warming group|Warming group patients are applied prewarming with bair-hugger (43'C)(warm touch, COVIDIEN, full body blanket) for 10 minutes in the preanesthetic unit prior to induction of anesthesia. During operation, prewarmed intravenous fluid which was stored in the warming cabinet for more than 8 hours is connected and infused. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
16254953|NCT04991272|No Intervention|no warming group|No warming group patients are not applied prewarming devices. Intravenous fluid stored in room air is connected and infused during the operation. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
16254954|NCT04991259|Experimental|Preemptive CRRT|In patients randomized to early CRRT, CRRT would be initiated within 12 hours of randomization.
16254955|NCT04991259|Active Comparator|Standard Medical Treatment|"In patients randomized to SMT group, CRRT would be initiated as per the existing standard protocol.
~in patients with worsening hyperammonemia despite two sessions of plasma-exchange
~patients meeting renal indications (hyperkalemia, volume overload, oliguria or metabolic acidosis etc)."
16254956|NCT04991246|Experimental|Students, teachers,administrative staff from the medical school of Paris-Saclay University|Students,teachers,administrative staff from the medical school of Paris-Saclay University
16254957|NCT04991233|Experimental|Endoscopic surgery|Endoscopic surgery group
16254958|NCT04991233|Active Comparator|Suboccipital craniotomy surgery|Suboccipital craniotomy surgery group
16254959|NCT04991220|Experimental|preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
16254960|NCT04991207|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
16254961|NCT04991207|Active Comparator|Bosentan|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple (twice daily [b.i.d.]) oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
16254962|NCT04991207|Experimental|BIA 5-1058 and Bosentan|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple b.i.d. oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5 1058 400 mg (4 x 100 mg tablets) and bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
16254963|NCT04991194|Experimental|BIA 5-1058 1200 mg (Part I)|Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days
16254964|NCT04991194|Experimental|BIA 5-1058 400 mg (Part II)|Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.
16254965|NCT04991181|Experimental|BIA 5-1058|Capsules; 400 mg; single dose; oral administration.
16254966|NCT04991168||Diabetic patients over 18 from the CHU Lapeyronie|Diabetic patients over 18 from the CHU Lapeyronie
16254967|NCT04991155|Experimental|PART 1 (400 mg BIA 5-1058)|Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3): Part 1: 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 1, 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 2, and 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 3.
16254968|NCT04991155|Experimental|PART 2 (800 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):
~Part 2: 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 1, 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 2, and 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 3."
16254969|NCT04991155|Experimental|PART 3 (1200 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):
~Part 3: 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 1, 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 2, and 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 3."
16254970|NCT04991142||Persons with Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c greater than or equal to 6.5%
16254971|NCT04991142||Persons with Pre-diabetes|Venous blood draw of fasting HbA1c greater than or equal to 5.7% and less than 6.5%
16254972|NCT04991142||Persons without Pre-diabetes or Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c less than 5.7%
16254973|NCT04991129|Experimental|WJ01024 5mg repeat dose every 28 days|
16254974|NCT04991129|Experimental|WJ01024 10mg repeat dose every 28 days|
16254975|NCT04991129|Experimental|WJ01024 20mg repeat dose every 28 days|
16254976|NCT04991129|Experimental|WJ01024 40mg repeat dose every 28 days|
16254977|NCT04991129|Experimental|WJ01024 60mg repeat dose every 28 days|
16254978|NCT04991129|Experimental|WJ01024 80mg repeat dose every 28 days|
16254979|NCT04991129|Experimental|WJ01024 100mg repeat dose every 28 days|
16254980|NCT04991129|Experimental|WJ01024 120mg repeat dose every 28 days|
16254981|NCT04991129|Experimental|WJ01024 140mg repeat dose every 28 days|
16254982|NCT04991129|Experimental|WJ01024 160mg repeat dose every 28 days|
16254983|NCT04991116|Experimental|TILD q12 weeks|
16255020|NCT04990817|Experimental|Average American Diet With SoFAS Replaced With Avocado|Average American diet with foods that provide the equivalent of 1 medium to large avocado per day. It is anticipated that energy from avocado would replace 12-15% of daily energy, roughly half from solid fats and half from added sugars (SoFAS).
16255021|NCT04990817|Placebo Comparator|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
16254985|NCT04991090|Experimental|escalation|The gross tumor volume (GTV) was defined as gross disease determined on MRI scans. The clinical target volume (CTV) was defined as the GTV plus areas considered at significant risk of harboring microscopic area. The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost. The planning target volume (PTV) was generated by adding an 8-mm margin around the GTV, GTVnd, and CTV in all directions. Doses of 58 Gy, 50 Gy, and 45 Gy were delivered to PTV-GTVnd, PTV-GTV, and PTV-CTV at 25 fractions, respectively. The dose of the normal organs at risk was constrained to the following criteria: bowel bag, V50 ≤ 5%; bladder, V50 ≤ 50%; femoral heads, V50 ≤ 5% .
16254986|NCT04991077||patients group|patients with malignant hypertension
16254987|NCT04991077||Control group|patients with severe hypertension (Grade 2 or 3 hypertension)
16254988|NCT04991064|Other|AB arm|participants allocated to this arm receive treatment A first, followed by treatment B.
16254989|NCT04991064|Other|BA arm|participants allocated to this arm receive treatment B first, followed by treatment A.
16254990|NCT04991038|Experimental|DAISe Thrombectomy Device|Mechanical Thrombectomy with DAISe
16254991|NCT04991038|Active Comparator|Stent Retriever|Mechanical Thrombectomy with TREVO or Solitaire Device
16254992|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers.|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
16254993|NCT04991012|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
16254994|NCT04991012|Active Comparator|Triamcinolone (Substance) therapy side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
16254995|NCT04990999|Experimental|Vestibular Root Extraction|
16254996|NCT04990999|Active Comparator|Atraumatic extractions using periotomes followed by conventional forceps|
16254997|NCT04990986|Other|Intervention|The complex intervention will be co-developed during first phase of the study.
16254998|NCT04990986|No Intervention|Control|Half of the group will be included as control and thus not exposed to the intervention.
16254999|NCT04990973|Experimental|Mediterranean Diet and then AAD|Healthy participants that are randomized to the MedDiet followed by a 4-week washout and a crossover to the AAD.
16255000|NCT04990973|Experimental|Average American Diet (AAD) and then Mediterranean Diet|Healthy participants that are randomized to AAD followed by a 4-week washout and a crossover to the Mediterranean Diet.
16255001|NCT04990960|Active Comparator|Physiotherapist|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements and actively worked on AWS cords with gentle extensions and / or energetic detachment maneuvers. No self-treatment methods were offered and required of the subject.
16255002|NCT04990960|Experimental|Self-treatment|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements. During each session the patient was also assessed and trained in self-treatment exercises assigned to treat their cords. Subjects were trained to perform self-treatment extension exercises with four exercises selected by the Physiotherapist
16255003|NCT04990947||Bariatric surgery (Roux-en-Y Gastric Bypass)|Patients who are eligible for RYGB
16255004|NCT04990947||Lifestyle group|Patients with a BMI > 30 who will start a lifestyle program
16255005|NCT04990934||Video Telemedicine|20 participants will have used video telemedicine for appointments with their treating oncologist.
16255006|NCT04990934||Telephone Telemedicine|10 participants will have used telephone telemedicine for appointments with their treating oncologist.
16255007|NCT04990921|Experimental|Palliative Radiation in Combination with Pembrolizumab|"Stereotactic radiation therapy will be delivered using either linac-based SBRT using 10x flattening filter-free (FFF) photons or Cyberknife Pencil Beam Technology utilizing 6X photons. Treatment will be delivered in 1-5 fractions. Fractionation and total dose (1500 - 3000 cGy) will depend on the site of disease, previous radiation treatment, and patient symptomatology.
~Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for intravenous infusion. Pembrolizumab at a dose of 200 mg will be administered intravenously every 3 weeks (± 3 days)."
16255008|NCT04990895|No Intervention|Control group|Participants in the control group will have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. Although they will not be asked to complete PROs in between clinic visits, they will be asked to respond to a series of HRQOL questionnaires at baseline, at 6 months (±2 weeks) from enrollment, and at completion of adjuvant systemic therapy if this date differs from the 6-month time point by more than 4 weeks. A satisfaction questionnaire will also be administered at the end of study.
16255009|NCT04990895|Experimental|Intervention|Participants in the intervention group will also have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. They will be asked to complete a series of HRQOL questionnaires at baseline, at 6 months, and at completion of adjuvant chemotherapy to evaluate their HRQOL and satisfaction levels with their care. In addition, however, they will also receive an email reminder at the mid-way point between scheduled clinic visits to prompt them to enter ePROs via the REDCap online system, including measures such as the ESASr, the EORTC-QLQ C30 and EORTC-BR23 or EORTC-CR29 and specific symptom questionnaires.
16255010|NCT04990882||Low Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of less than 30 studies.
16255011|NCT04990882||Intermediate Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 30 studies and less than 300 studies.
16255012|NCT04990882||High Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 300 studies.
16255013|NCT04990869|Experimental|COPD-NR|COPD patients receiving Nicotinamide Riboside
16255014|NCT04990869|Placebo Comparator|COPD-placebo|COPD patients receiving placebo
16255015|NCT04990869|Experimental|Control-NR|Lung-healthy controls receiving Nicotinamide Riboside
16255016|NCT04990869|Placebo Comparator|Control-placebo|Lung-healthy controls receiving placebo
16255017|NCT04990856|Experimental|Experimental arm|Blood flow of the tumor experimented
16257222|NCT04975490||ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts|
16255022|NCT04990804|Active Comparator|Standard Perioperative Pain Regimen|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
16255023|NCT04990804|Experimental|Opioid-Free Perioperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
16255024|NCT04990791|Other|Aspirin 20mg|Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD
16255025|NCT04990791|Other|Asprin 75mg|Aspirin 75 mg OD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD
16255026|NCT04990778|Experimental|Treatment (eprenetapopt, venetoclax)|Patients receive eprenetapopt IV over 6 hours on days 1-4 and venetoclax PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16255027|NCT04990765|Experimental|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
16255028|NCT04990765|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
16255029|NCT04990752||The ulinastatin group|In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. The recommended dosage of ulinastatin is 300,000 IU, q8h (Continuous administration for more than 5 days).
16255030|NCT04990752||The control group|In the control group, patients were treated with conventional treatment without ulinastatin.
16255031|NCT04990739|Experimental|Part A Dose-Escalation and Part B RP2D Dose-Expansion|"Study has two parts:
~Part A Dose-Escalation will evaluate MTB-9655 monotherapy administered in 21 days cycle,and will be conducted in 2 stages (accelerated titration and dose-escalation).
~The first stage will consist of accelerated titration in single-patient cohorts for the initial two dose levels.
~In the second stage, a conventional 3+3 schema using a modified Fibonacci dose titration strategy will be implemented. The first dose at every dose level and in every patient will be administered under close medical supervision, and the patients will be hospitalized for approximately 24 hours.
~Up to 30 participants will participate in this dose escalation arm.
~Part B dose-expansion will further explore the safety, PK and preliminary efficacy of MTB-9655 at the RP2D. The RP2D level will be no higher than the MTD identified in Part A."
16255032|NCT04990726||Observational (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline, 1 (optional), 3, 6, 12, 18, and 24 months.
16255033|NCT04990713|Placebo Comparator|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with saline placebo. Local anesthetic administered will be ropivacaine 0.2%.
16255034|NCT04990713|Experimental|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with local anesthetic. Local anesthetic administered will be ropivacaine 0.2%.
16255035|NCT04990700|No Intervention|Control Group|Includes patients undergoing routine thoracotomy
16255036|NCT04990700|Experimental|Intervention Group|The group that will undergo 1 cm partial rib resection during thoracotomy.
16255037|NCT04990687|Experimental|Intervention Group|Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.
16255038|NCT04990674|Experimental|REMOTION + TAU|
16255039|NCT04990674|Active Comparator|TAU|
16255040|NCT04990661|Experimental|Intervention group (massage group)|intradialytic massage for lower extremity was applied to the intervention group in three sessions a week and a total of six sessions for two weeks
16255041|NCT04990661|No Intervention|Control group|not administered except nursing interventions in the HD unit.
16255042|NCT04990648|Experimental|Buzzy group|Buzzy ® was placed on the left arm deltoid muscle site and kept there for 30 seconds. After 30 seconds, Buzzy ® was taken 1 cm up and MMR vaccine injection was administered to the left deltoid muscle site. After the vaccine injection, Buzzy ® was taken to the injection site and kept for another 30 seconds.
16255043|NCT04990648|No Intervention|Control group|MMR vaccine injection was administered to the left deltoid muscle without any intervention or application to the injection site.
16255063|NCT04990544|Experimental|Elderly Group 2d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
16255064|NCT04990544|Experimental|Elderly Group 2e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
16255065|NCT04990544|Experimental|Elderly Group 2f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
16255044|NCT04990622|Experimental|Dietary flavonoid group|"Participants will be encouraged to consume 2 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 2 weeks, above what they already consume each day, typically.
~Berry fruits (~120g) e.g. blueberries, raspberries, strawberries, blackberries, blackcurrants, mixed berries
~2 large squares of dark chocolate (at least 70% cocoa)
~4-5 cups of tea (black or green) or coffee (normal or decaf varieties)
~1 large glass of red wine* (250ml)
~1 portion of leafy green vegetables such as spinach or cabbage (~70g)
~1 glass (250ml) of fresh orange or grapefruit juice (not from concentrate)"
16255045|NCT04990622|No Intervention|Control group|Participants will be given no instructions regarding adding food items to their diet. They will be encouraged to continue their diet as normal for 2 weeks.
16255046|NCT04990609|Experimental|Neoadjuvant chemotherapy (NAC) plus Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA)|
16255047|NCT04990596||Age Group 50 to 59|"Inclusion criteria :
~age 50-100 years old,
~hospitalization in one of the participating centres,
~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.
~Non-inclusion criteria :
~treatment with another antithrombotic drug,
~myeloproliferative syndrome,
~platelet count < 100 gigas/liter,
~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
~dialysis."
16255048|NCT04990596||Age Group 60 to 69|"Inclusion criteria :
~age 50-100 years old,
~hospitalization in one of the participating centres,
~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.
~Non-inclusion criteria :
~treatment with another antithrombotic drug,
~myeloproliferative syndrome,
~platelet count < 100 gigas/liter,
~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
~dialysis."
16255049|NCT04990596||Age Group 70 to 79|"Inclusion criteria :
~age 50-100 years old,
~hospitalization in one of the participating centres,
~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.
~Non-inclusion criteria :
~treatment with another antithrombotic drug,
~myeloproliferative syndrome,
~platelet count < 100 gigas/liter,
~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
~dialysis."
16255050|NCT04990596||Age Group 80 to 89|"Inclusion criteria :
~age 50-100 years old,
~hospitalization in one of the participating centres,
~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.
~Non-inclusion criteria :
~treatment with another antithrombotic drug,
~myeloproliferative syndrome,
~platelet count < 100 gigas/liter,
~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
~dialysis."
16255051|NCT04990596||Age Group 90 to 100|"Inclusion criteria :
~age 50-100 years old,
~hospitalization in one of the participating centres,
~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.
~Non-inclusion criteria :
~treatment with another antithrombotic drug,
~myeloproliferative syndrome,
~platelet count < 100 gigas/liter,
~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
~dialysis."
16255052|NCT04990583|Experimental|Carium Condition|Participants assigned to the Carium condition will receive a single session intervention and receive 12 months of access to the Carium adherence application.
16255053|NCT04990583|Active Comparator|Control Condition|Participants assigned to the Control condition will receive a single session intervention only.
16255054|NCT04990570||Pediatric day-case surgical patients, encountered via Virtual clinic from June 2020 till July 2021|"Pediatric patients, with age ranging from 1 month-14 years, with day-case surgical problems, encountered during the era of Covid-19 pandemic.
~Telemedicine, in the form of Virtual clinic, was utilized to address this distressing problem, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship & encounter."
16255055|NCT04990570||Control group comprising of patients scheduled to the OPD clinic from June 2019 till June 2020|Cases of office OPD appointments in the period from June 2019 till June 2020 will be included as a control group
16255056|NCT04990557|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.
~A total of 1 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
16255057|NCT04990557|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.
~A total of 1 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.
~A total of 2 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
16255058|NCT04990557|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.
~A total of 4 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
16255059|NCT04990544|Experimental|Adult Group 2a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
16255060|NCT04990544|Experimental|Adult Group 2b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
16255061|NCT04990544|Experimental|Adult Group 2c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28.
16255062|NCT04990544|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
16255066|NCT04990544|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
16255067|NCT04990531|Other|Low-field magnetic resonance imaging|Label-free low-field magnetic resonance imaging (0.55 Tesla)
16255068|NCT04990492|Experimental|Paper Baseline|Half of the participants will complete the GAD 7 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 on the Mirror device equipped with Amazon Alexa.
16255069|NCT04990492|Experimental|Alexa Baseline|The other half of the participants will complete the GAD 7 on the Mirror device equipped with Amazon in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 in the traditional paper format.
16255070|NCT04990479|Experimental|Cohort 1a|Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.
16255071|NCT04990479|Experimental|Cohort 2a|Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.
16255072|NCT04990479|Experimental|Cohort 2b|Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).
16255073|NCT04990466|Experimental|Active Vaccine|IIBR-100 (VSV-ΔG) vaccine at 10 to the 8th strength in prime/boost separated by 28 days
16255074|NCT04990466|Active Comparator|Active Comparator|A currently approved vaccine for COVID-19 administered in prime/boost separated by 28 days
16255075|NCT04990453|Other|RPD frameworks fabricated from PEEK material|14 patients received extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
16255076|NCT04990453|Other|RPD frameworks fabricated from Co-Cr|14 patients received extracoronal precision attachment RPD frameworks fabricated from Co-Cr material using casting machine
16255080|NCT04990427|Experimental|CLBS201|CLBS201 will be administered in an open-label fashion into the renal arteries in 6 subjects and randomized in up to 24 subjects via intra-arterial infusion and the patients observed for 12 months after infusion
16255081|NCT04990427|Placebo Comparator|Placebo|Placebo will be randomly administered into the renal arteries in up to 16 subjects via intra-arterial infusion and the patients observed for 12 months after infusion
16255082|NCT04990414|Experimental|CBT for voices and dissociation|24 sessions of Cognitive Behavioural Therapy (CBT) over a 6-month period treatment window.
16255083|NCT04990401|Experimental|Behavioral Activation Teletherapy|All eligible participants will be assigned to receive the behavioral activation teletherapy intervention.
16255084|NCT04990388|Experimental|Stage 1: UX053 Dose Level 1S|Participants to receive a single, peripheral intravenous (IV) infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
16255085|NCT04990388|Experimental|Stage 1: UX053 Dose Level 2S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
16255086|NCT04990388|Experimental|Stage 1: UX053 Dose Level 3S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
16255087|NCT04990388|Experimental|Stage 1: UX053 Dose Level 4S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
16255088|NCT04990388|Experimental|Stage 2: UX053 Dose Level 1R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker every 2 weeks (Q2W) for 5 doses.
16255089|NCT04990388|Experimental|Stage 2: UX053 Dose Level 2R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
16255090|NCT04990388|Experimental|Stage 2: UX053 Dose Level 3R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
16255091|NCT04990388|Experimental|Stage 2: UX053 Dose Level 4R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
16255092|NCT04990388|Placebo Comparator|Stage 2: Placebo Dose|Participants randomized to receive a single, peripheral IV infusions of matching placebo, plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
16255093|NCT04990375|Sham Comparator|active vs. sham tDCS to reduce early relapse|We compare 5 sessions of active tDCS (2 mA) vs. 5 sessions of sham tDCS (0 mA) to observe if tDCS can reduce early relapse (2-week follow-up). The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
16255094|NCT04990375|Other|tDCS alone vs. combined tDCS with ICT to reduce early relapse|We compare 5 sessions of active tDCS alone vs. 5 sessions of tDCS combined with alcohol ICT vs.5 sessions of tDCS combined with neutral ICT vs. 5 sessions of sham tDCS to observe whether tDCS is better combined than alone to reduce early relapses (2-week follow-up). For all active and sham tDCS conditions there is 15-second ramping up and down and the session lasts 20 minutes. Patients are watching a documentary during the application of tDCS alone and there are two types of ICT combined with tDCS: one alcohol ICT (8 alcohol images associated to nogo response, 8 sport images associated to go response, 8 neutral images associated to nogo response and 8 neutral images associated to go response) and one neutral ICT (the same 16 neutral images).
16255095|NCT04990375|Sham Comparator|Craving|We compare scored craving before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
16255096|NCT04990375|Sham Comparator|Working memory|We compare reverse memory span before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
16255097|NCT04990375|Sham Comparator|Depressive symptoms|We compare scored BDI-II before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
16255098|NCT04990362|Experimental|MD + Seed oil|"Pomegranate oil + Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Pomegranate oil in a glass bottle of 30ml Dietary Supplement: Mediterranean dietary protocol
~Intervention:
~Mediterranean diet, Pomegranate oil"
16255099|NCT04990362|Active Comparator|MD|Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol Intervention: Mediterranean diet
16255100|NCT04990349|Experimental|Extracorporeal normoxemia|"After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%.
~The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg.
~PO2 postoxygenator is monitored at least twice a day by the nurse.
~If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after.
~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.
~Intervention will be applied for 7 days after randomization."
16255101|NCT04990349|Active Comparator|Extracorporeal hyperoxemia|"After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%.
~The objective is to maintain PO2 postoxygenator higher than 300 mmHg.
~PO2 postoxygenator is monitored at least twice a day by the nurse.
~If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.
~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.
~Intervention will be applied for 7 days after randomization."
16255102|NCT04990336|Experimental|DDC(Dachaihu decoction compound) Group|Treated with Dachaihu decoction compound and regular therapies
16255103|NCT04990336|Active Comparator|RSM(rhubarb single medicine) Group|Treated with rhubarb single medicine and regular therapies
16255104|NCT04990336|Other|N Group|Treated with regular therapies and without traditional Chinese medicine
16255105|NCT04990323|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen (Preferred: Clo/Flu/Bu90, Alternative: MIDI)
~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.
~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
16255106|NCT04990310|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of [14C]-CORT113176 450 mg (3 X 150 mg lipid formulation capsules) in the fed state.
16255107|NCT04990284|Experimental|50 mg opicapone once-daily|
16255108|NCT04990284|Experimental|100 mg of L-DOPA|
16255109|NCT04990271|Experimental|Conbercept intravitreal Injection|
16255110|NCT04990245||patients with ulcerative colitis|patients with ulcerative colitis and planned endoscopy as part of routine care
16255111|NCT04990232|Placebo Comparator|Standard of care|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days.
16255112|NCT04990232|Experimental|Immunotherapy|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day. More precisely, patients randomized for hyper-inflammation will receive anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. Patients having immunoparalysis will receive IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days. Especially for patients with creatinine clearance lower than 30 ml/min anakinra will be given half dose (i.e. 100 mg three times daily). Creatinine clearance is calculated by the Cockcroft Gault equation [(140-age in years)/ (72 x serum creatinine in mg/dl) for men; this is multiplied by 0.85 for women.
16255115|NCT04990206|Experimental|Intervention|TranS-C
16255116|NCT04990193|Active Comparator|Control group|Children in the control group received the conventional physical therapy protocol which was designed to improve axial stability and trunk steadiness during standing and walking.
16255117|NCT04990193|Experimental|Study group|The children in the study group received the conventional protocol given to the control group. Moreover, they wore TheraTog orthotic undergarment with its strapping system eight hours every day for twelve consecutive weeks.
16255118|NCT04990180|Experimental|Shared Decision Making Intervention|The intervention is a shared decision making consultation supported by a patient decision aid and decision coaching for healthcare professionals.
16255119|NCT04990167|Experimental|Tiotropium arm|"Subjects on this arm will start the study on tiotropium for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on the prescribed asthma controller medication."
16255120|NCT04990167|Active Comparator|ICS arm|"Subjects on this arm will start the study on the prescribed asthma medication for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on Tiotropium."
16255121|NCT04990154|Experimental|experimental group|The experimental group received a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
16255122|NCT04990154|No Intervention|control group|the control group maintained their usual lifestyles
16255125|NCT04990128|Experimental|Bone marrow aspirate concentrate|
16255126|NCT04990128|Active Comparator|Triamcinolone|
16255127|NCT04990115|Active Comparator|rotation|root canal preparation performed using rotating instruments
16255128|NCT04990115|Active Comparator|reciprocation|root canal preparation performed using reciprocating instruments
16255129|NCT04990102|Experimental|CPX-351|Dose Level 1: CPX-351 administered through intravenou infusion on Day 1 and Day 3 of 28 day cycle for 6 cycles or Dose Level -1: CPX-351 administered through intravenous infusion on Day 1 of each 28 day cycle for 6 cycles.
16255130|NCT04990089||VIVO|Patients in which VIVO is used.
16255131|NCT04990076||Patients planned for hysterectomy with a myometrial lesion of more than 1 cm.|
16255132|NCT04990063|Experimental|adoptive TKC transfer combined with chemotherapy|NK cells and γδT cells are isolated from the patients' PBMCs obtained before standard chemotherapy and then co-cultured ex-vivo. Patients will receive multiple TKC treatments under administration, 3 weeks/cycle. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. TKC cells are transfused to patients in a dosage escalated manner. Dose escalation starts at 1×10^8 cells/kg (based on the whole body weight). After the safety assurance of the initial administration, the next course, up to 8 courses, is resumed and the dose maybe increased subsequently at the discretion of the investigators, or reduced for safety reason.
16255133|NCT04990037|Experimental|CAN04 and FOLFIRINOX|Subjects will receive bi-weekly doses of CAN04 in combination with FOLFIRINOX given as standard regimen.
16255134|NCT04990024|Experimental|Mediterranean Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on Mediterranean diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
16255135|NCT04990024|Experimental|High protein/Low Carbohydrate Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on HP/LC diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
16255136|NCT04990024|Active Comparator|Low Fat Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on low fat diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
16255137|NCT04990011|Experimental|BioXclude amnion chorion membrane|
16255138|NCT04989998|Experimental|Hip7 Software on Kick/ CORI platforms|Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants.
16255139|NCT04989998|Active Comparator|Conventional procedures with standard, manual instrumentation and digital templating techniques|Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants.
16255140|NCT04989985|Active Comparator|Active Comparator|"SOX: Oxaliplatin+S-1
~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
~S-1:40~60mg Bid, d1~14, q3w;
~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
16255141|NCT04989985|Experimental|Experimental|"Sinitlimab + SOX； SOX: Oxaliplatin+S-1
~Sinitlimab: 200mg, ivdrip, d1, q3w;
~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
~S-1:40~60mg Bid, d1~14, q3w;
~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
16255142|NCT04989972|Experimental|Intervention arm|participants will take the active intervention PSIL428
16255143|NCT04989972|Experimental|placebo arm|participants will take the intervention 1 mg Oyster mushrooms
16255144|NCT04989972|Experimental|open label|all participants will take the active intervention PSIL428
16255145|NCT04989959|Experimental|Pre-Surgical|Patients with suspected RCC planned for surgery
16255146|NCT04989959|Experimental|Metastatic|Patients with metastatic ccRCC
16255150|NCT04989933|Active Comparator|ESP 20 ml|Ultrasound-Guided erector spinae plane block with 20 ml of 0.25% bupivacaine
16255151|NCT04989933|Active Comparator|ESP 30 ml|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine
16255152|NCT04989920|Experimental|CIMT (Constraint-Induced Movement Therapy)|Therapy intervention: This arm will deliver the signature Constraint-induced therapy protocol for 60 hrs of training over a two-week period.
16255153|NCT04989920|No Intervention|Delayed (Control) intervention group|"Subjects randomized to the delayed intervention group will receive the usual and customary services provided by their personal health care system."
16255154|NCT04989907||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) induction treatment in line with local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 12 months.
16255155|NCT04989881|Experimental|Da Vinci Simulator|Participants will undergo a single session of training using the da Vinci Simulator
16255156|NCT04989881|Active Comparator|Laparascopic training box|Participants will undergo a single session of training using a laparoscopic training box
16255157|NCT04989868|Experimental|Trans-Nasal Afferent Loop Decompression Arm|Patients will receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
16255158|NCT04989868|Active Comparator|No Trans-Nasal Afferent Loop Decompression Arm|Patients will NOT receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
16255159|NCT04989855|Experimental|Fruquintinib plus Tislelizumab|Fruquintinib 5mg QD d1-d14, Q3W; Tislelizumab 200mg IV Q3W d1
16255160|NCT04989842|Active Comparator|Intervention group 1|webbased aftercare
16255161|NCT04989842|No Intervention|Control group|care as usual
16255162|NCT04989842|Active Comparator|Intervention group 2|webbased aftercare
16255163|NCT04989842|Active Comparator|face-to-face aftercare|face-to-face aftercare
16255164|NCT04989829|Experimental|Treatment group|
16255165|NCT04989816|Experimental|T-DXd arm|T-DXd monotherapy
16255166|NCT04989803|Experimental|KITE-363|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363.
~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable."
16255167|NCT04989790|No Intervention|Baseline/Pre-implementation|Usual PICU care
16255168|NCT04989790|Active Comparator|Intervention/Post-implementation|PICU Up! is a multifaceted, inter-professional pathway that is integrated into routine PICU practice to safely optimize early and progressive patient mobility.
16255169|NCT04989777|No Intervention|Control group|Patients with AMI and shock stage B were received Standardized treatment
16255170|NCT04989777|Experimental|IABP group|Patients with AMI and shock stage B were received Standardized treatment and IABP treatment
16255171|NCT04989764||perioperative chemotherapy vs. adjuvant therapy in gastric ca patients|
16255172|NCT04989764||perioperative chemotherapy group vs. adjuvant chemotherapy group|
16255173|NCT04989751||LGMD patients|
16255174|NCT04989738|Experimental|THRIVE Condition|Specifically, parents will learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
16255175|NCT04989738|Active Comparator|Care As Usual - Healthy Steps Model|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
16255176|NCT04989725|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
16255177|NCT04989725|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
16255178|NCT04989712|Experimental|20 minutes MVPA|20 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 40 minutes from the start of the testing session following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
16255179|NCT04989712|Experimental|4 x 5 mins MVPA|4 bouts of 5 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 30 minutes from the start of the testing session and repeated at 60 mins, 90 mins and 120 mins following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
16255180|NCT04989712|Experimental|Uninterrupted sitting - No exercise, sitting session (control).|A sitting only exposure, glucose solution to be consumed at 0 mins.Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point
16255181|NCT04989699|Active Comparator|OTX-TKI|
16255182|NCT04989699|Active Comparator|Aflibercept|
16255183|NCT04989686||Cyclosporine A|"Males and females <18 years of age
~Greater than 5 kg
~Receiving cyclosporine A as the standard of care
~Has scheduled/anticipated blood draw to quantify the concentration of cyclosporine A for clinical indications
~Parental/guardian permission (informed consent), and subject's assent if applicable."
16255184|NCT04989686||Tacrolimus|"Males and females <18 years of age
~Greater than 5 kg
~Receiving tacrolimus as the standard of care
~Has scheduled/anticipated blood draw to quantify the concentration of tacrolimus for clinical indications
~Parental/guardian permission (informed consent), and subject's assent if applicable."
16255185|NCT04989686||Sirolimus|"Males and females <18 years of age
~Greater than 5 kg
~Receiving sirolimus as the standard of care
~Has scheduled/anticipated blood draw to quantify the concentration of sirolimus for clinical indications
~Parental/guardian permission (informed consent), and subject's assent if applicable."
16255186|NCT04989673||Exposed group (GE)|Pregnant women with symptomatic dengue fever, confirmed biologically between the presumed date of conception and the date of delivery.
16255187|NCT04989673||Unexposed group with fever (GNEF)|Pregnant women presenting a febrile syndrome not due to the dengue virus between the presumed date of conception and the date of delivery, excluding malaria, rubella, toxoplasmosis, chickenpox, listeriosis, CMV infection and primary HIV infection.
16255188|NCT04989673||Unexposed group without fever or dengue (GNES)|Pregnant women exhibiting neither febrile syndrome nor asymptomatic dengue fever between the presumed date of conception and the date of delivery.
16255189|NCT04989660|Experimental|Treatment Group|6% aqueous phenol, 1.5 mL per target site
16255190|NCT04989660|Placebo Comparator|Placebo Group|Isotonic saline, 1.5 mL per target site
16255191|NCT04989647|Experimental|A: Surgery only|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*. No further treatment will be administered.
~*PLND can be avoided in patients with tumours < 4cm"
16255192|NCT04989647|Experimental|B: Surgery + radiothrerapy|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*, followed by adjuvant treatment.
~*PLND can be avoided in patients with tumours < 4cm"
16255193|NCT04989634|Active Comparator|standard care|In the early pregnancy ( 8-12 weeks of pregnancy ) , a group education on dietary weight management will be carried out according to the current medical system and the regulations of our hospital , followed by routine prenatal examination . According to the corresponding diagnosis and treatment guidelines, examinations and follow-up interventions will be carried out if the metabolic diseases are occurred during pregnancy.
16255194|NCT04989634|Experimental|dietary and weight management|A randomized controlled trial in pregnant women will be initiated at 8-12 weeks of gestation util delivery. The intervention contents included health education , nutritional analysis and individualized dietary guidance combined with mobile medical treatment and face-to-face teaching during the early , middle and late pregnancy stages.
16255195|NCT04989621|Experimental|Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib|"Induction therapy: Patients receive Orelabrutinib at a dose of 25 mg once daily on days 1-28 and rituximab at a dose of 375mg/m2 on day 1. Treatment cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~If patients achieve CR or PR or SD, they will be treated with maintenance therapy Maintenance therapy: Patients receive Orelabrutinib every day at a dose of 150mg for up to two years in the absence of disease progression or unacceptable toxicity."
16255196|NCT04989608|Other|patients having suffered to transient ischemic accident|
16255197|NCT04989608|Other|healthy volunteers|
16255201|NCT04989582|Experimental|Nursing intervention|Nurses randomly assigned by applying a random selection method
16255202|NCT04989582|No Intervention|No intervention|Nurses randomly assigned by applying a random selection method
16255203|NCT04989569|No Intervention|control|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the control group will not be given to the dietitians for adjusting the diet formula according to the patient's body composition.
16255204|NCT04989569|Experimental|nutritional intervention|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the intervention group will be given to the dietitians for adjusting the diet formula according to the patient's body composition.
16255205|NCT04989556|Active Comparator|Arm I (standard symptom management)|Patients receive standard symptom management by palliative care team once every 4 weeks for 12 weeks. Patients and caregivers also may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
16255206|NCT04989556|Experimental|Arm II (weekly provider-initiated remote contact)|Patients in Phase I immunotherapy trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact every week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
16255207|NCT04989556|Experimental|Arm III (weekly provider-initiated remote contact)|Patients in Phase I non-immunotherapy clinical trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact once a week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
16255208|NCT04989543|Other|healthy population|"Interventions: vaginal swabs:
~Nugent scores,
~cytobacteriological examination (in particular to determine the Clue Cells)
~evaluation of the vaginal microbiota.
~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:
~healthy population
~pathological population with bacterial vaginosis"
16255209|NCT04989543|Other|pathological population|"Interventions: vaginal swabs:
~Nugent scores,
~cytobacteriological examination (in particular to determine the Clue Cells)
~evaluation of the vaginal microbiota.
~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:
~healthy population
~pathological population with bacterial vaginosis"
16255210|NCT04989530|Active Comparator|Low energy level of ESWT|
16255211|NCT04989530|Active Comparator|medium energy level of ESWT|
16255212|NCT04989530|Active Comparator|high energy level of ESWT|
16255213|NCT04989517|Experimental|AT193|Topical applied daily
16255214|NCT04989517|Placebo Comparator|Placebo|Topical applied daily
16255215|NCT04989504|Active Comparator|Arm I (standard of care)|Patients receive standard of care skin management during radiation therapy for up to 6 weeks.
16255216|NCT04989504|Experimental|Arm II (Mepitel Film)|Patients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.
16255217|NCT04989491|Experimental|Experimental group|Prophylactic treatment with Rituximab: one single dose of 375mg/m2 intravenous 7 days before transplantation in case of living donor or at time of transplantation (D0 or D1) in case of transplantation with a deceased donor.
16255218|NCT04989491|Active Comparator|control group|Immunosuppression treatment will be given according to the practice of the centers; use of Thymoglobuline is strongly discouraged because of EBV seronegativity and risk of lymphoma. Basiliximab is recommended for induction therapy. Recommended maintenance immunosuppression consists in a calcineurin inhibitor (tacrolimus or ciclosporine), MMF and Steroids
16255219|NCT04989465|Experimental|Experimental Group|450 Participants (including 150 subjects aged 2~17 years, 150 subjects aged18~60 years and 150 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd will be collected venous blood about 3.0~3.5 ml.
16255220|NCT04989465|Placebo Comparator|Control Group|150 Participants (including 50 subjects aged 2~17 years, 50 subjects aged18~60 years and 50 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Chengdu Institute of Biological Products will be collected venous blood about 3.0~3.5 ml.
16255263|NCT04989140|Experimental|IxaPD|Ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle , pomalidomide 25mg qd day 1~21 of every 28-day cycle, Dexamethasone 40 mg (20 mg for patients >75 years of age) was given on days 1, 8, 15, and 22 of every 28-day cycle.
16257296|NCT04974970|Experimental|Peanut allergenic extract|injected peanut extract.
16255221|NCT04989413|Active Comparator|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|Cannabidiol + Cannabigerol + Tetrahydrocannabinol in the maximum dosage of 133/66/4mg, divided in 2 doses of 66.5/33/2mg a day for 12 weeks. Each drop contain CBD/CBG/THC 1.66/0.8/0.05 mg, and medication will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drrops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day
16255222|NCT04989413|Placebo Comparator|Placebo|"Placebo capsules will be titrated up as follow:
~day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day"
16255223|NCT04989400|Experimental|ulipristal group|received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017,Then women had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
16255224|NCT04989400|Placebo Comparator|placebo|received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
16255225|NCT04989387|Experimental|Treatment Group A Dose Escalation and Expansion|INCA00186 will be administered as monotherapy every 2 or every 4 weeks.
16255226|NCT04989387|Experimental|Treatment Group B1 Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.
16255227|NCT04989387|Experimental|Treatment Group B2 Dose Escalation and Expansion|INCA00186 will be administered in combination with INCB106385. INCA00186 will be administered every 2 or 4 weeks and INCB106385 will be administered once or twice daily.
16255228|NCT04989387|Experimental|Treatment Group C Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab and INCB106385. INCA00186 will be administered every 2 to 4 weeks, retifanlimab every 4 weeks and INCB106385 once or twice daily.
16255229|NCT04989374||CD patients treated with WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these CD patients treated with WMT
16255230|NCT04989374||CD patients treated without WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these CD patients treated without WMT
16255231|NCT04989374||UC patients treated with WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these UC patients treated with WMT
16255232|NCT04989374||UC patients treated without WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these UC patients treated without WMT
16255233|NCT04989361|Experimental|Microneedle side|Apply soluble hyaluronic acid microneedle eye mask to the periorbital area after normal facial cleansing and skin care every night for 20 days. Press and hold for 3 minutes, and then remove it after 1 h. Every 2 days for the next 20 days, and every 3 days for the last 21 days. Follow-up time: every 20 days during the treatment period, and follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
16255234|NCT04989361|Active Comparator|Non-fractional laser side|The patient received non-ablative fractional laser treatment once. Follow-up time: follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
16255235|NCT04989348|Placebo Comparator|Antagonist group|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
16255236|NCT04989348|Active Comparator|PPOS group|"Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
~Gonadotrophin (human menopausal gonadotrophin or recombinant FSH) injections will be started. Ovarian response will be monitored by transvaginal scanning with or without serum hormonal level. Human chorionic gonadotrophin (hCG 1,000 IU) and GnRH agonist (decepepty 0.2mg) will be given for triggering of final maturation when at least 3 follicles reach >17mm in diameter. Blood will be checked for serum estradiol and progesterone levels. Transvaginal USS-guided oocyte retrieval will be performed 36 hours after the trigger."
16255237|NCT04989335|Experimental|Bisantrene combined with Fludarabine and Clofarabine|"Bisantrene 250 mg at final concentration of 0.5 mg/mL will be administrated by intravenous (IV) infusion, delivered by a controlled-rate programmable pump via a central line over 2 hours.
~Fludarabine (generic) and Clofarabine (generic) are commercially available as injection for intravenous infusion.
~The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence:
~First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2
~Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes
~Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours."
16255238|NCT04989322|Experimental|Treatment|
16255239|NCT04989309|Experimental|Experiment 2. Phonetic precision disrupted by TMS|"Experiment 2 tests the influence of temporary disruption of activity within the left or right temporal cortex on the speed and precision of phonetic decisions compared to vertex stimulation. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Immediately following stimulation pulses, participants will perform a visual analog scale (VAS) phonetic rating task on tokens from the four continua, embedded in speech-shaped noise. To control for the possibility that TMS leads to a generalized deficit in categorization, a control task will involve categorization of visual objects on a morphed dog to cat object continuum. (We expect this task to be unaffected by TMS). The variables of interest are the steepness of the categorization curve, mean reaction time to all items on the continuum, and the difference in reaction time for boundary vs. endpoint tokens."
16255264|NCT04989127||group 1|platelet-rich fibrin placed into the socket of the extracted tooth.+ Augmentin 1 gr tablet prescribed 3 times a day
16255265|NCT04989127||group 2|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
16255240|NCT04989309|Experimental|Experiment 3. Phonetic ambiguity in continuous speech|"Experiment 3 is designed to test whether left vs. right temporal lobe stimulation selectively disrupts processing of naturally-occurring phonetic ambiguity as compared to vertex stimulation (control). Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Stimuli will be nonsense sentences produced clearly or in a casual register. By-sentence phonetic ambiguity is estimated by the proximity of each token to other vowels belonging to different categories. Sentences will be embedded in speech-shaped noise to increase difficulty. Participants will listen to each sentence, then respond whether a visually-presented probe word appeared in the sentence (BRASS?). Dependent variables are accuracy and reaction time on this probe verification task."
16255241|NCT04989309|Experimental|Experiment 6: Disruption of talker-specific phonetic learning using TMS.|"Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in coal) and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. gain vs. cane). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker."
16255242|NCT04989296|Experimental|Level of NF-κB translocation in lymphocyte in children with psoriasis and in comparison group|The analysis of the relative count of cells with NF-κB translocation in the lymphocyte populations the group of patients with psoriasis and in the comparison group.
16255243|NCT04989296|Experimental|Level of NF-κB translocation in lymphocyte in children with psoriasis, based on the type of therapy|Determination of the level of NF-kB translocation in lymphocyte populations in patient groups depending on the type of therapy: Group 1 - patients receiving basic and external therapy; Group 2 - patients receiving methotrexate; and Group 3 - patients receiving therapy with biological drugs.
16255244|NCT04989296|Experimental|Severity of psoriasis based on level of NF-κB translocation in psoriasis who received biologics|Assessment of the level of NF-kB translocation in lymphocyte populations, assessment of PASI and BSA, assessment of the effectiveness of biological drugs in patients with psoriasis. Identification of patients in the stage of regression of the disease and in the progressive stage.
16255247|NCT04989270||Patients undergoing Cesarean section|Group of patients undergoing Cesarean section between Jan'2015 to Dec'2019
16255248|NCT04989257|Experimental|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
16255249|NCT04989257|Active Comparator|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
16255250|NCT04989231||Experimental Group|300 subjects who have received 4 doses of the experimental vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
16255251|NCT04989231||Control Group|150 subjects who have received 4 doses of control vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
16255252|NCT04989218|Experimental|Novel combination of chemotherapy and immunotherapy|"This study has one arm. All enrolled patients will receive a combination of a platinum based chemotherapy regimen (gemcitabine and cisplatin) and a combination of two immune check point inhibitors, anti- CTLA4 (Tremelimumab) and anti PDL-1 (durvalumab).
~Gemcitabine will be administered (gemzar) intravenously, 1000mg/m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles. Cisplatin (Platinol) will be administered intravenously, 25mg//m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles.
~Tremelimumab will be administered intravenously, 300mg flat dose, on Day 1 of cycle 1 only. Durvalumab will be administered intravenously 1500mg on Day 1 of a 21 day cycle for 4 cycles."
16255253|NCT04989205||HAP - group|The target group was individuals who engaged in regular or daily cannabis use, and who were motivated to quit cannabis. The formal inclusion criteria was a Severity of Dependence Scale (SDS) score ≥4 and being ≥16 years old. Exclusion criteria was polydrug use where cannabis was not the predominating substance of use and psychiatric comorbidity that was perceived as too severe to handle at the community-based centers .
16255254|NCT04989192|Other|CT scanner 1|Patients will undergo imaging on scanner 1.
16255255|NCT04989192|Other|CT scanner 2|Patients will undergo imaging on scanner 2.
16255256|NCT04989192|Other|CT scanner 3|Patients will undergo imaging on scanner 3.
16255257|NCT04989166|Active Comparator|Nano-curcumin|80mg of Nano-curcumin daily
16255258|NCT04989166|Placebo Comparator|Placebo|Placebo
16255259|NCT04989153||non-atrophic gastritis|No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment)
16255260|NCT04989153||mild-moderate atrophic gastritis|The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment)
16255261|NCT04989153||severe atrophic gastritis|The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment)
16255262|NCT04989153||gastric cancer|gastric cancer
16255266|NCT04989127||group 3|platelet-rich fibrin placed into the socket of extracted tooth + Clin 150 mg capsule prescribed 4 times a day
16255267|NCT04989127||group 4|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
16255268|NCT04989127||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
16255269|NCT04989114|No Intervention|standard care|In this arm, oxygen inhalation will be provided without positive end expiratory pressure
16255270|NCT04989114|Experimental|nasal continuous positive airway pressure|In this arm, positive end expiratory pressure will be provided by nasal continuous positive airway pressure
16255271|NCT04989101|Active Comparator|Nigelle Group|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
16255272|NCT04989101|No Intervention|Placebo Group|Follow-up should be done weekly for 1 month.
16255273|NCT04989088|Experimental|Left theta/beta and right beta/theta NF training|
16255274|NCT04989088|Placebo Comparator|Sham NF training|
16255275|NCT04989075|No Intervention|Control group|The control group will continue its usual oral hygiene practice.
16255276|NCT04989075|Experimental|Oral prophylactic intervention|For the study group, the oral prophylactic intervention will consist of provision of specfic package including soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
16255277|NCT04989062||Healthy children|Apparently healthy children at Year 1 to Year 6 in the primary school in Taiwan. Exclusion criteria are children with metal implant or splint, pacemaker implantation, limb defect or injury and pregnant.
16255278|NCT04989049|Active Comparator|intervention group or case group|topical folic acid on oral ulcers will be applied for 7 days and patients will be asked to visit after 7 days for follow up
16255279|NCT04989049|Placebo Comparator|control group|placebo drug for oral ulcers
16255280|NCT04989036|Experimental|CALCIUM HYDROXIDE™|Non-setting Calcium hydroxide Pulpotomy capping agent. Deepak. Promotion Industrial Park, Bari Brahmana, Jammu - 181133 India form : powder and liquid. application : Calcium hydroxide was mixed with saline to a thick consistency immediately before use. The paste was carefully placed on the pulp stump surface 2-3 mm thick over a small sterile wet cotton with a small condenser, and the excess material was scraped off.
16255281|NCT04989036|Experimental|Biodentine ™|Biodentine ™ Pulpotomy capping agent. Calcium Silicate-Based Material.Septodent®, Saint-Maurdes-Fosses, France form: capsule and liquid. application: According to the instructions of manufacture, Biodentine ™powder and liquid were mixed to achieve a creamy consistency, by mixing a single-unit powder part and 5 drops of a single-unit liquid part for 30 seconds by mixing device . Final mixing and adjustment were done manually to obtain the desired consistency for each case
16255282|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (80% limb occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
16255283|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
16255284|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (60% of the limb complete occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
16255315|NCT04988776|Active Comparator|group A|Patients received ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
16255316|NCT04988776|Active Comparator|group B|patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
16255352|NCT04988477|Experimental|Chronic care for tobacco use|Quarterly brief provider interventions about tobacco and 3 quarterly proactive outreach calls to connect patients to telephone cessation counseling and facilitate obtaining cessation medication.
16255285|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (max of 4/10 pain).
16255286|NCT04989010|Experimental|89Zr-NY005 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3 mCi) labeled anti-CLDN18.2 mAbs (89Zr-NY005)
16255287|NCT04988997|Active Comparator|Vurolenatide 50 mg/PBO|50 mg biweekly SC administration, PBO alternate weeks
16255288|NCT04988997|Active Comparator|Vurolenatide 100 mg/PBO|100 mg biweekly SC administration, PBO alternate weeks
16255289|NCT04988997|Active Comparator|Vurolenatide 50/50 mg|50 mg weekly SC administration
16255290|NCT04988997|Placebo Comparator|Placebo|PBO - weekly SC administration
16255291|NCT04988984||Suspected TB|Patient suspected of TB undergoing diagnostic testing.
16255292|NCT04988971|Experimental|Group C|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsules, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
16255293|NCT04988971|Placebo Comparator|Group D|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsule simulated placebo, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
16255294|NCT04988945|Experimental|Durvalumab + Tremelimumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD) and 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
16255295|NCT04988932|Experimental|Administration of iNO in SAH patients with severe vasospasm|iNO is started at a dose of 1 parts per million (ppm) and increased stepwise to 2 ppm, 5 ppm, 12 ppm, 25 ppm, until a maximum dose of 40 ppm is reached.
16255296|NCT04988919|Experimental|4D dietary supplement|Multi-ingredient supplement containing a proprietary blend with 150mg of caffeine, and other ingredients including vitamins, electrolytes, and BCAA blend (150mg).
16255297|NCT04988919|Placebo Comparator|placebo|flavored water (raspberry lemonade Crystal Light®)
16255298|NCT04988906|No Intervention|Before Arm|The before arm of the study prehospital providers will provide resuscitation as per standard practice. The providers will utilize the Zoll Accuvent device without activation of the real-time dashboard. This will allow us to collect baseline ventilation data.
16255299|NCT04988906|Active Comparator|After Arm|The after arm of the study the prehospital providers will provide resuscitation as per standard practice. The real-time ventilation dashboard will be activated and the providers will use real-time feedback to monitor ventilation quality during the resuscitation.
16255300|NCT04988893||Parturients with Normal Weight|Parturients undergoing elective caesarean delivery with a BMI <30 (control group)
16255301|NCT04988893||Parturients with Morbid Obesity|Parturients undergoing elective caesarean delivery with a BMI >40 (Study Group)
16255302|NCT04988880|Experimental|Relapsing multiple sclerosis group|Multiple sclerosis relapsing groups: each unit will provide a group of participant with relapsing multiple sclerosis
16255303|NCT04988880|Experimental|Progressive multiple sclerosis group|Multiple sclerosis progressive groups: each unit will provide a group of participants with progressive multiple sclerosis
16255305|NCT04988854|Experimental|Positive Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a positive facial expression (positive video)
16255306|NCT04988854|Experimental|Neutral Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a neutral facial expression (neutral video)
16255307|NCT04988854|Experimental|No-Food Control Condition|Children were exposed to a video of adult models putting pens away whilst showing a neutral facial expression (no-food control video)
16255310|NCT04988828|Active Comparator|Control|"deep squat
~1min*6repetitions"
16255311|NCT04988828|Experimental|Whole body vibration group|"deep squat on a whole body vibration platform with 30Hz and 4mm amplitude
~1min*6repetitions"
16255312|NCT04988815|Experimental|Ropeginterferon alfa-2b|Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.
16255317|NCT04988750|Experimental|FUS + re-RT or FUS + SRS|"The SRS treatment will be administered for 3 consecutive days (one fraction of 7-9 Gy per day; total dose 21-27 Gy), including SRS treatment 1 (SRS 1), SRS treatment 2 (SRS 2), and SRS treatment 3 (SRS 3). At the SRS 1 and SRS 3, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system.
~cRT will be administered for 5 consecutive days within one week, and a full course is two weeks (one fraction of 3-4 Gy per day; total dose: 30-40 Gy), including cRT treatment 1 to cRT treatment 10 (cRT 1-cRT 10). At the cRT 1, cRT 3, cRT 6, and cRT 8, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system."
16255318|NCT04988737|Experimental|CDS Group|Clinicians complete tasks using the CDS prototype. Briefly, the clinician scans the barcode on the syringe label immediately prior to medication administration. The scan triggers the CDS to display a dosing window with pertinent patient-specific information and/or alert(s) when necessary to prevent a medication error (ME) prior to the medication being administered. Medication data are then sent from the CDS application to the patient's anesthesia record for automatic documentation in real-time, eliminating the need to manually document the medication in the Anesthesia Information Management System (AIMS). When necessary, the CDS application generates alerts to prevent medication errors. Upon receiving an alert, the anesthesia clinician may accept the alert and revise the action that generated the alert, or override the alert and continue with the planned action.
16255319|NCT04988737|No Intervention|Control Group|Clinicians complete tasks using the conventional medication administration and documentation workflow in anesthesia.
16255320|NCT04988724|Experimental|Intervention|Intervention group that receive 30 min exercise training twice weekly in 12 weeks
16255321|NCT04988711|Experimental|Hb Oxymeter|Hb mesurment
16255322|NCT04988685||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of CAD patients treated with contemporary DCBs.
16255323|NCT04988646|Experimental|Acyclovir Tablet|Participants received Acyclovir Tablet 200 mg or 400 mg with 240 mL of water
16255324|NCT04988646|Active Comparator|Zovirax® Tablet|Participants received Zovirax® Tablet 200 mg or 2x200 mg with 240 mL of water
16255325|NCT04988633|Experimental|Intervention CFG App|
16255326|NCT04988633|Experimental|Control Group|
16255327|NCT04988620|Experimental|Whole Blood stored for 15-21 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 15-21 days
16255328|NCT04988620|Active Comparator|Whole Blood stored for less than 7 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for less than 7 days. We aim at using as fresh as possible.
16255329|NCT04988620|Active Comparator|Whole Blood stored for 8-14 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 8-14 days. This group may be added if deemed of interest after interim analysis.
16255330|NCT04988620|Active Comparator|Standard Blood Component|This group may be added for comparison if deemed of interest after interim analysis.
16255331|NCT04988607|Experimental|osimertinib plus bevacizumab|Osimertinib 80 mg (QD) in combination with Bevacizumab (15 mg/kg) (Q3W)
16255332|NCT04988607|Active Comparator|osimertinib|All patients randomized into this will only receive Osimertinib 80mg (QD)
16255333|NCT04988594|Experimental|Premium probiotic yogurt|Participants receive 300 g/d of yogurt with concentrated and freeze-dried probiotic cultures for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
16255334|NCT04988594|Experimental|Conventional yogurt|Participants receive 300 g/d of conventional yogurt for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
16255335|NCT04988594|Experimental|no fermented dairy|Participants followed the American Diabetes Association (ADA) recommendations without including fermented dairy.
16255336|NCT04988581|Experimental|Intensively Integrated Care of Microvascular Risk Factors|intensively integrated care of microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL])
16255337|NCT04988581|No Intervention|Usual Care of Microvascular Risk Factors|Usual care among patients with diabetes
16255338|NCT04988555|Experimental|Phase 1 Arm A without Antifungals|Patients not taking antifungals within 7 days of study entry
16255339|NCT04988555|Experimental|Phase 1 Arm B with Antifungals|Patients receiving anti-fungals that are moderate to strong cytochrome CYP3A4/5 inhibitors (i.e. Posaconazole, voriconazole, fluconazole)
16255340|NCT04988555|Experimental|Phase 2 Arm A AML with MLL (KMT2A) gene rearrangements|Patients with R/R AML w/MLL (KMT2A) gene rearrangements
16255341|NCT04988555|Experimental|Phase 2 Arm B: AML with NPM1c mutations|Patients with R/R AML w/ NPM1c mutations
16255342|NCT04988542|Experimental|Sleep supplement|Circadian Wellness sleep SL strip nightly for 30 days.
16255343|NCT04988542|Placebo Comparator|Control Group|Participants in the control group will have no intervention and no change in their usual daily routine or supplements. They will be asked to not take any sleep aid supplement during the study period.
16255344|NCT04988529|Experimental|Smartphone-based supported serious game intervention|Group that receives the smartphone-based serious game intervention and receives technical support
16255345|NCT04988529|No Intervention|Waiting list control|Group that does not receive any treatment
16255346|NCT04988516|Experimental|Virtual Reality Distraction|Use of Virtual Reality (VR) during MRI exam
16255347|NCT04988516|Active Comparator|Standard Treatment|Standard Treatment used at the radiology department
16255348|NCT04988503|Experimental|Second-generation hydrogel coil group|Treatment using second-generation hydrogel coils (had to constitute > 50% of the total coil length) for ruptured cerebral aneurysms
16255349|NCT04988503|Active Comparator|Bare platinum coil group|Treatment using bare metal coil only for ruptured cerebral aneurysms
16255350|NCT04988490||Daily cannabis users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report daily cannabis use
16255351|NCT04988490||Cannabis non-users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report no cannabis use
16255372|NCT04988347|Experimental|Spirulina|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
16255353|NCT04988464|Experimental|Sleep Scholar|Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
16255354|NCT04988464|Placebo Comparator|Building Healthy Habits|Building Healthy Habits will be used as the control condition. It combines two modules being utilized as the control condition in an ongoing randomized controlled trial. It is a single-session, self-guided, internet-based intervention that participants will read from a web browser on their electronic device. Building Healthy Habits was piloted by undergraduate research assistants to ensure that it was approximately the same duration as Sleep Scholar (i.e., 30 minutes). It consists of two successive text-based modules focused on healthy movement and healthy eating.
16255355|NCT04988451|Experimental|ASL Services - Adult ASL Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
16255356|NCT04988451|Experimental|ASL Services - Child Language Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
16255357|NCT04988438||esophageal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.
~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (Chicago 3 score)."
16255358|NCT04988438||anorectal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.
~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (London protocol)."
16255359|NCT04988425|Experimental|TNFα monoclonal antibody group|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
16255360|NCT04988425|Active Comparator|Methylprednisolone group|Injection of 500mg of methylprednisolone immediately after admission before surgery.
16255361|NCT04988425|Placebo Comparator|Control group|Injection of the same volume of saline immediately after admission before surgery.
16255362|NCT04988412|Active Comparator|CoMSM LD|Participants will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
16255363|NCT04988412|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
16255364|NCT04988412|Active Comparator|Co HD|Participants will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
16255365|NCT04988412|Active Comparator|CoMSM HD|Participants will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
16255366|NCT04988399|Experimental|Reiki Recipients|The Practitioner enters a gassho (two hands coming together at the heart) meditative state with the Distance Symbol. Reiji-ho - moving the joined hands until the thumbs touch the space between the brows. Going into a relaxed state by using a breathing technique. Say the person's name three times. Proceed with byosen (method using the sensitivity in the hands to treat those areas in need of Reiki) scanning technique. Chiryo (standard session visualizing all hand positions) for 5 minutes each: Jawbone-Back of the head-Throat-Lungs-Area of participant's concern-Stomach-Intestines-Kidneys-Spinal cord. At the end of the session, visualize towards the participant's feet to help integrate the healing. Visualize brushing the Biomagnetic field around the participant's body from head to feet. Inform the participant that the session has been completed. Include time to rest quietly for a few minutes. Encourage participant to sip water (if they prefer) and ask them about their experience.
16255367|NCT04988386|Experimental|AG10|Open-label study all participants will receive AG10 during this study.
16255368|NCT04988373|Experimental|Single aligner appliance|Modified aligner appliance with NiTi springs
16255369|NCT04988373|Active Comparator|Traditional fixed appliances|MBT-prescription of metallic brackets.
16255370|NCT04988360|Experimental|Group A: HMD first|Those assigned to group A will use the head-mounted display (HMD) VR intervention first. Caregivers will be trained to use the HMD-system and asked to use that system for the duration of T1 (weeks 1 & 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 & 4), they will then be trained to use the tablet-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. All throughout T1 and T2, the participant dyad will complete personal reflections each instance a session occurs (5 sessions/week). Each session is expected to include 24 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
16255371|NCT04988360|Experimental|Group B: Tablet first|Those assigned to group B will use the tablet VR intervention first. Caregivers will be trained to use the tablet-system and asked to use that system for the duration of T1 (weeks 1 & 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 & 4), they will then be trained to use the HMD-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. All throughout T1 and T2, the participant dyad will complete personal reflections each instance a session occurs (5 sessions/week). Each session is expected to include 24 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
16257297|NCT04974957|Experimental|SHR-1701+BP102|
16255373|NCT04988347|Placebo Comparator|Placebo|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
16255374|NCT04988334|Active Comparator|FAST|12 weeks of FAST, 2/week 45 minute sessions with half hour per week of education, same group of men and women
16255375|NCT04988334|Placebo Comparator|wait control|12 weeks of usual activity prior to intervention, same group of men and women
16255376|NCT04988321|Active Comparator|Primary motor cortex (M1)|Stimulation of the M1
16255377|NCT04988321|Active Comparator|Dorsolateral prefrontal cortex (DLPFC)|Stimulation of the DLPFC
16255383|NCT04988295|Experimental|Arm A: LACP (Lazertinib, Amivantamab, Carboplatin, and Pemetrexed)|Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as intravenous (IV) infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Lazertinib, Pemetrexed, and Amivantamab as maintenance until disease progression.
16255384|NCT04988295|Active Comparator|Arm B: CP (Carboplatin and Pemetrexed)|Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
16255385|NCT04988295|Experimental|Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
16255386|NCT04988282|Active Comparator|Steroid|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
16255387|NCT04988282|Other|control|standard symptom-relief therapy (since there is no current standard therapy for post-COVID Interstitial Lung Disease, patients in this arm will be commenced symptom-relief therapies including bronchodilators, inhaled corticosteroids, non-steroid anti-inflammatories, cough relievers, and long-term oxygen if the patient has respiratory failure)
16255388|NCT04988269||Patients (Cases)|"Adult consecutive patients that visited the Emergency Department of LAIKO General Hospital of Athens, Greece from May to July 2021 due to confirmed COVID-19 and related symptomatology.
~Blood sampling on the day of admission (one time point) and saliva sampling at 4 different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day)."
16255389|NCT04988269||Healthy Controls|Age and gender matched healthy individuals without COVID-19. Blood sampling (at day 1) and saliva sampling at different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day-day 2).
16255390|NCT04988256|Active Comparator|Cyclosporine|"All Patients start with 5 mg/kg/day (3 mg/kg/day if renal impairment) PO divided bid for 7 days (or IV if patient is NPO)
~If complete resolution, stop cyclosporine and monitor closely for relapse
~a. If patient relapses, give 5 (3 if renal impairment) mg/kg/day PO divided bid PO for 7 days
~i. If down-trending, start oral taper regimen
~ii. If not down-trending, switch to steroid arm
~If >25% improvement and labs are down-trending, start the oral taper regimen.
~If 0-25% improvement, give 5 (3 if renal impairment) mg/kg/day PO divided bid for 3 days
~If down-trending, start oral taper regimen
~If not down-trending, switch to steroid arm
~If no improvement or up-trending labs at 7 days, switch to steroid arm
~Oral Taper Regimen set as 3 mg/kg PO divided bid for 14 days, then 2 mg/kg PO divided bid for 20 days. If renal impairment, oral taper regimen set as 2 mg/kg PO divided bid for 14 days, then 1 mg/kg PO divided bid for 20 days"
16255391|NCT04988256|Experimental|Corticosteroids|"All Patients start with 500 mg IV Methylprednisolone for 3 days
~1. If >25% improvement (must be >25% in all involved organs), start the taper regimen 2. If 0-25% improvement (in ≥1 involved internal organ), give 500 mg IV Methylprednisolone for 4 days
~If no improvement, switch to cyclosporine arm of treatment
~If 0-25% improvement, give 500 mg IV Methylprednisolone for 3 days
~i. If labs are down-trending, start the taper regimen
~ii. If labs are not down-trending, switch to cyclosporine arm of the study
~c. If >25% improvement, start the taper regimen
~Taper Regimen set as:
~125 mg IV Methylprednisolone x3 days
~1.2 mg/kg PO prednisone x1 week
~1 mg/kg PO prednisone x1 week
~0.8 mg/kg PO prednisone x1 week
~0.6 mg/kg PO prednisone x1 week
~0.4 mg/kg PO prednisone x1 week
~0.2 mg/kg PO prednisone x1 week
~0.1 mg/kg PO prednisone x1 week
~0.05 mg/kg PO prednisone x1 week"
16255392|NCT04988243|Other|Prospective and retrospective study of subjects undergoing aortic valve surgery|This study is a prospective / retrospective, multicenter, and observational study after listing. The researchers can initially determine that they can be enrolled in the study according to the history diagnosis of the subjects. After fully informed, they sign informed consent form. After the evaluation of the researchers, they meet the TAVR selection requirements, and register the subjects in multiple centers at the same time
16255393|NCT04988230|Experimental|Time Restricted Feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
16255394|NCT04988230|Active Comparator|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
16255395|NCT04988217|Experimental|Part 1a: Interferon alpha 2b 2.5 MIU|Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)
16255396|NCT04988217|Experimental|Part 1b: Interferon alpha 2b 5 MIU|Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)
16255397|NCT04988217|Placebo Comparator|Part 1: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
16256062|NCT04983290|No Intervention|control|The control group will continue with its own feeding for the entire observation period of the experimental group.
16255398|NCT04988217|Experimental|Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1)|Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)
16255399|NCT04988217|Placebo Comparator|Part 2: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
16255400|NCT04988204|Experimental|Treatment Arm|Patients enrolled in 1 year program
16255401|NCT04988191|Experimental|Toripalimab combined with bevacizumab and chemotherapy|
16255402|NCT04988165|Experimental|Treatment arm|
16255407|NCT04988139|Active Comparator|Intervention group|traditional rehabilitation programs with additional individualized educational training
16255408|NCT04988139|No Intervention|Control group|traditional rehabilitation programs without additional individualized educational training
16255409|NCT04988126||Patient Group|Patient with Covid 19 Pneumonia
16255410|NCT04988100|Experimental|Patients who undergo Splenic artery ligation|If inclusion criteria are met, these group of patients will undergo splenic artery ligation .
16255411|NCT04988100|Active Comparator|No splenic artery ligation|If inclusion criteria are met, these group of patients will not undergo splenic artery ligation.
16255412|NCT04988087|Experimental|SjS participants: MHV370|SjS participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
16255413|NCT04988087|Placebo Comparator|SjS participants: Placebo|SjS participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
16255414|NCT04988087|Experimental|MCTD participants: MHV370|MCTD participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
16255415|NCT04988087|Placebo Comparator|MCTD participants: Placebo|MCTD participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
16255416|NCT04988074|Experimental|De-Escalated Therapy|Surgery (TORS) or Low-dose Radiation Therapy (42 Gy)
16255417|NCT04988074|Experimental|Non/Minimally De-Escalated Therapy|Surgery + Post-Operative Radiation Therapy (PORT) or 60 Gy Chemo-Radiation Therapy (CRT)
16255418|NCT04988061|Experimental|Counselling arm|Educating and Counselling are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
16255419|NCT04988061|No Intervention|standard arm|The information about hearing screening results and an appointment date are provided as a routine by either nurses or nurse assistances who perform the screening test.
16255420|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ ChAdOx1 nCoV-19|Heterologous: Gam-COVID-Vac C1/ ChAdOx1 nCoV-19
16255421|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / Gam-COVID-Vac C1|Heterologous: ChAdOx1 nCoV-19 / Gam-COVID-Vac C1
16255422|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ BBIBP-CorV|Heterologous: Gam-COVID-Vac C1/ BBIBP-CorV
16255423|NCT04988048|Active Comparator|BBIBP-CorV / Gam-COVID-Vac C1|Heterologous: BBIBP-CorV / Gam-COVID-Vac C1
16255424|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / BBIBP-CorV|Heterologous: ChAdOx1 nCoV-19 / BBIBP-CorV
16255425|NCT04988048|Active Comparator|BBIBP-CorV / ChAdOx1 nCoV-19|Heterologous: BBIBP-CorV / ChAdOx1 nCoV-19
16255426|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ mRNA-1273|Heterologous: Gam-COVID-Vac C1/ mRNA-1273
16255427|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / mRNA-1273|Heterologous: ChAdOx1 nCoV-19 / mRNA-1273
16255428|NCT04988048|Active Comparator|BBIBP-CorV / mRNA-1273|Heterologous BBIBP-CorV / mRNA-1273
16255429|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ Gam-COVID-Vac C2|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C2
16255430|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19|Homologous: ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19
16255431|NCT04988048|Active Comparator|BBIBP-CorV / BBIBP-CorV|Homologous: BBIBP-CorV / BBIBP-CorV
16255432|NCT04988048|Active Comparator|mRNA-1273 / mRNA-1273|Homologous: mRNA-1273 / mRNA-1273
16255433|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ Gam-COVID-Vac C1|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C1
16255518|NCT04987333|Experimental|Group 3: Japanese participants - efavaleukin alfa dose level 2|Japanese participants will receive a single dose of efavaleukin alfa at dose level 2.
16255438|NCT04988022|Experimental|Dupilumab|dupilumab 600mg loading dose at Baseline (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
16255439|NCT04988022|Placebo Comparator|Placebo|matching placebo loading dose at Baseline (given as two injections) followed by one weekly subcutaneous injection through Week 24. Starting at Week 24, dupilumab 600mg loading dose (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
16255440|NCT04988009||Observational (survey, medical chart review)|Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.
16255441|NCT04987996|Experimental|GR-MD-02 + pembrolizumab|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
16255442|NCT04987996|Placebo Comparator|Pembrolizumab Monotherapy|4 mg/kg placebo in combination with standard pembrolizumab treatment.
16255443|NCT04987983|Experimental|Experimental SLP-R|Infant placed in a SLP-R on the researcher's lap. Infant body positioned on side-lying position on the right side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
16255444|NCT04987983|Experimental|Experimental SLP-L|Infant placed in a SLP-L on the researcher's lap. Infant body positioned on side-lying position on the left side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands).
16255445|NCT04987970|Experimental|Sequence 1|Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition
16255446|NCT04987970|Experimental|Sequence 2|Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
16255447|NCT04987957|Experimental|Experimental group|"4 music genres with expert opinion will be presented to the preference of the participants in the intervention group, these types of music; Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music. The music is instrumental, 70 decibels and non-verbal. Participants will listen to a genre they choose and download to their mobile phones once for 5 days for 15 minutes. They will listen to the music in the environment they live in, at a time convenient for them, at the desired volume level and with headphones in accordance with the determined therapy program.
~Introductory Questionnaire and Trait Anxiety Inventory will be applied at the beginning of the research. On the 1st and 5th days of the study, the State Anxiety Inventory will be administered half an hour before and half an hour after the music therapy application."
16255448|NCT04987957|No Intervention|Control group|No application will be made to the participants in the control group, and the data collection tools will be applied with the same frequency as in the intervention group.
16255451|NCT04987931||Primary population: Talazoparib-treated patients with HER2- ABC with gBRCA1/2m|HER2-negative ABC patients with gBRCA1/2 mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
16255452|NCT04987905|Experimental|Experimental Group|"In the study, for 60 minutes once a week for 8 weeks the MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice). In addition to these, nurses will be required to keep a diary of the program. This app contains basic mindfulness exercises and does not pose any health risks to practitioners. While the MIND-BE program is carried out in the online environment, the cameras of the nurses in the experimental group will be turned on and the researcher who made the application will be able to see each nurse."
16255453|NCT04987905|No Intervention|Control Group|No intervention will be made to the control group, only the data will be collected at the same time as the study group. After all data are collected (after the 12th week), the training content will be explained to the nurses in the control group and the MIND-BE program will be started for them as well. In this way, both groups will benefit from this program.
16255454|NCT04987892|Active Comparator|Prostatic Lift|Treatment with the UroLift System
16255455|NCT04987892|Active Comparator|Medication|Treatment with Tamsulosin HCl 0.4mg
16255456|NCT04987879|Experimental|Exercise Arm 1|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
16255515|NCT04987346|Experimental|Treadmill walking|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
16255457|NCT04987879|Experimental|Exercise Arm 2|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min/wk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
16255458|NCT04987879|No Intervention|Standard of Care|This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.
16255459|NCT04987866|Experimental|group Vibration|The participants who were chose an opaque envelope containing yellow paper represented the vibration group (Group V). After 1 min of pre-treatment with the vibration device on the intravenous catheter trace, we manually injected 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunterand. Also asked the patients whether they had any discomfort. After the propofol injection, pain scores were observed during propofol injection and 20 seconds after the injection, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and after 20 seconds rocuronium injection.
16255460|NCT04987866|No Intervention|group Control|The participants who were chose an opaque envelope containing red paper represented the group control (Group C).Only propofol and rocuronium were given to these patients. propofol injection made manually 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Patients were observed during and after the injection of propofol for 20 seconds. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunter. During the injection of propofol, we also asked the patients whether they had any discomfort. After the propofol injection for 20 seconds, pain scores were observed, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and 20 seconds after the rocuronium injection.
16255461|NCT04987853||Acute COVID patients|Patients in the acute phase of the course of the disease
16255462|NCT04987853||Long Covid Patients|Patients with chronic symptoms after a previous Covid-19 (4-12 weeks)
16255463|NCT04987853||Postcovid patients|Patients with chronic symptoms after a previous Covid-19 (more than 12 weeks)
16255464|NCT04987814|Experimental|Elderly patients suspected of sarcopenia|
16255465|NCT04987788|Experimental|Motívate group|Participants will engage with an app on an iPad, smartphone or computer.
16255466|NCT04987788|Active Comparator|Control Group|Participant receive a link to watch a general health information video.
16255467|NCT04987775|Active Comparator|N-Acetyl Cysteine (NAC)|Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 20 weeks after the initiation of the first dose of study drug.
16255468|NCT04987775|Placebo Comparator|Placebo|Participants who are randomized to the placebo arm will take matching placebo two times a day for 20 weeks after the initiation of the first dose of study drug.
16255470|NCT04987749|Active Comparator|Active|"Participants received the real intervention of TBS (iTBS 600) over the right inferior frontal gyrus for 8 weeks (2 days/week).
~*iTBS = intermittent theta burst stimulation"
16255471|NCT04987749|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the right inferior frontal gyrus for 8 weeks (2 days/week).
16255472|NCT04987736||COVID-19 (RT-PCR +ve) patients|
16255473|NCT04987723|Other|AF + HFrEF cohort|"Left Ventricular Ejection Fraction (LVEF) < 50% by echocardiogram during routine screening or within 12 months prior to enrolment day. The echo must have been performed >3 weeks after optimisation of HF and rate control therapies, otherwise repeat imaging will be performed after this has been achieved
~With
~NYHA functional status II-III at the enrolment visit."
16255474|NCT04987723|Other|AF + symptoms cohort|"Left Ventricular Ejection Fraction (LVEF) > 50% by echocardiogram during routine screening or within 12 months prior to enrolment day
~With
~modified European Heart Rhythm Association symptom classification 2a-4."
16255475|NCT04987697|Other|Counseling and Surveys|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
16255476|NCT04987684|Other|Standard of Care|
16255478|NCT04987658|Experimental|Group 1 Olanzapine/ 5 mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)
16255479|NCT04987658|Experimental|Group 2 Olanzapine/ 10mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 10mg (Range: 5-20mg Olanzapine/samidorphan 10mg)
16255480|NCT04987645|Other|Water-Assisted Colonoscopy|If this intervention is chosen randomly, the trainee will use water only technique for insertion.
16255481|NCT04987645|Other|Water and Air Insufflation|If this intervention is chosen randomly, the trainee will use water and air insufflation technique for insertion.
16255482|NCT04987632|Experimental|Letrozole combined with acupuncture and Du Meridian moxibustion group|Letrozole combined with acupuncture and Du Meridian moxibustion was taken from 3-5 days of menstrual period (spontaneous menstruation or progesterone withdrawal bleeding). The acupuncture treatment was 3 times / week, with an interval of 2-4 days, 12 times a week, 30 minutes each time; Du Meridian moxibustion is 20 minutes each time, once a week, four times a week. The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. If not pregnant, the subjects received letrozole for up to 4 cycles to induce ovulation with acupuncture plus Du Meridian moxibustion.
16255516|NCT04987333|Experimental|Group 1: Chinese participants - efavaleukin alfa dose level 1|Chinese participants will receive a single dose of efavaleukin alfa at dose level 1.
16255517|NCT04987333|Experimental|Group 2: Chinese participants - efavaleukin alfa dose level 2|Chinese participants will receive a single dose of efavaleukin alfa at dose level 2.
16255483|NCT04987632|Active Comparator|Letrozole group|Letrozole was taken 3-5 days after menstruation (spontaneous menstruation or progesterone withdrawal bleeding). The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. In the absence of pregnancy, subjects were treated with letrozole for up to four cycles.
16255484|NCT04987619|Experimental|BJR|70 mL of beetroot juice (BEET It Sport®; James White Drinks Ltd., Ipswich, UK)
16255485|NCT04987619|Placebo Comparator|PLA|70 mL of blackcurrant beverage Capri-Sun.
16255486|NCT04987593|Experimental|Intervention|Four probiotic strains to be consumed once daily
16255487|NCT04987567|Active Comparator|Antioxidant docosahexaenoic acid (DHA)|"Antioxidant docosahexaenoic acid (Tridocosahexaenoin-AOX ® 70%) 50mg/kg/day:
~50mg/kg/day so:
~> = 13-17kg: 2 pearls (700mg DHA) every day, once or twice daily (od or bd)
~> = 18-24kg: 3 pearls (1050mg DHA) every day, od or bd
~> = 25-30kg: 4 pearls (1400mg DHA) every day, bd (2-0-2)
~> = 31-36kg: 5 pearls (1750mg DHA) every day, bd (2-0-3)
~> = 37-43kg: 6 pearls (2100mg DHA) every day, bd (3-0-3)
~> = 44-49kg: 7 pearls (2450mg DHA) every day, three times a day (td) (3-1-3)
~> = 50kg: 8 prearls (2800mg DHA) every day, td (3-2-3)."
16255488|NCT04987567|Placebo Comparator|Placebo|"Olive oil 50mg/kg/day so:
~> = 13-17kg: 2 pearls every day, once or twice daily (od or bd)
~> = 18-24kg: 3 pearls every day, od or bd
~> = 25-30kg: 4 pearls every day, bd (2-0-2)
~> = 31-36kg: 5 pearls every day, bd (2-0-3)
~> = 37-43kg: 6 pearls every day, bd (3-0-3)
~> = 44-49kg: 7 pearls every day, three times a day (td) (3-1-3)
~> = 50kg: 8 prearls every day, td (3-2-3)."
16255489|NCT04987554|Experimental|AM3 supplementation group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
16255490|NCT04987554|Placebo Comparator|Control Group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
16255491|NCT04987541|Active Comparator|Active|"Participants received the real intervention of TBS (iTBS 1200) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).
~*iTBS = intermittent theta burst stimulation"
16255492|NCT04987541|Sham Comparator|Sham|Participants received the sham intervention of TBS (sham-coil) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).
16255493|NCT04987528||Patients with pulmonary fibrosis|"All ICU patients for which one of the non-invasive criteria of pulmonary fibrosis is reached :
~Typical CT scan patterns (reticulation and/or bronchiectasia)
~Serum PIIINP above 16 µg/L
~BAL PIIINP above 9 µg/L"
16255494|NCT04987528||Patients without pulmonary fibrosis|All ICU patients for which none of the non-invasive criteria of pulmonary fibrosis are reached.
16255495|NCT04987515||Fenestration decompression|Design of the opening window reasonably；Making cyst plug；stage II curettage
16255496|NCT04987515||local curettage|The tumor was removed by local curettage only
16255497|NCT04987502|Experimental|Virtual reality treatment|Virtual reality immersion with 3D audio and visual rendering (8 weekly sessions)
16255498|NCT04987502|Active Comparator|Standard treatment|Counselling Relaxation techniques Sound enrichment
16255499|NCT04987489|Experimental|Etavopivat 400 mg daily - SCD with transfusions|Patients with sickle cell disease on chronic red blood cell transfusions
16255500|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia with transfusions|Patients with thalassemia on chronic red blood cell transfusions
16255501|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia|Patients with thalassemia not on chronic red blood cell transfusions
16255502|NCT04987476||ATRT|Children affected by an ATRT at time of surgical resection
16255503|NCT04987463|Experimental|Vigabatrin arm|Vigabatrin in capsules co-administered with placebo in liquid.
16255504|NCT04987463|Experimental|Rapamycin arm|Rapamycin in liquid co-administered with placebo in capsules.
16255505|NCT04987450||Study population|Plasma levels of SIRT-1, IL-6, FGF-23, sclerostin, calcium, phosphate, PTH and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous daily pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.
16255506|NCT04987411||Hemorrhagic group|Patients with bleeding confirmed with eFAST or CT.
16255507|NCT04987398||Intubation for respiratory reasons|All patients who were intubated for respiratory reasons (i.e. acute respiratory distress syndrome, pneumonias, pleural effusions for example)
16255508|NCT04987398||Intubation for neurological reasons|All patients who were intubated for neurological reasons (i.e. stroke, intracranial bleeding, cervical fracture with tetraparesia for example)
16255509|NCT04987398||Intubation for other reasons|All patients who were intubated for other reasons than respiratory or neurological (i.e. intubation before surgery, cardiac arrest, hemodynamic instability and polytraumatism without respiratory distress or neurological pathology necessitating intubation)
16255510|NCT04987385|Other|single arm: Phase 1: protein supplementation, Phase 2: Urea|
16255511|NCT04987372|No Intervention|Classical protocol|"Fentanyl Max. 15µg/kg IV Per-operative
~Ultiva (Remifentanyl) 0.02-0.1µg/kg/h IV Post-operative
~Paracetamol 4x1g /24h IV Post-operative
~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in cas of break through pain
~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
16255512|NCT04987372|Active Comparator|Multimodal protocol|"Lyrica (Pregabalin) 75mg PO 2 hours before the operation
~Dexdor (Dexmedetomidine) 0.8µg/kg/h IV Per-operative / Post-operative
~Ketalar (Ketamine) Bolus (0.5mg/kg) + 0.3mg/kg/h IV Per-operative until stop propofol
~Linisol (Lidocain) Bolus (1.5mg/kg) + 1.3mg/kg/h IV Per-operatiive until 12h post-op
~Magnesium Sulphate Induction (25mg/kg) + 25mg/kg weaning ECC IV Per-operative
~Fentanyl 2.5µg/kg IV Per-operative
~Paracetamol 4x1g /24u IV Post-operative
~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in case of Break through pain
~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
16255513|NCT04987359|Experimental|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling. The main objective of the structured exercise training is to improve cardiorespiratory fitness.
16255514|NCT04987359|No Intervention|Waitlist Control|The waitlist control group will be asked to maintain their current exercise and dietary habits for the 10-week study period. Upon providing study endpoint data at week 10, control group participants will be offered a 4-week multimodal lifestyle program that is similar to the intervention group.
16255519|NCT04987333|Experimental|Group 4: Caucasian participants - efavaleukin alfa dose level 2|Caucasian participants will receive a single dose of efavaleukin alfa at dose level 2.
16255520|NCT04987320|Experimental|Olpasiran Dose A|Participants will be administered Olpasiran dose A as a subcutaneous injection.
16255521|NCT04987320|Experimental|Olpasiran Dose B|Participants will be administered Olpasiran dose B as a subcutaneous injection.
16255522|NCT04987307|Experimental|Efavaleukin alfa|
16255523|NCT04987307|Placebo Comparator|Placebo|
16255524|NCT04987294|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. ALLN-346 will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
16255525|NCT04987294|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Placebo capsules will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
16255526|NCT04987281|Experimental|Device feasibility (bronchoscopy, CT, indocyanine green)|During standard of care surgical resection, patients undergo robotic bronchoscopy and CT. Patients also receive indocyanine green via injection.
16255527|NCT04987268||Current-smoking|exposure: smoking
16255528|NCT04987268||Smoking-cessation|exposure: smoking cessation
16255529|NCT04987268||non-smoking|exposure: none
16255530|NCT04987255|Active Comparator|Free visit|Free visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
16255531|NCT04987255|Experimental|Guided visit|Guided visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
16255532|NCT04987255|Other|Guided visit for individuals after stroke|This arm is specific for individuals with motor disability after stroke (non randomized condition)
16255533|NCT04987242|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days
16255534|NCT04987242|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days
16255536|NCT04987216|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
16255537|NCT04987203|Experimental|Tivozanib in Combination with Nivolumab|Subjects with refractory advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment [for nivolumab] whichever occurs first.
16255538|NCT04987203|Experimental|Tivozanib|Subjects with refractory advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.
16255539|NCT04987190||all cleft patients divided into unilateral and bilateral groups|One group of cleft patients received the alveolar bone graft surgery
16255541|NCT04987164||Feminabiane CBU Consumers|Group of consumers of Feminabiane CBU : 2 tablets of Feminabiane CBU® every day, to be swallowed with a glass of water.
16255542|NCT04987164||Control group|Control group of non consumers of Feminabiane CBU
16255543|NCT04987151|Experimental|Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
16255544|NCT04987151|Experimental|Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking,
16255545|NCT04987151|Experimental|Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups
16255546|NCT04987151|No Intervention|Control Group|All the patients in the wait-list control group will receive one of the three trainings immediately after the intervention.
16255579|NCT04986865|Experimental|ATG-101|"Dose Escalation Phase:
~Will be conducted with an enhanced PDx cohort.
~Dose Expansion Phase:
~Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled."
16256063|NCT04983277||Diabetes|patients with diagnosed Diabetes Mellitus
16255551|NCT04987125|Experimental|Dyspnea Neuroscience education|
16255552|NCT04987125|Active Comparator|Usual care|
16255553|NCT04987112|Experimental|CAN1012 single agent|CAN1012 intratumoral injection given alone
16255554|NCT04987099|Experimental|Experimental Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 550 mg of choline once daily for the duration of their pregnancy.
16255555|NCT04987099|Placebo Comparator|Control Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 25 mg of choline once daily for the duration of their pregnancy.
16255556|NCT04987086|Experimental|PSMA PET Arm|The PSMA PET arm received PSMA PET and enhanced CT at the same time in the diagnosis of the patients with suspected renal cancer.
16255557|NCT04987073|Experimental|patients with CYP24A1 mutation|
16255558|NCT04987060|Other|Intrastromal Fresh Human Lenticule Implantation|The aim of this study is to investigate the effect of intrastromal fresh corneal lenticule implantation using Smile module surgery after PK with primary objective to increase visual acuity by reducing irregular astigmatism according to high K values. The stromal pocket diameter was 8 mm, 2mm super incision, 140-µm cap thickness and fresh lenticular implantation is performed.
16255559|NCT04987047||Prescription with pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants based on the results of pharmacogenetics analyses.
16255560|NCT04987047||Prescription without pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants left to the discretion of the clinician without pharmacogenetics assistance.
16255561|NCT04987034||Direct and indirect PPG measurements|Measuring the portalsystemic pressure gradient in patients directly using the EchoTip® Insight™ and indirectly through the HVPG procedure.
16255563|NCT04986995|Experimental|Opicapone|50 mg hard capsules
16255564|NCT04986982|Experimental|Opicapone|
16255565|NCT04986982|Placebo Comparator|Placebo|Opicapone and placebo capsules will be identical in size, colour, taste and appearance. The packaging and labelling will not allow for any distinction between test and reference drug.
16255566|NCT04986969|Active Comparator|real-time, face-to-face, video-conferenced CBT (vcCBT)|vcCBT is cognitive behavioral therapy that consists of eight face-to-face video-conferencing sessions via tablet computers lasting approximately 45 minutes each.
16255567|NCT04986969|Active Comparator|self-administered internet-based CBT (iCBT)|iCBT is self-directed cognitive behavioral therapy using an interactive internet program, MoodGYM, which does not include direct interactions with a therapist.
16255568|NCT04986956|Placebo Comparator|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
16255569|NCT04986956|Active Comparator|Whole coffee cherry extract|Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (<2%; <4mg) levels of caffeine. The only content of the supplement is WCCE - there are no excipients, binders, or flow agents, nor are there any other materials. The coffee cherry is subjected to a food-grade water ethanol extraction; thus, after extraction, only 100% coffee-based components remain. 200mg of WCCE will be administered daily for 28 days.
16255570|NCT04986943||ABTHERA Advance without Wittmann patch|Patients with necrotizing pancreatitis that require an open abdomen after their initial operation will be treated with ABTHERA ADVANCE only, without the use of Wittmann patch.
16255571|NCT04986930|Experimental|SBRT+mFOLFIRINOX|"Stereotactic body radiotherapy: 3500 cGy (5 fractions)
~mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2"
16255572|NCT04986930|Active Comparator|mFOLFIRINOX|-mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
16255573|NCT04986917|Experimental|Su2ura® approximation device - study device group|Patients with a primary umbilical hernia will be recruited to the study and the hernia will be repaired using the Su2ura® approximation device
16255574|NCT04986904|Experimental|SHUTi (Sleep Healthy Using the Internet)|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
16255575|NCT04986891||subjects before first chemotherapy cycle with no neuropathy|at least 75 consecutive subjects sent for an evaluation before 1st chemotherapy cycle (TNSc score equal to 0 which means no neuropathy);
16255576|NCT04986891||subjects with stable CIPN condition after chemotherapy completion|subjects sent for an evaluation due to stable CIPN condition (CIPN defined as TNSc > or = 1) after chemotherapy completion (at least 2 months off treatment).
16255577|NCT04986878|Active Comparator|Single shot adductor canal block|Following sterile preparation and draping, an ultrasound survey of the medial thigh was performed, halfway between the superior anterior iliac spine and the patella. The superficial femoral artery has been identified beneath the sartorius muscle in a short-axis view, with the vein just inferior and the saphenous nerve just lateral to the artery. A 20 Gauge, 120 mm, non-cuttings tip echogenic needle (SonoPlex STIM, Germany) needle was introduced in-plane, and 2 to 3 mL of LA bolus (0.25 % Bupivacaine) was used to confirm proper needle placement in the adductor canal near the saphenous nerve. Then, a bolus of 20 ml of Bupivacaine 0.25 % was injected through the needle
16255578|NCT04986878|Active Comparator|Continuous adductor canal block|a catheter was secured in place using Tegaderm. The catheters were connected to a pump that infused local anesthetic, 20 mL of 0.25 % bupivacaine, followed by 48 hours of continuous infusion of 0.125 % bupivacaine at 5 mL/h.
16255580|NCT04986852|Experimental|Olinvacimab (TTAC-0001) 16 mg/kg and Pembrolizumab (Keytruda®) 200 mg|"Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15
~Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)"
16255583|NCT04986826||Healthy master athletes|
16255584|NCT04986826||Genotype positive phenotype negative transthyretin amyloidosis|
16255585|NCT04986826||Phenotype positive transthyretin amyloidosis|
16255586|NCT04986813|Active Comparator|Group Tranexamic Acid|50 patients were given 1 gram of Tranexamic acid (TXA) intravenously pre-operatively. Intravenous TXA was administered, at the time of start of surgical incision.
16255587|NCT04986813|Placebo Comparator|Control group|50 patients were kept as a control group and were not given TXA.
16255588|NCT04986800|Experimental|Intervention Group|Participants in the Intervention Group will receive 10 sessions of the PROACTIVE Parent intervention.
16255589|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - within-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS on a visual working memory task in aged HV
16255590|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - cross-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized cross-frequency fronto-parietal tACS stimulation on a visual WM task in aged HV
16255591|NCT04986787|Experimental|Cerebellar rTMS to modify the effects of cortico-cortical, fronto-parietal tACS in HV|double-blind, randomized, sham-controlled, cross-over trial assessing the effects of cerebellar stimulation on individualized fronto-parietal tACS stimulation during a visual WM task in aged HV
16255592|NCT04986787|Experimental|Neuromodulation protocol in MCI patients (precise protocol to be chosen on results of previous arms)|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS stimulation or a combination of rTMS-tACS on a visual working memory task in MCI patients
16255593|NCT04986774|Experimental|Rescue Intracranial Stenting (RIS)|RIS in Acute Ischemic Stroke caused by intracranial large vessel occlusion
16255594|NCT04986761|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
16255595|NCT04986761|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
16255596|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of small volume (≤ 30 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
16255597|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of large volume (> 30 and ≤ 100 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
16255598|NCT04986683|Experimental|Patients with drug-resistant epilepsy|All patients who undergo two-stage epilepsy surgery will receive two longitudinal evaluations of brain MRI and neuropsychology test: a month before surgery and 1.5 years after surgery.
16255599|NCT04986670|Experimental|NutriCare|The oncology care team will provide participants with nutrition toolkit involving printed educational materials, a nutrition prescription, referral to registered dietitians (RDs) for remotely-delivered medical nutrition therapy counseling, and home-delivery of medically tailored meals.
16255600|NCT04986670|Active Comparator|NutriTool|The oncology care team will provide participants with a nutrition toolkit involving printed educational materials.
16255601|NCT04986657|Experimental|Patients: ChromoSeq|ChromoSeq will be performed on bone marrow DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
16255602|NCT04986657|No Intervention|Stakeholders (Treating Physicians)|-Stakeholders (treating physicians) will complete surveys/questionnaires
16255603|NCT04986644|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
16255604|NCT04986644|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
16255605|NCT04986631|Experimental|Topiramate|Individuals will receive 75 mg of topiramate daily. The dose will start at 25 mg daily for the first week. The second week participants will receive 50 mg daily. Starting at week 3 participants will take 75 mg daily.
16255606|NCT04986618|Experimental|One-way Nordic Exercise Group|
16255607|NCT04986618|Experimental|Two-way Nordic Exercise Group|
16255608|NCT04986618|No Intervention|Control Group|
16255609|NCT04986605|Experimental|Administration of Extracorporeal Photopheresis Treatment|"Duration of treatment: 48 weeks. Treatments occur on 2 consecutive days every 4 weeks.
~Dose of UVADEX: Treatment Volume x 0.017 = mL of UVADEX for each treatment Treatment Volume (TV) is defined as: The total volume of Buffy Coat plus prime solution that will undergo photoactivation.
~Route of administration: Extracorporeal"
16255610|NCT04986579|Experimental|ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin.
~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
16255611|NCT04986579|Active Comparator|ERIBULIN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with Eribulin.
~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
16255612|NCT04986579|Experimental|SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN.
~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
16255613|NCT04986579|Active Comparator|SACITUZUMAB GOVITECAN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with SACITUZUMAB GOVITECAN.
~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
16255614|NCT04986579|Experimental|TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN.
~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
16255615|NCT04986579|Active Comparator|TRASTUZUMAB DERUXTECAN WITHOUT PAXMAN SCALP COOLING SYSTEM|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with TRASTUZUMAB DERUXTECAN.
~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
16255616|NCT04986566|Experimental|Arm I (telemonitoring)|Patients wear a Vivofit 4 daily for 30 days after hospital discharge for steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients assessments are monitored by the surgical team in real-time to identify outcome trends, including onset, worsening/improving measures, and sporadic versus consistent measures.
16255617|NCT04986566|Active Comparator|Arm II (enhanced usual care)|Patients wear a Vivofit 4 for daily steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients use standard procedures for reporting problems.
16255618|NCT04986553||50 subjects, male and female, at least 18 years of age|50 subjects who are candidates for surgery using the Arthrex Clavicle Plate for treatment of clavicle fractures.
16255619|NCT04986540|Experimental|Cohort 1|A single subcutaneous injection of SHR-1906/placebo dose 1 in healthy subjects
16255620|NCT04986540|Experimental|Cohort 2|A single subcutaneous injection of SHR-1906/placebo dose 2 in healthy subjects
16255621|NCT04986540|Experimental|Cohort 3|A single subcutaneous injection of SHR-1906/placebo dose 3 in healthy subjects
16255622|NCT04986540|Experimental|Cohort 4|A single subcutaneous injection of SHR-1906/placebo dose 4 in healthy subjects
16255623|NCT04986527|Active Comparator|24 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 24 hours prior to water seal
16255624|NCT04986527|Experimental|48 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 48 hours prior to water seal
16255625|NCT04986514||Patients with systemic sclerosis|
16255626|NCT04986501|Experimental|MucoPEG|Arm being compared to against Biotene
16255627|NCT04986501|Active Comparator|Biotene|Arm being compared against MucoPEG
16255628|NCT04986488||Without delirium|
16255629|NCT04986488||With delirium|
16255630|NCT04986475|Experimental|Music Therapy|Music therapy was applied during the non-stress test.
16255631|NCT04986475|No Intervention|Control|A routine non-stress test was performed.
16255632|NCT04986462||patients with bursal-side partial-thickness rotator cuff tears|Patients with bursal-side partial-thickness rotator cuff tears who underwent arthroscopic surgery and was followed up at Peking University Third Hospital.
16255633|NCT04986449|Experimental|Intervention group|All families will receive the culinary and nutritional intervention. Changes before-after will be assessed regarding culinary skills, knowledge and attitudes of families on cooking with plant-based foods
16255634|NCT04986436|Experimental|HS-10360|Either single or multiple doses of varying dose levels
16255635|NCT04986436|Placebo Comparator|Placebo|
16255636|NCT04986423|Experimental|Cohort A - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
16255637|NCT04986423|Active Comparator|Cohort A - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
16255638|NCT04986423|Experimental|Cohort B - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
16255639|NCT04986423|Active Comparator|Cohort B - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
16255640|NCT04986410||Myocardial Perfusion examination|
16255641|NCT04986397|Experimental|Cold Therapy & Standard Post Operative Analgesia|Patients in the cryotherapy group will have the ice water in their cryotherapy device maintained continuously for 2 days from initial application as this is the reported time of average patient disability and children typically return to school by post-operative day 3. The device will not be placed directly on the skin to minimize tissue damage. An additional protective barrier pad included with the cold therapy device will provide a barrier between the skin and the cooling device. This allows for continuous cooling at a higher target skin temperature. Aside from the cryotherapy, all surgical treatment will be standard of care.
16255642|NCT04986397|Active Comparator|Standard Post Operative Analgesia|
16255643|NCT04986384|Active Comparator|Active Treatment Group|Patients will be instructed to use the anti-pruritic spray for four weeks starting from the day which informed consent was signed in active treatment group. A follow-up visit will be on week 2 for a mid-term review.
16255725|NCT04985864|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
16255644|NCT04986384|Active Comparator|Wait-list Control Group|Patients will be instructed to start the treatment after two weeks from the day which consent was signed and for a duration of two weeks in wait-list control group. A follow-up visit will be on week 2 for a mid-term review and for the dispense of treating material.
16255645|NCT04986358|Other|Patient cohorte|Cohort of patients who will benefit from surgical management of their Hallux Valgus with post-operative follow-up at 2 years
16255646|NCT04986345|Experimental|Rest, HIIT-4, HIIT-10|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.
~This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10."
16255647|NCT04986345|Experimental|Rest, HIIT-10, HIIT-4|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.
~This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4."
16255648|NCT04986332|Experimental|"GROUP COPD"|100 participants, 50 males and 50 females with COPD and multiple chronic conditions
16255649|NCT04986332|Active Comparator|"GROUP HF"|100 participants, 50 males and 50 females with HF and multiple chronic conditions
16255650|NCT04986332|Active Comparator|"GROUP HEALTHY PARTICIPANTS"|"100 healthy participants or control group which will be compared to Group A and Group B by age and sex"
16255651|NCT04986319||Adequately sun-exposed healthy population|Healthy coastal fishermen of Cox's Bazar district of Bangladesh
16255652|NCT04986319||Inadequately sun-exposed healthy population|Healthcare workers of the selected hospitals of Dhaka, Bangladesh
16255653|NCT04986306||clinical tumor stage 1-3 (cT1-3) and nodal stage 1 (cN1) breast cancer patients|Patients who will undergo neoadjuvant chemotherapy were asked to participate in this study. Informed consent will be given. Clip will be placed over the positive lymph node by surgeon which was proven by fine-needle aspiration cytology. After completion of neoadjuvant chemotherapy, surgery of the breast and the axilla was executed in the same session. Different surgeons performed the procedure.
16255654|NCT04986280||Single Arm|Arm 1 - All patients will undergo PET/CT with 18F-PSMA-1007
16255655|NCT04986267||ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
16255656|NCT04986254||Benzylpenicillin|ICU patients receiving benzylpenicillin for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
16255657|NCT04986254||Ceftriaxone|ICU patients receiving ceftriaxone for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
16255658|NCT04986254||Meropenem|ICU patients receiving meropenem for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
16255659|NCT04986254||Piperacillin/tazobactam|ICU patients receiving piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
16255660|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction Without Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
16255661|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction With Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
16255662|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction Without Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
16255663|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction With Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
16255664|NCT04986241||Healthy sedentary Without Statin|Sedentary and healthy participant without use of statin; Without statin in the last 6 months.
16255665|NCT04986241||Healthy sedentary With Statin|Participant with dyslipidemia and sedentary with current use of statin.
16255666|NCT04986241||Healthy physically active Without Statin|Healthy, physically active participant without use of statin; Without statin in the last 6 months.
16255667|NCT04986241||Healthy physically active With Statin|Participant with dyslipidemia and physically active with current use of statin.
16255668|NCT04986228|Experimental|Digital aftercare|The group with the new digital aftercare is compared with the active control group with regular aftercare.
16255669|NCT04986228|Active Comparator|Treatment-as-usual (TAU)|The group with regular aftercare (TAU) serves as an active control group.
16255670|NCT04986215||Benign pancreatic space occupying group|
16255671|NCT04986215||Malignant pancreatic space occupying group|
16255672|NCT04986202|Experimental|Part A 2.5 mg|AZD4831 2.5 mg
16255673|NCT04986202|Experimental|Part A 5 mg|AZD4831 5 mg
16255674|NCT04986202|Placebo Comparator|Part A Placebo|Placebo
16255675|NCT04986202|Experimental|Part B Dose based on Part A|AZD4831 Dose based on Part A
16255676|NCT04986202|Placebo Comparator|Part B Placebo|Placebo
16255677|NCT04986189|Other|Invitation to have a low dose CT thorax|All participants are invited to undergo a low dose CT thorax
16255678|NCT04986176|Experimental|HC-1119 + Usual Care|4 (40mg) soft gel capsule, 160 mg total
16255679|NCT04986176|Placebo Comparator|Placebo + Usual Care|4 soft gel capsule
16255680|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor: the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
16255681|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|non invasive analgesia monitoring with ANSPEC-PRO and MEDSTORM the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
16255861|NCT04984876|Experimental|ligelizumab 120 mg|ligelizumab 120 mg subcutaneous injection for 52 weeks
16271705|NCT04873752|Experimental|UDI-001|Four cycles with 8 administrations
16255682|NCT04986163|Active Comparator|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
16255685|NCT04986137||Group 1|Acute kidney injury due to acute tubular necrosis
16255686|NCT04986137||Group 2|Acute kidney injury due to prerenal azotemia
16255687|NCT04986137||Group 3|Acute kidney injury due to hepatorenal syndrome type 1
16255688|NCT04986124||MDD patients|No intervention.
16255689|NCT04986111|Experimental|Linear skin closure with wound drain|Reduce fluid collection and dead space by inserting drain into the subcutaneous layer using the wound closure method previously used in the experimental center. The linear suture has a relatively quick time to stitch out.
16255690|NCT04986111|Active Comparator|Purse-string skin closure with negative pressure wound therapy|Close the wound with a purse-string suture which is better in terms of surgical site infection but known to take a long time for wound healing, and use negative pressure wound therapy to help granulation of tissues and help healing.
16255691|NCT04986085||GEP NET|GEP NET patients in Spain
16255692|NCT04986072|Experimental|Sodium Nitroprusside Arm|Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
16255693|NCT04986072|Placebo Comparator|Placebo Arm|5% Dextrose (0.5 μg/kg/min) for 4 hours
16255694|NCT04986059|Experimental|Pre-event massage|
16255695|NCT04986059|No Intervention|Control|
16255696|NCT04986046|Active Comparator|Fruit and vegetable prescription|Fruit and vegetable incentive program
16255697|NCT04986046|Experimental|Fruit and vegetable prescription + Home Plate Lite|Fruit and vegetable incentive program + asynchronous, electronic resources delivered over six weeks
16255698|NCT04986046|Experimental|Fruit and vegetable prescription + Virtual Home Plate|Fruit and vegetable incentive program + 45-minute, virtual, small-group classes twice weekly for six weeks
16255699|NCT04986020||Parkinson disease|Participants with a clinical diagnosis of Parkinson's disease
16255700|NCT04986020||Control|Controls
16255701|NCT04986007|Experimental|digital Cognitive Behavioral Therapy for Insomnia|Following baseline evaluation, participants in this group will receive 8 weeks of digital Cognitive Behavioral Therapy for Insomnia delivered using Sleep Healthy Using the Internet (SHUTi). After the interim assessment, participants will then crossover to 8 weeks of active monitoring.
16255702|NCT04986007|No Intervention|Waitlist Control|Following baseline evaluation, participants in this group will undergo weekly monitoring of insomnia and suicidal ideation for 8 weeks. Participants will continue whatever treatments they are currently receiving, but will receive no specific instructions or behavioral interventions for insomnia. After the interim assessment, participants will then crossover to receive digital Cognitive Behavioral Therapy for Insomnia.
16255703|NCT04985994||Tuberculosis Patients|"Diagnosed with pulmonary TB after detailed history collection, clinical examination, and laboratory assessment (sputum culture positive).
~Aged 18 years or above.
~Willing to participate in the study."
16255704|NCT04985994||Healthy Volunteers|"Healthy subjects with no symptoms or history of pulmonary TB
~Negative sputum culture
~Matched for sex and age (±5 years) with the TB patient group."
16255705|NCT04985968|Experimental|Cobitolimod 250 mg|"Dose of 250 mg cobitolimod
~2 treatments during induction study and subsequently every third week"
16255706|NCT04985968|Experimental|Cobitolimod 500 mg|"Dose of 500 mg cobitolimod
~2 treatments during induction study and subsequently every third week"
16255707|NCT04985968|Placebo Comparator|Placebo|"Dose of Placebo
~2 treatments during induction study and subsequently every third week"
16255710|NCT04985942|Experimental|Lumateperone 42 mg|
16255711|NCT04985942|Placebo Comparator|Placebo|
16255712|NCT04985929|Experimental|Healthy, Untrained|Untrained participants will be defined as having a V̇O2peak of 30-45 ml.kg-1.min-1 and will be between 18-40 years of age.
16255713|NCT04985929|Experimental|Healthy, Trained|Trained participants will be defined as having a V̇O2peak above 55 ml.kg-1.min-1 (females) and 60 ml.kg-1.min-1 (males) and will be between 18-40 years of age.
16255714|NCT04985916|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
16255715|NCT04985916|Experimental|ET-01, Dose 1|Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline
16255716|NCT04985916|Experimental|ET-01, Dose 2|Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline
16255717|NCT04985903|Experimental|Intervention|Clinicians in the intervention arm will receive a tailored communication training on smoking cessation skills and a general lecture on smoking cessation.
16255718|NCT04985903|Active Comparator|Control|Clinicians in the control arm will be asked to attend a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
16255719|NCT04985890|Experimental|UB-421 monotherapy|Subjects will receive 10 mg/kg UB-421 weekly infusion for 8 weeks.
16255720|NCT04985890|Experimental|UB-421 + chidamide combination therapy|Subjects will receive 10 mg/kg UB-421 weekly infusion and 10 mg chidamide twice a week administration for 8weeks.
16255721|NCT04985877|Experimental|Sarcopenia group|Yakult light 300 supplementation with sarcopenia patient
16255722|NCT04985877|No Intervention|Non sarcopenia group|no intervention to sarcopenia patient
16255723|NCT04985877|No Intervention|Control group|no intervention to non-sarcopenia people
16255724|NCT04985864|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
16255728|NCT04985838|Experimental|Online HEADS: UP|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered using a video communication platform e.g. Zoom. An informal introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course.
16255729|NCT04985838|No Intervention|Control|No intervention provided.
16255730|NCT04985825|Experimental|Imgatuzumab monotherapy|
16255733|NCT04985799|Active Comparator|Gynecare TVT Exact sling|Participants who are planning surgery for SUI are randomized to have placement of Gynecare TVT Exact sling and followed postoperatively for 1 year.
16255734|NCT04985799|Active Comparator|Neomedic KIM sling|Participants who are planning surgery for SUI are randomized to have placement of retropubic Neomedic KIM sling and followed postoperatively for 1 year.
16255735|NCT04985786|Experimental|AUD Intervention|Risk behavior specific intervention, targeting alcohol drinking
16255736|NCT04985786|Active Comparator|AUD Control|Non-risk behavior specific intervention, targeting cognitive exercises
16255737|NCT04985786|Experimental|AUD & SZ Intervention|Risk behavior specific intervention, targeting alcohol drinking
16255738|NCT04985786|Active Comparator|AUD & SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
16255739|NCT04985786|Experimental|SZ Intervention|Risk behavior specific intervention, targeting medication non-adherence
16255740|NCT04985786|Active Comparator|SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
16255741|NCT04985786|No Intervention|HC Control|Healthy control subjects will participate in fMRI assessments only
16255743|NCT04985760|Experimental|Randomized Blinded Trimer 4571 Vaccine 100mcg|Six (6) participants will receive Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant as a 1ml intramuscular injection at Day 0, Week 8 and Week 20.
16255744|NCT04985760|Placebo Comparator|Randomized Blinded Placebo for Trimer 4571 Vaccine 100mcg|Two (2) participants will receive the placebo control for Trimer 4571 vaccine 100mcg as a 1ml intramuscular injection at Day 0, Week 8 and Week 20.
16255745|NCT04985760|Experimental|Randomized Blinded Trimer 4571 Vaccine 500mcg|Eighteen (18) participants will receive Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant as a 1.1ml intramuscular injection at Day 0, Week 8 and Week 20.
16255746|NCT04985760|Placebo Comparator|Randomized Blinded Placebo for Trimer 4571 Vaccine 500mcg|Six (6) participants will receive the placebo control for Trimer 4571 vaccine 500mcg as a 1.1ml intramuscular injection at Day 0, Week 8 and Week 20.
16255747|NCT04985747|Experimental|Polished palate|Participants will receive maxillary complete dentures with smooth palatal surfaces without modification.
16255748|NCT04985747|Experimental|Roughened palate|Participants will receive maxillary complete dentures with roughened palatal surfaces
16255749|NCT04985747|Experimental|Open palate|Participants will receive maxillary complete dentures with opened palatal surfaces
16255750|NCT04985734|Experimental|Patients under diagnostic work-up|
16255751|NCT04985721|Experimental|Pamiparib and Tiselizumab|
16255752|NCT04985708||Patient with AMICS are likely to benefit from MCS|later
16255753|NCT04985708||Develop and maintain a patient registry of AMICS|later
16255754|NCT04985708||Classify patients based on shock severity.|later
16255757|NCT04985682|Experimental|Haemophilia A Group|Participants with hemophilia A will be treated with ADVATE according to a regimen determined by the study site treating physician study site and in accordance with the national product label under standard clinical practice.
16255758|NCT04985669|Experimental|prucalopride group|prucalopride group will receive prucalopride 2 mg once daily
16255759|NCT04985669|Active Comparator|Lubiprostone group|lubiprostone group will receive lubiprostone 8 microgram twice daily
16255760|NCT04985656|Experimental|Pevonedistat 20 mg/m^2 + Decitabine 35 mg + Cedazuridine 100 mg|Pevonedistat 20 mg/m^2, 60-minute intravenous (IV) infusion, once daily, on Days 1, 3, and 5 in each 28-day cycle in combination with decitabine 35 mg and cedazuridine 100 mg tablets, orally, once daily on Days 1 through 5 in each 28-day cycle up to 30 months.
16255761|NCT04985643||Participants With Complete Response (CR)|Participants diagnosed with MM will be grouped under CR and will be receiving first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second symptomatic relapse is identified.
16255762|NCT04985643||Participants With Very Good Partial Response (VGPR)|Participants diagnosed with MM will be grouped under VGPR and will be receiving first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second symptomatic relapse is identified.
16256064|NCT04983264|Experimental|Single-dose Period (Part A)|Refer to Study Description
16255763|NCT04985643||Participants With Partial Response (PR)|Participants diagnosed with MM will be grouped under PR and will be receiving first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second symptomatic relapse is identified.
16255764|NCT04985630|Experimental|Mitopure Challenge to assess blood levels of Urolithin A after dietary and Mitopure intake|Mitopure challenge with diet (Pomegranate juice- Before) followed by Mitopure supplementation (After) to compare levels in blood spots of UA-Glucuronide (in ng/mL)
16255765|NCT04985617|Experimental|Warmed Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
16255766|NCT04985617|No Intervention|Room Temperature Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the control group was given at room temperature without heating and without intervention
16255768|NCT04985591|Experimental|liposuction group|
16255769|NCT04985591|Placebo Comparator|Other plastic surgery group|
16255770|NCT04985578|Experimental|Dry needling Group|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
16255771|NCT04985578|Placebo Comparator|Sham dry needling|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP sham dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, sham dry needling technique will be performed on the TrP for 60 seconds with a needle without tip.
16255772|NCT04985578|No Intervention|Control|No Treatment will be perfomed in this group
16255773|NCT04985565|Experimental|Treatment (dietary intervention, radical prostatectomy)|Patients participate in the Mediterranean diet for 6 days per week for 4 weeks before undergoing standard of care radical prostatectomy.
16255774|NCT04985552|Experimental|ciNPT|
16255775|NCT04985552|Active Comparator|Conventional tape dressings|
16255776|NCT04985539||PD de novo|Observational.
16255777|NCT04985526|Experimental|Polymorphic light eruption patients|PLE patients subjected to MED testing and photoprovocation
16255778|NCT04985526|Other|Healthy subjects|Normal healthy subjects
16255779|NCT04985513|No Intervention|Group N|Stopping ventilation during cardiopulmonary bypass
16255780|NCT04985513|Active Comparator|Group V|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
16255781|NCT04985500|Experimental|ESP group|Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.
16255782|NCT04985500|Experimental|PIF group|Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.
16255783|NCT04985500|No Intervention|No Block group|Patient will not receive block.
16255784|NCT04985487||Brolucizumab|Patients prescribed with brolucizumab in the approved indication
16255785|NCT04985474||Pulmonary resection|
16255786|NCT04985448||Conbercept|In clinical treatment and research, the applied doses of Conbercept in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Conbercept ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
16255787|NCT04985448||Ranibizumab|In clinical treatment and research, the applied doses of Ranibizumab in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Ranibizumab ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
16255788|NCT04985448||Laser Treatment|
16255789|NCT04985435|Active Comparator|Choice group|50 patients will be randomized to the choice group, they will view a neutral information video on anti TNF and Filgotinib and will be given the opportunity to choose between these two treatments
16255790|NCT04985435|Active Comparator|Randomization group anti TNF|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with antiTNF
16255791|NCT04985435|Active Comparator|Randomization group Filgotinib|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with Filgotinib
16255792|NCT04985422|Experimental|Experimental group: Smartphone-based daily ecological momentary intervention (EMI)|"The experimental group receives 4 weeks of smartphone-based daily EMI. Participants are prompted 6 times a day (with an interval of at least 30 minutes between each digital prompt), on a daily basis over the 4-week period. Within 15 minutes of the digital prompt, participants are to first complete a brief (1-2 minutes) momentary survey (ecological momentary assessment [EMA]), and subsequently select 1 out of 5 personalised intervention actions of interest to complete in the moment (time to complete spans from 1 minute to 5 minutes).
~The interventions are brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done in the moment. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).
~Participants could also use the platform at any other times to redo intervention actions when preferred. Individualised reports for the EMI completed are provided."
16255862|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 120 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks
16256065|NCT04983264|Experimental|Multiple Ascending-dose Period (Part B)|Refer to Study Description
16255793|NCT04985422|Other|Control group: Smartphone-based weekly-delivered information|"The control group receives 4 weeks of smartphone-based weekly-delivered information. The smartphone system (SMS + Qualtrics) as well as the contents of the interventions are identical to those provided to the EMI group. Rather than interventions delivered in the moment on a daily basis over the 4-week period, participants in the control group are provided with a new set of information on a weekly basis over the 4-week period (4 sets in total, 1 new set each week). Participants in the control group are also required to complete a brief 5-minute assessment within 3 days.
~The information includes brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done anytime. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).
~Participants could complete any intervention of interest in the information provided at any time throughout the 4-week period."
16255794|NCT04985409|Experimental|Feedback|Participants in the intervention arm will receive a Fitbit upon admission and will receive feedback from the activity tracker and the in-room TV screen as demonstrated by the Study Navigator. Study participants in this arm will be engaging with their physicians around achievement of daily step goals by viewing the in-room TV display of their daily step counts on rounds.
16255795|NCT04985409|No Intervention|Control|Subjects in the control arm will receive a Fitbit upon admission for their transplant but neither the physician, nurse, nor patient will receive any feedback from the device. They will be blinded to any data capture by their activity monitor. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods to encourage ambulation.
16255796|NCT04985396|Experimental|Platelet Rich Plasma (PRP) group|The PRP will be prepared based on the Sengodan et al, 2020 study.
16255797|NCT04985396|Active Comparator|Steroid group|"Steroid group will be treated with steroid injection. In this group, 2ml of Inj. Depo-Medrol 80 mg (Methylprednisolone) along with 1 ml lignocaine (0.25%) will be loaded in 5cc syringe and then the cocktail will be injected into medial calcaneal tuberosity at the most tender point using an aseptic technique as mentioned by Nishanth et.at,2018.
~After the procedure, participants will be advised not to involve in any kind of rigorous activity with the affected foot for at least two days and then gradually return to their regular activities. All patients will be counseled to follow up in the next visit at 3 months and 6 months. The end-line information will be again recorded at 3 months and 6 months."
16255798|NCT04985383|Experimental|AKST1210 b2M apheresis device|AKST1210 column will be connected in series for the duration of each hemodialysis session.
16255799|NCT04985370|Experimental|Pain neuroscience education plus exercise|Three sessions of pain neuroscience education plus exercise.
16255800|NCT04985370|Active Comparator|Exercise alone|Exercise alone without pain neuroscience education.
16255801|NCT04985357||Breast Cancer|Diagnosis of stage III or IV breast cancer
16255802|NCT04985357||Lung Cancer|Diagnosis of stage III or IV lung cancer
16255803|NCT04985357||Acute myelogenous leukemia (AML)|Diagnosis of acute myelogenous leukemia.
16255804|NCT04985357||Multiple Myeloma|Diagnosis of relapsed multiple myeloma
16255805|NCT04985344|Experimental|Propranolol|Patient will receive oral propranolol
16255806|NCT04985344|Placebo Comparator|Placebo|Patient will receive oral placebo
16255807|NCT04985331|Experimental|W-GenZD|W-GenZD is powered by natural language processing and machine learning techniques, the brief, self-guided intervention draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT-A) and some elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile medical application is designed to be targeted, relevant, tailored, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.
16255808|NCT04985331|No Intervention|Psychoeducation Control|The control for this study is the scheduled delivery of digital psychoeducational files (PDFs). The PDFs were selected to provide information on depression, anxiety and stress, as well as outline common coping skills.
16255809|NCT04985318||Registergroup|Patients with acquired Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
16255810|NCT04985305|Experimental|Intervention Group|"Educational session for GPs
~Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs
~Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form
~Instructed to complete a teaching session at the nursing home with a pre-defined teaching material
~Instructed to contact the nursing home before the home visit to encourage participation of regular staff and relatives in the home visit or, alternatively, to obtain information from regular staff and relatives before the home visit
~Dialogue tool"
16255811|NCT04985305|Active Comparator|Control Group|"Educational session for GPs
~Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs
~Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form"
16255812|NCT04985292|Experimental|Probiotic|10^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
16255813|NCT04985292|Placebo Comparator|Placebo|Inactive substance packaged to be identical to active treatment
16255814|NCT04985279|Active Comparator|Standard clinical practice|"Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation using skin markers.
~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine.
~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.
~A usability questionnaire regarding the procedure will be completed."
16255815|NCT04985279|Experimental|Position and Angle Marking System (PAMS)|"PAMS will be attached to the ultrasound probe.
~Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation by gentle pressing PAMS into the simulated patient's back to create skin indentations.
~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine, and the angle read off a graduated scale.
~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.
~A usability questionnaire regarding the procedure will be completed."
16255816|NCT04985266|Active Comparator|Standard endocrine therapy|"Standard endocrine therapy will continue for up to 24 months on trial.
~Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane)."
16255817|NCT04985266|Experimental|Palbociclib and fulvestrant|"Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.
~Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.
~Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit."
16255818|NCT04985253||Operable breast neoplasm cohort|Operable breast cancer (OBC) ER +/Her2 neg or triple negative breast cancer patients diagnosed and treated at Tata Memorial Centre, Mumbai from 01 Jan 2010 to 31 Dec 2013 with a five-year follow up or events within the 5 years.
16255819|NCT04985240|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
16255820|NCT04985240|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Molibdenum crop lettuce.
16255821|NCT04985227|Experimental|Home weight monitoring|Weighing scales will be provided to the parents to weigh their infant and enter the weight daily during the weekdays into the patient portal.
16255822|NCT04985227|No Intervention|Control|The parents will visit their Primary Care office in the usual manner as recommended by their Pediatrician.
16255823|NCT04985214||Oral therapy|Patients included in the PK-E3i clinical study or patients with hemopathies starting treatment with oral therapy.
16255824|NCT04985201|Experimental|Simvastatin + Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
16255825|NCT04985201|Active Comparator|Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles)
16255826|NCT04985175|Experimental|QPL group|receive 2-pages ESRD QPL leaflets, circle the questions they want to ask before consultation. encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
16255827|NCT04985175|No Intervention|Usual care group|without receiving provision of QPL encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
16255828|NCT04985162|Experimental|Intervention|Intervention group (n=10) received differential learning based physiotherapy program: 3 times a week ordinary physiotherapy, 2 times a week differential learning based on physiotherapy, total 3 weeks
16255829|NCT04985162|Active Comparator|Control|Control group (n=10) received ordinary physiotherapy program 5 times a week, total 3 weeks
16255830|NCT04985149|Other|Grup 1; participants with fibromyalgia|Participants with fibromyalgia
16255831|NCT04985149|Other|Grup 2: patients without fibromyalgia|Patients without fibromyalgia
16255836|NCT04985123||Silicone Block patients|All subjects who received a successful penile implantation with the Silicone Block by the surgeons at the centers in this study.
16255837|NCT04985110|Experimental|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
16255838|NCT04985110|Placebo Comparator|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
16255839|NCT04985097|Active Comparator|Experimental group|Half an hour of active visual training per day for a period of 20 consecutive days with the Optictrain software
16255840|NCT04985097|Sham Comparator|Control group|Half an hour of using a videogame without specific stimuli to improve visual performance (Fun Kid Racing 3.53 for Android) per day for a period of 20 consecutive days
16255841|NCT04985084|Experimental|The intervention group|A 6-week dietary behavioral intervention provided by a registered nurse and a registered dietitian.
16255842|NCT04985084|Other|Usual care|General dietary advice provided by the nurses.
16255843|NCT04985058||Patients with advanced breast cancer|Patients with advanced breast cancer treated with abemaciclib in combination wih endocrine treatment
16255844|NCT04985045||Control group|Healthy women will be included
16255845|NCT04985045||Cerebral palsy group|Women with cerebral palsy will be included
16255846|NCT04985019|Experimental|I (Prepectoral)|VR treatment group Participants received the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for panic disorder.
16255847|NCT04985019|No Intervention|II (Subpectoral)|Waiting list Participants in a waiting list.
16255848|NCT04985006|Experimental|Moderate intensity aerobic exercise|each subject will undergo running in medium intensity.
16255849|NCT04985006|Active Comparator|High intensity aerobic exercise|each subject will undergo running in high intensity.
16255850|NCT04984993|Experimental|MED3000|MED3000 gel formulation topically applied to the glans penis
16255851|NCT04984993|Experimental|Tadalafil|Tadalafil (5 mg) tablets to be taken orally
16255852|NCT04984980|Experimental|combined treatment group|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab Gemcitabine: 1000mg/m^2, iv, d1, d8, q3w Oxaliplatin: 100mg/m^2, iv, d1, q3w Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 5mg/kg, d1, q3w
16255853|NCT04984967|Experimental|Insertion of peripheral venous catheter with micro-guide|
16255854|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|
16255855|NCT04984954|Experimental|Experimental group|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
16255856|NCT04984954|Placebo Comparator|Placebo group|The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.
16255857|NCT04984902|Experimental|Treatment|Treatment with Microbind® Affinity Blood Filter
16255858|NCT04984902|No Intervention|Control|Antibiotics
16255859|NCT04984889|Experimental|TAK-662 80 IU/kg|TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants. TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.
16255860|NCT04984876|Experimental|ligelizumab 240 mg|ligelizumab 240 mg subcutaneous injection for 52 weeks
16255863|NCT04984876|Experimental|Placebo 16 weeks and ligelizumab 120 mg/240 mg|Placebo subcutaneous injection for first 16 weeks and ligelizumab 120 mg OR 240 mg subcutaneous injection for 36 weeks
16255864|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 240 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks
16255865|NCT04984863|Experimental|magnetically controlled capsule endoscopy|magnetically controlled capsule endoscopy to evaluate the efficacy of the treatment of gastroesophageal varices
16255866|NCT04984850|Experimental|Intervention plus usual care|
16255867|NCT04984850|No Intervention|Usual care only|
16255868|NCT04984837|Experimental|Lacutamab|Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase
16255869|NCT04984837|Active Comparator|Standard of care|GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase
16255870|NCT04984824|No Intervention|No nap group|No nap opportunity will be given in this condition.
16255871|NCT04984824|Experimental|10 minute nap|Participants will be given a 10 minute nap.
16255872|NCT04984824|Experimental|30 minute nap|Participants will be given a 30 minute nap.
16255873|NCT04984824|Experimental|60 minute nap|Participants will be given a 60 minute nap.
16255875|NCT04984798|Experimental|Vitamin E Dose-Escalation|Subjects will take an oral Vitamin E (dl-alpha-tocopherol) supplement twice daily with a fat-containing meal for 6-9 weeks. The dose will be increased every 2-3 weeks over the course of the study (initial dose 600 IU twice daily, next dose 1,200 IU twice daily, final dose 2,400 IU twice daily). Formulations include softgel capsules in 200, 400, and 1,000 IU doses.
16255876|NCT04984759|Experimental|Primaquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤5 days old will be recruited into the primaquine arm. They will receive primaquine 0.5 mg/kg daily for 14 days directly observed in the clinic.
16255877|NCT04984759|Experimental|Tafenoquine in mature milk (mother-child pairs)|24 women who are breast feeding infants or young children > 14 days will be recruited into Arm 2. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic. We will begin with recruiting 2-4 women breastfeeding young children ≥12 months old.
16255878|NCT04984759|Experimental|Tafenoquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤ 5 days old will be recruited into Arm 3. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic.
16255879|NCT04984746|Experimental|No Intervention: (control group)|No Intervention: (control group) The control group was assigned to lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
16255880|NCT04984746|Experimental|Experimental: intervention group|Experimental: intervention group To the intervention group was assigned the biofortificated Molibdenum lettuce and Iodine lettuce.
16255881|NCT04984733|Experimental|Treatment|"Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV until progression.
~Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression. Patients who progress on TMZ will start monotherapy with nivolumab.
~Metronomic TMZ50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until progression. Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths until they progress
~Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until 24 months. Patients will remain on combination therapy up to a maximum of 24mths."
16255882|NCT04984720|Experimental|Smart phone based digital app arm|Digital smartphone application which tracks migraine and to offers pill reminders for medication adherence and community blog and disease related educational material for migraineurs will be given to the patients
16255883|NCT04984720|Active Comparator|Paper and pen diary arm|Clinic based education and traditional paper-pen diary will be administered in tracking headache parameters
16255884|NCT04984707|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.The applied dosage cohorts are 3mg, 12mg, 48mg and 96mg.
16255885|NCT04984707|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.
16255886|NCT04984694|Experimental|Computerized virtual reality training programs group (Hot-Plus group)|Participants who are in Hot-Plus group will divide several small groups which will be 4 persons with mild cognitive impairment. Participants will receive computerized virtual reality training program by Hot-Plus as a group activity for one hour, once a week for 12 weeks.
16255887|NCT04984694|Active Comparator|Social interaction group|The participants in the social interaction group will come as a group for social interaction one hour weekly for 12 weeks.
16255888|NCT04984694|No Intervention|Control group|The control group will maintain regular activities.
16255889|NCT04984681|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based stress reduction sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
16255890|NCT04984681|Other|Usual Care|The control condition will continue receiving usual care or standard of care.
16255891|NCT04984668|Experimental|GT90001+KN046|"GT90001, 100 mg/10 mL/vial. GT90001 will be administered via intravenous infusion (IV) for around 60 minutes, once every 2 weeks (Q2W) in each 14-day cycle.
~KN046, 40 mg/1.6 mL/vial, 300 mg/12 mL/vial KN046 will be administered via intravenous infusion (IV) for at least 120 minutes (up to 4h for the first 6 cycles), once every 2 weeks (Q2W) in each 14-day cycle, after 60 minutes post the GT90001 taken."
16255892|NCT04984655|Other|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|
16255893|NCT04984642|Experimental|healty subject|
16255894|NCT04984629|Experimental|HYDRAFIL Implant|Polymer Implant of HYDRAFIL into a one or two lumbar intervertebral discs
16255898|NCT04984577|Experimental|Compound Edaravone Injection-Low dose|
16255902|NCT04984551|Experimental|Arm I: ECHO Participants (ECHO clinics, workshop, education)|Participants participate in online ECHO clinics over 1 hour twice monthly for 12 months and in-country workshops twice per year. Participants also receive 5 core lectures through an internet-based professional education curriculum.
16255903|NCT04984551|Experimental|Arm II: Patients (questionnaire, medical chart review)|Patients complete 3 in-person or phone questionnaires over a total of 20 minutes every 3 months for 2 years about their symptoms, emotional and physical well-being, and their experience and satisfaction with outpatient oncology care. Patients' medical charts are reviewed for data collection. Patients complete a 15 minute interview in person or phone about the care they received by their physician at baseline, end of month 4 and month 12.
16255904|NCT04984551|Experimental|Arm III: Caregivers (questionnaire)|Caregivers complete an in-person or phone questionnaire over 5 minutes up to 8 times about their experience and satisfaction with the cancer care their family member has received. Caregivers complete a 15-minute interview in person or by phone their family member received by their physician.
16255905|NCT04984525|Experimental|Part 1 Cohort 1 MAD HV: SYNB1934 (3 x 10^11 live cells)|HV subjects receive SYNB1934 (3 x 10^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
16255906|NCT04984525|Experimental|Part 1 Cohort 2 Crossover HV: SYNB1934 (6 x 10^11 live cells)|HV subjects receive SYNB1934 (6 x 10^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 7-day washout period HV subjects receive SYNB1618 (6 x 10^11 live cells), at least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
16255907|NCT04984525|Experimental|Part 1 Cohort 3 MAD HV: SYNB1934 (1 x 10^12 live cells)|HV subjects receive SYNB1934 (1 x 10^12 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
16255908|NCT04984525|Experimental|Part 1 Cohort 4 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
16255909|NCT04984525|Experimental|Part 1 Cohort 5 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
16255910|NCT04984525|Experimental|Part 2 Crossover with PPI vs No PII|HV subjects receive SYNB1934 (at or below the MTD from Part 1) with PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 14-day washout period HV subjects receive SYNB1934 (at or below the MTD from Part 1) without PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
16255911|NCT04984512|Experimental|Mitizodone Phosphate tablet 10mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.
16255912|NCT04984512|Experimental|Mitizodone Phosphate tablet 20mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 7 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then placebo,orally,once daily for 1 weeks.
16255913|NCT04984512|Experimental|Mitizodone Phosphate tablet 40mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 40mg ,orally,once daily for 6 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks.
16255914|NCT04984512|Active Comparator|Placebo|Placebo,tablet,orally,once daily for 10 weeks.
16255915|NCT04984473|Sham Comparator|Sham arm|Perform inspiratory muscle training at 2% maximal inspiratory pressure for 12 weeks.
16255916|NCT04984473|Active Comparator|Non-sham arm|Perform inspiratory muscle training at 40% maximal inspiratory pressure for 12 weeks.
16255917|NCT04984460||life-style counseling|"A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.
~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd."
16255918|NCT04984447|Experimental|Feasibility of TNIB catheter|The feasibility of using the TNIB catheter to obtain microscopic images of the intestine. Healthy adult volunteers, and healthy pregnant women in their 2nd trimester of pregnancy will be enrolled, and their upper gastrointestinal tract will be imaged by the TNIB device
16255919|NCT04984434|Experimental|Experimental: Single Arm|
16255920|NCT04984421|Active Comparator|Basic|All schools will receive the HSS program. Schools randomly assigned to group 1 will receive implementation strategy bundle 1 (Basic).
16255921|NCT04984421|Experimental|Enhanced|All schools will receive the HSS program. Schools randomly assigned to group 2 will receive implementation strategy bundle 1+2 (Enhanced).
16255922|NCT04984408|Experimental|Arm 1: BBIBP-CorV|Study Arms 1 will have two groups: group 1 - HIV-uninfected receiving BBIBP-CorV; group 2 - HIV-infected receiving BBIBP-CorV .
16255923|NCT04984408|Experimental|Arm 2: Flu Quadrivalent|Study Arms 2 will have two groups: group 1 - HIV-uninfected receiving Flu Quadrivalent; group 2 - HIV-infected receiving Flu Quadrivalent. The Flu Quadrivalent is recommended as a single dose for adults, the second and the booster doses for Arm 2 will be placebo.
16255924|NCT04984408|Experimental|Arm 3: BBIBP-CorV and Flu Quadrivalent (Co-administration)|Arm 3 will have 1 group - HIV-uninfected co-administration group receiving both study vaccines.
16255925|NCT04984382|Experimental|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
16255926|NCT04984382|No Intervention|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
16255927|NCT04984369|Experimental|Never use other BRAF inhibitor therapy|Never use other BRAF inhibitor therapy
16255928|NCT04984369|Experimental|PD after other BRAF inhibitor therapy N=5~40|PD after other BRAF inhibitor therapy
16255929|NCT04984369|Experimental|SD but intolerant after other BRAF inhibitor therapy|SD but intolerant after other BRAF inhibitor therapy
16257408|NCT04974203|Experimental|CT Value 25+|Patients with CT value of 25 or higher
16255930|NCT04984356|Experimental|WU-CART-007|"A CD7-directed chimeric antigen receptor (CAR) T-cell product.
~A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy. Cyclophosphamide 500 mg/m2/day x 3 (days -5 to -3) Fludarabine 30 mg/m2/day x 3 (days -5 to -3)"
16255933|NCT04984330|Experimental|selinexor/ dexamethasone (Sd)|"Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity
~Dexamethasone
~• 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23"
16255935|NCT04984304|Experimental|Mild cough|Mild cough only slightly worsening the quality of life (VAS 1-3)
16255936|NCT04984304|Experimental|Moderate and severe cough|Moderate and severe cough that significantly worsen the quality of life (VAS 4-10)
16255937|NCT04984291|Experimental|Zimmer Biomet Total Shoulder Arthroplasty System|Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
16255938|NCT04984278|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Study dependent: Each spray delivers 100 microliters (μL) of nabiximols. A pre-determined number of sprays, but no less than 4 sprays, of nabiximols will be self-administered by participants as an oromucosal spray, under supervision of trial staff during 2 study visits to the trial site after they temporarily discontinued treatment with prescribed nabiximols (Sativex) as part of their regular medication.
16255939|NCT04984278|Placebo Comparator|Placebo|Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 μL containing no active ingredients.
16255940|NCT04984265|Experimental|Stereotactic Body rRadiotherapy (SBRT)|SBRT targeting the area of the circuit of Ventricular Tachycardia
16255941|NCT04984252|Active Comparator|Only Active components|15 minutes, once
16255942|NCT04984252|Sham Comparator|Inactive components|15 minutes, once
16255943|NCT04984252|Placebo Comparator|Distraction group|15 minutes, once
16255944|NCT04984239|Other|Acceptance and Commitment Therapy adapted for aphasia|There is only a single study arm, in which the adapted intervention will be developed using a successive cohort design.
16255945|NCT04984226|Experimental|Veverimer|6 grams daily
16255946|NCT04984226|Experimental|Sodium Bicarbonate|0.5mEq/kg lean mass daily
16255947|NCT04984226|Placebo Comparator|Sodium bicarbonate placebo|cornstarch
16255948|NCT04984226|Placebo Comparator|Veverimer placebo|Microcrystalline cellulose
16255949|NCT04984200||AB|
16255950|NCT04984187|Other|Laser group|High Intensity Laser Therapy only , this group will receive laser for 4 weeks three times /week
16255951|NCT04984187|Other|Exercise group|Exercise , selected physiotherapy exercises will receive for 4 weeks ,3times/week
16255952|NCT04984187|Experimental|High intensity laser grouo|High intensity laser plus exercise will receive the selected exercises and laser 4 weeks, 3 times/week
16255953|NCT04984148||Trial cohort：Chemoradiotherapy followed by immunotherapy|"Contrast-enhanced thoracic CT: before, during and after radiotherapy
~Radiomics
~PD-L1 testing (Histological analysis of biopsy)
~Molecular Markers (Histological analysis of biopsy)"
16255954|NCT04984135||Enrolled patients|Patients fulfilling the study criteria were included.
16255955|NCT04984122|Other|Control|GA group intravenous 2-3 μ/kg fentanyl followed by 2 mg/kg propofol. were administered for anesthesia induction. After a laryngeal mask insertion anesthesia was maintained by inhalation of sevoflurane in an oxygen (60%) and nitrous oxide (40%) mixture to maintain a minimal alveolar concentration (MAC) of 0.8%-1.3%.
16255956|NCT04984122|Other|Study|In the LA group, after positioning of the patient, injection 2% 1:1000.000 (2 % lidocaine with 1:100.000 epinephrine) was injected submucosally with a 27-gauge needle tip at 3,6,9,12 o'clock locations of the ectocervix.
16255957|NCT04984109|Sham Comparator|Control group|Patients will receive preoperative US-guided will receive sham PENG with an injection of just 1mL saline.
16255958|NCT04984109|Experimental|PENG Group|Patients will receive preoperative US-guided will receive real PENG with an injection of 20mL of bupivacaine 0.25%+ 0.2mg/mL dexamethasone.
16255959|NCT04984083|Experimental|Group I|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
16255960|NCT04984083|No Intervention|Group II|patients will not take vitamin k before cesarean section
16255961|NCT04984070|Experimental|PCOS treatment|Lifestyle intervention, oral contraceptive pills and metformin will be given to improve the symptoms of PCOS patients, such as obesity, hyperandrogegism, and insulin resistance, and to compare the different psychological status in PCOS.
16255962|NCT04984057|Experimental|PS is stopped when the pressure is equal between bPDA and aPDA|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
16255963|NCT04984057|Active Comparator|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
16255964|NCT04984044|Active Comparator|Experimental|This arm includes 33 Diabetic Peripheral Neuropathy patients receiving the antidiabetic therapy
16255965|NCT04984044|Placebo Comparator|Control|This arm includes 33 Diabetic Peripheral Neuropathy patients receiving the antidiabetic therapy
16255966|NCT04984031||Generalized grade C periodontitis|generalized aggressive periodontitis ( generalized Grade C ,as in new classification) patients characterized with Bone loss/age index more than 1 and extent more 30 %
16255967|NCT04984031||Molar-incisor grade C periodontitis|localized aggressive periodontitis ( Molar-incisor pattern Grade C ,as in new classification) patients characterized with limited affection on molars and incisors and their Bone loss/age index more than 1.
16255968|NCT04984018|Experimental|Chidamide plus Camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
16255969|NCT04984005|Experimental|Low intensity exercise training group|
16255970|NCT04984005|Experimental|Moderate intensity exercise training group|
16255971|NCT04984005|Experimental|Intermittent high intensity exercise training group|
16255972|NCT04983992||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
16255973|NCT04983992||control group|People suffered from excessive lateral pressure syndrome with conservative treatment
16255974|NCT04983979|Experimental|SZC|3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
16255975|NCT04983979|Placebo Comparator|Placebo|3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
16255976|NCT04983966|Experimental|Desflurane group|General anesthesia with volatile agent of desflurane
16255977|NCT04983966|Active Comparator|Remimazolam group|Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
16255978|NCT04983953||Abnormal|A patient diagnosed with intracranial haemorrhage after a brain CT scan
16255979|NCT04983953||Normal|A normal person or a patient not diagnosed with intracranial haemorrhage after a brain CT scan
16255980|NCT04983940|Experimental|Jatenzo Arm|Participants in this group will receive Jatenzo for 26 consecutive weeks.
16255981|NCT04983927||Ischemic stroke positive|Patients diagnosed with acute ischemic stroke after a brain CT scan
16255982|NCT04983927||Ischemic stroke negative with other brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan, but has been diagnosed with other brain diseases.
16255983|NCT04983927||Ischemic stroke negative and no brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan and has not been diagnosed with other brain diseases.
16255984|NCT04983901|Experimental|Group I (imipenem, cilastatin, relebactam)|Patients receive imipenem IV, cilastatin IV, and relebactam IV over 30-60 minutes q6h for 2 days for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h. Patients may continue to receive imipenem IV, cilastatin IV, and relebactam IV over 30-60 minutes for up to 14 days if clinically indicated by the assessment of the treating physician.
16255985|NCT04983901|Active Comparator|Group II (cefepime, meropenem, piperacillin/tazobactam)|Patients receive cefepime IV q8h for a minimum of 6 doses, meropenem IV q8h for a minimum of 6 doses, or piperacillin/tazobactam IV q6h for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h.
16255987|NCT04983875|Experimental|BAC-enhanced group|944 participants will receive a post-mammography results letter which includes information on their BAC results.
16255988|NCT04983875|Other|Waitlist control group|944 participants will receive a post-mammography results letter without BAC information, which is the current standard of care. These patients will receive BAC information following study completion (approximately 6 months after mammography).
16255990|NCT04983849|Active Comparator|hydrogel metronidazole 25%|metronidazole hydrogel in adjunct to non surgical periodontal therapy
16255991|NCT04983849|Active Comparator|scaling and root planing|the only use of scaling and root planing
16255992|NCT04983836|Experimental|Serratus Block|
16255993|NCT04983836|Other|Paravertebral Block|
16255994|NCT04983823|Experimental|Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|"Optimization of pharmacotherapy:
~This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.
~Exercise intervention: Individualized training program will be provided by an exercise physiologist"
16255995|NCT04983823|Active Comparator|Usual care|All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).
16255996|NCT04983810|Experimental|Phase I Dose escalation|"Phase I = Fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
~Phase 2 = Recommended Fadraciclib phase 2 dose and schedule administered orally in 28 day cycles."
16255997|NCT04983797|Experimental|OPTRELL Mapping Catheter|Participants diagnosed with cardiac arrhythmias who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for Atrial and ventricular procedures will be using multi-electrode OPTRELL mapping catheter.
16255998|NCT04983784|Experimental|The Effectiveness of Walking on Sleep ,Depression and Quality of Life on intervention|"experimental group:
~intervention home-style walking exercises
~performed 12 weeks of 30 minutes walking exercise 2-3 times per week
~assess on at baseline and 12 weeks"
16255999|NCT04983784|Experimental|No intervention group reaction|"control group:
~no intervention
~Routine care and follow-up
~assess on at baseline and 12 weeks"
16256000|NCT04983771||Expert in ultrasound-guided regional anaesthesia|"At least 15 UGRA experts, member of a relevant professional society (e.g., RA-UK, ESRA, ASRA) and meeting at least 3 of the following criteria) will be recruited from centres in the UK.
~Completed advanced training in UGRA or have >10 years of independent practice in UGRA
~Hold a qualification related to UGRA (e.g., EDRA, higher degree or equivalent)
~Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated
~Regularly teaches UGRA in the course of their clinical work, including advanced techniques (Plan B/C/D blocks) where indicated"
16256001|NCT04983758||PHP|
16256002|NCT04983758||Moderate PCP|
16256008|NCT04983693|Experimental|Dementia-friendly Worship Service|Caregiver and persons living with dementia dyads attending six dementia-friendly worship services in person or online.
16256009|NCT04983680|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training to treat emotional problems.
16256010|NCT04983667|Experimental|Orange|Zinc-AA, Tablet, 30 mg. PO, Once Daily for up to one year
16256011|NCT04983667|Placebo Comparator|Green|Placebo, Tablet, 30 mg. PO, Once Daily for up to one year.
16256012|NCT04983654|Experimental|Patients with limb ulcer|Patients with sickle cell disease and suffering from limb ulcer
16256013|NCT04983654|Experimental|Patients without limb ulcer|Patients with sickle cell disease without any limb ulcer
16256014|NCT04983641|No Intervention|Control - No Pre-Visit Message|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were not sent any reminder e-mails or MyChart messages concerning PROMIS form completion at any timepoint prior to their scheduled clinic visit.
16256015|NCT04983641|Experimental|E-mail Arm|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were sent an initial reminder e-mail message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patient's did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder e-mail message.
16256016|NCT04983641|Experimental|"Digital Patient Portal MyChart Arm"|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patient's in this arm were sent an initial reminder MyChart message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patients did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder MyChart message.
16256017|NCT04983615|Experimental|fentanyl-based sedation group|
16256018|NCT04983615|Active Comparator|midazolam-based sedation group|
16256019|NCT04983602|No Intervention|Usual care Control group|The usual care control group receives conventional care in the Emergency Department (ED) or Acute Medical Assessment Unit (AMAU)The comparison group will receive routine care as would be usual in the ED or AMAU. Currently there is no dedicated team to perform CGA in the ED and AMAU at UHL with ad hoc allied health assessment available only at the discretion of the referring ED doctor or medical team. This process will be continued during the study and will be documented. The participants in this group will under baseline data collection prior to randomisation and follow up.
16256020|NCT04983602|Experimental|Comprehensive Geriatric assessment arm|The intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team (consisting of a geriatric specialist registrar, specialist geriatric nurse, senior pharmacist, senior physiotherapist, senior occupational therapist, and senior medical social worker) in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED.
16256021|NCT04983602|Experimental|EDPLUS arm|The ED PLUS intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED. Additionally the participants in this arm will undergo a 6 week physiotherapy led intervention in the community involving 3 home visits and weekly telephone support. The intervention will involved assessment of the patients function in terms of strength, balance and mobility. Following assessment the intervention will be aimed at addressing deficits in the function of the participants, review of their medical management by a geriatrician trainee and focusing on self management of their own program.
16256024|NCT04983563|Experimental|Actigraphy|
16256025|NCT04983550|Experimental|Group A: SG001 + doxorubicin hydrochloride liposome injection|Two-thirds of the patients will be randomly assigned to group A to receive SG001 240 mg, IV, every 2 weeks (1 cycle every 4 weeks), and doxorubicin hydrochloride liposome injection 40 mg/m^2, IV, every 4 weeks (1 cycle).
16256026|NCT04983550|Active Comparator|Group B: doxorubicin hydrochloride liposome injection|One-third of the patients will be randomly assigned to group B to receive doxorubicin hydrochloride liposome injection 40 mg/m^2, IV, every 4 weeks (1 cycle).
16256027|NCT04983537|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
16256028|NCT04983537|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
16256029|NCT04983537|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
16256030|NCT04983524|Experimental|Propolis|intervention intracanal medicament
16256031|NCT04983524|Active Comparator|Calcium Hudroxide|Gold standard intracanal medicament
16256032|NCT04983511|Experimental|Electrical Epidural Stimulation Test (EST)|Postpartum women are given EST to predict epidural catheter reactivation for their subsequent procedures (i.e. tubal ligation).
16256067|NCT04983238|Experimental|BYON5667 & SYD985|BYON5667 eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
16256068|NCT04983238|Placebo Comparator|Placebo & SYD985|Placebo eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
16256069|NCT04983225|Experimental|1×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10^6 cells/periodontal defect site.
16256070|NCT04983225|Experimental|5×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 5×10^6 cells/periodontal defect site.
16256033|NCT04983498|Experimental|Prospective Experimental Group|For the experimental group, we will recruit 200 participants who will receive the Enhanced Recovery Pathway, which will be ordered as a standing order set by the attending provider and managed by their peri-procedural nurses. The modified ERP for this study includes the following interventions: nursing managed order sets with ERP instructions to receive goal-directed fluid management within anesthesia approved parameters utilizing the NMH Colorectal ERAS protocol for IV fluid administration, PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis, early mobilization up to chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters, and early PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters.
16256034|NCT04983498|No Intervention|Retrospective Control Group|The retrospective group will consist of 200 randomly selected medical records of patients who had colonoscopy procedures for a 6 month period prior to study implementation (between 10/1/2019 to 4/1/2020). The retrospective control group will have received the current standard of care including: IV fluids for management of intra-procedural hypotension as indicated/ordered by the physician, PO intake at 30-45 minutes, up to a chair at 60 minutes, and all procedure related complications will have been treated (e.g. PONV) per physician order as is the current standard of practice in the GI Lab recovery area.
16256035|NCT04983485||Observational Group|Individuals who were diagnosed with COPD by Bolu Abant İzzet Baysal University Medical Faculty Chest Diseases Department and referred to Bolu Abant İzzet Baysal University Health Sciences Faculty Physiotherapy and Rehabilitation Department will be included in the study.
16256036|NCT04983472||Observational Group|Individuals diagnosed with Chronic Obstructive Pulmonary Disease by the Department of Pulmonology of the Faculty of Medicine of Bolu Abant Izzet Baysal University will be referred to the Department of Physiotherapy and rehabilitation of the Faculty of Health Sciences of Bolu Abant Izzet Baysal University
16256037|NCT04983446|Experimental|Foralumab Arm + Standard of Care|Subjects in this arm would receive, intranasal foralumab 100 µg (50 µg in 0.1 ml solution into each nostril).
16256038|NCT04983446|Active Comparator|Placebo Arm + Standard of Care|Subjects in this arm would receive, placebo (0.1 ml vehicle solution into each nostril).
16256039|NCT04983420|Experimental|non-alcoholic Pilsner|1 L non-alcoholic Pilsner per day for 2 weeks
16256040|NCT04983420|Experimental|non-alcoholic wheat beer|1 L non-alcoholic wheat beer per day for 2 weeks
16256041|NCT04983420|Active Comparator|apple spritzer|1 L apple spritzer per day for 2 weeks
16256042|NCT04983420|Placebo Comparator|lemonade|1 L lemonade per day for 2 weeks
16256043|NCT04983407|Experimental|Phase 1b: AVB-S6-500+ nab-paclitaxel and gemcitabine|
16256044|NCT04983407|Experimental|Phase 2: AVB-S6-500+ nab-paclitaxel and gemcitabine|
16256045|NCT04983407|Active Comparator|Phase 2: nab-paclitaxel and gemcitabine alone|
16256046|NCT04983394|Experimental|Virtual Realty|Participants will play a motion-controlled video game with Microsoft XBox One Kinect for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance exercises
16256047|NCT04983394|Active Comparator|Conventional|Participants will do aerobic exercises for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance
16256048|NCT04983381|Experimental|Education Group|Participants were grouped as; those who were given information about vaginal examination in the training group (n=40) and those who were not given information about vaginal examination in the control group (n=40).
16256049|NCT04983381|No Intervention|Control Group|Women were not given information about vaginal examination in the control group
16256053|NCT04983355|Experimental|Peptidyss|"Dietary supplement : fish hydrolysate
~The experimental product is a dietary supplement composed of a hydrolysate of fish containing low molecular weight peptides (4 capsules/day providing 1,4 g of fish hydrolysate)"
16256054|NCT04983355|Placebo Comparator|Placebo|The placebo product containing mainly silica is presented in the same form as the active product, so that people handling the product cannot distinguish both formula (4 capsules/day)
16256055|NCT04983342|Experimental|Apollo Armband|Armband that can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain.
16256056|NCT04983329|Other|Improvement in administration of surgical antibiotic prophylaxis.|The eight-month module will include a baseline phase, educational interventions, real-time guidance from a remote telemedicine center, regular feedback regarding adherence to protocols related to that module, and continued silent monitoring.
16256057|NCT04983303|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive a picture as they want. They will be asked to trace and color the pictures that need coloring. After the procedure, the child will take his or her picture which he colored during the procedure.
16256058|NCT04983303|Experimental|Coughing trick|Coughing trick: Children in this group will be taught how to cough during the procedure. coughs with start moderate force and then coughs again which coincides with a needle procedure, such as venipuncture for example.
16256059|NCT04983303|Experimental|Balloon inflation group as intervention group|Balloon inflation group: In this group, the children will receive a balloon colored as their favorite, and they will be asked to inflate the balloon before starting the venipuncture procedure.
16256060|NCT04983303|No Intervention|Standard care provided group as control group|Standard care provided group as the control group
16256061|NCT04983290|Experimental|intervention|The participating subjects belonging to the experimental group, will receive at home a set of foods with modified textures that allow the patient to feed for the observation period of 4 months, will also be followed by the dietary service of the center and by personnel identified within the protocol in order to verify compliance, liability and information regarding the evaluation scales involved in the project.
16275191|NCT04849819||ever user of systemic medications|
16256071|NCT04983225|Experimental|1×10^7 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site.
16256072|NCT04983225|Experimental|2×10^7 cells/two sites group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, two locations in total, and the total cell injection volume is 2 × 10^7 cells/2 periodontal defect sites.
16256073|NCT04983225|Experimental|3~4×10^7 cells/three or four sites group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, three or four locations in total, and the total cell injection volume is 3 × 10^7 to 4 × 10^7 cells/3 to 4 periodontal defect sites.
16256074|NCT04983225|Placebo Comparator|Saline solution group|Saline solution: 0.6mL/periodontal defect site.
16256075|NCT04983186|Experimental|Participants|Participants wear the Empatica E4 wearable sensor and use the smartphone applications developed by the research team.
16256076|NCT04983173|Experimental|Experimental: Clomiphene Citrate (CC) + rFSH|Ovarian Stimulation with CC+rFSH
16256077|NCT04983173|Active Comparator|rFSH|Ovarian Stimulation with rFSH
16256078|NCT04983160|Active Comparator|Allopurinol|
16256079|NCT04983160|Placebo Comparator|Placebo|
16256080|NCT04983147|Experimental|health belief model based training manuel|"A training manual entitled Do Not Stay Silent Towards Obesity was prepared by the researcher to guide women in obesity management by affecting their beliefs on obesity in a positive way."
16256081|NCT04983147|Experimental|powerpoint presentation with computer|The presentation prepared based on the Health belief model was used in group training.
16256082|NCT04983147|Experimental|video for obesity based on health beliefs|In the literature; It is explained that the educator's use of representations such as video is more effective than verbal expression and reading, and facilitates learning both by hearing and seeing.For this reason, videos that will create awareness about the subject in the trainings were prepared by the researcher and used in the trainings.
16256083|NCT04983147|Experimental|successful patients in obesity management|Real-life stories of people who could manage obesity before and thought themselves healthier compared to their previous condition were shared with the group. People were invited to the trainings who had obesity before and managed to lose weight and trainings were given in the affective field.
16256084|NCT04983147|Experimental|Post-training follow-up|"After the trainings given to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.
~This follow-up will increase motivation and answer questions regarding obesity management.
~It was made by calling every 15 days.It will be made by phone call."
16256085|NCT04983134|No Intervention|Standard Intervention(SI)|the HealthStreet Standard Intervention to include a CHW referral to an accessible and acceptable lung cancer screening site to include a financial counselor (if needed), tobacco cessation and quit resources (if still smoking) and, additionally, will watch the Genentech lung cancer screening video with the CHW;
16256086|NCT04983134|Experimental|Enhanced CHW Intervention|After 1:1 randomization, 30 women will additionally receive a 6-hour four week Enhanced CHW Intervention (E-CHW-I) modelled on successful peer-partnered interventions and informed by Stages of Change theory, which will add to the SI, calls and texts (if appropriate) to help problem solve and encourage screening receipt and transportation to the screening (if needed);
16256087|NCT04983121|Experimental|combine treatment group|This study adopts a single-arm, multi-center, open design. As per the initial plan, 30 stage II-III human epidermal growth factor receptor 2(HER2)-positive breast cancer patients who have received neoadjuvant therapy containing trastuzumab and pertuzumab and have been assessed as stable disease (SD) during the neoadjuvant treatment (an increase of 0-20%), disease progression (PD), inoperable or failing to meet the breast-conserving requirements will be enrolled to receive pyrotinib combined with Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) neoadjuvant therapy. The main purpose of the study is to observe the efficacy and safety of pyrotinib combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer.
16256088|NCT04983095|Active Comparator|Standard treatment|ADT and local RT to de novo patients
16256089|NCT04983095|Experimental|SBRT+Standard treatment|SBRT to all PSMA+ lesions in addition to ADT and local RT to de novo patients
16256090|NCT04983043|Experimental|Low dose group|Low dose Qishenyiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
16256091|NCT04983043|Experimental|High dose group|High dose Qishenyiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
16256092|NCT04983043|Placebo Comparator|Placebo group|Qishenyiqi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day
16256093|NCT04983030|Experimental|Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus PGT121, PGDM1400, and VRC07-523LS bNAbs|Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
16256094|NCT04983030|Active Comparator|Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus Placebo|Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. Placebo will be administered at week 24, and at week 28.
16256095|NCT04983030|Active Comparator|Placebo Plus PGT121, PGDM1400, and VRC07-523LS bNAbs|Participants will receive Placebo at week 0 and 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
16256096|NCT04983017|Active Comparator|Dietary supplements|Dietary supplements are either (1) designated as Generally Recognized As Safe (GRAS) by the Food and Drug Administration or (2) compounds at similar concentrations to those found in foods.
16256097|NCT04983017|Placebo Comparator|Placebo|Placebo-matched formulations
16256098|NCT04983004|Experimental|experimental group (tele-rehabilitation)|"Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability.
~The intervention is used by the communication software to interact with each other in real time. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment."
16256099|NCT04983004|Active Comparator|control group (bedside rehabilitation)|Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability. It is carried out by the bedside therapist. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment.
16257409|NCT04974203|Experimental|Negative|Patients with negative PCR test result
16256100|NCT04982991|Experimental|SAR443820|Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods
16256101|NCT04982978|Active Comparator|PMT Threat Appraisal|The PMT present group will include an 8-minute informational video that explains the current research and health risks associated with vaping, within the context of a threat appraisal focus (Perceived Vulnerability and Perceived Severity). During this video intervention, the severity and vulnerability of vaping among young adults, both in the short and long-term health effects will be presented. In addition, the video will explain the negative impact of vaping and focus the attention of the participants on the lack of research and information that currently exists on popular vaping products and the potentially devastating impact it can have on the health of young adult populations.
16256102|NCT04982978|Sham Comparator|Nutrition and Lifestyle Control|"The PMT absent group will feature an 8-minute nutritional information video as an attention control strategy titled, Vaping Health Effects. During this video intervention, the general risks and benefits of nutrition and lifestyle will be presented. The focus of this video will be on how a balanced diet and proper lifestyle choices (i.e., adequate sleep, diet, etc.) can benefit the participants lives in the short-term and long-term."
16256103|NCT04982965|Experimental|Active THC|Participants will be administered 400mg of vaporized cannabis (5.1%) before pain testing and fMRI.
16256104|NCT04982965|Placebo Comparator|Placebo THC|Participants will be administered 400mg of vaporized cannabis (<.1%) before pain testing and fMRI.
16256105|NCT04982952|Experimental|Contingency Management (CM)|In addition to receiving usual cessation care at the Tom Waddell Urban Health Center (TWUHC), CM intervention participants with CO-verified abstinence will obtain a CM incentive payment, via gift cards and/or cash redeemable in national retail chains.
16256106|NCT04982952|Other|Control Group|Participants who choose to attend smoking cessation in the usual care setting at TWUHC will receive a basic $5 payment for attending each study visit.
16256107|NCT04982939|Experimental|Experimental Group-Sintilimab in combination with SOX|Preoperative treatment: three cycles of sintilimab in combination with SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX, Sintilimab up to one year.
16256108|NCT04982939|Active Comparator|Active Comparator-SOX|Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.
16256109|NCT04982926|Experimental|TAS2940 Dose Escalation|
16256110|NCT04982926|Experimental|Dose Expansion Non-small Cell Lung Cancer|
16256111|NCT04982926|Experimental|Dose Expansion Breast Cancer|
16256112|NCT04982926|Experimental|Dose Expansion Gliblastoma|
16256113|NCT04982926|Experimental|Dose Expansion Solid tumors|
16256114|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 1）|Healthy subjects receive sinele dose of HEC116094
16256115|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 2）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
16256116|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 3）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
16256117|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 4，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC116094 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
16256118|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 5）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
16256119|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 6）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
16256120|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 7）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
16256121|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 1）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
16256122|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 2）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
16256123|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 3）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
16256124|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 4）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
16256125|NCT04982913|Experimental|The interaction with Oseltamivir of HEC116094（ Part C）|Healthy subjects received HEC116094 in cycle 1, Oseltamivir in cycle 2, and a combination of HEC116094 and Oseltamivir in cycle 3.There are washout periods between the first cycle and the second cycle and between the second cycle and the third cycle
16256126|NCT04982900|Experimental|EGFR-TKI Treatment Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of Furmonertinib on the day of baseline follow-up. Patients in the treatment group should take Furmonertinib (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of Furmonertinib for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
16256127|NCT04982900|Placebo Comparator|Control Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of placebo on the day of baseline follow-up. Patients in the treatment group should take placebo (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of placebo for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
16256128|NCT04982887|Experimental|Experimental Group|
16256129|NCT04982887|No Intervention|Control Group|
16256130|NCT04982874|Experimental|Furosemide 40 mg tablet|volunteers received Furosemide 40 mg tablet with 240 mL of water
16275192|NCT04849819||current user of systemic medications|
16256131|NCT04982874|Active Comparator|Lasix® 40 mg Tablet|volunteers received Lasix® 40 mg tablet with 240 mL of water
16256132|NCT04982861|Experimental|Cefixime trihydrate 100 mg/5 mL dry syrup|Cefixime trihydrate 100 mg/5 mL dry syrup was dissolved by 20 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
16256133|NCT04982861|Active Comparator|Suprax® 100 mg/5 mL dry syrup|Suprax® 100 mg/5 mL dry syrup was dissolved by 33 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
16256134|NCT04982848||Talzenna treated group|Talzenna treated gBRCA Breast cancer patients in the real world setting in Korea
16256135|NCT04982835|Experimental|M6-C Artificial Cervical Disc|The M6-C is an investigational device composed of two outer and inner endplates made of titanium with a polycarbonate urethane nucleus (plastic center) and a polyethylene fiber annulus (strong thread-like binding). Around the polyethylene annulus is a polyurethane sheath (plastic cover). The outer endplates have keels to anchor the disc to bone. The outer endplates and keels are both coated with a titanium plasma spray. The M6-C is provided in two heights (6mm and 7mm) and four footprints (Medium, Medium Long, Large, Large Long).
16256136|NCT04982835|Active Comparator|Ant. Cervical Discectomy & Fusion (ACDF)|"ACDF will be performed using one of three FDA approved anterior cervical plate system and corticocancellous allograft bone. The three plating systems used in this study are:
~Medtronic Sofamor/Danek Venture Anterior Cervical Plate System
~DePuy Synthes: SKYLINE Anterior Cervical Plate System
~Stryker Aviator Anterior Cervical Plating System"
16256137|NCT04982809|Active Comparator|Betamethasone group|
16256138|NCT04982809|Active Comparator|Dexamethasone group|
16256139|NCT04982809|Active Comparator|Prednisolone group|
16256140|NCT04982796|Experimental|Psilocybin-enhanced psychotherapy|Psilocybin will be administered twice (25mg & 30mg two weeks apart) in addition to a 6-week psychotherapy protocol while admitted to a residential rehabilitation treatment program.
16256141|NCT04982796|Other|Treatment-as-Usual|Treatment-as-usual while admitted to a residential rehabilitation treatment program.
16256142|NCT04982770|Experimental|No intervention|The participants have to read ethical guidelines before the assessment of their pro-utilitarian tendencies with the Oxford Utilitarianism Scale and before they have been asked to resolve moral dilemmas.
16256143|NCT04982770|No Intervention|Intervention|The participants do not have to read ethical guidelines before the assessment of their pro-utilitarian tendencies with the Oxford Utilitarianism Scale and before they have been asked to resolve moral dilemmas.
16256144|NCT04982757|Experimental|Depression - DMPFC target to (for non-responders) LPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Partial responders will receive another 5-day course delivered to the DMPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the LPFC.
16256145|NCT04982757|Active Comparator|Depression - LPFC target to (for non-responders) DMPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Partial responders will receive another 5-day course delivered to the LPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the DMPFC.
16256146|NCT04982757|Experimental|OCD - DMPFC target to (for non-responders) LPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the DMPFC. Partial responders will receive another 5-day course delivered to the DMPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the LPFC.
16256147|NCT04982757|Active Comparator|OCD - LPFC target to (for non-responders) DMPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Partial responders will receive another 5-day course delivered to the LPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the DMPFC.
16256148|NCT04982744||Patients affected by Li Fraumeni and Li Fraumeni Like syndromes|The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes
16256214|NCT04982276|Experimental|AK104 and AK109 combined with chemotherapy|AK104 IV every 2 weeks (q4w) AK109 IV every 2 weeks (q4w) PTX iV 85mg/m2 day1 day8 day15(q4w)
16256154|NCT04982705|Experimental|[Part 1.1] IDG-16177|6 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
16256155|NCT04982705|Placebo Comparator|[Part 1.1] Placebo of IDG-16177|2 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
16256156|NCT04982705|Experimental|[Part 1.2] IDG-16177|8 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo.
16256157|NCT04982705|Placebo Comparator|[Part 1.2] Placebo|2 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo (QD).
16256158|NCT04982705|Experimental|[Part 2] IDG-16177|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
16256159|NCT04982705|Placebo Comparator|[Part 2] Placebo|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
16256160|NCT04982705|Active Comparator|[Part 2] Sitagliptin|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator (1:1:1 ratio).
16256161|NCT04982692|Experimental|Intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
16256162|NCT04982692|Placebo Comparator|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
16256163|NCT04982666|Experimental|Whole-Food, Plant-Based Diet Group|Subjects with a known diagnosis of Crohn's disease will follow a whole-food, plant-based diet for a total of 12 weeks
16256164|NCT04982666|Active Comparator|FODMAP Diet|Subjects with a known diagnosis of Crohn's disease will follow a FODMAP diet for a total of 12 weeks
16256165|NCT04982653|Experimental|Arm I (hepatectomy using small bites fascial closure)|Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
16256166|NCT04982653|Active Comparator|Arm II (hepatectomy using conventional fascial method)|Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
16256167|NCT04982640|Experimental|Yoga|12-week program, 60 minutes, twice weekly group-delivered Iyengar yoga
16256168|NCT04982640|Active Comparator|Standard Exercise|12-week, 60 minutes, twice weekly group-delivered aerobic exercise (e.g., walking) program
16256169|NCT04982627|Experimental|Brief Negotiation Interview Chatbot (BNI Chatbot)|Participants will receive a link to register for the chatbot. Following registration, they will complete the initial chat, which includes instructions for the entire study. The chatbot will then guide the participant through multiple BNIs focused on the goal of bup engagement, with the following steps: 1) Raise the Subject/Establish Rapport; 2) Enhance Motivation; 3) Provide & Elicit Feedback; and 4) Negotiate a Plan. The chatbot then reminds the participant of their reasons why they might engage in OUD treatment based on their responses to Steps 2 & 3, and their negotiated plan. The chatbot will electronically connect participants to a treatment provider of their choice, based on available options.
16256170|NCT04982627|Active Comparator|Standard Care (OUD Education & Referral Resources)|• SC: The RA will provide participants with an electronic link, which provides OUD and bup education, and lists OUD treatment options and descriptions and locations, including bup prescribers. After reviewing, participants will be asked to choose from among the list of and a referral will be made based on the receiving treatment providers' procedures. These participants will not have access to the BNI chatbot. However, the referral facilitation, the electronic link will direct participants to a short Feasibility, Acceptability and Satisfaction (FAS) Assessment to obtain feedback on the process.
16256171|NCT04982614|Experimental|2-dose regimen group|Boys and girls (aged 9-14 years) and young women (aged 15-26 years) living with HIV will receive a two-dose regimen of the HPV vaccine at baseline (Month 0) and Month 6.
16256172|NCT04982614|Active Comparator|3-dose regimen group (SOC)|HIV-uninfected young women (aged 15-26 years) will receive the standard of care three-dose regimen of the HPV vaccine at baseline (Month 0), Month 2 and Month 6.
16256173|NCT04982601|Experimental|Yoga Group|Yoga-based exercises were performed by a physiotherapist has Yoga training, by consisting of 10-person groups, 6 weeks, 3 days in a week for a total of 18 sessions. Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises and lasts about one hour. Especially combined movements with upper extremity and neck movements and breathing exercises were used in breathing exercises. In the warm-up exercises, the muscles were extended by giving exercises especially for stretching the muscles. In this way, asanas were prepared. Asanas Ardra kati cahkrasana, padahastasana, trikosana, sasankasana, varaksana poses have been performed. Asanas were modified and applied according to the patient's condition. Relaxation exercises were used both after breathing exercises and at the end of the exercise program. With relaxation, the patients were allowed to leave their muscles relaxed with the whole body relaxation
16256174|NCT04982601|No Intervention|Control Group|No kind of intervention has been applied to control group they awaited for therapy procedure for 6 week. They have assessed at the end of the 6 weeks.
16256175|NCT04982588|Experimental|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:
~CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)
~EnVeo™ PRO Delivery Catheter System (DCS)
~EnVeo™ PRO Loading System (LS)"
16256176|NCT04982575|Experimental|Cagrilintide 2.4 mg and semaglutide 2.4 mg|Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
16256177|NCT04982575|Active Comparator|Cagrilintide 2.4 mg and placebo (semaglutide)|Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
16256178|NCT04982575|Active Comparator|Semaglutide 2.4 mg and Placebo (cagrilintide)|Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
16278528|NCT04826653|Experimental|Timing suture removal_2 weeks|
16256179|NCT04982562|Other|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
16256180|NCT04982549|Experimental|Durvalumab + platinum-based chemotherapy and radiation|"All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:
~cisplatin/etoposide carboplatin/paclitaxel pemetrexed/cisplatin pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
16256181|NCT04982536|Experimental|VMCore Biopsy System|The VMCore biopsy needle will used to collect up to 10 tissue samples.
16256182|NCT04982536|Active Comparator|Standard of Care Biopsy Needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples.
16256183|NCT04982523|Experimental|Online Mental Health Program Group|The online mental health program of 8 sessions is provided. Data collection was collected pre-, post-, and one month after the program.
16256184|NCT04982523|No Intervention|Control Group|"Data collection was collected three times for three months. No intervention was provided during the study.
~If they wanted, they were provided the online mental health program same as the experimental group after data collection."
16256185|NCT04982510|Experimental|Thermoplastic tray definitive impression|
16256186|NCT04982510|Active Comparator|Conventional tray definitive impression|
16256187|NCT04982497|Experimental|Video game based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
16256188|NCT04982497|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
16256189|NCT04982471||First relapsed/refractory diffuse large B-cell lymphoma|First relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants who have initiated second-line (2L) systemic treatment within 60 days prior to enrollment (date of informed consent)
16256190|NCT04982471||Second relapsed/refractory diffuse large B-cell lymphoma|Second relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants who have initiated third-line (3L) systemic treatment within 60 days prior to enrollment
16256191|NCT04982471||First relapsed/refractory follicular lymphoma|First relapsed/refractory follicular lymphoma (FL) participants who have initiated 2L systemic treatment within 60 days prior to enrollment
16256192|NCT04982471||First relapsed/refractory primary mediastinal B-cell lymphoma|First relapsed/refractory primary mediastinal B-cell lymphoma (PMBCL) participants who initiated 2L systemic treatment within 60 days prior to enrollment
16256193|NCT04982445|Experimental|Participants receiving CABENUVA|
16256194|NCT04982432|Experimental|Orismilast|Orismilast tablet, oral administration, multiple titrated doses twice daily, 10 mg up to 40 mg, morning and evening, 16 weeks treatment.
16256195|NCT04982419|Active Comparator|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
16256196|NCT04982419|Sham Comparator|Sham remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
16256198|NCT04982380|Experimental|Experimental group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
16256199|NCT04982380|Placebo Comparator|Control group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
16256200|NCT04982367|Experimental|Sirolimus-eluting balloon angioplasty|Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
16256201|NCT04982367|Active Comparator|Paclitaxel-eluting balloon angioplasty|Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
16256202|NCT04982354|Experimental|Investigational Treatment|Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.
16256203|NCT04982341||HFNC/prone|awake patients with COVID-19 and severe acute respiratory failure receiving HFNC in prone position
16256204|NCT04982328||NAFLD|patients diagnosed with NAFLD and hospitalized due to the severe COVID-19
16256205|NCT04982328||non-NAFLD|patients hospitalized due to the with severe COVID-19 without NAFLD
16256206|NCT04982315|Experimental|Standard Acupuncture|Participants randomized to standard acupuncture will receive 8-15 acupuncture treatments over 3 months.
16256207|NCT04982315|Experimental|Enhanced Acupuncture|Participants randomized to enhanced acupuncture will receive 12-21 acupuncture treatments over 6 months.
16256208|NCT04982315|No Intervention|Usual Care|Participants assigned to the usual care arm will not receive acupuncture and will be asked to not get acupuncture over the one-year course of the study.
16256209|NCT04982302||Non-surgical periodontal treatment NSPT|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets in 2 or 4 appointments
16256210|NCT04982289|Experimental|ALXN1830 Dosing Arm 1|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
16256211|NCT04982289|Experimental|ALXN1830 Dosing Arm 2|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
16256212|NCT04982289|Experimental|ALXN1830 Dosing Arm 3|Participants will receive placebo for 8 weeks, then ALXN1830 for 8 weeks, followed by an Observation Period (no treatment) for 8 weeks.
16256213|NCT04982276|Experimental|AK104 and AK109|AK104 IV every 2 weeks (q4w) AK109 IV every 2 weeks (q4w)
16256217|NCT04982250|Experimental|"formal peer PrEP referral + HIVST delivery"|After a brief training, young female PrEP users are encouraged to refer 4 peers using PrEP educational materials and HIVST kits (2 kits/peer = 8 kits total).
16256218|NCT04982250|No Intervention|"informal peer PrEP referral"|After a brief training, young female PrEP users will be encouraged to refer 4 peers to PrEP using word-of-mouth, the current standard-of-care with PrEP delivery in Kenya.
16256219|NCT04982237|Experimental|AK104+chemotherapy± bevacizumab|AK104 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
16256220|NCT04982237|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
16256221|NCT04982224|Experimental|REGN5093-M114|
16256222|NCT04982211|Experimental|Propranolol and standard trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
16256223|NCT04982211|Placebo Comparator|Placebo and standard trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
16256224|NCT04982211|Active Comparator|Propranolol and mismatch trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
16256225|NCT04982211|Placebo Comparator|Placebo and mismatch trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
16256226|NCT04982198|Experimental|TKA assisted with ROSA® Knee System|TKA assisted with ROSA® Knee System
16256227|NCT04982198|Active Comparator|TKA with conventional surgical instrumentation|TKA with conventional surgical instrumentation
16256228|NCT04982185||Deep block|Deep neuromuscular block before initial (V1) vagal stimulation.
16256229|NCT04982185||Moderate block|Moderate neuromuscular block before initial (V1) vagal stimulation.
16256230|NCT04982172|Experimental|Interventional arm|Model-informed precision dosing of infliximab (intravenously administered) using a Bayesian forecasting software tool. Doses and dosing intervals will be derived from the software tool, aiming to maintain adequate exposure (trough concentration target 5 mg/L).
16256231|NCT04982172|Active Comparator|Historical control arm|The treating physician adjusted the intravenously administered infliximab doses and dosing intervals without being guided by a model-informed precision dosing software tool. The primary objective was to extend the dosing interval. Therefore, dose de-escalation (interval extension with/without dose adjustment) were performed following a scheme at the treating physician's discretion.
16256232|NCT04982159||Invasive Fusariosis|Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study.
16256233|NCT04982146|Experimental|Bromelain + N-Acetylcysteine|Patients with pseudomyxoma peritonei that are not candidates to surgical resection
16256234|NCT04982133|Active Comparator|Fortification adjusted according to urea|Fortification adjusted according to urea with FM 85 at 4% and oligopeptides. In this arm, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.
16256235|NCT04982133|Experimental|Individualized fortification according to the nutritional characteristics of breast milk|"Individualized fortification according to the nutritional characteristics of the mother's own milk or pasteurized milk taken by the premature infant.
~In this arm, fortification is adjusted based on the macronutrient analysis of breast milk or donated twice weekly."
16256236|NCT04982120|Experimental|Repris Needle|Reprise sheath and needle
16256237|NCT04982094|Experimental|Mental Health First Aid and Relationship Building Training (MHFA+RBT)|Mental Health First Aid training in conjunction with Relationship Building Training.
16256238|NCT04982094|Active Comparator|Mental Health First Aid (MHFA only)|Mental Health First Aid training alone.
16256239|NCT04982081|Experimental|hiPSC-CM therapy low dosage|
16256240|NCT04982081|Experimental|hiPSC-CM therapy high dosage|
16256241|NCT04982068|Experimental|Adult Group 1a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
16256242|NCT04982068|Experimental|Adult Group 1b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
16256243|NCT04982068|Experimental|Adult Group 1c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28
16256244|NCT04982068|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
16256245|NCT04982068|Experimental|Elderly Group 1d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
16256246|NCT04982068|Experimental|Elderly Group 1e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
16256247|NCT04982068|Experimental|Elderly Group 1f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
16256248|NCT04982068|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
16256249|NCT04982055|Experimental|Intravenous group|
16256250|NCT04982055|Active Comparator|Subcutaneous group|
16256251|NCT04982042|Experimental|Post COVID-19 Outpatient Pulmonary Rehabilitation Program|The outpatient Pulmonary Rehabilitation Program will be carried out at the Pulmonary Rehabilitation Laboratory, consisting of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
16256252|NCT04982042|Active Comparator|Post COVID-19 Home Pulmonary Rehabilitation Program|The Home Pulmonary Rehabilitation Program will be carried out at the patients' homes, consisting of the same combination of aerobic and strengthening exercises, lasting 12 weeks, 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance. Patients will be monitored weekly via whatsapp.
16257410|NCT04974190|Active Comparator|Patients treated with actual device with actual solution|
16256253|NCT04982029|Experimental|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
16256254|NCT04982029|Placebo Comparator|Placebo|All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.
16256255|NCT04982016|No Intervention|Control group|There is no treatment before anesthesia induction.
16256256|NCT04982016|Experimental|Crystal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml carbonated Ringer's solution was infused (infusion time >10min).
16256257|NCT04982016|Experimental|Colloidal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml colloidal fluid was infused (infusion time >10min).
16256258|NCT04982003|Experimental|Single Group|A single group of subjects with pretest, posttest, and one-month follow-up testing relative to 10-week drumming exercise classes
16256259|NCT04981990|Active Comparator|Single lung ventilation|Using double lumen endotracheal tube and lung isolation
16256260|NCT04981990|Active Comparator|Two lung ventilation|Using conventional single lumen endotracheal tube and intermittent two lung ventilation
16256261|NCT04981977|Experimental|Care Transitions Intervention|Patient participants in this arm will receive the Care Transition Intervention.
16256262|NCT04981977|Experimental|Care Transition Intervention and Peer Support|Patient participants in this arm will receive the Care Transition Intervention.
16256263|NCT04981977|Other|Usual Care|Patient participants in this arm will receive the usual discharge/transition care provided by the hospital.
16256264|NCT04981964|Experimental|Conventional physical therapy plus forward walking|25 minutes of the forward walking training program It is based on methods as described by Grecco et al. (2013) The children were instructed to walk at a comfortable, self-selected speed during the first and final five minutes of the session and encouraged to increase the speed during the other 15 minutes.
16256265|NCT04981964|Experimental|Conventional physical therapy plus backward walking|25minutes of the backward walking training It is based on methods as described by Davis (1992) Firstly, the subject is asked to take a step backwards within the parallel bar and can support him or herself with the unaffected hand as required. The therapist provides help to move the subject's leg in the correct pattern, preventing subject from moving the leg back in full extension, when the subject can move the leg back with the correct pattern, the therapist gradually reduces the amount of assistance. Secondly, as the movement components have been practiced and the subjects has taken over actively with only slight help, the therapist facilitates walking backward within the parallel bars. Thirdly, the subject walks backwards actively away from the parallel bars. Finally, the distance and speed of walking backwards is progressively increased.
16256266|NCT04981951|Experimental|Dexmedetomidine and Bupivacaine|Patients will be given Dexemtomidine ( the intervention) added to the Bupivacaine
16256267|NCT04981951|No Intervention|Bupivacaine alone|patients will be given Bupivacaine alone
16256268|NCT04981938||Lobectomy with angioplasty|81 patients who underwent lobectomy with pulmonary artery reconstruction during oncologic lung resection from January 2001 to December 2020
16256269|NCT04981925|Experimental|MBSR treatment|
16256270|NCT04981912|Experimental|Arm A|HDMP + rituximab as a means of debulking prior to initiating venetoclax.
16256271|NCT04981899|Experimental|Main arm|"Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT.
~Patients with <CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment."
16256272|NCT04981886|Experimental|Group 1: Normal tension glaucoma subjects with thin corneas|NTG subjects with CCT ≤ 540 nm will be randomized to receive either netarsudil or bimatoprost.
16256273|NCT04981886|Experimental|Group 2: Normal tension glaucoma subjects with thick corneas|NTG subjects with CCT > 540 nm will be randomized to receive either netarsudil or bimatoprost.
16256274|NCT04981860|Experimental|Treatment naïve participants First Group L|Treatment naïve participants randomized to receive Betadine on the left eye and Avenova on the right Eye
16256275|NCT04981860|Experimental|Treatment naïve participants Second Group R|Treatment naïve participants randomized to receive Avenova on the left eye and Betadine on the right Eye
16256276|NCT04981860|Experimental|Participants undergoing intravitreal injection First Group L|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group L are patients that are having intravitreal injections and will receive betadine in the left eye and Avenova in the right eye.
16256277|NCT04981860|Experimental|Participants undergoing intravitreal injection Second Group R|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group R are patients that are having intravitreal injections and will receive betadine in the right eye and Avenova in the left eye.
16256278|NCT04981847|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
16256279|NCT04981847|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern. There is also less calcium and vitamin D because it includes fewer dairy foods.
16256470|NCT04980599|Active Comparator|K56 very high dose -E1|Probiotic drink (lactobacillus paracasei K56 10^11CFU) 350ml/d , for 60days
16256280|NCT04981847|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
16256283|NCT04981821|Experimental|GO-EXCAP|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
16256284|NCT04981821|Active Comparator|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
16256285|NCT04981808|Experimental|Telemonitoring|The subjects will be telemonitored. All subject will use a CGM, a fit bit, and a smart pen during the entire trial period. Staff at the endocinology clinics will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject)
16256286|NCT04981808|No Intervention|Usual Care|The subjects will wear a blinded CGM the first and final 20 days of the trial. The subjects will use a blinded smart pen throughout the trial period. Hence, the subjects are unable to see their measured data during the trial, and they will not be monitored.
16256287|NCT04981795||Adults (> or = 18 years of age)|Adults (> or = 18 years of age) diagnosed with relapsed or refractory DLBCL and initiating second- or third-line therapy meeting inclusion criteria.
16256288|NCT04981782||healthy subjects|"No intervention
~Infants will be measured at different time points. At the age of 3,4,6 and 9 months."
16256289|NCT04981782||torticollis group|"No intervention
~Infants will be measured at their visit to a Chiropractor. Before and after treatment."
16256290|NCT04981769||Patients|Patients presenting to clinical sites for Covid-19 testing who are 2 years of age or older.
16256291|NCT04981743|No Intervention|group 1|Twenty five patients will be administered only the standard treatment regimen according to Ministry Of Health, and Population management protocol for COVID-19 patients (November 2020).
16256292|NCT04981743|Active Comparator|group 2|Twenty five patients will be administered a single dose (900mg) of Nigella Sativa capsule twice daily plus standard therapy
16256293|NCT04981743|Active Comparator|group 3|Twenty five patients will be administered a single dose (2000 IU) of vitamin D3 tablet once daily plus standard therapy
16256294|NCT04981743|Active Comparator|group 4|Twenty five patients will be administered a single dose (900 mg) of Nigella Sativa capsule twice daily, and single dose of vitamin D3 tablet (2000 IU) once daily plus standard therapy.
16256295|NCT04981730|Experimental|Guided web-based intervention|Participants in the intervention will receive both the standardized usual care and guided web-based, individually-tailored childbirth and parenting intervention program, consisting of 10 sessions completed in 10 weeks plus weekly email, message, or video-conference contact from their assigned nurse specialist.
16256296|NCT04981730|Experimental|Self-guided web-based intervention|Participants in the intervention will receive both the standardized usual care and self-guided web-based, individually-tailored childbirth and parenting intervention program, including 10 sessions completed in 10 weeks.
16256297|NCT04981730|No Intervention|Attention control|Participants in the control group will receive attention from the research nurse and the standardized usual care.
16256298|NCT04981717|Experimental|REGN1908-1909|Randomized 1:1
16256299|NCT04981717|Placebo Comparator|Placebo|Randomized 1:1
16256300|NCT04981704|Experimental|Part 1: Itraconazole/Poziotinib Drug-drug interaction (DDI)|On Day 1 of Treatment period 1, a single oral dose of 8 milligrams (mg) poziotinib will be administered. On Day 1 of Treatment Period 2, 200 mg itraconazole oral solution will be administered twice a day (BID) followed by 200 mg itraconazole oral solution once daily (QD) for 7 consecutive days (Day 2 to Day 8) with a single oral dose of 8 mg poziotinib coadministered on Day 4.
16256301|NCT04981704|Experimental|Part 2: Phenytoin/Poziotinib DDI|On Day 1 of Treatment period 1, a single oral dose of 16 mg poziotinib will be administered. In treatment period 2, an oral dose of 100 mg phenytoin will be administered three times daily (TID) for 17 consecutive days (Day 1 to Day 17) with a single oral dose of 16 mg poziotinib coadministered on Day 14.
16256302|NCT04981704|Experimental|Part 3: Paroxetine/Poziotinib DDI|On Day 1 of Treatment Period 1, a single oral dose of 8 mg poziotinib will be administered. On Day 1 and Day 2 of Treatment Period 2, an oral dose of 20 mg paroxetine will be administered BID followed by 20 mg paroxetine QD for 9 consecutive days (Day 3 to Day 11) with a single oral dose of 8 mg poziotinib coadministered on Day 7.
16256303|NCT04981691|Experimental|anti-MESO CAR-T cells|"The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time.
~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.
~Interventions:
~Drug: anti-MESO CAR-T cells
~Drug: Fludarabine
~Drug: Cyclophosphamide"
16256304|NCT04981678|Other|Buprenorphine Discontinuation|Patients instructed to discontinue buprenorphine prior to surgery
16256305|NCT04981678|Other|Buprenorphine Continuation|Patients instructed to reduce buprenorphine to 16mg the day prior to surgery and reduce to 8mg on the day of surgery.
16256306|NCT04981665|Experimental|Postoperative TACE + Tislelizumab 200mg IV Q3W|TACE will be performed after curative resection (4±1w) once and then Tislelizumab Injection will be initiated after TACE (5±2d). Tislelizumab will be administered every three weeks, until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.
16256471|NCT04980599|Placebo Comparator|control -E2|maltodextrin powder 1.5g/sachet , 3g/d for 60days
16256307|NCT04981652|Experimental|Whole Milk|Participants randomly assigned to the whole milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two whole milk experimental beverages (250 mL each serving, 3% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
16256308|NCT04981652|Experimental|Skim Milk|Participants randomly assigned to the skim milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two skim milk experimental beverages (250 mL each serving, 0% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
16256309|NCT04981652|Experimental|Almond Beverage|Participants randomly assigned to the almond beverage condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two almond experimental beverages (250 mL each serving) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
16256310|NCT04981639|Active Comparator|I (IVPCA)|Intravenous patient controlled analgesia will be performed.
16256311|NCT04981639|Active Comparator|II (IVPCA+TAP)|Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.
16256312|NCT04981639|Active Comparator|III (IVPCA, IMS, and TAP)|Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.
16256313|NCT04981626||Control|"Females
~Age : matched for the AN group
~No present or past eating disorders
~No past or current psychotic disorders
~No current substance abuse or dependence.
~No current psychiatric medication"
16256314|NCT04981626||AN group|"Females
~16 years ≤ Age ≤ 25 years
~Diagnostic of AN according to DSM-5 criteria
~No past or current psychotic disorders
~No current substance abuse or dependence (excluding tobacco).
~No current psychiatric medication"
16256315|NCT04981613|Experimental|Experimental group|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
16256316|NCT04981613|No Intervention|Control group|irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
16256317|NCT04981600|Active Comparator|Laser Group|Grade II-III hemorrhoids present a special challenge to surgeons since aggressive surgery exposes the patient to several per- and postoperative complications. Therefore new techniques have been developed and one of the most popular contemporary technique is laser hemorrhoidectomy. By this technique a laser probe is inserted above the dentate line and advanced to the apex of the cushion and several shots are delivered while pulling out the probe gradually. The idea is to compromise the vascular flow of corpus cavernosum recti, hence shrinking the hemorrhoidal cushion.
16256318|NCT04981600|Active Comparator|RF (Radiofrequency) Group|Another recent and similar method is radiofrequency coagulation which depends on transmitting radiofrequency waves to tissue. This transmission results in conversion of radiofrequency waves into heat and causes coagulation necrosis in corpus cavernosum recti. The necrosis leads to fibrosis of the surrounding vessels and consequently cushion shrinkage is achieved.
16256319|NCT04981587|Experimental|Intervention group|This is the group that receives strength exercise in addition to usual treatment
16256320|NCT04981587|Other|Control group|This is the group that only receives usual treatment
16256323|NCT04981561|Experimental|100 microgram GATE-251|GATE-251, 100 microgram tablet, PO, Single Dose with 28 day follow up
16256324|NCT04981561|Experimental|1 mg GATE-251|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up
16256325|NCT04981561|Experimental|3 mg GATE-251|GATE-251, 3 mg tablet, PO, Single Dose with 28 day follow up
16256326|NCT04981561|Experimental|10 mg GATE-251|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up
16256327|NCT04981561|Experimental|25 mg GATE-251|GATE-251, 25 mg tablet, PO, Single Dose with 28 day follow up
16256328|NCT04981561|Experimental|50 mg GATE-251|GATE-251, 50 mg tablet, PO, Single Dose with 28 day follow up
16256329|NCT04981561|Experimental|100 mg GATE-251|GATE-251, 100 mg tablet, PO, Single Dose with 28 day follow up
16256330|NCT04981561|Experimental|1 mg GATE-251 with CSF collection|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
16256331|NCT04981561|Experimental|10 mg GATE-251 with CSF collection|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
16256332|NCT04981561|Placebo Comparator|Placebo|Placebo tablet, PO, Single Dose with 28 day follow up
16256333|NCT04981548||raised intracranial pressure|more than 200 mmH2O
16256334|NCT04981548||the normal intracranial pressure group|more than 80 mmH2O and no more than 200 mmH2O
16256335|NCT04981535|Experimental|Patients undergoing upper gastrointestinal endoscopy with head box|experimental group
16256336|NCT04981535|No Intervention|Patients undergoing upper gastrointestinal endoscopy without head box|standard of care group
16256337|NCT04981522|Experimental|Active Treatment (AT): PM+ intervention|Active Treatment (AT) group will receive 05 sessions of indigenously adapted problem management plus (IA-PM+) intervention.
16256338|NCT04981522|No Intervention|Delayed Treatment Control (DTC): Treatment as usual|Delayed Treatment Control (DTC) group will receive routine treatment until the last follow-up.
16256340|NCT04981496||Study A: ILR implantation|These are participants attending hospital for a clinically indicated ICD/CRT-D implantation or box change who will undergo rapid atrial and ventricular pacing to simulate arrhythmias and RV lead noise simulation and have an ILR implanted during their procedure.
16256341|NCT04981496||Study B: ICD implantation|These are participants attending hospital for a clinically indicated ICD/CRT-D implantation or box change who will undergo rapid atrial and ventricular pacing to simulate arrhythmias and RV lead noise simulation who will not have an ILR implanted.
16256342|NCT04981496||Study C: VT Ablation|These are participants having a clinically indicated VT ablation who we will record ventricular arrhythmias during the procedure.
16256343|NCT04981496||Study D: Exercise Treadmill Test|These are participants who already have a cardioverter defibrillator implanted who can safely exercise and bring up their heart rate.
16256344|NCT04981496||Study E: Spontaneous Arrhythmias|These are participants who already have a cardioverter defibrillator implanted and come into hospital with an atrial or ventricular arrhythmia.
16256345|NCT04981483|Experimental|Any age and parity with placenta accreta spectrum|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle[outside in-in out then out in-in out] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
16256346|NCT04981470|Experimental|Investigational Device|Subjects implanted with the baroloop device
16256347|NCT04981457|Active Comparator|patients who recieve misoprostol alone|Group A (n =30 ) will receive only vaginal Misoprostol 800mcg (4 tablets Cytotec 200mcg ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or uterine contractions or bleeding assessed by the same doctor who made evaluation at the beginning.
16256348|NCT04981457|Active Comparator|patients who recieve misoprostol and iso sorbide mononitrate|Group B (n =30 ) will receive combined vaginal Misoprostol 800mcg (4 tablets Cytotec ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or start of uterine contractions or bleeding. with Isosorbide-5-mononitrate (20 mg). Effox 20 mg )once at the beginning with misoprostol until reaching cervical ripening or start of and uterine contractions assessed by the same doctor who made the evaluation at the beginning.
16256354|NCT04981418|Active Comparator|Control group|will receive standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource. The physiotherapist will teach participants a standardised programme of exercises, typical of those provided within usual physiotherapy practice. Written explanation/illustrations of these exercises will be provided and the women asked to undertake these at home, three times/week.
16256355|NCT04981418|Experimental|Intervention group|"In addition to the control groups intervention of exercise and advice, women in the intervention group will be fitted with the customised pelvic support shorts (DM Orthotics Ltd, https://www.dmorthotics.com).
~Prior to the first physiotherapy session, those women allocated to the intervention group will have recieved the support shorts in the post together with standardised written information on wear time/washing. At the first physiotherapy session (one hour), the woman will be asked to try them on so that the physiotherapist can review the fit and comfort of the shorts. The physiotherapist will reinforce the written advice about wear time and care of the shorts, and answer any queries / brainstorm any issues. At session two (30 minutes), ~10 days later, the physiotherapist will review the fit and wearing of the shorts, problem solve any issues that have arisen, and review exercises to ensure they are being performed correctly."
16256356|NCT04981405||Patients hospitalised to clinics of First Pavlov State Medical University of Saint - Petersburg|450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
16256357|NCT04981405||Patients referred to Medical Institute named after Berezin Sergey for computed tomography|Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
16256358|NCT04981392|Experimental|Multi-component intervention to promote COVID-19 vaccination|"The intervention will include the following components:
~An online library of brief videos depicting local PCPs responding to common questions & concerns about the COVID-19 vaccine with link to be disseminated to patients by text message
~Automated PCP text messaging to unvaccinated patients with evidence-based recommendations for COVID-19 vaccination
~Educational materials for PCPs to support their conversations with patients about the COVID-19 vaccine"
16256359|NCT04981392|No Intervention|Control|Eligible patients seen at a study clinic randomized to the control group will receive usual care with no text messaging intervention. Providers at a study clinic randomized to the control group will be not be invited to attend the education session or sent any educational materials.
16256360|NCT04981379|Active Comparator|Hydroxychloroquine + Favipiravir|Hydroxychloroquine 2x200 mg 5 days and favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
16256361|NCT04981379|Active Comparator|Favipiravir + Placebo (Hydroxychloroquine)|Favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine ) 2x200 mg (5 days)
16256362|NCT04981379|Active Comparator|Hydroxychloroquine + Placebo (Favipiravir)|Hydroxychloroquine 2x200 mg (for 5 days) + placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
16256363|NCT04981379|Placebo Comparator|Placebo (Favipiravir) + Placebo (Hydroxychloroquine)|Placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine) 2x200 mg (5 days)
16256364|NCT04981366|No Intervention|Control group (CTRL)|Patients allocated to this arm will not receive any intervention.
16256365|NCT04981366|Experimental|Caloric Restriction associated to exercise training plus protein supplementation (CREX+PTN)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus protein supplementation.
16256366|NCT04981366|Placebo Comparator|Caloric Restriction associated to exercise training plus isocaloric placebo (CREX+PLA)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus isocaloric placebo.
16256367|NCT04981353|Active Comparator|group 1|:(group 1) will be putted in sitting position and disinfecting her back. A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal direction
16256368|NCT04981353|Active Comparator|group 2|(group 2) patients will receive pethidine 25mg doses if NRS >4.
16256369|NCT04981340|Experimental|Standard urotherapy + Diaphragmatic breathing exercises+ pelvic floor exercises|Diaphragmatic breathing exercises will be demonstrated by a qualified physiotherapist. Exercises will be done in lying and sitting positions respectively. In supine, with the lower extremities supported over a pillow and hands positioned on the abdominal muscles, children will be asked to inhale the air through the nose, bulge the abdomen outwards as much as possible, hold their breath for a few seconds, and then exhale slowly through pursed lips. The same exercise will be then performed in both side-lying positions and in a sitting position in front of the mirror. Children will be instructed to watch the anterior abdominal wall movement during inspiration and to repeat the same action while seated on the toilet to initiate voiding. They will be asked to perform the diaphragmatic breathing exercises daily at home.
16256370|NCT04981340|Active Comparator|Standard urotherapy|Standard urotherapy will start with the education of the children and their parents about the normal function of the bladder and external urinary sphincter and the nature of their voiding disorder. The importance of regular fluid intake (200 ml 5-6 times per day) and regular voiding will be explained. Special voiding and defecation diaries that a child has to fill out at home will be provided. An optimal voiding posture will be demonstrated in front of a mirror: a sitting position, with feet supported, hips abducted and abdominal muscles relaxed.
16256371|NCT04981327|Experimental|Experimental|After a conventional course of 7 days of Apixaban 10mg BID, Apixaban 2.5mg BID during 3 months.
16256372|NCT04981327|Active Comparator|Standard|After a conventional course of 7 days of Apixaban 10 mg BID, Apixaban 5 mg BID during 3 months.
16256373|NCT04981314|Experimental|Treatment with echinacea|EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
16256374|NCT04981314|Placebo Comparator|Placebo|Hard caplets indistinguishable from EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
16256375|NCT04981301|Active Comparator|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.
16256376|NCT04981301|No Intervention|Group C = Control group|"Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.
~Wound local anesthetic infiltration will be applied to the patients in the control group."
16256377|NCT04981275||Women with PCOS|Women previously diagnosed with PCOS not using hormonal therapy and without other significant health or endocrine issues
16256378|NCT04981275||Healthy controls|Women self-identifying as generally healthy, not using hormonal therapy, and without any significant health or endocrine issues
16256379|NCT04981262|Experimental|Stimulance|4 weeks intervention with Stimulance for all participants
16256380|NCT04981262|Experimental|Stimulance 6 months|6 months intervention
16256381|NCT04981262|No Intervention|No intervention|6 months control group
16256382|NCT04981236|Active Comparator|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
16256383|NCT04981236|Experimental|Periarticular block|Participants receiving periarticular block
16256384|NCT04981223|Experimental|ExactVu Imaging|"EV29L transducer will be inserted in the subject's rectum. Cine sweeps will be performed to save images of:
~The entire prostate from posterior to anterior (may require 2 sweeps to cover base and apex)
~The peripheral zone using the highest zoom setting (30mm depth) on the system (may require 2 sweeps to cover base and apex). Analysis of these images will be performed after surgery but before prostatectomy"
16256385|NCT04981210||suspect LOPD|
16256386|NCT04981197|Experimental|Baduanjin exercise group|The Baduanjin exercise group received a 12-week Baduanjin exercise programme.
16256387|NCT04981197|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
16256388|NCT04981184|Other|Gait and balance measurement|"Gait analysis with surface electromyography measurement: surface electromyography signals (of affected and non-affected legs), gait and stance parameters are collected while the patient walks for 30 seconds on the treadmill with integrated sensor equipment (for measuring the force distribution).
~Balance analysis with Biodex balance system SD: measurements of postural stability, fall risk, limits of stability, sensory integration are collected."
16256472|NCT04980599|Active Comparator|K56 high dose-E3|Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10^10cfu) , for 60days
16256389|NCT04981171|Experimental|Electro-thumbtack Needle Therapy (ETN) group|Electro-thumbtack needles (0.25×2 mm) will be inserted into acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, turn on the device to produce a proper electric stimulation that the participant can tolerate.
16256390|NCT04981171|Sham Comparator|Sham Electro-thumbtack Needle Therapy (ETN) group|Sham electro-thumbtack needles (0.25×0.2 mm) which are specially produced have blunt tips instead of sharp needle tip. They will be taped on acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, produce a minimal level of electric stimulation for 30 seconds before turning off the device.
16256391|NCT04981158|Placebo Comparator|control group, group I|standard general anesthetic (GA) technique
16256392|NCT04981158|Active Comparator|Epidural /GA using TET group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using tolerable endotracheal tube (TET)
16256393|NCT04981145|Experimental|IGU Group|
16256394|NCT04981145|Active Comparator|HCQ Group|
16256395|NCT04981132|Experimental|Education Group|Group 1: Patients will have pain neuroscience education (PNE)
16256396|NCT04981132|Experimental|Exercise group|Group 2: Patients will have progressive therapeutic exercise training (PTE)
16256397|NCT04981132|No Intervention|Control Group|Group 3: Participants will be taken for the waiting list
16256398|NCT04981106|Experimental|Elastic Band Exercise|"All the participants were subjected to walking training and a standard postoperative care and exercise protocol until discharged from the hospital. During discharging, all the participants in both groups were provided with explanation and illustration about how to perform the exercises. In order to prevent any problem, the participants in both groups were recommended to start the at-home rehabilitation programs, which incorporate knee movement exercises, to be ready 2 weeks (14 days) after the surgery and they were asked to continue their current exercise programs thus far.
~The patients in intervention group were recommended to do, in addition to the at-home exercise program given to the patients in control group, elastic band exercises and researchers showed them how to use the elastic bands by making use of instructions."
16256399|NCT04981106|No Intervention|Exercise|The patients in control group were recommended to maintain only an at-home exercise program incorporating knee flexion and extension exercises.
16256400|NCT04981093|Experimental|Group Dexamethasone|"Group dexamethasone patients received intravenous injection after anesthesia induction
~Injection 0.15mg/kg dexamethasone (2ml）"
16256401|NCT04981093|Placebo Comparator|Group Saline|Group Control patients were also given 2ml of normal saline intravenously after induction of anesthesia
16256402|NCT04981080||Symptom of voiding dysfunction|Women with lower urinary tract symptoms including voiding symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
16256403|NCT04981080||No symptom of voiding dysfunction|Women with lower urinary tract symptoms but without cystocele or voiding symptoms who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
16256404|NCT04981067|Other|Sciatic nerve block using same or decreased concentration of local anesthetic|If the sciatic nerve block in the previous participant was successful, the concentration of local anesthetic would be maintained or decreased 0.05% in the next patient based on a random assignment.
16256405|NCT04981067|Other|Sciatic nerve block using increased concentration of local anesthetic|If the sciatic nerve block in the previous participant was not successful, the concentration of local anesthetic would be increased 0.05% in the next patient.
16256406|NCT04981054||cystocele with repairment|women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
16256407|NCT04981041|Experimental|Potent P2Y12-Inhibition|Prasugrel 10mg (5 mg in patients ≥ 75 years old or weighing < 60 kg) q.d. per os or Ticagrelor 90mg bid per os
16256408|NCT04981041|Active Comparator|Clopidogrel|Clopidogrel 75mg q.d. per os
16256409|NCT04981028||Patients with acute episode of thrombotic thrombocytopenic purpura (TTP)|Any adult patients with a suspected diagnosis of TTP (defined by low platelets and anaemia with evidence of red cell breakdown) and confirmed by a low ADAMTS13 enzyme level <10%
16256410|NCT04981028||Healthy volunteers|Non-blood relative / friend / carer
16256411|NCT04981028||Patients with known diagnosis of TTP|Any adult patients with a previously confirmed diagnosis of TTP (more than 12 months ago) based on an ADAMTS13 enzyme level <10% at initial diagnosis
16256412|NCT04981015||Women with lower urinary tract symptoms|Women with lower urinary tract symptoms without cystocele were included.
16256413|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - telemedicine self exam before face-to-face evaluation|First care will be performed via telemedicine with a clinical physician, guiding self-examination guided by telemedicine. After the remote consultation, a face-to-face evaluation will be performed with an orthopedist, according to institutional protocol.
16256414|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - only face-to-face evaluation|Face-to-face care with an orthopedist, according to institutional protocol.
16256415|NCT04980989|Experimental|Mobile software|Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.
16256416|NCT04980989|Active Comparator|Telephone calls|Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.
16256417|NCT04980976|Active Comparator|Conventional blind insertion technique.|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
16256418|NCT04980976|Experimental|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique to advance into esophagus under direct vision.
16256446|NCT04980729|Experimental|the template-guided group|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction using a modular hemipelvic prosthesis.
16257411|NCT04974190|Placebo Comparator|Patients treated with actual device with placebo solution|
16256419|NCT04980963|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention. Taking into consideration available psychoeducational assessment data, functional assessments from other agencies, and the participant's self-report regarding the functional difficulties that result from his or her ASD-related cognitive impairments, Scherer's (2012) Matching Person and Technology (MPT) protocol will guide the CST assessment. For purposes of the CST component of this intervention, the technological platform for cognitive accommodations will be an iPad II that is provided to each intervention-group participant at no charge (including wireless access if needed). The interventionist will provide training in the use of the iPad if necessary.
16256420|NCT04980963|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an in-person session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
16256421|NCT04980950|Experimental|gastric cancer patients (immunonutrition)|Experimental gastric cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
16256422|NCT04980950|Active Comparator|gastric cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
16256423|NCT04980950|Experimental|colorectal cancer patients (immunonutrition)|Experimental colorectal cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
16256424|NCT04980950|Active Comparator|colorectal cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
16256425|NCT04980937||Patients with perineal nerve damage after ski injury|Retrospectively aquired patients from insight in medical records. All patients with perineal nerve damage after ski injury in the time period of question were enrolled. Inclusion required operative management of the injury interns of microsurgical reconstruction of peroneal nerve.
16256426|NCT04980924||Pulmonary Embolism without reccurence or complication|Pulmonary Embolism without reccurence or complication
16256427|NCT04980924||Pulmonary Embolism with reccurence or complication|Pulmonary Embolism with reccurence or complication, in particular occurrence of pulmonary hypertension.
16256428|NCT04980898|Experimental|Electrical stimulation wound management system|Two daily electrostimulation sessions using the WoundEL® device on wound two for 30 minutes at an adjustable intensity, between 5 and 42 milliampere and chosen by the patient.
16256429|NCT04980898|Active Comparator|Standard of care|Use of dressings appropriate to the stage of healing according to French recommendations for the management of leg ulcers.
16256430|NCT04980885|Experimental|AK117+Azacitidine|"Phase Ib: Subjects will receive different doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;
~Phase II: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
16256432|NCT04980859|Experimental|Zebutinib Combined With CIT arm|Zebutinib Combined With FCR( under 60 years of age) or BR (over 60 years of age )
16256433|NCT04980846|Experimental|Intervention group|Intervention: Other: Driving under the influence of alcohol with a driving simulator
16256435|NCT04980820|Experimental|FFP2|This arm starts with a FFP2 mask and switches to a FFP3 mask.
16256436|NCT04980820|Experimental|FFP3|This arm starts with a FFP3 mask and switches to a FFP2 mask.
16256437|NCT04980807||CMT Patients|Individuals with Charcot-Marie-Tooth Disease Types 1 and 2.
16256438|NCT04980807||Healthy Controls|Healthy age-matched volunteers
16256439|NCT04980794|Experimental|Parent-Child Intervention|This is a four-dose intervention that includes psychoeducational modules and communication coaching administered through community organizations over the course of four weeks. Both participating adults and the participating child receive materials to review each week, paired with weekly contact from a family coach.
16256440|NCT04980794|Active Comparator|Self-study intervention|This is a four-dose intervention that include written self-study materials to review, paired with weekly contact with a family coach. Both participating adults receive self-study materials; the participating child does not receive separate materials.
16256441|NCT04980781|Experimental|Participants receiving PED-t|"Participants, i.e. females with bulimia nervosa or binge eating disorder, are recruited for therapy in the trained ERC. The treatment program consists of 20 behavioral therapy sessions covering 16 weeks, and with single follow-up sessions at 2-, and 4- months post-therapy.
~Participants are interviewed on the expectations to- and experiences from having therapy in the ECR, and monitored and evaluated on therapy effectiveness (i.e. diagnostic outcomes)."
16256442|NCT04980781|Experimental|Therapists and management in ERC offering PED-t|"Employees in the ECR and the management will be trained in giving PED-t in their facility, and will then perform therapy with a single group of participants recruited.
~Therapists/employees trained in PED-t will be interviewed about their expectations to- and experiences from giving the PED-t, and also being monitored according to therapy manual fidelity.
~The management at the facility offering PED-t will be interviewed about their experiences on administration and implementation of the PED-t in their facility."
16256443|NCT04980768|Other|Root canal treatment|Root canal treatment will be provided to all the participants with the diagnosis of apical periodontitis.
16256444|NCT04980755|Experimental|Phase one|"Participants will be asked to attend four weekly sessions of Body Reprogramming via group video call.
~Each session will include up to 8 patients and will consist of a 25-30 minute live presentation"
16256445|NCT04980755|Experimental|Phase two|We anticipate that participant sin phase two will complete the same intervention, but it may be somewhat modified following participant feedback in phase one.
16256447|NCT04980729|Active Comparator|the traditional operation group|In the traditional operation group (n = 14), acetabulum was manually reconstructed using a modular hemipelvic prosthesis by the surgeon's experience.
16256448|NCT04980729|Sham Comparator|the validation group|In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without acetabulum reconstruction.
16256449|NCT04980716|Experimental|The early intervention group|"The early intervention group: evaluation and intervention based on impedance cardiography results at multiple timepoints. Specific intervention measures include:
~cardiovascular drug treatment: based on the increase and decrease of the Golden Triangle
~ACEI, perindopril tert-butyrate 4mg qd
~β receptor antagonist, metoprolol succinate 47.5mg qd
~Spironolactone 20mg qd
~Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid
~Other therapeutic drugs include: loop diuretics, ARNI, sinus node If current selection specific inhibitors, statins, antiplatelet aggregation and nitrate drugs, etc.
~Exercise intervention: exercise prescription based on the initial cardiopulmonary exercise test results."
16256450|NCT04980716|No Intervention|The control group|This group will be under observation. When cardiovascular events (including ischemic cardiomyopathy, heart failure, arrhythmia requiring treatment, pericardial disease requiring treatment, valvular disease, etc.) happen, a cardiovascular specialist assessment and intervention will be given.
16256451|NCT04980703|Experimental|Grain moxibustion|Grain moxibustion +standard care
16256452|NCT04980703|Sham Comparator|Sham grain moxibustion|Sham grain moxibustion +standard care
16256453|NCT04980703|Other|Wait-list control|Standard care
16256454|NCT04980690|Experimental|Phase Ia - Dose escalation(Acceleration Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.
~Acceleration Stage: The initial increasing dose is 0.025 mg/kg, and the dose is increased in 100% increments. Each dose group will enroll 1 subject."
16256455|NCT04980690|Experimental|Phase Ia - Dose escalation(3+3 Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.
~3+3 Stage: The dose is increased in 30%-50% increments between adjacent dose groups, and the increment is determined by the investigator and the sponsor based on the safety data obtained in the previous period.Each dose group will enroll 3 to 6 evaluable subjects (evaluable: at least complete the DLT observation period), and this period continues until the maximum tolerated dose (MTD) is reached."
16256456|NCT04980690|Experimental|Phase Ib - Dose extension|"Phase Ib is an open, non-random, single-arm, multi-center research design.
~When phase Ia is transformed into 3+3 stage, a certain dose group meets the conditions for increasing the next dose group (after the DLT observation period of the last subject in the dose group has passed, the safety assessment of the current dose group will be completed) , The dose extension study of this dose group can be carried out, and 6 evaluable (evaluable: at least 2 cycles of dosing and observation) subjects with advanced malignant tumors who have failed standard treatments will be included in this dose group."
16256457|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group A)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.
~Group A: Recurrent or metastatic triple-negative breast cancer that failed standard treatment."
16256458|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group B)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.
~Group B: Locally advanced/metastatic non-small cell lung cancer without driver gene mutations that failed standard treatment."
16256459|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group C)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.
~Group C: Recurrent or metastatic head and neck squamous cell carcinoma that failed standard treatment."
16256460|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group D)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.
~Group D: Recurrent or metastatic peripheral T-cell lymphoma that failed standard treatment."
16256461|NCT04980677|Other|Children|Tangiball (Autism, Neurotypical group) - 20 minute play sessions with digital toy
16256462|NCT04980664|Experimental|Integrated intervention strategies|
16256463|NCT04980651|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16256464|NCT04980651|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16256465|NCT04980638|Experimental|ER004|Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor binding domain fusion protein.
16256466|NCT04980625|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16256467|NCT04980625|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16256468|NCT04980612|Experimental|Group 1|4 cohorts of 10 participants to MBPR (First 3 groups single-arm, final group of 10 randomly assigned to MBPR)
16256469|NCT04980612|Active Comparator|Group 2|The last 20 participants will be randomly assigned to MBSR or MBPR, which will results in a control group with ~10 participants undergoing MBSR
16256473|NCT04980599|Active Comparator|K56 middle dose-E5|Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10^9cfu) , for 60days
16256474|NCT04980599|Active Comparator|K56 low dose -E7|probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10^7cfu) , for 60days
16256475|NCT04980599|Active Comparator|K56 middle dose-E9|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^9cfu) ,for 60days
16256476|NCT04980599|Active Comparator|K56 high dose-E1K|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^10cfu), for 60days
16256477|NCT04980599|Active Comparator|K56 very high dose-E11|probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10^11cfu) ,for 60days
16256478|NCT04980586||Non-OSA Groups|Participants with apnea-hypopnea index < 5 events per hour of sleep.
16256479|NCT04980586||Mild OSA Group|Participants with apnea-hypopnea index > 5 < 15 events per hour of sleep.
16256480|NCT04980586||Moderate OSA group|Participants with apnea-hypopnea index > 15 < 30 events per hour of sleep.
16256481|NCT04980586||Severe OSA Group|Participants with apnea-hypopnea index > 30 events per hour of sleep.
16256482|NCT04980573|Experimental|Intervention|Participants receive a bottle of plant-based oil to inhale twice daily for 14 days.
16256483|NCT04980573|Placebo Comparator|Placebo|Participants receive a bottle of inert oil to inhale twice daily for 14 days.
16256484|NCT04980560||VAC cohort|Subjects who will take COVID-19 vaccines
16256485|NCT04980560||CON cohort|Subjects who are COVID-19 survivors
16256486|NCT04980547|Experimental|ACUMED® Scapholunate Repair System|All participants in this trial will undergo the surgical RASL procedure using the ACUMED® Scapholunate Repair System.
16256490|NCT04980521|Placebo Comparator|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
16256491|NCT04980521|Experimental|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
16256492|NCT04980508|Active Comparator|Patients that had COVID-19 and were treated as outpatients|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
16256493|NCT04980508|Active Comparator|Patients who were hospitalized due to COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
16256494|NCT04980508|Active Comparator|Patients who did not have COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
16256495|NCT04980495|Experimental|efgartigimod IV - I|Patients receiving efgartigimod IV treatment (Continuous regimen: efgartigimod 10 mg/kg q2w)
16256496|NCT04980495|Experimental|efgartigimod IV - II|Patients receiving efgartigimod IV treatment (Cyclic regimen: efgartigimod 10 mg/kg q7d for a total of 4 infusions per TP for 2 TPs with a fixed 4-week IP between each TP)
16256497|NCT04980482|Experimental|Cohort A, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:
~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
16256498|NCT04980482|Experimental|Cohort A, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:
~NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
16256499|NCT04980482|Experimental|Cohort B, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:
~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
16256500|NCT04980482|Experimental|Cohort B, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:
~NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
16256501|NCT04980469|Experimental|Vitex negundo + Zingiber officinale|Dosage: 200 mg/ Capsule;1 capsule twice daily Route: Oral
16256502|NCT04980469|Placebo Comparator|Placebo (MCC)|Dosage: 200 mg/ Capsule; 1 capsule twice daily Route: Oral
16256503|NCT04980456|Other|TOTAL30, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for nightly cleaning and disinfection.
16256504|NCT04980456|Other|Biofinity, then TOTAL30|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for nightly cleaning and disinfection.
16256505|NCT04980443|Experimental|FIT positive individuals|FIT-positive individuals of whom we will collect blood samples and who will undergo a colonoscopy after blood sampling.
16256506|NCT04980430||Primary Care and Ophthalmology clinic patients|Participants will be recruited from primary care and ophthalmology clinics in New York City
16256507|NCT04980417|Experimental|concomitant cholecystectomy|concomitant cholecystectomy with bariatric procedure
16256508|NCT04980417|Active Comparator|delayed cholecystectomy|delayed cholecystectomy
16278529|NCT04826653|Experimental|Timing suture removal_3 weeks|
16256509|NCT04980404|Experimental|Dose Escalation Inqovi|"Study will follow a standard '3+3' dose escalation design:
~Initial group of 3 participants will receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 42 day cycle/dose-limiting toxicity (DLT) period.
~Additional enrollment, dosage and study cyles will be determined by number of dose-limiting toxicity (DLT) that occur in initial group"
16256510|NCT04980404|Experimental|Recommended Phase 2 Dose Expansion (RP2S) Inqovi|Once the Recommended Phase 2 Dose Expansion (RP2S) is established, 10 additional participants will be enrolled and receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 28 day study cycle.
16256511|NCT04980391|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group receive a single dose of the RSV MAT vaccine administered intramuscularly between 24 and 36 weeks of gestation (Day 1) and are followed up until 180 days post-delivery.
16256512|NCT04980391|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group receive a single dose of placebo administered intramuscularly between 24 and 36 weeks of gestation (Day 1) and are followed up until 180 days post-delivery.
16256513|NCT04980378||Simplify Disc|Extended follow-up of IDE Subjects treated at two continuous levels with the Simplify Cervical Artificial Disc during IDE G150206
16256514|NCT04980365|Other|Mindfulness and Gratitude|Participants will be asked to use either the app Mindfulness Coach or the app Grateful daily for 10 minutes for 14 days.
16256515|NCT04980365|Other|Control|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
16256516|NCT04980339||ASO group|All participants with TGA/TBA after ASO
16256517|NCT04980326|Experimental|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2) in addition to Psychological First Aid (PFA) and care-as-usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.
~Participants allocated to the experimental arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria."
16256518|NCT04980326|Active Comparator|Psychological First Aid (PFA)|Participants allocated to the control arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.
16256519|NCT04980313|Experimental|Xenogenic collagen matrix|Volumetrically stable xenogenic collagen matrix
16256520|NCT04980313|Active Comparator|Autogenous connective tissue graft|Autogenous connective tissue graft obtained from the tuberosity area
16256521|NCT04980300|Experimental|Expanded Intervention|Virtual consultation sessions with a physical therapist, focusing on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis.
16256522|NCT04980300|Active Comparator|Brief Intervention|Web-based resources on knee osteoarthritis, including an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis.
16256523|NCT04980274||Group 1|Patients with SOFA score < 2 on admission
16256524|NCT04980274||Group 2|Patients with SOFA score equal to or > 2 on admission and who improved after 48 hours of treatment
16256525|NCT04980274||Group 3|Patients with SOFA score equal to or > 2 on admission and who did not improve after 48 hours of treatment
16256526|NCT04980261|Active Comparator|Control Group (ORIF + autograft)|The patients will receive the current gold standard to treat long bone defects.
16256527|NCT04980261|Experimental|Treatment Group (ORIF + FD BHA/Secretome composite)|The patients will receive a novel bone substitute following the ORIF procedure.
16256528|NCT04980248|Experimental|ALXN1850|Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.
16256530|NCT04980209||Ultrasonic and c-arm combination group|Ultrasound and c-arm were combined to evaluate intraoperatively conditions
16256531|NCT04980209||c-arm group|c-arm group was used to evaluate intraoperatively conditions
16256532|NCT04980196||(1) URODYNAEMICS GROUP|30 patients allocated for group (1) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed. And to urodynamic studies were performed before surgical intervention and then corrective procedures for POP had been done uroflowmetry and cystometry. All participants were followed-up with same questionnaire and clinical examination after 12 weeks post -operatively
16256533|NCT04980196||(2)NON URODYNAMICS GROUP|30 patients allocated for group (2) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed and then corrective procedures for POP had been done.All participants were followed-up with same questionnaire and clinical examination after 12 weeks post-- operatively
16256534|NCT04980183|Experimental|Arthroscopic surgical robot assisted navigation and positioning for cruciate ligament reconstruction|Patient undergoes cruciate ligament reconstruction with robot-assisted navigation and positioning under arthroscopic surgery
16256535|NCT04980183|Active Comparator|Conventional arthroscopic cruciate ligament reconstruction|The patient undergoes conventional arthroscopic cruciate ligament reconstruction
16256536|NCT04980170|Experimental|clindamycin group|Patients who take Clindamycin after Dental implants
16256537|NCT04980170|Experimental|Amoxicillin With Clavulanic Acid group|Patients who take Amoxicillin With Clavulanic Acid after Dental implants
16256539|NCT04980144|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks (28 days).
16256540|NCT04980144|Active Comparator|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 4 weeks (28 days).
16256541|NCT04980131|Experimental|Group C|Group C were received PPSF with pointed lotus-style regulator
16256542|NCT04980131|Experimental|Group B|Group B were received PPSF with Flat ended lotus root regulator
16256543|NCT04980131|No Intervention|Group A|Group A were received traditional PPSF
16256544|NCT04980118|Placebo Comparator|Control group|Individual nutritional intervention.
16256545|NCT04980118|Experimental|Experimental group|Individual nutritional intervention with two groupal sessions and physical activity.
16256546|NCT04980105|Experimental|Platelet-rich plasma arm|
16256547|NCT04980105|Active Comparator|Hyaluronic acid arm|
16256548|NCT04980105|Active Comparator|Methylprednisolone acetate arm|
16256549|NCT04980092||Post-ICU group|Observational foolow-up
16256550|NCT04980079|Active Comparator|group A -undergo primary ureteroscopy URS|Thirty children with calicular anuria will undergo primary ureteroscopy URS
16256551|NCT04980079|Active Comparator|the group B(30 patients) will undergo deferred ureteroscopy URS|group B (30) patients will be admitted to do urinary drainage through the insertion of a double-J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done
16256552|NCT04980066|Experimental|sticky bone and EDTA|treatment of gingival recession using sticky bone after root surface biomodification with EDTA
16256553|NCT04980066|Active Comparator|Sticky bone|treatment of gingival recession using sticky bone
16256554|NCT04980053|Experimental|Back Massage|"Back massage will be initiated in the first 2 hours after birth and it will be performed every 6 hours for 15 minutes until the mother is discharged from the hospital. After the mother's outfits are removed and the mother is situated in a suitable position, the back of the mother will be massaged by euphlorage, petrissage, friction methods. Then, the participants breast will be milked by hand every 3 hours and will be measured in the breast milk storage bag and delivered to the baby nurses until the 5th-7th day."
16256555|NCT04980053|Experimental|Breast Massage|Breast massage will be initiated in the first 2 hours after delivery and it will be practised every 6 hours until being discharged. After the researcher washes her hands, the participant's outfits are removed and she is situated in a sitting position, the massage will be practised on both breasts for 10 minutes by the researcher herself. After the mother's breast will be milked by hand every 3 hours and the milk obtained from the breast will be measured in the breast milk storage bag and delivered to the baby nurses.
16256556|NCT04980053|No Intervention|Control Group|No intervention will be made to the control group, standard hospital procedures will be applied and the relevant forms will be filled out. Until the mother is discharged from the hospital, the amount of milk obtained from the mother will be measured every 3 hours by the researcher.
16256557|NCT04980040||Nesina® Tablet|Participants with a diagnosis of Type 2 Diabetes who took Nesina® tablet (alogliptin), as prescribed by the physician, are observed in this study.
16256558|NCT04980027|Experimental|Insuline Glargine (U300) (Gla-300)|Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm
16256559|NCT04980014||NesinaAct® Tablet|Participants with a diagnosis of Type 2 Diabetes who took NesinaAct® tablet, a fixed dose combination of alogliptin along with pioglitazone, as prescribed by the physician, are observed in this study.
16256560|NCT04980001|Experimental|FOCUS TIC-COM arm|"Health care providers will be trained in FOCUS TIC-COM through professional development and from this group the investigators plan to recruit participants for the surveys about the training, intervention feasibility and acceptability. Health care providers will be encouraged to implement FOCUS TIC-COM will all of their pediatric patients who are overweight/obese.
~Parents / Caregivers of children who are overweight or obese will be recruited into the study after exposure to the intervention. Only those exposed to the intervention will be recruited to participate in the study which includes one survey and focus groups."
16256561|NCT04979988||Japanese patients with ALK+ NSCLC who received lorlatinib|lorlatinib as the second-line or later therapy after failure of alectinib treatment as the firstline therapy
16256562|NCT04979975|Experimental|Placebo|placebo matching UB-621
16256563|NCT04979975|Experimental|UB-621 low-dose|low-dose of UB-621
16256564|NCT04979975|Experimental|UB-621 high-dose|high-dose of UB-621
16256565|NCT04979962|Experimental|CAC Group|Inspection with computer assisted colonoscopy.
16256566|NCT04979962|No Intervention|CC Group|Inspection with conventional colonoscopy
16256569|NCT04979936|Active Comparator|early laparoscopic cholecystectomy|early laparoscopic cholecystectomy
16256570|NCT04979936|Active Comparator|percutaneous cholecystostomy|percutaneous cholecystostomy first followed by delayed laparoscopic cholecystectomy
16256571|NCT04979923|Experimental|Lidocaine group|
16256572|NCT04979923|Placebo Comparator|Salbutamol group|
16256573|NCT04979923|Active Comparator|Beclomethasone plus salbutamol|
16256574|NCT04979910|Active Comparator|Ixekizumab|Ixekizumab 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2 and 4 via subcutaneous route.
16256575|NCT04979910|Placebo Comparator|Placebo|Matching saline placebo at Week 0 (two injections), followed by one injection at Weeks 2 and 4 via subcutaneous route.
16256576|NCT04979897||Intensive care unit stay during high bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a high bed occupancy in the pandemic
16256577|NCT04979897||Intensive care unit stay during low bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a low bed occupancy in the pandemic
16256578|NCT04979884|Experimental|cyclosporine|patients will receive cyclosporine + (standard care treatment (± anticoagulant± antibiotic± antipyretic± steroid) according to Alexandria university hospitals protocol )
16256579|NCT04979884|Active Comparator|Standard of care treatment|patients will receive standard treatment (antiviral ± anticoagulant± antibiotic± antipyretic± steroid± interleukin ) according to Alexandria university hospitals protocol.
16256580|NCT04979858|No Intervention|Control Group|The subjects will choose their own mask and masking practices.
16256581|NCT04979858|Experimental|Treatment Group|The treatment group will receive and use the focal mask.
16256582|NCT04979845|Experimental|Telerehabilitation|
16256583|NCT04979845|Active Comparator|Video exercise|
16256584|NCT04979832|Experimental|Local administration of GM-CSF, fosfomycin and metronidazole in the pouch|"Local administration of 50 micrograms GM-CSF, 400 milligrams fosfomycin and 100 milligrams metronidazole in the pouch.
~In a Phase A of the trial, this will be applied as a single dose during endoscopy of the pouch. In Phase B of the trial, this will be applied as a first dose during endoscopy of the pouch, followed by 6 further daily doses for a total of 7 doses."
16256585|NCT04979819|Experimental|Multiple Sclerosis|Patients with multiple sclerosis will perform the UULEX and fill in the other mentioned parameters. Validity and reliability of the UULEX will be measured.
16256586|NCT04979806|Experimental|Cefepime-zidebactam (FEP-ZID)|
16256587|NCT04979806|Active Comparator|Meropenem|
16256588|NCT04979793|Active Comparator|Placebo|Oral placebo, 3 grams milk powder sachet, taken once daily
16256589|NCT04979793|Experimental|Daily L-citrulline|L-citrulline, 3 grams L-citrulline sachet, taken once daily
16256590|NCT04979780||Cancer patients with acute venous thromboembolism (VTE)|Cancer-associated thrombosis (CAT) patients treated with Rivaroxaban or any DOAC (Direct Oral Anticoagulants) or LMWH (Low molecular weight heparin).
16256591|NCT04979767||Sepsis|I. ≥ 50 years with ≥ 2 chronic comorbidities II. Highly suspected bacterial infection based on clinical or radiologic evidence III. ≥ 2 systemic inflammatory response syndrome (SIRS) criteria IV. Actual/anticipated admission to intensive care unit (ICU) V. Anticipated length of hospital stay ≥ 5 days
16256592|NCT04979767||Control|I. ≥ 50 years with ≥ 2 chronic comorbidities II. No suspected bacterial infection III. Actual/anticipated admission to intensive care unit (ICU) IV. Anticipated length of hospital stay ≥ 5 days
16256593|NCT04979754||RENAL TRANSPLANT RECIPIENTS|All patients with previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
16256594|NCT04979754||NON RENAL TRANSPLANT RECIPIENTS|All patients without previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
16256595|NCT04979715|Experimental|intervention group|"From the first postoperative day, with the approval of the surgeon performing the operation, the postoperative exercise program will be started once a day under the supervision of a physiotherapist during the stay of the participants in the hospital.
~At the same time, participants will be directed to moderate intensity aerobic exercise (walking, jogging…) for 150 min/week. Information will be given on the importance of physical activity and increasing the level of physical activity. In addition, a brochure containing explanatory information about the postoperative physiotherapy program after breast surgery will be given to the participants."
16256596|NCT04979715|Active Comparator|control group|The patients in the control group will be informed about the postoperative physiotherapy program and patient education will be provided by the physiotherapist before the operation. Within the knowledge and approval of the surgeon performing the operation, preoperatively, respiratory control, diaphragmatic breathing, relaxation exercises, passive-active assistive-active range of motion exercises are shown by the physiotherapist, and patient education is provided with information about possible postoperative complications and what needs to be considered. will be given.
16256597|NCT04979702|Active Comparator|Active Control|Patients will have access to our online exercise resources throughout the 12-week intervention.
16256598|NCT04979702|Experimental|Experimental: mHealth technology assisted exercise counselling (mHealth)|Participants will complete a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
16256599|NCT04979689|Experimental|Intensive physical therapy|Intensive session
16256600|NCT04979689|Other|Non intensive physical therapy|Non intensive session
16256601|NCT04979676|Experimental|Cognitive Therapy|Experimental group subjected to active individual psychotherapy based on helping adolescents adopt a more realistic perspective on social events, by focusing on clues from those events and acting based on the social information thus gathered. Assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
16256602|NCT04979676|Experimental|Compassion-focused Therapy|Experimental group subjected to active individual psychotherapy based on developing compassionate mind skills, which in turn sustain exposing and acting in social events with a compassionate attitude towards oneself and others (instead of focusing on a critical and threat-based attitude). Assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
16256603|NCT04979676|Experimental|Acceptance and Commitment Therapy|Experimental group subjected to active individual psychotherapy based on developing skills for acceptance, defusing, and focusing on the present moments, which in turn sustain acting in social events in line with ones valued actions instead of prioritizing the avoidance of negative internal experiences). Assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
16256604|NCT04979676|Placebo Comparator|Waiting-list control|Group of participants with a main dignosis os social anxiety disorder not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
16256605|NCT04979676|Placebo Comparator|Normative control|Group of participants without any psychiatric diagnosis not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
16256606|NCT04979663|Experimental|experimental group|Combination of Gemox, Donafenib and Tislelizumab
16256607|NCT04979650|Active Comparator|The intervention group|The intervention group will receive 1 gram of methylprednisolone succinate within 500 ccs of normal saline within 5 hours.
16256608|NCT04979650|Placebo Comparator|The control group|The control group will receive 500 g of normal saline without methylprednisolone succinate.
16256609|NCT04979611|Other|Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. PET/CT imaging will be performed at 30-60 min post-injection.Visual and semiquantitative method will be used to assess the PET/CT images.
16256610|NCT04979598||Acute unilateral vestibular deafferentiation|Patients suffering from acute dizziness due to a unilateral vestibular deafferentiation.
16256611|NCT04979585|Experimental|Experimental|Patients with untreated advanced mucosal melanoma
16256612|NCT04979572|Experimental|Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg|Single dose of TS-172 or placebo before breakfast
16256613|NCT04979572|Experimental|Part B (multiple dose) : Step 5: TS-172 90 mg|Multiple dose of TS-172 or placebo before breakfast and dinner
16256614|NCT04979559|Experimental|mHealth apps|The participants in this arm will receive information regarding mobile health applications used for screening and early intervention of the prediabetic states.
16256615|NCT04979559|Active Comparator|Standard care|The participant in this arm will receive regular practice or standard care of screening and early intervention of prediabetic state.
16256616|NCT04979546|Experimental|Intensive PROMs Intervention Arm|The intervention group will be asked to complete PROM questionnaires at baseline, 6 months, and 12 months via an online web-based delivery system. The treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group. Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
16256617|NCT04979546|Active Comparator|Control Arm|The control group will be asked to complete PROM questionnaires at baseline and 12 months via an online web-based delivery system. The treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group (unless critical values are reached on questionnaires - see below). Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
16256618|NCT04979533|Experimental|Oxygen Insufflation|Oxygen insufflation via oxygen tubing at 15 L/min
16256619|NCT04979520|Experimental|Brodalumab treated moderate-to-severe HS patients|Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
16256620|NCT04979507|Experimental|Experimental Group|
16256621|NCT04979507|Active Comparator|Control group|
16256622|NCT04979494||Post cardiac surgery|Patients admitted to ICU right after cardiac surgery with or without cardiopulmonary bypass, usually with cardiac shock.
16256623|NCT04979494||Sepsis and septic shock|Patients admitted to ICU with the major complication of sepsis or septic shock.
16256624|NCT04979494||Control|Patients admitted to ICU for post-surgery monitor in case of complications due to their baseline health condition(e.g. coronary artery disease, hypertension and so on), but without severe shock.
16256625|NCT04979481|Experimental|BRAVE Intervention Arm|The BRAVE campaign included 3-5 text messages per week, including 1 role model video per week and a related image.
16256626|NCT04979481|Active Comparator|STEM Control Arm|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image.
16256627|NCT04979468|Other|ARM A|Participants in Arm A will be randomized to switch to DTG/3TC 50/300 mg QD until week 48 (early switch).
16256628|NCT04979468|Other|ARM B|Participants in Arm B will continue the INSTI-based ART regimen until week 48, and then will be switched to DTG/3TC through week 96 (delayed switch).
16256629|NCT04979455||Exertional heat illness|Participants who experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
16256630|NCT04979455||Control|Participants who do not experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
16256633|NCT04979429|Experimental|PePS|4 sessions of telephone CBT-based pain self-management in addition to standard perioperative care.
16256634|NCT04979429|No Intervention|Standard Care|Standard perioperative care.
16256635|NCT04979416|No Intervention|Control|No video message
16256636|NCT04979416|Experimental|Video message 1|
16256637|NCT04979416|Experimental|Video message 2|
16256638|NCT04979416|Experimental|Video message 3|
16256639|NCT04979403|Active Comparator|Usual care in physiotherapy|The usual care group will receive interventions recommended by clinical guidelines: education on the nature of LBP, advice to stay active and to continue usual activities, specific exercise programs combined with orthopedic manual therapy.
16256725|NCT04978779|Experimental|Dose expansion of VIP152 Expansion|Investigating VIP152 in a dose expansion cohort in patients with CLL and Richter Syndrome.
16256726|NCT04978766|Experimental|Interactive Book Reading Group|Participants in this arm will take baseline measures, will receive the intervention and will take posttest measures.
16256640|NCT04979403|Experimental|Psychologically-informed physiotherapy intervention|The psychologically-informed physiotherapy group will receive the control intervention enhanced with specific interventions targeting psychosocial factors (e.g., positive reinforcement, mindfulness-based stress reduction, diaphragmatic breathing, graded exposure). Most of these techniques are efficient to mitigate the impact of psychological factors such as anxiety and fear of movement. To standardize the psychologically-informed physiotherapy approach, physiotherapists will receive a two-day training course by a physiotherapist expert with this approach in chronic pain conditions (Alain Gaumond).
16256641|NCT04979390|Experimental|Treatment group|
16256642|NCT04979377||Adult premenopausal women with type 1 diabetes mellitus|One-hundred and fifty women aged from 18 to 45 years old consecutively recruited from a type 1 diabetes clinic at a tertiary hospital of Madrid, Spain
16256643|NCT04979351|Experimental|Abdominal Massage Group|Abdominal massage for 15 minutes twice a day application.
16256644|NCT04979351|No Intervention|Placebo Group|Abdominal massage was not applied.
16256645|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #1|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points:
~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)
~Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine)
~Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine)
~Ultrasound guided Continuous Infraclavicular Brachial Plexus Block
~Ultrasound guided Continuous Femoral Nerve Block
~Pecs I & II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)"
16256646|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #2|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points:
~Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine)
~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
16256647|NCT04979338|Active Comparator|Surgery-specific general anesthetic + local anesthetic at incision site|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points:
~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)
~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
16256648|NCT04979299|Experimental|wheelchair group|"Patients included in the  wheelchair  group will be asked to sit in a wheelchair during the interview;"
16256649|NCT04979299|No Intervention|Control group|Patients included in the control group will sit in a regular chair during the interview.
16256650|NCT04979286|Experimental|Kinesiotaping Group|Y strip kinesiotaping will be applied to both the gastrocnemius muscles with approximately 20% tension.
16256651|NCT04979286|Placebo Comparator|Placebo Group|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
16256652|NCT04979273|Active Comparator|Control Group|Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip
16256653|NCT04979273|Experimental|Dextrose group|Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray
16256654|NCT04979247|Experimental|Oliceridine|Patients receive Oliceridine for pain control.
16256655|NCT04979234|Experimental|Interventional|Endoscopic gastric reduction
16256656|NCT04979221|Experimental|Cyproheptadine and usual care|"Patients allocated to the intervention group will receive cyproheptadine within 6 hours after randomization, at a dose of 8mg every 8 hours for 10 days.
~Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution."
16256657|NCT04979221|No Intervention|Usual care|Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.
16256658|NCT04979208||Acute myocardial infarction (AMI) cohort|Adult patients with recent acute myocardial infarction admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis all recent AMI patients less than 24 hours old diagnosed by emergency physicians on the basis of suggestive clinical symptoms and electrocardiogram (ECG) criteria, cared in the 30 emergency units and 19 mobil intensive care unit, with a coronary angiography or a percutaneous coronary intervention (PCI) realized in the 11 cathlabs in Aquitaine
16256659|NCT04979208||Stroke cohort|Adult patients with recent stroke admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis recent ischemic or hemorragic stroke patients with brain imaging managed in one of the 14 participating hospitals in Aquitaine (7 stroke units and 7 primary care centers).
16256660|NCT04979195||Group 1|patients with stable renal function.
16256661|NCT04979195||Group 2|Patients who developed AKI.
16256662|NCT04979169|No Intervention|Non-adherent control|Subjects who are determined to be non-adherent to screening guidelines and are assigned to usual treatment via randomization in REDCap.
16256663|NCT04979169|Experimental|Non-adherent intervention|Subjects who are determined to be non-adherent to screening guidelines and are assigned to intervention treatment (text messaging) via randomization in REDCap.
16256664|NCT04979156||SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
16256665|NCT04979143|Other|HoLVP with the use of Moses 2.0 technology|HoLVP with the use of Moses 2.0 technology
16256666|NCT04979143|Other|HoLVP without the use of Moses 2.0 technology|HoLVP without the use of Moses 2.0 technology
16256727|NCT04978766|No Intervention|Control Group|Participants in this arm will take baseline and posttest measures. For ethical purposes, they will receive the intervention after posttest measures are taken.
16256856|NCT04977882|Experimental|Abdominal drainage|19 Fr abdominal drainage placed intraoperatevely in right paracolic gutter
16256667|NCT04979130|Experimental|SC semaglutide|Participants receive a once weekly, subcutaneous, Semaglutide injection for 16 weeks in addition to the participants background metformin monotherapy. The participants in this arm will begin at a 0.25 mg dose during the randomization visit, at week 4 this will be escalated to a 0.5 mg dose and at week 8 it will be escalated again to a 1.0 mg dose if tolerable by the participant. If the participant cannot tolerate the 0.25 mg dose at randomization or the 0.5 mg dose at week 4 they will be withdrawn from the study.
16256668|NCT04979130|Placebo Comparator|Placebo|Participants in this arm will be given a once weekly, subcutaneous, placebo injection matching the Semaglutide experimental arm in addition to their background metformin monotherapy.
16256669|NCT04979117||Participants with plantar fasciitis|"Participants with the diagnose of plantar fasciitis; typical anamnesis (exacerbating pain by the first steps in the morning or after rest and with prolonged standing).
~The emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician.
~Thickening of the plantar fascia greater than 4 mm in ultrasonographic evaluation. measurement"
16256670|NCT04979117||Volunteers who has not foot complaints.|Volunteers who were not diagnosed with Plantar Fasciitis and without foot or heel pain when taking the first steps in the morning, with plantar fascia thickness less than 4 mm, painless, symptom-free and which had no additional rheumatic disease.
16256671|NCT04979104|Experimental|SL Cementless|Since the trial is not comparative, the only arm implies the use of the investigational device (SL cementless femoral stem)
16256672|NCT04979078|Experimental|Experimental group|The experimental group receives 9 sessions of photobiomodulation therapy (3x/week for 3 weeks).
16256673|NCT04979065|Experimental|Experimental Group|Probiotics and Vitamin D
16256674|NCT04979065|Placebo Comparator|Control Group|Placebo and placebo
16256675|NCT04979052|Active Comparator|Interferon-Gamma|Recombinant Interferon-Gamma 1b combined with standard therapy
16256676|NCT04979052|No Intervention|Standard of care|Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
16256677|NCT04979039||normal pregnancy|Adult pregnant women scheduled for cesarean section under spinal anesthesia
16256678|NCT04979026|No Intervention|active ankle pumping without any reminders|In group 1, active ankle pumping exercise for the operative limb was performed without any reminder during hospitalization and at home after being discharged.
16256679|NCT04979026|Active Comparator|intermittent pneumatic compression|In group 2, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
16256680|NCT04979026|Experimental|active ankle pumping with a regular watch alarm|In group 3, in addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge. The watch was continuously used until the 14th day when the patients returned to the hospital for examination.
16256681|NCT04979013|Experimental|Smoking Abstinence|14-day Smoking Abstinence
16256682|NCT04979000||Cases|Patients with a confirmed diagnosis of sinonasal cancer.
16256683|NCT04979000||Controls|Patients being seen for benign conditions at Johns Hopkins.
16256684|NCT04978974|Experimental|Patients with type 2 Diabetes mellitus and Hypertension|patients with type 2 diabetes mellitus and hypertension were selected by using purposive sampling technique to apply stress management program
16256685|NCT04978961|Experimental|Focused Acceptance and Commitment Therapy (FACT)|"Focused Acceptance & Commitment Therapy (FACT): FACT is a brief type of cognitive behavioral therapy that helps patients reduce disability through increased acceptance, reconnection with values, and reduced unhelpful control/coping strategies. Patients randomized to the intervention group received FACT per the study manual, delivered by an integrated Behavioral Health Consultant (BHC). Patients had one individual visit (30 minutes) and three consecutive weekly group visits (one hour) followed by a booster visit two months later. These classes (group visits) were rolling, not cohort-driven, meaning new and returning patients will be attending together. After the individual BHC visit and each class, patients had behavioral homework to complete."
16256686|NCT04978961|Active Comparator|Enhanced Treatment as Usual (ETAU)|"Patients randomized to the Enhanced-Treatment As Usual (ETAU) group received enhancement of usual primary care via 1-page (2-sided) educational handouts on four topic areas: Sleep, Pacing, Relaxation and Goal Setting. All topics have an evidence base in standard Cognitive Behavioral Therapy treatment of pain. One handout per assessment visit was given to each patient. Patients will continue to see their primary care clinicians and have access to all routine clinical services throughout the study."
16256687|NCT04978948||Myasthénie|Blood samples will be collected
16256688|NCT04978948||Myopathie inflammatoire (Myosite)|Blood samples will be collected
16256689|NCT04978948||Neuropathie autoimmune|Blood samples will be collected
16256690|NCT04978948||Néphropathies autoimmunes|Blood samples will be collected
16256691|NCT04978948||Hépatite auto-immune|Blood samples will be collected
16256692|NCT04978948||Pancréatite auto-immune|Blood samples will be collected
16256693|NCT04978948||Purpura Thrombopénique Immunologique|Blood samples will be collected
16256694|NCT04978948||Dermatose bulleuse|Blood samples will be collected
16256695|NCT04978948||Thyroïdite autoimmune|Blood samples will be collected
16256696|NCT04978948||Sclérose en plaque|Blood samples will be collected
16256697|NCT04978948||Sclérose latérale amyotrophique|Blood samples will be collected
16256698|NCT04978948||Polyarthrite Rhumatoïde|Blood samples will be collected
16256699|NCT04978948||Spondylarthrite axiale|Blood samples will be collected
16256700|NCT04978948||controls|Patients without autoimune desease* Blood samples will be collected
16256701|NCT04978935|No Intervention|Control group|In the control group (n=40), interventions for the position, mobilization and spirometry of the patient are applied to all patients in the clinic where the study was conducted. However, these applications are not made in accordance with a certain order and protocol. Shoulder exercises are not routinely taught to patients. In the study, no additional application will be made to the control group other than the routine treatment and care practice of the clinic.
16256728|NCT04978753|Experimental|treatment|Anlotinib (12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week) combine with Almonertinib (110mg, orally once a day)
16256702|NCT04978935|Experimental|Intervention|Care protocol will be applied to the study group (n=40), starting from the first day spent in the intensive care unit.Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises. The bed head of the patient will be raised 30°-45° in line with the application steps. In the study, the patient's in-bed and out-of-bed mobilization will be provided by considering the mobilization application steps, and the patient will be asked to stay out of bed for two hours on the 0 th day after surgery. The patient will be asked to stay out of bed for six hours from the first postoperative day until discharge. After the thoracotomy, the conditions that the doctor considers as complications will be recorded.The time of chest tube removal and the day of discharge will be recorded. In the study, the use of spirometry and shoulder exercises will be carried out by taking into account the implementation steps of the care protocol.
16256703|NCT04978922|Experimental|TelEPOC with Machine Learning (ML)|"Hospital with an active telemonitoring programme of readmitted COPD patients (TelEPOC) after application of an artificial intelligence system (Machine Learning: ML).
~* TelEPOC: The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own."
16256704|NCT04978922|No Intervention|TelEPOC without ML|Hospitals with an active telemonitoring programme of readmitted COPD patients (TelEPOC) without the application of an artificial intelligence system (Machine Learning: ML).
16256705|NCT04978896|Experimental|Intervention group: Stress-coping Program|Participants will complete an 8-day self-guided programme on stress-coping delivered via a mobile-phone application with daily exercises guided by cognitive-behavioural principles.
16256706|NCT04978896|Active Comparator|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile-phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
16256707|NCT04978883||pSS-ILD|diagnosis of pSS-ILD was based on abnormal HRCT and PFTs
16256708|NCT04978883||pSS non-ILD|pSS patients after exclusion of pSS-ILD and concomitant pulmonary diseases were considered as pSS non-ILD
16256709|NCT04978870||1 - Validation|Group 1 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison. A subgroup of patients will receive an additional delirium screening using the CAM-PACU. This screening will be performed by another operator blinded for the results from the initial delirium screening.
16256710|NCT04978870||2 - Cognition|"Group 2 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison.
~This group will undergo additional assessment of preoperative and postoperative cognitive function as well as a POD screening using the CAM-ICU starting at postoperative day 1 until discharge from hospital but no longer than postoperative day 5."
16256711|NCT04978857|Experimental|Virtual reality headset|
16256712|NCT04978844|Active Comparator|I-WotCH|I-WotCH- Inner World of the Child- is a novel innovative therapy developed in our clinic. The therapy is based on modern concepts of early childhood developments emphasizing themes related to emotional regulation, processes of socialization, observational research on interpersonal and behavior as well as recent developments on affiliative neuroscience. More specifically, the therapist, through play, identifies themes and emotions the child is preoccupied with. The therapist then assists the child in naming these emotions, validating them, exploring their nature and consequences. The therapists discussed ways of managing and self-regulating these emotions. These methods would include behavioral techniques, the ability to enlist help from others and reframing. In addition, the therapy will address dealing with complexed emotions and enhancing symbolic play and joyfulness.
16256713|NCT04978844|Active Comparator|Dyadic therapy|"Child parent psychotherapy: CPP consists of joint parent-child sessions that focus on the child's free play and spontaneous parent-child interaction. The CPP therapist acts to translate the developmental and emotional meaning of a child's emotions and actions to the parent. The target of treatment includes the both the child's and the caregiver's adaptive conflicts, including a parent's difficulty in providing sensitive and developmentally appropriate care. CPP fosters parent-child activities that foster mutual pleasure, interpersonal trust and understanding. In the purpose of this study only mothers will be included."
16256714|NCT04978844|No Intervention|Control|Healthy control.
16256715|NCT04978831|Experimental|Respiratory exercise device group|
16256716|NCT04978831|Experimental|Reading aloud group|
16256717|NCT04978831|No Intervention|Control group|
16256718|NCT04978818|Active Comparator|Vaxelis|165 infants will be randomized to the Vaxelis group, which is licensed for primary vaccination at 2, 4 and 6 months of age.
16256719|NCT04978818|Active Comparator|PedvaxHIB arm|165 infants will be randomized to the PedvaxHIB group, which is licensed for primary vaccination at 2 and 4 months of age.
16256720|NCT04978805|Experimental|Progressive Relaxation Exercise|A total of 56 sessions of progressive relaxation were performed, 7 days a week for 8 weeks. Each session is set as fifty minutes
16256721|NCT04978805|No Intervention|Control group|Routine maintenance will be applied
16256722|NCT04978792|Experimental|Self-compassion Intervention|The intervention will include 14 self-compassion exercises completed over a 3-week period. The intervention will include methods of psychoeducation, meditation, and self-compassion exercises similar to Beshai et al.'s (2020) self-compassion-based intervention. The psychoeducation will focus on self-compassion, the meditations will be kindness and loving meditations and self-compassion breaks. The self-compassion exercises will be based on the writing exercises available on Neff's self-compassion website.
16256723|NCT04978792|Active Comparator|Control Group|The active control will also include 14 exercises completed over a 3-week period. The 14 exercises will comprise of a psychoeducation video, writing exercises, video/audio-guided relaxation, and journal entries. The same psychoeducation video used in the intervention will be shown to participants, however, the other exercises will be altered to focus on factual information and not focused on self-compassion. The exercises will be matched to the self-compassion exercise so that similar exercises are completed in parallel time with the intervention.
16256724|NCT04978779|Experimental|Dose escalation of VIP152 Escalation|Investigating VIP152 in a dose escalation cohort in patients with CLL
16256729|NCT04978740|Experimental|Participants affected by cutaneous and systemic mastocytosis|Participants affected by cutaneous and systemic mastocytosis with or without eye disabilities
16256730|NCT04978727|Experimental|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.
~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.
~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
16256731|NCT04978727|Experimental|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.
~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.
~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
16256732|NCT04978727|Experimental|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.
~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.
~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
16256733|NCT04978714||Women with cystocele|All women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
16256734|NCT04978688|Experimental|Relugolix|Participants received relugolix 40 milligrams (mg) alone for 6 weeks.
16256735|NCT04978688|Experimental|Relugolix + E2/NETA|Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.
16256736|NCT04978675|Experimental|Diagnostic (F-18 rhPSMA-7.3, PET/MRI)|Patients receive F-18 rhPSMA-7.3 IV and after approximately 60 minutes of uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3 disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after the second dose of standard hormonal therapy.
16256737|NCT04978649|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
16256738|NCT04978649|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
16256739|NCT04978636|Active Comparator|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The investigator will investigate the effect of continuous low tidal volume ventilation with hyperoxia avoidance (using FiO2 of 0.21) on PPCs and 30-day mortality compared to low-tidal volume ventilation (with FiO2 of 0.21) or apnea during CPB.
16256740|NCT04978636|Active Comparator|Continuous low tidal volume ventilation with using FiO2 of 1.0|The investigator will investigate the effect of low tidal volume lung ventilation with hyperoxia avoidance (FiO2 of 0.21) on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or apnea during CPB.
16256741|NCT04978636|Active Comparator|Apnea|The investigator will investigate the effect of apnea during on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or hyperoxia avoidance (FiO2 of 0.21) during CPB.
16256742|NCT04978623||Patient with CIDP|CIDP, is an acquired chronic inflammatory neuropathy characterised by : progressive symmetrical weakness of the proximal and to a lesser extent distal muscles of the lower and/or upper limbs, altered sensitivity and a decrease/abolition of the osteotendinous reflexes. The condition can be relapsing (30% of cases), chronically progressive (60%), or monophasically with total subsequent recovery (10%). Cranial nerve involvement is possible (5-30% of cases). Neuropathic pain as well as respiratory muscle and sub-clinical central nervous system involvement are described.
16256743|NCT04978623||Patient with MMNCB|Patients with MMNCB are at the crossroads between chronic demyelinating neuropathies and motor neuron diseases, the latter for which they constitute a differential diagnosis. The disease usually presents asymmetrically and affects the upper limbs more frequently. The course of the disease is unpredictable, and may be limited to one or two motor nerves or progress to other motor nerves in the contralateral upper limb and possibly the lower limbs. In all cases, the motor deficit is asymmetrical, multi-truncular in distribution, and is usually accompanied by cramps and fasciculations, and eventually by amyotrophy. Osteotendinous reflexes are usually diminished or abolished in the affected areas, but they may also be preserved in the initial attacks. There is no sensory deficit, although some patients occasionally present with paresthesias, and exceptionally with damage to the cranial nerves (especially CN XII).
16256744|NCT04978623||Patient with Anti-MAG|Anti-MAG is a demyelinating neuropathy characterized clinically by a chronic progressive distal and symmetrical predominantly sensory involvement. This neuropathy belongs to the group of symmetrical acquired demyelinating neuropathies (Distal Acquired Demyelinating Neuropathy (DADS)) which is distinguished from PIDC by: 1. an essentially distal and rather sensitive clinical involvement (unlike PIDC which is proximal and distal with predominantily motor involvement); 2. a strong association with a monoclonal gammopathy of the IgM type (67% of DADS vs 22% of PIDC according to Katz et al, 3. a poor therapeutic response to first line of immunosuppressive drugs (in contrast to PIDC which generally responds well). Certain electrophysiological parameters, such as the demonstration of demyelinating damage with accentuated slowing of distal nerve conduction, make it possible to distinguish anti-MAG neuropathy from CIDP.
16256745|NCT04978623||Patient with L-S|Lewis-Sumner syndrome is an acquired demyelinating polyradiculoneuritis characterised by distal asymmetric upper and lower limb weakness and motor dysfunction that develops in adulthood. It is considered a variant of chronic inflammatory demyelinating polyradiculoneuritis. It has a prevalence of 1-9 per 1,000,000. The diagnosis is made with electroneuromyography (ENMG) which shows marked and persistent conduction blocks, in at least two nerves, having an asymmetric topography, mainly affecting the upper limb, outside the usual areas of compression. Lower limb blocks are much rarer (anterior tibial nerve), and are always located below the fibular neck.
16256746|NCT04978610|Experimental|Intervention (Immediate)|Participants in the intervention group will begin their 6-week vACT sessions first and complete baseline, the weekly surveys during intervention, post, one month follow-up, and three month follow-up.
16256747|NCT04978610|Other|Control (Waitlist)|Upon the intervention group's completion of the 6-week long vACT, the control group will then enroll into their own 6-week long ACT intervention. The research protocol for the second 6-week long ACT intervention will mirror the protocol with the original 6-week long ACT intervention, except for one change: participants will NOT complete an additional baseline questionnaire prior to starting the 6-week ACT therapy group. The rest of the protocol remains the same. Namely, before each session, each participant will be required to fill out a short survey on their stress and pain throughout previous week. At the conclusion of the final session, participants will follow the complete post-intervention battery of surveys, which mirrors the baseline measures plus the inclusion of satisfaction surveys assessing the effectiveness of the virtual therapy intervention. Participants will complete the post-intervention follow up battery of questionnaires at 1 and 3 months post-intervention.
16256748|NCT04978597|Experimental|Opicapone|OPC will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
16256749|NCT04978597|Placebo Comparator|Matching placebo|Matching placebo will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
16256750|NCT04978584|Experimental|Treatment (uLTRA, CHOP)|"COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr"
16256751|NCT04978571|Experimental|Active Neurostim Device|Patients in this group will receive the active devices for the initial 4 study weeks.
16256752|NCT04978571|Sham Comparator|Sham Neurostim Device|Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
16256753|NCT04978545|Experimental|calciumhydroxide|Participants received calciumhydroxide as an intracanal medicament for a one week period
16256754|NCT04978545|Experimental|chlorhexidine|Participants received chlorhexidine gel as an intracanal medicament for a one week period
16256755|NCT04978532|Experimental|Guided Imagery Group|One minute before venipuncture and during venipuncture, the children in the guided imagery group listened to a voice recording prepared in a studio. This voice recording named 'Stroll in the Forest' helped the children to imagine that they are strolling in a forest and guided them.
16256756|NCT04978532|Other|Control Group|No intervention was performed to reduce pain in the control group.
16256757|NCT04978519|Experimental|Cryotherapy|Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
16256758|NCT04978506|Experimental|BI 1569912 MRD: treatment group 1|Multiple rising dose (MRD) part
16256759|NCT04978506|Experimental|BI 1569912 POSO treatment group|Posology part (optional)
16256760|NCT04978506|Placebo Comparator|Placebo|
16256761|NCT04978506|Experimental|BI 1569912 MRD: treatment group 2|Multiple rising dose (MRD) part
16256762|NCT04978506|Experimental|BI 1569912 MRD: treatment group 3|Multiple rising dose (MRD) part
16256763|NCT04978506|Experimental|BI 1569912 MRD: treatment group 4|Multiple rising dose (MRD) part
16256764|NCT04978493|Experimental|BI 706321 + ustekinumab|
16256765|NCT04978493|Placebo Comparator|Placebo + ustekinumab|
16256767|NCT04978467|Experimental|single arm|All participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
16256776|NCT04978441||Type 1 diabetes mellitus (T1DM)|"Males or females above 18 years old
~Patients with a prior medical history diagnosis of T1DM
~Patients who are using a continuous glucose monitor (CGM or FGM)"
16256777|NCT04978428|Experimental|Epidiolex|Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)
16256778|NCT04978415|Experimental|subtenon's block|we use the subtenon cannula to inject the local anesthetic mixture
16256779|NCT04978415|Experimental|peribulbar block|we use the usual 25G sharp needle to inject the local anesthetic mixture
16256780|NCT04978376|Experimental|Time restricted eating|ad-libitum eating between 12:00-20:00
16256781|NCT04978376|Experimental|TRE with endurance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised endurance exercise per week
16256782|NCT04978376|Experimental|TRE with resistance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised resistance training per week
16256783|NCT04978376|No Intervention|Control|no change in diet or physical activity
16256784|NCT04978363|No Intervention|Arm 1. NONE|Participants will be tested while wearing no boot and no assistive device.
16256785|NCT04978363|Experimental|Arm 2. BOOT|The first intervention condition tested is a walking boot only on the subject's right lower extremity.
16256786|NCT04978363|Experimental|Arm 3. HFC+BOOT|The second intervention condition tested is a Hands Free Crutch (HFC) with the walking boot, both worn on the subject's right lower extremity.
16256787|NCT04978363|Experimental|Arm 4. SAC+BOOT|The third intervention condition tested is standard axillary crutches (SAC) with the walking boot worn in non-weight bearing on the subject's right lower extremity.
16256788|NCT04978363|Experimental|Arm 5. HFC|The fourth intervention condition tested is the Hands Free Crutch worn on the subject's right lower extremity without the walking boot.
16256789|NCT04978363|Experimental|Arm 6. SAC|The fifth and last intervention condition tested is standard axillary crutches with the subject non-weight bearing on the right lower extremity without the walking boot.
16256790|NCT04978350|Experimental|Educational Workbook Arm|Participants in the Educational Workbook Arm will receive an electronic PDF version of an educational workbook via email on cascade screening in families with Lynch Syndrome. Genetic counselors will introduce the workbook to enrolled patients with Lynch Syndrome. Patient participants will use the activities and information in the workbook to communicate about Lynch Syndrome with family members.
16256791|NCT04978337|Experimental|Treatment A: Rilematovir|Participants will receive oral dose of rilematovir 250 milligrams (mg), twice daily (bid) for 7 days.
16256792|NCT04978337|Placebo Comparator|Treatment B: Placebo|Participants will receive oral dose of placebo matching to rilematovir, bid for 7 days.
16256793|NCT04978324|Experimental|Autogenous Growth Factors Left Side|5-8mm pockets on the left side of the mouth will receive insertion of small treatment after deep cleaning. The right side of the mouth will receive deep cleaning only, the standard of care.
16256794|NCT04978324|Experimental|Autogenous Growth Factors Right Side|5-8mm pockets on the right side of the mouth will receive insertion of small treatment after deep cleaning. The left side of the mouth will receive deep cleaning only, the standard of care.
16256795|NCT04978311|Experimental|Mirror therapy (MT) priming with task-specific training|
16256796|NCT04978311|Active Comparator|Mirror therapy priming with impairment-oriented training|
16256797|NCT04978311|Active Comparator|Control therapy|
16256803|NCT04978285||Postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. Anaemia will be defined according to the World Health Organisation definition (males Hb <130 g/L, and female Hb <120 g/L).
16256804|NCT04978285||No postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. No anaemia will be defined according to the World Health Organisation definition (males Hb ≥130 g/L, and females Hb ≥120 g/L).
16256805|NCT04978272|Active Comparator|IPTc DP 1 year|DP given from 8 weeks to 52 weeks of age; DP placebo given from 52 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
16256806|NCT04978272|Active Comparator|IPTc DP 2 years|DP given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
16256807|NCT04978272|Placebo Comparator|No IPTc|DP placebo given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
16256808|NCT04978259|Experimental|Standard of care plus remdesivir|Local standard of care plus daily remdesivir infusion for up to 10 days (or until discharge)
16256809|NCT04978259|No Intervention|Standard of care|Local standard of care
16256810|NCT04978246||Study Group|The study group consists of 50 individuals aged 18-50 years who have received a positive COVID-19 RT-PCR test in the past 60 days.
16256811|NCT04978246||Control Group|The control group consists of 50 healthy individuals aged 18-50 years who have not had COVID-19.
16256812|NCT04978233||MUHC COVID-19 patients|COVID-19 infected patients, newly diagnosed at the RI-MUHC
16256813|NCT04978207|Experimental|Multilevel, religiously-culturally tailored COVID-19 testing and linkage to care|Church-based COVID19 promoted with a religiously-culturally tailored Faithful Response COVID19 Toolkit delivered by church health workers (trained in an enhanced communication style) through multilevel church outlets (e.g., sermon guide, responsive reading, church bulletin inserts, automated text messages) and linkage to care delivered by community health workers who also conduct contact tracing; inclusive of 2 church-based COVID-19 testing events at each participating site.
16256814|NCT04978207|Active Comparator|Standard COVID19 information (non-tailored) attention control arm|Standard COVID-19 information that has not been tailored delivered by trained church health workers via a toolkit; inclusive of 2 church-based COVID19 testing evens at each participating site.
16256815|NCT04978194|Experimental|Online group|"Online group: online university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included:
~9- video capsules (one per week)
~An exchange room on each video on a private discord group"
16256816|NCT04978194|Experimental|Hybrid group|"Hybrid group: hybrid university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included: 10 lessons of 2 hours including
~The viewing of the videos
~A time of exchange between students, and with the teacher"
16256817|NCT04978194|No Intervention|Control group|Control group: No intervention, only two measurement times of 9 weeks apart. Nothing has changed.
16256818|NCT04978168|Experimental|Implementation Core|During baseline Exploration, staff organizational surveys are collected. During Preparation, staff focus groups conduct needs assessment with system mapping of linkage points for screening, assessment, and referral, and the agencies/staff involved in these activities. During Implementation, sites use facilitated local change teams (LCT) provided with a core set implementation strategies to facilitate linkages between probation agencies and local community treatment providers. The LCTs identify barriers to change, approaches to overcome barriers, do goal selection using SMART (specific, measurable, achievable, relevant, timely) goals and evidence for medications, address stigma, and clarify needs/expectations/roles of probation officers and treatment providers, then choose and implement goals and strategies. Sustainability Phase: Facilitators work with LCTs for 12 months using a written action plan based on goal selection.
16256819|NCT04978168|Experimental|Randomized Trial of Peer Support Specialist Model|After Core implementation is complete, half of adult participants in probation who consent will be randomly assigned to a Peer Support Specialist (PSS) condition. PSS are assigned to adults diagnosed with OUD within 6 months of entry into probation, in addition to treatment as usual. PSS establish linkages to community providers (medical, mental health, substance use treatment); educate about recovery support services, transportation assistance, MOUD; provide experiential, non-clinical support to individuals with SUD; share skills, offer support for setting goals and navigating the recovery process); and provide referrals and support for treatment, housing, employment, drug court, and probation.
16256820|NCT04978168|Active Comparator|Randomized to Treatment as Usual|After Core Implementation is complete, half of adult participants in probation who consent will be randomly assigned to continue with usual care.
16256821|NCT04978155||Echo group|All the patients (n=90) who had an AVF creation with preoperative venous identification by the surgeon at CHU de TOULOUSE (echo group).
16256822|NCT04978155||Control|All the patients (n=93) who had a native AVF placed during the year 2019 without having received immediate preoperative ultrasound and therefore there was no alteration in the surgical project in relation to that planned at the time of the consultation
16256823|NCT04978142|Experimental|Active|Active tDCS stimulation at 2 mA for 20 minutes, with a 10 seconds of ramp-up and 10 seconds of ramp-down time as used in previous tinnitus studies. The stimulation will be delivered via two rubber electrodes attached using a layer of conductive paste (35 cm2). The anode will be placed over the right dlPFC and cathode over the left dlPFC).
16256824|NCT04978142|Sham Comparator|Sham|Placebo stimulation is performed using the same current intensity, but only applied for 45 seconds in addition to the 10 second ramp-up and 10 second ramp-down periods. The electrode configuration and placement will be identical to the active stimulation.
16256825|NCT04978129|Experimental|Online and Text Message Intervention|Participants randomized to the intervention will receive a link to the online intervention following baseline completion. The online and Text Message intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS. Intervention participants will receive personalized PBS Text Messages 3x per week (based on self-selections from the interactive online intervention) for 8 consecutive weeks timed to occur on a random weekday as well as Friday and Saturday.
16256855|NCT04977908|Active Comparator|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.
~The CGM will be the Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)"
16256826|NCT04978129|No Intervention|Wait List Control|The wait-list control condition will not receive any intervention content during the 8-week period of data collection, but will complete baseline, 2-month, and daily surveys according to the same schedule as the intervention group in order to assess event-level PBS use, PBS non-use, alcohol and marijuana use, CAM and SAM use, and related consequences for up to 24 days over an 8-week period. All wait-list control participants will receive the intervention at the end of the 8-week period of data collection for the pilot study.
16256827|NCT04978116|Experimental|Chest X-Ray (CXR)|Only CXR (image and standardized report) will be available to the clinician in charge of the patient (standard of care). LDCT and LUS will be performed but not available (clinician will be blinded to LDCT and LUS).
16256828|NCT04978116|Experimental|Low-dose CT scan (LDCT)|Only LDCT (image and standardized report) will be available to the clinician (first intervention arm). CXR and LUS will be performed but not available (clinician will be blinded to CXR and LUS).
16256829|NCT04978116|Experimental|Lung ultrasonography (LUS)|Only LUS (image and standardized report) will be available to the clinician (second intervention arm). CXR and LDCT will be performed but not available (clinician will be blinded to CXR and LDCT).
16256830|NCT04978103|Experimental|Single Arm|Hundred postmenopausal women were enrolled and received therapeutic dose of Gum Arabic (0.5 gm/kg/day) and followed for 12 weeks then the intended outcomes will be compared before and after completion of the study
16256831|NCT04978090|Experimental|Enteroatmospheric fistula (EAF) management solution|Participants will receive a custom fitted device designed to isolate EAF effluent independent of negative pressure wound therapy (NPWT) utilizing 3D printing technology to design a participant-matched device that more easily and effectively separates the participant's fistula and any emanated intestinal contents surrounding the wound.
16256832|NCT04978077|Experimental|High fat test meal first, high carbohydrate test meal second|Consumption of a high fat challenge first, consumption of a high carbohydrate challenge after two weeks wash out
16256833|NCT04978077|Experimental|High carbohydrate test meal first, high fat test meal second|Consumption of a high carbohydrate challenge first, consumption of a high fit challenge after two weeks wash out
16256836|NCT04978051|Active Comparator|Standard of Care (SoC)|
16256837|NCT04978051|Experimental|SoC + Icatibant|
16256838|NCT04978038|Experimental|mRNA-1273 Vaccine|Eligible participants will be vaccinated with the mRNA-1273 (Moderna COVID-19 Vaccine). A .5ml dose of the vaccine will be administered intramuscularly.
16256839|NCT04978038|Active Comparator|Pneumococcal Prevnar-13|Eligible participants will be vaccinated with Pfizer Prevar-13 (pneumococcal vaccine) in a blinded manner such that the vaccination with mRNA-1273 will be mimicked. That is, a .5ml dose of the vaccine will be administered intramuscularly. After completion of the study participants in the control arm will be offered a third dose of mRNA-1273 if our data shows that a third dose is effective in boosting the immune response.
16256840|NCT04978025|Experimental|Silver Group|"Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)
~By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
16256841|NCT04978025|Placebo Comparator|Placebo Group|"Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days
~By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days."
16256842|NCT04978012|Experimental|Combination of Fluzoparib and Camrelizumab|Fluzoparib,150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w
16256843|NCT04977999|Active Comparator|Eccentric training|Eccentron (BTE Technologies, Inc.) training
16256844|NCT04977999|Experimental|Aquatic training|Hydroworks aquatic training
16256847|NCT04977973|Experimental|Intervention group: Body Image|Participants will complete a 9-day self-guided programme on body image delivered via a mobile phone application with daily exercises informed by cognitive-behavioural and self-compassion principles.
16256848|NCT04977973|Active Comparator|Control group|Participants will complete a 9-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
16256849|NCT04977960|No Intervention|Reference group|"Patients randomized to the Reference Group will receive the standard-of-care treatments, according to institutional procedures in force:
~Dexamethasone i.v. 6 mg die for consecutive 5 days
~Methylprednisolone i.v. 40 mg bid for consecutive 10 days
~Low-molecular-weight-heparin i.v. at standardized dose of 70 UI/kg twice
~Remdesivir i.v. 200 mg in bolus (1st day) then 100 mg die for 4 days; remdesivir will be used only in patients supported with low-flow nasal cannula oxygen or Venturi mask
~Antibiotic therapy:
~azithromycin: 500 mg/die per os for 5 days
~ceftriaxone: 2 g i.v. die for 8 days"
16256850|NCT04977960|Experimental|Experimental Group|Patients randomized in the Experimental Group will receive canrenone as add-on therapy to standard-of-care treatments. Different starting doses of i.v. canrenone will be administrated in a single or double infusion per day, for 7 days, according to the serum concentration of potassium at randomization
16256851|NCT04977947|Experimental|Healthy Eating for My Infant Intervention|Participants and their parents will participate in a 6 session intervention targeting healthy introduction of complementary foods, and responsive feeding and mealtime behaviors. Intervention sessions will occur when the infant is 3, 4, 5, 6, 7, and 8 months of age.
16256852|NCT04977947|No Intervention|Control|Participants and their parents will complete baseline and post-treatment study visits to assess study outcomes. They will receive no intervention.
16256853|NCT04977921|Experimental|Elsiever clinical skill platform|
16256854|NCT04977908|Experimental|Fully closed-loop system with ultra-rapid Lispro insulin|"The fully closed-loop system (CamAPS HX) will consist of:
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
~An Android smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
~Cloud upload system to review CGM/insulin data.
~Participants will use ultra-rapid Lispro insulin in the closed-loop system"
16256857|NCT04977882|Experimental|Postoperative antibiotico-prophylaxis|postoperative antibiotico-prophylaxis with Ceftriaxone 2gr and Metronidazole 1.5gr
16256858|NCT04977882|No Intervention|Control group|No drainage nor postoperative antibiotico-prophylaxis
16256859|NCT04977869|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days after mechanical thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16256860|NCT04977869|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days after mechanical thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16256861|NCT04977856|Experimental|Guided ICBT|Participants in guided ICBT will receive internet-delivered CBT with therapist support. The treatment consists of 8 online modules with interactive features such as videos and illustrations, delivered over a maximum of 10 weeks. The main treatment focus is behavioral activation. The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The caregiver's program also consists of 8 chapters, including psychoeducation about depression and how to support their adolescent in treatment. The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support.
16256862|NCT04977856|Experimental|Self-guided ICBT|The self-guided arm is identical to the guided arm, however without the therapist support. To ensure patient safety, there will be clear instructions to the patients and primary caregivers on how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
16256863|NCT04977856|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical, or a combination of both. The content of TAU and the treatment techniques used will be monitored.
16256864|NCT04977843|Experimental|E-BAL|E-BAL carried out within 48 hours
16256865|NCT04977843|No Intervention|Conservative/Control|Standard of care management
16256866|NCT04977830|Other|Thoracic Insufficiency Group|Thoracic insufficiency syndrome patients undergoing surgery
16256867|NCT04977817||Control Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The control group will contain those that did not receive probiotics.
16256868|NCT04977817||Treatment Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The treatment group will contain those neonates that did receive the probiotic nutritional supplement.
16256869|NCT04977804|Active Comparator|Eccentric only training|This is the experimental control; where this group will be used as the standard active comparison condition.
16256870|NCT04977804|Experimental|Eccentric plus blood-flow restriction|This is the experimental condition involving the eccentric resistance training with blood flow restriction.
16256871|NCT04977778|Active Comparator|Fatty Acids Compounds (FAG)|Individuals taking FAG mouthwash
16256872|NCT04977778|Active Comparator|Stannous Fluoride (SF)|Individuals taking SF mouthwash
16256873|NCT04977765||Transgender Males|Individuals assigned female gender at birth but considering gender-affirming testosterone therapy. May self-identify as transgender or nonbinary etc.
16256874|NCT04977765||Cisgender Controls|Individuals assigned male or female at birth. May identify as cisgender or nonbinary etc. These individuals should not be undergoing or considering any form of hormone therapy.
16256875|NCT04977739||those with a condition|
16256876|NCT04977739||those without a condition|
16256877|NCT04977726|Experimental|STRIVE - Simulation Training for Resilience in Various Environments|
16256878|NCT04977726|Sham Comparator|Control|
16256879|NCT04977713|Experimental|Acupressure group|In the acupressure uterine contractions were checked before the care application began. Acupressure was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
16256880|NCT04977713|Experimental|Shower Group|The shower group, uterine contractions were checked before the care application began. A shower was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
16256881|NCT04977713|No Intervention|Control group|The women in the control group underwent routine hospital care. They were administered neither pharmacological nor nonpharmacological methods to reduce labour pain.
16256882|NCT04977700|Experimental|Intervention Group|Participants will be enrolled on a rolling basis and participate in SS for 4 months in the intervention condition. After pretesting, participants will receive sun protection messages from SS through emails/comments based on algorithm results from their profile and activity data. All participants will complete posttest survey 4 months from randomization.
16256883|NCT04977700|No Intervention|Control Group|A small control group will be included to see if a no-treatment control condition is acceptable to users and estimate follow-up rates for planning a randomized trial. Participants will be enrolled on a rolling basis and will complete a pretest at randomization. All participants will complete a posttest survey 4 months from randomization.
16256884|NCT04977674|Experimental|A: Visit 1) Naltrexone + Ketamine, Visit 2) Placebo + Ketamine|"Participants randomly assigned to arm A:
~VISIT 1) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.
~VISIT 2) Placebo before the administration of ketamine 0.5mg/kg.
~Study visits are separated by 14-28 days."
16279187|NCT04821973|Active Comparator|Control Respiratory Monitoring Group|
16256885|NCT04977674|Experimental|B: Visit 1) Placebo + Ketamine, Visit 2) Naltrexone + Ketamine|"Participants randomly assigned to arm B:
~VISIT 1) Placebo before the administration of ketamine 0.5mg/kg.
~VISIT 2) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.
~Study visits are separated by 14-28 days."
16256886|NCT04977661|Active Comparator|Group1|Group I (n = 34) received 400 IU Vitamin E (Vitamin E 400 IU®, MEPACO Pharmaceutical Company, Sharqia, Egypt) twice daily for 3 month
16256887|NCT04977661|Active Comparator|Group2|Group II (n =34) received 250 mg Ursodeoxycholic acid (Ursofalk 250 mg®, MINAPHARM Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
16256888|NCT04977661|Active Comparator|Group3|Group III (n = 34) received 400 mg sustained release (SR) Film-Coated Tablets of pentoxifylline (Trental 400 mg®, SANOFI Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
16256889|NCT04977635||600-cohort|"Patients with long-term (> 5 years) type 1 diabetes aged 16 years and older
~As this is an observational study there is no intervention."
16256890|NCT04977622||Primary Progressive MS (PPMS)|Clinically definite MS patients with identified primary-progressive disease onset, within 10 years of diagnosis
16256891|NCT04977622||Non-neurological controls (HC)|Age and sex matched to the PPMS patients
16256892|NCT04977609|Experimental|VR+MUSIC|Upper limb repetitive training activities through the imitation of movements (i.e., unscrew the cap of a bottle, pour water into a glass, drink water from a glass, sugaring coffee, placing an object in a box) synchronized with a musical accompaniment (i.e., a selection of classical music pieces). Participants will wear a VR headset (Gear VR, Samsung) through which they will observe egocentric 180° 3D videoclips shot from a first-person perspective, as if the patient himself was performing the movement, while listening to music.
16256893|NCT04977609|Experimental|VR|Upper limb repetitive training activities through imitation of movements, without any musical accompaniment. Participants will wear a VR headset through which they will observe egocentric 180° 3D silent videoclips.
16256894|NCT04977609|Active Comparator|TAU|Treatment as usual (TAU). Patients will be engaged in upper limb repetitive training activities through traditional physiotherapy rehabilitation.
16256895|NCT04977596||Group PNETs|The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018
16256896|NCT04977596||Group PDAC|Patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.
16256897|NCT04977583|Experimental|Screening|Participants in this arm will be screened for unmet social needs and receive a post card that includes a list of generic VA crisis and homeless hotlines.
16256898|NCT04977583|Experimental|Awareness|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, and receive a Resource Sheet tailored to the unmet needs identified in the unmet need screen. The Resource Sheet will include the names of available resources within the VA and/or local community that can help to address the identified need(s) and contact information and hours of operation.
16256899|NCT04977583|Experimental|Assistance|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, receive a tailored Resource Sheet, and be offered assistance from a Social Worker. If accepted, the SW will contact the participant and work with them over a period of 8 weeks to help facilitate their connection to resources than can help to address the unmet need(s) identified in the unmet need screen.
16256900|NCT04977570|Experimental|SYHA1805|subjects will be randomized to receive multiple ascending doses of SYHA1805 tablets.
16256901|NCT04977570|Placebo Comparator|Placebo|subjects will be randomized to receive the matching placebo tablets.
16256902|NCT04977557|Other|single arm|"its a quasi experimental study where single group is used (self controlled clinical trial).
~clinical features were compared before iand after intervention"
16256903|NCT04977544|Active Comparator|drug only|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
16256904|NCT04977544|Experimental|vert combine with drug|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
16256905|NCT04977531||6 months less|Stroke onset less than 6 months
16256906|NCT04977531||6 months to 2 years|Stroke onset between 6 months and 2 years
16256907|NCT04977531||over 2 years|Stroke onset over 2 years
16256908|NCT04977518||Patients diagnosed during 2008-2011|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2008-2011
16256909|NCT04977518||Patients diagnosed during 2012-2015|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2012-2015
16256910|NCT04977505||Pushlock|Patients with recurrent shoulder dislocation received surgery fixed by pushlock
16256911|NCT04977505||Gryphon|Patients with recurrent shoulder dislocation received surgery fixed by Gryphon
16256912|NCT04977492||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
16256913|NCT04977492||control group|People suffered from excessive lateral pressure syndrome with conservative treatment.
16256914|NCT04977479|Active Comparator|Active Vaccine|Participant receives the active mRNA COVID-19 vaccine
16256915|NCT04977479|Placebo Comparator|Placebo|All participants crossover and receive active vaccine but which day placebo vs active is given is randomized and blinded.
16256920|NCT04977453|Experimental|GI-101|"Dose escalation: GI-101, multiple ascending doses
~Dose expansion:"
16256921|NCT04977453|Experimental|GI-101 + Pembrolizumab|"Dose escalation: GI-101, multiple ascending doses
~Dose expansion:"
16256922|NCT04977453|Experimental|GI-101 + Lenvatinib|"Dose optimization:
~Dose expansion:"
16256923|NCT04977453|Experimental|GI-101 + Local Radiotherapy|"Dose optimization:
~Dose expansion:"
16256924|NCT04977440||standard protein|
16256925|NCT04977440||high protein|
16256926|NCT04977427|Active Comparator|Prednisolone Arm|Standard post-cataract surgery therapy arm; acts as control in each patient.
16256927|NCT04977427|Active Comparator|Dextenza Arm|Investigational arm to compare the effectiveness of the Dextenza insert to standard therapy.
16256928|NCT04977414|No Intervention|Waitlist control group|Hospitals assigned to this group will be placed in on a waitlist to receive the training intervention at a later date
16256929|NCT04977414|Experimental|"Making data count intervention group"|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
16256930|NCT04977401|Sham Comparator|Group Glycerol|Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
16256931|NCT04977401|Active Comparator|Group Gel ORISE|Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
16256932|NCT04977388|Active Comparator|Northera™ (Droxidopa) (Treatment A)|Northera (Droxidopa) (Treatment A) will be provided to adult subjects as a capsule with 100mg, 200mg, or 300mg of Northera (Droxidopa) contained within gelatin color capsules (sky blue and white, size 0) based on findings from the dose titration visit. These capsules are physically indistinguishable from the Treatment B (placebo) capsules. Frequency of administration (by mouth) will be twice daily for six weeks.
16256933|NCT04977388|Placebo Comparator|Placebo (Treatment B)|Empty gelatin color capsules (sky blue and white, size 0) filled with cellulose microcrystalline and physically indistinguishable from Treatment A capsules. Frequency of administration (by mouth) will be twice daily for six weeks
16256934|NCT04977375|Experimental|Pembrolizumab with stereotactic radiation therapy and surgical resection|
16256935|NCT04977362|Experimental|ERAS protocol (intervention group)|The innovative care process in the intervention group is characterized by an interdisciplinary approach according to the previously established enhanced recovery after surgery protocol. This process aims at improving the clinical outcome after cardiac surgery, increasing patient satisfaction and quality of life, enabling early professional reentry and participation, and optimizing the cost-effectiveness of service provision. In addition, intersectoral barriers are being broken down in order to establish an interdisciplinary and cross-sectoral overall care process for patients with heart valve surgery as a new form of care in the future.
16256936|NCT04977362|Active Comparator|Treatment as usual (control group)|The control group undergoes standard heart valve surgery. In this case, no preoperative interventions take place, the patient is operated on the affected heart valve in a minimally invasive procedure without prehabilitation. After surgery, the patient is transfered to an intensive care unit (not a specialized postanesthesia care unit) depending on the individual condition and then transfered to the general ward. Patients receive medical, nursing, and physiotherapeutic care in accordance with current hospital standards.
16256937|NCT04977349|Experimental|Wind Musicians|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assesment. And the manual therapy from the Active Comparator group.
16256938|NCT04977349|Active Comparator|Wind musicians|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, Sternocleidomastoid (ECOM), masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
16256939|NCT04977336|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
16256940|NCT04977336|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
16256941|NCT04977336|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
16256942|NCT04977323|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive the pictures they want. They will be asked to trace and color the pictures that need coloring. The nurse will color with children during the procedure. And after the procedure, the child will take his or her picture which he colored during the procedure.
16256943|NCT04977323|Experimental|Watching cartoons|Watching cartoons: In this group, children will watch cartoons as they like. Watching will continue until the procedure is complete.
16256944|NCT04977323|Experimental|Group listening to music|Listening to music: In this group, children will listen to cartoon music as they like. Listen will continue until the procedure is complete.
16256945|NCT04977323|No Intervention|Standard care provided group as control group|Control group. The kids in this group will be allowed to keep their family near. The routine blood taking
16256946|NCT04977310|No Intervention|Control|After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.
16257080|NCT04976374|Placebo Comparator|Group B|Group B will recive a bolus of saline then saline infusion identical to group A
16257081|NCT04976361|Experimental|Diabetic Patients with PDR|PRP for each diabetic patient included in this study.
16257087|NCT04976309|Experimental|Placebo + VIP and PACAP|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
16256947|NCT04977310|Experimental|Intervention|After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.
16256948|NCT04977297|Experimental|Move to Music Video Intervention|Participants in this arm will receive the Move to Music with Video (M2M-V) intervention. The participant will be asked to exercise twice daily for 5 consecutive days.
16256949|NCT04977297|Active Comparator|Move to Music Intervention|Participants in this arm will receive the Move to Music (M2M) only intervention without video. The participant will be asked to exercise twice daily for 5 consecutive days.
16256950|NCT04977284|Experimental|TCSCS|
16256951|NCT04977271|Experimental|Treatment Group|"Starting dose of oral venlafaxine immediate release (IR) 37.5 mg BID, to be taken with food. The dosing will be increased at a rate of 75mg per week for 3 weeks, to reach a desired dose of 300mg per day, taken as 150mg BID.
~For patients with hepatic impairment, severe renal impairment, or end-stage kidney disease, the starting dose is 37.5 mg once daily, and the dose is increased by increments of 37.5 mg per day, to a maximum of 187.5 mg per day, taken as 93.75 mg BID."
16256952|NCT04977271|No Intervention|Control Group|No intervention will be provided for this group
16256953|NCT04977258|Active Comparator|Control group|Only treadmill aerobic exercise with 60 min recovery in supine position.
16256954|NCT04977258|Experimental|Controlled hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water predetermined intake.
16256955|NCT04977258|Experimental|Ad Libitum hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water intake in an uncontrolled manner.
16256956|NCT04977245|Experimental|MBSR Intervention|The intervention group will take part in a group-based mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. This MBSR program will have a shortened session length of 1.5 hours compared to the traditional 2 hours, to reduce caregiver burden. Caregivers will be trained in meditation practices, like awareness of one's breath, body scan, and loving kindness meditation. Participants will also learn about mindfulness and stress theory, and have group discussions covering topics such as self-compassion.
16256957|NCT04977245|Active Comparator|Self-Guided Meditation eCourse|Participants in the active control group will participate in a self-guided, online program named GARDEN. The self guided material teaches skills about increasing the daily experience of positive emotion as a mechanism to assist with stress coping. The program consists of eight skills introduced and discussed over an eight week period.
16256958|NCT04977232|Experimental|Escitalopram + game intervention|Escitalopram treatment and game intervention are given in combinations for 8 weeks.
16256959|NCT04977232|Active Comparator|Escitalopram|Escitalopram treatment for 8 weeks
16256960|NCT04977219||Prism Adaptation Training;|Patients who received prism adaptation training for treatment of spatial neglect during their inpatient rehabilitation admission
16256961|NCT04977219||Standard Care|Patients who received standard treatment of spatial neglect during their admission
16256962|NCT04977206|No Intervention|No Intervention|Patients receiving usual care
16256963|NCT04977206|Experimental|Intervention|Patient's receiving care following nurse education on mutual goal-setting
16256964|NCT04977193|Experimental|Treatment group|
16256965|NCT04977180|Experimental|Treatment arm (beta blocker and ACE inhibitor)|Participants will receive a beta blocker (either metoprolol or carvedilol) and an ACE inhibitor (lisinopril) at standard doses based on tolerance starting from when they start induction therapy for AML through 90 days after the first day of the last cycle of therapy that includes an anthracycline (whether that is in the induction, re-induction, or consolidation phase of treatment). They will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
16256966|NCT04977180|No Intervention|Standard Clinical Care|Participants will receive standard clinical care, but will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
16256967|NCT04977167|Experimental|Part 1:HG146 Monotherapy, Dose-escalation Cohort|Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.
16256968|NCT04977167|Experimental|Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort|"Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle.
~Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated."
16256969|NCT04977167|Experimental|Part 2B-1：HG146 combination Expansion Cohort 1|Subjects who have not been treated with PD-(L)1 antibody，will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
16256970|NCT04977167|Experimental|Part 2B-2：HG146 combination Expansion Cohort 2|Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
16256971|NCT04977154||Trainers|
16256972|NCT04977141||Under-represented minority|Non-English speaking and/or non-White
16256973|NCT04977141||Non-under-represented minority|English-speaking and/or White
16256974|NCT04977128|Experimental|Experimental：89Zr-KN035 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
16256975|NCT04977115|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
16256976|NCT04977115|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
16257220|NCT04975490||SAPIENT = Sepsis ACLF patients|
16256977|NCT04977102|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
16256978|NCT04977102|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
16256979|NCT04977089||Ischemic heart disease patients .|Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.
16256980|NCT04977076|Active Comparator|Interrupted NOAC use (group 1)|Patients in group 1 will receive standard care. Therefore, DOAC use will be interrupted at least 24 hours in advance of ICA or PCI. Based on the renal clearance, last DOAC intake may be extended to 48 hours prior to the procedure [Table 2]. After the procedure, patients will continue using their DOAC as usual.
16256981|NCT04977076|Experimental|Uninterrupted NOAC use (group 2)|In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or PCI. After the procedure patients will continue to use DOAC from the next planned dose.
16256982|NCT04977063|Other|SmartPill and Atmo capsule|The SmartPill and Atmo gas capsule will be tested simultaneously. This will allow the ability of the Atmo gas capsule to measure gastrointestinal transit time to be compared to the SmartPill. The order of swallowing will be randomised using a computer-generated list. The two capsules will be swallowed within 5 minutes of each other
16256983|NCT04977050||Intervention Site|All miners in the New Mexico intervention mine site who will be administered nasal swabs for antigen testing every other work shift, and serological testing 3 months.
16256984|NCT04977050||Controled site|All miners in the Wyoming Control mine site who will be administered serological testing 3 months.
16256987|NCT04977024|Experimental|Arm I (COH04S1)|Patients receive one dose of COH04S1 IM in the upper arm on days 0 and 28.
16256988|NCT04977024|Experimental|Arm II (EUA SARS-CoV-2 vaccine)|Patients receive one dose of EUA SARS-CoV-2 vaccine IM in the upper arm on days 0 and 28.
16256989|NCT04977011|Experimental|experimental group|30 minutes music intervention for 3 days on bedside
16256990|NCT04977011|No Intervention|control group|usually care
16256991|NCT04976998||patients|those with symptoms of CTS
16256992|NCT04976998||control group|normal people those with no symptoms of CTS
16256993|NCT04976985|Experimental|Interventional Group receiving Osteopathic Manipulative Therapy (OMT)|70 patients with chronic migraine who consent to OMT will receive four standardized osteopathic manipulative treatment protocol over the course of twelve weeks at week 0,2,6,10. MIDAS and HIT-6 Questionnaires will be obtained at time of consent prior to first treatment and again at the conclusion of treatment period of twelve weeks.
16256994|NCT04976985|Other|Control Group with Standard of Care|70 patients with the diagnosis of migraine headache who are receiving the standard of care medications will complete a MIDAS and HIT-6 questionnaire at week 0 and week 12. A new prophylactic medication may be started at time of initial questionnaires and the patient can be on up to two prophylactic medications, with no changes during the 12 week period.
16256995|NCT04976972|Experimental|Robotic-Total Knee Replacement (R-TKR)|NAVIO/CORI Surgical System
16256996|NCT04976972|Active Comparator|Conventional-Total Knee Replacement (C-TKR)|Non-robotic conventional instrumentation
16256997|NCT04976959|Experimental|Parkinson's patients|Parkinson's patients who will receive a high fiber supplement
16256998|NCT04976959|No Intervention|Control subjects|no supplement will be given
16256999|NCT04976946||Urologists|Local and international consultant Urologists and accredited Urology trainees.
16257000|NCT04976946||Anaesthetists|Local and international consultant anaesthetists. Critical care physicians who are primarily Urological anaesthetists or have experience in complication reporting will be targeted.
16257001|NCT04976946||ICU specialists|Local and international consultant ICU specialists. Critical care physicians who are primarily Urological focused or have experience in complication reporting will be targeted.
16257003|NCT04976920||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.
~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.
~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation."
16257004|NCT04976907||Perioperative patients|Patients undergoing perioperative assessment of vital signs.
16257005|NCT04976881|No Intervention|Usual Care|Usual care includes: 1) no specific materials to promote medication reconciliation, reproductive planning, or patient education on diabetes self-management within the context of preconception care, 2) variable physician preconception counseling without any EHR notifications or counseling support; and 3) no specific patient support or prompts to promote healthy behaviors post-visits.
16257082|NCT04976348||Consenting participants|All subjects aged ≥16 years referred to the cardiology outpatient clinic of the MUMC+ for heart failure like symptoms (as stated in the ESC 2016 Guidelines) and/or for cardiac screening are eligible for inclusion.
16257083|NCT04976335|Active Comparator|Versawrap|
16257006|NCT04976881|Active Comparator|PREPARED Strategy|Our PREPARED strategy will utilize health information and consumer technologies to 'hardwire' preconception care and promote diabetes self-management among reproductive-aged, adult women with T2DM in primary care. PREPARED will leverage electronic health record technology at clinic visits to: [1] promote medication reconciliation and safety, [2] prompt provider preconception counseling, and [3] deliver low literacy print tools to reinforce counseling and promote diabetes self-care. Post-visit, text messaging will be used to: [4] encourage healthy lifestyle behaviors.
16257007|NCT04976868||Pimecrolimus Cream 1% - Elidel®|Elidel® as prescribed within routine clinical practice
16257008|NCT04976855|Placebo Comparator|Part I: Placebo|Healthy volunteers will receive placebo once daily for 7 days.
16257009|NCT04976855|Experimental|Part I: INDV-2000|Healthy volunteers will receive INDV-2000 once daily for 7 days.
16257010|NCT04976855|Placebo Comparator|Part II: Placebo|Healthy volunteers will receive placebo once daily for 28 days.
16257011|NCT04976855|Experimental|Part II: INDV-2000|Healthy volunteers will receive INDV-2000 once daily for 28 days.
16257012|NCT04976855|Experimental|Part III: INDV-2000 + SUBOXONE|Participants with opioid use disorder will receive SUBOXONE sublingual (SL) film for 6 days during the run-in period. Participants will then receive SUBOXONE SL film alone for 2 days, then SUBOXONE SL film and INDV-2000 for 7 days followed by INDV-2000 dosing alone for 4 days.
16257013|NCT04976842|Active Comparator|Opioid-free anesthesia|Opioid free anesthesia protocol for urological procedurs
16257014|NCT04976842|Active Comparator|Opioid-based anesthesia|Opioid based anesthesia protocol for urological procedures
16257015|NCT04976829||adult (≥ 18 years) inpatients (hospitalised ≥ 48h)|
16257016|NCT04976816|Experimental|A1 peri-levator betamethasone injection|patients with isolated thyroid-related upper lid retraction who will be given the Peri-levator injection of betamethasone suspension
16257017|NCT04976816|Experimental|A2 Peri-levator triamcinolone acetate injection|patients with isolated thyroid-related upper lid retraction who will be given Peri-levator injection of triamcinolone acetate
16257018|NCT04976816|Experimental|B1 Peri-levator and retrobulbar betamethasone injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of betamethasone suspension
16257019|NCT04976816|Experimental|B2 Peri-levator and retrobulbar triamcinolone acetate injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of triamcinolone acetate
16257020|NCT04976803||Group A|Deceased patients with archival tissue
16257021|NCT04976803||Group B|Living patients with archival tissue
16257022|NCT04976803||Group C|Living patients without archival tissue
16257023|NCT04976790|Experimental|Chinese Tuina group (CTG)|The participants in Chinese Tuina group will receive the traditional Chinese Tuina therapy on the basis of health education and home-exercise. All the treatment will cost 20-25 minutes. Patients in this group received 4 treatments over 14 days.
16257024|NCT04976790|Active Comparator|Flurbiprofen Cataplasms group (FCG)|The FCG group received flurbiprofen gel on the basis of the health education and home-exercise, twice daily, for 14 days.
16257027|NCT04976764||liver cirrhosis with cirrhotic cardiomyopathy|
16257028|NCT04976764||liver cirrhosis without cirrhotic cardiomyopathy|
16257029|NCT04976751|Experimental|Electrophysiological treatment group|Two electrodes covered the two acupoints of Zhongliao and Huiyang, one electrode covered the three acupoints of Zhongji, Guanyuan and Qihai, and two skin paste electrodes covered the three acupoints of Sanyinjiao, and connected the electric stimulation therapy instrument for 30 minutes. The intensity was based on the patient's tolerance. 4 weeks before the course of treatment, the treatment was performed once a day, 3 times a week.In the last 4 weeks, 20 times were performed twice a week.Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
16257030|NCT04976751|No Intervention|Regular treatment group|Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
16257031|NCT04976738|Experimental|Treatment arm: Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
16257032|NCT04976725|Experimental|Ostepathic manipulative treatment|The effects of osteopathy treatment method on the migraine
16257033|NCT04976725|Experimental|Myofascial relaxation Treatment|The effects of myofascial treatment method on the migraine
16257034|NCT04976725|Experimental|Control treatment|Control group will have just medication treatment
16257035|NCT04976686|Experimental|All study participants|All participants will undergo sample collection during their regular diet and after modification of their diet to a low carbohydrate diet
16257036|NCT04976673|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
16257037|NCT04976673|Active Comparator|Steroid side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
16257038|NCT04976660|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-4 is determined
16257039|NCT04976647|Active Comparator|A arm: HLX10+chemo|Participants receive 300mg HLX10 IV every 3 weeks (Q3W) in combination with carboplaitin (AUC5 or 6) IV Q3W and nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle.
16257040|NCT04976647|Experimental|B arm: HLX10+HLX07+chemo|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W with chemo.
16257041|NCT04976647|Experimental|C arm: HLX10+HLX07|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W.
16257084|NCT04976335|No Intervention|No Versawrap|
16257086|NCT04976309|Experimental|Placebo + saline|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
16257045|NCT04976608||Group 1|The BCVA of eyes is greater than 0.6
16257046|NCT04976608||Group 2|The BCVA of eyes is from 0.1 to 0.6
16257047|NCT04976608||Group 3|The BCVA of eyes is less than 0.6
16257049|NCT04976582|Experimental|interventional group|experimental group in which dry needling with conventional physical therapy treatment modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
16257050|NCT04976582|No Intervention|control group|control group in which kinesiotaping with conventional physical therapy treatment (modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
16257051|NCT04976569|Experimental|DBS Regulation Group|All participants will receive STN-DBS sleep regulation.
16257052|NCT04976543|Experimental|Anticoagulation group|low molecular weight heparin subcutaneously every 12ths for 6 months or for 14 days followed by warfarin orally with a initial dosage of 3mg daily for 5.5 months
16257053|NCT04976543|No Intervention|control group|no anticoagulation therapy
16257056|NCT04976517||non-diabetes group|patients who underwent heart tranplantation without diabetes
16257057|NCT04976517||pre-transplant diabetes group|patients who underwent heart tranplantation with diabetes before the transplantation
16257058|NCT04976517||post transplant daibetes group|patients who underwent heart tranplantation without diabetes until after the transplantation
16257059|NCT04976504||Oxygen reserve index|Male and female patients aged 18 to 80 years with ASA physical status I to III scheduled for elective surgery with planned arterial catheter placement before induction of general anesthesia and did not match the exclusion criteria.
16257060|NCT04976491||CD-C-Food group|During the first 3 months，participants received EEN；In the second 3months , CD-C-Food group received received CD-C-food .
16257061|NCT04976491||EEN group|During the period, participants received EEN for 6 months.
16257062|NCT04976478||observation group|All patients will be treated with Nimotuzumab combined with radiotherapy.
16257063|NCT04976465||combined with aPL(+)|the antiphospholipid antibodies appear in blood at least once
16257064|NCT04976465||combined with aPL(-)|the antiphospholipid antibodies never appear in blood
16257065|NCT04976452|Experimental|Group 1|Group 1 will include first year Physical Therapy students who will be trained for Blood Pressure (BP) measurement using a brief powerpoint lecture, completion of an interactive BP measurement module from the American Medical Association which includes a quiz assessment and certificate of completion, and a competency examination during the lab portion of class.
16257066|NCT04976452|No Intervention|Group 2|Group 2 consists of second year PT students who only had a powerpoint lecture on Blood Pressure measurement that was done virtually with no lab component or American Medical Association interactive module training.
16257067|NCT04976439||Age|
16257068|NCT04976439||Grade|
16257069|NCT04976439||Tumor location|
16257070|NCT04976439||Stage|
16257071|NCT04976439||Lymphovascular invasion|
16257072|NCT04976413|Experimental|Experimental|Experimental arm will receive eight phase EMDR treatment using standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12 -14 weeks . Follow up will be conducted after 12 weeks of treatment completion.
16257073|NCT04976413|Active Comparator|Control|Control group will receive treatment as usual (supportive counselling) for 12 -14 weeks
16257074|NCT04976400|Experimental|test group|Semi-individualized total knee arthroplasty
16257075|NCT04976400|Active Comparator|Control group|Zimmer standard prosthesis total knee replacement
16257079|NCT04976374|Active Comparator|Group A|Patients of group A will start dexmedetomidine (precedex 100 ug lmL, Hospira) infusion 0.4 ug {Kg}h after bolus of 0.5 ug 1 kg intravenously over 10 min
16257221|NCT04975490||PROACT = Portal mediators as ACLF Targets|
16257088|NCT04976309|Experimental|Lu AG09222 + VIP and PACAP|Lu AG09222, single dose intravenous infusion over 30 minutes
16257089|NCT04976296||Stage I-IIIA NSCLC patients after complete resection|For stage I-IIIA NSCLC patients who underwent complete resection.
16257090|NCT04976283|Active Comparator|Pioglitazone|The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
16257091|NCT04976283|Active Comparator|Empagliflozin|The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
16257092|NCT04976283|Active Comparator|Pioglitazone + Empagliflozin|The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.
16257093|NCT04976270|Experimental|GLPG3667 SD|Participants will receive a single dose of GLPG3667
16257094|NCT04976270|Placebo Comparator|Placebo SD|Participants will receive a single dose of matching placebo
16257095|NCT04976270|Experimental|GLPG3667 MD|Participants will receive repeated doses of GLPG3667 for 13 days.
16257096|NCT04976270|Placebo Comparator|Placebo MD|Participants will receive repeated doses of matching placebo for 13 days.
16257098|NCT04976244|Active Comparator|Brolucizumab|Arm B
16257099|NCT04976244|Active Comparator|Aflibercept|Arm A
16257103|NCT04976218|Experimental|Experimental arm|Enrolled patients in this arm will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner.
16257104|NCT04976205|Experimental|TMI/TMLI|"The standard planning optimization for TMI/TMLI preview a two-free-breathing-CT scan without contrast will be performed for simulation at day -15(-10) to the BMT. The same day a WB-MRI will be acquired for lymph-nodes delineation. WB-MRI scans will be performed using a 1.5T MR scanner. The two CT will be co-registered to the WB-MRI.
~CTV will be manually defined as the bones excluding mandible and hands (CTVBones), the spleen (CTVSpleen), and lymph nodes (CTVLN) using both MRI and CT images. The day -3 (4) to the BMT, further two-CT series will be acquired and co-registered to the first CTs for dose verification. Pre-treatment quality assurance (QA) will be performed the day before the treatment using the standard internal procedure.
~The treatment will be performed the day before the BMT."
16257105|NCT04976192|Experimental|TEV-45779-300 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
16257106|NCT04976192|Active Comparator|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
16257107|NCT04976192|Experimental|TEV-45779-150 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
16257108|NCT04976192|Active Comparator|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
16257109|NCT04976192|Experimental|TEV-45779-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to TEV-45779-300 mg in the Main Treatment period.
16257110|NCT04976192|Experimental|Xolair-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
16257111|NCT04976192|Active Comparator|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
16257112|NCT04976192|Experimental|TEV-45779-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to TEV-45779-150 mg in the main treatment period.
16257113|NCT04976192|Experimental|Xolair-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
16257114|NCT04976192|Active Comparator|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
16257115|NCT04976179|Experimental|FCM - Intravenous Ferric carboxymaltose|Intravenous Ferric Carboxymatlose administered in a single dose of 20mg/Kg to a maximum of 1000mg in 100mls of infusion given over minimum of 15 - 20 minutes at enrollment.
16257116|NCT04976179|Active Comparator|FS -Oral Ferrous sulphate|Oral Ferrous Sulphate (containing 65mg of elemental iron) to be taken as one 200mg tablet 3 times a day until delivery.
16257117|NCT04976166|Active Comparator|Conventional group|Videos and leaflets will be provided. Patients will have education using leaflets for 5 minutes in each hospital at months 0 and 2, respectively.
16257118|NCT04976166|Experimental|Extensive Informed Decision Making group|Videos, leaflets, and booklets will be provided. Patients in the EIDM group will receive more informed and detailed education than those in the conventional group. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
16257119|NCT04976166|Experimental|Shared Decision Making group|Videos, leaflets, and booklets will be provided. Patients will check self-assessment items, and then have education according to the patients' preference using a self-developed counseling calendar. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
16257120|NCT04976153|Experimental|aSMDC|Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence
16257121|NCT04976153|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product
16257122|NCT04976140|Experimental|Low dose group|The investigational product is intravenously administered according to the planned dose.
16257123|NCT04976140|Experimental|Intermediate dose group|The investigational product is intravenously administered according to the planned dose.
16257124|NCT04976140|Experimental|High dose group|The investigational product is intravenously administered according to the planned dose.
16257125|NCT04976127|Experimental|Talineuren dose escalation|14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg
16257126|NCT04976127|Experimental|Talineuren repeated dose|8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose)
16257127|NCT04976114|No Intervention|Control group|Standard of care
16257128|NCT04976114|Experimental|story book|Parents read a book with the chid previous to surgery.
16257129|NCT04976114|Experimental|video|Parents watch a video with the chid previous to surgery.
16257130|NCT04976114|Experimental|both instrument|Parents read a book and watch a video with the chid previous to surgery.
16257131|NCT04976101|Experimental|Sinusoidal Galvanic Vestibular Stimulation|"Treatment:
~1. Stimulation of the vestibular nerves with 0.025 Hz, 2 mA sinusoidal galvanic vestibular stimulation Depending on initial results, changes in frequency may range up to 0.1 Hz."
16257132|NCT04976101|Placebo Comparator|Placebo|"Treatment:
~1. Placebo (sham) (no current given however the electrodes and devise is placed and computer keys pressed). Depending on initial results, changes in frequency may range up to 0.1 Hz."
16257133|NCT04976088|Experimental|Group A Test|Test product: treated once a day (morning) with the medicated plaster containing 140 mg Diclofenac Sodium for seven days Diclofenac Sodium 140 mg medicated plaster
16257134|NCT04976088|Active Comparator|Group B Reference|Reference product: treated once a day (morning) with the medicated plaster containing DIEP 180 mg, Flector® for seven days Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®
16257135|NCT04976088|Placebo Comparator|Group C Placebo|Placebo: treated once a day (morning) with the placebo plaster for seven days
16257136|NCT04976075||Adults|Patients of 18 or more years old
16257137|NCT04976075||Pediatrics|Patients less than 18 years old
16257138|NCT04976049||Orthopedic infection|Subjects who have undergone previous trauma surgeries and have developed an infection will be assessed for protocol inclusion criteria. Patients will be administered a single, oral, 20mg/kg dose of 5-Aminolevulinic Acid (ALA) by a qualified member of their care team. This dose will be administered ideally 3 hours prior to surgery. Fluorescent imaging will be obtained pre and post irrigation and debridement.
16257139|NCT04976036|Experimental|Nintedanib|nintedanib 150 mg once a day for 2 weeks, then twice a day for 14 weeks
16257140|NCT04976036|Placebo Comparator|Placebo|placebo 150 mg once a day for 2 weeks, then twice a day for 14 weeks
16257141|NCT04976023|Active Comparator|Active Arm|14.55g of Yupingfeng Powder granules twice daily for 8 weeks
16257142|NCT04976023|Placebo Comparator|Placebo Arm|14.55g of placebo granules twice daily for 8 weeks
16257143|NCT04976010||CKD G3-5|Patients with CKD and an estimated eGFR < 60ml/min not yet on dialysis
16257144|NCT04976010||End stage kidney disease (ESKD) CKD G5 Hemodialysis|Patients on hemodialysis for at least 3 months
16257145|NCT04976010||Normal kidney function|Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR > 90ml/min
16257148|NCT04975971||Dextenza recepient|A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery
16257149|NCT04975958|Experimental|DLT Observation Period I - AN2025 and Atezolizumab|During the DLT Observation I, patients will be treated with AN2025 and Atezolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The starting dose of AN2025 is 50 mg. If tolerated, then a subsequent cohort will escalate to 100 mg. A dose de-escalation cohort to 80 mg may occur if the 100 mg is not well tolerated. The dose of Atezolizumab will remain constant at 1200 mg every 3 weeks (Q3W) for each dose level of AN2025 and in each cohort. Atezolizumab is administered intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
16257150|NCT04975958|Experimental|DLT Observation Period II - AN0025 and Atezolizumab|During the DLT Observation II, patients will be treated with AN0025 and Atezolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The starting dose of AN0025 is 250 mg. If tolerated, then a subsequent cohort will escalate to 500 mg. If 250 mg AN0025 is not tolerated, de-escalate to 125 mg. The dose of Atezolizumab will remain constant at 1200 mg Q3W for each dose level of AN0025 and in each cohort. Atezolizumab is administered intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
16257151|NCT04975958|Experimental|DLT Observation Period III - AN2025, AN0025 and Atezolizumab|The DLT Observation III will be started after safety data review by the investigators and the sponsor of the double combination treatments in Observations I and II. Patients enrolled in Observation III will start with the recommended dose of AN0025 from Observation II, 1200 mg Atezolizumab, and AN2025 will start from 50 mg QD. Patients will be treated with all three study drugs until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The dose of Atezolizumab will be the same (i.e., 1200 mg Q3W) regardless of dose levels of AN2025 and cohorts. Atezolizumab is administered intravenously over 60 minutes every three weeks. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. The dose of AN0025 as determined in Observation II will remain constant for each dose level of AN2025 and each cohort, unless the investigators and the sponsor determine that the toxicity comes from the AN0025 + Atezolizumab combination.
16257152|NCT04975945|Experimental|Local|Participants will receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml normal saline)
16257153|NCT04975945|Active Comparator|Parenteral|Participants will receive parenteral ceftriaxone (15-20mg/kg) for prolonged duration as per local protocol
16257154|NCT04975932||Study group: TACE+ICIs|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs
16257155|NCT04975932||Control group: TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
16257156|NCT04975919|Experimental|Treatment (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-10. Patients who achieve CR/CRi during consolidation/maintenance may receive decitabine and cedazuridine PO QD on days 1-5. Patients also receive venetoclax PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16257157|NCT04975906||Participants|All inpatient admissions with serum lactate, ketones and/or salicylates performed, and with urea, electrolytes and creatinine at the same time. The patients will be grouped into patients with organic (gap) acidosis (elevated serum lactate, ketones and/or salicylates) and patients with no organic acidosis.
16257158|NCT04975893|Other|CMV-seropositive and CMV-seronegative Participants|CMV-seropositive and CMV-seronegative participants who completed Study mRNA-1647-P202 will be followed every 6 months for 3 years in this study after the final visit in Study mRNA-1647-P202.
16257159|NCT04975880|Other|Hemodialysis Treatments|All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
16257160|NCT04975867|Experimental|Hypothermia group|Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
16257161|NCT04975867|Active Comparator|Normothermia group|For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
16257162|NCT04975854|Experimental|Virtual Reality Exposure|Participants complete three 30-40-minute sessions of exposure administered via a virtual reality headset. The exposure involve exposure to various heights and height cues in the virtual city environment. Experimental group also attends 20-minute online information session (prerecorded video).
16257163|NCT04975854|Other|Control|Control group attends a single 20-minute information session (prerecorded video) about general principles of exposure therapy and anxiety before the start of the study, but receives no exposure-based intervention.
16257164|NCT04975841|No Intervention|Standard of Care|Standard of Care (SOC) Study: The 6 subjects in the late injection group will start on Part 1. - The Part 1 study subject participation is 12 months. Two subjects will be enrolled at each of Months 0, 3 and 6. This will include an initial assessment and SOC follow-up. Subjects will continue standard of care treatment. Part 1 study duration (with staggering included) will be 18 months. After Part 1, the late injection subjects may proceed to Part 2 depending on safety data from the early injection group (see 3. below).
16257165|NCT04975841|Active Comparator|Stem Cell Injection|Stem Cell Injection: The three subjects randomized to early injections will proceed directly to Part 2 with staggered enrollment of 1 subject every 3 months. Once the safety data of the first subject at Month 3 is assessed, the second subject will be enrolled. Once the safety data of the first 2 subject (Subject 1 at Month 6 and Subject 2 at Month 3) are assessed, the third early injection subject will be enrolled in Part 2.
16257166|NCT04975828||patients type 2 DM with coronary artery disease and diabetic retinopathy.|
16257167|NCT04975828||patients type 2 DM with coronary artery disease and diabetic neuropathy.|
16257168|NCT04975828||patients type 2 DM with coronary artery disease and diabetic nephropathy|
16257169|NCT04975828||patient type 2 DM with coronary artery disease and non microvascular complications.|
16257170|NCT04975815||Non-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores0 will place the participants in Non-frail group.
~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
16257171|NCT04975815||Pre-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores1-2 will place the participants in Pre-frail group.
~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
16257172|NCT04975815||Frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores3-5 will place the participants in Frail group.
~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
16257173|NCT04975802|Placebo Comparator|0 mg coffeeberry beverage|Appearance-matched to the other products
16257174|NCT04975802|Experimental|100 mg coffeeberry beverage|Appearance-matched to the other products
16257175|NCT04975802|Experimental|300 mg coffeeberry beverage|Appearance-matched to the other products
16257176|NCT04975802|Active Comparator|75 mg caffeine beverage|Appearance-matched to the other products
16257177|NCT04975789|No Intervention|Usual Care Control|Standard of Care
16257178|NCT04975789|Experimental|InfoViz Intervention|Pain information visualization (InfoViz) tool, Trained interpreters will use the InfoViz tool twice, before and during the clinical encounter
16257179|NCT04975776|Experimental|Sleep restriction therapy|Four group sessions delivered at the participants' primary health care centers once a week for 3 weeks and again after a 4-week pause. The first session will last for 2 hours and the other sessions for 1 hour.
16257180|NCT04975776|Active Comparator|Sleep hygiene|Participants in the active comparator group will receive a brochure with sleep hygiene advice from the primary health care center at baseline.
16257181|NCT04975763|Experimental|Soybean Oil|Consumption of study foods each day made with soybean oil
16257182|NCT04975763|Placebo Comparator|Palm Oil|Consumption of study foods each day made with palm oil
16257183|NCT04975750|Experimental|Problem solving intervention|Problem solving as developed by Nexu and colleguages. First-line managers are trained in the problem solving intervention (1 1/2 day). Thereafter, they apply the problem-solving in 2 - 5 meetings (about 30 - 45 min each) with employees at risk of future sick leave due to common mental disorders.
16279188|NCT04821973|Experimental|Experimental Respiratory Monitoring Group|
16257184|NCT04975750|Active Comparator|Care as usual|First-line managers participate in a 3 hour lectur including a brief overview about worker health, occupational stress and the mismatch model and self-efficacy. Thereafter, they provide care-as-usual to employees at risk of future sick leave due to common mental disorders.
16257185|NCT04975737|Experimental|Vaccine Group|3590 healthy volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.
16257186|NCT04975737|Placebo Comparator|Placebo group|3590 healthy volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.
16257187|NCT04975724|Experimental|Group A Liposom Forte|Liposom Forte (2 ampoules of 28mg/2 ml) for 30 days + citalopram (10mg) for 90 days
16257188|NCT04975724|Placebo Comparator|Group B Placebo|Placebo (2 ampoules of 2 ml) for 30 days + citalopram (10mg) for 90 days
16257189|NCT04975711|Experimental|Sequence 1|Period 1: RLD2104 Period 2: HIP2105
16257190|NCT04975711|Experimental|Sequence 2|Period 1: HIP2105 Period 2: RLD2104
16257191|NCT04975698|Other|HST-NEETs|Participants will receive 2x107 /m2 cells as a single intravenous (IV) infusion. The cells will be cryopreserved ideally at 1x107 T cells per mL.
16257192|NCT04975685|Experimental|TAU + SMART|Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
16257193|NCT04975685|Sham Comparator|TAU + Sham training|Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
16257194|NCT04975685|No Intervention|TAU (treatment-as-usual)|Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
16257197|NCT04975659|Active Comparator|Nocebo|"We informed subjects in the N group a negative suggestion, using the following script: During the local anaesthetic injection, you are going to feel a sharp prick at your back; this is usually the painful part of the procedure"
16257198|NCT04975659|Placebo Comparator|Placebo|"We informed subjects in the P group a positive suggestion, using the following script: We will administer some local anaesthetic to numb your back; this will allow the procedure to be more comfortable and tolerable for you."
16257199|NCT04975646|Experimental|Test group|Prescribed exercise program
16257200|NCT04975646|No Intervention|Control group|Exercising at patient's own discretion
16257201|NCT04975633|Experimental|BodyPort Cardiac Scale|Patient will receive the Bodyport scale
16257202|NCT04975633|No Intervention|Control|Patients will receive usual care and no Bodyport scale
16257203|NCT04975620|Experimental|Franseen needle with three symmetric cutting edges|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using the Franseen needle (Acquire FNB needle; Boston Scientific): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
16257204|NCT04975620|Experimental|Multi-blade needle with three-prong tip with one tip longer than the other two|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using a multi-blade three-prong tip needle (Trident; Microtech): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
16257207|NCT04975581|Experimental|Rotator cuff repair Surgery with Augmentative patch|Open rotator cuff repair Surgery with additional application of augmentative human allograft patch
16257208|NCT04975581|Active Comparator|Rotator cuff repair surgery|Open Rotator cuff repair surgery
16257209|NCT04975568|Experimental|Therapeutic Exercise Controlled Through App With face-to-face|3 months treatment using app for HTEP and 6 people therapeutic exercise group every 15 days
16257210|NCT04975568|Active Comparator|Therapeutic Exercise Controlled Through App|3 months treatment using app for HTEP
16257211|NCT04975555|Experimental|Siltuximab|Patients who experience CRS/ICANS will receive this treatment
16257212|NCT04975542|Experimental|Treatment Group|
16257213|NCT04975542|Sham Comparator|Sham Group|
16257214|NCT04975529|Experimental|Intervention Arm|Participants in intervention schools received access to daily, online after school programming, including live sessions with sports providers (via Zoom; rotating to provide exposure to multiple sports over the course of the intervention), weekly team meetings with a health coach (via Zoom), text-messages via the Remind app, and monthly delivery of Activity Kits with sports equipment, activity books, fresh produce, and incentives directly to their homes over 6-months.
16257215|NCT04975529|Experimental|Comparison Arm|Participants in comparison schools received access to the Game on Philly app with workout and sports content that could be used asynchronously, and received one activity kit delivery with sports equipment and a self-guided activity book at the start of the program.
16257216|NCT04975516|Experimental|Group I (SBRT, chemotherapy)|Patients undergo SBRT QD or every other day for 5 fractions, and receive chemotherapy per standard of care.
16257217|NCT04975516|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy per standard of care.
16257218|NCT04975503||Young Women|Young women, aged 18 to 50 years, with documented atherosclerotic cardiovascular disease
16257219|NCT04975503||Older Women|Older women, aged >50 years, with documented atherosclerotic cardiovascular disease
16257223|NCT04975477||Training cohort|A cohort was used to develop the novel score for predicting liver decompensation
16257224|NCT04975477||Validation cohort|A cohort was used to validate the performance of novel score for predicting liver decompensation
16257225|NCT04975477||Exploratory cohort|A cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension
16257226|NCT04975464||Control|
16257227|NCT04975464||Mild CKD|
16257228|NCT04975464||CKD|
16257229|NCT04975464||Dialysis/Transplant|
16257230|NCT04975451|Experimental|ADCb|Anlotinib (anlotinib 12mg qd p.o. d1-14/21day/cycle)and Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve [AUC] 6, intravenously every 3 weeks) for six cycles
16257231|NCT04975438|Experimental|Group 1: Biologic Naïve participants receiving GSK1070806|
16257232|NCT04975438|Placebo Comparator|Group 1: Biologic Naïve participants receiving Placebo|
16257233|NCT04975438|Experimental|Group 2: Dupilumab inadequate responders receiving GSK1070806|
16257234|NCT04975438|Placebo Comparator|Group 2: Dupilumab inadequate responders receiving Placebo|
16257235|NCT04975412||acne vulgaris group (cases)|Filipino patients, aged 18-25 years old with diagnosis of Acne Vulgaris
16257236|NCT04975412||control group|healthy Filipino patients, aged 18-25 years old
16257238|NCT04975386|Active Comparator|spinal anesthesia|
16257239|NCT04975386|Active Comparator|lumbar plexus+sacral plexus block|
16257240|NCT04975373|Other|study group|study group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy
16257241|NCT04975373|No Intervention|control group|women will not receive hyaluronic acid after operative hysteroscopy
16257242|NCT04975360|Experimental|Caffeine|Administration of a time-controlled, pulsatile-release caffeine formulation (160 mg caffeine) at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
16257243|NCT04975360|Placebo Comparator|Placebo|Administration of a placebo formulation at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
16257244|NCT04975347|Experimental|kisspeptin, GnRH, naloxone|IV administration of kisspeptin 112-121; six boluses in a 35-hour period. IV administration of GnRH; two boluses in a 35-hour period. IV administration of naloxone; one bolus and an infusion over a 13-hour period.
16257245|NCT04975334|Experimental|kisspeptin, GnRH, naloxone|IV administration of kisspeptin 112-121; six boluses in a 35-hour period. IV administration of GnRH; two boluses in a 35-hour period. IV administration of naloxone; one bolus and an infusion over a 13-hour period.
16257246|NCT04975321|Active Comparator|Nu Smile Zirconia crown|Anterior primary teeth which received a NuSmile zirconia crown as a final restoration
16257247|NCT04975321|Active Comparator|Nu Smile pre veneered crown|Anterior primary teeth which received a NuSmile pre veneered crown as a final restoration
16257248|NCT04975321|Active Comparator|Composite strip crown|Anterior primary teeth which received a composite strip crown as a final restoration
16257251|NCT04975295|Experimental|LY3361237|LY3361237 administered subcutaneously (SC).
16257252|NCT04975295|Placebo Comparator|Placebo|Placebo administered SC.
16257253|NCT04975282||Bottle Feeding|The bottle feeding method was being used in the NICU (1 January -31 December 2018).
16257254|NCT04975282||Cup Feeding|The cup feeding method was being used in the NICU (1 January -31 December 2019).
16257255|NCT04975269|Active Comparator|Acetazolamide|Acetazolamide (active)
16257256|NCT04975269|Placebo Comparator|Placebo|Placebo
16257257|NCT04975256|Experimental|Dose escalation|Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
16257258|NCT04975256|Experimental|Dose expansion|Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
16257259|NCT04975243|Experimental|Unwanted Fine Facial Hair|Up to three (3) treatments with GentleMax Pro/ GentleMax Pro Plus TM for Laser Hair Removal
16257260|NCT04975230|Experimental|Sleep Self-Management|The Sleep Self-Management Intervention involves an initial 50-minute face-to-face interactive session in a private location. Participants are asked to extend time in bed by 1 hour and consistently maintain the extension on both weekends and weekdays. Bedtimes and waketimes will be assessed to ascertain which time is most modifiable for the participant's lifestyle and routine. There will be weekly follow-ups and in-person 3-week booster sessions. Sleep reports generated by the actigraphy will be shared with participants with brief action planning and goal setting to address progress towards goal achievement. A need to revise plans for future weeks will be the booster sessions' major goal.
16257261|NCT04975230|No Intervention|Diabetes Self-Management Education|The Attention Control arm will receive Diabetes Self-Management Education at the initial consultation visit via in-person contact at T1. There will be weekly follow-ups and in-person 3-week sessions. A Diabetes Self-Management Tracking Form will be used to monitor the weekly acquisition of information and plans for the 6-week intervention and at the 3-month and 6-month data points.
16257262|NCT04975217|Experimental|Treatment (FMT, FMT capsules)|Patients undergo FMT during colonoscopy. Patients also receive FMT capsules PO QW for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection of tumor(s).
16257264|NCT04975191|Other|Resources Program (RP)|
16257265|NCT04975191|Active Comparator|Personalized Feedback Program (PFP)|
16257266|NCT04975191|Active Comparator|Brief motivational intervention (BMI)|
16257267|NCT04975191|Active Comparator|Combined PFP+BMI|
16257268|NCT04975178|Experimental|MTBVAC|"Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results.
~MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vials should be stored in the site pharmacy between -20°C and -40ºC. A single vaccine vial will be used for each participant."
16257269|NCT04975178|Active Comparator|BCG|"BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
~One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial.
~BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC."
16257270|NCT04975165|Experimental|Staged total knee arthroplasty|Staged replacement of both knees in two separate surgeries.
16257271|NCT04975165|Experimental|Simultaneous total knee arthroplasty|Simultaneous replacement of both knees in a single surgery.
16257272|NCT04975152|Experimental|Neoadjuvant Cemiplimab Treatment|Participants will receive cemiplimab 350 mg IV at least 3 weeks prior to surgical resection. After surgery they will continue to receive 350 mg cemiplimab every 3 weeks for up to 8 additional doses.
16257273|NCT04975139||IDH-mutant Glioma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months and 24 months from the completion of RT (+/- 3 months), a second and third RS-fMRI will be performed.
16257274|NCT04975139||IDH-wildtype Glioma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months and 24 months from the completion of RT (+/- 3 months), a second and third RS-fMRI will be performed.
16257275|NCT04975139||Benign Brain Tumor|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months and 24 months from the completion of RT (+/- 3 months), a second and third RS-fMRI will be performed.
16257276|NCT04975126|Experimental|CatInfo tool + Face-to-face discussion with physician|audio-visual presentation (CatInfo tool) before face-to-face informed-consent discussion with the physician
16257277|NCT04975126|No Intervention|Face-to-face discussion with physician only|face-to-face informed-consent discussion with the physician only
16257278|NCT04975113|Experimental|Exercise group|Patients were given a progressive neuromuscular exercise program that included stabilization of the knee and hip joint . Green color elastic band was used in resistant exercises. When subjects used the green color Thera-Band®, they started with an easy length and increased relative to the Omni Scale .
16257279|NCT04975113|Experimental|Exercise and Taping group|"Patients in this group received the same exercises given in the exercise group for 12 weeks. In addition to these exercises, mechanical correction tape (5cm, Kinesio Tex Gold®) was applied for the knee and foot."
16257282|NCT04975087||Patients group|Individuals with primary Sjögren's syndrome
16257283|NCT04975074|Experimental|Anemia Correction Group|Continue to take the current medication orally at the current dose
16257284|NCT04975074|Experimental|Anemia uncorrected group|Continue to take the current medication orally at the current dose
16257285|NCT04975048|Experimental|Group A|Group A was consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. And it was first assigned egg yolk intervention during intervention period 1, and then macronutrient equivalent control during intervention period 2
16257286|NCT04975048|Other|Group B|Group B was also consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. It was first assigned macronutrient equivalent control during intervention period 1, and then egg yolk during intervention period 2
16257287|NCT04975035|Experimental|Zolodine group|
16257288|NCT04975022|Experimental|T group|
16257289|NCT04975022|Active Comparator|R group|
16257290|NCT04975009|Experimental|PTSD group|Participants will be screened and diagnosed using typical screening procedures and diagnostic criteria (e.g., the clinically administered PTSD scale). Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
16257291|NCT04975009|Experimental|Healthy control group|Participants will be healthy adults without a history of psychiatric illness. Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
16257298|NCT04974944|Experimental|Camrelizumab + Apatinib|On Day 1 and Day 15 of each 28-day cycle, participants receive an intravenous (IV) infusion of camrelizumab 200 mg Plus an oral apatinib 250 mg once daily. Apatinib will be administered 250 mg once every other day when completing twice tumor assessement. All treatments are administered until disease progression or unacceptable toxicity.
16257299|NCT04974944|Active Comparator|Paclitaxel + Cisplatin/Carboplatin + Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH bevacizumab 15 mg/kg). All treatments are administered until disease progression or unacceptable toxicity.
16257300|NCT04974931|Active Comparator|Patients applied with PREVENA system|This arm relates to the group of participants applied with PREVANA system post reversal of colostomy/ileostomy.
16257301|NCT04974931|No Intervention|Patients applied with conventional dressings|This arm relates to the group of participants applied with conventional dressings post reversal of colostomy/ileostomy
16257302|NCT04974918|Experimental|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of Lip defects|participants will be chosen according to liable age and information will be given about complications
16257303|NCT04974905|Other|patients with infrainguinal arterial occlusive disease after failed antegrade approach|
16257304|NCT04974892||low dose aspirin|high-risk women given LDA at ≤16 weeks.
16257305|NCT04974892||Non responders to low dose aspirin|high-risk women who have not responded to LDA and have gone on to develop PE.
16257306|NCT04974879|Experimental|study drug|osimertinib oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
16257307|NCT04974866|Experimental|study drug|EGFR TKIs
16257308|NCT04974853|Experimental|Ayurveda Formulation|Patients with hypercholesterolemia treated with Ayurveda formulation, Cardio-Complement
16257309|NCT04974840|Experimental|Treadmill training combined with thera-band|Participants will receive walking training on treadmill with thera-band at the waist. The direction of the thera-band resistance will be straight backward, backward-toward-right, and backward-toward-left. For each direction, the level of resistance and treadmill speed will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'.
16257310|NCT04974840|Active Comparator|Treadmill training alone|Participants will receive treadmill walking training at a speed that will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'. For each session, there will be three 10-min treadmill walking bouts.
16257311|NCT04974827|Experimental|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
16257312|NCT04974814|Placebo Comparator|control group|in this group patients will not receive statin before primary PCI
16257313|NCT04974814|Active Comparator|atorvastatin group|in this group patients will receive 80 mg atorvastatin single dose before primary PCI
16257314|NCT04974814|Active Comparator|rosuvastatin group|in this group patients will receive 40 mg rosuvastatin single dose before primary PCI
16257315|NCT04974801|Other|Provox Life HMEs followed by Usual Care HMEs|Use of Provox Life devices during a period of six weeks followed by use of Usual Care devices during a period of six weeks.
16257316|NCT04974801|Other|Usual Care HMEs followed by Provox Life HMEs|Use of Usual Care devices during a period of six weeks followed by use of Provox Life devices during a period of six weeks.
16257317|NCT04974788|Active Comparator|Low Intensity Respiratory Muscle Training Group|Low intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
16257318|NCT04974788|Active Comparator|Medium Intensity Respiratory Muscle Training Group|Medium intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
16257319|NCT04974788|Active Comparator|High Intensity Respiratory Muscle Training Group|High intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
16257320|NCT04974775||Critically Ill|Critically ill patients and patients in need of post-operative intensive care.
16257321|NCT04974775||Cardiac Arrest|Cardiac Arrest according to the ICD-10 I469 diagnosis.
16257322|NCT04974775||Sepsis|Sepsis according to the sepsis-3 criteria.
16257323|NCT04974775||Covid-19|Critically ill patients with a positive Covid-19 test.
16257324|NCT04974775||Influenza|Critically ill patients with a positive influenza test.
16257325|NCT04974775||Trauma|Critically ill patients after a severe traumatic event.
16257326|NCT04974775||Healthy controls|Healthy at the time of blood sampling
16257327|NCT04974762|Active Comparator|Wound infiltration|Standard intervention - surgical infiltration with local anesthetics
16257328|NCT04974762|Experimental|Truncal blocks|Truncal block for anesthetics
16257329|NCT04974749|Experimental|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight, infusion, intravenously every other week (EOW) for 52 weeks.
16257330|NCT04974736|Experimental|iEHR + Navigator|
16257331|NCT04974736|No Intervention|Usual Care Control|Usual care delivery in pediatric primary care offices.
16257332|NCT04974723||Patients Treated with Abaloparatide|Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
16257333|NCT04974723||Patients Treated with Teriparatide|Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.
16257334|NCT04974684|Experimental|Interventional group|
16257335|NCT04974684|No Intervention|Control group|
16257336|NCT04974671|Experimental|Stereotactic Body Radiation Therapy|
16257372|NCT04974463||Persistent Opioid Use at 3 months|Patients who continue to use opioids about 3 months after their joint replacement surgery
16257445|NCT04973995||Patients with shoulder pain who received backward traction test|
16257337|NCT04974658|Active Comparator|The block group (ISP)|After aseptic preparation of the injection area, the needle will be introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of 0.25% bupivacaine and 2 mg of dexamethasone on each side will be injected for each block.
16257338|NCT04974658|Placebo Comparator|control group (C)|No block will be performed
16257341|NCT04974632|Other|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
16257342|NCT04974619||Aim 1 Only: Online Survey group|Unvaccinated Spanish-language preferring young Latino men who have sex with men (YLMSM), ages 18-26 (approximately 130 in PR and approximately 130 in FL) will be asked to complete an online survey.
16257343|NCT04974619||Aim 2 Only: Interview group|Individual interviews will be conducted with key healthcare stakeholders (i.e.,healthcare clinical leadership, providers and staff, community-based organization staff)
16257344|NCT04974619||Aim 3 Only: Focus Groups|4-6 focus groups with 24 young Latino men who have sex with men (YLMSM) (12 in each site) will be conducted to obtain feedback on the intervention, using an iterative process, whereby researchers conduct 1 focus group in FL and a complementary focus group in Puerto Rico and then revise the content based upon feedback from those focus groups, prior to proceeding to the next round of focus groups.
16257345|NCT04974606|Experimental|Coffeeberry 100 mg beverage|Appearance-matched to the other beverages
16257346|NCT04974606|Experimental|Coffeeberry 300 mg beverage|Appearance-matched to the other beverages
16257347|NCT04974606|Placebo Comparator|Placebo beverage|Appearance-matched to the other beverages
16257348|NCT04974606|Active Comparator|Caffeine 75 mg beverage|Appearance-matched to the other beverages
16257349|NCT04974593|Experimental|H2BT-positive|
16257350|NCT04974593|Experimental|H2BT-negative|
16257351|NCT04974580|Experimental|CoachingOnlyArm|Phone Coaching; no Digital Coaching, no NRT: This arm will receive only the two phone counseling calls which all other arms will receive.
16257352|NCT04974580|Experimental|DigitalArm|Phone Coaching + Digital Coaching; no NRT: This arm will receive digital content (text messages with links to online materials) in addition to to the two phone counseling calls which all arms will receive.
16257353|NCT04974580|Experimental|CoachingNRTArm|Phone Coaching + NRT; no Digital Coaching: This arm will receive Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
16257354|NCT04974580|Experimental|DigitalNRTArm|This arm will receive digital content (text messages with links to online materials) AND Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
16257355|NCT04974567||Women recently diagnosed with breast cancer who have not undergone any treatment.|Tear sample collection
16257356|NCT04974554|Experimental|FIT Families|1. FIT Families is a 6 month comprehensive multicomponent family-based behavioral intervention delivered by Community Health Workers (CHWs). FIT Families integrates home-based service delivery, Motivational Interviewing (MI; intrinsic motivation), Cognitive Behavior Skills Treatment (CBST; skills acquisition), supervised physical activity (PA), and Contingency Management (CM; extrinsic motivation). Sessions occur twice weekly for the first three months, and weekly for the second three months.
16257357|NCT04974554|Active Comparator|Home-Based Family Support|2. Home-based Family Support (HBFS). Adolescents and their primary caregiver randomly assigned to HBFS will receive 6 months of weekly, home-based, client-centered, non-directive supportive family counseling.
16257358|NCT04974541|Experimental|Cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga
16257359|NCT04974541|Active Comparator|Cardiac rehabilitation with standard psychosocial care|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial education component
16257362|NCT04974515|Experimental|Low intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at low intensity application for 20 minutes per day for 6 consecutive weeks.
16257363|NCT04974515|Active Comparator|High intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at high intensity application for 20 minutes per day for 6 consecutive weeks.
16257364|NCT04974502|Experimental|Non-smoker group|
16257365|NCT04974502|Experimental|Smoker group|
16257446|NCT04973995||Patients with shoulder pain who received Cui's test|
16257373|NCT04974463||No Persistent Opioid Use at 3 months|Patients who do not use opioids after about 3 months following joint replacement surgery
16257374|NCT04974450|Experimental|Trigona Honey|The intervention will be given by oral route in a form of liquid of 70-gram trigona honey once daily for 8 weeks
16257375|NCT04974450|Active Comparator|Control|The intervention will be given by oral route in a form of liquid of 70-gram artificial honey once daily for 8 weeks
16257376|NCT04974411||Infection|Patients diagnosed with infection but did not reach the sepsis marker.
16257377|NCT04974411||sepsis|The patient was diagnosed with sepsis but did not develop septic shock
16257378|NCT04974411||sepsis shock|The patient was diagnosed with sepsis shock
16257379|NCT04974398|Experimental|Group A|Group A (study group): Penpulimab plus cisplatin and gemcitabine
16257380|NCT04974398|Placebo Comparator|Group B|Group B (control group): Placebo plus cisplatin and gemcitabine
16257381|NCT04974385|Experimental|Liposomal Bupivacaine|Experimental group will receive ISNB with admixed LB (10 mL) and 0.5% bupivacaine (10 mL) total of 20 mL.
16257382|NCT04974385|Active Comparator|Non-liposomal Bupivacaine|Comparator group will receive ISNB with 20 mL of 0.5% non-liposomal bupivacaine
16257383|NCT04974372||HT group|Patients have echocardiography examination before and after heart transplantation.
16257384|NCT04974372||Control group|healthy volunteers who had no history of hypertension, diabetes mellitus, renal failure or other organic diseases based on physical examinations, biochemical tests, electrocardiogram, echocardiography were enrolled as control group
16257385|NCT04974359|Experimental|Lu AG06466|Participants will receive an oral titrated dose of Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
16257386|NCT04974359|Placebo Comparator|Placebo|Participants will receive an oral dose of placebo matching to Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
16257387|NCT04974346|Experimental|study arm|"External beam radiotherapy:
~Pelvic and para-aortic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.
~Concurrent chemotherapy:
~Weekly cisplatin 40mg/m2 during external beam radiotherapy.
~Brachytherapy:
~High dose rate(HDR) Brachytherapy. The dose of high-risk clinical target volume(HR CTV) D90 or Point A should be 85Gy+/-10%. The dose of intermediate-risk clinical target volume(IR CTV) D98 should be 60Gy at least."
16257388|NCT04974346|Active Comparator|control arm|"External beam radiotherapy:
~Pelvic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.
~Concurrent chemotherapy:
~Weekly cisplatin 40mg/m2 during external beam radiotherapy.
~Brachytherapy:
~HDR Brachytherapy. The dose of HR CTV D90 or Point A should be 85Gy+/-10%. The dose of IR CTV D98 should be 60Gy at least."
16257389|NCT04974333|Experimental|Mobile health application|"Participants assigned to the intervention group will use a mobile application on their smart phones that will assist the patients with their diabetes control, provide and update information on their clinical history, offer a monitoring their nutritional and physical activity habits as well as anthropometric measurements, provide recommendations how to improve on nutritional habits and physical activity behavior, assist in planning and reminding on clinical appointments.
~The duration of the intervention will be 12 months. Each patient will be invited to follow-up visits and measurements each three months (month 3, month 6, month 9 and month 12)."
16257390|NCT04974333|No Intervention|Standard care|Participants assigned to the control arm will continue their regular standard diabetes care without mobile health technology assistance.
16257391|NCT04974320||MINOCA|All patients diagnosed with MINOCA in precision cohort (NCT04044066) will be included.
16257392|NCT04974320||acute myocardial infarction (AMI）|All patients diagnosed with acute myocardial infarction（AMI）in precision cohort (NCT04044066) will be included.
16257393|NCT04974320||unstable angina (UA)|The patients diagnosed with unstable angina（UA) in precision cohort (NCT04044066) will be selected according to the matching method.
16257394|NCT04974320||MINOCA （multi-center）|The patients diagnosed with MINOCA in multi-center cohort will be included.
16257395|NCT04974307|Experimental|Device|use of OrCam MyEye 2.0
16257396|NCT04974294|Active Comparator|PPV23|
16257397|NCT04974294|Active Comparator|PCV13|
16257398|NCT04974294|Placebo Comparator|Saline placebo|
16257399|NCT04974281|Other|PD-1+TACE+Len|PD-1 Antibody and Lenvatinib Plus TACE
16257400|NCT04974268|Experimental|Exercise and nutritional program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal (non-mandatory), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
16257401|NCT04974268|No Intervention|Control Group|Control group will receive recommendations for aerobic unsupervised exercise 150 min per week, standard dietary recommendations (Mediterranean diet pattern and 1800 Kcal diet), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
16257402|NCT04974255|Experimental|Operated Patients|Measurement of fibrosis degree and Anti-tTG levels
16257403|NCT04974242|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
16257404|NCT04974242|No Intervention|Waiting-list control|Continue on the waiting list for rotator cuff repair surgery, as per usual care.
16257405|NCT04974229||acute non-specific low back pain|patients with acute low back pain of (< 6 weeks) were consecutively included with or without radiating pain, aged 18 to 60 years with a pain-free episode for at least 3 months before the onset of their current back pain. They were also required to be able to read and understand the Dutch language.
16257406|NCT04974216|Experimental|R-Lena-Tafa|"12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide
~Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices"
16257407|NCT04974203|Experimental|CT Value <25|Patients with CT value <25
16257414|NCT04974151|Active Comparator|amlodipine (5mg/d)|Amlodipine besylate tablets (5mg/d)
16257415|NCT04974151|Experimental|amlodipine folic acid (5.8mg/d)|Amlodipine besylate and folic acid tablets (5mg:0.8mg)
16257416|NCT04974151|Experimental|amlodipine folic acid (5.8mg/d) + folic acid (0.8mg/d)|Amlodipine besylate and folic acid tablets (5mg:0.8mg) with 0.8mg/d folic acid tablets
16257417|NCT04974138|Active Comparator|CC with amlodipine 5mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besylate tablets (5mg/d)
16257418|NCT04974138|Experimental|CC with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
16257419|NCT04974138|Active Comparator|CT with amlodipine 5mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besylate tablets (5mg/d)
16257420|NCT04974138|Experimental|CT with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
16257421|NCT04974125|Experimental|Arm A :Aspiration of peritoneal gas through a drain|"Patients in experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out by a drain.
~Then, patients will be followed-up during 7 days after surgery."
16257422|NCT04974125|Active Comparator|Arm B : Manual evacuation of the peritoneal gas, via the trocar|"Laparoscopic or robotised laparoscopic surgery + Trocar
~Patient in this experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out carried out manually using the trocar (standard of care).Then, patient will be followed-up during 7 days after surgery."
16257423|NCT04974112||General Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
16257424|NCT04974112||Thoracic Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
16257425|NCT04974112||orthopedics|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
16257426|NCT04974112||Gastroenterology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
16257427|NCT04974112||Respiratory|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
16257428|NCT04974112||Neurology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
16257430|NCT04974086|Experimental|CDS Tool Evaluation|All participants will receive intervention and feasibility, acceptability, and usability of intervention will be assessed from each participant cohort group.
16257431|NCT04974073|No Intervention|control group|with traditional western medicine treatment based on underlined disease
16257432|NCT04974073|Experimental|PHY606|PHY606 7.5gm BID for 3 months
16257433|NCT04974073|Other|Healthy group|PHY606 7.5gm BID for 2 days
16257434|NCT04974060|Experimental|Remifentanil intervention|After the satisfactory analgesia and sedation, remifentanil will continuously infuse an escalating dose in the sequence of 0.02, 0.04, 0.06, and 0.08 μg/kg/min, each dose infusion lasting at least 30 minutes.
16257435|NCT04974047|Experimental|Cohort A (Responder)|Participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% will receive 3 cycles of tislelizumab (200 milligrams [mg]/cycle) plus 2 cycles of chemotherapy doublet (cisplatin + paclitaxel)
16257436|NCT04974047|Experimental|Cohort B (Non-responder)|Participants with a decrease in PET SUVmax < 35% will receive 3 cycles of tislelizumab (200 mg/cycle) plus 2 cycles of investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) plus concurrent radiotherapy (40 grays/20 fractions).
16257437|NCT04974021||Participants|HFrEF patients undergoing iron therapy with intravenous carboxymaltose (FCM). FCM administered dosage as per clinical routine. FCM administration is repeated no sooner than 3 months than last therapy, based on repeat ferritin and transferrin saturation levels.
16257438|NCT04974008|Experimental|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
16257439|NCT04973995||Patients with shoulder pain who received ER lag sign|
16257440|NCT04973995||Patients with shoulder pain who received External rotation resistence strength test|
16257441|NCT04973995||Patients with shoulder pain who received Patte's test|
16257442|NCT04973995||Patients with shoulder pain who received Errsair test|
16257443|NCT04973995||Patients with shoulder pain who received speed test|
16257444|NCT04973995||Patients with shoulder pain who received Yergason test|
16257449|NCT04973969|Other|study group|The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.
16257450|NCT04973956|Active Comparator|Relaxation group|This group will perform the APMR
16257451|NCT04973956|Active Comparator|Control group|This group will perform the control intervention
16257452|NCT04973930|Active Comparator|Tele-Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy is a time-limited, affect-focused treatment of repeatedly demonstrated efficacy for major depression in the general population. It was also helpful to patients with comorbid depression and breast cancer in our prior randomized controlled trial. IPT focuses on the connection between upsetting life circumstances (e.g., diagnosis of breast cancer) and their effect on mood, and vice versa. We have considerable experience, enhanced by the Covid-19 lockdown, in delivering IPT as a HIPAA-secure tele-therapy.
16257453|NCT04973930|Active Comparator|Tele-Serotonin Reuptake Inhibitor|Both venlafaxine and escitalopram are FDA-approved treatments with demonstrated efficacy in treating major depression in the general population. Although little formal research has been done in treating patients with depression and breast cancer, these two are the favored treatments among serotonin reuptake inhibitors due to minimal interference with oncotherapy. The choice between prescribing these two study medications will depend upon prior treatment history. Venlafaxine XR will be serially titrated under expert psychopharmacologist tele-guidance from 75 mg to 300 mg daily, depending on clinical response and tolerance. Escitalopram will similarly be dosed between 5 mg and 30 mg daily.
16257454|NCT04973917|Experimental|respiratory support after cardiac surgery.|respiratory support after cardiac surgery. Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
16257455|NCT04973904|Experimental|PD-1+Paclitaxel+Cisplatin+Bevacizumab|"Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W)
~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)
~Cisplatin 50mg/m2 (Q3W)
~Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)"
16257457|NCT04973878|Experimental|Group A|EGD performed before the Colonoscopy
16257458|NCT04973878|Experimental|Group B|Colonoscopy performed before the EGD
16257459|NCT04973865||Disease Population|50 Patients who have chronic diseases, such as cardiovascular, will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor. (ACSM risk stratification guide lines)
16257460|NCT04973865||Healthy|30 Healthy individual with no cardiac diseased.
16257461|NCT04973852|Experimental|Exoskeleton|5 sessions of overground ambulation with wearable exoskeleton where heart rate is monitored over each session.
16257462|NCT04973839|Experimental|Video optimizing expectations before PMR (unguided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided)
16257463|NCT04973839|Experimental|Video optimizing expectations before PMR (guided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided)
16257464|NCT04973839|Active Comparator|Neutral video before PMR (unguided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided),
16257465|NCT04973839|Active Comparator|Neutral video before PMR (guided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided)
16257466|NCT04973826|Experimental|ATM-AVI treatment arm|Chinese healthy volunteers
16257467|NCT04973813|Experimental|Guideline + Active Choice + action&coping planning (GA+)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning.
16257468|NCT04973813|Experimental|Guideline + Active Choice (GA)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
16257469|NCT04973813|Experimental|Guideline + Information (GI)|Participants received the national physical activity guideline, and information about pros and cons of physical activity, and possible barriers to physical activity.
16257470|NCT04973813|Other|Guideline (G)|Comparison arm. Participants received the national physical activity guideline.
16257471|NCT04973800|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg ON PO for 28-30 days
16257472|NCT04973800|Placebo Comparator|Control arm: Placebo|Sucrose placebo ON PO for 28-30 days
16257473|NCT04973787||axSpA|Patients with clinical diagnosis of axialSpondyloarthritis according to ASAS criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
16257474|NCT04973787||RA|Patients with clinical diagnosis of Rheumatoid arthritis according to 2010 ACR/EULAR classification criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
16257475|NCT04973787||Control|Healthy participants, e.g. with no clinical diagnosis of rheumatic inflammatory disease, crossed by age, gender and diet profile
16257476|NCT04973761|Other|Strip composite crowns|
16257477|NCT04973761|Experimental|Zirconium crowns|
16257478|NCT04973748|Active Comparator|Conrol|Pain: All patients will continue with standard multimodal analgesia (as above) while inpatient. The nursing staff will assess and document pain severity by Likert scale every 4 hours in EPIC, as is standard of care.
16257565|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in elderly subjects.|
16257479|NCT04973748|Experimental|Open Label Conditioning|Conditioning therapy in the Open label conditioning (OLC) group: Patients in the OLC group will receive conditioning therapy with all doses of opioids and placebo. Given reduced sense of smell and taste and administration of medications via nasogastric or gastric tube, taste of the medication will not be a consideration for formulation of placebo. At all times that oxycodone or placebo medication is administered, the patient will undergo conditioning therapy. As described here, the patient will 1) be given time to note the similar color and appearance of the medications and 2) be given simultaneous exposure to a clove oil Sniffin' sticks, which has been shown to stimulate both olfactory and trigeminal chemoreceptors.
16257480|NCT04973735|Experimental|30mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
16257481|NCT04973735|Experimental|150mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
16257482|NCT04973735|Experimental|600mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
16257483|NCT04973735|Experimental|1200mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
16257484|NCT04973735|Experimental|2400mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
16257485|NCT04973735|Placebo Comparator|Placebo|Placebo is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
16257486|NCT04973722|Experimental|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
16257487|NCT04973722|Active Comparator|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
16257488|NCT04973709||Delirium with dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
16257489|NCT04973709||Dementia without Delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
16257490|NCT04973709||Delirium without Dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
16257491|NCT04973709||No dementia, No delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
16257492|NCT04973696|Experimental|Toolkit for Optimal Recovery after Orthopedic Injury - Active|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
16257493|NCT04973696|Active Comparator|Minimally Enhanced Usual Care (MEUC) - Control|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
16257494|NCT04973683|Experimental|Treatment (AL101)|Patients receive AL101 IV over 60 minutes QW for 6-8 weeks in the absence of disease progression or unacceptable toxicity. Within 24-72 hours after the last infusion of AL101, patients undergo surgery per standard of care. Patients may continue AL101 after surgery at the discretion of the study doctor.
16257495|NCT04973670|Experimental|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h
16257496|NCT04973670|Active Comparator|placebo|The same amount of NS containing only sivelestat sodium excipients
16257497|NCT04973657|Experimental|VK0214 Active 20mg|20mg QD
16257498|NCT04973657|Experimental|VK0214 Active 40mg|40mg QD
16257499|NCT04973657|Placebo Comparator|Placebo|Placebo QD
16257500|NCT04973644|Experimental|Internet + Digital Hospital-remote home management mode|Remote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction.
16257501|NCT04973644|No Intervention|the traditional management mode|Routine dietary and exercise recommendations, education as well as monitor in the clinic.
16257502|NCT04973618|Experimental|APVO436|CD123 and CD3 epsilon bispecific antibody
16257503|NCT04973605|Experimental|Part 1 Dose Escalation|BGB-11417 + dexamethasone
16257504|NCT04973605|Experimental|Part 1 Dose Finding|BGB-11417 + dexamethasone + carfilzomib
16257505|NCT04973605|Experimental|Part 2 Cohort Expansion|BGB-11417 + dexamethasone or BGB-11417 + dexamethasone + carfilzomib
16257506|NCT04973592||Child with Blunt Abdominal Trauma|
16257507|NCT04973579||Simultaneous cardiac surgery and carotid stenting|Patients with Heart Team and NeuroVascular Team recommendation to perform simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) including proximal or distal neuroembolic protection and cardiac surgery (CABG or surgical valve replacement / repair procedure)
16257566|NCT04973189|Placebo Comparator|placebo in elderly subject|
16257511|NCT04973553|Experimental|participants with acute stroke|(a) a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation, (b) been admitted to the acute hospital for rehabilitation, (c) UL hemiparesis or hemiplegia with a ≥ trace of muscle contraction (≥grade 1 at wrist extensors measured by the MRC Scale and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS)[24], (d) the age of > 18 years and (e) the ability to provide informed consent.
16257512|NCT04973540|Experimental|IBS Angel|Iron Bioresorbable Scaffold System
16257513|NCT04973527|Experimental|LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
16257514|NCT04973501|Experimental|Manual physiotherapeutic correction (MFK) Method|The MFK was chosen for our clinical experience- it was developed in Czech Republic.The MFK Method consists of five established steps: anamnesis, assessment, diagnoses, treatment and checkup. In the course of all those steps, the computer MFK System software is used. This software allows us to display and visualize the patient´s functional muscle imbalance at the day of the assesment based on the assessment of muscle strength by manual muscle tests. Hereafter the physiotherapist performs muscle test and records results in the software. Then, the software visually describes the patient´s imbalance at the day of the assessment. Based on these diagnostic maps and the software suggestions the therapist chooses the body areas where the therapeutic techniques may be applied.
16257515|NCT04973501|Experimental|Dynamic Neuromuscular Stabilization (DNS) Method|Dynamic Neuromuscular Stabilization (DNS) is a neurophysiological rehabilitative approach encompassing a set of functional tests assessing the quality of postural stabilization patterns and a treatment approach based on developmental kinesiology models. DNS diagnosis is based on comparison of the individual's postural stabilization pattern to the developmental stabilization pattern of healthy infants. The assessor uses DNS evaluation sheet to screen client's posture in 11 developmental positions if the patient can perform them all. If not, only the tests that the patient can perform sufficiently and safely serve for functional assessment. The strategy of DNS manual treatment is to utilize only those functional exercises in developmental positions that are the most suitable for the specific client. The goal is to improve spinal and joint stability by focusing on the global stabilization system consequently improving quality of movement and mobility.
16257516|NCT04973488|Experimental|Treatment arm|In the treatment arm, Therapeutic plasma exchange will be conducted in the first 24 hours after being admitted into the intensive care unit, after which convalescent plasma from donors that have had COVID-19 will be transfused
16257517|NCT04973488|No Intervention|Control arm|In the control arm, patients will receive standard COVID-19 treatment
16257518|NCT04973475|Experimental|Experimental: Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic distal gastrectomy with lymph node dissection for gastric adenocarcinoma.
16257519|NCT04973462|Active Comparator|Triazavirin group|Patients will take the standard treatment COVID-19 + Triazavirin 250mg three times daily for 7 days]
16257520|NCT04973462|Active Comparator|Oseltamivir group|Patients will take the standard treatment COVID-19 + Oseltamivir 75 mg twice daily for 7 days]
16257521|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD1222|Previously vaccinated with AZD1222, dosing on day 1
16257522|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD2816|Previously vaccinated with AZD1222, dosing on day 1
16257523|NCT04973449|Other|mRNA booster: one dose of AZD1222|Previously vaccinated with an mRNA vaccine, dosing on day 1
16257524|NCT04973449|Other|mRNA booster: one dose of AZD2816|Previously vaccinated with an mRNA vaccine, dosing on day 1
16257525|NCT04973449|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
16257526|NCT04973449|Other|2 doses of AZD2816, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
16257527|NCT04973449|Other|2 doses of AZD2816, 12 weeks apart|Previously unvaccinated. First dose day 1, second dose day 85
16257528|NCT04973449|Other|one dose of AZD1222 + one dose AZD2816, 4 weeks apart|Previously unvaccinated. Dose of AZD1222 on day 1, dose of AZD2816 on day 29
16257529|NCT04973436|Experimental|Dialectical Behavioral Therapy Skills Training|The DBT-MLC intervention will teach participants dialectical behavioral therapy-based skills to reduce psychological distress through improved physical symptom management, emotion regulation, and tolerance of uncertainty. The DBT-MLC intervention will consist of 8-10 weekly sessions that will last approximately 60 minutes each.
16257530|NCT04973423|No Intervention|CALM|Tight control of inflammatory activity by calprotectin.
16257531|NCT04973423|Other|CALM + IRM|Tight control of inflammatory activity by calprotectin associated with transmural evaluation.
16257532|NCT04973410|Other|Group A|FFR negative/non-significant (>0.80) and IMR negative (<25)
16257533|NCT04973410|Other|Group B|FFR negative/non-significant (>0.80) and IMR positive (>25)
16257534|NCT04973371|Experimental|Home-based GeneXpert TB test|Screening household contacts + home-based GeneXpert® MTB/RIF TB testing for those with TB symptoms + immediate referral for clinic-based treatment initiation.
16257535|NCT04973371|No Intervention|Standard home-based TB symptom screening with immediate referral|Screening household contacts + immediate referral for clinic-based TB testing
16257536|NCT04973358|Experimental|BuccoTherm|buccotherm mouthwash
16257537|NCT04973358|Placebo Comparator|Placebo|placebo mouthwash
16257538|NCT04973345|Experimental|Terbutaline Arm A|• Arm A: (n=6) IV bolus (0.25 mg) over 5 minutes SQ administration (0.25 mg) Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
16257539|NCT04973345|Experimental|Terbutaline Arm B|• Arm B: (n=6) SQ administration (0.25 mg) IV bolus (0.25 mg) over 5 minutes Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
16257563|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in healthy young adults.|
16257540|NCT04973345|Experimental|Terbutaline Arm C|• Arm C: (n=6) SQ (0.25 mg) IV low dose over 5 minutes IV medium dose over 5 minutes IV high dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
16257541|NCT04973345|Experimental|Terbutaline Arm D|• Arm D: (n=6)SQ (0.25 mg) IV medium dose over 5 minutes IV high dose over 5 minutes IV low dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
16257542|NCT04973345|Experimental|Terbutaline Arm E|• Arm E: (n=6) SQ (0.25 mg) IV high dose over 5 minutes IV low dose over 5 minutes IV medium dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
16257545|NCT04973319|Experimental|test group|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment. The subject who has a second primary malignant tumor in a non-breast area will continue to be followed up until a recurrent disease or death due to primary breast cancer. The subjects who are hormone receptor-positive will be advised to receive endocrinotherapy simultaneously. Within 28 days after the last administration of the test drug, the subjects in the test group must complete the safety follow-up and the end-of-treatment visit and continue to receive the follow-up visit.
16257546|NCT04973319|Other|control group|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
16257547|NCT04973306|Experimental|Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody|Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
16257548|NCT04973306|Active Comparator|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
16257549|NCT04973293|Experimental|Neoadjuvant treatment|"Participants will receive 4 doses of sintilimab (200 mg, IV) and bevacizumab (15 mg/kg, IV) every 3 weeks (Q3W). Participants will also receive 4 doses of carboplatin (AUC=5, IV) and pemetrexed (500 mg/m2, IV) Q3W.
~Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.
~After the second dose of sintilimab, bevacizumab and chemotherapy, contrast-enhanced chest CT will be performed. Patients with progression disease will receive surgery without the last 2 doses of treatment."
16257550|NCT04973280||Healthcare Professionals (HCPs)|The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available. A sample of HCPs from EEA countries who manage care for patients with certain haematologic conditions and who may/do prescribe REBLOZYL will be recruited from the target population of HCPs who were sent the REBLOZYL aRMMs in these countries. The final list of countries to be included may include 1) only countries where reimbursement has been sought and gained, 2) a geographically representative sample (e.g., northern, southern, eastern, and western EU Members States to the degree possible based on the first criteria), 3) a mixture of countries with higher and lower REBLOZYL usage, and 4) other feasibility considerations such as the ability to conduct direct-to-HCP non-market research studies.
16257551|NCT04973267|Experimental|Game Plan for PrEP|Participants will be asked to use Game Plan for PrEP for however long they wish. Game Plan for PrEP is a web-based intervention that provides users with feedback about how much their risk for HIV is reduced on PrEP, their risk for bacterial STIs, and helps them make a plan to take their medication regularly and reduce their risk for STIs. Game Plan for PrEP also providers users with feedback about their alcohol use compared to others in their age group and encourages them to make a plan to reduce it.
16257552|NCT04973267|Sham Comparator|Lifestyle Habits Videos|Participants in this condition will view several videos that encourage them to adopt sleep hygiene and healthy diet behaviors. The videos were selected to last as long as the average time users engage with Game Plan for PrEP in its initial modules.
16257553|NCT04973254|Experimental|Community-based intervention|CAB-RPV LA delivered in community settings
16257554|NCT04973254|Active Comparator|Standard of care|HIV treatment (CAB-RPV LA or oral medication) delivered in the HIV clinic
16257555|NCT04973241||OPG|
16257556|NCT04973241||CBCT|
16257557|NCT04973228|Active Comparator|Experimental: ARQ-154 Foam 0.3%|
16257558|NCT04973228|Placebo Comparator|Placebo Comparator: ARQ-154 Vehicle Foam|
16257559|NCT04973215||work package 1|all participants in Norwegian introduction program and their family relations
16257560|NCT04973215||work package 2|strategic sample of refugees with health problems currently participating in the introduction program
16257561|NCT04973215||work package 3|3-6 families from which one or more participate in the introduction program and one or more have health problems
16257567|NCT04973176|Active Comparator|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Standard Bougie|Patients randomised to standard bougie will be intubated using standard bougie (Frova® airway intubation catheter )
16257568|NCT04973176|Active Comparator|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Flexi-tip Bougie|Patients randomised to Flexi-tio bougie will be intubated using Flexi-tip bougie (P3 medical Ltd, Bristol, UK)
16257569|NCT04973163|Experimental|Monotherapy Arm|Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
16257570|NCT04973163|Experimental|Combination Therapy Arm|Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
16257571|NCT04973150|Experimental|the children were given gauze covering training in one eye or both eyes|According to the operation method, the children were given gauze covering training in one eye or both eyes.
16257572|NCT04973150|No Intervention|Using regular tablet computer to play cartoon animation video|
16257575|NCT04973124|Active Comparator|SEVODEX Group|The SEVODEX group will receive intraoperative dexmedetomidine at a fixed infusion rate of 0.25 mcg/kg/h
16257576|NCT04973124|Placebo Comparator|SEVO Group|The SEVO group will not receive dexmedetomidine during surgery.
16257577|NCT04973111|Experimental|CT-868|SC dose of CT-868 Intervention: Drug: CT-868
16257578|NCT04973111|Placebo Comparator|Placebo|SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo
16257579|NCT04973111|Active Comparator|Active Comparator|SC dose of Active Comparator Intervention: Drug: Active Comparator
16257580|NCT04973098|Experimental|5 dose levels each with or without lymphocyte clearance were tentatively determined.|CT0181 Cells were transfused after lymphocyte clearance with fludarabine and cyclophosphamide or without lymphocyte clearance.
16257581|NCT04973085|Experimental|Cold circulated water|Research staff will help position the participant on the bed of the MRI scanner. An adhesive wrap will be applied to the front of the participant's neck. Participants will be in constant communication with study personnel throughout the intervention by means of a 2-way intercom. When ready, the water circulation machine will be turned on. Water will circulate from the machine, through a long set of tubes, to the neck wrap, then back to the machine in a closed-loop system. At the beginning of the intervention, body temperature water will be circulated through the neck wrap. Over 5-10 minutes, the study coordinator and the participant will work together to slowly lower the temperature of the circulated water to identify the lowest tolerable temperature. The participant will be maintained at the lowest tolerable temperature for the remainder of the 2 hour intervention, and can adjust the temperature of the circulated water as often as desired throughout the study.
16257582|NCT04973085|Active Comparator|Body temperature circulated water|The procedure for the body temperature study arm is identical to the cold study arm, except the water temperature will be kept at body temperature for the duration of the 2 hour intervention.
16257583|NCT04973072|No Intervention|Control|Participants in this arm will not receive any intervention.
16257584|NCT04973072|Experimental|One large reward|Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
16257585|NCT04973072|Experimental|Small wins|Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
16257586|NCT04973059|Active Comparator|Summer Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the summer. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
16257587|NCT04973059|No Intervention|Summer Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the summer no power assist.
16257588|NCT04973059|No Intervention|Winter Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the winter no power assist
16257589|NCT04973059|Active Comparator|Winter Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the winter. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
16257590|NCT04973033|Experimental|Tofactitinib|Tofacitinib 5mg twice a day
16257591|NCT04973020|Experimental|Treatment group|
16257592|NCT04973007|Active Comparator|Gadoxetate disodium exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
16257593|NCT04973007|Active Comparator|Gadobenate Dimeglumine exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
16257594|NCT04972994|Active Comparator|laparoscopic intracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic intracorporeal versus for right and left hemicolectomies in management of colonic cancers
16257595|NCT04972994|Active Comparator|laparoscopic extracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
16257596|NCT04972981|Experimental|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of ADCT-901 as monotherapy.
16257597|NCT04972981|Experimental|Part 2: Dose Expansion|"In Part 2 (dose expansion), participants will receive ADCT-901 monotherapy at the dose identified in Part 1 (dose escalation).
~Participants will be split into two groups:
~Group 1: An indication for which ADCT-901 showed in Part 1 to have preliminary activity.
~Group 2: A group of participants with Part 1 indications, except for the one selected in Group 1 of Part 2. No more than 30% of participants with the same indication are allowed in this basket group."
16257687|NCT04972396|Experimental|Part 3|
16257688|NCT04972383|Experimental|Platelet Rich Plasma group|single injection platelet rich plasma
16257602|NCT04972955||Pregnant women diagnosed with gestational diabetes|Pregnant women who have been diagnosed with gestational diabetes during the current pregnancy
16257603|NCT04972942|Other|Interventional|"Daratumumab (DARA) treatment post-HCT 8 mg/kg/dose
~Induction: DARA 16 mg/kg IV weekly x 8 doses (Weeks 1-8)
~Consolidation: DARA 16 mg/kg IV every 2 weeks x 8 doses (Weeks 9-24)
~Maintenance: DARA 16 mg/kg IV every 4 weeks x 5 doses following start of treatment (Weeks 25-44)"
16257604|NCT04972929|Experimental|Spinal Manipulation|The spinal manipulation (SM) group will receive manually delivered SM limited to the thoracic spine.
16257605|NCT04972929|Sham Comparator|Sham Spinal Manipulation|Sham-spinal manipulation will be delivered by setting the expansion control knob on an Activator II (Activator Methods®) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician. At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted.
16257606|NCT04972916|Other|Patient Navigation-based Tobacco Harm Reduction Intervention|All participants will receive a smoking cessation educational brochure and patient navigation intervention delivered over 2 months.
16257607|NCT04972903||Group 1.HIV+/SAM+|Group 1. HIV-infected with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV+/SAM+)
16257608|NCT04972903||Group 2. HIV+/SAM-|Group 2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)
16257609|NCT04972903||Group 3. HIV-/SAM+|Group 3. HIV-negative with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV-/SAM+)
16257610|NCT04972903||Group 4. HIV-/SAM-|Group 4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)
16257611|NCT04972890|Placebo Comparator|Control group|with 2cc saline/NaCl 0,9% solution once at baseline
16257612|NCT04972890|Experimental|Stem Cell Group|with umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution once at baseline
16257613|NCT04972877|Active Comparator|Treatment group|Treatment group protocol：participants will receive electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
16257614|NCT04972877|Sham Comparator|Control group|Control group protocol：participants will receive sham electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
16257615|NCT04972864|Active Comparator|Exercise training group|Individuals in the treatment group were given respiratory exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) and inspiratory muscle training with the Threshold IMT (T-IMT) device. Inspiratory muscle training was applied for 30 minutes, 3 times a day, 7 days a week for 6 weeks.
16257616|NCT04972864|Placebo Comparator|Control training group|Breathing exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) were taught in the control group and only the exercise link containing these exercises was sent.
16257617|NCT04972851|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
16257618|NCT04972851|Active Comparator|Implementation as Usual (IAU)|The organizations will implement SDLMI as usual. The research team will be available to provide support on the SDLMI intervention as needed.
16257619|NCT04972838|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
16257620|NCT04972838|Active Comparator|Implementation as Usual (IAU)|The organizations will implement RR as usual. The research team will be available to provide support on the RR intervention as needed.
16257621|NCT04972825|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
16257622|NCT04972825|Active Comparator|Implementation as Usual (IAU)|The organizations will implement Mind the Gap as usual. The research team will be available to provide support on the Mind the Gap intervention as needed.
16257623|NCT04972812||Usual care|Acute stroke patients receiving usual care
16257624|NCT04972799|Experimental|Treatment/Placebo|treatment sequence at day 0 and placebo sequence at 6 months
16257625|NCT04972799|Experimental|Placebo/Treatment|placebo sequence at day 0 and treatment sequence at 6 months
16257626|NCT04972786|Sham Comparator|Sham rTMS|Participants will receive sham rTMS for 10-20 minutes.
16257627|NCT04972786|Active Comparator|Active rTMS|Participants will receive active rTMS for 10-20 minutes.
16257628|NCT04972773|Experimental|MM + standard-therapy intervention group|In addition to receiving standard-therapy, participants will be asked to practice MM using a MM app for at least 10 minutes per day from weeks 0 to 8.
16257629|NCT04972773|No Intervention|Standard-therapy control group|Participants randomized to the standard-therapy control group will receive their typical in- or out-patient therapy. This is expected to include small doses of MM.
16257630|NCT04972760|Experimental|baricitinib arm|Patients receive baricitinib plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
16257631|NCT04972760|Placebo Comparator|placebo arm|Patients receive placebo plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
16257632|NCT04972747|Experimental|Suggest skin care with sunflower oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and sunflower oil will be applied twice a day for 14 days.
~Absorption of sunflower oil for preterm babies will be provided by using a baby massage application.
~Before the massage, 3-4 ml of sunflower oil will be applied to the whole body surface except the genital area and scalp..
~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
16257633|NCT04972747|Experimental|Suggest skin care with cocunut oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and coconut oil will be applied twice a day for 14 days.
~Absorption of coconut oil for preterm babies will be provided by using a baby massage application.
~Before the massage, 3-4 ml of coconut oil will be applied to the whole body surface except the genital area and scalp.
~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
16257634|NCT04972734|Experimental|NEC|premature newborns developing a NEC
16257635|NCT04972734|Active Comparator|Healthy control|premature newborns without NEC
16257636|NCT04972721||Questionnaire survey|Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
16257637|NCT04972708||Bipolar Disorder|100 patients after COVID-19 infection 100 patients without COVID-19 infection
16257638|NCT04972708||Healthy controls|100 controls after COVID-19 infection 100 controls without COVID-19 infection
16257639|NCT04972695||Glaucoma|People with diagnosis of Primary Open Angle Glaucoma (POAG)
16257640|NCT04972695||Ocular Hypertension / glaucoma suspect|People with diagnosis of Ocular Hypertension or POAG suspicion
16257642|NCT04972669|Sham Comparator|control group|sham electroaupuncture
16257643|NCT04972669|Experimental|experimental group|Electroaupuncture
16257644|NCT04972656|Experimental|Ambrisentan|Monotherapy using ambrisentan will start at a dose of 5 mg (once daily) and will be up-titrated to 10 mg (once daily) after 4 weeks apart if patients are tolerable.
16257645|NCT04972656|Placebo Comparator|Placebo|Placebo tablet
16257646|NCT04972643|Experimental|EPA and DHA intervention|EPA 1000mg and DHA 1000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
16257647|NCT04972643|Experimental|EPA intervention|EPA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
16257648|NCT04972643|Experimental|DHA intervention|DHA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
16257649|NCT04972643|Placebo Comparator|Placebo|Placebo 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
16257650|NCT04972630|Active Comparator|Control|"Control group participants will be recruited from the cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Participants will be recruited and consented by TMC researchers. There will be random allocation to the control or Pal-Care group. The control group (n=45) will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
16257651|NCT04972630|Experimental|Pal-Care|Intervention group participants will be recruited from cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Pal-Care will be delivered over a 6-month period. At baseline visit, the patient and their caregiver will meet with their community health worker (CHW) and clinical team and an individualized care plan will be created. Patients will be assigned to the CHW living nearest to their home. The CHW will make home visits to patients 1+ times weekly, depending on patient need. At each visit, the CHW will use resources from the WHO Palliative Care Toolkit to: 1)monitor patient condition, 2) provide basic palliative care (medication administration, wound care, catheter care), 3) deliver prescribed morphine, 4) teach caregivers to deliver care,5) monitor pain and symptom control, and 6) assist patients to access their oncologists and other resources. Timely communication between CHW and clinical team will be maintained using a tele-health platform.
16257652|NCT04972630|No Intervention|Post-Intervention Interviews|Semi-structured interviews of stakeholder groups will be conducted by MUSC researchers who are well-trained and speak the local language, to evaluate the Pal-Care intervention. We will conduct 20 key informant interviews/KIIs (or until saturation is reached), representing Pal-Care clinical team members, CHWs and patients/caregivers, who participated in the intervention at TMC, India. Clinicians will include social workers, oncology nurses, cancer center administrators, counselors, and palliative care oncologists. Patients/ caregivers will be purposefully selected to represent experiences across different cancers, clinical problems and assigned CHWs. Interviews will be performed in-person or over a telehealth platform, as needed. Interviews will query barriers, facilitators, optimal strategies, experiences, needs and expectations for palliative care delivery. Interviews will be digitally recorded, transcribed and analyzed.
16257689|NCT04972383|Experimental|Hyaluronic Acid group|single injection of hyaluronic acid
16257690|NCT04972370||Patients with Unilateral Cleft Lip with or without Cleft Palate|
16257691|NCT04972357||Standard RYGB|
16257692|NCT04972357||Banded RYGB|
16257693|NCT04972357||Extended pouch RYGB|
16257653|NCT04972617||observational group|"In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.
~The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.
~In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined."
16257654|NCT04972604||Duchenne and Becker muscular dystrophy|Individuals with Duchenne muscular dystrophy and Becker muscular dystrophy
16257655|NCT04972604||Carriers|Carriers of Duchenne muscular dystrophy and Becker muscular dystrophy
16257656|NCT04972591||CHB Group|Patients with CHB
16257657|NCT04972591||Compared Group|Healthy people
16257658|NCT04972578|Active Comparator|Screw Fixation|
16257659|NCT04972578|Active Comparator|Suture Button|
16257660|NCT04972565|Experimental|Usual Care plus Inspiratory Muscle Training (IMT)|"Participants will attend the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network. The program consists of i) an individualized home-based rehabilitation and exercise program (twelve weeks of aerobic, neuromotor, and resistance-based exercises), ii) a self-management education intervention, and iii) a community resource engagement plan. Furthermore, patients attend four on-site sessions (a baseline assessment and three follow-up visits).
~Participants in this group will also be provided with a personalized prescription for an IMT program for eight weeks to be performed in the home environment (two daily IMT sessions of 30 breaths, five days per week). Participants will be virtually supervised by the study team weekly with any adverse events closely monitored. Participants will receive instructions and feedback on how to optimize their home training efforts with direct observation of their IMT practice."
16257661|NCT04972565|No Intervention|Usual Care|Participants will participate in the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network.
16257662|NCT04972552|Active Comparator|Watermelon Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus diet high in watermelon
16257663|NCT04972552|Active Comparator|Usual Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus no watermelon in diet
16257664|NCT04972552|Placebo Comparator|Watermelon Diet & Placebo|Placebo pill plus diet high in watermelon
16257665|NCT04972552|Placebo Comparator|Usual Diet & Placebo|Placebo pill plus no watermelon in diet
16257666|NCT04972539|Experimental|Sequence A|Period 1: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose Period 2: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose
16257667|NCT04972539|Experimental|Sequence B|Period 1: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose Period 2: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose
16257668|NCT04972526||Out-of-hospital Cardiac Arrest|Patients receiving TEE as part of their clinical evaluation during cardiac arrest that occurred outside the hospital (e.g. in/at a home or residence, in a public area, during transport to the emergency department, etc.)
16257669|NCT04972526||In-hospital Cardiac Arrest|Patients receiving TEE as part of the clinical evaluation during cardiac arrest that occurred within a hospital (e.g in the emergency department, an Intensive Care Unit, a hospital ward, the operating room, etc.)
16257670|NCT04972526||Undifferentiated Shock or Acute Hemodynamic Decompensation|Patients receiving TEE as part of the initial evaluation of undifferentiated shock or acute hemodynamic decompensation
16257671|NCT04972526||Hemodynamic Monitoring in a Critically Ill Patient|Critically ill patients receiving TEE as part of hemodynamic monitoring
16257672|NCT04972526||Procedural Guidance|Patients receiving TEE as a means to assist providers performing procedures (e.g. intravenous pacemaker placement, veno-arterial or veno-venous extracorporeal membrane oxygenation [ECMO], impella heart pump placement, intra-aortic balloon pump placement, etc.)
16257673|NCT04972513||Prevention (survey, breathe tests, biospecimen collection)|Participants undergo computer-based spirometry testing, nitric oxide breath testing, airwave oscillometry, and an assessment of endothelial function. Participants will undergo collection of blood. Current e-cigarette users also vape their own e-cigarette device for 30 minutes.
16257674|NCT04972500|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
16257675|NCT04972500|No Intervention|Control|No intervention
16257676|NCT04972474|No Intervention|RADAR-MDD Questionnaire App as Usual|The RADAR-MDD questionnaire app as usual asks participants to complete 3x active tasks per week, with one reminder notification at 9am on a day that a questionnaire is due. The notification reads 'Questionnaire Time. Won't usually take longer than 3 minutes'. The participant is not able to view any data progress, aside from through the Fitbit app, which was present in the original RADAR-MDD study.
16257677|NCT04972474|Experimental|RADAR-MDD Adapted Questionnaire App|"The following components are also present:
~Notifications: The notification will alternate between the phrases 'Questionnaire Time. Symptom tracking might increase self-awareness of your emotions (Bakker & Rickard, 2018)', 'Questionnaire Time. Symptom tracking is a technique often used in treatment to increase insight into your symptoms (Kramer et al., 2014)', and 'Questionnaire Time. Tracking your symptoms through a smartphone and Fitbit might help research to better understand health conditions'.
~Progress visualisation: Participants will be able to view their questionnaire completion progress as a visualisation through the app, in the form of a graph.
~Additional components: An additional text on the home screen of the active app will read 'You can contact your research team between 9am-5pm Mon-Fri if you have questions, onradar-engage@kcl.ac.uk'."
16257678|NCT04972448||Group1|Chemotherapy+endocrine therapy+radiotherapy
16257679|NCT04972448||Group2|Chemotherapy+endocrine therapy
16257680|NCT04972448||Group3|endocrine therapy+radiotherapy
16257681|NCT04972448||Group4|endocrine therapy
16257682|NCT04972435|Experimental|Multifocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with multifocal intraocular lens implantation.
16257683|NCT04972435|Sham Comparator|Monofocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with monofocal intraocular lens implantation which are the standard IOL.
16257684|NCT04972422|Experimental|Single Agent Dose Escalation|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
16257685|NCT04972396|Experimental|Part 1|
16257686|NCT04972396|Experimental|Part 2|
16257694|NCT04972331|Active Comparator|CONTROL|Arthroscopic Partial menisectomy
16257695|NCT04972331|Experimental|INTERVENTION|Platet- Rich-Plasma
16257696|NCT04972318|Active Comparator|ARDSNet strategy|"Patients will receive a mechanical ventilation strategy based on fixed values of positive end-expiratory pressure according to inspired fraction of oxygen.
~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before.
~This arm is similar to the ARMA (Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome) trial."
16257697|NCT04972318|Experimental|STAMINA strategy|"Patients will receive a mechanical ventilation strategy based on positive end-expiratory pressure tailored to achieve the optimal respiratory system compliance and to have driving pressure limited to 14 cmH2O.
~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before."
16257698|NCT04972305|Experimental|Exercise group|12 weeks exercise programme, 3 days a week Bicycle ergonomics will be applied.
16257699|NCT04972305|Experimental|Ergonomics group|Bicycle ergonomics will be applied.
16257700|NCT04972305|No Intervention|Control group|No Intervention
16257701|NCT04972292|Experimental|Group 1: FDC of codeine 30 mg/dipyrone 500 mg from Eurofarma Laboratórios SA|Subjects randomized to this group will receive one (1) experimental drug tablet + one (1) Tylex® placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
16257702|NCT04972292|Active Comparator|Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)|Subjects randomized to this group will receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
16257703|NCT04972279|Experimental|Aggressive adaptation strategy|Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
16257704|NCT04972279|Experimental|Moderate adaptation strategy|Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
16257705|NCT04972253|Experimental|Infigratinib|"Infigratinib daily dosage per protocol 3-week on/1-week off schedule. 4 weeks will constitute 1 cycle of therapy.
~Participants will receive 2 cycles (i.e. 8 weeks) and the treatment will be administered as an outpatient.
~After completion of therapy, patients will undergo a CT of the chest, abdomen and pelvis (within 2 weeks of the last dose of therapy) and then proceed to Radical cystectomy 2-4 weeks after the last dose of therapy."
16257706|NCT04972240|Active Comparator|Customized PEEK abutment/ crown on a Ti base.|
16257707|NCT04972240|No Intervention|Prefabricated titanium abutment, supporting ceramometal separate crown.|
16257708|NCT04972227|Experimental|CY6463|CY6463 once-daily (QD) for 14 days
16257709|NCT04972227|Placebo Comparator|Placebo|placebo QD for 14 days
16257710|NCT04972214||Very Preterm Infants|preterm infants were born at gestational age of less than 32 weeks
16257711|NCT04972201||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected.
16257712|NCT04972201||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.
16257713|NCT04972188|Experimental|ZYIL1|Capsule administration. Six subjects will be recruited in each cohort. safety data up to day 14 will be evaluated. Single dose will be administered in ascending manner starting from 12.5 mg.
16257714|NCT04972175|Active Comparator|Rapid Insulin lispro - Conventional bolus|Participants will use subcutaneously-delivered rapid insulin (lispro) through pump therapy.
16257715|NCT04972175|Experimental|BC LisPram - Conventional bolus|Participants will use subcutaneously-delivered BC LisPram through pump therapy.
16257716|NCT04972175|Experimental|BC LisPram - Dual wave bolus|Participants will use subcutaneously-delivered BC LisPram through pump therapy. During dual wave bolusing, 50% of the prandial bolus is delivered immediately, and the other 50% delivered over the next 30 minutes.
16257717|NCT04972149||LC|laparoscopic surgery using conventional laparoscopic instruments
16257718|NCT04972149||LW|Using wristed laparoscopic instruments (Artisential Maryland dissector, Artisential Fenestrated grasper)
16257719|NCT04972149||RC|Conventional robotic surgery
16257720|NCT04972149||RSS|Use of single site system for reduced port robotic surgery
16257721|NCT04972149||RSP|Use of da Vinci SP system for reduced port robotic surgery
16257722|NCT04972149||RRI|A new surgical robot Revo-i developed by Meerae company in Korea
16257723|NCT04972136|Active Comparator|Active bilateral theta burst stimulation|An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). BL-TBS will be delivered at 90% RMT, corrected for scalp to cortex distance, to targeted left and right DLPFC sites, differing only in stimulation pattern and total number of pulses (triplet 50 Hz bursts, repeated at 200 msec (i.e., 5 Hz); right DLPFC (continuous TBS, cTBS): 120 seconds uninterrupted bursts (total of 600 pulses); left DLPFC (intermittent TBS, iTBS: 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds/hemisphere).
16257762|NCT04971863||Clareon Monofocal IOL|Patients bilaterally implanted with the Clareon monofocal IOL
16257724|NCT04972136|Sham Comparator|Sham bilateral theta burst stimulation|"An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used with the active coil facing away from the scalp, for sham stimulation. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). To reproduce the nociceptive qualities of the stimulation, the B65-type stimulation coil - sham side - includes a built in electrical stimulator in the coil connector which fires a synchronous electrical pulse along with the TMS stimulus through electrodes mounted on the forehead or near the area of stimulation, to generate auditory and somatosensory (vibration) stimuli."
16257725|NCT04972123|Experimental|CPC Adminstration|Single dose of CPC will be given during tilt table test
16257726|NCT04972123|Placebo Comparator|Placebo Adminstration|Single dose of Placebo will be given during tilt table test
16257727|NCT04972110|Experimental|Phase Ib Dose Escalation|Multiple dose levels of RP-3500 for oral administration in combination with Niraparib and/or Multiple dose levels of RP-3500 for oral administration in combination with Olaparib
16257728|NCT04972110|Experimental|Phase 2 Expansion Cohorts|Expansion cohort with RP-3500 + Niraparib and/or Expansion cohort RP-3500 + Olaparib
16257729|NCT04972097|Experimental|IRE Treatment Arm|All patients enrolled in this trial will receive IRE treatment with the NanoKnife System
16257730|NCT04972084|Experimental|Powerscope group|Class II patients which will receive treatment using Powerscope appliance
16257731|NCT04972071|Other|CSRS practice recommendation|Knowledge translation of the Canadian Syncope Risk Score (CSRS) based practice recommendations
16257732|NCT04972045|Experimental|CuminUP60®,then Curcumin capsules|Participants first received CuminUP60® 1600mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 1600mg on the eighth day in a fasting state.
16257733|NCT04972045|Experimental|Curcumin capsules,then CuminUP60®|Participants first received curcumin capsules 1600mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP60® 1600mg on the eighth day in a fasting state.
16257734|NCT04972032|Experimental|Estrogen Intrauterine Stent System|An Intrauterine Stent System with estrogen will be introduced into the uterine cavity after TCRA(transcervical resection of adheison).
16257735|NCT04972032|Other|Foley balloon combined with self-cross-link sodium hyaluronate gel|Subjects will be given Foley balloon (manufacturer: Zhanjiang Star Enterprise Co., Ltd.) combined with self-cross-linked sodium hyaluronate gel (manufacturer: BioRegen Biomedical (Changzhou) Co., Ltd.) after TCRA surgery.
16257736|NCT04972019|Experimental|Telerehabilitation experimental group|Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals being measured and logged. Data will be uploaded on a secure cloud server to which clinicians will have access.
16257737|NCT04972019|Sham Comparator|Telerehabilitation control group|Participants will perform web-based game play while wearing sham equipment. Duration and frequency of sessions will equal that of the experimental group training.
16257738|NCT04972006|Experimental|One week baseline|Participants randomized to baseline one will go through a one-week baseline period before beginning the treatment.
16257739|NCT04972006|Experimental|Two week baseline|Participants randomized to baseline two will go through a two-week baseline period before beginning the treatment.
16257740|NCT04972006|Experimental|Three week baseline|Participants randomized to baseline three will go through a three-week baseline period before beginning the treatment.
16257741|NCT04971993||Heart Failure NYHA Class II|Participants are diagnosed with NYHA Class II heart failure.
16257742|NCT04971993||Heart Failure NYHA Class III|Participants are diagnosed with NYHA Class III heart failure.
16257743|NCT04971993||At risk for arrythmias|Participants are indicated for an insertable cardiac monitor with no history of heart failure.
16257744|NCT04971980|Experimental|hUC-MSC infusion (BC-U001)|Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001
16257745|NCT04971967|Experimental|Intervention Group|Participants in the intervention group will receive crowdsourced partner services intervention, including postcards from the crowdsourcing contest that promote PS, provider referral and dual referral services, and take-home HIV self testing kits.
16257746|NCT04971967|No Intervention|Control Group|Participants in the control group will receive traditional partner services intervention, including referral cards that encourage the index patient to notify their partners by themselves.
16257747|NCT04971954|Experimental|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
16257748|NCT04971954|Placebo Comparator|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
16257749|NCT04971941|Active Comparator|active|Use of Dental Vibe with inferior alveolar nerve block
16257750|NCT04971941|Active Comparator|active long buccal|Dental Vibe with long buccal injection
16257751|NCT04971941|Experimental|Time for complete anesthesia|did dental vibe shorten time for complete anesthesia
16257752|NCT04971928|Experimental|Participants with Moderate (CP-B) hepatic impairment|
16257753|NCT04971928|Experimental|Participants with Mild (CP-A) hepatic impairment|
16257754|NCT04971928|Experimental|Healthy participants|
16257755|NCT04971915|Experimental|minimalist footwear|The participants in the experimental group will receive one pair of minimalist footwear and will be asked to use them for the interventional period.
16257756|NCT04971915|No Intervention|control|The participants in the control group will be asked to wear their standard footwear as before participating in the study.
16257757|NCT04971889|Active Comparator|Diabetes MNT plus MI|--Group-based dietary/dietary motivation intervention
16257758|NCT04971889|Active Comparator|Diabetes MNT|-Group-based dietary intervention
16257759|NCT04971876|Experimental|Group 1 - Lips Enhancement|Participants treated with HLR-1 for lip enhancement, with optional Touch-Up (TU) 4 weeks afterwards
16257760|NCT04971876|Experimental|Group 2 - Nasolabial Fold Correction|Participants treated with HLR-2 for nasolabial folds (NLFs) correction, with optional Touch-Up (TU) 4 weeks afterwards
16257761|NCT04971876|Experimental|Group 3 - Treatment of Midface Volume Deficit|Participants treated with HLR-3 for treatment of midface volume deficit, with optional Touch-Up (TU) 4 weeks afterwards
16279322|NCT04821076|Experimental|Energy restriction + exercise|
16257763|NCT04971863||Asqelio Monofocal IOL|Patients bilaterally implanted with the Asqelio monofocal IOL
16257764|NCT04971850|Experimental|Sleep-disordered breathing (SDB)|Patients aged 1 to 20 years old with a suspicion of SDB or a high-risk of SDB due to their pathology and hospitalized at Necker Hospital for a sleep study for their clinical care.
16257765|NCT04971837|Experimental|Two Visits Including A Test Meal|Separated by a minimum of 4 days.
16257766|NCT04971837|Experimental|Five Visits Not Involving A Test Meal|Separated by a minimum of 14 days.
16257767|NCT04971824|Experimental|Physiotherapeutic arm|"There will be the physiotherapeutic intervention, total duration for each participant is three months.
~The participants will be asked to fill three validated questionnaires in the beginning and in the end of study and keep records of their exercises, period and ovulation in their diaries."
16257770|NCT04971798|Experimental|Cell-free Stem cell-derived Extract Formulation (CCM)|Intraarticular administration of CCM
16257775|NCT04971772||"DCB (Legflow .035) group"|"treatment with Drug Coated Balloon angioplasty with the Legflow .035 Paclitaxel Balloon Dilatation catheter."
16257776|NCT04971772||POBA group|treatment with standard POBA (uncoated) angiplasty (type and brand at the physician's discretion)
16257777|NCT04971759|Experimental|Group L|30 Patients will receive Levobupivacaine 5%
16257778|NCT04971759|Experimental|LD group|30 patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
16257779|NCT04971759|Experimental|LF group|30 patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
16257780|NCT04971746|Experimental|GLPG4716 and pirfenidone|
16257781|NCT04971746|Experimental|GLPG4716 and nintedanib|
16257782|NCT04971733|Experimental|Phase 1b: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 12 weeks in Phase 1b
16257783|NCT04971733|Experimental|Phase 2: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 96 weeks in Phase 2.
16257784|NCT04971720|Experimental|Sacubitril/Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 7 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 7 days of intervention.
16257785|NCT04971720|Experimental|Sacubitril/Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 7 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 7 days of intervention.
16257786|NCT04971720|Active Comparator|Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 7 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 7 days of intervention.
16257787|NCT04971720|Active Comparator|Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 7 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 7 days of intervention.
16257788|NCT04971707|Active Comparator|standard exercise training|The physical exercises intervention will include a standardized aerobic exercises training, three sessions per week for 3 months.
16257789|NCT04971707|Experimental|HRV-guided exercise training|The physical exercises intervention will include an individualized aerobic exercises training, three sessions per week for 3 months.
16257790|NCT04971694||Inclusion Group|Infants born at <30 weeks and/or <1500g that were admitted to BUMCP between January 1, 2019 and December 31, 2020
16257791|NCT04971681|Experimental|Low frequency repetitive transcranial magnetic stimulation (rTMS)|
16257792|NCT04971681|Sham Comparator|Sham rTMS Stimulation|
16257793|NCT04971668|Experimental|Aromatherapy|Designated blend aromatherapy (ginger & lavender) and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
16257794|NCT04971668|Experimental|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
16257795|NCT04971668|Other|Placebo|Patient will simulate like chewing gum and inhale deeply with inert gauze for 5 minutes.
16257796|NCT04971655|Experimental|Music therapy group|When individuals with diabetes apply to diabetes education after their polyclinic examination, music therapy will be applied in addition to routine monitoring and applications throughout the education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered as options to the individuals in the intervention group and will be listened to throughout the process. During the training, the selected music will be played over the loudspeaker. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
16257797|NCT04971655|No Intervention|Control group|When individuals apply to diabetes education after their polyclinic examinations, routine monitoring and application will be made throughout the education. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
16257834|NCT04971421||Malignant ovarian tumors|All histological proven malignant ovarian tumors
16257835|NCT04971421||Borderline ovarian tumors|All histological proven borderline ovarian tumors
16257798|NCT04971642|Experimental|Ultrasound scanning|"The subjects recruited are existing patients of the Orthodontic Clinic - Oral Health Clinic-Dentistry, University of Alberta. An intraoral ultrasound scanning will be done on the buccal side of the upper and lower incisor/canine/premolar/molar teeth for a total of sixteen (16) teeth (four(4) teeth in each of the four quadrants) of these subjects.
~The ultrasound scans will be done separately by a research assistant not involved in patient care. The whole procedure for ultrasound scanning and data storage will take about 25-30 min including 3-5 min preparation time and 22-25 min of data acquisition and storage time."
16257799|NCT04971629||Cohort 1|Patients with knee osteoarthritis who use medical cannabis to manage MSK symptoms.
16257800|NCT04971629||Cohort 2|Patients with knee osteoarthritis who do not use medical cannabis.
16257801|NCT04971616||Group 1: Patients with shoulder, neck and lower back discomfort|Patients with shoulder, neck and lower back discomfort.
16257802|NCT04971603|Experimental|Acupuncture treatment group|The patients will receive 24-week acupuncture treatment and 12-week follow up. Seven visits will be arranged within the 24-wk treatment period and at the end of study at wk 6, 10, 14, 18, 22, 26 and 38 for medical consultation and investigation.
16257803|NCT04971590||Participants with Lupus Nephritis|
16257804|NCT04971577|Placebo Comparator|Control arm|
16257805|NCT04971577|Experimental|Treatment arm|
16257806|NCT04971564||Case|Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage
16257807|NCT04971564||Control|Patients without cerebral hypoxia
16257808|NCT04971551|Experimental|Jaktinib treatment|Participants began oral administration of Jaktinib at 75mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 100mg BID Or continue 75mg BID treatment .
16257809|NCT04971538|Experimental|HCV self-testing|the study staff will leave an HCV ST and instructions for use (IFU) with the household. The study team will also explain the HCVST process to the most senior member of the household, as well as leave a mobile number for the participant to contact for help conducting the test. The study team will follow up with the participant to inquire about if testing was completed, collect any testing results, and conduct a brief survey.
16257810|NCT04971538|No Intervention|Referral to clinic for HCV RDT|the study staff will leave information on HCV testing and direct them to the nearest clinic with screening services, the participant will not be left a HCVST. Study staff will also leave a mobile number for the participant to contact for further information on HCV testing. The study team will follow up with the participant to inquire about if testing was completed, collect any testing results, and conduct a brief survey
16257811|NCT04971525||Darvadstrocel Cohort|Participants diagnosed with CD and CPAF, who administered at least one dose of darvadstrocel in fistula tract tissue under surgical environment will be observed.
16257812|NCT04971525||Matched Control Cohort: Standard of Care (SoC)|Participants diagnosed with CD and PAF with no history of administration of darvadstrocel, matched age at index date (within 3 years), time from CD diagnosis (within 1 year), and sex to individuals in the darvadstrocel cohort who received the alternative Standard of Care (SoC), which varies from country to country and according to local centre expertise will be observed.
16257813|NCT04971512|Experimental|EDP-721 HV SAD Cohorts|EDP-721 Dose 1, Dose 2, Dose 3 and Dose 4, in one single administration
16257814|NCT04971512|Experimental|EDP-721 HV MAD Cohorts|EDP-721 Dose 1, Dose 2 and Dose 3, once daily for 14 days
16257815|NCT04971512|Placebo Comparator|EDP-721 HV SAD Placebo Cohort|Matching placebo, in one single administration
16257816|NCT04971512|Placebo Comparator|EDP-721 HV MAD Placebo Cohort|Matching placebo, once daily for 14 days
16257817|NCT04971512|Experimental|EDP-721+ EDP-514 HBV MAD Cohorts|EDP-721 once daily for 14 days followed by EDP-721+EDP-514 once daily for 28 days
16257818|NCT04971512|Placebo Comparator|EDP-721+ EDP-514 HBV MAD Placebo Cohorts|Matching placebo once daily for 42 days
16257819|NCT04971499|Experimental|Dose Confirmation|Dapansutrile starting at 1000 mg PO BID plus Pembrolizumab 200 mg IV every three weeks
16257820|NCT04971499|Experimental|Dose Expansion|Dapansutrile at the RP2D plus Pembrolizumab 200 mg IV every three weeks
16257821|NCT04971486|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
16257822|NCT04971486|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
16257823|NCT04971473|Experimental|rhTSH+Thyroid hormone withdrawal|"rhTSH: rhTSH(0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH.Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration.
~Thyroid hormone withdrawal: Patients stop taking thyroid hormone for 14 days, and then monitor the level of thyroid stimulating hormone every week. When TSH>30mU/L, an ablative activity of 131I was administered.and scanning was done 48 hours after the radioiodine administration."
16257824|NCT04971460||Mother and Baby Unit|Fathers and partners of women admitted to a Mother and Baby Unit
16257825|NCT04971460||Peri-natal Community Mental Health Services|Fathers and partners of women accessing community perinatal mental health services
16257826|NCT04971460||Control group|Fathers and partners of women who are not accessing mental health services in the perinatal period
16257827|NCT04971447|Experimental|Group: transgender men|
16257828|NCT04971447|No Intervention|Groupe: control cis-gender women|
16257829|NCT04971447|Experimental|Group: transgender women|
16257830|NCT04971447|No Intervention|Groupe: control cis-gender men|
16257831|NCT04971434|Experimental|laser|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
16257832|NCT04971434|Experimental|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
16257833|NCT04971421||Benign ovarian tumors|All histological proven benign ovarian tumors
16257836|NCT04971408|Other|control|passive heat stress x1 visit then no intervention for 8 weeks. participants continue regular exercise habits as usual.
16257837|NCT04971408|Experimental|Passive heat stress|After arm 1, passive heat stress 3x/week x8 weeks.
16257838|NCT04971395|Experimental|Single IV infusion of 2 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)
~After safety is confirmed, the remaining patients within the same cohort will be dosed.
~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
16257839|NCT04971395|Experimental|Single IV infusion of 4 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)
~After safety is confirmed, the remaining patients within the same cohort will be dosed.
~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
16257840|NCT04971382|Experimental|curcumin combined with particulate xenograft.|"Curcumin will be used in combination with xenograft after ridge splitting surgery
~Curcumin is widely used in medicine due to medicinal properties, cost-effectiveness, and simple extraction from a turmeric plant that grows in different regions in the world. Recent evidences have shown that curcumin possesses multiple biological activities and pharmacological properties including anti-inflammation , antioxidation , anticancer , antimicrobial , and free radical scavenger effects"
16257841|NCT04971382|Active Comparator|alveolar ridge splitting with use of particulate xenograft alone.|xenograft will be used alone after ridge splitting
16257842|NCT04971369|Experimental|89Zr-NY001 injection|Patients will receive a tracer (5 mg, IV) dose of Zr-89 (1.5-2 mCi) labeled NY001 (89Zr-NY001)
16257843|NCT04971356|Experimental|Experimental arm|1-month of Aspirin + Ticagrelor, followed by 5-month of Ticagrelor monotherapy; Afterward, Aspirin monotherapy for 6 months
16257844|NCT04971356|Active Comparator|Reference arm|12-month Aspirin plus Ticagrelor
16257845|NCT04971343||Unselected blood donors|
16257846|NCT04971343||Hospitalized patients|
16257847|NCT04971343||Known HIV-1 Ab positive|
16257848|NCT04971343||Known HIV-2 Ab positive|
16257849|NCT04971343||Known Acute HIV-1 p24 Ag positive|
16257850|NCT04971330||Known HCV Ab Positive Patients|leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for positive samples.
16257851|NCT04971330||Hospitalized Patients|"leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for hospitalized patient.
~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
16257852|NCT04971330||Unselected Blood Donors|"Leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. les. For blood donors, Abbott PRISM HCV will be used as reference.
~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status."
16257853|NCT04971317|Experimental|Sugar-Sweetened Beverage (SSB) Video|
16257854|NCT04971317|Experimental|Water Video|
16257855|NCT04971317|Active Comparator|Control|
16257856|NCT04971304||G-CSF originator receipt|Patients receiving filgrastim (Neupogen) or pegfilgrastim (Neulasta) per Health Care Procedural Coding System (HCPCS) J-codes.
16257857|NCT04971304||G-CSF biosimilar receipt|Patients receiving filgrastim biosimilars (filgrastim-aafi, filgrastim-sndz, tbo-filgrastim) or pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-bmez, pegfilgrastim-cbqv) per Health Care Procedural Coding System (HCPCS) J-codes.
16257858|NCT04971291|Experimental|AXS-05|45 mg dextromethorphan-105 mg bupropion
16257859|NCT04971291|Active Comparator|Bupropion SR|150 mg bupropion
16257860|NCT04971278||HealthFirst Intervention|Patients attributed to HealthFirst who will receive the intervention
16257861|NCT04971278||HealthFirst Control|Patients attributed to HealthFirst who will not receive the intervention
16257862|NCT04971278||Mortality Model Intervention|Patients who are identified as High Risk by the mortality predictive model and who receive the intervention.
16257863|NCT04971278||Mortality Model Control|Patients who are identified as High Risk by the mortality predictive model and who do not receive the intervention.
16257864|NCT04971265|Experimental|Low SES/High Supports|"Participants assigned to the Low SES/High Supports arm will see the Low SES/High Supports intervention"
16257865|NCT04971265|Experimental|Low SES/Low Supports|"Participants assigned to the Low SES/Low Supports arm will see the Low SES/Low Supports intervention"
16257866|NCT04971265|Experimental|High SES/High Supports|"Participants assigned to the High SES/High Supports arm will see the High SES/High Supports intervention"
16257867|NCT04971265|Experimental|High SES/Low Supports|"Participants assigned to the Low SES/High Supports arm will see the High SES/Low Supports intervention"
16257868|NCT04971252||Co existance of diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease
16257869|NCT04971252||Diabetes mellitus without chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only
16257870|NCT04971252||Chronic kidney disease without diabetes mellitus|Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus
16257871|NCT04971239|Active Comparator|topical methotrexate microemulsion|Group(A): topical methotrexate micro emulsion formulation, each patient will be instructed to apply a very thin film of 0.5 ml of it over the three psoriatic plaques three times weekly .
16257930|NCT04970888|Active Comparator|Usual care|Usual medical care with no interventions
16283057|NCT04795193|Experimental|MICS-CABG|Patients undergoing MICS-CABG.
16257872|NCT04971239|Experimental|combination of topical methotrexate microemulsion and excimer light|Group(B) : excimer laser will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks.
16257873|NCT04971239|Experimental|combination of topical methotrexate microemulsion and narrow band-ultraviolet B|Group(C) : Narrow band ultraviolet B will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks
16257876|NCT04971213|Active Comparator|Non Invasive Ventilation|Bilevel non-invasive ventilation. Support pressure will be set to obtain a 6-8 mL/kg of predicted body weight PEEP will be set within 5-10 cmH2O and FiO2 for a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure) All settings will be adjusted according tolerance of the patient.
16257877|NCT04971213|Experimental|High-flow nasal cannula heated and humidified oxygen|"Flow will be set at 60 L/min and ajusted according the tolerance of the patient.
~FiO2 will be set according a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure)"
16257878|NCT04971200|Experimental|Vitiligo Patients on Tildrakizumab|
16257879|NCT04971187|Experimental|Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)|Patients receive bintrafusp alfa IV over 1 hour on day 1 and pemetrexed IV over 10 minutes on day 1. Patients also receive carboplatin IV over 15 minutes or cisplatin IV over 6-8 hours at the physician's discretion on day 1 of cycles 1-4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16257884|NCT04971148|Active Comparator|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level that matches patient peak tidal inspiratory flow
16257885|NCT04971148|Experimental|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow
16257886|NCT04971148|Experimental|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow
16257887|NCT04971148|Experimental|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow
16257888|NCT04971135|Experimental|SAN711 (SAD)|6 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of SAN711
16257889|NCT04971135|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of Placebo
16257890|NCT04971135|Experimental|SAN711 (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of SAN711
16257891|NCT04971135|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of Placebo
16257893|NCT04971109|Active Comparator|TPOXX|Treatment Group 1: An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)
16257894|NCT04971109|Placebo Comparator|TPOXX Placebo|Treatment Group 2: An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)
16257895|NCT04971096|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
16257896|NCT04971096|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
16257897|NCT04971096|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
16257898|NCT04971096|No Intervention|Healthy Control|No intervention
16257899|NCT04971083|No Intervention|Usual Care|"Control (CG): receives Usual Care. Observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.
~Inflammation status will be recorded when data from routine blood draws is available"
16257900|NCT04971083|Active Comparator|Intervention Group|"Intervention Group (IG): The intervention consists of a built-in automated analysis that provide patient-tailored nutrition recommendations and behavioural tipps. Described in detail this means that dependent on the severity of the nutrition related symptom burden (NRSB) recorded, the patients in the intervention group only are, for example provided with detailed written nutrition information and cooking recipes and/or asked to discuss the symptoms with their health care provider, dietitian, and/or physician, or even asked to seek immediate medical care.
~Analog to the control group, observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.
~Inflammation status will be recorded when data from routine blood draws is available"
16257901|NCT04971070||Hypoglycemic disturbance group|
16257902|NCT04971070||Hypoglycemia was not a disorder of consciousness group|
16257903|NCT04971057|No Intervention|Control Group|The control group received routine care
16257904|NCT04971057|Experimental|Multimedia information Group|The experimental group received a multimedia information
16257907|NCT04971031|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.|
16257908|NCT04971031|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.|
16257909|NCT04971018|Experimental|Active ta-VNS|
16257910|NCT04971018|Placebo Comparator|Sham ta-VNS|
16257911|NCT04971005|Experimental|Intervention (aHSCT)|Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).
16257912|NCT04971005|Active Comparator|Control|In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).
16257913|NCT04970992|Experimental|Dose escalation and cohort expansion Q1W|DZ-002 treatment once every week
16257914|NCT04970979||patients with coronary artery disease|patients with coronary artery disease
16257915|NCT04970966|Experimental|PuraSinus|Placement of PuraSinus in ethmoid cavity following ESS
16257916|NCT04970966|Active Comparator|Bioresorbable Nasal Dressing|Placement of bioresorbable nasal dressing (PosiSep X) in ethmoid cavity following ESS
16257917|NCT04970953||Patients with intermediate risk for HFpEF at rest|Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.
16257918|NCT04970940|Experimental|Sequence 1|"Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days)
~Wash-out for 7 days
~Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days)
~Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)"
16257919|NCT04970914|Experimental|Anlotinib+Penpulimab|
16257920|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Gemcitabine (Arm A)|Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (500 mg/m^2 to 1000 mg/m^2) of gemcitabine on Day 1 of each cycle (where each cycle is 21 days).
16257921|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Lenalidomide (Arm B)|Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (15 mg to 25 mg) of lenalidomide once daily on a 2 weeks on and 1 week off schedule, starting on Day 1 of each cycle (where each cycle is 21 days).
16257922|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (1.4 mg/kg to 1.8 mg/kg) of polatuzumab vedotin on Day 1 of each cycle (where each cycle is 21 days).
16257923|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Umbralisib (Arm D)|Participants will receive loncastuximab tesirine on Day 1 of each cycle at a dose of 150 μg/kg for two cycles, then 75 μg/kg for subsequent cycles (where each cycle is 21 days). Participants will also receive escalating doses (600 mg to 800 mg) of umbralisib once daily, starting on Day 1 of each cycle (where each cycle is 21 days).
16257924|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Gemcitabine (Arm A)|Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with gemcitabine at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.
16257925|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Lenalidomide (Arm B)|Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with lenalidomide at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.
16257926|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with polatuzumab vedotin at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.
16257927|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Umbralisib (Arm D)|Participants with subpopulation of non-Hodgkin lymphomas (NHLs) (diffuse large B-cell lymphoma [DLBCL], high grade B cell lymphoma [HGBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and Burkitt lymphoma [BL] cohorts) will receive loncastuximab tesirine in combination with umbralisib at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.
16257928|NCT04970888|Experimental|Combined|Combined physical exercise and cognitive training. The combined intervention will include a cognitive training with aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
16257929|NCT04970888|Experimental|Exercise|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform exercise training sessions either home-based or centre-based.
16257931|NCT04970849||one group that is IBD endoscopist who perform the endoscopy for IBD patients|Complete the questionnaire online
16257932|NCT04970836|Experimental|Low titer with two doses of HB Vaccines|anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
16257933|NCT04970836|Active Comparator|Low titer with one dose of HB Vaccine|anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
16257934|NCT04970836|Active Comparator|Extremely low titer with two doses of HB Vaccines|anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
16257935|NCT04970836|Active Comparator|Extremely low titer with one dose of HB Vaccine|anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
16257936|NCT04970823|Experimental|The somatosensory interactive game|The somatosensory interactive game, an independent nursing intervention, promotes pain relief on the experimental group.
16257937|NCT04970823|Experimental|A VR (virtual reality) game|A VR (virtual reality) game promotes pain relief on the experimental group.
16257938|NCT04970810|No Intervention|Attention Control|Subjects monthly calls similar in structure to the intervention arms, but without support. (attention placebo control)
16257939|NCT04970810|Active Comparator|My Diabetes Goal|My Diabetes Goal protocol
16257940|NCT04970810|Active Comparator|My Diabetes Goal + Community Rx|My Diabetes Goal protocol + Community Rx protocol
16257941|NCT04970797||Conventional treatment group|Western medicine treatment
16257942|NCT04970797||Combination treatment group|Xinglouchengqi decoction combined with western medicine treatment
16257943|NCT04970784||Patients cared for by the adult sector|Patients admitted to emergencies, non-hospitalized and cared for by the adult sector of emergencies (classical emergencies)
16257944|NCT04970784||Patients cared for by the geriatric sector|Patients admitted to emergencies, non-hospitalized and cared for by the geriatric sector of emergencies
16257945|NCT04970771|Experimental|Solving Wellness Platform Group|Participants will receive a 1-year membership to the Solving Wellness virtual platform containing interactive wellness resources.
16257946|NCT04970758||study group|Athletes /strength exercise
16257947|NCT04970758||control group|
16257948|NCT04970745||high-risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of both tests are considered very high-risk patients,
16257949|NCT04970745||risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of 1 out of 2 tests are considered risk patients
16257950|NCT04970745||low-risk|After performing midbrain ultrasound and tremor analysis, patients with negative results of both tests are considered risk patients
16257951|NCT04970732|Experimental|Experimental group|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
16257952|NCT04970732|No Intervention|Control group|The control group received routine nursing after surgery.
16257953|NCT04970719|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
16257954|NCT04970719|Active Comparator|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5 -day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
16257955|NCT04970706||Healthy Volunteers|Volunteers were healthy people without ACL rupture
16257956|NCT04970706||Patients with ACL Rupture|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
16257957|NCT04970693|Experimental|Furmonertinib 80mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after first/second generation EGFR-TKI therapy. These patients will receive furmonertinib 80mg combined with radiotherapy as following therapy.
16257958|NCT04970693|Experimental|Furmonertinib 160mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after third generation EGFR-TKI therapy. These patients will receive furmonertinib 160mg combined with radiotherapy as following therapy.
16257959|NCT04970680|Active Comparator|blind glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block with the blind technique
16257960|NCT04970680|Active Comparator|ultrasonic glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block using the ultrasonic technique
16257961|NCT04970667|Experimental|Flupentixol melitracen tablets|The patients were treated with Flupentixol melitracen tablets according to their own conditions
16257964|NCT04970641|Experimental|3GT journaling group|Subjects will participate in the Three Good Things (3GT) Positive Psychology journaling activity daily for six weeks.
16257965|NCT04970641|No Intervention|Non-journaling group|Subjects will not participate in the evening journal activity.
16257966|NCT04970628||Study group|Patients performed airway obstruction after anterior cervical operation
16257967|NCT04970628||Control group|Patients did not perform airway obstruction after anterior cervical operation
16257968|NCT04970615||Two-dimensional images|Patients who receive pre-operativeinformation while the two-dimensional MR images are being shown to them by the neurosurgeon.
16257969|NCT04970615||Three-dimensional printed model|Patients who receive pre-operative information while the three-dimensional printed models are being shown to them by the neurosurgeon.
16257970|NCT04970602|Experimental|MB group|This group will be given 2mg/kg methylene blue infusion within 20 minutes, 2 hours later followed by 0.5mg/kg/h for 4 hours.
16257971|NCT04970602|No Intervention|control group|This group will be given conventional vasopressors, except methylene blue, based on the attending doctor's decision.
16258160|NCT04969328|Active Comparator|ParTNer-STEPs|Parents and adolescents will receive the ParTNER-STEPs program and standard care.
16257972|NCT04970589|Placebo Comparator|Lean/Placebo Capsule|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
16257973|NCT04970589|Experimental|Lean/Probiotics|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
16257974|NCT04970589|Experimental|Obese/Placebo Capsule|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
16257975|NCT04970589|Experimental|Obese/Probiotics|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
16257976|NCT04970576|Experimental|Treatment group|Patients in the intervention group will receive Rivaroxaban 20 mg once a day (OD) for three months
16257977|NCT04970576|Active Comparator|Control group|Patients in the control group will receive usual warfarin therapy dose adjusted as per the target INR of 2 to 3
16257978|NCT04970563|Experimental|Patients infected by SARS-COV-2 (RT-PCR +) and asymptomatic|
16257979|NCT04970563|Other|"Control group: patients infected by SARS-COV-2 (RT-PCR +) and symptomatic"|
16257980|NCT04970563|Other|"Healthy controls group: not infected by SARS-COV-2 (RT-PCR-) and asymptomatic."|
16257981|NCT04970524|Experimental|control group(conventional free gingival graft)|Conventional free gingival grafts are applied to the areas of the patients determined by randomization as suggested by Sullivan and Atkins.
16257982|NCT04970524|Experimental|test group(Partially de-epithelialized free gingival graft)|Partial free gingival graft is applied to the areas of the patients determined by randomization. Unlike the control group, the epithelium on the graft was partially epithelialized.
16257983|NCT04970511|Experimental|The group I: BBAT Face-to-Face Training group|"Exercises consist of supine, sitting, standing position awareness exercises and walking exercises.
~Considering eight weeks, the training is designed to progress gradually each week."
16257984|NCT04970511|Experimental|The group II: Online BBAT training group|"Patients in the Internet-based BFT group will conduct their training with a physiotherapist to be connected via an online video conference system.
~This group will be given the same training as the face-to-face BFT group."
16257985|NCT04970511|No Intervention|The group III: Control group|No training will be applied to the control group patients.
16257986|NCT04970498||acute myelosuppression group|WBC <4.0×10^9 14 days after radiotherapy
16257987|NCT04970498||chronic myelosuppression group|WBC <4.0×10^9 90 days after radiotherapy
16257988|NCT04970498||no myelosuppression group|WBC >4.0×10^9 during radiotherapy
16257989|NCT04970485|Experimental|Talking Matters intervention|Talking Matters is a group-level, two-pronged intervention for Black and African American 14 to 19 year old adolescents recruited from school- and community-based settings in Philadelphia, PA. Goals are to reduce teens' risk for unplanned pregnancy, sexually transmitted infections, and HIV, and to strengthen protective factors to improve health. The two prongs include (1) an adolescent-focused five-session, group-level intervention called We Get to Choose (WGTC) covering sexual and reproductive health (SRH) knowledge and skills, decision making and self-worth, healthy relationships, substance use and mental health; and (2) an adult-focused three-session, group-level training called Let's Talk Real Talk (LTRT) to build SRH knowledge and skills to communicate with teens about SRH. An opportunity to connect WGTC participants to trusted adults who completed LTRT is provided during one facilitated session conducted each quarter. LTRT participants are not human subjects of the study.
16257990|NCT04970485|No Intervention|Control Group|Business as usual
16257991|NCT04970472||patients with Urothelial bladder carcinoma|collection of blood, urines, stool and tumor samples
16257992|NCT04970459||Patients with Marfan syndrome or related syndromes|Children aged at least 3 years old or adult with Marfan syndrome or related syndromes
16257993|NCT04970446|Active Comparator|FMT arm|Anaerobically prepared, freeze-thawed faecal microbiota transplantation
16257994|NCT04970446|Placebo Comparator|Placebo arm|Placebo liquid formulation (normal saline, glycerol, food colorant)
16257995|NCT04970433|Experimental|Electroacupuncture (EA)|Acupoint regimen: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation using an EA apparatus, with a pair of electrodes connecting acupoints LI4 with PC6, and another pair of electrodes connecting ST36 with SP6. EA stimulation will last for 15 min with a continuous wave of 2 Hz and a current intensity of 0.1-1 mA.
16257996|NCT04970433|Active Comparator|Laser acupuncture (LA)|Participants allocated to the LA group will receive LA therapy at the same acupoints used in EA group. The laser will be applied to each point for 40 seconds, which delivered 3 J of energy at each of the acupoints.
16257997|NCT04970433|Sham Comparator|Sham laser acupuncture (SLA)|Participants in the control group will receive sham LA treatment without any laser output. The acupuncture points, application duration, and total number of treatments are the same as those in the LA group.
16257998|NCT04970420|Experimental|HeRFAPIW|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).
16257999|NCT04970420|Active Comparator|Control group|
16258000|NCT04970407|Experimental|Dysport®|40 Units (U) Intramuscular (IM) injection at day 1.
16258001|NCT04970407|Active Comparator|Botox®|16U IM at day 1.
16258002|NCT04970407|Active Comparator|Xeomin®|16U IM at day 1.
16258003|NCT04970394||Intervention|"The principal investigator reviews the medical notes of all individuals they consult over a period of three years to check if they are non responders. If confirmed as non responder, they receive a three-step verbal intervention:
~Your cervical cancer screening is now overdue.
~The test is easy to perform and saves thousands of lives from cervical cancer every year.
~Should we book an appointment for cervical screening now so that you make sure you have it done?
~Those who are seen face-to-face receive a fourth intervention:
~An appointment slip is given to the patient to hand to the receptionist. This includes the patient's name and the comment, book an appointment with practice nurse for cervical screening."
16258004|NCT04970394||Control|The control group receives standard unstructured reminders regarding their overdue status from any of the 6 other clinicians during appointments and / or reminder letters from the administration team.
16258005|NCT04970381|Experimental|Rivaroxaban|
16258006|NCT04970368|Experimental|Sentinel Node Surgical Staging|
16258007|NCT04970368|Experimental|Selective Surgical Staging|
16258008|NCT04970355|Experimental|Erenumab|Double-Blind Treatment Phase: Participants receive erenumab 280 mg subcutaneous (SC) injections (loading dose, week 0) followed by erenumab 140 mg s.c. in week 4.
16258009|NCT04970355|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Participants receive placebo subcutaneous (SC) injections in week 0 and week 4.
16258010|NCT04970342|Experimental|"Sober or Double Placebo"|Subject receives alprazolam capsule containing placebo (lactose). Subject receives placebo cannabis (0% THC / 0% CBD).
16258011|NCT04970342|Experimental|Active Alprazolam (Xanax), Placebo Cannabis|Subject receives active 0.75 mg alprazolam capsule. Subject receives placebo cannabis (0% THC / 0% CBD).
16258012|NCT04970342|Experimental|Placebo Alprazolam (Xanax), Active Cannabis|Subject receives alprazolam capsule containing placebo (lactose). Subject receives active cannabis (6.18% THC / <0.025% CBD).
16258013|NCT04970329|Experimental|Systane|Instill one drop three times a day for one month.
16258014|NCT04970329|Experimental|Tears Naturale 2|Instill one drop three times a day for one month.
16258015|NCT04970329|Placebo Comparator|Placebo|Instill one drop three times a day for one month.
16258016|NCT04970316||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
16258017|NCT04970316||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
16258018|NCT04970303||Case group|investigator will recruit 60 patients with ADHD (aged between 6 and 16). Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed. Patients with ADHD will receive treatment in a clinical practice and then will be followed up for 12 months. At the 12th month, the same procedures as those performed at the baseline will be replicated for patients with ADHD.
16258019|NCT04970303||Control group|investigator will recruit 60 age- and gender-matched control subjects. Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed.
16258021|NCT04970277|Experimental|drinking water group|Patients in this group drink colorless water after capsule ingestion.
16258022|NCT04970277|Other|control group|Patients in this group don't drink colorless water after capsule ingestion.
16258023|NCT04970238|Experimental|Levosimendan group|
16258024|NCT04970238|Placebo Comparator|placebo group|
16258025|NCT04970225|Experimental|Stable state|"45 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:
~With severe cftr mutations
~With or without PA chronic infection
~Treated or not with Ivacaftor-Lumacaftor"
16258026|NCT04970225|Experimental|Starting Ivacaftor-Tezacaftor-Elexacaftor|"40 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:
~With at least one severe cftr mutation
~With or without PA chronic infection
~Initiating Ivacaftor-Tezacaftor-Elexacaftor"
16258027|NCT04970225|Experimental|Exacerbation|15 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France and hospitalized for respiratory exacerbation
16258028|NCT04970212||Study Arm|Subjects will receive your standard liver ablation procedure, including ultrasound images. Data will be collected from the standard liver ablation procedure, including imaging. Subjects will receive a CT scan within 24 hours after the liver ablation procedure. There will then be an analysis of ultrasound images and research CT scan.
16258029|NCT04970199|Active Comparator|group 1|thirty lupus women will receive laser acupuncture (active) for one month (all-week days except Fridays) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser will be applied for 4 min on every acupiont).
16258030|NCT04970199|Sham Comparator|group 2|thirty lupus women will receive laser acupuncture (sham) for one month (all-week days except Fridays) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser will be applied for 4 min on every acupiont).
16258031|NCT04970173||1|patients taking very low-volume 1L-PEG plus ascorbate (plenvu) for open access colonoscopy
16258032|NCT04970173||2|patients taking low-volume 2L-PEG plus ascorbate (moviprep) for open access colonoscopy
16258033|NCT04970160||TSARP|Is a surgical procedure
16258034|NCT04970160||ASARP classic|Surgical procedure
16258035|NCT04970160||PSARP|Surgical procedure
16258036|NCT04970160||Modified ASARP|Surgical procedure
16258037|NCT04970134||Thyroid carcinoma|"Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types:
~Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants.
~Medullary thyroid carcinoma (MTC)."
16258038|NCT04970121|Experimental|Duloxetine arm|Chemotherapy regimens consisting of taxanes will be used according to treatment specifications. Subjects require therapeutic intervention for painful peripheral neuropathy will receive duloxetine 20 mg (orally, once daily) as the starting dose for 1 cycle of 7 days; the current dose will be maintained for effective pain control (NRS ≤ 3 points) and increased by 20 mg at the next cycle assessment for ineffective pain control (NRS > 3 points) up to a maximum dose of 60 mg (orally, once daily). Duloxetine administration will be maintained until the uncontrolled pain (under the condition of treatment with duloxetine at its maximum dose), intolerable toxicity, completed antineoplastic therapy or subject loss of visit, death, withdrawal of informed consent, or other conditions occur. The administration of duloxetine is up to a maximum of 12 weeks.
16258039|NCT04970108|Experimental|Egito|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:
~1 tablet Egito, oral;
~1 tablet empagliflozin placebo, oral;
~1 tablet telmisartan placebo, oral."
16258040|NCT04970108|Active Comparator|Empagliflozin + telmisartan|"The patient must take 3 tablets once a day, as follows:
~1 tablet Egito placebo, oral;
~1 tablet empagliflozin, oral;
~1 tablet telmisartan, oral."
16258041|NCT04970095|Experimental|cleft lip and palate patient|Clefts patient with transverse maxillary constriction and anteroposterior deficiency
16258042|NCT04970082|Experimental|FFR followed by FFR-DWP (investigation)|The FFR measurement is performed with the standard method first followed by the FFR measurement with the DWP method.
16258043|NCT04970082|Experimental|FFR-DWP (investigation) followed by FFR|The FFR measurement is performed with the DWP method first followed by the FFR measurement with the standard method.
16258044|NCT04970069|Active Comparator|Analgesic education|
16258045|NCT04970069|Placebo Comparator|General perioperative education|
16258052|NCT04970043|Experimental|Camrelizumab+ pemetrexed + platinum|
16258053|NCT04970030|Active Comparator|mechanical intracanal (ML) lithotripsy|TTS mechanical lithotripter
16258054|NCT04970030|Experimental|electrohydraulic intracolangioscopic (EHL) lithotripsy|electrohydraulic lithotripsy with Autolith probe
16258055|NCT04970004||Patients Diagnosed with HSCT-TMA|
16258056|NCT04969991|Experimental|Varespladib: 250 mg QD|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon and 1 placebo tablet in the evening.
16258057|NCT04969991|Experimental|Varespladib: 250 mg BID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning and in the evening. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon.
16258058|NCT04969991|Experimental|Varespladib: 250 mg TID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, in the afternoon, and in the evening.
16258059|NCT04969991|Placebo Comparator|Placebo|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, in the afternoon, and in the evening.
16258060|NCT04969978|Active Comparator|Arm I (Quitline eReferral)|Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
16258061|NCT04969978|Experimental|ARM II (Quitline eReferral plus enhanced AD)|Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions, written training materials for all providers and staff, including new hires, and monthly performance audit and feedback.
16258062|NCT04969965|Experimental|Aumolertinib|single dose oral 110mg of aumolertinib
16258063|NCT04969952|Experimental|Group A|Group A had watching educational module plus ACP brochure
16258064|NCT04969952|Active Comparator|Group B|Group B ACP brochure only
16258307|NCT04968301||control group|healthy volunteers
16258074|NCT04969900|Placebo Comparator|Placebo - Jojoba Oil (100% organic golden expeller-pressed Simmondsia chinensis)|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
16258075|NCT04969900|Active Comparator|Investigational Product - A 10% dilute Lavandula angustifolia - jojoba oil essential oil blend|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
16258076|NCT04969887|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 480mg every 4 weeks until progression (up to 2 years)
16258077|NCT04969874|Other|remote follow-up|patients with chronic disorders on sequelae of anti-cancer treatments after an intensive rehabilitation stay will undergo 5 months of remote follow-up with speech therapists including questionnaires and interview
16258080|NCT04969848||eMSGait|Record of IGP using IMU sensor (Metamotion R mbientlab) during T25FW.
16258083|NCT04969822|No Intervention|Embryo selection by standard morphologic criteria|The embryo for transfer will be selected by the embryologist on the basis of the morphologic appearances on day 5, according to the Gardner criteria using the ranking guideline.
16258084|NCT04969822|Experimental|Embryo selection by iDA|Time-lapse videos will be analyzed by iDA and the embryo for fresh transfer on day 5 will be prioritized on the strict basis of the embryo with the highest iDA score. For a frozen cycle; the first embryo to be warmed will be the one with the highest iDA score.
16258085|NCT04969809|Experimental|Patients on diet|We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment.
16258086|NCT04969809|Experimental|patients without diet|Half of the patients have abandoned the diet treatment and mostly no longer come for outpatient examinations.
16258087|NCT04969796|Experimental|REACH Hope|Participants receive the REACH behavioral intervention coupled with the Department of Defense Hope Box app.
16258088|NCT04969796|No Intervention|Wait list control|No intervention.
16258089|NCT04969783|Experimental|Ventilated Cigarette Filter|Filters with approximately 24-32% filter ventilation
16258090|NCT04969783|Experimental|Unventilated Cigarette Filter|Filters with approximately 0-5.0% filter ventilation
16258091|NCT04969770|Experimental|Neuromuscular scoliosis|Minor patients with neuromuscular scoliosis and followed at Necker Hospital
16258092|NCT04969770|Other|Neuromuscular pathologies without instrumented scoliosis|Minor patients with neuromuscular pathology without instrumented scoliosis and followed at Necker Hospital
16258093|NCT04969770|Other|Controls|Minor patients without neuromuscular pathology or scoliosis and followed at Necker Hospital
16258094|NCT04969757|Experimental|Predigraft|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.
~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
16258095|NCT04969744|Experimental|Intermittent Cold Exposure (ICE)|Stage 1- healthy volunteers aged 16-26 years will receive ICE for one day. stage 2a - controls aged 8-16 will receive ICE for one day. Stage 2b- NAFLD patients aged 8-16 years will receive ICE for one day or choose to continue for 5 days.
16258096|NCT04969731|Experimental|Immuncell-LC/Gemcitabine|Patients will receive 6 cycles Gemcitabine (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle) and Immuncell-LC 16 times during 60 weeks (4 treatments once a week, followed by 4 treatments every other week, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks)
16258097|NCT04969731|Active Comparator|Gemcitabine|Patients will receive 6 cycles Gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle)
16258098|NCT04969718|Experimental|LEADS Plus educational posters|A total of six group sessions with students using presentations and videos.
16258099|NCT04969718|Experimental|Question, Persuade, and Refer Plus educational posters|It is a manualised programme for gatekeepers (teachers). This includes both presentations and videos.
16258100|NCT04969718|Experimental|Screening by Professionals programme Plus educational posters|This is an indicated or selective intervention by health professionals who will review assessments (done using structured questionnaires) and refer students where necessary.
16258101|NCT04969718|Active Comparator|Educational poster|The control group will be exposed to the six educational posters.
16258102|NCT04969705|Active Comparator|Group A (spinal Dexmedetomidine)|. Spinal needles (22 G) will be introduced in sitting position after skin disinfection with povidine iodine, iliac crest will be palpated and thumb extended to meet the midline, feeling the space between L4 and L5. spinal needle penetrates through the dura matter, a pop will be felt and then after the needle puncture into the subarachnoid space and the appearance of clear cerebrospinal fluid, the intrathecal local anesthetic will be injected. All patients will be receiving 2 ml heavy bupivacaine 0.5% plus 5 µg dexmedetomidine to total volume of 2.5 ml.
16258103|NCT04969705|Active Comparator|Group B (spinal with transversus abdominus plane block)|Spinal needles (22 G) introduced in sitting position . patients receiving1.7 to 2.2 ml heavy bupivacaine 0.5%( according to weight and height ) + 1 ml normal saline = total volume of 2.5 ml then at surgery end under sonographic guide transducer placed in transverse plane above iliac crest.A 90 mm 22 G short beveled block needle inserted in-plane with transducer, in anterior-posterior direction. needle connected to syringe contains20 ml of bupivacaine 0.25%+10 µg dexmedetomidine to deposit local anesthetic deep into the fascial layer between internal oblique & transversus abdominis muscles on each side.
16258104|NCT04969705|Active Comparator|Group C ( controlled group ) Spinal Anesthesia only :|Patients will be anesthetized only with spinal anesthesia using Bupivacaine Hcl( 10 mg).
16258105|NCT04969692|No Intervention|non-warming group|
16258106|NCT04969692|Active Comparator|warming group|
16258107|NCT04969679|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Active group will receive E. coli Nissle 1917 (Mutaflor®).
16258108|NCT04969679|Placebo Comparator|Placebo|Placebo group will receive placebo drug.
16258109|NCT04969666|Experimental|IPED2015_dose 1|Active treatment
16258110|NCT04969666|Experimental|IPED2015_dose 2|Active treatment
16258111|NCT04969666|Placebo Comparator|Placebo|Placebo treatment
16258112|NCT04969653||Cases|All adults with an episode of active atopic dermatitis at any point between 1st Jan 2010 to 1st Jan 2015 will be included for analysis.
16258113|NCT04969653||Controls|Adults without atopic dermatitis or other skin conditions matched to cases by age, gender, and duration of practice registration.
16258114|NCT04969640||infective keratitis|50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.
16258115|NCT04969627|Active Comparator|Metformin (BMI<24)|Subjects: PCOS patients whoseBMI<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
16258116|NCT04969627|Experimental|Metformin (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
16258117|NCT04969627|Experimental|Combination (BMI<24)|Subjects: PCOS patients whoseBMI<24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
16258118|NCT04969627|Experimental|Combination (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
16258119|NCT04969614||kidney transplant recipients|kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine
16258120|NCT04969601|Experimental|Anti Covid with COMIRNATY® (BNT162b2) vaccine|Two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart
16258121|NCT04969588||Children and adult|Participants aged 6-65 years old are recruited for the measurements of depth camera, bioelectrical impedance analysis and dual energy X-ray absorptiometry.
16258122|NCT04969575||day 3 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.
~Media refreshment: Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3). Embryo grading will not be done day2-5. Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.
~Dishes will be equilibrated overnight in a CO2 incubator. Embryo grading should be done prior to media refreshment. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.
~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
16258123|NCT04969575||day 5 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.
~Media refreshment and embryo grading timings: Zygote scoring on day 1 (18-20hpi). Embryo grading and culture media refreshment will be done 114-118 hours post insemination (Day5).
~Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops. Dishes will be equilibrated overnight in a CO2 incubator.
~Embryo grading and media refreshment is done prior to blastocyst biopsy. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.
~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
16258124|NCT04969562|Experimental|experiment|Individuals with multiple sclerosis in the experimental group will be included in six sessions of EFT at seven-day intervals, in which one session lasts 30-45 minutes. SUDS will be applied before and after each EFT session. At the same time, resting heart rate and blood pressure will be measured in the EFT group before and after each session.
16258125|NCT04969562|No Intervention|control|They will continue their routine treatment.
16258126|NCT04969549|Other|Theta-burst stimulation (TBS)|Receive active iTBS, 1800 pulses, 100% MT over dlPFC.
16258127|NCT04969536|Experimental|Branched chain amino acid supplementation|Consumption of 8 ounces of water with addition of 2.5 g of leucine, 1.25 g of isoleucine, and 1.25 g of valine immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
16258128|NCT04969536|Placebo Comparator|Placebo|Consumption of 8 ounces of a flavor matched beverage sweetened with a sucralose-based drink mix immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
16258129|NCT04969523|Experimental|es-ketamine|es-ketamine 0.5mg/kg iv
16258130|NCT04969523|Placebo Comparator|saline|iv saline with the same volume of es-ketamine
16258131|NCT04969510|Experimental|PRAX-114 (10 mg)|10 mg PRAX-114 once daily
16258132|NCT04969510|Experimental|PRAX-114 (20 mg)|20 mg PRAX-114 once daily
16258133|NCT04969510|Experimental|PRAX-114 (40 mg)|40 mg PRAX-114 once daily
16258134|NCT04969510|Experimental|PRAX-114 (60 mg)|60 mg PRAX-114 once daily
16258135|NCT04969510|Placebo Comparator|Placebo|Placebo once daily
16258136|NCT04969497|Experimental|Sequence ABC|Receives interventions in the sequence, A, B, C.
16258137|NCT04969497|Experimental|Sequence CAB|Receives interventions in the sequence, C, A, B.
16258138|NCT04969497|Experimental|Sequence BCA|Receives interventions in the sequence, B, C, A.
16258139|NCT04969497|Experimental|Sequence CBA|Receives interventions in the sequence, C, B, A.
16258140|NCT04969497|Experimental|Sequence BAC|Receives interventions in the sequence, B, A, C.
16258141|NCT04969497|Experimental|Sequence ACB|Receives interventions in the sequence, A, C, B.
16258142|NCT04969484|Experimental|ImPAcTT intervention|Within 48-72 hours of enrollment in the study, the primary participant and family will receive an ImPAcTT Telehealth visit with the PC provider. The provider will conduct a comprehensive PC assessment aligned with the National Consensus Project for Quality Palliative Care guidelines. Visits, which may include remote physical assessment using a digital stethoscope, dermatoscope, etc., will be documented and transmitted to the NH. Advanced Care Planning (ACP) and goals of care discussions will be facilitated by the ability to virtually share and edit documents, such as the Physician Orders for Life Sustaining Treatment (POLST), in real time with primary participants and/or family. The PC provider will conduct follow-up visits 1 week following the initial visit, then on a case-by-case basis.
16258143|NCT04969484|No Intervention|Usual care|Participants will receive the standard of care established at the NH.
16258144|NCT04969471|Experimental|Thrombectomy Arm|enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
16258145|NCT04969471|Experimental|Conventional Treatment Arm|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
16258146|NCT04969458||participants|The study included individuals whose native language is Turkish, who are over the age of 18 and under the age 70, diagnosed with chronic low back pain, without Psychiatric disorder, Cognitive impairment, Dementia, or Alzheimer's and who want to participate in the study.
16258147|NCT04969445||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
16258148|NCT04969445||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
16258149|NCT04969432|Experimental|Telerehabilitation|
16258150|NCT04969432|Experimental|Face-to-face|
16258151|NCT04969419||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
16258152|NCT04969419||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
16258153|NCT04969406|Experimental|Imaging by BOSS System|Imaging by the BOSS System
16258154|NCT04969393|Experimental|Group A (High Intensity Laser therapy + Conventional Physical Therapy)|Patients in group (A) received conventional physical therapy program along with HILT. Patients received pulsed Nd: YAG laser treatment, produced by EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2).
16258155|NCT04969393|Active Comparator|Group B (Conventional Physical Therapy)|Patients in this group received the conventional physical therapy program in the form of splinting, tendon and neural gliding exercises. Patients were instructed to wear a neutral custom volar splint at night and while performing strenuous activities during the day for 5 weeks.Also, the patients performed nerve-and tendon-gliding exercise under direct supervision of the therapist during the treatment sessions. Each exercise was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
16258156|NCT04969380|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
16258157|NCT04969367||Observational (activity monitor)|Patients wear an activity monitor (Fitbit) for 90 days. Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.
16258158|NCT04969354|Experimental|CAR-T cell immunotherapy|The registered patients will received CAR-T cell immunotherapy for the new specific chimeric antigen receptor of CAIX antigen by infusion.
16258159|NCT04969341||Screening (survey, medical record review)|Patients complete survey over 20 minutes consisting of validated and piloted items related to cost and convenience barriers in lung cancer screening, personal financial and lung cancer risk perception questions, and the Telehealth Satisfaction and Usefulness questionnaire. Patients also have their medical records reviewed retrospectively.
16258161|NCT04969328|No Intervention|Standard care|The adolescent and their parents will receive standard care
16258162|NCT04969315|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-10 is determined
16258165|NCT04969289|Experimental|Dr. Eric Digital Health Intervention|"Participants will interact with an ED-based iPad and the Dr. Eric app for a recorded period of time. After completion, an animated video will explain the ERIC texting program and live office hours. The participant enters his phone number and then receives a welcome text. Weekly texts are sent directly to the participant phone via short message service (SMS)."
16258166|NCT04969289|No Intervention|Standard of Care|Participants randomized to the SC arm will receive standard medical care as determined by the ED provider, which is typically referral to a primary care or adolescent provider. Mobile telephone numbers will be collected for follow up purposes.
16258167|NCT04969276|Experimental|Group 1: Fluzone HD and Covid-19 vaccine|Concomitant administration of Fluzone High-Dose Quadrivalent vaccine and COVID-19 mRNA Vaccine
16258168|NCT04969276|Active Comparator|Group 2: Fluzone HD vaccine|Administration of Fluzone High-Dose Quadrivalent vaccine alone
16258169|NCT04969276|Active Comparator|Group 3: Covid-19 vaccine|Administration of COVID-19 mRNA Vaccine alone
16258170|NCT04969263|Experimental|mRNA-1273 vaccine (Pfizer/BioNTech)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine.
~Administration: One dose administered intramuscularly, upper arm."
16258171|NCT04969263|Experimental|mRNA-1273 vaccine (Moderna)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine.
~Administration: One dose administered intramuscularly, upper arm."
16258176|NCT04969237||healthy subjects 2019|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
16258177|NCT04969237||healthy subjects 2020|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
16258178|NCT04969237||healthy subjects 2021|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
16258179|NCT04969237||post-COVID subjects 2021|subjects with diseases not influencing vitamine D values without substitution with diagnosed post-COVID syndrome
16258181|NCT04969211|Experimental|Sequence A: VHX-896 then iloperidone|
16258182|NCT04969211|Experimental|Sequence B: Iloperidone then VHX-896|
16258184|NCT04969185||Group 1: Children eligible to receive SMC diagnosed with uncomplicated Plasmodium falciparum malaria|Children eligible to receive SMC (6-59 months of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility.
16258185|NCT04969185||Group 2: Children eligible to receive SMC presenting at health facility without malaria parasitemia|Group 2 will be defined as children eligible to receive SMC (6-59 months of age) who presented at the health facility and tested negative for malaria parasitemia.This group will serve as the control group to Group 1 Cases to compare the SP-AQ drug levels between children who did and did not get malaria.
16258186|NCT04969185||Group 3: Children 5-10 years of age diagnosed with uncomplicated Plasmodium falciparum malaria|Group 3 will be defined as children ineligible to receive SMC (5-10 years of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility. This group will serve as the control group to Group 1 Cases to compare the prevalence of SP and AQ resistance markers.
16258187|NCT04969172|Active Comparator|1010 Exosome|103 patients will receive either 1010 exosome particles.
16258188|NCT04969172|Placebo Comparator|Placebo|52 patients will receive placebo- saline.
16258189|NCT04969146|Experimental|Modified Cognitive Behavioral Therapy Intervention Dyadic|The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up.
16258190|NCT04969146|Experimental|Modified Cognitive Behavioral Therapy Intervention Patient Only|The patient in the patient only intervention arm will receive 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up
16258191|NCT04969133|Active Comparator|TAP Block|"Transverse abdominal block is realisated at the beginning of the surgery with ultrasound guided technique with levobupivacaine 2.5mg/mL, 0.3mL/kg each side.
~The patient receives usual analgesia protocol."
16258192|NCT04969133|Active Comparator|local infiltration of the trocar wounds|"local infiltration of the trocar wounds is realisated at the end of the surgery by the surgeon with levobupivacaine 2.5mg/mL 0.6mL/kg distributed in each trocar opening.
~The patient receives usual analgesia protocol."
16258193|NCT04969120|Active Comparator|(group 1) receiving intravenous metoclorpramide|this group receive 10mg intravenous metoclopramide
16258194|NCT04969120|Placebo Comparator|(group 2) receiving placebo|this group receive 10mg intravenous placebo(0.9 sodium chloride)
16258195|NCT04969107|Active Comparator|transanal TME (taTME)|patients with rectal cancer receiving transanal TME
16258196|NCT04969107|Active Comparator|abdominal TME (abTME)|patients with rectal cancer receiving open, laparoscopic or robotic TME
16258197|NCT04969094|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
16258198|NCT04969094|Active Comparator|MMBI|Participation in a multi-modality balance intervention
16258199|NCT04969081|Active Comparator|treatment as usual|usual substance use treatment
16258200|NCT04969081|Experimental|treatment as usual plus referral to work focused program|usual substance use treatment plus referral to a competitive or non-competitive work-focused program
16258201|NCT04969068|Experimental|The median effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg|
16258202|NCT04969055||patients with liver cirrhosis|cirrhosis based on either clinical/radiological parameters or liver histology
16258203|NCT04969055||control group|Subjects without cirrhosis and hepatitis
16258204|NCT04969042|Experimental|Stimulation|Participants will receive pre-implantation rehabilitation, implantation of the closed-loop spinal cord stimulator, and stimulation (according to the functional mapping) assisted rehabilitation post-implantation during the trial.
16258205|NCT04969029|Experimental|immunotherapy|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
16258206|NCT04969029|No Intervention|chemotherapy|The chemotherapy regimen of the standard chemotherapy group was XELOX regimen, oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 21 days. The duration of treatment was determined according to the patient's postoperative pathological stage (3 months for T4N0/ T1-3N1 and 6 months for T4N+/ T1-3N2).
16258207|NCT04969016|Experimental|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
16258208|NCT04969016|Active Comparator|Stapler|surgical wound closure with stapler
16258209|NCT04969003|Active Comparator|Transgender male (TM)|~90-second video of depressed transgender male
16258210|NCT04969003|Active Comparator|Cis-gender male (CM)|~90-second video of depressed cis-gender male
16258211|NCT04969003|Active Comparator|Transgender female (TF)|~90-second video of depressed transgender female
16258212|NCT04969003|Active Comparator|Cis-gender female (CF)|~90-second video of depressed cis-gender female
16258213|NCT04968990|Active Comparator|Favorable Histology Stage I & II and FH Stage III/IV|Favorable Histology Stage I & II and FH Stage III/IV Delayed Local Control with clear surgical margins and pathologically negative lymph nodes. Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
16258214|NCT04968990|Active Comparator|Stage III & IV Adjuvant RT and Stage V|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT.
16258215|NCT04968990|Active Comparator|Stage V Adjuvant RT:|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT
16258216|NCT04968977||UPLM-ISR|
16258220|NCT04968951|Active Comparator|FMT with Antibiotics|Participants will receive antibiotics before receiving Fecal Microbiota Transplantation
16258221|NCT04968951|Placebo Comparator|FMT with placebo|Participants will receive placebo before receiving Fecal Microbiota Transplantation
16258222|NCT04968938|Experimental|MDMA-assisted therapy|Two sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 mg initial dose and optional supplemental dose half that of initial dose 1.5 to 2 hours later
16258223|NCT04968925|Experimental|O1D/P1|Eligible subjects that are habitual wearers or daily disposable soft contact lenses will randomly be assigned sequence (O1D/P1)
16283136|NCT04794634|Active Comparator|healthy patient|
16258224|NCT04968925|Experimental|P1/O1D|Eligible subjects that are habitual wearers or daily disposable soft contact lenses will randomly be assigned sequence (P1/O1D)
16258228|NCT04968899|Experimental|Experimental group|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21
16258229|NCT04968899|Active Comparator|Control|IVIg (1g/kg D1-D2) plus prednisone (1 mg/kg/day x 21 days (3 weeks))
16258230|NCT04968873|Experimental|Patients with Choledocholithiasis|Patients were managed by elective open cholecystectomy and operative exploration of the common bile duct.
16258231|NCT04968860||Study group|Composed of children/adolescent individuals who have a definitive diagnosis of lymphoid leukemia or acute myeloid leukemia, who will be invited to participate in the research, regardless of race or gender.
16258232|NCT04968860||Control group|The control group is going to consist of healthy children/adolescent individuals, non-syndromic, without history of cancer, matched by age and gender in relation to the study group, who have not used antibiotics 48 hours before or in the day of evaluation.
16258233|NCT04968847|Experimental|FemaSeed|Investigational device and procedure
16258234|NCT04968834||GENOMIC PROFILING AND SPECIMEN BANKING REGISTRATION ARM|The research study procedures include screening for eligibility, reviewing and signing this consent form, collecting patient information and clinical data, obtaining previously collected bone marrow and blood samples, and completing a brief optional Household Survey. Bone marrow and blood samples may also be collected in the future as part of your routine clinical procedures
16258235|NCT04968821|Experimental|Physical Activity|Participants randomized to the physical activity intervention will receive usual postoperative care and a tele-health physical activity intervention.
16258236|NCT04968821|Other|Usual Care|Participants randomized to usual care will receive postoperative care as determined by their treating surgeon.
16258237|NCT04968808|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
16258238|NCT04968808|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
16258239|NCT04968795||Control|Participate in filling the questionnaire but NOT the meditation/wellness session (control).
16258240|NCT04968795||Wellness Group|Participate in filling the questionnaire and the meditation/wellness session
16258241|NCT04968782||Patients with acute appendicitis|
16258242|NCT04968769|Experimental|ischemic compression and exercise|"Individuals were positioned in a comfortable position in a chair with back support. By palpating the UT muscle, first the taut band and then the active TP on the muscle were determined. Before starting the treatment, , a statement was made to the individual that you will soon feel a high level of pain with pressure, and at the same time, you may feel pain, tingling, pricking in additional areas (head-neck-shoulder-arm), after a while the pain will decrease and disappear. In this process, try to stay as steady as possible and breathe regularly and calmly.'' The highest level of pressure that the patient could tolerate was applied to the determined TP with the thumb. Pressure time will be in the range of at least 10-20 seconds and at most 60 seconds; It was terminated after the therapist felt complete relaxation in the tissue under his thumb or after the patient received the return of pain completely disappeared"
16258243|NCT04968769|Experimental|kinesio taping and exercise|While performing KT, the individual was seated in a comfortable and upright position in a chair with back support. The subject was asked to bring his hand to his back in internal rotation of the shoulder of the taped side and to bring his head to the contralateral lateral flexion and contralateral rotation so that the UT muscle was in a tense position. KT was applied using 'muscle inhibition technique' to ensure correct contraction of the muscle with muscle length/tension optimization, to target the reduction of excessive muscle tension, and to increase circulation with the effects of the tape on the skin. In this technique, to inhibit the muscle, the tape direction is from the muscle insertion to the origin. KT was performed 5 cm below the acromion to the protuberantia occipitalis with 10% tension
16258244|NCT04968769|Active Comparator|exercise|In order for all the exercises to be done correctly and not to cause any pain, the individuals were asked to perform the movements in front of the mirror. Posture exercises given the individuals for scapular retraction. During the posture exercises individual was positioned in a chair without back support. By counting 5 it was requested to do 10 repetitions of each exercise. For the UT muscle stretching, individuals were asked to hold their right ear with their left hand over their head while sitting on a back-supported chair with their hips and back fully resting on the chair, and to bring their left ear closer to their left shoulder with the help of their hand and count to 20 from the outside.
16258338|NCT04968106|Experimental|Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab|Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery
16258245|NCT04968756|Experimental|Treatment with the SPECTRALIS CENTAURUS device|"In Stage 1, two laser pattern will be applied in areas of the retina that require ablative laser photocoagulation.
~In Stage 2, a laser pattern will be applied along and on the outside of the arcades. Furthermore, a treatment pattern will be applied to an area temporal to the fovea affected by intermediary age-related macular degeneration (AMD) and confluent soft drusen."
16258246|NCT04968743|Experimental|Participants With Unilateral Stroke|"Participants with self-reported unilateral stroke will take part in two experimental sessions:
~First, for assessment of stroke characteristics and MRI scan, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the unilateral stroke will be confirmed. In participants with stroke, TMS will be applied over the motor cortex on the affected and non-affected hemisphere at the intensity of up to 120% resting motor threshold."
16258247|NCT04968743|Experimental|Participants Without Unilateral Stroke|"Participants without self-reported unilateral stroke will take part in two experimental sessions:
~First, for assessment of stroke characteristics, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the lack of unilateral stroke will be confirmed. In participants without stroke, TMS will be applied targeting at the intensity of up to 120% resting motor threshold both left and right hemisphere."
16258248|NCT04968730|Placebo Comparator|control group A|routine nursing after operation
16258249|NCT04968730|Experimental|intervention group B|Nursing care after operation with stage intervention
16258254|NCT04968704||patients undergoing facial reconstructive surgery|Patients with facial cancer or disfigurement who require reconstructive surgery will be offered participation in this study.
16258255|NCT04968691|Experimental|Telerehabilitation group|The group to which a structured exercise program supported by telerehabilitation will be treated.
16258256|NCT04968691|Active Comparator|Control group|The group to which the home exercise program will be treated.
16258257|NCT04968665||healthy volunteers|gait testing and MRI at baseline for healthy volunteers
16258258|NCT04968665||ACL-deficient patients|gait testing and MRI at pre-operation, 6 months post-operation, 1 year post-operation, 2 years post-operation
16258259|NCT04968652||IBS-C Group|Result of ROME VI marked as 'IBS-C'.
16258260|NCT04968652||Non IBS-C Group|Result of ROME VI marked as 'Non IBS-C'
16258261|NCT04968639||Axial pain positive group|Postoperative VAS score ≥ 3 points at 3-month follow-up
16258262|NCT04968639||Axial pain negative group|Postoperative VAS score ≤ 2 points at 3-month follow-up
16258263|NCT04968626|Experimental|IS GROUP|Patients who received an operation to treat their isthmic spondylolisthesis (IS, Meyerding grade I-II)
16258264|NCT04968626|No Intervention|AS GROUP|The asymptomatic adults had no history of severe back pain or spinal trauma
16258265|NCT04968613|Experimental|Madopar monotherapy group|Patients in this group received Madopar monotherapy
16258266|NCT04968613|Active Comparator|senfrol monotherapy group|Patients in this group were treated with senfrol (D2 receptor agonist) alone
16258267|NCT04968613|Placebo Comparator|placebo group|Patients in this group were treated with selegiline alone
16258268|NCT04968600|Experimental|Posterior-cruciate-ligament-retaining (CR)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
16258269|NCT04968600|Experimental|posterior-cruciate-ligament-stabilized (PS)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
16258270|NCT04968587|Other|Group 1: RACD - RCA|First period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED and second period of treatment with Regional Citrate Anticoagulation SLED
16258271|NCT04968587|Other|Group 2 : RCA - RACD|First period of treatment with Regional Citrate Anticoagulation SLED and second period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED
16258272|NCT04968574|Experimental|ENV-101|taladegib, 200 mg tablet, once daily for 12 weeks
16258273|NCT04968574|Placebo Comparator|placebo|placebo, tablet, once daily for 12 weeks
16258274|NCT04968561||cohort 1|"Adult patients
~Admitted in the ENT and Cervico-Facial Surgery department of the Gabriel Montpied University Hospital in Clermont-Ferrand.
~From November 2020 to October 2021,
~Requiring endoscopic sinus surgery
~With good quality imaging (CT scan and/or MRI)"
16258275|NCT04968548||Cases Series|Subjects with confirmed lung cancer diagnosis
16258276|NCT04968548||Screening Series|Subjects undergoing LDCT for lung cancer screening
16258277|NCT04968535|Experimental|Therapy|Patients receiving suprathreshold electrotherapy in weekly intervals for a Duration of 30 min each. Device calibration with determination of the individual threshold was performed prior to the application of electrical current.
16258278|NCT04968535|Sham Comparator|Control|Patients receiving device calibration without consequent electrotherapy.
16258279|NCT04968535|No Intervention|Control of control|Patients lay on the mat without receiving device calibration nor electrotherapy.
16258280|NCT04968522|Placebo Comparator|Placebo comparator 2|Participants will be randomized to one of two treatment arms - either active drug or placebo first for 4 days in one week, then alternating to the opposite condition (active drug or placebo). Placebo will be matched in dose to their stimulant dose at enrolment to the trial as determined and titrated by their primary paediatrician. This dose will remain constant for the course of the trial (4 weeks). Placebo will be orally administered, unless this is not possible for clinical reasons.
16258339|NCT04968093|Other|Group sessions of mindfulness-based therapy|Education of patients followed by seven group sessions of mindfulness-based therapy
16258340|NCT04968080||Full Analysis Set|Participants will have their temperature collected by infrared thermal camera (IRT), oral, forehead, and ear thermometers.
16258281|NCT04968522|Experimental|Stimulant|"The stimulants used in the trial are commercially available and will be used in accordance with the approved labelling. Participants must be on a stable dose of stimulant medication for at last 1 month prior to the study. The dose is individualized and titrated by treating primary paediatrician. This will represent the starting dose for the trial, and this will remain stable through the course of the 4-week trial. This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. Based on pilot data from this group, psychostimulant medications prescribed in this population may include:
~Methylphenidate IR
~Methylphenidate LA
~Dexamphetamine
~Children will take the required number of capsules to match the total prescribed dose (e.g. 30mg Ritalin LA is 3x10mg capsules)."
16258282|NCT04968509|Experimental|treatment with PCSK9 inhibitor and statin|Patients in experimental group were treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab subcutaneously every two weeks ) and conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
16258283|NCT04968509|Other|statin-only treatment|Patients in control group were only treated with conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
16258284|NCT04968496|No Intervention|Food Insecure Group|Children randomized to the naturally-occurring Food Insecure group will receive a weekly newsletter with information on available area-specific food programs. The weekly newsletter will be sent in two ways: 1) a paper copy will be mailed and 2) a link to an electronic version will be sent via Ilumivu to families to remove any barriers to engagement with the information. In the absence of school meal programs, children from low-income households are at increased risk for food insecurity during the summer.37-39 Given low engagement in summer food programs, it is not expected that this newsletter will impact food security in this group.
16258285|NCT04968496|Experimental|Food Secure Group|Children randomized to the Food Secure group will receive breakfast and lunch meals for eight weeks throughout the summer. Weekly meals will be delivered to each participant's home by Yumble, a company that prepares meals for children ages 3 to 12 years and ships them fresh in insulated, food safe packaging to the home. The meals have similar nutrition standards to those offered via the National School Lunch Program and include fruits, vegetables, whole grains, and lean/ vegetarian proteins. To accommodate cultural preferences or dietary constraints, Yumble offers 20 different breakfast, lunch and dinner meals each week. Families will choose their weekly menus to improve adherence. Participants who have siblings in their home will be provided a family meal kit, which provides 24 meals each week. Additional meals will help to prevent household food insecurity and ensure that the child enrolled in the study consumes the meals each week.
16258286|NCT04968483||Study group|Patients with spine deformity undergoing surgical treatment
16258287|NCT04968444|Active Comparator|one to one traditional physiotherapy|For clarity, 1-1 physiotherapy takes the form of a private consultation between patient and therapist. A discussion of symptoms is had and an individual physical examination is undertaken to explore what is mechanically causing their pain and what can be offered to help. This is also when the initial outcome scores are taken. Treatments are then offered which can take the form of exercise therapy, massage, and manual therapy. Symptoms are regularly monitored for effectiveness of treatment and adjusted accordingly. The number of sessions that forms their treatment is variable depending on response to treatment and how they are coping. At the final session the end outcome scores will be taken.
16258288|NCT04968444|Active Comparator|BOOST workshop group|The BOOST workshop is a novel approach whereby participants are invited to a 2.5 hour interactive session. Subjective discussion at the start is had about how people are affected and impacted by their back pain, and outcome scores are completed. Then during the 2.5 hours there is a delivery of information and a practical exercise component to better inform the participants on how to manage their back pain and understand it better. Following this on 3 separate occasions, 1 month apart further top up information is sent to ensure they remember exercises and advice on practical management if a flare up occurs or they are struggling to fit activity in to day to day routines. Finally, at 3 months, there participants are invited back to complete the outcomes scores but also to discuss any concerns they are having and be given any advice to support them continuing with managing with any ongoing symptoms.
16258289|NCT04968431||Mitral Stenosis patient|
16258290|NCT04968405|Other|Single Arm|Intervention with a 510k cleared shoulder arthroplasty device
16258291|NCT04968392|Experimental|L group|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
16258292|NCT04968392|Experimental|LD group|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
16258293|NCT04968379|Experimental|Ferric Carboxymaltose|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM
16258294|NCT04968379|Experimental|Injectafer|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.
16258295|NCT04968366|Experimental|DC vaccine group|Subjects will receive five to eight doses of the DC vaccine through i.d. injection into regions near to the groin and axillary during they receive TMZ adjuvant chemotherapy
16258296|NCT04968353|Active Comparator|Incisally-beveled|Use of incisally-beveled attachment to extrude lateral incisor
16258297|NCT04968353|Active Comparator|Gingivally-beveled|Use of gingivally-beveled attachment to extrude lateral incisor
16258298|NCT04968353|Active Comparator|Optimized|Use of optimized attachment to extrude lateral incisor
16258299|NCT04968353|Active Comparator|Horizontal|Use of horizontal (unbeveled) attachment to extrude lateral incisor
16258300|NCT04968340|Other|• Group 1(conventional c s)|this arm will be exposed to the conventional method of cesserian section which entail introduction of the operator hand below the fetal head during its extraction
16258301|NCT04968340|Other|• Group2(EPO technique)|this group will be exposed to external pop out teqnique which entails support of lower uterine segment without introduction of the obstetrician hand into uterine incision
16258302|NCT04968327|Experimental|Micro-osteoperforations|
16258303|NCT04968327|Active Comparator|Canine retraction|
16258304|NCT04968314||ChiPP Groups|Parents enroll in Chicago Parent Program groups offered at their child's school
16258305|NCT04968301||hip developmental dysplasia group|patients with developmental dysplasia of hip
16258306|NCT04968301||femoroacetabular impingement group|patients with femoroacetabular impingement
16258309|NCT04968275|Experimental|CHAMPS and EIS|The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
16258310|NCT04968275|No Intervention|EIS alone|Early intervention services (EIS) for psychosis will be offered as per standard of care at participating clinical sites. Theses services vary but typically include pharmacotherapy and individual and/or group psychotherapy. Any visits and services offered in the EIS arm will be considered 'usual care' and administered either through in-person clinic visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
16258311|NCT04968262||Sepsis|Patients receive sepsis therapy.
16258312|NCT04968262||Sepsis-related acute kidney injury|Patients receive sepsis and sepsis-related acute kidney injury therapy.
16258313|NCT04968249||Gold 0|Participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 > 80% predicted; and COPD Assessment Test (CAT) score ≥ 10
16258314|NCT04968249||Gold 1|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-80% predicted.
16258315|NCT04968249||Gold 2|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-80% predicted.
16258316|NCT04968249||Prism|Participant must a >10 year smoking history, post-bronchodilator of FEV1 <80%, and a predicted DEV1/FVC >.70
16258320|NCT04968223||Patient Group|Patients with Schizophrenia
16258321|NCT04968223||Relatives Group|Healthy first-degree relatives of persons with schizophrenia
16258322|NCT04968223||Control Group|Healthy subjects without family history of psychotic illness
16258323|NCT04968210||Pulmonary arterial hypertension (PAH)|Patients that have been clinically diagnosed with pulmonary arterial hypertension and fall under the category of WHO group 1 PAH.
16258324|NCT04968197|Experimental|Stochastic Vestibular Stimulation (SVS) Condition|Subjects will perform standard clinical testing for balance and gait while wearing the Vestibular Intervention via Portable Electrical Stimulator (VIPES) system. The SVS device will be active throughout the testing at the respective current levels (i.e., 0.2mA to 1 mA at 0.2 mA increments).
16258325|NCT04968197|No Intervention|Control Condition|Subjects will perform standard clinical testing for balance and gait without SVS
16258326|NCT04968184|Placebo Comparator|Placebo|All eligible participants will receive KBP-5074 matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period, then up to 24 weeks during the Double-blind treatment Period and during the Open-label treatment period, and thereafter for 4 weeks, during the randomized Double-blind withdrawal period.
16258327|NCT04968184|Experimental|KBP-5074|All eligible participants will receive KBP-5074, for up to 24 weeks during the Double-blind treatment Period and during the Open-label treatment period. Thereafter, eligible participants will continue current dose of KBP-5074 at the end of the Open-label treatment period.
16258328|NCT04968171||People with newly diagnosed diabetes mellitus type 1|"People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.
~Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years."
16258329|NCT04968158|Experimental|Group A: Etoricoxib/Tramadol|Administered orally, one packet of etoricoxib / tramadol granules diluted in 100 ml of water, every 24 hours for 7 days.
16258330|NCT04968158|Active Comparator|Group B: Acetaminophen / Tramadol|Administered orally, one tablet, every 8 hours, for 7 days.
16258331|NCT04968145|No Intervention|Control Group|Participants in the control group receive routine follow up care which consists of (i) written instructions regarding potential complications and the contact information of their treating surgeon, (ii) a follow up telephone call 4 weeks following discharge by a member of the health care team and (iii) an in-person follow up visit in clinic with the treating surgeon 4-6 weeks following discharge.
16258332|NCT04968145|Experimental|Intervention Group|The participants in the intrevention group receive the same routine care as the control group in addition to post discharge monitoring with the Home to Stay app
16258333|NCT04968132|Active Comparator|Standard care group|This group will receive standard perioperative care, surgical treatment, and pain medications.
16258334|NCT04968132|Experimental|Opioid reduction group|Patients will participate in a multicomponent pathway coordinated by a trained coordinator who will facilitate patient participation and engagement with each interventional component.
16258335|NCT04968119|Experimental|Arm A (telehealth intervention)|Patients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
16258336|NCT04968119|Active Comparator|Arm B (delayed exercise intervention)|Patients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
16258337|NCT04968106|Other|Standard Arm A: treatment by neoadjuvant chemotherapy|Treatment by doxorubicin and ifosfamide followed by surgery
16284644|NCT04783909||Control|38 eyes with cataract only
16258341|NCT04968067|Experimental|App group|In addition to the usual care, the participant will receive a health talk , a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
16258342|NCT04968067|Active Comparator|Nursing telephone advice (NTA) group|In addition to the above usual care, the participant will receive a health talk , three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages.
16258343|NCT04968054|Active Comparator|Propofol group|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively
16258344|NCT04968054|Experimental|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
16258345|NCT04968041|Experimental|MI-CBT KNA Program|6-week group intervention using MI and CBT strategies to promote adherence to a ketogenic nutrition program.
16258346|NCT04968028|Experimental|ACAF|Participants underwent anterior decompression of Anterior Controllable Antedisplacement and Fusion
16258347|NCT04968028|Experimental|Laminoplasty|Participants underwent posterior decompression of Laminoplasty
16258348|NCT04968015|Experimental|VEN-CYTA|Venetoclax 600mg/day, Per Os (PO), D1 to D14 / 28 days cycle Cytarabine 50 mg/m2/12h Subcutaneous (SC), D1 to D5 / 28 days cycle
16258349|NCT04968015|Active Comparator|IDA-CYTA|Idarubicin 8mg/m2, Intravenous (IV), at D1 / 28 days cycle Cytarabine 50 mg/m2/12h, SC, D1 to D5 / 28 days cycle
16258350|NCT04968002|Experimental|Preoperative neoadjuvant therapy for patients with stage IIa-IIIa non-small cell lung cancer.|No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology. After informed consent is signed by the patients. The patients were treated according to the protocols.
16258351|NCT04967989|Experimental|First Randomization: Low Energy SLT|"Low energy SLT will consist of 100 treatment spots delivered at 0.4mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ is no bubbles are seen with 5 consecutive spots.
~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
16258352|NCT04967989|Active Comparator|First Randomization: Standard Energy SLT|"Standard SLT will be performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.
~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
16258353|NCT04967989|Experimental|Second Randomization: Annual Low Energy Repeat SLT|At month 12, subjects remaining medication-free will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
16258354|NCT04967989|Active Comparator|Second Randomization: As-Needed Repeat SLT at Initial Energy|At month 12, subjects remaining medication-free will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
16258355|NCT04967976|Experimental|Breast Reconstruction with breast mesh|The tissue expander-implant reconstruction with TiLoop Bra mesh.
16258356|NCT04967976|Active Comparator|Breast Reconstruction without breast mesh|The tissue expander-implant reconstruction without TiLoop Bra mesh. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
16258357|NCT04967963|Experimental|Transplantation of HAM|HAM was used after sequestrectomy in patients with stage-2 MRONJ
16258358|NCT04967950|Experimental|Secukinumab 300mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
16258359|NCT04967950|Experimental|Secukinumab 150mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
16258360|NCT04967950|Active Comparator|methotrexate|methotrexate
16258361|NCT04967937|Experimental|Single-Group|The neuromuscular training program will consist of three 90-minute training sessions per week for 6 weeks. The 3 components of the dynamic neuromuscular training protocol utilized in this study include: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training. Following the completion of the training program, each subject will be re-evaluated to determine change in total, anterior-posterior, and medial-lateral single-limb stability. Two-way analysis of variance models will be used to determine differences between pre-training and post-training and between limbs.
16258362|NCT04967924|Experimental|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
16258363|NCT04967924|Active Comparator|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
16258364|NCT04967911|Experimental|Rhythmic stabilization exercises|baseline physical therapy conventional treatment along Rhythmic stabilization exercises
16258365|NCT04967911|Other|Conventional treatment|Baseline physical therapy conventional treatment
16258366|NCT04967898|Experimental|bowen technique|group 1 will be treated with the Bowen technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up.
16258471|NCT04967105||elderly patients following liver resection|elderly patients (aged ≥60 years) scheduled for any type of liver resection due to benign or malignant hepatobiliary diseases
16258367|NCT04967898|Active Comparator|sustained stretching|group 1 will be treated with the sustained stretching technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up
16258368|NCT04967885|Experimental|Immediate Intervention|Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.
16258369|NCT04967885|Active Comparator|Waitlist|Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.
16258370|NCT04967859|Placebo Comparator|Group 1 (control):|Patients using placebo ointment at the exit site of the hemodialysis catheter
16258371|NCT04967859|Experimental|Group 2 (intervention)|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
16258372|NCT04967833|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-3x10^11 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
16258373|NCT04967807|Other|Cohort A - Symptomatic|Those with clinical findings suggestive of myocarditis/myocardial injury after COVID-19 vaccination
16258374|NCT04967807|Other|Cohort B - Asymptomatic|Those without signs or symptoms suggestive of myocarditis after COVID-19 vaccination and have had prior cardiac MRI at UHN
16258375|NCT04967794|Active Comparator|Group Whatsapp|Will receive standardized brushing Teleorientation consultation through the Whatsapp communication platform
16258376|NCT04967794|Active Comparator|Group Vídeo for Health|You will receive a standardized brushing Teleorientation consultation through the V4H Platform, created specifically for Teleconsultations
16258377|NCT04967794|Active Comparator|Group de Orientação presencial|You will receive a standardized face-to-face brushing orientation consultation.
16258378|NCT04967781||"Group Severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), severe and critical types were grouped into case group as Severe."
16258379|NCT04967781||"Group Non-severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), mild and moderate types were grouped into control group as Non-severe."
16258380|NCT04967755|Experimental|Jing-Si-Herbal-Tea(JSHT)|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians.
16258381|NCT04967742|Experimental|A group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.
16258382|NCT04967742|Experimental|B group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.
16258383|NCT04967742|Experimental|C group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.
16258384|NCT04967729|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
16258385|NCT04967716||Peroneal muscular atrophy|Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity. It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886. The prevalence is about 1/2500-4000. It is the most common hereditary peripheral neuropathy. Inheritance includes all forms of Mendelian inheritance. The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
16258386|NCT04967703|Experimental|Ultrasound therapy protocol|Patients in group A received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes).
16258387|NCT04967703|Experimental|Radial shock wave therapy protocol|Patients in group B received radial shock wave therapy protocol with the following parameters: (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz.
16258388|NCT04967703|Experimental|Combined therapy protocol|Patients in group C received a combination of both ultrasound therapy and radial shock wave therapy protocol.
16258389|NCT04967690|Experimental|SI-053|Single arm study. Dose escalation will follow a rule-based 3 + 3 design using increasing doses of SI-053. Subjects will receive a single i.c. dose of room-tempered SI-053 gel, which will be applied onto the walls of the cavity formed after tumor resection using a sterile spatula.This will be followed by chemo-radiotherapy commencing at least 21 and no later than 35 days after SI-053 administration. The dose escalation part of the trial will follow a rule-based 3 + 3 design using a total of six dose levels of SI-053 (optional dose of 50 mg will be used to de-escalate in case of DLT at 75 mg) that consist of increasing amounts of TMZ in a constant amount of excipient and sterile WFI. These dose levels are planned to be tested in 21 subjects, including three more subjects at preliminary RP2D.The dose expansion phase will enroll an additional six subjects,to be treated at the RP2D in order to gather additional safety and preliminary efficacy data at that dose.
16258390|NCT04967677||Czech healthy occupational therapy students|Czech healthy occupational therapy students will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test. Video of their performance will be obtained.
16258391|NCT04967664|Experimental|Qutenza (capsaicin) 8% topical system|Qutenza (capsaicin 8% topical system, containing capsaicin 179 mg or capsaicin 640 µg/cm2 of topical system)
16258392|NCT04967664|Active Comparator|Low-dose capsaicin control|capsaicin 0.04% topical system
16258393|NCT04967651||Patients with pulmonary complications following cardiac surgery|
16258394|NCT04967651||Patients without pulmonary complications following cardiac surgery|
16258395|NCT04967625|Experimental|Sintilimab + Anlotinib|sintilimab 200mg, IV, d1, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W; treatment until disease progression, unacceptable toxicity, or death
16258399|NCT04967599|No Intervention|Control (CONTROL)|Participants do not receive PHEN or GENE.
16258400|NCT04967599|Experimental|Phenotype Feedback (PHEN)|Participants receive the PHEN intervention.
16258401|NCT04967599|Experimental|Phenotype and Genotype Feedback (PHEN+GENE)|Participants receive the PHEN and GENE interventions.
16258402|NCT04967586||Preclinical medical students|
16258403|NCT04967586||Clinical medical students|
16258404|NCT04967573|Experimental|Prophylactic Anticoagulation|Rivaroxaban 10 mg od for 3 months
16258405|NCT04967573|Active Comparator|Therapeutic Anticoagulation|Rivaroxaban 20 mg od for 3 months
16258408|NCT04967547|Experimental|Intervention group|be evaluated by using the self-care PD feasibility assessment in addition to education on renal replacement therapy and dialysis
16258409|NCT04967547|Active Comparator|Control group|education on renal replacement therapy and dialysis
16258410|NCT04967534|Experimental|WB-EMS|
16258411|NCT04967534|Sham Comparator|social contact control group|
16258412|NCT04967521|Experimental|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
16258413|NCT04967521|Placebo Comparator|Placebo Arm|Patients will be randomized 1:1 and will receive placebo if they are randomized to the placebo arm of the study. Each cycle is 28 days.
16258414|NCT04967508|Experimental|SB17 (Proposed Ustekinumab Biosimilar)|
16258415|NCT04967508|Active Comparator|Stelara® (Ustekinumab)|
16258416|NCT04967495|Experimental|TACE-MKI-I|TACE combined with sorafenib/lenvatinib and iodion-125 seeds brachytherapy
16258417|NCT04967495|Active Comparator|TACE-MKI|TACE combined with sorafenib/lenvatinib
16258418|NCT04967482|Experimental|DEB-TACE|DEB-TACE will be performed for the patients who choose DEB-TACE as the primary treatment.
16258419|NCT04967482|Active Comparator|cTACE|cTACE will be performed for the patients who choose cTACE as the primary treatment.
16258420|NCT04967469|Experimental|take calcitriol|End-stage renal failure patients who is Hyperparathyroid with ESRD take calcitriol
16258421|NCT04967469|Experimental|take alphacalcidol|End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol)
16258422|NCT04967469|No Intervention|control|End-stage renal failure patients who is Hyperparathyroid with ESRD take standard treatment
16258423|NCT04967456|Active Comparator|Measurement of pulpal blood flow of traumatised tooth|In the split-mouth design, the traumatised maxillary incisor will be investigated using Laser Doppler flowmetry.
16258424|NCT04967456|Other|Measurement of pulpal blood flow of non-traumatised tooth|In the split-mouth design, this arm - the non-traumatised maxillary incisor, contralateral tooth, will be investigated using Laser Doppler flowmetry as a control tooth.
16258430|NCT04967430|Experimental|Treatment|To receive a dose of peginterferon lambda 180mcg SC at baseline (Day 0).
16258431|NCT04967430|Placebo Comparator|Placebo|"Patients in this arm will receive a single SC dose of 0.9% sodium chloride (normal saline) solution at baseline (Day 0).
~A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse."
16258432|NCT04967417|Experimental|Non-squamous cell carcinoma|"4 cycles of pemetrexed 500mg/m2 + carboplatin AUC 5.0 + pembrolizumab 200mg every 3 weeks
~Followed by pemetrexed 500mg/m2 + pembrolizumab 200mg every 3 weeks up to 35 cycles"
16258433|NCT04967417|Experimental|Squamous cell carcinoma|"4 cycles of paclitaxel 200mg/m2 + carboplatin AUC 6.0 + pembrolizumab 200mg every 3 weeks
~Followed by pembrolizumab 200mg every 3 weeks up to 35 cycles"
16258434|NCT04967404|Experimental|Phosphatidylserine, 800 mg per day, 10 days|
16258435|NCT04967404|Placebo Comparator|Maltodextrin, 800 mg per day, 10 days|
16258436|NCT04967391|Experimental|Tumescence During STSG Harvest|Prior to the split thickness skin graft (STSG) harvest, the tumescence technique will injection of 100-150 mL normal saline with 1:500,000 epinephrine injected into a deep dermal thigh tissue plane with 18-gauge spinal needle on a 60 mL syringe.
16258472|NCT04967092|Active Comparator|Modified Xiao-Feng Powder|Modified Xiao-Feng Powder granules will be taken twice daily for 12 weeks
16258437|NCT04967391|No Intervention|No Intervention|"Patients randomized to no tumescence will have their free flap donor site reconstructed with a split thickness skin graft (STSG) harvested at 0.0175 inches using the dermatome to obtain a graft from the thigh."
16258438|NCT04967378|Experimental|HEPPI program|
16258439|NCT04967378|No Intervention|Waiting-list control group|Receives access to HEPPI program at the end of the study.
16258440|NCT04967365||Case patients|500 patients who experience greater than or equal to 3 nights in a pediatric ICU with intensive care instrumentation.
16258441|NCT04967365||Control patients|250 patients who experience an overnight stay in a pediatric ICU without intensive care instrumentation.
16258442|NCT04967352||Developed Persistent Opioid Use after 3 months following surgery|
16258443|NCT04967352||Did not develop persistent opioid use after 3 months following surgery|
16258444|NCT04967339|Experimental|Foot deformity correcting insole arm|"Patients allocated to the foot deformity correcting insole arm will receive insoles to correct their foot deformities (plano-valgus foot deformity)."
16258445|NCT04967339|Active Comparator|Lateral wedge insole arm|"Patient allocated to the Lateral wedge insole arm will receive conventional lateral wedge insole."
16258446|NCT04967326|Experimental|Patients with epilepsy|The therapies of patients with epilepsy were optimized using pharmacists' interventions, including medication consultation, dosage adjustment, medication switching/discontinuation, or combination therapy.
16258447|NCT04967313|Experimental|Behavioral Change Techniques to Increase Walking|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps five days per week. Participants will be enrolled for a baseline period lasting two weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will receive daily text messages of behavior change techniques (BCTs) for eight weeks. The four BCTs utilized in this study are: goal setting, action planning, self-monitoring of behavior, and feedback on behavior. Each BCT will be delivered to participants daily for a two-week block. Four blocks (one BCT per block) will be delivered to the participant. The order in which the BCT interventions are presented to participants will be randomized by the study statistician. The goal of the BCT text messages will be to encourage walking behavior.
16258448|NCT04967300||First Visit|Children who visit dentist at first time
16258449|NCT04967300||Second Visit|Children who visit dentist at second time
16258452|NCT04967274|Experimental|Spinal cord injured subjects|
16258453|NCT04967248||alpelisib in combination with fulvestrant|Patients treated with alpelisib in combination with fulvestrant
16258454|NCT04967235|Active Comparator|Conventional Exercise-based Cardiac Rehabilitation|This interventional arm consists of a conventional exercise-based cardiac rehabilitation, composed of initial rest, warm-up, treadmill aerobic exercise, orthostatic passive recovery, and supine passive recovery.
16258455|NCT04967235|Experimental|Dance-Based Cardiac Rehabilitation|This interventional arm consists of a new dance-based cardiac rehabilitation, composed of initial rest, warm-up, dance therapy, orthostatic passive recovery and supine passive recovery.
16258456|NCT04967222|Experimental|Cognitive Reappraisal-by-Distancing (CRD)|Subjects will be coached to use cognitive reappraisal-by-distancing to downregulate their negative reactions to aversive emotional pictures usng practice pictures.
16258457|NCT04967222|Active Comparator|Control Downregulate Condition (CD)|Subjects will be coached to practice their customary emotion regulatory techniques in a treatment occurring twice a week for 6 weeks.
16258458|NCT04967196|Experimental|Treatment (ipilimumab, nivolumab)|Patients receive ipilimumab via DoseConnect on day 1 of cycle 1 and via IV over 30 minutes on day 1 of cycles 2-4. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16258459|NCT04967183|Experimental|Group I|Annual FIT surveillance
16258460|NCT04967183|Active Comparator|Group II|Endoscopic surveillance
16258461|NCT04967170|Experimental|Platelet Rich Plasma Group|Subject diagnosed with vulvar lichen sclerosus will receive Autologous Platelet-Rich Plasma (PRP)
16258462|NCT04967170|Sham Comparator|Sham Procedure Group|Subject diagnosed with vulvar lichen sclerosus will receive sham procedure of intralesional needle insertion without any injectate administered.
16258463|NCT04967157|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
16258464|NCT04967157|Experimental|Cognizin®|Intervention: Dietary Supplement: Citicoline supplement
16258465|NCT04967144||Carpal Tunnel syndrome|.Patients with carpal tunnel syndrome
16258466|NCT04967144||Control subjects|Healthy subjects
16258467|NCT04967131||PNF group|Proprioceptive Neuromuscular Fascilitation exercises were given this group
16258468|NCT04967118|Experimental|Skin-to-skin contact|Neonates will be placed ventral skin-to-skin position with their mother at least thirty minutes prior the heel lance to give time to calm down following transfer. Skin-to-skin positioning will be taken account comfortable position as possible for mother and the baby, easy to access heel for blood sample and interference minimizing during video recording and continuous NIRS, ECG, EMG and oxygen saturation measurement. Skin-to-skin contact will be continued for approximately thirty minutes after completion of blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
16258469|NCT04967118|Experimental|Mother's heartbeats as sound and vibration|Neonates will be placed in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The platform on which the mother's heartbeat will be played will be placed under mattress of the incubator or crib. The playing of the mother's recorded heartbeats will be started thirty minutes prior the heel lance and will be continued during and thirty minutes after the blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
16258470|NCT04967118|Active Comparator|30% oral glucose|Neonates will be placed on in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The neonates will be given a 30% oral glucose solution two minutes prior the heel lance
16258473|NCT04967092|Placebo Comparator|Placebo|Placebo granules will be taken twice daily for 12 weeks
16258474|NCT04967079|Experimental|Anlotinib + Trametinib|Anlotinib given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus trametinib 2 milligrams (mg) given orally, once daily.
16258475|NCT04967066||children with febrile convulsions|"Inclusion criteria
~Age from 6 months to 6 years.
~Seizures.
~Fever (≥38°C).
~Exclusion criteria
~Central nervous system infection.
~Epilepsy.
~Previous neurological abnormalities.
~Inborn errors of metabolism.
~Immunological diseases.
~Endocrinal diseases (e.g., diabetes mellitus).
~Obesity.
~Eating disorders.
~Gastrointestinal disorders (e.g., diarrhea)."
16258476|NCT04967066||Febrile children without convulsions|"Inclusion criteria
~Age from 6 months to 6 years.
~Fever (≥38°C) due to acute infection.
~Exclusion criteria
~Seizures.
~Central nervous system infection.
~Previous neurological abnormalities.
~Inborn errors of metabolism.
~Immunological diseases.
~Endocrinal diseases (e.g., diabetes mellitus).
~Obesity.
~Eating disorders.
~Gastrointestinal disorders (e.g., diarrhea)."
16258477|NCT04967066||Healthy control children|"Inclusion criteria
~Age from 6 months to 6 years.
~Presented for routine check-up.
~Exclusion criteria
~Fever.
~Seizures.
~Central nervous system infection.
~Previous neurological abnormalities.
~Inborn errors of metabolism.
~Immunological diseases.
~Endocrinal diseases (e.g., diabetes mellitus).
~Obesity.
~Eating disorders.
~Gastrointestinal disorders (e.g., diarrhea).
~Any illness in the last month."
16258478|NCT04967040|Active Comparator|group 1 : medial plantar artery flap|
16258479|NCT04967040|Active Comparator|group 2 : distally based sural artery flap|
16258480|NCT04967027|Experimental|TTFields group|patients with brain metastases who have been resistant to drug or radiation therapy, to be treated by continuous TTFields treatment using the ASCLU-300 TTF device.
16258481|NCT04967014|Experimental|Sequence A|Period I : RLD2104 Period II : HIP2104
16258482|NCT04967014|Experimental|Sequence B|Period I : HIP2104 Period II : RLD2104
16258483|NCT04967001|Experimental|PSMAPET-MRI|
16258484|NCT04967001|Experimental|MRI-PSMAPET|
16258485|NCT04966988||CAV 0(Not significant)|No detectable angiographic lesion
16258486|NCT04966988||CAV 1 (Mild)|Angiographic left main (LM) <50%, or primary vessel with maximum lesion of <70%, or any branch stenosis <70% (including diffuse narrowing) without allograft dysfunction
16258487|NCT04966988||CAV 2 (Moderate)|Angiographic LM <50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches
16258488|NCT04966988||CAV 3 (Severe)|Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology
16258489|NCT04966975||Histologically confirmed bladder cancer treated with NAC|
16258490|NCT04966962||Bladder cancer|Patients who diagnosis with incident or recurrent bladder cancer
16258491|NCT04966962||benign disease of urinary system|Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.
16258492|NCT04966949|Experimental|lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
16258493|NCT04966949|Active Comparator|nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
16258494|NCT04966936||Unilateral traumatic transfemoral amputee patients using C-Leg prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
16258495|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
16258496|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium-X3 prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
16258497|NCT04966923||Breast Cancer and documented pathogenic variant TP53|Documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and breast cancer diagnosis by histological confirmation. All patients met Revised Chompret criteria or Li Fraumeni like syndrome or family member of carrier TP53
16258498|NCT04966923||Breast Cancer and no documented pathogenic variants in genetic test|Control with patients breast cancer and no pathogenic variants documented in a genetic test
16258499|NCT04966910|Experimental|Stay Connected|Menu-driven set of strategies to combat loneliness, anxiety and depression in older adults
16258500|NCT04966910|Active Comparator|Treatment as usual|Treatment as usual in these practice settings typically includes regular check-in calls and offering resources and referrals
16258501|NCT04966897|Experimental|GBNS + PERT placebo|GBNS + PERT placebo (drink volume sufficient to supply 0.5 g of MAG per kg of body weight plus PERT placebo capsules according to patient body weight.
16258502|NCT04966897|Active Comparator|Standard Nutritional Supplement + PERT|Standard nutritional supplement + PERT (drink volume sufficient to supply 0.5 g of TAG per kg of body weight plus PERT capsules according to body weight).
16258503|NCT04966884|Experimental|A single-arm open-label pilot observational study|Patients were received a glucocorticoids (0.8mg-1mg/kg/day) and a combination with tofacitinib (at a dose of 5 mg twice daily).
16258504|NCT04966871|Experimental|Group A (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 3 doses of 9 x 10^5 PfSPZ Vaccine on days 1, 8, 29.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 14 by DVI injection."
16258505|NCT04966871|Experimental|Group B (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 9 x 10^5 PfSPZ Vaccine on days 1, 8, 29.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 42 by DVI injection."
16258506|NCT04966871|Experimental|Group C (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 9 x 10^5 PfSPZ Vaccine on days 1, 8, 29.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 70 by DVI injection."
16258507|NCT04966871|Placebo Comparator|Group A controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 14 by DVI injection."
16258508|NCT04966871|Placebo Comparator|Group B controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 42 by DVI injection."
16258509|NCT04966871|Placebo Comparator|Group C controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 70 by DVI injection."
16258510|NCT04966858|Experimental|Individualized Caloric Refeeding (ICR)|Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal
16258511|NCT04966858|Active Comparator|Higher Calorie Refeeding (HCR)|Starting 2000 kcal/d, increasing by 200 kcal/d to goal
16258512|NCT04966845||Smokers|Exclusive smokers of convnetional cigarettes
16258513|NCT04966845||HNBC|Exclusive smokers of Heat-Not-Burn Cigarettes (HNBC)
16258514|NCT04966845||Nonsmokers|Subjects that abstain from smoking for at least one year
16258515|NCT04966832|Experimental|XW10508|XW10508 capsules or tablets
16258516|NCT04966832|Placebo Comparator|Placebo|Placebo capsules or tablets
16258517|NCT04966819|Experimental|Survivorship Care|"Survivorship care will consist of:
~Regular meetings with the rectal cancer oncology pivot nurse
~Identification of a primary care physician
~Development of an individualized survivorship plan
~Educational resources for patients"
16258518|NCT04966819|No Intervention|Standard Care|The control arm will consist of patients treated at the same institution who are receiving standard of care. Standard of care consists of meeting with colorectal oncology pivot nurse as needed (i.e. by referral from specialist based on patient needs).
16258519|NCT04966806|Other|Percentage of Coma and SA to Total ocular HOA|
16258520|NCT04966793||Bronchiectasis patients group|Bronchiectasis patients group: Sputum specimens from bronchiectasis patients aged 18 to 79 years old .
16258521|NCT04966793||Healthy control group|Healthy control group: Sputum specimens from healthy people.
16258522|NCT04966741|Experimental|Setmelanotide|"Investigational product: Setmelanotide,10 mg/mL in a sterile solution for Subcutaneous (SC) injection
~The dose of setmelanotide used in this study will be based on the weight bands for the 2- to <6-year-old patients.
~The highest dose in this study for patients who weigh <20 kg will be 0.5 mg per day The highest dose in this study for patients who weigh 20 to <30 kg will be 1.0 mg per day* The highest dose in this study for patients who weigh 30 to <40 kg will be 1.5 mg per day The highest dose in this study for patients who weigh ≥40 kg will be 2.0 mg per day
~*This dose is limited by the amount of benzyl alcohol to be delivered to pediatric patients."
16258523|NCT04966728||suspected tear of the anterior superior labrum of the hip|One group consisted of patients with suspected tear of the anterior superior labrum of the hip.
16258524|NCT04966728||non-hip joint diseases|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
16258525|NCT04966715|Experimental|Patients planned for complete cytoreductive surgery|Only one arm in the study. All patients operated for complete cytoreductive surgery and who signed informed consent form
16258526|NCT04966702|Active Comparator|Albendazole|"The albendazole group will receive a single dose of 400 mg, given once a month for three months.
~Generic products will be used in both countries. Bendex in Mozambique and Alben in Tanzania"
16258527|NCT04966702|Experimental|Ivermectin human|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol
16258528|NCT04966702|Experimental|Ivermectin human and livestock|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol. For livestock, locally registered veterinary injectable ivermectin at 1% will be used
16258529|NCT04966689|Experimental|combined speech and music therapy|the telerehabilitation intervention that include both speech therapy and music therapy at the same time
16258530|NCT04966689|Active Comparator|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
16258531|NCT04966689|Active Comparator|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
16258532|NCT04966676|Experimental|Non-Small cell Lung Cancer|"Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks
~Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing.
~If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given."
16258533|NCT04966663|Experimental|Adjuvant chemo-immunotherapy therapy|"All participants will have blood taken for ctDNA testing.
~A cycle is 21 days. Pemetrexed (for participants with non-squamous non-small cell lung cancer), intravenously (by vein) on Day 1 of Cycles 1-4, OR gemcitabine (for all other participants) on Days 1 and 8 of Cycles 1-4.
~Cisplatin*, intravenously (by vein) on Day 1 of Cycles 1-4 Nivolumab, intravenously (by vein) on Day 1 of Cycles 1-4
~*If cisplatin is not tolerated, carboplatin may be given instead"
16258534|NCT04966663|Other|Observation|"All participants will have blood taken for ctDNA testing.
~Participants will be followed as per standard of care every 3 months."
16258535|NCT04966650|Experimental|Intervention group|For the intervention group, participants will receive a 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT). The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms. At the 2nd month, participants will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given a booster intervention. At 6th months, subjects will be assessed their depression symptoms and the level of physical activity changes via questionnaire.
16258536|NCT04966650|No Intervention|Control Group|A wellbeing leaflet from CHP will be provided to each participant. At the 2nd month, subjects will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given another wellbeing leaflets. At 6th months, subjects will be assessed their depression symptoms the level of physical activity changes via questionnaire.
16258537|NCT04966637||Individuals with COPD|"This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019.
~This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort"
16258538|NCT04966624|Experimental|interventional|
16258539|NCT04966624|Active Comparator|control|
16258540|NCT04966585|Experimental|Posaconazole|Subjects administered posaconazole (Noxifil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
16258541|NCT04966585|Placebo Comparator|Placebo|Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
16258542|NCT04966572|Experimental|Presurgical vacuum formed nasoalveolar molding aligners group|In this group, all patients will receive 1-2 VF-NAM aligners incorporated with palatal screw in addition to taping from day 1 for 4-6 Months with follow-up every 3 weeks
16258543|NCT04966572|Experimental|conventional Grayson acrylic formed nasoalveolar molding appliances group|This group will receive conventional Grayson acrylic formed nasoalveolar molding appliances without taping except some cases, with follow up every week for activation.
16258544|NCT04966559|Placebo Comparator|Placebo treatment|"Film-coated matched placebo-tablets consisting of:
~Core:
~Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP
~Coating:
~Opadry Yellow Purified Water, USP/EP"
16258545|NCT04966559|Active Comparator|Naldemedine treatment|"Film-coated matched active-tablets consisting of:
~Core:
~Naldemedine Tosylate (0,2 mg) Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP
~Coating:
~Opadry Yellow Purified Water, USP/EP"
16258546|NCT04966546|Experimental|Memantine|Subjects will be given memantine 10mg PO/ NG BID for 7 days
16258547|NCT04966546|Placebo Comparator|Placebo|Subjects will be given identical placebo syrup PO/NG BID for 7 days
16258548|NCT04966520|Experimental|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham|"Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months.
~Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered)."
16258549|NCT04966507|Active Comparator|Listerine Cool Mint Antiseptic Mouthwash|Daily use of an antibacterial mouthwash (Listerine Cool Mint Antiseptic Mouthwash) during the 12-week follow-up period.
16258550|NCT04966507|Placebo Comparator|Biotene Oral Rinse|Daily use of a placebo mouthwash with no known antibacterial qualities (Biotene Oral Rinse) during the 12-week follow-up period.
16258551|NCT04966494|Experimental|BOSB Group|This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.
16258552|NCT04966494|No Intervention|Control Group|This group corresponded to hypertriglyceridemic women who does not consume BOSB
16258553|NCT04966481|Experimental|Arm 1: Palbociclib + Cetuximab|"Palbociclib by mouth 125 mg/daily on Days 1-21 of each 28 day cycle
~Cetuximab: Initial dose 400mg/m^2 intravenous (IV); Subsequent doses 250 mg/m^2 IV, weekly"
16258554|NCT04966481|Active Comparator|Arm 2: Cetuximab|-Cetuximab: Initial dose 400mg/m^2 intravenous (IV); Subsequent doses 250 mg/m^2 IV, weekly
16258555|NCT04966468|Experimental|VR Group|Patients will be given the VR headset with non-interactive and interactive contents at home for four days
16258556|NCT04966468|Active Comparator|CTR group|Patients will be given a tablet at home for four days with relaxing non-interactive 2D videos with natural and artistic scenarios
16258557|NCT04966455|No Intervention|Control group|No intervention
16258558|NCT04966455|Experimental|Experimental group|Supplementation of 50 g daily of rainsins for 3 months
16258559|NCT04966442|Experimental|GrandAides|Patients randomized to this arm of the trial received access to a specially trained GrandAide to work as a credible messenger community health worker. This GrandAide received 6 weeks of education around congestive heart failure to support the patient in the outpatient setting.
16258560|NCT04966442|No Intervention|Standard of Care|This arm served as the control and included standard of care outpatient support for patients with heart failure.This support was done telephonically.
16258561|NCT04966429|Active Comparator|Maraviroc 150 mg per day|
16258562|NCT04966429|Active Comparator|Maraviroc 600 mg per day|
16258563|NCT04966429|Placebo Comparator|Placebo|
16258564|NCT04966416|Experimental|Pyrophosphate|
16258565|NCT04966416|Placebo Comparator|Placebo|
16258566|NCT04966403|Experimental|standard physical therapy|Participants in the standard physical therapy received the standard physical therapy (sPT) program, which was conducted according to the needs of each participant and was generally concerned with building strength, enhancing developmental skills, boosting balance, coordination, and postural control, improving physical fitness, and minimizing the development of the compensatory movement patterns that children with DS are likely to develop.
16258567|NCT04966403|Experimental|trampoline-based stretch-shortening cycle exercises|In addition to the sPT, the SSC group received 15-minute SSC exercise sessions, twice weekly, with a total of 24 sessions over 12 successive weeks.
16258596|NCT04966208|Active Comparator|root coverage surgeries using autologous connective tissue for treatment of gingival recession|root coverage surgeries using tunneling technique of autologous connective tissue as a treatment of Miller class two gingival recession
16258597|NCT04966208|Experimental|root coverage surgeries using xenogenic collagen matrix for treatment of gingival recession|root coverage surgeries using tunneling technique of mucodrm membrane ; xenogeneic collagen matrix as a treatment of Miller class two gingival recession
16258598|NCT04966195|Other|radiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
16258827|NCT04964531||Adults|group of adults includes all patients aging 19 years or more
16258568|NCT04966377|Experimental|Intervention Group|Intervention Group First, pre-tests were applied to the women in the experimental group. A 4-week training program created by taking into account the cultural characteristics of Syrian women; Explaining breast health, Explaining breast structure, Cancer, Breast cancer, Early diagnosis and its importance, BSE application, CBE and mammography, Barriers on breast cancer, Cancer Early Diagnosis, Screening and Education Center. A 'Nurse-directed screening counseling telephone support line' will be established for the women in the experimental group. Then, motivational interviews will be applied to the women in the experimental group by the researcher, who emphasizes the importance of early diagnosis in line with the health belief model. Reminders will be made by phone every week in the 3rd month. The final tests will be held 4 months after the end of the training.
16258569|NCT04966377|No Intervention|Control Group|Pre-tests will be applied to the women in the control group. No intervention will be applied to the women in this group and post-tests will be performed 4 months after the pre-test.
16258570|NCT04966364|Active Comparator|patients with hypotension prediction index guided|Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
16258571|NCT04966364|Other|patients without hypotension prediction index gudied|Patients will receive usual care during the operation without hypotension prediction index alerted.
16258572|NCT04966351|Experimental|Circadian misalignment (Condition A)|Participants will eat meals during the biological nighttime while remaining awake to mimic overnight work shifts.
16258573|NCT04966351|Experimental|Circadian misalignment with time-restricted feeding (Condition B)|Participants will fast during the biological nighttime while remaining awake to mimic overnight work shifts.
16258574|NCT04966338|Experimental|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
16258575|NCT04966338|Active Comparator|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
16258576|NCT04966325|Experimental|Treatment T (Therapeutic dose)|Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.
16258577|NCT04966325|Experimental|Treatment ST (Supratherapeutic dose)|Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).
16258578|NCT04966325|Placebo Comparator|Treatment P (Placebo)|Single oral dose of 3 × placebo tablets.
16258579|NCT04966325|Active Comparator|Treatment M (positive control)|Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)
16258580|NCT04966312|Other|study group|mothers receiving routine education plus digital video disk before surgery
16258581|NCT04966312|Other|control group|mothers receiving routine education
16258582|NCT04966299|Active Comparator|Sucrose|15 participants receive 25g sucrose per day during 5 weeks
16258583|NCT04966299|Experimental|Erythritol|15 participants receive 36g eryhtritol per day during 5 weeks
16258584|NCT04966286|Placebo Comparator|conventional education service program|received only standard enterostomy care brochure
16258585|NCT04966286|Experimental|multimedia education service program|received multimedia education service program introduction
16258586|NCT04966273|Experimental|Biosensors Microcatheter (BM)|Use of Biosensors Microcatheter
16258587|NCT04966260|Experimental|Standardized Virtual Reality|Participants in the standard virtual reality (VR) group will choose from the general library of VR experiences. Participants will be asked to select an experience they desire but have never experienced in person. The session will be facilitated by the therapeutic recreation staff on the unit.
16258588|NCT04966260|Experimental|Personalized Virtual Reality|There are two types of personalized VR: 1) Family/friends provide personalized content (e.g., life stories, photos, videos) that will be used during the VR session. Family/friends of participants in the personalized VR group will have the opportunity to upload custom photos, videos, life stories or capture their own 360° footage of family events using a GoPro camera that will be loaned to them for the study. This content will be uploaded to a cloud-based portal. 2) If the family/friends of those in the personalized VR arm are unavailable/unable/unwilling to provide personalized content the participant will select a video from the VR library of an experience that is personally memorable to them, such as their childhood hometown, a favourite vacation destination. The session will be facilitated by the therapeutic recreation staff on the unit.
16258589|NCT04966260|Active Comparator|Two-Dimensional Video|Participants in the active comparator group will choose a two-dimensional video such as a mountain view, ocean view or safari. Participants will view the two-dimensional video on an iPad and the session will be facilitated by the therapeutic recreation staff on the unit.
16258590|NCT04966247||Patients with Aortic Arch Pathology|Patients undergoing aortic arch surgery for aortic arch pathologies, such as aortic aneurysm and aortic dissection.
16258591|NCT04966234|Experimental|Posaconazole arm|"90 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will receive posaconazole for 12 weeks. Patients in the posaconazole arm will be stratified for body weight and positive sputum cultures for Aspergillus species.
~Patients will be followed-up for a total of 12 months post-randomization."
16258592|NCT04966234|No Intervention|Control arm|"45 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will not receive the active treatment.
~Patients will be followed-up for a total of 12 months post-randomization. If participants in the control arm are deteriorating during the first 3 months after randomization, it is up to the treating physician to consider treatment for the initial asymptomatic Aspergillus infection"
16258593|NCT04966221||Adult healthy volunteers|Adult healthy volunteers, age matched to patient volunteers. Will undergo a combination of functional and structural lung MRI scans.
16258594|NCT04966221||Adults with Chronic Obstructive Pulmonary Disease|Will undergo a combination of functional and structural lung MRI scans. Some participants in this cohort will have lung volume reduction (LVR) as part of their normal clinical care. These participants will be given the option to attend two study visits - one before and one after LVR.
16258595|NCT04966221||Adults with alpha-1-antitrypsin deficiency|Will undergo a combination of functional and structural lung MRI scans.
16258599|NCT04966169|Experimental|Sonendo GentleWave|Every participant will receive the same experimental treatment, which is root canal therapy using the Sonendo GentleWave System.
16258600|NCT04966156|No Intervention|Usual care group|No change to patient's usual care at Princess Margaret Cancer Centre.
16258601|NCT04966156|Experimental|CaRE-4-allBMT plus usual care|a longitudinal 6-month rehabilitation program that uses a person- centred strategy and a multidimensional approach targeting physical activity, nutrition, psychosocial distress and promoting self-management skills.
16258602|NCT04966143|Experimental|Treatment group|
16258603|NCT04966117|Experimental|Risk-Guided DMP|The intervention is a 12 month disease management program after hospital discharge for coronary artery disease that is overseen by a cardiac nurse.
16258604|NCT04966117|Active Comparator|Usual Care|Usual care patients will receive standard cardiology care.
16258605|NCT04966104|Experimental|ODYSSEE-vCHAT|ODYSSEE-vCHAT consists of (a) automated digital counselling resources (information pages, videos, and interactive digital tools and trackers), (b) moderated chatrooms, and (c) weekly 30-minute presentations led by a healthcare professional and/or a patient representative, followed by a 30-minute question-and-answer period. Each aspect of ODYSSEE-vCHAT is informed by a rotating schedule of seven weekly themes on chronic heart failure (CHF) self-care behaviours. Our server contacts participants by email on a weekly basis, inviting them to access the resources available to them. Participants login to our server using their password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) are recorded. Assessments occur online at baseline, months 2, 4, 6, 10, and 12, and end of trial (median = 14 months, range = 6 to 22 months).
16258606|NCT04966104|No Intervention|Enhanced usual care (eUC)|eUC provides educational chronic heart failure self-care resources and COVID-19 prevention guidelines that are available to the public on professional websites (e.g., Heart Failure Society of Canada, American Heart Association, European Society of Cardiology, Health Canada). Patients will have unlimited access to these resources. Subjects are invited by weekly emails to participate in these resources. Self-reported assessments are administered at baseline, at months 2, 4, 6, 10, and 12, and at trial completion (median = 14 months, range = 6 to 22 months).
16258607|NCT04966078|Active Comparator|liposuction|group A will be treated with liposuction
16258608|NCT04966078|Active Comparator|periareolar surgical excision|Group B will be treated with periareolar surgical excision
16258609|NCT04966052||COPD combined with TB group|COPD combined with pulmonary TB infection
16258610|NCT04966052||COPD non-TB control group|COPD combined without pulmonary TB infection
16258611|NCT04966052||TB non-COPD control group|pulmonary TB infection without COPD
16258612|NCT04966052||Non-smoking non-TB control group|Non-smoking without pulmonary TB infection
16258613|NCT04966039||monochorionic twin pregnancies with demise of one fetus|Twin pregnancy was diagnosed and one fetus died in utero, 20 pregnant women
16258614|NCT04966039||Twin control group|Twin pregnancy with one abnormal fetus, 20 pregnant women
16258615|NCT04966039||Singleton control group|Singleton pregnancy with abnormalities outside the fetal brain, 20 pregnant women
16258616|NCT04966026||COPD combined with CAP inpatients|(1) CAP meets the diagnostic criteria published in our 2016 CAP diagnosis and treatment guidelines; CPOPD and AECOPD meet the diagnostic criteria published in our 2013 COPD diagnosis and treatment guidelines; (2) age ≧ 18 years. Exclusion criteria: (1) age <18 years; (2) pregnancy; (3) positive human immunodeficiency virus (HIV) antibody; (4) suspected or confirmed tuberculosis or fungal infection of the lung.
16258620|NCT04966000|Experimental|Prism Adaptation Therapy|10 sessions (60 trials each) 1x/day of Prism Adaptation Therapy
16258621|NCT04965987|Active Comparator|Oxaloacetate|"Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase.
~Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to."
16258622|NCT04965987|Placebo Comparator|Placebo|Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to.
16258623|NCT04965974|Experimental|1 blue light blocking filter group|digital blue light blocking filter is installed laptops and mobile phones of 80 individual using digital devices more than 4 hours. asked them to use the filter continuously while using digital devices.
16258624|NCT04965974|Experimental|2 non filter users|Effect of time duration of digital screen on the dry eyes is checked.
16258625|NCT04965961|Experimental|Recombinant human erythropoietin treatment|Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.
16258626|NCT04965961|Placebo Comparator|Control group|Participants receive intravenous injections of ~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.
16258627|NCT04965948|Experimental|Active group|Snack enriched with camelina sativa oil
16258628|NCT04965948|Placebo Comparator|Placebo group|Snack no enriched with camelina sativa oil
16258629|NCT04965935|Experimental|Dapagliflozin Tablets|Patients will be randomized to therapy with dapagliflozin 10mg PO daily for 12 weeks.
16258630|NCT04965935|Placebo Comparator|Placebo Matching Dapagliflozin Tablets|Patients will be randomized to therapy with placebo matching dapagliflozin tablets PO daily for 12 weeks.
16258631|NCT04965922|Experimental|Multimodal intervention at inclusion|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
16258632|NCT04965922|Other|Multimodal intervention at 6 month|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
16258696|NCT04965389|Experimental|Sequence 2|
16258635|NCT04965896|Placebo Comparator|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
16258636|NCT04965896|Experimental|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
16258637|NCT04965883|Experimental|Early Excision and Grafting|"The early excision will be done surgically within 4-10 days post burn by whatson knife by tangential excision of burned tissue until capillary bleeding appears to make a good bed to be covered with grafts split thickness grafts STG at the same time.
~The first dressing will be in the fifth day post operative."
16258638|NCT04965883|Experimental|Dressing and Delayed Grafting|• Dressing will be done for the second group every other day until spontanous eschar seperation or after surgiacl debridrment of adherent eschar then for delayed grafting more than 10 days post burn.
16258639|NCT04965857||Slides from the German Co-Screening program|From 25,000 LBC slides (ThisPrep, Hologic Inc., USA) from the German Co-screening program evaluated using the Genius Digital cytology system all abnormal findings according to Munich III groups (II-p - V) and each 10th normal slide (Munich III group I and II) will be selected for the prospective evaluation by manual microscopy.
16258642|NCT04965831|Experimental|Furmonertinib|Furmonertinib as perioperation therapy
16258643|NCT04965818|Experimental|Futibitanib in combination with binimetinib|"Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease.
~Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC"
16258644|NCT04965805|Experimental|Cold plasma jet|The treatment scheme of the cold plasma jet will be applied in the following manner, quantity and frequency: Cold plasma is always applicated for 30 seconds/ cm^2 wound size. Wounds will be treated three times in the first week, twice in the second week and once per week in the following observation period. In case of locally infected ulcers, treatment will be performed 1x per day during the first week and afterwards in the same manner as in non-infected ulcers. After application of cold plasma, the wound will be covered with Adaptic perforated gauze and a non-active dressing.
16258645|NCT04965805|Active Comparator|Best Practice wound dressings|Immediately after dressing removal, the wound will be cleaned with a physiological saline solution soaked swab. In case of locally infected wounds, an antiseptic will be used instead of the physiological saline solution. Subsequently, a wound phase-adapted primary dressing will be applied according to the experience of the practitioner and, if necessary, the wound will be covered with a secondary dressing according to the experience of the practitioner as well. In case of locally infected wounds, silver dressings can be applied. The dressing will be changed at least every 2nd day and on weekends every 3rd day; in case of locally infected wounds, dressings will be changed daily. Dressing changes beyond visits can also be performed by the general practitioner, a nursing service, or by the participant him- or herself.
16258646|NCT04965792||HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients|Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.
16258647|NCT04965779|Experimental|Intervention group (Abdominal binder)|The abdominal binder is applied after the women come to the clinic (postpartum 1st hour) following cesarean delivery and removed after the postpartum 48th hour. Postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided together with the application of the abdominal binder.
16258648|NCT04965779|Active Comparator|Control group (No abdominal binder)|Only postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided with no abdominal binder or similar application.
16258649|NCT04965766|Experimental|U3-1402|All participants included in the study will receive a starting dose of 5.6 mg/kg of U3-1402 every 3 weeks until progression or until unacceptable toxicity
16258650|NCT04965753|Experimental|FHD-609|Up to approximately 70 patients will be enrolled in dose escalation and expansion.
16258651|NCT04965740||North American First Responders|Spread directly to union representatives for email and messaging to those interested in taking the survey
16258652|NCT04965740||Oceana and European first responders|First responder unions and groups that are located outside of North America - particularly Australia, New Zealand, United Kingdom, other commonwealth nations.
16258654|NCT04965714|Experimental|Treatment (nivolumab, pegargiminase)|Patients receive nivolumab IV over 30 minutes on day 1 and pegargiminase IM at 2 days before day 1 of cycle 1, day 8 of cycle 1, days 1 and 8 of cycle 2, and day 1 of cycle 3. Treatments repeat every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection at week 7. A cycle is 14 days.
16258655|NCT04965701||Untreated EGFR-mutant advanced non-small-cell lung cancer patients|
16258659|NCT04965662|Experimental|Arm A: Home PEPSE (Immediate)|Patients randomised to the immediate arm (ARM A) will receive a 5 day PEPSE 'Home pack' containing Truvada® (tenofovir disoproxil -as fumarate- 245 mg, emtricitabine 200 mg), ONE tablet OD and Maraviroc 300 mg, TWO tablets OD.
16258660|NCT04965662|No Intervention|Arm B: Standard of Care (Deferred)|Standard of care antiretroviral therapy for PEPSE as per the British Association for Sexual Health and HIV (BASHH) guidelines.
16258661|NCT04965649||Chronic Myeloid Leukemia|There will be approximately 10 patients with Chronic Myeloid Leukemia in this group
16258662|NCT04965649||Philadelphia+ Acute Lymphoblastic Leukemia|There will be approximately 20 patients with Philadelphia chromosome-positive Acute lymphocytic leukemia in this group
16258663|NCT04965636|Experimental|Participants receiving mepolizumab|
16258664|NCT04965610|Experimental|Preoxygenation via THRIVE/High Flow Nasal Cannula|Patients receive preoxygenation for induction of general anaesthesia via High Flow Nasal Cannula for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
16258665|NCT04965610|Active Comparator|Preoxygenation via face mask (PROX)|Patients receive preoxygenation for induction of general anaesthesia via tight fitting face mask for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
16258666|NCT04965597|Experimental|treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate|Patients will be treated with a preparative regimen of treosulfan (total dose 30-42 g/m2), fludarabine (total dose 150 mg/m2), and Thymoglobulin (total dose 6 mg/kg). GVHD prophylaxis will be with tacrolimus and methotrexate.
16258667|NCT04965584||Active Crohn's disease group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited, and patients with CDAI score ≥ 150 were included in this group.
16258668|NCT04965584||Crohn's disease remission group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological features and histological features were recruited, and patients with CDAI score < 150 were included in this group.
16258669|NCT04965584||Healthy control group|Normal healthy people were randomly recruited as the control group
16258670|NCT04965571||WD-seizures|Chinese WD patients with generalized epilepsy
16258671|NCT04965545||Wilson's disease cohort|Patients were clinically diagnosed according to the Leipzig Score and included in the study when they were confirmed to carry ATP7B pathogenic variants in 2 different alleles.
16258672|NCT04965532|Experimental|chemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
16258673|NCT04965532|Active Comparator|chemotherapy patients using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
16258674|NCT04965532|Active Comparator|nonchemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
16258675|NCT04965532|Active Comparator|nonchemotherapy patient using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
16258676|NCT04965519|Experimental|RC48-ADC|Eligible subjects received RC48-ADC treatment after enrollment, at a dose of 2.0 mg/kg, once every 2 weeks (the dosing time window in all cycles is -1 to 2 days), and the administration method is intravenous Drip.
16258677|NCT04965506|Experimental|IBI362 low dose|Participants receive low dose IBI362 by subcutaneous (SC) injection once a week.
16258678|NCT04965506|Experimental|IBI362 moderate dose|Participants receive medium dose IBI362 by subcutaneous (SC) injection once a week.
16258679|NCT04965506|Active Comparator|Dulaglutide|Participants receive Dulaglutide 1.5mg by subcutaneous (SC) injection once a week.
16258680|NCT04965506|Experimental|IBI362 high dose|Participants receive high dose IBI362 by subcutaneous (SC) injection once a week.
16258681|NCT04965506|Placebo Comparator|placebo|Participants receive placebo by subcutaneous (SC) injection once a week.
16258682|NCT04965493|Experimental|Arm A (PVR)|Fixed duration pirtobrutinib in combination with venetoclax and rituximab
16258683|NCT04965493|Active Comparator|Arm B (VR)|Venetoclax with rituximab
16258684|NCT04965467||Screening population|Screening for Fabry disease with early symptoms
16258685|NCT04965454|Experimental|Tested with Biomarkers|For this single arm study, all enrolled subjects will undergo diagnostic testing with FCH PET/CT and genomic liquid biopsy before treatment involving an immune checkpoint inhibitor agent. A fluorine-18 fluorodeoxyglucose (FDG) PET/CT may also be performed before treatment and after 8 weeks if the pre-treatment FCH PET/CT shows low or heterogeneous tumor uptake.
16258686|NCT04965441||Computer-assisted surgery (CAS) group|
16258687|NCT04965441||Non-CAS group|
16258688|NCT04965428|Experimental|Fear-focused Self-Compassion Therapy|Experimental group receives group face-to-face Fear-focused Self-Compassion Therapy for eight weeks.
16258689|NCT04965428|No Intervention|Usual care|The no intervention group receives usual care supported by hospital or coming from elsewhere for eight weeks.
16258690|NCT04965415|Active Comparator|Lagged|Businesses in the lagged arm participated in Health Links for one year from their baseline assessment to their first follow-up assessment one year later. They were eligible to participate in the Leadership Training after both assessments were completed.
16258691|NCT04965415|Experimental|Early|Businesses in this arm participated in Health Links + Leadership Training for one year from their baseline assessment to their first follow-up assessment one year later.
16258692|NCT04965402|Experimental|Panel 1: Dose 1|
16258693|NCT04965402|Experimental|Panel 2: Dose 2|
16258694|NCT04965402|Placebo Comparator|Placebo|
16258695|NCT04965389|Experimental|Sequence 1|
16258699|NCT04965376|Active Comparator|Glenohumeral joint injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
16258700|NCT04965376|Active Comparator|Suprascapular nerve block|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
16258701|NCT04965350|Experimental|2vHPV Consistency Lot 1|
16258702|NCT04965350|Experimental|2vHPV Consistency Lot 2|
16258703|NCT04965350|Experimental|2vHPV Consistency Lot 3|
16258704|NCT04965350|Active Comparator|2vHPV Pilot Scale Lot|
16258709|NCT04965324||Anaesthesia Depth BIS 35|BIS 35
16258710|NCT04965324||Anaesthesia Depth BIS 50|BIS 50
16258711|NCT04965311|Experimental|Treatment of POPF (botulinum toxin type A)|Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter of Oddi segment between 7-14 days prior to planned distal pancreas resection.
16258712|NCT04965298|Experimental|Active treatment arm|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
16258713|NCT04965298|Placebo Comparator|Matched-Placebo arm|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
16258718|NCT04965246|Experimental|Physical activity|the physical activity intervention will be structured to increase light-intensity aerobic physical activity, to achieve a total of 150 minutes per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity
16258719|NCT04965246|Other|Usual care|Participants randomized to the usual care control group will serve as the control group for 15 weeks, and receive no intervention during this time.
16258720|NCT04965233||Participants recruited in Denmark|Participants recruited in Denmark will consist of 63 healthy individuals and 187 individuals with atopic dermatitis
16258721|NCT04965233||Participant recruited in the United States of America|Participants recruited in the US will consist of 125 healthy individuals, 3000 individuals with atopic dermatitis
16258722|NCT04965220|Experimental|ATC|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
16258723|NCT04965220|Experimental|Primary brain tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
16258724|NCT04965220|Experimental|CRC(KRAS mutant)|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
16258725|NCT04965220|Experimental|other solid tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
16258726|NCT04965194|Experimental|Erector spinae plane block (ESPB)|20 ml of 0.25% bupivacaine will be administered to perform ESP block on each side
16258727|NCT04965194|Experimental|Quadratus lumborum plane block (QLPB)|The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1.
16258728|NCT04965194|Placebo Comparator|Control group|patients received no regional block
16258729|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol, iQuit Mindfully text messages, and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
16258730|NCT04965181|Experimental|iQuit Mindfully|"Participants will receive iQuit Mindfully text messages and nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
16258828|NCT04964531||children|group of children includes all patients aging less than 19 years
16258731|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT)|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
16258732|NCT04965181|Active Comparator|Usual Care|"Participants in the usual care condition are provided with nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
16258737|NCT04965155|Experimental|Isatuximab-Dexamethasone|Isatuximab-Dexamethasone pre and post transplant in relapsed multiple myeloma patients.
16258738|NCT04965142|Experimental|Home Exercise Group|The home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
16258739|NCT04965142|No Intervention|Control Group|Participants will receive one counselling session on healthy eating and physical activity at the start of the study.
16258740|NCT04965129|Placebo Comparator|Placebo Comparator: Placebo|Placebo Comparator: Placebo All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given four tablet/day for four mounths.
16258741|NCT04965129|Experimental|Experimental: Fish oil|All subjects will be given fish oil with a dose of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
16258742|NCT04965116|Experimental|Early Initiation d-POPs|Initiation of d-POPs 120-160 hours after delivery. Dosing is 4mg daily for 24 days followed by 4 daily inactive tablets for 2 months.
16258743|NCT04965116|Experimental|Early Initiation n-POPs|Initiation of n-POPs 120-160 hours after delivery. Dosing is 0.35mg daily for 28 days for 2 months.
16258744|NCT04965116|Placebo Comparator|Interval Initiation of d-POPs|Placebo starting 120-160 hours after delivery, continuing for 28 days. Followed by 24 days of 4mg daily of d-POPs and 4 daily inactive tablets.
16258745|NCT04965103|Active Comparator|Bridging|Tendon repair with graft interposition
16258746|NCT04965103|Experimental|SCR|Superior Capsule reconstruction
16258747|NCT04965090|Experimental|Patients with parenchymal brain metastases|All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh <80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.
16258748|NCT04965090|Experimental|Patients with leptomeningeal (LM) disease with or without parenchymal brain metastases|All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh <80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.
16258749|NCT04965077|Experimental|MIL97|
16258750|NCT04965064|Experimental|Experimental: Capecitabine and Neratinib.|"Neratinib 240 mg PO QD Daily On-going
~Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going"
16258751|NCT04965051|Experimental|IDegAsp group|IDegAsp twice daily
16258752|NCT04965051|Active Comparator|basal insulin plus pre-prandial insulin group|basal insulin once or twice daily plus pre-prandial insulin
16258753|NCT04965038|Active Comparator|Thrombolysis (interventional study)|Alteplase (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
16258754|NCT04965038|Placebo Comparator|Placebo (interventional study)|Placebo (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
16258755|NCT04965038|No Intervention|Observational study|The prospective REVISION observational study will enroll patients within 12 hours of symptom onset
16258756|NCT04965025|Experimental|Multi-stage urethroplasty with graft inlay in first stage|
16258757|NCT04965025|Active Comparator|Multi-stage urethroplasty with graft inlay in second stage|
16258758|NCT04965012|Experimental|CBT with MET treatment group|Participants in this arm will be provided with an MET-therapist guided introduction, in addition to the online CBT treatment.
16258829|NCT04964518|Experimental|APG2575 + Azacitidine|200 mg APG2575 dose ramp up +AZA
16259014|NCT04963179|No Intervention|Control|No IUA prevention - no placebo after adhesiolysis
16258759|NCT04965012|Experimental|CBT without MET treatment group|Participants in this arm will be provided with a brief non-MET research assistant-led welcome to the program, in addition to the online CBT treatment.
16258760|NCT04965012|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about cannabis and wellbeing.
16258761|NCT04964999|Experimental|Exercise|Participants will perform aerobic and strength exercises for 2 weeks.
16258762|NCT04964999|No Intervention|No exercise|Participants will not perform any exercises.
16258763|NCT04964986|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
16258764|NCT04964973|Active Comparator|Control Group|1. Control group. Patients have performed the conventional postsurgical program without adding TENS.
16258765|NCT04964973|Experimental|Experimental Group|Experimental group. The application of TENS has been added to the physiotherapy program. It had a frequency of 100 Hz and a phase duration of 100 µsec for a period of 30 minutes (through channel 1 of the TENS equipment), receiving and feeling the patient the physical sensation of the current.
16258766|NCT04964973|Placebo Comparator|Placebo Group|Placebo group. In this group, the same program as group 2 was proposed, using, in this case, channel 2, which did not activate the electric current, and the patient did not receive any physical sensation
16258767|NCT04964960|Experimental|Pembrolizumab with standard of care chemotherapy treatment|Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).
16258768|NCT04964947|Experimental|Tobramycin Treatment Group|Participants in this group receive a local aqueous tobramycin injection (2mg/mL) plus standard of care treatment.
16258769|NCT04964947|Placebo Comparator|Placebo Group|Participants in this group receive a placebo injection plus standard of care treatment.
16258772|NCT04964921||Impaired Fasting Glucose Individuals|The group contains subjects with various stages of impaired fasting glucose tolerance levels and diabetes (with or without complications). All subjects will be considered in one group since the heart rate variability and vital signs are monitored in a single visit.
16258774|NCT04964882|Experimental|C-E Mask ventilation under PIP 10 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
16258775|NCT04964882|Experimental|C-E Mask ventilation under PIP 15 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
16258776|NCT04964882|Experimental|C-E Mask ventilation under PIP 20 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
16258777|NCT04964882|Experimental|V-E Mask ventilation under PIP 10 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
16258778|NCT04964882|Experimental|V-E Mask ventilation under PIP 15 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
16258779|NCT04964882|Experimental|V-E Mask ventilation under PIP 20 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
16258780|NCT04964869|Experimental|Epinephrine solution injection group|In injected group, The saline epinephrine solution (1mg in 10ml N/S) is injected to 2 sites of cutted papilla (1 o'clock and 11 o'clock) by injected needle, at least 0.5ml per injected site, and must be protruded from submucosal layer.
16258781|NCT04964869|No Intervention|non-injection group|In non injection group, the saline epinephrine solution is not given
16258782|NCT04964856|Experimental|ERAS exercise in perioperative period.|The patients take ERAS exercise from hospitalization to 30 days after operation.
16258783|NCT04964856|Sham Comparator|No ERAS exercise in perioperative period.|The patients do not take ERAS exercise in perioperative period.
16258786|NCT04964830|Active Comparator|Children with large overjet|Overjet ≥6 mm, planned orthodontic treatment with functional appliance
16258787|NCT04964830|No Intervention|Control group|Neutral occlusion, no indication for orthodontic treatment, no prior orthodontic treatment
16258788|NCT04964804|Experimental|real-time ultrasound-CT fusion imaging|The experimental group of patients underwent selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging by sonographers
16258789|NCT04964804|Active Comparator|ultrasound alone|The control group underwent puncture under the guidance of ultrasound alone by sonographers
16258790|NCT04964778|Experimental|Arm1: SKED© only first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 1 will be in the following order: SKED© only; SKED©+OSS-II©; SKED©+Vacuum mattress; SKED©+foam padding
16258791|NCT04964778|Experimental|Arm 2: SKED©+Vacuum mattress first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 2 will be in the following order: SKED©+Vacuum mattress; SKED©+OSS-II©; SKED©+foam padding, SKED© only
16258792|NCT04964778|Experimental|Arm 3: SKED©+OSS-II© first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 3 will be in the following order: SKED©+OSS-II©;SKED©+Vacuum mattress; SKED© only; SKED©+foam padding
16258793|NCT04964778|Experimental|Arm 4: SKED©+foam padding first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 4 will be in the following order: SKED©+foam padding, SKED©+Vacuum mattress; SKED© only; SKED©+OSS-II
16258794|NCT04964752|Other|the upper arm group on Day 2|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 2.
16258795|NCT04964752|Other|the upper arm group on Day 15±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 15±1 day.
16258796|NCT04964752|Other|the upper arm group on Day 29±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 29±1 day.
16258797|NCT04964752|Other|the abdomen group on Day 2|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 2.
16258798|NCT04964752|Other|the abdomen group on Day 15±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 15±1.
16258799|NCT04964752|Other|the abdomen group on Day 29±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 29±1.
16258800|NCT04964739|Other|Cognitive Behavioral Therapy - Men|112 participants identifying as men will be enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They will receive a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist. Gender and hormonal factors will be examined as predictors of CUD remission and cannabis outcomes.
16258801|NCT04964739|Other|Cognitive Behavioral Therapy - Women|112 participants identifying as women will be enrolled in 8 weeks of behavioral treatment for CUD. They will receive a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist. Gender and hormonal factors will be examined as predictors of CUD remission and cannabis outcomes.
16258802|NCT04964726|Experimental|Real-time fMRI dyadic neurofeedback|
16258803|NCT04964713||type 2 diabetes|T2DM was defined according to the WHO 2006 criteria. Assessing the left heart and right heart structure and function of T2DM by speckle tracking echocardiography.
16258804|NCT04964713||Prediabetes|According to the WHO 2006 criteria, combining impaired fasting glucose and impaired glucose tolerance as prediabetes. Assessing the left heart and right heart structure and function of prediabetes by speckle tracking echocardiography.
16258805|NCT04964713||normal glucose metabolism(NGM)|Assessing the left heart and right heart structure and function of NGM by speckle tracking echocardiography.
16258806|NCT04964687||Transplanted patients seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
16258807|NCT04964687||Transplanted patients not seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
16258808|NCT04964674|Experimental|Attentional Tests|All participants will complete a series of behavioral tasks, including cued visual search with positive, negative, and neutral cues, Miyake executive attention tasks, and a visual working memory task. Single Arm.
16258809|NCT04964661||SpA women MRI|Women affected by spondyloarthritis and performed a sacroiliac MRI
16258810|NCT04964648||Inflammatory pancreatic lesions|older than 18 years with a diagnosis of acute or chronic pancreatitis
16258811|NCT04964648||Malignant pancreatic lesions|older than 18 years with a diagnosis of pancreatic neoplasm
16258812|NCT04964648||Control group|Healthy adult subjects
16258813|NCT04964622|Other|advil|sodium ibuprofen 1 tablet (256) 30 minutes before treatment administered once (oral)
16258814|NCT04964622|Placebo Comparator|placebo|starch tablet 30 minutes before treatment administered once (oral)
16258815|NCT04964596|Active Comparator|a colonoscopy as surveillance exam|patients will undergo Colonoscopy, finding will be documented. Findings of colonoscopy will be documented and treated according to the institutional standards. Study participation for patients ends after the colonoscopy and follow-up of pathology results and complication assessment.
16258816|NCT04964596|Active Comparator|undergoing a FIT as surveillance exam|if the FIT test is positive: patients will have subsequent colonoscopy within 3 months. Findings of FIT testing and if positive the colonoscopy will be documented and participation in the study will end after that. Findings of the FIT test and colonoscopy will be treated according to the institutional standards. If FIT test is negative patient will leave the study and will have a follow up with a colonoscopy or FIT test in 1 to 2 years outside of this study.
16258817|NCT04964596|Active Comparator|undergoing CT colonography as surveillance exam|If CTC is positive: patients will have subsequent colonoscopy within 3 months. Findings will be documented and participation in the study will end there. Findings of the colonoscopy will be addressed according to our institution's guidelines. If CTC is negative for polypoid lesions patient will leave the study and will have a follow up 5 years after with either a CTC or colonoscopy.
16258818|NCT04964583|Experimental|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
16258819|NCT04964583|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days.
16258820|NCT04964583|Placebo Comparator|Placebo|Placebo one tablet every 12 hours for ten days.
16258821|NCT04964570|Experimental|Video and behavioral change module (BCM) + booster|Participants will watch the video and read the BCM twice (day 1 and day 14)
16258822|NCT04964570|Experimental|Video and behavioral change module (BCM)|Participants will watch the video and read the BCM once (day 1 only)
16258823|NCT04964570|No Intervention|Control|This arm will recieved the same length video with a content that is not related to mental health and no BCM
16258830|NCT04964505|Experimental|Treatment (uproleselan, azacitidine, venetoclax)|Patients receive uproleselan IV over 1 hour Q12H on days 1-7, azacitidine IV or SC QD on days 1-7, and venetoclax PO QD on days 1-28. Beginning cycle 5, patients achieving MLFS or better response, may receive azacitidine IV or SC QD and uproleselan IV over 1 hour QD on days 1-6 and 8 or days 1-5 and 8-9 or days 1-5. Treatment with uproleselan repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Cycles with azacitidine and venetoclax repeat every 28 days in the absence of disease progression and unacceptable toxicity.
16258831|NCT04964492||responders to treatment|A patient will be defined as a responder to hydroxocobolamin infusion if there is an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
16258832|NCT04964492||non-responders to treatment|A patient will be defined as a non-responder to hydroxocobolamin infusion if there is not an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
16258833|NCT04964479|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
16258834|NCT04964479|Active Comparator|Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules|"Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
~Placebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
16258835|NCT04964466||Amount of PDGF-BB in PRF preparation vs. GEM21|The release kinetics of PDGF-BB will be assessed for one PRF preparation from each of the six individual participants and one GEM 21S sample. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
16258836|NCT04964466||PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
16258837|NCT04964466||: Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
16258838|NCT04964466||Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
16258839|NCT04964453|Experimental|Dose group 1|
16258840|NCT04964453|Experimental|Dose group 2|
16258841|NCT04964453|Experimental|Dose group 3|
16258842|NCT04964453|Experimental|Dose group 4|
16258843|NCT04964453|Placebo Comparator|Placebo|
16258844|NCT04964440||PURE EP Guided Procedures|Redo AF procedures guided by Pure EP System during an AF Ablation
16258845|NCT04964440||Standard Recording System Guided Procedures|Redo AF procedures guided by the Standard Recording System during an AF Ablation
16258846|NCT04964427|Experimental|anodal tDCS- sham tDCS- MPH|(A) anodal tDCS at t1 (B) sham tDCS at t2 (C) MPH at t3
16258847|NCT04964427|Experimental|anodal tDCS- MPH- sham tDCS|(A) anodal tDCS at t1 (C) MPH at t2 (B) sham tDCS at t3
16258848|NCT04964427|Experimental|sham tDCS- anodal tDCS- MPH|(B) sham tDCS at t1 (A) anodal tDCS at t2 (C) MPH at t3
16258849|NCT04964427|Experimental|sham tDCS- MPH- anodal tDCS|(B) sham tDCS at t1 (C) MPH at t2 (A) anodal tDCS at t3
16258850|NCT04964427|Experimental|MPH- anodal tDCS- sham tDCS|(C) MPH at t1 (A) anodal tDCS at t2 (B) sham tDCS at t3
16258851|NCT04964427|Experimental|MPH- sham tDCS- anodal tDCS|(C) MPH at t1 (B) sham tDCS at t2 (A) anodal tDCS at t3
16258852|NCT04964414|Active Comparator|Smell Retraining Only|Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
16258853|NCT04964414|Experimental|Smell Retraining + Budesonide|Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.
16258854|NCT04964401|Active Comparator|Thoracic Paravertebral Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the thoracic 5 spinous process, the US-compatible needle will be advanced to the paravertebral area with in-plane technique, and 20 ml of 0.25% bupivacaine hydrochloride will be injected into this area.
16258855|NCT04964401|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
16258856|NCT04964388||GLP-1 cohort|Participants on GLP-1 receptor agonists
16258857|NCT04964388||Non GLP-1 cohort|Participants not on GLP-1 receptor agonists
16258858|NCT04964375|Experimental|ABSK043|"Dose escalation of oral ABSK043 with a starting dose of 25mg once daily will be guided byBOIN escalation rules based on safety data until an MTD has been identified or a RDE. For each dose,In the escalation part, sequential cohorts of patients will receive an oral dose of ABSK043 QD in repeated 28-day cycles. Starting dose level will be 200 mg QD. Then, patients will continuously receive ABSK043 once daily (QD) in repeated 28-day cycles.For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043 at the RDE in repeated 28-day cycles."
16258859|NCT04964362||Individuals with Spinal Cord Injury|Individuals with recent spinal cord injuries, both veterans and civilians, will be followed for 1 year for inquiry into injustice appraisals.
16258860|NCT04964349|Experimental|Intralesional cortisosteroid injection|Intralesional corticosteroid injection
16258861|NCT04964349|Experimental|jessener solution|topical jessener solution
16258862|NCT04964336||Multiple sclerosis|Patients with relapsing-remitting multiple sclerosis
16258864|NCT04964310||APAP_DILI|"（①/②）+③+④：
~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L ④ liver impairment is caused by acetaminophen：Russel U-Calf Causality Assessment Method(RUCAM) causality score>6"
16258865|NCT04964310||APAP_NO-DILI（NDILI）|"（①/②）not（③/④）：
~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：ALT or AST ≥ 1000 IU/L④ liver impairment is caused by acetaminophen：RUCAM causality score>6"
16258866|NCT04964297|Other|Cohort 1: Predetermined points measurement|"Cohort 1: Predetermined points measurement: 10 subjects with measurement of bowel gas at 8 predetermined time points during right laparoscopic colectomy as follow:
~Initiation of surgery/laparoscopy start Insufflation
~Abdominal exploration
~Completion of colon mobilization
~Colon transection
~At Colotomy
~At Enterotomy
~Anastomosis completion
~End of surgery- after re-insufflation before closure"
16258867|NCT04964297|Other|Cohort 2: Continuous monitoring|Cohort 2: Continuous monitoring: 10 subjects with continuous monitoring of bowel gases through the surgery. The level of H2 and CH4 gases will be noted at the 8 predetermined time points during the continuous monitoring as well.
16258868|NCT04964284|Experimental|rhTSH group|Patients received thyroid hormone suppression therapy (Euthyrox) . rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
16258869|NCT04964284|Experimental|Thyroid hormone withdrawal group|After randomization, patients with thyroid hormone withdrawal therapy(i.e. Stop taking thyroid hormone for 14 days, and then monitor the level of thyroid-stimulating hormone every week). When TSH>30mU/L, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
16258870|NCT04964271||Low risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely low risk (PSA (prostate-specific antigen) <10 ng/ml, and stage T1/T2a and Gleason score 3+3).
16258871|NCT04964271||High risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely high risk (PSA (prostate-specific antigen) >20 ng/ml or stage T3 or higher or biopsy Gleason score 8-10).
16258872|NCT04964271||Healthy donor|Participants who are in good health and without history of cancer disease.
16258873|NCT04964258|Experimental|Part 1: TAK-105|TAK-105 at starting dose of 30 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part 1 (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12) may be used. After the pre-specified first dose, subsequent doses will be determined by dose escalation committee based on emerging safety, tolerability, and PK data from the study.
16258874|NCT04964258|Experimental|Part 2: TAK-105|TAK-105 dose to be decided (TBD) or TAK-105 matching-placebo, subcutaneously, once weekly for 4 weeks. Dose of multiple rising dose (MRD) Cohorts (Cohorts 13-17) of Part 2 will be determined based on emerging safety, immunogenicity, tolerability, and PK data from Part 1 (SRD) determined by dose escalation committee.
16258875|NCT04964258|Experimental|Part 3: TAK-105|TAK-105 dose TBD or placebo-matching solution, subcutaneously, once weekly for 2-4 weeks. Dose for the first 2 Cohorts (Cohorts 18-19) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 single rising dose (SRD) and Part 2 (MRD) as determined by dose escalation committee. The data from Cohorts 18-19 will further determine additional enrollment of Cohorts 20, 21, 22 and 23. Part 3 will evaluate whether dose titration result in different tolerability in relation with CV observations.
16258876|NCT04964258|Experimental|Part 4: TAK-105|TAK-105 dose TBD or placebo-matching solution, subcutaneously, once a week for 2 weeks, followed by a period of withholding drug and then redosing with a third dose. Part 4 (Cohorts 24 to 27) will provide an exploratory evaluation to assess the safety and CV tolerability profile of redosing with TAK 105.
16258877|NCT04964245|Experimental|Respiration monitoring group|The respiration is simultaneously measured by accelerometer, thermographic camera, Impedance Tomography, and mattress sensor.
16258938|NCT04963790|Active Comparator|Other health-related messaging|Patients assigned to the control group will receive health messages unrelated to COVID-19.
16258878|NCT04964232|Experimental|Temperature monitoring group|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
16258879|NCT04964219|Experimental|S-ketamine group|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.
~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
16258880|NCT04964219|Placebo Comparator|Control group|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.
~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
16258881|NCT04964206||Neuraxial analgesia exposure|For mothers who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided according to routine practice of each study center.
16258882|NCT04964206||No neuraxial analgesia exposure|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
16258883|NCT04964193|Experimental|Elzsa film-coated tablet|Participants received Elzsa film-coated tablet (2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
16258884|NCT04964193|Active Comparator|Diane-35 Sugar-coated tablet|Participants received Diane-35 Sugar-coated tablet ( 2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
16258885|NCT04964180|Active Comparator|indomethacin group|group indomethacin (40 patients) recived two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
16258886|NCT04964180|Active Comparator|intraperitoneal lidocaine|200 ml saline containing 200 mg 2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic space, left subdiaphragmatic space and around the cholecystectomy site , all patients were maintained in trendelenberg position
16258887|NCT04964167|Placebo Comparator|Group I (Standard Root Planning)|
16258888|NCT04964167|Active Comparator|Group II (Standard Root Planning + Photodynamic Therapy)|
16258889|NCT04964167|Experimental|Group III (Standard Root Planning + Aloe Vera)|
16258890|NCT04964154|No Intervention|BRAVE Non-Intervention|Survey participants in the BRAVE non-intervention arm will not have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
16258891|NCT04964154|Active Comparator|BRAVE Intervention|Survey participants in the BRAVE intervention arm will have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
16258892|NCT04964128|Experimental|meal gesture dosing for unannounced meals within the AHCL System|
16258893|NCT04964102|Experimental|Workshop|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
16258894|NCT04964089|Experimental|KSI-301 (Treatment Group A)|Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 36.
16258895|NCT04964089|Active Comparator|Aflibercept (Treatment Group B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 36. Sham injections will be administered at each monthly visit where an active treatment is not administered.
16258896|NCT04964076||COPD patients in the plateau|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to December 2021.
16258897|NCT04964076||COPD patients in the plain|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Peking University Third Hospital from January 2018 to December 2021.
16258898|NCT04964063|Other|Sensodyne Fresh Mint Toothpaste|"Participants will be asked to follow commercial tube instructions as recommended for sensitivity relief: Apply at least a 1-inch strip of the product onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute twice a day (morning and evening), and not more than 3 times a day, or as recommended by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing, Spit out after brushing."
16258902|NCT04964037||Treatment success group|No intervention
16258903|NCT04964037||Treatment failure group|No intervention
16258904|NCT04964024||Residents in Nursing homes|
16258905|NCT04964024||Health professionals in Nursing homes|
16258906|NCT04964011|Experimental|Board game group|The Board game group was led by an occupational therapist who has been working for six years. The intervention comprised 1 week of board game instruction and 11 weeks of board game tasks (combined with daily tasks), for a total of 12 weeks, once a week for 2 hours, for a total of 24 hours of intervention.
16258907|NCT04964011|Active Comparator|Health promotion group|MCI seniors in the health promotion group received general health promotion and were led by instructors from the long-term care facility for 12 weeks, including 4 weeks of physical activities, 4 weeks of singing activities, and 4 weeks of art activities, once a week for 2 hours, for a total of 24 hours.
16258908|NCT04963998|Experimental|Copper oxide dressings|Treatment of diabetic ulcers that were in a stagnated stage with copper oxide containing wound dressings
16258909|NCT04963985|Experimental|Tafamidis group|During the treatment period, each participant will receive 20 mg tafamidis meglumine once daily for 24 weeks.
16258910|NCT04963972|Experimental|Arm I (Lucid Lane)|Patients participate in the Lucid Lane therapy program including working with a mental health therapist on mindfulness, CBT, group therapy, and mind-body therapies for 3-9 months or until the tapering off period is complete.
16258911|NCT04963972|Active Comparator|Arm II (standard of care)|Patients receive standard of care post-surgical opioid education.
16258912|NCT04963959|Other|Healthy donor|
16258913|NCT04963946|Experimental|watch and monitor|After 18 months of acalabrutinib treatment, patients will stop acalabrutinib treatment for watch and monitor until month 60. If progression disease, patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.
16258914|NCT04963946|Active Comparator|Acalabrutinib|After 18 months of acalabrutinib treatment, patients will continue acalabrutinib treatment until month 60. If progression disease or unacceptable toxicity, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria
16258915|NCT04963933|Experimental|Patients treated with the device|Patients treated with the Nautilus will be followed up
16258916|NCT04963920|Experimental|SoC+CytoSorb treatment|patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines
16258917|NCT04963920|No Intervention|SoC|patients allocated to this group will receive only standard of care therapy according to applicable guidelines
16258918|NCT04963907|Active Comparator|Active CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Active devices are programmed to emit a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes. Participants will not be able to adjust the settings on the devices.
16258919|NCT04963907|Sham Comparator|Sham CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Sham devices are programmed to display a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes, but no current will be emitted from the device. Participants will not be able to adjust the settings on the devices.
16258920|NCT04963894|Experimental|Home functional balance physiotherapy|Participants perform physical therapy at home individually with a physical therapist. The experimental program of the study of balance exercise in functional context is implemented.
16258921|NCT04963894|No Intervention|Home functional daily activity|Participants stay in home without physiotherapy. Participants maintained their normal daily activities, which included housework, shopping, or daily walks.
16258922|NCT04963894|Active Comparator|Conventional physiotherapy|Participants perform physical therapy in a rehabilitation gym and in groups of 10 people. The conventional program of physiotherapy is implemented.
16258923|NCT04963868|Experimental|The novel strategy group|The stents were removed during the last necrosectomy when the endpoint of necrosectomy was achieved
16258924|NCT04963868|Active Comparator|The conventional strategy group|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image
16258925|NCT04963855|Active Comparator|CT300|GT300 capsule given once daily
16258926|NCT04963855|Placebo Comparator|Placebo|Microcrystalline cellulose capsule given once daily
16258927|NCT04963842|No Intervention|Conventional phase (use of conventional food packaging material)|During the conventional phase, participants are asked to maintain their usual habits for 5 days.
16258928|NCT04963842|Experimental|Intervention phase (use of bio-plastic and no plastic food packaging material)|During the 5-day long intervention period, all participants will be asked to: i) refrain from packaged (cans, plastic, paper) ready to consume foods, and foods from take away/delivery/fast food and ii) use the bio-based food packaging material to package their food.
16258929|NCT04963829|Active Comparator|Study Group (SG)|Participants who used the abovementioned gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration.
16258930|NCT04963829|Active Comparator|Control Group 1 (CG1)|Participants who were subjected to a standardized treatment (collagenase ointment was selected for this treatment),
16258931|NCT04963829|Active Comparator|Control Group 2 (CG2)|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum)
16258932|NCT04963816|Active Comparator|Group A Quadratus Lumborum Block with dexamethasone IV|QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline
16258933|NCT04963816|Active Comparator|Group B Quadratus Lumborum Block with dexamethasone locally|QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline
16258934|NCT04963816|Placebo Comparator|Group C Quadratus Lumborum Block with bupivacaine alone|Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.
16258935|NCT04963803|Experimental|Active transcranial direct current stimulation (tDCS) paired with speech-language therapy|Active transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
16258936|NCT04963803|Sham Comparator|Sham transcranial direct current stimulation (tDCS) paired with speech-language therapy|Sham transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
16258937|NCT04963790|Experimental|Tailored COVID-19 vaccine messaging|Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.
16258941|NCT04963764|Placebo Comparator|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (10 days)
16258942|NCT04963764|Active Comparator|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (10 days)
16258949|NCT04963712|Experimental|Zadaxin-HIV(n=20)|Study participants will be given Zadaxin (1.6 mg subcutaneous injection, once a day) in the first 2 weeks, and changed frequency (1.6 mg subcutaneous injection, twice a week) in the second 22 weeks.
16258950|NCT04963673||DFG> 40 ml / min|Kidney transplant population followed at CHU Amiens (group 1 ⇾ DFG> 40 ml / min).
16258951|NCT04963673||DFG < 40 ml / min|Kidney transplant population followed at CHU Amiens (group 2 ⇾ DFG < 40 ml / min).
16258952|NCT04963634||Patients with bradykinin angioedema|
16258953|NCT04963634||Patients with histamine-mediated angioedema|
16258954|NCT04963621|Experimental|Intervention|Child-Adolescent Emotion and Stress Intervention Program
16258955|NCT04963621|Active Comparator|waiting|treat as usual
16258956|NCT04963608||non-interventional study|Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
16258957|NCT04963595|Experimental|Pyrotinib and Vinorelbine with Inetetamab|
16258958|NCT04963595|Experimental|Pyrotinib and Vinorelbine without Inetetamab|
16258959|NCT04963582|Experimental|Acupuncture Group|Bilateral LI4 acupuncture is administered before IUD insertion. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
16258960|NCT04963582|No Intervention|Control Group|IUD insertion is proceeded without any intervention. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
16258961|NCT04963569||Albumin|Participants enrolled in the ABC Sepsis trial who have been randomised to 5% Human Albumin Solution as the sole resuscitative fluid in the first 6 hours.
16258962|NCT04963569||Balanced Crystalloid|Participants enrolled in the ABC Sepsis trial who have been randomised to Balanced Crystalloid as the sole resuscitative fluid in the first 6 hours.
16258963|NCT04963556|Experimental|Red Bull|Drinking of 355 ml Red Bull
16258964|NCT04963556|Placebo Comparator|Placebo|Drinking of 355 ml sweetened water
16258966|NCT04963530|Experimental|Wear of antagonist teeth to monolithic zirconia restorations|Evaluate enamel wear antagonist to monolithic zirconia restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
16258967|NCT04963530|Experimental|Wear of antagonist teeth to lithium disilicate restorations|Evaluate enamel wear antagonist to lithium disilicate restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
16258968|NCT04963530|Experimental|Wear of antagonist teeth to metalceramic restorations|Evaluate enamel wear antagonist to metal ceramic restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
16258969|NCT04963530|Experimental|Wear of natural enamel|Evaluate physiological enamel wear (control group) monitoring the short short and medium-term volume loss and assessing the factors that may influence this wear.
16258970|NCT04963517|Experimental|Exercise therapy|"8 weeks personalized, multi-modal exercise with focus on lower extremity
~Initial consultation with recommendations for general physical activity
~Brochure with exercise recommendations
~2x per week multi-modal group-based and supervised exercise (endurance, strength, mobility, coordination)
~week 1 and 2 supervised, week 3 and 4 partially supervised, week 5 and 6 only one supervised session, week 7 and 8 last two sessions supervised"
16258971|NCT04963517|Active Comparator|Information group|"Initial consultation with recommendations for general physical activity
~Brochure with exercise recommendations."
16258972|NCT04963504|Experimental|Rest-to-exercise|
16258973|NCT04963504|Experimental|Sitting-to-supine|
16258974|NCT04963491|Experimental|3D printed personalized TKA prosthesis|Design：Personalized TKA prosthesis Manufacture：3D
16258975|NCT04963491|Active Comparator|Zimmer NexGen TKA prostheses|Prosthesis has been widely used in clinic
16258976|NCT04963465||Before rupture of membranes|Vaginal swab collection prior to iatrogenic rupture of membranes
16258977|NCT04963465||After rupture of membranes|Vaginal swab collection after iatrogenic rupture of membranes
16258978|NCT04963452|Placebo Comparator|Group 1|Normal weight BMI 20-24.9 kg/m2
16258979|NCT04963452|Active Comparator|Group 2|Morbid Obese BMI : 40-49.9 kg/m2
16258980|NCT04963439|Experimental|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as final market image (FMI) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of macitentan as the clinical service formulation (CSF) in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
16258981|NCT04963439|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
16258982|NCT04963426|Experimental|Intervention arm|"The intervention consists of interactive workshops that will be facilitated by WHO and trained local personnel and involve students, teachers and local authorities. In the workshops, the Global Accelerated Action for the Health of Adolescents (Global AA-HA!) approach will be used to:
~identify adolescent health needs through exploring the collected baseline data;
~assess policies and practices already in place;
~identify gaps and needs for action to improve health. A menu of actions will be identified, prioritized, implemented and monitored."
16258983|NCT04963426|No Intervention|Control arm|The schools in the control arm will not participate in any intervention and continue 'as usual' after the baseline surveys.
16258984|NCT04963413|Experimental|Autologous DCs derived from PBMC loaded with RNA|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
16258985|NCT04963400||Patients with low disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of low severity (e.g. patients with retinal detachment)
16258986|NCT04963400||Patients with medium disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of medium severity (e.g. patients with an uncomplicated acute pancreatitis oder an acute exacerbation of a chronic inflammatory bowel disease)
16258987|NCT04963400||Patients with high disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of high severity (e.g. patients with a proximal femoral fracture)
16258988|NCT04963387|Experimental|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps vibration exposure was given in 1-minute bouts, with rest period of one to two minutes between bouts, with the exposure whole body vibration for about four minutes on every session. The duration of vibration exposure was preset with the automatic set time intervals in the vibration machine Prior to each vibration bout. When the predefined time was reached the machine automatically turned off . Based on previous researches the total exposure of four minutes per session interval was selected. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
16258989|NCT04963387|Active Comparator|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
16258990|NCT04963374||respiratory inpatient|respiratory inpatient with VTE
16258991|NCT04963361||fear of movement group|The score of fear of movement scale was more than 37
16258992|NCT04963361||non-fear of movement group|The score of fear of movement scale was no more than 37
16258993|NCT04963348||convolutional neural network (CNN)|a classical deep convolutional neural network (CNN) called Inception-V3 was applied to the image sets and validated the classification performance of the trained models
16258994|NCT04963335|Experimental|Intervention|Participants perform 16 exergame training (video game-based physical exercise) sessions over a period of 4 to 8 weeks (depending on in-patient or out-patient). Each training lasts between 15 to 25 minutes. Exergames automatically adjust the game difficulty to the abilities of the respective participant.
16258995|NCT04963335|No Intervention|Control|Participants of the control group are instructed to continue their normal daily routine for eight weeks and to record their physical activities.
16258996|NCT04963309||OR-EX|the group with endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
16258997|NCT04963309||NOR-EX|the group without endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
16258998|NCT04963296|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and Weeks 2, 24 and 26.
16258999|NCT04963296|Placebo Comparator|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1 and Weeks 2, 24 and 26.
16259000|NCT04963283|Experimental|Cabozantinib 40 mg orally daily in combination with nivolumab 480 mg IV every 28 days.|"Cabozantinib is supplied as 20-mg tablets and will be administered orally at a dose of 40 mg/day.
~Nivolumab is supplied in 100 mg/Vial (10 mg/mL) vials and will be administered IV at a dose of 480 mg every 28 days."
16259001|NCT04963270|Experimental|Satralizumab|Participants will receive Satralizumab at Weeks 0, 2, 4, and Q4W thereafter
16259002|NCT04963270|Placebo Comparator|Placebo|Participants will receive placebo at Weeks 0, 2, 4, and Q4W thereafter
16259003|NCT04963257|Experimental|sertraline combined with fluvoxamine|Sertraline combined with fluvoxamine treatment group: Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
16259004|NCT04963257|Active Comparator|sertraline combined with aripiprazole|sertraline combined with aripiprazole treatment group:Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
16259005|NCT04963244||AECOPD|
16259006|NCT04963244||Stable COPD|
16259007|NCT04963244||Control|
16259008|NCT04963231|Active Comparator|Setmelanotide|"Dosage:
~Patients 12 years of age and older: Setmelanotide 2 mg once daily (QD) for approximately 14 days, then increased to setmelanotide 3 mg QD for the remainder of the study.
~Patients 6 to <12 years of age: Setmelanotide 1 mg QD for approximately 7 days, then increased to setmelanotide 2 mg QD for approximately 7 days, then increased to setmelanotide 3 mg QD for the remainder of the study.
~Mode of administration:
~-Subcutaneous (SC) injection"
16259009|NCT04963231|Placebo Comparator|Placebo|Placebo (vehicle) in a sterile solution for injection
16259010|NCT04963205|Experimental|Adjustable bed backrest|Sleeping in elevated body position (>30 degrees from supine position) for 4 weeks is a requirement for the intervention group. Patients can define their own most comfortable position during the night.
16259011|NCT04963205|Active Comparator|Usual bed|"Sleeping in a standard bed and flat (<30 degrees from supine position) position for 4 weeks. Patients can define their own most comfortable position during the night."
16259012|NCT04963192|Experimental|OSA or COPD patients having an integrated management at home|OSA or COPD patients having an integrated management at home using connected devices, during 6 months
16259013|NCT04963179|Experimental|Womed Leaf|IUA prevention: The novel intrauterine barrier film (Womed Leaf) is inserted immediately after completion of the hysteroscopic adhesiolysis
16259019|NCT04963140|Experimental|Intervention|Intervention subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm signals when an increased risk of exacerbation is detected and subjects shall modify their treatment based on the action plan prescribed by the study doctor at enrolment and used for the self-management of their asthma
16259020|NCT04963140|Sham Comparator|Control|Control subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm used in the intervention arm is disabled. Subjects will follow the action plan prescribed by the study doctor at enrolment for the self-management of their asthma
16259021|NCT04963127||Prospective Cohort|400 patients who are scheduled to undergo a clinically requested CT scan of parts of the skeleton using a Dual-Energy/Multi-Energy/Spectral acquisition mode to exclude or further define bone fractures.
16259022|NCT04963127||Retrospective Cohort|400 patients who had undergone a clinically requested CT scan of the skeleton in standard acquisition mode in the past to exclude or further define bone fractures.
16259023|NCT04963114|Experimental|Art therapy|art therapy in the form of a one-hour guided tour of art works followed by a two-hour guided creative painting workshop on specific themes such as beauty and wonder and colors and emotions
16259024|NCT04963088|Experimental|TISLELIZUMAB、Anlotinib plus XELOX|
16259025|NCT04963075|Experimental|Unilaterally blind Subjects will be exposed to visual-auditory stimulation|The over-arching objective is to evaluate the functional recovery of vision in hemianopic patients engaged with a multisensory training paradigm. Unilaterally blind participants will participate in weekly training sessions in which they are exposed to high-density spatiotemporally congruent and consistent visual-auditory stimulation. The participants will be tested on a battery of visual tasks probing different levels of function in different environments in a longitudinal study to track recovery.
16259026|NCT04963062|Experimental|Participants treated with Holmium laser with the Moses laser|
16259027|NCT04963062|Experimental|Participants treated with Holmium laser with the thulium laser|
16259028|NCT04963049|Experimental|With Mask|
16259029|NCT04963036|Experimental|Entropy and NOL-Guided Goal Directed Anesthesia|
16259030|NCT04963036|Active Comparator|Standard of Care Group (Entropy and blinded NOL)|
16259031|NCT04963023||frequent exacerbation patients|
16259032|NCT04963023||non frequent exacerbation patients|
16259033|NCT04963023||Asthma-and-COPD overlap syndrome|
16259034|NCT04963023||Asthmatic patients (without COPD)|
16259035|NCT04963010|No Intervention|standard withdrawal colonoscopy|Observation of conventional colonoscopy
16259036|NCT04963010|Experimental|second forward view|second forward view examination of the proximal colon
16259037|NCT04962997||Transgender women|Major person identifying as a transgender women consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris) between 06/2021 and 10/2022
16259038|NCT04962984|Experimental|THAL +|patients with beta thalassemia major, requiring blood transfusion regimen. Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).
16259039|NCT04962984|Sham Comparator|THAL -|Patients with beta thalassemia trait, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
16259040|NCT04962984|Sham Comparator|Healthy volunteers|healthy subjects, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
16259041|NCT04962971||Exocyan Cran 40SD Cranberry extract|1 capsule per day (during 6 months) each containing 404 mg of a partially purified cranberry extract from the juice source. This extract was dosed at 40.1% PAC according to the Bate Smith method, which represents a daily PAC intake of 162.0 mg according to this method.
16259042|NCT04962971||Exocyan Cran 40G Cranberry extract|1 capsule per day (during 6 months) each containing 373 mg of a purified cranberry extract from the juice source combined with a pomace extract. This extract was dosed at 43.4% PAC according to the Bate Smith method, which represents a daily PAC intake of 162 mg according to this method.
16259043|NCT04962971||Exocyan Cran FG Cranberry extract|5 capsules per day (during 6 months) each containing 418mg of cranberry extract from a mixture of juice and pomace source, for a total extract intake of 2090mg per day. This extract was assayed at 7.75% PAC according to the Bate Smith method, which represents a daily intake of PAC of 162.0 mg according to this method.
16259044|NCT04962958|Experimental|HAIC+Donafenib|Donafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
16259045|NCT04962945|Active Comparator|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
16259046|NCT04962945|Active Comparator|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
16259047|NCT04962932|Experimental|Internet-delivered exposure-focused CBT|Internet-delivered CBT over 10 weeks The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
16259048|NCT04962932|Active Comparator|Internet-delivered stress management treatment|Stress management treatment for 10 weeks Participants randomized to The Stress Management Treatment will receive 10 weeks of stress managemen including relaxation technics, standard life style advice regarding physical activity, sleep and and standardized AF-information in line with current guidelines for AF. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
16259049|NCT04962919||Public institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
16259050|NCT04962919||Private institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
16259051|NCT04962906|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
16259052|NCT04962906|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
16259053|NCT04962906|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
16259054|NCT04962893|Experimental|VLP-Wuhan group (Group V1)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
16259055|NCT04962893|Experimental|VLP-Alpha (British) variant group (Group V2)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
16259056|NCT04962893|Experimental|VLP-Wuhan+Alpha group (Group V3)|"110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
~Initial vaccination with Wuhan followed by a booster of Alpha variant."
16259057|NCT04962854||Monoblock Cup|53 patients received a monoblock cup (RM Pressfit vitamys®)
16259058|NCT04962854||Modular Cup|64 patients received a modular cup (ANA.NOVA® Implantec)
16259059|NCT04962841||Frail older adults treated with nutraceuticals and drugs|
16259060|NCT04962841||Frail older adults not treated with nutraceuticals and drugs|
16259061|NCT04962828|Experimental|Collaboration group|This group of children will have targets and vocabulary that has been designed collaboratively and then the therapist and teacher both reinforce the vocabulary during the week
16259062|NCT04962828|Active Comparator|Non-collaborative group|This group of children will have targets and vocabulary that has been designed collaboratively but they will only be practiced with the therapist during the week
16259063|NCT04962802|Experimental|Manhood 2.0|Manhood 2.0 is a group-level intervention, delivered in 7 sessions over 13 hours, and is based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Sessions were delivered twice a week, for approximately 3.5 weeks. For the final session, participants received one hour of content and were administered the immediate post-intervention survey. The intervention takes a holistic, gender-transformative approach, includes reproductive health knowledge, healthy relationships, altering gender norms and stereotypes which drive reproductive health behavior, and explicit and proactive support of female partner contraceptive use. Activities are designed to engage young men in critical reflection and dialogue about gender norms, and then apply these discussions to a range of key issues including intimate relationships, gender-based violence, substance abuse, STIs, and early pregnancy.
16259064|NCT04962802|Placebo Comparator|Post-High School Readiness|The Post-High School Readiness Program helped youth build skills around identifying colleges or programs of interest, completing applications for programs, writing resumes and increasing financial literacy. The post-high school readiness curriculum was delivered by LAYC staff members and the content was delivered twice a week, for approximately 3.5 weeks (as with the intervention). For the final session, participants did not receive content and were administered the immediate post-intervention survey.
16259065|NCT04962789||with compaction|those whose endometrial thickness is calculated to decrease by the time of embryo transfer compared with the thickness at the day of ovulation trigger, analyzed according to the degree of compaction, i.e., 5%, 10%, 15%, or 20% decrease thickness
16259066|NCT04962789||without compaction|those who had an increase in their endometrial thickness or whose thickness decreased less than 5%
16259070|NCT04962763||Heart Failure|
16259071|NCT04962763||Control|
16259072|NCT04962750|Experimental|laser therapy|
16259073|NCT04962750|Sham Comparator|Control|
16259074|NCT04962737|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
16259077|NCT04962711|Experimental|Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)|"Optimization of pharmacotherapy: Cardioprotection with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol).Participants will be initially treated with ramipril at a dose of 1.25 or 2.5mg (according to baseline systemic arterial pressure), once or twice a day, and gradually up-titrated to 10mg/day, or to the maximal-tolerated dose. In patients receiving at least 2.5mg/day of ramipril, metoprolol will be started at an initial dose of 50 (25mg twice a day) and progressively up-titrated to the maximal dose of 100mg/day. Patients will be reviewed every 2 weeks during the up titration phase.
~Exercise intervention: Individualized training program provided by an exercise physiologist."
16259078|NCT04962711|Active Comparator|Usual care|Provided by participants' usual healthcare professional(s), guided by a brochure regarding optimal risk factor management addressing hypertension, lipids, alcohol intake and tobacco use.
16259079|NCT04962698|Experimental|All participants|All participants will receive various types of interventions in random order. The types of interventions are the same across subjects.
16259082|NCT04962672|Experimental|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide.
16259191|NCT04961905|Experimental|FDC fist, fasted|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
16259083|NCT04962672|Active Comparator|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group will received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide.
16259084|NCT04962659|Experimental|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (~1 hour) delivered via telehealth.
16259085|NCT04962659|No Intervention|Business as Usual Control|No treatment control.
16259086|NCT04962646|Experimental|Intervention|Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.
16259087|NCT04962646|No Intervention|Control|No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.
16259088|NCT04962633|Experimental|Probiotic Pasta Group|Subjects in the Probiotic Pasta group will consume 80 g per day of a probiotic pasta for 4 weeks
16259089|NCT04962633|Active Comparator|Control Pasta Group|Control Pasta Subjects in the Control Pasta group will consume 80 g per day of conventional pasta for 4 weeks.
16259090|NCT04962620||Longidaze|75 patients receiving combination therapy: Longidaze + dienogest
16259091|NCT04962620||Control|74 patients receiving only Dienogest.
16259092|NCT04962607||Study Group|"Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.
~Exposure of a vital pulp due to caries.
~No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.
~The possibility of proper restoration of the teeth."
16259093|NCT04962607||control group|"Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.
~Exposure of a vital pulp due to caries.
~No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.
~The possibility of proper restoration of the teeth."
16259097|NCT04962581||Group 1 : Covidien|This cohort will be monitored with the Covidien capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
16259098|NCT04962581||Group 2: General Électrique|This cohort will be monitored with the General Electrique capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
16259099|NCT04962568|Experimental|NHF-NIV|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
16259100|NCT04962568|Experimental|NIV-NHF|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
16259101|NCT04962555||Meniscus Suture|The patient underwent meniscus suture surgery
16259102|NCT04962555||Partial meniscus resection|The patient underwent partial meniscus resection
16259103|NCT04962555||Subtotal meniscus resection|The patient underwent Subtotal meniscus resection
16259104|NCT04962555||Complete meniscectomy|The patient underwent complete meniscectomy
16259105|NCT04962542|Active Comparator|ventilated group|the lungs will be kept inflated by delivery of oxygen : air 3 liter/min with FiO2 50% pressure-controlled mode, RR 20/min, PIP will be adjusted to keep Vt 2- 4 mL/kg as possible
16259106|NCT04962542|Active Comparator|CPAP group|lungs will be kept inflated by delivery of oxygen: air 3 liters/min with FiO2 50% and CPAP will be maintained via a circle system with airway pressure maintained at 5 cm H2O by PEEP valve
16259107|NCT04962542|No Intervention|controlled group|lungs will be deflated by disconnecting the breathing circuit from the ventilator (passive deflation).
16259108|NCT04962529||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
16259109|NCT04962516||Test group|
16259110|NCT04962516||Control group|
16259111|NCT04962503|Experimental|Afamelanotide|
16259112|NCT04962477||Pregnant|
16259113|NCT04962477||Non-pregnant|
16259114|NCT04962464|Experimental|Fasting Mimicking Diet + Supplement / Usual Routine|Participants in will be asked to begin the Peak Human Labs calorie mimetic supplement. They will also begin on day 1 the 5 day Fasting Mimicking Diet Program. Participants will continue the supplementation for the 90 days and repeat the 5 day Fasting Mimicking Diet Program on days 1, 29 and 57. Starting at day 91, they will return to their usual daily routine.
16259115|NCT04962464|Experimental|Supplement / Usual Routine|Participants will be asked to begin the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days. Starting at day 91, they will return to their usual daily routine.
16259116|NCT04962464|Experimental|Usual Routine / Fasting Mimicking Diet + Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91, they will begin the 5-day Fasting Mimicking Diet Program and start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days and repeat the 5-day Fasting Mimicking Diet Program on days 91, 120, and 148.
16259194|NCT04961892||surgical treatment|Patients with CAI undergoing surgical treatment
16259117|NCT04962464|Experimental|Usual Routine / Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91,start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days.
16259118|NCT04962451|Experimental|Intervention group|
16259119|NCT04962451|Placebo Comparator|Placebo group|
16259120|NCT04962438||Tumor patients using anti-VEGF drugs|
16259121|NCT04962425||The case group|Trastuzumab for the treatment of breast cancer patients with cardiotoxicity.
16259122|NCT04962425||The control group|Trastuzumab is used to treat patients with breast cancer who do not present with cardiotoxicity
16259123|NCT04962399||DKD group|Patients with type 2 diabetes mellitus complicated with diabetic nephropathy diagnosed by the second hospital of Shanxi Medical University
16259124|NCT04962399||TDM group|Type 2 diabetes mellitus without diabetic nephropathy
16259125|NCT04962399||control group|Health examination population in the same period
16259126|NCT04962386||Perimenopausal women who did not undergo HRT|Perimenopausal women who did not undergo HRT at baseline. And they did not receive any other drugs
16259127|NCT04962386||Perimenopausal women who did undergo HRT|Perimenopausal women who did undergo HRT received estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV. Weesp, The Netherlands).Take this medicine once a day. A course of treatment was defined as 28 days of continuous treatment.
16259128|NCT04962373||Adolescents|Adolescents with a contract for Brief admission by self-referral
16259129|NCT04962373||Parents|Parents to adolescents with a contract for Brief admission by self-referral
16259130|NCT04962373||Staff|Health care providers who work with adolescents with a contract for Brief admission by self-referral
16259131|NCT04962360|Experimental|Nutritional standardized supplementation formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.
16259132|NCT04962360|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
16259133|NCT04962334|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
16259134|NCT04962334|Placebo Comparator|Placebo|Low caloric formula (Powder added to waster) without added vitamins and minerals
16259136|NCT04962308|Experimental|Experimental Group|200 subjects in group A1 will receive one dose of booster immunization 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
16259137|NCT04962308|Experimental|Control Group|200 subjects in group A2 will receive one dose of booster immunization 5 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
16259138|NCT04962308|Experimental|Safety group|1000 subjects in group B will be enrolled and receive 1 dose of booster immunization more than 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine
16259139|NCT04962295||Cerebral Small Vessel Diseases group|CSVD patients
16259140|NCT04962282||group 1|Follow-up by telephone for researching compliance of patients receiving exercise prescriptions
16259141|NCT04962269||prostate cancer|The patient was pathologically diagnosed with prostate cancer
16259142|NCT04962269||benign prostatic hyperplasia|The patient was pathologically diagnosed with benign prostatic hyperplasia
16259143|NCT04962256||Study group|Patients with degenerative CSM or OPLL undergoing C3-7 open-door laminoplasty
16259144|NCT04962243||Patients undergoing repair of Achilles tendon rupture|Patients undergoing repair of Achilles tendon rupture
16259145|NCT04962243||Subjects who underwent physical examination during the same period|Subjects who underwent physical examination in the Physical Examination Center of Peking University Third Hospital during the same period
16259150|NCT04962191||Lung Cancer|The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.
16259151|NCT04962178|Experimental|Early Invasive Strategy|Procedure: Primary PCI
16259152|NCT04962178|Active Comparator|Conservative Strategy|Procedure: Optimal medical therapy with primary PCI not performed.
16259153|NCT04962165|Experimental|Experimental group|The group of SCI people will use a mandibular advancement device for treatment of obstructive sleep apnea.
16259154|NCT04962152|Experimental|Group Naldebain|ultrasound-guided intramuscular injection of Naldebain 150mg after the induction anesthesia immediately
16259155|NCT04962152|Placebo Comparator|Group Placebo|ultrasound-guided intramuscular injection of sesame oil (placebo) 2mL after the induction anesthesia immediately
16259156|NCT04962139|Experimental|ON101 Cream plus Standard of Care|ON101 cream will be applied twice daily for up to 20 weeks to the Target Ulcer. The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.
16259192|NCT04961905|Experimental|Single tablet fist, fed|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
16259193|NCT04961905|Experimental|FDC fist, fed|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
16259157|NCT04962139|Placebo Comparator|Vehicle Cream plus Standard of Care|"Vehicle cream will be applied twice daily for up to 20 weeks to the Target Ulcer.
~The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary."
16259158|NCT04962126|Experimental|Treatment naive advanced follicular lymphoma|All consenting participants will be receive an intravenous infusion of Obinutuzumab (1000mg) + Atezolizumab (1200mg) q3/52 x 6 cycles (plus 1000mg Obinutuzumab on day 8 and 15 of cycle 1). Responding participants (PR or SD) who do not achieve a CR at the end of cycle 2 will receive involved site radiotherapy (4Gy, 2 fractions) between cycle 3 and 4. At the end of cycle 6 and completion of the induction phase, responding participants (CR/PR/SD) will receive maintenance phase Obinutuzumab (1000mg IV) q8/52 for up to 12 cycles.
16259159|NCT04962113|Experimental|Tunnel group Tube bath during the phototherapy|
16259160|NCT04962113|No Intervention|Tunnel group rutin care|
16259161|NCT04962113|Experimental|LED group Tube bath during the phototherapy|
16259162|NCT04962113|No Intervention|LED group rutine care|
16259163|NCT04962100|Experimental|Study population|Male patients and donors who provide a sample of fresh ejaculated semen will be the population of this study, as well as female patients undergoing artificial insemination with their partner's semen or frozen donor semen.
16259164|NCT04962087|Experimental|Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
16259165|NCT04962087|No Intervention|Psychoeducation Control|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia.
16259166|NCT04962087|Experimental|Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
16259167|NCT04962087|No Intervention|Psychoeducation Control - Deprescribing|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia and information about the benefits of medication de-prescribing for those in Trial 2.
16259168|NCT04962074|Experimental|Density gradient method|Sperm prepared by density gradient method
16259169|NCT04962074|Experimental|Microfluidic chip|Sperm prepared by microfluidic chip method
16259170|NCT04962061|Experimental|Multidomain intervention|The multidomain intervention will combine a cognitive training with aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
16259171|NCT04962061|Experimental|Physical exercise intervention|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
16259172|NCT04962061|Active Comparator|Active control intervention|The active control intervention will include stretching and toning exercises, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
16259173|NCT04962048|Experimental|pulse-synchronized negative pressure (PSNP) device|One leg will be treated with the pulse-synchronized negative pressure (PSNP). The other leg serves as non-treated control.
16259174|NCT04962035||Alprem RTF Brain Follow-up|Neurocognitive Follow-up of children previously having participated in the Alprem RTF study
16259175|NCT04962022|Experimental|Period 1|PF-07321332/ritonavir orally
16259176|NCT04962022|Experimental|Period 2|Itraconazole + PF-07321332/ritonavir orally.
16259179|NCT04961983|Experimental|Intervention group|Tour guides who will receive a comprehensive travel health education model.
16259180|NCT04961983|No Intervention|Control group|Tour guides who will receive no intervention.
16259181|NCT04961970|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin
16259182|NCT04961970|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and cisplatin
16259183|NCT04961957|Active Comparator|Waterproof padding|Waterproof, short leg walking cast for 3-7 weeks
16259184|NCT04961957|Active Comparator|Non-waterproof padding|Non-waterproof, short leg walking cast for 3-7 weeks
16259185|NCT04961944||Hypersensitivity pneumonitis|see elegibility criteria
16259186|NCT04961931|Other|diabetes group|After qualifying for the study subjects with diabetes and chornic kidney disease received oral empagliflozin 10 mg once daily for 7 days.
16259187|NCT04961931|Other|non-diabetes group|After qualifying for the study subjects with chronic kidney disease without diabetes received oral empagliflozin 10 mg once daily for 7 days.
16259188|NCT04961931|Other|control|After qualifying for the study healthy subjects received oral empagliflozin 10 mg once daily for 7 days.
16259189|NCT04961918|Experimental|Treatment Group|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
16259190|NCT04961905|Experimental|Single tablet fist, fasted|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
16259195|NCT04961892||conservative treatment|Patients with CAI undergoing conservative treatment
16259196|NCT04961879|Active Comparator|Reversed Cross Finger Flap group 1|
16259197|NCT04961879|Active Comparator|Reversed island Homo-digital Flap group 2|
16259198|NCT04961866|Active Comparator|Group A|patients received 1 g/ kg of protein
16259199|NCT04961866|Active Comparator|Group B|patients received 2 g/ kg of protein
16259200|NCT04961853|Experimental|Cases|
16259201|NCT04961840||Cohort 1: Pregnant Women Exposed to Prucalopride|Pregnant women with clinically diagnosis of constipation who have been exposed to prucalopride during pregnancy will be observed.
16259202|NCT04961840||Cohort 2: Pregnant Women Not Exposed to Prucalopride|Pregnant women with clinical diagnosis of constipation who have been exposed to other laxative and not prucalopride constipation drugs during pregnancy will be observed.
16259203|NCT04961840||Cohort 3: Untreated Pregnant Women|Pregnant women with clinical diagnosis of constipation with no recorded prescription dispensed for any constipation drugs during pregnancy will be observed.
16259207|NCT04961801|Experimental|Acalabrutinib in combination with tacrolimus and methotrexate|"Phase I: To determine the maximum tolerated dose (MTD) of Acalabrutinib in combination with tacrolimus and methotrexate for Phase II.
~Phase II: To determine if acalabrutinib in combination with tacrolimus and methotrexate is safe and effective in reducing acute GVHD rate."
16259208|NCT04961788|Experimental|Gemox combined PD1 antibody|"Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.
~Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
16259211|NCT04961749|Experimental|Vibration group|This group will receive vibration stimulation while standing on a side-alternating vibration platform. Vibration sessions will occur three times per week over four-weeks. Each session will include three-minutes of vibration followed by three-minutes rest, completing this sequence three times per session
16259212|NCT04961749|No Intervention|Control group|This group will not receive vibration, but will rather hear a recording of the vibration, while still standing on the vibration platform. Still, this group will receive this training three times per week over four-weeks with a similar three-minute rotation as the vibration group.
16259213|NCT04961736||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
16259214|NCT04961736||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
16259215|NCT04961723|Experimental|MSM Postal delivery|Participants who identify primarily as MSM will receive a home delivered HCV self-test kit in non-identifiable packaging. The kit will include the test, instructions for use (IFU), and information about additional supporting materials, such as access to live chat and a call center for questions about testing
16259216|NCT04961723|Experimental|MSM Peer delivery|Participants who identify primarily as MSM will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
16259217|NCT04961723|No Intervention|MSM control|Participants who identify primarily as MSM will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
16259218|NCT04961723|Experimental|PWID peer delivery|Participants who identify primarily as PWID will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
16259219|NCT04961723|No Intervention|PWID control|Participants who identify primarily as PWID will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
16259220|NCT04961710|Experimental|Hetrombopag Olamine|
16259221|NCT04961710|Placebo Comparator|Placebo|
16259222|NCT04961697|Experimental|PICU with diaries|"The main family member of a critically ill child will receive a diary upon PICU admission.
~Except for the diaries intervention, this group of patients will be submitted to usual PICU routine care."
16259223|NCT04961697|No Intervention|PICU without diaries|This group of critically ill patients and family members will not receive diaries, but will also be submitted to usual PICU routine care.
16259224|NCT04961684|Experimental|Solver Pen|
16259225|NCT04961684|Active Comparator|Loceryl 5%|
16259229|NCT04961658|Experimental|Treatment Arm - Low Dose|Cohort of 3 subjects who receive a single dose of GEM00220 at 15 million cells
16259230|NCT04961658|Experimental|Treatment arm - Mid dose|Cohort of 3 subjects who receive a single dose of GEM00220 at 60 million cells
16259231|NCT04961658|Experimental|Treatment arm - High dose|Cohort of 3 subjects who receive a single dose of GEM00220 at 150 million cells
16259232|NCT04961645|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants will have two study visits. During the first visit, participants will have an fMRI scan to identify the OPA location in each individual participant. During the second visit, participants will receive rTMS. Each visit lasts approximately 90 minutes.
16259233|NCT04961632|Experimental|Dose-determination|
16259234|NCT04961632|Experimental|Dose-confirmation|
16259235|NCT04961619||dabrafenib and trametinib|patients on adjuvant treatment with dabrafenib + trametinib
16259236|NCT04961606||patients with coronary artery disease|
16259237|NCT04961606||medical professionals|
16259243|NCT04961554||Adult patients presenting with limited mouth opening|Adult patients presenting with limited mouth opening not allowing intubation by videolaryngoscopy, on mandibular surgical pathology requiring general anesthesia.
16259244|NCT04961541|Experimental|Group A - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
16259245|NCT04961541|Experimental|Group B -ICC Vaccine Formulation|2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.
16259246|NCT04961541|Experimental|Group C - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
16259247|NCT04961541|Experimental|Group D - ICC Vaccine Formulation|2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
16259248|NCT04961541|Experimental|Group E - ICC Vaccine Formulation|2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.
16259249|NCT04961541|Experimental|Group F- ICC Vaccine Formulation|2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.
16259250|NCT04961541|Experimental|Group G- ICC Vaccine Formulation|2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
16259251|NCT04961541|Experimental|Group H- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
16259252|NCT04961541|Experimental|Group I- ICC Vaccine Formulation|2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.
16259253|NCT04961541|Experimental|Group J -ICC Vaccine Formulation|2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.
16259254|NCT04961541|Experimental|Group K - ICC Vaccine Formulation|2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.
16259255|NCT04961541|Experimental|Group L - ICC Vaccine Formulation|2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.
16259256|NCT04961541|Experimental|Group M -ICC Vaccine Formulation|2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.
16259257|NCT04961541|Experimental|Group N- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
16259258|NCT04961541|Experimental|Group O - qNIV with Matrix-M1 adjuvant|2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.
16259259|NCT04961541|Experimental|Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant|2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.
16259260|NCT04961528|Experimental|Terlipressin|"Dosage: 1 mg /5 ml Pharmaceutical form: solution for infusion Posology: 1 mg /8 hours Treatment duration: 5 days
~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers"
16259261|NCT04961528|Experimental|Tranexamic Acid|"Dosage : 500 mg /5 ml Pharmaceutical form: solution for infusion Posology (and adjustments based on toxicity) : 500 mg/ 8 hours Treatment duration: 5 days
~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
16259262|NCT04961528|Placebo Comparator|Normal Saline Placebo|"Dose : normal saline solution (NaCl 0.9%) Pharmaceutical form : solution for infusion Posology : 5ml / 8 hours Treatment duration: 5 days
~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
16259263|NCT04961515|Experimental|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 250mg qd will be used for phase II trial.
~Orelabrutinib: orally daily Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks (maximum 12 total dose)"
16259264|NCT04961515|Experimental|Phase II|"Participants will receive orelabrutinib and sintilimab at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.
~Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg) Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks"
16259265|NCT04961502|Experimental|Elderly person|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
16259266|NCT04961502|Active Comparator|Younger adults (priority caregivers)|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
16259267|NCT04961476||GrM0|GrM0 - without supplementation
16259269|NCT04961463|Experimental|İnterventions group|İnterventions group:The 7-session psychoeducation program prepared on the basis of the Roy Adaptation Model was applied to the intervention group once a week for 90-120 minutes
16259270|NCT04961463|No Intervention|Control group|Except for the routine hospital controls, no intervention was made to the control group
16259271|NCT04961450||Patients|"Inclusion Criteria:
~Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020.
~Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines
~Informed consent signed
~Exclusion Criteria
~Patients who receive alternative diagnoses during the follow-up.
~Patients who refuse to sign informed consent."
16259272|NCT04961450||Control|"Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.
~Exclusion criteria:
~Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.
~Individuals who refuse to sign informed consent."
16259273|NCT04961437||Patients with de novo acute respiratory failure|"The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively):
~A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm.
~A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48."
16259274|NCT04961424||Symptomatic spinal epidural hematoma Group|Patients who performed thoracic decompression surgery and developed neurological deficit after surgery due to the symptomatic spinal epidural hematoma were enrolled into case group.
16259275|NCT04961424||Control group|hose who did not develop the symptomatic spinal epidural hematoma, underwent the same procedures of similar complexity at the same section of thoracic spine in the same period (the same year or the following year) were randomly selected from the pool of patients.
16259276|NCT04961411||published cases of patients with gallstone ileus|We will observe clinical signs, diagnostic procedures and therapeutic procedures and options
16259277|NCT04961385||ChAd0x1 nCoV-19 vaccinees|Participants who received first dose of ChAdox-1 n COV-19 were recruited. Participants were eligible if they were more than 18 years old
16259278|NCT04961372||Healthcare Workers|All healthcare professionals working at Gümüşhane Şiran Government Hospital
16259279|NCT04961372||Non-Healthcare Workers|Twice the number of health workers included in the study, non-health worker volunteers
16259280|NCT04961359|Experimental|Population Ⅰ|Population Ⅰ has 20 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅠis intramuscular injection of deltoid muscle of upper arm with vaccine.
16259281|NCT04961359|Placebo Comparator|Population Ⅱ|Population Ⅱ has 5 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅱ is a placebo intramuscular injection of deltoid muscle of the upper arm.
16259282|NCT04961359|Experimental|Population Ⅲ|Population Ⅲ has 20 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is intramuscular injection of deltoid muscle of upper arm with vaccine.
16259283|NCT04961359|Placebo Comparator|Population Ⅳ|Population Ⅳ has 5 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅳ is a placebo intramuscular injection of deltoid muscle of the upper arm.
16259284|NCT04961359|Experimental|Population Ⅴ|Population Ⅴ has 20 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅤ is intramuscular injection of deltoid muscle of upper arm with vaccine.
16259285|NCT04961359|Placebo Comparator|Population Ⅵ|Population Ⅵ has 5 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅵ is a placebo intramuscular injection of deltoid muscle of the upper arm.
16259286|NCT04961346|Experimental|Ultrapro®|Participants received incisional hernia repair with an Ultrapro mesh in a sublay technique.
16259287|NCT04961346|Experimental|Premilene®|Participants received incisional hernia repair with a Premilene mesh in a sublay technique.
16259288|NCT04961333|Experimental|Rehabilitation group|Rehabilitation group will be provided multidisciplinary interventions online and individually by ExorLive app. The screening with self-scored questionnaires and physical tests will be performed before and after 8 weeks rehabilitation.
16259289|NCT04961333|No Intervention|Waiting list controls|Passive waiting list or control group, which will be offered to participate in rehabilitation after at least 8 weeks of waiting time. The group will fulfil screening twice, following the time schedule of intervention group. When invited to rehabilitation a new screening will be asked to be completed if the waiting time after the last screening will be longer than 2 weeks.
16259290|NCT04961320|Experimental|Supportive care (OT, questionnaires)|Patients participate in OT sessions weekly for 3 weeks over 30 minutes each. Patients also complete questionnaires to assess anxiety, depression, fatigue and pain at baseline, 5 and 12 weeks.
16259291|NCT04961307||Women with breast cancer using trastuzumab|
16259292|NCT04961294|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
16259293|NCT04961294|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
16259294|NCT04961281|Active Comparator|Dexmeditomidine group|injection of 10 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
16259295|NCT04961281|Active Comparator|triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
16259296|NCT04961268|Active Comparator|Tramadol 50|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 50 mg in opaque yellow size 000 capsules."
16259297|NCT04961268|Active Comparator|Tramadol 100|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 100 mg in opaque yellow size 000 capsules."
16259298|NCT04961268|Active Comparator|Ibuprofen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg in opaque yellow size 000 capsules."
16259299|NCT04961268|Active Comparator|Ibuprofen/acetaminophen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg/acetaminophen 1000 mg in opaque yellow size 000 capsules."
16259300|NCT04961268|Placebo Comparator|Placebo|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received Placebo in opaque yellow size 000 capsules."
16259301|NCT04961255||Control group|Healthy individuals will be evaluated only once throughout the study. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated.
16259302|NCT04961255||COVID-19 positive participants who had moderate symptoms group|"These participants will be evaluated 4 times throughout the study.
~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.
~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.
~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.
~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.
~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
16259303|NCT04961255||COVID-19 positive participants who had severe symptoms group|"These participants will be evaluated 4 times throughout the study.
~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.
~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.
~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.
~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.
~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
16259304|NCT04961229|Experimental|Third dose of BNT162b2 vaccine with Immunosuppression reduction|Third dose of BNT162b2 vaccine with reduction of mycophenolic acid dose
16259305|NCT04961229|Experimental|Third dose of BNT162b2 vaccine without immunosuppression reduction|Third dose of BNT162b2 vaccine without reduction of mycophenolic acid dose
16259306|NCT04961229|Experimental|Third dose of BNT162b2 vaccine|Third dose of BNT162b2 vaccine with no change in immunosuppression for patients that are excluded from the randomised trial
16259307|NCT04961216|Experimental|OPTIMISE intervention|"After a baseline week of self-monitoring their meat consumption, participants will receive health and environmental feedback on their consumption and will be prompted to think about how they could reduce their intake. They will be asked to pre-select strategies from a list of meat consumption reduction actions and set themselves a meat reduction goal.
~During the following four weeks (weeks 2-5), participants will be asked every morning to log their meat consumption of the previous day, plan one of their chosen actions and formulate an if-then plan. Participants will receive weekly feedback on their achieved meat reduction in comparison to week 1.
~After the completion of the fifth week (follow-up 1), participants will be asked to continue performing the actions they found useful for the next four weeks (weeks 6-9). During the ninth week (follow-up 2) participants will be invited back to log their meat intake."
16259308|NCT04961216|No Intervention|Control|After a baseline week of self-monitoring their meat consumption participants will be asked to try and reduce their meat consumption over the next eight weeks, with no further guidance. They will be invited back to complete log their meat consumption of the previous day during weeks five and nine (follow-up 1 and 2).
16259309|NCT04961190|Active Comparator|Prolonged Exposure Therapy|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
16259310|NCT04961190|Active Comparator|Pharmacotherapy|20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
16259311|NCT04961190|Active Comparator|Combined treatment (Prolonged Exposure and Pharmacotherapy)|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
16259312|NCT04961177|Other|EITC & ACEs Training|Trainings for frontline health workers about EITC and ACEs.
16259313|NCT04961177|Other|EITC Outreach and Screening|Our partners will implement EITC outreach events and EITC screening with clients.
16259314|NCT04961177|Other|EITC Assistance|Our partners will screen clients for EITC and refer those who qualify for free tax preparation assistance and assistance submitting their tax returns.
16259317|NCT04961151|Experimental|Conductive Wrap Warming|Esophageal warming will be discontinued first
16259318|NCT04961151|Experimental|Esophageal Warming|Conductive wraps will be discontinued first
16259319|NCT04961138|Experimental|Neoadjuvant group|
16259320|NCT04961138|Active Comparator|Surgery group|
16259321|NCT04961125||colorectal polyposis|
16259322|NCT04961112|Experimental|Experimental - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.
~Participants will be administered cranial electrotherapy stimulation with a frequency of 100 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
16259363|NCT04960852|Experimental|a single shade structurally colored universal resin composite|Cavities will be prepared. one shade universal composite (Omnichroma) a will be applied according to the manufacturer.
16259364|NCT04960839|No Intervention|Standard group|Standard loco-regional treatment without prophylactic contralateral breast irradiation
16259323|NCT04961112|Experimental|Experimental - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.
~Participants will be administered cranial electrotherapy stimulation with a frequency of 100 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
16259324|NCT04961112|Sham Comparator|Sham - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.
~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
16259325|NCT04961112|Sham Comparator|Sham - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.
~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
16259326|NCT04961099|Experimental|low-dose group|low-dose group: HY01 10mg（20mg/ml）
16259327|NCT04961099|Experimental|high-dose group|high-dose group: HY01 20mg（40mg/ml）
16259328|NCT04961086|Experimental|energy drink arm|an open label branded energy drink which contains any one or more of the following ingredients: caffeine, ginseng, taurine
16259329|NCT04961086|Active Comparator|tea 5gm sugar arm|the usual easily available black tea with sugar 5 grams, and milk
16259330|NCT04961060||Eosinophilic exacerbation|COPD exacerbation associated with eosinophilia.
16259331|NCT04961060||Viral exacerbation|COPD exacerbation associated with viral infection.
16259332|NCT04961060||Bacterial exacerbation|COPD exacerbation associated bacterial infection.
16259333|NCT04961060||Pauci-inflammatory exacerbation|Pauci-inflammatory COPD exacerbation
16259334|NCT04961047|Experimental|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
16259335|NCT04961047|Active Comparator|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
16259338|NCT04961021|Active Comparator|Medial rectus advancement with resection|Surgery will be done to strengthen the medial rectus muscle with resection and anterior displacement again to the original insertion site 5 mm from limbus
16259339|NCT04961021|Active Comparator|Medial rectus advancement with lateral rectus recession|Surgery will be done to strengthen the medial rectus muscle with anterior displacement again to the original insertion site 4- 5 mm from limbus with weakening procedure to the lateral rectus muscle at the same time
16259340|NCT04961008|Experimental|Bottle-PEP|Bottle-PEP
16259341|NCT04961008|Active Comparator|Routine physiotherapy|v
16259342|NCT04960982||PCOS-RM|PCOS women with history of RM
16259343|NCT04960982||Non PCOS RM|Non PCOS women with history of RM
16259344|NCT04960982||Control|women with no history of RM
16259345|NCT04960969|Experimental|Time-restricted Feeding Group|Participants will apply time-restricted feeding (8 hours/day) for 28 days.
16259346|NCT04960969|No Intervention|Control Group|No intervention will be applied.
16259347|NCT04960943|Experimental|Pyrotinib|Pyrotinib with or without paclitaxel/trastuzumab treatment
16259348|NCT04960930|Experimental|FMX101|FMX101 4% minocycline foam
16259349|NCT04960930|Placebo Comparator|Vehicle Foam|Vehicle Foam
16259350|NCT04960917|Experimental|eHealth literacy workshop|Community members from pre-existing municipality groups will participate in a workshop aimed to raise their ehealth literacy level.
16259351|NCT04960904||In-Kone® UNIVERSAL|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® UNIVERSAL
16259352|NCT04960904||In-Kone® PRIMO|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® PRIMO
16259353|NCT04960904||twinKon® UNIVERSAL|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges twinKon® UNIVERSAL
16259354|NCT04960904||EVL® S|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® S
16259355|NCT04960904||EVL® K|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® K
16259356|NCT04960904||EVL® C|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® C
16259357|NCT04960904||3.0|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges 3.0
16259358|NCT04960878|Placebo Comparator|Placebo|1.5 g maltodextrin in a sachet once daily for 8 weeks.
16259359|NCT04960878|Experimental|Synbiotic|1.5 g synbiotics supplement of Lactobacillus rhamnosus HN001 (1.5×10^11 CFU) , Bifidobacterium lactis HN019 (7.5×10^10 CFU), and 500mg fructooligosaccharides in a sachet once daily for 8 weeks.
16259360|NCT04960865|Experimental|Experimental Group|Participants will be applied Kinesio tape with 50% tension.
16259361|NCT04960865|Sham Comparator|Sham Group|Participants will be applied Kinesio tape without any tension.
16259362|NCT04960865|Placebo Comparator|Placebo Group|Participants will be applied rigid tape without any tension
16259365|NCT04960839|Experimental|Prophylactic irradiation group|Standard loco-regional treatment with prophylactic contralateral breast irradiation
16259366|NCT04960826||Crohn's disease patients|
16259367|NCT04960826||Non IBD patients|
16259368|NCT04960813|Experimental|Kidpower - Structured Games|Structured Games Camp.
16259369|NCT04960813|Active Comparator|Kidpower - Playgroup|Playgroup camp
16259370|NCT04960800|Experimental|Intervention group|The participants in the intervention group will participate in a 12- week specific exercise programme led by an experienced women's health physiotherapist. These groups will take place at a private physiotherapy clinic twice a week. In addition, the participants will carry out a self-managed exercise program twice weekly for the same 12-week period. They will be provided with an exercise diary so that adherence to the intervention can be registered and monitored. This exercise diary will be sent to the participants once a week as an electronic questionnaire; this will ensure that the information recorded is standardized and that the research assistant can aid the participants to register their activity and encourage the participants to adhere to the intervention.
16259371|NCT04960800|No Intervention|Control group|The control group will not participate in any exercise intervention. The participants in the control group will be explained the importance of a control group in RCTs and will be recommended to continue with their normal activity levels. They will however, be recommended to follow national guidelines for general exercise during pregnancy and will receive information about these guidelines (15).
16259372|NCT04960787|Active Comparator|Group I (usual care)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
16259373|NCT04960787|Experimental|Group II (financial navigation intervention)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients also meet with CENTS counselor and PAF case manager over approximately 1 hour every month for 6 months (with each group). Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
16259374|NCT04960774||Control group|Patients with non-severe periodontitis or healthy people who were treated in our department in the same period were included as the control group.
16259375|NCT04960774||Severe periodontitis group|Severe periodontitis patients who meet the inclusion and exclusion criteria in the Department of Stomatology, the second affiliated Hospital of Medical College of Zhejiang University
16259376|NCT04960761|Experimental|Intervention Group|Pre-operative training will be given by the clinic nurse with audio and picture book. Training content with audio and picture book; Before the operation, the procedures performed during the admission of the patient to the service (introducing the clinic and staff to the patient), what are the preoperative preparations (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown), wearing a patient tag on the wrist, taking him to the operating room on a stretcher), which will be used during the operation anesthesia techniques and how to provide sedation (the anesthetic agent can be given by mask or IV catheter, the reasons are the clothes worn by doctors and nurses in the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.).
16259377|NCT04960761|No Intervention|Control Group|Routine training will be given by a nurse working in the clinic during the preoperative period. The content of the routine training: What are the procedures performed during the admission of the patient to the service before the operation (introducing the clinic and the staff to the patient), what the preoperative preparation is (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown, wearing a patient tag on the wrist, with a stretcher. being taken to the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.), there may be some medical materials that were applied to the patient during the surgery (nasogastric tube, IV catheter, types of drains placed in the wound site) includes information such as
16259380|NCT04960735|Experimental|Patients with cancer (patients with breast cancer and patients with lung cancer)|"Health-related Quality of Life evidence was collected from patients with cancer (patients with breast cancer and patients with lung cancer) for six months. The evidence was collected by means of health related and patient reported questionnaires (ICHOM standard sets for breast cancer and lung cancer).
~Patients were monitored for six months. Intervention outcomes were monitored at different times: for patients with breast cancer, at the start (on recruitment which coincided with diagnosis) and at six months; for patients with lung cancer, at the start (on recruitment which coincided with diagnosis), at three and at six months."
16259381|NCT04960722|Active Comparator|Control|autogenous bone graft
16259382|NCT04960722|Experimental|1.5 mg/g OIF/β-TCP|1.5 mg/g OIF/β-TCP
16259383|NCT04960722|Experimental|2 mg/g OIF/β-TCP|2 mg/g OIF/β-TCP
16259384|NCT04960722|Experimental|3 mg/g OIF/β-TCP|3 mg/g OIF/β-TCP
16259388|NCT04960696||primary school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
16259389|NCT04960696||middle school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
16259390|NCT04960696||high school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
16259391|NCT04960696||university/81 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
16259392|NCT04960683|Experimental|Robotic -assisted gait training group using Lokomat device|"5 sessions of 40 minutes of conventional therapy and
~5 sessions of 40 minutes on Lokomat per week"
16259393|NCT04960683|Active Comparator|Traditional therapy group|• 5 sessions of 40 minutes of conventional therapy
16259394|NCT04960670||Dyads|Mother/infant pairs will be evaluated for anthropometric parameters, prenatal (dietary/lifestyle maternal factors)/postnatal determinants (type of feeding, sleep patterns, speed of growth) before discharge and after different follow-up after birth. Infant urinary and stool samples will be collected and stored. The infant adiposity rebound will be monitored.
16259395|NCT04960657|Active Comparator|PACAP38 and glibenclamide|Participants will receive glibenclamide after PACAP38 infusion
16259396|NCT04960657|Active Comparator|PACAP38 and placebo|Participants will receive placebo after PACAP38 infusion
16259397|NCT04960644|Experimental|MTX and corticosteroid|perimental: MTX and corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response MTX (5-6mg/m^2/day,Maximum dose 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
16259398|NCT04960644|Active Comparator|corticosteroid|perimental: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response
16259399|NCT04960631||Clinical diagnosis of suspected malignant tumor by dual site CT guided needle biopsy|
16259400|NCT04960618|Experimental|Participants with confirmed mycosis fungoides/Sezary syndrome|Participants will have confirmed mycosis fungoides/Sezary syndrome, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher.
16259401|NCT04960605|Other|Test group|Patients with Primary Sjögren Syndrom
16259402|NCT04960605|Other|Control group|Patients with Primary Sjögren Syndrom, matched to the test group
16259403|NCT04960592||SCS Responders|Patients who receive Spinal Cord Stimulation treatment and experience greater than 50% reduction in pain score following treatment.
16259404|NCT04960592||SCS Non Responders|Patients who receive Spinal Cord Stimulation treatment and do not experience greater than 50% reduction in pain score following treatment.
16259405|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (single dose)|Dose escalation cohorts, administered intravenously as a single dose following a conditioning chemotherapy regimen. Rimiducid may be administered as indicated.
16259406|NCT04960566|Experimental|eCBT+|eCBT+ participants will be enrolled in 6, 45-minute sessions delivered via a secure video platform with a GI psychologist. To reinforce concepts reviewed in the sessions, participants will complete weekly home practice exercises. The targets are 1) improved maladaptive cognitive-affective processes associated with increased hypervigilance and symptom anxiety, 2) reduced behaviors associated with EHA including avoidance, increased medication/healthcare utilization and 3) reduced autonomic nervous system (ANS) arousal by increased HRV. Participants will learn to identify, question, and modify maladaptive thoughts, beliefs, and assumptions related to their symptoms (symptom anxiety). Systematic exposure to feared events are used to reduce maladaptive coping strategies (hypervigilance, PPI overuse, HCU). Specific, paced diaphragmatic breathing exercises (Resonance Frequency Breathing) designed to increase HRV are the last component (visceral hypersensitivity, reflux physiology).
16259407|NCT04960566|Sham Comparator|Sham-SOC Lifestyle Coaching|Patients randomized to the SOC condition will receive lifestyle guidance recommended for patients with GERD over a period of 6, 45-minute sessions with the GI psychologist to maintain consistency of delivery between the two intervention arms. Topics include maintaining a healthy weight, identifying triggering food and drink, making healthy food choices, eating behaviors, smoking and/or alcohol use, and timing of meals. The SOC condition will be carefully designed to not include any principles of the eCBT+ condition rather be based solely on patient education and encouragement to practice lifestyle changes on their own.
16259408|NCT04960553|Experimental|Device : Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up investigation : Up to 102 subjects with exuding chronic wounds deemed adequate by the Principle Investigator and Clinical Team for assigned treatment
16259409|NCT04960540||impaired speech comprehension processing in ALS|Brain functional network mechanism of impaired speech comprehension processing in ALS
16259410|NCT04960540||language use processing injury in ALS|Brain functional network mechanism of language use processing injury in ALS
16259411|NCT04960540||motor executive processing injury in ALS|Brain functional network mechanism of motor executive processing injury in ALS
16259412|NCT04960540||anguage cognitive impairment in ALS|Brain structural network mechanism of language cognitive impairment in ALS
16259413|NCT04960527|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK, 100% Montmorency) diluted with 220 mL water (totalling 250 mL). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries.
16259414|NCT04960527|Other|Water|250 mL water (neutral control)
16259415|NCT04960501||New tension band system|
16259416|NCT04960501||Patella reduction band system|
16259417|NCT04960488|Experimental|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
16259418|NCT04960488|Active Comparator|carotid endarterectomy|carotid endarterectomy
16259419|NCT04960475||A/D group|Chronic ankle sprain patient with anxity or depression
16259420|NCT04960475||Control group|Chronic ankle sprain patient with no emotional issues
16259421|NCT04960462||the treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement|The clinical data of patients with sacral cysts treated with nerve root sleeve reinforcement and reconstruction of the sacral canal cyst were summarized and followed up from 3 to 6 months after the operation to form a case summary and report.
16259480|NCT04960020||ACL injuries with e-scooter trauma|
16259481|NCT04960007||Group A|Sarcopenia patients.
16259422|NCT04960449||patients with partial-thickness rotator cuff tendon tears|Partial rotator cuff tears can be divided into three categories, bursa side tears, tendon tears and joint side tears. Studies have found that rotator cuff tendon tears account for 55% of partial tears, compared to the other two types of partial tears, there has been very little research on partial-thickness rotator cuff tendon tears, which has no consensus on diagnosis and treatment.
16259423|NCT04960436|Experimental|Meniscus Allograft Transplantation|The patient underwent Meniscus Allograft Transplantation
16259424|NCT04960436|Active Comparator|Meniscectomy|The patient underwent Meniscectomy
16259425|NCT04960410||Low air pollution|
16259426|NCT04960410||High air pollution|
16259434|NCT04960384|Placebo Comparator|Placebo|
16259435|NCT04960384|Experimental|Human Fibroblast Growth Factor-2 (FGF-2)|
16259436|NCT04960371||anxiety group|the score of Self-rating Anxiety Scale greater than 50
16259437|NCT04960371||non-anxiety group|the score of Self-rating Anxiety Scale less than 50
16259438|NCT04960358||Chronic LBP|Will be applied Surface Electromyography
16259439|NCT04960345||The traditional group|The traditional group underwent prosthesis placement using traditional intramedullary positioning method.
16259440|NCT04960345||The navigation group|The navigation group performed surgery using the Brainlab Knee 3 navigation system.Informed consent was signed after grouping.
16259441|NCT04960332|No Intervention|Standard treatment|Group A: Standard wound closure with staples and conventional wound dressing.
16259442|NCT04960332|Experimental|Prevena|Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).
16259443|NCT04960319|Experimental|Intravascular Lithotripsy|Study Device Treatment: IVL balloon catheter size is chosen in a 1:1 ratio to the distal reference vessel diameter. If the IVL balloon cannot be delivered into the target lesion a Guide catheter extension is recommended. The balloon catheter is then inflated to 4 ATM and 10 impulses are delivered. The balloon is then inflated to 6 ATM and deflated to reestablish blood flow. Up to 80 impulses can subsequently be delivered and the balloon can be repositioned within the lesion. In multiple lesions with different reference vessel diameters different sizes of IVL balloon can be used.
16259444|NCT04960319|Active Comparator|Rotational Atherectomy|Control group treatment: Rotablation should be performed as described in the ESC-Consensus document. Burr/vessel-ratio is 0.5 - 0.75. The use of different burr sizes as well as the use of a temporary pacemaker is left to the operator's discretion.
16259445|NCT04960306|Active Comparator|Fecal filtrate transplantation|Patients randomized to the fecal filtrate transplantation group
16259446|NCT04960306|Active Comparator|Conventional fecal microbiota transplantation|Patients randomized to the conventional fecal microbiota transplantation group
16259447|NCT04960293|Experimental|Spherical gelfoam|Patients who receive uterine artery embolization for symptomatic fibroids
16259448|NCT04960293|Active Comparator|Microsphere|Patients who receive uterine artery embolization for symptomatic fibroids
16259449|NCT04960280|Experimental|Computerized Auscultation|Patients presenting to the echocardiogram laboratory for routine clinically indicated echocardiography or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures will undergo a computerized auscultation using the ©CompuSteth stethoscope and will have their heart sounds auscultated and recorded.
16259450|NCT04960267|Experimental|Use of pre-peritoneal drainage after rTAPP|"Use of pre-peritoneal drainage after rTAPP
~Outcomes will be compared with retrospective cohort from our previous experiments"
16259482|NCT04960007||Group B|Dynapenia patients.
16259483|NCT04960007||Group C|Age and gender matched non-sarcopenia and non-dynapenia patients.
16259484|NCT04959981|Experimental|Dose Escalation (Part 1): ERAS-007 QW plus osimertinib|ERAS-007 will be orally administered QW in combination with osimertinib to study participants with advanced EGFRm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
16259515|NCT04959734||Bronchiolitis|Infants less than 2 years who the clinician has diagnosed Bronchiolitis
16259451|NCT04960241|Active Comparator|Homebased telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
16259452|NCT04960241|Active Comparator|Homebased rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
16259453|NCT04960241|Active Comparator|No physical rehabilitation|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
16259456|NCT04960215|Active Comparator|Coenzyme Q10|
16259457|NCT04960215|Placebo Comparator|Placebo|
16259460|NCT04960189|Experimental|Acupuncture|GB34 acupuncture will be applied every day. Patients will receive standard medical treatment
16259461|NCT04960189|No Intervention|Controls|Patients will only receive standard medical treatment
16259462|NCT04960176|Active Comparator|Acupuncture Group|Acupuncture will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
16259463|NCT04960176|Sham Comparator|Non-Invasive Sham Acupuncture Group|Non-invasive sham acupuncture using a blunted needle will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
16259464|NCT04960150|Experimental|Acupuncture group|Intervention of press tack needle acupuncture
16259465|NCT04960150|Placebo Comparator|Control group|Intervention of placebo acupuncture
16259466|NCT04960137|Experimental|Button Plates fixation system|Patients receiving surgery fixed with Button Plates fixation system
16259467|NCT04960137|Active Comparator|Non-absorbable Suture Anchor|Patients receiving surgery fixed with Non-absorbable suture anchor
16259473|NCT04960111|Experimental|knee arthroplasty with radiostereometry tecnique|patient underwent total knee arthroplasty with insertion of microsphere in tantallium for radiostereometry tecnique.
16259474|NCT04960098||patient underwent hip and knee arthroplasty|Patients with hip and knee osteoarthritis underwent hip and knee arthroplasty included in inclusion criteria.
16259475|NCT04960072|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-3x10^11 in vitro expanded autologous TILs will be infused i.v. to patients with relapsed/refractory malignant gastrointestinal tumors after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
16259476|NCT04960046|Active Comparator|Infraclavicular nerve block using a costoclavicular approach|The costoclavicular approach, more recently described, proposes an insertion of the needle under the lower edge of the clavicle but in a lateral way to the axillary artery which makes it possible to reach the nerves at a place where the 3 main nerve bundles are still joined together. The clustering of nerve structures at the injection site may facilitate the spread of local anesthetics.
16259477|NCT04960046|Placebo Comparator|Infraclavicular nerve block using a paracoracoid approach|The paracoracoid approach involves inserting a needle under the lower rim of the clavicle below the coracoid process. This approach makes it possible to reach the 3 different nerve bundles, located around the axillary artery, which are involved in the sensitivity of the hand.
16259478|NCT04960033||Osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
16259479|NCT04960033||women without osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was <20% or the 10-year probability of HF was <3%.
16259485|NCT04959981|Experimental|Dose Expansion (Part 2): ERAS-007 QW plus osimertinib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with osimertinib to study participants with advanced EGFRm NSCLC.
16259486|NCT04959968|Experimental|Intervention group|An eye patch and earplug will be applied to the intervention group in the intensive care unit on the day of craniotomy and on the post-operative 1st day between 22:00 and 06:00
16259487|NCT04959968|No Intervention|Control group|Standard care procedure will be applied to the control group
16259488|NCT04959955||AECOPD group|
16259489|NCT04959955||CAP group|
16259490|NCT04959942|Experimental|scapular stabilization exercise|the subjects will receive scapular stabilization exercise + postural correction exercise and advice three times per week for 10 weeks
16259491|NCT04959942|Experimental|postural correction exercise|the subjects will receive postural correction exercise and advice three times per week for 10 weeks
16259492|NCT04959942|Active Comparator|advice|the subjects will receive advice three times per week for 10 weeks
16259493|NCT04959929|Experimental|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to ~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
16259495|NCT04959903|Experimental|Adult patients affected by acute leukemia (AML, ALL)|
16259496|NCT04959903|Experimental|Pediatric patients affected by acute leukemia (AML, ALL)|
16259497|NCT04959890||Subjects Previously Treated with Strimvelis Gene Therapy|It is expected that this study will include approximately 70 eligible samples from approximately 15 subjects previously treated with gamma retroviral gene therapy (gRV-GT).
16259498|NCT04959877||1|Patients diagnosed with oropharyngeal dysphagia who require speech therapy treatment for this reason and who have voluntarily opted for the blended treatment modality.
16259499|NCT04959864|Experimental|Isitol® (Food supplement treated group)|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of Isitol® per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.
~1 sachet of Isitol® (2,1g) contains 1000 mg of myo-inositol, 300 mg of N-acetyl-cysteine, 150 % of the Nutritional Reference Values (NRV) in zinc and 100 % of the NRV: in vitamins B2, B3, B6, B9 and E."
16259500|NCT04959864|Placebo Comparator|Placebo treated group|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of placebo per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.
~1 sachet of placebo (2,1g) contains only excipients used in Isitol® and excipients to get similar organoleptic aspect (maltodextrin, sucralose, silicon dioxide, magnesium carbonate, citric acid and beta-carotene)."
16259501|NCT04959851||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are initiating or currently ongoing vedolizumab intravenous induction treatment or maintenance intravenous treatment in accordance with the current Summary of Product Characteristics (SmPC) along with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
16259502|NCT04959838|Experimental|Ophthalmology physicians and residents|"Ophthalmology physicians and residents will be followed during 34h, from 8 am to 6 pm the following day,in five different conditions:
~Control day (no work)
~Typical working day
~Working day + one night shift
~Emergency working day + two consecutive night shifts
~Night shift."
16259503|NCT04959825|Active Comparator|melatonin group|Melatonin group (group M )will receive melatonin as a premedication 1 hour before surgery in a dose of 5 mg
16259504|NCT04959825|Placebo Comparator|control group|15 patients will be enrolled for open nephrectomy will receive sugar-coated tablets. Control group(group C)
16259505|NCT04959812|Experimental|Sufentanil|Sufentanil (30 microgram tablet) will be administered via a sublingual pill
16259506|NCT04959812|Placebo Comparator|Placebo|Placebo will be administered via a sublingual pill
16259507|NCT04959786|Experimental|INTERVENTION ARM|
16259508|NCT04959786|No Intervention|standard of care|
16259509|NCT04959773||COVID+ with exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection.
~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.
~general conditions."
16259510|NCT04959773||COVID+ without exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life.
~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion."
16259511|NCT04959773||Control healthy subjects (CTRL)|Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.
16259512|NCT04959760|Experimental|BinaxNow Covid-19 Antibody test|The BinaxNOW™ Antibody Tests measure SARS-CoV-2 S-IgG antibodies.
16259513|NCT04959747|Experimental|acupuncture group|"Subject will be scheduled for a total of 8 sessions of acupuncture treatment, to be done by the 30 minutes for each session, twice per week over a 4-week period.
~Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).
~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
16259514|NCT04959747|Placebo Comparator|sham-acupuncture group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion. Its validity and credibility have been well demonstrated."
16259516|NCT04959734||LRTI|Infants less than 2 years who the clinician has diagnosed a viral or bacterial lower respiratory tract infection
16259517|NCT04959734||Wheeze|Infants less than 2 years who the clinician has diagnosed the first presentation of a viral wheeze
16259518|NCT04959721|Experimental|Injection group|Patients in the injection group will be injected 10 mg (0.25 mL) of triamcinolone acetonide, mixed with 0.25 mL of 0.125% bupivacaine and 0.5 mL of normal saline.
16259519|NCT04959708|Active Comparator|Control group|Participants in the control group will have the same exposure in time as the intervention group and will be asked to maintain their lifestyle during the whole study and to refrain from starting any new regular physical activity. In case they can not maintain the same lifestyle during the study period, they will be asked to inform the researchers at any of the assessments.
16259520|NCT04959708|Experimental|Intervention group|The intervention group will consist of the Ínsula method. Insula method will be developed twice a week for 12 weeks online form through videoconference platform. The intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
16259521|NCT04959695|Experimental|Prolonged exposure with PE Coach|The mobile application will be incorporated into each PE psychotherapy session and used to support homework between sessions.
16259522|NCT04959695|Active Comparator|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
16259523|NCT04959682|Experimental|Intervention group|Patients in the intervention group will receive 30 minutes of patient-tailored instrumental music in the beginning of one weekly hemodialysis treatment for a period of six weeks
16259524|NCT04959682|No Intervention|Control group|The procedure in the control group is the same as in the intervention group, except that they don't listen to music
16259525|NCT04959669|No Intervention|Control group|Usual care
16259526|NCT04959669|Experimental|Intervention group|DeSSBack (Decision Support System for Low Back Pain)
16259527|NCT04959656||X-ray|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
16259528|NCT04959656||CT|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
16259529|NCT04959656||MRI|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
16259530|NCT04959630|Other|Group A|Group A received first five patient cases and 3D models via DI and another five cases in the VR environment
16259531|NCT04959630|Other|Group B|Group B received first five patient cases and 3D models via VR and another five cases in the DI.
16259532|NCT04959604|Experimental|ICG-marked Colon Carcinoma|The participants will receive an endoscopic marking via ICG preoperatively
16259533|NCT04959591|Experimental|Experimental (Pre): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg after anesthetic induction/before surgical incision and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given at the end of surgery before skin closure.
16259534|NCT04959591|Experimental|Experimental(post): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg at the end of surgery before skin closure and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given after anesthetic induction/before surgical incision.
16259535|NCT04959591|Placebo Comparator|Placebo comparator : placebo|Participants will receive 1.5ml/kg placebo (0.9% saline) before and after surgery and the same dose will be given postoperatively at 8hour intervals for 24hours.
16259536|NCT04959578|Active Comparator|Erythropoietin|Recombinant Human Erythropoietin
16259537|NCT04959578|Experimental|Darbepoetin alfa|Darbepoetin Alpha
16259538|NCT04959565|Experimental|16 online lectures in sports nutrition + 8 individual consultations for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.
~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.
~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
16259539|NCT04959565|No Intervention|Control|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing).
~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation."
16259540|NCT04959565|Experimental|16 online lectures in sports nutrition for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.
~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.
~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
16259541|NCT04959539|Active Comparator|endoscopic transcanal tympanoplasty with attico-antrostomy|
16259542|NCT04959539|Active Comparator|endoscopic assisted canal wall up mastoidectomy|
16259543|NCT04959526|Experimental|Respiratory Function Testing|All subjects will receive standard respiratory function testing and ultrasound-based elastography measurements across various behaviors and conditions
16259544|NCT04959513|Experimental|GBR with L-PRF bone block|Guided bone regeneration using Leukocyte and platelet-rich fibrin
16259545|NCT04959500|Experimental|Experimental group|Experimental: Radiation therapy, Temozolomide and anlotinib Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 10 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
16259546|NCT04959500|Placebo Comparator|control group|Experimental: Radiation therapy, Temozolomide and Placebo Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Placebo will be given with a daily dose of 0 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
16259547|NCT04959487|No Intervention|Standard of care|Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. At the end of follow up, the control arm will receive similar services from POH to what the intervention arm received during the intervention, regardless POH eligibility criteria (6 months of DM-tailored food support to meet 67% of their daily requirements, video recording of the 4 CHEFS-DM education classes, and access to a POH dietitian at their request).
16259548|NCT04959487|Experimental|Food support and nutrition education|The intervention entails two components: 1) food support that consists of weekly medically tailored meals and healthy groceries that on average covers 75% of daily energy requirements from baseline to six months and 2) diabetes-tailored nutritional education that consists of two individual counseling sessions with a Registered dietitian and four group education sessions.
16259549|NCT04959474|Active Comparator|Arm I (standard dietary recommendations, SABR, surgery)|Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
16259550|NCT04959474|Experimental|Arm II (caloric restriction diet, SABR, surgery)|Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
16259551|NCT04959461|Experimental|webCHAT|Single session 20-40minute self-guided web program that discusses promotes healthy decision making around driving and discusses the risks of alcohol and cannabis-influenced driving.
16259552|NCT04959461|Active Comparator|Usual Care|Existing driving school education
16259553|NCT04959435||Case|Behcet's disease patients
16259554|NCT04959435||Controls|Controls that matched two to two at case according to sex,social status and diet.
16259555|NCT04959422|Experimental|Active scheduling|Children who fail instrument vision screens will be scheduled at a community vision specialist office before departure from clinic and all no shows at the vision specialist office will be tracked and rescheduled.
16259556|NCT04959409||Exposed Cohort|Children receiving topical analgesia
16259557|NCT04959409||Control / Unexposed Cohort|Children who do not receive topical analgesia
16259558|NCT04959396|Experimental|Treatment|IUB SEAD procedure
16259559|NCT04959383|Experimental|Low complexity Exergame balance training group|Wobble board based exergame balance training, the game complexity will be low for this group.
16259560|NCT04959383|Experimental|Moderate complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be moderate for this group.
16259561|NCT04959383|Experimental|High complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be high for this group.
16259562|NCT04959383|Active Comparator|Control group|Wii fit based Exergame training on a stable surface
16259563|NCT04959370|Experimental|Dynamic hip screw (DHS)|
16259564|NCT04959370|Active Comparator|Cannulated compression screw (CCS)|
16259565|NCT04959357||coronary microvascular dysfunction group|
16259566|NCT04959357||obstructive coronary artery disease|
16259567|NCT04959357||control group|
16259568|NCT04959344|Experimental|Kleb4V target dose|Study participants receive 2 target doses of the non-adjuvanted investigational product 2 months apart.
16259569|NCT04959344|Experimental|Kleb4V target dose + AS03|Study participants receive 2 target doses of the adjuvanted investigational product 2 months apart.
16259570|NCT04959344|Experimental|Kleb4V low dose|Study participants receive 2 low doses of the non-adjuvanted investigational product 2 months apart.
16259571|NCT04959344|Experimental|Kleb4V low dose + AS03|Study participants receive 2 low doses of the adjuvanted investigational product 2 months apart.
16259572|NCT04959344|Placebo Comparator|Placebo (Diluent)|Study participants receive 2 doses of the Placebo 2 months apart.
16259573|NCT04959331|Active Comparator|Short-course fosfomycin|3 g of fosfomycin once daily for two days (sachets)
16259574|NCT04959331|Active Comparator|Short-course nitrofurantoin|Five-day nitrofurantoin 100 mg t.i.d. (pills)
16259575|NCT04959331|Active Comparator|Short-course pivmecillinam|Three-day pivmecillinam 400 mg. t.i.d. (pills)
16259576|NCT04959331|Active Comparator|Single-dose fosfomycin|Single 3 g dose of fosfomycin (sachet)
16259577|NCT04959318|Experimental|Treatment group or counseling group|The treatment group will receive a counseling intervention addressing metabolic syndrome (comprised of abdominal adiposity, high blood pressure, high cholesterol, elevated fasting glucose, and elevated triglyceride level) and low vitamin D. This group will undergo baseline body composition measurements, phlebotomy, and an introduction to the digital app for recording diet and activity.
16259578|NCT04959318|Active Comparator|Control group or comparison group|Subjects randomized to the control group will undergo baseline body composition measurements, phlebotomy, and an introduction to the app for recording diet and activity. They will receive a packet of evidence-based pamphlets addressing Service-specific approaches to healthy eating and physical activity (e.g. Performance Triad). There will be no formal recurring interaction with an RD for those randomized to this control group.
16259579|NCT04959305|Experimental|Experimental 1|HCP1803-3
16259580|NCT04959305|Active Comparator|Active Comparator 1|RLD2003
16259581|NCT04959305|Active Comparator|Active Comparator 2|RLD2004
16259582|NCT04959305|Active Comparator|Active Comparator 3|RLD2005
16259583|NCT04959292||Meniscus regeneration|Reconstruction of the anterior cruciate ligament, total or partial meniscus resection was performed in our hospital, and two years after the operation, the meniscus regeneration was found under secondary arthroscopy.
16259584|NCT04959292||Meniscus without regeneration|Anterior cruciate ligament reconstruction, total or partial meniscus resection was performed in our hospital, and two years after the operation, no meniscus regeneration was found under secondary arthroscopy.
16259585|NCT04959279|Experimental|ED-TREAT|EHR-embedded clinical decision support (CDS) tool designed to overcome the challenges to risk assessment and suggest pre-emptive use of behavioral techniques in the emergency setting.
16259586|NCT04959279|No Intervention|Usual Care|
16259587|NCT04959266|Experimental|Arm A|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
16259588|NCT04959266|Experimental|Arm B|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
16259589|NCT04959266|Experimental|Arm C|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
16259590|NCT04959253|Experimental|Psilocybin 25mg PO|
16259591|NCT04959253|Placebo Comparator|Placebo PO|
16259592|NCT04959227||whirling dervish group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
16259593|NCT04959227||control group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
16259594|NCT04959214|Experimental|intervention: progressive relaxation exercise practice group|intervention: progressive relaxation exercise practice group: A group of 30 intensive care nurses who will practice the progressive relaxation exercise at home 3 days a week for 1 month.
16259595|NCT04959214|No Intervention|control: uninterrupted group|control: A group of 30 intensive care nurses who did not intervene for 1 month
16259596|NCT04959201|Experimental|NMDAE plus Antioxidant agent (AO)|An NMDA enhancer plus a drug with antioxidant property
16259597|NCT04959201|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
16259601|NCT04959175|No Intervention|Donors|Collection of research samples on bone marrow donors
16259602|NCT04959175|Experimental|Older, HLA-matched|Subjects age 60-85 with hematologic malignancies and an HLA-matched related or unrelated donor
16259603|NCT04959175|Experimental|Older, HLA-mismatched|Subjects age 60-85 with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
16259604|NCT04959175|Experimental|Younger, HLA-matched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-matched related or unrelated donor
16259605|NCT04959175|Experimental|Younger, HLA-mismatched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
16259606|NCT04959162|Experimental|E-learning preparation|Will receive e-learning prior to a hands-on course in musculoskeletal ultrasound
16259607|NCT04959162|Active Comparator|Conventional preparation|Will receive standard information (time, place etc) prior to a hands-on course in musculoskeletal ultrasound
16259608|NCT04959149|Experimental|face-to-face intubation|intubation approach from front of the patient
16259609|NCT04959149|Active Comparator|standard position intubation|intubation approach from behind the head of the patient
16259610|NCT04959136|Experimental|Ambulatory Monitoring Solution|The evaluable device (Ambulatory Monitoring Solution and its parts) is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
16259611|NCT04959123|Active Comparator|Ropivacaine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mL in each syringe) In the Ropivacaine only group, there is no adrenaline, the syringe loaded with ropivacaine is supplemented to 20 mL with a 0.9% sodium chloride solution"
16259612|NCT04959123|Experimental|Ropivacaine + Epinephrine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mLn each syringe) In the ropivacaine + epinephrine group, 0.1 mL of a 1 mg/mL ampoule of epinephrine is added to each syringe before making up to 20 mL (i.e., 100 µg of epinephrine for 20 mL of final solution, i.e., 5 µg/mL, i.e., 1 : 200000)."
16259613|NCT04959110|Experimental|Acute Liver Failure|Acute liver failure critically ill patients receiving CRRT
16259614|NCT04959110|Experimental|Acute on top Chronic Liver Failure|Acute on top chronic liver failure critically ill patients receiving CRRT
16259615|NCT04959084|Experimental|Acupuncture|Acupuncture group A , consisting of 20 women will be received laser acupuncture therapy and pelvic floor training every other day for 30 min , 3 times per week for 12 sessions
16259616|NCT04959084|No Intervention|Medical|Medical group B, consisting of 20 women will be maintained their ordinary medical treatment
16259617|NCT04959071|Experimental|Group A|Group A included participants who underwent VAC therapy for diabetic Foot ulcers
16259618|NCT04959071|Active Comparator|Group B|Group B included participants who underwent conventional dressings for diabetic foot ulcers
16259619|NCT04959058|Other|Volunteer|This study has only one arm for the brachial plexus evaluation with ultrasound
16284645|NCT04783870|Experimental|Dapagliflozin|Dapagliflozin 10 mg PO QD
16259620|NCT04959045|Experimental|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
16259621|NCT04959045|No Intervention|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
16259622|NCT04959032|Experimental|Lumateperone 42 mg|
16259623|NCT04959032|Placebo Comparator|Placebo|
16259624|NCT04959019|Experimental|Immediate Exercise|immediate participation in 6-week exercise program (intervention)
16259625|NCT04959019|Other|Delayed Exercise|6-week delay (no-intervention control) prior to participating in exercise program
16259626|NCT04959006|Placebo Comparator|Placebo group|Placebo drink - oral bolus (25ml) - colour/taste matched (prune juice/cola/tonic water, 1:1:1 ratio).
16259627|NCT04959006|Experimental|Antioxidant supplement|Experimental condition -oral bolus (25ml) olive extract drink(https://www.oliphenolia.it/uk/)
16259628|NCT04958993|Experimental|Anlotinib combined with concurrent chemoradiotherapy|"Radiotherapy: 1.8-2.0Gy, qd, 54-66Gy, 5 days a week Chemotherapy: squamous cell cancer: paclitaxel + platinum;Adenocarcinoma: pemetrexed + platinum;A cycle of 3W was used, and the appropriate chemotherapy dose was selected by the researcher according to the patient's situation without any restriction on the chemotherapy dose.Pre-induction chemotherapy is allowed.
~Anlotinib: QD, take 2 weeks and stop for 1 week (radiotherapy 1, 2, 4, 5 weeks)"
16259629|NCT04958980|No Intervention|Placebo|The control group will be evaluated in 2 stages: at the beginning and at the end of the study and will be accompanied only with scheduled medical consultations (also simulating the reality of basic health units with a traditional model of care) and the intervention group will undergo evaluations with the multiprofessional team on two occasions (at the beginning and at the end of the study)
16259630|NCT04958980|Active Comparator|Specific and educational guidelines on pathology care (diabetes mellitus)|"Multiprofessional educational guidelines and analysis of the following exams:
~Periodontal record, bleeding rate on and visible plaque;
~Body mass index (BMI): weight (kg) divided by height squared (m²);
~Serum glucose values;
~Glycated hemoglobin;
~Blood count: hemoglobin;
~Urea: male:
~Creatinine male;
~Uric acid;
~Oxalacetic glutamic transaminase;
~Glutamic pyruvic transaminase;
~Total cholesterol and fractions: Cholesterol, Non HDL, LDL, VLDL;
~Triglycerides;
~Type I urine;
~Vitamin D3 25OH;
~Microalbuminuria;
~Blood pressure: systolic;
~Abdominal circumference."
16259633|NCT04958954||Cohort 1: Pre-COVID|All participants meeting eligibility criteria in the Pre-COVID-19 period (immediately preceding the emergence of COVID-19) (Time Period 1) from 01 December 2018 to 30 November 2019
16259634|NCT04958954||Cohort 2: Active-COVID|All participants meeting eligibility criteria in the Active-COVID-19 period, Pre-Emergency Use Authorization (EUA) period (following the emergence of COVID-19 but before the first COVID-19 vaccine EUA) (Time Period 2) from 01 December 2019 to 10 December 2020 (1 day prior to first United States SARS-CoV-2 vaccine EUA)
16259635|NCT04958954||Cohort 3: Post-EUA|All mRNA-1273 vaccinated participants meeting eligibility criteria in the Post-EUA period (Time Period 3) from date of first United States SARS-CoV-2 vaccine EUA to 31 December 2022
16259639|NCT04958928||Persistent AF Group|
16259640|NCT04958915||30 ° flexion position|Scan the knee at 30° flexion
16259641|NCT04958915||conventional flexion position|Routine body scan of the knee joint
16259642|NCT04958902|Experimental|RESTORE intervention|Participants who screen eligible and consent will receive RESTORE with guidance.
16259643|NCT04958889||HIV+ adults with recent COVID-19 diagnosis|"Required study visits:
~Baseline questionnaire at enrollment or month 1.
~Follow up questionnaire at month 1 and month 4
~Height, weight, vital signs, and blood sampling at month 1 and month 4
~Optional study visits:
~• Follow up questionnaire at month 2, month 6, and month 12"
16259644|NCT04958889||HIV- adults with recent COVID-19 diagnosis|"Required study visits:
~Baseline questionnaire at enrollment or month 1.
~Follow up questionnaire at month 1 and month 4
~Height, weight, vital signs, and blood sampling at month 1 and month 4
~Optional study visits:
~• Follow up questionnaire at month 2, month 6, and month 12"
16259645|NCT04958889||HIV+ adults with no history of COVID-19|"Required study visits:
~Baseline questionnaire at enrollment.
~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.
~Height, weight, vital signs, and blood sampling at enrollment.
~Optional study visits:
~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
16259646|NCT04958889||HIV- adults with no history of COVID-19|"Required study visits:
~Baseline questionnaire at enrollment.
~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.
~Optional study visits:
~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
16259647|NCT04958876|Experimental|SP-104 crossover to naltrexone immediate release|SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
16259648|NCT04958876|Experimental|Naltrexone immediate release crossover to SP-104|Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
16259649|NCT04958863|No Intervention|No Mask|Runners do not use mask while running
16284646|NCT04783870|Placebo Comparator|Control|Placebo PO QD
16259650|NCT04958863|Experimental|Surgical Mask|Runners use surgical mask while running
16259651|NCT04958863|Experimental|Polyester Reusable Mask|Runners use polyester reusable mask while running
16259652|NCT04958837|Experimental|FIFA 11+ with dynamic core stability training|Participants in this group will undergo FIFA 11+ protocol along with additional Core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge will be given. Each exercise plan will be progressively increased.
16259653|NCT04958837|Active Comparator|FIFA 11+ protocol|Participants in this group will undergo traditional FIFA 11+ protocol which consists of slow paced running exercises, strength, plyometric & Balance exercises and high speed running with planting/cutting
16259654|NCT04958824|Experimental|Immediate return of results|The intervention for this study is the delivery of genetic test results that reflect pharmacokinetic and pharmacodynamic effects of specified genetic markers. We will use the Sanford panel being promoted by the VA through a clinical project entitled PHASER. The results are returned to the patient and provider approximately 1 week from randomization.
16259655|NCT04958824|No Intervention|Delayed return of results|In the control arm the genetic test results are not returned until 12 weeks when the main outcome is assessed.
16259656|NCT04958811|Experimental|Tiragolumab plus atezolizumab and bevacizumab|Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.
16259657|NCT04958798|Experimental|Culturally Centered MOUD Implementation|Culturally centered program-level implementation intervention to increase the use of medications for opioid use disorder in healthcare and treatment settings serving AI/AN communities
16259661|NCT04958772|Experimental|Filgrastim Megalabs|Filgrastim Megalabs injectable 5 μg/Kg/day in a single subcutaneous application during 5 days
16259662|NCT04958772|Active Comparator|Granulokine|Granulokine injectable 5 μg/Kg/day in a single subcutaneous application during 5 days
16259663|NCT04958759|Experimental|Functional Inspiratory Muscle Training Group|Functional inspiratory muscle training in patients with chronic kidney disease
16259664|NCT04958759|Experimental|Inspiratory Muscle Training Group|Inspiratory muscle training in patients with chronic kidney disease
16259665|NCT04958759|Experimental|Control Group|Breathing exercises in patients with chronic kidney disease
16259666|NCT04958746|Experimental|Ciprofol|Ciprofol group：0.4/0.2mg/kg
16259667|NCT04958746|Placebo Comparator|Propofol|Propofol group：2.0/1.0mg/kg
16259668|NCT04958733|Active Comparator|Autologous Bone Grafting|Excess bone obtained from graft preparation and the coring reamer will be used to fill the patellar and tibial donor sites.
16259669|NCT04958733|Placebo Comparator|Control|The control group will have their patellar and tibial defects remain unfilled.
16259670|NCT04958720||Cohort 1|Resectable non-advanced cancer
16259671|NCT04958720||Cohort 2|Unresectable advanced cancer
16259672|NCT04958707|Experimental|Informational support group|The participants in the intervention group will be added to a chat group in the Zalo app, created and managed by one investigator, which is named The Dementia Caregiver Support group. Weekly, the investigator will post one of the eight topics identified in Phase 1. Before posting the information, the investigator will ask the participants what topic they would like to read and discuss the week after by voting the answer. The posted information will be based on evidence-based resources and consulted by geriatricians, the neurologist, and the psychologist who specialize in dementia. Immediately after posting the topic, one investigator will call the participants to ensure they read and understand the post. The chat group monitor will also collect the questions or comments from the carers who are encouraged to share their feelings or experiences with relevant questions. Then the monitor will post the answers after consulting with the experts.
16259673|NCT04958707|Active Comparator|Controlled group|The participants will receive usual care, introduced to the website Alzheimer.org to search for eligible information. They will be interview by a questionnaire at baseline, post-intervention and 3 month post-intervention
16259674|NCT04958694|Experimental|CEDARS|Using an adapted stress-reduction intervention called the CEDARS, we will pilot the intervention in adolescents (N=50) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction.
16259675|NCT04958681||Covid-19 history positive|
16259676|NCT04958681||Covid-19 history negative|
16259677|NCT04958668|Active Comparator|Volatile procedere|Intensive care treatment with demand-adapted sedation with volatile anaesthetics
16259678|NCT04958668|No Intervention|Conventional procedere|Conventional Intensive care treatment with demand-adapted sedation with intravenous sedatives
16259679|NCT04958655|Other|Tetris, Positive Image|Participants randomised to order of intervention: this arm has; Tetris (Active Comparator) then Positive Future Image (Intervention).
16259680|NCT04958655|Other|Positive Image, Tetris|Participants randomised to order of intervention: this arm has; Positive Future Image (Intervention) then Tetris (Active Comparator).
16259681|NCT04958642|Experimental|Adrabetadex|All participants receive their prescribed dose of adrabetadex. Dose is allowed to be adjusted down or up to a maximum of 900 mg, at the investigator's discretion.
16259682|NCT04958629||non-FH Group|
16259683|NCT04958629||FH Group|
16259684|NCT04958616||Patients sensitive to HDM|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled.Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
16259685|NCT04958616||Patients not sensitive to HDM allergy.|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled .Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation).
16259686|NCT04958603||Traditional surgery group|Traditionally loosen the lateral support belt proximally
16259687|NCT04958603||New surgery group|"Laterally loosen the outer support belt, that is, L-shaped loosen"
16259688|NCT04958590||1 （asymptomatic）|the middle-aged and elderly Chinese asymptomatic population who underwent the whole spine X-ray in standing and sitting positions.
16259689|NCT04958590||2 （patients）|the patients who underwent posterior lumbar fusion surgery for lumbar degenerative disease has been followed up for three months.
16259692|NCT04958564|Active Comparator|group interlock|Intra medullary device used to treat tibial shaft fractures
16259693|NCT04958564|Active Comparator|group DCP (dynamic compression plate)|dynamic compression plate used to treat tibial shaft fractures
16259694|NCT04958538|Experimental|MTX and corticosteroid|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
16259695|NCT04958525||Endoscopic Surgery Group|After a full evaluation of the patient's condition, the informed consent was signed to perform keyhole neuroendoscopic ultrasound-guided hematoma removal for the patient.
16259696|NCT04958525||Microsurgery group|After a full evaluation of the patient's condition, the informed consent was signed to perform small bone window craniotomy for hematoma removal under microscope for the patient.
16259697|NCT04958512|Other|blank control group|
16259698|NCT04958512|Experimental|treatment group(Yangxue Qingnao pill)|
16259699|NCT04958512|Active Comparator|control group(hidezhen)|
16259700|NCT04958499|Experimental|Bio-Healthy Park|This group is the experimental group. The intervention program consisted in the realization of the program on bio-healthy machinery.
16259701|NCT04958499|No Intervention|Control|Adults and older assigned to the control group will not received any structured exercise programme. They will maintain their usual physical activities.
16259702|NCT04958486|Experimental|Treatment|
16259703|NCT04958473|Experimental|Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
16259704|NCT04958460|Experimental|Probiotics group|"Probiotics
~Candidates conditions excluded:
~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.
~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment
~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.
~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.
~Participated in other clinical research in the past month.
~Vegetarians or those currently undergoing special diet therapy.
~Evaluation by the host is not suitable for entering the test."
16259705|NCT04958460|Placebo Comparator|Control group|"Placebo
~Candidates conditions excluded:
~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.
~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment
~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.
~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.
~Participated in other clinical research in the past month.
~Vegetarians or those currently undergoing special diet therapy.
~Evaluation by the host is not suitable for entering the test."
16259706|NCT04958434|Experimental|Part A - Dose Escalation|Dosed every 3 weeks IV with TST005, starting dose is 1 mg/kg, and 5 dose levels will be tested.
16259707|NCT04958434|Experimental|Part B - Dose Expansion|Participants with any kind of advanced or HPV metastatic solid tumors dosed Q3W with the Part A Q3W recommended dose of TST005
16259708|NCT04958421|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
16259751|NCT04958109|Placebo Comparator|Placebo|• Intravenous administration of placebo x 16 hours
16284870|NCT04782323|Experimental|Group E aQII-9 Investigational|
16259709|NCT04958421|Experimental|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
16259710|NCT04958395||Myocardial bridge|Measure FFR and d-FFR
16259711|NCT04958382|Experimental|Ciprofol|
16259712|NCT04958382|Placebo Comparator|placebo|
16259713|NCT04958369|Active Comparator|Ultrasound-guided axillary venous access|Cardiac device implantation will be performed with ultrasound-guided axillary venous access.
16259714|NCT04958369|Active Comparator|Cephalic venous access|Cardiac device implantation will be performed with conventional cephalic venous access (cut-down technique).
16259715|NCT04958356||Children with increased risk for T1D and/or CeD|The participants carrying HLA-conferred susceptibility to type 1 diabetes will be screened annually for four diabetes predictive autoantibodies and followed up to 1-3 years of age. The participants carrying HLA-conferred susceptibility to celiac disease are screened for tissue transglutaminase antibodies (tTGA) at the age of 1 and 3 years. If a child tests positive for such autoantibodies, endomysial antibodies will be analyzed.
16259716|NCT04958343||reconstruction group|Patients will receive pelvic reconstruction following radical cystectomy during the operation.
16259717|NCT04958343||non-reconstruction group|Patients will not receive pelvic reconstruction following radical cystectomy during the operation.
16259718|NCT04958330||lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
16259719|NCT04958330||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles or lateral prostate capsule) during the operation.
16259720|NCT04958317|Placebo Comparator|Early exercise|Participants will exercise for 30 minutes prior to an evening meal
16259721|NCT04958317|Experimental|Late exercise|Participants will exercise for 30 minutes after an evening meal
16259722|NCT04958304||Moderna COVID-19 Vaccine in Pregnant Women|The Moderna COVID-19 Vaccine Pregnancy Registry will collect primary data from pregnant women who have received the Moderna COVID-19 vaccine and their healthcare providers (HCPs).
16259723|NCT04958291|Experimental|Administration of Dose A of CC-99677 or Placebo|Administration of Dose A of CC-99677 or Placebo
16259724|NCT04958291|Experimental|Administration of Dose B of CC-99677 or Placebo|Administration of Dose B of CC-99677 or Placebo
16259725|NCT04958291|Experimental|Administration of Dose C of CC-99677 or Placebo|Administration of Dose C of CC-99677 or Placebo
16259726|NCT04958265|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.
16259727|NCT04958252|Experimental|Single dose part: BI 1569912 low dose|
16259728|NCT04958252|Experimental|Single dose part: BI 1569912 lower medium dose|
16259729|NCT04958252|Experimental|Single dose part: BI 1569912 higher medium dose|
16259730|NCT04958252|Experimental|Single dose part: BI 1569912 high dose|
16259731|NCT04958252|Experimental|Multiple dose part: BI 1569912|Additional dose group for multiple dose part may be added based on experience gained during the single dose part
16259732|NCT04958252|Placebo Comparator|Placebo|
16259733|NCT04958239|Experimental|Arm A: BI 765179|
16259734|NCT04958239|Experimental|Arm B: BI 765179 + ezabenlimab|
16259735|NCT04958226|Experimental|Treatment (Midazolam + Capivasertib)|Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
16259736|NCT04958213|Other|Conventional physical therapy|Conventional physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises) will be applied to this group for 4 weeks (20 sessions).
16259737|NCT04958213|Active Comparator|Dextrose prolotherapy treatment|This group will be treated with 15% dextrose prolotherapy around and inside the knee, 2 times with a two-week interval, and home exercise program (isometric and isotonic exercises).
16259738|NCT04958200|Experimental|mhealth-pc for alcohol and chronic pain|Smartphone-based intervention
16259739|NCT04958200|Active Comparator|Treatment As Usual|In person session that provides enhanced treatment as usual
16259740|NCT04958187|Experimental|ANG-3777|Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
16259741|NCT04958174||Users|Users of the web-application
16259742|NCT04958161|Experimental|Exercise Therapy|Exercise therapy will be performed three times per week for 12 weeks.
16259743|NCT04958161|No Intervention|Wait List Control|Wait-list-control participants will be asked to continue their normal activities over the 12 week period.
16259744|NCT04958148|Experimental|High sodium|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 4,300 mg/d sodium for 4 weeks.
16259745|NCT04958148|Placebo Comparator|Placebo|Subjects will be counseled to consume a diet with 2,300 mg/d sodium and will supplement with taking placebo pills for 4 weeks.
16259746|NCT04958135|Experimental|Sequence 1: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:
~Period 1: Acoramidis as an immediate-release tablet under fasted conditions.
~Period 2: Acoramidis as an immediate-release tablet under fed conditions.
~There will be a washout period of at least 14 days between acoramidis dosing."
16259747|NCT04958135|Experimental|Sequence 2: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:
~Period 1: Acoramidis as an immediate-release tablet under fed conditions.
~Period 2: Acoramidis as an immediate-release tablet under fasted conditions.
~There will be a washout period of at least 14 days between acoramidis dosing."
16259748|NCT04958122|Experimental|Cefixime|Oral cefixime 400mg, taken twice a day for 10 days
16259749|NCT04958122|Active Comparator|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
16259750|NCT04958109|Experimental|Kisspeptin|• Intravenous administration of kisspeptin 112-121 x 16 hours
16259752|NCT04958096|Experimental|Prefrontal Cortex (PFC)|The Prefrontal Cortex (PFC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the PFC.
16259753|NCT04958096|Experimental|Anterior Cingulate Cortex (ACC)|The Anterior Cingulate Cortex (ACC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the ACC.
16259754|NCT04958083|Experimental|aortopathy patient|Patients who have proximal aortic conditions and are referred to the aortic team in Royal Brompton and Harefield Hospitals will be screened for eligibility. For this pilot study and in view of the volume of aortic surgery in the Trust (approx. 100 cases per year), 30 patients will be recruited in the first year of this project to be followed for at least one year for clinical outcomes.
16259755|NCT04958057|No Intervention|Routine prenatal care|Routine prenatal care: All women participating in the study will receive routine prenatal care by their obstetric provider, consisting of 1 prenatal visit a month up to 28 weeks of gestation, 1 prenatal visit every 2 weeks during 28-36 weeks and weekly visits during 36-40 weeks.
16259756|NCT04958057|Experimental|SAIL intervention|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
16259757|NCT04958044|Experimental|Calcium electroporation|Calcium gluconate 0.23 mmol/ml Maxium dosage 20 ml Intra tumoral injection
16259758|NCT04958031|Experimental|CVL-871 1.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 1.0 milligrams (mg) until Day 85 during the treatment period.
16259759|NCT04958031|Experimental|CVL-871 3.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 3.0 milligrams (mg) until Day 85 during the treatment period.
16259760|NCT04958031|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-871 tablets orally QD until Day 85 during the treatment period.
16259765|NCT04957992|Active Comparator|Control Feeding Group|Milk based product
16259766|NCT04957992|Experimental|Experimental Feeding Group|Milk based product with oligosaccharides
16259767|NCT04957979||Nursing/Medical Model of Care Coordination|Someone with medical/nursing training coordinates involvement of various medical resources and provides patients with education, self-management support, and referrals to community resources.
16259768|NCT04957979||Medical/Social Model of Care Coordination|In addition to the services provided in the Medical/Nursing Model, a social worker by education has dedicated FTE as a member of the care team at the clinic, providing some direct services for care coordination patients and either spending some time on-site or in regular communication with its clinicians in addition to providing social work services.
16259769|NCT04957966|Experimental|Music listening vs. No music listening|Random assignment (50:50) of every participant to one of the following two conditions: Music listening after a stressful/discriminatory event (i.e., intervention condition) or no music listening after a stressful/discriminatory event (i.e., control condition).
16259771|NCT04957940|Experimental|SMOF lipid 20% IV infusion|Intravenous fish-oil-based lipid (SMOF lipid 20%) emulsion supplementation to standard enteral nutrition.
16259772|NCT04957940|Placebo Comparator|Saline placebo IV infusion|Intravenous 0.9% saline supplementation to standard enteral nutrition.
16259773|NCT04957927|Experimental|Intranasal Fluticasone Propionate Group|Intranasal Fluticasone Propionate 50mcg/actuation in each nostril 24 hourly
16259774|NCT04957927|Experimental|Montelukast Group|Montelukast 4mg oral granule formulation 24 hourly
16259775|NCT04957914|Active Comparator|Insulin Glargine (Period 1)|Insulin glargine administered subcutaneously (SC).
16259776|NCT04957914|Experimental|LY3209590 (Period 2)|LY3209590 administered SC.
16259777|NCT04957888||training group|the observational group to find out the potential biomarker
16259778|NCT04957888||validation group|the validation group to validate the parameters used for early diagnosis
16259779|NCT04957875||urgent endoscopy group|endoscopy <6h after admission
16259780|NCT04957875||early endoscopy group|endoscopy 6-24h after admission
16259781|NCT04957862|Active Comparator|Surgery Group|For patients who choose early conservative treatment, after the hematoma enters the subacute stage, complete the relevant imaging examinations and perform robotic minimally invasive aspiration.
16259782|NCT04957862|No Intervention|Conservative treatment Group|Patients who are unwilling to undergo surgery and have hemorrhage in the deep functional area of the brain within 30ml.
16259783|NCT04957849|Active Comparator|Trans-frontal keyhole approach|After general anesthesia, the patient was placed in supine position with head frame fixed. A straight or arc incision was made in the hairline of the affected side. The incision was 3cm beside the midline. The length of the incision was about 4cm and the diameter of the bone window was about 2.5cm. According to the preoperative thin-layer CT scan, the dura mater and part of the cerebral cortex were cut, and the endoport and other hard channels were inserted. The incision reached 2 / 3 of the length of the hematoma along the direction parallel to the long axis of the hematoma, During the operation, mini aneurysms were clipped to close the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity. The external drainage tube led out the skin through the subcutaneous tunnel, and the dura was sutured.
16259815|NCT04957589|Experimental|VLCD & HIIT|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) No additional protein supplementation
16260281|NCT04954209||Non hospital program of resumption|Program of resumption outside hospital with discovery sessions
16259784|NCT04957849|Active Comparator|Trans-occipital keyhole approach|After general anesthesia, the patient was placed in prone position with head frame fixed. According to the preoperative thin-layer CT scan, the long axis of hematoma was perpendicular to the ground, and the occipital puncture point was found along the extension line of the long axis of hematoma. Taking the puncture point as the center, a straight or arc incision parallel to the sagittal sinus was taken. The length of the incision was about 4cm, and the diameter of the bone window was about 2.5cm, Endoport and other hard channels were inserted to reach 2 / 3 of the long diameter of the hematoma along the direction parallel to the long axis of the hematoma. Under the neuroendoscope, the hematoma was aspirated or resected in blocks. During the operation, mini aneurysm clamp was used to clamp the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity.
16259785|NCT04957823||Diseased|type II diabetic patients with documented coronary artery disease.
16259786|NCT04957823||Control|type II diabetic patients without coronary artery disease.
16259787|NCT04957810|No Intervention|Patients who are given regular home functional exercises and discharged from the hospital|Discharge guidance using regular home function exercises, that is, existing regular missions and paper-based brochures
16259788|NCT04957810|Active Comparator|Patients who are guided by conventional discharge guidance and the optimized WeChat official account|Use regular discharge guidance and optimized WeChat public account guidance
16259789|NCT04957797|Other|ROT-Group|reamed with round tunnel
16259790|NCT04957797|Experimental|FLT-Group|reamed with flat tunnel
16259791|NCT04957771|Experimental|Regular exercise group|
16259792|NCT04957771|No Intervention|non-regurlar exercise group|
16259793|NCT04957758|Active Comparator|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
16259794|NCT04957758|Placebo Comparator|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray
16259795|NCT04957745|Other|Visual confusion|The study participants will respond to various visual confusion stimuli presented on a stereoscopic display designed to simulate binocular/monocular visual confusions
16259796|NCT04957732|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, Standard of Care (SoC), which was normal saline, was used.
16259797|NCT04957732|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
16259798|NCT04957719|Experimental|Selatogrel|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
16259799|NCT04957719|Placebo Comparator|Placebo|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
16259800|NCT04957706||Acute injury|injury ≤ 2 months
16259801|NCT04957706||Chronic injury|injury > 2 months
16259802|NCT04957693|Experimental|treatment arm|vegan diet and lifestyle change
16259803|NCT04957680|Experimental|computer-based cognitive behavioral therapy|
16259804|NCT04957680|Active Comparator|online stress management program|
16259805|NCT04957680|No Intervention|waitlist|
16259806|NCT04957654|Experimental|VST with collagen plug soaked in blood|
16259807|NCT04957654|Active Comparator|VST with Allograft Demineralized bone matrix Grafton|
16259808|NCT04957654|Active Comparator|VST with autogenous cortical chips and bovine deprotinzed particles|
16259809|NCT04957641||Participants with HAE|Participants' data will be collected retrospectively from electronic medical records using chart review of de-identified data on participant demographics, HAE medical history and information on diagnostics, treatments and disease course assessments that are routinely performed in accordance with current guidelines and/or local standard of care which are entered into an Electronic data capture (EDC) system over multiple data collection waves up to 6 months.
16259810|NCT04957628||Control group|2500 participants will be recruited before the intervention procedures are implemented at the respective hospitals. Baseline data on alcohol, psychoactive medicinal and illicit drug use (AUDIT-4 and DUDIT), stages-of-change questionnaire on alcohol, medicinal drugs and illicit drug use, and mental distress will be recorded. Left-over full blood from routine diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the control group will receive acute medical treatment according to hospital procedures. After 12 months, the data from baseline will be coupled to data from patient journals and data from relevant registries.
16259811|NCT04957628||Case group|2500 participants will be recruited after the intervention procedures are implemented. Baseline data on alcohol, psychoactive medicinal and illicit drug use, stages-of-change questionnaires, and mental distress will be recorded. Left-over blood from diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the case group will receive treatment according to new hospital procedures, including screening for harmful alcohol use and non-prescribed use of psychoactive medicinal drugs and intervention. If feasible, a new blood sample will be collected 2 months after inclusion, which will be analyzed for PEth. After 12 months, the data from baseline will be coupled to patient journals and relevant registries.
16259812|NCT04957615|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16259814|NCT04957589|Experimental|VLCD & HIIT & protein supplementation|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, no free expenditure) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) 200kcal/day whey protein supplementation
16259916|NCT04956900|Experimental|Aurase wound gel X2.5|Cohort 3: Aurase wound gel X2.5 dose concentration
16284871|NCT04782323|Experimental|Group F aQII-10 Investigational|
16259816|NCT04957589|Active Comparator|VLCD only|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) No additional exercise or protein supplementation
16259817|NCT04957576|Sham Comparator|Asynchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in an asynchronous way, i.e. with a time-delay between one hand-touch and the other
16259818|NCT04957576|Experimental|Synchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in synchronously, i.e. without a time-delay between one hand-touch and the other
16259819|NCT04957563|Experimental|experimental rehabilitation|recived olfactory rehabilitation
16259820|NCT04957563|No Intervention|control|withouth olfactory rehabilitation
16259821|NCT04957550|Experimental|Treatment group A|SHR0302 tablets dose 1+ Placebo dose 2
16259822|NCT04957550|Experimental|Treatment group B|SHR0302 tablets dose 2+ Placebo dose 1
16259823|NCT04957550|Placebo Comparator|Treatment group C|Placebo dose1 + placebo dose 2
16259824|NCT04957537|Other|6 weeks phase A|"According to SCED methodology design :
~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 weeks (i.e. 18 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
16259825|NCT04957537|Other|8 weeks phase A|"According to SCED methodology design :
~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 8 weeks (i.e. 24 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
16259826|NCT04957524|Active Comparator|Set Amplitude|This arm is to test a specific amplitude. Participants will be instructed to set the amplitude to 20 mA, frequency to 20 Hz, and pulse duration to 5 mS. The parameters will stay the same for the entire session. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
16259827|NCT04957524|Experimental|Customizable Amplitude|In this arm, the participant will set the frequency to 12 Hz and pulse duration to 1 millisecond. The participant will be instructed to increase the amplitude gradually and set it at the maximal tolerable amplitude. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
16259828|NCT04957498|Active Comparator|FBT|Family Based Treatment (FBT) includes up to 15 session (50-60 minutes) with a trained therapist.
16259829|NCT04957498|Experimental|FBT-GSH|Family Based Treatment Guided Self-Help (FBT-GSH) includes an online website with educational videos, readings, discussion groups, and journals. Parents assigned to this arm will have up to 12 coaching sessions (20-30 minutes) with a trained therapist.
16259830|NCT04957485|Active Comparator|JYNNEOS + TPOXX|An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours [±30 minutes]) for 28 days and a single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29. JYNNEOS will be administered with TPOXX concomitantly on Day 1
16259831|NCT04957485|Placebo Comparator|JYNNEOS + matching TPOXX placebo|An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours [±30 minutes]) for 28 days and a single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29. JYNNEOS will be administered with TPOXX placebo concomitantly on Day 1.
16259832|NCT04957446|Experimental|Group 1|Subjects will receive 3 treatments of 1mL Poly-L-Lactic Acid (Sculptra Aesthetic)
16259833|NCT04957446|Placebo Comparator|Group 2|Subjects will receive 3 treatments of 1mL Saline solution.
16259834|NCT04957433||Cohort A|Patients new to The Lung Health Check (TLHC) pilot who are attending their first lung health check
16259835|NCT04957433||Cohort B (Nodule Suveillance)|Patients who have already undergone one lung health check as part of the TLHC programme, and are now being followed up at 3 months (B1), 12 months (B2) or other (BX) due to an indeterminate finding (e.g. lung nodule)
16259836|NCT04957433||Cohort C (Incident Scan)|Patients who are already part of TLHC attending for routine 'incident' round follow-up scanning (usually at approximately 24 months)
16259837|NCT04957433||Cohort D|Participants with interstitial lung abnormalities (ILAs) identified as part of TLHC, who are referred to the interstitial lung disease (ILD) unit at Royal Brompton Hospital.
16259838|NCT04957420||Neupro gruop|Patients using Neupro according to the standard clinical practice of therapists
16259839|NCT04957407||non-atrophic gastritis|OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)
16259840|NCT04957407||mild-moderate atrophic gastritis|OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)
16259841|NCT04957407||severe atrophic gastritis|OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)
16259842|NCT04957407||gastric cancer|gastric cancer
16259843|NCT04957394|Experimental|Experimental (Family Partner)|The treatment group will receive six hours follow-up and support weekly. The service will be provided by a dedicated Family Partner.
16259844|NCT04957394|No Intervention|Control group|"The control group will receive defult support from the child welfare services. The service will be business as usual, provided by the local staff at the child welfare services."
16259845|NCT04957381||low to moderate CRF with low MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and low muscular fitness (MF).
16259846|NCT04957381||low to moderate CRF with moderate MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and moderate muscular fitness (MF).
16259847|NCT04957381||low to moderate CRF with high MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and high muscular fitness (MF).
16259848|NCT04957381||high CRF with low to moderate MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and low to moderate muscular fitness (MF).
16259849|NCT04957381||high CRF and high MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and high muscular fitness (MF).
16259850|NCT04957368|Experimental|Nitrous Oxide + saline solution|
16259851|NCT04957368|Active Comparator|Oxygen + Midazolam|
16259917|NCT04956900|Experimental|Aurase wound gel X5|Cohort 4: Aurase wound gel X5 dose concentration
16259918|NCT04956900|Experimental|Aurase wound gel X9|Cohort 5: Aurase wound gel X9 dose concentration
16259852|NCT04957355|Experimental|Experimental|"All individuals will be assigned to the experimental group and will undergo the testing and training procedure across two separate sessions. During the first session, the participants will go through the complete initial screening process. If eligible for the study, the participants will perform the experimental training protocols during the second session.
~Experimental Protocol The quadriceps, hamstrings, tibialis anterior, gastrocnemius, and the trunk muscle group on the stroke-affected side (weaker side) will be stimulated according to the participant's comfort and tolerance. The range of the intensity allowed by the device is 0-50milliamperes (mA). The frequency of the electrical stimulation device ranges from 1-60Hz."
16259853|NCT04957342|Active Comparator|Sutures|Patients assigned to Sutures group will not have the allograft placed on the donor site. One current clinical standard of practice is to place sutures on donor site. Patients assigned to Sutures group will have sutures placed on donor site.
16259854|NCT04957342|Experimental|Allograft and Sutures|Patients assigned to Allograft and Sutures will have allograft placed and secured with sutures on the donor site.
16259855|NCT04957329|Active Comparator|BAK-preserved|Xalatan eye drop
16259856|NCT04957329|Active Comparator|Preservative-free|Monoprost eye drop
16259857|NCT04957316|No Intervention|Control group|Conventional treatment of severe septic shock.
16259858|NCT04957316|Experimental|Blood purification group|Conventional treatment of severe septic shock and blood purification.
16259859|NCT04957290|Experimental|Part 1: Dose Cohort 1: NOX66 800 mg|
16259860|NCT04957290|Experimental|Part 1: Dose Cohort 2: NOX66 1200 mg|
16259861|NCT04957290|Experimental|Part 1: Dose Cohort 3: NOX66 1600 mg|
16259862|NCT04957290|Experimental|Part 1: Dose Cohort 4: NOX66 2400 mg|
16259863|NCT04957290|Experimental|Part 2: Arm 1: Patients with mCRPC (RP2D NOX66)|
16259864|NCT04957290|Experimental|Part 2: Arm 2: Patients with BC and NSCLC (RP2D NOX66)|
16259865|NCT04957277|Experimental|load modulation|Participants will experience different body weight loading conditions - with body weight added by a weighted vest or removed using the ZeroG overhead harness.
16259866|NCT04957251|Experimental|Anterior approach|Patient's undergoing an anterior approach to the hip
16259867|NCT04957251|Active Comparator|Posterior Approach|Patient's undergoing an posterior approach to the hip
16259868|NCT04957238|Experimental|ARBORea decision-making tool|After a period of presentation and training on the dedicated decision-making tool (face-to-face, video and paper supports), nurses will be asked to use ARBORéa decision tree. This will be in the form of an electronic file and will give a suggestion of whether or not to use physical restraints. This is based on an algorithm based on specific and mandatory elements (neurological state : RASS (Richmond assessment sedation scale) and CAM-ICU (confusion assessment method-ICU) scores, modification of sedation dosage, equipment levels, presence and adhesion of the family) that will be completed online. ARBORea's suggestion will be collected as well as final caregiver's decision in order to evaluate relevance of the tool. Observations will also be made at least every 8 hours. This period will also be of random duration (stepped wedge)
16259869|NCT04957238|No Intervention|Subjective physical restraints use|After study presentation and required data collection description, nurses will complete elements related to ARBORea's tool variables, and inform their actual practices of physical restraints use, at least every 8 hours. ARBORea data concern patient's neurological state (RASS and CAM-ICU scores) and changes in sedation doses. The conditioning will then be filled in to stratify the risk incurred. Pain management will be notified. Finally, the presence and involvement of the families will be collected. Other data, relating to working conditions of the nurses will be collected: nurse to patient ratio, special and time consuming events (new patient admission, in ICU emergencies, need to conduct a patient to CT-scan facility or operative room, change of patient's equipment). Nurse seniority in ICU will be specified. Incidents that have occurred (fall, self-injury, removal of a level C2 equipment). The random duration of this control period will be determined by stepped wedge sequencing.
16259870|NCT04957225|Experimental|Direct intervention|Goal level 60 hours of intensive treatment during 6 weeks. Intensive treatment of aphasia and AOS in ICAP-format (MIRAA).
16259871|NCT04957225|No Intervention|Waiting group|No intervention during 6 weeks, testing directly before and after the waiting period. After the waiting period the participants receives the same intervention as the direct intervention arm.
16259872|NCT04957212|Experimental|TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; pertuzumab® (CinnaGen Co.) is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
16259873|NCT04957212|Active Comparator|TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; Perjeta® is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
16259874|NCT04957199||Community|Individuals with or without COVID-19 in society
16259875|NCT04957186|Active Comparator|Patient Focus Group|Group consisting of 10 patients who have undergone breast cancer surgery (tumorectomy, mastectomy, lymph node dissection).
16259876|NCT04957186|Active Comparator|Caregiver Focus Group|Group consisting of 10 caregivers composed of 3 surgeons, 3 algologists, 3 oncologists and one study coordinator.
16259877|NCT04957173|Other|Intensive lifestyle intervention|Participants will undergo an intensive lifestyle intervention, implemented virtually by a medical team with expertise in the management of T2DM. This team will be made up of an endocrinologist, a nutritionist and a nurse.
16259878|NCT04957160||Cohort 1|
16259879|NCT04957160||Cohort 2|
16259880|NCT04957147||Group A: patients with dilated cardiomyopathy|Patients with recent-onset dilated cardiomyopathy
16259881|NCT04957147||Group B: healthy volunteers|Healthy volunteers with no known heart disease
16259984|NCT04956406|Experimental|MIAKTR|MIAKTR is an acronym that defines Motivational Interviewing for Adult Kidney Transplant Recipients
16259882|NCT04957134|Experimental|Electro-acupuncture with lifestyle intervention|Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.While the intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
16259883|NCT04957134|Placebo Comparator|Sham electro-acupuncture with lifestyle intervention|Participants will receive the treatment of sham electro-acupuncture 3 times a week to fulfill a 8-session treatment course, A superficial skin penetration (2-3 mm in depth) at nonacupoints will be performed in the sham acupuncture group, without needle manipulation for De qi. The internal output power cord of the electrical acupuncture stimulation instrument is interrupted.The intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
16259884|NCT04957121||on-hours|"Hip surgeries with the start time of anesthesia between 8:00 and 17:59 were coded as on-hours."
16259885|NCT04957121||off-hours|"Hip surgeries with anesthesia beginning between 18:00 and 7:59 were coded as off-hours. Besides, taking the long duration of hip surgery into account, if the anesthesia began before 18:00 but ended after 20:00, it was also defined as off-hours."
16259886|NCT04957108||All cardiac implantable devices|Assessed separately by Pacemaker ID app and cardia-x algorithm
16259889|NCT04957082|Active Comparator|White Flint Registry: General|"White participants receive general consumption video information about SARS-CoV-2 antibody testing."
16259890|NCT04957082|Active Comparator|African American Registry: General|"African American participants receive general consumption video information about SARS-CoV-2 antibody testing."
16259891|NCT04957082|Experimental|African American Registry: Culturally Targeted|African American participants receive culturally targeted video information about SARS-CoV-2 antibody testing.
16259892|NCT04957069||Avulsion fracture|avulsion fracture of the Achilles tendon
16259893|NCT04957069||Rupture|Achilles tendon rupture
16259894|NCT04957056||Study object|A young patient hospitalized in the Department of Neurosurgery of the Third Hospital of Beijing University of Medicine underwent CT examination of cervical vertebrae. The patient had no cervical bony deformity, no cervical degeneration, and no history of trauma
16259895|NCT04957030|Experimental|ULDCT group|underwent ultralow-dose chest CT(ULDCT)
16259896|NCT04957030|No Intervention|LDCT group|underwent conventional chest CT(LDCT)
16259897|NCT04957017|Active Comparator|Intervention group|"The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled with the volunteer ones face-to-face at their homes, complying with the social distance rules before the training. After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training. The data collection forms were re-filled three months after the training."
16259898|NCT04957017|No Intervention|Control group|The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled face-to-face at their homes with the ones volunteering to participate in the study, complying with the social distance rules. The same survey was re-filled after three months. No training was given to the women with chronic disease during the three-month period. After the research was completed, a 45 minute-training which is the same with the one provided to the intervention group was given individually to the control group, complying the social distance rules.
16259899|NCT04957004||OSA patients|Patients with OSA who have not been treated with CPAP
16259900|NCT04957004||control group|health control except OSA by using sleep monitorin
16259901|NCT04956991||CDAI≤220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group A (CDAI≤220)
16259902|NCT04956991||CDAI>220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group B (CDAI>220)
16259903|NCT04956978|Experimental|Patient Decision Support Tool|Patient decision support tool to be used in conjunction with physician counseling to discuss the risk and benefits of systemic oral anticoagulation.
16259904|NCT04956978|No Intervention|Usual Healthcare Counseling|Traditional physician counseling regarding the risk and benefits of systemic oral anticoagulation
16259905|NCT04956965|Active Comparator|Patient free cardiac amyloidosis|Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.
16259906|NCT04956965|Experimental|Patient with Transthyretin cardiac amyloidosis|Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).
16259907|NCT04956952|Other|Enhanced External Counterpulsation (EECP)|1 hour of treatment with EECP
16259908|NCT04956939||Group 1|PD patients receiving low frequency dose of levodopa.
16259909|NCT04956939||Group 2|PD patients receiving high frequency dose of levodopa.
16259910|NCT04956939||Control Group|Spouses of PD patients without PD diagnosis
16259911|NCT04956926|Experimental|JS201|
16259912|NCT04956913||Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
16259913|NCT04956913||Machintosh|Patients of this group were intubated using the classic Macintosh laryngscoscope
16259914|NCT04956900|Experimental|Aurase wound gel X0|Cohort 1: Aurase wound gel x0 dose concentration
16259915|NCT04956900|Experimental|Aurase wound gel X1|Cohort 2: Aurase wound gel x1 dose concentration
16259919|NCT04956887|Experimental|Intervention|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
16259920|NCT04956887|Placebo Comparator|Placebo|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning.
16259921|NCT04956874|Experimental|Experimental Group|Participants will complete the FL-REACH annualized caregiver intervention.
16259922|NCT04956874|No Intervention|Control Group|No-intervention control group
16259923|NCT04956861|No Intervention|Phase 1|Phase 1 is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 7 hours/night (short sleep).
16259924|NCT04956861|Experimental|Phase 2|Phase 2 is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep less than 7 hours/night.
16259925|NCT04956848|No Intervention|Embryo selection supported by KIDScore™ D5|Each embryo reaching at least developmental stage of 3BB will annotated by an embryologist using the parameters required by the KIDScore™ D5. The embryo with the highest KIDScore™ will be selected proposed for transfer.
16259926|NCT04956848|Experimental|Embryo selection supported by iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed selected for transfer.
16259927|NCT04956822||ALS|Amyotrophic lateral sclerosis group
16259928|NCT04956822||CMT|peroneal muscular dystrophy group
16259929|NCT04956822||KD|Kennedy's disease group
16259930|NCT04956822||Control|Healthy control group
16259933|NCT04956796||Group A|At the beginning of Phase 1, participants from Group A will be exposed to the video airway library in addition to the conventional airway training. At the beginning of Phase 2, participants will continue with conventional airway training only. Each phase will last for 1 month.
16259934|NCT04956796||Group B|At the beginning of Phase 1, participants from Group B will be exposed to the conventional airway training only. At the beginning of Phase 2, the participants in Group B will be exposed to the video airway library. Each phase will last for 1 month.
16259935|NCT04956770|Experimental|Rehabilitation supported by TESS|"Patient will be asked to come to the hospital for three types of patient sessions:
~Stimulation configuration sessions: TESS protocols will be setup and optimized during this phase.
~Duration: minimum 4 sessions over 2 weeks, maximum 20 sessions over a month. In addition, some sessions at a free frequency as needed during rehabilitation will be programed (maximum once a week).
~TESS-supported rehabilitation sessions: Patients will undergo an in-clinic rehabilitation training regime supported by TESS.
~Duration: 24 sessions spread over minimum three months and maximum five months
~Pre- and post-rehabilitation evaluation sessions: four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits."
16259936|NCT04956757|Experimental|Intervention Group|"exercise program consists of progressive scapula retraction exercises will be applied two times a week total 24 sessions.
~Home exercise program will also advised two times a day."
16259937|NCT04956757|No Intervention|Control Group|Control group will not perform scapula retraction exercises. AHD values of the control group will be compared to intervention groups both retracted and non-retracted conditions.
16259938|NCT04956744|Experimental|Low Dose|Low dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
16259939|NCT04956744|Experimental|High Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
16259940|NCT04956744|Experimental|Optional Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1 and at Month 6.
16259941|NCT04956731|Experimental|Pharmacist provision of medication abortion|This is a single arm study with 10 participants undergoing start to finish medication abortion provided by a pharmacist.
16259944|NCT04956705|Experimental|The Model for Improvement|Together with the health care staff at the nursing homes, the project group will identify which strategies to implement in order to increase the number of residents receiving the recommended daily supplements of 20 µg of vitamin D and 800-1000 mg of calcium. The Model for Improvement will be the methodological framework for defining, implementing, and evaluating strategies.
16259985|NCT04956406|Active Comparator|Control Group|routine care
16260282|NCT04954196|Experimental|Amlodipine arm|Single dose per os Amlodipine 5mg administration per day
16259947|NCT04956679||Family members in the study|Community groups that meet the inclusion criteria
16259948|NCT04956666|Experimental|Lyophilized S95014|"Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL.
~The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water For Injection to obtain a 750 U/mL solution for single use."
16259949|NCT04956653||Patients diagnosed with Cervical Degenerative Disease|Patients who suffered from Cervical Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to CDD group.
16259950|NCT04956653||Patients diagnosed with Thoracic Degenerative Disease|Patients who suffered from Thoracic Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to TDD group.
16259951|NCT04956653||Patients diagnosed with Lumbar Degenerative Disease|Patients who suffered from Lumbar Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to LDD group.
16259952|NCT04956640|Experimental|LY3537982 (Dose Escalation)|LY3537982 administered orally.
16259953|NCT04956640|Experimental|LY3537982 (Dose Expansion)|LY3537982 administered orally either alone or with another investigational agent.
16259954|NCT04956627|Experimental|BMS-986166|
16259955|NCT04956627|Experimental|BMS-986166 + Itraconazole|
16259956|NCT04956627|Experimental|BMS-986166 + Phenytoin|
16259957|NCT04956627|Experimental|BMS-986166 + Gemfibrozil|
16259958|NCT04956614|Experimental|suture of Achilles tendon without immobilisation|
16259959|NCT04956614|Experimental|suture of Achilles tendon with immobilisation|
16259960|NCT04956601|Experimental|VBT|CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
16259961|NCT04956601|Active Comparator|EBRT|Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.
16259962|NCT04956588|Experimental|experimental group|
16259963|NCT04956588|Active Comparator|control group|
16259964|NCT04956575|Experimental|mRNA-1010 Dose Level A|Participants will receive mRNA-1010 at dose level A by intramuscular (IM) injection on Day 1.
16259965|NCT04956575|Experimental|mRNA-1010 Dose Level B|Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
16259966|NCT04956575|Experimental|mRNA-1010 Dose Level C|Participants will receive mRNA-1010 at dose level C by IM injection on Day 1.
16259967|NCT04956575|Experimental|Placebo|Participants will receive placebo matching to mRNA-1010 by IM injection on Day 1.
16259968|NCT04956562||Vaccinated with sinovac|Vaccinated COVID-19 patients over 65 years consisted the study group
16259969|NCT04956562||Unvaccinated|Unvaccinated patients over 65 years composed the control group
16259970|NCT04956549|Experimental|Physical Activity|150 minutes of physical activity weekly
16259971|NCT04956549|Experimental|Successful Aging|Low intensity activity program and a healthy aging educational component
16259972|NCT04956536||Group 1|Anterior cruciate ligament-injured patients
16259973|NCT04956484|Experimental|Belimumab 10 mg/kg plus standard of care|Standard of care and Belimumab: 10 mg per kilogram of body weight，days 1 (baseline), 15, and 29 and every 28 days thereafter to week 52
16259974|NCT04956484|Other|Standard of care|Standard of care: Steroid(≤1mg/kg/d) with or without proper immunosuppressants which doctors prescribed，including CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
16259975|NCT04956471||hospitalized patients with swallowing disorder after stroke,.|
16259976|NCT04956458|Experimental|Lumbar motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.
~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.
~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
16259977|NCT04956458|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
16259978|NCT04956445||Population 1|Once a positive diagnosis of COVID-19 has been made in the clinical setting, the clinical team caring for the patient will ask the patient / family whether they would be willing to be contacted by the study team about the study. If so, a trained member of the study team will describe the study in person or by telephone. Community members who see the study flyer will also be able to reach out to the study team to learn more about the study and to find out if they meet eligibility criteria. If the eligible patient / legally authorized representative / legal guardian would like to participate. The verbal informed consent / verbal HIPAA, assent, and/or parental permission (as appropriate) will then be obtained in person.
16259979|NCT04956445||Population 2|Persons with a history of past (>14 days ago) diagnosis of COVID-19 infection will be invited to participate in this study. In addition, persons who have had significant exposure to a patient with COVID-19 (contact at a distance of less than 6 feet without personal protective equipment) and have remained asymptomatic for 14 days following exposure will be recruited. Candidates will be identified through initial enrollment in Population 1, or by clinicians who have been informed of the study but are not part of the study team. Then, the clinical care team will ask the patient if he/she is willing to be contacted by the study team. Community members who see the study flyer or are otherwise informed of the study will also be able to reach out to the study team. Additionally, individuals with no defined past COVID-19 infection, but the potential to have been exposed to, and mounted antibodies against, COVID-19 will also be enrolled in Population 2 for this study.
16259980|NCT04956432|Experimental|Treatment group A|SHR4640+Allopurinol Placebo；once a day, orally, for 16 weeks
16259981|NCT04956432|Active Comparator|Treatment group B|Allopurinol+ SHR4640 Placebo；once a day, orally, for 16 weeks.
16259982|NCT04956419|Experimental|Treatment group A|SHR8008 capsule
16259983|NCT04956419|Active Comparator|Treatment group B|Fluconazole capsule
16259986|NCT04956393|Experimental|Immediate SOAR Program|Participants with a past sport-related knee injury randomized to the 'immediate intervention' group will complete an 8-week (weeks 1-8) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) followed by an additional 8 weeks (weeks 10-17) of home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and optional weekly group-based exercise classes. Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more immediate SOAR group knee injury participants.
16259987|NCT04956393|Other|Delayed SOAR Program|Participants with a past sport-related knee injury randomized to the 'delayed intervention' group will have a 9-week unstandardized delay before completing an 8-week SOAR program (weeks 10-17). During the delay (weeks 1-9) the delay comparison intervention will be unstandardized to reflect usual care in Canada. After the 9-week delay, these participants will complete an 8-week (weeks 10-17) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and an optional weekly group-based exercise classes). Consented trained physiotherapists will deliver the SOAR program from week 10 to week 17 to one or more delayed SOAR group knee injury participants.
16259988|NCT04956380|Experimental|Joint Count + Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered tender joint count (out of 68 joints on a homunculus) and self-administered Early Inflammatory Arthritis Detection Tool that were completed by the patient. Rheumatologist then uses the information provided in these tools by the patient to determine whether they should advance the urgency rating of the case.
16259989|NCT04956380|Experimental|Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered Early Inflammatory Arthritis Detection Tool that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
16259990|NCT04956380|Experimental|Joint Count|Rheumatologist reviews both the self-administered Patient Tender Joint Count that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
16259991|NCT04956380|No Intervention|Control|Rheumatologist does not review any of the self-administered tools completed by the patient.
16259992|NCT04956367|Experimental|CO2 laser with PRP|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, PRP will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
16259993|NCT04956367|Placebo Comparator|CO2 laser with placebo|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, pNSS will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
16259996|NCT04956341|Experimental|Standard treatment from PCM or Mental Health or both + auricular acupuncture|
16259997|NCT04956341|Placebo Comparator|Standard treatment from Primary Care Manager (PCM) or Mental Health or both|
16259998|NCT04956328|Experimental|OCA Tablets 5-10 mg|OCA 5 mg once daily in combination with UDCA for 24 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
16259999|NCT04956328|Placebo Comparator|Placebo|Placebo once daily in combination with UDCA for 48 weeks.
16260000|NCT04956315||Examiner effect group|Two examiners performed the test on one healthy subject with both devices for ten consecutive days. We measured the AD of both knees and calculated the ADD of every test. We evaluated the contralateral-side effect by comparing the AD standard deviations of each knee with both devices, and compared the average ADD tested by different examiners with the same device, to estimate examiner effect.
16260001|NCT04956315||Method effect group|The experienced examiner performed tests on 20 healthy subjects using both devices. The means and standard deviations of both knees were calculated. We examined the difference in measurements using each device to determine the method effect.
16260002|NCT04956315||Equipment effectiveness group|The experienced examiner performed tests on 200 ACL ruptureand 200 healthy subjects using each device. Effectiveness was analyzed using 1.5 mm and 3 mm threshold values in ACL tears.
16260003|NCT04956302|Experimental|Treatment (panobinostat, daratumumab, bortezomib, dexa)|Patients receive panobinostat PO QD on days 1, 3, 5, 15, 17, 19, daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, bortezomib SC on days 1, 8, 15, 22 and dexamethasone PO (IV on days of daratumumab and hyaluronidase-fihj administration) QD on days 1, 8, 15, 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16260004|NCT04956289|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
16260102|NCT04955561|Experimental|Randomised to begin with oxygen-supplementation at 10L/min during ESWT|Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
16260005|NCT04956276|Experimental|Cohort 1: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
16260006|NCT04956276|Experimental|Cohort 2: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
16260007|NCT04956276|Experimental|Cohort 3: ALXN1830|If initiated, participants will receive ALXN1830. Treatment will be received for 12 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
16260008|NCT04956263|Experimental|Treatment A|YG1699 10 mg
16260009|NCT04956263|Experimental|Treatment B|YG1699 25 mg
16260010|NCT04956263|Active Comparator|Treatment C|Dapagliflozin 10 mg
16260011|NCT04956250|Experimental|Traffic Calming Curb Group|
16260012|NCT04956250|Experimental|In-Street Sign Group|
16260013|NCT04956237||Tenonian surgery|Hospital recruitment with outpatient surgery without the presence of an anesthesiologist, without loco-regional anesthesia and without intravenous route
16260014|NCT04956237||Peribulbar surgery|Gold standard: City recruitment with outpatient surgery with the presence of an anesthesiologist and with loco-regional anesthesia
16260017|NCT04956211|Experimental|Non-surgical periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments .
16260018|NCT04956211|Active Comparator|Conventional periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Supragingival cleaning and polishing of all dentition will be delivered to individuals in this group.
16260019|NCT04956198||Patients with newly diagnosed as well as relapsed/refractory sarcomas.|The investigators intend to enroll newly diagnosed or refractory/relapsed pediatric patients with all types of sarcomas where tumor tissue would be available for ex vivo drug screening and genomic profiling. This observational study will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas
16260020|NCT04956172|Active Comparator|Tone A|Tone A uses an 80dB standard tone
16260021|NCT04956172|Experimental|Tone B|Tone B uses a 93dB standard tone
16260022|NCT04956159|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) twice daily for two weeks (20 sessions). The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
16260023|NCT04956159|Sham Comparator|Sham iTBS rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse twice daily for two weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.
16260024|NCT04956146|Experimental|Fruquintinib Combined With Sintilimab and Chemotherapy|
16260025|NCT04956133|Experimental|Physical activity|Participants will be offered online, individualized physical activity sessions 2-3 times/week for 15-45 minutes/session for 8-12 weeks.
16260026|NCT04956120|Experimental|Citrate Dialysate then Standard Dialysate|Participants receiving hemodialysis using a citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a non-citrate acid concentrate dialysate (standard dialysate) for the second year of the study.
16260027|NCT04956120|Active Comparator|Standard Dialysate|Participants receiving hemodialysis using a non-citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a citrate acid concentrate dialysate for the second year of the study.
16260028|NCT04956107||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
16260029|NCT04956107||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
16260030|NCT04956094||First Trimester Prenatal Visit|Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.
16260031|NCT04956081|Experimental|virtual neuro-navigation|The specific area within the L-DLPFC will be identified by a software using MR images. TMS will be administered to the identified area.
16260032|NCT04956081|Experimental|on-line neuro-navigation|The specific area within the L-DLPFC will be identified by a person using MR images. TMS will be administered to the identified area.
16260033|NCT04956068|Experimental|Unresectable PM group|Patients who have progressed on conventional systemic therapy and PIPAC is used as a palliative strategy.
16260034|NCT04956068|Experimental|Extensive PM group|Patients who have significant volume of peritoneal disease are treated with the intent for potential conversion to curative surgery. Role of PIPAC is as an adjunct to systemic chemotherapy to downstage peritoneal metastases.
16260035|NCT04956055|Experimental|Experiment group|Experimental group to be applied hand reflexology
16260036|NCT04956055|No Intervention|Control group|experimental group for which hand reflexology will not be applied
16260037|NCT04956042|Experimental|Cohort 1 - Fosciclopirox only|An initial 14 study participants will be enrolled in Cohort 1a and will be treated with fosciclopirox. If there is a disease response, an additional 14 study participants will be enrolled into Cohort 1 (Cohort 1b).
16260161|NCT04955158|Experimental|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack
16260038|NCT04956042|Experimental|Cohort 2 - Fosciclopirox + Cytarabine|To be implemented if a disease response is not seen in Cohort 1a. Cohort 2a will have an initial 14 study participants treated with fosciclopirox and cytarabine. If a disease response is seen, an additional 14 study participants will be enrolled (Cohort 2b).
16260039|NCT04956016|Active Comparator|classic rTMS treatment|Arm A: classic rTMS treatment (use of the 8-shaped coil) and standard therapy
16260040|NCT04956016|Active Comparator|treatment with deep rTMS|Arm B: treatment with deep rTMS (use of the H-shaped coil (helmet)) and standard therapies
16260041|NCT04956003|No Intervention|Control Group|No intervention, but assessment of cardiometabolic health and cognition
16260042|NCT04956003|Experimental|Intervention Group|Implementing a daily 45-minute physical activity session as an integral part of learning.
16260043|NCT04955990|Experimental|Participants with PAH|Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a real-world clinical setting, either as first-line therapy, as replacement therapies, or or concomitant with other PAH therapies. The primary data source for this study will be the medical records of each participant.
16260044|NCT04955977|Experimental|G1: People with a diagnosis of COPD stratified in GOLD 1-2.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.
~People with a diagnosis of COPD categorized in GOLD 1-2, with no record of respiratory crises in the last 3 months.
~People with a diagnosis of COPD categorized by lung function in GOLD 1,2,3 and 4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.
~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.
~People who have read and signed informed consent and who have membership in a mandatory health plan."
16260045|NCT04955977|Experimental|G2: People with a diagnosis of COPD stratified in GOLD 3-4.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.
~People with a diagnosis of COPD categorized in GOLD 1,2,3 and 4, with no record of respiratory crises in the last 3 months.
~People with a diagnosis of COPD categorized by lung function in GOLD 3-4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.
~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.
~People who have read and signed informed consent and who have membership in a mandatory health plan."
16260046|NCT04955977|Active Comparator|G3: Control - People without a COPD diagnosis.|Healthy people, over 40 years old. No history of cigarette smoking or exposure to wood smoke. Who do not present diagnoses of musculoskeletal injuries and who are residents at 2600 meters above sea level for more than 14 months. With affiliation to a mandatory health plan and signature of informed consent.
16260047|NCT04955964||All Participants|Participants with diagnosis of HAE who have received at least one dose of lanadelumab according to currently approved indications in routine clinical practice settings in Argentina will be observed in this study.
16260048|NCT04955951||polarized light group|group A (20 patients) will receive Polarized light therapy
16260049|NCT04955951||topical corticosteroid group|group B (20 patients) will receive topical corticosteroid therapy
16260050|NCT04955938|Experimental|Arm A - Participants with IDH1 Mutations|"After genetic testing, if participants are found to have IDH1 Mutations (a genetic mutation) then they will be assigned to this group and will receive the following study drugs:
~Single agent Phase (Cycles 1-3):
~The initial phase of treatment will consist of 3 cycles (lasting 28 days) of ivosidenib 500mg daily x 28 days
~Combination Phase (Cycle 4 onwards):
~If a participant shows clinical benefit (including their disease stabilizing) following the first 3- cycle phase, he or she may go onto the combination phase. Combination treatment will consist of ivosidenib daily x 28 days along with fedratinib daily x 28 days."
16260051|NCT04955938|Experimental|Arm B - Participants with IDH2 Mutations|"After genetic testing, if participants are found to have IDH2 Mutations (a genetic mutation) then they will be assigned to this group and will receive the following study drugs:
~Single agent Phase (Cycles 1-3):
~The initial phase of treatment will consist of 3 cycles (lasting 28 days) of enasidenib 100mg daily x 28 days
~Combination Phase (Cycle 4 onwards):
~If a participant shows clinical benefit (including their disease stabilizing) following the first 3- cycle phase, he or she may go onto the combination phase.Combination treatment will consist of enasidenib 100mg daily x 28 days along with fedratinib daily x 28 days."
16260052|NCT04955925||Sevoflurane group|Anesthesia is maintained with sevoflurane during the surgery.
16260053|NCT04955925||Propofol group|Anesthesia is maintained with total venous anesthesia using propofol during the surgery.
16260054|NCT04955912|Experimental|Experimental group|Music medicine
16260055|NCT04955912|No Intervention|Control group|not routinely do anything to reduce premenstrual symptoms
16260057|NCT04955886|Experimental|Recurrent or Metastatic Nasopharyngeal Carcinoma.|Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma were given Surufatinib Combined With Toripalimab.
16260058|NCT04955873|Experimental|Test - Group A - Dentsply biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Dentsply Sirona Symbios Xenograft Granules and the resorbable collagen membrane Dentsply Sirona Symbios Collagen Membrane SR."
16260059|NCT04955873|Active Comparator|Active comparator - Group B - Geistlich biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Geistlich Bio-oss Collagen and the resorbable collagen membrane Geistlich BioGide."
16260060|NCT04955873|No Intervention|Control - Group C - Spontaneous healing|Spontaneous postextraction alveolar healing
16260061|NCT04955860||Study Group|Individuals with bilateral posterior crossbite will be included.
16260062|NCT04955860||Control Group|Individuals with no anterior and/or posterior crossbite and transversal malocclusion will be included.
16260063|NCT04955847||PGE2|In period 1, the service protocol for induction at term on an unfavorable cervix indicated the use of a PGE2. In nulliparous women, Propess® was introduced intra-vaginally for 24 hours or until regular painful uterine contractions occurred. In the case of a multiparous woman, Prostine® gel, one or two mg depending on the cervical conditions at the time of induction, was introduced intravaginally and the cervix was reassessed after six hours. If the cervix remained unfavorable and the kinetics of the contractions were not optimal, a new dose of Prostine® one or two mg was administered to the patient.
16260064|NCT04955847||misoprostol|In period 2, patients who were induced with an unfavorable cervix at term were induced with misoprostol. Regardless of parity, the patient received oral misoprostol 25 μg, one tablet orally every two hours until a maximum of eight tablets per day, or 200 µg, was reached, with cessation of the tablets when painful, regular contractions were obtained.
16260065|NCT04955834|Experimental|Insulin degludec injection|Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
16260066|NCT04955834|Active Comparator|Tresiba®|Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
16260067|NCT04955821||VAP group|Children with respiratory tract infection by mechanical ventilation
16260068|NCT04955808||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.
16260069|NCT04955795|Active Comparator|Alcohol Brief Intervention (BI)|At the time of trial enrollment, participants will receive a session of alcohol brief intervention (BI) via telephone.
16260070|NCT04955795|Experimental|Common Elements Treatment Approach (CETA) via Telemedicine|Participants will be provided with 6 to 12 weekly CETA sessions via telephone.
16260071|NCT04955782||62-84 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
16260072|NCT04955782||1-3 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
16260073|NCT04955756|Experimental|mNGS group|
16260074|NCT04955756|Experimental|PCR group|
16260075|NCT04955743|Experimental|Cohort 1: Melanoma|Participants who are melanoma (PD-1/PD-L1-experienced)
16260076|NCT04955743|Experimental|Cohort 2: Renal Cell Carcinoma|Participants who are Renal Cell Carcinoma (PD-1/PD-L1 experienced).
16260077|NCT04955730|Experimental|NPWT - Negative Pressure Wound Therapy|Participants will receive Negative Pressure Wound Therapy (NPWT) after surgery and wear the NPWT until postop day 3. NPWT dressing will be removed and a new NPWT will be replaced until Postop day 7, where NPWT dressing will be removed.
16260078|NCT04955730|No Intervention|Standard of Care Wound Therapy|Participants will receive standard of care wound therapy after surgery. Postop day 3, dressings will be removed and new sterile dressings will be applied if needed.
16260079|NCT04955717|Experimental|Testing and treatment|Participants will receive CT and NG testing and treatment (if necessary) at their first antenatal care visit and a visit during their third trimester. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
16260080|NCT04955717|No Intervention|Standard of care|Participants will receive the standard of care for STI management, which is treatment based on signs and symptoms. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
16260081|NCT04955691|Experimental|low carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the low carbohydrate group will limit carbohydrate intake to 15% of total daily calories.
16260082|NCT04955691|Active Comparator|standard carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the standard carbohydrate group will follow an ad libitum diet with standard carbohydrate intake.
16260083|NCT04955678|Experimental|ZG-801|
16260084|NCT04955678|Placebo Comparator|Placebo|
16260085|NCT04955665||Bone block procedure|patients with recurrent peroneal tendon dislocation underwent the bone block procedure
16260086|NCT04955665||Reattachment of the superior peroneal retinaculum|patients with recurrent peroneal tendon dislocation underwent reattachment of the superior peroneal retinaculum
16260087|NCT04955652|Active Comparator|Standard of Care|A health maintenance topic, actionable sidebar item, and a single-click best practice alert are presented.
16260088|NCT04955652|Experimental|Silent Best Practice Alert|A health maintenance topic and an actionable sidebar item are presented. The best practice alert is set to be silent and will not appear in the patient's chart.
16260089|NCT04955639|Active Comparator|Control|A commercially available mobile phone app and program
16260090|NCT04955639|Active Comparator|Pivot|Pivot mobile phone app and program
16260093|NCT04955613|Active Comparator|Standard care|"12 sessions in total: sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:Mirror therapy (standard care) for a total of 10 sessions over a period of 5 weeks (15-20 minutes per session).
~sessions 12: Meeting with a doctor and physical therapist."
16260094|NCT04955613|Active Comparator|MyMove/VR system|"sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:MyMove devices and VR gear for a total of 10 sessions over a period of 5 weeks 15-20 minutes per session.
~sessions 12: Meeting with a doctor and physical therapist."
16260095|NCT04955600||elderly patients with multimorbidity, relatives, health care personal|The care team consists of four nurses, two of whom are employed by the region and two by the municipality, 20 municipally employed assistant nurses and one physician. Other professions associated with the team are psychologist, dietitian, pharmacist, counsellor, physiotherapist, occupational therapist, and family consultants. All participants in the team will be invited to participate in the study. The technology will be place in 20-25 patients' home and patients and family members will be invited to participate in the study. Self-care education will be given to the patients and family members according to the middle-range theory of self-care of chronic illness.
16260096|NCT04955587||Patients with longstanding complicated fatigue|The participants receive no intervention as part of this study.
16260097|NCT04955587||Healthy controls|The participants receive no intervention as part of this study.
16260098|NCT04955587||Controls with rheumatic disease|The participants receive no intervention as part of this study.
16260099|NCT04955574|Experimental|Probiotic + Antibiotic Placebo|
16260100|NCT04955574|Experimental|Probiotic + Antibiotic|
16260101|NCT04955574|Placebo Comparator|Probiotic Placebo + Antibiotic Placebo|
16260348|NCT04953676|Experimental|Experimental group|flat tunnel
16260103|NCT04955561|Experimental|Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
16260104|NCT04955561|Experimental|Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
16260105|NCT04955548|Experimental|arthroscopic microfracture with autologous adipose gel|The experimental group will be treated with arthroscopic microfracture with autologous adipose gel.
16260106|NCT04955548|Active Comparator|arthroscopic microfracture|The control group will be treated with arthroscopic microfracture.
16260107|NCT04955522||metastases|patients with spinal metastases
16260108|NCT04955522||multiple myeloma|patients with spinal multiple myeloma
16260109|NCT04955509||Training|random splitting based on random sequences generated by engineers to train and optimize a machine learning model
16260110|NCT04955509||Testing|random splitting based on random sequences generated by engineers to evaluate the performance of the model
16260111|NCT04955496||ERAS Group|Patients were treated by enhanced recovery after surgery
16260112|NCT04955496||Control Group|Patients were not treated by enhanced recovery after surgery
16260113|NCT04955483||Virtual single-energy imaging reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev)
16260114|NCT04955483||Virtual single energy (70-140Kev, interval 10Kev) combined with MAR reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev) combined with MAR reconstruction group
16260115|NCT04955470|Experimental|Intravenous ketamine|Infusion of 0.5 mg/kg of ketamine, at maximum dose of 40 mg, over 40 minutes.
16260116|NCT04955470|Active Comparator|Intravenous midazolam|Infusion of 0.03 mg/kg of midazolam, at maximum dose of 2 mg, over 40 minutes.
16260117|NCT04955470|Placebo Comparator|Intravenous saline|Infusion of 0.9% saline over 40 minutes.
16260118|NCT04955444|No Intervention|Historical control group|The historical control group underwent a thyroidectomy or parathyroidectomy procedure prior to implementation of the quality improvement bundle.
16260119|NCT04955444|Experimental|Post-implementation group|The post-implementation group will have a thyroidectomy or parathyroidectomy procedure after bundle implementation and will receive care that is enhanced by the quality improvement bundle.
16260120|NCT04955431|Placebo Comparator|Normal Sleep (with 250 ug/m^3 PM2.5)|Participants will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m^3 PM2.5 with moderate intensity exercise).
16260121|NCT04955431|Experimental|Restricted Sleep (with 250 ug/m^3 PM2.5)|Participants will have a restricted sleep opportunity (~4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m^3 PM2.5 with moderate intensity exercise).
16260122|NCT04955418|Active Comparator|Epi-no Group|The study group was evaluated before the intervention (between 30 and 32 weeks) and 6 months after delivery.From the 34th week onwards, they performed 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device. The pregnant woman was placed in the supine position and EPI-NO® was inserted into vaginal canal. After the introduction of the deflated tube, it was minimally inflated until the perception in the vaginal canal. The first 5 minutes were for perception of the pelvic floor with 10 contractions and relaxation of the perineum in order to maintain muscle strength. After 15 minutes for stretching the perineum, the device was gradually inflated and always respecting the pregnant woman's tolerance. After a total of 20 minutes, the pregnant woman was asked to relax the pelvic floor in order for the inflated device to gently exit her vaginal cavity. The perimeter was measured using a tape measure in its largest diameter.
16260123|NCT04955418|Placebo Comparator|Control Group|The control group was evaluated only once, six month after delivery.
16260126|NCT04955392|Experimental|Intervention group|Group of patients that will receive the 4 techniques proposed to evaluate the changes on sleep quality
16260127|NCT04955392|Sham Comparator|Control group|Group of patients that will receive a sham technique
16260128|NCT04955379|Other|Measurements|Subjects will be tested with the Autorefractor and the EQ103 device
16260129|NCT04955366|Active Comparator|Belatacept group (Control Group)|"Participants will receive the following:
~Belatacept: 5 mg/kg i.v. monthly
~Blood draws for PD studies at baseline/Month 0 and Month 6 fora total of two timepoints.
~HLA labs at 6, 12 and 24 months
~Basic chemistry panel (CP Basic) every 3 months per clinical protocol for efficacy analysis
~Hemoglobin A1c at Screening visit
~Urine pregnancy test via test kit for WOCP at Screening visit"
16260130|NCT04955366|Experimental|Abatacept Group (Conversion Group)|"Participants will receive the following:
~Abatacept 125 mg s.c. weekly
~Safety labs every 2 weeks (months 0-3) then monthly (months 4-12)
~Blood draws forPK atMonth 6, Month 12, and two random time points in between Month 6 and Month 12 for a total of four time points.
~Blood draws for PD studies at baseline/Month0 and Month 6 fora total of two timepoints.
~HLA labs at 6, 12 and 24 months
~Basic chemistry panel (CP Basic) at each study visit per clinical protocol for efficacy analysis
~Hemoglobin A1c at Screening visit
~Urine pregnancy test via test kit for WOCP at screening"
16260131|NCT04955353|Experimental|AVC-H2|Participants received Avicenna Hydrolyzed Chicken Collagen Type II (AVC-H2), 2.5g daily, for 8 weeks.
16260132|NCT04955353|Placebo Comparator|Placebo|Participants received placebo of matching amount to that of AVC-H2 daily for 8 weeks.
16260133|NCT04955340|Experimental|[14C]-resminostat|single dose of 400 mg [14C]-resminostat
16260134|NCT04955327|Experimental|A. Paniculata150 mg|Extract from Andrographis Paniculata
16260135|NCT04955327|Experimental|A. Chilensis 300 mg|Extract from A. Chilensis
16260136|NCT04955327|Experimental|A. Panicluata 150 mg + A. Chilensis 300 mg.|combination of extract of A. Paniculata and A. Chilensis
16260137|NCT04955327|Placebo Comparator|Microcrystalline Cellulose +/-450 mg|Comparator
16260138|NCT04955314|Experimental|PA mobilizations on their main painfull vertebral segment|Patients who will be treated with PA mobilizations on their main painfull vertebral segment.
16260162|NCT04955158|Experimental|Ketamine|50 mg ketamine soaked pharyngeal pack
16260163|NCT04955158|Experimental|Saline placebo|20 ml 0.9% saline soaked pharyngeal pack
16260139|NCT04955314|Experimental|PA mobilizations on an adjacent vertebral segment from the most painful|Patients who will be treated with PA mobilizations on an adjacent vertebral segment from the most painful.
16260140|NCT04955301|No Intervention|Control message group|Participants will not receive the priming manipulation.
16260141|NCT04955301|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
16260142|NCT04955301|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
16260143|NCT04955301|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
16260144|NCT04955288|Experimental|Aortic balloon Assisted resuscitation group|The aortic balloon-assisted resuscitation group uses aortic balloon occlusion technology on the basis of the traditional resuscitation mode, that is, when the cardiopulmonary resuscitation begins, the aortic balloon catheter is quickly punctured and inserted to the distal end of the aortic area I via ultrasound. (Septum level), then continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
16260145|NCT04955288|Active Comparator|Traditional cardiopulmonary resuscitation group|The traditional cardiopulmonary resuscitation group uses the traditional manual chest compression mode, that is, referring to the latest version of the cardiopulmonary resuscitation guidelines, manual chest compressions are performed under the monitoring of the compression quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, Conditions such as a fixed compression position and sufficient chest wall rebound.
16260146|NCT04955288|Experimental|Esophageal cooling group|The esophageal cooling group adopts a new transesophageal cooling method, that is, an esophageal cooling catheter is placed after resuscitation in patients with cardiac arrest, and then a small temperature-controlled water circulation system is continuously perfused with 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature is adjusted Control the water circulation system to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
16260147|NCT04955288|Active Comparator|Traditional cooling group|The traditional cooling group uses the traditional body surface ice blanket cooling method, that is, the patients with cardiac arrest lie on the temperature control blanket after resuscitation, and then use the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃ After that, adjust the ice blanket host to control the circulating water temperature to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
16260148|NCT04955275|Experimental|Parkinson's Disease Patients receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will undergo 10 weeks of Lumosity training, 2 times a week an hour at a time. Also patients pre- and post-intervention RBANS and PDQ-39 scores.
16260149|NCT04955275|No Intervention|Parkinson's Disease Patients not receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will receive no intervention, but still undergo pre- and post-intervention RBANS and PDQ-39 scores.
16260150|NCT04955262|Experimental|Part 1 Initial Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214, 3 injections of 89Zr-Df-IAB22M2C, and 6 PET/CT scans. Starting with Cycle 2, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. Once the PET/CT imaging data from Part 1 have been reviewed, Part 2 will open for enrollment.
16260151|NCT04955262|Experimental|Part 2 Expansion Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214 or nivolumab, 2 injections of 89Zr-Df-IAB22M2C, and 3 PET/CT scans. In Cycle 2 and beyond, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. During Cycle 2, patients will receive 1 injection of 89Zr-Df-IAB22M2C and 1 PET/CT scan.
16260152|NCT04955249|Experimental|Dexmedetomidine group|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
16260153|NCT04955249|Placebo Comparator|Control group|Patients in this group receive routine patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
16260156|NCT04955223|Experimental|Yinhu Qingwen Granule|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.
16260158|NCT04955197||the histo-pathological picture|"In the present study, the exfoliated cytology of group II and III will be compared to the histo-pathological picture of the lesion reference standard. That is because the histopathology analysis is the definitive diagnosis of oral mucosal lesions"
16260159|NCT04955171|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
16260160|NCT04955171|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
16260164|NCT04955145|Active Comparator|Ruta C 60 group|Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg Dosage:2 tablets three times daily for 4 months
16260165|NCT04955145|Active Comparator|C- Retard group|Ascorbic acid 500mg capsule dosage: 1 capsule two times daily for 4 months
16260166|NCT04955145|No Intervention|Control group|No intervention
16260169|NCT04955119|Experimental|Fusion imaging contrast-enhanced ultrasound LI-RADS|"Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.
~Drug: SonoVue"
16260170|NCT04955106|Other|Sample for reliability|Reliability and validity of SEM Scanner : intra rater, inter rater and inter novice/trained 8(2 trained rater, 2 novice rater, each one performed twice)measured will be performed on each patient.
16260171|NCT04955093|Experimental|Intervention|
16260172|NCT04955093|No Intervention|Control|
16260173|NCT04955067||Normal control group-Grade 0|Arthroscopic examination of the ankle joint was normal, and the ligament was intact without injury or tear.
16260174|NCT04955067||Ligament injury -Grade 1|Arthroscopic examination of the ankle joint showed ligament degeneration or injury, but no local or complete tear.
16260175|NCT04955067||Ligament tear-Grade 2|Arthroscopy of the ankle joint revealed partial or complete loss of ligaments.
16260176|NCT04955054||control|patients without coronary artery disease
16260177|NCT04955054||UAP|patients without unstable angina pectoris
16260178|NCT04955054||AMI|patients with acute myocardial infarction
16260179|NCT04955041||mild CSM|preoperative modified Japanese Orthopedic Association (mJOA) score ≥15
16260180|NCT04955041||moderate CSM|preoperative mJOA score 13~14
16260181|NCT04955041||severe CSM|preoperative mJOA score ≤12
16260182|NCT04955028||intraoperative massive hemorrhage|blood loss of ≥200 mL with or without artery embolization (UAE) or local CSP resection by laparoscopy or laparotomy as additional interventions.
16260183|NCT04955028||the non-massive hemorrhage group|blood loss of <200 mL
16260184|NCT04955015||patients|patients with caotid atherosclerosis refering to carotid endarterectomy
16260185|NCT04955002||Healthy UK adults|Healthy UK adults
16260186|NCT04954989|Experimental|Erythropoietin injectable in a single subcutaneous application.|
16260187|NCT04954989|Active Comparator|Erythropoietin Eprex®|
16260188|NCT04954963||conventional examination|patients undergo conventional examination
16260189|NCT04954963||Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
16260190|NCT04954950||sports injuries|Patients were classified according to self-reported years of participation in skiing and snowboarding: beginner (first season), medium (1-5 years), advanced (5-10 years) and expert (≥10 years). Date of injury was divided into weekdays and weekends/ holidays according to the Chinese government holiday arrangement.
16260191|NCT04954924|No Intervention|Control group - standardized physiotherapy program|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes.
16260192|NCT04954924|Experimental|Experimental group - standardized physiotherapy program and Kinesio tape|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes. The Kinesio tape (KT) technique was chosen on the basis of K. Kase et al.'s (2003) recommendations. KT (Japan) was applied to the injured leg using muscular and functional-corrective techniques on the quadriceps femoris and the hamstring muscle. There were 6 KT procedures per participant in the experimental group. The CON group received KT only during the baseline and final assessment to assess short-term effect of KT.
16260193|NCT04954898|Experimental|Study Lens|TECNIS Multifocal Toric 1-piece lens, Model ZMT
16260194|NCT04954885||Ancillary-correlative (biospecimen, questionnaire, testing)|Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).
16260195|NCT04954872|Active Comparator|Training as usual|Standard Problem Management Plus training.
16260196|NCT04954872|Experimental|Equip-based training|Training that uses the Equip platform to assess competencies and incorporate this information into trainers and supervisors activities.
16260199|NCT04954846|Experimental|OMNi-BiOTiC SR-9|Treatment is taken twice a day for 3 months
16260200|NCT04954846|Placebo Comparator|Control|Placebo is taken twice a day for 3 months
16260201|NCT04954820|Experimental|Experimental arm|2 additional infusions of Lutathera® according to the marketing authorization schema
16260202|NCT04954820|No Intervention|Control arm|No treatment with active monitoring (clinical, biological and radiological follow-up) every 2 months.
16260203|NCT04954807|Active Comparator|Human Milk Fortifier|human milk fortifier which contains protein, lipid, carbohydrate and micronutrients
16260204|NCT04954807|Placebo Comparator|placebo|Placebo is made of polysaccharides (0.9 g/1 g placebo) and maltose (0.1 g/1 g placebo) and minerals.
16260205|NCT04954794|Experimental|TACE in combination with Sintilimab plus a bevacizumab biosimilar|
16260206|NCT04954781|Experimental|TACE in combination with Tislelizumab|
16260207|NCT04954755||RFS|
16260208|NCT04954755||non-RFS|
16260245|NCT04954482||The validation group|The included specimens were used to validate the new posterior fork reconstruction procedure.
16260209|NCT04954742|Other|Riociguat|Riociguat (1 mg, 1.5 mg, 2 mg and 2.5 mg three times daily) starting at 1.0 mg three times daily at the beginning of the study. Dosage will be individually up-titrated up to a maximum dosage of 2.5 mg three times daily after 8 weeks. Study medication will be provided orally with or without food. Tablets should be taken three times daily approximately 6 to 8 hours apart.
16260210|NCT04954729||Experimental Group|The experimental group underwent neuropsychological testing, 18F-FDG PET/CT, 3T resting state fMRI examinations.
16260211|NCT04954729||MRI Control Group|The MRI control group underwent neuropsychological testing and 3T resting state fMRI examinations
16260212|NCT04954729||PET Control Group|The PET control group underwent 18F-FDG PET/CT examination
16260213|NCT04954716|Experimental|Deep Neck Flexor Massage|INTERVENTIONAL GROUP(DEEP Neck FLEXOR MASSAGE)
16260214|NCT04954716|Active Comparator|Post-Isometric Relaxation Technique|CONTROL GROUP (POST-ISOMETRIC RELAXATION TECHNIQUE)
16260215|NCT04954703|Experimental|Muscle energy technique of gluteus maximus and tensor fascia lata|INTERVENTIONAL GROUP (muscle energy technique of gluteus maximus and tensor fascia lata)
16260216|NCT04954703|Active Comparator|Myofascial release of iliotibial band|CONTROL GROUP(Myofascial release of iliotibial band)
16260217|NCT04954690|Placebo Comparator|Usual Care|Patients randomized to usual care will receive recommendations for exercise based on the Surgeon General's recommendations for physical activity among adults as well as the American Heart Association and American College of Sports Medicine recommendations for older individuals or individuals with chronic conditions. These guidelines are applicable to this patient population. Patients will not receive coaching but will receive accelerometers to obtain data for comparison to the intervention groups at each time point (baseline, 8 weeks, and 3 months post-KT).
16260218|NCT04954690|Active Comparator|Weekly Coaching|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise
16260219|NCT04954690|Active Comparator|Weekly Coaching + Caregiver Participation|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise with the addition of caregiver participation to promote adherence and engagement
16260220|NCT04954677|Experimental|Participates being subjected to capsule endoscopy (AI-box assistant)|In this group ,Participates will be subjected to magnet controlled capsule endoscopy with AI-box assistant.
16260221|NCT04954677|No Intervention|Participates being subjected to capsule endoscopy|In this group ,Participates will be subjected to magnet controlled capsule endoscopy without AI-box assistant.
16260222|NCT04954664|Experimental|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
16260223|NCT04954664|Active Comparator|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
16260224|NCT04954651||VAC|Vaccinated subject against Sars-Cov2
16260225|NCT04954638||sodium hypochlorite|group 1: control group with sodium hypochlorite desinfection
16260226|NCT04954638||hyperpure chlorine dioxide|group 2: study group with hyperpure chlorine dioxide desinfection
16260227|NCT04954625|Experimental|Autologous Blood Patch|
16260228|NCT04954625|Active Comparator|Standard of Care (Per physician)|
16260229|NCT04954599|Experimental|Module 1A Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 monotherapy in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
16260230|NCT04954599|Experimental|Module 1B Monotherapy Dose Expansion Cohort|Expansion cohort dosing CP-506 monotherapy in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
16260231|NCT04954599|Experimental|Module 2A Combination with carboplatin Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with carboplatin in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
16260232|NCT04954599|Experimental|Module 2B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with carboplatin in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
16260233|NCT04954599|Experimental|Module 3A Combination with Immune Checkpoint Inhibitor Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with Immune Checkpoint Inhibitor in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
16260234|NCT04954599|Experimental|Module 3B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with Immune Checkpoint Inhibitor in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
16260235|NCT04954586|Experimental|PainCare Yoga|This will be an 8-week in-person group exercise program held twice weekly, in which participants will receive pain care yoga (60 minutes) and education (15 minutes), with instructions provided for a third home session. Home sessions will be facilitated by exercise handout sheets and access to audio files for the pain care yoga portion. The pain care yoga component has been developed by a team member and will be delivered by an experienced yoga teacher.
16260236|NCT04954573|Other|Morphea|
16260237|NCT04954573|Other|Sclerotic graft-versus-host disease (GVHD)|
16260238|NCT04954560|Active Comparator|losartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
16260239|NCT04954560|Active Comparator|eprosartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
16260240|NCT04954547|Experimental|Subsidy Arm|Participants in the arm will receive $$50 if they reach the PBF goal and will be subsidized on approved health-improving expenses.
16260241|NCT04954547|Experimental|Cash Arm|Participants in the arm will receive S$350 if they reach the PBF goal.
16260242|NCT04954534|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood-derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
16260243|NCT04954508||P|patients suffering form shoulder pain and/or weakness or dislication
16260244|NCT04954482||The experimental group|The included specimens were used to establish a new posterior fork reconstruction procedure.
16284872|NCT04782323|Experimental|Group G aQII-11 Investigational|
16260246|NCT04954469|Experimental|CoVAC-1 Vaccine|Peptide vaccination should be started as soon as possible after the screening visit. Or in case of two vaccinations: Peptide vaccination should be started as soon as possible after the screening visit (V1) and on day 42 (V5)
16260247|NCT04954456|Experimental|QLS31901|"Part 1 (Dose escalation): QLS31901will be administered in sequential cohorts each receiving 1 of 6 doses of QLS31901 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.
~Part 2 (Dose Expansion): The PK parameters of QLS31901 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
16260248|NCT04954443|Experimental|Removing urinary catheter at 24 hours after surgery|The participants will removing urinary catheters at 24 hour after vaginal surgery of pelvic organ prolapse.
16260249|NCT04954443|Placebo Comparator|Removing urinary catheter at 48 hours after surgery|The participants will removing urinary catheters at 48 hour after vaginal surgery of pelvic organ prolapse.
16260250|NCT04954430||fatigue|After enrollments, subjects were assigned to perform mental fatigue-inducing experiment-a 90 min of monotonous simulated driving task. They underwent repeated measurements of quantitative pupillary light reflex (PLR) using an automated quantitative pupillometer at baseline and at an interval of 30 min during the task. Subjective ratings, heart rate variability (HRV), and electroencephalography (EEG) were performed simultaneously.
16260251|NCT04954417||MSCT image|Scanning of the vertebral body using MSCT
16260252|NCT04954417||micro-CT image|Scanning of the vertebral body using micro-CT
16260253|NCT04954404|Experimental|Transcatheter mitral valve repair/replacement|
16260254|NCT04954391|Active Comparator|PRF one nerve|Ultrasound guided PRF neuromodulation of suprascapular nerve and block axillary nerve, and articular branch of the lateral pectoral nerve with ropivacaine and dexamethasone
16260255|NCT04954391|Active Comparator|PRF three nerves|Ultrasound guided PRF neuromodulation of suprascapular, axillary nerves, and articular branch of the lateral pectoral nerve
16260256|NCT04954378||Positive lymph node metastasis|pathological diagnosis :Positive lymph node metastasis
16260257|NCT04954378||Negative lymph node metastasis|pathological diagnosis :Negative lymph node metastasis
16260258|NCT04954365||Cohort 1|Patients that received rescue treatment according to the standard of care (SOC).
16260259|NCT04954365||Cohort 2|Patients that received rescue treatment with IV amisulpride.
16260260|NCT04954339|Experimental|Atezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
16260261|NCT04954326|Experimental|S95014 lyophilizate|Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
16260262|NCT04954326|Active Comparator|S95014 liquid|Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.
16260263|NCT04954313|Experimental|Treatment Group|The Treatment Group will receive the same periodontal treatment in addition to having subgingival chlorhexidine irrigation. All subjects will also complete a set of questionnaires (PANAS & PMT) using an online form. A subset of 50 subjects from each group will be randomly selected to have oral images captured using an intra-oral scanner at Baseline and a subset of follow-up visits. Additionally, subjects in the Treatment Group will also receive brief behavioral advice from dental professionals focusing mainly on motivation and acknowledgement.
16260264|NCT04954313|Active Comparator|Control Group|"The Control Group will receive an initial periodontal treatment consisting of a pre-procedural rinse and scaling & root planning (SRP).
~Subjects in the Control Group will receive no products during the course of the study. They will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) at the end of the study.Subjects will be scheduled to receive flow mediated dilation (FMD) and carotid intima media thickness (IMT) measurements prior to Baseline and approximately 4 weeks after their Baseline visit."
16260265|NCT04954300||open|open: open ICU
16260266|NCT04954300||negative|negative: negative-pressure laminar flow ward
16260267|NCT04954300||positive|positive: laminar flow ward
16260268|NCT04954287|Experimental|Young adult cohort (age 18-55), low dose|CVXGA1 administered as a single dose of 1 x 10^6 PFU by intranasal route on Day 1
16260269|NCT04954287|Experimental|Young adult cohort (age 18-55), high dose|CVXGA1 administered as a single dose of 1 x 10^7 PFU by intranasal route on Day 1
16260270|NCT04954287|Experimental|Older adult cohort (age 56-75), low dose|CVXGA1 administered as a single dose of 1 x 10^6 PFU by intranasal route on Day 1
16260271|NCT04954287|Experimental|Older adult cohort (age 56-75), high dose|CVXGA1 administered as a single dose of 1 x 10^7 PFU by intranasal route on Day 1
16260272|NCT04954274|Experimental|Fertiline group|Treated by supplementation of the culture medium with the molecule.
16260273|NCT04954274|No Intervention|Control group|No supplementation
16260274|NCT04954248|Experimental|Covid-19 Negative/Uninfected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
16260275|NCT04954248|Experimental|Covid-19 Positive/Infected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
16260276|NCT04954235||Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia who received treatment with 2 infusions of 4 mg / Kg each of hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) separated by 48 hours
16260277|NCT04954235||Not Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia not exposed to hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) during hospitalization corresponding to the period prior to the approval of the hyperimmune anti-SARS-CoV-2 serum for its use.
16260280|NCT04954209||Hospital program of resumption|Program of resumption with physical activities in the hospital
16260283|NCT04954196|Placebo Comparator|Placebo arm|Single dose per os placebo ( microcrystalline cellulose) administration per day
16260284|NCT04954170||RCT patients|Patients suffering from rotator cuff injury
16260285|NCT04954157|Placebo Comparator|Healthy Subjects|This arm will consist of health subjects, not infected with COVID-19
16260286|NCT04954157|Active Comparator|COVID 19 Subjects|This arm will consist of subjects who are currently diagnosed with COVID-19 and fit all other criteria to be enrolled in this study.
16260287|NCT04954144|Experimental|Leap Motion Sensor|The Leap Motion Sensor is an optical hand tracking module that captures the movements of hands with unparalleled accuracy.
16260288|NCT04954144|Experimental|Neurodevelopmental Treatment Approach|Neurodevelopment treatment approach is used to influence the quality of the motor response and is carefully matched to the patient's abilities to use sensory information and adapt movements.
16260289|NCT04954131|Experimental|SCB-2019 vaccine|Investigational SCB-2019 vaccine contains 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants, in each 0.5 mL dose
16260290|NCT04954131|Placebo Comparator|Placebo|Saline solution (0.9%)
16260291|NCT04954118|Active Comparator|Group P|The clinicians performed an internal jugular vein cannulation using only personal protective equipment.
16260292|NCT04954118|Active Comparator|Group P&A|The clinicians performed an internal jugular vein cannulation using personal protective equipment and aerosol box.
16260293|NCT04954092|Experimental|1/10 of full adult dose|
16260294|NCT04954092|Experimental|1/5 of full adult dose|
16260295|NCT04954092|Experimental|Selected dose for second stage of the trial|
16260296|NCT04954092|Placebo Comparator|Placebo for second stage of the trial|
16260297|NCT04954040|Experimental|Hydroxychloroquine + Azithromycin|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin. 1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0
~Oral intake in all cases. Pills will be taken simultaneously."
16260298|NCT04954040|Active Comparator|SOC (Standard of Care)|"SOC for symptoms treatment
~Acetaminophen or Metamizole, 1-1-1 Antitussives if needed"
16260299|NCT04954027||Patients with a use-related disorder weaning for a substance|
16260300|NCT04954014|Experimental|BEVACIZUMAB|Patients will receive best available treatment (BAT) for COVID-19 plus single dose bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
16260301|NCT04954014|Active Comparator|BEST AVAILABLE TREATMENT|Patients will receive best available treatment for COVID-19.
16260302|NCT04954001|Experimental|Single Arm|
16260303|NCT04953988|Experimental|Robotic surgery group|
16260304|NCT04953988|Active Comparator|Manual operation group|
16260305|NCT04953962|Experimental|Arm 1: CBP501 (25) + Cisplatin + Nivolumab|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
16260306|NCT04953962|Experimental|Arm 2: CBP501 (16) + Cisplatin + Nivolumab|CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
16260307|NCT04953962|Experimental|Arm 3: CBP501 (25) + Cisplatin|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
16260308|NCT04953962|Experimental|Arm 4: Cisplatin + Nivolumab|Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
16260309|NCT04953949|Experimental|NU-MAX®|Topical Hemostat
16260310|NCT04953936|Experimental|HMB|The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)
16260311|NCT04953936|Placebo Comparator|Placebo|The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.
16260312|NCT04953923|Experimental|Treatment A|Cedazuridine at a therapeutic dose
16260313|NCT04953923|Experimental|Treatment B|Cedazuridine at a supratherapeutic dose
16260314|NCT04953923|Placebo Comparator|Treatment C|Placebo control
16260315|NCT04953923|Active Comparator|Treatment D|Moxifloxacin positive control
16260316|NCT04953910|Experimental|Group B: Moderate hepatic impairment|Cancer participants with moderate hepatic impairment [total bilirubin > 1.5x - 3x upper limit of normal (ULN); any aspartate aminotransferase (AST) level]
16260317|NCT04953910|Experimental|Group C: Severe hepatic impairment|Cancer participants with severe hepatic impairment (> 3x ULN; any AST level)
16260318|NCT04953910|Active Comparator|Group A: Normal hepatic function|Cancer participants with normal hepatic function (total bilirubin ≤ ULN; AST ≤ ULN)
16260319|NCT04953897|Experimental|Group A: Severe Renal Impairment|Cancer participants with severe renal impairment not requiring dialysis (creatinine clearance [CLcr] <30 mL/min/1.73m^2)
16260320|NCT04953897|Active Comparator|Group B: Normal Renal Function|Cancer participants with normal renal function (CLcr ≥80 mL/min/1.73m^2)
16260321|NCT04953884|Experimental|wilate treatment|PK: Single dose of 80 IU/kg body weight (BW). Prophylactic treatment: 30-50 IU/kg BW administered 2-3 times per week at the recommended dose of over 12 months. Minor haemorrhage: loading dose 30-50 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours to achieve von Willebrand factor activity (VWF:Ac) and FVIII:C trough levels of >30%. Major haemorrhage: loading dose 50-80 IU/kg BW followed by a maintenance dose of 30-50 IU/kg BW every 12-24 hours to achieve VWF:Ac and FVIII:C trough levels of >50%. Minor surgery: loading dose of 40-60 IU/kg BW followed by a maintenance dose of 20-30 IU/kg BW every 12- 24 hours for up to 3 days, to achieve VWF:Ac peak levels of 50% after loading dose and trough levels >30% during maintenance. Major surgery: loading dose of 60-80 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours for up to 6 days or longer, to achieve VWF:Ac peak levels of 100% after loading dose and trough levels >50% during maintenance
16260322|NCT04953871|Experimental|Spondyloarthritis|Spondyloarthritis patients who was initiated TNF alfa blocker
16260323|NCT04953858|Other|Social Network Strategy|All study participants will receive social network strategy intervention as linkage method to receive HIV testing and care
16260324|NCT04953832|Experimental|Cognitive Training + exposure|Participants will complete adaptive computerized cognitive training plus a series of speech tasks
16260325|NCT04953832|Active Comparator|No training + exposure|Participants will complete a low-dose computerized cognitive program plus a series of speech tasks
16260349|NCT04953663|Experimental|Low dose group|0.5 × 10 ^ 6 / kg (body weight) of it-hMSC per person
16260326|NCT04953819||Revascularization group|This group includes patients with dialysis who have received revascularization by percutaneous coronary intervention or coronary artery bypass grafting for coronary artery disease.
16260327|NCT04953819||Medical treatment group|This group includes patients who have received medical therapy for coronary artery disease, not percutaneous coronary intervention or coronary artery bypass grafting.
16260328|NCT04953806|Experimental|Step-CBT|Participants will complete Step-CBT, an integrative 12-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
16260329|NCT04953806|No Intervention|Wait-list control|Participants are assigned to wait-list control
16260330|NCT04953793|Experimental|TAY SUCCESS intervention|This intervention group received the TAY SUCCESS intervention over the course of 1 school year approximately 30 sessions.
16260331|NCT04953793|Active Comparator|Usual Care|This usual care group received typical High school or transition program curriculum over the course of 1 school year.
16260332|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 1|"Induction Phase (It usually lasts 29 days):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.
~The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).
~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.
~A single cycle of consolidation may last between 4-8 weeks in duration."
16260333|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 2|"Induction Phase (It usually lasts 29 days):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.
~The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).
~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine(every 21 days ( per cycle).
~A single cycle of consolidation may last between 4-8 weeks in duration."
16260334|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 3|"Induction Phase (It usually lasts 29 days):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High- dose Cytarabine.
~The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).
~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.
~A single cycle of consolidation may last between 4-8 weeks in duration."
16260335|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 4|"Induction Phase (It usually lasts 29 days):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.
~The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).
~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):
~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.
~The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine per cycle.
~A single cycle of consolidation may last between 4-8 weeks in duration."
16260336|NCT04953767|Experimental|Blue light therapy|The participants receive blue light therapy for 2hours, between 8am to 12pm in the morning.
16260337|NCT04953767|Sham Comparator|White light|The participants receive white light for 0.5 hour, between 8am to 12pm in the morning.
16260338|NCT04953754|Experimental|Melatonin Group|This group will get melatonin 5mg nightly
16260339|NCT04953754|Active Comparator|Control Group|This group will not get any treatment (melatonin)
16260340|NCT04953741|Active Comparator|Stop Fluticasone propionate Inhaled Aerosol Firstly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day
16260341|NCT04953741|Active Comparator|Stop Montelukast Secondly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day
16260342|NCT04953741|Active Comparator|Stop Montelukast Firstly|stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day
16260343|NCT04953728|Experimental|Subjects with IBS-C|All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.
16260344|NCT04953715||1 - This is a multicenter microbiome and pharmacokinetic study.|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied. To assess the relationship between kidney graft outcomes and stool, oral, nasal and urine microbiome diversity. To assess the relationship between transplant graft outcomes and urinary transcriptome.
16260345|NCT04953689|Experimental|Intervention|
16260346|NCT04953689|No Intervention|Waitlist Control|
16260347|NCT04953676|Other|Control Group|round tunnel
16260350|NCT04953663|Experimental|Middle dose group|1 × 10 ^ 6 / kg (body weight) of it-hMSC per person
16260351|NCT04953663|Experimental|High dose group|2 × 10 ^ 6 / kg (body weight) of it-hMSC per person
16260352|NCT04953663|Experimental|Highest dose cell group|Highest dose of it-hMSC
16260353|NCT04953663|Experimental|Sub high dose cell group|Sub high dose of it-hMSC
16260354|NCT04953663|Placebo Comparator|placebo group|placebo
16260357|NCT04953637|Experimental|Physiotherapy group|Participants assigned to the physiotherapy group will receive physiotherapy treatment at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks. They will begin to receive the physiotherapy treatment at 4 months following their surgery and once their DBS settings are optimized.
16260358|NCT04953637|No Intervention|Control group|Participants assigned to the control group will not receive any additional intervention and will be precluded from starting formal physiotherapy for the duration of the study. However, they will be encouraged to keep an active lifestyle. In order to stay active, they will be recommended to do simple home exercises following a home exercise video that will be presented to them. They will be asked to do it 3 times/week for 8 weeks and keep an exercise log to help them stay on track.
16260359|NCT04953624||CNAQ≤28|ALS patients with CNAQ ≤ 28
16260360|NCT04953624||CNAQ>28|ALS patients with CNAQ > 28
16260361|NCT04953611||Group A in GOLD|CAT<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year<2；
16260362|NCT04953611||Group B in GOLD|CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year<2
16260363|NCT04953611||Group C in GOLD|CAT<10、mMRC 0-1、 FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
16260364|NCT04953611||Group D in GOLD|CAT≥10、mMRC≥2、FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
16260365|NCT04953611||Control Group|not COPD
16260366|NCT04953598||acetabular labrum tears|Patients with clinically diagnosed acetabular labrum tears
16260367|NCT04953598||Patients with non-hip injuries|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
16260368|NCT04953585||Normal D-dimer group|preoperative plasma D-dimer levels less than or equal to 1mg/L
16260369|NCT04953585||Elevated D-dimer group|preoperative plasma D-dimer levels greater than 1mg/L
16260370|NCT04953572|Experimental|test group|Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy
16260371|NCT04953572|Active Comparator|control group 1|Patients in the control group 1 received microfracture surgical treatment
16260372|NCT04953572|Active Comparator|control group 2|Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane
16260373|NCT04953572|Active Comparator|control group 3|Patients in the control group 3 received autologous osteochondral transplantation
16260374|NCT04953559|Experimental|Active cTBS first, then sham cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
16260375|NCT04953559|Experimental|Sham cTBS first, then active cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
16260376|NCT04953546||ACL group|According to the previous clinical diagnosis, volunteers who has suffered the ACL injury.
16260377|NCT04953533||patients with gout|"age:year of 25~60;
~consistent with the 2015 ACR gout diagnostic criteria ,and serum uric acid >420umol/L;
~The patient are willing to take part in our study."
16260378|NCT04953533||patients with hyperuricemia|"age:year of 25~60;
~A medical record in our hospital showed that the person is healthy, without key disease;
~serum uric acid >420umol/L without gout flares."
16260379|NCT04953533||healthy controls|"age:year of 25~60;
~A medical record in our hospital showed that the person is healthy, without key disease;
~serum uric acid ≤420umol/L."
16260380|NCT04953520|Experimental|Ultrasound-CT fusion imaging guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
16260381|NCT04953520|Active Comparator|Pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
16260382|NCT04953507|Experimental|Thermal Radiofrequency|T2, T3 block by thermal radiofrequency lesioning at 80°c for 60-90 seconds
16260383|NCT04953507|Active Comparator|Chemical Neurolysis|T2, T3 block by chemical neurolysis using 2-3 ml of phenol in glycerin 6%
16260384|NCT04953494||Amyotrophic lateral sclerosis patients group|
16260385|NCT04953481||Amyotrophic lateral sclerosis group|Patients with amyotrophic lateral sclerosis undergoing home care.
16260386|NCT04953481||Caregiver group|Caregivers
16260387|NCT04953468||ANXA2 high expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level ≥6 points were identified as the ANXA2 high expression group
16260388|NCT04953468||ANXA2 low expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level <6 points were identified as the ANXA2 low expression group
16260389|NCT04953468||ANXA2 high expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level ≥2 were regarded as the ANXA2 high expression group
16260390|NCT04953468||ANXA2 low expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level <2 were regarded as the ANXA2 low expression group
16260391|NCT04953455||pre-operation|Within one month before operation of diagnoses with a ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
16260392|NCT04953455||early after operation|Within three months after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
16260393|NCT04953455||lately after operation|within three months to one year after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement
16260394|NCT04953455||healthy volunteers|Healthy people without abnormalities
16260395|NCT04953442|Experimental|Intervention|Fitbit Device Self-Determination Theory Text Messages
16260396|NCT04953442|No Intervention|Wait List Control|Informational flyer of evidence-based strategies on engaging in healthy physical activity and sleep lifestyle habits.
16260397|NCT04953429||nurses|nurses in a third-grade hospital in Beijing
16260398|NCT04953416|Experimental|Scalp treatment with ResurFX|
16260399|NCT04953390|Experimental|Experimental|Group using hearing aids
16260400|NCT04953377|Experimental|Intervention|PFMT educational intervention including a 120 min workshop and 8 weeks of self training
16260401|NCT04953364|Experimental|SMART|The experimental group will receive access to SMART online platform (6 weeks). SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. SMART will also allow asynchronous contact with trainers through a secure website.
16260402|NCT04953364|Active Comparator|Control|The control group will receive a care booklet and weekly contacts.
16260403|NCT04953351|Experimental|cognitive registration targeted biopsy|
16260404|NCT04953351|Active Comparator|MRI-ultrasound fusion targeted biopsy|
16260405|NCT04953338||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
16260406|NCT04953338||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
16260407|NCT04953325|Experimental|Experimental Group|180 subjects (including 90 adults aged 18-59 years and 90 elderly aged 60 year and older）will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28
16260408|NCT04953325|Placebo Comparator|Control Group|90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older）will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28
16260409|NCT04953312|Experimental|COVID-19 patients (group 1)|Patients with a recent diagnosis (<7 days since first symptoms) of moderate or severe COVID-19
16260410|NCT04953312|Experimental|Chronic myeloid malignancies (group 2)|Adults with chronic myeloid malignancies including myelodysplastic syndromes with low risk MDS ; high risk MDS according to IPSS-R or with dysplastic or proliferative chronic myelomonocytic leukemia according to WHO2016
16260411|NCT04953312|Other|Control group (group 3)|Age-matched healthy donors
16260412|NCT04953299|Experimental|Functional Imagery training|The FIT sessions will occur weekly for four weeks and last an hour per session. The sessions will be conducted over Zoom. Sessions will be facilitated by the PI who is trained in FIT, and attended by 4 participants.
16260413|NCT04953299|Active Comparator|Control|The control condition will ask participants to complete the 12 week NHS weight loss plan.
16260414|NCT04953286|Other|Case group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis
16260415|NCT04953286|Other|Control group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease
16260416|NCT04953273|Experimental|Vigitrauma|"Contact by phone at 3 weeks after the consultation in a clinical forensic medicine unit, and a second phone call if necessary.
~If the subject is not contacted after the second phone call, he will receive a postcard."
16260417|NCT04953273|No Intervention|Control group|Usual follow-up.
16260418|NCT04953260|No Intervention|GTR group|only conventional GTR technique was used to treat periodontal bone defect,
16260419|NCT04953260|Active Comparator|APRF+GTR group|GTR technique combined with APRF was used to treat periodontal bone defect
16260524|NCT04952506|Experimental|T1-T2-R|"Period 1: Test 1
~Period 2: Test 2
~Period 3: Reference"
16260420|NCT04953260|Active Comparator|CGF+GTR group|GTR technique combined with CGF was used to treat periodontal bone defect
16260421|NCT04953247||Methylprednisolone|"As there was no consensus on the use of steroids in the early stage of the COVID-19 pandemic, all steroid therapies were initiated at the time of admission at the discretion of attending physicians on the basis of clinical symptoms and CT images. According to our previous experience, intravenous methylprednisolone at a dose of 1.0-1.5 mg/kg every 12 h was initiated for 5 days or until oxygen saturation improved, followed by gradual tapering by 0.5 mg/kg every 3-5 days.
~Standard care such as the use of antibiotics, ventilation, laboratory testing, and hemodynamic management were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China."
16260422|NCT04953247||Standard care|Standard care were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China.
16260423|NCT04953234|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care
16260424|NCT04953221||M1 Test group|YJ001 for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
16260425|NCT04953221||M1 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
16260426|NCT04953221||M2 Test group:|YJ001 for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
16260427|NCT04953221||M2 control group:|YJ001 simulant for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
16260428|NCT04953221||M3 Test group|YJ001 for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
16260429|NCT04953221||M3 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
16260430|NCT04953208|Active Comparator|Active treatment|active tDCS (using the Neuroelectrics Starstim tCS 5G kit) and cognitive and emotional control video game
16260431|NCT04953208|Sham Comparator|Sham treatment|sham tDCS (using the Neuroelectrics Starstim tCS 5G kit) and non-active videogame
16260432|NCT04953195|Experimental|levothyroxine sodium|levothyroxine sodium
16260433|NCT04953182||Around the clock analgetic treatment|Patients that underwent hemorrhoidectomy and pain killers are prescribed every specific hour independent of pain degree, if necessary drugs can be administered on demand.
16260434|NCT04953182||On demand analgetic treatment|A pain killers list is prescribed by the physician and the nurse decides which drug to administer depending on a protocol of treatment based on the visual analog scale.
16260435|NCT04953169|Other|Video|The video is information regarding biobanking
16260436|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
16260437|NCT04953156||Nitroglycerin|data of patients meeting the eligibility criteria and received nitroglycerine infusion will be retrieved from medical records.
16260438|NCT04953156||Dexmedetomidine|patients will receive dexmedetomidine bolus dose of 1 mic/kg over 20 minutes followed by intravenous infusion of 0.2-0.7 mic/kg/hr adjusted according to each patient hemodynamic response
16260439|NCT04953143|Experimental|Pilot|"Inpatient longitudinal palliative care intervention that includes the following domains:
~Therapeutic relationship: Developing trust and credibility with patients and their families
~Symptom management: Proactive symptom management for common advanced liver disease symptoms including pain, fatigue, anorexia, breathlessness, depression and anxiety
~Coping with illness: Introduction of strategies to improve adjustment and meaning in life; bolstering caregiver coping
~Prognostic awareness and illness understanding: Assessing patients' level of prognostic awareness and discussing strategies to help patients cope with uncertainty
~Treatment decision-making: Supporting patients and caregivers in their medical decision-making and assessing their values in decision-making
~End-of-life care: Review/discuss selection of healthcare proxy, preferences for end-of-life care"
16260440|NCT04953130|Experimental|Male vaccination + national HPV vaccination programme|Single dose of the 4-valent HPV vaccine (Gardasil®; Merck & Co.) offered to all eligible boys aged 14 to 18 years in the 13 intervention communities. Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
16260441|NCT04953130|Active Comparator|National HPV vaccination programme only|Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
16260442|NCT04953117|Experimental|small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort
16260443|NCT04953117|Active Comparator|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB in small vessel cohort
16260444|NCT04953117|Other|very small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter<2.00 mm) in very small vessel cohort
16260445|NCT04953104|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeats every 28 days (4 weeks) for up to 2 years in the absence of disease or unacceptable toxicity.
16260446|NCT04953078|Experimental|10 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (10 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
16260447|NCT04953078|Experimental|50 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (50 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
16260448|NCT04953078|Experimental|100 μg Baiya SARS-CoV-2 VAX1, Adult Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
16260449|NCT04953078|Experimental|10 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (10 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
16260450|NCT04953078|Experimental|50 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (50 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
16260451|NCT04953078|Experimental|100 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
16284873|NCT04782323|Active Comparator|Group H QII Active Comparator|
16260452|NCT04953065||interventional|Single arm, interventional. All participants will be contacted over the phone to answer questions from a COVID-19 vaccine hesitancy and acceptance survey.
16260455|NCT04953026||Normal control group-Grade 0|Arthroscopic examination of the labrum was normal, and the labrum was intact without injury or tear.
16260456|NCT04953026||Ligament injury -Grade 1|Arthroscopic examination of the shoulder showed labrum degeneration or injury, but no local or complete tear.
16260457|NCT04953026||Ligament tear-Grade 2|Arthroscopy of the shoulder revealed partial or complete loss of labrum.
16260458|NCT04953013||sodium bicarbonate group|Sodium bicarbonate was initiated within 48 hours after ICU admission.
16260459|NCT04953013||non-sodium bicarbonate group|Patients were not infused with sodium bicarbonate.
16260460|NCT04953000||All Participants|Male participants with severe or moderate hemophilia A who have been treated with FVIII concentrate octocog alfa (Advate) during at least 12 months prior to the study enrollment, who started octocog alfa treatment in 2021 or currently being treated with octocog alfa will be observed in this study.
16260461|NCT04952961|Experimental|Single Arm Intervention|Participants will be shown how to perform vulval self-examination in a face-to-face intervention and provided with an information leaflet. They will be sent reminders to self-examine each month.
16260462|NCT04952948|Experimental|PILATES Method Training Group|The PILATES program at moderate intensity lasted 12 weeks, at a frequency of 3 times a week, and with duration of 60 minutes for each exercise session.
16260463|NCT04952948|Sham Comparator|CONTROL Group|While the PILATES Group participated in the intervention with physical exercises, the CONTROL group only participated in the functional capacity and blood pressure assessments. However, at the end of the intervention in the PILATES Group, the CONTROL Group was invited to participate in a similar training program.
16260464|NCT04952935|Experimental|True Acupuncture|
16260465|NCT04952935|Sham Comparator|Sham Acupuncture|
16260466|NCT04952909|Experimental|ShortCut™|
16260467|NCT04952896||Group of patients with good prognosis|Western Ontario and McMaster University Osteoarthritis Index (WOMAC) self-assessment questionnaire scale assesses the frequency of osteoarthritis pain, the severity of pain, body stiffness, and physical dysfunction. The visual analog scale (VAS) is used to evaluate the pain The degree is represented by a total of 11 numbers from 0 to 10 (0 means no pain, 10 means the most painful), and patients are scored according to their own pain levels.
16260468|NCT04952896||Group of patients with poor prognosis|Western Ontario and McMaster University Osteoarthritis Index (WOMAC) self-assessment questionnaire scale assesses the frequency of osteoarthritis pain, the severity of pain, body stiffness, and physical dysfunction. The visual analog scale (VAS) is used to evaluate the pain The degree is represented by a total of 11 numbers from 0 to 10 (0 means no pain, 10 means the most painful), and patients are scored according to their own pain levels.
16260469|NCT04952883||COPD patients|The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection.
16260470|NCT04952870||COVID-19 group|Perinatal COVID-19 infection group, including newborns born from COVID-19 infected mothers and newborns with postnatal COVID-19 infections;
16260471|NCT04952870||NO group|Newborns admitted in NICU and receiving inhaled NO for respiratory failure
16260472|NCT04952870||Control group|Newborns admitted in NICU for respiratory failure not receiving iNO and not infected with COVID-19;
16260473|NCT04952857|Experimental|Intervention|Vitamn D 6 lakh IU oral stat
16260474|NCT04952857|Placebo Comparator|Placebo|Placebo equal volume/ weight
16260475|NCT04952831||Patients with mild CSM|mJOA score ≥15
16260476|NCT04952831||Patients with moderate CSM|mJOA score 13~14
16260477|NCT04952831||Patients with severe CSM|mJOA score ≤ 12
16260478|NCT04952831||Controls|health volunteers
16260479|NCT04952818||RANK/RANKL low expression|
16260480|NCT04952818||RANK/RANKL high expression|
16260481|NCT04952805|Experimental|Interventional Arm _400 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 400 mg.
16260482|NCT04952805|Experimental|Interventional Arm _100 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 100 mg.
16260483|NCT04952805|Placebo Comparator|Placebo Arm|To all the patients enrolled is admistrated with single dose of placebo
16260484|NCT04952792|Experimental|Apixaban|Apixaban treatment, oral, 2.5 mg/12h, 28 days
16260485|NCT04952779||Xultophy®|Korean adults with type 2 diabetes mellitus (T2DM) initiating Xultophy® under routine clinical practice and according to approved label in Korea.
16260486|NCT04952766|Other|immunocompromised and healthy subjects|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.
~Biological samples :
~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests
~Nasopharyngeal samples (not mandatory)
~Associated data :
~Demographic data
~Description of clinical manifestations related to vaccination
~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning
~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
16260487|NCT04952753|Experimental|Safety run-in: NIS793+SOC (Investigational arm 1)|In the safety run-in part for investigational arm 1, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of the NIS793
16260488|NCT04952753|Experimental|Expansion: NIS793+SOC (Investigational arm 1)|In the expansion part, participants in the investigational arm 1 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
16260489|NCT04952753|Active Comparator|Expansion: SOC (control arm)|In the expansion part, participants in the control arm will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
16260490|NCT04952740|Experimental|Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
16260491|NCT04952740|Active Comparator|No Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.)
16260492|NCT04952727|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
16260493|NCT04952727|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
16260494|NCT04952727|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months
16260495|NCT04952727|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
16260496|NCT04952714||Dynamic Cohort|"Initially, participants who meet the inclusion criteria will be recruited to assemble a cohort of patients with sepsis and those who develop sepsis-induced acute kidney injury will be observed.
~Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device (Baxter), at a dose of 25 mL / Kg of PrismaSate dialysis solution (Baxter) and the removal filter oXiris® cytokines (Baxter) vs. the standard filter, for patients who require it, in the presence of a confirmed diagnosis of acute renal failure.
~Hemodynamic and ventilatory parameters will be monitored every 24 hours, and inflammatory parameters every 48 hours. A follow-up will be done at 28 days to establish mortality."
16260497|NCT04952701|Active Comparator|Control Lens|All subjects will wear control lenses for two weeks and then will wear Test lenses for two weeks.
16260498|NCT04952701|Experimental|Test Lens|After wearing control lenses for two weeks, all subjects will wear test lenses for two weeks.
16260499|NCT04952688|Experimental|Experimental|"Inclusion
~Before Anti-VEGF treatment: opht"
16260500|NCT04952675||low-risk group|Risk Index∈[0,0.5)
16260501|NCT04952675||high-risk group|Risk Index∈[0.5,1)
16260502|NCT04952649||pacemaker dependent patients after cardiac surgery|Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm.
16260503|NCT04952636|Experimental|Arthroscopic Cuistow|Patients who receive arthroscopic Cuistow procedure
16260504|NCT04952636|Experimental|Open Cuistow|Patients who receive open Cuistow procedure
16260505|NCT04952623|Experimental|E-learning Group|Participants will enroll in a 4-week e-learning program immediately after completing the pre-intervention assessment measures.
16260506|NCT04952623|Active Comparator|Wait-list Control Group|Participants will enroll in a 4-week e-learning program, 4-5 weeks after completion of the pre-intervention assessment measures.
16260507|NCT04952610|Experimental|Etripamil NS 70 mg|Self- administration of a single dose of 70 mg of etripamil. A maximum of 3 devices will be dispensed at any visit, including the initial study visit. The patient will be counselled that no more than 1 device should be used in any 24-hour period.
16260508|NCT04952597|Experimental|Arm A: Ociperlimab|Ociperlimab + tislelizumab + eCRT for 4 cycles followed by ociperlimab + tislelizumab
16260509|NCT04952597|Experimental|Arm B: Tislelizumab|Tislelizumab + eCRT for 4 cycles followed by tislelizumab alone
16260510|NCT04952597|Experimental|Arm C: Concurrent Chemoradiotherapy (cCRT)|eCRT for 4 cycles
16260511|NCT04952584|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.
~Dose Level 1: 1 × 10^8 CD30.CAR-EBVST cells
~Dose Level 2: 4 × 10^8 CD30.CAR-EBVST cells
~Dose Level 3: 1 × 10^9 CD30.CAR-EBVST cells"
16260512|NCT04952571|Experimental|GBM at first relapse|
16260513|NCT04952571|Experimental|GBM at second relapse|
16260514|NCT04952558||Cross sectional observational study|"Cross sectional observational study will be conducted among 700 patients of Egyptian inflammatory bowel diseased patients for different regions
~Detailed history will be taken from all included patients focus on
~age ,sex , special habit ,residence .
~education level -socioeconomic status
~type of the inflammatory bowel disease
~lag time for reaching the proper diagnosis of inflammatory bowel disease which definite as time from the first symptoms presentation to reaching definite diagnosis
~symptoms that causing patients seeking medical advice
~number of Inflammatory bowel diseased patients referred for first time from surgeons
~number of patients have perianal symptoms
~number of patients have previous history of appendicectomy"
16260515|NCT04952545|Experimental|Cohort 1: ALXN2050 (Dose 1)|Participants will receive ALXN2050 (Dose 1) as follows under fasting conditions: 120-milligrams (mg) single dose, 3-day washout, then 120-mg twice daily (BID) dosing.
16260516|NCT04952545|Experimental|Cohort 1: Placebo (Dose 1)|Participants will receive placebo (Dose 1) as follows under fasting conditions: 120-mg placebo single dose, 3-day washout, then 120-mg placebo BID dosing.
16260517|NCT04952545|Experimental|Cohort 2: ALXN2050 (Dose 2)|Participants will receive ALXN2050 (Dose 2) as follows under fasting conditions: 180-mg single dose, 3-day washout, then 180-mg BID dosing.
16260518|NCT04952545|Experimental|Cohort 2: Placebo (Dose 2)|Participants will receive placebo (Dose 2) as follows under fasting conditions: 180-mg placebo single dose, 3-day washout, then 180-mg placebo BID dosing.
16260520|NCT04952519|Experimental|Amantadine|
16260521|NCT04952519|Placebo Comparator|Placebo|
16260522|NCT04952506|Experimental|R-T1-T2|"Period 1: Reference
~Period 2: Test 1
~Period 3: Test 2"
16260523|NCT04952506|Experimental|T2-R-T1|"Period 1: Test 2
~Period 2: Reference
~Period 3: Test 1"
16260525|NCT04952506|Experimental|T2-T1-R|"Period 1: Test 2
~Period 2: Test 1
~Period 3: Reference"
16260526|NCT04952506|Experimental|T1-R-T2|"Period 1: Test 1
~Period 2: Reference
~Period 3: Test 2"
16260527|NCT04952506|Experimental|R-T2-T1|"Period 1: Reference
~Period 2: Test 2
~Period 3: Test 1"
16260528|NCT04952493|Experimental|anlotinib + RAI|Patients in this arm will receive anlotinib 6 cycles around RAI treatment ( 4 cycles before and 2 cycles after RAI)
16260529|NCT04952493|Other|RAI only|Patients in this arm will receive RAI treatment as scheduled.
16260530|NCT04952480|Experimental|Dose-escalated adaptive chemoradiotherapy|Concurrent with standard of care platinum doublet based chemotherapy (cisplatin + etoposide), radiation treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk: Phase 1 dose prescription = 14 Gy in 7 fractions; Phase 2 dose prescription = 10 Gy in 5 fractions starting the day after the final (7th) fraction is delivered; Phase 3 dose prescription = either a) 70 Gy in 35 fractions, or if this cannot be safely reached without exceeding the dose limit of an organ-at-risk, b) the maximum safe prescribe-able dose tolerance specified in the protocol. Either 3D conformal radiotherapy or IMRT planning and delivery techniques will be employed, including contouring relevant thoracic organs-at-risk. All CT simulation scans will be without contrast.
16260531|NCT04952467|Experimental|Drug: (14C)-XEN1101|Subjects will receive oral 14C-XEN1101 under fed conditions.
16260532|NCT04952454|Active Comparator|External DCR|Patients treated with External DCR for functional epiphora
16260533|NCT04952454|Active Comparator|Endonasal DCR|Patients treated with Endonasal DCR for functional epiphora
16260534|NCT04952454|Active Comparator|Transcanalicular DCR|Patients treated with Transcanalicular DCR for functional epiphora
16260535|NCT04952441|Experimental|Intervention Group|Intervention group will attend the RISE program which consists of eight 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor
16260536|NCT04952441|Active Comparator|Wait-list Control Group|The control group will attend the RISE program after the 3 month wait-list period (study months 6-7)
16260537|NCT04952428||Peri-implant group|It is based on clinical and radiographic bone loss. Implants should have clinical inflammation in combination with bleeding on probing and/or suppuration, also progressive bone loss when compared with baseline radiograph shall be demonstrable, as well as an increase in probing pocket depth (PPD) from the baseline examination (Baseline record are referred to those obtained after definitive prosthesis delivery). In those cases where no baseline records were available, marginal bone loss > 3mm and probing > 6mm were stated as requirements (2).
16260538|NCT04952428||Peri-implant mucositis group|The case definition of peri-implant mucositis it is based on clinical inflammation in combination with profuse bleeding on probing and/or suppuration with increasing of probing pocket depths and absence of bone loss beyond crestal bone level (initial remodelling) (2).
16260539|NCT04952428||Healthy patients group|The case definition of peri-implant health was based on absence of clinical inflammation, lack of bleeding on probing and absence of bone loss following initial healing (< 2mm) (2).
16260546|NCT04952363|Experimental|HFCWO+WBVT|Subjects received HFCWO+WBVT intervention twice a week for a period of 8 weeks
16260547|NCT04952363|Active Comparator|HFCWO only|Subjects received HFCWO intervention twice a week for a period of 8 weeks
16260550|NCT04952324||Pregnant women with GDM|Pregnant women with GDM
16260551|NCT04952324||Pregnant women without GDM|Pregnant women without GDM
16260552|NCT04952311|Experimental|Group A|Tagrelor combined with aspirin
16260553|NCT04952311|Experimental|Group B|Clopidogrel combined with aspirin
16260554|NCT04952285||Normal saline（I）|Intravenous infusion of 0.9% saline when start to cut the skin，do not intravenous tranexamic acid during the surgery
16260555|NCT04952285||Tranexamic acid（II）|Intravenous infusion of tranexamic acid 1g when start to cut the skin in 1 hour
16260556|NCT04952259|Experimental|Intervention group|Shexiang Tongxin dripping pills + routine treatment
16260557|NCT04952259|Active Comparator|Control group|routine treatment
16260558|NCT04952246||multiple sclerosis group|
16260559|NCT04952246||non-prognosis group|
16260560|NCT04952220||native septic arthritis of the knee|"Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee:
~thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)"
16260561|NCT04952207||DAA Group|Chronic hepatitis C patients treated with DAA
16260562|NCT04952194|Experimental|Stalevo group|Stalevo is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
16260563|NCT04952194|Active Comparator|Control group|Carbidopa and Levodopa Sustained-release Tablets is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
16260564|NCT04952181|Experimental|optical biometry|
16260565|NCT04952181|Experimental|ultrasonic biometry|
16260566|NCT04952168|Experimental|Almonertinib group|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
16260567|NCT04952155|Experimental|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
16260568|NCT04952142|Experimental|minimal water exchange|We suctioned the lumen and infused water by constant pressure on the air-water valve button of the endoscope at the rectum to open the lumen.
16260569|NCT04952142|No Intervention|traditional water exchange colonoscopy|The water exchange colonoscopy reached the cecum through continuous infusion and suction of water in the whole colon via an additional flushing pump.
16260570|NCT04952129|Experimental|Selenomethionine|50 micrograms of selenium as Selenomethionine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
16260571|NCT04952129|Experimental|Methylselenocysteine|50 micrograms of selenium as Methylselenocysteine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
16260572|NCT04952116|Other|Eyelid reconstruction|Direct eyelid closure will be done in small defects after periocular defects with or without canthyolysis , Larger defects will be reconstructed with anterior and posterior lamella reconstruction using grafts and flaps
16260573|NCT04952077|Experimental|Experimental|
16260574|NCT04952064|Experimental|200 mg group|Monosialoganglioside GM1, 200 mg/day, for 12-14 days
16260575|NCT04952064|Experimental|400 mg group|Monosialoganglioside GM1, 400 mg/day, for 12-14 days
16260576|NCT04952051|Experimental|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
16260577|NCT04952051|Active Comparator|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
16260578|NCT04952038||ALS patients with sleep disorder|
16260579|NCT04952038||ALS patients without sleep disorder|
16260580|NCT04952025||ALS patients|
16260581|NCT04952025||normal controls|
16260582|NCT04952012||ATA-positive|
16260583|NCT04952012||ATA-negative|
16260584|NCT04951999|Other|Blood sampling|
16260585|NCT04951986|Experimental|High dose Rifampicin plus Levofloxacin|Standard TB treatment plus additional Rifampicin 35 mg/kg/day PLUS Levofloxacin for 14 days
16260586|NCT04951986|Experimental|Prednisone|Prednisone 1.5 mg/kg for 14 days
16260587|NCT04951986|Active Comparator|Standard TB treatment|High dose rifampicin/levofloxacin comparator
16260588|NCT04951986|Placebo Comparator|Placebo|Prednisone comparator
16260589|NCT04951960|Other|A group from higher PEEP to lower PEEP|Patient allocated for this arm are received from higher to lower PEEP setting.
16260590|NCT04951960|Other|A group from lower PEEP to higher PEEP|Patient allocated for this arm are received from lower to higher PEEP setting.
16260591|NCT04951934|Experimental|Treated Group|The Treated Group will undergo treatment with EmoLED twice a week for 5 consecutive weeks. The therapy, in this case, in addition to the standard treatment, will also include a treatment with the EmoLED device.
16260592|NCT04951934|Active Comparator|Control Group|The Control Group will follow the standard treatment indicated.
16260593|NCT04951921|Experimental|Hyperpolarized 13C pyruvate DNP-MRI scan|Patients receive hyperpolarized 13C pyruvate through IV injection less than 1-2 minute then undergo MRI over 3-5 minutes at baseline and 2 weeks after CCRT treatment. Total 2 times of MRI scan.
16260594|NCT04951908||control group|NORMAL TMJ
16260595|NCT04951908||Study group|Patients with TMJ internal derangement
16260596|NCT04951895||control group|patients with normal TMJ
16260597|NCT04951895||Study group|Patients with TMJ internal deragement
16260598|NCT04951882|Placebo Comparator|hUC-MSCs treatment|Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.
16260599|NCT04951882|No Intervention|non-cell therapy|Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.
16260600|NCT04951869|Experimental|Protescal group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, 1 mL Protescal gel was applied at the uterine suture site in Protescal group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). Protescal gel (0.5 mL) was applied over the subcutaneous tissue prior to skin closure in Protescal group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
16260601|NCT04951869|No Intervention|Control group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, No Protescal gel was applied at the uterine suture site in this Control group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). No application of Protescal gel (0.5 mL) over the subcutaneous tissue prior to skin closure in this Control group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
16260674|NCT04951401||Normal & abnormal lipid parameters value|parameters value among normal and abnormal lipid profile
16260602|NCT04951856|Experimental|Evolocumab + SOC|Investigational Product is open label Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
16260603|NCT04951856|Active Comparator|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
16260604|NCT04951843|Experimental|Black soybean koji product|Oral supplement 2 servings of black soybean koji product per day, for 10 weeks.
16260605|NCT04951830||control group|NORMAL TMJ
16260606|NCT04951830||Study group|patients with TMJ internal derangement
16260607|NCT04951817|Experimental|Ga68-PSMA ligand|Glass vial with 5~20 mCi(185-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), ≧ 0.33 mCi/mL @ EOS。
16260608|NCT04951804|Active Comparator|EUS-CPN with bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL preceded by injection of 10 ml of bupivacaine 0.5%.
16260609|NCT04951804|Experimental|EUS-CPN without bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL only.
16260610|NCT04951791|Experimental|treatment|patients will receive intravenous infusion of SMOFlipid 20%
16260611|NCT04951791|Placebo Comparator|control|patients will receive intravenous infusion of normal saline 0.9%
16260612|NCT04951778|Experimental|Participants with R/R AML and R/R HR-MDS - Part A|Part A (Dose Escalation) of the study will enroll R/R AML (Relapsed or Refractory Acute Myeloid Leukemia) and R/R HR-MDS (Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes) participants and will evaluate the safety and tolerability of escalating doses of CC-91633, administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
16260613|NCT04951778|Experimental|Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML participants.
16260614|NCT04951778|Experimental|Participants with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R HR-MDS participants.
16260615|NCT04951765|Experimental|Arm A|Cycle1 Day 1：fasting；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：low-fat meal
16260616|NCT04951765|Experimental|Arm B|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：fasting
16260617|NCT04951765|Experimental|Arm C|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：high-fat meal
16260618|NCT04951765|Experimental|Arm D|Cycle1 Day 1：fasting；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：high-fat meal
16260619|NCT04951765|Experimental|Arm E|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：low-fat meal
16260620|NCT04951765|Experimental|Arm F|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：fasting
16260621|NCT04951752||Hemicolectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
16260622|NCT04951752||Hemicolectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
16260623|NCT04951752||Nephrectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
16260624|NCT04951752||Nephrectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
16260625|NCT04951752||Percutaneous nephrolithotomy, Active treatment|1x30mL 0.75% Ropivacaine administered by way of transmuscular quadratus lumborum block
16260626|NCT04951752||Percutaneous nephrolithotomy, Placebo treatment|1x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
16260627|NCT04951752||Hysterectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
16260628|NCT04951752||Hysterectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
16260629|NCT04951752||Elective Caesarean section, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
16260630|NCT04951752||Elective Caesarean section, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
16260631|NCT04951739||Achalasia cardia patients - post peroral endoscopic myotomy|All the patients who will undergo peroral endoscopic myotomy for the treatment of achalasia cardia patients.
16260632|NCT04951726|Active Comparator|IV push|2 mg slow intravenous injection over five minutes repeated q6hr until resolution for up to 24 hours. (8 mg total in 24 hours)
16260633|NCT04951726|Experimental|IV continuous infusion|5 mg/50cc intravenous infusion at 4cc/hr or 0.4 mg/hr over 12 hours. If no clinical response, then increase rate to 8 cc/hr or 0.8 mg/hr until 24 hours. (16 mg total in 24 hours)
16260634|NCT04951726|Experimental|subcutaneous|1.0 mg subcutaneous repeated q8hr until resolution for up to 24 hours (3.0 mg total in 24 hours)
16260635|NCT04951713|Experimental|XZP-3287 combined with clarithromycin|XZP-3287 combined with clarithromycin
16260636|NCT04951713|Experimental|XZP-3287 combined with rifampicin|XZP-3287 combined with rifampicin
16260637|NCT04951700||Schizophrenia|Women and men, all races and ethnicities, aged 18-65 years, meeting diagnostic DSM-5 criteria for schizophrenia or schizoaffective disorder.
16260638|NCT04951700||Healthy Controls|Women and men, all races and ethnicities, aged 18-75 years, without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives.
16260639|NCT04951687|Experimental|Active: Ecologic Barrier©|"Dietary supplement: Ecologic Barrier©
~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate, and probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58).
~Subjects will consume 2g (5 billion CFU)/day of Ecologic Barrier©. The intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
16260675|NCT04951388|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16260676|NCT04951388|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
16260879|NCT04949971||Low volume group|The tidal volume of the non-exposed group was 6ml/kg ideal body weight
16260640|NCT04951687|Placebo Comparator|Placebo|"Dietary supplement: placebo powder
~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate.
~As with the active treatment, the intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
16260641|NCT04951674|Experimental|DIET|Participants will receive four individual, approximately 30-minute long dietary education sessions. The participants will receive detailed instructions (including meal plans, information on high fiber foods and serving sizes) on how to consume at least 30 grams of fiber per day.
16260642|NCT04951674|Placebo Comparator|CONTROL|No diet education. Group will spend same amount of time with study dietitian, but discussion is limited to review of current eating habits and minimal input on eating habits with referencing the standard food pyramid.
16260643|NCT04951661|Experimental|All Participants|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
16260644|NCT04951648|Experimental|Almonertinib|
16260645|NCT04951648|Active Comparator|Platinum-based doublet chemotherapy|
16260646|NCT04951635|Experimental|Almonertinib|
16260647|NCT04951635|Placebo Comparator|Placebo Almonertinib|
16260648|NCT04951622|Experimental|Nipocalimab|"Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.
~Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion from OLE Day 1 to 24 weeks. Participants who are stable on the q2w dosing regimen can be transitioned to a dosing regimen every 4 weeks (q4w) during OLE phase."
16260649|NCT04951622|Placebo Comparator|Placebo|Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
16260652|NCT04951583|Experimental|Immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT).|"Metastatic or advanced NSCLC: Single-agent Pembrolizumab (2 mg/kg or 200 mg every 3 weeks) in combination with investigational FMT capsules as follows: Full FMT at least 7 days prior to first cycle of Pembrolizumab, followed by supportive FMT within 7 days of the second cycle of Pembrolizumab, followed by supportive FMT within 7 days of the third cycle of Pembrolizumab.
~Metastatic melanoma and uveal melanoma: Combination therapy of Ipilimumab plus Nivolumab (Ipilimumab 3 mg/kg every 3 weeks and Nivolumab 1 mg/kg every 3 weeks x 4 doses, followed by Nivolumab 3 mg/kg or 240mg every 2 weeks or 6 mg/kg or 480mg every 4 weeks) in combination with investigational FMT capsules as follows: full FMT at least 7 days prior to first treatment with Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the second cycle with combination Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the third cycle of Ipilimumab plus Nivolumab."
16260653|NCT04951570||Hematoma Expansion (HE) group|
16260654|NCT04951570||non-HE group|
16260655|NCT04951544|Experimental|Intervention Group|This arm will start the intervention using LetSync app v1.0 from T1 to T4, baseline/Month 0 to Month 14.
16260656|NCT04951544|Active Comparator|Waitlist-Control Group|This arm will wait to begin the intervention using the LetSync app v2.0 from T3 to T4, Month 8 to Month 14.
16260657|NCT04951531|Experimental|BPTB double-bundle allograft group|The patient underwent arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
16260658|NCT04951531|Active Comparator|BPTB single-bundle allograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
16260659|NCT04951531|Active Comparator|BPTB single-bundle autograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
16260660|NCT04951518||Van Positive|Large Vessel Occlusion Positive
16260661|NCT04951518||Van Negative|Large Vessel Occlusion Negative
16260662|NCT04951505|Experimental|cefepime-taniborbactam|
16260663|NCT04951492|Experimental|Treatment (Olaparib)|Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16260664|NCT04951479|Experimental|Gel-Bead Embolization|
16260665|NCT04951466|Experimental|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to the MBTI will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
16260666|NCT04951466|Active Comparator|Healthy Lifestyle Education|Participants in the control group will receive sessions on the following topics: Introduction to health promotion, disease prevention and screening, healthy eating, physical activity, communication, and endings.
16260670|NCT04951440|Experimental|Intervention group|"Intervention group: 30min intravenous point. Infusion of 1400 mg of tetranitrone was given to bed I with a dose of 100ml, twice a day, with an interval of 12 hours, and continued administration for 7 days, that is, a total of about 14 times.
~version"
16260671|NCT04951440|Placebo Comparator|Placebo group|Placebo group: 30 minutes to earn pulse, I, 1, and dripping Yunmi gave 100mL placebo (sodium chloride injection). It is administered twice a day for 1 to 2 hours, and the pattern is transferred to about 7 people, that is, about 14 times in total.
16260672|NCT04951414||ICF|
16260673|NCT04951414||Control|
16260677|NCT04951362|Active Comparator|intranasal Ivermectin group|49 pateints with anosmia received ivermectin nanosuspension nasal spray
16260678|NCT04951362|Placebo Comparator|saline nasal spray|47 pateints with anosmia received saline nasal spray
16260679|NCT04951349|Experimental|Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.
16260680|NCT04951349|Placebo Comparator|Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.
16260681|NCT04951349|Experimental|Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.
16260682|NCT04951349|Placebo Comparator|Placebo Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.
16260685|NCT04951323|Experimental|Injection of anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Injection of two doses (at Day 1 and Day 21) of the anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
16260686|NCT04951310|No Intervention|Control|No Intervention: Control participants (residents of Bucks County, Montgomery County, Delaware County, and Allegheny County, PA) are not eligible for the sweepstakes.
16260687|NCT04951310|Experimental|Selected Zip Code Treatment|Selected Zip Code Treatment participants will have a significantly greater chance to win a prize in the sweepstakes than all other Philadelphia residents. Half of all prizes in every drawing will go to Philadelphia residents in the selected zip code.
16260688|NCT04951310|Experimental|All other Philadelphia Residents Treatment|All other Philadelphia Residents Treatment participants will be eligible for the sweepstakes. Half of all prizes in every drawing will go to Philadelphia residents outside of the selected zip code.
16260689|NCT04951284||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16260690|NCT04951284||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16260691|NCT04951284||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16260692|NCT04951284||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16260693|NCT04951271|Experimental|Intervention (SFA) group|solution-focused approach intervention was applied for 7 weeks
16260694|NCT04951271|No Intervention|Control (no intervention) group|No intervention was made.
16260695|NCT04951258|Experimental|Multicomponent exercise group|
16260696|NCT04951258|Active Comparator|Video home exercise group|
16260697|NCT04951245|Experimental|Ultrasound guidance combined with a carbon nanoparticle suspension(CNS) tracer|"1-ml carbon nanoparticle suspension(CNS) (China Food and Drug Administration approval H20041829, Lai Mei Pharmaceutical Co, Chongqing, China) which is sub cutaneously injected into the periareolar area. The breast is massaged for approximately 15 min so that the CNS is absorbed into the lymphatic duct.
~Ultrasound guidance:The investigators scribe a line on the axillary skin surface to locate the surgical incision. The investigators can find lymph nodes use the ultrasound diagnostic system. The investigators assesse the distance of the body surface to the lymph nodes by ultrasound to guide the depth of surgical incision. Ultrasound diagnostic system(TOSHIBA APLIO 400, Japan) is used for preoperative ultrasound positioning to locate lymph nodes."
16260698|NCT04951245|Active Comparator|Indocyanine Green combined With a carbon nanoparticle suspension(CNS)Tracer|"1-ml carbon nanoparticle suspension(CNS) (China Food and Drug Administration approval H20041829, Lai Mei Pharmaceutical Co, Chongqing, China) which is sub cutaneously injected into the periareolar area. The breast is massaged for approximately 15 min so that the CNS is absorbed into the lymphatic duct.
~Indocyanine Green(ICG) 2.5 mg of ICG in 1 mL of injectable water，ICG is injected intradermally into one spots at the same periareolar region followed by another 5-min massage.
~Fluorescence Tracer System（Device） (Dipu Medical Technology Co., Ltd, Zhuhai, China) is used to track subcutaneous lymph vessels and localized sentinel lymph nodes."
16260699|NCT04951232|Experimental|Test group (cinnarizide maleate injection group)|
16260700|NCT04951232|Placebo Comparator|control group (placebo group)|
16260701|NCT04951219|Experimental|Single-blind 80 mg Daily|Single-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
16260702|NCT04951219|Experimental|Single-blind 100 mg Daily|Single-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
16260703|NCT04951219|Experimental|Open-label 100 mg Daily|Open-label resmetirom 100 mg for an additional 52 weeks
16260704|NCT04951206|Active Comparator|Clobetasol Group|Clobetasol propionate 0.05% ointment is the active ingredient that will be compounded and combined with base ointment. Participants will be instructed to apply 1-3 clicks of the ointment dispensed via topiclick (35 gram) dispenser to the affected tissues once daily for 1 month, then 2-3 times a week for the remainder of the study.
16260736|NCT04950920||Y-2 sublingual test group|Y-2 sublingual tablets: Edaravone 30mg and d-borneol 6mg.
16260737|NCT04950920||placebo group|60 μg d-borneol
16260738|NCT04950907|Experimental|treatment|Uniportal VATS biopsy
16260705|NCT04951206|Placebo Comparator|Placebo Group|Placebo ointment will be identical in base ingredients but it will not contain clobetasol propionate. Participants will be instructed to apply the ointment to the affected tissues once daily for 1 month, then 2-3 times a week for the remainder of the study.
16260706|NCT04951193|Experimental|Goal2QuitVaping|Participants in the Goal2QuitVaping group will be asked to download the Goal2QuitVaping app to their smartphone. Goal2QuitVaping focuses on mood management as well as on quitting vaping nicotine. Participants will be asked to use Goal2QuitVaping regularly, at least once per day, for the study duration. Participants will also be asked to complete questionnaires weekly for 4 weeks.
16260707|NCT04951193|Other|Treatment as Usual|Participants in the treatment as usual group will be provided with educational material about quitting vaping nicotine and it will be suggested that they discuss any questions about mood management and about quitting vaping with their primary care provider. The educational material is from the National Cancer Institute's SmokeFree Teen website and includes information on recognizing reasons for quitting vaping, avoiding dual use of e-cigarettes and other tobacco products, setting a quit date, understanding triggers, and accessing social support.
16260708|NCT04951180||Group 1|Femoral acetabular impingement syndrome (FAIS) patients with gluteus medius lesions
16260709|NCT04951167|Active Comparator|PB: prophylactic bolus|an IV bolus of 4 mcg Norepinephrine will be administered immediately after spinal anesthesia, and then SF infusion will be started at 1 ml/min.
16260710|NCT04951167|Active Comparator|PI:prophylactic infusion|1ml of saline is administered immediately after spinal anesthesia, and then infusion will be started with the study drug at 1 ml/min.(4mcg/min)
16260711|NCT04951167|Active Comparator|TB:therapeutic bolus|immediately after spinal anesthesia, 1 ml of saline, followed by 1 ml/min infusion of SF, and when the blood pressure decreases by 20%, 1 ml of working solution and then 1 ml/min of saline infusion will be started.
16260712|NCT04951167|Active Comparator|TBI:therapeutic bolus-infusion|1 ml of study drug and 1 ml/min of study drug infusion will be started immediately after spinal anesthesia, after 1 ml of saline followed by 1 ml/min of SF infusion when blood pressure decreases by 20% of the entry
16260714|NCT04951141|Experimental|anti-GPC3 CAR-T|
16260715|NCT04951128|Experimental|Tranexamic acid arm|Eyelid(s) that received tranexamic acid in the local anesthetic
16260716|NCT04951128|Active Comparator|Control|Eyelid(s) that receive local anesthetic without tranexamic acid
16260717|NCT04951115|Experimental|Radiation + Chemo-Immunotherapy|
16260718|NCT04951102|Experimental|Group A Patients who receive SDM intervention|Group A patients will complete a pre-visit electronic Asthma SDM App. They may also receive educational information regarding asthma, medication management, smoking cessation, COVID-19 and COVID-19 vaccines.
16260719|NCT04951102|Active Comparator|Group B Patients who receive standard care|Group B patients will receive standard care.
16260720|NCT04951102|Experimental|Group A Physicians who receive SDM training and electronic Asthma SDM App data|Group A physicians will view an SDM Physician Training Video and receive the patients' reported data from the pre-visit asthma SDM App prior to the patients' visits.
16260721|NCT04951102|Active Comparator|Group B Physicians who provide standard care|Group B physicians will provide standard care.
16260722|NCT04951089|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation i-gel supraglottic device insertion for oxygenation and ventilation
16260723|NCT04951089|Experimental|Air-Q SP supraglottic insertion for oxygenation|Air Q SPsupraglottic device insertion for oxygenation Air-Q SP supraglottic device insertion for oxygenation and ventilation
16260724|NCT04951076|Experimental|BNC210|
16260725|NCT04951076|Placebo Comparator|Placebo|
16260726|NCT04951063|Experimental|Concurrent radiotherapy and chemotherapy|"All patients will receive segmented adaptive intensity-modulated radiotherapy once a day, 5 days a week. Three weeks after the end of the first course of radiotherapy, the therapy efficacy will be evaluated. Lung function and lung perfusion imaging will be also evaluated. For patients whose tumors reached partial response and lung function can tolerate radiotherapy supplements, The second course of radiotherapy will be performed.
~Under the premise of keeping the bioequivalent dose unchanged (BED=90GY), a single radiation dose climbing is carried out:
~Level 1: The first course: total dose (DT) 5100cGy/17f/300cGy, the second course: DT 1800cGy/6f/300cGy.
~Level 2: Thefirst course: DT 4000cGy/10f/400cGy, the second course DT 2400cGy/6f/400cGy.
~Level 3: The first course: DT 3000cGy/6f/500cGy, the second course DT 3000cGy/6f/500cGy."
16260728|NCT04951037|Experimental|Fully Asynchronous Online Savvy Program|Family caregivers of PLWD taking part in a fully asynchronous online caregiver education program.
16260729|NCT04951024|Experimental|Thoracolumbar interfacial plane (TLIP) Block|Thoracolumbar interfacial plane (TLIP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
16260730|NCT04951024|Active Comparator|Erector Spinae Plane (ESP) Block|Erector Spinae Plane (ESP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance
16260732|NCT04950985||Participants|Adults undergoing a CT scan to investigate possible NOE.
16260734|NCT04950933|Experimental|Test group|
16260735|NCT04950933|Placebo Comparator|Control group|
16260740|NCT04950894|Active Comparator|Active|HGN therapy activation at Month 1 - compared at Month 7 to Control group, continued stimulation through Month 13
16260741|NCT04950894|Other|Control|HGN therapy NOT activated at Month 1 - compared at Month 7 to Active group, stimulation will start at Month 7 + 1 Day and continue through Month 13
16260742|NCT04950881|Sham Comparator|Control group|Conventional monitor and treatment The surgery is performed after patient is under general anesthesia. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate.
16260743|NCT04950881|Experimental|Nerve block group|After the patient is under general anesthesia, an attending physicians perform the ultrasound-guided cervical vagus nerve block (using a 50mm Braun nerve stimulation needle, and the patients were injected with 10ml of lidocaine). Then the operation starts. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate. After endotracheal tube is removed, the patient will be followed up for next 24 hours.
16260744|NCT04950868|Experimental|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
16260745|NCT04950855||Pregnant Women|Healty pregnant women between 18-45 years,with no history of eye surgery and systemical disease.In 1st , 2nd and 3rd trimesters the measurements will be repeated
16260746|NCT04950855||Control Group|Healty non-pregnant women between 18-45 years with no history of eye surgery and systemical disease.
16260747|NCT04950842|Experimental|JB-101|induced T cell with suppressive function
16260748|NCT04950829|Active Comparator|Conventional brackets|Patients will receive an orthodontic treatment using conventional brackets until achieving appropriate alignment of the upper anterior teeth.
16260749|NCT04950829|Experimental|Self-ligating brackets|Patients will receive an orthodontic treatment using self-ligating brackets until achieving appropriate alignment of the upper anterior teeth.
16260750|NCT04950829|Experimental|3- Self-Ligating brackets with fapless corticotomy|Patients will receive an orthodontic treatment using self-ligating brackets with corticotomy until achieving appropriate alignment of the upper anterior teeth.
16260751|NCT04950816|Experimental|tailored MBI (.b)|
16260752|NCT04950816|Active Comparator|attention control condition|
16260753|NCT04950803|Active Comparator|Active arm|Subjects will take microbiome immunity formula (SIM01) daily for 3 months
16260754|NCT04950803|Placebo Comparator|Placebo arm|Subjects will take active vitamin daily for 3 months
16260755|NCT04950790|Experimental|Test group|Shuxuening injection + basic treatment
16260756|NCT04950790|Placebo Comparator|Control group|placebo (sterilized water for injection) + basic treatment
16260757|NCT04950777|No Intervention|standard of care|
16260758|NCT04950777|Experimental|patient education|The intervention group will receive the patient education document with their questionnaire, randomization will occur by the study team prior to subject visits. The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
16260761|NCT04950751|Experimental|SCB-2020S Standard Dose|Day 1 and 22: standard dose SCB-2020S with CpG 1018/alum adjuvant
16260762|NCT04950751|Experimental|SCB-2020S Low Antigen Dose|Day 1 and 22: low dose SCB-2020S with CpG 1018/alum adjuvant
16260763|NCT04950751|Experimental|SCB-2020S Low Adjuvant Dose|Day 1 and 22: standard dose SCB-2020S with low dose CpG 1018/alum adjuvant
16260764|NCT04950751|Experimental|SCB-2020S Mixed Series|Day 1 (Dose 1) standard dose SCB-2020S with CpG 1018/alum adjuvant and Day 22 Dose 2) standard dose SCB-2020S with alum adjuvant
16260765|NCT04950751|Active Comparator|SCB-2019|Day 1 and 22: standard dose SCB-2019 with CpG 1018/alum adjuvant
16260766|NCT04950738|Experimental|Acupuncture with press tack needle group (Acu)|Patients in acupuncture group will receive traditional Chinese acupuncture using Press Tack Needle (PYONEX 0.20 x l.5mm made by Seirin Corporation). The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), LI 4 (He Gu), SP 3 (Tai Bai,) ST 44 (Nei ting), LIV 3 (Tai Chong). The treatment will use bilateral acupuncture Interventions will be given on day 1, 3, and 5 after patient's enrolment.
16260767|NCT04950738|Placebo Comparator|Placebo group press tack placebo (Con)|Patients randomized to the control group will receive a press lack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to the acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), L1 4 (He Gu), SP 3; (Tat Bai), ST 44 (Ne1 tmg), LIV 3 (Tat Chong). Interventions will be given on days 1, 3, and 5 after the patient's enrolment.
16260768|NCT04950725|Experimental|Low respiratory muscle training|Low dose of RMT and fewer repetitions and use of RMT device per week
16260769|NCT04950725|Experimental|Respiratory muscle training for strengthening|Higher number of sets with a slightly lower number of repetitions per set
16260770|NCT04950725|Experimental|Respiratory muscle training for strengthening and nasal breathing|Higher number of sets with a slightly lower number of repetitions per set RMT accompanied with sets of nasal breathing
16260771|NCT04950725|Experimental|Respiratory muscle training for endurance|One set of RMT with a higher number of repetitions
16260772|NCT04950725|Experimental|Respiratory muscle training for endurance and nasal breathing|One set of RMT with a higher number of repetitions accompanied with sets of nasal breathing
16260946|NCT04949438|Experimental|Cohort 2 :Healthy participants|Healthy participants will receive a single oral dose of AZD4831 on Day 1.
16260774|NCT04950699||Control|Patients without typical symptoms of coronary heart disease, and coronary angiography or coronary CT showed no significant stenosis (coronary stenosis less than 30%), they were non coronary heart disease group, namely control group.
16260775|NCT04950699||myocardial infarction|This group includes acute myocardial infarction (ST segment elevation and non ST segment elevation) and old myocardial infarction. The diagnostic basis of acute myocardial infarction: cardiac biomarkers (cardiac troponin and / or myocardial enzymes) increased or decreased, at least once the value exceeded the upper limit of normal, and there was the following evidence of myocardial ischemia: (1) clinical symptoms of myocardial ischemia（ 2) New changes of myocardial ischemia appeared in ECG, i.e. new ST segment changes or left bundle branch block（ 3) Pathological Q wave appeared in ECG（ 4) Imaging evidence showed new loss of myocardial viability or regional wall motion abnormalities. Diagnosis of old myocardial infarction: the patient provided a history of previous myocardial infarction and confirmed as old myocardial infarction by the third or First Hospital of Peking University.
16260776|NCT04950686|Experimental|Intervention - Media Aware for Young Adults|This arm will receive Media Aware for Young Adults between the pretest and posttest questionnaire. Media Aware for Young Adults is a web-based sexual and relationship health promotion program that uses a media literacy education (MLE) approach. The program is self-paced and includes four modules.
16260777|NCT04950686|Active Comparator|Active Control - Health Aware for Young Adults|This arm will receive Health Aware for Young Adults in between the pretest and posttest questionnaire. Health Aware for Young Adults is a web-based sexual and relationship health promotion program. The program contains the same health content as Media Aware for Young Adults but without the media literacy education components. The program is self-paced and includes four modules.
16260778|NCT04950686|No Intervention|Delayed Intervention Control|Participants in this condition will not receive a sexual or relationship health promotion program until after the 12-month follow-up survey. After that survey is complete, they will receive access to the Media Aware for Young Adults program.
16260779|NCT04950673||Subjects who had COVID-19 infection and recovered at 3 months|500 subjects who have had a history of COVID19 infection and recovered 3 months prior to the enrollment
16260780|NCT04950673||Subjects who never had COVID-19 infection|500 subjects who never had a history of COVID19 infection prior to the enrollment
16260783|NCT04950647|Experimental|Test group 1|Nitroketazine tablet 600 mg group
16260784|NCT04950647|Experimental|Test group 2|Nitroketazine tablets 1200 mg group
16260785|NCT04950647|Placebo Comparator|Control group|placebo group
16260786|NCT04950621|Experimental|Remimazolam|In remimazolam group, a 0.1 mg/kg dose of intravenous remimazolam was administered for induction, and 0.3-0.7 mg/kg/h infusion for maintenance after intubation.
16260787|NCT04950621|Active Comparator|Propofol|In propofol group, a 2 mg/kg dose of intravenous propofol was administered for induction, and 4-12 mg/kg/h infusion for maintenance after intubation.
16260788|NCT04950608|Experimental|PATH|"The research study procedures include screening for eligibility, and study intervention including preparation, evaluations, one psilocybin session and follow up visits.
~-The treatment regimen consists of a single administration of psilocybin 25 mg orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions"
16260789|NCT04950595|Experimental|Beef mince group|The test meal provided at lunch will be made up of 45% beef mince, with all remaining ingredients the same as the other arm.
16260790|NCT04950595|Experimental|Plant-based mince group|The test meal provided at lunch will be made up of 45% plant-based mince, with all remaining ingredients the same as the other arm.
16260791|NCT04950582||UTI-high risk patients|patients who are at high risk for developing a urinary tract infection (UTI).
16260792|NCT04950569|Experimental|Levosimendan|Receive standard heart failure treatment, plus levosimendan treatment.
16260793|NCT04950569|No Intervention|Control|Receive standard heart failure treatment, without levosimendan treatment.
16260794|NCT04950556|Experimental|Exercise group|Fast and slow contractions will be taught in PFMT. For fast contractions, they will be asked to contract and relax the pelvic floor muscles quickly. For slow contractions, they will be asked to contract the pelvic floor muscles slowly, keep them at maximum contraction and relax slowly. Ten slow contractions in addition to 10 fast contractions will be considered as 1 set of exercises. For the first week, they will be asked to do 5 sets of exercises per day, every day. Then, the number of sets will be increased by 5 each week and the number of sets will reach 30 in the 6th week. PFMT will be applied by the patients as a home program every day of the week for 6 weeks.
16260795|NCT04950556|Other|Control group|Waiting list will included in control group.
16260796|NCT04950543||Meditation|
16260797|NCT04950530|Experimental|Arm 1|"Biktarvy - one tablet once daily, orally administered for the first 28 days of the study.
~No treatment for the last 44 days of the study."
16260798|NCT04950530|Experimental|Arm 2|No treatment for the first 28 days of the study. Biktarvy - one tablet once daily, orally administered for the last 28 days of the study (day 44-72).
16260799|NCT04950517||Wave 1 participants|The study consists of three work packages. Wave 1 participants will be included in all work packages.
16260800|NCT04950517||Wave 2 participants|The study consists of three work packages. Wave 2 participants will only be recruited for work package 2.
16260801|NCT04950504|Experimental|CNP-201 250 mg|200 mL intravenous infusion on Day 1 and Day 8: 250 mg CNP-201
16260802|NCT04950504|Experimental|CNP-201 450 mg|200 mL intravenous infusion on Day 1 and Day 8: 450 mg CNP-201
16260803|NCT04950504|Experimental|CNP-201 650 mg|200 mL intravenous infusion on Day 1 and Day 8: 650 mg CNP-201
16260804|NCT04950504|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
16260805|NCT04950491|Experimental|Test group (s-CAIS)|The test group workflow used a fully computer-guided implant surgical protocol.
16260806|NCT04950491|Other|Control group (CIS)|The control group workflow used a conventional implant surgical protocol.
16260807|NCT04950478|Experimental|Virtual Reality|The children wore the virtual reality headset and game was started one minute before the venipuncture. The children took off the virtual reality headset after the venipuncture ended.
16260808|NCT04950478|No Intervention|Control Group|No intervention was performed to reduce pain in the control group
16260809|NCT04950465|Experimental|Test Dentifrice|Apply a full ribbon of toothpaste on the head of the toothbrush provided. Brush teeth for 1*-timed minute, followed by brushing of the qualifying sensitive teeth. Following brushing rinse once with 10 milliliter (ml) of water from the rinsing cup provided.
16260810|NCT04950465|Active Comparator|Negative Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
16260811|NCT04950465|Active Comparator|Positive Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
16260812|NCT04950452|Experimental|CLL-EX|Subjects will undergo supervised exercise training 3 x per week for 12 weeks. Three/sessions per week will consist of intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes. Following this, on 2 occasions/week subjects will complete muscular endurance resistance training on machine weights.
16260813|NCT04950452|No Intervention|CLL-CON|Subjects will not receive supervised exercise training and will be asked to maintain their daily lifestyle behaviors.
16260814|NCT04950439|Other|Myocardial CT|The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
16260815|NCT04950426|Experimental|Treatment with reconsolidation therapy|Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet
16260816|NCT04950413|Active Comparator|Traditional Treatment Arm|conventional physical therapy program (infrared, stretching exercise, isometric strengthening exercise)
16260817|NCT04950413|Experimental|IASTM treatment arm|Instrument-assisted soft tissue mobilization (IASTM) is a therapeutic technique that is based on the soft tissue mobilization rationale introduced by James Cyriax.
16260818|NCT04950413|Experimental|Phonophoresis treatment arm|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2.
16260819|NCT04950413|Experimental|Combined IASTM and phonophoresis treatment arm|Combined phonophoresis and M2t Blade
16260820|NCT04950400|Experimental|Carrelizumab + chemotherapy + apatinib|
16260821|NCT04950387|Experimental|Experimental group|Participants took part in breathing exercises
16260822|NCT04950387|No Intervention|Control group|Participant did not take part in intervention
16260823|NCT04950374|Experimental|Moisturizer Body Lotion and Lip Moisturizer Regimen|All participants will receive and use both products.
16260824|NCT04950348|Experimental|3D printed personalized TKA prosthesis|Patients in the experimental group received 3D printed personalized TKA prosthesis treatment
16260825|NCT04950348|Active Comparator|Zimmer NexGen TKA prostheses|Patients in the active comparator group received Zimmer NexGen TKA prostheses treatment
16260826|NCT04950335||AOPT|patients underwent AOPT to treat large cystic OLTs (>10mm)
16260827|NCT04950335||AOCT|patients underwent AOCT to treat large cystic OLTs (>10mm)
16260828|NCT04950322|Experimental|Treatment group A|
16260829|NCT04950322|Placebo Comparator|Treatment group B|
16260831|NCT04950296|Active Comparator|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
16260832|NCT04950296|Active Comparator|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
16260833|NCT04950296|Placebo Comparator|Microcrystalline Cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
16260834|NCT04950283||Magnetic resonance examination and anthropometric, metabolic characterization|
16260835|NCT04950270||Group|Critically ill adult patients meeting all eligibility criteria with MRI-based PRES diagnosis within the last 48 hours
16260836|NCT04950257|Active Comparator|waiting list control group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination after a 6-week wait.
16260837|NCT04950257|Experimental|treatment group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination immediately.
16260838|NCT04950218||Psoriasis patients|Eligible psoriasis patients will be identified from the daily outpatient program, at the Department of Dermato-Allergology, that is the department will provide the patient's contact information to the project group. As most outpatient clinic psoriasis is classified as moderate to severe, in order to approximate a random sample as accurate as possible including patients with mild psoriasis, all people with a diagnosis of psoriasis will a general invitation to participate in the study through appropriate channels such as the Danish Psoriasis Foundation's newsletter.
16260839|NCT04950218||Control group|The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
16261192|NCT04947748|Experimental|24 hour oral antibacterial therapy|T.Augmentin 1g x 3 p/o
16285839|NCT04775615|Experimental|Treatment group B|
16260840|NCT04950205|Experimental|Sevoflurane post conditioning group（S1）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery ,1% sevoflurane plus after open Carotid artery until the end of surgery
16260841|NCT04950205|No Intervention|The control group（P）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery without sevoflurane
16260842|NCT04950192||Prospective Observational|Prospective observational subjects undergoing planned cardiac procedures utilizing image guidance
16260844|NCT04950153|Other|HIV Testing Intervention|Combination HIV testing and linkage to care intervention includes social media engagement and peer navigation
16260845|NCT04950153|Other|HIV Treatment Intervention|Combination HIV treatment outcomes (retention, ART adherence and viral suppression) intervention includes SMS text messaging and peer navigation
16260846|NCT04950140|Experimental|Robot Assisted Laparoscopic|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
16260847|NCT04950140|Active Comparator|Conventional Laparoscopic Surgery|Conventional Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
16260848|NCT04950127|Experimental|Participants receiving linerixibat|
16260849|NCT04950127|Experimental|Participants receiving linerixibat followed by placebo|
16260850|NCT04950127|Placebo Comparator|Participants receiving placebo|
16260851|NCT04950127|Experimental|Participants receiving placebo followed by linerixibat|
16260852|NCT04950114|Experimental|120 mg Dose Cohort|Participants who received GFB-887 or placebo at dose level 2 (120 mg) in GFB-887-201 will receive the same daily dose level upon enrollment. Participants who received GFB-887 or placebo at dose level 1 in GFB-887-201 will receive GFB-887 at the dose level 2 (120mg).
16260853|NCT04950114|Experimental|320 mg Dose Cohort|Participants who received GFB-887 or placebo at dose level 3 (320 mg) in GFB-887-201 will receive the same daily dose level upon enrollment
16260854|NCT04950101|Active Comparator|HAS-N|In this arm the patient without HIV using PrEP will be included
16260855|NCT04950101|Active Comparator|HAS-P|In this arm the patient with HIV will be included
16260856|NCT04950088|Active Comparator|Game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
16260857|NCT04950088|Active Comparator|no game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
16260860|NCT04950062|Experimental|High intensity interval training|Group A included 30 subjects who will participate in high intensity interval training on a treadmill for 12 weeks, 3 times/week.
16260861|NCT04950062|Active Comparator|Intermittent fasting|Group B that included 30 subjects will participate in intermittent fasting for 12 weeks, 3 times/week.
16260862|NCT04950049|Active Comparator|2 ml dexamethasone (5 mg/ml)|50 patients receive 2 ml dexamethasone (5 mg/ml) , the injection time of dexamethasone was less than 2s.
16260863|NCT04950049|Experimental|5 ml dexamethasone (2mg/ml)|50 patients receive 5 ml dexamethasone (2mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
16260864|NCT04950049|Experimental|10 ml dexamethasone (1mg/ml)|50 patients receive 10 ml dexamethasone (1mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
16260865|NCT04950049|Experimental|20 ml dexamethasone (0.5mg/ml)|50 patients receive 20 ml dexamethasone (0.5mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
16260866|NCT04950036||Normal control group-Grade 0|Arthroscopic examination of the hip was normal, and the labrum was intact without injury or tear.
16260867|NCT04950036||Ligament injury -Grade 1|Arthroscopic examination of the hip showed labrum degeneration or injury, but no local or complete tear.
16260868|NCT04950036||Ligament tear-Grade 2|Arthroscopy of the hip revealed partial or complete loss of labrum.
16260869|NCT04950023||early COPD|1) <60 years old; 2) smoking ≥ 10 pack years. 3) with any of the following anomalies: a. Post-bronchodilator FEV1/FVC< 0.7. b. CT image abnormalities: emphysema, air trapping or bronchial wall thickening; c.Rapid decrease of FEV1 (>60 ml/yr).
16260870|NCT04950023||Control|1) <60 years old; 2) Pre-bronchodilator FEV1/FVC≥70% and FEV1 ≥ 80% predicted; 3) no exposure to harmful factors such as cigarettes and dust pollution.
16260871|NCT04950010|Experimental|High-Intensity Interval Training (HIIT)|Breast cancer survivors randomized to HIIT will participate in a high-intensity interval training program for 12 weeks.
16260872|NCT04950010|Active Comparator|Moderate-Intensity Exercise (MOD)|Breast cancer survivors randomized to MOD will participate in a moderate-intensity aerobic exercise program for 12 weeks.
16260873|NCT04950010|No Intervention|Usual Care (UC)|Individuals randomized to UC will be instructed to continue standard cancer care and engage in habitual lifestyle behaviors.
16260874|NCT04949997||control|patients without heart failure
16260875|NCT04949997||HF|patients with heart failure
16260876|NCT04949984|Experimental|Bright light therapy|The devices used for the intervention were bright white light lamps providing an intensity of 10,000 lux. Four users participated in each session, placing two users per lamp, seated in a comfortable chair with armrests 70 cm from the lamp. The sessions were 30 minutes/day in the time slot between 10:30 and 12:00 in the morning, 5 days a week (Monday to Friday) for 4 weeks (total 20 sessions). Two groups of participants per day were established, the first shift being from 10:30 to 11:00, and the second from 11:15 to 11:45 a.m., which means the stimulation of 8 people per day (month). During the sessions, while exposed to light, participants were watching documentaries on neutral topics (nature, Spanish and Galician culture, etc.).
16260877|NCT04949984|No Intervention|Control group|Participants were evaluated before and after the experimental group finishes the intervention program (pre- vs. postintervention) to facilitate an examination of the changes in the outcome measures.
16260878|NCT04949971||High volume group|The tidal volume of the exposed group was 10ml/kg ideal body weight.
16260880|NCT04949958|Experimental|Experimental: Exercise Based Manual (Supervised)|Supervised Exercises with exercise based Manual (exercise & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of different type of exercises including warm up and rest interval
16260881|NCT04949958|Experimental|Experimental: Exercise Based Manual (Home Based)|Experimental: Exercise Based Manual (Home Based) Home Based- Exercise Manual (Exercise & Educational Component) for 16 weeks. Subject will be asked to maintain a regular exercise.
16260882|NCT04949958|Placebo Comparator|Placebo Comparator: Control|Age matched Control Group followed for 16 weeks with General Advise to active
16260883|NCT04949945|Experimental|CHF patients who will receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients)(experimental group) will receive guided self help culturally adapted cognitive behavioral therapy.
16260884|NCT04949945|No Intervention|CHF patients will not receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients) (control group) will not receive Self Help Culturally Cognitive Behavior Therapy.
16260885|NCT04949932|Experimental|Intervention Arm|Poly herbal powder (PHP)
16260886|NCT04949932|Placebo Comparator|Placebo Arm|Powder of Cicer arietinum
16260887|NCT04949919|Experimental|ESRD patients with supervised training|The participants will receive in-hospital supervised exercise training prior to HD
16260888|NCT04949906||The experimental group|The application of raising serum brain granules
16260889|NCT04949906||The control group|No nourishing serum brain granules are used
16260890|NCT04949880|Experimental|Group A|Drug-Eluting Balloon Dilatation Catheter
16260891|NCT04949867|Active Comparator|Dual-hormone Closed-loop|FiAsp® and GlucaGen®.
16260892|NCT04949867|Placebo Comparator|Single-Hormone Closed-loop|FiAsp® and isotonic saline.
16260896|NCT04949828||Participants on CREON|
16260897|NCT04949802|Experimental|laser|treated with Vialase laser
16260903|NCT04949776|Experimental|Double reading of all cases with and without Transpara software|Double reading of all cases with and without Transpara software
16260904|NCT04949750|Experimental|Paper based cognitive training|Patients with Alzheimer's disease in the early stage receive 12 weeks paper based cognitive training and standard care (medication)
16260905|NCT04949750|No Intervention|Control group|Patients with Alzheimer's disease in the early stage only receive standard care (medication)
16260906|NCT04949737||Helicobacter Pylori detection|Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).
16260909|NCT04949698||No TMA|parturients without thrombotic microangiopathies
16260910|NCT04949698||TMA with plasma exchange|parturients with thrombotic microangiopathies, and treated with plasma exchange
16260911|NCT04949698||TMA without plasma exchange|parturients with thrombotic microangiopathies, but not treated with plasma exchange
16260912|NCT04949685||symptomatic plantar plate rupture|plantar plate repair operation for symptomatic lesser metatarsophalangeal joint instability
16260913|NCT04949672||Open TME|Total Mesorectal Excision (TME) is the gold standard surgical treatment of rectal cancer. According to the technique first described by Bill Heald, TME entails the resection of the rectum including the whole mesorectal fat and an intact mesorectal fascia. Open TME is accomplished through a midline xifo-umbilical laparotomy and requires a complete mobilization of the left colon and central ligature of inferior mesenteric artery and vein.
16260914|NCT04949672||Laparoscopic TME|Laparoscopic TME mirrors the procedure performed through laparotomy with the same operative steps and performing rectal resection including the excision of the surrounding mesorectal fat and fascia.
16261227|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation and Mechanical insufflation/ exsufflation|
16260915|NCT04949672||Robotic TME|Robotic TME mirrors the procedure described by Bill Heald for open surgery but the operation is performed by the master-slave DaVinci System under 3D laparoscopic guidance. The rectal resection is performed including mesorectal fat and fascia.
16260916|NCT04949672||TransAnal TME|TaTME has first described by Antonio Lacy in 2012. This procedure has two steps: abdominal and perineal. The abdominal step is performed through a laparoscopic approach as described for laparoscopic TME but the caudal dissection is stopped right below the level of the peritoneal rectal reflection (Douglas pouch). The perineal step is accomplished transanally inserting a specially designed platform into the anal canal and performing the total mesorectal excision under endoscopic guidance.
16260917|NCT04949659|Experimental|Low pressure pneumoperitoneum|Use of low pressure pneumoperitoneum during laparoscopic appendectomy
16260918|NCT04949659|Experimental|Medium pressure pneumoperitoneum|Use of medium pressure pneumoperitoneum during laparoscopic appendectomy
16260919|NCT04949646|Experimental|pIONM|"In the experimental group pIONM will be performed intraoperatively. For the implementation of pIONM, a special device, that allows simultaneous monitoring of sphincter signals and bladder manometry, will be introduced. This device will employ the placement of a bipolar electrode in the internal and external anal sphincter. Moreover, another electrode will be placed on the surrounding tissues. For bladder manometry, the catheter will be connected to the pressure sensor, and subsequently to the pIONM monitor. Intraoperatively, depending on the approach (open or laparoscopic), the respective bipolar stimulator will be used.
~Prior to the initiation of pIONM, urinary bladder will be drained and filled with 200 ml R/L. The pIONM parameters will be the following: 1-25 milliampere current, 30 Hz frequency and 200 μs monophasic pulses."
16260920|NCT04949646|No Intervention|Control|In the control group pIONM will not be performed intraoperatively
16260923|NCT04949620|Experimental|REThink game, then responder monitoring|Participants in this group will have access to the REThink game for four weeks; based on their response to the intervention, they will be monitored for an additional period of four weeks.
16260924|NCT04949620|Experimental|REThink game, then online parent intervention for non-responders|Participants who are allocated to the REThink game and do not respond to the four-week intervention will be allocated to the online
16260925|NCT04949620|No Intervention|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks) and the online parenting program (after an additional four weeks).
16260926|NCT04949607|Experimental|Chronic Traumatic Brain Injury|Subjects aged 18-70 years with chronic traumatic brain injury receiving Inulin treatment.
16260927|NCT04949607|Experimental|Healthy Controls|Healthy subjects aged 18-70 years receiving Inulin treatment.
16260928|NCT04949581|Experimental|bioelectric therapy|patients will receive micro-current electrical stimulation three times/week for four weeks
16260929|NCT04949581|Active Comparator|cardiac rehabilitation programe|patients will receive a cardiac rehabilitation program three times/week for four weeks
16260930|NCT04949568||Cohort|Adul Haitian immigrants.
16260931|NCT04949542|Experimental|Bolster|Participants in the experimental arm will be provided access to the Bolster smartphone application designed to support caregivers of young adults with early psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary.
16260932|NCT04949542|Other|Control|Participants in the control condition will be provided support resources from mental health advocacy organizations representing currently available resources for caregivers (including a selection from the National Alliance on Mental Illness and Mental Health America). They will also have access to the research team by phone for technical troubleshooting and support as necessary.
16260933|NCT04949516|Experimental|Mono Antiplatelet and Colchicine Therapy|Aspirin-free, single P2Y12 inhibitor (prasugrel or ticagrelor) and colchicine treatment
16260934|NCT04949503||study group|Patients of study group were all treated with chemoradiotherapy plus nimotuzumab.
16260935|NCT04949503||control group|Patients of control group were only treated with chemoradiotherapy, and were collected at least 3 times as many patients as the study group.
16260936|NCT04949490|Experimental|Group A, BNT162b2s01 30 µg (1 dose)|
16260937|NCT04949490|Experimental|Group A, BNT162b2 30 µg (1 dose)|
16260938|NCT04949490|Experimental|Group B, BNT162b2 30 µg (2 doses)|
16260939|NCT04949477|Active Comparator|Group (D)|The patient will receive intranasal dexmedetomidine.
16260940|NCT04949477|Active Comparator|Group (P)|The patient will receive paracetamol orally.
16260941|NCT04949464|Experimental|Prevention (smoking cessation, nicotine replacement, LDCT)|Patients use the smartphone application, Positively Smoke Free - Mobile, for 42 days. Patients also receive nicotine replacement therapy for 12 weeks. Within 60 days of study registration, patients undergo LDCT.
16260942|NCT04949451|Placebo Comparator|TRF-C|Follows time restricted feeding protocol.
16260943|NCT04949451|Experimental|TRF-P|Follows time restricted feeding protocol, consumes protein supplement
16260944|NCT04949451|Experimental|TRF-S|Follows time restricted feeding protocol, consumes ketogenic supplement
16260945|NCT04949438|Experimental|Cohort 1: Participants with severe renal impairment|Participants with severe renal impairment will receive a single oral dose of AZD4831 on Day 1.
16262150|NCT04940923||Healthy controls|Age and gender matched healthy controls
16260947|NCT04949425|Experimental|Patients with advanced solid tumours|Patients with advanced solid tumours will receive Adavosertib once daily for 5 days followed by 2 days off for 2 weeks out of a 21-day cycle.
16260948|NCT04949412||non-severe COVID19|Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types or A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura.
16260949|NCT04949412||Severe Covid19|Severe pneumonia was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR ≥30 times/minute; ii) hypoxia: oxygen saturation (resting state) ≤93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) ≤ 300 mmHg (millimeters of Mercury); or iv) the occurrence of respiratory or other organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
16260952|NCT04949386|Experimental|Treatment with S-1226 (8%)|Subjects randomized to this treatment arm will receive S-1226(8%) twice daily for 7 consecutive days. S-1226 will be administered by inhalation for 3-4 minutes.
16260953|NCT04949386|Placebo Comparator|Placebo|Subjects randomized to receive placebo will be administered with medical grade air with 3ml saline (0.9% NaCl) using the Circulaire II hybrid system. Placebo will be administered by inhalation for 3-4 minutes.
16260954|NCT04949373|Experimental|HILT+nerve/tendon gliding exercise+rest splint|Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for three weeks (one session per day for a total of 15 sessions). A 3-phase treatment program will be performed in each session, and a physiotherapist will then apply nerve/tendon gliding exercises program to the patients once daily. The patients will use rest splint at night.
16260955|NCT04949373|Sham Comparator|Sham HILT+nerve/tendon gliding exercise+rest splint|Patients will receive sham laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for three weeks (one session per day for a total of 15 sessions). A 3-phase treatment program will be performed in each session, and a physiotherapist will then apply nerve/tendon gliding exercises program to the patients once daily . The patients will use rest splint at night.
16260956|NCT04949360|Active Comparator|Standard CBTi (CBTi-S):|This is a positive control group/active comparator, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structured appointments with a board-certified sleep psychologist. The professionals performing the CBTi sessions will not be part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
16260957|NCT04949360|Placebo Comparator|Minimal intervention - Sleep hygiene (MI-SH):|This group corresponds to a negative control group/placebo comparator, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no-treatment or waiting list controls, due to the behavioral nature of insomnia.
16260958|NCT04949360|Experimental|Online CBTI (CBTI-O)|This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
16260959|NCT04949360|Experimental|Online CBTi + additional features (CBTi-O+)|This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.
16260960|NCT04949347||Glycerin-preserved, human-donor, cornescleral patch grafts|Consecutive glaucoma patients who had undergone glaucoma drainage device implantation using glycerin-preserved, human-donor, cornescleral patch grafts
16260961|NCT04949334|Experimental|Dofin Breathing Strength Builder|Usual post stroke care and respiratory muscle training
16260962|NCT04949334|No Intervention|Usual post stroke care|Usual post stroke care
16260963|NCT04949321|Experimental|Gadovist (gadobutrol) / two MRI|60 Meniere's Disease patients and 20 healthy volunteers (sample of 5 volunteers per MRI machine)
16260964|NCT04949308||Genetic diagnosis|Genetic: Genetic diagnosis No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
16260965|NCT04949295||the hemodialysis group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
16260966|NCT04949295||the normal group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
16260967|NCT04949282||Lutathera|
16260968|NCT04949269|Experimental|Part A|
16260969|NCT04949269|Experimental|Part B|
16260970|NCT04949269|Experimental|Part C|
16260971|NCT04949269|Experimental|Part D|
16261228|NCT04947423|Experimental|DPI-386 Nasal Gel|Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
16260974|NCT04949243||People who use the self administered SARs-CoV-2 antigen testing kits|
16260975|NCT04949230||COVID-19 Patients|Subjects who have recovered from COVID-19
16260976|NCT04949217|Experimental|Inlay Bristow Group|Inlay Bristow procedure
16260977|NCT04949217|Active Comparator|Onlay Bristow Group|Onlay Bristow procedure
16260978|NCT04949204||Migraine patients|Wearable wrist sensor + headache application on smartphone
16260979|NCT04949204||Cluster Headache Patients|Wearable wrist sensor + headache application on smartphone
16260980|NCT04949191|Experimental|Study Treatment 1: Pemigatinib (INCB054828)|Pemigatinib will be taken orally once daily
16260981|NCT04949191|Experimental|Study Treatment 2: Pemigatininb+ Retifanlimab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks
16260982|NCT04949191|Experimental|Study Treatment 3: Pemigatininb + Pembrolizumab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.
16260983|NCT04949178||Critically ill cirrhotics with septic shock and AKI undergoing CRRT|Consecutive critically ill cirrhotics with septic shock and AKI who give written informed consent will be included in this prospective study
16260984|NCT04949165|Experimental|Iron Supplementation|
16260985|NCT04949165|No Intervention|Control|
16260986|NCT04949139|Active Comparator|Rapid intermittent bolus group|"A : males < 65 ; B : females < 65 or males ≥ 65 ; C : females ≥ 65 yrs
~<During the first 3 h>
~Primary treatment over 1h A: 5DW 8 B: 5DW 7 C: 5DW 6 mL/kg
~If undercorrected, Repeat the 5DW amount infused during primary treatment after 3 h
~<At 3-24 h> Modify protocol based on sNa at each time point (6/12/18/24 h)
~Check U/S ratio at 0 h
~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h
~≥ 0.5: repeat the amount infused during primary treatment q 6 h
~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion
~<At 24-48 h> Modify protocol based on sNa at each time point (30/36/42/48 h)
~Check U/S ratio at 24 h
~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h
~≥ 0.5: repeat the amount infused during primary treatment q 6 h
~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion"
16260987|NCT04949139|Active Comparator|Slow continuous infusion group|"Participants will be divided into three groups same as above
~<During the first 3 h>
~Primary treatment A: 5DW 1.8 B: 5DW 1.57 C: 5DW 1.35 mL/kg/h
~Modify protocol as described below based on sNa measurement at 3 h
~undercorrection: maintain the infusion rate
~target correction: stop the infusion
~<At 3-24 h> Modify protocol based on sNa measurement at each time point (6/12/18/24 h)
~Check U/S ratio at 0 h
~• undercorrection
~< 0.5: increase the infusion rate to twice that of the primary treatment
~≥ 0.5: maintain the infusion rate
~• target correction
~< 0.5: maintain the infusion rate
~≥ 0.5: stop the infusion
~<At 24-48 h> Modify protocol based on sNa measurement at each time point (30/36/42/48 h)
~Check U/S ratio at 24 h
~• undercorrection
~< 0.5: increase the infusion rate to twice that of the primary treatment
~≥ 0.5: maintain the infusion rate
~• target correction
~< 0.5: maintain the infusion rate
~≥ 0.5: stop the infusion"
16260988|NCT04949126||acute pain of pulpal origin|no intervention
16260989|NCT04949126||anxious group|no intervention
16260990|NCT04949113|Experimental|A: Neoadjuvant|"2 cycles of neoadjuvant ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by a total lymph node dissection (TLND) and if applicable, resection of in-transit metastases.
~Patients not achieving a pathologic response in arm A will also receive adjuvant nivolumab 480 mg every 4 weeks 11 cycles. In case of BRAF V600E/K mutation-positivity, patients will be treated with adjuvant dabrafenib plus trametinib for 46 weeks instead."
16260991|NCT04949113|Active Comparator|B: Adjuvant|Standard upfront total lymph node dissection (TLND) and if applicable, resection of in-transit metastases followed by 12 cycles adjuvant nivolumab 480 mg every 4 weeks
16260992|NCT04949100|Experimental|Microcurrent|
16260993|NCT04949100|Placebo Comparator|Placebo|
16260994|NCT04949087|Experimental|Corticosteroid Injection Group|80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection
16260995|NCT04949087|Active Comparator|Platelet-Rich Plasma Injection Group|15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP
16260996|NCT04949074||RNA extracted from Positive NSP samples|RNA extracted from NSP samples, found positive for the presence of SARS-CoV-2
16260997|NCT04949074||RNA extracted from Positive saliva samples|RNA extracted from saliva samples found positive for the presence of SARS-CoV-2
16260998|NCT04949074||RNA extracted from negative NSP samples|RNA extracted from NSP samples, found negative for the presence of SARS-CoV-2
16260999|NCT04949074||RNA extracted from negative saliva samples|RNA extracted from saliva samples found negative for the presence of SARS-CoV-2
16261000|NCT04949061|Experimental|Intervention Arm: Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
16261001|NCT04949061|Other|Control Arm: Enhanced Treatment as Usual (ETA-U)|The control group will receive the information about freely available psychological support options. Also, they will receive brief psychoeducation about the mental health problems and psychological distress via online leaflets. After all the measurements are completed, the control group will be able to receive the CA-CBI.
16261002|NCT04949048|Experimental|Magneto PE Kit|Treatment with Magneto PE Kit
16261003|NCT04949035||COVID-19 survivors|
16261004|NCT04949022|Experimental|Hybrid closed loop system|Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a three month study phase with advanced hybrid closed loop Auto mode
16261005|NCT04949009||Patients with primary immune thrombocytopenia (ITP)|"Ever been diagnosed as ITP patients. The diagnostic criteria comply with the Chinese Guidelines for the Diagnosis and Treatment of Adult Primary Immune Thrombocytopenia (2020 Edition)"
16261006|NCT04948996|Experimental|El Buen Consejo Móvil- Group (EBCM-G)|Participants in the group condition will be placed in groups of five participants within the app. Their version of EBCM will have the functionality to connect individuals to one another via a facilitator-guided chat room (EBCM-G), where they can respond to suggested strategies within the app and communicate with each other or their facilitator guide using voice or text.
16261007|NCT04948996|Active Comparator|El Buen Consejo Móvil- Individual (EBCM-I)|Participants randomized to EBCM-I will receive the same program contents without the group functionality.
16261008|NCT04948983|Active Comparator|Intervention group|"The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records.
~The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?"
16261009|NCT04948983|Placebo Comparator|Control group|"The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system.
~The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records."
16261010|NCT04948957||esmolol (Group E)|
16261011|NCT04948957||nitroglycerin (Group N)|
16261012|NCT04948944|Experimental|active transcranial direct current stimulation|The investigators use Soterix mini-CT Stimulator to deliver 30 minutes 2mAmp tDCS to the bilateral DLPFC (optimized lateral electrode placement montage), with the the anode on the left hemisphere and the cathode on the right hemisphere. The electrodes are rubber and are placed in an MRI compatible holder and affixed with conductive paste. The investigators will use a bespoke headstrap to place the electrodes, which are held in place by the conductive paste.
16261013|NCT04948944|Sham Comparator|sham transcranial direct current stimulation|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
16261014|NCT04948931|Experimental|Lavender aromatherapy|As an intervention to this group, lavender application will be made by inhalation. Participants will apply lavender oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
16261015|NCT04948931|Experimental|Rosemary aromatherapy|As an intervention to this group, rosemary application will be made by inhalation. Participants will apply rosemary oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
16261016|NCT04948931|Placebo Comparator|Control|Distilled water will be used for the application to this group. The application will be made every night for a month, half an hour before going to bed, under the supervision of a relative. Participants will apply distilled water by dropping three drops on cotton, holding it 5-10 cm away from the nose, for five minutes and breathing normally.
16261017|NCT04948918|Experimental|Distal renal denervation|The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system.
16261018|NCT04948905||Patients diagnosed as having Borderline Personality Disorder|These patients have been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
16261019|NCT04948905||Healthy Controls (Patients not diagnosed as having Borderline Personality Disorder )|These patients have NOT been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
16261022|NCT04948879||Vascular reconstruction|Patients who have undergone resection with or without reconstruction of a major blood vessel in the context of surgery for a locally advanced pelvic malignancy. This will mostly refer to patients who have had resection/reconstruction of their internal iliac vessels, or less likely common iliacs.
16261023|NCT04948866|Experimental|Intervention Condition: ADRD-PC Program|"Dementia-specific palliative care delivered by hospital-based specialty interdisciplinary palliative care teams.
~Standardized caregiver education will be provided by the palliative care team. Clinicians will share and discuss the booklet Advanced Dementia: A Guide for Families, which addresses common concerns and treatment decisions.
~Transitional care will be provided by the palliative care team, including facilitation of community-based services and two post-discharge telephone calls."
16261024|NCT04948866|Active Comparator|Control Condition|Patient-family caregiver dyads randomized to the control arm will receive educational materials from the Alzheimer's Association, specifically designed for late-stage ADRD caregivers. The patient will receive usual hospital and post-acute care.
16261025|NCT04948853|No Intervention|Treatment as usual|Treatment as usual, with respect to employment, for individuals on probation typically entails the probation officer informing the probationer that probationer is responsible for obtaining employment or could entail a referral from a probation officer to an employment or job assistance service, such as vocational rehabilitation. The probationer is responsible for follow up with that service.
16261026|NCT04948853|Experimental|Intervention - Individual Placement Support-Supported Employment|Subjects in this condition will receive services from a 1.5 FTE IPS-SE team that will work to provide one-on-one person-centered services to help obtain employment, including but not limited to career profiling, resume assistance, job placement, training and other activities.
16261027|NCT04948840|Other|Group A|Patients with early grade ≥2 radio-induced epidermis Intervention : blood sample
16261028|NCT04948840|Other|Group B|Patients with early grade 0-1 radiation-induced epidermis Intervention : blood sample
16261029|NCT04948840|No Intervention|Group C|Patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
16261030|NCT04948840|No Intervention|Group D|Patients without late pathologic radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
16261031|NCT04948840|No Intervention|Group E|Control group : patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
16261032|NCT04948827|Experimental|Part A - Single-Dose (Active)|Each Part A cohort will be randomized to either active SBP-9330 or matching placebo in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
16261033|NCT04948827|Placebo Comparator|Part A - Single-Dose (Placebo)|Each Part A cohort will be randomized to either active SBP-9330 or matching placebo in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
16261034|NCT04948827|Experimental|Part A - Single-Dose Food-Effect (Active)|In this two-period food-effect cohort, each subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
16261035|NCT04948827|Placebo Comparator|Part A - Single-Dose Food-Effect (Placebo)|In this two-period food-effect cohort, each subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
16261036|NCT04948827|Experimental|SBP-9330 - Multiple-Dose (Active)|Each Part B cohort will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
16261037|NCT04948827|Placebo Comparator|Placebo - Multiple-Dose (Placebo)|Each Part B cohort will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
16261038|NCT04948814|Experimental|ASD children|50 ASD children who meet the eligibility requirements will receive a fecal microbiota transplantation following a 2-week treatment with Vancomycin (40mg/kg/day). Fresh stool sample will be obtained from the donor. Fecal bacteria transplantation will be achieved via endoscopy, nasogastric/nasointestinal tubes, the proximal colon by colonoscopy, or the distal colon by enema, rectal tube, or sigmoidoscopy or a combined approach. The amount of fecal bacterial liquid transplantation for children is 5ml/kg each time. Fecal microbiota transplantation will be conducted at week 3-4, week 6-7, week 9, week 11 and week 13 for total 5 round.
16261039|NCT04948814|No Intervention|healthy children|stool donor
16261040|NCT04948801||genotype 3a HCV|genotype 3a hepatitis C
16261041|NCT04948801||genotype 6 HCV|genotype 6 hepatitis C
16261042|NCT04948801||genotype 3b HCV|genotype 3b hepatitis C
16261043|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 1)|
16261044|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 2)|
16261045|NCT04948788|Experimental|GemOx (Stage 2)|
16261046|NCT04948775|Experimental|Intervention Group|"A progressive home-based cervical stabilization exercise program is going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
~Home exercises are going to be prescribed three times in a week for six weeks. Repeats and durations of the exercises are going to be increased every week to provide progression."
16261047|NCT04948775|No Intervention|Control Group|Patients in control group are not going to receive any exercise intervention.
16261090|NCT04948515||group 2 patients with non severe covid 19 respiratory infections|Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17
16261151|NCT04948060|Experimental|Intervention 1-1|In addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator.
16261193|NCT04947735|Experimental|CYPRESS Extension Test Arm|Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
16261051|NCT04948749|Experimental|DES with aggressive medical treatment group|"Device: drug eluting stent The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
~Aggressive Medical treatment The medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment), intensive management of the primary risk (systolic blood pressure and low density lipoprotein [LDL]), and management of secondary risk factors (diabetes, non-high-density lipo- protein [non-HDL], smoking, weight, and exercise)."
16261052|NCT04948749|Active Comparator|Standard medical treatment group|The standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment), intensive management of the primary risk factors (systolic blood pressure and low density lipoprotein [LDL]), and management of secondary risk factors (diabetes, non-high-density lipo- protein [non-HDL], smoking, weight, and exercise).
16261055|NCT04948697|Experimental|Arm A: ociperlimab + tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks
16261056|NCT04948697|Experimental|Arm B: tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks
16261057|NCT04948684||Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease|Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT
16261058|NCT04948684||Patients with atypical Parkinsonism or Parkinson's disease and no dystonia|Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia
16261059|NCT04948671||not bone looser|patients affected by primary hyperparathyroidism not bone looser
16261060|NCT04948671||bone looser|patients affected by primary hyperparathyroidism bone looser
16261067|NCT04948632|Active Comparator|Complete LeoMed application|LeoMed application with integrated artificial intelligence
16261068|NCT04948632|Placebo Comparator|Basic LeoMed application|LeoMed application without artificial intelligence
16261069|NCT04948619|Other|Arm A - Single booster vaccines|Those subjects randomized to Arm A, single dose vaccine boosters, will receive non live vaccine boosters at the 3 and 12 month visits. Boosters for live vaccines will be given at the 6 month visit. Boosters will only be given as applicable for low titers tested at the baseline assessment visit.
16261070|NCT04948619|Other|Arm B - Staged revaccination series|Those subjects randomized to Arm B, the full revaccination series, will receive vaccines when titers are low (below normal range) at baseline. When indicated, non-live vaccines will be given at the 3 month visit and live vaccines at the 6 month visit.
16261071|NCT04948606||Diroximel Fumarate (DRF)|Participants with a confirmed diagnosis of MS who are newly prescribed DRF in routine clinical practice and who satisfy the approved therapeutic indication for DRF will be enrolled.
16261072|NCT04948580|Experimental|ICC-T|5.5 days with 8 hours of training for teachers aiming at changing attitudes towards violence and equipping teachers with non-violent discipline strategies
16261073|NCT04948580|No Intervention|Monitoring condition|No intervention
16261074|NCT04948567|Experimental|split-dose of Magnesium Sulfate solution|Those assigned to MSS group were instructed to take 30ml of 50% magnesium sulfate solution and then drink 600ml water on the evening before colonoscopy. 70ml of 50% MMS and then 1500ml water was taken at least 4 hours before procedure on the colonoscopy day.
16261075|NCT04948567|Placebo Comparator|split-dose of PEG|Patients in PEG group were instructed to take first dose of 1.5L PEG on the evening before colonoscopy and take the second dose of 1.5L PEG at least 4 hours before the colonoscopy procedure on the morning.
16261085|NCT04948541|Experimental|treatment|
16261086|NCT04948541|Experimental|no treatment|
16261087|NCT04948528||Case group:|All suspected upper tract urothelial carcinoma participants will be assigned to case group.
16261088|NCT04948528||Control group|All suspected upper tract urothelial benign participants such as ureteral/renal calculi, ureteral stricture, upper urinary tract polyps, pyelonephritis, urinary tuberculosis will be assigned to control group.
16261089|NCT04948515||group 1 patients with severe covid 19 respiratory infections|Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17
16261091|NCT04948502|Experimental|SaExten Vena Cava Filter System|Manufacturer: ShenZhen KYD BioTech Co., Ltd. SaExten IVCF system is a retrievable IVCF system consists of two parts: the vena cava filter and the transporting system.The vena cava filter is a mesh filtering device that prevents the formation of pulmonary embolism by filtering the thrombus. SaExten IVCF system can be inserted through jugular or femoral veins, and can be retrieved through femoral veins within 90 days or indwelled permanently.
16261092|NCT04948502|Active Comparator|Denali inferior vena cava filter|Manufacturer: C. R. BARD. Inc, US
16261093|NCT04948489|Experimental|LNG IUD+ Norethindrone Acetate|All eligible participants will have the LNG-IUD. Experimental participants will also receive norethindrone acetate 5 mg by mouth daily for 12 months.
16261094|NCT04948489|Placebo Comparator|LNG IUD+Placebo|All eligible participants will have the LNG-IUD. Participants in the placebo comparator group will also receive a placebo tablet, 1 tablet by mouth daily for 12 months.
16261095|NCT04948476|Experimental|Standardized Dialysis and Structured Discontinuation (S2D2)|Prescription to minimize dialysis-induced ischemia and standardize dialysis discontinuation
16261096|NCT04948476|Active Comparator|Usual Care|Dialysis prescription ordered by their primary nephrologist/intensivist.
16261097|NCT04948463|Experimental|Early Stopping|Stopping empiric FN antibiotics after resolution of fever for 48 hours, irrespective of absolute neutrophil count (ANC)
16261098|NCT04948463|Active Comparator|Standard of care|Continuing empiric FN antibiotics until resolution of fever for 48 hours and recovery of ANC as defined by the treating clinician but usually to ≥200-500/mm3
16261099|NCT04948450|Experimental|Intervention group|"Physical activity intervention:
~Individual progressive resistance training with physiotherapists
~Cognitive stimulation intervention:
~Cognitive Stimulation Therapy with rehabilitation experts.
~Metabolic and vascular risk factors:
~Metabolic and vascular risk factors of the intervention group will be evaluated by cardiologists and endocrinologists. The study subjects will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologist and endocrinologists. The targets for blood pressure is less than 120/90 mmHg and the targets for HbA1c is less than 7 %"
16261100|NCT04948450|No Intervention|Control group|The control group will receive general health advice every 3 months based on their physical examination and blood findings. They will be provided information on the vascular risk factors for dementia and will be received instruction on exercise, lifestyle change.
16261101|NCT04948385|Active Comparator|Patients|Deep sedation for digestive endoscopy.
16261102|NCT04948385|Other|Escorts|Accompanying persons are the adults who accompany the patients home. They do not receive any medication or intervention.
16261103|NCT04948372|Experimental|The terlipressin group|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
16261104|NCT04948372|Placebo Comparator|The usual care group|Patients in the usual care group were treated with standard care.
16261105|NCT04948359||Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size internal diameter (ID) endotracheal cuff tube.
16261106|NCT04948359||Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size internal diameter (ID) endotracheal cuff tube.
16261107|NCT04948359||Group III (The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size internal diameter (ID) endotracheal cuff tube.
16261108|NCT04948346||patient with ALS|
16261109|NCT04948346||patient'spouse(without ALS)|
16261110|NCT04948333|Experimental|ABL001|Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
16261111|NCT04948320||Temporomandibular Disorder Group|
16261112|NCT04948320||Control Group|
16261113|NCT04948307|Other|SL BUP/NAL SOC background therapy|standard of care. Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
16261114|NCT04948307|Experimental|SL BUP/NAL + OXD01|standard of care + OXD01 (digital therapy). Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
16261115|NCT04948294|Experimental|Channeled group|Group of patients using a channeled blade for videolaryngoscopy
16261116|NCT04948294|Active Comparator|Non-channeled group|Group of patients using a non-channeled blade (standard type) for videolaryngoscopy
16261117|NCT04948281||Infection Group|A group of joint infection patients after arthroscopic ACL reconstruction surgery , diagnose was made according to American CDC criteria of joint infection
16261118|NCT04948281||Control Group|A group of patients which were matched to infections group retrospectively one-to-three who did not sustain any kind of infection after ACL reconstruction.
16261119|NCT04948268|Experimental|Adaptive digital mental health intervention without coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and to prioritize psychological strategies to meet participant preferences.
16261120|NCT04948268|Experimental|Static digital Mental Health intervention without coaching|The static intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Messages and content will not be tailored based on participants profile or usage.
16261150|NCT04948060|Experimental|Control 1-1|Patients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS).
16261191|NCT04947748|Active Comparator|24 hour intravenous antibacterial therapy|S.Augmentin 1,2g x 3 i/v
16261121|NCT04948268|Experimental|Adaptive digital mental health intervention with coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and to prioritize psychological strategies to meet participant preferences. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
16261122|NCT04948268|Experimental|Static digital Mental Health intervention with coaching|The static intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Message content, timing, and number, as well as the ordering of psychological content, will not be tailored based on participants profile or usage. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
16261123|NCT04948268|Active Comparator|Active control|The active control condition will provide a brief text message that includes a URL link to psychoeducational content, but will not include the messaging component described in experimental arms.
16261124|NCT04948255||Healthcare Workers at the Gill Medical Centre|Clinical and non-clinical staff at the Gill Medical Centre will complete a validated stress questionnaire during the Covid-19 pandemic. A baseline was established in May, 2019.
16261125|NCT04948242||Consecutive critically ill patients admitted to ICU with severe SARS-CoV-2 infection|Consecutive adult patients (> 16 years) with laboratory confirmed SARS-CoV-2 infection, detected by RT-PCR positive test of nasopharyngeal, oropharyngeal , swab or invasive respiratory samples according to the WHO recommendations. The follow-up of patients was to ICU discharge or death whichever occurred first. No interventions will be made. Only anonymized demographic data, clinical data, laboratory data and ventilatory support data will be collected. There is no standardized pharmacological treatment protocol. Only basic data are collected about the different treatments administered by the attending physician.
16261126|NCT04948229||Control Group|This group will be included subjects who had no history or diagnosis of any disease, no infection history within last two weeks, no history of any particular medication, who were admitted to emergency department (ED) with complaints other than infectious issues, and who gave their written consent to participate in the study.
16261127|NCT04948229||Moderate Disease Group|This group will be consisted of the patients whose diagnoses of moderate COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
16261128|NCT04948229||Severe/Critical Disease Group|This group will be consisted of the patients whose diagnoses of severe/critical COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
16261129|NCT04948203|Active Comparator|Sirolimus 0.5mg|Subject will take Sirolimus 0.5mg orally daily for 14 days.
16261130|NCT04948203|Active Comparator|Sirolimus 1mg|Subject will take Sirolimus 1mg orally daily for 14 days.
16261131|NCT04948203|Active Comparator|Sirolimus 2mg|Subject will take Sirolimus 2mg orally daily for 14 days.
16261132|NCT04948190||SARS-CoV-2 Infected/ positive group|Has tested positive for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages). Aged 16 years or older, willing and able to provide informed consent.
16261133|NCT04948190||SARS-CoV-2 negative group|Has tested negative for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages, and in phase 2 part 1, 2 and 4 enrolment may be accepted using symptoms-based criteria). Aged 16 years or older, willing and able to provide informed consent.
16261134|NCT04948177||Group A|Group A: Individuals who had normal pyloric orifice structure;
16261135|NCT04948177||Group B|Group B: Individuals who have abnormal pyloric orifice structure
16261136|NCT04948164|Experimental|Test group|
16261137|NCT04948164|Placebo Comparator|Control group|
16261138|NCT04948151|Experimental|Sildenafil Cream, 3.6%|
16261139|NCT04948151|Placebo Comparator|Placebo Cream|
16261140|NCT04948138|Experimental|MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome|Patients with MELAS syndrome that will receive oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations)
16261141|NCT04948125|Experimental|treatment group|camrelizumab combined with apatinib
16261144|NCT04948099|Experimental|VIB1116|A single dose of VIB1116, SC or IV administration on Day 1
16261145|NCT04948099|Placebo Comparator|Placebo|A single dose of Placebo, SC or IV administration on Day 1
16261146|NCT04948086||TT MTHFR genotype|
16261147|NCT04948086||Non-TT (i.e. CC/CT) MTHFR genotype|
16261148|NCT04948073|Experimental|Experimental Group|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment. DNS group's protocol will involve 5 min warm-up, 40 min DNS movements (4 different parts, each part lasts for 10 min) accompanied with breathing exercises, and 5 min cool-down. DNS exercises will include diaphragmatic breathing, Baby Rock, Rolling, Side Lying, Oblique Sit, Tripod, Kneeling, Squat, Prone, and Czech Get Up (CGU). Week one specifically will involve training and practicing basic DNS exercises. The complexity of the exercises will increase gradually by adding a new task to an already practiced task every week. An increase in the complexity of a task will help the performer to automate performance. We will use the dual-task paradigm to examine if the task is automated or not (e.g. no new task should disturb the diaphragmatic breathing).
16261149|NCT04948073|Active Comparator|Control Group|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration). All patients will also continue their usual activities and receive advices related to the daily living activites in the form of a leaflet. Participants will be asked to refrain from seeking any other types of rehabilitation treatments during the trial. The conventional physical therapy program for both groups includes: TENS therapy for the low back (15 min 3 days/week), with a frequency of 100 Hz and fixed pulse; ultrasound for 5 minutes, 1 Hz, continuous mode of application 1.5 w/cm2. The exercise programs will consist strengthening, stretching exercises for the abdominal, back, pelvic, and lower limb muscles.
16261152|NCT04948060|Experimental|Control 1-2|Patients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced.
16261153|NCT04948060|Experimental|Intervention 1-2|In addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing.
16261154|NCT04948060|Experimental|Intervention 1-3|In addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation.
16261155|NCT04948060|Experimental|Intervention 1-4|In addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative.
16261156|NCT04948060|Experimental|Intervention 1-5|In addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support.
16261157|NCT04948047||Malignant pulmonary nodules|Patients with pulmonary nodule diagnosed as malignant cancer by pathological examinations after surgical resection.
16261158|NCT04948047||Benign pulmonary nodules|Patients with pulmonary nodule diagnosed as benign disease by pathological examinations after surgical resection.
16261159|NCT04948034|Experimental|Treatment Arm|"A total of 68 metastatic colorectal cancer patients who have failed the first-line standard treatment will receive multisite SABR followed by Fruquintinib and Tislelizumab within two weeks from completion.
~The dosing of Tislelizumab will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
16261160|NCT04948008|Experimental|Treatment group 1|The subjects received IBI306 150 mg Q2W subcutaneously injected into the abdomen each time for 12 weeks;
16261161|NCT04948008|Experimental|Treatment group 2|The subjects received IBI306 300 mg Q4W subcutaneously injected into the abdomen each time for 12 weeks;
16261162|NCT04947995||Gastric cancer group|
16261163|NCT04947995||Precancerous lesion group|
16261164|NCT04947995||Healthy group|
16261165|NCT04947982|No Intervention|Control|All laparoscopic surgical procedures were performed at 12 mmHg CO2 pressure throughout the surgery
16261166|NCT04947982|Experimental|Study|All laparoscopic surgical procedures were performed at 8 mmHg CO2 pressure throughout the surgery
16261167|NCT04947969|Experimental|Rear laser acupuncture group|Patients in the Real laser acupuncture group will receive real laser pen irradiation.
16261168|NCT04947969|Sham Comparator|Shame laser acupuncture group|Patients in the Shame laser acupuncture group will receive shame laser pen irradiation.
16261169|NCT04947917|Experimental|Lymph Node SpotTM Tattoo|"Spot™ ink tattooing will be administered once prior to surgery.
~Initial test set of participants with previous sampled lymph nodes positive for metastasis will have SpotTM ink administered at time of standard of care pre-surgery radioseed localization.
~A feasibility set of participants will have SpotTM ink administered at time standard of care lymph nodes sampling."
16261170|NCT04947904|Experimental|Optimised Restrictive Strategy|The volume of non-resuscitative fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in ICU according to a special protocol.
16261171|NCT04947904|No Intervention|Control|Resuscitation fluids, maintenance fluids, nutrition and drugs will be administered as usually performed and following most recent guidelines.
16261172|NCT04947891||Study group|Patients will be treated with intensive recovery method after surgery.
16261173|NCT04947891||Control group|Patients will be treated with regular recovery method after surgery.
16261174|NCT04947878|No Intervention|Standard care|will not review a prompt list before their visit.
16261175|NCT04947878|Experimental|Prompt list|The patients in the intervention group will review a prompt list before their visit.
16261176|NCT04947865|Experimental|Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
16261177|NCT04947865|Experimental|Healthy Individuals|Healthy Individuals
16261178|NCT04947852|Experimental|Investigation Mask|Bi Level CPAP Mask
16261179|NCT04947852|Active Comparator|Comparator Mask|Bi Level CPAP Mask
16261180|NCT04947826|Experimental|HAIC + HLX10 + HLX04|HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, up to 2 years; HLX04: 15.0mg/kg, iv, q3w, up to 2 years.
16261181|NCT04947826|Placebo Comparator|HAIC + Placebo|HAIC: FOLFOX, q3w, up to 8 times; Placebo1: saline, iv, q3w, up to 2 years; Placebo2: saline, iv, q3w, up to 2 years.
16261182|NCT04947800|Experimental|Arm A: 12 week intervention, 8 week control|Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
16261183|NCT04947800|Experimental|Arm B: 8 week intervention, 12 week control|Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
16261184|NCT04947800|Experimental|Arm C: 4 week intervention, 16 week control|Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
16261185|NCT04947787|Experimental|Intervention Group|Participants receive a physical activity referral scheme.
16261186|NCT04947787|Active Comparator|Control Group|Participants receive physical activity advice from general practitioners.
16261187|NCT04947774||prophylactic cranial irradiation group|The extensive-stage SCLC patients will receive prophylactic cranial irradiation after standard first-line chemotherapy combined with immunotherapy, until disease progression or death.
16261188|NCT04947774||Observation group|Patients with extensive-stage SCLC do not receive preventive craniocerebral irradiation after standard first-line chemotherapy combined with immunotherapy until the disease progresses or death.
16261189|NCT04947761|Experimental|modified Cheonwangbosimdan Hydrogel patch|Group receiving modified Cheonwangbosimdan Hydrogel patch
16261190|NCT04947761|Placebo Comparator|Placebo patch|Group receiving placebo patch
16261194|NCT04947735|Placebo Comparator|CYPRESS Extension Control Arm|Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm
16261195|NCT04947722|Experimental|PREVENT Program|
16261196|NCT04947722|No Intervention|Control Group|Residents in homes allocated to the control group will receive usual care as provided within their home.
16261197|NCT04947709|Experimental|Physical activity intervention group|The physical activity intervention will be structured to increase moderate-to-vigorous intensity aerobic physical activity, to achieve the 60-minute goal, five days per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity intervention.
16261198|NCT04947709|Other|Delayed-intervention control group|Participants randomized to the delayed-intervention control group will serve as the control group for 12 weeks, and will not receive physical activity intervention during this time and will not receive weekly support calls. After completion of the control group, participants will be offered physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations. This delayed-intervention control group design is used not only to boost recruitment, but to eventually confer the benefits of physical activity to all those who enter the trial.
16261199|NCT04947696||1|Patients undergoing a Whipples procedure for pancreatic cancer
16261200|NCT04947670|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
16261201|NCT04947670|Sham Comparator|Control Group|Sham intervention, maintenance of heart failure medications with option for cross-over renal denervation treatment after 12 months
16261202|NCT04947644|Active Comparator|Thoracic epidural analgesia group|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
16261203|NCT04947644|Experimental|Ultrasound guided continuous erector spinae plane block group|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
16261204|NCT04947631|Experimental|DKF-313|Dutasteride 0.5mg + Tadalafil 5mg
16261205|NCT04947631|Active Comparator|Dutasteride|Dutasteride 0.5mg
16261206|NCT04947631|Active Comparator|Tadalafil|Tadalafil 5mg
16261213|NCT04947566|Experimental|Naproxen|in this group patients were given Naproxen
16261214|NCT04947566|Experimental|Ibuprofen|in this group patients were given ibuprofen
16261215|NCT04947553|Experimental|AXS-05 (dextromethorphan-bupropion)|Up to 24 weeks
16261216|NCT04947527|Experimental|Test Varnish|Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
16261217|NCT04947527|Active Comparator|Control Varnish|Control Varnish. 5% (w/v) Sodium Fluoride .
16261218|NCT04947514|Active Comparator|Treatment Side (Right or Left)|Each patient undergoing routine bilateral breast reduction will be randomized to receive the study drug (topical tranexamic acid) either to the right or left breast at the conclusion of the operation, prior to closure of the incisions. The other breast will receive topical saline.
16261219|NCT04947514|Placebo Comparator|Placebo Side (Right or Left)|Each patient undergoing routine bilateral breast reduction will be randomized to receive the study drug (topical tranexamic acid) either to the right or left breast at the conclusion of the operation, prior to closure of the incisions. The other breast will receive topical saline.
16261220|NCT04947501|Experimental|Participants with newly-diagnosed HR-Neuroblastoma|This pilot study of N9 as induction chemotherapy will enroll 15 patients with newly-diagnosed HR-NB.
16261221|NCT04947488|Active Comparator|Bioarginina C|vials based on L-arginine and liposomal vitamin C
16261222|NCT04947488|Placebo Comparator|Placebo|vials without L-arginine and liposomal vitamin C
16261223|NCT04947475|Experimental|Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program|There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder.
16261224|NCT04947462|Experimental|Chronically Implanted Neural and Muscular Interface|6 eligible participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
16261225|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation|
16261230|NCT04947410|Active Comparator|OSAS Patients treated with CPAP|"Patients with OSAS will have 1 in 2 chance of being randomized into CPAP group"
16261231|NCT04947410|Sham Comparator|OSAS Patients treated with nasal dilators|"Patients with OSAS will have 1 in 2 chance of being randomized into nasal dilators group"
16261232|NCT04947410|No Intervention|Non OSAS Patients|Non OSAS Patients will be the parallel control group
16261233|NCT04947397|No Intervention|Group 1|Traditional deep extubation at 1.5 minimum alveolar concentration (MAC)
16261234|NCT04947397|Experimental|Group 2|Deep extubation guided by pupillometry -- at < 0.5 MAC of vapor + propofol and fentanyl
16261235|NCT04947384||Patients with moderate mitral valve disease, undergoing interventions|Patients with established WHO-2 diagnosis of PH undergoing open and interventional mitral valve procedures.
16261236|NCT04947384||Patients undergoing mitral valve interventions without pulmonary hypertension|Patients with no PH undergoing open and interventional mitral valve procedures. This group will serve as a control.
16261237|NCT04947384||Patients with precapillary pulmonary hypertension scheduled for right heart catheterization|Patients with established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. This group will serve as a control.
16261238|NCT04947371|Experimental|Anlotinib Hydrochloride|Oral anlotinib 12 mg/d
16261239|NCT04947345|Experimental|Experimental group: Remimazolam Besylate|Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of Remimazolam is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.2-1 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and Remimazolam, no analgesic or sedative could be used during the experimental time period.
16261240|NCT04947345|Active Comparator|Positive control group: Propofol|"Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of propofol is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.3-4.0 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and propofol, no analgesic or sedative could be used during the experimental time period.
~Rescue therapy for experimental group During the treatment of the experimental group, if the RASS cannot be maintained at 0 to -2 points at the maximum Remimazolam maintenance dose of 1 mg/kg/h, a loading dose of propofol (0.2 mg/kg) can be given intravenously. If RASS fails to satisfied after three loading doses of propofol, Remimazolam is discarded and 0.3-4.0 mg/kg/h of propofol are used as rescue therapy for experimental group."
16261241|NCT04947332|Other|Auto-inoculation recipients|Auto-inoculation of wart to be performed
16261242|NCT04947319|Experimental|Tirabrutinib monotherapy|Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.
16261243|NCT04947306||All subjects|"Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia at our Institution in which the administration of rocuronium for neuromuscular blockade is anticipated.
~All participants will be monitored with both TOF Watch and Tetragraph neuromuscular monitors."
16261244|NCT04947293|Experimental|Yoga Exercise|Subjects in the experimental group will be invited to participate in 60-minute yoga sessions twice a week for 12 weeks. Each session will include postural (asanas), breathing (pranayama), and meditative exercises. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, blankets, blocks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support.
16261245|NCT04947293|Active Comparator|Fitness and mobility exercise|Subjects in the control group will be invited to participate in more conventional exercise sessions, based on a fitness and mobility exercise (FAME) program, 60-minute per sessions twice a week for 12 weeks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support. The effectiveness of this program has already been demonstrated in previous studies.
16261246|NCT04947280|Experimental|Fractionated Stereotatic Radiation Therapy|
16261247|NCT04947267|Experimental|3% mepivacaine|3% mepivacaine was administered via inferior alveolar nerve block.
16261248|NCT04947267|Active Comparator|2% mepivacaine with 1:100,000 epinephrine|2% mepivacaine with 1:100,000 epinephrine was administered via inferior alveolar nerve block.
16261249|NCT04947254|Active Comparator|Group A (Apa, ADT, XRT)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16261250|NCT04947254|Experimental|Group B (Apa, ADT, XRT, AAP, niraparib)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive abiraterone acetate PO QD, prednisone PO BID, physician's choice ADT, and niraparib PO QD. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16261251|NCT04947241|Experimental|Neoadjuvant therapy|Patients included are going to receive neoadjuvant therapy, surgery and adjuvamt therapy post surgery. Before surgery, patients will receive therapy as follows: PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
16261252|NCT04947228|Experimental|intervention group|in addition to the usual therapy, the patients were given access to the trackPAD app
16261253|NCT04947228|No Intervention|control group|patients in this group were treated as usual in the clinic without additional interventions.
16261342|NCT04946617||H group|healthy periodontium, BOP at \20 % of the sites and no sites with probing depth (PD) [3 mm and clinical attachment level (CAL) [2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38
16261254|NCT04947215||Cases group|It includes 100 neonates who are admitted in the neonatal intensive care unit in Assiut University children hospital suffering from RDS. The cases will be subdivided into subgroups according to1. Full term or preterm, 2. Type of pregnancy (normal or complicated), 3. Mode of delivery, and 4. LPCAT1 genetic polymorphism.
16261255|NCT04947215||control group|include 60 neonates without RDS.
16261256|NCT04947202||Safil Mesh|
16261257|NCT04947189|Experimental|Seviteronel, dexamethasone and docetaxel|"Part 1: Seviteronel will be administered orally beginning with 450 mg (3 x 150 mg tablets) once daily along with 0.5 mg dexamethasone, continuously in 28-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.
~Part 2: The recommended phase 2 dose for seviteronel (established in Part 1) once daily along with 0.5 mg dexamethasone, continuously in 21-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly."
16261258|NCT04947176|Active Comparator|Active|200mg of pentadecanoic acid (C15:0) supplementation in capsules form
16261259|NCT04947176|Placebo Comparator|Placebo|Matching placebo in capsules form
16261260|NCT04947163|Experimental|IMT group|"Standard exercise protocol according to ACSM's guidelines Standard exercise protocol according to ACSM's guidelines
~Balance training - Otago Exercise Program (OEP)
~warm-up (10-15 min)
~strengthening exercises (~20 min)
~balance activities (~20 min)
~cool-down (5-10 min) Balance training - OEP
~warm-up (10-15 min)
~strengthening exercises (~20 min)
~balance activities (~20 min)
~cool-down (5-10 min)
~IMT through POWERBREATHE
~30 quick breaths twice daily at an adjustable resistance (equivalent to ~50% of [baseline] MIP).
~Will be increased up to 35 breaths as per patient's tolerance Sham IMT
~60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP)
~training load adjustment will be prevented using sticky tape applied to the device's load adjuster."
16261261|NCT04947163|Sham Comparator|Sham IMT|"Standard exercise protocol according to ACSM's guidelines Standard exercise protocol according to ACSM's guidelines
~Balance training - OEP
~warm-up (10-15 min)
~strengthening exercises (~20 min)
~balance activities (~20 min)
~cool-down (5-10 min) Balance training - OEP
~warm-up (10-15 min)
~strengthening exercises (~20 min)
~balance activities (~20 min)
~cool-down (5-10 min)
~IMT through POWERBREATHE
~30 quick breaths twice daily at an adjustable resistance (equivalent to ~50% of [baseline] MIP).
~Will be increased up to 35 breaths as per patient's tolerance Sham IMT
~60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP)
~training load adjustment will be prevented using sticky tape applied to the device's load adjuster."
16261262|NCT04947150|Experimental|LOCATION TRIGGERED MESSAGING|Weekly message is triggered when arriving at grocery store.
16261263|NCT04947150|Experimental|COACH MONITORING|Coaches view grocery purchases via web portal, send weekly messages about purchases they observe, and conduct three brief phone calls to discuss purchases.
16261264|NCT04947150|Experimental|BENEFITS OF CHANGE|Attend an extra workshop session and three phone calls to identify and reflect on benefits of dietary change. Content added to standard weekly messages about benefits of change.
16261265|NCT04947150|Experimental|HOUSEHOLD SUPPORT|An adult household member attends one workshop session and three phone calls with the index participant. This household member receives weekly text messages for 20 weeks about program goals and ways to support the index participant.
16261266|NCT04947137|Experimental|Subjects Free of Inflammatory Disease|The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
16261267|NCT04947137|Experimental|Healthy Controls and RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
16261270|NCT04947111|Other|Serological survey|A blood sample will be taken to estimate the specific serotype prevalence for dengue virus in groups of 5 to 35 years in areas of low and high dengue endemicity.
16261273|NCT04947072|Experimental|Erector Spinae Plane Block|Patient will receive single-shot ultrasound-guided erector spinae plane block at the level of T9 on the side which will be operated on.
16261274|NCT04947072|Active Comparator|Spinal Anesthesia|Patient will receive spinal anesthesia at the level of L3-L4 or L4-L5
16261275|NCT04947059|Active Comparator|Gemcitabine|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with gemcitabine hydrochloride 2gr in 100ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
16261276|NCT04947059|Active Comparator|Epirubicin|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with epirubicine hydrochloride 50mg in 50ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
16261277|NCT04947033|Experimental|TJ210001 Injection|Single Arm Dose expansion
16261278|NCT04947020||Rectal cancer|Patients with primary rectal cancer operated on between 2013 and 2019.
16261279|NCT04947007|Active Comparator|Group 1|In this group, US guided suprascapulary and axillary nerve block will be performed with 15cc+15c local anesthetic.
16261280|NCT04947007|Active Comparator|Group 2|In this group, US guided suprascapulary and axillary nerve block will be performed with 10cc+10c local anesthetic.
16261281|NCT04947007|Active Comparator|Group 3|In this group, US guided suprascapulary and axillary nerve block will be performed with 5cc+5c local anesthetic.
16261282|NCT04947007|Active Comparator|Group 4|In this group, US guided suprascapulary and axillary nerve block will be performed with serum physiologic.
16261283|NCT04946994|Experimental|High intensity interval training|
16261284|NCT04946994|Active Comparator|Continuous moderate intensity exercise|
16262222|NCT04940390|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
16261285|NCT04946981|Other|Randomized Crossover_Sequence 1|Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
16261286|NCT04946981|Other|Randomized Crossover_Sequence 2|Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
16261287|NCT04946968|Experimental|Dacomitinib|Oral Dacomitinib tablets, once daily.
16261290|NCT04946942|Experimental|Caregiver Checklist (CHEC)|CHEC is composed of two elements: 1) a checklist to identify the needs and concerns of unpaid/family caregivers who accompany older adults (aged 65+) to their primary care visits and 2) Tip Sheet for clinicians.
16261291|NCT04946942|Active Comparator|Usual care|Attendance at primary care appointments as usual.
16261292|NCT04946929|Experimental|Ticagrelor, 2-3mg/kg, 12h|2-3mg/kg, q12h, p.o. for 2w
16261293|NCT04946929|Active Comparator|low molecular weight heparin|half amount low molecular weight heparin
16261294|NCT04946916|Experimental|Participant with psychiatric condition without cognitive impairment|In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria.
16261295|NCT04946916|Experimental|Participant with psychiatric condition with cognitive impairment|In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities.
16261296|NCT04946916|Experimental|Patients with biological Alzheimer's disease|Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria.
16261297|NCT04946916|Experimental|Patient with fronto-temporal dementia|Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset.
16261298|NCT04946903|Experimental|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008,
~Period 2: Fasted state + HCP1902"
16261299|NCT04946903|Experimental|Sequence 2|"Period 1: Fasted state + HCP1902,
~Period 2: Fasted state + RLD2007 + RLD2008"
16261300|NCT04946890|Experimental|MRX2843 orally 80 mg/d|"Participants received 80 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days
~1 to 21 of a 21-day cycle."
16261301|NCT04946890|Experimental|MRX2843 orally 120 mg/d|"Participants received 120 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days
~1 to 21 of a 21-day cycle."
16261302|NCT04946890|Experimental|MRX2843 orally 180 mg/d|"Participants received 180 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days
~1 to 21 of a 21-day cycle."
16261303|NCT04946877||case group|100 ADHD patients; will be taken from outpatient clinic of child and adolescence psychiatry of Assiut university hospitals.
16261304|NCT04946877||control group|100 normal children; they will be selected from neurology clinic complaining from minor neurological complaint e.g : headache, will match with the case group for age, sex and educational level.
16261305|NCT04946864|Experimental|single arm|APG2575
16261306|NCT04946864|Experimental|combination arm|APG2575+palbociclib i
16261307|NCT04946851||non-treatment-seeking individuals|Participants across the spectrum of drinking (from non-drinkers to heavy drinkers) who are not interested in treatment for alcohol use disorder
16261308|NCT04946851||treatment-seeking individuals with alcohol use disorder|Volunteers with an AUD diagnosis who are seeking treatment for the condition
16261309|NCT04946838|Experimental|TENS|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
16261310|NCT04946838|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
16261311|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with nicotine replacement therapy and text support|Participants in this arm will be instructed to quit tobacco cigarettes with nicotine replacement therapy (patches and lozenges) and text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
16261312|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with nicotine replacement therapy and text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with nicotine replacement therapy (patches and lozenges) and text message support.
16261313|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with text support.|Participants in this arm will be instructed to quit tobacco cigarettes with text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
16261314|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with text message support.
16261315|NCT04946812|Experimental|Intervention group|The velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%. While the speed of the treadmill will not change throughout the study, the duration of the training will increase each week. In the first week, the SBTM training will take place for 10 minutes. There will be a 5-minute rest period, and the split-belt conditions will continue for another 10 minutes of training (total training time= 20 minutes).
16261316|NCT04946812|Active Comparator|Control group|"The subject will continue to walk under tied-belt conditions adjusted to the over-ground walking speed. In the first week, the treadmill training will be for 10 minutes. They will get a 5-minute break, similar to the intervention group, and continue for another 10 minutes under tied-belt conditions.
~The duration of each session will increase by 8 minutes every week. For example, in week 1, the treadmill training will be for a total of 20 minutes; in week 2, for 28 minutes; in week 3, for 36 minutes, and so forth, until it gets to 60 minutes by week 6. The rest period will remain at 5 minutes each session, and will always take place at the halfway mark. All 3 sessions in the week will have the same duration of training.
~If the subject cannot tolerate the velocity or duration of the session, the protocol will be adjusted to most recently tolerated session (and will be recorded for further interpretation and analysis)."
16261317|NCT04946799|Experimental|Low-intensity training combined with blood flow restriction group (LI-BFR)|
16261318|NCT04946799|Active Comparator|High-intensity aerobic exercise group (HI)|
16261319|NCT04946799|Placebo Comparator|Low intensity group (LI)|
16261320|NCT04946773||Malignancy Cohort|Patients with hepatic or hepatobiliary malignancy at enrolment
16261321|NCT04946773||Control Cohort|Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment
16261322|NCT04946760|Sham Comparator|Sham Protocol|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention. To provide a sham for the OMT-WB protocol, subjects will lie supine with the physician's hands under the occiput, palms toward the table, so that the subject's head rests on the dorsal aspect of the physician's hands. The time used in the sham procedures will be approximately 20-25 minutes.
16261323|NCT04946760|Experimental|Whole-Body Protocol|"The whole-body protocol will include all the techniques in the OMT-ND protocol, but will also include techniques focused on the expected cranial dysfunctions [Rivera-Martinez 2002]. The OMT-WB protocol will last approximately 25-30 minutes.
~The techniques will include:
~Evaluation for strain pattern(s)
~Occipitolatlantal decompression
~Sphenobasilar synchondrosis decompression
~Occipitomastoid suture V-spread
~Temporal bone balancing
~Venous sinus drainage technique"
16261324|NCT04946760|Experimental|Neck-down protocol|"The neck-down protocol takes into consideration previous relevant studies [Lopez 2011, Wells 1999]. OMT will be used bilaterally on the following areas with one or more techniques, including myofascial release, articulatory, muscle energy, and balanced ligamentous tension. The OMT-ND protocol will last approximately 15-20 minutes.
~Cervical spine
~Thoracic spine
~Lumbar spine
~Shoulder girdle
~Sacroiliac joint
~Innominates
~Leg muscles (including psoas, piriformis, hamstring, adductors)
~Ankles"
16261325|NCT04946747|Active Comparator|Trained|"Both groups will be shown how to use the Virtual Reality goggles. The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
~Both groups will also wear our smart head-impact sensor system to measure their response to training."
16261326|NCT04946747|Active Comparator|Control|Both groups will be shown how to use the Virtual Reality goggles. The Control group will also receive the same CS and the same US, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge. Both groups will also wear our smart head-impact sensor system to measure their response to training.
16261327|NCT04946734|Experimental|Test Arm|Device PFO closure
16261328|NCT04946734|Other|Control Arm|Drugs only
16261331|NCT04946708|Experimental|Small group zoom meeting|Group one: will be asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants e.g. questions, perceptions, etc.).
16261332|NCT04946708|Experimental|YouTube pre-recorded video|Group two: will be asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
16261333|NCT04946695|Experimental|Telefisio India|Feasibility and efficacy of the use of Telephysiotherapy for improving functional independence and quality of life in children and young people with lower limb fracture in a low resource setting in Anantapur (India).
16261334|NCT04946682|Experimental|Group of mNGS|
16261335|NCT04946682|Experimental|Group of PCR|
16261336|NCT04946669|Experimental|Refractory Dermatomyositis|Patients who have been receiving glucocorticoids in combination with at least one immunosuppressive therapy for at least 3 months and who have failed therapy or are intolerant to therapy
16261338|NCT04946630|Experimental|Seretide Evohaler forte according to SmPc|Single dose inhalation of fluticasone propionate/salmeterol 250 µg/25 µg administered via the Evohaler in accordance with instruction in the SmPC for Seretide Evohaler forte.
16261339|NCT04946630|Experimental|Whole lung exposure|Single dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for whole lung exposure. The entire 300 mL aerosol volume produced by the single dose from the inhaler will be inhaled at a flow rate in accordance with instructions for the Evohaler.
16261340|NCT04946630|Experimental|Alveolar bolus/ Breath hold exposures|A subdivided dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for six repetitive 70 mL Alveolar bolus/ Breath hold exposures. Each 70 mL bolus will be extracted from a freshly generated volume of 300 mL aerosol produced by actuation of a single dose from the inhaler.
16261341|NCT04946630|Experimental|Bronchial bolus/ Breath hold exposures|A subdivided dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for six repetitive 70 mL Bronchial bolus/ Breath hold exposures. Each 70 mL bolus will be extracted from a freshly generated volume of 300 mL aerosol produced by actuation of a single dose from the inhaler.
16262223|NCT04940390|Experimental|STS101 Placebo|STS101 Placebo
16261343|NCT04946617||G group|gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL [3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);
16261344|NCT04946617||CP group|chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at [≥80 % of the proximal sites and radiographic evidence of interproximal bone loss
16261345|NCT04946604|Other|Ashtangayoga|Participants attanded eight yoga sessions, one hour long.
16261346|NCT04946578|Experimental|Prebiotic intervention group|Prebiotic supplementation
16261347|NCT04946578|Placebo Comparator|Placebo control group|Maltodextrin
16261348|NCT04946565||Sinopharm vaccine group|Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
16261349|NCT04946552|Active Comparator|Individuals with normal BMI|(BMI 18-25 kg/m2)
16261350|NCT04946552|Active Comparator|Individuals with obesity|(BMI 30-40 kg/m2)
16261351|NCT04946539||Spondyloarthritis|
16261352|NCT04946526|Active Comparator|Broccoli seed extract|A single dose dietary supplement made up of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR) and 100 mg vitamin C (as ascorbic acid).
16261353|NCT04946526|Experimental|Broccoli seed extract with mustard seed powder|A single dose dietary supplement made up of a mixture of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR), 145 mg mustard seed powder containing enough active myrosinase (enzyme) to fully hydrolyze the GR in the capsule to SF post-ingestion (~30 units myrosinase activity) and 100 mg vitamin C (as ascorbic acid).
16261354|NCT04946513||Group 1|Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy。
16261355|NCT04946500||Clindamycin and Rifampicin|Patients treated with Clindamycin and Rifampicin
16261356|NCT04946500||Clindamycin and Fluoroquinolone|Patients treated with Clindamycin and Fluoroquinolone
16261357|NCT04946487||group 1|patients in this group destructed the posterior ligamentous complex of the adjacent segment
16261358|NCT04946487||group 2|patients in this group did not destruct the of the posterior ligamentous complex of the adjacent segment
16261359|NCT04946474|Experimental|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
16261360|NCT04946474|Placebo Comparator|Placebo group|Xingnaojing injection simulation agent + Naoxueshu oral liquid simulation agent treatment was given.
16261361|NCT04946461||group 1; lisdex - dex|subjects are assigned to group 1 based on the type of medication prescribed by the practitioner. Subjects which started with lisdexamphetamine are assigned to group 1.
16261362|NCT04946461||group 2; dex - lisdex|subjects are assigned to group 2 based on the type of medication prescribed by the practitioner. Subjects which started with dexamphetamine are assigned to group 1.
16261363|NCT04946448|Experimental|FIT group|Patients treated with biological treatment and the FIT diet
16261364|NCT04946448|No Intervention|Control group|Patients treated with biological treatment and the standard diet
16261365|NCT04946435|Experimental|Drug: Antibiotic Irrigation, and Procedure/Surgery: Nasal Packing|Experimental group will receive nasal packing with antibiotic irrigation.
16261366|NCT04946435|Active Comparator|Procedure/Surgery: Nasal Packing|Patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group.
16261367|NCT04946422||sports injury-related injuries|"Patients who are discharged from the hospital and diagnosed in accordance with sports injury-related injuries, and those whose service item names in the detailed database contain the keyword arthroscope. Any one of the above will be included in this topic."
16261368|NCT04946396|Experimental|dexmedetomidine intravenous infusion|Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
16261369|NCT04946396|Sham Comparator|0.9% saline solution intravenous infusion|Patients who will receive continuous infusion of 0.9% saline solution (sham group).
16261370|NCT04946383|Experimental|Quercetin and Dasatinib supplements|500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.
16261371|NCT04946370|Experimental|Pembrolizumab + 225Ac-J591 + ARPI|Patients will receive one dose of 225Ac-J591 (single dose, either 65 or 90 Kbq/kg) in combination with pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule, examples of ARPI include enzalutamide and apalutamide).
16261372|NCT04946370|Experimental|Pembrolizumab + ARPI|Patients will receive pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule) without 225Ac-J591.
16261373|NCT04946357|Experimental|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))
16261374|NCT04946357|Experimental|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))
16261375|NCT04946344|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 3 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant will be prescribed an individual walking prescription by the exercise leader, which will be adjusted accordingly, as each participant progresses throughout the 3 months. The exercise will be of moderate intensity. Alternate forms of aerobic exercise, such as but not limited to stationary bike, elliptical trainer, or treadmill walking, can be used in place of over-ground walking. This choice could be based on participant preference, the limitations of the exercise facility, or the participant's pain level.
16261376|NCT04946344|Active Comparator|Attention Control|The attention control intervention will cover an 3 month period. There will be two face to face group meetings over the 3 months, with one meeting each at months 1 and 3; and during the other months (month 2) participants will receive a combination of text messages, emails, and phone calls based on continued monitoring of participant needs and delivered via their preferred mode of contact.
16261377|NCT04946331|Experimental|Control|participants receive no surgical treatment
16261378|NCT04946331|Experimental|Rib Fixation Surgery|participants receive surgical treatment
16261708|NCT04944056|Experimental|Experimental Group|It includes ultrasound therapy, glides, exercises, compression mobilization and home plan.
16261385|NCT04946305||Lutathera|Patients administered Lutathera by prescription
16261386|NCT04946292|Experimental|Theory-derived intervention|Questionnaire will be used including the scales for three dominant theoretical models, Health Belief Model (HBM), Theory of planned behaviour (TPB) and Social Cognitive Theory (SCT). The theoretical model that best explains the health behaviours of the selected participants will be selected for designing oral health intervention.The theory-derived intervention will address the constructs/domains of the selected model(s) in the context of the three target behaviours (diet, toothbrushing and dental flossing).
16261387|NCT04946292|Active Comparator|Conventional health education|Participants will be randomly assigned to the control group, stratified by gender and education level. Allocation concealment will be ensured by using sealed opaque envelopes.
16261388|NCT04946279|Experimental|Arm I (conversation tool)|Patients receive the conversation tool.
16261389|NCT04946279|Active Comparator|Arm II (usual care)|Patients receive usual care.
16261390|NCT04946253|Active Comparator|DOCC with standard implementation (No TEAM or LEAD)|Practices in this arm will receive DOCC materials/training and technical support, but will not receive care team coaching/consultation (TEAM) or practice leadership facilitation (LEAD) after the training phase.
16261391|NCT04946253|Experimental|DOCC with TEAM implementation|Practices in this arm will receive DOCC training and materials and one type of implementation support after the training: coaching/consultation for the provider care team (TEAM).
16261392|NCT04946253|Experimental|DOCC with LEAD implementation|Practices in this arm will receive DOCC training and materials and only one type of implementation support after the training: facilitation for practice leadership (LEAD).
16261393|NCT04946253|Experimental|DOCC with TEAM + LEAD implementation|Practices in this arm will receive DOCC training and materials and both types of implementation support after the training: coaching/consultation for the provider care team (TEAM) and facilitation for practice leadership (LEAD).
16261394|NCT04946240|Experimental|Supervised (BRACE) Group|the self-developed protocol (BRACE) is used in the experiment with a combination of balance, resistance, aerobic and cognitive exercises for 12 weeks with repetition of different tasks
16261395|NCT04946240|Active Comparator|Conventional Balance Exercises Group|The unsupervised home plan included balance and resistance exercise was guided to conventional group
16261396|NCT04946227|Experimental|Single Arm|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor.
16261397|NCT04946214|Other|Smart Water Bottle Intervention Arm|Patients will receive a smart water bottle, then instructed on bowel and bladder preparation for daily standard of care radiotherapy treatments for up to 10 weeks.
16261398|NCT04946201||With Extractions|Patients in this group will undergo dental extractions.
16261399|NCT04946201||Without Extractions|Patients in this group will not undergo dental extractions.
16261400|NCT04946188|Experimental|Opuz NICGM|Participants will be provided with one non-invasive, custom-built prototype device (study device), which they will use throughout their day-to-day life/activities over the study period.
16261401|NCT04946162|Experimental|Tadalafil Group|Each patient will be given tadalafil 40 mg one time
16261402|NCT04946136|Experimental|Gait modification|In this pilot study, participants modify their gait patterns guided by real-time visual feedback on their medial knee load while walking on an instrumented treadmill.
16261403|NCT04946123|No Intervention|methimazole (control)|Patients with hyperthyroidism under methimazole treatment
16261404|NCT04946123|Experimental|methimazole+L-carnitine+selenium (intervention)|Patients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium
16261406|NCT04946097|Experimental|study group|received the conventional selected exercise program in addition to gross Myofascial Release
16261407|NCT04946097|Experimental|control group|the control group which received the conventional selected exercise program
16261408|NCT04946084|Other|Healthy Children|Samples taken from nasal swabs, nasal wash, blood draws and in the case of acute otitis media, tympanocentesis
16261409|NCT04946071|No Intervention|Control|Period in which each group will not receive the arts-based HIV stigma intervention.
16261456|NCT04945733|Experimental|Amivantamab: Esophageal Cancer (EC) Cohorts|Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight <80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight >=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
16261410|NCT04946071|Experimental|Group 1|"Arts-based HIV stigma intervention for three 8-week periods (24 weeks). The intervention will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
16261411|NCT04946071|Experimental|Group 2|"Arts-based HIV stigma intervention for two 8-week periods (16 weeks). Each intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
16261412|NCT04946071|Experimental|Group 3|"Arts-based HIV stigma intervention for one 8-week period. The intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
16261413|NCT04946045|Experimental|İntervention (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking) Group|"Tactile/Kinesthetic Stimulation (15 min): It was applied 3 times a day, once every 3 hours for 10 days.
~Nonnutritive Sucking: It was applied 8 times a day for 10 days with Orogastric (OG) feeding throughout the feeding."
16261414|NCT04946045|No Intervention|Control (Nonnutritive Sucking) Group|1) Nonnutritive Sucking: Administered during feeding with Orogastric (OG) 8 times a day for 10 days.
16261415|NCT04946032|Active Comparator|4 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 4 cm.
16261416|NCT04946032|Active Comparator|5 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 5 cm.
16261417|NCT04946019|Experimental|MR-Linac Guided Adaptive FSRT|Patients will receive FSRT (30Gy in 5 fractions) on the MR-Linac treatment machine.
16261418|NCT04946006|Experimental|Oxytocin infusion rate 2 IU/h|The maintenance infuson rate of oxytocin will be 2 IU/h.
16261419|NCT04946006|Experimental|Oxytocin infusion rate 4 IU/h|The maintenance infuson rate of oxytocin will be 4 IU/h.
16261420|NCT04946006|Experimental|Oxytocin infusion rate 6 IU/h|The maintenance infuson rate of oxytocin will be 6 IU/h.
16261421|NCT04946006|Experimental|Oxytocin infusion rate 8 IU/h|The maintenance infuson rate of oxytocin will be 8 IU/h.
16261422|NCT04946006|Experimental|Oxytocin infusion rate 10 IU/h|The maintenance infuson rate of oxytocin will be 10 IU/h.
16261423|NCT04946006|Experimental|Oxytocin infusion rate 12 IU/h|The maintenance infuson rate of oxytocin will be 12 IU/h.
16261424|NCT04946006|Experimental|Oxytocin infusion rate 14 IU/h|The maintenance infuson rate of oxytocin will be 14 IU/h.
16261425|NCT04946006|Experimental|Oxytocin infusion rate 16 IU/h|The maintenance infuson rate of oxytocin will be 16 IU/h.
16261426|NCT04945980|Experimental|Low-MUFA ground beef|Participants consumed ground beef low in monounsaturated fatty acids.
16261427|NCT04945980|Experimental|High-MUFA ground beef|Participants consumed ground beef high in monounsaturated fatty acids.
16261428|NCT04945967|Experimental|New Method|This intervention will be given once a day (in up to 10 days), 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 18 minutes.
16261429|NCT04945967|Active Comparator|Fucile Method|This intervention will be given once a day (in up to 10 days), 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 15 minutes.
16261430|NCT04945954|Experimental|Cyclophosphamide|
16261431|NCT04945928|Experimental|Surgery after conversion therapy|Participants with locally advanced or advanced NSCLC who received first-line treatment have been evaluated as resectable after multidisciplinary discussion involving the department of thoracic surgery, respiratory medicine, radiology and oncology.
16261432|NCT04945902|Active Comparator|Asynchronous Group|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
16261433|NCT04945902|Experimental|Synchronous Group|If you are assigned to the synchronous intervention group, you will be required to complete the asynchronous interventions on Brightspace AND attend a weekly one-hour support group. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connections and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
16261434|NCT04945902|No Intervention|Waitlist|If you are assigned to the wait-list group, you will not have access to the asynchronous or synchronous interventions during the course of this study. After this study is completed, you will have access to the asynchronous intervention on Brightspace.
16261435|NCT04945889||Geriatric inpatients at risk for sepsis|"Consecutive patients admitted to an Acute Geriatric Unit for any reason presenting at least one National Institute for Health and Care Excellence (NICE) risk factor for sepsis (age ≥75 years, impaired immune function, long-term corticosteroid therapy, immunosuppressive or antineoplastic drug treatment, surgery or other invasive procedures within 6 weeks, any breach of skin integrity, intravenous drug misuse, indwelling lines or catheters).
~In those with suspected infection (i.e. antibiotic prescription and a culture test within 24 hours before-72 hours after), clinical parameters (respiratory rate, blood pressure, heart rate, body temperature, peripheral oxygen saturation, mental status) were assessed at least twice daily throughout hospital stay and used by study investigators to determine the qSOFA, NEWS and MEWS."
16261436|NCT04945876|No Intervention|Control group|"Participants is encouraged to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. No further follow up except for testing at 12 weeks and six months.
~After the completion of the study the control group will be offered a session of individual exercise and diet guidance as well as a period of digital follow-up as needed."
16261437|NCT04945876|Experimental|Intervention group|Participants will receive a session of individual exercise and diet guidance with focus on goals and motivation for diet and exercise and help to overcome any barriers for self-efficacy. They will also receive an activity tracker and an introduction on how to use it. Further they will receive a monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise. The participants can also send sms if they have questions during the follow-up period. They will be encouraged to continue to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. If needed they can get help to find suitable exercise groups in their own municipality. The Garmin wristband will be used to facilitate daily activity and continuing exercise at recommended intensity level at home. Participants who are malnourished, or at risk of malnutrition, will receive specific guidance session on nutrition.
16261438|NCT04945850||Covid negative|"20 patients undergoing ocular surgery who are COVID negative will be included as control patients and undergo the same procedures.
~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed
~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
16261439|NCT04945850||Covid positive|"60 patients undergoing ocular surgery with previous COVID infection will be stratified into three groups by time since diagnoses: 3, 6, 12 months ~ 20 patients per group.
~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed
~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
16261440|NCT04945837|Other|unique study arm|Initial socio-demographic questionnaire 5 timepoints psychologic and self-administered questionnaires
16261441|NCT04945824|Experimental|Novel Intracanalicular Insertion Device|
16261442|NCT04945811|Experimental|Interlukein 6 and procalcitonin|Interlukein 6 and procalcitonin levels in COVID 19 patients
16261443|NCT04945798|No Intervention|No OMT|
16261444|NCT04945798|Active Comparator|OMT|
16261445|NCT04945785||control|Before switch Advagraf to Envarsus
16261446|NCT04945785||case|After switch Advagraf to Envarsus
16261447|NCT04945772|Experimental|vMCO-010- High Dose|Participants receive 1.2E11gc/eye of vMCO-010
16261448|NCT04945772|Experimental|vMCO-010- Medium Dose|Participants receive 0.9E11gc/eye of vMCO-010
16261449|NCT04945772|Sham Comparator|Sham Injection|Participants receive sham injection
16261450|NCT04945759|Experimental|Isokinetic Exercise (İE) Group:|"Isokinetic Exercise (IE) Group:
~(Knee Joint Flexion / Extension, Hip Joint Internal / External Rotation and Abduction / Adduction Strengthening Program)
~Patients will be seated on the isokinetic Cybex-Humac Norm device in a 90° upright sitting position. It will be fixed to the seat with torso, pelvis and thigh straps. During this training, patients will be told that the dynamometer arm will bring the knee from extension to flexion. During this exercise, the patient will be advised to resist the dynamometer as much as possible while moving the knee in flexion/extension, internal/external rotation, and abduction/adduction with the dynamometer."
16261451|NCT04945759|Active Comparator|Isokinetic Exercise + Aussie Current (IE+AC)Group:|Aussie Current and Isokinetic Exercise program will be applied to the patients. The distal electrode is placed on the anterior part of the thigh and superior to the patella. The proximal electrode will be placed on the thigh. One electrode will be placed between the anterior superior and posterior superior iliac spine of the PFPS(Patellofemoral Pain Syndrome) side and the other electrode will be placed in a triangle on the greater trochanter of the femur in the gluteus medius muscle. By contacting the Turkish authorities of the BTL 4825SPREMIUM device, the current was adjusted in the Aussie Current 1 kHz frequency, 400 ms phase time, 50 hz burst frequency, 4 ms duration device. This new burst modality medium frequency alternating current will be applied to the patient for 20 minutes.
16261452|NCT04945759|Active Comparator|Isokinetic Exercise + Russian Current (IE+RC) Group:|"Isokinetic Exercise program will be applied to the patients. Similarly, as with the Aussie Current, the Russian current will be applied to the vastus lateralis-medialis and gluteus medius muscles.
~Russian current will be set as 2500 Hz sinusoidal current, 200 ms phase time, 50 hz burst frequency, 50% duty cycle, 10 ms duration.
~The patient will be treated for 20 minutes."
16261453|NCT04945759|Placebo Comparator|Isokinetic Exercise + placebo Electrical Stimulation (IE+PES) Group:|Isokinetic Exercise program will be applied to the patients. The appropriate modalities will be set on the electrical stimulation device, but the device will not operate. It will be applied for 20 minutes.
16261454|NCT04945746|Experimental|Software VX1 + Stability|Utilization of the software VX1 + Stability
16261455|NCT04945733|Experimental|Amivantamab: Gastric Cancer (GC) Cohorts|Participants in Phase 2a GC cohorts will receive intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (<) 80 kilograms (kg) will receive IV infusion of amivantamab 1,050 milligrams (mg) and participants with body weight greater than or equal to (>=) 80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Phase 2b GC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
16285840|NCT04775615|Experimental|Treatment group C|
16261459|NCT04945707|Active Comparator|Arm 1|Ferric derisomaltose (Monoferric®) 1000 mg X 1 (for subject <50 kg, 20 mg/kg X1)
16261460|NCT04945707|Placebo Comparator|Arm 2|Normal Saline
16261461|NCT04945694|Experimental|Ultrasound-guided bilateral pecto-intercostal fascial block|Patients will receive bilateral ultrasound-guided pecto-intercostal fascial block
16261462|NCT04945694|Placebo Comparator|Intravenous fentanyl|Patients will receive only incremental doses of intravenous fentanyl
16261463|NCT04945681|Experimental|Mass vaccination|Mass vaccination of children aged 6 weeks to 14 years old with pneumococcal conjugate vaccine. Children 6 weeks to 11 months old receive two doses, spaced 4 weeks apart. All other children receive a single dose. Vaccination is simultaneous, as per a campaign delivery strategy.
16261464|NCT04945668|Other|Pericapsular nerve group block|combined ultrasound and fluoroscopy-guided technique for pericapsular nerve group block
16261465|NCT04945655|Experimental|Arm 1: component 1 + component 2 + component 3|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2) + Access to vaccination at school (component 3)
16261466|NCT04945655|Experimental|Arm 2: component 1 + component 2|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2)
16261467|NCT04945655|Experimental|Arm 3: component 1 + component 3|Adolescents and parents' education and motivation at school (component 1) + Access to vaccination at school (component 3)
16261468|NCT04945655|Experimental|Arm 4: component 1|Adolescents and parents' education and motivation at school (component 1)
16261469|NCT04945655|Experimental|Arm 5: component 2|General practitioners' training (component 2)
16261470|NCT04945655|No Intervention|Arm 6: Control|No intervention
16261471|NCT04945642|Experimental|Treatment (HDR-BT, SBRT)|Patients undergo HDR-BT for up to 24 hours and undergo SBRT every other day or consecutive days for up to 14 consecutive chronologic days in the absence of disease progression or unacceptable toxicity.
16261472|NCT04945629|Active Comparator|Simple suture|Atraumatic exodontia followed by simple suture
16261473|NCT04945629|Experimental|PRGF-Endoret|Atraumatic exodontia followed by simple suture
16261474|NCT04945616|Experimental|group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1)|
16261475|NCT04945616|Experimental|group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2)|
16261476|NCT04945616|Experimental|group C： Aspirin + Ticagrelor + placebo or SHR2285|
16261477|NCT04945603||Poor Grade Subarachnoid Hemorrhage|"All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm.
~The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols."
16261478|NCT04945590|Experimental|Latino/Hispanic Virtual Intervention Program|Latino/Hispanic individuals will participate in culturally tailored virtual intervention program following a community-based collaborative design.
16261479|NCT04945577||Experimental: Mild Clinical Group|patients showing mild clinical symptoms without pneumonia.
16261480|NCT04945577||Experimental: Moderate Clinical Group|patients with fever, other respiratory symptoms, and pneumonia findings based on radiological imaging
16261481|NCT04945577||Experimental: severe/critical clinical group|severe one of these as follows; patients with hypoxia (≤93% oxygen saturation), respiratory distress (RR >30 times per minute), partial pressure of arterial blood oxygen (PaO 2 )/the fraction of inspired oxygen (FiO 2 ) ≤ 300 mmHg, patients whose chest imaging shows that lung damage develops significantly within 24 to 48 hours, or critical one of these as follows; respiratory failure requiring mechanical ventilation, signs of septic shock with multiple organ failure requiring intensive care unit admission.
16261482|NCT04945564|Experimental|Oxygen therapy and physical therapy|
16261483|NCT04945564|Active Comparator|Oxygen therapy|
16261484|NCT04945551|Experimental|Diabetes|Aerobic exercise training
16261485|NCT04945551|Experimental|Healthy|Aerobic exercise training
16261486|NCT04945525|Experimental|Care Continuity Program + Education|Participating clinics (and their prescribers and patients) will be randomly selected to implement the Care Continuity Program (CCP) intervention, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients will receive welcome letters and be required to complete CCP self-assessments before each appointment. Prescribers will begin using the generated CCP summary page at each appointment to help make decisions about initiating or maintaining an opioid prescription for an individual patient.
16261487|NCT04945525|No Intervention|Education Alone|Participating clinics (and their prescribers and patients) will be randomly selected to the control group, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients and prescribers will continue treatment as usual in their clinic.
16261490|NCT04945499|Other|D-glucose|During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.
16261491|NCT04945486|Experimental|Peer-mentoring|The patients (mentees) are matched with a peer-mentor i.e. a person with a similar life situation or health problem as one self
16261492|NCT04945486|No Intervention|Usual care|Usual care provided by professional healthcare workers
16261493|NCT04945473|Experimental|Revision|"BMI≥30 or total weight loss (TBWL) < 10% and relaxation of gastric tubulisation at 6 months after ESG.
~Additional stitches will be placed during the follow-up gastroscopy at 6 months."
16261494|NCT04945473|No Intervention|Without revision|The control gastroscopy will be performed without any additional procedure (no additional stitches).
16261498|NCT04945447|Experimental|Intervention group - Medical clinics|Medical clinics receiving the pharmacist intervention described in the intervention group for patient level
16261499|NCT04945447|No Intervention|Control group - medical clinics|All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with.
16261500|NCT04945447|Experimental|Intervention group - patient level|"The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else.
~The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant"
16261501|NCT04945447|No Intervention|Control group - patient level|The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector
16261502|NCT04945434|Experimental|S53P4 BAG intervention group|Patients recruited and enrolled in study for treatment with S53P4 BAG
16261503|NCT04945421|Experimental|Sintilimab and IBI310 (single arm)|The test group will be treated with either (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
16261504|NCT04945395|Experimental|FES and conventional training|The experimental group will wear the Functional electrical stimulation system L3100 Go for dorsiflexion of the ankle during conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
16261505|NCT04945395|Active Comparator|AFO and Conventional training only|The control group will wear an ankle-foot-orthosis (AFO) to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
16261506|NCT04945382|Experimental|Scotchbond universal 3M|Application of dental sealant with Scotchbond universal 3M adhesive.
16261507|NCT04945382|Active Comparator|Control (Single bond 3M)|Application of dental sealant with Single Bond 3M adhesive
16261508|NCT04945369|Experimental|Children born prematurely included in the EPIPOD protocol and now in the peripubertal period|"At inclusion in the INFANTPOD study :
~Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.
~Assessment of body composition by a commercialized device called BOP-POD and by impedancemetry
~Assessment of pulse wave by a commercialized device called popmetre
~Questionnaires for analysis of eating behaviour and of neuropsychological development."
16261509|NCT04945356|Experimental|upper limb virtual training|6-week virtual training of the affected upper limb using the Physiotec application
16261510|NCT04945343|Other|Children who had growing rods instrumentation for correction of Early Onset Scoliosis|Growing spine profiler instrumentation
16261519|NCT04945317|Other|ROSE arm|Presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist
16261520|NCT04945317|Other|NO-ROSE arm|Absence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist
16261521|NCT04945304||Magnetic bariatric surgery|Bariatric procedure performed in a human using magnetic assistance in the steps of the surgery
16261522|NCT04945291|Experimental|research built JA Method mobile application + Counting method using the hands|The participant will watch a video that explains a new counting method using the hands and use the research built mobile application to log and track the calories
16261523|NCT04945291|Active Comparator|FitnessPal mobile application (or Arabic alternative) + Counting method using the hands|the participants will watch a video that explains a new counting method using the hands and they will be asked to use a commercial mobile app to log and track the calories
16285863|NCT04775407||Screening|Serological SARS-CoV-2 test
16261524|NCT04945291|Active Comparator|Fitness Pal Mobile Application (or Arabi alternative)|The participants will watch a generic video about the mobile app and they will be asked to use a commercial mobile app to log and track the calories
16261525|NCT04945278|Other|Patients|"Both patients and healthy volunteers arms will undergo the double mirror test within a day.
~But the patients arm will additionally respond to the EASE test."
16261526|NCT04945278|Other|Healthy volunteers|Both patients and healthy volunteers arms will undergo the double mirror test within a day.
16261527|NCT04945265||Women aged <30|
16261528|NCT04945265||Women aged 30-36|
16261529|NCT04945265||Women aged 37-40|
16261530|NCT04945265||Women aged >40|
16261531|NCT04945265||Women undergoing egg freezing/male factor infertility/genetic testing|
16261532|NCT04945265||unidentified cause of infertility|
16261533|NCT04945265||PCOS|
16261534|NCT04945265||endometriosis|
16261535|NCT04945265||tubal disorders|
16261536|NCT04945265||ovulatory disorders|
16261537|NCT04945265||other causes of infertility e.g., fibroids.|
16261538|NCT04945252|Experimental|Care Navigation group|The teachers will signpost dental caries based on ICCMS visual criteria and refer to the nearest service. Annual monitoring of caries
16261539|NCT04945252|No Intervention|No internvention|Caries experience (dmft) activity monitored annually
16261540|NCT04945239|Experimental|Amplification of Positivity Training (6 Sessions)|
16261541|NCT04945239|Active Comparator|Stress Management Training (6 Sessions)|
16261542|NCT04945226|Active Comparator|Propecia|Propecia Tablet, QD, PO
16261543|NCT04945226|Experimental|IVL3001 (A mg)|S.C, Single Dose.
16261544|NCT04945226|Experimental|IVL3001 (B mg)|S.C, Single Dose.
16261545|NCT04945226|Experimental|IVL3001 (C mg)|S.C, Single Dose.
16261548|NCT04945187|No Intervention|Standard care|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management before each cycle of chemotherapy conducted by physicians.
16261549|NCT04945187|Experimental|Intervention group|Intervention: This arm will be assigned to the intervention which will be nurse-led consultations based on electronic patient-reported outcomes. The patients will report ePRO weekly during chemotherapy and the answers will be used proactively in the nurse-led consultations. Nurses will conduct the clinical assessment regarding side effects and management before each cycle of chemotherapy.
16261550|NCT04945174|Active Comparator|Exercise|12 weeks of supervised cardiorespiratory exercise twice a week (6 weeks at the hospital and 6 weeks in the local municipality) combined with patient education and individual follow-up sessions
16261551|NCT04945174|No Intervention|Usual care|The usual care group is encouraged to perform home-based aerobic exercise on their own
16261552|NCT04945161|Experimental|Arm A: N = 6 ON101 plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.
~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
16261553|NCT04945161|Placebo Comparator|Arm B: N = 6 Placebo plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.
~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
16261554|NCT04945148|Experimental|Metformin|Patients who have been selected with an OXPHOS+ status, will start standard radiotherapy (RT, 60Gy/6 weeks), concomitant TMZ chemotherapy (75mg/m²/day), and metformin by 7 weeks after surgery and adjuvant TMZ + metformin will follow onwards until the 12th cycle of TMZ. Patients still in remission after this time-point will continue metformin alone until progression.
16261555|NCT04945135||liver donors|
16261556|NCT04945122|Experimental|Pitavastatin|Patients diagnosed AMI with abnormal glucose metabolism use pitavastatin (4mg po Qn) to control cholesterol for 6 months.
16261557|NCT04945122|Active Comparator|Atorvastatin|Patients diagnosed AMI with abnormal glucose metabolism use atorvastatin (20mg po Qn) to control cholesterol for 6 months.
16261560|NCT04945096|Experimental|Acetylcysteine + decitabine|Acetylcysteine (1.2g twice a day, oral administration, from day -10 to day 365 after HSCT). Conditional regimen: decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen); semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
16261561|NCT04945096|Active Comparator|Standard Treatment|Conditional regimen: semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
16261562|NCT04945083|Experimental|Experimental Nutritional Pudding|2 servings per day
16261563|NCT04945070|Experimental|iGlarLixi|Subjects switched from MDI to iGlarLixi
16261564|NCT04945070|Active Comparator|Control|Patients continuing with previous MDI
16261565|NCT04945057|Experimental|Intervention group|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns
16261566|NCT04945044|Experimental|Computed adenoma detection system (CADe)|Tis system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions
16261567|NCT04945044|Active Comparator|Control group (absence of CADe)|This is the control group. As in the routine colonoscopy the endoscopist is in charge of the detection of the lesions.
16261568|NCT04945031||cannabis-induced psychosis|
16261569|NCT04945018|Experimental|HS-001 Low dose|HS-001 Low dose Administration
16261570|NCT04945018|Experimental|HS-001 High dose|HS-001 High dose Administration
16261571|NCT04945005||Lead implantation with transesophageal echocardiography|All patients undergoing pacemaker/CRT implantation with concomitant transesophageal echocardiography in addition to fluoroscopic guidance
16261572|NCT04945005||Lead implantation without transesophageal echocardiography (retrospective)|All patients undergoing standard pacemaker/CRT implantation guided by fluoroscopy only (retrospective historical control group)
16261575|NCT04944979|Experimental|Experimental: Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
16261576|NCT04944966|Experimental|Group 1|"• Experimental: Group 1a: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 400mg once a day to test its safety and tolerability.
~Interventions:
~o Drugs: Maytenus senegalensis
~• Experimental: Group 1b: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 600mg once a day to test its safety and tolerability.
~Interventions:
~o Drugs: Maytenus senegalensis
~• Experimental: Group 1c: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.
~Interventions:
~o Drugs: Maytenus senegalensis
~• Experimental: Group 1d: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.
~Interventions:
~o Drugs: Maytenus senegalensis"
16261577|NCT04944966|Experimental|Group 2a|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Maytenus senegalensis.
~Patients will be treated with Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days.
~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection
~Interventions:
~o Drugs: Maytenus senegalensis"
16261578|NCT04944966|Active Comparator|Group 2b|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Artemether-lumefantrine Patients will be treated with Artemether 20mg/lumefantrine 120mg administered orally by a six-dose regimen over 3 days.
~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection
~Interventions:
~o Drugs: Artemether 20mg/lumefantrine 120mg"
16261579|NCT04944953|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®) 100 Unit
16261580|NCT04944953|Experimental|Botulinum toxin type A(HG-102)|Botulinum toxin type A(HG-102) 100 Unit
16261583|NCT04944927||Patients with Alternating Hemiplegia of Childhood|"Patients that meet the clinical diagnostic criteria (Aicardi et al, 1995) for typical alternating hemiplegia with or without identified mutations in ATP1A3.
~At least one prolonged ECG study available is required."
16261584|NCT04944914|Experimental|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy, and then receive stereotactic body radiotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
16261585|NCT04944914|Active Comparator|Camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
16261586|NCT04944901|Experimental|SB-121|"One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated.
~Administration: Oral"
16261587|NCT04944901|Placebo Comparator|Placebo|"One dose of placebo daily for 28 days according to the treatment group to which they are allocated.
~Administration: Oral"
16261592|NCT04944875|Active Comparator|Group I; group headphone|In the first group of the patients in the isolation group wear the headphones but do not listen to music during the procedure. Then patients were sedated by midazolam and propofol.
16261593|NCT04944875|Active Comparator|Group II; group music|"In the second group of the patients wear the headphones and listen to Vivaldi's The Four Seasons violin concertos by sound isolating headphones during the procedure.
~Then patients were sedated by midazolam and propofol."
16261594|NCT04944875|Active Comparator|Group III; group maternal voice|In the third group of the patients wear the headphones and listen the maternal voice during the procedure.Then patients were sedated by midazolam and propofol.
16261599|NCT04944849||digital gamer group|Individuals with computer use more than 14 hours a week were included in this group.
16261600|NCT04944849||player group|Individuals with computer use less than 14 hours a week were included in this group.
16261601|NCT04944836|Placebo Comparator|Control|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the control group, these will be placebo. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
16261602|NCT04944836|Experimental|Clomiphene|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
16261603|NCT04944823||Patients with COVID 19 infection who develop bacterial coinfection.|Follow-up for 24 months
16261604|NCT04944823||Patients with COVID 19 infection who do not develop bacterial coinfection.|Follow-up for 24 months
16261605|NCT04944810||Magnetic bariatric surgery|Perform a bariatric surgery using the magnetic device like a second assitant in the steps of the surgery in order to perform the surgery with less incisions and with the same safety
16261610|NCT04944771|Experimental|Treatment ABC|Participants will be randomized to receive oral doses of Treatment A, Treatment B and Treatment C.
16261611|NCT04944771|Experimental|Treatment ACB|Participants will be randomized to receive oral doses of Treatment A, Treatment C and Treatment B.
16261612|NCT04944771|Experimental|Treatment BAC|Participants will be randomized to receive oral doses of Treatment B, Treatment A and Treatment C.
16261613|NCT04944771|Experimental|Treatment BCA|Participants will be randomized to receive oral doses of Treatment B, Treatment C and Treatment A.
16261614|NCT04944771|Experimental|Treatment CAB|Participants will be randomized to receive oral doses of Treatment C, Treatment A and Treatment B.
16261615|NCT04944771|Experimental|Treatment CBA|Participants will be randomized to receive oral doses of Treatment C, Treatment B and Treatment A.
16261616|NCT04944758|Other|Light therapy|Daily exposure on weekdays to a standard light device (e.g., fluorescent light box such as the Carex Day-Light Classic, emitting 4000 Kelvin white light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter) for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am. Participants will also taper and discontinue their antidepressant medication.
16261617|NCT04944745|Experimental|Myofascial release (MFR)|The pectoral MFR will be completed by an experienced registered massage therapist (RMT). They will stand on the participant's right side slightly rotated to the left facing towards the participant's left hip and apply a cross-hand MFR technique to the superficial pectoral fascia on the right side. The therapist will begin by placing the distal region of the anterior palm of the anchoring hand (therapist's right hand) on the right edge of the anterior sternum at the level of the 3rd to the 6th ribs on the skin and the draping over the pectoral fascia. They will then apply a gentle posterior pressure to hold the fascia in place. The forearm of the mobilizing hand (RMT's left hand) will be directed to the right shoulder wit hate right forearm crossing over the left and the contact of are of the mobilizing hand will be the skin superficial to the pectoral fascia and insertion of pectorals major on the anterior aspect of the humerus. This will be held for four minutes.
16261618|NCT04944745|Sham Comparator|Soft-touch Control (CON)|This control treatment will be set up the same way in regards to the RMT's hand placement, except no pressure will be applied. The RMT's hands will simply be resting over the contact points. This treatment will also be held for four minutes.
16261619|NCT04944732||Patients with Creutzfeldt Jakob disease|Patients with Creutzfeldt Jakob disease
16261653|NCT04944472||group II|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:
~in group II - only text publications (total 8)."
16261654|NCT04944472||group III|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:
~in group III - first text publications, and then video publications (16 in total)."
16261620|NCT04944719||chronically ill adult patients colonized by streptococcus pneumoniae|At baseline, adult patients with chronic disease who are colonized with Streptococcus pneumoniae will be identified. Then, after determining the colonized subjects, monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be taken to determine colonization by other serotypes or resolution of colonization status in these patients.
16261621|NCT04944719||chronically ill adult patients not colonized by streptococcus pneumoniae|Subjects who are not colonized with S. pneumoniae will be followed by monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be collected every six months to determine colonization during the follow-up time in the study.
16261622|NCT04944706|Experimental|Low dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
16261623|NCT04944706|Experimental|High dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
16261624|NCT04944706|Experimental|Placebo group|The standard basic treatment is given according to the guidelines related to the underlying disease
16261625|NCT04944693||Cohort 1|Anterior cruciate ligament-injured patients with excessive ATS
16261626|NCT04944693||Cohort 2|Anterior cruciate ligament-injured patients with minimal ATS
16261627|NCT04944680|No Intervention|Control group|Stroke patients accept the traditional rehabilitation alone.
16261628|NCT04944680|Active Comparator|Transcranial Direct Current Stimulation group|Stroke patients accept the Transcranial Direct Current Stimulation alone.
16261629|NCT04944680|Active Comparator|Motor imagery group|Stroke patients do the motor imagery alone.
16261630|NCT04944680|Experimental|Transcranial Direct Current Stimulation and motor imagery group|Stroke patients accept the Transcranial Direct Current Stimulation and do the motor imagery at the same time.
16261631|NCT04944667|Active Comparator|TAVR standard|TAVR planning evaluated without VR
16261632|NCT04944667|Active Comparator|TAVR evaluated with VR|TAVR planning after VR analysis
16261633|NCT04944654|Experimental|Assigned intervention|Biktarvy OD for 96 weeks
16261634|NCT04944641|Experimental|A: Routine AED group|Routine and proper antiepileptic drugs group
16261635|NCT04944641|Experimental|B: AED and education group|Routine, proper antiepileptic drugs and education group
16261636|NCT04944615|Experimental|Intravascular ultrasound guidance|"All targeted CTO lesions will be examined and documented using a commercially available IVUS catheter (Opticross HD) according to its instructions (if not contraindicated, preoperative vasodilation with nitroglycerin to prevent spasm).
~IVUS examination must be performed at least once before and after stent implantation."
16261637|NCT04944615|Active Comparator|Angiographic guidance|The patient will choose the appropriate length and diameter of the stent to be implanted by visual estimation. All commercially available drug-eluting stents (except first-generation DES, such as Taxus, Excel, Partner, Firebird, etc.) can be used. DES with high quality clinical evidence is strongly recommended. The type, diameter, and length of the stent are determined by the surgeon. The stent length should be selected to ensure complete coverage of the CTO lesion. If dissection is present, additional stents are implanted. Repeat angiograms were performed immediately after surgery in the same view as before surgery.
16261638|NCT04944602|Experimental|SYN008|patients received a dose of SYN008 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
16261639|NCT04944602|Active Comparator|Omalizumab|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
16261640|NCT04944589|Experimental|single visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in single visit including access cavity, chemo-mechanical preparation and obturation, all were done in one visit
16261641|NCT04944589|Experimental|Multiple visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in multiple visit including access cavity, chemo-mechanical preparation and obturation, all were done in two or three visits
16261642|NCT04944563|Experimental|Segmentectomy|Patients receive segmentectomy
16261643|NCT04944563|Active Comparator|Lobectomy|Patients receive lobectomy
16261644|NCT04944537||ICU management for patients with severe trauma|Group to investigate the current status of ICU management for patients with severe trauma
16261645|NCT04944524|Experimental|Tofactitinib|partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
16261646|NCT04944524|Active Comparator|Methotrexate|partcipants would be given tablets of methotrexate (2.5mg per tablet) from the initial dose of 15mg (6 tablets) and add to the maximal and optimal dose of 20mg (8 tablets), once per week, the treatment duration will last 12 months during the whole follow-up period.
16261647|NCT04944511|Experimental|PD-1 antibody for mixed chimerism|PD-1 antibody (Toripalimab Injection) used for mixed chimerism in HLH patients after allo-HCT
16261648|NCT04944498|Experimental|Intervention Group|Patients who received surgery with modified tarsorrhaphy technique
16261649|NCT04944498|Active Comparator|Control group|Patients who received surgery with gold weight implant technique
16261650|NCT04944485|Active Comparator|class V cavities treated with putty nanohybrid resin composite|Selective enamel etching will be done and a universal adhesive (Prime&Bond universal™ ,Dentsply)will be applied to both enamel and dentin. After gentle dryness and solvent evaporation the bonding agent will be cured for 20 seconds. Composite (Neo Spectra™ST, Dentsply, Sirona, USA) will be placed incrementally and light cured for 20 seconds
16261651|NCT04944485|Experimental|class V cavities treated with Self adhesive giomer containing nanohybrid flowable composite|Cleaning and gentle air blowing of the preparation. Then applying FIT SA F03 (Low Flow), SHOFU, USA. Spread in a thin layer (≤0.5mm) on the prepared surface with needle tip, microbrush and gently air-blow leave for 20 seconds then light cure for 5 seconds. Then,apply additional increments (≤2mm) of FIT SA and light cure each increment for 10 seconds then finish and polish
16261652|NCT04944472||group I|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:
~in group I, project participants will only be presented with video publications on each of the declared topics (8 in total)."
16261709|NCT04944043|Experimental|TQ05105 Tablet|TQ05105 tablet 10mg given orally, twice daily in 28-cycle.
16261655|NCT04944472||group IV|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:
~in group IV - first video publications, and then text publications (16 in total)."
16261656|NCT04944459|Experimental|Muse-S|multi-sensor neurofeedback-assisted mindfulness training device (Muse-S)
16261657|NCT04944446|Experimental|Group myofascial treatment|"The trial group will also be referred by the rehabilitating doctor to the physiotherapy room, these patients will be treated by two physiotherapists with training in myofascial release therapy with which they will carry out a treatment protocol that will consist of myofascial release of the shoulder blade angle, subscapularis and global pectoral technique as well as superficial myofascial release of said musculature with a during 12-15 minutes, in addition to a 30-minute session of active kinesitherapy with exercises and mechanotherapy. Same as the control group.
~These mobilizations are carried out in the absence of pain, although the difference between joint tension or stretching and pain is explained to the patient."
16261658|NCT04944446|Active Comparator|Group Kinesitherapy treatment|"This group will be treated in a protocolized way with techniques such as passive kinesitherapy, active-assisted and active kinesitherapy to win mobility.
~They consist of mobilizing the affected arm in the movements of flexion (upward), separation (towards the outer side) and rotation, these lateral decubitus (bring the hand to the nape of the neck) and internal (bring the hand to the lower back) trying to win joint amplitude.
~These mobilizations are performed in the absence of pain, although the difference between joint tension or stretching and pain will be explained to the patient. The treatment will be carried out as usual with a duration of about 12-15 minutes of mobilization and about 30 minutes of active kinesitherapy with exercises and mechanotherapy, these consist of active shoulder mobility exercises. Emphasis will be placed on working with the pain threshold so as not to cause damage or negative nociceptive reactions."
16261659|NCT04944420|Experimental|Intervention|"Intervention group will have access to Health enSuite Caregivers, an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal or informal help received from others. It also recommends specific strategies to promote well-being and provides tools to help caregivers implement these strategies in their everyday lives.
~Health enSuite Caregivers is designed to offer advice to caregivers of persons with dementia based on an assessment of their specific needs. Topics are divided into five main content areas, which are recommended based on an assessment of the caregivers current challenges and sources of stress."
16261660|NCT04944420|No Intervention|Waitlist Control|Participants in the control group will be wait-listed and receive only treatment as usual from their healthcare providers during the study. After their participation is the study has ended, participants in the control group will be given access to the full Health enSuite Caregivers program.
16261661|NCT04944407|Experimental|LHP GROUP|patients recieved minimal invasive LHP procedure with diode laser
16261662|NCT04944407|Active Comparator|MM GROUP|patients received conventional MM hemorroidectomy
16261663|NCT04944394||hospital professionals|all professionals working in hospitals in France
16261664|NCT04944381|Experimental|SARS-Cov-2 mRNA vaccine immunization group|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd.
16261665|NCT04944381|Experimental|Inactivated SARS-Cov-2 vaccine immunization group|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
16261666|NCT04944368|Experimental|Vaccine candidate|
16261667|NCT04944368|Placebo Comparator|Saline placebo|
16261668|NCT04944342||Individuals who have had COVID-19.|Individuals who have had COVID-19 and who treated by a standart medical treatment at home.
16261669|NCT04944342||Individuals who have not a COVID-19 illness history.|Individuals who have not a COVID-19 illness history.
16261670|NCT04944329||COLCOVID|adults undergoing hip fracture surgery
16261671|NCT04944316|Active Comparator|Low-fat, vegan diet|For a 12-week period, participants will be asked to follow a low-fat, vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
16261672|NCT04944316|Active Comparator|Portion-controlled diet|For a 12-week period, participants will be asked to follow a portion-controlled diet that is compliant with American Diabetes Association (ADA) guidelines. This diet will include individualized diet plans that reduce daily energy intake by 500-1,000 kcal for overweight (body mass index > 25 kg/m2) participants and keep carbohydrate intake reasonably stable over time. It will derive 15-20% from protein, <7% saturated fat, 60-70% carbohydrate and monounsaturated fats and ≤200 mg/day of cholesterol/day.
16261673|NCT04944303|Active Comparator|Sugammadex|In the early group, the injection of muscle relaxant was stopped 2min the operation finish, and 4mg kg-1 of sugammadex was injected .
16261674|NCT04944303|Placebo Comparator|Normal Saline|the injection of muscle relaxant was stopped 2min the operation finish, and equal normal saline was injected .
16261675|NCT04944290|Experimental|Perrigo active|
16261676|NCT04944290|Active Comparator|Reference active|
16261677|NCT04944277|No Intervention|Without ThoughtFullChat Application|Participants will not use the app during the 3 months
16261678|NCT04944277|Experimental|With ThoughtFullChat Application|Participants will be using the app during the 3 months
16261679|NCT04944264|Active Comparator|Immediate start|Behavioral: Stress Management and Resiliency Training (SMART) program
16261680|NCT04944264|Active Comparator|Delayed start|Wait time control
16261681|NCT04944251|Experimental|aerobic exercise group|the patients in the aerobic group started to exercise at a heart rate corresponding to 60% of the maximal VO2, by adjusting the pedal resistance of the exercise bike, consistent with the Karvonen formula. This was followed by exercise cycling at a heart rate corresponding to 70% of maximal VO2 in the second month, and 80% of maximal VO2 in the third month, for 30 minutes, 3 days a week
16261706|NCT04944069|Experimental|Almonertinib With Bevacizumab|Almonertinib 110 mg oral once daily with Bevacizumab 15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
16261707|NCT04944056|Active Comparator|Control Group|It includes ultrasound therapy, glides, exercises and home plan.
16286036|NCT04773964|Placebo Comparator|MET642 Placebo|
16261682|NCT04944251|Experimental|strength exercise group|The patients included in the strength exercise group performed weight training exercises involving 10 large muscle groups (leg press, chest press, leg curl, lateral pull down, leg extension, dumbbell lateral raise, calf press, upright row, sit up, quadruped arm opposite leg raise), 3 days a week; including 1 set of 12-15 repetitions in the first month, 2 sets of 12-15 repetitions in the second month, and 3 sets of 12-15 repetitions in the third month (Figure 1). Participants' working weights were set as 60% of the maximum weight they could lift.
16261683|NCT04944251|No Intervention|control group|The patients who didn't want to exercise were included in the control group.
16261684|NCT04944238||Patients implanted with Ankoris IOL|To assess the IOL stability, slitlamp photos of the consecutive 30 patients with respect to time will then be analysed with a 5% confidence interval.
16261685|NCT04944225|No Intervention|Control group: Pain management during the standard of care phase|In the standard of care phase, anesthetic and surgical care will be as per standard practice (according to local hospital protocol) for both the control and the intervention group. Generally, this means patients will be maintained on a more liberal opioid regime than in the opioid reduction strategy phase and will receive opioid and other medications for the acute postoperative pain. The choice of opioids will be at the discretion of the managing team. There will be a minimum 2-month baseline period before entry of the first randomized cluster to the intervention arm.
16261686|NCT04944225|Experimental|Intervention group: Pain management in the opioid reduction strategy phase|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
16261687|NCT04944199|No Intervention|Control Group|
16261688|NCT04944199|Active Comparator|Intervention Group|
16261689|NCT04944186|Experimental|Structured Pressure Injury Patient Education|Patients in the experimental group will receive structured pressure injury patient education. It is consists of 2 sessions followed by biweekly follow-up for 12-week. The first session lasts for two days; the duration is 80 minutes (40 minutes /day for two days). Method of delivery is face to face, one to one with the aid of PowerPoint presentation and booklet. In the second session, the duration remains the same (80 minutes; 40 minutes/day for 2 days). The method of delivery also the same but teaching aid video presentation will be used. Three videos with a duration of approximately 2 - 3 minutes. In the second session, participants will be given a task to perform and document in the booklet given to monitoring its adherence. Upon completion of the two sessions, the patient will be follow-up biweekly and monitored their progress.
16261690|NCT04944186|Active Comparator|Standard Patient Education|Patients in this group shall continue with the standard patient education in the ward. Standard patient education routinely delivers through an informal verbal method after wound dressing is done.
16261691|NCT04944173|Experimental|MRD Negative|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have no detectable ctDNA at MRD landmark and will receive no further therapy.
16261692|NCT04944173|Experimental|MRD Positive, no further therapy|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to no further therapy.
16261693|NCT04944173|Experimental|MRD Positive, consolidation durvalumab|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to eight additional cycles of durvalumab
16261694|NCT04944160||Pre Covid-19 cohort|Children hospitalized in the Pediatric Department of the Hôpital Femme Mère Enfant, Lyon, France with a RT-PCR positive for RSV during the 2019-2020 winter epidemic
16261695|NCT04944160||Post Covid-19 cohort|Children hospitalized in the Pediatric Department of the Hôpital Femme Mère Enfant, Lyon, France with a RT-PCR positive for RSV during the 2020-2021 winter epidemic
16261696|NCT04944147|Experimental|Anodal tDCS + cognitive training|
16261697|NCT04944147|Placebo Comparator|Sham tDCS + cognitive training|
16261698|NCT04944147|Active Comparator|Sham tDCS + Progressive Muscle Relaxation training|
16261699|NCT04944121|Experimental|RSLV-132|RSLV-132 is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes and thereby render them biologically inert. A dose of 10 mg/kg will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
16261700|NCT04944121|Placebo Comparator|Placebo|Sodium chloride 0.9% will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
16261701|NCT04944108|Experimental|Surfactant administration with less invasive surfactant administration (LISA) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter)
16261702|NCT04944108|Active Comparator|Surfactant administration with intubation (INSURE) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
16261703|NCT04944095||SARS-CoV-2 Antibody Levels|This is a single arm study by Southlake Diagnostics Inc. whereby changes in plasma antibody levels (IgG and total) are determined over 12 months on individuals residing in over 300 associated nursing homes, extended care facilities and over-55 residences following vaccination with one of the authorized SARS-CoV-2 vaccines (Pfizer, Moderna or J &J). No interventions are involved. The investigators are not responsible for administering the vaccines or determining subject eligibility or willingness to receive the vaccine. Blood samples will be drawn and plasma IgG and total antibodies will be determined at baseline, 3, 6, 9 and 12 months post-vaccination.
16261704|NCT04944082|No Intervention|Remdesivir only|(Dose 200 mg day one, 100 mg daily days 2-5), duration may extend to 10 days of remdesivir (200 mg day one, 100 mg daily days 2-10)
16261705|NCT04944082|Experimental|Combination remdesivir plus ivermectin group|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
16261710|NCT04944030|Experimental|SCLC (small cell lung cancer)|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
16261711|NCT04944030|Experimental|NSCLC (no small cell lung lung cancer) without oncogenic addiction:|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
16261712|NCT04944030|Experimental|NSCLC (no small cell lung lung cancer) with oncogenic addiction|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
16261713|NCT04944017|Experimental|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
16261714|NCT04944017|Placebo Comparator|Saline Infusion|Participants will receive 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry
16261715|NCT04944004|Experimental|Experimental CBCT Group|Participants of CBCT group will attend individual computer-based cognitive training sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
16261716|NCT04944004|Active Comparator|Training As Usual (TAU) Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CBCT training.
16261717|NCT04943991|Other|Patients with HCM/LVH at University Hospital Wuerzburg|
16261718|NCT04943978||Liver disease|Patients with either acute or chronic liver disease
16261719|NCT04943965||Patient undergoing a cardiac surgery|Patients undergoing cardiac surgeries listed in inclusion criteria will be in this group.
16261720|NCT04943965||Clinicians|Clinicians defined as physicians (e.g. attendings, fellows, residents) or advanced practice providers (e.g. nurse practitioners and physician assistants) will be in this group.
16261723|NCT04943913|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-3x10^11 in vitro expanded autologous TILs will be infused i.v. to patients with brain glioma after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
16261724|NCT04943900|Experimental|Part 1A: Monotherapy (BMS-986416)|
16261725|NCT04943900|Experimental|Part 1B: Combination Therapy (BMS-986416 + Nivolumab)|
16261726|NCT04943887|Experimental|PwMS eSupport Groups|12-weeks active treatment of eSupport Health's Weekly Group Sessions, a formal semi-structured program of psychoeducational support delivered in a small group format by licensed therapists who specialize in MS. The active treatment period will follow a 12-week waitlist period that will be used to enable a within-subject control design. Note that the very first group enrolled (N~10) will not have a 12-week waitlist period but will instead enter directly into the 12-week treatment.
16261727|NCT04943874|Other|Technology Based Intervention 1|
16261728|NCT04943874|Other|Technology Based Intervention 2|
16261731|NCT04943848|Experimental|"Lead In: rHSC-DIPGVax Monotherapy"|rHSC-DIPGVax for 8 total doses
16261732|NCT04943848|Experimental|Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first)
~Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 12 years or older. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B."
16261733|NCT04943848|Experimental|Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first)
~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 12 years or older. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C."
16261734|NCT04943848|Experimental|Part C: Dose Expansion|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first)
~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity."
16261735|NCT04943822|Placebo Comparator|conventional education service program|Including the written and verbal health education on preoperative preparation, stoma surgery and postoperative stoma care. At discharge, ET nurses offered teaching information and support for patients, including selection of pouching appliances, drug instructions, health education At each outpatient follow-up, both stomas and patients needed to be assessed. The condition of stoma and peristomal skin, nature and volume of effluent, date of pouch appliances and stoma complications were recorded by ET nurses.
16261755|NCT04943640|Placebo Comparator|placebo taping groups|"Placebo taping was applied to patients in this group using betafix, an elastic stabilization tape, as material. A straight line of betafix was applied to the non-painful scapular inferior alignment of the spine, right and left, while the patient was standing upright.
~Treatment with taping was administered to all groups every 2 days by the same physiotherapist ."
16261756|NCT04943627|Experimental|Monotherapy with Balstilimab (BAL)|300 mg IV once every 3 weeks for up to 24 months
16261793|NCT04943367|Placebo Comparator|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
16262224|NCT04940364|Experimental|Cohort 1|Pozelimab: Single-dose SC on day 1
16261736|NCT04943822|Experimental|mobile care device|The participants in the intervention group were given the same routine care as the control group pre- and postoperatively. ET nurses taught patients and their family members how to use the home care mobile app before discharge. The home care mobile app was designed and developed for the discharged stoma patients by the research team and an information technology company in March 2021. Patients could receive stoma care from ET nurses through this mobile app at home, not just going to an outpatient clinic. The Major function modules of this mobile app were as follows: (a) appointment: The app users were able to complete the basic personal and medical information and make an appointment with the ET nurse; (b) photograph diagnosis: The ET nurses could make a diagnosis based on the patients' uploaded stoma photographs; and (c) consultation: Patients were able to contact their ET nurses for help and support. This mobile app was used to supplement the outpatient follow-up.
16261737|NCT04943809||POD 26P AY FT|26 patients with corneal astigmatism higher than 1.0D in both eyes and lower than 2.5D and will be implanted with the POD 26P AY FT
16261738|NCT04943809||POD 26P AY F|26 patients with corneal astigmatism lower than 1.0D in both eyes will be implanted with the POD 26P AY F
16261739|NCT04943796||Participants with ADHD|To collect information from participants who are underdiagnosed of ADHD with psychiatric disorders in daily clinical practice for up to 9 months.
16261740|NCT04943783|Experimental|Atorvastatin|Atorvastatin, 20mg once a day, for six months
16261741|NCT04943783|No Intervention|No drug|no drug
16261742|NCT04943770||WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|"Patients will be randomised 4:4 to a specific stimulating rates order (A, B, C, D) for approx. 3-6 weeks per rate (12-24 weeks in total). Each period is followed by a wash-out phase.
~At each frequency systematic assessment of the sweet-spot(s) will be performed. Various pulse width and amplitude values may be used to optimize therapy (up to 1KHz). These programmes will be saved in the subject's remote control based on the pre-generated rate randomization sequence."
16261743|NCT04943757|Experimental|PTBCy graft-versus-host disease prophylaxis|Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration
16261744|NCT04943744||String Test|Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.
16261745|NCT04943731|Other|Provox Life™|"Phase 1: Provox Life™. Like-for-like transition from Provox (or other brand) to Provox Life™ under guidance from Speech Pathologist who will assess when the participant is ready to commence the 6 week study observation period.
~Phase 2: Provox Life™ with Day/Night regimen. Establishment of optimal day/night routine under guidance of Speech Pathologist who will assess when the participant is ready to commence the 6 week observation period."
16261746|NCT04943718|Experimental|personalized vaccine|patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.
16261747|NCT04943705|Experimental|Yin and Yang Regulating Moxibustion|1.The acupoints will be selected as Shenque and Mingmen.The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Each treatment was 60min, once a week, Wenyang Yishen moxibustion and Peiyuan Guben moxibustion were performed alternately. Each patient received WenYang Yishen moxibustion and then Peiyuan Guben moxibustion for a total of 12 weeks of treatment and 12 weeks of follow-up at the end of the treatment. 2.The diet and exercise control implementation plan is as follows:Participants weighed ≤113.6 kg (250 lbs) and had a prescription diet of 1200-1499 kcal/day, including traditional foods, of which protein was about 15-20 kcal, fat was about 20-35%, and the rest came from carbohydrates. People weighing ≥113.6 kg are prescribed 1500-1800 kcal per day. They were also instructed to continue moderate-intensity physical activities (such as jogging, brisk walking) at least 5 days a week, at least 210 minutes a week, preferably ≥270 minutes a week。
16261748|NCT04943705|Active Comparator|Mild Moxibustion|1.The acupoints will be selected as Zhongwan, Guanyuan, Sanyinjiao (double).The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Light one end of the moxa stick and hang it about 2-3cm above the skin, taking the patient's local skin redness and conscious warmth as the degree. Moxa-box moxibustion will be used for 20 minutes each treatment, once every other day, 3 times a week, for a total of 12 weeks of treatment, and 12 weeks of follow-up after the treatment. 2.Lifestyle modification:It will be performed as the same as the Yin and Yang Regulating Moxibustion group.
16261749|NCT04943692|Experimental|Group A: Metformin glycinate 1050 mg|Metformin glycinate 1050 mg Orally twice a day.
16261750|NCT04943692|Active Comparator|Group B: Metformin hydrochloride 850 mg|Metformin hydrochloride 850mg Orally twice a day.
16261751|NCT04943679||Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b|Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years
16261752|NCT04943653|Experimental|Intraperitoneal paclitaxel + XELOX|"Intraperitoneal paclitaxel Day1, Day8 + *XELOX
~*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1 q 3 weeks"
16261753|NCT04943640|Experimental|kinesio taping|"The patient was advised to clean the skin with alcohol and shave the hairy areas. The standing patient was asked to take off high heels if he/she was wearing them.
~The paravertebral technique was used with 5 cm x 5 m kinesio tape material. While the patient was standing in an upright position, two longitudinal pieces were cut by taking the tape and slightly rolling its corners. The patient was asked to lean forward. The lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. The patient was asked to do a slight rotation to the left, and while in this position, the tape was attached to T11-T12 without stretching at all. Kinesio tape was attached to the opposite side of the vertebrae with the same procedure."
16261754|NCT04943640|Experimental|rigid taping|The patient was asked to lean forward, and 5 cm x 5 m rigid tape material was used in the right paravertebral region. When bonding the tape, first, the lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. Then, the patient was asked to do a slight rotation to the left, and while in this position, the hypoallergenic tape (beta fix) was applied with no tension [23]. Then, rigid tape was applied upward onto the paravertebral muscles. The left paravertebral region was taped with the same procedure as the right paravertebral region .
16261792|NCT04943367|Active Comparator|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
16261757|NCT04943627|Active Comparator|Monotherapy with Investigator Choice (IC) Chemotherapy per Institutional guidelines|Topotecan: 1 or 1.25 mg/m^2 IV on Days 1 to 5, every 21 days or Vinorelbine: 30 mg/m^2 IV on Days 1 and 8, every 21 days or Gemcitabine: 1000 mg/m^2 IV on Days 1 and 8, every 21 days or Irinotecan: 100 or 125 mg/m^2 IV weekly for 28 days, every 42 days or Pemetrexed: 500 mg/m^2 IV on Day 1, every 21 days
16261758|NCT04943614|Experimental|BIODEX training group|These individuals will receive conventional along with postural stability training with biodex balance system which stimulates specific movement patterns or strategies by placing markers on a specific location on-screen grid subject attempted to touch targets nine times using an onscreen cursor manoeuvred by the subject leg on the device platform
16261759|NCT04943614|Active Comparator|Conventional therapy group|These individuals will perform balance exercises including proprioception exercises, balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program (advices).
16261760|NCT04943601|Experimental|Action observation training group|The experimental group will receive a training program with Action observation by watching videos of complex tasks while imitating them. All the movements will be performed bilaterally so that regardless of the affected side the patient had the correct perspective to perform the exercise.
16261761|NCT04943601|Active Comparator|Conventional therapy group|The control group will receive conventional rehabilitation, with exercises of bimanual activities that will target their shoulder, elbow, wrist and finger joints similar to the experimental group but without Action observation
16261762|NCT04943588||HCV Negative|"At initial screen, this population will be HCV negative via the diagnostic testing. They will be eligible if they fulfil the following:
~over 18 yrs old.
~willing to participate
~no previous history of therapy with oral medication for chronic HCV infection"
16261763|NCT04943588||HCV Positive with first-line treatment success|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir plus daclatasvir. After treatment, their blood sample will show that they have achieved a sustained virological response (SVR) defined as HCV RNA undetectable.
16261764|NCT04943588||HCV positive with first-line treatment failure|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir/daclatasvir. After treatment, this proportion of people will NOT achieve an (SVR - defined as HCV RNA undetectable).
16261765|NCT04943588||Cirrhotic Patients|Hepatitis C RNA positive that have cirrhosis
16261766|NCT04943575|Active Comparator|Intervention 1|EZC Pak
16261767|NCT04943575|Active Comparator|Intervention 2|EZC Pak+D
16261768|NCT04943575|Placebo Comparator|Placebo|
16261769|NCT04943562||Healthy participants|Participants from 20 to 40 years old, from both genders and with no sleep disorders
16261770|NCT04943562||Participants with sleep disorders|one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia (as measured by the insomnia severity index), 30% should have high risk to sleep apnea (as measured by the STOP-BANG questionnaire) and 70% should have excessive sleepiness scale (as measured by the Epworth sleepiness scale).
16261771|NCT04943549|Active Comparator|Group (A)|History of addiction.
16261772|NCT04943549|Placebo Comparator|Group (N)|No history of addiction to any drug.
16261773|NCT04943536|Experimental|Biolen+Radiation Therapy|Localized single delivery of the Biolen implant (polymer + bicalutamide) with radiation therapy
16261774|NCT04943523|Placebo Comparator|Placebo|vegetable oil 4g/day
16261775|NCT04943523|Active Comparator|Krill Oil|Krill Oil 4g/day
16261776|NCT04943510|Experimental|Physical exercices arm|three randomizations will be used to determine the order of the tests that will be proposed to the subjects: on the one hand for the exercise modalities (match, anaerobic, aerobic) and, on the other hand, for the exercise modalities included in the anaerobic and aerobic exercise families: Anaerobic agility / anaerobic - linear sprints Aerobic - shuttle / aerobic - linear
16261777|NCT04943497||ribociclib + AI/fulvestrant|Patients administered ribociclib + AI/fulvestrant by prescription AI: Aromatase inhibitor
16261778|NCT04943497||aplelicib + fulvestrant|Patients administered aplelicib + fulvestrant by prescription
16261779|NCT04943497||mono endocrine therapy|Patients administered mono endocrine therapy by prescription
16261780|NCT04943497||chemotherapy|Patients administered chemotherapy by prescription
16261781|NCT04943484||Gastric cancer|Male and female subjects, over 18 years of age, with histological diagnosis of locally advanced gastric carcinoma (AGC), surgically resectable, without evidence of distant metastases (cT2-T4a; N0-3; M0) for which a surgical intervention with curative purposes is indicated both as a first treatment and following preoperative neoadjuvant chemotherapy
16261782|NCT04943471||All patients will be given a questionnaire|All patients will be given the Big Five Questionnaire
16261783|NCT04943458||Cardiac surgery group|
16261784|NCT04943458||Glaucoma group|
16261785|NCT04943458||Control group|
16261787|NCT04943432|Experimental|People who inject drugs|People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention
16261788|NCT04943419||Colorectal cancer|Patients with colorectal cancer qualified for elective operations.
16261789|NCT04943393||Individuals with PKU|Adults with early-treated PKU
16261790|NCT04943393||Individuals without PKU|Adults without PKU who are otherwise healthy
16261791|NCT04943380|Other|patients with hematuria undergoing investigation for UC|Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as > 3 red blood cells per high-powered microscopy field for a properly collected urine sample.
16286654|NCT04769648|Experimental|Pro-ocular™ Topical Gel 1%|
16261794|NCT04943354|Experimental|Study of single-nucleotide polymorphisms|Study of single-nucleotide polymorphisms genes of the reninangiotensin-aldosterone system group (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), pro-inflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9).
16261796|NCT04943328|Other|TrendHip®|
16261797|NCT04943315|Experimental|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia crowns
16261798|NCT04943315|Active Comparator|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic crowns
16261799|NCT04943302|Experimental|Isatuximab + bendamustine|Bendamustine will be administered by IV at a dose of 70mg/m2 on cycle days 1 and 8 for up to 6 cycles. Isatuximab will be administered by IV at a dose of 10mg/kg on cycle 1 days 1, 8, 15, and 22; cycle 2-6 days 1,8; and cycle 7-12 day 1.
16261801|NCT04943276|Experimental|Embr Watch|Participants will receive the device and a technical onboarding video 3 days prior to study start to allow time for familiarization with the device and troubleshooting any technical questions or problems prior to study start. The study will consist of baseline measurements prior to using the Embr device and weekly outcome assessments at Week 1, 2, 3, and 4
16261802|NCT04943263|Experimental|Tracheal Temperature|Intubation done with a temperature sensor located on the cuff surface of the endotracheal tube
16261803|NCT04943224|Experimental|R1 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 DAS score in three consecutive tests in three month intervals.
16261804|NCT04943224|Experimental|R2 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 DAS score in in five consecutive tests in three month intervals.
16261805|NCT04943211|Other|R1|
16261806|NCT04943198|Experimental|R1 time of vemurafenib treatment|vemurafenib will be given to 6 months after BRAF negativization
16261807|NCT04943198|Experimental|R2 time of vemurafenib treatment|vemurafenib will be given to 12 months after BRAF negativization
16261808|NCT04943185|Other|Ab interno technique|Ab Interno is traditional method of stent XEN implantation, where the device will injected through a small corneal incision that closes with the preloaded XEN injector.
16261809|NCT04943185|Other|Ab externo technique|The ab externo approach does this without any incision, less invasive, and the implant is directly injected through the conjunctiva into the anterior chamber of the eye. Both methods create a new way out through the subconjunctival space, which is the traditional target of trabeculectomy.
16261813|NCT04943146||control group|
16261814|NCT04943146||P+A group|aspirin: tablet 100mg qd 2-5weeks prednisone: tablet 10mg qd 2-5weeks
16261815|NCT04943133|Active Comparator|3rd-term group: Pregnant women included in the last 3 months of pregnancy|Comparison of the profile of the curve according to whether there is presence or absence of blood pressure disorders.
16261816|NCT04943133|Active Comparator|Before 20 weeks group. Pregnant women (normal blood pressure) included before 20 weeks of pregnancy.|Comparison of the profile of the curve according to the presence or absence of risk factors for pre-eclampsia
16261817|NCT04943120|Experimental|"Snow-Plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
16261818|NCT04943120|Active Comparator|Bulk Fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
16261819|NCT04943107||healthy control|adults without glaucoma history or hypertension history
16261820|NCT04943107||glaucoma patients|adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history
16261821|NCT04943107||hypertension patients|adults with primary hypertension history; without glaucoma history
16261822|NCT04943107||glaucoma+hypertension|adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history
16261823|NCT04943094||TURBT alone|Patients treated with TURBT without adjuvant instillation therapy
16261824|NCT04943094||TURBT and mitomycin C|Patients treated with TURBT followed by six adjuvant instillations with mitomycin C
16261825|NCT04943094||TURBT and bacillus Calmette-Guerin|Patients treated with TURBT followed by six adjuvant instillations with BCG
16261826|NCT04943081|Experimental|Case group|Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.
16261827|NCT04943068|Experimental|Bremelanotide|Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period
16261828|NCT04943068|Placebo Comparator|Placebo|Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period
16261829|NCT04943055|Experimental|Low temperature plasma ablation with lacrimal duct catheterization|The experimental group received low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
16261830|NCT04943055|Placebo Comparator|YAG lacrimal duct laser combined with lacrimal duct catheter|Control group received YAG lacrimal duct laser combined with lacrimal duct catheterization
16261831|NCT04943042||Full-analysis set (FAS)|The FAS includes all enrolled patients. The FAS will be used for all analyses.
16261832|NCT04943029|Experimental|PD-1+Chemo+surgery+PD-1|Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.
16261878|NCT04942678||Pediatric patients ages 8-12 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
16261879|NCT04942665|Experimental|Low Dose|Prior to surgery these patients will be given a ICG dose of 0.05 mg IV.
16261833|NCT04943016|Experimental|CD19 Chimeric Antigen Receptor (CAR) T Cells|The dose is escalated in standard 3 +3 design with a starting dose of 1x10^6 cell/kilogram and maximum treatment dose of 5 x 10^6 cell/kilogram. The minimum number of 9 subjects would occur if no dose-limiting toxicities are observed in the 3 dose escalation cohorts. The maximum sample size of 18 subjects would be enrolled in 3 dose escalation cohorts (six in each cohort) for meeting dose-limiting toxicities request. In addition, we hypothesize that we will be able to successfully manufacture CAR T cells to meet the established release criteria at a minimum target dose of 1 X 106 +-30% cells/kilogram in this patient population using the Miltenyi CliniMACS Prodigy® closed transduction system.
16261834|NCT04943003|Experimental|Active tDCS|"SimNIBS will be used for modeling. It is a free and open source software package for the simulation of electric field induced by tDCS in the individual brain.
~Modeling will be done using T1-weighted anatomical images of each subject to reconstruct a high-resolution head model of each individual. For electrode placement, we will simulate areas F5 and F6, according to the EEG 10-20 system, for the anode and cathode, respectively, targeting the left and right Dorsolateral Prefrontal Cortex (DLPFC). This group will receive active tDCS, for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area."
16261835|NCT04943003|Sham Comparator|Sham tDCS|The electrodes will be placed in the same way as in the Active tDCS group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Afterwards, the device will be turned off, no longer emitting current.
16261836|NCT04942990|Experimental|exercise training group|The duration of the study was targeted as 8 weeks. Our trainings consist of 3 sessions per week, with an average of 45 minutes of calisthenic exercises per session. Exercises initially started with an average of 30 minutes, 10 repetitions, gradually increased difficulty once every two weeks, time increased to 45 minutes movements were modified for those who were forced to perform the exercise program. The program was completed with 5 minutes of warm-up and 5 minutes of cooling exercises before exercise training. All exercises were conducted on a video chat platform supervised by an experienced physiotherapist.
16261837|NCT04942990|No Intervention|control group|no exercise was given
16261838|NCT04942977|Experimental|Cardiac tele-rehabilitation|Patients in the Intervention Group will come to the hospital 4 times during two consecutive weeks, undergoing physical exercise sessions and the same educational talks as in the control group. Subsequently, they will follow the scheduled physical activities and adherence to the risk factor management according to individualised guidelines in their App, until the end of the study period. All data generated are recorded on the professional website. The degree of compliance with the objectives set is monitored by means of 7 coloured icons, which vary according to the target achievement.
16261839|NCT04942977|Active Comparator|Centre-based cardiac rehabilitation|Patients in the control group will come to the hospital 16 times during eight weeks for cycling and muscle strengthening exercises. Educational talks will be given. At the end of the hospital phase, a conventional outpatient follow-up by primary care and the corresponding specialist will be carried out.
16261840|NCT04942964|Experimental|ASP0367: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
16261841|NCT04942964|Experimental|ASP0367: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
16261842|NCT04942964|Experimental|ASP0367: Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of ASP0367 under fasting conditions on day 1.
16261843|NCT04942951||Pregnant women with the diagnosis of urinary incontinence (Study group)|The pregnant women who were diagnosed with the urinary incontinence (n=80) with category 0 or category 1 Pelvic Organ Prolapse Quantification (POP-Q) score in physical examination.
16261844|NCT04942951||Healthy pregnant women (Control group)|Control group consisted of healthy women with uncomplicated pregnancies (n=80). They had no complaint of urinary incontinence and their gynecological examination did not reveal any finding of pelvic organ prolapse.
16261845|NCT04942938|Experimental|NeuBie Treatment|"Participants in this study will participate in intervention treatment with the NeuBie for 6 weeks. Outcome measures objective and subjective will be collected at the beginning and end of the study. The treatments will include:
~Manual activations to underactive, spastic or limited in sensory muscles/regions
~NeuBie Mapping mode scanning process to scan for 1) spots that stimulate movement they couldn't do before per initial assessment, 2) spots that allow movement which is a greater range than available before per initial assessment, 3) spots that lead to decreased spasticity, and 4) diminished sensation areas - drive signal to increase sensory nerves and become metabolically active.
~Train using physical therapy exercises with Neubie in training mode and Hz current adjusted for tolerance (perceived 7/10) and ability to work through or decrease spasticity in (500 Hz) in the areas which show spasticity, contraction, are dead/diminished sensation, and hot spots."
16261846|NCT04942925|Other|Precision1, then Infuse|Verofilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16261847|NCT04942925|Other|Infuse, then Precision1|Kalifilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16261848|NCT04942912||French patients with juvenile Pompe disease|We aim to include all French patients with juvenile Pompe disease (maltase acid deficiency without cardiomyopathy)
16261849|NCT04942886|Experimental|Treatment group|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation. The intervention group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months.
16261850|NCT04942886|No Intervention|delayed treatment group|The delayed treatment group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months. If the patient in the delayed treatment group shows HBV reactivation (positive HBsAg or HBV DNA ≥10 IU/mL), entecavir treatment is started.
16261851|NCT04942873||dabigatran group|NVAF patients who taking dabigatran capsule 110mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran.
16261880|NCT04942665|Placebo Comparator|Standard Dose|Prior to surgery these patients will be given the ICG standard dose of 2.5 mg IV.
16286655|NCT04769635|Experimental|CPAP ttt|
16261852|NCT04942873||Rivaroxaban group|NVAF patients who taking rivaroxaban tablet 15mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
16261853|NCT04942873||wafarin group|NVAF patients who taking wafarin tablet during 2016.2-2021.1，the duration of continuous medication was more than 3 months， the dosage is adjusted according to INR. MMAS-8 scale was used to evaluate the compliance of patients with rivaroxaban.evaluate the compliance of patients with wafarin.
16261854|NCT04942860|Active Comparator|Methotrexate 1% gel|1% methotrexate gel applied onto a predefined limb
16261855|NCT04942860|Active Comparator|Methotrexate 0.5% gel|0.5% methotrexate gel applied onto a predefined limb
16261856|NCT04942860|Placebo Comparator|Vehicle gel|Vehicle gel applied onto a predefined limb
16261857|NCT04942847|No Intervention|The control group|The control group received routine nursing, including diet nursing, life nursing, direct and indirect training, health education and so on. Patients were followed up regularly by telephone after discharge
16261858|NCT04942847|Experimental|Dual task training group|On the basis of routine swallowing function training, the use of sucking training rehabilitation device is mainly used for tongue muscle training and lip muscle training to improve the control and delivery ability of tongue muscle to food.At the same time,adopt Troup's playing and comprehensive analysis ability training.Disrupt the three sets of cards, instruct the patient to read words or say colors, and measure the patient's reaction time with an electronic timer.Comprehensive analysis ability training: including digital training or item classification training.
16261859|NCT04942834|Active Comparator|Drug treatment group|receive class I or class III AAD to restore or maintain sinus rhythm.
16261860|NCT04942834|Experimental|cryoballoon ablation group|receive cryoballoon ablation to restore sinus rhythm.
16261861|NCT04942821|Experimental|Platelet rich fibrin and coronally advanced flap|Coronally advanced flap and platelet rich fibrin were used in treatment arms.
16261862|NCT04942821|Active Comparator|Connective tissue graft and coronally advanced flap|Coronally advanced flap and connective tissue graft were used in treatment arms.
16261863|NCT04942795||Mechanical thrombectomy|Patients who underwent mechanical thrombectomy for large vessel occlusion of the anterior circulation
16261864|NCT04942782|Experimental|lumbopelvic stabilization exercises|the patients will receive trunk stabilization exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
16261865|NCT04942782|Experimental|Pilates exercises|the patients will receive trunk pilates exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
16261866|NCT04942782|Active Comparator|conventional therapy|the patients will receive trunk stabilization exercise three times/ week for three months
16261867|NCT04942769|Experimental|selenium|selenium was administered to patients with autoimmune thyroiditis
16261868|NCT04942756|Experimental|Continuous Glucose Monitoring|"The FreeStyle Libre 2 Flash Glucose Monitoring System (FSL2) is a CGM device with real time alarms capability indicated for the management of diabetes in persons aged 4 and older. The Sensor holds eight (8) hours of data at a time. In order to have a daily diary of the Glucose level the patients or family or HCP must read the sensor (with reader or app) at least every height (8) hours. Every day at least three (3) scans of the sensor should be performed using the reader or the Smartphone App, generally at wake up in the morning, in the afternoon and at the time to go to sleep.
~The alarm system will be activated, so that the Glucose level is over the cut off limit of 180 mmol/L or when it is lower than the cut-off limit of 80 mmol/L, the patient and/or the family members and/or the caregiver will check the Glucose level by scanning the reader/smartphone over the sensor."
16261869|NCT04942756|Active Comparator|Standard Care|"This arm will perform the usual standard routine for blood glucose monitoring in patients with insulin therapy, that is represented by at least three finger pricks/die according to the usual standards routine of each center.
~Different frequency of finger pricks glucose measurements could be performed on the basis of health care professional patient assessment of each patient's needs."
16261870|NCT04942743||control group|patients with normal TMJ
16261871|NCT04942743||Study group|patients with TMJ internal derangement
16261872|NCT04942730|Experimental|FluBuBe|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
16261873|NCT04942717||Aim 1|For the survey component, recruitment will focus on patients who have not participated in a semi-structured interview as part of the Aim 1 research. For Aim 1, we will seek to recruit approximately 36 patients and 12 family members for the initial key informant interviews, 20 patients for the followup survey, and 10 for the English/backtranslated-English side-by-side comparison.
16261874|NCT04942717||Aim 2|"Patients who provide consent during Months 9-11 (i.e., first three months of Control Period of pilot trial) will be in the control group, with follow-up for outcomes data collection occurring during Months 12-14. Patients who provide consent during Months 16-18 (after implementation of the intervention at the end of Month 15) will be in the intervention group and will be followed for three more months (Months 19-21) for outcomes data collection. We will enroll a total of 130 patients (65 in control period, 65 in intervention period) during the pilot trial across the two trial sites, SBH and Jacobi, to reflect, as much as possible, the relative patient numbers and the demographic composition of the sites. During the intervention period, family who accompany patients to clinic and are included (patient option to include one family member) in the CONVO values discussions will be approached (in person or via video conferencing platform or telephone) for participation at the clinic."
16261875|NCT04942691|No Intervention|non-exercise group (control group)|The control group not performed physical activity for a total of 20-weeks.
16261876|NCT04942691|Experimental|exercise group|The exercise group performed SuperJump® training that will be performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.
16261877|NCT04942678||Pediatric patients ages 4-7 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
16262225|NCT04940364|Experimental|Cohort 2|Pozelimab: Single-dose IV on day 1
16261881|NCT04942652|Experimental|Itraconazole 200 mg under fasted condition|A single oral administration of itraconazole 200 mg under fasted condition
16261882|NCT04942652|Experimental|Itraconazole 200 mg under fed condition|A single oral administration of itraconazole 200 mg under fed condition
16261883|NCT04942652|Experimental|Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition|Oral administration of esomeprazole 40 mg once daily for 6 days and then a single oral administration of itraconazole 200 mg under fasted condition
16261884|NCT04942639|Experimental|Standard + JOE|Standard Maintenance Treatment plus JOE robot
16261885|NCT04942639|No Intervention|Standard|Standard maintenance Treatment
16261886|NCT04942626|Other|Chemoradiotherapy with Anakinra followed by either TME surgery or Watch and Wait|Capecitabine 500 mg/m2 bid or Capecitabine 650 mg/m2 bid or Capecitabine 825 mg/m2 bid combined with Radiotherapy and Kineret
16261887|NCT04942613|Experimental|Multicomponent Telehealth Intervention (Group1)|This group will be randomized to receive the 12-week multicomponent intervention first. They will receive individual physical therapy sessions, group physical therapy sessions, and biobehavioral interventions emphasizing program engagement and increased daily physical activity. Most interventions will be provided synchronously through videoconferencing. Each participant will receive an individualized home exercise program.
16261888|NCT04942613|Other|Education (Group2)|This group will be randomized to 12-week waitlist control condition. They will receive a one-hour education session every 2 weeks (6 sessions total) on general health topics (e.g., basic nutrition, stress reduction, sleep hygiene). At the end of 12 weeks, they will transition to the 12-week multicomponent intervention
16261889|NCT04942600|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|1 session (3,000 pulses) of high-frequency (10Hz) repetitive stimulation applied over the right temporal parietal junction (TPJ) gyrus in individuals with Functional Neurological Disorder using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
16261890|NCT04942587|Experimental|mother's voices|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of mother's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
16261891|NCT04942587|Experimental|father's voices group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of father's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
16261892|NCT04942587|No Intervention|control group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes.Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
16261893|NCT04942574|Experimental|First experimental visit : Total Sleep Deprivation|The participants enrolled in this arm will have a total sleep deprivation on their first experimental visit and a normal sleep on their second experimental visit.
16261894|NCT04942574|Experimental|First experimental visit : Normal Sleep|The participants enrolled in this arm will have a normal on their first experimental visit and a total sleep deprivation sleep on their second experimental visit.
16261895|NCT04942561|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for PIVC placement (i.e., a topical numbing spray and Buzzy® Bee, a vibrating device placed near the PIVC site for pain distraction).
16261896|NCT04942561|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction. Patients began gameplay <5 minutes before their PIVC placement and concluded after successful vascular access.
16261897|NCT04942548|Experimental|HFpEF|Patients diagnosed with obesity related heart failure with preserved ejection fraction(HFpEF)
16261898|NCT04942548|Experimental|PH-HFpEF|Patients diagnosed with obesity related pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF)
16261899|NCT04942535|Experimental|Social Incentive Gamification|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.
~Participants in this arm receive the Social Incentive Gamification intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
16261900|NCT04942535|Experimental|Social Goals through Incentives to Charity|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.
~Participants in this arm receive the Social Goals through Incentives to Charity intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
16261901|NCT04942535|Active Comparator|Control|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.
~Participants in this arm receive Daily Performance Feedback during the 12 month intervention and 6 month follow up."
16261902|NCT04942522|Experimental|ASD children A|Participants received probiotics PS128 [6×10^10 CFU(colony forming unit)/capsule} one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
16261903|NCT04942522|Experimental|ASD children B|Participants received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received probiotics PS128(6×10^10 CFU/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
16261904|NCT04942509|Experimental|Coloring|This group did mindful coloring for at least 5 days or at least 100 minutes in total during a 10-day period
16261905|NCT04942509|No Intervention|Wait-list control|This group did not do mindful coloring at all during a 10-day period.
16261906|NCT04942496|Active Comparator|Test Product 1 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261907|NCT04942496|Active Comparator|Test Product 2 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261908|NCT04942496|Active Comparator|Test Product 3 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261909|NCT04942496|Active Comparator|Test Product 4 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261910|NCT04942496|Active Comparator|Test Product 5 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261911|NCT04942496|Active Comparator|Test Product 6 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261912|NCT04942496|Active Comparator|Test Product 7 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261913|NCT04942496|Active Comparator|Test Product 8 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261914|NCT04942496|Active Comparator|Test Product 9 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
16261915|NCT04942496|Placebo Comparator|0.1% Sodium Lauryl Sulfate|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product with known irritancy potential.
16261916|NCT04942496|Placebo Comparator|Distilled Water|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product known not to cause irritancy
16261917|NCT04942483||Preschool children with a history of wheeze, aged 1 to 5 years old|"This is a pragmatic, observational study involving preschool children with wheeze aged one to five years old. All treatment and routine monitoring decisions will be at the discretion of their treating general practitioner (GP) or paediatrician (as per usual clinical practice), blinded to the study measurements.
~The following three biomarker tests will be performed a) atopic sensitisation, b) blood eosinophil count and c) FeNO (off-line method)."
16261918|NCT04942470|Experimental|Experimental:Intervention Arm|For the experimental group patients, sponges prepared by impregnating cream containing Aloe Vera and Propolis will be sterilized in the sterilization device. If any contamination occurs in the wound area of the patient (in the presence of feces, discharge), the product is applied to the wound bed after cleaning the wound with 0.9% isotonic sodium chloride washing solution. And the effects of the product on the wound will be monitored. The solution will be applied 2 times a day for the first 10 days. The second 10 days will be applied daily 1x1. Application results will be recorded and wound healing status will be monitored. In order to prevent and maintain pressure injury, the experimental group patients will be given an in-bed position every 2 hours. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure, etc.), necessary treatment and care is performed.
16261919|NCT04942470|No Intervention|No Intervention:Control Arm|In control group patients, if any pollution occurs in the wound area (feces, discharge) in the sterile dressing performed in the morning and evening at 10-22 hours, the wound area will be cleaned with the help of 0.9% isotonic sodium chloride washing solution and the clinical routine application of the pressure injury of the hospital will be carried out according to the physician's order. In patients in the control group, the results of the application will be recorded and wound healing status will be observed. An in-bed position will be given every 2 hours for the prevention and care of pressure injury patients of the control group patients. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure and other), the necessary treatment and care will be performed.
16261920|NCT04942457|Experimental|Fasting|Participants will be councelled and accompanied to follow a prolonged fasting regime of 7-10 days in an outpatient setting under medical supervision.
16261921|NCT04942457|Active Comparator|Weight-loss|8 x dietary counselling for weight-loss
16261922|NCT04942457|Placebo Comparator|Counselling on nutrients|1 x dietary counselling on important nutrients while trying to conceive, usual diet should be maintained
16261923|NCT04942444|No Intervention|Control Group|Patients from the control group kept on taking the same medical treatment that they received before randomization
16261924|NCT04942444|Experimental|Dry needling group|Besides maintaining their current medical treatment, patients from the experimental group received an additional weekly one-hour session of dry needling over the 18 tender points for a 6-week-period.
16261925|NCT04942431|Experimental|Interventiongroup|60 min per day school based Physical activity program (for one year)
16261926|NCT04942431|No Intervention|Waitinggroup|Intervention starts after one year.
16261927|NCT04942418|Active Comparator|Multicolor feldspathic ceramic laminate veneers|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
16261928|NCT04942418|Experimental|Multicolor hybrid ceramic laminate veneers.|Multi-shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
16261931|NCT04942392|Experimental|digital dance for PD|
16261932|NCT04942379|Experimental|Asthma Link|Site providers will be trained to efficiently discuss school-supervised medication administration with families and school nurses. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment in Asthma Link to provide school-supervised asthma therapy. Ongoing communication occurs between the pediatric practice, school nurse and families through electronic medical record messaging and phone communication. Data will be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
16262099|NCT04941222|Experimental|"With robotic seal PARO"|The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.
16261933|NCT04942379|Active Comparator|Enhanced Usual Care|Sites will receive pediatric pulmonologist-delivered training and a workbook for pediatric practices to provide to patients on behavioral strategies to help promote asthma medication adherence. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment to this Enhanced Usual Care condition of study (receipt of workbook). Data will also be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
16261934|NCT04942366|Experimental|HIIT Group|High intensity interval training will be performed thrice a week using a treadmill.
16261935|NCT04942366|Active Comparator|ST Group|Strength training will be performed thrice a week, each session will consist of eight dynamic drills (with resistance of 60 - 70 % of 1 repetition maximum).
16261936|NCT04942353|Experimental|Home-based Exercise Rehabilitation|
16261937|NCT04942353|Active Comparator|Usual Care|
16261938|NCT04942340|Active Comparator|Phase 1: Atipamezole & caffeine's in a 1:1 ratio|Is this arm, subjects will be randomized to IV administration of Atipamezole & caffeine's in a 1:1 ratio
16261939|NCT04942340|Placebo Comparator|Phase 1: Precedex & Saline in a 1:1 ratio|Is this arm, subjects will be randomized to receive IV administration of Precedex & Saline in a 1:1 ratio
16261941|NCT04942314||Complete remission off therapy|"no clinical activity and serological activity
~stop taking corticosteroid and immunosuppressive drugs
~antimalarials allowed"
16261942|NCT04942314||Complete remission on therapy|"no clinical activity and serological activity
~corticosteroid≤5 mg/day and immunosuppressive drugs allowed
~antimalarials allowed"
16261943|NCT04942314||Clinical remission off therapy|"no clinical activity but serological activity allowed
~stop taking corticosteroid and immunosuppressive drugs
~antimalarials allowed"
16261944|NCT04942314||Clinical remission on therapy|"no clinical activity but serological activity allowed
~corticosteroid≤5 mg/day and immunosuppressive drugs allowed
~antimalarials allowed"
16261945|NCT04942314||Low disease activity state|(1) SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever), and no haemolytic anaemia or gastrointestinal active involvement; (2) no new lupus disease activity compared with the previous assessment; (3) a PGA ≤1; (4) a current predni- sone (or equivalent) dose ≤7.5mg/day; and (5) well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
16261946|NCT04942314||Not in LDAS or Remission|At the end of follow-up, the disease state of SLE children was not in LDAS or any remissions defined above.
16261947|NCT04942314||Never in LDAS|During the follow-up, the disease state was never get LDAS.
16261948|NCT04942301|Experimental|Endostar pump for three days|Group A: The first cycle, Endostar 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump for 72 hours;
16261949|NCT04942301|Experimental|Endostar pump for seven days|Group B: Cycle 1, Endo 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump injection for 168 hours;
16261950|NCT04942288|Experimental|Acupressure + Massage Group|"Acupressure + Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention. On the second day, VAS will be applied before and after the intervention. On the third day, VAS before and after the intervention VAS, GMSSS will be applied.
~Second menstrual cycle
~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
16261951|NCT04942288|Experimental|Massage Group|"Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention (1st hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied.
~Second menstrual cycle
~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
16261952|NCT04942288|No Intervention|Control Group|"Control Group First menstrual cycle
~- On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF-36 will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.
~Second menstrual cycle - On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.
~Third menstrual cycle
~- On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS and Quality of Life Scale Short Form SF-12 will be applied."
16261953|NCT04942275|Experimental|Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification|"All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including:
~The standard functional assessment recommended before performing an SBRT.
~A perfusion PET/CT scan
~The treatment planning will be carried out in 2 stages:
~First, an anatomical planning will be carried out, blinded to the PET results.
~Then, a functional planning, respecting the standard constraints applied during anatomical planning, but also incorporating a new functional lung volume constraint defined by pulmonary PET, will then be carried out.
~A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months"
16261986|NCT04942015|Experimental|Honghuaruyi Wan|Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
16262023|NCT04941716|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-28. Patients receive acalabrutinib alone for the first three 28 day cycles. Venetoclax is added beginning with Cycle 4. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16261954|NCT04942262|Experimental|denture adhesive use|Participants were instructed to use a cream-type denture adhesive (Polident®, GlaxoSmithKline, Ireland) once a day in the morning and use it throughout the day. They applied denture adhesive onto the tissue surface of their maxillary and mandibular dentures using a spot method. The participants had to remove the DA and clean the denture every day after the last meal by soaking and brushing the CD with liquid soap and a soft toothbrush under running tap water. Two gauze pads were used to remove DA from the denture and oral mucosa. After the 1-month trial period of DA use. The outcomes were evaluated with all participants using DA, and they had to choose whether they wanted to continue or discontinue using DA for another 1 month. At 1-month after continuing or discontinuing DA use. At this time, some participants used DA during the outcome evaluations, while some did not, depending on the patient's decision on DA use.
16261955|NCT04942249||Symptomatic|167 symptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
16261956|NCT04942249||Asymptomatic|167 asymptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
16261957|NCT04942249||No evidence of infection|167 Swiss army recruits with no evidence of infection (who also were tested for SARS-CoV-2 in 2020)
16261958|NCT04942223|Other|Subjects undergoing virtually planned GBR for extended and complex alveolar defects.|"Subjects undergoing virtually planned GBR for extended and complex alveolar defects.
~The subjects were selected from the population of patients referring to the Oral & Maxillofacial Surgery Unit of S.Orsola-Malpighi University Hospital for oral function rehabilitation. Eligibility criteria were: the presence of horizontal and vertical alveolar defects in both jaws, inadequate for the placement of at least two fixtures, even ≤6 mm long ones; ≥ 18 years; informed consent signed."
16261959|NCT04942210|Experimental|vYF|1 injection of vYF at Day 1
16261960|NCT04942210|Active Comparator|YF-VAX|1 injection of YF-VAX at Day 1
16261961|NCT04942197|Experimental|Arm 1|Participants who received three dimensional ultrasound with pregnancy application
16261962|NCT04942197|Placebo Comparator|Arm 2|Participants who received three dimensional ultrasound without pregnancy management application
16261963|NCT04942184|Experimental|Group 1- 15 Mild AD and 15 MCI due to AD|In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.
16261964|NCT04942184|Active Comparator|Group 2- 15 Mild AD and 15 MCI due to AD|"In Group 2, for the first 2 weeks participants will be reminded to try hard to remember the items although they will not be given any specific strategies. At week 2 the subjects will be taught memory strategies and reminded to use them each day from week 2 to week 4."
16261965|NCT04942171|Experimental|Atrial fibrillation catheter ablation group|catheter ablation
16261966|NCT04942171|Active Comparator|Medical therapy group|standard treatment include anti-arrhythmic drug
16261969|NCT04942145|Active Comparator|Virtual Reality Group|With virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
16261970|NCT04942145|Experimental|Control Grooup|Without virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
16261971|NCT04942132|Experimental|Treatment|A Smartphone self-administered cognitive-behavioral based intervention
16261972|NCT04942119|No Intervention|Routine standard care group|This group will continue to receive the usual recommended care provided in the clinic and usual follow-up appointment as well as clinical assessment. Any required nutrition education by the dietitian or medication counseling will be provided at any visit or when requested.
16261973|NCT04942119|Experimental|Multifactorial intervention group|"Correction of magnesium and/or potassium levels, and correction of the underlying disease, if possible by a endocrinologist.
~Education at each follow-up visit by a specialized dietitian, reinforcing optimal diet and exercise, with pre-& post-nutrition and physical activity assessment using the validated revised summary of diabetes self-care activities (SDSCA) scale.
~Medication reconciliation and counseling, online post adherence questionnaire and confirm adherence by fixed medication possession ratio (FMPR) approach."
16261974|NCT04942106|Other|Side-lying position followed by Supine position|In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position.
16261975|NCT04942106|Other|Supine position followed by Side-lying position|In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position.
16261976|NCT04942093|Experimental|With diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
16261977|NCT04942093|Other|Without diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
16261978|NCT04942080|Experimental|CALRSUIVI cohort|
16261979|NCT04942067|Experimental|APG2575 +Pd or LD|APG2575+ Pomalidomide 4mg QD x 21 days + dexamethasone
16261980|NCT04942067|Experimental|APG2575+LD|APG2575+ Lenalidomide +Dexa Days 1 through 21 of each 28-day cycle,
16261982|NCT04942041||local thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the local center
16261983|NCT04942041||distant thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the distant center
16261984|NCT04942028|Experimental|Internet-delivered exposure-based treatment|10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
16261985|NCT04942028|Active Comparator|Internet-delivered standardized education and prolonged assessment|10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
16262100|NCT04941222|No Intervention|"Without robotic seal PARO"|The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.
16261987|NCT04942015|Placebo Comparator|Placebo|Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
16261988|NCT04942002|Placebo Comparator|Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution
16261989|NCT04942002|Experimental|Standard treatment + intervention|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + retrobulbar injection of 2 cc (40 mg/mL) to methylprednisolone acetate
16261990|NCT04941989|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
16261991|NCT04941989|Experimental|Part 2 Multiple Ascending Dose|Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
16261992|NCT04941976|Experimental|0.3% benzydamine hydrochloride spray oromucosal solution|A single application of 0.3% benzydamine hydrochloride spray oromucosal solution, corresponding to 2.04 mg of benzydamine (4 nebulizations)
16261993|NCT04941976|Active Comparator|3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine|A single 3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine.
16261994|NCT04941950|Experimental|PlaySmart|Video game intervention.
16261995|NCT04941950|Other|Control Game|Control video game intervention.
16261996|NCT04941937|Experimental|Arm I: Selinexor+Thalidomide+Dexamethasone|Arm I is given XTd regimen Selinexor 60mg/d QW, Thalidomide 100mg/d, d1-28 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
16261997|NCT04941937|Experimental|Arm II: Selinexor+Lenalidomide+Dexamethasone|Arm II is given XRd regimen Selinexor 60mg/d QW, Lenalidomide 25mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
16261998|NCT04941937|Experimental|Arm III: Selinexor+Pomalidomide+Dexamethasone|Arm III is given XPd regimen Selinexor 60mg/d QW, Pomalidomide 4mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
16261999|NCT04941924|Experimental|Intervention|Biliary stenting plus radio-frequency ablation of the bile duct
16262000|NCT04941924|Active Comparator|Control|Biliary stenting alone
16262001|NCT04941911|Active Comparator|Intervention group|Octreotide intravenous infusion, 100mcg bolus with a subsequent infusion of 100mcg per hour during surgery.
16262002|NCT04941911|Placebo Comparator|Placebo group|Sodium chloride 0.9% w/v
16262003|NCT04941898||TAK-660 15-50 international units per kilograms (IU/kg)|Participants will receive TAK-660 15-50 IU/kg slow intravenous injection every 8- 24 hours until the bleeding is resolved or wound healing.
16262004|NCT04941885|Experimental|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab(8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days) plus cyclophosphamide metronomic chemotherapy(50mg once a day orally) plus aromatase(once a day orally).
16262005|NCT04941872|Experimental|68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of and 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
16262006|NCT04941859|Experimental|experimental group|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
16262007|NCT04941859|No Intervention|control group|The treatment plan of control group was carried out according to the diagnosis and treatment standard of acute poisoning.
16262008|NCT04941833|Experimental|Desogestrel group|Desogestrel group
16262009|NCT04941833|Placebo Comparator|Control group|Placebo
16262010|NCT04941820|Experimental|Clinical pharmacist intervention + usual care arm|Patients in the clinical pharmacist intervention + usual care arm received the clinical pharmacist intervention as well as usual care provided by the surgical team
16262011|NCT04941820|No Intervention|Usual care arm (Control arm)|Patients in the control arm received usual care by the surgical team without a coordinated contribution from the clinical pharmacist
16262012|NCT04941807|Experimental|Platelet-rich plasma|The proximal nail fold is cleansed with alcohol and platelet-rich plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
16262013|NCT04941807|Placebo Comparator|Platelet-poor plasma|The proximal nail fold is cleansed with alcohol and platelet-poor plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
16262014|NCT04941781|Experimental|PIPE-307|Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of [11C] PIPE- 307.
16262015|NCT04941768||Avelumab + Axitinib|There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
16262016|NCT04941755|Experimental|Sequence AB|
16262017|NCT04941755|Experimental|Sequence BA|
16262018|NCT04941742||Active eosinophilic esophagitis|
16262019|NCT04941742||Eosinophilic esophagitis in remission|
16262020|NCT04941742||No eosinophilic esophagitis|
16262021|NCT04941729|Experimental|Study Arm (dual mobility)|OR3O™ Dual Mobility in subjects who undergo Primary THA.
16262022|NCT04941729|Active Comparator|Controlled Arm (conventional)|A conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
16262101|NCT04941209||Case|Inpatients/Outpatients with confirmed COVID-19 with and without pulmonary symptoms.
16262024|NCT04941703|Experimental|Magnesium Citrate plus a Probiotic Arm:|Participants assigned to the magnesium citrate plus a probiotic arm will receive 1 bottle of magnesium citrate 296 mL PO once to be taken within a 4-hour period, (about 10 oz.). Because magnesium citrate remains within the intestinal lumen, a second bottle can be provided if there is limited bowel movement. Patients will be asked to take 2 capsules of probiotics twice daily for six days or until discharge, whichever is earlier.
16262025|NCT04941703|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive matching placebo 296 mL PO once to be taken within a 4-hour period, (about 10 oz.) and 2 cellulose capsules twice daily for six days or until discharge, whichever is earlier. The placebo will be flavored to match the taste of the interventional arm.
16262026|NCT04941690||Men seen for preconception physicals|Ready to conceive, i.e. not having contraception and not having children for less than 1 year
16262027|NCT04941690||Men seen for infertility|Couples who have not used contraception and have not had children for more than 1 year
16262028|NCT04941690||Men who visited the clinic for their wives' miscarriage|Couples whose wives were previously pregnant but terminated the pregnancy due to fetal abortion, spontaneous abortion, biochemical pregnancy, fetal malformation or ectopic pregnancy
16262029|NCT04941677||schizophrenia group|No intervention age between 20-65, diagnosed schizophrenia by DSM-5.
16262030|NCT04941664|Other|Levobupivacaine|Superior trunk nerve block will be done under ultrasound guidance to patients scheduled for shoulder surgeries. Local anesthetic agent (0.5% levobupivacaine) 8ml will be injected at the superior trunk of the brachial plexus in order to produce surgical anesthesia or analgesia for shoulder surgeries.
16262031|NCT04941651|Experimental|OBE-COACH program|The OBE-COACH experimental group: access to the complete OBE-COACH program
16262032|NCT04941651|Active Comparator|e-learning program|The control group: access to an e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health) and provision of connected devices (auto-tensiometer and balance).
16262033|NCT04941625||non-AKI|patients do not have post-HIPEC AKI
16262034|NCT04941625||AKI|patients have post-HIPEC AKI
16262035|NCT04941612|Experimental|Activa IM-Nail|Activa IM-Nail
16262036|NCT04941599|Active Comparator|2-Hydroxybenzylamine (2-HOBA)|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
16262037|NCT04941599|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for 6 weeks.
16262038|NCT04941586|Experimental|Education in pain, Manual Therapy and Exercises|The therapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 60 minutes, for one month. Each therapy will last 20 minutes.
16262039|NCT04941586|Active Comparator|Manual Therapy and Exercises|The terapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 40 minutes, for one month. Each therapy will last 20 minutes.
16262040|NCT04941573|Experimental|Hyperpolarized Xenon MRI for lung transplant diagnosis|"All post lung transplant patients will undergo hyperpolarized 129-Xenon MRI and conventional proton MR imaging of the lung. Recent HRCT and spirometry measurements as part of clinical care will be available in the medical history for comparison. There will be multiple administered inhalation of HP Xenon during an imaging session. Maps of xenon ventilation (distribution) will be used for analyzing function of the lungs. These maps will be compared against 3D high-resolution CT images for regional correlations, and against spirometry as global measurements of lung health status. Additionally, xenon dissolved in lung parenchyma and blood, allows for measurement of gas exchange properties.
~Each subject will have a secondary imaging session after six-months for evaluating potential changes in the lung function and early detection of lung transplant complications such as CLAD."
16262041|NCT04941560||Algorithm training and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to training and validate the algorithm for CAD detection based on facial photos.
16262042|NCT04941521|Experimental|Exenatide and Drug Counseling|Participants will receive once weekly exenatide injections and drug counseling sessions.
16262043|NCT04941508|Experimental|Mother's recorded voice|Children will be exposed to the mother's voice.
16262044|NCT04941508|Experimental|Dexmedetomidine IV|Children will be given dexmedetomidine injection.
16262045|NCT04941508|Placebo Comparator|Saline placebo IV|Children will be given normal saline.
16262046|NCT04941495|Active Comparator|Control Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education
16262047|NCT04941495|Experimental|Experimental Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education. It also include the cervical proprioceptive training
16262048|NCT04941482|Experimental|Multi-intervention program|A multi-intervention program will design for stroke patients including [1] periodic health examination for assessment of physical and mental health, recurrence risks, and harmful behaviors; [2] guiding the appropriate rehabilitation exercises for improving the physical status and monitoring through daily online report; [3] using the motivational interviewing methods to improve and prevent mental disorder; [4] applicating the technique of functional near-infrared spectroscopy (fNIRS) for measurement of oxy-hemoglobin on cortex prefrontal to early detect mental disorder and stroke recurrence risks.
16262049|NCT04941482|Active Comparator|Standard care|Standard health check and fNIRS measure
16262050|NCT04941469|Experimental|Specifically optimized off-the-counter foot orthosis|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type."
16262051|NCT04941469|Active Comparator|Plain off-the-counter foot orthosis|The control device for this study would be the plain original Formthotics (Original Dual Hard).
16262052|NCT04941456|Active Comparator|Open Tracheostomy|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
16262053|NCT04941456|Experimental|PMV in place|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
16262054|NCT04941443|Experimental|Oral methadone|Participants will be given a preemptive analgesic in addition to a standard dose of ibuprofen while undergoing early medication abortion with mifepristone and misoprostol (not provided as part of the study). All participants will also be provided with supplementary non- opioid analgesics to be used at their own discretion during the process.
16262056|NCT04941417|Experimental|neoadjuvant PD-(L)1 inhibitor with chemotherapy followed by PD-(L)1 inhibitor for up to 1 year|
16262057|NCT04941404|Experimental|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
16262060|NCT04941378|Experimental|OTL 38|The study drug in question is an Investigational New Drug (IND), folate analog ligand conjugated with an indole cyanine green-like dye called OTL38. There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, completed at least 1 hour prior to intraoperative imaging
16262061|NCT04941365|Experimental|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
16262062|NCT04941352|Experimental|Experimental: Study group|Study group intervention consists 6-session Interpersonal Relations Theory-Based Motivational Interviews and 3-month follow-up.
16262063|NCT04941352|No Intervention|No Intervention: Control group|Control group receives general care and the training booklet at the end of the study. Also includes 3-month follow-up.
16262064|NCT04941339|Experimental|MRG002|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG002 on Day 1 of every 3 weeks (21-day cycle).
16262065|NCT04941326|Active Comparator|Spinal mobilization group|Spinal mobilization will be applied to the application group for 4 weeks in addition to the treatments applied to the sham group
16262066|NCT04941326|Sham Comparator|Sham group|Diaphragmatic stimulation with proprioceptive neuromuscular facilitation techniques (PNF), diaphragmatic breathing techniques, costal mobilization treatments and sham mobilization will be applied to the sham group.
16262067|NCT04941313|Experimental|Single Dose Escalation-3D229|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
16262068|NCT04941313|Placebo Comparator|Single Dose Escalation- placebo|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
16262069|NCT04941313|Experimental|Repeat Dose-3D229|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
16262070|NCT04941313|Placebo Comparator|Repeat Dose-placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
16262075|NCT04941274|Experimental|1/Dose Determination/De-Escalation|Abemaciclib (de-escalating dose)
16262076|NCT04941274|Experimental|2/Dose Expansion: Group 2a|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 15 participants previously treated with at least 1 line of systemic therapy.
16262077|NCT04941274|Experimental|2/Dose Expansion: Group 2b|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 10 previously untreated participants.
16262078|NCT04941261|Experimental|18-59 years old group A|
16262079|NCT04941261|Experimental|18-59 years old group B|
16262080|NCT04941261|Placebo Comparator|18-59 years old group C|
16262081|NCT04941261|Experimental|6-17 years old group A|
16262082|NCT04941261|Experimental|6-17 years old group B|
16262083|NCT04941261|Placebo Comparator|6-17 years old group C|
16262084|NCT04941261|Experimental|3-5 years old group A|
16262085|NCT04941261|Experimental|3-5 years old group B|
16262086|NCT04941261|Placebo Comparator|3-5 years old group C|
16262087|NCT04941261|Experimental|6-35 months old group A|
16262088|NCT04941261|Experimental|6-35 months old group B|
16262089|NCT04941261|Placebo Comparator|6-35 months old group C|
16262090|NCT04941261|Experimental|6-35 months old group D|
16262091|NCT04941261|Experimental|6-35 months old group E|
16262092|NCT04941261|Placebo Comparator|6-35 months old group F|
16262093|NCT04941248||Healthy controls|All healthy subjects will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
16262094|NCT04941248||Patients with decreased EF value or aortic stenosis|All patients will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
16262095|NCT04941235|Active Comparator|NU group|Bth nerve stimulator and ultrasound guided interscalene brachial plexus block
16262096|NCT04941235|Active Comparator|U group|Ultrasound guided interscalene brachial plexus block
16262097|NCT04941235|Active Comparator|N group|Nerve stimulator guided interscalene brachial plexus block
16262098|NCT04941235|No Intervention|C group|No block only IV analgesics
16262102|NCT04941209||Matched-Control|Outpatients without COVID-19 without known non-pulmonary diagnoses or symptoms.
16262338|NCT04939558||Chronic Obstructive Pulmonary Disease|245 participants - GOLD 1, 2, 3 / A, B, C
16262103|NCT04941196|Experimental|Test Group|Oral administration of Anplag® 90mg (Ticagrelor) whole Tablet, manufactured by PharmEvo Private Laboratories (Pak) Ltd., after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
16262104|NCT04941196|Active Comparator|Reference Group|Oral administration of Brilinta® 90mg (Ticagrelor) Whole Tablet, manufactured by AstraZeneca Pharmaceuticals., after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
16262105|NCT04941183|Experimental|NTR-441|Single Ascending Dose; Multiple Ascending Dose.
16262106|NCT04941183|Placebo Comparator|Placebo|Single Ascending Dose; Multiple Ascending Dose.
16262107|NCT04941170|Active Comparator|Group (T)|receive preoperative bilateral ultrasound-guided oblique subcostal transversus abdominis plane block.
16262108|NCT04941170|Active Comparator|Group (E)|receive preoperative bilateral ultrasound-guided erector spinae plane block.
16262109|NCT04941157|Experimental|Prophylactic cerebrospinal fluid drain placement|Patients randomized to receive the experimental treatment will have a prophylactic cerebrospinal fluid drain placed prior to their endovascular aortic repair. All components of the endovascular aortic repair are standard of care treatments.
16262110|NCT04941157|No Intervention|Selective cerebrospinal fluid drain placement|Patients randomized to the control arm of the study will not receive a prophylactic cerebrospinal fluid drain prior to their endovascular aortic repair. Patients will receive a CSF drain post-operative as needed to treat any symptoms of spinal cord ischemia. This arm of the study is current standard of care.
16262111|NCT04941144||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
16262112|NCT04941131|Experimental|chlorhexidine digluconate mouthwash|
16262113|NCT04941131|Experimental|chlorhexidine digluconate lozenges|
16262114|NCT04941131|Experimental|povidone iodine mouthwash|
16262115|NCT04941131|No Intervention|tap water|
16262116|NCT04941118|Sham Comparator|Control group|Only saline and local anesthetic (lidocaine)
16262117|NCT04941118|Active Comparator|Dextrose prolotherapy group|Dextrose, saline and local anesthetic (lidocaine)
16262118|NCT04941105|Experimental|PCSK9 inhibitor (evolocumab)|140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations
16262119|NCT04941105|Placebo Comparator|Usual Care|1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2.
16262120|NCT04941092||patients with ARDS induced by SARS CoV 2|
16262121|NCT04941092||patients with ARDS induced by influenza|
16262122|NCT04941079||Immune-related Myopathy Patient (myasthenia gravis and inflammatory myopathy)|
16262123|NCT04941079||Health Control|
16262124|NCT04941066|Experimental|Active neurofeedback|Receiving feedback signals from the rumination-related brain functional connectivity.
16262125|NCT04941066|Sham Comparator|Sham neurofeedback|Receiving artificially generated feedback signals.
16262126|NCT04941053||group 1 chronic haemodialysis patients|seroprevalnce of COVID 19
16262127|NCT04941053||healthy control|seroprevalnce of COVID 19
16262130|NCT04941014|Active Comparator|Light Physical Activity (LPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
16262131|NCT04941014|Active Comparator|Moderate Physical Activity (MPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
16262132|NCT04941014|Active Comparator|Vigorous Physical activity (VPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
16262133|NCT04941001|Active Comparator|Healthcare professional using ReferID Tool in primary care|The asthma review will be undertaken by a healthcare professional with the use of the ReferID tool in primary care
16262134|NCT04941001|No Intervention|Usual care in primary care|A cohort of patients will be recruited who continue to receive usual care in primary care
16262135|NCT04941001|Active Comparator|Healthcare professional using ReferID Tool in secondary care|The follow up (post A&E attendance) review will be undertaken by a healthcare professional with the use of the ReferID tool in secondary care
16262136|NCT04941001|No Intervention|Usual care post A&E attendance|The usual care post A&E attendance in secondary care.
16262137|NCT04940988||See alert|The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool.
16262138|NCT04940988||Do not see alert|The non intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.
16262139|NCT04940975|Experimental|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
16262140|NCT04940975|Active Comparator|Insomnia educational program (Treatment as Usual Group)|A program composed of four educational talks on sleep hygiene and relaxation training, plus two individual sessions for the reviewing of sleep patterns.
16262141|NCT04940962|Experimental|Non-diabetic obese|
16262142|NCT04940962|Experimental|Diabetic obese|
16262143|NCT04940962|Active Comparator|Witnesses|
16262144|NCT04940949|Experimental|Single Intravenous (IV) Dose of Lu AF90103|Participants will receive a single IV dose of Lu AF90103.
16262145|NCT04940949|Placebo Comparator|Single IV Dose of Placebo|Participants will receive a single IV dose of placebo matching to Lu AF90103.
16262146|NCT04940949|Experimental|2 Single IV Doses of Lu AF90103|Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.
16262147|NCT04940936|No Intervention|A - control|The patients are offered high or lower dose according to usual practice
16262148|NCT04940936|Experimental|B - Intervention|The Patient Decision Aid is used during the consultation to aid in the decision on high or lower dose.
16262151|NCT04940910|Experimental|Black rice bran extract group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 1 g/day)
16262152|NCT04940910|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 0 g/day)
16262154|NCT04940884|Experimental|Supervised exercise training|Pre- and Post- exercise training effects. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised exercise training (SET) and the remaining participants follow the above instruction without additional supervised exercise training. After the 24 sessions of SET, they were then followed a 16-week of follow-up of their daily activities without additional exercise training.
16262155|NCT04940884|Active Comparator|home exercise training|All included subjects were instructed to walk>=8000 steps per day (stp/d), which was recorded by wrist-worm smart watches
16262156|NCT04940871|Experimental|Favipiravir HU + SOC|Favipiravir HU + SOC
16262157|NCT04940871|Placebo Comparator|Placebo HU + SOC|Placebo HU + SOC
16262158|NCT04940845|Experimental|HS-20090-2|
16262159|NCT04940845|Active Comparator|Prolia®|
16262160|NCT04940832|Active Comparator|radiofrequency with corticosteroids|corticosteroids- 80mg depo-medrol Pulsed radiofrequency to 42 derees celsius for 6 minutes
16262161|NCT04940832|Active Comparator|radiofrequency without corticosteroids|Pulsed radiofrequency to 42 derees celsius for 6 minutes
16262162|NCT04940819|Experimental|Mobile Application Intervention|Participants in this arm will receive mobile application dietary intervention as well as usual CKD dietary care.
16262163|NCT04940819|No Intervention|Care as Usual|Participants in this arm will receive usual CKD dietary care.
16262164|NCT04940806||120 patients with narcolepsy|
16262165|NCT04940793||Group 1|Patients indicated for cataract surgery who are candidates for a trifocal IOL implantation and have corneal astigmatism over 1.00 D will be selected for inclusion by the investigators
16262166|NCT04940780|Active Comparator|Patient Preference Arm|patients who specify their preference for either acupuncture or touch therapy
16262167|NCT04940780|Active Comparator|Randomized Treatment Arm|with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup
16262168|NCT04940767|Experimental|Treatment Group A|Patients will concomitantly receive once daily treatment of oral isotretinoin and topical AMZEEQ® for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
16262169|NCT04940767|Experimental|Treatment Group B|Patients will receive once daily treatment of oral isotretinoin for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
16262170|NCT04940754|Other|Stabilzation of Fracture|Arthrodesis nail used for stabilzation of a fracture, single patient
16262171|NCT04940741|Experimental|VER-01|VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).
16262172|NCT04940741|Placebo Comparator|Placebo|The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.
16262173|NCT04940728|Experimental|Creative Thinking Group|"Nursing students who took the Self-Knowledge and Communication Techniques course for the first time in March and agreed to participate in the study were divided into experimental (30) and control (30) groups using a simple randomization method.
~Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were administered to the participants who volunteered to participate in the research using the Online Questionnaire System.
~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups.
~An intervention program based on creative thinking techniques was applied to the experimental group and post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
16262174|NCT04940728|No Intervention|Standart Group|"Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were applied to the participants who volunteered to participate in the study by using the Online Questionnaire System.
~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills of the 4 main topics in the course; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups by using the Online Questionnaire System.
~After the interim tests were applied, no intervention was made to the control group until the end of the period. At the end of the semester, post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
16262175|NCT04940715|Experimental|Passive joint mobilization|Patients lay down on a prone position, with their hands around the body and neck placed comfortable. The therapist performed a postero-anterior joint mobilization using Maitland's technique, applying pressure to spinous process of targeted vertebra (the one who reproduces patient's symptoms).
16262176|NCT04940715|Experimental|Mobilization with movement|Patients perform their painful movement (flexion, extension…). If pain wasn't reproduced, a combination of movements will be performed (flexion + rotation…). The most painful vertebral level was assessed too with passive accessory vertebral movements. Afterwards, with the patient on a seated position on a stretcher with feet supported and a belt around the waist, the therapist performed a sustained glide on the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level.
16262177|NCT04940715|No Intervention|Control group|"Patients were measured at baseline and then were placed on wait list until the end of the study. At this time, they were measured again."
16262178|NCT04940702|Experimental|Focal Vibration Group|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.
~the training is the same as the contol group with the difference of FV addiction."
16262179|NCT04940702|Active Comparator|Blood Flow Restriction Group|"Training with Blood Flow Restriction a pressure cuff occludes in the proximal part of the lower limb. Time of training 20-25 min.
~the training is the same as the contol group with the difference of BFR addiction."
16262226|NCT04940364|Experimental|Cohort 3|Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1
16262180|NCT04940702|Active Comparator|Training Group|"Traditional training. 3 times a week
~Warm-up:
~Main work:
~Aerobic training
~Strength training
~Balance and coordination training
~Return to calm"
16262181|NCT04940689|Active Comparator|Standard arm|"General anesthesia strategy with morphine:
~Within 10 minutes before the induction of general anesthesia: administration of a placebo of 50 mL of 0.9% NaCl by slow IV
~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with IV curare and remifentanil (morphine derivative) IV for a concentration target of 3-6 ng / mL.
~Maintenance of anesthesia will be carried out with propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qs bispectral index 40-60) and remifentanil (target concentration 1-10 ng / mL). The administration of curare will be carried out as needed. In order to anticipate the sudden end of the analgesia, an administration of morphine 0.15 mg / kg IV will be carried out 30 minutes before the end of the intervention as recommended"
16262182|NCT04940689|Experimental|OFA arm|"General anesthesia strategy without morphine
~Within 10 minutes before the induction of general anesthesia: pre-induction dose of dexmedetomidine 0.5 g / kg and lidocaine 1.5 mg / kg by slow IV.
~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with an IV curare
~The maintenance of the anesthesia will be carried out by propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qsp bispectral index 40-60), dexmedetomidine 0.5-1.0 g / kg / h, lidocaine 2 mg / kg / h. The administration of curare will be carried out as needed."
16262183|NCT04940676|Active Comparator|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
16262184|NCT04940676|Placebo Comparator|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding of 5 minutes after breakfast and dinner for 7 days
16262185|NCT04940663|Other|Ecological Momentary Assessment (EMA)|
16262186|NCT04940650|Other|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
16262187|NCT04940637|Experimental|Niraparib and Dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
16262190|NCT04940611||Participants With CPF-CD|Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
16262191|NCT04940611||Participants With CD-RVF|Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
16262192|NCT04940611||Participants With CCF|Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
16262193|NCT04940598|Experimental|High intensity interval exercise|High intensity interval arm crank exercise
16262194|NCT04940598|Other|No-Exercise Control|No-exercise control group
16262195|NCT04940585|Experimental|Rose Program Group|ROSE is a 7-session intervention. Participants will attend 6 weekly group sessions virtually, through a program on the computer called WebEx or at the clinic, and then one individual session after delivery. Participants will complete a few questionnaires at three different timepoints, including demographics, stress, social support, physical and mental health, and trauma.
16262196|NCT04940585|No Intervention|Comparison Group|Participants will complete three sets of questionnaires including demographics, stress, social support, physical and mental health, and trauma.
16262197|NCT04940572|Experimental|Depakine (VPA)|"Depakine Chrono 500 mg (VPA)
~VPA will be administered orally:
~From D1 to D3: During the first week 10-15 mg sodium valproate/kg bodyweight per day will be taken daily.
~From D3 to W156: The dose will be increased every 3 days in steps of 10 mg sodium valproate/kg bodyweight per day with VPA plasma concentration monitoring until the total daily dose corresponding to the optimal plasma level between 40 and 100 mg/l (ie, 300 to 700 micromol/l) is reached, till the 156 weeks corresponding to the end of treatment (EOT) visit.
~The total daily dose will be taken in one or two doses during meals."
16262198|NCT04940559|Experimental|Group 1: Sequence 1|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:
~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 3: Danicopan as a tablet under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
16262199|NCT04940559|Experimental|Group 1: Sequence 2|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:
~Period 1: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 2: Danicopan as a tablet under fasted conditions. Period 3: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
16262227|NCT04940364|Experimental|Cohort 4|Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
16262228|NCT04940364|Experimental|Cohort 5|Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
16262339|NCT04939558||Asthma|55 participants - Mild to moderate, not labelled as severe.
16262200|NCT04940559|Experimental|Group 1: Sequence 3|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:
~Period 1: Danicopan as a tablet under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. Period 3: Danicopan as a tablet under fed (medium-fat meal) conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
16262201|NCT04940559|Experimental|Group 2: Sequence 1|"Participants received danicopan once each period as a single dose under fasted conditions as follows:
~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a softgel capsule under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
16262202|NCT04940559|Experimental|Group 2: Sequence 2|"Participants received danicopan once each period as a single dose under fasted conditions as follows:
~Period 1: Danicopan as a softgel capsule under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
16262203|NCT04940546|Experimental|Sintilimab + XELOX + Bevacizumab|"Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every 3 weeks for 2 cycles.
~Details are as follows:
~Sintilimab: 200mg intravenously, d1 Oxaliplatin: 135mg/m2 intravenously, d1 Capecitabine: 2g/m2 orally, d1-14 for Bevacizumab: 7.5mg/kg intravenously, d1
~After neoadjuvant treatment, if there are no new lesions upon radiological and Multidisciplinary Team (MDT) assessment, radical surgery is performed within 6 weeks. If there are new lesions the surgical team will assess the optimal time for surgery.
~After surgery 4 cycles of XELOX regimen is advised for adjuvant therapy."
16262204|NCT04940533||Participants receiving CFTR modulator therapy - Trikafta|This is a single arm study. Participants in this study are receiving CFTR modulator therapy.
16262205|NCT04940520|Active Comparator|Control group|Group A: control group, drug recommended by the Brazilian Society of Dermatology
16262206|NCT04940520|Active Comparator|Alpha-bisabolol and laser|Group B: alpha bisabolol-based product associated with low-level laser therapy
16262207|NCT04940520|Active Comparator|Alpha bisabolol|Group C: alpha bisabolol based product
16262208|NCT04940507|Experimental|Tumor cohort|"Intervention 1:
~Participants will undergo a partial tumor ablation with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel). Blood and CSF samples will be drawn on several timepoints before and after the procedure.
~Intervention 2:
~Participants will undergo a standard of care tumor biopsy/excision one day after the Intervention 1. Blood samples will be drawn on several timepoints before and after the procedure."
16262209|NCT04940507|Other|Essential tremor cohort|To identify the levels of circulating free DNA release after MRgFUS procedure in non-tumoral patients and to check whether the MRgFUS procedure induce tumoral mutations itself, we will draw blood samples from essential tremor patients before and after standard of care MRgFUS thalamotomy procedure.
16262210|NCT04940468|Active Comparator|Arm 1: Diet Intervention|Based on participant food preferences, diet higher in fiber and lower in fat than the participant's typical diet will be provided.
16262211|NCT04940468|No Intervention|Arm 2: No Diet Intervention|No diet changes will be made for participants
16262212|NCT04940455|Experimental|Educational digital platforms|"Nursing students from the Experimental Group (GE), will participate in educational activities made available on digital platforms on nursing care for patients with signs and symptoms of sepsis"
16262213|NCT04940455|Active Comparator|High-Fidelity Simulation|Nursing students in the Control Group (GC) will be exposed to high-fidelity simulation in the intensive care setting, where they must solve situations and procedures related to the nurse's performance in recognizing the signs and symptoms of sepsis.
16262214|NCT04940442|Experimental|Active choice|FIT or colonoscopy
16262215|NCT04940442|Experimental|Sequential choice|FIT offered first, then colonoscopy offered to those still unscreened
16262216|NCT04940429||Roux n Y Gastric Bypass (RYGB)|"Participants in this arm will include patients who will be having a RYGB after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.
~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit.
~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
16262217|NCT04940429||Sleeve gastrectomy (SG)|"Participants in this arm will include patients who will be having a SG after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.
~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit:
~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
16262218|NCT04940416||Cirrhosis|These will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
16262219|NCT04940416||Non-cirrhosis|These will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
16262220|NCT04940403|Active Comparator|Unimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will only train their hemiparetic arm (unimanual tasks only).
16262221|NCT04940403|Experimental|Bimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will train their hemiparetic arm as well as interacting with the contralateral arm for bimanual tasks (unimanual + bimanual tasks).
16262229|NCT04940351|Experimental|GROUP - A: PIEZOCISION GROUP|This group will receive piezocision using piezotome inbetween the roots of mandibular anteriors after the placement of initial arch wire.
16262230|NCT04940351|Experimental|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive Micro-Osteoperforation using orthodontic mini-implants and mini-implant screw driver after the placement of initial arch wire.
16262231|NCT04940338|Experimental|Bromfenac|Group 1 will receive topical bromfenac (0.9 mg/mL) 2x daily, 7 days before the surgery
16262232|NCT04940338|Experimental|Dexamethasone|Group 2 will receive topical dexamethasone (1mg/mL) 3x daily before the surgery
16262233|NCT04940338|Placebo Comparator|Placebo|Group 3 will receive topical placebo (artificial tears substitute) 2x daily before the surgery
16262234|NCT04940325|Experimental|DS-1062a|All participants included in the study will receive a starting dose of 6 mg/kg of DS-1062a every 3 weeks until progression or until unacceptable toxicity
16262235|NCT04940312||Usual Care Group|Individuals with heart failure receiving standard medical care
16262236|NCT04940312||Intervention Group 1 (pedometer-monitoring only)|Individuals with heart failure receiving a pedometer for measurement of daily step count
16262237|NCT04940312||Intervention Group 2 (app-based coaching)|Individuals with heart failure receiving an individualized, app-based physical activity coaching on the basis of pedometer-based assessment of daily step count
16262238|NCT04940299|Experimental|Cohort 1 (ipilimumab, nivolumab, tocilizumab)|Patients with melanoma will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
16262239|NCT04940299|Experimental|Cohort 2 (ipilimumab, nivolumab, tocilizumab)|Patients with urothelial cancer will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
16262240|NCT04940299|Experimental|Cohort 3 (ipilimumab,, nivolumab, tocilizumab)|Patients with NSCLC receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 2 weeks for up to 2 years. Patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses). Treatment continues in the absence of disease progression or unacceptable toxicity.
16262241|NCT04940286|Experimental|Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)|Patients receive durvalumab IV over 1 hour on day 1, oleclumab IV over 1 hour, nab-paclitaxel IV, and gemcitabine IV over 1 hour over 30-40 minutes on days 1 and 15. Treatment repeats every 28 days for 2-6 cycles. Within 4-8 weeks after completion of last cycle of treatment, patients undergo surgical resection. After surgical resection, patient may receive adjuvant therapy with durvalumab and oleclumab, durvalumab, oleclumab, gemcitabine, and nab-paclitaxel, other chemotherapy, or observation only at the discretion of the treating physician.
16262242|NCT04940273|Experimental|remifentanil|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
16262243|NCT04940234|Experimental|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
16262244|NCT04940234|Experimental|Black Layperson|Survey respondents are exposed to a Black person wearing layperson's attire.
16262245|NCT04940234|Experimental|White Expert|Survey respondents are exposed to a white person wearing expert attire.
16262246|NCT04940234|Experimental|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
16262247|NCT04940221|Experimental|Phone-delivered decision-counseling program for shared decision making in lung cancer screening|All individuals who are eligible for lung cancer screening according to USPSTF criteria were invited to participate in the study and all patients who accepted the invitation and consented were slated to receive the intervention which was a phone-delivered on line decision-counseling program (DCP) and there was no one randomized or enrolled into a control group, nor was anyone randomized or enrolled into a usual care group.
16262248|NCT04940208||post COVID-19 ICU survivors|Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave
16262249|NCT04940182|Experimental|XC221|XC221 100 mg orally. 1 tablet of XC221 100 mg 2 times a day during 14 full days of treatment period
16262250|NCT04940182|Placebo Comparator|Placebo|Placebo orally. 1 tablet of Placebo 2 times a day during 14 full days of treatment period
16262251|NCT04940169|Experimental|quadriceps tendon autograft|Ramdomized half of the patient underwent quadriceps graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
16262252|NCT04940169|Experimental|hamstring tendon autograft|Ramdomized half of the patient underwent hamstring graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
16262253|NCT04940156|Other|Confirm Rx|Patient with cardiac implantable electronic devices with an atrial lead will have Confirm Rx Implantable Cardiac Monitor injected in the anterior chest wall.
16262254|NCT04940156|Other|LINQ|Patient with cardiac implantable electronic devices with an atrial lead will have LINQ Implantable Cardiac Monitor injected in the anterior chest wall.
16262255|NCT04940143|Experimental|Botulinum toxin-A|Botulinum toxin-A (Onabotulinum toxin type-A) injection with electrical stimulation guidance will be administered to spastic ankle plantar flexor muscles. After the injection, the patients will be included in the comprehensive physiotherapy program.
16262256|NCT04940130|Experimental|Arm 1 (PfSPZ Vaccine)|111 children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10^5 PfSPZ) via DVI at 1, 8, and 29 days
16262257|NCT04940130|Placebo Comparator|Arm 2 (normal saline)|111 children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days
16262258|NCT04940117|Experimental|blood test data before and after taking|Checking eGRF value before and after taking Eefooton oral solution
16262259|NCT04940104|Experimental|Botox|
16262260|NCT04940104|No Intervention|Control No Botox|
16262261|NCT04940091||Epidural labor analgesia|All participants will receive epidural analgesia during labor.
16262262|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide in separate syringes|Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.
16262263|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide combined in DV3384 device|Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.
16262264|NCT04940078|Experimental|Part B: Cagrilintide and semaglutide combined in DV3384 device|Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.
16262266|NCT04940052|Experimental|Dabrafenib plus trametinib|Participants will be treated with dabrafenib twice daily and trametinib once daily
16262267|NCT04940052|Placebo Comparator|Placebo dabrafenib plus placebo trametinib|Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily
16262269|NCT04940026|Experimental|SAR439859|Single oral dose of SAR439859 at Day 1 in fasted condition followed by intravenous administration of [14C]-SAR439859 microtracer 3 hours later, and single oral dose of [14C]-SAR439859 at Day 7 in fasted condition
16262270|NCT04940013|Other|Study participants|Study participants will be persons who have late period of up to 14 days
16262271|NCT04940000|Experimental|Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.|
16262274|NCT04939974|Active Comparator|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
16262275|NCT04939974|Placebo Comparator|placebo|Placebo packet same in colour, smell and constituent to that of placebo one packet daily for 24 weeks
16262276|NCT04939961|Experimental|Hericium erinaceus|8 gram of mushroom Hericium erinaceus (containing 5 milligram of erinacines) per day
16262277|NCT04939961|Placebo Comparator|Placebo capsule|8 gram of allergen free corn starch per day
16262278|NCT04939935|Experimental|Intervention|"Participants randomised to the intervention group receive Metformin XR plus standard of care for 104 weeks.
~Dosage will depend on individual participant's level of tolerance to Metformin XR as well as their estimated glomerular filtration rate (eGFR). The dosage will be between 1000-2000mg/day."
16262279|NCT04939935|Placebo Comparator|Control|Participants randomised to the control group receive placebo plus standard of care for 104 weeks.
16262280|NCT04939922||Migraine|Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3
16262281|NCT04939922||Other Primary Headache Disorders|Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
16262282|NCT04939922||Vertigo|Patients with other vertigo disorders (excluding vestibular migraine).
16262283|NCT04939922||Secondary Headache Disorders|Patients with secondary headache disorders as defined by ICHD-3.
16262284|NCT04939922||Normal control|Normal people do not have headache and vertigo.
16262285|NCT04939909|Other|Patients treated with Botulinum toxin type A|Patients were treated with Botulinum toxin type A
16262286|NCT04939896||Compliance with rehabilitation|The patients' compliance with rehabilitation was followed up at 2, 6, 8, 12 and 24 weeks after onset, respectively
16262287|NCT04939883|Experimental|Intervention Group|Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy.
16262288|NCT04939883|Placebo Comparator|Control Group|Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
16262289|NCT04939870||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stage G3b-G4 CKD) with moderate or severe decrease in eGFR (eGFR 44-29 ml / min / 1.73 m2),
16262307|NCT04939792|Experimental|Vitamin D3 and L-Cysteine|VD+LC group will take daily two capsule containing 1000 IU+500 mg LC. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
16262340|NCT04939558||Congestive cardiac failure|55 participants
16262290|NCT04939870||END-STAGE RENAL DISEASE GROUP|patients with ESRD (n=78) - (eGFR <15 ml/min /1.73 m2) undergoing renal replacement therapy. Depending on the method of renal replacement therapy used, two subgroups are distinguished: PD subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, initially, due to the treatment technique, two groups were separated, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique, and a group of patients (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), HD subgroup (n = 43) including patients treated with repeated hemodialysis. Hemodialysis procedures were performed in each patient three times a week, via an arteriovenous fistula from own or artificial vessels. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min.
16262291|NCT04939870||CARDIOLOGY GROUP|• CARD group (n = 37) - patients with at least one history of cardiovascular events, admitted to hospital for elective angiography, without any signs of impaired kidney function. The studies in this group were to show the changes that occur as a result of diseases of the cardiovascular system and the functioning of the kidneys.
16262292|NCT04939870||HEALTHY VOLUNTEERS|Healthy volunteers, (n = 32) - it was composed of healthy people, with no evidence of impairment in renal function and cardiovascular function in the history and at the time of enrollment in the study.
16262293|NCT04939857|Experimental|experimental group|Trimetazidine was given 2 weeks before radiotherapy, 20 mg each time, three times a day for 3 months.
16262294|NCT04939857|No Intervention|control group|No intervention
16262295|NCT04939844|Experimental|NDMM ineligible for transplant|"All participants will receive isatuximab in combination with bortezomib, lenalidomide and dexamethasone for 2 cycles, followed by isatuximab in combination with bortezomib and lenalidomide for 6 cycles, followed by isatuximab in combination with lenalidomide for 10 cycles, followed by continuous lenalidomide until disease progression. The cycle duration is 28 days.
~Isatuximab will be administered IV at a dose of 10 mg/kg
~on D1, D8, D15 and D22 during Cycle 1
~on D1 and D15 during Cycles 2-18
~Bortezomib will be administered SC at a dose of 1,3mg/m2
~-on D1, D8 and D15 during Cycles 1-8
~Lenalidomide will be administered PO at a dose of 25mg/day (15 mg/day in participants with GFR <30mL/minute/1.73m2)
~-on D1 to D21 during all Cycles.
~Dexamethasone will be administered PO at a dose of 20 mg -on D1, D8, D15 and D22 during Cycles 1 and 2"
16262296|NCT04939831|Experimental|1|the group of LRH
16262297|NCT04939831|Active Comparator|2|the group of ARH
16262298|NCT04939818||Group 1: Cognitive Disorders|"Alzheimer's Disease (AD) Meet National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia
~Dementia with Lewy bodies (DLB) Diagnosis of possible or probable DLB based on the criteria defined by The Dementia with Lewy Bodies Consortium (2015)
~Non-AD non-DLB MCI Diagnosis of 'probable' and 'possible' behavioral variant frontotemporal dementia (bvFTD) according to the International Behavioral Variant FTD Criteria Consortium OR semantic variant or nonfluent-agrammatic variant primary progressive aphasia (PPA) FTD according to Mesulam's criteria OR Vascular Dementia according to NINDS-AIREN International Workshop
~AND
~Date of diagnosis not more than five years prior to consent Subjects must have MMSE scores of 23-30 (inclusive); or TICS40 score of 20-40 (inclusive) based on a test not older than 1 month at the time of consent.
~Age of 50-85 years (inclusive)"
16262299|NCT04939818||Group 2: Motor disorders|"Parkinson's Disease (PD)
~Diagnosis of idiopathic Parkinson's Disease based on the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria
~Date of diagnosis not more than five years prior to consent
~Hoehn and Yahr stage 2 or less
~Age of 30-85 years (inclusive)
~Motor neuron Disease (MND)
~Diagnosis of Amyotrophic Lateral Sclerosis based on gold-standard clinical criteria
~Stage 3 or less on the King's ALS Staging system
~Age of 18-85 years (inclusive)"
16262300|NCT04939818||Group 3: Affective disorders|"Major Depressive Disorder (MDD)
~Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current major depressive episode (MDE) as assessed by the MINI
~Current episode of at least moderate severity as assessed by the Clinical Global Impression (CGI) scale.
~Date of diagnosis (using MINI assessment) and severity (CGI) maximum of two months prior to consent.
~Age of 18-85 years (inclusive).
~Bipolar Disorder (BD)
~Meet DSM-5 criteria for BD as assessed by the MINI (type 1 or type 2)
~Current depressive episode as assessed by the MINI
~Current episode of at least moderate severity as assessed by the Clinical Global Impression (CGI) scale.
~Date of diagnosis (using MINI assessment) and severity (CGI) maximum of two months prior to consent.
~Age of 18-85 years (inclusive)."
16262301|NCT04939818||Group 4: Unaffected Controls|"Group 4 specific recruitment criteria matched for the 'Group 1: Cognitive Disorders' cohort:
~Age of 50-85 years (inclusive)
~Approximately age, gender and education matched to AD subjects on a group level.
~In otherwise good health condition.
~Group 4 specific recruitment criteria matched for the 'Group 2: Motor Disorders' cohort:
~Age of 30-85 years (inclusive)
~Approximately age, gender and education matched to PD subjects on a group level.
~In otherwise good health condition.
~Group 4 specific recruitment criteria matched for the 'Group 3: Affective Disorders' cohort:
~Age of 30-85 years (inclusive).
~Approximately age, gender and education matched to MDD/BD subjects on a group level.
~In otherwise good health condition."
16262302|NCT04939805|Experimental|Selective CRP apheresis as an adjunct to standard of care|Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
16262303|NCT04939805|No Intervention|Standard of care according to current guideline recommendations|
16262304|NCT04939792|Placebo Comparator|Placebo|"Initially, all of the study subjects will be provided placebo supplementation as a placebo run-in period for one month before randomization. The placebo run-in period is meant to stabilize subjects in the study and will prevent any effect due solely to inclusion in the study. Placebo and supplement capsules will be similar in appearance, taste, texture, and smell, and will be provided by the pharmacist, who will have the codes for which subjects are assigned to which supplement or placebo.
~During testing, the placebo group will take two placebo capsules a day in the morning. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle"
16262305|NCT04939792|Experimental|L-Cysteine|LC group will receive two capsules of LC daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
16262306|NCT04939792|Experimental|Vitamin D3|VD group will take two capsules and each capsule will contain 1000 IU VD daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
16262308|NCT04939779|Experimental|Group A|Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
16262309|NCT04939779|Experimental|Group B|Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
16262310|NCT04939766|Other|Type 1 diabetic patients under CSII eligible for closed loop use|Diabetic patients age 13 or above under CSII with continuous glucose monitoring matching eligibility criteria for the use of a closed loop during a 6 months period. During the study, 4 physical appointments with a diabetologist and 3 phone contacts are anticipated.
16262311|NCT04939753||Sevoflurane group|Patients that received sevoflurane while in ICU care.
16262312|NCT04939727|Experimental|OUD-CDS + Suicide Risk Model associated CDS (Intervention arm)|Providers that practice in the clinics in this intervention arm will receive access to the OUD-CDS + Suicide Risk Model associated CDS, for all eligible encounters.
16262313|NCT04939727|No Intervention|Control|"Providers that practice in the clinics in this control arm will not receive any access to the OUD-CDS + Suicide Risk Model associated CDS, however these clinical decision-support tools will run silently in the background, collecting data on eligible encounters."
16262314|NCT04939714|Experimental|Psychoeducational Intervention|Caregivers receiving the psychoeducational intervention immediately.
16262315|NCT04939714|No Intervention|Waitlist|Caregivers on a waitlist to receive the psychoeducational intervention after a waiting period of 8 weeks.
16262316|NCT04939701|Experimental|Phase 1 ASP0739 Monotherapy Dose Escalation|Participants with R/R solid tumors known to express NY-ESO-1 will receive ASP0739 on day 1 of each 28-day cycle for up to 6 doses, to determine the RP2D.
16262317|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Safety Lead-in|Participants with R/R SS, MRCL or ovarian cancer will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses in combination with receiving 4 doses of pembrolizumab every 6 weeks starting on Cycle 1 Day 1 to determine the RP2D of ASP0739 with pembrolizumab. An additional 13 doses of pembrolizumab may be available for qualifying participants.
16262318|NCT04939701|Experimental|Phase 2 ASP0739 Monotherapy Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, NSCLC-adenocarcinoma, squamous cell, and ESCC) will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses.
16262319|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer will receive RP2D of ASP0739 with pembrolizumab on day 1 of each 28-day cycle for up to 6 doses, in combination with 4 doses of Pembrolizumab administered every 6 weeks. An additional 13 doses of Pembrolizumab may be available for qualifying participants.
16262320|NCT04939688|Experimental|Patients requiring a CT scan in the search for cranial lesions following head trauma|All patients will undergo both conventional dose AND ultra low-dose CT scans in the search for cranial lesions following head trauma.
16262321|NCT04939675|Experimental|Anti-seizure medication|The intervention group will receive anti-epileptic drug treatment according to the guideline of American Epilepsy Society 15 for 12 weeks. The recommended regimens include zonisamide, lamotrigine, or levetiracetam at the minimal therapeutic doses (zonisamide 100mg twice daily, levetiracetam 500mg twice daily, lamotrigine 50mg twice daily), and the choices depend on tolerability of the participants and contraindications (allergy to any drugs, or allergy to sulphonamides in zonisamide users). The participants will be followed every 4 weeks.
16262322|NCT04939675|No Intervention|Observation|The participants will be followed every 4 weeks without anti-seizure medication.
16262323|NCT04939662|Experimental|Olaparib+Bevacizumab to SCLC patients|"Regimen and administration:
~Administration of olaparib Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.
~Administration of bevacizumab Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.
~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
16262324|NCT04939649|Experimental|Ketamine|Participants will receive up to a four-week course of twice-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
16262325|NCT04939649|Active Comparator|Midazolam|Participants will receive up to a four-week course of twice-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
16262326|NCT04939636|Active Comparator|Vitamin D3 capsules 4000IU/100µg|Get Vitamin D3 capsules 4000IU/100µg.
16262327|NCT04939636|Active Comparator|Vitamin D3 capsules 600IU/15µg|Get Vitamin D3 capsules 600IU/15µg.
16262328|NCT04939623|Active Comparator|Probenecid 500 mg PO BID|Probenecid 500 mg X 1 PO BID and Placebo X 1 PO BID
16262329|NCT04939623|Active Comparator|Probenecid 1000 mg PO BID|Probenecid 500mg X 2 PO BID
16262330|NCT04939623|Placebo Comparator|Placebo PO BID|Placebo X 2 PO BID
16262331|NCT04939610|Experimental|Phase 1: Dose Escalation|Up to 30 patients with solid tumors.
16262332|NCT04939610|Experimental|Phase 1: RP2D Expansion Cohort|Up to 20 patients with solid tumors.
16262333|NCT04939610|Experimental|Phase 2: Specific Solid Tumors|Cohorts of up to 40 patients each with Advanced or Solid Tumors
16262334|NCT04939597|Experimental|Arm I (memantine hydrochloride)|Patients receive memantine hydrochloride PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 30, and 60 months.
16262335|NCT04939597|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 30, and 60 months.
16262336|NCT04939584|Experimental|Intervention|"The study will be conducted using the venous cannulations that are standard of care for the indicated procedure. Additional access points may be necessary if access to coronary sinus is difficult from existing femoral venous cannulations. Sterile study leads or EP catheters will be temporarily placed into the RA, CS, and RV (for R-wave sensing using intracardiac electrograms - optional) which will be connected to the investigational device (CESS).
~Up to two MPTs will be delivered and subject responses following each MPT regarding perception and acceptability of MPT to treat AF will be obtained. MPT voltages will not exceed 100V."
16262337|NCT04939571||Preterm born infants treated for ROP|
16262341|NCT04939558||Anaemia|55 participants - with at least 50% of participants recruited having no history of chronic cardiorespiratory conditions
16262342|NCT04939558||Bronchiectasis|55 participants - Acquired or genetic, e.g. cystic fibrosis or other primary ciliary dyskinesias
16262343|NCT04939558||Lung cancer|55 participants - including rare types e.g. mesothelioma
16262344|NCT04939558||Interstitial Lung Disease|55 participants - including pulmonary fibrosis pneumoconiosis, asbestosis, sarcoidosis, amyloidosis
16262345|NCT04939558||Long COVID|55 participants
16262346|NCT04939558||Upper airway obstruction disorder|55 participants
16262347|NCT04939558||Healthy|55 participants - with no previous or current chronic cardiorespiratory diagnoses
16262350|NCT04939532|Active Comparator|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants with high risk for either infection or severe disease and proactivity reaches those participants via text message for symptom/exposure screening and testing recommendation when applicable. This is a bi-directional text messaging system.
16262351|NCT04939532|Active Comparator|Text-Messaging plus Patient Navigation (TM+PN)|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD testing.
16262352|NCT04939519|Active Comparator|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants who are eligible for the COVID-19 vaccine and proactively reach those participants for vaccine scheduling. This is a bi-directional text messaging system.
16262353|NCT04939519|Active Comparator|Text-Messaging plus Patient Navigation|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD vaccination.
16262354|NCT04939506|Experimental|Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing|Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
16262355|NCT04939493|Experimental|Rhythmic Auditory Cueing|Group (B): Patients in this group will receive the same designed physical therapy program given to the control group in addition to auditory cueing during bilateral arm training using the metronome.
16262356|NCT04939493|Active Comparator|Bilateral arm training|Patients in this group will receive a standard physical therapy program in addition to Bilateral arm training.
16262357|NCT04939480|Experimental|Atezolizumab|Pre-operative administration of atezolizumab 1200 mg followed by definitive resection of the tumor, followed by standard of care radiotherapy or radio-chemotherapy.
16262360|NCT04939454|Experimental|sarcopenic COPD patient|
16262361|NCT04939454|Other|non-sarcopenic COPD patient|
16262362|NCT04939441|Experimental|TAF group|TAF [Vemlidy® 25mg QD] monotherapy
16262365|NCT04939415|Experimental|modified Qing Fei Pei Du Tang|encapsulated modified Qing Fei Pai Du Tang
16262366|NCT04939415|Placebo Comparator|Placebo|Organic brown rice
16262367|NCT04939402|Other|General|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
16262368|NCT04939376||Group A|Women with hysteroscopically or ultrasonographic detected uterine anomalies(adenomyosis,fibroid) intracavitary lesions ( like polyp, adhesion or septum) and those with detected endometrial abnormalities (like hypervascularization,pale endometrium) ,cervical lesion and cervical canal lesion or pelvic lesion
16262369|NCT04939376||Group B|Matched women (eg. Age,parity, BMI, ovarian reserve….) with no uterine or ovarian abnormalities assessed by hysteroscopy or ultrasonography.
16262403|NCT04939077|Experimental|CABG with hUC-MSC treatment group|In the CABG with hUC-MSC treatment group, 1×10^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.
16262404|NCT04939077|No Intervention|CABG group|CABG was performed under general anesthesia.
16262370|NCT04939363|Experimental|combination of Ibrutinib, Venetoclax and Obinutuzumab|"Obinutuzumab intravenous infusion:
~Cycles 1: Day 1: Obinutuzumab 100 mg Day 1 (or 2): Obinutuzumab 900 mg Day 8: Obinutuzumab 1000 mg Day 15: Obinutuzumab 1000 mg Cycles 2-6: Day 1: Obinutuzumab 1000 mg The first infusion of Obinutuzumab may be administered at the full dose (1000 mg) on day 1 of cycle 1, if the infusion of a test-dosage of 100 mg is well tolerated by the patient. Alternatively, if the first 100 mg infusion on day 1 is not well tolerated, the remaining 900 mg of the first dose should be administered on day 2.
~Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.
~Venetoclax with an accelerated ramp-up and close inpatient TLS monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:
~Cycle 1: Day 15: Venetoclax 20 mg Days 16-17: Venetoclax 50 mg Days 18-21: Venetoclax 100 mg Days: 22-28: Venetoclax 200 mg Cycles 2-12: Days 1-28: Venetoclax 400 mg"
16262371|NCT04939337|Experimental|TH-SC01|TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
16262372|NCT04939324|Other|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection
~Blood samples at 2 sites: peripheral vein and tumor-draining vein
~Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
16262373|NCT04939311|Experimental|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
16262374|NCT04939311|Placebo Comparator|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
16262375|NCT04939298|Experimental|Patients under mechanical ventilation|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation
16262376|NCT04939285|Experimental|PEEP=5cmH2O|In PSV mode,PS = 8 cmH2O,PEEP= 5 cmH2O, and FiO2 level was consistent with that before SBT
16262377|NCT04939285|Experimental|PEEP=0cmH2O|In PSV mode,PS = 8 cmH2O,PEEP=0 cmH2O, and FiO2 level was consistent with that before SBT
16262378|NCT04939272|Experimental|Treatment (copanlisib hydrochloride, venetoclax)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
16262379|NCT04939259|Experimental|New Music Program|The new hearing aid contains the new music program will be worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
16262380|NCT04939259|Active Comparator|Standard Listening Program|The new hearing aid also contains the standard listening program worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
16262381|NCT04939246|Other|Single-fraction SABR|Patients will receive SABR in a single-fraction regiment treatment with one single dose of radiation therapy per lesion. Patients may be treated for up to a total of ten lesions. Each lesion will be treated in one fraction.
16262382|NCT04939233|Experimental|Exoskeleton Glove|Perform a feasibility trial of the robotic orthosis device by providing it to a small cohort of adult patients suffering from paralysis due to a brachial plexus injury.
16262383|NCT04939220|Active Comparator|Control Group|Deep sedation with propofol and natural airway
16262384|NCT04939220|Experimental|Experimental Group|SGA Placement and maintenance with inhalational anesthetic or propofol
16262385|NCT04939207|Experimental|CT-derived FFR|In this study arm, the need for coronary revascularization will be determined by CT-derived Fractional Flow Reserve (FFR) calculations
16262386|NCT04939207|Experimental|Angiography-derived FFR|In this study arm, the need for coronary revascularization will be determined by FFR-calculations derived from angiographic images
16262387|NCT04939207|Active Comparator|Routine Care|In this study arm, the need for coronary revascularization will be determined by angiography and invasive FFR-measurements
16262388|NCT04939194|Experimental|Fast Track Protocol|the 22 items of ERAS (Early Recovery After Surgery) society
16262389|NCT04939194|No Intervention|Conventional perioperative care program|standard perioperative care
16262390|NCT04939181|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
16262391|NCT04939181|Placebo Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
16262392|NCT04939155||Patients infected with SARS-CoV-2|The first part of this study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after they contracted SARS-CoV-2
16262393|NCT04939155||Patients who have received an mRNA vaccination|The second part of the study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after SARS CoV-2 mRNA vaccine injection.
16262394|NCT04939142|Experimental|SVd (Selinexor+Bortezomib+dexamethasone)|Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.
16262395|NCT04939142|Experimental|Vd(Bortezomib+dexamethasone)|Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.
16262396|NCT04939116|Experimental|200 mg QD|200 mg of ANG-3070 will be taken once daily for 12 weeks.
16262397|NCT04939116|Experimental|400 mg QD|400 mg of ANG-3070 will be taken once daily for 12 weeks
16262398|NCT04939116|Experimental|300 mg BID|300 mg of ANG-3070 will be taken twice a day for 12 weeks.
16262399|NCT04939116|Placebo Comparator|Placebo|Placebo capsules will be taken once or twice daily for 12 weeks.
16262400|NCT04939103||1|those with the examination of EUS-FNA ,CT,MR,enteroscope
16262401|NCT04939090|Experimental|Arm I (olanzapine)|Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
16262402|NCT04939090|Active Comparator|Arm II (megestrol acetate)|Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
16262543|NCT04938115|Experimental|CD7 CAR-T|
16262544|NCT04938102|No Intervention|Abnormal DI - Control|Patients' whose distensibility index is measured <2.8 will receive no intervention.
16262410|NCT04939051|Experimental|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
16262411|NCT04939051|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
16262412|NCT04939038|Active Comparator|Control Arm|Standard wound care for diabetic wound ulcer
16262413|NCT04939038|Experimental|Immediate revascularization|Patient will have revascularization 0 - 7 days after randomization and then receive standard wound care for diabetic wound ulcer
16262414|NCT04939025|No Intervention|Historic cohort|
16262415|NCT04939025|Other|Multi-interventional program cohort|
16262418|NCT04938999|Experimental|MVgPA group|"The MVgPA group consists of 24 sessions conducted over 12 weeks for the study participants by the staff of residential care facilities.
~The structured MVgPA group session (10 - 12 participants) will be conducted twice per week. The 75-min music-paced physical activities will be presented in the PowerPoint slideshow. The instructions for an upper limb exercise will be presented in a large number pad in the slideshow, and the participants will then be asked to follow the actions and directions presented on the slide."
16262419|NCT04938999|Other|Control group|residential care facilities will conduct their usual activities during the study period. A trained RA2 will record the activities conducted by the residential care facilities during the study period.
16262420|NCT04938986|Experimental|IMMUNOSCORE®|
16262421|NCT04938973|Experimental|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|The patient will undergo RAMIE using the standard Ivor-Lewis approach. This will be a two-stage operation involving a first stage through a 5-port robotic approach through the abdomen to achieve a proximal gastrectomy and D2 nodal dissection. A feeding jejunostomy would not be inserted, as per the enhanced recovery pathway for esophagectomy. In addition, the vascularization of the conduit can be confirmed using the near-infrared camera of the robot. The second stage of the operation will involve a 4-port robotic approach through the right chest to achieve thoracic nodal dissection, esophagectomy, and a hand-sewn anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
16262422|NCT04938973|Active Comparator|Open Transthoracic Esophagectomy (OTE)|The patient will undergo OTE using the standard Ivor-Lewis approach. This is a two-stage operation involving a first stage through laparotomy, proximal gastrectomy, D2 nodal dissection, and insertion of feeding jejunostomy. The second stage of the operation will involve a right thoracotomy, thoracic nodal dissection, esophagectomy, and a stapled anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
16262423|NCT04938960||Biological Heart Valve|Participants receiving a biological heart valve
16262424|NCT04938960||Mechanical Heart Valve|Participants receiving a mechanical heart valve
16262425|NCT04938947|Experimental|High-Intensity Resistance Training Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each resistance training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure (likely 8-12 repetitions) using 80% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2).
16262426|NCT04938947|Experimental|Low-Intensity Resistance Training with Blood Flow Restriction Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure using 30% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2). Participants in this group will perform all leg extensions with blood flow restriction cuffs applied to the proximal thigh of both legs. The pressure that the cuffs are inflated to will be calculated based on estimates of each subject's arterial occlusion pressure from their thigh circumference. Once the target pressure is reached, the cuffs will not be deflated until after the final set of the training session.
16262427|NCT04938934|Experimental|Aversive conditioning|
16262428|NCT04938934|Sham Comparator|Sham conditioning|
16262429|NCT04938908|Experimental|Ophthalmic probiotic|1 drop in each eye/ 5 hours for 4 weeks
16262430|NCT04938908|Placebo Comparator|Placebo|1 drop in each eye/ 5 hours for 4 weeks
16262431|NCT04938895|Experimental|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
16262432|NCT04938895|Experimental|Black Layperson|Survey respondents are exposed to a Black person wearing layperson attire.
16262433|NCT04938895|Experimental|White Expert|Survey respondents are exposed to a white person wearing expert attire.
16262434|NCT04938895|Experimental|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
16262435|NCT04938882|Placebo Comparator|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
16262436|NCT04938882|Active Comparator|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
16262437|NCT04938882|Active Comparator|Compound lidocaine at low-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
16262545|NCT04938102|Active Comparator|Abnormal DI - Botox|Patients' whose distensibility index is measured <2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
16262438|NCT04938882|Active Comparator|Compound lidocaine at high-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
16262439|NCT04938869|Experimental|Supportive care (CGM)|Prior to hospital discharge, patients receive CGM application and education on how to apply the CGM, and how to use the sensor and its associated smart phone app. Patients also receive basic diabetes mellitus education. After hospital discharge, patients use CGM for up to 28 days.
16262440|NCT04938856|Experimental|Test Group|Oral administration of Lamnet (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
16262441|NCT04938856|Active Comparator|Reference Group|Oral administration of Lamictal (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
16262442|NCT04938843|Experimental|F. prausnitzii and D. piger|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
16262443|NCT04938843|Placebo Comparator|Placebo|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
16262450|NCT04938804|Experimental|Screening group|
16262452|NCT04938778|Experimental|Intervention Arm|8 week 14 hour prolonged nightly fasting intervention.
16262453|NCT04938765|Experimental|Magnesium sulfate arm|MgSo4 diluted to 20% will be administered at 40 mg/kg dosed to ideal body weight over 10min to the study arm followed by 10mg/kg/hr infusion.
16262454|NCT04938765|Placebo Comparator|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
16262455|NCT04938752|Experimental|Sequence I|
16262456|NCT04938752|Experimental|Sequence II|
16262457|NCT04938739|Experimental|Cognitive Behavioral therapy|to modify any erroneous beliefs about pain and disability and to promote coping strategies and self-efficacy through a graded activity.
16262458|NCT04938739|Active Comparator|Home program exercises|Patients in both groups carried out exercise therapy for six weeks. There will be an educational session for each patient to make sure the exercises will be done successfully and supervision once per week.
16262461|NCT04938713|Active Comparator|AB group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.
~The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
16262462|NCT04938713|Other|BA group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.
~The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
16262463|NCT04938700|Experimental|Probiotics intervention group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of probiotic intervention and conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
16262464|NCT04938700|Active Comparator|Contrast group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
16262465|NCT04938674||Standard process for blood collection using Ultrasonic Guided puncture|
16262466|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab (CON)|Participants will be prescribed 36 sessions of center-based CR. This includes supervised exercise sessions, cooking demonstrations, didactic lectures, video presentations, group support, and stress management education. During sessions, participants have direct access to the medical director, case manager, registered nurse, exercise physiologist, and stress management specialists.
16262467|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab + mHealth (CON+)|"Participants will be prescribed 36 sessions of center-based CR as noted above. In addition, participants will be provided access to the mHealth platform which provides e-Learning modules with factsheets, videos, quizzes, and questionnaires (coinciding with activities being conducted during the CON program), a Social Network Module will allow patients to communicate via secure network with other patients who are part of their invited network. The Social Network Module also allows for secure two-way interaction with healthcare providers in the event that patients are experiencing signs or symptoms suggestive of worsening condition. This platform also contains a Personal Health Record Module allowing patients to upload, archive, and retrieve personal health data (e.g. fitness tracker data, heart rate monitor data, blood pressure recordings, etc.) and record vital signs, symptoms, treatments, and medical history."
16262468|NCT04938661|Active Comparator|Home-Based Cardiac Rehab + mHealth (HOM+)|Participants will be provided paper copies of educational content at the time of event/discharge. In addition, these participants will be provided access to the same mHealth platform as the CON+ group. Participants in this group will be encouraged to exercise three days per week while also completing the additional questionnaires and educational content provided by the mHealth platform in accordance with the CR program. Participation will be tracked using web/internet analytics.
16262469|NCT04938648|Experimental|Intervention|"The intervention consists of the following:
~mailing deprescribing educational materials to care partners and people living with dementia (PLWD);
~dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;
~pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
16262470|NCT04938648|Active Comparator|Delayed Intervention (wait list control)|"The delayed intervention consists of the following:
~mailing deprescribing educational materials to care partners and people living with dementia (PLWD);
~three months after mailing the deprescribing educational materials, dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences.
~pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
16262471|NCT04938635|Experimental|VIT-2763 60 mg QD|VIT-2763 60 mg administered once daily
16262472|NCT04938635|Experimental|VIT-2763 60 mg BID|VIT-2763 60 mg administered twice daily
16262473|NCT04938635|Experimental|VIT-2763 120 mg BID|VIT-2763 120 mg administered twice daily
16262474|NCT04938635|Placebo Comparator|Placebo|Placebo capsule administered twice daily
16262475|NCT04938622|Experimental|Sedentary Control|Participants did not exercise but consumed a diet that has an appropriate number of calories to maintain body weight throughout the intervention (3 menstrual cycles).
16262476|NCT04938622|Experimental|Exercising control|Participants exercised but were given extra calories to remain in energy balance throughout the intervention (3 menstrual cycles).
16262477|NCT04938622|Experimental|15 percent energy deficit (ED1)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles.
16262478|NCT04938622|Experimental|30 percent energy deficit (ED2)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles.
16262479|NCT04938622|Experimental|30 percent energy deficit 15/15 (ED2)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 15 percent to total a 30 percent energy deficit.
16262480|NCT04938622|Experimental|60 percent energy deficit (ED3)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 30 percent to total a 60 percent energy deficit.
16262481|NCT04938609|Experimental|Pembrolizumab + SBRT + Surgery|Pembrolizumab administration (3 dose) every 3 weeks and 1 dose before radiation (5 days) therapy followed by an additional administration of Pembrolizumab (2 doses) prior to restaging and surgical resection followed by risk-adapted adjuvant therapy, per standard of care. Patient will then be treated with adjuvant pembrolizumab every 3 weeks for 14 additional doses (17 doses total)
16262482|NCT04938596|Experimental|Respiratory Bundle Group|The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
16262483|NCT04938596|No Intervention|Standard of care|Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.
16262484|NCT04938583|Experimental|oregovomab, bevacizumab, paclitaxel and carboplatin|Combination of anti-angiogenesis and Chemo-immunotherapy
16262485|NCT04938570||University-level and amateur rugby players|"University-level and amateur rugby players will be recruited and assessed (motor, visual and symptom assessment) over one season ( June 2021 to August 2022).
~Participants will be stratified according to gender (males n≈100, and females n≈100). Although the number of SRC that will be observed during the season is not known, the investigators will compare a number of head injuries/SRC to the results from cohort baseline testing. Participants that do not sustain a concussion will also have follow up testing at the end of the season."
16262546|NCT04938102|No Intervention|Normal DI - Control|Patients' whose distensibility index is measured >2.8 will receive no intervention.
16262486|NCT04938557|Experimental|An Automated Closed-loop Insulin Delivery (AiD) System.|The intervention being evaluated in this trial is automated closed-loop insulin delivery (AiD). The closed-loop system comprises of three components: an insulin pump, a continuous glucose monitor (CGM) and a computer-based model predictive control (MPC) algorithm to compute information from the CGM into a recommended insulin dose.
16262487|NCT04938557|Active Comparator|A Standard Insulin Delivery System|This can include either: an insulin pump (Continuous Subcutaneous Insulin Infusion - CSII) or multiple daily injections (MDI) without closed-loop.
16262488|NCT04938531|Experimental|Exercise|Exercise, passive
16262489|NCT04938492|Experimental|Cognitive Behavioral Therapy (CBT)|CBT delivered over the course of 6, ~45 minute sessions delivered via telehealth.
16262490|NCT04938492|Active Comparator|Health Education|Health education sessions delivered over the course of 6, ~45 minute sessions delivered via telehealth.
16262491|NCT04938466||Transition to long-acting growth hormone (LAGH)|Participants in this arm will transition between daily growth hormone treatment and long-acting growth hormone treatment.
16262492|NCT04938466||Consistent daily growth hormone (DGH)|Participants in this group will continue with daily growth hormone treatment.
16262493|NCT04938453|Experimental|Treatment sequence 1 (T-R)|first test (T), then reference (R) treatment
16262494|NCT04938453|Experimental|Treatment sequence 2 (R-T)|first reference (R), then test (T) treatment
16262495|NCT04938440||Prescribers of Instanyl®|Healthcare professionals (Oncologists, oncoradiologists, anaesthesiologists, pain management prescribers, palliative care prescribers, internal medicine prescribers and other specialties) who are current and potential prescribers of Instanyl® will be assessed before and after the implementation of the updated EMs via web-based survey questionnaire.
16262498|NCT04938414|Experimental|subarachnoid hemorrhage|Patients with subarachnoid hemorrhage
16262499|NCT04938414|Experimental|Control|patients with non-neurological diseases
16262500|NCT04938401||epistaxis|Postoperative pituitary tumor group with epistaxis
16262501|NCT04938401||no epistaxis|Postoperative pituitary tumor group without epistaxis
16262502|NCT04938388|Active Comparator|Oral Semaglutide (OS) with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the OS dose will be maintained or decreased at the study physician's discretion.
~Participants will be instructed to swallow the OS tablet whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
16262503|NCT04938388|Placebo Comparator|Oral Semaglutide (OS) Placebo with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the Placebo will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the Placebo will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of Placebo will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the Placebo will be maintained or decreased at the study physician's discretion.
~Participants will be instructed to swallow the matched OS Placebo whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
16262504|NCT04938362||Brain abscess patients with cognitive dysfunction and/or fatigue|This group of patients experience cognitive dysfunction and/or fatigue after brain abscess.
16262505|NCT04938362||Brain abscess patients without cognitive dysfunction and/or fatigue|This group of patients does not experience cognitive dysfunction and/or fatigue after brain abscess.
16262506|NCT04938349|Experimental|Single session dual task perturbation training-OAwMCI|Participants will receive single session training of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
16262547|NCT04938102|Active Comparator|Normal DI - Botox|Patients' whose distensibility index is measured >2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
16262548|NCT04938089||ICS|Irregular compliant smoker
16262549|NCT04938089||RCS|Regular compliant smoker
16262550|NCT04938089||ICN|Irregular compliant non-smoker
16262551|NCT04938089||RCN|Regular compliant non-smoker
16262507|NCT04938349|Experimental|Multiple session dual task perturbation training-OAwMCI|All participants will undergo stance and walking perturbation training for 4 weeks. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
16262508|NCT04938349|Active Comparator|Single session dual task perturbation training-CIOA|All participants will receive only one training session of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
16262509|NCT04938336||expert healthcare professionals|Delphi Procedure
16262510|NCT04938336||healthcare professionals, patients and informal carers|interviews
16262511|NCT04938323|Experimental|BCG Vaccine|Participants randomized to the BCG Vaccine Arm will receive the vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
16262512|NCT04938323|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines': upper arm.
16262513|NCT04938310|Active Comparator|Control Group|Sleeve gastrectomy
16262514|NCT04938310|Experimental|Support garment group|Sleeve gastrectomy followed by a period of 12-month with a support garment
16262515|NCT04938297|Experimental|Primary CNS Lymphoma，age>65|8 cycles of induction ZR2 , followed by Zanubrutinib or Lenalidomide maintenance for CR/PR fit patients through randomization by 1:1 ration
16262516|NCT04938297|Experimental|Recurrent/refractory primary CNS lymphoma|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
16262517|NCT04938297|Experimental|Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
16262518|NCT04938284|Experimental|PAS and VNS|
16262519|NCT04938284|Active Comparator|PAS and sham VNS|
16262520|NCT04938284|Active Comparator|PAS|
16262521|NCT04938284|Active Comparator|VNS|
16262523|NCT04938258|Experimental|Intensive Case Management Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.
~Receiving the CM intervention doesn't exclude treatment as usual."
16262524|NCT04938245||Observed Cohort|Participants with chronic pain scheduled to undergo externalized trial for assessment of spinal cord stimulation will undergo intraoperative stimulation and up to three postoperative visits where already externalized electrodes (used clinically for stimulation) will be used to record and stimulate using evoked complex action potentials (ECAPs) while also measuring other electrophysiological responses.
16262525|NCT04938232|Experimental|Stable disease after previous therapy (Cohort 1)|"Participants will receive a combination of Ipilimumab and Nivolumab, followed by a maintenance regimen of Nivolumab.
~Combination: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles
~Maintenance: Nivolumab every 4 weeks for up to 15 study cycles"
16262526|NCT04938232|Experimental|Disease Progression after previous therapy (Cohort 2)|"Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab
~Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles
~Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles
~Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles"
16262527|NCT04938219|Experimental|Shivering Treatment Group|Participants will be observed, and intervention will begin when a shivering score of 2 or higher is reached. The participants in the treatment group will receive one glove filled with warm water into each hand.
16262528|NCT04938219|No Intervention|Control Group|Participants in the control group will only be observed, and not given additional treatment for the shivering.
16262529|NCT04938206|Experimental|management reduction strategy|Patients classified as low risk by the DRC who will have a reduction in the management of their post-chemotherapy NF.
16262530|NCT04938206|Active Comparator|standard management|Patients classified as low risk by the DRC who will have standard management of post-chemotherapy NF.
16262531|NCT04938193|Experimental|68Ga-citrate PET/CT|
16262532|NCT04938180|Experimental|Cohort A|Low-Dose AMB-05X Each subject will receive a low dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
16262533|NCT04938180|Experimental|Cohort B|Mid-Dose AMB-05X Each subject will receive a mid-dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
16262534|NCT04938180|Experimental|Cohort C|High-Dose AMB-05X Each subject will receive a high-dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
16262535|NCT04938167|No Intervention|Standard arm|target preductal SpO2 - 91 to 95%
16262536|NCT04938167|Experimental|Intervention arm|target preductal SpO2 - 95 to 99%
16262537|NCT04938154|Experimental|DBS On|
16262538|NCT04938154|Sham Comparator|DBS Off|
16262539|NCT04938141||Acalabrutinib|CLL patients initiating acalabrutinib alone or in combination with an anti-CD20 mAb
16262540|NCT04938141||Ibrutinib|CLL patients receiving ibrutinib alone or in combination with an anti-CD20 mAb
16262541|NCT04938128|Experimental|CPAP treatment|This group will receive CPAP treatment
16262542|NCT04938128|No Intervention|Control|This group will receive Diet and Lifestyle advice only
16262552|NCT04938076|Experimental|tDCS group|"tDCS stimulation
~affected side :
~primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)
~2mA anode (+) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)
~contralateral unaffected side
~primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)
~2mA cathode (-) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)"
16262553|NCT04938076|Sham Comparator|Sham group|". Sham stimulation
~1) the current ramps up to 2mA and slowly decreased over 30 s to ensure the typical initial tingling sensation"
16262554|NCT04938063||Cerebral palsy children|Sample size estimation was carried out to determine the recruited number of the diplegic CP children from the outpatient clinic at the Faculty of Physical Therapy, Cairo University, Physical Therapy Department at the National Institute of Neuromotor Disorder, Abu El-Reesh Hospital, and private physiotherapy clinics. The age of patients will range from 18 months to 5 years old. Both sexes will participate in this study
16262555|NCT04938037|Experimental|SSNB through the spinoglenoid notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
16262556|NCT04938037|Active Comparator|SSNB through the suprascapular notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
16262557|NCT04938024|Experimental|People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
16262558|NCT04938024|Experimental|People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)|Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
16262559|NCT04938024|Active Comparator|People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
16262560|NCT04938011|Experimental|Progesterone + 7|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
16262561|NCT04938011|Active Comparator|Progesterone + 6|the transfer of day 6 blastocysts on the 6th day of progesterone supplementation
16262562|NCT04937998|Experimental|Autologous PRP injection|This group of patients will be treated with single intra-articular injection of Autologous PRP.
16262563|NCT04937998|Active Comparator|HA injection|This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)
16262564|NCT04937985||UULEX Test Group|Patients with chronic neck pain
16262565|NCT04937972|Experimental|SHR-1701 Combined With fluzoparib|
16262566|NCT04937959||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16262567|NCT04937959||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16262568|NCT04937959||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16262569|NCT04937959||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16262570|NCT04937946|Experimental|Fentanyl|Fentanyl will be given within 24 hours from the initiation of mechanical ventilation at an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
16262571|NCT04937946|No Intervention|Placebo|Will receive continuous infusion of IV fluid up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
16262572|NCT04937933|Active Comparator|Coolant spray group|Coolant spray (Cryos ®Spray, Phyto Performance, Italy) was applied as suggested by the manufacturer (at a distance of 20 cm from the injured area for 5-10 s). Saline solution was sprayed for the same duration and at the same distance from the injured area as well. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
16262573|NCT04937933|Placebo Comparator|Placebo group|A standard saline solution in a bottle covered with opaque white paper and refrigerated at 4°C was prepared. Saline solution was sprayed for the same duration and at the same distance from the injured area as well like coolant spray application. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
16262576|NCT04937907|Experimental|Hydroxychloroquine Cohort|Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months. During treatment with HCQ, patients also received enalapril(5-10mg qd).
16262577|NCT04937907|Sham Comparator|Comparator Cohort|During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).
16262578|NCT04937881|Experimental|TAF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
16262579|NCT04937881|Active Comparator|TDF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
16262614|NCT04937634|Experimental|Melphalan|
16262580|NCT04937868||Blunt trauma patients undergoing abdominopelvic computed tomographic imaging|"The study will be observational and not alter the care or management of blunt injury victims. Medical decisions will be made by treating physicians using current standards of care. Thus, to reduce the potential for bias, the study will seek to enroll all blunt injury victims who undergo A/P imaging as part of their ED trauma evaluation. This may include children, the elderly, all races, both sexes, and any other demographic or social groups that may present among blunt injury patients. An individual will become eligible for the study when the treating physician determines that A/P CT imaging is needed for their trauma evaluation. Inclusion or exclusion will not be based on age, gender, pregnancy or child-bearing potential, or racial/ethnic origin.
~There will be no exclusion criteria."
16262581|NCT04937855||Control group|25 gender and age matching healthy controls
16262582|NCT04937855||ARDS group 1|100 ARDS patients at the time of check in hospital
16262583|NCT04937855||ARDS group 2|100 ARDS patients at the time of 24h after check in hospital
16262584|NCT04937855||ARDS group 3|100 ARDS patients at the time of 48h after check in hospital
16262585|NCT04937855||ARDS group 4|100 ARDS patients at the time of 72h after check in hospital
16262586|NCT04937842|Experimental|MST|standard chemotherapy with microtransplantation
16262587|NCT04937842|No Intervention|CT|standard chemotherapy only, without microtransplantation
16262588|NCT04937829|Experimental|BI 1569912 treatment group|
16262589|NCT04937829|Placebo Comparator|Placebo group|
16262590|NCT04937816||EMPA-REG - Placebo|Participants of the EMP-REG OUTCOME study (1245.25) who received placebo.
16262591|NCT04937816||EMPA-REG - Empagliflozin low dose|Participants of the EMPA-REG OUTCOME study (1245.25) who received a low dose of empagliflozin once daily (QD).
16262592|NCT04937816||EMPA-REG - Empagliflozin high dose|Participants of the EMP-REG OUTCOME study (1245.25) who received a high dose of empagliflozin once daily (QD).
16262593|NCT04937816||EMPEROR-Preserved - Empagliflozin|Participants of the EMPEROR-Preserved study (1245.110) who received empagliflozin once daily (QD).
16262594|NCT04937816||EMPEROR-Preserved - Placebo|Participants of the EMPEROR-Preserved study (1245.110) who received placebo once daily (QD).
16262595|NCT04937816||EMPEROR-Reduced - Empagliflozin|Participants of the EMPEROR-Reduced study (1245.121) who received empagliflozin once daily (QD).
16262596|NCT04937816||EMPEROR-Reduced - Placebo|Participants of the EMPEROR-Reduced study (1245.121) who received placebo once daily (QD).
16262597|NCT04937803|Experimental|Drug-coated balloon group|Patients assigned to drug-coated balloon group will receive angioplasty with drug-coated balloon for treatment of lesions.
16262598|NCT04937803|Active Comparator|Stent group|Patients assigned to drug-eluting stent group will receive a Zotarolimus -Eluting Coronary Stent treatment .
16262599|NCT04937790|Experimental|Core stabilization group (CSG)|This arm consists core stabilization exercises including abdominal hallowing, supine bride, bride dog, side plank, curl-up and modified push up exercise. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
16262600|NCT04937790|Experimental|Wobble board group ( WBG)|This arm consists balance training exercises which performed on computerized wobble board for primarily lower limb and anti- gravity muscle. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
16262601|NCT04937790|No Intervention|Control group (CG)|This arm was planned as a control group. Therefore, any intervention will not be performed. Patients in this arm going to participate only one session of patient education at the beginning of the program
16262602|NCT04937777||Group pre-2010|Patients who initiated first-line treatment between 2004 and 2010 (pre-2010).
16262603|NCT04937777||Group post-2010|Patients who initiated first-line treatment between 2011 and 2018 (post-2010).
16262604|NCT04937764||Study population|Population who underwent a surgical arthrodesis procedure for arthritic or inflammatory involvement of the Lisfranc tarsometatarsal joint
16262605|NCT04937751||Invasive fusariosis|
16262606|NCT04937751||Fusarium keratitis|
16262607|NCT04937738|Active Comparator|XELOX|Oxaliplatin 130 mg/m2, d1 Capecitabine 1000 mg/m² two times per day (BID), d1-14, every 3 weeks (q3w) 4 cycles (12 weeks) pre-OP and 3 cycles (12 weeks) post-OP
16262608|NCT04937738|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
16262609|NCT04937725||Patients without neurological pathologies|Patients with no history of neurological diseases
16262610|NCT04937699|Active Comparator|Standard-Does Ticagrelor plus aspirin (SD.T+A)|"Patients will be randomized after PCI, and receive standard-does ticagrelor plus aspirin in this arm as followed:
~Ticagrelor 90mg bid+Aspirin 100mg qd for 12months"
16262611|NCT04937699|Experimental|Low-Does Ticagrelor monotherapy (LD.T)|"Patients will be randomized after PCI, and receive low-does ticagrelor plus aspirin for the first month and switch to low-does ticagrelor monotherapy in the following 5 months, and then further de-escalated to clopidogrel monotherapy till 1 year in this arm as followed:
~Ticagrelor 60mg bid+Aspirin 100mg qd for 1 month; Ticagrelor 60mg bid, for 5 months; clopidogrel 75mg qd, for 6 months."
16262612|NCT04937673|Experimental|Camrelizumab+ Paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
16262613|NCT04937673|Experimental|Camrelizumab+ Albumin bound paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
16262615|NCT04937621||SARS-CoV-2 infection|This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
16262616|NCT04937608||COVID-19 group|men aged 18 to 45 who have been infected with SARS-CoV-2 in the past 6 months
16262617|NCT04937608||Control group|healthy men aged 18 to 45 with normal sperm parameters (WHO 2010 criteria) and who have never contracted COVID-19
16262618|NCT04937582|Experimental|Confirmed cognitive disorder|"Patients with abnormal QPC score at screening visit and confirmed cognitive disorder on the neuropsychological assessment during Visit V1.
~Intervention Completed by MRI (magnetic resonance imaging), EEG (Electroencephalogram) and possible psychiatric evaluation at Visit 1B.
~Follow-up 2 years after initial hospitalisation (Visit 2 : neuropsychological assessment ; if needed MRI, EEG, lumbar puncture)"
16262619|NCT04937582|Experimental|Absence of cognitive disorder|Patients with abnormal QPC score at screening and absence of cognitive disorder on the neuropsychological assessment during Visit V1.
16262620|NCT04937569|Active Comparator|Group 1: Ivermectin + standard treatment|Patients will receive 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard treatment (Azithromycin 500mg once daily for 5 days, Paracetamol 500mg every 8 hours, vitamin C 1gm once daily, Zinc 50 mg once daily, Lactoferrin 100mg sachets twice daily and prophylactic or therapeutic anticoagulation if D-dimer is elevated.
16262621|NCT04937569|Other|Group-2: Standard treatment only|This group will receive the standard treatment protocol as outlined above according to the Egyptian Ministry of Health protocol of treating cases with mild COVID-19.
16262622|NCT04937556|Active Comparator|Probiotic: Lactobacillus salivarius + Vit D + Zinc|Lactobacillus strain during 28 days, approximately 1*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.
16262623|NCT04937556|Placebo Comparator|Placebo|Placebo supplement in 1 capsule per day during 28 days.
16262624|NCT04937543|No Intervention|No intervation|patients receiving standart of care
16262625|NCT04937543|Active Comparator|Experimental intervation one|patients receiving standart of care + inhaled beclometasone
16262626|NCT04937543|Active Comparator|Experimental intervation two|patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium
16262627|NCT04937530|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
16262628|NCT04937530|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
16262629|NCT04937504|Active Comparator|STAIR-PC Group|Participants in the Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) group will complete five (30 minute each) therapist-led sessions in-person or via Telehealth for up to 12 weeks.
16262630|NCT04937504|Experimental|WebSTAIR Group|Participants in the WebSTAIR group will complete 10 self-guided, web-based modules for up to 12 weeks.
16262631|NCT04937491||Healthy volunteers|Adult healthy volunteers (students). Intervention 1: Intake of water (2% of body weight) Intervention 2: Intake of sports drink (2% of body weight) Intervention 3: Intake of soya saus (salt): 10 ml (equal to 8 g salt) Intervention 4: Intake of 90 g sugar (jelly figures)
16262632|NCT04937478||Hemodialysis patients|Patients who undergo hemodialysis in hospital every two oe three days.
16262633|NCT04937465||Elderly|Elderly (> 70 yrs) eligible for a short term rehabilitation
16262634|NCT04937452|Experimental|Rotigotine 4 mg|Rotigotine 4 mg/24 hours transdermal patch administration
16262635|NCT04937452|Experimental|Rotigotine 6 mg|Rotigotine 6 mg/24 hours transdermal patch administration
16262636|NCT04937452|Placebo Comparator|Placebo|Placebo transdermal patch administration
16262637|NCT04937439|Experimental|Segmental trunk training A|Children in this group will receive specially designed physical therapy program while wearing a segmental trunk support from the level of pelvis to a level just below the rib cage.
16262638|NCT04937439|Active Comparator|Segmental trunk training B|Children in this group will receive the same program given to (group A) while wearing a segmental trunk support from the level of pelvis to a level just below the inferior angle of scapula.
16262639|NCT04937439|Active Comparator|Segmental trunk training C|will receive the same program given to (group A and B) while wearing a segmental trunk support from the level of last rib to the level of the inferior angle of scapula.
16262640|NCT04937426|Experimental|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|During gastroscopy additional biopsies are taken in cases where infection with helicobacter pylori is suspected. It will then undergo laboratory analysis with fluorescent-labeled urease inhibitor marker. Results will be compared to standard analysis to determine efficacy.
16262641|NCT04937413|Experimental|Single dose of evolocumab|420 mg of evolocumab subcutaneous injection 7-14 days before scheduled surgery for malignant glioma
16262642|NCT04937400||Pediatric Stem Cell Transplant Patients|A consecutive cohort of children admitted to the hospital for stem cell transplantation
16262643|NCT04937387|Experimental|Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler|
16262644|NCT04937387|Experimental|Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler|
16262645|NCT04937387|Experimental|Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler|
16262646|NCT04937387|Experimental|Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler|
16262649|NCT04937348||GDM G1|Mothers diagnosed with gestational diabetes mellitus, treated with diet; and their newborns
16262650|NCT04937348||GDM G2|Mothers diagnosed with gestational diabetes mellitus, treated with insulin; and their newborns
16262651|NCT04937348||non-GDM / control group|"Healthy, non-diabetic mothers, without disturbances in glucose metabolism; and their newborns.
~Control group."
16262652|NCT04937335||Non-hemorrhage group|Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation
16262653|NCT04937335||Hemorrhage group|Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation
16286823|NCT04768478|Placebo Comparator|Control|
16262654|NCT04937322||Interventional Endoscopy procedures|All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations for pancreatico-biliary disorders since June 2011 and extending forward through June 2023.
16262655|NCT04937309|Experimental|intervention|standard anti emetic treatment use of non invasive vagal stimulation twice a day from the day before chemotherapy till 4 days after, with a transcutaneous auricular device. This stimulation is to be done for the three first cycles of chemotherapy.
16262656|NCT04937309|Sham Comparator|control|"standard anti emetic treatment use of non invasive vagal stimulation twice a day from the day before chemotherapy till 4 days after, with a transcutaneous auricular sham device. This stimulation is to be done for the three first cycles of chemotherapy."
16262657|NCT04937296|Placebo Comparator|Usual care|
16262658|NCT04937296|Experimental|Physical activity|
16262659|NCT04937283|Experimental|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy. When lymph node metastasis is present or resection margin is not cancer-free, the surgical procedure must be converted to a lobectomy.
16262660|NCT04937283|Active Comparator|Lobectomy with systemic lymph node dissection|"lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
~The distance from the dissection margin to the tumor edge must be evaluated intraoperatively. If the distance is either less than the maximum tumor diameter or ,20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery."
16262661|NCT04937270|Experimental|High frequency application time is 5 minutes|The group which treats for 5 minutes by using the high-frequency therapy device
16262662|NCT04937270|Experimental|High frequency application time is 7 minutes|The group which treats for 7 minutes by using the high-frequency therapy device
16262663|NCT04937270|Experimental|High frequency application time is 9 minutes|The group which treats for 9 minutes by using the high-frequency therapy device
16262664|NCT04937257|Active Comparator|Virtual Reality|"Participants randomized to the immersive virtual reality study arm, considered the intervention group received training on donning and doffing PPE using a program developed by Axon Park Inc. (California, USA)"
16262665|NCT04937257|Placebo Comparator|E-module|"Participants randomized to the e-module study arm, considered the control group received training on donning and doffing PPE using an e-module containing a video and slide show."
16262666|NCT04937244|Experimental|Patients with new or recurrent malignant gliomas|
16262670|NCT04937218|Experimental|Egg demand creation campaign|Egg demand creation campaign using Above-the-line and Below-the-line methods for 14 months. Above-the-line interventions include television, radio, celebrity ambassadors and out-of-home advertising (e.g., billboards). Below-the-line interventions include interpersonal communication activation, trade promotions, point-of-sale materials, food demonstrations and giveaways and door-to-door activation.
16262671|NCT04937218|No Intervention|Comparison|Comparison arm with no campaign
16262672|NCT04937205||Cohort 2|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on February 13, 2019.
16262673|NCT04937205||Cohort 3|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on November 5, 2019.
16262674|NCT04937205||Cohort 4|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on October 22, 2020.
16262675|NCT04937192||Kidney stone former|
16262676|NCT04937179|Sham Comparator|Ischemic Conditioning Low|Blood flow restriction with low compression
16262677|NCT04937179|Active Comparator|Ischemic Conditioning High|Blood flow restriction with high compression
16262678|NCT04937166|Experimental|DSP107 monotherapy and in combination with azacitidine or azacitidine plus venetoclax.|"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.
~Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.
~Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards."
16262679|NCT04937153|Experimental|Single arm|GEN1046 open label, single arm trial where GEN1046 will be administered
16262680|NCT04937140||rheumatoid arthritis patients|90 RA patients diagnosed according to the American college of rheumatology (ACR) -EULAR RA classification criteria 2010
16262681|NCT04937140||control group|50 age and sex matched healthy controls. All
16262682|NCT04937127||Experimental Group|The experimental group will be made up of patients from nursing homes whose carers have received I-Learn training.
16262683|NCT04937127||Control Group|The control group will consist of nursing homes patients whose caregivers have not received I-Learn training and will continue their usual care, regardless of the practices already implemented.
16262684|NCT04937114|Experimental|Flap will be approximated using conventional, simple continuous suturing with barbed sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with unidirectional barbed sutures.
16262685|NCT04937114|Active Comparator|Flap will be approximated using conventional, simple continuous suturing with conventional sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with conventional sutures.
16289727|NCT04747964|Experimental|A single low dose of treatment group|
16262686|NCT04937101|Experimental|Antihistamine treatment group|Chlorpheniramine, the concentration is 10mg/ml per unit point, the highest dose is 1ml
16262687|NCT04937101|No Intervention|Control group|
16262688|NCT04937088|Placebo Comparator|Placebo|Soy Bean Oil identical packaging as the active arm, taken once daily by mouth for 30 days.
16262689|NCT04937088|Active Comparator|Liquid ASA|Aspirin 150 mg liquid formulation (2.5%w/w) taken once daily by mouth for 30 days
16262690|NCT04937075||Before period without multiplex PCR identification|
16262691|NCT04937075||After period with multiplex PCR identification|
16262692|NCT04937062|Experimental|Phenylbutyrate|"Participants will be enrolled for 14 weeks, including 4 weeks of baseline information, 6 weeks of medication administration at the full dose, 2 weeks taper, and 2 weeks follow up. Note this is 8 weeks total of exposure to the medication for the duration of the trial.
~After clinical assessment by the investigator if deemed safe and appropriate, and requested by the caregiver, participants may continue to take phenylbutyrate for an additional 12 months, for additional monitoring of safety and tolerability."
16262693|NCT04937049|Experimental|EMAeHealth digital tool|This team has designed a digital tool called EMAeHealth involving healthcare professionals. It is organized into 4 areas: 1) an Information area, 2) a Communication area, 3) a Health Self-management area, 4) a Clinical data area, The tool is conceived as a complement that can reinforce maternal health education with resources that facilitate its accessibility, and rapid remote response, which will also improve its results. It will be incorporated into the Osakidetza-Basque Health Service corporate Website.
16262694|NCT04937049|No Intervention|No EMAeHealth digital tool|Usual care. This group, like experimental group, receives the usual care, which includes traditional maternal education, but does not receive the EMAeHealth intervention
16262695|NCT04937036||COMISA group|Patients with diagnosed COMISA.
16262696|NCT04937036||Healthy controlls|Healthy indyviduals.
16262697|NCT04937023|Experimental|UDCA gel will be injected using a syringe with blunt cannula into the defect site|In the test group, the prepared UDCA gel will be injected using a syringe with blunt cannula into the two or three wall intra-bony defects with probing pocket depth ≥3mm after performing SRP.
16262698|NCT04937023|Placebo Comparator|placebo gel will be injected in to the defect site using a syringe with blunt cannula.|In patients allocated to control group, placebo gel will be injected in to the defect site using a syringe with blunt cannula after scaling and root planing.
16262699|NCT04937010|Active Comparator|Industry standard stimulation|Standard sub threshold stimulation parameters
16262700|NCT04937010|Sham Comparator|Experimental stimulation|Sham stimulation
16262701|NCT04936997|Experimental|3rd COVID-19 vaccine (2nd booster)|Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
16262702|NCT04936984|Experimental|Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
16262703|NCT04936984|Experimental|Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
16262704|NCT04936984|Experimental|Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
16262705|NCT04936984|Experimental|Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
16262706|NCT04936971|Experimental|Everolimus|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.
~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS) as per local practice."
16262707|NCT04936971|Active Comparator|Mycophenolate Mofetil|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.
~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Mycofenolate Mofetil (MMF) 500mg/bid and Corticosteroids (CS) as per local practice."
16262708|NCT04936958||patients having had an osteomyelitis since 2017|
16262709|NCT04936945|Active Comparator|arthroscopy plus platelet rich plasma.|Group A: will be treated with operative arthroscopy plus intra-articular injection of platelet rich plasma
16262710|NCT04936945|Active Comparator|arthroscopy plus hyaluronic acid.|Group B: will be treated with operative arthroscopy plus intra-articular injection of hyaluronic acid
16262711|NCT04936932|Active Comparator|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
16262712|NCT04936932|Active Comparator|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
16262713|NCT04936919|Experimental|Treatment Arm|
16262714|NCT04936906|Experimental|Extra Care (EC) Treatment Group|Participants in this group will receive the EC intervention pre and post standard of care (SoC) scheduled Mohs Surgery.
16262715|NCT04936906|Active Comparator|Usual Care (UC) Group|Participants in this group will receive the usual care provided to patients undergoing standard of care (SoC) scheduled Mohs Surgery.
16262716|NCT04936893|Experimental|HeadSpace Mobile App|Mindfulness practice
16262717|NCT04936893|Active Comparator|Lumosity Mobile App|Cognitive games
16262718|NCT04936880|Experimental|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
16262719|NCT04936880|Active Comparator|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
16290344|NCT04743518|Active Comparator|tofacitinib|
16262720|NCT04936854|Active Comparator|Sirolimus|Patients with active thyroid eye disease will receive 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
16262721|NCT04936854|Active Comparator|Corticosteroids|Patients with active thyroid eye disease will receive 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks.
16262722|NCT04936841|Experimental|NKTR-214, anti-PD therapy plus Palliative Radiation|"Cycle 1 consists of anti-PD-1 therapy (200mg) and NKTR-214 (0.006 mg/kg3 administered intravenously), followed by palliative radiation (8 Gy x 3 or 4 Gy x 5 fractions) combined with anti-PD-1 therapy and NKTR-214 in cycle 2.
~In subsequent cycles participants will receive NKTR-214 and anti-PD-1."
16262723|NCT04936828|Experimental|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
16262724|NCT04936828|No Intervention|Control group|Receive general mental health information through instant message.
16262725|NCT04936815|Experimental|Echocardiographic screening|Echocardiographic screening during the first antenatal visit
16262726|NCT04936815|No Intervention|Control arm|Routine antenatal are
16262727|NCT04936802|Experimental|Transcatheter tricuspid valve repair system (Trialign)|Subjects who received transcatheter tricuspid valve repair with Trialign will be included in this arm.
16262728|NCT04936789|Experimental|Single arm|Single arm. All subjects will receive the intervention. Comparator device will be subjects' own prosthesis at baseline.
16262729|NCT04936776||Text message 1|Text messaging frame = safety and cleanness of clinic site. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
16262730|NCT04936776||Text message 2|Text messaging frame = importance of vaccines. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
16262731|NCT04936776||No text message|No text sent.
16262732|NCT04936763|Experimental|Janesse 20|
16262733|NCT04936737|Experimental|Beta-alanine supplementation and high intensity exercise|Individuals will participate in a high-intensity exercise and will be supplemented with beta-alanine. This protocol will be conducted for six non-consecutive days.
16262734|NCT04936737|Experimental|Beta-alanine supplementation only|In this protocol, the individuals will be supplemented with beta-alanine without the exercise protocol for six non-consecutive days.
16262735|NCT04936724|Experimental|Condition A (Lesser-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting lesser-known harms of tobacco use.
16262736|NCT04936724|Experimental|Condition B (Well-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting the well-known harms of tobacco use.
16262737|NCT04936711|Experimental|Back Massager Device + Standard Pain Treatment|"Resteck Shiatsu Neck and Back Massager (brand name), with recommended use for at least every 2 hours for at least 15 minutes on the first post-operative day and then every 4 hours for 2 days and then as needed.
~Standard pain treatment:
~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)
~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth
~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed
~Tylenol 650 mg Tab: oral administration every 6 hours"
16262738|NCT04936711|Active Comparator|Marcaine spray + Standard Pain Treatment|"30cc of 0.25% Marcaine spray on the diaphragm at the end of surgery.
~Standard pain treatment:
~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)
~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth
~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed
~Tylenol 650 mg Tab: oral administration every 6 hours"
16262739|NCT04936711|No Intervention|Standard Pain Treatment|"will receive standard pain treatment include local anesthetic agent at the incision sites + oral Tylenol and oral or IV opioid as breakthrough pain treatment postoperatively as needed.
~Standard pain treatment:
~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)
~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth
~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed
~Tylenol 650 mg Tab: oral administration every 6 hours"
16262740|NCT04936698||Hyperthyroidism|Elevated fT4, low TSH
16262741|NCT04936698||Hypothyroidism|Elevated TSH, low fT4
16262742|NCT04936698||Euthyroid|Normal TSH/fT4 level
16262743|NCT04936685|Experimental|MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection at Day 01
16262744|NCT04936672|Experimental|Brisk walking group|"Type of exercise is brisk walking. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.
~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time."
16262745|NCT04936672|Experimental|Tai Chi Chuan|"Type of exercise is Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.
~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate."
16262746|NCT04936672|Experimental|Brisk walking combined with Tai Chi Chuan|"Type of exercise is brisk walking combine with Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.
~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity of brisk walking is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time.
~The intensity of Tai Chi Chuan is 50%-70% of the individual's maximum heart rate."
16262747|NCT04936672|No Intervention|Control Group|Keeping their daily life.
16262748|NCT04936659|Experimental|Treatment group|
16262749|NCT04936646|Experimental|Classic rTMS Stimulation using the B65 Coil|
16262750|NCT04936646|Experimental|Deeper rTMS Stimulation using the B70 Coil|
16262751|NCT04936646|Sham Comparator|control group with a sham stimulation using a sham coil|
16262752|NCT04936633|No Intervention|No intervention by medical staff|The patients who start FSGM and receive general education on FSGM only.
16262821|NCT04936126|Experimental|Amantadine group|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment
16262753|NCT04936633|Experimental|Intervention by medical staff based on a cloud system|The patients who start FSGM and receive general education on FSGM and remote intervention based on a cloud system.
16262754|NCT04936620|Active Comparator|Duroplasty|Duroplasty (includes Surgery with Laminectomy)
16262755|NCT04936620|Active Comparator|No duroplasty|No duroplasty (but includes surgery with Laminectomy)
16262756|NCT04936607|Experimental|Personnalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio <2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
16262757|NCT04936607|Active Comparator|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
16262758|NCT04936594|Experimental|Intermittent Theta Burst Stimulation (iTBS)|Subjects randomized to the experimental arm will receive 1800 pulses of intermittent TBS using MagVenture B65 A/P coil
16262759|NCT04936594|Sham Comparator|Sham TMS|Sham TMS will be delivered using MagVenture B65 A/P coil
16262760|NCT04936581||Open Total Mesorectal Excision|Patients undergoing open low anterior resection
16262761|NCT04936581||Laparoscopic Total Mesorectal Excision|Patients undergoing laparoscopic low anterior resection
16262762|NCT04936581||Robotic Total Mesorectal Excision|Patients undergoing robotic low anterior resection
16262763|NCT04936581||Transanal Total Mesorectal Excision|Patients undergoing transanal Total Mesorectal Excision (taTME)
16262764|NCT04936568|No Intervention|control|standard oncology care
16262765|NCT04936568|Experimental|intervention|standardized referral to outpatient palliative care by oncologists
16262766|NCT04936555|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
16262767|NCT04936555|No Intervention|No Intervention|Control group Routine maintenance will be applied
16262770|NCT04936529|Experimental|Group 1|Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years). Participants will not receive GM-CSF.
16262771|NCT04936529|Experimental|Group 2|Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). Participants also receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14. The treatment includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).
16262772|NCT04936529|Experimental|Group 3|Group 3 will include participants who cannot be randomized (e.g., due to allergy to GMCSF). It will also include participants previously treated with this vaccine and oral β-glucan on the predecessor MSK protocol IRB# 05-075 or on this protocol (participants can therefore be enrolled more than one time on this protocol). These participants will be treated as in Group 1. The analyses in this group will be exploratory.
16262775|NCT04936503|Experimental|High-level athletes|"High level athletes are rugby players, intervention unit agents of the National Police, sports students.
~Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.
~The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects."
16262778|NCT04936477|Experimental|Assessment of alveolar surface area by functional morphometry|Non-invasive measurements of V/Q
16262779|NCT04936464|Experimental|Intervention Group|
16262780|NCT04936464|Sham Comparator|Sham Group|
16262781|NCT04936451|Other|TENS / TENS ECOMODYN|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. ARM TENS / TENS ECOMODYN Patients first start with TENS during 2 months puis change with TENS ECOMODYN during 2 months with a wash-out period of 15 days
16262782|NCT04936451|Other|TENS ECOMODYN / TENS|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. ARM TENS ECOMODYN / TENS Patients first start with TENS ECOMODYN during 2 months puis change with TENS during 2 months with a wash-out period of 15 days
16262783|NCT04936425|Experimental|OTSC Stentfix|
16262784|NCT04936425|No Intervention|Stent Suturing|
16262785|NCT04936412|Experimental|Personalized brace group|Personalized brace for patients
16262786|NCT04936412|Active Comparator|Conventional brace group|Conventional brace for patients
16262787|NCT04936399||Cohort 1|Participants with Squamous Cell Oesophageal Carcinoma Receiving Nivolumab
16262788|NCT04936386||Healthcare professionals|Healthcare professionals (medical specialists and general practitioners, medical residents, midwives, professional nurses, medical students).
16262789|NCT04936360||Patient Group|Patients with non-progressive non-neurodegenerative acquired brain damage, who were over 18 years of age, who could establish voluntary social communication will be included in the study.
16262790|NCT04936360||Caregivers Group|Caregivers over the age of 18, who took care of the patient for at least 1 month, and who did not have premorbid medical or psychological problems will be included in the study.
16262791|NCT04936347|Experimental|Cold knife|The interference of the experimental group is to perform intrauterine adhesiolysis with scissors
16262792|NCT04936347|Other|Hot knife|The interference of the control group is to perform intrauterine adhesiolysis with bipolar electric needle electrode, part of the scar tissue removed by electronic loop when it is necessary.
16262793|NCT04936334|Experimental|Men diagnosed with clinically significant prostate cancer who are scheduled for prostatectomy|1. Men diagnosed with clinically significant prostate cancer who are scheduled or for prostatectomy will undergo injection of 68Ga-PSMA-11 at the time of their pre-treatment PSMA PET. Followed until 12 mo post surgery
16262794|NCT04936321|Active Comparator|Sleep Education + CBT for Pain|Participants will receive access to internet-delivered sleep education during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
16262795|NCT04936321|Experimental|CBT for Insomnia + CBT for Pain|Participants will receive access to internet-delivered CBT for insomnia during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
16262796|NCT04936308|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
16262797|NCT04936308|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
16262798|NCT04936308|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive guselkumab SC.
16262799|NCT04936295|Experimental|Fulvestrant plus Anlotinib|Each participant receives fulvestrant combined with anlotinib.
16262800|NCT04936282|Experimental|Steroids, tacrolimus, mycophenolate and Grafalon|Normal treatment for first 90 days, then add Grafalon single-dose if borderline lesions are present in protocol biopsy (performed at third month post-transplantation)
16262801|NCT04936282|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
16262802|NCT04936269||Group 1|Children under five years old
16262803|NCT04936256||Bilateral implantation of the Clareon monofocal IOL|Clareon monofocal intraocular lens (IOL)
16262804|NCT04936243|Experimental|FOLLOW UP VISIT-TELEMEDICINE|After initial in-person routine followup care, participants will be randomly assigned to receive telemedicine care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
16262805|NCT04936243|Experimental|FOLLOW UP VISIT-FACE TO FACE|After initial in-person routine followup care, participants will be randomly assigned to receive face-to-face care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
16262808|NCT04936217||Patients operated for Continent Cutaneous Urinary Diversion, April 2004 - October 2017|The study focuses of a population of 70 patients operated between April 2004 and October 2017 au Nîmes University Hospital for Cutaneous Urinary Diversion.
16262809|NCT04936204|Experimental|Group 1 ConnettivinaBio Plus cream|ConnettivinaBio Plus cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% Other components: Silver Sulfadiazine 1%, The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
16262810|NCT04936204|Active Comparator|Group 2 ConnettivinaBio cream|ConnettivinaBio Cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
16262811|NCT04936191|Experimental|DynamX Bioadaptor Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor DES and DESyne DES groups.
16262812|NCT04936191|Active Comparator|DESyne Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor DES and DESyne DES groups.
16262813|NCT04936178|Experimental|NB003|Dose escalation cohort: NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
16262814|NCT04936165|Experimental|Healthy experimental participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.
~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min intervention, the same 4.5-min process of the wrist cuff, VO and rest.
~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
16262815|NCT04936165|No Intervention|Healthy controlled participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.
~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min rest, the same 4.5-min process of the wrist cuff, VO and rest.
~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
16262816|NCT04936152|Active Comparator|mime therapy using tablet PC mirror application|these individuals will receive mime therapy using tablet PC mirror application
16262817|NCT04936152|Experimental|the control intervention including the mime therapy|these individuals will receive the control intervention including the mime therapy).
16262818|NCT04936139|Experimental|Art Therapy|Patients assigned to the intervention group will participate in 12 weekly group therapy workshop sessions.
16262819|NCT04936139|No Intervention|Control group|"Patients assigned to the control group will receive the usual follow-up care of each center provided for the cancer patient and will not perform art therapy workshops.
~They will be offered the opportunity to participate in the workshops once they have completed their participation in the study, putting them on a waiting list."
16262820|NCT04936126|Active Comparator|Quetiapine group|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment.
16262822|NCT04936126|Experimental|Pramipexole group|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment
16262824|NCT04936100|Experimental|"Visual acuity assessment using Vision Screening module of Easy Vision application"|
16262825|NCT04936100|Experimental|"Visual acuity assessment using Test Yourself module of Easy Vision application"|
16262826|NCT04936100|Experimental|"Visual acuity assessment using Peek Acuity application"|
16262827|NCT04936100|Other|Visual acuity assessment using the conventional methods|
16262828|NCT04936087|Other|WHO 8-steps|Single group intervention and described in the Intervention section.
16262829|NCT04936074|Experimental|Muscle preserving selective laminectomy (D-group)|Muscle-preserving selective laminectomy is performed with a posterior midline incision and longitudinal dividing of the nuchal fascia. The spinous process is split using a high-speed drill/ultrasound knife and without disturbing the bilateral deep extensor muscles the spinous process is divided at its base. Laminectomy is performed with a width no more than 2-3 mm wider than the spinal cord. The bilateral facet joints are not exposed. Finally, the split fragments of the spinous process are sutured together.
16262830|NCT04936074|Active Comparator|Posterior decompression with instrumented fusion (DF-group)|Posterior decompression and fusion is performed with a midline incision over the appropriate levels defined as the same levels as the extension of laminectomy plus one level above and below but not extending beyond C3-C7. Soft tissue dissection and retraction is performed to identify osseous landmarks. Special care is taken to spare muscle attachments on C2 and C7. Spinal instrumentation is performed with lateral mass or pedicle screws (C3-C7) combined with rod fixation. Laminectomy is performed with a width not extending more than 2 mm outside the dural borders. Facet joint injury should be avoided. Special care is taken to spare the C7 spinous process and distal half of C7 lamina. The sagittal alignment is corrected before spinal fixation. No collar or restrictions will be used in either group.
16262831|NCT04936061|Experimental|High flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
16262832|NCT04936061|Experimental|Low flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
16262833|NCT04936061|Sham Comparator|Sham flow ambient air|15 minute transnasal air flow therapy with the CoolStat sham device as an abortive treatment for migraine attack.
16262834|NCT04936048|Active Comparator|Music therapy/Play therapy|"This sequence of interventions begins with 12 weeks of music therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of play therapy intervention.
~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, and interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
16262835|NCT04936048|Active Comparator|Play therapy/Music therapy|"This sequence of interventions begins with 12 weeks of play therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of music therapy intervention.
~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
16262841|NCT04936022|Other|Control|To receive standard care lifestyle advice only
16262842|NCT04936022|Experimental|Isometric Exercise|To receive standard care lifestyle advice plus 3 sessions of isometric exercise per week
16262843|NCT04936009|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
16262844|NCT04936009|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
16262845|NCT04935996|Experimental|Pleuropulmonary echography|
16262846|NCT04935983|Active Comparator|High CHO|High CHO diet for 36 h
16262847|NCT04935983|Experimental|Low CHO|Low CHO diet for 36 h
16262848|NCT04935970||patients with peripherial vestibular disorder|Forty patients with BPPV, vestibular neuritis or another peripherial vestibular disorder
16262849|NCT04935970||patients with central vestibular disorder|Forty patients vestibular disorder of central origin
16262850|NCT04935970||healthy controls|twenty healthy control without balance problems
16262851|NCT04935957||Single-group|Male and female adult subjects with controlled diabetes 1 and 2.
16262853|NCT04935931|Experimental|Pilot|Pre/post fMRI
16262854|NCT04935918|Experimental|Study Arm 1|Children with bladder exstrophy or isolated epispadias
16262855|NCT04935892|Experimental|Slippers|Patients wear slippers any time they are out of bed with a goal of avoiding any contact between socks/feet and the floor
16262856|NCT04935892|No Intervention|Control|Patients receive standard care with no intervention
16262857|NCT04935879|Experimental|inclacumab, 30 mg/kg|Participants will receive inclacumab 30 mg/kg administered IV every 12 weeks
16262858|NCT04935879|Placebo Comparator|placebo|Participants will receive placebo administered IV every 12 weeks.
16262859|NCT04935840|Experimental|FertyBiotic Pregnancy|Participants received FertyBiotic Pregnancy one capsule a day
16262860|NCT04935840|Placebo Comparator|Control|Participants received 400 mcg of folic acid once a day
16262861|NCT04935827||Patients initiating dialysis for end-stage kidney disease|"Patients whose start of dialysis is from 12/1/2007-11/30/2017. We use the following inclusion criteria:
~Adult (>= 18 years old)
~Did not die or have a transplant prior to the 90th day of dialysis
~Valid medical evidence form
~Medicare Part A/B as primary payer in the 30 days prior to initiating dialysis
~Initiating dialysis in the USA"
16262862|NCT04935814|Experimental|Continuous vasopressin infusion|After general anesthesia, patients will receive a continuous infusion of vasopressin in order to improve mean arterial pressure by 20 mmHg.
16262863|NCT04935801|Sham Comparator|LD Vehicle_GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (14.8ug) without peptides
16262864|NCT04935801|Experimental|LD PepGNP-Dengue|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (14.8ug) plus peptides
16262865|NCT04935801|Sham Comparator|HD vehicle-GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (44.5ug) without peptides
16262866|NCT04935801|Experimental|HD PepGNP-Dengue|High dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (44.5ug) plus peptides
16262867|NCT04935788|Experimental|milk protein|milk protein supplement
16262868|NCT04935788|Experimental|micellar casein|casein supplement
16262869|NCT04935788|Experimental|pea protein|pea protein supplement
16262870|NCT04935788|Experimental|milk/pea protein|a blend of milk and pea protein
16262875|NCT04935736|Experimental|CORTISOMOL SP|Zinc oxide/Eugenol-type sealer containing 1% Prednisolone Acetate. The sealer is used in combination with gutta percha points for the permanent obturation of root canals.
16262876|NCT04935736|Active Comparator|SEALITE REGULAR|The Zinc oxide/Eugenol-type sealer is used in combination with gutta percha points for the permanent obturation of root canals.
16262877|NCT04935723|Experimental|EFFECT OF REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the reiki/sham reiki group were taken to a quiet single room and reiki/sham reiki was applied for approximately 25-30 minutes. will be applied. Reiki application will be applied by a researcher who has Reiki I and Reiki II level training.
16262878|NCT04935723|Placebo Comparator|EFFECT OF SHAM REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. Sham Reiki will be applied by a health professional who has not received Reiki training.
16262879|NCT04935723|No Intervention|ANXIETY, FEAR PAIN LEVELS AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|The control group will be given routine post-operative care without any intervention and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
16262882|NCT04935697|Experimental|nVNS|nVNS treatment will be applied three times daily. One treatment is defined as 2 consecutive doses. One dose is applied to the left side of the neck and one is applied to the right side, three times a day (in the morning 30 minutes prior to breakfast, mid-day 30 minutes prior to lunch, and 30 minutes prior to the evening meal). Will also receive SOC for TBI
16262883|NCT04935697|Other|SOC only|Patients will be managed according to the institutional best practices and SOC for TBI.
16262884|NCT04935684|Experimental|Group 1: Fecal Microbiota Transplantation (FMT)|"Patients randomized in the FMT group will received FMT. FMT product will be made by the the pharmacy of the Clermont-Ferrand University Hospital from stools of healthy volunteer donors within 6 hours after defecation in order to preserve the viability of the bacteria. The preparation will be standardized: 50g aliquots will be prepared and diluted in 250mL of 0.9% NaCl containing 10% glycerol, until a homogeneous suspension is obtained. The preparation will be rapidly frozen at -80°C until use, with a maximum shelf life of 18 months."
16262885|NCT04935684|No Intervention|Group 2: no intervention|"The comparator group will be constituted by patients randomized in the no FMT group. For ethical reasons, these patients will not receive any FMT and therefore no enema or colic preparation. No placebo will be administered. Prophylactic anti-infective treatments can be introduced at any time."
16262886|NCT04935671|Active Comparator|Arm A|"20mg of chamomile and 1 mg saffron in form of teabag for preparation of herbal decoction in dose of two teabags per day for a month as an ADJUVANT THERAPY with standard allopathic treatment for depression."
16262887|NCT04935671|No Intervention|Arm B|Only allopathic medication for depression.
16262888|NCT04935658|Experimental|Virtual Reality Group|in this group, patients will use virtual reality during the oocyte retrieval plus the standard anesthesic procedure (local anesthesia)
16262889|NCT04935658|Sham Comparator|Standard Group|in this group, patients will receive the standard anesthesic procedure during the oocyte retrieval wich is local anesthesia
16263332|NCT04932395|Experimental|Anshen Buxin Liuwei Pills|15 pills/time, 2 times/day, orally，for 8 weeks
16262890|NCT04935645|Experimental|Experimental Group|The experimental group was informed about progressive muscle relaxation (PMR) before colonoscopy. PMR audio recordings were given to the patients. Abdominal pain and distention scores were determined after colonoscopy. PMR was applied to the patients for 30 minutes. These scores were determined again after exercise and at the 2nd, 4th, 8th, 12th, 16th, and 24th hours.
16262891|NCT04935645|No Intervention|Control Group|VAS pain and VAS distension scores of the control group were determined after colonoscopy and 30 minutes later. VAS form was given to all patients to determine VAS abdominal pain and VAS distension scores at the 2nd, 4th, 8th, 12th, 16th and 24th hours after the procedure. The day after the colonoscopy, post test data were collected.
16262892|NCT04935632||Before implementation|Prior to the implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
16262893|NCT04935632||After implementation|After implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
16262894|NCT04935619|Other|Non-Contingency Reinforcement Group|Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.
16262895|NCT04935619|Experimental|Contingency Reinforcement Group|Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.
16262896|NCT04935606|Experimental|Usual Care|Usual Care participants will receive their standard medical care as usual (no provider advice or telephone coaching sessions) and all screening and study assessments. To reduce biases, Usual Care arm patients will be given a cancer screening booklet and will be shown a cancer screening Video Doctor. They will also receive 2 re-contact telephone sessions at weeks 2 and 6 corresponding to the timing of the coaching sessions for the QUIT and QUIT-Mobile arms. All participants will also receive re-contact calls monthly from 7-weeks to 12-months. The re-contact calls (5 min) provide attention control for the Usual Care arm, motivate continued trial participation by reminding them of the next research assessment, but do not provide an active intervention. At study end, the Usual Care arm will receive the QUIT video doctor and drug use reduction booklet brochure materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
16262897|NCT04935606|Experimental|QUIT|The QUIT brief intervention protocol will consist of 5 steps corresponding to the 5A's approach for assisting behavior change in the clinic setting (Ask, Advise, Assess, Assist, and Arrange) that will focus on patients' HSD (highest scoring drug on the baseline ASSIST) use in the past 30 days.
16262898|NCT04935606|Experimental|QUIT-Mobile|"QUIT-Mobile will include a mobile platform with self-monitoring surveys and feedback message and robust data transfer protocols across three mobile technology platforms to meet diverse patient's preferences and needs regardless of literacy and phone type: a mobile-optimized web-app (using any smart phone's web-browser, not native apps), SMS (text-messaging), and IVR (automated voice calls for low literacy patients). Data collected during this study on patient platform preferences and exploratory analyses on intervention efficacy across platform types will inform the development of future effectiveness trials that can evaluate effectiveness of different mobile platforms."
16262899|NCT04935593|Experimental|Renew Intervention Group|Participants in the group will receive training to help children strengthen social, emotional and behavioral knowledge and resilience.
16262900|NCT04935593|No Intervention|Parallel Control Group|Participants in the group will receive the usual bible lessons and activities
16262901|NCT04935580|Experimental|GC012F treatment|GC012F will be infused at a dose of 3 x 10^5 CAR+ T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
16262902|NCT04935567|Experimental|Predicted responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (≥50% seizure reduction).
16262903|NCT04935567|Active Comparator|Predicted non-responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (<50% seizure reduction).
16262904|NCT04935554|Active Comparator|Intervention|"Baseline testing with blood samples, blood pressure and 6 minute walking test. After answering a comprehensive screening tool questionnaire and a conversation with a resource person about What is important to you, the study participant will chose one or several of the following interventions: physical activity, nutrition, motivation, health competence, psychosocial."
16262905|NCT04935554|No Intervention|Control|Baseline testing with blood samples, blood pressure, 6 minute walking test and screening tool questionnaire.
16262906|NCT04935541|Active Comparator|Dexmedetomidine infusion|Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
16262907|NCT04935541|Active Comparator|Remifentanil infusion|Remifentanil (Ultiva, Glaxo SmithKline, Turkey) infusion was started at a dose of 0.05 µg/kg/min-1, 10 minutes before the start of the surgery as baseline infusion and continued at the same infusion dose throughout the surgical procedure.
16262908|NCT04935528|Other|vaccined salaried staff (group 1)|vaccined salaried staff group
16262909|NCT04935528|Other|non vaccined salaried staff (group 2 - witnesses)|non vaccined salaried staff group wtih positive SARS-CoV-2
16262910|NCT04935528|Other|vaccined patients (group 3)|vaccined patient group
16262911|NCT04935515|Experimental|Mild|Patients with mild symptoms and normal CRP.
16262912|NCT04935515|Experimental|Moderate|Patients with mild symptoms and less than 10 fold increase in CRP.
16262913|NCT04935515|Experimental|Severe|Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP.
16262914|NCT04935502|Experimental|Home based exercises with postural and ergonomic training|Home based exercises which consist of stretching, strengthening exercises along with postural and ergonomic training will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education
16262915|NCT04935502|Experimental|Home based exercises|Home based exercises which consist of stretching and strengthening exercises will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education.
16262916|NCT04935489|Experimental|Patients receiving accelerated rTMS|
16262917|NCT04935476|Active Comparator|Treatment|"Participants will receive standard of care and Dapsone per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.
~Dosage form: Dapsone oral tablet"
16262918|NCT04935476|Placebo Comparator|Control|"Participants will receive standard of care and placebo per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.
~Dosage form: Placebo oral tablet"
16262919|NCT04935437|Active Comparator|Intervention|The patients in this arm will be enrolled in a 2 months supervised rehabilitation program. Evaluation will take place at recruitment time and at the end of the program (2 months).
16262920|NCT04935437|No Intervention|Control|The patients in this arm will not be enrolled in a supervised rehabilitation program. Evaluation will take place at recruitment and at 2 months.
16262921|NCT04935424||Experimental：Leukoderma|Device: ApolloVue® S100 image system
16262922|NCT04935411||nAMD patients|patients diagnosed with Neovascular Age-Related Macular Degeneration
16262923|NCT04935398|Experimental|Manual therapy|Football players with adductor tendinopathy undergoing treatment consisting of manual therapy and therapeutic exercise.
16262924|NCT04935398|Experimental|Electrotherapy|Footballers with adductor tendinopathy undergoing electrotherapy treatment
16262925|NCT04935385||Study Cohort|Patients aged 18 and above undergoing elective surgeries (including general surgery, neurosurgery, ear nose and throat surgeries, cardiac surgery, orthopedic surgeries, vascular surgeries and urological surgeries) at Rabin Medical Center under general anesthesia
16262926|NCT04935372||Subjective cognitive decline|Male and female, aged 55 to 80 years with subjective cognitive decline, either cognitively unimpaired or with mild cognitive impairment
16262930|NCT04935333||Leiomyoma samples|Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
16262931|NCT04935333||Leiomyosarcoma samples|Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
16262932|NCT04935333||Control samples|Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour
16262933|NCT04935320|Experimental|Oral Solution Fasted|HTL0016878.HCl 10 mg, single dose, oral solution, fasted
16262934|NCT04935320|Experimental|Oral Capsule Fasted|HTL0016878.citrate 10 mg, single dose, oral capsule, fasted
16262935|NCT04935320|Experimental|Oral Capsule Fed|HTL0016878.citrate 10 mg, single dose, oral capsule, fed
16262936|NCT04935307|Experimental|Patients with multiple chemical sensitivity (MCS)|MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses.
16262937|NCT04935307|Experimental|Patients with multi-systemic functional somatic disorders (FSD)|Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group).
16262938|NCT04935307|Experimental|Healthy controls|Healthy participants
16262939|NCT04935294|Experimental|Group 1: Matched Control Group Of Healthy Participants|Participants received a single 200-milligram (mg) treatment on Day 1.
16262940|NCT04935294|Experimental|Group 2: Severe RI And Not On Dialysis|Participants received a single 200-mg treatment on Day 1.
16262941|NCT04935281||percutaneous repair with an intraoperative assissted ultrasound|a radiologist did an intraoperative ultrasound before the repair for identification the course of sural nerve and outline the medial and lateral edges of torn tendon.
16262942|NCT04935281||percutaneous repair without an intraoperative assissted ultrasound|the course of the sural nerve was determined according to the technique described by Blackmon et al .This technique depends on the leg length for location the point where the nerve crosses the lateral edge of the tendon
16262943|NCT04935255||Single Arm|The participating patients are treated according to local standard treatment (consisting of etoposide 100mg/m2 and cisplatin 20 mg/m2 during 5 consecutive days). Anti-emetic treatment with aprepitant will be given during days 3 to 7.
16262944|NCT04935229|Experimental|SD-101|3 weekly doses of SD-101 given via hepatic artery infusion over 2 cycles
16262945|NCT04935203|No Intervention|Control message group|Participants will not receive the priming manipulation.
16262946|NCT04935203|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
16262947|NCT04935203|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
16262948|NCT04935203|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
16262949|NCT04935190||Group 1|Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.
16262950|NCT04935190||Group 2|Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will be assigned to Group 2.
16263016|NCT04934748|Active Comparator|Routine Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
16262953|NCT04935164||Male patients with gender dysphoria|"male patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation
~patients without psychotropic treatments
~patients who do not benefit of hormone therapy
~patients who have not yet received gender reassignment surgery
~patients aged 18 to 60 years
~patients with normal or corrected vision
~patients without mental defect
~patients without neurological impairment"
16262954|NCT04935164||Female patients with gender dysphoria|"female patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation
~patients without psychotropic treatments
~patients who do not benefit of hormone therapy
~patients who have not yet received gender reassignment surgery
~patients aged 18 to 60 years
~patients with normal or corrected vision
~patients without mental defect
~patients without neurological impairment"
16262955|NCT04935164||Male volunteers without gender dysphoria|"male volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation
~volunteer aged 18 to 60 years
~volunteer with normal or corrected vision
~volunteer without mental defect
~volunteer without neurological impairment"
16262956|NCT04935164||Female volunteers without gender dysphoria|"female volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation
~volunteer aged 18 to 60 years
~volunteer with normal or corrected vision
~volunteer without mental defect
~volunteer without neurological impairment"
16262957|NCT04935151|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
16262958|NCT04935151|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
16262959|NCT04935125|Active Comparator|Standard Program|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks.
16262960|NCT04935125|Experimental|Strength training|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks twelve 30-minute daily sessions of supervised peripheral limb muscle training, 2 set of 6-12 repetitions
16262961|NCT04935112|Experimental|Group 1 Treatment A (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
16262962|NCT04935112|Experimental|Group 1 Treatment B (sitravatinib and pantoprazole)|Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7
16262963|NCT04935112|Experimental|Group 2 Treatment C (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
16262964|NCT04935112|Experimental|Group 2 Treatment D (sitravatinib and famotidine)|Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1
16262965|NCT04935099|Experimental|Blueberry/Placebo|In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later.
16262966|NCT04935099|Experimental|Placebo/Blueberry|In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later.
16262967|NCT04935086||MACE Group|MACE Group includes the patients suffered from any component of MACE after RA-CABG until the latest follow-up.
16262968|NCT04935086||Non-MACE Group|Non-MACE Group includes the patients freed from any component of MACE after RA-CABG until the latest follow-up.
16262969|NCT04935073|Experimental|Traditional Chinese Medicine herbs treatment group|the treatment group will receive treatment with the Chinese herbal formula on the 5th day of the menstrual cycle and lasts to 14 days after IVF-ET.
16262970|NCT04935073|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
16262973|NCT04935047|Experimental|Experimental (Multilingual Support)|The treatment group will receive seven hours multilingual support weekly.
16262974|NCT04935047|No Intervention|Control group|The control group will receive the same amount of support as the experimental group, but from a person without multilingual qualifications.
16262975|NCT04935034|Experimental|Vitamin D enriched mixed micelles dairy drink|20ug vitamin D in pre-formed mixed micelle dairy drink
16262976|NCT04935034|Active Comparator|Vitamin D enriched olive oil dairy drink|20ug vitamin D in olive oil dairy drink
16262977|NCT04935034|Active Comparator|Vitamin D enriched fish oil dairy drink|20ug vitamin D in fish oil dairy drink
16262978|NCT04935034|Active Comparator|Vitamin D enriched fat-free dairy drink|20ug vitamin D in fat-free dairy drink
16262979|NCT04935021|Experimental|ATTR-CM|Patients or Gene carrier
16262980|NCT04935008|Experimental|Effect of recruitment maneuver on intracranial pressure|In patients with decreased oxygen saturation due to atelectasis, a recruitment maneuver will be performed by applying 30 cm H2O positive pressure support for 30 seconds. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver.
16262981|NCT04934995||Study Population|Adult women undergoing cesarean delivery at The Ohio State University Wexner Medical Center under spinal anesthesia, ASA physical status I-III with a BMI during pregnancy ≥ 35 kg/m2 and singleton pregnancy.
16262982|NCT04934982|Experimental|1|the group of LRH
16262983|NCT04934982|Active Comparator|2|the group of ARH
16263094|NCT04934189|Experimental|Empowerment Self-Defense Training- Pilot Trial 3|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW. The intervention administered in Trial 3 will be an tailored version of the curriculum used in Trial 2, adapted based on Trial 2 data.
16262984|NCT04934956|Experimental|Intervention: Split-belt walking; Multiple transitions between split-belt and tied-belt walking|"Split-belt walking will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.
~This second intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018)."
16262985|NCT04934943||Intervention _mini_FC|"The fluid challenge consists of 4 ml*Kg of Crystalloids' solution infused over 10 minutes, administered via either a central or a peripheral line.
~The patient is already connected to the PICCO monitoring for clinical purpose of hemodynamic monitoring (before study enrollment)
~The MOSTCARE system is connected to the MONITOR of the patient (and not to the patient itself) by means of a cable inserted into the connections system.
~The echocardiography will be performed by a senior intensivist/cardiologist. The stroke volume is calculated by measuring VTI and diameter at the same point. This is best performed by measuring the diameter of the LVOT in the parasternal long axis (PLAX) view"
16262986|NCT04934930|Experimental|Reduced number of bendamustine cycles in patients with mid-induction MRD negativity|Patients with follicular lymphoma treated with obinutuzumab bendamustine & achieving MRD negativity as well as complete metabolic response on PET-CT at mid-induction would continue obinutuzumab treatment while omitting bendamustin after 4 cycles.
16262987|NCT04934917||Patients with disc degenerative disease (DDD)|Patients suffering from disc degenerative disease, age 30-60 years that are on the waiting list for surgery (fusion/disc implants) at Stockholm Spine Center, Stockholm, Sweden.
16262988|NCT04934917||Healthy controls (HC)|Healthy controls matched according to age and sex, no chronic pain conditions.
16262989|NCT04934904|Experimental|Experimental Group|On the basis of the clinical routine treatment of AGI in severe patients, the Experimental Group will receives ultrasound-guided erector spinae plane block with routine treatment of AGI for 7 days or until transferring to the general ward.
16262990|NCT04934904|No Intervention|Controlled Group|the routine clinical treatment of AGI is given to severe patients, such as gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy
16262993|NCT04934878||Referral information|first visit to our hospital/transfer from another hospital
16262994|NCT04934865|Other|Patients treated for their lung cancer and Moovcare® Lung follow-up.|
16262995|NCT04934852|Experimental|ephedrine (4mg)|
16262996|NCT04934852|Experimental|ephedrine (8mg)|
16262997|NCT04934852|Experimental|ephedrine (12mg)|
16262998|NCT04934839|Experimental|Patients with osseointegrated prostheses|Patients with an osseointegrated prosthesis following a lower limb amputation
16262999|NCT04934839|Experimental|Patients with socket prostheses|Patients with a socket-mounted prosthesis following a lower limb amputation
16263000|NCT04934826|Experimental|Hydrolized proteins|Group receiving hydrolyzed proteins in the postprandial metabolic test
16263001|NCT04934826|Active Comparator|Intact proteins|Group receiving intact proteins in the postprandial metabolic test
16263002|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with collagen sponge.|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with collagen sponge (CS).
16263003|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
16263004|NCT04934813|Experimental|Alveolar ridge preservation with particulated xenograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Demineralized bovine bone mineral xenograft (DBBM) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
16263005|NCT04934813|Experimental|Alveolar ridge preservation without bone grafting covered with socket sealing mean|Alveolar ridge preservation after tooth extraction. No bone graft was applied and the socket was covered with free gingival graft (FGG).
16263007|NCT04934787|Experimental|ENMS-BSF assisted gait training|The participants will receive the full assistance of the ENMS-BSF during a 20-session gait rehabilitation.
16263008|NCT04934787|Active Comparator|Partial ENMS-BSF assisted gait training|The participants will receive a partial assistance of the ENMS-BSF during a 20-session gait rehabilitation.
16263009|NCT04934787|Sham Comparator|Sham ENMS-BSF assisted gait training|The participants will only wear the device without assistance during a 20-session gait rehabilitation.
16263010|NCT04934774|Experimental|anti-CD7 CAR T cells|anti-CD7 CAR T cells Dose escalation phase: anti-CD7 CAR T cells transduced with a lentiviral vector to express CD7 chimeric receptor domain on T cells with an escalation approach, 1 e6 to 5 e6 CAR-T cells/kg.
16263011|NCT04934761|Experimental|capacity shock|2ml/kg succinylateol gelatin
16263012|NCT04934761|Other|routine management|conventional strategy
16263013|NCT04934748|Active Comparator|Tight Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
16263014|NCT04934748|Active Comparator|Tight Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
16263015|NCT04934748|Active Comparator|Routine Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial
16290637|NCT04741607|Experimental|Test group|Immediate implant placement
16263017|NCT04934735|Active Comparator|The intervention group: received a complex case-management rehabilitation program|The intervention group was followed at 6, 12, 18, 24 months after entering the study. The follow-up was conducted by the case manager for patients in the intervention group, and by a research assistant for patients in the control group. Medical data were retrieved from the computerized medical records in the relevant hospitals.
16263018|NCT04934735|No Intervention|The control: group received the standard care|The control group received regular care.
16263019|NCT04934722|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab intravenously (IV) every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
16263020|NCT04934722|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
16263021|NCT04934709|Experimental|PBMT-sMF|Volunteers underwent intervention (active PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
16263022|NCT04934709|Placebo Comparator|Placebo|Volunteers underwent intervention (placebo PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
16263023|NCT04934696|Experimental|BMS-986166 + Oral contraceptive|
16263024|NCT04934683|Active Comparator|Routine Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
16263025|NCT04934683|Active Comparator|Routine Pressure Management with propofol induction|Propofol will be used as an induction agent.
16263026|NCT04934683|Active Comparator|Tight Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
16263027|NCT04934683|Active Comparator|Tight Pressure Management with propofol induction|Propofol will be used as an induction agent.
16263028|NCT04934670|Experimental|T-Guard|Participants will be administered four doses of T-Guard intravenously for a 4-hour period every other day
16263029|NCT04934670|Active Comparator|Ruxolitinib|Participants will take ruxolitinib twice daily for continuous daily dosing
16263030|NCT04934657||normal steps|patients in this group have normal preoperative step counts
16263031|NCT04934657||low steps|patients in this group have low preoperative step counts
16263032|NCT04934644|Experimental|Hyperbaric oxygen treatment|30 HBO treatments and standard care. If surgery is needed an additional 10 HBO treatments postoperative.
16263033|NCT04934644|No Intervention|Control|Standard care. Surgery if needed.
16263034|NCT04934631||CBT-ED trainees and therapists.|Qualified clinicians delivering CBT-ED throughout a variety of treatment settings, working with adult eating disorder patients. Clinicians will audio-record CBT-ED therapy sessions with their eating disorder patients.
16263035|NCT04934631||Eating Disorder patients.|Adult (18+ years) eating disorder patients currently accessing CBT-ED from one of the CBT-ED therapists/trainees stated above. Patients will have one of their therapy sessions audio-recorded.
16263036|NCT04934631||Raters/Judges.|Either experts or non-experts in the field of CBT-ED. Raters will use the CBTS-ED to assess clinician competence when listening to the therapy session audio-recordings.
16263037|NCT04934618|Experimental|Carelizumab Combined With Irinotecan and Apatinib|Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）
16263038|NCT04934579|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
16263039|NCT04934566|Experimental|patients|patients receiving temporary veno-arterial assistance whose weaning, or transfer to a heart transplant, or to long-term assistance or discontinuation is envisaged.
16263040|NCT04934553|Experimental|Amplification of Positivity for Alcohol Use Disorders (AMP-A; 12 sessions)|
16263041|NCT04934553|Active Comparator|Cognitive-behavioral Therapy (CBT; 12 sessions)|
16263042|NCT04934540||Patients undergoing ERBT|Patients who are diagnosed with bladder tumors and planning for ERBT.
16263043|NCT04934527|Experimental|Experimental|Patients with positive CMV serology at transplantation will receive 6 infusions of Cytotect every 15 days with the first injection on the day of transplantation. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
16263044|NCT04934514|Experimental|Ia stage-Dose escalation|"Using the 3+3 model, 1 subject was included in the 6 mg/kg dose group, and then 3 to 6 patients with HER2-positive advanced solid tumors that failed standard treatment were included in the fixed 3 dose groups (10 mg/kg, 15 mg/kg, and 20 mg/kg) ."
16263045|NCT04934514|Experimental|Ib stage-Dose extension|In the three fixed dose groups (10 mg/kg, 15 mg/kg and 20 mg/kg), when a certain dose group meets the condition of increasing the dose to the higher dose (after the DLT observation period for the last subject in the dose group), the second phase of the dose expansion study for this dose group can be carried out. Each dose group includes 6 patients with HER2-positive advanced solid tumors who have failed the standard treatment, and the interval between enrollment is determined by the investigator.
16263046|NCT04934514|Experimental|IIa stage-Single-agent study (cohort 1)|After the completion of the dose escalation in the 20 mg/kg dose group (Phase Ia), a total of 30 patients with HER2-positive advanced biliary system tumors who have failed standard treatment will be enrolled in the 20 mg/kg dose group. Every 3 weeks is a cycle, and the drug is administered once on the first day of each cycle, and the treatment is continued until any end-point event occurs.
16263095|NCT04934176||Group 1|Group 1 will have had a muscle transfer driven by the trigeminal nerve (nV).
16263096|NCT04934176||Group 2|Group 2 will have had a muscle transfer driven by a cross-face nerve graft (nVII).
16263333|NCT04932395|Placebo Comparator|Placebo|15 pills/time, 2 times/day, orally. for 8 weeks
16263047|NCT04934514|Experimental|IIa stage - IAH0968 combined GP regimen study (cohort 2)|After the completion of the dose escalation in the 20 mg/kg dose group (phase Ia), a total of 30 patients with newly treated HER2-positive advanced biliary system tumors will be enrolled in the 20 mg/kg dose group combined with the GP regimen (gemcitabine + cisplatin) . Every 3 weeks is a cycle, treatment until any end-point event occurs.
16263048|NCT04934501||PAD patients|The entire cohort exists of patients recently treated with an endovascular stent placement in the superficial femoral artery (SFA).
16263049|NCT04934488|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1). The experimental group will also receive care as usual from their healthcare providers.
16263050|NCT04934488|Other|Waitlist Control|The waitlist control group will receive care from usual healthcare providers and will receive the intervention at the conclusion of the study period (T2, 12 weeks after enrollment).
16263051|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A|"Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12) 6 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):
~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)
~Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)
~Lenalidomide: 25 mg per day orally from days 1 to 21
~Dexamethasone: 40 mg orally on day 1, 8, 15, 22"
16263052|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B|"Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2) 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):
~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)
~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)
~Lenalidomide: 25 mg per day orally from days 1 to 21
~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
16263053|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C|"Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation. 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):
~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)
~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)
~Lenalidomide: 25 mg per day orally from day 1 to day 21
~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
16263054|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D|tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.
16263055|NCT04934462|Other|non-surgical treatment|All participants will undergo 6 months of non-surgical treatment.
16263056|NCT04934462|Other|arthroscopic treatment|Those participants with failed non-surgical treatment at 6 months will undergo arthroscopic treatment.
16263057|NCT04934449|Experimental|Hard splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, hard occlusal splints for 6 weeks during sleep
16263058|NCT04934449|Experimental|Hard splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, hard occlusal splints for 6 weeks during sleep
16263059|NCT04934449|Experimental|Soft splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, soft occlusal splints for 6 weeks during sleep
16263060|NCT04934449|Experimental|Soft splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, soft occlusal splints for 6 weeks during sleep
16263061|NCT04934436|Experimental|Intervention Group|According to their chronotype, the intervention group will then be given sleeping glasses and earplugs at night for those who are in the morning type, and till afternoon during the day for those who are in the evening type. Moreover, patients in the intervention group will be given 5000 Lux daylight during the time they are awake depending on their circadian rhythms. An Android smartwatch will be used to determine patients' sleeping and waking up times, sleep quality and sleep depth. Nursing care will also be provided when patients are awake per their chronotype. Before the study, intensive care nurses will be trained to provide appropriate care according to the circadian rhythm and chronotype to have consistency in the care. Patients will be observed for three days and during this time cortisone and melatonin levels will be checked in both control and intervention groups. At the end of the third day, surveys will be conducted once again with both groups.
16263062|NCT04934436|No Intervention|Control Group|All surveys that will be used in the study will be applied to both groups during the first and last interviews. The control group will not have any interventions, only the standard ICU care to be provided.
16263063|NCT04934423|Experimental|active tDCS|tDCS active, for 30 minutes for 5 consecutive days, with an anode positioned in the left dorsolateral prefrontal cortex and cathode electrode placed over the right supraorbital area. The EEG International 10-20 system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (MRI) to estimate and individualize a dose to be administered.
16263064|NCT04934423|Sham Comparator|Sham tDCS|The electrodes will be positioned in the same way as in the intervention group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Subsequently, the device is switched off, no longer emitting current.
16263068|NCT04934397|Experimental|Study Infant Formula|Feed ad libitum during study period
16263069|NCT04934384||Positive prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
16263070|NCT04934384||Negative or not performed prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
16263097|NCT04934176||Group 3|Group 3 will have had a muscle transfer driven by dual innervation using both the trigeminal and cross-face nerve graft.
16264096|NCT04927169|Placebo Comparator|PLACEBO|IM administration of Saline at the same volume
16263071|NCT04934371|Active Comparator|active TDCS and listening therapy|TDCS will be administered with NeurConn1 Channel DC-Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes at 2mA with a 15-s ramp-up and ramp-down period. Excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks.
16263072|NCT04934371|Sham Comparator|sham TDCS and listening therapy|The sham stimulation will also last for 20 min with 15 sec ramp-up and ramp-down, except the current will be turned down gradually to 0 milliamperes (mA) after 30 seconds. The sham procedure provides the same tingling and itching sensation felt during active tDCS. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
16263073|NCT04934358|Experimental|Physical activity program and motivational intervention|Physical activity program agreed with the patient / family and according to functional status (based on the 6-minute walk test) and motivational intervention. In addition to the care provided in usual care, a progressive physical exercise program based on basal functional capacity is prescribed. The exercise will be developed at home.
16263074|NCT04934358|Active Comparator|Treatment as usual|Multidisciplinary rehabilitation provided by professionals in the hospital and primary care settings, according to the individual needs of patients at different times of their recovery and the accessibility and availability of services in the different care settings.
16263075|NCT04934345||FC administration|"All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.
~After the first episode of hypotension (MAP < 65 mmHg) the PPV is checked.
~PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')
~PPV < 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion."
16263076|NCT04934332|Experimental|Newly hospitalized patients|Patients admitted for the first time to a post intensive care rehabilitation unit after severe neurological trauma.
16263077|NCT04934319|Experimental|Balance training|A single training group
16263078|NCT04934306||Patients without cleft|Patients without developmental speech disorder (including articulation disorder) or hearing impairment
16263079|NCT04934306||Patients with a cleft|Patients with a hard and/or soft palate cleft and for whom the perceptual speech-language pathology evaluation revealed a velopharyngeal insufficiency
16263082|NCT04934280|Other|2D transvaginal ultrasonography|
16263083|NCT04934267|Experimental|Eccentric exercise of elbow in order to induce Delayed Onset of Muscle Soreness|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1RM).Both groups will perform 1 set of standing eccentric bicep curls based on their 1RM to failure in order to induce DOMS.The exercise will stop when the participant cannot volitionally keep up with the 5 second count lowering the weight. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
16263084|NCT04934254||Newborn Nurses|
16263085|NCT04934241|Experimental|Self-Acupressure|Self-Acupressure Each application to the acupressure points (HT 7, CV17,PC 6, LI4,SP 6) will be done in 2 minutes and right and left)
16263086|NCT04934241|No Intervention|Control group|Routine maintenance will be applied
16263087|NCT04934228|Placebo Comparator|Placebo|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant.
~The placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug.
~Participants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug."
16263088|NCT04934228|Experimental|Clonidine|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant.
~Planned use in this study
~Condition/disease indication(s): Vascular function and blood flow
~Subject population: Hypertension
~Dose(s): 0.1 mg (oral)
~Administration: Oral
~Dosing regimen: 0.1 mg twice daily by mouth"
16263089|NCT04934228|Experimental|Hydrochlorothiazide (HCTZ)|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant.
~Planned use in this study
~Condition/disease indication(s): Hypertension
~Subject population: Hypertension
~Dose(s): 25 mg/day
~Administration: Oral
~Dosing regimen: 12.5 mg twice per day"
16263090|NCT04934202||Patients from the 1st epidemic wave|"One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC 1st wave in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above."
16263091|NCT04934202||Patients from the 2nd epidemic wave|"As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages:
~During a teleconsultation, to which all eligible patients will be invited, systematically looking for general, neurological, cognitive and respiratory symptoms
~During a hospitalization in an outpatient clinic to which all survivors who have stayed in an intensive care unit (ICU) will be invited and, among patients who have not stayed in an ICU, those who have residual symptoms detected during the teleconsultation."
16263092|NCT04934189|Experimental|Empowerment Self-Defense Training- Pilot Trial 1|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW.
16263093|NCT04934189|Experimental|Empowerment Self-Defense Training- Pilot Trial 2|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW. The intervention administered in Trial 2 will be an tailored version of the curriculum used in Trial 1, adapted based on Trial 1 data.
16263596|NCT04930614||Transgender and non-binary people|Adult transgender and non-binary people in Flanders and Brussels (Belgium)
16264097|NCT04927156||BALT medical devices|
16263098|NCT04934176||Group 4|Group 4 will have had manipulations that involve performing direct coaptation between the trigeminal nerve and a branch to the native zygomaticus major muscle (5-7 transfer) and selective neurolysis in which several facial nerve branches that innervate muscles antagonistic to the smile animation.
16263099|NCT04934163|Experimental|60 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 60 L/min after extubation.
16263100|NCT04934163|Experimental|40 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 40 L/min after extubation.
16263101|NCT04934150|Active Comparator|M1 stimulation|10 Hz stimulation of left motor area
16263102|NCT04934150|Active Comparator|DLPFC stimulation|5 Hz stimulation of left dorsolateral prefrontal cortex
16263103|NCT04934150|Sham Comparator|Sham TMS|Sham TMS over the left M1 area
16263104|NCT04934137|Active Comparator|WiSAT first intervention|Group 1 participants will receive the WiSAT intervention during the first intervention phase for 4 weeks, and then the AW-Shift intervention during the second intervention phase for 4 weeks.
16263105|NCT04934137|Active Comparator|AW-Shift first intervention|Group 2 participants will receive the AW-Shift intervention during the first intervention phase for 4 weeks, and then the WiSAT intervention during the second intervention phase for 4 weeks.
16263106|NCT04934124|Experimental|Cohort 1: 0.03 mg ITI-333 or placebo|
16263107|NCT04934124|Experimental|Cohort 2: 0.09 mg ITI-333 or placebo|
16263108|NCT04934124|Experimental|Cohort 3: 0.25 mg ITI-333 or placebo|
16263109|NCT04934124|Experimental|Cohort 4: 0.75 mg ITI-333 or placebo|
16263110|NCT04934124|Experimental|Cohort 5: 2.25 mg ITI-333 or placebo|
16263111|NCT04934124|Experimental|Cohort 6: 6.75 mg ITI-333 or placebo|
16263112|NCT04934124|Experimental|Cohort 7: 15 mg ITI-333 or placebo|
16263113|NCT04934124|Experimental|Cohort 8: 30 mg ITI-333 or placebo|
16263114|NCT04934111|Experimental|LNP-nCOV saRNA-02 Vaccine arm|Participants that have evidence of previous infection with SARS-CoV-2 and those with no evidence of previous infection will all receive receive LNP-nCOV saRNA-02 Vaccine. Both groups will be given a dose of 5.0ug at 0 weeks and 4 weeks.
16263115|NCT04934098|Experimental|Adjustable compression wrap|Daily use of the Adjustable Compression Wrap on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
16263116|NCT04934098|Active Comparator|Compression Bandage|Daily use of compression bandage on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
16263117|NCT04934085||Study group|subjects who had tested positive and recovered from COVID-19
16263118|NCT04934085||Control group|healthy subjects who did not have COVID-19, the controls will be matched to the study group for gender and age
16263121|NCT04934059|Experimental|Yuxuebi tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
16263122|NCT04934059|Placebo Comparator|Placebo tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
16263123|NCT04934046|Experimental|DaTSCAN brain scan images from the new CZT SPECT system|All patients will undergo additional SPECT acquisition (30min added time approximately), with no added radiation, with both new multipurpose CZT camera (StarGuide system, GE Healthcare, Haïfa, Israel) and conventional SPECT camera (Discovery 670, GE Healthcare, Haïfa, Israel)
16263124|NCT04934033|Other|Healthy volunteers|The participants will constitue a cohort of healthy volunteers, they will have a MRI, and language and cognitive assessment.
16263125|NCT04934007|Experimental|Active stimulation|Active rTMS stimulation , 2 session per day during 10 days.
16263126|NCT04934007|Sham Comparator|Sham Stimulation|Sham rTMS stimulation , 2 session per day during 10 days.
16263127|NCT04933994||Coronavirus disease; Influenza A(H1N1)|two independent cohorts of COVID-19 pneumonia (n=405) and H1N1 influenza pneumonia (n=78) retrospectively, all patients were confirmed by RT-PCR. Four hundred and five cases of COVID-19 pneumonia were confirmed in nine hospitals of Zhejiang province, China from January 21 to February 20, 2020. Seventy-eight cases of H1N1 influenza pneumonia were confirmed in our hospital from January 1, 2017 to February 29, 2020.
16263128|NCT04933981||interventional nursing home (INH).|regular, twice to three times weekly, and voluntary, i.e. non-mandatory, on-site testing for SARS-CoV-2 of HCW and visitors (INH)
16263129|NCT04933981||control nursing home (CNH)|routine setting without frequent regular testing for SARS-CoV-2 (control nursing homes; CNH). Testing only performed by local health authorities upon medical indication, i.e. non-surveillance testing
16263130|NCT04933968|Placebo Comparator|Placebo|Placebo, visually identical to ALVR106
16263131|NCT04933968|Active Comparator|ALVR106|ALVR106, visually identical to placebo
16263132|NCT04933955|Active Comparator|biodentine|pulptomy with biodentine
16263133|NCT04933955|Active Comparator|Theracal PT|pulpotomy with Theracal PT
16263134|NCT04933955|Active Comparator|Neo Putty|pulpotomy with Neo putty
16263135|NCT04933942|Active Comparator|Control group|Lomustine alone
16263136|NCT04933942|Experimental|Experimental group|Lomustine plus Romiplostim
16263137|NCT04933929|Experimental|"Coronavirus disease Positive group Covid (+)"|Positive PCR test.
16263138|NCT04933929|Active Comparator|"Coronavirus disease Negative group Covid (-)"|Negative PCR test.
16263139|NCT04933916|Experimental|EMB-001 Active|720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
16263140|NCT04933903|Experimental|Protocol Therapy|Ipilimumab: 1mg/kg IV day 1. Nivolumab: 3mg/kg IV days 1, 15, 29. SBRT delivered as 1-2 fractions to the gross primary tumor and nodal disease following day 1 infusion and completed by day 3 (7Gy x 1; 4Gy x 2).
16263163|NCT04933695|Experimental|Sotorasib: Dose A|Participants with metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation whose tumors express < 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib dose A. Participants will be stratified by known presence of STK11 mutation.
16263164|NCT04933695|Experimental|Sotorasib: Dose B|Participants with metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation whose tumors express < 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib dose B. Participants will be stratified by known presence of STK11 mutation.
16290638|NCT04741594|Experimental|Versah group|
16263141|NCT04933877|Active Comparator|Serratus Anterior Plan block|The SAPB was performed in the operative room (OR) after anesthesia induction using the same ultrasound machine (SonoSite) and linear ultrasound transducer 8- 12 Hz. The patient was positioned in a lateral position with the operative side up and arm flexed forward; then, a linear ultrasound transducer was placed in a sagittal plane over the mid-clavicular line of the thoracic cage. Then, moving inferior-lateral direction till the fifth rib was identified in the mid-axillary line. The following structures were recognized: the rib, pleura, teres major muscle (superior), latissimus dorsi muscle (superficial and posterior), and serratus muscles muscle (deep and inferior). Under complete sterile conditions, a 22-gauge echogenic needle was introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle. Then, 0.4 ml/kg of 0.25% bupivacaine was injected with continuous ultrasound guidance.
16263142|NCT04933877|Active Comparator|Erector spinae plane block|Patients in Group ESPB receive US erector spinae plane block by injecting 0.4ml/kg (bupivacaine 0.25%). Under strict aseptic precautions, The T3 spinous process is located by palpating and counting down from the C7 spinous process. A high-frequency 12 MHz linear ultrasound transducer is placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Using an in-plane approach a 22 G needle is inserted in caudal-cephalad direction until the tip is deep to erector spinae muscle. Correct needle tip location is confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, bupivacaine is injected, and visualizing the fascial plane.
16263143|NCT04933864|Experimental|Methylene Blue and Photodynamic Therapy|Methylene Blue 1 mg/kg water solution. Participants have orally received Methylene Blue solution of 1 mg/kg concentration one time in addition to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose was performed.
16263144|NCT04933864|No Intervention|Control group|COVID-19 positive participants treated with standard medical supportive therapy (e.g. azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.).
16263145|NCT04933851|Experimental|ACT1VATE|Participants assigned to the intervention group will be offered a psychological intervention specifically designed to address diabetes-related emotional distress.
16263146|NCT04933851|Active Comparator|DSME/S (usual care)|Participants randomized to the usual care group will be offered standard diabetes self-management education and support (DSME/S).
16263147|NCT04933838|Placebo Comparator|Control Group|1% licocaine 3 mL + Normal saline 3 mL mixture
16263148|NCT04933838|Experimental|Atelocollagen group|1% lidocaine 3 mL + atelocollagen 3 mL mixture
16263149|NCT04933825|Experimental|"Four escalating dose-levels of ET-02 will be evaluated using a 3+3 design."|
16263150|NCT04933812|Other|Group Social Support Meetings and Facebook Group|Facebook group where community doulas will be providing information on various pregnancy and support topics in addition to 8 possible group Zoom meetings that will include pregnancy-related/reflection topics.
16263151|NCT04933799|Active Comparator|PF-06650833 + Standard of Care treatment|Subjects randomized to the PF-06650833 arm of the study will receive 400 mg PF-06650833 (2 x 200 mg tablets) of the MR formulation orally QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). Subjects who cannot take tablets PO will receive PF-06650833 200 mg IR suspension formulation every 6 hours (NG tube or OG tube, or equivalent). Subjects for whom concomitant administration of a strong inhibitor of CYP3A4 (eg, ritonavir) will have the dose reduced to either 200 mg MR or IR QD. All dosing of study drug will be in addition to current hospital SOC treatment that must include treatment targeting SARS-CoV-2.
16263152|NCT04933799|Placebo Comparator|Placebo + Standard of Care treatment|Placebo will match the Active comparator in dosage form, dosage, frequency and duration.
16263153|NCT04933786|Experimental|Digital Health Nudging|During 12-week intervention period participants receive daily text messages via WhatsApp on their smartphone to encourage them to be physically active in their daily lives.
16263154|NCT04933786|No Intervention|Control|During 12-week control period participants receive no text messages.
16263155|NCT04933773|Experimental|Set averaging times: 2-4 seconds and 8 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 2-4 seconds, the second pulse oximeter is set to an averaging time of 8 seconds.
16263156|NCT04933773|Experimental|Set averaging times: 8 seconds and 16 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 8 seconds, the second pulse oximeter is set to an averaging time of 16 seconds.
16263160|NCT04933721|Experimental|BCX7353 Capsules 150 mg once daily|Berotralstat (BCX7353) 150 mg capsule orally administered once daily.
16263161|NCT04933708|Experimental|Labor Podcast Group|"1) Labor Podcast Group - Women randomized to this arm will receive access to a link to download six HUP physician created labor podcasts in addition to usual care during labor, delivery, and postpartum
~o Podcast topics: Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth
~LAS-10 and Birth Satisfaction survey - Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)
~EPDS - Women will receive this survey on postpartum day 7 via method they desire"
16263162|NCT04933708|No Intervention|Usual Care|"2. Usual care Women randomized to this arm will receive usual care during labor, delivery, and postpartum with the following exceptions:
~LAS-10 and Birth Satisfaction survey Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)
~EPDS Women will receive this survey on postpartum day 7 via method they desire"
16263165|NCT04933682|Experimental|Part 1: ALXN2050 plus Fluconazole|"Period 1: Participants will receive a single dose of ALXN2050 alone and in the presence of multiple doses of fluconazole.
~Period 2: Participants will receive multiple doses of ALXN2050 alone and in the presence of multiple doses of fluconazole.
~Scheduled pharmacokinetics (PK) blood samples for both ALXN2050 and fluconazole will be collected, with a washout period of at least 14 days between the last dose of fluconazole in Period 1 and the first dose of ALXN2050 in Period 2."
16263166|NCT04933682|Experimental|Part 2: ALXN2050 plus Rifampin|"Participants will receive a single dose of ALXN2050 alone and in the presence of both single and multiple doses of rifampin.
~Scheduled PK blood samples for both ALXN2050 and rifampin will be collected."
16263167|NCT04933669|Experimental|Imatinib neoadjuvant|Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
16263168|NCT04933656|Experimental|50g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
16263169|NCT04933656|Experimental|90g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
16263170|NCT04933656|Experimental|130g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
16263171|NCT04933656|Experimental|170g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
16263172|NCT04933643||well prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that the stomach is well prepared when GCS ≥ 18
16263173|NCT04933643||inadequate prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that GCS < 18 is inadequate.
16263176|NCT04933604||LPN group|39 patients with high complexity renal tumors who underwent laparoscopic partial nephrectomy
16263177|NCT04933604||LRN group|39 patients with high complexity renal tumors who underwent laparoscopic radical nephrectomy
16263178|NCT04933591|Active Comparator|study group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein before and after administration of Venarus® (100 mg hesperidin + 900 mg diosmin) for 2 months
16263179|NCT04933591|No Intervention|control group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr vein. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein at inclusion and 2 months later/
16263180|NCT04933578||Children|"The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children.
~The children's preferences for the appearance of dentists were determined in the second part.
~Routine dental examinations of children with a dental mirror and artificial light were completed by an experienced pediatric dentist according to the World Health Organization (WHO) guidelines and criteria."
16263181|NCT04933578||Parents|"The questionnaire including demographic information (age, sex, and medical and dental history) was applied to the parents.
~In the second section, the MDAS was administered to parents, differently from children.
~The parents' preferences for the appearance of dentists were determined in the second part."
16263182|NCT04933565|Experimental|ORG-129|Single ascending dose, 4 cohorts, followed by multiple ascending dose, 3 cohorts
16263183|NCT04933565|Placebo Comparator|Placebo|Single ascending dose, 4 cohorts, followed by multiple ascending dose, 3 cohorts
16263188|NCT04933526|Active Comparator|Flumatinib|600mg QD orally form 1 to 12 months
16263189|NCT04933526|Placebo Comparator|Dasatinib|100mg QD orally form 1 to 12 months
16263190|NCT04933513||preoperative Parkinson' disease|pre DBS parkinson's disease patients responding to the DBS-PS scale preoperatively
16263191|NCT04933500||Conventional epidural|epidural needle: Tuhoy needle 1.3mm (18 G) with 20G multi-orifice epidural catheter
16263192|NCT04933500||Dural puncture epidural|epidural needle;Tuhoy needle 1.3mm (18G)with 20G multi-orifice epidural catheter and 25G Whitacre spinal needle
16263193|NCT04933487|Experimental|Ankoris IOL Implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris
16263194|NCT04933474|Experimental|2D mHealth intervention therapy|Patients allocated to this arm will use one of the most widely-validated mHealth interventions for pain management called painTRAINER®, which is a standardized, 56-day program delivering skills training and Cognitive behavioral therapy (CBT)-related treatments through daily virtual experiences.
16263195|NCT04933474|Experimental|3D Immersive Virtual Reality (VR) therapy|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
16263268|NCT04932889||No change|the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)
16263196|NCT04933461|Other|Simulation of skin pricking by using Medlance Plus|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
16263197|NCT04933461|Other|Simulation of skin pricking by using myLance|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
16263198|NCT04933448|Experimental|Prospective Intervention Group|Participants will receive standard of care for acute management of moderate to severe traumatic brain injury, together with a weight-based ketogenic diet added for up to fourteen days.
16263199|NCT04933448|No Intervention|Historical Control Group|Medical records of past TBI patients will be used as controls matched for age, gender, socioeconomic status (type of health care coverage including private insurance vs. government-funded coverage), lowest first 24 hour post-injury Glasgow Coma Score (GCS) (<8 or 8-12), and pre-injury school program (regular or special education).
16263200|NCT04933435|Active Comparator|Interventional Radiology Liver Directed Therapies (ILDT)|ILDT includes ablations such as microwave ablation and percutaneous local ablation and embolotherapies including bland embolization, chemoembolization and radioembolization.
16263201|NCT04933435|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is a non-invasive, outpatient procedure typically delivered in 3-10 fractions of radiation.
16263202|NCT04933422|Experimental|CM93 pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), pre-treatment with CM93 prior to surgical resection of recurrent glioblastoma
16263203|NCT04933422|No Intervention|No pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), no pre-treatment prior to surgical resection of recurrent glioblastoma
16263204|NCT04933409|Experimental|3D printed replica of Donor tooth|3D printed replica of Donor tooth
16263205|NCT04933409|Active Comparator|Conventional|Conventional method of autotransplantation.
16263206|NCT04933383|Experimental|AQ001S 0.125 mg/ml|AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.
16263207|NCT04933383|Active Comparator|budesonide inhalation suspension 0.125 mg/ml|Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.
16263208|NCT04933370|Active Comparator|Industry standard stimulation|Industry standard stimulation settings
16263209|NCT04933370|Sham Comparator|Experimental stimulation|Experimental stimulation settings
16263210|NCT04933357|Experimental|Dose escalation|
16263211|NCT04933357|Active Comparator|Standard dose|
16263212|NCT04933344||patients having had BJI or PJI treated with daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK
16263213|NCT04933331||Curodont Repair Fluoride Plus (Curodont) cohort|The effectiveness of Curodont treatment in this group will be compared to other treatment options and cohorts. Curodont will be professionally applied in the dental clinic. The treatment time takes about 5 minutes. Patients receive one professional dose application and be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months.
16263214|NCT04933331||Other tooth-specific initial lesion interventional treatments cohort(s)|"Silver Diamine Fluoride (SDF). The treatment time is about 2 minutes.
~Glass Ionomer Sealants: The treatment time takes about 5 minutes per sealant. Typically four sealants are completed in one visit.
~All patients will be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months."
16263215|NCT04933331||Control cohort, no tooth-specific treatment or whole mouth treatment.|If a patient or their caregivers choose no tooth-specific treatment, they will be included in the control cohort. This group includes patients who chose to receive no treatment at all, as well as those who choose whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste.
16263216|NCT04933331||Orthodontic cohort|Patients in active orthodontic care will be analyzed separately from other patients to account for the impact of orthodontic appliances on treatment outcomes. Orthodontic appliances are recognized by the American Dental Association Caries Risk Assessment as a risk factor for caries because they create dental plaque stagnation areas that are difficult to clean. Initial caries lesions are very frequently seen immediately surrounding orthodontic brackets (braces), yet continued plaque stagnation over the treated areas may heavily influence the success of any treatment. All groups/cohorts above will be represented in the orthodontic cohort in parallel.
16263217|NCT04933318|Active Comparator|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)- analgesic current therapy
16263218|NCT04933318|Sham Comparator|shamTENS|shamTranscutaneous electrical nerve stimulation (TENS)- analgesic current therapy
16263219|NCT04933318|Active Comparator|Interferential current therapy (IFC)|Interferential current therapy (IFC)- analgesic current therapy
16263220|NCT04933318|Sham Comparator|shamIFC|shamInterferential current therapy (IFC)- analgesic current therapy
16263221|NCT04933305||RYGB patients|Patients that already received RYGB one year prior commencement of their participation in the study
16263222|NCT04933292|Experimental|Methylprednisolone and Mycophenolate mofetil|
16263223|NCT04933292|Active Comparator|Methylprednisolone and Azathioprine|
16263224|NCT04933279|Experimental|Potassium iodide group|administrated the subjects with 150 ml - 200 ml iodine-containing spareribs soup delivering ≈ 600 µg or 1200 µg iodine
16263225|NCT04933279|Experimental|Natural kelp group|administrated the subjects with a bowl of 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine in natural kelp).
16263226|NCT04933266|Active Comparator|Low dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 5ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 5ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 10ml will be given).
16263269|NCT04932876||ESKD - HD|End Stage Kidney Disease on Long Term Dialysis
16263227|NCT04933266|Active Comparator|High dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 10ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 10ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 20ml will be given).
16263228|NCT04933253|Experimental|Experimental|this cohort will receive 2 L of warm 37celsius saline irrigation of the mediastinum prior to closure of the chest
16263229|NCT04933253|No Intervention|Control|this cohort will receive the normal standard of care as established by the primary surgeon
16263230|NCT04933240|Active Comparator|Tamoxifen|tamoxifen 10mg daily for 7 days
16263231|NCT04933240|Active Comparator|Estradiol|estradiol 1mg daily for 7 days
16263232|NCT04933240|Placebo Comparator|placebo|placebo daily for 7 days
16263233|NCT04933227|Experimental|Atezo + Tira + XELOX|Atezolizumab plus tiragolumab in combination with XELOX (oxaliplatin and capecitabine) will be administered during Cycles 1-4 (each cycle is 21 days). During Cycle 5 and beyond atezolizumab and tiragolumab will be administered on Day 1 of each 21-day cycle. Participants will receive study treatment until disease progression, unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16263234|NCT04933201|Experimental|Music group|Perioperative music intervention
16263235|NCT04933201|Active Comparator|Control group|No perioperative music
16263236|NCT04933188||control|Lean health controls with a BMI<25kg/m2
16263237|NCT04933188||overweight|patients with a BMI of 25-30kg/m2
16263238|NCT04933188||obesity|patients with a BMI of over 30kg/m2
16263239|NCT04933175|Experimental|fluzopali combined with anlotinib|Patients 18 years of age or older, 75 years of age or younger with histologically proven small cell carcinoma of the lung were assessed by radiography as having an extensive stage (according to the American Veteran Lung Cancer Association). Patients received first-line two-drug chemotherapy with standard cisplatin, carboplatin, or lobaplatin, combined with or without immunotherapy, and developed radiologically evaluated disease progression during treatment or within 6 months of completion of treatment.
16263240|NCT04933162|Experimental|High Protein and Low Fiber Group|Subjects will consume a high protein and low fiber diet for 8 weeks
16263241|NCT04933162|Experimental|Low Protein and High Fiber Group|Subjects will consume a low protein and high fiber diet for 8 weeks
16263242|NCT04933149|Experimental|Ketamine Infusion Group|Subjects will receive ketamine infusion during their planned surgery and postoperatively.
16263243|NCT04933149|No Intervention|Standard of Care Group|Subjects will receive general anesthesia as standard of care during their planned surgery
16263244|NCT04933110||Multiple Sclerosis|Individuals with early-stage multiple sclerosis
16263245|NCT04933110||Healthy Volunteers|Healthy volunteers of similar age and sex as individuals with multiple sclerosis
16263246|NCT04933097|Experimental|Sarcopenia|Only one arm with the sarcopenia assessment.
16263247|NCT04933084|No Intervention|Usual Care|During their pre-operative visit, the usual care group will undergo usual pre-surgery patient education care dependent on their provider.
16263248|NCT04933084|Experimental|Text Handout|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout.
16263249|NCT04933084|Experimental|Text handout and Pre-recorded Video|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout AND pre-recorded video.
16263250|NCT04933071|Experimental|Podcast Education|Residents will be given access to podcasts during their rotation They will complete a survey after each obstetrics rotation
16263251|NCT04933071|No Intervention|Usual Teaching|Residents will have usual teaching They will complete a survey after each obstetrics rotation
16263252|NCT04933058|Experimental|Opioid-free anesthesia|"IV propofol 1-1.5 mg/kg
~IV acetaminophen 1000mg
~IV dipyrone 1000mg
~IV lidocaine 1mg/kg
~IV dexacort 4mg
~PR diclofenac 50 mg"
16263253|NCT04933058|Active Comparator|Opioid-supplemented anesthesia|"IV propofol 1-1.5 mg/kg
~IV fentanyl 1.5 mcg/kg
~IV dipyrone 1000mg
~IV lidocaine 1mg/kg
~IV dexacort 4mg
~PR diclofenac 50 mg"
16263254|NCT04933045||Syndesmotic Fixation Group|Cohort of patients treated with anatomic ATFL reconstruction for syndesmotic ankle injury.
16263255|NCT04933019|Other|Clindamycin Resistance Genes among Staphylococcus Isolates by Using Real Time PCR|
16263256|NCT04933019|Other|Clindamycin sensetive Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|
16263257|NCT04932993|No Intervention|Standard care|Will not write down goals their goals for their medical care (usual care).
16263258|NCT04932993|Experimental|Writing down goals|Will write down goals their goals for their medical care.
16263259|NCT04932980|Active Comparator|Aflibercept ® rapid treatment extension (T&E)|Early treat and extend (T&E) with Aflibercept ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
16263260|NCT04932980|Active Comparator|Brolucizumab ® rapid treatment extension (T&E)|Early treat and extend (T&E) with Brolucizumab ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
16263261|NCT04932941|Experimental|MP1032|Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.
16263262|NCT04932941|Placebo Comparator|Placebo|Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.
16263263|NCT04932928|Experimental|FreeStyle Libre (CGM) Group|Device: FreeStyle Libre (ver 1.0) Education on lifestyle modification
16263264|NCT04932928|Active Comparator|Self Monitoring of Blood Glucose (SMBG) Group|Device: Blood glucose meter Education on lifestyle modification
16263267|NCT04932889||Change|the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)
16263271|NCT04932863||Subjects with cancer of any type and stage under active or prior medical treatment|BNT162b2 mRNA Covid-19 Vaccine as two injections, 21 days apart, of 30 μg per dose in the deltoid muscle.
16263272|NCT04932850|Experimental|Active|"3 active cohorts are involved into study: Cohort 1 (48 mg), Cohort 2 (100 mg) and Cohort 3 (400 mg).
~Each cohort is composed of two groups. The subjects enrolled in the first group of each cohort (groups 1, 3 and 5 for Cohorts 1, 2 and 3, respectively) will be sentinel subjects and will be treated one at the time at 48 h intervals in order to evaluate possible treatment-related adverse events."
16263273|NCT04932850|Placebo Comparator|Placebo|Placebo will be administered to 2 subjects for each cohort.
16263274|NCT04932837||migrant worker residents|The target population will be the 124 residents in the 2 migrant worker residences who were included in the previous seroprevalence study and those who arrived at the 2 residences since September 1st, 2020
16263275|NCT04932824|No Intervention|Subjects Without Treatment Cross-over|these subjects will not receive any vaccination during this study.
16263276|NCT04932824|Active Comparator|Subjects With Treatment Cross-over (From 1st Dose of Active Study Vaccine Onwards)|Once the treatment assignments of study CLO-SCB-2019-001 are unblinded, those subjects who have received placebo and provided there is active study vaccine available, will be given the option to receive 2 doses of active study vaccine 21 days apart (ie, treatment cross-over)
16263277|NCT04932798||High-Risk group|: Montreal Heart Institute biobank participants with a high specific genome-wide polygenic risk scores for atrial fibrillation G
16263278|NCT04932798||Low-Risk group|Montreal Heart Institute biobank participants with a low specific genome-wide polygenic risk scores for atrial fibrillation G
16263279|NCT04932785|Active Comparator|Regular Diet|Patient randomized to regular diet will begin with a regular diet.
16263280|NCT04932785|Active Comparator|Clear Liquid Diet|Patient randomized to clear liquid diet will begin with a clear liquid diet.
16263281|NCT04932772|Experimental|Group A (kinesiotaping group)|include 24 women will receive kinesiotaping combined with abdominal exercise (2sessions /week for eight weeks).
16263282|NCT04932772|Active Comparator|Group B (abdominal exercise group)|include 24 women will receive abdominal exercise only.
16263283|NCT04932759|No Intervention|control group|In the control group there will be no music listening
16263284|NCT04932759|Experimental|experimental group|In this group patients will listen to music while their dental treatments are being made.
16263285|NCT04932746|Experimental|The dexmedetomidine group:|"An initial dose of 1 mcg / kg 1 dexmedetomidine will be given 10 minutes after the start of anesthesia infusion within 10 minutes, after which the dexmedetomidine infusion is maintained at a dose of 0.4 mcg / kg / hour.
~The injection will be stopped before the skin is closed."
16263286|NCT04932746|Experimental|The Placebo group (the control group):|After the same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol.
16263287|NCT04932733|Experimental|Isometric exercise|Quadriceps isometric exercise.
16263288|NCT04932733|Active Comparator|Active exercise|Quadriceps active range of motion exercise.
16263289|NCT04932720|Experimental|experimental group|Experimental group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
16263290|NCT04932720|No Intervention|control group|Also the control group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
16263291|NCT04932707|Experimental|Study group 1|sub-occipital muscle inhibition applied plus passive stretch of hamstring muscle
16263292|NCT04932707|Experimental|Study group 2|Received neural slump sliding stretch plus passive stretch of hamstring muscle
16263293|NCT04932707|Active Comparator|control group|Received passive stretch of hamstring muscle
16263294|NCT04932694|Experimental|Study group|Core stabilization exercises will be conducted for 8 weeks, 3 sessions per day at home, and exercises will be supervised remotly.
16263295|NCT04932694|No Intervention|Control group|No exercise will be given to the participants in the control group
16263296|NCT04932681||Qualitative group|Interview about the use of Complementary and Alternative Medecine
16263297|NCT04932681||Quantitative group|Questionnaire about the use of Complementary and Alternative Medecine
16263298|NCT04932668|Experimental|Home-based Electrical Stimulation Program for lower limb spasticity|Single arm prospective intervention study to assess the feasibility and impact of a home-based program. Patient will apply home-based NMES on their leg for 20 minutes, 5 days a week for 4 weeks. At the end of the study, an outcome measures will be assessed and patient will be required to answer a questionnaires on their experience.
16263299|NCT04932655|Other|Fasted|Phase 3 simufilam 100 mg tablet dosed under fasted conditions.
16263300|NCT04932655|Other|High Fat|Phase 3 simufilam 100 mg tablet dosed 30 min after start of a high-fat meal.
16263301|NCT04932655|Other|Low Fat|Phase 3 simufilam 100 mg tablet dosed 30 min after start of a low-fat meal.
16263302|NCT04932655|Other|Phase 2 tablet|Phase 2 simufilam 100 mg tablet dosed under fasted conditions.
16263303|NCT04932642|Experimental|High-intensity interval training plus resistance training (HIIT+RT)|The HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points. Second, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of as many repetitions as possible in 60 seconds, followed by 60 to 120 seconds of passive recovery.
16263334|NCT04932382|Other|Misoprostol group|400 µg misoprostol vaginally ; these tablets will be introduced by the principal investigator, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position
16263335|NCT04932382|Other|No misoprostol group|will not receive any pre-insertion medications.
16263796|NCT04929288|Experimental|Females|Participants in this group will be adult female drinkers. Data will be segregated by menstrual cycle phase.
16263304|NCT04932642|Experimental|Resistance training plus High-intensity interval training (RT+HIIT)|Firstly, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of 60 seconds, followed by 60 to 120 seconds of passive recovery, as previously reported. Secondly, in the HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points.
16263305|NCT04932629|Experimental|Experimental Group|The eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
16263306|NCT04932616||Face To Face (Clinic) Group Functional Gait Assessment|"Evaluations to be applied for the cultural adaptation and reliability study of the scale:
~Functional Gait Assessment, Timed Up and Go Test, Four-Step Square Test, Timed 25-Foot Walk Test, 12-Item Multiple Sclerosis Walking Scale Berg Balance Scale"
16263307|NCT04932616||Tele- Assessment Group Functional Gait Assessment|"The evaluation to be applied for the tele-evaluation reliability study of the scale:
~Functional Gait Assessment"
16263308|NCT04932603||experimental|Patients with AF, hospitalized in one of the 6 geriatrics units participating in the study, aged 75 years or over, without evaluation of their antithrombotic treatment by the multidisciplinary team. The lack of review of patient's file by the multidisciplinary team is based on physician decision.
16263309|NCT04932603||Standard of care|
16263310|NCT04932590|Experimental|Patients|Patients less than 2 years old admitted in the pediatric intensive care unit of the Armand-Trousseau hospital, under invasive mechanical ventilation and in whom a volume expansion is planned by the attending physicians.
16263311|NCT04932577|Experimental|Faecal microbiota transplantation|The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.
16263312|NCT04932577|Placebo Comparator|Placebo|The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.
16263313|NCT04932564|Experimental|Leflunomide Arm|Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
16263314|NCT04932551||Physician|
16263315|NCT04932538|No Intervention|Control Group|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy.
16263316|NCT04932538|Experimental|Kinesio Taping|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy. Sessions were 40 minutes. The children in the taping group were taped 6 days per week for 4 weeks. The children were checked for allergies before applying the tape. A 5-cm tape was applied and kept in position for 3 days, and the region was then left to rest for 24 hours.
16263317|NCT04932525|Experimental|solid tumor or hematological malignancy|
16263320|NCT04932499|Active Comparator|Control group|Standard of care
16263321|NCT04932499|Experimental|Mindfulness Meditation|Mindfulness meditation in addition to standard of care
16263322|NCT04932486|Active Comparator|Transcutaneous electrical stimulation|
16263323|NCT04932486|Sham Comparator|Inactive transcutaneous electrical stimulation|
16263324|NCT04932460|Experimental|CEUS+blue dye|The included patients will accept essential tests and CEUS before and after neoadjuvant chemotherapy to evaluate axillary lymph nodes status. When patients finish neoadjuvant therapy, SLNB with or without axillary lymph node dissection will be performed using CEUS lymphatic mapping to mark SLN on the skin combined with blue dye.
16263327|NCT04932434|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately two weeks apart, with preparation sessions before and integration sessions after.
16263328|NCT04932421|Experimental|Experimental group (UP-C intervention)|UP-C intervention 15 weekly sessions, for children and parents
16263329|NCT04932421|Active Comparator|Control group (ABC of emotions intervention)|ABC of emotions - a psychoeducational intervention 5 sessions every 3 weeks for children
16263330|NCT04932408|Experimental|Hip Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed around the hip region.
~Warm up: 5-10 mins
~Exercises:
~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.
~Cool down. Post intervention- Semi-structured Interview schedule"
16263331|NCT04932408|Experimental|Chest Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).
~Warm up: 5-10 mins
~Exercises:
~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.
~Cool down. Post intervention- Semi-structured Interview schedule"
16263377|NCT04932109||Hand Injuries Group|
16263336|NCT04932369|Experimental|ER GROUP|The training sessions were based on the Dialectical Behavior Therapy Skills (Linehan, 2015). The students in the experimental conditions were divided into 10 groups, there were 10 students in each group. Each group received eight 90-min sessions of the emotion regulation training (one session per week) carried out by qualified clinical psychologists in online settings using Microsoft Teams. The training includes online group gathering, homework and telephone consultation as needed.
16263337|NCT04932369|No Intervention|Control group|they completed two assessments, 2-months apart
16263338|NCT04932356|Other|Therapeutic Education by phone|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit and then reinforcement each 15 days over the weak points of this visit.
16263339|NCT04932356|Other|Traditional Therapeutic Education|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit.
16263340|NCT04932330||ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score < 48 out of a maximal score of 60 when discharged.
16263341|NCT04932330||no ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score ≥ 48 out of a maximal score of 60 when discharged.
16263342|NCT04932304|Active Comparator|Active stimulation|Participants recieving active trancranial direct current stimulation (tDCS) Parameters: 20 minutes anodal tDCS 1mA. Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
16263343|NCT04932304|Placebo Comparator|Sham stimulation|Participants recieving passive / sham trancranial direct current stimulation (tDCS) Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
16263344|NCT04932291|Experimental|vafidemstat 1.2mg|Vafidemstat is administered as capsules.
16263345|NCT04932291|Placebo Comparator|placebo|Placebo is administered as capsules.
16263346|NCT04932278|Active Comparator|Usual Care Group|Participants in this group will receive routine care for the management and treatment of concussions
16263347|NCT04932278|Experimental|OMT Group|Participants who are randomized into OMT group will receive OMT in addition to their usual care.
16263348|NCT04932265|Active Comparator|Red ginseng HRG80|16 subjects will receive 200 mg of red ginseng preparation HRG80 in one capsule
16263349|NCT04932265|Experimental|Red ginseng HRG80 incorporated in gamma-cyclodextrin|16 subjects will receive 200 mg of red ginseng preparation HRG80 incorporated in gamma-cyclodextrin in two chewable tablets
16263350|NCT04932252|Experimental|A4368 - Dose 1|Single dose of A4368 or placebo tablet, orally administered
16263351|NCT04932252|Experimental|A4368 - Dose 2|Single dose of A4368 or placebo tablet, orally administered
16263352|NCT04932252|Experimental|A4368 - Dose 3|Single dose of A4368 or placebo tablet, orally administered
16263353|NCT04932252|Experimental|A4368 - Dose 4|Single dose of A4368 or placebo tablet, orally administered
16263354|NCT04932252|Experimental|A4368 - Dose 5|Single dose of A4368 or placebo tablet, orally administered
16263355|NCT04932252|Experimental|A4368 - Dose 6|Single dose of A4368 or placebo tablet, orally administered
16263356|NCT04932252|Experimental|A4368 - Dose 1 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
16263357|NCT04932252|Experimental|A4368 - Dose 2 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
16263358|NCT04932239|Experimental|Road traffic crashes first aid education module|It is an education module aiming to address the topics related to first aid: Recognizing emergency, Call for help, Scene safety, Airway and breathing, Haemorrhage control, First aid kit, Immobilization of fractures and transport of injured people.
16263359|NCT04932239|Placebo Comparator|Tuberculosis prevention education module|This education module covers the definition of the disease, types ways of prevention in working place, and its management
16263360|NCT04932226|Other|All participants|Each participant is his/her own control. Each will have all four interventions in random order.
16263361|NCT04932213|Active Comparator|Tropicamide 0.5%|This group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.
16263362|NCT04932213|Active Comparator|Tropicamide 1%|This group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.
16263363|NCT04932200||urgent-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy < 6 hours
16263364|NCT04932200||early-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy between 6 and 24 hours
16263365|NCT04932187|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
16263366|NCT04932174|Experimental|High-intensity Interval Training|Group 2: the included 15 subjects will participate in High intensity Interval training exercise running on treadmill for 12 weeks, 3 times / week.
16263367|NCT04932174|Active Comparator|Low-intensity Continuous Training|Group 1: the included 15 subjects will participate in low intensity continuous exercise on treadmill for 12 weeks, 3 times / week
16263368|NCT04932161|Experimental|Titanium Granules as a bone graft in intrabony defects|In test group, after reflection of flap and degranulation, bone graft i.e., titanium particles will be placed in the void created by the defect and sutures will be placed.
16263369|NCT04932161|Active Comparator|Hydroxyapatite as a bone graft in intrabony defects|In control group, after reflection of flap and degranulation, bone graft i.e., hydroxyapatite will be placed in the defect and sutures will be placed.
16263370|NCT04932148|Experimental|Incremental HD|Participants randomised to incremental HD will commence HD twice weekly and continue until an indication for an increase to three sessions/week (trigger point) is reached.
16263371|NCT04932148|Other|Conventional HD|Participants randomised to conventional HD will commence HD thrice weekly from the first HD session.
16263372|NCT04932135||Group Treatment|Patients with newly diagnosed hyperthyroidism due to Graves' disease, if anti thyroid drug treatment is planned.
16263373|NCT04932135||Group Surveillance|Patients suffering from Graves' disease in whom discontinuation of the anti-thyroid therapy is planned.
16263374|NCT04932122|Active Comparator|Dorsal wrist ganglion alone (DWG)|Dorsal wrist ganglion excision alone
16263375|NCT04932122|Active Comparator|DWG with PIN|Dorsal wrist ganglion excision with posterior interosseus neurectomy (PIN)
16263376|NCT04932109||Healthy Group|
16263378|NCT04932096|Experimental|Melatonin and sleep plan|(melatonin doses of 1mg, 3mg, or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days) and sleep management plan based on patient age
16263379|NCT04932096|Placebo Comparator|Placebo|Placebo and standard care
16263380|NCT04932083|Placebo Comparator|Bupivacaine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml sterile water.
16263381|NCT04932083|Experimental|Fentanyl|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml fentanyl (25µg).
16263382|NCT04932083|Experimental|Nalbuphine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water.
16263383|NCT04932083|Experimental|Midazolam|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 2mg of midazolam in 0.5 ml sterile water.
16263384|NCT04932070|Experimental|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
16263390|NCT04932044|Experimental|Early Sleep Facilitation Program|Perform sleep circadian rhythm training during hospitalization, and provide caregivers with nursing guidance to promote sleep of premature infants before discharge
16263391|NCT04932044|Active Comparator|routine care and provide general discharge care and nursing guidance|Routine care and provide general discharge care and nursing guidance.
16263392|NCT04932031||Study group|Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel
16263393|NCT04932018|Experimental|Interventional|The intervention group will participate in a round table educational session with a study facilitator/mentor farmer and occupational health nurse plus receive an invitation to participate in an interactive virtual community providing ongoing resources and support from community farmers and agriculture experts.
16263394|NCT04932018|Sham Comparator|Attention Control|The second group (attention control) will receive an invitation to participate in the virtual community without mentor interaction.
16263395|NCT04932005|Experimental|DZD2269|This study includes three parts. In Part A, a single dose of DZD2269 at different dose levels will be given. In Part B, a single dose of DZD2269 at a selected dose level will be given in 2 treatment periods (under fasted conditions or after a low fat meal). In Part C, DZD2269 at selected dose levels will be given once or twice daily for 7 days.
16263396|NCT04932005|Placebo Comparator|Placebo|In Part A, a single oral dose of placebo will be given. In Part C, placebo will be given once or twice daily for 7 days.
16263397|NCT04931992||Molecular relapse|Confirmed molecular relapse, without overt cytological relapse
16263398|NCT04931992||Cytological relapse|Overt cytological relapse, without prior molecular relapse
16263399|NCT04931992||Persistent responders|No molecular or cytological relapse during follow-up
16263400|NCT04931979|Experimental|Treatment|Pembrolizumab 200mg i.v. three-weekly in combination with salvage radiation therapy (SRT) according to standard of care
16263401|NCT04931966|Active Comparator|Group A|Adductor canal block
16263402|NCT04931966|Active Comparator|Group B|Adductor canal block plus IPACK
16263403|NCT04931966|Active Comparator|Group C|Adductor canal block plus PAI
16263404|NCT04931953|Active Comparator|Group 1|iTBS intervention lasting 30 minutes, given 4 days a week, for 1 week
16263405|NCT04931953|Active Comparator|Group 2|iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks
16263406|NCT04931953|Active Comparator|Group 3|iTBS intervention lasting 30 minutes, given 4 days a week, for 4 weeks
16263407|NCT04931953|Sham Comparator|Group 4|Sham iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks.
16263408|NCT04931940|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
16263409|NCT04931940|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
16263410|NCT04931927|Active Comparator|Control|Participants and clinicians randomized to treatment as usual (TAU)
16263411|NCT04931927|Experimental|MCI-T|Participants and clinicians randomized to the Making Connections Intervention-Telehealth (MCI-T) plus treatment as usual (TAU)
16263412|NCT04931914||Group c|Patients admitted from June 9, 2020 to june 31, 2021.
16263413|NCT04931901|Experimental|Stimpod NMX450X|
16263414|NCT04931901|Active Comparator|Datex-Ohmeda E-NMT|
16263415|NCT04931888|Experimental|Intervention|The intervention arm will receive the EMPOWER curriculum between the pre- and post-evaluations.
16263416|NCT04931888|Other|Waitlist|"The waitlist control arm will receive the EMPOWER curriculum after the evaluations. They will receive a second set of evaluations at the same time as the post evaluations of the control arm."
16263417|NCT04931875||Total-body PET/CT (uExplorer)|The diagnostic value of dynamic parameters(K1、Ki etc) to evaluate the prognosis of lymphoma compared to the static ones(SUV、MTV、TLG etc).
16263418|NCT04931862|Experimental|WVE-004 (Dose A) or placebo|
16263419|NCT04931862|Experimental|WVE-004 (Dose B) or placebo|
16263420|NCT04931862|Experimental|WVE-004 (Dose C) or placebo|
16263421|NCT04931862|Experimental|WVE-004 (Dose D) or placebo|
16263422|NCT04931849|Experimental|Experimental: Avatrombopag|Avatrombopag 40 mg daily by mouth (PO)
16263423|NCT04931836|Experimental|Experimental Group|Participants in this group will complete the physical activity intervention.
16263424|NCT04931836|No Intervention|Control Group|Participants in this group will be asked to maintain their normal level of physical activity.
16263459|NCT04931615|Placebo Comparator|without ARTISS|Surgery performed without active comparative
16263460|NCT04931615|Active Comparator|with ARTISS|Surgery performed with active comparative
16263425|NCT04931823|Experimental|Part A: Dose Escalation|"CPO-100 administered intravenously
~At Dose Level 1 & 2: 2 patients will be enrolled. Cohort(s) may be expanded up to 6 patients if a Dose Limiting Toxicity (DLT) occurs within the first 4 weeks after first dosing.
~At Dose Level 3 - 7: 3-6 patients will be enrolled. Cohort(s) will be expanded up to 6 patients if a DLT occurs within the first 4 weeks after first dosing.
~Dose escalation will end once the maximum tolerated dose (MTD) has been reached. Once the MTD is identified, a recommended Phase 2 dose (RP2D) will be chosen based on accumulated PK, safety data, and further assessed in Part B dose expansion cohorts in patients with advanced solid tumors."
16263426|NCT04931823|Experimental|Part B: Cohort 1|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced solid tumors of gastric, head and neck, lung, and ovarian.
16263427|NCT04931823|Experimental|Part B: Cohort 2|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced breast cancer.
16263428|NCT04931823|Experimental|Part B: Cohort 3|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced prostate cancer.
16263429|NCT04931823|Experimental|Part B: Cohort 4|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with either ovarian or/and breast cancer who have failed prior taxane treatment (ie, either progressed on a taxane regimen or within 6 months of receiving a taxane regimen).
16263430|NCT04931810|Experimental|All Nations Breath of Life|ANBL is a culturally tailored smoking cessation program that incorporates group-based and individual counseling. Participants may elect to take pharmacotherapy, but are not required to do so.
16263431|NCT04931797|Experimental|Video|Video decision aid and advance care planning discussion
16263432|NCT04931797|Active Comparator|Control arm|A standardized written form that details advance care planning options.
16263433|NCT04931784|Active Comparator|Nitrate Group|with administration of intra-coronary nitrate before percutaneous coronary intervention
16263434|NCT04931784|Placebo Comparator|Control Group|without administration of intra-coronary nitrate before percutaneous coronary intervention
16263435|NCT04931771|Experimental|vFFR guided revascularization|
16263436|NCT04931771|Active Comparator|FFR guided revascularization|
16263437|NCT04931758||Patients with low back pain|
16263438|NCT04931758||Controls|
16263442|NCT04931732||Diagnosis|
16263443|NCT04931732||Relapse|
16263444|NCT04931719|Active Comparator|the PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
16263445|NCT04931719|Experimental|the PRP+HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
16263446|NCT04931706||N-Sleve patients|Patient that were selected for surgery
16263447|NCT04931693|Active Comparator|control|conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg and atracurium top ups at a dose of 0.1mg/kg. every 30 minutes.
16263448|NCT04931693|Active Comparator|PECs|Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block and atracurium top ups upon request.
16263449|NCT04931680||Patients with treatment success|"Patients with diagnosis of confirmed or clinical scabies and treatment success"
16263450|NCT04931680||Patients with treatment failure|"Patients with diagnosis of confirmed or clinical scabies and treatment failure"
16263451|NCT04931667|Experimental|0.07 mg Lorecivivint|One intra-articular injection of 0.07 mg Lorecivivint in 2 ml vehicle in one or both knees as clinically indicated. Bilateral injection of 0.07 mg LOR are allowed.
16263455|NCT04931641|Experimental|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g galacto-oligosaccharides|
16263456|NCT04931641|Placebo Comparator|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g maltodextrin|
16263457|NCT04931628|Active Comparator|salvianolic acid group|salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
16263458|NCT04931628|Placebo Comparator|0.9% NaCl|0.9%NaCl 250ml, injection, 14 days
16263461|NCT04931602||Model A|"Patients will be followed-up at bone, endocrine and rheumatology clinic after discharge depending upon availability of the consultant. Multifaceted risk-factor assessment for identifying patients at risk will be conducted including formal future fracture risk assessment/life style/medication review and fall risk assessment.
~Comprehensive laboratory designed package including calcium (Ca), albumin (ALB), phosphate (P), bone alkaline phosphatase (BAP), C terminal peptide of type 1 collagen (CTx), vitamin D (25OHD) and intact parathyroid hormone (iPTH) will be performed at first clinic visit for all patients between 6-8 weeks post fracture. Screening for secondary causes of osteoporosis will be conducted for those identified in need. BMD testing as per guidelines for patients with fragility fractures will be conducted at clinic visit and recorded with risk assessment form (12)."
16263462|NCT04931602||Model B|All routine intervention except treatment initiation-the responsibility of patient's general practitioner for prevention of secondary fracture. Those included in this intervention arm, will be identified and risk assessment will be performed at hospital admission. Recommendations for the treatment will be made to be initiated by the patient's general physician. Patients will be followed at 6 months on telephone, and a questionnaire related to treatment compliance &/or non-compliance will be filled by the coordinator.
16263463|NCT04931602||Model C|Health education only provided at the time of admission with handover to family physician for follow-up. Patients will be given an appointment to follow-up at community health center of Aga Khan University
16263464|NCT04931602||Model D|Health Education provided. There is no physician contact with the person's general practitioner for prevention of secondary fracture. Education material for the patient have been prepared and will be provided to patient along with counselling by the nurse at the time of discharge
16263465|NCT04931576|No Intervention|Routine application of drainage tube|After TOETVA, patients will receive one drainage tube through anterior cervical area.
16263466|NCT04931576|Experimental|Omission of drainage tube|After TOETVA, patients will receive complete omission of drianage tube and directly close the incision.
16263469|NCT04931524|Experimental|carbon-14-[14C]-ANG-3777|Administered IV as a single dose over 30 minutes on the morning of Day 1 following an 8 hour overnight fast and remain in the clinical unit until up to 168 hours after dosing (to Day 8). If mass balance criteria have not been met on Day 8, the clinical unit residency may be extended up to an additional 96 hours (to Day 12).
16263470|NCT04931511|Experimental|Gluteal muscle injection plus physical therapy group|Gluteal muscle injection (corticosteroid 1ml+sodium chloride 4ml) Subacromial Ultrasound Guided injection (sodium chloride 5ml) Physical therapy
16263471|NCT04931511|Experimental|Subacromial Ultrasound Guided injection plus physical therapy group|Gluteal muscle injection(sodium chloride 5ml)) Subacromial Ultrasound Guided injection(corticosteroid 1ml+sodium chloride 4ml) Physical therapy
16263472|NCT04931498||GMPR sub-study|Study population will be split into five haplotypes based on a combination of rare and common variants at the GMPR locus. A total of 26 volunteers per genotypic group in a comparison between heterozygous and homozygous individuals will be tested.
16263473|NCT04931498||SWAP70 sub-study|To assess genotype-specific effects on SWAP70 protein levels as well as coronary artery disease-related immune processes, we will recruit 50 volunteers stratified by variant genotype, i.e. major and minor homozygotes only (25 participants will be recruited to each group).
16263474|NCT04931485|Experimental|Intervention: REDUCE Protocol|Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.
16263475|NCT04931485|Active Comparator|Standard of Care|Fluid resuscitation and de-resuscitation according to the standard of care
16263478|NCT04931446||Gastroenteropancreatic neuroendocrine neoplasms|
16263479|NCT04931433|Experimental|Lignocaine|This arm will receive intravenous Lignocaine bolus and infusion
16263480|NCT04931433|Placebo Comparator|Placebo|This arm will receive Normal saline 0.9% bolus and infusion
16263481|NCT04931420|Experimental|Arm A - Participants Who Receive Sequential Procedures|"All participants in this arm will receive standard of care chemotherapy based on the particular type of gastrointestinal cancer they have for three months. Afterward, based on how the participant's cancer responds to chemotherapy, the participant will receive additional sequential procedures to remove or destroy the remaining tumors present in their body.
~These procedures can include surgery, radiation or ablation (a minimally invasive, needle-based treatment that uses extreme hot or cold temperatures created by radiation to kill targeted spots of cancer cells without damaging surrounding organs in the body).
~If you're selected to be in this arm, the type of procedure you receive will vary based on your cancer and what the study doctor recommends for treatment."
16263482|NCT04931420|Other|Arm B (Control) - Participants Who Receive Standard of Care Treatment|Participants in this arm receive the current standard of care treatment for their specific type of gastrointestinal cancer. This treatment may include the continuation of chemotherapy and a few procedures which may improve your quality of life.
16263483|NCT04931407|Experimental|Interdiciplinary complex intervention|The intervention includes patient education, physical exercise, a group-based cognitive behavioral program and individual nutritional counseling
16263484|NCT04931394|Experimental|Organoid-Guided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
16263591|NCT04930679|Experimental|Group II|2 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
16263797|NCT04929275|Other|Enhanced recovery program|
16263485|NCT04931394|No Intervention|Physician-decided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
16263486|NCT04931381|Experimental|Organoid-Guided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
16263487|NCT04931381|No Intervention|Physician-decided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
16263488|NCT04931368|Active Comparator|Control treatment (Arm A)|Patients receive four courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) as induction treatment. Response assessment with gadolinium-enhanced brain MRI (centrally reviewed) takes place after course two and four. Patient with at least PR proceed to 3rd course of MATRix after first response assessment and to HCT-ASCT (BCNU 400 mg/m2, Thiotepa 4 x 5 mg/kg; i.v.) after second response assessment. Collection of autologous stem cells is planed after the second course of MATRix.
16263489|NCT04931368|Experimental|Experimental treatment (Arm B)|As induction treatment, patients receive one course of Rituximab/HD-Methotrexate (Rituximab 375 mg/m2, HD-Methotrexate 3.5 g/m2; i.v.). In the absence of clinical signs of progression, patients proceed to two courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) followed by a response assessment with gadolinium-enhanced brain MRI (centrally reviewed). Patients with at least PR will proceed to HCT-ASCT (BCNU 400 mg/m2, thiotepa 4 x 5 mg/kg; i.v.). Collection of autologous stem cells is planed after the first course of MATRix
16263490|NCT04931355|Experimental|Acupuncture treatment group|Method: Acupuncture at Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi. The acupuncture treatment starts on the 5th day of the menstrual cycle and lasts to the days before IVF-ET
16263491|NCT04931355|Active Comparator|Western medicine group|The western medicine group will be treated with conventional western medicine
16263492|NCT04931342|Experimental|Ipatasertib + Paclitaxel|Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
16263493|NCT04931342|Experimental|Cobimetinib|Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
16263494|NCT04931342|Experimental|Trastuzumab Emtansine|Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
16263495|NCT04931342|Experimental|Atezolizumab + Bevacizumab|Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16263496|NCT04931303||Study Group|Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.
16263497|NCT04931277|Other|stepped cataract surgery|
16263498|NCT04931264|Experimental|YuWell YE660D and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE660D Electronic Sphygmomanometer (YuWell YE660D) and with Desk Mercury Sphygmomanometer.
16263502|NCT04931225|Experimental|Landiolol injection|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
16263503|NCT04931225|No Intervention|Usual tachycardia management|No treatment, usual tachycardia management.
16263504|NCT04931212|Experimental|Intervention|
16263505|NCT04931199|Active Comparator|CBT|
16263506|NCT04931199|Experimental|CBT+App|
16263507|NCT04931186||all patients|
16263592|NCT04930653|Experimental|Treatment (ECP, mogamulizumab)|Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
16263508|NCT04931173|Active Comparator|Group A: IV and Oral antibiotics (IVA+OA)|Patients will receive cefazolin 2g IV and metronidazole 500 mg IV administered by the anesthesiologist within 60 minutes prior to the skin incision on the day of surgery. Standardized re-dosing of cefazolin 2g IV will occur every 4 hours and metronidazole 500 mg IV will occur every 8 hours during the surgical procedure. Following surgery, no further IVA will be given for SSI prophylaxis. In addition, patients will self-administer 1g neomycin and 1g metronidazole orally at 1500, 1700 and 2300 hours the day before surgery. Following this, they will not receive any further OAs for SSI prophylaxis.
16263509|NCT04931173|Active Comparator|Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)|Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
16263510|NCT04931160|Active Comparator|Sjögren patients|patients diagnosed Sjögren
16263511|NCT04931160|Other|Non-Sjögren witnesses|patients diagnosed no Sjögren
16263512|NCT04931147|Experimental|Part A SAD - Cohort 1|This is the first treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive 2 mg of RXC007 on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263513|NCT04931147|Experimental|Part A SAD - Cohort 2|This is the second treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Cohort 1 Dose Escalation Data Review) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263514|NCT04931147|Experimental|Part A SAD - Cohort 3|This is the third treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263515|NCT04931147|Experimental|Part A SAD - Cohort 4|This is the fourth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263516|NCT04931147|Experimental|Part A SAD - Cohort 5|This is the fifth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263517|NCT04931147|Experimental|Part A SAD - Cohort 6|This is the sixth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263518|NCT04931147|Experimental|Part A SAD - Optional Cohort 7|This is an optional seventh treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263519|NCT04931147|Experimental|Part A SAD - Optional Cohort 8|This is an optional eighth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
16263520|NCT04931147|Experimental|Part B MAD - Cohort 1|This is the first treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
16263521|NCT04931147|Experimental|Part B MAD - Cohort 2|This is the second treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD and previous MAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
16263522|NCT04931147|Experimental|Part B MAD - Optional Cohort 3|This is an optional third treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
16263523|NCT04931147|Experimental|Part B MAD - Optional Cohort 4|This is an optional fourth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
16263524|NCT04931134|Experimental|Active stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.
~Trigeminal nerve stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Active stimulation will occur at 120 Hz with a 250 µs pulse width and with a duty cycle of 30 seconds on to 30 seconds off."
16263593|NCT04930640|Experimental|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 1x10^9 CFU/day, GF101 200 U/day)]
16263594|NCT04930640|Placebo Comparator|placebo group|1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 0 CFU/day, GF101 0 U/day)]
16263595|NCT04930627|Experimental|oral administration of Empagliflozin|
16263525|NCT04931134|Sham Comparator|Sham stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.
~Sham stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Sham stimulation will use the same parameters of active stimulation, but after 60 seconds the stimulator will turn off."
16263526|NCT04931121||Osteoarthritic patients|Subjects are patients referred for knee osteoarthritis and treated with an hyaluronic acid injection (viscosupplementation)
16263527|NCT04931108|Experimental|Sequence 1|One pill of nitrendipine/atenolol combination (5/10mg) once daily for 6 weeks first, and followed by monotherapy for another 6 weeks, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily.
16263528|NCT04931108|Experimental|Sequence 2|Monotherapy for 6 weeks first, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily, followed by one pill of nitrendipine/atenolol combination (5/10mg) once daily for another 6 weeks.
16263529|NCT04931095|Placebo Comparator|Placebo cannabis + placebo alcohol|Participants administer oral cannabis containing 0mg THC in combination with a placebo alcohol drink.
16263530|NCT04931095|Experimental|low dose cannabis with placebo alcohol|Participants administer oral cannabis containing 10mg THC in combination with a placebo alcohol drink.
16263531|NCT04931095|Experimental|high dose cannabis with placebo alcohol|Participants administer oral cannabis containing 25mg THC in combination with a placebo alcohol drink.
16263532|NCT04931095|Experimental|low dose cannabis with low dose alcohol|Participants administer oral cannabis containing 10mg THC in combination with an alcohol drink (0.05 percent BAC).
16263533|NCT04931095|Experimental|high dose cannabis with low dose alcohol|Participants administer oral cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
16263534|NCT04931095|Experimental|Placebo cannabis + low dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
16263535|NCT04931095|Experimental|Placebo cannabis + high dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
16263536|NCT04931082|Active Comparator|Probiotics|One capsule per day for 12 weeks
16263537|NCT04931082|Placebo Comparator|Placebo|One capsule per day for 12 weeks
16263538|NCT04931069|Experimental|Microbiota analysis|Mircobiota analysis on blood, stool and saliva and bile, pancreatic and intestinal mucosa samples
16263542|NCT04931030|Experimental|Low carbohydrate diet (LCBD)|Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
16263543|NCT04931030|No Intervention|Low protein diet only (LPD)|Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.
16263544|NCT04931017|Experimental|Cohort A (metformin ER)|Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity.
16263545|NCT04931017|Active Comparator|Cohort B (metformin ER with waiting period))|Participants receive no intervention for 26 weeks, then cross-over to Cohort A.
16263546|NCT04931004|Experimental|0.075% Cetylpyridinium Chloride|
16263547|NCT04931004|Experimental|1.5% Hydrogen peroxide|
16263548|NCT04931004|Experimental|Chlorhexidine gluconate|
16263549|NCT04931004|Placebo Comparator|Water rinse|Control for impact on viral load changes from mechanical rinsing
16263550|NCT04930991|Experimental|Arm A (High Dose)|Omeprazole, 80 mg, PO, BID for 2 weeks prior to surgical therapy of pancreatectomy. All 30 subjects in Arm A to be enrolled prior to Arm B cohort enrollment.
16263551|NCT04930991|Placebo Comparator|Arm B (Normal Dose)|Omeprazole, 20 mg, PO, QD for 2 weeks prior to surgical therapy of pancreatectomy.
16263552|NCT04930978||TB patients with SARS-CoV-2 PCR+|50 TB patients with SARS-CoV-2 PCR+ will be recruited in group 1
16263553|NCT04930978||TB patients with SARS-CoV-2 Ab+|100 TB patients with SARS-CoV-2 Ab+ will be recruited in group 2
16263554|NCT04930978||TB patients negative for SARS-CoV-2 PCR and Ab|100 TB patients with SARS-CoV-2 PCR and Ab negative will be recruited in group 3
16263555|NCT04930965|Experimental|Intervention|
16263556|NCT04930965|No Intervention|Usual care|
16263557|NCT04930939|Experimental|Heart rate variability-guided training group|Patients allocated to heart rate variability-guided training group trained 3 days a week for 6 weeks. These patients carried out moderate continuous traininig sessions or high intensity interval training sessions based on their daily heart rate variability assessments follwing a decision schema.
16263558|NCT04930939|Active Comparator|Predefined training group|Patients allocated to predefined training group also trained 3 days a week for 6 weeks. Nonetheless, these patients performed a predefined training program regarless of their parasympathetic modulation status.
16263559|NCT04930926||INFECTION DISEASE PATIENTS WITH PNEUMONIA OR SARHS COVID19|NO SPECIFIC INTERVENTION
16263560|NCT04930900|Experimental|ARS-1 with URTI|ARS-1 with URTI
16263561|NCT04930900|Experimental|ARS-1 without URTI|ARS-1 without URTI
16263562|NCT04930887|Experimental|Exparel, Then Saline|Participants first received an endoscopically guided injection of Exparel (Bupivacaine). After 3 weeks they then received Placebo treatment (Saline).
16263563|NCT04930887|Experimental|Saline, Then Exparel|Participants first received Placebo treatment (Saline). After 3 weeks they then received an endoscopically guided injection of Exparel (Bupivacaine).
16263564|NCT04930874|Experimental|ICU patients with COVID-19|NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.
16263565|NCT04930861|Experimental|Covidir|Patient (adults aged ≥18 years) with mild or moderate COVID-19 and flu-symptoms onset within 72 hours prior to inclusion. Treatment begins at the hospital. On the 4th day, participants who are well will be discharged and continue treatment up to Day 10 at home. All participants will receive Codivir 20 mg SC 2 x daily.
16263566|NCT04930848|Experimental|Intervention Arm|Euphorbia hirta
16263567|NCT04930848|Placebo Comparator|Placebo Arm|Terminalia arjuna and Terminalia bellerica
16263568|NCT04930835|Active Comparator|Conventional Loading|implants are loaded at least after two months of healing
16263569|NCT04930835|Experimental|Immediate Loading|implants are loaded the same day of surgery
16263570|NCT04930822|Active Comparator|Table Top Visual Intervention|Interventions will include six, 20 minute sessions using pen and paper word search, scanning activities, and saccade visual training. All activities will be conducted with an occupational therapist/investigator.
16263571|NCT04930822|Experimental|Bioness Integrated Therapy System Visual Intervention|Intervention will includes six sessions using the Bioness Integrated Therapy System for 20 minutes using the programs of visual scanning, visual pursuits and/or visual motor.All activities will be conducted with an occupational therapist/investigator.
16263572|NCT04930809|Experimental|VER-01 single dose (2.5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 2.5 mg THC (Group A).
16263573|NCT04930809|Experimental|VER-01 single dose (5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 5 mg THC (Group B).
16263574|NCT04930809|Experimental|VER-01 single dose (10 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 10 mg THC (Group C).
16263575|NCT04930809|Experimental|VER-01 single dose (20 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 20 mg THC (Group D).
16263576|NCT04930809|Experimental|VER-01 multiple dose (5 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 5 mg THC in the morning and 5 mg THC in the evening on 4 consecutive days (Group E).
16263577|NCT04930809|Experimental|VER-01 multiple dose (10 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 10 mg THC in the morning and 10 mg THC in the evening on 4 consecutive days (Group F).
16263578|NCT04930809|Experimental|VER-01 multiple dose (12.5 / 20 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 12.5 mg THC in the morning and 20.5 mg THC in the evening on 4 consecutive days (Group F).
16263579|NCT04930796|Experimental|VER-01 following overnight fast (Day 1) and a high-fat breakfast (Day 4)|The PK profile of VER-01 is investigated after oral intake of a single dose VER-01 (corresponding to 10 mg THC) in the morning after a 10-hour fasting period on day 1, and 30 minutes after the intake of a standardised high-fat breakfast has been started on day 4 (Group 1).
16263580|NCT04930796|Experimental|VER-01 following a high-fat breakfast (Day 1) and overnight fast (Day 4)|The PK profile of VER-01 is investigated after oral intake of a single dose VER-01 (corresponding to 10 mg THC) in the morning 30 minutes after the intake of a standardised high-fat breakfast has been started on day 1 and after a 10-hour fasting period on day 4 (Group 2).
16263581|NCT04930783|Experimental|CDX-301 + Neovax + Nivolumab|"Participants will undergo metastatic tumor biopsy with vaccine made from collected tissue.
~Participants will receive Nivolumab at a flat dose every 4 weeks up to two years.
~Participants will receive CDX-301 at a predetermined dose dependent on the number of participants previously enrolled for 5 days starting 2 days before the initiation of NeoVax. CDX-301 will then be administered at a predetermined dose dependent on the number of participants previously enrolled 2 days before and for 5 days coinciding with the administration of NeoVax on days 50 and 78."
16263582|NCT04930770|Experimental|Renal/renopancreatic transplant's patients with a verified seronegativity|
16263583|NCT04930757||Patients with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.|Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.
16263584|NCT04930744|Active Comparator|Standard Tuberculosis Medicine|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months.
16263585|NCT04930744|Experimental|Standard TB Medicines and Metformin|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months. For this arm, they will also take Metformin hydrochloride one 500 mg tablet daily starting one week after the initiation of tuberculosis medicines, then increasing to one 500 mg table twice daily through study week-12 for a total 11 weeks of metformin exposure.
16263586|NCT04930718|Active Comparator|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life;
16263587|NCT04930718|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise home program with a laptop.
16263589|NCT04930692|Experimental|Preoperative SLNs mapping provided by CT-lymphography method|Sentinel lymph nodes will be mapped by contrast-enhanced CT lymphography in breast cancer patients. A mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride will be used as a contrast agent provided by periaoreolar injection. No later than 10 days after the CT lymphography patients will receive surgical treatment with sentinel lymph node biopsy using the ICG-fluorescence method.
16263590|NCT04930679|Experimental|Group I|1 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
16263597|NCT04930575|Experimental|Muscle Energy Technique group|"Patients in the group (B) will receive muscle energy technique on tonic muscles in the neck (sternocleidomastoid, scalenes, levator scapulae, and upper trapezius) in addition to strengthening exercise for deep cervical flexors and advice to correct positions three times per week for 4 weeks.
~The aim of the Muscle Energy Technique in the context of NP is to decrease pain, improve movement, motor control, and function and thereby reduce disability.
~A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body thus alleviating the patient's signs and symptoms."
16263598|NCT04930575|Experimental|Mulligan Technique group|Patient in group A will receive specialized SNAGs technique adapted from Mulligan (2005), in addition to strengthening exercise for DNF muscles and advice to correct position three times per week for 4 weeks.
16263599|NCT04930562|Experimental|200mg qd|200mg qd po.
16263602|NCT04930536|Experimental|Acalabrutinib Capsule|Single-arm study
16263603|NCT04930523|Active Comparator|Decompression|It include the pre- Physiotherapy treatment than decompression and post physiotherapy treatment.
16263604|NCT04930523|Experimental|Experimental|It includes the Pre physiotherapy treatment than ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precaution and Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) then Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes and at last Post physiotherapy treatment
16263605|NCT04930510||Group 1 : Elderly 80 years or over patients referred for TAVI with CAD|Elderly 80 years or over patients referred for TAVI with CAD Group 1: Coronary lesion defined as significant (>50% narrowing) on the coronary angiography performed before TAVI, with or without PCI (decision of the heart team) Description of the coronary lesions included: proximal/non proximal, number of lesions, location of lesion
16263606|NCT04930510||Group 2 : No significant coronary disease group|No significant coronary disease group in the cohort of elderly 80 years or over referred for TAVI
16263607|NCT04930497|Experimental|vestibular socket technique with bone grafting|
16263608|NCT04930497|Active Comparator|vestibular socket technique without bone grafting|
16263609|NCT04930471||Metformin (all participants)|Patients with a new indication for Metformin (standard dosage as assigned by the treating physician) therapy. Samples will be collected before and after 12 weeks of Metformin treatment.
16263610|NCT04930458|Experimental|Nanosilver fluoride group|Nanosilver fluoride will be applied on carious lesion
16263611|NCT04930458|Active Comparator|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate group|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate will be applied on carios lesion
16263612|NCT04930458|Active Comparator|Sodium fluoride varnish group|Sodium fluoride varnish will be applied on carios lesion
16263613|NCT04930445||Oxbryta Product Registry|
16263614|NCT04930432|Experimental|MCLA-129|In the dose escalation phase 1 part, MCLA-129 will be administered every two weeks with increasing doses to patients with advanced solid tumors. In Part 2, patients with NSCLC and other advanced solid tumors in each corhort will be dosed with MCLA-129 every two weeks at the RP2D.
16263615|NCT04930419|Other|Videolaryngoscopy group|
16263616|NCT04930419|Other|Direct laryngoscopy group|
16263617|NCT04930406||Historical control group|
16263618|NCT04930406||Intervention group|
16263619|NCT04930393|Active Comparator|PECS II Block|This group will receive an interscalene block in addition to a pectoral nerve block under ultrasound guidance with local anesthetic injected in the plane between the pectoralis minor and serratus anterior muscles
16263620|NCT04930393|Active Comparator|Axillary Ring Block|This group will receive an interscalene block in addition to a ring block with local anesthetic injected subcutaneously along the axilla from anterior to posterior direction.
16263621|NCT04930380||Cases|"male and female aged 25 years or more
~diagnosis of defined MS
~written informed consent must be obtained before the enrolment."
16263622|NCT04930380||Controls|"male and female aged 25 years or more
~written informed consent must be obtained before the enrolment no history of MS"
16263623|NCT04930367|Active Comparator|Enhanced Standard of Care|To be implemented at all 12 clinic sites, includes a set of interventions aimed at optimizing the national standard of care (billboards/posters and radio shows, healthcare worker training, one-stop adolescent and youth friendly services, information/motivation walls, pill containers and tools to be used by clinic staff during clinical visits)
16263624|NCT04930367|Experimental|CombinADO Strategy|"To be implemented at 6 randomly selected clinic sites, includes all interventions in the Enhanced Standard of Care arm plus five additional intervention components, including 1) Mental health screening and linkage to adolescent-focused mental health support, 2) peer navigation support, 3) an informational video, 4) peer support groups for AYAHIV and 5) support groups for caregivers of AYAHIV"
16263625|NCT04930354|Experimental|Single arm|Single arm dose escalation study; ECP1014 oral capsule of10mg, 20mg, 40mg, 80mg and 160mg given once daily for 28 days
16263626|NCT04930341|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
16263627|NCT04930341|No Intervention|Control group|Routine maintenance will be applied
16263629|NCT04930315|Experimental|neoadjuvant and adjuvant group|Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles
16263630|NCT04930315|Active Comparator|adjuvant group|Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles
16263631|NCT04930289||LungGuard patients|Patients whose donor lung(s) was transported with the LungGuard device.
16263632|NCT04930289||Standard Transport Patients|Patients whose donor lung(s) was transported with a method other than the LungGuard
16263798|NCT04929262|Active Comparator|Researcher-Only|The researcher-facilitated presentation, led by two clinical psychology graduate students, will be the same for all schools.
16290851|NCT04739826||flumatinib|flumatinib 600mg QD, fasting administration
16263633|NCT04930276|Experimental|GDM group|After participants are enrolled, they would be given medical nutrient treatment. Besides, they need have a follow-up visit every two weeks. Blood glucose, body weight, lifestyle and clinical information are collected. Blood samples and stool samples are collected in 28 and 32 pregnant weeks, respectively.
16263634|NCT04930276|Other|non-GDM group|After participants enrollment, they also would be given medical nutrient treatment. And the other conditions are same as the group of GDM.
16263635|NCT04930263|Experimental|walking exercise|"Behavioral: walking exercise
~The intervention was 24 weeks walking intervention program
~5 sessions a week for 30 minutes per section
~walking exercise with moderate-intensity
~wearable device assisted."
16263636|NCT04930263|Active Comparator|Balanced life|Given a balanced life health education manual for the participants.
16263637|NCT04930250|Experimental|Oat bran fibre processed with method A|Beverage powder with 12% oat bran processed with method A
16263638|NCT04930250|Experimental|Oat bran fibre processed with method B|Beverage powder with 12% oat bran processed with method B
16263639|NCT04930250|Experimental|Oat bran fibre processed with method C|Beverage powder with 12% oat bran processed with method C
16263640|NCT04930250|Active Comparator|Minimally-processed oat bran (positive control)|Beverage powder with minimally-processed oat bran (Positive Control)
16263641|NCT04930250|Placebo Comparator|Readily-digestible carbohydrate (negative control)|Beverage powder with readily digestible carbohydrate (Negative Control)
16263642|NCT04930237||Experimental Group|Patients who receive RELISTOR
16263643|NCT04930237||Observational Group|Patients that receive standard of care
16263644|NCT04930224||Proliferative Diabetic retinopathy|40 patients with proliferative diabetic retinopathy
16263645|NCT04930224||Non-Proliferative Diabetic retinopathy|40 patients with non-proliferative diabetic retinopathy
16263646|NCT04930224||Healthy individuals|40 healthy persons
16263647|NCT04930211|Active Comparator|Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
16263648|NCT04930211|Active Comparator|Degenerative disc disease without Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
16263649|NCT04930198|Other|Social Incentive|"For the social incentive, the mHealth application will track the participant's individual adherence score (% of doses taken), track the top scorers (leaderboard), and provide a figure highlighting the proportion of their peers with poor (<80%), medium (80-94%), or high (>94%) adherence scores. The display of the individual's adherence score relative to peer scores is considered a descriptive norm and is meant to portray what most people are doing, as young people often inaccurately estimate behaviors for their peer groups. Participants will also receive an injunctive norm, or an indication of what they ought to be doing. This will come in the form of an emoji or congratulatory vs. motivating text for those with high or low adherence scores, respectively. When coupled with descriptive norms, injunctive norms have counteracted regression to the mean for individuals who demonstrate desirable behaviors relative to their peers."
16263650|NCT04930198|Other|Social Plus Financial Incentive|"For the financial incentive, the top 5 scorers in the PEER+ arm will be eligible win a lottery prize each month of the 24 week pilot of 1000 Nigerian Naira (NGN) of data that can be directly loaded onto the winner's phone. Behavioral economics theory tells us that individuals are more averse to losses than rewarded by gains, so that even incentives/prizes should be framed in terms of losses. Accordingly, participants in the financial incentive arm will receive weekly motivating messages such as take your dose today or you lose the chance of winning the lottery."
16263651|NCT04930185|Experimental|Pamphlet|Participants will received pamphlet about COVID-19 vaccination
16263652|NCT04930185|Experimental|Webinar|Participants will received webinar about COVID-19 vaccination
16263653|NCT04930185|Experimental|SMS|Participants will received SMS about COVID-19 vaccination
16263654|NCT04930172||Steerable introducers|
16263655|NCT04930159|No Intervention|Enhanced usual care|Written materials in an appealing package.
16263656|NCT04930159|Active Comparator|Facilitated group support|Weekly group gatherings.
16263657|NCT04930159|Active Comparator|1:1 Peer Support|Individual peer support calls.
16263658|NCT04930146|Experimental|Intervention group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8
~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
~Evaluating the meridian energy by M.E.A.D"
16263659|NCT04930146|No Intervention|Control group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8
~Conventional treatment.
~Evaluating the meridian energy by M.E.A.D"
16263660|NCT04930146|Experimental|Intervention group (Moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13
~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
~Evaluating the meridian energy by M.E.A.D"
16263661|NCT04930146|No Intervention|Control group (moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13
~Conventional treatment.
~Evaluating the meridian energy by M.E.A.D"
16263662|NCT04930133||Cohort A|T790M+ patients sequentially treated with osimertinib in cohort A
16263663|NCT04930133||Cohort B|T790M- patients treated with chemotherapy or other treatments in cohort B
16263664|NCT04930133||Cohort C|patients with unknown mutation status in cohort C
16263665|NCT04930133||Cohort D|Cohort D included patients who were still ongoing with afatinib.
16263666|NCT04930120||Transferred group|The transferred group includes all severe COVID patients admitted in a French ICU ward and then transferred between the 03/13/2020 and 04/10/2020 to another ICU located outside the region of the initial ICU stay.
16263667|NCT04930120||Control group|The control group includes patients selected out of those whose entire ICU care has taken place in one of the hospitals which transferred patients. Up to 4 control patients will be selected for each transferred patient.
16263668|NCT04930107|Active Comparator|Recurrent Infection Cohort|
16263669|NCT04930107|Active Comparator|Assumed First-Time Infection Cohort|
16263670|NCT04930107|No Intervention|Asymptomatic Cohort|
16263671|NCT04930094|Experimental|Secukinumab 300 mg|AIN457
16263672|NCT04930094|Placebo Comparator|Placebo|Placebo
16263673|NCT04930081|Experimental|Parent Management Training|The well-researched Postivie Parenting Program (Triple P) is selected as the intervention program for the parent management training arm. It is an 8-week program that aims at equipping parents with effective parenting strategies.
16263674|NCT04930081|Experimental|Mindful Parenting Program|The Mindful Parenting program, developed by Prof Susan Bogel is selected as the intervention program for the mindful parenting arm. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in the parenting context.
16263675|NCT04930081|No Intervention|Waitlist Control Group|The waitlist control group will not receive any service until two months after the intervention arms complete their training. Depending of the availability of the program instructor, either the Parent Management Training or the Mindful Parenting program will be offered to this group.
16263676|NCT04930068|Experimental|ultra-sound|ultrasonic cavitation applied on abdominal region for 30 minutes, 2 times per week for 6 weeks.
16263677|NCT04930068|Experimental|aerobic exercise|aerobic exercises through treadmill (60-70% of VO2 max.) for 30 minutes, 2 times per week for 6 weeks
16263678|NCT04930055||Group 1|Patients with solid tumors receiving courses of cytotoxic therapy.
16263679|NCT04930055||Group 2|Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
16263680|NCT04930055||Group 3|Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
16263681|NCT04930055||Group 4|Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
16263682|NCT04930055||Group 5|Patients receiving immune checkpoint inhibitors.
16263683|NCT04930055||Group 6|Patients who underwent allogeneic stem cell transplant within 12 months.
16263684|NCT04930055||Group 7|Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.
16263685|NCT04930055||Group 8|Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches
16263686|NCT04930055||Group 9|Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
16263687|NCT04930055||Group 10|Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
16263688|NCT04930055||Group 11|Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
16263689|NCT04930055||Group 12|Patients who have a cancer diagnosis but do not fall into group 1-11
16263690|NCT04930042|Experimental|AVT04 45 mg SC|Test Product: AVT04 (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
16263691|NCT04930042|Active Comparator|EU Stelara 45 mg SC|Comparator ref product: EU Stelara (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
16263692|NCT04930029||OAGB150|One anastomosis gastric bypass with 150cm biliary limb
16263693|NCT04930029||OAGB200|One anastomosis gastric bypass with 200cm biliary limb
16263694|NCT04930016||Former DIQOL intervention group|In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the intervention group of the completed RCT DIQOL with the following intervention: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively. Results were transferred to a QoL-profile consisting of 13 QoL scales. Three experts with various professional background used the individual patient's QoL-profile and clinical and sociodemographic information to generate a QoL-report including therapy recommendations which was sent to the patient's doctor. Specific therapeutic options for the treatment of QoL had been defined: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, and fitness.
16263695|NCT04930016||Former DIQOL control group|In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the control group of the completed RCT DIQOL: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively but their doctor neither received a QoL-profile nor a QoL-report.
16263696|NCT04930003|Experimental|Experimental: Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16263697|NCT04930003|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16263698|NCT04930003|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16263699|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16263700|NCT04930003|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
16263701|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
16263702|NCT04929990|Experimental|Inpiratory and expiratory muscle training|The initial intensity of training was set on 30% of the MIP and MEP for inspiratory and expiratory muscle training, respectively. The intensity was adjusted to add 5% of resistance each week
16263703|NCT04929990|Active Comparator|Inspiratory muscle training|The initial resistance of the breathing trainer was also set on 30% of MIP, and the following adjustments were also in accordance to the protocol of the experimental group
16263704|NCT04929977|Other|Wearable device with smart mobile phone|20 mother/care provider-infant pairs practicing Kangaroo Mother Care, from a tertiary super-specialty hospital selected to wear the device ( few days in the hospital and for a week at home when discharged)
16263705|NCT04929964||Breast cancer|
16264265|NCT04925908||Control Group|Infants of mothers with suspected but negative for COVID-19
16263706|NCT04929951|Experimental|MFAT (Micro Fragmented Adipose Tissue)|Intra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.
16263707|NCT04929951|Active Comparator|Conventional Therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg)
16263708|NCT04929938|Experimental|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Treatment As Usual Plus Virtual group Therapy applying the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. The treatment consists in 15 weekly sessions of 120 minutes that combines cognitive-behavioural techniques to improve emotional self-regulation skills.
16263709|NCT04929938|Active Comparator|Treatment As Usual|General Cognitive Behavioural Therapy plus Pharmacotherapy.
16263710|NCT04929899|Other|Bright Ideas- CIN Training|"The PSST will be delivered by a trainer in a minimum of three 30-minute to 1-hour sessions with a parent and patient (if developmentally appropriate).
~During the first session, the study team member will build rapport by understanding relevant personal background and medical information; introduce PSST and the Bright IDEAS paradigm; review the patients experience with nausea as reported in Phase 1 and at other times during treatment; promote problem-solving strategies and skills; and develop an anti-nausea action plan. During the second session, the trainer will discuss how well the prior action plan worked and reinforce successful outcomes or, if unsuccessful, return to the problem-solving steps to generate a new action plan. The third session will review progress on CINV control, assist in problem-solving as needed, and discuss how to continue to use the Bright IDEAS framework to resolve future issues with CINV or symptom management more broadly."
16263711|NCT04929873|Placebo Comparator|routine treatment|routine nursing
16263712|NCT04929873|Experimental|Experimental group|Immediately after the establishment of the side branch cycle, the closed transdone is connected for real-time monitoring of pressure, and clinical nursing practice is guided by transdictor pressure.
16263713|NCT04929860|Active Comparator|handwashing|This arm receives a scalable social marketing campaign using innovative behaviour change approaches to improve handwashing. The intervention is delivered by a commercial social marketing business unrelated to the investigating organisations
16263714|NCT04929860|No Intervention|control|
16263715|NCT04929847|Experimental|Group 1|These patients will first receive the experimental emollient during 6 weeks, followed by no treatment for 6 weeks. In between there will be a washout period of 1 week.
16263716|NCT04929847|Experimental|Group 2|These patients will first receive no treatment during 6 weeks, followed by the experimental emollient for 6 weeks. In between there will be a washout period of 1 week.
16263717|NCT04929834|Experimental|Group 1|These patients will first receive the experimental emollients during 3 months, followed by no treatment for 3 months. In between there will be a washout period of 1 week.
16263718|NCT04929834|Experimental|Group 2|These patients will first receive no treatment during 3 months, followed by the experimental emollient for 3 months. In between there will be a washout period of 1 week.
16263719|NCT04929821|Other|Study Device Treated Group|Treated with the study device, UNITY-B Biodegradable Balloon-Expandable Biliary Stent System.
16263720|NCT04929808|Active Comparator|Control group|Will receive the standard institutional skin care for acute radiodermatitis
16263721|NCT04929808|Experimental|Experimental group|Will receive the novel, self-prepared skin care product
16263722|NCT04929795|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of music beat serving as a type of rhythmic auditory stimulation (RAS).
16263723|NCT04929795|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
16263724|NCT04929795|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of RAS.
16263725|NCT04929795|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
16263726|NCT04929782|Active Comparator|Resin-based sealant|A dental isolation device was used (Mr. Thisty One Step, Zirc Dental, Buffalo, MN, USA) and the treatments were conducted by one operator according to following steps; Group 1: Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
16263727|NCT04929782|Active Comparator|Giomer sealant|Group 2: Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
16263728|NCT04929769|Experimental|1|the group of LRH
16263729|NCT04929769|Active Comparator|2|the group of ARH
16263730|NCT04929756||Fixation PRL|Visual feedback will be provided at the the preferred retinal locus (PRL) to train subjects to attend to a fixation location. Feedback consists of a gaze-contingent ring whose size varies depending on task performance. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Gaze behavior will be measured with an eye tracker.
16263731|NCT04929756||Smooth Pursuit PRL|Visual feedback will be provided to train subjects to attend to a PRL for smooth pursuit eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on a drifting target. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Smooth pursuit tracking behavior will be measured with an eye tracker.
16263757|NCT04929535|Experimental|30% hydrogen peroxide|30% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
16263732|NCT04929756||Saccade PRL|Visual feedback will be provided to train subjects to attend to a PRL for saccadic eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on an abruptly shifting dot. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Saccadic eye movement behavior will be measured with an eye tracker.
16263733|NCT04929756||Scotoma Awareness PRL|Subjects are often unaware of their scotomas because they are filled in with the surrounding background texture. The investigators will exploit this filling in to increase awareness of the scotoma by surrounding the scotoma with a visible disk that will be perceptually completed across the scotoma, rendering the scotoma visible. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Scotoma Awareness Disk at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
16263734|NCT04929756||Meta-Guidance PRL|Oculomotor control can be promoted in the location around our hands. The investigators will exploit this meta-guidance advantage by asking subjects to move their hand and their PRL to an on-screen target. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Hand Movement at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
16263735|NCT04929743|Experimental|4.5 implants|
16263736|NCT04929743|Active Comparator|6.5 implants|
16263737|NCT04929730|No Intervention|Control group|Patients with an acute kidney injury in laborytory testing receive usual care. Nephrology co-supervision only on enquiry of the ward physician
16263738|NCT04929730|Other|Interventional group|Patients with an acute kidney injury in laborytory testing receive nephrology co-supervision in hospital and information about the importance of ambulant follow-up care.
16263739|NCT04929717|Experimental|Intervention|The personal information form and BSES-SF were administered to women in the hospital before the intervention. Breastfeeding education and counseling were provided via social media (WhatsApp) to support women for breastfeeding and to ensure the continuity of breastfeeding in the postpartum period. Breastfeeding education was given to women in the first four weeks after discharge from the hospital. After the breastfeeding education was completed via social media, the counseling process started. Counseling was conducted via social media with a question-answer method between the first and 6th months of postpartum.
16263740|NCT04929717|Other|Control|The women in the control group were pre-tested at the hospital before discharge. The BSES-SF was re-administered by phone at the 3rd and 6th postpartum months. The control group received the routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures. Except for routine breastfeeding training, no intervention was applied to the control group.
16263741|NCT04929691|Experimental|CPAP- Helmet Users|Patients admitted to a study site with suspected or confirmed COVID-19 and who consented to using the CPAP helmet
16263742|NCT04929691|Active Comparator|Non-CPAP helmet users|Patients admitted to a study site with suspected or confirmed COVID-19 but who did not use a CPAP helmet
16263743|NCT04929678|Experimental|Braive™ Growth Modulation System (Braive™ GMS)|
16263744|NCT04929665|Active Comparator|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
16263745|NCT04929665|Active Comparator|Erector spinae block|Patients who are planned to have an erector spina block will be advanced to the interfacial area under the erector spinae muscle by ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
16263746|NCT04929665|Active Comparator|Thoracic Paravertebral block and Erector spinae Block|In patients who are planned to have combined erector spinae block and thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 10 ml of 0.25% bupivacaine will be given to this area. Then, with the same needle, return 1-2 cm from the paravertebral area and inject 10 ml of 0.25% bupivacaine into the interfacial area under the erector spinae muscle.
16263747|NCT04929652|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combine With Immunotherapy and Chemotherapy.
16263748|NCT04929626|Active Comparator|Nebulized Ventolin|Nebulized Ventolin will given to 1st group after every 20 min for 1 hour
16263749|NCT04929626|Experimental|Nebulized Magnesium Sulphate + Ventolin|Dose of Nebulized Magnesium sulphate will vary in 3 subgroups.
16263750|NCT04929613|Experimental|Mindfulness-Based Resilience Training|Designed to train participants in a number of experiential exercises evoking qualities of mindfulness: mental focus, sustained attention and personal and situational awareness. These exercises include versions of the body scan (body awareness exercise), sitting meditation, mindful movement, walking meditation, eating meditation, mindful martial arts exercises and other elements of mindfulness.
16263751|NCT04929600|Experimental|Experimental|One pill of sacubitril/valsartan (200mg tablet) + one pill of matching placebo of amlodipine daily. If possible, dosage titration should be conducted.
16263752|NCT04929600|Active Comparator|Comparator|One pill of amlodipine (5mg tablet) + one pill of matching placebo of sacubitril/valsartan daily. If possible, dosage titration should be conducted.
16263753|NCT04929574||beta thalassemia patients|
16263754|NCT04929561|Experimental|Video-conferencing group|The mothers in the video-conferencing group were counseled via video-conferencing a total of six times (three times a week, at equal intervals) during the first 2 weeks after birth. Each interview was approximately 15-20 minutes. In video-conferencing sessions, the breastfeeding position, the mother's grasping the breast, the baby's latch-on, and sucking duration were observed. Mothers' questions were answered and solutions were offered for breastfeeding problems (sore nipple, engorgement, etc.).
16263755|NCT04929561|No Intervention|Control group|The mothers in the control group were given usual care before discharge and no intervention was made after discharge.
16263756|NCT04929548|Experimental|ECPy-THP Programs|Epirubicin 100 mg/m2, iv cyclophosphamide 600 mg/m2, iv + Pyrotinib 400 mg/d, po 4-week treatment, sequential docetaxel 80 mg/m2, iv + trastuzumab 6 mg/kg (first dose 8 mg/kg), iv + patuximab 420 mg (first dose 840 mg), iv ,po 4 weeks of treatment
16264266|NCT04925908||Case Group|Infants Born to COVID-19 positive mothers
16263758|NCT04929535|Placebo Comparator|3% hydrogen peroxide|3% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
16263759|NCT04929522|Active Comparator|IANB/inferior alveolar nerve block|patients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
16263760|NCT04929522|Active Comparator|IANB+IO|patients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
16263761|NCT04929522|Active Comparator|IANB+PDL|patients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
16263762|NCT04929522|Active Comparator|IANB+BI|patients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
16263763|NCT04929509|Experimental|self-assembling peptide (P11-4)|"Curodont Repair; Credentis will be applied to the
~white spot lesion at baseline."
16263764|NCT04929509|Active Comparator|nanosilver fluoride varnish|"(Study group) Nano-silver fluoride varnish will be applied to the
~white spot lesion at baseline."
16263765|NCT04929509|Placebo Comparator|sodium fluoride varnish|"(Control group) Fluoride varnish (Duraflor) will be applied to the
~white spot lesion at baseline and 6 months follow up."
16263766|NCT04929496|No Intervention|Angiographical guidance only|Standard of care
16263767|NCT04929496|Experimental|Post-PCI FFR guidance|Post-PCI Fractional Flow Reserve and non-hyperemic pressure ratios measurement
16263768|NCT04929483|Experimental|BIO89-100 - 15 mg QW|
16263769|NCT04929483|Experimental|Experimental: BIO89-100 - 30 mg QW|
16263770|NCT04929483|Experimental|Experimental: BIO89-100 - 44 mg Q2W|
16263771|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo QW|
16263772|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo Q2W|
16263773|NCT04929457||Individuals screened for Familial Hypercholesterolemia|Individuals participating in diagnostic activities in the digiphysical health care screening program for Familial Hypercholesterolemia and have provided informed consent are included in the cohort.
16263774|NCT04929444|Active Comparator|Training group|The professionals of the primary care teams that are in Intervention group would receive the training at the beginning of the study
16263775|NCT04929444|No Intervention|Common Practice|The professionals of the primary care teams that are in Control group will be offered the training after the conclusion of the study
16263776|NCT04929418|Other|10 km continuous running|Participants will perform a test of 10 km coninuous running.
16263777|NCT04929418|Other|1.5 km swimming|Participants will perform a test of 1.5 km coninuous swimming.
16263779|NCT04929392|Experimental|Treatment (chemoradiation, pembrolizumab, lenvatinib)|"CHEMORADIATION PHASE: Patients receive carboplatin IV and paclitaxel IV QW for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT over 6 weeks and receive pembrolizumab IV over 30 minutes on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.
~WINDOW PERIOD: Patients receive pembrolizumab IV over 30 minutes on day 1 of week 3 and lenvatinib mesylate PO QD at weeks 3-6 in the absence of disease progression or unacceptable toxicity.
~SURGERY/SURVEILLANCE: Patients without complete response undergo standard of care surgical resection. Patients with complete response/pursue non-operative management undergo surveillance via periodic endoscopic biopsy."
16263780|NCT04929379|Experimental|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
16263781|NCT04929379|Placebo Comparator|Placebo|Inactive tablets identical to fenofibrate
16263782|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 1|
16263783|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 2|
16263784|NCT04929353|Other|ARM A|Self-Reporting by electronic survey consisting of 14 items selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0)
16263785|NCT04929353|Other|Arm B|Standard symptom reporting following the conventional modalities of clinical oncology practice
16263786|NCT04929340|Experimental|experimental|5 drops each day before bedtime but after toothbrushing. L. reuteri DSM 17938, L. reuteri ATCC PTA 5289, with a minimum of 100 million live bacteria of each strain.
16263787|NCT04929340|Placebo Comparator|placebo|5 drops each day before bedtime but after toothbrushing. The placebo drops had identical composition color and taste but no probiotic bacteria.
16263788|NCT04929327|Active Comparator|Self-etch resin based sealant|Self-etch resin based sealant (prevent seal) without prior sandblasting.
16263789|NCT04929327|Active Comparator|Prior Sandblasting|Self-etch resin based sealant prevent seal) with prior sandblasting.
16263790|NCT04929327|Active Comparator|Total-etch resin based sealant|Total-etch resin based sealant (ultraseal XT) (Ultradent Pro. Inc., USA)
16263791|NCT04929314|Experimental|Intervention|Participants in the intervention group receive specialised nursing care that focuses on the interactive communication model. The nurses who deliver care to participants in the intervention group receive specific education and training in order to be able to provide nursing based on the interactive communication model and more individualised nursing based on health literacy level.
16263792|NCT04929314|No Intervention|Control|The participants in the control group receive usual care. The 98 municipalities in Denmark have a specialised role in community care and rehabilitation where nursing and practical help is carried out in the patients' own homes. Community care is usually provided at regular intervals based on a clinical evaluation of the patients' needs.
16263793|NCT04929301|Experimental|AME Hand-Expression|Participants in the antenatal milk expression (AME) group will learn hand-expression from a certified lactation consultant beginning at 37 weeks of pregnancy. At the same visit, the PI or RA will also provide oral and written instructions for AME at home, specifically instructing participants to do AME 1-2 times per day for no longer than 10 minutes.
16263794|NCT04929301|Active Comparator|Education|Participants in the education group will receive a weekly educational hand-out on varying breastfeeding topics (e.g., latch).
16263795|NCT04929288|Experimental|Males|Participants in this group will be adult male drinkers.
16263799|NCT04929262|Experimental|Key Opinion Leader|The key opinion leader (KOL) co-facilitated presentations will include the same core principles as the researcher-facilitated presentation but may vary by school in terms of specific examples and content emphasized based on KOL feedback. A caregiver KOL from the local community (selected by the parent teacher association or a similar group) will co-facilitate the presentation with a clinical psychology graduate researcher.
16263802|NCT04929236|Experimental|Panzyga High Dose|
16263803|NCT04929236|Experimental|Panzyga Low Dose|
16263806|NCT04929210|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.
16263807|NCT04929210|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
16263808|NCT04929210|Experimental|Group 3: Placebo followed by Guselkumab|Participants will receive matching placebo and will cross over to receive guselkumab SC.
16263809|NCT04929197|Experimental|Wear Personalized breast holder system (PERSBRA) to receiving radiotherapy|Wear PERSBRA to the end of radiotherapy.
16263810|NCT04929184|Experimental|Adults who stutter (AWS)|Participants will have 2 visits.
16263811|NCT04929184|Other|Healthy Adults|Participants will have 2 visits.
16263812|NCT04929184|Experimental|Children who Stutter|Participants will have 1 visit.
16263813|NCT04929184|Other|Healthy Children|Participants will have 1 visit.
16263814|NCT04929171||Patients with myofascial pain having centralized pain features|Adult patients with myofascial pain having centralized pain features who will be undergoing physical therapy
16263815|NCT04929158|Experimental|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Intravascular ultrasound guided surgery
16263816|NCT04929158|No Intervention|Angiography-Guided Primary Percutaneous Intervention (PCI)|Angiography-Guided guided surgery
16263817|NCT04929145||MICROMS|No intervention will be administered. Stool, hair, and blood samples will be collected at baseline and three months post baseline. Clinical follow-up will occur at year 1, 2, and 4.5 (neurological consultation) and in-between visits (regular follow-up).
16263818|NCT04929119||Before wearing the Orthokeratology|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
16263819|NCT04929119||Wear Orthokeratology for a week|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
16263820|NCT04929119||Wear Orthokeratology for a month|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
16263821|NCT04929119||Wear Orthokeratology for three months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
16263822|NCT04929119||Wear Orthokeratology for six months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
16263823|NCT04929106|Experimental|MHealth intervention|Tailored physical activity program with motivational mobile health support on everyday levels of physical activity
16263824|NCT04929093|Experimental|Novel dose adjustment schedule|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with novel dose adjustment schedule.
16263825|NCT04929093|Active Comparator|Conventional dose adjustment|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with conventional dose adjustment schedule.
16263826|NCT04929093|Active Comparator|Continuous cluster SCIT schedule|The subjects had a routine cluster SCIT schedule without interrupted period.
16263827|NCT04929080|Experimental|200mg, Q3W until to 2 years|
16263828|NCT04929080|Experimental|600mg, Q3W until to 2 years|
16263829|NCT04929067|Experimental|Immunotherapy combined with neoadjuvant chemotherapy forlocally advanced HNSCC|
16263830|NCT04929041|Experimental|Arm A (immunotherapy, +/- chemotherapy)|See Detailed Description
16263831|NCT04929041|Experimental|Arm B ( immunotherapy, +/- chemotherapy, SBRT)|Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of SBRT every other day.
16263832|NCT04929028|Experimental|High-risk stratum (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16263833|NCT04929028|Experimental|Low-risk stratum (mitomycin|Patients receive mitomycin IV on day 1 and either fluorouracil IV on day 1 or capecitabine PO BID on Monday-Friday until the completion of radiation therapy at the discretion of the treating physician. Patients also undergo IMRT QD for 20-23 treatment sessions over 6 weeks.
16263868|NCT04928833|No Intervention|Evaluation of Quality of Life|Quality of Life was evaluated with Parkinson's Disease Questionnaire-39 (PDQ-39).
16264346|NCT04925323|Experimental|a plastic or repair surgery indication generating surgical waste|
16263834|NCT04929015|Experimental|Diagnostic (biospecimen collection)|"Patients will receive standard treatment with surgery, HIPEC, and chemotherapy as appropriate to the patient situation, extent of disease and multi-disciplinary evaluation.
~Patients undergo blood sample collection for ctDNA analysis at baseline, pre-surgery, post-surgery and every 3 months up to 2 years.
~Patients undergo tissue collection before or during surgery and their medical records are reviewed."
16263835|NCT04929002||McArdle Disease|
16263836|NCT04929002||Pompe disease|
16263837|NCT04929002||Controls|
16263838|NCT04928989|Active Comparator|Convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
16263839|NCT04928989|Experimental|Neck-specific exercise in addition to convergence dialogue meeting|Neck-specific exercise with digital web-based support and four visits to a physiotherapist. Neck-specific exercise will be performed based on a well-structured framework of neck-specific exercise for facilitation of deep neck muscles, increased muscle coordination, improved neck posture and increased neck muscle endurance. Plus additional convergence dialogue meeting as treatment arm no 1.
16263840|NCT04928976||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16263841|NCT04928976||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16263842|NCT04928976||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16263843|NCT04928976||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16263846|NCT04928950|Experimental|Adults undergoing TEMLA|Adults undergoing TEMLA (Transcervical Extended Mediastinal Lymphadenectomy) take Oral Activated Charcoal (OAC) dissolved in apple juice a night before the surgery
16263847|NCT04928937||bariatric surgery|consisting of gastric bypass surgery: Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)
16263848|NCT04928937||conservative therapy|consisting of medical visits, nutritional counseling, physiotherapy, anti-obesogenic medication and psychological coaching
16263849|NCT04928911||Adults receiving COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
16263850|NCT04928885|Experimental|WW Treatment Group|Individuals will receive the 12-week Wits Workout Program. Individuals will take the baseline, 3 mos and 6 mos follow-up surveys. They will also take the Wits Workout satisfaction survey and participate in the 6 mos focus-groups.
16263851|NCT04928885|Other|WW Control Group|Individuals will be on a waitlist and will take the baseline, 3 mos and 6 mos. assessments. They will receive the Wits Workout workshop after the 6 month study period is completed.
16263852|NCT04928872||Non-diabetic older adults|Non-diabetic older adults
16263853|NCT04928859||the albumin group|The albumin group, the patients who used albumin for resuscitation during their hospitalization in the burn ward constituted the albumin group.
16263854|NCT04928859||the control group|The control group, the patients who did not use albumin during their hospitalization in the burn ward constituted the control group.
16263857|NCT04928833|Experimental|Pilates Group|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks.
16263858|NCT04928833|Active Comparator|Control Group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
16263859|NCT04928833|No Intervention|Evaluation of 'Core' Stability|"Core stability was evaluated with two important dimensions, core strength and endurance tests."
16263860|NCT04928833|No Intervention|Ultrasound Examination of M. Transversus Abdominus and M. Multifidus|M. transversus abdominus (TrA) and m. multifidus (MF) muscles were visualized by ultrasonography and the evaluations were performed by an experienced radiologist who was blind to the case groups.
16263861|NCT04928833|No Intervention|Evaluation of Lower Extremity Functional Strength|Lower extremity functional strength was evaluated with the 5-Times Sit-and-Stand Test.
16263862|NCT04928833|No Intervention|Evaluation of Balance|Balance was evaluated using the Berg Balance Scale (BBS).
16263863|NCT04928833|No Intervention|Evaluation of Functional Mobility|Functional mobility was evaluated using the Timed Up and Go Test (TUG).
16263864|NCT04928833|No Intervention|Evaluation of Functional Exercise Capacity|Functional exercise capacity was evaluated using the 6 Minute Walking Test (6-MWT).
16263865|NCT04928833|No Intervention|Activities of Daily Living and Evaluation of Motor Impairment|Activities of daily living and motor impairment were evaluated with activities of daily living (II) and motor impairment (III) sub-dimensions of the Unified Parkinson's Disease Rating Scale (UPDRS).
16263866|NCT04928833|No Intervention|Evaluation of Freezing|The Freezing of Gait Questionnaire (FOGQ) was used to identify and evaluate the subjective perception of Parkinson's patients regarding the severity and effect of freezing on gait performance.
16263867|NCT04928833|No Intervention|Evaluation of Fatigue|Fatigue, one of the non-motor findings associated with Parkinson's, was evaluated with the Parkinson's Fatigue Scale-16 (PFS-16).
16263901|NCT04928560||non-disease free survival|non-disease free survival
16263869|NCT04928820|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
16263870|NCT04928807|Experimental|Short course radiotherapy sequential camrelizumab and chemotherapy|"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX and camrelizumab, for 2 cycles.
~The patients were operated within 10 weeks after the last radiotherapy, and the surgical method is total mesorectal excision.
~Postoperative adjuvant therapy will be started 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX + camrelizumab) for 6 cycles"
16263871|NCT04928807|Active Comparator|Long term concurrent chemoradiotherapy and sequential chemotherapy|"The patients received neoadjuvant therapy of CAPOX 2 weeks after long-term concurrent chemoradiotherapy (28*1.8Gy, during the same period, capecitabine was 825 mg / m2, twice a day, 5 days a week).
~The patients were operated within 10 weeks after the last radiotherapy. Adjuvant therapy should begin within 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX) for 6 cycles"
16263872|NCT04928794|Other|Peripheral Nerve Block with 2 Techniques|
16263873|NCT04928781|Experimental|Smoking Cessation Counseling - Intervention Arm|Intervention arm. All patients enrolled in the study will be provided with smoking cessation counseling.
16263874|NCT04928781|No Intervention|Retrospective Chart Review - Control Arm|Control arm. A retrospective chart review will be conducted to create a randomly selected cohort of patients that meet inclusion and exclusion criteria and did not receive smoking cessation counseling to serve as the control arm.
16263875|NCT04928742|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in a 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. All participants in the treatment group will be mailed a hardcopy of the program manual.
16263876|NCT04928742|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from Niagara Region Public Health, their obstetrician, midwife, and/or family physician.
16263880|NCT04928703|Experimental|Arm 1|Visit 2: Placebo - Placebo Visit 3: Placebo - Ketamine Visit 4: Placebo - Ketamine
16263881|NCT04928703|Experimental|Arm 2|Visit 2: Placebo - Ketamine Visit 3: Placebo - Placebo Visit 4: Placebo - Ketamine
16263882|NCT04928703|Experimental|Arm 3|Visit 2: Placebo - Ketamine Visit 3: Placebo - Ketamine Visit 4: Placebo - Placebo
16263883|NCT04928690||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16263884|NCT04928690||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16263885|NCT04928690||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16263886|NCT04928690||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16263887|NCT04928677|Experimental|Codrituzumab|For Phase A of the study, we will use the 3+3 study design, with 2 planned dose levels, starting at 50% of the adult RP2D to confirm the pediatric RP2D/MTD. 6-9,43 Phase B will include an expansion cohort for patients with hepatoblastoma.
16263890|NCT04928651||Clonidine|Preterm infants (< gw 37+0) who are in need for analgesic or sedative medication will receive treatment with clonidine according to an algorithm based on pain and sedative scoring results
16263891|NCT04928638|Experimental|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
16263892|NCT04928638|Experimental|Written educational intervention|Educacional intervention about the disease, the use of medication and the context of pandemic
16263893|NCT04928638|No Intervention|Control intervention|Control intervention
16263894|NCT04928625|Experimental|SHR-A1904|
16263895|NCT04928612|Experimental|Part A -CBP-1018 Dose escalation/Part B- CBP-1018 monotherapy|"Part A: CBP-1018 administrated iv Q 2 W (4 weeks/cycle), utilizing accelerated titration at lower doses (0.03 mg/kg and 0.06 mg/kg) and an i 3+3 design at following doses (0.08 mg/kg,0.10 mg/kg,0.12 mg/kg and 0.14 mg/kg, etc.), respectively.
~Part B：Further evaluate the efficacy and safety profile of CBP-1018 in 4 tumor-specific cohorts.Cohort 1 (Metastatic castration resistant prostate cancer, mCRPC)；(Advanced renal cell cancer, RCC); Cohort 3 (Advanced lung squamous cell cancer, LSCC); Cohort 4 (Other advanced solid tumors)."
16263896|NCT04928599||Health Services Research (survey, interview, chart review)|Parents complete surveys over 15-30 minutes at the beginning of index child's induction chemotherapy, at the beginning of index child's maintenance chemotherapy, and after index child's last chemotherapy. Parents may also complete interview over 30-45 minutes. Index children's medical records are reviewed.
16263897|NCT04928586|Experimental|Pirfenidone group|CTD-ILD patients treated with DMARDs and pirfenidone
16263898|NCT04928586|Active Comparator|No-Pirfenidone group|CTD-ILD patients treated with DMARDs, without pirfenidone
16263899|NCT04928573||Group I|"All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11 already completed, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries.
~The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and the reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of lymphoma other than large B cell (LDGCB) CD20 positive."
16263900|NCT04928560||disease free survival|disease free survival
16263904|NCT04928534||Athletes with rmTBI history|50 active or retired athletes from the Weightlifting, Wrestling, Judo, Boxing and Taekwondo Sports Management Center of Tianjin Sports Bureau
16263905|NCT04928534||Patients with rmTBI history|50 patients with multiple (≥2 times) exposure to brain trauma attending Tianjin Medical Insurance designated hospitals such as Tianjin Medical University General Hospital
16263906|NCT04928534||Healthy volunteer|20 healthy volunteers
16263907|NCT04928521|Active Comparator|ESP block with 20 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 20 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
16263908|NCT04928521|Active Comparator|ESP block with 30 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
16263910|NCT04928495|Placebo Comparator|Treatment group 1|Control placebo (Vitamin C - 500mg / day, for 10 days)
16263911|NCT04928495|Active Comparator|Treatment group 2|N-acetylcysteine (NAC; 1800 mg / day, for 10 days)
16263912|NCT04928495|Active Comparator|Treatment group 3|NAC (1800 mg / day) + bromhexine-BMX (32 mg / day for 10 days)
16263913|NCT04928482|Experimental|27 session group|Participants in this arm will receive 27 sessions of backward walking training.
16263914|NCT04928482|Active Comparator|18 session group|Participants in this arm will receive 18 sessions of backward walking training.
16263915|NCT04928469||P.1|Patients infected with the P.1 SARS-CoV-2 variant
16263916|NCT04928469||Other variants|Patients infected with SARS-CoV-2 variants other than P.1
16263917|NCT04928456|Experimental|OMT Intervention Arm|"OMT will include:
~Myofascial release of the thoracic inlet: gentle pressure applied to shoulders and neck to move the tissue in different directions with a gentle motion.
~Pectoral traction: The armpit will be contacted with the finger pads of the doctor and each side will be gently grasped and have a slow pulling force applied towards the shoulders.
~Diaphragm release with MFR: The doctor will touch below the ribs on each side and will apply gentle pressure and move the tissue from side to side.
~Splenic pump: below the ribs on the left hand-side, the doctor will apply pressure and release pressure several times to create a vibration over the area just below the ribs.
~Thoracic pump: The doctor will place their hands over the chest wall on each side and will apply pressure and release pressure several times to generate a pumping action of about 100 times in one minute.
~Treatment will last 5 minutes with each technique lasting 1 minute."
16263918|NCT04928456|No Intervention|Control|Participants in the control group will undergo the same assessments as the OMT intervention arm and will receive their vaccinations, but will not receive any OMT.
16263919|NCT04928443||Scar dressing group|Patients planning to treat surgical scar with scar dressing
16263920|NCT04928443||Regular care group|Patients treated with adhesive tapes or strips or did not take care of surgical scar.
16263921|NCT04928430|Experimental|XAV-19|XAV-19
16263922|NCT04928430|Placebo Comparator|Placebo|
16263923|NCT04928404|Other|obstructive sleep apnea patients|
16263924|NCT04928391|Experimental|Group D|Dexmedetomidine IV at the end of surgery
16263925|NCT04928391|Experimental|Group N|Nalbuphine IV at the end of surgery
16263926|NCT04928391|Placebo Comparator|Group C|Same volume of saline placebo IV at the end of surgery
16263927|NCT04928365|Other|Advanced melanoma patients|
16263928|NCT04928365|Other|Stage III and IV melanoma patients after radical surgery|
16263929|NCT04928352|Experimental|Group B1|Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
16263930|NCT04928352|Experimental|Group B2|Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
16263931|NCT04928352|Placebo Comparator|Group C|Same volume of nebulized saline placebo
16263932|NCT04928339|Experimental|PIFB intervention|bilateral PIFB with a mixture of standard 0.25% bupivacaine (15 mL) and 133 mg liposomal bupivacaine (10mL)
16263933|NCT04928339|Sham Comparator|Saline Control|bilateral PIFB with 25 mL saline only
16263934|NCT04928326||Patients with heart failure undergoing right heart catheterization|Subjects with a diagnosis of NYHA class II-IV heart failure who meet the inclusion and exclusion criteria will be eligible for participation in this study.
16263935|NCT04928300|Experimental|Group D|Dexmedetomidine infusion IV for 5 days.
16263936|NCT04928300|Experimental|Group K|Ketamine infusion 2.5 µ/kg/min for 5 days.
16263937|NCT04928300|Placebo Comparator|Group C|The same dose and duration of normal saline will be given.
16263940|NCT04928274|Other|ball retained mandibular over denture|each patient in this group received 3 implant installed in mandible and 3 ball attachments for retention of over denture
16263941|NCT04928274|Other|locator retained mandibular over denture|
16263942|NCT04928274|Other|telescopic retained mandibular over denture|
16263943|NCT04928261|Experimental|De-escalated HER2 targeted treatment|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery.
16263944|NCT04928248|Experimental|Diabetes Dashboard integrated with Disease Manager App|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated Diabetes Dashboard that is integrated with the diabetes module of the Disease Manager App).
16263945|NCT04928235||All Participants|All participants will have thermal imaging of their lower extremities. The temperature values will be shared with the attending physician. The physician will be asked questions about their diagnostic confidence before and after seeing the temperature values.
16263946|NCT04928222|Placebo Comparator|Placebo-containing MNA|A placebo-containing array will be applied to subjects.
16263947|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 50 µg|A doxorubicin-containing array of 50 µg will be applied to subjects.
16263948|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 100 µg|A doxorubicin-containing array of 100 µg will be applied to subjects.
16263949|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 200 µg|A doxorubicin-containing array of 200 µg will be applied to subjects.
16263950|NCT04928222|Experimental|Placebo MNA for Training|Training phase for application of arrays
16263951|NCT04928209|No Intervention|Usual Care (High-Income)|This group will receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments. They will not be randomized to receive supplemental teletherapy (intervention) and usual care.
16263952|NCT04928209|No Intervention|Usual Care (Low-Income)|"This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy but are not randomized to receive the intervention after allocation. Like the Usual Care (High-Income) arm, they will only receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments and usual care."
16263953|NCT04928209|Experimental|Usual Care + Teletherapy (Low-Income)|This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy and are randomized to receive the intervention. They will receive both 3x comprehensive assessments every 9 months AND access to supplemental speech-language teletherapy for the 18-month study period.
16263954|NCT04928183|Sham Comparator|Room Air Rebreathe|Rebreathe protocol will be completed with a room air syringe rather than CO
16263955|NCT04928183|Experimental|CO Rebreathe|Rebreathe protocol will be completed with Carbon Monoxide
16263956|NCT04928170||HALLOA|306 individuals with knee pain in the age between 30 and 65 years, without cruciate ligament injury
16263957|NCT04928157|Experimental|CPAP|Use of CPAP, a device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
16263958|NCT04928157|No Intervention|Control|No CPAP use, otherwise usual care
16263959|NCT04928144|Experimental|0.025% SHJ002|0.025% SHJ002 Sterile Ophthalmic Solution
16263960|NCT04928144|Experimental|0.080% SHJ002|0.080% SHJ002 Sterile Ophthalmic Solution
16263961|NCT04928144|Experimental|0.25% SHJ002|0.25% SHJ002 Sterile Ophthalmic Solution
16263962|NCT04928144|Experimental|SHJ002 - Maximum tolerated concentration|Maximum tolerated concentration of SHJ002
16263963|NCT04928131||Anorectal|Patients presenting with anorectal pain.
16263964|NCT04928131||TMJ|Patients presenting with temporomandibular joint pain.
16263965|NCT04928131||Foot/Ankle|Patients presenting with foot and ankle pain.
16263966|NCT04928118||Impella protected Percutaneous coronary intervention (PCI)|Patients undergoing Impella protected PCI as deemed necessary by interventional cardiologist - VCU Medical Center case based standard of care
16263967|NCT04928105|Experimental|CD7 CAR-T|
16263968|NCT04928092||Active research group|Patients undergoing intravascular imaging guided, low contrast PCI procedure as part of standard care
16263969|NCT04928066|Experimental|Tofacitinib (TF)+Iguratimod (IGU)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.
~Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.
~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
16263970|NCT04928066|Other|Tofacitinib (TF)|"Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.
~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
16263971|NCT04928053|Experimental|phenotypic data and a blood prelevment|
16263972|NCT04928040|Experimental|Fluid challange|Fluid challange effects on optic nerve diameter
16263973|NCT04928027||Persons with PD|Adults with PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Self-Assessment
16263974|NCT04928027||Significant Others of those with PD|Adults whose significant other has a diagnosis of PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Observer report
16263975|NCT04928014||Underserved Populations|
16263976|NCT04928014||Larger Employers|
16263977|NCT04928001|Other|Youth Thrive iCBT program|Youth Thrive iCBT online program
16263983|NCT04927949|Sham Comparator|patients without HPR|standard primary PCI
16263984|NCT04927949|Experimental|patients with HPR randomized to cangrelor|Cangrelor perfusion started before PCI
16263985|NCT04927949|Placebo Comparator|patients with HPR randomized to standard of care|standard primary PCI
16263986|NCT04927936|Active Comparator|Janssen vaccine only|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination, blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.
~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
16263987|NCT04927936|Experimental|Janssen vaccine - Janssen vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Janssen vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.
~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
16263988|NCT04927936|Experimental|Janssen vaccine - Moderna vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Moderna vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.
~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
16265527|NCT04916886|Experimental|800L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
16263989|NCT04927936|Experimental|Janssen vaccine - Pfizer vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Pfizer vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.
~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
16263990|NCT04927923|Active Comparator|hope-focused motivational interview-experimental group|"Volunteering to participate in research
~Being over the age of 18
~Being able to read and write"
16263991|NCT04927923|No Intervention|control group|"Volunteering to participate in research
~Being over the age of 18
~Being able to read and write"
16263992|NCT04927910|Experimental|True self-acupressure|1) two individual/group acupressure training sessions over 2 weeks and (2) self-acupressure for 6 weeks.
16263993|NCT04927910|Sham Comparator|Sham self-acupressure|Same protocol to the true self-acupressure group but on the sham acupoints
16263994|NCT04927910|Other|Usual care|General advise on managing symptoms provided by healthcare providers
16263995|NCT04927897||Observational|In addition to standard workup and treatment, patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures.
16263996|NCT04927884|Experimental|All subjects|Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK)
16263997|NCT04927871|Experimental|Hybridized Lyfestile Intervention|The participants will receive three interventions including Total Diet Replacement, Medical Nutrition Therapy, and the Diabetes Prevention Program
16263998|NCT04927871|Active Comparator|Only Diabetes Prevention Program|The comparison group will receive only the Diabetes Prevention Program
16263999|NCT04927858||Population 1|Patients ≥ 18 years old on 31st of December 2017 with Type 2 Diabetes Mellitus (T2DM) who were alive on 31st of December 2017 and had at least one registration in the Swedish National Diabetes Registry (NDR) between 1996 - 2017.
16264000|NCT04927858||Population 2|Population 2 is a sub-population of population 1. Patients with Type 2 Diabetes Mellitus (T2DM) who were initiated on Empagliflozin between 1st of January 2015 and 31st of December 2017, who had at least one registration in the Swedish National Diabetes Register (NDR).
16264001|NCT04927845|Experimental|Immediate Intervention Condition|Participants in this condition will receive 7-8 weeks of online intervention modules. Specific modules will be selected based on a campus-wide needs assessment conducted in May 2021.
16264002|NCT04927845|No Intervention|Waitlist Condition|Participants in this condition will wait to receive StriveWeekly until after the Immediate Intervention condition is complete and participants from both conditions have completed the posttest survey.
16264003|NCT04927832|Experimental|Patient with chronic autoimmune pathology|
16264004|NCT04927832|Experimental|Patients with unexplained pain syndrome|
16264005|NCT04927819||short-length implant (<6.5 mm)|
16264006|NCT04927819||non-short length implant (≥6.5 mm)|
16264007|NCT04927806|Experimental|SilverKnight group|Silver Knight is an anti-microbial additive that uses silver ions to disrupt the normal enzymatic activities of bacteria
16264008|NCT04927806|No Intervention|Control group|The control group uses standard ventilator circuits.
16264009|NCT04927793|Experimental|Single arm EDP-938|
16264012|NCT04927767|Experimental|Denture adhesives|Participants will be shown to apply the adhesive following the manufacturer's instructions. The denture is pressed firmly into place, then held firmly as the participant bites down to secure it. Participants will be instructed to apply the adhesive twice daily with an 8-hour interval.
16264013|NCT04927754|Experimental|Group 1 (cartoon movie, then tell-show-do technique)|Group 1: Dental treatment was carried out with showing cartoon movie as a visual/auditory distraction during the treatment in the second visit. The third visit did not consist any visual/auditory distractions, tell-show-do technique was used as a behavioural guidance technique.
16264014|NCT04927754|Experimental|Group 2 (tell-show-do technique, then cartoon movie)|Group 2: Dental treatment was carried out using tell-show-do technique without any visual/auditory distraction in the second visit. The third visit consisted cartoon movie as a visual/auditory distraction.
16264015|NCT04927741|Experimental|Method 1: Sweet Marjoram Essential Oil + Grapeseed Oil with Massage|Subjects randomized will receive dilution of sweet marjoram essential oil (mixed with grapeseed oil), which will be applied topically with massage after IUD insertion.
16264016|NCT04927741|Active Comparator|Method 2: Grapeseed Oil with Massage|Subjects randomized will grapeseed oil applied topically with massage after IUD insertion.
16264017|NCT04927741|No Intervention|Method 3: Control Group (no oil or massage)|Subjects will serve as control and no essential oils or massage will be applied.
16264018|NCT04927728|Experimental|Audio MP|Participants of the audio mental practice (MP) group will complete MP via audio-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
16264019|NCT04927728|Experimental|Video MP|Participants of the video mental practice (MP) group will complete MP via video-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
16264020|NCT04927728|Experimental|Repetitive-Task Practice|Participants of the repetitive-task practice group will complete repetitive practice of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each participant completed at least 20 repetitions of the task.
16264021|NCT04927728|Active Comparator|Traditional Therapy|The control group received traditional occupational therapy stroke rehabilitation.
16264022|NCT04927715||Diseased|Females with peripartum cardiomyopathy
16264023|NCT04927715||Control|Healthy females
16264024|NCT04927702|Experimental|Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
16264025|NCT04927702|Active Comparator|Diabetic Foot Ulcer Participants Assigned to Lyophilized Acellular Fish Skin (Kerecis® Omega3 Wound)|Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
16264026|NCT04927702|Experimental|Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
16264027|NCT04927702|Active Comparator|Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
16264028|NCT04927663|Experimental|Cohort A: 11C-YJH08 with PET/MRI or PET/CT|Patients receive approximately 20 millicurie (mCi) of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline.
16264029|NCT04927663|Experimental|Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression|Patients receive approximately 20 mCi of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline and at time of disease progression.
16264030|NCT04927650||Screening|Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.
16264031|NCT04927637||Orthopedic Infection|Subjects who have undergone previous orthopaedic trauma surgery and have developed and infection will be assessed for protocol inclusion criteria. Patients who meet all inclusion criteria and no exclusion criteria will be administered a single dose 2.5-5 mg/kg ICG dose intravenously ideally 24h prior to surgical debridement. Fluorescent images will be obtained pre and post irrigation and debridement
16264032|NCT04927624|Active Comparator|transversus abdominis plane|In the group in which Transversus Abdominis Plan Block was applied, the patient was placed in the supine position. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and the anterolateral abdominal wall. After visualizing the external-internal obliq and transversus abdominis muscles, 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration by advancing the needle into the fascia between the internal obliq muscle and the transversus abdominis muscle with the in-plane technique.
16264033|NCT04927624|Active Comparator|quoadratus lumborum block|In the Quadratus Lumborum Block (Lateral approach) group, the patient was placed in the lateral position with the side to be blocked on top. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and costa edge. After visualizing the extarnal-internal obliq and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum muscle and thoracolumbar fascia were visualized. The needle was advanced to the anterolateral border of the quadratus lumborum muscle with the in-plane technique and 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration.
16264034|NCT04927611||Gastroenteropancreatic neuroendocrine neoplasms|Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
16264035|NCT04927611||Pancreatic ductal adenocarcinoma|Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
16264036|NCT04927585|Experimental|Group 1 (Treatment): DNA Vaccine + Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0, and Months 3, 6, and 12.
16264037|NCT04927585|Placebo Comparator|Group 1 (Control)|"Participants will receive placebo at Day 0, Months 3, 6, and 12.
~Interventions:"
16264038|NCT04927585|Experimental|Group 2 (Treatment): Admixture of DNA Vaccine and Protein Vaccine|Participants will receive admixture of 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine (no adjuvant) at Day 0, and Months 1, 3, 6, and 8.
16264039|NCT04927585|Placebo Comparator|Group 2 (Control)|"Participants will receive placebo at Day 0, and Months 1, 3, 6, and 8.
~Interventions:"
16264042|NCT04927559||Observational (survey)|Patients complete a survey over 5-10 minutes about their understanding of radiation therapy.
16264043|NCT04927546|Experimental|IL-6 blockade|RA patients under pharmacological treatment with interleukin-6 blockade.
16264044|NCT04927546|Experimental|Anti-TNF-alpha|RA patients under pharmacological treatment with anti-TNF-alpha.
16264045|NCT04927546|Experimental|Healthy controls|Healthy participants.
16264046|NCT04927533|Experimental|Older adults with psychiatric problems|The target group is a group of older adults with psychiatric problems (≥60 years old) admitted to a residential psychogeriatric department of the Psychiatric Clinic of the Alexians Care Group Tienen. The following exclusion criteria apply: a score of less than 21 on the MMSE (excluding dementia or other moderate to severe cognitive disorders), a mother tongue other than Dutch and having undergone surgery and/or chemotherapy in the last 3 months.
16264047|NCT04927520||Endovascular therapy group|Unruptured middle cerebral artery aneurysms treated with coil embolization
16264048|NCT04927520||Clipping surgery group|Unruptured middle cerebral artery aneurysms treated with clipping surgery
16264049|NCT04927507|No Intervention|Control group|The control group was given routine nursing.
16264050|NCT04927507|Experimental|Observation group|The observation group was given the Internet plus nursing home rehabilitation mode.
16264051|NCT04927494|Experimental|Black women cervical cancer screening|Participants in this group with receive the Health is Wealth intervention.
16264052|NCT04927481|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced HER2 negative breast cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for about 6 cycles.
16264053|NCT04927468|Experimental|supramaximal rectus recession|supramaximal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
16264054|NCT04927468|Active Comparator|normal rectus recession|normal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
16264061|NCT04927403||Chronic gastroenterological diseases|Irritable Bowel Syndrome, Crohn's disease, Ulcerative colitis
16264062|NCT04927403||Chronic Pain patients|Chronic pain syndrome, Rheumatism, Fibromyalgia
16264063|NCT04927390|Experimental|Mycophenolate Mofetil (MMF) Arm|Participants will receive mycophenolate mofetil (MMF) for up to 96 weeks, in addition to their background Standard of Care medication for systemic sclerosis related symptoms. They will receive 500mg twice daily over the first 4 weeks following their randomisation, and if tolerated the dose will be increased to a target dose of 1g twice daily starting from week 5 until their Final visit.
16264064|NCT04927390|No Intervention|Control Arm|Standard of Care (no immunosuppression) for systemic sclerosis related symptoms.
16264067|NCT04927364|Experimental|Active rTMS and DBT skills training|"Participants will receive 20 rTMS treatments over 2 weeks, delivered 4-5 days/week. Each treatment visit will last 20-30 minutes in total.
~Participants will also attend 6 hour-long dialectical behavioral therapy (DBT) sessions with a licensed clinical psychologist over the course of 2-3 weeks."
16264068|NCT04927364|Experimental|DBT skills training|Participants will also attend 6 hour-long dialectical behavioral therapy (DBT) sessions with a licensed clinical psychologist over the course of 2-3 weeks.
16264069|NCT04927351|Experimental|Intervention|New electronic medical record based discharge medication order set.
16264070|NCT04927351|No Intervention|Control|Usual Care
16264071|NCT04927338|Experimental|Bacopa|Eligible participants will be randomized to receive 12 weeks of BacoMind® (300 mg/day)
16264072|NCT04927338|Placebo Comparator|Placebo|Eligible participants will be randomized to receive 12 weeks of matching placebo
16264073|NCT04927325|Other|central line with a reddened exit site|A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)
16264074|NCT04927325|Other|Control Group: central line without a reddened exit site|A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)
16264076|NCT04927299|Experimental|Group A: Losartan + chlorthalidone|Administered orally, one tablet a day, for 2 months.
16264077|NCT04927299|Active Comparator|Group B: Losartan + hydrochlorothiazide|Administered orally, one tablet a day, for 2 months.
16264078|NCT04927286|Experimental|Mentoring+Mindfulness|
16264079|NCT04927286|Active Comparator|Mentoring as usual|
16264080|NCT04927247|Experimental|inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
16264081|NCT04927247|Placebo Comparator|placebo|Placebo administered IV
16264082|NCT04927234|Experimental|Standard of care + geko™ Therapy|In addition to their standard of care, for patients randomised to the intervention arm, geko™ therapy will be applied immediately post-surgery on the operated leg and administered for 24 hours / day whilst the patient remains in hospital, after which geko™ therapy will then be applied for 12hrs / day until the patient returns for their first post-operative follow-up visit (Day 14 ± 2 days post-surgery)
16264083|NCT04927234|No Intervention|Standard of care|Patients will receive their standard of care as per hospital practice.
16264084|NCT04927221|Experimental|DC371739 20mg Dose MAD|Orally administered DC371739 tablets QD afer meal
16264085|NCT04927221|Placebo Comparator|DC371739 Placebo MAD|Placebo orally administered
16264086|NCT04927208|Experimental|Improved skeletal muscle function due to protein supplementation|Experimental: Intervention group Improved skeletal muscle function due to protein supplementation
16264087|NCT04927195|Experimental|Cohort 1|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10^11 cells, capsules, once daily, 14 days total
16264088|NCT04927195|Experimental|Cohort 2|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10^12 cells, capsules, once daily, 14 days total
16264089|NCT04927195|Experimental|Cohort 3|24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
16264090|NCT04927195|Experimental|Cohort 4|24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
16264091|NCT04927195|Experimental|Cohort 5|24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
16264095|NCT04927169|Experimental|CYT107|IM administration of CYT107 / Interleukin-7
16265670|NCT04915950|Experimental|Temanogrel (Stage A Dose 1)|
16264098|NCT04927143|Sham Comparator|Control|Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
16264099|NCT04927143|Experimental|Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The Low group will receive incentives worth $2-$8."
16264100|NCT04927143|Experimental|Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The High group will receive incentives worth $4-$16."
16264101|NCT04927143|Experimental|De-Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The Low group will receive incentives worth $6-12."
16264102|NCT04927143|Experimental|De-Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The High group will receive incentives worth $10-$20."
16264103|NCT04927130||Women in age 35 to 65 with confirmed breast cancer|
16264104|NCT04927130||Healthy Volunteers|
16264105|NCT04927117||high myopic group (group1:AL≥26.0 mm)|axial length≥26.0 mm)
16264106|NCT04927117||age-matched control group|axial length<26.0mm
16264107|NCT04927104|Experimental|PEEK Knee Prosthesis|In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis.
16264108|NCT04927091|No Intervention|Specialty Addiction Clinic|
16264109|NCT04927091|Experimental|ECHO-IC/QI-enhanced primary care clinic|
16264110|NCT04927091|Active Comparator|ECHO-IC/QI-enhanced primary care clinic with Pay for Performance|
16264111|NCT04927078||Participants with COVID 19 diagnosis|We will measure the breathing rate (BR) before and after the clinical diagnosis of COVID 19.
16264112|NCT04927078||Participants without COVID 19 diagnosis|Breathing rates will be measured for the same time duration as the cases.
16264113|NCT04927065|Experimental|Part A: mRNA-1273.211 50 ug|Participants will receive 1 intramuscular booster dose of 50 ug of mRNA-1273.211 on Day 1.
16264114|NCT04927065|Experimental|Part A: mRNA-1273.211 100 ug|Participants will receive 1 intramuscular booster dose of 100 ug of mRNA-1273.211 on Day 1.
16264115|NCT04927065|Experimental|Part B: mRNA-1273 100 ug|Participants will receive 1 intramuscular booster dose of 100 ug of mRNA-1273 on Day 1.
16264116|NCT04927065|Experimental|Part C: mRNA-1273.617.2 100 ug|Participants will receive 1 intramuscular booster dose of 100 ug of mRNA-1273.617.2 on Day 1.
16264117|NCT04927052|Active Comparator|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine is a clear, colorless gel in 1.2 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
16264118|NCT04927052|Active Comparator|Juvederm Voluma with Lidocaine|Juvederm Voluma with Lidocaine is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine.
16264119|NCT04927039|Placebo Comparator|Control group|
16264120|NCT04927039|Experimental|Iloprost group|
16264121|NCT04927026|Experimental|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|Solution-focused brief therapy (SFBT) involving psychoeducation and structured life review therapy, as well as mindfulness-based training
16264122|NCT04927026|No Intervention|Control|No intervention
16264123|NCT04927013|Experimental|Message-based Outreach Intervention (MBI) for Survivors|Cancer survivors randomized to receive a targeted letter with a unique website log in, access to the expanded website, free genetic counseling, and short message service (SMS) reminders.
16264124|NCT04927013|Active Comparator|Standard Outreach for Survivors|Cancer survivors randomized to receive the standard outreach consisting of a standard letter with website access, access to a condensed version of the study website, and free genetic counseling.
16264125|NCT04927013|Experimental|Message-based Outreach Intervention for Close Relatives|Close relatives of cancer survivors who were randomized to receive the message-based outreach. Close relatives will have access to the expanded version of the study website and free genetic counseling.
16264126|NCT04927013|Active Comparator|Standard Outreach for Close Relatives|Close relatives of cancer survivors who were randomized to receive the standard outreach. Close relatives will have access to a condensed version of the study website and free genetic counseling.
16264127|NCT04927000|No Intervention|control group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)].
~All subjects were treated with Glucocorticoid (10-15mg)/Days)."
16264128|NCT04927000|Experimental|Tofacitinib treatment group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)].
~All subjects were treated with Glucocorticoid (10-15mg)/Days). All subjects were treated with Tofacitinib 5mg/BID."
16264129|NCT04926974|Experimental|Seeing AI Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
16264130|NCT04926974|Experimental|Supervision+ Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
16264131|NCT04926974|Experimental|Aira Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
16264132|NCT04926961|Experimental|Sham stimulation first, then real stimulation|Participants will first be delivered sham TMS stimulation. Then on a separate day, participants will be delivered real TMS stimulation.
16264133|NCT04926961|Experimental|Real stimulation first, then sham stimulation|Participants will first be delivered real TMS stimulation. Then on a separate day, participants will be delivered sham TMS stimulation.
16264161|NCT04926662||Aim 1: Focus Groups|Focus groups will be conducted in 2 New Hampshire and 2 Vermont towns to better understand patient knowledge, attitudes, and preferences regarding access to lung cancer screening.
16264134|NCT04926948|Experimental|Treatment (SBRT, immunotherapy)|Patients undergo 3-5 daily fractions of SBRT in the absence of disease progression or unacceptable toxicity. Patients also receive immunotherapy at the discretion of the treating medical oncologist.
16264135|NCT04926935||Patients hospitalized in the ICU during the study period.|Patients hospitalized in the ICU during the study period with clinically suspected infection.
16264137|NCT04926896|Experimental|Minimally invasive bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.
~Use the cortical bone opening device to open two bone holes with a diameter of 7.5 mm side by side in the iliac bone cortex ,place disposable battery-powered bone harvesting device for iliac crest bone harvesting operations.
~The direction of the tool bit should be parallel to the outer iliac plate, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.
~.Scrap and collect the cancellous bone by tool bit during operation.
~. After collecting sufficient amount of cancellous bone, turn off the power, screw out the cabin, and pour out the cancellous bone.
~. Suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage."
16264138|NCT04926896|Placebo Comparator|Traditional iliac crest bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.
~Use a bone chisel to open a lid on the iliac crest ridge cortex ,open the cover length at 3cm.
~Lift the iliac crest ridge cortex plate cover, use bone knife and scraper to harvest bone in the iliac bone marrow cavity.
~Avoid violence when using bone knives and scrapers, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.
~After collecting sufficient amount of cancellous bone, suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage"
16264139|NCT04926883|Active Comparator|Sonic fill|
16264140|NCT04926883|Active Comparator|X-tra fill|
16264141|NCT04926870|Experimental|PACS group|PACS administration during teaching
16264142|NCT04926870|Active Comparator|Traditional group|Traditional teaching without PACS
16264143|NCT04926844|Experimental|Study group|Children receiving levetiracetam + midazolam
16264144|NCT04926844|Placebo Comparator|Control group|Children receiving placebo + midazolam
16264145|NCT04926831|Experimental|Cohort A|Participants with NSCLC with MET exon 14 skipping mutations, irrespective of MET gene copy number (GCN) will take 400 mg tablet orally twice per day
16264146|NCT04926831|Experimental|Cohort B|Participants with NSCLC with high level MET amplification will take 400 mg tablet orally twice per day
16264150|NCT04926805|Experimental|Mask A|Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.
16264151|NCT04926805|Active Comparator|Mask B|Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.
16264152|NCT04926766|Experimental|SHF-WBI|Patients with an indication for whole breast irradiation will receive 5.2 Gy in 5 fractions to whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
16264153|NCT04926753|Experimental|Experimental|5-Fluorouracil(750 mg/m2/d, CIV d1-5) Cisplatin(75mg/m2,d1)/Carboplatin(AUC5, d1) Toripalimab 240mg d1
16264154|NCT04926740|Experimental|Ringer's lactate|The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
16264155|NCT04926740|Active Comparator|Normal saline|The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
16264156|NCT04926727||Pregnant women|"600 Pregnant women between the 18th and 22nd week.
~200 from Northern Italy;
~200 from Central Italy;
~200 from Southern Italy and the Islands."
16264157|NCT04926701|Experimental|Single ascending dose|Single dose of inhaled ETD001/placebo on one occasion
16264158|NCT04926701|Experimental|Multiple ascending dose (7 days)|Twice daily doses of ETD001/placebo for 7 consecutive days
16264159|NCT04926701|Experimental|Multiple ascending dose (14 days)|Twice daily doses of ETD001/placebo for 14 consecutive days
16264160|NCT04926675|Experimental|Combined intervention|Participants accessing one-to-one psychological therapy from the IAPT service will be asked if they have any money worries affecting their mental health. Suitable participants will be offered one-to-one support from a money advisor, who they will access in tandem to their therapy.
16264162|NCT04926662||Aim 2: Cross Sectional Survey|Based on focus group feedback, the investigators will visit each proposed site to survey on 2 separate dates to confirm days and times of high traffic. The investigators will also survey patrons at the proposed locations to further determine prospective patient mobile screening preferences and evaluate willingness to participate in screening.
16264163|NCT04926662||Aim 3: Survey with follow up data|The investigators will pilot mobile lung cancer screening clinics at each chosen location using the knowledge acquired from focus group experience and local patient survey. Surveys will be conducted at these clinics, and patients will be followed for up to 5 years.
16264164|NCT04926649|Sham Comparator|Conventional ventilation group|Conventional SLV and complementary with DLV when necessary. When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. The right lung was totally collapsed. If the SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted.
16264165|NCT04926649|Active Comparator|CPAP group|"SLV of left lung and CPAP of right lung, and complementary with DLV when necessary.
~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, CPAP was started with the pressure less than 8 cmH2O. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
16264166|NCT04926649|Experimental|HFLVV group|"SLV of left lung and HFLVV of right lung, and complementary with DLV when necessary.
~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, HFLVV was started with tidal volume of 2ml/kg, respiratory rate of 60 bpm. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
16264167|NCT04926636|No Intervention|Standard Mobile App|This group will be supplied with Novidan DTC hearing aids and documentation following standard of care as a control. They will be provided with the mobile application allowing for the monitoring of data for study analysis and personal control of their hearing aids, but not Health and Wellness Coaching features.
16264168|NCT04926636|Experimental|Enhanced Mobile App with Health Coaching|This group will also be supplied with the Novidan DTC hearings aids and documentation, same as the control group, but will be supplied the enhanced mobile application that allows for participation in health coaching features. They will be assigned to a health coach and will have coaching sessions scheduled.
16264169|NCT04926623|Active Comparator|CGM with Structured Education|
16264170|NCT04926623|Active Comparator|CGM with Standard Education|
16264171|NCT04926623|No Intervention|SMBG with Standard Education|
16264172|NCT04926610|Experimental|proactive clinical ethics consultation group|
16264173|NCT04926610|No Intervention|routine care group|
16264174|NCT04926597|Experimental|Intervention group: individualized nutritional support|Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed
16264175|NCT04926597|Other|Control group: general information on healthy food habits|Control group patients will receive nutritional counselling (general information on healthy food habits) at discharge, but no nutritional support strategy will be used during follow-up
16264176|NCT04926571||Dexamethasone versus non-users of corticosteroids|
16264177|NCT04926571||Dexamethasone versus non-users of dexamethasone|
16264178|NCT04926571||Dexamethasone versus methylprednisolone active comparator|
16264179|NCT04926545|Experimental|Irinotecan naive cohort|"This cohort will enroll 6 postmenopausal female patients who have never received irinotecan treatment before. Patients in irinotecan naive cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 4 rounds of pharmacokinetic studies will be conducted.
~Round 0 (before chemotherapy): pharmacokinetic testing (raloxifene 60mg as probe) before XCHT administration, then XCHT for 4 days with pharmacokinetic testing (raloxifene 60mg as probe) on the 4th day of XCHT administration.
~Round 1(1st cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (without raloxifene) on day 4.
~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3.
~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
16264180|NCT04926545|Experimental|Irinotecan used cohort|"This cohort will recruit 18 patients who were treated with irinotecan previously and have at least one diarrhea episode with a severity of more than grade 2. Patients in irinotecan used cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 3 rounds of pharmacokinetic studies will be conducted.
~Round 1(1st cycle of chemotherapy): FOLFIRI, with pharmacokinetic testing (raloxifene 60mg as probe) on the first day of chemotherapy.
~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 4.
~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
16264181|NCT04926532|Experimental|Toripalimab + Sorafenib|Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Sorafenib was taken orally after meals, twice a day.
16264182|NCT04926519||Aggressive periodontitis|Patients that got the diagnosis aggressive periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
16264183|NCT04926519||Chronic periodontitis|Patients that got the diagnosis chronic periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
16264184|NCT04926506|Experimental|Xiyanping injection combined with routine treatment|
16264185|NCT04926506|No Intervention|routine treatment|
16264186|NCT04926493||BIOPAVIR Cohort|Critically ill patient > 18 years of age with mechanical ventilation for >2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.
16264187|NCT04926480|Experimental|low flow Anesthesia group|Antioxidant parameters are measured in the low flow anesthesia group.
16264188|NCT04926480|Active Comparator|high flow Anesthesia gruop|Antioxidant parameters are measured in the high flow anesthesia group.
16264189|NCT04926467|Experimental|Anakinra plus Chemotherapy|Patients will receive Anakinra during both pre-operative chemotherapy with Nab-paclitaxel, gemcitabine and cisplatin, followed by surgery and post-operative chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan.
16264190|NCT04926454|Experimental|TAP block|patients will receive general anesthesia followed by Tap block at the end of the operation.
16264191|NCT04926454|Experimental|Caudal block|patients will receive general anesthesia followed by caudal block at the beginning of the operation.
16264192|NCT04926441||Students from 8 European Universities, regardless of field of study and academic year|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
16264193|NCT04926428|Experimental|experimental arm|In situ thrombolysis with tPA
16264197|NCT04926402|No Intervention|Standard of care|The control group received standard routine care
16264198|NCT04926402|Experimental|Kangaroo care education program|The experimental group received a maternal kangaroo care education program
16264199|NCT04926389|Experimental|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|
16264200|NCT04926389|Active Comparator|low-level laser therapy applied every 3 weeks|
16264201|NCT04926350|No Intervention|Control|Tracking of outcomes during a normal week
16264202|NCT04926350|Experimental|Resistance Exercise|Tracking of outcomes during a normal week with the addition of daily resistance exercise breaks (8 breaks per day)
16264203|NCT04926337||Tight fitting facemask|Preoxygenation with tight facemask, 100% oxygen.
16264204|NCT04926337||High flow nasal oxygen|Preoxygenation with high flow nasal oxygen, 100% oxygen
16264205|NCT04926324|Experimental|Cohort 1 (starting)|niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
16264206|NCT04926324|Experimental|Cohort 2|niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
16264207|NCT04926311||Developmental Language Disorder patients|
16264208|NCT04926285|Experimental|Cohort 1|Omacetaxine 0.625 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
16264209|NCT04926285|Experimental|Cohort 2|Omacetaxine 1.25 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
16264210|NCT04926285|Experimental|Cohort 3|Omacetaxine 2.0 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
16264211|NCT04926285|Experimental|Cohort 4|Omacetaxine 2.5 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
16264212|NCT04926272|Experimental|18F-92, PET/CT|PET/CT perform after injecting 18F-92
16264213|NCT04926259|Experimental|18F-T807, PET/CT|PET/CT perform after injecting 18F-T807
16264214|NCT04926246|Experimental|Part 1: T1|T1: Test Product M, under fasted conditions
16264215|NCT04926246|Experimental|Part 1: T2|T2: Test Product N, under fasted conditions
16264216|NCT04926246|Experimental|Part 1: T3|T3: Test Product O, under fasted conditions
16264217|NCT04926246|Experimental|Part 1: T4|T4: Test Product O, under fed conditions
16264218|NCT04926246|Experimental|Part 1: R1|R1: Reference Product X, under fasted conditions
16264219|NCT04926246|Experimental|Optional Part 2: R2|R2: Reference Product Y, under fasted conditions
16264220|NCT04926246|Experimental|Optional Part 2: T5|T5: Test Product P, under fasted conditions
16264221|NCT04926246|Experimental|Optional Part 2: T6|T6: Test Product P, under fed conditions
16264222|NCT04926246|Experimental|Optional Part 2: T7|T7: Test Product Q, under fasted conditions
16264223|NCT04926246|Experimental|Optional Part 3: R3|R3: Reference Product Z, under fasted conditions
16264224|NCT04926246|Experimental|Optional Part 3: T8|T8: Test Product S, under fasted conditions
16264225|NCT04926246|Experimental|Optional Part 3: T9|T9: Test Product S, under fed conditions
16264226|NCT04926246|Experimental|Optional Part 3: T10|T10: Test Product U, under fasted conditions
16264227|NCT04926233||COPD patients from US IBM Marketscan database|
16264228|NCT04926233||COPD patients from UK CPRD GOLD database|
16264230|NCT04926207|Experimental|Physical Activity Breaks Intervention|Participants will sit continuously for 3 hours and interrupt their sitting by walking on a treadmill at a moderate intensity for 3 min.
16264231|NCT04926207|Active Comparator|Talking Breaks Control|Participants will sit continuously for 3 hours. They will interrupt solitary sitting activities (while remaining seated) by talking to a researcher for 3 min on pre-selected topics of general interest.
16264232|NCT04926194|Experimental|Patient with MDS/MPN|DSCs will be given 1 × 10^6 cells per kilogram of participant's body weight intravenously, administered once per week up to a maximum of six weeks depending on the clinical response.
16264233|NCT04926181|Experimental|Single Arm: Apalutamide + Cetrelimab|Participants will be given Apalutamide tablets combined with infusions of Cetrelimab in 28-day cycles, for up maximum of two years.
16264234|NCT04926168||Adjuvant TMZ (Treatment group):|"Adjuvant TMZ (temozolomide) will be given to patients as standard of Care (SOC) treatment is administered on an outpatient basis.
~Patients will be provided with medication diaries and instructed in their use. TMZ will be dispensed as SOC."
16264235|NCT04926168||Delay TMZ (Observation group):|"Patients in this cohort will have their TMZ in the adjuvant setting delayed and they will be observed with SOC procedures. Once the patient recurs, will be off observation and will be able to either have TMZ prescribed or something other."
16264236|NCT04926155|Experimental|Metformin+ADT+abiraterone|Patients in this arm will be treatet with metformin plus ADT and abiraterone
16264237|NCT04926155|No Intervention|ADT+abiraterone|Patients in this arm will be treatet with ADT and abiraterone, Abiraterone 1000mg once daily until disease progression.
16264238|NCT04926142||Patients planned for percutaneous PFO closure|Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.
16264239|NCT04926129||Subgroup 1|Participant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution [LogMAR] 0.2) will be enrolled.
16264240|NCT04926129||Subgroup 2|Participant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled.
16264241|NCT04926116|Experimental|AK3280 Cohort 1|Eligible subjects will be administered a single oral dose of 200 mg AK3280 under fasted conditions on Day 1. A multiple dosing period follows with daily 200 mg AK3280 b.i.d. administered with a concurrent low-fat meal intake from Day 4 to Day 16 and a 200 mg AK3280 q.d. dosing on Day 17.
16264242|NCT04926116|Experimental|AK3280 Cohort 2|The dose level of AK3280 for Cohort 2 will be determined by the SRC (Safety Review Committee) based on the safety and PK data gleaned in Cohort 1. Subjects will receive AK3280 following the same dosing schedule as that in Cohort 1, i. e., a single oral dose of AK3280 under fasted conditions on Day 1, multiple AK3280 b.i.d. administration with a concurrent low-fat meal intake from Day 4 to Day 16, and an AK3280 q.d. dose on Day 17.
16264243|NCT04926116|Experimental|AK3280 Optional Cohort|This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.
16264244|NCT04926116|Placebo Comparator|Control Arm|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
16264245|NCT04926103|Experimental|Open label FMT therapy|FMT from a related or unrelated healthy donor screened for known communicable disease
16264246|NCT04926090|Experimental|Emotional Support Plan - Clinician Guided (ESP-C) + (Bi)Weekly Monitoring|This will involve brief assessment visits throughout the fall semester, without prompting to use the ESP-C. Visits will be weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
16264247|NCT04926090|Experimental|Emotional Support Plan - Clinician Guided (ESP-C) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will also participate in brief assessment visits conducted weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
16264248|NCT04926090|Experimental|Emotional Support Plan - Self Guided (ESP-S) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will be asked to complete questionnaires weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
16264250|NCT04926051|Experimental|Part A: SAD|SAD = Single Ascending Dose
16264251|NCT04926051|Experimental|Part B: MAD|MAD = Multiple Ascending Dose
16264252|NCT04926051|Experimental|Part C: JMAD|JMAD= Japanese Multiple Ascending Dose
16264253|NCT04926051|Experimental|Part D: FE/BA|FE/BA = Food Effect/Relative Bioavailability
16264254|NCT04925986|Experimental|Group 1A: PD-L1 1-49%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
16264255|NCT04925986|Experimental|Group 1B: PD-L1 1-49%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
16264256|NCT04925986|Experimental|Group 2A: PD-L1 ≥ 50%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
16264257|NCT04925986|Experimental|Group 2B: PD-L1 ≥ 50%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
16264258|NCT04925973|Experimental|Treatment arm|Tofacitinib 10mg PO BID
16264259|NCT04925960|Experimental|Epalrestat|Epalrestat will be administered orally, 4 times per day (QID) spaced out as evenly as possible over 24 hours in a divided dose (3 mg / kg / day) starting on Day 1 of the Study.
16264260|NCT04925947|Experimental|KN046|KN046 will be given intravenously every 2 weeks.
16264261|NCT04925934|Experimental|VIB7734 SC (dosing interval 1)|
16264262|NCT04925934|Experimental|VIB7734 SC (dosing interval 2)|
16264267|NCT04925895|Experimental|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization (DSTM) is a soft tissue mobilization technique use to treat tight spasm using progressive muscle activation.
16264268|NCT04925895|Active Comparator|Proprioceptive neuromuscular facilitation stretching|PNF stretching technique, a type of flexibility training that is effective in improving muscle flexibility and restore functional ranges using a wide array of techniques.
16264269|NCT04925882|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levopubivacaïne for the realization of the erector spinae plane block."
16264270|NCT04925882|Placebo Comparator|Placebo|"The Placebo group corresponds to the reference group, that is to say that it will consist of patients who benefit from an injection of physiological serum for the realization of the erector spinae plane block."
16264271|NCT04925869||The hospitals of Besançon|Adult patients with MRI-confirmed CVA admitted to the hospitals of Besançon
16264272|NCT04925869||the hospitals of Cayenne|Adult patients with MRI-confirmed CVA admitted to the hospitals of Cayenne.
16264273|NCT04925869||the hospitals of Tours|Adult patients with MRI-confirmed CVA admitted to the hospitals of Tours.
16264274|NCT04925856|Experimental|Experimental|"4 différents cohorts:
~Paclitaxel cohort (N=30)
~Epirubicine - cyclophosphamide cohort (N=30)
~Eribuline cohort (N=30)
~Palbociclib ou Abemaciclib ou Ribociclib cohort (N=60)
~Study diagram :
~Inclusion and screening visite
~Visit 1: J1C1
~Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort
~Visit 3 :J21C1
~Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort
~During these visits, we collect, before the start of treatment administration ;
~Vital signs,
~Concomitant treatments,
~Blood sample:
~1 heparinized tube (4 mL) for collection of plasma and storage
~1 heparinized tube (4 mL) for immunophenotyping,
~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
16264275|NCT04925843||Patients undergoing liver transplant for end-stage liver disease|The investigators propose to conduct a retrospective cohort study to explore the association between fibrinogen concentration and intraoperative bleeding in patients who underwent a liver transplant between July 2008 and December 2020.
16264278|NCT04925817|Experimental|Diagnostic (ultrasound microvessel imaging)|Patients undergo 3 D ultrasound microvessel imaging over 45 minutes. Patients' medical records are reviewed.
16264279|NCT04925791|Experimental|The IPC group|subjects will get a standardized pre-conditioning treatment 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of occlusion alternating with 5 minutes of reperfusion while seated.
16264280|NCT04925791|Other|The CON group|subjects will get a controlled treatment of 20% of limb occlusion pressure 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of minimal occlusion alternating with 5 minutes of reperfusion while seated.
16264281|NCT04925765|Experimental|Virtual Reality Session|All participants in this study will complete a 1 hour virtual reality session.
16264282|NCT04925752|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF|"Participants will receive the following for at least 52 weeks:
~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks
~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily
~Oral LEN 600 mg on Days 1 and 2"
16264283|NCT04925752|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:
~SC LEN placebo every 26 weeks
~Oral F/TDF 200/300 mg once daily
~PTM Oral LEN on Days 1 and 2"
16264284|NCT04925752|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.
~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.
~Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and OLE Week 52 and will also receive oral LEN 600 mg on OLE Days 1 and 2."
16264285|NCT04925752|Experimental|PK Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.
~Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Coverage Phase.
~Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last injection of LEN."
16264286|NCT04925739||OSA patients treated with CPAP|"OSA patient, not previously treated with CPAP, are treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask during 30 days, monitored by the home care provider AGIRADOM.
~After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected."
16264287|NCT04925726|Active Comparator|Land based exercise|Land based exercise
16264288|NCT04925726|Active Comparator|Water based exercise|Water based exercise
16264289|NCT04925713|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion|One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
16264290|NCT04925700|Experimental|Probiotic Lozenge|
16264291|NCT04925700|Placebo Comparator|Placebo Lozenge|
16264292|NCT04925687|Experimental|Intravitreal autologous CD34+ cells|Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions
16265671|NCT04915950|Experimental|Temanogrel (Stage A Dose 2)|
16264293|NCT04925674|Experimental|HEC53856|HEC53856 Oral TIW There will be a total of 3 dose cohorts in the hemodialysis: 100mg，150mg，200mg； There will be only one dose cohort in the peritoneal dialysisp:100mg.
16264294|NCT04925661|Experimental|HEC53856|Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
16264295|NCT04925661|Active Comparator|Roxadustat|Drug: roxadustat TIW dosing There will be only one cohort: 70mg
16264296|NCT04925661|Placebo Comparator|Placebo|Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
16264299|NCT04925635||experimental group|The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group.
16264300|NCT04925635||control group|Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given.
16264304|NCT04925609|Other|Phase 1|"Phase 1:
~To estimate the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.
~To characterize the PK of brigatinib administered as monotherapy in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.
~Note that:
~If the MTD is not reached at the highest proposed test dose, no further dose-escalation will be performed.
~Pediatric PK data, compared to exposure in adults, and cumulative toxicity, will be taken into consideration to determine the RP2D regimen."
16264305|NCT04925609|Other|Phase 2|"Phase 2:
~• B1, ALK+ IMT: To establish the activity (ORR by RECIST 1.1) of single agent brigatinib when administered to children with ALK+ IMT.
~• B2, ALK+ ALCL: To establish the efficacy (EFS) of single agent brigatinib when administered to children with ALK+ ALCL for a duration of 2 years, without SCT in consolidation."
16264306|NCT04925596|Experimental|Intervention|general practitioners randomized to intervention group will be given access to ePrimaPrescribe online program
16264307|NCT04925596|Active Comparator|Control|general practitioners randomized to control group will be given access to an online program concerning doctor-patient communication
16264308|NCT04925583|Experimental|Level 0|Total dose 50 Gy, (10 x 5 Gy single dose)
16264309|NCT04925583|Experimental|Level 1|Total dose 55 Gy, (10 x 5.5 Gy single dose)
16264310|NCT04925583|Experimental|Level 2|Total dose 60 Gy, (10 x 6 Gy single dose)
16264311|NCT04925583|Experimental|Level 3|Total dose 65 Gy, (10 x 6.5 Gy single dose)
16264312|NCT04925570|Experimental|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
16264313|NCT04925570|Sham Comparator|Education Only|"Education Only delivers weekly fact sheets that include information on:
~Alcohol-specific topics;
~Drug-specific topics;
~General addiction topics;
~Statistics relating to alcohol and substance use."
16264314|NCT04925557|Active Comparator|Ocrevus|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Ocrevus by their neurologist.
16264315|NCT04925557|Active Comparator|Mayzent|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Mayzent by their neurologist.
16264316|NCT04925544|Experimental|VK-2019_arm|1800 mg VK 2019 once daily, cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
16264317|NCT04925531||Antibiotic use for <3 days|a retrospective chart review to examine if either the utility of antibiotics administered for 3 days make a difference in the clinical outcomes after facial fractures
16264318|NCT04925531||Antibiotic use for 5 days|a retrospective chart review to examine if either the utility of antibiotics administered for 5 days make a difference in the clinical outcomes after facial fractures
16264319|NCT04925518|Active Comparator|Conventional Ventilation Mode|Patients mechanically ventilated with a conventional mechanical ventilation mode until steady state is achieved for several hours.
16264320|NCT04925518|Experimental|Closed Loop Ventilation Mode|Once steady state on the conventional mechanical ventilation mode is achieved for several hours, switch to closed loop ventilation mode for the remainder of the study period.
16264321|NCT04925505||BPB success|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the SUCCESS (or failure) of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
16264322|NCT04925505||BPB failure|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the (success or) FAILURE of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
16264347|NCT04925310||RSV Bronchiolitis Group|hospitalized children with confirmed RSV infection between the first month of life and second year of life
16264348|NCT04925297||Non-NS ( Non-neurological sequelae) group|Patients who do not develop neurological dysfunction after acute carbon monoxide poisoning
16264323|NCT04925492|Experimental|Finding Optimal Scan Timing|Group A will receive two PET scans after the radiotracer injection to learn the best timing of the scan for the rest of the people in the study during participant's baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
16264324|NCT04925492|Experimental|Scan at Determined Optimal Timepoint|Group B participants will receive an injection of the radiotracer and undergo only one PET scan during a baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
16264325|NCT04925479|Experimental|Asciminib|"This arm consists of 2 groups:
~The pediatric formulation group where the dose is based on body weight (1mg/kg) except for participants of ≥ 1 to < 2 years of age, where age is taken into account in addition to body weight
~The adult formulation group where participants will receive a flat dose of 40mg BID"
16264326|NCT04925466|Experimental|Treatment with CPAP at 10cmH2O|Patients with OSA will be treated with CPAP at 10cmH2O during sleep.
16264327|NCT04925466|Experimental|Treatment with CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
16264328|NCT04925453|Experimental|Active tDCS|"Based on previous studies targeting working memory, focality of current delivery, and comfort and tolerance levels, (Paulo S. Boggio et al., 2006; Hill et al., 2016; Hoy et al., 2013; Teo, Hoy, Daskalakis, & Fitzgerald, 2011), we will use a 2 mA current administered via two circular carbon rubber core electrodes in saline-soaked surface sponges (25 cm2), placed in a neoprene headcap with marked locations based on the 10-10 EEG system. The anodal stimulating electrode will be at location F3, over left dorsolateral prefrontal cortex (DLPFC) and the cathodal electrode at location F4, over right DLPFC. Two reference electrodes, CMS and DRL, will be attached to the EarClip and applied to the earlobe with conductive gel.
~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
16264329|NCT04925453|Sham Comparator|Sham tDCS|"For sham stimulation, the electrodes will be placed at the same positions as for active stimulation (F3 and F4). After an initial ramp-up period of 30 seconds, stimulation fades out over a period of 30 seconds. Additionally, at the end of the sham stimulation period, stimulation will fade in over a period of 30 seconds and then end with a final 30 second ramp-down period. Participants will feel the initial itching sensation associated with tDCS and experience the ramp-down period at the end of the sham stimulation period but will receive no active current during the rest of the sham stimulation period. This method of sham stimulation has been shown to be reliable (Gandiga et al., 2006).
~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
16264330|NCT04925440|Experimental|Probiotic|Probiotic capsules. Participants will consume 2 capsules once a day for 8 weeks.
16264331|NCT04925440|Placebo Comparator|Placebo|Placebo capsules. Participants will consume 2 capsules once a day for 8 weeks
16264332|NCT04925427|Experimental|Case Management and Peer Recovery|Participants in the CM/PRC + OEND arm will receive one year of service delivery. During the initial intake interview the CM will identify primary, secondary, and tertiary barriers to treatment initiation and completion, then create an action plan tailored to each client. PRCs with lived SUD or incarceration experience will address recovery barriers, while CMs will focus on service barriers. Where beneficial and desired by the clients, PRCs will accompany clients to provider and select service appointments to promote engagement and retention. CM/PRC teams will provide OEND upon community re-entry. The teams will provide follow-up phone calls and home visits to facilitate service linkages. Contact frequency will depend on clients' individual barriers (e.g., transportation, homelessness), but will include at least weekly in-person or telephone check-ins for first six months, reduced to monthly check-ins after that.
16264333|NCT04925427|Placebo Comparator|Naloxone-Only|Participants randomized to the Usual care + OEND condition will be trained on naloxone administration by research staff at the time of randomization. Upon community re-entry,they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
16264334|NCT04925414|Experimental|oxygenotherapy|
16264335|NCT04925414|Placebo Comparator|placebo air aerosol|
16264336|NCT04925401|Experimental|Information brochure Arm|The experimental group will receive an information brochure on fever in children and how to deal with a febrile episode and usual medical management.
16264337|NCT04925401|No Intervention|Habitual care|The control group will receive the usual medical management
16264338|NCT04925388|Experimental|multiplex PCR|peritoneal samples will be analysed using Unyvero IAI test and using conventional method
16264339|NCT04925388|Other|conventional method|peritoneal samples will be analysed using only conventional method
16264340|NCT04925375|Experimental|Abatacept|"Pediatric subjects weighing <50 kg will be placed in an single arm with abatacept with dosing based on weight. Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26.
~Pediatric dosing:
~Abatacept subcutaneous every week:
~10-25 kg: 50 mg; 25-50 kg: 87.5 mg; >50 kg: 125 mg
~Adult dosing:
~Abatacept: 125 mg subcutaneous every week"
16264341|NCT04925375|Placebo Comparator|Placebo|Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26. The composition of the placebo is the same as the active study drug without the abatacept. To maintain the blind, injection volumes will be the same as the active treatment.
16264342|NCT04925362|Other|Patients|Patients with histologically confirmed NAFLD
16264343|NCT04925349||affected subjects|"adult patients with adrenomyeloneuropathy/adrenoleukodystrophy
~children with adrenoleukodystrophy
~children with metachromatic leukodystrophy"
16264344|NCT04925349||control subjects|-healthy children
16264345|NCT04925336|Experimental|Experimental|Nociceptive intervention arm
16264349|NCT04925297||NS (Neurological sequelae) group|Patients who develop neurological dysfunction after acute carbon monoxide poisoning
16264350|NCT04925284|Experimental|XB002 Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
16264351|NCT04925284|Experimental|XB002 Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), urothelial cancer (Cohort C), epithelial ovarian cancer [EOC] (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F) and pancreatic cancer (cohort G)
16264352|NCT04925271|Experimental|X-Tack|The gastrointestinal tract mucosal or submucosal defect is closed using the X-Tack device.
16264353|NCT04925271|Active Comparator|Overstitch|The gastrointestinal tract mucosal or submucosal defect is closed using the Overstitch device.
16264354|NCT04925258|No Intervention|Services-as-usual|Services-as-usual (referral list for online and telehealth parenting and family mental health services).
16264355|NCT04925258|Experimental|SPACE Parenting Program|"The experimental groups of Manitoba-based parent-child dyads (children ages 3-4 years old) include:
~1. Weekly parenting materials, including online videos and mailed out parenting activities, that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program. Also included are weekly drop-in group sessions with other parents facilitated by trained MA-level or higher psychology students or psychologists."
16264356|NCT04925245|Experimental|Clinical Reminder|
16264357|NCT04925245|No Intervention|No Reminder|
16264358|NCT04925232|Experimental|One group|All participants will undergo 2 weeks (5 times each week) of repetitive TMS
16264359|NCT04925219|Experimental|Remotely supervised exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.
~Intervention = electronic walking log and fortnightly video/telephone call with physiotherapist for 3 months."
16264360|NCT04925219|Active Comparator|Self-directed exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.
~Control = electronic walking log and instructions to exercise 4 times per week for 3 months"
16264361|NCT04925206|Experimental|ET-01|
16264366|NCT04925167|Experimental|argatroban group|Patients received argatroban for anticoagulation during V-V ECMO.
16264367|NCT04925167|Active Comparator|UFH group|Patients received UFH for anticoagulation during V-V ECMO.
16264370|NCT04925141|Experimental|Dasatinib tablets|Dasatinib tablets 100 mg orally once daily
16264371|NCT04925128|Experimental|Interventional Group|Hot pack for 10 min OR Infrared rays for 10 min Tens for 10 min Grade 2 mobilizations through maitland technique Treadmill walk for 30 to 150 minutes
16264372|NCT04925128|No Intervention|Control Group|Hot pack or Infrared rays for 10 min Tens for 10 min Grade 2 mobilizations through maitland technique
16264373|NCT04925115|Experimental|Interventional group|"Interventional group:
~Warm up and cool down (10 minutes before physical activity)
~Brisk walking ( 30 minutes each session for 5 days in a week)
~Week 1 to week 6 same protocol"
16264374|NCT04925115|No Intervention|Control group|Routine activity of daily life
16264375|NCT04925102||GMFCS level I|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level I will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
16264376|NCT04925102||GMFCS level II|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level II will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
16264377|NCT04925102||GMFCS level III|Goal specific treatment protocol with respect to the problem enlisted in GMFCS level III will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
16264378|NCT04925102||GMFCS level IV|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level IV will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
16264379|NCT04925102||GMFCS level V|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level V will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
16264380|NCT04925076|Experimental|Family History Positive|People reporting at least one parent with a history of alcohol problems.
16264381|NCT04925076|Experimental|Family History Negative|People who do not report having a parent with a history of alcohol problems.
16264382|NCT04925063|Experimental|Metformin+ADT+abiraterone|Drug: Metformin The starting daily dose of metformin is 500mg once daily, to be increased to 2000mg once daily if tolerated until disease progression Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
16264383|NCT04925063|No Intervention|ADT+abiraterone|Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
16264384|NCT04925050|Active Comparator|Drug VB0004|Experimental, Single Ascending dose , Multiple Ascending dose in healthy subjects and naive patients with mild or moderate hypertension with low cardiovascular risk
16264385|NCT04925050|Placebo Comparator|Placebo|Matching Placebo for VB0004
16264388|NCT04925011|Other|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
16264389|NCT04924998||AL-CM|
16264390|NCT04924985|Experimental|Physiological Feedback CPR|
16264391|NCT04924985|Active Comparator|Non-Physiological (Audiovisual) Feedback CPR|
16264392|NCT04924972||Intracutaneous Suture|
16264393|NCT04924972||running Suture|
16264394|NCT04924959||Modeling Group|
16264395|NCT04924959||Validation Group|
16264396|NCT04924933|Experimental|Patients (Epilepsy group)|Patients with drug-resistant focal epilepsy in whom an accelerated long-term forgetting is suspected (presence of a subjective memory complaint and absence of objective deficit in memory tests conducted in the frame of a routine comprehensive neuropsychological assessment)
16264397|NCT04924933|Active Comparator|Healthy volunteers (control group)|Age-matched healthy volunteers
16264398|NCT04924920|Experimental|Intervention EEO_SIGH|Single arm intervention. All the patients will receive the two tests (SIGH and EEOT) in 1:1 random sequence order (6 patient-block)
16264399|NCT04924907||Dysbiosis microbiota|microbiota with proinflammatory pattern or dysbiosis
16264400|NCT04924907||Normal microbiota|microbiota with antiinflammatory pattern or normal
16264401|NCT04924881|Experimental|Active Arm|COVID Rehab Formula granules once daily for 8 weeks
16264402|NCT04924881|Placebo Comparator|Placebo Arm|Placebo granules once daily for 8 weeks
16264403|NCT04924868|Active Comparator|UDCA (Ursodeoxycholic Acid) group|"Patients receiving Ursodeoxycholic Acid, capsules containing 300 mg, 10 mg/Kg per day:
~Patients 40 to 70 kg: 2 capsules/day >70 to 100 Kg: 3 capsules/day >100 kg: 4 capsules/day"
16264404|NCT04924868|Placebo Comparator|Placebo group|Capsules containing placebo, indistinguishable from active treatment.
16264405|NCT04924842||Children|Hospitalized children, 0 to 17 years of age, 30 subjects, consecutive sample survey, recruitment in quotas of five age ranges.
16264406|NCT04924842||Adults|Hospitalized adults, 18 years and above, 60 matched subjects
16264407|NCT04924829||Tocilizumab|Group that received tocilizumab (8mg/kg, maximum dose 800 mg, only once) while being admitted with severe COVID-19 pneumonia.
16264408|NCT04924829||Non-tocilizumab|Group that did not receive tocilizumab but share the same indication according to the elegibility criteria for it as the tocilizumab group while admitted with severe COVID-19 pneumonia.
16264409|NCT04924803|Experimental|No video condition|Participants in the no video condition will receive weekly text messages designed to increase vaccination among our sample.
16264410|NCT04924803|Experimental|Video text condition|Participants in the video text condition will receive the text messages designed to increase vaccination among our sample, along with links to iteratively developed intervention videos
16264411|NCT04924790||COVID-19 Urinary Stone|Patients diagnosed with obstructive urinary stones in the COVID-19 period
16264412|NCT04924790||PreCOVID-19 Urinary Stone|Patients diagnosed with obstructive urinary stones in the preCOVID-19 period
16264413|NCT04924777|Experimental|Brisk walk|
16264414|NCT04924777|Experimental|Aerobic Training|
16264415|NCT04924777|Experimental|Strength Training|
16264416|NCT04924764|Active Comparator|Follow-up on daily basis|Patient receiving treatments on daily basis (5 days a week)
16264417|NCT04924764|Active Comparator|Follow-up on alternate days|Patients receiving treatment on alternate days (3 days a week)
16264418|NCT04924751|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area was performed. After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
16264419|NCT04924751|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
16264420|NCT04924738||MOZART_SG|Women treated for hyperglycemia in pregnancy. Observational data are to be collected at follow-up visits during pregnancy, at delivery and postpartum.
16264421|NCT04924725|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area under CEH mode was performed.
16264560|NCT04923789||ASCT Without CART|Patients who undergone ASCT successfully and did not receive CART cell infusion.
16264422|NCT04924725|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4).
16264423|NCT04924712||Initial disease : nephrotic INS vs INS in remission|"25 nephrotic INS patients in primary visit: harvesting of 25 ml supplementary blood, urine and feces. No intervention, no treatment administration other than usual/routine INS treatment.
~vs. the same 25 patient in INS remission : harvesting of 25 ml supplementary blood, urine and feces at the remission visit. No intervention."
16264424|NCT04924712||Post-transplantation recurrence : recurring vs non-recurring INS|"25 INS patients recurring the initial disease after renal transplantation in post-recurrence visit: harvesting of 25 ml supplementary blood, urine and feces. No intervention, no treatment administration other than usual/routine INS treatment.
~vs. the 25 others INS patient non recurring after renal transplanatation: harvesting of 25 ml supplementary blood, urine and feces. No intervention."
16264425|NCT04924699|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
16264426|NCT04924686||Crohn's disease|The fecal and plasma were collected
16264427|NCT04924686||Ulcerative colitis|The fecal and plasma were collected
16264428|NCT04924686||Diabetes mellitus, type 2|The fecal and plasma were collected
16264429|NCT04924686||Atherosclerotic cardiovascular disease|The fecal and plasma were collected
16264430|NCT04924686||Colorectal cancer|The fecal and plasma were collected
16264431|NCT04924660|Experimental|TXA127|An investigational peptide agonist of Mas receptors.
16264432|NCT04924660|Experimental|TRV027|An investigational peptide biased agonist of the AT1 receptor.
16264433|NCT04924660|Placebo Comparator|Placebo|NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027).
16264434|NCT04924647|Experimental|RD|lenalidomide and dexamethasone
16264435|NCT04924634||Students|Students from 4 universities, regardless of field of study and academic year
16264436|NCT04924621|Experimental|THRIVE group|Patients in group T received mask ventilation(oxygen concentration: 100%, flow rate: 6L /min, head height: 30°) for 5 minutes, and then THRIVE device (device model: Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.) was set 100% oxygen, flow rate 30L /min, temperature 34℃.
16264437|NCT04924621|Placebo Comparator|Control group|The Control Group will receive mask ventilation (oxygen concentration: 100%, flow rate: 6L /min, head height: 30°) for 5 minutes
16264438|NCT04924608|Experimental|Arm A|Selumetinib
16264439|NCT04924608|Placebo Comparator|Arm B|Placebo
16264440|NCT04924595|No Intervention|Regular treatment|
16264441|NCT04924595|Experimental|Exercise Intervention|
16264442|NCT04924582|Experimental|Capacity Coaching|Participants randomized to the Capacity Coaching arm will receive three months of coaching with a Health and Wellness coach. They will receive one one-hour session and five half-hour sessions approximately two weeks apart.
16264443|NCT04924582|No Intervention|No Capacity Coaching|Participants randomized to the No Capacity Coaching arm will receive usual care.
16264444|NCT04924569||Standard of Care|Individuals using an intermittent catheter to void urine through the urethra. Participants use their currently prescribed intermittent catheter per their clinician's standard of care.
16264445|NCT04924543|Active Comparator|Received short refresher training on optical diagnosis|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 Half of participants randomized 1:1 will also receive access to brief refresher training by week 8
16264446|NCT04924543|Active Comparator|No refresher training|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 This arm does not also receive access to brief refresher training
16264447|NCT04924530|Sham Comparator|Maltodextrin|Glucose polymer; a common sugar substitute
16264448|NCT04924530|Active Comparator|Sucrose|Fructose-glucose disaccharide
16264449|NCT04924530|Experimental|Lactose|Galactose-glucose disaccharide
16264450|NCT04924517|Experimental|Extended Evening Fasting|Participants will eat between 8am-4pm
16264451|NCT04924517|Active Comparator|Control|Participants will eat between 8am-8pm
16264452|NCT04924504||Type A|Healthy pregnant women without pregestational or gestational diabetes
16264453|NCT04924504||Type B|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose <= 75 units/day
16264454|NCT04924504||Type C|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose >= 100 units/day
16264455|NCT04924491|Experimental|10.000.000 thyTreg /kg|Autologous thyTreg 10.000.000
16264456|NCT04924491|Experimental|20.000.000 thyTreg /kg|Autologous thyTreg 20.000.000
16264457|NCT04924478||Severe Asthma Patients Treated with Mepolizumab|Following treatment, patients will be stratified into responders or non-responders
16264458|NCT04924465||Anti-Jo1|Patients with anti-Jo1 antibodies
16264459|NCT04924465||Anti-PL7|Patients with anti-PL7 antibodies
16264460|NCT04924465||Anti-PL12|Patients with anti-PL12 antibodies
16264461|NCT04924465||Anti-EJ|Patients with anti-EJ antibodies
16264462|NCT04924465||Anti-OJ|Patients with anti-OJ antibodies
16264463|NCT04924452|Experimental|Er:YAG laser therapy|Er:YAG laser will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment.
16264464|NCT04924452|Active Comparator|Conventional therapy|Conventional rotary instruments will be used for caries treatment.
16264465|NCT04924439|Experimental|experimental group (foot reflexology group)|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).
~Different rooms were allocated for the participants in the intervention and control groups not to affect each other.
~Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks."
16264561|NCT04923789||ASCT Bridging CART|Patients who undergone ASCT and received CART cell infusion sequently within 1 month. Patients with disease recurrence or progression prior to the infusion of CART cells will be excluded.
16264466|NCT04924439|No Intervention|control group|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).
~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
16264467|NCT04924426||Patients with AMI|Patients with AMI
16264468|NCT04924426||Patients with no AMI|Patients with no AMI
16264469|NCT04924413|Experimental|L-TIL and Tislelizumab|L-TIL（3-10）x10*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year
16264470|NCT04924400|Active Comparator|CHIP Program|GHP members randomized to the intervention arm will participate in the CHIP Program.
16264471|NCT04924400|Active Comparator|Usual Diabetes Care|GHP members assigned to the control arm will receive the routine standard of care for GHP members.
16264472|NCT04924387|Experimental|Experimental Group (EXP group)|The experimental group (EXP Group) is going to follow a programme of stabilisation through specific therapeutic exercises of the lumbopelvic centre. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each sesión will have a duration of 60 minutes, the first 5 minutes for a warm-up and the last 10 for a cool-down phase of active stretching. All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercices will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercies of 2-3 minutes.
16264473|NCT04924387|Active Comparator|Experimental Group and Manual Therapy (MT Group)|Additionally to the core exercises previously exposed in Group EXP, Group MT will lay on the stretcher first, where the physiotherapist will work on a manual therapy thrust. The patient will receive an impulse technique in lateral decubitus position, with high velocity and low range on both sides.
16264474|NCT04924387|Active Comparator|Experimental Group and Kinesio Tape (KT Group)|"The experimental group plus kinesio tape (KT Group) will go previously through physiotherapy, where a kinesio tape band will be applied (kinesio tape Nondolens 5cm x 5cm black color), in Y technique, by applying the KT base in neutral position of the lumbar spine without any tension on the tape."
16264477|NCT04924361||Early onset dementia|Dementia patients with onset age lower than 65y/o
16264478|NCT04924361||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
16264479|NCT04924361||Oldest old dementia|Dementia patients with onset age older than 85y/o
16264480|NCT04924361||Cognitive normal control|cognitive normal control
16264481|NCT04924348|Experimental|WALANT procedure|Local anesthesia of the WALANT type
16264482|NCT04924348|Active Comparator|Axial ALR|Axillary loco-regional anesthesia
16264483|NCT04924348|Active Comparator|Truncal ALR|Truncal loco-regional anesthesia
16264484|NCT04924335|Active Comparator|ESP group|ESP group patients will be performed ultrasound-guided erector spinae plane block with 20 ml 0.025% Bupivacaine, preoperatively and will receive ERAS cardiac anesthesia protocol
16264485|NCT04924335|No Intervention|Conventional group|The conventional group will receive ERAS cardiac anesthesia protocol
16264486|NCT04924322|Experimental|Enoxaparin (Older Children Prophylactic)|Prophylactic dose of enoxaparin for older children 1-17 years old.
16264487|NCT04924322|No Intervention|Control (Older Children)|Usual care without placebo for older children 1-17 years old.
16264488|NCT04924322|Experimental|Enoxaparin (Infants Therapeutic High Anti-Xa Target)|Therapeutic dose of enoxaparin for infants <1 year old with anti-Xa target of >0.5-1 IU/mL.
16264489|NCT04924322|Experimental|Enoxaparin (Infants Therapeutic Low Anti-Xa Target)|Therapeutic dose of enoxaparin for infants <1 year old with anti-Xa target of 0.2-0.5 IU/mL.
16264490|NCT04924322|No Intervention|Control (Infants)|Usual care without placebo for infants <1 year old.
16264491|NCT04924309||Patients undergoing assisted reproductive technology with donor sperm|
16264492|NCT04924309||Patients undergoing assisted reproductive technology with husband's semen due to male factor|
16264493|NCT04924296|Experimental|Treatment group A|
16264494|NCT04924296|Placebo Comparator|Treatment group B|
16264495|NCT04924283|Experimental|Cognitive Interference Task|Participants in this arm will complete random assessments of alcohol use and cravings on their phone, and be prompted to play Tetris on their phone after reporting cravings for alcohol.
16264496|NCT04924283|Active Comparator|Assessment Only|Participants in this arm will complete random assessments of alcohol use and cravings on their phone.
16264497|NCT04924270|Experimental|cFMT|
16264498|NCT04924270|Placebo Comparator|Placebo|
16264499|NCT04924257|Experimental|Intranasal Esketamine|
16264500|NCT04924257|Active Comparator|ECT|
16264501|NCT04924244|Active Comparator|No Music|No music will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
16264502|NCT04924244|Experimental|Music Therapy|Music of the subject's preferred genre will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
16264503|NCT04924218|Active Comparator|rigid cystoscopy|Group undergoing endoscopic urethral procedure with rigid cystoscopy after radical prostatectomy
16264504|NCT04924218|Active Comparator|flexible cystoscopy|Group undergoing endoscopic urethral procedure with flexible cystoscopy after radical prostatectomy
16264505|NCT04924218|Active Comparator|semi-rigid ureterorenoscopy|Group undergoing endoscopic urethral procedure with semi-rigid ureterorenoscopy after radical prostatectomy
16264506|NCT04924205|No Intervention|Outpatient Physical Therapy|
16264507|NCT04924205|Experimental|Smart Orthotic Device (FM2 Knee Brace)|
16265672|NCT04915950|Placebo Comparator|Placebo (Stage A)|
16264508|NCT04924192|Experimental|TQB3616 capsules+Anlotinib hydrochloride capsules|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.
16264509|NCT04924192|Experimental|TQB3616 capsules +Irinotecan Hydrochloride for Injection|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.
16264510|NCT04924179|Experimental|Tislelizumab plus Surufatinib and SBRT|
16264511|NCT04924166|Placebo Comparator|Placebo|matching capsule PO
16264512|NCT04924166|Active Comparator|HCORT|180 mg capsule PO
16264513|NCT04924153||EIMFS and EOEE (Up to 2 years)|Participants who have been diagnosed with epilepsy of infancy with migrating focal seizures (EIMFS) and early-onset epileptic encephalopathy (EOEE) with duration of symptoms for up to 2 years will be enrolled.
16264514|NCT04924153||EIMFS and EOEE (More than 2 years)|Participants who have been diagnosed with EIMFS and EOEE with duration of symptoms for more than 2 years will be enrolled.
16264515|NCT04924153||SHE (Up to 2 years)|Participants who have been diagnosed with sleep-related hypermotor epilepsy (SHE) with duration of symptoms for up to 2 years will be enrolled
16264516|NCT04924153||SHE (More than 2 years)|Participants who have been diagnosed with SHE with duration of symptoms for more than 2 years will be enrolled.
16264524|NCT04924088|Experimental|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
16264525|NCT04924088|Active Comparator|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
16264527|NCT04924062|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
16264528|NCT04924062|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
16264529|NCT04924049|Experimental|Experimental|The video-assisted education group also received routine treatment and care per protocol. Additionally, this patient group watched patient education through video in the patient room before TKR. The contents of the VE were developed by the researchers and included early postoperative care for TKR (knee positioning, early mobilization, pain control, and cold application), ADLs at home (bathing and toileting, eating, sleeping, vehicle driving, housekeeping, sexual life, praying, and maintaining home safety), and gradual exercise at home (for the first 90 days after discharge).
16264530|NCT04924049|No Intervention|Control|The control group received routine treatment and care per protocol.
16264531|NCT04924036|Other|Glycopyrronium Cloths then Placebo|Participants that are randomized to Glycopyrronium cloths for 4 weeks, then 2 week wash out, then cross over to placebo cloths for 4 weeks.
16264532|NCT04924036|Other|Placebo then Glycopyrronium Cloths|Participants that are randomized to placebo cloths for 4 weeks, then 2 week wash out, then cross over to Glycopyrronium cloths for 4 weeks.
16264591|NCT04923607|Experimental|TQC2731 injection(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .
16265673|NCT04915950|Experimental|Temanogrel (Stage B Dose 1)|
16264533|NCT04924023|Experimental|Kaleidoscope Group|Children in this group were told what a kaleidoscope is and how to use it before their central venous catheter dressing. The children were then asked if they would like to look into the kaleidoscope. The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished. The kaleidoscope was disinfected before each use. A kaleidoscope was provided for all children in this group by the same researcher. Parents accompanied their children during the catheter dressing.
16264534|NCT04924023|No Intervention|Control Group|No intervention was performed to reduce pain and anxiety for children in the control group. Parents accompanied their children during the procedure.
16264535|NCT04924010|Active Comparator|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy (CBT) is a talking therapy that can help patients manage problems by changing the way they think and behave. It's most commonly used to treat anxiety, depression and chronic pain conditions.
16264536|NCT04924010|Placebo Comparator|Education and Mindfulness|Education and mindfulness therapy refers to lessons on techniques to calm the mind and body - can reduce the negative effects of stress
16264537|NCT04923997|Experimental|HealthScore Health Coaching|Participants on this arm of the study receive a physical activity tracker, weekly surveys and weekly health coaching for 6 months.
16264538|NCT04923984|Experimental|Embolization of Middle Meningeal Artery for Subdural Hematoma|All patients with CSDH will undergo embolization of Middle Meningeal artery
16264539|NCT04923971|Active Comparator|0C Trial|Participants will be sitting in a chair performing hand dexterity tasks in 0C (32F) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
16264540|NCT04923971|Active Comparator|-10C Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C (14F) conditions.Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
16264541|NCT04923971|Active Comparator|-20C Surrogate Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C + 3m/s wind (14F+6 mph wind) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
16264542|NCT04923958|Experimental|Evaluation of various novel TB triage and diagnostic tests.|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 1500 patients, including 300 people living with HIV and 300 people with diabetes, for evaluation of various novel TB triage and diagnostic tests.
16264543|NCT04923958|Experimental|Evaluation of novel rDST assays|Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 200 patients for evaluation of novel rDST assays.
16264544|NCT04923945|Experimental|Savolitinib|NSCLC
16264545|NCT04923932|Experimental|Savolitinib|GC
16264546|NCT04923919|Experimental|Single arm|CLL-1 targeting CAR-T treatment
16264547|NCT04923906|Experimental|Aumolertinib and platinum-based chemotherapy|
16264548|NCT04923906|Active Comparator|Aumolertinib|
16264549|NCT04923893|Experimental|Arm A: VRd+Rd (Standard Therapy)|Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 25 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity.
16264550|NCT04923893|Experimental|Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel)|Participants will receive VRd regimen for 6 cycles before randomization. Following randomization, participants in Arm B will undergo apheresis and receive two more cycles of VRd as bridging therapy. In VRd treatment, participants will receive bortezomib 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each cycle for Cycles 1 to 8; oral lenalidomide 25 mg on days 1 to 14 of each cycle for Cycles 1 to 8 and oral dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle for Cycles 1 to 8. Each cycle will consist of 21 days. After 8 cycles of VRd, participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg).
16264551|NCT04923880|Other|Implementation of Primary Palliative Care Intervention in CF Centers|Implement a Primary Palliative Care intervention comprising screening-and-triage workflows, best practice treatment guides for high frequency problems, patient/family and provider education, and a quality improvement (QI) toolkit in 5 CF centers.
16264552|NCT04923867||Supratentorial Procedure Group|Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.
16264553|NCT04923867||Infratentorial Procedure Group|Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.
16264554|NCT04923867||Spinal Procedure Group|Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.
16264555|NCT04923841|No Intervention|Control|Subjects in control will receive single vision spectacle lenses and a placebo desk lamp
16264556|NCT04923841|Experimental|BLT monotherapy|Subjects in BLT monotherapy group will receive a high intensity light box for bright light therapy and single vision spectacle lenses
16264557|NCT04923841|Experimental|BLT and DIMS|Subjects in BLT and DIMS group will receive a high intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
16264558|NCT04923815||AVNRT|atrioventricular nodal reentrant tachycardia
16264559|NCT04923815||AVRT|atrioventricular reentrant tachycardia, including Wolff-Parkinson-White syndrome（WPW）
16264562|NCT04923776|Experimental|Experimental: Chemotherapy+SBRT|"Addition of SBRT, directed at liver metastases, to standard of care (SOC) treatment atezolizumab+chemotherapy in SCLC. All patients must undergo a mandatory biopsy of a liver lesion prior to chemotherapy initiation.
~Cycle 1 of chemoimmunotherapy will be administered as per standard of care, with radiation planning to be done subsequently in anticipation of liver-directed SBRT."
16264563|NCT04923763||Tongue_examination|The general public will be invited for tongue examination. The data will be used to establish the automatic tongue video analysis system.
16264564|NCT04923737|Active Comparator|Dexmedetomidine group|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
16264565|NCT04923737|Placebo Comparator|Control group|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
16264566|NCT04923724|Active Comparator|Tourniquet during surgery|Patients in this group get a tourniquet during surgery.
16264567|NCT04923724|Active Comparator|No Tourniquet during surgery|Patients in this group do not get a tourniquet during surgery.
16264568|NCT04923711|Experimental|Moderate Intensity Group|Group received a moderate exercise prescription of moderate intensity
16264569|NCT04923711|Experimental|High Intensity Group|Group received a moderate exercise prescription of high intensity
16264570|NCT04923698|Active Comparator|yoga|The yoga program consisted of 12 exercises, , 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
16264571|NCT04923698|Active Comparator|antidepressant|All women in group A were treated by antidepressant only for 12 weeks
16264572|NCT04923685||MDD with elevated CM and suicidality scores|Major Depressive Disorder with elevator childhood maltreatment and suicidality scores.
16264573|NCT04923685||MDD with CM history but lower suicidality|Major Depressive disorder with childhood maltreatment history but lower suicidality scores.
16264574|NCT04923685||MDD without CM but with elevated suicidality|Major Depressive Disorder without childhood maltreatment, but with elevated suicidality scores.
16264575|NCT04923685||MDD without CM but with lower suicidality|Major Depressive Disorder without childhood maltreatment but with lower suicidality scores.
16264576|NCT04923685||Healthy controls with CM history|Healthy controls with childhood maltreatment history,
16264577|NCT04923685||Healthy controls without CM history|Healthy controls without childhood maltreatment history.
16264578|NCT04923672|No Intervention|Control group|Participants will be asked to wear an Apple watch through about 30 days after surgery and will be asked to maintain their current activity level.
16264579|NCT04923672|Active Comparator|Moderate continuous training group|"Apple watch and a smartphone application
~Increase activity to 5 days a week, 40 minutes a day of continuous moderate intensity exercise prior to surgery."
16264580|NCT04923672|Active Comparator|High intensity interval training group|"Apple watch and a smartphone application
~Increase activity to 5 days a week, 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery."
16264581|NCT04923659|Experimental|LIFUS|Low Intensity Focussed ultrasound.
16264582|NCT04923646|Experimental|Active|Primer
16264583|NCT04923646|No Intervention|Control|No Primer
16264584|NCT04923633||Phase I Instrument-Assisted Soft Tissue Manipulation (IASTM) Stroke Pattern Analysis|Fifteen (n=15) experienced clinicians, each with 8 or more years experiences in instrument-assisted soft tissue manipulation (IASTM), will participate in an observational studying analyzing their application of basic stroke patterns (linear, curved) to a consistent research assistant/model. IASTM is a type of massage that uses rigid devices. A Quantifiable Soft Tissue Manipulation (QSTM) device system will be used for determining objective metrics of stroke parameters (e.g. stroke force, rate, angle) and results will be compared between participants to determine characteristic stroke profile patterns for use in training and research.
16264585|NCT04923633||Phase II Consistency of IASTM Force Application|"The reproducibility of applying a targeted STM stroke force will be determined within and between therapists, both with and without visual monitoring of the QSTM metrics and graphic display. Two novice and two experienced therapists will be trained using QSTM. A novice is defined as a clinician with <1 year and an experienced with >8 years of practice. Fifty (n=50) healthy, non-obese subjects will be enrolled that meet the inclusion/exclusion criteria. First, the clinicians will apply a self-perceived moderate force for 15sec (non-therapeutic dose), within subject tolerance, without using QSTM feedback. Then, the clinician will apply a targeted force of 10N with visual monitoring of QSTM feedback. This process will be repeated 5-7 days later to determine repeatability. After testing, subjects will participate in simple back and/or leg stretches and an ice pack applied."
16264586|NCT04923633||Phase III Reliability of Dynamic Pressure Pain Threshold Assessment|"The reliability of dynamic pressure pain threshold (DPPT) assessment over a specified area will be determined. Two novice and two experienced clinicians will be trained using QSTM. Subjects (n=50) will be recruited that meet the inclusion/exclusion criteria of healthy, non-obese, younger (≥18 but ≤30yo) and older individuals (≥50 but ≤75yo) (males and females). The clinicians will apply force to standardized areas of the back and thigh regions for 1 min, using the Quantifiable Soft Tissue Manipulation (QSTM) device system. The force applied will be applied up to but below the threshold of when a subject says to stop when they feel the pressure change into any sort of irritating discomfort/pain. Secondary clinical outcomes will be assessed before and after testing since testing could have effects on the soft tissue, pain, and physical performance measures. After testing, the subject will be instructed in simple back and/or leg stretches and an ice pack applied."
16264587|NCT04923607|Experimental|TQC2731 injection(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once.
~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 ."
16264588|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once.
~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg)."
16264589|NCT04923607|Experimental|TQC2731 injection(SAD,iv.)|Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
16264590|NCT04923607|Placebo Comparator|Matching Placebo(SAD,iv.)|Healthy subjects received 210mg matching placebo intravenously (iv.) once.
16264592|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .
16264595|NCT04923581|Experimental|Condition 1|Participants will receive the constant component only.
16264596|NCT04923581|Experimental|Condition 2|Participants will receive the constant component and storytelling videos .
16264597|NCT04923581|Experimental|Condition 3|Participants will receive the constant component and oral health promotion messages.
16264598|NCT04923581|Experimental|Condition 4|Participants will receive the constant component and a motivational interview session.
16264599|NCT04923581|Experimental|Condition 5|Participants will receive the constant component, oral health promotion messages and storytelling videos.
16264600|NCT04923581|Experimental|Condition 6|Participants will receive the constant component, oral health promotion messages, storytelling videos, and a motivational interview session.
16264601|NCT04923581|Experimental|Condition 7|Participants will receive the constant component, oral health promotion messages and a motivational interview session.
16264602|NCT04923581|Experimental|Condition 8|Participants will receive the constant component, storytelling videos, and a motivational interview session.
16264603|NCT04923568|Experimental|EaseVRx sessions|This is a study of patients with chronic pain to identify interest in participating in a large VR trial and, for those willing to join us to test the device in person, to pilot 2 sessions of VR to assess usability and collect preliminary data on pain and mood and to obtain data on patient satisfaction with device use. The entire session will last 45 minutes to 1 hour. All patients recruited will be in the active arm; this is not a randomized pilot study.
16264604|NCT04923555|Experimental|Group/Cohort1|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in cysteine, leucine and arginine (VP, vegetable proteins) only once during the visit
16264605|NCT04923555|Experimental|Group/Cohort2|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in animal proteins (AP) only once during the visit
16264606|NCT04923555|Placebo Comparator|Group/Cohort3|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt without any proteins (T) only once during the visit
16264609|NCT04923529|Experimental|TAS-102|Single group assignment of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma
16264610|NCT04923503|Experimental|lean ramadan fasting|conduct ramadan fasting for 30 days
16264611|NCT04923503|Experimental|obese ramadan fasting|conduct ramadan fasting for 30 days
16264612|NCT04923503|Experimental|diabetics ramadan fasting|conduct ramadan fasting for 30 days
16264613|NCT04923477|Experimental|Exercise Group|Therapeutic exercise of resistance and mobility training delivered by a trained health professional x 4 weeks.
16264614|NCT04923464||ELX/TEZ/IVA|CF participants who are currently on a stable regimen of commercially available ELX/TEZ/IVA will be evaluated for the performance of wearable technology devices. Wearable devices include a wrist-worn actigraphy sensor and an ambulatory cough monitoring system.
16264615|NCT04923451|Active Comparator|Patient with sexual addiction - active stimulation|25 patients with sexual addiction will be stimulated by active tDCS during 5 consecutive days
16264616|NCT04923451|Sham Comparator|Patient with sexual addiction - sham stimulation (placebo)|25 patients with sexual addiction will be stimulated by sham tDCS stimulation (placebo) during 5 consecutive days
16264617|NCT04923438|Experimental|telerehabilitation|The exercises will be applied twice a week for a total of 12 weeks, and each program will last roughly 30 minutes.
16264618|NCT04923438|Active Comparator|control|The same exercise program will be prepared and given as a printout and they will be asked to do their exercises at home. This group will also be included in the study as a control group.
16264619|NCT04923425||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
16264620|NCT04923425||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
16264621|NCT04923425||Non exposure|Non-pharmacological treatment (psychotherapy)
16264622|NCT04923412|Experimental|Pulmonary branch of vagus nerve preserved|Pulmonary branch of vagus nerve is preserved during the mediastinal lymph node dissection using minimally invasive surgery
16264623|NCT04923412|Experimental|Pulmonary branch of vagus nerve not-preserved|Pulmonary branch of vagus nerve is not preserved during the mediastinal lymph node dissection using minimally invasive surgery
16264624|NCT04923399||TN (Trigeminal Neuralgia) group|Trigeminal neuralgia patients undergoing trigeminal nerve microvascular decompression
16264625|NCT04923399||Non-TN group|patients without chronic pain or history of chronic pain
16264626|NCT04923386||Diabetics who receive mRNA COVID-19 vaccine|Patients that have a history of Diabetes Mellitus Type I or Type II who received Pfizer-N-Biotech or Moderna mRNA COVID-19 vaccines
16264627|NCT04923373|Experimental|telerehabilitation|physiotherapeutic programme brochure exercises 7/week controlled by phone every week (5x in total)
16264628|NCT04923373|Active Comparator|standard physiotherapy|"Supervised physical therapy 3/ week,
~+ physiotherapeutic programme brochure 4/week"
16264629|NCT04923347|Experimental|Participants receiving FF/UMEC/VI via ELLIPTA inhaler|
16264689|NCT04922957|Experimental|ALLOCETRA-OTS|Single IV dose of Allocetra-OTS containing 10x10^9 cells
16265674|NCT04915950|Experimental|Temanogrel (Stage B Dose 2)|
16264630|NCT04923334|Experimental|Brief Pain Teleconsult|Participants randomized to Brief Pain Teleconsult will receive the brief teleconsult intervention in Phase 1 (1-12 weeks) Responder status to the Phase 1 treatment will be examined at the 12 week assessment. Participants determined to be non-responders will receive the Telehealth Physical Therapy intervention. Responders receive no additional treatment.
16264631|NCT04923334|Experimental|Brief Pain Teleconsult plus Telehealth Physical Therapy|Participants randomized to Brief Pain Teleconsult plus Telehealth Physical Therapy will receive the brief teleconsult intervention in Phase 1 followed by the 10-week physical therapy intervention. No additional treatment is provided after the 12 week assessment.
16264632|NCT04923321||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
16264633|NCT04923321||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
16264634|NCT04923321||Non exposure|Non-pharmacological treatment (psychotherapy)
16264635|NCT04923308||Intervention group|
16264636|NCT04923308||Control group|
16264637|NCT04923295|Experimental|Pre Treatment and post treatment|Patients on Peritoneal Dialysis will be evaluated by PET and transport status Patients on Peritoneal Dialysis will be evaluated by PET after treatment with Dapagliflozin
16264638|NCT04923282|Active Comparator|Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo|single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
16264639|NCT04923282|Active Comparator|Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo|single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
16264640|NCT04923282|Active Comparator|Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo|single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
16264641|NCT04923282|Active Comparator|Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3|1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
16264642|NCT04923269|Experimental|LY3532226|Single ascending doses of LY3532226 administered subcutaneously (SC).
16264643|NCT04923269|Placebo Comparator|Placebo|Placebo administered SC.
16264644|NCT04923256|Experimental|Experimental: Approach Bias Modification|Participants will complete 2 x 5-7 min training sessions of approach bias modification for the period of four weeks
16264645|NCT04923256|Active Comparator|Control: Minimal intervention|Participants will complete a standardised alcohol approach-avoidance training task (AAT) on a weekly basis for four weeks.
16264646|NCT04923243||Delirium group|Group of patients with postoperative delirium
16264647|NCT04923243||Non delirium group|Group of patients without postoperative delirium
16264648|NCT04923230|Experimental|CAP Intervention|CAP is a parent-focused intervention being developed to help parents in states with legalized medical marijuana to address adolescent marijuana use. The proposed intervention will address the effects of marijuana on adolescent behavioral health, brain development, and social functioning and enhance parent motivation to use CAP concepts. Guided by formative research, CAP will build skills and provide strategies to: (1) restrict adolescent exposure to cannabis products and parent cannabis use in the home, (2) improve parent communication about their own cannabis use and expectations about youth marijuana use, (3) improve monitoring, (4) increase positive reinforcement for youth abstinence, and (5) address parent negative emotions. Parents will meet in groups with an interventionist for two 75-minute sessions. Presentations, discussion, and roleplay will be used to help parents gain mastery of preventive parenting behaviors and related strategies to reduce adolescent marijuana use.
16264649|NCT04923230|No Intervention|Wait List|Parents randomly assigned to Wait List Delayed CAP (WL) will receive no intervention for the baseline to 3-month follow-up period. Thus, the WL condition will serve as a comparison group from baseline to the 3-month assessment point. After the 3-month follow-up assessment, WL parents will be offered the CAP intervention. The final assessment for the WL participants will function as a 3-month follow-up assessment, allowing us to aggregate data all 60 parent-adolescent dyads to conduct within group analyses of pre- to post-intervention change on key variables of interest.
16264650|NCT04923204||Bipolar depression pharmacogenetics|Patients 18 years and older, with a diagnosis of bipolar disorder with an index episode of depression with or without associated psychotic symptoms (according to the Diagnostic Manual of Mental Disorder 4th Edition Text Revision, DSM-IV-TR), who attended the Bipolar Disorder Program of the Psychiatry Service of the Hospital Clínic de Barcelona (Spain).
16264651|NCT04923191|Other|Angiography-derived Physiology Guidance (Quantitative Flow Ratio, QFR)|
16264652|NCT04923191|Other|Local routine diagnostic procedure (LRDP) and usual care|
16264659|NCT04923165||patients with stroke|Inpatients and outpatients admitted to the investigators' rehabilitation facility .
16264660|NCT04923152|Experimental|moderate dose statin|Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day
16264661|NCT04923152|Active Comparator|high dose statin|patients 1 month post PCI, allocated to 40 mg rosuvastatin
16264662|NCT04923139||Japanese VTE patients including Ca-VTE patients|Include a large number of adult VTE patients (including Ca-VTE patients) prescribed rivaroxaban who visited facilities covered by the MDV database
16264663|NCT04923126|Experimental|Phase I: Recurrent and/or progressive low-grade glioma without prior exposure to MEK inhibitors|Participants will receive mirdametinib at one of the dose levels twice daily days 1-28. For the first cycle of treatment, participants will take mirdametinib tablets dissolved in water. After the first cycle of treatment, participants may receive the medicine the same way (dissolved in water) or may receive capsules. Treatment repeats every 28 days for up to 26 cycles of treatment (24 months) in the absence of disease progression or unacceptable toxicity.
16264664|NCT04923126|Experimental|Phase 2, Cohort 1: Newly diagnosed and/or previously untreated (except surgery)|Participants will receive the RP2D of mirdametinib. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
16264665|NCT04923126|Experimental|Phase 2, Cohort 2: Recurrent and/or Progressive without prior exposure to MEK inhibitors|Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
16264666|NCT04923126|Experimental|Phase 2, Cohort 3a:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants with previous exposure to mirdametinib may receive a starting dose lower than the RP2D, depending on the dose they tolerated during their previous exposure. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
16264667|NCT04923126|Experimental|Phase 2, Cohort 3b:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
16264668|NCT04923113|Experimental|patients who meet the inclusion criteria|5 different methods will be performed to detect H. pylori infection in patients who meet the inclusion criteria，and patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.
16264669|NCT04923087||Patient hospitalized in geriatrics or EHPAD|Subjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents
16264670|NCT04923074||DTI group|the patient in this group will receive DTI evaluation
16264671|NCT04923074||routine group|the patient in this group will receive routine evaluation
16264672|NCT04923061|Experimental|Acupressure group|The experimental group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
16264673|NCT04923061|Sham Comparator|Sham acupressure group|The sham group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
16264674|NCT04923048|Experimental|GB261|Participants will receive GB261 via intravenous (IV) infusion as a single agent on Day 1, Day 8 and Day 15 of Cycle 1 and 2 followed by Day 1 of each cycle（21 days per cycle） afterwards until disease progression or other situations specified in the protocol, whichever comes earlier.
16264675|NCT04923035||Case|"Children aged 5 years and below with clinically diagnosed pneumonia and attending the outpatient's department or admitted as a hospital inpatient at three sentinel sites. Pneumonia. Suspected pneumonia cases will be identified by a family physician or paediatrician based on medical history and clinical symptoms.
~Pneumonia is defined as (WHO Fact Sheet 2019) patient with history of:
~cough and/or
~difficulty/rapid breathing and/or
~intercostal recession,
~with or without fever. and supported by chest x-ray findings."
16264676|NCT04923035||Control|Healthy children aged 5 years and below without any intercurrent respiratory illness and who is in good health as determined by a brief medical history and/or clinical judgement of the investigator whose parent/LAR is willing and able to give informed consent.
16264677|NCT04923022|Experimental|Vegan diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last for eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
16264678|NCT04923022|Experimental|Therapeutic exercise|"The participants in the therapeutic exercise group will perform the following therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
~The patient, sitting in the cervical spine neutral position, performs flexion, extension and rotation of the cervical spine, unloaded and in the maximum possible range of motion.
~While the patient is in the supine position, she performs passive lateral mobilization to the neck with the help of a physiotherapist.
~In the supine position, the patient performs isometric neck flexion, lateral flexion and rotation movements against the manual resistance given by the physiotherapist
~The patient lying on his back does isometric neck extension movement against gravity
~The patient performs isometric neck flexion, lateral flexion and rotation movements against the elastic band in the sitting position"
16264679|NCT04923022|No Intervention|Control group|Participants in this group will not receive any intervention.
16264680|NCT04923009|Experimental|Simple-ICE group|Patients undergoing ablation using only ICE visualization and ablation catheter
16264681|NCT04923009|Active Comparator|Standard mapping catheter without ICE|Patients undergoing ablation using standard approach including diagnostic and mapping electrodes as well as ablation electrode
16264682|NCT04922996||Ongoing|Patients already on calcium dobesilate treatment
16264683|NCT04922996||New|Patients with approved indication for calcium dobesilate treatment but not already on treatment
16264684|NCT04922983|Sham Comparator|Group I: Placebo isometric measure, no injection|Group I: no isometric yoga-like exercise, no injection given.
16264685|NCT04922983|Placebo Comparator|Group II Isometric yoga-like exercise, placebo injection given|Group II isometric yoga-like exercise, injection of preservative-free normal saline.
16264686|NCT04922983|Active Comparator|Group III: True isometric exercise, botulinum injection|Group III: Isometric yoga-like exercise, botulinum injection given
16264687|NCT04922970|Experimental|Strength training|"In this arm participants will go through the Strength training intervention."
16264688|NCT04922957|Placebo Comparator|Placebo|Ringer's lactate solution
16264750|NCT04922463|Experimental|1x PLASOMA|
16264690|NCT04922931||Post-COVID-19 group|The Post-COVID-19 group or case group includes post-COVID patients (confirmed by PCR) >18 years undergoing scheduled surgery without pulmonary disease prior to SARS-CoV-2 infection that at the time of surgery present negative PCR and absence of clinic due to SARS-CoV-2.
16264691|NCT04922931||Control group|The control group includes patients over the age of 18 who did not have COVID-19 and without moderate-severe pulmonary pathology prior to surgery and in conditions of hemodynamic and respiratory stability at time of surgery.
16264692|NCT04922918|Experimental|Probiotic arm|Administration of Ligilactobacillus salivarius MP101 (>9 log10cfu, daily) for 4 months
16264693|NCT04922905|Other|NEURO +|"Patients neuro + are those with a CASE score ≥ 2, Neuro + patients will benefit from additional evaluations using paraclinical examinations"
16264694|NCT04922905|Other|NEURO -|"Patients neuro - are those with a CASE score < 2"
16264695|NCT04922892|Experimental|Total Parathyroidectomy Alone|Total Parathyroidectomy Alone , without autotransplantation
16264696|NCT04922892|Active Comparator|Total Parathyroidectomy With Autotransplantation|Total Parathyroidectomy With Autotransplantation
16264697|NCT04922879|Experimental|Individualized lung rehabilitation programme|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
16264698|NCT04922866||elderly patients following hepatectomy|elderly patients (aged ≥65 years) scheduled for any type of liver resection
16264699|NCT04922853|Experimental|2 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.
16264700|NCT04922853|Other|4 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.
16264701|NCT04922840|Experimental|High-intensity exercise (HIT)|"Usual care; CVD risk assessment including general lifestyle advice and relevant medication.
~The 12-week intervention is carried out as individual or group sessions with maximal 4 patients and supervised by physiotherapists in primary health care. The HIT group complete two weekly HIT sessions and a third weekly session with continuous exercise at moderate intensity. Due to differences in CRF levels, exercise is tailored to each individual to provide the same relative exercise stress and to ensure progression. Target exercise intensity is tracked by a heart rate monitor.
~Patients are asked to record individual exercise session in a training diary. Succeeding the intervention, an electronic questionnaire will be distributed to patients in the experimental group. Additionally, semi-structured interviews, face-to-face or by telephone/video, will target physiotherapists in charge of supervising the exercise sessions as well as 5-7 patients in the intervention group."
16264702|NCT04922840|No Intervention|Usual care|Control group participants receive the same treatment as usual care; CVD risk assessment including general lifestyle advice and relevant medication. Control group participants are invited to a physiotherapist-led theoretical and practical HIT session following study completion.
16264703|NCT04922827|Experimental|Infliximab + Standard of Care|
16264704|NCT04922827|Active Comparator|Standard of Care|
16264705|NCT04922814|No Intervention|Control group(group A)|Only sedation for mechanically ventilated COVID patients
16264706|NCT04922814|Experimental|Muscle relaxant group(group B)|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
16264707|NCT04922801||Neuroendocrine Toumours|"Patients will undergo 177LU-Dotatate Neoruendocrine Tumours MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.
~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.
~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.
~Post-treatment patient-led self-monitoring.
~Complete a feedback questionnaire relating to the use of self radiation monitoring."
16264708|NCT04922801||Thyroid Cancer|"Patients will undergo 131I-Thyroid cancer MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.
~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.
~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.
~Post-treatment patient-led self-monitoring.
~Complete a feedback questionnaire relating to the use of self radiation monitoring."
16264709|NCT04922801||Hyperthyrodism|"Patients will undergo 131I-Hyperthyroidism MRT in accordance with existing protocols at GSTTFT. Patients will have one whole-body scan at 24 hr post MRT which will not involve any additional radiation. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.
~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.
~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.
~Post-treatment patient-led self-monitoring.
~Complete a feedback questionnaire relating to the use of self radiation monitoring."
16264710|NCT04922788|Experimental|25 mcg Dose|Intramuscular injection, two doses given 28 days apart
16264711|NCT04922788|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
16264712|NCT04922775|Other|conventional taping-Chinese medicine technique taping|Participants will accept conventional taping before muscle fatigue exercise for the first course then accept Chinese medicine technique taping before muscle fatigue exercise for the second course.
16264713|NCT04922775|Other|Chinese medicine technique taping-conventional taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise for the first course then accept conventional technique taping before muscle fatigue exercise for the second course.
16264714|NCT04922762|Experimental|Moderate Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, normal volume exercise training
16264715|NCT04922762|Experimental|High Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of high intensity, normal volume exercise training
16264751|NCT04922463|Experimental|2x PLASOMA|
16264716|NCT04922762|Experimental|Moderate Intensity, High Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, high volume exercise training
16264717|NCT04922749|No Intervention|TAU|Treatment as usual (TAU); consist mainly of pharmacological treatment and psychotherapy.
16264718|NCT04922749|Experimental|MULTI+|Lifestyle treatment
16264719|NCT04922723|Experimental|Daratumumab|"Daratumumab, IV, 16 mg/KG -
~1 dose prior to surgery or biopsy; Weeks 1 - 8 = 1 dose weekly; Weeks 9 - 24 = 1 dose every other week; Weeks 25 onward (determined by disease progression) = 1 dose every 4 weeks"
16264720|NCT04922710|Experimental|Home-based aerobic exercise|Un-supervised exercise will be held 3 times a week for 60 minutes in the participant's home
16264722|NCT04922684|Active Comparator|Lower austic sub-group|16 times of mimicking emotional expressions
16264723|NCT04922684|Experimental|Higher austic sub-group|16 times of mimicking emotional expressions
16264724|NCT04922658|Experimental|Surufatinib|
16264725|NCT04922658|Experimental|Surufatinib plus Vinorelbine|
16264726|NCT04922645|Experimental|Ferric citrate (commercially available, Auryxia)|Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
16264727|NCT04922645|Active Comparator|Standard of care phosphate lowering therapy|Non-Auryxia phosphate-lowering therapy administered as standard of care.
16264728|NCT04922632|Experimental|Transcendental Medication (TM)|Transcendental Meditation (TM): a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
16264729|NCT04922632|Experimental|Experience Resolution Methodology (ERM)|Experience Resolution Methodology (ERM): is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
16264730|NCT04922632|Experimental|TM+ERM|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM): an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
16264731|NCT04922632|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU): is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
16264734|NCT04922606|Other|US of GSV|Ultrasound of the Great Saphenous Vein
16264735|NCT04922593|Experimental|LY03010 treatment group|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA. The chemical name is (±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3yl)piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4oxo-4Hpyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89 g/mol.
~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 141."
16264736|NCT04922593|Active Comparator|INVEGA SUSTENNA treatment group|"INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available. INVEGA SUSTENNA is provided in a prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber).
~In SUSTENNA treatment group, all subjects will receive the first dose of 234 mg IM injection in the deltoid muscle on Day 1, and a second dose of 156 mg of IM injection in the deltoid muscle on Day 8, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 148."
16264737|NCT04922580||Hospitalization group|Newborns of ICP mothers require hospitalization after birth
16264738|NCT04922580||without Hospitalization group|Newborns of ICP mothers don't require hospitalization after birth
16264739|NCT04922567|Experimental|lenalidomide + CHOP regimen|
16264740|NCT04922567|Active Comparator|CHOP regimen|
16264743|NCT04922528|Experimental|Near-Infrared Fluorescence Cholangiography|Standard laparoscopic cholecystectomy completed with a combination of white light imaging and near-Infrared fluorescence cholangiography after administering 5 mg of a 25 mg/10 mL solution of indocyanine green (ICG) intravenously prior to the operation
16264744|NCT04922528|Active Comparator|White Light Imaging|Standard laparoscopic cholecystectomy completed with only standard white light imaging only
16264745|NCT04922502|Active Comparator|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
16264746|NCT04922502|Active Comparator|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
16264747|NCT04922489||Patients with Astra Tech EV|Patients who has receive Astra Tech dental implant system placement.
16264748|NCT04922476|Experimental|Probiotic|Alflorex® The participants consume one probiotic capsule a day for 12 weeks.
16264749|NCT04922463|No Intervention|Control group|
16264752|NCT04922450|Experimental|Camrelizumab，albumin paclitaxel and cisplatin.|Participants will be given intravenous administration of Camrelizumab (200mg)，Albumin Paclitaxel(260mg/m²) and Cisplatin（80mg/m²）,After completing three times every three weeks of neoadjuvant therapy, The Participants will undergo surgery and Postoperative intensity modulated chemotherapy. The duration of treatment will till death, or unacceptable toxicity show up.
16264753|NCT04922437||Enterocystoplasty (EC)|Patients who had an implantation of the catheterizable continent channel by seromuscular plicature on the anterior wall of the bladder augmentation.
16264754|NCT04922437||Detrusor (D)|Patients who had an implantation of the catheterizable continent channel in the detruosr of their native bladder (Lich-Gregoir or Cohen).
16264755|NCT04922424|Experimental|atorvastatin|We are testing that the lipid sensitive statin, atorvastatin treatment will reduce low density lipoprotein cholesterone, sympathetic nerve activity, increase endothelium-dependent vasodilation and improve autonomic function in trans men, while having little impact on cis women.
16264756|NCT04922424|Placebo Comparator|Placebo|We are testing that the placebo will have little effect on low density lipoprotein cholesterone, sympathetic nerve activity, endothelium-dependent vasodilation, autonomic function in trans men or cis women.
16264757|NCT04922411||Pilot Group|Participants (ages 20-75 years) who enroll as part of the Pilot Group of up to10, will follow the same inclusion criteria as the Control group with the exception of matching the age and sex distribution of the DBS group. The purpose of this group is to test the fluidity of the testing day as well as all of the measures, assessments, and scans (DOT and MRI).
16264758|NCT04922411||Control Group|Controls will match the age and sex distributions of the pre and post-surgical DBS groups. Participants will be males or females between 50 and 75 years of age who do not meet criteria for clinically definite PD. This group must be able to complete the testing day as well as all of the measures, assessments, and scans (DOT and MRI).
16264759|NCT04922411||Pre-Surgical Group|Subjects with PD who have been clinically consented for bilateral STN DBS surgery will be recruited from the DBS program within the Movement Disorders Clinic at WUSM. Pre-surgical STN DBS patients will be males or females between 50 and 75 years of age who meet criteria for clinically definite PD. This group must be able to complete the testing day as well as all of the measures, assessments, and scans (DOT and MRI).
16264760|NCT04922411||Post-Surgical Group|STN DBS: Subjects with PD who have been clinically consented for bilateral STN DBS surgery will be recruited from the DBS program within the Movement Disorders Clinic at WUSM (directed by Dr. Ushe, co-I). STN DBS patients will be males or females between 50 and 75 years of age who meet criteria for clinically definite PD. This group must be able to complete the testing day as well as all of the measures, assessments, and scan (DOT).
16264761|NCT04922398|Active Comparator|Group A: PRP group|Preparation of PRP sample fro the patient own blood then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.
16264762|NCT04922398|Placebo Comparator|Group B: saline group|consists of 30 patients, who will receive 4 ml of a normal saline inj. 0.9% Nacl. then injected into each ovary by TVUS.
16264763|NCT04922385|Experimental|CBT|Individual 4-week CBT protocol
16264764|NCT04922372|Experimental|intervention arm copping veneered with composite resin|
16264765|NCT04922372|Active Comparator|control arm copping veneered with manual layering|
16264766|NCT04922359|Experimental|Experimental: Lidocaine group|
16264767|NCT04922359|Placebo Comparator|Placebo Comparator: comparator group|
16264768|NCT04922346||Healthy Pregnant|All volunteer pregnant women who were in the 2nd and 3rd trimesters (between 14-40 weeks) and who met the inclusion criteria in the study
16264769|NCT04922333|Experimental|Bisphosphonate|Participants in this arm will receive six months of 150 mg once monthly oral risedronate
16264770|NCT04922333|Placebo Comparator|Placebo|Participants in this arm will receive six months of placebo
16264771|NCT04922320|Experimental|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
16264772|NCT04922320|Placebo Comparator|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
16264773|NCT04922307|Experimental|Blood Sparing Protocol|The intervention group (120 patients) will undergo radical nephrectomy with blood-sparing techniques. Acute Normovolemic Hemodilution (ANH) collects patients own blood prior to the start of surgical procedure; Cell saver is the collection of blood lost during surgery with subsequent auto-transfusion of the patients own cells; Veno-venous bypass will be used for patients with anticipated large loss of blood during surgery (>1L). The patients in the interventional group will be blinded to which blood sparing techniques utilized.
16264774|NCT04922307|Active Comparator|Standard Blood Replacement|The control group of one hundred and twenty (120) patients will undergo radical nephrectomy without blood sparing techniques (ie. Standard of care). Patients who need blood transfusion will receive cross-matched allogenic blood products.
16264775|NCT04922281|Active Comparator|ICM-guided Management|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
16264776|NCT04922281|Placebo Comparator|Conventional Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
16265675|NCT04915950|Placebo Comparator|Placebo (Stage B)|
16264777|NCT04922268|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
16264778|NCT04922268|Experimental|External focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
16264779|NCT04922255|Active Comparator|disposable urethral support device|disposable urethral support device
16264780|NCT04922255|Active Comparator|Reusable Underwear|Reusable Underwear
16264781|NCT04922255|Active Comparator|pelvic floor muscle therapy (PFMT)|Pelvic floor muscle therapy
16264782|NCT04922242|Experimental|Population 1: NICU Study Staff|Interdisciplinary Professional Clinical Staff who are employed to work as a nurse, therapist, social worker or physician in the NICU.
16264783|NCT04922242|Experimental|Population 2: Mother-infant dyads in NICU|Parent and infant dyads admitted to a NICU for over 72 hours.
16264784|NCT04922229|Active Comparator|Root canal treatment (RCT)|For cases with this diagnosis RCT is the standard of care and will be done according to clinically approved protocols
16264785|NCT04922229|Experimental|Vital Pulp Therapy (VPT)|VPT with tricalcium silicates has shown high clinical success in these cases. However, it is not known how this success compares to RCT under similar conditions and with an intent-to-treat study design, which will be employed here.
16264786|NCT04922216|Experimental|Condition 1|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + No Choice
16264787|NCT04922216|Experimental|Condition 2|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + Choice
16264788|NCT04922216|Experimental|Condition 3|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + No Choice
16264789|NCT04922216|Experimental|Condition 4|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
16264790|NCT04922216|Experimental|Condition 5|Core+Standard Diet Monitoring+Daily Activity Goal+Adaptive Timing+Standard Content+No Choice
16264791|NCT04922216|Experimental|Condition 6|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Standard Content + Choice
16264792|NCT04922216|Experimental|Condition 7|Core+ Standard Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
16264793|NCT04922216|Experimental|Condition 8|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Adaptive Content + Choice
16264794|NCT04922216|Experimental|Condition 9|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + No Choice
16264795|NCT04922216|Experimental|Condition 10|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
16264796|NCT04922216|Experimental|Condition 11|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + No Choice
16264797|NCT04922216|Experimental|Condition 12|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
16264798|NCT04922216|Experimental|Condition 13|Core+Standard Diet Monitoring+Weekly Activity Goal+Adaptive Timing+Standard Content+No Choice
16264799|NCT04922216|Experimental|Condition 14|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Standard Content + Choice
16264800|NCT04922216|Experimental|Condition 15|Core + Standard Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
16264801|NCT04922216|Experimental|Condition 16|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content + Choice
16264802|NCT04922216|Experimental|Condition 17|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ No Choice
16264803|NCT04922216|Experimental|Condition 18|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ Choice
16264804|NCT04922216|Experimental|Condition 19|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
16264805|NCT04922216|Experimental|Condition 20|Core + Simplified Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
16264806|NCT04922216|Experimental|Condition 21|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
16264807|NCT04922216|Experimental|Condition 22|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ Choice
16264808|NCT04922216|Experimental|Condition 23|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
16264809|NCT04922216|Experimental|Condition 24|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ Choice
16264810|NCT04922216|Experimental|Condition 25|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Standard Content+ No Choice
16264811|NCT04922216|Experimental|Condition 26|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
16264812|NCT04922216|Experimental|Condition 27|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
16264813|NCT04922216|Experimental|Condition 28|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
16264814|NCT04922216|Experimental|Condition 29|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
16264815|NCT04922216|Experimental|Condition 30|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ Choice
16264816|NCT04922216|Experimental|Condition 31|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
16264817|NCT04922216|Experimental|Condition 32|Core + Simplified Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content+Choice
16264818|NCT04922203|No Intervention|Control group|Anesthesiology residents do not receive any in situ simulation sessions during the observation period
16264819|NCT04922203|Experimental|Simulation group|Anesthesiology residents receive in situ simulations sessions during the observation period
16264882|NCT04921631|No Intervention|No intervention|Usual ICU care; each study ICU has a policy for family meetings within 72 hours of admission and at least weekly thereafter.
16264883|NCT04921618||Index patients|"People aged 18 or more diagnosed with >= 1 STI in testing centers.
~[STI = bacterial STIs and/or HIV and/or acute hepatitis C virus (HCV)]"
16264885|NCT04921605|Experimental|Tricuspid regurgitation|Subjects received the Dragonfly system for the treatment of tricuspid regurgitation.
16264820|NCT04922190|Experimental|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
16264821|NCT04922177|Experimental|CAD/CAM Group|For the CAD/CAM group, an indirect ceramic restoration will be made using an optical impression.
16264822|NCT04922177|Active Comparator|Direct method Group|For the direct method group, a restoration using a Glass Ionomer Cement will be performed.
16264823|NCT04922164|No Intervention|Control group|Receive education-based messages about the health benefit of breastfeeding
16264824|NCT04922164|Other|Social normative cues|Receive social normative cues related to breastfeeding
16264825|NCT04922164|Other|Goal-related cues|Receive goal-related cues related to breastfeeding
16264826|NCT04922151|Experimental|group I|601 1.25mg
16264827|NCT04922151|Active Comparator|group II|Ranibizuman 0.5 mg
16264828|NCT04922138|Experimental|Aumolertinib group|Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day .
16264829|NCT04922125|Experimental|Pulse flour|Puree produced from pulse flours and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
16264830|NCT04922125|Experimental|Pre-processed pulse flour|Puree produced from pre-processed pulse flour with different structural aspects and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
16264831|NCT04922112|Experimental|Research group|Sleep apnea testing will be performed with this group, in the form of quality of life and sleep questionnaires, home sleep study results, as well as information collected from their electronic medical record. The investigator will also obtain blood laboratory specimens to measure serum TNF-alpha and IL-6.
16264832|NCT04922086|Experimental|Test group|Patients will be submitted to ACL planned using cone beam computed tomography (CBCT), digital planning and guided dual technique.
16264833|NCT04922086|Active Comparator|Control group|Patients will be submitted to the conventional ACL planned using clinical examination.
16264834|NCT04922047|Experimental|Experimental: Intravenous tislelizumab / Intravesical BCG|"Drug: tislelizumab / BCG
~Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
~Other Name: BGB-A317"
16264837|NCT04922008|Experimental|IRIS-C|
16264838|NCT04922008|Experimental|IRIS-D|
16264839|NCT04921995|Experimental|Experimental|Patients will be given tislelizumab plus investigator's choice chemotherapy, with re-irradiation postponed or omitted.
16264840|NCT04921982|Experimental|Propranolol|
16264841|NCT04921982|Placebo Comparator|Placebo|
16264842|NCT04921969|Experimental|Ruxolitinib (1.5% Cream)|Study drug will be administered twice daiily.
16264843|NCT04921969|Experimental|Ruxolitinib (0.75% cream)|Study drug will be administered twice daily.
16264844|NCT04921969|Placebo Comparator|Vehicle Cream|Vehicle cream will be administered twice daily.
16264845|NCT04921943|Experimental|Hypertonic saline|Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.
16264846|NCT04921943|Active Comparator|Standard of Care|Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.
16264847|NCT04921930|Experimental|Artesunate|"Dose escalation of oral artesunate:
~Step 1: 25 mg daily (1 tablet) during one week Step 2: 50 mg daily (2 tablets) during one week (if no effect on biomarker and no adverse reaction at step 1) Step 3: 75 mg daily (3 tablets) during one week (if no effect on biomarker and no adverse reaction at step 2) Step 4: 100 mg daily (4 tablets) duing one week (if no efficacy and no adverse reaction at step 3)"
16264848|NCT04921917|No Intervention|Control|Standard of care: neoadjuvant radiation therapy (NRT).
16264849|NCT04921917|Experimental|Neoadjuvant Exercise Regimen|Subjects will receive conventional NRT in conjunction with a prescribed exercise regimen during the usual 10-week duration of NRT treatment prior to tumor resection.
16264850|NCT04921904|Experimental|Abemaciclib plus Ramucirumab|Abemaciclib 150mg dose administered orally twice daily every day plus Ramucirumab dose 8mg/kg iv every 2 weeks until evidence of disease
16264851|NCT04921891|Active Comparator|Blocked arm|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
16264852|NCT04921891|Active Comparator|Unblocked arm|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
16264884|NCT04921618||Notified partners|"People aged 18 or more getting STI testing in testing centers after being notified by a sexual partner.
~[STI = bacterial STIs and/or HIV and/or acute HCV]"
16265676|NCT04915937|Experimental|Study Infant Formula|Feed ad libitum during study period
16264853|NCT04921878|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 24 mg/m2, and then the dose is sequentially escalated to 30 mg/m2, 36 mg/m2 and 40 mg/m2.
~Dose-expansion phase: After DLT observation, two to four dose cohorts will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection."
16264854|NCT04921865||Patients treated with the DPS VA-LCP® Clavicle Plate 2.7 System or Hook Plate 2.7 System|Any patient undergoing surgical treatment for the fixation of clavicle bone fragments and acromioclavicular joint dislocations using the DPS VA-LCP® Clavicle Plate 2.7 System or DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 .
16264855|NCT04921852|Active Comparator|costoclavicular group|
16264856|NCT04921852|Active Comparator|lateral sagittal group|
16264857|NCT04921813|Experimental|Schroth method + brace|3-dimensional scoliosis exercise program according to Schroth method + brace.
16264858|NCT04921813|Experimental|Schroth + balance-coordination exercises + brace.|3-dimensional scoliosis exercise program according to Schroth + balance-coordination exercises + brace.
16264859|NCT04921813|Experimental|Brace|Only brace treatment.
16264860|NCT04921813|No Intervention|healthy individuals|Age-matched control group
16264861|NCT04921800|Experimental|Wearable Sensor Applied|For these participants, the wearable ADAM sensor will be placed in the sternal notch to record anatomical data during the post-surgical period for up to 14 days
16264862|NCT04921787|Active Comparator|Low Intensity|MOUD training and support through the use of educational materials.
16264863|NCT04921787|Experimental|High Intensity|MOUD training and support through the use of educational materials in addition to practice facilitation.
16264864|NCT04921761|Placebo Comparator|Group A|Women who received the conventional epidural technique (group A).
16264865|NCT04921761|Active Comparator|Group B|Women who received the dural puncture epidural technique (group B).
16264866|NCT04921748||PD+FOG group|Patients affected by Parkinson's Disease with freezing of gait (PD+FOG group)
16264867|NCT04921748||PD-FOG group|Patients affected by Parkinson's Disease without freezing of gait (PD+FOG group)
16264868|NCT04921735||Elderly|patients aged 80 years or older
16264869|NCT04921735||young|patients aged 18-40 years
16264872|NCT04921709||IBD Patients with Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems .
~Age (18-65 years)
~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
16264873|NCT04921709||IBD Patients without Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have no renal problems .
~Age (18-65 years)
~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
16264874|NCT04921696||RBC transfusion|RBC was transfused to the infants.
16264875|NCT04921696||no-RBC transfusion|RBC was not transfused to the infants.
16264876|NCT04921683|Experimental|Treatment LIFUP|LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone to minimize bone absorption and refraction. Accurate aiming will be ensured using the Brain Sight neuronavigation device, customized for tracking our LIFUP transducer. Following LIFUP, the patient will undergo a second EEG session, except for the EEG cap being fit to the patient's head prior to the LIFUP session so that, as soon as LIFUP administration is complete, the EEG paradigm can be promptly administered. The patient will then be allowed to rest (~1h).The patient will then be administered a second dose of tracer in order to undergo a second PET measurement. Finally, at the end-of-day, the clinical coordinator will collect an Adverse Event Questionnaire and will fit the PSG device for night monitoring.
16264877|NCT04921670||Group A-Standard monitoring group (Reactive drug monitoring)|Participants assigned to this group will be managed the same as normally done per routine care, which involves adjusting their infliximab dose and/or dosing interval based on Inflammatory Bowel Disease (IBD) symptoms and routine care laboratory test results. The primary gastroenterologist will not be given the results of the infliximab and infliximab antibody level results of participants in this group unless their routine laboratory test results or IBD symptoms suggest their IBD may be worsening.
16264878|NCT04921670||• Group B- Infliximab level and infliximab antibody monitoring group (Proactive drug monitoring)|Participants assigned to the infliximab level and infliximab antibody level monitoring group will be managed based on the infliximab level and infliximab antibody level results as well as their IBD symptoms and the results of routine care laboratory tests. The goal is to keep infliximab levels in the optimal range with little to no antibodies. The primary gastroenterologist will remain blinded to the results of the infliximab level/infliximab antibody level test results and the participants' dose will be adjusted by one of the other study doctors who is not blinded to the results.
16264879|NCT04921657||Patients treated with statin.|Patients with hypercholesterolemia treated with rosuvastatin 10 mg daily or simvastatin 40 mg daily.
16264881|NCT04921631|Experimental|Intervention|The intervention arm will receive early specialty palliative care integrated with standard critical care.
16265678|NCT04915911||adult patients with Crohn's disease|multi-center cross-sectional study
16264886|NCT04921592|Experimental|transcutaneous stimulation|"transcutaneous stimulation 60 sessions
~Transcutaneous stimulation 40sessions
~Transcutaneous stimulation 20 sessions"
16264887|NCT04921579|Experimental|En masse retraction|six anterior teeth are retracted by en masse technique using a crimpable hook distal to upper lateral incisor and a power chain.
16264888|NCT04921579|Experimental|two step retraction|six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to upper lateral incisor and a power chain.
16264889|NCT04921566|Other|Sequence TR|13 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16264890|NCT04921566|Other|Sequence RT|13 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16264891|NCT04921540|Experimental|Dermatologic intervention|Surgery with chemical cauterisation TCA
16264892|NCT04921540|Active Comparator|Orthopedic intervention|Only surgery
16264893|NCT04921527|Experimental|Chiauranib plus weekly paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most,Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
16264894|NCT04921527|Placebo Comparator|placebo plus weekly paclitaxel|Patients receive the combined treatment of placebo plus paclitaxel, 21 days for a cycle, 6 cycles at most,placebo is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of placebo.
16264895|NCT04921514|Experimental|Patient and relatives|
16264896|NCT04921501|Experimental|Proven or suspected arrhythmias group|
16264897|NCT04921488|Experimental|Patients with indication for colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
16264898|NCT04921475||Renal regional oxygen saturation|Renal regional oxygen saturation is measured by using near infrared spectroscopy during transcatheter aortic valve implantation
16264899|NCT04921462|Active Comparator|Silastic group|included patients who underwent nasal septoplasty followed by insertion of silastic intranasal splint
16264900|NCT04921462|Active Comparator|Quilting group|included patients who underwent septoplasty followed by quilting suture (Septal through and through suture)
16264901|NCT04921449|Experimental|Embedded ED Physical Therapy (NEED-PT)|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol (NEED-PT) that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The NEED-PT intervention will supplement any usual care performed by the treating physician.
16264902|NCT04921449|Other|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
16264903|NCT04921436|Experimental|cardiac surgery patients with preventive treatment|"In addition to standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery), the following antibiotic regimens will be used perioperatively:
~Doxycycline (the day before surgery 200 mg and 100 mg on days 1 and 2 after surgery) or Rimfampicin (150 mg 2 times a day before and after surgery) + Gentamicin (240 mg 3 times a day before and 2 days after surgery) or Clarithromycin (500 mg once daily for up to 2 days after surgery).
~The route of administration (oral / intravenous) will depend on the condition of the patient."
16264904|NCT04921436|No Intervention|cardiac surgery patients without preventive treatment|standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery)
16264905|NCT04921423|Experimental|situational simulation teaching|Clinical case role play and empathy skill practice
16264906|NCT04921423|No Intervention|Clinical Case (Problem Based Learning)|Clinical Case discuss (Problem Based Learning)
16264907|NCT04921410|Experimental|Biofeedback Sleeve Effects on Preventive Biomechanics|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive an 'active' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide haptic feedback directly associated with potentially injurious events as determined by previously established cut-off values and artificially-intelligent algorithms.
16264908|NCT04921410|Sham Comparator|Sham Biofeedback|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive a 'sham' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide random feedback at random intervals not directly associated with potentially injurious events.
16290852|NCT04739826||nilotinib|nilotinib 300mg BID, fasting administration
16264912|NCT04921371|Other|Healthy Reference Group|Participants who are identified as healthy will be a comparison group for the microbiome analysis. This group will participate in the examinations and plaque sampling only and will not receive a prophylaxis or product.
16264913|NCT04921371|Experimental|5% Hydroalcohol Mouthrinse (Negative control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 milliliter (mL) of 5 percent (%) Hydroalcohol Mouthrinse twice daily (morning and evening) up to 6 weeks.
16264914|NCT04921371|Experimental|Listerine® Cool Mint® (Positive control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept curve winter series Toothbrush will rinse mouth for 30 seconds with 20 mL of Listerine® Cool Mint® twice daily (morning and evening) up to 6 weeks.
16264915|NCT04921371|Experimental|Mouthrinse Prototype 1|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 1 twice daily (morning and evening) up to 6 weeks.
16264916|NCT04921371|Experimental|Mouthrinse Prototype 2|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 2 twice daily (morning and evening) up to 6 weeks.
16264917|NCT04921358|Experimental|Arm A: Tislelizumab in combination with Sitravatinib|tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day
16264918|NCT04921358|Active Comparator|Arm B: Docetaxel|docetaxel 75 mg/m2 intravenously once every 3 weeks
16264919|NCT04921345|Experimental|Cohort 1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
16264920|NCT04921345|Experimental|Cohort 2: Participants aged 2-6 years|Participants aged 2-6 years will receive nemolizumab for 52 weeks.
16264921|NCT04921332|Experimental|Bright Light Therapy (BLT)|The intervention will consist of daily BLT sessions lasting 30 minutes at approximately 10AM (since many CF patients do not awaken until this time) starting on the day of admission through discharge for a goal of seven consecutive days. The intervention will use a 10,000-lux light box placed approximately 16-24 inches from the patient's face.
16264922|NCT04921319|Experimental|VExUS-Guided Arm|Will receive 24 hour fluid balance target based on daily VExUS score.
16264923|NCT04921319|No Intervention|Usual Care Control Arm|Treating team will be blinded to results of daily VExUS score and will set 24 hour fluid balance target based on usual care.
16264924|NCT04921306|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 28 days.
~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
16264925|NCT04921306|Placebo Comparator|Placebo|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 28 days.
~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
16264926|NCT04921293|Active Comparator|Standard Diet|Standard diet incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with bitter taste placebo.
16264927|NCT04921293|Experimental|Endogenous Ketosis|Ketogenic diet incorporating current recommendations for heart failure (<50gr of carbohydrates, low sodium, and liquids) for 10 days.
16264928|NCT04921293|Experimental|Exogenous ketosis|Standard incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with exogenous ketones (ketone monoester) for 10 days.
16264929|NCT04921280||Treatment group|Patients who have received treatment for severe health anxiety at the Internet Psychiatry Clinic, Psychiatry Southwest, Karolinska University Hospital Huddinge between April 2018 to April 2021.
16264930|NCT04921267|Experimental|trained group|group receives training with sounds that correspond to simulated hearing protection
16264931|NCT04921267|No Intervention|Control|group receives no training
16264932|NCT04921254|Experimental|BSG005|Active antifungal drug
16264933|NCT04921254|Placebo Comparator|PÅlacebo|Will be a 5% glucose infusion
16264934|NCT04921241||SARS-CoV-2 Exposed Dyads|Mothers who had SARS-CoV-2 during pregnancy and their offspring
16264935|NCT04921241||SARS-CoV-2 Unexposed Dyads|Mothers who were not known to have SARS-CoV-2 during pregnancy and their offspring
16264936|NCT04921228|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training will be administered via a smartphone app (Optimal HRV) that reads the participants' pulse rate through a Bluetooth connected photoplethysmography (PPG) sensor attached to the finger or thumb.
16264937|NCT04921215|Active Comparator|0 hours of sleep restriction|Bedtime will be the same as baseline.
16264938|NCT04921215|Experimental|1.5 hours of sleep restriction|Bedtime will be 1.5 hours later than baseline.
16264939|NCT04921215|Experimental|3 hours of sleep restriction|Bedtime will be 3 hours later than baseline.
16264940|NCT04921215|Experimental|4.5 hours of sleep restriction|Bedtime will be 4.5 hours later than baseline.
16264941|NCT04921202||without metabolic syndrome and BMI<24|100 volunteers aged between 35-70 years old with body mass index(BMI)<24 without Metabolic syndrome
16264942|NCT04921202||Metabolic Syndrome with BMI>27|80 Metabolic syndrome patients with BMI>27 were included in the study
16264943|NCT04921189|Active Comparator|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|The combined administration of 3 drugs will be administered through intravenous infusion over 60 min every 12 h for 3 days for the out-of-hospital cardiac arrest survivors treated with targeted temperature management.
16264944|NCT04921189|Placebo Comparator|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
16264945|NCT04921163|Active Comparator|aluminium|4-day test periode with intake of aluminium pancakes
16264946|NCT04921163|Placebo Comparator|placebo|4-day test periode with aluminium-free pancakes
16264947|NCT04921163|Placebo Comparator|second placebo|Again a 4-day test periode with aluminium-free pancakes
16264948|NCT04921137|Experimental|Omission of endocrine therapy|Omission of endocrine therapy
16264949|NCT04921137|Active Comparator|Administration of endocrine therapy for at least 5 years|Administration of endocrine therapy for at least 5 years
16291416|NCT04735809|Experimental|Treatment|Whole Cell Algae Fermentate
16264950|NCT04921124|Experimental|Treatment|"Teriparatide, 20 µg Subcutaneous (S/C) per day.
~Two doses in total."
16264951|NCT04921111|Experimental|Healthy Women Aged 18 to 26 Years|120 healthy women aged18 to 26 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil®9 : placebo =3:1:1.
16264952|NCT04921111|Experimental|Healthy Women Aged 27 to 45 Years|120 healthy women aged 27 to 45 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil® : placebo =3:1:1.
16264953|NCT04921098|Experimental|Refractory glaucoma|
16264954|NCT04921085||adult inpatients|adult inpatients with 7 categories of diseases (including digestive system, respiratory system, cardiovascular and endocrine system, tumor, nervous system, and urinary system)
16264955|NCT04921072|Experimental|CG - Constant practice condition group|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
16264956|NCT04921072|Experimental|VG - Variable practice condition group|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session in a random order, which means that each session will consist of 90 SPSIC like CG.
16264957|NCT04921046|Active Comparator|Group Lignocaine|Group of 112 patients ASA-I and II (American Society of Anesthesiology)ages from 25-44 undergoing elective surgical procedure.
16264958|NCT04921046|Active Comparator|Group Midazolam|Group of 112 patients ASA-I and II ages from 25-44 undergoing elective surgical procedure.
16264959|NCT04921033|Experimental|Exclusive Enteral Nutrition|35kcal/kg/day EEN (Nestle Modulen®) - Subjects will take medicine and EEN solution orally themselves.
16264960|NCT04921033|Active Comparator|Standard of care|"Budesonide 9mg/day for mild disease
~Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.
~Patients with moderate-to-severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
16264961|NCT04921020||Normal participants|
16264962|NCT04921020||Patients with blepharoptosis|
16264963|NCT04921020||Patients with blepharospasm|
16264964|NCT04921020||Patients with dry eye disease|
16264965|NCT04921020||Patients with Graves' disease|
16264966|NCT04921007|Active Comparator|Group (A) Sacral ESP block|Ultrasound guided sacral erector spinae plane (ESP) block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
16264967|NCT04921007|Active Comparator|Group (B) Caudal block|Ultrasound guided caudal block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
16264968|NCT04920994|Active Comparator|Group A (M-TAPA )|Ultrasound-guided M-TAPA block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
16264969|NCT04920994|Active Comparator|Group B (SCTAP)|Ultrasound-guided SCTAP block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
16264970|NCT04920968|Experimental|Obinutuzumab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
16264971|NCT04920968|Active Comparator|Rituximab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
16264972|NCT04920955||G1, CRC Relapse|Patients with an actual relapse of CRC, within 5 years from primary surgery. A single blood sample is collected at relapse diagnosis.
16264973|NCT04920955||G2, CRC Disease-free|Patients previously diagnosed with CRC and declared disease-free for at least 36 months but less than 5 years. A single blood sample is collected at standard monitoring visit.
16264974|NCT04920955||G3, CRC Disease-free (longitudinal)|Patients declared disease-free for at least 3 months but less than 18 months. Longitudinal blood samples will be collected during standard monitoring visits up to relapse, or for a maximum of 4 time points.
16264975|NCT04920955||G4, Primary CRC (longitudinal)|Patients with an actual diagnosis of CRC who are eligible for a treatment with curative intent. Blood samples will be collected pre and post-surgery (~6 weeks) and, eventually, at relapse.
16264976|NCT04920942|Experimental|Treatment group|Ivermectin 0.4mg/kg/day for 5 days + standard-of-care
16264977|NCT04920942|No Intervention|Control group|Standard-of-care only
16264978|NCT04920929|Active Comparator|Hydrophilic BioMaterial|Hydrophilic BioMaterial- HydroPICC
16264979|NCT04920929|Active Comparator|Thermoplastic Polyurethane|TPU- 4 French Single Lumen PowerPICC
16264980|NCT04920916|Experimental|Dupilimab|Active Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
16264981|NCT04920916|Placebo Comparator|Placebo|Dupilimab Placebo: placebo (normal saline) will be given as two one mL subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (1 mL) will be given on days 14 and 28.
16264982|NCT04920903|Experimental|COR588|
16264983|NCT04920903|Placebo Comparator|Placebo|
16264984|NCT04920890|Active Comparator|Patients receiving radiofrequency treatment.|Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive radiofrequency treatment.
16264985|NCT04920890|Placebo Comparator|Patients receiving placebo.|Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; to those who will be administered placebo (device off, without emitting).
16264986|NCT04920877|Experimental|Central catheter-related bloodstream infection rates in intensive care units|
16264987|NCT04920864|Experimental|Active 10 Hz dlPFC rTMS|10 Hz dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
16264988|NCT04920864|Sham Comparator|Sham dlPFC rTMS|inactive dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
16264989|NCT04920864|Experimental|Active 1 Hz mPFC rTMS|1 Hz medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
16264990|NCT04920864|Sham Comparator|Sham mPFC|inactive medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
16264991|NCT04920851||Covid with sepsis|Covid patient with sepsis
16264992|NCT04920851||covid without sepsis|Covid patient without sepsis
16264993|NCT04920838|Active Comparator|Paracetamol|Patients in this arm will receive paracetamol during 14 days
16264994|NCT04920838|Experimental|Nitazoxanide and Ciclésonide|Patients in this arm will receive the combination of ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg) during 14 days
16264995|NCT04920838|Experimental|Telmisartan|Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days
16264996|NCT04920825|Active Comparator|Sacha Inchi Oil softgel|Oral Sacha Inchi oil softgel supplement
16264997|NCT04920825|Placebo Comparator|Corn oil softgel|Oral corn oil softgel
16264998|NCT04920812||Mitochondrial diseases|annalysing with methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy.
16264999|NCT04920799|Active Comparator|Nitrate rich beetroot juice|
16265000|NCT04920799|Placebo Comparator|Nitrate depleted beetroot juice|
16265001|NCT04920786|Experimental|TB006 70 mg - 5000 mg IV|TB006 infused intravenously over 1 hour
16265002|NCT04920786|Placebo Comparator|Placebo|0.9% normal saline infused intravenously over 1 hour
16265003|NCT04920773|Experimental|Ayurveda Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati
16265004|NCT04920773|Active Comparator|Usual Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
16265005|NCT04920760|No Intervention|Control|Participants receiving standard treatment alone.
16265006|NCT04920760|Experimental|Vitamin A|Participants receiving standard treatment with an additional vitamin A supplementation.
16265007|NCT04920747||S group|platin-5FU + trastuzumab
16265008|NCT04920747||T group|taxanes + platin-5FU + trastuzumab
16265009|NCT04920721||Allergic|suspected of immediate hypersensitivity reaction to platinum salts with positiv skin tests
16265010|NCT04920721||Non allergic|suspected of immediate hypersensitivity reaction to platinum salts with negativ skin tests
16265011|NCT04920708|Experimental|Palbociclib + Fulvestrant + Ipatasertib (Interventional arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to interventional arm receive Palbociclib + Fulvestrant + Ipatasertib. n = 87.
16265012|NCT04920708|Active Comparator|Palbociclib + Fulvestrant (Comparison arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to Comparison arm receive Palbociclib + Fulvestrant. n = 87.
16265013|NCT04920708|Active Comparator|Standard of Care (No ctDNA observational arm)|Where no ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 50.
16265014|NCT04920708|Active Comparator|Standard of Care (Low ctDNA observational arm)|Where low ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 100.
16265015|NCT04920695|Placebo Comparator|Placebo Control|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquid Healthcare, Montreal, Quebec, Canada).
16265016|NCT04920695|Active Comparator|Inhaled Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX™ gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; Control # 198879, DIN 02451328).
16265017|NCT04920682|Active Comparator|Group M (reversion with moderate neuromuscular blockade)|Administration of neostigmine 60 mcg/kg and atropine 30 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4.
16265018|NCT04920682|Active Comparator|Group S (reversion with superficial moderate neuromuscular blockade)|Administration of 0.9% saline solution (SF) when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4.
16265019|NCT04920682|Active Comparator|Group N (two-step reversal of neuromuscular blockade)|Administration of neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4 .
16265020|NCT04920682|Placebo Comparator|Group P (placebo)|Administration of 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4.
16265021|NCT04920669|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
16265022|NCT04920669|Experimental|erector spinae block + dexmedetomidine|erector spinae block with 19 ml bupivacaine + dexmedetomidine
16265023|NCT04920669|No Intervention|control group|standard general anesthesia without any block
16265024|NCT04920656||Breast cancer patients|All adult patients with a confirmed diagnosis of breast cancer, aged 18 or older at time of cancer diagnosis, will be invited to participate.
16265027|NCT04920630|Experimental|CBT-I|5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.
16265067|NCT04920331|Experimental|Erenumab|Subjects with episodes of status migrainosus will receive a single dose of IV erenumab
16265160|NCT04919707|Experimental|Younger Adolescent Soccer Players|10 male, 10 female soccer players, grades 6-7, age 12-13 Neurocognitive measures, physical measures, header session, MRI
16265031|NCT04920604||Teleconsultation|
16265032|NCT04920604||Control group|
16265033|NCT04920591|Experimental|doll therapy (DT)|doll therapy (emathy dolls)
16265034|NCT04920591|No Intervention|Standard treatment (ST)|standard clinical practice
16265038|NCT04920565|Experimental|cardiac surgery patients with multiple organ dysfunction|hemoperfusion procedure with polymyxin B will be performed for 12 hours
16265039|NCT04920565|No Intervention|cardiac surgery patients|without hemoperfusion with polymyxin B
16265040|NCT04920552|Placebo Comparator|Placebo binder first|"Participants in this arm will wear the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
16265041|NCT04920552|Active Comparator|Elastic abdominal binder first|"Participants in this arm will wear the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
16265042|NCT04920539|Experimental|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
16265043|NCT04920539|Placebo Comparator|Placebo|Placebo (saline solution) administered intravenously.
16265044|NCT04920526||QHPV Vaccine|all participants have received QHPV
16265045|NCT04920500|Experimental|Daunorubicin Cytarabine liposome for injection|Induction 1: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (>90 min) d1,3
16265046|NCT04920500|Active Comparator|Vyxeos + Daunorubicin Cytarabine liposome for injection|Induction 1: Vyxeos[100 U/m²] i.v. (120 min) d1; Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (>90 min) d1,3
16265047|NCT04920461|Experimental|Additional MRI sequences|
16265048|NCT04920448|Experimental|N-Acetylcysteine 150 mg/kg|Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).
16265049|NCT04920435||training population|patients from which we will develop the prediction model
16265050|NCT04920435||testing population|patients on whom we will test the prediction model
16265051|NCT04920422||Metastatic colorectal cancer patients.|Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.
16265052|NCT04920409|Experimental|FAWGT Diet|Composed of fruit, avocado, whole grains and trout
16265053|NCT04920409|Active Comparator|Usual diet (UD)|Based on the food which the participants usually consumed prior to the study in their normal lifestyle.
16265054|NCT04920396|Experimental|IRPL|Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45
16265055|NCT04920396|Active Comparator|Warm compress|Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes
16265057|NCT04920370|Experimental|ALXN1720 Single Dose SC|Participants will receive a single dose of ALXN1720 SC.
16265058|NCT04920370|Experimental|ALXN1720 Multiple Dose SC|Participants will receive multiple doses of ALXN1720 SC.
16265059|NCT04920370|Experimental|ALXN1720 Single Dose SC + rHuPH20|Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20.
16265060|NCT04920370|Experimental|ALXN1720 Single Dose IV|Participants will receive a single dose of ALXN1720 IV.
16265061|NCT04920370|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
16265062|NCT04920357||Post-COVID-19|Persons with a verified previous COVID-19 infection
16265063|NCT04920357||COVID-19 naive|Persons that have no history of COVID-19
16265064|NCT04920344|Active Comparator|GROUP I - Low Risk Recurrence (transoral surgery, clinical observation))|After standard of care transoral surgery, patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
16265065|NCT04920344|Experimental|GROUP II - Medium Risk Recurrence (transoral surgery, EBRT 50Gy)|Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) RT 50Gy for 5 weeks in the absence of disease progression or unacceptable toxicity.
16265066|NCT04920344|Experimental|GROUP III - High Risk Recurrence (transoral surgery, EBRT 60Gy, cisplatin 30 mg/m2)|"Patients whose tumor has a positive margin, which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT RT 60 Gy for 6 weeks and receive cisplatin intravenously (IV) weekly 30mg/m2 for 6 weeks in the absence of disease progression or unacceptable toxicity."
16291584|NCT04734535|Experimental|investigational|HEMOBLAST™ Bellows
16265068|NCT04920318|Experimental|active TDCS|During intervention excitatory/anodal tDCS will be administered alongside speech-language therapy 5 days a week for 2 weeks. The exact location of the stimulation and electrode configuration will be targeted individually based on the optimal site identified in fMRI. TDCS will be administered with NeurConn1 Channel DC- Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes using sponge electrodes with a 30-s ramp-up and ramp-down period
16265069|NCT04920318|Sham Comparator|sham TDCS|The sham will be administered alongside speech-language therapy 5 days a week for 2 weeks. For sham, stimulation will be ramped up and then down to 0 milliamperes (mA) in the first minute of stimulation. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
16265070|NCT04920305|Experimental|Phosphatidylserine group|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
16265071|NCT04920305|Placebo Comparator|Bean powder group|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.) for 6 months.
16265075|NCT04920279||The patients with diabetes mellitus|When patients with diabetes mellitus admitted to our outpatient clinic if they have inclusion criteria, we have used the ABC questionnaire. And we have done perform Time Up And Go Test twice respectively.
16265076|NCT04920266|Experimental|Smart sweat patch for sweat rate and sweat chloride concentration|Epidermal microfluidic patch that is a flexible 27 cm2 platform with an adhesive backing that collects sweat through a skin-facing inlet port. Custom software uses the smartphone camera to capture and analyze the microfluidic patch.
16265077|NCT04920266|Placebo Comparator|Reference sweat patch for sweat rate and sweat electrolytes|Regional absorbent patch technique for sweat rate (gravimetry) and electrolytes (sodium, potassium, chloride) by ion chromatography
16265078|NCT04920266|Experimental|Smart Cap bottle fluid measurement|Fluid level sensor integrated into the squeeze bottle cap measures the amount of fluid remaining in the bottle via light reflection
16265079|NCT04920266|Other|Reference method bottle fluid measurement|Scale weight of bottle (gravimetry method) for Smart Cap bottles (running and fitness subjects) and non-Smart Cap bottles (cyclists)
16265080|NCT04920253|Experimental|debritom+|Group 1: Medaxis debritom+
16265081|NCT04920253|Active Comparator|Sharp Scalpel|Group 2: SOC (Sharp Scalpel Debridement)
16265082|NCT04920240|Placebo Comparator|routine group|"In accordance with the intensive care unit hospital infection prevention and control norms requirements"
16265083|NCT04920240|Experimental|Experimental group|Implement a multi-center unified ICU high-frequency contact surface standardized cleaning and disinfection mode
16265084|NCT04920227|Experimental|CLASS+PHACO|CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification
16265085|NCT04920227|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery
16265086|NCT04920214||Experimental group|"patients with hepatic focal lesions
~patients with non-high risk factors for hepatocellular carcinoma"
16265087|NCT04920201|Experimental|Over-ground walking without GEMS-H|
16265088|NCT04920201|Experimental|Over-ground walking with GEMS-H with resist mode|
16265089|NCT04920201|Experimental|Stair ascent with GEMS-H with assist mode|
16265090|NCT04920201|Experimental|Incline walking with GEMS-H with assist mode|
16265091|NCT04920175||NICU Cohort|Participants will undergo a standard polysomnogram
16265092|NCT04920162|Other|Skin deseases biospecimens collection|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
16265093|NCT04920149|Experimental|Mesalamine|Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
16265094|NCT04920149|Placebo Comparator|Placebo|Placebo for Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
16265097|NCT04920123|Experimental|Game Intervention|Study participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).
16265098|NCT04920123|No Intervention|No Intervention|Study participants do not engage in any cognitive training.
16265099|NCT04920110||Phase 1: Qualitative Interviews|Approximately 20 parents/caregivers will discuss typical communication abilities of their loved one and complete the ORCA measure for determination of its content validity through a hybrid approach of concept elicitation and cognitive testing.
16265100|NCT04920110||Phase 2: Cross-Sectional Assessment of Psychometric Properties|Approximately 250 parents/caregivers will complete the ORCA measure and additional measures to determine its psychometric properties including reliability, floor/ceiling effects and construct validity.
16265101|NCT04920097|Experimental|APA Group|A self-guided smartphone application to self-administered APA
16265102|NCT04920097|Experimental|Virtual APA group|A virtual APA (vAPA): APA app+ plus secure zoom sessions for APA coaching with questions and answers
16265103|NCT04920097|Active Comparator|Usual Care Control|Wait-List Usual Care Control (UC)
16265104|NCT04920084|Experimental|Plant-based meals|Patients who will be administered a whole-foods plant-based diet for 12 weeks with nutrition counselling for 24 weeks.
16265105|NCT04920071||Control|150 healthy control participants
16265106|NCT04920071||AMD Cohort high-contrast VA group i|Better than 0.4 logMAR
16265107|NCT04920071||AMD Cohort high-contrast VA group ii|0.4-0.6 logMAR
16265108|NCT04920071||AMD Cohort high-contrast VA group iii|0.6-0.8 logMAR
16265109|NCT04920071||AMD Cohort high-contrast VA group iv|0.8-1.0 logMAR
16265110|NCT04920058|Experimental|Wellness Program combined with Continuous Glucose Monitoring (CGM)|Continuous Glucose Monitoring (CGM) sensor combined with Levels CGM software that provides real-time visualization, analysis and feedback will be added to a Wellness Program incorporating a low carbohydrate diet (<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
16265111|NCT04920058|Active Comparator|Wellness Program|Wellness Program incorporating a low carbohydrate diet (<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
16265112|NCT04920045|Active Comparator|Liberal Transfusion Arm|Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
16265113|NCT04920045|Active Comparator|Restrictive Transfusion Arm|Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
16265114|NCT04920032|Experimental|TASIRI|"Patients randomized to the experimental arm (TASIRI) will be treated with TAS-102 25mg/m2 p.o. on days 1-5 and irinotecan 180mg/m2 i.v. on day 1 every 14 days. If ANC <1500/uL on day 1 of a cycle, then G-CSF will be added on day 6 for three days."
16265115|NCT04920032|Active Comparator|Standard Arm|Patients randomized to the standard arm (i.e. continuation of the original regimen) are managed per investigator's discretion. Based on tolerability, the goal in the standard arm should be to complete a total of six months of adjuvant treatment.
16265116|NCT04920019|Experimental|Thoracic continuous epidural analgesia|"Thoracic continuous epidural analgesia at T7-8 or T8-9 combined with IV PCA fentanyl (bolus mode only 15 ug/bolus, 5 minutes lockout, 4 hours limit 200 ug).
~Multimodal analgesia Intraoperative : thoracic epidural infusion with 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h, morphine 2 mg epidurally are given.
~Postoperative: 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h is given combined with IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug, multimodal analgesia: paracetamol 1000 mg iv every 6 hours until patient can take orally, change to 1000 mg orally every 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (etoricoxib 90 mg orally x2 days)"
16265117|NCT04920019|Active Comparator|intravenous opioid|IV PCA fentanyl, IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug multimodal analgesia: paracetamol 1000 mg IV every 6 hours until patient can take orally, change to 1000 mg orally q 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (Etoricoxib 90 mg orally x2 days)
16265118|NCT04920006|No Intervention|Aim 1: Focus Groups|A series of three sequential focus groups will be used to gather ADRD caregiver feedback about EnACT intervention techniques, including frequency, duration, delivery, feasibility, acceptability, and relevance of the intervention. Between focus groups, we will refine and edit the EnACT intervention in an iterative process. Intervention scenarios and activities will be chosen and refined as part of Aim 1 in preparation for testing feasibility and acceptability.
16265119|NCT04920006|Experimental|Aims 2 & 3: Intervention|A Stage 1b pilot study will be conducted to test the feasibility and acceptability (Aim 2) of the EnACT intervention and potential mechanisms of change over time and their subsequent impact on proximal and distal outcomes (Aim 3). This arm will use a randomized waitlist control design.
16265121|NCT04919980|Experimental|Treatment|MV replacement with Innovalve MR system
16265122|NCT04919967|Experimental|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course an also receive support through the Virtual Implementation Protocol.
16265123|NCT04919967|Active Comparator|E-learning/toolkit alone|Participants assigned to the e-learning/toolkit alone group will only complete the e-learning course/receive the e-learning toolkit.
16265124|NCT04919967|No Intervention|Treatment as usual|Participants assigned to this group will not be provided any additional training or implementation assistance. They will be able to take trainings outside of study protocol if they would otherwise plan or want to do so. They will be offered the study-specific training and implementation assistance after they have completed the final study assessments.
16265125|NCT04919954|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 7 doses of tebipenem, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours following the last dose.
16265126|NCT04919954|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of tebipenem, followed by sampling of interstitial tissue fluid by a microdialysis probe inserted in a thigh over 8 hours following the last dose.
16265127|NCT04919941|Experimental|Decision aid|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
16265128|NCT04919941|No Intervention|Control|Did not receive the decision aid.
16265129|NCT04919928|Experimental|Bimodal solution with cochlear implant and hearing aid (CI+HA)|"This Arm will serve as the intervention group. Patients referred for evaluation of cochlear implant candidacy at Odense University Hospital will be screened for eligibility in this study and invited to participate. All patients receive new replacement HAs that can later be fitted with the CI in a bimodal solution. The patients will use the new replacement HAs for one month and are then randomized to either the intervention group with CI+HA or to the control group with continuous use of HA+HA (bilateral) for another two months. Patients randomized to the intervention group CI+HA will undergo surgery as soon as possible after randomization.
~Patients with the bimodal solution CI+HA will undergo follow-up one, three, six and twelve months after CI fitting."
16265130|NCT04919928|Experimental|Bilateral new replacement Hearing Aids (HA+HA)|This Arm will serve as the control group. The patients in the control group will use the new replacement HAs for one month like the intervention group and then for another three months, if they complete the study. The control group using the new replacement HAs for three months after randomization, will be offered the bimodal solution with CI to the poorer hearing ear and have the same follow-up period as the intervention group after a total of four months with new replacement HAs.
16265131|NCT04919915|Other|Intervention group|Households are randomly assigned to the intervention group with asthma education and received two HEPA air cleaners designed to reduce PM and NH3.
16265132|NCT04919915|No Intervention|Control group|Households are randomly assigned to the control group. They only received the asthma education during the study period. These households receive a HEPA air cleaner at the end of the study.
16265133|NCT04919902||Electric cardioversion|Patients who underwent elective cardioversion for atrial arrhythmia
16265134|NCT04919876|Experimental|fruit/vegetable supplement (FVS)|The experimental product will be prepared by combing Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend in an equal proportion.
16265135|NCT04919876|Placebo Comparator|placebo|The placebo comprises microcrystalline cellulose and 0.5% magnesium stearate.
16265136|NCT04919863|Experimental|NTP42:KVA4|
16265137|NCT04919863|Placebo Comparator|Placebo|
16265138|NCT04919850|Active Comparator|Intervention group|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
16265139|NCT04919850|Placebo Comparator|Placebo group|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
16265140|NCT04919837|Experimental|Algorithm assisted group|Patients receive assisting devices fitting services from human doctors assisted by the machine learning model
16265141|NCT04919837|Experimental|Human doctor group|Patients receive assisting devices fitting services from humanr doctors
16265142|NCT04919824|Experimental|Creo Medical Speedboat RS2|ESD procedure performed with Creo Medical Speedboat RS2.
16265143|NCT04919824|Active Comparator|Olympus DualKnife J|ESD procedure performed with Olympus DualKnife J.
16265144|NCT04919811|Experimental|Taletrectinib|Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib
16265145|NCT04919798|Experimental|Urinating with NIBED first, without NIBED second|Urinating with NIBED first, without NIBED second
16265146|NCT04919798|Experimental|Urinating without NIBED first, with NIBED second|Urinating without NIBED first, with NIBED second
16265147|NCT04919785|Experimental|Deep brain stimulation|Deep brain stimulation in the bed nucleus of stria terminalis
16265148|NCT04919772||Stroke survivors|Chronic stroke, generally speaking chronic stroke refers to the period of recovery that takes place at least six months after the initial stroke event
16265149|NCT04919759|Active Comparator|Rashakaty Basic (R-Basic)|Participants in the R-Basic intervention arm had access to a website that contained the study questionnaires and nutrition education materials
16265150|NCT04919759|Experimental|Rashakaty Enhanced (R-Enhanced)|Participants in the R-Enhanced intervention were given access to smart phones applications for monitoring diet and physical activity levels as well as an online access to a nutritionist
16265151|NCT04919746|Experimental|Group Acupuncture 1 - GA1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
16265152|NCT04919746|Experimental|Group Acupuncture 2 - GA2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
16265153|NCT04919746|Experimental|Group Acupuncture 3 - GA3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
16265154|NCT04919746|No Intervention|Group Control 1 - GC1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
16265155|NCT04919746|No Intervention|Group Control 2 - GC2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
16265156|NCT04919746|No Intervention|Group Control 3 - GC3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
16265157|NCT04919733|Experimental|Non fluoroscopy CIED implant|Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system
16265158|NCT04919720|Other|Human Factors Interventions|A 'bundle' of human factors interventions designed to improve response to deteriorating patients.
16265159|NCT04919707|Experimental|Older Adolescent Soccer Players|10 male, 10 female soccer players, grades 11-12, age 16-18 Neurocognitive measures, physical measures, header session, MRI
16265161|NCT04919694|Experimental|combination of orbital compression and strabismus surgery|orbital compression and strabismus surgery are performed at the same time
16265162|NCT04919694|Active Comparator|perform strabismus surgery after orbital compression|Firstly, perform orbital compression, after about 3 to 6 months ,strabismus surgery is done.
16265163|NCT04919681|Experimental|Stretching|Static stretching of the knee flexors
16265164|NCT04919668|Sham Comparator|Low budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
16265165|NCT04919668|Active Comparator|High budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
16265166|NCT04919668|Active Comparator|Low budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
16265167|NCT04919668|Active Comparator|High budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
16265172|NCT04919629|Experimental|Cohort 2B-1 (pegcetacoplan, pembrolizumab)|
16265173|NCT04919629|Experimental|Cohort 2B-2 (pegcetacoplan, pembrolizumab, bevacizumab)|
16265174|NCT04919629|Experimental|Cohort 2B-3 (bevacizumab)|
16265175|NCT04919616|Experimental|Single-arm|
16265176|NCT04919603|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
16265177|NCT04919603|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)>.
16265181|NCT04919577||RSS- Group|Patients without RSS after distal gastrectomy.
16265182|NCT04919577||RSS+ Group|Patients with RSS after distal gastrectomy.
16265183|NCT04919564|Experimental|Furosemide|Low dose continuous furosemide 2 mg/hour for a period of 12 hours since anesthetic induction
16265184|NCT04919564|Placebo Comparator|Control|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
16265185|NCT04919551|Experimental|KGD|Oral administration after fasting/high-fat meal/low-fat meal
16265186|NCT04919551|Experimental|GDK|Oral administration after high-fat meal/low-fat meal/fasting
16265187|NCT04919551|Experimental|DKG|Oral administration after low-fat meal/fasting/high-fat meal
16265188|NCT04919538||Relapsing Polychondritis Cohort|
16265189|NCT04919525|Experimental|TrainPain Intervention|Daily TrainPain protocol - gamified sensory perceptual training
16265190|NCT04919512|Experimental|Cohort 1: TAR-200 + Cetrelimab|Participants will receive TAR-200 in combination with cetrelimab.
16265191|NCT04919512|Experimental|Cohort 2: Cetrelimab|Participants will receive cetrelimab.
16265192|NCT04919499|Experimental|Part A: BI 765128 low dose|
16265193|NCT04919499|Experimental|Part A: BI 765128 medium dose|
16265194|NCT04919499|Experimental|Part A: BI 765128 high dose|
16265195|NCT04919499|Experimental|Part B: BI 765128|Highest safe dose from Part A
16265196|NCT04919499|Sham Comparator|Part B: Sham comparator|
16265197|NCT04919486|Experimental|Experiment group|non-weight bearing visual feedback intervention under the of Labview software, and used rowing machine equipment for exercise training for 30 minutes,then eselastic band exercise training for 30 minutes.
16265198|NCT04919486|Active Comparator|elastic band exercise|elastic band exercise under the Physiotherapist, and used elastic band for exercise training for 60 minutes,include muscles flexion the hip joint, muscles extention the hip joint,etc.
16265199|NCT04919473|Experimental|vMCO-I High dose|Participants received 3.5E11vg/eye of vMCO-I
16265200|NCT04919473|Experimental|vMCO-I Low Dose|Participants received 1.75E11vg/eye of vMCO-I
16265257|NCT04919005|Experimental|Elderly people with Alzheimer's in the initial phase|Seven elderly people with Alzheimer's in the initial phase. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
16265201|NCT04919460|Other|clinical observation combined with pathological biopsy|Clinical observation (including inspection and palpation) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
16265202|NCT04919460|Experimental|Clinical observation, in vivo staining combined with pathological biopsy|Clinical observation (including inspection and palpation), in vivo staining (reagent: toluidine blue) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
16265203|NCT04919434|Other|Intervention|Women will be asked NOT to use their own personal care product during the intervention. They will only have to use the substitute one given by the research team
16265204|NCT04919421|Active Comparator|Virtual reality|Participants will wear a virtual reality headset during the dental injection in which a video is playing.
16265205|NCT04919421|Active Comparator|Topical gel|Participants will receive application of topical anesthetic gel on the site of dental injection.
16265206|NCT04919408|Experimental|Patients scheduled for cesarean section under spinal anesthesia|Patients scheduled for cesarean section under spinal anesthesia ASA I and II according to The ASA Physical Status Classification System
16265207|NCT04919382|Experimental|Cohort I (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16265208|NCT04919382|Experimental|Cohort II (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive temozolomide PO QD on days 1-14 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16265210|NCT04919343|Experimental|BBC Tiny Happy People intervention|Parents will be sent links each month directing them to BBC Tiny Happy People content via SMS text message using the secure service FireText. This content will be aimed at supporting language development. Parents will be asked to watch the video content and incorporate it into their parenting practices. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits.
16265211|NCT04919343|Active Comparator|Physical health control|Similar to the experimental condition, parents will be sent links each month via SMS text message using FireText. These links will direct them to publicly available web content with tips to promote the healthy development of their baby, focusing on things such as healthy eating, physical activities, and dental care. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits
16265212|NCT04919330|Experimental|ACT Group|One four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP) and routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation.
16265213|NCT04919330|Other|Wait-list Control Group|Routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation
16265214|NCT04919317|Placebo Comparator|Control|Control group patients received 29mL bupivacaine plus 1mL 0.9% saline. Like the experimental group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
16265215|NCT04919317|Experimental|Experimental|Experimental group patients received 29mL bupivacaine plus 1mL of 4mg/mL dexamethasone. Like the control group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
16265216|NCT04919291|Active Comparator|Topoguided LASIK|Topoguided ablation profile on dominant eye
16265217|NCT04919291|Active Comparator|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
16265218|NCT04919278|Experimental|Intervention group|Participants will be evaluated for any health contraindication. Once reviewed they will received full spine chiropractic treatment for 4 weeks, at the rate of one adjustment per week. After three visits they will complete the outcome measures
16265219|NCT04919278|No Intervention|Control group|Paticipants will be selected amongst thse attending predelivery sessions. They receive no chiropracti care. They will complete the outcomes at the same time as the Intervention group and then 4 weeks later.
16265220|NCT04919265||Mother and Infant|The cohort will be followed for 2 years with 8 follow-up measurement points of the infants until the age of 1 year.
16265221|NCT04919252|Experimental|Vedolizumab|"Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.
~Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
16265222|NCT04919239|Experimental|RUTI® arm|A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
16265223|NCT04919239|Placebo Comparator|Placebo arm|Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
16265224|NCT04919226|Experimental|Peptide Receptor Radionuclide Therapy (PRRT) Arm|
16265225|NCT04919226|Active Comparator|CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)|
16265417|NCT04917731|Experimental|Botox|
16265418|NCT04917731|Placebo Comparator|Placebo|
16265226|NCT04919213||Individuals with Intellectual Disabilities|Individuals will be invited to take part in an online survey (paper version will also be available). The participants will be recruited through advertisements on relevant platforms (e.g., Facebook, Twitter) and through relevant social care organisations. The study hopes to recruit 100 individuals from all over England (UK). A subgroup will be asked if they would like to take part in a one-to-one open-ended interview (n=20) and/or in direct observations (n=30).
16265227|NCT04919213||Family carers|Family carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of family carers (n=7) will be asked if they would like to take part in a focus group.
16265228|NCT04919213||Paid carers|Paid carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of paid carers (n=7) will be asked if they would like to take part in a focus group.
16265229|NCT04919213||Professionals with safeguarding responsibilities|Professionals with safeguarding duties (e.g., social workers, learning disability nurses, police and safeguarding adults board members) supporting people with ID in England who use the internet will also be invited to take part in an online survey (n=50). A subgroup (n=7) from London and Kent (England, UK) will be asked if they would like to take part in a focus group.
16265230|NCT04919200||modeling group|Of these 628 individuals, we set 407 patients enrolled from January 2018 to November 2019 as the modeling group
16265231|NCT04919200||verification cohort|221 patients enrolled from December 2019-December 2020 served as a prospective verification cohort
16265232|NCT04919174|Active Comparator|Control group|Patients receive dexmedetomidine for sedation
16265233|NCT04919174|Experimental|Test group|Patients receive remimazolam for sedation
16265234|NCT04919161|Active Comparator|Body weight support system control group|In this arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system.
16265235|NCT04919161|Experimental|Body weight support system with balance perturbations|Similar to the control group arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system, with the inclusion of 8 total balance perturbations each session, including 2 in the posterior, anterior, left lateral, and right lateral directions.
16265236|NCT04919161|No Intervention|Historical Standard of Care control|Retrospective anonymized Berg Balance Score data of stroke inpatients was collected from an institutional report for fiscal year 2018. 2018 was chosen as it preceded the implementation of the ZeroG body weight support system and reflects a no-intervention control baseline. This data was then filtered to show only patients with a Berg score of 21 or greater to match the study's inclusion criteria.
16265237|NCT04919148|No Intervention|Participants receive control message|Participants only receive standard heat risk warning
16265238|NCT04919148|Experimental|Participants receive intervention message|Participants receive standard heat risk warning plus figures incorporating the health impacts of heat and pro-environment behaviors.
16265239|NCT04919135|Experimental|Treatment (UC-MSC trasnplatation)|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
16265240|NCT04919135|Other|control arm|standard frailty treatment and supplementary medication
16265242|NCT04919109|Placebo Comparator|Placebo comparator|Administered as nose drops
16265243|NCT04919109|Experimental|Experimental: CodaVax-RSV 10^6 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
16265244|NCT04919096|Experimental|SCB-420|Subjects randomized to SCB-420 will receive SCB-420 2mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
16265245|NCT04919096|Active Comparator|Aflibercept|Subjects randomized into Aflibercept (Eylea) group will receive Aflibercept (Eylea) 2 mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
16265246|NCT04919083||Non-exposed cohort (protective factor)|Group of patients operated on during the year 2021 in San Juan de Dios Hospital for hip fracture and to which the new programme implementing functional recovery and therapeutic exercise will be applied with follow-up for one year. The implementation of a functional recovery plan and subsequent follow-up is considered a protective factor in relation to the loss of functionality.
16265247|NCT04919083||Exposed cohort (retrospective)|Complete cohort of patients operated on during the year 2020 in San Juan de Dios Hospital for hip fracture and to whom no specific functional recovery plan was applied.
16265248|NCT04919070|Experimental|Connect for Caregivers|Connect for Caregivers is a single session behavioral intervention with three components: 1) psychoeducation on the importance of connectedness for health and well-being; a card sort-based discussion prioritization tool that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; 3) personalized resources to address the identified barriers and targets.
16265249|NCT04919057|Experimental|Robotic perineal radical prostatectomy|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
16265250|NCT04919044|Experimental|Motor Imagery|The participants were instructed to imagine and visualize to straighten both knees with eyes closed. You have to see and feel only what you would see and feel if you had to perform the action to straighten both of your knees in sitting position. Imagine the movement using the most comfortable way for you, and make sure not to contract your muscles.
16265251|NCT04919044|No Intervention|Control|No intervention provided.
16265254|NCT04919018||Primary Ciliary Dyskinesia (PCD)|Subjects with a confirmed diagnosis of PCD
16265255|NCT04919018||Primary Immune Deficiency (PID)|Subjects with a confirmed diagnosis of PID
16265256|NCT04919005|Experimental|Healthy elderly people|Twelve healthy elderly people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
16265258|NCT04919005|Experimental|Healthy young people|Fifteen healthy young people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
16265259|NCT04918953|Experimental|group 1|oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days
16265260|NCT04918953|Experimental|group 2|oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days
16265261|NCT04918953|Experimental|group 3|budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks.
16265262|NCT04918940|Experimental|Post-vaccination immunity|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
16265265|NCT04918914|Other|Intervention|
16265266|NCT04918901||Severe COVID-19|Comparative Analysis of Clinical Parameters and Radiographic Changes
16265267|NCT04918888||Overall study population|All new oncologic patients of the outpatient-clinic of the department of radiooncology
16265268|NCT04918888||First dose received (Subpopulation 1)|Patients, who received one or two doses of SARS-CoV-2 vaccine prior to radiotherapy
16265269|NCT04918888||Vaccination during therapy (Subpopulation 2)|Patients, who will receive at least one dose of SARS-CoV-2 vaccine during or up to 6 weeks after radiotherapy
16265270|NCT04918875||Patients 12 years of age or older with suspected or confirmed COVID-19, deemed to require oxygen.|
16265271|NCT04918862|Active Comparator|Granisetron 1 mg|Granisetron 1 mg: 105 patients received 1mg granisetron
16265272|NCT04918862|Active Comparator|Granisetron 3 mg|Granisetron 3 mg: 105 patients received 3mg granisetron
16265273|NCT04918849||Community Sample|We plan to recruit a community sample of 1000 from the Indian Population.
16265274|NCT04918823|Other|Single arm|All subjects will receive Restasis in this study
16265275|NCT04918810|Experimental|Arm 1: Intermittent docetaxel treatment|suspend docetaxel prior to cycle 4, recommencement based on mGSTP1 monitoring
16265276|NCT04918810|Active Comparator|Arm 2: Standard of Care docetaxel treatment|Docetaxel administered as per Standard of Care: as per clinician recommendation
16265277|NCT04918797|Experimental|Study vaccine|SARS-COV2 vaccine
16265278|NCT04918784|Experimental|Treatment with Synthetic Hybrid-Scale Fiber Matrix|Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.
16265279|NCT04918784|Active Comparator|Treatment with Standard of Care|Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.
16265280|NCT04918771|Experimental|Rafamin|Tablet for oral use.
16265281|NCT04918771|Placebo Comparator|Placebo|Tablet for oral use.
16265282|NCT04918758|Experimental|Purastat Arm|Purastat 5ml once monthly for 3 months
16265283|NCT04918758|Other|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks
16265284|NCT04918745|Other|ABC|"A = Unmodulated
~B = Angular modulation
~C = Linear modulation"
16265285|NCT04918745|Other|ACB|"A = Unmodulated
~C = Linear modulation
~B = Angular modulation"
16265286|NCT04918745|Other|BAC|"B = Angular modulation
~A = Unmodulated
~C = Linear modulation"
16265287|NCT04918745|Other|BCA|"B = Angular modulation
~C = Linear modulation
~A = Unmodulated"
16265288|NCT04918745|Other|CAB|"C = Linear modulation
~A = Unmodulated
~B = Angular modulation"
16265289|NCT04918745|Other|CBA|"C = Linear modulation
~B = Angular modulation
~A = Unmodulated"
16265290|NCT04918719|Experimental|NAC arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine (NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.
~The dosing of NAC will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours."
16265291|NCT04918719|Placebo Comparator|Placebo arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine(NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.
~The placebo will consist of a 5% Dextrose in Water (D5W) instead of NAC (dosage and timings are the same as the NAC arm)."
16265292|NCT04918706|Experimental|MSC week 4 and 3 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv
16265293|NCT04918706|Placebo Comparator|Placebo week 4 and 3 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
16265294|NCT04918706|Experimental|MSC week 12 and 11 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv
16265295|NCT04918706|Placebo Comparator|Placebo week 12 and 11 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
16265419|NCT04917718|Experimental|Extended Release Tacrolimus|All participants who consent to the study will be in this group.
16265420|NCT04917692|Experimental|empagliflozin|empagliflozin 2.5 mg daily
16265296|NCT04918693||Participant|All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
16265297|NCT04918693||Trainee|All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
16265298|NCT04918680||EcoFit® Total Hip System with implacross® E Polyethylene|Subjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.
16265299|NCT04918667|Experimental|Berberine MetX™ Ultra Absorption|16 healthy subjects will receive orally 500 mg of berberine in two capsules of Berberine MetX™ Ultra Absorption.
16265300|NCT04918667|Active Comparator|Berberine MetX™|16 healthy subjects will receive orally 500 mg of berberine in one capsule of Berberine MetX™ (reference product).
16265301|NCT04918654||Study Subjects|
16265302|NCT04918641||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral, and imaging measures.
16265303|NCT04918628|Experimental|Arm A|Neoadjuvant Chemotherapy Combined With CCRT Followed by Adjuvant Chemotherapy and Anti-PD-1 Antibody(Sintilimab 200mg intravenous drip every three weeks until PD or 2 years).
16265304|NCT04918615|Experimental|Sirolimus coated balloon catheter|Manufacturer: Shanghai MicroPort Medical Group Co, Ltd.
16265305|NCT04918615|Active Comparator|Paclitaxel coated balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd
16265306|NCT04918589|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
16265307|NCT04918589|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
16265308|NCT04918576|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
16265309|NCT04918576|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
16265310|NCT04918563|Active Comparator|nitroglycerin|"NO donor (Nitropohl) vs pgysiological saline
~1mg/ml nitorhlycerin"
16265311|NCT04918563|Active Comparator|acethylcholine|10 mg/ml acetylcholine vs physiological saline
16265312|NCT04918537|Experimental|Intervention walnuts|During the 3 last weeks of the study, the participants will eat a 30g daily walnut serving
16265313|NCT04918524||The Antiphospholipid syndrome (APS)|The cohort includes that patients who meet the proposed Sydney criteria.
16265314|NCT04918524||Undifferentiated connective tissue disease (UCTD)|The cohort includes the patients who are diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, aPL, and anti-cyclic citrullinated peptide (CCP) antibody, with or without at least one symptoms or signs suggesting CTD ,while not fulfilling any classification criteria of a defined CTD.
16265315|NCT04918511|Experimental|Dose cohort 1|In dose cohort 1, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level of 30 mg/m2 (dose based on body surface area)
16265316|NCT04918511|Experimental|Dose cohort 2|In dose cohort 2, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 1
16265317|NCT04918511|Experimental|Dose cohort 3|In dose cohort 3, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 2
16265318|NCT04918511|Experimental|Dose cohort 4|In dose cohort 4, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 3
16265319|NCT04918511|Experimental|Dose cohort 5|In dose cohort 5, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 4
16265320|NCT04918511|Experimental|Dose cohort 6|In dose cohort 6, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 5
16265321|NCT04918511|Experimental|Dose cohort 7|In dose cohort 7, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 6
16265322|NCT04918498|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
16265323|NCT04918498|Experimental|Experimental group|Implement early physiotherapy programs. The early physiotherapy program for VV-ECMO patients mainly includes the establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy.
16265324|NCT04918485|Experimental|the experimental group received psychological intervention|
16265325|NCT04918485|No Intervention|the control group receive normal process before surgery|
16265326|NCT04918472|Experimental|MCCE|Magnetically controlled capsule endoscopy will be performed before UGI endoscopy.
16265327|NCT04918459||EUS guided cyanoacrylate injection|EUS guided cyanoacrylate injection to prevent EV rebleeding.
16265328|NCT04918459||variceal band ligation|variceal band ligation to prevent EV rebleeding.
16265329|NCT04918446|Experimental|T-POSE|Technology based brief educational intervention for hospitalized patients that will be discharged with an opioid prescription.
16265330|NCT04918446|Other|Usual Care|Standard discharge instructions provided.
16265331|NCT04918433|Active Comparator|TRANSEVERSUS THORACIS MUSCLE PLANE BLOCK (TTPB)|After induction of anaesthesia, ultrasound guided transverses thoracis muscle plane block will be done using 0.25% bupivacaine
16265332|NCT04918433|Active Comparator|PECTO-INTERCOSTAL FACIAL PLANE BLOCK (PIFB)|After induction of anaesthesia, ultrasound guided pectointercostal facial plane block will be done using 0.25% bupivacaine
16265333|NCT04918420|Experimental|Group A|Flow diverter(Ton-bridgeMT, China)
16265334|NCT04918407|Experimental|Empagliflozin|Adding 25mg Empagliflozin on Insulin
16265335|NCT04918407|Active Comparator|Insulin alone|Just contriling the blood glucose with Insulin
16265336|NCT04918394||Asthma patients unexposed to mold / moisture|No mold / moisture exposure is defined by a negative response to all of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
16265337|NCT04918394||Asthma patients exposed to mold / moisture|Mold / moisture exposure is defined by a positive response to at least one of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
16265338|NCT04918381|Experimental|CellFX Procedure|Treatment of the BCC with CellFX System
16265339|NCT04918368||Pregnant women between 18-45 years old, being in second and third trimester of a singleton pregnancy|
16265340|NCT04918355||Provider Group 1: no alert|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
16265341|NCT04918355||Provider Group 2: Mandated alert|Control group where providers will see a generic pop-up alert within the Electronic Health Record (EHR) whenever they initiate an opioid or benzodiazepine prescription without recording use of the PDMP. Patient risk factors are not assessed or presented in the alert. Providers in ambulatory clinics will not be assigned to this group. Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.
16265342|NCT04918355||Provider Group 3: PDMP alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on past/current prescriptions received. Patient risk factors are assessed and presented in the alert. Risk factors included are numbers of active or recent opioid and benzodiazepine prescriptions, overlapping prescriptions, co-prescribing of benzodiazepines and opioids, and use of long-acting opioids in opioid naïve patients.
~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
16265343|NCT04918355||Provider Group 4: PDMP + EHR alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on both prescriptions and other factors recorded in the patient's Electronic Health Record. Patient risk factors are assessed and presented in the alert. Risk factors included the risks described as in Group 3, along with a history of accidental opioid overdose, diagnosis of Opioid Use Disorder, multiple recent acute care incidents with opioid use, or high risk psychiatric diagnoses.
~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
16265344|NCT04918342|Active Comparator|Individual Exercise Instruction|The participant will receive individual exercise instruction.
16265345|NCT04918342|Experimental|Group Exercise Instruction|The participant will receive the instruction in a group of up to 9 other participants.
16265346|NCT04918316|Active Comparator|Corneal gas permeable lens first|"Device: corneal gas permeable contact lenses (RoseK2 corneal Blanchard Contact Lens, Inc. Manchester, NH).
~Participants with an odd study ID will be fit with the corneal gas permeable lens first."
16265347|NCT04918316|Active Comparator|Scleral lens first|"Device: scleral lenses (SynergEyes VS (Synergeyes, Inc., Carlsbad CA).
~Participants with an even study ID will be fit with the scleral lens first."
16265348|NCT04918303|Experimental|SKNA group|
16265349|NCT04918290|Experimental|Tegaderm Left|After general anesthesia is administered, Tegaderm will be placed on the left eye and Transpore will be placed on the right eye
16265350|NCT04918290|Experimental|Transpore Right|After general anesthesia is administered, Transpore will be placed on the right eye and Tegaderm will be placed on the left eye.
16265351|NCT04918264||Uracil concentration <16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage <16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot [Lyon], Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon].
16265352|NCT04918264||Uracil concentration ≥16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage <16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot [Lyon], Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon].
16265353|NCT04918251||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
16265354|NCT04918251||Amyotrophic lateral sclerosis patients|
16265355|NCT04918251||Multiple sclerosis patients|
16265356|NCT04918251||Frontotemporal dementia patients|
16265357|NCT04918238|Active Comparator|conventional treatment Arm|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
16265358|NCT04918238|Experimental|muscle energy technique arm|Group A received muscle energy technique with lateral recumbent positioning along with Conventional Physiotherapy Program
16265359|NCT04918225||Progressive Multiple Sclerosis patients|Progressive Multiple Sclerosis patients
16265360|NCT04918225||Healthy Volunteers|Healthy Volunteers
16265361|NCT04918212|Experimental|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
16265362|NCT04918199||Paris Transplant Group cohort|400 (10%) of the patients were randomly selected from 4,000 consecutive patients over 18 years of age prospectively enrolled at the time of kidney transplantation from a living or deceased donor at Necker Hospital, Saint-Louis Hospital, Foch Hospital, and Toulouse Hospital between January 1, 2005, and January 1, 2014, in France.
16265363|NCT04918186|Experimental|Durvalumab + BA3011|
16265364|NCT04918186|Experimental|Durvalumab + BA3021|
16265365|NCT04918186|Experimental|Sub Study X (etc.)|
16265366|NCT04918173|Experimental|Atenativ treatment|Patients will receive a single intravenous infusion of Atenativ for PK analysis. Patients will receive a single intravenous dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients
16265421|NCT04917679|Experimental|Combination group|Eltrombopag plus diacerein
16265422|NCT04917679|Placebo Comparator|Monotherapy group|Eltrombopag monotherapy
16266093|NCT04913090|Experimental|Part B-experimental|multiple ascending dose (MAD) phase
16265369|NCT04918147|Experimental|Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper.
~Elotuzumab: 10 mg/kg administered once weekly, intravenously (IV push or bolus), per protocol.
~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
16265370|NCT04918147|Experimental|Cohort 1b: Elotuzumab-Three-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.
~Elotuzumab: 10 mg/kg administered as referenced above, intravenously (IV push or bolus), per protocol.
~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
16265371|NCT04918147|Experimental|Cohort 2: Arm A- Elotuzumab (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).
~Forty-two participants will receive elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.
~Elotuzumab: 10 mg/kg administered as referenced above, intravenously (IV push or bolus), per protocol.
~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
16265372|NCT04918147|Placebo Comparator|Cohort 2: Arm B-Placebo (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).
~Twenty-one participants will receive placebo for elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.
~Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously (IV push or bolus), per protocol.
~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
16265373|NCT04918121|Experimental|Yutiq|A sustained-release steroid insert (Yutiq) will be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
16265374|NCT04918121|No Intervention|Control|Non-study eye will not receive the Yutiq insert
16265376|NCT04918095||Moderate-Severe COPD|COPD patients diagnosed GOLD 2- 3, C- D for moderate-severe, poorly controlled
16265377|NCT04918069|Experimental|Capsaicin|2g of 0.075% topical capsaicin ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
16265378|NCT04918069|Placebo Comparator|Placebo|2g of topical placebo ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
16265379|NCT04918056||beta thalassemia patients|
16265380|NCT04918043||HUCS, NKL|Newborns and their mothers at the Helsinki University Central Hospital maternity ward.
16265381|NCT04918030|Active Comparator|In-hospital staged PCI|Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions.
16265382|NCT04918030|Experimental|Out-hospital staged PCI|Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.
16265383|NCT04918017|Active Comparator|International Guidelines Arm (Treatment based on subtypes: Esomeprazole or Itopride)|"International Guidelines: Treatment based on subtypes: either Epigastric Pain Syndrome (EPS) or Postprandial Distress Syndrome (PDS)
~EPS: treat with esomeprazole 40mg OD (proton pump inhibitor) PDS: treat with itopride 50mg TDS (prokinetic) Overlapped EPS/PDS: treat with itopride 50mg TDS first and add esomeprazole 40mg OD (if partially responded) or change to esomeprazole 40mg OD (if not responded)"
16265384|NCT04918017|Active Comparator|Routine Practice Arm (Esomeprazole)|Treat with esomeprazole 40mg OD regardless of subtype of functional dyspepsia
16265385|NCT04918004|Experimental|Case group|Patients in the case group were given one-to-one sleep hygiene training by researchers and, a brochure containing 10 lifestyle changes related to sleep hygiene as well as they assessed at the first interview and the last interview, received routine health care, and
16265386|NCT04918004|No Intervention|Control group|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
16265387|NCT04917991|Experimental|Extra Virgin Olive Oil Group|Subjects will consume 100 grams of Extra Virgin Olive Oil-enriched chocolate spread for 14 days.
16265388|NCT04917991|Active Comparator|Palm oil Group|Subjects will consume 100 grams of palm oil enriched chocolate spread for 14 days.
16265389|NCT04917978||beta thalassemia patients|
16265390|NCT04917965||Healthy Term Neonates|Infants born at 37 weeks gestational age or greater born to mothers of any age with uncomplicated pregnancies. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
16265492|NCT04917146||Caregivers (CG)|Caregivers of patients with systemic Scleroderma
16265391|NCT04917965||Term infants of diabetic mothers|Infants born at 37 weeks gestational age or greater to mothers of any age with gestational diabetes or Type 1 or Type 2 diabetes, managed with either diet or insulin. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
16265392|NCT04917952|Experimental|BFR group|The intervention group will receive resisted knee extension 30% of 1RM with blood flow restriction.
16265393|NCT04917952|Placebo Comparator|Sham BFR group|The control group will receive resisted knee extension 30% of 1RM with sham blood flow restriction.
16265394|NCT04917939||epilepsy with HS|
16265395|NCT04917939||epilepsy without HS|
16265396|NCT04917926|Experimental|Financial and social intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, social incentives and weekly feedback on performance for 6 months.
16265397|NCT04917926|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
16265398|NCT04917926|Experimental|Financial intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, and weekly feedback on performance for 6 months.
16265399|NCT04917913|Experimental|Intervention|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
16265400|NCT04917913|Placebo Comparator|Placebo|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
16265401|NCT04917900|Experimental|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
16265406|NCT04917848||Older adults with cancer|Participants will be 70 years old or older with a diagnosis of gastrointestinal or gynecological cancer. Participants will be receiving or about to receive adjuvant medical cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy, biological agents)
16265407|NCT04917835|Experimental|treatment with argon- and nitrogen-NTAPP|PLADUO (argon- and nitrogen- non-thermal, atmospheric-pressure plasma) treatment
16265408|NCT04917822|Experimental|Emotion regulation arm|The emotion regulation arm aims at improving emotional regulation skills among parents and children.
16265409|NCT04917822|Active Comparator|Information provision arm|The information provision arm aims at providing information about Hong Kong, such as education, community resources, medical care, employment, housing, and job-seeking among parents and children.
16265411|NCT04917796|Experimental|Electroacupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
16265412|NCT04917796|Placebo Comparator|Sham Acupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
16265413|NCT04917783|Other|Standard of Care|Caregivers in the standard of care-arm will receive immediate verbal feedback by a psychologist on their neurocognitive testing results, recommendations, and guidance for implementing recommendations (e.g., sending a 504 Plan request to the school). This report will contain information regarding background, test results, a summary and impressions, and bullet-pointed recommendations.
16265414|NCT04917783|Experimental|Health Literacy|"Participants randomized to the experimental health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations of their neurocognitive testing results along with the full written report. The domains listed as either satisfactory or needing help listed on the passport card will directly correspond to those listed on the full report."
16265415|NCT04917770|Experimental|Sintilimab in combination with Multimodality Radiotherapy group|The dose of sintilimab was 200mg per dose, intravenously, once every 3 weeks. Multimodal radiotherapy methods: ①SBRT: ≥1 independent lesion was selected, with a single dose of 8-10Gy and a total dose of 40-60Gy, divided into 5-6 times of radiotherapy. The final frequency and total dose of radiotherapy were determined by the radiologist.② Low-dose radiotherapy: ≥1 independent lesion was selected, and the single dose, the final frequency of radiotherapy and the total dose were determined by the radiologist.
16265416|NCT04917744||Ancillary-correlative (blood collection, chart review)|Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.
16265423|NCT04917666|Experimental|Treatment|Participants joined a 8-session horticultural therapy group program (60 minutes per session) over 8 weeks.
16265424|NCT04917666|Other|Comparison|Participants joined 4 sessions of individual, parallel, and table-top activities of their own interest, e.g. reading, drawing, coloring.
16265425|NCT04917653||Atrial fibrillation|"Patients with recent-onset atrial fibrillation treated by cardioversion intervention.
~Intervention:
~Device: Heart rhythm monitoring with portable device. Biomarkers: Biomarker kinetics based on blood samples."
16265426|NCT04917640||SBRT|Patients treated with Stereotactic Body Radiation Therapy (SBRT)
16265427|NCT04917640||IMRT|Patients treated with Intensity Modulated Radiation Therapy (IMRT)
16265428|NCT04917627|Active Comparator|vancomycin group (intervention arm)|We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
16265429|NCT04917627|No Intervention|control group|no vancomycin powder will be used
16265430|NCT04917614|Active Comparator|group teas|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at Hegu (LI4), Neiguan (PC6), and Zusanli (St 36) with an electronic acupuncture device.
16265431|NCT04917614|Sham Comparator|Control Group|In the sham group, the patients were connected to the electronic acupuncture, but electronic stimulation was not applied.
16265432|NCT04917601|Experimental|Evira Care treatment|"The intervention arm will receive Evira Care in combination with Standard Lifestyle Care. If the standard treatment, after the first month of treatment, contains more frequent visits than every third month, the number of standard visits shall be reduced to a maximum of one visit every third month. During the first 2-4 weeks, participants will receive information about the system and how to utilize the daily weighings and communication system. The families will be informed about possible lifestyle changes that may be effective and that they are supposed to do lifestyle changes primarily regarding energy intake that they do consider feasible in their specific living situations.
~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
16265433|NCT04917601|Active Comparator|Standard Lifestyle Care|"The control group will receive the standard care of treatment for childhood obesity, which addresses lifestyles without any restriction in visits or clinical support.
~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
16265434|NCT04917588|Experimental|Saypha® FILLER HQ|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma HQ Facility in order to correct moderate to severe deficiency of lip volume.
~The treatment will be administered at the Baseline visit (Day 0)."
16265435|NCT04917588|Active Comparator|Saypha® FILLER C1|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma C1 Facility in order to correct moderate to severe deficiency of lip volume.
~The treatment will be administered at the Baseline visit (Day 0)."
16265436|NCT04917575|Experimental|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing, risk assessment tool, and HIV and pre-exposure prophylaxis (PrEP) locators embedded within the game.
16265437|NCT04917575|Active Comparator|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
16265438|NCT04917549||Patients diagnosed with COVID-19|
16265439|NCT04917536|Active Comparator|rotator cuff approach|the nail is inserted through the supra-spinatus tendon, which is closed at the end of the surgery
16265440|NCT04917536|Experimental|rotator cuff split approach|the nail is inserted through the rotator cuff split, between the supra-spinatus tendon and the long part of the biceps
16265441|NCT04917523|Experimental|Aged 3-6 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
16265442|NCT04917523|Experimental|Aged 7-12 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
16265443|NCT04917523|Experimental|Aged 13-17 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
16265444|NCT04917523|Active Comparator|Aged ≥18 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
16265445|NCT04917510|Active Comparator|Control|Will not receive erector spinae block. Will be administered 30 mL of 0.5% Marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
16265446|NCT04917510|Experimental|Study|Will receive an erector spinae block prior to surgery using 30-45 mL of 0.25 bupivacaine w/ epinephrine and 5 mL of dexmedetomidine. Will be administered 30 mL of 0.5% marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
16265447|NCT04917497||Levosimendan Treated Group|All patients consecutively admitted to the medical ICU of the University Hospital Zurich aged over 18 years, with an underlying cardiogenic shock, receiving Levosimendan.
16265448|NCT04917484|Active Comparator|Standard|Patients in this arm receive our standard treatment. Four treatment with standard dose of 7.4 GBq Lu-177-DOTATOC
16265449|NCT04917484|Experimental|Dosimetry|Patients in this treatment arm receive individualized calcuted treatment depending on kidney function and kidney dose. The treatment activity can differ from one treatment to the next.
16265450|NCT04917471|Active Comparator|Nitrate-rich beet root juice|Nitrate-rich Beet root juice 70 ml bid
16265451|NCT04917471|Placebo Comparator|Placebo|Nitrate-depleted beet root juice 70 ml bid
16265452|NCT04917458|Experimental|Cholecalciferol|-Vitamin D 25 (OH) 4000 IU capsules, tablet @ 1000 IU One capsule for once a day for 30 days of study period.
16265453|NCT04917458|Placebo Comparator|Control Group|Placebo will be administrated orally, One capsule once a day for 30 days of study period
16265454|NCT04917445|Experimental|SPIKES Protocol Compassionate Call|Nurses trained to contact IVF patients with negative pregnancy test results who were trained on the SPIKES-focused bad news delivery script.
16293838|NCT04718844|Experimental|10.0mg/kg - Thalassaemia multi dose|
16265455|NCT04917445|No Intervention|Control: Standard of Care Call|Nurses who will continue to deliver bad news as they have been in the past without a script.
16265456|NCT04917432|Active Comparator|IVUS guided CTO revascularization|To assess the effects of IVUS usage in CTO revascularization compared to conventional non-IVUS guided CTO-PCI as regard technical success and procedural success, MACE within 6 months.
16265457|NCT04917432|Active Comparator|Non-IVUS guided CTO revascularization|To compare this conventional non-IVUS guided CTO-PCI arm with the other IVUS guided arm as regard technical success and procedural success, MACE within 6 months.
16265458|NCT04917419|Experimental|Luminotherapy and Psychoeducation Program|
16265459|NCT04917419|Active Comparator|Psychoeducation Program|
16265460|NCT04917406|Experimental|Use of iontophoresis|Lidocaine (local anesthetic) associated with dexamethasone (corticosteroid) will be administered by iontophoresis technique. Dose per session and iontophoresis: 10 minutes with an intensity of 4 mA.
16265461|NCT04917406|Active Comparator|Use of ultrasound|The treatment for the control group will be applied with a frequency of 3 times a week as usually performed in the ACP of the University of Seville. The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and 1MZ head.
16265462|NCT04917393|Experimental|Multi-organ denervation|Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System
16265463|NCT04917380||Gram-negative bacteria group|Gram-negative bacteria intracranial infection after neurosurgery
16265464|NCT04917380||Gram-positive bacteria group|Gram-positive bacteria intracranial infection after neurosurgery
16265465|NCT04917367||Conventional surgery group|Conventional surgery with Preoperative foreign body localization
16265466|NCT04917367||New surgery group|new surgery with Intraoperative localization of foreign body
16265467|NCT04917354||hepatic lesion|
16265468|NCT04917341||preoperative endometrial sampling result (secondary hospital)/1|Endometrial biopsy samples taken at the stage 2 state hospital
16265469|NCT04917341||preoperative endometrial sampling result (tertiary hospital)/2|Endometrial biopsy samples taken at the stage (tertiary hospital)
16265470|NCT04917341||final postoperative pathology/3|final postoperative pathology results with grade (endometrium cancer)
16265471|NCT04917328|Experimental|Patient with clinical suspicion of deep vein thrombosis|
16265472|NCT04917315|Experimental|JLP-2002|Drug: JLP-2002
16265473|NCT04917315|Placebo Comparator|Placebo|Drug: Placebo
16265474|NCT04917302|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
16265475|NCT04917302|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
16265476|NCT04917289|Experimental|Treatment Arm|Patients in this arm will receive treatment or change current adjuvant therapy immediately after detecting CTC.
16265477|NCT04917289|No Intervention|Control Arm|Patients in this arm will keep follow-up after detecting CTC until radiology evidence of recurrence appear.
16265478|NCT04917276||Training Group|The training cohort that used to built the response prediction model
16265479|NCT04917276||Validation Group|The validation cohort that used to validate the response prediction model
16265480|NCT04917263||Retrospective|
16265481|NCT04917263||Prospective|
16265482|NCT04917250|Experimental|treatment arm|Treated with gemcitabine, pegaspargase, etoposide and dexamethasone
16265483|NCT04917224|Experimental|Cohort A: Central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from a lobar bronchus
16265484|NCT04917224|Experimental|Cohort B: Ultra-central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from the mainstem bronchus, trachea, or esophagus
16265485|NCT04917211|Experimental|virtual reality mask|During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible
16265486|NCT04917198|Experimental|median sternotomy|median sternotomy in penetrating cardiac trauma and hemodynamically unstable patients, does it affect morbidity and mortality.
16265487|NCT04917185|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
16265488|NCT04917185|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
16265489|NCT04917172||Pancreaticoduodenectomy patients|Patients scheduled to receive elective Pancreaticoduodenectomy (PD) (according to Kausch-Whipple or Longmire-Traverso) for all kinds of pancreatic disease (benign, malignant or premalignant) will be enrolled, after having signed a proper informed consent. Each patient will undergo PD once checked the presence of a resectable mass as provided by the normal clinical practice through high-quality cross-sectional imaging. Pre-operative management will follow institutional standards, serum pancreatic amylase and lipase activity will be measured as a part of the standard pre-operative evaluation.
16265490|NCT04917159|Experimental|ACT Group|The ACT intervention was structured to take place over one month on a weekly basis. Each roughly 2-hour session will consist of a group-based ACT (1.5 hours) and a brief health education talk on CHF self-management (0.5 hours), the contents of which are the same as that offered to the control group. Each training session will serve about 7-8 dyads. In addition, each participant will receive one set of session handouts on CHF education, ACT skills, and a homework assignment at the beginning of each session.
16265491|NCT04917159|Placebo Comparator|HE group|The participants of the control group will receive four weekly 2-hour sessions of structured health education on CHF self-management over four consecutive weeks, delivered by a registered nurse working in the study hospital. Each session will include a brief health education talk (0.5 hours), a section in which participants share their experiences (0.5 hours), a discussion of the main topics (0.5 hours), and a Q&A section (0.5 hours) to evaluate the participant's understanding of the key concepts. Each session will be offered to 7-8 patient-caregiver dyads. In addition, each participant will receive session handouts on the main topic related to CHF self-management at the beginning of each session and will be invited to review them as homework assignments.
16265493|NCT04917133|Experimental|Adapted Physical workshops|The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective care : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests
16265494|NCT04917133|Other|Control|"Standard of care The control group will have the classic program performed in the standard of care with : kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, creation)."
16265496|NCT04917107|Experimental|Qigong First|Participants in this group will complete the 12-week Qigong intervention first and then the 12-week observation period.
16265497|NCT04917107|Experimental|Observation First|Participants in this group will complete the 12-week observation period first and then the 12-week Qigong intervention.
16265498|NCT04917094|Experimental|Below the knee compression stocking|
16265499|NCT04917081|Experimental|Mindful Self-Compassion|
16265500|NCT04917081|Active Comparator|Progressive Muscle Relaxation|
16265501|NCT04917068||Bulimia Nervosa|Participants with diagnosed bulimia nervosa (BN) who will complete all tasks during Visits 1 and 2 in addition to ecological momentary assessment (EMA) procedures following Visit 2.
16265502|NCT04917068||Healthy Control|Participants without diagnosed BN or other current or past eating disorders who will complete all tasks during Visits 1 and 2 and will not complete EMA procedures following Visit 2.
16265503|NCT04917055|Active Comparator|Active Treatment|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
16265504|NCT04917055|Placebo Comparator|Placebo|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
16265505|NCT04917042|Experimental|tazemetostat|
16265506|NCT04917029|Active Comparator|Active:Group A|Group A: receive 40 ml bupivacaine 0.25% +5 ml placebo in FICB perineurally in generally anaesthetized patients with intravenous infusion of 0.5 µg/kg/h of Dexmedetomidine.
16265507|NCT04917029|Active Comparator|(Group B|Group B: receive FICB with dexmedetomidine 80µg diluted in 5 ml normal saline and 40 ml bupivacaine 0.25% added perineurally in generally anaesthetized patients without dexmedetomidine infusion.
16265508|NCT04917016||Study group|Women undergoing hysteroscopy for removal of RPOC
16265509|NCT04917003|Experimental|RIC group|"Patients who are allocated into RIC group will undergo the first EDAS surgery combined 3-month remote ischemic conditioning (RIC) treatment. The opposite operation will be performed at 3 months after the first operation.
~RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm.
~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used."
16265510|NCT04917003|Other|control group|"Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used. Under certain circumstances, depending on the territory at risk, the occipital artery was also used. The donor vessel with the strip of galea (the arterial bridge) was detached from the pericranium or the fascia below, and two burr holes are made beneath the proximal and distal ends of the arterial bridge. The burr holes, with an average size of 3.0 × 8.0 cm, were connected by mill to make an oval bone flap and the dura was exposed. The target artery was then sewn to the dura using 10-0 Prolene suture. The bone flap was closed after cutting out the entry and exit sites for the target artery."
16265513|NCT04916977||FD patients|
16265514|NCT04916964|Experimental|Test & Exercise home-based program (T&E)|Eight home-based physiotherapy sessions will occur in two months, once a week
16265515|NCT04916951|No Intervention|Amoxicillin - standard-of-care dose|Obtain amoxicillin plasma concentrations in patients already receiving amoxicillin
16265516|NCT04916951|No Intervention|Cephalexin - standard-of-care dose|Obtain cephalexin plasma concentrations in patients already receiving cephalexin
16265517|NCT04916951|Experimental|Amoxicillin - study dose|Obtain amoxicillin plasma concentrations after a study-administered dose of amoxicillin
16265518|NCT04916951|Experimental|Cephalexin - study dose|Obtain cephalexin plasma concentrations after a study-administered dose of cephalexin
16265519|NCT04916938|Experimental|Interactive Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
16265520|NCT04916938|Active Comparator|Treatment as usual|Mother child psychotherapeutic sessions without video feed back.
16265521|NCT04916925|Experimental|pcos resistant to cc plus vit d|100 patients who are PCOS and resist CC will receive Vitamin D 10000 IU orally plus 150mg clomid orally for 3 months number and size of growing follicles will be monitored
16265522|NCT04916912||CABG-1|A group of non-obese patients (BMI less than 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
16265523|NCT04916912||CABG-2|A group of obese patients (BMI over 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
16265524|NCT04916899||Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Pharmaceutical Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Administration way: oral
16265525|NCT04916886|Experimental|50L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
16265526|NCT04916886|Experimental|500L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
16293839|NCT04718844|Experimental|Xmg/kg - Thalassaemia multi dose|
16265528|NCT04916886|Experimental|800L Scale Lot 1 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
16265529|NCT04916886|Experimental|800L Scale Lot 2 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
16265530|NCT04916886|Experimental|800L Scale Lot 3 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
16265531|NCT04916886|Experimental|800L Scale Lot 1 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
16265532|NCT04916886|Experimental|800L Scale Lot 2 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
16265533|NCT04916886|Experimental|800L Scale Lot 3 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
16265534|NCT04916860|Experimental|CD7 CAR-T|
16265535|NCT04916847||children with controlled HIV|Children over 0 days and under 16 years old, with controlled HIV
16265536|NCT04916847||children with hematologic Malignancy treated by conventional chemotherapy|Children over 0 days and under 16 years old, with Hematologic Malignancy treated by conventional chemotherapy
16265537|NCT04916847||Children with inflammatory bowel disease treated by anti-TNF|Children over 0 days and under 16 years old, with inflammatory bowel disease treated by anti-TNF
16265538|NCT04916847||Children with idiopathic juvenile arthritis|Children over 0 days and under 16 years old, with idiopathic juvenile arthritis treated by methotrexate:
16265539|NCT04916847||Children treated by renal transplantation|Children over 0 days and under 16 years old, treated by renal transplantation from more than 3 months:
16265540|NCT04916847||Children attending consultation|Children over 0 days and under 16 years old, attending consultation for preoperative assessment or congenital abnormalities of the kidney and urinary
16265541|NCT04916821|Experimental|water extract of propolis|Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week
16265542|NCT04916821|Experimental|olive oil extract of propolis including perga|Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week
16265543|NCT04916821|No Intervention|control|control group (patients not given any investigational product)
16265544|NCT04916808||Ductal Carcinoma In Situ (DCIS)|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
16265547|NCT04916782||Observational group|
16265548|NCT04916769|Experimental|Bosutinib capsule contents mixed with applesauce|Bosutinib capsule contents mixed with applesauce to healthy participants
16265549|NCT04916769|Experimental|Bosutinib capsule contents mixed with yogurt|Bosutinib capsule contents mixed with yogurt to healthy participants
16265550|NCT04916769|Active Comparator|Bosutinib intact capsules|Bosutinib intact capsules to healthy participants
16265551|NCT04916756|Experimental|baricitinib 2mg per day|
16265552|NCT04916743|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
16265553|NCT04916743|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
16265554|NCT04916730|Placebo Comparator|Standard of Care (SOC)|Participants will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
16265555|NCT04916730|Experimental|TRE + SOC|Participants in this arm will receive standard of care nutritional behavioral counseling and will implement a daily, self-selected, 10-hour window within which they must consume all calories. They will also be required to log their caloric intake through the use of a smartphone app
16265556|NCT04916717|Other|Counseling|Quasi-experimental design. Face-to-face and telephone counseling were applied to individuals in the intervention group.
16265557|NCT04916691|Other|EPSB for rib fractures|EPSB for rib fractures
16265560|NCT04916652||Infant Cohort|"aged from 1.5-6 months. Includes predominantly breastfed infants and formula-fed infants.
~This is an observational trial so no intervention will be provided, with exception of study assessments, including MRI."
16265561|NCT04916652||Toddler Cohort|"aged from 9-15 months. Includes follow-up formula-fed / growing-up milk-fed infants & toddlers.
~This is an observational trial so no intervention will be provided, with exception of study assessments, including MRI."
16265562|NCT04916639|Experimental|Active group|Physiomer®, undiluted seawater nasal spray
16265563|NCT04916639|No Intervention|control group|
16265564|NCT04916626|Experimental|OPUS YOUNG|OPUS YOUNG is a two years out-patients specialized early intervention services for children and adolescents with a first episode psychosis. OPUS YOUNG is characterized by a multidisciplinary team, assertive outreach, tailored cognitive behavioral case management, and low caseload and insensitive psychoeducational family involvement
16265565|NCT04916626|Active Comparator|Treatment as Usual, TAU|Treatment as Usual will be carried out by outpatient clinic in Child and Adolescent Mental Health Services (CAMHS). Patients will be offered treatment following national Danish guidelines and local guidelines, provided by a multidisciplinary team, case-management (no defined upper-case load), family support. In general, office visits take place in outpatient clinics.
16265566|NCT04916613|Experimental|ADT + darolutamide|ADT + darolutamide 600 mg po bid
16265567|NCT04916613|Placebo Comparator|ADT + placebo|ADT + placebo po bid
16265570|NCT04916587|Active Comparator|Multifaceted Implementation Strategy|The core implementation strategy components are: 1) short video-trainings for clinic personnel (care team staff and providers) on the administration of caregiver-reported screening tools; 2) technical implementation support using an approach comprised of external academic consultants, and internal FQHC personnel to increase inner context capacity, 3) use of a validated clinical screening tool - Pediatric Symptoms Checklist (PSC-17), used in pediatric primary care settings to assess behavioral and social/emotional development. For this study, we will use the PSC tools that are tailored to children ages 0 to 5 years old with the Baby Pediatric Symptomatology Checklist (BPSC) for ages 0 to 18 months, and the Preschool Pediatric Symptom Checklist (PPSC) for ages 18 to 60 months. This screening tools is needed as the PEARLS only assesses ACEs exposure and not mental health symptomatology; and 4) use of a technology based tailored ACEs algorithm that incorporates multiple data sources.
16265571|NCT04916587|Other|ACEs Screening|"Adverse Childhood Experiences (ACEs) are potentially traumatic events occurring before age 18, such as maltreatment, harsh migration experiences or exposure to violence. ACEs screening are increasingly recommended to prevent and address physical and mental health conditions associated with ACEs. To promote ACEs screening uptake, the state of California issued the ACEs Aware 2020 policy; a fee-for-service health policy that provides a financial incentive to Medicaid-serving clinics to promote yearly ACEs pediatric screenings in primary care settings. This study will focus on screening children ages 0-5, in line with the partnering FQHC's ACEs screening priorities."
16265572|NCT04916574|Active Comparator|BioBlock® concentration 0.2 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
16265573|NCT04916574|Active Comparator|BioBlock® concentration 0.1 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
16265574|NCT04916548|Experimental|Intravenous Ketamine|Open-label ketamine infusion
16265575|NCT04916535|Experimental|diagnostic flow|all patients with MAD as assessed during routine transthoracic echocardiography will undergo to the following further exams: i) 12-lead electrocardiogram (ECG), ii) 24-hour ECG monitoring, iii) cardiac magnetic resonance imaging (CMR), iv) cardiological visit
16265576|NCT04916522|Experimental|Colchicine|Colchicine 0.5 mg once daily
16265577|NCT04916522|Placebo Comparator|Placebo|Placebo once daily
16265578|NCT04916509||Palbociclib plus an aromatase inhibitor|"Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor.
~Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.
~Aligned with Locally Approved Indication"
16265579|NCT04916509||palbociclib plus fulvestrant|"Adult metastatic breast cancer patients who initiated Palbociclib + fulvestrant. Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.
~Aligned with Locally Approved Indication"
16265580|NCT04916496|Experimental|ACT-LCP Group|An Acceptance and Commitment Therapy-based healthy lifestyle counselling programme (ACT-LCP) and routine psychiatric outpatient/rehabilitation services of the study hospital.
16265581|NCT04916496|Placebo Comparator|Control Group|A healthy lifestyle talk and routine psychiatric outpatient/rehabilitation services of the study hospital.
16265582|NCT04916483|Experimental|Exploring the effectiveness of GCST in people with schizophrenia.|The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
16265583|NCT04916483|No Intervention|Control group|The control group maintains the usual care.
16265586|NCT04916457||group ND|control group without DM non-intervention
16265587|NCT04916457||group VD|"very low-risk group: diabetic patient with no loss of protective sensation(LOPS) and no peripheral artery disease(PAD).
~non-intervention"
16265588|NCT04916457||group LD|low-risk group: diabetic patient with LOPS or PAD non-intervention
16265589|NCT04916457||group MD|moderate-risk group: diabetic patient with LOPS + PAD non-intervention
16265590|NCT04916457||group HD|"high-risk group: diabetic patient with LOPS or PAD, and one or more of the following:
~history of a foot ulcer
~a lower-extremity amputation (minor or major)
~end-stage renal disease
~non-intervention"
16265591|NCT04916444|Active Comparator|Active rTMS|Active rTMS will use a figure of eight TMS coil that will deliver real neurostimulation pulses to the patients.
16265592|NCT04916444|Sham Comparator|Sham rTMS|Sham rTMS will use a sham figure of eight TMS coil that sounds and looks like a real rTMS coil, except no neurostimulation is being delivered to the patient.
16265593|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 1|Participants will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.
16265594|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 1|Participants will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.
16265595|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 2|Participants will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.
16265596|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 2|Participants will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.
16265597|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 3|Participants will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.
16265598|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 3|Participants will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.
16265599|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 4|Participants will receive 1 dose of Dose Level 4 of mRNA-6231 by subcutaneous injection on Day 1.
16265600|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 4|Participants will receive 1 dose of Dose Level 4 of mRNA-6231 by subcutaneous injection on Day 1.
16265601|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 5|Participants will receive 1 dose of Dose Level 5 of mRNA-6231 by subcutaneous injection on Day 1.
16265602|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 5|Participants will receive 1 dose of Dose Level 5 of mRNA-6231 by subcutaneous injection on Day 1.
16265603|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 6|Participants will receive 1 dose of Dose Level 6 of mRNA-6231 by subcutaneous injection on Day 1.
16265604|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 6|Participants will receive 1 dose of Dose Level 6 of mRNA-6231 by subcutaneous injection on Day 1.
16265605|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 7|Participants will receive 1 dose of Dose Level 7 of mRNA-6231 by subcutaneous injection on Day 1.
16265606|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 7|Participants will receive 1 dose of Dose Level 7 of mRNA-6231 by subcutaneous injection on Day 1.
16265607|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 8|Participants will receive 1 dose of Dose Level 8 of mRNA-6231 by subcutaneous injection on Day 1.
16265608|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 8|Participants will receive 1 dose of Dose Level 8 of mRNA-6231 by subcutaneous injection on Day 1.
16265609|NCT04916418|Placebo Comparator|G1, Placebo|Intravenous saline (NaCl 0,9%) will be administered. G1 group will be administered an initial dose of placebo (20ml) per catheter bilaterally (total volume 40ml) after TTP has been placed. This is followed by 20ml doses of placebo per catheter every 8 hours until 72 hours from the first dose has passed.
16265610|NCT04916418|Active Comparator|G2, Ropivacaine|Ropivacaine 0.5%. G2 group will be administered an initial dose of ropivacaine (20 ml) per catheter bilaterally (total volume 40ml) after the TTP has been placed. This is followed by 20 ml doses of ropivacain per catheter every 8 hours until 72 hours from the first dose has passed.
16265611|NCT04916392||liposomal bupivacaine|Nerve block will be preformed using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline.
16265612|NCT04916392||standard bupivacaine|Nerve block will be preformed using 10ml of 0.5% standard bupivacaine.
16265613|NCT04916379|Experimental|Momordica charantia|Two 500 mg capsules of Momordica charantia twice daily before breakfast and dinner for 12 weeks
16265614|NCT04916379|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 12 weeks
16265615|NCT04916366|Experimental|Kinesio taping|In this arm, patients will be treated with blue Kinesio taping in a muscle relaxation position during 4 days.
16265616|NCT04916366|Placebo Comparator|Placebo|In this arm, patients will be treated with conventional bandage in a muscle relaxation position during 4 days.
16265617|NCT04916366|No Intervention|Control|In this arm, patients will be not treated but the outcomes will be measure after 4 days.
16265618|NCT04916353|Experimental|20% hypertonic dextrose water injection group|echo guide 20% dextrose water 3ml was injection in lesion site
16265619|NCT04916353|Active Comparator|Steroid injection group|Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group
16265620|NCT04916340|Experimental|Muscular Strength|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular strength
16265621|NCT04916340|Experimental|Muscular fitness|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular fitness
16265622|NCT04916327|Experimental|Antioxidant then Placebo|Subjects will ingest an antioxidant cocktail prior to their second visit and a placebo prior to third second visit
16265623|NCT04916327|Experimental|Placebo then Antioxidant|Subjects will ingest a placebo prior to their second visit and an antioxidant cocktail prior to their third visit.
16265624|NCT04916314|Experimental|Low Carbohydrate Diet|". The intervention, provided by Second Nature, involves diet, activity and behaviour change components. It comprises a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application. Each participant will also receive a hard copy of an instructional handbook and a recipe book."
16265625|NCT04916314|No Intervention|Standard NHS type 2 diabetes care|Participants randomised to the control group will receive no additional intervention, and will continue to receive their usual NHS diabetes care from their general practice.
16265626|NCT04916275||Staff working in a nursing home in Occitanie|
16265627|NCT04916262||TSH < 30uIU/mL group|Clinical information was collected from patients with TSH < 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
16265628|NCT04916262||TSH ≥ 30uIU/mL group|Clinical information was collected from patients with TSH ≥ 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
16265629|NCT04916249|Experimental|Tibetree pain relieving plaster|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
16265630|NCT04916249|Placebo Comparator|Placebo plaster groups|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
16265631|NCT04916236|Experimental|Phase I - Dose-escalation|This is a single-center open-label phase I dose-finding study (3+3 classical design) evaluating the RP2D of RMC-4630 in combination with LY3214996. Based on the safety, tolerability, and PK and PD data from the dose-finding stage of the study, a RP2D will be defined for the expansion phase.
16265632|NCT04916236|Experimental|Phase Ib|The phase Ib expansion cohort study is intended to further characterize the safety, tolerability and PK/PD of the selected dose of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC. Furthermore, it will explore the clinical activity of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC.
16265633|NCT04916223|Experimental|3 x 10-minute massage|Subject receives a 10-minute massage daily for three consecutive days
16265634|NCT04916223|Experimental|3 x 20-minute massage|Subject receives a 20-minute massage daily for three consecutive days
16265635|NCT04916223|Active Comparator|Single 20-minute massage|Subject receives one 20-minute massage
16265677|NCT04915924|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
16265636|NCT04916197|Experimental|Dexmedetomidine prolonged group|Dexmedetomidine 0.1~1.0 μg/kg/h for 24h after patients finished mechanical thrombectomy and returned to ICU. Maintain Ramsay score 2-3.
16265637|NCT04916197|Placebo Comparator|placebo group|Placebo（Equal dose of saline）24h after patients finished mechanical thrombectomy and returned to ICU. If Ramsay Sedation score was 1, midazolam was given 0.02 ~ 0.1mg/kg. If the dose of midazolam was more than 0.2mg/kg within 1 hour after operation, the Ramsay Sedation score was still 1, propofol was given to maintain sedation.
16265638|NCT04916184|Active Comparator|aerobic exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
16265639|NCT04916184|Active Comparator|Combined exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
16265640|NCT04916171||Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome|"The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by palpation of the endometriotic nodule on pelvic examination or surgical confirmation.
~The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical confirmation."
16265641|NCT04916171||Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis|For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.
16265642|NCT04916145|No Intervention|No any treatment|Participants randomly assigned to this group will maintain a routine life without any treatments (no use of SAT-008).
16265643|NCT04916145|Experimental|Use of SAT-008|Participants randomly assigned to this group will be treated by SAT-008 during the study.
16265644|NCT04916132||Peolpe with T2DM and albuminuria|Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.
16265645|NCT04916119|Experimental|IBI323|Phase Ia enrolls in patients with advanced malignancies. Phase Ib cohort A enrolls in NSCLC(IO-refractory), cohort B NSCLC(IO-naive), cohort C NSCLC(PD-L1 TPS≥1%), cohort D ES-SCLC or neuroendocrine tumors, cohort E MPM, cohort F UC, cohort G nccRCC, cohort H HCC, cohort I NPC, cohort J CC or HNSCC, cohort K GC or GEJC with HER2 negative, cohort L TNBC
16265646|NCT04916106|Experimental|One parameter TEA group for 4weeks|Choose several acupoints,give 25Hz dilatational wave stimulation for 4 weeks.
16265647|NCT04916106|Experimental|Another parameter TEA group for 4weeks|Choose several acupoints,give 100 Hz dilatational wave stimulation for 4weeks.
16265648|NCT04916106|Experimental|no TEA group 2 weeks, and the 2 parameters TEA for the next 2 weeks.|Choose several acupoints, tape over the electrode but don't give electroacupuncture stimulation in the first 2 weeks, give 25Hz and 100Hz dilatational wave electroacupuncture stimulation in the next 2 weeks.
16265649|NCT04916093|Experimental|Sitagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.
16265650|NCT04916093|Experimental|Vildagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received vildagliptin 50 mg therapy twice daily before breakfast and supper.
16265651|NCT04916093|Active Comparator|Metformin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received control 1 gm twice daily
16265652|NCT04916080|Experimental|after treatment|chronic kidney disease patients after receiving NAC for 3 months
16265653|NCT04916067|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
16265654|NCT04916041||Vivity|Patients who have undergone bilateral implantation of Vivity intraocular lens
16265655|NCT04916041||Eyhance|Patients who have received bilateral implantation of an Eyhance intraocular lens
16265656|NCT04916041||EMV|Patients who have undergone bilateral implantation of Vivity intraocular lens
16265657|NCT04916041||Panoptix|Patients who have undergone bilateral implantation of Panoptix intraocular lens
16265658|NCT04916041||Rayner Trifocal|Patients who have undergone bilateral implantation of Rayner trifocal intraocular lens
16265659|NCT04916015||children (0-14 years)|
16265660|NCT04916015||AYAs (15-25 years)|
16265667|NCT04915989|Experimental|GX-19N|Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29. (Optional administration on day 57)
16265668|NCT04915963|Experimental|vitamin D group|170 patients receiving a single dose of 400,000 IU of VD3 (2 vials of 200,000 IU VD3; B.O.N., BOUCHARA RECORDATI) orally or through a nasogastric tube
16265669|NCT04915963|Sham Comparator|Placebo group|170 patients receiving distilled water (2 vials of 1 ml distilled water) orally or through a nasogastric tube
16265679|NCT04915898|Active Comparator|Oral Care Hygiene Intervention Group|Providing oral care kits designed to facilitate adherence to brushing teeth after meals and before sleep. Providing continuous education and feedback on performance to team members on the interventional units. Encouraging patients to brush their teeth and use the kits or own materials if desired.
16265680|NCT04915898|No Intervention|Control group - standard of care oral care on units|These units will perform their 'usual' or standard of care for oral hygiene practices without use of the oral care kits, no encouragement to perform outside of usual care
16265681|NCT04915885|Other|Control arm|routine contraceptive counseling and care and a range of family planning methods that are routinely available at field level
16265682|NCT04915885|Experimental|Intervention package|contraceptive counseling package but still with a range of family planning methods that are routinely available at field level
16265683|NCT04915885|Experimental|Intervention package & expanded methods|contraceptive counseling package but with an expanded range of family planning methods that are recommended by national guidance
16265684|NCT04915872||Participant|Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy
16265685|NCT04915859|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
16265686|NCT04915859|Placebo Comparator|No Intervention|"Participants will participate in passive cooling where they sit in a chair during rest"
16265687|NCT04915846|Experimental|Drug: ApoTamox 10mg|Drug: Tamoxifen (tamoxifen citrate); ApoTamox 10 mg tablets orally twice daily for 6 months
16265688|NCT04915846|Placebo Comparator|Placebo|Placebo (no active ingredients) tablets orally twice daily for 6 months
16265689|NCT04915833|Experimental|Patients for CRC screening and diagnostic colonoscopy|Consecutive patients >45 years of age submitted for diagnostic colonoscopy
16265690|NCT04915820|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
16265691|NCT04915820|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
16265692|NCT04915807||Prospective population|The target group for the purpose of prospectively collecting the clinical data (RWD) of patients using ramucirumab/paclitaxel as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
16265693|NCT04915807||Historical retrospective population|The target group for the purpose of retrospectively collecting the clinical data (RWD) of patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018, when health insurance coverage for the ramucirumab/paclitaxel combination therapy started in South Korea.
16265694|NCT04915794|Experimental|Simulation based education|Simulation is a technique that creates a situation or environment that allows people to experience the representation of a real event, practice, learn, evaluate, test, or gain an understanding of systems or human actions
16265695|NCT04915794|No Intervention|Traditional education|Necessary procedures explained theoretically
16265696|NCT04915781||Tobacco users|Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers. For FinSote 2018 and 2020, we will also compare never users of (1) smokeless tobacco (snus), (2) electronic cigarettes with and without nicotine or (3) nicotine replacement therapy products with respective former, occasional and daily users.
16265697|NCT04915768|Experimental|Treatment|CH505 TF chTrimer plus adjuvants administered at months 0, 2, 4, 8 and 12.
16265700|NCT04915742|Experimental|exercises and thetahealing|
16265701|NCT04915742|Active Comparator|exercises|
16265702|NCT04915729|Experimental|tenecteplase|Treatment Group
16265703|NCT04915729|Active Comparator|alteplase|Active control group
16265704|NCT04915716||healthy pregnant woman|healthy pregnant woman
16265705|NCT04915716||pregnant women with GDM|pregnant women with gestational diabetes mellitus
16265706|NCT04915703|Experimental|Intervention|flushing of internal external PTBD catheter 3 times a day
16265707|NCT04915703|No Intervention|Standard of Care|no flushing of PTBD catheter
16265708|NCT04915677|Active Comparator|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at edentulous area with subepithelial connective tissue graft harvested from the patient's palate
16265709|NCT04915677|Experimental|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at edentulous area with xenogenic volume stable collagen matrix
16265710|NCT04915651|Experimental|Gallbladder Cryoablation|High-risk patients who undergo gallbladder cryoablation
16265711|NCT04915638|Experimental|Intervention group|Schoolchildren received enriched cookies containing a multiple micronutrients formula. Enriched cookies (20g) with a daily dose of 0.33g of organic mix formula were given in the morning during 4-weeks. The formulation is an industrial secret of UNAM.
16265712|NCT04915625||Death group|Retrospective observational studies
16265713|NCT04915625||Survival group|Retrospective observational studies
16265714|NCT04915612|Experimental|Treatment (CPX-351, GO)|"INDUCTION 1 (28 days): Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.
~INDUCTION 2: Patients who do not attain a defined clinical response after cycle Induction 1 receive CPX-351 IV on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Beginning 4 weeks after last induction, patients receive CPX-351 IV over 90 minutes on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity."
16265740|NCT04915417|Experimental|Borderline Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|20 Borderline Resectable PDAC patients will receive a DCE-CT scan prior to neoadjuvant chemotherapy, a PET/MRI and DCE-CT after neoadjuvant chemotherapy and before SABR, DCE-CT at 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
16265741|NCT04915404|Experimental|pK Assessment of Berubicin and its active metabolite|The first 18 patients will undergo a pK assessment of Berubicin and it's active metabolite Berubicinol during the dosing days of the first two cycles. After 18 patients are done n intern analysis will new performed.
16265715|NCT04915599|Experimental|Intervention group|Patients are assigned to using the Cooral® MCD after radiotherapy for 60 min. along with general oral care (GOC). The MCD will be placed into the subjects' mouth and remain intraorally for 60 minutes. After each fraction, i.e. session of RT, the subjects insert the MCD inside their mouth and can start the Cooral ® thermostat system themselves when they feel comfortable. The stopwatch will be started by the patient as soon as thermostat is running. The patient is asked to write down the starting and the stopping time of the 60-minute procedure. Thereafter the subject will receive a questionnaire to record the tolerance for the device. Patients will be also informed about standard of care (SOC) that should be regularly performed.
16265716|NCT04915586|Experimental|Treatment Arm|"Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
~Intervention Drug: Combination Alteplase and pulmozyme (DNase)"
16265717|NCT04915573||patients with Cirrhosis|Patient with clinical evidence of liver disease, portal hypertension, ultrasound or computed tomography results, laboratory data will be used to confirm liver disease
16265718|NCT04915560|Experimental|ORTEC Employee|ORTEC professional employees performing an industrial cleaning task.
16265719|NCT04915547|Experimental|Group-Based Exercise|The group-based exercise (GBE) programme will be delivered by a physiotherapist. The GBE comprises three sessions per week of group-based exercise in a local community centre, for 8 weeks.
16265720|NCT04915547|No Intervention|Control Group|Participants randomly allocated to the control group will remain on a waiting list. In addition, weekly contact will be made to ensure that they do not start treatment during the study protocol. After the end of the study, participants randomly allocated to the control group will receive the same intervention as the Group-Based Exercise.
16265721|NCT04915534|Other|Women - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
16265722|NCT04915534|Other|Men - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
16265723|NCT04915534|Other|Women - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
16265724|NCT04915534|Other|Men - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
16265725|NCT04915521|Active Comparator|erector spinae plane block group|ESPB group received ultrasound-guided bupivacaine and lidocaine injection at T9 vertebral level before anesthesia induction.
16265726|NCT04915521|No Intervention|non block control group|Control group received 5 ml 0.5% bupivacaine injection to each trocar site (total of 25 ml) at the beginning of the operation.
16265727|NCT04915508|Experimental|Treatment (SBRT, hormone therapy)|Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.
16265728|NCT04915495|Experimental|Singe-arm Study|Experimental device being evaluated for sensitivity and specificity.
16265729|NCT04915482|Experimental|Combined use of eltrombopag with low-dose rituximab|The starting dose of eltrombopag is 75mg daily. Before or within 4 weeks after the treatment, rituximab 375mg/m2 will be used once. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance. If the continuous application of 75 mg once a day of eltrombopag for 6 weeks is still ineffective, discontinue the use of eltrombopag.
16265730|NCT04915482|Active Comparator|The best available therapy other than combined use of eltrombopag with rituximab|The best available therapy except for combined use of eltrombopag with rituximab includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists other than eltrombopag, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
16265731|NCT04915469|No Intervention|Pre-standardization group|Pre intervention- patient level data are abstracted retrospectively from the charts of patients with VL >1000 copies/ml on demographic characteristics and clinical outcomes and facility level data from summary forms for up to 24 months prior to the implementation of the standardized EAC package.
16265732|NCT04915469|Other|Post-standardization group|This group of participants will receive the standardized enhanced adherence package. After implementation of the standardized EAC package, data will be prospectively collected from participants with high viral load (>1000 copies).
16265733|NCT04915456|Experimental|Systemic steroid (Prednisolone)|Prednisolone 50mg (tapered down until postoperative day (POD) 14, then 5mg for 14 days), tablets
16265734|NCT04915456|Placebo Comparator|Placebo|Lactose monohydrate, tablets
16265735|NCT04915443|Experimental|Periotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using H.ZEPF 26.182.13 & 26.182.11 periotome instrument.
16265736|NCT04915443|Experimental|Piezotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using SOLO LED PIEZOTOME Kit with ESSENTIAL tips from SATELEC ACTEON.
16265737|NCT04915430|Active Comparator|Supervised training regimen|"This training regimen consisted of 3 phases: the 1st focused on restoring motion, the 2nd on strengthening of the rotator cuff muscles, and the 3rd on strengthening of the scapular muscles. Stretching completed every training session.
~Motion training consisted of 6 exercises.
~Postural training: shoulder shrugs and shoulder retraction exercises.
~Glenohumeral training: pendulum exercises, and active assisted flexion, abduction and external rotation.
~Strengthening of the rotator cuff: side lying external rotation, internal rotation and scaption.
~Strengthening of the scapular muscles: press-up, push-up with a plus, serratus anterior supine punch, standing rowing (low row), and seated rowing (high row).
~Training sessions ended with 4 stretches: anterior shoulder stretch, posterior shoulder stretch, inferior capsular stretch, sleepers stretch.
~Exercises were performed 3 times a week, with progression after the 1st week, and thereafter every 2nd week."
16265738|NCT04915430|Active Comparator|Home training regimen|"The program consisted of the following:
~1 motion exercise: upper trapezius relaxation
~3 strengthening exercises: serratus anterior strengthening exercise, humeral external rotation with the arm at the side of the body, and humeral external rotation with a rubber band and the arm at 90 degrees abduction.
~2 stretching exercises: posterior shoulder and pectoralis minor stretching, Exercises were performed daily, with weekly progression."
16265739|NCT04915417|Experimental|Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|10 Resectable PDAC patients will receive a hybrid PET/MRI before SABR and DCE-CT before SABR, 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
16266094|NCT04913090|Placebo Comparator|Part B-placebo|multiple ascending dose (MAD) phase
16265742|NCT04915391||Group of controls|Control group of 40 patients with ≥1 bare metal stent which in a posterior catheterization performed by clinical follow-up had no restenosis
16265743|NCT04915391||Group of cases|Group of cases with 20 patients with ≥1 bare metal stent and 20 patients with ≥1 drug eluting stent which had restenosis in a posterior catheterization performed by clinical follow-up.
16265744|NCT04915365|Experimental|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
16265745|NCT04915365|Placebo Comparator|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses
~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
16265747|NCT04915339|Experimental|Group 1: physical activity then cognitive training|Using an online-computerized application, physical activities will be prescribed for one month. After a 15 days break, cognitive training activities will be prescribed the same way. A feedback by the patient will be asked fallowing each activity to control the observance.
16265748|NCT04915339|Experimental|Group 2: Cognitive training then physical activity|Contrary to the first group, the second one starts with cognitive training intervention then engages in physical activity in same way as the first group. A feedback by the patient will also be asked fallowing each activity to control the observance
16265749|NCT04915339|Experimental|Group 3 : resonance frequency breathing then combined physical activity and cognitive training|The third group takes part in a 1 month breathing exercise program. After a 15 days break (as the groups 1 and 2), a combined physical activity and cognitive training program is administrated for 1 month. As the others arms, a feedback by the patient will be asked fallowing each activity to control the observance
16265750|NCT04915326||Retrospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The first step will be a retrospective and exploratory analysis of FFPE slides retrieved from the pathology archives testing a panel of molecular marker exploring the immune reaction to the cancer (i.e. antigen presenting cells and T lymphocytes activation).
16265751|NCT04915326||Prospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The second step will be a prospective and validating analysis. Tissue samples will be obtained from normal rectal mucosa adjacent to the cancer at the time of the trans anal or trans abdominal resection. In patients with early rectal cancer, the combination of immunological markers on healthy rectal mucosa adjacent to the cancer obtained in the part 1a of the study will be validated to identify the patients that will have not any nodal metastasis.
16265752|NCT04915313|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 4 weeks.
16265753|NCT04915313|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 4 weeks..
16265754|NCT04915300|Active Comparator|Apabetalone|100mg BID, 24-week (168±3 days) Treatment Period.
16265755|NCT04915300|Placebo Comparator|Placebo|24-week (168±3 days) period.
16265756|NCT04915287|Experimental|Avatrombopag|Oral administration of Avatrombopag Maleate Tablets to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whose mean baseline platelet count is less than 50 × 10^9/L. RhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc., are prohibited during the trial.
16265757|NCT04915287|Experimental|Conventional treatment|Conventional treatment (platelet transfusion if needed or rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.) to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whoes mean baseline platelet count is less than 50 × 10^9/L.
16265758|NCT04915274|Experimental|Adult cancer patients|Patients will be provided with the QuestOnco application for monitoring
16265759|NCT04915261|Active Comparator|Strict Arm|"The strict arm group will be given the following restrictions. These restrictions are the current institutional protocol at the study site and falls within common practice pattern across Canada:
~No arm or shoulder movement x 24 hours
~No movement of affected arm overhead x 8 weeks
~No lifting anything heavier than 5 lbs (2.5kg) and avoid any kind of sports or other vigorous activities including golf, tennis, swimming or sweeping x 8 weeks
~Avoid any kind of shovelling x 8 weeks"
16265760|NCT04915261|Active Comparator|Lenient Arm|"The lenient arm restriction group will be given the following restrictions. The justification for the selected lenient restriction is based on the current recommendations at a Canadian center as identified by the national survey:
~No shoveling 7 days,
~No golfing/swimming/tennis 14 days
~No other restrictions (overhead activity and weight lifting no limitation)"
16265761|NCT04915248|Experimental|All patients registered in the DALYA trial|"Treatment consists of an induction phase (every 21 days) planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).
~Patients achieving at least a SD after induction will be addressed to the maintenance phase (every 28 days), planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator decision."
16265762|NCT04915222|Experimental|Natural apophyseal glides|This group receives natural apophyseal glides along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
16265763|NCT04915222|Active Comparator|Cervical manual traction|This group receives cervical manual traction along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
16265764|NCT04915209|Other|Narrative interviews|Narratives are stories that are based on the unfolding of events or actions from the perspective of a patient's life experience. Patients and care partners tell their stories of illness and how they live with illness over time . The researcher could focus on the care priorities, the support needed, the information needed and the challenges faced. The narrative interview will be used to get an overview of the patient's trajectory.
16265984|NCT04913714|Active Comparator|Intervention|A district where the radio intervention will be broadcast.
16265765|NCT04915196||Ferrous Sulphate|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Ferrous Sulphate for iron replacement
16265766|NCT04915196||Liposomally-bound Iron|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Liposomally-bound Iron for iron replacement
16265769|NCT04915170|Experimental|High intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
16265770|NCT04915170|Experimental|Low intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
16265771|NCT04915157|Other|Group A: High Density stimulation - No Stimulation|Patients in this group will receive high density stimulation (parasthesia free form of stimulation) during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive no stimulation during the final 6 months of the study period.
16265772|NCT04915157|Other|Group B: No Stimulation - High Density Stimulation|Patients in this group will receive no stimulation during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive high density stimulation (parasthesia free form of stimulation) during the final 6 months of the study period.
16265773|NCT04915144|Active Comparator|Standard PRRT|For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.
16265774|NCT04915144|Experimental|Personalized PRRT|For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.
16265775|NCT04915118||Patients with HFrEF|Patients with HFrEF (Heart failure with reduced ejection fraction) who had a previous decompensation event.
16265776|NCT04915105|Experimental|Prescreen on psoriasis and psoriatic arthritis treatment|Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients.
16265777|NCT04915092|Experimental|Intervention group|The app is explained and installed during the recruitment to the family in the intervention group. Some families in this group will be selected to take part to the qualitative research.
16265778|NCT04915092|No Intervention|Control group|Every months during the first year of study a newsletter is sent only to the members of the control group.
16265779|NCT04915079|Experimental|PRISM|Patients in this arm will be recipients of the PRISM intervention
16265780|NCT04915079|No Intervention|Usual Care|Patients in this arm will not receive the PRISM intervention, but will continue to receive usual care the discretion of their treating clinicians.
16265781|NCT04915053|Experimental|ABG Black Garlic Extract|Daily intake of a 550 mg tablet, containing 250 mg of Black Garlic Extract and 300 mg of excipients.
16265782|NCT04915053|Placebo Comparator|Placebo|Daily intake of a 550 mg tablet, containing 250 mg of microcrystalline cellulose and 300 mg of excipients
16265783|NCT04915040|Experimental|Behavioral Activation for Depression|
16265784|NCT04915027|Experimental|Intervention i.e. with Rehabkompassen®|The participants will use the digital graphic Rehabkompassen® at the out-patient follow-up.
16265785|NCT04915027|Active Comparator|Control exposure i.e. without Rehabkompassen®|"The participants will use Post-Stroke Checklist at the out-patient follow-up as recommended by Socialstyrelsen."
16265786|NCT04915014|Experimental|laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)|One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)
16265787|NCT04915014|Sham Comparator|laparoscopic Roux-en-Y gastric bypass (RYGB)|One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)
16265788|NCT04914975|Experimental|NMES Group|Participants will receive neuromuscular electrical stimulation of the abdominal wall before defaecation for 30 minutes over the course of 16 weeks.
16265789|NCT04914962|Active Comparator|monolithic glazedcrowns|glazed Celtra due crowns
16265790|NCT04914962|Experimental|monolithic polished crowns|polished Celtra due crowns
16265791|NCT04914949||ESRD Patients|ESRD patients will wear the Alio SmartPatch on top of their newly created vascular access
16265792|NCT04914936|Experimental|Part 1: ACP-196 and Calcium carbonate|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and a single oral dose of calcium carbonate 1 g tablet coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 2.
16265793|NCT04914936|Experimental|Part 2: ACP-196 and Omeprazole|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of omeprazole 40 mg capsules once daily (QD) for 5 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 5 of Period 2.
16265794|NCT04914936|Experimental|Part 3: ACP-196 and Rifampin|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of rifampin 600 mg capsule QD for 9 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 and Day 9 of Period 2.
16265795|NCT04914923|Experimental|Cognitive Behaviour Therapy|This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.
16265796|NCT04914923|Experimental|Mindfulness-based Cognitive Therapy|This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.
16265797|NCT04914923|No Intervention|Waitlist|This study arm will not receive an intervention for 12 weeks.
16265798|NCT04914910|Experimental|780G-780G|Participants will use MiniMed 780G system for 14 weeks + 14 weeks
16265799|NCT04914910|Placebo Comparator|Usual Care - 780G|Participants will continue with their usual insulin pump for 14 weeks. After completion of the first 14-week periode, they switch to 780G for another 14 weeks.
16265985|NCT04913714|No Intervention|Control|A district where the radio intervention will not be broadcast.
16265806|NCT04914884||intraocular inflammation group|
16265807|NCT04914884||Cataract patients group|
16265808|NCT04914871|Experimental|The experimental protocol UN Lifeguard Kids in the Tunja version|Group to which the experimental protocol will be offered.
16265809|NCT04914871|Placebo Comparator|Educational session, accident prevention and wound management.|The control group will be offered the Educational session.
16265810|NCT04914858|Experimental|Education group|Education
16265811|NCT04914858|No Intervention|Control group|No Intervention
16265812|NCT04914845|Active Comparator|De-escalation Cohort; 20mg|For the purposes of dose escalation decisions, a standard 3+3 dose escalation design will be used.The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg. If the MTD is exceeded at cohort 1, de-escalation to cohort 0 (20 mg) will occur. If the MTD is not exceeded in cohort 1, dose escalation will continue based on a standard 3+3 design at the dose levels.
16265813|NCT04914845|Active Comparator|Cohort 1; 30 mg|The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg.
16265814|NCT04914845|Active Comparator|Cohort 2; 40mg|Dose escalation to 40 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
16265815|NCT04914845|Active Comparator|Cohort 3; 60mg|Dose escalation to 60 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
16265816|NCT04914845|Active Comparator|Cohort 4; 80mg|Dose escalation to 80 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
16265817|NCT04914845|Active Comparator|Cohort 5; 100mg|Dose escalation to 100 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
16265818|NCT04914832|Experimental|All individuals who register on the National Vaccination Registry|This will be open-label, single-arm implementation study in Eswatini. All individuals who register on the National Vaccination Registry will be eligible for enrolment. Participants will receive appointments for vaccination using the registry.
16265819|NCT04914819|Active Comparator|Online Behavioral Weight Loss|Participants will attend a virtual introduction to weight loss session and be enrolled in a 16-week online behavioral weight loss program. Participants will complete a virtual weigh-in at the start and end of the study.
16265820|NCT04914819|Active Comparator|Usual Care|Participants will complete a virtual weigh-in at the start and end of the study. No additional intervention will be provided.
16265821|NCT04914806||Cases|Infants treated with iNO (from birth to 1-3 weeks of life) or sequential treatment with iNO and sildenafil (for 1 to 3 months).
16265822|NCT04914806||Controls|Infants matched to cases (gestational/postnatal age, gender, disease state) and no iNO treatment.
16265823|NCT04914793|No Intervention|Reference phase|"At the start (month 0), a point prevalence surveys (PPS) on hospital antimicrobial use are performed (more details on conduct of PPS are given in following section) to collect baseline data before introducing paper-based guidelines.
~All medical doctors of each participating hospital are asked to complete an AMS knowledge survey and pre-prescribing guidelines survey after PPS is conducted. Then, paper-based prescribing guidelines in both adult and paediatric versions (one adult guideline and one paediatric guideline) are distributed to all doctors at participating hospitals, followed by guideline introductory session of the guidelines. After introduction of the paper-based guidelines, all six hospitals are formally included in the reference period."
16265824|NCT04914793|Experimental|Intervention phase|"Antimicrobial Prescribing guidelines mobile phone application (MicroGuide) Both paediatric and adult antimicrobial prescribing guidelines are transferred to MicroGuide; which is a medical guideline application. MicroGuide is an offline application, free-of-charge for the individual users. The app can monitor the number of users and which guidelines are being accessed. The app is installed to the personal smart phones of local physicians by the PI. Both mobile app and paper guidelines will be available in Lao languages.
~Antimicrobial stewardship (AMS) training AMS training sessions are given to prescribers in participating hospitals when they firstly enter to the intervention phase. This session is given alongside an introduction of mobile phone app prescribing guideline. The training focus on good practices of antimicrobial prescription. Providing training after introducing treatment guidelines is not routine practice in many hospitals in Laos."
16265825|NCT04914780|Experimental|Intervention group|4 weeks training with mobile application
16265826|NCT04914780|No Intervention|Control group|No intervention will be made for 4 weeks
16265827|NCT04914767|Experimental|Nigella|"The patient will receive a study treatment containing 100 capsules:
~One capsule every two hours for the first three days.
~From the fourth day, the patient will take one capsule, three times a day for 12 days."
16265828|NCT04914767|Placebo Comparator|Placebo Group|"The patient will also receive a study treatment containing 100 capsules:
~One capsule every two hours for the first three days.
~From the fourth day, the patient will take one capsule, three times a day for 12 days."
16266089|NCT04913116||SARS-CoV-2 negatives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
16265829|NCT04914754||Long COVID with severe exercise impairment|"Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue or exercise intolerance.
~An abnormal response on 6 minute walk test including any one of:
~Peripheral oxygen desaturation
~< 85% predicted walk distance
~Lactate rise> 1.0 from baseline
~Borg score > 5 for breathlessness or fatigue at end of test"
16265830|NCT04914754||Long COVID with preserved exercise capacity|Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue.
16265831|NCT04914741|Experimental|Glofitamab plus R-CHOP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by R-CHOP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
16265832|NCT04914741|Experimental|Glofitamab plus polatuzumab vedotin-RCHP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
16265833|NCT04914728|Experimental|mini-invasive lumbar arthrodesis|"The patient will be admitted to the hospital on the morning of the surgery, operated on the same morning by either the posterior or anterior mini-invasive approach.
~The choice of the approach depends on the specificity of the pathology leading to the arthrodesis procedure and the surgeon's experience. It is the surgeon who decides this in agreement with the patient. The patient will be discharged in the evening after agreement of the anaesthetist and the surgeon."
16265834|NCT04914715|Experimental|Non-invasive High Frequency Oscillatory Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirefment more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.
~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option."
16265835|NCT04914715|Active Comparator|Conventional Invasive Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirement more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.
~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to invasive ventilation through endotracheal tube, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40."
16265836|NCT04914702||Everion® only|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
16265837|NCT04914702||CORE® only|A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
16265838|NCT04914702||Everion® first, CORE® second|"Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
~Then a CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene."
16265839|NCT04914702||CORE® first, Everion® second|"A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
~Then two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene."
16265840|NCT04914702||Everion® and CORE® simultaneously|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, and one CORE® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
16265841|NCT04914689|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
16265842|NCT04914689|Experimental|Visual external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
16265843|NCT04914689|Experimental|Auditory external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving auditory feedback of their movement patterns.
16265844|NCT04914676|Experimental|Prospective HiDAC Treatment (HiDAC 123)|Subject on this arm will be treated with HiDAC prospectively.
16265845|NCT04914676|Other|Historical HiDAC Treatment (HiDAC 135)|Subjects on this arm will be historical controls who have previously received treatment with HiDAC.
16265846|NCT04914663|Experimental|All-extremity exercise|
16265847|NCT04914663|Active Comparator|Treadmill exercise|
16265848|NCT04914663|No Intervention|Usual Care|
16265849|NCT04914650|Experimental|Telerehabilitation intervention|
16265850|NCT04914637|Active Comparator|interlaminar epidural steroid injection plus dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. Also, dry needling will be applied to the active trigger points for the patients in this group.
~Interlaminar epidural steroid injection will be applied at week 0, while dry needling will be applied in 3 sessions per week (week 0, week 1, week 2). The first session of the dry needling will be in the same day with interlaminar epidural steroid injection."
16266090|NCT04913103|Experimental|single arm, open-label|combination of polatuzumab-vedotin, bendamustine and rituximab
16265851|NCT04914637|Sham Comparator|interlaminar epidural steroid injection plus sham dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered same as the arm titled interlaminar epidural steroid injection plus dry needling. The only difference in the interventions in this arm is that dry needling is applied without penetrating the skin. The blunt tip of the needle will be used in sham intervention.
~Interlaminar epidural steroid injection will be applied at week 0, while sham dry needling will be applied in 3 sessions per week (week 0, week 1, week 2)"
16265852|NCT04914637|Other|interlaminar epidural steroid injection only|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). No dry needling or sham dry needling will be used.
16265853|NCT04914624|Placebo Comparator|Regular ACBT training|Including quitting smoking, ACBT training, cough practicing.
16265854|NCT04914624|Experimental|Positive expiratory pressure therapy|Use acpella®PEP therapeutic system and regular nursing care.
16265855|NCT04914624|Experimental|External diaphragm pacemaker|Patients are trained to use external diaphragm pacemaker and receive regular nursing care.
16265856|NCT04914611||HBsAg Positive|Patients with chronic hepatitis B infection as defined by HBV surface antigen positive
16265857|NCT04914598|Active Comparator|ENDOSTAR combined with cisplatin|
16265858|NCT04914598|Placebo Comparator|Placebo combined with cisplatin|
16265859|NCT04914572|Experimental|Therapeutic rainforest & MIndful walking|The first arm uses mindful walking through a 2km forest trail in Singapore. All Interventional and Control arms will conduct their walk between 8 am to 11 am for five occasions weekly. At the T1, participants will attend a Zoom orientation session to familiarize themselves with the route. During this session, participants will need to answer the self-report questionnaire and provide the first saliva sample for the baseline measurement. In T2, a pre-intervention and post-intervention saliva sample will be taken before the walk. This will follow by T3 the following week. At T4, participants will attend a 60 mins reflection session and answer the self-report questionnaire. On T5 and T6, the participants will continue with the therapeutic rainforest mindfulness walk. On T7, a pre-intervention and post-intervention saliva sample will be taken. On T8, participants will attend a 60 mins reflection session and answer the self-report questionnaire.
16265860|NCT04914572|Experimental|Therapeutic rainforest walk|The second arm of the intervention includes walking through a guided forest trail suggested by NParks Board. The collection of samples and answering of the self-report questionnaire will follow the same sequence as the 1st arm of the 3-arm RCT.
16265861|NCT04914572|Active Comparator|Campus green walk|The control for this study includes guided casual walking around the campus green trial conducted at the same intervals as per the interventions. The collection of samples and answering of the self-report questionnaire will also follow the same sequence as the 1 arm of the 3-arm RCT.
16265862|NCT04914559|Active Comparator|Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
16265863|NCT04914559|Active Comparator|Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
16265864|NCT04914546|Experimental|LY3819469 (Part A)|Single ascending doses of LY3819469 administered subcutaneously (SC).
16265865|NCT04914546|Experimental|LY3819469 (Part B)|Single doses of LY3819469 administered SC in Japanese Participants.
16265866|NCT04914546|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
16265867|NCT04914546|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
16265868|NCT04914533|Experimental|Intervention Arm|Luminance Red Treatment Arm
16265877|NCT04914507|Other|Anterior Vertebral Body Tethering|The subject is will receive anterior vertebral body tethering surgery, as clinically indicated, after all pre-operative assessments are complete.
16265878|NCT04914481||Classical Low-Flow, Low-Gradient Aortic Stenosis|Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction <50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
16265879|NCT04914481||Paradoxical Low-Flow, Low-Gradient Aortic Stenosis|Paradoxical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction ≥50% and SVi ≤35 mL/m2 by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
16265880|NCT04914481||High-Gradient Aortic Stenosis (Control group)|High-Gradient Aortic Stenosis is defined as valve area <1 cm2 and mean gradient >40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.
16266091|NCT04913090|Experimental|Part A-experimental|Single Ascending Dose (SAD) phase
16265881|NCT04914481||Conservative treatment (Control group)|The subgroup includes all patients with (severe or non-severe) aortic stenosis, who underwent conservative treatment. Data on aortic valve calcification is not mandatory for this control group.
16265882|NCT04914468||TMVR|Patients undergoing Transcatheter Mitral Valce Replacement (TMVR)
16265883|NCT04914468||TEER|Patients undergoing mitral Transcatheter Edge-to-Edge Repair (TEER) after screening for TMVR
16265884|NCT04914468||Surgery|Patients undergoing mitral valve surgery (repair or replacement) after screening for TMVR
16265885|NCT04914468||Medical therapy|Patients undergoing medical therapy after screening for TMVR
16265886|NCT04914455||Fluid responsiveness groups (responders and non-responders)|Fluid responsiveness is defined as an increase in stroke volume of 10% and more form baseline.
16265889|NCT04914416|Placebo Comparator|Verum T1|
16265890|NCT04914416|Experimental|Verum T2|
16265891|NCT04914416|Experimental|Verum T3|
16265892|NCT04914416|Experimental|Verum T4|
16265893|NCT04914416|Experimental|Verum T5|
16265894|NCT04914416|Experimental|Verum T6|
16265895|NCT04914416|Experimental|Verum T7|
16265896|NCT04914416|Experimental|Verum T8|
16265897|NCT04914416|Experimental|Verum T9|
16265898|NCT04914416|Experimental|Verum T10|
16265899|NCT04914416|Experimental|Verum T11|
16265900|NCT04914416|Experimental|Verum T12|
16265901|NCT04914416|Experimental|Verum T13|
16265902|NCT04914416|Experimental|Verum T14|
16265903|NCT04914416|Experimental|Verum T15|
16265904|NCT04914416|Experimental|Verum T16|
16265905|NCT04914403|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
16265906|NCT04914390|Experimental|Tislelizumab + Anlotinib + Chemotherapy|Participants receive Tislelizumab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + AT regimen (Q3W) x 6 cycles as neoadjuvant therapy prior to surgery.
16265907|NCT04914377|Experimental|Active Drug|Capsules containing TQ Formula
16265908|NCT04914377|Placebo Comparator|Placebo|Capsules containing corn oil
16265909|NCT04914364||Patients who have tested positive for COVID-19|
16265910|NCT04914351|Experimental|Dose Escalation|"Cohort 1: 0.03 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 2: 0.3 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 3: 1 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.
~Cohort 4: 2 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.
~Cohort 5: 4 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.
~Cohort 6: 10 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort."
16265911|NCT04914338|Experimental|Supportive care (MDT-intervention)|Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.
16265912|NCT04914325|Experimental|Intervention arm :copings veneered with CAD/CAM composite resin|
16265913|NCT04914325|Active Comparator|Control arm : copings veneered with manual layering|
16265914|NCT04914312|Experimental|Maqui berry extract and omega-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
16265915|NCT04914312|Placebo Comparator|Control|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
16265916|NCT04914299|Experimental|A novel mobile-App based intervention|"An App-based positive intelligence intervention consisting of 6 weeks of weekly videos and support group sessions, and 6 weeks of daily App-guided practices."
16265917|NCT04914299|Active Comparator|Standard of Care|Standard prenatal care and follow up
16265918|NCT04914286|Experimental|GFH018+Toripalimab|Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).
16265919|NCT04914273|Experimental|Sequence A: 1. Ingestion 2. Inhalation|Group A is treated in the following sequence: 1. oral drug 2. inhalative drug
16265920|NCT04914273|Experimental|Sequence B: 1. Inhalation 2. Ingestion|Group B is treated in the following sequence: 1. inhalative drug 2. oral drug
16265921|NCT04914234|Active Comparator|Group A (n=30)|Atenolol group
16265922|NCT04914234|Active Comparator|Group M (n=30)|Metoprolol group
16265923|NCT04914221|Experimental|Group I|Period I- comparator / Period II- comparator / Period III-JLP-2002
16265924|NCT04914221|Experimental|Group II|Period I- comparator / Period II- -JLP-2002 / Period III- comparator
16265925|NCT04914221|Experimental|Group III|Period I- JLP-2002/ Period II- comparator / Period III- comparator
16265926|NCT04914208|Active Comparator|Wearing a face mask for 4 hours|Participants are wearing different kinds of face masks for 4 hours each. Masks are worn on different days and the order is randomly assigned.
16265927|NCT04914208|Other|4 hours without wearing a face mask|Participants do not wear any face mask for 4 hours.
16265928|NCT04914195|Experimental|Leuprolide acetate 3.75 mg Depot (Luprodex)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
16265929|NCT04914195|Active Comparator|Leuprolide acetate 3.75 mg Depot (Lucrin)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
16265986|NCT04913701||1 - Health workers|A total number of 200-300 healthcare workers, exposed to close contact with patients, will be asked to participate to the study and will be asked to sign the informed consent.
16265930|NCT04914182|Experimental|LASER|In the intervention group, the laser will be applied to the points of the edges of the lesion, with a distance of one centimeter between them. The laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
16265931|NCT04914182|Sham Comparator|CONTROL|In the control group, the sham laser will be applied the exact same way as the real laser, to the points of the edges of the lesion, with a distance of one centimeter between them. The sham laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
16265932|NCT04914169||Indoor cycling training|8 subjects were asked to complete indoor cycling training, 3 times a week for 4 weeks. Each session of training consisted of 30-minute stationary biking (5 minutes of warm-up, 20 minutes of training and 5 minutes of cooldown).
16265933|NCT04914156|Experimental|Personalised, genetic-based advice for sport performance|This group will receive personalised nutrition advice for sports performance based on their genetic test results and tailored to their current dietary intake.
16265934|NCT04914156|Active Comparator|Personalised nutrition advice for sport performance based on population-based evidence|This group will receive personalised nutrition advice on key nutrients relating to sports performance based on current best practice, population-based sport nutrition guidelines. These will be tailored to their current dietary intake
16265935|NCT04914143|Experimental|Experimental group|
16265936|NCT04914143|Placebo Comparator|placebo comparator group|
16265937|NCT04914130||Older HIV-positive cohort (n=500)|"documented HIV infection
~age >50 years at study entry
~Korean ethnicity
~likely route of HIV acquisition via sexual exposure by male to male exposure
~able to comprehend study patient information leaflet.
~Virologically suppressed subjects Subjects with primary HIV infection are eligible and investigators are encouraged to recruit such subjects. Our target population (those infected with HIV via sexual routes of men who have sex with men) has been chosen as this group represent the vast majority of older HIV-positive individuals attending for care in Korea; analyses of other groups (e.g. injection drug users, those infected through blood/blood products and transgender individuals), who may have very different needs and outcomes, would likely be under-powered."
16265938|NCT04914130||Younger HIV-positive cohort (n=250)|"documented HIV infection
~age <50 at study entry*
~Korean ethnicity
~likely route of HIV acquisition via sexual exposure by male to male exposure
~able to comprehend study patient information leaflet * this group will comprise of at least 70 subjects in each of the following age groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study Monitoring Team"
16265939|NCT04914130||HIV-negative cohort (n=250)|"documented negative HIV test at screening
~age >50 years at study entry
~Korean ethnicity
~self reported sexual preferences of men who have sex with men
~To enroll matched control, we will try to match age, sexual orientation, and participating clinic."
16265941|NCT04914104|Experimental|Intervention|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
16265942|NCT04914104|No Intervention|Control|The control group will receive standard of care, which does not involve routine in-person or free access to mobile mindfulness therapy.
16265943|NCT04914091||Patients with diffuse large B-cell lymphoma treated with CART-cells|
16265944|NCT04914078||Mepolizumab treated patients|Severe eosinophil severe asthmatic patients treated with anti IL-5 monoclonal antibody Mepolizumab
16265945|NCT04914052||Study group|"Patients will be requested to sign an informed consent in which they will agree to have their face filmed in the post-anesthesia care unit.
~The facial expressions will be filmed in 30 second segments. A pain assessment will be measured immediately following filming of each segment using two modalities:
~Pain score assessed by an attending anesthesiologist assigned to the study team.
~VAS assessment by the patient. Following data collection, the data will be forwarded in a coded manner, according to Clalit's data security regulations, to Third Eye systems a facial recognition software company.
~Third Eye systems will analyze and process the data using AI and machine learning models and develop an algorithm that can predict pain level by watching facial expressions."
16265946|NCT04914039||CTA examination|CTA examination group for suspected brain death
16265947|NCT04914039||Confirmed|Confirmed group for brain death
16265948|NCT04914000|Experimental|Self Help Materials|Participants will receive a smoking cessation booklet/pamphlet corresponding to their cancer type.
16265949|NCT04913987|Experimental|Total knee|Standard care
16265950|NCT04913987|Experimental|Partial knee|Intervention using relatively new partial knee.
16265951|NCT04913974||Uni-condylar knee arthroplasty|A cohort of patients who will undergo uni-condylar knee replacement surgery with the Univation X system and have biomechanical anaylsis
16265952|NCT04913961|Experimental|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study.
16265953|NCT04913961|Active Comparator|Control|The control group will get the western medicine conventional therapy with some additional tests for the study.
16265954|NCT04913948||Pregnant|Pregnant women with confirmed COVID-19 at any point during pregnancy or suspected (as identified at local hospital) of COVID-19 at time of delivery, who will be delivering at a participating hospital within Ontario
16265955|NCT04913935||TMC OA|women who were diagnosed with TMC OA
16265956|NCT04913935||Control|healty volunteer women
16265957|NCT04913922|Experimental|Combination therapy|"5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1
~repeat day 28"
16265958|NCT04913909|Active Comparator|Dentoblis™ group|In Probiotic group; Dentoblis™, as a test lozenge, contains 4 billion CFU/g S. salivarius M18 strain probiotic isolated from a healthy oral microbiota, has been utilized one lozenge a day for 30 days.
16266086|NCT04913129|No Intervention|Control Group|Standard physician-guided medical care after COVID-19
16265959|NCT04913909|Placebo Comparator|Placebo group|The placebo was indistinguishable in form, size, color, smell and taste from the probiotic lozenge, but contained no bacteria and utilized one lozenge a day for 30 days . Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code.
16265960|NCT04913896||Single Group Assignment|Patients with AGC who underwent neoadjuvant immunotherapy and/or chemotherapy would recieve MRI and CT examination before and after 3 cycles treatment.
16265961|NCT04913870|Experimental|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers will be given orally once a day for 2 years.
16265962|NCT04913870|Placebo Comparator|Placebo|Participants will receive a matched placebo orally once a day for 2 years.
16265963|NCT04913857|Experimental|24-week SUDOKU Training Programme|"The SUDOKU training program include a 12-week face-to-face training session and a 12-week facilitated self-practice. The 12-week (60-minute sessions) training program will be evenly divided into 3 modules of increasing difficulty for the suboptimal cognitive function of the participants with MCI. As the use of T-code in solving the SUDOKU allows communicating the way a number is assigned to a box, participants are grouped into a small team of 3, so that they will work together during the tutorial practice.
~Facilitated self-practice will last for another 12 weeks immediately after the group training session. The instructor will give them a workbook with 12 SUDOKU puzzles of increasing level of difficulty for completion. The instructor will encourage and facilitate their accomplishment by giving them guidance on the taught method through regular phone call. Solutions of the assigned puzzle and the T-code will be provided in the following week."
16265964|NCT04913857|Active Comparator|wait-list|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
16265965|NCT04913844||Skiers group|"The skiers group was formed from licensed ski athletes (17 male, 17 female) who have been active in sports for at least the last 2 years.
~There will be no interventions. Physical performance tests and observational assessments will be conducted."
16265966|NCT04913844||Control group|"The control group was composed of non-athletic and age-matched participants (17 male, 17 female) with no skiing experience.
~There will be no interventions. Physical performance tests and observational assessments will be conducted as in the Skiers Group."
16265967|NCT04913831|Experimental|Cerebrolysin|
16265968|NCT04913831|Placebo Comparator|Placebo|
16265969|NCT04913818|Experimental|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40 minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements in order to achieve a feeling of 'somewhat hard' at the Borg RPE rating of 12-14. The training session will end with a 10-minute cool down exercise session.
16265970|NCT04913818|Active Comparator|Usual Care|Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
16265974|NCT04913792||ZXR00|The ZXR00 group included 30 patients bilaterally implanted with the Tecnis Symfony IOL (Abbott Medical Optics, Inc.)
16265975|NCT04913779|Active Comparator|Anti-SARS-CoV-2|Administration of 10 ml of a concentrated equine hyperimmune serum solution with neutralizing activity of SARS-CoV-2 not less than1/5120, administered in slow intravenous infusion (10 ml diluted in100 ml of physiological solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
16265976|NCT04913779|Placebo Comparator|Placebo|Administration of 10 ml of a control-solution with no-neutralizing activity of SARS-CoV-2, administered in slow intravenous infusion (10ml diluted in 100 ml of physiological solution, administered over 50 to60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0when incorporated into the study -initial dose- and at 48 hours -second dose-).
16265977|NCT04913766|Active Comparator|Services as usual|Persons screening positive for depression will be referred from community-based organizations. The referrals will be made to mental health specialists who will provide care based on their standard of care.
16265978|NCT04913766|Experimental|Problem Management Plus|Persons screening positive for depression will be offered Problem Management Plus delivered by community based organization staff.
16265979|NCT04913753|Experimental|No systematic CBEU|Patients will not have bacterial culture performed before double J removal.
16265980|NCT04913753|Active Comparator|Systematic CBEU|Patients will have a systematic urine culture performed before double J removal.
16265981|NCT04913740|No Intervention|Control group|health care workers who did not use any preventive measures on the basis of tertiary protection
16265982|NCT04913740|Experimental|Experimental group|"On the basis of three-level protection, skin correlation prevention is carried out:
~pay attention to the protection of exposed skin, so that it is local dry.
~Do a good job of facial moisturizing work before workuse moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.
~Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.
~After work, avoid using irritantsto clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
16265983|NCT04913727|Experimental|Treatment Arm|Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.
16265987|NCT04913701||2 - Patients|A total number of 100-200 patients admitted to the rehabilitation facility, referred from other healthcare facilities or from their own home, will be asked to participate to the study.
16265988|NCT04913701||3 - Real life participants|A total number of 100 real-life participants, will be represented by volunteers (other employees, staff not in contact with patients
16265989|NCT04913688||suspected DVT group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, the patients become eligible for study subjects.
16265993|NCT04913662|Experimental|PIPAC Paclitaxel with FOLFOX|PIPAC (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
16265994|NCT04913649|Experimental|Intravenous iron (ferric derisomaltose)|The intervention consists of a single dose of ferric derisomaltose (Monofer®) 100 mg/mL solution for infusion (Monofer® is a registered product with a marketing authorization in the Netherlands (RVG number: 103070). Manufacturer: Pharmacosmos A/S, Denmark. Dutch marketing authorization holder: Cablon Medical B.V). The method of administration and dosage of the investigational medication are standard treatment. The ferric derisomaltose dose will calculated for each patient depending on body weight (20mg/kg) and diluted in 250 ml NaCl 0.9%. Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
16265995|NCT04913649|Placebo Comparator|Placebo|Single dose of sodium chloride 0.9% (250ml). Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
16265996|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in cemented THA|
16265997|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in non cemented THA|
16265998|NCT04913610|Experimental|Part 1: Arm A|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
16265999|NCT04913610|Experimental|Part 1: Arm B|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by ABBV-4083 for 7 days.
16266000|NCT04913610|Experimental|Part 1: Arm C|Participants will receive ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
16266001|NCT04913610|Experimental|Part 1: Arm D|Participants will receive ABBV-4083 + albendazole for 3 days followed by ABBV-4083 + placebo for albendazole for 4 days followed by placebo for ABBV-4083 for 7 days.
16266002|NCT04913610|Experimental|Part 1: Arm E|Participants will receive placebo for ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
16266003|NCT04913610|Experimental|Part 2: Arm K|Participants will receive active regimen from Part 1 followed by ivermectin at Month 6.
16266004|NCT04913610|Experimental|Part 2: Arm L|Participants will receive active regimen from Part 1 followed by placebo for ivermectin at Month 6.
16266005|NCT04913610|Experimental|Part 2: Arm M|Participants will receive active regimen from Part 1 followed by placebo for ivermectin or matching placebo at Month 6.
16266006|NCT04913610|Experimental|Part 2: Arm N|"Scenario 1: Participants will receive placebo for ABBV-4083 + placebo for albendazole followed by ivermectin at Month 6.
~Scenario 2: Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for appropriate duration followed by ivermectin or matching placebo at Month 6."
16266007|NCT04913597||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and avatrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 14 days as initial treatment. After initial treatment, maintenance therapy were performance. At initial therapy, rhTPO will be suspended when platelet counts ≥100×10^9 / L. During maintenance therapy, patients with platelet counts >150×10^9 / L will suspend treatment until platelet counts drop to ≤150×10^9 / L. Dosing interval will be prolonged when platelet count is ≥100×10^9 / L to ≤150×10^9 / L. Dose modification is not required when platelet count is ≥30×10^9 / L to <100×10^9 / L. The efficacy, safety, and patient/physician preference will be assessed.
16266008|NCT04913597||Avatrombopag group|Patients who fail previous steroids and rh-TPO and then switch to avatrombopag will be enrolled. The reason for switch will be recorded. Patients will be given avatrombopag 20mg once daily as initiate treatment, and adjust the dosage according to the count of platelets. The maximum dose of avatrombopag is 40mg daily.Avatrombopag will be terminated any time the platelet counts increased above 250×10^9/L. Dose adjustment of avatrombopag will be allowed to maintain platelet counts between 30×10^9/L and 150×10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
16266009|NCT04913584|Experimental|Immediate Intervention|Online Group CBT for PPD. Women in the treatment group will attend an online 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by eight lay-peers.
16266010|NCT04913584|Experimental|Wait-List Controls|Online Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however, they will begin the CBT group 9 weeks after enrolling in the study.
16266011|NCT04913571|Experimental|TMB High group|
16266012|NCT04913571|Experimental|PD-L1 positive group|
16266013|NCT04913571|Experimental|Immunomodulatory (IM) group|
16266014|NCT04913571|Experimental|NanoString superiority group|
16266015|NCT04913571|Experimental|other types|
16266016|NCT04913558|Active Comparator|Traditional Treatment Arm|This group will consist of thirty employed lactating women suffering from stress and fatigue. This group will receive the same lifestyle modification advice that will be given to the aerobic exercise group during the six weeks of the program period.
16266087|NCT04913129|Experimental|Interventional (exercise training) Group|8 week home-based exercise training
16266092|NCT04913090|Placebo Comparator|Part A-placebo|Single Ascending Dose (SAD) phase
16266017|NCT04913558|Experimental|Aerobic exercise group|This group will consist of thirty employed lactating women suffering from stress and fatigue. These women will perform aerobic exercise for 30 minutes for each session, 5 times per week, for 6 weeks in the form of treadmill training (60- 70% of HR max) and do some modifications of their routine by following lifestyle modification advice given to them during the 6 weeks of the program period.
16266018|NCT04913545||normal group|participants with out any systemic medical problemes or oral lesions. we will only take saliva sample.
16266019|NCT04913545||potientially malignant group|participants with suspicious oral lesions without any medical diseases. we will take saliva sample and take a biopsy sample .
16266020|NCT04913545||malignant group|participants with already diagnosed oral malignant lesions without receiving any treatment yett
16266021|NCT04913532|Experimental|Hypofractionation with SIB|Hypofractionation with SIB
16266022|NCT04913519|Experimental|SAD Cohorts 1 -3 TDM-105795 topical solution|Single dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01%
16266023|NCT04913519|Placebo Comparator|Placebo for TDM-105795 topical solution|Single dose administration of Placebo forTDM-105795 Topical Solution
16266024|NCT04913506|Active Comparator|Group Mirror|Along with conventional rehabilitation techniques, patients will be given ROM exercises in all directions, in front of the real mirror, by the practitioner on the healthy upper extremity for 30 minutes.
16266025|NCT04913506|Active Comparator|Group NMES|Along with conventional rehabilitation techniques, NMES will be applied to the hemiplegic arm for 30 minutes by the practitioner while the patients are sitting in a chair.
16266026|NCT04913506|Active Comparator|Group Mirror+NMES|In addition to conventional rehabilitation techniques, patients will be given ROM exercises for 30 minutes in all directions in front of the real mirror to the healthy extremity, which the practitioner will synchronize with visual or auditory stimuli, and NMES treatment for 30 minutes to the paretic upper extremity.
16266027|NCT04913493|No Intervention|Control group|Patients will only receive FloTrac/Vigileo monitoring which is standard of care.
16266028|NCT04913493|Experimental|Experimental group|Patients will receive an additional medical imaging intervention. Namely sublingual microcirculation imaging with Cytocam-IDF.
16266029|NCT04913480|Experimental|Durvalumab and stereotactic body radiation therapy|"Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles, starting 1 week before commencement of stereotactic body radiation therapy
~Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days"
16266033|NCT04913454|Experimental|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks).
16266034|NCT04913454|Active Comparator|Cognitive training only|Cognitive training only (1 hour per day, per 5 days/week, for a total of 8 weeks).
16266035|NCT04913441|Experimental|Routine physical therapy|"Patients in this group will get every session of 30 min 3 times per week on alternative days for 12 weeks
~TENS and hot pack for 15 minutes
~Ultra sound for 5 minutes
~ROM exercises repeats 5 times for 10 minutes"
16266036|NCT04913441|Experimental|Manual physical therapy with routine physical therapy|"Patients in group B will get every session 30 minutes 3 times per week on alternative days
~TENS and hot pack for 15 minutes
~Ultra sound for 5 minutes
~Mulligan technique (NAGS and SNAGS) will repeats 5 times for 10 minutes"
16266037|NCT04913441|Experimental|Stretching physical therapy with routine physical therapy|"Patients in this group will get every session 30 minutes 3 times per week on alternative days
~TENS and hot pack for 15 minutes
~Ultra sound for 5 minutes
~Stretching exercises repeats 5 times for 10 minutes"
16266038|NCT04913428|Experimental|Interdigital exercise group|"Interdigital exercises:
~12 repetitions in 3 sets of 4 repetitions
~Conventional Physical Therapy:
~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
16266039|NCT04913428|Active Comparator|Blow-Bottle technique group|"Blow-Bottle technique:
~12 repetitions in 3 sets of 4 repetitions
~Conventional Physical Therapy:
~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
16266040|NCT04913415|Other|Low Suction Strategy of Chest Tube Management|
16266041|NCT04913415|Other|Standard Suction Strategy of Chest Tube Management|
16266042|NCT04913402||Consultation|Patient who were administered sufentanil in acute trauma by paramedics after phone call consultation with medical doctor.
16266043|NCT04913402||Competency|Patient who were administered sufentanil in acute trauma by paramedics with competence to administer sufentanil without any consultation with medical doctor.
16266044|NCT04913389|Active Comparator|Acetazolamide|Acetazolamide (oral capsules)
16266045|NCT04913389|Placebo Comparator|Placebo|Placebo (oral capsules)
16266046|NCT04913376|Experimental|Hilotherapy|
16266047|NCT04913376|No Intervention|Standard care|
16266048|NCT04913363|Experimental|Walking|This contemplative activity will see users taken to a local green space area near their center and encouraged to walk around the space. It is anticipated walks will last around 15-20 minutes.
16266049|NCT04913363|Experimental|Citizen Science|This cerebral activity sees users engage with local green spaces, under the instruction of a citizen scientist, to learn about the intricacies of the space. This may include lichen counts (or similar) where the main outcome is learning based.
16266050|NCT04913363|Experimental|Planting|This physical activity will see users, lead by a local Master Gardener, engage with planting vegetables/fruit in raised beds. Not only will this allow users a chance to engage physically with nature, but it is anticipated that the grown produce will be used for center users.
16266088|NCT04913116||SARS-Cov-2 positives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
16266051|NCT04913350|Experimental|Russian current and elbow support group|participants in the experimental group will apply elbow support and will receive Russian current on biceps and triceps muscles of the unaffected elbow three therapy sessions per week for 4 weeks.
16266052|NCT04913350|Active Comparator|elbow support group|Participants in this group will apply elbow support only.
16266053|NCT04913337|Experimental|NGM707 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
16266054|NCT04913337|Experimental|NGM707 Combination Dose Finding with pembrolizumab|Part 1b NGM707 plus pembrolizumab
16266055|NCT04913337|Experimental|NGM707 Monotherapy Dose Expansion Arm A|NGM707 in RCC
16266056|NCT04913337|Experimental|NGM707 Monotherapy Dose Expansion Arm B|NGM707 in CRC
16266057|NCT04913337|Experimental|NGM707 Monotherapy Dose Expansion Arm C|NGM707 in Ovarian Cancer
16266058|NCT04913337|Experimental|NGM707 Combination Dose Expansion Arm E|NGM707 with pembrolizumab in NSCLC
16266059|NCT04913337|Experimental|NGM707 Combination Dose Expansion Arm F|NGM707 with pembrolizumab in SCCHN
16266060|NCT04913324|Experimental|Virtual Care|
16266061|NCT04913324|No Intervention|Standard of Care|
16266062|NCT04913311||Observational (biospecimen collection, standard treatment)|Patients undergo collection of blood, stool and saliva samples at baseline. Patients receive standard of care treatment consisting of concurrent chemoradiation from baseline up to week 62 and immune checkpoint inhibitors from week 10-62. Patients also undergo the collection of blood, stool, saliva and BAL samples at week 10. During the course of treatment, patients also complete routine tests and procedures to monitor for side effects per standard of care including CT within 4 weeks, lung function tests including home spirometry TIW from week 10-62, bronchoscopy and/or a nasal wash to check for viral infection. Patients also complete questionnaires about symptoms and quality of life QW for weeks 1-9, BIW during weeks 5-54, and once a month until week 62.
16266063|NCT04913298|Other|Cytosorb therapy|blood samples are taken before and after the cytokine adsorber at given times
16266064|NCT04913285|Experimental|Dose Escalation|Dose escalation of KIN-2787 in patients with solid tumors harboring Class I, Class II, or Class III BRAF alterations
16266065|NCT04913285|Experimental|Dose Expansion|Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 in patients with NSCLC, melanoma, and other solid tumors harboring Class II or Class III BRAF alterations
16266066|NCT04913272|Experimental|US-APR2020|Patients in this group will be administered US-APR2020 orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals, (for a total daily dose of 90 Billion CFUs).
16266067|NCT04913272|Placebo Comparator|Placebo|Patients in this group will be administered placebo orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals.
16266068|NCT04913259|Other|Remote monitoring for elderly patients with cancer|
16266069|NCT04913220|Experimental|Cohort A: Melanoma|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
16266070|NCT04913220|Experimental|Cohort B: cutaneous squamous cell carcinoma (CSCC)|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
16266071|NCT04913207|Sham Comparator|Traditional echo-fluoroscopy guided group|LAA angiography is performed with a 6F pigtail catheter in LAA at the view of RAO 30°, CAU 20° and RAO 30°, CRA 20°. Next, the outline of the LAA will be drawn on the screen according to the LAA angiography. LAmbre device size selection is based on diameters of LAA ostium and landing zone measured on LAA angiography. The process of device implantation, assessment, releasing will be carried out at RAO 30°, CAU 20°. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
16266072|NCT04913207|Experimental|3D-CTA guided group|Patients in 3D-CTA based perimeter group will undergo CCTA examination before LAAO and a 3D model of the left atrium is reconstructed by a workstation. LAmbre device size selection is based on perimeters of LAA ostium and landing zone which are obtained by the measurement method shown previously in this protocol. After transseptal puncture, LAA angiography is performed with a 6F pigtail catheter in LAA at the tangent angle view which is obtained preoperatively by 3D-CCTA. Then, the outline of the LAA will be drawn on the screen according to the LAA angiography. The process of device implantation, assessment, releasing will be carried out at this tangent angle view. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
16266073|NCT04913194|Experimental|Immediate Treatment|Participants in this arm will receive the intervention within 2 weeks of completing the intake session.
16266074|NCT04913194|Other|Waitlist Control|Participants in this arm will not receive any intervention for two weeks. Participants will complete the treatment after 4-6 weeks of being on the waitlist after their intake session.
16266075|NCT04913181||Sepsis prediction model|This group of people was used for the clinician's decision, and the sepsis prediction model was used simultaneously for the prediction, but the model was not involved in the decision, and was only used for verification
16266076|NCT04913181||Daily clinical judgment of doctors|This group of people was used for the clinician's decision without sepsis prediction model.
16266077|NCT04913168|Experimental|Control Group|Control Group; no intervention
16266078|NCT04913168|Experimental|Intervention Group|Intervention Group; receives 13 month intervention
16266079|NCT04913155|Other|Reporting group (coronary calcium score and emphysema score)|Coronary calcium score and emphysema score are reported to subjects
16266080|NCT04913155|Other|Reporting group (coronary calcium score only)|Only coronary calcium score is reported to subjects
16266081|NCT04913155|Other|Reporting group (emphysema score only)|Only emphysema score is reported to subjects
16266082|NCT04913155|Other|Non-reporting group|Coronary calcium score and emphysema score are not reported to subjects
16266083|NCT04913155|No Intervention|Low-risk group|No CT screening, collection of health data only
16266084|NCT04913142||control|patients not suffering from COVID-19 hospitalized in intensive care unit
16266085|NCT04913142||patients COVID-19|patients suffering from COVID-19 hospitalized in intensive care unit
16266095|NCT04913090|Experimental|Part C1-experimental|Food Effect (FE) phase
16266096|NCT04913090|Experimental|Part C2-experimental|Food Effect (FE) phase
16266097|NCT04913077|Other|Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
16266098|NCT04913064|Experimental|Prevention (white button mushroom)|Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.
16266099|NCT04913038||case group|children over 2 years of age and prepubescent ventilated and sedated in pediatric intensive care.
16266100|NCT04913025|Active Comparator|Standard interval|Standard of care regimen Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 4 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 6 weeks
16266101|NCT04913025|Experimental|Extended interval|Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 8 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 12 weeks
16266102|NCT04913012|Experimental|Aerobic training booster group|Will receive 12 weeks of aerobic training followed by booster sessions + standard care in the 40 follow up period
16266103|NCT04913012|Active Comparator|Aerobic training control group|Will receive 12 weeks of aerobic training followed by standard care in the 40 follow up period
16266104|NCT04913012|Experimental|Resistance training booster group|Will receive 12 weeks of resistance training training followed by booster sessions + standard care in the 40 follow up period
16266105|NCT04913012|Active Comparator|Resistance training control group|Will receive 12 weeks of resistance training followed by standard care in the 40 follow up period
16266106|NCT04913012|No Intervention|Control group|Will receive standard care throughout the study
16266107|NCT04912986|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
16266108|NCT04912986|Experimental|Experimental group|The intervention was implemented in accordance with the Early Lung Rehabilitation Training Programme for Adult Double Lung Transplant Patients
16266109|NCT04912973|Active Comparator|inverse Kinematic Alignment|
16266110|NCT04912973|Active Comparator|adjusted Mechanical Alignment|
16266111|NCT04912947|Active Comparator|Dietary supplement|One cp/day of the IMMUSYSTEM food supplement for 3 months
16266112|NCT04912947|Placebo Comparator|Placebo|One cp/day of Placebo for 3 months
16266113|NCT04912934||MetS diagnosis|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The MetS group for the research included individuals with metabolic syndrome diagnosis according to IDF-2005 diagnostic criteria.
16266114|NCT04912934||non-MetS|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The non MetS group in the research included healthy individuals not using any psychiatric medications, without any chronic disorder, and with similar BMI to the individuals in the subject group.
16266115|NCT04912921|Experimental|palmitoylethanolamide|Levagen
16266116|NCT04912921|Placebo Comparator|Placebo|microcrystalline cellulose
16266117|NCT04912895|Experimental|SARS-CoV-2 Positive|Participants who test positive for SARS-CoV-2 with the Polymerase Chain Reaction (PCR) test.
16266118|NCT04912895|Active Comparator|Non-COVID-19 Acute Respiratory Illness|Participants who have an acute respiratory illness other than SARS-CoV-2 infection.
16266119|NCT04912895|Other|Healthy Controls|Participants without any acute respiratory illness.
16266120|NCT04912882||Training Group|Training group including about 500 patients that be using to building the prognosis model
16266121|NCT04912882||Validation Group|Validation group including about another 500 patients that be using to validating the prognosis model
16266122|NCT04912869|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
16266123|NCT04912869|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching Placebo.
16266126|NCT04912843|Experimental|NR082 injection|0.5×10v9 viral genomes (vg), 0.05 mL eye/dose ,single-dose,only one eye per subject; 1.5×10v9 viral genomes (vg), 0.05 mL eye/dose single-dose,only one eye per subject; 4.5×10v9 viral genomes (vg) , 0.05 mL eye/dose single-dose,only one eye per subject
16266129|NCT04912817|Experimental|Off the Shelf VR (PR-VR program + usual care)|"One session per week x 4 weeks; total 4 sessions over 1 month
~PR-VR program (30 min) + Usual care (30 min SVPT)
~Total intervention time = 4 hours
~10 selected for post-study telephone interview"
16266130|NCT04912817|Experimental|Custom VR (Modified PR-VR program + usual care)|"One session per week x 4 weeks; total 4 sessions over 1 month
~Mod PR-VR program (30 min) + Usual care (30 min SVPT)
~Total intervention time = 4 hours
~10 selected for post-study telephone interview"
16266131|NCT04912817|No Intervention|Standard Virtual Physiotherapy Treatment (control; usual care),|"One session per week x 4 weeks; total 4 sessions over 1 month
~Usual care (60 min SVPT)
~Total intervention time = 4 hours"
16266132|NCT04912804||COVID-19 Patient|Patient discharged from a conventional short-stay hospitalization unit.
16266134|NCT04912778||Persons who had a covid-19 infection.|Male and female adults who were previously infected with covid-19.
16266135|NCT04912765|Experimental|Neoantigen Dendritic Cell Vaccine and Nivolumab|"NA DC vaccine every 2 weeks at a dose of 3-5 million cells.
~Adjuvant nivolumab every 2 weeks at 240mg when given concurrently with the vaccine; every 4 weeks at 480mg after vaccine treatment is completed for a total duration of 1 year."
16266136|NCT04912752|Other|Case-Control|Copy number variation
16266137|NCT04912752|Experimental|Case-Control 1|Gene expression
16266138|NCT04912726|Experimental|Intervention|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
16266139|NCT04912726|No Intervention|Placebo|The control group will receive placebo at the same loading dose and infusion with 0.9% saline solution plus standard management under the unit protocol immediately after the echocardiographic diagnosis.
16266140|NCT04912713|Active Comparator|Arm 1|This group will be randomly immersed in ice water (2°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the arithmetic task of counting backwards from the number 2043 as quickly and accurately as they can. Each time they make a mistake in the mental task, they will be given negative feedback and must start again from the number 2043. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively.
16266141|NCT04912713|Active Comparator|Arm 2|This group will not be falsely recorded or evaluated. They will be randomly immersed in warm water (35-37°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the simple counting task, in which they will have to count consecutively from 1 to 25 at their own pace. If they reach 25 they must start again and will never be given negative feedback. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively
16266142|NCT04912700||Unvaccinated|Unvaccinated individuals are defined as having positive laboratory COVID-19 testing with no record of immunization against COVID-19 or first-dose vaccination after symptom onset.
16266143|NCT04912700||Partially vaccinated|Partially vaccinated individuals are defined as having positive laboratory COVID-19 testing and symptom onset after a single dose of either mRNA (Pfizer, Moderna) vaccine, or < 14 days after the second dose of either mRNA vaccine (Pfizer, Moderna) or < 14 days after the administration of the single dose of viral vector vaccine (Johnson & Johnson).
16266144|NCT04912700||Fully vaccinated|Fully vaccinated individuals are defined as having positive laboratory testing for COVID-19 and symptom onset >14 days since administration of second dose of either mRNA vaccine, or >14 days since administration of viral vector vaccine (Johnson & Johnson).
16266145|NCT04912687|Experimental|All patients|"For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.
~As per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample."
16266147|NCT04912661|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
16266148|NCT04912661|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
16266149|NCT04912648||Women age 18 years and older|"baseline anthropometry
~bloods for metabolic phenotype; targeted and nontargeted Metabolomics
~saliva and urine for steroid Metabolomics
~bioimpedance
~muscle biopsy for transcriptomics"
16266150|NCT04912635|No Intervention|Control|
16266151|NCT04912635|Experimental|Intervention|
16266152|NCT04912622|Experimental|Control|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
16266153|NCT04912622|Experimental|Patient|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
16266154|NCT04912596|Placebo Comparator|Placebo|Two different Reference Placebo inhalers and two different Test Placebo inhalers
16266155|NCT04912596|Active Comparator|Reference 1|One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers
16266156|NCT04912596|Active Comparator|Reference 2|Two different Reference inhalers and two different Test Placebo inhalers
16266157|NCT04912596|Experimental|Test|One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers
16266158|NCT04912583|Active Comparator|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
16266159|NCT04912583|Active Comparator|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
16266393|NCT04910893|Experimental|Cytokine Adsorption Arm|Intervention with CytoSorb
16266160|NCT04912570|Experimental|Manual Thrombus Aspiration|Manual Thrombus aspiration in STEMI patients with Heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
16266161|NCT04912570|Active Comparator|Standard PCI|Conventional PCI according to the most recent guidelines in STEMI patients with no heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
16266162|NCT04912557||Patients|Open major abdominal surgery patient (predicted operative time ≥ 2 hours) with Peridural Analgesia accepted
16266163|NCT04912544|Experimental|Arm 1|Patient talking with microphone first turned on and then off
16266164|NCT04912544|Experimental|Arm 2|Patient talking with microphone first turned off and then on
16266165|NCT04912531|No Intervention|Usual Care Arm|No intervention will be given to patients in the usual care arm.
16266166|NCT04912531|Experimental|Virtual Reality and Olfactory Stimuli Arm|Patients will undergo a virtual reality and olfactory stimuli therapy session at their appointment where they receive their pulmonary function test, 90 minutes before surgery, and each morning and evening they recovery in the hospital. In addition, patients will receive nighttime olfactory stimulation using a bedside olfaction device.
16266167|NCT04912518|Active Comparator|Dexmedetomidine (DEX) group|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
16266168|NCT04912518|Placebo Comparator|Placebo (Saline) group|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX group.
16266170|NCT04912492|Active Comparator|RealConsent 1.0 with Alcohol|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target breath alcohol concentration (BrAC=.08).
16266171|NCT04912492|Active Comparator|RealConsent 1.0 with Placebo|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
16266172|NCT04912492|Experimental|RealConsent2.0 with Alcohol|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target BrAC=.08).
16266173|NCT04912492|Experimental|RealConsent2.0 with Placebo|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
16266174|NCT04912492|Active Comparator|Stress Management with Alcohol|Men assigned to complete a web-based stress management program. Men assigned to alcohol intoxication arm (target BrAC=.08).
16266175|NCT04912492|Active Comparator|Stress Management with Placebo|Men assigned to complete a web-based stress management program. Men assigned to a no-alcohol placebo control arm.
16266178|NCT04912466|Experimental|IBI322|Singal arm
16266179|NCT04912453|Experimental|Primary anastomosis group|
16266180|NCT04912453|Experimental|Enterostomy group|
16266181|NCT04912440||MSE-ERCP|Group of patients, that received motorized spiral enteroscopy assisted ERCP in altered anatomy at the single study center
16266182|NCT04912427|Experimental|Isatuximab + Boretezomib + Dexamethasone|"Each cycle is 28 days
~Cycle 1
~Days 1, 8, 15, and 22: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time
~Cycles 2-8
~Days 1 and 15: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time
~Days 8 and 22: Dexamethasone at start time and Bortezomib at 30 minutes after start time
~Cycles 9+
~Days 1 and 15: Dexamethasone at start time and Isatuximab at 30-60 minutes after start time"
16266183|NCT04912414|Experimental|Brief Family Therapy (BFT) for the treatment of psychosomatic symptoms in Rwanda|The participants from the control group were assigned to the Brief Family Therapy for reducing the medically unexplained symptoms. But the control group was not assigned to the intervention (BFT).
16266184|NCT04912388|Experimental|The stabilization group|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
16266185|NCT04912388|Experimental|The general exercise group|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
16266186|NCT04912388|No Intervention|The control group|Individuals in the control group will not be treated.
16266187|NCT04912375|Experimental|Low EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
16266188|NCT04912375|No Intervention|Low EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a similar puzzle task but the statements they searched are neutral.
16266189|NCT04912375|Experimental|High EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
16266190|NCT04912375|No Intervention|High EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a similar puzzle task but the statements they searched are neutral.
16266191|NCT04912362|Experimental|YAG iridotomy+CLASS|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
16266192|NCT04912362|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery only
16293847|NCT04718831|Experimental|General dose|Taking 6g spirulina
16266193|NCT04912349|Experimental|Test Group|Patients received the transurethral split of the prostate(TUSP) treatment.
16266194|NCT04912349|Active Comparator|Control Group|Patients received the transurethral resection of the prostate(TURP) treatment.
16266195|NCT04912336||VV-ECMO|Patients supported because of respiratory failure by Veno-Venous Extra Corporeal Membrane Oxygenator.
16266196|NCT04912336||VA-ECMO|Patients supported because of circulatory failure by Veno-Arterial Extra Corporeal Membrane Oxygenator.
16266197|NCT04912323|Experimental|MAGNITUDE® Scaffold|Subject with up to three study lesions treated by implanting a maximum of 3 R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffolds
16266198|NCT04912310|Experimental|Acute angle closure glaucoma|Argon laser peripheral iridoplasty
16266199|NCT04912297||PCV10 2+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 2+1 schedule (two vaccinations with minimum 8-week intervals followed by a booster dose at least 4 months after the last primary dose).
16266200|NCT04912297||PCV10 3+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 3+1 schedule (three vaccinations with minimum 4-week intervals, followed by a booster dose at least 4 months after the last primary dose).
16266201|NCT04912284||General population|Questionnaire administered to adult population
16266202|NCT04912284||Health care workers|Questionnaire administered to adult health care workers
16266203|NCT04912271|Experimental|Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone|Patients received granisetron transdermal patch plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Granisetron transdermal patch Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
16266204|NCT04912271|Active Comparator|Palonosetron, aprepitant or fosaprepitant, dexamethasone|Patients received intravenous palonosetron plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Palonosetron 0.25 mg IV D1 Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
16266205|NCT04912258|Experimental|Arm A|DEB-TACE before liver surgery
16266206|NCT04912258|No Intervention|Arm B|direct liver surgery
16266207|NCT04912245|Other|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
16266208|NCT04912232||Trauma Patients|"Patients suffering blunt and/or penetrating trauma but without physiologic criteria suggestive of ongoing hemorrhage:
~Awake and alert GCS >14
~Admission systolic blood pressure greater than 90 and heart rate less than 120
~Without signs of clinically significant ongoing external hemorrhage with no active bleeding documented on radiology/ultrasound and stable vital signs (no signs of hemodynamic deterioration) during initial evaluation (approximately 15 minutes post admission)"
16266209|NCT04912219|Experimental|Treatment|
16266210|NCT04912219|No Intervention|Control|
16266211|NCT04912206|Experimental|Intervention|Point-of-Care Ultrasound on top of diagnosis work-up
16266212|NCT04912206|No Intervention|Control|Usual diagnosis work-up without Point-of-Care Ultrasound
16266213|NCT04912193||antithrombin III < 50 %|preoperative antithrombin III levels <50%
16266214|NCT04912193||Antithrombin III ≥ 50 %|preoperative antithrombin III levels ≥ 50 %
16266215|NCT04912167|Experimental|ARNI-Sacubitril-Valsartan|patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.
16266216|NCT04912167|Active Comparator|ACEI-Enalapril|patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril
16266217|NCT04912154|Experimental|Traditional rehabilitation protocol|Traditional rehabilitation protocol after the surgery will be conducted
16266218|NCT04912154|Active Comparator|Accelerated rehabilitation protocol|Accelerated rehabilitation protocol under ultrasonic monitoring after the surgery will be conducted
16266219|NCT04912141|Placebo Comparator|Conestat alfa 50 U/kg - Placebo|50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
16266220|NCT04912141|Active Comparator|Conestat alfa 50 U/kg - Conestat alfa 50 U/kg|50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
16266221|NCT04912141|Active Comparator|Conestat alfa 100 U/kg - Conestat alfa 50 U/kg|100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
16266222|NCT04912141|Placebo Comparator|Placebo - Placebo|Placebo pre-angiography and 3 hours after the first dose
16266223|NCT04912128||Anlotinib group|Patients in Anlotinib group took Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1~14, 21d/cycle. All patients received SBRT for brain metastases.
16266224|NCT04912128||SBRT group|Patients in SBRT group took no anti-angiogenic drugs. All patients received SBRT for brain metastases.
16266227|NCT04912102|Active Comparator|Group H|Oxygen will be delvered via HFNO canula at 20 L/min, Fio2 0.4 and temperature of 37o c using Vapotherm Precision Flow.
16266228|NCT04912102|Active Comparator|Group M|Mask group will be provided with nasal CPAP (10cmH2O) at an oxygen flow rate of 15 L/min.
16266229|NCT04912102|Active Comparator|Group C|In the Control group, oxygen via a nasal cannula at a flow rate of 5 L/min will be delivered
16266230|NCT04912089|Experimental|Cognitive Training Low Dose|Cognitive training completed for 8 sessions
16266231|NCT04912089|Experimental|Cognitive Training High Dose|Cognitive training completed for 16 sessions
16266232|NCT04912089|No Intervention|Repeat Assessment|
16266398|NCT04910828|Experimental|Common foods of varying glycemic indices|Common foods of varying glycemic indices
16266233|NCT04912076|Experimental|BM41|9 treatment visits where subcutaneous injections with BM41 (adsorbed to aluminium hydroxide) will be given in a blinded fashion starting with 12.5 nanogram increasing to 20 microgram which is maintenance dose. Subsequently 3 maintenance doses will be given.
16266234|NCT04912076|Placebo Comparator|Placebo|Placebo consisting of only aluminium hydroxide will be administered blinded in amounts according to BM41.
16266235|NCT04912076|Active Comparator|Alutard|Alutard SQ (ALK) will serve as the comparator and administration is open. Up-dosing is performed according to the official cluster scheme, reaching maintenance of 100.000 SQ-E
16266236|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
16266237|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
16266238|NCT04912063|Experimental|Lemzoparlimab + Azacitidine in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
16266239|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
16266240|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
16266241|NCT04912050||Tablo Hemodialysis System|Hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy > 12 hours on the Tablo Hemodialysis System
16266242|NCT04912037|Experimental|with AI-assisted system|The novice doctors are trained in colonoscopy with an artificial intelligence assisted system that can indicate abnormal lesions and the speed of withdrawal in real time, as well as feedback on the percentage of overspeed.
16266243|NCT04912037|No Intervention|without AI-assisted system|The novice doctors receive routine colonoscopy training without artificial intelligence assistance system and no special tips
16266244|NCT04912024||Tablo Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on the Tablo Hemodialysis System at a dialysate flow rate of 300 mL/min
16266245|NCT04912024||Conventional Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on conventional hemodialysis systems (Non-Tablo) with dialysate flow rates of ≥ 500 mL/min
16266246|NCT04912011|Experimental|Canrenoate potassium|Administration of 200 mg of potassium Canrenoate potassium dissolved in 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
16266247|NCT04912011|Placebo Comparator|Placebo|Administration of 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
16266248|NCT04911985||ICU Patients with PAC|All patients admitted to the Medical ICU of the University Hospital Zürich, complying with the inclusion criteria and monitored by a pilmonary artery catheter
16266249|NCT04911972||Functional muscle transfer group|Patients who have undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
16266250|NCT04911972||Non-functional muscle transfer group|Patients who have not undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
16266251|NCT04911959|Other|control group|
16266252|NCT04911959|Experimental|Intervention group|
16266253|NCT04911946||R1|Resident of the first year of orthopedics and traumatology at IOT-HC-FMUSP.
16266254|NCT04911946||R2|Resident of the second year of orthopedics and traumatology at IOT-HC-FMUSP.
16266255|NCT04911946||R3|Resident of the third year of orthopedics and traumatology at IOT-HC-FMUSP.
16266256|NCT04911933|Experimental|Intervention|The form of treatment involve systemic family therapy sessions every two weeks about an hour each.
16266257|NCT04911933|No Intervention|Waitlist Control|Participants assigned to the control condition will be placed on a waitlist for future enrollment. After primary data collection has ceased, those assigned to the control arm will receive the identical intervention delivered in the experimental condition.
16266258|NCT04911920|Other|Patients with lateral epicondylitis|Patients with lateral epicondylitis who are treated with at least one ACP injection.
16266259|NCT04911907|Experimental|Squamous cell carcinoma of head and neck: Utidelone Injection|Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy
16266260|NCT04911907|Experimental|Esophageal cancer: Utidelone injection|Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.
16266261|NCT04911907|Experimental|Stomach cancer: Utidelone injection|Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.
16266262|NCT04911907|Experimental|Pancreatic cancer: Utidelone Injection|Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.
16266263|NCT04911907|Experimental|Ovarian cancer: Utidelone Injection|Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.
16266264|NCT04911907|Experimental|Cholangiocarcinoma: Utidelone|Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy
16266265|NCT04911907|Experimental|Other solid tumors: Utidelone Injection|Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy
16266266|NCT04911894|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
16266267|NCT04911881|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
16266268|NCT04911842||TPU|Thermoplastic polyurethane
16266269|NCT04911842||HBM|Hydrophilic BioMaterial
16266270|NCT04911829|Active Comparator|Inpatient treatment|High intensity high dosage inpatient short-term psychodynamic psychotherapy
16266271|NCT04911829|Experimental|Outpatient treatment|Low dosage outpatient short-term psychodynamic psychotherapy
16266272|NCT04911816|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate
16293848|NCT04718831|Experimental|Double dose|Taking 12g spirulina
16266273|NCT04911803|Experimental|Anxiety Group|Participants will download the anxiety application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the anxiety application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the anxiety group are asked to complete daily brief exercises. For example, they will practice noticing worry thoughts and journal them down.
16266274|NCT04911803|Active Comparator|Procrastination Group|Participants will download the procrastination application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the procrastination application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the procrastination group are asked to complete daily brief exercises. For example, they will practice to reduce procrastination-related thoughts.
16266276|NCT04911777|Experimental|Pentarlandir™ UPPTA - High Dose|6 capsules of Pentarlandir™ UPPTA, q8h (over 3 hours postprandially)
16266277|NCT04911777|Experimental|Pentarlandir™ UPPTA - Low Dose|3 capsules of Pentarlandir™ UPPTA and 3 capsules of placebo, q8h (over 3 hours postprandially)
16266278|NCT04911777|Placebo Comparator|Placebo|6 capsules of placebo, q8h (over 3 hours postprandially)
16266279|NCT04911764|Experimental|Three-min Step Test and Exercise desaturation detection in COPD|Each patient recruited will performed both field tests, being therefore his or her own witness.
16266280|NCT04911751|Experimental|Low dose group|39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
16266281|NCT04911751|Experimental|High dose group|39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.
16266282|NCT04911738|Experimental|Plane A for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane A, which corresponds to the following order: verticality perception (Baseline, effect during the intervention, post-effect), then active vertical body orientation (Baseline, effect during the intervention). The intervention is an immersion in a virtual static and tilted environnement (18°).
~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
16266283|NCT04911738|Experimental|Plane B for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane B, which corresponds to the following order: active vertical body orientation (Baseline, effect during the intervention), then verticality perception (Baseline, effect during the intervention, post-effect). The intervention is an immersion in a virtual static and tilted environnement (18°).
~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
16266284|NCT04911725|Experimental|With device use|Volunteers included will use IMD during one of the two periods of the study.
16266285|NCT04911725|No Intervention|Without device use|Volunteers included will not use IMD during the other period of the study (reverse of experimental)
16266286|NCT04911712|Active Comparator|Randomly selected malnourished patients for normal protein liquid diet supplementation|Randomly selected malnourished patients for normal protein liquid diet supplementation
16266287|NCT04911712|Experimental|Randomly selected Malnourished patients with high protein liquid diet supplementation|Malnourished patients with high protein liquid diet supplementation
16266288|NCT04911699||breast adenocarcinoma|"The surgical pathological tissue report confirms the diagnosis of breast adenocarcinoma women with stage I~III
~Those who are admitted to the hospital and receive adjuvant chemotherapy for the first time.
~Age (inclusive) over 20 years old."
16266289|NCT04911699||Control|"The surgical pathological tissue report establishes women diagnosed as stage 0 to stage III breast cancer
~Those who are admitted to the hospital to receive anti-hormonal drug treatment.
~Age (inclusive) over 20 years old."
16266290|NCT04911673|Experimental|Music group|"Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song was composed by Juan Martin Saavedra.
~In the first month, music group was filled the State Anxiety Inventory (SAI) between 10 and 20th of the menstruation that SAI consists of 20 statements that ask people to describe how they generally feel. In the second month, pain scores were measured on the first day of menstruation using a visual analogue scale (VAS) of 10 cm (0 no pain at all, and 10 the worst possible pain) and Trait Anxiety Inventory (TAI) was filled to assess the anxiety.In the third month, after the participants were listening the music in three days before menstruation and the first day of menstruation (during four days), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety."
16266291|NCT04911673|Experimental|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them. In the first month, chocolate group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation.In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety.In the third month, after the participants were eating 40 mg of dark chocolate per day in three days before menstruation and the first day of menstruation (during four days/total 160 mg), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
16266292|NCT04911673|No Intervention|Control group|Control group had no intervention. In the first month, control group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation. In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety. In the third month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
16266490|NCT04910165|Active Comparator|Control|Ropivacaine use as active ingredient in the block
16266295|NCT04911647|Active Comparator|The Plastic stent|Patient group with plastic stent inserted in biliary obstruction through endoscope
16266296|NCT04911647|Experimental|The metal stent|Patient group with metal stent inserted in biliary obstruction through endoscope
16266297|NCT04911621|Experimental|Stratum A (newly diagnosed)|Dendritic cell vaccination plus temozolomide-based chemoradiotherapy
16266298|NCT04911621|Experimental|Stratum B (prior treatment)|Dendritic cell vaccination plus optional conventional anti-glioma treatment (in line with standard-of-care practice, at the investigator's discretion)
16266299|NCT04911608|Experimental|cervical manipulation|"The cervical spinal manipulation will consist of one session of a standard technique that will be performed by an experienced (>10 years) doctor of physical therapy practitioner. The technique is described by Gibbons and Tehan as a high-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restrcition. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation. This type of cervical manipulation procedure is described by Gibbons and Tehan as Minimal Leverage Thrust and it results in optimal patient comfort while receiving the treatment thus reducing post-treatment soreness/pain."
16266300|NCT04911608|Experimental|cervical mobilization|The cervical spinal mobilization treatment will also consist of one session of a standard technique that will be performed by an experienced (>10 years) doctor of physical therapy practitioner. For this procedure, the participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments. The magnitude of a mobilization-or how hard the therapist pushes on the spine-is usually reported as the magnitude of force. For an oscillatory posterior-anterior (PA) mobilization technique, the maximum magnitude of applied force is usually reported as the mean of the force peaks that occur during a specified period.34 The cervical mobilization will consist of oscillations of 1Hz and magnitude forces of 30 Newtons (N) for 30 seconds, 90N for 120 seconds and 30N for 30 seconds at the localized segment.
16266301|NCT04911608|No Intervention|postural correction education|Participants will be presented with a standardized educational short video regarding the importance of postural correction movements.
16266302|NCT04911582|Active Comparator|Cafestol 6 mg|6 mg cafestol
16266303|NCT04911582|Active Comparator|Cafestol 12 mg|12 mg cafestol
16266304|NCT04911582|Placebo Comparator|Placebo|Placebo
16266305|NCT04911569|Experimental|Cryoneurolysis|All 25 patients will receive cryoneurolysis
16266306|NCT04911556|Placebo Comparator|the placebo group|A placebo made of starch
16266307|NCT04911556|Experimental|Bifidobacterium longum group 1|Bifidobacterium longum 274
16266308|NCT04911556|Experimental|Bifidobacterium longum group 2|Bifidobacterium longum 4-1
16266309|NCT04911556|Experimental|Bifidobacterium longum group 3|Bifidobacterium longum gs
16266313|NCT04911530||elderly patients (aged ≥ 65 years)|elderly patients undergo surgeries
16266315|NCT04911504||Questionnaire survey group|All nurses were recruited from 3 tertiary hospitals in central China from 3rd October, 2019 to 15th December, 2019. A total of 992 clinical nurses from different nursing departments were recruited through convenience sampling. Data were collected using General information questionnaire, the Professional Quality of Life Scale, the Connor-Davidson Resilience Scale and General Perceived Self-Efficacy Scale.
16266316|NCT04911491|Experimental|IMST|This group will perform high-resistance (75% of maximal inspiratory pressure) inspiratory muscle strength training (IMST), 30 inhalations/session, 6 days/week.
16266317|NCT04911491|Sham Comparator|Control|This group will perform low-resistance (15% of maximal inspiratory pressure) inspiratory muscle strength training, 30 inhalations/session, 6 days/week.
16266318|NCT04911478||Rollover subjects from Adicet Bio allogeneic T cell interventional studies.|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in any Adicet Bio allogeneic gamma delta T cell study.
~Patients will be followed for up to 15 years after initial dosing of Adicet Bio allogeneic gamma delta T cell investigational products."
16266319|NCT04911465||Pediatric Trauma Patients|All pediatric patients >31 days who meet criteria for highest level trauma activation (Level Red or Level 1) at the Children's Hospital Colorado.
16266320|NCT04911452|No Intervention|Control|Standard Neonatal Intensive Care Unit (NICU) care
16266321|NCT04911452|Experimental|Calmer|Calmer placed and left in infant incubator for the 3-week study period. Calmer treatment provided for minimum total of 3 hours/day (can be discontinuous).
16266322|NCT04911439|Active Comparator|Low Arousal|This group will see 25 affective images of the International Affective Picture System with low arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
16266656|NCT04908995|Experimental|EC5026|Single 8 mg oral dose of EC5026
16266323|NCT04911439|Active Comparator|Medium Arousal|This group will see 25 affective images of the International Affective Picture System with medium arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
16266324|NCT04911439|Active Comparator|High Arousal|This group will see 25 affective images of the International Affective Picture System with high arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
16266325|NCT04911426|No Intervention|Treatment as usual|Individuals in the treatment as usual condition will participate in substance use treatment as part of the standard police opioid diversion program model.
16266326|NCT04911426|Experimental|Treatment plus telehealth|Individuals in the treatment plus telehealth condition will receive telehealth support services, including seven brief motivational interviewing sessions, delivered by a licensed substance use counselor via live interactive video calls during the 12-week intervention.
16266327|NCT04911413|Experimental|low-dose group,|A bolus of 10 mg/kg Tranexamic Acid followed by a maintenance dose of 10 mg/kg/h Tranexamic Acid until the end of surgery
16266328|NCT04911413|Experimental|middle-dose group,|A bolus of 20 mg/kg Tranexamic Acid followed by a maintenance dose of 15 mg/kg/h Tranexamic Acid until the end of surgery
16266329|NCT04911413|Experimental|high-dose group|A bolus of 30 mg/kg Tranexamic Acid followed by a maintenance dose of 20 mg/kg/h Tranexamic Acid until the end of surgery
16266330|NCT04911400|Experimental|Upper-lower clear plastic retainers + Class III elastics|Upper-lower clear plastic retainers + Class III elastics
16266331|NCT04911400|Active Comparator|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
16266332|NCT04911374|Other|Anti-Aging Face Moisturizer and Eye Cream|"Dual Regimen:
~Multi-ingredient anti-aging face moisturizer
~Multi-ingredient anti-aging eye cream"
16266333|NCT04911361|Active Comparator|Topical loteprednol suspension in both eyes|25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
16266334|NCT04911361|Experimental|Lower eyelid canaliculi DEXTENZA insertion (study group)|25 subjects will be randomized to receive treatment of OTX-DED
16266335|NCT04911335|Experimental|phase 2 open intervention|All patients assisted by the palliative care center (hospice and home) will receive the oral hygiene protocol and the propolis-based product. The oral hygiene protocol will be applied starting from the day of taking care of the patient in the service and until discharge / death. Administration of the study product will be continued for 2 weeks or stopped sooner if the patient loses the ability to swallow.
16266336|NCT04911309|Active Comparator|Group 1: 12 weeks functional exercise training followed by standard therapy|"12 weeks functional exercise training twice per week, each session lasting 60 min, additionally to standard therapy. Training sessions will be performed in a group-setting consisting of minimum 4 and maximum 8 participants and coached by experienced sport scientists with the supervision of a medical doctor. The exercises will be individually pants and constantly recorded in order to allow a progression over the course of the 12 week-period. The motor tasks and exercises will be tailored to individual capacity by experienced and trained sport scientists and coaches, therefore insuring the participants' safety and a continuous and progressive monitoring of training load.
~After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks."
16266337|NCT04911309|Active Comparator|Group 2: 12 weeks standard therapy / treatment followed by 12 weeks functional exercise training|"12 weeks standard therapy / treatment; the standard therapy group receives no additional exercise sessions. After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks.
~After 12 weeks the groups will switch the intervention method. Group 2 will perform the same intervention which Group 1 received over the first course of 12 weeks."
16266338|NCT04911296|Other|Swallow Group|
16266339|NCT04911283||MCs type 1 patients (study group; n=37)|
16266340|NCT04911283||MCs type 2 patients (comparator group; n=44)|
16266341|NCT04911283||healthy controls (n=37)|
16266345|NCT04911244|Experimental|VAP group|patients confirmed diagnosis of VAP with bronchoalveolar lavage
16266346|NCT04911244|Experimental|Non VAP group|patients confirmed not VAP with bronchoalveolar lavage
16266349|NCT04911205|Experimental|Intervention Group|Patients who were randomly allocated to intervention group (N=44) completed a 6-week preoperative training program, 5 days per week prior to surgery
16266350|NCT04911205|No Intervention|Control Group|Patients who were randomly allocated to control group (N=44), they continued to live as usual, prior to surgery
16266351|NCT04911192|No Intervention|systemic thrombolysis group|patients without any contraindications for systemic fibrinolytic therapy will be treated with traditional systemic thrombolysis (intravenous administration of streptokinase).
16266352|NCT04911192|Active Comparator|mechanical fragmentation group|patients will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy.
16266394|NCT04910893|Other|Historical Comparison|Patients extracted from a septic shock population treated at the same institution between 2010 and 2018 and matched to the intervention group.
16266395|NCT04910867|No Intervention|Control Arm|No intervention will be administered. Usual care will be administered.
16266353|NCT04911192|Active Comparator|In Situ thrombolysis group|patients will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC(Swan-Ganz pulmonary artery catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
16266354|NCT04911179|Experimental|Combined multicomponent physical exercise and cognitive stimulation (Vivfrail-Cog)|"The supervised multicomponent exercise training program (resistance, endurance, balance and flexibility) will be comprised of upper and lower body exercises tailored to the individual's functional capacity. Subjects will be encouraged at performing strength and endurance exercise at a moderate intensity. Exercise will progress in terms of intensity and difficulty upon individual adaptation.
~The cognitive intervention will include the performance of different exercises with pencil and paper in order to train different cognitive areas, especially the executive functions."
16266355|NCT04911179|No Intervention|Usual care|The usual care group will receive normal outpatient care (including the evidence-based Otago exercise program).
16266356|NCT04911166|Experimental|Atezolizumab and Interleukin-12 Gene Therapy|
16266357|NCT04911153||Aim 1: Physical Activity|250 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of physical activity on cardiometabolic health among veterans with and without PTSD.
16266358|NCT04911153||Aim 2: Diet Quality|200 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of diet quality on cardiometabolic health among veterans with and without PTSD.
16266359|NCT04911153||Supplemental Aim: Instrument Validation|100 participants will be recruited to examine the validity of a self-report clinical measure of physical activity against objectively measured physical activity obtained via accelerometry.
16266360|NCT04911140|Active Comparator|Photobiomodulation twice a week|This group will receive the application of photobiomodulation (PBM) twice a week for 4 weeks.
16266361|NCT04911140|Active Comparator|Photobiomodulation three times a week|This group will receive the application of photobiomodulation (PBM) three times a week for 4 weeks.
16266362|NCT04911140|Placebo Comparator|Simulated Photobiomodulation|This group will receive the application of simulated photobiomodulation (PBM) twice a week for 4 weeks.
16266363|NCT04911127|Placebo Comparator|Placebo|Participants will receive capsules containing medium chain triglyceride (MCT) oil
16266364|NCT04911127|Experimental|200mg CBD twice daily|
16266365|NCT04911127|Experimental|400 mg CBD twice daily|
16266366|NCT04911114|Experimental|Intervention Arm|This is a single arm pilot study of group base exercise
16266367|NCT04911101|Experimental|7G needle|7G needle dimension used
16266368|NCT04911101|Experimental|10G needle|10G needle dimension used
16266369|NCT04911088||Analgesic calibration|Participants will receive calibration of electromyography at state entropy of 90.
16266370|NCT04911088||Sedated calibration|Calibration will be started at state entropy of 70.
16266371|NCT04911088||No calibration|Participants will not receive calibration of electromyography. Measurements will start simultaneously to the standard electromyography with a default current of 50mA at state entropy of 50.
16266372|NCT04911075|Experimental|85% TCA Group|"Participants are subject who will undergo an elective total hysterectomy procedure for indications of gynecological organ abnormalities, whether benign, pre-cancerous, or malignant other than cervical pathology.
~The 85 percent TCA solution will be applied to participants cervical tissue 24 hours before surgery."
16266373|NCT04911062|Experimental|Cohort 1: Bupivacaine HCl|Bupivacaine HCl without epinephrine, via injection into the surgical site.
16266374|NCT04911062|Experimental|Cohort 2: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
16266375|NCT04911062|Experimental|Cohort 3 (optional): HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
16266376|NCT04911036||Mothers and/or fathers with an antenatal diagnosis|
16266377|NCT04911036||Mothers and/or fathers with a postnatal diagnosis|
16266378|NCT04911023||Patients operated by fissurectomy|
16266379|NCT04911023||Patients operated by fissurectomy with anoplasty|
16266380|NCT04911010|Experimental|Experimental: Prolonged Exposure + Treatment as usual|"Participants in this arm will receive 16 weekly sessions with Prolonged Exposure Therapy (RT) over 4 months in addition to their treatment as usual.
~Interventions:
~Behavioral: Prolonged Exposure Therapy Other: Treatment as usual"
16266381|NCT04911010|No Intervention|Waiting-Controll-Group|"Treatment as usual Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally.
~Intervention: Other: Treatment as usual"
16266382|NCT04910997|Experimental|HRV Group|Heart rate variability training group
16266383|NCT04910997|Active Comparator|Traditional Exercise Group|Traditional (e.g. standard) exercise training
16266384|NCT04910997|No Intervention|Control Group|Usual care
16266385|NCT04910984|Experimental|Chatbot group|
16266386|NCT04910984|Placebo Comparator|TAU group|
16266387|NCT04910971||Group 1: Recipients of BNT162b2 mRNA Covid-19 Vaccine|
16266388|NCT04910971||Group 2: Recipients of mRNA-1273 SARS-CoV-2 Vaccine|
16266389|NCT04910932|Experimental|Breathing Exercises group|Breathing exercises will be applied via teleconference by a physiotherapist 1 day a week. Individuals will perform exercises by themselves at their homes on the remaining 6 days of the week. Exercise program will be applied for 4 weeks. Individuals will also be informed about COVID-19 for once at baseline.
16266390|NCT04910932|Other|Control group|Individuals will be informed about COVID-19 for once at baseline.
16266399|NCT04910815|Experimental|Primary recruitment|Capsules will be ingested within 30 minutes prior to endoscopy pre- and post-antimicrobial intervention (if the patients has had a treatment) to determine if it can be used to identify increased microbial load through gas detection, and to identify responders to therapy.
16266400|NCT04910815|Active Comparator|Active SIBO Arm - Rifaximin|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of Rifaximin (550g) 1 capsule twice a day for 14 days. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.
~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
16266401|NCT04910815|Placebo Comparator|Active SIBO Arm - Placebo|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of placebo capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.
~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
16266402|NCT04910802|Experimental|HPV-vaccination|Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.
16266403|NCT04910789|Experimental|Thoracoabdominal approach|Radical surgery should be finished via Thoracoabdominal approach.
16266404|NCT04910789|Active Comparator|Transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach.
16266405|NCT04910776|Experimental|Avalglucosidase alfa|Administered intravenously every 2 weeks
16266406|NCT04910763|Experimental|Resistance Exercise|Resistance exercise will be training all major muscle groups 2x/week (2 days upper body, 2 days lower body) at 40-50% 1 repetition max (RM; estimated from 10 RM baseline testing) for 3 sets of 10-12 reps. This equals 4x/week for the 3 week intervention period.
16266410|NCT04910724|Experimental|20% Energy Deficit|Energy Deficit equal to 20% total daily energy requirements.
16266411|NCT04910724|Experimental|40% Energy Deficit|Energy Deficit equal to 40% total daily energy requirements.
16266412|NCT04910724|Experimental|60% Energy Deficit|Energy Deficit equal to 60% total daily energy requirements.
16266413|NCT04910711|Active Comparator|DTG/LNG|Receiving dolutegravir-based antiretroviral therapy and initiating the levonorgestrel implant
16266414|NCT04910711|Other|NEG/LNG|HIV negative, not receiving antiretroviral therapy and initiating the levonorgestrel implant
16266415|NCT04910711|Active Comparator|DTG/MPA|Receiving dolutegravir-based antiretroviral therapy and the depot medroxyprogesterone acetate injection
16266416|NCT04910711|Other|NEG/MPA|HIV negative, not receiving antiretroviral therapy and receiving the depot medroxyprogesterone acetate injection
16266417|NCT04910698||Short course treatment|Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
16266418|NCT04910698||Long course treatment|Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
16266419|NCT04910685|Experimental|(Part 1) BLU-263 Dose 1 + BSC|Patients will receive best supportive care (BSC) and Dose 1 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
16266420|NCT04910685|Experimental|(Part 1) BLU-263 Dose 2 + BSC|Patients will receive best supportive care (BSC) and Dose 2 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
16266421|NCT04910685|Experimental|(Part 1) BLU-263 Dose 3 + BSC|Patients will receive best supportive care (BSC) and Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
16266422|NCT04910685|Placebo Comparator|(Part 1) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily until completion of Part 1
16266423|NCT04910685|Experimental|(Part 2) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for approximately 24 weeks
16266424|NCT04910685|Placebo Comparator|(Part 2) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily once daily for approximately 24 weeks
16266425|NCT04910685|Experimental|(Part 3) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablet in an open-label fashion for up to 5 years.
16266426|NCT04910685|Experimental|(Part M) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for the duration of participation in the study.
16266657|NCT04908995|Placebo Comparator|Placebo|Single dose of matching oral placebo
16266427|NCT04910685|Experimental|Optional PK Groups (Dose 2 or RD)|Patients will receive best supportive care (BSC) and Dose 2 or the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally for the duration of participation in the study.
16266428|NCT04910672|Active Comparator|Control Group|The control group (n = 30) will only carry out a bilateral global pelvic manipulation
16266429|NCT04910672|Experimental|Experimental Group|The experimental group (n = 30) will be treated following an osteopathic treatment, through a bilateral global pelvic manipulation and a specific internal technique for mobility of the cervix
16266430|NCT04910659|Active Comparator|acupuncture|Group1, laser acupuncture was applied to each of the previously described P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds
16266431|NCT04910659|Sham Comparator|false acupuncture|P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds while laser acupuncture closed
16266432|NCT04910646|Experimental|orange peel fermentation|
16266433|NCT04910646|Placebo Comparator|placebo|
16266434|NCT04910633||Solid Tumor and COVID-19|Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.
16266435|NCT04910620|Placebo Comparator|Placebo|Placebo without TCI378 and TCI507
16266436|NCT04910620|Experimental|TCI378|probiotics TCI378 (Lactobacillus plantarum TCI378)
16266437|NCT04910620|Experimental|TCI507|TCI507 (Lactobacillus plantarum TCI507)
16266438|NCT04910607||Patient|Participating patients will be recruited from the Specialised Obesity Centres =CSO (CHU and Follow-up and rehabilitation care (SSR), as well as patient associations) to fill in a questionnaire and take part in an interview (varied panel representative of the target population in terms of place of residence, socio-professional category, sex and age).
16266439|NCT04910607||Professional|Medical and paramedical staff involved in the partner CSOs will also be asked to participate in a semi-structured interview.
16266440|NCT04910581|Active Comparator|Experimental stimulation|Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
16266441|NCT04910581|Placebo Comparator|Sham stimulation|Patients receive a treatment of rTMS using placebo coil (MCF P B65 coil) for 30 minutes at 1Hz (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
16266443|NCT04910555||women over 65 years old with OAB|Community-dwelling women over 65 years old, with non-neurogenic OAB, with or without UI
16266444|NCT04910542|Other|EpI-Net community intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
16266445|NCT04910529|Experimental|Yoga group|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students. This application includes the most basic yoga exercises and does not pose any health risks for practitioners. During the yoga practice in the online environment, the cameras of the students in the yoga group will be turned on and the researcher who has the application will be able to see each student. Yoga will be applied to this group twice a week for 60 minutes each for three menstrual cycles (12 weeks).
16266446|NCT04910529|No Intervention|Control group|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
16266447|NCT04910516|No Intervention|Control Group|The nurses in the control group were informed about the purpose of working in a quiet room. STAI-D, STAI-S, SUD, P19-S scales were filled face-to-face by the investigator after their informed consent was obtained. The scales were filled again by the researcher after a break of 7 (seven) days.
16266448|NCT04910516|Experimental|Experiment Group|In order to avoid bias in the intervention applied in our study, the experimental group was started after the control group was finished. The participants were informed about the purpose of working face-to-face in a quiet room so that EFT, which will be applied online for 7 (seven) days by the researcher, can be applied effectively and accurately. STAI-D, STAI-S, SUD, P19-S scales were completed after their consent was obtained. The researcher, who has the EFT certificate, first showed the application steps on himself with the guidance of the EFT guideline, and ensured that the application steps were applied again simultaneously on both himself and the participant. After this application, it was provided to make EFT online for 7 (seven) days. STAI-D, STAI-S, SUD, P19-S scales were filled in after the last EFT application.
16266449|NCT04910503|Active Comparator|Usual strategy|
16266450|NCT04910503|Experimental|Innovative strategy|
16266451|NCT04910490||Patients received stereotaxic aspiration|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
16266452|NCT04910490||Patients received conservative therapy|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
16266453|NCT04910477|Experimental|Dexmedetomidine|Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
16266454|NCT04910477|Experimental|Neostigmine/atropine|Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
16266455|NCT04910477|Placebo Comparator|Saline placebo|Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.
16266456|NCT04910464|Experimental|Tranexamic acid|Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.
16266457|NCT04910464|Placebo Comparator|Saline placebo|Give the same volume (100 ml normal saline) and same duration (first three days).
16266458|NCT04910425|Experimental|Diagnostic (18F-DCFPyL PET/MRI, mpMRI)|Patients receive fluorine F 18 DCFPyL IV and undergo PET/MRI. Patients also receive either gadobutrol IV or gadobenate dimeglumine IV (per radiologist preference), and undergo mpMRI. Within approximately 60 days after PET/MRI and mpMRI, patients undergo TRUS guided prostate biopsy per standard of care.
16266459|NCT04910412|Experimental|Anodal tDCS with gait training|Anodal tDCS will be applied over the primary motor cortex (M1) (anodal or active electrode on M1 area, cathodal or reference electrode on supraorbital area) for 20 mins with 2 mA intensity before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
16266460|NCT04910412|Active Comparator|Sham tDCS with gait training|Sham tDCS will be applied over the primary motor cortex for 20mins before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
16266461|NCT04910399|Experimental|Blue fish hydrolysate|The test product is a food supplement named BrainBooster in our project. It is presented as a capsule containing a blue fish hydrolysate, containing peptides and n-3 polyunsaturated fatty acids.
16266462|NCT04910399|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
16266463|NCT04910386|Experimental|Envafolimb|"Envafolimab plus Gemcitabine&Cisplatin Envafolimab: 300 mg on Day 1 of each cycle, subcutaneous injection. Every 21 days is a treatment cycle.
~Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.
~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
16266464|NCT04910386|Active Comparator|Gemcitabine&Cisplatin|"Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.
~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
16266465|NCT04910373|Experimental|Experimental Extensively Hydrolyzed Formula|Administered during food challenge and at home feeding period
16266466|NCT04910373|Placebo Comparator|Placebo Extensively Hydrolyzed Formula|Administered during food challenge
16266467|NCT04910360||ICU patients with severe COVID-19 pneumonia|Without using any intervention, this group has been included in the study to research certain genetic dispositions determining the severity of the COVID-19 pneumonia
16266468|NCT04910360||Random population|This group has been included as a control group to compare the genetic predisposition of ICU patients with severe COVID-19 pneumonia with the normal population.
16266469|NCT04910347|Experimental|Single Arm|Nivolumab
16266470|NCT04910308|Experimental|Dose painting|Dose painting
16266471|NCT04910282||Eye Disease Patients|Patients with eye diseases age 65 and above will be included. Patients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person, based on inclusion and exclusion criteria.
16266472|NCT04910269|Experimental|Treatment Group|Participants in this group will receive the investigational treatment in addition to standard of care.
16266473|NCT04910269|Placebo Comparator|Placebo Group|Participants in this group will receive a placebo in addition to standard of care.
16266474|NCT04910256|Experimental|HuaTuo ZaiZao group|"In this arm, patients take 8g of HuatuoZaizao pill three times a day. Besides，participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
16266475|NCT04910256|Active Comparator|Control group|"participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
16266478|NCT04910230|Experimental|nicotinamide plus usual care|
16266479|NCT04910230|No Intervention|usual care|
16266480|NCT04910217|Experimental|Lokomat intervention|Patients randomized into the Lokomat arm will undergo therapy with Lokomat Pro FreeD for 20-50 minutes 5-times a week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.
16266481|NCT04910217|Experimental|Leg/lower body exerciser|Patients in this arm will undergo therapy with leg/lower body exerciser for 20-50 minutes, 5 times per week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.
16266482|NCT04910204|Experimental|Early FEST + TST|Participants will receive FEST+TST at 3 to 6 months from SCI onset.
16266483|NCT04910204|Experimental|Delayed FEST + TST|Participants will receive FEST+TST at 6 to 9 months from SCI onset.
16266484|NCT04910191|Experimental|Open Label|"Up to 200 patients will participate in this open study. Before each examination with the study device, data from each patient (Current medical condition, medical history and demographic data) will be inserted to a computer and added to the database of the study for further processing in conjunction with the study device results.
~The study device electronic stethoscope membrane will be put on the patient's chest area in predefined anterior and posterior points. At the end of each examination the data will be transferred to a computer and stored in the patient's file. Each patient will be requested to attend the examination once."
16266485|NCT04910178|Experimental|Empa group|patients will be given Empagliflozin 25 mg once daily
16266486|NCT04910178|Experimental|PTX group|patients will be given PTX 400 mg twice daily or 3 times daily
16266487|NCT04910178|Experimental|UDCA group|patients will be given UDCA 500 mg twice daily
16266488|NCT04910178|Placebo Comparator|Placebo|patients will be given a placebo
16266489|NCT04910165|Experimental|Exparel|Liposomal Bupivacaine use as active ingredient in the block
16266491|NCT04910152|Experimental|Treatment for aGVHD (BRD4 inhibitor PLX51107)|Patients receive BRD4 inhibitor PLX51107 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16266492|NCT04910139|Experimental|Treatment|Treatment using acoustic energy
16266493|NCT04910126|Experimental|experiment group|adriamycin and Camrelizumab
16266494|NCT04910126|Active Comparator|control group|adriamycin
16266495|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 1 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
16266496|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
16266497|NCT04910100|Experimental|Timolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
16266498|NCT04910100|Active Comparator|Timolol Ophthalmic Solution 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
16266499|NCT04910087|Active Comparator|Group K: Ketofol|"A ketofol mixture of 15 cc propofol 2%, 2 cc ketamine 50 mg/ml, and 13 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through perfuser device. (at a ratio of 100 mg ketamine/300 mg propofol) After the loading dose is administered at 1 mg/kg IV in 5 minutes based on propofol, 0.5 cc/kg/hour ketofol infusion will be initiated.
~If patients cannot tolerate the ERCP procedure or have a BIS value >85 or FPS (Faces Pain Scale)> 3, 0.25 mg/kg propofol will be administered as a separate IV push."
16266500|NCT04910087|Active Comparator|Group P: Propofol|"A propofol mixture of 15 cc propofol 2% and 15 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through the perfuser device.
~After the loading dose is administered at 1 mg/kg IV propofol in 5 minutes ,0.5 cc/kg/hour propofol infusion will be initiated.
~If patients cannot tolerate the ERCP procedure or have a BIS value >85 or FPS (Faces Pain Scale)> 3, 0.25 mg/kg propofol will be administered as a separate IV push"
16266501|NCT04910074|Experimental|Low-level therapy intervention|Patients will receive low-level laser therapy on the skin overlying the mandible for 40 seconds per side. All other post-operative care will be as per clinic routine.
16266502|NCT04910074|Placebo Comparator|dummy intervention|Patients will receive no dose of laser, but the handpiece will be used against their skin top mimic the LLLT. All other post-operative care will be as per clinic routine.
16266503|NCT04910061|Experimental|NMN-C|Healthy individuals receiving NMN-C
16266504|NCT04910048|Active Comparator|Standard of Care|The first arm consists of UAMS standard of care (SOC), including providing a brochure with information (contact information, brief educational information) for the patient to consult with a nutritionist to help with self-directed weight loss.
16266505|NCT04910048|Experimental|Intervention (POPOP)|The second arm is a specified 2-month POPOP focused on weight loss administered by the external partner, 20Lighter. The program includes customized meal plans; vitamin, mineral and nutritional supplementation; and daily engagement via a smartphone app with a 20Lighter health care provider. Video conferencing appointments will occur approximately every 3 weeks. The program does not require any exercise or physical engagement but does necessitate that patients have a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection. During the first 40 days the customized meal plans are adhered to, then from days 41-60 patients will transition back to a normal dietary lifestyle via a customized plan based on considerations including, food preferences, physical engagement and height.
16266506|NCT04910035|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
16266507|NCT04910035|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
16266508|NCT04910022|Experimental|Phase 1_Dose escalation and MTD expansion cohort|Patients with diffuse gliomas
16266509|NCT04910022|Experimental|Phase 1_Glioblastoma expansion cohort|Patients with IDH wild type recurrent glioblastoma
16266510|NCT04910022|Experimental|Phase 2_Arm A_NMS-03305293+TMZ|Patients with IDH wild type recurrent glioblastoma
16266511|NCT04910022|Active Comparator|Phase 2_Arm B_Lomustine|Patients with IDH wild type recurrent glioblastoma
16266512|NCT04910009|No Intervention|Theoretical training group|Students participating in only theoretical training of the privacy education for two 40-minute sessions.
16266513|NCT04910009|Experimental|Digital story and ethical case analysis group|Students participating in 2 sessions of 40-minute theoretical training and then participating in 4 sessions of 60-minute digital story and ethical case analysis preparation and presentation.
16266514|NCT04910009|Experimental|Only ethical case analysis group|Students participating in 2 sessions of 40 minutes of theoretical training and then participating in 4 sessions of 60-minute ethical case analysis preparation and presentation only.
16266515|NCT04909996|Experimental|Group A: Sentinox treatment performed 3 times/day for 5 days (as add-on to the standard therapy)|
16266516|NCT04909996|Experimental|Group B: Sentinox treatment performed 5 times/day for 5 days (as add-on to the standard therapy)|
16266517|NCT04909996|No Intervention|Group C: no Sentinox treatment; only the standard therapy will be performed|
16266518|NCT04909983|Experimental|Intervention|Medical Device, an occlusive patch for 3 days.
16266519|NCT04909983|Active Comparator|Control|Standard of Care
16266520|NCT04909970|Experimental|Self hypnosis|Self-hypnosis program associated to usual practice of stress management
16266521|NCT04909970|Other|control group (waiting list)|Usual practice of stress management. This group will practice self-hypnosis after the intervention group has practiced self-hypnosis (waiting list).
16266522|NCT04909957||Absence of invaded lymph node after extensive lymph node dissection|Absence of invaded lymph node after extensive lymph node dissection
16266523|NCT04909957||Presence of invaded lymph node after extensive lymph node dissection|Presence of invaded lymph node after extensive lymph node dissection
16266524|NCT04909944|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation and ventilation
16266525|NCT04909944|Experimental|laryngeal tube suction disposable supraglottic insertion for oxygenation|laryngeal tube suction disposable insertion for oxygenation and ventilation
16266526|NCT04909931|Experimental|vitamin D supplementation group|First arm ; add on vitamin D 40,000 IU/week for 12 weeks
16266527|NCT04909931|Experimental|second arm|add on placebo
16266528|NCT04909918|Experimental|(Group D )Dexamethasone|Intravenous dexamethasone 8 mg/day given for 7 days
16266529|NCT04909918|Experimental|(Group M) methylprednisolone|Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
16266530|NCT04909905|Experimental|Group EN (standard enteral nutrition)|Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission
16266531|NCT04909905|Experimental|Group GN (glutamine supplemented enteral nutrition)|Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.
16266532|NCT04909892|Experimental|COVI-MSC 1 vial|Subjects will receive intravenous infusions of COVI-MSC (one vial, ~18.5 million cells) on Day 0, Day 2, and Day 4.
16266533|NCT04909892|Experimental|COVI-MSC 2 vials|Subjects will receive intravenous infusions of COVI-MSC (two vials, ~37 million cells) on Day 0, Day 2, and Day 4.
16266534|NCT04909879|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
16266535|NCT04909879|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
16266536|NCT04909866|Experimental|TACE+Lenvatinib+Camrelizumab|
16266537|NCT04909853|Experimental|PF-07321332|PF 07321332/ritonavir
16266538|NCT04909840|Experimental|dental floss|Instructions of oral hygiene with toothbrush plus dental floss
16266539|NCT04909840|Active Comparator|without dental floss|Individuals who will use only toothbrush
16266540|NCT04909827|Experimental|group A|3D printed microfilled hybrid composite Endocrowns
16266541|NCT04909827|Experimental|group B|prefabricated zirconia crowns
16266542|NCT04909814||Vaccinated women with positive screening test|All women in one Swedish county taking their first screening test within the organized cervical screening program
16266543|NCT04909801|Experimental|Arm 1: Abatacept + Methotrexate|
16266544|NCT04909801|Experimental|Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate)|
16266545|NCT04909788||Healthy adults with regular exercise|Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km).
16266546|NCT04909775|Experimental|Arm 1|Patients will receive 4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before cystectomy discussion. The patients reach clinical complete remission will receive tislelizumab maintenance therapy for a year or 13 cycles.
16266547|NCT04909762|Other|Early rehabilitation and mobilisation|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package, provided by health care professionals from multiple disciplines and parents/carers within intensive care settings to promote recovery, both physical (e.g. movement, functional activities, ambulation) and non-physical (e.g. speech, play, psychological, cognitive). In adult intensive care, ERM has been shown in clinical trials to improve long term physical functioning and return to independence. It can also shorten the length of ventilation and stay in intensive care and hospital with significant economic benefit.
16266548|NCT04909749|Experimental|PGx-guided antidepressant therapy|These individuals will be prescribed medication guided by the Oneome RightMed Test.
16266549|NCT04909749|No Intervention|Treat as usual based on Clinical Physician Recommendation|These individuals will receiving medication as usual based on the clinics internal guidelines and physician recommendations.
16266550|NCT04909736|Experimental|Music Exposure|Patient will listen to a specified duration of music.
16266559|NCT04909710|Experimental|Autism Case Group|Autistic participants will receive mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
16266560|NCT04909710|Other|Neurotypical Sibling Control Group|Neurotypical control participants will receive the same mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
16266561|NCT04909697|Sham Comparator|Saline|
16266562|NCT04909697|Experimental|Sivelestat Sodium|
16266563|NCT04909684|No Intervention|Standard of care|100% pembrolizumab
16266564|NCT04909684|Experimental|Intervention|75% pembrolizumab
16266565|NCT04909671|Active Comparator|CAD arm|Patients allocated to CAD arm will receive during colonoscopy withdrawal high definition white light endoscopy aided with artificial intelligence device (Gi Genius, Medtronic)
16266566|NCT04909671|Placebo Comparator|WLE arm|Patients allocated to WLE arm will receive during colonoscopy withdrawal high definition white light endoscopy as standart of care.
16266567|NCT04909658|Experimental|ACT matrix protocol|Parents of childrens with Autism Spectrum Disorders (ASD). The ACT protocol group received exercises to improve the psychological well-being of the parents.
16266568|NCT04909658|Active Comparator|PT protocol|Parents of childrens with Autism Spectrum Disorders (ASD).
16266569|NCT04909645|Experimental|Clearsight (finger cuff)|
16266570|NCT04909632|Experimental|To establish metabolite pattern and biomarkers of tongue fur in DM|
16266995|NCT04906798|Experimental|Sequence2|"Period 1: Test drug(CKD-385)
~Period 2: Reference drug(D744)"
16266571|NCT04909619|Experimental|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|Patients randomized to this arm will receive an ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg of 0.2% ropivacaine per side, for a total of 0.3 ml/kg immediately after induction of general anesthesia and prior to incision. Participants will also receive local infiltration of the palate with an equivalent injection volume of 0.9% saline with 1:400,000 epinephrine at 2 ml/kg. Pediatric anesthesiologists with fellowship training in regional anesthesia will perform the nerve block. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
16266572|NCT04909619|Active Comparator|Local anesthetic infiltration of the palate|Patients randomized to this arm will receive local infiltration of the palate using 0.125% bupivacaine + 1:400,000 epinephrine at a dose of 2 ml/kg intraoperatively. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
16266573|NCT04909606|Experimental|Nurse-led prevention program|Patients will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
16266574|NCT04909606|Active Comparator|Standard of care|Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)
16266575|NCT04909593|Experimental|Spinal Cord Stimulation|SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.
16266576|NCT04909580|Experimental|decision coaching|Decision coaching with a patient decision aid guided by the Ottawa Decision Support Framework
16266577|NCT04909567|Experimental|Intervention arm|"Optimisation:
~Diet, organised exercise, psychosocial support"
16266578|NCT04909567|No Intervention|Control arm|Current standard preparation before surgery
16266579|NCT04909541||Patient with ureteral stent|Patients with ureteral stent that meet the inclusion, exclusion criteria complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
16266580|NCT04909528|Experimental|Experimental Group|Low-level tragus stimulation
16266581|NCT04909528|Sham Comparator|Control Group|Sham stimulation
16266582|NCT04909515|Experimental|naxitamab + GM-CSF + isotretinoin|8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
16266583|NCT04909502|Experimental|EHP-101 Once a day (OD)|
16266584|NCT04909502|Experimental|EHP-101 Twice a day (BID)|
16266585|NCT04909489||PDR group|Phlegm-Dampness Retention syndrome group
16266586|NCT04909489||SKYD group|Spleen and Kidney Yang Deficiency syndrome group
16266587|NCT04909489||NC group|Normal Control group
16266588|NCT04909476||Severe COVID pneumonia with ET|Severe COVID 19 pneumonia undergoing endotracheal intubation
16266589|NCT04909463|No Intervention|Unilateral rib fractures only, no device intervention|Unilateral rib fractures only, no device intervention
16266590|NCT04909463|Experimental|Unilateral rib fractures, device intervention|Unilateral rib fractures, will receive device intervention
16266591|NCT04909463|No Intervention|Bilateral rib fractures, no device intervention|Bilateral rib fractures, no device intervention
16266592|NCT04909463|Experimental|Bilateral rib fractures, device intervention|Bilateral rib fractures, will receive device intervention
16266593|NCT04909450|Experimental|CSB-001 Investigational Treatment Arm|One drop CSB-001 four times daily for 8 weeks in the study eye
16266594|NCT04909450|Placebo Comparator|Vehicle Control Arm|One drop matching vehicle four times daily for 8 weeks in the study eye
16266595|NCT04909437|Experimental|Mycobiotic group|
16266596|NCT04909437|Placebo Comparator|Placebo group|
16266597|NCT04909411|Other|Exposed arm|child infected with chikungunya virus during childbirth
16266598|NCT04909411|Other|Non-exposed arm|child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified
16266599|NCT04909398|Experimental|Dynamic pupillometry sessions|"It is planned to include 60 participants divided into different groups:
~15 healthy subjects, called controls.
~15 patients with retinitis pigmentosa.
~15 patients with Leber's hereditary optic neuropathy.
~15 patients with Stargardt's disease."
16266600|NCT04909385||Bronchoalveolar lavage (BAL) samples for pulmonary TB|
16266601|NCT04909385||(EBUS-TBNA) samples for mediastinal TB|
16266602|NCT04909372|No Intervention|No labelling|Food products without any label in the virtual supermarket.
16266603|NCT04909372|Experimental|Environmental labelling|Food products with an environmental label in the virtual supermarket.
16266604|NCT04909359||Crohn's disease (CD)|People with CD recently receiving vedolizumab as standard of care will be followed up to 5 years.
16266605|NCT04909359||Ulcerative colitis (UC)|People with UC recently receiving vedolizumab as standard of care will be followed up to 5 years.
16266606|NCT04909333|Experimental|Group A (EHH Patients)|Group A will receive a placebo injection (0.9% saline solution) on Day 1 and 10μg Exenatide injection on Day 2.
16266607|NCT04909333|Experimental|Group B (EHH Patients)|Group B will receive a 10μg Exenatide injection on Day 1 and placebo injection (0.9% saline solution) on Day 2.
16266608|NCT04909320|Experimental|Intervention group|
16266609|NCT04909320|Active Comparator|Control group|
16266610|NCT04909294|Experimental|stereotaxic external radiation therapy|
16266611|NCT04909281||Long-term non-attenders in the cervical screening program|All women who had not attended tthe cervical screening program in Sweden for at least 10 years were eligeble.
16266612|NCT04909268||Patients with positive pneumococcal antigenuria|
16266613|NCT04909255|Active Comparator|Antimuscarinic|oxybutynin, tolterodine, solifenacin
16266614|NCT04909255|Experimental|B3-agonist|mirabegron
16266615|NCT04909242|Experimental|single oral dose of DZD9008|single dose of DZD9008 (50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
16266616|NCT04909242|Placebo Comparator|single oral dose of placebo|single dose of placebo (matching placebo, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
16266617|NCT04909229|Experimental|PEAR-003b PDT Intervention|Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
16266618|NCT04909229|Placebo Comparator|Control Arm|Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
16266619|NCT04909216|Experimental|Mindful Attention Workshop|50 participants will be randomized to the Mindful Attention Training (MAT) workshop. The 90-minute workshop will be conducted in group, online format.
16266620|NCT04909216|No Intervention|Waitlist Control|"50 participants will be randomized to the waitlist control condition (as usual condition)."
16266621|NCT04909203|Experimental|iKinnect2.0|Parent-Youth dyads assigned to the iKinnect2.0 condition will be given access to the iKinnect2.0 app that has been developed for this study. Parent and youth will be asked to download the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
16266622|NCT04909203|Placebo Comparator|Attention-Control Placebo App & Supporting Materials|Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.
16266623|NCT04909190|No Intervention|1xIFU|Subjects in this arm are randomized to have a saline flush volume according to the IFU of the used device.
16266624|NCT04909190|Experimental|4xIFU|Subjects in this arm are randomized to have a saline flush volume of 4x of what is stated in the IFU of the used device.
16266625|NCT04909177|Experimental|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
16266626|NCT04909177|No Intervention|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
16266627|NCT04909164||Immunotherapy group|Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
16266628|NCT04909164||Cytotoxic chemotherapy group|Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
16266629|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.5km/h|
16266630|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.8km/h|
16266631|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 1.1km/h|
16266632|NCT04909138|Active Comparator|DRG stimulation therapy at 20 Hz and 30 seconds ON, 90 seconds OFF|
16266633|NCT04909138|Active Comparator|DRG stimulation therapy at 5 Hz and 30 seconds ON, 90 seconds OFF|
16266634|NCT04909125|Active Comparator|Hypofractionation Arm|40Gy / 15 fractions, 2.67Gy per fraction, over 3.5 week (9 fractions per fortnight)
16266635|NCT04909125|Other|Standard /Conventional fractionation Arm|50Gy / 25 fractions, 2Gy per fraction, over 5.5 week (9 fractions per fortnight)
16266636|NCT04909112|Other|group 1: patients with Sjogren's syndrome|Patients with Sjogren's syndrome
16266637|NCT04909112|Other|group 2: patients without sicca syndrome|Patients without sicca syndrome
16266639|NCT04909086|Active Comparator|Standard Physical Therapy|Control group for the study.
16266640|NCT04909086|Experimental|Open Kinetic Chain|Standard care in addition to open kinetic chain exercises for the knee joint muscles.
16266641|NCT04909086|Experimental|Closed Kinetic Chain|Standard care in addition to closed kinetic chain exercises for the knee joint muscles.
16266642|NCT04909073||Afatinib 30 mg daily|Oral afatinib 30 mg tablet once daily, continuously
16266643|NCT04909047|Experimental|Parasacral transcutaneous electrostimulation outpatient|electrostimulation device
16266644|NCT04909047|Experimental|transcutaneous tibial electrostimulation outpatient|electrostimulation device
16266645|NCT04909047|Experimental|home parasacral electrostimulation|electrostimulation device
16266646|NCT04909034|Experimental|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 48 weeks.
16266647|NCT04909034|Placebo Comparator|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 48 weeks.
16266648|NCT04909021|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1
16266649|NCT04909021|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2
16266650|NCT04909021|Experimental|Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3
16266651|NCT04909021|Experimental|Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3 followed by a second identical dose of the investigational RSV vaccine 28 days later
16266652|NCT04909021|Placebo Comparator|Placebo (Single-dose)|Participants in this arm will receive a single intranasal dose of placebo
16266653|NCT04909021|Placebo Comparator|Placebo (Two-dose)|Participants in this arm will receive a single intranasal dose of placebo followed by a second identical dose of placebo 28 days later
16266654|NCT04909008|Experimental|Exercise Training|Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
16266655|NCT04909008|No Intervention|Control Groups|Two sets of exercise testing while continuing with standard medical care in between.
16266658|NCT04908982|Experimental|Aspirin|Participants in this arm will be instructed to take 1 81mg aspirin daily beginning between weeks 12 and 16 of pregnancy and continuing until delivery.
16266659|NCT04908982|No Intervention|No Aspirin|Participants in this arm will receive no aspirin.
16266661|NCT04908943|Experimental|Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)|RENEW was created by researchers, doctors, and patients with scleroderma. It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
16266662|NCT04908943|No Intervention|Waitlist|Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
16266663|NCT04908917|Experimental|PAC with HEPA|Intervention group (N=100) to use a portable air cleaner (with a HEPA filter in PAC)
16266664|NCT04908917|Sham Comparator|PAC without HEPA|control group (N=100) with a sham portable air cleaner (no HEPA filter in PAC)
16266667|NCT04908891|Experimental|persons with Multiple Sclerosis|
16266668|NCT04908891|Active Comparator|Healthy controls|
16266669|NCT04908891|Active Comparator|Stroke Patients|
16266670|NCT04908878|Experimental|Group I (pectoral nerve (PECS) block -transversus thoracic plane (TTP) block group)|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
16266671|NCT04908878|Experimental|Group II (serratus anterior plane (SAP) block group)|Patients will receive US-guided SAP block after induction of general anesthesia.
16266672|NCT04908865|Experimental|Pediatric participants receiving belimumab|
16266673|NCT04908852||Cohort 1|This is a prospective, longitudinal, observational exploratory study. Ten subjects will be enrolled and will complete baseline and week 4 blood draws and symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
16266674|NCT04908839||case: patient with otosclerosis|Diagnosis of otosclerosis with indication for primary stapedial surgery by the combination of arguments
16266675|NCT04908839||case: otosclerosis patient with surgery|otosclerosis patient with surgery
16266676|NCT04908839||controle: Absence of known otological pathology|Absence of known otological pathology
16266677|NCT04908826|Active Comparator|Group A (standard cholangiography during surgery)|All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
16266678|NCT04908826|Active Comparator|Group B (cholangiography with iv administration of icg prior to surgery)|All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
16266679|NCT04908826|Active Comparator|Group C (cholangiography with direct administration of icg to the bile duct system during surgery)|All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
16266680|NCT04908813|Experimental|HLX22(25mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 25mg/kg HLX22 IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
16266681|NCT04908813|Experimental|HLX22(15mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 15mg/kg HLX22 IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
16266682|NCT04908813|Active Comparator|Placebo +Trastuzumab + Chemotherapy (XELOX)|Participants receive placebo IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
16266683|NCT04908800|Experimental|Part A single ascending dose (SAD) and Part B multiple ascending dose (MAD): KRP-A218|Administration Route: Oral
16266684|NCT04908800|Placebo Comparator|Part A (SAD) and Part B (MAD): Placebo|Administration Route: Oral
16266685|NCT04908800|Experimental|Part C drug-drug interaction (DDI): KRP-A218 and itraconazole|Administration Route: Oral
16266686|NCT04908787|Experimental|BD0801+chemotherapy|BD0801 is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
16266687|NCT04908787|Placebo Comparator|Placebo+chemotherapy|Placebo is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
16266688|NCT04908774|Experimental|Fasting Mimicking Diet Group|The intervention group follows a fasting mimicking diet for 5 days every 6-8 weeks (a total of 3 times in 5 months).
16266689|NCT04908774|No Intervention|Control Group|This group maintains their individual diet during the whole time of the study. After 6 months they are offered a fasting intervention.
16266690|NCT04908761|Experimental|Transmuscular quadratus lumborum block group|Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
16266691|NCT04908761|Placebo Comparator|Control group|For patients assigned to the control group, 30cc of 0.9% normal saline is used for Transmuscular Quadratus Lumborum block.
16266692|NCT04908748|Experimental|Active Arm|Esflurbiprofen Hydrogel Patch containing 165 mg Esflurbiprofen
16266693|NCT04908748|Placebo Comparator|Control Drug|Placebo patch that does not contain the active ingredient but is otherwise indistinguishable from the investigational drug Esflurbiprofen Hydrogel Patch
16266694|NCT04908735|Experimental|Ruxolitinib Treatment|
16294167|NCT04716673|Experimental|Healthy children (4-11y)|
16266701|NCT04908709|Experimental|Diagnostic (sMRI)|Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.
16266702|NCT04908709|Active Comparator|Group 2|Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and/or at any time of suspected tumor recurrence.
16266703|NCT04908696||TLM treatment for LC and PHC patients with early stage|TLM group: Laryngeal carcinoma (LC) (supraglottic type and glottic type) and hypopharyngeal carcinoma (HPC) (pyriform sinus and posterior pharyngeal wall) patients with T1 and T2 stages can be treated with transoral laser microsurgery (CO2 laser resection) for proper indications (NCCN 2020).
16266704|NCT04908696||OPL treatment for LC and PHC patients with T1, T2, and T3 stages|OPL group: Open partial laryngectomy with laryngeal function preservation is performed for patients with laryngeal carcinoma (LC) (supraglottic type, glottic type, and subglottic type) and hypopharyngeal carcinoma (PHC) (pyriform sinus, postcricoid, and posterior pharyngeal wall) with proper indications (NCCN 2020).
16266705|NCT04908696||R treatment for LC and PHC patients with early stage|R group: radiotherapy is treated for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications (NCCN 2020).
16266706|NCT04908696||TORS treatment for LC and PHC patients with early stage|TORS group: transoral robotic surgery is performed for proper laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications.
16266707|NCT04908696||SPA treatment for LC and PHC patients with advanced stage|SPA group: surgical treatment (S) ± postoperative adjuvant (PA) therapy is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
16266708|NCT04908696||CCR treatment for LC and PHC patients with advanced stage|CCR group: concurrent chemoradiotherapy (CCR) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
16266709|NCT04908696||ARC treatment for LC and PHC patients with advanced stage|ARC group: neoadjuvant therapy (A) + radiotherapy/chemoradiotherapy (RC) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
16266710|NCT04908696||ASRC treatment for LC and PHC patients with advanced stage|ASRC group: neoadjuvant therapy (A) + surgery (S) + radiotherapy (R) or chemoradiotherapy (C) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
16266713|NCT04908670|Active Comparator|PNE group|5 minute video :Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI.
16266714|NCT04908670|Active Comparator|Manipulation group|PA grade I-II oscillation on C7, T4 and L4
16266715|NCT04908657|Experimental|Treatment group|treatment group will administrate oral sildenafil 20 mg three times per day for 3 years
16266716|NCT04908657|No Intervention|Control group|the control group will not receive any specific therapy for decreasing the pulmonary vascular resistance
16266717|NCT04908644|Experimental|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
16266718|NCT04908644|Placebo Comparator|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
16266720|NCT04908618|Active Comparator|digital impression with normal abutment for dental implant|digital impression using a ready-made abutment for dental implant
16266721|NCT04908618|Experimental|digital impression with scan abutment for dental implant|digital impression with scan body abutment for dental implant
16266722|NCT04908618|Experimental|open tray conventional dental implant impression|Digitized open tray dental implant impression
16266723|NCT04908618|Experimental|closed tray impression for dental implant|Digitized closed tray dental implant impression
16266724|NCT04908605|Active Comparator|Mirtazapine group (Group I) (n=55)|
16266725|NCT04908605|Active Comparator|Melatonin group (Group II) (n=55)|
16266726|NCT04908605|Placebo Comparator|Placebo group (Group III) (n=55)|
16266729|NCT04908579|Active Comparator|- GROUP (I): 30 patients|
16266730|NCT04908579|Active Comparator|- GROUP (II): 30 patients|
16266731|NCT04908579|Active Comparator|- GROUP (III) (Control): 30 patients|
16266732|NCT04908566|Experimental|PD-1 antibody combined with FOLFIRINOX regimen|
16266733|NCT04908566|Active Comparator|PD-1 antibody combined with SOX program|
16266734|NCT04908553|Other|low dose group|Remimazolam Tosilate for Injection 0.1mg/kg at induction
16266735|NCT04908553|Other|medium dose group|Remimazolam Tosilate for Injection 0.15mg/kg at induction
16266736|NCT04908553|Other|high dose group|Remimazolam Tosilate for Injection 0.2mg/kg at induction
16266996|NCT04906785|Experimental|Sequence1|"Period 1: Reference drug(D744)
~Period 2: Test drug(CKD-385)"
16266737|NCT04908540|Active Comparator|MARPE/ Conventional (Control) (Group A)|patients will open the appliance in its conventional way; 2 quarter turn (0.2 mm) in the morning, and 2 quarter turn in the evening until overcorrection achieved.
16266738|NCT04908540|Experimental|MARPE/ ALT-RAMEC (Group B)|Patients will open 2 quarter turn (0.2mm) in the morning, and 2 in the evening in the first week, then alternate with closing 2 quarter turn in the morning and 2 in the evening in the second week. And then continuing opening and closing till end with opening in the 7th week and continue opening until overcorrection achieved.
16266739|NCT04908527|Experimental|Walk group|Patients walked to operating room (OR)
16266740|NCT04908527|No Intervention|Bed group|Patients go to OR while in bed
16266741|NCT04908514|Experimental|ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.|
16266742|NCT04908501||Intervention group|Services of the non-transversal clinical departments of the Bordeaux University Hospital willing to participate to the programme.
16266743|NCT04908501||Control group|Services of the non-transversal clinical departments of the Bordeaux University Hospital not willing to participate to the programme.
16266744|NCT04908488|Other|P1fA, then AMfA|Verofilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16266745|NCT04908488|Other|AMfA, then P1fA|Etafilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16266749|NCT04908462|Experimental|Part A Healthy volunteers: Single ascending doses|
16266750|NCT04908462|Experimental|Part B Healthy Volunteers Multiple ascending doses|
16266751|NCT04908462|Experimental|Part C Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)|"The dose levels for Part C will be determined following completion of the MAD portion (Part B) of the study.
~Adult participants with a confirmed diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are expected to be enrolled at each of two dose levels."
16266752|NCT04908449|Experimental|Serratus anterior plane block with PIFB (experimental arm)|PIFB with local anesthetic with SAPB with local anesthetic (bupivacaine)
16266753|NCT04908449|Placebo Comparator|Serratus anterior plane block with PIFB (placebo arm)|PIFB with local anesthetic with SAPB placebo (saline)
16266754|NCT04908436|Experimental|Normal renal function|Healthy participants with creatinine clearance (CLCR) >80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
16266755|NCT04908436|Experimental|Mild renal impairment|Participants with CLCR 50-80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
16266756|NCT04908436|Experimental|Moderate renal impairment|Participants with CLCR 30-<50 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
16266757|NCT04908436|Experimental|Severe renal impairment|Participants with CLCR <30 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
16266758|NCT04908423|Experimental|Xeomin®|Participants will be injected via electromyographic guidance with a total of 200 units of Xeomin® into the pectoralis major, biceps brachii, brachioradialis, and latissimus dorsi muscles of the hemiparetic side using a standardized injection protocol (16). An additional 100 units of Xeomin® will be available at the discretion of the investigator for injection into additional affected upper extremity muscles
16266759|NCT04908397|Experimental|Supplement|Form: 500 mg L-carnitine tablet Dosage: Subjects 50-90kg: 3g/day Subjects <50kg or >90kg: 50mg/kg/day Frequency: twice a day for 2 weeks
16266760|NCT04908384|Experimental|IMPACT Intervention|IMPACT health application and wearable device
16266761|NCT04908384|No Intervention|Usual care control|Usual care control.
16266762|NCT04908371|Active Comparator|Selective Trunk Block (SeTB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. After identifying the three trunks of the brachial plexus, ultrasound guided selective trunk block will be done using local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 20ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
16266763|NCT04908371|Active Comparator|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC-BPB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove. The unique sonomorphology of the C7 transverse process will be used as the key anatomical landmark to identify the individual elements of the brachial plexus. Under ultrasound guidance, local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 30ml) will be injected at the interscalene groove and at the supraclavicular fossa in order to anesthetize the whole upper limb.
16266764|NCT04908358|Sham Comparator|Sham preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
16266765|NCT04908358|Sham Comparator|Sham preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by Sham Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
16266766|NCT04908358|Experimental|Stimulation preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
16266997|NCT04906785|Experimental|Sequence2|"Period 1: Test drug(CKD-385)
~Period 2: Reference drug(D744)"
16266767|NCT04908358|Experimental|Stimulation preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
16266768|NCT04908358|Other|cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham One time RAVANS versus one time Sham Two weeks wash-out
16266769|NCT04908358|Other|cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) One time RAVANS versus one time Sham Two weeks wash-out
16266770|NCT04908345|Experimental|Methadone|Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery
16266771|NCT04908345|Active Comparator|Fentanyl|Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery
16266772|NCT04908332|Experimental|Kangaroo baby Massage|The mother will apply the massage. The baby kangaroo will be exposed to the KBM for 10 minutes once a day during the time that the infant need to stay in kangaroo position at home. If the baby wakes up and wants to eat the KBM will be interrupted immediately and the baby will be fed, The temperature will be measured before and after the intervention. The massage will begin 60 minutes after the feed.
16266773|NCT04908332|Active Comparator|Kangaroo position|The infant must be in Kangaroo position with the mother semi sitting on bed with elevation of at least 30 degrees during 10 minutes every day until the infant doesn´t need to stay in kangaroo position at home.The temperature will be measured 60 minutes after the feed and 10 minutes after KP. If the baby wakes up and wants to eat the KP will be interrupted immediately and the baby will be fed, then the KP will be completed of time ( 10 minutes) to measure the temperature.
16266776|NCT04908280|Experimental|Discoid lupus erythematosus|Patients with discoid lupus erythematosus will be given ruxolitinib cream to be used twice daily for 12 weeks.
16266777|NCT04908254|Experimental|Dayspring Active Wearable Compression Device|The Dayspring Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure full-arm compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
16266778|NCT04908254|Active Comparator|Advanced Pneumatic Compression Device|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
16266779|NCT04908241|Experimental|TRAIL|TRAIL is a 4-week progressive exercise and self-management intervention for lower extremity recovery delivered by a trained registered physical therapist, in a 2:1 participant-to-therapist ratio. Each participant grouping will receive two telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours).
16266780|NCT04908241|Active Comparator|EDUCATION|"The EDUCATION control arm is a 4-week education program focusing on stroke knowledge and risk factors. It will be delivered by health professionals who have experience working with individuals with stroke, knowledge of chronic disease self-management (e.g. physical or occupational therapists, nurses, kinesiologists), and who have completed study-specific training on the EDUCATION program
~Participants will receive video conferencing sessions with the same schedule and 2:1 participant-to-coach ratio as TRAIL. Each participant grouping will receive two educational telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours)."
16266781|NCT04908228|Experimental|Ibrutinib + obinutuzumab|Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).
16266782|NCT04908215|Experimental|INM-755 (cannabinol) cream|Cannabinol cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
16266783|NCT04908215|Placebo Comparator|Vehicle cream|Vehicle cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
16266784|NCT04908202|Experimental|Deucravacitinib|
16266785|NCT04908202|Placebo Comparator|Placebo|
16266789|NCT04908176|Experimental|Patients with metastatic, unresectable GIST|Patients will receive 5 mg of midazolam orally on Day 1 and Day 18. Patients will receive avapritinib 300 mg, orally on Day 3 through Day 19.
16266790|NCT04908163|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one month. Four visits will be scheduled for participants assigned to this group:
~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured."
16266791|NCT04908163|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group will receive a written nutrition educational information as well as eight online nutritional and cooking classes during the one-month intervention period. Four visits will be scheduled for participants assigned to this group:
~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.
~Participants will receive 8 culinary workshops between visit 2 and visit 3. In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.
~Volunteers will be also contacted by phone after 6 months of the end of the intervention to collect information about food and culinary habits."
16266792|NCT04908150|Experimental|Core Group|The Core Group carried out core stability exercises. Their training consisted of the following exercises: bridge, Klapp, front plank and lateral plank
16266793|NCT04908150|Active Comparator|Abdominal Group|The Abdominal Group performed traditional exercises: trunk flexion or abdominal crunch, trunk extensions, lower abdominals with hip lifts and crunch with crossed legs
16266794|NCT04908137|Experimental|2-Octyl Cyanoacrylate (Dermabond) Group|2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks topical application around post-circumcision site subcoronal area immediately after the circumcision devise is removed and circumcision procedure was done
16266795|NCT04908137|No Intervention|Control Group|will receive Vaseline cream application around the post-circumcision site immediately after circumcision
16266796|NCT04908124|Experimental|Lubricant A - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.
~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
16266797|NCT04908124|Experimental|Lubricant B - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.
~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
16266798|NCT04908124|Experimental|Lubricant C - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.
~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
16266799|NCT04908124|Experimental|Lubricant D - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.
~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
16266800|NCT04908124|Experimental|Lubricant E - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.
~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
16266801|NCT04908124|Experimental|Lubricant A - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.
~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
16266802|NCT04908124|Experimental|Lubricant B - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.
~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
16266803|NCT04908124|Experimental|Lubricant C - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.
~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
16266804|NCT04908124|Experimental|Lubricant D - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.
~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
16266805|NCT04908124|Experimental|Lubricant E - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.
~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
16266806|NCT04908111|Experimental|Safety Run In|Three evaluable patients will receive the trial vaccines with standard of care treatment to confirm they are safe before opening the next stage of the trial. These patients will not be randomised.
16266807|NCT04908111|Experimental|Arm A: Trial vaccines with standard of care treatment|Approximately 40 patients will be randomised to receive the trial vaccines with standard of care treatment in this arm.
16266808|NCT04908111|Other|Arm B: Standard of care treatment|Approximately 40 patients will be randomised to receive standard of care treatment alone in this arm.
16266809|NCT04908098|Experimental|Laser group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling. Laser application was then applied to the areas where root planning was applied. Laser was applied in continuous phase at 0.80W power, 940 nm wavelength and 0.80 J / s energy level.
16266810|NCT04908098|Active Comparator|Control group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling.
16266811|NCT04908085|Experimental|OPC|Occupational Performance Coaching delivered by telephone
16266812|NCT04908085|No Intervention|Waitlist control|Intervention provided after post intervention assessment
16266813|NCT04908072|Active Comparator|Virtual Reality Training|Will participate in an Intensive virtual reality (R) cataract simulation course that includes a five day instructor led VR course using the Orbis-FundamentalVR cataract surgical simulator, in addition to standard resident training at the training facility.
16266814|NCT04908072|No Intervention|Traditional Training|Will receive standard resident training at the training facility.
16266815|NCT04908046|Experimental|HMPL-295S1 open-label treatment arm|"During dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.
~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
16266816|NCT04908033||myocardial pacing group|patients with the pacing lead placed into the right ventricle to obtain myocardial capture
16266817|NCT04908033||physiological pacing group|patients with the pacing lead placed into the His bundle or left bundle branch area
16266818|NCT04908020||Follow up|"The group is made up by children and adolescents, aged from 9 to 17, who received a cancer diagnosis, who completed oncological treatment and who are included in a clinical follow-up program since less than 3 years.
~Furthermore, the study involves one parent for each patient to collect demographics and clinical data."
16266819|NCT04908007||Professional qualitative group|Qualitative analysis of crisis management by interviewing professionals most involved during the crisis in each university hospital.
16266820|NCT04908007||Professional quantitative group|Quantitative analysis of crisis management using the WHO grid adapted sent to the target persons identified within the establishments
16266821|NCT04908007||Patient quantitative group|Quantitative analysis of crisis management using a questionnaire sent to patients hospitalized in the first wave asking them about their perception of crisis and post-crisis management.
16266822|NCT04908007||Tools development|Development of tools to prepare for situations of uncertainty
16266823|NCT04907994||Older patients and/or with chronic diseases|Retrospective cohort study of exposed/unexposed individuals in the national health data system (SNDS). The study population is composed of individuals aged 70 years or older and patients with a chronic disease. Exposure to containment is defined as the period between 17 March 2020 (beginning of week 12, start of containment) and 10 May 2020 (end of week 19, end of containment). The end of monitoring is set at 12 months after the start of the containment, on 17 March 2021. The unexposed group consists of random samples of comparable individuals (aged 70 years or older and/or chronically ill) for the two years prior to the outbreak (2015 and 2016). The second study period (May 10, 2020 to March 17, 2021) may be subdivided depending on the evolution of the health crisis and the governmental measures adopted. Measurement of the outcome measures and comparison between exposed and unexposed will be carried out at the end of each of the two periods.
16266824|NCT04907981||Novel coronavirus infection|All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids.
16266825|NCT04907981||Not infected by novel coronavirus|Healthy controls and patients with liver disease
16266826|NCT04907981||Recovered patients with nucleic acid negative after infection with novel coronavirus|Novel coronavirus nucleic acid changed from positive to negative.
16266829|NCT04907955|Active Comparator|panoptix PANFOCAL intraocular lens|panoptix PANFOCAL intraocular lensis a single-piece aspheric non-apodized diffractive panfocal IOL that distributes light energy to three focal points in both small and large pupil conditions
16266830|NCT04907955|Active Comparator|Trifocal Diffractive the AT LISA intraocular lens|Trifocal Diffractive the AT LISA is a preloaded single-piece aspheric diffractive trifocal IOL and made of hydrophilic acrylic with a hydrophobic surface with an ultraviolet absorber. This aspheric IOL is aberration -correcting in order to reduce and compensate for corneal spherical aberrations.
16266831|NCT04907955|Active Comparator|Symphony EDOF (extended depth of focus) intraocular lens|SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.
16266832|NCT04907942|Active Comparator|EMA Alone|3 weeks of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey.
16266833|NCT04907942|Experimental|EMA + Automated Text Message Intervention|"1 week of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey followed by
~2 additional weeks of EMA in combination with 2 text messages per day with content related to stress management techniques."
16266834|NCT04907929|Experimental|post-implantation care|
16266835|NCT04907903|Experimental|RinasciMENTE|Participants will receive the internet-based intervention.
16266836|NCT04907903|No Intervention|Waiting-list|Participants will no receive the internet-based intervention.
16266837|NCT04907890||Cases|All survivor patients hospitalised for COVID-19 and previously recruited in the CORIST study
16266838|NCT04907890||Controls 1|Individuals who had a positive diagnosis for SARS-Cov-2 infection in the past (at least 6 months) and that was never hospitalised for COVID-19 as he/she had not severe symptoms.
16266839|NCT04907890||Controls 2|Individuals who was never diagnosed for SARS-Cov-2 infection
16266840|NCT04907877|Experimental|Probiotic|NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for X-30 plus 28 days of the disease
16266841|NCT04907877|Placebo Comparator|Placebo|Maltodextrine administered once a day for X-30 plus 28 days of the disease
16266842|NCT04907864|Experimental|MIC|Multi-modal intervention
16266843|NCT04907864|No Intervention|CPC|Conventional Palliative Care
16266844|NCT04907851|Experimental|Module 1 - RNF43 Mutated Advanced (unresectable)/Metastatic Pancreatic Cancer (Stage III/IV)|Patients (Karnofsky performance status ≥70) will be recruited and dosed with RXC004 (2 mg once daily [QD], orally) within 6 weeks of progression following 1st line SoC treatment.
16266845|NCT04907851|Experimental|Module 2 -Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage III/IV)|Patients (Eastern Cooperative Oncology Group [ECOG] performance status 0-1) will be recruited and dosed with RXC004 (2 mg QD, orally) within 6 weeks of progression, following 1st line SoC treatment.
16266846|NCT04907838|Experimental|Type 2 diabetics|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
16266847|NCT04907838|Experimental|Healthy controls|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
16266848|NCT04907825|Experimental|Pharmacist Intervention Arm|Pharmacist to prescribe/monitor/manage oral anticoagulation therapy for atrial fibrillation stroke prophylaxis (under collaborative practice agreement with participants primary care provider) in accordance with ACC/AHA/HRS Guidelines.
16266849|NCT04907825|Active Comparator|Enhanced Usual Care Control Arm|Pharmacist to notify primary care provider that patient has 'actionable' atrial fibrillation and provide current medication list.
16266850|NCT04907812|Experimental|Tranexamic Acid (TXA)|Patients in the TXA arm will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before their surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after the first dose on the day of their surgery
16266851|NCT04907812|Placebo Comparator|Standard of Care (SOC)|Patients in the (SOC) arm will receive 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) before their surgery and 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) 3-6 hours after the first dose on the day of their surgery
16266852|NCT04907799|Experimental|Daily Caloric Restriction|The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.
16266853|NCT04907799|Other|Standard Advice Control|The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.
16266854|NCT04907786||Study population|All patients eligible for participation in this registry are aged 18-80 years old and undergoing invasive coronary angiography because of abnormalities found on CCTA in either the left or right coronary artery and no or minimal stenosis (CAD-RADS 0-1; 0-24% stenosis) in the contralateral coronary artery. Patients will be asked for written informed consent to register their clinical data in an anonymized database. The period between CCTA and ICA may not exceed 90 days, in order to prevent possible aggravation of coronary artery disease between both examinations.
16266855|NCT04907773|Other|Potassium measurement|
16266856|NCT04907760|Experimental|With a personalized care program|The strategy implemented is a personalized care pathway that includes participant follow-up by a nurse for 5 years with contact every 4 months for the first year, then every 6 months
16266857|NCT04907760|No Intervention|Without a personalized care program|The comparison strategy does not include any specific management. The patient will not receive individualized management with the nurse coordinator.
16266858|NCT04907747|Experimental|Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 10days
16266859|NCT04907747|Experimental|Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
16266860|NCT04907747|Active Comparator|Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days|Esomeprazole 20 mg bid, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
16266861|NCT04907721|Experimental|Measuring glucagon sensitivity in humans|Participants will be subjected to two experimental days.
16266862|NCT04907708|No Intervention|Normal healthy controls|females in second trimester with normal glucose levels
16266863|NCT04907708|No Intervention|Diet controlled|females in second trimester with blood sugar levels below 129mg/dl
16266864|NCT04907708|Experimental|Metformin|females in second trimester with blood sugar levels above 130mg/dl treated with Metformin
16266865|NCT04907708|Experimental|Insulin|females in second trimester with blood sugar levels above 130mg/dl being treated with Insulin
16266866|NCT04907695||Video Laryngoscopy|Seeking all patients undergoing intubation for which the clinician chooses to use Video Laryngoscopy. The participants will undergo intubation with the investigators chosen device.
16266867|NCT04907682|Active Comparator|Intravenous ribavirin|"standard treatment: Irrua regimen
~100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)
~25 mg/kg days 2-7
~12.5 mg/kg days 8-10"
16266868|NCT04907682|Experimental|Oral favipiravir|"Oral favipiravir
~Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16)
~Day 2-10 1200mg twice daily (BD)"
16266869|NCT04907669|Experimental|Group 1a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized into Group 1a and Group 1b to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
16266870|NCT04907669|Experimental|Group 1b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
16266871|NCT04907669|Experimental|Group 1c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk decreased or did not change, they will remain receiving BCIs monthly as Group 1c.
16266872|NCT04907669|Experimental|Group 2a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a.
16266873|NCT04907669|Experimental|Group 2b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
16266874|NCT04907669|Experimental|Group 2c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
16266875|NCT04907656|Experimental|dCBT Condition|The dCBT used in this study (Daylight) was selected due to its noted efficacy in treating GAD. 25 interventions will be provided in four modules, with an average duration of 20 minutes. Sessions are unlocked weekly, and completion of an initial assessment drives an algorithm to personalize the program. Individuals may progress through treatment at a slower pace than weekly sessions; 6 weeks is allowed for treatment completion. Treatment is based on principles of applied relaxation, stimulus control, cognitive restructuring, and imaginal exposure. Participants schedule a time for each session and receive prompts if they miss the appointment. All interventions are aided by the use of an animated therapist.
16266876|NCT04907656|No Intervention|Waitlist (control) Condition|Participants allocated to the waitlist (control) condition will not receive an active intervention during the study. Participants will still complete all scheduled study assessments. They will receive access to the dCBT after completion of all study assessments.
16266877|NCT04907643|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
16266878|NCT04907643|Experimental|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
16266879|NCT04907643|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
16294168|NCT04716673|Experimental|Healthy teenagers (12-17y)|
16266880|NCT04907630|Experimental|intervention group-antenatal education of health literacy (HL-AE)|It is the group that is given antenatal education based on improving health literacy (HL-AE).
16266881|NCT04907630|Experimental|intervention group-Antenatal Education (AE)|It is the group that gives antenatal education (AE)
16266882|NCT04907630|Experimental|Control group|No Intervention
16266883|NCT04907617|Experimental|G1|After the induction of anaesthesia, the first group will be heated with only forced-air warming device.
16266884|NCT04907617|Experimental|G2|After the induction of anaesthesia, the second group will receive only warmed IV and irrigation fluids.
16266885|NCT04907617|Experimental|G3|After the induction of anaesthesia, forced-air warming as well as warmed IV and irrigation fluids will be applied to the third group
16266886|NCT04907617|Experimental|G4|After the induction of anaesthesia, the fourth group will be the control group without any intervention.
16266887|NCT04907604|Other|First intervention group|Clusters 1 and 2 (group 1) will start the intervention at month 1, immediately after completing the baseline assessment. After 7 weeks of using the app and having access to the EMPOWER website (with material related to the anti-stigma campaign and recommendations for employees to deal with psychosocial risk factors), they will answer a post-treatment assessment protocol through the app.
16266888|NCT04907604|Other|Second intervention group|Clusters 3 and 4 (group 2) that serve as control group of cluster 1 and 2 (group 1), will also complete the assessment at T1. Clusters 3 and 4 (group 2) will start the intervention in step 2, after completing the second assessment.
16266889|NCT04907604|Other|Third intervention group|Clusters 5 and 6 (group 3), that serve as control group of group 1 and 2, will also complete the assessment at T2. Clusters 5 and 6 (group 3) will start the intervention in step 3. All clusters will answer a total of five assessments
16266890|NCT04907591|Experimental|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band for 12 months.
16266891|NCT04907591|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
16266892|NCT04907578||postpartum full term neonates|immediate postpartum full term neonates with no intrauterine growth restricted
16266893|NCT04907578||intrauterine growth restricted neonates|preterm or full-term intrauterine growth restricted neonates
16266894|NCT04907565||Obese patients|BMI >30kg/m2
16266895|NCT04907565||non obese patients|BMI between 18 to 29kg/m2
16266896|NCT04907539|Experimental|Arm A: RXC004 monotherapy|"Patients will receive RXC004 (1.5 mg once daily [QD], orally).
~Patients in Arm A may crossover to Arm B treatment if they have progressive disease on the first Response Evaluation Criteria in Solid Tumours, (RECIST) scan (if Arm B is open at the time of progression)."
16266897|NCT04907539|Experimental|Arm B: RXC004 + Nivolumab|"Patients will receive RXC004 (1.5 mg QD, orally) in combination with Nivolumab (480 mg every 4 weeks [q4w], intravenous [IV] infusion).
~Arm B will be opened once a RP2D for RXC004 in combination with Nivolumab is established in the phase I dose escalation study (NCT03447470). RXC004 dose to be used in combination with Nivolumab will be based on data from the phase 1 study (NCT03447470)."
16266898|NCT04907526|Experimental|Treatment Arm|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.
16266899|NCT04907526|No Intervention|Control Arm|Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.
16266900|NCT04907513||Amotivational Syndrome|Patients required an external drainage of the cerebrospinal fluid.
16266901|NCT04907500|Experimental|Multifocal IOL|Implantation of a multifocal intraocular lens
16266902|NCT04907487||SEP|With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria
16266903|NCT04907487||NO SEP|For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease
16266904|NCT04907474|Other|1 Mist|One mist of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
16266905|NCT04907474|Other|2 Mists|Two mists of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
16266906|NCT04907461|Experimental|Laparoscopic guided TAP block|"The surgeon uses a laparoscopic technique to visualise the peritoneum from the inside of the abdomen and guides the hypodermic needle through the abdominal wall from the outside. When the needle point is visible through the peritoneum and almost enters the abdominal cavity, the surgeon retracts the needle around 5 mm. Then by deploying a test dose of the local anaesthetics a so called Doyle's bulge sign can confirm the right position in the nervous plane. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin."
16266907|NCT04907461|Active Comparator|Ultrasound guided TAP block|The anaesthesiologist uses ultrasound to identify the nervous plane in-between the external and transverse abdominal muscles. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
16266908|NCT04907448|Experimental|IsoK-ST group|Participants in this group received the usual physical rehabilitation program in addition to an IsoK-ST program.
16266909|NCT04907448|Active Comparator|Control group|Participants in this group received the usual physical rehabilitation program only.
16266910|NCT04907435||patient with simultaneous laparoscopic operations|
16266911|NCT04907435||patient with simultaneous open operations|
16266912|NCT04907422||CXPA group|carcinoma ex pleomorphic adenoma of major and minor salivary glands.
16266913|NCT04907422||PA group|Benign pleomorphic adenoma of major and minor salivary glands.
16266914|NCT04907422||Control group|normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
16266945|NCT04907201||Patients|A group pf 30 patients with lower limb spasticity who are already candidate for cryoneurotomy will be invited to have an extra electrophysiological test for participation in this study. The test will be done for both limbs for a better comparison.
16267313|NCT04904614|Other|single arm|Letermovir 480 mg daily for cmv prophylaxis
16266915|NCT04907383||Diverticular disease|"All consecutive patients admitted to a Surgical Unit with a diagnosis of left-side colinic diverticulitis will be enrolled in the registry. Patients will be identified through their medical record numbers. One investigator in each center will obtain written informed consent from each patient and keep the patients updated on data collection.
~Inclusion criteria: 1) imaging-proven colonic diverticular disease 2) patient aged > 18 years old; 3) Written informed consent obtained. 4) A colonoscopy showing diverticular disease will be required during the follow-up or before surgical treatment if possible"
16266916|NCT04907370|Experimental|Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of toripalimab are administrated concurrently with IC and IMRT, respectively. After 3 weeks of the completion of IMRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
16266917|NCT04907370|Active Comparator|Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by concurrent chemoradiotherapy (CCRT; every 3 weeks × 2 cycles of cisplatin + IMRT 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day). PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of CCRT, involving the whole-course of IC + CCRT. The first and last 3 cycles of toripalimab are administrated concurrently with IC and CCRT, respectively. After 3 weeks of the completion of CCRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
16266918|NCT04907357|Active Comparator|rTMS|Participants will receive up to 30 rTMS sessions within the 8-week treatment period.
16266919|NCT04907357|Sham Comparator|Sham (Placebo)|Participants will receive up to 30 sham rTMS sessions within the 8-week treatment period.
16266920|NCT04907344|Experimental|Part 1: Camrelizumab + Chemotherapy|
16266921|NCT04907344|Experimental|Part 2: Camrelizumab + Chemotherapy|
16266922|NCT04907344|Active Comparator|Part 2: Chemotherapy|
16266923|NCT04907331|Active Comparator|Corminaty twice|The participants receive Comirnaty twice 3-7 weeks apart
16266924|NCT04907331|Active Comparator|Vaxzevria twice|The participants receive Vaxzevria twice 12 weeks apart.
16266925|NCT04907331|Experimental|Heterologous|The recipients receive Vaxzevria followed by Comirnaty 12 weeks apart
16266926|NCT04907318||ANKORIS|Cataract surgery performed with POD26PAYT
16266927|NCT04907318||FINEVISION TORIC|Cataract surgery performed with POD26PAYFT
16266928|NCT04907305||Feed-forward PRO|Participants in this group will participate in monthly learning collaborative webinars. Feed-forward of patient reported outcomes (PRO) data collected from the main study (NCT04735406) will be used.
16266929|NCT04907305||Control Group (Usual Care)|Participants in the control group will receive usual care practices during the clinical encounters.
16266930|NCT04907292||Planned Cesarean delivery|Patients who have an elective Cesarean delivery at Mount Sinai Hospital
16266931|NCT04907292||Unplanned Cesarean delivery|Patients who have an unplanned Cesarean delivery at Mount Sinai Hospital
16266932|NCT04907253|Active Comparator|Quercetin|Patients receiving 500 mg quercetin twice daily
16266933|NCT04907253|Placebo Comparator|Placebo|Patients receiving placebo twice daily
16266942|NCT04907227|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
16266943|NCT04907227|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).
~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
16266944|NCT04907214|Experimental|Empagliflozin|Individuals receive empagliflozin 25mg/day orally for 12 weeks
16266946|NCT04907201||Healthy participants|A group of 30 healthy participants will be invited as a control group, and they will have a single session of electrodiagnostic test for their lower limb in dominant side.
16266947|NCT04907162||Neuromuscular disease (NMD) Patients|"The patient has one of the following neuromuscular diagnoses:
~histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or
~genetically confirmed late-onset Pompe disease (LOPD), or
~genetically confirmed spinal muscular atrophy type 3 (SMA3), or
~genetically confirmed myotonic dystrophy type 1, or
~genetically confirmed myotonic dystrophy type 2, or
~genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD)."
16266948|NCT04907162||Healthy control|no known neuromuscular disorder
16266949|NCT04907149|Experimental|Absolute Bioavailability - Period 1|Participants will receive GLPG3970 under fasted conditions followed by an intravenous (i.v.) microtracer microdose of [14C]GLPG3970 on Day 1.
16266950|NCT04907149|Experimental|Mass Balance - Period 2|Participants will receive [14C]GLPG397 under fasted conditions on Day 1.
16266951|NCT04907136|Experimental|Preferred ENDS|All participants will complete a lab visit where they will use their preferred ENDS ad libitum for up to 60 minutes
16266952|NCT04907136|Experimental|Preferred ENDS with HWL|All participants will complete a lab visit where they will use their preferred ENDS with a HWL on the device ad libitum for up to 60 minutes
16266953|NCT04907123|Experimental|UNa+ Driven Intensive Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 6 hours; if therapeutic goal is not met, treat according to the following step.
~Therapeutic goal: Spot Urinary Sodium > 70 mEq/L AND mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
16266954|NCT04907123|Active Comparator|Standard Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 12 hours; if therapeutic goal is not met, treat according to the following step.
~Therapeutic goal: mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
16266955|NCT04907110|Experimental|Exercise + NR|Participants will be asked to take two pills of NR (250mg/pill) twice daily (a total of 4 pills/day; 1000mg/day), for 40 days. During days 17-38 of the NR intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of NR supplementation.
16266956|NCT04907110|Placebo Comparator|Exercise + Placebo|Participants will be asked to take two pills of placebo, twice daily (a total of 4 pills/day), for 40 days. During days 17-38 of the intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of the placebo supplementation.
16266957|NCT04907097|Other|MOF/placebo|During period 1 (4 weeks) participants will receive monomeric and oligomeric flavanols and during period 2 (4 weeks) placebo. Wash out period between two interventions will be 4 weeks. The daily dose of monomeric and oligomeric flavanols will be 200 mg (2 capsules once a day) and for placebo (2 capsules once a day).
16266958|NCT04907097|Other|Placebo/MOF|During period 1 (4 weeks) participants will receive placebo and during period 2 (4 weeks) monomeric and oligomeric flavanols. The wash out period between two interventions will be 4 weeks. The daily dose of placebo will be 2 capsules once a day and for monomeric and oligomeric flavanols 200 mg (2 capsules once a day).
16266959|NCT04907084|Experimental|Serine 200 mg/kg/day|Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
16266960|NCT04907084|Experimental|Serine 400 mg/kg/day|Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
16266961|NCT04907084|Experimental|Fenofibrate 160 mg/day|Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.
16266962|NCT04907084|Experimental|Serine 200 mg/kg/day and Fenofibrate 160 mg/day|"Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
16266963|NCT04907084|Experimental|Serine 400 mg/kg/day and Fenofibrate 160 mg/day|"Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
16266964|NCT04907084|No Intervention|No treatment|Control group: no investigational product taken
16266965|NCT04907071|Experimental|Primary Cohort|"Primary Cohort: Patients presenting to hospital with AAD meeting criteria for malperfusion syndrome preoperatively which includes both components:
~Imaging findings indication reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery
~Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) -OR- Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte derangements)"
16266966|NCT04907071|Experimental|Secondary Cohort:|"Secondary Cohort: Patients who develop new clinical signs or laboratory results indicting distal malperfusion after proximal repair of the AAD is complete and proximal blood flow is redirected into the true lumen.
~New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky extremities
~New Laboratory signs include: Rising lactate (>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs
~All subjects implanted will be followed at baseline, peri- and post-procedure, at discharge or death and at 1, 7, and 30 days post-procedure (whichever comes first)."
16266967|NCT04907058|Experimental|Treatment with CO2|Patients were treated with an effective lowest concentration of CO2 delivered by the novel CO2 supply system.
16266968|NCT04907045|Experimental|Standard Implementation Plus Health Coaching|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
16266994|NCT04906798|Experimental|Sequence1|"Period 1: Reference drug(D744)
~Period 2: Test drug(CKD-385)"
16266969|NCT04907045|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
16266970|NCT04907032|Experimental|Posterior Tibial Nerve Stimulation with Mirabegron|One arm of the study will receive PTNS combined with mirabegron. In the PTNS with mirabegron arm, the patient will take a 50 mg dose daily for 12 weeks of the trial. This arm of the study will have 27 patients randomized to this arm of the study. The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
16266971|NCT04907032|Placebo Comparator|Posterior Tibial Nerve Stimulation Plus Placebo|The other arm of the study will receive PTNS with placebo. In the PTNS with placebo arm, the patient will receive a placebo daily during the 12-week trial. PTNS will be performed as described: The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
16266972|NCT04907019|Experimental|Group-drugs interaction|24 subjects were enrolled in this study. The effects of rifampicin single dose and steady-state on the pharmacokinetics of sy-004 will be analyzed.
16266973|NCT04907006|Experimental|Group-1|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.
~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.
~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
16266974|NCT04907006|Experimental|Group-2|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.
~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.
~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
16266975|NCT04906993|Experimental|camrelizumab combined with famitinib malate|
16266976|NCT04906993|Active Comparator|platinum-based chemotherapy|
16266977|NCT04906980|Experimental|JNJ-64281802|Participant will receive 2 initial loading doses of JNJ-64281802, 800 milligram (mg) every 8 hours (q8h) followed by 4 doses of 400 mg q8h then 2 single doses of 400 mg on Day 4 and Day 5.
16266978|NCT04906980|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily from Day 1 to Day 5.
16266979|NCT04906967|Active Comparator|modified sural flap|modified sural flap used to cover soft tissue defect around ankle
16266980|NCT04906967|Active Comparator|anterolateral thigh flap|anterolateral thigh flap used to cover soft tissue defect around ankle
16266981|NCT04906954|Other|Neuromuscular electrical stimulation (NMES)|"30 NMES sessions will be performed by patients for 30 min, for a period of 8 weeks, according to a standardized protocol.
~The number of sessions per week will be gradually increased to reach 5 sessions/week at week 4."
16266982|NCT04906915|Experimental|Ketamine|The experimental group was continuously pumped with remifentanil + ketamine for analgesia, and the control group was continuously pumped with remifentanil + placebo (normal saline) for analgesia. RASS and CPOT scores were performed to evaluate the pain degree of the patients.
16266983|NCT04906902|Experimental|Acalabrutinib Dose Escalation|"Phase 1 Dose escalation will occur using a 3+3 dose escalation approach, evaluating three separate dose levels.
~Acalabrutinib 200mg 2x daily
~Acalabrutinib 300mg 2x daily
~Acalabrutinib 400mg 2x daily"
16266984|NCT04906902|Experimental|Acalabrutinib Dose Expansion|"Phase 2
~Participants will receive Acalabrutinib at the pre-determined dosage established in Phase 1."
16266985|NCT04906889|Experimental|dexmedetomidine-lidocaine|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
16266986|NCT04906889|Active Comparator|remifentanil|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy
16266987|NCT04906876|Experimental|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
16266988|NCT04906876|Experimental|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
16266989|NCT04906863||Mild Cognitive Impairment|Individuals with mild cognitive impairment that began before age 70
16266990|NCT04906863||Dementia/Alzheimer's Disease|Individuals with Alzheimer's Disease or other dementia that began before age 70
16266991|NCT04906863||Cognitively Healthy|Cognitively healthy individuals over the age of 30 years
16266992|NCT04906811|Active Comparator|Fat grafting with the AuraGen 1-2-3 with AuraClens System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.
16266993|NCT04906811|Active Comparator|Fat grafting with the Revolve System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.
16266998|NCT04906772|Experimental|Group KD|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
16266999|NCT04906772|Active Comparator|Group KP|participants received loading of ketamine 1 mg/kg and propofol 1 mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25 µg/kg/hr dexmedetomidine throughout the procedure.
16267000|NCT04906759|Experimental|Meals plus exercise|
16267001|NCT04906759|Experimental|Meals only|
16267002|NCT04906746|Experimental|Dosing Regimen for Ruxolitinib|"Level 1: Ruxolitinib 0 MG po bid for 1 month
~Level 0: Ruxolitinib 10 MG po bid for 1 month
~Level -1: Ruxolitinib 15 MG po bid for 1 month"
16267003|NCT04906733||Cancer patient|RAS/RAF wild-type metastatic right colon cancer patients receiving chemotherapy or chemotherapy combined target therapy treatment.
16267004|NCT04906720|No Intervention|Standard of care|Usual standard of care post atrial fibrillation ablation.
16267005|NCT04906720|Experimental|Colchicine|0.6mg colchicine oral twice daily for 7 days.
16267006|NCT04906707|Experimental|EaseVRx Group|Participants will be asked to complete the 8-week program with assigned modules each week. Each week, participants will be asked to complete 7 modules, averaging 5 minutes in duration and ranging from 2 to 16 minutes in duration, for a total of 56 modules across the program. Participants will be instructed not to use the device while ambulating, and that they should use the headset a maximum of 3 times per 24-hour period (morning, noon, and evening) for not more than 30 minutes consecutively.
16267007|NCT04906707|Active Comparator|Active control Group|Participants in the control group will be asked to use the audio-only version of EaseVRx that excludes references to visual content. They will receive an electronic link to the audio recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer. Each week, participants will be asked to complete 7 audio sessions.
16267008|NCT04906694|Experimental|COVI-DROPS|10, 20, or 40 mg of COVI-DROPS administered intranasally
16267009|NCT04906694|Placebo Comparator|Placebo|2 mL administered intranasally
16267010|NCT04906681|Experimental|Arthroplasty, hip or knee|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
16267011|NCT04906681|Experimental|Neurology: stroke or Parkinson disease|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
16267012|NCT04906668|Active Comparator|Pulmonary-vein isolation with any form of energy|
16267013|NCT04906668|Active Comparator|Ablation of atrioventricular-node and Pacemaker implantation|
16267014|NCT04906655|Experimental|Cohort A glycopyrronium 30 minutes cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:
~30 minutes residence time in cotton gloves
~Complete daily diary.
~Remove all jewelry.
~Tear open the top of the pouch at the notch.
~Wash hands thoroughly with warm water, and dry them.
~Remove the wipe from the pouch and unfold the wipe.
~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).
~Return the wipe to the pouch and put it back in the box.
~Carefully put cotton gloves on both hands.
~Set timer for 30 minutes.
~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
16267015|NCT04906655|Experimental|Cohort B glycopyrronium 30 minutes under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:
~30 minutes residence time under occlusion
~Complete daily diary.
~Remove all jewelry.
~Tear open the top of the pouch at the notch.
~Wash hands thoroughly with warm water, and dry them.
~Remove the wipe from the pouch and unfold the wipe.
~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).
~Return the wipe to the pouch and put it back in the box.
~Carefully put gloves on both hands.
~Set timer for 30 minutes.
~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
16267016|NCT04906655|Experimental|Cohort C glycopyrronium overnight in cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:
~Overnight in cotton gloves
~Complete daily diary
~Remove all jewelry.
~Tear open the top of the pouch at the notch.
~Wash hands thoroughly with warm water, and dry them.
~Remove the wipe from the pouch and unfold the wipe.
~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).
~Return the wipe to the pouch and put it back in the box.
~Carefully put on the cotton gloves on both hands and go to bed.
~In the morning, after at least 4 hours of wearing the gloves , remove the cotton gloves and throw them away.
~Immediately wash hands thoroughly with warm water and soap, and dry them."
16267017|NCT04906655|Experimental|Cohort D glycopyrronium overnight under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:
~Overnight under occlusion
~Complete daily diary
~Remove all jewelry.
~Tear open the top of the pouch at the notch.
~Wash hands thoroughly with warm water, and dry them.
~Remove the wipe from the pouch and unfold the wipe.
~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).
~Return the wipe to the pouch and put it back in the box.
~Carefully put on the occlusive gloves and go to bed.
~In the morning, after at least 4 hours of wearing the gloves, remove the occlusive gloves and throw them away.
~Immediately wash hands thoroughly with warm water and soap, and dry them."
16267018|NCT04906642|Active Comparator|Standard of Care|"Each of the following procedures will be conducted according to general or local site Standard of Care (SoC):
~Medication administration at surgery
~Surgical irrigation and wound debridement
~Surgical fracture preparation/fixation
~Surgical closure"
16267019|NCT04906642|Experimental|Standard of Care plus Next Science|In addition to the SoC, the blinded product will be applied in place of saline irrigation as the wound is closed (after bone fracture preparation/fixation), depending on the randomization.
16267020|NCT04906629|Experimental|INO-4201|One intradermal injection of INO-4201 followed by electroporation
16267021|NCT04906629|Placebo Comparator|Placebo|One intradermal injection of normal saline followed by electroporation
16267022|NCT04906616|No Intervention|Control Comparison|Standard of care, e.g. regular HIV care plus brief advice on alcohol use
16267023|NCT04906616|Experimental|Mlambe Intervention|A couples-based intervention to reduce problematic drinking and improve economic and HIV outcomes.
16267024|NCT04906603|Experimental|TBS Headache|
16267025|NCT04906590|Experimental|Study Drug|All participants will receive PI-2620.
16267026|NCT04906577|Experimental|VIZOLF|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to the body odour emitted by the child during the first 5 days of life
16267027|NCT04906577|Experimental|VIZ|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to a neutral odour during the first 5 days of life
16267028|NCT04906564||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:
~1. Written informed consent is obtained; 2. Patients with age between 4-60 years; 3. Cerebral digital subtraction contrast angiography (DSA) reveal severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'.
~Exclusion Criteria:
~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
16267029|NCT04906538|Active Comparator|anterior cruciate ligament reconstruction with internal suture augmentation technique|This group will be operated by using all-inside ACLR technique with internal suture augmentation technique
16267030|NCT04906538|Active Comparator|anterior cruciate ligament reconstruction without internal suture augmentation technique|This group will be operated by using all-inside ACLR technique without internal suture augmentation technique
16267031|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
16267032|NCT04906525|Experimental|Resistance training|Participants will undergo 6 weeks of supervised resistance training
16267033|NCT04906512|Experimental|Tegaderm CHG Dressing|Tegaderm CHG dressing is used to cover and protect insertion catheter sites and to secure devices to skin. It is available in a variety of shapes and sizes. Tegaderm CHG Dressing is intended to reduce skin colonization and catheter colonization and to suppress regrowth of microorganisms commonly related to bloodstream infections. Tegaderm CHG dressing is intended to reduce catheter-related bloodstream infections (CRBSI) in patients with central venous or arterial catheters.
16267034|NCT04906512|Active Comparator|Tegaderm Standard Dressing|Tegaderm Standard Dressing is used to cover and protect insertion catheter sites and to secure devices to skin.
16267035|NCT04906499|Experimental|Physical Activity Promotion Group|Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day.
16267036|NCT04906486||Observational: Patients with restless legs syndrome|A total of 70 patients who diagnosed with primary restless legs syndrome according to the five essential criteria as established by the International Restless Legs Syndrome Study Group.
16267037|NCT04906486||Observational: Healthy controls|The control group consisted of 85 age- and gender-matched healthy volunteers.
16267038|NCT04906473|Experimental|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
16267039|NCT04906460|Experimental|WVE-N531|
16267040|NCT04906447|No Intervention|Control arm|Participants randomized to the control arm will receive usual care
16267041|NCT04906447|Experimental|Acupuncture|Acupuncture treatments twice a week for five weeks
16267042|NCT04906447|Experimental|Guided Relaxation|Daily use of a guided relaxation app for 6 weeks
16267043|NCT04906434|Experimental|ABSK011 60mg cohort|60mg cohort：1 patient will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, the patient will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
16267044|NCT04906434|Experimental|ABSK011 120mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
16267045|NCT04906434|Experimental|ABSK011 180mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
16267046|NCT04906434|Experimental|ABSK011 240mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
16267047|NCT04906434|Experimental|ABSK011 320mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
16267048|NCT04906434|Experimental|ABSK011 400mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
16267052|NCT04906408|Experimental|Prevena|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
16267053|NCT04906408|Experimental|Prineo|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
16267054|NCT04906408|Active Comparator|Standard Dressing|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
16267055|NCT04906395|Experimental|Active Comparator: TOL2506|TOL2506 in combinatination with standard endocrine therapy (Tamoxifen & Aromatase Inhibitors)
16267056|NCT04906382|Experimental|Treatment (tislelizumab)|Patients receive tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients who are chemotherapy naive with progressive disease, stable disease, or partial response, also receive carboplatin IV and paclitaxel IV every 21 days per standard of care for 6-9 cycles at the discretion of the treating physician.
16267057|NCT04906369||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.
16267058|NCT04906356||Study group|Single group observational study
16267059|NCT04906343|No Intervention|Group 1 (2 years)|Group 1, surveillance colonoscopy in two years after the last complete colonoscopy in SPS patient.
16267060|NCT04906343|Active Comparator|Group 2 (3 years)|Group 2, surveillance colonoscopy in three years after the last complete colonoscopy in SPS patient.
16267061|NCT04906330||PPHM-0000-21|50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.
16267062|NCT04906317|Active Comparator|Sedation and Analgesia|0.05 mg/kg midazolam and 5mg dezocine iv infusion
16267063|NCT04906317|Active Comparator|Anesthesia|continuous 1.5mg/kg propofol iv infusion
16267064|NCT04906304|Experimental|Evrolimus|The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral) low dose pluse cellcept
16267065|NCT04906304|Active Comparator|Control|0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral)standard dose plus cellcept
16267066|NCT04906291|Experimental|H.A.F. toothpaste (1000 ppm F-)|The children were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
16267067|NCT04906291|Active Comparator|Fluoridated toothpaste (1000 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
16267068|NCT04906291|Experimental|H.A.F. toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
16267069|NCT04906291|Active Comparator|Fluoridated toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
16267070|NCT04906278|Other|Amniotomy group|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip.
16267071|NCT04906278|Other|No-amniotomy group|No-amniotomy will be done
16267072|NCT04906265|Active Comparator|High Intensity Functional Exercise|The intervention comprises the HIFE protocol as a rehabilitation method and, if necessary, other completing exercises. HIFE consists of five exercise categories depending on the capabilities of the patient.
16267073|NCT04906265|Experimental|High Intensity Functional Exercise and wearable sensor|The intervention comprises the HIFE protocol as a rehabilitation method and, if necessary, other completing exercises. HIFE consists of five exercise categories depending on the capabilities of the patient. In addition, follow-up and feedback during the rehabilitation period will be given via a wearable inertial measurement unit (IMU).
16267074|NCT04906265|Active Comparator|Standard rehabilitation|The intervention comprises the standard rehabilitation services: walking training and adaptions to the walking pattern of the patient prior to surgery together with func-tional exercises. The intervention is tailored to each patient, based on the type of fracture, type of surgery, and assessment by the PT as well as treatment goals.
16267075|NCT04906252||Ventricular Fibrillation|Patients presenting to the Emergency Department after Ventricular Fibrillation (Vfib) Cardiac Arrest or Patients demonstrating Vfib during cardiac arrest
16267076|NCT04906252||PEA|Patients presenting to the Emergency Department after Pulseless Electrical Activity (PEA) Cardiac Arrest. Patients demonstrating PEA during cardiac arrest
16267077|NCT04906252||Asystole Cardiac Arrest|Patients presenting to the Emergency Department after Asystolic Cardiac Arrest. Patients demonstrating Asystole during cardiac arrest
16267078|NCT04906239|Active Comparator|Group ESP|While the patient is in a sitting position, A ultrasound probe covered with a sterile sheath will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After the T 4-5 transverse process and the erector spinae muscle above it are shown, a quincke-type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal with the entrance made using the in-plane technique. When the transverse process is touched, the needle will be pulled out and a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.The same procedure will be repeated on the contralateral side of the T5 spinous process and half of the remaining bupivacaine dose will be injected. The total volume of bupivacaine injected on both sides will be 20 mL.
16267079|NCT04906239|No Intervention|Group Control|"No block will be made to the control group.
~After extubation, 1mg / kg tramadol will be applied routinely to both groups, and PCA (Patient Control Analgesia) and morphine consumption and VAS (visual analog scale) pain scores of both groups will be evaluated and recorded at the 1st, 4th, 12th and 24th hour. When VAS is 3, patients will be advised to press the PCA device."
16267080|NCT04906226|Experimental|Intervention group|Individuals participating in the study will be divided into intervention and control groups. The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
16267081|NCT04906226|No Intervention|Control group|There will be no additional application other than routine to the control group, data collection forms will be applied and recorded at the beginning of the study and at the end of four weeks.
16267082|NCT04906213|Active Comparator|Arm I: With Type II Diabetes|Kidney Transplant recipient with Type II diabetes, randomized to either dapagliflozin or a placebo.
16267083|NCT04906213|Active Comparator|Arm 2: Without Diabetes|Kidney Transplant recipient without Type II diabetes, randomized to either dapagliflozin or a placebo
16267084|NCT04906200|Experimental|Group A (YES portal)|Patients receive access to YES portal for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months.
16267085|NCT04906200|Active Comparator|Group B (usual care)|Patients receive usual care for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months. After 9 months, patients may also receive access to YES portal for 3 months.
16267086|NCT04906187|Experimental|Arm A : Experimental group with intraoperative ANI monitoring of nociception|
16267087|NCT04906187|Other|Arm B : Control group without ANI intraoperative monitoring of nociception|
16267088|NCT04906174||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
16267089|NCT04906161||Successful dental implant|Patients showed a successful implant placement with no complications before loading
16267090|NCT04906161||Early dental implant failure|Early complications and failure of dental implant before loading
16267091|NCT04906148|Experimental|Smokers|Smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
16267092|NCT04906148|Experimental|Non-smokers|Non-smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
16267093|NCT04906135|Experimental|Usher Syndrome|Adult and pediatric cochlear implant users with Usher syndrome
16267094|NCT04906135|Active Comparator|Idiopathic Hearing Loss|Adult and pediatric cochlear implant users with idiopathic hearing loss
16267095|NCT04906122|Experimental|Experimental group|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
16267096|NCT04906122|No Intervention|Control Group|Control Group: No additional attempt or routine call will be made to grandmother and mothers in the control group. The questionnaires will be given to the mothers at the same time for filling the surveys after birth, one month, 3 and 6 months follow up will be done with grandmothers and mothers.
16267097|NCT04906109|Experimental|Reference-Test|
16267098|NCT04906109|Experimental|Test-Reference|
16267099|NCT04906096|Experimental|PAXALISIB|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.
~Paxalisib (GDC-0084)
~Each study treatment cycle lasts 28 days, up to 24 months."
16267100|NCT04906083|Experimental|Intervention group|Avatrombopag+Standard medical treatment
16267101|NCT04906083|Other|Control group|Standard medical treatment
16267102|NCT04906070|Experimental|HB-001 DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16267103|NCT04906057|Experimental|Forced Aerobic Exercise (FE)|The FE group (N=10) will complete 45 minutes of FE on the custom-engineered cycle designed to augment pedaling rate to greater than 70 revolutions per minute (RPM's). The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer at their self-selected cadence without assistance.
16267104|NCT04906057|Active Comparator|Voluntary Aerobic Exercise (VE)|The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer for 45 minutes at their self-selected cadence without assistance.
16267105|NCT04906044|Experimental|Total Neoadjuvant Treatment combined with Tilelimumab|
16267106|NCT04906031|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
16267107|NCT04906018||volunteer group - BMI less than 30|Each subject with a BMI less than 30 will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
16267108|NCT04906018||volunteer group - BMI of 30 and above|Each subject with a BMI of 30 and above will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
16267109|NCT04906005|Experimental|gadopiclenol|"Dose per administration: dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.025; 0.05 or 0.1 mmol/kg BW (depending on each group).
~6 volunteers will receive gadopiclenol per group"
16267110|NCT04906005|Placebo Comparator|Placebo|"Dose per administration: similar dose (Volume/weight) as the one used for Gadopiclenol in the considered group.
~3 volunteers will receive gadopiclenol per group"
16267111|NCT04905992|Experimental|Single daily session (Hypertonic saline + airway clearance techniques)|The experimental group will perform a daily session at home including nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
16267504|NCT04903197|Experimental|Arm 1B|VAY736 single agent dose expansion in patients with DLBCL
16267112|NCT04905992|Active Comparator|Twice daily session (Hypertonic saline + airway clearance techniques)|The control group will perform two daily sessions at home involving nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
16267113|NCT04905979|Experimental|AD113|Two oral capsules administered before bed
16267114|NCT04905979|Experimental|Atomoxetine|Two oral capsules administered before bed
16267115|NCT04905966|Experimental|Nutrition education + Physical activity intervention|Physical Activity and Nutrition Education: An additional 45 minute weekly physical education class and 5 weekly active break sessions of 10 minutes each will be added to the provisions of the children's curriculum. In addition, schools will receive high intensity nutrition education, that is, 3 weekly nutrition education classes of one hour in each session over a period of 6 months.
16267116|NCT04905966|No Intervention|Control|Schools receiving a lower intensity nutrition education served as control. This group received 3 sessions of 1 hour with a total of 3 educational sessions over the 6 month period. The educational material was the same as the intervention group but the development of lessons was not as specific and deep as the intervention group.
16267120|NCT04905914|Active Comparator|50mg Capsule|
16267121|NCT04905914|Active Comparator|100mg Capsule|
16267122|NCT04905914|Active Comparator|200mg Capsule|
16267123|NCT04905914|Active Comparator|400mg Capsule|
16267124|NCT04905914|Active Comparator|800mg Capsule|
16267125|NCT04905901|Experimental|Tranexamic acid 500 mg|Nebulized tranexamic acid 500 mg 15 minutes before operation
16267126|NCT04905901|Experimental|Tranexamic acid 1gm|Nebulized tranexamic acid 1 gm 15 minutes before operation
16267127|NCT04905901|Placebo Comparator|Saline placebo|Normal saline nebulization 15 minutes before operation
16267128|NCT04905888|Experimental|Hyperbaric oxygen therapy|Treatment with hyperbaric oxygen
16267129|NCT04905888|No Intervention|Control|Control, no treatment.
16267130|NCT04905875||Critically ill patients with COVID-19|n centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing PP - that are homogeneous in terms of both clinical and treatment characteristics - will be prospectively observed.
16267131|NCT04905862||Hemodialyzed patients|Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
16267132|NCT04905862||Patients treated with peritoneal dialysis|Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
16267133|NCT04905862||Patients without chronic kidney disease|Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
16267134|NCT04905862||Kidney transplant recipients|Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
16267135|NCT04905849|Experimental|Adaptive Cognitive Control Trainer (ACCT)|There are three modules within the game, each training a different aspect of cognitive control (attention, goal management, working memory): a visual search task for attention abilities, a spatial span task for working memory, and a task switching paradigm for goal management abilities. There are also 3 different levels of difficulty associated with each module; advancing to the next level delivers an advanced challenge that enhances the difficulty in performing the given cognitive task. Participants advance to the next level of difficulty following 6 training sessions occurring over 2 weeks, with the total training experience being 6 weeks of training (3 days/week), with each training session lasting 36 minutes (not including self-paced breaks).
16267136|NCT04905849|Active Comparator|Active Control Group|An active control application will be used for this arm. The total training experience here will also be for 6 weeks (3 days/week), with each training session lasting ~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.
16267139|NCT04905823||Type 1 diabetes patients|Patients with type 1 diabetes
16267140|NCT04905823||Non-diabetic subjects|Subjects in whom diabetes has not been diagnosed
16267141|NCT04905823||Type 2 diabetes patients|Patients with type 2 diabetes
16267142|NCT04905810|Experimental|Treatment (azacitidine, decitabine, venetoclax)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 (for patients with prior decitabine use), or decitabine IV on days 1-5 (for patients with prior azacitidine), and venetoclax PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16267143|NCT04905797||Deliberate self-harm|Individuals with psychiatric disorders and persistent DSH
16267144|NCT04905797||Clinical cases who ceased self-harm|Individuals with psychiatric disorders who have ceased DSH
16267145|NCT04905797||Clinical cases with no self-harm|Individuals with psychiatric disorders who never had DSH
16267146|NCT04905797||Healthy controls|Healthy controls who never had DSH
16267147|NCT04905784|Active Comparator|Control group: Usual brushing.|Usual motivation to brush teeth in the clinic (KAI brushing technique) in addition to brushing teeth by the parents.
16267148|NCT04905784|Experimental|Test group: Differential learning group.|Use of differential learning of tooth brushing at home, including children and parents.
16267149|NCT04905758|Experimental|Maxi-Z plus dental implant|platform switched dental implants
16267150|NCT04905758|Active Comparator|Maxi-Z dental implant|platform matched dental implants
16267151|NCT04905745||Facial palsy|Adulthood facial palsy patients group who receive Korean integrative medicine.
16267152|NCT04905732|Experimental|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
16267505|NCT04903197|Experimental|Arm 2A|VAY736 + lenalidomide dose escalation in patients with DLBCL
16267153|NCT04905732|Active Comparator|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
16267154|NCT04905719||Patients with dyspnea|Patients who visit a general practitioner for dyspnea will undergo a Point-of-Care ultrasound examination of the lungs to identify the presence or the absence of A-profile, B-profile and pleural effusion.
16267155|NCT04905719||Patients with abdominal pain|Patients who visit a general practitioner for abdominal pain in the right upper quadrant will undergo abdominal Point-of-Care ultrasound examination to identify cholecystolithiasis.
16267156|NCT04905719||Patients with suspected deep vein thrombosis|Patients who visit a general practitioner for pain and / or swelling of the lower extremity will undergo compression ultrasound testing to identify proximal deep vein thrombosis.
16267157|NCT04905706||3D laparoscopic adrenalectomy|Operations are done with an high definition 3D laparoscopic system (Olympus, Tokyo, Japan); all personnel wear polarized glasses to achieve stereoscopic imaging in the operating room. Dissection is realized using a hybrid energy system (Thunderbeat, Olympus Europe Se & Co, Hamburg, Germany).
16267158|NCT04905693|Experimental|Inhaled Treprostinil|Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.
16267159|NCT04905680|No Intervention|Control group|The health screening before the study and at the end of study will collect anthropometric data (height, weight, waist and hip circumference), blood pressure data, and blood samples (for testing of HbA1c, fasting blood glucose, fasting insulin and lipid profile). Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications. For participants in the control arm, there is no health coaching or study activities until the end of the study, where individuals will attend a 20- to 30-minute session with a coach to have their baseline lifestyle tracking results explained to them and receive personalised suggestions on lifestyle modifications.
16267160|NCT04905680|Experimental|Experimental group|The activities during health screening before the study and at the end of study is similar to the control. Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications, which will be used for the lifestyle tracking sessions. The experimental arm will go through 4 additional lifestyle tracking sessions (i.e., total of 5 including baseline), of which 1 will include Continuous Glucose Monitoring (CGM) tracking. For this CGM tracking session, participants will receive real-time feedback through the study applications, which will display the CGM trace. The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans.
16267161|NCT04905667|Experimental|GB221 group|6 mg/kg, single dose, intravenous infusion, 90-100 min
16267162|NCT04905667|Active Comparator|Herceptin group|6 mg/kg, single dose, intravenous infusion, 90-100 min
16267163|NCT04905654|Active Comparator|Levcromakalim|
16267164|NCT04905654|Placebo Comparator|Saline|
16267165|NCT04905628||Dexcom CGM System|Dexcom CGM System
16267166|NCT04905615|No Intervention|Baseline Measures|The first two-weeks within each school children's baseline physical activity data will be collected. Children will be blinded to the data, receiving no feedback. Teachers will be instructed not to change normal school practices or encourage children's physical activity.
16267167|NCT04905615|Experimental|Data-Driven Strategy Based Intervention|During the following 2-weeks teachers will be implementing strategies to improve their class' physical activity. These are individualised strategies which will be co-developed during semi-structured interviews where teachers will discuss data visualisations with the researcher which depicts their class' physical activity over the 2-week baseline period. Teachers will then implement these strategies over the subsequent 2-weeks. During this time teachers are able to share the physical activity data with their pupils if they wish.
16267168|NCT04905602|Experimental|Cohort 1|A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects
16267169|NCT04905602|Experimental|Cohort 2|A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects
16267170|NCT04905602|Experimental|Cohort 3|A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects
16267171|NCT04905602|Experimental|Cohort 4|A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects
16267172|NCT04905602|Experimental|Cohort 5|A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects
16267173|NCT04905602|Experimental|Cohort 6|A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma
16267174|NCT04905589|Placebo Comparator|ARM A|"Subsequent order of intake :
~Iso-voluminous water, breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
16267175|NCT04905589|Active Comparator|ARM B|"Subsequent order of intake :
~MCT in liquid form (75 ml of BetaQuik™), breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
16267176|NCT04905589|Active Comparator|ARM C|"Subsequent order of intake:
~MCT in liquid form (75 ml of BetaQuik™), breakfast, WPI in liquid from (12.5g of WheyBasics in 200ml water), lunch, WPI in liquid from (12.5g of WheyBasics in 200ml water)), dinner"
16267177|NCT04905576|Experimental|Relaxation training following daily radiation|All relaxation sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving relaxation will learn exercises to release tension through muscle relaxation, breathing, and imagery
16267178|NCT04905576|Experimental|Healing touch therapy following daily radiation|All Healing Touch sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving Healing Touch will receive a series of standardized therapeutic techniques designed to promote optimal flow of energy throughout the body.
16267179|NCT04905576|Active Comparator|No intervention|The no intervention group will receive no special intervention other than standard medical care, which includes the regular medical care given by the patient's physician and health care professionals.
16267180|NCT04905563|Other|Control|Standard of care- weight based dose of liquid acetaminophen-hydrocodone- 0.15 mg/kg/dose every six hours with a max dose of 10 mg/dose
16267506|NCT04903197|Experimental|Arm 2B|VAY736 + lenalidomide dose expansion in patients with DLBCL
16267181|NCT04905563|Experimental|Treatment|Weight based dose of liquid acetaminophen and ibuprofen- acetaminophen 15 mg/kg/dose and ibuprofen 10 mg/kg/dose every six hours with a max dose of 650 mg/dose of acetaminophen and 600 mg/dose of ibuprofen.
16267182|NCT04905550|Experimental|Craniocerebral radiotherapy combined with Almonertinib 110mg p.o qd|"Almonertinib mesylate tablet, 110mg, qd; until the disease progresses or unacceptable toxicity.
~The craniocerebral radiotherapy was acceptable from 1 week before to 6 weeks after treatment with Almonertinib.
~Dose adjustment and delay of Almonertinib are allowed. Delay of Almonertinib is allowed for up to 9 weeks, calculated from the time of last administration, otherwise, treatment is terminated."
16267183|NCT04905537||Sick Neonates or Stillbirth|Infants and their parents enrolled through Neonatal Intensive Care Unit or stillbirths through Obstetrics Department of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/ physical exam, and the results of the genomic sequencing report.
16267184|NCT04905524|Other|Intervention arm|All participants received the intervention in this trial (VPNP diet and supplement recommendations).
16267185|NCT04905511|Experimental|TRUE Vascular Graft|Patients will be implanted with the TRUE Vascular Graft in the upper arm or forearm
16267186|NCT04905498|Placebo Comparator|Control|Children were exposed to food commercials without narratives.
16267187|NCT04905498|Experimental|Intervention|Children were exposed to narrative statements that were shown and read aloud in between commercials played.
16267188|NCT04905485|Other|Intervention|All participants received the intervention in this trial. They received recommendations on their diets and supplements based on their results of microbiome expression.
16267189|NCT04905472|Experimental|Vestibular & Cochlear Implant Patients|"scheduled for CI surgery because of deafness
~a minimum of five year history of documented absence of auditory and vestibular function, based on review of their audiograms and vestibular tests.
~Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes.
~Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears"
16267190|NCT04905459||Retinal Imaging and Mydriatic Agents|Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.
16267191|NCT04905446|Other|Healthy male subjects|
16267192|NCT04905433|Experimental|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
16267193|NCT04905433|Active Comparator|cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
16267198|NCT04905394|Experimental|Treatment with subchondroplasty for bone edema in the knee|Patients treated with subchondroplasty for bone edema of the knee
16267201|NCT04905355|Active Comparator|Virtual Reality (VR)|Patient with VR experience during the ambulatory orthopedic surgery
16267202|NCT04905355|No Intervention|NO VR|Patient without any VR experience during the ambulatory orthopedic surgery
16267203|NCT04905342|Experimental|NVP-1805|NVP-1805 (80/10/20.8mg)
16267204|NCT04905342|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
16267205|NCT04905329||"Patients with high and gray zone risk reccurrence early breast cancer"|
16267206|NCT04905329||Patients with gastointestinal cancers|
16267207|NCT04905329||Patients with gynecological malignancies|
16267208|NCT04905316|Experimental|Canakinumab with Chemoradiation and Durvalumab|Treatment will consist of canakinumab (ACZ885) administered as a subcutaneous injection every 3 weeks for 3 cycles concurrent with standard of care concurrent chemoradiation, followed by canakinumab administered intravenously every 4 weeks for up to 12 total infusions concurrent with standard of care durvalumab. Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
16267241|NCT04905043|Experimental|SmartPill® + Acalabrutinib|Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.
16268084|NCT04899206||ARBs Group|Hypertensive patients under pharmacological treatment with ARBs
16267209|NCT04905290|Experimental|Single Arm|On the date of implant, subjects will undergo Conduction System Pacing Optimized Therapy (CSPOT) lead placement, then Conduction System Pacing Optimized Therapy (CSPOT) acute pacing protocol, and then device implant. During the acute pacing protocol, all subjects will undergo three types of pacing configurations (defined in the intervention descriptions), and will serve as their own control. The subject will then be implanted with the cardiac resynchronization therapy defibrillator (CRT-D) or cardiac resynchronization therapy pacemaker (CRT-P) device will be implanted. Each subject's device will be programmed to conduction system pacing optimized therapy (CSPOT) configuration. Subjects will be followed for 6 months.
16267210|NCT04905277|Experimental|Atenolol|Study subjects will take Atenolol 50 mg daily over 2 years
16267211|NCT04905277|Placebo Comparator|Placebo|Study subjects will take a placebo daily over 2 years
16267212|NCT04905264||Adults admitted in participating Rehabilitation Units for Severe Acquired Brain Injuries|Adults admitted in study's participants Rehabilitation Units for Severe Acquired Brain Injuries from the 1st of July 2021 to the 31st of December 2023. Patients entered into these units more than 14 weeks after the acute event are excluded
16267213|NCT04905238|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
16267214|NCT04905238|No Intervention|Conservative treatment|Diet and general life style recommendations.
16267215|NCT04905225||Ascending aortic replacement|Ascending aortic replacement in ascending aortic aneurysm in men and women
16267216|NCT04905212|Experimental|Telitacicept 160mg|Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
16267217|NCT04905212|Experimental|Telitacicept 240mg|Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
16267218|NCT04905212|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly, and a total of 24 doses
16267219|NCT04905199||Non-floating catheter|When using non-floating catheter.
16267220|NCT04905199||Floating catheter|When using floating catheter.
16267221|NCT04905186||healthy adults|This is a cross-over study with no intervention.
16267223|NCT04905160|Experimental|Subjects Hospitalized with a Primary Diagnosis of ADHF or Acute MI|Phase 1 subjects 18 years or above hospitalized with a primary diagnosis of ADHF or acute MI. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
16267224|NCT04905160|Experimental|Subjects Testing Positive Covid-19 Antigen Test|Phase 2 subjects 50 years or older with positive Covid-19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in this arm of the study. Subjects will be randomized within 48 hours of Covid-19 antigen positive status. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
16267225|NCT04905147|Active Comparator|The mosapride group|The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
16267226|NCT04905147|Placebo Comparator|The control group|The control group received 15 mg of placebo drug with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
16267230|NCT04905121|Experimental|Psilocybin|
16267231|NCT04905108|Active Comparator|Riboflavin drop every 2 minutes|Administration of one drop of Riboflavin every 2 minutes during UV exposure
16267232|NCT04905108|Active Comparator|Riboflavin drop every 10 minutes|Administration of one drop of Riboflavin every 10 minutes during UV exposure
16267233|NCT04905095|Experimental|EWS|Early Warning Score will be implemented in the computer system of the nursing station
16267234|NCT04905095|No Intervention|Control|Nursing supervision will be carried out in the usual way.
16267235|NCT04905082|Active Comparator|Arm I (usual care)|Patients receive education pamphlet about WES and have their genomics test results returned by their clinician in a typical manner.
16267236|NCT04905082|Experimental|Arm II (genomics test results, HOPE-Genomics)|Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available.
16267237|NCT04905082|Experimental|Arm III (HOPE-Genomics, genomics test results)|Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool.
16267240|NCT04905056|Experimental|ablation therapy in the treatment of lung cancer presenting as ground-glass nodules|
16294169|NCT04716673|Experimental|Healthy young adults (18-30y)|
16267242|NCT04905030|Experimental|Immigrant mother stratum|The receiver is an immigrant mother born in Eritrea, Somalia, Syria, Afghanistan, Iran or Iraq.
16267243|NCT04905030|Experimental|Educ 1 stratum|The receiver is a mother born in Sweden whose education does not exceed 3 years of high school.
16267244|NCT04905030|Experimental|Educ 2 stratum|The receiver is a mother born in Sweden whose education is at least 3 years of high school but no more than high school diploma.
16267245|NCT04905030|Experimental|Educ 3 stratum|The receiver is a mother born in Sweden whose education is at least some college (undergrad) but does not exceed an undergraduate degree
16267246|NCT04905030|Experimental|Educ 4 stratum|The receiver is a mother born in Sweden whose education is an undergraduate degree plus at least some graduate education
16267247|NCT04905017|Experimental|Treatment with the Trisol System|
16267248|NCT04905004|Experimental|2-week reactivation interval|Replacement of elastomeric chain every 2 weeks and reestablishing a 150 g force
16267249|NCT04905004|Active Comparator|4-week reactivation interval|Replacement of elastomeric chain every 4 weeks and reestablishing a 150 g force
16267250|NCT04905004|Experimental|6-week reactivation interval|Replacement of elastomeric chain every 6 weeks and reestablishing a 150 g force
16267251|NCT04905004|Experimental|8-week reactivation interval|Replacement of elastomeric chain every 8 weeks and reestablishing a 150 g force
16267252|NCT04904991|Experimental|Qigong group|Participants in the Qigong group were given a structured program about Chan-Chung qigong for 3 months which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice . The movements should be repeated and maintained for 10 minutes per time, 3 time a day .
16267253|NCT04904991|No Intervention|Control group|those in the control group received usual care for cognitive impairment during the same study period.
16267254|NCT04904978|Experimental|Trial Group|Use of Blanx Black Toothpaste + Mouthwash.
16267255|NCT04904978|Active Comparator|Control Group|Use of Blanx Nordic Toothpaste.
16267256|NCT04904965|Experimental|Propofol Group 1|Patients will receive induction of anesthesia with Propofol at a rate of 2.0 mg/kg/hr.
16267257|NCT04904965|Experimental|Propofol Group 2|Patients will receive induction of anesthesia with Propofol at a rate of 4.0 mg/kg/hr.
16267258|NCT04904965|Experimental|Propofol Group 3|Patients will receive induction of anesthesia with Propofol at a rate of 6.0 mg/kg/hr.
16267259|NCT04904965|Experimental|Propofol Group 4|Patients will receive induction of anesthesia with Propofol at a rate of 8.0 mg/kg/hr.
16267260|NCT04904952|Active Comparator|Experimental|This arm includes 30 OCD patients receiving SSRIs
16267261|NCT04904952|Placebo Comparator|Control|This arm includes 30 OCD patients receiving SSRIs
16267262|NCT04904926||Older Individuals|
16267263|NCT04904926||Healthy young to middle aged Individuals|
16267264|NCT04904913|Experimental|IBI362 high dose|high dose IBI362 administered subcutaneously (SC) once a week.
16267265|NCT04904913|Experimental|IBI362 low dose|Low dose IBI362 administered subcutaneously (SC) once a week.
16267266|NCT04904913|Placebo Comparator|placebo|placebo administered subcutaneously (SC) once a week.
16267267|NCT04904913|Experimental|IBI362 moderate dose|moderate dose IBI362 administered subcutaneously (SC) once a week.
16267268|NCT04904887|Other|Assessment of intermediate vision, defocus curve|"Standardized logarithm of the minimum angle of resolution (logMAR) charts were used for visual acuity measurement at 4 m, 80 cm, and 40 cm.
~he binocular defocus curve: The binocular defocus curve was done to evaluate the functional range of vision. The curve was obtained while the patient wearing his distance correction to provide the best distance visual acuity in both eyes. The test was performed under photopic conditions (85 candelas/m2) using ETDRS charts at a distance of 4m with the introduction of defocusing lenses from +1.00 D to -4.00 D in 0.50 D steps."
16267269|NCT04904874|Other|flourescein staining, miboscore|
16267270|NCT04904861|Experimental|Videoconference Intervention group|Brief group videoconferencing attachment-based intervention (sessions once a week for 4 weeks)
16267271|NCT04904861|Active Comparator|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks)
16267272|NCT04904835||Unselected blood donors|leftover samples from unselected blood donors from at least 2 donation centers. Leftover samples to be tested by Access HBV serological marker assays and CE-marked (european compliance marked) predicate assays
16267273|NCT04904835||Hospitalized patients|Leftover samples to be tested by Access HBV serological marker assays and CE-marked predicate assays
16267274|NCT04904835||Presumed HBsAg positive patients|"Leftover samples from patients at different stages of HBV infection (acute and chronic, minimum 10 per stage of infection), HBsAg positive by a Confirmatory testing of a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling), and minimum 20 high positive samples (>26 IU/mL) and minimum 20 samples in the cut-off range. If not enough samples in the cut-off range are obtained during the clinical trial, additional HBsAg specimens in the cut-off range will be tested by Research &Development to fit with Common Technical Specification requirements.
~Leftover samples to be tested by Access HBsAg assays and CE-marked predicate assays"
16267275|NCT04904835||Patients having recovered from natural HBV infection, presumed Anti-HBs positive|"Leftover samples from Patients positive for Anti-HBs and Anti-HBc Total by CE-marked assays. Target is to have at least ¾ of them recovered without HBV antiviral treatment.
~Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays"
16267276|NCT04904835||Patients having received HBV vaccination, presumed Anti-HBs positive|Leftover samples Confirmed as vaccinated by testing at the time of enrollment (i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays
16267277|NCT04904835||Presumed Anti-HBc Total positive patients|"Leftover samples from Patients at different stage of infection (acute, chronic or recovered, minimum 10 per stage of infection) positive for Anti-HBc Total by a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling).
~Leftover samples to be tested by Access anti-HBc Total and CE-marked predicate assays"
16267278|NCT04904835||Presumed Anti-HBc IgM positive patients|"left over samples from Patients with acute/recent HBV infection, positive for Anti-HBc IgM by a CE-marked assay.
~Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assays"
16267279|NCT04904835||Presumed HBeAg positive patients|"Leftover samples from Patients at different stages of infection (acute and chronic, minimum 5 per stage of infection), positive for HBeAg by a CE-marked assay.
~Leftover samples to be tested by Access HBeAg assay and CE-marked predicate assays"
16267280|NCT04904835||Presumed Anti-HBe positive patients7|"Leftover samples from Patients at different stages of infection (chronic and recovered, minimum 5 per stage of infection), positive for Anti-HBe by a CE-marked assay.
~Leftover samples to be tested by Access anti-HBe assay and CE-marked predicate assays"
16267281|NCT04904835||Patients with chronic HBV infection|Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assay
16267282|NCT04904822|Experimental|Study group|Vaginal bisection of uterus
16267283|NCT04904822|Experimental|Control group|Abdominal bisection
16267284|NCT04904809|Experimental|All Registered Pts|All registered patients will have multiple access sites in a single vein closed utilizing the ProGlide Suture Mediated Closure System and/or Prostyle Suture Mediated Closure and Repair System (when available).
16267285|NCT04904796|Experimental|Constraint-induced Movement Therapy With Home-based Hand-arm Bimanual Intensive Therapy|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours), and 2-hour home-based HABIT sessions, 3 days/week for 5 weeks (30 hours).
16267286|NCT04904796|Active Comparator|Constraint-induced Movement Therapy only|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours).
16267287|NCT04904783|Active Comparator|Study arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and give written informed consent would be in study arm. All patients, belong to both study and control groups would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease. Only low dose radiotherapy would be added to patients in the study arm.
16267288|NCT04904783|No Intervention|Control Arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and have not given written informed consent would be in study arm. These patients would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease except low dose radiotherapy.
16267291|NCT04904757|Other|CESM Pre and Post Survey|"Subject will be asked to complete a questionnaire that will ask you about your general attitude toward Contrast-Enhanced Spectral Mammography (CESM). Questions will include:
~Thoughts regarding risk of breast cancer
~Concerns regarding contrast procedures such as the CESM
~Past mammogram/breast imaging experience"
16267292|NCT04904744|Placebo Comparator|No message|No message sent
16267293|NCT04904744|Active Comparator|Low tailored message|2 text or phone reminders that child is overdue for well child check visit
16267294|NCT04904744|Active Comparator|Low tailored message plus COVID-19 vaccine message|2 text or phone reminders that child is overdue for well child check visit AND COVID-19 vaccine is available
16267295|NCT04904718|Experimental|DreaMed Advisor Pro tool used for insulin optimization|
16267296|NCT04904705|Active Comparator|Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"It will be given a home program. Then The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach will be applied by video conferencing method in a total of 10 sessions, 2 sessions per week, through 5 weeks, and a total of 12 sessions with initial and final evaluations.
~The Cognitive Orientation for Daily Activity Performance (CO-OP) approach is a person-oriented, performance-solving. and problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills."
16267297|NCT04904705|Active Comparator|Home Program|It will be given a home program only.
16267298|NCT04904692||COVID-19 positive|"Peripheral blood draw:
~Day 1 of admission: blood draw.
~Day 7-10 of hospitalization: blood draw.
~Follow-up consultation: blood draw (selected patients).
~Bronchoscopic sampling:
~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.
~Swabs for SARS-CoV-2 PCR:
~Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative.
~Day 7-14 of hospitalization: NP swab or clinically available alternative will be executed on day 7 repeated weekly."
16267299|NCT04904692||COVID-19 negative|"Peripheral blood draw:
~Day 1 of admission: blood draw.
~Follow-up consultation: blood draw (selected patients).
~Bronchoscopic sampling:
~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.
~Swabs for SARS-CoV-2 PCR:
~o Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative."
16267300|NCT04904679|Active Comparator|Amniotic Membrane group|Patients who will be treated with a amniotic membrane plug
16267301|NCT04904679|Active Comparator|Internal Limiting Membrane group|patients who will be treated with a internal limiting membrane flap
16267302|NCT04904666||Bleach baths with .0125%|
16267303|NCT04904666||Clorhexidine 2%|
16267304|NCT04904666||Soap and water|
16267305|NCT04904666||Bleach baths with .005%|
16267306|NCT04904653|Experimental|Hemopatch Group:|Hemopatch + suction drainage
16267307|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
16267308|NCT04904640||CLS stem|CLS Zimmer stem implantation (single wedge, tapered stem) using the 3D CT based software for surgical pre-operative planning
16267309|NCT04904640||Wagner cone stem|Wagner cone Zimmer stem implantation (conical tapered stem) using the 3D CT based software for surgical pre-operative planning
16267310|NCT04904640||Aptafix stem|Aptafix Ortho stem implantation (anatomical stem) using the 3D CT based software for surgical pre-operative planning
16267311|NCT04904627||Polyehtylene vs Poliìycarbonate|super rigid vs rigid material
16267312|NCT04904627||Free pelvis vs classic pelvis|fixed pelvis versus free pelvis, allowing adjustment in the sagittal plane.
16267314|NCT04904601|Active Comparator|Experimental Group: Kale|This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.
16267315|NCT04904601|Placebo Comparator|Placebo Group: Green Peas|This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.
16267323|NCT04904575|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levobupivacaine for the realization of the erector spinae plane block."
16267324|NCT04904575|Placebo Comparator|Placebo|"The placebo group corresponds to the reference group, that is to say that it will consist of patients who will benefit from an injection of physiological serum for the realization of the erector spinae plane block."
16267325|NCT04904562|Active Comparator|Treatment|Angiotensin II administered as an intravenous (IV) infusion will be increased every 5 minutes by 5-10ng/kg/min increments up to 80ng/kg/min
16267326|NCT04904562|Placebo Comparator|Control|Intravenous (IV) infusion (saline)
16267327|NCT04904549|Experimental|Stage 1: SARS-CoV-2 vaccine|2 injections of monovalent SARS-CoV-2 vaccine at Day 1 and Day 22
16267328|NCT04904549|Placebo Comparator|Stage 1: Placebo|2 injections of placebo at Day 1 and Day 22
16267329|NCT04904549|Experimental|Stage 2: SARS-CoV-2 vaccine|2 injections of bivalent SARS-CoV-2 vaccine at Day 1 and Day 22
16267330|NCT04904549|Placebo Comparator|Stage 2: Placebo|2 injections of placebo at Day 1 and Day 22
16267331|NCT04904536|Experimental|Study Medication Arm|6-monthly supplies of atorvastatin 40mg on top of standard care for a period of 18 months.
16267332|NCT04904536|Active Comparator|Standard Care Arm|Standard care for a period of 18 months.
16267333|NCT04904523||Cases|"Cases:
~1. Children and young people up to age 18 years, admitted to PCCU with probable or confirmed COVID-19, irrespective of severity of illness. This includes patients transferred from other hospitals as well as those admitted from Accident and Emergency department."
16267334|NCT04904523||Controls|"Controls:
~Children proven to have a non COVID infectious illness on laboratory testing.
~Children with sepsis or septic shock due to non-COVID infectious illness.
~Children or young people admitted to PCCU following accidental trauma."
16267335|NCT04904510|Experimental|Dual-Track Testing Algorithms A|In Approach A, a preliminary positive result from the INDICAID™ Rapid Test would expedite the corresponding patient VTM sample for laboratory-based RT-PCR. Expedited testing would obtain results typically within an additional 8 hours compared to the standard approach requiring 48-hour government mandated turnaround time.
16267336|NCT04904510|Experimental|Dual-Track Testing Algorithms B|In Approach B, a preliminary positive result from the INDICAID™ Rapid Test result would trigger the testing of the corresponding patient VTM sample with an onsite rapid nucleic acid amplification test (cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test on the cobas® Liat system, Roche Molecular Diagnostics). Results from the onsite rapid nucleic acid amplification test would typically be obtained within an additional hour. In addition to the onsite rapid RT-PCR test, the corresponding patient VTM sample was also sent for expedited laboratory-based RT-PCR testing. All samples testing negative with the INDICAID™ Rapid Test were sent for RT-PCR testing with the standard approach by the ONCO Medical Laboratory in batches.
16267337|NCT04904497|Experimental|Early Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
16267338|NCT04904497|No Intervention|Standard|"The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.
~Occupational Therapy interventions for control group will be allowed for this group only before 1 week after the first day on light sedation"
16267341|NCT04904458|Experimental|Experimental group|The experimental group receives the Enfacement Illusion toward a happy emotional face through a head mounted display.
16267342|NCT04904458|Sham Comparator|Control Group|The control group receives the exposure to a pleasant virtual environment through a head mounted display
16267343|NCT04904432|Other|young ACS patients|
16267344|NCT04904406|Experimental|dolutegravir/lamivudine|50 mg dolutegravir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
16267345|NCT04904406|No Intervention|dolutegravir/abacavir/lamivudine|50 mg dolutegravir, 600 mg abacavir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
16267346|NCT04904380|Experimental|Intervention|HMS, HBS and peer learning in combination with AIR and PRISMS
16267347|NCT04904380|Active Comparator|Comparison arm|HMS, HBS and peer learning in combination with PRISMS but no AIR
16267348|NCT04904367|Active Comparator|Deep tissue massage|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation(TENS) to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 Megahertz(MHz) and at a dosage of 1 w / cm2. Also, administered DTM to the back and neck region for 20 min in 12 sessions in addition to the conventional physical therapy.
16267349|NCT04904367|Experimental|Conventional physiotherapy|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
16267352|NCT04904341|Experimental|active|The first Cerebrolysin infusion (30 ml mixed with 250 mL of saline) is intended to be initiated as soon as possible after successful recanalization is achieved and within 8h of AIS stroke onset. Cerebrolysin treatment will be continued (30 ml/d) once daily until day 21 (first cycle). The patients will receive a second cycle of treatment (30 ml/d for 21 days given in the Outpatient Department or Neurorehabilitation Clinic) from day 69 to 90 (± 3 days).
16267353|NCT04904341|No Intervention|historical control|Historical data will be obtained by retrospective clinical chart reviews of patients hospitalized in the study center between 2017 and Dec.2020 and fulfilling the same clinical and radiological inclusion criteria in whom 12-month follow-up (including mRS, NIHSS, BI, EQ-5D-5L) could be obtained.
16267354|NCT04904328|Active Comparator|Lumishade® active lens|Treatment of photosensitive migraine with a Lumishade® active device.
16267355|NCT04904328|Sham Comparator|Lumishade® sham lens|Treatment of photosensitive migraine with a Lumishade® sham device.
16267356|NCT04904302|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16267357|NCT04904289||Sepsis with MODS|Patients with sepsis occurred MODS.
16267358|NCT04904289||Sepsis without MODS|Patients with sepsis did not occur MODS.
16267359|NCT04904276||Initiating treatment with fostamatinib as second-line therapy|
16267360|NCT04904276||Treated with fostamatinib for at least 12 weeks as second-line therapy|
16267361|NCT04904250|Experimental|Emboshield NAV6|using Emboshield NAV6 distal embolism protection device during CAS
16267362|NCT04904250|Active Comparator|SpiderFX|using SpiderFX distal protection device during CAS
16267363|NCT04904237|Experimental|aza-ven +MBF|treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning
16267364|NCT04904224|Active Comparator|PICE|Participants receive a panintestinal video capsule endoscopy (PICE)
16267365|NCT04904224|Active Comparator|Colonoscopy|Participants receive an (Ileo-)Colonoscopy
16267366|NCT04904211|Experimental|Feasiblity and Safety|All eligible patients will be assigned to this arm
16267367|NCT04904198|Experimental|Care Management Intervention for Non-cardiac chest pain|Multicomponent care management intervention.
16267368|NCT04904185|Other|Part A|Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
16267369|NCT04904185|Other|Part B|Six patients will be includede in Part B. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21.
16267370|NCT04904172||Acute ischemic stroke who undergo intravenous thrombolytic and / or endovascular thrombectomy|Patients with acute ischemic stroke who applied to Ege University Emergency Service and decided to undergo intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments by a Neurology Specialist.
16267371|NCT04904159||Benign|Patients who have benign pathologies after thyroidectomy
16267372|NCT04904159||Malign|Patients who have malign pathologies after thyroidectomy
16267373|NCT04904146||Patients with Mycosis fungoides and Sézary syndrome|
16267374|NCT04904146||Healthy volontaires|
16267375|NCT04904133|Active Comparator|Saccharine Group|140 mg saccharin (Hermesetas) dissolved in 330 mL water for 4 weeks.
16267376|NCT04904133|Active Comparator|Sucralose Group|66 mg sucralose (Splenda) dissolved in 330 mL water for 4 weeks.
16267377|NCT04904133|Active Comparator|Aspartame+Acesulfame-K Group|88 mg aspartame+88 mg acesulfame-K (Takita) dissolved in 330 mL water for 4 weeks.
16267378|NCT04904133|Placebo Comparator|Control Group|330 mL water for 4 weeks.
16267379|NCT04904120|Active Comparator|[203Pb]VMT01 first|Participants randomized to this arm will receive imaging agent [203Pb]VMT01 and undergo SPECT/CT imaging first. Later, participants in this arm will receive [68Ga]VMT02 and undergo PET/CT imaging.
16267380|NCT04904120|Active Comparator|[68Ga]VMT02 first|Participants randomized to this arm will receive imaging agent [68Ga]VMT02 and undergo PET/CT imaging first. Later, participants in this arm will receive [203Pb]VMT01 and undergo SPECT/CT imaging.
16267405|NCT04903951|Active Comparator|Best medical treatment for stroke, including rehabilitation|Best medical treatment for stroke, including rehabilitation.
16268085|NCT04899206||ACEIs Group|Hypertensive patients under pharmacological treatment with ACEIs
16267381|NCT04904107|Experimental|Intervention group|"Chest pain patients in the intervention group will be assessed by EMT personnel by performing the modified HEART score (including POC high sensitive troponin-I measurement (POC HS cTnI)) and the referral policy depends on the result.
~In case of a low modified HEART score (modified HEART 0-3) patients will not be referred to the cardiac ED.
~Patients with a modified HEART score >3 are directly referred to the cardiac ED after evaluation. These patients will receive standard care."
16267382|NCT04904107|Active Comparator|Control group|Chest pain patients in the control group will receive standard triage and standard care according to the local (EMT) protocol.
16267383|NCT04904094|Experimental|Intervention group|This group will receive casting of the lower limb for approximately 2 weeks combined with a passive stretching program of the knee flexors, followed by a homebased stretching exercise program for the plantar flexors and hamstrings for 4 weeks after casting.
16267384|NCT04904094|No Intervention|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic devices.
16267385|NCT04904081|Experimental|Treatment Arm (Indocyanine Green [ICG])|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
16267386|NCT04904081|No Intervention|Control Arm (Standard Care)|The Standard Care group will have no change to the medical and surgical care they receive while in the hospital. The surgeon will perform the surgery as they normally would outside of this study. This involves a laparoscopic-assisted transanal pullthrough surgery.
16267387|NCT04904068||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease.
16267388|NCT04904068||Healthy|Healthy individuals with no known neurological disorders.
16267389|NCT04904055||Value-based Formulary Beneficiaries|enrolled in the value-based formulary
16267390|NCT04904055||Standard Formulary Beneficiaries|enrolled in a standard (i.e., non-value-based formulary)
16267391|NCT04904042|Experimental|Use of plasma of neutral argon|Use of plasma of neutral argon in the eradication of tumor implants at the mesentery level, with different doses (established according to the percentage of energy used) and distances of application and time. It will also be compared in-vivo with control therapy of Monopolar electrofulguration at a power of 100 in cut mode with ball-tip terminal.
16267392|NCT04904029|Experimental|1. Digital Assessment Routing Tool (DART) 2. Physiotherapy-led remote triage|Participants complete the Digital Assessment Routing Tool (DART), which is followed by physiotherapy-led remote triage with the usual care clinician.
16267393|NCT04904029|Experimental|1. Physiotherapy-led remote triage 2. Digital Assessment Routing Tool (DART)|Participants complete their physiotherapy-led remote triage with the usual care clinician, which is followed by the Digital Assessment Routing Tool.
16267394|NCT04904016|Experimental|Intervention FlowOx treatment|Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.
16267395|NCT04904003|Experimental|Experienced LLA - intervention|Experienced lower-limb amputees that complete a 4-week semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
16267396|NCT04904003|Experimental|Experienced LLA - controls|Experienced lower-limb amputees that will be tested with a 4-week interval. No intervention. This group will be matched to the group of experienced lower-limb amputees.
16267397|NCT04904003|Experimental|New LLA learning to use prosthesis|New lower-limb amputees that complete a 8-11 weeks semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
16267398|NCT04903990||Patients|"women 18-50 years
~with previous history of a male birth
~scheduled for malignant breast tumor surgery"
16267399|NCT04903990||Controls|"women 18-50 years
~with previous history of a male birth
~scheduled for benign breast tumor surgery
~or cancer free"
16267400|NCT04903977|Experimental|Impedance spectroscopy|ONIRY examination
16267401|NCT04903964|Experimental|oral nutrition only group that received nutrition education|This group consists of children who are fed orally according to their chronological age. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the hospitalized child after the operation will be determined and the measurements will be checked.
16267402|NCT04903964|Experimental|group that received nutrition education and fed with nutritional support|This group consists of children who receive nutritional support provided by oral food supplements, oral food supplements, enteral tube feeding and / or parenteral nutrition. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the child hospitalized after the operation will be determined and the measurements will be checked.
16267403|NCT04903964|No Intervention|control group|While collecting research data on the specified dates; Comparison group (KG) will be selected as many as the number of volunteers who want to participate in the research. No nutritional attempt will be made to the child included in this group. The parameters used in the evaluation of growth (height, head and chest circumference measurement) and the Ankara Development Screening Inventory (AGTE) will be applied to children aged 0-3 who are followed up due to congenital heart disease.
16267404|NCT04903951|Experimental|ASV therapy + best medical treatment for stroke, including rehabilitation|Adaptive Servoventilation (ASV) therapy plus best medical treatment for stroke, including rehabilitation.
16267406|NCT04903938||Criminal-Antisocial Personality Disorder|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
16267407|NCT04903938||Non-criminal group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
16267408|NCT04903938||Control group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
16267409|NCT04903925|Experimental|Group 1|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a probiotic for 21 days (2 tablets/day).
16267410|NCT04903925|Placebo Comparator|Group 2|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a placebo of the probiotic for 21 days (2 tablets/day).
16267411|NCT04903899|Experimental|177Lu-DOTATATE|A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.
16267412|NCT04903886||All patient colonized with ESBL-E in Brest Intensive Care unit|All patient colonized with ESBL-E in Brest Intensive Care unit, in a 5 years period (2015-2019)
16267413|NCT04903873|Experimental|EU101: Dose Escalation Cohort|Participants with advanced solid tumors will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with escalating doses starting from 0.05 milligrams per kilogram (mg/kg) to 10 mg/kg until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
16267414|NCT04903873|Experimental|EU101: Dose Expansion Cohort 1|Participants with CRC will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with a determined recommended phase 2 dose until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
16267415|NCT04903873|Experimental|EU101: Dose Expansion Cohort 2|Participants with NSCLC will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with a determined recommended phase 2 dose until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
16267416|NCT04903860|Active Comparator|Single use reamers|Total hip replacement with the use of disposable reamers
16267417|NCT04903860|Active Comparator|conventional ancillary|Total hip replacement with the use of conventional reamers
16267418|NCT04903847|No Intervention|Dolutegravir/tenofovir disproxil/lamivudine|Continue dolutegravir 50 mg, tenofovir disproxil 245 mg, ,and lamivudine 300 mg once daily for 48 weeks.
16267419|NCT04903847|Experimental|dolutegravir/lamivudine|dolutegravir 50 mg/lamivudine 300 mg once daily for 48 weeks
16267420|NCT04903847|Experimental|doravirine/tenofovir disproxil/lamivudine|100 mg doravirin, 245 mg tenofovirdisoproxil and 300 mg lamivudine once daily for 48 weeks.
16267421|NCT04903834||COVID-19 - no hyperinflammation|Confirmed Sars-CoV-2 infection Hospitalised case
16267422|NCT04903834||COVID-19 - hyperinflammation|Sars-CoV-2 infection Hospitalised case
16267427|NCT04903808|Experimental|Allium sativum oil|The pulp stumps of the molars are dressed with a cotton pellet that is made damp with Allium Sativum oil for 1 min .
16267428|NCT04903808|Active Comparator|Mineral Trioxide Aggregate|The material will be prepared according to the manufacturer's instructions , applied to the pulp chamber and a moistened cotton pellet was placed over the MTA paste to allow the material to set.
16267429|NCT04903795|Experimental|hEGFRvIII-CD3 (BRiTE) with and without peripheral autologous T-cell (ACT) infusion|Four escalating doses of BRiTE are planned: #1: 57.0 ng/kg, #2: 570.0 ng/kg, #3: 5700.0 ng/kg, and #4: 57000.0 ng/kg. With the second injection of BRiTE, patients will each receive 3 x 10^7 T-cells per kg.
16267430|NCT04903782||Children and adolescents with newly diagnosed malignancy|
16267431|NCT04903769|Other|Parkinson's Patients and Caregivers|Will participate in the 8-session SMART-PD program as a participant with Parkinson's disease or as a caregiver of a participant with Parkinson's disease
16267432|NCT04903756||Patients|Adult patients where major lower limb amputation is being considered.
16267433|NCT04903756||Healthcare professionals|Surgeons, anaesthetists, and allied health professionals involved in decision making with patients where a major lower limb amputation is being considered.
16267434|NCT04903743|Placebo Comparator|group B|28ml of 0.25% bupivacaine and 2ml normal saline
16267435|NCT04903743|Active Comparator|group BM|received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
16267436|NCT04903730|Experimental|AER-901 Solution for Nebulization|AER-901 is supplied in two solution strengths (5 mg/mL and 40 mg/mL) for nebulization delivered via the FOX® MOBILE device.
16267437|NCT04903730|Placebo Comparator|Placebo|A volume-matching placebo (0.45% sterile saline for injection) is to be delivered via the FOX® MOBILE device.
16267438|NCT04903717|Experimental|Intervention - Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record which alerts to the presence of HFrEF and the fact that the patient is not currently prescribed an MRA. A link to an order set for MRAs (or to potassium binders should a patient be hyperkalemic) will provided, along with a link to current best practices surrounding the use of MRAs.
16267439|NCT04903717|No Intervention|Usual Care|Providers will not receive a best practice alert for eligible patients and will continue to care for patients as usual.
16267440|NCT04903704|Other|Sit to Stand testing|"Participants will undergo an ISWT in the hospital setting. This test is a standard of clinical care and it is essential to the patient assessment on their clinical visit. This test will therefore be conducted first in all cases.
~They will be allowed a 30 minute rest before undertaking the 1MSTS test.
~Clinical observations (heart rate, blood pressure, oxygen saturations) will be taken before and after both tests. Heart rate and oxygen saturations will be monitored during both tests.
~Patient reported measures of dyspnoea and perceived exertion will be recorded on completion of both tests.
~Adverse events e.g. dizziness, syncope or the participant becoming unwell be recorded.
~Descriptive and inferential statistical analysis will be used to determine the safety of 1MSTS in the hospital setting and comparability between 1MSTS and ISWT for participants. We will also examine comparability between 1MSTS outcomes and other available routinely collected clinical data."
16267441|NCT04903691|Experimental|Exercise training|130 patients who underwent open heart surgery and are cleared for exercise.These will include patients who enter supervised cardiac rehabilitation as well as patients who enter a supervised exercise program focusing strength training, endurance of functional training.
16267442|NCT04903691|No Intervention|Additional controls|5 patients who choose not to enter any organized exercise program.
16267443|NCT04903678|Experimental|intrathecal chemotherapy in patients with central metastases|Systemic chemotherapy and intrathecal chemotherapy are performed every 3 weeks. After three treatment cycles, the treatment response is comprehensively evaluated including cerebrospinal fluid, intracranial and orbital tumors. If necessary, local radiotherapy and arterial interventional chemotherapy are performed for local solid tumors. Cerebrospinal fluid is detected in each treatment cycle. If RB tumor cells still exist in cerebrospinal fluid, chemotherapy and intrathecal chemotherapy are continued until the end event. If cerebrospinal fluid was negative, intrathecal chemotherapy is supplemented for another 2 cycles with a total of 6 cycles of systemic chemotherapy. The patients are followed up after treatment.
16267444|NCT04903665||Cancer Arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.
16267445|NCT04903665||Benign Arm|Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.
16267446|NCT04903652|Experimental|Pyrotinib plus Vinorelbine|
16267447|NCT04903639||obese COPD|COPD patient with BMI more than 30
16267448|NCT04903639||non obese COPD|COPD patient with BMI less than 30
16267450|NCT04903600|Experimental|Probiotics|32g probiotics fruit vegetable fiber powder product contained 1.12*10(11) CFU of probiotics for 12 weeks
16267451|NCT04903600|Placebo Comparator|Placebo|32g placebo contained only maltodextrin (100%) for 12 weeks
16267452|NCT04903574|Experimental|Sedentary behavior smartphone app|This arm will be assigned to download and use a smartphone app that prompts you to stand up when your smartphone detects 30 minutes of sitting.
16267453|NCT04903574|Active Comparator|Pregnancy smartphone app|This arm will download and use a commercially available pregnancy smartphone app that does not attempt to change activity behavior.
16267454|NCT04903561|Experimental|Intervention|In the experimental arms, the woman will be asked to collect a vaginal sample with the Evalyn® Brush or a urine sample with the Colli-PeeTM. Women shall receive this self-sampling device directly from the GP or shall pick it up at a close by pharmacist with a prescription of the GP. In four GP practices (1, 2, 5, 6) the patient has to collect the SS preferentially in the GP practice (at home if the GP practice is not well equipped) whereas in the other four GP practices (3, 4, 7, 8), the patient has to collect the SS at home and send it to the laboratory by using a prepaid envelope.
16267455|NCT04903561|No Intervention|control|Women in the control group will receive an oral recommendation given by the GP with a reminder of the current screening policy to have a cervical sample taken by a physician chosen by the woman. This clinician-taken cervical sample will be sent to a laboratory for processing with the usual screening test. Today the usual screening test still is cytology, but this will change in the future (date to be defined) to an HPV test.
16267456|NCT04903535||Healthy Volunteers|Study will enroll 5 healthy volunteers to test the assay
16267457|NCT04903522|Experimental|Depressive patients|Patients suffering from major depressive disorder with anxiety symptoms
16267458|NCT04903509|Experimental|BI 1820237|Part 1 and part 2 of the trial.
16267459|NCT04903509|Placebo Comparator|Placebo|Part 1 and part 2 of the trial.
16267460|NCT04903509|Experimental|BI 1820237 + liraglutide|Part 3 of the trial.
16267461|NCT04903509|Placebo Comparator|Placebo + liraglutide|Part 3 of the trial.
16267466|NCT04903483|Other|target-controlled infusion (propofol) with depth of anesthesia monitoring|In this group, propofol dosing is adjusted with bispectral index monitoring.
16267467|NCT04903483|Other|target-controlled infusion (propofol) without depth of anesthesia monitoring|In this group, propofol dosing is adjusted without bispectral index monitoring.
16267468|NCT04903470|Experimental|Effect of atropine on the defecation|Atropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine.
16267503|NCT04903197|Experimental|Arm 1A|VAY736 single agent dose escalation in patients with diffuse large B cell lymphoma (DLBCL)
16267469|NCT04903470|Experimental|Effect of bisacodyl on the defecation|Bisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl.
16267470|NCT04903457|Experimental|Real stimulation before motor learning training|Patients receive five sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
16267471|NCT04903457|Active Comparator|Sham stimulation before motor learning training|Patients receive five sessions of sham stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
16267472|NCT04903444|Experimental|with AI navigation system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
16267473|NCT04903444|No Intervention|without AI navigation system|The endoscopists in the contrpl group performs ERCP routinely without special prompts.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
16267474|NCT04903431|Active Comparator|Clinician-administered Crisis Response Plan|Clinicians will administer the Crisis Response Plan to 75 military veterans.
16267475|NCT04903431|Experimental|Self-administered Crisis Response Plan|Participants will complete a self-guided version of the Crisis Response plan online.
16267476|NCT04903405||Sepsis|
16267477|NCT04903392|Experimental|Backward Walking Group|Conventional therapy + Backward Walking Training
16267478|NCT04903392|Other|Forward Walking Group|Conventional therapy + Forward Walking Training
16267479|NCT04903379|Other|Pain science education and self management strategies|The intervention will be educational in the form of the provision of contemporary pain science education and supportive advice from people with a history of persistent pain. The duration of the webinar will be 90 minutes.
16267480|NCT04903366||Chronic wound|Any chronic wound, for greater than 30 days with minimal improvement
16267481|NCT04903366||Glaucoma|Any diagnosis of glaucoma and active prescription of timolol drops
16267482|NCT04903353|Active Comparator|Treatment with Risperidone|Patients prescribed Risperidone
16267483|NCT04903353|Active Comparator|Treatment with Aripiprazole|Patients prescribed Aripiprazole
16267484|NCT04903327|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
16267485|NCT04903327|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
16267486|NCT04903314|Experimental|Cohort I|Xcopri to be administered to ages 12 to < 18 years not to exceed 400 mg/day.
16267487|NCT04903314|Experimental|Cohort IIa|Xcopri to be administered to ages 6 to < 12 years not to exceed 400 mg/day.
16267488|NCT04903314|Experimental|Cohort IIb|Xcopri to be administered to ages 4 to < 6 years not to exceed 400 mg/day.
16267489|NCT04903314|Experimental|Cohort III|Xcopri to be administered to ages 2 to < 4 years not to exceed 400 mg/day.
16267490|NCT04903301|Experimental|Study Group|Contoura Vision LASIK using Phorcides Analytic Software
16267491|NCT04903288|Experimental|Eladocagene Exuparvovec|Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.
16267492|NCT04903275|Experimental|Fluoride and Laser|In the split-mouth design, the left maxillary anterior teeth receive topical fluoride application and carbon dioxide (CO2) laser irradiation.
16267493|NCT04903275|Active Comparator|Fluoride|In the split-mouth design, this arm - the contralateral teeth (right maxillary incisors), will receive topical fluoride application.
16267494|NCT04903262|Experimental|ECCO2R|"Patients will be treated with standardized ventilation: constant flow, assist/control; VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45. ECCO2R blood flow between 1000 and 1500 mL/min. Anticoagulation with unfractionated heparin to a target aPTT of 1.5 - 2.0x baseline. Target: maintain PaCO2 at baseline value ± 20% of baseline settings with a VT = 6 mL/kg provided that pH remains ≥ 7.30. Following 2-hour run-in time, VT will be reduced to 5 mL/kg. Sweep gas will be initiated and VT decreased to 4.5 then 4 mL/kg, and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cmH2O. Respiratory rate progressively decreased to a minimum of 12 bpm (eventual increases in sweep gas flow). If PaCO2 > 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT."
16267495|NCT04903262|No Intervention|Standard of care|"Patients will be treated with standardized ventilation: constant flow, assist/control; VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45."
16267496|NCT04903249|Experimental|Affect-regulated exercise prescription|"Participants receive instructions to adjust their pace of exercise so that they feel fairly good or better (i.e., a rating of +1 or higher on the Feeling Scale) while exercising and to avoid any increases in intensity that promote feeling fairly bad or worse. If no intensity of exercise feels at least fairly good participants will be told to exercise at an intensity that feels as positive as possible."
16267497|NCT04903236||Non-patient healthy volunteer|Undertake MR Imaging to enable development of sequences.
16267498|NCT04903236||Patient|Provide weekly blood and urine samples during period of radiotherapy as well as additional MR images.
16267501|NCT04903210|Experimental|NMN group|NMN10000 WRIGHT LIFE® + lifestyle modification.
16267502|NCT04903210|Other|Control group|Lifestyle modification only.
16268116|NCT04898959||Group 1|Lower extremity amputees
16267507|NCT04903184|Experimental|Group RUTI|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
16267508|NCT04903184|Placebo Comparator|Group Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
16267509|NCT04903171|No Intervention|GROUP ONE|The participants do not receive incentive to visit any gardens
16267510|NCT04903171|Placebo Comparator|GROUP TWO|The participants receive incentives by carers to visit regularly a conventional sensory garden
16267511|NCT04903171|Experimental|GROUP THREE|The participants receive incentives by carers to visit regularly an enriched garden
16267512|NCT04903158|Experimental|Test group|Test formulation of SHR3680
16267513|NCT04903158|Other|Reference group|Reference formulation of SHR3680.
16267514|NCT04903119|Experimental|Level 1|Patients in this group will receive 100mg Nilotinib PO BID.
16267515|NCT04903119|Experimental|Level 2|Patients in this group will receive 200mg Nilotinib PO BID.
16267516|NCT04903119|Experimental|Level 3|Patients in this group will receive 300mg Nilotinib PO BID.
16267517|NCT04903119|Experimental|Level 4|Patients in this group will receive 400mg Nilotinib PO BID.
16267518|NCT04903106|Experimental|Meniscal Tear|Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
16267519|NCT04903106|Experimental|Meniscal Insufficiency|Subject requires a MAT for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.
16267520|NCT04903093|Experimental|Part A: Abrocitinib Tablet|
16267521|NCT04903093|Experimental|Part A: Abrocitinib Suspension F1|
16267522|NCT04903093|Experimental|Part A: Abrocitinib Tablet + Famotidine|
16267523|NCT04903093|Experimental|Part B: Abrocitinib Suspension F1|
16267524|NCT04903093|Experimental|Part B: Abrocitinib Suspension F2|
16267525|NCT04903093|Experimental|Part B: Abrocitinib Suspension F3|
16267526|NCT04903093|Experimental|Part B: Abrocitinib Suspension F4|
16267527|NCT04903093|Experimental|Part B: Abrocitinib Suspension F5|
16267528|NCT04903093|Experimental|Part B: Abrocitinib Suspension F6|
16267529|NCT04903093|Experimental|Part B: Abrocitinib Suspension F1 + Famotidine|
16267530|NCT04903093|Experimental|Part B: Abrocitinib Suspension F2 + Famotidine|
16267531|NCT04903093|Experimental|Part B: Abrocitinib Suspension F3 + Famotidine|
16267532|NCT04903093|Experimental|Part B: Abrocitinib Suspension F4 + Famotidine|
16267533|NCT04903093|Experimental|Part B: Abrocitinib Suspension F5 + Famotidine|
16267534|NCT04903093|Experimental|Part B: Abrocitinib Suspension F6 + Famotidine|
16267535|NCT04903080|Experimental|Treatment (HER2 CAR T cells), Phase I Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
16267536|NCT04903080|Experimental|Treatment (HER2 CAR T cells), Surgical Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0 followed by surgical tumor resection 4-6 weeks following HER2 CAR T cell infusion. Treatment repeats every 8 to 15 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
16267537|NCT04903054|Experimental|Lulizumab + SOC|"N=27 participants will receive a loading dose of lulizumab on Day 0, the day of surgery. This will be followed by a maintenance dose administered on a weekly basis (weeks 1 through 26 post-transplant), followed by administration every two weeks (weeks 28 through 52 post-transplant). Method of administration: subcutaneously. Dose unit of measure: milligrams (mgs).
~Plus (+) Standard of Care (SOC) Regimen, per protocol-
~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:
~Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.
~Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.
~Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.
~Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
16267538|NCT04903054|Active Comparator|Tacrolimus + SOC|"N=27 participants will receive tacrolimus initiated according to local standard of care and adjusted over time (maintenance) to target optimal trough levels measured in ng/mL: 0 to 6 months, 7 to 12 months and, thereafter, until completion of study participation. Dose unit of measure: mg/kg.
~Plus (+) Standard of Care (SOC) Regimen, per protocol-
~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:
~Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.
~Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.
~Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.
~Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
16267539|NCT04903028|Sham Comparator|Sham rTMS|Participants will be fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device with adjustable output amplitude and powered by a 9-V battery. We will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses or 1 Hz over mOFC total 900 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
16267540|NCT04903028|Active Comparator|Active rTMS 10 Hz DLPFC|A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.
16267614|NCT04902547|Experimental|Multidisciplinary Tapering Program Only|Patients in this arm will take part in the clinical multidisciplinary opioid tapering program (MTP).
16268117|NCT04898946||BNT162b2|Subjects who receive mRNA vaccine BNT162b2.
16267541|NCT04903028|Active Comparator|Active rTMS 1 Hz mOFC|A stimulation frequency of 1Hz, E-field-modeling to determine TMS intensity and coil orientation, session time of 15 minutes, and 900-total pulses per day, will be the same for all subjects (both active and sham). TMS will be delivered over the left mOFC.
16267542|NCT04903015|Experimental|professional Soccer players|
16267543|NCT04903015|Active Comparator|athletes not exposed to head injuries.|
16267544|NCT04903002|Other|Crossover sequence 1: Oxytocin first|Patients receive 2-weeks courses of 24-IU oxytocin, placebo, 48-IU oxytocin.
16267545|NCT04903002|Other|Crossover sequence 2: placebo first|Patients receive 2-weeks courses of placebo, 24-IU oxytocin, 48-IU oxytocin.
16267546|NCT04902976|Active Comparator|CPC+Zn|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride associated with 0.28% zinc lactate solution.
16267547|NCT04902976|Active Comparator|CPC|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride solution.
16267548|NCT04902976|Placebo Comparator|Negative Control|patients submitted to mouth rinse with distilled water.
16267549|NCT04902963|Experimental|Meeting indication for short term ventilation tube placement|Adult patients meeting standard criteria for short-term ventilation tube placement were offered placement of a bioabsorbable ear tube in place of a durable ear tube that would later be removed.
16267550|NCT04902950|Placebo Comparator|Group 1|The solution of saline will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 1 will undergo application of three normal saline soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
16267551|NCT04902950|Experimental|Group 2|The solution of Tranexamic Acid (TXA) will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 2 will undergo application of three (TXA) soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
16267552|NCT04902937||premenopausal patients|
16267553|NCT04902937||postmenopausal patients|
16267554|NCT04902924|Experimental|Repeated cold-water immersion|In this arm, the participants undergo repeated cold water immersion at 10°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crest
16267555|NCT04902924|Active Comparator|Repeated warm-water immersion|In this arm, the participants undergo repeated warm water immersion at 40°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crestParticipants will be immersed up to the iliac crest.
16267556|NCT04902924|Other|Control|In this arm, the participants undergo the control intervention which comprises to remain seated for 12.5 min. The participants, that will perform the muscle damaging protocol under hypoxia will also be treated with the control condition.
16267557|NCT04902911|Experimental|Antigen testing in those who have history of COVID-19|Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
16267558|NCT04902911|Experimental|Antigen testing in those who do not have history of COVID-19 and COVID immunization|Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
16267559|NCT04902898|Other|Circumcision|Adult patients treated with circumcision
16267560|NCT04902898|Active Comparator|Circumcision with device|Adult patients treated with sterile single-use circular stapling device CIRCCURERII (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
16267561|NCT04902885|Active Comparator|Trilaciclib, carboplatin, etoposide|Trilaciclib plus Carboplatin combined with Etoposide (first line ES-SCLC patients)
16267562|NCT04902885|Placebo Comparator|Placebo, carboplatin, etoposide|Placebo plus Carboplatin combined with Etoposide (first line ES-SCLC patients)
16267563|NCT04902885|Active Comparator|Trilaciclib, Topotecan|plus Topotecan (second/third line ES-SCLC patients)
16267564|NCT04902885|Placebo Comparator|Placebo, Topotecan|Placebo plus Topotecan (second/third line ES-SCLC patients)
16267565|NCT04902872|Experimental|Phase 1 Dose Escalation (Daily Dosing x 5)|CBX-12 administered on a daily x 5 every 3 weeks schedule
16267566|NCT04902872|Experimental|Phase 1 Dose Escalation (Daily Dosing x 3)|CBX-12 administered on a daily x 5 every 3 weeks schedule
16267567|NCT04902872|Experimental|Phase 2 Ovarian Cancer Expansion Cohort|CBX-12 administered on a daily x 5 every 3 weeks or on a daily x 3 every 3 weeks schedule
16267568|NCT04902872|Experimental|Phase 2 Small Cell Lung Cancer Expansion Cohort|CBX-12 administered on a daily x 5 every 3 weeks or on a daily x 3 every 3 weeks schedule
16267569|NCT04902859|Experimental|Clonidine with eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
16267570|NCT04902859|Placebo Comparator|Placebo with eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
16267571|NCT04902859|Experimental|Clonidine without eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
16267572|NCT04902859|Placebo Comparator|Placebo without eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
16267573|NCT04902846||Control (no kidney injury)|Patients who receive ICI but no develop kidney injury
16267574|NCT04902846||Case (kidney injury)|Patients who receive ICI and develop kidney injury
16267575|NCT04902833||Cohort I|"Approximately 75 anemic (Hgb <11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis.
~- Single Blood Draw"
16267576|NCT04902833||Cohort 2|"25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia
~-Single Blood Draw"
16267612|NCT04902586|No Intervention|C group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）
16268173|NCT04898569|Placebo Comparator|Normal saline|
16267577|NCT04902820|Experimental|PrEPTECH intervention recipients|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and an online pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
16267578|NCT04902820|Active Comparator|Control resource-list only recipients|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
16267579|NCT04902807||Patients|"based on the potential for inclusion of patient's cohort followed in Necker hospital with PIDs and poly-autoimmunity related to known genetic defects. Recruitments will be made at Pediatric Rheumatology Immuno Hematology department, and paediatric Gastroenterology department (n=250).
~Collection of blood, urine and stools at inclusion and blood at 12 months consultation/ follow-up."
16267580|NCT04902807||Patients' relatives (control)|Brothers or sisters of the patients (n=125). Collection of blood, urine and stools at inclusion.
16267581|NCT04902807||Patients with unrelated diseases (control)|"Recruitments will be made at the Paediatric Gastroenterology Department, in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery at Necker's Hospital. Participants will be included if not diagnosed PIDs and poly-autoimmunity (n=125).
~Collection of blood, urine and stools."
16267582|NCT04902794|Experimental|Light Emitting Diode|Light Emitting Diode in the Treatment of Menopause Genitourinary Syndrome
16267583|NCT04902794|Sham Comparator|Light Emitting Diode Sham|Light Emitting Diode device turned off
16267584|NCT04902781|Experimental|Experimental: AT-007|AT-007 The starting dose in Part A will be 5 mg/kg for all age groups. For each age group, Part B of the study will not start until the optimum dose evaluated in Part A has been identified
16267585|NCT04902781|Placebo Comparator|Placebo|Placebo given orally
16267586|NCT04902768||Adults with congenital heart disease|
16267587|NCT04902742|Active Comparator|Ganglion impar block group|Fluoroscopy-guided ganglion impar block is applied to patients in this group.
16267588|NCT04902742|Active Comparator|Caudal epidural steroid injection group|Fluoroscopy-guided caudal epidural steroid injection is applied to patients in this group.
16267589|NCT04902729|Active Comparator|Oxytocin 1IU|Oxytocin 1IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
16267590|NCT04902729|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16267591|NCT04902716|Experimental|Precision Nursing, Frail women, Cognitive function, Sleep quality, Emotional state,|According to the characteristics of the elders in the community and making good use of health policies and local resources, a 12-week appropriate diversified curriculum is arranged as intervention measures.
16267592|NCT04902703|Experimental|Sargramostim|250 mcg/m2/day subcutaneously 5 days/week for 24 weeks
16267593|NCT04902703|Placebo Comparator|Placebo Control - Saline|Placebo comparator (saline) subcutaneously 5days/week for 24 weeks
16267594|NCT04902677||School|
16267595|NCT04902664|Experimental|Intervention Arm|Intervention arm physicians will receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals, along with physician-facing education materials. This email will be sent before each patient visit for all ten patients in the study. Ten patients of intervention arm physicians with upcoming physicals will receive patient education materials one to two days before their visit.
16267596|NCT04902664|Placebo Comparator|Control Arm|Control arm physicians receive an email with information on the general visit preparation tips that their patients will receive. Ten patients of control arm physicians with upcoming physicals will receive general visit preparation tips one to two days before their visit.
16267597|NCT04902651|Experimental|HM242-Gel|
16267598|NCT04902651|Active Comparator|Intrasite Gel|
16267599|NCT04902638|Active Comparator|Diabetic patients with steroid|
16267600|NCT04902638|Placebo Comparator|Diabetic patients without steroid|Injection of normal saline
16267601|NCT04902638|Active Comparator|Pre-diabetic patients with steroid|
16267602|NCT04902638|Placebo Comparator|Pre-diabetic patients without steroid|Injection of normal saline
16267603|NCT04902638|Active Comparator|Non-diabetic patients with steroid|
16267604|NCT04902638|Placebo Comparator|Non-diabetic patients without steroid|Injection of normal saline
16267605|NCT04902625|Active Comparator|Naltrexone-Bupropion combination|The patients in this arm will receive 2 tablets of naltrexone-bupropion 8/90mg 2 times daily in combination with the Back On Track module.
16267606|NCT04902625|No Intervention|Control|The patients is this arm will only participate in the Back On Track module and will not receive any investigational or placebo product.
16267607|NCT04902612|Experimental|HM242-Solution|
16267608|NCT04902612|Active Comparator|Saline|
16267609|NCT04902599|Active Comparator|Vaser ulstrasound-assisted dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with the Vaser ultrasound-assisted dissection technique.
16267610|NCT04902599|Active Comparator|Blunt dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with blunt dissection technique.
16267611|NCT04902586|Experimental|E group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）and TTFields therapy during RT. The TTFields therapy started on the day the radiotherapy started.
16267613|NCT04902573||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
16267615|NCT04902547|Experimental|Patient Education Workshop & Multidisciplinary Tapering Program|As above, though patients in this group will also take part in an opioid education workshop
16267616|NCT04902534|Experimental|Naoqingzhiming Tablets|"Naoqingzhiming Tablets, specification:500mg(contains echinacoside 180mg) Single dose ascending. Qualified subjects will enter 6 dose groups in order from low to high: 180mg, 360mg, 720mg, 1080mg, 1620mg and 2160mg, with increasing dose design The first group (180mg) is a pre-experiment. Two subjects were selected and all received the test drug.
~Groups 2 to 6 received the experimental drug in 8 patients per group. Multi-dose ascending was divided into two groups: 360mg and 720mg. 10 subjects in each group received the test drug 3 times a day for 14 consecutive days."
16267617|NCT04902534|Placebo Comparator|placebo (without active ingredients echinoside)|Placebo Tablets, specification: 500mg(without echinoside) Single dose. Groups 2 to 6 received the placebo in 2 patients per group. Multi-dose ascending. Two people in each group received placebo 3 times a day for 14 consecutive days.
16267618|NCT04902521|Experimental|Transcranial magnetic stimulation with constraint induced movement therapy|CIMT/TMS: Five participants will receive a one-hour weekly occupational therapy session of CIMT with 2-hours of daily home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of TMS 1HZ.
16267619|NCT04902521|Sham Comparator|constraint induced movement therapy Sham transcrianial magnetic stimulation|(CIMT/sham TMS): Five participants will receive a one-hour weekly session of CIMT with 2-hours daily of home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of sham TMS 1HZ.
16267620|NCT04902508|Experimental|Explicit Master Plus No Additional Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
16267621|NCT04902508|Experimental|Explicit Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of explicit treatment."
16267622|NCT04902508|Experimental|Explicit Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of implicit treatment."
16267623|NCT04902508|Experimental|Explicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of explicit treatment."
16267624|NCT04902508|Experimental|Explicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of implicit treatment."
16267625|NCT04902508|Experimental|Implicit Master Plus No Additional Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
16267626|NCT04902508|Experimental|Implicit Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of implicit treatment."
16267627|NCT04902508|Experimental|Implicit Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of explicit treatment."
16267628|NCT04902508|Experimental|Implicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of implicit treatment."
16267629|NCT04902508|Experimental|Implicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of explicit treatment."
16267630|NCT04902495|Experimental|Pulp Dressing MTA Angelus|pulp therapy
16267631|NCT04902495|Experimental|Pulp Dressing MTA Pro Root|pulp therapy
16267632|NCT04902495|Experimental|Pulp Dressing Biodentine|pulp therapy
16267633|NCT04902482|Experimental|iCycle training|Participants will attend 3 training sessions per week at the RNOH. During these sessions, participants will tether their wheelchair (from under the seat) to the front of the iCycle, and their feet will be attached to the iCycle pedals. For training, participants will complete virtual reality cycle races displayed on a large screen in front of the iCycle: the more voluntary effort the participant contributes the greater the speed of the avatar. During cycling, a motor will control cycling speed, and muscle stimulation (FES) will be applied to the leg muscles (right and left gluteus, quadriceps and hamstrings) on alternative revolutions of the pedals. A dashboard screen will display controls for the stimulation, speed, brake, game switch and an emergency stop. Sessions will increase from 20 mins or the maximum achievable at the start (whichever is lower) up to at least 1 hour.
16267634|NCT04902469|Experimental|Pleasant Odor|Participants in this condition will sniff the olfactory cue they rate as both pleasant (>5 on the 1-9 scale) and the most intense following cigarette cue exposure.
16267635|NCT04902469|Other|Odor Blank|Participants in this condition will sniff a neutral olfactory cue (odor blank) following cigarette cue exposure.
16267636|NCT04902456|Experimental|Power Chain and Crimpable hook for En-masse retraction|"Retraction will start on a 0.017x0.025 Stainless Steel wire using elastomeric chain ( force applied will be 212 g per side ) extending between the crimpable hooks and the miniscrew"
16267637|NCT04902456|Experimental|T-loop|"Closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine."
16267640|NCT04902430|Experimental|En-Masse Retraction using sliding mechanics (Friction)|6 anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
16267641|NCT04902430|Experimental|En-Masse Retraction using segmental mechanics (Frictionless)|6 anterior teeth (en-Masse) retracted using a T- loop
16267642|NCT04902417|No Intervention|Low Dairy Habitual Diet|Participants will follow their usual diet for 6-weeks, which includes low dairy consumption as screened for with the inclusion criteria.
16267643|NCT04902417|Experimental|High Dairy Diet|Participants will be provided with 3 servings of dairy per day to replace other foods within their diet (preventing weight gain over the intervention period) for 6-weeks
16294170|NCT04716660||Women receiving epidural analgesia for labor|
16267644|NCT04902404|Experimental|First Pathways Group|Parents in the First Pathways Game group will be instructed to log into the First Pathways website daily and play First Pathways games with their child. They will receive daily reminders for the first month after randomization but will not receive reminders for the second month.
16267645|NCT04902404|No Intervention|Wait-list Control|Parents in the wait-list control group will receive access to the First Pathways game after completing their final two-month study assessment.
16267646|NCT04902391|Experimental|Acute Mental Health Care Bundle|We developed an evidence-based bundle of care to address current gaps in care. The bundle: 1) brings together multiple evidence-based assessment tools (ASQ, HEADS-ED) to ensure efficient, high-value ED-based care; 2) removes barriers to assessment and builds connections to care: Assessments are conducted by a mental health care provider and families have access to urgent follow-up care; and 3) prioritizes family engagement: A shared decision-making framework (Choice and Partnership) is used to promote children and youth as stewards of their care and support partnership between EDs and follow-up services with the duration of care determined collaboratively by the patient and their provider.
16267647|NCT04902391|No Intervention|Usual ED-Based Mental Health Care|Local standards of ED-based mental health care will be delivered at control sites. Site leads have determined that this care does not involve the 3 specific core innovations in the bundle. Local care standards are similar across study sites and include use of CTAS score at triage (but no mental health risk assessment tool), ED physician medical clearance and assessment of consultation need, and no consistent mental health follow-up plan. Sites that are randomized to the control arm will not adopt core bundle elements.
16267648|NCT04902378|Experimental|Tandem t:slim X2 insulin pump with Control IQ technology plus CGM|Participants randomized to the intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology and Dexcom G6 Continuous Glucose Monitor.
16267649|NCT04902378|No Intervention|Standard insulin delivery (multiple daily injections (MDI) or pump) and CGM|Participants randomized to the control group will be fitted with the Dexcom G6 Continuous Glucose Monitor. They will continue to use standard insulin delivery (MDI or pump) and CGM.
16267650|NCT04902365|Active Comparator|Patients group 1|This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome
16267651|NCT04902365|Placebo Comparator|Patients group 2|This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome
16267652|NCT04902352|Experimental|Periadventitial dissection|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process."
16267653|NCT04902352|Active Comparator|NO periadventitial dissection|For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
16267654|NCT04902339|Experimental|MORE+NF|
16267655|NCT04902339|Active Comparator|MORE|
16267656|NCT04902339|Active Comparator|Supportive Psychotherapy|
16267657|NCT04902326|Active Comparator|Enhanced Usual Care (EUC)|Receives one intervention: automated educational text messages
16267658|NCT04902326|Experimental|Financial Incentives|Receives two interventions: automated educational text messages and financial incentives.
16267659|NCT04902326|Experimental|Tailored Messages|Receives two interventions: autonomy-supportive automated educational text messages and tailored text messages.
16267660|NCT04902326|Experimental|Combo Arm-Financial Incentives Plus Tailored Messages Arm|Receives three interventions: autonomy-supportive automated educational text messages, tailored text messages, and financial incentives.
16267661|NCT04902313|Experimental|Cancer patients|Youths (10-18 y) with newly diagnosed cancer, as well as their family members.
16267662|NCT04902313|Active Comparator|Pediatric patients|Youths (10-18 y) with a chronic somatic disease receiving care at a pediatric outpatient facility.
16267663|NCT04902300||Adolescent|adolescent attending high school
16267664|NCT04902287|Experimental|TIES Engagement Strategies|Participants in this arm will receive a 30-minute TIES engagement intervention during their referral phone call.
16267665|NCT04902287|No Intervention|Referral as Usual|Participants in this arm will receive a standard call to schedule an intake appointment by an administrative assistant with no clinical training.
16267666|NCT04902274|Experimental|Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the experimental group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute application of tDCS during each treatment session via the Halo Sport (Halo Neuroscience, San Francisco, CA) headset. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
16267667|NCT04902274|Sham Comparator|Sham Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the sham control group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute sham tDCS treatment, where the patient is wearing the tDCS headset, but stimulation is only applied for 30 seconds of the 20-minute period. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
16267668|NCT04902261|Experimental|Tislelizumab combined with Nab-paclitaxel and Gemcitabine|
16267669|NCT04902261|Active Comparator|Nab-paclitaxel and Gemcitabine|
16267670|NCT04902248|Experimental|Over-the-scope clips|"The OTSC® System Set is an instrument for flexible endoscopy
~The OTSC® System Set consists of an applicator cap with a mounted OTSC® clip, thread, thread retriever and a hand wheel for clip release.
~The OTSC® clip is delivered by means of an applicator cap mounted to the tip of gastroscopes or colonoscopes. The clip is released by tightening the thread with the hand wheel.
~The OTSC® clip for flexible endoscopy is a superelastic Nitinol device for compression and approximation of tissue in the digestive tract"
16267736|NCT04901845||Patients applying to Primary Healthcare Consultation|Consequent patients applying to the Primary healthcare to consult for any reason during 2 week period
16267737|NCT04901845||Patients applying to Specialized Healthcare Consultation|Consequent patients applying to the Specialized healthcare to consult for any reason during 2 week period
16267671|NCT04902248|Experimental|angiographic embolization|"The procedure was performed in the angiographic suite and under local anaesthetics to the patient's groin. The celiac and then gastroduodenal artery or the left gastric artery was selectively cannulated depending on ulcer location.
~Coils were deposited distal to the bleeding point. Gel foam particles were then packed into the artery and its collaterals. This was followed by further coils deposited in its proximal portion until complete cessation of arterial flow. Our protocol requested empiric embolisation of the artery even in the absence of active contrast extravasation or a pseudoaneurysm."
16267672|NCT04902235|Experimental|CRH administration|Experimental: CRH administration
16267673|NCT04902235|Placebo Comparator|Placebo administration|Control: Placebo administration
16267674|NCT04902222||Patients undergoing primary hip or knee arthroplasty|Patients undergoing primary hip or knee arthroplasty
16267675|NCT04902209||1- study group- patients after surgical treatment of acetabular fracture|1- study group- patients after surgical treatment of hip acetabular fracture
16267676|NCT04902209||2- control group- healthy subjects|2- control group- healthy subjects age, BMI matched
16267677|NCT04902196|Experimental|Group 1|persons with chronic low back pain of an non-specific origin
16267678|NCT04902196|Active Comparator|Group 2 (Control group)|"healthy persons (pain-free)"
16267679|NCT04902183|Experimental|10^9 dose of exosomes overexpressing CD24|The patients will receive the dose of 10^9 exosomes overexpressing CD24
16267680|NCT04902183|Experimental|10^10 dose of exosomes overexpressing CD24|The patients will receive the dose of 10^10 exosomes overexpressing CD24
16267681|NCT04902170|Experimental|study group|Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 30mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
16267682|NCT04902170|Active Comparator|control group|Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 27mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
16267684|NCT04902131|Experimental|MENOPUR pen|
16267685|NCT04902131|Active Comparator|MENOPUR powder|
16267686|NCT04902105|Other|Cohort A|"Ecopipam HCL - 2 doses of 200mg
~Mefenamic acid 250mg Q6H for 7 days"
16267687|NCT04902105|Other|Cohort B|"Ecopipam HCL - 2 doses of 200mg
~Divalproex acid 1250mg QD for 10 days"
16267688|NCT04902092|Active Comparator|High Intensity Physical Training|12-week, 36 session, cardiorespiratory-focussed physical exercise program delivered by an accredited exercise physiologist
16267689|NCT04902092|Active Comparator|Low Intensity Physical Training|12- week, 36 session, strength-focussed physical exercise program delivered by an accredited exercise physiologist
16267690|NCT04902066|Experimental|Cognitive Behavioural Virtual Reality Therapy (CBT-VR)|The CBT-VR consists of traditional CBT with the augmentation of virtual reality exposure. The virtual reality exposure comprises four virtual social environments (a bus, café, street, and supermarket). These are daily social situations that generally elicit paranoid thinking in patients with a schizophrenia spectrum disorder. While virtually engaging in these distressing situations, the therapist will facilitate a CBT dialogue aimed at generating alternative (i.e. non-threatening) thinking, diminishing safety behaviours (e.g. social isolation), and building up new coping strategies. This is expected to alleviate distress, anxiety, and improve daily social functioning. Preliminary findings reveal this virtual reality program to be well-tolerated and highly effective in reducing paranoia and anxiety in psychosis. Patients will be offered 10 individual sessions.
16267691|NCT04902066|Active Comparator|Traditional Cognitive Behavioural Therapy|The treatment in the CBT group will follow the core principles of CBT used for psychotic disorders. The CBT treatment facilitates an individualised, problem-oriented approach, and uses key CBT techniques such as developing a problem and goal list, normalising psychotic-like experiences, evaluation of appraisals, and removing or diminishing safety behaviour. Patients will be offered 10 individual sessions.
16267692|NCT04902040|Experimental|Arm A (radiation therapy, plinabulin, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients receive plinabulin IV over 30-60 minutes on days 1 and 4 of cycle 1, days 1 and 4 of cycle 2 (if receiving radiation therapy in cycle 2), and day 1 and or 15 (any day receiving immunotherapy) of subsequent cycles. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
16267693|NCT04902040|Active Comparator|Arm B (radiation therapy, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
16267694|NCT04902027|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Rrecurrent/metastatic Head and Neck Cancers will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles
16267695|NCT04902014|Active Comparator|Education|
16267696|NCT04902014|Experimental|Motivational Interviewing|
16267697|NCT04902014|Experimental|Wearable Fitness Tracker|
16267698|NCT04902014|Experimental|Wearable Fitness Tracker+|
16267699|NCT04902001|Experimental|Adolescents with obesity|Adolescents with obesity aged 12-16 years old
16267700|NCT04901988|No Intervention|Arm A|In Arm A, patients and clinicians will remain blinded to the ctDNA result and will be managed as per standard of care with regular clinical review and imaging, and treated if they develop evidence of disease recurrence.
16267701|NCT04901988|Experimental|Arm B|Patients randomised to Arm B will not be blinded to the positive ctDNA result and will be treated with the intervention.
16267702|NCT04901975|Experimental|Spironolactone|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.
~All SV children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation.
~Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every ~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg.
~Spironolactone administration will begin after the Fontan procedure in the hospital prior to discharge or at the first outpatient visit ~ 2 weeks after discharge."
16267703|NCT04901975|No Intervention|Observational|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.
~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
16267704|NCT04901975|No Intervention|Control|"The purpose of this study is to non-invasively characterize the fibrotic consequences of SV physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion (figure 1) along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.
~Control subjects who are non-SV patients but who have normal heart function who are undergoing CMR for evaluation (eg patients undergoing CMR for vascular ring evaluation, family history of congenital heart disease but found to be normal, etc) will have study related MRI and CMR sequences performed."
16267705|NCT04901962|Experimental|JOBST® Confidence compression garments|The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.
16267706|NCT04901949||BMI Group 1|If BMI is less than 24,9 kg/m2
16267707|NCT04901949||BMI Group 2|If BMI is between 25 - 30 kg/m2
16267708|NCT04901949||BMI group 3|If BMI is more than 30,1 kg/m2
16267709|NCT04901936|Experimental|Pegcetacoplan|
16267710|NCT04901923|Experimental|Part 1 Cohort 1|Participants will receive ACP-196 2.5 mg capsule orally BID on Day 1.
16267711|NCT04901923|Experimental|Part 1 Cohort 2|Participants will receive ACP-196 5 mg (2 x 2.5 mg capsules) orally BID on Day 1.
16267712|NCT04901923|Experimental|Part 1 Cohort 3|Participants will receive ACP-196 25 mg capsule orally BID on Day 1.
16267713|NCT04901923|Experimental|Part 1 Cohort 4|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally BID on Day 1.
16267714|NCT04901923|Experimental|Part 1 Cohort 5|Participants will receive ACP-196 100 mg (4 x 25 mg capsules) orally QD on Day 1.
16267715|NCT04901923|Experimental|Part 2 Cohort 6|Participants will receive ACP-196 75 mg (3 x 25 mg capsules) orally QD on Day 1 and Day 8.
16267716|NCT04901923|Experimental|Part 3 Cohort 7|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally QD on Day 1, itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then ACP-196 50 mg (2 x 25 mg capsules) along with itraconazole 200 mg capsule QD on Day 9 under fasting state.
16267717|NCT04901910|Experimental|Physical Activity (PA) Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
16267718|NCT04901910|Experimental|Verdi plus PA Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
16267719|NCT04901910|No Intervention|Attention-Control condition Social Media Group|This will be an 8 week Social Media Group available to the participant with social media topics.
16267720|NCT04901897|Experimental|kalifilcon A|kalifilcon A daily disposable contact lens
16267721|NCT04901897|Active Comparator|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
16267722|NCT04901897|Active Comparator|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
16267723|NCT04901884|Experimental|One arm / exploratory study|Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours.
16267724|NCT04901871|Active Comparator|1 (0.02 mg/kg, age<65)|Remimazolam of 0.02 mg/kg will be infused in patients aged<65.
16267725|NCT04901871|Active Comparator|2 (0.07 mg/kg, age<65)|Remimazolam of 0.07 mg/kg will be infused in patients aged<65.
16267726|NCT04901871|Active Comparator|3 (0.12 mg/kg, age<65)|Remimazolam of 0.12 mg/kg will be infused in patients aged<65.
16267727|NCT04901871|Active Comparator|4 (0.17 mg/kg, age<65)|Remimazolam of 0.17 mg/kg will be infused in patients aged<65.
16267728|NCT04901871|Active Comparator|5(0.22 mg/kg, age<65)|Remimazolam of 0.22 mg/kg will be infused in patients aged<65.
16267729|NCT04901871|Active Comparator|6(0.27 mg/kg, age<65)|Remimazolam of 0.27 mg/kg will be infused in patients aged<65.
16267730|NCT04901871|Active Comparator|7 (0.02 mg/kg, age≥65)|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
16267731|NCT04901871|Active Comparator|8 (0.07 mg/kg, age≥65)|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
16267732|NCT04901871|Active Comparator|9 (0.12 mg/kg, age≥65)|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.
16267733|NCT04901871|Active Comparator|10 (0.17 mg/kg, age≥65)|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
16267734|NCT04901871|Active Comparator|11 (0.22 mg/kg, age≥65)|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
16267735|NCT04901871|Active Comparator|12 (0.27 mg/kg, age≥65)|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
16267738|NCT04901832|Experimental|Experimental Group|The intervention in this group is stretching exercises with the aim of prevention and reduction of leg muscle cramps among patients undergoing hemodialysis
16267739|NCT04901832|No Intervention|Control Group|The participants in this group used as reference group
16267742|NCT04901793|Experimental|Virtual Reality Intervention Group|Patient is fitted with a Virtual Reality headset and handheld remote control. Subject is able to play an interactive game during the duration of the in-office procedure.
16267743|NCT04901793|No Intervention|Control Group|standard of care
16267744|NCT04901780|Experimental|PPCS|Novel intervention
16267745|NCT04901780|Active Comparator|CBS|Cross arm stretch gave to individuals
16267746|NCT04901767||Receiving drug coated balloon (DCB)|
16267747|NCT04901767||Receiving drug eluting stent (DES)|
16267748|NCT04901754|Experimental|Camrelizumab Plus Apatinib|camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally
16267749|NCT04901741|Experimental|Arm 1: olaptesed pegol + pembrolizumab + nanoliposomal irinotecan + 5-FU + LV|
16267750|NCT04901741|Experimental|Arm 2: olaptesed pegol + pembrolizumab + gemcitabine + nab-paclitaxel|
16267751|NCT04901728||Target Population|People living with HIV and following a DTG/3TC drug regimen
16267752|NCT04901728||Control Group on Dual Regimens|The first control population will include a group on dual regimens other than DTG/3TC and a group on triple therapy. In the control group of patients receiving dual therapies, we will include patients (i) on Juluca (DTG/rilpivirine[RPV]), (ii) on boosted darunavir plus lamivudine (DRV/r or DRV/c + 3TC), and (iii) on boosted darunavir plus raltegravir (DRV/r or DRV/c + RAL).
16267753|NCT04901728||Control Group on Triple Regimens|The second control population will include a group on triple regimens including: 2 NRTIs + 1 NNRTI; 2 NRTIs + 1 INSTI, and 2 NRTIs + 1 PI/b.
16267754|NCT04901715|Active Comparator|Genotypes associated mild phenotype|Subjects with 2 confirmed mutations in RSPH1, Radial Spoke Head Component 9 (RSPH9), Radial Spoke Head Component 4A (RSPH4a), or Dynein Axonemal Heavy Chain 11 (DNAH11). This group may also include subjects with mutations in newly identified genes that are associated with a milder clinical phenotype.
16267755|NCT04901715|Active Comparator|Genotypes associated with severe phenotype|Subjects with 2 confirmed mutations in DNAH5, Dynein Axonemal Intermediate Chain 1 (DNAI1), Coiled-Coil Domain Containing 39 (CCDC39), or Coiled-Coil Domain Containing 40 (CCDC40). This group may also include subjects with mutations in newly identified genes that are associated with a more severe clinical phenotype.
16267756|NCT04901702|Active Comparator|(Arm A) ONI plus TAL|The phase I/II study will evaluate a treatment regimen; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL)
16267757|NCT04901702|Active Comparator|(Arm B) ONI plus TMZ|The phase I/II study will evaluate a treatment regimen; Onivyde (ONI) plus temozolomide (TMZ)
16267760|NCT04901676|Experimental|Leronlimab|Leronlimab subcutaneously once a week (up to 4 doses) until hospital discharge. The first dose will be of 700 mg, followed by weekly doses of 350 mg.
16267761|NCT04901676|Placebo Comparator|Placebo|Placebo subcutaneously once a week (up to 4 doses) until hospital discharge
16267762|NCT04901663|Active Comparator|Omeprazole Group|Omeprazole 20 mg BD Amoxicillin 1000 mg BD Clarithromycin 500 mg BD
16267763|NCT04901663|Experimental|Vonoprazan Group|Vonoprazan 20 mg BD Amoxicillin 1000 mg BD
16267764|NCT04901650||Inpatient population|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
16267765|NCT04901624|Experimental|Personal Risk + Loss Protection|Personal Risk + Loss Protection
16267766|NCT04901624|Experimental|Personal Risk + Lottery Incentive|Personal Risk + Lottery Incentive
16267767|NCT04901624|Experimental|Family Risk + Loss Protection|Family Risk + Loss Protection
16267768|NCT04901624|Experimental|Family Risk + Lottery Incentive|Family Risk + Lottery Incentive
16267769|NCT04901611|Experimental|Parental touch (pre-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance will be administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just before the control procedure and clinical heel lance.
16267770|NCT04901611|Placebo Comparator|Parental touch (post-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance was administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just after the control procedure and clinical heel lance.
16267771|NCT04901585||Totally intracorporeal distal gastrectomy|All patients who underwent minimally invasive distal gastrectomy with intracorporeal anastomosis for gastric cancer
16267772|NCT04901572|Other|QART Imaging|"Cells will be individually selected with the system's micromanipulator under bright-field imaging. The cells will be representative of the cell population to be selected in ICSI procedures, covering the entire range of human sperm cell dimensions. Each selected cell will be simultaneously imaged by the QART system in two modalities:
~Standard brightfield.
~QART's imaging methodology."
16267773|NCT04901559||BQT|Patients treated with the Bone Quadriceps Tendon (BQT) autograft
16267774|NCT04901559||STG|Patients treated with the Semitendinosus-Gracilis (STG) autograft
16267775|NCT04901559||BPTB|Patients treated with the Bone-Patellar Tendon-Bone (BPTB) autograft
16267776|NCT04901546|Experimental|Infants with Esophageal Atresia|Starting at 3 weeks, infants will be administered 1 mL of their own saliva via gastrostomy tube, with each feed (8x/day) for one week.
16267777|NCT04901546|No Intervention|Comparison Infants without Esophageal Atresia|Infants do not have EA and thus can swallow their own saliva.
16267865|NCT04900909||Aortic valve replacement with bioprostheses|
16268080|NCT04899232|No Intervention|AT3 less than 100% with SOC only|Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
16267778|NCT04901533|Experimental|cervical manipulation|The objective of this technique is to restore joint mobility between the joints of the occipital, first (atlas) and second cervical vertebra (axis). It is a technique performed in rotation on a vertical axis that passes through the odontoid process of the axis, without placing flexion or extension, and with very slight sidebending; it is done bilaterally.
16267779|NCT04901533|Active Comparator|Cranial Listening|Cranial palpation maneuver
16267780|NCT04901520|Experimental|High Intensity Training (HIT)|Participants trained at 80-90% of 1RM for 12 weeks, twice per week.
16267781|NCT04901520|Experimental|Moderate Intensity Training (MIT)|Participants trained at 65-75% of 1RM for 12 weeks, twice per week.
16267782|NCT04901520|Experimental|Low Intensity Training (LIT)|Participants trained at 50-60% of 1RM for 12 weeks, twice per week.
16267783|NCT04901520|No Intervention|Control Group (CG)|Participants did not participate in any training and they advised to do their daily activity
16267784|NCT04901507|Experimental|The Voutia System|The Voutia System oral irrigation device
16267785|NCT04901494||SSRI for at least one year prior to the diagnosis of MCI|subjects with an initial diagnosis of MCI who were treated with an SSRI for at least one year prior to the diagnosis of MCI
16267786|NCT04901494||SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI|SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI
16267787|NCT04901494||Subjects without SSRI use|Subjects without SSRI use
16267788|NCT04901481|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower active treatment.
16267789|NCT04901481|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower sham treatment.
16267790|NCT04901455|Experimental|COPD Frequent Exacerbators|Individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
16267791|NCT04901455|Experimental|COPD Infrequent Exacerbators|Individuals with less than two episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
16267792|NCT04901455|Experimental|Healthy Control|Individuals with spirometry-confirmed normal lung function and no asthma history
16267793|NCT04901442|Active Comparator|Running with an Orthotic|Group A will receive an L700 Speed Orthotic (https://www.aetrex.com/running-orthotic/?lang=en_US) according to participants shoe size and will run with this Orthotic in the participants normal running shoes. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to run as normal over the 8-week trial period
16267794|NCT04901442|No Intervention|Running without an Orthotic|Group B will not be provided with the Orthotic and will run in the participants normal running shoes during the course of the study. The group will be asked to run as normal over the 8-week trial period. At the end of the study and following collection of data participants in Group B will also be provided with an L700 Speed Orthotic.
16267795|NCT04901429|Experimental|Truncal Vagotomy|Truncal vagotomy will be performed during other routine procedure.
16267796|NCT04901429|No Intervention|No Truncal Vagotomy|No truncal vagotomy will be performed during other routine procedure.
16267797|NCT04901416|Experimental|Experimental Arm|"Lymphodepleting (LD) chemotherapy will be administered daily for 3 days to all subjects prior to DVX201. Lymphodepleting chemotherapy will consist of the following:
~Cyclophosphamide 300 mg/m2 IV over 30 to 60 minutes daily x 3 (day -5 to day - 3)
~Fludarabine 30 mg/m2 IV over 30 minutes daily x 3 (day -5 to day -3)
~Patients will receive DVX201 at one of 3 prespecified doses infused on day 0 and 7 (± 1 day) for 1 cycle."
16267798|NCT04901403|Other|Education intervention|Parents in the treatment group will receive information about Earned Income Tax Credit, including how to sign up for free. They will also receive help with budgeting and finances from their home visitor.
16267799|NCT04901403|Other|Control group|Control group families will receive home visiting services as usual.
16267800|NCT04901390|Experimental|Yogurt with B. lactis and added cane sugar|Participants will consume yogurt with B. lactis and added cane sugar twice daily for 14 days.
16267801|NCT04901377||Combined oral contraception: Estradiol valerate / Dienogest|Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
16267802|NCT04901351|Experimental|Patients chronically infected with HPV|The study will be offered to patients with chronic HPV infection as part of an annual consultation scheduled in the gynecology care package.
16267803|NCT04901338||Veno-arterial ECMO patients|Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.
16267804|NCT04901338||Veno-venous ECMO patients|Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.
16267805|NCT04901325|Experimental|Baricitinib for PG|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
16267806|NCT04901312|Experimental|Enhanced A-CRA (E-ACRA)|ACRA, T4 and MI
16267807|NCT04901312|Experimental|ACRA Lite|Only 4 weeks of ACRA, minus the caregiver component; plus ACC and MI
16267808|NCT04901312|Experimental|Education|Opioid Education Workbook
16267810|NCT04901286|No Intervention|Seated Rest|Behavioral: Seated Rest In the seated rest control condition, participants will sit on the bike for 30 minutes. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
16268081|NCT04899232|No Intervention|AT3 more than 100% with SOC only|Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.
16267811|NCT04901286|Active Comparator|Exercise Only|Behavioral: Exercise Only In the exercise-only condition, participants will complete a total of 30-minutes on the stationary bike. This will include a) 5-min warm-up at low resistance, b) 20 minutes of moderate-vigorous intensity cycling, and c) a 5-min cool-down at low resistance. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
16267812|NCT04901286|Experimental|Exercise + Non-Immersive Virtual Reality|"Behavioral: Exercise + Non-Immersive Virtual Reality In the exercise with non-immersive Virtual Reality condition, participants will complete a total of 30-minutes on the stationary bike while watching a video on an iPad. The cycling session will be identical to that in the Exercise Only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, a YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]) will play on an iPad placed on the front of the bike. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
16267813|NCT04901286|Experimental|Exercise + Immersive Virtual Reality|"Behavioral: Exercise + Immersive Virtual Reality In the exercise with immersive virtual reality condition, participants will complete a total of 30-minutes on the stationary bike while wearing Oculus Quest 2 goggles. The bout of cycling will be identical to the prescription given in the exercise only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, the Oculus YouTubeVR app will play a 360° version of the YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]). Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart Rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
16267814|NCT04901273|Experimental|Homologous PRP|This group of patients will be treated with single intra-articular injection of Homologous PRP. At the 6-month follow-up visit, the patient will be informed about the treatment received.
16267815|NCT04901273|Placebo Comparator|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
16267816|NCT04901260||Quality Initiative|Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff.
16267817|NCT04901247||day 3|embryo grading and culture refreshment will be done 67-69 hours post insemination
16267818|NCT04901247||day 5|embryo grading and culture medium refreshment will be done 114-118 hours post insemination
16267819|NCT04901234|Active Comparator|Standard radiotherapy|Radiotherapy as planned at baseline, with replanning allowed only if significant weight loss or change in anatomy due to unforeseen circumstances (eg that would affect dosimetry and treatment delivery of baseline treatment plan). No adaptation to shrinking tumour is allowed.
16267820|NCT04901234|Experimental|Adaptive radiotherapy|Systematic radiation treatment plan adaptation according to the shrinking tumour on mid-treatment MRI.
16267821|NCT04901221|Experimental|Extrusion arch|
16267822|NCT04901208|Active Comparator|Users of Juul|Individuals who use Juul devices to vape nicotine
16267823|NCT04901208|No Intervention|Controls|Healthy non-smokers
16267826|NCT04901182|Active Comparator|White sesame soy milk smoothie (WS)|a formula developed from natural ingredients such as soybean and white sesame
16267827|NCT04901182|Active Comparator|Chicken shitake smoothie (CS)|a formula developed from natural ingredients such as chicken and shitake mushroom
16267828|NCT04901182|Placebo Comparator|Ensure|a conventional well-known commercial formula
16267829|NCT04901169|Experimental|Angiotensin II (Giapreza)|Giapreza (synthetic human angiotensin II), initiated at 5 ng/kg/min and titrated to between 1.25 ng/kg/min and 40 ng/kg/min, administered by continuous intravenous infusion.
16267830|NCT04901169|Placebo Comparator|Saline|Sterile 0.9% saline, initiated and titrated at an equivalent volume infusion rate to the study drug, administered by continuous intravenous infusion.
16267831|NCT04901156|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
16267832|NCT04901156|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
16267833|NCT04901130|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through colonoscopy examination with the assitance of AQCS.
16267834|NCT04901130|No Intervention|Control group|Patients in control group will go through conventional standard colonoscopy examination without the assistance of the AQCS.
16267835|NCT04901117|Experimental|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.
~The dosage of each drug is:
~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
16267866|NCT04900870||Neck pain|Diagnostic Test: A self-administered questionnaire A self-administered questionnaire will be used to screen VAS scores, bournemouth neck questionnaire, demographic information and for temporomandibular pain Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments Axis I TMD Pain Screener, Symptom questionnaire and Axis II PHQ-4, Oral Behaviors Checklist .
16268082|NCT04899219|Experimental|Group A (subjects with severe renal impairment)|
16267836|NCT04901117|Active Comparator|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.
~The dosage of each drug is:
~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
16267837|NCT04901104||thymosin α1 group|The patient was treated with thymosin α1 in sepsis
16267838|NCT04901104||placebo group|The patient was treated without thymosin α1 in sepsis
16267839|NCT04901091||study group№ 1|patients who have left ventricular aneurysm without thrombosis
16267840|NCT04901091||study group№ 2|patients who have left ventricular aneurysm with thrombosis
16267841|NCT04901091||control group|patients who have not left ventricular aneurysm
16267842|NCT04901078|Experimental|Active|KNX100 which will be provided in capsule form as both 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
16267843|NCT04901078|Placebo Comparator|Placebo|KNX100 matching placebo will be provided in capsule form for oral administration. The placebo will be encapsulated in HPMC dark green opaque size 0 capsules and packaged in 100 mL HDPE bottles with PP twist-off closures.
16267844|NCT04901065|Experimental|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle.
16267845|NCT04901065|Sham Comparator|Control|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery.
16267846|NCT04901052|Experimental|n-3 supplementation group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus Omega 3 supplementation, the dosage was 2 capsules per day, containing 1.5 g of omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch.
16267847|NCT04901052|Placebo Comparator|Placebo group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus placebo capsules (2 capsules per day made from sunflower oil)
16267848|NCT04901039||Decompensated heart failure|Previously diagnosed heart failure presenting with decompensation to the emergency department
16267849|NCT04901026|Active Comparator|An in-house manikin|Participants use an in-house manikin
16267850|NCT04901026|Sham Comparator|A manikin in market|Participants use a manikin from market
16267851|NCT04901013|Active Comparator|Affinity plus SOC|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM). Affinity is human allograft tissue that is regulated as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) as defined by FDA 21 CFR Part 1271. Affinity may be applied as a wound covering to partial- and full-thickness acute and chronic wounds
16267852|NCT04901013|No Intervention|Standard of Care (SOC)|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
16267853|NCT04901000||Carotid Endarterectomy under Local Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under local anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
16267854|NCT04901000||Carotid Endarterectomy under General Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under general anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
16267855|NCT04900987|Experimental|Treatment group|After putting adequate manual pressure proximal to radial puncture site, dry and sterile application of steri-strip followed by pneumatic TR band for 1 to 2 hour.
16267856|NCT04900987|No Intervention|Control group|Application of pneumatic TR band alone for 4 hours as per usual practice
16267857|NCT04900974|Experimental|Doravirine|100mg doravirine given by mouth once at each sampling visit.
16267858|NCT04900961|Active Comparator|Intervention|A personalised, resistance-based exercise intervention for patients during the convalescence phase in-hospital through to 3-months post-discharge, a duration reflecting chronic, maintenance treatment studies. To maximise enrolment of eligible patients, the intervention may be initiated in-hospital or in the community post-discharge. Resistance bands may be used according to the exercise guideline.
16267859|NCT04900961|No Intervention|Control|Standard of care treatment
16267860|NCT04900948|Experimental|Experimental group №1|proactive therapy with local calcineurin inhibitors + emollients
16267861|NCT04900948|Active Comparator|Experimental group №2|proactive therapy with local glucocorticosteroids + emollients
16267862|NCT04900935|Experimental|POISE|"The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits:
~Three surveys: baseline, 12-week, and 24-week post-enrollment
~Four 60-minute visits with a trained palliative care clinician
~Semi-structured exit interview
~Chart review"
16267863|NCT04900922||Healthy tennis players|Participants in this group need to perform three times of shoulder elevation and five times of tennis serving before and after a fatigue protocol. The fatigue the participants will receive will be conducted with a dynamometer. Surface electromyography on pectoralis major, anterior deltoid ,and latissimus dorsi will be used to detect muscle activity related to fatigue.
16267864|NCT04900909||Aortic valve replacement with mechanical valves|
16267867|NCT04900870||Neck pain with temeporomandibular pain|Diagnostic Test: A self-administered questionnaire A self-administered questionnaire will be used to screen VAS scores, bournemouth neck questionnaire, demographic information and for temporomandibular pain Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments Axis I TMD Pain Screener, Symptom questionnaire, Clinical Examination Form, Axis II Pain Drawing Graded Chronic Pain (version 2), JFLS-8 ,PHQ-4 Oral Behaviors Checklist.
16267868|NCT04900857|Active Comparator|Dry needling treatment group|Dry needling treatment group will be treated with acupuncture needles (0.25x25 mm Hua Long Brand).In this group, one active trigger point area in the trapezius muscle was precisely determined and marked with a permanent pen, and dry needling treatment was applied to that area with disposable acupuncture needles in a single session. the trigger point was palpated. From the center, the needle tip was inserted perpendicular to the skin quickly into the subcutaneous tissue and inserted into the muscle with the needle tip until it found the trigger point in the muscle band. Local twitch responses (LTRs) were similar to Hong's rapid entry and exit technique. It was obtained by inserting a large number of rapid needles in and out of. The needle was not removed from that area for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
16267869|NCT04900857|Experimental|Localized vibration treatment group|The tight band in the muscle was determined by palpation, and the location of the most painful points (the middle of the most vertical fibers of the upper part of the trapezius muscle) in the muscle tension band was digitally determined. It was determined with a permanent marker. The skin was cleaned with a suitable antiseptic agent. Localized vibration therapy was applied for 20 minutes with a vibration frequency of 110 Hz and an amplitude of 5.57 mm using a vibrator device. Vibration therapy was applied to our patients by attaching an apparatus with a small area of 1 cm2 to the skin on the trigger point in the trapezius muscle and fixed with medium pressure. We applied a total of 3 sessions every other day in hospital conditions by a single practitioner to all patients.
16267871|NCT04900831||Group 1|
16267872|NCT04900818|Experimental|Dose Escalation: TJ033721|"Dose Escalation:: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi-weekly (Q2W)
~During dose expansion, TJ033721 will be administered Q2W, starting at the highest dose to have cleared the DLT period.
~After the conclusion of dose expansion TJ033721 will be administered Q2W at the MAD or RP2D."
16267873|NCT04900792|Experimental|Cohort 1 (starting)|"Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.
~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, then at radiation treatments 6, 25, and 31 (± 1 radiation treatment)
~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks. T
~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for 42 days or until radiation is completed (whichever comes first)."
16267874|NCT04900792|Experimental|Cohort 2 (-1 dose level)|"Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.
~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, then at radiation treatment 25 (± 1 radiation treatment)
~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks. T
~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for 42 days or until radiation is completed (whichever comes first)."
16267875|NCT04900766|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with unresectable or metastatic bone and soft tissue sarcoma will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for a maximum of 6 cycles.
16267876|NCT04900740|Active Comparator|Standard care - catheter fixation with surgical stitch|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed in the standard way, using a surgical stitch.
16267877|NCT04900740|Experimental|Experimental - catheter fixation with glue|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed using the glue.
16267878|NCT04900727||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
16267879|NCT04900727||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
16267880|NCT04900727||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
16267881|NCT04900714|Experimental|Decremental PEEP|Every participant will be exposed to a stepwise decremental PEEP.
16267882|NCT04900701|Experimental|Hypocaloric|Participants placed in energy restriction.
16267883|NCT04900701|Experimental|Energy Balance|Participants placed in energy balance.
16267884|NCT04900701|Experimental|Hypercaloric|Participants placed in energy surplus.
16267885|NCT04900688|Other|Ureteroscopy (URS) with the LithoVue 2.0 disposable flexible ureteroscope|Ureteroscopy will be done using the LithoVue 2.0 disposable flexible ureteroscope instead of the satandard ureteroscope
16267886|NCT04900675|Experimental|bright white light intervention|exposure to 5,000 lux with polychromatic white light with 5,300 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
16267887|NCT04900675|Placebo Comparator|dim reddish light intervention|exposure to 50 lux with polychromatic reddish light with 2,200 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
16267888|NCT04900649|Experimental|study group|the study group has conducted chest resisted exercise combined with chest expansion exercise in addition to a usual chest physiotherapy. For chest resistance exercise, the children in the study group underwent sequential 12-week chest resistance exercise and chest expansion exercise, three sessions a week. Chest resistance exercises have been consisted of manual resistance exercise and resistance exercise via POWER breath KH2.
16267889|NCT04900649|Experimental|control group|12-week usual chest physiotherapy in form of bilateral vibration and gentle percussion for 3-5 minutes with distal finger phalanges to the upper apical lobes in modified drainage positions, placing the patient in a side-lying position or a prone position to increase oxygenation, at least 2-3 times a week
16267890|NCT04900636|Experimental|Telemedicine Arm|Use of a telemedicine platform combined with face-to-face visits according to protocol
16267891|NCT04900636|No Intervention|Control Arm|conventional follow-up according to routine clinical practice.
16268083|NCT04899219|Experimental|Group B (control subjects)|
16267892|NCT04900623|Experimental|LOW RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits
~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what radiation dose received . The specimens will be de-identified. The specimens will be banked for future use.
~Radiation Therapy: Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.
~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.
~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
16267893|NCT04900623|Experimental|HIGH RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits
~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what dose of radiation received. The specimens will be de-identified. The specimens will be banked for future use.
~Radiation Therapy: Higher risk participants will receive standard radiation dose for up to 7-8 weeks
~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.
~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.
~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
16267894|NCT04900610|Active Comparator|Vitamin K2|1mg/day per os
16267895|NCT04900610|Placebo Comparator|Placebo|matching placebo
16267896|NCT04900597|Experimental|Elecare - Nourish - Real Foods Blends|Elecare for first bolus, Nourish for second bolus, Real Foods Blends for third bolus
16267897|NCT04900597|Experimental|Nourish - Real Foods Blends - Elecare|Nourish for first bolus, Real Foods Blends for second bolus, Elecare for first bolus
16267898|NCT04900597|Experimental|Real Foods Blends - Elecare - Nourish|Real Foods Blends for first bolus, Elecare for second bolus, Nourish for third bolus
16267899|NCT04900584|Experimental|Intervention group|The intervention group is managed by applying all three types of intervention.
16267900|NCT04900584|No Intervention|non-Intervention group|Non-intervention group is managed by conventional heart failure treatment.
16267901|NCT04900571|Experimental|Nitrofurantoin|Measuring pain score using numerical pain scale post-operatively at different time intervals.
16267902|NCT04900571|Experimental|Calcium Hydroxide|Measuring pain score using numerical pain scale post-operatively at different time intervals.
16267903|NCT04900571|Experimental|Control|Measuring pain score using numerical pain scale post-operatively at different time intervals.
16267904|NCT04900558||Radical Cystectomy|Patients who underwent radical cystectomy for bladder cancer in our centre
16267905|NCT04900545||beta blocker navie patients with acute coronary syndrome|
16267906|NCT04900532|Experimental|Effects of supplementation with tocotrienol on chronic kidney disease patients|Administration of tocotrienol-rich-fraction (TRF) capsules, containing 360mg of tocotrienol and 80mg of tocopherol twice a day for six months.
16267907|NCT04900532|Placebo Comparator|Effects of supplementation with tocotrienol on lipid profile of chronic kidney disease patients|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
16267908|NCT04900519|Experimental|STI-6643|5, 10, 20, 30, 40, 50, or 60 mg/kg administered intravenously Q1W during Cycle 1, then Q2W for Cycles 2 and up
16267909|NCT04900506|Active Comparator|cemented hemiarthroplasty , posterior SPAIRE approach|Posterior SPAIRE approach: lateral decubitus position, preservation of the piriformis tendon and obturator internus, detatchment of obturator externus , capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair, repair of obturator externus.
16267910|NCT04900506|Active Comparator|cemented hemiarthroplasty, anterior approach|Anterior approach: supine position, both legs washed and draped, intermuscular plane between m. tensor fascia lata and m. sartorius, capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair
16267911|NCT04900480|No Intervention|Public subsidy to physiotherapy continue as usual|This control arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, where the access and public subsidy to physiotherapy continue as usual.
16267912|NCT04900480|Experimental|Direct access to publicly subsidized physiotherapy|This intervention arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, introducing temporary exemption on the legal required general practitioner referral for public subsidy for treatment in general physiotherapy.
16267913|NCT04900467|Active Comparator|Pfizer-Pfizer|Pfizer-Pfizer Length of use : 1 day
16267914|NCT04900467|Experimental|Pfizer-Moderna|Pfizer-Moderna Length of use : 1 day
16267915|NCT04900467|Active Comparator|Moderna- Moderna|Moderna- Moderna Length of use : 1 day
16267916|NCT04900467|Experimental|Moderna - Pfizer|Moderna - Pfizer Length of use : 1 day
16267917|NCT04900454|Experimental|DVX201 infusion|"Subjects will enroll and the MTD and/or the recommended phase 2 dose of DVX201 will be determined utilizing a modified 3+3 enrollment schema.
~This study will enroll a minimum 3 subjects who each receive a single dose of DVX201 and who are evaluable for toxicities at each dose level. Depending on the occurrence of DLTs and the number of dose levels evaluated, additional subjects may be enrolled (approximately 3-15 additional subjects). All subjects will be followed for 28 days post infusion of DVX201."
16267918|NCT04900428|Experimental|COVI-DROPS|10 mg or 20 mg of COVI-DROPS administered intranasally
16267919|NCT04900428|Placebo Comparator|Placebo|1 mL administered intranasally
16267920|NCT04900415|Experimental|Vitamin A and smell training|14-day course of daily oral vitamin A 7500µg RAE in combination with smell training three times per day for 4 weeks
16267921|NCT04900415|Active Comparator|Smell training|Smell training three times per day for 4 weeks
16267922|NCT04900415|No Intervention|Control|Observation
16267956|NCT04900155|Active Comparator|Atorvastatin 80 mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
16267925|NCT04900389||Case Group: Nurses with COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark the answer Yes to the question Have you been diagnosed with COVID-19? 5th question; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
16267926|NCT04900389||Kontrol Group: Nurses who have not had COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark No to the question Have you been diagnosed with COVID-19? And move on to the 4th question in the same section.
~The 5th question in Annex 2 of the questionnaire form; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
16267927|NCT04900376||vaccinated group|
16267928|NCT04900376||unvaccinated group|
16267929|NCT04900363|Experimental|AK112|Subjects receive AK112 monotherapy intravenously (IV) until no more benefits from treatment.
16267930|NCT04900350|Experimental|AK117+ azacitidine|"Phase 1: Subjects will receive escalating doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;
~Phase 2: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
16267931|NCT04900337|Experimental|AMOR 18 Powder & Inhalation|"AMOR_inhaled Double Pack- Each kit contains two tubes that after mixing result with 1.14 % ACC in 10 ml suspension.
~AMOR_powder- ACC in a dry powder (up to 2000mg Calcium/day sublingually)."
16267932|NCT04900337|Placebo Comparator|Placebo|"Placebo_Inhaled Double Pack - Each kit contains two tubes of saline at different volumes (similar to investigational product) after mixing the results remains saline at a final volume of 10ml.
~Placebo_Powder: Each sachet contains powder at the same particle size and weight as the powder of the investigational product."
16267933|NCT04900324|Experimental|MRI guidance|Injections of botulinum toxin performed using MRI guidance
16267934|NCT04900324|Experimental|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
16267935|NCT04900311|Experimental|pyrotinib + trastuzumab + nab-paclitaxel|
16267936|NCT04900311|Active Comparator|pertuzumab + trastuzumab + nab-paclitaxel|
16267937|NCT04900298|Experimental|Intervention Arm|Use of SafeHaven hand hygiene system in the operating room
16267938|NCT04900298|No Intervention|Control Arm|Standard of care hand hygiene
16267939|NCT04900285|Other|Dental Device Arm|Subjects in this single arm study serve as their own control by recording snoring on the SnoreLab device for five days and completing the Snore Outcomes survey. After five nights with now device, the lower dental device is used for five nights and snoring is recorded in the SnoreLab app. At the end of the five nights the subjects complete the Comfort and Difficulties Form and the bed partner completes the Snore Outcomes Survey. If the lower device was tolerated well, the process is repeated with the upper dental device used with the lower device.
16267940|NCT04900272|Experimental|VIPA device and companion booklet|For Aim 2, we will recruit a total of 20-40 older adult homebound patients who are likely to be socially isolated, through the Geriatric and General Internal Medicine clinics at Northwestern (over 2,300 homebound older adults) to use the VIPA and accompanying instructional booklet focused on social-isolation. Either the study PI or Research Study Coordinator (RSC) will visit the participant's home, or assist the patient virtually, once consented, to set up the Google Home or Amazon Alexa device for them and review the companion VIPA booklet with them.
16267941|NCT04900259||COVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the COVID-19 period
16267942|NCT04900259||PreCOVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the preCOVID-19 period
16267943|NCT04900246|Experimental|Visual Inspection + BWX Radiographic Assessment + Assessment of the iTero Element 5D scan|In this group, the evaluations will follow this order. First the visual inspection, then the bitewing X-ray assessment and, lastly, the iTero assessment.
16267944|NCT04900246|Experimental|Visual Inspection + Assessment of the iTero Element 5D scan + BWX Radiographic Evaluation|In this group, the evaluations will follow this order. First the visual inspection, then the iTero assessment and, lastly, the bitewing X-ray assessment.
16267945|NCT04900233||Control group|
16267946|NCT04900233||Pandemic group|
16267947|NCT04900220|Active Comparator|Betamethasone|betamethasone
16267948|NCT04900220|Active Comparator|Methylprednisolone|methylprednisolone
16267949|NCT04900207||Observed Group|Participants will be enrolled in the study at the time of their first-trimester screen (10w3d-13w6d weeks of gestation) to the time of their delivery. Collection of first-trimester 3D-volume ultrasound imaging to measure the placental volume, blood flow, and vascularity and maternal serum markers will occur over a 6-12 months period. Collection of descriptive and pregnancy outcome information will be obtained from the electronic medical records will continue through their pregnancy episode (typical 9 months).
16267950|NCT04900194|Experimental|MBSC group|counseling group
16267951|NCT04900194|No Intervention|Control group|standard care group
16267952|NCT04900181|Experimental|the same-day discharge surgery|Patients in the the same-day discharge surgery group were admitted to hospital, operated and discharged within 24 hour
16267953|NCT04900181|No Intervention|inpatient surgery|Patients in inpatient surgery follow routine procedures and do not need to be discharged on the same day.
16267954|NCT04900168||ICP monitoring group|patients received ICP monitoring
16267955|NCT04900168||conventional treatment group|patients without ICP monitoring and received conventional treatment
16267991|NCT04899960|No Intervention|Observational Group|
16267957|NCT04900155|Active Comparator|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
16267958|NCT04900142|Experimental|1500 mW|1500 mW of Power
16267959|NCT04900142|Active Comparator|1000 mW|Standard treatment, 1000 mW
16267960|NCT04900129|Experimental|Study Group|This group inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg. These drugs have no systemic and local side effects in these small doses, though it may cause slight eye irritation.
16267961|NCT04900129|No Intervention|Control Group|This group inhaled plain aquatic vapor in addition to conventional treatment.
16267962|NCT04900116|Active Comparator|Group 1|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
16267963|NCT04900116|Active Comparator|Group 2|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
16267964|NCT04900116|Active Comparator|Group 3|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
16267965|NCT04900116|Placebo Comparator|Group 4|In this group, US guided PENG block will be performed with 20 ml saline solution (%0.9 NaCl) using a 22 gauge 10 mm block needle.
16267966|NCT04900103|Experimental|Tech-volunteer|"A complex intervention with two phases is proposed.
~First phase: volunteers new technologies training (tech-volunteering). Volunteers will be trained in the use of NT and their interconnectivity as tools to support their volunteer work. This training will be integrated into the PC volunteer training programme.
~Second phase: using the NT with patients and relatives."
16267967|NCT04900103|No Intervention|Usual volunteer|the control group will receive standard volunteer service.
16267968|NCT04900090|Experimental|Case group : gout patients|Epidemiological study
16267969|NCT04900090|Experimental|Control group|Epidemiological study
16267970|NCT04900077|Experimental|treatment group|treated with Carriere Motion appliance
16267971|NCT04900077|No Intervention|control group|no treatment
16267972|NCT04900064|Experimental|Diagnostic Assessment - Given self-help CBT|"The diagnostic assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview (MINI - International Neuropsychiatric Interview) and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).
~In the primary analysis, only patients receiving treatment with self-help CBT are included."
16267973|NCT04900064|Active Comparator|Contextual Assessment - Suitable for self-help CBT but given brief interventions|"The contextual assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.
~In the primary analysis, only patients suitable for self-help CBT are included. This is decided by an algorithm based on data from their screening, which takes into account symptom severity and type, patient preference and known variables that make self-help CBT a worse fit."
16267974|NCT04900064|Experimental|Diagnostic Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they receive treatment with self-help CBT or brief interventions."
16267975|NCT04900064|Active Comparator|Contextual Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they are deemed suitable for self-help CBT or not."
16267976|NCT04900038|Experimental|Blinded GSK3640254 100 mg + unblinded DTG|Participants will receive blinded GSK3640254 100 mg + unblinded DTG through Week 24 (double blind phase). The participants will receive optimal dose of unblinded GSK3640254 + unblinded DTG from Week 24 to 52 (open label phase).
16267977|NCT04900038|Experimental|Blinded GSK3640254 150 mg + unblinded DTG|Participants will receive blinded GSK3640254 150 mg + unblinded DTG through Week 24 (double blind phase). The participants will receive optimal dose of unblinded GSK3640254 + unblinded DTG from Week 24 to 52 (open label phase).
16267978|NCT04900038|Experimental|Blinded GSK3640254 200 mg + unblinded DTG|Participants will receive blinded GSK3640254 200 mg + unblinded DTG through Week 24 (double blind phase). The participants will receive optimal dose of unblinded GSK3640254 + unblinded DTG from Week 24 to 52 (open label phase).
16267979|NCT04900038|Active Comparator|Blinded 3TC 300 mg + unblinded DTG|Participants will receive blinded 3TC 300 mg capsules + unblinded DTG through Week 24 (double blind phase). The participants will receive unblinded 3TC 300 mg tablets + unblinded DTG from Week 24 to 52 (open label phase).
16267980|NCT04900025|Experimental|Bright lighting followed by Placebo lighting|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
16267981|NCT04900025|Placebo Comparator|Placebo lighting followed by bright lighting|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
16267982|NCT04900012||Distal pancreatectomy|All cases operated on performing distal pancreatectomy in involved Units
16267983|NCT04899999|Experimental|Financial reward graphic message|
16267984|NCT04899999|Experimental|Health reward graphic message|
16267985|NCT04899999|Experimental|Self-efficacy graphic message|
16267986|NCT04899999|Experimental|Social norms graphic message|
16267987|NCT04899986|Experimental|Trial Group|Patients from this group will use chlorhexidine Biorepair gel and toothpaste for home oral care.
16267988|NCT04899986|Active Comparator|Control Group|Patients from this group will not use chlorhexidine and Biorepair gels and toothpastes, but will perform home oral care with standard toothpastes.
16267989|NCT04899973|Experimental|Experimental, LEAD IT! Programming|Participants in the Experimental / LEAD IT! arm will take part in LEAD IT! programming for 18 weeks. The programming will occur twice per week, for a total of 36 sessions.
16267990|NCT04899973|No Intervention|Control, Standard Care / Programming|Participants in the Control arm will receive standard care / programming.
16267994|NCT04899934|Experimental|Mobile and technology assisted aftercare|participants randomized to this condition will receive up to 26 sessions with a community support specialist aftercare provider and 6 months of access to behavioral health mobile applications.
16267995|NCT04899934|Active Comparator|Treatment as usual (TAU)|Participants randomized to this condition receive standard treatment services available to persons discharging from a CSU.
16267996|NCT04899921|Experimental|Safety Run-In|Up to three cohorts of patients will be treated in a 3+3 design with the triple drug combination of Ipilimumab + Nivolumab + Troriluzole to provide dosing information and an early assessment of safety.
16267997|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole|"Participants will be randomly assigned and receive:
~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Troriluzole self-administered at a predetermined dose orally twice a day
~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Troriluzole self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
16267998|NCT04899921|Experimental|Ipilimumab + Nivolumab + Placebo|"Participants will be randomly assigned and receive:
~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Placebo self-administered at a predetermined dose orally twice a day
~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Placebo self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
16268001|NCT04899882|No Intervention|Control group|
16268002|NCT04899882|Experimental|KinHémo group|
16268003|NCT04899869|Other|Active microbiota first|Patients will first receive two enemas of active study microbiota mixture (deep-frozen stored stool microbiota mixed from eight donors in order to increase its diversity), then after eight weeks they will receive two enemas with placebo.
16268004|NCT04899869|Other|Inactive microbiota first|Patients will first receive placebo, then the active study microbiota mixture.
16268005|NCT04899869|Other|Inactive microbiota only|Patients will receive similarly timed enemas with placebos only.
16268008|NCT04899830|Experimental|Installation of a telepresence robot in the home of a disabled person hospitalized in a PRM center|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
16268009|NCT04899817|Active Comparator|Group G|will receive granisteron 1mg after induction of general anesthesia
16268010|NCT04899817|Placebo Comparator|Group C|Will receive metoclopramide 10 mg after induction of general anesthesia
16268011|NCT04899804||Validity and Reliability Group|This study will be completed in two phases. In the first phase, the participants included in the study will be evaluated first by tele-assessment. One hour later, all assessments will be repeated face-to-face procedures by the researchers; thus, the validity of the tele-assessment method will be determined. Before the tele-assessment, participants will be informed about having a chair whose floor-to-seat height is 48 cm and tape measure. In the second phase of the study, to determine the reliability of the tele-assessment method, all tests will be applied to the previously tested participant by the same researcher one week later and at the same time of the day using only the tele-assessment method.
16268012|NCT04899791|Experimental|Wheat bread enriched with hydroxytyrosol|
16268013|NCT04899791|Active Comparator|Wheat bread|
16268014|NCT04899778|Experimental|Oral Contraceptive Pill|Oral contraceptive, 1/day, for one year
16268015|NCT04899778|No Intervention|No Oral Contraceptive|No intervention
16268016|NCT04899765|Experimental|Measles vaccine|Measles vaccine in standard dose of 0.5 ml.
16268017|NCT04899765|Experimental|BCG vaccine|BCG vaccine in standard dose of 0.1 ml.
16268018|NCT04899765|Placebo Comparator|Placebo|Saline injection
16268019|NCT04899752|Experimental|Traditional OPCR|Those who are in the traditional group will discuss topics like medication adherence, physical activity questions, or eating habits without a clear from of autonomy or nonautonomy basis as is currently completed in OPCR. This will occur in a face to face format.
16268020|NCT04899752|Experimental|OPCR + MI|The MI group will be consistent with the spirit of MI and utilize a high autonomy communication style to provide support for behavior change across multiple behaviors. This will occur in a face to face format.
16268021|NCT04899752|Experimental|OPCR + Clinician centered|The OPCR + CC group will participate in low-autonomy face to face interviews. Meaning the communication style will be clinician centered, providing goals to the participants without valuing their input.
16268022|NCT04899739|Experimental|Peripancreatic and distant lymph node assessment|All patients programmed for an endoscopic ultrasound in the context of a pancreatic cancer
16268023|NCT04899726|Experimental|Intervention|Oncology patients candidate for rectal surgery (tumors located up to 15 cm from the anal margin) and meet inclusion criteria. Rectoscope (P201630551) allows the identification of the distal section margin.
16268024|NCT04899713||Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)|Patients treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : zoledronic acid 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with zoledronic acid 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
16268025|NCT04899713||Control group (neo-adjuvant chemotherapy alone)|Patients treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
16268026|NCT04899700|Placebo Comparator|WLE-LCI|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with WLE. Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
16268027|NCT04899700|Active Comparator|LCI-WLE|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with Linked Color Imaging (LCI). Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
16268028|NCT04899687|Experimental|Group A: fluoxetine then fluoxetine plus dextromethorphan|Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
16268029|NCT04899687|Experimental|Group B: fluoxetine plus dextromethorphan then fluoxetine|Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.
16268030|NCT04899674|Experimental|Bupropion (Reference, R) - BI 1358894 + Bupropion (Test, T)|
16268031|NCT04899661||Molidustat|Participants diagnosed with renal anemia treated with Molidustat at the discretion of investigators
16268032|NCT04899648|Experimental|Behavioral Intervention|Receives nutrition and exercise intervention classes
16268033|NCT04899648|No Intervention|Control Group|Does not receive any intervention classes
16268034|NCT04899635||Diseased cardiac tissue|Heart muscle or cells (cardiomyocytes) will be obtained from patients undergoing cardiac surgery, namely coronary artery bypass grafting or for severe valvular heart disease.
16268035|NCT04899635||Healthy cardiac tissue|Healthy donor hearts from deceased individuals that are not transplantable due to technical reasons
16268036|NCT04899622|Experimental|Combined MBSR and exercise|Group A will take part in live online weekly mindfulness sessions based on the Mindfulness Based Stress Reduction (MBSR) programme, in addition to supervised exercise classes.
16268037|NCT04899622|Active Comparator|Online Self-Management Guide|Group B will be invited to interact with an online self-management guide accessible in the members area of the study website.
16268038|NCT04899583|Experimental|Treatment Group|a Sirolimus Coated Balloon
16268039|NCT04899583|Active Comparator|Control Group|a Paclitaxel Coated Balloon Catheter
16268040|NCT04899570|Experimental|Zanubrutinib combined with R-CHOP|"The experimental arm will be treated zanubrutinib combined with R-CHOP regimen for 8 cycles. The interim evaluation will be performed after 4 cycles, and the patients who can't achieve PR or CR will be withdrawn from this trial and receive salvage regimens.
~After 8 cycles of ZR-CHOP, the patients will be followed for 2 years to evaluate the PFS."
16268041|NCT04899544|Experimental|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|A 16-week center-based PRT intervention (PRT-C) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
16268042|NCT04899544|Experimental|Home-Based Pivotal Response Treatment (PRT) Intervention (PRT-H)|A 16-week home-based PRT intervention (PRT-H) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
16268043|NCT04899544|No Intervention|Treatment As Usual (TAU)|This is a control group that consists of children who are receiving treatment as usual (TAU) for a 16-week period. These families will be invited to participate in PRT after completing the 16-week TAU phase.
16268044|NCT04899531||Longitudinal observation|No specific intervention, pre-post measurements only
16268045|NCT04899518|Placebo Comparator|Vehicle Ophthalmic Solution|
16268046|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 1|
16268047|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 2|
16268053|NCT04899479|Experimental|SGLT-2 inhibitor|The SGLT-2 inhibitor group will receive SGLT-2 inhibitor once daily until the end of the study period.
16268054|NCT04899479|Placebo Comparator|Control|The control group will not receive any additional drugs.
16268055|NCT04899466|Experimental|ActiGraft|Whole blood clot (WBC) gel
16268056|NCT04899453|Experimental|Zanubrutinib/rituximab & intravitreal MTX|Experimental arm will be treated with rituximab plus zanubrutinib (ZR) regimen for 6 cycles and followed by zanubrutinib maintenance for 2 years, meanwhile, intravitreal methotrexate will be given as protocol during the 1st year of treatment.
16268057|NCT04899427|Experimental|orelabrutinib combined with PD-1 inhibitor|"The experimental arm will be treated orelabrutinib plus PD-1(programmed death）inhibitor every 21 days as one cycle. The responses will be evaluated every 2 cycles during the first 6 cycles and every 3 months until progression.
~The investigators can choose Sintilimab Injection or Tislelizumab Injection at the beginning of treatment，but they can't exchange to another during the whole treatment."
16268058|NCT04899414|Experimental|Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma|4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT
16268059|NCT04899401|Experimental|Standard of care +PediaFlù®|
16268060|NCT04899401|Active Comparator|Standard of care|
16268061|NCT04899388|Active Comparator|PENG|"The patient is placed in the supine position. After sterilization of the skin and drapping, the low frequency convex probe of Sonosite M Turbo ultrasonography( FUJIFIM sonosite, Inc., Bothell, WA, USA) is placed..
~A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly."
16268062|NCT04899388|Active Comparator|ESPB|"The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.
~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%, 10 ml normal saline was administered leading to hydrodissection to confirm correct location. All LA was administered to this location between the transverse process and the erector spinae muscle"
16268063|NCT04899388|Placebo Comparator|control|Patients will receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
16268064|NCT04899375|Experimental|One group taking part in 2 separate conditions|Subjects will be randomly assigned to either group A or B. Session 1 will serve to familiarize all participants with the battery of tests including the 100 mm VAS, Short-form Mcgill Pain Questionnaire (SF-MPQ), Likert perception scale adapted from Kiefer et al. (2017), algometry, manual muscle testing, assessed via hand-held dynamometer (HHD), and grip strength assessed via hydraulic hand dynamometer; subjects will also be instructed in the AROM protocol. Familiarization will be conducted a minimum of 24 hours prior to the first condition. There will be a minimum washout period of 1 week to reduce both order and carry-over effects. Only the principal investigator will be abreast to the order of intervention, sufficiently blinding the raters. Prior to each trial, participants will be instructed to refrain from resistance training for a minimum of 48 hours and to abstain from the use of stimulants or analgesic medication for a minimum of 6 hours prior to reporting to the lab.
16268065|NCT04899362|Experimental|RIC group|RIC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take 14 RIC intervention, blood collection and 10 dCA measurements.
16268066|NCT04899349|Experimental|Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR|Alpelisib 300mg orally once daily starting at Cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants will receive a combination treatment of dapagliflozin+metformin XR (as a single tablet or as two separate tablets, at the discretion of the investigator) at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily which can be titrated to a maximum dose of 10 mg dapagliflozin + 2000 mg metformin XR once daily.
16268067|NCT04899349|Active Comparator|Alpelisib + Fulvestrant + Metformin XR|Alpelisib 300mg orally once daily starting at cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants will receive metformin XR 500mg orally once daily which can be titrated to a maximum dose of 2000 mg once daily.
16268070|NCT04899323||Cohort|Perform a 250cc vascular filling over 10 minutes and then perform a cardiac ultrasound. Repeat the vascular filling followed by the ultrasound as long as the patient is responsive.
16268071|NCT04899310|Experimental|mRNA-3705|Treatment Period (during the Dose Optimization Stage and the Optional Dose Expansion Stage): 1 of up to 5 possible doses of mRNA-3705, administered intravenously (IV), once every 2 to 4 weeks (q2W to q4W), depending on participant's weight for up to 10 doses over approximately 40 weeks.
16268072|NCT04899297||Quality of life|
16268073|NCT04899284|Experimental|Infants eligible for Early Intensive Bimanual Stimulation|Infants between 3 and 12 months of age at the time of inclusion, with unilateral brain injury and clinical signs of underuse of one of the two upper limbs
16268076|NCT04899258|Other|Pre-surgery and post-surgery|femtosecond assisted LASIK
16268077|NCT04899245|Experimental|School Staff|"50 school staff from Waisman Early Childhood Program (WECP) will be recruited to participate in this study. School staff will send a letter to all WECP staff inviting them to participate. Staff new to the school or who initially decline participation and then reconsider may join at any time.
~Additionally, staff who are vaccinated will be asked to participate in testing."
16268078|NCT04899245|Experimental|Parent/Child with Children with medical complexity (CMC)|"65 children and their parents will be recruited to participate. School staff will send a letter to all parents with children enrolled in the Waisman Early Childhood Program (WECP) inviting them to participate. Families new to the school or who initially decline participation and then reconsider may join at any time. Participants will also be offered the option of as needed symptomatic home testing.
~Additionally, parents who are vaccinated will be asked to participate in testing. Siblings may be enrolled in the study."
16268079|NCT04899232|Experimental|AT3 less than 100% with SOC plus AT3 supplement|Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
16268086|NCT04899206||ARBs and ACEIs Group|Hypertensive patients under pharmacological treatment with ARBs and ACEIs
16268087|NCT04899193|Experimental|Sequence 1: First Reference, Then Test 1, Then Test 2|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
16268088|NCT04899193|Experimental|Sequence 2: First Test 1, Then Test 2, Then Reference|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
16268089|NCT04899193|Experimental|Sequence 3: First Test 2, Then Reference, Then Test 1|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
16268090|NCT04899193|Experimental|Sequence 4: First Reference, Then Test 2, Then Test 1|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
16268091|NCT04899193|Experimental|Sequence 5: First Test 1, Then Reference, Then Test 2|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
16268092|NCT04899193|Experimental|Sequence 6: First Test 2, Then Test 1, Then Reference|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
16268096|NCT04899154|Experimental|Patients with spondyloarthritis (Spa)|
16268097|NCT04899154|Experimental|Healthy subjects|
16268098|NCT04899141||Coronary Artery Disease|
16268099|NCT04899128||Observational Group|Patients receive pyrotinib-based therapy after lapatinib progression.
16268100|NCT04899115|Placebo Comparator|Placebo|
16268101|NCT04899115|Experimental|VE303|VE303 is a live biotherapeutic product comprising 8 nonpathogenic commensal strains of Clostridia.
16268102|NCT04899102|Experimental|Time-Restricted, Intermittent Fasting Group|Special type of diet for 6 weeks, called time-restricted, intermittent fasting.
16268103|NCT04899089|Experimental|Video Game Training Condition|Participants complete a 10 week long computerized cognitive training intervention. Participants play the games for 45 minutes, three times per week.
16268104|NCT04899089|Active Comparator|Trivia Training Condition|Participants complete a 10 week long computerized trivia training. Participants complete the trivia training for 45 minutes, three times per week.
16268105|NCT04899037||Osseointegrated Device Uptake|The participants in this group will be in the 18-85 year age range who have a hearing loss configuration that would benefit from an OID and choose to uptake an OID.
16268106|NCT04899037||Osseointegrated Device Non Uptake|The participants in this group will be in the 18-85 year age range and who a hearing loss configuration that would benefit from an OID but choose to not uptake an OID.
16268107|NCT04899024|Experimental|PARTI and CM (Contingency Management)|The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence
16268108|NCT04899024|Active Comparator|Attention-Control and CM (Contingency Management)|The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence
16268109|NCT04899011||Middle ear surgery|
16268110|NCT04898998|Experimental|TENS to alleviate the effect of thirsty after surgery|Transcutaneous electrical nerve stimulation (TENS) on experimental group 20 mins to treatment postoperative thirsty.
16268111|NCT04898998|Placebo Comparator|Routine care to alleviate the effect of xerostomia (dry mouth) after surgery|routine care
16268112|NCT04898985||500 patients in the LLS COVID-19 Registry with no/limited antibody response|Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in this Research Study.
16268113|NCT04898985||500 patients also participating in the LLS COVID-19 Registry with antibody response|500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled in this Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).
16268114|NCT04898972|Experimental|Mindfulness-based stress reduction intervention|Patient-family caregiver dyads will take part in 8-week Mindfulness-based stress reduction intervention (MBSR).
16268115|NCT04898972|Active Comparator|information booklet|Patient-informal caregiver dyads will receive an informative booklet on stress reduction strategies
16268118|NCT04898946||CoronaVac|Subjects who receive inactivated vaccine, CoronaVac.
16268119|NCT04898920|Placebo Comparator|Control Group|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
16268120|NCT04898920|Experimental|Dexamethasone Group|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
16268121|NCT04898907|Experimental|ANG-3777 (Therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
16268122|NCT04898907|Placebo Comparator|Normal Saline|The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
16268123|NCT04898907|Active Comparator|Moxifloxacin Hydrochloride|The comparator will be administered as a single dose oral Moxifloxacin Hydrochloride tablet (open-label), with a total of 240 mL of water. There will be a minimum washout of 3 days between each study drug administration.
16268124|NCT04898907|Experimental|ANG-3777 (Supra-therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
16268125|NCT04898894|Experimental|Treatment|"Dose Escalation Phase:
~Venetoclax plus selinexor will initially be given at dose level 1 in combination with intravenous (IV) cytarabine and fludarabine. Dosing of venetoclax and selinexor will be based on tolerability.
~Intrathecal (IT) chemotherapy (IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are all acceptable) will be given.
~G-CSF SC may be given.
~Dose Expansion Phase:
~Two expansion cohorts will be treated at the recommended phase 2 dose (RP2D). Cohort A will include venetoclax-naïve patients, whereas Cohort B will include patients with prior exposure to venetoclax."
16268126|NCT04898881|Active Comparator|Breast Milk|2 ml of Breast milk given one time, two minutes prior to the heel lance
16268127|NCT04898881|Other|24 %Sucrose|0.5 ml sucrose to be given once, two minutes prior to the heel lance
16268128|NCT04898868|Experimental|vaginal delivery with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
16268129|NCT04898868|Experimental|vaginal delivery with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
16268130|NCT04898868|Experimental|CS with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
16268131|NCT04898868|Experimental|CS with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
16268132|NCT04898855|Experimental|SONO (internet-delivered cognitive-behavioral treatment for insomnia)|Participants assigned to the experimental group receive immediate access to the SONO program, a web-based self-guided cognitive-behavioral intervention for insomnia consisting of 6 weekly sessions. A certified psychologist will monitor the participant's progress and provide feedback.
16268133|NCT04898855|No Intervention|waitlist control|Participants assigned to the waitlist control group receive access to the SONO program after 7 weeks.
16268134|NCT04898842|Experimental|4 stage bowel obstruction diet|"All eligible participants will be assessed by a specialist dietitian and a diet history and symptoms will be recorded. Depending on the degree of sub-acute bowel obstruction, symptoms and type of diet being followed, patients will be given detailed instructions on which stage of the 4 stage diet to use. They will be followed up by telephone or face to face weekly for a 4 week period and shown how to alter their diet by moving up and down the stage of the diet if symptoms resolve or worsen. This is current standard of care.
~Additional assessments will be carried out at the start and end of the study when participants will complete the Memorial Symptom Assessment Scale (MSAS) and EORTC QLQ-30 quality of life questionnaire. They will be asked to complete a daily diet diary, and an 'ease of use' questionnaire at the end of the 4 week period."
16268136|NCT04898816|Experimental|Group A|Application of cyanoacrylate tissue adhesive over the surgical wound
16268137|NCT04898816|Active Comparator|Group B|Suturing the surgical wound using braided black silk
16268138|NCT04898803||conventional gastroscopy training course|physicians receive the DGVS-recommended training, consisting of a 2-day course with 1 hour of simulator training
16268139|NCT04898803||extended simulator course|physicians receive a two-day simulator course with a minimum of 6 hours of simulator training per trainee, structured in stages in the sense of progressive or mastery learning. The initial part of the training will be part-task training.
16268140|NCT04898790|No Intervention|Feedback for Preliminary Adaptation|Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.
16268174|NCT04898556|Active Comparator|Active Treatment|Patients who will undergo treatment with Intrarosa (Prasterone 6.5mg) in ovules, will apply one ovule a day before going to bed for 12 weeks.
16294466|NCT04714645|Experimental|Intervention group|VR+ training
16268141|NCT04898790|Experimental|Adapted CHAMPS-II intervention|All participants in Aim 2, and those randomized to the physical activity intervention in Aim 3 will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.
16268142|NCT04898790|Active Comparator|Survivorship Education Active Control Condition|Participants in Aim 3 who are randomized to the Survivorship Education active control condition will receive the survivorship education program. Testing for outcome measures will be completed, and feedback on the survivorship education program will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.
16268143|NCT04898777|Active Comparator|ERCP-BD|ERCP Biliary Drainage by papillary approach with stent placement.
16268144|NCT04898777|Active Comparator|EUS-BD|Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
16268145|NCT04898764|No Intervention|Healthy Volunteers|This study arm will only participate in part A of the study (Characterisation study) and thus will not receive the study drug. A maximum of 25 healthy volunteers will be included in this study arm.
16268146|NCT04898764|Experimental|Patients with long-term use of nasal decongestants|"A maximum of 100 patients with long-term use of nasal decongestants will be included in this study arm, for part A of the study (Characterisation study).
~The investigators will consecutively recruit patients from part A (Characterisation study) into part B of the study (Intervention study) until a total of 25 patients completed all study-related visits of part B. During the intervention study, patients with long-term use of nasal decongestants will administer Mometasone furoate intranasally, two doses (50µg/actuation) in each nostril, twice daily (total daily dose of 400µg) during a 12 week period."
16268147|NCT04898751||Cutaneous toxicity|Patients who reported a cutaneous immune related adverse event following ICI initiation with appropriate chronology that indicates drug toxicity.
16268148|NCT04898738|Active Comparator|Alcohol-based hand sanitizer|Half the study households with receive ABHS through the course of the study
16268149|NCT04898738|No Intervention|No Alcohol-based hand sanitizer|Half the study households with not receive ABHS through the course of the study
16268150|NCT04898725|Experimental|Vit D Group (randomized)|Subjects will be randomly assigned to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks
16268151|NCT04898725|No Intervention|Control Group (randomized)|Subjects will be randomly assigned to receive a placebo for 8 weeks.
16268152|NCT04898725|Experimental|Preference Vit D Group (non-randomized)|Subjects with a strong preference to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks.
16268153|NCT04898725|No Intervention|Preference no Vit D Group (non-randomized)|Subjects with a strong preference to receive usual care (not receiving vitamin D supplements) for 8 weeks.
16268154|NCT04898712|Experimental|Tranexamic Acid Arm|"Participants in the experimental arm will receive tranexamic acid (TXA) during surgery for CSDH evacuation with a single 1000mg intraoperative intravenous (IV) dose. Participants with a body weight 60-100kg will also receive a post-operative dose regimen of 500 mg TXA orally, 3 times a day (TID).
~Weight deviations from this body weight range will be considered with a dose adjustment of 1000mg TXA two times a day (BID) for a body weight >100 kg, and 500 mg TXA BID for body weight <60kg."
16268155|NCT04898712|Placebo Comparator|Placebo Control Arm|Participants in the control arm will placebo according to the same administration regimen.
16268156|NCT04898699|Experimental|PrEP+|PrEP+ is an experimental pre-exposure prophylaxis (PrEP)-focused prevention strategy providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with two adherence self-management interventions: (1) real-time feedback from point-of-care urine drug-level assay, (2) HIV self-testing and (3) 2-way text message reminders in addition to standard of care HIV risk-reduction counseling among male clients (MC) of female sex workers in Kisumu, Kenya.
16268157|NCT04898686|Active Comparator|Probiotic group|daily use of a probiotic chewable for 8 weeks
16268158|NCT04898686|Placebo Comparator|Placebo group|daily use of the placebo chewable for 8 weeks
16268159|NCT04898673|Experimental|CP1110 Sound Processor|
16268160|NCT04898673|Active Comparator|CP1000 Sound Processor.|
16268161|NCT04898647|Experimental|Patients with confirmed HVS|presence of unexplained elsewhere fundoscopic abnormalities AND either IgM concentration above 30 g/L (densitometry) or cryoglobulin activity
16268162|NCT04898647|Active Comparator|Patients with confirmed absence of HVS|
16268163|NCT04898647|Experimental|Remaining patients|
16268164|NCT04898634|Experimental|JNJ-78278343|Participants will receive JNJ-78278343 subcutaneously (SC). The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 SC at recommended phase 2 dose (RP2D) as determined in Part 1.
16268165|NCT04898621|Experimental|Group A|Subjects in Group A will drink 75g fructose solution daily for 4 weeks.
16268166|NCT04898621|Experimental|Group B|Subjects in Group A will drink 150g fructose solution daily for 4 weeks.
16268167|NCT04898608|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
16268168|NCT04898608|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
16268169|NCT04898595|No Intervention|Usual Process of Care|No intervention
16268170|NCT04898595|Experimental|Standardized approach to discontinuation of CRRT|Criteria-driven approach
16268171|NCT04898582|Other|20 women 20-60 years old with sensitive skin and persistent centrofacial erythema of rosacea|"The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions. The subjects were allowed to use their habitual foundation and makeup products on the whole face.
~The side of application of the product M89 Probiotic Fractions (right or left side of the face) was randomized among the subjects.
~The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study centre on the first day."
16268172|NCT04898569|Experimental|Ferinject®|
16268175|NCT04898556|Placebo Comparator|Control Group|Patients who will not undergo any treatment for vulvovaginal atrophy for 12 weeks.
16268176|NCT04898543|Experimental|Cohort 1: Subjects newly diagnosed|Cohort 1: Subjects newly diagnosed with high-risk solid tumors who have not received treatment.
16268177|NCT04898543|Experimental|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies.
16268178|NCT04898504|No Intervention|2nd line chemotherapy|2nd line chemotherapy is the current standard treatment for patients with CRLM and progression on 1st line chemotherapy. We will include 18 patients in this treatment arm thus empowering the study to show non-inferiority between HAI and 2nd line chemo.
16268179|NCT04898504|Active Comparator|Liver transplant|Liver transplantation (LTX) has emerged as a possible solution for some patients with unresectable CRLM who otherwise have good prognosis based on available scorings systems. We will include 9 patients in this treatment arm. They will be given 2nd line chemotherapy followed by Liver-Tx. Including 9 patients will only empower the study to show non-inferiority between Liver-Tx and 2nd line chemo (where we expect a large difference in the primary end-point) but not between HAI and Liver-Tx.
16268180|NCT04898504|Active Comparator|Hepatic artery infusion (HAI) chemotherapy|The biological rationale for intra-arterial chemotherapy is that the hepatic artery rather than the portal vein is responsible for most of the blood supply to liver tumors. Floxuridine has for years been established as viable treatment option for similar patients at The Memorial Sloan Kettering Cancer Institute, New York, but has yet to gain foothold in Europe despite promising results. We will include 18 patients in this arm receiving 6 cycles of HAI-Floxuridine and a full course of 2nd line chemotherapy.
16268181|NCT04898478|Experimental|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|This arm will consist of a behavioral intervention to increase treatment seeking among Pacific Islanders with opioid use disorders.
16268182|NCT04898465|Experimental|Social Paediatric Intervention|Multiprofessional social paediatric meeting with the family.
16268183|NCT04898465|No Intervention|Control group|Normal post-DGA dental programme.
16268184|NCT04898452||Patients needing antibiotics infusion|Patients needing antibiotics infusion A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
16268185|NCT04898452||Next of kin|Next of kin A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
16268186|NCT04898452||Health professionals|A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
16268187|NCT04898439|Experimental|Green school|The children from schools that are being greened will be investigated and compared to the control school. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing.
16268188|NCT04898439|No Intervention|control school|The children from schools that are not being greened will be investigated and used as a control group. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing
16268189|NCT04898426|No Intervention|Standard Bowel Preparation Instruction|Patients receive the standard-of-care bowel preparation instruction.
16268190|NCT04898426|Experimental|Enhanced Bowel Preparation Instruction|Patients receive enhanced instructions (SMS, phone call, info website) in addition to the standard-of-care bowel preparation instruction.
16268191|NCT04898413|Experimental|Group-based acceptance and commitment therapy (ACT)|Participants assigned to the group-based ACT intervention will receive eight sessions through face-to-face or Zoom video conferencing over the course of four months. Participants will also receive individualized support between sessions to help them better understand the program using phone or Zoom video conferencing. If participants' care recipient hopes to receive psychological treatment, they will be invited to participate in a group-based reminiscence therapy held once a month, each lasting about 60-90 minutes, over the course of about nine months.
16268192|NCT04898413|Active Comparator|Group-based cognitive behavior therapy (CBT)|Participants assigned to the group-based CBT intervention will receive eight sessions through face-to-face or Zoom video conferencing over the course of four months. Participants will also receive individualized support between sessions to help them better understand the program using phone or Zoom video conferencing. If participants' care recipient hopes to receive psychological treatment, they will be invited to participate in a group-based reminiscence therapy held once a month, each lasting about 60-90 minutes, over the course of about nine months.
16268193|NCT04898400|Experimental|Subjects with Obesity|Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure
16268194|NCT04898387|Experimental|T4030 Group|
16268195|NCT04898387|Active Comparator|Ganfort Group|
16268196|NCT04898374|Experimental|Induction Arm|patients will receive three cycles of IC Gemcitabin/Cisplatin followed by radical CRT
16268197|NCT04898374|Active Comparator|Adjuvant Arm|Patients will receive radical CRT followed by three cycles of AC Gemcitabin/Cisplatin
16268198|NCT04898361|Active Comparator|PFO closure|Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring.
16268199|NCT04898361|No Intervention|NO PFO|Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring.
16268200|NCT04898348|Placebo Comparator|Placebo (after Vancomycin pre-treatment)|3 capsules twice a day dosing of Placebo (after Vancomycin pre-treatment)
16268201|NCT04898348|Experimental|KBL697 (after Vancomycin pre-treatment)|3 capsules twice a day dosing of KBL697 (after Vancomycin pre-treatment)
16268202|NCT04898335||Tendyne|all patients treated with a Tendyne Mitral Valve System
16268213|NCT04898296||Patients over 55 Years with coronary heart disease|Questionnaire and semistructured Interview 45 -60 minutes
16268214|NCT04898296||physical therapists working with patients with coronary heart disease|Focus group 60 -90 minutes
16268215|NCT04898283|Experimental|10,000 MG01 + 10,000 T521|10,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
16268216|NCT04898283|Experimental|30,000 MG01 + 10,000 T521|30,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
16268217|NCT04898283|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
16268218|NCT04898270|Experimental|MARTAs combined with flupentixol|"Flupentixol tablets are indicated for:
~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.
~Other Names:
~Fute tables, Fluanxol
~Multi-acting receptor-targeted antipsychotics (MARTAs): clozapine, olanzapine, quetiapine."
16268219|NCT04898270|Active Comparator|Multi-acting receptor-targeted antipsychotics (MARTAs)|clozapine, olanzapine, quetiapine
16268220|NCT04898257|Other|Lactibiane Tolerance®|30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.
16268221|NCT04898231|Active Comparator|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
16268222|NCT04898231|Active Comparator|Methylprednisilone (steroids)|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
16268223|NCT04898231|Active Comparator|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
16268224|NCT04898218|Active Comparator|Group A (Aerobic Exercise Group)|Warm-up exercises were performed by the participants on a cycle ergometer for a duration of 5-10 minutes. Group A was advised to start walking at a comfortable speed on a treadmill for the duration of 30-60 minutes; the intensity of the exercises was 55-75% of MHR, calculated by using a Karvonen method. Initially with the minimum intensity that was gradually raised up to the intensity of Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase for 5-10 min.
16268225|NCT04898218|Active Comparator|Group B (Resistance Exercise Group)|Group B was instructed for strengthening exercises of ten major muscle groups that include Biceps, Triceps, Pectoralis Major, Deltoid, Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight-bearing exercises was calculated using 1 Repetition Maximum (RM) method.
16268226|NCT04898218|Experimental|Group C (Osteoanabolic Exercise Group)|"Group C was performed Osteoanabolic exercise divided into two different phases:
~Aerobic Conditioning Phase Participants were instructed to walk on treadmill for 30-60 min. The intensity of the exercises was 55-75% MHR, calculated by Karvonen method. Intensity gradually raised up to the Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase. The participants performed 3 days per week for 12 weeks on alternative days.
~Anaerobic (Resistance) Conditioning Phase Resistance training was started on every alternative day of the aerobic conditioning (3 days per week) for 45 min. The intensity of the weight-bearing exercises was calculated using 1 RM method. Resistance training muscle and protocol was the same as for Group B. The participants performed warm-up and cool down similar to that of group A and group B."
16268227|NCT04898205|Experimental|Treadmill Exercise with Supplemental Oxygen|Participants will receive 24 sessions (2 x week for 12 weeks) of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
16268228|NCT04898205|Sham Comparator|Treadmill Exercise with Air|Participants will receive 8 sessions (2 x week for 4 weeks) of treadmill exercise combined with air delivered via nasal cannula during exercise and 5-minutes of recovery. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
16268264|NCT04897932|Active Comparator|Adult nocturia|Use of device over 28 days
16268229|NCT04898205|Sham Comparator|Supplemental Oxygen Only|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of 6 liters per minute of continuous oxygen via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
16268230|NCT04898205|Placebo Comparator|No Intervention|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of air via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
16268231|NCT04898179||Telecare group|"When discharged, patients will be followed at home by a telecare nursing and specialist teleconsultation program for 3 months. The key element of the program will be a structured nurse-managed telephone support and, when necessary, video consultations, to follow patients, for the first month. During these contacts, the nurse will conduct a standardized interview enquiring about the general clinical condition of the patient. In the case of any symptom or problem, the patient will be able to call the service. At the end of the third month, patients will contact again to check their clinical condition and to close the program. Patients will be provided with a pulse oximeter to measure O2 saturation.
~At the start and end of the program, patients were administered the SF-12 quality of life questionnaire."
16268232|NCT04898179||Control group|The patients in the control group will be followed by their general practitioner and they will be contacted after three months to check their clinical condition.
16268233|NCT04898153|Experimental|aXess|Patients will be implanted with the Xeltis hemodialysis access graft (aXess)
16268234|NCT04898140||Healthy volunteers|Individuals who were not infected and not having been demonstrated COVID-19 symptoms since December 2019.
16268235|NCT04898140||Recovered|Individuals who were recovered from COVID-19 with different severity.
16268236|NCT04898140||Vaccinated|"Individuals who were vaccinated against SARS-CoV-2 with Sputnik V vaccine."
16268237|NCT04898140||Special group|Individuals who recovered from COVID-19 concomitant with other immune-related comorbidities (tuberculosis, chronic obstructive pulmonary disease, HIV infection, hematological neoplasia).
16268238|NCT04898127|Experimental|Rapid test and concert|Participants in this arm will be offered access to a concert, after a negative rapid test.
16268239|NCT04898127|No Intervention|Control|Participants in this are will not be offered access to a concert during the study period.
16268240|NCT04898114|Experimental|NebMag|Nebulized magnesium sulfate and oral sildenafil
16268241|NCT04898114|Placebo Comparator|Control|Nebulized placebo (isotonic saline) and oral sildenafil
16268242|NCT04898101|Experimental|Cohort 1|Participants will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose, participants will receive a single microtracer (<10 μg; <=1 μCi) [14C]ACP-196 as a 5 mL IV push over 2 minutes.
16268243|NCT04898101|Experimental|Cohort 2|Participants will receive a single 100 mL oral solution of acalabrutinib, 1 mg/mL oral solution containing a microtracer dose (<10 μg; <=1 μCi) of [14C]ACP-196.
16268244|NCT04898088|Experimental|Conventional Therapy|
16268245|NCT04898088|Experimental|Conventional Therapy with Add-On MSC therapy|
16268246|NCT04898075|Experimental|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
16268247|NCT04898075|Placebo Comparator|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
16268248|NCT04898062|Active Comparator|CRP-apheresis|Patients randomized to this group will undergo 4 apheresis treatments, each lasting 4-7 hours.
16268249|NCT04898062|No Intervention|Control|Patients randomized to this group will not undergo a apheresis treatments. They will be treated according to the current conventional treatment concept for covid-19 disease
16268250|NCT04898036|Experimental|Sham First, then Experimental|Participants in this group will receive the sham treatment first, then the experimental treatment.
16268251|NCT04898036|Experimental|Experimental First, then Sham|Participants in this group will receive the experimental treatment first, then the sham treatment.
16268252|NCT04898023|Experimental|zinc-green tea extract-ascorbic acid|Compounded capsules will be prepared containing each 50mg of zinc citrate, 400mg of green tea extract, and 100mg of ascorbic acid. Randomized patients will take two (2) capsules taken orally two (2) hours following a meal twice daily x5 days.
16268253|NCT04898023|Placebo Comparator|Placebo|"Compounded capsules will be prepared containing each 650mg of microcrystalline cellulose.
~Randomized patients will take two (2) capsules taken orally two (2) hours following a meal twice daily x5 days"
16268254|NCT04897997||non smokers|never having smoked patients
16268255|NCT04897997||smokers|actively smoking patients
16268256|NCT04897997||acute coronary syndrome|patients with the coronary indication of ACS
16268257|NCT04897997||stable|patients with the coronary indication of stable or silent ischemia
16268258|NCT04897984|Experimental|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
16268259|NCT04897971||Spine implant associated infection cohort|Adult patients undergoing revision spine surgeries with suspected infection of previous instrumentation.
16268260|NCT04897958||Degarelix|Reference group
16268261|NCT04897958||Leuprolide|Exposure group
16294467|NCT04714645|Sham Comparator|Control group|VR- training
16268265|NCT04897932|Active Comparator|Adult urge urinary incontinence|Use of device over 28 days
16268266|NCT04897932|Active Comparator|Adult frequency urinary incontinence|Use of device over 28 days
16268267|NCT04897932|Active Comparator|Adult functional incontinence|Use of device over 28 days
16268268|NCT04897919|Experimental|dihydroartemisinin-piperaquine|"First dose will be given supervised. The rest will be provided and the parents should take it at home.
~Dihydroartemisinin-piperaquine dosing as recommended by manufacturer"
16268269|NCT04897919|No Intervention|artemether-lumefantrine|"First dose will be given supervised. The rest will be provided and the patients should take it at home.
~Artemether-lumefantrine dosing as recommended by manufacturer"
16268270|NCT04897906|Experimental|Experimental group|Experimental group; It is the group that will be given mother and neonatal care education.
16268271|NCT04897906|No Intervention|Control Group|Control group; It is the group in which no intervention will be made other than data collection.
16268272|NCT04897893|Experimental|Experimental Treatment|All subjects enrolled in the study will receive an identical dose of 2g/day (4 capsules of MAG-EPA) which will be taken by the subject at home. The duration of treatment should not be prolonged in the event of missed doses, that is, treatment should end on the 84th day as planned. A deviation of ± 3 days is acceptable, which means that treatment can be stopped from day 81 to day 87 of subject's participation.
16268273|NCT04897880|Experimental|Osteosarcoma [arm closed]|
16268274|NCT04897880|Experimental|Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumor|
16268275|NCT04897880|Experimental|Neuroblastoma [arm closed]|
16268276|NCT04897867|Experimental|CoolSculpting® Elite System|Participants received up to two CoolSculpting® Elite treatment sessions for the abdomen and flanks plus optional additional body areas 8 weeks apart. At the investigator's discretion, per treatment session, up to 8 treatment cycles were performed for the midsection, and if applicable, up to 2 treatment cycles for the submental area, up to 4 cycles to upper arms, and up to 4 cycles each to inner and/or outer thighs.
16268277|NCT04897854|Active Comparator|Immediate treatment|The treatment schedule will be direct (start within 3 weeks of bate of diagnosis) FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.
16268278|NCT04897854|Active Comparator|Delayed treatment|"The treatment schedule will be delayed treatment (based on symptoms) with FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.
~Chemotherapy will start as soon as one of the following criteria is met:
~Decline in performance status to ECOG < 1 or Karnofsky < 80%
~Weight loss more than 5% of the total body weight from the time of study entry
~Persistent nausea requiring medication
~Pain requiring regular narcotic analgesics
~Development of clinically significant third-space fluid collections
~Liver function deterioration in the presence of progressive liver metastases"
16268279|NCT04897841|Placebo Comparator|control arm|The control arm will receive 30 mL of bupivacaine HCl plus 50 mL of saline injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
16268280|NCT04897841|Experimental|Intervention: liposomal bupivacaine|The intervention arm will receive 30 mL of bupivacaine HCl plus 30 mL of saline plus 20 mL of liposomal bupivacaine injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
16268281|NCT04897828||Covered Stent Group|Patients with a dysfunctional hemodialysis vascular access undergoing treatment procedure using a covered stent (stent graft).
16268282|NCT04897815||20 patients with type 2 diabetes mellitus|Fasting blood glucose and TCD will be measured in 20 patients with type 2 diabetes mellitus, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
16268283|NCT04897815||20 healthy volunteers whose sex and age and BMI matched with the experimental group|Fasting blood glucose and TCD will be measured in healthy control group, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
16268284|NCT04897802|Experimental|Experimental: GLP1-RA administration|A single dose of 10 mcg of GLP1-RA (exenatide) will be injected subcutaneously and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after GLP1-RA:placebo administration to assess OT secretory patterns
16268285|NCT04897802|Placebo Comparator|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than GLP1-RA (exenatide) administration
16268286|NCT04897789||children/pregnant women|children/pregnant women (2,310)
16268287|NCT04897789||parents|parents (2,310)
16268288|NCT04897789||classrooms/teachers|classrooms/teachers (840)
16268289|NCT04897789||home visitors|home visitors (630)
16268290|NCT04897789||center directors|center directors (493)
16268291|NCT04897789||program directors|program directors (140)
16268294|NCT04897763|Experimental|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
16268295|NCT04897750|Experimental|Active|a target dose of intranasal sufentanil 0,5 mcg/kg + ketamine 0,5 mg/kg, (2-4 puffs) and an additional dose if needed as premedication before placement of a PVC for induction of anaesthesia.
16268296|NCT04897737|Experimental|Intervention|HIV self-testing kits and counseling on use for participant and partner use + enhanced adherence counseling including urine tenofovir test to provide biofeedback in women using PrEP
16268297|NCT04897737|No Intervention|Control|Standard of care intervention including facility based HIV testing, referral for partner to attend facility for testing, and PrEP adherence counseling without biofeedback
16268298|NCT04897724|Other|patients have carious lesions in one or more surface of molars and premolars|patients received direct composite restorations using a nanohybrid and a nonofil composite restorations
16268299|NCT04897711|Experimental|Perceptual training with a speaker with dysarthria|To examine the effect of perceptual training with speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases, in which speech samples from a single speaker with dysarthria are utilized for all three phases.
16268300|NCT04897698|Placebo Comparator|Placebo|Four capsules containing rice flour will be given to the placebo group daily.
16268301|NCT04897698|Experimental|Single dose|"Two capsules of probiotics and two capsules of placebo daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
~The placebo is made of rice flour."
16268302|NCT04897698|Experimental|Double dose|Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
16268303|NCT04897685|Experimental|Nature-based treatment group|The participants in the treatment group were offered 12 nature-based group therapy sessions in addition to standard care.
16268304|NCT04897685|No Intervention|Control group|The participants in the control group continued treatment as usual in the health care services.
16268305|NCT04897672||case|case: Children aged 6 to 17 years old reffered to the pediatric cardiology consultation with a chronic renal disease and renal insufficiency
16268306|NCT04897672||control|control : Children aged 6 to 17 years old reffered to the pediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography
16268307|NCT04897633|Experimental|Patients ON|Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)
16268308|NCT04897633|Experimental|Patients OFF|Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)
16268309|NCT04897633|Experimental|Healthy volunteers|Healthy volunteers will performed Simon's task with tDCS active or sham
16268312|NCT04897594|Experimental|Part 1: TERN-201 dose level 1|Orally administered.
16268313|NCT04897594|Placebo Comparator|Part 1: Placebo|Orally Administered
16268314|NCT04897594|Experimental|Part 2: TERN-201 dose level 2|Orally administered
16268315|NCT04897594|Placebo Comparator|Part 2: Placebo|Orally administered
16268316|NCT04897581|Experimental|Brief Behavioral Therapy for Insomnia, BBTI|Participants in this group will receive 3 sessions of BBTI over telehealth.
16268317|NCT04897581|Experimental|Physical Self-Regulation, PSR|Participants in this group will receive 3 sessions of PSR over telehealth.
16268318|NCT04897568|No Intervention|Control|The control group will consist of each participant and clinic before the intervention (baseline, first 2 months).
16268319|NCT04897568|Active Comparator|Patient decision aid|The intervention group will consist of each participant and clinic once they move to the intervention phase (stepped-wedge design: practices will be randomized into step 1, 2 or 3; for step 1: the intervention will start at 2 months, for step 2: the intervention will start at 4 months, for step 3: the intervention will start at 6 months).
16268320|NCT04897555|Experimental|LLLT Active Treatment|LLLT Therapy will be administered to the treatment site.
16268321|NCT04897555|No Intervention|No LLLT Comparator|No LLLT Therapy will be administered to the comparator site.
16268322|NCT04897542|Experimental|Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT|"Each patient receive a single intravenous injection of Gallium-68 DOTATATE (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
~All patients have to do a Gallium-68 NODAGA-JR11 PET/CT scan (40ug/150-200MBq, 40-60 min post-injection) for comparison on the next day of DOTATATE scan."
16268323|NCT04897516|Experimental|Short regimen of benznidazole|Participants will receive an investigational treatment of benznidazole for 2 weeks.
16268324|NCT04897516|Active Comparator|Standard treatment with benznidazole|Historical controls who received the standard treatment of benznidazole (8 weeks).
16268325|NCT04897503|Active Comparator|CXL using Riboflavin/Dextran solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 20% dextran
16268326|NCT04897503|Active Comparator|CXL usinng Riboflavin/Methylcellulose solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 1.0% hydroxypropylmethylcellulose ( HPMC)
16268327|NCT04897490||Adult APL in first line|Patients >/= 18 years old with recent diagnosis of acute promyelocytic leukemia who receive treatment with ATO/ATRA according to our local guidelines. HR patients will receive 2-3 aditional doses of idarrubicin.
16268328|NCT04897477|Experimental|combination of Azacytidine, Bendamustine and Piamprizumab|combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma, every 28 days
16268329|NCT04897464|Experimental|Treatment|
16268330|NCT04897451||Women with cervical ripening in the context of artificial labor induction|
16268431|NCT04896606|Active Comparator|Standard of Care Only|Patients will NOT received COVID CTLs but will get standard of care.
16268331|NCT04897438|Experimental|Intervention|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. If absolute levels of dd-cfDNA are > 50 copies/ml, the patients receive a kidney allograft biopsy. Additionally, kidney allograft biopsies are performed according to standard of care as determined by the treating physicians.
16268332|NCT04897438|No Intervention|Control|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. These measurements are not used to guide kidney allograft biopsies. Those are performed according to standard of care as determined by the treating physicians.
16268333|NCT04897425|Experimental|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"The participant can choose between one, two, or five interventions per week depending on their availability.
~Steps of each intervention:
~Pain Evaluation: Numeric Rating Scale (NRS)
~Functional Assessments (1st, 5th, 10th, and last sessions)
~Preparation:
~Locate participant in a comfortable position for training (comfortable chair, about a meter distance to the screen, pleasant arm position)
~Placement of the surface electrodes
~Positioning of the feedback wearable device over the affected body part
~Placement of the brain modulation cap
~Treatment modalities:
~Motor training
~Sensory training
~Sensorimotor training
~Assessments
~Step 4 is repeated for different phantom movements, initially one at a time, progressing to several joints simultaneously. A treatment session lasts 2 hours."
16268334|NCT04897412|Experimental|CBL-514|
16268335|NCT04897412|Placebo Comparator|Placebo: 0.9% Sodium Chloride|
16268336|NCT04897386|Experimental|Duvalizumab Combined With Neoadjuvant Chemotherapy|
16268337|NCT04897360|Experimental|Normocapnic SRT, Hypocapnic SRT, Recovery SRT|Sharpened Romberg Test
16268338|NCT04897347|Experimental|Robotic Trunk-Support-Trainer (TruST)|Postural-reaching control intervention with TruST
16268339|NCT04897347|Active Comparator|Static Trunk Support|Postural-reaching control intervention with Rigid Trunk Support
16268340|NCT04897334|Active Comparator|Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
16268341|NCT04897334|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of sham tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
16268342|NCT04897321|Other|Treatment Phase|During the treatment phase, the participant receives an infusion of the B7-H3-CAR T cells that were made in the Collection and Manufacturing Phase. Chemotherapy is given for several days prior to the cellular infusion. Patients are then monitored for possible side effects, as well as effects of the treatment on their cancer.
16268343|NCT04897308|Active Comparator|Suprascapular nerve block|This group will include will under go suprascapularnerve block as following :10 ml of .5% bupivacaine and 2 ml of methylpradnisolon 40mg/ml
16268344|NCT04897308|Active Comparator|Hydrodilatation of shoulder capsule|This group will undergo intraarticular hydrodilatation by injection of :first lidocaine10ml%followed by 1ml of methylprednisolon 40mg/ml and finally 20ml of .9 % sodium chloride slowly in the gleno humeral joint
16268345|NCT04897308|Active Comparator|Hydrodilatation of shoulder interval|This group will undergo interval hydrodilatation by injection of :first mepivacaine 10ml folowed by 20ml of sterile water slowly in the shoulder interval
16268348|NCT04897269|No Intervention|Control group|In the control group, the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg two times per day for 14 days, without any progesterone supplementation. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
16268349|NCT04897269|Experimental|Study group|In the interventional group,the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg x 2 per day for 14 days, supplemented with intramuscular progesterone (Progesterone 25mg/ml) 25 mg x 2 at one time per day for 14 days. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
16268352|NCT04897243||Multidisciplinary model of care|The Chronic Viral Illness Service at the Glen hospital of the MUHC will provide care with a multidisciplinary assessment, according to local current standard practice. Each newly-referred patient at the CVIS will be first received by a dedicated nurse, who then orients referral to a physician and/or a social worker and/or a pharmacist.
16268430|NCT04896606|Experimental|SARS-CoV-2 CTLS + Standard of Care|Patients will get family donor derived SARS-CoV-2 cytotoxic t-lymphocytes up to 5 times every 2 weeks along with Standard of care of COVID-19.
16268353|NCT04897243||Physician-only model of care|The Jewish General Hospital will provide care as per current local standard practice. Each newly-referred patient will be assessed by a clinician. Blood tests will be performed by central laboratory nurses who are not part of the HIV clinic.
16268354|NCT04897230|Active Comparator|Hatha Yoga Condition|An experienced yoga instructor led the 30 minutes yoga condition session which consisted of 5 minutes warm up, 5 minutes breathing exercises, and 20 minutes yoga poses practice. The yoga props were used according to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably.
16268355|NCT04897230|Placebo Comparator|Control Condition|Participants in the control condition were watching a neutral video on a television.
16268356|NCT04897217|Active Comparator|Megestrol Acetate Arm - Control Arm|Megestrol Acetate 160 mg by mouth daily
16268357|NCT04897217|Experimental|Levonorgestrel IUD - Comparison Arm|Levonorgestrel intrauterine device with 52 mg progestin (Releases 20mcg/daily)
16268358|NCT04897204|Experimental|Left Atrial Appendage Electrical Isolation with One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion and additional left atrial appendage electrical isolation operation.
16268359|NCT04897204|Other|One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion.
16268360|NCT04897191||Healthy|Healthy people age 20-70 years
16268361|NCT04897178||Fetuses with normal anatomy|Fetuses with normal anatomy scan who demonstrate no structural abnormalities of different systems (CNS, chest and heart, abdomen, skeletal system)
16268362|NCT04897178||Fetuses with abnormal anatomy|Fetuses with abnormal anatomy scan who demonstrate any structural abnormalities that can be detected with ultrasound
16268363|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|
16268364|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|
16268365|NCT04897165|No Intervention|Waitlist controls|
16268366|NCT04897139|Experimental|treatment arm|treatment arm
16268367|NCT04897126|Active Comparator|Experimental group|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
16268368|NCT04897126|Placebo Comparator|Placebo group|The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.
16268369|NCT04897113|Experimental|plasmapheresis with albumin compensation|a course of hardware plasmapheresis procedures with replacement by colloidal (5% albumin solution) and crystalloid solutions (saline) in a ratio of 1: 3
16268370|NCT04897113|Experimental|plasmapheresis without albumin compensation|a course of hardware plasmapheresis procedures without replacement by albumin solution, only crystalloid solutions (saline).
16268371|NCT04897100|Experimental|Needle tenotomy|
16268372|NCT04897100|Active Comparator|Blade tenotomy|
16268374|NCT04897061||Participants undergoing major pelvic organ prolapse surgery|
16268375|NCT04897048|Experimental|Oxygen|Supplemental oxygen will be applied via a mask during CPET
16268376|NCT04897048|Sham Comparator|Air|Sham ambient air will be applied via mask during CPET
16268377|NCT04897035|Experimental|Subjects with Lower Extremity Lymphedema and phlebolymphedema|Lower Extremity Lymphedema and phlebolymphedema
16268378|NCT04897022|Experimental|Participants with malignant pleural mesothelioma (MPM)|Participants will be diagnosed with malignant pleural mesothelioma and be deemed unresectable per thoracic surgeon assessment
16268379|NCT04897009||Observational (biospecimen collection)|Patients undergo blood sample collection at baseline (prior to first NAC treatment), after taxane and prior to first dose of A/C (for patients receiving a taxane), end of NAC, 1-4 weeks and 6 months post-surgery. Patients also undergo tissue collection at 1-4 weeks and 6 months post-surgery.
16268380|NCT04896996|Experimental|Whole eggs (WE)|consume 10 additional eggs per week
16268381|NCT04896996|Experimental|Egg substitute (ES)|consume the yolk-free egg substitute equivalent to 10 eggs per week
16268382|NCT04896996|No Intervention|Control group|Regular school meals
16268385|NCT04896944||ICU Centre Hospitalier de Saint Denis|
16268386|NCT04896944||ICU Hôpital Ambroise Paré Boulogne|
16268387|NCT04896918||Cohort of adult client of public dental clinics in Region Stockholm|Tobacco use (cigarette smoking and/or snus use) will be considered as exposure. Information on tobacco use will be extracted by public dental clinic records in Stockholm Region (October 2015-January 2020). Any diagnosis of COVID-19, hospitalization, receiving intensive care, and death because of COVID-19 will be examined as outcomes. Diagnoses of COVID-19 will be obtained through record linkage with health care registers of inpatient and outpatient care (February 2020-August 2021).
16268388|NCT04896905||Isolation group with active Covid19|Patients assigned to rehab which had to be treated in isolation wards dur to active disease
16268389|NCT04896905||Post-Covid-group|Patients assigned to rehab after active disease, still having restrictions in activity and particiaption
16268390|NCT04896905||Control group|Pateints assigned to rehabilitation in the same time period without any signs of Sars-coV-2 infection
16268391|NCT04896892||Total Knee Arthroplasty|Patients in this group will be undergoing total knee arthroplasty.
16268392|NCT04896892||Total Hip Arthroplasty|Patients in this group will be undergoing total hip arthroplasty.
16268393|NCT04896879||Patients|Patients with major LARS
16268394|NCT04896879||Informal caregivers|Informal caregivers of patients with major LARS
16268395|NCT04896879||Healthcare professionals|Healthcare professionals taking care for patients with LARS
16268398|NCT04896853|Experimental|Treatment|Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells.
16268399|NCT04896840|Experimental|Treatment group|Telerehabilitation and motor learning principles will be applied.
16268400|NCT04896840|Experimental|Control Group|Motor learning principles will be applied in the clinic.
16268401|NCT04896827||Chronic pain|Patients with chronic pain (n=100)
16268402|NCT04896827||Healthy participants|Healthy participants (n=144)
16268403|NCT04896814|Experimental|Transcutaneous tibial nerve stimulation|The participant will receive an intervention session per week that will be held for a period of 12 weeks. The total application time will be 30 minutes. A symmetrical biphasic current will be applied, with a frequency of 20 Hz in continuous mode and a pulsed frequency of 200 µs.
16268404|NCT04896814|Placebo Comparator|Placebo|The participant will receive one intervention session per week will be performed during a 12 weeks period time. The total application time will be 30 minutes. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied in other localization.
16268405|NCT04896801|Experimental|MR-guided prostate stereotactic body radiotherapy|Patients will receive MR-guided RT in 5 fractions over 7 days (daily excluding weekend, i.e. start on Wednesday or Thursday, until Tuesday or Wednesday respectively the week after).
16268406|NCT04896788|Other|Monitoring of the immune response|Immune response controlled with blood sample at 3, 6, 12, 18 and 24 months
16268407|NCT04896775|Experimental|NiteCAPP CARE|Cognitive Behavioral Treatment-Insomnia. 4 online treatment sessions focusing on behavior and cognitions related to sleep.
16268408|NCT04896775|Experimental|NiteCAPP SHARE|Sleep Hygiene and Related Education. 4 online treatment sessions focusing on sleep hygiene and related education.
16268409|NCT04896762||Extrapulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with extrapulmonary system affection
16268410|NCT04896762||pulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with pulmonary disease
16268411|NCT04896749|Experimental|Group A/ Nerve mobilization group|In this group, patients will receive nerve mobilization exercises along with routine physical therapy. Patients will also be given home plan for cervical isometric exercises.
16268412|NCT04896749|Active Comparator|Group B/ Conventional physical therapy group|In this group, patients will receive routine physical therapy and also given home plan for cervical isometric exercises
16268413|NCT04896736|Experimental|Multisite tissue oxygenation monitoring-guided care|"Details are as follows. • Monitoring: SctO2 monitored using two probes placed on left and right forehead. SstO2 monitored using one probe placed over the forearm brachioradialis muscle on the arm not used for non-invasive blood pressure monitoring.
~• Baseline: The first baseline is measured 12-48 hours before surgery, with the patient supine, awake, calm, eyes closed, and breathing room air or oxygen that is equivalent to the home oxygen rate for patients using home oxygen.
~Goals: Maintain both SctO2 and SstO2 within 90-110% of the baseline level.
~Trigger of intervention: SctO2/SstO2 outside of the 90-110% baseline range.
~Diagnosis:
~Care team: The caregivers providing SctO2/SstO2-guided care will be trained and given the opportunity to use the intervention protocol in at least 20 patients before the formal study.
~Treatments: Refer to the algorithm to restore SctO2/SstO2 within 90-110% baseline range."
16268414|NCT04896736|Active Comparator|Usual care|Patients in the control group will be managed by clinical staff according to usual care. Patients in this group will be monitored using the same tissue oximeter used in the intervention group; however, the screen will be covered by an opaque cloth to prohibit the care givers seeing the monitoring data. The same baseline measurements will be performed in patients allocated to the usual care group.
16268415|NCT04896723||Chronic liver disease|
16268416|NCT04896723||Healthy volunteers|
16268417|NCT04896710|Experimental|Self administration|The participant will self administer the SD Biosensor. Their rapid antigen test result will be compared to health care professional administered SD Biosensor
16268418|NCT04896697|Experimental|Part 1A - Dose Escalation|Part 1A Dose Escalation of XTX101 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
16268419|NCT04896697|Experimental|Part 1B - Pharmacodynamic (PD) Dose Expansion|Part 1B XTX101 at the RP2D will be administered to further examine XTX101 as monotherapy in patients with select advanced solid tumors.
16268420|NCT04896684||Patient screened or followed-up for IBS or IBD or colorectal cancer|Blood and colon biopsy sampling
16268421|NCT04896671|Experimental|Intervention group|Each participant joins a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes.
16268422|NCT04896671|No Intervention|Waitlist control group|They receive no treatments.
16268423|NCT04896658|Experimental|Arm A|"Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.
~Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles."
16268424|NCT04896658|Experimental|Arm B|"Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.
~Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles."
16268426|NCT04896632|Experimental|INE963|Part A is a single ascending dose (SAD) study with 4 planned cohorts Part B is a multiple dose (MD) study with 1 planned cohort q24h x 3 day of either INE963 or placebo
16268427|NCT04896632|Placebo Comparator|Placebo group|Part A is a single ascending dose (SAD) study with 4 planned cohorts Part B is a multiple dose (MD) study with 1 planned cohort q24h x 3 day of either INE963 or placebo
16268428|NCT04896619|Experimental|Daily dose of Kori-tofu mixed in 3 slices of bread|Kori tofu as part of bread
16268429|NCT04896619|Active Comparator|Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread|Whey protein, soy oil and maltodextrin as part of bread
16268433|NCT04896580|Experimental|Active|Participants will be asked to complete a 12 week exercise program
16268434|NCT04896567|Experimental|Intervention|Patients will have kidney biopsy designated for cell isolation and culture.
16268435|NCT04896554|Active Comparator|quit smoking|patients who have quit smoking
16268436|NCT04896554|Active Comparator|not quit smoking|patients who have not quit smoking
16268437|NCT04896541|Experimental|AZD7442|Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
16268438|NCT04896541|Experimental|placebo|Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
16268439|NCT04896528|Experimental|Avatrombopag|"Avartripopa is a new generation of oral TPO receptor agonist that simulates the biological effects of TPO in vitro and in vivo.
~TPO stimulates megakaryocytes through binding and activation of TPO receptor, which is expressed in hematopoietic stem cells, megakaryotic cell lines and platelets.
~By binding to the transmembrane region of the thrombopoietin receptor, Ava Tripopa activates the thrombopoietin receptor in humans, stimulates signal transduction and mimics the biological effects of thrombopoietin, leading to an increase in platelet count."
16268440|NCT04896515||Standard Nutrition Arm|"In INTENT (the parent study) participants will be randomised to the i) Standard Nutrition or ii) Intensive Nutrition arm. A brief description of each is below.
~In ICU:
~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.
~Parenteral Nutrition (PN) will only be used if the above methods have been attempted, or an absolute contraindication to enteral nutrition (EN) develops.
~After ICU:
~1. Nutrition management will be as per usual site management at that hospital."
16268441|NCT04896515||Intensive Nutrition Arm|"In ICU:
~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose will be determined by the amount of energy received in the 24 hours prior to randomisation
~The need for the intervention will be based on the adequacy of nutrition provision and assessed daily until ICU discharge
~If there is an interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.
~After ICU:
~1. An intensive nutrition intervention will be provided on the ward.
~The goal of nutrition care across the hospital stay will be to ensure 80-100% of participant's estimated energy requirements are met."
16268442|NCT04896502|Experimental|Telemedicine Arm|For the proposed study, participants will randomized to receive TM home assessments/interventions performed by a trained home visitor (HV) or standard of care asthma trigger education by the HV. Those who are randomized to TM home assessments/interventions will complete a baseline home assessment and two follow-up visits, 2 months apart. Visits will assess the presence of potential asthma triggers in the home and frequency of asthma symptoms/exacerbations. TM participants will be provided education and materials necessary to reduce asthma triggers in the home. Follow-up visits will assess the interval change in presence of asthma triggers, change in daily asthma symptoms/exacerbations, and participant/family retention of education.
16268443|NCT04896502|Active Comparator|Standard of Care Education|For subjects randomized to receive standard of care asthma education, written and verbal information will be provided regarding identification and removal of potential asthma triggers in the home but no formal assessment of the home will be performed, nor will participants in this arm receive trigger reduction materials.
16268444|NCT04896489|Experimental|hydrocortisone|Participants receive hydrocortisone (20mg)
16268445|NCT04896489|Placebo Comparator|placebo|Participants receive placebo.
16268446|NCT04896476|Experimental|EchoMark|All subjects will undergo a physician exam prior an arteriovenous fistula creation per the institution's standard of care. After the fistula creation is completed, but prior to closure, the EchoMark will be implanted under the outflow vein.
16268447|NCT04896450|Experimental|Test group|Test subjects receive GTR and early initiation of OTM.
16268448|NCT04896450|Active Comparator|Control group|Control subjects receive only GTR.
16268449|NCT04896424|Other|Cryoballoon-based pulmonary veins isolation cohort|Patients treated with a 28-mm second-generation cryoballoon (Arctic Front Advance, Medtronic) for paroxysmal atrial fibrillation and screened over a 2-year post-ablation period.
16268450|NCT04896411|Experimental|Alternative Phrase|This arm will have the code status question randomized to offer CPR vs the alternative phrase
16268451|NCT04896411|Active Comparator|Standard of care phrase|This arm will have the code status question randomized to offer CPR vs the standard of care phrase
16268452|NCT04896398|Experimental|ESWT Group|A total of 5 sessions of ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the patients in this group for 2 weeks. Median nerve and tendon shifting exercises will be taught to the patients and they will be asked to do it regularly.
16268453|NCT04896398|No Intervention|Control Group|Patients in the control group will be asked to do median nerve and tendon shifting exercises only for the wrist.
16268454|NCT04896385|Experimental|Ruxolitinib cream|Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
16268455|NCT04896385|Placebo Comparator|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
16268456|NCT04896372|Experimental|ACT intervention|The ACT condition (comprehensive of standard care) comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and a psychological intervention based on ACT combined with a standard psychological assessment and support to the hospitalization.
16268457|NCT04896372|Other|Standard care|The TAU comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and the standard psychological assessment and support to the hospitalization
16268458|NCT04896359|Experimental|Vitamin C|i.v. infusion of 12.5 g vitamin C 48 h before surgery, immediately before surgery, and 48 h after surgery
16268459|NCT04896359|Placebo Comparator|Control|i.v. infusion of placebo 48 h before surgery, immediately before surgery, and 48 h after surgery
16268460|NCT04896346||Previous Treatment: Biologic StrataGraft Skin Tissue|"This consists of areas that were treated with Stratagraft Skin Tissue under a previous clinical study STRATA2016.
~No new interventions will occur."
16268461|NCT04896346||Previous Treatment: Autograft Comparator|"This consists of areas that were treated with autograft comparator under a previous clinical study STRATA2016.
~No new interventions will occur."
16268463|NCT04896320|Experimental|Gemcitabine + Tucatinib + Trastuzumab|Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
16268464|NCT04896320|Experimental|Vinorelbine + Tucatinib + Trastuzumab|Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
16268466|NCT04896294|Active Comparator|Group 1 - HAP-containing toothpaste|"The use of HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.
~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
16268467|NCT04896294|Experimental|Group 2 - Zn Mg HAP-containing toothpaste|"The use of Zn Mg HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.
~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Zn-Mg-hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
16268468|NCT04896294|Experimental|Group 3 - FAP-containing toothpaste|"The use of FAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.
~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Fluorapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene."
16268469|NCT04896281|Experimental|phenylalanine-free diet|phenylalanine-free diet for patients with hyperphenylalaninemia
16268470|NCT04896268|Experimental|Radiofrequency|Rafaelo's technique consists of delivering a low temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end. The intracellular water in the tissue and the injection of a locally injectable Xylocaine cushion serve as resistance to the vaporisation waves without releasing water vapour, thus avoiding the damage usually encountered in electrosurgery. The delayed phenomenon is cell volatilisation. Vaporisation of the tissue allows significant haemostasis without burns. Tissue changes will depend directly on the temperature emitted and the duration of exposure to the radiofrequence current. The fibrosis process starts during the session and continues for several days to weeks, allowing the reduction of the haemorrhoidal cushions.
16268471|NCT04896268|Active Comparator|Arterial ligation then recto-anal repair with Doppler|"Arterial ligation aims to de-arterialise the haemorrhoids by selectively decreasing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return. It is distinguished from mucopexy or recto anal repair (RAR®) which fixes the prolapsed hemorrhoidal plexus. Instead of excising the haemorrhoids, the principle is to reduce their size and to restore the anatomical relationships of the haemorrhoidal plexuses in the anal canal."
16268472|NCT04896255||interferon cohort|Patients who are going to take peginterferon alpha based regimen
16268473|NCT04896255||nucleos(t)ide cohort|Patients who are going to take nucleos(t)ide alone
16268474|NCT04896229|Experimental|Experimental: Intervention|Parent/student/dyads in the treatment condition will be sent program materials via mail and text or email, including smart-speaker hardware, wireless network bridges for wireless network connectivity, and web links to Talk STEM Familia, including set-up video tutorials, and graphic instructions. Intervention activities will take place in participants' homes over the 24-week intervention period and will include using the dual-language Talk STEM Familia technology to receive instruction, practice, and feedback on academic vocabulary.
16268475|NCT04896229|No Intervention|Treatment as usual|Parent/student dyads in this arm will receive treatment-as-usual (the vocabulary instruction regularly provided in their schools). They will receive the TSF technology after post-test data has been collected.
16268476|NCT04896216|Experimental|Stigma Reduction Intervention|A Stigma Reduction Intervention curriculum will be developed using data generated from Stage 1 of the study.
16268477|NCT04896216|No Intervention|Control|This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
16268478|NCT04896203||Group 1|Ulcerative Colitis or Crohn's Disease patients, in remission according to inclusion criteria
16268479|NCT04896203||Group 2|Ulcerative Colitis or Crohn's Disease patients, with activity defined by the inclusion criteria
16268480|NCT04896190|Experimental|Experimental group|Before the evaluation of EMG amplitude on dynamic balance position, the Q angle was measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device were recorded. Q angle evaluations, static and dynamic balance and functional status of all participants were evaluated.
16268481|NCT04896177|Experimental|Sirolimus drug-eluting coronary balloon catheter|Manufacturer: Shenzhen Salubris Pharmaceuticals Co., Ltd. This product is a sirolimus drug eluting balloon catheter for coronary artery therapy. It is a rapidly exchangeable PTCA balloon catheter (RX), effective length is 140cm, and compatible with 0.014 in. (0.36mm) guide wire. The balloon at the distal end of the catheter was coated with sirolimus, an anti-proliferative and anti-inflammatory drug.
16268482|NCT04896177|Active Comparator|Drug-eluting balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd Coated with paclitaxel.
16268483|NCT04896164|Experimental|Investigational arm|Patients in the investigational arm will receive curcumin lozenges (4 gm BD containing 400 mg curcumin BD) as prophylaxis from two days prior to receiving high dose chemotherapy .
16268484|NCT04896164|Placebo Comparator|Control arm|patients in the control arm will receive matching placebo lozenges from two days prior to receiving high dose chemotherapy
16268485|NCT04896151|Active Comparator|Standard MMPI|Participants will be instructed to complete the MMPI-2-RF-EX and other measures under standard conditions (e.g., to not simulate underreporting of suicide risk).
16268486|NCT04896151|Experimental|Simulation MMPI|Participants will be instructed to conceal current suicide risk when completing the MMPI-2-RF-EX and other measures.
16268487|NCT04896138||ILD Cohort|Patients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
16268488|NCT04896138||Control Cohort|Control group of patients and family members of those with an Interstitial Lung Disease
16268489|NCT04896125||Lumigan PF|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.03% bimatoprost (preservative-free) (Lumigan PF, Allergan Inc., CA, USA).
16268490|NCT04896125||Xalatan|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.005% latanoprost (containing 0.02% BAK as a preservative) (Xalatan, Pfizer, NY, USA).
16268491|NCT04896125||Control|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were not diagnosed with glaucoma.
16268492|NCT04896112|Experimental|Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg|Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles
16268493|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg|LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles
16268494|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg|LNK01002 45 mg BID, followed by a 3-day observation period then 45 mg BID in 28-day treatment cycles
16268495|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg|LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles
16268496|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg|LNK01002 80 mg BID, followed by a 3-day observation period then 80 mg BID in 28-day treatment cycles
16268497|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg|LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles
16268498|NCT04896112|Experimental|Patients with Acute Myeloid Leukemia With Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
16268499|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
16268500|NCT04896112|Experimental|Patients with Primary or Secondary Myelofibrosis|LNK01002 at the RP2D dose in 28-day treatment cycles
16268501|NCT04896086|Experimental|Group 1A-1B|20 mcg of FluMos-v1
16268502|NCT04896086|Experimental|Group 2A-2B|60 mcg of FluMos-v1
16268503|NCT04896086|Active Comparator|Group 3A-3B|standard dose of 60 mcg of the licensed QIV Flucelvax
16268508|NCT04896047|Experimental|CKD patients|Patients with CKD, non-diabetic, without a history of renal transplantation, without digestive pathology, aged 18 to 70 and an estimate of the glomerular filtration rate (eGFR) <60 ml / min / 1.73m2 according to the formula of CKD-EPI.
16268509|NCT04896047|Active Comparator|Haemodialysis patients|Patients on hemodialysis, for more than 3 months, with no history of kidney transplantation, without digestive pathology, aged 18 to 70 with a BMI between 18 and 30 kg / m2
16268510|NCT04896047|Active Comparator|Healthy volunteers|Healthy volunteers (controls) recruited from the population of living kidney donors
16268511|NCT04896034|Placebo Comparator|" control 1  fake MILTA device"|Fake device (control 1) which emits 10% red light (and no infrared) so that the difference between the two machines cannot be seen with the naked eye. The magnets present in the real device are absent in the fake machine and replaced by inert materials of the same mass.
16268512|NCT04896034|Experimental|MILTA Device|The MILTA device used for the study is composed of a panel which gathers 18 emitters composed of red, green and blue LEDs, 3 nanopulsed infrared laser diodes (cold laser), 3 infrared diodes and a permanent magnet
16268513|NCT04896034|No Intervention|" control 2  standard pain management with medication"|In first intention: PARACETAMOL: max 1 g x 4 / 24 h Second intention: IBUPROFEN: max 100 mg x 2 for 48 h Third intention: ACUPAN 20 mg in sugar 3 times per 24 h Last intention: ACTISKENAN 10 mg x 4 / 24 h
16268514|NCT04896021|Experimental|Intervention|On referral to Tasmanian pathology services for blood cholesterol, intervention participants will have their blood pressure measured and collated with other cardiovascular disease risk factors. An absolute cardiovascular disease risk score is calculated, interpreted according to guideline recommendations and reported to referring doctors via the established pathology system. High risk is highlighted in red as per usual practice for pathology tests outside of normal range, and advice provided regarding appropriate action according to National Vascular Disease Prevention Alliance guidelines.
16268515|NCT04896021|Active Comparator|Control|On referral to Tasmanian pathology services for blood cholesterol, control participants will have their blood pressure measured and collated with other cardiovascular disease risk factors as per the intervention arm. However, only the results relating to blood cholesterol are reported to the referring doctor, as per usual practice.
16268516|NCT04896008|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy
16268517|NCT04896008|Experimental|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy
16268518|NCT04895995|Experimental|Digital Cognitive Behavior Therapy (dCBT) for Generalized Anxiety Disorder|
16268519|NCT04895995|No Intervention|Waitlist Control|
16268521|NCT04895956|Active Comparator|Intra-sheath injection|In patients randomized to the intra-sheath, corticosteroids will be injected directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
16268522|NCT04895956|Experimental|Extra-sheath injection|In patients randomized to the extra-sheath arm, corticosteroids will be injected surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
16268523|NCT04895943||Group with adjustable IGB|
16268524|NCT04895943||Group with non-adjustable IGB|
16268526|NCT04895917|Experimental|Pomalidomide and daratumumab|
16268527|NCT04895891|Experimental|EOS imaging|For each patient, EOS images are compared with computed tomography [CT] images
16268528|NCT04895865|Experimental|Self-selected|"Participants in the self-selected arm will choose the initial resistance in view of their preferences, and complete as many repetitions as they wish in order to reach the target rating of perceived exertion RPE of 7/10"
16268529|NCT04895865|Active Comparator|Predetermined|"Participants in the predetermined arm will be instructed to complete ten repetitions per set and exercise, while aiming to reach a rating of perceived exertion (RPE) of 7/10 by the 10th repetition. This means that participants will need to select and adjust the resistance of each exercise (e.g., band's resistance) to achieve this goal."
16268530|NCT04895852|Experimental|TEAS group|Transcutaneous Electrical Acupoints Point Stimulation，TEAS
16268531|NCT04895852|Other|Control group|No TEAS treatment participation. The rest of the treatment was the same as the TEAS group.
16268532|NCT04895839|Experimental|Intervention Arm|
16268533|NCT04895826||Back pain and no back pain|Participants with and without back pain will be included in the study and they will be asked to perform standard functional movements that would be used for a physiotherapy assessment for a back condition. The participants will also perform these movements in front of a camera for video recordings to be analysed by the CV system. The measurements by the CV system will be compared to the measurements by the physiotherapist. Additionally, participants will perform and record videos of the same set of movements at home to test the feasibility of the CV system in a home environment.
16268534|NCT04895813|Experimental|Group 1:|The patient will be given training on the day the appointment is made for colonoscopy, educational material will be given as a reminder, information will be given on the phone and the training will be reminded on the day he should start diet for colonoscopy. No different application will be made on the day and after the colonoscopy.
16268535|NCT04895813|No Intervention|Group 2|Routine information in the service will be made
16268536|NCT04895800|Experimental|Herbal Supplement|(Phytovive™); comprised of Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
16268537|NCT04895800|Active Comparator|Caffeine|Green tea caffeine extract (170 mg; to deliver 34 mg caffeine [20% natural caffeine]),
16268538|NCT04895800|Placebo Comparator|Placebo|Flavored placebo
16268539|NCT04895787|Experimental|Aerobic exercise group (AEX)|Gait training followed by 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle.
16268540|NCT04895787|Experimental|Resistance exercise group (REX)|Gait training followed by 20 minutes of resistance training targeting major muscle groups.
16268541|NCT04895787|Active Comparator|Conventional physical therapy group (CPT)|Gait training followed by 20 minutes of conventional PT programs that do not involve aerobic or resistance exercise.
16268542|NCT04895787|Active Comparator|Control group (CON)|Gait training followed by 20 minutes of rest (sitting on a chair and read magazines).
16268594|NCT04895449|Active Comparator|Active Comparator|COVID-19 Vaccine on day 0, and placebo on day 28
16268556|NCT04895709|Experimental|Part 1A: BMS-986340 Dose Escalation|
16268557|NCT04895709|Experimental|Part 2A: BMS-986340 Dose Expansion|
16268558|NCT04895709|Experimental|Part 1B: BMS-986340 + Nivolumab Dose Escalation|
16268559|NCT04895709|Experimental|Part 2B: BMS-986340 + Nivolumab Dose Expansion|
16268560|NCT04895696|Experimental|BMS-986256: Dose 1|
16268561|NCT04895696|Experimental|BMS-986256: Dose 2|
16268562|NCT04895696|Experimental|BMS-986256: Dose 3|
16268563|NCT04895696|Placebo Comparator|Placebo|
16268564|NCT04895683|Active Comparator|Arm 1 - Control SMS|Control (current practice) text message invitation
16268565|NCT04895683|Experimental|Arm 2 - Behavioural Science informed SMS content|Experimental text message invitation
16268566|NCT04895683|Experimental|Arm 3 - Pre-alert and behavioural science informed SMS content|Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.
16268567|NCT04895657|Other|Piperacillin/Tazobactam Intermittent infusion|4.5 gm Piperacillin/Tazobactam I.V intermittent over 30 min. every 8 hours.
16268568|NCT04895657|Other|Piperacillin/Tazobactam Continuous infusion|4.5 gm Piperacillin/Tazobactam I.V extended infusion over 4 hours every 8 hours.
16268569|NCT04895644|Experimental|No Hard Collar|Patient randomised to not wearing a Hard Collar for 12 weeks
16268570|NCT04895644|No Intervention|Standard Care Arm - Hard Collar|Patient randomised to wearing a Hard Collar for 12 weeks - standard care
16268571|NCT04895631|Experimental|Fluorocholine PET Imaging|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
16268572|NCT04895592|Experimental|Arm A (SRS, low dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive low dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
16268573|NCT04895592|Experimental|Arm B (SRS, high dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
16268574|NCT04895579|Experimental|Copanlisib (30mg flat dose)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days). They will also receive Copanlisib at a 30mg flat dose (IV infusion on days 1 and 15, q 28 days).
16268575|NCT04895579|Experimental|Copanlisib (45mg flat dose)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days). They will also receive Copanlisib at a 45mg flat dose (IV infusion on days 1 and 15, q 28 days).
16268576|NCT04895579|Experimental|Copanlisib (60mg flat dose)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days). They will also receive Copanlisib at a 60mg flat dose (IV infusion on days 1 and 15, q 28 days).
16268577|NCT04895579|Experimental|Copanlisib (expansion cohort)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days). They will also receive Copanlisib on a dose based on the results of the dose feasibility study.
16268578|NCT04895566|Experimental|monoclonal antibody (Mab) sB24M|Therapy by injecting 200 mg of the monoclonal antibody (Mab) sB24M into the areas affected by pyoderma
16268579|NCT04895553||Cohort Apixaban|"patients who have switched from low molecular weight heparin (LMWH) to apixaban at the recommended dose of the treating physician.
~FDA approved dose 10 mg twice daily (BID) for 7 days followed by 5 mg PO BID OR physician prescribed dose"
16268580|NCT04895540||Diagnosed ACM patients|
16268581|NCT04895540||First degree relatives of ACM patients|
16268582|NCT04895540||Relatives of ACM patients who have suffered an SCD|
16268583|NCT04895514|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of gamma-irradiated preserved corneal tissue
16268584|NCT04895501|Active Comparator|running with stiff shoes|21 km of running with stiff shoes followed by a time-to-exhaustion run.
16268585|NCT04895501|Experimental|running flexible shoes|21 km of running flexible shoes followed by a time-to-exhaustion run.
16268588|NCT04895475||Lactating Mothers|Lactating mothers who plan to receive or have received the SARS-CoV-2 vaccine within 60 days.
16268589|NCT04895462||Ischemic Stroke and COVID-19|Ischemic stroke patients with COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
16268590|NCT04895462||Control group: Ischemic Stroke without COVID-19|Ischemic stroke patients without COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
16268591|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose)|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28)
16268592|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose)|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28)
16268593|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28)
16294543|NCT04714099|Placebo Comparator|Control|Placebo group
16268595|NCT04895436|Experimental|Cohort 1 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.
16268596|NCT04895436|Experimental|Cohort 2 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.
16268597|NCT04895423|Experimental|Group №1: Methotrexate therapy|
16268598|NCT04895423|Experimental|Group №2: Mycophenolate mofetil therapy|
16268599|NCT04895423|Experimental|Group №3: Cyclosporine therapy|
16268600|NCT04895423|Experimental|Group №4: Dupilumab therapy|
16268601|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab (TJ01133)|Participants will receive lemzoparlimab (TJ01133) in 28 day cycles.
16268602|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) + pomalidomide + dexamethasone in 28 day cycles.
16268603|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) + carfilzomib + dexamethasone in 28 day cycles.
16268604|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) + daratumumab + dexamethasone in 28 day cycles.
16268605|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab|Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion in 28 day cycles.
16268606|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.
16268607|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.
16268608|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.
16268609|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone|Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.
16268610|NCT04895397|Active Comparator|Group A: (30 patients)|modified pectoral nerve block will be done.
16268611|NCT04895397|Active Comparator|Group B: (30 patients)|serratus plane block will be done.
16268612|NCT04895384||Surgical Cohort|Placement of Edwards ClearSight and Masimo SET on patient intraoperatively.
16268613|NCT04895371|Experimental|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
16268614|NCT04895371|Active Comparator|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
16268617|NCT04895345|Experimental|TQB2450+Intensity modulated radiotherapy|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week.
16268618|NCT04895306|Experimental|Testosterone|Weekly intramuscular administration at a dose of 3 mg
16268619|NCT04895306|Placebo Comparator|Placebo|Weekly intramuscular administration of placebo
16268620|NCT04895293|Experimental|RBM-007 Injectable Solution - 0.2 mg|Single intravitreal injection in study eye
16268621|NCT04895280|Other|Group 1 (marcaine)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine
16268622|NCT04895280|Experimental|Group 2 (ketorolac)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
16268623|NCT04895280|Other|Group 3 (kenalog)|4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care
16268624|NCT04895267|Experimental|Real Low-field thoracic magnetic stimulation (LF-ThMS)|Crossover, single-blind session of low field thoracic magnetic stimulation (real LF-ThMS)
16268625|NCT04895267|Sham Comparator|Sham Low-field thoracic magnetic stimulation (LF-ThMS)|In the same patients the coils are positioned in the same coordinates for sham exposure, but the pulse generator is not turned on. Subjects are blinded for the real LF-ThMS or sham stimulation conditions.
16268626|NCT04895254||Experimental: Motorized spiral Enteroscopy|Consecutive patients with difficult colonoscopies to be enrolled to achieve total colonoscopy using the motorized spiral enteroscope.
16268630|NCT04895228|Active Comparator|SpA patients recieving local steroid injection|the active group will receive triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance.
16268631|NCT04895228|Placebo Comparator|placebo group|Group 2 will receive similar amount of saline injecteed subcutaneously
16268636|NCT04895163||Foreign workers|Foreign workers aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
16268637|NCT04895163||Local patients|Local patients aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
16268638|NCT04895150||Patients|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
16268639|NCT04895150||Healthy controls;|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
16268640|NCT04895137|Experimental|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colon and upper rectum cancer
16268641|NCT04895124||Healthy volunteers|
16268642|NCT04895124||Healthy smokers|
16268643|NCT04895124||COPD GOLD I|
16268644|NCT04895124||COPD GOLD II|
16268645|NCT04895124||COPD GOLD III/IV|
16268646|NCT04895111||Patients with suspected sarcoidosis|Consecutive patients with clinical and radiological (CT scan +/- PET) suspect of sarcoidosis
16268647|NCT04895098||combination therapy group|750 Subjects in the statin and ezetimibe combination therapy group
16268648|NCT04895098||monotherapy group|250 Subjects in the statin monotherapy group
16268649|NCT04895085|Experimental|Caregiver of Children with medical complexity (CMC)|
16268652|NCT04895059|Experimental|Group A: Rosuvastatin / Ezetimibe fixed dose|In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral
16268653|NCT04895059|Active Comparator|Group B: Rosuvastatin (Crestor®)|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
16268654|NCT04895059|Active Comparator|Group C: Ezetimibe (Ezetrol®)|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral
16268656|NCT04895033|Experimental|Responsibility vs No Responsibility|Within-subjects experimental manipulation of responsibility vs. no-responsibility condition
16268657|NCT04895020|Experimental|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
16268658|NCT04895007||Group, vaccinated with Inactive Vaccine (Sinovac Life Sciences, Beijing, China).|- Any person, male or female, over 18 years of age, were vaccinated with Inactive Vaccine.
16268659|NCT04895007||Group, vaccinated with recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V).|- Any person, male or female, over 18 years of age, were vaccinated with recombinant human adenovirus serotype number 26.
16268660|NCT04895007||Group, vaccinated with mRNA Vaccine (Pfizer/BionTEC).|- Any person, male or female, over 18 years of age, were vaccinated with mRNA Vaccine.
16268661|NCT04894994|Experimental|FLX475 and ipilimumab combination therapy|
16268662|NCT04894981|Experimental|Immersive condition|Performance driving wheelchair in immersive condition (in Cave automatic environment or with HMD)
16268663|NCT04894981|Experimental|Non Immersive condition|Performance driving wheelchair in non immersive condition (with screen and physical simulator or screen only)
16268664|NCT04894929|Experimental|A. Multi-conponente exercise|"A 6-week therapeutic multi-component physical exercise program will be carried out. The ministerial guide will be followed by carrying out 5 weekly sessions (from Monday to Friday), offering the application through a web link of the weekly programming of the exercises for the patient (type of exercise, video of its execution, number of repetitions and description) having a approximate duration of 40 minutes.
~Said sessions will be carried out daily and from the center a call was made at the end of the week to mark the follow-up and resolve any questions related to symptoms"
16268665|NCT04894929|Experimental|B. Vestibular exercise|"The vestibular exercises will be performed with the instructions of a physiotherapist, in sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:
~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.
~and. Along with push up 30sec and squat 30sec All participants will have a weekly follow-up from Monday to Friday to control attendance and compliance via telephone."
16268667|NCT04894903|Experimental|Intervention|"Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention.
~."
16268668|NCT04894903|No Intervention|Usual Care|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).
16268669|NCT04894890||secukinumab|Patients administered secukinumab by prescription
16268670|NCT04894877||Active Comparator: Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
16268671|NCT04894877||Active Comparator: Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
16268672|NCT04894864|Active Comparator|Opioid-Based Anesthesia Analgesia|Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg. Anesthesia maintenance: Desflurane set at approximately 1 MAC, Morphine 0.1-0.12mg/kg, Fentanyl 1-2mcg/kg during induction and 50-100mcg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, along with Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU stay sedation: Remifentanil infusion, until removal of the endotracheal tube. Surgical ward: PCA pump with Morphine for the first 3 postoperative days. Additional postoperative analgesia: Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
16268673|NCT04894864|Active Comparator|Opioid-Free Anesthesia Analgesia|Premedication: Pregabalin 150mg 1x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexdmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at ~1 MAC, Dexmedetomidine 0.5-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU sedation: Dexmedetomidine + Lidocaine infusions, until removal of the ETT. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os 1x1 and 25mg 1x1, Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
16268674|NCT04894851|Experimental|Contingency Management|Receives contingency payments each month based on decluttering scores
16268675|NCT04894838|Experimental|Distal gastric bypass type I|Laparoscopic distalisation of RYGB type I. The RYGB is modified by dividing the Roux limb (AL) at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long biliopancreatic limb (BPL). In cases of initial AL lengths shorter than 100 cm, the CC lengths should be adjusted to create a TALL of at least 300 cm.
16268676|NCT04894838|Experimental|Distal gastric bypass type II|Laparoscopic distalisation of RYGB type II. The RYGB is modified by dividing the BPL at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long AL.
16268677|NCT04894825|Experimental|Dose Escalation Cohort|"Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
~Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design.
~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days)."
16268678|NCT04894825|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, 1~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.
16268679|NCT04894812|Active Comparator|Group A|Neurodevelopmental Treatment. Total duration of treatment will be 20 minutes, 3 sessions per for 3 months
16268680|NCT04894812|Experimental|Group B|Neurodevelopmental Technique and Vestibular stimulation. Total duration of treatment will be 50 minutes (20 min NDT+ 30 MIN VS) 3 sessions per week for 3 months.
16268681|NCT04894799|Experimental|Vestibular stimulation|all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
16268682|NCT04894799|Active Comparator|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
16268683|NCT04894786|Experimental|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization & Sleeper Stretch
16268684|NCT04894786|Active Comparator|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique and Sleeper Stretch
16268685|NCT04894773|Experimental|Imaginary Resisted Exercises|Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
16268766|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 3 according to 0,28-day immunization schedule.
16294709|NCT04713072|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
16268686|NCT04894773|Experimental|Physical Resisted Exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
16268687|NCT04894747|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g of protein.
16268688|NCT04894747|Experimental|Pea protein|Bolus ingestion of pea protein providing 25g of protein.
16268689|NCT04894747|Experimental|Mycoprotein/pea protein dry blend|Bolus ingestion of mycoprotein/pea protein dry blend providing 25g of protein.
16268690|NCT04894747|Experimental|Bolus ingestion of mycoprotein/pea protein extrudate blend|Bolus ingestion of mycoprotein/pea protein extrudate blend providing 25g of protein.
16268691|NCT04894734|Experimental|EES on|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.
16268692|NCT04894734|Placebo Comparator|EES off|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.ES off. Those in the EES off category will have their EES turned on at the 9-month timepoint.
16268693|NCT04894721|Experimental|Experimental Group|The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care
16268694|NCT04894721|Placebo Comparator|Control Group|The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care
16268695|NCT04894708|Other|AI colonoscopy|colonoscopy with artificial intelligence added
16268696|NCT04894708|Sham Comparator|conventional colonoscopy|conventional colonoscopy
16268697|NCT04894695||healthy control (HC)|healthy control
16268698|NCT04894695||Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus
16268699|NCT04894695||lupus nephritis (LN)|lupus nephritis
16268700|NCT04894682||Vaccinated Case|Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
16268701|NCT04894682||Vaccinated Healthy Control|Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
16268702|NCT04894682||Unvaccinated Case|Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2
16268703|NCT04894656|Experimental|Gastroparesis patients|
16268704|NCT04894656|Active Comparator|Healthy volunteers|
16268705|NCT04894643|Other|Preoperative, proton- radiotherapy combined with chemotherapy|Patients treated with three cycles of chemotherapy with Nab-PACLitaxel (Abraxane®) (125 mg/m² on day 1, 8, 15; powder for making a infusion solution) and Gemcitabine (1000 mg/m² on day 1, 8, 15; powder for making a infusion solution), followed by concomitant chemotherapy with capecitabine (1.660ml/m² on 5 days per week during the radiation therapy) and proton-therapy (with simultaneous integrated boost (SIB) 50.4 Gy Relative Biological Effectiveness (RBE) and 60.2 Gy (RBE) in 28 fractions of 1.8 Gy (RBE) and 2.15 Gy (RBE) 5 days per week), followed by re-evaluation and surgery
16268706|NCT04894630|Other|infective keratitis|150 patients with mean age 30 (range 12 to 85 years), 90 patients (60 %) were males and 60 (40%) were females, clinically diagnosed as infective corneal ulcer, attending the Ophthalmology Department - Faculty of Medicine. Minia University, Minia, Egypt. From 2018 to 2020.
16268707|NCT04894617|Active Comparator|Amantadine|The intervention group will receive a dose at day 1 of amantadine 100 mg followed by 100 mg amantadine after 6 hours. The following 4 consecutive days, study participants will receive a daily dose of 200mg amantadine, 100 mg (1 capsule) morning and 100 mg (1 capsule) evening, yielding 5 days of treatment in total (10 capsules in total).
16268708|NCT04894617|Placebo Comparator|Placebo|The control group will receive placebo treatment with lactose monohydrate; 1 capsule, followed by 1 capsule after 6 hours on day 1. The following 4 consecutive days, study participants will receive 1 capsule morning and 1 capsule evening, yielding 5 days of treatment in total (10 capsules in total).
16268709|NCT04894604|Experimental|Subjects with a low to moderate exuding surgically closed incision|Up to 34 study Subjects with a low to moderate exuding surgically closed incision deemed adequate by the Principal Investigator and clinical team for NPWT treatment.
16268710|NCT04894578|Active Comparator|Group A|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a reverse distal metatarsal minimal-invasive osteotomy
16268711|NCT04894578|Active Comparator|Group B|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a fusion of one or more midfoot (tarsometatarsal) joints
16268712|NCT04894565|Experimental|intervention|effect of rehabilitation program in the intervention arm
16268713|NCT04894552|Experimental|One arm clinical trial|Convenience sampling method in which the first twenty cases of endometrial carcinoma patients who will undergo laparoscopic hysterectomy will be included. All cases will undergo laparoscopic hysterectomy. Sentinel lymph node biopsy will be detected, dissected and isolated. Then standard lymphadenectomy will be done
16268714|NCT04894539|Experimental|TENS1|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
16268715|NCT04894539|Experimental|TENS2|TENS with 80/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
16268716|NCT04894539|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
16268717|NCT04894526|Experimental|Alternating energy intake schedule|To alternate between caloric overconsumption and caloric underconsumption from day-to-day
16268718|NCT04894526|Active Comparator|Regular energy intake schedule|To consume the usual energy intake on a daily basis
16268719|NCT04894513|Experimental|study group|the study group received the conventional selected program in addition to Kabat motor control re-education
16268720|NCT04894513|Experimental|control group|the control group received the conventional selected program
16268794|NCT04893980|Experimental|Low-dose interleukin-2 treatment group|Use Interleukin-2 to treat CSU during day1-day28.
16268721|NCT04894487|No Intervention|Control Group|The babies have got sternum incision after the pediatric cardiac surgery. Experiment is about the dressing of the sternum incision. There is no extra intervention during sternum dressing at control group like routine of pediatric cardiovascular surgery intensive care clinic. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
16268722|NCT04894487|Experimental|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABIES GROUP|Baby mobile and Brahms Lullaby started before the 10 minutes of sternum dressing process and controlled permanence of the baby mobile and Brahms Lullaby during sternum dressing. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
16268723|NCT04894474|Experimental|BI 767551 inhalation and placebo intravenous infusion|
16268724|NCT04894474|Experimental|BI 767551 intravenous infusion and placebo inhalation|
16268725|NCT04894474|Placebo Comparator|Placebo inhalation and placebo intravenous infusion|
16268726|NCT04894461|Experimental|Moxibustion|Moxibustion treatment sessions eight weeks from the baseline.
16268727|NCT04894461|No Intervention|Waiting|A waiting period of eight weeks by moxibustion treatment sessions in the same way with moxibustion group.
16268728|NCT04894448||PLWH|HIV positive
16268729|NCT04894448||Control|HIV negative
16268730|NCT04894435|Active Comparator|Group 1: Moderna, Moderna - 28 Days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268731|NCT04894435|Active Comparator|Group 2: Moderna, Moderna - 112 days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268732|NCT04894435|Active Comparator|Group 3: Moderna, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268733|NCT04894435|Active Comparator|Group 4: Moderna, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268734|NCT04894435|Active Comparator|Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268735|NCT04894435|Active Comparator|Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268736|NCT04894435|Active Comparator|Group 7: Pfizer/BioNTech, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268737|NCT04894435|Active Comparator|Group 8: Pfizer/BioNTech, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268738|NCT04894435|Active Comparator|Group 9: Astra Zeneca, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268739|NCT04894435|Active Comparator|Group 10: Astra Zeneca, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268740|NCT04894435|Active Comparator|Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268741|NCT04894435|Active Comparator|Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.
~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
16268742|NCT04894422||No face mask|Volunteers who did not wear a face mask
16268743|NCT04894422||Cotton face mask|Voluntarily wearing a cotton face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
16268744|NCT04894422||Surgical face mask|Voluntarily wearing a surgical face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
16268745|NCT04894409|Experimental|Experimental group|The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution.
16268746|NCT04894409|Active Comparator|Control group|"The control group was instructed to do mouthwashes and nose rinse in a conventional way."
16268792|NCT04893993|Other|Thiamine-Placebo|"12 weeks: 4 weeks with Thiamine, 4 weeks wash-out, 4 weeks placebo
~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
16268793|NCT04893993|Other|Placebo-Thiamine|"12 weeks: 4 weeks placebo, 4 weeks wash-out, 4 weeks with Thiamine
~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
16268747|NCT04894396|Experimental|Prefabricated Orthotics with metatarsal pad|Participants in Group A will receive the Orthotic with the metatarsal pad (L 2305) according to participants shoe size (https://www.aetrex.com/search?q=l2305&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities.
16268748|NCT04894396|Active Comparator|Prefabricated Orthotics without metatarsal pad.|Participants in Group B will receive the neutral Orthotic with a cupped heel (L 2300) according to participants shoe size (https://www.aetrex.com/search?q=l2300&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the Orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities
16268749|NCT04894383|Experimental|Prefabricated Orthotics in shoes & indoor comfort sandals with built-in arch support|Participants from Group A will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) and an Aetrex comfort sandal with built-in arch support (https://www.aetrex.com/aetrex-flips-black-L3000M.html?lang=en_US or https://www.aetrex.com/fiji-flips-women-watermelon-L7009W.html?lang=en_US) according to participants shoe size. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the orthotic/comfort sandal wherever possible.
16268750|NCT04894383|Active Comparator|Prefabricated Orthotics in shoes only|Group B will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) alone. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the Orthotic wherever possible.
16268751|NCT04894370|Experimental|Experimental|"Phase 1: Radiotherapy (8 Gy on target lesions)
~Phase 2: Combination immunotherapy and mDCF regimen mDCF regimen every 2 weeks for 8 cycles
~Docetaxel (40 mg/m², day 1),
~Cisplatin (40 mg/m², day 1)
~5-FU (1200 mg/m²/day for 2 days) Spartalizumab: 400 mg intravenous will be administrated every 4 weeks
~Phase 3 : Multimodal treatment of residual disease The multimodal treatment is recommended in oligometastatic anal cancer. The support by ablative treatment (surgery, hypofractionnated radiotherapy or by radiofrequency) improve survival.
~In absence of progression disease:
~Ablative treatment: surgery, hypofractionnated radiotherapy or by radiofrequency of residual metastases
~and Chemo-radiotherapy (CRT) for local disease
~Phase 4: Maintenance treatment with Spartalizumab 400 mg intravenous every 4 weeks for 12 months from enrolment maximum"
16268752|NCT04894344|Experimental|Educational program|"Participants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks.
~Urine samples of 24 h before and after the Intervention will be analyzed."
16268753|NCT04894344|No Intervention|Control group|Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed.
16268754|NCT04894331||SNAS patients|Patients with (a) history of SNAS (coexistence of typical cutaneous and gastrointestinal symptoms); (b) positive Ni-patch test; (c) clinical improvement of at least 70% from baseline after 4 weeks of low-Ni diet; (d) positivity of a double-blind placebo-controlled oral Ni challenge (DBPCO). Exclusion criteria include (a) age < 18 years and >65 years; (b) other organic gastrointestinal diseases, such as peptic ulcer, inflammatory bowel diseases, celiac disease, gastrointestinal infections, and small intestinal bacterial overgrowth; (c) diabetes mellitus; (d) hepatic, renal or cardiac dysfunction; (e) thyroid disease or tumour; (f) concomitant treatment with steroids and/or antihistamines in the previous 4 weeks; (g) pregnancy and lactation; (h) smoking, abuse of alcohol, coffee, tea, and cola intake, and (i) inability to give written informed consent.
16268755|NCT04894318|Other|Low-fat, low-cholesterol diet|Patients diagnosed with dyslipidemia by the endocrinologist were followed up for 12 weeks with a low-fat, low-cholesterol diet on a monthly basis, provided that they were suitable for each.
16268758|NCT04894292||Adenomyosis Group|
16268759|NCT04894292||Non-adenomyosis Group|
16268760|NCT04894266|Other|Standard of Care|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
16268761|NCT04894266|Experimental|Standard of Care plus apabetalone|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.
16268762|NCT04894253||Single group of 30 patients with systemic lupus|
16268763|NCT04894240|Experimental|Monepantel treatment arm|Monepantel tablets will be administered to participants in this arm daily for 28 days. Dose escalation will occur at the end of each 28 day period according to a modified Fibonacci sequence based upon recommendations from the safety management committee
16268764|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 1 according to 0,28-day immunization schedule.
16268765|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 2 according to 0,28-day immunization schedule.
16268767|NCT04894214||"Sequential baseline PCV - FCV - VCV"|Each participant will be subjected to baseline pressure controlled ventilation (PCV) during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during baseline PCV will be set.
16268768|NCT04894201||All patients with relevant dental findings|
16268769|NCT04894188|Experimental|Neoadjuvant RT and ADT|"Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
~Gosereline 3.6mg sc injection at week 1, week 5, and week 9"
16268770|NCT04894188|Active Comparator|Neoadjuvant ADT|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
16268771|NCT04894162|Other|Sequential recruitment of all inpatients|"Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a questionnaire about research preferences.
~This is not part of standard care and results do not contribute to usual care - thus is an 'interventional' study."
16268772|NCT04894149|Experimental|Physiotherapy|
16268773|NCT04894136||ICSI-TESE cycles for obstructive azoospermia|Couples who underwent ICSI-TESE cycles for obstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
16268774|NCT04894136||ICSI-TESE cycles for nonobstructive azoospermia|Couples who underwent ICSI-TESE cycles for nonobstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
16268776|NCT04894110|Experimental|EO2002 treatment|
16268777|NCT04894097|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
16268778|NCT04894097|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy
16268779|NCT04894084|Experimental|Test product|
16268780|NCT04894071|Experimental|QA102 group|
16268781|NCT04894071|Placebo Comparator|Placebo group|
16268782|NCT04894058|Active Comparator|10 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 10 ° reverse Trendelenburg position
16268783|NCT04894058|Active Comparator|20 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 20 ° reverse Trendelenburg position
16268784|NCT04894058|Sham Comparator|Standard lithotomy|Patients who underwent ureteroscopic lithotripsy in standard lithotomy position
16268785|NCT04894045|Other|Personalized management group|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
16268786|NCT04894045|No Intervention|Control group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients in the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
16268787|NCT04894019|Experimental|Continuous monitoring group|In patients randomized to the continuous monitoring group, continuous invasive arterial blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
16268788|NCT04894019|Active Comparator|Intermittent monitoring group|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous invasive arterial blood pressure monitoring.
16268789|NCT04894006|Experimental|Home visit intervention by community health workers|The caregiver-centered, culturally and language specific home visit intervention with wearable devices (smartwatch/ring) will be delivered by trained bilingual community health workers (CHW) for Latino, Vietnamese, Korean, non-Hispanic White caregivers of PWD. The home visit intervention components will include (1) stress reduction techniques; mindful breathing and compassionate support/listening and (2) weekly education on dementia caregiving skills to handle difficult behaviors of PWD and knowledge of resources available for dementia care. The duration of the intervention will be 12 weeks that include 6 home visits (4 times for the first month and then once a month for two months) carried out in the participant's home. The on-site home visit intervention delivered by CHWs will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions.
16268790|NCT04894006|Active Comparator|Attention Control with wearable smartwatch/ring|The caregivers randomly assigned to the Attention Control (AC) group will be asked to wear smartwatch during the day time and smart ring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months asking about the WIoT technology and answering general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
16268791|NCT04894006|Placebo Comparator|Usual Care Group|The caregivers randomly assigned to Usual Care (UC) group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. At recruitment, the participants will be told that at the end of the 6 months they will receive a smartwatch and a smartring for their participation. CHWs will contact them monthly for 6 months by phone answering only general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
16268795|NCT04893980|Other|Control group|Use Interleukin-2 to treat CSU during day15-day28.
16268802|NCT04893954|Other|Obese patients|
16268803|NCT04893941|Experimental|CM310 75mg arm|75mg for 3 doses, every 2 weeks, SC
16268804|NCT04893941|Experimental|CM310 150mg arm|150mg for 3 doses, every 2 weeks, SC
16268805|NCT04893941|Experimental|CM310 300mg arm|300mg for 3 doses, every 2 weeks, SC
16268806|NCT04893941|Experimental|CM310 600(1st)+300mg(2nd,3rd) arm|600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC
16268807|NCT04893941|Placebo Comparator|placebo arm|placebo for 3 doses, every 2 weeks, SC
16268808|NCT04893915|Experimental|Lead In Cohort Recipient: Cytokine-induced memory-like NK cells|"Fludarabine and cyclophosphamide beginning on Day -6.
~NK cell product will be infused on Day 0.
~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
~NK cell product will be infused into the recipient on Day +14.
~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
~In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
~Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
16268809|NCT04893915|Experimental|Phase II Recipient: Cytokine-induced memory-like NK cells|"Fludarabine and cyclophosphamide beginning on Day -6.
~NK cell product will be infused on Day 0.
~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
~NK cell product will be infused into the recipient on Day +14.
~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
~Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
~Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
16268810|NCT04893915|Experimental|Donor|"The allogeneic donor will undergo non-mobilized large volume (20-L) leukapheresis on Day -1.
~On Day +13 the allogeneic donor will again undergo non-mobilized large volume (20-L) leukapheresis"
16268811|NCT04893902|Active Comparator|conventional ear impression|
16268812|NCT04893902|Experimental|digital auricular impression without marker using intra oral scanner|
16268813|NCT04893902|Experimental|digital auricular impression with marker using intra oral scanner|
16268814|NCT04893889|Experimental|Fabry disease patients|Patients diagnosed with Fabry disease. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
16268815|NCT04893889|Active Comparator|Amyloidosis transthyretin with cardiac commitment|Patients diagnosed with amyloidosis who present cardiac commitment. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
16268816|NCT04893889|Placebo Comparator|Healthy subjects|Healthy patients. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test.
16268817|NCT04893863|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
16268818|NCT04893863|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
16268819|NCT04893850|Experimental|BRIDGE-KIDTHINK Condition|Caregivers in this group will participate in 16 sessions of online therapy delivered through a combination of asynchronous material and virtual support groups. These sessions will include Dialectical Behaviour Therapy (DBT) and parenting training. This group will be asked to evaluate the program with surveys completed pre-program, immediately post-program, and three months post-program. This group will also be invited to complete weekly surveys expected to take 5 minutes.
16268820|NCT04893850|Experimental|Services as Usual Condition|Caregivers in this group will not participate in Dialectical Behaviour Therapy (DBT) and parenting training. Rather, this group will be asked to refer to a list of community mental health and family support services as part of the BRIDGE therapy program. This group will be asked to complete weekly surveys expected to take 5 minutes.
16268821|NCT04893837||Standard care plus infrascans|"All participants will receive regular clinical neurological assessments as ordered by the clinical care team. In addition, a research team member will perform an infrascan. This process will be repeated hourly at the same timepoint as the clinical neurological assessments. If a patient's neurological status deteriorates at any time point, and the medical team orders an early (unplanned) CT scan, the neurological data collection will cease once the patient is sent to CT.
~Infrascan results will not be shared with the clinical care team, and will not guide the participants' care in any way."
16268823|NCT04893798|Experimental|Sayana Press, Upper Arm injection|Sayana Press, administered subcutaneously into upper arm
16268824|NCT04893798|Active Comparator|Sayana Press, anterior thigh|Sayana Press, administered subcutaneously into anterior thigh
16268825|NCT04893798|Active Comparator|Sayana Press, abdomen|Sayana Press, administered subcutaneously into abdomen
16268826|NCT04893785|Experimental|Cabozantinib and Temozolomide|"All patients will receive:
~Cabozantinib 40 mg os QD
~Temozolomide 100 mg/m2/day seven days followed by seven days of stop (regimen one week on / one week off)."
16268828|NCT04893746|Placebo Comparator|Placebo|
16268829|NCT04893746|Experimental|TWK10-L|Low dose
16268830|NCT04893746|Experimental|TWK10-H|High dose
16268831|NCT04893733|Experimental|Vitamin B complex|Randomized patients with AKI to this arm will received during 5 consecutive days IV Vitamin B complex each 12 hours. They will also received the Institution standard of care for AKI.
16268832|NCT04893733|Placebo Comparator|Placebo|Randomized patients with AKI to this arm will received during 5 consecutive days IV placebo each 12 hours. They will also received the Institution standard of care for AKI.
16268833|NCT04893707|Experimental|CM310|600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.
16268834|NCT04893681|Experimental|Fluoridated bottle water|Crystal Springs purified fluoridated water in 5-gallon bottles
16268835|NCT04893681|Placebo Comparator|Non-fluoridated bottled water|Crystal Springs purified non-fluoridated water in 5-gallon bottles
16268836|NCT04893668||Exposed with COVID 19|The participant with confirmed RT-PCR Covid 19 at the beginning of the study
16268837|NCT04893668||Unexposed with COVID 19|The participant without confirmed RT-PCR Covid 19 at the beginning of the study until 6 month follow up period
16268838|NCT04893655|Experimental|Dobutamine|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
16268839|NCT04893642|Active Comparator|Abdominal suture rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
16268840|NCT04893642|Active Comparator|Abdominal resection rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
16268841|NCT04893642|Active Comparator|Perineal Delorme|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
16268842|NCT04893642|Active Comparator|Perineal Altemeier|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
16268843|NCT04893629|Experimental|intervention group|children diagnosed with dilated cardiomyopathy , will undergo trans endocardium injection of mono nuclear cells
16268844|NCT04893629|Active Comparator|control group|children diagnosed with dilated cardiomyopathy ,will continue the classic medical treatment
16268845|NCT04893616|Experimental|Intervention Arm|These facilities will be those selected to have the intervention carried out.
16268846|NCT04893603|Experimental|Severe Aortic Valve Stenosis|Patients will be treated with Transcatheter Aortic Valve Systerm
16268847|NCT04893590|Experimental|Fatigue self-management SMS intervention|The participants will receive a 12-week fatigue self-management SMS text intervention using mobile phones to target patient activation levels in people with disabilities.
16268848|NCT04893577|Experimental|Study Drug (EDTA Eye Drops)|Patients will treat herpes simplex eruption with EDTA eye drops.
16268849|NCT04893577|Active Comparator|Active Comparator (Abreva)|Patients will treat herpes simplex eruption with Abreva.
16268850|NCT04893551|Experimental|Tilvestamab|Participants will receive tilvestamab at a low starting dose level (Cohort A) given via intravenous (IV) infusion every 2 weeks. Dose escalations to subsequent cohorts (Cohort B and Cohort C) will be decided by the Protocol Steering Committee (PSC) after review of all Cycle 1 (28 days cycle) safety and pharmacokinetics (PK) data up to Cycle 1 Day 22 for all participants in the ongoing cohort.
16268851|NCT04893538||A|First analysis: Patients with high Lymphocyte count Second analysis: Patients with low monocyte count Third analysis: Patients with high Lymphocyte/monocyte ratio
16268852|NCT04893538||B|First analysis: Patients with low Lymphocyte count Second analysis: Patients with high monocyte count Third analysis: Patients with low Lymphocyte/monocyte ratio
16268853|NCT04893525|Active Comparator|Buprenorphine/naloxone Microdosing|"Participants with Opioid use disorder will receive a Buprenorphine/naloxone microdosing package from the ED. This will consist of a five-day take-home packages with gradually increasing doses of 2mg/0.5mg buprenorphine/naloxone tablet employing a four times daily dosing schedule over five days.
~Day 1: Buprenorphine 0.5 mg-naloxone 0.125 mg SL* QID** (One quarter tablet),
~Day 2: Buprenorphine 1 mg-naloxone 0.25 mg SL QID (One half tablet),
~Day 3: Buprenorphine 2 mg-naloxone 0.5 mg SL QID (1 tablet),
~Day 4: Buprenorphine 3 mg-naloxone 0.75 mg SL QID (1.5 tablets)
~Day 5: Buprenorphine 16 mg-naloxone 4 mg SL once daily (8 tablets).
~*SL: Sublingual
~** QID: four times daily"
16268878|NCT04893330||patients|children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV
16268879|NCT04893317|Experimental|Ablation in the ventricle with the Adagio VT cryoablation system|
16268880|NCT04893304|Other|1 group of 20 patients doing both types of lasers on 2 sites|comparing both types of laser
16268881|NCT04893291|Active Comparator|Everolimus Eluting Stent|
16268882|NCT04893291|Experimental|Magic Touch Sirolimus Coated Balloon|
16268883|NCT04893278||Virtual reality|
16268952|NCT04892771||Experimental group|Patients who have honored two consultations per year for two years.
16268854|NCT04893525|Active Comparator|Buprenorphine/naloxone Standard Dosing|"The control intervention will be provision of a buprenorphine/naloxone standard dosing package from the ED. This will consist of a five day package with a commonly accepted standard dosing regimen aiming to achieve a therapeutic buprenorphine/naloxone dose within 24 hours of initiation. Standard dosing packages are currently available in EDs in BC and Alberta as standard of care.
~Day 1: Buprenorphine 2 mg-naloxone 0.5 mg SL q1h prn to a maximum of 6 tablets in the first 24 hours (1 tablet),
~Day 2: Buprenorphine 12 mg-naloxone 3 mg SL once daily (6 tablets),
~Day 3: Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets),
~Day 4:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets).
~Day 5:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets)."
16268855|NCT04893512|Experimental|Orally administered CoV2-OGEN1- 2 dose schedule|50mcg,100mcg and 200mcg will be tested as single oral dose on day 1 and day 15. The dose will be in the form of oral suspension.
16268856|NCT04893499|Experimental|Low-dose mastic group|This arm will consume 600 mL of a sparkling water enriched with Chios mastic per day for a 3-month period.
16268857|NCT04893499|Placebo Comparator|Low-dose control group|This arm will consume 600 mL of a standard sparkling water per day for a 3-month period.
16268858|NCT04893499|Experimental|High-dose mastic group|This arm will consume 600 mL of a sparkling fruit juice enriched with Chios mastic per day for a 3-month period.
16268859|NCT04893499|Placebo Comparator|High-dose control group|This arm will consume 600 mL of a standard sparkling fruit juice per day for a 3-month period.
16268862|NCT04893473||Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.
~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
16268863|NCT04893473||Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.
~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
16268865|NCT04893447|Experimental|SPI+: Safety Planning Intervention plus structured phone-based follow-up|The Safety Planning Intervention (SPI+) includes safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus a structured telephone-based intervention from a suicide prevention hotline
16268866|NCT04893447|Experimental|Caring Contacts: Safety Planning Intervention plus Caring Contacts (SP+CC)|SP+CC will include safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus caring text messages or emails from a suicide prevention hotline.
16268867|NCT04893434|Experimental|DCE-MR images with Gadobutrol (GBCA)|10 volunteers will undergo a single DCE-MRI of the normal cervix to fine-tune parameters and test the performance of reconstruction and quantification algorithms. Goldenangled radial LAVA data will be continuously acquired for 5 minutes and the contrast agent will be injected intravenously after 1 minute (same contrast agent and injection rate. 60 cervical cancer patients will be enrolled (inclusion criterion: newly diagnosed FIGO stage IB2-IVA cervical cancer scheduled for standard of care pelvic MRI for staging). Data from 30 of the patients will be used to assess repeatability; DCE-MRI will be acquired at baseline and repeated 48 hours (+/- 24 h) later (no therapy between the 2 scans). Data from the other 30 patients will be used to document treatment induced changes in DCE-MRI; patients in this group will undergo DCE-MRI at baseline and repeated after 2 weeks (+/- 3 days) of completion of chemoradiation treatment.
16268868|NCT04893421|No Intervention|Standard of Care WGS or RSL|Patients will undergo the institutional standard of care approach (WGS or RSL) for BCS. For WGL, a hooked wire will be implanted to mark the center or outer edges of the lesion under imaging guidance. For RSL, patients will be implanted with a radioactive seed using an impregnated needle under imaging guidance. A special handheld probe will be used to find the radioactive seed during the lumpectomy surgery.
16268869|NCT04893421|Experimental|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
16268870|NCT04893395|Experimental|Pharmacogenomic Screening|Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.
16268871|NCT04893382|Experimental|PlasmaLyte|Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
16268872|NCT04893382|Experimental|Ringer's Lactate|Seven (7) severely burned patients will be infused with Ringer's Lactate (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
16268873|NCT04893369|Experimental|The Low Back Pain and Disability Drivers Management model|Participating clinicians in the intervention arm will use the PDDM model to guide assessment and treatment of their patients and data will be collected over a 12-weeks period.
16268874|NCT04893369|Active Comparator|Low back pain clinical practice guidelines|Participating clinicians in the active comparator arm will perform assessment and treatment of their patients based on the recommendations from the most recent and high-quality clinical practice guidelines (CPGs) and data will be collected over a 12-weeks period.
16268875|NCT04893356||Dacarbazine treated sarcoma patients|"Approximately 75 patients with histological diagnosis of Leiomyosarcoma (SCL) and Solitary Fibrous Tumor(SFT), previously treated with dacarbazine alone or associated with anthracyclines, will be enrolled, diagnosed from 2010 to 2020.
~From formalin fixed tumor samples, DNA will be extracted and MGMT expression and MGMT promoter methylation analyzed."
16268876|NCT04893343||Neonatal infection with antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
16268877|NCT04893343||Neonatal infection without antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
16268884|NCT04893265|Active Comparator|Text Messaging Only|Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing over 12 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 testing related information. The messages will be responsive to the rapid evolving developments and changes related to COVID-19 testing guidelines. Some of the messages will include a link to allow participants to get to the entire message/information on the study website.
16268885|NCT04893265|Experimental|INFORMED|"Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing as described in the Text Messaging Only. In addition, participants will receive a Lay Health Worker (LHW) Educational Outreach Program, which includes 2 group sessions via video calls like Zoom or another video conferencing platform and 2 follow-up contacts via telephone, text or other media assignment."
16268886|NCT04893252|Experimental|vactosertib in combination with durvalumab|single arm study
16268889|NCT04893213|Active Comparator|Baseline availability|Baseline availability of lower energy meal options
16268890|NCT04893213|Experimental|Increased availability|Increased availability of lower energy meal options
16268891|NCT04893200||Lung adenocarcinoma|Imaging from patients with surgically treated lung adenocarcinoma were collected and processed for the construction of the radiomics-based prediction model
16268892|NCT04893187|Experimental|Part 1: Single Dose Escalation SSS17|Escalating doses of SSS17, single dose administration
16268893|NCT04893187|Placebo Comparator|Part 1: Single Dose Escalation matching Placebo|Escalating doses of matching placebo, single dose administration
16268894|NCT04893187|Experimental|Part 2: Multiple Dose Escalation SSS17|Escalating doses of SSS17, multiple dose administration
16268895|NCT04893187|Placebo Comparator|Part 2: Multiple Dose Escalation matching Placebo|Escalating doses of matching placebo, multiple dose administration
16268896|NCT04893187|Experimental|Part 3: Treatment Sequence 1 (A to B)|The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
16268897|NCT04893187|Experimental|Part 3: Treatment Sequence 2 (B to A)|The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
16268898|NCT04893174|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.
16268899|NCT04893161|Other|belimumab|All patients with SLE receive belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48. The patients who had SRI-4 response at week 48 were divided into response group and the patients without SRI-4 response at week 48 were divided into no response group.
16268900|NCT04893148|Active Comparator|iGlar/Lixi|"Switching to IGlarLixi from insulin glargine iGlar/Lixi starts with the following doses depending on the existing insulin glargine dose: 1) insulin glargine <20 unit/day = iGlar/Lixi 10 unit/day, 2) insulin glargine >=20 unit/day = iGlar/Lixi 20 unit/day.
~Training to increase the iGlar/Lixi dosage every 3 days to meet the target fasting blood glucose level to 80~130 mg/day"
16268901|NCT04893148|Active Comparator|Dulaglutide plus insulin glargine|Adding Dulaglutide to insulin glargine. Keep insulin glargine and dulaglutide start at 0.75 mg per week and increase to 1.5 mg per week after 1 month with evaluating compliance and tolerability.
16268902|NCT04893135|No Intervention|G1A|Uncontrolled diabetes (HbA1c> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, without the practice physical activity
16268903|NCT04893135|Experimental|G1B|Uncontrolled diabetes (HbA1c> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, with the practice physical activity
16268904|NCT04893135|No Intervention|G2|Controlled diabetes (HbA1c level <7%). This group will study the natural course of RANKL levels in balanced diabetic patients.
16268905|NCT04893109|Experimental|Arm A. T-DM1 followed by Trastuzumab SC|Randomized participants will receive intravenous T-DM1 every 3 weeks for 6 cycles (18 weeks) and then Trastuzumab SC (subcutaneous) every 3 weeks for 11 cycles
16268906|NCT04893109|Experimental|Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone|Randomized participants will receive weekly intravenous Paclitaxel for 12 weeks (4 cycles) and Trastuzumab SC (subcutaneous) every 3 weeks for 17 cycles. The first 4 doses Trastuzumab SC are given with Paclitaxel.
16268907|NCT04893096|Experimental|MOR202 (felzartamab) infusion|Participants will receive active treatment for a total of nine doses during 24 weeks.
16268908|NCT04893083||LRRK2 Mutant PD|Patients with a G2019S mutation
16268909|NCT04893083||LRRK2 Wild Type PD Low burden|Patients with a low burden of genetic modifiers
16268910|NCT04893083||LRRK2 Wild Type High burden|Patients with a high burden of genetic modifiers
16268911|NCT04893070||COVID+|Questionnaires on COVID-19 symptomatology and quality of life
16268912|NCT04893070||COVID-|Questionnaires on quality of life
16268913|NCT04893057||Pregnant women|Women admitted to hospital for a live birth.
16268914|NCT04893057||Blood donors|Subjects qualified for whole blood donation
16268915|NCT04893044|Experimental|Exposure|These participants watched a 3 minute long video prior to a long weekend. The intent was to see if watching the video altered their alcohol consumption compared to a group that did not watch the video. Urine alcohol metabolites were measured before and after the weekend.
16268916|NCT04893044|No Intervention|Control|These participants did not watch a video, and their urine alcohol metabolites were measures at the same dates as the exposure group above.
16268951|NCT04892784|No Intervention|Control|
16268917|NCT04893031||Tocilizumab treatment group|Symptoms of hypoxia and systemic inflammation (SpO2 <90% on room air with accompanying elevation of any two of the systemic inflammatory markers such as CRP, LDH and Ferritin) and / or acute bilateral infiltrations on chest radiography or rapid progression of existing infiltrations, but who did not need mechanical ventilation at admission and were given tocilizumab treatment.
16268918|NCT04893031||Standard treatment group|Patients who did not require mechanical ventilation in intensive care admission and did not receive tocilizumab treatment during any period of hospitalization.
16268919|NCT04893018|Experimental|Treatment (efineptakin alfa)|Patients receive efineptakin alfa IM on day 1. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16268920|NCT04892992|Experimental|Intervention group I|6 sessions of intervention DFG starting at once (baseline). After DFG treatment as usual at Helsinki University hospital. The change between before the intervention (baseline) and after the intervention (3 months later) is being assessed.
16268921|NCT04892992|Experimental|Intervention group II|6 sessions of intervention DFG starting 3 months after baseline (3 months on waiting list). Between baseline and 3 months waiting list families were getting treatment as usual at Helsinki University hospital. The change between baseline - after 3 months waiting list (3 months from baseline)/ before the intervention - and after intervention (6 months from baseline) is being assessed. Also the difference between Intervention group I and II is assessed.
16268922|NCT04892979|Experimental|Centre-based|Centre-based exercise cardiopulmonary rehabilitation program for 6 weeks
16268923|NCT04892979|Experimental|Online-based|Online-based exercise cardiopulmonary rehabilitation program for 6 weeks
16268924|NCT04892979|Experimental|Combined|Combined centre- and online-based exercise cardiopulmonary rehabilitation program for 6 weeks
16268925|NCT04892966|Experimental|TXI (TXI group)|Arm undergoing normal colonoscopy with TXI light
16268926|NCT04892966|Active Comparator|WLI (White Light Imaging Group)|Arm undergoing normal colonoscopy with standard white light
16268927|NCT04892953|Experimental|Cohort A (oligoprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16268928|NCT04892953|Experimental|Cohort B (polyprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every 21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of disease progression or unacceptable toxicity.
16268929|NCT04892940|Experimental|Virtual Reality group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
16268930|NCT04892940|Active Comparator|Control group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
16268932|NCT04892901||c-ESPB group|Postoperative analgesia ensured by continuous ultrasound-guided ESPB performed at the end of surgery.
16268933|NCT04892901||c-SAPB group|Postoperative analgesia ensured by continuous SAPB performed by surgeons at the end of surgery.
16268934|NCT04892901||ICNB-group|"Postoperative analgesia ensured by one-shot ICNB + continuous intravenous administration of tramadol by elastomeric pump."
16268935|NCT04892888||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
16268936|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)|Concurrent weekly cisplatin with radiation and zimberelimab therapy followed by adjuvant zimberelimab
16268937|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)|Concurrent weekly cisplatin with radiation + etrumadenant + zimberelimab with adjuvant combined etrumadenant + zimberelimab
16268938|NCT04892875|Active Comparator|Concurrent Cisplatin/Radiation Therapy|Concurrent weekly cisplatin with radiation therapy control arm
16268939|NCT04892862|Active Comparator|dorsal surgical approach|dorsal surgical approach
16268940|NCT04892862|Active Comparator|volar surgical approach|volar surgical approach
16268941|NCT04892849||Trial cohort|"The study cohort consist of patients suffering from HNSCC (palliative), NSCLC (separately palliative and adjuvant) and other solid tumors (including in particular esophageal carcinomas, urothelial and renal carcinomas, small cell bronchial carcinomas and squamous cell carcinomas of the skin [depending on the current drug approval]) which will be treated with ICI (PD-1/PD-L1) and potential radiation of metastases at Department of Radiation Oncology of Universitätsklinikum Erlangen."
16268942|NCT04892836|Experimental|High Intensity Training (HIT)|They have trained at 80-90% of 1RM for 12 weeks, twice per week
16268943|NCT04892836|Experimental|Moderate Intensity Training|They have trained at 65-75% of 1RM for 12 weeks, twice per week
16268944|NCT04892836|Experimental|Low Intensity Training|They have trained at 50-60% of 1RM for 12 weeks, twice per week
16268945|NCT04892836|No Intervention|Control Group|This groups subjects did not participate in any training
16268946|NCT04892823||Supportive care (EAR, questionnaires, biospecimen collection)|Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
16268947|NCT04892810||RFA|Patient with HCC and decision of treatment with ablation
16268948|NCT04892810||MWA|Patient with HCC and decision of treatment with ablation
16268949|NCT04892797||Covid-19+|Hospitalized patients with Covid-19 infection confirmed by PCR test
16268950|NCT04892784|Experimental|Press tack needle acupuncture|
16268953|NCT04892771||Control group|Patients who have not honored two consultations per year for two years.
16268954|NCT04892758||Formoterol fumarate 10 mcg|Reference Group
16268955|NCT04892758||Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Exposure Group
16268956|NCT04892732||Budesonide|Reference Group
16268957|NCT04892732||Budesonide-formoterol|Exposure Group
16268958|NCT04892719|Other|Participants who underwent a lung transplant at Duke|Participants will undergo fluoroscopic chest imaging with 4Dx technology software analysis
16268959|NCT04892706|Experimental|IDP-126 Gel|
16268960|NCT04892706|Placebo Comparator|IDP-126 Vehicle Gel|
16268961|NCT04892706|Active Comparator|Epiduo® Forte Gel|
16268962|NCT04892693|Experimental|Talazoparib|; Talazoparib should be taken orally once daily (ie, continuous daily dosing) at approximately the same time each day (preferably in the morning). Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the discretion of the treating physician.
16268963|NCT04892680|Experimental|Online Diabetes Self-Management Education and Support (DSMES) Program|Participants will receive access to a 6-month online DSMES program that includes several components that are standard to DSMES. Participants receive online curriculum, access to a live Certified Diabetes Care and Education Specialist (CDCES), interactive group message forums, and connected devices for monitoring food intake, weight, physical activity and glucose levels.
16268964|NCT04892680|No Intervention|Matched Control|A de-identified dataset of control subjects matched on baseline demographics and clinical characteristics will be cultivated for comparison to the active intervention arm.
16268965|NCT04892667|Other|Patients with lymphoma (Hodgkin's or non Hodgkin's)|
16268966|NCT04892654|Experimental|Immediate Switch|Two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 96 weeks.
16268967|NCT04892654|Other|Delayed Switch|Participants will continue their current triple cART regimen for 48 weeks. Patients will then be switched to two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 48 weeks.
16268968|NCT04892641|Experimental|Epetraborole for Dose Ranging|Epetraborole hydrochloride 250 mg, 500 mg, 750 mg, or 1000 mg PO q24h or 500 mg or 1000 mg PO q48h
16268969|NCT04892641|Placebo Comparator|Placebo for Dose Ranging|Matching placebo for dose ranging
16268970|NCT04892641|Experimental|Epetraborole for Food Effect|Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts
16268971|NCT04892641|Placebo Comparator|Placebo for Food Effect|Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts
16268972|NCT04892628|Other|Aerobic training group|"The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
~Exercises will include:
~Flexion, extension and abduction at the shoulder joint for anterior, middle and posterior fibers of deltoid
~Flexion and extension at the elbow for biceps and triceps trachii
~Flexion and extension at the knee joint for quadriceps and hamstring muscles
~Plantar flexion at the ankle joint for gastrocnemius and soleus
~Three sets of ten repetitions of each exercise will be done."
16268973|NCT04892628|Experimental|Resistance training group|"The intervention group will undergo a progressive resistance training program consisting of active muscle stretching and resistance training. Exercise for intervention group will consist of:
~Resisted flexion, extension and abduction at the shoulder joint for anterior, middle and posterior deltoid, using dumbbells
~Resisted flexion and extension at the elbow for biceps and triceps trachii, using dumbbells
~Resisted flexion and extension of knee joint for quadriceps and hamstring muscles, using therabands
~Resisted dorsiflexion and plantar flexion of gastrocnemius and soleus, using therabands
~Resistance will be increased on basis of progressive overload principle. Three sets of ten repetitions will be performed per muscle group. Initial weight of the dumbbells will be 1kg and will be increased by 0.5kg per week."
16268974|NCT04892615||Cohort A|The drainage tube was removed on the 5th day after surgery.
16268975|NCT04892615||Cohort B|The drainage tube was removed on the 7th day after surgery.
16268976|NCT04892602||Rheumatiod arthritis patients|
16268977|NCT04892602||Psoaritic arthritis|
16268978|NCT04892602||Control group|
16268979|NCT04892589||Active Comparator: Control group|Thumb orthosis at night and day for 3 to 4 hours during Activities of Daily Living that included thumb metacarpophalangeal joint (MCP) for three months. In addition to a classic home exercise program.
16268980|NCT04892589||Experimental: Experimental group|The experimental group will receive thumb orthosis at night and daytime use for 3 to 4 hours during Activities of Daily Living that included the thumb MCP for three months. In addition to a classic home exercise program and a proprioceptive home exercises program divided in three phases.
16268981|NCT04892576|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program.
16268982|NCT04892576|Experimental|SSC group|Participants in this group received the standard physical rehabilitation program as the control group in addition to the SSC exercise program
16268983|NCT04892563|Experimental|ESPB Block|Patients with rib fracture randomized to block group
16268984|NCT04892563|Active Comparator|Standard Care|Patients with rib fracture receiving IV analgesia/standard care
16268985|NCT04892550|Experimental|Traction group|"Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
~In addition, the participants in the intervention group will receive the Denneroll™ thoracic traction orthosis. All participants will begin at 3-minutes per session of DTTO application, each visit they will be encouraged to increase the duration by 2-3 minutes, until such time they will be able to reach the goal of 15-20 minutes per session."
16268986|NCT04892550|Active Comparator|Control group|Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises. The multimodal program will be delivered by the same physiotherapist, with 10 years of experience and training in the specific manual techniques in order to minimize inter-therapist variation and enhance fidelity.
16268987|NCT04892537|Active Comparator|CSR|Coronary Sinus Reducer implantation
16268989|NCT04892524|Experimental|Virtual multidisciplinary review|Participants in this arm will be reviewed in a virtual clinic by a multidisciplinary team
16268990|NCT04892524|No Intervention|Face-to-face review|Participants in this group will be reviewed in a face-to-face clinic
16268991|NCT04892511|No Intervention|Standard treatment|"Post-thrombectomy patients will have their blood pressure measured every hour for the first 24 hours after thrombectomy, and every 6 hours from 24 to 72 hours. The target blood pressure is not predefined by the study, but in patients who have received previous treatment with rt-PA, it is advisable to keep it below 180/110 mmHg. If the patient has not received rt-PA, there is no limitation, although the guidelines recommend keeping the pressure below 200/120 mmHg.
~The hypotensive or hypertensive treatments used will be noted."
16268992|NCT04892511|Experimental|Optimized hemodynamic treatment|"Post-thrombectomy patients will have their blood pressure measured every 30 minutes for the first 24 hours after thrombectomy, and every 1 hour from 24 to 72 hours. Blood pressure objectives will depend on the degree of recanalization achieved after thrombectomy (see intervention section).
~The hypotensive or hypertensive treatments used will be noted."
16268993|NCT04892498|Experimental|RT+PD-1+GM-CSF+IL-2|
16268994|NCT04892485||CF patients|
16268995|NCT04892485||Controls|
16268996|NCT04892472|Experimental|Study Arm|Pembrolizumab and TTFields
16268997|NCT04892459|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
16268998|NCT04892459|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
16268999|NCT04892459|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months.
16269000|NCT04892459|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
16269001|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Daratumumab)|"Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) will receive magrolimab as per protocol and daratumumab 1800 mg subcutaneously (SC) or 16 milligrams per kilogram (mg/kg) intravenously (IV) on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days).
~."
16269002|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days).
16269003|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Bortezomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and bortezomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days).
16269004|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Daratumumab)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and daratumumab 1800 mg SC or 16 mg/kg IV on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days).
16269005|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days).
16269006|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Bortezomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and bortezomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days).
16269007|NCT04892420|Active Comparator|Group DX|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia
16269008|NCT04892420|Active Comparator|Group DM|The patients receive 20 ml plain bupivacaine(0.5%)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
16269009|NCT04892420|Active Comparator|Group M|The patients receive 20 ml plain bupivacaine(0.5%)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
16269010|NCT04892420|Placebo Comparator|Group C|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
16269011|NCT04892407|Experimental|Algeness DF 3.5%|This arm is with the Sponsor's product. The product is already CE Marked and sold for this indication for the majority of participating countries.
16269012|NCT04892407|Active Comparator|Juvéderm Voluma|This arm is with a Control product that is already CE Marked and sold for this indication.
16269013|NCT04892394|Experimental|Video Group|Detailed visual video information was given to the video group patients before endodontic treatment by the clinician.
16269014|NCT04892394|Experimental|Control Group|Basic verbal information was given to the control group patients before endodontic treatment by the clinician.
16269015|NCT04892381||Lichen Planus group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA in lesional and non lesional skin
16269016|NCT04892381||Control group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA
16269017|NCT04892368|Active Comparator|Home supervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions. They will also receive 3-4 home visits by physiotherapists between recruitment and surgery, to conduct exercises in their homes.
16269018|NCT04892368|No Intervention|Home unsupervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions.
16269019|NCT04892355|Experimental|Conventional Syringe Irrigation Group|During the final irrigation procedure, a 30 - G side vented needle was placed 2 mm shorter than the working length and was applied without agitation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
16269020|NCT04892355|Experimental|Xp Endo Finisher Group|Xp Endo Finisher file was used with VDW Silver (VDW) endomotor at 800 rpm speed and 1 Ncm torque according to the manufacturer's instructions. The Xp Endo Finisher file was placed in the canal, 2 mm shorter than the working length, and was used with slow movements of 7-8 mm amplitude in the canal during activation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
16269021|NCT04892355|Experimental|EDDY Group|An EDDY tip of size 25/04 was used for sonic activation. The EDDY was placed in the duct 2 mm shorter than the working length and the activation process was performed with slow movements with an amplitude of 2-4 mm. In the irrigation process, 5 mL of 2.5% NaOCI was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
16269022|NCT04892355|Experimental|Endoactivator Group|Medium Endoactivator tip of 25 / .04 size was used for irrigation activation. Medium type was placed in the canal 2 mm shorter than the working length and activation was performed by making short strokes of 2-3 mm. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
16269023|NCT04892342|Experimental|ESG401 dose level 1|
16269024|NCT04892342|Experimental|ESG401 dose level 2|
16269025|NCT04892342|Experimental|ESG401 dose level 3|
16269026|NCT04892342|Experimental|ESG401 dose level 4|
16269027|NCT04892342|Experimental|ESG401 dose level 5|
16269028|NCT04892342|Experimental|ESG401 dose level 6|
16269029|NCT04892329|Experimental|EUS AI navigation system augmentation|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
16269030|NCT04892329|No Intervention|without EUS AI navigation system augmentation|The endoscopists in the contrpl group performs the examination routinely without special prompts.
16269031|NCT04892316||Junior doctor group|Patients receive assisting devices fitting services from junior doctors
16269032|NCT04892316||Senior doctor group|Patients receive assisting devices fitting services from senior doctors
16269033|NCT04892316||Algorithm assisted group|Patients receive assisting devices fitting services from junior doctors assisted by the machine learning model
16269034|NCT04892303|Other|High-risk thyroid cancer patients|All study patients will have histologically confirmed recurrence of thyroid cancer that is incompletely responsive to initial surgery.
16269035|NCT04892290||Group C|Postdural puncture headache patients treated with Conservative treatment
16269036|NCT04892290||Group SGB|Postdural puncture headache patients treated with Sphenopalatine Ganglion Block and conservative treatment
16269037|NCT04892277|Experimental|Treatment (cyclophosphamide, fludarabine, IC19/1563)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5, -4, -3 and IC19/1563 IV on day 0.
16269038|NCT04892264|Experimental|Arm A (belantamab mafodotin, lenalidomide, daratumumab)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles (starting cycle 13), lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
16269039|NCT04892264|Experimental|Arm B (belantamab mafodotin, lenalidomide, daratumumab, Dxevo)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of cycles 2, 4, 6, 8, 10, and 12, lenalidomide PO QD on days 1-21, daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 3, and days 1 and 15 on cycles 5, 7, 9, and 11. Patients also receive dexamethasone PO on days 1, 8, 15 and 22. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of even numbered cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1 of odd numbered cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
16269040|NCT04892251|Experimental|MORE+KAP|8 weeks of Mindfulness-Oriented Recovery Enhancement plus two ketamine assisted psychotherapy sessions
16269041|NCT04892251|Active Comparator|MORE|8 weeks of Mindfulness-Oriented Recovery Enhancement
16269042|NCT04892238||Treatment-naïve|Subjects without previous experience of treatment provided for H.pylori infection
16269043|NCT04892238||treatment experienced|Subjects who were previously tested positive for H.pylori infection and who were treated for H.pylori infection with at least 2 antibiotics in combination with proton pump inhibitor not less than 6 weeks before the 13C-urea breath test
16269044|NCT04892225|Experimental|Intervention group|Individuals in this group will be randomly assigned to text message in Urdu language on dietary sodium and fluid restriction daily for 8 weeks.
16269045|NCT04892225|No Intervention|Control group|Randomly assigned Control group will not receive any text message.
16269198|NCT04891172|No Intervention|Control|The Control group will be receive Standard of care only
16269304|NCT04890535|Active Comparator|Part 2 Dose Level 2: XXX mg TBAJ-587|XXX mg TBAJ-587
16269046|NCT04892212|Experimental|Sirolimus group|"The initial dose of sirolimus is 1mg/day. And the serum trough level of sirolimus is monitored at Week 2, Week 4, Week 8, and Week 12，respectively. The target serum trough level of sirolimus is 5-8 ng/mL. The dose of sirolimus is titrated according to therapeutic drug level monitoring.
~The previous immunosuppressive medication is not allowed to be changed during the 3-month follow-up, unless premature discontinuation from study."
16269047|NCT04892199|Active Comparator|Semaglutide injection once-weekly|
16269048|NCT04892199|Placebo Comparator|Semaglutide-Placebo injection once-weekly|
16269049|NCT04892186|Experimental|Myo-inositol|30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g, orally, twice a day for 6 months.
16269050|NCT04892186|Active Comparator|Metformin|30 women with resistance insulin or glucose intolerance will receive metformin, orally, three times a day for 6 months
16269051|NCT04892173|Experimental|Arm A|NBTXR3, as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. NBTXR3 is given as a single intratumoral injection as a dose of 33% of the Gross Tumor Volume
16269052|NCT04892173|Active Comparator|Arm B|Investigator's choice of RT alone or RT in combination with cetuximab
16269053|NCT04892160|Other|Guided Imagery First/Virtual Reality Second|Patients will be played a guided imagery experience first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the virtual reality intervention.
16269054|NCT04892160|Experimental|Virtual Reality First/Guided Imagery Second|Patients will have the VR interactive experience played first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the guided imagery intervention.
16269055|NCT04892147|Experimental|Experimental group|Randomly selected to participate first in MOBA group
16269056|NCT04892147|Other|Wait-list-control group|Randomly selected for study assessments parallel with experimental group. Participates in MOBA after completion of the experimental group
16269059|NCT04892108|Experimental|Group STARR|Patients undergoing transanal prolassectomy with mechanical stapler (STARR: Stapled Trans Anal Rectal Resection) randomly
16269060|NCT04892108|Experimental|Group LVR|Patients undergoing Laparoscopic suspensory correction of rectal prolapse by ventral rectopexy with biological prosthesis (LVR) randomly
16269061|NCT04892095||Study participants|Adult subjects (men and women) aged 18 years or more, living in 12 European countries
16269062|NCT04892082|Experimental|Mindful Moment|Mothers who present parenting stress equal or above 41 score on PSS will receive a web-based intervention to reduce parenting stress (the Mindful Moment program).
16269063|NCT04892082|Active Comparator|Control|All mothers who present parenting stress will have access to Mindful Moment intervention. The control group only receive the intervention at the end of the intervention group.
16269064|NCT04892069||Ryzodeg®|Participants are patients with Type 2 Diabetes (T2D) treated with Ryzodeg® (Insulin Degludec/Insulin Aspart) in a real-world adult population in Lebanon
16269065|NCT04892056|Experimental|Anterior Segment Retraction using Friction mechanics by elastomeric power chains|"Elastomeric power chains extending from 8mm crimpable hooks, distal to the lateral incisors, on 0.017x0.025 Stainless Steel WIres, to the mini-screws. The power chains delivered 160g of force per side."
16269066|NCT04892056|Experimental|Anterior Segment Retraction using Frictionless mechanics by T-loops|"T shaped closing loops were fabricated on 0.017x0.025 Titanium- Molybdenum wires (TMA) were used to deliver 160g of force per side by 4mm distal activations."
16269067|NCT04892043|Experimental|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-AAC-HPV as a monotherapy is administered every 3 weeks for up to a year.
~There are 3 groups (Cohorts) in this Phase as follows:
~Cohort 1a: low dose SQZ-AAC-HPV
~Cohort 1b: intermediate dose SQZ-AAC-HPV
~Cohort 1c: high dose SQZ-AAC-HPV"
16269068|NCT04892043|Experimental|Part 2 Combination Safety Phase|"In Part 2, SQZ-AAC-HPV in combination with immune checkpoint inhibitors (1) ipilimumab, (2) nivolumab, or (3) nivolumab plus ipilimumab is administered every 3 weeks up to a year, but the immune checkpoint inhibitors may be administered up to 2 years. There are 3 groups (Cohorts) in this Phase as follows:
~Cohort 2a: SQZ-AAC-HPV RP2D (Recommended Phase 2 Dose) plus ipilimumab
~Cohort 2b: SQZ-AAC-HPV RP2D plus nivolumab
~Cohort 2c: SQZ-AAC-HPV RP2D plus nivolumab and ipilimumab"
16269069|NCT04892030|Experimental|Intervention|All participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies remotely, through an e-learning platform.
16269070|NCT04892017|Experimental|Dose Escalation (Part 1-A Monotherapy)|DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation will continue to the next planned dose cohort.
16269071|NCT04892017|Experimental|Dose Escalation (Part 1-B Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.
16269072|NCT04892017|Experimental|Expansion Cohort 1 (Part 2)|DCC-3116 tablets BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with pancreatic ductal adenocarcinoma (PDAC).
16269073|NCT04892017|Experimental|Expansion Cohort 2 (Part 2)|DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC).
16269074|NCT04892017|Experimental|Expansion Cohort 3 (Part 2)|DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC).
16269075|NCT04892017|Experimental|Expansion Cohort 4 (Part 2)|DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma.
16269076|NCT04892004|No Intervention|Control group|Standard information defined as the standard care, unplanned, provided for Heart Failure patients and not personalized.
16269077|NCT04892004|Experimental|Interventional group|A nurse provides the intervention with expertise in Heart Failure and addresses reinforcements on: a) an explanation on signs and symptoms of Heart Failure and how to recognise them; b) importance on daily fluid management, by planning 1.5-2 litres of liquids per day (e.g., soup, milk, coffee, water, tea and yoghurts); and c) when doctors or nurses should be contacted (when symptoms escalation or a weight gain of 2 kg in three days or 5 kg in a week were detected).
16269078|NCT04891991|Active Comparator|Infliximab group|This group will receive 1 mg/0.05 mL of intravitreal infliximab at the end of standard pars plana vitrectomy.
16269079|NCT04891991|Sham Comparator|Standard of care group|This group will undergo standard pars plana vitrectomy.
16269081|NCT04891965|Experimental|ART24 (Cohort A)|In Cohort A, subjects will receive ART24 or placebo daily for 7 days
16269082|NCT04891965|Placebo Comparator|Placebo (Cohort A)|In Cohort A, subjects will receive ART24 or placebo daily for 7 days
16269083|NCT04891965|Experimental|ART24 (Cohort B)|In Cohort B, subjects will receive ART24 or placebo daily for 28 days
16269084|NCT04891965|Placebo Comparator|Placebo (Cohort B)|In Cohort B, subjects will receive ART24 or placebo daily for 28 days
16269085|NCT04891939|Experimental|The intervention Arm|This arm will receive the novel intervention package for a period of three months to prevent smoking initiation and increase quit rate. The intervention will consist of 4 lessons which will be taught for about one hour each day. This will be segmented into two broad areas as knowledge and skill development. Under the knowledge-based program, participants will be taught, the global challenge of tobacco and tobacco products, correcting the erroneous impression about tobacco, the media and advertisement, and the harmful effects of smoking. The skill development program teaches about refusal skills (self-esteem, interpersonal relationship skills, and problem-solving skills). The participants will understand the tobacco advertising and marketing strategies; peer influence, and skills for resisting influences to smoke.
16269086|NCT04891939|Active Comparator|The Control Arm|The control arm will not receive novel intervention program but will continue with the usual School Health and Education program (SHEP) however, at the end of the intervention, all the materials will be sent to the control arm to also benefit from the lessons.
16269087|NCT04891926|Experimental|Hormonal therapy|Patients choosing to start hormoanl treatment using ural or transdermal estrogen.
16269088|NCT04891913|Experimental|15mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.
16269089|NCT04891913|Experimental|30mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.
16269090|NCT04891913|Experimental|60mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.
16269091|NCT04891900|Experimental|TQB2450 combined with anlotinib, oxaliplatin and capecitabine in the treatment of GC or AEG|In this study, all subjects were treated with TQB2450 (PD-L1 inhibitor) plus anlotinib combined with oxaliplatin and capecitabine, once every 3 weeks, six cycles of chemotherapy with oxaliplatin and capecitabine. Subsequently, TQB2450 (PD-L1 inhibitor) combined with anlotinib was maintained until disease progression, intolerable toxicity, withdrawal of informed consent, loss of follow-up or death, or other circumstances that the researcher judged should stop treatment, whichever occurred first.
16269092|NCT04891887|Experimental|Intervention|Health education program
16269093|NCT04891874|Experimental|SBRT group|Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.
16269094|NCT04891874|No Intervention|Surgery alone group|Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.
16269095|NCT04891861|Active Comparator|1 week restart|restart DOAC at 1 week post injury at label dose and frequency
16269096|NCT04891861|Active Comparator|4 week restart|restart DOAC at 4 weeks post injury at label dose and frequency
16269097|NCT04891848||migraine with aura|51 patients with MA
16269098|NCT04891848||migraine without aura|51 patients with migraine without aura
16269099|NCT04891848||tension type headache|48 patients with tension type headache
16269100|NCT04891848||healthy controls|80 healthy participants
16269101|NCT04891822||E (ERAS protocol)|receive ERAS protocol 8 hours of fasting and ingestion of oral carbohydrate 2 hour before surgery TIVA(Total intra-venous anesthesia) TAP(transversus abdominis plane) block IV-PCA using NSAIDs after surgery Resuming oral intake 2 hours after surgery.
16269102|NCT04891822||C (Control)|receive standard perioperative care 8 hours of fasting before surgery Inhalation anesthesia IV-PCA using NSAIDs Resuming oral intake 6 hours after surgery.
16269103|NCT04891809|Experimental|IRd followed by IR|Induction: 8 cycles isatuximab+lenalidomide+dexamethasone; Maintenance: up to 24 cylces isatuximab+lenalidomide
16269104|NCT04891809|Other|Rd followed by R|Induction: 8 cycles lenalidomide+dexamethasone; Maintenance: up to 24 cylces lenalidomide
16269105|NCT04891796||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
16269106|NCT04891796||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
16269107|NCT04891796||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
16269108|NCT04891783||50 patients diagnosed as AS|50 patients diagnosed as AS according to 1984 modified New York criteria of AS .including radiographic and non-radiographic AS according to ASAS criteria these patients will undergo carotid ultrasound examination
16269109|NCT04891783||30 patients with psoriatic arthritis|30 patients with psoriatic arthritis who will be diagnosed according to the Classification Criteria of Psoriatic Arthritis (CASPAR) study these patients will undergo carotid ultrasound examination
16269110|NCT04891783||40 healthy controls|healthy controls will undergo carotid ultrasound examination
16269199|NCT04891172|Experimental|C-IVIG|The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care
16269233|NCT04890925|No Intervention|Control group|Women who have experienced intimate partner violence but no sustained brain injury (Brain Injury Severity Assessment; BISA = 0)
16269305|NCT04890535|Placebo Comparator|Part 2 Dose Level 2: placebo|placebo
16269116|NCT04891744|Experimental|Selinexor in combination with thalidomide and Dexamethasone|Selinexor in combination with thalidomide and Dexamethasone. Thalidomide will be given at 100mg/d d1-28,and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. Treatment will be administered in 28-day cycles,include a total of 12 cycles. Selinexor dose escalation: 60, 80, 100mg respectively on day 1,8,15,22 for 4-week cycles. Then Selinexor will be given at the recommended dose level on phase II.
16269117|NCT04891731||leuprorelin 3M plus AIs|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year AIs: anastrozole 1mg /letrozole 2.5mg/exemestane 25mg daily for 1 year
16269118|NCT04891731||leuprorelin 3M plus TAM|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year TAM: daily for 1 year
16269119|NCT04891718|Experimental|MVC-101 and Nivolumab|Patients with HNSCC who are scheduled for surgical biopsy or tumour resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline and solution stabilizer), a pre-cleaved/pre-activated drug control (cMVC-101), MVC-101 (the prodrug), or nivolumab as single agents or as combinations. Each drug will be delivered in subtherapeutic microdoses, and each microdose is simultaneously injected in a columnar fashion through each of 3, 5, or 8 needles (in a device configuration determined by tumour dimensions) into a single solid tumour or effaced metastatic lymph node.
16269120|NCT04891705||Pleural Effusion|Adult and pediatric subjects with suspicion of pleural effusion
16269121|NCT04891705||Lung Consolidation|Adult and pediatric subjects with suspicion of lung consolidation
16269122|NCT04891692|Experimental|Phasic Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's phasic setting. Treatment at 3 kHz, modulation 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
16269123|NCT04891692|Experimental|Combined Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's combined (tonic and phasic) setting. Treatment at 3 kHz, modulation 4 Hz and 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
16269124|NCT04891679|Active Comparator|Group A (Titrated OMS)|Titrated oral misoprostol solution
16269125|NCT04891679|Active Comparator|Group B (Static OMS)|Static oral misoprostol solution
16269126|NCT04891666|Experimental|Lactobacillus plantarum DSM 33464|1 sachet of Lactobacillus plantarum DSM 33464 (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks
16269127|NCT04891666|Placebo Comparator|placebo|1 sachet of placebo (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks
16269128|NCT04891653|Experimental|5-65mg QD|
16269129|NCT04891640|Active Comparator|TNFi Standard Therapy|Continue fixed standard treatment (i.e., no change from current therapy)
16269130|NCT04891640|Experimental|TNFi fixed longer dosing intervals|Fixed longer dosing intervals of TNFi (i.e., increased time between doses)
16269131|NCT04891640|Experimental|TNFi Therapy Withdrawal|Stop TNFi treatment
16269132|NCT04891627||Healthy control groups|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
16269133|NCT04891627||Periodontitis group|Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4. Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.
16269134|NCT04891627||Periodontitis with diabetes group|"Inclusion criteria for T2DM patients were based on the American Diabetes association published in 2010. Individuals to the T2DM group; It was selected from individuals diagnosed with T2DM for more than 5 years by their own physicians according to daily plasma glucose (200 mg / dl) and hemoglobin A1c (HbA1c ≥6.5%).
~Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4. Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C."
16269135|NCT04891614|Experimental|Treatment|Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
16269136|NCT04891601|Active Comparator|Group II MA Mesh alone repair|patient use mesh alone as treatment of inguinal hernia
16269137|NCT04891601|Active Comparator|Group I CMD Combined Mesh & darn|patients utilize both mesh and darn repair
16269138|NCT04891588|Experimental|Switching the preserved to preservative free prostaglandin analog-timolol FC|To switch preserved prostaglandin analog- timolol FC (Fixapost 50 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC in order to investigate whether that can result in alleviation or elimination of OSD and improvement of local tolerability.
16269139|NCT04891575|Active Comparator|Active Control Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes who is randomized to this arm will attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The index participant will attend the sessions as an individual and will receive standard individual-focused lifestyle modification education.
16269140|NCT04891575|Experimental|Family Dyad Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes and a co-participating family member will together attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The dyadic intervention sessions also incorporate family-focused throughout each session to encourage dyadic support.
16269141|NCT04891562|Experimental|pDCD (hildren with (probably) Developmental Coordination Disorder)|children with (probably) Developmental Coordination Disorder (pDCD)
16269142|NCT04891562|Active Comparator|TDC (Typically Developing Children)|Typically Developing Children
16269143|NCT04891549|Active Comparator|Tension band fixation|Surgical fixation of the patella fracture utilizing the AO principles using K-wires, screws, cerclage and sutures by surgeons choice.
16269144|NCT04891549|Experimental|Plate fixation|Surgical fixation of the patella fracture utilizing the AO principles and a locking plate with the number of screws by surgeons choice. Additional fixation by surgeons choice.
16269145|NCT04891536|Experimental|Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy|
16269146|NCT04891523|Other|Placebo-Probiotic|First receive placebo, then active probiotics.
16269147|NCT04891523|Other|Probiotic-Placebo|First receive active probiotics, then placebo.
16269148|NCT04891510|Active Comparator|REVOLVE Advanced Adipose System|Participants will receive the REVOLVE Advanced Adipose System technique during breast reconstruction.
16269149|NCT04891510|Active Comparator|LipoGrafter|Participants will receive the LipoGrafter technique during breast reconstruction.
16269150|NCT04891510|Active Comparator|Standard Decantation|Participants will receive the Standard decantation technique during breast reconstruction.
16269151|NCT04891497|Experimental|Intraarterial Treatment plus Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
16269152|NCT04891497|Placebo Comparator|Intraarterial Treatment plus placebo|Placebo 240mg orally twice daily for 3 consecutive days
16269153|NCT04891484|Experimental|Ondansetron group|Group O :patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
16269154|NCT04891484|Placebo Comparator|Control group|Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
16269155|NCT04891471|Experimental|SRS/SBRT arm|Patients with five or more brain metastasis assigned by randomization to Stereotactic RadioSurgery (SRS) or Stereotactic Body RadioTherapy (SBRT) will be treated with a highly-conformal metastasis-directed single dose between 15 and 24 Gy or fractionated dose (e.g. 27 Gy in 3 fractions), respectively, depending on lesion size, while sparing clinically negative brain. The treatment will be delivered using five non-coplanar arcs and a mono-isocentric technique.
16269156|NCT04891471|Active Comparator|WBI arm|Patients with five or more brain metastasis assigned by randomization to Whole Brain Irradiation (WBI) will be treated using a 3D-Conformal RadioTherapy technique for a uniform dose delivery of 30 Gy in 10 daily/fractions to the target, that is entire brain.
16269157|NCT04891458|Experimental|Patients received lighter sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 0-2.
16269158|NCT04891458|Experimental|Patients received heavier sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 3-5.
16269159|NCT04891458|Experimental|Patients received lighter sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 0-2.
16269160|NCT04891458|Experimental|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 3-5.
16269161|NCT04891445|Active Comparator|As usual|"Patients will be directly referred to their family doctor with a report on the data obtained in the analysis (presence of HCV and positive viral load), so that they can follow the usual treatment (as usual) in these cases in the Andalusian Health Service.
~The usual treatment implies, once the presence of Virus C has been confirmed, referral by the patient's family doctor to the specialized service, in this case the Gastroenterology Service of the referral Hospital, through the usual appointment procedure. Generally the delay in this process is usually approx. 2-3 months for the first appointment."
16269162|NCT04891445|Experimental|Nurse-Navigation Programme|"A Clinical Pathway (CP) of nursing monitoring will be activated, that is, patients will be accompanied throughout the evaluation and treatment process until their complete cure is guaranteed.
~CP will include the activation of care in the Gastroenterology Service by the nurse. By requesting a first appointment in the Gastroenterology Service, via email, the nurse will activate the patients' access to this first appointment, which consist in a one-step intervention: liver evaluation analysis on the genotype, determine the most appropriate type of treatment and, dispensing treatment by the Hospital Pharmacy Unit. To guarantee attendance, in all cases the patient will be accompanied, either by a competent available family caregiver, or by the mental health nursing team.
~All the intervention will be operationalized through the mentioned CP developed for this purpose, with the participation of those involved."
16269163|NCT04891419|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants will be treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel in temple. Participants are eligible for touch up treatment
16269164|NCT04891419|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 6.
16269301|NCT04890535|Placebo Comparator|Part 1 Dose Level 6: placebo|placebo
16269165|NCT04891406|Other|ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)|"Subjects use product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes on Day 1, then switch to use product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 min on Day 2, then product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 min on Day 3, then D (Swave Daquiri, nicotine pouch, 10.6 mg/pouch) on Day 4 and finally E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette), smoked in approximately 5 minutes with puffs taken at regular intervals approximately 30 seconds apart, on Day 5.
~Subjects can use their assigned product ad libitum on each study day, after all study assessments are performed, until 10pm. A washout period of product abstinence is observed between products, overnight."
16269166|NCT04891406|Other|ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)|Same as previous arm but in a different randomization order.
16269167|NCT04891406|Other|Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)|Same as previous arm but in a different randomization order.
16269168|NCT04891406|Other|Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)|Same as previous arm but in a different randomization order.
16269169|NCT04891406|Other|Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)|Same as previous arm but in a different randomization order.
16269170|NCT04891393|Experimental|Caffeine|Single-dose, orally ingested, instant coffee.
16269171|NCT04891393|Placebo Comparator|Inactive Placebo|Single-dose, orally ingested, instant decaffeinated coffee (equal weight to intervention dose).
16269172|NCT04891380|Other|Cardiac arrest patients|Cardiac arrest patients receiving cardiopulmonary resuscitation with LUCAS 2 Active Decompression 2.
16269173|NCT04891380|Other|Hypotension|Patients developed or may develope hypotension of non traumatic origin.
16269174|NCT04891380|Other|Intensive care patient transport|Patients who are transported from one intensive department to another.
16269175|NCT04891380|Other|LUCAS 2 Active Decompression|The hemodynamic measurements of the cardiac arrest patients in the present study will be compared with the hemodynamic measurements achieved in the previous study NCT02479152.
16269176|NCT04891367|Experimental|Group CBT|Group cognitive behavioral therapy for obsessive compulsive disorder in youth
16269177|NCT04891354|Experimental|The experimental arm PDNO in increasing doses|The Investigational medicinal product, PDNO is given intravenously, in part 2 the doses is increased twice.
16269178|NCT04891354|Placebo Comparator|Placebo|The placebo comparator, NaCl is given intravenously, before the PDNO is given.
16269179|NCT04891341|Experimental|Technology Supported Task-Oriented Circuit Therapy Group|Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.
16269180|NCT04891341|Active Comparator|Home-based Telerehabilitation Group|To the telerehabilitation group; A home program consisting of strengthening, balance and coordination exercises determined according to the needs of volunteers with MS will be given. A session will be applied in the home program under the guidance of a physiotherapist. The exercise will take 1 hour. The exercise participation status of the patient will be monitored with a mobile (smartphone) application. Exercises will be constantly updated according to the needs of the patient, the updated exercises will be sent to the mobile application via video, and the patient will be able to communicate with the physiotherapist via video conference whenever he / she wishes. Progress and complication of the treatment program will be achieved by increasing the weights used, changing the ground characteristics and support surface during balance exercises and increasing the complexity of coordination exercises.
16269181|NCT04891315||Pregnant women|Women aged 16+ in early pregnancy (before 20 weeks of gestation).
16269182|NCT04891302|Experimental|Clevudine|Clevudine 150 mg once a day for 10 days
16269183|NCT04891302|Placebo Comparator|Placebo|Matching Placebo once a day for 10 days
16269184|NCT04891289|Experimental|HAI FUDR plus GemOx|"Surgical HAI pump placement. 2. HAI FUDR [(0.12 mg/kg/day) x wt (kg) x (20ml) X 0.9) / pump flow rate (1ml/day)] and dexamethasone [1 mg/day * 20] / pump flow rate (1 ml/day) on Day 1 of each cycle.
~Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. 3. Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/ m2 IV over 120 minutes on Days 1 and 15 of each cycle; however, for patients in Arm 1, initiation of systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first dose of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter."
16269185|NCT04891289|Active Comparator|GemOx alone|Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.
16269186|NCT04891263|Experimental|Suture-Septoplasty|Participants will receive suture-septoplasty technique, and will be followed for three months postoperatively.
16269187|NCT04891250|Experimental|Intervention|Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio
16269188|NCT04891250|Experimental|Prophylaxis|An additional group of patients will be recruited will be randomized to either Ivermectin as prophylaxis (Intervention) or Standard of Care with no ivermectin (Control arm) in a 1:1 ratio
16269189|NCT04891237|Experimental|10,000 MG01 + 10,000 T517|10,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
16269190|NCT04891237|Experimental|30,000 MG01 + 10,000 T517|30,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
16269191|NCT04891237|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
16269192|NCT04891224|Other|Pathway Platform application use|Study participants will download the Pathway app to their mobile device. This app will gather patient health data, present standardized questionnaires and research data collection tools. Subject responses will be visible to their provider via interface with the electronic medical record.
16269193|NCT04891211|Active Comparator|Pediatric endocrinologist|Patient selection by pediatric endocrinologist on the basis of vitamin D
16269194|NCT04891211|No Intervention|Ophthalmologist|"Evaluation of the results by 2 different retina specialists during the examination of patients
~Interpretation of the results without knowing the vitamin D level of patients"
16269195|NCT04891198|Experimental|Subjects with TMB-H/TMB-L|Subjects receive KN035 400 mg Subcutaneously on Day 1 of every 4-week cycle (Q4W)
16269200|NCT04891159||Shared decision making|During the first consultation (V1), the doctor will present the patient on the therapeutic treatment information related to diabetes according to the shared decision making (options, benefits, risks) with the assistance of decision support tools. The decision-making visit will take place after a reflection period of 8 to 15 days after V1. A discussion based on the feedback from this period of reflection will take place between the two actors and either there is a common agreement on the decision taken (shared decision-making), or the decision is taken by the patient, or the decision is made by the physician at the request of the patient. A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing. After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires: SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire
16269201|NCT04891159||Control group|"Decision-making for insulin therapy is based on the usual practice defined in each Cystic Fibrosis Centers Competences with decision-making procedures specific to each center and doctor. The decision-making process is generally carried out in two consultations.
~A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing.
~After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires (SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire)."
16269202|NCT04891146||Inhalation anesthesia|Sevoflurane for opioid remifentanyl used
16269203|NCT04891146||Total Intravenous Anesthesia|Propofol for opioid remifentanyl used
16269204|NCT04891133|Experimental|Active arm|4mg Baricitinib up to 14 days + SoC
16269205|NCT04891133|Placebo Comparator|Comparator|Matching placebo up to 14 days + SoC
16269206|NCT04891120|Experimental|With, then without a mask|Participants will first perform a treadmill test with a mask and 48 hours or more later will perform another similar treadmill test without a mask.
16269207|NCT04891120|Experimental|Without, then with a mask|Participants will first perform a treadmill test without a mask and 48 hours or more later will perform another similar treadmill test with a mask.
16269208|NCT04891107|Experimental|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Will walk for 30 minutes at a time, 5 times a week, for 4 weeks using the wearable sensor system at home or in the community.
16269209|NCT04891081||Patients with cyanotic Congenital Heart Disease|
16269210|NCT04891081||Patients with acyanotic Congenital Heart Disease|
16269211|NCT04891068|Experimental|Single arm with previously untreated high risk early stage breast cancer|All participants will receive azacitidine 50mg/m2 SC daily for five consecutive days.
16269212|NCT04891055||patients treated with nivolumab|Patients candidates for II line therapy with Nivolumab from clinical practice
16269213|NCT04891055||patients treated with TKI|Patients candidates for II line therapy with TKI from clinical practice
16269214|NCT04891042||Latent Phase of Labour|
16269215|NCT04891042||Active Phase of Labour|
16269216|NCT04891016|Experimental|experimental group|patients received FLOT regimen on day 1 and toripalimab on day 3.
16269217|NCT04891016|Other|control group|patients received FLOT regimen and toripalimab on day 1.
16269218|NCT04891003||Patients Diagnosed with Endometriosis (or endometrioma alone)|Nulliparous patients who had diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
16269219|NCT04891003||Patients With No Gynecological Pathology|Nulliparous patients who had not diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
16269220|NCT04890990|Active Comparator|Black girl, control (BC)|~120-second video of a Black adolescent girl, without depression
16269221|NCT04890990|Active Comparator|Black girl, depressed (BD)|~120-second video of a Black adolescent girl, depressed
16269222|NCT04890990|Active Comparator|Black girl, depressed, adjusted (BDa)|~120-second video of a Black adolescent girl, depressed - adjusted for the specifics of being a Black girl (as informed by a focus group of Black girls and women)
16269223|NCT04890977|Experimental|Talking Story|Talking Story is a modular behavioral intervention intended to increase mental health treatment-seeking among Pacific Islanders through the use of narrative films and other culturally syntonic approaches.
16269224|NCT04890977|Placebo Comparator|Wait-list control|The wait-list control will be administered as a control arm to the active Talking Story arm.
16269225|NCT04890964|Active Comparator|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
16269226|NCT04890964|Sham Comparator|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
16269227|NCT04890964|Active Comparator|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
16269228|NCT04890964|Placebo Comparator|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
16269229|NCT04890951||Uterine Preservation|
16269230|NCT04890951||Hysterectomy|
16269231|NCT04890938|Experimental|Sputum-guided management and comprehensive care management|The intervention consists of 6-months of CCM and sputum biomarker-directed treatment of airway inflammation, including hospital and clinic visits. Clinic visits at 2, 6, and 16 weeks. The key elements of CCM will be provided, including case management, self-management education, and coordination of community/hospital resources (1). Clinic nurse will review inhaler technique with the patient. Sputum (spontaneous) biomarkers will be measured with results used to direct therapy at the time of AECOPD and during clinic visits after hospital discharge, at both sites.
16269232|NCT04890938|Active Comparator|Standard of Care|This group will also receive clinic visits at 2, 6, and 16 weeks with a study physician, and also education material, inhaler technique assessment and education, and case management from the clinic personnel. The study physician will pursue further investigation and/or further intervention if they see fit, including an inhaler regimen following the Canadian Thoracic Society guidelines (2).
16269234|NCT04890925|Experimental|Community Support Network (CSN) intervention group|The SOAR Community Support Network (CSN) intervention includes cognitive training, aerobic exercise, mindfulness meditation, counselling, quality of life tracking.
16269235|NCT04890925|Active Comparator|Usual care|Participants in this group will receive dose-equivalent usual care
16269238|NCT04890886||Pre-existing Type 1 Diabetes and Type 2 Diabetes|Women with type 1 diabetes and type 2 diabetes diagnosed prior to pregnancy
16269239|NCT04890886||Gestational Diabetes|Women with gestational diabetes diagnosed in pregnancy by the oral glucose tolerance test
16269240|NCT04890886||Intrahepatic cholestasis of pregnancy|Women with intrahepatic cholestasis of pregnancy
16269241|NCT04890886||Control|Women without metabolic disease in pregnancy
16269242|NCT04890873|Experimental|ERX1000|"ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension
~Proposed dose level for Part A: 4 mg
~Proposed dose level for Part B: 4 mg. The dose administered will not exceed the highest dose administered in Part A."
16269243|NCT04890873|Placebo Comparator|Placebo|Reference product: Magnesium hydroxide carbonate powder prepared in an oral suspension
16269244|NCT04890860|Experimental|Adults patients undergoing mitral and / or tricuspid valve surgery with cardiopulmonary bypass.|
16269245|NCT04890847||human-machine collaboration group|healthcare professionals and machine collaboration for annotation and AI model development
16269246|NCT04890847||pure mannual group|healthcare professionals for pure manual annotation and AI model development
16269247|NCT04890834|Active Comparator|Arm I (Standard of care)|Patients and caregivers receive standard care including education pertaining to symptom management, prophylactic dental hygiene and possible extraction, speech pathology for baseline swallowing assessment and prophylactic treatment, and dietary services for regular nutrition consults during CRT. Psychiatry, social work, interventional radiology and supportive care services are consulted as needed.
16269248|NCT04890834|Other|Arm II (exercise, yoga sessions)|Patients and caregivers receive standard care as in arm I. Patients and caregivers also participate in yoga sessions 3 times per week over 60 minutes each for a total of 15 sessions.
16269249|NCT04890821|Experimental|CI Percutaneous Ring Annuloplasty System|Patients treated with the CI Percutaneous Ring Annuloplasty System
16269250|NCT04890808|Experimental|Over-the-Counter Dietary Supplement Inosine|capsules containing 500 mg of inosine Two capsules Twice Daily Other Name: hypoxanthine 9-β-D-ribofuranoside 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl) oxolan-2-yl]-1H-purin-6-one
16269251|NCT04890808|Experimental|Over-the-Counter Dietary Supplement IP6|"capsules containing 500mg of IP6 Two capsules Twice Daily Other Name: Inositol hexaphosphate
~(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexakis[dihydrogen (phosphate)]"
16269252|NCT04890795|Experimental|AL8326|Subject will received AL8326 once daily for 28-days cycle until intolerable toxicity or disease progression or death or voluntary withdrawal the end of this study.During treatment, subjects will be evaluated for anti-tumor efficacy and corresponding safety examinations every 2 cycles, and tumor disease status will be according to RECIST 1.1.
16269253|NCT04890782||MMD group|Consecutive patients diagnosed with MMD during hospitalization in Beijing Tiantan Hospital, Capital Medical University will be recruited.
16269254|NCT04890782||Healthy control group|Age and sex matched subjects will be invited to join the study as the control.
16269255|NCT04890769||Participants|Patients with exuding wounds
16269256|NCT04890756||Reliability Group|100 Healthy Adults
16269257|NCT04890756||Validity Group|45 Healthy Adults
16269258|NCT04890743|Experimental|Conventional TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
16269259|NCT04890743|Experimental|Pseudo-acupuncture TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
16269260|NCT04890743|Experimental|Trabert ultrastimulation group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
16269261|NCT04890743|Placebo Comparator|Placebo group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
16269262|NCT04890730||Southern Medical University of Nanfang Hospital|Southern Medical University of Nanfang Hospital
16269263|NCT04890730||Tongji Hospital Affiliated to Tongji University|Tongji Hospital Affiliated to Tongji University
16269264|NCT04890730||The Second Affiliated Hospital Of Nanchang University|The Second Affiliated Hospital Of Nanchang University
16269265|NCT04890717||ASD and/or ADHD children (Case group)|Suspected or confirmed cases of ASD and/or ADHD children (Case group); no intervention(s) to be administered.
16269266|NCT04890717||Parent group|Parents of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
16269267|NCT04890717||Sibling group|Typically developed siblings of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
16269268|NCT04890717||Control group|Typically developed children not related to the case group ; no intervention(s) to be administered.
16269269|NCT04890704|Experimental|Curcumioids|The investogators prescribed curcuminoids 1,500 mg/day . The regimen was curcuminoids 500 mg three times a day from three days before the procedure until two days after. All patients also received standard prophylaxis protocol which included 0.9% sodium chloride 1 mL/kg/hour, given 12 hours before and 12 hours after CAG unless contraindicated.
16269270|NCT04890704|Placebo Comparator|Placebo|The placebo was identical capsule given three times daily and the remaining protocols were the same as the active group
16269271|NCT04890691|Experimental|BLT-1|Light therapy (wavelengths between 470nm and 525nm), 30 minutes/day for 4 weeks.
16269272|NCT04890691|Placebo Comparator|BLT-2|Placebo light (wavelength between 620nm and 750 nm), 30 minutes/day for 4 weeks.
16269302|NCT04890535|Active Comparator|Part 2 Dose Level 1: XXX mg TBAJ-587|XXX mg TBAJ-587
16269273|NCT04890678|Experimental|22 residentsat risk for PU development|"22 residents at risk for PU development, defined by a Braden score < 12 and/or a Braden subscale 'Mobility' score ≤ 2 and/or the presence of non-blanchable erythema in the sacral area.
~aged 65 years or over"
16269274|NCT04890678|Experimental|18 residents at least one PU category III-IV in the sacral area|18 residents at least one PU category III-IV in the sacral area aged 65 years or over
16269275|NCT04890665|Experimental|Experimental: Self-applied psychological intervention for healthcare workers|Participants in this group will receive 9 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, stress, burnout, fatigue compassion, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life. The participants will have the option to do 3 extra modules that are complimentary for the intervention.
16269276|NCT04890665|Active Comparator|Control: Self-applied psychological intervention for healthcare workers|The participants in this group will receive exactly the same intervention but delivered through a therapist in a weekly session through an online video call. The participants will be informed also about the 3 extra modules and briefly what it is the contents of these modules so they can accept or not receive these extra contents.
16269277|NCT04890652|Other|Risky drinkers|All participants will receive the same 4 week intervention.
16269278|NCT04890639|Experimental|AIH group|Hypoxia will be administered by a specialized face mask which controls oxygen content in inhaled air while breathing into a gas mixing device (HYP123, Hypoxico Inc).The hypoxia administering unit will be manually adjusted to reach the targeted level (approximately 21%-normal oxygen, 17%, 13%, and 9%) for each of the four sessions. These hypoxia sessions consist of breathing in normal air followed by 15 cycles of hypoxia for up to 60 seconds combined with 90 second room air breaths between hypoxic sessions. An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered (MAX-250E, Maxtec Inc.).
16269279|NCT04890626|Experimental|Main randomization.Arm: Emtricitabine / Tenofovir disoproxil fumarate|Emtricitabine / Tenofovir disoproxil fumarate
16269280|NCT04890626|No Intervention|Main randomization.Arm: No treatment|No treatment
16269281|NCT04890626|Other|Rescue randomization: Arm: Dexamethasone + Baricitinib|Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
16269282|NCT04890626|Other|Rescue randomization: Arm: Dexamethasone|Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
16269283|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
16269284|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
16269285|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
16269286|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
16269287|NCT04890587|Experimental|AL8326|"Part 1:(closed)Cohort 1 will initiate with AL8326 for single dose and multiple dose (28-Day cycles) . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, several additional cohorts will be sequentially for the same 28-day cycles.
~Part 2 :(open)Each subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.
~Part 3:(open)Cohort 3 will initiate with AL8326(bid), for 28-Day cycles . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at decreased dose of AL8326 for the same 28-day cycles."
16269288|NCT04890561|Experimental|Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1.
16269290|NCT04890535|Active Comparator|Part 1 Dose Level 1: 25 mg TBAJ-587|25 mg TBAJ-587
16269291|NCT04890535|Placebo Comparator|Part 1 Dose Level 1: placebo|placebo
16269292|NCT04890535|Active Comparator|Part 1 Dose Level 2: 50 mg TBAJ-587|50 mg TBAJ-587
16269293|NCT04890535|Placebo Comparator|Part 1 Dose Level 2: placebo|placebo
16269294|NCT04890535|Active Comparator|Part 1 Dose Level 3: 100 mg TBAJ-587|100 mg TBAJ-587
16269295|NCT04890535|Placebo Comparator|Part 1 Dose Level 3: placebo|placebo
16269296|NCT04890535|Active Comparator|Part 1 Dose Level 4: 200 mg TBAJ-587, Part one food effect cohort|200 mg TBAJ-587, Part one food effect cohort
16269297|NCT04890535|Placebo Comparator|Part 1 Dose Level 4: placebo|placebo
16269298|NCT04890535|Active Comparator|Part 1 Dose Level 5: 400 mg TBAJ-587|400 mg TBAJ-587
16269299|NCT04890535|Placebo Comparator|Part 1 Dose Level 5: placebo|placebo
16269300|NCT04890535|Active Comparator|Part 1 Dose Level 6: 800 mg TBAJ-587|800 mg TBAJ-587
16269306|NCT04890535|Active Comparator|Dose Level 3: XXX mg TBAJ-587|XXX mg TBAJ-587
16269307|NCT04890535|Placebo Comparator|Dose Level 3: placebo|placebo
16269308|NCT04890522|Experimental|Experimental group|5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days, and intravenous infusion of cisplatin 80 mg/m2 on day 1 and day 28, and intravenous infusion of JS001 240mg on day 1 and day 21, every 60 days.
16269309|NCT04890522|Active Comparator|Control group|gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1, and intravenous infusion of JS001 240mg on day 1, every 21 days.
16269310|NCT04890509|Experimental|Standard of Care + Bemcentinib|Bemcentinib will be administered for up to 15 days, or until discharge from hospital, whichever comes sooner. SoC will be administered based on local guidelines.
16269311|NCT04890509|Active Comparator|Standard of Care|The SoC will be administered based on local guidelines in place at the time of treatment during the study.
16269312|NCT04890496||inpatients of ZOC|Patients have retrospective hopitalization record of ZOC from 1998 to 2020.
16269313|NCT04890483|Experimental|Intervention|The ARD patients with post-acute COVID-19 will receive tDCS sessions for one week.
16269314|NCT04890470|Experimental|oxytocin group|subjects with oxytocin treatment
16269315|NCT04890470|Experimental|vasopressin group|subjects with vasopressin treatment
16269316|NCT04890470|Placebo Comparator|placebo group|subjects with placebo treatment
16269317|NCT04890457|Experimental|Tragus then earlobe stimulation|
16269318|NCT04890457|Experimental|Earlobe then tragus stimulation|
16269319|NCT04890431|Experimental|Oxygen|
16269320|NCT04890431|Placebo Comparator|Placebo|
16269321|NCT04890418|Active Comparator|Study drug|0.3 mg/kg intravenous ketamine diluted into 10mL saline after the realization of peripheral nerve block (PNB), before tourniquet set up and beginning of surgery
16269322|NCT04890418|Placebo Comparator|Placebo|10 mL 0.9% saline after the realization of PNB, before tourniquet set up and beginning of surgery
16269323|NCT04890405|Active Comparator|FMT group|Standardized FMT once.Extract all the flora from the feces provided by the donor to make fecal bacteria transplant capsules. The patient took orally on an empty stomach, each time using 3.2g of fecal bacteria.
16269324|NCT04890405|Experimental|JZ group|1.6g Po perday,for 28 days. probiotics that are effective against diarrhea were selected to make precise flora capsules, which are taken when the patient is on an empty stomach, once a day, using 1.6 g of bacteria per day, orally for 28 consecutive days.
16269325|NCT04890392|Experimental|PD-1 with SOX|S-1: 40~60mg Bid，d1~14, q3w Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w
16269326|NCT04890379|Experimental|standard management plus Dimethyl Fumarate|
16269327|NCT04890379|Placebo Comparator|standard management plus placebo|
16269328|NCT04890366|Experimental|Alteplase plus Dimethyl Fumarate|
16269329|NCT04890366|Placebo Comparator|Alteplase plus placebo|
16269330|NCT04890353|Experimental|standard management plus Dimethyl Fumarate|
16269331|NCT04890353|Placebo Comparator|standard management plus placebo|
16269332|NCT04890340||Women in age 35 to 65 with suspected breast cancer|Women in age 35 to 65 with suspected breast cancer, previously untreated. Additionally, eligible patients should have appropriate mammography results, either breast ultrasound or breast MRI.
16269333|NCT04890340||Healthy Volunteers|Healthy woman in age 35 to 65.
16269334|NCT04890327|No Intervention|Standard of Care|Patient presents to new Gynecologic Oncology appointment, family health history is collected by the physician during the clinic visit. Both the subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
16269335|NCT04890327|Experimental|Office|Patient presents to new Gynecologic Oncology appointment, subject is given access to a desk top computer in office and instructed to complete web-based family health history tool. Physician reviews results of patients web-based family health history tool.Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
16269336|NCT04890327|Experimental|Home|Patient is emailed a link containing web-based family health history tool prior to presenting for new Gynecologic Oncology appointment. Physician reviews results of patients web-based family health history tool. Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
16269337|NCT04890314||Active Surveillance (AS)|Doctor will monitor the patient without directly treating the cancer.
16269338|NCT04890314||Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment of prostate cancer requiring less than 2 weeks of treatment.
16269339|NCT04890314||Intensity-Modulated Radiation Therapy (IMRT)|Radiation treatment of prostate cancer requiring more than 2 weeks of treatment.
16269340|NCT04890314||Partial Gland Ablation (PGA)|Prostate cancer treatment that involves only treating part of the prostate that has cancer. Examples include, but are not limited to, high intensity focused ultrasound (HIFU) and cryotherapy.
16269341|NCT04890314||Radical Prostatectomy (RP)|Prostate surgery that removes the whole prostate.
16269342|NCT04890301|Experimental|Puncture Template and CT group|Puncture Template assisted CT guided lung biopsy was performed.
16269343|NCT04890301|Active Comparator|CT group|Simple CT guided lung biopsy was performed.
16269344|NCT04890288|Experimental|Intervention group - High flow|High-flow nasal cannula oxygen 2L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic oxygenation during laryngoscopy.
16269345|NCT04890288|Experimental|Intervention group - Low flow:|Low-flow oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.
16295142|NCT04710251|Active Comparator|Colonoscopy with the speedometer|
16269346|NCT04890288|No Intervention|Conventional|Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of 1.0, followed by bag mask ventilation after induction before oral intubation without apneic oxygenation.
16269347|NCT04890275|Experimental|BFR|Participants will participate in a supervised low load lower body blood flow restriction resistance exercise program twice a week for 12 weeks
16269348|NCT04890275|Active Comparator|NON-BFR|Participants will participate in a supervised low load lower resistance exercise program twice a week for 12 weeks (matched training volume as experimental arm but without BFR)
16269349|NCT04890262||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) treatment in line with current Summary of Product Characteristics (SmPC) or local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
16269350|NCT04890249|Experimental|Investigational Lens Device #1|Investigational IOL Model C1V000
16269351|NCT04890249|Experimental|Investigational Lens Device #2|Investigational IOL Model C2V000
16269352|NCT04890249|Active Comparator|Control Lens|Control IOL Model ICB00
16269353|NCT04890236|Experimental|Treatment (duvelisib)|Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.
16269354|NCT04890223|Experimental|Intervention group|The participants in the intervention group will be asked to identify an unfavourable behaviour that they wish to change when filling out the baseline questionnaire. The research nurse will conduct the individual face-to-face brief MI interviews for this purpose, which will last for approximately five to ten minutes. After the face-to-face brief MI interviews, the participants in the intervention group will receive brief MI messages individually by means of mobile instant messaging for six months from the baseline. After six months, the brief MI messages will cease to be delivered to the participants in the intervention group, with whom the research team will then maintain only minimal contact until the 12-month follow-up.
16269355|NCT04890223|Placebo Comparator|Control group|Participants in the control group will be asked to identify an unfavourable behaviour that they want to change at the baseline but, rather than brief MI interviews delivered face-to-face, received generic health advice consultations on the selected unfavourable behaviour that lasted approximately five to ten minutes. Each participant will receive a self-help smoking cessation booklet titled Be Smart, Quit Smoking! published by the Hong Kong Council on Smoking and Health with information about the negative health consequences of smoking, reasons to quit, strategies for quitting, and smoking cessation services available in Hong Kong along with a public quitline number (specifically, 1833183). Those who express the intention to quit at follow-ups will receive usual smoking cessation support.
16269356|NCT04890210|Experimental|Early Diet Group|"1st diet: 100 ml of clear fluid (1 hour after esophageal variceal ligation)
~2nd diet: 100 ml of clear fluid (4 hours after the 1st diet)
~3rd diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 4 hours after the 2nd diet
~4th diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 3rd diet
~5th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 4th diet
~6th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 5th diet
~7th diet: soft rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 6th diet
~8th diet: regular rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 7th diet"
16269357|NCT04890210|Active Comparator|Late Diet Group|"1st diet : 100 ml of clear fluid (6 hours after esophageal variceal ligation)
~After the 1st diet (Day 1): 6x100 ml of clear fluid for 24 hours
~Day 2: soft porridge (the amount will be calculated according to patient's caloric needs) for 24 hours
~Day 3: porridge (the amount will be calculated according to patient's caloric needs) for 24 hours
~Day 4: soft rice (the amount will be calculated according to patient's caloric needs) for 24 hours
~Day 5: regular rice (the amount will be calculated according to patient's caloric needs) for 24 hours and beyond"
16269358|NCT04890197|Active Comparator|tahini|48 gr per day
16269359|NCT04890197|Placebo Comparator|control|no intervention
16269360|NCT04890184|Active Comparator|grape juice|100 g of grape juice daily
16269361|NCT04890184|Placebo Comparator|control|no dietary intervention
16269362|NCT04890171|Active Comparator|Endoscopic treatment arm|Endoscopic submucosal dissection
16269363|NCT04890171|Active Comparator|Surgical treatment group|Gastrectomy with lymph node dissection
16269364|NCT04890158|Experimental|Prone positioning for a total of 6 hours daily by study protocol|Patients will be positioned prone for 3 hours then placed supine for 3 hours then prone again for 3 additional hours. The change in position from prone t osupine and back is to more reliably document possible changes in ventilation, oxygenation, other vital signs and respiratory support required.
16269365|NCT04890158|No Intervention|usual positioning|"Patients in the newrbon intensive care unit are physically handled usually every 3-4 hours. Those study participants who are radomly assigned to usual position may rest in a variety of positions in any order based on nursing or perceived patient preference. Positions may include supine, right lateral, left lateral, and prone as well."
16269366|NCT04890145|Experimental|Mild to severe hearing loss|
16269367|NCT04890132|Experimental|Normal Controls|normal control participants - no history of neurologic or inner ear disease
16269368|NCT04890132|Experimental|Peripheral Vestibular Dysfunction|"Patients with unilateral vestibular damage due to monophasic illness such as vestibular neuritis or vestibular schwannoma (VS).
~For VS patients, the investigators will test them in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months)."
16269369|NCT04890106|Experimental|Bimatoprost 0.01% Ophthalmic Solution|"Bimatoprost Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Mankind Pharma Limited, India.
~Intervention Drug: Test - Bimatoprost 0.01% Ophthalmic Solution"
16269370|NCT04890106|Active Comparator|LUMIGAN® 0.01% Ophthalmic Solution|"LUMIGAN® ( Contains Bimatoprost) Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Allergan, Inc.,
~Intervention Drug: Reference - Bimatoprost 0.01% Ophthalmic Solution"
16269373|NCT04890080|Experimental|PR Group|Patients diagnosed with COPD according to GOLD and completed the 2-day / 8-week PR program
16269374|NCT04890067||Localized Osteosarcoma|This cohort include patients affected by localized Osteosarcoma, referred to participating Institutions.
16269375|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 1|In year 1, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
16269376|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 2|In year 2, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
16269377|NCT04890041|Experimental|Treatment group|20 subjects will be enrolled with the indicated treatment dose of avatrombopag
16269378|NCT04890028|Experimental|F-DOPA PET/CT|Drug: 18 F-DOPA Radiation: F-DOPA PET CT
16269379|NCT04890015|Experimental|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
16269380|NCT04890015|No Intervention|Non intraoperative transanal decompression tube placement|The usual postoperative care approved by the unit will be followed.
16269381|NCT04890002|Experimental|Far-infrared emitting pyjamas (FIR pyjamas) group|Subjects in this group will be provided the Far-infrared emitting pyjamas. The FIR pyjamas was fabricated by using two textile materials, pure cotton fibres and the proposed man-made FIR fibres with the far-infrared emitting function.
16269382|NCT04890002|Sham Comparator|Sham-pyjamas Group|To control the placebo effect in the FIR pyjamas group, participants in this group will receive pyjamas with identical physical appearance which are produced using the same fabrication process as the pyjamas received in FIR pyjamas group. The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function. The participants will be asked to wear the sham-pyjamas daily at night for 6 consecutive weeks.
16269383|NCT04889989|Other|Microwave Ablation of Lung Tumor|Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors who plan to receive percutaneous microwave ablation.
16269384|NCT04889976|Experimental|Double-active|Active home-use transcranial direct current stimulation (tDCS) and active app-based behavioral therapy (BT).
16269385|NCT04889976|Active Comparator|tDCS-only|Active home-use transcranial direct current stimulation (tDCS) and sham app-based behavioral therapy (BT).
16269386|NCT04889976|Sham Comparator|Double-sham|Sham home-use transcranial direct current stimulation (tDCS) and sham app-based behavioral therapy (BT).
16269387|NCT04889963|Placebo Comparator|control group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)
16269388|NCT04889963|Active Comparator|conditioned medium group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium
16269389|NCT04889963|Active Comparator|stem cells group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition
16269390|NCT04889963|Experimental|composite group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium
16269391|NCT04889950|Experimental|Tixel Group|Tixel C Group: Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
16269392|NCT04889950|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits, Treatment- 1 single treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
16269394|NCT04889924|Experimental|Axillary radiotherapy without lymphadenectomy|Axillary radiotherapy (level I and II) + level III and supraclavicular +/- internal mammary chain without lymphadenectomy
16269395|NCT04889924|Active Comparator|Axillary lymph node dissection|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
16269396|NCT04889911|Experimental|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a structured, 20-session group-based treatment called that combines psychoeducation, cognitive restructuring, and elements of narrative psychotherapy. NECT-YA will be modified to meet the needs of people who have experienced an FEP and may have fewer sessions or be provided in individual format or via telehealth for this study. NECT-YA will be offered to participants who are also receiving treatment within Coordinated Specialty Care programs for First Episode Psychosis.
16269397|NCT04889911|Active Comparator|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based treatment for FEP that includes multiple treatment components. The FEP programs in at the recruiting site follow the Coordinated Specialty Care model.
16269398|NCT04889898|Experimental|ALS Patients|All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
16269399|NCT04889898|Experimental|Listeners|Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
16269400|NCT04889885|Experimental|High-intensity laser therapy (HILT)|The participants in the intervention group were treated by HILT which was applied to the knee joint (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
16269401|NCT04889885|Sham Comparator|Sham laser|The control group received a sham laser by the same laser machine (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
16269404|NCT04889859|Active Comparator|long RL group|long Roux limb Roux-en-Y reconstruction
16269405|NCT04889859|Experimental|long BPL group|long biliopancreatic limb Roux-en-Y reconstruction
16269626|NCT04888247|Experimental|Treatment|Trans-septal mitral valve replacement
16269408|NCT04889833|Experimental|Hypnosis Therapy Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a pre-recorded video (~19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Before & after the video, they will rate pain/anxiety levels. On the day of surgery, they will watch the video again & answer questions about their average anxiety and pain level. After surgery, they will watch the video each day and report on pain/anxiety, medication use, satisfaction, and sleep disturbance until postoperative day 7. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication & study doctor will be the same as any shoulder arthroplasty patient regardless of study participation.
16269409|NCT04889833|No Intervention|Usual Care Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a daily questionnaire about their pain & anxiety over the last 24 hours. On the day of surgery, before they are given any anesthesia, they will answer questions about their average anxiety & pain levels. Starting the next morning on the day following surgery and every day for the subsequent week, they will be given questionnaires about their pain & anxiety levels, medication use, satisfaction, and sleep disturbance due to pain. Their postoperative course will be otherwise completely standard of care, including a first postoperative clinic visit at 10 days after surgery, where the patients will be given these same questionnaires. Finally, patients will answer them one more time on postoperative day 49 and this will constitute a study endpoint. The whole process each day should take approximately 10 minutes.
16269410|NCT04889820|Active Comparator|The Control group|- The patients who are assigned into control group take a curative surgery within 2 weeks after successful SEMS placement. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during 6 months (total 12 cycles).
16269411|NCT04889820|Experimental|The Experimental group|- The patients who are assigned into the experimental group take a neoadjuvant FOLFOX chemotherapy within 2 weeks after successful SEMS placement. After three cycles of FOLFOX, they will take a curative surgery. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during about 4 months (total 9 cycles). The perioperative FOLFOX chemotherapy in the experimetal group will be totally 12 cycles during 6months.
16269412|NCT04889807||Patients who need fluid perfusion|
16269413|NCT04889794|Experimental|Exposed FMGs to GPS intervention|Patients who are followed by FMGs exposed to the GPS intervention. They will receive the GPS intervention.
16269414|NCT04889794|No Intervention|Non exposed FMGs to GPS intervention|Patients who are part of the FMGs not exposed to the GPS intervention. They will receive the usual care and services.
16269415|NCT04889781|Experimental|Rotatory Instruments without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy without Intramuscular Dexamethasone injection
16269416|NCT04889781|Experimental|Rotatory Instruments with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
16269417|NCT04889781|Experimental|Piezosurgery technique without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique without Intramuscular Dexamethasone injection
16269418|NCT04889781|Experimental|Piezosurgery technique with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
16269419|NCT04889768|Experimental|Experimental: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"surgical exploration, if PCI<20, then we perform this study.
~HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.
~Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.
~Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.
~After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
16269420|NCT04889755|Other|SibACCESS|This is a single-arm trial of a group-based, posttraumatic stress intervention for adolescent siblings of children with cancer. The intervention includes one parent session and seven bi-weekly sibling sessions.
16269627|NCT04888234|Experimental|Treatment group|The treatment group receive topical treatment of Ru-Yi-Jin-Huang Powder.
16269628|NCT04888234|No Intervention|Control group|The control group receive regular management for radiation-induced dermatitis.
16269421|NCT04889742|Experimental|Hyperthermia|Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.
16269422|NCT04889729||GENOMED4ALL - MDS patients|Information on targeted mutation screening (NGS including 60 genes related to MDS) from 8200 MDS patients
16269423|NCT04889716|Experimental|Cohort 1|Participants receive mosunetuzumab 60 mg for cycles 1 and 2 (although fractionated for cycle 1), and 30 mg for all subsequent cycles after standard-of-care therapy with CD19-directed CAR T-cells
16269424|NCT04889716|Experimental|Cohort 2|Participants receive obinutuzumab (1000 mg for each subject) and glofitamab after standard-of-care therapy with CD19-directed CAR T-cells. The dose of glofitamab for each subject will be 30 mg, other than for cycle 1, which will be 12.5 mg glofitamab fractionated over two weeks.
16269425|NCT04889703|Experimental|15% Trichloroacetic acid (TCA) chemical peel|15% trichloroacetic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
16269426|NCT04889703|Experimental|30% Salicylic acid chemical peel|30% salicylic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
16269427|NCT04889690|Experimental|Cohort 1: 200 mg|All participants under fasted conditions received 200 mg of danicopan or placebo twice daily (BID) over a 14-day period.
16269428|NCT04889690|Experimental|Cohort 2: 500 mg|All participants under fasted conditions received 500 mg of danicopan or placebo BID over a 14-day period.
16269429|NCT04889690|Experimental|Cohort 3: 800 mg|All participants under fasted conditions received 800 mg of danicopan or placebo BID over a 14-day period.
16269430|NCT04889690|Experimental|Cohort 4: 75 mg|All participants under fasted conditions received 75 mg of danicopan or placebo thrice daily (TID) over a 7-day period.
16269431|NCT04889677|Experimental|Group 1: 200 mg|All participants (fasted) received either 200 mg of danicopan as a single oral dose or dose-matched placebo.
16269432|NCT04889677|Experimental|Group 2: 600 mg|All participants (fasted) received either 600 mg of danicopan as a single oral dose or dose-matched placebo.
16269433|NCT04889677|Experimental|Group 3: 1200 mg|All participants (fasted) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
16269434|NCT04889677|Experimental|Group 4: 2400 mg|All participants (fasted) received either 2400 mg of danicopan administered as 2 single doses of 1200 mg each, 12 hours apart, or dose-matched placebo.
16269435|NCT04889677|Experimental|Group 5: 1200 mg|All participants (fed) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
16269436|NCT04889664|Experimental|Ketamine and Written Exposure Therapy|Intravenous Ketamine 0.5 mg/kg and Written Exposure Therapy
16269437|NCT04889651|Experimental|A(TRTR)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).
~* Sequence A: T-R-T-R
~T: BR9004, oral single-dose administration, 1 tablet per day
~R: BR9004-1, oral single-dose administration, 1 tablet per day
~Washout interval between periods: 7 days"
16269438|NCT04889651|Experimental|B(RTRT)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).
~* Sequence B: R-T-R-T
~T: BR9004, oral single-dose administration, 1 tablet per day
~R: BR9004-1, oral single-dose administration, 1 tablet per day
~Washout interval between periods: 7 days"
16269439|NCT04889638|Experimental|Cessation intervention|Participants will undergo pre-/post-comparisons of a personalized, remote smoking cessation intervention composed of two main elements: a) prescription and monitoring of nicotine (e.g., replacement therapy) and/or non-nicotine pharmacotherapies (e.g., varenicline) and b) cessation-centered motivational messaging.
16269440|NCT04889612|Experimental|motor coordination and grip strength in dominant/non-dominant hand|Dominant and non-dominant hand motor coordination and grip strength were tested in the stable position of the trunk and the upper arm, in post-stroke patients (study group) and in healthy subjects (control group).
16269441|NCT04889599|Experimental|BH009 (Docetaxel Injection)|Patients will receive single dose BH009 75 mg/m2, as a 1-hour IV infusion.
16269442|NCT04889599|Active Comparator|Docetaxel Injection|Patients will receive single dose Docetaxel Injection 75 mg/m2, as a 1-hour IV infusion.
16269443|NCT04889586|Experimental|Experimental Group|The subjects were clinically assessed with a define clinical protocol. After that, the subjects executed the device test with EMG-biofeedback wearable armband.
16269445|NCT04889560|Experimental|Experimental group|Experimental group receives Home CoRe (Home CoRe Group)
16269446|NCT04889560|Other|Control group|Control group receives CoRe software (CoRe Group)
16269447|NCT04889547|Experimental|Dexamethasone|Patient will receive intraoperative dexamethasone during distal radius open reduction and internal fixation
16269448|NCT04889547|Placebo Comparator|No dexamethasone|Patient will not receive intraoperative dexamethasone during distal radius open reduction and internal fixation
16269449|NCT04889521||HIV and painful neuropathy|Persons living with HIV who also have painful distal sensory polyneuropathy in the feet.
16269450|NCT04889521||HIV without painful neuropathy|Persons living with HIV who do NOT have painful distal sensory polyneuropathy in the feet.
16269451|NCT04889508|Experimental|Socio-emotional mental training|The socio-emotional intervention will consist of 10 weeks of daily Affect Dyad practice with a partner.
16269452|NCT04889508|Experimental|Mindfulness-based mental training|The intervention will consist of 10 weeks of daily individual Breathing Meditation practice.
16270023|NCT04885452||Patients treated according to other ATU protocols for COVID-19|
16269453|NCT04889508|Other|Retest Control Group (Waitlist control)|"The retest control group, which is also a waitlist control group, will first not undergo an intervention, but will be tested prior to and after the 10-week period at Pre- and Post-test wherein other groups undergo the interventions.
~In a second step, the waitlist control group will then also undergo a 10-week period of socio-emotional intervention.
~During the first 10-week intervention period, this group will only be tested serving as a re-test control group. After Post-test, however, they will be given the chance to also enroll in a 10-week socio-emotional mental training with the exact same protocol as the socio-emotional intervention experimental group above.
~Both the experimental intervention arm groups will be given the possibility to continue their daily assigned practices (respective socio-emotional and mindfulness-based training exercises) after post-test for the duration of the 10-weeks during which the waitlist control group undergoes the socio-emotional intervention."
16269454|NCT04889495||Participants receiving Zirabev|Participants receiving Zirabev
16269455|NCT04889469||Breast hypertrophy operated|Women who have had a breast reduction in the public health care system
16269456|NCT04889469||Breast hypertrophy controls|Women with symptoms of breast hypertrophy, who do not fulfill the requirements to have a breast reduction in the public health care system
16269457|NCT04889469||Augmented controls|Patients who have breast hypertrophy due to cosmetic breast augmentation
16269458|NCT04889469||The general public|Random sample of the general public
16269459|NCT04889456|No Intervention|Surgical variations laparoscopic right hemicolectomy|
16269460|NCT04889456|Active Comparator|Implementing standardised laparoscopic right hemicolectomy with proctoring|
16269461|NCT04889456|Active Comparator|Implementing standardised laparoscopic right hemicolectomy without proctoring|
16269465|NCT04889391|Experimental|[14C]-Danicopan|Participants were administered a single oral dose of danicopan between 151 and 154 mg (nominal dose of 150 mg), providing approximately 100 μCi of [14C] radiolabel in the form of [14C]-danicopan.
16269466|NCT04889378||Pre-habilitation|participants will join prehabilitation with very low calories diet (800-1000kcal/day) and moderate intensive aerobic exercise (1 hour per section; 3 sections per day) for 2 weeks before bariatric surgery.
16269467|NCT04889365||COVID-19 positive, asymptomatic|COVID-19 positive, asymptomatic (i.e. no current symptoms of COVID-19, confirmed PCR positive for COVID-19)
16269468|NCT04889365||COVID-19 positive, symptomatic|COVID-19 positive, symptomatic (i.e. current symptoms of COVID-19, confirmed PCR positive for COVID-19)
16269469|NCT04889365||COVID-19 negative|COVID-19 negative (i.e. no current or previous symptoms of COVID-19, confirmed PCR negative for COVID-19)
16269470|NCT04889352|Experimental|Access to colonoscopy web app|Ten individual endoscopy physicians (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the intervention group where they are provided access to an application which indicates recommended timing of follow-up colonoscopy given values for various entered factors. In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). Access to the application will be password-protected, thereby avoiding exposure of the non-intervention group to the application. The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.
16269471|NCT04889352|No Intervention|Control|Ten individual endoscopy physicians (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the group where they are not provided access to the application (control group).
16269472|NCT04889339|Experimental|Test group: Braces designed with growth modulation simulation|The braces will be designed using a growth modulation method.
16269473|NCT04889339|Active Comparator|Control group: Conventional method|The braces will be designed by an orthotist without growth modulation simulation.
16269474|NCT04889326||patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination|
16269475|NCT04889300|Experimental|Best Possible Self|Positive affect and optimism will be induced through the Best Possible Self (BPS) Intervention. In the optimism intervention, participants will be asked to imagine a future in which everything went well and in which all their wishes are fulfilled. This procedure is known to reliably generate positive affect and positive future expectations (Carrillo et al., 2019). Orientated at Flink et al. (2015) the BPS condition was adapted for a pain population.
16269476|NCT04889300|Active Comparator|Typical Day|In the control condition, participants are asked to describe and visualize a typical day (TD). We adapted the TD condition in order to take possible changes in participants´ TD due to the COVID-19 pandemic into account.
16269477|NCT04889287|Experimental|Rosuvastatin and/or elinzanetant|The participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.
16269478|NCT04889274|Experimental|Part A: Male healthy volunteers|
16269479|NCT04889274|Experimental|Part A: Female healthy volunteers|
16269480|NCT04889274|Active Comparator|Part B: Nitrate-rich beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) containing ~5mmol of inorganic nitrate
16269481|NCT04889274|Placebo Comparator|Part B: Nitrate-deplete beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted
16269482|NCT04889248|Experimental|Intervention|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual
16269483|NCT04889248|No Intervention|Control|Without inspiratory muscle training. Treatment as usual.
16269484|NCT04889235||Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
16269485|NCT04889235||No Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
16269501|NCT04889196|Active Comparator|control group|The group that have caries in primary molars and treat them with hall technique
16269502|NCT04889196|Experimental|experimental group|the group that have caries in primary molars and treat them with silver diamine fluoride (SDF) solution would exert a prevention result in managing early childhood caries ECC
16269503|NCT04889183|Experimental|Semaglutide|Patients will be treated with semaglutide 3 mg/ml s.c. once weekly for 24 weeks. The starting dose of semaglutide will be 0.24 mg subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg once weekly.
16269504|NCT04889183|Placebo Comparator|Placebo|Patients will receive a matching placebo s.c. once weekly.
16269505|NCT04889170||Biofeedback therapy + Voice training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
16269506|NCT04889170||Biofeedback therapy + Swallow training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
16269507|NCT04889157|Experimental|PF-06882961|Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
16269509|NCT04889144|Experimental|PLAN intervention|PLAN is a manualized three session intervention designed to improve engagement in advance care planning. It consists of five modules, covering the following for advance care planning: (1) checking awareness of core concepts; (2) clarifying misconceptions; (3) knowledge transferring; (4) goal setting; and (5) rehearsal or communication of advance care planning to loved ones and doctors. All sessions are delivered by a trained and licensed social worker. Patients also receive a 47-page manual to guide them through the intervention.
16269510|NCT04889144|No Intervention|Control condition|Usual, standard care.
16269511|NCT04889131|Experimental|Yoga Program|12-week yoga program begins immediately
16269512|NCT04889131|Active Comparator|Wait-list Control|Wait-listed to take the Yoga Program in 12-weeks time
16269513|NCT04889118|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
16269514|NCT04889118|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
16269515|NCT04889105|Other|Performance evaluation|Preliminary performance evaluation to refine the Smart MOVE! intervention.
16269516|NCT04889105|Active Comparator|Smart MOVE!|Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.
16269517|NCT04889105|Placebo Comparator|Usual care|Participants will receive general walking advice for 12 weeks.
16269518|NCT04889092|Experimental|blood flow restriction exercise|8 weeks (20 sessions) of blood flow restriction knee extension/flexion exercise
16269519|NCT04889092|Active Comparator|traditional resistance exercise|8 weeks (20 sessions) of traditional knee extension/flexion resistance exercise
16269520|NCT04889079||Adolescent females, aged 15-18|Adolescents females aged 15-18, who selected a contraceptive implant to prevent pregnancy.
16269521|NCT04889079||Adolescent females, aged 19-24|Adolescents females aged 19-24, who selected a contraceptive implant to prevent pregnancy.
16269522|NCT04889066|Active Comparator|Durvalumab and standard fSRT|Fractionated stereotactic radiotherapy (fSRT) will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 fractions total, delivered every other day (~2 times/week) with first cycle of Durvalumab
16269523|NCT04889066|Experimental|Durvalumab and PULSAR|Personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR), will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 fractions total, delivered once monthly with each cycle of Durvalumab.
16269524|NCT04889053||D2M, Vascular calcification-free|Meet the inclusion criteria, there is no calcification detected by low dose prospectively triggered sequential dual-source CT coronary angiography
16269525|NCT04889053||D2M with vascular calcification|Meet the inclusion criteria, and have coronary artery calcification ( be confirmed by low dose prospectively triggered sequential dual-source CT coronary angiography)
16269526|NCT04889040|Experimental|RO7496998 (AT-527)|Orally administered, 550 mg twice daily (BID) for 5 days
16269527|NCT04889040|Placebo Comparator|Placebo|The dose and regimen of the placebo will match that of AT-527.
16269528|NCT04889014|Active Comparator|Personal genomic educational testing (PGET)|PGET group participants received their own pharmacogenomic testing results prior to the course modules covering material tested in the knowledge assessment
16269529|NCT04889014|Placebo Comparator|No personal genomic educational testing (NPGET)|No PGET (NPGET) group participants did not receive their own pharmacogenomic testing results until after study completion.
16269530|NCT04889001|Other|Before/After|Before and after comparison- one arm study
16269531|NCT04888988|Experimental|Arm 1 (EXCAP exercise)|Patients undergo the EXCAP exercise intervention consisting of a home-based, self-directed, individually tailored progressive walking and resistance program for up to 6 weeks. In addition, patients meet with a certified exercise instructor over 45 minutes at baseline and 2 additional booster meetings over 15-30 minutes during weeks 2 and 3 or weeks 4 and 5.
16269532|NCT04888988|No Intervention|Arm 2 (usual care)|Patients receive usual care for 6 weeks. At the end of the study, patients may receive the exercise kit and complete the EXCAP program as in Arm 1.
16269533|NCT04888975|Experimental|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery
16269534|NCT04888962||Prospective cohort group|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
16269535|NCT04888962||Control group|This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
16269536|NCT04888949|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
16269537|NCT04888949|Placebo Comparator|Placebo|Saline
16269541|NCT04888910||asthma with nasal polyps|severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)
16269542|NCT04888910||severe asthma without nasal polyps|severe asthma without involvement of the upper airways
16269543|NCT04888871||Only Fundal Pressure (Kristeller Maneuver)|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Only Fundal Pressure (Kristeller Maneuver) and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
16269658|NCT04888013|Experimental|experimental 1|Building childbirth environment and labor delivery recovery room
16269544|NCT04888871||Only Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying only vacuum extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
16269545|NCT04888871||Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
16269546|NCT04888858|Experimental|Epidural Analgesia|All subjects will be given epidural analgesia to treat their labor pain. As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
16269547|NCT04888845|Active Comparator|Structured interview and Safety Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
16269548|NCT04888845|Active Comparator|Structured interview and Crisis Response Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
16269549|NCT04888845|Active Comparator|Narrative assessment and Safety Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk."
16269550|NCT04888845|Active Comparator|Narrative assessment and Crisis Response Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation."
16269551|NCT04888832|No Intervention|Control Group|No change to work requirements or recertification period
16269552|NCT04888832|Active Comparator|Intervention Group 1|Standard 6-month recertification period, additional 6-month work requirement exemption
16269553|NCT04888832|Active Comparator|Intervention Group 2|Standard 6-month recertification period, additional 12-month work requirement exemption
16269554|NCT04888832|Active Comparator|Intervention Group 3|Standard 6-month recertification period, additional 12-month work requirement exemption
16269555|NCT04888832|Active Comparator|Intervention Group 4|12-month recertification period (6-month extension), additional 6-month work requirement exemption
16269556|NCT04888819|Experimental|fed state group|just after a meal
16269557|NCT04888819|Experimental|fasted state group|before a meal
16269558|NCT04888806|Experimental|Camrelizumab+ablation +chemotherapy|The enrolled patients received ablation of liver metastases/pulmonary metastasis first, followed by chemotherapy (standard treatment plan for advanced colorectal cancer, determined by the investigator) and camrelizumab treatment (200mg, iv, q3w) one week later. If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times. Sequential chemotherapy and camrelizumab is administered one week after each ablation therapy. Treatment will continue until disease progression, unacceptable toxicity, or voluntary patient withdrawal.
16269559|NCT04888793||Cancer Patients on active treatment|
16269560|NCT04888793||Bone marrow transplant patients|
16269561|NCT04888793||Solid organ transplant recipients|
16269562|NCT04888793||HIV patients|
16269563|NCT04888793||Rheumatic disease patients|
16269564|NCT04888793||Healthy controls|
16269565|NCT04888780|Experimental|Experiment adolescent group|The web-based Watson's Human Care Theory oriented training and support program are applied to the intervention group.
16269566|NCT04888780|No Intervention|Control adolescent group|No intervention is applied to the control group.
16269567|NCT04888767|No Intervention|Control group|Patients benefiting from the usual re-training sessions
16269568|NCT04888767|Experimental|ITHI Group|Patients benefiting from ITHI re-training sessions
16269569|NCT04888741|Active Comparator|Control Arm Thymoglobulin + Cyclosporine + MMF|"Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.
~Patients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.
~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
16269629|NCT04888221|Experimental|tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks|Tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks
16269630|NCT04888221|Placebo Comparator|placebo administered subcutaneously (SC) weekly during 24 weeks|Placebo administered subcutaneously (SC) weekly during 24 weeks
16269631|NCT04888208|Experimental|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
16269570|NCT04888741|Experimental|Experimental arm (PTCy + Cyclosporine + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.
~Patients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.
~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
16269571|NCT04888741|Experimental|Experimental arm (PTCy + Sirolimus + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.
~Sirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.
~MMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
16269572|NCT04888728|Experimental|DWN12088 and Nebivolol|Period 1 - Nebivolol A mg, Tablet, oral, once daily, Period 2 - DWN12088 X mg, Tablet, oral, twice daily, Period 3 - 1) Nebivolol A mg, Tablet, oral, once daily & DWN12088 X mg, Tablet, oral, twice daily, 2) DWN12088 X mg, Tablet, oral, once daily
16269573|NCT04888728|Experimental|DWN12088 and Paroxetine|Period 1 - DWN12088 X mg, Tablet, oral, once daily , Period 2 - Paroxetine B mg, Tablet, oral, once daily, Period 3 - 1) DWN12088 X mg, Tablet, oral, once daily & Paroxetine B mg, Tablet, oral, once daily, 2) Paroxetine B mg, Tablet, oral, once daily
16269574|NCT04888715|Experimental|DWN12088 and Pirfenidone|T1 - Pirfenidone A mg, Tablet, oral, once daily, T2 - 1) DWN12088 X mg, Tablet, oral, once daily, 2) DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Pirfenidone A mg, Tablet, oral, once daily
16269575|NCT04888715|Experimental|DWN12088 and Nintedanib|T1 - Nintedanib B mg, Tablet, oral, once daily, T2 - DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Nintedanib B mg, Tablet, oral, once daily
16269576|NCT04888702|Experimental|SMA patients|Patients with type 2 or 3 spinal muscular atrophy undergoing Spinraza° or risdiplam treatment.
16269577|NCT04888689|Experimental|MS patients|Ambulant patients with multiple sclerosis
16269578|NCT04888676|Experimental|Self- Adhesive Bulk fill Resin Composite ( Surefil one™ ,Dentsupply Sirona)|New Surefil one™ restorative Self-adhesive: no etching, bonding or cavity conditioning inserted in increments of up to 4 mm in thickness.
16269579|NCT04888676|Active Comparator|Bulkfill Resin Composite. (GrandioSO x-tra® bulk)|after selective etching of enamel and bonding, the bulk-fill composite resins are inserted in increments of up to 4 mm in thickness.
16269580|NCT04888663|Experimental|Study treatment|(Phase Ib part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel 80 or 70 mg/m2 IV (according to dose level) (Phase II part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel at RP2D (80 or 70 mg/m2 IV)
16269581|NCT04888650||angiodema hereditary patients|Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire
16269582|NCT04888637||All Subjects|MEG baseline session Receptive Language Task Memory Task
16269583|NCT04888624|Experimental|DrySee® dressing with moisture detection|DrySee® dressing with moisture detection
16269584|NCT04888624|Active Comparator|Tegaderm® + Pad transparent film dressing|Tegaderm® + Pad transparent film dressing
16269587|NCT04888598||Type 1 diabetic patients|Recently diagnosed type 1 diabetes patients
16269593|NCT04888559|Active Comparator|Whole grain breakfast product|
16269594|NCT04888559|Placebo Comparator|Reference|
16269595|NCT04888546|Other|Anlotinib hydrochloride capsules combined with TQB2450 injection|Anlotinib hydrochloride capsules (10mg po qd, Two weeks off for one week) combined with TQB2450 injection (1200mg ivgtt, q3W)
16269596|NCT04888533||All Patients evaluated by PESP during the trial period.|EHSSA tool applied to every patient in cohort.
16269632|NCT04888208|No Intervention|Control Arm|The control group will be offered sources of conventional health information (government and institutional websites) on a terminal located in the virtual world.
16269633|NCT04888195||Questionnaire|This study aims to examine the cancer patient's symptom clusters and their changes over chemotherapy among pediatric patients with blood cancer in Hong Kong
16269634|NCT04888182|Active Comparator|intervention|Individual nutritional guidance of a protein intake of ≥25 E%.
16269635|NCT04888182|No Intervention|control|Free diet
16269659|NCT04888000|Other|single|Educational intervention.
16269597|NCT04888520|Experimental|Tensioning protocol of the elastic bandage (WT)|The group will have progressive tension throughout the week - based on the reduction of the tape in relation to the size of the applied area (which will always be the same), which generates a longitudinal tension of the tape in relation to the participant's skin. The Therapy Tex® brand has the elastic deformation capability of up to 40%. The tensioning protocol of the elastic bandage will work with 20% of the elastic deformation capacity of the bandage. The tension will be given from point A to point B in order to generate excitatory stimuli. The percentage of 20% reduction in tension will be distributed over the 7 weeks of intervention, and the first week of the protocol included application without tension. The tape reduction will be controlled by the formula: (size of the application area on the skin*20% /7 weeks= size of the tape to be cut in each of the 7 applications starting from the second week. Tape size and tape application area will be calculated in centimeters (cm).
16269598|NCT04888520|Placebo Comparator|Free tension|The group will have no tension in any of its tape applications; that way the size of the tape over the applied area will always be the same.
16269599|NCT04888507|Experimental|Pozelimab+Cemdisiran|
16269602|NCT04888481|Experimental|68Ga-HA-DOTATATE PET/CT scan|2.64 MBq/kg (minimum 37 MBq, maximum 250 MBq) 68Ga-HA-DOTATATE intravenous single-dose administration for PET/CT imaging
16269603|NCT04888468|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
16269604|NCT04888455||Painful neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with probable or definite neuropathic pain according to the NeuPSIG algorithm.
16269605|NCT04888455||Painless neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with unlikely neuropathic pain according to the NeuPSIG algorithm.
16269606|NCT04888442|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
16269607|NCT04888429|Experimental|Camrelizumab + Famitinib|Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.
16269608|NCT04888416|Experimental|Acute care|Acute care practitioners who will receive the I-STROM intervention
16269609|NCT04888416|Experimental|Inpatient|Inpatient practitioners who will receive the I-STROM intervention
16269610|NCT04888416|Experimental|Outpatient|Outpatient practitioners who will receive the I-STROM intervention
16269611|NCT04888403|Experimental|Toripalimab combined with neoadjuvant radiotherapy and chemotherapy Single arm study|"Induction period:
~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.
~Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy."
16269612|NCT04888390|Experimental|Intervention group|The intervention group will receive multi-model exercise intervention 2-3 times per week for 3 months.
16269613|NCT04888390|Active Comparator|Usual care group|The Usual care group will receive heart failure disease and exercise-related education.
16269616|NCT04888351||Mastectomies with IBR|Every women>18 years who underwent mastectomies followed by IBR (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) for breast cancer in Hôpital de la Croix-Rousse between January 2016 and January 2020
16269617|NCT04888351||Mastectomies without IBR|Every women>18 years who underwent mastectomies for breast cancer followed by delayed reconstructions (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) or no reconstructions between January 2016 and January 2020 in Hôpital de la Croix-Rousse
16269618|NCT04888338||Observational (data collection)|Patients medical records are reviewed for details about CAR-T and RT treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. Patients' imaging scan data is collected at baseline, within 2 months of the first treatment of RT or CAR-T, and at 3, 6, 12 months, and then annually for 5 years after RT completion.
16269619|NCT04888325|Experimental|Oral glucose|ORal glucose consumption 1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours
16269620|NCT04888325|Experimental|Intravenous glucose|0% intravenous glucose infusion at a rate of 3.6 ml/kg/h
16269621|NCT04888312|Experimental|Intravenously administered mitazalimab given in combination with chemotherapy|Mitazalimab, a human monoclonal antibody targeting CD40, administered intravenously every 14 days, in combination with standard of care chemotherapy modified FOLFIRINOX.
16269622|NCT04888286||patients who underwent mismatched allogeneic transplantation|Pediatric and adult patients who underwent mismatched allogeneic transplantation, from January 2014 to June 2017.
16269623|NCT04888273|Experimental|All adolescents and parents who meet the eligibility criteria|The adolescents and parents will be invited to participate in a 5-component intervention that will hopefully empower and prepare the pair for the transition to adult care.
16269624|NCT04888260||Coronary Artery Disease Group|Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
16269625|NCT04888260||Control Group|The control group consisted of healthy people with normal coronary arteries angiographically
16269636|NCT04888169|Experimental|Attention Bias Modification - Word Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
16269637|NCT04888169|Active Comparator|Attention Bias Modification - Face Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
16269638|NCT04888169|Experimental|Attention Control Training - Word Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (i.e. one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
16269639|NCT04888169|Active Comparator|Attention Control Training - Face Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
16269640|NCT04888169|Placebo Comparator|Placebo Attention Training - Word Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral words) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
16269641|NCT04888169|Placebo Comparator|Placebo Attention Training - Face Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral faces) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
16269642|NCT04888169|Sham Comparator|Control - Questions|The Control - Questions condition will only deliver a set of daily questions for participants to answer. Questions will ask about a variety of psychological factors such as mood, stress experiences, daily exercise and more.
16269643|NCT04888156||GAT IOP below 15 mmHg|Glaucoma patients with an IOP measured with GAT below 15 mmHg prior performance of self-tonometry with iCare Home
16269644|NCT04888156||GAT IOP equal or above 15 mmHg|Glaucoma patients with an IOP measured with GAT equal or above 15 mmHg prior performance of self-tonometry with iCare Home
16269645|NCT04888130||Cases|This study comes following an outbreak signal that occurred in May 2020, after the detection of numerous cases of cutaneous leishmaniasis in military personnel probably contaminated during a training course (Training Center in the Equatorial Forest, CEFE) in the town of Regina. To date, around 40 cases have been detected.
16269646|NCT04888130||Controls|A case-control study can therefore be carried out using a questionnaire offered to all course participants over the 1st semester of 2020. The controls will then be participants who have not been infected. A comparison can also be made between the military personnel present in French Guiana during the first half of 2020 and having carried out missions in the forest, by opposing the participants and non-participants of the CEFE.
16269647|NCT04888117||Laparoscopic cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a laparoscopic cholecystectomy.
16269648|NCT04888117||Robotic-assisted cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a robotic-assisted cholecystectomy.
16269649|NCT04888091|Active Comparator|Cervical mucus removal with cotton swab|Cervical mucus will be removed with cotton swab before embryo transfer
16269650|NCT04888091|Active Comparator|Cervical mucus removal with cannula|Cervical mucus will be removed with cannula before embryo transfer
16269651|NCT04888091|No Intervention|No cervical mucus removal|Cervical mucus will not be removed prior to embryo transfer
16269652|NCT04888052|Experimental|Group 1|
16269653|NCT04888026|Experimental|Automated QST procedure|The QST robot will autonomously perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. All verbal information is giving through the computer
16269654|NCT04888026|Active Comparator|Manual QST procedure|The research assistant will perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. All tests are performed manually without using the robot.
16269655|NCT04888026|Active Comparator|Semi-automated QST procedure|The QST robot will with guidance from the research assistant perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. However and in contrast to the first arm, all verbal information and procedure guiding is given by a research assistant.
16269656|NCT04888013|Placebo Comparator|control group|Routine care for childbirth
16269657|NCT04888013|Experimental|experimental 2|Building childbirth environment
16269660|NCT04887987|Experimental|Lumbar strengthening training combined with LED PBMT (TR+LED)|Each participant will be submitted to a 16-wk lumbar strengthening training program and will receive the LED PBMT 30 minutes before each training session.
16269661|NCT04887987|Placebo Comparator|Lumbar strengthening training combined with placebo PBMT (TR+PLA)|Each participant will be submitted to a 16-wk lumbar strengthening training program and will receive the placebo PBMT 30 minutes before each training session.
16269662|NCT04887974|Experimental|Canine retraction|The canines will be retracted by extending short silver elastomeric chains between the power arms in the canine brackets and the TADs. The applied force will be checked and adjusted to 150 g.
16269663|NCT04887961|Experimental|Single Arm|PLD 30 mg/mq 1 h iv + Trabectedin 1.1 mg/mq 3 h iv d1q21 up to 6 cycles or PD.
16269664|NCT04887948|Experimental|Coadministration Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
16269665|NCT04887948|Active Comparator|20vPnC-only Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
16269666|NCT04887948|Active Comparator|BNT162b2-only Group|Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.
16269667|NCT04887935|Experimental|Dapagliflozin|"Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy
~Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy."
16269668|NCT04887922|No Intervention|Pre-Surgery: No Incentive Spirometry (IS)|-Will not receive a incentive spirometer prior to surgery
16269669|NCT04887922|Experimental|Pre-Surgery: Standard Incentive Spirometry (IS)|"Will receive a conventional spirometer prior to surgery
~Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery."
16269670|NCT04887922|Experimental|Pre-Surgery: Digital Incentive Spirometry (IS) + Text Message|"Will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.
~Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery. Absence of spirometry for 24 hours will trigger a text message reminder to encourage compliance with IS."
16269671|NCT04887922|Active Comparator|Post-Surgery: Standard Incentive Spirometry (IS)|"After surgery, the participants will receive a conventional spirometer.
~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3
~The conventional spirometer will be equipped with an accelerometer that will allow the research team to determine whether the spirometer moves throughout the patients' postoperative stay (as a proxy for IS use)"
16269672|NCT04887922|Experimental|Post-Surgery: Digital Incentive Spirometry (IS) + Text Message|"After surgery, the participants will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.
~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3
~Will receive text reminders to perform spirometry if they do not perform spirometry in a 24-hour period."
16269673|NCT04887896|Experimental|GS500 flexible dose|3, 2, or 4 GS500 capsules 2 times per day
16269674|NCT04887896|Placebo Comparator|Placebo flexible dose|3, 2, or 4 placebo capsules 2 times per day
16269675|NCT04887883||Males|10 young healthy biological males aged 18 - 30 y
16269676|NCT04887883||Females|10 young healthy biological females aged 18 - 30 y
16269677|NCT04887870|Experimental|Phase 2/3: Open label extension of parent study|The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
16269678|NCT04887857|Experimental|CC-486 in combination with Venetoclax in AML participants|Phase 1b dose-finding is designed to explore up to 4 combined dose levels of CC-486 (ONUREG, oral azacitidine) with venetoclax, using dose determination rules based on a Modified Toxicity Probability Interval (mTPI)-2 method. Phase 2 will open when MTD/RP2D has been reached in Phase 1b.
16269679|NCT04887844|Active Comparator|Group I|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per American College of Rheumatology (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
16269680|NCT04887844|Active Comparator|Group II|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
16269681|NCT04887844|Other|Group III|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
16269684|NCT04887818|Experimental|Topical diltiazem + lidocaine|
16269685|NCT04887818|Active Comparator|Topical nifedipine + lidocaine|
16269686|NCT04887805|Experimental|Treatment (pembrolizumab, lenvatinib mesylate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib mesylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16269689|NCT04887779|Experimental|Intervention|Patient viewing ex-planted organ and microscopy with pathologist
16269690|NCT04887766|Active Comparator|Active|GS300: Three (3) GS300 capsules [approximately 0.65 grams (g)] two (2) times per day ingested 10 minutes (min) before meals (i.e., lunch and dinner) - total of 3.9 g per day
16269691|NCT04887766|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day 10 min before meals (i.e., lunch and dinner)
16269692|NCT04887753|Experimental|persons with cerebellar lesions|
16269693|NCT04887753|Active Comparator|Healthy controls|
16269694|NCT04887727|Experimental|Healthy, recreationally-active adult males - Muscle Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine and L-ring-[2H5]phenylalanine with a primed-constant infusion of L-[555-2H3]leucine to assess myofibrillar protein synthesis rates
16269695|NCT04887727|Experimental|Healthy, recreationally-active adult males - Whole Body Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine with a primed-constant infusion of L-[555-2H3]leucine to whole-body protein turnover, amino acid oxidation, and net protein balance
16269696|NCT04887714|Experimental|Mask|cloth mask wearing
16269697|NCT04887714|No Intervention|control|control, without mask.
16269700|NCT04887675|Active Comparator|Patients switched from PI/EFV based ART to INSTI based ART|60 patients on PI/EFV based ART, stable on treatment (undetectable viral load for at least 6 months). At the beginning of the study they are switched to INSTI based regimen. The reasons for the switch will be side effects or long-term toxicities like hyperlipidemia, diarrhea, (PI), insomnia, headache (EFV), high Framingham score (PI/EFV)
16269701|NCT04887675|Active Comparator|Patients initially treated with INSTI based regimens|60 patients initially started on INSTI based ART (raltegravir and dolutegravir), stable on treatment (undetectable viral load for at least 6 months).
16269702|NCT04887662|No Intervention|Control|The control group will be asked to follow their usual diet, but will receive print materials about a diet for cardiovascular health.
16269703|NCT04887662|Experimental|Fermented vegetable|The fermented vegetable group will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week for 8 weeks.
16269704|NCT04887649|Placebo Comparator|Placebo|Patients en treatment whit placebo, salIne solution in peridural cateter
16269705|NCT04887649|Active Comparator|Morphine|Epidural Catheter morphine 2mg
16269706|NCT04887649|Active Comparator|morphine|Epidurla cateter morphine 3 mg
16269707|NCT04887636||Normal women group|I. Women of childbearing age who are physically and mentally healthy, have regular menstruation and are between 20-45 years old; II. Women who are evaluated as normal by vaginal microbiome morphological characterization; III. Women who agree to participate in this study and have signed an informed consent form; IV. Those who have full capacity for civil and legal conduct; V. The quality of vaginal samples meets the evaluation requirements of this program.
16269708|NCT04887610|Sham Comparator|Ischemic preconditioning control|
16269709|NCT04887610|Active Comparator|Ischemic preconditioning|
16269710|NCT04887610|Active Comparator|High fat meal|
16269711|NCT04887610|Placebo Comparator|Low fat meal|
16269712|NCT04887597|Experimental|Secukinumab Treatment|all patients receive Secukinumab as well as a biopsy before and after treatment
16269713|NCT04887584|Experimental|Group 1|"Order of treatments:
~A: Control diet B: Low pulse diet C: High pulse diet"
16269714|NCT04887584|Experimental|Group 2|"Order of treatments:
~A: Control diet C: High pulse diet B: Low pulse diet"
16269715|NCT04887584|Experimental|Group 3|"Order of treatments:
~B: Low pulse diet A: Control diet C: High pulse diet"
16269716|NCT04887584|Experimental|Group 4|"Order of treatments:
~B: Low pulse diet C: High pulse diet A: Control diet"
16269717|NCT04887584|Experimental|Group 5|"Order of treatments:
~C: High pulse diet A: Control diet B: Low pulse diet"
16269718|NCT04887584|Experimental|Group 6|"Order of treatments:
~C: High pulse diet B: Low pulse diet A: Control diet"
16269719|NCT04887571||Observational ACS Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an acute coronary syndrome will be recruited into the PERFUSION registry across the study duration.
16269720|NCT04887558|Active Comparator|NCI QuitGuide and NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free NRT.
16269721|NCT04887558|Experimental|Smart-T Mental Health and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive NRT.
16269779|NCT04887077|Experimental|Kiplin intervention|Kiplin intervention composed of the access to a mobile app and to telecoaching sessions. The number of teleocaching sessions per week will decrease over 3 months.
16269722|NCT04887558|Experimental|Smart-T Mental Health+ and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. During the pre-quit and post-quit period, the app will also send messages that encourage the use of the nicotine patch and lozenges according to recommended practices. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free NRT.
16269723|NCT04887545||Thoracentesis|Patients who need removal of excess pleural effusion and assessed for the possibility of lung cancer.
16269724|NCT04887532|Experimental|HR19042 capsule|
16269725|NCT04887519||All Participants|Participants with advanced or metastatic ALK positive NSCLC who have been prescribed with brigatinib in real-world will be observed both prospectively and/or retrospectively at the local clinical practice setting and data will be taken from medical records of the routine visit after every 12 weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression or treatment discontinuation, whichever occurs first.
16269728|NCT04887493|Experimental|Sublingual misoprostol|Sublingual misoprostol group will receive misoprostol 25µg by sublingual routes; the dose will be given repeatedly every 4 hours by sublingual route till there is labour pain or contraction or to a maximum of 6 dosages.
16269729|NCT04887493|Experimental|Vaginal misoprostol|Vaginal misoprostol group will receive misoprostol 25µg by per vaginal routes; the dose will be given repeatedly every 4 hours by per vaginal route till there is labour pain or contraction or to a maximum of 6 dosages.
16269730|NCT04887480|Active Comparator|Negative Wound Pressure Therapy|Negative Pressure Would Therapy
16269731|NCT04887480|Active Comparator|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation
16269732|NCT04887467|Experimental|Patients with Parkinson disease|Apomorphine 5mg/mL, solution for infusion, intraveinous use
16269733|NCT04887454|Experimental|Once-Weekly HIIT|Once-weekly HIIT for 16 weeks, led by certified athletic coaches
16269734|NCT04887454|Experimental|Thrice-Weekly HIIT|Thrice-weekly HIIT for 16 weeks, led by certified athletic coaches
16269735|NCT04887454|Other|Usual Care|Bi-weekly health education, led by research personnel
16269736|NCT04887415|Experimental|Respiratory strength training|Enrolled cardiac surgical patients will undergo 4 weeks of preoperative respiratory strength training using two respiratory strength training devices.
16269737|NCT04887402||clomiphene citrate sensitive|"Based on the ovulation pattern, these patients will be divided into two groups, one who ovulated with CC maximum 150 mg and others who did not ovulate considered as CC resistant. The patients who ovulated will be further classified into three subgroups based on whether they ovulated with 50 mg or 100 mg or 150 mg of CC.
~The various parameters will be compared between the CC-resistant and CC-sensitive groups."
16269738|NCT04887402||clomiphene citrate resistent|"Based on the ovulation pattern, these patients will be divided into two groups, one who ovulated with CC maximum 150 mg and others who did not ovulate considered as CC resistant. The patients who ovulated will be further classified into three subgroups based on whether they ovulated with 50 mg or 100 mg or 150 mg of CC.
~The various parameters will be compared between the CC-resistant and CC-sensitive groups."
16269739|NCT04887389|Experimental|Group of • Nano Silver Fluoride varnish ( NSF)|"Selected children will be divided randomly into three groups:
~Group 1: Children receiving Nano Silver Fluoride varnish (NSF) (n =50)."
16269740|NCT04887389|Experimental|group of Nano hydroxyapatite varnish (n-HAP)|Group 2 Children receiving Nano-hydroxyapatite varnish (n = 50)
16269741|NCT04887389|Experimental|group of Sodium Fluoride Varnish (NaF)|Group 3: Children receiving Sodium Fluoride Varnish (n = 50)
16269742|NCT04887376|Active Comparator|Mirror Therapy|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors. In addition to this application, mirror therapy was applied simultaneously with NMES.
16269743|NCT04887376|Placebo Comparator|Control|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors.
16269744|NCT04887363|Experimental|Core exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
16269745|NCT04887363|Experimental|Tai Chi exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
16269746|NCT04887363|No Intervention|Young adults group|The healthy young adults who have not any neurological, musculoskeletal or rheumatic disease were recruited as a reference group. They would not receive any training program in the study.
16269747|NCT04887350|Experimental|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership is a phone administered talk therapy.
16269748|NCT04887350|Active Comparator|Problem Solving Therapy (PST)|Problem Solving Therapy is a phone administered talk therapy.
16269749|NCT04887350|Other|Wait List Control (WLC)|Participants in the WLC will continue with their regular treatments for the 12 week study period but not receive any study related intervention during this 12 weeks. Following completion of all study assessments WLC participants will self-select either SSIPP or PST. Participants in WLC will not complete study assessments after week 12.
16269750|NCT04887337|Active Comparator|Arthroscopic stabilization|Patients will have an initial evaluation with a diagnostic shoulder arthroscopy and examination under anesthesia will be performed to confirm the degree of anterior instability and assess range of motion of the affected shoulder. Diagnostic arthroscopy will commence with the use of 3 standard shoulder portals (posterior viewing and two anterior working portals for suture passing), and a detailed arthroscopic examination will be performed. Once the soft tissue tear (including the labrum, and capsule labrum ligaments) is identified, it will be mobilized using a rasp or elevator and a burr will then be used to create a surface for a bleeding bone bed. Capsulolabral repair will then commence with the labrum fixed to the glenoid using suture anchors (the Bankart repair). Following surgery, subjects in this group will follow the same rehabilitation protocol as the comparison group.
16269751|NCT04887337|Active Comparator|Rehabilitation including a period of immobilization followed by physical therapy|Subjects in this group will use an internal-rotation shoulder immobilizer, using a standard sling for 6 weeks from the day of enrollment. Subjects will be advised to maintain range of motion (ROM) in the elbow and wrist during this period of time. The immobilizer can be removed for passive pendulum exercises and elbow ROM during the period of immobilization up to 4 times per day. Formal physiotherapy commences at 4 weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
16269752|NCT04887311|Experimental|Cohort 1|"Group 1 Patients ≥13 years old will receive a total daily dose of 1200 mg/day.
~Group 2 - Group 4
~Patients 4-12 years old will receive group weight-tiered doses at 17 mg/kg:
~Group 2
~Patients aged 4-12 years weighing 15kg to <25 kg will take 340 mg/day. Group 3
~Patients aged 4-12 years weighing 25kg to <35 kg will take 510 mg/day. Group 4
~Patients aged 4-12 years weighing ≥35 kg will take 850 mg/day."
16269753|NCT04887298|Experimental|Liposomal Annamycin (L-Annamycin)|
16269754|NCT04887285|Experimental|Virtual reality (VR)|Subjects in the VR group will be fitted with an HTC headset and headphones with disposable ear covers. They will choose from a menu of 6 different programs. They will also receive 1% superficial anesthesia.
16269755|NCT04887285|Active Comparator|Sedation|Conscious sedation will be accomplished by the use of midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). All medications will be titrated to conscious sedation by a board-certified anesthesiologist. Subjects will also receive 1% superficial anesthesia.
16269756|NCT04887285|Other|Standard care|Patients in this arm will be administered only 1% lidocaine as superficial anesthesia, similar to the other 2 arms.
16269757|NCT04887272|Active Comparator|Exercise Training (EXT)|Research participants will complete six weeks of supervised progressive aerobic and resistance exercise training (EXT). Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post EXT.
16269758|NCT04887272|Experimental|Inspiratory Muscle and Exercise Training (IMET)|Research participants will complete six weeks of supervised aerobic and resistance exercise training in addition to supervised respiratory muscle training (IMET). IMET sessions will be performed similar to EXT, with the exception of having sessions of at-home IMT training. On these days, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle, and end of the session. Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post IMET.
16269759|NCT04887259|Experimental|Single arm|"In part 1 (dose escalation) LAVA-051 will be administered via intravenous infusion with dose escalation until an estimated therapeutic dose level has been reached.
~In part 2 (dose expansion) patients will receive LAVA-051 at the recommended phase 2 dose(s) established in part 1 of the study in disease specific cohorts for MM and/or CLL and/or AML"
16269760|NCT04887246||UNISALUD population|Refers to all affiliated members or beneficiaries of the UNISALUD entity, who got any of tthe COVID-19 vaccines available in Colombia
16269761|NCT04887233|Experimental|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
16269762|NCT04887233|Placebo Comparator|Placebo nasal spray|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
16269763|NCT04887194|Experimental|Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy|To evaluate the potential for drug-drug interactions (DDI) with sitravatinib monotherapy. To determine the effect of sitravatinib on the pharmacokinetics (PK) of midazolam (CYP3A4 probe substrate), warfarin (CYP2C9 probe substrate), dextromethorphan (CYP2D6 probe substrate), rosuvastatin (BCRP probe substrate), and digoxin (P-gp probe substrate).
16269764|NCT04887194|Experimental|Phase 1, Part 2 Combination Therapy|To evaluate safety and tolerability of Sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.
16269765|NCT04887181|Active Comparator|Teethmate Desensitizer|Tetracalcium phosphate and dicalcium phosphate containing desensitizer
16269766|NCT04887181|Active Comparator|Gluma Desensitizer|%35 hydroxyethyl methacrylate and %5 glutaraldehyde containing desensitizer
16269767|NCT04887181|Active Comparator|Hybrid Bond|Self-etch adhesive resin
16269768|NCT04887168|Experimental|Compressed|Treatment delivered at higher intensity - twice weekly
16269769|NCT04887168|Experimental|Spaced|Treatment delivered at lower intensity - once weekly
16269770|NCT04887155|Experimental|Cognitive behavioral therapy (CBT)|
16269771|NCT04887142||The discharged subjects|The COVID-19 inpatients treated with standard care who survived the disease and discharged from hospital.
16269772|NCT04887142||The deceased subjects|The COVID-19 inpatients treated with standard care who died from the disease.
16269773|NCT04887129|Experimental|Students and staff at Mary Cariola Center|All students enrolled at the Mary Cariola Center in Rochester, NY. All staff working at the Mary Cariola Center in Rochester, NY.
16269774|NCT04887116|Experimental|Virtual Reality Exposure Therapy|Virtual Reality Exposure Therapy
16269775|NCT04887103|Experimental|hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
16269776|NCT04887103|No Intervention|Control group|There will be no intervention other than routine follow-up and maintenance.
16269777|NCT04887090|Experimental|Acupuncture and drug compound technology group|Routine perioperative management and transcutaneous electrical acupoints stimulation treatment
16269778|NCT04887090|Other|Control group|Routine perioperative management
16269816|NCT04886830||Appendectomy performed with a clip to appendiceal stump|Appendectomy performed with a clip for closure of appendiceal stump
16269780|NCT04887077|Active Comparator|face-to-face supervised PA (usual care at the University Hospital of Clermont-Ferrand, France)|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
16269781|NCT04887064|Experimental|Normal Hepatic Function|
16269782|NCT04887064|Experimental|Moderate Hepatic Impairment|
16269783|NCT04887064|Experimental|Severe Hepatic Impairment|
16269784|NCT04887051|Experimental|telerehabilitation|pre-post telerehabilltation
16269785|NCT04887038|Active Comparator|Drug :SRT-015|Experimental, Single and Multiple Oral escalating dose and Food Effect Cohort
16269786|NCT04887038|Placebo Comparator|Matching Placebo for SRT-015|
16269787|NCT04887025|Experimental|Dose Escalation|Subjects will be treated with RGV004 as a single injection, one time.
16269788|NCT04887012|Experimental|CAR-NK019|All subjects were intravenously administrated with CAR-NK019
16269789|NCT04886999|Experimental|Inhaler A CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.
~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator."
16269790|NCT04886999|Active Comparator|Inhaler B CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.
~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator"
16269791|NCT04886986|Experimental|All Subjects|Patients enrolled in the study will receive the study drugs 225Ac-J591 and 177Lu-PSMA-I&T, along with 68Ga-PSMA-11.
16269792|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
16269793|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) < 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
16269794|NCT04886960|Experimental|Amniotic Fluid Injection|Amniotic Fluid Injection, 3ml, one time dose.
16269795|NCT04886960|Active Comparator|Standard of Care Steroid Injection|Corticosteroids, 3ml, one time dose.
16269796|NCT04886947|Experimental|stem cell intervention|"Arm A patients who will have surgery with stem cell added.
~Arm B only surgery with no stem cell added."
16269797|NCT04886934|Experimental|Safety and clinical performance of the CS1 system|Placement of the CS1 device on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery.
16269798|NCT04886921|Experimental|TRAM abdominal muscle training group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.
~All subjects will receive 1-hr training sessions consisting of core stability exercises for 12 weeks for the TRAM group."
16269799|NCT04886921|No Intervention|TRAM control group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.
~The control group was not received any exercise program."
16269800|NCT04886921|No Intervention|Healthy women group|A control group comprising female volunteers who were apparently healthy and had comparable socioeconomic backgrounds and physical conditions was recruited by convenience sampling from communities.
16269801|NCT04886895|Experimental|Let's Move Intervention|Let's Move intervention will be administered and videotaped for 20 infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, there will be two clinic-based sessions followed by 2 telehealth-based sessions
16269802|NCT04886882|Placebo Comparator|Group placebo|Isotonic solution will be administered daily to 6 female rats.
16269803|NCT04886882|Sham Comparator|Group sham|Base cream to be applied twice a day to 6 female rats.
16269804|NCT04886882|Experimental|Group %1 mgso4|Cream containing 1% MgSO4 will be applied twice a day to 6 female rats.
16269805|NCT04886882|Experimental|Group %10 MgSO4|Cream containing 10% MgSO4 will be applied twice a day to 6 female rats.
16269806|NCT04886882|Active Comparator|Group positive control|Cream containing centella asiatica will be applied twice a day to 6 female rats.
16269807|NCT04886869|Experimental|Coffee|Oral consumption of 3 cups of coffee containing 240 mg caffeine
16269808|NCT04886869|Experimental|Energy drink|Oral consumption of 750 mL of a commercial energy drink containing 240 mg caffeine
16269809|NCT04886869|Placebo Comparator|Placebo|Oral consumption of 750 mL water
16269812|NCT04886843|Active Comparator|Cold Therapy|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week. In addition to this application, a cold pack was applied on the affected side dorsiflexor muscle skin. The cold pack was applied on a moist towel for five minutes. A five-minute break was given and a further 5-minute cold application was repeated. The cold application was done simultaneously with NMES.
16269813|NCT04886843|Placebo Comparator|Control|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week.
16269814|NCT04886830||Appendectomy performed with single endoloop to appendiceal stump|Appendectomy performed with single endoloop for closure of appendiceal stump
16269815|NCT04886830||Appendectomy performed with two endoloops to appendiceal stump|Appendectomy performed with two endoloops for closure of appendiceal stump
16295143|NCT04710251|No Intervention|Colonoscopy without the speedometer|
16269817|NCT04886817|No Intervention|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
16269818|NCT04886817|Experimental|Intervention|"Intervention group participants will receive a 6-month behavioral intervention with the following components:
~A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, and a children's book about water consumption, as well as instructions for other intervention components (how to view video, download app, and prepare for calls)
~A 5-minute educational video that introduces parents to healthy drink choices for the family.
~Ready, Set Gulp! A smartphone application for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water.
~A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices."
16269819|NCT04886804|Experimental|Phase Ia - Dose escalation part|Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.
16269820|NCT04886804|Experimental|Phase Ib - Dose expansion part|
16269823|NCT04886778|Experimental|Group A or Trial group|Group A was treated with a 12-week low-carbohydrate diet combined with probiotic compound preparations.
16269824|NCT04886778|Placebo Comparator|Group B or Placebo control group|Group B was treated as a control group with a 12-week low-carbohydrate diet combined with placebo treatment.
16269825|NCT04886765|Experimental|ALMB-0168|"Dose Escalation Cohort ：The accelerated titration and traditional 3+3 design will be used in the dose-escalation phase. Seven dose cohorts will be evaluated. ALMB-0168 will be administered intravenously once every 3 weeks until either the disease progresses or intolerable toxicity occurs.
~Dose Expansion Cohort: Based on the results of Part I, 1-3 dose expansion cohorts will be started to further evaluate the safety and efficacy of ALMB-0168."
16269826|NCT04886752|Sham Comparator|vitamin C without liposome|vitamin C without liposome
16269827|NCT04886752|Placebo Comparator|liposomal process A vitamin C|liposomal process A vitamin C
16269828|NCT04886752|Experimental|liposomal process B vitamin C (Double Nutri™)|liposomal process B vitamin C (Double Nutri™)
16269829|NCT04886739|Experimental|CGB-400 Topical Gel|Topical administration twice daily for 12 weeks
16269830|NCT04886739|Placebo Comparator|Vehicle Gel|Topical administration twice daily for 12 weeks
16269831|NCT04886726|Experimental|PTCY and uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
16269832|NCT04886713||Obese HFpEF|Left ventricular-EF ≥ 50%, N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, Left ventricular-hypertrophy or Left atrial-dilatation) BMI ≥30 kg/m²
16269833|NCT04886713||Obese controls|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI ≥ 30kg/m²
16269834|NCT04886713||Lean control|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI < 30kg/m²
16269835|NCT04886700|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
16269836|NCT04886674||Remuverol|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for < 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
16269837|NCT04886661||PATIENTS WITH CHRONIC NECK PAIN|Patients between the ages of 18-65 who are eligible for the inclusion criteria will be included in the study who have cervical X-RAY and cervical MRIs taken in the last 3 months.
16269838|NCT04886648|Experimental|Mother Voıce|Premature baby group with mother voıce application.
16269839|NCT04886648|Experimental|Lullably|Premature baby group with lullably application.
16269840|NCT04886648|No Intervention|Control|Premature baby group with no application
16269841|NCT04886622|Experimental|DT2216|DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year.
16269842|NCT04886596|Experimental|RSVPreF3_L1 Group|Participants in this group receive lot 1 of the RSVPreF3 OA vaccine
16269843|NCT04886596|Experimental|RSVPreF3_L2 Group|Participants in this group receive lot 2 of the RSVPreF3 OA vaccine
16269844|NCT04886596|Experimental|RSVPreF3_L3 Group|Participants in this group receive lot 3 of the RSVPreF3 OA vaccine
16269845|NCT04886596|Experimental|RSVPreF3_L4 Group|Participants in this group receive lot 4 of the RSVPreF3 OA vaccine
16269846|NCT04886596|Placebo Comparator|Placebo Group|Participants in this group receive 1 dose of placebo
16269847|NCT04886583||Gabi Baby Band|GSC 1
16269848|NCT04886557||DDS fixation|Adult patients with degenerative spondylolisthesis over L4-L5 received DDS with a minimum of 2-year follow-up were reviewed. Surgical indications were patients who failed to respond to conservative treatment for at least 6 months. The exclusion criteria were: (1) presence of degenerative scoliosis or spinal deformity, (2) prior spine surgery, (3) lost to follow-up, or (4) failure to complete the questionnaires or radiographic examinations.
16269849|NCT04886544|Experimental|Test group|Hyaluronic acid dermal filler at Week 0
16269850|NCT04886544|No Intervention|Control group|Remain untreated until Week 26
16269851|NCT04886531|Experimental|A|"Weeks 1-3* patients receive either (a) Neratinib, (b) Letrozole or Anastrozole or (c) Neratinib + Letrozole or Anastrozole Weeks 4-24 patients receive Neratinib + Letrozole or Anastrozole and Trastuzumab
~*Starting drug intervention varies for the first 3 weeks depending on arms: a, b, and c by randomization."
16269852|NCT04886518|Active Comparator|High dose pitolisant|"Double-Blind Treatment Phase:
~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
16269853|NCT04886518|Active Comparator|Low dose pitolisant|"Double-Blind Treatment Phase:
~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning"
16269854|NCT04886518|Placebo Comparator|Placebo|"Double-Blind Treatment Phase:
~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
16269855|NCT04886505|Experimental|Treatment|Single arm study - treatment with Electrolytic eCLIPs Bifurcation System
16269856|NCT04886492||NMO|Pts presenting to enrolling sites across the northern America are invited to enroll if eligible
16269857|NCT04886479|Experimental|Daily Disposable Silicone Hydrogel Contact Lens|Subjects will be randomized to wear Daily Disposable Silicone Hydrogel Contact Lens in one eye and will be patched for 3 hours with the contralateral eye remain open.
16269858|NCT04886479|Active Comparator|Habitual Daily Disposable Hydrogel Contact Lens|Subjects will be randomized to wear Daily Disposable Hydrogel Contact Lens in one eye and will be patched for 3 hours with the contralateral eye remain open.
16269859|NCT04886479|Active Comparator|Non-lens wearers|Subjects with no previous history of contact lens wear
16269860|NCT04886466|Experimental|The trunk movement coordinated and legs coordination during walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in post-stroke patients (study group).
16269861|NCT04886466|Experimental|The coordinated movement of the trunk and legs during fast walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in patients with back pain syndrome, but without neurological deficits (control group).
16269862|NCT04886453|Experimental|Intervention|
16269863|NCT04886453|Active Comparator|Controle|
16269864|NCT04886427||Quickscan for patients and their kin|Patients and/or kin who are treated in the hospitals will be invited to fill in the quickscan.
16269865|NCT04886427||Quickscan for healthcare professionals|Healthcare professionals working in the hospitals will be invited to fill in the quickscan.
16269866|NCT04886414|Experimental|Phone-based monitoring without blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer (ABHS).
16269867|NCT04886414|Experimental|Phone-based monitoring without blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
16269868|NCT04886414|Experimental|Phone-based monitoring with blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer.
16269869|NCT04886414|Experimental|Phone-based monitoring with blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
16269870|NCT04886414|Experimental|In-person monitoring with blood oxygenation monitoring with ABHS|Study staff will perform daily in-person home-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a patient monitoring form. Oxygen saturation level will be assessed at the time of the in-person evaluation by a project study staff member. The lowest stable (ie without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer.
16269871|NCT04886414|Experimental|In-person monitoring with blood oxygenation monitoring without ABHS|Study staff will perform daily in-person home-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a patient monitoring form. Oxygen saturation level will be assessed at the time of the in-person evaluation by a project study staff member. The lowest stable (ie without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
16270021|NCT04885452||Patients treated with casirivimab/imdevimab according to the ATU protocol|
16269872|NCT04886388|Experimental|BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
16269873|NCT04886388|Active Comparator|Standard of Care|Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
16269874|NCT04886375|Active Comparator|esp group|The investigators performed erector spina plane block to that patient group for postoperative analgesia
16269875|NCT04886375|Active Comparator|pecs group|The investigators performed modified pectoral nerve block to that patient group for postoperative analgesia
16269876|NCT04886362|Experimental|Intervention Group|Ivermectin 600 mcg/kg every 12 hours for 5 days.
16269877|NCT04886362|Placebo Comparator|Control Group|Same volume like ivermectin
16269878|NCT04886336||Tenofovir Disoproxil Fumarate(TDF) switch to TAF|The indications of TDF switching to TAF due to adverse events of TDF or physician's judgement according to clinical conditions.
16269879|NCT04886336||Entecavir(ETV)switch to Tenofovir Alafenamide(TAF)|In entecavir switch group, at least 30 patients should have baseline BW data before entecavir treatment. The indications of entecavir switching to TAF include suboptimal HBV suppression (defined as detectable HBV DNA after at least one year of entecavir treatment), adverse events due to entecavir, physician's judgement according to clinical conditions.
16269880|NCT04886336||observation groups with take either entecavir (25patients) or TDF (25 patients).|observation groups with total 50 patients who continuously take either entecavir (25patients) or TDF (25 patients) will be enrolled.Examination schedules for these two additional groups are the same as switching groups.
16269881|NCT04886323|Experimental|cold atmospheric plasma treatment group|Patients are treated with a plasma device. Each treatment time was 5min/cm2 based on the skin lesion area.The frequency of treatment is once every two days. The duration of the treatment period is 1-4weeks.
16269882|NCT04886323|Active Comparator|2% ketoconazole cream treatment group|Patients are treated with 2% ketoconazole cream, twice a day.The duration of the treatment period is 1-4weeks.
16269883|NCT04886297|Placebo Comparator|placebo|"The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).
~Intervention: Drug: Mega Resveratrol® capsules"
16269884|NCT04886297|Experimental|100mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.
~Intervention: Drug: Mega Resveratrol® capsules"
16269885|NCT04886297|Experimental|300mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.
~Intervention: Drug: Mega Resveratrol® capsules"
16269886|NCT04886297|Experimental|600mg/d resveratrol|"During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.
~Intervention: Drug: Mega Resveratrol® capsules"
16269887|NCT04886284|Experimental|Ertapenem|Ertapenem 1g IV daily infused over 2 hours x 5 days
16269888|NCT04886284|Placebo Comparator|Placebo|Saline placebo infused daily over 2 hours x 5 days
16269889|NCT04886271|Experimental|HX009|
16269892|NCT04886245|Experimental|facial palsy|Patient with peripheral facial palsy, irrespective of grade, whether or not previously treated
16269893|NCT04886245|Sham Comparator|healthy volunteers|- Subject without major facial sequelae
16269899|NCT04886193|Experimental|FLOT combined with PD-1|"The enrolled patients will receive 4 cycles of FLOT regimen + teriprizumab treatment before surgery Q2W.
~If the transformation is successful, the patient undergoes R0 surgical resection of D2 lymph node dissection, and will continue to receive 4 cycles of FLOT regimen + Teripril after surgery. Anti-treatment, the treatment plan is the same as before.
~After completing the 4 cycles of treatment, oral Tiggio Capsule (S-1) and Teriprizumab were maintained for 1 year."
16269900|NCT04886180|Experimental|Experimental|
16269901|NCT04886180|Active Comparator|Control|
16269902|NCT04886167|Active Comparator|120U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 120 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.025mL (5 U).
~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 18 injection sites, with each injection site receiving 0.025mL (5 U)."
16269903|NCT04886167|Active Comparator|180U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 180 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.0375mL (7.5 U).
~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.0375mL (7.5 U)."
16269904|NCT04886167|Active Comparator|240U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 240 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.05mL (10 U).
~At the 14 day visit, an optional touch-up using up to 120 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.05mL (10 U)."
16270022|NCT04885452||Patients treated with bamlanivimab/etesevimab according to the ATU protocol|
16269916|NCT04886141|No Intervention|Standard of Care treatment with Scales|Patients will receive the standard of care restorative procedure with the addition of the FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale to create a baseline data of pain to compare with the experimental group.
16269917|NCT04886141|Experimental|Virtual Reality Headset|Instead of receiving the Nitrous that would be used to help calm patients during the standard of care restorative procedure. Patients will be given a the Oculus Quest 2 Virtual realty headset and a video will be played. The FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale data will be collected to compare the patients pain level between the two groups.
16269918|NCT04886128||Aim 1/Outcome 1|Secondary analysis of frozen plasma samples from the existing STRATIFY cohort of patients with and without acute heart failure presenting to emergency departments. n= ~900
16269919|NCT04886128||Aim2/Outcome 2|Secondary analysis of frozen plasma samples from the existing EMROC cohort of patients with and without acute heart failure presenting to emergency departments. n= ~900
16269920|NCT04886128||Aim 3/Outcome 3|Prospective recruitment of approximately 1000 patients with and w/o acute heart failure presenting to emergency departments.
16269921|NCT04886115|Experimental|Eccentric pedalling group at 15 rpm|
16269922|NCT04886115|Experimental|Eccentric pedalling group at 60 rpm|
16269923|NCT04886115|Active Comparator|Control|
16269924|NCT04886076||Participants with RBD|Participants with REM Sleep Behavior Disorder
16269925|NCT04886076||Participants without RBD|Age- and gender-matched controls, without REM Sleep Behavior Disorder
16269926|NCT04886063|Experimental|Treatment|Daily subcutaneous (SC) injection of ATH-1017
16269927|NCT04886050|Active Comparator|LC350189 Formulation A (Tablet)|Each subject will be administered a single LC350189 200mg (QD) Tablet on Day 1 and Day 5, respectively.
16269928|NCT04886050|Active Comparator|LC350189 Formulation B (Capsule)|Each subject will be administered two LC350189 100mg (QD) Capsules (2 x 100-mg capsules) on Day 1 or Day 5, respectively.
16269929|NCT04886037||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
16269930|NCT04886037||control|It consists of healty women between the ages of 18-45
16269931|NCT04886024||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
16269932|NCT04886024||control|It consists of healthy women between the ages of 18-45
16269933|NCT04886011|Placebo Comparator|placebo gel|Methylcellulose gel was applied to the ulcer till complete healing
16269934|NCT04886011|Experimental|camel whey protein gel|camel whey protein dissolved in methycellulose gel was applied to the ulcer till complete healing
16269935|NCT04885998|Experimental|Phase 1: Dose Exploration|The recommended phase 2 target dose (RP2D) of AMG 757 in combination with AMG 404 will be estimated using a modified toxicity probability interval (mTPI-2) design. A combination RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an maximum tolerated dose (MTD).
16269936|NCT04885998|Experimental|Phase 2: Dose Expansion|Participants will receive the RP2D of AMG 757 in combination with AMG 404 identified in Phase 1 (dose exploration) of the study.
16269937|NCT04885985|Experimental|DEB catheter|Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm
16269938|NCT04885972|Experimental|Resiniferatoxin|7.5 mcg, 10 mcg, 12.5 mcg, 15 mcg, or 20 mcg in 5 mL injected once intra-articularly
16269939|NCT04885972|Active Comparator|Zilretta|32 mg in 5 mL injected once intra-articularly
16269940|NCT04885972|Placebo Comparator|Placebo|5 mL injected once intra-articularly
16269941|NCT04885959|Placebo Comparator|Usual diet|Participants are subjected to received general dietary advice from attended nurses or physician during their antenatal visits.
16269942|NCT04885959|Experimental|PPBe Diet|Participants will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate.
16269943|NCT04885946|Experimental|Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, FMT.
16269944|NCT04885946|Placebo Comparator|Vancomycin 125 x 4 for 10 days + 2 Placebo|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, placebo.
16269945|NCT04885946|Other|Open-label for screened, but not randomized patients with fulminant CDI|This arm exists for patients with fulminant CDI and for randomization to placebo may be considered unethical.
16269946|NCT04885933||COPD exacerbation|
16269947|NCT04885920||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who initiated or are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for at least 12 months.
16269948|NCT04885907|Active Comparator|Experimental group|Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle
16269949|NCT04885907|Placebo Comparator|Comparator Group|Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle
16269950|NCT04885894||MS Zeposia|Individuals with MS who will begin taking Zeposia as part of standard care.
16269951|NCT04885894||MS High dose efficacy medication|Individuals with MS who will begin taking high dose efficacy oral medication as part of standard of care.
16269952|NCT04885894||Healthy Control|Healthy controls, all of whom will be matched on age, education and gender to the MS groups.
16269953|NCT04885881|Active Comparator|Ozone therapy group|Patients with myofascial pain syndrome receiving ozone injection
16269954|NCT04885881|Active Comparator|Lidocaine injection group|Patients with myofascial pain syndrome receiving lidocaine injection
16269955|NCT04885855|Experimental|8-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 8 weeks.
16269956|NCT04885855|Active Comparator|12-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 12 weeks.
16269957|NCT04885842|Experimental|Study Group|injection I-PRF with brackets
16269958|NCT04885842|No Intervention|Control Group|applying brackets only
16269959|NCT04885829|Experimental|DRL_TC|Subcutaneous injection of DRL's Tocilizumab
16269960|NCT04885829|Active Comparator|RP and RMP|Subcutaneous injection of Actemra and RoActemra (Commercially available Tocilizumab)
16269963|NCT04885803|Experimental|Nano Liquid D3|Arm receiving Nano Liquid Vitamin D3
16269964|NCT04885803|Active Comparator|Softgel D3|Group receiving Softgel Vitamin D3
16269965|NCT04885803|Placebo Comparator|Placebo Control|Liquid mixture, identical in process, taste, smell, and appearance to Nano Liquid D3, but containing no active ingredient (no Vitamin D3)
16269967|NCT04885777|Active Comparator|Lidocaine group|One ml of a solution containing 20 mg/ml of lidocaine was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group.
16269968|NCT04885777|Placebo Comparator|Placebo group|The Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril).
16269969|NCT04885751|Experimental|eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
16269970|NCT04885751|Active Comparator|rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
16269971|NCT04885738||Chronic Cough|cough as a sole presenting lasted more than 8 weeks; with an age of 18-70years; with a normal chest X-ray; without steroids treatment in the last 4 weeks.
16269972|NCT04885738||Asthma|classic asthma
16269973|NCT04885738||COPD|patients with COPD in stable stage or acute exacerbation
16269974|NCT04885712|Experimental|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
16269975|NCT04885712|Experimental|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
16269976|NCT04885712|Active Comparator|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo
16269977|NCT04885686|Experimental|Endomethasone N RCS|Endomethasone N RCS is used in combination with gutta percha points for the permanent obturation of root canals.
16269978|NCT04885686|Active Comparator|Endomethasone SP RCS|Endomethasone SP RCS is used in combination with gutta percha points for the permanent obturation of root canals.
16269979|NCT04885673|Active Comparator|Group A (High flow nasal cannula group)|(Vapotherm) will be used during the bronchoscopy time flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
16269980|NCT04885673|Active Comparator|Group B (Apeieoc oxygenation group)|The standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
16269981|NCT04885660|Experimental|Compound lisinopril tablets|a single oral of Compound lisinopril tablets test formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
16269982|NCT04885660|Active Comparator|Compound lisinopril tablets(Lisonorm®)|a single oral of Compound lisinopril tablets reference formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
16269983|NCT04885647|Experimental|Arm1|Low dose once every 2 weeks group
16269984|NCT04885647|Experimental|Arm2|Low dose once every 4 weeks group
16269985|NCT04885647|Experimental|Arm3|High dose once every 2 weeks group
16269986|NCT04885647|Experimental|Arm4|High dose once every 4 weeks group
16269987|NCT04885634|Active Comparator|Intervention group|Semaglutide 2.4 mg subcutaneously once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
16269988|NCT04885634|Placebo Comparator|Control group|Placebo treatment with volume-matched placebo s.c. once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
16269989|NCT04885621||underserved patients with diabetes mellitus|patients with type 2 diabetes mellitus living in underserved, financially challenged areas of Southwest Virginia who are poorly controlled
16269990|NCT04885608|Experimental|PReGe|Group that will perform the intervention with therapeutic exercise.
16269991|NCT04885595|Active Comparator|Forceps-Cryo 1.1 mm|Forceps biopsy following cryobiopsy with a 1.1mm cryoprobe are obtained within the same session
16269992|NCT04885595|Active Comparator|Forceps-Cryo 1.7 mm|Forceps biopsy following cryobiopsy with a 1.7mm cryoprobe are obtained within the same session
16269993|NCT04885582||Patients with biliary complications|patients with postoperative biliary fistula, biliary stenosis
16269994|NCT04885582||Patients without biliary complications|patients without postoperative biliary fistula and biliary stenosis
16269995|NCT04885569|Experimental|CBT based Motivational Interviewing Group (MICBT)|Participants in this arm will receive a total of 12 weekly sessions of CBT based Motivational Interviewing over a period of 12 weeks.
16269996|NCT04885569|Experimental|Mindfulness based Relapse Prevention Group (MBRP)|Participants in this arm will receive a total of 12 weekly sessions of mindfulness intervention over a period of 12 weeks.
16269997|NCT04885569|Experimental|Integrated MICBT and MBRP Group (CAMIAB)|This will be integrated MICBT plus MBRP intervention. Participants will receive a total of 12 weekly sessions of this integrated CAMIAB intervention.
16269998|NCT04885569|No Intervention|Treatment as usual (TAU)|This will be routine care psychological treatment that they will be receiving.
16269999|NCT04885556|Experimental|Immediate Use|Subjects in this arm will be instructed to use the study device for 2 minutes and remove
16270000|NCT04885556|Experimental|1 hour use|Subjects in this arm will be instructed to use the product for one hour and then remove
16270001|NCT04885530|Experimental|Arm A - Ivermectin|"Ivermectin - 7-mg tablets
~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
16270002|NCT04885530|Placebo Comparator|Arm A - Placebo|"Placebo -7mg tablets
~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
16270003|NCT04885530|Experimental|Arm B - Fluvoxamine|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
16270004|NCT04885530|Placebo Comparator|Arm B- Placebo|Placebo will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
16270005|NCT04885530|Experimental|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
16270006|NCT04885530|Placebo Comparator|Arm C - Placebo|Placebo is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
16270007|NCT04885517|Experimental|Spontaneous breathing, Venturi Mask FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 0.5 (Venturi Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270008|NCT04885517|Experimental|Spontaneous breathing, Non Rebreathing Mask, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 1 (Non Rebreathing Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270009|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270010|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, supine decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during supine decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270011|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, prone decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during prone decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270012|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270013|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (12 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270014|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
16270015|NCT04885491|Experimental|Treatment arm|Observational period with placebo treatment and then experimental treatment
16270016|NCT04885491|Placebo Comparator|Observational period (placebo)|Starting with observational period with placebo treatment
16270017|NCT04885478||Healthy health care workers|"≥ 18 years of age
~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.
~To be a health care professional worker infected or exposed to SARS-CoV-2
~RT-PCR (SARS-CoV2), negative at baseline or follow up
~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), negative positive at baseline or follow up"
16270018|NCT04885478||Infected health care workers|"≥ 18 years of age
~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.
~To be a health care professional worker infected or exposed to SARS-CoV-2
~RT-PCR (SARS-CoV2), positive at baseline or follow up
~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), positive at baseline or follow up"
16270019|NCT04885465|Experimental|Intervention group|Study participants will receive a web-based support program
16270020|NCT04885465|No Intervention|Control group waiting list|Study participants in the control group waiting list will receive standard support from health care and municipalities. After study termination they will receive access to the same web-based program as the experimental group
16270024|NCT04885439|Experimental|NextSteps Intervention|Patients and caregivers will each receive their own tailored manual and six weekly 45-minute telephone calls that correspond to the manual, delivered by a Masters level trained interventionist.
16270025|NCT04885439|No Intervention|Usual Medical Care|UMC consists of standard oncologic care for the patient from the point of diagnosis of advanced cancer.
16270026|NCT04885426|Experimental|low-dose metformin group|low-dose metformin, 250mg/day
16270027|NCT04885426|Experimental|high-dose metformin group|high-dose metformin, 500mg/day
16270028|NCT04885426|Placebo Comparator|control group|placebo
16270029|NCT04885413|Experimental|study arm|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
16270030|NCT04885400|Experimental|iJobs|All the participants will be included in the program.
16270031|NCT04885387|Other|Standard protocol using chest CT|
16270032|NCT04885387|Experimental|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|
16270033|NCT04885374||Amyotrophic lateral sclerosis patients|Amyotrophic lateral sclerosis patients with traditional Chinese medicine
16270034|NCT04885361|Experimental|Arm 1 injection|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
16270035|NCT04885361|Experimental|Arm 2 injections separated by 21 days|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
16270036|NCT04885348|Experimental|Dental Home Visits and Dental Home Education Leaflets|Two trained dental home visitors made 6-monthly Dental Home Visits (DHVs) to families in the Intervention Group. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion.
16270037|NCT04885348|Active Comparator|Dental Home Education Leaflets|Only Dental Home Education Leaflets were provided every six months for 2 years.
16270038|NCT04885322|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
16270039|NCT04885322|Experimental|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
16270040|NCT04885322|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
16270041|NCT04885309|Active Comparator|Obturator Nerve Block + Spinal Anaesthesia|Patients who underwent obturator nerve block with spinal anesthesia prior to TURBT
16270042|NCT04885309|Sham Comparator|Spinal Anaesthesia|Patients who underwent spinal anesthesia prior to TURBT
16270043|NCT04885270|Experimental|Arm i.p|paclitaxel i.v. and cisplatin i.p.
16270046|NCT04885244||Operative|Multicenter, prospective, nonrandomized analysis of ASD patients w/diagnosis of congenital, degenerative, idiopathic, neuromuscular, inflammatory or iatrogenic spinal deformity. Participants must be scheduled to have 3 or more levels of Percutaneous posterior spinal instrumentation or 3 level stand alone lateral surgery within next 6 months.
16270047|NCT04885231|Experimental|Opioid-Limiting Perioperative Pain Management Education and Counseling|"Patients will be instructed to take oxycodone only as a last resort if the pain becomes unbearable. The goal should be to take as little oxycodone as possible."
16270048|NCT04885231|Active Comparator|Traditional Perioperative Pain Management Education and Counseling|"Patients will be instructed to take opioids as needed for severe pain to manage and stay ahead of the postoperative pain"
16270049|NCT04885218|Experimental|Cohort 1：SHR-1209 / placebo|
16270050|NCT04885218|Experimental|Cohort 2：SHR-1209 /placebo|
16270051|NCT04885218|Experimental|Cohort 3：SHR-1209 / placebo|
16270052|NCT04885205|Experimental|CBT-I Initial Group|The CBT-I Initial Group will start the CBT-I intervention immediately following baseline assessments. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
16270053|NCT04885205|Active Comparator|Wait List Group|The WL will wait 6 weeks before starting the CBT-I intervention. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
16270054|NCT04885179||Individuals with SPLIS|Individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
16270055|NCT04885179||Parents of individuals with SPLIS|Parents of individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
16270056|NCT04885179||age and gender-matched controls|The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
16270057|NCT04885166|Experimental|Web-based simulation intervention|Participants in this condition will receive psychoeducation about stimulant medication diversion, stimulant medication misuse, and will practice navigating and resisting requests for their medication with a virtual human.
16270058|NCT04885166|Placebo Comparator|Placebo condition|Participants in this condition will learn about psychological conditions that affect college students most often (e.g., depression), causes of those conditions, and pharmacological/behavioral treatments for those conditions.
16270059|NCT04885153|Experimental|Intervention Group|Subjects who were given simvastatin 10 mg and fenofibrate 200 mg.
16270060|NCT04885153|Placebo Comparator|Control Group|Subjects who were given simvastatin 10 mg and placebo (lactic acid) 200 mg.
16270096|NCT04884919|Experimental|Chitosan Dressing Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a chitosan dressing made of chitosan material. The chitosan dressing is applied on another half side of the wound.
16270097|NCT04884906|Experimental|Camrelizumab combined with radiotherapy and chemotherapy|
16270061|NCT04885140|Experimental|Feedback-based health education health education and Routine health education|"Feedback-based health education:(1) Implementation of the feedback method includes information transmission, patient feedback, clarification and correction, and confirmation of understanding.① One day before surgery: Health education team members provided bedside one-on-one education for patients, 15-20 min per session, twice a day.
~② One week after surgery: One-on-one education on rehabilitation exercise was conducted for the patients by the health education team members, 15-20 min per session, twice a day.
~③ Two to four weeks after surgery: The health education group members guided the patients through functional rehabilitation exercises via WeChat. Each intervention lasted 20-30 min. The patients interacted once through WeChatB1, and their questions were answered at any time.
~④ Five to 12 weeks after surgery: The health education group members guided patients through the functional rehabilitation exercises via WeChat."
16270062|NCT04885140|Experimental|Routine health education|"Routine health education:
~Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method."
16270063|NCT04885127|Experimental|All patients|All patients enrolled in this trial will be referred to palliative care for planned monthly virtual visits, be instructed on the use of a digital application Noona that can be downloaded on their personal electronic device, and will be prompted to fill out symptom questionnaires using Noona prior to palliative care visits (required) as well as weekly (optional).
16270064|NCT04885114|Experimental|Cohort 1 Unilateral low dose|3.0 x 10^9 (vg/mL) rAAV1-miHHT
16270065|NCT04885114|Experimental|Cohort 2 Bilateral low dose|3.0 x 10^9 (vg/mL) rAAV1-miHHT
16270066|NCT04885114|Experimental|Cohort 3 Bilateral mid dose|1.7 x 10^10 (vg/mL) rAAV1-miHHT
16270067|NCT04885114|Experimental|Cohort 4 Bilateral high dose|9.9 x 10^10 (vg/mL) rAAV1-miHHT
16270068|NCT04885101|Experimental|LISWT Group|Participants who will submitted to active procedure with Low Intensuty Shockwave Therapy.
16270069|NCT04885101|Experimental|NARFT Group|Participants who will submitted to active procedure with Non-Ablative Radiofrequency Therapy
16270070|NCT04885101|Sham Comparator|Sham Group|Participants who submitted to sham procedure with vaccum therapy.
16270071|NCT04885088||Interventions|"Device: Wisdom bracelet
~Other Names:
~control group (routine medical)"
16270072|NCT04885088||control|routine medical Non-invasive Wearable Device
16270073|NCT04885075|Other|Intravenous Diazepam|Intravenous diazepam (0.2mg/kg/dose) single dose stat
16270074|NCT04885075|Other|Intranasal Midazolam|Intranasal midazolam (0.2mg/kg/dose) single dose stat
16270075|NCT04885062|Experimental|UH-Participant|Potential participants with suspected OSA will be identified from the schedule of the UH Beachwood and Bolwell sleep labs.Those subjects who satisfy the study inclusion and exclusion criteria will be approached and invited to participate in the study.
16270076|NCT04885049|Experimental|Group A|Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
16270077|NCT04885049|Experimental|Group B|Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
16270078|NCT04885036|Active Comparator|Treatment As Usual|This group will receive treatment as usual within the family unit
16270079|NCT04885036|Experimental|EFST brief intervention|This group will receive a two days EFST intervention in addition to TAU
16270080|NCT04885036|Experimental|EFST extended intervention|This group will receive an EFST stand alone treatment consisting of a two days EFST course and 6 individual parental guidance sessions
16270081|NCT04885023|Experimental|Study group|Twenty six patients who received hippotherapy combined with Schroth exercises for ten weeks
16270082|NCT04885023|Other|Control group|Twenty six patients who received only Schroth exercises for ten weeks
16270083|NCT04885010|Experimental|Probiotics|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
16270084|NCT04885010|Placebo Comparator|Placebo|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
16270085|NCT04884997|Active Comparator|Arm A|toripalimab 3mg/kg, Q2w;
16270086|NCT04884997|Experimental|Arm B|toripalimab 3mg/kg, Q2w; Temozolomide 150mg/m2,d1-5,Q4w
16270087|NCT04884984|Experimental|CLL1 positive relapsed or refractory acute myeloid leukemia|
16270088|NCT04884971|Experimental|Microbiota Treatment Arm|Participants will receive the encapsulated microbiota intervention daily for seven days and will be subsequently monitored for six months.
16270089|NCT04884958||Index patient|Adults with confirmed clinical infection caused by Staphylococcus aureus, including skin and soft tissue infection or infection of a normally sterile site. These cases will be identified following admission to Anuradhapura General Hospital.
16270090|NCT04884958||Household contacts|This cohort are resident in the same household as the index patient (maximum of four).
16270091|NCT04884945|Active Comparator|Robotic Surgery|Robotic-Assisted Laparoscopic Pyeloplasty (RALP), standard of care treatment option for UPJ obstruction
16270092|NCT04884945|Active Comparator|Open Surgery|Open Pyeloplasty (OP), standard of care treatment option for UPJ obstruction
16270093|NCT04884932|Experimental|30 kHz stimulation|"Percutaneous application of high frequency electrical current at 30 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16270094|NCT04884932|Experimental|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
16270095|NCT04884919|Placebo Comparator|Regular Gauze Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a regular gauze made of traditional cotton yarn. The regular gauze is applied on the half side of the wound.
16270098|NCT04884893|Experimental|Intermittent nitrous oxide|10 minutes of 50% nitrous oxide + 10 min 100% oxygen + 10 min 50% nitrous oxide + 10 min 100% oxygen
16270099|NCT04884893|Experimental|Continuous nitrous oxide|20 min 50% nitrous oxide + 20 min 100% oxygen
16270100|NCT04884880|Experimental|Luo-Fu-Shan Plaster 10g|10g，once daily，4 weeks
16270101|NCT04884880|Placebo Comparator|Placebo|10g，once daily，4 weeks
16270102|NCT04884867|Experimental|Supportive life skills coaching|CBT-based supportive like skills delivered by phone by lay coaches
16270103|NCT04884841||Patients with postoperative complications|Patients with postoperative complications
16270104|NCT04884841||Patients without postoperative complications|Patients without postoperative complications
16270105|NCT04884828||one group|patients from the Pulmonology Service of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) who met the following criteria: over 18 years of age, hospital admission for acute chronic respiratory failure, home NIV (single-limb system with intentional leakage) users for more than 6 months with adequate compliance (greater than or equal to 5 hours/night). Patients with underlying psychiatric disease were excluded. The study was conducted during the patient's predischarge phase (the same day or the day before)
16270116|NCT04884802|Experimental|Tight pressure management|"In patients assigned to tight blood pressure control, angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.
~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.
~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
16270117|NCT04884802|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
16270118|NCT04884789|Experimental|Post-Burn Face scar|Use of 3d printed TFO with silicone interface (COFIS 3D)
16270119|NCT04884776|Active Comparator|Active arm|Subject will be instructed to take microbiome immunity formula 2 sachets daily for a total of 12 weeks.
16270120|NCT04884776|Placebo Comparator|Placebo arm|Subject will be instructed to take active placebo daily for a total of 12 weeks.
16270121|NCT04884763|Active Comparator|Arm A|Arm A: erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
16270122|NCT04884763|Placebo Comparator|Arm B|Arm B: placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
16270123|NCT04884750|Experimental|High engagement mechanisms, tailed content|During this time the investigators will conduct a 2x2 factorial RCT (with the individual the unit of random assignment and measurement) to assess the impact of two app design features on engagement and outcomes: (1) the investigators will manipulate engagement mechanisms (ENGAGEMENT), including reminder notifications and trust-building dialogue by the ECA and, (2) independently manipulate cultural tailoring of vaccination promotion counseling language used by the agent (TAILORING) to either adaptive religiosity (tailored) or secular (non-tailored). The investigators' primary hypotheses are that participants with have significantly greater vaccination completion rates in the high engagement and tailored conditions at 6 months (H1) and 12 months (H2) compared to other conditions.
16270124|NCT04884750|Experimental|Low engagement mechanisms, tailed content|manipulate low engagement mechanisms while provide adaptive religiosity (tailored) content
16270125|NCT04884750|Experimental|High engagement mechanism, non-tailed content|manipulate high engagement mechanisms while provide secular (non-tailored) content
16270126|NCT04884750|Experimental|Low engagement mechanism, non-tailed content|manipulate low engagement mechanisms and provide secular (non-tailored) content
16270127|NCT04884737|No Intervention|Pre-Intervention|Pre-Intervention Group participants will have 6 visits. During the pre-intervention baseline (3 months) participants will undergo visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, conducted by the research staff: 1.) consent and preoperative, 2.) immediately following surgery in the Post Anesthesia Recovery (PAR) Unit, 3.) on transfer to the floor unit, 4.) post-operative day 1, 5.) post-operative day 3 and 6.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 40 minutes.
16270179|NCT04884308|Experimental|Non Cystic Fibrosis Bronchiectasis|Participants with Non Cystic Fibrosis Bronchiectasis.
16270180|NCT04884308|Active Comparator|Healthy Volunteer|Participants with no condition (healthy volunteers).
16270128|NCT04884737|Experimental|Intervention|Intervention Group participants will have 7 visits. During intervention (3 months) research staff will conduct the visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, and place the MBF dressings to the face (chin, cheeks, forehead), chest and iliac crest: 1.consent and preoperative, 2. MBF dressing placement, 3.) immediately following surgery in the PAR unit with the MBF dressings removed , 4.) on transfer to the floor unit, 5.) post-operative day 1, 6.) post operative day 3 and 7.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 55 minutes.
16270129|NCT04884724|Experimental|Adaptive Dance Exercise Group|"In addition to the routine physiotherapy programs received in the rehabilitation center for children and adolescents with cerebral palsy, an adaptive dance exercise program will be applied 2 days a week in the rehabilitation center for 5 weeks and online for 3 weeks in the presence of a physiotherapist. The duration of each session of the adaptive dance exercises to be applied is planned to be 45-60 minutes. It is planned that the adaptive dance exercises to be applied will be accompanied by the selected song.
~Before and after the 8-week exercise program, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests."
16270130|NCT04884724|No Intervention|Control Group|Children and adolescents diagnosed with Cerebral Palsy will continue their routine physiotherapy and rehabilitation programs in the rehabilitation center. At the beginning of the study and after 8 weeks, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests.
16270131|NCT04884711||Interviews: Older people living at the Leach Court (Brighton, UK).|Older adults who will be enrolled at the Leach Court (Brighton, UK) as a part of the INNOVATEDIGNITY project will be involved in 1:1 open ended interviews.
16270132|NCT04884711||Focus Group Discussions: Older People Living at the Leach Court (Brighton, UK)|10 older people who have previously participated in the interview stage will be involved in two focus group discussions in a group of 5 participants each to co-design digital health technologies that are 'dignity' sensitive and aims to resolve the barriers older people face in technology adoption.
16270133|NCT04884698|Experimental|Phrenic nerve stimulation with Stimit Activator|
16270134|NCT04884685|Experimental|Experimental Group|Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
16270135|NCT04884685|Placebo Comparator|Control Group|Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28.
16270136|NCT04884659|Experimental|Timed restricted feeding|"Time restricted feeding then usual feeding pattern Day 1, testing
~Day 2-7 all meals will be consumed as follows:
~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm. Day 8 testing. Day 9-14 crossover to usual feeding pattern arm (meals consumed ad lib with 50% of calories consumed after 4 PM) for 6 days."
16270137|NCT04884659|Experimental|Usual feeding pattern|"Usual feeding pattern, then time restricted feeding Day 1 testing
~Day 2-7 all meals will be consumed as follows:
~Meals consumed ad lib with 50% of calories consumed after 4 PM. Day 8 testing. Day 9-14 crossover to time restricted feeding arm with all meals consumed as follows:
~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm for 6 days."
16270138|NCT04884646|Experimental|Virtual Reality with Routine Physical Therapy|The duration of the VR will be from 10 to 15 minutes during each session and Routine Physical Therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
16270139|NCT04884646|Experimental|Motor imagery technique with Routine Physical Therapy|Motor Imagery techniques will be given for 5 to 10 minutes along with routine physical therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
16270140|NCT04884646|Experimental|Routine Physical Therapy|Only routine physical therapy will be given (including warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
16270141|NCT04884620||Cross-sectional cohort|Healthy children and adolescents from twenty-five selected schools in the metropolitan area
16270142|NCT04884620||Longitudinal cohort|Cases with first-time diagnoses of extremely early puberty within the period 1995-2019 in the National Patient Registry and five randomly selected references drawn from the general background population in the Danish Civil registry (CPR) matched on age and sex for each case
16270143|NCT04884607|Experimental|Study group|Study group will receive subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes.
16270144|NCT04884594|Experimental|AAV8-hCocH Low dose: 2e12 vg/kg|Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
16270145|NCT04884594|Experimental|AAV8-hCocH Medium dose: 6e12vg/kg|Cohort 2: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
16270146|NCT04884594|Experimental|AAV8-hCocH High dose: 2e13 vg/kg|Cohort 3: Participant receives one-time IV administration of high dose 2e13 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
16270147|NCT04884581|Experimental|GI Genius CADx device|
16270148|NCT04884568|Experimental|Exufiber|This is an open, non-randomised , single arm study
16270149|NCT04884555||post-stroke patient|patients with subacute stroke who have a stroke for the first time and admitted to the hospital for the first rehabilitation treatments
16270150|NCT04884555||Control|healthy volunteers who have not got any known disease and any sign in physical examination
16270151|NCT04884529|Experimental|Chair Yoga Treatment Group|The chair-yoga session will occur for 8-weeks (60 minutes/week) on Zoom. The chair-yoga intervention will include gentle seated postures, relaxation using breathing techniques, and a mindfulness component.
16270152|NCT04884529|No Intervention|Waitlist Control Group|These participants will be on a waitlist to receive the chair yoga program after data collection has been completed (e.g., after 8-weeks).
16270153|NCT04884516|Other|Intervention arm|Participants take retinol gummy once a day
16270251|NCT04883827||Healthy Volunteer|
16270154|NCT04884503|Experimental|Patients diagnosed with BMS traeting with Clonazepam|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
16270155|NCT04884503|Active Comparator|Patients diagnosed with BMS treating with tongue pads|patients wearing tongue pads 3 times a day for 20 minutes for 4 weeks to exclude parafunctions
16270156|NCT04884490|Experimental|Intervention|"Eligible patients will be receiving either to oral co-trimoxazole + standard therapy.
~Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
~The following treatments are recommended as standard therapy:
~Antibiotics for secondary bacterial infection as per institutional guidelines
~Supplemental oxygen (to keep saturations between 92% to 96%)
~Intravenous hydration (to maintain euvolumia)
~Thrombo-prophylaxis as per local guidelines
~Paracetamol (oral or I/V 1gram QDS as required or regular)
~To consider steroids in appropriate cases.
~Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally."
16270157|NCT04884490|Placebo Comparator|Standard|"Standard therapy along with placebo.
~Placebo thrice (8 hourly) for 7 days.
~The following treatments are recommended as standard therapy:
~Antibiotics for secondary bacterial infection as per institutional guidelines
~Supplemental oxygen (to keep saturations between 92% to 96%)
~Intravenous hydration (to maintain euvolumia)
~Thrombo-prophylaxis as per local guidelines
~Paracetamol (oral or I/V 1gram QDS as required or regular)
~To consider steroids in appropriate cases.
~Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture"
16270158|NCT04884477||COVID-19 with previous anti-CD20 therapy and Convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy and who received Convalescent plasma in addition to standard treatment for COVID-19
16270159|NCT04884477||COVID-19 with previous anti-CD20 therapy and no convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy treated with standard COVID-19 treatment and who did not receive Convalescent plasma treatment for COVID-19
16270160|NCT04884464||Hyaluronic acid-based gel|The composition of the gel, ranked by weight is: xylitol, glycerin, Rosa damascena petal extract, xanthan gum, polycarbophil, hyaluronic acid sodium salt (0.24%), pectin, potassium sorbate, sodium benzoate, panthenol, Aloe barbadensis leaf extract, stevia.
16270161|NCT04884464||Chlorhexidine gluconate|Chlorhexidine gluconate at a concentration of 0.2%.
16270162|NCT04884451|Experimental|Intervention|Participants will receive nutritional counselling from the researcher based on Stage-Based, Nutrition Education Package for Childhood Obesity (ST-NEPCO). Nutritional advice and educational tools will be provided according to participants' stages of change.
16270163|NCT04884451|No Intervention|Control|Participants will receive counseling from dietitians based on the routine care for the management of childhood obesity.
16270164|NCT04884425|Active Comparator|PEMF Device Group|This arm will consist of participant's who have been randomly assigned to use the PEMF device daily for 30 mins for an overall 3 months
16270165|NCT04884425|No Intervention|Waiting List Control Group|These participants will be randomly selected to be on the waiting list group. All waiting list participants will be offered the use of the PEMF device after the study has completed
16270166|NCT04884412|Experimental|PARKEO 2 targeting with asleep deep brain stimulation procedure|Participant with parkeo 2 targeting procedure
16270167|NCT04884412|Active Comparator|Usual DBS procedure|Participant with usual targeting and surgery
16270168|NCT04884399|Experimental|CMAB818|0.5 mg by intravitreal injection once on the first day.
16270169|NCT04884399|Active Comparator|Lucentis®|0.5 mg by intravitreal injection once on the first day.
16270170|NCT04884386|Experimental|robot-assisted gait training|
16270171|NCT04884386|Active Comparator|conventional locomotion therapy|
16270172|NCT04884373||Fasted adult patients for elective surgery|"Age ≥ 18 years
~Fasted according to national guidelines
~Elective surgery
~ASA physical status I-II
~Ability to assume both supine and right lateral decubitus position.
~Able to understand and to sign informed consent"
16270175|NCT04884347|Experimental|Alline proMEN|The qualitative and quantitative formula is as follows: 500 mg Keratin, 225 mg Inactive dried yeast rich in vitamin (containing 200 mg Saccharomyces cerevisiae 100% inactivated, 11.218.4 mg Vitamin B3, 6.8-7.2 mg Vitamin B5, 1.6-1.8 mg Vitamin B6, 1.6-1.8 mg Vitamin B2, 1.6 -1.8 mg Vitamin B1, 0.2-0.4 mg Vitamin B9, 0.2 mg Vitamin B8, 5.6 μg Vitamin B12), 150 mg Venus hair fern extract, 117.6 mg Iron gluconate (containing 14.7 mg Iron), 84.2 mg Sodium ascorbate coated, 76.8 mg Zinc gluconate (11 mg Zinc) 24 mg Beta carotene 20%, 14.8 mg Vitamin E, 256.3 mg Acacia gum, 100 mg Microcrystalline cellulose, 11.3 mg Magnesium stearate, 78 mg White coating (containing: 23.4-39 mg Hydroxypropylmethylcellulose (E464), 15.6-23.4 mg Calcium sulfate anhydrous (E516), 15.6-23.4 mg Magnesium carbonate, light (E504), 7.8-15.6 mg Hydroxypropylcellulose (E463), 3.9-11.7 mg Stearic acid (E570)).
16270176|NCT04884347|Placebo Comparator|Placebo|1095 mg Microcrystalline cellulose, 5 mg Magnesium stearate, 55 mg White coating (containing: 16.5-27.5 mg Hydroxypropylmethylcellulose (E464), 11.0-16.5 mg Calcium sulfate anhydrous (E516), 11.0-16.5 mg Magnesium carbonate, light (E504), 5.5-11.0 mg Hydroxypropylcellulose (E463), 2.8-8.2 mg Stearic acid (E570).
16270177|NCT04884334||VAC-Stent® treatment|spontaneous, iatrogenic or postoperative leakage of the oesophagus or colon
16270178|NCT04884308|Experimental|Cystic Fibrosis|Participants with Cystic Fibrosis.
16270181|NCT04884295|Experimental|XVR011|Phase 1: low - medium - high dose; Phase 2: recommended dose from Phase 1
16270182|NCT04884295|Placebo Comparator|Placebo|Phase 2 only
16270183|NCT04884282|Experimental|Arm A - tedopi + docetaxel|Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.
16270184|NCT04884282|Experimental|Arm B - tedopi + nivolumab|Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal
16270185|NCT04884282|Other|Arm C - docetaxel|Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).
16270186|NCT04884256|Placebo Comparator|CBT-004|
16270187|NCT04884256|Experimental|0.01% CBT-004|
16270188|NCT04884256|Experimental|0.024% CBT-004|
16270189|NCT04884243|Placebo Comparator|CBT-006|
16270190|NCT04884243|Experimental|2.5% CBT-006|
16270191|NCT04884243|Experimental|10% CBT-006|
16270192|NCT04884230||Group A|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
16270193|NCT04884230||Group B|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
16270194|NCT04884217|Active Comparator|Pro-ocular™|Pro-ocular™ Topical Gel
16270195|NCT04884217|Placebo Comparator|Placebo|Placebo Topical Gel
16270196|NCT04884204|Experimental|Symptom management with Lee Symptom Scale|Participants will receive disease specific questionnaires electronically, cGVHD-PRO (Lee Symtpom Scale), one week prior to their scheduled visit in the outpatient clinic. The participants will be asked to answer the questionnaire from home without any involvement from clinicians. Afterwards the PRO data will be used during the scheduled clinical consultations as an instrument to discover symptoms on chronic GVHD and systematically to monitoring symptoms developing over time.
16270197|NCT04884191|Experimental|Pacritinib 100 mg QD|
16270198|NCT04884191|Experimental|Pacritinib 100 mg BID|
16270199|NCT04884191|Experimental|Pacritinib 200 mg BID|
16270200|NCT04884178|Experimental|Trifocal Preloaded IOL Delivery System|Bilateral trifocal IOLs implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
16270201|NCT04884165|Experimental|Intervention|Remote monitoring using SRETT (CE marked device) + home mechanical ventilation (non-invasive ventilation, NIV) and usual care.
16270202|NCT04884165|Active Comparator|Control|Home mechanical ventilation (non-invasive ventilation, NIV) with usual care.
16270203|NCT04884152|Active Comparator|Home Exercise Group|"The home Exercise program includes an educational training program about parafunctional activities of patients having bruxism with myofascial temporomandibular disorders. The program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
16270204|NCT04884152|Experimental|Telerehabilitation Group|"The program includes the same stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises using telerehabilitation once a week by video call, and reminder messages will be sent to the patients 3 times a week.
~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
16270205|NCT04884139|Experimental|Dovato arm|DTG/3TC
16270206|NCT04884139|Active Comparator|Biktarvy arm|BIC/FTC/TAF
16270207|NCT04884126||One stage dental implants placement|
16270208|NCT04884126||Second stage dental implants placement|
16270209|NCT04884113|Experimental|Experimental: Motorized Spiral Enteroscopy|"Procedure: Motorized Spiral Enteroscopy:
~PowerSpiral enteroscope will be inserted and advanced with the assistance of motorized spiral rotation, After reaching the point of maximum insertion, cecum or if no further advancement of the enteroscope can be achieved, the enteroscope will be withdrawn using motorized counter-clockwise spiral rotation. When no total enteroscopy is reached, submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde enteroscopy is then performed in the same session or at second session"
16270210|NCT04884100|Other|PPG recording|arrhythmia recording using PPG monitor
16270211|NCT04884087|Experimental|EMA, 3x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
16270212|NCT04884087|Experimental|EMA, 6x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
16270213|NCT04884087|Experimental|EMA, 3x/day, prize-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
16270252|NCT04883814|Experimental|Initial Staging|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive locally advanced breast cancer
16270214|NCT04884087|Experimental|EMA, 6x/day, prized-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
16270215|NCT04884074|Experimental|The study group|The procedure done to this group is Sleeve Gastrectomy with Anterior Crural Repair (ACR)
16270216|NCT04884074|Other|The control group|The procedure done to this group is the Standard Sleeve Gastrectomy (SSG)
16270217|NCT04884061||Experimental|Patients hospitalized with SARS-CoV2 infection proven by RT-PCR test
16270218|NCT04884061||Comparator|Patients hospitalized with lower respiratory tract infections unrelated to SARS-CoV2 (RT-PCR negative for SARS-CoV2)
16270219|NCT04884061||Comparator 2|Patients who have had bronchoscopy performed as part of the assessment of a distal pulmonary nodule (RT-PCR negative for SARS-CoV2).
16270220|NCT04884048||Benign bone tumors|Patients with benign lesions confirmed either by histology or imaging follow-up showing lesion stability.
16270221|NCT04884048||Malignant bone tumors|Patients with malignant lesions confirmed by histology.
16270222|NCT04884035|Experimental|Administration of CC-220 with R-CHOP-21|CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
16270223|NCT04884035|Experimental|Administration of CC-99282 with R-CHOP-21|CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
16270224|NCT04884022|Experimental|Miniplates in mandibular symphysis & infrazygomatic|
16270225|NCT04884022|Active Comparator|Miniplates in external oblique ridge & anterior maxillary region|
16270226|NCT04884022|No Intervention|Growing skeletal Class II subjects|
16270227|NCT04884009|Experimental|SHR-1701+ Famitinib|
16270228|NCT04884009|Experimental|SHR-1701|
16270229|NCT04883996|Active Comparator|EXP039|At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.
16270230|NCT04883996|Placebo Comparator|Saline control|At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.
16270231|NCT04883983|Active Comparator|Pain Medication as Standardly Prescribed|Patients will receive pain medication as standardly prescribed. Refills at the 2 week followup will be provided as per the standard treatment protocol.
16270232|NCT04883983|Experimental|Open Label Placebo|Initial post-op pain medication will be prescribed. On 2 week followup, refill request will be filled with an open label placebo.
16270233|NCT04883970|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 124I-18B10(10L) PET/CT scans
16270234|NCT04883957|Experimental|Cohort A: R/R NHL|Participants with R/R NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or transformed NHL, will receive oral BGB-11417 until the MTD (or maximum ascending dose [MAD]) and the RP2D can be determined.
16270235|NCT04883957|Experimental|Cohort B: R/R CLL/SLL (low tumor burden)|Participants with low tumor burden R/R CLL/SLL will receive oral BGB-11417 until the MTD (or MAD) and the RP2D can be determined.
16270236|NCT04883957|Experimental|Cohort C: R/R CLL/SLL (high tumor burden)|Participants in this cohort will not be enrolled until the RP2D for Cohort B is established. Participants will be treated with the monotherapy ramp-up schedule and the RP2D established in Cohort B.
16270237|NCT04883944|Experimental|Intervention group|All the enrolled infants will receive the heel stick procedure with the maternal involvement after mother will be trained on the application of the non-pharmacological techniques during the performance of the procedure.
16270238|NCT04883944|Active Comparator|Standard care|All the enrolled infants will receive the heel stick procedure according to local protocol without the maternal involvement. The non-pharmacological techniques will be performed by a second nurse not involved in the heel stick procedure itself.
16270239|NCT04883931|Experimental|Intervention group|With in 48-72 hour after birth, infants will receive 0.5 ml breast milk for own mother as a eye drop twice in a day until the discharge or need for laser coagulation. Fresh milk was used as eye drop ( not exceed 6 hours after milking).
16270240|NCT04883931|Placebo Comparator|Placebo group|With in 48-72 hour after birth, infants will receive 0.5 ml 0.9% normal saline as a eye drop twice in a day until the discharge or need for laser coagulation.
16270241|NCT04883918|Experimental|ASC930|Experimental Arm
16270242|NCT04883905||Patients with AHP|Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
16270243|NCT04883892|Experimental|BMAC injection|Single injection of Bone Marrow Aspirate Concentrate (BMAC) into the ankle joint
16270244|NCT04883892|Active Comparator|HA injections|"two injections of Hyaluronic Acid (HA) into the ankle joint - one injection every 15 days.
~After 12 months patients are allowed to cross-over in the BMAC arm."
16270245|NCT04883866|Experimental|Intervention Group|"Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.and implementing a Telephone Breastfeeding Support Program."
16270246|NCT04883866|Experimental|Control Group|Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.
16270247|NCT04883853|Experimental|Mild -Moderate Ptosis with good levator function (more than 8 mm)|The upper eyelid crease was marked for the incision site, up to 5-7 mm from the lid margin, guided by the fellow eyelid crease position. The skin incision was done and the orbicularis occuli muscle was dissected to the tarsus. The anterior surface of the tarsal plate was then identified with the aponeurosis at its insertion, the orbital septum was then opened with a resultant fat prolapse, and the levator aponeurosis exposed until Whitnall's ligament. Three double-armed 5/0 polyester white braided, non-absorbable sutures, with spatulated needle 1/4 circle (Astralen, Assut Medical Sàrl, Pully-Lausanne, Switzerland) were passed between the levator aponeurosis near Whitnall's ligament and the anterior surface of the tarsus in a mattress form
16270248|NCT04883840|Placebo Comparator|Placebo|
16270249|NCT04883840|Experimental|Rosuvastatin 10 mg|
16270250|NCT04883827||RCC with clear cell component|
16270253|NCT04883814|Experimental|Suspected disease recurrence|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive breast cancer and suspected disease recurrence
16270254|NCT04883801||COVID-19 case group|Newborns born to pregnant women diagnosed with COVID-19 during hospitalization for delivery
16270255|NCT04883801||Control group|Newborns born to pregnant women who were not diagnosed with COVID-19 in their medical history and hospitalization for delivery
16270256|NCT04883788||Pandemic group|Patients undergone hip and knee replacement during pandemic period (June-december 2020)
16270257|NCT04883788||Pre-pandemic group|Patients undergone hip and knee replacement during the pre-pandemic period (january-march 2020)
16270258|NCT04883775|Experimental|89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging|All subjects will receive a single, fixed, intravenous dose of MVT-2163, consisting of 3 mg (nominal mass - actual mass administered will likely vary between 2.0 and 2.5 mg) of MVT-2163 radiolabeled from 5 mCi to no less than 1.0 mCi (adjusted as of 16-Mar 2017) of 89Zr.Cohort 1 subjects will receive MVT-2163, with no MVT-5873 pre-dosing. Subjects in subsequent cohorts 2 and 3 will receive a dose of MVT-5873 15 minutes, ~ 2 hours, and ~4 hours prior to administration of MVT-2163. Future cohorts 4 and 5 may evaluate alternate time frames. Other cohorts may evaluate administration of MVT-5873 one week prior (D-7) to the day of MVT-2163 administration and a second administration of MVT-5873 the day of (D0) MVT-2163 administration. The re-entry (RE) and pre-surgery (PS) cohorts will administer MVT-2163 3 ± 1 hour after administration of MVT-5873.
16270259|NCT04883762|Experimental|Fecal Microbiota Transplantation (FMT)|Study subjects will undergo standard bowel preparation and diagnostic colonoscopy with routine biopsies for pathologic assessment. FMT will be performed at the proximal extent of the colon reached, according to the same protocol used in prior randomized studies. FMT will use healthy donor stool provided by OpenBiome, a nonprofit 501(c)(3) organization that provides clinicians and hospitals with screened, filtered and frozen stool to be used for FMT.
16270260|NCT04883749|Experimental|Acalabrutinib|Acalabrutinib will be administered up to 24 cycles (= approx. 24 months total) until progression of disease (PD) or intolerable toxicity
16270261|NCT04883736|Experimental|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16270262|NCT04883736|Active Comparator|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16270263|NCT04883736|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16270264|NCT04883723|Experimental|Experiment I (Shotblocker) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position. The determined injection site was cleaned with a cotton pad with alcohol, with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. The protruding surface of the Shotblocker was placed in the area just before the injection, so that the needle entry point would not be contaminated. It was lightly pressed into the shotblocker with fingertips and the injection was performed. ShotBlocker has been removed after removing the needle. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
16270265|NCT04883723|Experimental|Experiment II (Manual Pressure) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
16270266|NCT04883723|No Intervention|Control Group|The patients in the Manual Pressure group were given detailed information about the procedure and the research, and the patients who agreed to participate in the study were signed by an informed consent form. Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Injection was given using the normal intramuscular injection procedure. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
16270267|NCT04883684|Experimental|Patients(Care givers)|"400 patients(caregivers) are enrolled and use the personal health wallet service (Personal Health Records service).
~They fill out questionnaire to evaluate the service
~Some of them are invited for an in-depth interview."
16270268|NCT04883671|Active Comparator|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
16270269|NCT04883671|Experimental|Stereotactic Body Radiotherapy (SBRT) 1-3 Metastatic Sites|"Participants will be randomly assigned and receive SBRT to 1-3 sites of metastatic disease over the course of 1-8 business days to each area of cancer.
~After SBRT is completed participant may go on to receive systemic therapy (like chemotherapy, immunotherapy, or targeted therapies) per discretion of their treating physician"
16270270|NCT04883658|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 2: CKD-348(2) - A single oral dose of 1 tablet under fasting condition
~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 4: CKD-348(2) - A single oral dose of 1 tablet under fasting condition"
16270271|NCT04883658|Experimental|Sequence 2|"Period 1: CKD-348(2) - A single oral dose of 1 tablet under fasting condition
~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 3: CKD-348(2) - A single oral dose of 1 tablet under fasting condition
~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
16270272|NCT04883645|Experimental|Experimental: Topical Aldara|"All patients receive the same treatment (there is no placebo arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria."
16270273|NCT04883632|Experimental|Volume Lidocaine HQ|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma HQ Facility
16270274|NCT04883632|Active Comparator|Volume Lidocaine C1|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma C1 Facility
16270278|NCT04883606||All Participants|Retrospective data will be collected from participants who followed up at least 6 months before teduglutide initiation or intestinal failure associated with SBS-IF diagnosis and at least 6 months of follow-up after teduglutide treatment initiation.
16270279|NCT04883593|Experimental|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
16270280|NCT04883593|Placebo Comparator|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
16270281|NCT04883580|Experimental|experimental group|
16270282|NCT04883580|Active Comparator|control group|
16270283|NCT04883567||AI arm|AI would be used to assist the trainee endoscopist
16270284|NCT04883567||Non-AI arm|Trainee endoscopist would perform OGD as usual.
16270285|NCT04883554|Experimental|Olfactory therapy group|"The therapeutic group takes place in specific stages on a weekly basis and lasts approximately 45 minutes. The group consists of a maximum of 6 patients of approximately the same age. The therapists leading the therapeutic group choose in advance the smells that will be offered to patients, based on one odor for each of the following categories: food and woody / flowery. The odors circulate between the participants of the group (patients and therapists), on wipes of blotting paper soaked in the bottles and soaked in the odors. The first step of the therapeutic group is olfactory perception: this is the moment when the odors selected for the session are presented to the patients. Each scent goes around the patients and therapists, three times and without verbalization. Therefore, patients can express their feelings through drawing or writing on distributed sheets. .
~In a second step, called rendering, patients are asked to express what they think of the smell presented."
16270286|NCT04883554|Active Comparator|Body therapy group|"The therapeutic group takes place according to very specific stages at a weekly frequency and lasts 1 hour. The group is made up of a maximum of 6 patients.
~This workshop includes three times divided equally over a period of 1 hour:
~Kinesic time or time to set the body in motion (20 min):
~These techniques involve lying on the floor on a mat and approaching the movement slowly. The movements are suggested by the patients and then imitated by the rest of the group.
~Kinesthetic time: time of slow movements (20 min):
~During this time, the patient is asked to find a period of calm close to immobility without imposing the instruction. They are asked to touch the different parts of the body as slowly as possible in isolation, starting and ending in the center of the body.
~Talk time (20 min):
~Patients are invited to verbalize what they felt bodily"
16270287|NCT04883541|Experimental|The Study Group|Pregnant women participated in the applications, which lasted two days a week, for ten weeks, and for 60 minutes a day.
16270288|NCT04883541|Placebo Comparator|Control Group|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
16270289|NCT04883528|Experimental|Sacubitril/valsartan|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.
~Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
~Other Name: LCZ696"
16270290|NCT04883528|Placebo Comparator|Placebo|"Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.
~Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, adminstered twice daily orally."
16270291|NCT04883515|Experimental|Oral glutamine supplementation|patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
16270292|NCT04883515|Active Comparator|Oral protein powder supplementation|patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
16270293|NCT04883476||Chronic Low Back Pain and Neck Pain|
16270294|NCT04883463|Experimental|Epidural Stimulation for Respiratory Function|Self-controlled longitudinal safety and feasibility of stimulation and respiratory training.
16270295|NCT04883450||Risk of pancreatic cancer|Subjects with an increased predicted 18-month risk of pancreatic cancer
16270296|NCT04883437|Experimental|Treatment (acalabrutinib, obinutuzumab)|"INDUCTION PHASE: Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 3, then on day 1 of cycles 4-8. Treatments repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
~FOLLOW-UP PHASE: After cycle 12, patients who are in CR are randomized to either discontinue acalabrutinib or to continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after cycle 12 continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with disease progression after cycle 12 discontinue study treatment. Patients with disease progression at any time prior to the conclusion of cycle 12 may continue study therapy if they are felt to be benefiting by the treating physician, but not past cycle 12."
16270297|NCT04883424|Experimental|Diabetes Education Program Based on Health Belief Model|Experimental group After the diabetic patients were determined according to the research criteria, they were randomly divided into intervention and control groups. First, pre-tests were applied to diabetics and family members in the experimental group. Diabetes Education Program Based on Health Belief Model It will be administered in two sessions to people with diabetes and their family members. This program; definition of diabetes, the importance of healthy nutrition in diabetes, the importance of exercise, the importance of regular medication, fingertip blood glucose measurement, acute and chronic problems that may develop in diabetic patients, diabetic foot care, personal self-care and family support. A reminder text message will be sent twice a week to diabetics and family members in the intervention group to manage their diabetes well. Once a month, both the diabetic patient and their family member will be called by phone for counseling.
16270298|NCT04883424|No Intervention|Control Group|First of all, pre-tests will be applied to diabetic patients in the control group. Diabetics in this group will not be intervened and their final tests will be made 3 months after the pre-test.
16270299|NCT04883411|Experimental|Treatment|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System.
16270300|NCT04883398||Breast cancer survivors|Breast cancer survivors ages 50-70 with AJCC stages 0-3 breast cancer who are at least 1 year post-treatment (including surgery, radiation, and chemotherapy, with or without current endocrine therapy)
16270301|NCT04883398||Healthy controls|Healthy controls ages 50-70 with no history of cancer.
16270302|NCT04883359||Healthy Volunteers|From the Washington, D.C. metropolitan area
16270304|NCT04883333|Experimental|Cohort A1 LEO 153339|single ascending dose (Part 1)
16270305|NCT04883333|Experimental|Cohort A2 LEO 153339|single ascending dose (Part 1)
16270306|NCT04883333|Experimental|Cohort A3 LEO 153339|single ascending dose (Part 1)
16270307|NCT04883333|Experimental|Cohort A4 LEO 153339|single ascending dose (Part 1)
16270308|NCT04883333|Experimental|Cohort A5 LEO 153339|single ascending dose (Part 1)
16270309|NCT04883333|Experimental|Cohort A6 LEO 153339|single ascending dose (Part 1)
16270310|NCT04883333|Experimental|Cohort A7 LEO 153339|single ascending dose (Part 1)
16270311|NCT04883333|Experimental|Cohort B1 LEO 153339|single ascending dose (Part 1)
16270312|NCT04883333|Placebo Comparator|All SAD cohorts placebo|single ascending dose (Part 1), all participants receiving placebo in Cohorts A1-A7 and B1
16270313|NCT04883333|Experimental|Cohort C1 LEO 153339|multiple ascending doses (Part 2)
16270314|NCT04883333|Experimental|Cohort C2 LEO 153339|multiple ascending doses (Part 2)
16270315|NCT04883333|Experimental|Cohort C3 LEO 153339|multiple ascending doses (Part 2)
16270316|NCT04883333|Experimental|Cohort C4 LEO 153339|multiple ascending doses (Part 2)
16270317|NCT04883333|Experimental|Cohort C5 LEO 153339|multiple ascending doses (Part 2)
16270318|NCT04883333|Placebo Comparator|All MAD cohorts placebo|multiple ascending doses (Part 2, all participants receiving placebo in Cohorts C1-C5
16270319|NCT04883320||participants with no asthma|Have no evidence of any long term lung condition or any other disabling condition and they must not have had a chest infection in the preceding 4 weeks.
16270320|NCT04883320||participants with mild/moderate asthma|
16270321|NCT04883320||participants with severe asthma|
16270322|NCT04883307|Experimental|Coaching Intervention|Paired with a coach outside of their specific area of interest; encouraged to meet 3 times over 9 months for a 1:1 coaching meeting
16270323|NCT04883307|Active Comparator|Wellness Resources|Emailed wellness resources
16270324|NCT04883294||Disease Group|A disease group including patients older than 18 years old with any kind of histopathologically proven malignancy of the thyroid gland (including Papillary thyroid cancer (PTC), Follicular thyroid cancer (FTC), Medullary thyroid cancer (MTC), and Anaplastic thyroid cancer);
16270325|NCT04883294||Control|A control group including patients older than 18 years old with any kind of histopathologically proven benign thyroid gland disease (including adenoma, hyperplasia).
16270326|NCT04883281|Active Comparator|Involved Nodal Radiotherapy with conventional margins w or w/o chemotherapy|If a patient loses a significant amount of weight on treatment, or the tumor contour changes substantially, repeat CT simulation and re-planning is allowed in the CM arm. However, the gross tumor volume may not be reduced due to tumor shrinkage. The original extent of disease must be included in the replanned GTV.
16270327|NCT04883281|Experimental|Involved Nodal Radiotherapy with marginless Daily Adaptive Radiotherapy w or w/o chemotherapy|Patients in the ML/DART Arm will have their radiation plan adapted with every fraction. The adaptation process will be performed automatically on the Varian Ethos adaptive therapy software under the supervision of the treating physician.
16270328|NCT04883268|Experimental|Intervention Group|Participants in the intervention group completed the Expand Your Horizon programme (Alleva et al., 2015).
16270329|NCT04883268|No Intervention|Comparison Group|Participants in the comparison group did not complete any intervention (i.e., this was a waitlist comparison group).
16270330|NCT04883255|Experimental|HIV-positive subjects|Adult human subjects seropositive for HIV-1
16270331|NCT04883255|Active Comparator|Healthy Comparison Volunteers|Adult human subjects without HIV
16270463|NCT04882254|No Intervention|Standard-of-care|Standard-of-care, which is hypothermic kidney machine perfusion in the Netherlands.
16270332|NCT04883242|Experimental|Treatment (isatuximab, carfilzomib, pomalidomide, steroid)|"INDUCTION: Patients receive isatuximab IV on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
16270333|NCT04883229|Experimental|tDCS +speech therapy followed by sham tDCS + speech therapy|
16270334|NCT04883229|Active Comparator|sham tDCS +speech therapy followed by tDCS + speech therapy|
16270335|NCT04883203|Active Comparator|VITD|A single vial of Cholecalciferol (1 ml) (200,000 IU / 1 m), Oral form,
16270336|NCT04883203|Placebo Comparator|Placebo|A single vial of physiological salin Oral form
16270337|NCT04883190||1. after SARS-CoV-2 infection|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.
~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
16270338|NCT04883190||2. control group with negative antibody test|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.
~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
16270339|NCT04883164||Healthy non-immunocompromized subjects|"Healthy individuals are those with no pre-existing conditions that cause immune deficiency, and who are not receiving drugs to suppress the immune system.
~•"
16270340|NCT04883164||Immunocompromized|Immunocompromised subjects are those receiving immunosuppressive or immunomodulatory drugs such as those given for autoimmune disease, inflammatory bowel disease, malignancies and transplantation. Bone marrow transplant recipients and subjects with known immune deficiency diseases are also considered immunocompromised.
16270341|NCT04883151|Experimental|SOFUS pilot program|
16270342|NCT04883138|Experimental|5 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 5 mg GIGA-2050 per kg BW
16270343|NCT04883138|Experimental|15 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 15 mg GIGA-2050 per kg BW, or as determined by SRC review
16270344|NCT04883138|Experimental|50 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 50 mg GIGA-2050 per kg BW, or as determined by SRC review
16270345|NCT04883125|Active Comparator|Interventional no|Patients treated with both drugs ( imatinib and pioglitazone)
16270346|NCT04883125|No Intervention|Control|Historical control (treated with imatinib only)
16270347|NCT04883112|No Intervention|No Intervention: ankle dorsiflexion|ankle dorsiflexion pre measurement with bipedestation position, will be performed
16270348|NCT04883112|Experimental|Experimental: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
16270349|NCT04883112|Placebo Comparator|Placebo: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
16270350|NCT04883099|Experimental|APIOC for Presbyopia and Presbyopia with Astigmatism|Presbyopic Spherical or Toric Contact Lens
16270351|NCT04883086||diabetic group ( Case)|Total of 91 participants diagnosed with diabetes type 2
16270352|NCT04883086||Non diabetic group (control)|Total of 91 participants healthy and not diagnosed with diabetes Mellitus
16270353|NCT04883073|Experimental|Endo App use|use of Endo App during trial
16270354|NCT04883073|No Intervention|control|no use of Endo App during trial
16270355|NCT04883060|Experimental|Intervention|Patients undergoing ventriculoperitoneal surgery where the midline localizer was used
16270356|NCT04883047|Experimental|experiment|"Women in the experimental group will be given care at the first stage of labor (will start in the latent phase) using Integrated Birth Support Strategies created in line with the Algorithm for Coping with Birth Pain.
~Among the interventions made into a checklist, the interventions applied to the woman will be marked by the midwives and nurses working in the delivery room. The Scale for Coping with Birth Pain (DABS), which will be applied once in each phase (latent phase, active phase and transition phase), will guide the delivery of care; Care practices will differ depending on the woman's ability to cope with labor pain.At least 3 of each sub-heading of the physical comfort parameter, at least 1 of each sub-heading of the parameter of providing emotional comfort, at least 2 of each sub-heading of informative support and advocacy sub-parameters will be applied to pregnant women by midwives / nurses working in the delivery room."
16270357|NCT04883047|No Intervention|control|Pregnant women assigned to the control group will be followed up with the routine care applied in the delivery room.
16270358|NCT04883034|Placebo Comparator|pain management post total knee arthroplasty with analgetic oral|Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day.
16270359|NCT04883034|Active Comparator|pain management post total knee arthroplasty with adductor canal block|On postoperative day 14 (POD 14), the ACB was performed for ACB group
16270360|NCT04883021|Experimental|Dual Target Theta Burst Stimulation|The TMS intervention is open-label dual-target theta burst stimulation delivered in sequential fashion to the DLPFC and the MPFC.
16270361|NCT04883008||Intervention|CorPath GRX with technIQ automated movements enabled (technIQ ON)
16270362|NCT04883008||Control|CorPath GRX with technIQ automated movements disabled (technIQ OFF).
16270363|NCT04883008||CTO Registry|CorPath GRX with technIQ automated movements enabled (technIQ ON) in subjects undergoing robotic-assisted PCI for chronic total occlusions (CTOs)
16270364|NCT04882995|Experimental|Intervention - Received fiber|
16270365|NCT04882995|No Intervention|Control - Did not receive fiber|
16270366|NCT04882982|Experimental|Caria app|"The Caria app is publically available on the Apple app store. It is an interactive native app that provides education on menopause as well as symptom tracking/feedback features, social support as well as cognitive behavioral and relaxation techniques. Participants will be given an unlocked version with all content available at no charge. The app sends out occasional automated emails to users to remind of features of the app and to encourage them to return to the app. Users can opt out of reminder features."
16270728|NCT04880460|Active Comparator|Experimental|This arm includes 45 MDD patients receiving SSRIs
16270367|NCT04882982|Active Comparator|Menopause education|Participants will receive educational material about menopause from the North American Menopause Society, a well respected menopause organization.
16270368|NCT04882969|Experimental|Fractionated Thulium Laser and KeraFactor|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied KeraFactor every 2 weeks for 12 week period.
16270369|NCT04882956|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
16270370|NCT04882956|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
16270371|NCT04882943||patients with unexplained or refractory chronic cough|Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
16270372|NCT04882930|Experimental|Functional Near-Infrared Spectroscopy (fNIRS) acquisitions|The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
16270375|NCT04882904|Experimental|Patient with ALS|Patient with amyotrophic lateral sclerosis
16270376|NCT04882891|Experimental|MS patients|Ambulant patients with multiple sclerosis
16270380|NCT04882865||"healthy volunteers as patients"|"use of the device (AMMP) and the process on 5 healthy volunteers undergoing proning, as well as general care (movement up or down the bed, rotated laterally). As well, repositioning sheets will be used for general care. Surveys of the impressions of team members of the value (ease of use, efficiency, safety, physical demands) of using the AMMP and the repositioning sheets with these patients will be completed.
~The impressions of the volunteers as patients will be surveyed, with particular reference to comfort and security during movement"
16270381|NCT04882865||ICU patients severe respiratory failure|patients with severe respiratory failure eligible for prone ventilation will be recruited with surveys provided to team members to gauge their impressions of the value of using the AMMP with the proning process for these patients. Surveys for 40 proning processes will be obtained. Movement from back to stomach or from stomach to back is considered a single process. A single patient may undergo multiple proning processes as prone ventilation is delivered for several days, with multiple healthcare team members participating in their care. We anticipate this will involve 10 patients, and 3 team members to be involved with each proning process.
16270382|NCT04882865||Patients admitted to the ICU|40 patients will have the AMMP used for general care. An additional 40 will have repositioning sheets used for general care. Healthcare team members involved with the care of these patients will be surveyed re their impressions of the value of using the AMMP or the repositioning sheets. We cannot predict the number of healthcare team members involved with the care of each patient s because of clinical conditions and length of stay
16270383|NCT04882839|Experimental|Active participants|Participants undertaking to full therapeutic protocol including psychotherapy sessions and Psilocybin sessions
16270384|NCT04882826|Other|Sequence TR|22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16270385|NCT04882826|Other|Sequence RT|22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16270386|NCT04882813||Dapagliflozin|Exposure group
16270387|NCT04882813||Sitagliptin|Reference group
16270388|NCT04882800|Experimental|Study Device|Participants will be fit with study devices first for two weeks, and then fit with Comparator devices for two weeks
16270389|NCT04882800|Active Comparator|Comparator Device|Participants will be fit with Comparator devices first for two weeks, and then fit with Study devices for two weeks.
16270390|NCT04882787|Experimental|BTE hearing aid model|BTE or SP-BTE (super power) hearing aid fitting
16270391|NCT04882774|No Intervention|Fluid Management|Fluid management protocol only
16270392|NCT04882774|Experimental|Oral Treprostinil|Drug - oral treprostinil
16270393|NCT04882761|Active Comparator|Socket shield in direct contact with dental implant|eight partially extracted sockets where implant (Neobiotech) was placed in direct contact to socket shield
16270394|NCT04882761|Active Comparator|Socket shield with gap and xenograft with dental implant|eight partially extracted sockets where a gap was left between implant (Neobiotech) and socket shield
16270513|NCT04881994|Experimental|Mild hepatic impairment (Child Pugh A)|Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.
16270397|NCT04882735|Experimental|Acoramidis HCI 800 mg (two 400mg tablets)|TTR stabilizer administered orally twice daily (BID)
16270398|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 1 default|Receiver-in-canal hearing aid with current default compression strategy
16270399|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 2|Receiver-in-canal hearing aid from a different manufacturer with default compression strategy
16270400|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 1|Receiver-in-canal hearing aid with modified compression strategy 1
16270401|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 2|Receiver-in-canal hearing aid with modified compression strategy 2
16270402|NCT04882709|No Intervention|No device|Stimuli recordings without hearing aid
16270403|NCT04882696|No Intervention|usual care with bare feet|patients will be treated barefoot during their stay
16270404|NCT04882696|Experimental|specific care with anti-slip socks|Patients in this group will wear non-slip socks
16270405|NCT04882683|Experimental|control group|Prednisone+Azathioprine/Adalimumab
16270406|NCT04882683|Experimental|UCB-MNCs group|Prednisone+Azathioprine/Adalimumab+UCB-MNCs
16270407|NCT04882670||hip fracture|
16270408|NCT04882644|Experimental|Aerobic Exercise Intervention Group|The subjects receive an intensive aerobic exercise for 6 months and a health education content for 12 months.
16270409|NCT04882644|No Intervention|Control Group|The subjects do not change their physical activity routine and receive a health education content for 12 months.
16270410|NCT04882631|Experimental|Cumulative Irritation Test|Participants will receive topical applications of three concentrations of PBI-100 Topical Cream, one application of vehicle, one application of sodium lauryl sulfate as a positive control and one application of a plain patch as a negative control daily (excluding weekends) for 21 days or 15 applications.
16270411|NCT04882618|Experimental|ICG group|ICG injection before LRRP via cystoscopy
16270412|NCT04882605||Donor/recipient couple with Matched Sibling Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation
~+ its 10/10 HLA-matched donor recruited among his siblings"
16270413|NCT04882605||Donor/recipient couple with Haploidentical Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation
~+ its 5/10 HLA-matched donor recruited among his relatives"
16270414|NCT04882579|Experimental|PoCUS group|Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ
16270415|NCT04882579|No Intervention|Control group|Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation
16270416|NCT04882553|Experimental|Incremental inspiratory effort|"Every participant will be subjected to a stepwise incremental inspiratory effort:
~Ventilated
~Baseline spontaneous breathing with deep anesthesia (minimal alveolar concentration 1.5)
~Spontaneous breathing with PEEP 10 and deep anesthesia (minimal alveolar concentration 1.5)
~Spontaneous breathing with PEEP 0 and deep anesthesia (minimal alveolar concentration 1.5)
~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0)
~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +7cmH2O
~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +15cmH2O"
16270417|NCT04882540|Experimental|brivaracetam|This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.
16270418|NCT04882527|Experimental|anodal stimulation of the rIFL|Anodal stimulation over the right inferior frontal lobe
16270419|NCT04882527|Experimental|cathodal stimulation of the rIFL|Cathodal stimulation over the right inferior frontal lobe
16270420|NCT04882527|Experimental|anodal stimulation of the lIFL|Anodal stimulation over the left inferior frontal lobe
16270421|NCT04882527|Experimental|cathodal stimulation of the lIFL|Cathodal stimulation over the left inferior frontal lobe
16270422|NCT04882527|Experimental|anodal stimulation of the rSPL|Anodal stimulation over the right superior parietal lobe
16270423|NCT04882527|Experimental|cathodal stimulation of the rSPL|Cathodal stimulation over the right superior parietal lobe
16270424|NCT04882527|Sham Comparator|sham stimulation|Sham stimulation over either of the three real stimulation areas
16270425|NCT04882514|Experimental|Vaccine p*17-K4S2 (25 µg/mL) Vaccine|To evaluate the safety and immunogenicity of *17-CRM197 (12.5µg) + K4S2-CRM197 (12.5µg): TOTAL 25 µg
16270426|NCT04882514|Experimental|Vaccine p*17-K4S2 (50 µg/mL) Vaccine|To evaluate the safety and immunogenicity of p*17-CRM197 (25µg) + K4S2-CRM197 (25µg): TOTAL 50 µg
16270427|NCT04882514|Experimental|Vaccine p*17-K4S2 (100 µg/mL) Vaccine|To evaluate the safety and immunogenicity *17-CRM197 (50µg) + K4S2-CRM197 (50µg): TOTAL 100 µg
16270428|NCT04882514|Experimental|J8-K4S2 (100 µg/mL ) Vaccine|To evaluate the safety and immunogenicity -CRM197 (50µg) + K4S2-CRM197 (50µg): TOTAL 100 µg
16270429|NCT04882514|Sham Comparator|Rabavert Vaccine|Comparator vaccine (RABAVERT)
16270430|NCT04882501|Active Comparator|Actual aromatherapy product|QUEASEEase quick tab Aromatherapy product 50 % chance of participant receiving based on randomization
16270431|NCT04882501|Placebo Comparator|Placebo product|Placebo product (normal saline) 50% chance of participant receiving based on randomization
16270514|NCT04881994|Experimental|Moderate hepatic impairment (Child Pugh B)|Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.
16270515|NCT04881994|Experimental|Healthy participants|Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.
16270432|NCT04882475||MCL patients relapsed or refractory to rituximab and induction chemotherapy with curative intent|"An historical cohort of patients will be identified and selected both on a clinical base and according to the availability of Formaline-fixed paraffin-embedded (FFPE) material, frozen material or viable cryopreserved cells at Mantle Cell Lymphoma (MCL) diagnosis. Samples will be analyzed in 4 subgroups, each with different clinical specificity:
~refractory to Induction Chemoimmunotherapy (CIT);
~refractory to Bruton Tyrosine kinase (BTK) inhibitors (BTKi);
~sensitive to Induction Chemoimmunotherapy (CIT);
~sensitive to Bruton Tyrosine kinase (BTK) inhibitors (BTKi)."
16270433|NCT04882462|Experimental|single arm|
16270435|NCT04882436||severe pneumonia|Patients with severe pneumonia
16270436|NCT04882423|Experimental|Test meal 1 - grilled hamburger (7 oz) with no vegetables|Randomly assigned participants are given grilled hamburger (7 oz) with no vegetables
16270437|NCT04882423|Experimental|Test meal 2 - grilled hamburger with steamed broccoli and Brussels sprouts|Randomly assigned participants are given grilled hamburger with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
16270438|NCT04882423|Experimental|Test meal 3 - grilled hamburger with steamed parsnips, fresh parsley, and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
16270439|NCT04882423|Experimental|Test meal 4- grilled hamburger with broccoli, Brussels sprouts, parsnips, parsley and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
16270440|NCT04882397|Experimental|Instrument Assisted Soft Tissue Mobilization|In the application group, Instrument Assisted Soft Tissue Mobilization will be applied to the Trapezius and Sternocleideomastoideus muscles for 90 seconds.
16270441|NCT04882397|Sham Comparator|Sham Instrument Assisted Soft Tissue Mobilization|In the sham application group, 90 degrees to 90 seconds will be applied to the Trapezius and Sternocleideomastoideus muscles without applying pressure.
16270442|NCT04882397|No Intervention|Control|No application will be made to the control group.
16270443|NCT04882384|Experimental|Peripheral Nerve Block (PENG)|Patients will receive the Pericapsular Nerve Group Block.
16270444|NCT04882371||MRI RECIST|Radiological responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) and changes in contrast enhancement patterns on MRI
16270445|NCT04882371||PET-CT PERCIST|Radiological responses were evaluated according to the classification of PET Response Criteria in Solid Tumors (PERCIST) on PET-CT.
16270446|NCT04882358|Experimental|GROUP 1 DIRECT SODIUM REMOVAL + SGLT-2 INHIBITOR|SUBJECTS TREATED WITH DSR + STANDARD DOSE OF APPROVED SGLT-2 INHIBITOR
16270447|NCT04882358|Experimental|GROUP 2 DIRECT SODIUM REMOVAL|SUBJECTS TREATED WITH DSR
16270448|NCT04882345|Experimental|Almonertinib group|Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
16270449|NCT04882332||metformin usage index and vitamin B12 level|Samples for correlation between metformin usage index and vitamin B1 level will be withdrawn from 108 type 2 diabetes patients
16270450|NCT04882319|Experimental|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously.
16270451|NCT04882306|Other|Main study group|
16270452|NCT04882293|Experimental|Group A: Atorvastatin / Fenofibrate in fixed dose|Group A: Atorvastatin / Fenofibrate in fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg /160 mg Adminstration way: Oral
16270453|NCT04882293|Active Comparator|Group B: Atorvastatin (Lipitor ®)|Group B: Atorvastatin (Lipitor ®) Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
16270454|NCT04882280|Experimental|Low room|Low intensity (80 lux) room light
16270455|NCT04882280|Experimental|Normal room|Normal intensity (150 lux) room light
16270456|NCT04882280|Experimental|Bright room|High intensity (500 lux) room light
16270457|NCT04882280|Experimental|Bright|Very high intensity (1000 lux) room light
16270458|NCT04882267|No Intervention|Determination of attitudes and perceived barriers to exercise|Adults with CF will take part in a quantitative modified Exercise Benefits/Barriers Scale (EB/BS) survey to identify universal and unique benefits and barriers to regular exercise activity. Subjects will be surveyed on potential ways to engage in exercise, including perceptions and prior use of smart device exercise technology. Qualitative input will be incorporated to better understand potential solutions to barriers, and develop more personalized plans for exercise engagement.
16270459|NCT04882267|No Intervention|Determination of baseline exercise activity (Baseline Period)|Adults with CF who identify as 'willing to use technology' and own compatible smart phones/tablets will undergo the Short General Health Questionnaires (GHQ 12) to establish baseline levels of general and mental health. Subjects will be fitted with wrist actigraphy and monitored for four weeks to establish baseline levels of exercise activity at home. Anticipated outcomes: Access to actigraphy will encourage personal accountability, and physical activity will increase during the first two weeks before reaching a plateau.
16270460|NCT04882267|Experimental|Engagement in home self-directed exercise incorporating Team and Technology (Intervention Period)|"Subjects will take part in a live demonstration of three subscription-based AI-learning home exercise apps, and one self-directed exercise website designed by a CF patient partner. Subjects will be surveyed on willingness to use technology, and provide feedback on exercise options. They will be given free full access to the apps and website (Technology), and receive a phone call once a week from their CF specialty team offering encouragement and positive reinforcement (Team). App and website usage, actigraphy, EB/BS and GHQ 12 scores will be measured at the end of four weeks. Anticipated outcomes: Activity will increase significantly during the Team and Technology intervention period, barriers on the EB/BS score will decrease, and GHQ 12 scores will increase."
16270461|NCT04882267|Active Comparator|Determination of sustainability (Sustainability Period)|Phone calls will cease, but subjects will maintain access to apps, websites, and actigraphy. After four weeks, EB/BS and GHQ 12 scores, physical activity, app and website use will be reassessed. Anticipated outcomes: Activity will decrease during the sustainability period, but will remain significantly greater than the pre-intervention period. Overall GHQ 12 and EB/BS scores will improve.
16270462|NCT04882254|Experimental|Normothermic machine perfusion|Additional 2 hours of normothermic machine perfusion of donor kidney with a red cell based perfusate.
16270464|NCT04882241|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
16270465|NCT04882241|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
16270466|NCT04882241|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.
~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
16270467|NCT04882241|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.
~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
16270468|NCT04882228|Experimental|Entelon Tab.150mg|
16270469|NCT04882228|Active Comparator|Venitol tab.|
16270470|NCT04882215|Experimental|Adaptive Training (AT)|For AT participants, difficulty of the training tasks is progressively increased in response to task performance.
16270471|NCT04882215|Active Comparator|Non Adaptive Training (NA)|For NA participants, task difficulty is fixed at a relatively low level across all sessions.
16270472|NCT04882202|Experimental|Acetaminophen group|patients receiving acetaminophen
16270473|NCT04882202|Placebo Comparator|Placebo group|patients receiving equal amount of normal saline
16270474|NCT04882189||Capsulorhexis|Capsulotomies conducted by Capsulorhexis
16270475|NCT04882189||ZEPTO Precision Capsulotomy Device|Capsulotomies conducted by ZEPTO Precision Capsulotomy Device
16270476|NCT04882176|Experimental|LM061 Dose Escalation Level 1, 2.5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~first dose: 2.5mg QD, n=1;"
16270477|NCT04882176|Experimental|LM061 Dose Escalation Level 2, 5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~second dose: 5mg QD, n=3;"
16270478|NCT04882176|Experimental|LM061 Dose Escalation Level 3, 10mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~third dose: 10mg QD, n=3;"
16270479|NCT04882176|Experimental|LM061 Dose Escalation Level 4, 20mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~fourth dose: 20mg, n=3;"
16270480|NCT04882176|Experimental|LM061 Dose Escalation Level 5, 30mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~fifth dose: 30mg, n=3;"
16270481|NCT04882176|Experimental|LM061 Dose Escalation Level 6, 40mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~sixth dose: 40mg, n=9;"
16270482|NCT04882176|Experimental|LM061 Dose Escalation Level 7, 60mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~seventh dose: 60mg, n=15;"
16270483|NCT04882163|Experimental|CC-220 + Polatuzumab vedotin + rituximab- Cohort A|Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
16270484|NCT04882163|Experimental|CC-220 + Tafasitamab- Cohort B|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
16270485|NCT04882163|Experimental|CC-220 + Rituximab + Chemo (Cohort C)|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
16270486|NCT04882163|Experimental|CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)|Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
16270516|NCT04881981|Experimental|SCART Arm|Single Arm patients will be treated with SCART to different dose levels.
16270517|NCT04881968|No Intervention|Control: Usual Care|The control arm occurs prior to receipt of the video game intervention and reflects usual care. Each hospitalist 'crosses over' from control to intervention at a single time point.
16296657|NCT04699734|Active Comparator|Xylocaine|Nerve block
16270487|NCT04882163|Experimental|CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E|Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
16270488|NCT04882163|Experimental|CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)|Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
16270489|NCT04882150|Experimental|Part A: SAD|SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.
16270490|NCT04882150|Experimental|Part B: MAD|MAD = multiple ascending dose. Each participant will receive multiple doses of BMS-986196 or placebo.
16270491|NCT04882150|Experimental|Part C: FE/Formul.|FE/Formul. = food and formulation effects and relative absorption. Participants will receive two formulations of BMS-986196 (solution and suspension), each formulation with and without food.
16270492|NCT04882137|No Intervention|Standard Education|Pediatric Providers in this arm will receive a continuing medical education on etonogestrel contractive implant but will not receive specialist coaching on how to manage side effects.
16270493|NCT04882137|Experimental|Standard Education plus Coaching|Pediatric Providers in this arm will receive a continuing medical education program on etonogestrel contraceptive implant. Providers in this arm will also receive a tip-sheet on how to manage side effects as well as a number to directly access a specialist who places them if needed.
16270497|NCT04882111|Experimental|Discharged Cancer Patients|25 patients, adults ≥ 18, with stage II - IV solid tumor malignancy discharging from an acute care hospital to a SNF in the metro Denver area who have decisional capacity to consent and are English speaking.
16270501|NCT04882085|Experimental|CAZ-AVI|ceftazidime 2g plus avibactam 0.5g
16270502|NCT04882085|Active Comparator|Best Available Treatment|Based on investigative site practice and local epidemiology and guideline
16270503|NCT04882072|Experimental|Ustekinumab|"Double-blind (DB) Period: Participants will receive weight-ranged based ustekinumab (6 milligrams/kilogram[mg/kg]) as IV infusion at Week 0 followed by ustekinumab 90mg injection SC 8 weeks after initial IV dose, then every 8 weeks (q8w) thereafter until the end of the DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.
~Open Label Extension (OLE) period: Participants will receive ustekinumab SC injection at Week OL-0, followed by ustekinumab 90mg SC injection with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from first SC administration after end of DB period whichever is later.
~Long-term Extension (LTE) Period: Participants who completed OLE period may be eligible to enter LTE and continue to receive ustekinumab 90mg SC injection q8w."
16270504|NCT04882072|Placebo Comparator|Placebo|"DB period: Participants will receive placebo intravenous (IV) infusion at Week 0 followed by placebo subcutaneous (SC) injection administration, 8 weeks after the initial IV dose, then q8w thereafter until the end of DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.
~OLE period: Participants will receive ustekinumab SC at Week OL-0, followed by SC administration of ustekinumab with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from the first SC administration after the end of DB period, whichever is later.
~LTE Period: Participants who complete their participation in OLE period may be eligible to enter the LTE and continue to receive 90 mg SC ustekinumab q8w."
16270505|NCT04882046|Other|patients diagnosed by a clinician who suspects leptospirosis|
16270506|NCT04882033|Experimental|Concurrent chemoradiotherapy plus anlotinib|Concurrent chemoradiotherapy plus anlotinib for 4-6 cycles This study will include a sequential evaluation of 3 subjects per dose group. Low-dose groups: anlotinib 8mg per day with concurrent chemoradiotherapy. Middle-dose groups: anlotinib 10mg per day with concurrent chemoradiotherapy. High-dose groups: anlotinib 12mg per day with concurrent chemoradiotherapy.
16270507|NCT04882020||AHI ≤ 5|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≤ 5 events / hour; prior blood collection between 7-9 am and questionnaires.
16270508|NCT04882020||AHI ≥ 30|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≥ 30 events / hour; prior blood collection between 7-9 am and questionnaires.
16270509|NCT04882007|Experimental|OSE-127 High dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
16270510|NCT04882007|Experimental|OSE-127 Low dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
16270511|NCT04882007|Placebo Comparator|Placebo induction phase|Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6
16270512|NCT04882007|Experimental|OSE-127 High dose optional extension phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34
16270518|NCT04881968|Experimental|Video Game Intervention|Each hospitalist 'crosses over' from control to intervention at a single time point by receiving a link to the Hopewell Hospitalist game via email and logging in to play the video game.
16270519|NCT04881955|Experimental|[14C]-Ecopipam|Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of [14C]-ecopipam HCl
16270520|NCT04881942|Experimental|e-Vapor Product A|Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion [2.5% nicotine by weight {NBW}])
16270521|NCT04881942|Experimental|e-Vapor Product B|Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic [4.0% NBW])
16270522|NCT04881942|Experimental|e-Vapor Product C|Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint [3.5% NBW])
16270523|NCT04881942|Experimental|e-Vapor Product D|Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol [4.0% NBW])
16270524|NCT04881929|Experimental|KN026 + Docetaxel|KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles
16270525|NCT04881916||Sample Collection|"Participation In:
~Initial data completion: Telephone collection of information on disease, treatment and testing
~Medical record collection: Collection of medical records regarding cancer, testing, and treatment history
~Archival tissue collection: Collection of tumor from prior standard of care procedure
~Saliva collection: Saliva collection with at home kit
~Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years."
16270526|NCT04881903|Experimental|MIST intervention followed by MIRA intervention|These are both mobile interventions that use interpretation bias modification (IBM) techniques to reduce cognitive biases. The MIST app targets suicidal cognitions and the MIRA app targets hostile interpretation bias (which contributes to anger). The MIRA application has already been developed, but the MIST application is newly developed based on the same procedures. All participants will complete the MIST intervention and provide feedback so that we can refine it. We will also be collecting EMA data on to examine how changes to suicide cognitions and hostile interpretation bias (by use of the two apps) affects suicidal ideation and functioning.
16270527|NCT04881890|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
16270528|NCT04881877|Experimental|Synthetic nitrite Condom|Participants will be randomized to condom use order. Participants will be provided with 5 synthetic nitrite condoms at the first visit and switched to 5 of either the latex graphene condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study
16270529|NCT04881877|Experimental|Latex and graphene Condom|Participants will be randomized to condom use order. Participants will be provided with 5 latex graphene condoms at the first visit and switched to 5 of either the synthetic nitrite condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study.
16270530|NCT04881877|Experimental|Standard latex condom:|Participants will be randomized to condom use order. Participants will be provided with 5 latex condom at the first visit and switched to 5 of either the latex graphene condom or synthetic nitrite condoms at visit 2 and 3. All couples will use each of the 3 condom types during the study.
16270531|NCT04881864|Experimental|Tele-EF|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
16270532|NCT04881851|Experimental|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
16270533|NCT04881851|Experimental|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
16270534|NCT04881851|Placebo Comparator|Folic acid|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
16270535|NCT04881838|Experimental|High risk group|"Stage I, unresected; Stage I with B syndrome
~Stage II
~Stage III
~Stage IV without CNS involvement"
16270536|NCT04881825|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
16270537|NCT04881812|Experimental|Drug-coated balloon|Patients will receive stenting of the actual CTO body with additional DCB treatment of the residual disease of the coronary artery.
16270538|NCT04881812|Active Comparator|Drug-eluting stent|Patients will receive complete stenting of the CTO body and residual disease of the coronary artery.
16270539|NCT04881799|Placebo Comparator|Placebo-Controlled Period|Participants in this phase of the study will be randomized 1:1 to receive either phentermine/topiramate or placebo.
16270540|NCT04881799|Experimental|Open Label Extension|Participants in this phase of the study will receive open label phentermine/topiramate.
16270541|NCT04881786|No Intervention|Untreated teeth control group|Premolars without orthodontic forces
16270542|NCT04881786|Experimental|Moderate force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 45º with a force of 56 g. Forces were measured with an orthodontic dynamometer. For 7 days
16270543|NCT04881786|Experimental|Severe force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 90º with a force of 224 g. Forces were measured with an orthodontic dynamometer. For 24 hours
16270544|NCT04881760|Experimental|LY3437943 Dose 1|LY3437943 administered subcutaneously (SC)
16270545|NCT04881760|Experimental|LY3437943 Dose 2|LY3437943 administered SC
16270546|NCT04881760|Experimental|LY3437943 Dose 3|LY3437943 administered SC
16270547|NCT04881760|Experimental|LY3437943 Dose 4|LY3437943 administered SC
16270548|NCT04881760|Placebo Comparator|Placebo|Placebo administered SC
16270549|NCT04881747|Active Comparator|Lasmiditan (DOSE 1)|Participants will receive lasmiditan as immediate-release (IR) tablet formulation administered orally.
16270550|NCT04881747|Experimental|Lasmiditan (DOSE 2)|Participants will receive lasmiditan as oral-disintegrating (OD) tablet formulation administered orally without water.
16270551|NCT04881747|Experimental|Lasmiditan (DOSE 3)|Participants will receive lasmiditan as oral-disintegrating (OD) tablet formulation administered orally with water.
16270552|NCT04881734||the control group and the overtime group|Patients who started surgery between 8:00 and 16:59 were included in the control group.
16270553|NCT04881734||the overtime group|Patients who started surgery from 17:00 to 22:00 were included in the overtime group.
16270591|NCT04881435|Experimental|Hydrogen gas inhalation therapy accompanied with standard steroid treatment|
16270554|NCT04881708|No Intervention|Current Care Group|The current care group will receive the standard of care currently in place within the subspecialty practices in the Department of Surgery, Mayo Clinic Rochester. This includes postoperative inpatient care directed by the surgical team, including timing of discharge and follow-up.
16270555|NCT04881708|Active Comparator|Remote Care Group|Patients randomized to the remote monitoring arm will engage in a Connected Care Remote Patient Monitoring (RPM) Complex Care program. RPM Complex Care programs utilize established and standardized equipment, logistics/reverse logistic, engagement methods, and nursing clinical practice. Use of RPM Complex Care programs in this manner, is considered standard practice. Patients will be monitored for 30 days by the Connected Care nursing team as is standard for surgical RPM Complex Care programs.
16270556|NCT04881695||Patients|Women aged 18-26 years with congenital (Turner syndrome or other determined or undetermined genetic cause) or acquired (post-therapeutic)
16270557|NCT04881695||Controls|Women aged 18-26 years who do not have a condition that compromises their fertility
16270558|NCT04881682|Experimental|Immunoadsorption|3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)
16270559|NCT04881682|Active Comparator|Immunoglobulins|5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.
16270560|NCT04881669|Experimental|low group|low thickness group
16270561|NCT04881669|Experimental|moderate group|moderate thickness group
16270562|NCT04881669|Experimental|high group|high thickness group
16270563|NCT04881656|Experimental|HIIYH|Help is in Your Hands is a series of online modules for parents with narrated videos of specific interactive strategies for supporting toddlers' communication development.
16270564|NCT04881656|No Intervention|Comparison|No additional materials
16270565|NCT04881643|Experimental|Blended treatment for PTSD|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
16270566|NCT04881630|Active Comparator|Standard Care (SC)|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
16270567|NCT04881630|Experimental|Contingency Management (CM)|CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
16270568|NCT04881617|Experimental|Lexical Retrieval Treatment|
16270569|NCT04881617|Experimental|Script Training|
16270570|NCT04881604|Experimental|Adjustable Compression Wrap|Daily use of the adjustable compression wrap on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy.
16270571|NCT04881604|Active Comparator|Compression Sleeve|Daily use of the compressive sleeve on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy
16270572|NCT04881591|Experimental|APP+Usual Treatment|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
16270573|NCT04881565|Experimental|Reactive balance training plus functional electrical stimulation|
16270574|NCT04881565|Active Comparator|Reactive balance training|
16270575|NCT04881552||Group 1|non-spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade 0-II)
16270576|NCT04881552||Arm 2|spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade III)
16270577|NCT04881539|Experimental|Cannabidiol (CBD)|Each group member will receive one dose of CBD daily for 8 weeks.
16270578|NCT04881539|Placebo Comparator|Placebo|Each group member will receive a calorie matched placebo daily for 8 weeks.
16270579|NCT04881526|Active Comparator|Ketone ester drink|
16270580|NCT04881526|Placebo Comparator|Placebo drink|
16270581|NCT04881513|Other|Structure /function of the taste buds and QoL|"The structure of the taste buds is measured by Narrow Band Imaging (NBI) technique prior to the operation, one month and six months after the surgery.
~The tongue sensation is measured by two point discrimination before the operation, one month and six months after the operation.
~The taste is tested by the taste strips prior to, on month and six month after the surgery.
~The quality of life is measured by the SF36 questionnaire. The threshold change is measured by the stimulating electrode at the beginning and at the end of the surgery."
16270582|NCT04881500|Experimental|Motivational interview|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.
~If the patient was randomized to the intervention group, the patient will receive 2 individual sessions (motivational interview) by telephone within 1 month of inclusion. They will then be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
16270583|NCT04881500|Active Comparator|Routine Care|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.
~If the patient has been randomized to the control group, the patient will be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
16270586|NCT04881474|Active Comparator|ibuprofen and paracetamol|
16270587|NCT04881474|Active Comparator|paracetamol only|
16270588|NCT04881461|Placebo Comparator|Placebo|Glycerol, carbonate, sodium chloride One single-dose container (0.5 ml) once daily
16270589|NCT04881461|Experimental|5-grass mix SLIT-drops|Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.
16270593|NCT04881422|Experimental|Experimental group|A group of pwMS participate in a multidimensional integrate high-motivating rehabilitation program for the change of lifestyle and bad habits.
16270594|NCT04881409|Experimental|nasal high-flow|Patient with AECOPD is treated with NHF.
16270595|NCT04881409|Active Comparator|non-invasive ventilation|Patient with AECOPD is treated with NIV
16270596|NCT04881396||All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine|Serological response is defined by a 4 fold increase of IgG anti-spike protein of SARS-Cov2 between Day 0 (before vaccination) and after complete vaccination (evaluated at Day 7 - 14 post-boost).
16270597|NCT04881383||Patients from Primary Care Clinics|Participating Chinese adults aged 18-84 from Primary Care clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
16270598|NCT04881357|Experimental|Experimental Group|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
16270599|NCT04881357|Placebo Comparator|Control Group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
16270600|NCT04881344|Experimental|The laser hemorrhoidoplasty (laser group, intervention group)|
16270601|NCT04881344|Active Comparator|The hemorrhoidopexy (mucopexy group, control group)|
16270602|NCT04881318|Experimental|Waist-High Compression Tights and Medications|Participants will wear the waist-high compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of waist-high compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
16270603|NCT04881318|Experimental|Waist-High Compression Tights and No Medications|Participants will wear the waist-high compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of waist-high compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
16270604|NCT04881318|Experimental|Abdominal Compression Garments and Medications|Participants will wear the abdominal compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of abdominal compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
16270605|NCT04881318|Experimental|Abdominal Compression Garments and No Medications|Participants will wear the abdominal compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of abdominal compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
16270606|NCT04881305||Cases|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, with cognitive/emotional complaints.
16270607|NCT04881305||Controls|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, reporting no cognitive/emotional complaints.
16270608|NCT04881279||Control|Trauma admissions in April-June 2016.
16270609|NCT04881279||Ransomware Group|Trauma admissions in April-June 2017.
16270610|NCT04881266||Post Critical Illness due to COVID-19|
16270611|NCT04881266||Caregivers of Post critically ill COVID-19 patients|
16270612|NCT04881240|Experimental|Group A|Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
16270613|NCT04881240|Experimental|Group B|Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.
16270614|NCT04881227|Experimental|Chatbot condition|Participants randomly assigned to this arm will access to a Chatbot condition, in which they had the opportunity to interact with the chatbot on COVID-19 vaccine hesitancy.
16270615|NCT04881227|Active Comparator|Control condition|Participants randomly assigned to this arm will access to a brief text describing the way vaccines work.
16270616|NCT04881214|No Intervention|Control|Patients in this arm will receive standard of care
16270617|NCT04881214|Experimental|Pulmonary Rehabilitation|Patients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included.
16270618|NCT04881201|Other|Patients Charcot-Marie-Tooth|
16270619|NCT04881201|Other|Control subjects|
16270620|NCT04881188||Patients with chronic low back pain|Patients suffering from chronic low back pain (duration longer than 3 months) undergoing a multimodal pain therapy
16270621|NCT04881175|Experimental|FlexSure Applicator|The TempSure FlexSure applicator will be used on the abdomen or flanks.
16270622|NCT04881162|Experimental|NOVIS Transcarotid Neuroprotection System (NPS)|Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.
16270623|NCT04881149|Experimental|TempSure Device|The TempSure will be used on the flanks during this study.
16270624|NCT04881136|Experimental|Reveal LINQ|The Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present is implanted to the participants who are have experienced non accidental falls. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data.
16296658|NCT04699734|Placebo Comparator|Isotonic saline|Nerve block
16270627|NCT04881110|Experimental|Liraglutide group|Patients in this arm will receive liraglutide, according to the current clinical practice.
16270628|NCT04881110|Other|Control group|Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.
16270629|NCT04881084|Experimental|Digital storytelling group (Group 1)|Participants will be randomly assigned to the digital storytelling group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six digital storytelling videos which will be assessed using a between-subjects design.
16270630|NCT04881084|Active Comparator|Social marketing/fundraising group (Group 2)|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
16270631|NCT04881071|Experimental|Scarf|
16270632|NCT04881071|No Intervention|Usual clinical practice|
16270633|NCT04881058|Experimental|PicoSure Device|The PicoSure device will be used on the face for the treatment of pigmentation and mild to moderate wrinkles.
16270637|NCT04881032|Experimental|AGuIX + chemoradiotherapy (radiotherapy + temozolomide)|addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II
16270638|NCT04881032|Sham Comparator|chemoradiotherapy (radiotherapy + temozolomide)|standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II
16270639|NCT04881019||Type 2 Diabetes|Individuals who have been diagnosed with Type 2 diabetes.
16270640|NCT04881019||Non type 2 diabetes|Individuals who have not been diagnosed with Type 2 diabetes.
16270641|NCT04881006|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
16270642|NCT04881006|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
16270643|NCT04880993|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
16270644|NCT04880993|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
16270645|NCT04880980|Active Comparator|Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral terbinafine for the treatment of dermatophyte skin infections.
16270646|NCT04880980|Active Comparator|Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral itraconazole for the treatment of dermatophyte skin infections
16270649|NCT04880954|Experimental|Soft Tissue Mobilization|
16270650|NCT04880954|Experimental|Rehabilitation|
16270651|NCT04880954|Experimental|Soft Tissue Mobilization and Rehabiliation|
16270652|NCT04880941|Experimental|Progressive Relaxation Exercise|The Progressive Relaxation Exercise will be held 7 days for 4 weeks, a total of twenty eight sessions. Each session is set as fifty minutes
16270653|NCT04880941|No Intervention|Control group|Routine maintenance will be applied
16270656|NCT04880915|Experimental|SMOKE PROTECTION|Pre- and post-operative blood and urine samples of the surgical team (surgeon, surgical resident, anaesthesiologist, scrub nurse, circulating nurse, support staff and researcher), who worked in the standard practice, and the use of four different preventive measures that may affect the surgical smoke exposure during total mastectomy surgery in the operating room of the General Surgery Department of a University HospitaL. The surgical resident, anaesthesiologist, anaesthesia technician and support staff included in the study did not consist of the same people due to the change in the work schedules. Blood and urine samples were collected from a team of seven people before and after surgery [7 volunteers × 2 (blood and urine before and after surgery) = 14 (14 blood analysis + 14 urine analysis) 14 × 5 surgery = 70 (70 blood analysis + 70 urine analysis)].
16270657|NCT04880902|Experimental|sleeve gastrectomy followed by volumetric assessment|
16270658|NCT04880889|Experimental|BL 3000|One capsule, once a day for 180 days.
16270659|NCT04880889|Active Comparator|Reference - Pantogar -|One capsule, three times a day for 180 days
16270660|NCT04880876|Experimental|Open Label 6-11 years of age: Eluxadoline 50mg|Eluxadoline two 25mg tablets, oral administration, twice daily with food. Take at approximately the same time each day.
16270661|NCT04880876|Experimental|Open Label 12-17 years of age: Eluxadoline 100 mg|Eluxadoline one 100mg tablet, oral administration, twice daily with food. May use 25mg tablets to administer 100mg dose. Take at approximately the same time each day.
16270662|NCT04880876|Experimental|Double Blind 6-11 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
16270663|NCT04880876|Experimental|Double Blind 6-11 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
16270664|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
16270665|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
16270666|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 100mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
16270668|NCT04880850|Experimental|insulin icodec + insulin aspart|Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart
16270669|NCT04880850|Active Comparator|Insulin glargine + insulin aspart|Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart
16270670|NCT04880837|Experimental|Prevention (educational session, handout, survey)|Participants attend educational session about HPV-related cancers, screening, and HPV vaccination and guidelines and receive informational infographic handout on HPV vaccination. Participants also complete surveys pre and post education session over 5 minutes each to assess HPV vaccination status among children of participants, HPV knowledge, and intentions to get the HPV vaccination, and screening among participants. In addition, participants complete surveys over telephone or face-to-face at 3 and 6 months.
16270671|NCT04880824||PG cohort|800 randomized surgical study patients with a frailty syndrome (Pre-frail and frail) of the intervention study PRÄP-GO (PG cohort). 400 study patients receive the intervention and 400 study patients receive standard of care.
16270672|NCT04880824||NFC cohort|400 non-frail surgical control group (NFC cohort)
16270673|NCT04880824||NO cohort|300 non-operative control group (NO cohort)
16270674|NCT04880824||GB cohort|25 participants with health professions (GB cohort)
16270675|NCT04880811|Experimental|Afatinib plus toripalimab|
16270676|NCT04880798|Experimental|124I PET/CT|All eligible patients will be allocated to this arm (single-arm study).
16270677|NCT04880785|Experimental|Dovato (Dolutegravir+lamivudine)|Treatment: Dolutegravir 50 mg/Lamivudine 300 mg, one film coated-tablet once daily during 96 weeks
16270678|NCT04880772|No Intervention|Standard care|Standard Care: Surgery school as per ELHT pre-operative guidelines (includes generic pre-operative information, advice and optimisation e.g correction of anaemia)
16270679|NCT04880772|Experimental|Prehabilitation|Surgery School plus Moderate intensity exercise & Forceval (multivitamin)
16270680|NCT04880759|Experimental|Bike desks in classroom|All participants receive the same intervention: the use of bike desks during school.
16270681|NCT04880746|Active Comparator|BEAC|Patients in this arm will receive BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
16270682|NCT04880746|Experimental|Cladribine combined with BEAC|Patients in this arm will receive Cladribine combined with BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
16270683|NCT04880733|Experimental|Acupuncture|This arm will receive acupuncture for pain management, and any pain medications will be delayed until after receipt of acupuncture.
16270684|NCT04880733|Active Comparator|Usual Care|This arm will receive usual care for pain management.
16270685|NCT04880720||COVID-19 Patients|
16270686|NCT04880720||Rheumatoid Arthritis Patients|
16270687|NCT04880720||Healthy Comparator|
16270688|NCT04880707|Active Comparator|Twin Block with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
16270689|NCT04880707|Placebo Comparator|Twin Block with sterile normal saline|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block using sterile normal saline, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
16270690|NCT04880694|Experimental|Cohort 1: STC3141 58.3mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72 hours) N=10
16296956|NCT04697745|Active Comparator|dexamethasone intrathecal|
16270691|NCT04880694|Experimental|Cohort 2: STC3141 87.5mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72 hours) N=10
16270692|NCT04880694|No Intervention|Cohort 3: Comparator|Only to receive appropriate standard of care N=5
16270693|NCT04880681|Experimental|Novel needle|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.
16270694|NCT04880681|Active Comparator|Standard Tru Cut needle|Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000).
16270695|NCT04880668|No Intervention|Control - No aerosol box|Participants will perform the AGMP without an aerosol box
16270696|NCT04880668|Experimental|Intervention - Aerosol box|Participants will perform the AGMP with an aerosol box
16270697|NCT04880655|Experimental|Intervention|Dressed with WSD and petrolatum gauze
16270698|NCT04880655|Active Comparator|Control|Dressed with bacitracin and petrolatum gauze
16270701|NCT04880616|Experimental|Sequence 1|In treatment period 1 participants will receive increasing doses of NBI-827104 for 28 days. After a 14-day washout period, participants will receive matching placebo for 28 days in treatment period 2.
16270702|NCT04880616|Experimental|Sequence 2|In treatment period 1 participants will receive matching placebo for 28 days. After a 14-day washout period, participants will receive increasing doses of NBI-827104 for 28 days in treatment period 2.
16270703|NCT04880603|Active Comparator|A - Standard of Care|
16270704|NCT04880603|Experimental|B - Restrata Graft|
16270705|NCT04880590||Sex Intercourse|women with a heterosexual sexual relationship after embryo transfer
16270706|NCT04880590||Non sex intercourse|women without a heterosexual sexual relationship after embryo transfer
16270709|NCT04880564|Experimental|A (CN1 0.5mg/kg and CN401 400mg)|"Patients were administered with CN1, 0.5mg/kg, once every three week in combination with 400mg CN401 twice a day, fasted.
~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral
~Three to six patients are expected to be enrolled in each arm."
16270710|NCT04880564|Experimental|B (CN1 1mg/kg and CN401 600mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 600mg CN401 twice a day, fasted.
~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral
~Three to six patients are expected to be enrolled in each arm"
16270711|NCT04880564|Experimental|C (CN1 1mg/kg and CN401 800mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.
~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral
~Three to six patients are expected to be enrolled in each arm"
16270712|NCT04880564|Experimental|D (CN1 3mg/kg and CN401 800mg)|"Patients were administered with CN1, 3mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.
~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral
~Three to six patients are expected to be enrolled in each arm"
16270713|NCT04880564|Experimental|E (CN1 10mg/kg and CN401 800mg)|"Patients were administered with CN1, 10mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.
~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral
~Three to six patients are expected to be enrolled in each arm"
16270714|NCT04880551||COPD patients with a recent Spirometry|Patients that have a diagnosis of COPD and have completed a recent Pulmonary Function Test - Spirometry.
16270715|NCT04880538||Asymptomatic patients for any motility disorder|
16270716|NCT04880538||Patients with gastrointestinal dysmotility|
16270717|NCT04880525|Experimental|Study Group|The study group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). In addition to pilates, the women in the SG followed a personalized weight loss diet. In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
16270718|NCT04880525|No Intervention|Control Group|The control group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). Individuals in the CG received no dietary or nutritional intervention. On any diet, the status of women in the CG was frequently questioned.
16270719|NCT04880512|Experimental|SYHX 1901 tablets for SAD|Two subjects will be enrolled in a single dose group which is recommended as the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of SYHX 1901 tablets in fasted state.
16270720|NCT04880512|Placebo Comparator|Placebo for SAD|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo in fasted state
16270721|NCT04880512|Experimental|SYHX 1901 tablets for MAD|8 out of 10 healthy subjects will be randomized to receive multiple doses of SYHX 1901 tablets in fasted state
16270722|NCT04880512|Placebo Comparator|Placebo for MAD|2 out of 10 healthy subjects will be randomized to receive multiple doses of placebo in fasted state
16270723|NCT04880499|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus other cofactors for hematopoiesis, other than the standard of care.
16270724|NCT04880499|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
16270725|NCT04880486|Sham Comparator|Control group|usually care with extra health education on upper limb exercise
16270726|NCT04880486|Experimental|Exercise group|usually care with extra supervision upper limb exercise with VR
16270727|NCT04880473|Experimental|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
16270729|NCT04880460|Placebo Comparator|Control|This arm includes 45 MDD patients receiving SSRIs
16270731|NCT04880434|Experimental|Brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma will receive conditioning chemotherapy consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg, with a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 3.
16270732|NCT04880395|Experimental|Experimental : Dolutegravir plus Lamivudine|DOVATO: Dolutegravir 50mg/lamivudine 300 mg, FDC, 1 coformulated tablet QD
16270733|NCT04880395|Active Comparator|active comparator : TDF/XTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)|"Unit Dose:
~TDF/FTC 300/200 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD OR
~TDF/3TC 300/300 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD"
16270734|NCT04880382|Other|Standard Arm A: treatment by ICI will be continued|After achieving objective response between 6 and 12 months after treatment onset, for these patients ICI treament will continue as per market authorization
16270735|NCT04880382|Experimental|Experimental Arm B: treatment by ICI will be discontinued|After achieving objective response between 6 and 12 months after treatment onset, for these patients first-line or second line regimen should be discontinued. Patients will be followed as per standard management.
16270736|NCT04880369|Experimental|Lignan capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
16270737|NCT04880369|Experimental|Isoflavones capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
16270738|NCT04880369|Placebo Comparator|Placebo capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
16270739|NCT04880356||Retrospective study|collection of retrospective data from adult patients with ultra-rare inherited neurological diseases
16270740|NCT04880356||Prospective study|prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years
16270741|NCT04880343|No Intervention|Group (C)|Control
16270742|NCT04880343|Experimental|Group (A)|Treatment
16270743|NCT04880343|Experimental|Group (B)|Treatment
16270744|NCT04880330|Experimental|Experimental: Cryo-Auriculotherapy|Patients benefit from 1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
16270745|NCT04880330|Sham Comparator|Sham Comparator: Control group|Patients benefit from 1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points..
16270746|NCT04880317|Experimental|Single arm|
16270747|NCT04880304|Experimental|ADHD diagnosis and subconcussive head impacts|"ADHD Group: Individuals clinically diagnosed with ADHD, currently taking his/her prescribed ADHD medication.
~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
16270748|NCT04880304|Experimental|No history or current diagnosis of ADHD and subconcussive head impacts|"Non-ADHD Group: Individuals with no current or prior diagnosis of ADHD.
~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
16270749|NCT04880291|Active Comparator|GFB-024 SAD Active|Single ascending dose arm of GFB-024 treatment
16270750|NCT04880291|Placebo Comparator|SAD Placebo|Single ascending dose arm of placebo treatment
16270751|NCT04880291|Active Comparator|GFB-024 Repeat-dose Active|Repeat-dose arm of GFB-024 treatment
16270752|NCT04880291|Placebo Comparator|Repeat-dose Placebo|Repeat-dose arm of placebo treatment
16270753|NCT04880278|Active Comparator|Nabilone|In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
16270754|NCT04880278|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
16270755|NCT04880265||Patients undergoing cardiac surgery|
16270756|NCT04880239|Active Comparator|Sacralcolpopexy with posterior colpoperineorrhaphy|
16270757|NCT04880239|No Intervention|Sacralcolpopexy without posterior colpoperineorrhaphy|
16270758|NCT04880226|Other|Healthy Volunteers|Imaging of healthy volunteers would performed to optimize image parameters (contrast, SNR) prior to clinical imaging of actual patients receiving treatment.
16270759|NCT04880226|Experimental|Patients receiving MRI-guided procedures|As described in the study protocol this imaging would be performed to evaluate a given sequence for potential benefit during MR-guided interventions.
16270760|NCT04880213|Experimental|Japanese: M5049 Dose A (low dose)|
16270761|NCT04880213|Experimental|Japanese: M5049 Dose B (medium dose)|
16270762|NCT04880213|Experimental|Japanese: M5049 Dose C (high dose)|
16270763|NCT04880213|Experimental|Caucasian: M5049 Dose A (low dose)|
16270764|NCT04880213|Experimental|Caucasian: M5049 Dose B (medium dose)|
16270765|NCT04880213|Experimental|Caucasian: M5049 Dose C (high dose)|
16270766|NCT04880200|Experimental|POC NAT & Adherence Intervention|These participants will receive the POC NAT test during their study visit. The result will be conveyed to their provider, who will deliver the result and an adherence intervention.
16270767|NCT04880200|No Intervention|Standard of Care|These participants will receive the clinical standard of care during their visit.
16270768|NCT04880187|Active Comparator|AXA1125 22.6g|22.6 g AXA1125 administered orally BID with or without food
16270769|NCT04880187|Active Comparator|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
16270770|NCT04880187|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
16270771|NCT04880174|Other|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
16270772|NCT04880161|Experimental|Active|Ampion
16270773|NCT04880161|Placebo Comparator|Control|Placebo
16270774|NCT04880148|Experimental|Thyme and Honey-based oral spray|Thyme and Honey-based oral spray
16270775|NCT04880148|Placebo Comparator|Placebo oral spray|Placebo oral spray
16270776|NCT04880135|Experimental|Supervised stretching and strengthening exercise|Stretching and strengthening exercises will be performed under the supervision of Physical therapist for a period of one month
16270777|NCT04880135|Experimental|Home-based stretching and strengthening exercises|Stretching and strengthening exercises will be performed at home by individuals having musculoskeletal pain due to quarantine for a period of one month.
16270778|NCT04880122|Experimental|Nursing home residents/staff members|Matched venous blood/dried blood spots collection in a single arm.
16270781|NCT04880096||chronic pain patients|All adult patients followed-up in participating pain clinics
16270782|NCT04880083|Experimental|Formula-Fed (FF) Group|Subjects will be fed commercial bovine milk-based, whey-predominant, α-lactalbumin-enriched term formula with high sn-2 palmitate fat blend, supplemented with oligofructose for 6 weeks.
16270783|NCT04880083|No Intervention|Breast-Fed (BF) Group|Subjects will continue exclusive/ predominant breastfeeding for 6 weeks. Breastmilk may be consumed directly from the breast or breast milk may be expressed and fed through infant feeding bottle.
16270784|NCT04880070|Experimental|Shockwave Device|The Shockwave device will be used on multiple areas of the body for the purpose of treating connective tissue.
16270785|NCT04880057|Active Comparator|Resistance+Aerobic training group|Resistance+Aerobic training group (RAeT) RAeT includes resistance training (RT) program and aerobic training (AeT) program.
16270786|NCT04880057|Experimental|Agility training group|Agility training
16270787|NCT04880044|Experimental|EC/EG & EGD|"Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay
~If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected)
~If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent"
16270788|NCT04880031|Experimental|Cohort A1: BOS-580 Dose 1 or placebo (PBO)|
16270789|NCT04880031|Experimental|Cohort A2: BOS-580 Dose 2 or PBO|
16270790|NCT04880031|Experimental|Cohort A3: BOS-580 Dose 3 or PBO|
16270791|NCT04880031|Experimental|Cohort A4: BOS-580 Dose 4 or PBO|
16270792|NCT04880031|Experimental|Cohort A5: BOS-580 Dose 5 or PBO|
16270793|NCT04880018|Experimental|Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd|Specification model: CTR1109、CTR1210、CTR1311、CTR1412、CTR1513 Manufacturer: Eyebright Medical Technology (Beijing) Co., Ltd.
16270794|NCT04880018|Active Comparator|Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd|Specification model: TENSIOBAG 10、TENSIOBAG 11、TENSIOBAG 12、TENSIOBAG 13、TENSIOBAG14 Manufacturer: Carl Zeiss Medical Technology Co., Ltd.
16270795|NCT04880005|Experimental|The intervention group|The three core elements of the intervention are: 1) individualized data-driven recommendations to GPs on how to treat each individual T2D patient, as well as 2) individualized digital coaching of T2D patients, and 3) on-line presentation of patient registered outcomes (PRO) to GPs.
16270796|NCT04880005|No Intervention|Control group|Usual care
16270797|NCT04879992|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
16270798|NCT04879992|Experimental|rifabutin triple therapy|Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid
16270799|NCT04879979|Experimental|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) designed for the treatment of Cancer-Related Cognitive Impairment (CRCI)
16270800|NCT04879966||UC cohort|the patiente of Moderate to Severe Ulcerative Colitis who recieved infliximab(IFX) or corticosteroids(CS) as induction therapy would be enrolled in this cohort
16270801|NCT04879953||PIPAC CHEM|PIPAC associated with systemic chemotherapy
16270802|NCT04879953||ONLY CHEM|systemic chemotherapy alone
16270804|NCT04879927|Experimental|RESOURCE Matching|Participants randomized into the intervention arm will receive customized resource matching
16270805|NCT04879927|Active Comparator|Usual Care|Participants randomized into the control group will receive a pre-existing pamphlet detailing DFCI resources
16270806|NCT04879914|Experimental|Butyrate|Patients taking butyrate
16270807|NCT04879914|Experimental|Placebo|Patients taking placebo
16270808|NCT04879901|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
16270809|NCT04879888|Experimental|Vacuna|Triple-negative breast cancer patients with specific tumor mutation, with six doses of peptide-pulsed autologous dendritic cells after surgery.
16270810|NCT04879875|Experimental|Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.
~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
16270811|NCT04879875|Experimental|Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.
~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
16270814|NCT04879849|Experimental|Combination Dose Escalation Phase: Radiation + Pembrolizumab + TAK-676|Participants will receive image-guided radiation therapy between Day -8 and Day -1. Participants will then receive pembrolizumab 200 milligram (mg), infusion, intravenously, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by TAK-676 infusion with escalating doses (0.2 mg and above), intravenously, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurs first.
16270815|NCT04879836||Teething Ring + Teething Gel|
16270816|NCT04879836||Teething Ring|
16270817|NCT04879823|Experimental|Dexamethasone|"IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup.
~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.
~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
16270818|NCT04879823|Placebo Comparator|Placebo|"An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.
~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
16270819|NCT04879810|Active Comparator|Ginger exosomes|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
16270820|NCT04879810|Active Comparator|Curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
16270821|NCT04879810|Active Comparator|Ginger exosomes plus curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
16270822|NCT04879797|Other|Maternal Safety Bundles Implementation|The first intervention targets obstetric hemorrhage, severe hypertension and maternal health equity by implementing three relevant AIM bundles: Obstetric Hemorrhage, Severe Hypertension in Pregnancy, and Reduction of Peripartum Racial/Ethnic Disparities. The Perinatal Neonatal Quality Improvement Network (PNQIN) will facilitate this collaborative QI project and support participating hospitals by providing guidance, education, and technical assistance to hospitals to support implementation of bundles using the QI process. Implementation strategies are based on the Institute for Healthcare Improvement (IHI) improvement model and the AIM program implementation toolkit and have previously been used by PNQIN to implement the Obstetric Care for Women with Opioid Use Disorder AIM bundle in 22 hospitals, including the five hospitals for this study.
16270823|NCT04879797|Other|Doula Services|The second intervention that this study evaluates is doula services. Investigators are evaluating doula services that are offered by two doula organizations at three hospitals. Investigators will provide top-up training to these doulas in order to provide some standardization and quality assurance of the services delivered. The training is developed and delivered by an obstetrician (Meadows) and doula (Gebel) and will take place among providers (staff associated with three chosen hospitals), patient navigators, and two doula groups, Birth Sisters and Accompany Doula Care, on factors that comprise the risk profile and how to offer targeted doula services to women who fit the risk profile. All sites will use standardized data instruments to evaluate the number of factors in the risk profile being met as well as standardized language and recruitment materials for mothers.
16270824|NCT04879784||Stored antenatal sera|Antenatal sera from women booking for antenatal care at six centres in England
16270825|NCT04879771||Morning GIE|
16270826|NCT04879771||Afternoon GIE|
16270827|NCT04879758|No Intervention|Control Group|The control group will receive a Fitbit device and general lifestyle advice e-leaflet, which includes information about T2D, health impacts of T2D and lifestyle advice on 4 major risk markers of T2D (e.g., PA, diet, smoking, weight management) as recommended by the World Health Organization.
16270828|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk of T2D in addition to the Fitbit and e-leaflet.
16270829|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
16270830|NCT04879745|Experimental|Decision Aid Users|Patients with a rheumatic disease who are given access to the MyVoice:Rheum decision aid
16270831|NCT04879745|Active Comparator|Pamphlet Users|Patients with a rheumatic disease who are given access to a widely-accessible pamphlet about family planning
16270832|NCT04879745|Experimental|Rheumatologists|Rheumatologists who interact with patients who have used the MyVoice: Rheum decision aid
16270833|NCT04879732|Other|ACTIS hip stem|All participants will receive the ACTIS hip stem.
16270834|NCT04879719|Experimental|Ego-depletion group|Participants in this condition are asked to suppress their emotion while watching an emotional video of a surgery. Suppressing the natural emotional reaction to such a video demands cognitive resources and thus can induce a state of ego-depletion.
16270835|NCT04879719|Active Comparator|Control group|Participants in the control group are asked to watch the same emotional video. However, they are required to simply watch the video without suppressing any emotions.
16270836|NCT04879706||AKI necessitating KRT|Patients with AKI necessitating KRT
16270837|NCT04879693|Experimental|Hospitalized Patients|To assess performance of CGM compared to comparator measurement.
16270838|NCT04879667|No Intervention|group (1)|surgical management of gastrocutaneous fistula after laparoscopic sleeve gatrectomy by surgical exploration
16270839|NCT04879667|Active Comparator|group (2)|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
16270840|NCT04879654|Experimental|endonasal endoscopic surgery with adjuvant therapy|endonasal endoscopic surgery followed by Toripalimab,radiotherapy and/or chemotherapy
16270841|NCT04879641|No Intervention|1_Waiting List control|Randomized participants will only get the full intervention after study completion period (6 months since the randomization)
16270842|NCT04879641|Experimental|2_Exposure only|Randomized participants will only get the Exposure component
16270843|NCT04879641|Experimental|3_Attention Training only|Randomized participants will only get the Attention Training component
16270844|NCT04879641|Experimental|4_Exposure + Attention Training|Randomized participants will get Exposure + Attention Training components
16270845|NCT04879641|Experimental|5_Cognitive Restructuring only|Randomized participants will only get the Cognitive Restructuring component
16270846|NCT04879641|Experimental|6_Cognitive Restructuring + Exposure|Randomized participants will get Cognitive Restructuring + Exposure components
16270847|NCT04879641|Experimental|7_Cognitive Restructuring + Attention Training|Randomized participants will get Cognitive Restructuring + Attention Training components
16270848|NCT04879641|Experimental|8_Cognitive Restructuring + Attention Training + Exposure|Randomized participants will get Cognitive Restructuring + Attention Training + Exposure components
16270849|NCT04879641|Experimental|9_Psychoeducation only|Randomized participants will only get the Psychoeducation component
16270850|NCT04879641|Experimental|10_Psychoeducation + Exposure|Randomized participants will get the Psychoeducation + Exposure components
16270851|NCT04879641|Experimental|11_Psychoeducation + Attention Training|Randomized participants will get the Psychoeducation + Attention Training components
16270852|NCT04879641|Experimental|12_Psychoeducation + Attention Training + Exposure|Randomized participants will get the Psychoeducation + Attention Training + Exposure components
16270853|NCT04879641|Experimental|13_Psychoeducation + Cognitive Restructuring|Randomized participants will get the Psychoeducation + Cognitive Restructuring components
16270854|NCT04879641|Experimental|14_Psychoeducation + Cognitive Restructuring + Exposure|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Exposure components
16270855|NCT04879641|Experimental|15_Psychoeducation + Cognitive Restructuring + Attention Training|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training components
16270856|NCT04879641|Experimental|16_full version (Psychoeducation + Cognitive Restructuring + Attention Training + Exposure)|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training + Exposure components
16270857|NCT04879628|Experimental|IV SAR441344|SAR441344 IV
16270858|NCT04879628|Placebo Comparator|IV Placebo|Placebo IV
16270859|NCT04879628|Experimental|SC SAR441344|SAR441344 SC
16270860|NCT04879628|Placebo Comparator|SC Placebo|Placebo SC
16270861|NCT04879615|Experimental|Alteplase with standard therapy|
16270862|NCT04879615|No Intervention|Standard therapy|
16270863|NCT04879602|Experimental|Bronchoscopy group|patients receive suction before extubation by bronchoscopy in PACU
16270864|NCT04879602|No Intervention|Control group|patients receive routine ordinary suction in PACU
16270865|NCT04879589|Experimental|SC ATRS-2002|3 different dosages (25mg, 75mg and 200mg) will be tested as single SC injection into the abdomen.
16270866|NCT04879589|Active Comparator|Oral Abiraterone Acetate|A single dose of 1000mg of commercially available oral formulation of abiraterone acetate will be administered to enrolled participants in Cohort 4
16270867|NCT04879576|Experimental|Treatment Group|
16270868|NCT04879576|No Intervention|Control Group|
16270869|NCT04879563|Experimental|ASCAPE-based follow-up strategy|Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions.
16270870|NCT04879550||thrombotic event developing / not|Group I: Patients with no bleeding/thrombosis complications Group II: Patients with Thrombotic and/or thromboembolic complications Group III: Patients with bleeding complications
16270871|NCT04879537|No Intervention|Control|Participants in this group are routinely treated.
16270872|NCT04879537|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
16270873|NCT04879524||Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|100 units of Botulinum toxin type A (Botox, Allergan, Ireland) injection into the puborectalis muscle to each side of the midline, achieving a total of 200 units
16270874|NCT04879511|Active Comparator|Receiving metformin|Active group receiving metformin with basal /bolus insulin
16270875|NCT04879511|Placebo Comparator|Placebo|Control group receiving Placebo with basal/bolus insulin
16270876|NCT04879498|Experimental|Monolithic zirconia|Monolithic zirconia posterior 3-unit fixed partial dentures
16270877|NCT04879498|Active Comparator|Veneered zirconia|Veneered zirconia posterior 3-unit fixed partial dentures
16270878|NCT04879498|Active Comparator|Metal-ceramic|Metal-ceramic posterior 3-unit fixed partial dentures
16270879|NCT04879485|No Intervention|Standard transfusion|Includes standard transfusion with a mixture of red blood cells and plasma
16270880|NCT04879485|Active Comparator|Plasma|Transfusion with plasma
16270881|NCT04879485|Active Comparator|Red Blood cells|Transfusion with red blood cells
16270882|NCT04879472||Age 50 years and below|"Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement
~Surgical approach either posterior, lateral or anterolateral
~Type of anaesthesia either general or spinal
~Presence or absence of comorbidities
~Sex"
16270981|NCT04878679|Experimental|"Strength training + WB-EMS"|Strength training combined with WB-EMS : 2 times/week for 20 minutes
16270883|NCT04879472||Age more than 50 years|"Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement
~Surgical approach either posterior, lateral or anterolateral
~Type of anaesthesia either general or spinal
~Presence or absence of comorbidities
~Sex"
16270884|NCT04879459||Intervention Group IG|"The IG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0 (same video as in CG). Participants undertake 3 times a one-day CUS course consisting in 2 practical sessions of 10 times 10 minutes on 10 healthy volunteers on day 0, day 7 and day 10. One practical session takes place before lunchtime, the second one after lunchtime.
~Participants of IG don't have any contact with CG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
16270885|NCT04879459||Control Group CG|"The CG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0. Participants of CG undertake 2 practical CUS sessions of 10 times 10 minutes on 10 volunteers, at least 50% of them suffering from gallstones on day 0, day 7 and day 10. One session takes place before lunchtime, the second one after lunchtime.
~Participants of CG don't have any contact with IG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
16270886|NCT04879446|Experimental|A-PRF Test Group|Advanced Platelet Rich Fibrin liquid applied into the implant cavity and implant surface. That is the only difference between A-PRF control group and A-PRF test group.
16270887|NCT04879446|Experimental|CGF Test Group|Concentrated growth factor liquid applied into the implant cavity and implant surface. That is the only difference between CGF control group and CGF test group.
16270888|NCT04879446|Experimental|A-PRF Control Group|Dental implant applications were made with traditional methods.
16270889|NCT04879446|Experimental|CGF Control Group|Dental implant applications were made with traditional methods.
16270890|NCT04879420||Teriparatide|Reference Group
16270891|NCT04879420||Risedronate|Exposure Group
16270892|NCT04879407||Warfarin|Reference group
16270893|NCT04879407||Rivaroxaban|Exposure group
16270894|NCT04879394|Experimental|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
16270895|NCT04879394|No Intervention|Control|Receives standard care as usual. Assessments will be made in the same time points as experimental group, but without undergoing intervention.
16270896|NCT04879381||Cystic Fibrosis patients|Sputum samples
16270897|NCT04879368|Experimental|RegoNivo|"Participants in the RegoNivo arm will;
~self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and;
~receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion.
~After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days."
16270898|NCT04879368|Active Comparator|Standard of Care|"Participants in the control arm will receive investigator choice chemotherapy with any of the following agents
~taxane (paclitaxel or docetaxel)
~irinotecan or
~oral trifluridine/tipiracil (TAS102)
~All treatment groups will receive Best Supportive Care (BSC)."
16270899|NCT04879355|Experimental|Spinal needle|Fine needle aspiration from thyroid nodules using af spinal needle.
16270900|NCT04879355|Active Comparator|Conventional fine needle|Fine needle aspiration from thyroid nodules using af conventional fine needle, which is traditionally used.
16270901|NCT04879342|Experimental|VIP Program Group|Participants in this group will receive a 26 week course on risk reduction strategies.
16270903|NCT04879316||adult patients with NSCLC initiating nivolumab or pembrolizumab|Patients underwent a multidisciplinary evaluation including consultation with an oncologist and a dietitian. Such an assessment includes subjective and objective parameters such as medical history, weight loss, current dietary intake (including energy and protein balance), physical examination and anthropometric measurements, functional and mental assessment, medications, Resting Energy Expenditure measurement using indirect calorimetry and laboratory values.
16270904|NCT04879303|Experimental|Robot-assisted social skill intervention|Social robotics will be used by the instructor to conduct the social skill training activities.
16270905|NCT04879303|Active Comparator|Human-only instruction program on social skill training|The children will receive only the human-delivered social skill training.
16270906|NCT04879303|No Intervention|Control|There will be no intervention conducted during the tested period
16270907|NCT04879290|Active Comparator|Control Group FiO2=1|FiO2 = 1 (100%) 10mn before emergence of general anesthesia
16270908|NCT04879290|Experimental|Intervention Group FiO2 0.5|Fi02 = 0.5 (50%) 10mn before emergence of general anesthesia
16270909|NCT04879277|Other|Healthy subject|"The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
~Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex."
16270910|NCT04879277|Other|Patient with phenylketonuria|The intervention, specific to the study, is to take blood samples on patients with phenylketonuria
16270911|NCT04879264|Experimental|Patients irradiated for breast cancer|Participants with breast cancer who receive adjuvant radiotherapy following breast-conserving surgery or mastectomy.
16270912|NCT04879238|Experimental|Yoga-Mindfulness Intervention|Completing single session of yoga blended with mindfulness.
16270913|NCT04879225|Experimental|E-liquid Availability|Flavor availability is manipulated
16270914|NCT04879212|Experimental|PCIA +Acupuncture group|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, but no electricity. Acupuncture was given once a day. PCIA（patient controlled intravenous analgesia）.
16270979|NCT04878692|Experimental|Onco-Rash arm|"In this arm label, patients will apply the Onco-Rash cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.
~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks."
16270915|NCT04879212|Experimental|PCIA +2 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 2Hz, continuous wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
16270916|NCT04879212|Experimental|PCIA +20/100 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 20 / 100Hz, density wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
16270917|NCT04879199|Experimental|Typically Developing (TD) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) who are typically developing, 3) able to stand and walk alone without using assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
16270918|NCT04879199|Experimental|Spastic Cerebral Palsy (sCP) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) with the diagnosis of spastic CP or CP similar (both unilateral and bilateral), functionally classified level I or II according to the Gross Motor Function Classification System (GMFCS) [98], 3) being able to stand and walk alone without assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
16270919|NCT04879186||Patients undergoing peripheral endovascular angioplasty|Patients undergoing peripheral endovascular angioplasty. No intervention other than what was already completed as part of routine clinical care, as this is a retrospective cohort.
16270920|NCT04879173||Hyperthyroidism caused by Graves' disease|
16270921|NCT04879173||Hyperthyroidism caused by painless/subacute thyroiditis|
16270927|NCT04879147||Syncope|Subjects admitted immediately after syncopation.
16270928|NCT04879147||Seizre|Subject admitted immediately after cerebarl seizure
16270929|NCT04879134|Experimental|Apomorphine Injections|
16270930|NCT04879134|Placebo Comparator|Placebo Injections|
16270931|NCT04879121|Experimental|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of unacceptable toxicity. Patients who experience disease progression and are deriving clinical benefit from larotrectinib may continue treatment per physician discretion.
16270932|NCT04879108|Experimental|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation approaches after thoracic surgery.
~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.
~TENS therapy was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy rehabilitation for 30 min, twice a day, 5 day a week.
~Patients were evaluated before the surgery and the end of postoperative 5th day."
16270933|NCT04879108|Active Comparator|Physiotherapy rehabilitation Group|"This group was enrolled only physiotherapy and rehabilitation program after thoracic surgery.
~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.
~Patients were evaluated before the surgery and the end of postoperative 5th day."
16270934|NCT04879082||ILD|Patients with ILD, whose file has been discussed in a multidisciplinary meeting since May 2020 at the Louis Pradel Pneumological Hospital, and who have benefited from a professional interview in the Occupational pathology consultation center of the Hospital Center Lyon Sud.
16270935|NCT04879069||Intermediate-high risk PE|Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level
16270936|NCT04879069||High-risk PE|"Confirmed PE causing hemodynamic instability:
~Cardiac arrest (need for cardiopulmonary resuscitation) or,
~Obstructive shock (systolic blood pressure < 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or
~Persistent hypotension (systolic blood pressure < 90 mmHg for at least 15 minutes)"
16270937|NCT04879056||intra-system|reviewing selected features on images from three iterations of the same scanner.
16270938|NCT04879056||inter-system|reviewing selected features on images from three different scanners.
16270939|NCT04879043|Experimental|HDP-101|"Participants will receive HDP-101 intravenously at one dose every 3 weeks (21 day cycle) until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.
~During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered."
16270940|NCT04879030|Active Comparator|beta-lactam monotherapy|only beta-lactam antibiotics
16270941|NCT04879030|Experimental|beta-lactam and fluoroquinolone combination therapy|one beta-lactam antibiotic and one fluoroquinolone
16270943|NCT04879004|Experimental|Ropivacaine Group|ESPB performed with infusion of Ropivacaine 0,375% (20 ml at ech side)
16270944|NCT04879004|Placebo Comparator|Control Group|ESPB performed with infusion of N/S 0,9% (20 ml at each side)
16270980|NCT04878692|Placebo Comparator|Onco-Neutre arm|"In this arm label, patients will apply the Onco-Neutre cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.
~Onco-Neutral cream will be used as an experimental comparator to Onco-Rash cream.
~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks."
16296957|NCT04697745|Active Comparator|dexmedetomidine intrathecal|
16270945|NCT04878991||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.
~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.
~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation."
16270946|NCT04878978|Active Comparator|Routine care|Women who present with PPROM or threatened PTL and have routine care
16270947|NCT04878978|Experimental|Amniocentesis and biofire directed antibiotic use|Women who present with PPROM or threatened PTL and randomised to amniocentesis and biofire directed antibiotic treatment
16270948|NCT04878965|Other|Smartwatch|Individuals receiving the smartwatch
16270949|NCT04878952|No Intervention|Arm I: Usual Care|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
16270950|NCT04878952|Experimental|Arm II: Usual Care + Continuous physical activity monitoring via a wearable device|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.
16270951|NCT04878939|Experimental|Anterior segment retraction using sliding mechanics (friction)|Power chain
16270952|NCT04878939|Experimental|Anterior segment retraction using segmental mechanics (frictionless)|T-loop
16270953|NCT04878926|Active Comparator|Group A (n=30)|IV Sedation + TAP block
16270954|NCT04878926|Active Comparator|Group B (n=30)|IV Sedation + LA infiltration
16270955|NCT04878913||C21|Subject treated with C21 in the VP-C21-006 trial
16270956|NCT04878913||Placebo|Subject treated with placebo in the VP-C21-006 trial
16270957|NCT04878887|Other|IP-DRA|In plane distal radial artery catherterization
16270958|NCT04878887|Other|IP-PRA|In plane proximal radial artery catherterization
16270959|NCT04878874|No Intervention|No Intervention:hip flexion|hip flexion pre measurement with extension knee will be performed
16270960|NCT04878874|Experimental|Experimental: hip flexion|hip flexion post experimental application measurement with Magnetic tape Application with extension knee will be performed
16270961|NCT04878874|Placebo Comparator|Placebo Comparator: hip flexion|hip flexion post placebo application measurement with kinesiology tape Application with extension knee will be performed
16270962|NCT04878861|Experimental|Training in blind field|All participants undergo this intervention. Internal control is comparing sighted and non-sighted parts of the field.
16270963|NCT04878848|Experimental|Proprioceptive Neuromuscular Facilitation Group|"Participants in the proprioceptive neuromuscular facilitation group will be given a treatment protocol consisting of rhythmic initiation, repeated stretch and hold-relax PNF techniques for upper extremity flexion-abduction-external rotation pattern and the scapular patterns of anterior elevation, posterior depression, anterior depression, posterior elevation for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks."
16270964|NCT04878848|Experimental|Conventional Rehabilitation Group|Participants in the conventional rehabilitation group will be given a treatment protocol consisting of stretching, strengthening exercises and joint mobilization techniques for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks.
16270965|NCT04878835|No Intervention|Control group|No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery
16270966|NCT04878835|Experimental|Intervention group|The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery
16270967|NCT04878809|Experimental|Experimental group|People attending L'Horitzó School (students, teachers, administrative and service staff)
16270968|NCT04878809|Other|Control Group|Escola John Talabot, will provide the incidence rate of infections by SARS-CoV-2
16270969|NCT04878770|Active Comparator|Topical corticosteroids (control)|This group will receive topical corticosteroids.
16270970|NCT04878770|Active Comparator|Systemic cyclosporine|This group will receive topical corticosteroids and systemic cyclosporin.
16270971|NCT04878770|Active Comparator|Systemic dupilumab|his group will receive topical corticosteroids and systemic dupilumab.
16270972|NCT04878757|Experimental|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
16270973|NCT04878757|No Intervention|Control - Business-As-Usual|Involves participation in the schools' typical math program
16270974|NCT04878744|Experimental|Noticing the good things about green spaces|"The intervention condition will prompt participants once a day to notice the good things about green spaces, write notes about the 'good things in nature' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of species variety).
~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation.
~Both the intervention and active control conditions are based on gratitude interventions. Practicing gratitude in controlled psychological intervention settings has been shown to have lasting effects on dispositional gratitude and psychological wellbeing (Seligman et al. 2005)."
16270975|NCT04878744|Active Comparator|Noticing the good things about built spaces|"In the control condition, participants will not be prompted to notice nature, rather they will be prompted to record the good things about the built environment, write notes about the 'good things in built spaces' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of the area being built-up).
~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation."
16270976|NCT04878731|Experimental|single arm|PF-06741086 300mg subcutaneous(SC)
16270977|NCT04878705|Experimental|TWP-201|
16270978|NCT04878705|Placebo Comparator|placebo|
16270982|NCT04878679|Experimental|Cardiovascular training + WB-EMS|Cardiovascular training, using rowing machine, combined with WB-EMS : 2 times/week for 20 minutes
16270983|NCT04878679|Active Comparator|Control group|No physical activity
16270984|NCT04878640|Active Comparator|Group A|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
16270985|NCT04878640|Active Comparator|Group B|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
16270988|NCT04878614|Active Comparator|Standard Levothyroxine Management|Participants will continue with the same regimen
16270989|NCT04878614|Experimental|Liquid Levothyroxine Management|Participants will be treated with dose equivalent regimen through enteral feeding tube
16270990|NCT04878601|Experimental|hbART|Home-Based ART initiation and continuation for 3-months with male-specific counseling and assisted facility navigation at 4-months.
16270991|NCT04878601|Active Comparator|fbART|Facility-Based ART initiation and continuation with male-specific counseling.
16270992|NCT04878588||patients receiving esophagectomy|the patients receiving esophagectomy during perioperative period. They receive barium examination and high resolution impedance manometry at the same time
16270993|NCT04878575||ASD group|120 ASD patients (aged 5-18 years)
16270994|NCT04878575||ADHD group|120 ADHD patients (aged 5-18 years)
16270995|NCT04878575||TDC group|120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders
16270996|NCT04878562|Experimental|I-COPE Intervention|5 out of the 25 participating primary care sites are randomly assigned to any of the 5 steps. The ICOPE intervention is implemented after a pre interventional period of 3-15 months. The intervention is implemented during 8 weeks. The length of the post interventional period is 11-23 months.
16270997|NCT04878562|No Intervention|No intervention|Standard of care offered to all patients.
16270998|NCT04878549||Febrile Adults|1200 adult participants (15 to 45 years old) with a febrile illness without localising features and reported duration of 3-14 days.
16270999|NCT04878549||Controls|400 afebrile, healthy adult participants (15 to 45 years old).
16271000|NCT04878549||Febrile Children|400 child participants (2 to 14 years old) with a febrile illness without localising features and reported duration of 3-14 days. This is an exploratory arm of the study.
16271001|NCT04878536|Placebo Comparator|Placebo drink|
16271002|NCT04878536|Experimental|Collagen drink|
16271003|NCT04878523|Placebo Comparator|Placebo drink|
16271004|NCT04878523|Experimental|multi berries juice|
16271005|NCT04878510|Experimental|Dexmedetomidine Intervention|Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada. Guidelines, the infusion will start at a mid-range dose of 0.6mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (Richmond Agitation-Sedation Scale [RASS] = -2 to +1 or Riker Sedation-Agitation Scale [SAS] 3-4).
16271006|NCT04878510|Placebo Comparator|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 50mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.
16271007|NCT04878497||Warfarin|New users of warfarin
16271008|NCT04878497||Dabigatran|New users of dabigatran
16271009|NCT04878497||Rivaroxaban|New users of rivaroxaban
16271010|NCT04878497||Apixaban|New users of apixaban
16271011|NCT04878497||Edoxaban|New users of edoxaban
16271012|NCT04878484|Experimental|Cohort 1: TCRT-ESO-A2: 0.3 × 1010 TCRT-ESO-A2 cells * ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
16271013|NCT04878484|Experimental|Cohort 2: TCRT-ESO-A2: 1.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor.
16271014|NCT04878484|Experimental|Cohort 3: TCRT-ESO-A2 : 3.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
16271015|NCT04878471|Experimental|ASP5354|Three participants in three dose levels will receive a single intravenous dose of ASP5354 on Day 1 under fasting conditions.
16271220|NCT04877067|Active Comparator|Only WJ-MSC|WJ-MSC was applied only one time for both eyes.
16271016|NCT04878471|Placebo Comparator|ASP5354 Matching Placebo|One participant in three dose levels will receive a single intravenous dose of matching placebo on Day 1 under fasting conditions.
16271017|NCT04878458|Experimental|PEI+GSL+GT|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
16271018|NCT04878458|Experimental|PEI+Trab|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy.
16271019|NCT04878445||Cohort A: 10 participants with no COPD|"Control patients Have no physician diagnosis of COPD Have no other significant chronic lung disease (asthma, fibrotic diseases) or ongoing lung infection other than the suspected cancer for which they have been referred for surgery.
~Lifelong never-smokers or ex-smokers (< 10 pack years). (1 pack year= 20 cigarettes/day for 1 year)."
16271020|NCT04878445||Cohort B: 10 participants with COPD - chronic bronchitis|Have a physician diagnosis of COPD with primarily a chronic bronchitis presentation (determined via CT, spirometry, histopathology, GOLD COPD classification).
16271021|NCT04878445||Cohort C: 10 participants with COPD emphysema|Have a physician diagnosis of COPD with primarily a emphysema presentation (determined via CT, spirometry, histopathology, GOLD COPD classification) .
16271022|NCT04878432|Experimental|MBG453 (sabatolimab) + HMA|MBG453 + HMA (azacitidine, decitabine, or INQOVI (oral decitabine))
16271023|NCT04878419|Experimental|Virtual Educational Intervention|Virtual Educational Intervention
16271024|NCT04878406|Experimental|1.7 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 1.7 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
16271025|NCT04878406|Placebo Comparator|Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
16271026|NCT04878406|Experimental|8.6 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 8.6 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
16271027|NCT04878406|Placebo Comparator|Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
16271028|NCT04878406|Experimental|30 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 30 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
16271029|NCT04878406|Placebo Comparator|Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
16271030|NCT04878393||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment
16271031|NCT04878380|Active Comparator|Tracking|Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.
16271032|NCT04878380|Experimental|Goal-Setting|"Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.
~During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight."
16271035|NCT04878354|Placebo Comparator|Placebo|Gelatine (fish source), mannitol and sodium hydroxide
16271036|NCT04878354|Experimental|Intervention/treatment|Sublingual allergy immunotherapy tablet, for daily administration SQ tree SLIT-tablet
16271037|NCT04878341|Experimental|Erector Spinae plane Block|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and the transverse process of T5-T7 vertebrae and Erector Spinae (ES) fascia will be located with a linear ultrasound probe. A 19G or 20G epidural needle (according to age) will be positioned under the ES muscle and a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered; after hydrodissection, the catheter will be threaded, followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
16271038|NCT04878341|Active Comparator|Thoracic Epidural Anesthesia|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and a 19G or 20G epidural needle (according to age) will be positioned at T5-T7 level with cathether placement; a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered and followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
16271039|NCT04878328|Experimental|onsite Point-of-care (o-POC)|CHWs will reach out to participants to schedule O-PoC visits. At O-PoC visits, CHWs will provide: 1. COVID-19 education; 2. PoC Cepheid XpertXpressSARS-CoV-2PCR tests; 3. Needs assessments and facilitated access to masks and hygiene supplies; 4. Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5. Supportive counseling. Due to SCT's emphasis on social influence, external and internal social reinforcement, we propose our O-PoC intervention delivered by CHWs onsite at Fortune locations over a 12-month period will lead to increased uptake of mitigation behaviors.
16271040|NCT04878328|No Intervention|Standard of Care (SOC)|he current standard of care (SoC) for SARS-CoV-2 testing for Fortune clients is referral to offsite community testing sites and informal, unstructured education. In the SoC arm, Fortune staff will provide clients with a list of offsite SARS-CoV-2 testing locations, which are published online and available to all NYC residents. Those without insurance are not subject to a copay.Participants in SoC will continue to receive Fortune's suite of services as they are delivered (remote and/or in-person) at the time of study participation.
16271041|NCT04878315|Experimental|Treatment sequence TRR|Participants will receive Capoten (T) in period 1 followed by Captopril (R) in period 2 followed by Captopril (R) in period 3.
16271042|NCT04878315|Experimental|Treatment sequence RTR|Participants will receive Captopril (R) in period 1 followed by Capoten (T) in period 2 followed by Captopril (R) in period 3.
16271043|NCT04878315|Experimental|Treatment sequence RRT|Participants will receive Captopril (R) in period 1 followed by Captopril (R) in period 2 followed by Capoten (T) in period 3.
16271044|NCT04878302|Experimental|Experimental: Taming Tics Together Protocol|"Families will participate in the 5-day telehealth-based intensive intervention and will receive three treatment formats which will provide CBIT and co-occurring diagnosis treatment:
~Child/teen-only groups
~Individual one-to-one sessions
~Parent/caregiver-only groups"
16271045|NCT04878302|No Intervention|1-Month Waitlist Control|Families in the 1-month waitlist control group will participate in the initial intake assessment, then receive no treatment for a 1-month period. Following the 1-month period, families will participate in an assessment, then will be offered a place in a Taming Tics Together group
16271046|NCT04878289|Experimental|TOTAL Intervention|TOTAL video and participate in three one-on-one, 30-minute motivational sessions via VVC at 1-week, 6-months, and 12-months
16271047|NCT04878276||Dimet 5|"Dimet 5 is a certified medical device for the treatment of head lice infestation. It contains only (liquid) dimeticone oil and, when used correctly, enables physical killing of head lice and their eggs."
16271048|NCT04878276||Hedrin Once Liquid Gel|Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).
16271049|NCT04878263|Active Comparator|Control group|
16271050|NCT04878263|Experimental|FIL-EAS ic group|
16271051|NCT04878250|Experimental|Bintrafusp alfa|
16271052|NCT04878237|Placebo Comparator|Non Allergic Patients|
16271053|NCT04878237|Active Comparator|Allergic Asthma Patients|Allergy to Grass Pollen
16271054|NCT04878237|Active Comparator|Allergic Rhinitis Patients|Allergy to Grass Pollen
16271055|NCT04878211|Experimental|Ofatumumab - vaccine 2 weeks prior|RMS participants will receive non-live COVID-19 mRNA vaccine at least two weeks prior to start of ofatumumab (20 mg subcutaneous)
16271056|NCT04878211|Experimental|Ofatumumab -vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least four weeks after start of ofatumumab (20 mg subcutaneous)
16271057|NCT04878211|Active Comparator|Interferon or glatiramer acetate - vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least 4 weeks after start of prescribed interferon or glatiramer acetate
16271058|NCT04878198|Experimental|Jogging intervention|This intervention will be a 10-week jogging program consisting of 50 sessions (5 sessions per week, 30 min per session) in each participating school. The jogging program is confined to morning sessions based on the favourable sleep outcomes from previous study. To counteract the possible influence of natural sunlight exposure, all jogging sessions will be confined to indoor setting. Each session will be conducted in an identical format with 5 minutes of warm-up activities, followed by 20 minutes of jogging (intervention), and 5 minutes of cool-down activities. Participants are instructed to jog at a moderate intensity level. The intensity level of jogging will be measured by heart rate monitor (Polar H1). Meanwhile, questionnaire will be given to the research staff assisting the jogging intervention to assess the adherence of the intervention at T2.
16271059|NCT04878198|Experimental|Melatonin supplement group|Participants in this intervention group will undergo a 10-week melatonin supplement intervention period, where melatonin supplement (Natrol®, Chatsworth CA) will be provided 30 minutes before bedtime. The prescription time (i.e. 30 minutes before bedtime) and the dosage of 3mg will be used because these are optimal for most of the participants as suggested by Malow and colleagues. 1 mg and 9 mg are not suggested to ensure the effectiveness of the intervention while preventing the potential daytime sleepiness. Similar to the aforementioned intervention, adherence of the intervention will be assessed at T2.
16271060|NCT04878198|Experimental|Combination group|Participants will receive the jogging program and supplemental melatonin dose with identical format as that in the intervention A and B (e.g., identical duration, identical manpower, identical warm-up and cool-down, identical dose, identical acclimation procedure before the intervention adherence of the intervention for this group will also be assessed at T2.
16271061|NCT04878198|No Intervention|Control group|Participants in the placebo control group will receive no jogging and melatonin supplement dosing activity. However, they will be given a placebo flavored similar to the melatonin supplement (compounded by Pharmacare, Mt. Juliet, NT®). Meanwhile, they will also be required to wear an actigraph to control for their physical activity level at the assessment points (i.e. T1, T2, and T3). They will be expected for following their daily routine without participating in any additional formal physical exercise training program throughout the whole study period (T1-T3). After T3, they will be assisted with jogging program to recognize their contribution as controls.
16271062|NCT04878185|Experimental|Exercise|"A high-intensity, home-based, exercise program consisting of inspiratory muscle training (IMT), endurance- and functional strength exercise. The sessions will supervised by a physiotherapist during six occasions and start 2-3 weeks before surgery. IMT will be conducted with an intensity starting from 50 % of maximal capacity, with a self-reported effort of 5-7 on the Borgs CR-10 scale. Endurance and functional strength exercises will be performed at a self-reported effort of 7-8. Interval training, chair stand- and step-up exercises will be key components of the exercise program. Furthermore, the program will include task-specific exercises based on the participants self-expressed needs.
~On non-supervised days, participants will perform IMT twice a day as well as endurance and strength training, 2-3 days per week with 1-2 days per week of active recovery in the form of moderate intensity walks. This will be monitored with an activity journal and an accelerometer."
16271063|NCT04878185|No Intervention|Control group|Participants in the control group receive pre- and postoperative care as usual. In addition, they will be encouraged to follow the WHO guidelines of moderate intensity aerobic physical activity for at least 150 min per week. Their activity level will be monitored with an accelerometer.
16271146|NCT04877548|Experimental|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
16271068|NCT04878159||Emergency high-risk abdominal surgery|Patients undergoing emergency high-risk abdominal surgery, defined as immediate emergency laparoscopy or laparotomy, including intestinal obstruction, perforated viscus, intestinal ischemia and intraabdominal bleeding. Includes both primary surgery and re-operation after elective surgery.
16271069|NCT04878146|Active Comparator|Sacrocolpopexy|Used as the standard intervention for prolapse
16271070|NCT04878146|Experimental|Sacro-spinous fixation|To be demonstrated as non inferior
16271071|NCT04878133|Experimental|Exsperimental Arm|
16271072|NCT04878133|No Intervention|Control Arm|
16271073|NCT04878120|Active Comparator|Standard Hybrid Closed Loop Control (USS Virginia)|Use of Standard Hybrid Closed Loop Control
16271074|NCT04878120|Experimental|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI|Use of Hybrid Closed Loop Control with Enhanced Prandial Dosing
16271075|NCT04878107|Experimental|SBRT/LDRT + Camrelizumab +Apatinib|SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）
16271076|NCT04878107|Active Comparator|SBRT + docetaxel|docetaxel 75mg/m2 SBRT（8Gy×3f）
16271077|NCT04878094|Active Comparator|Arm A|Randomized to standard technique and assessment of anastomosis without the use of NIR angiography
16271078|NCT04878094|Experimental|Arm B|Randomized to additional assessment of proximal colonic stump and anastomotic perfusion using NIR angiography
16271079|NCT04878068||Rapid Antigen Saliva Test|Participants who have had a COVID-19 PCR test will self-administer the saliva test. The research team will conduct the processing of the test for the results of positive, negative or inconclusive
16271080|NCT04878055|Experimental|Reparixin|Reparixin oral tablets, 1200 mg three times daily (TID) (2 tablets 600 mg each, TID) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care
16271081|NCT04878055|Placebo Comparator|Placebo|placebo, 2 tablets TID (identical to Reparixin tablets) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care.
16271082|NCT04878042|Experimental|Active|Mouth wash and nasal spray containing a diluted solution of hydrogen peroxide
16271083|NCT04878042|Placebo Comparator|Placebo|Mouth wash and nasal spray not containing a diluted solution of hydrogen peroxide
16271084|NCT04878029|Experimental|Treatment (cabozantinib, enfortumab vedotin)|Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16271085|NCT04878016|Experimental|ZKAB001＋carboplatin+etoposide|"The induction phase will consist of four cycles of ZKAB001 plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, patients will receive drug infusions in the following order:
~ZKAB001 → carboplatin → etoposide"
16271086|NCT04878016|Placebo Comparator|placebo + carboplatin + etoposide|"The induction phase will consist of four cycles of placebo plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, all eligible patients will receive drug infusions in the following order:
~placebo → carboplatin → etoposide"
16271087|NCT04878003|Experimental|Arm 1|KRT-232 administered orally as 240 mg once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles
16271088|NCT04878003|Experimental|Arm 2|TL-895 administered orally as 150 mg twice daily continuously in 28-day cycles
16271089|NCT04877990|Experimental|Long-Term Extension Rollover Study: BMS-986165|
16271092|NCT04877964||pediatric patients with scoliosis|Patients aged 3-14 years with scoliosis and who request epidural analgesia
16271093|NCT04877951|Other|Effect of LSVT BIG therapy on Postural Control and Gait Parameters|LSVT BIG is a commonly used protocol to manage functional movement for those with Parkinson's Disease. This study measured postural control and gait parameters following a 4-week course of LSVT BIG therapy.
16271094|NCT04877938|Experimental|Echological Intervention|A starting point for this 'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV). Taking into consideration the guidance provided by ecologic models of health behavior evidences about specific constructs to guide EEI may be derived from behavioral research on physical activity.
16271095|NCT04877938|Active Comparator|Standard Physical Activity Intervention|People included in this group will be assigned to a standard physical activity program that will follow the guidelines of the American College of Sport and Medicine. The program will include moderate intensity aerobic and strength training, three times a week for a total amunt of 200 min of physical activity/week.
16271096|NCT04877938|No Intervention|Control group|Individuals included in this group will be asked to keep their life style,without taking part in any physical activity program.
16271097|NCT04877925|Active Comparator|Standard Group|Patients with 2 standard chest tubes
16271098|NCT04877925|Experimental|Coaxial Group|Patients with 1 coaxial tube
16271099|NCT04877912||Biopsy Group|We will scan 50 women who are scheduled for a breast biopsy. Subjects will receive an MRI exam that is research-only prior to the biopsy.
16271100|NCT04877912||MRI Unknown Cancer Status Group|We will scan 150 women with dense breasts and/or women who have intermediate risk of breast cancer for this study. Subjects will receive an MRI exam that is research-only.
16271101|NCT04877886|Experimental|Ultrasound with IV contrast|use ultrasound with IV contrast to perform in acute flank pain patient
16271102|NCT04877886|Active Comparator|CT with IV contrast|to compare with ultrasound with IV contrast in acute flank pain patient
16271103|NCT04877886|Active Comparator|Ultrasound without IV contrast|baseline for the Ultrasound with IV contrast
16271104|NCT04877886|Active Comparator|CT without IV contrast|baseline for the CT with IV contrast
16271105|NCT04877860|Experimental|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Access to the PaiNEd system.
16297054|NCT04697095|Sham Comparator|Patientes with No AMD|
16271106|NCT04877860|Active Comparator|Multimodal rehabilitation program + traditional biomedical information|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Dossier with traditional biomedical recommendations on the management of pain and disability.
16271107|NCT04877860|Active Comparator|Control group|Information dossier with recommendations on pain control and dysfunction improvement.
16271108|NCT04877847|Experimental|Low-Frequency Therapeutic Ultrasound|LOTUS system will be operated per operated per normal instructions
16271109|NCT04877847|Sham Comparator|Sham Control|LOTUS system will be set to Control setting
16271110|NCT04877834|Experimental|DelanzoTMDR group|Subjects will take DelanzoTMDR 60 mg Capsule, manufactured by SAMI Pharmaceuticals (Pvt.) Ltd. after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
16271111|NCT04877834|Active Comparator|Dexilant® Group|Subjects will take Dexilant® 60 mg Capsule, manufactured by Takeda Pharmaceutical Company Limited after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
16271112|NCT04877821|Experimental|Sintilimab + Anlotinib + Chemotherapy|Experimental: Sintilimab + Anlotinib + Chemotherapy Participants receive Sintilimab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + (Nab paclitaxel weekly + carboplatin (Q3W) x 4 cycles followed by epirubicin + cyclophosphamide Q3W x 4 cycles) as neoadjuvant therapy prior to surgery. After surgery, those who exhibited residual disease were treated with capecitabine (1000-1250 mg/m2) given two-times a day for 1-14 days and cycled every 21 days for a total of 6-8 cycles.
16271113|NCT04877795||Cardiac Surgery|Adult Patients undergoing elective on-pump cardiac surgery (i.e. Coronary artery bypass graft surgery (CABG) and/or valvular surgery)
16271114|NCT04877782||Healthy older participants|Healthy older participants receiving both stimulation conditions (experimental and placebo) randomized across scanning sessions.
16271115|NCT04877769|Experimental|AT-527 Group A|n=8
16271116|NCT04877769|Experimental|AT-527 Group B|n=8
16271117|NCT04877769|Experimental|AT-527 Group C|n=8
16271118|NCT04877756|Experimental|Arm A 2.0 mg/cm OLX10010 biweekly|Arm A- half the scar treated with 2.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
16271119|NCT04877756|Experimental|Arm B 5.0 mg/cm OLX10010 biweekly|Arm B- half the scar treated with 5.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
16271120|NCT04877756|Experimental|Arm C 2.0 mg/cm OLX10010 weekly|Arm C- half the scar treated with 2.0 mg/cm of OLX10010 weekly, other half treated with OLX Placebo
16271121|NCT04877743||Prospective Cohort|This prospective cohort study will include participants who receive the AZD1222 vaccine. Enrolment is permitted within 28 days of the first dose of AZD1222 and can be completed at the vaccination site or remotely.
16271122|NCT04877730|Experimental|FCL (Fully Closed Loop)|Closed-loop control without meal anticipation module without meal bolus
16271123|NCT04877730|Experimental|FCL+ (Fully Closed Loop with meal anticipation)|Closed-loop control with meal anticipation module without meal bolus
16271124|NCT04877730|Experimental|HCL (Hybrid Closed Loop)|Closed-loop control without meal anticipation module with meal bolus
16271125|NCT04877717|Experimental|SHR-A1904|
16271126|NCT04877704|Experimental|Symprove|Symprove probiotic
16271127|NCT04877704|Placebo Comparator|Placebo|Matched placebo provided by Symprove. Identical in appearance to Symprove probiotic.
16271132|NCT04877652||ADHF patients|Patients with acute decompensated heart failure (ADHF) having insufficient response to diuretic therapy following a dose escalation protocol in keeping with AHA guidelines for the management of heart failure.
16271133|NCT04877639|Active Comparator|Esmketamine group|Intravenous injection of 1.0mg/kg esmketamine was given, and nasal endoscopy was started 3 minutes later to maintain 1.0mg/kg/h esmketamine
16271134|NCT04877639|Active Comparator|Dexmedetomidine group|Dexmedetomidine 1 μg/ kg at least 10 min after intravenous injection + maintain 1 μ After intravenous injection of dexmedetomidine 1 ug / kg, sufentanil 0.05 mg / kg was given 5 minutes
16271135|NCT04877626|Active Comparator|AQ+AS|Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).
16271136|NCT04877626|Active Comparator|AM+L|Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
16271137|NCT04877613|Experimental|Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion|
16271138|NCT04877613|Experimental|Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion|
16271139|NCT04877613|Experimental|Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion|
16271140|NCT04877613|Experimental|Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion|
16271141|NCT04877600||gender difference|dual task performance
16271142|NCT04877587|Experimental|Ascorbate in combination with Gemcitabine|"The study will begin with a safety run-in.
~A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. Gemcitabine is administered following standard fixed dose infusion practice adopted at The University of Iowa Hospitals & Clinics. Ascorbate is infused prior to gemcitabine. Cycles are 28 days. Patients will be treated for a total of 6 cycles and assessed every 2 cycles for disease response."
16271143|NCT04877574|Experimental|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI index.
16271144|NCT04877574|Active Comparator|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
16271145|NCT04877548|Experimental|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
16271147|NCT04877548|Placebo Comparator|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
16271148|NCT04877535|Experimental|Intervention|ML will be used to create a report card for each patient that summarizes the preoperative assessment and intraoperative data. Report card data will be made available to providers through multiple methods: integration into electronic health records workflows, electronic health records notifications, mobile device notifications, and print outs in the paper chart
16271149|NCT04877535|No Intervention|Pre-intervention|The standard of care. The report card will be electronically generated (to determine eligibility) but it will not be visible to clinicians.
16271150|NCT04877522|Experimental|Asciminib 40 mg BID single agent group|participants with CML-CP, from Novartis sponsored asciminib studies, including but not limited to ABL001A2301 and ABL001A2202 studies, that were receiving asciminib
16271151|NCT04877522|Other|Bosutinib single agent group|participants with CML-CP, from Novartis sponsored asciminib study ABL001A2301, that were receiving bosutinib
16271152|NCT04877522|Experimental|Bosutinib-asciminib switch group|participants with CML-CP, from Novartis sponsored asciminib study ABL001A2301 that were receiving bosutinib treatment and switched to asciminib when entering this study or during the course of this study
16271153|NCT04877522|Experimental|Asciminib 40 mg QD combined with imatinib group|participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving asciminib combined with imatinib
16271154|NCT04877522|Experimental|Asciminib 60 mg QD combined with imatinib group|participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving asciminib combined with imatinib
16271155|NCT04877522|Other|Imatinib single agent group|participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving imatinib
16271156|NCT04877522|Other|Nilotinib single agent group|participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving nilotinib
16271157|NCT04877509||Over 50 year's COVID-19 patients hospitalized at HCL from 1st March to 29th May 2020.|
16271158|NCT04877496||Immunocompetent controls|Participants aged at least 18 years, no history of COVID19, no history of anti-CD20 treatment
16271159|NCT04877496||Patients with a treatment history of rituximab|Participants aged at least 18 years, no history of COVID19, history of at least 1 dose of anti-CD20 treatment received since 01/01/2010
16271160|NCT04877483|Experimental|Group GB20|Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
16271161|NCT04877483|Experimental|Group GB20 plus BL2|Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
16271162|NCT04877483|Other|Healthy control|Healthy control group will not received any treatment. And we could use the proteomics, oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.
16271163|NCT04877470||Newly referred patients visiting the spine-centre|Newly referred patients visiting the spine-centre at Zuyderland Medical Centre Heerlen in 2019, from 01.01.2019 until 31.12.2019.
16271164|NCT04877457|Experimental|Ocrelizumab|Three courses of ocrelizumab will be administered over the course of the study.
16271165|NCT04877457|Placebo Comparator|Placebo|Three courses of placebo will be administered over the course of the study.
16271166|NCT04877444|Experimental|Aerobic exercise (AEx) + upper extremity rehabilitation|Subject will receive a total of 24 intervention sessions. In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.
16271167|NCT04877444|Experimental|Stretching (CON) + upper extremity rehabilitation|Subjects will perform 15 minutes of lower extremity stretching. Following lower extremity stretching subjects will receive 200 repetitions of DDP.
16271168|NCT04877431||De Nova Participants|De nova participants who had received teduglutide after marketing authorization will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
16271169|NCT04877431||Legacy Participants|Legacy participants who received teduglutide treatment prior to marketing authorization under expanded access type of program will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
16271170|NCT04877418|Experimental|TeleCIMT group|"One month after baseline evaluations, patients will receive a 3-week program through TeleCIMT.
~Task Oriented Repetitive Training
~Use of the Affected Upper Extremity
~Transfer Package"
16271171|NCT04877392|No Intervention|Control|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure.
16271172|NCT04877392|Experimental|Case|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure. The neonate also had a 7 x 7 cm gauze pad with 1 drop (43.75 mg) of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under their nose for 2 minutes prior to starting the frenotomy and for the duration of the procedure.
16271173|NCT04877379|Experimental|Part 1|Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.
16271174|NCT04877379|Experimental|Part 2A|Multiple dose administration of VNRX-7145 q8h for 10 days
16271175|NCT04877379|Placebo Comparator|Part 2B|Multiple dose administration of placebo q8h for 10 days
16271176|NCT04877379|Experimental|Part 3A|Multiple dose administration of low dose VNRX-7145 + VNRX-5024
16271177|NCT04877379|Experimental|Part 3B|Multiple dose administration of high dose VNRX-7145 + VNRX-5024
16271178|NCT04877379|Placebo Comparator|Part 3C|Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)
16271179|NCT04877366|Active Comparator|ARM A: Sprinkled Format REDUCOSE|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
16271180|NCT04877366|Placebo Comparator|ARM B: Placebo B: Standard Meal|A placebo matching to the test product will be used as control
16271181|NCT04877366|Placebo Comparator|ARM C: Placebo C: Acarbose|Acarbose 100 mg tablet (provided in open-label format)
16271182|NCT04877353|Experimental|Group N|50 patients.NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
16271183|NCT04877353|No Intervention|group C|50 patients recieved conventional oxygen therpy.
16271184|NCT04877340|Other|Standard FNA 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a standard FNA 22G needle
16271185|NCT04877340|Experimental|Franseen 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a FNB 22G needle. The sequence of the use of needles will be randomized.
16271188|NCT04877314|Experimental|Intermittent fasting|
16271189|NCT04877301|Experimental|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter.
16271190|NCT04877301|Active Comparator|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter.
16271191|NCT04877288|Experimental|Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap|Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)
16271192|NCT04877288|Active Comparator|Arm 2: Continue calcineurin inhibitor-based regimen|
16271193|NCT04877275|Experimental|Arm I: Selinexor+Pegylated liposomal doxorubicin +Dexamethasone|Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects. 4 weeks per cycle and include a total of 12 cycles.
16271194|NCT04877275|Experimental|Arm II: Selinexor+Cyclophosphamide+Dexamethasone|Arm II is given XCd regimen (ATG-010 100mg/d QW, Cyclophosphamide 300mg/m2, d1and Dexamethasone 40mg/d QW). 4 weeks per cycle and include a total of 12 cycles.
16271195|NCT04877262|Experimental|Diet period 1|Participants will be provided a weight-maintenance diet for 9 consecutive days on 2 separate occasions, separated by at least 3 weeks.
16271196|NCT04877262|Experimental|Diet period 2|Participants will be provided a weight-maintenance diet for 9 consecutive days on 2 separate occasions, separated by at least 3 weeks.
16271197|NCT04877249|Experimental|Gait training for stroke|
16271198|NCT04877249|Active Comparator|Gait training for healthy|
16271199|NCT04877236|Experimental|Green Sun Medical Brace|This study only has one arm, administration of the Green Sun Medical Whisper Brace.
16271200|NCT04877223||CF|Patients with Cystic Fibrosis
16271201|NCT04877210|Experimental|Topical Insulin|Insulin (Actrapid) diluted in normal saline
16271202|NCT04877210|Placebo Comparator|Normal Saline|Normal saline eyedrops
16271203|NCT04877210|Active Comparator|Standard Artifical Tear|Gutt systane ultra
16271204|NCT04877197|Experimental|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
16271205|NCT04877197|Active Comparator|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
16271206|NCT04877184|Experimental|Transcranial ultrasound stimulation and rehabilitation|The investigators expect to enroll 10 people in the experimental group.
16271207|NCT04877184|Active Comparator|Rehabilitation|The investigators expect to enroll 10 people in the control group.
16271208|NCT04877171|Experimental|telemedicine neurology consultation|Starting on day 12-14 post-discharge, participants will receive a phone call for a drug conciliation. Participants at 1-month post-discharge will receive a telemedicine consultation, another at 3 months and 6 months.
16271209|NCT04877171|Active Comparator|in-person neurology consultation|Starting at 1-month post-discharge, participants will attend an in-person neurology consultation and the following consultations depend on their physician's criteria until completed 6 months post-discharge.
16271210|NCT04877158|Experimental|Self-Blame and Perspective-Taking Intervention|These participants are enrolled with intent to participate in the group therapy intervention.
16271211|NCT04877145|Experimental|single drill|one drill to place the implants 3.25mm diameter stainless steel drill was used.
16271212|NCT04877145|Active Comparator|sequential drills|For the control group, four drills (2.2mm, 2.75mm, 3.25mm and 4mm diameter),
16271213|NCT04877106|Active Comparator|Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®)|JANUMET®, 50mg/850mg, batch no. M047893, manufactured by MSD Pharma (Singapore) Pte.Ltd
16271214|NCT04877106|Experimental|Sitagliptin Phosphate/metformin Hydrochloride Tablets|50mg/850mg, batch no. 161006, manufactured by Tonghua Dongbao Pharmaceutical Co., Ltd.
16271217|NCT04877080|Experimental|Fast Dual CAR-T treatment|CD19+ R/R B-NHL patients be treated with a single dose of Fast Dual CAR-T cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
16271218|NCT04877067|Active Comparator|WJ-MSC combine witf rEMS|WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.
16271219|NCT04877067|Active Comparator|Only rEMS|rEMS applications were repeated 10 times with a 1-week interval.
16271223|NCT04877041|Experimental|Exercise (Intradialytic Cycling)|Participants will receive a standardized baseline exercise counseling session as per control and then participate in a supervised intradialytic cycling program for 12-weeks
16271224|NCT04877041|No Intervention|Usual Care|Participants will receive a standardized baseline exercise counseling session. Participants in the control group will not undergo formal exercise intervention, but will not be prohibited from participating in exercise outside of hemodialysis. They will be asked to not to participate in intradialytic cycling during the study (16 weeks total).
16271227|NCT04877002|Experimental|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participated in two arms of the study:
~One arm was for obtaining performance data of the Sona Saliva C-19 Rapid test and the comparator arm was to obtain data from the primary care route using approved RT-PCR testing."
16271228|NCT04876989|Active Comparator|US-SGB|5 ml of 1% mepivacaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
16271229|NCT04876989|Active Comparator|US-TPVB|10 ml of 1% mepivacaine is injected for thoracic paravertebral block using the Ultrasound(US)-guided sagittal approach at the second thoracic paravertebral space.
16271230|NCT04876976|Experimental|Cases of group (I) cyanoacrylate glue|Cases of group (I) underwent multilayered closure using dartos facial flap and cyanoacrylate glue as an interposition layer.
16271231|NCT04876976|Active Comparator|Cases of the control group (II) , classic repair|Cases of the control group (II) underwent the same procedure without using cyanoacrylate.
16271232|NCT04876950|Experimental|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-2 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take would photos during the 30 days after randomization. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
16271233|NCT04876950|No Intervention|Standard Care|Standard post-surgical care.
16271234|NCT04876937|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1-0.2 ug/kg/h during mechanical ventilation, for a maximum of 7 days.
16271235|NCT04876937|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 7 days.
16271236|NCT04876924|Experimental|BBP-711 for SAD|A single dose of BBP-711 will be administered orally.
16271237|NCT04876924|Placebo Comparator|Placebo for SAD|A single dose of matching placebo will be administered orally.
16271238|NCT04876924|Experimental|BBP-711 for MAD|A dose of BBP-711 will be administered orally for multiple days.
16271239|NCT04876924|Placebo Comparator|Placebo for MAD|A dose of matching placebo will be administered orally for multiple days.
16271240|NCT04876924|Experimental|BBP-711 for SAD Food Effect|A single dose of BBP-711 will be administered orally.
16271241|NCT04876924|Placebo Comparator|Placebo for SAD Food Effect|A single dose of matching placebo will be administered orally.
16271242|NCT04876911|No Intervention|Control/Usual Care|No intervention delivered and care is provided as usual.
16271243|NCT04876911|Experimental|Simulated Presence Therapy (SPT)|Participants begin to receive the SPT.
16271244|NCT04876885|Other|General public|The individuals recruited to the study will include those who are age 16 and older. Due to recruitment feasibility we will focus efforts on individuals living in Ontario. We intend to recruit individuals from COVID-19 assessment centres that are partnering in our study as well as through social media posts (Facebook, Twitter, LinkedIn).
16271245|NCT04876885|Other|Healthcare professionals and public health professionals|The individuals recruited to the study will include healthcare professionals and public health professionals impacted by infectious disease outbreaks. Social media will be used to disseminate surveys to physicians, nurses, nurse practitioners, pharmacists, and healthcare workers. Public health units will disseminate surveys to their workforce.
16271246|NCT04876872||pediatric patients|whole pediatric patients who admitted to the pediatric emergency unit in Farabi Hospital, Trabzon, Turkey
16271247|NCT04876859|Active Comparator|Conventional Radiofrequency Group|Will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
16271248|NCT04876859|Sham Comparator|Anesthetic plus steroid group|The sham group will be submitted to the same anesthetic block as described in the intervention group, followed by a simulation of CRF use.
16271249|NCT04876846|Experimental|Interventional/Observational|The Gen 3 device will be positioned on the maternal abdomen to measure light scattering and absorption for a period of about 10-20 minutes. A second measurement may be obtained for a total of up to 40 minutes. Subject's end their participation in the study after that time period.
16271250|NCT04876833||HC，healthy control|18-65 years old，no smoking history，normal pulmonary function，normal compatible computed tomography.
16271251|NCT04876833||HG，high-risk COPD group|18-60 years old，≥10 pack-years smoking history，normal pulmonary function，normal compatible computed tomography.
16271285|NCT04876599|Experimental|Intervention (IN FOCUS)|Participants will be randomly assigned and participate in approximately eight weekly virtual group sessions to learn mind-body, cognitive behavioral, and positive psychology skills.
16271252|NCT04876833||EG，early COPD group|"18-60 years old，≥10 pack-years smoking history，and with any of the following abnormalities：
~Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 80%;
~Compatible computed tomography abnormalities：airway abnormality and/or emphysema，air trapping, or bronchial thickening；
~FEV1 decline (≥60 mL per year)."
16271253|NCT04876833||MG，mild and moderate COPD group|18-65 years old，FEV1/FVC<70%，FEV1%predicted ≥50%.
16271254|NCT04876820|Experimental|Pharmacist-led intervention|
16271255|NCT04876820|Sham Comparator|Standard of care|
16271256|NCT04876807|Experimental|Part 1 (Acidic formulation)|In Part 1 of the study, the participants will receive Dose 1 of ACP-196 (reference or acidic formulation as applicable) with 240 mL water in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
16271257|NCT04876807|Experimental|Part 2 (Orange drink)|In Part 2 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or acidic beverage as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
16271258|NCT04876807|Experimental|Part 3 (Grapefruit juice)|In Part 3 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or grapefruit as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
16271259|NCT04876794|Experimental|Arm 1|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
16271260|NCT04876768|Experimental|Use of 80% oxygen(high oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 80% FIO2(supplemental perioperative high oxygen fraction). 80% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of > 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter > 92%.
16271261|NCT04876768|Active Comparator|Use of 30% oxygen(normal oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 30% FIO2 (normal oxygen fraction). 30% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of > 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter > 92%.
16271262|NCT04876755|Experimental|Cohort 1|Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.
16271263|NCT04876755|Experimental|Cohort 2|Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.
16271264|NCT04876755|Experimental|Cohort 3|Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.
16271265|NCT04876755|Experimental|Cohort 4|Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.
16271266|NCT04876755|Experimental|Cohort5|Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.
16271267|NCT04876755|Experimental|Cohort 6|Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.
16271268|NCT04876742|Experimental|0.5 liters of alcoholic beer|
16271269|NCT04876742|Active Comparator|0.5 liters of non-alcoholic beer|
16271270|NCT04876729|Experimental|Otago Exercise Program|An individualized Otago Exercise Program will be delivered by community health representatives (CHR) in participants homes. There will be 10 home visits over a 12 month period.
16271271|NCT04876729|No Intervention|Education|The control group will receive education on fall risk reduction. This will be delivered by the CHR with 6 home visits over 12 months
16271272|NCT04876716|Active Comparator|Azole monotherapy|"Azole monotherapy
~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care."
16271273|NCT04876716|Experimental|Azole + Anidulafungin|"Azole + Anidulafungin
~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care.
~Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose adjustment is needed in patients with renal or hepatic insufficiency of any grade."
16271274|NCT04876703|Experimental|Excite group (Group A)|The experimental group (Group A) will receive standard motor retraining of the affected upper extremity in addition to functional electrical stimulation provided by means of Xcite system 4 days per week for 30 minutes for two weeks.
16271275|NCT04876703|Active Comparator|Standard motor training group (Group B)|The control group (Group B) will receive standard motor retraining of the upper extremity.
16271276|NCT04876690||All Participants|Participants diagnosed with CD and CPF in the Portuguese routine clinical practice will be assessed. Retrospective data on healthcare resource utilization related with CPF management in the previous three years will be obtained from the medical records.
16271277|NCT04876677|Experimental|CHF5993|Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation
16271278|NCT04876664|Experimental|Ambulatory monitoring solution|this study has only one arm
16271279|NCT04876651|Experimental|Group A|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care
16271280|NCT04876651|Active Comparator|Group B|Participants will receive the Standard of Care
16271281|NCT04876625|Experimental|OA plus MS 8wk|Oral Appliance plus Mouth Shield for 8-weeks
16271282|NCT04876625|Active Comparator|OA Alone 4wk|Oral Appliance is used alone for first 4 weeks followed by 4 weeks of Oral Appliance plus Mouth Shield
16271283|NCT04876612|Placebo Comparator|Patients who received placebo after transforminal epidural steroid injection|Patients who took placebo for 12 weeks after TFESI
16271284|NCT04876612|Experimental|Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection|Patients who took limaprost (Opalmon®) for 12 weeks after TFESI
16271286|NCT04876599|Active Comparator|Usual Care|Participants will be randomly assigned and receive usual care, which is a referral for virtual group supportive services for cancer survivors provided in the community.
16271287|NCT04876573|Experimental|Cyproheptadine|
16271288|NCT04876560|Active Comparator|CDSS (intervention) group|Personalised nutritional advice: daily dietary programme with specific meals, products, recipes, food portions (in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a food database clinical decision support system (CDSS). Scheduled phone interviews every 15 days with the appointed dieticians assisted nutritional and lifestyle consultation.
16271289|NCT04876560|Other|Control group|"General lifestyle advice: based on the updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention via scheduled phone interviews every 15 days."
16271290|NCT04876547||In pregnancy|Appendectomy in pregnancy (n=12)
16271291|NCT04876547||In postpartum|Appendectomy in postpartum first six week (n=20)
16271292|NCT04876534|Experimental|Tocilizumab|32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks
16271293|NCT04876534|Active Comparator|Methylprednisolone|32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks
16271294|NCT04876521|Experimental|Amisulpride Group|The patients will receive low dose Amisulpride at 100-300 mg/day.
16271295|NCT04876521|Active Comparator|Olanzapine-Fluoxetine Group|the patients will receive Olanzapine-Fluoxetine Combinations at 5/10-5/20 mg/day.
16271296|NCT04876508|Experimental|Acupressure group|Patients in the acupressure group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
16271297|NCT04876508|No Intervention|Control group|No intervention will be applied
16271298|NCT04876495|Active Comparator|Whey protein|Whey protein isolate (45.5g total protein content)
16271299|NCT04876495|Active Comparator|Potato protein|Potato protein isolate (45.3g total protein content)
16271300|NCT04876495|Active Comparator|Rice protein|Rice protein isolate (45.5g total protein content)
16271301|NCT04876482|Sham Comparator|Control|Without the willingness of surgery, those participants waiting for oral appliance (Device), losing weights and using continuous positive airway pressure (Device) were distribute to control group.
16271302|NCT04876482|Experimental|Transoral robotic surgery (TORS)|The participants underwent TORS. TORS is a kind of surgery that the surgeons would remove the tonsils and the fat tissue of tongue base and suspend the soft palate.
16271303|NCT04876482|Experimental|TORS+OPR|The participants started OPR 6 weeks after TORS. Each exercise was repeated 10 times, 1-3 cycles per day, 3-5 sessions per week at their home and performed for 3 months. Patients were supervised by physical therapist once a week for 30 minutes.
16271304|NCT04876469|Active Comparator|Radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level) in both groups.
~In patients in the Radiocontrast media group, contrast material will be given before the application, and primarily the localization of the DRG will be determined. After this stage, the needle will be directed towards the detected localization. Finally, the localization of the dorsal root ganglion will be confirmed by sensory and motor stimuli."
16271305|NCT04876469|Active Comparator|Non-radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level).
~In patients in the Non-radiocontrast media group, the localization of the dorsal root ganglion will be determined just by sensory and motor stimuli."
16271306|NCT04876456|Experimental|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
16271307|NCT04876443||Alcohol-related liver disease|
16271308|NCT04876430|Experimental|Meropenem plus Best Available Therapy plus|"Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.
~Polymyxin B or colistimethate;
~Amikacin or gentamicin;
~Tigecycline;
~Another antimicrobial with in vitro susceptibility.
~Doses will be defined by the assistant team."
16271309|NCT04876430|No Intervention|Best Available Therapy|"The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.
~Polymyxin B or colistimethate;
~Amikacin or gentamicin;
~Tigecycline;
~Another antimicrobial with in vitro susceptibility.
~Doses will be defined by the assistant team."
16271310|NCT04876417|Active Comparator|tDCS and fatigue|This group will receive the active form of tDCS.
16271311|NCT04876417|Sham Comparator|Sham and fatigue|This group will receive the sham form of tDCS.
16271312|NCT04876404||Parkinson's Disease|Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)
16271313|NCT04876404||Healthy Controls|Healthy control individuals with no neurological or mood disorders.
16271315|NCT04876378||Diagnostic (questionnaires, MRI)|Patients complete a series of questionnaires over 15 minutes about knee function and pain, as well as physical activity. Patients also undergo an MRI over 60 minutes.
16271317|NCT04876352|Experimental|VR-training|Upper limb/handwriting exercises in an immersive virtual reality setting
16271318|NCT04876352|Active Comparator|RS-training|The same upper limb/handwriting exercises in a real setting
16271319|NCT04876352|Other|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare clinical and fMRI characteristics at baseline.
16271320|NCT04876339|Experimental|"Gait rehabilitation with sonification"|"The rehabilitation exercises with sonification are supported by the musical component (see Interventions section for details)."
16271321|NCT04876339|Active Comparator|Standard gait rehabilitation (without sonification)|The same rehabilitation exercises are performed without musical support.
16271322|NCT04876326|Active Comparator|Autologous Adipose MSC Group|This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month
16271323|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.
16271324|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC and Adipose Secretome Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month.
16271325|NCT04876313|Experimental|Combined Drugs|Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles
16271326|NCT04876300||Menotropin Cohort|
16271327|NCT04876287||patients treated by 1.1 GBq|
16271328|NCT04876287||patients treated by 3.7 GBq|
16271329|NCT04876274|Experimental|Intervention group|Patients in the intervention group received the TMU line-oriented video education and care in addition to usual care
16271330|NCT04876274|No Intervention|Control group|Patients in the control group received usual care
16271331|NCT04876261|Active Comparator|Group A|Group A will receive Oliphenolia® bitter on intervention visit 1 followed by Oliphenolia® on intervention visit 2 and followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on the third and final intervention visit
16271332|NCT04876261|Active Comparator|Group B|Group B will receive Oliphenolia® on intervention visit 1 followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 2 and followed by Oliphenolia® bitter on the third and final intervention visit
16271333|NCT04876261|Active Comparator|Group C|Group C will receive La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 1 followed by Oliphenolia® bitter on intervention visit 2 and followed by Oliphenolia® on the third and final intervention visit
16271335|NCT04876235|Experimental|LAMS group|place LAMS under endoscopic ultrasound. Direct endoscopic necrosectomy(DEN) was performed through the LAMS with a forward viewing gastroscope if necessary
16271336|NCT04876235|Active Comparator|DPPS group|Place DPPS under endoscopic ultrasound. When required, DEN was performed once the cystogastrostomy/duodenostomy tract had matured. This was done by first removing the stents followed by dilation of the tract with a radial expansion balloon and insertion of a forward viewing gastroscope through the tract for DEN
16271337|NCT04876222|Active Comparator|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
16271338|NCT04876222|No Intervention|Subacute CAG|The patient is triaged to the coronary care unit (CCU) for rhythm surveillance, and additional diagnostics, and in case there is found indication for CAG, it is planned for the coming day in daytime (12-24 hours after cardiac arrest). Revascularization is performed if indicated according to guidelines.
16271339|NCT04876196|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Bulimia Nervosa)
16271340|NCT04876196|No Intervention|Waitlist Control Group|12-week waiting period
16271341|NCT04876183|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Binge Eating Disorder)
16271342|NCT04876183|No Intervention|Waitlist Control Group|12-week waiting period
16271343|NCT04876170|Active Comparator|VS-EFP Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, participants will receive musical feedback driven by their own VS-EFP
16271344|NCT04876170|Sham Comparator|Yoked sham Neurofeedback|"Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, the musical feedback will be provided based on another participant's VS-EFP signal. Hence, each participant from the sham group is paired with a participant from the test group, thus receiving feedback based on the paired test participant. This way, both groups are exposed to the exact proportion of sound manipulation that indicates their success level. To account for a possible contribution of the temporal order of feedback presentation, in half of the control participants, the feedback pattern will be replayed forward (maintaining the original temporal pattern of VS-EFP that the paired participant has received), and in half - backward (flipping the original temporal pattern right-to-left)."
16271345|NCT04876157|Experimental|Artificial intelligence-aimed ultrasound image interpretation|
16271346|NCT04876144|No Intervention|Usual care group - clinical|Usual prenatal and postpartum psychiatric care involves regular visits with a psychiatrist from the perinatal psychiatric outpatient clinic of the National Institute of Mental Health, Czechia.
16271347|NCT04876144|No Intervention|Usual care group - general|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
16271348|NCT04876144|Experimental|Kogito - clinical|Usual prenatal and postpartum psychiatric care in perinatal psychiatric outpatient clinic of the National Institute of the National Institute of Mental Health, Czechia plus use of the Kogito app.
16271349|NCT04876144|Experimental|Kogito - general|Usual prenatal/postpartum care plus use of the Kogito app.
16271379|NCT04875949|Experimental|Anti-AChRs Abs positive patients|Immunoabsorption
16271350|NCT04876131|Experimental|Early switch|"Single dose IV to cover Gram negative bacteria followed by oral antibiotics until Day 3
~(with or without) Single dose IV to cover Enterococcus spp followed by oral antibiotics until Day 3.
~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data. Once the IV component is complete the patient will be given an oral antibiotic (cefalexin) on day 2 and 3 of the study."
16271351|NCT04876131|Active Comparator|3-days IV|"3 days IV to cover Gram negative bacteria
~(with or without) 3 days IV antibiotics to cover Enterococcus spp.
~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data."
16271352|NCT04876118|Experimental|Fat Reduction|The treatments are designed to see if the appearance of cellulite can be reduced on the outer thigh with a new applicator design.
16271353|NCT04876105||Acute-subacute group|According to the duration of low back pain, it is classified as acute pain if it lasts less than a month, subacute pain if it lasts for 1-3 months.
16271354|NCT04876105||Chronic group|According to the duration of low back pain, it is classified as chronic pain if it lasts for more than 3 months.
16271355|NCT04876092|Experimental|JNJ-67856633 and Ibrutinib|Participants in Part A (dose escalation) will receive JNJ-67856633 together with Ibrutinib orally on a 21-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in Part B (cohort expansion) will receive JNJ-67856633 together with Ibrutinib orally at one of the RP2D(s) determined in Part A.
16271356|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose < 4.0 mmol/L|16g of carbohydrates will be given when glucose levels are below 4.0 mmol/L (management per guidelines)
16271357|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 4.5 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 4.5 mmol/L.
16271358|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 5.0 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 5.0 mmol/L.
16271359|NCT04876066|Experimental|Ketamine dose|The recommended ketamine dose of 0.5 mg/kg will be administered using a transmucosal route of administration wherein the subject will be instructed to place the liquid solution beneath their tongue and hold it in their mouth for 5 minutes. The pharmacy will prepare two 0.5 mg/kg solutions of ketamine in two syringes for each subject based on subject weight. For example, a 70 kg adult subject will receive a 0.35 mL solution of ketamine. The patient will receive a dose every 7 days for two weeks, for a total of two doses.
16271360|NCT04876053|No Intervention|Standard Care|
16271361|NCT04876053|Experimental|Healthy Food Delivery Intervention|9000 calorie / week food box
16271362|NCT04876040|Experimental|PCI+Impella plus SSO2|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated post-procedure with an infusion of SSO2 Therapy for a duration of 60 minutes.
16271363|NCT04876040|Active Comparator|PCI+Impella|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated with Standard of Care.
16271364|NCT04876027|Experimental|GLP-1 RAs and calorie restrict diet group|Intervention with GLP-1 RAs and calorie restrict diet until reaching the target weight loss(7%)
16271365|NCT04876027|Active Comparator|calorie restrict diet group|Intervention with calorie restrict diet until reaching the target weight loss(7%)
16271366|NCT04876014|Experimental|GMBPMI group|Participants in the experimental group will receive GMBPMI. A new participant (a pregnant woman in the second trimester) is expected to complete the 6 EBMI lessons in 6 weeks, and do the mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. Participants will also be asked to keep log of daily mindfulness practice from T0 to T3 using Google Form. The project RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice. The RA is backed up by the PI and co-I's who are experienced mental health practitioner and mindfulness teacher. One of them is an obstetrics and gynaecology specialist.
16271367|NCT04876014|Active Comparator|Perinatal Psycho-education group|To control for attention and placebo effects, every new participant in the control group will receive weekly web-based psychoeducation program for perinatal care. The project RA will also be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences of the psychoeducation program.
16271368|NCT04876001|Experimental|Face-to-face BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call."
16271369|NCT04876001|Experimental|Web-based BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call. All treatments will be delivered using pre-established web and telephone."
16271370|NCT04876001|No Intervention|Waiting-list|The participant in this arm will be asked to filled the online questionnaires at weeks 0 (baseline), 1 (mid-treatment), 2 (post-treatment), 4 and 12 (follow up). After the final follow up, all participants will be allowed to join the web-based BBTI treatment.
16271371|NCT04875988|Active Comparator|POCUS-assisted IV placement|using ultrasound to help with placement
16271372|NCT04875988|Active Comparator|Traditional IV placement|Standard of care
16271375|NCT04875962|Experimental|Cohort 1 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
16271376|NCT04875962|Experimental|Cohort 2 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
16271377|NCT04875962|Placebo Comparator|Cohort 1 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
16271378|NCT04875962|Placebo Comparator|Cohort 2 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
16271380|NCT04875936|Experimental|Motor Imagery and Contingent Neurofeedback (NFB)|This group will receive real-time fMRI NFB on the bases of participant's own brain activity
16271381|NCT04875936|Sham Comparator|Motor Imagery and Non-contingent Neurofeedback (NFB)|This group will receive group will receive fMRI NFB based on another participant's brain activity
16271382|NCT04875910|Experimental|Stroke survivors participants|"Subjects who have been diagnosed with stroke 6 months or more.
~1)Either right and left hemiparesis. 2) Subjects able to walk with or without assistive device. 3) age between 40-80. 4) Subjects can understand and follow commands.
~Exclusion criteria is: 1) subjects with uncontrolled Blood pressure, heart rate or breathing problems. 2) Having an orthopedic problem or"
16271383|NCT04875897|Experimental|treatment with keepMED PAP device|Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab
16271384|NCT04875884|Experimental|MRI group|Subjects enrolled in this study will undergo both standard and new MRI techniques. The standard MRI is needed for your routine care and as ordered by the referring doctor. The new MRI is performed for research purposes. Participants will be imaged with both methods and the results will be compared.
16271385|NCT04875871|Experimental|High-dose group|3 fractions of 12 Gy Relative Biological Effectiveness (RBE)
16271386|NCT04875871|Experimental|Reduced-dose group|3 fractions of 8-10 Gy RBE
16271387|NCT04875858|Active Comparator|healthy old adults aged 70-75 years who received PPSV23|Recruitment of 254 healthy 70-75-year healthy old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
16271388|NCT04875858|Experimental|old adults who have diabetes mellitus aged 70-75 years who rec|Recruitment of 254 healthy 70-75-year diabetic old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
16271389|NCT04875845||6-hours fasting gastric volume|gastric volume measured after 6-hours fasting
16271390|NCT04875845||8-hours fasting gastric volume|gastric volume measured after 8-hours fasting
16271391|NCT04875832|Experimental|Intervetion Group|EMDR intervention group
16271392|NCT04875819|Experimental|Menveo + Bexsero|
16271393|NCT04875819|Experimental|Prevenar13 + Pneumovax23|
16271394|NCT04875806|Experimental|NC762|NC762 for IV infusion of various dose strengths administered in 14 day dosing cycles
16271395|NCT04875793|Experimental|List of health centers that randomly allocated to receive the intervention|The intervention is the integrated system which is composed of psychologist, endoscopy physician, family physician, community outreach, and audiovisuals in the waiting area. In addition to text messages of information, education and communication (IEC) delivered to the participants at the outreach, and education campaigns to mobilize individuals going for screening.
16271396|NCT04875793|No Intervention|List of health centers that randomly allocated to receive routine care|The comparators will be individuals with an average risk of colorectal cancer of both genders attending the randomly selected health centres
16271400|NCT04875767|Experimental|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|Those allocated to the scaffold treatment group will have 30 ml of BMA harvested from the ipsilateral iliac crest under fluoroscopic guidance. The hip arthroscopy will then be resumed, and the damaged cartilage lesion will be debrided using a mechanical shaver to remove loose and calcified tissue. Once the walls of the lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The biodegradable HA-based scaffold (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) will be prepared by cutting it to fit the focal defect. Once the cartilage lesion is dried manually, this scaffold will be implanted into the defect after it has been soaked in the BMA. The scaffold will then be secured to the defect in a press-fit fashion to the surrounding cartilage. In the case where additional fixation of the scaffold is needed, such as uncontained shoulder of cartilage, fibrin glue will be used to secure the scaffold.
16271401|NCT04875767|Active Comparator|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
16271402|NCT04875754|Experimental|Group 1: ICM-203 (Low dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e12 vg (n=6) or placebo (n=2) into the target knee at Day 1
16271403|NCT04875754|Experimental|Group 2: ICM-203 (Medium dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 2x10e13 vg (n=6) or placebo (n=2) into the target knee at Day 1
16271404|NCT04875754|Experimental|Group 3: ICM-203 (High dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e13 vg (n=6) or placebo (n=2) into the target knee at Day 1
16271405|NCT04875741|Active Comparator|Neural mobilization|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Neural mobilization technique will be applied to the subjects in addition to conventional treatment.
16271406|NCT04875741|Experimental|Muscle energy technique|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Muscle energy technique will be applied to the subjects in addition to conventional treatment.
16271407|NCT04875728|Active Comparator|Arm A (cefazolin, surgical resection)|Patients receive cefazolin IV and then undergo standard of care surgical resection within 1 hour.
16271408|NCT04875728|Experimental|Arm B (surgical resection)|Patients undergo standard of care surgical resection.
16271409|NCT04875715|Experimental|Almond oil|Almond Oil Pressed Cold
16271410|NCT04875715|Active Comparator|Hydroquinone|Hydroquinone 2% cream
16271411|NCT04875702|Active Comparator|TTT-SU|The participants randomized to the Treat-to-Target-Serum Urate (TTT-SU) group will be counseled about gout, generalized lifestyle and dietary issues and will be provided with a three-month supply of allopurinol as well as a treatment to prophylax against attacks that might occur during the up-titration of urate lowering therapy. Allopurinol dose increases will occur until SU concentrations achieve a target level < 6.0 mg/dL.
16271412|NCT04875702|Active Comparator|TTASx|Subjects randomized to the treat-to-avoid-symptoms (TTASx) group will receive the same education as the TTT-SU group. In addition, they will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone); enough to treat up to six flares over the ensuing three months.
16271413|NCT04875689|Experimental|Group A (Experimental)|Patient receive laser therapy along with conventional therapy
16271414|NCT04875689|Other|Group B: Conventional treatment|patient will receive conventional therapy
16271415|NCT04875676|Active Comparator|Cohort 1 (4-week boost vaccination)|(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4
16271416|NCT04875676|Active Comparator|Cohort 2 (8-week boost vaccination)|(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8
16271417|NCT04875676|Active Comparator|Cohort 3 (12-week boost vaccination)|(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12
16271418|NCT04875663|Experimental|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
16271419|NCT04875663|Experimental|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
16271420|NCT04875663|No Intervention|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
16271421|NCT04875650|Experimental|Physics Forceps|
16271422|NCT04875650|Other|Conventional Forcep|
16271423|NCT04875637|Other|MEMR Diagnostic Evaluation|Middle Ear Muscle Reflex using wideband acoustic reflectance to assess hearing status.
16271424|NCT04875624||Hypoglycemic neonates|Preterm or small for gestational age neonates at risk for hypoglycemia who were found to be hypoglycemic during the screening for hypoglycemia
16271425|NCT04875624||Normoglycemic neonates|Preterm or small for gestational age neonates who were found to be normoglycemic during the screening for hypoglycemia
16271426|NCT04875611|Experimental|Experimental therapy:OPDIVO (Nivolumab)|
16271427|NCT04875598|Active Comparator|Group 1|30 patients will be injected with local anesthetic into the fascia between the transversus abdominis and internal oblique muscles with the help of ultrasound from the designated area (Before the operation starts, TAPBwith 20 ml 0.25 % bupivacaine will be applied to the surgical side under ultrasonography)
16271428|NCT04875598|Active Comparator|Group 2|30 patients, local anesthetic injection will be made to the same area under laparoscopic direct vision. 50 mg Bupivacaine (0.25 % 20 ml bupivacaine solution) has been determined as the application dose and this amount will be applied in both groups.
16271429|NCT04875585|Experimental|Treatment Arm|neoadjuvant therapy with Pembrolizumab/Lenvatinib in combination with surgical resection of primary tumor followed by adjuvant Pembrolizumab therapy
16271430|NCT04875572|Experimental|Study group|Since this is a single group study, all patients enrolled will receive the same care, as described in the study description above.
16271431|NCT04875559||Breast cancer surgery patients.|Patients scheduled for day-case unilateral breast conserving surgery or mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy. No intervention.
16271432|NCT04875546|Active Comparator|Standard treatment|"A 5'A' and '5'R' models
~STAR method for quitting"
16271433|NCT04875546|Active Comparator|Integrated Intervention|"A 5'A' and '5'R' models
~Receive brief advice on alcohol use based on the FRAMES model
~Complete the Alcohol Use Disorders Identification Test"
16271434|NCT04875546|Sham Comparator|Control|Participants will receive two leaflets.
16271437|NCT04875520|Active Comparator|Weekly Screening testing plus symptomatic testing|Among 16 middle and high schools, 8 will be randomized to offer students and staff weekly SARS-CoV-2 testing. Additionally, these schools will offer testing for symptomatic students, staff, household members in all age groups.
16271438|NCT04875520|Active Comparator|Symptomatic testing|All 16 schools will have testing available for individuals that have symptoms or need a test for other reasons.
16271439|NCT04875507|Active Comparator|Positive psychology|The experimental group(n=60), who will receive a 1.5-hour workshop covering positive psychology techniques delivered by a qualified research assistant, in groups of less than 5 people.
16271440|NCT04875507|No Intervention|Control|The control group will receive no intervention.
16271441|NCT04875494|Experimental|Physical Exercise|
16271442|NCT04875494|Active Comparator|Counseling/support group therapy|
16271443|NCT04875494|No Intervention|Control|no intervention
16271444|NCT04875481||ASD group|450 ASD from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
16271445|NCT04875481||TD group|100 healthy typical developing control (TDC) from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
16299324|NCT04680637|Placebo Comparator|Placebo + Standard of Care|
16271446|NCT04875468|Active Comparator|Zirconia crown cemented by adhesive resin cement|MultiRein link adhesive resin cement (non MDP, non-calcium and fluoride releasing cement)
16271447|NCT04875468|Experimental|Zirconia crown cemented by self-adhesive resin cement|TheraCem self-adhesive resin cement (MDP, calcium and fluoride releasing cement)
16271448|NCT04875455|Experimental|Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|PhysIOL POD F GF: 50 (bilateral implantation) PhysIOL POD F: 50 (bilateral implantation) Alcon PanOptix: 20 (bilateral implantation) In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
16271449|NCT04875442|Experimental|Memowave emitting sound|Patients worn Memowave during one night, and the device emits sounds to increase slow brain signals
16271450|NCT04875442|Placebo Comparator|Memowave not emitting sound|Patients worn Memowave during one night, and the device doesn't emit sounds
16271451|NCT04875429|Experimental|Aortic abdominal aneurysm|
16271452|NCT04875416||Primary participants|Patients that have or are suspected to have ALS or a related neurodegenerative disease
16271453|NCT04875416||Secondary Participants|Family members of primary participants enrolled in the study
16271454|NCT04875403|Experimental|Respiratory muscle training group|Inspiratory muscle training with linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).The resistance training protocol will consist of the exercises of the front pull, the extension chair and the vertical bench press, covering large muscle groups in the dorsal region of the quadriceps and chest, respectively. Each year consist of three sets of 10 repetitions with a load equivalent to 60% of a test Repetition Maximum (1RM), which will be changed every week (1 to week 60%, 2 to week 65%;. 3 the . week 70%, 4 to week. 75%, 5 to week 80%).
16271455|NCT04875403|Active Comparator|Aerobic exercise group|Exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate, training has to be equivalent to 40% to 60%% target intensity.
16271456|NCT04875390|Other|group E|Intraoperative Erector spina plane block ( 0.3 ml/kg bupivacaine 0.25% at thoracic level 7 and 0.3 ml/kg bupivacaine 0.25% bupivacaine at thoracic level 11, totaling 0.6 ml/kg of 0.25% bupivacaine) will be performed after the surgery is completed.
16271457|NCT04875390|Other|group L|Intraoperative local infiltration (0.6 ml/kg of 0.25% bupivacaine will be given to the wound lips at the end of the surgery.
16271458|NCT04875377|Experimental|Reformulated pizza|Participants must consume a nutritionally balanced pizza reformulated with seaweed (Ascophyllum nodosum) as an ingredient 3 times a week for 24 weeks
16271459|NCT04875377|Placebo Comparator|Control pizza|Participants must consume a nutritionally balanced pizza without seaweed, 3 times a week for 24 weeks
16271460|NCT04875377|Experimental|Seaweed capsule|Participants must consume a capsule containing powdered Ascophyllum nodosum 3 times a week for 24 weeks
16271461|NCT04875377|Placebo Comparator|Control capsule|Participants must consume an empty capsule 3 times a week for 24 weeks
16271462|NCT04875364|Experimental|Early PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will be set up with a loaner CPAP for 8 weeks to initiate therapy right away.
16271463|NCT04875364|Experimental|Usual PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will remain untreated until they are set up with their clinically prescribed CPAP (typically takes about 8 weeks).
16271464|NCT04875351||Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing|Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.
16271465|NCT04875338|Active Comparator|saline injection|2ml %0.9 NACI(Saline )injection to effected lateral epicondyle
16271466|NCT04875338|Active Comparator|platet riched plasma injection|2 ml prp )injection to effected lateral epicondyle
16271467|NCT04875338|Active Comparator|betametazon injection|2 ml betametazon )injection to effected lateral epicondyle
16271468|NCT04875325|Experimental|Standardized surveillance|Standardized surveillance strategy with routine imaging and serum tumor marker testing.
16271469|NCT04875325|No Intervention|Non-standardized surveillance|Non-standardized surveillance strategy according to current clinical practice.
16271470|NCT04875312|Experimental|Group USC|Effect of ultrasound cavitation sessions on sex hormones in obese infertile patients with poly cystic ovarian syndrome
16271471|NCT04875312|Experimental|Group EA|Effect of electro acupuncture on sex hormones in obese infertile patients with poly cystic ovarian syndrome
16271472|NCT04875299||adalimumab TDM|Patients with active ankylosing spondylitis receiving adalimumab treatment.
16271473|NCT04875286||Observational (medical record review, questionnaires))|Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
16271474|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
16271475|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 2 kg|press on the spinous processes with the algometer perpendicularly.
16271476|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 3 kg|press on the spinous processes with the algometer perpendicularly.
16271477|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
16271478|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
16271479|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
16271511|NCT04875078|Experimental|UVA-1 Treated hand|This hand will be treated with UVA-1 phototherapy.
16271480|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
16271481|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
16271482|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
16271483|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
16271484|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
16271485|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
16271486|NCT04875273|No Intervention|Pre: Ankle Dorsiflexion|ange of motion in ankle dorsiflexion is measured with LegMOtion®
16271487|NCT04875273|Placebo Comparator|Post Pla: Ankle Dorsiflexion|ange of motion in ankle dorsiflexion is measured with LegMOtion®
16271488|NCT04875273|Experimental|Post Exp: Ankle Dorsiflexion|ange of motion in ankle dorsiflexion is measured with LegMOtion®
16271489|NCT04875260||Critically ill patients|Patients received critical care in the intensive care units
16271490|NCT04875247||Single arm|All patients will be assigned to this cohort.
16271491|NCT04875234||Legally Blind Dry AMD Patients|Legally Blind Dry AMD Patients with either unilateral or bilateral blindness
16271492|NCT04875221|Experimental|Experimental neurofeedback arm|The experimental arm will be able to view a feedback display that informs them of the strength of connectivity between the target regions. In both arms, feedback signals will be relayed back to the participant in the scanner through visualization software as a thermometer that increases or decreases as the extent to which the neural target model dominates (in other words, as the strength of directed connectivity between regions increases).
16271493|NCT04875221|Sham Comparator|Sham-control neurofeedback arm|Participants in the sham-control arm will receive yoked sham neurofeedback signal (or fake signal), corresponding to a replayed feedback signal from a successful participant in the experimental group in order to ensure similar motivational states and following standard methods.
16271495|NCT04875182||group delirium|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score over 14 points will be included in the Group Delirium. And second blood samples for zonulin and interleukin-8 levels will be taken at the time of diagnosis.
~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
16271496|NCT04875182||group control|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score under 14 points for postoperative 72 hours will be included in the Group Control. And second blood samples for zonulin and interleukin-8 levels will be taken at the postoperative 72. hour.
~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
16271497|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
16271498|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
16271499|NCT04875169|Placebo Comparator|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
16271500|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
16271501|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
16271502|NCT04875156|Other|normal volunteers|normal volunteers between 18 and 40 years old, men and women. Measurement of the range of motion of the metacarpophalangeal joint with a goniometer and pinch strength of the thumb with a dynamometer
16271503|NCT04875143|Placebo Comparator|PLACEBO|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
16271504|NCT04875143|Experimental|Citrus aurantium L.|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
16271505|NCT04875130||confirmed pulmonary embolism|"Patients with intermediate high and high risk of an acute pulmonary embolism with clinical symptoms.
~On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).
~Age under 18.
~Written agreement to the examination."
16271506|NCT04875117||Intervention|Participants who are due to receive their first-ever hearing aid(s) as part of their routine audiological care.
16271507|NCT04875117||Control|Participants with hearing loss who have not experienced any change in hearing aid status for at least 1 year.
16271508|NCT04875104|Active Comparator|Invisalign|Patients treated with Invisalign aligners
16271509|NCT04875104|Experimental|Spark|Patients treated with Spark aligners
16271510|NCT04875091|Experimental|Intervention|
16271512|NCT04875078|No Intervention|The untreated hand|This hand will be gloved when the patient undergoes UVA-1 phototherapy treatments.
16271513|NCT04875065|Experimental|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
16271514|NCT04875052|Active Comparator|Standard ACL Rehabilitation|Patients will complete a 20-week supervised, progressive rehabilitation protocol directed by physical therapists at 1 of 3 participating clinics. While the specific rehabilitation exercises and techniques used for a given patient may vary depending on clinician preference/experience and patient responsiveness and progress, the general rehabilitation protocol will be standardized and follow current best practices emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control consistent with the Multicenter Orthopaedics Outcomes Network (MOON) rehabilitation protocol.
16271515|NCT04875052|Experimental|Whole Body Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to whole body vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
16271516|NCT04875052|Experimental|Local Muscle Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to local muscle vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
16271517|NCT04875039|Active Comparator|Perineural dexamethasone|Addition of dexamethasone 2mg to local anesthetics in infraclavicular brachial plexus block
16271518|NCT04875039|Experimental|Perineural dexamethasone plus dexmedetomidine|Addition of dexamethasone plus dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
16271519|NCT04875026|Experimental|5-fluorouracil 4% (Tolak) + Dexeryl|This group will apply 5-FU once daily for 4 weeks, and Dexeryl once daily for 8 weeks.
16271520|NCT04875026|Other|5-fluorouracil 4% (Tolak)|This group will only apply 5-FU once daily for 4 weeks.
16271521|NCT04875013|Experimental|Vestibular rehabilitation with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
16271522|NCT04875000|Active Comparator|UltraEZ|"Group of patients randomly assigned to receive the the application of the commercial fluoride remineralizing and desensitizing agent UltraEZ (Ultradent Products, Inc, South Jordan, UT, USA) after teeth bleaching"
16271523|NCT04875000|Experimental|Arginine|Group of patients randomly assigned to receive the the application of the 2.5% arginine solution after teeth bleaching
16271524|NCT04875000|Experimental|Nano-hydroxyapatite|Group of patients randomly assigned to receive the application of the 2.5% nano-hydroxyapatite solution after teeth bleaching
16271525|NCT04874974|Experimental|Metacognitive and Defusion Training|All participating patients are allocated to the same five-week experimental group therapy, which consists of three different modules (Module I: Psychoeducation on cognitive processes and rational of the therapy - week 1; Module II: Metacognition - week 2+3; Module III: Cognitive Defusion - week 4+5). Group therapy will start with a psychoeducation session of 60 minutes in the first week and will then take place twice a week with each session lasting 60 minutes.
16271526|NCT04874961|Experimental|Standardized olive extract (Tensiofytol)|3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea), equivalent to 100 mg oleuropeïne and 20 mg hydroxytyrosol
16271527|NCT04874961|Experimental|Combination preparation (Cholesfytol NG)|"3 capsules/day during dinner
~Per day:
~67.2 mg red yeast rice powder (Monascus purpureus; equivalent to 2.9 mg monacoline K)
~1000 mg amla dry extract (Phyllanthus emblica)
~100 mg walnut leave dry extract (Juglans regia)
~50 mg olive dry extract (Olea europaea; equivalent to 10 mg hydroxytyrosol)"
16271528|NCT04874961|Placebo Comparator|Placebo|3 capsules/day during dinner
16271530|NCT04874935|Active Comparator|Lansoprazole arm|33 patients who will receive neoadjuvant chemotherapy and lansoprazole 60 mg twice daily four days before starting chemotherapy regimen and then the same dose will be used during chemotherapy cycles
16271531|NCT04874935|Placebo Comparator|Placebo arm|33 patients who will receive neoadjuvant chemotherapy and placebo capsules.
16271532|NCT04874922|Experimental|Case group|The case group will first receive standard diabetes training from the hospital. After 28-30. Diabetes training based on Planned Behavior Theory will be given three times between gestational weeks. Each training will take an average of 45 minutes. After that, the data evaluation phase will be started.
16271533|NCT04874922|Other|Control Group|The control group will only receive standart diabetes training from the hospital. Then, only follow-up will be done and the data will be evaluated.
16271534|NCT04874909|Other|"Case Patient"|Patient with ciliopathy
16271535|NCT04874909|Other|Healthy related individual|Individual without ciliopathy but related to a patient with ciliopathy (father, mother, brother, sister)
16271536|NCT04874909|Other|"Negative Control patient"|patient without renal disease
16271537|NCT04874909|Other|"Positive Control patient"|"patient with renal disease other that ciliopathy but with a similar renal function to the ciliopathy group (case patient)"
16271538|NCT04874896|Active Comparator|Control|Patients of this branch will not have autotransplantation of gut microbiota in capsules and will follow their usual post-transplant treatment
16271539|NCT04874896|Active Comparator|Microbiota autotransplantation|Patients in this branch will receive autotransplantation of intestinal microbiota in capsules for 6 months post-transplantation
16271540|NCT04874883|Active Comparator|Intervention Group|You will receive 6 grams of the symbiotic (association of fructooligosaccharides, prebiotics, and four probiotic strains: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus Acidophilus, and Bifidobacterium bifidum) either enterally or twice a day.
16271541|NCT04874883|Placebo Comparator|Control Group|Will receive 6 grams of the maltodextrin placebo (carbohydrate easily absorbed and digested, not fermented by colonic bacteria and which does not interfere in the microbial ecology of the gastrointestinal tract or in the metabolism and function of the intestine), either enterally or orally in two sachets times a day
16299431|NCT04679909|Placebo Comparator|Single Dose Placebo|
16271542|NCT04874870|Active Comparator|No Splint Group|This group will receive Xiaflex injection only
16271543|NCT04874870|Active Comparator|Splint Group|This group will receive Xiaflex injection and hand-based custom orthosis to maintain finger extension
16271544|NCT04874857|Experimental|Intervention group (Aromatherapy group)|With a mixture of Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L. essential oils, the foot and lower leg will be massaged for three sessions a week for 30 minutes in each session for four weeks.
16271545|NCT04874857|Experimental|Placebo group|The foot and lower leg will be massaged with baby oil for four weeks, three sessions a week, 30 minutes in each session.
16271546|NCT04874857|No Intervention|Control group|No application will be made in addition to standard HD treatment.
16271547|NCT04874844|Other|Test drug group|Phase II Dose Addition Stage JY025 12MG / KG and 16mg / kg Q3W Givenate Combined EGFRTKI (Gifan Totibi 250mg or Erlotini 150mg) QD scheme, 6 cases of each dose group in group (Gifanibini 3 cases of Erlotini); 1 or 2 doses of JY025 in dose expansion phase Q3W administration combined with EGFR-TKI (50mg or Ellotini 150mg) QD scheme, each dose group 6 Examples of subjects (3 cases of Gifeng Tinib and Ellotini).
16271548|NCT04874844|Active Comparator|Group type|Phase III 396 patient JY025 injection and placebo combined with Notes Totibi / Erlotini (Gifeng Totibi 250mg or Erlotini 150mg) Q3W QD treatment group is randomly packet in 1: 1 ratio (in each group) Gifanibi and Erlotini are 2: 1)
16271549|NCT04874831|Experimental|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
16271550|NCT04874818||lymphopenia|lymphocyte counts (<1.0 x10e9/L)
16271551|NCT04874818||normal lymphocyte numbers|lymphocyte counts ((1.0 - 3.5 x10e9/L))
16271552|NCT04874805|Experimental|Major patient admitted to the ICU for COVID|
16271553|NCT04874779||Acute kidney injury (AKI) group|Acute kidney injury (AKI) group met the guidelines of Kidney Disease, Improving Global Outcomes (KDIGO)
16271554|NCT04874779||NON-Acute kidney injury (non-AKI) group|NON-Acute kidney injury (non-AKI) group not met the guidelines of Kidney Disease Improving Global Outcomes (KDIGO)
16271557|NCT04874740||Kidney transplant recipients|Collection of data from kidney transplant patients at regular outpatient check-ups.
16271558|NCT04874727||Study Population|The five or six individual patients enrolled are the members of the sole group, the study population. These individuals all have been diagnosed with obstructive sleep apnea and have take a Cone-beam CT scan with and without the new bite technique.
16271559|NCT04874714|Experimental|MM09-MG01(30.000-30.000)|30,000 AU/mL of MM09 and 30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
16271560|NCT04874714|Experimental|MG01(30.000)|30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
16271561|NCT04874714|Experimental|MM09(30.000)|30,000 AU/mL of MM09 of subcutaneous immunotherapy once a month for 11 months
16271562|NCT04874714|Placebo Comparator|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
16271563|NCT04874701|Experimental|Capsimax|
16271564|NCT04874701|Placebo Comparator|Placebo|Placebo, 2 capsules per day, for 12 weeks
16271565|NCT04874688|Active Comparator|IYCF-Only|Infants in the IYCF-only arm will receive white maize and SQ-LNS daily from 6 months of age, and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
16271566|NCT04874688|Experimental|IYCF-Plus|Infants in the IYCF-plus arm will receive orange provitamin A-fortified maize and SQ-LNS daily from 6 months of age, plus powdered NUA-45 sugar beans, moringa leaf powder, and powdered whole egg; and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
16271567|NCT04874675|Active Comparator|Diclofenac /Acetaminophen/Codeine|routine pain medication used in post extraction pain management
16271568|NCT04874675|Active Comparator|Ibuprofen/Acetaminophen/codeine|routine pain medication used in post extraction pain management
16271569|NCT04874662|Active Comparator|Investigational NAM/B6|"2 VCaps® capsules daily (commercial vegetarian capsules made of Hydroxy Propyl Methyl Cellulose, a polymer of cellulose)
~Dosage per capsule: 357mg of nicotinamide, 9.5mg of pyridoxine and 195mg of microcrystalline cellulose
~Form:The VCaps® Size 00 will be used. They have a volume of 0.95 ml for 23.3 mm length and a diameter of 8.51 mm head / 8.16 mm body.daily of NAM/B6
~Frequency and duration: 2 capsules daily for 9 days"
16271570|NCT04874662|Placebo Comparator|Placebo control group|"2 capsules daily of microcrystalline cellulose excipient (337mg per capsule)
~Frequency and duration: 2 capsules daily for 9 days"
16271571|NCT04874649|Experimental|Balloon-blowing breathing|"Start by measuring the vital capacity using a balloon to determine. The width of the balloon diameter for each blow and used the value to make a balloon size control device to give to the sample group and parents to use it for home training.
~Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks"
16271572|NCT04874649|Experimental|Sustained maximal inspiration breathing|Participants sitting in a chair, back and head close to the wall. Inhale through their nose fully and hold for 3 seconds for a full breath, then slowly exhale through their mouth and hold for 1 second of exhalation, counted as 1 breathing cycle.Do this 3 times in a row for 1 set. Practice each time doing a total of 3 sets, with 1 minute rest between sets. Participants were required to complete breathing exercise 5 times per week for 8 weeks.
16271575|NCT04874623|Experimental|CDI|
16271576|NCT04874610||BMI > 95|Cohort 1: greater than or equal to 95%ile body mass index
16271577|NCT04874610||BMI < 95|Cohort 2: less than 95%ile body mass index
16271580|NCT04874571|Experimental|Muscle Energy Technique group|In the first group, according to Lewit's post-isometric relaxation (Muscle energy technique) method, scalene (anterior / medius / posterior), levator scapula, sternocleidomastoid, trapezius, pectoral muscles, serratus anterior and latismus dorsi muscles are set 3 days a week ( Each set includes three repetitions) The treatment will be applied for 4 weeks. The hypertonic muscle will be taken to the first point that resists movement without straining. The patient will be asked to perform an isometric contraction for 7 seconds, corresponding to 20% of the maximum isometric contraction force where the restriction is felt. After the application, the patient will be asked to exhale and relax completely. 30 seconds will be waited for each stretching and then the neck will be taken back to the barrier point and three repetitions per session will be performed.
16271581|NCT04874571|Other|Home Exercise|The individuals in the second group will be asked to do the home exercise program shown to them for 4 weeks, 3 days a week. Individuals included in this group will be given a program that includes stretching and posture exercises for the same muscle groups. Individuals in the control group will be called weekly during the 4-week period. Before, after, and 6 weeks after the study, re-evaluation parameters will be applied to all individuals included in the study.
16271582|NCT04874558||Low-dose contrast-enhanced chest CT exam|Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines.
16271583|NCT04874545|Experimental|Propofol group|Maintenance of anaesthesia will be done using Propofol total intravenous anesthesia (TIVA) 6-12 mg/ kg/h by syringe pump, 100 % O2.
16271584|NCT04874545|Active Comparator|sevoflurane group|Maintenance of anaesthesia will be done using sevoflorane1.5-2%, 100 % O2.
16271587|NCT04874519||Participants with Fibrolamellar Carcinoma/FLC|Participants will have a personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)
16271588|NCT04874506|Experimental|Cohort 1|"Cohort 1 will receive standard of care concomitantly with1000 mg/day of MBM-02.
~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:
~1 week run-in with MBM-02 prior to radiotherapy;
~6 weeks of radiotherapy and concomitant temozolomide;
~4 weeks of rest post-radiotherapy and concomitant temozolomide; and
~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
16271589|NCT04874506|Experimental|Cohort 2|"Cohort 2 will receive standard of care concomitantly with1200 mg/day of MBM-02.
~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:
~1 week run-in with MBM-02 prior to radiotherapy;
~6 weeks of radiotherapy and concomitant temozolomide;
~4 weeks of rest post-radiotherapy and concomitant temozolomide; and
~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
16271590|NCT04874506|Experimental|Cohort 3|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.
~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:
~1 week run-in with MBM-02 prior to radiotherapy;
~6 weeks of radiotherapy and concomitant temozolomide;
~4 weeks of rest post-radiotherapy and concomitant temozolomide; and
~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
16271591|NCT04874506|Experimental|Cohort 4|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.
~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:
~1 week run-in with MBM-02 prior to radiotherapy;
~6 weeks of radiotherapy and concomitant temozolomide;
~4 weeks of rest post-radiotherapy and concomitant temozolomide; and
~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
16271592|NCT04874493||Observational (questionnaire)|Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.
16271593|NCT04874480|Experimental|Treatment (tegavivint, decitabine)|"PART I: Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~PART II: Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22 and decitabine IV over 30-60 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16271594|NCT04874467|Experimental|Keratinized Mucosa ≥ 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
16271595|NCT04874467|Experimental|Keratinized Mucosa < 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
16271596|NCT04874454|Experimental|vocal cord movement among the stroke patients|
16271597|NCT04874441|No Intervention|blood culture-based diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
16271598|NCT04874441|Experimental|C. glabrata / krusei PCR diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
16299432|NCT04679909|Placebo Comparator|Two Dose Placebo|
16271599|NCT04874428|Experimental|Rivaroxaban|Pharmacokinetics and pharmacodynamics of rivaroxaban
16271600|NCT04874428|Experimental|Apixaban|Pharmacokinetics and pharmacodynamics of apixaban
16271601|NCT04874415|Experimental|Condition 1|1RLD=One text per day, ramped goal, loss incentive, daily goal time period.
16271602|NCT04874415|Experimental|Condition 2|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
16271603|NCT04874415|Experimental|Condition 3|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
16271604|NCT04874415|Experimental|Condition 4|1RGW=One text per day, ramped goal, gain incentive, weekly goal time period.
16271605|NCT04874415|Experimental|Condition 5|2RLD=Two texts per day, ramped goal, loss incentive, daily goal time period.
16271606|NCT04874415|Experimental|Condition 6|2RLW=Two texts per day, ramped goal, loss incentive, weekly goal time period.
16271607|NCT04874415|Experimental|Condition 7|2RGD=Two texts per day, ramped goal, gain incentive, daily goal time period.
16271608|NCT04874415|Experimental|Condition 8|2RGW=Two texts per day, ramped goal, gain incentive, weekly goal time period.
16271609|NCT04874415|Experimental|Condition 9|1FLD=One text per day, fixed goal, loss incentive, daily goal time period.
16271610|NCT04874415|Experimental|Condition 10|1FLW=One text per day, fixed goal, loss incentive, weekly goal time period.
16271611|NCT04874415|Experimental|Condition 11|1FGD=One text per day, fixed goal, gain incentive, daily goal time period.
16271612|NCT04874415|Experimental|Condition 12|1FGW=One text per day, fixed goal, gain incentive, weekly goal time period.
16271613|NCT04874415|Experimental|Condition 13|2FLD=Two texts per day, fixed goal, loss incentive, daily goal time period.
16271614|NCT04874415|Experimental|Condition 14|2FLW=Two texts per day, fixed goal, loss incentive, weekly goal time period.
16271615|NCT04874415|Experimental|Condition 15|2FGD=Two texts per day, fixed goal, gain incentive, daily goal time period.
16271616|NCT04874415|Experimental|Condition 16|2FGW=Two texts per day, fixed goal, gain incentive, weekly goal time period.
16271617|NCT04874402|Active Comparator|Prepectoral approach|Immediately following mastectomy, participants will undergo prepectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
16271618|NCT04874402|Experimental|Partial subpectoral approach|Immediately following mastectomy, participants will undergo partial subpectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
16271619|NCT04874389||Recreationally active males and females|"Subjects to be considered recreationally must regularly engage in >150 min/wk of physical activity (e.g., resistance training, sport or activity specific exercise, group exercise, or aerobic exercise). Healthy participants, defined as not currently injured, or recovering from an injury within the past 12 months, or undergone surgery within the last 12 months, or with any known history of moderate to severe traumatic brain injury resulting in impaired judgment or inability to make sound decisions or mild traumatic brain injury (mTBI, also commonly named concussion) within the last 12 months."
16271620|NCT04874389||Athletes or performing artists with reported history of concussion|Participants will be considered if they are recreationally active or considered an athletic performer (i.e.,history of participation in athletics at the university, amateur, elite or professional levels, or a military veteran), or a performing artist (i.e., stunt actors, circus artists, dancers or acrobats) with reported history of concussion incident(s), with most recent incident occurring >1 month and less than five years from the study testing dates.
16271621|NCT04874376|Experimental|IOL retrospective data collection|Experimental arm: Premium Monofocal intraocular lens.
16271622|NCT04874363||smoker|active smokers
16271623|NCT04874363||non-smoker|Patients who have never smoked
16271624|NCT04874350|Experimental|LPCN 1148|Oral LPCN 1148 capsules, administered as BID.
16271625|NCT04874350|Placebo Comparator|Placebo|Oral matching placebo capsules, administered as BID.
16271626|NCT04874337|Experimental|Experimental group|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
16271627|NCT04874337|No Intervention|Control Group|
16271628|NCT04874324|Experimental|WCK 2349|"WCK 2349 800mg, 1000mg, and 1200mg . 1 dose given orally twice daily at 12 hourly interval for five days.
~Dosage form : Oral"
16271629|NCT04874324|Placebo Comparator|Placebo|Matching Placebo administered as Oral
16271630|NCT04874311|Experimental|Experimental Arm A: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
16271631|NCT04874311|Other|Standard Arm B: treatment by doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with doxorubicin for 6 cycles
16271632|NCT04874311|Experimental|Experimental Arm C: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
16271633|NCT04874311|Other|Standard Arm D: treatment by doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with doxorubicin for 6 cycles
16271634|NCT04874298|Experimental|Intervention Arm 1 (Ginger Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use ginger oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
16271666|NCT04874090|Other|Exercises group|Patients will perform only neck exercises.
16271667|NCT04874077||Case|
16271668|NCT04874077||Control|
16299474|NCT04679558|Active Comparator|Comparator|Preventive protocol
16271635|NCT04874298|Experimental|Intervention Arm 2 (Peppermint Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
16271636|NCT04874298|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
16271637|NCT04874285|No Intervention|control group|Women with risk factors for abortion, treated with progesterone
16271638|NCT04874285|Experimental|study group|Women with risk factors for abortion, treated with progesterone and a dietary supplement containing hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
16271639|NCT04874272|No Intervention|Pre-Intervention|Pre-intervention: participants complete research surveys about codes and are asked to participate in an interview with the research team.
16271640|NCT04874272|Experimental|Pilot (Single Unit Recruitment)|Pilot intervention: participants participate in a chaplain led post-code debrief, participants complete research surveys about codes.
16271641|NCT04874272|Experimental|Pilot (Hospital-wide Recruitment)|Pilot intervention: participants participate in a chaplain led post-code debrief, participants complete research surveys about codes.
16271642|NCT04874259|Experimental|Colorectal cancer liver metastasis|Liver transplantation for the treatment of unresectable colorectal cancer liver metastasis
16271643|NCT04874246|Active Comparator|Diluted Vasopressin Group 1|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.
16271644|NCT04874246|Active Comparator|Diluted Vasopressin Group 2|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
16271645|NCT04874246|Active Comparator|Diluted Vasopressin Group 3|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
16271646|NCT04874233|Experimental|Active Treatment: HU6 150 mg; N = 20|
16271647|NCT04874233|Experimental|Active Treatment: HU6 300 mg; N = 20|
16271648|NCT04874233|Experimental|Active Treatment: HU6 450 mg; N = 20|
16271649|NCT04874233|Placebo Comparator|Placebo Comparator Non-active study drug N = 20|
16271650|NCT04874207|Experimental|Patients|Patients
16271651|NCT04874194|Experimental|Treatment (omacetaxine, venetoclax)|Patients receive omacetaxine SC BID on days 2-3 or 2-4, and venetoclax PO on days 1-7, 1-10 or 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16271652|NCT04874181|Experimental|Silverfit 3D|The subject will use SIlverfit 3D for rehabilitation of his/her shoulder/knee strength post stroke.
16271653|NCT04874168|Active Comparator|In the TAP group (Group A )|"after completion of surgery, bilateral ultrasound-guided TAP block was performed .
~Description of the intervention: a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used ;A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
16271654|NCT04874168|Active Comparator|In the infiltration group (Group B )|at the end of surgery, 40 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (20 mL in each of the upper and lower sides) by the obstetrician before skin closure.
16271655|NCT04874168|Placebo Comparator|In placebo group (Group C )|routine analgesic was administered and recorded .
16271656|NCT04874155|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation
16271657|NCT04874155|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation.
16271658|NCT04874142|Experimental|A Group|Two cohort, single sequence
16271659|NCT04874142|Experimental|B Group|Two cohort, single sequence
16271660|NCT04874129|Other|A Group|Two-way Crossover
16271661|NCT04874129|Other|B Group|Two-way Crossover
16271662|NCT04874116|Experimental|Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging|Participants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.
16271663|NCT04874116|Active Comparator|Mobile phone text messaging|Participants receive mobile phone text messaging alone for 12 months.
16271664|NCT04874103||EUS guided gallbladder drainage and cholecystoscopy|"EUS-GBD will be performed using LAMS (such as Hot-AxiosTM device). A 10mm x 10mm stent system will be used if the largest gallstone is smaller than 10mm in size and a 15 x 10mm stent will be used if the largest gallstone is larger than 10mm.
~Colecystoscopy will be subsequently performed after at least 2 weeks using standard or therapeutic gastroscope. Lithotripsy will be performed using mechanical lithotripsy or laser lithotripsy."
16271665|NCT04874090|Experimental|Interventional group|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program.
16271669|NCT04874051|Experimental|Experimental Group (EG)|In the EG the subjects will perform balance exercises using the OAK system under the supervision of a trained physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
16271670|NCT04874051|Active Comparator|Control Group (CG)|In the CG the subjects will be asked to perform conventional balance exercises under the supervision of a physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
16271671|NCT04874038|Experimental|Intervention|Intraoperative intravenous lidocaine/placebo infusion
16271672|NCT04874038|Placebo Comparator|Control|Intraoperative intravenous lidocaine/placebo infusion
16271673|NCT04874012|Placebo Comparator|Placebo|Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.
16271674|NCT04874012|Active Comparator|Taurine|Participants will receive 6 gy taurine divided into twice/day orally administration for 12 weeks.
16271675|NCT04873973|No Intervention|Control|Participants in this group are routinely treated.
16271676|NCT04873973|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
16271677|NCT04873947||healthy adult volunteer|Subject is 18 to 50 years of age. Subject is a non-smoker or who has not smoked within 2 days prior to the study.
16271678|NCT04873934|Experimental|Inclisiran with Usual Care|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
16271679|NCT04873934|No Intervention|Usual Care|Usual Care Alone
16271680|NCT04873921|Experimental|Group 1: Sterile Kinesio tape application|Sterile Kinesio Taping application will be applied with Sterile Web Cut Kinesio Tape (Sterile Kinesio Tex Tape, Alberquerque, USA) without tension.
16271681|NCT04873921|No Intervention|Group 2: Control group|Group 2 will not receive any taping
16271682|NCT04873908|Other|conventional rehabilitation|
16271683|NCT04873908|Experimental|Modified constraint-induced therapy|
16271684|NCT04873908|Experimental|Proprioceptive Training|
16271685|NCT04873895|Experimental|TACE+axitinib+HCQ|2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.
16271686|NCT04873869|Placebo Comparator|Placebo|Participants will receive matching placebo for up to 18 weeks.
16271687|NCT04873869|Experimental|NBI-921352|In the first 6 weeks participants will receive increasing doses of NBI-921352 (Titration Period) based on weight, followed by 10 weeks of treatment at their final tolerated dose (Maintenance Period) and 2 weeks of treatment with decreasing doses (Taper Period).
16271688|NCT04873856|Experimental|Intervention group|"Intervention contains:
~individual nutritional plan
~regular contact
~friendly reminder/informal caregiver and
~weight dairy."
16271689|NCT04873856|No Intervention|Control Group|Standard of care
16271690|NCT04873843|Experimental|Functional digital game training group|These functional digital game programs have been developed to improve the intelligence and vitality in the community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
16271691|NCT04873843|Experimental|Individual cognitive training|Individual cognitive training has been used to improve the intelligence and cognitive function in community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
16271692|NCT04873830|Experimental|Group I (VCMX)|includes 10 patients where implant placement will be performed followed by volume stable collagen matrix placement to augment the buccal defect.
16271693|NCT04873830|Experimental|Group II (control)|Will include 10 patients where implant placement will be performed followed by connective tissue grafting to augment the buccal defect.
16271694|NCT04873817||IonicRF Generator and compatible accessories|IonicRF Radiofrequency Generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator will be used.
16271695|NCT04873804|Active Comparator|LEFT DLPFC|The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.
16271696|NCT04873804|Active Comparator|RİGHT PPC|The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.
16271697|NCT04873804|Sham Comparator|Sham|Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.
16271698|NCT04873791||Group 1|"Assessment Geriatric Individuals Living at Home were joined in Group 1.
~Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.
~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.
~Assessments were made as described in section of outcome measures, in one session."
16271699|NCT04873791||Group 2|"Assessment Geriatric Individuals Living in Nursing Home were joined in Group 2. Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.
~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.
~Assessments were made as described in section of outcome measures, in one session."
16271700|NCT04873778|Experimental|Dynamic taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
16271701|NCT04873778|Experimental|kinesio taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
16271702|NCT04873778|Placebo Comparator|control group|use Kinesio taping for placebo effect
16271703|NCT04873765|Experimental|Pegfilgrastim Megalabs|Pegfilgrastim injectable 6 mg in a single subcutaneous application.
16271704|NCT04873765|Active Comparator|Pegfilgastrim Neulastim|Neulastim injectable 6 mg in a single subcutaneous application.
16271706|NCT04873739||20 patients SLE with dry eye|Anterior segment OCT for SLE patients with dry eye
16271707|NCT04873739||30 patients SLE without dry eye|Anterior segment OCT for SLE patients without dry eye
16271708|NCT04873739||50 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
16271709|NCT04873726|No Intervention|Pre: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
16271710|NCT04873726|No Intervention|Pre: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
16271711|NCT04873726|No Intervention|Pre: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
16271712|NCT04873726|Experimental|Post Exp: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
16271713|NCT04873726|Experimental|Post Exp: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
16271714|NCT04873726|Experimental|Post Exp: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
16271715|NCT04873726|Placebo Comparator|Post Pla: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
16271716|NCT04873726|Placebo Comparator|Post Pla: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
16271717|NCT04873726|Placebo Comparator|Post Pla: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
16271718|NCT04873713|No Intervention|No Intervention: internal hip rotation|internal hip rotation pre measurement with knee and hip flexion at 90º, internal hip rotation will be performed
16271719|NCT04873713|Experimental|Experimental: internal hip rotation|internal hip rotation post experimental application measurement with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
16271720|NCT04873713|Placebo Comparator|Placebo Comparator: internal hip rotation|internal hip rotation post placebo application measurement with Placebo tape Application with knee and hip flexion at 90o, internal hip rotation will be performed
16271721|NCT04873700||All Participants|Participants diagnosed with moderate to severe UC or CD will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of UC and CD.
16271722|NCT04873687|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention therapy (i.e eligible stable angina pectoris patients in intervention arm who agree to participate)
16271723|NCT04873687|No Intervention|Control|Eligible stable angina pectoris patients in the control arm will receive no intervention therapy
16271724|NCT04873674||ASD group|240 ASD patients (aged 4-25 years)
16271725|NCT04873674||Unaffected siblings of ASD|60-100 unaffected siblings of ASD probands
16271726|NCT04873674||TD group|120 age-, and sex matched TDC from the same geographic areas of the ASD group via referral by teachers, or advertisement at college or community.
16271727|NCT04873661|Experimental|Hypnosis|In the hypnosis-based intervention, patients (in groups of approximately 10 participants) will participate in 8 weekly sessions (2 hours each) during which they will benefit from guided hypnosis exercises, and learn how to implement self-hypnosis. They will also receive a CD with hypnosis exercises for home practice. At-home practice is encouraged between sessions.
16271728|NCT04873661|Experimental|Cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
16271729|NCT04873661|Experimental|Meditation|The meditation-based intervention will consist of 8 weekly sessions (2h45 each) in groups of approximately 10 participants, as well as half a day of intensive practice between the fifth and the sixth session. Participants will learn how to implement self-compassion meditation, through practical exercises proposed during the sessions. At-home practice is encouraged between sessions.
16271730|NCT04873661|No Intervention|Control group|Participants in the control group will not receive any intervention during the whole duration of the study. They will be assessed at the same times and in the same ways than the 3 experimental groups. After the study, they will have the opportunity to participe in one of the 3 interventions if they want to.
16271731|NCT04873648|Experimental|food addiction and binge eating follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric reduced -intermitted fasting diet
16271732|NCT04873648|Active Comparator|food addiction and binge eating follow caloric restriction diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric restriction diet
16271733|NCT04873648|Experimental|binge eating disorder follow follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder follow caloric reduced -intermitted fasting diet
16271734|NCT04873648|Active Comparator|binge eating disorder follow caloric restriction diet|Obese women diagnosed with binge eating disorder follow a caloric restriction diet
16271735|NCT04873648|Placebo Comparator|obese women without food addiction and binge eating follow caloric restriction diet|Obese women without eating disorder follow a caloric restriction diet
16271736|NCT04873635||Patients who had excised pathological jaw lesions and will receive implant rehabilitation|
16271737|NCT04873622|Experimental|RESTORE intervention|Participants who screen eligible and consent will receive RESTORE with guidance.
16271738|NCT04873609|No Intervention|No primary care provider (PCP) appointment, No patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
16271739|NCT04873609|Active Comparator|No PCP appointment, Patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
16299835|NCT04676945||treated patients|ANY MDS disease modifying therapy
16271740|NCT04873609|No Intervention|PCP appointment, No patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
16271741|NCT04873609|Active Comparator|PCP appointment, Patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
16271742|NCT04873596|Active Comparator|nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
16271743|NCT04873596|Active Comparator|nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
16271744|NCT04873583|Experimental|Steroids + Standard of care|Standard of care (including aspirin) and intravenous steroids, followed by oral tapering.
16271745|NCT04873583|No Intervention|Standard of care|Standard of care (including aspirin)
16271746|NCT04873570|Experimental|Test Group|Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
16271747|NCT04873570|Active Comparator|Reference Group|Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
16271748|NCT04873557|Experimental|Copper Intervention|Intervention with copper-based surfaces plus copper-enriched linen
16271749|NCT04873557|No Intervention|Control Group|Control group without copper intervention
16271750|NCT04873544|Experimental|Common protocols for TKA|Common protocols for TKA
16271751|NCT04873531|Experimental|Neostigmine|"For the Neostigmine (N) group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.
~Investigators evaluate the quality of signal of IONM during the surgery."
16271752|NCT04873531|Placebo Comparator|Normal saline|"For the Normal saline (NS) group, normal saline with a same volume of the N group will be administered just after tracheal intubation.
~Investigators evaluate the quality of signal of IONM during the surgery."
16271756|NCT04873505|Experimental|Troches|25 persons take one probiotic troche after each meal.
16271757|NCT04873505|Placebo Comparator|Troches do not contain probiotics|25 persons take one troche that does not contain probiotics after each meal.
16271758|NCT04873492|Other|Retrospective Aggressive MS patients|Patients from who the clinical outcome is already known and classified as poor based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
16271759|NCT04873492|Other|Retrospective Non Aggressive MS patient|Patient from who the clinical outcome is already known and classified as non-aggressive based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
16271760|NCT04873492|Other|Healthy volunteers|Prospective arm use as comparator.
16271761|NCT04873492|Other|Prospective MS patients|MS patients from who the clinical outcome will be established at the end of the follow up. Blood sample will be collected after the first event to validate molecules of interest from OMIC results by using FACS a different technology and classify MS patient.
16271762|NCT04873479|Experimental|test group|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
16271763|NCT04873479|Other|control group|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.2-0.3ug/kg,Etomidate 0.2-0.3mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.1-0.3ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
16271764|NCT04873466|Experimental|Enzyme-rich malt extract|Enzyme-rich malt extract (15 ml b.i.d with food)
16271765|NCT04873453|Active Comparator|Full-spectrum Cannabidiol|150mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
16271766|NCT04873453|Experimental|Broad-spectrum Cannabidiol|150mg/day of broad-spectrum cannabidiol, containing 0%THC.
16271767|NCT04873453|Placebo Comparator|Placebo|150mg/day of hemp-seed oil with no cannabinoids present.
16271768|NCT04873440|Experimental|Manganese plus Radiotherapy|Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site. Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months. The same systemic therapy before the enrollment will be maintained.
16271769|NCT04873427||early metastatic prostate cancer patients|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
16271770|NCT04873427||non-relapsing/non-metastatic patients with indolent malignant disease|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
16271771|NCT04873414|Experimental|Treatment group|Subjects in the Treatment Group are given 200 ml of Plasma collected from Convalescent Patients recovered from COVID-19 at two-day intervals in addition to standard supportive treatment
16271772|NCT04873414|No Intervention|Control group|Subjects in the Control Group are given standard supportive treatment
16271773|NCT04873401|Experimental|Chain Referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing; these recruits are then trained to do the same."
16271774|NCT04873401|Experimental|Credible Messenger|In the credible messenger intervention, peers identified as popular and socially influential individuals within their respective communities with lived experience are trained to engage within formal and informal social networks to promote behavior change.
16271775|NCT04873375|Experimental|Cemiplimab|After inclusion, all patients will be treated with Cemiplimab 350mg intravenously every three weeks
16271776|NCT04873362|Active Comparator|Arm A: Placebo + Trastuzumab Emtansine|Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
16271777|NCT04873362|Experimental|Arm B: Atezolizumab + Trastuzumab Emtansine|Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
16271778|NCT04873349|Active Comparator|Olive leaf capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a 50% standardized olive leaf capsule 750 mg (700 mg oleuropein/day; the active principle in olive leaf) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the active comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
16271779|NCT04873349|Placebo Comparator|Starch capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a placebo starch capsules (750 mg) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the placebo comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
16271780|NCT04873323|Experimental|TS-142 10 mg|TS-142 therapeutic dose oral tablet (low dose)
16271781|NCT04873323|Experimental|TS-142 30 mg|Description: TS-142 supratherapeutic dose oral tablet (high dose)
16271782|NCT04873323|Experimental|Moxifloxacin 400 mg|Moxifloxacin tablet
16271783|NCT04873323|Experimental|Placebo|Placebo oral tablet
16271784|NCT04873310|Experimental|Triple P online with professional support|In the online version with professional support, the psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions, as well as answering questions and doubts that the participants may have regarding the program and its implementation.
16271785|NCT04873310|Experimental|Triple P online without professional support|In the version without professional support, the role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
16271786|NCT04873310|No Intervention|Control group|Control group without any intervention.
16271789|NCT04873284|Experimental|Fosaprepitant|Patients received intravenous Granisetron plus dexamethasone followed by fosaprepitant infusion
16271790|NCT04873284|Experimental|Aprepitant|Patients received intravenous Granisetron plus dexamethasone followed by oral aprepitant
16271793|NCT04873232|Experimental|Engensis|Patients who have received Engensis in protocol VMDN-003-2
16271794|NCT04873232|Placebo Comparator|Placebo|Patients who have received Placebo in protocol VMDN-003-2
16271795|NCT04873219|Active Comparator|CAD/CAM milled complete denture|the dentures were milled out of a block of pre-polymerized PMMA resin (Avadent, Global dental Science, Netherlands)
16271796|NCT04873219|Experimental|CAD/CAM rapid prototyped complete denture|the dentures will be 3D-printed from a liquid PMMA, including the teeth (NexDent, Netherlands)
16271797|NCT04873206||Functional/ Cyclical Endometrial group.|cases of normal endometrium will be obtained from hystrectomy specimens done for causes other than hyperplasia or adenocarcinoma, for example; uterine fibroids, uterine prolapse.
16271798|NCT04873206||Hyperplastic Endometrial group.|cases of endometrial hyperplasia obtained by D&C or hystrectomy will be stained by H&E stain and categorized into typical or atypical hyperplasia.
16271799|NCT04873206||Primary Endometrial Adenocarcinoma group.|cases of primary endometrial adenocarcinoma obtained by D&C or hystrectomy operations
16271800|NCT04873193|Other|Oscillometry + Pneumotach Procedure with Leo Device measurements|"All patients will undergo oscillometry procedure, followed by pneumotach procedure to measure tidal volume in different sitting positions. The Leo device will be worn throughout both procedures to measure the chest electrical impedance and compare against pneumotach measurements.
~Oscillometry and pneumotach are part of standard of care."
16271801|NCT04873167|Experimental|Low Fat Diet|subjects subjected to a low-fat dietary regime
16271802|NCT04873167|Experimental|Mediterranean Diet|subjects subjected to a mediterranean dietary regime
16271803|NCT04873141||Case Group|All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.
16271827|NCT04872959|No Intervention|Usual Care Arm|Will not use HealthReveal to titrate the doses of Entresto/ other treatments for HFrEF.
16271873|NCT04872530|Experimental|Pea-protein concentrate|Pea-protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
16271874|NCT04872530|Experimental|Fava-bean protein concentrate|Fava-bean protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
16272975|NCT04865367||DEG n3: medium arrested embryos|culture media derived from arrested embryos
16271804|NCT04873128|Experimental|Healthy adults|"Healthy adults who had no infection with SARS-CoV-2 virus before or had recovered from COVID-19 and plan to take the various COVID-19 experimental vaccine candidates or had already one dose of COVID-19 vaccine and are going to have the second vaccination with a different vaccine.
~Study related procedures:
~1-3 days before application of the first vaccine dose (blood sample 1) 7-10 days after first dose of vaccine (blood sample 2), 1-3 days before second dose of vaccine (blood sample 3) 7-10 days after second vaccine dose (blood sample 4) 6-12 Months after second vaccine dose (blood sample 5, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
16271805|NCT04873128|Experimental|COVID-19 vaccinated subjects with side effects|"COVID-19 vaccinated subjects with diagnosed central thrombosis, anaphylactic shock or other major or minor complications such as dermatitis.
~Study related procedures: Blood sample will be taken without time frame 1-3 days after admission to the hospital (severe side effects) or consulting a doctor (mild side effects) (blood sample 1) during treatment (blood sample 2) After subject is recovered (blood sample 3) 6-12 Months after recovering (blood sample 4, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
16271806|NCT04873115|Active Comparator|Sialanar|Sialanar administered as per the SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
16271807|NCT04873115|Placebo Comparator|Placebo|Placebo administered as per the Sialanar SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
16271808|NCT04873102|Experimental|Danazol in Treatment of Cytopenias|AGENT: Danazol 600mg, Oral, Daily for 24 months
16271809|NCT04873089||RV3278A arm|RV3278A study product is applied twice a day (morning and evening) on the face during the whole study.
16271810|NCT04873089||Control Group|Subjects included in the control group did not receive the test product or other associated product
16271811|NCT04873076|Experimental|Audiovisual distraction using 2d video glasses from HappyMed GmbH|"During the catheter ablation, the patients in the intervention group receive 2D video glasses with headphones. Immediately before and after the procedure they receive a questionnaire. During the procedure vital parameters of all patients regardless of the studygroup are monitored using Zoll X-Series Monitor Defibrillator. The study includes blood pressure (in mmHg), heart rate (in beats per minute) and patient's level of alertness, which is assessed using the Richmond Agitation-Sedation Scale(RAAS). During the procedure the patients in the intervention group receive the glasses and remote control. All patients receive their individual dosage to ensure painless ablation. The drugs used are limited to the opioids remifentanil and benzodiazepine midazolam."
16271812|NCT04873076|No Intervention|Controll arm|"In patients in the control group, catheter ablation is performed as usual without the use of video glasses. They receive immediately before and after the ablation the same questionnaire as the patients in experimental arm. (Omitting the question about the videoglasses).
~While the procedure is performed, the analgosediation is as well in the controll arm as in the experimental arm titrated until the patient is treated, sedated and painless."
16271813|NCT04873063|Experimental|Reference/Test|"3 mg BDP suppositories (R product) delivered twice daily for 7 days
~Washout period (at least 7-day and preferably no more than 9 days)
~6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product."
16271814|NCT04873063|Experimental|Test/Reference|"6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.
~Washout period (at least 7-day and preferably no more than 9 days)
~3 mg BDP suppositories (R product) delivered twice daily for 7 days"
16271815|NCT04873050|Experimental|Semaglutide Pen Injector (Ozempic)|Weekly injections of semaglutide for 8 months total (2 months of titration; 6 months of full dose- 1mg/week)
16271816|NCT04873050|Sham Comparator|Placebo|Weekly injections of placebo for 8 months total
16271817|NCT04873037|Active Comparator|Emsella Chair Active Treatment|Active subjects will be asked to sit on the center of the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the reminder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
16271818|NCT04873037|Placebo Comparator|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (less than 10% power).
16271819|NCT04873024|Experimental|Intervention-first|Participants in this arm will receive the Intervention treatment on the first night, and the control treatment on the second night.
16271820|NCT04873024|Experimental|Control-first|Participants in this arm will receive the Control treatment on the first night, and the Intervention treatment on the second night.
16271821|NCT04873011|Experimental|Quinine hydrochloride|The bitter tastant, quinine hydrochloride, will be acutely infused via a nasogastric feeding tube into the stomach. 320 mg of quinine hydrochloride is dissolved in 10 mL of water and all is infused.
16271822|NCT04873011|Placebo Comparator|Placebo|10 mL of water is infused via a nasogastric feeding tube into the stomach.
16271823|NCT04872998|Experimental|Reduced Activity|Reduction of daily step count by 70% for two weeks
16271824|NCT04872985|Experimental|Arm 1: Pyrotinib+ AC/EC followed by T|400 mg Pyrotinib orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
16271825|NCT04872985|Placebo Comparator|Arm 2: Placebo+ AC/EC followed by T|400 mg placebo orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
16271826|NCT04872972|Other|Before/After|Before and after simulation; Institutional faculty and facilities
16272023|NCT04871633|Other|Conventional|patients having Standard Conventional therapy only.
16271828|NCT04872959|Experimental|Interventional- Health Reveal|"The interventional arm will be provided tools to augment quality of care and build the patient and physician relationship through trust and shared goal-setting.
~Prior to each patient appointment, on a customized GDMT Dashboard, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' electronic health record (EHR). The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.
~Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed."
16271829|NCT04872946|Experimental|InnerCalm+skin care|An oral supplement and topical agent will be assigned.
16271830|NCT04872946|Experimental|InnerCalm only|An oral supplement will be assigned.
16271831|NCT04872946|Experimental|Skincare Only|A topical agent only will be assigned.
16271832|NCT04872933|Other|Non-Waitlist|Patient will attend a total of 3 virtual assessments whilst in the study: at baseline, at 12 weeks then at 6 months. The online intervention will commence straight after completing the baseline visit.
16271833|NCT04872933|Other|Waitlist|Patient will be complete assessments at baseline and 12 weeks but will only start the online intervention after the 12-week assessment.
16271834|NCT04872907|Experimental|adhesive system + flowable composite|Side of the mouth randomlly assigned to this arm will receive self etch adhesive system and flowable composite combination on temporary molars and self etch adhesive system on anterior temporary teeth at baseline, M6, M12, M18
16271835|NCT04872907|Active Comparator|Fluoride varnish|Side of the mouth randomly assigned to this arm will receive the fluride varnish at baseline, M6, M12, M18 on the temporary teeth
16271836|NCT04872881|Active Comparator|ETT Group|"ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
16271837|NCT04872881|Active Comparator|LMA Group|"After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
16271838|NCT04872842||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
16271839|NCT04872842||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
16271840|NCT04872829||multifocal IOL group|patients with unilateral and bilateral multifocal IOL
16271841|NCT04872829||monofocal IOL group|patients with unilateral and bilateral monofocal IOL
16271842|NCT04872816|Experimental|Continuous airway positive pressure|All participants in continuous airway positive pressure arm will use CPAP (model S10-Resmed®) with expiratory relief and nasal mask.
16271843|NCT04872816|Sham Comparator|SHAM continuous airway positive pressure|Individuals in SHAM continuous airway positive pressure arm will use CPAP (model S7-Resmed®) with expiratory relief and nasal mask. The Sham-CPAP consists of a modified CPAP so that the pressure in the mask was less than 1 cm H2O. In this study, the Sham-CPAP equipment includes an increase in the expiratory orifice of the CPAP mask to eliminate airflow resistance, and a resistor with a small orifice was placed between the CPAP and the circuit. The noise produced by the ventilator and the airflow through the mask will be very similar to that of the effective CPAP. The diameter of the expiratory orifice was 10 cm H2O, and a 4 mm diameter resistor was placed between the trachea and the CPAP flow generator.
16271844|NCT04872790|Experimental|Treatment (prednisone, dasatinib, venetoclax, rituximab)|"INDUCTION PHASE: Patients receive prednisone PO QD on days -6 to 21 and taper off days 22-28, dasatinib PO QD days 1-28, venetoclax PO QD days 3-28 or days 3-21, rituximab IV on days 8 and 15, and methotrexate IT once during week 1 and once during week 3 in the absence of disease progression or unacceptable toxicity.
~POST-INDUCTION PHASE: Patients receive dasatinib PO QD days 1-28, venetoclax PO QD on days 1-28 or 1-21, rituximab IV on days 1 and 15, and methotrexate IT on days 1 and 15. Treatment repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with clinical benefit may continue to receive treatment for up to 12 months per the discretion of the physician."
16271845|NCT04872777|No Intervention|Standard of care|"Standard of care (SOC) control condition: Following study group assignment, the following procedures will be completed for SOC control:
~Digital scale provision (subjects may keep the scale)
~Reinforcement of need to comply with SOC treatment as directed by their NASH clinician
~Capture of available clinical information over preceding 28-days."
16271846|NCT04872777|Experimental|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:
~Noom application set-up and troubleshooting on smartphone (license provided)
~Digital scale provision (subjects may keep the scale)
~Capture of available clinical information over preceding 28-days."
16271847|NCT04872764||COVID-19 patients with acute kidney injury|COVID-19 patients with acute kidney injury
16271848|NCT04872764||COVID-19 patients without acute kidney injury|COVID-19 patients without acute kidney injury
16271849|NCT04872738||Vaccinated Breast Cancer Patients|Patients who enroll in the trial and decided to get the COVID-19 vaccine will complete surveys to indicate their experiences, side effects, location of vaccination (i.e. right arm, left arm, or leg). This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
16271850|NCT04872738||Unvaccinated Breast Cancer Patients|Patients who enroll in the trial and did not choose to receive the COVID-19 vaccine once it was available to them with complete a survey to indicate why they chose not to receive the vaccine. This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
16271872|NCT04872543|Experimental|ASTX727 (cedazuridine and decitabine)|Patients who meet the eligibility criteria will be treated with oral ASTX727 (INQOVI) on days 1-5 of each 28-day cycle. A delay in the start of subsequent cycles due to holidays, weather, or other circumstances will be permitted up to 7 days and not considered a protocol deviation.
16271851|NCT04872712|Active Comparator|Press Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with Press Needles treatment will be treated with 2-week needle retention, 20-second pressing 3 times a day and needle replacement performed every 5 days. The needles are inserted 0.9 mm deep at the acupuncture points HT7 Shenmen, PC6 Neiguan, ST36 Zusanli and SP6 Sanyinjiao.
16271852|NCT04872712|Active Comparator|Filiform Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with filiform needles treatment will be treated with 20-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The needles are inserted approximately 12 mm deep at the acupuncture points HT7 Shenmen and PC6 Neiguan and 25 mm deep at the ST36 Zusanli and SP6 Sanyinjiao.
16271853|NCT04872686|Experimental|Oral and nasal spray to moderately ill COVID-19 positive patient|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: Single
16271854|NCT04872686|Experimental|Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: hourly for 4 hours in a single day
16271855|NCT04872686|Experimental|Oral and nasal spray to healthy volunteer|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: 3-4 times interval but not more than 4 times a day for 30 days
16271856|NCT04872686|Placebo Comparator|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled water Dosage form: Oral and Nasal spray will be provided by Distilled water
16271857|NCT04872660|Experimental|GSATP group|Gushen Antai Pill (GSATP, 6g* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
16271858|NCT04872660|Placebo Comparator|Placebo group|Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
16271859|NCT04872647|No Intervention|Usual Diabetic Care|Usual diabetic care for this study will include a diabetic visit with their primary care provider at the beginning and end of the 12 weeks. They will also be asked to continue their current level of physical activity and eating habits.
16271860|NCT04872647|Experimental|Usual Diabetic Care Plus Virtual Health Coaching|"For the duration of the 12 weeks, Healthy at Home will provide health coaching in 10-20 minute phone calls weekly. They will request daily blood glucose logs as this is part of Healthy at Home's normal procedure. The health coach and subject will choose a patient-directed overarching goal such as lose weight, or improve my blood sugar numbers, etc. that the health coach will then help the patient turn into a SMART goal. They will do this by utilizing a list of lifestyle change categories as top priority goals from which to choose from in their patient-directed health coaching sessions. Texting will be utilized to request daily blood glucose and provide real-time coaching via text."
16271861|NCT04872634|Experimental|SNK01 (4ⅹ10^9 cells) + GC|Administration of SNK01 4ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
16271862|NCT04872634|Experimental|SNK01 (4ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 4ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
16271863|NCT04872634|Experimental|SNK01 (6ⅹ10^9 cells) + GC|Administration of SNK01 6ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
16271864|NCT04872634|Experimental|SNK01 (6ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 6ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
16271865|NCT04872608|Experimental|Letrozole, Palbociclib, and Onapristone ER|This study has two stages: a dose-finding stage and a dose expansion stage. Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle. Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.
16271866|NCT04872595|Experimental|P-rATG with total body irradiation, thiotepa, cyclophosphamide|"P-rATG days (always starting on Day -12 to -10)
~Hyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6
~Thiotepa (5mg/kg/day x 2 day) Day -5 to -4
~Cyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2
~GCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
16271867|NCT04872595|Experimental|P-rATG with busulfan, melphalan and fludarabine|"P-rATG days (Appendix A - always starting on Day -12 to -10)
~Busulfan -Day -9 to -7
~Initial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5
~Fludarabine (25mg/m2/day x 5 days) Day -6 to -2
~GCSF Day +7"
16271868|NCT04872582|Experimental|PD-1 immune checkpoint inhibitor combined with bevacizumab|
16271869|NCT04872569|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
16271870|NCT04872556|Experimental|Laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
16271871|NCT04872556|Sham Comparator|Pseudo-laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day 3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
16271875|NCT04872530|Experimental|Chickpea protein concentrate|Chickpea protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
16271876|NCT04872530|Experimental|Red lentil protein concentrate|Red lentil protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
16271877|NCT04872530|Experimental|Non-essential amino acid blend|Non-essential amino acid blend dosed at 0.33 g/kg body mass in 500 ml of water.
16271878|NCT04872530|Experimental|Whey protein concentrate|Whey protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
16271879|NCT04872517|Experimental|34 head and neck cancer patients, expected to proceed chemotherapy or radiotherapy in hospital.|Total 34 anticipants will recruit in this research. Age was limited between 20years old to 75 years old. All of anticipants agree to join this trail and be followed through treatment , and without underlying disease that threaten life.
16271880|NCT04872504|Experimental|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen
16271881|NCT04872491||Participants With UC or CD|Participants diagnosed with UC or CD who are prescribed and will start treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, 6, and every 8 weeks thereafter for up to 54 weeks will be observed prospectively for 72 weeks.
16271882|NCT04872478|Experimental|Dose Escalation - Level 1|MRX-2843 capsules, QD - 28 day cycles
16271883|NCT04872478|Experimental|Dose Escalation - Level 2|MRX-2843 capsules, QD - 28 day cycles
16271884|NCT04872478|Experimental|Dose Escalation - Level 3|MRX-2843 capsules, QD - 28 day cycles
16271885|NCT04872478|Experimental|Dose Escalation - Level 4|MRX-2843 capsules, QD - 28 day cycles
16271886|NCT04872478|Experimental|Dose Escalation - Level 5|MRX-2843 capsules, QD - 28 day cycles
16271887|NCT04872478|Experimental|Expansion Arm at RP2D|MRX-2843 capsules, QD - 28 day cycles
16271888|NCT04872465|Active Comparator|Experimental|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
16271889|NCT04872465|Placebo Comparator|Sham Comparator|Participants will receive sham (placebo) TBS treatment the same as experimental group
16271890|NCT04872452|Experimental|Gastrointestinal dysmotility participants|
16271891|NCT04872452|Other|Healthy participants|
16271892|NCT04872439||Antibody isolation|
16271893|NCT04872426|Experimental|Low intensity exercise|70% of maximal leg work load capacity
16271894|NCT04872426|Experimental|High intensity exercise|70% and 95% of maximal work load capacity (alternately every 5 min)
16271895|NCT04872426|Experimental|Low intensity exercise + intermittent ischemia-reperfusion|70% of maximal leg work load capacity with intermittent ischemia (25 seconds every 2 min)
16271896|NCT04872413|Experimental|Screening (biospecimen collection)|Patients undergo blood, saliva or tissue sample collection for mRNA analysis and drug efficacy testing. Patients assigned treatment per the results are followed every 1 cycle of therapy for 1 year, every 2 months for 1 year, every 4 months for 1 year then every 6 months thereafter.
16271897|NCT04872400|No Intervention|Control|Subjects randomized to the Control Arm will receive standard of care open fracture wound care (no powder) by the clinical team.
16271898|NCT04872400|Experimental|Vancomycin|Subjects randomized to the Intervention arm will receive standard of care plus 1 gram of vancomycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
16271899|NCT04872400|Experimental|Tobramycin|Subjects randomized to the Intervention arm will receive standard of care plus 1.2 grams of tobramycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
16271900|NCT04872387|Experimental|BAY2586116 Dose step 1 and Placebo|"Each participant of Dose step 1 will receive a single dose of BAY2586116 or placebo.
~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
16271901|NCT04872387|Experimental|BAY2586116 Dose step 2 and Placebo|"Each participant of Dose step 2 will receive a single dose of BAY2586116 or placebo.
~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
16271902|NCT04872387|Experimental|BAY2586116 Dose step 3 and Placebo|"Each participant of Dose step 3 will receive single and multiple doses of BAY2586116 or placebo administered once daily (OD) for 5 consecutive days.
~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
16271903|NCT04872374|Experimental|Young adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
16271904|NCT04872374|Active Comparator|Older adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
16271905|NCT04872361|Placebo Comparator|Low PEEP|Low positive end-expiratory pressure (PEEP) and no recruitment maneuver (RM)
16271906|NCT04872361|Active Comparator|High PEEP|High positive end-expiratory pressure (PEEP)
16271907|NCT04872361|Active Comparator|High PEEP/RM|High positive end-expiratory pressure (PEEP) and recruitment maneuver (RM)
16271908|NCT04872348||Eyes receiving OMNI intervention after medication washout|
16271909|NCT04872348||Eyes receiving OMNI intervention without medication washout|
16271910|NCT04872335|Experimental|Gong's Mobilization|Subjects received gong's mobilization three times in a week for 4 weeks.
16271911|NCT04872335|Experimental|Gradually Graded Exercise Therapy|Subjects received gradually graded exercise therapy three times in a week for 4 weeks.
16271912|NCT04872322|Active Comparator|Standard Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive an initial injection of 0.5% ropivacaine as the initial anesthetic followed by continuous injection of 0.25% ropivacaine.
16271913|NCT04872322|Active Comparator|Partial Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive 0.25% ropivacaine initially followed by the usual continuous injection of 0.25% ropivacaine during surgery
16271914|NCT04872309||Asthma Patients|Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).
16271915|NCT04872309||COPD Patients|Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)
16271916|NCT04872309||ICU COVID-19|Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)
16271917|NCT04872309||Moderate/Severe COVID-19|Adults hospitalised with COVID-19
16271918|NCT04872309||Mild- Non-hospitalised COVID-19|Adult with proven COVID-19 infection, not hospitalised for COVID-19
16271919|NCT04872309||Non-hospitalised symptomatic (long-COVID group)|Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.
16271920|NCT04872296|Active Comparator|Early weight bearing|Participants treated for an ankle fracture will be allowed to weight bear early after surgery starting at 2 weeks post operatively
16271921|NCT04872296|Active Comparator|Postponed weight bearing|Participants treated for an ankle fracture will be treated with standard protocol of non-weight bearing for 6 weeks post operatively.
16271922|NCT04872283|Active Comparator|Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive 30 mg of IV ketorolac during surgery as well as 20 mg ketorolac pills to take after surgery for pain
16271923|NCT04872283|Active Comparator|No Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive the standard treatment of 30 tablets of oxycodone-acetaminophen to take as needed for pain
16271924|NCT04872270|Active Comparator|Caffeine Group|2 week supply of 100mg caffeine + aspirin 325mg + standard pain regimen (experimental)
16271925|NCT04872270|Active Comparator|No Caffeine Group|aspirin 325mg + standard pain (control)
16271926|NCT04872257|Experimental|Oral Vitamin D + NB-UVB Phototherapy|
16271927|NCT04872257|Placebo Comparator|Placebo + NB-UVB Phototherapy|
16271928|NCT04872244|Experimental|patients with isthmosele that mirena ( levonorgestrel releasing intrauterine device) was applied|outcome measures of patients suffering from postmenstruel spotting due to ısthmosele whom mirena ( levonorgestrel releasing intrauterine device) was applied
16271929|NCT04872231|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
16271930|NCT04872231|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
16271931|NCT04872218|Experimental|Abatacept|
16271932|NCT04872218|Placebo Comparator|Placebo|
16271933|NCT04872192|Active Comparator|transversus|patients received transversus thoracic muscle plane block and injection of 15 ml bupivacaine 0.25% on each side.
16271934|NCT04872192|Sham Comparator|general anaesthesia group|the same bilateral technique was done on both sides and 15 ml saline was injected during each side of TTPB technique.
16271935|NCT04872166|Experimental|BTX-A51 Dose Cohort 1|Starting dose (SD) of BTX-A51 administered orally 5 times per week in a 28-day cycle
16271936|NCT04872166|Experimental|BTX-A51 Dose Cohort 2|Up to 2-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
16271937|NCT04872166|Experimental|BTX-A51 Dose Cohort 3|Up to 3.5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
16271938|NCT04872166|Experimental|BTX-A51 Dose Cohort 4|Up to 5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
16271939|NCT04872166|Experimental|BTX-A51 Dose Cohort 5|Up to 7-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
16271940|NCT04872166|Experimental|BTX-A51 Dose Cohort 6|Up to 10-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
16271941|NCT04872153|Experimental|Intervention Group|The patients allocated to the intervention group will conduct simultaneously combined cognitive-motor training in form of exergames using the Dividat Senso in addition to the standard rehabilitation treatment plan. Both the Dividat Senso and the training games are specifically developed considering the needs and requirements of older adults but also clinicians/therapists.
16271942|NCT04872153|No Intervention|Control Group|The patients of the control group follow the standard rehabilitation treatment plan including: 3x 30min physiotherapy, 8x 30min group therapy, 3x 45min group therapy (group therapy includes body- focused therapy, mindfulness therapy, respiratory therapy, gymnastics, hiking etc.)
16271946|NCT04872127|Experimental|CAS with proximal protection|using proximal embolism protection device during CAS
16271947|NCT04872127|Active Comparator|CAS with distal protection|using distal protection device during CAS
16271948|NCT04872114|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
16271951|NCT04872088|No Intervention|Control|The control group will receive preventive (BCC on child health and nutrition) and screening services from existing unsupervised Nutrition Activity Support Groups (NASGs) without additional support from the IRAM project. Children with wasting are eligible to be enrolled in the existing national Community Management of Acute Malnutrition (CMAM) program.
16271952|NCT04872088|Experimental|Intervention|"The intervention group will receive the integrated package of interventions that will be delivered by the NASGs.
~The NASG platform will be strengthened by the IRAM project by increasing their number proportional to the size of the population of the catchment area they serve and by regular formative supervision by NGO and health center staff.
~The package of interventions includes:
~Social and Behavioral Change Communication by NASGs during home visits and group sessions
~Monthly delivery of preventive SQ-LNS to children 6-17 months of age
~Screening and referral of children 6-59 months of age through the introduction of the MUAC family approach (distribution MUAC tapes to families and offering formative supervision by NASGs to enhance measurement quality)
~Cooking demonstrations for complementary foods using nutrientdense foods in the community."
16271953|NCT04872075|Experimental|Experimental|People at the concert
16271954|NCT04872075|Active Comparator|Control|People staying at home
16271955|NCT04872062||Chronic hypercapnic respiratory failure treated by home non-invasive ventilation (NIV)|
16272976|NCT04865367||DEG n4: control culture medium|pure culture media without contact to embryos
16271956|NCT04872023|Experimental|Patients|All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment
16271957|NCT04871984||Holmium laser lithotripsy|Stone fragmentation are performed with Holmium laser in ureteroscopy
16271958|NCT04871984||Thulium laser lithotripsy|Stone fragmentation are performed with Thulium laser in ureteroscopy
16271964|NCT04871958|Experimental|rtCGM/MDI|Real-time CGM, insulin therapy by multiple daily injections managed according to CGM
16271965|NCT04871958|Experimental|rtCGM/V-Go|Real-time CGM, insulin therapy by V-Go insulin pump managed according to CGM
16271966|NCT04871958|No Intervention|blindCGM/MDI|Blind CGM, insulin therapy by multiple daily injections managed according to standard care (capillary glucose measurements)
16271967|NCT04871932||Recently unvaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, human papillomavirus [HPV] vaccine, and severe acute respiratory syndrome [SARS]-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Female)．
16271968|NCT04871932||Recently unvaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Male)．
16271969|NCT04871932||Recently vaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Female)．
16271970|NCT04871932||Recently vaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Male)．
16271971|NCT04871919||Filgotinib|Individuals will receive treatment for moderate to severe active rheumatoid arthritis with at least one dose of filgotinib in accordance with the product label
16271972|NCT04871906|Experimental|Stretching exercises|Interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks.
16271973|NCT04871906|No Intervention|Control group|Maintain their daily activity level in the 8 weeks. We use the study desigh-''waiting list control'' in this group.
16271974|NCT04871893|Other|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal|Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.
16271975|NCT04871880|Experimental|Dietitian led life style modification intervention.|Lifestyle changes supervised by dietitians
16271976|NCT04871880|Experimental|Conventional care (control)|Receive routine care
16271977|NCT04871854|Experimental|Breast cancer group infected Covid-19|Arm one breast cancer patients with confirmed sever COVID 19 infection admitted to ICU
16271978|NCT04871854|Active Comparator|non Cancer pateints infected Covid -19|Arm two non cancer patients with confirmed sever COVID 19 infection admitted to ICU
16271979|NCT04871841||Sputnik V Vaccinees|Participants (healthy adults aged >=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.
16271980|NCT04871828|Experimental|Treatment|"Zafirlukast plus the standard treatment according to Saudi CDC protocol (combination experimental arm)
~Description of investigational drug Zafirlukast is leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet and is usually dosed twice daily. It is approved by USFDA and currently commercially marketed under the name of Accolate 20 mg oral tablet. The drug will be acquired from the pharmacy and will be received by the patient during the hospital admission via research coordinator. The study drug will be stored in at room temperature (15 - 25 c) in the hospital's pharmacy and a delegated pharmacist will be responsible for dispensing and return of any drugs.
~The study drug will be administrated to the patient in the dose of 20 mg orally twice daily for 10 days (fixed dose with no staring or escalating dose)."
16271981|NCT04871828|Placebo Comparator|Control|placebo plus the standard treatment according to Saudi CDC protocol
16271982|NCT04871815|Experimental|Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray|This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.
16271983|NCT04871802|Experimental|Taxifolin Aqua group|Taxifolin Aqua 30 mg per day in addition to standard therapy
16271984|NCT04871802|No Intervention|Control group|No intervention
16271985|NCT04871789||Patients with severe COVID-19 pneumonia|
16271986|NCT04871789||Patients who had an asymptomatic COVID-19 3 months ago|
16271987|NCT04871789||People who had close contact with patients with confirmed COVID-19 3 months ago but did not get sick|
16271988|NCT04871776|Experimental|"Why messaging"|In this arm, patients will be sent two messages separated by two weeks each, either by electronic patient portal or by mail. Messages will focus on reasons to get the COVID vaccine, including protecting self and loved ones or the idea of herd immunity.
16271989|NCT04871776|Experimental|"How messaging"|"In this arm, patients will be sent two messages separated by two weeks each, either by electronic patient portal or by mail. How messages will focus on the details of scheduling a vaccination appointment, what to expect, and how to prepare for the visit."
16271990|NCT04871776|Experimental|"How messaging with a vaccine marked as reserved"|"In this arm, patients will be sent two messages separated by two weeks each, either by electronic patient portal or by mail. The how messaging with a vaccine marked as reserved will provide the same information as the how messaging arm and will be enhanced by saying a vaccine has been reserved for you and a prompt to schedule at the MGB vaccination location closest to the patient's address."
16271991|NCT04871776|Active Comparator|Usual Care|In this arm, patients will be sent two messages separated by two weeks each, either by electronic patient portal or by mail. The messages will be the routine messages that are sent to patients notifying them of eligibility to schedule a COVID vaccine.
16271995|NCT04871750|Experimental|Soy protein|30 g powder/day, contains 50 mg of isoflavones
16271996|NCT04871750|Placebo Comparator|Casein protein|30 g powder/day, no isoflavones
16271997|NCT04871737|Experimental|Low Dose, IM-IM|Group 1. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
16271998|NCT04871737|Experimental|Intermediate dose, IM-IM|Group 2. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days
16271999|NCT04871737|Experimental|High dose, IM-IM|Group 3. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
16272000|NCT04871737|Experimental|Low dose, IN-IN|Group 4. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
16272001|NCT04871737|Experimental|Intermediate dose, IN-IN|Group 5. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
16272002|NCT04871737|Experimental|High dose, IN-IN|Group 6. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
16272003|NCT04871737|Experimental|Low dose, IN-IM|Group 7. Dose: 10 7.0-7.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
16272004|NCT04871737|Experimental|Intermediate dose, IN-IM|Group 8. Dose: 10 7.5-7.99 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
16272005|NCT04871737|Experimental|High dose, IN-IM|Group 9. Dose: 10 8.0-8.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
16272006|NCT04871724|Experimental|EDP-938 and Fluconazole interaction|
16272009|NCT04871685||Covid Center UOC Vanvitelli, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272010|NCT04871685||Covid Center Cotugno Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272011|NCT04871685||"Covid Center Del Mare Hospital, Naples"|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272012|NCT04871685||Covid Center Santa Maria delle Grazie Hospital, Pozzuoli|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272013|NCT04871685||Covid Center Monaldi Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272014|NCT04871685||Covid Center Vannini Hospital, Rome|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272015|NCT04871685||Covid Center Bassini Hospital, ASST Milano Nord|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272016|NCT04871685||Covid Center Melfi Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272017|NCT04871685||Covid Center Messina University Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
16272018|NCT04871672|Experimental|pilates and home exercises (PAH) group|these subjects will receive pilates and home exercises.
16272019|NCT04871672|Active Comparator|control home exercises group (COH)|these subjects will receive only home exercises.
16272020|NCT04871646|Experimental|CKD-314|Treatment with CKD-314 + SOC
16272021|NCT04871646|Placebo Comparator|CKD-314 Placebo|Treatment with CKD-314 Placebo + SOC
16272022|NCT04871633|Active Comparator|Remdesivir|patients having drug Remdesivir in addition to conventional treatment according to disease grade (steroids, anticoagulants, antibiotics if needed, oxygen therapy, paracetamol, antihistamine)
16272024|NCT04871620||Hemodynamic optimization|Patients scheduled for intermediate and high-risk abdominal surgery were eligible to participate
16272026|NCT04871594|Experimental|Cohort A1: domatinostat + nivolumab|Day 1-56: domatinostat 200 mg BID Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
16272027|NCT04871594|Active Comparator|Cohort A 2: nivolumab|Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
16272028|NCT04871594|Experimental|Cohort B1: domatinostat + ipilimumab + nivolumab|Day 1-56: domatinostat 200 mg QD Day 1: ipilimumab 240 mg Day 22: ipilimumab 240mg + nivolumab 80 mg Day 43: nivolumab 240 mg
16272029|NCT04871594|Active Comparator|Cohort B2: ipilimumab + nivolumab|Day 1: ipilimumab 240 mg Day 22: ipilimumab 240mg + nivolumab 80 mg Day 43: nivolumab 240 mg
16272030|NCT04871581|Active Comparator|Device|Subjects receiving the FDA-cleared device
16272031|NCT04871581|Placebo Comparator|Placebo|Subjects receiving the sham device
16272032|NCT04871568|Active Comparator|Right subclavian vein catheterization|The temporary central dialysis catheter is placed in the right subclavian vein.
16272033|NCT04871568|Active Comparator|Right internal jugular vein catheterization|The temporary central dialysis catheter is placed in the right internal jugular vein.
16272034|NCT04871555||mesio-temporal epilepsy|patients suffering from mesiotemporal epilepsy type
16272035|NCT04871555||basal temporal epilepsy|patients suffering from basal temporal epilepsy type
16272036|NCT04871555||temporal lateral epilepsy|patients suffering from temporal lateral epilepsy type
16272037|NCT04871555||operculo insular epilepsy|patients suffering from operculo insular epilepsy type
16272038|NCT04871555||temporo-insular epilepsy|patients suffering from temporo- insular epilepsy type
16272039|NCT04871555||healthy subjects|non epileptic patients
16272040|NCT04871542||Observational (biospecimen collection, questionnaire)|Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study.
16272041|NCT04871529|Experimental|Arm A (avelumab, gemcitabine, carboplatin, surgery)|Patients receive avelumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up 4 in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks after final systemic therapy, patients undergo standard of care surgery.
16272042|NCT04871529|Experimental|Arm B (surgery)|Patients undergo standard of care surgery.
16272043|NCT04871516|Experimental|Treatment (radiation therapy boost, WBI)|Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
16272044|NCT04871503|Experimental|HIFEM+RF (HR)|The HR group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with mild heating of the muscles.
16272045|NCT04871503|Experimental|HIFEM (H)|The H group will receive a treatment with the intensities of the magnetic field just below the patient's tolerance threshold without the use of radiofrequency.
16272046|NCT04871490|Other|Study Group|All eligible participants.
16272047|NCT04871477||Observational (audio recording)|Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
16272048|NCT04871464|Experimental|Probiotics|Bifidobacterium triple viable capsules（BIFICO），containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis(each ≥ 1.0×10^7 CFU/capsule)，Day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
16272049|NCT04871464|Placebo Comparator|Placebo|Placebo，day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
16272050|NCT04871464|No Intervention|Healthy control|Healthy subjects without constipation matched for age and sex to PD subjects
16272051|NCT04871451|Experimental|ABP-450 - Between Low Dose and High Dose|ABP-450 Between Low Dose and High Dose - Intramuscular injections into affected neck muscles.
16272052|NCT04871438|Experimental|FGM|Flash glucose monitoring at weeks 0-2, weeks 6-8 post-discharge
16272053|NCT04871438|No Intervention|SMBG|Self-monitoring of blood glucose at least 4 times a day, 3 days a week
16272054|NCT04871425|Experimental|Ketamine|Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved.
16272055|NCT04871425|Active Comparator|Fentanyl|Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.
16272056|NCT04871412|Experimental|Integrative Care (Treatment)|Participants in the Integrative arm will receive standard surgical and oncologic care at The Ottawa Hospital plus complementary care guided by a naturopathic doctor at The Centre for Health Innovation
16272057|NCT04871412|No Intervention|Standard Care (Control)|Participants in the control arm will receive standard surgical and oncologic care at The Ottawa Hospital
16272058|NCT04871399|Active Comparator|Conventional Right hemicolectomy (Non-CME)|Patients will undergo conventional non-CME procedure.
16272059|NCT04871399|Experimental|Right hemicolectomy with CME+CVL|Patients will undergo Right hemicolectomy CME+CVL procedure.
16272097|NCT04871152||Patients with chronic migraine|In the same group of patients, the response to triptans will be analyzed at 3 different times with respect to the start of treatment with onabotulinumtoxinA: before treatment, after 4 months and after 7 months of treatment.
16272060|NCT04871386|Experimental|Acceptance and commitment therapy (ACT)|"14 consecutive days of exercises (prompted via email every morning) derived from acceptance and commitment therapy (ACT); the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
16272061|NCT04871386|Experimental|Positive psychology intervention (PP)|"14 consecutive days of exercises (prompted via email every morning) derived from positive psychology (PP) interventions; the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
16272062|NCT04871386|No Intervention|Control group|"completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?); no additional intervention"
16272063|NCT04871373|Experimental|Experimental group|A trained periodontist delivered oral hygiene instructions and motivational interviewing sessions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
16272064|NCT04871373|Active Comparator|Control group|A trained periodontist delivered only oral hygiene instructions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
16272065|NCT04871360|Experimental|Citrulline group|Group of adolescents supplemented orally with 6 g / day of pure L-citrulline in capsules. The dose will be met by taking four (3 g) capsules in the morning before the first meal and four capsules (3 g) in the evening after the last meal.
16272066|NCT04871360|Placebo Comparator|Placebo group|Group of adolescents supplemented with placebo (carboxymethyl cellulose). The indication for taking will be the same as in the experimental group, four capsules in the morning before the first meal and four capsules at night, after the last meal.
16272067|NCT04871347|Experimental|Dose Escalation Cohort|Three dose levels of TWP-101 will be tested by a conventional 3 + 3 study design.
16272068|NCT04871347|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
16272069|NCT04871334|Experimental|Dose Escalation Cohort|Six dose levels of TWP-101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
16272070|NCT04871334|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
16272071|NCT04871321||Gem/Cis/nab-P|Gemcitabine + Cisplatin + Nab-Paciltaxel
16272072|NCT04871308|Placebo Comparator|Control|Placebo group using normal saline infusion
16272073|NCT04871308|Active Comparator|Dexmedetomidine|From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.
16272074|NCT04871295|No Intervention|Wait List|
16272075|NCT04871295|Experimental|Noom Healthy Weight|
16272081|NCT04871269|Experimental|Drug: Dronabinol before the trauma film paradigm|
16272082|NCT04871269|Experimental|Drug: Dronabinol after the trauma film paradigm|
16272083|NCT04871269|Placebo Comparator|Placebo before and after the trauma film paradigm|
16272084|NCT04871256|Experimental|Inver|"Intervention: after screening, patient´s obstruction will be evaluated by anterior rhinomanometry (RNMa), and quality of life wil be scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire about daily life activity, sleep, psychology and perception of affection by allergic rhinitis.
~Symptoms will be evaluated with visual analogue scale (VAS) and clinical history. Symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal corticosteroid, antileukotrienes, antihistamine eye drops, antihistamine) frequency use will be registered"
16272085|NCT04871230||Pregnant women suspected TB|This group enrolled as cases
16272086|NCT04871230||Pregnant women without signs suspected TB|This group enrolled as controls
16272087|NCT04871217|Experimental|Acute ST-elevation myocardial infarction or chronic coronary artery occlusion|68-Ga-NODAGA-RGD PET after acute ST-elevation myocardial infarction or before and after re-opening of a chronic coronary artery occlusion
16272088|NCT04871204|No Intervention|Control|Standard treatment
16272089|NCT04871204|Experimental|Octreotide|3 monthly intramuscular injections of 10 mg Octreotide
16272090|NCT04871191|Active Comparator|Rituximab + cDMARD|Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
16272091|NCT04871191|Experimental|Tocilizumab|Tocilizumab will be administered subcutaneously every week at a fixed dose of 162 mg per week.
16272092|NCT04871191|Experimental|Abatacept|Abatacept will be administered subcutaneously every week at a fixed dose of 125 mg per week.
16272093|NCT04871178|No Intervention|Control Group|Care as usual: (i.e. best medical treatment)
16272094|NCT04871178|Experimental|Mindfulness-Based Intervention|Care as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based educational and training program.
16272095|NCT04871165||Oncohematological patient group|Adult patients with prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
16272096|NCT04871165||Healthy control group|Adult subjects without prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
16272098|NCT04871139|Experimental|Diagnostic (iodine-based contrast, CEM)|Patients receive iodine-based contrast agent IV and the undergo CEM over 10-15 minutes.
16272099|NCT04871126||LVT group|left ventricular thrombus in acute anterior myocardial infarction patients with left ventricular dysfunction
16272100|NCT04871126||non-LVTgroup|acute anterior myocardial infarction patients with left ventricular dysfunction while without LVT
16272106|NCT04871100|Experimental|UP-A|Cognitive behavior therapy using the Unified Protocol for Emotional Disorders with supplemental skills-based alcohol modules.
16272107|NCT04871100|Active Comparator|Problem Solving therapy|Skills based approach for managing negative moods and stress.
16272108|NCT04871087|Other|Allay lamp (narrow band green light)|Comparing effects of NBGL vs. white light on anxiety level before and after psychotherapy treatment sessions.
16272109|NCT04871074|Active Comparator|Cognitively unimpaired|Results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review.
16272110|NCT04871074|Active Comparator|Mild Cognitive Impairment|Abnormal cognitive status of MCI as judged by consensus or expert review using NIA-AA 2018 criteria.
16272111|NCT04871074|Active Comparator|Mild dementia|Abnormal cognitive status of dementia as judged by consensus or expert review using NIA-AA 2018 criteria.
16272112|NCT04871061|Active Comparator|PENG Block|For patients with hip fracture and having hip surgery this study evaluates the analgesic effects of Pericapsular Nerve Group (PENG) block for positioning before spinal anesthesia.
16272113|NCT04871061|Active Comparator|Control|in this group, standardised opioid doses (drug: Fentanyl) will be used for analgesia for positioning pain
16272114|NCT04871048|Experimental|active tDCS stimulation|Transcranial direct current stimulation tDCS-Stimulation will be performed using a Neurocan DC-Stimulator Plus
16272115|NCT04871048|Sham Comparator|sham tDCS stimulation|Transcranial direct current stimulation tDCS-The control group will receive the sham stimulation following the same regimen, using the sham procedure .
16272116|NCT04871035||Immunoadsorption|
16272117|NCT04871035||Plasma Exchange|
16272118|NCT04871022|Active Comparator|Double layer unlocked uterine closer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
16272119|NCT04871022|Experimental|Purse uterine closer|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
16272120|NCT04871009|Placebo Comparator|Standard of Care|routine clinical psychotherapy
16272121|NCT04871009|Experimental|Neurofeedback Intervention plus standard of care|routine clinical psychotherapy plus 3 to 4 neurofeedback interventions per week.
16272122|NCT04870996|Experimental|Active transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent active tDCS and CT on five consecutive days. The participants received a ramp-up of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then a ramp-down of 30 seconds.
16272123|NCT04870996|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent sham tDCS and CT on five consecutive days. The current was only delivered in the 30-second ramp-up and 30-second ramp-down periods.
16272124|NCT04870983||SAE group|SAE was defined as cerebral dysfunction in the presence of sepsis or septic shock and the absence of any of the exclusion criteria. For patients undergoing sedation during the ICU stay, the GCS scores were evaluated before sedation; for patients who have been sedated prior to ICU admission, the assumed GCS scores, i.e., the scores measured before any administration of sedative/relaxant drug were used for analysing; for postoperative patients, the GCS scores measured before surgery was used. The CAM-ICU was assessed daily by the nurse or the physician in charge of the patient during the ICU stay. For patients who were sedated, spontaneous awakening trials were performed daily; the longest evaluate time after withdrawal of sedation was 24 h during the trials. In this evaluation period, patients should be awake to evaluate their consciousness, and they were diagnosed of SAE if the patients were not awake.
16272125|NCT04870983||non-SAE group|The patient was diagnosed with sepsis or septic shock but could not be diagnosed with SAE
16272126|NCT04870970||Tobacco Users|Participants in this group use some form of tobacco.
16272127|NCT04870970||Non-Tobacco Users|Participants in this group do not use tobacco products.
16272128|NCT04870957|Experimental|MBSR (mindfulness-based stress reduction)|Run-in treatment then MBSR.
16272129|NCT04870957|Experimental|PT and exercise|Run-in treatment then PT and exercise
16272130|NCT04870957|Experimental|Acupressure|Run-in treatment then Acupressure
16272131|NCT04870957|Experimental|Duloxetine|Run-in treatment then Duloxetine
16272132|NCT04870957|Experimental|MBSR then PT and exercise|Run-in treatment then 8 weeks of MBSR, and then 8 weeks of PT and exercise.
16272133|NCT04870957|Experimental|MBSR then Acupressure|Run-in treatment, then 8 weeks of MBSR, and then 8 weeks Acupressure.
16272134|NCT04870957|Experimental|MBSR then Duloxetine|Run-in treatment, then 8 weeks of MBSR, and then approximately 8 weeks of Duloxetine
16272135|NCT04870957|Experimental|PT and exercise then MBSR|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of MBSR.
16272136|NCT04870957|Experimental|PT and exercise then Acupressure|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of Acupressure
16272137|NCT04870957|Experimental|PT and exercise then Duloxetine|Run-in treatment, then 8 weeks of PT and exercise, and then approximately 8 weeks of Duloxetine
16272138|NCT04870957|Experimental|Acupressure then MBSR|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of MBSR
16272139|NCT04870957|Experimental|Acupressure then PT and exercise|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of PT and exercise.
16272140|NCT04870957|Experimental|Acupressure then Duloxetine|Run-in treatment, then 8 weeks of Acupressure, and then approximately 8 weeks of Duloxetine
16272141|NCT04870957|Experimental|Duloxetine then MBSR|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of MBSR.
16272142|NCT04870957|Experimental|Duloxetine then PT and exercise|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of PT and exercise
16272143|NCT04870957|Experimental|Duloxetine then Acupressure|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks Acupressure.
16272144|NCT04870957|Experimental|PainGuide|Run-in treatment only with no additional treatments.
16272145|NCT04870944|Experimental|Treatment (CBL0137)|Patients receive CBL0137 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
16272146|NCT04870931||TEM-Group|All patients that underwent TEM
16272147|NCT04870931||TEM-ESD-Group|All patients that underwent TEM-ESD
16272148|NCT04870918|Experimental|self-care intervention|First, health education will be carried out by the nurse. The consultations will be individual, weekly (Wednesdays), the others, therefore, will be biweekly, extending to the 30/30 days the following, individually in order to observe the difficulties and doubts of each patient. Counting the meetings in a total of 12 in the first 6 months.
16272149|NCT04870918|No Intervention|usual care|The control group will go through medical consultations as instructed by the doctor and will not receive intervention for health education by the nurse.
16272150|NCT04870905|Experimental|ICRT arm|
16272151|NCT04870892||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to modify the norepinephrine dose.
16272152|NCT04870892||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to give fluid infusion
16272153|NCT04870879|Experimental|Study arm|Liver transplant
16272154|NCT04870879|Other|Parallel arm|Chemotherapy
16272155|NCT04870866|Experimental|NR treated|Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™
16272156|NCT04870853||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
16272157|NCT04870840|Experimental|Treatment (proton therapy)|Patients undergo radiation therapy QD 5 days a week (Monday through Friday) for the first 18 days and then BID for 15 days in the absence of disease progression or unacceptable toxicity.
16272158|NCT04870827||Affected Subjects|Subjects diagnosed with moderate- severe psoriasis
16272159|NCT04870827||Healthy Controls|Females and males 18 years of age or older
16272160|NCT04870814|Active Comparator|SOFTT® Gen 4 tactical tourniquet|The SOFTT® Gen 4 (Tactical Medical Solutions, Anderson) tactical tourniquet will be assessed.
16272161|NCT04870814|Active Comparator|CAT® Gen 7 tactical tourniquet|The CAT® Gen 7 (C-A-T® Resources, Rock Hill) tactical tourniquet will be assessed.
16272162|NCT04870814|Active Comparator|SAM XT® tactical tourniquet|The SAM XT® (SAM Medical Products®, Wilsonville) tactical tourniquet will be assessed.
16272163|NCT04870814|Active Comparator|RMT® 1.5 tactical tourniquet|The RMT® 1.5 (m2®, Winooski) tactical tourniquet will be assessed.
16272164|NCT04870801|No Intervention|Low Oxygen Visits without Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
16272165|NCT04870801|Experimental|Low Oxygen Visits with Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
16272166|NCT04870788|Experimental|Group I (mindfulness program)|Patients and their partners participate in mindfulness program over 60 minutes consisting of meeting with a mindfulness coach to build awareness of thoughts, emotions, feelings, and sensations QW for 4 weeks.
16272167|NCT04870788|Active Comparator|Group II (mindfulness waitlist)|Patients and their partners participate in mindfulness program as in Group I beginning 12 weeks after starting the study
16272168|NCT04870775|Experimental|Experimental group|The intervention administered to the experimental group will be a mindfulness training program
16272169|NCT04870775|No Intervention|Control group|The control group will not receive any intervention
16272172|NCT04870749||lower urinart tract syptoms|Lower urinary tract symptoms (LUTS) are common in older men and one of the main reasons for this is the enlargement in prostate gland volume caused by hormonal changes.
16272173|NCT04870736||Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
16272174|NCT04870736||Resusci Anne QCPR AED (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
16272175|NCT04870736||Resusci Baby QCPR (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
16272267|NCT04870164|Experimental|ensovibep dose 11 (IM injection)|
16272268|NCT04870164|Experimental|ensovibep dose 12 (IM injection)|
16272269|NCT04870164|Experimental|ensovibep dose 13 (IM injection)|
16272718|NCT04867083|Experimental|Arm 1: 4 days/7|4 days/7 Patients included in this arm will take their ARV treatment 4 consecutive days per week during 48 weeks.
16272176|NCT04870723|Experimental|Immediate|Behavioral: Motivational interviewing (MI)-based peer counseling: MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness.
16272177|NCT04870723|Other|Waitlist|"Behavioral: Motivational interviewing (MI)-based peer counseling: After the immediate group completes the intervention, the waitlist group will receive the intervention.
~MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness."
16272178|NCT04870710|Experimental|cathodal transcranial direct current stimulation (tDCS)|Two, twenty minute sessions of cathodal tDCS to the bilateral extrastriate visual cortex for 5 days (10 total sessions).
16272179|NCT04870710|Experimental|Anodal transcranial alternating current stimulation (tACS)|Two, twenty minute sessions of anodal tACS delta phase aligned for 5 days (10 total sessions).
16272180|NCT04870697|Experimental|ACT group|In addition to usual care, participants in the ACT group will receive ACT intervention. ACT intervention will be conducted in an individual-based format with four weekly sessions. The first session is a face-to-face format and the other three sessions are online live format.
16272181|NCT04870697|Other|Control group|Participants in the control group will receive usual care in the study setting delivered by clinical staff. The rationale for adopting usual care as a control group is not only because it is more commonly used but also for practical and ethical considerations, as usual care is what is already being delivered clinically, therefore the results of the study can support any necessity of changes to clinical practice or not.
16272182|NCT04870684||sucess of revascularization|group of patients for whom after thrombolysis neurological improvement will be observed and recanalization on imaging will be seen.
16272183|NCT04870671|Experimental|High Adherence|TDF/FTC (300/200 mg), 7 pills/week. Total of 14 pills
16272184|NCT04870671|Experimental|Low Adherence|TDF/FTC (300/2200 mg), 3 pills/week. Total of 6 pills
16272185|NCT04870658||Complication|Any patients with biological or mechanical complication in dental implant treatment.
16272186|NCT04870645|Experimental|Diagnostic (advanced MRI)|Patients undergo conventional and advanced MRI over 60 minutes within 14 days before the start of scheduled brain radiation treatment. Patients then undergo 7 additional MRI over 60 minutes each between 4-16 weeks apart.
16272187|NCT04870632|Sham Comparator|Control group|Patients in control group received the education booklet with words and pictures.
16272188|NCT04870632|Experimental|Video group|Patients in intervention group watched YOUTUBE videos to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
16272189|NCT04870632|Experimental|Booklet group|Patients in intervention group read education booklet with words and pictures to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
16272192|NCT04870593|Experimental|Community receives buddy and gossip treatment, individual informed directly (arm (1))|"(i) Individual elder given vaccination information.
~(ii) Individual elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated.
~(iii) Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders and to encourage their communities to use the buddy system to get elders vaccinated."
16272193|NCT04870593|Experimental|Community receives buddy and gossip treatment, individual not informed directly (arm (2))|Individual elder lives in community with elders in arm (1).
16272194|NCT04870593|Experimental|Community receives gossip treatment, individual informed directly (arm (3))|"(i) Individual elder given vaccination information.
~(ii) Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders."
16272195|NCT04870593|Experimental|Community receives gossip treatment, individual not informed directly (arm (4))|Individual elder lives in community with elders in arm (3).
16272196|NCT04870593|Experimental|Community receives buddy treatment, individual informed directly (arm (5))|"(i) Individual elder given vaccination information.
~(ii) Individual elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
16272197|NCT04870593|Experimental|Community receives buddy treatment, individual not informed directly (arm (6))|Individual elder lives in community with elders in arm (5).
16272198|NCT04870593|Experimental|Community receives information, individual informed directly (arm (7))|Individual elder given vaccination information.
16272199|NCT04870593|Experimental|Community receives information, individual not informed directly (arm (8))|Individual elder lives in community with elders in arm (7).
16272200|NCT04870580|Other|Intervention arm|PET/CT with fluorodopa tracer
16272201|NCT04870567|Active Comparator|High dose rate brachytherapy|After spinal anesthesia steel or plastic needle placement performed under TRUS guidance. Pre- and post-insertion ultrasound based planning is obligatory in all cases. Two fractions of 13Gy are delivered with 2 separate implantations and 2-3 weeks interval. The CTV was defined as the prostate capsule with 1mm (low-risk) - 3 mm (intermediate risk) expansion plus proximal 1/3 of seminal vesicles. The PTV was equal to CTV. The rectum, bladder and urethra are contoured as organs at risk. The dosimetry plan objectives are the following: prostate D90 - above 104% and V100% - above 92%; urethra D10 < 110% , rectum D2cc<75% (below 75Gy EQD2).
16272291|NCT04870008|Active Comparator|2 mm|The side of patient's scar that will receive the sutures placed at 2 mm from wound edge.
16273913|NCT04858464||Patients group|Individuals with primary Sjögren's syndrome
16272202|NCT04870567|Experimental|Stereotactic ablative radiotherapy|"Before SBRT three fiducial markers are obligatory inserted into the prostate.Planning MRI on diagnostic table with subsequent fusing with simulation CT is obligatory. CTV to planning target volume (PTV) expansion was 3-5 mm in all direction except posteriorly (in the direction of the rectum) where it is 1-3 mm. Dose must be delivered as 5 fraction of 7.25Gy. V100% for PTV ≥ 95%. Main dose constraints are as follows: D 2cm³ ≤ 36Gy for rectum (below 75Gy EQD2)., V 37.5 Gy <5 cm³ for bladder, V 20 Gy <10 cm³ for femoral heads. Androgen deprivation therapy is not permitted.
~All treatments must be performed on conventional linear accelerators with cone beam CT guidance before each fraction, intrafractional motion monitoring is optional."
16272203|NCT04870554|No Intervention|Continuous Feeding|Enteric feeding will be given continuously.
16272204|NCT04870554|Experimental|Timed Feeding|Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
16272205|NCT04870541|Active Comparator|Patients receiving Ondansetron|
16272206|NCT04870541|Active Comparator|Patients receiving Nefopam|
16272207|NCT04870528|Experimental|Experimental group|- This group will be composed of 30 patients with lower limb burn of second-degree. Subjects will receive pulsed magnetic field over thigh areas for 24 sessions over a period of 8 weeks (3sessions/week) with receiving strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living.
16272208|NCT04870528|Active Comparator|control group|Subjects will receive strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living for 24 sessions over a period of 8 weeks (3sessions/week)
16272209|NCT04870515|Experimental|Group I (diet, physical activity)|Patients attend 10 in-person or virtual sessions with a registered dietician over 6 months to receive diet instructions. Patients also attend 2 one-on-one sessions with an exercise psychologist to receive instruction to complete aerobic physical activity and strength/resistance training. Patients may also complete up to 21 additional supervised exercise sessions.
16272210|NCT04870515|Active Comparator|Group II (standard lifestyle recommendations)|Patients receive standard lifestyle recommendations and attend an individual session with a dietitian over 20-30 minutes including US dietary guidelines, activity goal of 30 minutes of physical activity 5 days/week; and discussion of the health benefits of weight loss along with general behavior change suggestions for weight loss.
16272211|NCT04870502|Active Comparator|Clomiphene citrate and Ubiquinol|Controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals).
16272212|NCT04870502|Active Comparator|Human Menopausal Gonadotropins (hMG)|Controlled ovarian stimulation (COS) was done by Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response.
16272213|NCT04870489|Active Comparator|Isotretinoin + Co2 ablative laser|Isotretinoin treatment while being treated with CO2 laser
16272214|NCT04870489|Active Comparator|Co2 ablative laser|6 months to 1 year without isotretinoin treatments to start second side of face with CO2 ablative laser only
16272215|NCT04870476|Experimental|"Internet-delivered treatment: One step at the time"|"Internet-delivered treatment: One step at the time. All participants receive the internet-delivered therapist-assisted 11-modules treatment program One step at the time."
16272216|NCT04870463|Active Comparator|Gold Standard Group|Patients treated with multi-braces fixed appliances and a conventional sequence of aligning and levelling arches (Ni-Ti arches with the same force in all sections)
16272217|NCT04870463|Experimental|Intervention Group|Patients treated with multi-braces fixed appliances and a different sequence of aligning and levelling arches (some arches provide individual forces for each group of teeth (incisors, premolars and molars))
16272218|NCT04870450||Healthcare professionals|No intervention. Gathering data on their experiences of using video diaries.
16272219|NCT04870450||Family members of ICU patients|No intervention. Gathering data on their experiences of using video diaries.
16272220|NCT04870437|Experimental|Extracorporeal phototherapy|
16272223|NCT04870411||Patients with auto-immune or autoinflammatory diseases|Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics
16272224|NCT04870411||Patients without auto-immune or autoinflammatory diseases|Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics
16272225|NCT04870398|Active Comparator|MTA partial pulpotomy|Profound local anesthesia of the tooth and the surrounding tissues will be achieved The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of MTA. After the placement of MTA, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
16272292|NCT04870008|Active Comparator|5 mm|The side of patient's scar that will receive the sutures placed at 5 mm from wound edge.
16272293|NCT04869995||Intervention|Senior abdominal and pelvic cavity surgeons (i.e., visceral surgeons, gynecologist surgeons, and urologists) having completed their robot-assisted surgery training, and commonly doing laparoscopic surgery.
16272294|NCT04869982|Experimental|RZV Group|Participants randomized to the RZV Group receive 1 dose of RZV at Day 1 and 1 dose at Month 2 and are followed up until the study end.
16272719|NCT04867083|Active Comparator|Arm 2: 7 days/7|Patients included in this arm will take their ARV treatment 7 days per week during 48 weeks
16272226|NCT04870398|Active Comparator|Total Fill partial pulpotomy|The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of Total Fill BC. After the placement of the material, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
16272227|NCT04870385|Experimental|Treatment|5-week online prevention program
16272228|NCT04870385|Other|Control|Waitlist control
16272229|NCT04870372|Experimental|Selegiline|Subjects who meet all of the inclusion and none of the exclusion criteria will be received Selegiline.The study medication dosage will be escalated from 5mg/daily to the target dose(5~10mg/daily) in 2 weeks and then maintained for the remaining 6 weeks.
16272230|NCT04870359|Active Comparator|Pre-emptive Treatment (Prednisolone and/or AZA/MMF)|"Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.
~Adjustment of the 2nd agent would be as follows:
~For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.
~For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day."
16272231|NCT04870359|No Intervention|Control|Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression.
16272232|NCT04870333|Active Comparator|Niclosamide|"INN: Niclosamide Ethanolamine Chemical name (IUPAC): 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide.2 aminoethanol CAS registry number: 1420-04-8 Lab code: UNI911
~140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid)."
16272233|NCT04870333|Placebo Comparator|Placebo|Placebo to match niclosamide will be supplied, stored, labelled, dispensed and dosed as for the active formulation. The placebo product is formulated to have the same appearance as the active solution.
16272234|NCT04870320|Experimental|Arm I (Endeavor)|Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
16272235|NCT04870320|Active Comparator|Arm II (Words!)|Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
16272236|NCT04870307|Other|Primary Care Practices|A practice-based implementation study will be conducted with 50 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members.
16272237|NCT04870294|Active Comparator|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material, considered a control group.
16272238|NCT04870294|Experimental|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
16272240|NCT04870268||PD group|percutaneous drainage group
16272241|NCT04870268||END group|endoscopic approach group
16272242|NCT04870268||INT group|surgical internal derivation of WON group
16272243|NCT04870268||NE group|surgical necrosectomy group
16272244|NCT04870255|Active Comparator|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
16272245|NCT04870255|Active Comparator|Dorsomedial Prefrontal Cortex (DMPFC)|The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
16272246|NCT04870255|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
16272247|NCT04870242||pediatric surgery patients|all pediatric surgery patients, aged from 6 months up to 18 years, underwent surgery between January 2017 to December 2018
16272248|NCT04870229|Active Comparator|Carnosine|Each participant will be given a daily oral dose 1g of methycellulose powder for 6 months
16272249|NCT04870229|Placebo Comparator|Placebo|Each participant will be given a daily oral dose 1g of placebo for 6 months
16272250|NCT04870216||Medical student|Medical student aged more than 18, presenting menstrual cycles, and agreeing to participate in the study.
16272251|NCT04870203|Experimental|baricitinib + adalimumab|
16272252|NCT04870203|Placebo Comparator|baricitinib + placebo|
16272253|NCT04870190|Experimental|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
16272254|NCT04870190|Active Comparator|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
16272255|NCT04870177|Experimental|Advanced gynecological neoplasms|
16272256|NCT04870164|Experimental|ensovibep dose 1 (infusion)|
16272257|NCT04870164|Experimental|ensovibep dose 2 (infusion)|
16272258|NCT04870164|Experimental|ensovibep dose 3 (infusion)|
16272259|NCT04870164|Placebo Comparator|placebo (infusion)|
16272260|NCT04870164|Experimental|ensovibep dose 4 (IV bolus)|
16272261|NCT04870164|Experimental|ensovibep dose 5 (IV bolus)|
16272262|NCT04870164|Experimental|ensovibep dose 6 (SC injection)|
16272263|NCT04870164|Experimental|ensovibep dose 7 (SC injection)|
16272264|NCT04870164|Experimental|ensovibep dose 8 (SC injection)|
16272265|NCT04870164|Experimental|ensovibep dose 9 (SC injection)|
16272266|NCT04870164|Experimental|ensovibep dose 10 (IM injection)|
16272270|NCT04870151|Experimental|Anterolateral approach|"The minimally invasive anterolateral approach (Watson-Jones approach) is performed with the patient in supine position. An oblique incision is made from just dorsal to the anterior superior iliac spine, and extended distally to the greater trochanter. After the fascia is incised, deep dissection continues in the plane between the tensor fasciae latae and the gluteus medius muscles. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.
~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).
~After implantation of the prosthesis, the fascia, subcutis and skin is closed in separate layers with sutures."
16272271|NCT04870151|Active Comparator|Direct lateral approach|"The direct lateral approach (Hardinge approach) is performed with the patient in a lateral decubitus position. A straight or curved longitudinal incision is made over the greater trochanter, and the fascia is incised longitudinally. The anterior aspect of the gluteus medius and minimus muscles are separated from the greater trochanter. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.
~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).
~After implantation of the prosthesis, the gluteus medius and minimus muscles are reinserted using osteosutures. The fascia, subcutis and skin is closed in separate layers with sutures."
16272272|NCT04870138|Experimental|Mixed FA7527/FA1090|Bacterial inoculum containing a mixture of equivalent numbers of the isogenic LptA mutant and wild-type (WT) strain administered once to the anterior urethra. N= up to 25
16272273|NCT04870138|Experimental|Mutant FA7527|Bacterial inoculum containing only the isogenic LptA mutant N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
16272274|NCT04870138|Experimental|Wild-type FA1090|Bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
16272275|NCT04870125|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
16272276|NCT04870125|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
16272279|NCT04870099|Experimental|Guided self-help|"Participants are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
16272280|NCT04870073|Experimental|Retrograde autologous priming + mannitol|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
16272281|NCT04870073|Experimental|Retrograde autologous priming alone|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
16272282|NCT04870073|Experimental|Conventional priming + mannitol|Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
16272283|NCT04870073|Active Comparator|Conventional priming alone|Participants will receive conventional priming alone.
16272284|NCT04870060|No Intervention|Control|Patients in this arm received only standard supportive care
16272285|NCT04870060|Experimental|Curcumin|Patients in this arm received curcumin lozenges (4 lozenges BD) along with standard supportive care
16272286|NCT04870047|Experimental|p64/p48 MW HPC Flow Diverter + SAPT|
16272287|NCT04870047|Experimental|p64/p48 MW Flow Diverter + DAPT|
16272289|NCT04870021|Experimental|Intervention Arm|"After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).
~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy."
16272290|NCT04870021|Other|Control Arm|"In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).
~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan."
16274340|NCT04855565|Placebo Comparator|Matching placebo for ALY688-SR|single dose subcutaneous injection
16272295|NCT04869982|Placebo Comparator|Placebo Group|Participants randomized to the Placebo Group receive 1 dose of placebo at Day 1 and 1 dose at Month 2 and are followed up until the study end.
16272296|NCT04869969|Experimental|supine percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the supine position
16272297|NCT04869969|Active Comparator|prone percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the prone position
16272298|NCT04869956|Other|control|patients will receive standard nutritional recommendations
16272299|NCT04869956|Experimental|intervencion|high-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
16272302|NCT04869930||Autism Spectrum Disorder (ASD)|Early childhood (pre-diagnosis) OR existing diagnosis of moderate/severe ASD
16272303|NCT04869930||Fragile X Syndrome (FXS)|Existing diagnosis of Fragile X Syndrome
16272304|NCT04869930||Healthy Controls|No diagnosed chronic conditions
16272305|NCT04869917|Experimental|In-person intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid which reviews information about the benefits and risks of intensive lifestyle intervention and metformin
16272306|NCT04869917|Experimental|Automated intervention|Participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent by Erie's health education department using their existing secure text messaging platform.
16272307|NCT04869917|Experimental|In-person intervention + automated intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid. Additionally, participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent by Erie's health education department using their existing secure text messaging platform.
16272308|NCT04869917|Placebo Comparator|Usual Care|Usual care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
16272309|NCT04869904||Patients with Alzheimer's disease|
16272310|NCT04869904||patients without Alzheimer's disease|
16272311|NCT04869865|Experimental|Intervention|Detoxification cleanse
16272312|NCT04869852|Experimental|Mango|85g mango, 4x/week
16272313|NCT04869852|No Intervention|No Mango|No mango intake
16272314|NCT04869826||Outpatients Complicated Hypertension Clinic|This study population consists of approximately 200 adult male and female patient participants (≥ 19 years of age; minimum 30% male/female) who are referred to the Complicated Hypertension Clinic at the Saint John Regional Hospital (SJRH) and who are willing to volunteer to consent to participate in the study.
16272315|NCT04869813||Heart failure patients|"Inclusion criteria:
~Age > or = 40 yrs
~Stable chronic heart failure
~Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less
~Exclusion criteria:
~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease
~Contraindications to MRI such as:
~Heart pacemaker/defibrillator
~Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires
~Cochlear implant or other ear implants
~Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)
~Programmable shunt
~Aneurysm clips and coils
~Stents • Filters (for example, blood clot filters)
~Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
16272316|NCT04869813||Healthy volunteers (Controls)|"Inclusion criteria:
~Age > or = 40 yrs
~No diagnosed heart failure or sarcopenia
~Exclusion criteria
~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease
~Contraindications to MRI such as:
~Heart pacemaker/defibrillator
~Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires
~Cochlear implant or other ear implants
~Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)
~Programmable shunt
~Aneurysm clips and coils
~Stents • Filters (for example, blood clot filters)
~Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
16272317|NCT04869800|Experimental|Sequence 1|"Period 1: Reference drug(CKD-501, D745)
~Period 2: Test drug(CKD-398)"
16272318|NCT04869800|Experimental|Sequence 2|"Period 1: Test drug(CKD-398)
~Period 2: Reference drug(CKD-501, D745)"
16272319|NCT04869787|Other|SCD Treatment|Pediatric patients receiving SCD + CRRT for up to 10 days
16272320|NCT04869774|Active Comparator|Virtual Monitoring|Patients discharged from hospital after colorectal surgery will have virtual monitoring of their surgical incision and symptoms, using the mobile application How2Trak, post-operatively.
16272321|NCT04869774|No Intervention|Standard of Care|Patients discharged from hospital after colorectal surgery will receive standard of care with no virtual monitoring of their surgical incision and symptoms.
16272322|NCT04869761|Experimental|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.
16272323|NCT04869761|Experimental|Dose Arm 2|Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0.
16272324|NCT04869748|Experimental|experimental group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Perfetti method on affected elbow flexor.Immediate after session, last outcome assessment was collected.
16272497|NCT04868578|Active Comparator|PPI placebo+Eti|The patient take PPI placebo caps and Etidrontate caps
16272325|NCT04869748|Active Comparator|control group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Passive stretching on affected elbow flexor.Immediate after session, last outcome assessment was collected.
16272326|NCT04869735||With information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given
16272327|NCT04869735||Without information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given.
16272328|NCT04869722|Experimental|Liquid Model|Whey protein beverages varying in protein levels
16272329|NCT04869722|Experimental|Solid Model|Protein fortified scones varying in fat levels
16272330|NCT04869709|Active Comparator|Late Preterm Steroids 2 Days|
16272331|NCT04869709|Active Comparator|Late Preterm Steroids 7 Days|
16272332|NCT04869683|Other|MDS follow up|it is a description MDS patients study
16272333|NCT04869670|Experimental|G-POEM|
16272334|NCT04869670|Sham Comparator|Sham procedure|
16272335|NCT04869657|Active Comparator|Sustainment 1: Coaches with CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by Children's Hospital of Philadelphia (CHOP) research consultants. In Year 2, schools in Sustainment 1 will receive reduced support for Tier 2 interventions provided by school district coaches. The coaches will in turn receive diminished support from research consultants. In Year 3, schools in both conditions will implement Tier 2 interventions with support from school district coaches; coaches will not receive direct assistance from research consultants.
16272336|NCT04869657|Active Comparator|Sustainment 2: Coaches without CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by CHOP research consultants. In Years 2 and 3, schools in Sustainment 2 will receive support from school district coaches but coaches will not receive help from research consultants.
16272338|NCT04869631||Aortic valve stenosis undergoing aortic valve replacement|Aortic valve stenosis undergoing aortic valve replacement.
16272339|NCT04869592|Experimental|Phase 1 low-dose group|
16272340|NCT04869592|Experimental|Phase 1 high-dose group|
16272341|NCT04869592|Placebo Comparator|Phase 1 placebo group|
16272342|NCT04869592|Experimental|Phase 2 low-dose group A|
16272343|NCT04869592|Experimental|Phase 2 low-dose group B|
16272344|NCT04869592|Experimental|Phase 2 low-dose group C|
16272345|NCT04869592|Experimental|Phase 2 low-dose group D|
16272346|NCT04869592|Experimental|Phase 2 high-dose group A|
16272347|NCT04869592|Experimental|Phase 2 high-dose group B|
16272348|NCT04869592|Experimental|Phase 2 high-dose group C|
16272349|NCT04869592|Experimental|Phase 2 high-dose group D|
16272350|NCT04869592|Placebo Comparator|Phase 2 placebo group A|
16272351|NCT04869592|Placebo Comparator|Phase 2 placebo group B|
16272352|NCT04869592|Placebo Comparator|Phase 2 placebo group C|
16272353|NCT04869592|Placebo Comparator|Phase 2 placebo group D|
16272354|NCT04869579|Experimental|Selenious Acid + Standard Of Care (SOC)|Participants who are moderately-ill, severely-ill, or critically ill will receive a Selenious Acid infusion of 2000µg on day 1 as a loading dose infusion, followed by a continuous infusion of Selenious Acid at a maintenance dose of 1000µg daily on days 2-14 together with continued Standard Of Care therapy.
16272355|NCT04869579|Active Comparator|Standard Of Care (SOC) + Placebo|Participants will receive a Saline-based placebo infusion of 2000µg on day 1 as a loading dose, followed by continuous infusion of a Saline-based placebo at a maintenance dose of 1000µg daily on days 2-14. Standard Of Care is to be determined according to patients' clinical picture and may include Dexamethasone, Azithromycin, Ceftriaxone, Remdesivir, Convalescent Plasma.
16272356|NCT04869566||Athletes with traumatic knee injury|Youth athletes, aged 16-19, with traumatic knee injury
16272357|NCT04869553|Experimental|ABC's arm|The 3 pain managements are in the ABC's order.
16272358|NCT04869553|Experimental|BCA's arm|The 3 pain managements are in the BCA's order.
16272359|NCT04869553|Experimental|CAB's arm|The 3 pain managements are in the CAB's order.
16272360|NCT04869540|Active Comparator|Usual care|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources.
16272361|NCT04869540|Experimental|Usual care + PSE|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources and will also receive a family-based problem solving eduction (PSE) intervention.
16272362|NCT04869514|Active Comparator|either lumbar manipulation (LMANIP)|LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
16272363|NCT04869514|Active Comparator|thoracic manipulation (TMANIP)|TMANIP will consist of high velocity low amplitude (HVLA) SMT at the T4/5 motion segment. TMANIP consists of supine SMT to the right and left (order pseudorandomized) using a thenar contact at facet joint level T4/5
16272364|NCT04869514|Sham Comparator|lumbar mobilisation (LMOB)|LMOB will be applied with the same positioning as in the LMANIP procedure, but instead of a thrust, a slow, a slow, passive mobilization without impulse will be applied
16272561|NCT04868110|No Intervention|Usual Care|Women in the usual care group, will received standard care from the obstetrician.
16272365|NCT04869514|No Intervention|No intervention|A natural history arm will serve to further control for potential specific and non-specific effects of TMANIP and LMOB. Subject will rest in side-lying position for the same duration as during the active interventions.
16272366|NCT04869488|Experimental|Fluzoparib|
16272367|NCT04869488|Active Comparator|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|
16272368|NCT04869488|Experimental|Fluzoparib Combined With Apatinib|
16272369|NCT04869475|Experimental|Experimental|arsenic trioxide 7mg/m2 ivgtt d1-14, q3w
16272370|NCT04869449|Experimental|Ketoconazole|Participants will be taking 400 mg of the study drug (two 200 mg tablets) by mouth twice a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation) and in the evening after their biopsy or surgery (after the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
16272371|NCT04869436|Experimental|Dupilumab group|Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.
16272372|NCT04869423|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. Assessments will be conducted before and after the 7wk program but patients in this group will not take part in it
16272373|NCT04869423|Experimental|Experimental group|Participants in this group will take part in 7 dog-assisted therapy sessions (1 per week). This therapy will be added to their usual daily living and therapies. Assessments will be conducted before and after the 7-week program.
16272374|NCT04869410|Active Comparator|Broselow Tape|Patient will given an intubation using uncuffed endotracheal tube size based on Modified Broselow Tape
16272375|NCT04869410|Active Comparator|Cole Formula|Patient will given an intubation using uncuffed endotracheal tube size based on Cole Formula
16272376|NCT04869397|Experimental|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Intravenous administration, 1 dose, for 20 minutes
16272377|NCT04869397|Placebo Comparator|Placebo|Intravenous administration, 1 dose, for 20 minutes
16272378|NCT04869384|Experimental|Intervention|Subjects will receive reminders and feedback to improve their adherence via a sensor attached to Easyhaler inhaler and mobile application
16272379|NCT04869384|Active Comparator|Usual care|Subjects do not receive reminders and feedback, but receive treatment as usual.
16272380|NCT04869371|Experimental|Androgen Deprivation Therapy with Docetaxel|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.
16272381|NCT04869371|Active Comparator|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.
16272382|NCT04869358|Experimental|Vaccination before treatment initiation|Patients will receive SARS-CoV-2 mRNA vaccines before starting ofatumumab treatment (approx. 1 month later)
16272383|NCT04869358|Experimental|Vaccination during treatment|Patients will receive SARS-CoV-2 mRNA vaccines while already stable on ofatumumab treatment (at least 4 weeks since first dose)
16272384|NCT04869345|Experimental|LARKSPUR intervention|Lessons in Affect Regulation to Keep Stress and Pain UndeR control
16272385|NCT04869345|No Intervention|Attention Control Condition|Daily emotion reporting/no intervention
16272386|NCT04869332|Active Comparator|three-screw group|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck
16272387|NCT04869332|Experimental|four-screw group|the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
16272388|NCT04869319||MyChart message|MyChart message subjects with high A1C blood tests to help manage their diabetes and prevent some of the complications caused by high sugars. The message recommends that they schedule a visit with their doctor who can recheck the blood test and help get their diabetes under control.
16272389|NCT04869319||No MyChart message|No message
16272390|NCT04869306|Active Comparator|Hyaluronic acid|hyaluronic acid gel application after lower third molar removal
16272391|NCT04869306|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier after lower third molar removal
16272392|NCT04869306|No Intervention|Standard treatment|standard treatment after lower third molar removal (i.e., blood clot only)
16272393|NCT04869293|Experimental|3D virtual reality|Use of Hypnosis 3D virtual reality headset
16272394|NCT04869293|No Intervention|Control|Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone
16272395|NCT04869280||Cohort-1: Pregnant Women Exposed to Prucalopride Prior to Enrollment|Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.
16272396|NCT04869280||Cohort-2: Pregnant Women Not Exposed to Prucalopride|Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.
16272397|NCT04869267|Experimental|ACT group|Participants in the intervention group will receive ACT intervention, consisting of four individual sessions (First session by face to face, the last three sessions by Wechat) of 60-90 min each (once/week), in addition to usual care.
16272398|NCT04869267|Other|Usual care group|Participants randomized to the control group will receive usual care, including treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge.
16272399|NCT04869254||Hematopoietic stem cells transplantation|patients undergone allogeneic or autologous bone marrow transplant who received immunomodulatory therapy with Thymoglobulin
16272400|NCT04869241|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
16272403|NCT04869215|Experimental|EverVita Pro consumed at breakfast followed by an ad lib meal|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include EverVita Pro bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
16272404|NCT04869215|Placebo Comparator|Control consumed at breakfast followed by an ad lib meal.|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include the control bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
16272405|NCT04869189|Experimental|High Sphere-Game/Video/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively.
16272406|NCT04869189|Experimental|High Sphere-VA/Video/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
16272407|NCT04869189|Experimental|High Sphere-VA/Game/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
16272408|NCT04869189|Experimental|High Sphere-Game/VA/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
16272409|NCT04869189|Experimental|High Sphere-Video/VA/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
16272410|NCT04869189|Experimental|High Sphere-Video/Game/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
16272411|NCT04869189|Experimental|Low Sphere-Game/Video/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video, or continuous VA test).
16272412|NCT04869189|Experimental|Low Sphere-VA/Video/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game).
16272413|NCT04869189|Experimental|Low Sphere-VA/Game/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video).
16272414|NCT04869189|Experimental|Low Sphere-Game/VA/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video).
16272415|NCT04869189|Experimental|Low Sphere-Video/VA/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game).
16272416|NCT04869189|Experimental|Low Sphere-Video/Game/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test).
16272417|NCT04869176|Experimental|On Caffeine, maintenance dose|During receiving maintenance dose of 5 mg/kg caffeine citrate (i.e. 2,5 mg/kg caffeine) in the form of solution, orally or intravenously, Holter electrocardiogram and vital functions were monitored for 40 minutes.
16272418|NCT04869176|Experimental|Off caffeine|100 hours after caffeine withdrawal Holter electrocardiogram and vital functions were monitored for 40 minutes.
16272419|NCT04869163|Active Comparator|red meat consumers|Consumes red meat 3 times a week
16272420|NCT04869163|Experimental|non-red meat consumers|Consumes a non-red meat comparison product 3 times a week
16272421|NCT04869150||those with myocardial bridges|
16272422|NCT04869150||those without myocardial bridges|
16272423|NCT04869137|Experimental|Lenvatinib plus Pembrolizumab|Participants with Merkel cell carcinoma amenable to complete resection will receive two cycles (6 weeks) of therapy with the combination of lenvatinib plus pembrolizumab and then proceed to planned resection within 2-4 weeks following completion of cycle 2. Following surgical recovery and completion of adjuvant radiation therapy (if indicated), treatment will resume with pembrolizumab monotherapy with intent to complete 17 cycles total of pembrolizumab.
16272424|NCT04869124|Active Comparator|Dapagliflozin|Dapagliflozin tablet (10mg/tablet), orally, once daily for 12 weeks.
16272425|NCT04869124|Placebo Comparator|Placebo|Placebo tablet, matching Dapglilflozin, orally, once daily for 12 weeks.
16272426|NCT04869111|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
16272427|NCT04869098|Experimental|Whey protein preload condition|Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.
16272428|NCT04869098|Placebo Comparator|Placebo condition|Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,
16272429|NCT04869085|Experimental|e-PainSupport Condition|e-PainSupport is a self-administered, digital pain application. Over the course of the two weeks, caregivers and patients will record the severity of patient's pain and how much pain medicine they use to control patient's pain in the e-PainSupport application.
16272430|NCT04869085|No Intervention|Standard Care Condition|Patients and caregivers will be given a paper copy of the same list of resources for pain management included in the Education Module of the e-PainSupport condition at baseline.
16272431|NCT04869059|Experimental|Transcranial direct current stimulation|30 minutes of 1 milliamp transcranial direct current stimulation to presupplementary motor area for 15 session at 1 session per week
16272432|NCT04869059|Sham Comparator|Sham transcranial direct current stimulation|30 minutes of sham transcranial direct current stimulation to presupplementary motor area for 15 session at 1 session per week
16272433|NCT04869046|Experimental|Levobupivacaine group|Instillation of 0,1 ml/kg (0,5 mg/kg) levobupivacaine 0,5% in surgical wound before fascia closure
16272434|NCT04869046|Placebo Comparator|Control Group|Instillation of 0,1 ml/kg 0,9% Sodium Chloride in surgical wound before fascia closure
16272435|NCT04869033|Experimental|Farinelli's breathing group|Complete Farinelli's breathing exercise 5 times per week for 8 weeks.
16272436|NCT04869033|Other|Diaphragmatic breathing group (control group)|Complete Diaphragmatic breathing exercise 5 times per week for 8 weeks.
16272437|NCT04869020|Other|Otoband efficacy versus Sham A|Participants in Arm 1 will receive, in random order, an OtoBand or Sham Device A to use for two weeks each. Sham Device A is an OtoBand in which the transducer is modified so that the vibrations do not target the vestibular system. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham or effective).
16272438|NCT04869020|Other|Otoband efficacy versus Sham B|Participants in Arm 2 will receive, in random order, a OtoBand or Sham Device B. Sham Device B is an OtoBand that operates at settings found to be non-therapeutic in motion sickness studies. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham, or effective).
16272439|NCT04869007||Patients with a history of cesarean section and a hysterosonographically diagnosed isthmocoele|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
16272440|NCT04869007||Patients with a history of cesarean section without isthmocoele hysterosonographically diagnosed|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
16272441|NCT04868994|Experimental|ENMG and muscle analyses on whole body muscles MRI.|Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
16272442|NCT04868981|Experimental|GST-HG141|GST-HG141 tablets at varying dosages by mouth for 28 days
16272443|NCT04868981|Placebo Comparator|Matching Placebo for GST-HG141|Placebos for GST-HG141 tablets at varying dosages by mouth for 28 days
16272444|NCT04868968|Experimental|DFV890|DFV890
16272445|NCT04868955|Experimental|Intervention group|Usual care and oral screen (IQoro®) training.
16272446|NCT04868955|No Intervention|Control group|Usual care.
16272447|NCT04868942|Experimental|Participant assisting to the event|Attending to musical event protected by established protection measures (protection kit, distancing, flow management, health mediation).
16272448|NCT04868942|No Intervention|Participant with no other constraints than national recommendations|A group control participant will not attend to the event
16272450|NCT04868903|Active Comparator|Low Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 400 IU/day) for 9 continuous months.
16272451|NCT04868903|Active Comparator|Medium Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 4,000 IU/day) for 9 continuous months.
16272452|NCT04868903|Active Comparator|High Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 10,000 IU/day) for 9 continuous months.
16272453|NCT04868890|Experimental|Active|Ampion
16272454|NCT04868890|Placebo Comparator|Control|Placebo
16272455|NCT04868877|Experimental|MCLA-129|
16272456|NCT04868864||Moderate to severe COVID-19 infection|COVID-19 patients with radiographic changes on CXR or CT which had not resolved or had persistent hypoxia due to COVID-19 at the time of discharge will be enrolled. All participants will undergo a LDCT and PFT.
16272457|NCT04868864||Persistent LDCT or PFT abnormalities|Participants with abnormalities on LDCT and or PFT will be invited to continue with a follow-up sub-study. This will involve follow up with repeated LDCT and PFT at subsequent time points to monitor and manage the abnormalities detected until the abnormalities fully resolve or to the last time point at 9 months of the study.
16272458|NCT04868851|Active Comparator|Here for Health only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
16272459|NCT04868851|Experimental|mHealth technology assisted exercise counselling (mHealth)|Patients will complete the Here for Health Healthy Lifestyle intervention before completing a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
16272460|NCT04868838|Experimental|Daratumumab|Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).
16272461|NCT04868825|Experimental|Experimental (Intervention)|
16272462|NCT04868825|Active Comparator|Active Comparator|
16272562|NCT04868110|Experimental|High fiber|Women in high fiber group will receive education on consuming a high fiber diet, including weekly lessons and daily snacks.
16300178|NCT04674566|Experimental|Cohort 2|COR-101 mid dose 1
16272463|NCT04868812|Experimental|Patient|All participants will be screened to ensure inclusion/exclusion criteria are met. A biopsy will be taken from each patient one month before the first laser treatment and one month after the last laser treatment. The MonaLisa treatment will be performed monthly for 3 months. A clinical evaluation will be recorded for each patient using validated questionnaires at baseline and one month after the last procedure.
16272464|NCT04868799||ATRT|Patients <18 years with an ATRT having frozen samples
16272465|NCT04868786|Experimental|Mycophenolate Mofetil|
16272466|NCT04868773|Experimental|Cabozantinib in Combination with TAS-102 (trifluridine/tipiracil)|Subjects will receive cabozantinib in combination with TAS-102. Patients will receive cabozantinib on Days 1 - 28 and TAS-102 on Days 1-5 and Days 8-12, for a cycle length of 28 days.
16272467|NCT04868760|Active Comparator|Group B: ipilimumab|Ipilimumab, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
16272468|NCT04868760|Experimental|Group A: IBI310|IBI 310, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
16272469|NCT04868747|Experimental|study group|The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.<120 mg/h).
16272470|NCT04868747|Placebo Comparator|control group|The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
16272471|NCT04868734|Experimental|Supportive Psychotherapy|Supportive Psychotherapy do to subjects
16272472|NCT04868734|No Intervention|Casual Treatment|Do Casual Intervention
16272473|NCT04868721|No Intervention|control side|Conventional side Canine retraction was commenced without micro-osteoperforations.
16272474|NCT04868721|Experimental|single Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed for one time only distal to the maxillary canine before starting retraction.
16272475|NCT04868721|Experimental|Multiple Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed on repeated basis distal to the maxillary canine evey 28 days before canine retraction.
16272476|NCT04868708|Experimental|AK104+Paclitaxel+Cisplatin/Carboplatin|"AK104 intravenously(IV) every 3 weeks (Q3W)
~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)
~Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W)"
16272477|NCT04868708|Experimental|AK104+Bevacizumab+Paclitaxel+Cisplatin/Carboplatin|"AK104 every 3 weeks (Q3W)
~Bevacizumab 15mg/kg IV every 3 weeks (Q3W)
~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)
~Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W)"
16272478|NCT04868708|Experimental|AK104|AK104 IV every 2 weeks (Q2W)
16272479|NCT04868695|Experimental|Bilateral Spheno-Ethmoidectomy:|
16272480|NCT04868695|Experimental|Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b|
16272481|NCT04868695|Experimental|Draf Typ 3|
16272484|NCT04868669|Experimental|Intervention|In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
16272485|NCT04868669|No Intervention|Control|Pregnant women in this arm will receive standard antenatal care.
16272486|NCT04868656|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
16272487|NCT04868656|Experimental|Enhanced REP|Enhanced REP begins with the same activities as Foundational REP. Sites that do not meet adoption benchmarks within 6 months will continue with Foundational REP and also receive higher intensity support for a period of 4-6 months. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship and CONNECT, a complexity science-based bundle of interaction-oriented activities designed to supplement implementation efforts by promoting team function and readiness for change. Facilitation will be provided by Function QUERI team members.
16272488|NCT04868643|Other|In-Center arm|Subjects undergo In-Center treatment in Phase 2 as defined.
16272489|NCT04868643|Other|In-Home arm|"Subjects undergo In-Home treatments in Phase 4 as defined.
~Subjects in Phase 2 and Phase 4 will be the same."
16272490|NCT04868630||Outpatients; Atlantic Sleep Centre & SJRH Respiratory Clinic|The study population consists of approximately 80 adult, outpatient participants recruited from the Atlantic Sleep Centre and the Respiratory Clinic at the Horizon Health Network, Saint John Regional Hospital.
16272491|NCT04868617|Experimental|Test Product|The non-CE marked test product is a stoma product based on the flat SenSura® Mio 1-piece (1-pc) and the flat 2-piece with mechanical coupling (2-pc MC) product that includes a novel skin protective layer in the baseplate.
16272492|NCT04868617|Active Comparator|Sensura Mio Comparator - Standard of Care|"The following comparator products will be used in this investigation:
~SenSura® Mio 1-piece (1-pc) flat, Midi bag with normal outlet and
~SenSura® Mio 2-piece with mechanical coupling (2-pc MC) flat, Maxi or Midi bag with normal outlet"
16272493|NCT04868604|Experimental|67Cu-SAR-bisPSMA|"In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA.
~In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA.
~In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA.
~In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation).
~In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation."
16272494|NCT04868591|Active Comparator|Single session APP arm|Participants in this group will received one session with the advanced practice physiotherapist.
16272495|NCT04868591|Experimental|Multiple sessions APP arm|Participants in this group will received 6 sessions (in 12 weeks) with the advanced practice physiotherapist.
16272496|NCT04868578|Experimental|PPI+Eti placebo|the patient take PPI caps and Etidronate placebo caps
16300179|NCT04674566|Experimental|Cohort 3|COR-101 mid dose 2
16272498|NCT04868565|Experimental|ongoing caffeine with oxygen supplement (group 1)|"samples assigned to the ongoing caffeine with oxygen supplement (group 1) will continue caffeine administration combining with oxygen supplement until the patients are weaned from oxygen."
16272499|NCT04868565|Active Comparator|discontinuing caffeine with oxygen supplement (group 2)|"samples assigned to the discontinuing caffeine with oxygen supplement (group 2) will discontinue caffeine immediately after randomization, while oxygen supplement is going on."
16272500|NCT04868552|Experimental|Naloxone education|These participants will receive a pre-hospital naloxone education module during their pre-operative joint class
16272501|NCT04868552|No Intervention|Standard Education|These participants will receive the standard pre-hospital education including pain management and opioid safety, but will not specifically be given the new naloxone-education module in the pre-hospital setting
16272502|NCT04868539|Experimental|Sleep Restriction with Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction Group with Extended Duration Artificial Light At Night (ALAN) first, the sleep episodes will be shortened to 5 hours, centered at the same time as the baseline sleep (with bedtime 2.5 hours later and wake time 2.5 hours earlier).
16272503|NCT04868539|Experimental|Sleep Restriction without Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction group without Extended Duration ALAN, the sleep episodes will be shortened to 5 hours as in the ALAN Condition (centered at the same time as the baseline sleep with bedtime 2.5 hours later and wake time 2.5 hours earlier), but the participant will remain sitting in bed in near darkness (< 1 lux) for the 2.5 hours before and after the 5-hour sleep episode, such that their exposure to room lighting and activity (14 hours/day) will remain similar to that in the Baseline condition.
16272504|NCT04868526|Experimental|Control-Dietary Intervention|Control condition first, then to Dietary intervention
16272505|NCT04868526|Experimental|Dietary intervention-Control|Dietary intervention first, then to Control condition.
16272506|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
16272507|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
16272508|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
16272509|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
16272510|NCT04868500|Experimental|Clinical Pilot|Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and MGH clinical staff.
16272511|NCT04868487|Experimental|Intervention|The intervention group received four weekly training sessions of health literacy education. Each educational session lasted an average of 50 minutes. The students were divided into four groups with an average of 25 students in each group.
16272512|NCT04868487|No Intervention|Control|The control group had no educational interaction with the researcher after the pre-test. The control group was administered the one-week and three-month posttest THLS-32 by the researcher simultaneously with the intervention group.
16272513|NCT04868474|Active Comparator|Usual care training|A refresher training course will be the equivalent of 'enhanced' usual care. Enhanced because the course will likely augment short-term knowledge of smoking cessation treatments, and participation in the study could trigger more discussions about smoking cessation than routine practice. However, it will be impossible to have any blinding between groups without at least some training.
16272514|NCT04868474|Experimental|Intervention training|The training course and decision aid aim to make treatment of tobacco use the default choice
16272515|NCT04868461|Active Comparator|Unheated whey protein (UWP)|"Participants are given a preload of 200 mL of unheated whey protein (UWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
16272516|NCT04868461|Active Comparator|Heated whey protein (HWP)|"Participants are given a preload of 200 mL of heated whey protein (HWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
16272517|NCT04868461|Active Comparator|Casein (Cas)|"Participants are given a preload of 200 mL of Casein (Cas) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
16272518|NCT04868461|Placebo Comparator|Water|The water has the same banana flavor and sweetness to match the protein beverages. Participants receive the same amount of water like protein beverages - 200mL.
16272519|NCT04868448||Vaccinated participants|Participants who received 1or 2 doses of the Covid-19 vaccines
16272520|NCT04868448||Unvaccinated participants|Participants who have not received any dose of the Covid-19 vaccines
16272521|NCT04868422|Experimental|Telemonitoring|After CPAP titration, patients will be followed with telemonitoring device attached to the fixed pressure CPAP device
16272522|NCT04868422|No Intervention|Usual care|Patients with fixed pressure CPAP will be followed according to routine protocol without telemonitoring
16272523|NCT04868409|Active Comparator|Rocuronium group|Rocuronium 1 mg/kg
16272524|NCT04868409|Active Comparator|Suxamethonium group|Suxamethonium 1 mg/kg
16272525|NCT04868396||Glioblastoma patients|Glioblastoma patients selected to undergo surgical removal of a glioblastoma (based on MRI image).
16272526|NCT04868383|Experimental|Single pilot arm|In this single arm pilot study, all participants will receive access to a novel smartphone app designed to support PrEP uptake and adherence for a 6 month period.
16272527|NCT04868370||Multiple Sclerosis (MS)|
16272528|NCT04868370||Healthy Subject|
16272594|NCT04867954||Patients with large, high-risk GEV|7 patients with large, high-risk Gastroesophageal varices (GEV) will be recruited.
16272529|NCT04868357|Experimental|Hypnosis|Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group hypnosis. It includes 1 hypnotic induction, multiple suggestions of relaxation and a feeling of air entering the lungs, and a closing exercise. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness. This arm is structured following the classic format of didactic hypnosis interventions, were patients discover the exercise by doing it, and receive keys to be able to recreate the hypnotic state on their own.
16272530|NCT04868357|Active Comparator|Relaxation|"Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group dynamic relaxation. It includes 1 exercise to liberate tension, 3 exercises to increase proprioception and calmness, and 3 exercises for calming and regulating the breath. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness.
~Provides additional care that motivates the patients to participate in the control group.
~Allows the controlling of number of group interventions accross arms (2).
~Allows to control for motivation, as both arms are introduced identically: the benefits and interest of using self-relaxation techniques for complementary care in anxiety and anxiety-related dyspnea are underscored.
~It allows the disentanglement of hypnosis and relaxation effects . This was crucial, inasmuch as hypnosis too includes physical relaxation and breathing exercises."
16272531|NCT04868344|Experimental|MRG003|Phase Ia: MRG003 will be administrated by an IV infusion of escalating doses (0.1, 0.3, 0.6, 1.0, 2.0, 2.5, 3.0 mg/kg) on Day 1 of every 3 weeks (Q3W); Phase Ib: MRG003 will be administrated by an IV infusion of MTD/RP2D.
16272532|NCT04868331|Experimental|AIS girls|Girls between the ages of 10-16 will be recruited if they have a diagnosis of AIS.
16272533|NCT04868331|Active Comparator|Healthy Controls|Healthy adolescent girls matched in age and puberty maturity without spinal deformity
16272534|NCT04868318|Experimental|VHP(very-high protein) group|In VHP(very-high protein) group, we will provide pre-digested formula of 37% protein to the experimental group for at least 3 days to up to 7 days.
16272535|NCT04868318|Active Comparator|SHP(standard-high protein) group|SHP(standard-high protein) group is the control group, standard-high protein formula (16% of energy) would be given to the control group for at least 3 days to up to 7 days.
16272536|NCT04868305|Active Comparator|Intramedullary nail|Intramedullary nail with proximal lagscrew and distal locking screw(s)
16272537|NCT04868305|Active Comparator|Hip arthroplasty|Hemiarthroplasty (HA) or Total hip arthroplasty (THA). A cemented dual-mobility cup will be utilized in THA. Addition of cerclage/trochanter claw plate to fixate trochanter major will be used when suitable.
16272539|NCT04868279|Experimental|Interventional Gruop|"Web-based interactive nurse support program with the intervention group will continue for 3 months, the implementation will last 6 months in total. Individuals in the intervention group will be able to access the training content by accessing the website designated for the study from devices such as computers or mobile phones.
~Data collection forms will be applied to the intervention group 3 times in total, before starting the Web-based interactive nurse support program, at the end of the Web-based interactive nurse support program (in the 3rd month) and in the 6th month."
16272540|NCT04868279|No Intervention|Control Group|Web-based interactive nurse support program will not be opened to the control group, only access to data collection tools will be provided.
16272541|NCT04868266|Experimental|end tidal carbon dioxide monitoring|
16272542|NCT04868266|No Intervention|Oxygen saturation monitoring|
16272543|NCT04868253|Experimental|EMB-001|EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).
16272544|NCT04868240|Experimental|Concurrent Training Group|The experimental group will perform 16-weeks of the concurrent training exercise.
16272545|NCT04868240|No Intervention|Control Group|Maintain their usual habits/activities, including not participate in any type of physical exercise.
16272546|NCT04868227|Experimental|INTERVENTION STUDY|TREATED WITH 3200IU FULTIUM VITAMIN D3
16272547|NCT04868201|Experimental|0-anxiety|0-anxiety is based on the principles of VRT and CBT, which currently is the most researched and used treatment for anxiety disorders. The 0-anxiety intervention is an app-based intervention consisting of six modules that can be followed according to a user's own timing and without the intervention of a therapist.
16272548|NCT04868201|No Intervention|wait-list condition|
16272549|NCT04868188||Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support|Adult (>18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.
16272550|NCT04868175|Active Comparator|Group 1|control (hypromellose), then Timolol, then Travatan
16272551|NCT04868175|Active Comparator|Group 2|Timolol, then Travatan, Hypromellose
16272552|NCT04868175|Active Comparator|Group 3|Travatan, then Hypromellose, Timolol
16272553|NCT04868162|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
16272554|NCT04868149|Experimental|Laparoscopic ALPPS|Laparoscopic ALPPS procedure
16272555|NCT04868149|Active Comparator|Open ALPPS|Open ALPPS procedure
16272556|NCT04868136|Experimental|Warm-up, then no warm-up|Participants' visit 2 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session. Participants' visit 3 consisted of the 30 minute exercise session without a warm-up.
16272557|NCT04868136|Experimental|No warm-up, then warm-up|Participants' visit 2 consisted of the 30 minute exercise session without a warm-up. Participants' visit 3 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session.
16272558|NCT04868123|Experimental|Mindfulness Meditation|6 weeks of daily mindfulness meditation (guided by audio recordings) performed at home
16272559|NCT04868123|Experimental|Transcutaneous nerve stimulation (TENS)|6 weeks of daily TENS treatment performed at home
16272560|NCT04868123|No Intervention|Usual Care|Usual care (no additional treatment)
16272563|NCT04868084|Experimental|Intervention group|"Physical Literacy in the early years. The intervention was delivered by an external provider and designed to provide nursery teachers, teaching assistants and others working with children under age five the knowledge, skills and confidence to deliver enjoyable and engaging lessons which focus on the development of core fundamental skills. The course was developed in conjunction with leading Physical Education (PE) consultants, Sports Scientists and Office for Standards in Education, Children's Services and Skills (Ofsted) advisors which covered both the theory about FMS and physical literacy, and practical demonstrations of age-appropriate ways to teach and develop FMS. Staff from the Intervention settings received the six-hour training session. After the training session, school nurseries which were encouraged to speak with the training provider to follow-up the understanding of the training and provide additional help for implementation of the practice learned."
16272564|NCT04868084|No Intervention|Control|The control nurseries followed their usual practice.
16272565|NCT04868071|Experimental|High-Speed Resistance Training|Participants performed exercises 8 times (sets) with 3-5 repetitions at 70%-75% of the maximal strength.
16272566|NCT04868071|Experimental|Low-Speed Resistance Training|Participants performed exercises 4 times (sets) with 8-10 repetitions at 70%-75% of the maximal strength.
16272567|NCT04868071|No Intervention|Control Group|No activities
16272568|NCT04868058|Experimental|1 AF SAPB|Atrial fibrillation. Serratus anterior plane block
16272569|NCT04868058|Experimental|2 AF ESPB|Atrial fibrillation. Erector spinae plane block
16272570|NCT04868058|Experimental|3 VT SAPB|Ventricular Tachycardia.Serratus anterior plane block
16272571|NCT04868058|Experimental|4 VT ESPB|Ventricular Tachycardia. Erector spinae plane block
16272572|NCT04868058|Experimental|5 ISNT SAPB|Inappropriate Sinus node tachycardia. Serratus anterior plane block
16272573|NCT04868058|Experimental|6 ISNT ESPB|Inappropriate Sinus node tachycardia. Erector spinae plane block
16272574|NCT04868045|Experimental|Patients with a history of thyroid hormone suppression (TSH<0.5 mU/L) for at least 5 years|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
16272575|NCT04868045|Experimental|Patients with no history of TSH suppression|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
16272576|NCT04868032|Experimental|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
16272577|NCT04868032|Active Comparator|Enhanced Usual Care Control|Participants randomized to this condition will be provided with a Fitbit, but will not receive any intervention phone calls or the written manual.
16272578|NCT04868019|Experimental|Group A|Groups A will receive solution A .i.e fenofibrate suspension
16272579|NCT04868019|Placebo Comparator|Group B|Group B will receive solution B i.e placebo.
16272580|NCT04868006|Experimental|End-range mobilization + proprioception training|End-range Maitland mobilization performed in end-range internal rotation of the shoulder accompanied with 8--week long proprioception training
16272581|NCT04868006|Active Comparator|Non end-range mobilization+ proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
16272582|NCT04868006|Sham Comparator|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
16272583|NCT04867993|Active Comparator|asphyxiated neonates treated with amikacin and hypothermia|Amikacin (Likacin®; 500 mg/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
16272584|NCT04867993|Placebo Comparator|asphyxiated neonates treated with amikacin|Amikacin (Likacin®; 500m g/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
16272585|NCT04867980|Experimental|ABCD|Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be >= 5 days between each dose.
16272586|NCT04867980|Experimental|BDAC|Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be >= 5 days between each dose.
16272587|NCT04867980|Experimental|CADB|Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be >= 5 days between each dose.
16272588|NCT04867980|Experimental|DCBA|Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be >= 5 days between each dose.
16272589|NCT04867967|Experimental|Iyengar Yoga Intervention|"8-week yoga class; once weekly; 90 minutes
~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
16272590|NCT04867967|Active Comparator|Mindfulness-based stress reduction|"8-week MBSR class; once weekly; 90 minutes
~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
16272591|NCT04867967|No Intervention|Waitlist control|Waitlist control, ususal care
16272592|NCT04867954||Healthy volunteers|7 healthy participants will be recruited.
16272593|NCT04867954||Patients with small, low-risk GEV|7 patients with small, low-risk Gastroesophageal varices (GEV) will be recruited.
16272595|NCT04867954||Patients scheduled for screening or surveillance esophagogastroduodenoscopy (EGD)|"100 patients diagnosed with cirrhosis and scheduled for screening or surveillance esophagogastroduodenoscopy (EGD) procedure will be recruited. Participants will complete a single research visit, lasting approximately 2 hours, that will include the following procedures:
~Participants will fast for 12 hours prior to arriving.
~An IV will be placed and a blood sample collected (~11 mL, if necessary).
~All participants will undergo research MRI lasting approximately 1.5 hours"
16272596|NCT04867941|Experimental|Part1: Mild hepatic insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
16272597|NCT04867941|Experimental|Part 1: Moderate hepatic insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
16272598|NCT04867941|Experimental|Part 1: Normal hepatic function|Participants with normal hepatic function will receive a single oral dose of 50 mgACP-196 (2 x 25 mg capsules) on Day 1 of the study.
16272599|NCT04867941|Experimental|Part 2: Severe hepatic insufficiency|Participants with sever hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
16272600|NCT04867928|Experimental|Venetoclax+azacitidine|subjects will receive treatment until alloSCT
16272601|NCT04867902|Experimental|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
16272602|NCT04867889|Active Comparator|Active Treatment iTBS|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 20 sessions on 20 week days, one session per day.
16272603|NCT04867889|Sham Comparator|Sham treatment|Sham treatment given either with a sham stimulation coil or by flipping an active coil 90 degrees.
16272604|NCT04867876|Experimental|Intervention Cohort|Physical Therapy
16272605|NCT04867850|Active Comparator|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice. Usual care for clinicians includes a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm.
16272606|NCT04867850|Experimental|Clinician Nudge|Clinicians receive a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm as well as performance feedback compared to peers.
16272607|NCT04867850|Experimental|Patient Nudge|Patients receive a nudge consisting of a normalizing message prompting patients to complete an electronic questionnaire designed to prime patients towards having an SIC.
16272608|NCT04867850|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
16272609|NCT04867837|Experimental|Octaplex Low-dose|Participants to receive 1 Octaplex infusion intravenously
16272610|NCT04867837|Experimental|Octaplex High-dose|Participants to receive 1 Octaplex infusion intravenously
16272611|NCT04867824|Active Comparator|Control|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
16272612|NCT04867824|Experimental|Case|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure vanilla essential oil (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
16272613|NCT04867811|Experimental|group A|received conventional therapy
16272614|NCT04867811|Experimental|group B|received TENS in addition to conventional therapy
16272615|NCT04867811|Experimental|group C|received cupping therapy with conventional therapy
16272616|NCT04867811|Experimental|group D|TENS and cupping therapy plus conventional therapy
16272623|NCT04867772|Other|Usual Care|Participants will receive the care that would usually be received in the local hospital setting. this has been determined as between 1 and 6 sessions of physiotherapy
16272624|NCT04867772|Experimental|Intervention|Participants will receive a home based rehabilitation programme with 1-7 sessions of physiotherapy delivered over 12 weeks.
16272625|NCT04867759||Study group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
16272626|NCT04867759||Control group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
16272687|NCT04867291|Experimental|Seaweed Powder|Consumption of a portion of seaweed powder in a capsule equivalent to 200 µg of iodine (0.25g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
16275246|NCT04849390|Experimental|ESO-101|Oral use of 1 hard gelatin capsule (800 μg)
16272627|NCT04867733|Experimental|Micropatch application|All participants will complete this arm. Three sites each on the upper arm, volar (inner) forearm, and palm will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, and color will be made at each site. Baseline optical coherence tomography (OCT) scans will be made at each site. Color will only be measured at baseline. One site at each location will undergo the following interventions: 1) micropatch application and an occlusive covering, 2) micropatch application, but remain uncovered, 3) occlusive covering, no micropatch application. Micropatch application will only occur on the first day and does not contain any drug substance. Trans-epidermal water loss and electrical resistance are re-measured after micropatch removal, along with an additional OCT scan. Electrical resistance and OCT scans will be repeated at all sites for 2 days. Measurements from the 2nd and 3rd sites allow each subject to serve as their own control in data analysis.
16272628|NCT04867720|Experimental|CertiroBell Tablet|Use in combination with Tacrolimus at least 6 months after liver transplantation.
16272629|NCT04867707|Experimental|Zanamivir treatment|Study participants will receive 5 days of treatment with a zanamivir inhaler.
16272630|NCT04867694|No Intervention|Control|The control group receiving the standards of care and the usual activities of the partners without additional support from the IRAM project for the implementation of the PASIM. This includes the usual Community Management of Acute Malnutrition (CMAM) program. This group will also continue to benefit from the BCC and screening services already existing in their areas.
16272631|NCT04867694|Experimental|Intervention|"The PASIM is delivered by the care groups. Each beneficiary is visited at home at least once a month (up to once a week if possible).
~The package of activities includes :
~Behavior change communication (all children in care groups)
~Monthly delivery of a nutritional supplement: limited to [6-11] months old children diagnosed as non-wasted (green MUAC) or for [6-59] months old for 6 months after discharge from the national CMAM program.
~Monthly delivery of a water purification input: limited to households with [6-11] months old children or with [6-59] months old children under CMAM treatment and for 6 months after discharge.
~Delivery of micronutrient powders to [12-23] months old children.
~Screening and referral for [6-59] months old children, formative supervision of MUAC measurement in families."
16272632|NCT04867681|Experimental|Administration of a short psycho-education programme|
16272633|NCT04867681|No Intervention|Control group|
16272634|NCT04867668|Experimental|Digital intervention|Participants will be randomized to receive variable levels of exposure (including no exposure control) of digital anti-vaping and anti-smoking messages. We will evaluate the effects of experimental condition and exposure on outcomes (tobacco product use).
16272635|NCT04867668|No Intervention|Control|No exposure control condition
16272636|NCT04867655|Experimental|Orange juice only|Experimental test for 24 hours after consumption of orange juice only (Tropicana 'with bits').
16272637|NCT04867655|Experimental|Orange Juice mixed with either 6g or 3 g of β-Glucan|Experimental test for 24 hours after consumption of orange juice (Tropicana 'with bits') with either 6g or 3 g of β-Glucan.
16272638|NCT04867642|Experimental|Part A Sequence 1|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
16272639|NCT04867642|Experimental|Part A Sequence 2|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
16272640|NCT04867642|Experimental|Part B UCB0022|Study participants randomized to Part B will receive multiple ascending doses of UCB0022 at pre-specified time points during the Treatment Period of cohorts in a parallel design.
16272641|NCT04867642|Placebo Comparator|Part B Placebo|Study participants randomized to Part B will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period of cohorts in a parallel design.
16272642|NCT04867642|Experimental|Part C UCB0022|Study participants randomized to this cohort in Part C will receive fixed multiple doses of UCB0022 at pre-specified time points during the Treatment Period.
16272643|NCT04867642|Placebo Comparator|Part C Placebo|Study participants randomized to this cohort in Part C will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period.
16272644|NCT04867629|Experimental|Rapeseed oil|Participants asked to consume 20mL of rapeseed oil raw every day for 12 weeks
16272645|NCT04867629|Active Comparator|Sunflower oil|Participants asked to consume 20mL of sunflower oil raw every day for 12 weeks
16272646|NCT04867629|No Intervention|Habitual diet|Participants asked to maintain their habitual diet for 12 weeks
16272647|NCT04867616|Experimental|Dose level 1 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 1) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
16272648|NCT04867616|Experimental|Dose level 2 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 2) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
16272649|NCT04867616|Placebo Comparator|Placebo Arm|Participants randomized to this arm will receive Placebo to maintain the blinding during the Double-blind Treatment Period and will re-randomized during the Open-label Extension Period to receive pre-specified doses of bepranemab.
16272650|NCT04867603|Experimental|Digital PET/CT using [Ga-68]PSMA|Following prostate Standard of Care MRI, eligible participants will receive a single injection of [Ga-68]PSMA followed by digital PET/CT imaging approximately 60 minutes later. PET/CT takes approximately 30-35 minutes, where the participant would lay still on a scanner table.
16272651|NCT04867590|Experimental|EndoRotor|"The ENDOROTOR is a new system for the resection of superficial lesions within the digestive tract and composed of a reusable generator, a single-use probe and additional accessories.
~The device is used in the resection of mucosa in the digestive tract: flat or slightly raised lesions in the digestive mucosa, or treatment of the lateral margins following a resection carried out using another technique.
~Resected tissue is aspirated away through a rotating catheter: the cutting and removal of tissue as well as the collection of specimens are combined into one act."
16272688|NCT04867291|Experimental|Potassium Iodide Supplement|Consumption of a portion of Piping Rock Potassium Iodide supplements equivalent to 200 µg of iodine (1.3 tablets) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
16275247|NCT04849390|Placebo Comparator|Placebo|Oral use of 1 hard gelatin capsule
16272652|NCT04867590|Active Comparator|Radiofrequency|Endoscopic treatment using the HALO® 360 or 90 system is a thermal ablation system for superficial mucosa. First and foremost, the examination includes an endoscopy to locate the upper limits of the BE and its distribution, so as to choose the most appropriate type of probe. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.
16272653|NCT04867577||vertebral osteoporotic compression fracture|Patients with osteoporotic vertebral compression receiving vertebroplasty or cemented screws reconstruction
16272654|NCT04867564||NSCLC patients treated with curative radiotherapy|Consecutive NSCLC patients treated with standard RT with curative intent with or without platinum-based CHT
16272655|NCT04867551|Experimental|KDT-3594|
16272656|NCT04867525||Colorectal Cancer Metastatic|
16272657|NCT04867512|Experimental|Intervention Group|Participants will be taking one liquid tincture orally per day as well as 2 capsules orally at night. At week 10, non-responders will take another supplement consisting of 2 capsules orally along with the liquid tincture until week 14.
16272658|NCT04867473|Experimental|Teleyoga|Lyme disease participants will attend home-based yoga sessions using HIPAA-compliant telehealth software and devices and complete pain inventory questionnaires pre and post-treatment
16272659|NCT04867460|Experimental|Ultrasound guided venous access|Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
16272660|NCT04867460|No Intervention|Standard of care|Vascular access of the axillary or subclavian vein will be performed using anatomical landmarks, fluoroscopy and/or injection of X-ray contrast in the antecubital vein, at the choice of the implanter. One or more vascular punctures will be performed, as needed.
16272661|NCT04867447||Case-Immigrants psychotic patients|"Individuals who have presented at least one non-affective psychotic episode with an immigrant status, defined as a person who migrates to another country, usually for permanent residence"
16272662|NCT04867447||Control-Non immigrants psychotic patients|Individuals who have presented at least one non-affective psychotic episode who do not have an immigrant status.
16272663|NCT04867434|Active Comparator|RZL-012 50mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses 270 mg for the high doses. Each injection point will be dosed with 7.5 mg for the high dose in a volume of 0.15 mL/injection site.
16272664|NCT04867434|Active Comparator|RZL-012 34mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses of 183.6 mg for the low dose. Each injection point will be dosed with 5.1 mg RZL-012 for the low dose in a volume of 0.15 mL/injection site.
16272665|NCT04867434|Placebo Comparator|Placebo|Placebo (vehicle) subjects will be injected with a 0.15 mL vehicle per each injection site. The maximal injection volume for all groups will be up to 5.4 mL.
16272666|NCT04867421||TANOs|Adult patients with osteosarcoma or chondrosarcoma
16272667|NCT04867408||Main group|Patients with/suspected Inflammatory Bowel Disease attending for an endoscopic procedure
16272668|NCT04867408||Control|Patients without Inflammatory Bowel disease attending for an endoscopic procedure
16272669|NCT04867395|No Intervention|Usual Care|75 participants will receive standard care, consisting of verbal discharge counseling given by doctors and nurses supplemented by written instructions (all unstandardized).
16272670|NCT04867395|Experimental|Intervention group|75 participants will be randomized to receive behavioral intervention, consisting of discharge counseling using the health literacy-informed discharge instructions
16272671|NCT04867382|Experimental|Intervention|PCCs in clinics randomized to Opioid Wizard will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Both arms will receive a case-based training on how to use the Opioid Wizard tool. The intervention arm will receive an online training that includes patient narratives and videos and person-first language.
16272672|NCT04867382|Placebo Comparator|Comparison training|PCCs in clinics randomized to Opioid Wizard will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Both arms will receive a case-based training on how to use the Opioid Wizard tool.
16272673|NCT04867369|Experimental|Pecs II block|80 patients scheduled for open biceps tenodesis
16272674|NCT04867369|Active Comparator|Surgical infiltration|80 patients scheduled for open biceps tenodesis
16272675|NCT04867356|Active Comparator|Spinal Stabilization Exercises (SSE)|
16272676|NCT04867356|Experimental|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|
16272677|NCT04867343|Experimental|HR020602 injection|
16272678|NCT04867343|Active Comparator|fentanyl injection + remifentanil injection|
16272679|NCT04867330|Experimental|conventional treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
16272680|NCT04867317|Active Comparator|Growth Hormone Replacement Therapy|Recombinant Human Growth Hormone
16272681|NCT04867317|Placebo Comparator|Placebo|Placebo
16272682|NCT04867304||Healthy controls|Individuals without any known illnesses and normal labs./USG w/a. This group was used to compare baseline depression, magnetic resonance spectroscopy and plasma metabolites.
16272683|NCT04867304||Chronic pancreatitis without depression|This group contains patients with CP who does not have depression based on the Beck Depression inventory.
16272684|NCT04867304||Chronic pancreatitis with depression|This group contains patients with CP who has depression based on the Beck Depression inventory.
16272685|NCT04867291|Experimental|Pizza|Consumption of a portion of Eat Balanced pizza equivalent to 200 µg of iodine (half a pizza) consumed with 450 mL water. Collection of urine for 36 hours following pizza ingestion. Collection of one fecal sample up to 24 hours following pizza ingestion.
16272686|NCT04867291|Experimental|Seaweed Sheets|Consumption of a portion of Itsu Crispy Seaweed Thins equivalent to 200 µg of iodine (10g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
16272855|NCT04866147||Chronic postsurgical pain patients|Patients who undergo various common surgical procedures
16272689|NCT04867278|Experimental|External Beam Radiation (XRT) with Debridement|Patients will receive gluteus minimus debridement in the OR, which is the standard of care at Shock Trauma. If randomized to the treatment group, patients that undergo surgical fixation of an acetabular fracture via a posterior or combined anterior and posterior approach will undergo a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery. This treatment is currently the standard procedure performed for all patients who undergo a posterior or combined approach at our institution.
16272690|NCT04867278|Active Comparator|Debridement Alone (Control)|The control treatment arm will only include gluteus minimus debridement in the OR and will not receive XRT.
16272691|NCT04867265|Active Comparator|Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
16272692|NCT04867265|Active Comparator|Resusci Anne QCPR AED (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
16272693|NCT04867265|Active Comparator|Resusci Baby QCPR (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
16272694|NCT04867252|Active Comparator|Combination Therapy Group|ARM 1: Resveratrol (1000mg Twice a day) Myoinositol (1000mg Twice a day)
16272695|NCT04867252|Other|Standard Therapy Group|ARM 2:Metformin 500mg (Twice a day) Pioglitazone (15mg Twice a day)
16272696|NCT04867239|Other|A two-day education program|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise for metabolic syndrome. Participants visited at 3- and 6-month after camp for follow-up.
16272697|NCT04867226|Active Comparator|colchicine drug|participant in this group will be given a colchicine tablet alone or add to their Current treatment, Colchicine 0.5 mg twice daily (reduced to 0.5 mg/day, in patients with low body weight or develop side effect like gastrointestinal symptoms ),For 14 days or until symptoms subsides.
16272698|NCT04867226|Active Comparator|usual care|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
16272699|NCT04867213||SARS-CoV-2 Positive|Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g. RT-PCR) and with a positive result and clinical features in keeping with COVID-19 illness. The investigators aim to collect breath samples within 7 days of symptom onset in 50% of Covid positive patients, with the remaining patients breath samples collected after 7 days of symptoms onset.
16272700|NCT04867213||SARS-CoV-2 Negative|Patients with a negative RT-PCR COVID-19 test and without any clinical features to suggest COVID-19 illness.
16272701|NCT04867200|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)
~Period 2: Test drug(CKD-344 60 mg)"
16272702|NCT04867200|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)
~Period 2: Reference drug(Lixiana 60 mg)"
16272703|NCT04867187|Experimental|rTMS active and active mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.
16272704|NCT04867187|Sham Comparator|rTMS active and sham mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.
16272705|NCT04867174|Placebo Comparator|Control Arm|No messaging about COVID-19 vaccination
16272706|NCT04867174|Experimental|Emotional message|Participants view an emotional video from the state of California about getting back to normal.
16272707|NCT04867174|Experimental|Safety and effectiveness message|Participants view a video with information about the safety and effectiveness of the COVID-19 vaccines
16272708|NCT04867174|Experimental|Consequences message|Participants view a video with information about the consequences of not getting vaccinated against COVID-19.
16272709|NCT04867161||Patients with COVID-19 pneumonia without superinfection|Patients with confirmed COVID-19 pneumonia not fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
16272710|NCT04867161||Patients with COVID-19 pneumonia with superinfection|Patients with confirmed COVID-19 pneumonia fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
16272711|NCT04867148|Experimental|Gait analysis|Gait analysis of patients with ankylosing spondylitis, patients with adoldescent idiopathic scoliosis and control group.
16272712|NCT04867135||No Sepsis / Sepsis|To compare amikacin PK / PD models of newborns with a confirmed diagnosis of sepsis (clinical or microbiological) and with ruled out sepsis.
16272713|NCT04867122|Placebo Comparator|Attention Control|"Family caregivers in the attention control study arm will receive three sessions of attention-matched control in addition to the services and support provided as part of usual outpatient palliative care. Attention-matched control will consist of three friendly visits with a trained research staff person."
16272714|NCT04867122|Experimental|Problem Solving Therapy Intervention|Family caregivers in the intervention study arm will participate in three problem-solving therapy sessions with a trained interventionist in addition to receiving the services and support provided as part of usual outpatient palliative care.
16272715|NCT04867122|Other|In-Depth Interviews for non-FCG Stakeholders and FCGs|"Each year of the project, the investigators will recruit 6 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the PST intervention into clinical practice: 3 from the rural site and 3 from the urban sites, for a total of 30 unique stakeholders who will be interviewed over the duration of this 5-year study.
~A subsample of 25% of the FCGs randomized to the intervention group will participate in in-depth interviews"
16272716|NCT04867096|Experimental|Physical activity intervention|"Arm A : standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months."
16272717|NCT04867096|No Intervention|Control|"Arm B : standard oncologic care."
16275323|NCT04848857|Placebo Comparator|Control Group|placebo, one pill a day, oral intake
16272720|NCT04867070||LLDN with ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
16272721|NCT04867070||LLDN without ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
16272722|NCT04867057|Experimental|Experimental: Trichomylin for SAD|6 out of 8 subjects will be randomized to receive Trichomylin in a single dose.
16272723|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for SAD|2 out of 8 subjects will be randomized to receive placebo in a single dose.
16272724|NCT04867057|Experimental|Experimental: Trichomylin for MAD|6 out of 8 subjects will be randomized to receive Trichomylin in multiple doses.
16272725|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for MAD|2 out of 8 subjects will be randomized to receive Placebo in multiple doses.
16272726|NCT04867044||STUDY GROUP|patient diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
16272727|NCT04867044||CONTROL GROUP|healthy women volunteers
16272728|NCT04867031|Experimental|White fish (cod)|Participants will consume 1 portion (~130g) of white fish (Bird's Eye Inspirations Cod Fillets with Tomato & Rosemary), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
16272729|NCT04867031|Experimental|Semi-skimmed milk|Participants will consume 1 portion (~450mL) of milk (Tesco UHT Semi-Skimmed), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
16272730|NCT04867031|Experimental|Dried seaweed sheets|Participants will consume 1 portion (~6g) of dried seaweed sheets (Itsu Crispy Seaweed Thins), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
16272731|NCT04867018||Orthopaedic Trauma, Pediatrics and Joint Patients|Patients will have an additional 9ml of blood drawn during their normal course of care for this study up to 4 times. Intraoperatively, we will request a tissue sample of the debrided injured muscle from the area where the surgeon is operating. There will be no additional tissue sample taken during the surgery, but what is removed in the normal course of the operation will be used for analysis in our study.
16272732|NCT04867018||Healthy Volunteer|Blood will be taken from healthy, nonpregnant adults who weigh at least 110 pounds. All volunteers will have a single blood draw of 100ml at the time of consent.
16272733|NCT04867005|Active Comparator|Online traininig group. A|This arm included 5 primary care teams, that carried out a 10 hours online course.
16272734|NCT04867005|Experimental|online and face-to-face training group. B|This arm included 5 primary care teams, that carried out a 10 hours online course plus a 6h hours face-to-face course
16272735|NCT04866979|Experimental|Combination of continuous TBS plus cognitive training (cTBS + CT)|Continuous mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
16272736|NCT04866979|Experimental|Combination of intermittent TBS plus cognitive training (iTBS + CT)|Intermittent mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
16272737|NCT04866979|Experimental|Continuous TBS only (cTBS)|TBS in continuous mode application, only (without cognitive training).
16272738|NCT04866979|Experimental|Intermittent TBS only (iTBS)|TBS in intermittent mode application, only (without cognitive training).
16272739|NCT04866979|Active Comparator|Cognitive training only (with sham TBS) (CT).|"TBS Sham will be implemented using the same set-up as a true TBS protocol but with sham stimulation. Directly following sham stimulation (as in the true combination of stimulation + cognitive training protocols), patients will undergo 25 minutes of cognitive training."
16272740|NCT04866966|Experimental|Intervention Group|The group undergoing the intervention will participate in 90-minute group visits occurring weekly for 4 weeks, then biweekly for a total of 26 weeks/15 visits. Each visit will focus on intensive lifestyle changes. Further, these patients will each have the opportunity to meet one-on-one with a member of the research team at the end of each visit in order to discuss individual goals and progress. Pharmacotherapy therapy changes will be recommended to reduce or avoid use of medication which may contribute to weight gain and medications for weight loss will be prescribed as an individualized treatment strategy during one-on-one time with the pharmacist or physician if the patient can afford it and no contraindications exists.
16272741|NCT04866966|No Intervention|Control Group|The control group will have their measurements done at the beginning and end of the study. They will continue with usual medicare care during the study and will not receive any education from the investigators during the study. They will be offered the option of a delayed intervention after the completion of the study.
16272742|NCT04866953||<30 units PRBC|Patients who underwent surgery within 24 hours of admission and received less than 30 units of pRBC within 24 hours.
16272743|NCT04866953||>/=30 units PRBC|Patients who underwent surgery within 24 hours of admission and received >/=30 units of pRBC within 24 hours.
16272744|NCT04866940|Experimental|Sequence validation|This research aims to provide a generic framework to test the feasibility of MRI sequences requested as part of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of images obtained.
16272745|NCT04866927||Adults|"Inclusion criteria: Healthy, non-pregnant women, adults aged 18-65 years, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range.
~Exclusion criteria: Children and elderly (over 65), pregnant women, individuals diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study."
16272746|NCT04866914|Experimental|ACT for Insomnia|
16272747|NCT04866914|Active Comparator|CBT for Insomnia|
16272748|NCT04866914|No Intervention|Wait List|
16272856|NCT04866134|Experimental|Dose Escalation (Part A): ERAS-007 Monotherapy, BID-QW dosing|ERAS-007 monotherapy will be administered BID-QW in sequential ascending doses to participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
16272749|NCT04866901|Experimental|Slow-Paced Breathing (SPB)|Participants will first be provided with a brief overview of the science of breathing and benefits for autonomic regulation. Then, participants will receive specific practice instruction and guided breathing at a rhythm of 6 breaths/min (4-6 count) via auditory tones. Each participant will be encouraged to breathe as comfortably and effortlessly as possible, while keeping the lungs moving in accordance with the audio guidance. The accompanying training and daily instruction reminder will emphasize the importance of following the specific rhythm of breathing, without regard to thoughts or inner experience. A soft but firm tone of voice will be employed to minimize likelihood of relaxing effects, while maintaining similarity to the tone of voice used in the other conditions.
16272750|NCT04866901|Experimental|Mindfulness (M)|Procedures are based on Berghoff et al., providing a brief history of mindfulness practices, definitions, instructions for practice, common challenges, and recommendations. An audio recording will then guide the mindfulness practice. Specific to this study, in order to further distinguish the three conditions, the guided audio recording will emphasize the importance of attending to the quality of experience while not changing or attending to breathing patterns.
16272751|NCT04866901|Experimental|Yogic Breathing (SPB+M)|Information from the other two conditions will be synthesized with the aim of eliciting attention to the same breathing instruction used for SPB, while also observing the quality of experience during the practice, as conducted for M.
16272752|NCT04866888|Experimental|pregnant women with placenta accreta spectrum|"Bladder will be dissected and mobilized down to the vagina after skeletonization and securing of bridging vessels either by electro-coagulation or ligation. Uterus will be incised 5mm above the placenta bulge, delivering the fetus followed by Carbetocin 100 microgram /1 ml intravascular. Repair of the uterine wall defect will be done. If extrauterine bleeding is excessive we may revert to internal iliac artery ligation followed by insertion of intra-peritoneal drain and regular abdominal wall closure.
~After 3 months from delivery, ultrasound with different modalities will be done to all patients and outpatient hysteroscopy if symptomatic patients or with abnormal sonography."
16272753|NCT04866875|Active Comparator|Rapid weight loss|Participants in this group will be deprived in 1000 kcal/day (calculated based on their individual energy requirements) for 10 weeks
16272754|NCT04866875|Experimental|Slow weight loss|Participants in this group will be deprived in 500 kcal/day (calculated based on their individual energy requirements) for 20 weeks
16272755|NCT04866862|Experimental|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+ Camrelizumab 200mg d1; Repeated every 4 weeks
16272756|NCT04866849||STUDY GROUP|"patient diagnosed with bruxism The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
16272757|NCT04866849||CONTROL GROUP|healthy volunteers
16272758|NCT04866836|Experimental|tislelizumab combined with radiotherapy|To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.
16272763|NCT04866797|Active Comparator|cyclic merocyanine long-UVA absorber|
16272764|NCT04866797|Placebo Comparator|placebo|
16272765|NCT04866784|Experimental|High Sensation TENS|"Active TENS is delivered for 30mins at a frequency of 100 Hz and pulse duration of 100μsec using the EMPI Select TENS unit (calibrated using an oscilloscope prior to study). The intensity will be increased until patients feel a maximally strong but comfortable sensation to ensure an analgesic effect."
16272766|NCT04866784|Placebo Comparator|Low Sensation TENS|Placebo TENS parameters will be identical to Active TENS (100 Hz and 100 μsec), but a novel placebo TENS unit, previously tested and validated will be used (Rakel et al., 2010). The placebo device provides a current for 30sec and ramps off over 15sec to zero output. An indicator light remains on so it appears to the subject that the unit is still producing current. This unit has demonstrated nearly 100% blinding of investigators such that the investigator applying the TENS is unable to distinguish between the active and the placebo unit; approximately ~50% of subjects are successfully blinded using this unit.
16272767|NCT04866784|No Intervention|No Treatment Control|The No Treatment Control includes application of TENS electrodes identical to the other 2 conditions, but the unit remains off. This condition will control for potential effects of repeat testing and any placebo effect.
16272768|NCT04866771|Experimental|Transcranial Direct Current Stimulation (tDCS)|Facilitatory transcranial direct current stimulation (tDCS)
16272769|NCT04866771|Sham Comparator|Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group|Sham tDCS followed by a switch to anodal tDCS.
16272770|NCT04866758||Cancer Survivors|Ambulatory cancer population already seeking psychosocial support.
16272857|NCT04866134|Experimental|Dose Expansion (Part B): ERAS-007 Monotherapy, QW dosing|ERAS-007 monotherapy will be administered at 250 mg QW to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
16272888|NCT04865926|Experimental|Control Group|McKenzie and Kendall exercises will be given to the participants in the control group. Exercises will be done 3 sessions a week over a 4-week period.
16272771|NCT04866745|Experimental|Magnetotherapy plus exercise|"The patients will receive a total of 12 sessions, 3 sessions per week of magnetotherapy. The duration of treatment will be 20 minutes with a magnetic field frequency of 50Hz and a power of 100 Gauss.
~After the magnetotherapy treatment, the patient will have to perform 12 sessions, 3 sessions per week of a program of therapeutic exercise with a duration of 25 minutes. This exercise program will be the same in the microwave and sham groups."
16272772|NCT04866745|Placebo Comparator|Sham Magnetotherapy plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of sham magnetotherapy. For the simulated/sham magnetotherapy group, it will be applied in the same way as the real MT group, but the equipment will be programmed to apply 0 Gauss. The physiotherapist performing the application will not have access to the magnetotherapy parameters on the display of the device, but will only have to enter the code. After the application of sham magnetotherapy, the patient will have to perform a program of therapeutic exercise.
16272773|NCT04866745|Active Comparator|Microwave plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of microwave therapy. The duration of the session will be 20 minutes, 10 minutes on the anterior side and 10 minutes on the posterior side of the joint in case of unilateral knee osteoarthritis. In the case of bilateral knee osteoarthritis, the MW will be applied 20 minutes over the anterosuperior side of both knees. After the microwave session, the patient will have to perform a program of therapeutic exercise.
16272774|NCT04866732|Experimental|Needs assessment and feasibility group|Based on our target population's needs/preferences, an existing Physical Activity (PA) program will be modified and tailored to the needs of the target population. We anticipate that this PA program will include the following components: a) PA component - ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to CVD risk factors prevention; c) daily diary to record if they are facing any barriers in completing various components of the intervention; d) problem-solving sessions
16272775|NCT04866719|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
16272776|NCT04866693||Service users|Up to 20 people with current or recent experience of using community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
16272777|NCT04866693||Carers|Up to 20 family members/ carers with experience of supporting another adult who is accessing community-based mental health services, will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
16272778|NCT04866693||Healthcare professionals|Up to 20 healthcare professionals from different disciplinary backgrounds and community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
16272779|NCT04866680|Experimental|Personalized Circulating DNA follow-up|FFPE tissue sample + blood sample (20ml)
16272780|NCT04866667||antidiabetic drugs including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs including GLP-1 RAs
16272781|NCT04866667||antidiabetic drugs not including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs not including GLP-1 RAs，such as metformin，insulin
16272782|NCT04866654|Experimental|Study group|Nivolumab, total dose 5760 mg milligram
16272783|NCT04866641|Experimental|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit will be administered via intravenous infusion once every 4 weeks. T-1201 Injection 100 mg Kit is required to be reconstituted with its specific Injection Diluent supplied in the kit, then further diluted with 5% Dextrose solution prior to the intravenous infusion in patients.
16272784|NCT04866628|Experimental|Helichrysum italicum|1 g of milled plant material (Helichrysum italicum) immersed in hot water (200 mL, 100 °C) for 10minutes
16272785|NCT04866628|Active Comparator|Helichrysum arenarium|1 g of milled plant material (Helichrysum arenarium) immersed in hot water (200 mL, 100 °C) for 10minutes
16272786|NCT04866615||50 patients newly diagnosed SLE with no treatment|OCT & OCTA for newly diagnosed SLE patients
16272787|NCT04866615||50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years|OCT & OCTA for on treatment SLE patients
16272788|NCT04866615||50 normal subjects as control group of similar age and gender|OCT & OCTA for normal subjects
16272789|NCT04866602|Experimental|Atoguanil|Atovaquone 500 mg + Proguanil 348 mg
16272790|NCT04866602|Active Comparator|Malarone®|Atovaquone 1000 mg + Proguanil HCl 400 mg
16272791|NCT04866589|Experimental|Distribution of free face masks|Face masks will be handed out for free to all customers entering the grocery stores.
16272792|NCT04866589|No Intervention|Control|Business as usual.
16272793|NCT04866576|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER: 2 pouches per day, each pouch contains (12-15 gms of fermented soy powder)
16272794|NCT04866576|Placebo Comparator|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
16272795|NCT04866563|Experimental|AX-8 to Placebo|AX-8 BID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.
16272796|NCT04866563|Experimental|Placebo to AX-8|Placebo BID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.
16272797|NCT04866550||Connected tablet|Patients aged over 60, living at home, with heart failure and / or chronic obstructive pulmonary disease, potentially requiring care cross-border (France and Belgium).
16272798|NCT04866537||Pregnant women who received a fetal heart ultrasound between 2015 and 2019.|Pregnant women who received a fetal heart ultrasound between 2015 and 2019.
16272799|NCT04866524||ICSI technique|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
16272800|NCT04866524||Conventional IVF|In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
16272801|NCT04866511|Experimental|NET intervention|This study will follow a single case design and will involve delivering and evaluating the child-friendly protocol of NET. Therefore, there will only be one arm (NET intervention) and no comparators.
16272889|NCT04865900||Covid19 Vaccinated Patients|Patients who are planning to receive Pfizer-BioNTech BNT162b2 vaccines against Covid19
16272890|NCT04865887|Experimental|Pembrolizumab with Lenvatinib|
16272802|NCT04866498||Analgosedation in ICU patients after head and neck tumor resection in general anesthesia|Head and neck tumor resections were performed in general anesthesia. Midazolam and etomidate or propofol were used in introduction and then anesthesia was maintenance with sevoflurane. Patients received intravenous continuous infusion of oxycodone as an analgesic component and sedatives (propofol/dexmedetomidine/midazolam) during analgosedation in ICU.
16272803|NCT04866485|Experimental|HBM4003+pembrolizumab|HBM4003 combined with pembrolizumab in subjects with advanced NSCLC and other solid tumors
16272804|NCT04866472|Other|Video Laryngoscope and GlideRite Ridgid Stylet|
16272805|NCT04866472|Experimental|Video Laryngoscope and TCI Articulating Introducer|
16272806|NCT04866446||normal airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
16272807|NCT04866446||normal airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
16272808|NCT04866446||difficult airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
16272809|NCT04866446||difficult airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
16272810|NCT04866433|Experimental|Binaural group|Play realtime binaural sound applied music through headphones
16272811|NCT04866433|Active Comparator|Audio group|Play music through headphones.
16272812|NCT04866433|Sham Comparator|Control group|Wear headphones that do not produce sound.
16272813|NCT04866420||Poststroke fatigue|Participants who are experiencing fatigue post stroke.
16272814|NCT04866407|Experimental|Mentha x piperita|A diluted solution of Mentha x piperita in carrier oil will be applied to the subject's interventional extremity.
16272815|NCT04866407|Experimental|Eucalyptus globulus|A diluted solution of Eucalyptus globulus in carrier oil will be applied to the subject's interventional extremity.
16272816|NCT04866407|No Intervention|No intervention|Each participant will have one extremity that receives no essential oil intervention.
16272817|NCT04866394|Experimental|Hypofractionated Pelvic Radiation|
16272818|NCT04866381|Experimental|SHR-6390|SHR-6390
16272819|NCT04866381|Experimental|SHR-6390 combined with Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
16272820|NCT04866381|Experimental|Camrelizumab (SHR-1210) combined with SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
16272821|NCT04866368|Active Comparator|The erector spinae plane block|The ultrasound-guided Erector spinae plane block (ESPB) with 1 ml/kg 0,25 % bupivacaine at the lumbar vertebral level will perform before surgery to all patients in the ESPB group.
16272822|NCT04866368|Active Comparator|The penile block|The penile block with 0,5ml/kg 0,25 % bupivacaine will be performed after the patients give standard general anesthesia and a laryngeal mask is applied.
16272823|NCT04866355|Experimental|Lumbar spine manipulation|Application of lumbar spine manipulation by a physical therapist.
16272824|NCT04866355|Active Comparator|Lumbar spine manipulation plus pharmacological therapy|Application of lumbar spine manipulation by a physical therapist along with pharmacological therapy.
16272825|NCT04866355|Active Comparator|Pharmacological therapy|Application of pharmacological therapy
16272826|NCT04866342|Experimental|Servo control - Masimo oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.
~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
16272827|NCT04866342|Active Comparator|Servo control - Nellcor oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.
~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
16272828|NCT04866329||In Vitro Fertilisation protocol|Women followed in the department for an in vitro fertilisation protocol
16272829|NCT04866316||GSH Participants|"Qualitative - Semi-structured focus group discussions with care recipients
~Quantitative - Pre-test post-test design using survey-based data collection
~Quantitative - Retrospective cohort design with propensity score matched comparators"
16272830|NCT04866316||Policy owners, implementers & care partners, health and social care professionals|"Qualitative - Semi-structured in-depth interview with key policy and programme decision-makers
~Qualitative - Semi-structured focus group discussions with health and social care professionals
~Qualitative - Participant observations
~Quantitative - Longitudinal monitoring of process indicators"
16272831|NCT04866303|Experimental|Active delivery|For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.
16272832|NCT04866303|Experimental|Passive delivery|Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.
16272858|NCT04866134|Experimental|Dose Expansion (Part C): ERAS-007 Monotherapy, BID-QW dosing (if necessary)|Depending on data generated from Part A, ERAS-007 monotherapy may be administered at the BID-QW RD to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
16272891|NCT04865874|Experimental|PPV-GDT|Intra-operative fluid-therapy based (lactated Ringer) on continous PPV monitoring (target ≤5.8%)
16272892|NCT04865874|Active Comparator|Zero balance|Intra-operative fluid-therapy (lactated Ringer) based on 1:1 compensation of urinary output
16272833|NCT04866277|Experimental|Intervention|"Women who present at least one of the four risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will be eligible to receive the intervention. The intervention will be the activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study. All pregnant women referred by the STOP LBW project would have access to consultations or other health activities, such as counselling and group meetings, within a maximum of seven days, in reference services available in each metropolitan area. The activation of the fast-track referral will be the responsibility of the doctor/nurse who applies the questionnaires to identify the risk factors. The intervention ends with childbirth, abortion or if the participant decides to abandon the study."
16272834|NCT04866277|No Intervention|Standard of care|Women who present at least one of the risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will receive the standard of care currently existing in each PHCU. The standard of care varies across the various PHCU and may include several approaches: routine screening with care by the antenatal care provider; routine screening with referral to other health professional in the same health unit; and routine screening with referral to other health services, with the time elapsed for consultation depending on the health resources available in each area. In each PHCU, different standards of care may exist for each of the four risk factors.
16272835|NCT04866264|Active Comparator|Outpatient Group|"After signing the informed consent, outpatients will be invited for a clinical baseline visit at the Center on Aging and Mobility (CAM), where they will complete the dietary assessment with the eNutrition optimizer at the CAM guided by the study physicians, who will also interpret the immediate results and recommendations produced by the tool to the study participant.
~For validating the eNutrition-Optimizer tool, participants will be asked to report their dietary intake in the past 24h during a 24-h diet recall phone call conducted by a trained interviewer on random days (weekday and weekend), so the participant cannot prepare or alter their habits. This 24h diet recall phone calls will be performed 4 times during the second half of the follow-up (month 4 to 6). In addition participants will complete the System Usability Scale at baseline and the subjective effectiveness questionnaire at month 6."
16272836|NCT04866264|Active Comparator|Inpatient Group|After signing the informed consent, inpatients (Senior trauma center/heart surgery) will do the dietary assessment with the eNutrition optimizer with supervision of a trained study physician to assess user feasibility in the inpatient setting. In addition they will have a follow-up phone call at month 3 to 6 to assess the subjective effectiveness of the eNO.
16272837|NCT04866251|Active Comparator|Healthy young subject|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272838|NCT04866251|Active Comparator|Healthy older subjects|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272839|NCT04866251|Active Comparator|Acute stroke patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272840|NCT04866251|Active Comparator|Patients with Parkinson´s Disease|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272841|NCT04866251|Active Comparator|Patients with Multiple Sclerosis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272842|NCT04866251|Active Comparator|Patients with Myasthenia gravis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272843|NCT04866251|Active Comparator|Geriatric patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
16272844|NCT04866238|Active Comparator|Vestibular fixed appliances|Adult patients in this group will be treated using fixed appliances.
16272845|NCT04866238|Experimental|Clear aligners|Adult patients in this group will be treated using clear aligners.
16272846|NCT04866225|Experimental|Study arm|One arm of healthy male participants administered a single oral dose of [14C]PF-06865571; followed by a single dose of unlabeled PF-06865571, and IV administration of [14C]PF-06865571 three hours later.
16272847|NCT04866212||Children with Type 1 Diabetes Group|"Children with type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.
~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
16272848|NCT04866212||Children without Type 1 Diabetes Group|"Children without type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.
~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
16272849|NCT04866199||High-risk colon or bladder surgical patients|Patients who are diagnosed with colon or bladder cancer requiring surgical resection.
16272850|NCT04866173|Experimental|Dog|Being subjected to two standardised stress situations with a dog and its handler present
16272851|NCT04866173|Experimental|No Dog|Being subjected to two standardised stress situations without a dog present, but in the presence of a person (dog handler)
16300180|NCT04674566|Experimental|Cohort 4|COR-101 high dose
16272859|NCT04866121|No Intervention|Standard Treatment|Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
16272860|NCT04866121|Active Comparator|Single point (P6) Acupuncture|"Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol to the P6 point bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards.
~Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia."
16272861|NCT04866121|Experimental|Double point (P6+ST36) Acupuncture|Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol both to the P6 and ST36 points bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For ST6 acupuncture stimulation 0,25x50mm steel needles will be immersed for 5cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards. Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
16272862|NCT04866108|Experimental|Experimental|Fruquintinib, 4mg/d, qd po, 2 weeks on, 1 week off; Capecitabine: 825mg/m2, bid po, 2 weeks on, 1 week off
16272863|NCT04866095|Experimental|Surgery|All patients, who have given their consent, aged over 18 years, with a sinus rhythm, requiring a surgical procedure that allows obtaining high quality transthoracic echocardiogram imaging without pain and discomfort.
16272865|NCT04866069|Experimental|Low-Dose Group (Group A)|20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
16272866|NCT04866069|Experimental|High-Dose Group (Group B)|20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
16272867|NCT04866069|Placebo Comparator|Placebo Group|10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
16272868|NCT04866056|Experimental|Treatment(Jaktinib+Azacitidine)|Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16272869|NCT04866043||NostraData Database|All prescriptions for lisdexamfetamine dimesylate available in the NostraData database at any time in the last 12 months will be collected in Australia.
16272870|NCT04866043||Physician Survey|Physician will provide de-identified data of participants who have been prescribed lisdexamfetamine dimesylate at least once during the study period for indications other than attention deficit hyperactivity disorder (ADHD) in Australia.
16272871|NCT04866030||NostraData Database|All prescriptions for Intuniv available in the NostraData database in Austrialia will be analyzed in this study.
16272872|NCT04866030||Physician Survey|Physician will collect medical record data of 100 participants who have been prescribed Intuniv at least once during the study period to treat participants with ADHD.
16272876|NCT04866004|Experimental|Contingency Management - Cannabis|Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.
16272877|NCT04865991|Experimental|TCI propofol group|Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
16272878|NCT04865991|Active Comparator|sevoflurane group|Subjects in the sevoflurane group received sevoflurane 2 volume%, which were titrated up/down every 5 minutes to get a targeted BIS score of 40-60.
16272881|NCT04865965|Experimental|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
16272882|NCT04865965|No Intervention|No Exercise|No Exercise Session
16272883|NCT04865952|Experimental|intra-surgical HA application (treatment group - HA)|periodontal surgery + intra-surgical HA application + buccal attached gingival (G) biopsies 24 hr after surgical procedure
16272884|NCT04865952|Other|NO intra-surgical HA application (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
16272887|NCT04865926|Experimental|Scapular and Neck Proprioceptive Neuromuscular Facilitation Group|Participants in the intervention group will be applied neck and scapular Proprioceptive Neuromuscular Facilitation exercises lasting 40 minutes for 3 sessions a week for 4 weeks.
16272893|NCT04865848|Experimental|Mandibular infiltration dental anesthesia with Articaine|"Step-by-step:
~Reflect tissue to expose injection site.
~Orient bevel of the needle to be parallel to the bone and insert needle into mucobuccal fold
~Proceed to the depth that approximates the apices of the buccal roots of the primary molars.
~Aspirate.
~Deposit bolus of local anesthetic slowly at a rate of 1 ml/min.
~Remove needle.
~A subsequent lingual infiltration is delivered.
~The armamentarium includes: 4% articaine HCl with 1:100,000 epinephrine (Septocaine ®, Septodont, Lancaster, Penn. USA) in 1.7 ml cartridges and 30-gauge short needle manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
16272894|NCT04865848|Active Comparator|Inferior Alveolar Nerve Block with Lidocaine|"Step-by-step:
~Dry injection site with gauze.
~The barrel of the syringe should be directed on a plane between the two primary molars on the opposite side of the arch. It is advisable to inject a small amount of the solution as soon as the tissue is penetrated and to continue to inject minute quantities as the needle is directed toward the mandibular foramen.
~Insert to the depth that is adjacent to bone.
~Aspirate.
~Slowly inject bolus of anesthetic at a rate of 1 ml/min.
~Remove needle.
~The armamentarium includes 2% lidocaine HCl with 1:100,000 epinephrine (Henry Schein ® Lidocaine, Novocol, Cambridge, Ontario, Canada) in 1.7 ml cartridges, as well as 27-gauge long needles manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
16272895|NCT04865835|Placebo Comparator|placebo and metformin|single dose of placebo + single dose of metformin-HCl 850 mg (approximately 663 mg metformin) (placebo will be dosed 1 hour prior to metformin administration)
16272896|NCT04865835|Experimental|SEP-363856 and metformin|single dose of SEP 363856 100 mg + single dose of metformin-HCl 850 mg (SEP 363856 will be dosed 1 hour prior to metformin administration)
16272897|NCT04865822|Experimental|Pain Education|Participant will attend a single session pain education course
16272898|NCT04865822|No Intervention|wait list control|Participants will be wait listed then receive intervention
16272899|NCT04865809|Experimental|Trial Group|Patients from this group will use Peribioma Toothpaste and Mousse for home oral care.
16272900|NCT04865809|Active Comparator|Control Group|Patients from this group will use standard toothpastes for home oral care.
16272901|NCT04865796|Experimental|Group 1|Patients will use products based on lactoferrin.
16272902|NCT04865796|Experimental|Probiotics|Patients will use products based on probiotics for home oral care.
16272903|NCT04865796|Active Comparator|Standard therapy|Patients will use standard toothpastes for home oral care.
16272904|NCT04865783|Active Comparator|Cryospray|Cryospray will be sprayed from a distance of 20-30 cm to the back of one hand.
16272905|NCT04865783|Placebo Comparator|Placebo|A saline solution will be sprayed from a distance of 20-30 cm to the back of the hand.
16272908|NCT04865757|Experimental|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
16272909|NCT04865744|Active Comparator|Oral semaglutide 7 mg|The semaglutide 7 mg tablet taken orally with 120 ml of water.
16272910|NCT04865744|Placebo Comparator|Placebo|The placebo tablet taken orally with 120 ml of water.
16272911|NCT04865731|Experimental|Dermaprazole|30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
16272912|NCT04865731|Active Comparator|Aquaphor|15 HNC patients using Aquaphor, the current clinical standard of care
16272913|NCT04865718||neurovascular surgery group|Subjects undergoing neurovascular surgery including aneurysm clipping
16272914|NCT04865705|Experimental|Tilelizumab+Albumin Paclitaxel + Carboplatin/Cisplatin|Tilelizumab 200mg d1 Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1IV,Q3W *2cycles
16272915|NCT04865692|Experimental|Interventional group|The interventional group received resisted knee extension 20% of 1RM with blood flow restriction along with routine physical therapy.
16272916|NCT04865692|Other|Control Group|The Control group received routine physical therapy alone including knee isometrics and resisted knee extension
16272917|NCT04865679|Experimental|Axoguard Nerve Cap®|"Active Comparator: Porcine derived extracellular matrix (ECM) based Nerve Termination Device
~Implantation of appropriate diameter of Axoguard Nerve Cap® (sizes 5-7 mm) at the time of surgery"
16272918|NCT04865666|Experimental|movr App Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior for the 8-week intervention period and to avoid any specialized exercise training for that time period, but they were also asked to use the movr app to supplement their current activity.
16272919|NCT04865666|No Intervention|Waitlist Control Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior over the 8-week study period and to avoid any specialized exercise training for that time period. Following the 8-week study period, individuals in the control group were permitted to download and use the movr app if they chose to.
16272920|NCT04865653|Experimental|Oral drinking solution of LSD base|Oral drinking solution of 0.1 mg LSD base in 96% ethanol
16272921|NCT04865653|Experimental|Solid orodispersible film containing LSD base|Solid orodispersible film containing 0.1 mg LSD base
16272922|NCT04865653|Experimental|Oral drinking solution of LSD tartrate|Oral drinking solution of 0.146 mg LSD tartrate in water
16272923|NCT04865653|Experimental|Intravenous administration of LSD tartrate|Intravenous administration of 0.146 mg LSD tartrate in water
16272924|NCT04865653|Placebo Comparator|Placebo|Placebo for all formulations
16272925|NCT04865640||Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
16272971|NCT04865380|No Intervention|No Tranexamic Acid|The anesthesiologist will not administer Tranexamic Acid at any point.
16272972|NCT04865380|Experimental|Intravenous Tranexamic Acid|1g of Tranexamic Acid will be administered intravenously prior to the start of the operation.
16272973|NCT04865367||DEG n1: euploid medium|culture media derived from euploid embryos
16272974|NCT04865367||DEG n2: aneuploid medium|culture media derived from aneuploid embryos
16272926|NCT04865640||Pathologic Cohort|The target population for this cohort is adult patients who have been diagnosed with cardiopulmonary conditions. These can include chronic pulmonary conditions, chronic cardiac conditions, and those who are taking diuretic medications, living with heart failure, Chronic Obstructive Pulmonary Disorder (COPD), or recovering from coronary-artery disease-related events. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders as well as conditions outlined above (e.g. at least 5 each of COPD, HF, recovering from a coronary artery disease-related event, and taking diuretic medication)
16272927|NCT04865627||independent walking with walking aid|the participant is able to walk with a walking aid and does not need further assistance.
16272928|NCT04865627||dependent walking with walking aid|the participant is able to walk with assistance and a walking aid
16272931|NCT04865601||CRC|Patient affected by any sporadic colorectal cancer
16272932|NCT04865601||FAP|Patients affected by familial adenomatous polyposis coli
16272933|NCT04865601||HNPCC|Patient affected by hereditary non polyposis colorectal cancer
16272934|NCT04865601||Lynch|patient affected by lynch syndrome
16272935|NCT04865601||others|Patients affected by ulcerative colitis, chron disease, diverticulitis and other colon diseases, which represent the control
16272936|NCT04865588|Active Comparator|rotational atherectomy + cutting balloon|angioplasty with rotational atherectomy followed by cutting balloon
16272937|NCT04865588|Active Comparator|rotational atherectomy + plain old balloon|angioplasty with rotational atherectomy followed by plain old balloon
16272938|NCT04865575||controlled asthmatics|moderate-to-severe asthmatic children with good asthma control
16272939|NCT04865575||uncontrolled asthmatics|moderate-to-severe asthmatic children with poor asthma control / recurrent exacerbations
16272940|NCT04865562|Experimental|testosterone|7mg testosterone propionate
16272941|NCT04865562|Placebo Comparator|placebo|125 mg 0.5% cholorbutanol, 50mg saline, pH5
16272942|NCT04865549|Experimental|TAD arm|Sentinel Node Biopsy + Targetted Axillary Dissection (Clipped cN1 node) extraction + lymphadenectomy.
16272943|NCT04865536|Active Comparator|Cohort 1 TBI-223 1800 mg, fasting|1800 mg, fasting
16272944|NCT04865536|Active Comparator|Cohort 1 TBI-23 1800, fed|TBI-23 1800, fed
16272945|NCT04865536|Placebo Comparator|Cohort 1 Placebo, fed|Placebo, fed
16272946|NCT04865536|Placebo Comparator|Cohort 1 Placebo fasting|Placebo fasting
16272947|NCT04865536|Active Comparator|Cohort 2 TBI-223, 2400mg,fed|2400mg,fed
16272948|NCT04865536|Active Comparator|Cohort 2 TBI-223, 2400 mg fasting|2400 mg fasting
16272949|NCT04865536|Placebo Comparator|Cohort 2 Placebo, fed|Placebo, fed
16272950|NCT04865536|Placebo Comparator|Cohort 2 Placebo, fasting|Placebo, fasting
16272951|NCT04865536|Active Comparator|Cohort 3 3000mg, fed|3000mg, fed
16272952|NCT04865536|Placebo Comparator|Cohort 3 placebo, fed|placebo, fed
16272953|NCT04865523|Experimental|Manual Lymphatic Drainage|
16272954|NCT04865523|No Intervention|No intervention|
16272955|NCT04865510|Active Comparator|Citrate|The RCA group CRRT were performed with Prisma flex or (Baxter Healthcare/Gambro Spain) or Informed machine with citrate pump. The function mode was continuous venovenous hemodiafiltration (CVVHDF) in postdilution mode with ST 150 filter sets. The substitution fluid was Accusol or Prismocal B22 .The dose of dialysis was 20-25 ml/kg/hr with blood flow 150-200 ml/min. Trisodium citrate solution (4%,136mmol/L) was infused into the arterial line prior to the blood pump at a dose of 4 mmol/L of plasma flow. Calcium chloride (5% 340 mmol/L elemental calcium) was infused into the venous return to maintain systemic ionized calcium in the normal range (0.99-1.30 mmol/L) and the targets values for ionized calcium (iCa2+) after the dialysis membrane were 0.25-0.35 mmol/L. The rale of calcium infusion was adjusted in a timely manner based on repeated measurements of calcium concentration
16272956|NCT04865510|Placebo Comparator|Heparin-free|The heparin- free group The circuit was periodically flushed with 50 ml saline via access limb every 30 minutes .When pre-filter pressure started to rise, additional saline flushes would be given.
16272957|NCT04865497|Experimental|High dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
16272958|NCT04865497|Experimental|Low dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
16272959|NCT04865497|Other|Adjuvant-free Group|Adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
16272960|NCT04865497|Other|Control Group|Haemophilus b Conjugate Vaccine,10μg/dose
16272961|NCT04865484|Experimental|SRES group|Surgical resection plus endoscopic stricturotomy for multiple fibrous stenosis
16272962|NCT04865484|Active Comparator|SRS group|Surgical resection plus strictureplasty for multiple fibrous stenosis
16272963|NCT04865471|Experimental|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
16272964|NCT04865458|Experimental|HEC89736 treatment|HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle
16272965|NCT04865445|Experimental|AT-527 550 mg + midazolam (simultaneous)|n=12
16272966|NCT04865445|Experimental|AT-527 mg + midazolam (staggered)|n=12
16272967|NCT04865432|Experimental|UVB treatment|The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 4-week study where they will be exposed to their individualized titration evaluation.
16272968|NCT04865419|Experimental|Module 1: AZD0466 monotherapy|Participants will receive intravenous infusion of AZD0466 monotherapy once weekly during Cycle 1 (35 days), Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
16272969|NCT04865419|Experimental|Module 2: AZD0466 + Voriconazole|Participants may receive IV infusion of AZD0466 in combination with or without voriconazole during Cycle 1 (21 days), and Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
16272970|NCT04865393|Experimental|SPR206|SPR206 100mg single-dose IV infused over 1 hour
16272977|NCT04865354|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16272978|NCT04865354|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16272979|NCT04865341|Experimental|IMB|Individuals randomized to this arm will receive a behavioral intervention based on the Information-Motivation-Behavior (IMB) model designed to increase HIV self-testing, among other protective behaviors.
16272980|NCT04865341|No Intervention|No Intervention|Individuals randomized to this arm will receive no intervention.
16272981|NCT04865328||OAB group|Group with diagnosed overactive bladder.
16272982|NCT04865315||Low grade glioma patients|Patients who have a MRI lesion suspected for a low grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
16272983|NCT04865315||High grade glioma patients|Patients who have a MRI lesion suspected for a high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
16272986|NCT04865276|Active Comparator|Intervention|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
16272987|NCT04865276|Active Comparator|Control|Home visit by a Community Health Worker during which the participant is scheduled to attend the tobacco cessation program at the public health system
16272988|NCT04865250|Experimental|treatment|ATEZOLIZUMAB; Carboplatin; Nab-Paclitaxel
16272989|NCT04865237|Experimental|Healthy Volunteers|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
16272990|NCT04865211|Experimental|Liposomal Bupivicaine|Administration of a combination of lioposomal bupivicane 20ml/266mg mixed with 20mL of 0.375% bupivicaine
16272991|NCT04865211|Active Comparator|Bupivicane|Administration of 40 ml of 0.375% Bupivicaine with epinephrine 1:400,000
16272992|NCT04865211|Placebo Comparator|Placebo|Saline injection with 40mL preservative-free saline
16272993|NCT04865198||Patients with Autism Spectrum Disorder (ASD)|Patients diagnosed with ASD in a child psychiatry clinic.
16272994|NCT04865198||Patients with High Functioning Autism (HFA)|Patients diagnosed with ASD in a child psychiatry clinic and with an IQ above 70.
16272995|NCT04865198||Healty control|Healthy volunteers who are in the age range compatible with the patient groups.
16272996|NCT04865185|Active Comparator|Xylocaine spray 100mg/ml|Topical application
16272997|NCT04865185|Placebo Comparator|Ethanol|Topical application
16272998|NCT04865172||Patient-caregiver dyads, patients with behavioural variant frontotemporal dementia|20 patient-caregiver dyads, patients with behavioural variant frontotemporal dementia
16272999|NCT04865172||Patient-caregiver dyads, patients with Alzheimer disease|20 patient-caregiver dyads, patients with Alzheimer disease
16273000|NCT04865172||Healthy control dyads|20 healthy control dyads
16273001|NCT04865159|Other|Single Group Assignment|Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1.
16273002|NCT04865146||TRIGEN™ INTERTAN™|Confirmed femoral fracture subjects who are scheduled for repair using INTERTAN 10S Nail
16273003|NCT04865133||Observational (biospecimen collection, medical record)|Patients undergo blood sample collection at baseline (prior to first vaccination), prior to second vaccination, 1, 6, and 12 months after the last vaccination. Patients who receive the types of COVID-19 vaccines that do not require the second injection omit the blood sample collection prior to the second vaccination. For patients who have already received COVID-19 vaccines, medical records are reviewed retrospectively.
16273004|NCT04865120|Active Comparator|merocyanine|
16273005|NCT04865120|Placebo Comparator|placebo|
16273006|NCT04865107|Experimental|MSCs Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
16273007|NCT04865107|Placebo Comparator|Placebo Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
16273008|NCT04865094|Active Comparator|cyclic merocyanine|long-UVA absorber
16273009|NCT04865094|Placebo Comparator|placebo|
16273010|NCT04865081|Experimental|VACCIN box group|The anesthesiologist will intubate the participants in the VACCIN box group while using the VACCIN box that will be placed over the participants' head.
16273011|NCT04865081|No Intervention|Control group|Enrolled participants in the control group will be intubated without the use of the VACCIN intubation box (standard anesthesia).
16273012|NCT04865068|Experimental|African migrant's population located in la region New Aquitaine.|Echocardiography norms will be harvested data on SSA participants located in la region New Aquitaine, France
16273013|NCT04865055|Active Comparator|cyclic merocyanine|cyclic merocyanine long-UVA absorber
16273014|NCT04865055|Placebo Comparator|placebo|
16273015|NCT04865042|Experimental|Gabapentin|
16273016|NCT04865042|Placebo Comparator|Placebo|
16273017|NCT04865029|Experimental|Treatment Arm|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission and Progesterone 200mg by mouth daily for 5 days starting at admission.
16273018|NCT04865029|Other|Control Arm|"Standard of Care along with placebo injection and placebo pill
~Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines"
16273019|NCT04865016|Active Comparator|MIOL Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with a low add (+2.75 Diopters [D]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group).
16273020|NCT04865016|Active Comparator|EDOF Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with an EDOF (Tecnis Symfony [ZXR00]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
16273021|NCT04865003||DNI group|patients with infection of two or more deep neck spaces (DNI group)
16273022|NCT04865003||DNI + DNM group|patients with infection of two or more deep neck spaces with secondary descending necrotizing mediastinitis (DNI + DNM group)
16273023|NCT04864977|Experimental|LY2963016|Participants with type 2 diabetes will be started on insulin glargine and dose will be titrated. Insulin glargine will be delivered via insulin pen each evening subcutaneously (SC). They will also check fasting blood glucose values on a study meter and prior to treating hypoglycemia. Participants will be asked to report the time and dose of their last administration.
16273024|NCT04864964|Other|combined conventional and pulsed radiofrequency of trigeminal nerve nucleus|"The technique of the CCPRF is described as follows;
~the classic Hartle technique is used to reach the Gasserian ganglion
~Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .
~After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:
~Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds
~Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.
~Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given ."
16273025|NCT04864951|Other|Transpeople|"1x urine sampling for HPV analysis
~1x survey"
16273026|NCT04864938||Patients: ICU treated covid-19 patients|Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
16273027|NCT04864938||Control group 1, covid-19 patients treated in the regular wards|As above, without 6 minute walk test or routine chest x-ray
16273028|NCT04864938||Control group 2, persons with covid-19 without hospitalization|As above, but without respiratory testing
16273029|NCT04864938||Control group 3, non-covid controls|As control group 2
16273030|NCT04864925|Experimental|Colgate Total Clean Mint|Brush with toothpaste for a minimum of 2 minutes
16273031|NCT04864925|Active Comparator|Tom's Botanically Bright Peppermint|Brush with toothpaste for a minimum of 2 minutes
16273032|NCT04864899|Experimental|Recovered COVID-19 patients|
16273033|NCT04864899|Experimental|Recovered non-COVID-19 viral respiratory infections patients|
16273034|NCT04864899|Experimental|Age and gender matched controls|
16273035|NCT04864886||Healthy volunteers|Control group
16273036|NCT04864886||Patients with atopic dermatitis|Physician-diagnosed atopic dermatitis
16273037|NCT04864886||Patients with primary immunodeficiency|Confirmed by genetic diagnosis or suspected by genetic variant of unconfirmed significance and a history consistent with immunodeficiency
16273038|NCT04864886||Patients with psoriasis|Physician-diagnosed psoriasis
16273039|NCT04864873|Active Comparator|Standard diagnostic pathway|Part of each patient sample will be tested using current standard microbiological techniques.
16273040|NCT04864873|Experimental|mNGS pathway|Part of each sample will be testing using mNGS methodology, which will be compared to the standard diagnostic pathway.
16273041|NCT04864860|Experimental|intervention arm|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). This dose was selected to be similar to previous studies that shows no harm or sever adverse effect on participants (12, 14)."
16273042|NCT04864860|Placebo Comparator|placebo arm|"The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
16273045|NCT04864821|Other|T cell injection targeting CD276 chimeric antigen receptor|
16273046|NCT04864808|Experimental|Behavioral Parenting Training|
16273047|NCT04864795||Single Cohort|Patient data will be collected from patient records and/or during a routine clinical visit. This will include treatments prescribed, routine assessments and measurements collected at routine clinical visits, as well as hospitalisations and other relevant patient data.
16273048|NCT04864782|Experimental|Cohort A|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6)
16273049|NCT04864782|Experimental|Cohort B-arm1|On Day 1 of each 21-day cycle, participants receive an IV infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)
16273050|NCT04864782|Experimental|Cohort B-arm2|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)
16273051|NCT04864769|Experimental|Krill Protein Hydrolysate|Krill Protein Hydrolysate
16273052|NCT04864769|Active Comparator|Soy protein isolate|Soy Protein isolate
16273053|NCT04864769|Active Comparator|Whey protein isolate|Whey protein isolate
16273054|NCT04864769|Sham Comparator|Control|Water
16273055|NCT04864756|Experimental|Before/After|Grade performance before and after introduction of simulation based learning
16273056|NCT04864743|Experimental|Arm 1-ADVATE+FRSW117(25 IU/kg)|Subjects received two treatments: 25 IU/kg ADVATE in the first period, followed by 25 IU/kg FRSW117 in the second period, with a washout period before each treatment.
16273057|NCT04864743|Experimental|Arm 2-ADVATE+FRSW117( 50 IU/kg)|Subjects received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW117 in the second period, with a washout period before each treatment.
16273058|NCT04864743|Experimental|Arm 3-ADVATE+FRSW117(65 IU/kg)|Subjects received two treatments: 65 IU/kg ADVATE in the first period, followed by 65 IU/kg FRSW117 in the second period, with a washout period before each treatment.
16273059|NCT04864730||CT scans|No intervention Data of voxels will be integrated to the final model
16273060|NCT04864717|Active Comparator|Doxycycline|Doxycycline 100mg po once daily x 6 months
16273061|NCT04864717|Active Comparator|Isotretinoin|Isotretinoin 40mg po once daily x 6 months
16273062|NCT04864704|Active Comparator|Infraspinatus|Subjects infraspinatus stiffness was measured and observed
16273063|NCT04864704|Active Comparator|Erector spinae|Subjects erector spinae stiffness was measured and observed
16273064|NCT04864704|Active Comparator|Gastrocnemius|Subjects gastrocnemius stiffness was measured and observed
16273065|NCT04864691|Experimental|endovascular recanalization plus standard medical treatment|patients with symptomatic non-acute intracranial artery occlusion treated by endovascular recanalization and standard medical treatment after procedure
16273066|NCT04864691|Active Comparator|standard medical treatment|Patients take aspirin 100 mg/day or clopidogrel 75mg/day for the entire follow-up period (EVR patients take aspirin 100 mg/day and clopidogrel 75mg/day for 30-90 days after procedure)
16273067|NCT04864678||Young people who are experiencing or at risk of homelessness|Young people aged 15-24 years who have accessed a homeless youth service, refuge, or flexible learning center in Melbourne, Australia.
16273068|NCT04864665|Experimental|Formula fed|0 - 6 months: a formula with prebiotics and milk fat (Stage 1); >6 - 12 months: a formula with prebiotics and milk fat (Stage 2); >1 - 2 years: a formula with prebiotics and milk fat (Stage 3)
16273069|NCT04864652|Experimental|Single Arm|CHILLS Procedure
16273070|NCT04864639|Experimental|Transition of Care|Experimental: 32 participants discharge to a culturally relevant plan All 32 participants will be discharge to a culturally relevant discharge plan
16273071|NCT04864626||patient with eating disorder|
16273072|NCT04864600|Active Comparator|Standard Stearin Candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
16273073|NCT04864600|Experimental|Modified low emission candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
16273074|NCT04864600|No Intervention|Clean Air|No candles in the chamber.
16273075|NCT04864587||Restorative colectomy with ileoanal pouch|Patients with restorative colectomy with ileoanal pouch who receive pouchoscopy for detection of pouchitis or neoplasm
16273076|NCT04864574|Experimental|Group 1 - Intervention|Participating children have daily access to the fruit and vegetable garden beginning Year 1.
16273077|NCT04864574|Experimental|Group 2 - Wait-list control (delayed intervention)|Participating children have daily access to the fruit and vegetable garden beginning Year 2.
16273078|NCT04864574|No Intervention|Group 3 - Control|No intervention
16273081|NCT04864548|Experimental|Group 1A: Low dose challenge|"Intranasal viral challenge with 1 x 10^1 TCID_50
~N= 8 participants"
16273082|NCT04864548|Experimental|Group 1B: Mid-dose challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50
~N= 8 participants"
16273083|NCT04864548|Experimental|Group 1C: High-dose challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50
~N= 8 participants"
16273084|NCT04864548|Experimental|Group 2: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 1a-c (1x10^1, 1x10^2 or 1x10^3 TCID_50)
~N=10-40 participants"
16273085|NCT04864522|Experimental|SLAMF7 BATs|Participants will undergo apheresis to collect cells to make SLAMF7 BATs. These cells will be allowed to grow in the lab and a drug will be added to them to make them activated against multiple myeloma. About 4 weeks after apheresis, participants will start receiving SLAMF7 BATs. Throughout treatment, participants will have blood taken for labs, to check disease status and also to look at immune response. Study treatment will stop if the participant has disease progression.
16273086|NCT04864509|Active Comparator|Melatonin 10mg|Nightly oral dose
16273087|NCT04864509|Placebo Comparator|Placebo|nightly oral dose
16273088|NCT04864496|Active Comparator|Prescribe N-acetylcysteine tablets|
16273089|NCT04864496|Placebo Comparator|Prescribe placebo tablets|
16273090|NCT04864483|Experimental|Early sahoor with predawn snack|"To take the Sahoor meal 1:30-2 hours before dawn with insulin dose then a pre-dawn snack with no insulin
~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
16273091|NCT04864483|Experimental|Late Sahoor meal (within 30 minjted of dawn) with insulin dose|"To take sahoor meal as late as possi le with usual insulin dose
~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
16273092|NCT04864470|Experimental|Intervention|"Stroke Odysseys is a performing arts intervention for people who have had strokes which provides an opportunity for communication of experiences of stroke to an audience through acquired skills in movement, music, song and the spoken word.
~Stroke Odysseys comprises three distinct stages:
~weekly workshops over 12 weeks for stroke participants facilitated by an integrated team of expert artists and ambassadors from the charity Rosetta Life
~a smaller group of ambassadors recruited from the workshops will be trained to become co-facilitators (stroke ambassadors)
~a performance tour including education and taster workshops for audiences."
16273093|NCT04864457||Normal|Patients without coronary atherosclerotic burden
16273129|NCT04864249|Active Comparator|Usual Care|Will receive the current standard of care of safe sleep education in the postpartum period
16273130|NCT04864236|Experimental|Intervention group|This group will undergo airway management in the operating room as part of the anesthesia for surgery in the presence of the novel isolation device.
16273131|NCT04864236|No Intervention|Control group|
16273094|NCT04864457||Chronic coronary syndrome (CCS)|"CCS covers the different stages of development of coronary heart disease in addition to the clinical manifestations dominated by acute coronary thrombosis, including asymptomatic myocardial ischemia, vasospasm, and microcirculatory lesions. The six most common types of CCS include:Suspected coronary heart disease and stable angina symptoms, whether or not patients with dyspnea; Patients with newly emerged heart failure or left ventricular dysfunction suspected of CAD; Patients with no symptoms or stable symptoms within 1 year after ACS, or patients with recent revascularisation; Patients with or without symptoms more than 1 year after initial diagnosis or revascularization; Patients with angina pectoris, suspected vasospasm or microcirculatory diseases; Asymptomatic patients with coronary heart disease are found during screening."
16273095|NCT04864457||Acute coronary syndrome (ACS)|ACS is a group of clinical syndromes commonly characterized by acute myocardial ischemia, including unstable angina pectoris (UA); Acute non-ST-segment elevation myocardial infarction (NSTEMI); Acute ST-segment elevation myocardial infarction (STEMI).
16273096|NCT04864444|Experimental|MDA with DHA-PPQ + SLD-PQ|Participants in intervention villages will be given three rounds of MDA with DHA-PPQ and SLD-PQ. Prior to the intervention, participants will have received piperonyl butoxide (PBO) treated LLINs and proactive community case management. Unlike control villages, MDA-randomized villages will not receive SMC.
16273097|NCT04864444|No Intervention|Standard malaria control interventions|Participants in the control villages will receive standard malaria control interventions as implemented by the Senegal PNLP. This will include the distribution of PBO LLINs, proactive case management, and SMC.
16273098|NCT04864431|Active Comparator|Vitamin D group|Daily vitamin D3 2000 IU on day 1 through day 180 Intervention: vitamin D3 2000 IU
16273099|NCT04864431|Placebo Comparator|Control group|Daily placebo (saccharum lactis) on day 1 through day 180 Intervention: placebo
16273100|NCT04864418|Experimental|Cohort group of AST-021p for dose-escalation|"4 cohort groups for AST- 021p administration:
~Group 1) 1.2mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF
~Group 2) 2.4mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF
~Group 3) 3.6mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF
~Group 4) 4.8mg AST- 021p, Montanide ISA 51 VG and rhuGM-CSF"
16273101|NCT04864405|Active Comparator|Morning administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient wake up time
16273102|NCT04864405|Active Comparator|Evening administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient bed time
16273103|NCT04864392|Experimental|LNA043 Dosing Regimen A|LNA043 injection to the knee with dosing regimen A
16273104|NCT04864392|Experimental|LNA043 Dosing Regimen B|LNA04 injection to the knee with dosing regimen B
16273105|NCT04864392|Experimental|LNA043 Dosing Regimen C|LNA043 injection to the knee with dosing regimen C
16273106|NCT04864392|Experimental|LNA043 Dosing Regimen D|LNA043 injection to the knee with dosing regimen D
16273107|NCT04864392|Placebo Comparator|Placebo|Injection to the knee
16273108|NCT04864379|Experimental|RFA+PD-1+iNeo-Vac-P01|Patients will undergo radiofrequency ablation. At Week 3, patients will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks. At Week 12,all patients,regardless of their disease status,iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
16273109|NCT04864379|Experimental|RFA+iNeo-Vac-P01+PD-1|Patients will undergo radiofrequency ablation. At Week 12, patients will receive iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit. At Week 16, patients,regard of their disease status,will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks.
16273110|NCT04864366||Treatment naive patients|"HBV DNA> 20000 IU/ml
~ALT>2×ULN；or ALT>1×ULN，but liver biopsy showed inflammation greater than or equal to G2, or/and liver fibrosis greater than or equal to S2
~No treatment with NA or/or αIFN within 1 year"
16273111|NCT04864366||ETV treatment experienced patients|"ETV treatment for 1 to 2 years before
~HBsAg>5000IU/mL
~HBV DNA<20IU/mL
~ALT<1×ULN
~No other NA therapy prior to entecavir treatment
~Patients had a desire to convert to TAF therapy"
16273112|NCT04864353|Experimental|Experimental: Intervention|Participants will after baseline receive a guided intervention with weekly therapist support.
16273113|NCT04864353|No Intervention|Control: Waitlist|Participants will not receive intervention until 7 weeks after baseline.
16273114|NCT04864340|Experimental|threshold stimulation (tetanic)|
16273115|NCT04864340|Experimental|upper threshold stimulation (tetanic)|
16273116|NCT04864340|Experimental|threshold stimulation (pressure)|
16273117|NCT04864340|Experimental|upper threshold stimulation (pressure)|
16273118|NCT04864340|Placebo Comparator|non nociceptive procedure (fine touch)|
16273119|NCT04864327|No Intervention|control|Usual care
16273120|NCT04864327|Other|intervention|5 minutes brief smoking cessation advise
16273121|NCT04864314|Placebo Comparator|Control group|Group supplemented with a daily dose of placebo
16273122|NCT04864314|Experimental|Experimental group|Group supplemented with a daily dose of TetraSOD®
16273123|NCT04864301|Active Comparator|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
16273124|NCT04864301|Active Comparator|Conventional Measurement technique|The control group (N=12) will receive no intraoperative ICI. Following maximal corporal dilatation, cylinder length will be estimated conventionally by adding up the internally measured distal and proximal corpora to the length of the corporotomy.
16273125|NCT04864288||1|male patients (age ≥ 21) with erectile dysfunction (ED) and non-responders to intracorporal injection
16273126|NCT04864288||2|age matched thirty men with normal erectile function
16273127|NCT04864262|Experimental|Photovoice|
16273128|NCT04864249|Experimental|SNOO Responsive Bassinet|Will receive and be instructed on the use of the SNOO responsive bassinet for their newborn + the current standard of care of safe sleep education in the postpartum period
16275803|NCT04845529|Experimental|2 tDCS Frontal|Anodal tDCS applied to the medial frontal cortex
16273132|NCT04864210|Experimental|Liposomal bupivacaine|The patient will receive an intercostal nerve block by the surgeon in the operating room after anesthetic has been administered. The surgeon will use thoracoscopic guidance to administer the intercostal nerve block. The medication used in this block will liposomal bupivacaine (Exparel).
16273133|NCT04864210|Active Comparator|Bupivacaine|The patient will receive a paravertebral block by the anesthesiologist staffing the pain service area within the hospital prior to surgery. This regional anesthesia will be done using ultrasound guidance. The medication used in this block will be plain bupivacaine with epinephrine.
16273134|NCT04864197|Experimental|prf group|prf membrane placement over implant site for gingival thickening
16273135|NCT04864197|Experimental|control group|no prf placement
16273136|NCT04864184|Experimental|Breathing intervention|Participants will complete 2-minute breathing exercises following the Breathing App every 15 minutes during a 4-hour postprandial period following high-fat meal consumption.
16273137|NCT04864158|Experimental|RSA-group|Surgery
16273138|NCT04864158|Experimental|Exercise-group|Exercise
16273139|NCT04864145|Active Comparator|Medical therapy|Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
16273140|NCT04864145|Experimental|Transcatheter Aortic Valve Implantation|Patients in TAVR group will receive transcatheter aortic valve replacement.
16273141|NCT04864132||Subjects survived from COVID-19|The subjects who had confirmed COVID-19 infection aged between 18-30/years
16273142|NCT04864132||Subjects never had COVID-19|"The subjects aged between 18-30/years who have not been diagnosed with COVID-19 as of March 11of 2020 and who have not been in contact and risky according to the Life Fits Into Home application"
16273143|NCT04864106|Experimental|Study Group|Participants will undergo a endoscopic airway assessment in addition to the airway classification using the Mallampati score.
16273144|NCT04864080|Active Comparator|Healthy Comparison Group|Behavioral tasks and surveys online.
16273145|NCT04864080|Experimental|Pain/Depression patients from clinic|MRI, TMS and EEG, and behavioral tasks and surveys online.
16273146|NCT04864067|Experimental|Short Course Radiotherapy and Consolidation Chemotherapy|This arm will receive short course radiotherapy (5x5 Gy) during 1 week. Between 7 to 14 days after radiotherapy, patient will receive 9 cycles of FOLFOX. CapeOX may be given as alternative for FOLFOX.
16273147|NCT04864054|Experimental|ECT204|A minimum of twelve (12) subjects will be treated to determine the RP2D.
16273148|NCT04864041||Patients hospitalised in ICU for vaso-occlusive crisis|
16273149|NCT04864028|Experimental|Healthy volunteer|
16273150|NCT04864015|Placebo Comparator|Conventional mouthpiece|Patients undergoing standard EGD using a conventional mouthpiece
16273151|NCT04864015|Active Comparator|Droplet reduction mouthpiece|Patients undergoing standard EGD using a new droplet reduction mouthpiece
16273152|NCT04863989|Experimental|Small sized chest tube|Insertion of small sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
16273153|NCT04863989|Active Comparator|Large sized chest tube|insertion of large sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
16273154|NCT04863976|Experimental|Dynamic stretching|
16273155|NCT04863976|Active Comparator|Passive stretching|
16273156|NCT04863976|Active Comparator|Self-stretching|
16273157|NCT04863963||Milligan Morgan|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Milligan-Morgan hemorrhoidectomy surgery.
16273158|NCT04863963||Dearterialization with mucopexy|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Doppler-guided or non-Doppler guided HAL surgery associated with mucopexy
16273160|NCT04863937|Experimental|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
16273161|NCT04863924||Advanced NSCLC|Patients with radiologic evidence of advanced (unresectable stage III or IV) non-small cell lung cancer
16273162|NCT04863898|Other|Pre-post with HIV care and treatment clinic staff|Pre-post with HIV care and treatment clinic staff
16273163|NCT04863885|Experimental|Phase 1 Dose Level 1|Participants will be treated at dose level 1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 8 mg/kg IV will be administered days 1 and 8 every 3 weeks.
16273164|NCT04863885|Experimental|Phase 1 Dose Level 2|Participants will be treated at dose level 2: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 10 mg/kg IV will be administered days 1 and 8 every 3 weeks.
16273165|NCT04863885|Experimental|Phase 1 Dose Level -1|If dose reduction is indicated, participants will be treated at dose level -1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 6 mg/kg IV will be administered days 1 and 8 every 3 weeks
16273166|NCT04863885|Experimental|Phase 2: Treatment at Maximum Tolerated Dose (MTD)|Participants will be treated at with Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks plus the maximum tolerated dose of Sacituzumab Govitecan.
16273167|NCT04863872|Active Comparator|Proactive Care Management|
16273168|NCT04863872|Experimental|Proactive Care Management + my hypo compass education program|
16304463|NCT04644536||HA paste in Spine|Spinal cage filling
16273175|NCT04863846||Clinical standard (first study phase)|Current clinical standard, non-algorithm-based decision-making (prior to implementation of the algorithm)
16273176|NCT04863846||Algorithm-based allocation (second study phase)|New algorithm-based allocation to an intubation technique (after implementation of the algorithm)
16273177|NCT04863807||Thoracic epidural for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare National Health Service (NHS) Trust 'Invasive rib fracture management pathway'
16273178|NCT04863807||Erector Spinae block for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
16273179|NCT04863807||Serratus Anterior block for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
16273180|NCT04863794|Experimental|RO7248824|In Part 1 of the study RO7248824 and [89Zr]-labeled RO7248824 will be administered as a single bolus IT injection following a standard IT Administration procedure. In Part 2 of the study, it is planned to test up to 3 additional IT procedures. This part is tentative with regard to its conduct and the number of procedures that may be tested.
16273181|NCT04863781|Experimental|Intervention|All 11 modules will include the following elements: introduction to the topic; two types of assessments (1) adherence to at-home relaxation training practice (following week 2) and (2) 3-5 topic-specific questions to tailor video-based content; a cognitive component; a relaxation component; and a wrap up that includes a brief assessment of module comprehension. Each user will view 5-7 videos per module. Videos will be tailored to user and will last between 2 and 4 minutes. Total time per module will be 20 to 30 minutes. Between modules, users will receive (based on their timing preferences) supportive texts intended to motivate continued engagement or to affirm the life experiences of African American women
16273182|NCT04863781|Active Comparator|Control|Two mobile courses: Introduction to Stress Management and Techniques for Coping with Stress. Users will be informed that the courses will be completed on their phone, that they are video-based, and that they should spend between 20 and 30 minutes each week, for the next 11 weeks, learning the material. The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
16273183|NCT04863755|Other|DASH diet only|Patients receive a DASH diet and orientation to maintain their physical activity
16273184|NCT04863755|Other|DASH diet with pedometer|Patients receive a DASH diet and orientation to increase their physical activity with a pedometer steps count
16273185|NCT04863742|Experimental|Dextenza Arm|
16273186|NCT04863742|Active Comparator|Prednisolone Acetate 1%|
16273187|NCT04863729|Experimental|Intervention|The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
16273188|NCT04863729|No Intervention|Control|Girls and their female caregivers randomized to the control group will receive 4 retention incentives that are mailed to them monthly. These incentives will each be <$10 per dyad, examples include: water bottles, lanyards, pencil cases and tote bags. The control condition was selected by community members and allows for minimal contamination and/or overlap between the AB curriculum and control group
16273189|NCT04863716|Active Comparator|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered to this group.
16273190|NCT04863716|Active Comparator|Control Group|No regional anesthesia technique will be applied to the control group.
16273191|NCT04863703||One group with HBV/HDV coinfection|Measurement of HVPG before antiviral treatment of HBV/HDV coinfection and one year after treatment initiation with Bulevirtide. Administration of Bulevirtide and HVPG measurement is independent from this study.
16273192|NCT04863690|Experimental|Sleep Intervention System - No Coaching|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations), as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks.
16273193|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will also work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
16273194|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching plus Human Coaching|The procedure will be identical to Group 2 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
16273238|NCT04863469|Sham Comparator|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on spin bike] and a computerized low-load task for 60 minutes, 3 times per week, for 6 weeks
16273239|NCT04863456|Experimental|HIPA group of Puget grade 1|the tumor abuting or displacing the hypothalamus in the preoperative MR images
16273195|NCT04863690|No Intervention|Control|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery), plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and (depending on group), sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
16273196|NCT04863677|Experimental|High Intensity Interval Training(HIIT)|The HIIT sessions include brief, intermittent bouts of high-intensity exercise interspersed with periods of low-intensity exercise (active recovery).HIIT include 20 intervals of high-intensity (30-60s at rating of perceived exertion (RPE; Borg scale of 6-20) of 15 to 17) and low-intensity (1min at RPE <10 or totally rest). The whole exercise cycle takes around 40-50 minutes.
16273197|NCT04863677|Experimental|Moderate Intensity Continuous Training(MICT)|Patients perform 40-50 minutes at a RPE of 12 to 14(a total of 4 groups, each group 5-8 min, interspersed with 2-minute rest)
16273198|NCT04863677|No Intervention|Control Group|No additional rehabilitation treatment or physical exercise was added in Control Group.
16273200|NCT04863651||Securely Attached Parturients|Parturients who have a secure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
16273201|NCT04863651||Insecurely Attached Parturients|Parturients who have an insecure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
16273202|NCT04863638|Experimental|A1 aged ≥ 71|300 subjects age ≥ 71 （A1）receive 3 doses of vaccine
16273203|NCT04863638|Experimental|A2 aged ≥ 71|200 subjects age ≥ 71 （A2）receive 3 doses of vaccine
16273204|NCT04863638|Experimental|A3 aged ≥ 71|200 subjects age ≥ 71 (A3) receive 3 doses of vaccine
16273205|NCT04863638|Experimental|B1 aged 60-70|300 subjects age 60-70 (B1) receive 3 doses of vaccine
16273206|NCT04863638|Experimental|B2 aged 60-70|200 subjects age 60-70 (B2) receive 3 doses of vaccine
16273207|NCT04863638|Experimental|B3 aged 60-70|200 subjects age 60-70 (B3) receive 3 doses of vaccine
16273208|NCT04863638|Experimental|C1 aged 18-59|300 subjects age 18-59 (C1) receive 3 doses of vaccine
16273209|NCT04863638|Experimental|C2 aged 18-59|200 subjects age 18-59 (C2) receive 3 doses of vaccine
16273210|NCT04863638|Experimental|C3 aged 18-59|200 subjects age 18-59 (C3) receive 3 doses of vaccine
16273211|NCT04863638|Experimental|C4 aged 18-59|300 subjects age 18-59 (C4) receive 2 doses of vaccine
16273212|NCT04863638|Experimental|D1 aged 9-17|300 subjects age 9-17 (D1) receive 3 doses of vaccine
16273213|NCT04863638|Experimental|D2 aged 9-17|200 subjects age 9-17 (D2) receive 3 doses of vaccine
16273214|NCT04863638|Experimental|D3 aged 9-17|200 subjects age 9-17 （D3）receive 3 doses of vaccine
16273215|NCT04863638|Experimental|D4 aged 9-17|300 subjects age 9-17 （D4）receive 2 doses of vaccine
16273216|NCT04863638|Experimental|E1 aged 3-8|300 subjects age 3-8 （E1） receive 3 doses of vaccine
16273217|NCT04863638|Experimental|E2 aged 3-8|200 subjects age 3-8 （E2）receive 3 doses of vaccine
16273218|NCT04863638|Experimental|E3 aged 3-8|200 subjects age 3-8 （E3）receive 3 doses of vaccine
16273219|NCT04863638|Experimental|E4 aged 3-8|300 subjects age 3-8 （E4）receive 2 doses of vaccine
16273220|NCT04863625|Experimental|Experimental group|748 students from two secondary schools for the intervention group will be selected and participated in a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).
16273221|NCT04863625|No Intervention|Control group|748 students from two secondary schools for the control group will selected and receive t their school's regular curriculum.
16273222|NCT04863599|Other|OMS procedure under general anesthesia or sedation|Questionnaire
16273223|NCT04863586||Tested positive for SARS-CoV-2|Eligible participants who have had a positive SARS-CoV-2 test will be included in the case group of the study.
16273224|NCT04863586||Not tested for SARS-CoV-2|A random sample of age, sex, and DMT matched people with MS who have not been tested for SARS-CoV-2 will be included in the control group of the study.
16273225|NCT04863560||Hoehn & Yahr stage I (H&YI)|- 20 Hoehn & Yahr stage I (early disease, minimal symptoms)
16273226|NCT04863560||Hoehn & Yahr stage II (H&YII)|- 30 Hoehn & Yahr stage II (mild disease, no balance issues)
16273227|NCT04863560||Hoehn & Yahr stage III (H&YIII)|- 30 Hoehn & Yahr stage III (moderate disease, balance issues)
16273228|NCT04863547||Exposed|Patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1
16273229|NCT04863547||Non exposed|Patients hospitalized for COVID-19 to SARS-CoV-2 corresponding to wild type 20A variants. EU1 or 20A. EU2
16273230|NCT04863521|Experimental|MHP Users|A subset of the population within the clinical setting will be requested to participate in this pilot while the rest of the population will receive standard of care.
16273231|NCT04863508||Low-risk hypertensive patients|Patients without diabetes, chronic kidney disease, hypertension-mediated organ damage, or established cardiovascular diseases
16273232|NCT04863508||With-risk hypertensive patients|Patients with diabetes, chronic kidney disease, hypertension-mediated organ damage, but without established cardiovascular diseases
16273233|NCT04863508||Hypertensive patients with cardiovascular diseases|Patients with established cardiovascular diseases
16273234|NCT04863482|Active Comparator|Critical view of Safety (CVS-WL)|Group CVS-WL (control group): the visualization of the biliary tree is achieved in white light, without the utilization of an intraoperative imaging technique, the CVS in white light was selected as the control group since it constitutes the actual recognized standard in clinical practice.
16273235|NCT04863482|Experimental|Intra-operative Cholangiography (IOC)|Group IOC: the visualization of the biliary tree is achieved with the help of intraoperative cholangiography
16273236|NCT04863482|Experimental|Near-Infra Red Cholangiography (NIR-C)|Group NIR-C: the visualization of the biliary tree is achieved with the help of near-infrared fluorescence cholangiography
16273237|NCT04863469|Experimental|B-POC high load Intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on spin bike] and a computerized high-load task for 60 minutes, 3 times per week, for 6 weeks
16273240|NCT04863456|Experimental|HIPA group of Puget grade 2|hypothalamic involvement (the hypothalamus is no longer identifiable) in the preoperative MR images
16273241|NCT04863430|Experimental|Apatinib with chemotherapy|Apatinib with oxaliplatin and S-1 treatment
16273242|NCT04863417|Experimental|Cohort 1 (2000 cm2 Body Surface Area)|
16273243|NCT04863417|Experimental|Cohort 2 (4000 cm2 Body Surface Area)|
16273244|NCT04863404|Experimental|Bone-anchored maxillary protraction group|Face mask with hybrid-hyrax
16273245|NCT04863404|Experimental|Tooth-borne maxillary protraction group|Face mask with conventional bonded RME
16273246|NCT04863404|No Intervention|Control group|Control group consisting of 14 non-treated Class III malocclusion subjects
16273247|NCT04863391||early/none vs.|For identification of early/none (i.e., non-referral level) Age Related Macular Degeneration (ARMD)
16273248|NCT04863391||intermediate/late AMD|intermediate/late (i.e., referral level) Age Related Macular Degeneration (ARMD)
16273249|NCT04863378|Experimental|Walkers|Walkers continuously wear an actigraph watch to assess activity level. Daily sleep behavior is captured on an under-the-mattress sleep sensor. Participants walk 1-mile routes in triads, three times a week for 16 weeks while engaging in prompted conversational reminiscence recorded for a digital archive.
16273250|NCT04863365|Placebo Comparator|Placebo treatment|A matching placebo ophthalmic solution, TID
16273251|NCT04863365|Experimental|PHP-201 treatment|PHP-201 0.5% ophthalmic solution, TID
16273252|NCT04863352||Study group|Men who have been treated for localized or locally advanced prostate cancer with curative intent
16273253|NCT04863352||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019
16273254|NCT04863339|Experimental|Tranexamic Acid|Participants in the Tranexamic Acid arm will receive a dose of Tranexamic Acid.
16273255|NCT04863339|Placebo Comparator|Placebo|Patients in the placebo arm will receive a saline placebo.
16273256|NCT04863326|Experimental|Making Proud Choices|This evaluation tests the effect of the MPC School Edition, the version of the MPC 5th Edition designed for implementation in school. This edition includes 9.5 hours of content implemented in 14 40-minute modules. Schools assigned to the MPC condition received MPC in a targeted class.
16273257|NCT04863326|Active Comparator|Business as usual|The control group continued with their regular programming in the targeted class, which was often a health or Reserve Officer Training Corps (ROTC) class.
16273258|NCT04863313|Experimental|Group receiving the probiotic capsules|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
16273259|NCT04863313|Placebo Comparator|Group receiving the placebo capsules|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
16273260|NCT04863300|Experimental|Intervention group|Participants in the intervention group will receive a collaborative stepped care programme provided by registered social workers and trained Peer Supporters from aged care service units - the Districts Elderly Community Centres (DECC), and mental health service units - the Integrated Community Centre on Mental Wellness (ICCMW), all are local NGOs. In the collaborative stepped care model (see attachment Table 1), older persons are matched to the intervention module that most suits their current needs. The person does not have to start at the lowest level of intervention to progress to the next level of intervention. Rather, they enter the service with the intervention level aligned to their needs, e.g., level of risks, symptom severity (measured by the Patient Health Questionnaire, PHQ-9), and intervention response. Home visits or other format of contact will be delivered by trained Peer Supporters employed by the NGOs to detect and engage hidden cases.
16273261|NCT04863287|Experimental|0.5 mg/kg of 2217LS|Single dose subcutaneous injection
16273262|NCT04863287|Experimental|1.5 mg/kg of 2217LS|Single dose subcutaneous injection
16273263|NCT04863287|Experimental|5 mg/kg of 2217LS|Single dose subcutaneous injection
16273264|NCT04863287|Experimental|10 mg/kg of 2217LS|Single dose subcutaneous injection
16273265|NCT04863287|Placebo Comparator|0.9% Sodium Chloride (NaCl)|Single dose subcutaneous injection
16273266|NCT04863274||Expanded consultation group|In an expanded consultation group is being conducted in the study group on the importance of primary prevention of cardiovascular diseases and on the reduction of cardiovascular risk by taking statins. Patients are given brochures and information materials on the risk factors for cardiovascular diseases and the possibility of their correction. Also, the patients of the study group are regularly reminded (2 times a month) with the help of SMS mailings and calls of health workers about the need to follow the doctor's recommendations for taking atorvastatin and returning to the medical institution.
16273269|NCT04863248|Experimental|trilaciclib + docetaxel|Patients will receive trilaciclib administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.
16273270|NCT04863248|Placebo Comparator|placebo + docetaxel|Patients will receive placebo administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.
16273271|NCT04863235|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week, and set a physical activity goal. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Monitoring Physical Activity Session 4: Action and Coping Planning. Session 5: Self-Efficacy (master and vicarious experiences). Session 6: Self-Efficacy (modeling experiences, verbal persuasion). Session 7: Physical Activity Enjoyment and Barriers. Session 8: Making long-term Change. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, blood pressure, cholesterol, benefits of water, benefits of vitamin D, the Infodemic).
16273334|NCT04862676|Experimental|Experimental Arm:single|Repeated treatments with hyperbaric oxygen on Days 0, +1 and +2 of high-dose therapy melphalan and autologous transplants.
16277887|NCT04831021|Experimental|Patients issued from dialysis units (clinic)|
16273272|NCT04863235|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week and set a physical activity goal. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Introduction to self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Mindfulness and Resistance. Session 6: Meeting Difficult Emotions. Session 7: Embracing the Good. Session 8: Applying Self-compassion to Physical Activity and Moving Forward.
16273273|NCT04863222|Experimental|MTA, then Biodentine|The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.
16273274|NCT04863222|Experimental|Biodentine, then MTA|Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.
16273275|NCT04863209|Experimental|Upper cervical manipulation group|The patient will be in the supine position. The cephalic hand will make contact with one side of the patient's skull, leaving the sternocleidomastoid muscle between the third and fourth fingers. The caudal hand will make global contact with the patient's skull on the opposite side. The therapist should place his torso on the patient's head, leaving the two forearms aligned with the axis of the patient's spine, as this technique is applied to the axis of the odontoid process of the ax. With neutral flexion-extension the therapist will place the rotation parameter to the opposite side (70-80 degrees) and a small contralateral inclination. Then it will search for the driving barrier with a small axial traction movement. When the driving barrier is found, the thrust should be applied in a helical direction, increasing rotation and traction. It will be applied bilaterally.
16273276|NCT04863209|Experimental|Sphenopalatine ganglion group|The patient will be supine on the bench and the therapist with gloves will sit next to the patient contralateral to the manipulated sphenopalatine ganglion (SPG). One of the therapist's hands will be placed flat in contact with the apex of the patient's head to stabilize it. The patient will be instructed to open his mouth and deviate the mandible laterally to the same side of the ganglion to be treated. The therapist will then apply pressure to the SPG with the fifth finger of your other hand in the patient's mouth, moving up along the alveolar process of the maxilla teeth to reach the pterygoid process. The therapist will keep the patient's head elevated until the lateral pterygoid muscle relaxes. Then, the pressure will be applied into the pterygopalatine fossa. The therapist will then apply gentle pressure on the SPG with the pulp of the fifth finger until tissue relaxation. He will then release the contralateral SPG in the same way.
16273277|NCT04863209|No Intervention|Control Group|The patient will lie down on the bench for 10 minutes.
16273278|NCT04863196|Experimental|Laser therapy Treatment Group|"Treatment evaluation and follow-up will be done for 15 days. The application of the laser at first will be done three times a week.
~The application will be by points with continuous or selective technique, which will depend on each patient. The device is a pen type that will be by contact or without contact with the lesion, irradiation and the dose will be according to the calculation for each patient, using power in milliwatt and fluency, where the dose will vary according to area and patient, and may vary from 0.1 to 1J / cm² as calculated.
~The laser tip will be disinfected before each use with 70% alcohol and later coated with plastic film. Patients, companion and operator will wear specific eye protection glasses and all biosafety rules will be followed during therapy."
16273279|NCT04863196|Active Comparator|Barrier Dust Treatment Group|"The evaluation and follow-up of the treatment will be done for 15 days. The principle application will be made three times a week using the protective barrier powder over the entire affected area, forming a protective barrier when adhering to the skin.
~For all patients, the injured area will be previously cleaned with 0.9% saline solution."
16273280|NCT04863183|Active Comparator|Group 1 (control-Triamcinolone acetonide)|Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).
16273281|NCT04863183|Experimental|Group 2 (experimental- CELLISTEM-OA)|CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time).
16273282|NCT04863157|Experimental|Survivor-SHIP|Parents/guardians will take part in 3 education sessions over a one month period. During the sessions, they will learn more about common sleep problems following cancer treatment and ways to understand their child's unique patterns. They will then be educated about behavioral changes they can make to improve their child's sleep.
16273283|NCT04863131|Experimental|EXG-5003|
16273284|NCT04863131|Placebo Comparator|Placebo|
16273285|NCT04863118|Experimental|Strength training protocol performed in shallow water and dry land|Parkinson Disease and healthy individuals
16273286|NCT04863118|Experimental|High-intensity training protocol performed in shallow and deep water|Parkinson Disease and healthy individuals
16273287|NCT04863105|Experimental|Conference-Abiraterone acetate tablet|Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)
16273288|NCT04863105|Experimental|test-Abiraterone acetate tablet|Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd)
16273289|NCT04863092|Experimental|Underrepresented Population|A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty
16273290|NCT04863079|Experimental|Pembrolizumab for Postoperative Adjuvant Treatment of ESCC|Participants receive pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance as postoperative adjuvant treatment of ESCC with pN+.
16273291|NCT04863066|Experimental|CAR-T-cell therapy|Four patients with plasma HIV RNA <50 copies/ml and CD4+T cell count more than 350 cells/μl receiving at least one-year antiviral treatment are injected intravenously with 1×10^5 CAR-T cells/kg body weight. If the dosage of 1×10^5 CAR-T cells/kg body weight is well tolerated, 5×10^5 CAR-T cells/kg body weight will be infused for another 4 subjects who meet the inclusion and exclusion criteria.
16273292|NCT04863053||Stable CHD patient|Patients aged ≥ 18 years who have a history of stable coronary heart disease (CHD) receiving long-term mono-antiplatelet therapy with aspirin (80 mg once daily)
16273360|NCT04862442|Experimental|Group 1=Video-conference based Qigong exercises|After initial result evaluation, participants of Group A will perform Qigong exercises for 40 to 45 minutes per session for 3 days a week for 6 weeks via the online video conference method.
16273293|NCT04863040|No Intervention|Usual classroom teaching methodology|Students in the CG will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT materials once the interventions are completed.
16273294|NCT04863040|Experimental|Usual classroom teaching methodology + MOVI-HIIT intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of one school year and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
16273295|NCT04863014|Experimental|evinacumab|Randomized 1:1
16273296|NCT04863014|Placebo Comparator|Placebo|Randomized 1:1
16273297|NCT04862975||Drug of Interest|Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
16273298|NCT04862962||Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®)|Rosuvastatin /Ezetimibe fixed dose (TREZETE®) Pharmaceutical Form: Tablets Dosage: 10 mg / 10 mg or 20 mg / 10 mg Administration way: Oral
16273299|NCT04862949||Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
16273300|NCT04862923||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
16273301|NCT04862910|Experimental|Kinect Based Virtual Reality Training|Kinect-Based Virtual Reality Training. Routine Medication and routine diet will be continued.
16273302|NCT04862910|Other|Control Group|Moderate-level regular physical activity with a routine diet and routine Medication
16273304|NCT04862884|Experimental|HRS4800 tablets|
16273305|NCT04862884|Placebo Comparator|placebo|
16273306|NCT04862871|No Intervention|Healthy Controls|A cohort (n=10) of participants will be recruited who do not have any neurological conditions and are age and sex-matched to participants in Arms 2 and 3.
16273307|NCT04862871|No Intervention|Chronic Widespread Pain|A cohort (n=10) of participants who have not yet begun the exercise program and are currently on the waitlist for the exercise program at the PPRC
16273308|NCT04862871|Active Comparator|Chronic Widespread Pain - Exercise|A cohort (n=10) of participants who have completed the exercise program at the PPRC. These individuals will be evaluated the day of their last treatment visit
16273309|NCT04862858|Active Comparator|Intervention|The educational outreach intervention will entail a multi-faced strategy to provide patients resources to learn more about reducing their risk for heart disease and supporting providers in the care of their patients by sharing recent guideline-recommended treatments for these high-risk individuals.
16273310|NCT04862858|No Intervention|Control|Patients and primary care providers randomly selected and assigned to the control arm will not receive any of the educational outreach communications.
16273311|NCT04862845|Active Comparator|Patients in group I (PD group)|
16273312|NCT04862845|Active Comparator|patients in group II (P group)|
16273313|NCT04862845|Sham Comparator|patients in group III (C groups)|
16273314|NCT04862832|Experimental|CPT - LLM - MLM|On day 1: CPT On day 2: LLM On day 3: MLM
16273315|NCT04862832|Experimental|CPT - MLM - LLM|On day 1: CPT On day 2: MLM On day 3: LLM
16273316|NCT04862819|Active Comparator|scaling root planning|patients in this group will have a scaling root planing procedure only
16273317|NCT04862819|Experimental|scaling root planning with new local drug delivery|patients in this group will have a scaling root planing procedure and a drug administered
16273318|NCT04862806|Experimental|Israel CLL study group|BNT162b2 mRNA vaccine
16273319|NCT04862793|Experimental|Feedback|Feedback system through CoPS and CoRS
16273320|NCT04862793|No Intervention|Standard procedure|Performing the standard procedure in accordance with the departments usual conduct.
16273321|NCT04862780|Experimental|BLU-945|"Dose Escalation: Multiple doses for BLU-945 for oral administration
~Dose Expansion: Oral dose of BLU-945 as determined during Dose Escalation"
16273322|NCT04862767|Experimental|TASO-001|level 1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)(3+3) next than level 2 or level -1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)
16273323|NCT04862754|Experimental|interval training|Aerobic interval training. It consisted of a modified interval cycle ergometer training program (3 days a week for 8 weeks). AIT consisted of 8 min warm up, followed by four times of 4-min intervals with HR at 80% of submaximal predetermined HR, with active phases of 3 min of cycling at 60% of submaximal predetermined HR. The exercise session was terminated by 5 min cool down
16273324|NCT04862754|No Intervention|medical treatment|hypertensive medication
16273325|NCT04862741|Experimental|NX-13 250mg IR|Oral
16273326|NCT04862741|Experimental|NX-13 500mg IR|Oral
16273327|NCT04862741|Experimental|NX-13 500mg MR|Oral
16273328|NCT04862741|Placebo Comparator|Placebo|Oral
16273329|NCT04862715|Active Comparator|Treatment|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.
~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
16273330|NCT04862715|Placebo Comparator|Placebo|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
16273331|NCT04862702|Active Comparator|ProTaper Next rotary file system (Dentsply Sirona)|
16273332|NCT04862702|Experimental|TruNatomy rotary system (Dentsply Sirona)|
16273333|NCT04862689|Experimental|Experimental|Adult subjects clinically indicated for non-emergent percutaneous coronary intervention (PCI) as a stand-alone procedure or following non-emergent diagnostic angiography performed during the same procedure that, in the physician's estimation, requires prolonged balloon inflation with distal perfusion.
16273335|NCT04862663|Experimental|Capivasertib Plus Palbociclib and Fulvestrant|"Drug: Capivasertib:
~Phase Ib: potential range 200 mg, 320 mg, 400 mg, all BD, 4days on/3 days off per week for 4 weeks (28 days cycle) Phase III: 400 mg BD, 4days on/3 days off per week for 4 weeks, depending on tolerability observed in Phase Ib.
~Drug: Palbociclib:
~Phase Ib: potential range 75, 100 or 125 mg (OD, dosed continually for 21 days out of 28 days).
~Phase III: 125 mg PO, OD, dosed continually for 21 days out of 28 days.
~Drug: Fulvestrant:
~Both phases: 500 mg IM, monthly (Day 1 of a 28-day cycle) with a loading dose of 500 mg 2 weeks after the first dose."
16273336|NCT04862663|Placebo Comparator|Placebo Plus Palbociclib and Fulvestrant|Phase Ib: Not applicable. Phase III: 400 mg (BD 4 days on 3 days off/week for 4 weeks), depending on tolerability observed in Phase Ib
16273337|NCT04862650|Experimental|Treatment (cemiplimab, paclitaxel, carboplatin)|Patients receive cemiplimab IV over 30 minutes every 3 weeks (Q3W) for up to 104 weeks, and paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes once weekly (QW) for up to 24 weeks. Treatment continuous in the absence of disease progression or unacceptable toxicity.
16273338|NCT04862637|Experimental|pull through group|the patients receiving the pull though method during the tongue cancer surgery
16273339|NCT04862637|Placebo Comparator|mandibular-lip split group|the patients receiving the traditional mandibular lip split method during the tongue cancer surgery
16273340|NCT04862624|Experimental|Story-based media|Participants will receive a link to our story-based media with Latina characters.
16273341|NCT04862624|Active Comparator|Attention control media|Participants will receive a link to non-story based media that is informational and does not involve story characters.
16273342|NCT04862598|No Intervention|Control|The patient will be positioned on the operating table and have routine monitoring attached (ECG, blood pressure, O2 saturations, end tidal carbon dioxide monitoring (ETCO2). A surgical safety time out will be performed. The patient will receive routine operative and nursing care. The study team member will record highest and lowest heart rate and blood pressure as well as lowest O2 saturation and the total intra-operative dose of fentanyl and midazolam administered to the patient. At the end of the procedure, the patient is assisted into a wheelchair and will return to the recovery area. After 15 minutes of recovery, a member of the study team will give them the post-operative questionnaires which will consist of answering how anxious they felt during the procedure and the 11 question Iowa Satisfaction with Anesthesia scale (ISAS). The patient will then be free to leave once they have met the standard discharge criteria.
16273343|NCT04862598|Experimental|VR Group|The patient wears the VR headset after being positioned on the table and the surgical time out has been completed. The VR scene and accompanying music will continue until the end of the procedure or until the patient wishes for it to be removed. The patient will receive standard operative and nursing care. The study team member will record the intra-operative vitals as detailed in the control group procedure. At the end of the procedure, the patient will be moved to recovery and will receive standard care. At 15 minutes, they will be provided with the anxiety questionnaire and the ISAS. Additional questions will be asked; their level of VR immersion and if they would like to receive the VR technology again if they were to undergo another procedure in the future. They will then be free to leave once they have met the standard discharge criteria.
16273346|NCT04862572|Experimental|People with tinnitus|People with tinnitus will undergo all interventions (audiology test, MRI scans, tinnitus-related questionnaires).
16273347|NCT04862572|Experimental|People without tinnitus|People with tinnitus will undergo most of all interventions (audiology test, MRI scans) except filling up the tinnitus-related questionnaires.
16273348|NCT04862559|Experimental|NovaCross|Subjects in this arm are treated with the investigational device, NovaCross micro-cetheter, to facilitate the opening of a chronic total occlusion (CTO)
16273349|NCT04862546|Experimental|Laser Acupoint|Laser will be performed 3 times per week for 2-week measurement. The duration of each cession will be 10 minutes treatment.
16273350|NCT04862546|Active Comparator|Tap water iontophoresis|Tap water iontophoresis will be performed 3 times per week for 2-weeks. The duration of each cession will be 20 minutes treatment session.
16273351|NCT04862533|Experimental|Beta-alanine + PFMT|Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
16273352|NCT04862533|Experimental|Placebo + PFMT|Participants will ingest a placebo supplement containing no beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
16273353|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging undergoing thrombectomy|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.
16273354|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging not undergoing thrombectomy|acute stroke patients treated with or without thrombolysis
16273355|NCT04862494||diaphragmatic eventation with medical surveillance|Patients with a diagnosis of diaphragmatic eventration without respiratory or digestive consequences, thus not requiring surgical repair.
16273356|NCT04862494||diaphragmatic eventration treated with plication|Patients with a diagnosis of diaphragmatic eventration with respiratory or digestive repercussion, requiring surgical repair.
16273357|NCT04862468|Experimental|Treatment|
16273358|NCT04862468|Sham Comparator|Control|
16273359|NCT04862455|Experimental|Treatment (NBTXR3, RT, pembrolizumab)|Patients receive hafnium oxide-containing nanoparticles NBTXR3 via injection intratumorally or intranodally on day 1. Beginning as early as day 3 and within 8 days of NBTXR3 injection, patients undergo SBRT QOD or hypofractionated RT QD over 1-2 weeks at the discretion of the treating radiation oncologist. Starting on the same day as radiation therapy, patients also receive pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16273597|NCT04860661|Placebo Comparator|N group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline
16273361|NCT04862442|Experimental|Group 2=A-synchronized video Qigong exercises|"Group B will perform the same routine via a-synchronized video sections for 6 weeks.
~Basic Qigong exercises will be performed by volunteers for 6 weeks and progression will be logged."
16273364|NCT04862416|Experimental|1A 30μg R0.6C Alhydrogel|3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
16273365|NCT04862416|Experimental|1B 30μg R0.6C Alhydrogel + Matrix M1|3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
16273366|NCT04862416|Experimental|2A 30μg R0.6C Alhydrogel|5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
16273367|NCT04862416|Experimental|2B 30μg R0.6C Alhydrogel + Matrix M1|5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
16273368|NCT04862416|Experimental|3A 100μg R0.6C Alhydrogel|3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
16273369|NCT04862416|Experimental|3B 100μg R0.6C Alhydrogel + Matrix M1|3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
16273370|NCT04862416|Experimental|4A 100μg R0.6C Alhydrogel|5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
16273371|NCT04862416|Experimental|4B 100μg R0.6C Alhydrogel + Matrix M1|5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
16273372|NCT04862403|Experimental|Intervention group I|In intervention group I - clamped at a distance of 2 cm - umbilical cord was measured 2 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 2 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group I.
16273373|NCT04862403|Experimental|Intervention group II|In intervention group II - clamped at a distance of 3 cm - umbilical cord was measured 3 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 3 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group II.
16273374|NCT04862403|No Intervention|Control group|Control group - clamped without measuring - no intervention was made in defining the distance at which the umbilical cord of the newborn would be clamped. Another healthcare workers measured the distance at which the umbilical cord had been clamped. The same researcher used a standard measuring tape to measure the distance between the umbilical cord to the clamping point.
16273375|NCT04862390||Normal Pregnancy|Pregnant women with no diabetes
16273376|NCT04862390||Gestational diabetes on diet alone|
16273377|NCT04862390||Gestational diabetes on diet + Metformin therapy|
16273378|NCT04862377|Active Comparator|Standard treatment group|"Infants randomised to the standard treatment arm will receive intratracheal surfactant as per usual clinical indications of respiratory distress syndrome in these preterm infants.
~In that sense, and based in those clinical indications, we have developed a risk calculator for surfactant administration in preterm infants ≤32 weeks GA. We will use it to decide what patients will receive surfactant (calculator available on: https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP)."
16273379|NCT04862377|Experimental|Interventional treatment group|"Infants randomised to the interventional treatment arm will receive intratracheal surfactant mixed with budesonide. Indication of surfactant, as equal as for the standard treatment arm, will be decided using the calculator."
16273380|NCT04862377|No Intervention|Control group|Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.
16273381|NCT04862351|Experimental|TecHCR|12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log
16273382|NCT04862351|Other|Centre-based|12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log
16273383|NCT04862338|Experimental|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
16273384|NCT04862325|No Intervention|Usual care|"Control group will follow the standard preoperative measures Enhanced Recovery After Surgery (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them."
16273385|NCT04862325|Experimental|Multimodal prehabilitation|Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program
16273386|NCT04862312|Experimental|VideoDine|Use of video chat to eat a meal with a dining partner.
16273387|NCT04862286|Experimental|Risankizumab|Participants will receive risankizumab subcutaneous (SC) injection every 12 weeks for 204 weeks.
16273388|NCT04862273||Native T1 CMR|Diagnostic accuracy of native T1 CMR and ATTR probability estimator are tested against the reference methods (99mTc-DPD scintigraphy, laboratory screening for multiple myeloma / AL amyloidosis; or cardiac biopsy, if noninvasive evaluation is inconclusive)
16273389|NCT04862260|Experimental|Multipathway cholesterol metabolism disruption|Twelve to fifteen patients will receive a combination of daily atorvastatin 40 mg, twice daily ezetimibe 10 mg and evolocumab 420 mg subcutaneously every month. This multipathway cholesterol metabolism disruption will be combined to standard chemotherapy (FOLFIRINOX).
16273390|NCT04862247|Experimental|Imaginal Exposure Condition|Participants will complete one phone session including education about the treatment followed by four online sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
16273391|NCT04862247|Active Comparator|Writing and Thinking Condition|Participants will complete one phone session including education about the treatment followed by four online sessions of a writing and thinking intervention across a one month time period. Each session is separated by 1 week.
16273392|NCT04862234|Experimental|Dulaglutide|Dulaglutide is a fusion protein of a GLP-1 analogue and a modified IgG Fc fragment, leading to a longer acting, relatively flat insulinotropic profile with increased plasma half-life suitable for once-weekly administration.
16273393|NCT04862234|Placebo Comparator|Placebo|Saline placebo.
16273394|NCT04862221|Experimental|High-dose methylprednisolone|Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.
16273395|NCT04862221|Experimental|Equine anti-thymocyte globulin|Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.
16273396|NCT04862221|Placebo Comparator|Supportive care|Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.
16273397|NCT04862208|Experimental|Carbohydrate-based breakfast + exercise|maltodextrin
16273398|NCT04862208|Experimental|Protein-based breakfast + exercise|whey
16273399|NCT04862208|Experimental|Fasted breakfast + exercise|water
16273400|NCT04862208|Sham Comparator|Carbohydrate-based breakfast + no exercise|maltodextrin
16273403|NCT04862169|Placebo Comparator|Control group|"In the control group, they will only receive electronic version of the modules. They are able to access the module on their own devices.
~The observation arm will receive the link of eLOK at the end of data collection and follow-ups (week 14). With this link, then they are able to access modules, videos and case studies provide in SPARK."
16273404|NCT04862169|Experimental|Intervention group|The intervention on this RCT is an educational training program: SPARK (Strengthening PAlliative caRe in the community by enhancing nurses' Knowledge). This is an educational intervention using an online method with learning method system (LMS) eLOK hosted by Universitas Gadjah Mada Yogyakarta (Affiliation of authors' team). The intervention includes online discussions and access to eLOK for study materials (modules and videos) and some synchronous meetings.
16273406|NCT04862117|Active Comparator|Active stimulation QD|
16273407|NCT04862117|Active Comparator|Active stimulation QID|
16273408|NCT04862104|Experimental|Intervention group (Discharge Training)|In addition to the general care provided by health professionals, the study group received discharge training created according to the Nursing Interventions Classification.
16273409|NCT04862104|No Intervention|Control group (Usual Care)|The control group continued to receive the routine care
16273410|NCT04862091|Experimental|Abiraterone Acetate Tablets (I)|
16273411|NCT04862091|Active Comparator|ZYTIGA®.|
16273412|NCT04862078|Experimental|Shared decision making group|The Study arm - shared decision making when deciding surveillance strategy
16273413|NCT04862078|Other|Usual surveillance group|The control arm - surveillance with usual care
16273414|NCT04862052|Active Comparator|Xience chromium-cobalt everolimus eluting stent|The Xience chromium-cobalt everolimus eluting stent will be evaluated in prior implanted coronary drug eluting stent restenosis.
16273415|NCT04862052|Experimental|Emperor paclitaxel coated balloon|The Emperor paclitaxel coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
16273416|NCT04862052|Experimental|Magic Touch sirolimus coated balloon|The Magic Touch sirolimus coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
16273417|NCT04862039|Experimental|Virtual Reality (VR) devices|intervention group (VR).
16273418|NCT04862039|No Intervention|control group|the standard of care (control group, no VR)
16273419|NCT04862026||Telemonitoring group|The telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments.
16273420|NCT04862026||Control group|Patients with standard administration.
16273421|NCT04862000||Endometriosis or adenomyosis|participants suffering pelvic endometriosis, endometrioma, deep infiltrating endometriosis or adenomyosis
16273422|NCT04861987|Experimental|PCS6422 + Capecitabine|Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles
16273423|NCT04861974||Robotic Distal Pancreatectomy|
16273424|NCT04861974||Laparoscopic Distal Pancreatectomy|
16273425|NCT04861974||Robotic Gastrectomy|
16273426|NCT04861974||Laparoscopic Gastrectomy|
16273427|NCT04861974||Robotic Funduplication|
16273428|NCT04861974||Laparoscopic Funduplication|
16273429|NCT04861974||Robotic Hernioplasty|
16273430|NCT04861974||Laparoscopic Hernioplasty|
16273431|NCT04861974||Robotic Rectal Resection|
16273432|NCT04861974||Laparoscopic Rectal Resection|
16273433|NCT04861961|Active Comparator|Laparoscopic duodenal switch (DS)|Standard duodenal switch (double anastomoses). Roux-en-Y reconstruction.
16273434|NCT04861961|Active Comparator|Laparoscopic Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S)|"Simplified duodenal switch with one anastomosis. Duodeno-ileal omega reconstruction (Billroth II-like)."
16273435|NCT04861961|Active Comparator|Laparoscopic one anastomosis gastric bypass (OAGBP)|Gastric bypass of one anastomoses. Gastro-jejunal omega reconstruction (Billroth II).
16273436|NCT04861948|Experimental|Cohort A|
16273437|NCT04861948|Experimental|Cohort B|
16273438|NCT04861948|Experimental|Cohort C|
16273439|NCT04861948|Experimental|Cohort D|
16273440|NCT04861935|Placebo Comparator|ultrasound evaluation of sacral region in normal pediatric patients|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.
~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
16277960|NCT04830566|Experimental|Myofascial release technique group|
16273441|NCT04861935|Active Comparator|ultrasound evaluation of sacral region in patients with sacral dimple|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.
~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
16273442|NCT04861922|Experimental|Unfractionated Heparin|A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.
16273443|NCT04861922|Placebo Comparator|Normal saline|The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.
16273444|NCT04861909||AT LISA tri 839MP|Patients implanted with AT LISA tri 839MP
16273445|NCT04861896|Experimental|"My Guide (psychoeducation & self management program)"|Smartphone-based program plus standard clinical care.
16273446|NCT04861883||76 healthy the Middle and Third Trimester pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
16273447|NCT04861883||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
16273450|NCT04861857|Experimental|Parmigiano Reggiano|participants will consume 50 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
16273451|NCT04861857|Active Comparator|Whey Protein|participants will consume 20 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
16273452|NCT04861844|Experimental|Mindfulness training|
16273453|NCT04861844|Active Comparator|Active listening|
16273454|NCT04861831|Experimental|Immediate PCS Intervention|After the pre-intervention clinical assessments, immediate (within one week) begin with the PCS exercise program (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required). Post-intervention clinical assessments within one week after the last intervention class, followed by a 12-week follow-up period (continuation of exercise program at home recommended but not required). Final clinical assessments within one week after the 12-week follow-up period.
16273455|NCT04861831|Experimental|Delayed PCS Intervention|During the 12 weeks that the Immediate Intervention (II) group participates in the PCS intervention, the Delayed Intervention (DI) group waits (there is no control intervention) and serves as a control arm comparison for the II group during this time. After the 12 weeks, the DI group will undergo a second pre-intervention assessment to document any change in baseline measures that may have occurred in those 12 weeks. No significant changes are expected. The DI group then begins the same exercise intervention (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required) that the II group underwent, given by the same instructors. Post-intervention clinical assessments, 12-week follow-up period, and final clinical assessments after the follow-up period as described for the II group. After the trial, pooled data from both groups will provide results on the overall changes in outcome measures post- versus pre-intervention.
16273456|NCT04861818|Experimental|Morning group|Participant are assigned to the morning group (7-9am) for 30-min exercise/rest interventions.
16273457|NCT04861818|Experimental|Afternoon group|Participant are assigned to the afternoon group (3-5pm) for 30-min exercise/rest interventions.
16273458|NCT04861805|Other|Vienna Aortic Valve|transcatheter aortic valve implantation (TAVI)
16273459|NCT04861792|No Intervention|Usual Care|Patients seen before the randomly assigned intervention launch date.
16273460|NCT04861792|Experimental|Quality Improvement Intervention|Patients seen after the randomly assigned intervention launch date.
16273461|NCT04861792|Experimental|Quality Improvement Intervention Plus Decision Aid|Patients at 50% of practices (nested within waves) that are randomized to receive the patient decision aid for AUD in addition to the Michigan SPARC intervention.
16273462|NCT04861779|Experimental|Phase 1a Dose Escalation|Multiple dose levels of HSK29116 to be evaluated; determination of MTD/Phase 1b recommended dose
16273463|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R CLL or SLL|CLL/SLL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
16273464|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R MCL|MCL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
16273465|NCT04861779|Experimental|Phase 1b Dose Expansion in other R/R B-cell Malignancy|Patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
16273466|NCT04861766|Experimental|Treatment group Stylage L ®|"Each subject will receive STYLAGE® L in both NLFs.
~STYLAGE® L will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
16273467|NCT04861766|Active Comparator|Control group Active Comparator|"Each subject will receive the Active Comparator in both NLFs.
~Active Comparator will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
16273468|NCT04861753||Reiki|"The modern-day Reiki (pronounced ray-kee) practiced in the United States originated in Japan with Mikao Usui in the early 1900s. Reiki is a complementary and adjuvant therapeutic technique. Reiki, which is classified as an energy healing therapy, is a technique of channeling universal energy in order to reduce stress, promote relaxation, and enhance well-being."
16273469|NCT04861753||Back massage|Massage therapy involves the manipulation of the soft tissues of the body by touch. It consists of gentle movements such as effleurage, petrissage and percussion.
16273470|NCT04861753||Control|Routine postoperative care was given to the control group without any intervention
16273471|NCT04861740|Experimental|Screening + Autism ALERT|Clinics in the intervention arm receive Autism ALERT plus an ASD screening intervention (START Autism).
16273472|NCT04861740|Active Comparator|Screening Only|Clinics in the comparison intervention (control) arm receive the ASD screening intervention only (START Autism).
16273473|NCT04861727|No Intervention|Group control|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment
16273474|NCT04861727|Active Comparator|Intervention group|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
16273475|NCT04861714|Active Comparator|Regeneten|Standard subscapularis repair with Regeneten augmentation group
16273476|NCT04861714|Other|Standard repair|Standard subscapularis repair
16273477|NCT04861701|Experimental|Stretching exercise group (SE)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
16273478|NCT04861701|No Intervention|Control group (CON)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
16273479|NCT04861688|Active Comparator|NeuroAiD II™ (MLC901)|Recommended treatment is 2 capsules orally, 3 times a day (i.e. 6 capsules per day). Treatment is 12 weeks.
16273480|NCT04861688|Placebo Comparator|Placebo|Capsule 2 capsules orally, 3 times a day
16273481|NCT04861675||Prospective follow up cohort study|Assessment of Changes in Oral Health-related Quality of Life , Oral Hygiene status and Body Growth in Egyptian Children with Special Health Care Needs following Dental Treatment under General Anaesthesia
16273482|NCT04861662|No Intervention|Keratinized Mucosa Sufficient (KMS)|Implants exhibiting the width of keratinized mucosa (KM) ≥2 mm at the midbuccal aspect
16273483|NCT04861662|No Intervention|Keratinized Mucosa Deficient (KMD)|Implants exhibiting KM<2 mm at the midbuccal aspect
16273484|NCT04861662|Experimental|Free Gingival Graft (FGG)|Implants with KM<2 mm initially and having surgically increased keratinized mucosa with free gingival graft after prothesis delivery
16273485|NCT04861649|Experimental|Effect and mechanism of fecal microbiota transplantation on patients with COPD malnutrition|"During COPD stable period, nasal and intestinal tubes were placed and fecal bacteria were transplanted from healthy people (three transplants per course of treatment).
~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
16273486|NCT04861636|Experimental|HealthTRAC|Both the standard behavioral weight control (SBWC) and HealthTRAC interventions include 4 months of intensive treatment, followed by monthly maintenance sessions for a 12-month program. SBWC includes attention to diet and activity coupled with behavioral modification strategies. HealthTRAC integrates these key constructs with an emotion regulation intervention with documented efficacy in teens.
16273487|NCT04861636|Active Comparator|Standard Behavioral Weight Control (SBWC)|4 months of intensive treatment focused on attention to diet and activity coupled with behavioral modification strategies, which is then followed by monthly maintenance sessions for a 12-month program.
16273488|NCT04861623|Active Comparator|Orange Juice then Placebo juice (Fanta)|Participants will be provided orange juice for 84 days in this arm. After 28 days wash-out period, participants will receive Fanta for 84 days.
16273489|NCT04861623|Active Comparator|Placebo (Fanta) then Orange juice|Participants will be provided Fanta for 84 days in this arm. After 28 days wash-out period, participants will receive Orange juice for 84 days.
16273490|NCT04861610|Experimental|Brief mindfulness based program|A four session program, each last for 2.5 hours. Brief mindfulness exercises promote stress reduction, with an introduction of mindfulness to caregivers and home practice is encouraged with guidance.
16273491|NCT04861610|Active Comparator|Psychoeducation|A four session program, each last for 2.5 hours. It promotes the coping and problem solving of caregivers. Brief home application included.
16273492|NCT04861610|No Intervention|Treatment-as-usual|
16273495|NCT04861584|Experimental|Toripalimab+Gemcitabine/Cisplantin（GC）|Subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. . Toripalimab is given every 21 days for 4 doses starting C1D1. Subjects will then have consolidative surgery to remove their primary tumor within 6 weeks after their last dose of neoadjuvant therapy.
16273496|NCT04861571|Experimental|Single arm|All subjects will receive VLCD for 8 weeks.
16273499|NCT04861519||adult subjects who underwent a clinically indicated invasive coronary angiography|adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.
16273500|NCT04861506||acute or subacute thromboembolic occlusions of lower extremity|The patients are confirmed with acute or subacute thromboembolic occlusions of lower extremity, and which are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as PMT pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
16273501|NCT04861493||Smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and smoking at least 10 cigarettes /day for a minmum of 5 years.
16273600|NCT04860648|No Intervention|Control group|patients receive no lung ultrasound examination and other intervention
16273502|NCT04861493||Non-smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and they are never smoked before.
16273503|NCT04861493||Healthy patients|patients free from periodontitis or any systemic disease and never smoked before.
16273504|NCT04861480|Experimental|C-4-29 cells|Infusion of C-4-29 cells by dose-escalating
16273505|NCT04861467|Experimental|Experimental: Camrelizumab|camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)
16273506|NCT04861467|No Intervention|observation|observation after Chemoradiation
16273507|NCT04861467|Experimental|Exploration：Camrelizumab|camrelizumab for maintenance after chemoradiation( evaluation results：CR)
16273508|NCT04861454||surgical|internal browbexy and brassier suture were done after blepharoplasty
16273509|NCT04861441|Experimental|Continuous Cryotherapy|Subjects will use continuous cryotherapy post operative for pain control
16273510|NCT04861441|Active Comparator|Icepack|Subjects will use standard icepacks post operative for pain control
16273511|NCT04861428|Experimental|IQOS / Smoking as usual|Two weeks of IQOS, followed by two weeks of cigarette smoking as usual.
16273512|NCT04861428|Active Comparator|Smoking as usual / IQOS|Two weeks of cigarette smoking as usual, followed by two weeks of IQOS.
16273513|NCT04861415|Active Comparator|Conventional Fractionated Radiation|"Prostate Only Radiation - 37.5Gy in 15 daily fractions to the prostate and proximal/entire seminal vesicle
~Prostate + Nodal Radiation - 46Gy in 23 daily fractions to the prostate, seminal vesicle and regional lymph nodes"
16273514|NCT04861415|Experimental|Stereotactic Body Radiotherapy|"Prostate Only Radiation - 25Gy in 5 fractions to the prostate and proximal/entire seminal vesicle
~Prostate + Nodal Radiation - 25Gy in 5 fractions to the prostate, seminal vesicle and regional lymph nodes"
16273515|NCT04861402||Non-intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h Non-intubated during the monitoring carried out in the study Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
16273516|NCT04861402||Intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h For intubated group time between IUC admission and study inclusion ≤ 72h Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
16273517|NCT04861402||Health control group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring No symptoms of COVID-19 on the last 15 days
~• For healthy group: No previous neurological disease No chronic disease as Diabetes Mellitus Type 2, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, hypertension or Chronic Kidney Disease (CKD) No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
16273518|NCT04861402||Non-COVID-19 and non-neurological disease intubated group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring
~• For intubated group: ICF signed by the participant or his/her legal representative* Intubated patients for others causes than COVID-19 or neurological diseases IUC admission and study inclusion ≤ 72h No symptoms of COVID-19 on the last 15 days No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
16273519|NCT04861389|Experimental|Distal transradial access (dTRA)|Distal transradial access for primary percutaneous coronary intervention in STEMI patients
16273520|NCT04861389|Active Comparator|Transradial access (TRA)|Transradial access for primary percutaneous coronary intervention in STEMI patients
16273521|NCT04861376|Experimental|Pueraria lobata group|Pueraria lobata will be made into granules.
16273522|NCT04861376|Experimental|Pueraria thomsoni group|Pueraria thomsoni will be made into granules.
16273523|NCT04861376|Placebo Comparator|Placebo group|The dosage form, specifications and packaging of the placebo will be no different from those of Pueraria lobata and Pueraria thomsoni Granules, and the smell and taste will be basically the same.
16273524|NCT04861350|Experimental|imagery training|The subjects will perform the exercises mentally for 3 sets with video.
16273525|NCT04861350|Experimental|physical training|The subjects will perform the exercise physically for 3 sets with supervision of investigator.
16273526|NCT04861350|Experimental|imagery combined with physical training|The subjects will perform the exercise mentally with video for 1 set and physically with supervision of investigator for 2 sets, 3 sets totally
16273527|NCT04861337|Experimental|Remimazolam Group|Remimazolam infusion is initiated after induction of general anesthesia at a rate of 0.25 mg/kg/h and stopped 15 minutes before the end of surgery.
16273528|NCT04861337|Placebo Comparator|Placebo Group|Placebo (0.9% saline) infusion is initiated after induction of general anesthesia at the same rate as in the remimazolam group and stopped 15 minutes before the end of surgery.
16273529|NCT04861324|No Intervention|Prenatal Care/Nutrition Education|Standard prenatal care with primary care physician with USDA-based federal guidelines
16273530|NCT04861324|Experimental|Fruit/veggie + postprandial physical activity|Nutrition education on increasing fruit and vegetable consumption and physical education on increasing postprandial physical activity for the duration from GDM diagnosis till delivery
16273531|NCT04861311|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
16273747|NCT04859608|Experimental|Therapeutic drug monitoring|Tailored dosing schedule for eculizumab based on therapeutic drug monitoring
16273532|NCT04861311|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
16273533|NCT04861298|Active Comparator|Standard of care (SOC)|This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
16273534|NCT04861298|Experimental|Quercetin|This arm will receive standard of care + oral Quercetin for two weeks
16273535|NCT04861285|Experimental|RACESTYPTINE Solution with cord|The participant will receive RACESTYPTINE Solution into the sulcus. The solution is used in combination with a non-medicated gingival retraction cord.
16273536|NCT04861285|Experimental|RACEGEL with cord|The participant will receive RACEGEL into the sulcus. The gel is used in combination with a non-medicated gingival retraction cord.
16273537|NCT04861285|Experimental|RACEGEL without cord|The participant will receive RACEGEL into the sulcus. No cord will be added.
16273538|NCT04861259|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] C5 SNP (Single Nucleotide Polymorphism) Cohort - participants with documented C5 polymorphism.
16273539|NCT04861246|Experimental|Experimental|Epidermal pigmented lesion
16273540|NCT04861233||All Participants|Participants diagnosed with constipation who have been prescribed with lubiprostone for the first time in a real-world setting will be observed prospectively and followed up for 12 months after initiation of study medication. Treatment regimen, frequency of laboratory and clinical assessments will be determined by investigator in a routine clinical practice.
16273541|NCT04861220|Experimental|Pre-habilitation group|The patients in the intervention group will be instructed to practice physical exercises at home 05 times a week until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
16273542|NCT04861220|No Intervention|Control group|Patients allocated to this group will not participate in the pre-habilitation program and will be instructed to continue their usual activities.
16273543|NCT04861207|Experimental|Cladribine|
16273544|NCT04861194|Experimental|Neurovascular-sparing 5x7.25 Gy MRgRT|MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb
16273545|NCT04861181|Experimental|Pharmacokinetics, Dosage of Niraparib|Patients received 3 cycles of Niraparib (200 mg or 300 mg/day). Each cycle lasts 28 days. Serum niraparib assays will be performed for all patients over 3 courses immediately prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
16273546|NCT04861168|Experimental|Driving pressure guided ventilation|Patients will be mechanically ventilated with driving pressure guided ventilation with VT 6-8 ml /kg of predicted body weight, and after recruitment we will return to the baseline PEEP 5 cmH2O that will be increased by 2 cmH2O until reaching the lowest possible driving pressure for every patient. Each PEEP level will be applied for 10 respiratory cycles and DP will be calculated at the last cycle.
16273547|NCT04861168|Active Comparator|Conventional protective lung strategy|Patients will be mechanically ventilated with conventional protective lung strategy with VT 6-8 ml /kg of predicted body weight, after recruitment, we will return to the baseline PEEP 5 cmH2O and will be maintained until the end of surgery.
16273548|NCT04861155|Experimental|Intervention Arm|The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.
16273549|NCT04861142||Patients adherent to the anti-osteoporotic medication|
16273550|NCT04861142||Patients non-adherent to the anti-osteoporotic medication|
16273551|NCT04861129|Experimental|Bowen therapy group|The experimental group will receive Bowen therapy according to ISBT Bowen Therapy® (Black & Murray, 2005). It may include sequences 1, 4, 2, hamstrings (movements 1-6) and sacrum sequences in the prone position, and hamstrings sequence (7-18 movements) and 3 in the supine position,. The sequences may also include Bowen movements in the scalenes, trapezius, all erector spinae, sacro-iliac joint ligaments, gluteus maximus and medius, tensor fasciae latae, and gastrocnemius. The application of Bowen sequences is varied between sessions and participants depending on the presenting functional deficit and treatment response.
16273552|NCT04861129|Sham Comparator|Sham Bowen Therapy group|The control group will receive a sham Bowen therapy with the same number of treatment session, treatment time and rest time, that received in the experimental group. However, it consists of gently placing the hands over the areas just enough to maintain contact for the desired time as required by Bowen Therapy, without applying Bowen movement, which is considered the active principle of this technique.
16273553|NCT04861116|Experimental|Intervention program for test anxiety|12 weekly ICT-delivered individual sessions.
16273554|NCT04861116|No Intervention|Control|Waiting list that will have access to the intervention program after the 6-month follow-up assessment.
16273555|NCT04861103|Experimental|Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing|Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.
16273556|NCT04861090||Participants With Hereditary Angioedema|Participants with HAE type I or type II who had initiated long-term prophylaxis (LTP) treatment with lanadelumab which was administered every two weeks (Q2W) or every four weeks (Q4W) or every six weeks (Q6W) or every eight weeks (Q8W) in accordance to Summary of Product Characteristics (SmPC), during a routine clinical setting will be followed up to 38 months.
16273598|NCT04860661|Experimental|Es group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.
16273599|NCT04860648|Experimental|LUS group|patients receive lung ultrasound examination, and doctors give the treatment according to the LUS results
16273558|NCT04861064|Experimental|Treatment Group|
16273559|NCT04861051|Other|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
16273560|NCT04861038|Experimental|aerSleep II|Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP
16273561|NCT04861025||Users Group|Patients admitted to any Hospitalization Unit belonging to Geriatrics Department
16273562|NCT04861025||Health Professionals Group|All health professionals working at some Hospitalization Unit belonging to CSAPG Institution
16273563|NCT04860999|Experimental|Somatic Dysfunction|This is the single study arm. All participants completed an osteopathic postural examination and an osteopathic manipulative treatment. Participants also completed a biomechanical assessment prior to and following the osteopathic manipulative treatment to evaluate effects of the treatment on the gait asymmetry.
16273564|NCT04860973|Experimental|Weighted blankets|Provided with weighted blanket suitable for participant's weight
16273565|NCT04860973|No Intervention|Standard linen|Use of standard hospital linen
16273566|NCT04860960|Experimental|Experimental|Intravenous administration of 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) (based on body weight) diluted with 0.5N saline over at least 6.5 hours every 2 weeks
16273567|NCT04860960|Placebo Comparator|Placebo comparator|Intravenous administration of 0.5N saline over at least 6.5 hours every 2 weeks
16273568|NCT04860960|Experimental|Open Label sub-study for Infants up to age 3|Up to 12 patients age 0 - 3 yrs in countries following EMA guidance may be enrolled in this open label sub-study. All patients will receive 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) diluted with 0.5N saline at the clinician's discretion over 6.5 hours every 2 weeks. Outcome measures are safety, clinician and caregiver impressions.
16273569|NCT04860947||MS patients|
16273570|NCT04860934|Active Comparator|Physical therapy|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks
16273571|NCT04860934|Experimental|Physical therapy + Dual Task Training Program|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the selected physical therapy program as control group three times weekly for 8 successive weeks.
16273572|NCT04860908||covid exposed|women who were exposed to covid 19 during pregnancy
16273573|NCT04860908||covid vaccinated|women who were vaccinated to covid 19 during pregnancy
16273574|NCT04860895|Other|Nasopharyngeal swabs|Nasopharyngeal swabs samples of volunteers who is referred with suspicion of Covid19.
16273575|NCT04860869||Post-COVID|32 patients with Post-COVID syndrome
16273576|NCT04860856|Experimental|Hematoma block|Fracture site injection of 20 mL of 0.5% ropivacaine with an 18-gauge needle (150 mm length).
16273577|NCT04860856|Placebo Comparator|Normal saline injection|Fracture site injection of 20ml of normal saline.
16273578|NCT04860843|Experimental|Local anesthetic TPVB + Local anesthetic PecsII block|Patients will receive a thoracic paravertebral with pecs II block, both with local anesthetic infiltrate.
16273579|NCT04860843|Sham Comparator|Local anesthetic TPVB + Sham PecsII block|Patients will receive a thoracic paravertebral with local anesthetic infiltrate and a pecs II block with saline infiltrate.
16273582|NCT04860817|Experimental|Target CD7 CAR-T cells|Three dose levels will be evaluated. The CAR-T cells will be administered with Cytoxan and fludarabine.
16273583|NCT04860804|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
16273584|NCT04860804|Active Comparator|OK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine
16273585|NCT04860791||Multiple Sclerosis patients|
16273586|NCT04860778|Experimental|BDNF Essentials|A proprietary blend of botanical extracts and isolates.
16273587|NCT04860765||TPVR|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
16273588|NCT04860739|Experimental|VACCINATION|One standard dose of COMIRNATY in adult subjects (18 years old) having received prior VAXZEVRIA vaccination.
16273589|NCT04860739|No Intervention|NO INTERVENTION|No vaccination in adult subjects (18 years old) having received prior VAXZEVRIA vaccination. If primary analysis at day 14th confirms the starting hypothesis, subjects randomized to this arm will be considered for administration of one dose of COMINARTY at day 28th according to Public Health Department of the Ministry of Health recommendations on heterologous vaccination.
16273590|NCT04860726|Experimental|GROUP A|Joint mobilization
16273591|NCT04860726|Experimental|GROUP B|Myofascial release
16273592|NCT04860726|Experimental|GROUP C|Joint Mobilization & Myofascial release
16273593|NCT04860713|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
16273594|NCT04860713|Active Comparator|Nurtec (Rimegepant) Group|Drug: 75 mg of ODT
16273595|NCT04860700|Experimental|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16273596|NCT04860674|Experimental|PD-1+ICE|PD-1 inhibitor combined with icyclophosphamide, carboplatin, etoposide chemotherapy
16273785|NCT04859387|Active Comparator|group B|traditional physical therapy
16273601|NCT04860635|Experimental|F14 (sustained release celecoxib)|Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia
16273602|NCT04860622||Pregnant women|500 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment, and are TPOAb negative. Serum thyroid function tests will be obtained on the first visit.
16273603|NCT04860609|Active Comparator|Conventional Physiotherapy|It includes the pre-physiotherapy session by conventional physiotherapy
16273604|NCT04860609|Experimental|Lumber spinal decompression|It includes the pre-physiotherapy session iby lumber spinal decompression along with conventional therapy.
16273605|NCT04860596|Experimental|collaborative health management model program|nursing education and self care program
16273606|NCT04860596|No Intervention|Routine care|Tranditional education program
16273607|NCT04860570||Open Appendectomy (OA) + Double-ring wound-edge protector (2RWEP)|Intervention group: Patients with diagnosis of acute appendicitis treated by open appendectomy using a double-ring wound-edge protector.
16273608|NCT04860570||Laparoscopic Appendectomy (LA)|Control group: Patients with diagnosis of acute appendicitis treated by laparoscopic appendectomy.
16273609|NCT04860557||problematic video game player|
16273610|NCT04860557||control subjects|
16273611|NCT04860531|Active Comparator|Group (I) Platelet Rich Plasma|The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
16273612|NCT04860531|Active Comparator|Group (II) Corticosteroids|The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .
16273613|NCT04860518|Experimental|IV IFN beta-1a|Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
16273614|NCT04860518|Active Comparator|IV Dexamethasone|Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
16273615|NCT04860505|Experimental|Doxycycline and Biktarvy|Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.
16273616|NCT04860492|Active Comparator|Renalof|Patients will be given and, advised to take Renalof tablets 325mg three times a day for 90 days
16273617|NCT04860492|Placebo Comparator|Placebo|Patients will be given and, advised to take Placebo three times a day for 90 days
16273618|NCT04860479||Infants: 28 days - 12 month|inguinal sonoanatomy
16273619|NCT04860479||small children: 13 months - 36 months|inguinal sonoanatomy
16273620|NCT04860479||preschool age: 37 months - 72 months|inguinal sonoanatomy
16273621|NCT04860479||school age: 73 months - 9 years|inguinal sonoanatomy
16273622|NCT04860479||Preadolescant: >9 years - 12 years|inguinal sonoanatomy
16273623|NCT04860479||Adolescants: >12 years - 18 years|inguinal sonoanatomy
16273624|NCT04860466|Experimental|Administration of CC-96673|CC-96673 will be administered on a once weekly (Q1W) or once every 2 weeks (Q2W) schedule
16273625|NCT04860453|Experimental|Affected participants with 5 or more discordant cancers - WES|"Affected individuals with a family history of 5 or more discordant cancers in unilateral descent with a 3-generation pedigree will receive SOC CLIA/CAP multicancer panel (DNA collected via blood draw or punch biopsy) to examine monogenic variant diagnostic yield. Eligible participants (families with no mutations and at least 2 affected and 1 non-affected family members) may move forward with WES.
~Any identified monogenic variants of interest will be sent to an industry partner with CLIA/CAP certification for validation. A 6-month follow-up visit will take place during which variants will be discussed and participants who underwent gHFI variant counting (those who were not considered a gene candidate) will have results explained. Appropriate genetic counselling, recurrence risk, and additional clinical referrals will be made as necessary"
16273626|NCT04860453|Active Comparator|SOC genetic counseling (routine clinical care)|"Affected individuals (cancer) with a family history suggestive of a known hereditary syndrome or meeting NCCN criteria for germline testing will receive SOC CLIA/CAP multicancer panel in order to examine monogenic variant diagnostic yield (retrospective data)
~This arm would also include prospective participants from the 5 or more discordant cancers group who DID have a variant identified and therefore did not move on to WES."
16273627|NCT04860440||End-Stage Renal Disease on haemodialysis|Wearing accelerometer (fitness tracker) for 7 days.
16273628|NCT04860440||Low clearance pre-dialysis patients|Wearing accelerometer (fitness tracker) for 7 days.
16273629|NCT04860427|Active Comparator|Trapezoidal condylar plate|Trapezoidal condylar plate open reduction and internal fixation of subcondylar fractures
16273630|NCT04860427|Active Comparator|two miniplates|two miniplates open reduction and internal fixation of subcondylar fractures
16273631|NCT04860414|Experimental|Major Cognitive Impairment|
16273632|NCT04860414|Experimental|Minor Cognitive Impairment|
16273633|NCT04860414|Active Comparator|No Cognitive Impairment|
16273634|NCT04860388|Active Comparator|unilateral labially impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of labially impacted maxillary canines compared with the contralateral canines that served as control teeth.
16273668|NCT04860128|Experimental|"ADIDAS Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
16273635|NCT04860388|Active Comparator|unilateral palatally impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of palatally impacted maxillary canines compared with the contralateral canines that served as control teeth.
16273636|NCT04860375|Experimental|Multidisciplinary, holistic and patient-centered care|Based on the outcome from the assessment and disease phenotype, personalized care plans will be prepared and given to the patients, including dietary program, adjusted exercise program, psychological counselling, treatment of comorbidities etc. Patients will come for planned follow-up visits, according to the protocol (total 5 visits).
16273637|NCT04860375|Active Comparator|Standard care|The control group will be recruited from the Swedish Airway Register at the end of the study. Selection will be based on propensity score matching to the intervention group.
16273638|NCT04860362|Experimental|Treatment|PEERS weekly sessions - parallel teens and parent/caregiver groups
16273639|NCT04860362|Other|Wait List Control|Offered intervention at a later date
16273640|NCT04860349|Experimental|High Intensity Interval Training|20 minutes of High Intensity Interval Training for experimental group.
16273641|NCT04860349|No Intervention|Control|No intervention for the control group.
16273642|NCT04860336||Pregnant women less than or equal to 14w0d gestation|
16273643|NCT04860323|Experimental|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 703/HPTN 081 (NCT02568215).
16273644|NCT04860310||21 years old group|
16273645|NCT04860310||28 years old group|
16273646|NCT04860310||35 years old group|
16273647|NCT04860310||42 years old group|
16273648|NCT04860310||49 years old group|
16273650|NCT04860284|Active Comparator|Intervention arm|Participants will receive 400mg of hydroxychloroquine tablets 12-hourly on day 1 and 200mg 12-hourly on day 2 to day 5 in addition to standard of care treatment for COVID-19
16273651|NCT04860284|No Intervention|Control arm|Participants will receive only standard of care treatment for COVID-19
16273652|NCT04860271|Active Comparator|Filiform Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 6 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first treatment, after the third treatment, after the sixth treatment and at 2 weeks after the sixth treatment.
16273653|NCT04860271|Active Comparator|Press Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 3 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first needle placement, after replacing the first sets of needles, after removing the third sets of needles and at 2 weeks after removing the third sets of needle.
16273654|NCT04860258|Experimental|CVnCoV Vaccine|Participants will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29.
16273655|NCT04860219|No Intervention|Control Group|None of the participants in the Control Group received lactoferrin
16273656|NCT04860219|Active Comparator|200 mg lactoferrin orally once daily Group|received 200 mg lactoferrin orally once daily
16273657|NCT04860219|Active Comparator|200 mg lactoferrin orally twice daily Group|received 200 mg lactoferrin orally twice daily
16273658|NCT04860180|Experimental|A, surgery|adrenalectomy
16273659|NCT04860180|No Intervention|B, observation|conservative follow up
16273660|NCT04860167|No Intervention|Group A|The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
16273661|NCT04860167|Active Comparator|Group B|The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
16273662|NCT04860167|Active Comparator|Group C|Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure & topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
16273663|NCT04860154|Experimental|PDT with stent|Before photodynamic therapy, candidate patients undergoing biliary biopsy and biliary duct drainage. If pathology shows a bile duct malignancy, PDT therapy will carry out until total bilirubin drops below 100 μmol/L.Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or metal stent will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
16273664|NCT04860154|No Intervention|ERCP stent|After obtaining bile duct biopsy, the candidates were placed with biliary plastic stents or metal stents directly.
16273665|NCT04860141|Experimental|Gabapentin group|The patient in this group will take gabapentin 600mg PO 2 hours prior to his or her surgery.
16273666|NCT04860141|Placebo Comparator|Placebo group|The patient in this group will take a placebo that looks like gabapentin PO 2 hours prior to his or her surgery.
16273667|NCT04860128|Experimental|"RUNKEEPER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
16273669|NCT04860128|Experimental|"SAMSUNG Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
16273670|NCT04860128|Experimental|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
16273671|NCT04860128|No Intervention|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
16273672|NCT04860115|Experimental|Block group|Patients in a Block group will be anesthetized and receive PECS II+PIFB with dexmetomidine prior to their surgery.
16273673|NCT04860115|No Intervention|Control group|Patients in a Control group will receive a standard general anesthesia the same way as patients in the interventional group but without regional anesthesia.
16273674|NCT04860102|Experimental|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
16273675|NCT04860102|No Intervention|hands off|standard of care
16273676|NCT04860089|Active Comparator|Research vouchers for high THC product|Research vouchers for high THC soft-gel capsules
16273677|NCT04860089|Active Comparator|Research vouchers for high CBD product|Research vouchers for high CBD soft-gel capsules
16273678|NCT04860063|Placebo Comparator|Placebo|Placebo three times daily for 6 months
16273679|NCT04860063|Experimental|Berberine|Berberine 500 mg three times daily for 6 months
16273680|NCT04860050|Experimental|TPG|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 24 weeks
16273681|NCT04860050|Placebo Comparator|Control|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (colored acacia gum) product during 24 weeks
16273682|NCT04860024||ADHD|"Blood sample for miRNA qRT-PCR
~Behavioral and neuropsychological assessments"
16273683|NCT04860024||Healthy|"Blood sample for miRNA qRT-PCR
~Behavioral and neuropsychological assessments"
16273684|NCT04860011|Experimental|SGLT2i|Sodium-glucose Co-transporter-2 inhibitors
16273685|NCT04860011|Experimental|Thiazide|Thiazide or thiazide like diuretic
16273686|NCT04859998|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. They will be assessed before and after the 10 week program but will not take part in it.
16273687|NCT04859998|Experimental|Experimental group|Participants in this group will take part in the 20 session dog-assisted therapy. This therapy will be added to their usual daily living and therapies. They will be assessed before and after the 10 week program.
16273688|NCT04859985|Experimental|SELUTION SLR DEB|Device: SELUTION SLR DEB. For patients randomized to the DEB strategy, all target lesions should be treated with DEB after appropriate lesion preparation, but provisional DES implantation is acceptable if the angiographic result is considered insufficient either after lesion preparation of after DEB treatment (poor flow, dissection type C or higher, residual stenosis > 30%). For bifurcation lesions, when both main and side- branch are considered to require treatment, a DEB should be used for both.
16273689|NCT04859985|Other|DES|Device: Drug Eluting Stent. For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
16273691|NCT04859959|Experimental|68Ga-Pentixafor PET/CT scan|Intravenous Inject 68Ga-Pentixafor and perform PET/CT scan 1h later.
16273692|NCT04859946|Experimental|Supportive care (itacitinib)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.
~STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib PO QD on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO BID."
16273693|NCT04859933||AVNA group|Group of historical controls beeing treated with AV-node ablation
16273694|NCT04859933||AVNI group|Inculudes all patients beeing treated with AV-node isolation
16273695|NCT04859907|Experimental|Clamp-like system|
16273696|NCT04859907|Active Comparator|Plates and screws|
16273697|NCT04859894||Covid19|Patients aged >18 years with confirmed Covid19 disease with symptoms >12 weeks, not better explained by other disease
16273698|NCT04859881||Barotrauma/cases|Cases were defined as patients with barotrauma consulted with the Surgery Department
16273699|NCT04859881||No braotruma/Controls|Controls were selected from a random sample of the COVID-19-ARDS cohort.
16273700|NCT04859868|Experimental|Galvanic Vestibular Stimulation during the entire session|Subjects will be given galvanic vestibular stimulation (GVS), which applies low electrical currents to the vestibular system, during the entire session.
16273701|NCT04859868|No Intervention|Placebo Group|Subjects will be not be given galvanic vestibular stimulation (GVS) during the entire session.
16273702|NCT04859868|Experimental|Galvanic Vestibular Stimulation starting from mid-session|Subjects will be given galvanic vestibular stimulation (GVS), which applies low electrical currents to the vestibular system, starting from mid-session.
16273703|NCT04859855|Experimental|Restrictive strategy (arm A)|Transfusion of RBC if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
16273704|NCT04859855|Experimental|Liberal strategy (arm B)|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL.
16273746|NCT04859621|Placebo Comparator|Placebo|Placebo Oral Tablet plus standard antibiotic therapy
16304690|NCT04643093|Active Comparator|Ezetimibe|Ezetimibe
16273708|NCT04859829||Patients with autoimmune dysmotility receiving IVIG infusions|
16273709|NCT04859829||Patients with autoimmune dysmotility without IVIG infusions|
16273710|NCT04859816|Experimental|Roux-en-Y gastric bypass operated participants|Roux-en-Y gastric bypass operated participants in weight stable phase > 1 year from surgery
16273711|NCT04859816|Experimental|Control participants|Age, sex, and BMI-matched un-operated participants.
16273712|NCT04859803|Active Comparator|Group R (RIB)|patients will receive rhomboid intercostal block under ultrasound guidance.
16273713|NCT04859803|Sham Comparator|Group C|patients will receive sham block
16273714|NCT04859790|Active Comparator|Active SCAR Intervention|In this arm, participants will complete baseline measures, receive the SCAR intervention, and complete follow-up measures one month following the intervention.
16273715|NCT04859790|No Intervention|Waitlist Control|Participants assigned to the waitlist control condition will complete baseline measures and measures one month following their baseline appointment. After they complete the follow-up measures, they will be offered the SCAR intervention.
16273716|NCT04859777|Experimental|Part A:|Dose-escalation oral MPT-0118 BID
16273717|NCT04859777|Experimental|Part B:|Dose-escalation oral MPT-0118 BID + pembrolizumab (IV)
16273718|NCT04859777|Experimental|Part C:|Dose-expansion oral MPT-0118 BID + pembrolizumab (IV)
16273719|NCT04859764|Experimental|Reparel Sleeve Group|Reparel sleeve and corticosteroid injection
16273720|NCT04859764|Placebo Comparator|Placebo Sleeve Group|Placebo sleeve and corticosteroid injection
16273721|NCT04859751|Experimental|VB4-845 Injection|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.
~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
16273722|NCT04859738|Experimental|Experiment I Group (Lidocaine Spray)|Lidocaine Spray was applied to Experiment I group before peripheral intravenous catheter application.
16273723|NCT04859738|Experimental|Experiment II Group (Benzokain Sprey)|Benzokain Sprey was applied to Experiment II group before peripheral intravenous catheter application.
16273724|NCT04859738|Placebo Comparator|Placebo Group|Alcohol was administered to the placebo group prior to peripheral intravenous catheter application.
16273725|NCT04859725|Experimental|Hyperspectral Imaging with Snapscan camera|"Included patients will undergo a resection of the low grade glioma as standard-of-care. Hyperspectral imaging data will be acquired by the SnapScan HSI camera mounted on the (standard) surgical microscope.
~As such, the surgical procedure does not deviate from the common, standard-of-care surgical procedures, apart from the acquisition of intraoperative scanning images using the SnapScan HSI camera on the microscope. The objective of this all is to get an initial high quality in vivo dataset to start exploring the potential of the technology."
16273726|NCT04859712||Trial group: 45 patients with lumbar disc herniation|"The Pulse Detection System of Sound Waves  was used to collect three parts and five layers of pulsed sound waves from the hands of 45 patients with lumbar disc herniation."
16273727|NCT04859712||Control group :45 relatively healthy people|"The Pulse Detection System of Sound Waves  was used to collect the three-parts and five-layers pulse sound waves of the hands of 45 relatively healthy people."
16273730|NCT04859686|Experimental|Treatment|Participants underwent intervention.
16273731|NCT04859686|No Intervention|Waitlist|Participants received no intervention.
16273732|NCT04859673|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
16273733|NCT04859673|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy. Stimulation will not deliver as the transmitter head will be removed. The patients will receive the same frequency of air pressure and sound
16273734|NCT04859660|Experimental|Tamsulosin- intervention group|
16273735|NCT04859660|Placebo Comparator|Placebo group|
16273736|NCT04859647|Other|Therapy Intervention|Method of Levels Therapy Intervention - Clients will choose how many sessions to attend during the 6 months therapy window. Clients will also choose how often to attend sessions and the duration of each session.
16273737|NCT04859634||Zhongshan Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
16273738|NCT04859634||Shenzhen Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
16273739|NCT04859634||Beijin Tongren Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
16273740|NCT04859634||Xudong Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
16273741|NCT04859634||IKang Physical Examination Center|The participant only needs to take an ultra-widefield fundus image as usual.
16273742|NCT04859634||Yangxi General Hospital People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
16273743|NCT04859634||Guangdong Provincial People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
16273744|NCT04859621|Experimental|Vitamin D3 4000 IU|4000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
16273745|NCT04859621|Experimental|Vitamin D3 2000 IU|2000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
16304691|NCT04643093|Experimental|1PC111|1PC111
16273748|NCT04859608|No Intervention|Control|Initial eculizumab schedule is continued (real-life arm). No eculizumab dosages are performed in this arm.
16273749|NCT04859595|Experimental|telephone follow-up arm|"The experimental arm corresponds to the patient benefiting from a monthly telephone follow-up during the first 6 months of their discharge from the reeducation center : CRIL (from M1 to M6). They will be contacted each month by CRIL's speech therapist for a telephone interview (20 to 30 minutes)."
16273750|NCT04859595|No Intervention|control arm|The comparison group will follow the standard follow-up protocol. A technician will contact the patients in the control arm to obtain the TIMES score each month. No further telephone follow-up will be carried out.
16273751|NCT04859582|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
16273752|NCT04859582|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
16273753|NCT04859569|Experimental|LY01011|Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.
16273754|NCT04859569|Active Comparator|Xgeva®+LY01011|After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.
16273755|NCT04859556|Experimental|10k 25G cutter|New cutter, with a 10,000 cut per minute blade
16273756|NCT04859556|Active Comparator|5k 25G cutter|Traditional cutter, with a 5,000 cut per minute blade
16273757|NCT04859543|Other|Diagnostic group|Tumor and blood samples will be collected from each patient and broad molecular profiling will be performed. The results of the evaluation of the tumor specimens will determine if the patient's tumor has an actionable mutation for which treatment is available.
16273758|NCT04859530|Experimental|AVC test|
16273761|NCT04859504|Active Comparator|Active tACS|Active tACS will be applied twice daily for 5 days. In each session, dual-channel high-density theta(7Hz) tACS stimulations will be delivered over the right DLPFC (one anodal electrode at F4, between -1.2mA and 1.2 mA; two cathodal electrodes at AF4 and FC6, between -0.6mA and 0.6mA) and cerebellum (one anodal electrode at Oz, between -1 mA and 1mA; two cathodal electrodes at PO3 and PO4, between -0.5mA and 0.5mA) lasting 20 minutes.
16273762|NCT04859504|Sham Comparator|Sham tACS|Sham tACS will be also applied twice daily for 5 days.The parameters of tACS electrodes numbers, locations, and current duration are all the same with active tACS. But sham tACS begin with a fade in over 3s to the peak, followed immediately by no current stimulation for 20 minutes and a fade out of 3s.
16273763|NCT04859491|Active Comparator|Carbohydrate|Carbohydrate in the amount of 1.2 g/kg of body weight (bw). Gatorade®, Chicago, IL, USA.
16273764|NCT04859491|Active Comparator|Carbohydrate-Protein|Carbohydrate in the amount of 0.8 g/kg bw (Gatorade®, Chicago, IL, USA) plus protein in the amount of 0.4 g/kg bw (biPro Elite, Agropur Inc., Appleton, WI, USA).
16273765|NCT04859491|Placebo Comparator|Placebo|Flavored water (G Zero, Gatorade®, Chicago, IL, USA).
16273766|NCT04859478|Other|All eligible patients|All patients undergo the same CT protocol in addition to standard care.
16273767|NCT04859465|Experimental|Abraxane combined with liposomal doxorubicin|Abraxane combined with liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma
16273768|NCT04859452|Experimental|The DDI of DBPR108 tablets and Metformin hydrochloride tablets|Subjects will receive a single dose of metformin hydrochloride on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of metformin hydrochloride on Day 8.
16273769|NCT04859452|Experimental|The DDI of DBPR108 tablets and Glibenclamide tablets|Subjects will receive a single dose of Glibenclamide on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Glibenclamide on Day 8.
16273770|NCT04859452|Experimental|The DDI of DBPR108 tablets and Valsartan Capsules|Subjects will receive a single dose of Valsartan on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Valsartan on Day 8.
16273771|NCT04859452|Experimental|The DDI of DBPR108 tablets and Simvastatin tablets|Subjects will receive a single dose of Simvastatin on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Simvastatin on Day 8.
16273772|NCT04859439|Experimental|Mild Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
16273773|NCT04859439|Experimental|Moderate Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
16273774|NCT04859439|Experimental|Severe Renal function|Subjects will receive a single dose of 100 mg DBPR108
16273775|NCT04859439|Experimental|Kidney failure|Subjects will receive a single dose of 100 mg DBPR108
16273776|NCT04859439|Experimental|Normal Renal function|Subjects will receive a single dose of 100 mg DBPR108
16273777|NCT04859426|Experimental|Mild Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
16273778|NCT04859426|Experimental|Moderate Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
16273779|NCT04859426|Experimental|Normal hepatic function|Subjects will receive a single dose of 100 mg DBPR108.
16273780|NCT04859413||the young group|healthy participants age between 20 and 40
16273781|NCT04859413||the elder group|healthy participants age over 60
16273782|NCT04859400|Experimental|Intervention|"standardized nutritional program including a nutritional supplement
~standardized exercise program
~app for monitoring."
16273783|NCT04859400|No Intervention|Control|"standard of care
~limited version of the app (e.g. without the help function)."
16273784|NCT04859387|Experimental|group A|set of pragmatic shoulder techniques
16273786|NCT04859374|Other|Treatment as usual (TAU)|Any pharmacological therapy used for managing chronic pain or chronic migraine
16273787|NCT04859374|Other|TAU plus behavioral approach|Any pharmacological therapy used for managing chronic pain or chronic migraine added with behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
16273788|NCT04859361|Experimental|Treatment with imiquimod|Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
16273789|NCT04859361|Active Comparator|Treatment with LLETZ|Standard treatment will be scheduled after patients' first period.
16273790|NCT04859348|Experimental|Group-A ( RPT+ Insulin Therapy)|Group A includes participants received the routine physical therapy only.
16273791|NCT04859348|Experimental|Group-B (RPT+ Antenatal Exercises+ Insulin therapy)|Group B includes participants were given antenatal exercise program from 20- 24 weeks of gestation to till the date of delivery, with addition of the routine physical therapy plan.
16273792|NCT04859335|Other|Schwannomas patients needing gammaknife radiosurgery|"Patients will undergo balance and hearing questionnaires before and after gammaknife radiosurgery.
~This is a before/after analysis needing only one arm: the before data will serve as control to the after data"
16273793|NCT04859322|Experimental|Healthy Participants|20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention
16273794|NCT04859309|Experimental|ActiveHip Intervention|"The ActiveHip tele-rehabilitation mobile application.
~The program consists of a multidisciplinary home-based tele-rehabilitation program delivered through a mobile application. It is comprised by an occupational therapy program and a physical exercise program.
~The intervention group have the opportunity to perform three online-based sessions per week (two sessions of physical exercise and one of occupational therapy), each lasting 30-60 min. It is able to realize a fourth session, called bonus session.
~In addition, the intervention group will receive the educational program, which has a total of 7 modules. 5 modules are for patients and caregivers, and 2 modules are specific for caregivers."
16273795|NCT04859309|Active Comparator|Standard care|Participants of this group will receive the standard care for hip fracture patients at hospital discharge.
16273805|NCT04859283|Active Comparator|DEX-group|intranasal dexmedetomidine 1 µg/kg
16273806|NCT04859283|Placebo Comparator|PLACEBO-group|intranasal saline 10 µL/kg
16273807|NCT04859257||Disease Group|Cohort 1 (Disease Group) of the study will collect blood and urine samples from participants who are either diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific inclusion criteria.
16273808|NCT04859257||Control Group|Cohort 2 (Control Group) of the study will collect blood and urine samples from participants who have NOT been diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific exclusion criteria.
16273809|NCT04859244|Experimental|Part 1: GS-441524 (QD, 7 days)|750 mg GS-441524 administered QD for 7 days
16273810|NCT04859244|Experimental|Part 2: GS-441524 (TID, 3 days)|750 mg GS-441524 administered TID for 3 days
16273811|NCT04859231|Active Comparator|Control|
16273812|NCT04859231|Experimental|Investigational|
16273813|NCT04859231|No Intervention|Mother's-own Breast Milk|
16273814|NCT04859218|Experimental|ABO non-identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
16273815|NCT04859218|Active Comparator|ABO identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
16273816|NCT04859205|Experimental|Intervention|"All participants partaking the SUPPORT-Pro study will receive the full intervention for 3 months which implies: (1) Full access to the platform (2) a newsletter sent by email every 2 weeks to inform them on the new blogs posted on the platform.
~During the following 9 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase)."
16273817|NCT04859192|Experimental|study group|For 6 weeks, students in study group will receive their routine flipped classroom in addition to gamified activities that they are required to complete before class session.
16273818|NCT04859192|No Intervention|control group|The control group will not receive any intervention only their routine flipped classroom education
16273819|NCT04859153||sprinter|
16273820|NCT04859153||non-sprinter|
16273871|NCT04858802|Active Comparator|Balloon Sinus Dilation Alone|Following successful in-office bilateral balloon dilation, placement of no implant on the contralateral side.
16273821|NCT04859140|Experimental|Foam rolling|The foam rolling routine consisted in unilateral exercises alternatively performed on both legs and bilateral exercises on lower and back muscles. All participants started with the feet in a standing up position with a lacrosse ball. Then, participants performed on the ground the foam rolling exercises with the foam roller targeting leg and back muscles.
16273822|NCT04859140|Experimental|Manual massage|Participants in the manual massage group received manual massage by a professional physiotherapist who was blinded to the purpose of the experiment (20 years of registered practice). Participants were lying in the prone position on a massage table. To facilitate the physiotherapist's maneuvers, massage oil was used. The manual massage protocol reproduced several features of the foam rolling intervention, i.e., order of the areas massaged, massage time per muscles and total duration of the session.
16273823|NCT04859140|Active Comparator|Autogenic relaxation|Participants in the relaxation group listened to a 16 min relaxation audio tape, based on the autogenic training method. Participants were lying on the massage table in supine position, wearing headphones. During this desensitization-relaxation technique, they were guided to visualize bodily perceptions of heaviness and warmth in their arms, thorax and legs. To facilitate concentration, participants were left alone in a dark room.
16273824|NCT04859127||Patient Group|"The criteria for inclusion in the study were determined as voluntary patients between the ages of 18-65 with neck pain lasting more than 3 months who were clinically diagnosed with chronic neck pain by a specialist physician.
~Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc."
16273825|NCT04859127||Control Group|Asymptomatic individuals between the ages of 18-65 who have not experienced neck pain during the last 1 year will be included in the control group. Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc.
16273826|NCT04859114|Active Comparator|Text-only outcome data, 30% survival|Participants in this arm are provided a repeat of the outcome data in a text-only format, displaying a 30% chance of survival.
16273827|NCT04859114|Active Comparator|Text-only outcome data, 60% survival|Participants in this arm view a repeat of the outcome data in a text-only format, displaying a 60% chance of survival.
16273828|NCT04859114|Experimental|Static pictograph outcome data, 30% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 30% chance of survival.
16273829|NCT04859114|Experimental|Static pictograph outcome data, 60% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 60% chance of survival.
16273830|NCT04859114|Experimental|Iterative pictograph outcome data, 30% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 30% chance of survival.
16273831|NCT04859114|Experimental|Iterative pictograph outcome data, 60% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 60% chance of survival.
16273832|NCT04859101|Experimental|Gum|Group 1 will receive gum immediately prior to transport to the operating room. They will be asked to chew the gum for 2 minutes and then spit the gum in the garbage.
16273833|NCT04859101|Other|Control|Group 2 will not receive any gum. They will be asked to swallow twice and have no other intervention.
16273834|NCT04859088|Experimental|Partial Enteral Nutrition|Patients allocated to Partial Enteral Nutrition study arm will be asked to replace 50% of their daily energy requirements with a proprietary formula (Modulen IBD, Nestle) for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
16273835|NCT04859088|No Intervention|Unrestricted diet|Patients allocated to unrestricted diet study arm will be asked to follow their normal diet for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
16273836|NCT04859049||infromedial single injection|adult patient ASA 1& 2
16273837|NCT04859036||Transchateter VSD closure group|VSD cases treated with transcatheter closure method.
16273838|NCT04859036||Control group|Healty children
16273839|NCT04859023|Experimental|mass screening SARS-COV-19|"20 0000 participant will be included during mass screening SARS-COV-19 of the population of the city of Saint-Etienne.
~They will have two strategies both based on self-samples: (i) a saliva sample combined to an anterior nare self-swabbing tested by antigenic test versus (ii) a saliva sample tested by RT-PCR."
16273840|NCT04858997|Experimental|Palbociclib-AI|ER(+)/HER2(-) patients with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease receive palbociclib PO daily on days 1-21, combined with AI as first-line treatment Disease assessments measured by CT imaging will be performed at first 4 weeks, 8weeks, then every 8weeks (± 7 days) from the date of randomization until radiographic/clinical documentation of progressive disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
16273841|NCT04858984|Experimental|Virtual reality group|"All participants experienced an immersive guided meditation virtual reality (VR1) and an interactive game virtual reality (VR2) experience during labour. Both VR interventions were offered for 10 minutes. Before and immediately after an intervention, the patient was asked to fill out a Numeric Rating Scale (NRS) score for pain.
~During the 30-minute intermission after the VR intervention the patient completed the post-intervention questionnaire.
~VR1 consisted of a video of an exotic location guided by the sound of the waves and a calm English-speaking voice. VR2 required women to use the controller to throw snowballs in order to catch presents and reach the next level. Patients were allowed to stop using the VR at any moment during the intervention.
~Five days post-partum all participants who completed both VR interventions were contacted by telephone for an interview."
16273842|NCT04858971||Control|No source will be indicated on information provided for review
16273843|NCT04858971||Government source|A government logo will be shown on information provided for review
16273844|NCT04858971||Medical source|A medical logo will be shown on information provided for review
16273845|NCT04858971||Social media source|A social media logo will be shown on information provided for review
16273846|NCT04858958|Experimental|treated subjects will receive Furmonertinib 160mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
16273847|NCT04858958|Experimental|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
16273848|NCT04858958|Experimental|treatment-naïve subjects will receive Furmonertinib 240mg/day|Treatment naïve patients with EGFR exon 20 insertion mutation positive NSCLC
16273851|NCT04858932||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
16273852|NCT04858932||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
16273853|NCT04858932||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
16273854|NCT04858919|Other|study group|virgins with genital tract lesion
16273855|NCT04858906|Active Comparator|from neutral to sniffing position|The patients in this group will be assessed firstly in the neutral position then subsequently in the sniffing position.
16273856|NCT04858906|Active Comparator|from sniffing position to neutral position|The patients in this group will be assessed firstly in the sniffing position then subsequently in the neutral position.
16273857|NCT04858893||Subjects affected from Parkinsonims|Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator
16273858|NCT04858893||Health Controls|CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator
16273859|NCT04858880|Experimental|Continued salvage radiotherapy + lymph node irradiation (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present) + the addition of lymph node irradiation (46 Gy/23 fractions) given in sequence. Total number of fractions: 35 + 8 = 43 with 15 of the lymph node irradiation fractions delivered concomitant with the prostate bed/local recurrence irradiation. These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
16273860|NCT04858880|Active Comparator|Continued salvage radiotherapy (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
16273861|NCT04858880|No Intervention|Continued salvage radiotherapy (responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as responders according to weekly PSA measurements during the first 4 weeks of radiotherapy, and are not followed according to the study protocol, follow up according to clinical practice.
16273862|NCT04858867|Other|Cohort 1|"Study procedures
~Lenvatinib during week 1-12
~rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12
~rhTSH-stimulated I-131 therapy at week 13 (if eligible)
~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)
~Biopsy at week 0 and 6
~F-18 FDG PET/CT at week 0, 6, 12, 24 and 36
~Tg levels at week 0, 6, 12, 24 and 36
~QoL assessment at week 0, 6, 12, 24 and 36"
16273863|NCT04858867|Other|Cohort 2|"Study procedures (in case of 12-wk lenvatinib):
~Lenvatinib during week 1-12
~rhTSH-stimulated I-124 dosimetry at week 0 and 12
~rhTSH-stimulated I-131 therapy at week 13 (if eligible)
~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)
~Biopsy at week 0 and 6
~F-18 FDG PET/CT at week 0, 12, 24 and 36
~Tg levels at week 0, 6, 12, 24 and 36
~QoL assessment at week 0, 6, 12, 24 and 36
~Study procedures (in case of 6-wk lenvatinib)
~Lenvatinib during week 1-6
~rhTSH-stimulated I-124 dosimetry at week 0 and 6
~rhTSH-stimulated I-131 therapy at week 13 (if eligible)
~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)
~Biopsy at week 0 and 6
~F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36
~Tg levels at week 0, 6, 12, 24, 30 and 36
~QoL assessment at week 0, 6, 12, 24, 30 and 36"
16273866|NCT04858841|Experimental|Levetiracetam|The group receives oral levetiracetam.
16273867|NCT04858841|Experimental|Perampanel|The group receives oral perampanel.
16273868|NCT04858841|Placebo Comparator|Placebo|The group receives oral placebo.
16273869|NCT04858815|Experimental|Administration of yogic breathing program|This will be a single arm longitudinal trial designed to evaluate the feasibility and estimate the efficacy of implementing a self-administered yogic breathing program for stress reduction among anesthesiology practitioners at one academic medical center.
16273870|NCT04858802|Experimental|PROPEL Contour Sinus Implant|Following successful in-office bilateral balloon dilation, placement of PROPEL Contour Sinus Implant in the randomized side.
16273872|NCT04858789|Experimental|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
16273873|NCT04858789|No Intervention|Control|The control (care as usual) group will receive the information about freely available psychological support options. After all the measurements are completed, the control group will be able to receive CA-CBI, too.
16273874|NCT04858776|Experimental|Treatment|
16273875|NCT04858776|Sham Comparator|Control|
16273876|NCT04858763||2020 Cohort|This is the 2020 MS cohort who experienced a clinician confirmed relapse during April - June 2020, during the first wave of the COVID-19 pandemic.
16273877|NCT04858763||2019 Cohort|2019 MS cohort who experienced a clinician confirmed relapse during April - June 2019.
16273878|NCT04858750|Other|Cook D-J stent group|"Patients randomized to this group received Cook (Limerick, Ireland, USI-626-R) D-J stent.
~Note: USI is an unexpandable acronym."
16273879|NCT04858750|Other|KYB anti-reflux D-J stent group|Patients randomized to this group received KYB (Shenzhen, China, 3201162) anti-reflux D-J stent.
16273880|NCT04858750|Other|Urovision trigonal D-J stent group|"Patients randomized to this group received Urovision (Bad Aibling, Germany, ST-230726) trigonal D-J stent.
~Note: ST is an unexpandable acronym. Aibling is a German region name."
16273881|NCT04858737|Experimental|e-predicD-Work intervention|In this arm, worker participants will receive an online personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS).
16273882|NCT04858737|Active Comparator|m-Health control|In this arm, worker participants will continue receiving the usual care from their health providers. In addition, they will use an App with the same appearance as the e-predictD-Work App but it will only send weekly short messages about stress and general health that will be extracted from brochures and websites of official agencies.
16273885|NCT04858698|Experimental|Reduced fluoroscopy arm|Patients exposed to 20 seconds or less of fluoroscopy to implant a single chamber device with aid of ultrasound / echocardiography.
16273886|NCT04858698|Active Comparator|Conventional arm|Patients exposed to more than 20 seconds of fluoroscopy to implant a single chamber device with/without the aid of ultrasound / echocardiography.
16273887|NCT04858659|Experimental|PK101 group|
16273888|NCT04858659|Active Comparator|PK101-002 group|
16273889|NCT04858646|Experimental|Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
16273890|NCT04858646|Active Comparator|Conventional physical therapy|Traditional physical therapy The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes. Treatment duration for both groups will be 30 minutes. Each subject received total 30 sessions of the treatment, with 5 treatment sessions per week for 6 weeks. Post treatment reading were collected after end of 6th weeks.
16273891|NCT04858633|Active Comparator|PEP group|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg)
16273892|NCT04858633|Placebo Comparator|Control group|Placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
16273893|NCT04858620|No Intervention|No treatment|
16273894|NCT04858620|Experimental|Treatment|
16273895|NCT04858620|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
16273896|NCT04858607||Immunocompromised individuals|Patients with primary or secondary immunodeficiency planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
16273897|NCT04858607||Healthy individuals|Healthy people planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
16273898|NCT04858594||Arm A: with Periodontitis|Patients with periodontitis
16273899|NCT04858594||Arm B: without Periodontitis|Patients without periodontitis
16273900|NCT04858581|Other|Healthcare workers who had a diagnosis confirmed by a nasopharyngeal RT-PCR test with SARS-CoV-2|Survey, RT-PCR test and blood test.
16273905|NCT04858542|Experimental|Mask-wearing healthcare workers|All participants in this arm will view the educational health modules and their subjective/objective outcomes will be measure pre/post module viewing.
16273906|NCT04858529|Experimental|THP|
16273907|NCT04858529|Active Comparator|TCHP|
16273908|NCT04858516|Experimental|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib|
16273909|NCT04858503|Experimental|internet-based cardiac rehabilitation enhancement intervention|internet-based cardiac rehabilitation enhancement intervention
16273910|NCT04858503|No Intervention|conventional cares as arranged by hospital or community centers|Participants will receive conventional cares as arranged by hospital or community centers
16273911|NCT04858490|Experimental|Symptom-triggered diazepam treatment|Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score above 10 on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
16273912|NCT04858477|Other|Colonoscopy Patients + their Gastroenterology Fellows|Inpatient and outpatient colonoscopies performed by fellows at NYU Langone Health, NYU Langone Hospital Brooklyn, Bellevue Hospital Center, and Manhattan VA Medical Center from October 2020 - March 2021. These will include all colonoscopies with polyps done in adults age 45 and above.
16273914|NCT04858451|Experimental|All participants|"In Part 1, up to 48 patients will be administered single ascending doses of RESP301 (1-6ml; 8 patients per dose cohort). Provided that individual stopping criteria are not met in ≥3 participants, and there are no serious adverse events that are at least possibly related to RESP301, the next dose cohort can be enrolled. Patients can be enrolled into more than one dose cohort provided they did not meet individual stopping criteria.
~In Part 2, a minimum of 150 patients will be enrolled. This may include patients who took part in Part 1. At least the first 50 patients will receive a test dose of RESP301 before enrolment into the dormant phase. Patients who experience flare-up symptoms while in the dormant phase, may proceed to the treatment phase where they will self-administer RESP301 at home for 7 days."
16273915|NCT04858438|Active Comparator|Standard Insufflation Group|Patients will receive standard insufflation during surgery (15 mm Hg).
16273916|NCT04858438|Experimental|Low Insufflation Group|Patients will receive a lower level of insufflation during surgery (12 mm Hg or lower).
16273919|NCT04858412|Active Comparator|HMB enriched amino acid arm|The patients randomized to the HMB enriched amino acid (HMB/EAA) arm will be given HMB/EAA for 90 days.
16273920|NCT04858412|Placebo Comparator|Balanced amino acid arm|The patients randomized to the Balanced amino acid (BAA) arm will be given BAA for 90 days.
16273921|NCT04858399||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
16273922|NCT04858399||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
16273923|NCT04858399||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour
16273924|NCT04858373|Experimental|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16273925|NCT04858373|Experimental|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16273926|NCT04858373|Experimental|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16273927|NCT04858373|Experimental|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16273928|NCT04858360|Experimental|Study group|
16273931|NCT04858321|Experimental|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
16273932|NCT04858308|Active Comparator|Test Group|Take both YYC506 and Placebo(Control)
16273933|NCT04858308|Active Comparator|Control Group|Take both Contral and Placebo(YYC506)
16273934|NCT04858295|Active Comparator|Texting Arm|"Participants will receive automated text message reminders to check their blood pressure (BP) at least three days per week (participants will choose which days and times to receive reminders). Participants will transmit BP readings with text message to the Way to Health server. If a BP reading is not received within 3 hours, another reminder will be sent. Automated text message feedback will be sent with a tailored message. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
16273973|NCT04857983|Placebo Comparator|TCT + PBO|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
16306265|NCT04632550|Experimental|POBI+Anterior linear ablation(AL) group|
16273935|NCT04858295|Active Comparator|mHealth app Arm|"Participants randomized to the mHealth app (Omron Connect) arm will receive reminder messages to check their BP via push notifications from the Omron Connect app at least three times weekly. Upon receipt of the BP reading to the research platform from Omron Connect, participants will receive automatic tailored text message feedback similar to the texting arm. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
16273936|NCT04858282|Experimental|shared decision-making group (SDMG)|Receiving mobile application( BC-SDM)
16273937|NCT04858282|No Intervention|usual care group (UCG)|Receiving material health education
16273938|NCT04858269|Experimental|Combination of Chemotherapy and Immunotherapy|The intervention will be administered on an outpatient basis. The treatment regimen will consist of combination chemotherapy and immunotherapy administered as: Pembrolizumab PLUS Carboplatin PLUS Paclitaxel.
16273939|NCT04858256|Experimental|Cohort 1: PTCL, NOS|Patients will receive single agent pacritinib.
16273940|NCT04858256|Experimental|Cohort 2: AITL/TFH PTCL|Patients will receive single agent pacritinib.
16273941|NCT04858256|Experimental|Cohort 3: CTCL (MF/SS)|Patients will receive single agent pacritinib.
16273942|NCT04858256|Experimental|Cohort 4: Less common PTCL subtypes|Patients will receive single agent pacritinib.
16273943|NCT04858243|Active Comparator|Facility-Based ART|Men escorted to nearest health facility for ART initiation and continuation.
16273944|NCT04858243|Experimental|Home-Based ART|Home-based ART initiation and continuation provided for 3-months.
16273945|NCT04858230|Experimental|LymphoPilot|Patient will be implanted with the medical device under investigation, LymphoPilot, through a surgical procedure performed in loco-regional anesthesia. Lymphedema outcomes will be monitored for 8 weeks after implantation and compared to baseline values before device implantation. Safety data will be collected throughout the study.
16273946|NCT04858191||Pediatric PCD|Pediatric participants with PCD
16273947|NCT04858178|Experimental|Individuals with spinal cord injury|
16273948|NCT04858178|Experimental|Individuals without spinal cord injury|
16273949|NCT04858165|No Intervention|CONTROL|without MY GERYFS
16273950|NCT04858165|Other|INTERVENTION|with MY GERYFS
16273951|NCT04858152|Experimental|Experimental Arm: Transplantation of hair follicles to non-hair bearing areas affected by vitiligo|Punch biopsies will be used to extract hair follicles from area on participant's body that is not affected by vitiligo and has hair growth. The follicles will then be transplanted into an area of the body affected by vitiligo that is hairless.
16273952|NCT04858139|Placebo Comparator|placebo|patients will be injected with placebo
16273953|NCT04858139|Active Comparator|Lactate|patients will be injected with lactate solution
16273954|NCT04858126|Experimental|Single Group Assignment|ECOM endotracheal cardiac output monitor in patients undergoing cardiac and liver surgery.
16273955|NCT04858113|Placebo Comparator|Baby Shampoo|Conventional Baby shampoo
16273956|NCT04858113|No Intervention|No intervention|Baseline condition without intervention
16273957|NCT04858113|Experimental|Blephaclean|Intervention
16273958|NCT04858100|Experimental|Surgery|Each patient will receive the surgical excision of the lesion and subsequent follow-up
16273959|NCT04858100|Active Comparator|Wait and see|Each patient will receive clinical follow-up of the lesion with periodical incisional tissue biopsy.
16273960|NCT04858087||All students|All participating students were screened for Pf infection using malaria rapid diagnostic tests (mRDTs) and treated if positive. All were followed 1, 2, and 6 weeks after screening-and-treatment.
16273961|NCT04858074|Experimental|Active medication- PECKO-D|Participants will be randomly allocated to experimental drug
16273962|NCT04858074|Placebo Comparator|Placebo|Corn-Starch will be administered as placebo agent
16273965|NCT04858048||Group with general anesthesia performed during the forefoot surgery|
16273966|NCT04858048||Group with WALANT anesthesia performed during the forefoot surgery|
16273967|NCT04858035|Experimental|Online Speech Training|"Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks. Finally, participants will complete a 3-session maintenance phase in which perception and production are probed but not treated. Perception will be measured using the identification and category goodness judgment.
~Following completion of perception training all participants will complete two weeks of production training. The production training will consists of 4, 60-minute sessions. Each session will provide instruction and practice trials."
16273968|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Treatment|"Condition1: Treatment-first
~Children with RSE and typical perception will be allocated to a randomized controlled trial measuring the efficacy of online visual-acoustic biofeedback treatment. Ten children with RSE will receive 10 weeks of visual-acoustic biofeedback training via video call."
16273969|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Wait|"Condition 2: Waitlist-first
~Following the initial evaluation, 10 children with RSE will be allocated to a 10 week no treatment condition."
16273970|NCT04858009|Experimental|Treatment (HIPEC)|Patients undergo HIPEC with mitomycin and cisplatin over 60 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with mitomycin and cisplatin up to 5 times.
16274083|NCT04857229||All patient|All recruited patient will have their margins assessed with the confocal microscope with comparison of accuracy against gold standard histology.
16274084|NCT04857216||Infraclavicular Group|Block Characteristics of Ultrasound Guided Infraclavicular Block with the Perfusion Index
16274085|NCT04857216||Costoclavicular Group|Block Characteristics of Ultrasound Guided costoclavicular Block with the Perfusion Index
16273974|NCT04857983|Active Comparator|TCT + MEM|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
16273975|NCT04857970||Electronic HRQoL questionnaires with feedback to physicians|40 patients allocated in this arm will answer HRQOL questionnaires using an electronic form in CHES Software. The HRQoL scores, presented as graphics, will be transmitted to physicians.
16273976|NCT04857970||Paper-pencil HRQoL questionnaires w.o. feedback to physician|"40 patients allocated in this arm will answer HRQOL questionnaires using pencil-paper, without transmission of the HRQoL scores to physicians."
16273977|NCT04857957|Experimental|Cohort 1|300 mg oral dose TID
16273978|NCT04857957|Experimental|Cohort 2|600 mg oral dose TID
16273979|NCT04857957|Experimental|Cohort 3|800 mg oral dose TID
16273980|NCT04857957|Experimental|PDN cohort|Dose based on safety in healthy Cohorts 1-3
16273981|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app with motivational messages (A)|After study entry and baseline assessments, subjects will attend the one-month IDEA group sessions aimed at promoting physical activity and exercise. Participants randomly assigned to this study arm will use the smart band and the app with the motivation set enabled, allowing participants to receive the messages according to their compliance and adherence to the personalised prescriptions. After group sessions (week 4), study subjects will start receiving motivational messages up until the end of the trial (8 consecutive months).
16273982|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app without motivational messages (B)|Subjects will follow the same procedure as intervention A, with the difference that the app will have the motivation set disabled, therefore participants will not receive any messages regarding their compliance. After group sessions, study subjects will be expected to continue using the smart band and app up until the end of the trial (8 consecutive months).
16273983|NCT04857944|Sham Comparator|Fitness tracker + app without motivational messages (CG)|After study entry and baseline assessments, all patients assigned to the control group will receive both the app and the smart band, but the motivation set will be disabled. Study subjects will be expected to use the smart band and app up until the end of the trial.
16273987|NCT04857918|Experimental|Social identity informed virtual running group|Participants will join running groups of six people (males and females) for eight weeks. Each running group will be given the group goal/challenge to collectively run/brisk walk the distance across the province of British Columbia (940 km) over the course of the eight week intervention (Estabrooks et al., 2008), and encouraged to complete 150 minutes of moderate-to-vigorous exercise per week. Participants can record other moderate-to-vigorous exercise to contribute to the group goal. Running groups will be created on the fitness application Strava, and participants will record/post their runs on the Strava app so that members of their running group can provide 'kudos' and words of encouragement. Running groups will have a weekly a coffee chat (via Zoom) to socialize and discuss their experiences running/exercising and progress and challenges associated with meeting the group goal. Participants will also be provided running tip videos, phone armbands, and t-shirts with the study logo.
16273988|NCT04857918|Active Comparator|Attention control group|This group of participants will act as an attention control condition. This group will be asked to download the fitness application Strava to their smartphone, and track all of their runs and walks on Strava. Similar to the intervention group, participants will be provided with phone armbands to carry their phone during a run or walk so they can record the run or walk on Strava, and will be asked to try participating in 150 minutes of moderate-to-vigorous exercise per week.
16273989|NCT04857905|Other|Microsurgical Resection of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling
~-> Patients who after counseling decide for microsurgical resection of their brain metastasis"
16273990|NCT04857905|Other|Radiosurgery of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling
~-> Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis"
16273991|NCT04857892|Experimental|Part 1 : Treatment sequence ABC|Participants will receive a single oral dose of GSK3640254 25 milligrams (mg) (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 1, followed by a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 2. In Period 3, participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C).
16273992|NCT04857892|Experimental|Part 1 : Treatment sequence BCA|Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).
16274086|NCT04857203||Group 1|Low levels of Vitamin D
16274087|NCT04857203||Group 2|High levels of Vitamin D
16273993|NCT04857892|Experimental|Part 1 : Treatment sequence CAB|Participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in period 1, followed by a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B).
16273994|NCT04857892|Experimental|Part 2 : Treatment sequence DE|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 2.
16273995|NCT04857892|Experimental|Part 2 : Treatment sequence ED|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 2.
16273996|NCT04857879|Experimental|Good Life with Osteoarthritis (GLA:D) Program|Participants will attend 2 sessions aimed at providing disease-specific education followed by 12 sessions of neuromuscular exercises, each 1 hour in length, delivered twice a week over 6 weeks.
16273997|NCT04857879|Active Comparator|Control intervention group|Participants allocated to the control intervention will receive disease-specific education and training to learn home exercises in a 1-hour group session. They will receive a booster session 4-weeks after the first session.
16273998|NCT04857866|Experimental|Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B or C|
16273999|NCT04857866|Placebo Comparator|Single Ascending Dose - Placebo Subcutaneous injection of placebo|
16274000|NCT04857853|Experimental|Exercise Without Rest Breaks|Exercise Without Rest Breaks
16274001|NCT04857853|Experimental|Exercise With Rest Break|Exercise With Rest Break
16274002|NCT04857853|Experimental|Rest Break|Rest Break
16274003|NCT04857840|Experimental|Arm A: Investigational Product /Period 1,2 and 3 if any (open label)|Firibastat 1000 mg tablets QD - 12 weeks
16274004|NCT04857840|Placebo Comparator|Arm B: Placebo/Period1 only|Placebo tablets QD 12 weeks in Period 1 only, followed by open label Period 2 and 3 if any.
16274005|NCT04857827|Experimental|QLS-101 ophthalmic solution 1.0%|Ophthalmic solution one time daily.
16274006|NCT04857827|Active Comparator|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution one time daily.
16274007|NCT04857827|Experimental|QLS-101 ophthalmic solution 2%|Ophthalmic solution one time daily.
16274008|NCT04857814|Experimental|Device|All participants will wear the device to assist in determining the feasibility of wearing the device.
16274009|NCT04857788|Experimental|Pandah Application only|Design is a controlled randomized Study with two parallel arms after randomization with a three months follow-up of the two arms that are (Group 1) Care as usual for patients in follow-up list; (Group 2) PANDAH App proposed alone with only 15-20 minutes setup with investigator at start-up (digital accompaniment only); Patients of the 2 groups will have a three months follow-up period before secondary evaluation and entering into the so-called extension period.
16274010|NCT04857788|No Intervention|Care as usual|Design is one period of 3 months with 2 parallel groups (with or without application) following by extension period of 3 months with all subject accessing to the application.
16274011|NCT04857775|Experimental|Intervention group|A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups. Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal.
16274012|NCT04857749|Active Comparator|Control group|Data from patients in the control group will be collected as in the experimental group. In the first interview, the patients in the control group will be given a training booklet. Apart from this, the standard approach, treatment and care of the clinic will be applied to all patients.
16274013|NCT04857749|Experimental|Navigation grup|While the standard treatment approaches of the hospital are applied to all patients, a nursing navigation program will be applied in addition to the patients in the experimental group. The navigation program will be started on the first day of radiotherapy by giving a 30-minute visual training and handbook related to expected side effects. Afterwards, patient follow-up will continue with phone reminders and weekly follow-up for seven weeks.
16274014|NCT04857736||Trial group: 62 healthy female college students during menstruation|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during menstruation will be collected by thePulse Detection System of Sound Waves."
16274015|NCT04857736||Control group :62 healthy female college students during non-menstrual period|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during non-menstrual period will be collected by the Pulse Detection System of Sound Waves."
16274016|NCT04857710|Active Comparator|Control (CONT)|A control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations
16274017|NCT04857710|Experimental|Conventional neuromuscular electrostimulation (CONV)|The CONV (conventional) modality allows us to compare with the current clinical application and the majority of the literature on the adaptations induced by NMES (neuromuscular electrostimulation) training.
16274018|NCT04857710|Experimental|Wide-pulse neuromuscular electrostimulation (WP)|The use of wide-pulse (WP) stimulations allows, in addition to the direct activation of the muscle fibers, the use of sensory pathways. This more global solicitation of the neuromuscular system (i.e. information going back to the spinal cord and even to the brain) prejudges more nervous adaptations and therefore a greater functional benefit.
16274019|NCT04857697|Experimental|Supportive care (biospecimen collection, probiotic)|Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics PO once on day 1, and then BID or TID for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.
16274020|NCT04857684|Experimental|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Participants will:
~undergo a pre-treatment biopsy with fiducial marker placement
~receive Stereotactic beam radiation therapy (SBRT) on three treatment days which will be arranged on an every-other-day basis
~receive two 3-week (21 days) cycles of atezolizumab plus bevacizumab
~receive Atezolizumab on day 1 for 2 study cycles.
~receive Bevacizumab 1x weekly for 2 study cycles
~Surgery after SBRT and the two cycles of atezolizumab and bevacizumab, unless participants are otherwise informed by their doctor. The planned surgery will take place 6-8 weeks after the last infusions of atezolizumab and bevacizumab."
16274021|NCT04857671|Experimental|Botulinum toxin A injections|Botulinum toxin A (Botox)
16274022|NCT04857671|Placebo Comparator|placebo injections|Isotone saline water
16274023|NCT04857658|Active Comparator|extraction treatment|patients will be referred for extraction of the upper and lower first premolars to relieve the crowding.
16274024|NCT04857658|No Intervention|non-extraction treatment|Leveling and alignment of the moderate crowding will be performed through a recall visits of 4 weeks for wire activation. inter-proximal reduction step might be done if needed.
16274025|NCT04857645|Experimental|ASTX727 treatment|
16274028|NCT04857619||Retrospective: Cohort 1|All patients recruited outside China, including Australia, Brazil, Singapore, Taiwan, Korea, and Hong Kong special administrative region (SAR) and who are diagnosed with HER2-positive unresectable or mBC since 01 January 2017 and have received at least 2 LOTs in the advanced setting will be included.
16274029|NCT04857619||Retrospective: Cohort 2|Patients from all countries, including China who are diagnosed with HER2-positive unresectable or mBC, since 01 January 2017 and have received at least 2 LOTs in the advanced setting will be included.
16274030|NCT04857606|Experimental|AMG 609|Up to 8 cohorts ranging by various dose levels.
16274031|NCT04857606|Experimental|Placebo|Participants will receive the matching placebo.
16274032|NCT04857593|Experimental|Intervention|"M4M online is a 6-week intervention for mothers with PND. The original M4M programme would be delivered face-to-face in groups of 8-12 mothers in weekly sessions lasting one hour. However, due to the current situation with COVID-19, we will therefore modify the original face-to-face intervention for this online study, as follows:
~Run groups of around 15-17 women to ensure that all participants can be visible on one screen during online delivery to create a stronger sense of community and connection
~Offer 6 weeks of intervention, also building on the evidence from the face-to-face intervention that by 6 weeks there is already a significant improvement in depressive symptoms compared with control interventions24
~Introduce a two-week lead-in period before the beginning of the six-session course, where mothers will be able to use WhatsApp and at least one (monitored) Zoom session to get to know each other."
16274033|NCT04857580|Experimental|CTS device|
16274034|NCT04857580|No Intervention|Control|
16274035|NCT04857567|Experimental|Three Self-Commitment (TSC) program|
16274036|NCT04857554|Experimental|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16274037|NCT04857554|Experimental|White bread as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16274038|NCT04857554|Experimental|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16274039|NCT04857554|Experimental|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16274040|NCT04857554|Experimental|Cocoa drink|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16274041|NCT04857541||Health adult|
16274042|NCT04857541||COPD-like|
16274043|NCT04857541||COPD|
16274088|NCT04857190|Active Comparator|Group DS (n=30)|Parker Flex-it Directional Stylet group
16274089|NCT04857190|Active Comparator|Group MS (n=30)|Conventional Malleable Stylet group
16274090|NCT04857177|Experimental|CKD-701|Drug: CKD-701 (proposed ranibizumab biosimilar)
16274091|NCT04857177|Active Comparator|Lucentis®|Drug: Lucentis® (ranibizumab)
16274303|NCT04855825|Active Comparator|Conventional Gait Therapy|Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT
16274044|NCT04857528||Retrospective (Participants Who Have Already Been Treated for HPV-Related Cancer Before Study)|This group will use medical records from participants who have already received chemoradiation for their HPV-related anal or cervical cancer at a time before this study started. Because they have already received treatment, these participants will provide previous blood/tumor tissue samples that contain detectable HPV DNA as well as at least one post-treatment sample that their doctor collected before the study. Data from these previously collected samples will be compared to current samples from participants who are actively enrolled in this study in present day (chart review).
16274045|NCT04857528||Prospective (Participants Who Will Receive Radiation Treatment for HPV-Related Cancer During Study)|This group is for participants who plan to receive radiation treatment (with or without chemotherapy) for their HPV-related anal or cervical cancer during the time this study will be conducted. Participants in this group will sign a consent form allowing researchers to collect their blood samples and analyze/compare them to the samples from the retrospective group of participants.
16274046|NCT04857515||Cigarette Smokers|Adult cigarette smokers who only smoke combustible cigarettes
16274047|NCT04857515||Dual-Users|Adult smokers who smoke both combustible cigarettes and vape
16274048|NCT04857502|Experimental|Diagnostic (99mTc-PSMA-I&S, SPECT/CT)|The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I&S IV followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I&S IV before standard of care surgery.
16274049|NCT04857489||Patients with Relapse Remitting Multiple Sclerosis|Blood sample
16274050|NCT04857489||Healthy Controls|Blood Sample
16274051|NCT04857476|Other|skin psoriasis participants|Single arm study
16274052|NCT04857463|Experimental|Nutritional supplement drink|Nutritional supplement, this group receives a nutritional supplement for a period of 12 weeks.
16274053|NCT04857463|Placebo Comparator|Nutritional education|Qualified clinical dietitians provide regular nutrition education and ensure the effectiveness of nutrition education
16274054|NCT04857450|Sham Comparator|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
16274055|NCT04857450|Active Comparator|Ketamine-Etomidate|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
16274056|NCT04857437|Experimental|Part 1|Single, Escalating Doses of PF-07202954 or Placebo (Cohorts 1 and 2)
16274057|NCT04857437|Experimental|Part 2|Repeated, Escalating Doses of PF-07202954 or placebo from Day 1 to Day 14, inclusive (Cohorts 3, 4, 5, 6 7, and optional Cohort 8)
16274058|NCT04857437|Experimental|Part 3|Single dose of PF-07202954 with a high-fat/high-caloric meal and a single dose following an overnight fast of ≥10 hours
16274059|NCT04857424||ERCP|Subjects with benign and malignant biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography (ERCP)
16274060|NCT04857424||PTBD|Subjects with benign and malignant biliary obstruction who have or will undergo percutaneous trans-hepatic biliary drainage (PTBD).
16274061|NCT04857411|Experimental|Participant 'Buddies'|Participants will have an 8-week program initiation phase followed by a maintenance phase through 6-months, supported by Ambassadors.
16274062|NCT04857398|Experimental|Insulin icodec|The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks
16274063|NCT04857385|Active Comparator|Terumo TR Band|Physical standard of care radial hemostasis device.
16274064|NCT04857385|Experimental|StatSeal|Potassium-ferrate based chemical hemostasis device.
16274065|NCT04857385|Experimental|Axiostat|Chitosan based biological hemostasis device.
16274069|NCT04857359|Experimental|Dipraglurant TID|
16274070|NCT04857359|Placebo Comparator|Placebo TID|
16274071|NCT04857346|Experimental|Controlled Type 2 diabetes mellitus|
16274072|NCT04857346|Experimental|Uncontrolled Type 2 diabetes melltius|
16274073|NCT04857346|Active Comparator|Non-diabetic patients|
16274074|NCT04857333||Pulmonary Nodule|Patients are recommended for using antibiotics, solely follow-up or surgical resection according to the current clinical guideline for management of indeterminate pulmonary nodule. No intervention is administered for this observatory study.
16274075|NCT04857320|Experimental|Main Experimental|Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight
16274077|NCT04857294|Experimental|Discectomy|Unilateral Discectomy
16274078|NCT04857281|Experimental|nVNS device|Candidates who, after the screening period are eligible to receive the nVNS device.
16274079|NCT04857268|Experimental|ATP-C120 application|ATP-C120 will be applied to the high patients for new-onset atrial fibrillation
16274080|NCT04857255|Active Comparator|Technology Assisted Language Intervention (TALI)|Augmentative and alternative communication software incorporated into active speech-language therapy
16274081|NCT04857255|Active Comparator|Treatment as Usual|Speech language therapy child is typically receiving (no change to current care)
16274082|NCT04857242|Experimental|apnea test, recruitment manoeuvre|"Continuous electric impedance tomography (EIT) recording. Recording of initial vital parameters and arterial blood gas results. Adjusment of PaCO2 between 38-42 mmHg, 10 minutes of preoxygenation with FiO2 of 1.0 then disconnection of the patient from the ventilator.
~Continuous administration of 6 L/min O2 flow via a catheter into the tracheal tube.
~Arterial blood gas sampling and recording of vital parameters in every second minutes. Detection of any spontaneous respiratory movement by the apnoe test investigator or by EIT signals.
~Reconnection with respirator if there is any sign of spontaneous breathing effort or if there is no spontaneous breathing effort and the PaCO2 is over 60 mmHg. Recording of vital parameters.
~Recruitment manoeuvre (PEEP 20 cmH2O, pressure control 20 cmH20 for 40 minutes) then set up of the initial ventilator parameters.
~Terminal arterial blood gas results and vital parameters 5 minutes following the end of the recruitment manoeuvre."
16307404|NCT04625088|Experimental|Standardized liquid test meal|
16274092|NCT04857164|Experimental|Pembrolizumab combined with Chemotherapy|"Chemotherapy regimen* is as follows, selected by the investigator, 3 weeks (21 days) is a cycle，combined with pembrolizumab 200 mg intravenously on day 1, every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated(Less than or equal to 35 cycle)
~*1) Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2) 3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)"
16274095|NCT04857138|Experimental|Part 1: Dose Escalation (RO7300490 Monotherapy)|Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
16274096|NCT04857138|Experimental|Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)|Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
16274097|NCT04857138|Experimental|Part 3: Dose Expansion (Disease-specific Expansion(s))|Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
16274098|NCT04857125|Active Comparator|Multicomponent intervention|Pre-, intra- and postoperative interventions applied using the Fast-IM method.
16274099|NCT04857125|No Intervention|Standard care|Patients are receiving standard care.
16274100|NCT04857112|Experimental|Low Dose|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
16274101|NCT04857112|Experimental|High Dose|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
16274102|NCT04857112|Placebo Comparator|Placebo|Matching placebo, QD (Day 1-85)
16274103|NCT04857099||Macular edema|
16274104|NCT04857086||Group1|About 1400 DTC patients with more than 5 years long-term follow-up from the date of signing the informed consent form (ICF) in DTCC 1st to signing ICF in DTCC 2nd will be collected data retrospectively.
16274105|NCT04857073|Active Comparator|Control group - glucose check every day|Patients will be instructed to check their glucose 4 times a day, every day. This is currently the standard of care.
16274106|NCT04857073|Experimental|Experimental group - glucose check every other day|Patients will be instructed to check their glucose every other day, 4 times glucose monitoring
16274107|NCT04857060|No Intervention|Usual Care|Subjects in this arm do not meet with ACP Educator during their index hospitalization.
16274108|NCT04857060|Experimental|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
16274109|NCT04857047|Experimental|Group A|"[Period1] administration of BR9003A 1mg twice a day for six days
~- Wash out for 9days -
~[Period2] administration of BR9003 2mg once a day for six days"
16274110|NCT04857047|Experimental|Group B|"[Period1] administration of BR9003 2mg once a day for six days
~- Wash out for 9days -
~[Period2] administration of BR9003A 1mg twice a day for six days"
16274111|NCT04857034|Experimental|Active Treatment: BMS-986165 Dose 1|
16274112|NCT04857034|Experimental|Active Treatment: BMS-986165 Dose 2|
16274113|NCT04857034|Placebo Comparator|Placebo|
16274114|NCT04857021|Active Comparator|GABA|Take GABA capsule once daily before sleep for 14 days.
16274115|NCT04857021|Placebo Comparator|Placebo|Take placebo capsule once daily before sleep for 14 days.
16274116|NCT04857008|Experimental|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
16274117|NCT04856995||working in the operating|operating room workers exposed to surgical smoke
16274118|NCT04856995||working in internal units|Internal unit workers not exposed to surgical smoke
16274119|NCT04856982|No Intervention|Part A: Natural History Run-in|Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.
16274120|NCT04856982|Experimental|Part B: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive BIIB067 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
16274121|NCT04856982|Experimental|Part C: Open-Label Extension|Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive BIIB067 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years. Participants who received BIIB067 during Part B will receive BIIB067 100 mg on Days 1, 29, and every 28 days thereafter for up to 2 years, with a dose of placebo on Day 15 to maintain the study blind.
16274122|NCT04856982|Experimental|Part D: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will be randomized to receive BIIB067 100 mg or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
16274123|NCT04856969|Active Comparator|Arm A|ATB-1011: 1tab/d for 5days , ATB-1011+ATB-1012: each 1tab/d for 5days
16274124|NCT04856969|Active Comparator|Arm B|ATB-1012: 1tab/d for 5days / ATB-1011+ATB-1012: each 1tab/d for 5days
16274125|NCT04856956|Experimental|Intervention (Use of diagnostic decision support software)|Trainee or nurse practitioner sees patient and uses diagnostic decision support software in developing their differential diagnosis and plan
16274126|NCT04856956|No Intervention|Control (Current process)|Trainee or nurse practitioner sees patient but doesn't use diagnostic decision support software in developing their differential diagnosis and plan
16274127|NCT04856943|Experimental|smartconsent group|Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
16274128|NCT04856943|Placebo Comparator|control group|Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.
16274129|NCT04856930|Experimental|ANB019 Biological Humanized Monoclonal Antibody Low Dose|
16274130|NCT04856930|Experimental|ANB019 Biological Humanized Monoclonal Antibody High Dose|
16274131|NCT04856930|Placebo Comparator|Placebo Solution|
16274132|NCT04856917|Experimental|High Dose Arm: Imsidolimab Biological humanized antibody|
16274133|NCT04856917|Experimental|Low Dose Arm: Imsidolimab Biological humanized antibody|
16274134|NCT04856917|Placebo Comparator|Placebo|
16274135|NCT04856904|Placebo Comparator|Trifarotene Vehicle Cream|
16274136|NCT04856904|Experimental|Trifarotene (CD5789) 50 mcg/g Cream|
16274137|NCT04856891|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.
16274138|NCT04856891|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.
16274139|NCT04856878|Experimental|Intervention|Standard of care (SOC) + single-dose intravenous vancomycin 15mg/kg
16274140|NCT04856878|No Intervention|Control|Standard of care (SOC)
16274141|NCT04856865|Experimental|Arm 1|
16274142|NCT04856865|Experimental|Arm 2|
16274143|NCT04856852|Experimental|Iodine-125+Chemotherapy|Iodine-125; Temozolomide
16274144|NCT04856852|Active Comparator|Surgical resection+Radiochemotherapy|Surgical resection; Radiotherapy; Temozolomide:
16274145|NCT04856839||syringomyelia group|
16274146|NCT04856839||Other neurodegenerative diseases|such as hydrocephalus
16274147|NCT04856839||Normal group|
16274150|NCT04856813|Experimental|active|this is the group that does a treatment with active movement, a program of pain education and a program of home exercise.
16274151|NCT04856813|Active Comparator|non active|this is the group that does a treatment without active movement, a program of pain education and a program of home exercise.
16274152|NCT04856800|Experimental|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). 20 g of whey protein will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
16274153|NCT04856800|Placebo Comparator|Placebo|The placebo will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
16274154|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX（Phase 2）|
16274155|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX （Phase 3）|
16274156|NCT04856787|Placebo Comparator|placebo in combination with BP102 and XELOX|
16274157|NCT04856774|Experimental|SHR -1701 + BP102|
16274158|NCT04856761||Cape Group|In this group, capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
16274159|NCT04856761||S-1 Group|In this group, S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
16274160|NCT04856735|Active Comparator|IPLA:intraperitoneal local anesthetic|intraperitoneal local anesthetic:after the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon. The 20 ml solution containing bupivacaine and lidocaine was injected into the uterine peritoneal region by spraying 5 mL to each quadrant of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer was sutured or left open at the surgeon's preference. At the end of the operation, 20 ml of saline solution was applied subcutaneously in the form of LWI instead of the incision before the skin was closed.
16274161|NCT04856735|Active Comparator|LWI:Surgical wound infiltration|Surgical wound infiltration:a solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed.
16274162|NCT04856735|Active Comparator|C: CONTROL GROUP|one of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
16274163|NCT04856722|Experimental|mini-PNL group|In which PCNL will be performed using miniature nephroscope
16274164|NCT04856722|Experimental|RIRS group|In which RIRS will be performed using a flexible ureteroscope
16274165|NCT04856722|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
16274166|NCT04856709|Other|study group|Women with stage 2 to 4 uterine prolapse. BMI from ≤ 35 kg\m2. Women of any parity including nulliparas will be included. Age of female patients ranges from 20 to 40 years.
16274167|NCT04856696|Experimental|combined non-invasive PGT-A & PGT-A|Infertility women who underwent both non-invasive PGT-A and PGT-A
16274168|NCT04856696|Experimental|non-invasive PGT-A|Infertility women who underwent non-invasive PGT-A only
16274169|NCT04856696|Active Comparator|PGT-A|Infertility women who underwent PGT-A only
16274170|NCT04856683||Patients with endocrine and metabolic diseases|Patients with endocrine and metabolic diseases (hypothalamic-pituitary-gonadal and adrenal diseases, type 2 diabetes mellitus and bone diseases)
16274171|NCT04856670||Control patients undergoing manual cataract surgery|As above
16274172|NCT04856670||Control patients undergoing FLACS|Femtosecond laser assisted cataract surgery
16274173|NCT04856670||Diabetic patients undergoing manual cataract surgery|As Above
16274174|NCT04856670||diabetic patients undergoing FLACS|As Above
16274304|NCT04855812|Experimental|MyoPro|Receiving MyoMo training in-clinic and at home for 6-weeks
16274177|NCT04856644|Experimental|4-month regimen (2HZPM/2HPM)|"Eight weeks of daily treatment with isoniazid (H), pyrazinamide (Z), rifapentine (P), and moxifloxacin (M), followed by
~Nine weeks of daily treatment with isoniazid, rifapentine and moxifloxacin"
16274178|NCT04856644|No Intervention|Standard 6-month regimen (2HERZ/4HR) historical control|"a standard, six-month regimen, with
~Eight weeks of daily treatment with isoniazid (H), rifampin (R), pyrazinamide (Z) and ethambutol (E) followed by
~Eighteen weeks of daily treatment with isoniazid and rifampin, with or without ethambutol"
16274179|NCT04856631|Experimental|Experimental group|Toripalimab Injection (JS001) + Cetuximab
16274180|NCT04856618||Massive Transfusion Positive|Massive Transfusion Positive
16274181|NCT04856618||Massive Transfusion Negative|Massive Transfusion Negative
16274182|NCT04856592|Experimental|VICI Stent|
16274183|NCT04856579|Other|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
16274188|NCT04856553|Experimental|Handgrip exercise (morning)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the morning.
16274189|NCT04856553|No Intervention|Control|In the control session, the participants will remain at rest for the same period of time as in the handgrip exercise protocol.
16274190|NCT04856553|Experimental|Handgrip exercise (afternoon)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the afternoon.
16274191|NCT04856527|Experimental|Experimental Group|Participants will receive physical therapist support to reduce postural sway while completing a precision aiming task in virtual reality, whether or not they require the support.
16274192|NCT04856527|No Intervention|Control Group|Participants will receive no physical therapist support while completing the task.
16274193|NCT04856514|Experimental|Treatment Group|Participation in 16 week telehealth administration of the PEERS protocol for teens (parallel teen and parent/caregiver groups)
16274194|NCT04856501|Experimental|PALS intervention condition|
16274195|NCT04856501|Active Comparator|Control condition|
16274196|NCT04856488|Experimental|Iodine Potassium Iodide solution|Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment
16274197|NCT04856488|No Intervention|No intervention|Participants continue with standard preoperative treatment
16274198|NCT04856475|Experimental|HER2 metastatic breast cancer locally pretreated for previous CNS events and currently progressive|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.
~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
16274199|NCT04856475|Experimental|HER2 positive metastatic breast cancer patients with newly diagnosed brain metastases|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.
~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
16274200|NCT04856475|Experimental|HER2 positive metastatic breast cancer patients with leptomeningeal carcinomatosis|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.
~At screening and during the study treatment period (every 9 weeks), contrast-enhanced neuraxis brain and spine MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. CSF cytological assessment should also be performed.
~Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
16274201|NCT04856462|Experimental|Education Support Group|Caregivers receiving structured education and support
16274202|NCT04856462|Active Comparator|Control Group|Caregivers participating in weekly support calls
16274203|NCT04856449|Experimental|DBT Skills Training|This intervention will consist of a 6-month-group DBT-skills training continuation, in which participants will be trained in mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.
16274204|NCT04856449|Active Comparator|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR will consist of individual therapy sessions that will be focused on processing traumatic memories. Participants will receive up to 16 individual EMDR sessions, of 60 min each.
16274205|NCT04856436||Pregnant women with exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and were filled at least one benzodiazepine prescription during the first trimester (first 90 days of pregnancy).
16274206|NCT04856436||Pregnant women without exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and did not fill a benzodiazepine prescription during the 3 months before the pregnancy onset through the end of the first trimester
16274207|NCT04856423||Us-qFIT group|People in this group will detect fecal hemoglobin concentration by us-qFIT before colonoscopy.
16274208|NCT04856410|Experimental|2-Month Arm|Astronauts on 2-month International Space Station missions will be exposed to spaceflight for a duration of 2 months. Biometric and cognitive data will routinely be collected.
16274209|NCT04856410|Experimental|6-Month Arm|Astronauts on 6-month International Space Station missions will be exposed to spaceflight for a duration of 6 months. Biometric and cognitive data will routinely be collected.
16274210|NCT04856410|Experimental|12-Month Arm|Astronauts on 12-month International Space Station missions will be exposed to spaceflight for a duration of 12 months. Biometric and cognitive data will routinely be collected.
16274211|NCT04856410|Experimental|No Intervention|Subjects matched to 12-month astronauts that stay on Earth and are investigated at similar time points.
16274212|NCT04856397|Other|Control group|"Responders will be in this category. These patients will be maintained on intravitreal anti-VEGF therapy for 1 year, with a monthly PRN (as needed) treatment regimen post 5 monthly loading doses."
16274213|NCT04856397|Experimental|Early switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 3 monthly loading intravitreal eylea.
16274214|NCT04856397|Experimental|Late switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 6 monthly loading intravitreal eylea
16274215|NCT04856397|Other|Non-switch|Suboptimal responders who continue to receive monthly intravitreal anti-VEGF injections.
16274216|NCT04856384|Experimental|persons with Multiple Sclerosis|
16274217|NCT04856384|Experimental|Healthy controls|
16274218|NCT04856371|Experimental|CYH33 + fulvestrant|Participants will receive CYH33 in combination with a standard fixed dose of fulvestrant 500 mg.
16274219|NCT04856371|Experimental|CYH33 + fulvestrant + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of fulvestrant (500 mg) and palbociclib (125 mg).
16274220|NCT04856371|Experimental|CYH33 + letrozole + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of letrozole (2.5 mg) and palbociclib (125 mg)
16274221|NCT04856358|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 3 dose levels in ascending order
16274222|NCT04856358|Placebo Comparator|Placebo SAD|Single doses of placebo
16274223|NCT04856358|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 3 dose levels in ascending order
16274224|NCT04856358|Placebo Comparator|Placebo MAD|Multiple doses of placebo
16274225|NCT04856358|Experimental|GLPG3121 FE fed|Single dose of GLPG3121 in fed state
16274226|NCT04856358|Experimental|GLPG3121 FE fasted|Single dose of GLPG3121 in fasted state
16274227|NCT04856345|Experimental|Music with synchronising|walking to music that one can synchronise to
16274228|NCT04856345|Active Comparator|Music without synchronising|walking to music that one cannot synchronise to
16274229|NCT04856345|Sham Comparator|No music|walking without music.
16274230|NCT04856319|Active Comparator|Prophylaxis|2 g amoxicillin+clavulanic acid 1 hour prior to dental implant surgery
16274231|NCT04856319|Placebo Comparator|Placebo|placebo 1 hour prior to dental implant surgery
16274232|NCT04856306||Myomectomy|After routine patient counseling on fibroid treatments, this group chooses surgical myomectomy of any type (abdominal/laparoscopic/hysteroscopic)
16274233|NCT04856306||Uterine artery embolization|After routine patient counseling on fibroid treatments, this group chooses uterine artery embolization procedure.
16274234|NCT04856306||Elagolix|After routine patient counseling on fibroid treatments, this group chooses the following medication: every morning (AM), 300mg elagolix, 1mg estradiol, and 0.5mg norethindrone acetate capsules taken in one combined capsule and every evening (PM), 300mg elagolix capsule. In our study, this medication will be administered for 12 months unless the subject withdraws from the study. It is FDA-approved for continuous use of up to 24 months.
16274235|NCT04856293|Experimental|Three Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial, and a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules)
16274236|NCT04856293|Experimental|Two Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
16274237|NCT04856280|Experimental|The kinesiological taping (KT) group (n=15)|6 sessions of taping was applied to the kinesiological taping group, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended. Using the KT ligament technique, it was applied to the supra pubic region with 100% tension in order to reduce contraction in the uterus
16274238|NCT04856280|Active Comparator|The aerobic exercise (AE) group (n=15)|"In the AE group, walking and climbing stairs were given during the menstrual cycle, 45 minutes session per day, 3 days a week over 3 weeks. The exercise protocol consists of 5 minute warm up, 35 min AE and 5 minute cool-down exercises. Warm-up and cool-down exercises include an active range of motion (ROM) exercises for upper and lower extremity. Aerobic exercise includes 30 min of moderate walking and climbing stairs. The aerobic exercise was performed in accordance with the definition of moderate-intensity exercise of the World Health Organization; It was given to the participants that during moderate exercise, the individual should walk with a tempo in a way that he can speak but cannot sing"
16274239|NCT04856280|No Intervention|The control group (n=15)|No intervention was applied to the control group.
16274240|NCT04856267||Systemic AL Amyloidosis study cohort|"Eligible patients will undergo subcutaneous implantation of a cardiac monitor device (Brand name - LINQ device, Medtronic - referred to in the application as implantable loop recorder or ILR)"
16274267|NCT04856072|Experimental|Treatment|All patients will be implanted with a deep brain stimulation system and will receive personalized fornix stimulation; parameters will be selected based on the dose finding cognitive tests.
16274241|NCT04856241|Experimental|Supported Implementation (Intervention)|Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support & networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
16274242|NCT04856241|Active Comparator|Unsupported implementation (Control)|"The unsupported implementation arm will be usual care. Access to the Prep-to-Play resources, including videos, downloadable manuals and posters, are freely available to coaches online. The online resources incorporate the same four concepts as described in the supported implementation - dynamic warm-up, strength exercises, football fundamentals, and education. In the control arm, no additional resources, education, or support will be provided."
16274243|NCT04856228|Other|diagnostic single group|Patients diagnosed with lateral epicondylitis with physical examinations will be evaluated with electrophysiology After electrophysiological evaluations, patients' effected extremity evaluated with ultrasonography for lateral epicondylitis and radial tunnel syndrome and compared with uneffected side 30 minutes after posterior interosseous nerve block with 1 cc 2% lidocaine with USG guide, full examination will be repeated for evaluation of NRS score changing to exact diagnose of radial tunnel syndrome 30 minutes after lateral epicondyle 1 cc 2% lidocaine injection with USG guide, full examination will be repeated for evaluation of NRS score changing to final diagnose of lateral epicondylitis
16274244|NCT04856215|Experimental|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The medicinal product consists of the murine IgG1 anti-CD66 monoclonal antibody radio-labelled with 111In for imaging and dosimetry and with 90Y for therapy.
~Dosage indications The [111In]-labeled anti-CD66 monoclonal antibody (MAb) will be given at an infused activity of 100MBq/sqm between 1-4 weeks before the therapeutic dose of radiolabelled antibody.
~[90Y]-yttrium-labeled anti-CD66 MAb will be given as a single infusion on day - 14 prior to transplant. [90Y]-yttrium labelled anti-CD66 MAb will be given to target an absorbed dose to the bone marrow of 45 Gy +/- 10%. The maximum dose to be delivered to the liver and the kidneys is 15 Gy and 10 Gy, respectively."
16274245|NCT04856202|Active Comparator|Intervention|A trained facilitator will schedule two facilitated Respecting Choices interviews with the patient and preferably, if the patient agrees, in the presence of a caregiver or relative.
16274246|NCT04856202|No Intervention|Control|Care as usual
16274247|NCT04856189|Experimental|Treatment (selinexor, pembrolizumab)|Patients receive selinexor PO on days 1, 8 and 15, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
16274248|NCT04856176|Experimental|GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed|All patients will receive GM-CSF plus maintenance pembrolizumab with or without pemetrexed, following completion of 4 cycles of chemo-immunotherapy
16274249|NCT04856163|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 24 weeks post-partum. Services will be available through mobile phone app.
16274250|NCT04856163|No Intervention|ebook|Participants in the control arm will receive care as usual. They will also receive a ebook with content on infant care.
16274251|NCT04856150|Experimental|Q-1802|Q-1802 dose exploration and Q-1802 dose extension
16274252|NCT04856137|Experimental|single arm|ruxolitinib, paclitaxel, and rituximab
16274253|NCT04856124||Treatment resistant depressed outpatients|Subjects had a clinically meaningful response to IV racemic ketamine and remained on other psychotropic medications during treatment with both IV ketamine and IN esketamine. Concomitant medication classes included CNS stimulants (n = 7), atypical antipsychotics (n = 6), selective serotonin reuptake inhibitors (n = 5), serotonin/norepinephrine reuptake inhibitors (n = 4), anticonvulsants (n = 3), antipsychotics (n = 3), mood stabilizers (n = 3), benzodiazepines (n = 2), norepinephrine/dopamine reuptake inhibitors (n = 2), alpha 2 antagonists (n=1), and sedative hypnotics (n = 1). Two patients (20%) previously underwent ECT with partial but transient relief from depressive symptoms, two (20%) failed TMS, and no patients reported any period of greater than 50% improvement during their current depressive episode prior to ketamine treatment.
16274254|NCT04856111|Active Comparator|Pirfenidone|Pirfenidone will be started at a dose of 600 mg/day. The dose will be escalated by 600 mg/day every 3-7 days up to a targeted dose of 2400 mg/day. The subjects will be administered the maximum tolerated dose for a total period of 24 weeks from randomization.
16274255|NCT04856111|Active Comparator|Nintedanib|Subjects in this group will be administered nintedanib at a dose of 150 mg twice daily. The liver function tests will be monitored as above. The dose will be reduced to 100 mg twice daily, if there is intolerance to 300 mg/day dose.
16274256|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 2 capsules, Batch A|
16274257|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A|
16274258|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 1 capsule, Batch A|
16274259|NCT04856098|Experimental|Part 2 Ultibro Breezhaler 2 capsules, Batch A|
16274260|NCT04856098|Experimental|Part 2 Ultibro Breezhaler 2 capsules, Batch B|
16274261|NCT04856085|Experimental|Cohort 1a (VIR-2218 + VIR-3434)|Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
16274262|NCT04856085|Experimental|Cohort 2a (VIR-2218 + VIR-3434)|Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
16274263|NCT04856085|Experimental|Cohort 3a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
16274264|NCT04856085|Experimental|Cohort 4a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
16274265|NCT04856085|Experimental|Cohort 5a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
16274266|NCT04856085|Experimental|Cohort 6a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
16274302|NCT04855825|Experimental|Robotic Exoskeleton Therapy|Gait rehabilitation provided using a wearable robotic exoskeleton
16274268|NCT04856059|Other|Cardiac MRI, ECG and Blood Biomarkers|Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.
16274269|NCT04856046||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. Patients' previously collected tissue samples are analyzed. Patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years.
16274270|NCT04856033|Experimental|TM|Transcendental Mediation
16274271|NCT04856033|Active Comparator|PCT|Present Centered Therapy
16274272|NCT04856007|Experimental|Dapagliflozin 5mg + Metformin 500mg XR|co-administration of a single oral dose of a 5mg dapagliflozin (Forxiga® 5mg) tablet and a 500mg metformin XR (Glucophage XR®) tablet
16274273|NCT04856007|Experimental|Dapagliflozin/metformin XR FDC 5/500 mg|single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR subject
16274274|NCT04856007|Experimental|Dapagliflozin 10mg + Metformin 1000mg XR|co-administration of a single oral dose of a 10mg dapagliflozin (Forxiga® 10mg) tablet and two 500mg metformin XR (Glucophage XR®) tablets
16274275|NCT04856007|Experimental|Dapagliflozin/metformin XR FDC 10/1000 mg|ingle FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR
16274276|NCT04855994|Active Comparator|paravertebral group|The investigators performed Paravertebral block to that patient group for postoperative analgesia
16274277|NCT04855994|Active Comparator|pectoral group|The investigators performed pectoral block to that patient group for postoperative analgesia
16274278|NCT04855981|Experimental|whole body vibration|the subjects will receive whole-body vibration three times per week for twelve weeks +supplementations
16274279|NCT04855981|Experimental|aerobic exercise|the subjects will receive aerobic exercise three times per week for twelve weeks+supplementations
16274280|NCT04855981|Active Comparator|supplementations|the subjects will receive supplementations three times per week for twelve weeks
16274281|NCT04855968|Active Comparator|control (CON)|will receive the usual standard of care post-operative pain pills for the involved shoulder (Control Group)
16274282|NCT04855968|Experimental|Mindfulness/Meditation (MM)|will receive the usual standard of care post-operative pain pills for the involved shoulder with the addition of access to the Headspace application for mindfulness/meditation (Mindfulness/Meditation Group)
16274283|NCT04855942|Experimental|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
16274284|NCT04855942|Active Comparator|Physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
16274285|NCT04855929|Experimental|ANV419 single agent, Q2W|
16274286|NCT04855929|Experimental|ANV419 in combination with CPI or Immunostimulatory agent, Q2W|
16274287|NCT04855916|Experimental|ABLE Exoskeleton - KAFO|Participants belonging to this arm start the study by performing the training program using the ABLE Exoskeleton. After the resting period, they repeat the training program using KAFO orthoses.
16274288|NCT04855916|Experimental|KAFO - ABLE Exoskeleton|Participants belonging to this arm start the study by performing the training program using the KAFO orthoses. After the resting period, they repeat the training program using the ABLE Exoskeleton.
16274289|NCT04855903|Experimental|Arm 1 (early phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 3 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks
~These 2 phases will be followed by a follow-up phase during 5 weeks"
16274290|NCT04855903|Experimental|Arm 2 (mid phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 4 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks
~These 2 phases will be followed by a follow-up phase during 4 weeks"
16274291|NCT04855903|Experimental|Arm 3 (late phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 5 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks
~These 2 phases will be followed by a follow-up phase during 3 weeks"
16274292|NCT04855890|Active Comparator|Cryo-Ablation|Cryo-Balloon (Arctic Front Advance ProTM, Medtronic, Minneapolis, MN, USA) will be advanced to the LA and navigated to the PV's using an inner-lumen circular mapping catheter (Achieve AdvanceTM, Medtronic, Minneapolis, MN, USA). After confirming complete PV sealing by the CB using occlusion angiograms cryothermal energy will be applied for min 120 seconds aiming at PV isolation of all PV's according to the clinical standard.
16274293|NCT04855890|Active Comparator|High Power Short Duration-Ablation|"A detailed electroanatomical map of the left atrium during sinus rhythm will be acquired using Ensite (Abbott, St. Paul, MN, USA).
~Upon completion of the LA map, a second transseptal puncture will be performed in order to insert an ablation catheter. To achieve antral PVI irrigated radiofrequency current ablation will be performed using a power of 70W and a flush rate of 8-30ml/min with a duration of 5 seconds for the anterior and 7 seconds for the posterior LA. Ablation catheters used will contain Flexibilty (Abbott, St. Paul, MN, USA) and TactiFlex (Abbott, St. Paul, MN, USA)."
16274294|NCT04855877|Active Comparator|Oral Tranexamic Acid|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
16274295|NCT04855877|Placebo Comparator|Placebo|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
16274296|NCT04855864|Other|BCR TKA|Patients with intact and functional ACL and PCL will be treated with the BCR design
16274297|NCT04855864|Other|BCS TKA|Patients with an afunctional or absent ACL and/or PCL will be treated with the BCS design
16274298|NCT04855851|Experimental|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|Subjects will receive 6 PAIN NEUROSCIENCE EDUCATION (PNE) sessions and 12 weeks (3 times/week) of STRENGTH TRAINING (ST)
16274299|NCT04855851|Active Comparator|USUAL CARE|The subjects of this group will receive Usual Care. In Spain, the treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients, and recommendation of aerobic and flexibility exercise
16274300|NCT04855838|Experimental|Intervention group|Intensive training with oral neuromuscular device (intervention group) and traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
16274301|NCT04855838|No Intervention|Control group|Traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
16307405|NCT04625088|Experimental|Atropine + Standardized liquid Test meal|
16274305|NCT04855812|Active Comparator|Myo-SB|Receiving MyoMo training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
16274306|NCT04855812|Active Comparator|Control|Receiving conventional therapy/training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
16274308|NCT04855786|Experimental|Thoracic Duct Drainage|This is the main study group of patients with thoracic duct drainage
16274309|NCT04855773|Experimental|PrEPmate|Participants randomized to this study arm will receive the PrEPmate mHealth intervention (bi-directional text messaging with PrEP navigators/clinic staff) to support PrEP adherence and continuation.
16274310|NCT04855773|Experimental|Dot Diary mobile application|Participants randomized to this study arm will download and use the Dot Diary mobile application on a personal device, to support PrEP adherence and continuation.
16274311|NCT04855760|Experimental|REL-1017 25 mg|Participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).
16274312|NCT04855747|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
16274313|NCT04855747|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
16274314|NCT04855734|Experimental|FACE-Rare Intervention|"FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions.
~Sessions 1&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child.
~Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions."
16274315|NCT04855734|No Intervention|Treatment-as-Usual (TAU) Control|To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.
16274316|NCT04855721|Experimental|AUR101 400 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
16274317|NCT04855721|Experimental|AUR101 200 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
16274318|NCT04855721|Experimental|AUR101 400 mg PO QD|Patients will receive AUR101 / placebo in double blind, double dummy manner
16274319|NCT04855721|Placebo Comparator|Placebo|Patients will receive AUR101 / placebo in double blind, double dummy manner
16274320|NCT04855708|Experimental|Virtual visit|Patients will have 2-week post-operative virtual visit
16274321|NCT04855708|Active Comparator|Office visit|Patients will return to the office for a 2-week post-operative visit
16274322|NCT04855695|Experimental|Acalabrutinib, Venetoclax, and Obinutuzumab|"This study will consist of 2 parts (Parts A and B) and begin in the relapsed/refractory (R/R) MCL setting (Part A) with the phase 1 portion consisting of a dose finding stage to determine the recommended phase 2 dose (RP2D).The phase 1 dose finding stage will follow a 3+3 dose finding schema, such that there will be a safety pause and evaluation after the first 3 participants at any given dose level have completed therapy through cycle 5, day 1. If there are no dose limiting toxicities (DLTs) seen, an additional 3 participants will be treated at the same dose level and if there are 0 or 1 DLTs seen, the RP2D will have been determined.
~Each study drug is given according to a different schedule.
~Each treatment cycle lasts 28 days (4 weeks).
~Acalabrutinib:
~Obinutuzumab:
~Venetoclax:"
16274323|NCT04855682||A|Endoscopic discectomy
16274324|NCT04855682||B|Microdisectomy
16274325|NCT04855682||C|Hemilaminectomy
16274326|NCT04855656|Experimental|Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study|Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
16274327|NCT04855643|Experimental|Treatment|
16274328|NCT04855643|Sham Comparator|Control Group|
16274329|NCT04855630|Experimental|Sleep Only|
16274330|NCT04855630|Active Comparator|Exercise Only|
16274331|NCT04855630|Active Comparator|Exercise + Sleep|
16274332|NCT04855617||Patients Receiving Multiple Sclerosis care|Patients currently receiving ocrelizumab or initiating ocrelizumab per their MS treating physician.
16274333|NCT04855591|Experimental|SHR-1703 Dose Level 1|Dose level 1 SHR-1703
16274334|NCT04855591|Experimental|SHR-1703 Dose Level 2|Dose level 2 SHR-1703
16274335|NCT04855591|Experimental|SHR-1703 Dose Level 3|Dose level 3 SHR-1703
16274336|NCT04855591|Experimental|SHR-1703 Dose Level 4 (optional)|Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review
16274337|NCT04855578|No Intervention|Usual Medical Care|During the control period, patients admitted to the study sites who qualify for the trial will receive a pharmacy medication reconciliation as part of usual medical care. Study participants will be informed that the goal of the trial is to evaluate medication use and medication changes after discharge, but they will not be informed that gabapentinoids are specifically being targeted. Medical staff will not receive specific information about the trial, or particular instructions with regards to deprescription during the control period.
16274338|NCT04855578|Experimental|In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid Prescription|During the intervention period, patients admitted to the study sites who qualify for the trial will receive an in-hospital educational brochure. Additionally, the medical team will attend an educational session about gabapentinoid prescription.
16274339|NCT04855565|Active Comparator|ALY688-SR|single dose subcutaneous injection
16274341|NCT04855552|Experimental|Single-Arms Longitudinal Group|Behavioral weight-loss program via telehealth (video conferencing). Participants will receive weekly group sessions of lifestyle counseling for the first 20-weeks, followed by every other week sessions in weeks 22 and 24, for a total of 6-months of intervention.
16274342|NCT04855539||wave 1|
16274343|NCT04855539||wave 2|
16274344|NCT04855526|Experimental|Occasional Users - High THC and High CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit
16274345|NCT04855526|Experimental|Occassional Users - High THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit
16274346|NCT04855526|Experimental|Occassional Users - No THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD
16274347|NCT04855513|No Intervention|standard care|The control group will receive standard care treatment including aspirin according to ACOG guidelines. The control group estimated number of enrollment is 207 patients.
16274348|NCT04855513|Experimental|Metformin|The intervention group will be give metformin 500 mg orally three times daily in addition to standard of care. The estimated number to be enrolled are 207 patients.
16274349|NCT04855487|Experimental|Intervention group|Adolescents/young adults with cancer will participate in a 5-week online expressive storytelling intervention. They will independently create digital stories about themselves while their target audiences are their primary nurses. They will then participate in weekly online meetings with nursing research staff, during which they introduce their stories and discuss their reflections. In the final session, they will create a one-page or five-slide story to share with their primary nurses, if they want.
16274350|NCT04855474|Experimental|Low Protein|0.2 g/kg/day of protein provided as crystalline amino acid made after egg protein.
16274351|NCT04855474|Experimental|Moderate Protein|1.2g/kg/day of protein provided as crystalline amino acid made after egg protein.
16274352|NCT04855474|Experimental|High Protein|2.0 g/kg/day of protein provided as crystalline amino acid made after egg protein.
16274353|NCT04855448|Experimental|Surgeon A|This group is consisted of 56 cases performed using the Micro Hand S robot and da Vinci robot by one single surgeon in low anterior resection for rectal cancer
16274354|NCT04855448|Active Comparator|Surgeon B|This group is consisted of 56 cases performed using the da Vinci robot by one single surgeon in low anterior resection for rectal cancer
16274355|NCT04855435|Experimental|MBS8(1V270)|Treatment arm (single arm study)
16274356|NCT04855422||Stable SPK recipients without rejection and/or BKV viremia|All SPK transplant recipients are monitored for routine labs twice a week first month, weekly at 2nd and 3rd month, every 2 weeks between 3-6 months, once a month between 6-12 months and then once every 2 months.
16274357|NCT04855422||Acute T-Cell Mediated Rejection (TCMR )|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
16274358|NCT04855422||Antibody Medicated Rejection (ABMR)|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
16274359|NCT04855422||BKV viremia|All patients will be monitored for BKV viremia monthly after transplantation up to 6 months and at 9, 12 and 24 months. Luminex SAB will be monitored at 1, 3, 12 and 24 months. Spot urine protein and creatinine and HbA1c will be monitored every 3 months after transplantation
16274360|NCT04855422||Follow-up of subjects with acute TCMR, ABMR and BKV viremia after treatment|BKV viremia, Luminex SAB, spot urine protein and creatinine is studied at the time clinically indicated biopsy and/o worsening kidney function and proteinuria.
16274361|NCT04855409||Bipolar Depression|Subjects with bipolar type I disorder depressive episode diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
16274362|NCT04855409||Healthy|Healthy control subjects matched with bipolar depressive patients by age and sex
16274363|NCT04855396||Patients with Severe Traumatic Brain Injury|Participants will be enrolled in the HOBIT trial
16274364|NCT04855383|Experimental|The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
16274365|NCT04855383|No Intervention|The group of frozen embryo transfer without intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Embryo transfer will be done without human chorionic gonadotropin intramuscular injection.
16274366|NCT04855370|Experimental|Patients diagnosed with Pulmonary Embolism|Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention.
16274367|NCT04855357|Experimental|Smoke-free home permanent supportive housing (PSH) resident intervention + Staff Intervention|Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.
16274368|NCT04855357|Other|Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident intervention|The current standard of care includes no interventions for smoke-free home adoption or referrals to smoking cessation resources. Wait-list group receives Smoke-Free Home (SFH) intervention after intervention group complete 6-month follow-up
16277961|NCT04830566|Sham Comparator|Simulated myofascial release technique group|
16274369|NCT04855331|Active Comparator|Minimally invasive radical pancreatectomy|After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent laparoscopic or robotic radical pancreatectomy.
16274370|NCT04855331|Active Comparator|Open radical pancreatectomy|After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent open radical pancreatectomy.
16274371|NCT04855305|Active Comparator|Patients with Interstitial Lung Disease|
16274372|NCT04855305|Active Comparator|Healthy Volunteers|
16274373|NCT04855292|Experimental|TG103 injection 15 mg|TG103 injection (15 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
16274374|NCT04855292|Experimental|TG103 injection 22.5 mg|TG103 injection (22.5 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
16274375|NCT04855292|Experimental|TG103 injection 30 mg|TG103 injection (30 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
16274376|NCT04855279|Placebo Comparator|Control|
16274377|NCT04855279|Active Comparator|Topical neutral sodium fluoride|
16274378|NCT04855279|Active Comparator|ACP-CCP gel|
16274379|NCT04855279|Active Comparator|nano-hydroxyapatite solution|
16274380|NCT04855266|Experimental|Iron Sucrose Group|Subjects will receive intravenous iron sucrose during a tilt table test
16274381|NCT04855266|Placebo Comparator|Placebo Group|Subjects will receive intravenous placebo during a tilt table test
16274382|NCT04855253|Experimental|Dose level 1 : E7777 at 5 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
16274383|NCT04855253|Experimental|Dose level 1 : E7777 at 7 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
16274384|NCT04855253|Experimental|Dose level 1 : E7777 at 9 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
16274385|NCT04855253|Experimental|MTD from phase 1|Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy
16274386|NCT04855240|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
16274387|NCT04855240|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
16274388|NCT04855240|Placebo Comparator|Placebo|Placebo
16274389|NCT04855227||Laparoscopic ventral hernia repair|These subjects will undergo a laparoscopic primary umbilical or incisional hernia repair.
16274390|NCT04855227||Robotic-assisted ventral hernia repair|These subjects will undergo a robotic-assisted primary umbilical or incisional hernia repair.
16274391|NCT04855214||Body-powered Prosthesis User|Individuals who use a prosthesis that relies on a system of cables or harnesses which are operated using other parts of the body like the shoulders, chest, or elbows.
16274392|NCT04855214||Single degree-of-freedom (DOF) myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform only one movement.
16274393|NCT04855214||Multi-DOF myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform more than one movement.
16274394|NCT04855214||Sensory Augmentation|Individuals who experience augmented prosthesis sensory feedback through vibrating devices or pressure bladders, using electrical stimulation applied to the residual limb, or using neural implants.
16274397|NCT04855188|Experimental|YVOIRE Y-Solution 540|
16274398|NCT04855188|Active Comparator|YVOIRE volume plus|
16274399|NCT04855175|Active Comparator|Autograft group|The autologous group will receive bone harvested from the patient's own body
16274400|NCT04855175|Active Comparator|Allograft group (ClearFit)|The allograft group will receive a synthetic bone known as ClearFit
16274401|NCT04855149||WALANT|anesthesia performed with WALANT technique
16274402|NCT04855149||BAx|anesthesia performed with axillary block under ultrasound control
16274403|NCT04855136|Experimental|Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)|bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.
16274404|NCT04855136|Experimental|Arm B- bb2121 in combination with BMS-986405 (JSMD194)|bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion.
16274405|NCT04855136|Experimental|Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib|"bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agents will be administered as follow:
~Cohort 1 (DPd) DARA, POM and dexamethasone at M3D1 until disease progression.
~Cohort 2 (PVd) POM, BTZ and dexamethasone at M3D1 until disease progression"
16274406|NCT04855123|Other|patient|
16274407|NCT04855110|Active Comparator|Day 2 warfarin group|warfarin will be administered on day 2 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
16274408|NCT04855110|Active Comparator|Day 5 warfarin group|warfarin will be administered on day 5 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
16274409|NCT04855097|Experimental|Standard care group|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will be blinded to the results and will choose between a low-moderate and high diuretic dose based on usual care clinical assessment of volume status.
16274410|NCT04855097|Experimental|BVA-guided treatment arm|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will receive the results and will choose between a low-moderate and high diuretic dose based on measured volume status.
16274438|NCT04854902|Active Comparator|Suture|6/0 polyvinylidene fluoride sutures are used for stabilization, while the donor site is left untreated.
16274439|NCT04854889|Experimental|Decitabine|Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.
16307406|NCT04625075||Healthy Volunteer|Age and sex matched healthy volunteer
16274411|NCT04855084|Experimental|Complete Digital Fixed Dental Prosthesis|"Following the Digital Impression using 3 Shape Trios Intraoral scanner, digital design, and manufacturing of the Monolithic Zirconia FDPs.
~Monolithic FDPs: before adjustment
~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs before the occlusal adjustment.
~Monolithic FDPs: after adjustment
~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs after the occlusal adjustment."
16274412|NCT04855084|Active Comparator|Analog Fixed Dental Prosthesis|"Following the Conventional Impression, transfer to the articulator with Face bow. Manufacturing of the FDPs with lost wax technique and veneering.
~Metal fused porcelain FDPs: before adjustment
~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs before the occlusal adjustment.
~Metal fused porcelain FDPs: after adjustment
~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs after the occlusal adjustment."
16274413|NCT04855071|Active Comparator|Interventional group|"The intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
~Furthemore, active RF will be applied intracavitary, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session)."
16274414|NCT04855071|Sham Comparator|Comparator group|The intervention will be the same that in IG (exercises to balance the pelvis and their muscles, etc) an also standards of water, urination, food, defecation, postural hygiene and physical activity for their generalization at home and life habit advices. The application of RF in the control group will follow the same application procedure as in the intervention group with the only difference that no parameter is applied to the RF device (in terms of temperature, power, frequency and dose); that is, it remains off for the entire duration of the session.
16274415|NCT04855045|Experimental|Group 1 - open label|
16274416|NCT04855045|Experimental|Group 2 - open label|
16274417|NCT04855045|Experimental|Group 3: open label|
16274418|NCT04855045|Experimental|Group 4: double-masked, randomized to one of 2 dose cohorts|
16274419|NCT04855032|Experimental|Reactive Perturbations|
16274420|NCT04855032|Experimental|Proactive Perturbations|
16274421|NCT04855019|Active Comparator|periarticular injection group (PI)|the group to be given a periarticular injection by an orthopedist
16274422|NCT04855019|Active Comparator|Combined suprascapular-axillary nerve block group (CSAB)|the group in which an anesthesiologist will perform combined suprascapular axillar border block under ultrasound guidance
16274423|NCT04855006|Experimental|Vaginal Microbiome Transplant|Women are given the vaginal microbiome transplant at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
16274424|NCT04855006|Placebo Comparator|Vaginal Microbiome Transplant Placebo|Women are given the vaginal microbiome transplant placebo at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
16274425|NCT04855006|Experimental|Vaginal Microbiome Donors|Women allocated in the donor group will donate their vaginal secretion, which will be processed and analyzed throughy before it is used as a transplant. In total, the donors will each provide approximately 10 donations of vaginal secretion.
16274426|NCT04854993|Experimental|Increased dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
16274427|NCT04854993|Active Comparator|Standard dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
16274428|NCT04854980||Experimental:|Blood Sample Taken
16274431|NCT04854941|Experimental|Probiotics group (PRO)|99 patients with COVID-19 infection who have been supplemented with a Lactobacillus and Bifidobacterium containing probiotic in addition to standard regimen (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
16274432|NCT04854941|No Intervention|Control group (CON)|101 patients with COVID-19 infection who have been treated with standard regimen only (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
16274433|NCT04854928|Experimental|LTX-109 treatment|Single Dose by Nasal application of LTX-109 gel 3%, 250 microliters in each nostril.
16274434|NCT04854928|Placebo Comparator|Placebo|Single Dose by Nasal application of placebo gel, 250 microliters in each nostril.
16274435|NCT04854915|Active Comparator|Liverpool Overweight and Obesity Programme (LOOP) only|Patients will continue to follow the LOOP@ Alder Hey programme.
16274436|NCT04854915|Experimental|LOOP + mHealth technology assisted exercise counselling|Patients will continue to work with the LOOP MDT. However, exercise and physical activity advise will be taken over by an exercise specialist. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
16274437|NCT04854902|Experimental|Cyanoacrylate|The graft is stabilized and the donor site is coated with cyanoacrylate.
16307422|NCT04624919|Active Comparator|Hot/Dry|
16274440|NCT04854876|Experimental|Vaccinated with 1st dose of COVID-19 Vaccine & treated with 5-ALA Phosphate/SFC|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) and that will be treated with 150mg 5-ALA Phosphate/SFC for 28 days
16274441|NCT04854876|No Intervention|Vaccinated with 1st dose of COVID-19 Vaccine|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) only (Control)
16274442|NCT04854850|Experimental|Apollo|Participants will all receive Apollo devices.
16274443|NCT04854837||Hemodialysed patients received remdesivir|Remdesivir: day-1: 200 mg intravenously; day 2-5: 100 mg intravenously
16274444|NCT04854837||Hemodialysed patients not received remdesivir|Standard of care
16274445|NCT04854824||'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
16274446|NCT04854824||'Historic control' cohort|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS and treated at home by family physicians with drug regimens that are not necessarily guided by those proposed in the recommendations
16274449|NCT04854798|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
16274450|NCT04854798|No Intervention|Control Group|Control Group
16274451|NCT04854785||Group 1 (DNP-mild)|Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
16274452|NCT04854785||Group 2 (DNP-moderate)|Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
16274453|NCT04854785||Group 3 (Healthy Control Participants)|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
16274454|NCT04854772|Experimental|Mind Body Syndrome Therapy for Long Covid|"The participants will receive an initial one-on-one interview, followed by 1 to 2 hour biweekly group interactive, educational sessions for 12 weeks. This program also includes a day-long retreat at the end of the required course period. Participants will also be provided reading materials to study during the intervention period"
16274455|NCT04854759|Experimental|Study group|
16274456|NCT04854759|Placebo Comparator|Control group|
16274457|NCT04854746|Active Comparator|Cohort 1 Low Dose Active|VXA-GI.1-NN tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log10
16274458|NCT04854746|Active Comparator|Cohort 3 High Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log11
16274459|NCT04854746|Placebo Comparator|Cohort 1 Low Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
16274460|NCT04854746|Placebo Comparator|Cohort 3 High Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
16274461|NCT04854746|Active Comparator|Cohort 2 Medium Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 3x10Log11
16274462|NCT04854746|Placebo Comparator|Cohort 2 Medium Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
16274463|NCT04854733||Referees|There will be no interventions. Motor and cognitive assessments will be conducted.
16274464|NCT04854733||Athletes|There will be no interventions. Motor and cognitive assessments will be conducted.
16274465|NCT04854720|Experimental|Group 1 (Fuji II LC-Fuji Triage)|In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
16274466|NCT04854720|Experimental|Group 2 (Clinpro XT Varnish-Fuji Triage)|In Group 2, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA) (test 2). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
16274467|NCT04854720|Experimental|Group 3 (Beautiful Flow- Fuji Triage)|In Group 3, newly erupted mandibular permanent first molars were sealed with Giomer containing fissure sealant material (Beautifil Flow, Shofu, Kyoto, Japan) (test 3). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
16274473|NCT04854694|Experimental|All Subjects|"All participants will be fit tested for the masks to ensure that the appropriate size is used. Some participants will wear the FaceView Mask™ (first) for 5 minutes before wearing the conventional surgical N95 respirator for 5 minutes. Others will wear the conventional surgical N95 respirator (first) for 5 minutes before wearing the FaceView Mask™ for 5 minutes.
~All subjects will complete the study survey after exposure to the interventions."
16274474|NCT04854681|Experimental|TQB2928 injection|Dose Escalation: intravenous (IV) infusion of TQB2928 as monotherapy
16278530|NCT04826640||Pregnant women who receive COVID-19 vaccine|Pregnant women who receive COVID-19 vaccine
16274475|NCT04854668|Experimental|Anlotinib + CapeOx|Anlotinib combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Anlotinib combined with Capecitabine.
16274476|NCT04854668|Active Comparator|Bevacizumab + CapeOx|Bevacizumab combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Bevacizumab combined with Capecitabine.
16274477|NCT04854655|Active Comparator|Control|Conventional resin composite
16274478|NCT04854655|Experimental|Intervention 1|Activa Presto
16274479|NCT04854655|Experimental|Intervention 2|Giomer
16274480|NCT04854642|Experimental|T - R|Subjects were assigned to the sequence of treatments TR to receive Ladarixin in fed conditions (T treatment) during period 1 and in fasting conditions (R treatment) in period 2.
16274481|NCT04854642|Experimental|R - T|Subjects were assigned to the sequence of treatments RT to receive Ladarixin ini fasting conditions (R treatment) in period 1 and in fed conditions (T treatment) during period 2.
16274482|NCT04854629|Experimental|Spinomed active orthosis|Wearing the orthosis for 16 weeks
16274483|NCT04854629|No Intervention|Control group|No intervention: non spinomed active control
16274484|NCT04854616|Experimental|CoSTED Intervention|"CoSTED is an opportunistic smoking cessation intervention comprising three elements:
~brief smoking cessation advice
~the provision of an e-cigarette and training in its use
~referral to stop-smoking services"
16274485|NCT04854616|No Intervention|Treatment as Usual|Signposting to NHS smoking cessation services through provision of written information about local services.
16274486|NCT04854603|Experimental|Chocolate milk with a regular added sugar content|Dairy product with a regular sugar content
16274487|NCT04854603|Experimental|Chocolate milk with a reduced added sugar content|Dairy product with a reduced sugar content
16274488|NCT04854603|Experimental|Yogurt with a regular added sugar content|Dairy product with a regular sugar content
16274489|NCT04854603|Experimental|Yogurt with a reduced added sugar content|Dairy product with a reduced sugar content
16274490|NCT04854603|Experimental|Energy-free control|Potable water
16274491|NCT04854577|Experimental|"Intervention group: Opioid Free Anesthesia with a pecto-intercostal fascial plane block"|Patients to whom a standardized opioid free anesthesia consisting of esketamine, lidocaine and dexmedetomidine will be administered with a pre-incisional pecto-intercostal fascial plane block.
16274492|NCT04854577|Active Comparator|"Control group: Traditional Opioid-based Anesthetic Regimen"|Patients who will receive a traditional opioid based anesthetic regimen. The administered dose of opioids is at the discretion of the attending anesthesiologist.
16274493|NCT04854564||End-stage liver disease (ESLD) patients|These potential liver transplant candidates are patients with end-stage liver disease (ESLD) who have been assigned to the liver transplant waitlist.
16274494|NCT04854564||Caregivers of potential liver transplant candidates|They are the primary caregivers for the patients.
16274495|NCT04854551|Experimental|Healthy adults: placebo first|This arm will receive placebo first, then active medication second
16274496|NCT04854551|Experimental|Healthy adults: active medication first|This arm will receive active medication first, then placebo second
16274497|NCT04854538|Experimental|T test|Test drug (Ekmasonid) 1 tablet contains 9 mg Budesonide
16274498|NCT04854538|Experimental|B reference (first dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
16274499|NCT04854538|Experimental|B reference (second dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
16274500|NCT04854525||One Stage Reconstruction With pre-reconstruction Radiotherapy|
16274501|NCT04854525||Two Stage Reconstruction With pre-reconstruction Radiotherapy|
16274502|NCT04854525||Autologous Reconstruction With pre-reconstruction Radiotherapy|
16274503|NCT04854525||One Stage Reconstruction Without pre-reconstruction Radiotherapy|
16274504|NCT04854525||Two Stage Reconstruction Without pre-reconstruction Radiotherapy|
16274505|NCT04854525||Autologous Reconstruction Without pre-reconstruction Radiotherapy|
16274506|NCT04854512|Experimental|Investigational Arm (Metformin DR plus metformin IR placebo)|Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
16274507|NCT04854512|Placebo Comparator|Placebo Arm (Metformin DR placebo plus metformin IR placebo)|Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
16274508|NCT04854512|Active Comparator|Active Control Arm (Metformin DR placebo plus metformin IR)|Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).
16274509|NCT04854499|Experimental|Safety Run-in Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum|"Participants with untreated metastatic or unresectable, locally recurrent head and neck squamous cell carcinoma (HNSCC) regardless of programmed cell death ligand 1 (PD-L1) status will receive the following:
~magrolimab
~pembrolizumab 200 mg on Day 1 of each cycle
~5-fluorouracil (5-FU) 1000 mg/m^2/day Days 1-4 of each cycle (for up to 6 cycles)
~platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin area under the concentration versus time curve (AUC) 5 per investigator choice (for up to 6 cycles))
~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the recommended Phase 2 dose (RP2D) is determined. Each cycle is 21 days."
16274510|NCT04854499|Experimental|Safety Run-in Cohort 2, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive the following:
~magrolimab
~docetaxel 75 mg/m^2 on Day 1 of each cycle
~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
16274534|NCT04854356|Active Comparator|HIE with BFR during interval phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each during the interval
16274535|NCT04854356|No Intervention|HIE without BFR|Cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
16274536|NCT04854343||Case|200 patients with a suspicion of prostate cancer
16274511|NCT04854499|Experimental|Pre-expansion Safety Run-in Cohort, Magrolimab + Pembrolizumab|"The pre-expansion safety run-in cohort may be conducted at the sponsor's discretion prior to the initiation of Phase 2 Cohort 2.
~Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.
~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
16274512|NCT04854499|Experimental|Phase 2 Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.
~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
16274513|NCT04854499|Experimental|Phase 2 Cohort 1, Pembrolizumab + 5-FU + Platinum|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.
~Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
16274514|NCT04854499|Experimental|Phase 2 Cohort 2, Magrolimab + Pembrolizumab|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab at the RP2D determined in the Safety run-in cohort 1 and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.
~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
16274515|NCT04854499|Experimental|Phase 2 Cohort 3, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and docetaxel 75 mg/m^2 on Day 1 of each cycle. Each cycle is 21 days.
~Magrolimab and docetaxel will be continued until loss of clinical benefit, unacceptable toxicity, or death."
16274516|NCT04854486|Experimental|Treatment Group|Xylitol + GSE
16274517|NCT04854486|Placebo Comparator|Control placebo|Saline
16274518|NCT04854473|Experimental|Impedance measurement|Subjects with Exero's Smart Drain Device Attached This arm contains subjects which will have Exero's leak detection Device used: Exero Smart Drain is placed on their large bowel during colonic resection surgery (either open, laparoscopic or robotic). The study aims to demonstrate that the parameters measured by the device in in-vivo, non-disrupted tissue are different than parameters measured in ischemic tissue. Once this data is collected a detection algorithm can be trained. This procedure will add no more than 20 minutes to the existing procedure that is performed per hospital standard overall and will enable collection of control vs. ischemia induced clinical data, essential to developing the detection algorithms.
16274519|NCT04854460|Experimental|T test|Test drug (Revemact) 1 tablet contains 6 mg Ivermectin
16274520|NCT04854460|Active Comparator|B reference (first dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
16274521|NCT04854460|Active Comparator|B reference (second dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
16274522|NCT04854447|Experimental|Study Group|Part-time myopia correction with single-vision spectacles
16274523|NCT04854447|Active Comparator|Control Group|Full-time myopia correction with single-vision spectacles
16274524|NCT04854434|Experimental|Arm A: Selinexor 80 mg|Participants will receive a single dose of 80 milligrams (mg) of selinexor once weekly (QW) (4 oral tablets of 20 mg each) on Day 1 of each week (days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) until progressive disease (PD), intolerable toxicity, or withdrawal from the study.
16274525|NCT04854434|Experimental|Arm B: Selinexor 80 mg and Pembrolizumab 400 mg|Participants will receive a single dose of 80 mg of selinexor tablets QW (4 oral tablets of 20 mg each) of selinexor oral tablets QW on Day 1 of each week (days 1, 8, 15, 22, 29, and 36) in combination with pembrolizumab 400 mg intravenously (IV) once every 6 weeks of each 42-day cycle until PD, intolerable toxicity, or withdrawal from the study.
16274526|NCT04854434|Active Comparator|Arm C: Standard of care (SOC)|Participants will receive combination of trifluridine and tipiracil 35 milligrams per square meter (mg/m^2) per dose (15 mg tablet + 20 mg tablet) as oral tablets twice daily (BID) (maximum 80 mg allowed per dose) as SOC on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until PD, intolerable toxicity, or withdrawal from the study.
16274527|NCT04854421||healthy adults|Community dwelling and have no life-threatening conditions or diseases that would alter body composition from what is typical for their age, sex, ethnicity, and BMI.
16274528|NCT04854395|Active Comparator|Group A: Active FTB + Active PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml for IFCN + 10 ml Marcain 5 mg/ml is used for PPB
16274529|NCT04854395|Active Comparator|Group B: Active FTB + Sham PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml is used for IFCN
16274530|NCT04854395|Active Comparator|Group C: Sham FTB + Sham PPB + Active ACB|Single shot bolus of 25 ml Marcain 5 mg/ml is used for ACB
16274531|NCT04854382|Active Comparator|Intervention group|Tailored information about coronavirus using information videos followed by a teach-back procedure
16274532|NCT04854382|No Intervention|Control group|Controls have access to information videos, but do not receive the teach-back procedure (the intervention)
16274533|NCT04854356|Experimental|HIE with BFR during exercise phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
16274537|NCT04854343||Control A|(a) 50 patients with benign prostate hyperplasia (BPH)
16274538|NCT04854343||Control B|(b) 30 male subjects older than 50 years with neither prostate disease nor any other neoplasia
16274539|NCT04854330|Active Comparator|Ketone ester|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml. Immediately following ingestion of the ketones, participants will be given 20 ml of calorie-free sparkling spring water (The Holywell Water Company Ltd, UK) in an attempt to remove any remaining flavour of the supplement.
16274540|NCT04854330|Placebo Comparator|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
16274541|NCT04854317||Patients undergoing adjustable or nonadjustable fluid-filled intragastric balloon placement|Obese patients with I and II grade obesity (BMI >30 and <40 kg/m2) and previous multiple failed attempts of diet.
16274542|NCT04854317||Patients undergoing Endoscopic Sleeve Gastroplasty|Obese patients with I and II grade obesity (BMI >30 and <40 kg/m2) and previous multiple failed attempts of diet.
16274543|NCT04854317||Patients undergoing Endoluminal Vertical Gastroplasty|Obese patients with I and II grade obesity (BMI >30 and <40 kg/m2) and previous multiple failed attempts of diet.
16274544|NCT04854317||Patients undergoing Primary Obesity Surgical Endolumenal 2|Obese patients with I and II grade obesity (BMI >30 and <40 kg/m2) and previous multiple failed attempts of diet.
16274545|NCT04854291|Experimental|Donor FMT|FMT from a healthy donor
16274546|NCT04854291|Placebo Comparator|Placebo|NaCl + glycerol mixture (carrier solution of FMT arm)
16274547|NCT04854278||Pilot study|Pilot study with 22 cases, no intervention
16274548|NCT04854278||Baseline measurement|Baseline measurement of +/- 100 cases, no intervention
16274549|NCT04854278||Post measurement|Post measurement of +/- 100 cases after implementation of a Massive Open Online Course
16274550|NCT04854252|Experimental|Inflammatory response to opioid vs opioid free anesthesia|Patients were randomly assigned to two anesthesia groups: opioid-containing (n=20) or opioid-free (n=20). The opioid used in the opioid-containing anesthesia group was fentanyl.
16274551|NCT04854239|Experimental|Machine-driven group|In the machine-driven group, after guided implant bed preparation, implant insertion was performed with contra-angled handpiece.
16274552|NCT04854239|Experimental|Manual group|In the manual group, after guided implant bed preparation, implant insertion was performed with torque-wrench.
16274553|NCT04854226|Experimental|Macronutrient_CARB|High carbs, low fat composition.
16274554|NCT04854226|Active Comparator|Macronutrient_FAT|Low carbs, high fat composition.
16274555|NCT04854213|Other|Liquid biopsy|Blood samples for liquid biopsy
16274556|NCT04854187|Active Comparator|Intervention Arm - Indoor air purifier and N95 mask|Intervention arm will be for 4 weeks. Blood pressure and/or blood glucose will be recorded on day 0; end of week 2 and end of the intervention. Participants in the intervention group will be asked to use an indoor air purifier (Atlanta Healthcare 7-Stage 43-Watt Air Purifier) daily for 4 weeks between the hours of ¬8 PM and 8 AM. The purifier will be placed in their bedroom or in the room where participants sleep at night. When the participants are outdoors (commuting, working outdoors, running errands, etc.), they will be asked to use a N95 mask (PureMe Reusable N95 Anti-Pollution Mask). It is a reusable mask which can be washed by the participants. Every 2 weeks, the filter of the mask will be replaced, and the filter of the indoor purifier will be washed.
16274557|NCT04854187|No Intervention|Washout period - No intervention|At the end of either control or intervention arm, participants will have a washout period of 2 weeks, after which participants will be crossed over to the other group for the subsequent 4 weeks. For example, after Participant AB is in intervention arm for 4 weeks, he/she will then have a wash out period of 2 weeks in which they will return to their usual state of living. At the end of the washout period, the participant AB will be put in the control arm for 4 weeks.
16274558|NCT04854187|Sham Comparator|Controlled Arm - Indoor air purifier and N95 mask with sham filter|Control arm will be for 4 weeks. Blood pressure, blood glucose and indoor air pollution level will be recorded similarly as in the intervention group on day 0, end of week 2 and week 4. The participant will be provided an air purifier and a N-95 mask (of the same manufacturer), with the filter removed. At the end of two weeks, the health worker will make dummy adjustments to the mask and indoor air purifier, to maintain blinding of the participant.
16274559|NCT04854174|Experimental|Healthy Volunteer|Healthy Volunteer
16274560|NCT04854161|Experimental|Compassion and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Compassion training program is based on Compassion Cultivation Training, CCT
16274561|NCT04854161|Active Comparator|Focusing and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Focusing training program is based on Focusing-Oriented Therapy
16274562|NCT04854148||Experimental|Each participant will perform a Smartphone movement health assessment and a series of 12 gold standard tests under the supervision of a licensed physical therapist or other research study staff
16274563|NCT04854135|Experimental|CGM Intervention|All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.
16274564|NCT04854122|Experimental|Combined exercise intervention Down syndrome|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week.In the exercise sessions, the participant will work with the trainer on their strength, balance and aerobic endurance. Each session consists of 10 min of strength exercises (Foundational Exercise), 10 min of Hip Strengthening, 10 min of Vestibular and Balance Exercise, and 20 min of Aerobic Exercise, and starts with a warming up and ends with stretching/cooling down. Each new exercise will be introduced in easy steps and practiced until the participant is comfortable executing it.
16274565|NCT04854122|Sham Comparator|Usual care Down Syndrome|The control condition consists of usual activities.
16274566|NCT04854122|No Intervention|Reference group without Down syndrome|This reference group of age- and sex-matched inactive individuals without Down syndrome will undergo the same baseline testing as the other groups but without intervention or post-intervention measures.
16274567|NCT04854096|Experimental|NS-018|Self-administered NS-018 300 mg orally, twice daily, preferably at the same time each day in consecutive 4-week (28-day) cycles
16274568|NCT04854096|Active Comparator|Best Available Therapy (BAT)|Single agent per Investigator discretion or no therapy
16274569|NCT04854083|Experimental|Semaglutide|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to semaglutide 1.34mg/ml treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
16274570|NCT04854083|Placebo Comparator|Placebo|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to placebo treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
16274571|NCT04854070|Experimental|IVUS-guided PCI|Method is already used in standard care, but in this trial compared to another method also already used in standard care
16274572|NCT04854070|Active Comparator|Angio-guided PCI|Method is standard care
16274573|NCT04854057|Active Comparator|Intermittent Hypoxia (AIH) + Transcutaneous Electrical Spinal Cord Stimulation (TESS)|"Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes
~TESS + Functional Task Practice Duration: 45 minutes"
16274574|NCT04854057|Sham Comparator|Intermittent Room Air (SHAM) + Transcutaneous Electrical Spinal Cord Stimulation (TESS)|"Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes
~TESS + Functional Task Practice Duration: 45 minutes"
16274575|NCT04854044|Experimental|Arm I (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 PO daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
16274576|NCT04854044|Experimental|Arm II (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. After recovery from surgery, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
16274577|NCT04854031||Cochlear Implant Recipients|30 participants who lost their hearing and received one or two cochlear implants as adults will participate in this study. We will include unilaterally and bilaterally implanted individuals listening with their everyday hearing configuration. Individuals with residual acoustic hearing better than 60 dBA at any audiometric frequency will be excluded. Participants will range in age between 19 and 80 years old, although most are expected to be within 50 - 75 years of age.
16274578|NCT04854018|Experimental|Single Arm|Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
16274579|NCT04854005||Breast Cancer|Patients with cT1-2cN1 HR+/HER2- tumors who are scheduled to undergo BCS will undergo in-house AUS to characterize suspicious-appearing lymph nodes, as is part of routine practice.
16274582|NCT04853979|Experimental|PRONE|Any combination of prone or side position for 3 hours, 3 times a day for 3 days.
16274583|NCT04853979|Active Comparator|NO PRONE|Usual care
16274584|NCT04853966|Experimental|Counseling group|
16274585|NCT04853966|No Intervention|Control Group|
16274586|NCT04853953||COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
16274587|NCT04853953||Non-COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill Non-COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
16274588|NCT04853927|Active Comparator|Proxalutamide + Standard of Care|Proxalutamide + standard of care as determined by the PI
16274589|NCT04853927|Placebo Comparator|Placebo + Standard Care|Placebo + Standard of care as determined by the PI
16274590|NCT04853914|Experimental|HIFU intervention|Patients will benefit of an HIFU treatment of their Benign Prostatic Hyperplasia.
16274591|NCT04853901|Experimental|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone 1-2mg/kg for 5-7 days
16274592|NCT04853901|Active Comparator|Standard of care therapy|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days + Methylprednisolone 1-2mg/kg for 5-7 days
16274593|NCT04853888|Other|Intervention group|"A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.
~Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal."
16274594|NCT04853875|Experimental|Group A (Tetracycline, Metronidazole, and Bismuth)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Tetracycline 2g, Metronidazole 2g, and Bismuth subcitrate 480 mg
16274595|NCT04853875|Active Comparator|Group B (Amoxicillin, Metronidazole, and Clarithromycin)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Amoxicillin 3g, Metronidazole 2g, and Clarithromycin 1g
16274646|NCT04853485|Active Comparator|Active TMS targeting both cerebellum and right dorsolateral prefrontal cortex.|Subjects identified as with prominent negative symptoms will be randomized into active group, who will receive active rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
16307423|NCT04624919|Experimental|Warm/Humid|
16274598|NCT04853823|Experimental|PDC-APB|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
16274599|NCT04853823|Placebo Comparator|Vehicle|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
16274600|NCT04853810||Major diabetic subjects having used a system with adhesives|Major diabetic subjects, whatever the etiology of diabetes, using or having used in the last 10 years a system with skin adhesives, i.e. insulin patch pump (e.g. OMNIPOD®, cell Novo®), pump with externalized catheter (e.g. MINIMED 640G®, YpsoPump®) or continuous glucose measurement system (Free Style®, DexCom® sensors, Enlite® sensors).
16274601|NCT04853797|Active Comparator|Ivabradine|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of ivabradine (15 mg orally).
16274602|NCT04853797|Placebo Comparator|Placebo|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of placebo.
16274603|NCT04853784||Totally laparoscopic colon surgery|Totally laparoscopic colon surgery/intracorporeal anastomosis
16274604|NCT04853784||Laparoscopic-assited colon surgery|Laparoscopic-assited colon surgery/extracorporeal anastomosis
16274605|NCT04853771|Experimental|experiment|24-25. Between the weeks of gestation, one-time progressive muscle relaxation exercise training prepared by the researcher will be given to the pregnant women. Exercise will be demonstrated in training. Later, pregnant women will be asked to explain and practice the exercise. Women will be repeated until they do the exercise completely correctly (Check-list 1). After the training, pregnant women will be asked to do progressive relaxation exercises at least 3 times a week (every other day). With the progressive muscle relaxation exercise daily follow-up schedule prepared by the researcher, the pregnant women will be followed for 8 weeks and weekly reminders will be made (via whatsapp® or text message). The final test application (31-32 weeks) will be done online at the end of 8 weeks to the pregnant women. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
16274606|NCT04853771|No Intervention|control|No intervention will be applied to pregnant women, other than the routine training given in the pregnancy school. In the maternity school, training is given on physiological and psychological changes that occur during pregnancy, baby care, postpartum period, family planning. However, pregnant women are not given any information about RLS, coping methods, creating a healthy lifestyle, and progressive muscle relaxation exercises. Final test application to pregnant women; 31-32. It will be held online between weeks. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
16274607|NCT04853758|Active Comparator|Sacubitril/Valsartan|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan.
16274608|NCT04853758|Active Comparator|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril.
16274609|NCT04853745||sodium bicarbonate group|Sodium bicarbonate-based powder (CLASSIC®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
16274610|NCT04853745||glycine group|Glycine-based powder (PERIO®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
16274647|NCT04853485|Sham Comparator|Sham TMS targeting both cerebellum and right dorsolateral prefrontal cortex|Subjects identified as with prominent negative symptoms will be randomized into sham group, who will receive sham rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
16274648|NCT04853485|Active Comparator|Active TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into active group, who will receive active rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
16275014|NCT04851002|Experimental|A-PRF CONTROL GROUP|Dental implant applications were made with traditional methods.
16274611|NCT04853745||erythritol group|Erythritol-based powder (PLUS®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
16274612|NCT04853732||Chronic Low Back Pain Cases|
16274613|NCT04853732||Chronic Pain-Free Controls|
16274614|NCT04853719|Experimental|Vascular dose|Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
16274615|NCT04853719|Active Comparator|Aspirin|Aspirin 100 mg OD for 6 months
16274616|NCT04853706|Other|Delirium|
16274617|NCT04853693|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
16274618|NCT04853693|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
16274619|NCT04853680|Experimental|Treatment|Use of Anti-adhesion barrier on the thyroidectomy space. After the thyroidectomy, anti-adhesion barrier will be applied on the thyroidectomy space, around the trachea, cricothyroid muscle and platysma muscle before the closure of surgical wound.
16274620|NCT04853680|No Intervention|Control|No use of anti-adhesion barrier. After the thyroidectomy, don't use the anti-adhesion barrier before the wound closure.
16274621|NCT04853667||Patients with hereditary epidermolysis bullosa|Minor patients with hereditary epidermolysis bullosa
16274622|NCT04853667||Parents|Parents of patients with hereditary epidermolysis bullosa
16274623|NCT04853654|Experimental|Selective training|selective training on lower extremity for 3 days/week
16274624|NCT04853654|Experimental|Downhill walking|downhill walking training on the treadmill for 2 days/week
16274625|NCT04853654|Experimental|Uphill walking|uphill walking training on the treadmill for 2 days/week
16274626|NCT04853641||Living Donor Liver Transplant Recipient|Patients who have received a living donor liver transplant.
16274627|NCT04853641||Deceased Donor Liver Transplant Recipient|Patients who have received either a Deceased by Circulatory Death or Deceased by Brain Death Liver Transplant
16274628|NCT04853628|Experimental|Alerta Alcohol|The EC-1 receives Alerta Alcohol, which consists of session 1 or baseline, two sessions in three scenarios: at home, celebrations, and public places, and two follow-up evaluations. The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, four booster sessions are given at home to reinforce the contents of the three scenarios. Evaluations take place after six and twelve months.
16274629|NCT04853628|Experimental|Alerta Alcohol 2.0|The EC-2 receives an improved version of Alerta Alcohol (Alerta Alcohol 2.0) using animated videos and new gamification strategies. Evaluations take place after six and twelve months.
16274630|NCT04853628|No Intervention|Control condition|The CC just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list). Evaluations take place after six and twelve months from baseline.
16274631|NCT04853615||Group 1|1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast
16274632|NCT04853615||Group 2|2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
16274633|NCT04853615||Group 3|3rd group will receive the SGLT2i empagliflosin 25 mg once daily
16274634|NCT04853615||Group 4|4thwill receive allopurinol and empagliflosin.
16274635|NCT04853589|Active Comparator|Hyaluronic acid|hyaluronic acid gel application
16274636|NCT04853589|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier
16274637|NCT04853589|No Intervention|Standard treatment|standard treatment (i.e., blood clot only)
16274639|NCT04853563|Experimental|High PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 8 cmH2O with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. Thereafter, the PEEP level is adjusted to 1 cmH2O higher to a minimum PEEP level of 10 with every 30 minutes.
16274640|NCT04853563|Active Comparator|Low PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 5 cmH2O with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. In this arm, the PEEP level is adjusted to 1 cmH2O lower to a minimum PEEP level of 3 with every 30 minutes while maintaining a partial pressure of arterial blood oxygen above 65 mmHg or SpO2 >92% with pulse oxymetry.
16274641|NCT04853537|Experimental|study group|• 126 women will fast 16 consecutive hours per day including sleeping hours. and follow them from 26w till 36w by GTT(glucose tolerance test) and the weight gain and incidence of gestational diabetes
16274642|NCT04853537|No Intervention|control group|• 126 women will not fasting with the same life style and follow the incidence of gestational diabetes
16274643|NCT04853524|Experimental|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) plus JNJ-56136379|Participants will receive a single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 1. Multiple oral doses of JNJ-56136379 once daily on Day 6 to Day 24. A single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 20.
16274644|NCT04853511||OCT-FLIM dual modal intravascular imaging with serial 18F-FDG-PET/CT assessment|Group of patients undergoing PCI with comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular imaging followed by serial 18F-FDG-PET/CT imaging
16274645|NCT04853498|Experimental|TQB3720 tablets|TQB3720 tablets administered orally, once daily in 28-day cycle.
16274685|NCT04853290|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse from a clinical inpatient unit.
16274649|NCT04853485|Placebo Comparator|Sham TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into sham group, who will receive sham rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
16274650|NCT04853485|Active Comparator|Active deep TMS using Brainways H7 coil targeting ACC|Subjects identified as with positive symptoms will be randomized into active group, who will receive active deep rTMS over ACC using H7 coil.
16274651|NCT04853485|Placebo Comparator|Sham deep TMS using Brainways H7 coil targeting ACC|Subjects identified with positive symptoms will be randomized into sham group, who will receive sham deep rTMS over ACC using H7 coil.
16274652|NCT04853472||Early Stage Peri-Menopause|Mild cycle irregularity over the last 3-6months (minimum), variation of >6 days in length between consecutive cycles including shortened and longer cycles (but not >60 days in length)
16274653|NCT04853472||Late Stage Peri-Menopause|Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea >60 days in length (but less than 12 months)
16274654|NCT04853472||Post-Menopause|Greater than 12 months since last menstrual period
16274655|NCT04853459|Experimental|Retention|After Border modeling by traditional and light cure. Amount of force required to dislodge.
16274656|NCT04853459|Experimental|Vestibular depth measurement|Casts By using Ney Surveyor
16274657|NCT04853446|Placebo Comparator|Placebo|Capsulated glucosemonohydrate will be used as placebo. Two capsules of placebo will be adminstered.
16274658|NCT04853446|Experimental|Dexamethasone 12 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. One capsule of 12 mg dexamethasone and one capsule of placebo for a total dose of 12 mg of dexamethasone will be administered.
16274659|NCT04853446|Experimental|Dexamethasone 24 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. Two capsules of 12 mg dexamethasone for a total for 24 mg of dexamethasone will be administered.
16274660|NCT04853433|Experimental|Radiation therapy group|Single-institution pilot study to evaluate the safety and efficacy of radiation therapy (RT) for the treatment of unresected keloids. The primary endpoint will be toxicity within 10 weeks of follow-up. Secondary endpoints will include cessation of growth or shrinkage of keloids, symptomatic response, and impact on quality of life.
16274661|NCT04853407|Experimental|LY03005 extended-release tablets 80 mg group|orally once a day
16274662|NCT04853407|Experimental|LY03005 extended-release tablets 160 mg group|orally once a day
16274663|NCT04853407|Placebo Comparator|Placebo group|orally once a day
16274666|NCT04853381|Experimental|1st Group: Traditional diet recommendations|Traditional diet recommendations will apply for 4 weeks.
16274667|NCT04853381|Experimental|2nd Group: Low FODMAP diet|Low FODMAP diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
16274668|NCT04853381|Experimental|3rd Group: Gluten-free diet|Gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
16274669|NCT04853381|Experimental|4th Group: Low-FODMAP gluten-free diet|Low-FODMAP gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
16274674|NCT04853355|Experimental|Spironolactone Treatment|Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
16274675|NCT04853342|Experimental|Furmonertinib|Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
16274676|NCT04853342|Placebo Comparator|Placebo Furmonertinib|Matching placebo for Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
16274677|NCT04853329|Experimental|PartA- Arm A|"Arm A 1-6 subjects will be enrolled at dose levels of CPO107 at (1, 3, 6, 12, 20 mg/kg).
~Each subject group will receive multiple cycles of a weekly dose of CPO-107 (1 cycle=21 days=3 treatments)."
16274678|NCT04853329|Experimental|PartA- Arm B|Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks (1 cycle=21 days=1 treatment). The starting dose for Arm B will be the dose level below the Arm A level that provides an equivalent dose over a 3-week period.
16274679|NCT04853329|Experimental|Part B|Part B with either: second or greater relapse OR refractory patients, as defined by not achieving a CR after 2 cycles of a standard first line chemoimmunotherapy regimen or not achieving a CR following 1 cycle of a second line chemotherapy regimen.
16274680|NCT04853316||Case: Exposed (SARS-CoV-2 positive)|Participants found positive by SARS-CoV-2 testing.
16274681|NCT04853316||Control: Unexposed (SARS-CoV-2 negative)|Participants found negative by SARS-CoV-2 testing.
16274682|NCT04853303|Experimental|Hypnosis VR|The experimental group will receive a 15-minute hypnosis using virtual reality when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain.
16274683|NCT04853303|No Intervention|Control|The control group will receive no intervention.
16274684|NCT04853290|Experimental|Intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
16278531|NCT04826614|Experimental|optimized treatment|early adjust dose or change drug
16274686|NCT04853277|Experimental|Education Group|Participants will receive an educational intervention focusing on psychosocial stressors and timeline of symptoms associated with the transplant/CAR-T experience.
16274687|NCT04853264|Experimental|Experimental: intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
16274688|NCT04853264|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse.
16274689|NCT04853251|Experimental|Port Delivery System with Ranibizumab|Participants will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
16274690|NCT04853238||Cohort 1: Participants with newly and previously diagnosed stable disease|
16274691|NCT04853238||Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization|
16274692|NCT04853238||Cohort 3: Participants requiring hospitalization for an acute exacerbation|
16274693|NCT04853225||Main cohort|COPD, chronic bronchitis and healthy participants (never smoker) from Type A and Type B hospitals will be included.
16274694|NCT04853225||Sub-cohort|COPD, chronic bronchitis and healthy participants (never smoker) from selected Type A hospitals will be included.
16274695|NCT04853212|Active Comparator|SPA patient|Patients with SPA
16274696|NCT04853212|Sham Comparator|Subject without SPA|Health subjects without SPA, planned to undergo a digestive endoscopy.
16274697|NCT04853199|Experimental|Quercetin group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
16274698|NCT04853199|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
16274699|NCT04853173|Experimental|ambulatory protocol after adult tonsillectomy|prescription of analgesics for outpatient procedure with hospital surveillance
16274700|NCT04853160||All Participants With Gout|Participants with gout, initiating febuxostat therapy on or after 01 June 2016 will be included in the study.
16274701|NCT04853147|Experimental|triple therapy|Triple combination of Fosaprepitant, Palonosetron and Dexamethasone were administered
16274702|NCT04853147|Other|double therapy|double combination of Palonosetron and Dexamethasone were administered
16274703|NCT04853134|Placebo Comparator|Standard Care|Standard of care as determined by the PI
16274704|NCT04853134|Active Comparator|Proxalutamide + Standard Care|Proxalutamide + standard of care as determined by the PI
16274705|NCT04853121|Active Comparator|tapered implant|
16274706|NCT04853121|Placebo Comparator|straight implant|
16274707|NCT04853108||Remote Monitoring of COVID-19|Patients with COVID-19 who completed acute clinical monitoring of at least 30 days from symptom onset or positive COVID-19 test.
16274708|NCT04853095|Experimental|Intervention group (PerFix)|Peritoneal fixation technique
16274709|NCT04853095|Active Comparator|Control group (no PerFix)|Standard of care (i.e. no fixation)
16274710|NCT04853082|Active Comparator|Limonene capsules(marketed product in China)|Limonene capsules(marketed product in China) donate by pharmaceutical company
16274711|NCT04853082|Placebo Comparator|Limonene capsules(Placebo)|Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules
16274712|NCT04853069|Active Comparator|Oestrogen Therapy|Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.
16274713|NCT04853069|No Intervention|Control Group|Patients will receive only standard care.
16274714|NCT04853056|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the peripheral IV line insertion
16274715|NCT04853056|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be inserted peripheral IV line
16274716|NCT04853056|No Intervention|Control group|Standart care
16274717|NCT04853043|Experimental|Cetuximab|
16274718|NCT04853030|Experimental|Minimed 670G 4.0 closed loop with Faster Insulin aspart|
16274719|NCT04853030|Active Comparator|Minimed 670G 4.0 closed loop with Standard Insulin aspart|
16274722|NCT04852991|Active Comparator|Modified Purandare cervicopexy|Apical prolapse will be corrected by Modified Purandare cervicopexy
16274723|NCT04852991|Active Comparator|Abdominal sacrohysterpexy|Apical prolapse will be corrected by Abdominal sacrohysterpexy
16274731|NCT04852939|Experimental|Bowen's Technique|Bowen's Technique
16274732|NCT04852939|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy including stretching and strengthening exercises
16274733|NCT04852926||A prospective cohort of patients|Female patients treated for non-metastatic breast cancer and followed up in the Observatory of fertility at Jeanne de Flandre Hospital
16274734|NCT04852913|Experimental|Bowen's Technique|Bowen's Technique The session lasted for 20 minutes, 3 sessions/week 6th week
16274735|NCT04852913|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy with myofascial release The session lasted for 20 minutes, 3 sessions/week 6th week
16274736|NCT04852900|Experimental|Decompression with 30%|Decompression with 30% and mobilization
16274737|NCT04852900|Experimental|Decompression with 40%|Decompression with 40% and mobilization
16274738|NCT04852900|Experimental|Decompression with 50%|Decompression with 50% and mobilization
16274739|NCT04852887|Active Comparator|Arm 1: Breast Radiation Therapy + Endocrine Therapy|Radiation therapy to the breast and hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
16307652|NCT04623242|Placebo Comparator|Matching placebo (Gantenerumab)|
16274740|NCT04852887|Active Comparator|Arm 2: No Breast Radiation Therapy + Endocrine Therapy|No radiation therapy, only hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
16274741|NCT04852874|Experimental|Ultrasound-guided Quadratus Lumborum Block|
16274744|NCT04852848|Experimental|Connect2Test Intervention|A brief MI intervention to motivate individuals to participate in COVID-19 testing after receiving syringe exchange services
16274745|NCT04852848|No Intervention|Control|Services as usual
16274747|NCT04852770|Experimental|Trial-Based Cognitive Therapy|TBCT (de Oliveira, 2008) is a novel transdiagnostic approach (Wenzel, 2017). It has been shown to be effective for depression (Hemanny et al., 2019), social anxiety disorder (Neufeld et al., 2020; Caetano et al., 2018; de Oliveira et al., 2011; Powell et al., 2013), and PTSD (Duran et al., 2020). TBCT differs from other CBT approaches in that it introduces a new, organized, and systematic approach to change dysfunctional negative core beliefs, and allows cognitive, emotional, and experiential work to be done simultaneously (de Oliveira, 2016). Interestingly, it incorporates a courtroom metaphor to challenge dysfunctional core beliefs conceptualized as self-accusations (de Oliveira, 2016). TBCT is an example of assimilative psychotherapy integration that relies on Beckian CBT (de Oliveira, 2016). It incorporates and integrates components of other psychotherapies (Delavechia et al., 2016).
16274748|NCT04852770|Active Comparator|Mindfulness-Based Health Promotion|The Mindfulness-Based Stress Reduction (MBSR) program was created by Jon Kabat-Zinn and colleagues at the University of Massachusetts Medical Center in 1979, and it is an intervention whose effects on mental health and quality of life has produced several studies worldwide, both in clinical and non-clinical populations. Several protocols have been developed based on the MBSR aimed at specific publics, such as the Mindfulness-Based Health Promotion (MBHP) program developed by the Mente Aberta - Brazilian Center for Mindfulness and Health Promotion. The MBHP program was inspired by the original MBSR model but adapted to the context of the Brazilian Health Care (SUS) system, addressing chronic conditions and mental disorders as well (TROMBKA et al., 2018; LOPES et al., 2019; SALVO et al., 2018).
16274749|NCT04852770|Active Comparator|Positive psychotherapy|Positive psychotherapy (PPT) seeks to understand positive emotions, psychological potentialities and healthy human / social / institutional functioning, and to apply this knowledge to help people and institutions, with a focus on prevention and promotion of mental health (SELIGMAN et al., 2005). Originally, PP focused on happiness and subjective well-being (SELIGMAN, 2010; SELIGMAN; CSIKSZENTMIHALYI, 2000). Then, the studies gained a broader view of psychological well-being and another similar proposal entitled PERMA, which is composed of the following five spheres: positive emotions - P; engagement - E; relationships - R; meaning - M; and achievement - A. (RYFF, 2013; SELIGMAN, 2012). Although positive psychology aims to be a way of looking at life, some psychotherapeutic proposals, such as positive psychotherapy (PPT), have been developed, and clinical studies have been replicated in different clinical and cultural contexts (RASHID; SELIGMAN, 2019; RICHES et al., 2016).
16274750|NCT04852744|Other|Borderline girls with PTSD|"female
~Age between 13 and 17 years inclusive
~Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)
~Post-traumatic stress disorder according to DSM-5 criteria (American Psychiatric Association, 2013; K-SADS-PL)
~Level of general psychopathology compatible with participation in the study (score> 20 on the CGA-S)
~Oral and written comprehension of the French language
~Affiliation to the social security scheme
~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
16274751|NCT04852744|Other|Borderline girls without PTSD|"female
~Age between 13 and 17 years inclusive
~Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)
~Level of general psychopathology compatible with participation in the study (score> 20 on the CGA-S)
~Oral and written comprehension of the French language
~Affiliation to the social security scheme
~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
16274752|NCT04852744|Other|Healthy controls|"female
~Age between 13 and 17 years inclusive
~Absence of mental disorder according to DSM-5 (American Psychiatric Association, 2013 ; K-SADS-PL et SIDP-IV)
~Oral and written comprehension of the French language
~Affiliation to the social security scheme
~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
16274753|NCT04852731|Experimental|Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :
~According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG,
~And specifically for research purposes : injected cardiac MRI and a blood collection."
16274754|NCT04852731|Experimental|Group A (b) : patients without mitral regurgitation with ventricular extrasystole (>10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :
~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,
~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
16274755|NCT04852731|Experimental|Group B : patients with Mitral valve prolapse with trivial mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :
~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,
~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
16278532|NCT04826614|Active Comparator|routine treatment|slowly adjust dose or change drug
16274756|NCT04852731|Experimental|Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :
~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,
~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
16274757|NCT04852705|Experimental|candidate vaccine|
16274758|NCT04852705|Placebo Comparator|Placebo|
16274759|NCT04852692||Part A: Retrospective Phase|Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.
16274760|NCT04852692||Part B: Prospective Phase|Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.
16274761|NCT04852679|Other|lanreotide Autogel 120 mg|Subjects will be treated with lanreotide Autogel® 120mg, every 28 days (+/- 3 days).
16274762|NCT04852666||IBD Partners cohort|IBD Partners is an internet-based cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the University of North Carolina School of Medicine in conjunction with the Crohn's & Colitis Foundation. There is no intervention for this study.
16274763|NCT04852666||SPARC-IBD cohort|SPARC-IBD is a multi-center cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the Crohn's & Colitis Foundation. There is no intervention for this study.
16274764|NCT04852653||Patients with adenocarcinoma of rectum histologically proven|
16274765|NCT04852640|Experimental|Active Rehabilitation Program (ARP)|Participants will be treated for symptomatic shoulder instability with the evidence-based, targeted treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. Exercises in the ARP include: Low-load and high-duration rotator cuff strengthening exercises, progressive scapular muscle endurance training, plyometric strengthening exercises, and surface electromyographic (EMG) biofeedback. Each prescribed exercise in the ARP will be increased to match the participant's function at the discretion of the study clinician. Although the components of the ARP will be pre-determined, the parameters and volumes of the components will be determined and documented over the treatment phase.
16274766|NCT04852640|Experimental|Nonspecific Passive Intervention (NPI)|Participants will be treated for symptomatic shoulder instability with the non-specific, generalized treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. The NPI consists of a general approach to treating shoulder pain with passive modalities for pain modulation. These interventions are commonly practiced but have little evidence to support their use in the treatment of symptomatic shoulder instability. Although the components of the NPI will be pre-determined, the parameters and volumes of the components will be determined and documented by a study clinician over the treatment phase.
16274767|NCT04852627|Active Comparator|Exercise group|Will brisk walk 30 minutes 3 times weekly
16274768|NCT04852627|No Intervention|Control group|No intervention
16274769|NCT04852601|Experimental|ToolboxDetect Strategy|"All practices randomized to the intervention arm will implement the ToolboxDetect battery as the standard of care routine cognitive assessment to fulfill the Medicare Annual Wellness Visit (AWV) requirement. The 7-8 minute ToolboxDetect battery contains self-administered versions of the NIH ToolBox Picture Sequence Memory Test (PSM) and the NIH ToolBox Dimensional Change Card Sorting (DCCS). PSM measures episodic memory and DCCS tests executive functioning.
~The validated ToolboxDetect application will be imparted either as an application on an iPad or on a PC desktop/laptop computer commonly found in a clinical exam room for EHR access."
16274770|NCT04852601|No Intervention|Enhanced Usual Care|"At Northwestern Medicine, cognitive assessments included in Annual Wellness Visits or other routine or sick/problem-based visits vary by practice and also by clinician. However, the choice of test was limited to either a Mini-Cog©, Montreal Cognitive Assessment (MoCA), or Mini Mental Status Exam (MMSE).
~While we will not make any explicit recommendations to these practices with regard to their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to an Epic SmartData element, which will allow the clinician to record the results of the test as discrete data (which can then be queried), and that 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will also be provided to each clinic's medical leadership."
16274771|NCT04852588|Experimental|Treatment Arm|Small pieces of suspicious chest lymph nodes will be removed with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA).
16274772|NCT04852562|Experimental|Modified radical endoscopic sinus surgery(MRESS)|The experimental group intends to adopt a modified radical endoscopic sinus surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a radical cure of ethmoid sinus. Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
16274773|NCT04852562|Experimental|Functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique, operation procedures including full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
16274774|NCT04852549|No Intervention|No intervention group|The control group continued with routine training after evaluations.
16274775|NCT04852549|Experimental|Oculomotor exercise group|After the evaluation, the intervention group performed oculo-motor exercises for 4 weeks, 6 days a week, morning and evening, twice a day for 10 minutes, in addition to normal ball training. While doing the exercises, individuals were taught to focus on the purpose they held in their hands, move their head, and aim fast enough to see the image clearly. Two repetitions each week were added to the exercise numbers. Ten seconds rest between two sets and five seconds rest between movements.
16274776|NCT04852536||HD-tDCS4x1|All data will be acquired from patients of the triple-blind clinical trial that will investigate the effectiveness of treatment for neuropathic pain after brachial plexus injury with HD-tDCS. There will be collection and analysis of EEG data before the clinical trial protocol, to later assess the prediction of response to the technique employed. At the end, they will be grouped into responders and non-responders to HD-tDCS, according to the numerical scale of pain, with assignments serving as targets for the analyzes with machine learning. The labels for clinical improvement used to classify machine learning will be determined based on the data obtained in the baseline and post-treatment assessments, according to similar studies. Thus, the EEG data of these patients will be retrospectively examined, identifying possible neurophysiological characteristics and biomarkers related to the frequency bands that allow predicting which patients are most likely to improve with this treatment.
16274777|NCT04852523|Experimental|18F fluciclovine Administration|"Initial normal standardized uptake values (SUV) of the pancreas, liver, and blood pool will be obtained from 50archived previous 18F-Fluciclovine studies, as there are no normal ranges in the literature. This will be done by retrospective medical record review after a waiver of consent/authorization is obtained from the local IRB.
~Informed consent will be obtained from 10 patients with pancreatic allografts, and each will undergo an 18F-Fluciclovine study. These patients will not be suspected of having current rejection or allograft dysfunction. Timing of 18F-Fluciclovine PET/CT scans will be planned to coincide with standard-of-care imaging studies and laboratory tests.
~The 18F-Fluciclovine study will be compared with the patients' standard-standard-of-care US and/or CT with the assessment of ease of visualization of the pancreatic allograft."
16274778|NCT04852510|Active Comparator|Group A|Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA).
16274779|NCT04852510|Active Comparator|Group B|A combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
16274780|NCT04852484|Active Comparator|local anesthetic and morphine group|paravertebral block with local anesthetic and morphine, followed by a continuous infusion of local anesthetic and morphine in the paravertebral space
16274781|NCT04852484|Active Comparator|local anesthetic and ketamine group|paravertebral block with local anesthetic and ketamine, followed by a continuous infusion of local anesthetic and ketamine in the paravertebral space
16274782|NCT04852484|Active Comparator|local anesthetic group|paravertebral block with local anesthetic only, followed by a continuous infusion of local anesthetic only in the paravertebral space
16274783|NCT04852471|Active Comparator|Standard Post-Operative Counseling + FACT-G (Control Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. Patients will complete the Functional Assessment of Cancer Therapy - General (FACT-G).
16274784|NCT04852471|Experimental|Standard Post-Operative Counseling + PROM survey + FACT-G (Intervention Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. The intervention arm will receive and complete the Patient-Reported Outcome Measure (PROM) survey via the SMS text messaging service on a set schedule. Patients will complete the FACT-G.
16274785|NCT04852458|Experimental|Intravenous hydrocortisone|
16274786|NCT04852458|No Intervention|Observational|Participants will complete assessments/surveys only.
16274787|NCT04852445||Stroke|We will include: 60 patients aged 18 years or older with clinical symptoms of hemispheric ischemic stroke due to occlusion of a large cerebral blood vessel, onset within 48 hours and NIHSS of 1 or more;
16274788|NCT04852445||Controls|30 healthy controls, age- and sex- matched with stroke study population
16274789|NCT04852445||Carotid arterectomy after stroke|10 patients undergoing carotid endarterectomy within 30 days after stroke
16274790|NCT04852445||Carotid endarterectomy for asymptomatic stenosis|3 patients without stroke undergoing carotid endarterectomy for asymptomatic carotid stenosis.
16274791|NCT04852432|No Intervention|Control group|Nasal prong is applied, but sedation is performed without oxygen administration.
16274792|NCT04852432|Experimental|Low flow group|Oxygen administration by nasal cannula
16274793|NCT04852432|Experimental|High flow group|Oxygen is administered at a rate of 2L/kg/min using an Optiflow device
16274794|NCT04852419|Experimental|ZN-c5 50mg QD dose cohort|Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily. Safety lead in phase will be applied.
16274795|NCT04852419|Experimental|Zn-c5 150mg QD dose cohort|Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
16274796|NCT04852406|Experimental|Intervention group|Participants in this group receive protocol-based management of perioperative antithrombotic therapy.
16274797|NCT04852406|Sham Comparator|Control group|Participants in this group receive routine management of perioperative antithrombotic therapy.
16274798|NCT04852393||Block|Patients undergoing ultrasound-guided cervical medial branch blocks as part of their usual care
16274799|NCT04852380||Patients treated by PRP injection|
16274800|NCT04852367|Active Comparator|Arm A (Doxorubicin)|a single intravenous dose of Doxorubicin, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered as per local practice.
16274801|NCT04852367|Experimental|Arm B (ThermoDox + Focused Ultrasound)|under general anaesthetic, patients receive FUS, which is moved through the target tumour volume to raise the bulk tumour temperature above the thermal release threshold. At presumed target temperature, a single intravenous dose of ThermoDox®, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered concurrently to FUS, in line with the pharmacy manual provided by the manufacturer. FUS will continue following infusion, for no longer than two hours from infusion commencing.
16274802|NCT04852341||Corneal horizontal diameter ≤9.00mm group|
16274803|NCT04852341||Corneal horizontal diameter 9.00mm~9.50mm group|
16274804|NCT04852341||Corneal horizontal diameter 9.50mm~10.00mm group|
16274805|NCT04852341||Corneal horizontal diameter >10.00mm group|
16278533|NCT04826601|Experimental|Experimental|
16274809|NCT04852315|Experimental|Caffeine supplementation|Acute caffeine supplementation
16274810|NCT04852315|Placebo Comparator|Placebo supplementation|Acute placebo supplementation
16274818|NCT04852263|Other|Group I|Fiberoptic intubation was carried out without nasopharyngeal airway
16274819|NCT04852263|Other|Group II (NPA group)|Fiberoptic intubation was performed with a modified nasopharyngeal airway.
16274820|NCT04852250||FOLFOXIRI plus bevacizumab and centralized tumour board|
16274821|NCT04852250||FOLFOXIRI plus bevacizumab but no centralized tumour board|
16274822|NCT04852237||Pregnancies from ICSI-TESE cycles for obstructive azoospermia.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI-TESE cycles for obstructive azoospermia.
16274823|NCT04852237||Pregnancies from ICSI cycles with ejaculated sperm.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI cycles with ejaculated sperm.
16274827|NCT04852211|Active Comparator|Open major hepatectomy|Resection of the tumor together with 3 or more liver segments using open standard techniques of hepatectomy
16274828|NCT04852211|Active Comparator|Laparoscopic major hepatectomy|Resection of the tumor together with 3 or more liver segments using minimally invasive techniques of hepatectomy
16274829|NCT04852198|Active Comparator|OAGB|149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm
16274830|NCT04852198|Active Comparator|RYGB|149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm
16274831|NCT04852185|Experimental|Vi-TT Arm|A single dose of Vi-TT to children 9 months to 15 years of age.
16274832|NCT04852185|Active Comparator|MCV-A arm|A single dose of MCV-A vaccine to the comparator group.
16274833|NCT04852172|Active Comparator|Arm 1 (L-citrulline)|25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
16274834|NCT04852172|Active Comparator|Arm 2 (L-citrulline)|50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
16274835|NCT04852172|Active Comparator|Arm 3 (L-citrulline)|100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
16274836|NCT04852172|Active Comparator|Arm 4 (L-citrulline)|100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
16274837|NCT04852172|Active Comparator|Part 2 Arm 1 (L-citrulline)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.
16274838|NCT04852172|Placebo Comparator|Part 2 Arm 2 (normal saline (0.9% NaCl) D5 ½)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.
16274839|NCT04852146||Professional|The sample of professionals will be made up of doctors and nurses of the emergency structures (pre and intra-hospital), doctors and nurses of interventional cardiology and ambulance drivers practising in an establishment of the 7 participating SAMU zones
16274840|NCT04852146||Patient|The patient sample will consist of patients included in the REANIM registry during the study period (the entire period of the stepped wedge randomised controlled trial).
16274843|NCT04852120||Compound Sodium Picosulfate Granules|
16274844|NCT04852107|Active Comparator|SCS/ DRGS/DUAL /Dual*|
16274845|NCT04852107|Active Comparator|SCS/DUAL/DRGS/DRGS*|
16274846|NCT04852107|Active Comparator|DRGS/SCS/DUAL/DUAL*|
16274847|NCT04852107|Active Comparator|DRGS/DUAL/SCS/SCS*|
16274848|NCT04852107|Active Comparator|Dual/DRGS/SCS/SCS*|
16274849|NCT04852107|Active Comparator|Dual/SCS/DRGS/DRGS*|
16274850|NCT04852094||Parents|parents of hospitalized children, speaking and understanding enough French, not presenting psychiatric disorders, voluntary to participate in focus groups
16274851|NCT04852094||Professionals|Nurses, assistant nurses, psychologist, physiotherapist, physicians, residents and fellows
16274852|NCT04852081||patients with HR+, HER2- advanced or metastatic breast cancer|patients with HR+, HER2- advanced or metastatic breast cancer
16274853|NCT04852068|Experimental|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
16274854|NCT04852068|Experimental|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
16280161|NCT04815551|Experimental|AV-380 SC 1 mg/kg|Subcutaneous injection of AV-380 at dose level 1 mg/kg
16274855|NCT04852068|Active Comparator|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
16274856|NCT04852068|Active Comparator|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
16274857|NCT04852055|No Intervention|Usual Care|Patients and proxies in assisted living centers randomized to the usual care arm have advance care planning discussions with a clinician at admission, annually, and sometimes with a hospitalization or other change in condition. There is no standardized decision- or conversation-support tools used to have these discussions.
16274858|NCT04852055|Experimental|Information Only|Patients and proxies in assisted living centers randomized to the information only arm will receive a letter from their clinician with a link to an educational video describing the goals of care and how specific treatment decisions align with these goals. Patients and proxies will also continue to receive usual care advance care planning conversations.
16274859|NCT04852055|Experimental|Information and Clinician Outreach|Patients and proxies in assisted living centers randomized to the information and clinician outreach arm will receive the letter from their clinician with a link to an educational video describing the goals of care and how specific treatment decisions align with these goals. Clinicians will also call patients and proxies to have a structured advance care planning conversation within a month of sending the educational materials.
16274860|NCT04852042|Experimental|mHealth Group|12 month text messaging program about diet and physical activity behavioral goals
16274861|NCT04852042|Experimental|mHealth+Community Health Worker (CHW) support|same as mHealth group + monthly behavioral phone counseling by a CHW
16274862|NCT04852042|No Intervention|Control group|Assessments only
16274863|NCT04852029|Active Comparator|Control Group|to remain on current dose of low dose hCG
16274864|NCT04852029|Experimental|Intervention Group|increased dose of low dose hCG prescribed
16274865|NCT04852016|Experimental|Digital Educational Platform|Study participants randomized to the DEP+SVC group (intervention) will be presented with an iPad with a link to an interactive DEP module discussing the indications for LC, alternatives, risks, complications, expectations and anticipated recovery. They will be asked to review the DEP module at their own pace and will be required to confirm understanding of all of the material presented on the DEP. Upon completion of the module, a member of the surgery team will ask the patient if they have any additional questions or require further clarification regarding the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery. Once all of participant's questions are answered, an informed paper-based consent form for LC will be signed.
16274866|NCT04852016|Active Comparator|Standard Verbal Consent|Study participants randomized to the SVC group (control) will discuss the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery with a member of the surgery team. The study participant will be given the opportunity to ask questions and once all of the questions have been answered, an informed paper-based consent form for LC will be signed.
16274867|NCT04852003|Experimental|SHR0410 Injection|
16274868|NCT04852003|Placebo Comparator|Placebo for SHR0410 Injection|
16274869|NCT04852003|Active Comparator|Morphine|
16274870|NCT04851990|Experimental|Large Patch|"To Better Days Large Patch
~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
16274871|NCT04851990|Experimental|Small patch|"To Better Days Small Patch
~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
16274872|NCT04851977|Experimental|Cohort 1: low dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
16274873|NCT04851977|Placebo Comparator|Cohort 2: low dose|IM injection on Day 0 and at Day 30 (12 active, 3 placebo) with follow up at 7 days post vaccination (Day 7 ± 1 day and Day 37 ± 1 day) and Day 60 ± 5 days and a final follow up/ EOS teleconference assessment at Day 90 ± 5 days.
16274874|NCT04851977|Experimental|Cohort 3: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
16274875|NCT04851977|Placebo Comparator|Cohort 4: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
16274876|NCT04851964|Experimental|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorized pre-filled syringe.
16274877|NCT04851964|Placebo Comparator|Placebo|Placebo subcutaneous injection, in an accessorized pre-filled syringe.
16274878|NCT04851951||patients treated by one-shot PRP injection|
16274879|NCT04851938|Active Comparator|Active TENS 1 Group|
16274880|NCT04851938|Active Comparator|Active TENS 2 Group|
16274881|NCT04851938|Placebo Comparator|Placebo Group|
16274882|NCT04851938|Sham Comparator|Control Group|
16274883|NCT04851912||General|Participants with or without psychiatric disorders
16274884|NCT04851899|Experimental|Low dose Phaeosol group|1 Phaeosol softgel of 500mg/day (containing 218mg/d of active ingredients) and 1 placebo softgel of 500mg/day (218mg of sunflower oil -look like softgel of Phaeosol product) + 1 Guarana capsule of 500mg/day (Organic guarana extract containing 8-11% of native cafeine)
16274885|NCT04851899|Experimental|High dose Phaeosol group|2 Phaeosol softgels of 500mg/day (each containing 218mg of active ingredients) + 1 Guarana capsule of 500mg/day (Organic guarana extract containing 8-11% of native cafeine)
16274886|NCT04851899|Placebo Comparator|Placebo group|2 placebo softgels of 500mg/day (each 218mg of sunflower oil -look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of guarana)
16274887|NCT04851886|Active Comparator|Individual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 sessions of robot-assisted upper-limb rehabilitation. During the sessions, a therapist will administer one-on-one therapy (i.e. each study volunteer will work with a single therapist).
16280162|NCT04815551|Placebo Comparator|Placebo|
16274888|NCT04851886|Experimental|Group robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will also undergo 18 sessions of robot-assisted upper-limb rehabilitation. However, a therapist will administer the intervention as group therapy with up to three subjects participating in the session at the same time. To facilitate the deliver of the therapeutic intervention, the robot will be equipped with a camera system (called PostureCheck) designed to track the quality of the exercises.
16274890|NCT04851860|Other|allergic rhintis children|sublingual immunotherapy is used for allergic rhintis children by dosing Allergen immunotherapy extract as sublingual drops which were kept under the tongue for a couple of minutes and then swallowed. The sublingual drops were administered in the morning on an empty stomach .
16274891|NCT04851847|Experimental|MatrixflexTM resorbable collagen membrane|Experimental arm using the Matrixflex Resorbable Collagen Membrane for treatment of periodontal intrabony defects
16274892|NCT04851847|Active Comparator|control group membrane|Control arm using the Comparator Xenograft Resorbable Collagen Membrane or treatment of periodontal intrabony defects
16274893|NCT04851834|Experimental|NTX-301 Monotherapy Dose Escalation|NTX-301 monotherapy dose escalation in patients with advanced solid tumours
16274894|NCT04851834|Experimental|NTX-301 platinum-based doublet therapy Dose Escalation|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian & bladder cancer
16274895|NCT04851834|Experimental|NTX-301 platinum-based doublet therapy Dose Expansion|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian & bladder cancer
16274896|NCT04851834|Experimental|NTX-301 Temozolomide doublet therapy Dose Escalation|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
16274897|NCT04851834|Experimental|NTX-301 Temozolomide doublet therapy Dose Expansion|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
16274898|NCT04851821|Experimental|Quercetix group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
16274899|NCT04851821|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
16274900|NCT04851795|Experimental|interventional study|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
16274901|NCT04851795|Other|control group|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
16274902|NCT04851782|Experimental|Braun Infusomat Pump and ivEAD tubing|ivEAD tubing
16274903|NCT04851782|No Intervention|Braun Infusomat Pump and standard tubing|Standard tubing
16274904|NCT04851782|Experimental|Standard pump and ivEAD tubing|ivEAD tubing
16274905|NCT04851782|No Intervention|Standard infusion pump and standard tubing|Standard tubing
16274906|NCT04851769|Experimental|alirocumab plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
16274907|NCT04851769|Active Comparator|standard statin therapy|Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target <100 mg/dL.
16274908|NCT04851756|Experimental|CRet Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis
16274909|NCT04851756|Sham Comparator|CRet Sham Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis with turned on CRet device at power 0
16274910|NCT04851743|Experimental|Dry needling Group|Participants will be used as their own controls, with 1 lower extremity randomly receiving intervention. The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
16274911|NCT04851743|No Intervention|Control Group|Participants will be used as their own controls, with 1lower extremity randomly receiving intervention. The control extremity did not receive any intervention, and outcomes were assessed 2 minutes apart.
16274912|NCT04851730|Experimental|Orthopedic Intervention|All subjects are receiving an orthopedic intervention that is specific to their presentation but made up of all intervention categories: Manual therapy, dry needling, deep breathing, stretching, strengthening, and progressive overload.
16274913|NCT04851717|Experimental|All Patients|All paediatric patients undergoing diagnostic and/or therapeutic procedures
16274914|NCT04851704|Experimental|Intervention: Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
16274915|NCT04851704|No Intervention|Control: Business as usual|"Control groups have business as usual, and then get offered the intervention program after 6 months follow-up assessment."
16274916|NCT04851691|Experimental|EHR CDS tool|Multi-pronged electronic health record (EHR) clinical decision support (CDS) tool intervention to reduce physician prescriptions of new antipsychotic medications among older adults with ADRD
16274917|NCT04851691|Experimental|Control|Physicians will not receive intervention and perform duties as usual.
16274918|NCT04851678||Individuals with Tourette syndrome (TS)|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
16274919|NCT04851639|Experimental|Proof of principle|Proof of principle of the efficacy and utility of the WATapp
16274920|NCT04851626|Experimental|Intervention group - hypnotic intervention for persistent pelvic pain|Participants underwent education about persistent pain and a 7 week 7 recording online hypnotic intervention. Women with persistent pelvic pain.
16274921|NCT04851626|Other|Control group - waitlist control|Control group of women with persistent pelvic pain no intervention completed assessment and concluding measures but did not undergo hypnotic intervention.
16283058|NCT04795193|Active Comparator|OPCABG|Patients undergoing thoracotomy OPCABG.
16274922|NCT04851613|Experimental|Afuresertib and Fulvestrant Safety Run In|Safety run-in Cycle 1 (a cycle is 28 days) will be performed in the first 6 patients of the phase Ib. Combination regimens during the safety run-in period are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
16274923|NCT04851613|Experimental|Afuresertib and Fulvestrant|Combination regimens are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
16274924|NCT04851600||Early introduction|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
16274925|NCT04851587|Experimental|In-Person (or Remote) Intervention Visits|Participants will initially complete a baseline assessment assessing study eligibility. The intervention consists of 16 in-person group sessions (1.5 hours each) targeting standard weight loss and pain treatment content and eight individual phone calls (30 minutes each) focusing on increasing reward and positive affect. Participants will monitor their pain, mood, and physical activity via a smartwatch for 7 days prior to their baseline session and 7 days prior to their final appointment.
16274926|NCT04851574||Group I with dose of Sugammadex of 0.5 Mg/kg|After general anesthesia children received one dose of 0.5 Mg/kg of Sugammadex to reverse neuromuscular blockade.
16274927|NCT04851574||Group II with dose of Sugammadex of 1.0 Mg/kg|After general anesthesia children received one dose of 1.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
16274928|NCT04851574||Group III with dose of Sugammadex of 2.0 Mg/kg|After general anesthesia children received one dose of 2.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
16274929|NCT04851561||Cases|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), cases will be defined as such if fulfill for the following criteria: individuals who report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks.
16274930|NCT04851561||Controls|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), did not report fatigue symptoms at any time point following their diagnosis with COVID-19.
16274931|NCT04851548|Active Comparator|Group A (control)|"preoperative cone-beam computed tomography (CBCT) scans N=9
~open flap debridement.
~use membrane without hyaluronic acid. (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments|)"
16274932|NCT04851548|Active Comparator|Group B (test)|"preoperative cone-beam computed tomography (CBCT )scans N= 9
~open flap debridement.
~use membrane and 8% hyaluronic acid gel (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments|)."
16274933|NCT04851535|Experimental|Jaktinib 100mg Bid|Jaktinib twice daily for 6 consecutive 28-day cycles, orally, empty stomach
16274934|NCT04851522|Experimental|Di-Dak-Sol + White Petrolatum|"Participants will receive Di-Dak-Sol (dilute bleach compresses) prior to receiving radiation. This will continue throughout their radiation therapy and for one week after.
~Participants will also be asked to apply white petrolatum ointment 2x daily throughout treatment: once after radiation and once in the evening.
~Participants will be provided with a log and asked to document information (dates/times of application) about the study treatment ."
16274935|NCT04851509|Active Comparator|Dynamic rotational locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The helical screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance less than 25mm. The compression nut will be used to compress the fracture. The helical screw will be rotationally locked by using the 5mm hex flexible screwdriver by advancing the set screw until it stops completely. The screw will then be turned counterclockwise by a ½ turn.
16274936|NCT04851509|Experimental|Static locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The helical screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance of less than 25mm. The compression nut will be used to compress the fracture. The helical screw will then be statically locked using the 6Nm torque-limiting blue handle with 6mm hex coupling to completely lock the set screw down on the helical screw.
16274937|NCT04851496||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16274938|NCT04851496||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16274939|NCT04851496||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16274940|NCT04851496||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16307653|NCT04623242|Placebo Comparator|Matching Placebo (Solanezumab)|
16274946|NCT04851457|Experimental|Intervention group|The participants in the experimental group will receive intravenous tirofiban combined with a standard MT protocol recommended by the current guidelines for the management of AIS
16274947|NCT04851457|No Intervention|Control group|Patients are treated with MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered. Besides, they will receive a standard pharmacological treatment as per current clinical guidelines.
16274948|NCT04851444|Experimental|SI-F019|SI-F019 administered intravenously (IV).
16274949|NCT04851431|Experimental|One-to-One Peer Mentoring|Caregiver will be matched based on characteristics such as age, date of patient injury, level of patient injury, cause of patient injury, marital status, work status before and after patient injury, interests, and leisure activities. After participant is matched with a peer mentor, they will be required to have at least one weekly one-to-one interaction from time of match until 30 days post- discharge.
16274950|NCT04851431|Active Comparator|Usual Care|Participants received the usual discharge planning and family support services offered by the ABI program. These services include nurse instruction in care routines, case management support for discharge, peer support services, referral to family counseling and community services as indicated, and general information resources about brain injury. Participants in both the intervention and usual care groups also had access to the online peer support community created for ABI caregivers (facebook.com/shepherdbi.peers). In addition, usual care participants could request one-to-one visits with peer mentors and, indeed, most usual care participants received at least one peer mentoring visit.
16274951|NCT04851418||Possible NSTE-ACS|All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
16274952|NCT04851405|Active Comparator|Otago Exercise Programme+ Intervention Group (OEP+)|"Physiotherapists receive OEP training, a 2 hour workshop on the coaching protocol using the OEP app, and online training on the Brief Action Plan Approach.
~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up OEP app and Fitbit. PT will return bi-weekly over the course of two months (four visits total) for follow-up. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit. Between Months 7-12, PTs will continue to a phone call follow-up once a month to review the exercise routine.
~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also have access to the OEP app which allows the PT to prescribe exercises and record the participant's exercise goal."
16274953|NCT04851405|Placebo Comparator|Otago Exercise Programme Group (OEP)|"Physiotherapists receive OEP Training and a 2 hour workshop on just the coaching protocol.
~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up the Fitbit. For the first two months, PTs will provide bi-weekly home visits. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit.
~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also receive a Fitbit. Between Months 7-12, older adults will receive follow-up phone calls from the research staff."
16274954|NCT04851392|Experimental|THC condition|"THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC.
~Route of administration: vaporised and inhaled.
~Frequency: once.
~Duration: inhaled in < 18 minutes."
16274955|NCT04851392|Experimental|THC+CBD condition|"THC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD.
~Route of administration: vaporised and inhaled.
~Frequency: once.
~Duration: inhaled in < 18 minutes."
16274956|NCT04851392|Placebo Comparator|PLA condition|"PLA condition: Placebo cannabis with no THC or CBD.
~Route of administration: vaporised and inhaled.
~Frequency: once.
~Duration: inhaled in < 18 minutes."
16274957|NCT04851366|Experimental|PROCARE+ (with add-on modules)|In addition to core UP-A preventive intervention, PROCARE will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include, but not limited to social, parental, stress-related (including CoVid19 impact) risk factors, and health. Dosage (number of modules) will be included as covariate in all subsequent analyses.
16274958|NCT04851366|Experimental|PROCARE (UP-A for selective purposes)|To ensure cost-effectiveness, PROCARE core intervention will be designed as a brief 8-session child-focused programme which aims to build resilience for adolescents by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical selective preventive intervention format focused on cost-effectiveness.
16274959|NCT04851366|Active Comparator|Active control condition.|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for two alternative compare conditions to PROCARE. The U Talk programme support-based group condition will be used as active control condition."
16274960|NCT04851353|Active Comparator|GT+VC|Gentle touch +Verbal comfort
16274961|NCT04851353|Experimental|GT+VC+Smell|Gentle touch +Verbal comfort+ Smell breast milk
16274962|NCT04851353|Experimental|GT+VC+Smell+Taste|Gentle touch +Verbal comfort+ Smell breast milk+ Taste milk
16274963|NCT04851340|Experimental|Cow's Milk First|Participants in this group will eliminate all cow's milk products during the first 10 days of the study and receive the cow's milk intervention first and then will cross-over to eliminate soy products in the second 10 days of the study and receive the soy milk intervention during the second diet intervention.
16274987|NCT04851171|Active Comparator|Semi-rigid Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo semi-rigid ureteroscopy for treatment of the stone.
16307654|NCT04623229|Experimental|MCS|
16274964|NCT04851340|Experimental|Soy Milk First|Participants in this group will eliminate all soy products during the first 10 days of the study and receive the soy milk intervention first and then will cross-over to eliminate cow's milk products in the second 10 days of the study and receive the cow's milk intervention during the second diet intervention.
16274965|NCT04851327|Experimental|High energy|"Child will be given a high energy drink: a flavoured high energy milk or juice-based drink, used clinically to supplement the diet of preschool children (either Pediasure plus or Duocal). This will provide 1.5 kcals per ml in various flavours as preferred. The amount given will supply 10% of the child's daily energy requirements per Kg - for example for a 2-year-old child weighing 15 KG this would be 80 mls of drink supplying 120 Kcal.
~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing a range of pre-packaged foods of known energy content suitable for their age, chosen in consultation with the parents."
16274966|NCT04851327|Experimental|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink, made either of skim milk or sugar free fruit juice, with a similar sugar free flavour; for above example this will supply 25 kcal.
~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of pre-packaged foods as above."
16274967|NCT04851314|Active Comparator|ICU certified ventilator|Participants assigned to receive ventilation with the ICU certified ventilator
16274968|NCT04851314|Active Comparator|Non-ICU certified ventilator|Participants assigned to receive ventilation with the Non-ICU certified ventilator
16274969|NCT04851301|Active Comparator|Naloxone|NARCAN® Naloxone Nasal Spray will be used to determine how the opioid tone shapes VR-induced hypoalgesia. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
16274970|NCT04851301|Sham Comparator|Saline|Saline group, where participants will be given saline solution (4mg) via an identical spray device. Participants will be stratified for sex and then randomized to saline arm (The dose of saline will be (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
16274971|NCT04851301|Other|Natural History|Natural history group, where participants will not be given any drugs. Participants will be stratified for sex and then randomized to the Natural History group.
16274972|NCT04851288|Experimental|MitoQ, 20 mg/day|Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
16274973|NCT04851288|Placebo Comparator|Placebo|Matched placebo capsules.
16274974|NCT04851275|Experimental|Shared decision making for men with lower urinary tract symptoms|Participants used the Visual Analogue Uroflowmetry Score so report their symptoms and were attended by Primary Care Physicians trained in shared decision making
16274975|NCT04851275|Active Comparator|No shared decision making for men with lower urinary tract symptoms|Participants did not use the Visual Analogue Uroflowmetry Score to report their symptoms and received usual care by Primary Care Physicians not trained in shared decision making
16274976|NCT04851262|Experimental|Intervention|The intervention is a 12-week home-based resistance training programme with phased progression. The intervention will have three phases: (i) an initial phase focused on training the target muscle(s)/movements with minimal or no external weight; (ii) an intermediate phase targeting muscle strength with increased practice resistance; and (iii) an advanced phase targeting the further enhancement of muscle strength by challenging multiple muscle groups. Each phase will involve exercises targeting the trunk, back, hip, upper-limb and lower-limb muscles.
16274977|NCT04851262|Other|Waitlist control|The waitlist control participants will start the intervention 12 weeks after the baseline assessment.
16274978|NCT04851249||Adult participants operated for Hallux Valgus deformity|All adult participants accepted for hallux valgus corrective surgery at østfold hospital trust (ØHT) is asked to participate in the study. The goal is to include 200-250 participants.
16274979|NCT04851236|Active Comparator|Massage Arm|Standard of care treatment.
16274980|NCT04851236|No Intervention|Usual Care|
16274981|NCT04851223||Pre Diabetics|
16274982|NCT04851197|Experimental|control group|"The students in the control group will be filled with the Introductory and Self-Testicular Examination Characteristics Question Form, Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale, which will be prepared with Microsoft teams forms before the training. Later, the students will be given an average of 20-30 minutes of training from Powerpoint presentation and video presentation. Students' questions will be answered in the last 10 minutes. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and KKTM Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled out."
16274983|NCT04851197|Experimental|Intervention|"Before the training, the students in the intervention group will fill the Introductory and Characteristics Question Form on Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale. Educational materials (lecture presentation, video) will be loaded on the system in accordance with the inverted learning model, and students will be asked to come prepared for the planned lesson. Classical presentations will not be made to the students, and the education will be given in the form of question and answer discussion. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and Self Testicular Examination Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled."
16274984|NCT04851184|Active Comparator|Usual Vestibular Rehabilitation Care|Participants in this arm will perform typical PT in the clinic and home environment. They will be asked to keep a log to track their HEP.
16274985|NCT04851184|Experimental|Home Exercises Using Virtual Reality Device|Participants in this arm will perform typical PT in the clinic, but will use the virtual reality device as part of their HEP.
16274986|NCT04851184|No Intervention|Healthy Control|Age-matched healthy control subjects will perform all balance, gait, vestibular, and patient reported outcome measure assessments, including performing 30 seconds of each level of gaze stability exercise for an active comparison to outcomes obtained to those with vestibular disorders.
16283137|NCT04794621|No Intervention|Standard of Care Only|This will be group 1
16274988|NCT04851171|Active Comparator|Flexible Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo flexible ureteroscopy for treatment of the stone.
16274989|NCT04851158|Experimental|ShotBlocker|ShotBlocker will be used on 35 patients. For the patient group that is applied ShotBlocker, after cleansing the skin, the protruding surface of the device is placed facing the skin surface. The injection is applied with the appropriate technique, then ShotBlocker is removed and a light pressure is applied to the area with a cotton pad for 15-20 seconds.
16274990|NCT04851158|Experimental|Local Vibration|Local Vibration will be used on 35 patients. For the patient group that was subject to local vibration, local vibration was applied to the region with a vibrator for five minutes prior to injection, following a previous study on this subject. After that, 70% alcohol was used to cleanse the skin. The injection was applied with the appropriate technique, then a light pressure was applied to the area with a cotton pad for 15-20 seconds.
16274991|NCT04851158|No Intervention|Control|For the control group (n=35), IM injection into the ventrogluteal region without using any tools is performed with the appropriate technique.
16274992|NCT04851145|Experimental|Experimental|
16274993|NCT04851132|Experimental|Exprimental Arm|IMRT plus Durvalumab
16274994|NCT04851119|Experimental|Treatment (tegavivint)|Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. A cycle of therapy is considered to be 28 days. A cycle may be repeated for a total of 26 cycles, up to a total duration of therapy of approximately 24 months. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg.
16274995|NCT04851106||Patient with a solid pancreatic lesion of an undetermined nature|Patient with a solid pancreatic lesion of an undetermined nature
16274996|NCT04851093|Experimental|TCM granule plus conventional drug|The experimental group will receive three types of TCM granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
16274997|NCT04851093|Placebo Comparator|TCM placebo granule plus conventional drug|The control group will receive three types of TCM placebo granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
16274998|NCT04851080||Schoolchildren|Schoolchildren of Vladikavkaz secondary schools aged 13-16 years
16274999|NCT04851080||Students|Students of North-Ossetian State Medical Academy at the age of 19-22 years
16275000|NCT04851080||Volunteers|Scientists of the North Caucasian Research Institute of Mountain and Foothill Agriculture at the age of 30-56 years
16275001|NCT04851067|Active Comparator|Dry Needling and Therapeutic Exercises (DNTEx)|"Dry Needling - A fine needle, of 5-10 mm, will be used to penetrate the skin, subcutaneous tissues, and muscle with the intent to stimulate Myofascial Trigger Point (MTrP) or mechanically disrupt tissue without the use of an anesthetic.
~Therapeutic Exercises - Are exercises will be performed to achieve a specific physical benefit, including increasing and maintaining range of motion, strengthening weak muscles, increasing joint flexibility, or improving cardiovascular and respiratory function."
16275002|NCT04851067|Active Comparator|Manual Therapy and Therapeutic Exercises (MTTEx)|"Joint Mobilization - A manual therapy technique comprising of a continuum of skilled passive movements to the joint complex will be applied at varying speeds and amplitudes. It will include a low-grades/velocity (grades I and II), high grades (grades III and IV), and small- or large-amplitude passive movement techniques within the patient's physiological range of motion and within the patient's control with the intent to restore optimal motion, function, and/ or to reduce pain.
~Joint Manipulation - A passive, high velocity, low amplitude thrust will be applied to a localized joint segment/s within its anatomical limit with the intent to restore optimal motion, function, and/ or to reduce pain."
16275003|NCT04851054||Patients after surgery for colon cancer with intention to cure|Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention
16275004|NCT04851041|Experimental|Potato group|The participants in this group consume every day 150g of boiled potatoes for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well
16275005|NCT04851041|Active Comparator|Pasta/rice|"The participants in this group consume every day either rice or pasta for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well.
~The portion of rice and pasta must be as isocaloric as 150g of boiled potatoes."
16275006|NCT04851028|Experimental|One2One|1) Weekly individual (one2one) Music Therapy intervention lasting 5 months (n=20 sessions)
16275007|NCT04851028|Experimental|Small-group|2) Weekly small group (max 8 people per group) Music Therapy intervention lasting 5 months (n=20 sessions)
16275008|NCT04851028|No Intervention|Control|Standard weekly music social listening in large group available in all care-homes. Lasting 5 months (n=20 sessions)
16275009|NCT04851015|Experimental|Reduced dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 10mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as a dose of 10mg/kg/day open label with additional placebo tablets or intravenous placebo solution given to simulate 15mg/kg/day. All doses will be adjusted for obesity and renal function.
16275010|NCT04851015|Active Comparator|Standard dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 15mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as 10mg/kg/day open label plus an extra masked 5mg/kg/day of tablets or intravenous solution. All doses will be adjusted for obesity and renal function.
16275011|NCT04851002|Experimental|CGF TEST GROUP|Concentrated growth factor liquid applied into the implant cavity. Also CGF membrane covered the implant and the socket. That is the only difference between CGF control group and CGF test group
16275012|NCT04851002|Experimental|A-PRF TEST GROUP|Advanced Platelet Rich Fibrin liquid applied into the implant cavity. Also A-PRF membrane covered the implant and the socket. That is the only difference between A-PRF control group and A-PRF test group
16275013|NCT04851002|Experimental|CGF CONTROL GROUP|Dental implant applications were made with traditional methods.
16275015|NCT04850989|Experimental|Virtual reality exposure therapy|Participants were allowed to choose one of two themes. For both themes, each scene was developed to be more anxiety-provoking as the VRE progressed. Greater anxiety-inducing scenes had interviewers and other actors who displayed less compassionate, friendly, humorous, and pleasant verbal and non-verbal behaviors and demeanors to elicit elevated anxiety (Carless & Imber, 2007). Also, a virtual therapist was embedded within the VRE. It functioned to coach the participant through each distinct scene by orienting and prompting them to the exposure therapy task(s), continually conveying core principles of exposure therapy, and repeating the instructions if the participant was not responsive within five seconds. Each scene started with a paused video, during which participants were oriented by the virtual therapist to the context.
16275016|NCT04850989|No Intervention|Waiting list|Participants started treatment 2-4 weeks post-randomization.
16275017|NCT04850976|Experimental|Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group|The self-assembled modified Macintosh videolaryngoscope (SAM-VL) used in this study was constructed from a portable video camera with Wi-fi connection (Wi-fi Endoscope Video Camera model YPC99) attached to a no. 4 Macintosh Laryngoscope blade (Riester® no.7040). The video signal is transmitted to an Android-based mobile phone (Android version 7.0). The portable 2 megapixels video camera is 8 mm in diameter with 8 Light Emitting Diode (LED) lights for adjustable lighting level and 3 meters cable length. Video resolution output is 640x480 pixels (VGA) and 1280x720 pixels (HD). The camera has 70º visual angle with focus length of 4- 6cm and is water-resistant. The camera was taped to the Macintosh blade at a distance of 5 cm from the distal end of the blade, using transparent waterproof Leukofix® tape.
16275018|NCT04850976|Active Comparator|McGrath MAC® videolaryngoscope (McGrath) group|The McGrath MAC® videolaryngoscope used in this study was equipped with disposable blade no.4
16275019|NCT04850963|Experimental|Group 1 - tDCS active|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).
~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20, in which the anode will be applied in the primary motor area (C3 / C4) ipsilateral to the lesion and the cathode in the contralateral supra-orbital region. The current intensity will be defined based on computational modeling, using the patient's magnetic resonance as a basis, in order to estimate and individualize the dosage to be administered."
16275020|NCT04850963|Sham Comparator|Group 2 - tDCS sham|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).
~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20, in which the anode will be applied in the primary motor area (C3 / C4) ipsilateral to the lesion and the cathode in the contralateral supra-orbital region."
16275021|NCT04850950|Experimental|Arm 1|Tenofovir alafenamide fumarate discontinued at delivery date.
16275022|NCT04850950|Experimental|Arm 2|Tenofovir alafenamide fumarate discontinued at postpartum month 1.
16275023|NCT04850937|Experimental|Group S|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction During administration, blood pressure and heart rate were observed.
16275024|NCT04850937|Placebo Comparator|Group C|The control group will receive the same amount of normal saline after anesthesia induction
16275025|NCT04850924||children impact by the Alex storm|
16275026|NCT04850911|Experimental|Ketamine|Participants in this arm will receive a single intravenous, antidepressant dose of ketamine hydrochloride (0.5mg/kg)
16275027|NCT04850911|Placebo Comparator|Placebo|Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride).
16275030|NCT04850885|Experimental|Dexamethasone Group ( Group DXN)|Group DXN has received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml)
16275031|NCT04850885|Active Comparator|Adreanaline Group ( Group ADN)|Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline)
16275032|NCT04850872|Experimental|Experimental|PLAYwithHEART Programme is a manualized mindfulness, acceptance, and compassionate-based group intervention for adolescent competitive athletes. It included 8 weekly group sessions, 45 minutes each, run in small groups (ranging from 8 to 12 participants). Participants of this group complete also self-report measures.
16275033|NCT04850872|No Intervention|Control|Participants of control group do not receive the intervention Programme (PLAYwithHEART), nor any other program, and only complete self-report measures.
16275034|NCT04850859||group of scapulae bones|Human adult dry scapulae bones 40 of unknown sex and age will be collected.
16275035|NCT04850859||group of hip bones|Human adult dry hip bones 40 of unknown gender and age will be collected
16275036|NCT04850846|Experimental|Metformin|Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last 6 months.
16275037|NCT04850846|Experimental|Placebo|Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months.
16275038|NCT04850820|Experimental|Novel essential amino acid supplementation (EAA+)|Arm will investigate the effect of a novel essential amino acid-based formula (essential amino acids enriched with active botanical compounds; EAA+) developed by Iovate Health Sciences International Inc. on post-exercise anabolism. The formulation was recently granted a Natural Product Number (NPN: 80087022) and approved by the Natural and Non-prescription Health Products Directorate of Health Canada.
16275039|NCT04850820|Active Comparator|Branched-chain amino acid supplementation (BCAA)|Arm will used a branched-chain amino acid supplement developed by Iovate Health Sciences International Inc. to compare with the experimental arm after exercise.
16275040|NCT04850820|Placebo Comparator|Isocaloric carbohydrate supplementation|Carbohydrate supplement that is isocaloric to the EAA+ supplement and designed to function as a placebo to the experimental arm after exercise.
16275041|NCT04850820|Other|Rested control|Carbohydrate supplement that is isocaloric to the EAA+ supplement but consumed at rest to serve as the baseline control
16275042|NCT04850807|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting
16275043|NCT04850807|Experimental|Music & Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences at early signs of agitation
16275046|NCT04850781|Active Comparator|Daily Meals|A lunch-time meal delivered to participants' homes multiple times per week with wellness check and socialization.
16275047|NCT04850781|Experimental|Frozen, Drop-shipped Meals|10 frozen meals that are mailed to participants every two weeks.
16275048|NCT04850768||Periodontitis|Individuals with Periodontitis
16275049|NCT04850768||Gingivitis|Individuals with Gingival Inflammation
16275050|NCT04850768||Healthy|Individuals with Periodontally Healthy
16275051|NCT04850755|Experimental|patients with advanced solid malignancies|Patients will be dosed with selinexor once a week continuously in a 6 week cycle. Nivolumab will be administered on biweekly of each cycle . Ipilimumab will be dosed only on D1 of each cycle . Ipilimumab will continue for a maximum of 4 cycles. Nivolumab and selinexor will continue for up to 24 months or until discontinuation criteria is met.
16275052|NCT04850742|Experimental|Cryopreserved aorta|After resection of a segment of tracheal or bronchial lesion, reconstruct the airway with cryopreserved aortic allograft.
16275053|NCT04850703|Experimental|Premature Ejaculation participants who receive Brain Weak Currents in IFG brain cortex|"Participants receive tRNS (weak currents < 2 mA) sessions at IFG brain cortex for 25 minutes 2 times a day 3 times per week during 3 weeks.
~After 4 hours they end the last session, a new brain mapping is performed."
16275054|NCT04850703|Active Comparator|Premature Ejaculation participants who take Dapoxetine|Participants take 1 tablet of the drug between 1 and 3 hours before the brain mapping
16275055|NCT04850703|Sham Comparator|Placebo Group|Participants who do not take medication or receive tRNS sessions
16275056|NCT04850703|Other|Controls|44 Healthy humans not clinically not diagnosed with LPD and withouth expression the LPE endophenotype. In this way, the investigators what would be the patients diagnosed clinically with LPE who present the endophenotype or neurophysiological biomarker of LPE.
16275057|NCT04850690||Children with hemiparetic Cerebral palsy|15 children with CP, between 9-15 years old
16275058|NCT04850677||Total|All subjects in the study belong to the same group/cohort. As this is an observational study there is no intervention planned.
16275059|NCT04850664|Experimental|CBOT + TAU|CBOT consists of 40 cycles of olfactory stimulation and OFC training tasks, lasting ~45 minutes, once daily over 3 months. Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
16275060|NCT04850664|Sham Comparator|Sham + TAU|Sham is a CBOT device that uses artificially-scented compressed room air instead of olfactory stimulants and has no OFC cognitive tasks. Similar to the CBOT, sham will be used daily for 45 minutes. TAU is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
16275062|NCT04850638|Experimental|SHR4640 tablets|
16275063|NCT04850625||Pyrotinib Plus Vinorelbine|lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)
16275064|NCT04850625||Lapatinib Plus Capecitabine|pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days)
16275065|NCT04850612||Healthcare professionals and researchers (HCPR)|All researchers and healthcare professionals involved in the management of patients with CSDH
16275066|NCT04850612||Patients and carers|Patients who have previously had a diagnosis of CSDH, and their carers
16275068|NCT04850586|Experimental|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
16275069|NCT04850586|No Intervention|Control Group|Routine education was given to the patients in the control group. Routine education was administered by a nurse working in the clinic after the patients were admitted to the hospital. The patients in this group were not trained by a multidisciplinary team. In the routine training, patients were only informed about preoperative preparation.
16275070|NCT04850573|Experimental|EAA|Participants in this arm will take part in eight weekly thirty minute sessions of equine facilitated learning where they interact with a horse and learn basic horsemanship skills.
16275071|NCT04850573|No Intervention|Control|
16275072|NCT04850560|Experimental|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|
16275073|NCT04850534||EGD+NSBB|Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices
16275074|NCT04850534||EGD|Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices
16275075|NCT04850521||Remote monitoring|Remote monitoring software + connected devices
16275076|NCT04850495|Experimental|Treatment (zanubrutinib, R-CHOP)|Patients receive zanubrutinib PO on days 1-21, rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16275077|NCT04850482|Experimental|Intervention Arm|Participants get immediate access to the intervention on completion of baseline assessment.
16275078|NCT04850482|No Intervention|Wait list control Arm|Participants get access to the intervention in 10 weeks after completion of the baseline and follow up assessment.
16275079|NCT04850469||trial group|Mesenchymal Stem Cell-Derived Exosomes
16275080|NCT04850469||control group|conventional treatment
16275081|NCT04850456||trial group|Human Gamma Globulin
16275082|NCT04850456||control group|conventional treatment
16275083|NCT04850443||trial group|tocilizumab siltuximab
16275084|NCT04850443||control group|conventional treatment
16275085|NCT04850430|Experimental|Gastric venous congestion following total pancreatectomy|The gastric venous outflow will be reconstructed after TP. The patients will be assessed concerning gastric venous congestion and gastric ischemia intraoperatively before and after venous outflow reconstruction through onsite evaluation by the surgeon, endoscopic examination, indocyanine green, gastric venous drainage flowmetry, and spectral imaging.
16275086|NCT04850417|Experimental|Beta-blockers and Short Antiplatelet Therapy|"Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy
~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
16275087|NCT04850417|Experimental|Beta-blockers and Long Antiplatelet Therapy|"Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy
~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
16275088|NCT04850417|Experimental|No Beta-blockers and Short Antiplatelet Therapy|"No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy
~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
16275089|NCT04850417|Active Comparator|No Beta-blockers and Long Antiplatelet Therapy|"No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy
~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
16275090|NCT04850404|Experimental|the group of abdominal nerve block combined with moderate NMB|The patients of group N-M received the rectus abdominis block combined with transverse plane block.
16275091|NCT04850404|No Intervention|moderate NMB group|The patients of group M received moderate NMB through the surgery.
16275092|NCT04850391|Active Comparator|Lean-overweight|BMI 18.5 - 30 kg/m2
16275093|NCT04850391|Active Comparator|Obese|BMI > 30 kg/m2
16275094|NCT04850391|Active Comparator|Obese OSA|OSAS patients with BMI > 30 kg/m2
16275095|NCT04850378|No Intervention|Coagulation profile in Nephrotic syndrome|Investigation of the biochemical coagulation profile in patients with nephrotic syndrome.
16275096|NCT04850378|Experimental|Nephrotic syndrome|Nephrotic patients without diabetes.
16275097|NCT04850378|Experimental|Membranous nephropathy and nephrotic syndrome|Membranous nephropathy and nephrotic syndrome.
16275098|NCT04850378|Active Comparator|Atrial fibrillation|Atrial fibrillation with no kidney disease.
16275099|NCT04850365|Other|Abdominal sacral hysteropexy|The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.
16275100|NCT04850365|Other|Vaginal sacrospinous hysteropexy|"This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.
~The outcomes will be obtained as follow;"
16275101|NCT04850352|Experimental|Heukcha Extracts|Take Heukcha Extracts capsule once daily for 8 weeks.
16275102|NCT04850352|Placebo Comparator|Placebo|Take placebo capsule once daily for 8 weeks.
16275103|NCT04850339|Active Comparator|ANXV single dose|ANXV in a single ascending dose pattern in four dose levels.
16275104|NCT04850339|Placebo Comparator|Placebo single dose|Placebo in a single ascending dose pattern in four dose levels.
16275105|NCT04850339|Active Comparator|ANXV multiple dose|ANXV in a multiple ascending dose pattern in three dose levels.
16275106|NCT04850339|Placebo Comparator|Placebo multiple dose|Placebo in a multiple ascending dose pattern in four dose levels.
16275107|NCT04850326|Experimental|AP green tea extract|
16275108|NCT04850326|No Intervention|No intervention control|
16275109|NCT04850313|No Intervention|Conventional Treatment|"Corneal ulcer scraping sent for microbial culture
~Admission to the hospital for initiation of fortified vancomycin 25mg/mL every 1 hour alternating with fortified tobramycin 15mg/mL every 1 hour, preservative free artificial tears every 2 hours, and doxycycline 100mg twice daily.
~After 48 hours of conventional treatment, consent will be obtained regarding the use of experimental treatment with ProKera Plus® versus continuing conventional method of treatment"
16275110|NCT04850313|Experimental|ProKera Plus® Treatment|1. Experimental Treatment Arm , ProKera Plus® will be placed in the eye with the corneal ulcer
16275111|NCT04850300|Experimental|Total knee prosthesis 1|prosthesis with medial condylar stabilization
16275112|NCT04850300|Active Comparator|Total knee prosthesis 2|traditional prosthesis with central pivot stabilization
16275113|NCT04850287|Placebo Comparator|Control|
16275114|NCT04850287|Experimental|Intervention|
16275115|NCT04850287|Experimental|Optimal|
16275116|NCT04850274|Experimental|Remote Therapy Intervention|Youth will receive the maximal dose of six S-RTI therapy sessions delivered by a remote therapist with no alteration in intensity
16307655|NCT04623229|Experimental|ReLACS Early|
16275117|NCT04850274|Experimental|Artificial Intelligence Remote Therapy Intervention|Youth will first receive a remote therapy session in the Emergency Department (ED). The RL system will then make decisions about the intensity of each subsequent therapy session (the initial decision is seven days post ED visit and bi-weekly [i.e., every other two weeks] thereafter) for the next 11 weeks. Potential treatment decisions include a 30-minute remote therapy session delivered via phone or video chat (mirroring the S-RTI), a less intensive tailored Motivational Interviewing (MI)-adherent electronic remote therapy (delivered by an electronic robot), or an assessment only without intervention.
16275118|NCT04850274|No Intervention|Enhanced Usual Care|The youth's retaliatory risk will be assessed and a pamphlet with referrals for violence, substance use, and mental health services will be provided.
16275119|NCT04850261|Active Comparator|Intervention A: hCG injection|Ovulation induction by subcutaneous injection of 5.000 IU hCG
16275120|NCT04850261|Experimental|Intervention B: nasal application of Nafarelin|Ovulation induction by nasal application of 200 microgram Nafarelin
16275121|NCT04850235|Experimental|TPX neoadjuvant chemotherapy +CCRT|Patients receive neoadjuvant chemotherapy with Nab-PTX (150/175/200/225/250 mg/m2, D1) , cisplatin (75 mg/m2, D1) and capecitabine (1000 mg/m2, BID, D1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100 mg/m2) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT)
16275122|NCT04850222|Experimental|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
16275123|NCT04850222|Active Comparator|Subjects randomized to get Calcium Supplmentation|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
16275124|NCT04850209|Other|Control group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education
16275125|NCT04850209|Experimental|Wechat group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.
16275126|NCT04850196|Experimental|TEAS group|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
16275127|NCT04850196|Sham Comparator|Control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS.
16275128|NCT04850183|Experimental|Intervention group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the intervention group at baseline. The patients were assigned to the intervention group at random and participated in a one-to-one training program consisting of a 30-min onset session. The Rheumatoid Arthritis Patient Education Booklet prepared by the researchers was administered to patients in the intervention group during education. In the 3rd month, all forms were applied again to the patients in the intervention group.
16275129|NCT04850183|No Intervention|Control group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.
16275130|NCT04850170|Experimental|Experimental group|"The first ten subjects will be enrolled in a pilot study. The following sixty subjects will be separated randomly to experimental group and control group.
~The first ten subjects and the experimental group will be arranged manual therapy and rehabilitation for six months."
16275131|NCT04850170|Active Comparator|Control group|The control group will be arranged rehabilitation.
16275132|NCT04850157|Experimental|Tislelizumab+IMRT|
16275140|NCT04850131|Active Comparator|Desarda|Forty-one patients who were randomly assigned to the Desarda group underwent the Desarda repair for their problem. Patients were followed for various data point values during operation, immediately after the operation, and for a period of one year post-operatively.
16275141|NCT04850131|Active Comparator|Lichtenstein|Forty-one patients randomly assigned to the Lichtenstein group underwent the standard mesh repair and were followed for the same data point values and variables for the same specified period of time.
16275142|NCT04850118|Active Comparator|Group 1: Low Dose|Male subjects 8-50 years of age treated by subretinal injection with the low dose of AGTC-501
16275143|NCT04850118|Active Comparator|Group 2: High Dose|Male subjects 8-50 years of age treated by subretinal injection with the high dose of AGTC-501
16275144|NCT04850118|Other|Group 3: Control|Male subjects 8-50 years of age in the untreated control group. Subjects randomized to the untreated control group will be followed for a minimum of 12 months. After this time, they will be treated by subretinal injection with the high dose of AGTC-501.
16275147|NCT04850092||Non-hypotensive|Mean blood pressure is maintained after positional change from supine to prone.
16275148|NCT04850092||Hypotensive|Mean blood pressure decrease < 20% after positional change from supine to prone.
16275149|NCT04850066|Experimental|Equine-assisted intervention|Brief program (3 sessions)
16275150|NCT04850066|No Intervention|Control|Standard care with treatments as usual
16275151|NCT04850053||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
16275152|NCT04850053||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
16275153|NCT04850053||Cognitively normal controls|Individuals with normal cognitive function
16275154|NCT04850040|Experimental|Camrelizumab+Apatinib Mesylate+Oxaliplatin|An study of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.
16275155|NCT04850027||Lower rectal cancer patients with a LLN ≥ 5mm|Patients with lateral lymph node short diameter ≥ 5mm evaluated by MRI were included.
16275156|NCT04850014||Poisoned patients|All subjects with paracetamolemia in the context of paracetamol poisoning
16275157|NCT04850014||Control group|Acetaminophen-poisoned patient being non-obese
16275158|NCT04850001||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
16275159|NCT04850001||Healthy Control|Healthy control are free from intracranial stenosis
16275160|NCT04849988|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - Intramuscular injections into affected neck muscles.
16275161|NCT04849988|Experimental|ABP-450 - Medium Dose|ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.
16275162|NCT04849988|Experimental|ABP-450 - High Dose|ABP-450 High Dose - Intramuscular injections into affected neck muscles.
16275163|NCT04849988|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
16275164|NCT04849975|Experimental|Pelvimetry group|The participants oh this group will successively perform MRI pelvimetry and EOS imaging.
16275165|NCT04849962|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
16275166|NCT04849962|Experimental|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
16275167|NCT04849949|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
16275168|NCT04849949|Experimental|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
16275169|NCT04849949|Experimental|English Walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
16275170|NCT04849936||evaluation of fecal biomarkers|comparison of the biomarker levels between different gastrointestinal diseases
16275171|NCT04849923|No Intervention|controll group|This group has no additional strength training
16275172|NCT04849923|Experimental|1 training per week|This group performs one strength training session per week
16275173|NCT04849923|Experimental|3 trainings per week|This group performs two strength training sessions per week
16275174|NCT04849910|Experimental|Cohort 1|VOR33 infusion followed by Mylotarg Dose Level 1
16275175|NCT04849910|Experimental|Cohort 2|VOR33 infusion followed by Mylotarg Dose Level 2
16275176|NCT04849910|Experimental|Cohort 3|VOR33 infusion followed by Mylotarg Dose Level 3
16275177|NCT04849897|Active Comparator|Active Comparator: Audio Only Guided Imagery Audio Recordings of Guided Imagery via tablet|Listen to narrative scripts based on traditional GI audio recordings. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the GI experience.
16275178|NCT04849897|Experimental|Experimental: Virtual Reality Guided Imagery Platform and VR Headset|VR headset for guided imagery with audiovisual computer-generated VR content to accompany the GI narration. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the VR-GI experience.
16275179|NCT04849884|Experimental|CORI Tensioner|Subjects having a robotic TKA procedure with the CORI Surgical System including the use of the REAL INTELLIGENCE Tensioner accessory.
16275180|NCT04849871|Experimental|Arm S_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 20 Gy-1 fraction)|-External Beam APBI 20 Gy to surgical bed surface (7 Gy to 1 cm from surgical bed in 1 fraction)
16275181|NCT04849871|Experimental|Arm F_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 30 Gy-5 fractions)|-External Beam APBI 30 Gy in 5 fractions over 5 days.
16275182|NCT04849858|Active Comparator|Bupivacaine TAP Block|The first 15 patients enrolled will receive perioperative plain bupivacaine TAP blocks.
16275183|NCT04849858|Active Comparator|Liposomal Bupivacaine TAP Block|After enrolling all 15 participants in the first arm, the next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine TAP blocks.
16275184|NCT04849858|Active Comparator|Liposomal Bupivacaine TAP Block with Re-dosing|After enrolling all 30 patients in the first two arms, the final 15 patients enrolled will receive perioperative Liposomal Bupivacaine TAP blocks followed by redosing of the TAP blocks in 48-60 hours.
16275185|NCT04849845|Experimental|Afrezza|The test product is defined as Afrezza [insulin human] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.
16275186|NCT04849832|Experimental|SIC|4mg of Fe will be given as 102 mg of SIC as a solution
16275187|NCT04849832|Experimental|SIC + tea|4 mg of Fe will be given as 102 mg of SIC as a solution along with 200 ml of black tea
16275188|NCT04849832|Active Comparator|FeSO4|4 mg of Fe will be given as Ferrous sulfate solution
16275189|NCT04849832|Active Comparator|FeSO4 + tea|4 mg of Fe will be given as Ferrous sulfate solution along with 200 ml of black tea
16275190|NCT04849819||never receive systemic medications|
16275193|NCT04849806||COPD patients (n=60)|"The following parameters will be determined in 60 consecutive patients with COPD without established cardiovascular disease (i.e. without an indication for beta blocker therapy or other pharmacological treatments attacking on the neurohormonal pathways like angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists).
~OSA severity.
~Determination of PH and right HF severity (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography;
~Comprehensive lung function and inspiratory muscle function testing ;Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis;
~Assessment of systemic inflammation"
16275194|NCT04849806||Controls (n=20)|(and in a group of healthy controls [3:1] matched for age, sex and BMI).
16275195|NCT04849793|Experimental|Experimental|Before the intervention, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. After rubbing, each individual's pain threshold level will be taken as a basis in order not to cause tissue damage. The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes. In the study group, an average of 13 minutes will be applied to HT7, LI4 and EX-HN3 points (five points in total) for two minutes each. The nursing students participating in the research will be given a total of 12 acupressure intervention remotely, three days a week, for four weeks, at least two hours after dinner and when they are calmest.
16275196|NCT04849793|No Intervention|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
16275197|NCT04849780|Experimental|ARM 1|Eligible subjects will be randomized to the TEST lens to wear in both eyes for approximately 2 weeks.
16275198|NCT04849780|Experimental|ARM 2|Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.
16275199|NCT04849767||Transgender people living with HIV|Transgender person Living with HIV Followed in clinical service
16275200|NCT04849754|Other|Patients with transthyretin related cardiac amyloidosis|Bone scintigraphy
16275206|NCT04849715|Active Comparator|Treatment Group A|Participants will be administered parsaclisib once daily and will receive Bendamustine and Rituximab periodically for 6 months.
16275207|NCT04849715|Placebo Comparator|Treatment group B|Participants will be administered placebo once daily and will receive Bendamustine and Rituximab periodically for 6 months.
16275208|NCT04849702||Postoperative complication after colorectal resection|Documentation of all postoperative complications after colorectal resections
16275209|NCT04849676|Experimental|Upper limb subacute spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.
~Diagnostic Tests:
~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)
~Perceived Spasticity level questionnaire on impact of spasticity
~Spinal Cord Independence Measure questionnaire on level of independence of patients
~Diary of spastic episodes
~Grip strength - measure of hand and forearm muscle strength using dynamometer
~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position
~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device
~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)
~Brief Visual Analog Scale self-assessment of performance and mental strategies
~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
16275210|NCT04849676|Experimental|Upper limb chronic spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.
~Diagnostic Tests:
~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)
~Perceived Spasticity level questionnaire on impact of spasticity
~Spinal Cord Independence Measure questionnaire on level of independence of patients
~Diary of spastic episodes
~Grip strength - measure of hand and forearm muscle strength using dynamometer
~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position
~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device
~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)
~Brief Visual Analog Scale self-assessment of performance and mental strategies
~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
16275211|NCT04849676|Experimental|Lower limb subacute spinal cord injury (sLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.
~Diagnostic Tests:
~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)
~Perceived Spasticity level questionnaire on impact of spasticity
~Spinal Cord Independence Measure questionnaire on level of independence of patients
~Diary of spastic episodes
~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position
~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device
~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)
~Brief Visual Analog Scale self-assessment of performance and mental strategies
~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
16275248|NCT04849377|Experimental|Group I - 50 Gy/200 mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1,T2 N0 RT 5 days per week for 6 weeks and Cisplatin weekly for 5 weeks
16275249|NCT04849377|Experimental|Group II - 54 Gy/200mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
16275250|NCT04849377|Experimental|Group III - 60 Gy/240 mg/m2|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
16275287|NCT04849104||patients with mild to moderate COPD|Patients with mild to moderate COPD: age <65 years, FEV1/FVC<70%, FEV1 predicted value ≥50%
16275212|NCT04849676|Experimental|Lower limb chronic spinal cord injury (cLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.
~Diagnostic Tests:
~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)
~Perceived Spasticity level questionnaire on impact of spasticity
~Spinal Cord Independence Measure questionnaire on level of independence of patients
~Diary of spastic episodes
~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position
~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device
~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)
~Brief Visual Analog Scale self-assessment of performance and mental strategies
~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
16275213|NCT04849663|Experimental|study group|Use of free fat graft to cover exposed root
16275214|NCT04849663|Active Comparator|control group|use of sub epithelial connective tissue graft to cover exposed root
16275215|NCT04849650|Experimental|Renal Impairment Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
16275216|NCT04849650|Experimental|Healthy Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
16275217|NCT04849637|Experimental|Standard of care plus adjunctive virgin coconut oil supplementation|Standard of care plus virgin coconut oil
16275218|NCT04849637|No Intervention|COVID-19 Standard of care treatment|Standard of care
16275219|NCT04849624||ICU COVID-19 patients|COVID-19 patients that are admitted into the ICU and fulfilled the eligibility criteria
16275220|NCT04849624||ICU non-COVID-19 patients|Non-COVID-19 patients that are admitted into the ICU matched with ICU COVID-19 patients that are recruited and fulfilled the eligibility criteria
16275221|NCT04849598|Experimental|ESWT Order A and B|First Endurance Shuttle Walk Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2, the second Endurance Shuttle Walk Test using the prescribed constant flow oxygen therapy.
16275222|NCT04849598|Experimental|ESWT Order B and A|First Endurance Shuttle Walk Test using the prescribed constant flow oxygen therapy, the second Endurance Shuttle Walk Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2.
16275223|NCT04849598|Experimental|Stairs Order A and B|First Stair Walking Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2, the second Stair Walking Test using the prescribed constant flow oxygen therapy.
16275224|NCT04849598|Experimental|Stairs Order B and A|First Stair Walking Test using the prescribed constant flow oxygen therapy, the second Stair Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2.
16275225|NCT04849572|Active Comparator|Sleep Education|Also referred to as Arm 1. Arm 1 receives sleep education initially.
16275226|NCT04849572|Active Comparator|Delayed Sleep Education|Also referred to Arm 2. Arm 2 receives no initial sleep education.
16275227|NCT04849559|Experimental|Tradipitant|Oral Capsule
16275228|NCT04849559|Placebo Comparator|Placebo|Oral Capsule
16275229|NCT04849533|Experimental|Group D Bela/EVR|rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml
16275230|NCT04849533|Active Comparator|Group E Bela/MMF|rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study
16275231|NCT04849520|Experimental|High flow|Application of high flow nasal cannula during apnea
16275232|NCT04849520|Active Comparator|Buccal|Application of buccal oxygenation during apnea
16275233|NCT04849507|Active Comparator|active taVNS|We will deliver taVNS via the BabyStrong system, with pulses paired with oral feeding, off with rest during 2 feeds a day. Current will be delivered at 0.1milliAmpere (mA) < perceptual threshold (PT), 500microseconds, 25 Hertz (Hz).The ear electrode will be positioned on left tragus for active taVNS.
16275234|NCT04849507|Sham Comparator|sham taVNS|The ear electrode positioned on left tragus as for active taVNS. We will test the PT with active stimulation, and then program a sham setting on the BabyStrong unit to deliver no current after the PT is determined.
16275235|NCT04849494||Late preterm AGA infants/Group 1|According to the new BALLARD scoring system gestational age was 34-36 6/7 and those who were at the 10-90th percentile according to the Fenton growth curves
16275236|NCT04849494||Newborns with Intrauterine growth restriction/Group 2|Term or preterm infants below 10th percentile according to the values calculated according to Fenton growth curves
16275237|NCT04849494||Control/Group 3|the healthy term (gestation week 38-42 weeks), AGA newborns, who born between January 2006 and December 2008
16275238|NCT04849468|Active Comparator|Diclofenac (D) group|Diclofenac (D) group which will receive 75 mg (3ml) intramuscular Diclofenac in a 5ml syringe in the holding area 30 minutes before spinal block
16275239|NCT04849468|Active Comparator|Saline (S) group|Saline (S) group which will receive 3ml intramuscular saline in a similar 5ml syringe in the holding area 30 minutes before spinal block
16275240|NCT04849455|Experimental|Active Treatment|This group will receive a continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 120 minutes with 2ml/hr continuous infusion (14mls total every 2 hours per catheter)
16275241|NCT04849455|Placebo Comparator|Placebo|This group will receive a superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
16275242|NCT04849429|Placebo Comparator|Placebo|Placebo (trigger point injection under C-arm)
16275243|NCT04849429|Experimental|Platelet rich plasma (PRP) with exosomes|PRP with exosomes at the center of the nucleus pulposus (2ml)
16275244|NCT04849416|Experimental|LOXO-305|LOXO-305 administered orally.
16275245|NCT04849403|Other|The group USG was applied|USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.
16275251|NCT04849377|Experimental|Group IV - TPF Induction followed by 60 Gy and Carboplatin AUC 1.5|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T4, N2c, >3 nodes, ENE, or Matted Nodes Induction Therapy: Cisplatin, Docetaxel, Fluorouracil followed by RT 60 GY + Carboplatin AUC 9.0 Docetaxel every 21 days for 3 cycles, Cisplatin every 21 days for 3 cycles, Fluorouracil continuous infusion over 4 days (every 21 days for 3 cycles). Followed by RT 5 days per week for 6 weeks and Carboplatin weekly for 6 weeks.
16275252|NCT04849364|Experimental|Arm 1|"Arm 1a: Patients who are ctDNA-positive and harbor a genomic target. DNA repair pathway = talazoparib + capecitabine
~Arm 1b: Patients who are ctDNA-positive and harbor a genomic target. Immunotherapy pathway = atezolizumab + capecitabine
~Arm 1c: Patients who are ctDNA-positive and harbor a genomic target. PI3K Pathway = inavolisib + capecitabine
~Arm 1d: Patients who are ctDNA-positive and harbor a genomic target. DNA Repair + Immunotherapy = talazoparib + atezolizumab + capecitabine"
16275253|NCT04849364|Active Comparator|Arm 2|Arm 2 subjects have plasma ctDNA positive but do not have a genomically driven treatment option. Treatment of physician's choice will be given with strong consideration for capecitabine. Dose, schedule and duration of treatment to be determined by treating physician.
16275254|NCT04849364|Active Comparator|Arm 3|Arm 3 subjects have plasma ctDNA negative. Treatment of patient and physician's choice will be given with strong consideration for capecitabine. Dose, schedule and duration of treatment to be determined by treating physician.
16275255|NCT04849351|Experimental|Relapsed/Refractory MZL and FL|Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
16275256|NCT04849325|Experimental|IBS Titan|
16275257|NCT04849325|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|
16275258|NCT04849312||Training|A subset of patients that are used to train the machine learning algorithm.
16275259|NCT04849312||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
16275260|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (simultaneous)|n=12
16275261|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (staggered)|n=12
16275262|NCT04849286|Experimental|Group 1|10 mg dose, CSF sample 2 hours post-dose
16275263|NCT04849286|Experimental|Group 2|10 mg dose, CSF sample 6 hours post-dose
16275264|NCT04849286|Experimental|Group 3|20 mg dose, CSF sample 2 hours post-dose
16275265|NCT04849286|Experimental|Group 4|20 mg dose, CSF sample 6 hours post-dose
16275266|NCT04849273|Experimental|TPX-0131|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.
~The Phase 2 part of the study will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts."
16275267|NCT04849260|Experimental|Pexa-Vec combined with ZKAB001|"The combined treatment group is divided into two dose groups. The principle of 3+3 is adopted to determine RP2D, and RP2D will be used in subsequent patients in this cohort."
16275268|NCT04849260|Active Comparator|ZKAB001 monotherapy|ZKAB001 monotherapy.
16275269|NCT04849247|Experimental|177Lu-DOTA-FAPI dose escalation therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. Patients with sufficient lesion uptake of 68Ga DOTA-FAPI PET/CT will be offered therapy. Escalating doses of 30-150 mCi of 177Lu-DOTA-FAPI will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
16275270|NCT04849247|Experimental|Recommended Phase 2 dose 177Lu-DOTA-FAPI therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. 10 patients will be enrolled in the dose expansion cohort and received the highest dose achieved in the 177Lu-DOTA-FAPI dose escalation therapy study
16275271|NCT04849234||New born|New born population aged 37 Weeks of Amenorrhea (SA) to 42 Weeks of Amenorrhea (SA) will be included. Their cries will be longitudinally registered.
16275272|NCT04849221||Patients|Head trauma, patient operated on for an intracranial lesion, or other condition (hemorrhagic stroke)
16275273|NCT04849221||healthy subjects|No otologic or neurological history
16275274|NCT04849195||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
16275275|NCT04849182|Active Comparator|Vertistop D|Patients with deficiency (<20 ng/mL, <50 nmol/L) or insufficiency (20-30 ng/mL, 50-75 nmol/L) of Vitamin D
16275276|NCT04849182|Active Comparator|Vertistop L|Patients with normal vitamin D levels (>30 ng/mL, >75 nmol/L)
16275277|NCT04849182|No Intervention|Control group|Patients meeting the inclusion criteria with normal levels of vitamin D (>30 ng/mL, >75 nmol/L)
16275278|NCT04849169|Experimental|Experimental Arm|Adult subjects who experience a perforation of a coronary vessel during percutaneous coronary intervention (PCI) and require management of hemorrhage until a definitive treatment is determined.
16275279|NCT04849143|Experimental|Honey dressing group|A thin layer of honey will be applied to the wounds
16275280|NCT04849143|Active Comparator|Gel dressing group|A thin layer of gel will be applied to the wounds
16275281|NCT04849130|Active Comparator|Static reconstruction technique according to Schöttle|Static reconstruction technique according to Schöttle
16275282|NCT04849130|Active Comparator|Dynamic reconstruction technique according to Becher|Dynamic reconstruction technique according to Becher
16275283|NCT04849117||Systemic analgesia|Patients received only systemic analgesia : Acetaminophen, Ketoprofen, and Nefopam were administered systematically. Morphine was administered if necessary, according to our institutional pain management protocol.
16275284|NCT04849117||Bilateral TTMP block + systemic analgesia|Patients received the same protocol of systemic analgesia associated with a bilateral TTMP block performed during the first four hours after ICU admission, before tracheal tube removal.
16275285|NCT04849104||COPD high-risk patients|age <60 years old, long-term smoker (≥10 pack years), CT without macroscopic airway abnormalities and/or mild or moderate emphysema, air retention or bronchial thickening, normal lung function
16275286|NCT04849104||Early-stage COPD patients|"those who are younger than 60 years old, long-term smokers (≥10 pack years) and have any of the following abnormalities:
~Forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) <lower limit of normal value (LLN, 80%);
~CT abnormalities: abnormal airway and/or emphysema, air retention or bronchial wall thickening;
~FEV1 drops rapidly (≥60 mL/year);"
16275322|NCT04848857|Experimental|Treatment Group|colchicine (0.5mg), one pill a day, oral intake
16275288|NCT04849091||iReadMore users|"Participants will be iReadMore users who completed a baseline reading test between XX/XX/XXXX and XX/XX/XXXX, and who performed at least 5 hours of reading training and a second (interval) reading test.
~iReadMore users will self-register to participate in the study."
16275289|NCT04849065|Experimental|MNC (Mononuclear cells)|"MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles).
~This group would consist of 74 patients."
16275290|NCT04849065|Placebo Comparator|Saline|(patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.
16275291|NCT04849052|Experimental|MASTERY Intervention|Participants will complete a positive psychology activity, work towards a physical activity goal, and use a stress reduction technique, then will complete weekly text message sessions. In the first six weeks, participants will review the activities they performed the prior week, be introduced to new material, choose activities to perform that week, and set a new physical activity goal during the text message sessions. In the final 6 weeks, participants will review progress towards prior goals, set new physical activity goals, and choose positive psychology and stress reduction skills to use that week. Finally, over the course of the program participants will complete three brief calls with a study trainer to discuss progress.
16275292|NCT04849052|Active Comparator|Attentional control|Participants will receive the same physical activity component noted in MASTERY along with added messages providing education and guidance about physical activity, from our past work. Control participants will not receive PP or midlife-related content.
16275293|NCT04849039||Mechanicaly ventilated adult patients for non-pulmonary conditions|
16275294|NCT04849026|Experimental|Group A|"Period 1: WID-CLZ18
~Period 2: Clozaril 100 mg (Clozapine)"
16275295|NCT04849026|Experimental|Group B|"Period 1: Clozaril 100 mg (Clozapine)
~Period 2: WID-CLZ18"
16275296|NCT04849013|Placebo Comparator|Placebo + Placebo|
16275297|NCT04849013|Active Comparator|Mescaline-100 + Placebo|
16275298|NCT04849013|Active Comparator|Mescaline-200 + Placebo|
16275299|NCT04849013|Active Comparator|Mescaline-400 + Placebo|
16275300|NCT04849013|Active Comparator|Mescaline-800 + Placebo|
16275301|NCT04849013|Active Comparator|Mescaline-800 + Ketanserin|
16275302|NCT04849000|Experimental|SHR-1209|
16275303|NCT04849000|Placebo Comparator|SHR-1209 Placebo|
16275304|NCT04848987|Active Comparator|Etch-and-rinse (Variolink N) resin cement|For etch-and-rinse resin cement, 40 inlays were cemented by Variolink N resin cement.
16275305|NCT04848987|Placebo Comparator|Self-etch (Panavia F2.0) resin cement|Regarding self-etch resin cement, 40 inlays were cemented by Panavia F2.0 resin cement.
16275306|NCT04848987|No Intervention|Self-adhesive (RelyX Unicem) resin cement|For self-adhesive resin cement, 40 inlays were cemented by RelyX Unicem resin cement.
16275307|NCT04848974|Experimental|Treatment (uproleselan, cladribine, cytarabine)|"INDUCTION THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q 12 hours on days 2-12, cladribine IV over 1-2 hours on days 1-5 and cytarabine SC BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR or CRi after cycle 1 may receive a second induction cycle.
~CONSOLIDATION/MAINTENANCE THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q12 hours on days 2-1. Patients who have achieved at least CR/CRi or morphologic leukemia-free state after induction therapy receive uproleselan IV QD on days 1-12. Patients also receive cladribine IV over 1-2 hours on days 1-3 and cytarabine SC BID on days 1-10. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16275308|NCT04848961|Experimental|Women who have had a mammogram|Participants will consist of eligible women who have had a mammogram
16275309|NCT04848948|Experimental|F.X.Mayr & Biofeedback|two weeks of F.X. Mayr diet and biofeedback
16275310|NCT04848948|Active Comparator|F.X.Mayr|two weeks of F.X. Mayr diet
16275311|NCT04848948|Experimental|VLCD & Biofeedback|two weeks of very low calorie diet and biofeedback
16275312|NCT04848948|Active Comparator|VLCD|two weeks of very low calorie diet
16275313|NCT04848935|Experimental|CURATE.AI|A cognitive evaluation and a Digital Diagnostic (DD) session performed anytime before radiotherapy will serve as the baseline. After the radiotherapy treatment, which can last between 1 to 6.5 weeks, patients will have a variable recovery time (0 to 4 weeks). Subsequently, patients will be subject to a cognitive evaluation and a DD session, right before starting the Digital Intervention (DI) training. This training will comprise ten weeks of DI (three 10-15 minute sessions per week). Patients will complete cognitive evaluations and DD sessions at the end of DI, and 16 and 32 weeks after the end of DI.
16275314|NCT04848922|Experimental|Intervention Group|Took a hot shower intervention and usual care.
16275315|NCT04848922|No Intervention|Control Group|No intervention other than usual care.
16275316|NCT04848909|Experimental|Men with prostate cancer post-prostatectomy|Men with localized prostate cancer who are considered candidates for post-prostatectomy radiation.
16275317|NCT04848896|Experimental|CORI|Subjects in need for total knee arthroplasty (TKA) as decided by their doctor and treated with CORI Robotics System.
16275318|NCT04848896|Active Comparator|Conventional Procedure|Subjects in need for total knee arthroplasty (TKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.
16275321|NCT04848870||Sjögren patients|Patients in specialized consultations for Sjögren's patients in the oral medicine department of the Charles Foix Hospital AP-HP France
16275324|NCT04848844||Patient transplanted due to ACHD and heart failure|Patients successfully transplanted due to congenital heart failure.
16275325|NCT04848844||ACHD listed due to heart failure for heart or heart and combined organ transplantation|Patients on the actual waiting list for heart or heart and combined organ transplantation. They can have either outcome transplantation or the primary outcome death on the waiting list or delisting due to clinical worsening. The secondary outcome is as well delisting due to clinical improvement.
16275326|NCT04848844||ACHD evaluated for heart transplantation|All patients evaluated for heart or heart and combined organ transplantation at the hospital level
16275327|NCT04848818|Active Comparator|K-wire group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
16275328|NCT04848818|Active Comparator|Activa-IM Nail group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
16275329|NCT04848805||liver recipients with hepatocellular and cohlangiocarcinoma diagnosis|liver recipients
16275330|NCT04848792|Experimental|SFN supplement|The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
16275331|NCT04848792|Placebo Comparator|Placebo|Placebo capsules provided by Cell-Logic.
16275332|NCT04848779||Cohort 1|
16275333|NCT04848766||De-escalation treatment group|Patients diagnosed as acute coronary syndrome, and who receive de-escalation antiplatelet therapy after percutaneous coronary intervention
16275334|NCT04848766||Conventional treatment group|Patients diagnosed as acute coronary syndrome, and who receive conventional (non-de-escalation) antiplatelet therapy after percutaneous coronary intervention
16275335|NCT04848753|Active Comparator|Experimental Group|Toripalimab combined with cisplatin and paclitaxel
16275336|NCT04848753|Placebo Comparator|Control Group|Placebo combined with cisplatin and paclitaxel
16275337|NCT04848740|Other|FRESH CORNEAL LENTICULE IMPLANTATION|"The aim in our study is to describe the importance of stroma as criteria of corneal thickness at implanting human fresh corneal lenticule in progressive corneal disease.
~We have conclude that every biomechanical instability of corneal stroma function(abnormal increase collagen activity,decrease proteinase inhibitors,excessive premature keratocyte apoptosis) describe the role of stroma in corneal thickness."
16275338|NCT04848727||Atelectasis or Pneumothorax|Infants with asymmetric lung disease (i.e. atelectasis or pneumothorax) confirmed by chest radiograph
16275339|NCT04848714|Experimental|Group A: ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab´)2]|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab´)2] lyophilized powder for solution 10 mL
16275340|NCT04848701|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
16275341|NCT04848688|Experimental|Moxidectin|8 mg Moxidectin at day 0 administered orally
16275342|NCT04848688|Experimental|Ivermectin|200 ug/kg Ivermectin at day 0 administered orally
16275343|NCT04848675|Experimental|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
16275344|NCT04848675|Active Comparator|Brisk walking|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
16275345|NCT04848662|Experimental|BDA MDI (PT027) 160/180 μg|
16275346|NCT04848662|Active Comparator|Pulmicort Respules 1 mg|
16275347|NCT04848649|Experimental|Arm 1|
16275348|NCT04848636||Healthy Controls|"Age greater than or equal to 18 years
~lack of kidney disease, cardiovascular disease, diabetes, liver cirrhosis and peripheral edema"
16275349|NCT04848636||Chronic Kidney Disease Patients|"Age greater than or equal to 18 years
~evidence of kidney disease persisting > 3 months and no indications to start dialysis"
16275350|NCT04848636||Hemodialysis Patients|"Age greater than or equal to 18 years
~more than 3 months duration of therapy"
16275351|NCT04848597|Experimental|Single Arm|Recombinant humanized anti-PD-1 monoclonal antibody injection:200mg once every 3 weeks
16275352|NCT04848584||Fully vaccinated|2 doses of BNT162b2 received with ≥7 days between receipt of the 2nd dose and the index date. This group will serve as the 'exposed' group evaluated in the primary objective.
16275353|NCT04848584||Partially vaccinated|1 dose (only) of BNT162b2 received with ≥14 days between receipt of the 1st dose and the index date.
16275354|NCT04848584||Ever vaccinated|≥1 dose of BNT162b2 received with ≥14 days between index date and receipt of the 1st dose
16275355|NCT04848584||Never vaccinated|never received BNT162b2. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all VE analyses
16275356|NCT04848571|Placebo Comparator|control group|Pregnant women who received IVF and not taken Chinesene fetal protection medicine until sampling
16275357|NCT04848571|Experimental|medicine group|Pregnant women who received IVF and have taken Chinesene fetal protection medicine from the fourth week during early pregnancy
16275360|NCT04848545||Live-born sons (with and without testicular cancer diagnosis) from a Danish pregnancy Cohort|"Pregnancy cohort: Biological samples from 128,702 of pregnant women were stored for research purposes in the Danish National Biobank, in the period from 1976-2004.
~Present study: live-born sons (with/without testicular cancer ascertained via data linkage in the Danish Cancer Registry)"
16275361|NCT04848532|Experimental|Adolescent-specific behavioral weight loss treatment|
16275565|NCT04847115|Active Comparator|Operative|The patients in this arm will be treated operatively with intramedullar screw osteosynthesis. In addition to this, they will weight bear as tolareted in a walking boot orthosis for six weeks.
16275362|NCT04848519|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for propranolol hydrochloride and every 3 or 6 weeks for pembrolizumab for up to 2 years in the absence of disease progression or unacceptable toxicity.
16275363|NCT04848506|Experimental|CK-3773274 up to 15 mg|Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.
16275364|NCT04848493||HEMATOLOGICAL MALIGNANCIES|"1a. Newly diagnosed patients with ANY haematological malignancy requiring treatment (No.=100).
~1b. Patients with ongoing treatments or with treatments completed within 6 months (chemotherapy and target therapies) other than antibodies. More specifically: patients with ongoing or completed chemotherapy (No.=50) or patients with ongoing or completed Ibrutinib (No.=50) or patients with ongoing or completed ruxolitinib (No.=50)
~1c. Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy OR patients receiving CAR-T cells: patients treated anti-B-cell (No.=50) or patients treated anti-CD30 (No.=50) or patients treated anti-PD1 (No.=50).
~1d. Patients at three months after autologous or allogeneic transplantation without active immune suppressive therapy: after autologous transplantation (No.=50) or after allogenic transplantation (No.=50)."
16275365|NCT04848493||SOLID TUMORS|"2a. Chemotherapy in adjuvant therapy. All patients with a diagnosis of solid tumors apart resected basal-cell or squamous-cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, and carcinoma in situ of the Breast. Under curative surgery (stage II-III) for the solid tumor or hemotherapy alone or in combination with target therapies or radiotherapy (No.=100).
~2b. Chemotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing chemotherapy alone or in combination with immunotherapy or target therapy (No.=100).
~2c. Immunotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing immunotherapy alone (No.=100).
~2d. Target therapies in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), Undergoing target therapy alone (No.=100)"
16275366|NCT04848493||IMMUNORHEUMATOLOGICAL DISEASES|3a. Patients with ANCA-associated vasculitis classified according to Chapel Hill Consensus Conference nomenclature, treated with immunodepressants agents with/without glucocorticoids (No.=50) or treated with RTX with/without glucocorticoids (No.=50) 3b. Interstitial Lung Disease in Autoimmune Conditions. Patients with a diagnosis of a specific CTD, myositis or rheumatoid arthritis based on validated classification criteria, and clinically significant ILD defined as disease treated with traditional immunodepressants or rituximab and fibrotic and/or inflammatory changes on chest CT not attributable to infection, and no evidence of obstructive lung disease. Patients treated with traditional immunodepressive agents with/without glucocorticoidspatients (No.=50) or patients treated with rituximab with/without glucocorticoids (No.=50)
16275367|NCT04848493||NEUROLOGICAL DISEASES|"4a. Patients with a diagnosis of multiple sclerosis, age < 60 years with relapsing-remitting MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50) or with secondary/primary progressive MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50).
~4b. Generalized Myasthenia Gravis, on immunosuppressive polytherapies or on B-cell targeted biological treatments, with lymphocytes count < 1 cell/microliter, or with thymoma (No.=100)"
16275368|NCT04848480|Experimental|Insulin icodec + insulin aspart|insulin icodec once a week in combination with 2-4 times daily injections of insulin aspart at meal times
16275369|NCT04848480|Active Comparator|Insulin degludec + insulin aspart|insulin degludec once a day in combination with 2-4 times daily injections of insulin aspart at meal times
16275370|NCT04848467|Experimental|Group 1: Co-ad group|Participants will receive CVnCoV at the same visit as QIV: first dose of CVnCoV and a dose of QIV in opposite arms at Day 1, the second dose of CVnCoV at Day 29, and a placebo injection at Day 57.
16275371|NCT04848467|Experimental|Group 2: Control group|Participants will receive QIV and CVnCoV at two different visits: one dose of placebo and one dose of QIV in opposite arms at Day 1, the first dose of CVnCoV at Day 29 and the second dose of CVnCoV at Day 57.
16275373|NCT04848428|Experimental|Online Mindfulness-based intervention|Four weekly sessions are planned. The first session will focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
16275374|NCT04848428|Active Comparator|Online standardized education|In addition to usual care, the CG will have access to one 15-minute standardized educational online session on persistent post-surgical pain, how pain and stress may interact and their potential impact on recovery.
16275375|NCT04848402|Experimental|On-Body Delivery System (OBDS)/Multiple Bolus Injector|On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
16275376|NCT04848402|Experimental|Single Auto Injector|Single auto injector used to administer placebo SC.
16275377|NCT04848389|Experimental|Skin adhesive|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
16275378|NCT04848389|Other|Standard suture|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed with the same thread with a subcutaneous stitch.
16275379|NCT04848376||Spine surgery|"Use these system:
~(1) SmartLoc (2) SmartLoc Evo(3) Winloc (4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L"
16275380|NCT04848363|Experimental|Study group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
16307656|NCT04623229|Experimental|ReLACS Standard|
16275381|NCT04848363|Placebo Comparator|Control group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.
16275382|NCT04848350|Placebo Comparator|placebo group|Only a saline solution was applied to the placebo group
16275383|NCT04848350|Active Comparator|lavender group|The lavender essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
16275384|NCT04848350|Active Comparator|frankincense group|The frankincense essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
16275386|NCT04848324|Active Comparator|Intervention group|14 patients (14 hands) who received US-guided corticosteroid hydrodissection
16275387|NCT04848324|Active Comparator|Control group|14 patients (14 hands) who received US-guided corticosteroid injection
16275388|NCT04848311|Experimental|ICG group|Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
16275389|NCT04848311|No Intervention|CLgroup|Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.
16275390|NCT04848298|Experimental|Mobile Health Arm|
16275391|NCT04848298|No Intervention|Control Arm|The Control Arm will receive standard of care including tailored prescription of physical activity
16275392|NCT04848285|Active Comparator|Standard care group|Standard of care (SC) mobility protocol performed by the Stroke Unit nursing and physiotherapy staff. The SC consists of one or two sessions per days of out-of-bed sitting and standing, adapted to patient´s tolerability, and one session of physiotherapy per day. Mobilization will be schedule to start from 24 hours from symptoms onset according to the local Stroke Unit protocol.
16275393|NCT04848285|Experimental|Intensive mobilization group|The Intensive mobilization intervention will include the standard care plus at least two additional sessions each day of at least 20 minutes each session focused on task specific sitting, standing and walking activities. The intervention will be schedule to start at 24 hours from symptoms onset and will last 14 days or until the patient is discharged.
16275394|NCT04848272|Placebo Comparator|Saline control|Saline control
16275395|NCT04848272|Experimental|Lanadelumab 30 mg|Lanadelumab 30 mg
16275396|NCT04848272|Experimental|Lanadelumab 100 mg|Lanadelumab 100 mg
16275397|NCT04848272|Experimental|Lanadelumab 300 mg|Lanadelumab 300 mg
16275398|NCT04848259|Placebo Comparator|Control|No drug given before surgery
16275399|NCT04848259|Active Comparator|Dexamethason|Dexamethason will be given IV before surgery
16275400|NCT04848259|Active Comparator|Natural honey|Honey will be placed locally after impaction removal
16275401|NCT04848259|Active Comparator|Dexamethason and natural honey|Dexamethason will be given IV before surgery and Honey will be placed locally after impaction removal
16275402|NCT04848246|Experimental|Bupropion|
16275403|NCT04848246|Experimental|Behavioural Change Communication|
16275404|NCT04848246|No Intervention|Control|
16275405|NCT04848233|Other|Drink intervention|Placebo and two drinks containing a blend of five amino acids and chromium picolinate, are included with every main meal and served in a standardized, non-randomised order.
16275406|NCT04848220|Experimental|Stage A (Dose Cohort 1) and Stage B (Dose Group 1)|
16275407|NCT04848220|Experimental|Stage A (Dose Cohort 2) and Stage B (Dose Group 2)|
16275408|NCT04848220|Placebo Comparator|Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)|
16275409|NCT04848207|Other|Digital impression technique|- 3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
16275410|NCT04848207|Other|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .
~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
16275411|NCT04848194|Other|All patients|All patients with psoriasis recruted by dermatological departement.
16275412|NCT04848181|Active Comparator|cyproterone acetate|20 patients received cyproterone acetate 50 mg twice per day for two weeks before TURP
16275413|NCT04848181|Active Comparator|finasteride group|20 patients received finasteride 5 mg once per day for two weeks before TURP
16275414|NCT04848181|Placebo Comparator|control group|20 patients received no treatment before TURP
16275415|NCT04848155|Active Comparator|Older adults with MCI|
16275416|NCT04848155|Active Comparator|Caregivers|
16275417|NCT04848142||Primary Group (parent-child)|parents (i.e., guardians/caregivers) and children age ≥ 8 years,will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment. Optional qualitative interviews may be completed individually for participants (age ≥ 12 years with P/LP variant and aware of results, or their parent)
16275418|NCT04848142||Parent Only Group|parents of children age < 8 years, will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment.
16275419|NCT04848116|Experimental|Cohort 1|Nivolumab + HuMax (BMS-986253) will be administered as an IV infusion.
16275420|NCT04848116|Experimental|Cohort 2|Nivolumab + Cabiralizumab will be administered as an IV infusion.
16275421|NCT04848116|Experimental|Cohort 3|Nivolumab + another agent (which will be determined depending on results from Cohort 1 and Cohort 2) will be administered as an IV infusion.
16275422|NCT04848103|Experimental|Radial extracorporeal shockwave therapy|
16275423|NCT04848090|Other|Neonate WGS Testing|Neonate subjects who are eligible and whose parents consent to study will undergo blood sampling which will be sent for whole genome sequencing and bioinformatics analysis, filtering first a targeted panel of 1722 genes most likely to cause genetic disorders in the first year of life, and then with a whole exome filter if no obvious diagnosis is determined using the 1722 gene panel filter.
16275424|NCT04848077|Experimental|Very high dose|Very large proportional increase in stepcount relative to baseline stepcount.
16275425|NCT04848077|Experimental|High dose|Large proportional increase in stepcount relative to baseline stepcount.
16275426|NCT04848077|Experimental|Intermediate dose|Medium proportional increase in stepcount relative to baseline stepcount.
16275427|NCT04848077|Active Comparator|Active controls|Small proportional increase in stepcount relative to baseline stepcount.
16275428|NCT04848064|Experimental|Treatment (mogamulizumab, chemotherapy, NK cells)|Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
16275429|NCT04848051|Experimental|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
16275430|NCT04848051|Experimental|CRC Reminder & Short message|Participants randomized to the CRC Reminder & short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
16275431|NCT04848051|Experimental|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
16275432|NCT04848051|Experimental|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
16275437|NCT04848025|Experimental|3D customized airway stents|
16275438|NCT04848012|No Intervention|Usual non-invasive ventilation|The usual therapy the participant is receiving via non-invasive ventilator.
16275439|NCT04848012|Experimental|Auto-titrating non-invasive ventilation|A novel auto-titrating non-invasive ventilator
16275440|NCT04847999|Experimental|Conventional Dark Chocolate|A standard dark chocolate bar.
16275441|NCT04847999|Experimental|Ross Dark Chocolate|A dark chocolate bar sweetened with stevia, erythritol, and inulin.
16275442|NCT04847986|Experimental|acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
16275443|NCT04847986|Sham Comparator|Control group|care as usual with psychoeducation materials provided
16275444|NCT04847973|Experimental|12 weeks of medically-tailored meals (MTMs)|12 weeks of home-delivered medically-tailored meals (MTMs), prepared and delivered by the non-profit Community Servings. The MTM has be developed specifically for patients with heart failure, with an approximate protein intake range of 1.1-1.5 g/kg body weight/day and a maximum of 2000 mg sodium/day.
16275445|NCT04847960|Experimental|L.reuterii probiotic lozenges from BioGaia|Subjects were willing to provide 2 samples of saliva, dental plaque and gingival fluid (gum fluid), on the first day (before consuming lozenges) and on the 14th day after the subject consumed lozenges containing L. reuteri probiotic. Probiotics are taken once a day for two weeks after breakfast and brushing their teeth.
16275446|NCT04847947|Experimental|Interventional group|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks.
16275447|NCT04847947|Placebo Comparator|Control Group|Oral capsule Placebo once daily and Calcium Lactate 500 mg once daily for 12 weeks.
16275448|NCT04847934|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the intramuscular injection
16275449|NCT04847934|Experimental|Manual Pressure Vibration Technique Group|Application of manual pressure vibration technique to the area where the intervention will be made
16275450|NCT04847934|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be injected
16275451|NCT04847934|No Intervention|Control Group|Standart care
16275452|NCT04847921|Experimental|people who use drugs with severe Gram-positive infections|As per inclusion and exclusion criteria
16275454|NCT04847895||Lucentis|Patients administered Lucentis by prescription
16275455|NCT04847882||Cystic fibrosis, children from 6 to 17.|This group is made up of children with cystic fibrosis followed at the Strasbourg pediatrics CRCM, aged from 6 to 17 years old, not hospitalized at the time of inclusion, without any other criterion prejudging the seriousness of the pathology.
16275456|NCT04847882||Control group, children from 6 to 17.|"This group is the control group. It is made up of children consulting in pediatric surgical emergencies, aged 6 to 17 years. Surgical emergencies were chosen because it is a point of consultation, rather accidental, where sleep has often not been impacted in the previous months and where the frequency of chronic pathology is not higher than the general population.
~An other criteria is that these children are accompanied by at least one of their parents and that they can read and understand French well."
16275457|NCT04847869|Experimental|NIR laser treatment 200mW/cm2 dose|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.
~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
16275458|NCT04847856|Experimental|List of health centers that randomly allocated to receive the intervention|The intervention was structured Diabetes self-care information, education, and communication (IEC) delivered to the participants at the selected primary health care center level. The Information, education, and communication intervention were delivered by relevant and trained health animators working in chronic care clinics. The intervention was composed of sessions and the participants were planned to attend five structured sessions on diabetes self-care at months: 1, 2, 3,4,5&6. Besides, the participants were provided with a single-page checklist with a to-do list of activities and simple advice that covering the various aspects of diabetes self-care.
16275459|NCT04847856|No Intervention|List of health centers that randomly allocated to receive routine care|The comparators were type II diabetic patients of both genders attending the selected primary health care centres that receiving routinely provided diabetic care including advice from the health care providers. Participants were interviewed at the start of the trial to collect the baseline data about self-care with measurements of blood glucose level, serum cholesterol level, blood pressure, BMI, and waist circumference. At the end of the trial, the sam participants were interviewed to collect end-line data and similar measurements.
16275460|NCT04847843|Experimental|Mindfulness Orientated Recovery Enhancement (MORE) Intervention|8-week MORE intervention adapted for preventing weight regain
16275461|NCT04847843|Active Comparator|Control Intervention|8-week control intervention based on the Diabetes Prevention Program's Prevent T2 for Life program.
16275462|NCT04847830|Experimental|Laser|One side of the mouth will undergo root surface debridement using hand instruments and ultrasonic scaler, with the addition of the Er:YAG laser
16275463|NCT04847830|Placebo Comparator|Control|The other side of the mouth undergo root surface debridement using hand instruments and ultrasonic scaler alone
16275464|NCT04847817||Index cases|Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .
16275465|NCT04847817||Households cases|Household contacts of SARS-Cov2 hospitalized COVID-19 patients.
16275466|NCT04847804||Positive case|The sample will be tested by microfluidic device and shows positive
16275467|NCT04847804||Negative control|The sample will be tested by microfluidic device and shows negative
16275468|NCT04847791|Experimental|Group A|Standard Anti-Covid-19 Therapy + Oral Administration of Bovine Lactoferrin 400mg (two capsules of Mosiac 200 product) every 12 h (i.e., fixed dose 800 mg / day) for 30 days and still away from meals
16275469|NCT04847791|Placebo Comparator|Group B|Standard anti-Covid-19 therapy + Placebo administration (capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
16275470|NCT04847778|Active Comparator|Masked arm|"Participants will be instructed on the correct installation and use of the Insulclock device and app on masked mode for recording insulin bolus information.
~Participants do not receive any other information and will not have access to the Insulclock 360 application from the Internet.
~Participants will keep administering insulin treatment as usual."
16275471|NCT04847778|Active Comparator|Active arm|"Participants will receive detailed instructions on using the Insuclock 360 app and Insulclock device
~Participants will be instructed and motivated for full use of all system functions: alarms, messages to the caregivers and investigation team."
16275472|NCT04847765|Experimental|Combined pressure measurement and MRI|Gastric motility is evaluated simultaneously by means of the investigational medical device and by means of cine-MRI.
16275473|NCT04847739|Experimental|Standard of Care Treatment + AVB-114|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.
16275474|NCT04847739|Active Comparator|Standard of Care Treatment|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.
16275475|NCT04847726|Experimental|CEUS with perfluorobutane and sulfur hexafluoride|Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.
16275476|NCT04847713||Fabry's disease|children and adults male or female between 6 and 70 years old, patients with diagnosis of FD, treated and non-treated
16275477|NCT04847713||Healthy controls|age and sex-matched group of healthy subjects with a negative family history for lysosomal storage disorders and no clinical signs of FD.
16275478|NCT04847700|Active Comparator|Minimally invasive vestibular neurectomy|
16275479|NCT04847700|Active Comparator|Tenotomy of the stapedius and tensor tympani muscles|
16275480|NCT04847687||Group 1|Patients who are started on 1 mg/kg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
16275481|NCT04847687||Group 2|Patients who are started on 250 mg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
16275485|NCT04847661|Active Comparator|Mefloquine arm|"Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
~30kg≤BW<45kg: 825mg followed by 275mg after 6-8 hours
~45kg≤BW<60kg: 825mg followed by 550mg after 6-8 hours
~60kg≤BW: 825mg followed by 550mg after 6-8 hours and then 275mg 6-8 hours after the second dose"
16275486|NCT04847661|Placebo Comparator|Control arm|A similar tablet of non-active gradients was specifically manufactured for the study by EVA Pharma company. The placebo tablets exactly resemble the active treatment mefloquine tablets (the same shape, size and color).
16275596|NCT04846946|No Intervention|Control|Time attention control condition.
16308683|NCT04616287|Sham Comparator|healthy elderly subjects|
16275487|NCT04847648|Active Comparator|Control - Mechanical instrumentation of implant surface|The control group will be subjected to non-surgical and surgical mechanical decontamination including the use of hand instruments and polishing cups aiming at the removal of all supra-mucosal soft and hard deposits from the implant surfaces.
16275488|NCT04847648|Experimental|Test - Mechanical instrumentation and air-polishing of implant surface|In the test group the mechanical instrumentation will be supplemented by the use of an air-polishing device, both, during non-surgical and during surgical therapy.
16275489|NCT04847635|Experimental|Subthreshold laser group|To evaluate the efficacy of Subthreshold laser in the treatment of reticular pseudodrusen.
16275490|NCT04847635|Sham Comparator|Sham group|The light from the retinal illumination system on the laser device will be used instead of the laser beam in all follow-up evaluations.
16275491|NCT04847622||Target Population|Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.
16275492|NCT04847596||participants with RMS treated with ofatumumab|Relapsing MS participants receiving a full course (two doses) of a COVID-19 mRNA vaccine after starting ofatumumab 20 mg subcutaneous treatment
16275493|NCT04847583|Experimental|Telacebec (Q203) with COVID-19 standard of care (SoC)|
16275494|NCT04847583|Active Comparator|COVID-19 Standard of care (SoC)|
16275495|NCT04847570|Experimental|Music listening experience|It is a single-arm non-randomised study. The same inclusion and exclusion criteria applies to all the participants.
16275498|NCT04847544|Experimental|ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.|
16275499|NCT04847544|Placebo Comparator|Placebo administered orally BID for up to 28 days.|
16275500|NCT04847531||Stage 3 chronic kidney disease patients|Patients with two consecutive eGFR measurements indicating stage 3 CKD (≥30 and <60 mL/min/1.73m2) during the observation period
16275501|NCT04847518|Experimental|Kan Jang|70 patients take Kan Jang, two capsules three times a day for the two weeks in the treatment period. Daily dose - 90-120 mg of andrographolides.
16275502|NCT04847518|Placebo Comparator|Placebo|70 patients take Placebo, two capsules three times a day for the two weeks in the treatment period
16275503|NCT04847505|Experimental|Neuroendocrine cancer patients|"All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician.
~Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed."
16275504|NCT04847492|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy.
16275505|NCT04847492|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy.
16275506|NCT04847479|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to their close contacts.
16275507|NCT04847479|Active Comparator|Test referral distribution|Participants in the test referral arm receive text messages providing testing information to send to their close contacts.
16275510|NCT04847440|Experimental|ATI-2173 and Viread|ATI-2173 + Tenofovir disoproxil fumarate (Viread)
16275511|NCT04847440|Active Comparator|Placebo and Viread|ATI-2173 Placebo + Tenofovir disoproxil fumarate
16275512|NCT04847427|Experimental|Core exercises training|Participants will perform 4 core exercises
16275513|NCT04847427|Experimental|Structural exercises training|Participants will perform 4 structural (Olympic lifting) exercises
16275514|NCT04847427|Experimental|Accentuated eccentric exercises training|Participants will perform 4 exercises with eccentric loading
16275515|NCT04847427|Experimental|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
16275516|NCT04847414||prospective group|all needed data will be collected from patients in this group through performing full medical examination and doing all necessary investigations for them
16275517|NCT04847414||retrospective group|all needed data will be collected from medical records either electronic or paper based from different diabetes clinics in upper Egypt
16275518|NCT04847401||Group 1|patients with Irritable Bowel Syndrome
16275519|NCT04847401||Group 2|normal
16275520|NCT04847388||ART-naive HIV Patients with substance abuse and without substance abuse|Group A Group B
16275521|NCT04847388||Group A and B|Group A: ART-naive HIV seropositive with H/O substance abuse Group B: ART-naive HIV seropositive without H/O substance abuse
16275522|NCT04847375|Experimental|Nebulized Surfactant|The patients in this group will receive exogenous surfactant using nebulizer mask as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19; in addition they will receive standard care based on the national guidelines
16275523|NCT04847375|No Intervention|Standard Care|The patients in this group will receive standard care based on the national guidelines as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19
16275524|NCT04847362|Experimental|Experimental|The mothers in this group will be given telehealth training for 4 weeks.
16275525|NCT04847362|No Intervention|Control|Mothers in this group will not be given telehealth education, they will receive care within the scope of routine care.
16275526|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, standard dose|Combination of a standard dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
16275686|NCT04846335|Placebo Comparator|Placebo|subject without the mutation will be treated with plac
16275527|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, high dose|Combination of a high dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
16275528|NCT04847349|Placebo Comparator|Placebo for live microbial (probiotic) consortium|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics, taken once per day with breakfast for 21 days.
16275529|NCT04847336||Women|Women of any age who gave births in hospitals from WHO European Region, from 1 march 2020
16275530|NCT04847336||Health workers|Health workers directly involved in assistance at childbirth (pregnancy, childbirth and peripartum) at hospital level in WHO European Region, from 1 march 2020
16275531|NCT04847323|Active Comparator|V-bend Bonded Retainer|"The V-bend retainer is bonded in the lingual surface of the anterior teeth. The retainer is constructed using 0.024 stainless steel wires. Differently from the conventional bonded retainers, this retainer presents V-bends in the sagittal direction, parallel to the occlusal plane in each interproximal contact point of the incisors and canines.
~The retainers will be bonded after adequate etching with phosphoric acid and application of adhesive with a low viscosity resin."
16275532|NCT04847323|Active Comparator|Vacuum-formed Retainer|The removable Vacuum-formed retainers will be made of acetate 1mm thickness. They will be made at the same appointment of debonding using plaster models. The patients will be instructed to use the retainers only during nights.
16275533|NCT04847310|Experimental|Group 1|
16275534|NCT04847310|Experimental|Group 2|
16275535|NCT04847310|Active Comparator|Group 3|
16275536|NCT04847297||Preoperative biliary drainage and pancreatoduodenectomy|Patients receiving preoperative biliary drainage before the removal of the tumor.
16275537|NCT04847297||Pancreatoduodenectomy only|Patients undergoing only surgical intervention, without preoperative drainage.
16275538|NCT04847284|Experimental|Single arms|To determine the efficiency and safety of IORT with low-energy photons to the cavity after resection of brain metastases
16275539|NCT04847271|Experimental|Physical activity on prescription|Physical activity on prescription is a behaviour change intervention comprising 3 components: a person-centred pre-intervention dialogue, a written prescription for individually tailored physical activity, and a structured follow-up.
16275540|NCT04847245|Active Comparator|Pregabalin group|Pregabalin capsules were administered orally (75 mg, tid), combined administration of duloxetine.
16275541|NCT04847245|Experimental|0.125 mg/kg esketamine group|Intravenous administration of esketamine 0.125 mg/kg，and duloxetine is co- administered orally.
16275542|NCT04847245|Experimental|0.25 mg/kg esketamine group|Intravenous administration of esketamine 0.25mg/kg，and duloxetine is co- administered orally.
16275543|NCT04847245|Experimental|0.50 mg/kg esketamine group|Intravenous administration of esketamine 0.50 mg/kg，and duloxetine is co- administered orally.
16275546|NCT04847219|Placebo Comparator|Professional flash glucose mornitoring|Professional flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via capillary blood glucose tests, but nor FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
16275547|NCT04847219|Active Comparator|Personal flash glucose mornitoring|Personal flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
16275548|NCT04847206|Experimental|MDMA (100 mg MDMA-hydrochloride)|MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base)
16275549|NCT04847206|Experimental|MDA (93.9 mg MDA-hydrochloride)|MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base)
16275550|NCT04847206|Experimental|lysine-MDMA (171.7mg lysMDMA dihydrochloride|lysine-MDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base)
16275551|NCT04847206|Experimental|lysine-MDA (165.6 mg lysMDA dihydrochloride;|lysine-MDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base)
16275552|NCT04847206|Placebo Comparator|Placebo|Placebo
16275553|NCT04847193|Experimental|Placebo|Participants receive a study drink supplemented with a placebo over a time period of 5 days.
16275554|NCT04847193|Experimental|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.
16275555|NCT04847193|Experimental|Iso-alpha acids|Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.
16275556|NCT04847193|Experimental|Xanthohumol/Iso-alpha acids|Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.
16275557|NCT04847180|Experimental|Instability shoulder group|Patients operated for an antero-inferior shoulder instability
16275558|NCT04847180|Other|Non instability shoulder group|Patients without shoulder instability, operated for another reason.
16275559|NCT04847167|Experimental|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|All ERCP was performed with the patient in the prone position using a SBE (SIF-H290S; Olympus Corp., Japan) under CO2 insufflation and conscious sedation. A soft transparent hood (D-201-11804; Olympus Corp., Japan) was used in all cases. The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
16275560|NCT04847141|Experimental|C19-IG 20% 1 g|Participants will receive 1 gram (g) of C19-IG 20% subcutaneous (SC) infusion containing one syringe of 5 mL C19-IG 20% plus one syringe of 5 mL 0.9% sodium chloride on Day 1 in a double-blind manner.
16275561|NCT04847141|Experimental|C19-IG 20% 2 g|Participants will receive 2 g of C19-IG 20% SC infusion containing two syringes 5 mL each of C19-IG 20% on Day 1 in a double-blind manner.
16275562|NCT04847141|Placebo Comparator|Placebo|Participants will receive C19-IG 20% matching placebo as SC infusion containing two syringes of 5 mL each sterile 0.9% sodium chloride injection on Day 1 in a double-blind manner.
16275563|NCT04847128|Experimental|Arm I|Participants receive exercise intervention 3 times weekly for 8 weeks.
16275564|NCT04847128|No Intervention|Arm II|Participants keep sedentary life without exercise for 8 weeks.
16275566|NCT04847115|Active Comparator|Non-operative|The patients in this arm will have non-operative treatment with a walking boot orthosis for six weeks. They will weight bear as tolerated
16275567|NCT04847102|Experimental|Study group|
16275568|NCT04847102|Placebo Comparator|Control group|
16275569|NCT04847089|Experimental|Motor Imagery BCI training|Complete intervention with motor imagery BCI training. Patients recruited by physiotherapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
16275570|NCT04847076|Experimental|m-health version of WWWT intervention|Include: a) Psychoeducational information for understanding and managing infant behavior and on parenting. This information will be delivered through instant messaging service for mobile phones (i.e., Whatsapp) 3 times a week for four-week period. Each module will include a very brief video offering information regarding a specific topic, a proposed personal exercise and the invitation to assess the perceived usefulness of the information received. Some modules include links to external, complementary information from the Chilean Infancy Policy. b) Contact with the program facilitator. It will allow mothers to ask questions that arise from the topics addressed in the psychoeducational videos. The answers seek to promote the understanding and elaboration of the contents, and operate by providing expert support; c) A virtual group meeting.
16275571|NCT04847076|Other|TREATMENT AS USUAL|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age. The objective of the routine health care check is to carry out a comprehensive evaluation of the child's development and growth, guide parents and caregivers regarding child development, health and upbringing of the child. Also, promoting exclusive breastfeeding, healthy mother/child bonding (by detecting relevant alterations in this area) and encouraging paternal participation in upbringing and care of the child. Finally, in the health check-ups at 2 and 6 months of age of the child, Edinburgh Postpartum Depression Scale is used for screening depressive symptoms in mothers. At risk cases are referred for mental health assessment and care.
16275576|NCT04847050|Experimental|1|100 microgram (0.5 mL) mRNA-1273 injection on D1 and 29
16275577|NCT04847037|Experimental|Connected Tools|For the experimental group, the postoperative procedure requires the use of personal connected tools: a smartphone, a digital tablet or a computer with internet connection. A scale and a connected watch will also be loaned to patients so that they can take the necessary measures. Before returning home, patients must be trained to take correct measures and inform them on the dedicated platform.
16275578|NCT04847037|No Intervention|No Connected Tools|Patients randomized to the control group will be operated according to the same protocol as the experimental group. For them, there will be no home follow-up, so no special procedure to follow.
16275579|NCT04847024|Experimental|Parecoxib|Parecoxib 40 mg reconstituted in 2ml of saline solution, to pass IV as a bolus, every 12hrs + acetaminophen 1g in 100cc of saline solution to pass IV in 15 minutes, every 6hrs.
16275580|NCT04847024|Experimental|Dexketoprofen|Dexketoprofen 50 mg in 100 cc of saline solution, protected from sunlight, to be given IV in 15 minutes, every 8hrs + acetaminophen 1g in 100 cc of saline solution to be given IV in 15 minutes, every 6hrs.
16275581|NCT04847011|Experimental|RA - longitudinal arm|
16275582|NCT04847011|Experimental|PD - longitudinal arm|
16275583|NCT04847011|No Intervention|RA - crosssectional arm|
16275584|NCT04847011|No Intervention|PD - crossectional arm|
16275585|NCT04847011|No Intervention|Healthy controls - crosssectional arm|
16275586|NCT04846998|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.
~*sequence 1: A-B-C"
16275587|NCT04846998|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.
~*sequence 2: A-C-B"
16275588|NCT04846998|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.
~*sequence 3: B-A-C"
16275589|NCT04846998|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.
~*sequence 4: B-C-A"
16275590|NCT04846998|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.
~*sequence 5: C-A-B"
16275591|NCT04846998|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.
~*sequence 6: C-B-A"
16275592|NCT04846972||Control group|After inclusion, patients will receive standard care. Women allocated in this group will have the standard care.
16275593|NCT04846972||FASTRACS intervention group|Women allocated in the FASTRACS intervention group will follow a structured care pathway comprising three successive steps (end of chemotherapy interview with a nurse, transitional visit with their GP, pre-RTW visit with their OP), plus one optional step (late visit with an OP- RTW to work coordinator). Four tools will be used during the intervention (RTW guide or checklist for the patient, the GP, the OP and the employer).
16275594|NCT04846959||Pregnant Women Exposed to Risankizumab|Pregnant women of any age in the United States (US) who are diagnosed with plaque psoriasis and exposed to risankizumab at any time during pregnancy.
16275595|NCT04846959||Pregnant Women Not Exposed to Risankizumab|Pregnant women of any age in the US who are diagnosed with plaque psoriasis and not exposed to risankizumab, but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.
16275597|NCT04846946|Experimental|Intervention, Module 1 - Knowledge|20-minute module that aims to improve HIV prevention knowledge.
16275598|NCT04846946|Experimental|Intervention, Module 1 - Stigma|20-minute module that aims to reduce SGM- and HIV- related stigma.
16275599|NCT04846946|Experimental|Intervention, Module 1 - Prevention|20-minute module that aims to promote HIV prevention strategies including testing and PrEP.
16275600|NCT04846933||HGSOC patients treated with Neoadjuvant chemotherapy (NACT)|"Diagnostic laparoscopy followed with 3-4 cycles of platinum-taxane NACT and interval debulking surgery (IDS). Treatment response is monitored with FDG PET/CT. IDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines).
~Digital H&E slides and WGS, RNAseq are obtained from performed surgeries including relapse operations/ascites drainages. Patients are followed with longitudinal ctDNA sampling."
16275601|NCT04846933||HGSOC patients treated with primary debulking surgery (PDS)|PDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines). Digital H&E slides and WGS, RNAseq obtained from PDS and possible relapse operations/ascites drainages when performed. Patients are followed with longitudinal ctDNA sampling.
16275606|NCT04846907||Healthcare personnel working in pediatric intensive care units during COVID-19 pandemic|Physicians, registered nurses, nurse technicians, physical therapists and other professionals; on duty, routine staff or fellow/residents working in participants PICU
16275607|NCT04846894|Experimental|Biochemical Recurrence|Prostate cancer patient with biochemical recurrence
16275612|NCT04846855|Experimental|Ropivacaine 35%|Local Anesthesia with Ropivacaine
16275613|NCT04846842|Experimental|Gimatecan group|In Phase II study, patients will receive gimatecan at fixed dose level (0.8mg/m2/d, oral, every 4 weeks) until progressive disease (PD)、complete remission（CR）).
16275614|NCT04846829|Placebo Comparator|Placebo infusion|Placebo comparator to active study drug
16275615|NCT04846829|Active Comparator|intravenous citalopram hydrochloride (CIT)|A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
16275616|NCT04846829|Experimental|intermittent Theta Burst Stimulation|"10 sessions of treatment with cTBS to right DLPFC
~TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).
~iTBS paradigm of a 2 s train repeated every 10 seconds"
16275617|NCT04846829|Experimental|continuous Theta Burst Stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC
~TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).
~1800 pulses of cTBS will be delivered"
16275618|NCT04846816|Experimental|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
16275619|NCT04846803|Experimental|Patients prophylatic treated with ABU|Patients with prophylactic bladder flushing with an ABU strain.
16275620|NCT04846803|Placebo Comparator|Patients control group|The control group with bladder flushing with saline solution.
16275621|NCT04846790|No Intervention|Control|The control group will complete the first three assessments similar to the two treatment groups but will not participate in the nature-based or virtual mindfulness interventions. At the end of their study participation (~week 3), they will be offered the opportunity to partake in the nature-based and virtual mindfulness interventions.
16275622|NCT04846790|Active Comparator|Nature Only|The nature-based intervention is three days long, is offered at various locations throughout the United States, and includes activities such as hiking, mountain-biking, and kayaking. The healthcare workers can participate in the programs that are offered locally pending availability. Each program will enroll between 15 and 30 healthcare workers. All First Descents nature-based interventions have been intentionally designed with input from more than 450 hospital partners nationwide to improve psychosocial health, nurture supportive peer relationships, and better position healthcare workers to carry out their critical mission. There is no cost to attend, and meals and lodging are included. Special precautions against SARS-CoV-2 transmission are implemented.
16275623|NCT04846790|Experimental|Nature+Mindfulness|In the combined nature-based and virtual mindfulness intervention, participants will complete the nature intervention followed by the mindfulness intervention. The virtual mindfulness intervention is 10 days long and offered online. Each day the participant will receive a notification that a new mindfulness audio is ready for viewing, which is from 10 to 25 minutes long. Mindfulness exercises include mindful breathing, body scan, and loving-kindness meditation. Participants can view the daily audio as many times as they wish but cannot view the next day's content to maintain treatment fidelity. At the end of each day, participants will be asked to indicate if they viewed the mindfulness audio to track adherence.
16275624|NCT04846777|Experimental|Mindfulness ecological momentary intervention|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
16275687|NCT04846322|Other|ED delirium & dementia screening & outpatient referral|Routine ED screening for delirium and memory problems with referral for outpatient assessment of cognitive impairment.
16275688|NCT04846309|Experimental|Treatment: all patients|
16283404|NCT04792593|Experimental|Senl-h19 CAR-T|Patients will be treated with Senl-h19 CAR-T cells
16275625|NCT04846777|Placebo Comparator|Self-monitoring placebo|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
16275626|NCT04846764|Active Comparator|Healthy volunteers|"60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Visit 1
~Neuropsychological tests
~A cranial MRI
~Visit 2
~• Neuropsychological tests"
16275627|NCT04846764|Experimental|Patients with neurological diseases of the central nervous system|"36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Visit 1
~Neuropsychological tests
~A cranial MRI
~Visit 2
~• Neuropsychological tests"
16275628|NCT04846751|Active Comparator|AEROBIC EXERCISE|50 min of aerobic exercise by pedaling a cycleergometer at 60% of VO2max
16275629|NCT04846751|Placebo Comparator|PLACEBO REST|No exercise, resting during 50 min.
16275630|NCT04846738||brain damaged patients|"All major brain damaged patients (stroke or head trauma) admitted to reanimation will be included.
~In the usual practice, they have a Transcranial Doppler and the measurement of the photomotor reflex by quantitative Pupillometry.
~It is planned to collect the simultaneous values of the different parameters during 2,000 measurements.
~The data will be collected retrospectively from 01/12/2020, and prospectively from 01/04/2021."
16275631|NCT04846725||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) inserted between April 2012 and November 2019. Follow up data is collected up to July 2020.
16275632|NCT04846712||patients with a first ankle sprain|100 patients with a first ankle sprain will be included. Data will be collected of medical record.
16275633|NCT04846699||group 1|bulls eye localization
16275634|NCT04846699||group 2|stone targeted technique renal access
16275635|NCT04846699||group 3|triangulation renal access technique
16275636|NCT04846686||preeclampsia group|"25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized.
~Placenta pathological examination will be performed."
16275637|NCT04846686||control group|"10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized.
~Placenta pathological examination will be performed."
16275638|NCT04846673|Experimental|Pregabalin and alpha-lipoic acid combination therapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
16275639|NCT04846673|Experimental|Pregabalin monotherapy|Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
16275640|NCT04846673|Active Comparator|Alpha-lipoic acid monotherapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.
16275641|NCT04846660|Experimental|Production pressured environment|Participants in this group were exposed to 4 audio recordings applying standardized pressure. Unlimited time.
16275642|NCT04846660|No Intervention|Regular environment|The control group was asked to complete the same task also with unlimited time. They were not exposed to the audio recordings.
16275643|NCT04846647||Unexplained hypophosphatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
16275644|NCT04846634|Experimental|neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab|
16275645|NCT04846634|Experimental|neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
16275646|NCT04846634|Experimental|neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
16275647|NCT04846621|Other|group Nicorandil|women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
16275648|NCT04846621|Other|group Nifedipine|Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
16275649|NCT04846608||Nursing home residents with behavioural problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for disorientation, agitation, dementia or behavioural problems during the study period
16275650|NCT04846608||Nursing home residents with other problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for other reasons
16275651|NCT04846595|Other|Self questionnaire|The study will be offered to all patients who have been treated for HIV infection for at least 6 months, during a follow-up consultation. A self questionnaire will be administered only once per patient during the usual consultation, there is no follow-up planned.
16275652|NCT04846569|Experimental|Transition Theory-based Intervention|Participants in the intervention arm will receive the Transition Theory-based intervention consisting of 4 sessions with a community health worker (2 during pregnancy, 2 postpartum) to support their transition from pregnancy to postpartum.
16275653|NCT04846569|Active Comparator|Enhanced Standard of Care Control|Participants in the control arm will receive the standard of care plus one session with a community health worker.
16275654|NCT04846556||venous thromboembolic event related to cancer|Patients admitted for a venous thromboembolic event related to their cancer will be included A data collection will be realized. Patients admitted between 2017 and 2019 at Saint-Etienne University Hospital, Louis-Mourier Hospital (AP-HP) and Amiens University Hospital.
16275655|NCT04846543|Other|MRI scan 1st and 2nd year|Additionally to routinely follow up, there will be an MRI scan of enrolled patients after one and two years in some of the study sites
16275689|NCT04846296||study group|Between 10-20 years old Cobb angle >10 degrees or more Being treated with conservative or surgical treatment for spinal deformities Accepted to answer the questionnaire
16275727|NCT04846088|Experimental|Product usage order FGEHDICAB|Subjects will use each of the 9 products (FGEHDICAB) during a familiarization period, followed by a 3 hour Test Session
16275657|NCT04846517|Other|TMS Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.
~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
16275662|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 1|
16275663|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 2|
16275664|NCT04846491|Active Comparator|Nucleot(s)ide-treated patients-Control Group|
16275665|NCT04846491|Other|Treatment Naive Group|
16275666|NCT04846478|Experimental|Dose Escalation Talazoparib + Tazemetostat|"Standard 3+3 dose escalation will be followed, participants will initially receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications.
~During each 28 day study treatment cycle participants will take:
~Talazoparib once daily.
~Tazemetostat twice daily."
16275667|NCT04846478|Experimental|Dose Expansion Talazoparib + Tazemetostat|"Participants will receive talazoparib and tazemetostat at the safe dose identified in the first part (dose escalation) of the study.
~During each 28 day study treatment cycle participants will take:
~Talazoparib once daily.
~Tazemetostat twice daily."
16275668|NCT04846465||male|normal Sohag healthy male (≥18 & ≤ 60 years)
16275669|NCT04846465||female|normal Sohag healthy female (≥18 & ≤ 60 years)
16275670|NCT04846452|Experimental|NSCLC patients with negative driver genes|Patients with negative driver genes advanced or metastatic NSCLC will receive sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens as first-line treatment.
16275672|NCT04846426||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16275673|NCT04846426||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16275674|NCT04846426||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16275675|NCT04846426||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16275676|NCT04846413||Patients|Patients affected by neurologic disorders showing a prominent voice impairment.
16275677|NCT04846400|Experimental|ssNPA|self-supporting nasopharyngeal airway to be used nightly for approximately 8 weeks.
16275678|NCT04846387||Females with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.
~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A urinary pouch will be used to collect the participant's urine while in the scanner."
16275679|NCT04846387||Males with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.
~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A condom catheter will be used to collect the participant's urine while in the scanner."
16275680|NCT04846374||PowerPort Subjects|This study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
16275681|NCT04846361|Experimental|Hygiene wash plus metronidazole|Hygiene wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
16275682|NCT04846361|Placebo Comparator|placebo wash plus metronidazole|Placebo wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
16275683|NCT04846361|No Intervention|Healthy control|Asymptomatic healthy women with BV negative test
16275684|NCT04846348|Experimental|Skin Guard|"Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:
~Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor"
16275685|NCT04846335|Experimental|Active Bassado|patients with D178N/M129 mutation on prion protein will be treated with Bassad
16275690|NCT04846283||Biomarker-group|We considered for the study all patients aged >16 y undergoing elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure. Both patients undergoing open and minimally invasive surgery were considered eligible.
16275691|NCT04846270|Experimental|Investigational Device|TENA SmartCare Change Indicator
16275692|NCT04846244||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for radiographic axial spondyloarthritis (r-axSpA).
16275693|NCT04846231|Active Comparator|Rosuvastatin|5 mg once per day
16275694|NCT04846231|Placebo Comparator|Placebo|comparable to rosuvastatin 5 mg once per day
16275695|NCT04846231|Active Comparator|Fish Oil|Nature Made 2 soft gels per day
16275696|NCT04846231|Active Comparator|Cinnamon|1200mg, 2 capsules per day
16275697|NCT04846231|Active Comparator|Garlique|Manufactured by Focus Consumer Health Marketgate,1 tablet per day
16275698|NCT04846231|Active Comparator|Turmeric|Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day
16275699|NCT04846231|Active Comparator|Plant Sterol|Nature Made CholestOff Plus, 2 soft gels twice a day
16275700|NCT04846231|Active Comparator|Red Yeast Rice|Arazo Nutrition 1200 mg, 2 capsules per day
16275701|NCT04846218|Active Comparator|Group 1|They will receive a single dose of 0.2 mg triptorelin (Decapeptyl® Ipsen Pharmaceutical Company, France) and follow up with daily 125 IU HCG injections
16275702|NCT04846218|Active Comparator|Group 2|They will receive a single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg IM (Prontogest®).
16275703|NCT04846205||Patients who underwent a systematic etiological|Patients who underwent a systematic etiological assessment in the context of their cryptogenic ischemic stroke between 2015 and 2020. A collect data in medical record will be realized.
16275704|NCT04846192||Patients|
16275705|NCT04846179|Experimental|Ginkgo biloba extract group|Group receiving ginkgo biloba extract supplementation
16275706|NCT04846166||Control|
16275707|NCT04846166||Periodontitis|
16275708|NCT04846153|Other|Human-based Quantification|No intervention. No support tool will be used for quantifying airway stenosis from the bronchoscopic images collected previously.
16275709|NCT04846153|Active Comparator|Computer-based Quantifiction|Computer based support tool will quantifying airway stenosis from the bronchoscopic images collected previously.
16275716|NCT04846114|Active Comparator|Control group (Cg)|"The control group (Cg) comprised 20 procedures performed in patients not on OAT.
~Buccal and palatal-lingual flaps were repositioned and sutured with simple stitches using 5/0 monofilament nylon yarn, and a dry gauze was applied for 30 minutes."
16275717|NCT04846114|Experimental|Tranexamic acid group (TXAg)|TXAg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound for 30 minutes using a gauze soaked in the contents of a 500mg ampoule of TXA, after which a new gauze soaked in the contents of a 500mg ampoule of TXA was applied for two hours.
16275718|NCT04846114|Experimental|Bismuth subgallate group (BSg)|BSg group comprised 20 procedures performed in patients OAT. At the moment of surgery, the contents of an anestube (1.8 ml) were mixed with a sufficient amount of BS powder to obtain a paste similar in consistency to tooth-paste (29). A thin layer of the paste was applied on the bone ridge, and buccal and palatal-lingual flaps were then repositioned and sutured as in the Cg. compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
16275719|NCT04846114|Experimental|Dry gauze group (DGg)|DGg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
16275720|NCT04846101|Experimental|Anterior restorations using single shade OMNICHROMA composite|Anterior class III and Class IV cavities will be restored using single shade composite material according to standard protocols of etching, bonding and composite placement.
16275721|NCT04846101|Active Comparator|Anterior restorations using multi-shade composite|Shade selection for the tooth will be performed prior to the placement of the restoration. Anterior class III and Class IV cavities will be restored using multi-shade composite material according to standard protocols of etching, bonding and composite placement.
16275722|NCT04846088|Experimental|Product usage order ABICHDGEF|Subjects will use each of the 9 products (ABICHDGEF) during a familiarization period, followed by a 3 hour Test Session
16275723|NCT04846088|Experimental|Product usage order BCADIEHFG|Subjects will use each of the 9 products (BCADIEHFG) during a familiarization period, followed by a 3 hour Test Session
16275724|NCT04846088|Experimental|Product usage order CDBEAFIGH|Subjects will use each of the 9 products (CDBEAFIGH) during a familiarization period, followed by a 3 hour Test Session
16275725|NCT04846088|Experimental|Product usage order DECFBGAHI|Subjects will use each of the 9 products (DECFBGAHI) during a familiarization period, followed by a 3 hour Test Session
16275726|NCT04846088|Experimental|Product usage order EFDGCHBIA|Subjects will use each of the 9 products (EFDGCHBIA) during a familiarization period, followed by a 3 hour Test Session
16275728|NCT04846088|Experimental|Product usage order GHFIEADBC|Subjects will use each of the 9 products (GHFIEADBC) during a familiarization period, followed by a 3 hour Test Session
16275729|NCT04846088|Experimental|Product usage order HIGAFBECD|Subjects will use each of the 9 products (HIGAFBECD) during a familiarization period, followed by a 3 hour Test Session
16275730|NCT04846088|Experimental|Product usage order IAHBGCFDE|Subjects will use each of the 9 products (IAHBGCFDE) during a familiarization period, followed by a 3 hour Test Session
16275731|NCT04846088|Experimental|Product usage order FEGDHCIBA|Subjects will use each of the 9 products (FEGDHCIBA) during a familiarization period, followed by a 3 hour Test Session
16275732|NCT04846088|Experimental|Product usage order GFHEIDACB|Subjects will use each of the 9 products (GFHEIDACB) during a familiarization period, followed by a 3 hour Test Session
16275733|NCT04846088|Experimental|Product usage order HGIFAEBDC|Subjects will use each of the 9 products (HGIFAEBDC) during a familiarization period, followed by a 3 hour Test Session
16275734|NCT04846088|Experimental|Product usage order IHAGBFCED|Subjects will use each of the 9 products (IHAGBFCED) during a familiarization period, followed by a 3 hour Test Session
16275735|NCT04846088|Experimental|Product usage order AIBHCGDFE|Subjects will use each of the 9 products (AIBHCGDFE) during a familiarization period, followed by a 3 hour Test Session
16275736|NCT04846088|Experimental|Product usage order BACIDHEGF|Subjects will use each of the 9 products (BACIDHEGF) during a familiarization period, followed by a 3 hour Test Session
16275737|NCT04846088|Experimental|Product usage order CBDAEIFHG|Subjects will use each of the 9 products (CBDAEIFHG) during a familiarization period, followed by a 3 hour Test Session
16275738|NCT04846088|Experimental|Product usage order DCEBFAGIH|Subjects will use each of the 9 products (DCEBFAGIH) during a familiarization period, followed by a 3 hour Test Session
16275739|NCT04846088|Experimental|Product usage order EDFCGBHAI|Subjects will use each of the 9 products (EDFCGBHAI) during a familiarization period, followed by a 3 hour Test Session
16275740|NCT04846075||Ramadan Group|Diurnal fasting and spiritual practices. Operationally assessed by the level of compliance to Sawm, Salat, and Zakat.
16275741|NCT04846062|Active Comparator|Intervention|Intervention arm will receive nutrition behavior Children's mothers/caregivers will receive explanatory education and behavior about micronutrient essentiality and utilization. Also, dietary diversification and demonstration in the process of enriching child complimentary food will be given for participants every month for the consecutive six months. Posters and video shows will be used.
16275742|NCT04846062|Active Comparator|control|Control arm will not receive nutrition behavior
16275743|NCT04846049||Comprehensive Care|"Veterans with complex medical conditions that may need more help. This intervention will provide extra care coordination after a complete assessment of their health.
~Research team will assess veteran's memory, physical function, strength, balance, and from there, find the areas they need the most help with and coordinate services at home. This is in addition to their regular primary care provider."
16275744|NCT04846049||Standard Care|Veterans receiving standard of care
16275747|NCT04846023|Experimental|amplitude EEG (aEEG) via VEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes.
16275748|NCT04846010|Active Comparator|antigen|The antigen is the cell that is destroyed by inflammation, which can perform as swollen, fatty, apoptosis, necrosis, and lethal pathological states. Some pathological cells can be saved and returned to customary conditions, like swollen, fatty, early apoptosis, but necrosis, lethal.
16275749|NCT04846010|Active Comparator|Internal environment|The internal environment is critical to the damaged cells recovering. Mainly it is covered by two major parts: metabolites and thrombus.
16275750|NCT04846010|Active Comparator|Communication between cells|The communication between organs, cells, helps the damaged cells recover and reduce symptoms.
16275751|NCT04845971|Experimental|Adult male and female patients who are hospitalized with COVID-19-induced pneumonia.|Eligible patients will be treated with Saisei MAF capsules stronger version, oral administration 2-3 capsules, 3 times per day, 30 minutes before food or in the morning, afternoon and before bed time. The treatment duration will be 21 days. Patients are also provided with nutritional supplementation of Vitamin D3, 10.000 IU per day, monitoring the blood levels of such a vitamin. Efficacy and safety assessments will be performed on Days 0, 7, 14, 21, and 28.
16275752|NCT04845958||Pediatric Patients with Unexplained Enlarged Spleen|
16275753|NCT04845945||PCV13 only|Draw blood for ELISA and OPA, then administer PCV13
16275754|NCT04845945||PPS23 only|Draw blood for ELISA and OPA, then administer PPS23
16275755|NCT04845945||PCV13 and PPS23|Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV13
16275756|NCT04845919|Experimental|5-ALA mediated sonodynamic therapy|
16275757|NCT04845906||Healthy volunteers|There will be 4 separate StatLock™ devices being tested, which will be randomly applied to the participants on their inner (ventral) forearms. Each participant will have 2 separate devices applied, one to each arm. Those participants who have the StatLock ™ Arterial Plus, StatLock™ Dialysis II, or the StatLock IV Select, will also have the foam strip applied.
16275758|NCT04845893||Skeletal Ewing Sarcoma|This cohort include patients affected by Ewing Sarcoma of bone, referred to participating Institutions.
16275759|NCT04845880|Other|SARS Cov_2 Incidence of Healthy Health Workers|
16275760|NCT04845867||Measurement and digital documentation|continuous measurement and digital documentation with alarms and display off
16275761|NCT04845841|Experimental|Participants receive study medication on time point 1|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
16275762|NCT04845841|Experimental|Participants receive study medication on time point 2|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
16275763|NCT04845828|Experimental|Sentinel lymph node mapping|The group composed of patients who undergo sentinel lymph node mapping
16275802|NCT04845529|Experimental|1 tDCS Parietal|Anodal tDCS applied to the right inferior parietal cortex
16275764|NCT04845828|Active Comparator|Routine lymph node dissection|The group composed of patients who undergo routine pelvic lymph node dissection
16275765|NCT04845802|Experimental|Training Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily [morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
16275766|NCT04845802|Sham Comparator|Sham Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily [morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
16275767|NCT04845789||Family caregivers|Family caregivers who were main caregiver to the person with dementia and who spent at least 10 hours a week providing care to the person with dementia.
16275768|NCT04845776|Experimental|Treatment Group|This group receives the vitamin/mineral supplement, ANRC Essentials Plus, for 3 months
16275769|NCT04845763||Intervention|Each patient complete the french version of the QoR-15 score (FQoR-15) at 3 times (before surgery, on Day 1, on Day 2).
16275770|NCT04845750|Experimental|Rodeo Micro Mapping Catheter|Determination of pulmonary vein isoation during cryoablation procedure
16275771|NCT04845737|Other|Fibromyalgia patient group|Sympathetic skin response measurements will be made in patients who meet the diagnosis criteria of fibromyalgia. Vitamin D levels will be measured and hemogram values will be checked in these patients.
16275772|NCT04845737|Other|Control Group|The participant in this group will be chosen from healthy volunteers. Sympathetic skin response will be measured of the participants. Vitamin D levels and hemogram values will be recorded.
16275773|NCT04845724|Active Comparator|Standard Diet|The standard diet was based on the current dialysis diet sheet. The standard diet main meal contained a higher proportion of foods with a higher phosphorus to protein ratio (salmon and dairy), and foods with higher phosphorus bioavailability (cake). The diet was tailored for each participant to provide 1.1g protein/kg ideal body weight. The major differences between the diets were at the main meal.
16275774|NCT04845724|Experimental|Modified Diet|The modified diet, representative of the proposed modified phosphorus diet used food of lower phosphorus to protein ratio such as beef and less dairy. Approximately 30% dietary phosphorus in the modified diet came from foods with significant phytate content such as pulses, nuts and whole grains. The modified diet was tailored for each participant to provide 1.1g protein/kg ideal body weight.
16275775|NCT04845711|Placebo Comparator|Control group|patients will receive general anesthesia only.
16275776|NCT04845711|Experimental|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
16275777|NCT04845711|Experimental|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
16275778|NCT04845698|Experimental|With i-Dashboard|Multi-disciplinary rounds are conducted with the assistance of i-Dashboard.
16275779|NCT04845698|No Intervention|Without i-Dashboard|Multi-disciplinary rounds are conducted without the assistance of i-Dashboard. The team members collect data using standard electronic medical records.
16275781|NCT04845672|Experimental|2% chlorhexidine gluconate|4% Chlorhexidine gluconate solution and one to one water will be used to create a 2% Chlorhexidine gluconate solution.
16275782|NCT04845672|Active Comparator|soap-free body cleaning solution|It supports and protects the natural barrier function of the skin's natural protective layer.
16275783|NCT04845659|Experimental|Intervention|Avatrombopaq administration
16275784|NCT04845646|Experimental|ASC41 + Itraconazole group|"ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11.
~Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16."
16275785|NCT04845646|Experimental|ASC41 + Phenytoin group|"ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19.
~Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19."
16275786|NCT04845646|Experimental|ASC41 group|(1) ASC41 5 mg po. One 5 mg ASC41 tablet on day 1.
16275787|NCT04845633|Other|Healthy children using conventional toothbrush|
16275788|NCT04845633|Experimental|Healthy children using toothbrush with Customized Handle|
16275789|NCT04845633|Other|Children with Down syndrome using conventional toothbrush|
16275790|NCT04845633|Experimental|Children with Down syndrome using toothbrush with Customized Handle|
16275791|NCT04845620|Experimental|ARQ-151 Cream 0.05%|Active comparator
16275792|NCT04845620|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
16275793|NCT04845607|Experimental|Prophylactic amiodarone|
16275794|NCT04845607|No Intervention|Conventional management|
16275795|NCT04845594|Experimental|MySmileBuddy|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will receive a family-focused intervention called MySmileBuddy.
16275796|NCT04845594|No Intervention|Control|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will not receive any intervention.
16275797|NCT04845568|No Intervention|Video|This is the control condition, which views a short video and online interactive game with psychoeducational material on healthy eating and consideration of future consequences.
16275798|NCT04845568|Experimental|Virtual Reality|This is the intervention condition, which participates in the virtual reality experience; the experience includes psychoeducational material on healthy eating and consideration of future consequences.
16275799|NCT04845555||Patients with hemophilia A|Patients suffering from moderate or severe hemophilia A (FVIII <5%) over the age of 12 years.
16275800|NCT04845542|Experimental|ReStoreD|8-week intervention that is remotely delivered, consisting of psychoeducation and positive psychology activities. Participants complete two activities individually and two together each week.
16275801|NCT04845542|No Intervention|Waitlist-control|Participants will be waitlisted for 8 weeks.
16275804|NCT04845529|Sham Comparator|3 Sham|Sham tDCS (control, no stimulation delivered). Following a standard sham protocol, in this condition the tDCS will be active the first 30seconds and the last 30seconds of the session, but silent during the other 19minutes
16275805|NCT04845516||plasma exchange|All patients underwent plasma exchanges between 2014 and 2019 for a neuropediatric pathology
16275806|NCT04845516||immunoadsorption|All patients who underwent immunoadsorptions between 2014 and 2019 for a neuropediatric pathology
16275807|NCT04845503|Experimental|MR-guided Radiotherapy (5 x 7,5 Gy)|5 x 7,5 Gy prescribed on the PTV
16275808|NCT04845490|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with Mitomycin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.
~Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
16275809|NCT04845490|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.
~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
16275810|NCT04845490|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.
~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
16275811|NCT04845477|No Intervention|internal hip rotation pre measurement|with knee and hip flexion at 90º, internal hip rotation will be performed
16275812|NCT04845477|Experimental|internal hip rotation post experimental application measurement|with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
16275813|NCT04845477|Placebo Comparator|internal hip rotation post placebo application measurement|with Placebo tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
16275814|NCT04845464||Study Group|A group of young adults aged between 18 to 25
16275815|NCT04845438|Active Comparator|hand-sewn gastroenteroanastomosis|
16275816|NCT04845438|Active Comparator|stapler gastroenteroanastomosis|
16275817|NCT04845412||Children of GDM parents|Children of mothers who have gestational diabetes mellitus
16275818|NCT04845412||Children of non-diabetic parents|Children of mothers without diabetes
16275819|NCT04845399|Experimental|Arm 1|Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
16275820|NCT04845386||TOF Cuff on arm and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
16275821|NCT04845386||TOF Cuff on lower leg and TOF Scan on adductor pollicis|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
16275822|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on toe|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
16275823|NCT04845386||TOF Scan on adductor pollicis and TOF Cuff on arm|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
16275824|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
16275825|NCT04845373|Experimental|Mediterrenean diet|Mediterranean diet:Target macronutrient energy contributions were 40% from carbohydrate, 35%-40% from fat (with <10% of energy as saturated fat), and 20% of energy as protein.Participant in this group were trained to consume fish, legumes at least 2-3 times a week, walnuts and olive oil every day in accordance with the Mediterranean diet model.
16275826|NCT04845373|Active Comparator|Low fat diet|Low fat diet:Target macronutrient energy contributions for the low fat diet diet were 50-60% from carbohydrate, <30% from fat (with <10% of energy as saturated fat), and 20% from protein.Participants in this group were especially recommended to consume low-fat foods.
16275827|NCT04845360|Experimental|pregnancy and differences in gender can be found in the radial arterial pulse|Establishing the meridian through harmonics of blood pressure waves could be a powerful tool to qualitatively and quantitatively indicate physiologic and pathologic factors.
16275828|NCT04845347|Experimental|Bright Light Therapy|
16275829|NCT04845347|Sham Comparator|Dim Light Therapy|
16275830|NCT04845334|Experimental|Clinical RR intervention|Clinical RR intervention
16275831|NCT04845334|No Intervention|Standard care|Standard care
16275832|NCT04845321|Experimental|VNRX-9945|Oral dosing
16275833|NCT04845321|Placebo Comparator|Placebo|Oral dosing
16275836|NCT04845295|Experimental|Fast Tempo|Performed training intervention with a tempo of 1 second for eccentric and 1 second for concentric phase
16275837|NCT04845295|Experimental|Slow Tempo|Performed training intervention with a tempo of 4 seconds for eccentric and 1 second for concentric phase
16283891|NCT04789083|Placebo Comparator|Group 3 (Plassebo)|Medical treatment and plassebo will be applied.
16275838|NCT04845282|Experimental|Graded Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with a gradation of protein over the 12 week study duration.
16275839|NCT04845282|Active Comparator|RDA Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with the recommended daily allowance of protein over the 12 week study duration.
16275840|NCT04845256||SOMAVAC 100 Sustained Vacuum System|New sustained vacuum system
16275841|NCT04845243|Other|Emotion recognition training|All participants have to complete the online emotion recognition training E.V.A. as well as the pre- and post training tasks: GERT and social decision making task.
16275842|NCT04845230|Active Comparator|Enhanced Usual Care|"The control group in this study will still receive some services above and beyond the usual standard of care offered to pregnant women on Medicaid. In addition to the case management services offered through their managed care provider, Operation Food Search will offer this group access to the hunger hotline, a service provided by Operation Food Search to help them find food assistance around St. Louis; assistance in enrolling in public nutrition assistance programs like SNAP and WIC; and guidance on food pantry access in St. Louis."
16275843|NCT04845230|Experimental|Treatment 1: Nutrition Services|"This treatment group will receive all the services offered to the control group, as well as the following services:
~Weekly food deliveries of fresh food meal kits with step-by-step recipes from the time of program enrollment through 60 days post-partum. Access to necessary cooking tools for their kitchen (e.g., spatulas, cutting boards , etc.), should they need them. Access to online cooking resources to help guide them on culinary skills and recipe preparation. Nutrition education and counseling provided by a registered dietitian."
16275844|NCT04845230|Experimental|Treatment 2: Integrated Care Services|This treatment group will receive all the services offered to Treatment Group 1, as well as the services of a Licensed Masters Social Worker who will provide trauma-informed integrative care services to participants. These services will focus on an array of potential needs that may emerge in participants' lives, such as assistance in finding stable housing, assistance navigating social services, connections with other community organizations, and other needs.
16275845|NCT04845217|Experimental|Peppermint Oil|Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).
16275846|NCT04845217|Placebo Comparator|Coconut Oil|Participants in the placebo (coconut oil) arm will receive soft gels of enteric coated coconut oil. The enteric coated coconut oil soft gel utilized in this study is Coconut Oil from Schwabe North America (Nature's Way Brand).
16275847|NCT04845204|Active Comparator|Relaxation Treatment|Relaxation treatment (RT) is applied additional to standard physiotherapy treatment. RT includes 8 sessions (2 times a day, for four days after surgery) of relaxation exercises.
16275848|NCT04845204|Active Comparator|Standard Exercises|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
16275849|NCT04845191|Experimental|Experimental: Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
16275850|NCT04845191|Experimental|Experimental: Cohort 2: hAd5-S-Fusion+N-ETSD Subcutaneous and Oral|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Oral on Day 1
16275851|NCT04845178|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
16275852|NCT04845178|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles.
16275853|NCT04845178|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.
16275854|NCT04845165||Patients with FPL2 genetically confirmed|patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.
16275855|NCT04845139|Experimental|Nivolumab administration|Nivolumab administration Q2W intrathecally by lumbar punctuation
16275856|NCT04845100|Experimental|Intervention|"The Effect Of Animal Assisted Activities On The Stress And Social Anxiety Levels Of Disabled Children
~Animal Assisted Activity Program (HayDAP)"
16275857|NCT04845100|Other|Control group|No intervention
16275858|NCT04845087|Experimental|Trial Group|Patients from this group will receive treatment with ozonized water.
16275859|NCT04845087|Placebo Comparator|Placebo Group|Patients from this group will receive placebo with water.
16275860|NCT04845074|Experimental|TSA-group|Surgery
16275861|NCT04845074|Experimental|Exercise-group|Exercise
16275862|NCT04845061|Placebo Comparator|nebivolol then placebo|Comprises15 copd patients, after recruitment in study and written informed consent, patient's administered nebivolol (1.25 mg for one week then2.5mg fore another one week and 5 mg at 8am for 10 weeks)and washout period4 weeks then shifted to placebo for 12 weeks
16275863|NCT04845061|Active Comparator|placebo then nebivolol|Contain 15 copd patient's after recruitment and Written informed consent administered placebo for 12 weeks and washout period for 4 weeks then shifted to nebivolol for 12 weeks
16275864|NCT04845048||Health care professionals between 18 and 59 years old|
16275865|NCT04845048||General population 75 years old or more|
16275866|NCT04845048||General population 60 and 74 years old|
16275867|NCT04845035|Experimental|BFM + Tyrosine Kinase Inhibitor|This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.
16275868|NCT04845009|Experimental|progressive muscle relaxation|progressive muscle relaxation tape guided
16275869|NCT04845009|Placebo Comparator|usual care|usual care
16276050|NCT04843969|Experimental|Stress task and neutral cue|Exposure to a psychosocial stress task followed by neutral video cues
16283892|NCT04789070|Active Comparator|Sirolimus|2mg capsules once daily
16275870|NCT04844996|Experimental|Ezetimibe group|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the 9 rats in the ezetimibe group for 28 days postoperatively.
16275871|NCT04844996|Placebo Comparator|Control groups|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization saline (1 ml/kg/day) was administered orally with gavage methodology to the 9 rats in the control group for 28 days postoperatively.
16275879|NCT04844970|Experimental|Anamorelin|Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
16275880|NCT04844970|Placebo Comparator|Placebo|Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
16275881|NCT04844957|Other|Clinical Study of Vitamin D in Children With (POTS)|Clinical Study of the Effect of Vitamin D on the RAAS System in Children With Chronic Orthostatic Intolerance (POTS)
16275882|NCT04844944||Heart Failure|Hospitalized patients diagnosed with Heart Failure. No Intervention.
16275883|NCT04844944||Coronary Artery Disease|Hospitalized patients diagnosed with Coronary Artery Disease. No Intervention.
16275884|NCT04844944||Atrial Fibrillation|Hospitalized patients diagnosed with Atrial Fibrillation. No Intervention.
16275885|NCT04844931|Experimental|RIC + PostC in addition to standard treatment|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery in addition to standard treatment.
16275886|NCT04844931|Active Comparator|Standard treatment|
16275887|NCT04844918|Experimental|Tirzepatide Regimen A|Tirzepatide Regimen A administered subcutaneously (SC)
16275888|NCT04844918|Experimental|Tirzepatide Regimen B|Tirzepatide Regimen B administered subcutaneously (SC)
16275889|NCT04844918|Placebo Comparator|Placebo|Placebo administered SC
16275890|NCT04844905|Experimental|Ivermectin Mass Drug Administration|Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
16275891|NCT04844905|Placebo Comparator|Placebo Mass Drug Administration|Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
16275892|NCT04844892|Experimental|PROTECT Diaphragm Pacing Therapy|
16275893|NCT04844879|Experimental|Single-arm|Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.
16275894|NCT04844866|Experimental|MB-CART2019.1|Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight.
16275895|NCT04844866|Active Comparator|SoC|Immunochemotherapy will be administered from the following 2 predefined regimens: R-GemOx (8 cycles of 14 days each) or BR plus polatuzumab vedotin (6 cycles of 21 days each). BR plus polatuzumab vedotin will be capped at a maximum of 10% of participants; i.e. a maximum of 8 participants will be randomised to the BR plus polatuzumab vedotin regimen.
16275896|NCT04844853|Experimental|Preterm 2|2-year-olds born prematurely
16275897|NCT04844853|Experimental|Term 2|2-year-olds born at term
16275898|NCT04844853|Experimental|Typical 6|6-year-olds with typical developement
16275899|NCT04844853|Experimental|NDD 6|6-year-olds with neurodevelopmental disorders
16275905|NCT04844827||malignant pleural effusion|Patients with malignant pleural effusion who underwent pleural biopsies and blood tests under general anesthesia
16275906|NCT04844814|Experimental|Anakinra|Anakinra 100 mg/d+Placebo of Prednisone
16275907|NCT04844814|Active Comparator|Prednisone|Prednisone 30 mg/d+Placebo of Anakinra
16275908|NCT04844801|Active Comparator|Risk control strategy|Magnesium sulfate + control of the modifiable NOSVA risk factors
16275909|NCT04844801|Active Comparator|Rate control strategy|"Risk-control + low-dose amiodarone"
16275910|NCT04844801|Active Comparator|Rhythm control strategy|"Risk-control + high-dose amiodarone +/- electrical cardioversion"
16276051|NCT04843969|Active Comparator|Control task and smoking cue|Exposure to a control task followed by smoking video cues
16275911|NCT04844775|Experimental|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®)
~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
16275912|NCT04844775|Experimental|Drep-HIV-PT1 1.0mg and CN54gp140/MPLA-L|"0.5mL of DREP-HIV-PT1 will be administered intramuscularly in the LEFT deltoid muscle using the a needle-free device (Pharmajet Stratis®)
~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
16275913|NCT04844775|Experimental|DNA HIV PT123 4mg and CN54gp140/MPLA-L|"1ml of DNA-HIV-PT123 will be injected into the LEFT deltoid muscle using a needle and syringe.
~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
16275914|NCT04844762|Active Comparator|usual brand menthol cigarette (UBMC)|Study participant's usual brand menthol cigarette
16275915|NCT04844762|Active Comparator|menthol roll-your-own cigarette (mRYO)|Mentholated pipe tobacco in a roll-your-own cigarette tube
16275916|NCT04844762|Active Comparator|menthol filtered little cigar (mFLC)|The menthol filtered cigar will be Cheyenne (Cheyennecigars.com) Seneca (senecacigars.com)
16275917|NCT04844762|Active Comparator|non-menthol cigarette (nmC)|The non-menthol cigarette will be Newport non-menthol cigarettes.
16275920|NCT04844736|Other|Radiology Treatment Planning/Review|After patient consultation and enrollment, the patient will undergo routine CT simulation to initiate the radiation treatment planning process. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes. If the initial radiology review reflects concern for inadequate target volume delineation, the case will be flagged for multidisciplinary discussion between the radiation oncologist and radiologist.
16275921|NCT04844710|Experimental|Treatment|Manual acupuncture and standard care
16275922|NCT04844710|Other|Control|Standard care only
16275923|NCT04844684||Obese/non-diabetic patients undergoing gastric bypass surgery|
16275924|NCT04844658|Experimental|NASAFYTOL®|"Minimum 25 patients will receive NASAFYTOL® as a supportive therapy to standard treatment of hospitalized patients infected with COVID-19.
~For each patient, 8 capsules of NASAFYTOL® taken orally per day (4 capsules in the morning and 4 capsules in the evening before meal ,with a full glass of water. ) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and during the period of hospitalization and maximum for 14 days"
16275925|NCT04844658|Active Comparator|FULTIUM® - D3 800|"Minimum 25 patients will receive vitamin D , FULTIUM® - D3 800 as a supportive treatment to standard treatment of hospitalized patients infected with COVID-19.
~For each patient,1 capsule of Vitamin D taken orally per day (1 capsule in the morning) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and for the duration of the hospitalization and maximum for 14 days"
16275926|NCT04844645|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
16275927|NCT04844645|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
16275928|NCT04844619|Active Comparator|4mg/ml KDR2-2 group|The patients with NVG will receive 4.0 mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.
16275929|NCT04844619|Active Comparator|16mg/ml KDR2-2 group|The patients with NVG will receive 16mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.
16275933|NCT04844593||Participants With CD|Participants with CD diagnosed with or without CPF will be identified from EMRs through medical language application program interface (API) software. The AI will apply NLP and machine learning to identify and analyse text information in EMRs and thereby, extract medical information. The study will consist of two sequential phases: Phase 1 (validation process) and Phase 2 (data collection and NLP).
16283893|NCT04789070|Placebo Comparator|Placebo|2mg capsules once daily
16275934|NCT04844580|Placebo Comparator|Standard Treatment + Placebo|Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations.
16275935|NCT04844580|Experimental|Standard Treatment + Inhaled Aviptadil|In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
16275936|NCT04844567|Experimental|COVVR|All participants receive Virtual Reality feedback in two consecutive blocks, one condition per block (synchronous or asynchronous), randomised across participants.
16275937|NCT04844554|Experimental|Group 1 - 4.0 mA HD-tDCS|HD-tDCS with 4.0 milliamperes (mA) of intensitive
16275938|NCT04844554|Experimental|Group 2 - 2.0 mA HD-tDCS|HD-tDCS with 2.0 milliamperes (mA) of intensitive
16275939|NCT04844541||Sub-population A|Symptomatic non-hospitalized SARS-CoV-2 infected adults
16275940|NCT04844541||Sub-population B|SARS-CoV-2 contacts, as defined as adults residing in the same residential care facility setting as a SARS-CoV-2 confirmed case
16275941|NCT04844528|Experimental|Treatment: all patients|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
16275942|NCT04844528|Placebo Comparator|Arm 2: Placebo|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
16275943|NCT04844502|No Intervention|Control Group|Frequent life activities.
16275944|NCT04844502|Experimental|Intervention Group|Protocol of physical exercises
16275945|NCT04844489|Other|Blood samples|
16275951|NCT04844437||Digital examination of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by digital examination and fetal head station evaluated by two clinicians.
16275952|NCT04844437||Transperineal assessment of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by transperineal ultrasound and fetal head station evaluated by two experienced clinicians.
16275995|NCT04844346|Experimental|Plant stanol group|This arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).
16275996|NCT04844346|Placebo Comparator|Placebo group|This arm receives mini drinks without added plant stanols (delivered as plant stanol esters).
16276052|NCT04843969|Active Comparator|Control task and neutral cue|Exposure to a control task followed by neutral video cues
16275993|NCT04844398|Experimental|Clown visits (four times)|Children and adolescents in psychiatric care participate in clown visits in a group setting on a weekly basis over four consecutive weeks.
16275994|NCT04844385|Experimental|Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy|Patients in experimental group receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, then followed by daily simultaneous modulated accelerated radiotherapy combined with Capecitabine.
16276207|NCT04842721|Placebo Comparator|Plain Water Control Arm|The Control Rinse is a 25 ml of Plain Tap Water.
16275997|NCT04844333|Experimental|Extubation under deep anesthesia|When the patient is in sedation or anesthesia state, including no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, stable circulation, the endotracheal tube is removed.
16275998|NCT04844333|No Intervention|Awake extubation|When the patient is in awake state, including bispectral index >70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, the cough and swallowing reflex are obvious and the circulation is stable, the endotracheal tube is removed.
16275999|NCT04844320|Active Comparator|> 50 %EWL|Postoperative weight loss in first year > 50 % EWL
16276000|NCT04844320|Active Comparator|50 - 25 % EWL|Postoperative weight loss in first year 25 - 50 % EWL
16276001|NCT04844320|Active Comparator|< 25 % EWL|Postoperative weight loss in first year < 25 % EWL
16276002|NCT04844307|Active Comparator|Standard PT group|The standard PT group (control) will be receiving the standard 30 minute PT sessions 5 days a week. There will be no variations from standard inpatient PT treatment except that subjects may receive more days of PT than patients who are not participating in study.
16276003|NCT04844307|Experimental|Divided session PT group|The divided session PT group (experimental) will be receiving 15 minute sessions twice a day, five days a week. The total number of minutes of PT time per day/week will be identical to the standard PT group, but divided into shorter and more frequent sessions.
16276004|NCT04844294|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|
16276005|NCT04844294|Active Comparator|Present-Centered Therapy (PCT)|
16276007|NCT04844268|Experimental|Cohort 1|Intramuscular (IM) injection of VACINA RNA MCTI CIMATEC HDT at a dose of 1 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
16276008|NCT04844268|Experimental|Cohort 2|Intramuscular (IM) injection of VACINA RNA MCTI CIMATEC HDT at a dose of 5 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
16276009|NCT04844268|Experimental|Cohort 3|Intramuscular (IM) injection of VACINA RNA MCTI CIMATEC HDT at a dose of 25 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
16276010|NCT04844268|Placebo Comparator|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride). Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
16276011|NCT04844255|Other|Pre and post intervention group|Same individuals are examined before and after taking 2 tablets of salt
16276012|NCT04844242||Group 1|Prior SARS-CoV2 infection as defined by being positive for IgG
16276013|NCT04844242||Group 2|COVID-19 disease as defined as children positive by RT-PCR
16276014|NCT04844242||Group 3|Children with MIS-C according to the WHO or CDC criteria
16276015|NCT04844242||Group 4|Control children who are negative for both RT-PCR and antibody
16276016|NCT04844229|No Intervention|Control group|21 patients will receive conservative management for PDPH in the form of oral paracetamol 1000 mg/8hours, and caffeine 300-500 mg/day, 1000 mL 0.9% normal saline infusion over the initial 4 hours with increasing oral fluids and bed rest to be maintained. After 6 hour of starting treatment if the above measures failed to control pain with the VAS ≥ 4 non-steroidal anti-inflammatory drugs (NSAID) will be added in the form of ketorolac 30 mg IV which can be repeated every 12 hours if needed. Participants will be followed up after 1 hour, 6 hours and 24 hours with assessment of VAS score, modified Lybecker clas¬sification score and TCD parameters. EBP will be considered after 24 hours of treatment if pain still not controlled with VAS ≥ 4 and modified Lybecker clas¬sification score ≥ 2 and after patients' consent.
16276017|NCT04844229|Active Comparator|Interventional group|"21 patients will receive the same conservative management as in control group together with bilateral transnasal sphenopalatine ganglion block.
~After one hour Participants who will show improvement in pain scores will be followed up after 6 hours and 24 hours, while, patients who will show persistent headache will be subjected for bilateral ultrasound guided greater occipital nerve block.
~then these patients will be assessed after 1 h, 6 h, and 24 h of the block. If still suffering epidural blood patch will be indicated and performed after gaining patients' consent."
16276018|NCT04844216|Experimental|Nasolabial fold treated with experimental device|"STYLAGE® L Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.
~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
16276019|NCT04844216|Active Comparator|Nasolabial fold treated with comparator|"The active comparator is a hyalorunic acid injectable gel whose intended purpose is the filling of mid and/or deep depressions of the skin via mid and/or deep dermal injection.
~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
16276020|NCT04844203||Patients with unsteadiness|Patients with unsteadiness referred for an ENMG
16276047|NCT04843982|Experimental|esketamine plus propofol|"After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).
~After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days."
16276048|NCT04843982|No Intervention|propofol|After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).
16276049|NCT04843969|Experimental|Stress task and smoking cue|Exposure to a psychosocial stress task followed by smoking video cues
16276021|NCT04844190|Experimental|Addition of ADM and EndoFLIP to pre-G-POEM evaluation|During the preoperative upper endoscopy, the EndoFLIP catheter is inserted through the mouth with endoscopic guidance and placed through the gastric pylorus. Once deployed, water is sequentially added at set volumes to a balloon that can be used to measure pyloric diameter, cross-sectional area, pressure, and distensibility at set volumes of 30, 40, and 50 mL for at least five seconds. We will record this data for each patient. The EndoFLIP catheter will then be removed. Subsequently, a high resolution ADM catheter will be inserted through the nose and placed through the pylorus to measure baseline intragastric, transpyloric, and intraduodenal pressures. The patient will be observed for up to four hours to assess a migrating motor complex (MMC). After the MMC is observed, the patient will be given a meal and observed for meal response with the manometry catheter. The meal will be water and two pieces of toast/bread. Following the meal, the catheter will be removed.
16276022|NCT04844177|Experimental|intervention/treatment|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:
~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)
~Cyclophosphamide 120 mg/kg (days -5, -4, -3)
~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)
~Melphalan 180 mg/m2 (day -2)
~Rituximab 100 mg/m2 (day -1)
~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
16276023|NCT04844164|Experimental|Cushing's Disease|
16276024|NCT04844164|Experimental|Acromegaly|
16276025|NCT04844164|Experimental|Diabetes Mellitus Type 1|
16276026|NCT04844164|Experimental|Primary Hyperparathyroidism|
16276027|NCT04844164|Experimental|Control group|
16276028|NCT04844151||Acute myocarditis|Patients hospitalized for an acute myocarditis.
16276029|NCT04844138|Experimental|Online Self-Directed Program|Participants in this condition will complete our six-week online self-directed program as soon as it's available.
16276030|NCT04844138|Other|Waitlist|Participants in this condition will receive treatment as usual for six weeks, after which point they will be invited to complete our online program.
16276031|NCT04844125|Experimental|SHR-1209|
16276032|NCT04844125|Placebo Comparator|SHR-1209 Placebo|
16276033|NCT04844112|Experimental|Experimental arm|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.
~Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
16276034|NCT04844099|Experimental|Intervention arm|The intervention will be oral dihydroartemisinin (20mg) and piperaquine (160 mg) and administered once weekly at approximate doses of dihydroartemisinin 2.5mg/kg/day and piperaquine 20mg/kg/day based on participants' weight categories
16276035|NCT04844099|Active Comparator|Comparator|The active control will be Sulphadoxine-Pyrimethamine (SP), the current standard of care for malaria chemoprevention for SCA in Uganda and Malawi. This will also be provided by Guilin Pharmaceutical Co. Ltd as their generic World Health Organization-approved sulphadoxine-pyrimethamine 500/25mg tablets. It will be administered as monthly single-day courses of SP at approximate doses of S=25mg/kg and P=1.25mg/kg.
16276036|NCT04844086|Experimental|Infusion RPM CD19-mbIL15-CAR-T cell|"In this study, anti-CD19 autologous chimeric antigen receptor T-cells infusion produced by rapid personalized manufacture are used to treat patients with relapsed/refractory Advanced Lymphoid Malignancies.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to RPM CD19-mbIL15-CAR-T cell infusion.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16276037|NCT04844073|Experimental|MVC-101|CD3 engaging conditionally active bispecific protein binding EGFR and CD3
16276038|NCT04844060||Patients with cognitive impairment|All patients with cognitive disorders observed at the memory center of Strasbourg and in whom a lumbar puncture is performed as part of the patient's diagnosis.
16276039|NCT04844047|Active Comparator|FAST|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in the community. Participants attended a 30-minute fall prevention education session once per week. FAST followed the same principles as Standard, with the addition of the following goals: 1) Increase UE strength (shoulder girdle/arm) utilizing both concentric and eccentric contractions, 2) Improve trunk and neck postural control during slow and fast body motions, 3) Optimize forward descent strategies via practice of quick response reaching, landing and controlled descent with hands on the wall or on the floor as able. Training progression for strength and body control included increasing the distance standing from the wall, progressing to one arm descents, increasing reps and speed and moving to greater gravity and body weight resistance such as hands and knees position on the floor as able. Quick movement practice targeted unexpected reaching activities, balloon and ball toss
16276040|NCT04844047|Placebo Comparator|Standard|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in a community site (assisted living residence). Participants also attended a 3o minute fall prevention education session once per week. The Standard intervention consisted of a fall prevention exercise program designed for community-dwelling older adults. Exercises focussed on balance, leg strength, walking and mobility exercises designed to decrease fall risk.
16276041|NCT04844034|Active Comparator|Active treatment|High-EPA multinutrient supplement.
16276042|NCT04844034|Placebo Comparator|Placebo|Inert oil mix.
16276043|NCT04844021|Experimental|Nudge|"Clinics randomized to the Nudge condition will receive the EHR prompt only. The investigators will add default language to the standard Well Child Visit workflow to serve as a reminder and allow for tracking of SAFE Firearm implementation. The clinician will be asked to denote whether the program was delivered (e.g., whether conversation around firearm storage was conducted, whether cable firearm lock was offered) to the patient during the visit. This EHR prompt will remain turned on from active implementation through the sustainment period."
16276044|NCT04844021|Experimental|Nudge+|This arm consists of Nudge as described above, as well as facilitation. Facilitation (i.e., external support delivered by health system employees not employed within the clinic site) will be offered for 12 months to each clinic, in keeping with other implementation trials. The investigators will use a train-the-trainer model to train facilitators at both health systems to ensure they achieve facilitator core competencies with an eye toward implementation of SAFE Firearm. The role of the facilitator is to engage with study clinics, to assist each clinic in setting change and performance goals around the implementation of SAFE Firearm, and to troubleshoot implementation barriers.
16276045|NCT04844008|Experimental|Nanobubble|Sports drink nanobubble drink
16276046|NCT04844008|Placebo Comparator|control|Flavoured drink- no active ingredients
16276053|NCT04843956|Experimental|Patients with solid pancreatic lesions|Patients who will undergo endoscopic ultrasound biopsy. Samples of at least 3 passes will be obtained, each pass obtained with a different technique (capillary with suction, capillary without suction and wet suction)
16276054|NCT04843943|Experimental|Sintilimab+Bevacizumab|
16276055|NCT04843930|Experimental|AKL-T01 Intervention|Participants in the experimental group will complete 6 weeks of the AKL-T01 intervention. Participants enrolled in the intervention arm will play the game via an iPad application for 20-25 minutes daily for at least 5 days a week (but up to 7 days a week). Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms and gameplay adherence.
16276056|NCT04843930|No Intervention|Waitlist Control|Participants in the Waitlist Control arm will not be engaging in any active control condition. Participants in the waitlist control arm will continue any ongoing self- or provider-based cognitive intervention (or no intervention) during the initial 6-week waitlist period. Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms. The control arm will be offered the intervention at the end of 6 weeks waitlist period to ensure all participants ultimately have access to the intervention.
16276057|NCT04843904|Experimental|Venetoclax|"Participants will be separated into two cohorts: Cohort A: Patients at low risk for TLS. Cohort B: Patients with both median and high risk for TLS.
~Five (5) participants from cohort A will be initially enrolled, if these first 5 participants tolerate the accelerated ramp-up, cohorts A and B will enroll simultaneously.
~All participants will be hospitalized and receive venetoclax daily with accelerated dose increases over 5 days to reach full dose. After reaching full dose, participants will be discharged and continue daily venetoclax at home.
~Per doctor assessment, some participants may also receive rituximab or obinutuzumab as part of the treatment regimen with venetoclax.
~Rituximab: Given every 28 days starting on the second study cycle and continuing for up to 6 cycles as per standard of care.
~Obinutuzumab: Days 1, 2, 8, and 15 of cycle 1 and once every 28 days there after for up to 6 cycles as per standard of care."
16276058|NCT04843891|Experimental|Healthy Volunteers|In 10 healthy volunteers the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied.
16276059|NCT04843891|Experimental|Cardiovascular Disease|In 30 subjects with a history of recent myocardial infarct, the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the infarct site will be correlated with cardiac MRI.
16276060|NCT04843891|Experimental|Cancer|In 30 subjects with an epithelial malignancy the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
16276061|NCT04843891|Experimental|Sarcoidosis|In 30 subjects with sarcoidosis the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
16276062|NCT04843878||Positive|Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.
16276063|NCT04843878||Negative|Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.
16276064|NCT04843865|Experimental|Chinese Herbs|Participants received standardized Chinese Herbs treatment orally twice daily for 1 week.
16276067|NCT04843839|Experimental|Test Eye|These eyes will be given the Test drug, that is Nepafenac Eye Drops 0.1% w/v, at the dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
16276068|NCT04843839|Placebo Comparator|Control Eye|These eyes will be given the placebo, that is Carboxy-methylcellulose sodium lubricant eye drops 0.5%w/v, at the same dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
16276069|NCT04843826|Experimental|delayed implant|"Patients 18 years or older.
~Periodontally and systemically healthy.
~Sufficient bone width and height for implant placement
~Adequate mesiodistal width and inter-arch space for placement of a delayed implant.
~Full mouth plaque index less than 15% (Bentley and Disney, 1995)
~cooperative patients who will comply to follow up visits"
16276070|NCT04843813|Experimental|Lutein|
16276071|NCT04843813|Placebo Comparator|Safflower Oil|
16276072|NCT04843800|Experimental|Acupuncture|The acupuncture treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. The acupuncture treatment protocol will be semi standardized according to usual practice. All patients will be treated with a selection of local and distant points, comprising 10 minutes of insertion time, 30 minutes of needle retention and manipulation to achieve de qi (an irradiating feeling) if possible.
16276073|NCT04843800|Experimental|Chiropractic|The chiropractic treatments will consist of one 20-minute session weekly, for 3 consecutive weeks. The Diversified technique is one of the most commonly practiced techniques by chiropractors. In the treatment of low back pain, this technique involves the application of a quick (high-velocity), short (low-amplitude) thrust (adjustment) to the lombo-pelvic area.
16276074|NCT04843800|Experimental|Waiting list and Therapeutic Massage|The therapeutic massage treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. A technique called Fascial Release will be used. Tension related to back pain is believed to be present not only in the back but also in various parts of the body such as the legs, through the connection of fascia, the membrane that surrounds the muscles. The purpose of this treatment is to reduce the tension connected to the lower back.
16276075|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 1|Intervention: SLV213, 8 subjects will receive 200mg oral doses twice a day for seven consecutive days.
16276076|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 1|Intervention: Placebo, 4 subjects will receive an equivalent number of oral doses twice a day for seven consecutive days.
16276077|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 2|Intervention: SLV213, 8 subjects will receive 400mg oral doses twice a day for seven consecutive days.
16276078|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 2|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses twice a day for seven consecutive days.
16276079|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 3|Intervention: SLV213, 8 subjects will receive 800mg oral doses once a day for seven consecutive days.
16276080|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 3|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses once a day for seven consecutive days.
16276081|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 4|Intervention: SLV213, 30 subjects will receive the MTD (200mg twice a day, 400mg twice a day or 800 mg once a day) oral doses for seven consecutive days.
16276082|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 4|Intervention: Placebo, 15 subjects will receive the equivalent number of oral doses once a day or twice a day for seven consecutive days.
16276083|NCT04843774||COVID-negative Multiple Sclerosis patients treated with ocrelizumab|
16276088|NCT04843748|Experimental|single arm|single arm open label study
16276089|NCT04843722|Experimental|Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
16276090|NCT04843722|Experimental|Cohort 2: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual on Day 1
16276091|NCT04843709|Experimental|MRG004A|All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
16276092|NCT04843696|Experimental|NPV group|"The hospital-based maintenance NPV program includes NPV support, breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice. The patients in the NPV group undergo the hospital-based NPV once per week in the maintenance program at least three times per month.
~The patients received NPV with breathing training via a cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy) for 60 min, once per week.
~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
16276093|NCT04843696|Active Comparator|Control group|"Control group receives breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice.
~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
16276094|NCT04843670||patients operated for pancreas tumors|duodenopancreatectomy for head of the pancreas tumors
16276095|NCT04843644|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.
~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
16276096|NCT04843644|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).
~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
16276097|NCT04843644|Placebo Comparator|control|Routine care to encourage oral care three times a day.
16276098|NCT04843631|Experimental|Arm A: BFI-751|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL BFI-751
16276099|NCT04843631|Active Comparator|Arm B: EU-STELARA®|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL EU- STELARA®
16276100|NCT04843631|Active Comparator|Arm C: US-STELARA®.|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL US- STELARA®
16276101|NCT04843592||Type II diabetes|using mobile app
16276102|NCT04843579|Experimental|Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)|"Selinexor
~• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.
~Dexamethasone
~Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.
~Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).
~Clarithromycin
~Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.
~Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.
~Pomalidomide
~Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.
~Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle."
16276103|NCT04843566|Active Comparator|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
16276104|NCT04843566|Active Comparator|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
16276105|NCT04843553|Active Comparator|active|Participants receiving oral vitamin B-3
16276106|NCT04843553|Placebo Comparator|placebo|Participants receiving oral inactive pill
16276107|NCT04843540|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of rifampin on Day 4 through Day 15, with a single oral dose of CTP-543 being co-administered on Day 14.
16276108|NCT04843527|Active Comparator|FreeStyle Libre|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.
16276267|NCT04842292|Experimental|Nebulized heparin|Nebulized heparin 25,000 units in 3 mL inhalation every 6 hours
16276109|NCT04843527|Active Comparator|FreeStyle Libre plus food logging|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.
16276110|NCT04843501|Experimental|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|The CMB curriculum is divided into four developmentally appropriate e-cigarette lessons (approximately 20-30 minutes each) for middle school aged youth (6th - 8th grade). A variety of educational strategies are used and include cooperative learning groups, large group discussions, interviews, role-play, media, reports, and goal setting. CMB will provide study materials to teachers and schools through a state-of-the art online delivery portal. A site-based management team will oversee program implementation. Teachers will be trained via webinar. Project staff will visit all participating schools to assemble and train the CATCH site-based management team, and answer questions about the study. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar with Dr. Kelder, which will be offered at multiple times to accommodate teaching schedules.
16276111|NCT04843501|Active Comparator|Texas Education Agency required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes online lessons and support materials.
16276112|NCT04843488|Active Comparator|Ridge Augmentation with a perforate PTFE mesh|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
16276113|NCT04843488|Experimental|Ridge Augmentation with a perforate PTFE mesh covered with a collagen membrane|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The mesh will be covered with a native collagen membrane. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
16276114|NCT04843475||MPNs patients who have echocardiographic probability of PH.|
16276115|NCT04843475||MPNs patients who do not have echocardiographic probability of PH|
16276116|NCT04843462|Experimental|edupression.com® + treatment-as-usual|Patients are receiving treatment with edupression.com® in addition to TAU (treatment-as-usual) with esketamine nasal spray
16276117|NCT04843462|Active Comparator|treatment-as-usual|Patients are receiving TAU (treatment-as-usual) with esketamine nasal spray
16276118|NCT04843449|Experimental|Inhibitor group|"ASC40 50mg, once daily on the 1st and 11th days before meal;
~Itraconazole 200mg, once daily from the 6th day to the 15th day."
16276119|NCT04843449|Experimental|Inducer group|"ASC40 50mg, once daily on the 1st and 19th days before meal;
~Rifampicin 600mg, once daily from the 6th day to the 19th day."
16276120|NCT04843436|Experimental|Symani|Patients treated with Symani for any indications expressed in Inclusion/Exclusion criteria
16276121|NCT04843423|Experimental|Cariprazine treatment|
16276122|NCT04843410|Experimental|Experimental: exercise group|
16276123|NCT04843410|No Intervention|No Intervention: Control Group|
16276124|NCT04843397||Single Arm|Patients referred for clinically indicated EGD, without known precancerous condition. Patients will receive endoscopy with standardised biopsy and photodocumentation protocol
16276125|NCT04843384|Experimental|Reiki|"One of these methods, reiki, has roots which go back thousands of years. Modern reiki was rediscovered and introduced by Mikao Usui in Japan at the end of the 19th century. Reiki means universal life energy . The aim in reiki, in which healing energy is purposefully directed, is to provide restoration of unbalanced energy layers which might be the source of physical, emotional or psychological pain."
16276126|NCT04843384|Sham Comparator|Sham reiki|With the Sham Reiki patients, a nurse without reiki training performed Sham Reiki randomly for approximately, following a protocol which did not include the body's energy centers or chakras.
16276127|NCT04843384|No Intervention|Control|The control group received no intervention beyond routine care.
16276128|NCT04843371||Patient Group|All patients undergoing an echocardiogram at Tulane Medical Center may be asked to participate in the study. Doctors, including PI and co-PI, will identify eligible patients from their clinic using their clinical knowledge and expertise and the patients' medical history and records. They will provide patients with information regarding the study and if interested, patients will be consented prior to their scheduled echocardiogram.
16276129|NCT04843358|Experimental|Emotional Disclosure|Participants in the emotional disclosure arm will be told to write continuously for 20 min about their deepest thoughts and feelings regarding their breast cancer experience
16276130|NCT04843358|Active Comparator|Non-Emotional Writing|Participant allocated to the control group will be asked to describe in detail their daily activities in a non-emotional manner in accord with Pennebaker's published instructions
16276131|NCT04843345||Reduced Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen positive for reduced salivary flow
16276132|NCT04843345||Normal Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen negative for reduced salivary flow
16276133|NCT04843332|No Intervention|Usual Oncology Care|This arm is the control group. They will receive usual oncology care from their regular oncologist and care team with no change in their care plan or treatment as a result of the intervention. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
16276134|NCT04843332|Experimental|Community Health Worker Intervention|This arm is the treatment group. Patients randomized into the intervention will be assigned a community health worker who will contact the patient to begin the intervention. They will receive usual oncology care from their regular oncologist and care team but will also receive supplemental support and health education from a community health worker. The lay health worker will assist patients in ensuring that patients discuss the following with their cancer care teams: 1) precision medicine 2) cancer diagnosis and treatment plan 3) adherence to treatments and 3) goals of care and 4) symptom burden. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
16276136|NCT04843306|Experimental|ABC technique plus biofeedback|Patients will utilize biophysical feedback and coaching during the planning and treatment sessions for radiotherapy to help patients with the ABC technique.
16276137|NCT04843306|Active Comparator|Standard of care ABC technique.|Patients will standard of care instructions for using the ABC technique during the planning and treatment sessions for radiotherapy.
16276268|NCT04842292|Placebo Comparator|Nebulized placebo|Sodium chloride 0.9% 5 mL inhalation every 6 hours
16276138|NCT04843293|Experimental|Experimental Group: Olfactory stimulation group|Preterm newborns in the initiative group were sniffed the smell of breast milk before and during feeding, except for routine application
16276139|NCT04843293|No Intervention|Control Group|Premature newborns in the control group feeds gavage according to the routine of the clinic, and no attempt will be made during feeding.
16276140|NCT04843280|Active Comparator|Traditional Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of formal outpatient physical therapy
16276141|NCT04843280|Active Comparator|Internet Based Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of internet based rehabilitation regime in the home through the online recovery program, FORCE Therapeutics
16276142|NCT04843228|Experimental|Active Cognitive Bias Modification Group|This group of participants will receive 4 sessions of CBM targeting their interpretation biases for perfectionism and intolerance to uncertainty.
16276143|NCT04843228|Placebo Comparator|Placebo-Control Cognitive Bias Modification Group|This group of participants will receive 4 sessions of inactive CBM.
16276144|NCT04843215|Experimental|Experimental group/D2 radical gastrectomy with partial omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.
16276145|NCT04843215|No Intervention|Control group/D2 radical gastrectomy with total omentectom|Control group with total omentectomy
16276146|NCT04843189||Da Vinci Robotic Surgery Group|Da Vinci Robotic Surgery Group
16276147|NCT04843189||Laparoscopy-assisted surgery group|Laparoscopy-assisted surgery group
16276148|NCT04843176|Active Comparator|Prototype AI algorithm|In-house prototype deep learning artificial intelligence algorithm
16276149|NCT04843176|Placebo Comparator|LI_RADS interpretation|LI-RADS criteria will be assessed independently by two specified abdominal radiologists with at least 10 years of experience in cross-sectional abdominal imaging
16276150|NCT04843163|Experimental|Wave A (Immediate NAMI Basics)|Once a participant has completed the questionnaires, that participant will be randomly assigned to either an immediate NAMI Basics class (Wave A), or an 8-week delay (Wave B) condition. Those in the immediate condition will be assigned to take the next available NAMI Basics class. Participants in both groups will be assessed at three time points. Participants in the immediate Basics group (Wave A) condition will be assessed pre-class, post-class, and 6 months after class has ended.
16276151|NCT04843163|No Intervention|Wave B (Waitlist Control)|Participants in the 8-week delay condition will be able to participate in a NAMI Basics class immediately following the 8-week time frame. Participants in the 8-week delay group (Wave B) will be assessed before the 8-week delay, after the 8-week delay (prior to their Basics course), and after the Basics course.
16276152|NCT04843137||Individuals with cervical spinal cord injury|Cohort of individuals who have experiences a chronic spinal cord injury at the cervical level (specifically C5-C7).
16276153|NCT04843124|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
16276154|NCT04843124|Active Comparator|Control group|Traditional hearing aid adjustment
16276155|NCT04843111||Pregnant women and their offspring(s)|Pregnant women and their offspring(s) exposed to MenQuadfi® during their pregnancy or within 30 days prior to their LMP
16276156|NCT04843098|Experimental|Single arm, open label|Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
16276157|NCT04843085||O1|the more aggressive subgroup of oligodendroglioma samples of 30 patients
16276158|NCT04843085||O2|subgroup 2 of oligodendroglioma samples of 30 patients
16276159|NCT04843085||O3|subgroup 3 of oligodendroglioma samples of 30 patients
16276160|NCT04843085||IDH-mutant astrocytomas|patients with IDH-mutant astrocytomas, samples of 15 patients
16276161|NCT04843085||IDH-wildtype glioblastomas|patients with IDH-wildtype glioblastomas, samples of 15 patients
16276162|NCT04843072|Experimental|Evolut R/Pro bioprosthesis|Study subjects will receive a self-expanding-valve (either the Evolut R or PRO device)
16276163|NCT04843072|Active Comparator|Edwards Sapien S3/Ultra bioprosthesis|Study subjects will receive a balloon-expanding-valve (either the Edwards Sapien S3 or Ultra)
16276164|NCT04843059|Other|the resident memory T-cell infiltrate in perilesional vitiligo skin|"To compare the resident memory T-cell infiltrate in perilesional vitiligo skin after 6 months of treatment with OMP and UVB, between three groups of patients suffering from non-segmental vitiligo, using flow cytometric analysis.
~First group will include patients with a long-lasting disease (more than 2 years) and no new or growing lesions for at least 2 years: Old vitiligo with Old lesions
~The second group will include patients with a long-lasting disease (more than 2 years) and with at least one new lesion developed in the last 6 months: Old vitiligo with new lesions
~The third one will include patients developing, for the first-time, vitiligo lesions with all the lesions no older than 6 months: New vitiligo"
16276165|NCT04843046|Active Comparator|CBT + pioglitazone|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a pioglitazone (45 mg) capsule every day during weeks 1-12.
16276166|NCT04843046|Placebo Comparator|CBT + placebo|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a placebo capsule every day during weeks 1-12.
16276167|NCT04843033|Experimental|Daily oral administration of SH3809 tablet|
16276168|NCT04843020|Experimental|Drug subcutaneous injection|Monthly injection of ION 682884, administered subcutaneously at a dose of 45 mg.
16276169|NCT04842994|Experimental|IONM arm|Intra operative nerve monitoring (IONM) is a technique of monitoring the RLN during surgery, to help identification and safe guarding of the nerve during total thyroidectomy as well as central compartment clearance (CCC). This is a well established technique with many centers in the world routinely using monitoring during surgery.
16276170|NCT04842994|No Intervention|Visual Identification arm|Patients randomized to this arm will undergo total thyroidectomy as per standard procedures with visual identification of the RLNs
16276171|NCT04842981|Experimental|Interleukin 6 receptor antibody|Tocilizumab, 162 mg subcutaneous, once every week OR Sarilumab, 200 mg subcutaneous, once every two weeks.
16276208|NCT04842708|No Intervention|Healthy Volunteers that are not to be vaccinated against COVID19|Healthy Volunteers that are not eligible to be vaccinated against COVID19
16276172|NCT04842968|Experimental|Methylene blue|Methylene blue solution (50 mg in 30 ml of saline solution) was injected in the cannulated main supplying artery of the freshly removed specimen, ex vivo. Colorectal specimen was then processed in the routine pathological work-up way.
16276173|NCT04842968|No Intervention|Control|Colorectal specimens were processed in the routine pathological work-up way.
16276174|NCT04842955|Experimental|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
16276175|NCT04842955|Sham Comparator|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
16276176|NCT04842942|Experimental|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
16276177|NCT04842929|Active Comparator|Active Stimulation|Active Comparator: Active stimulation with pulses emitted according to intervention description
16276178|NCT04842929|Sham Comparator|Sham Stimulation|Sham Comparator: The blinding will be done with a sham coil, which consists of a coil that reproduces the sound that the true coil does, but without generating the magnetic field.
16276179|NCT04842916||Gastric cancer patients|gastric cancer patients with histologically confirmed, potentially resectable adenocarcinoma of the stomach or the gastroesophageal junction receiving the standard of medical care in Europe
16276180|NCT04842903|Experimental|Experimental Group|Therapeutic touch and standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
16276181|NCT04842903|No Intervention|Control Group|Only standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
16276182|NCT04842890|Other|Stereotactic body radiation therapy (SBRT) with Pencil Beam Scanning (PBS) proton therapy|
16276183|NCT04842877|Experimental|Experimental arm|Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
16276184|NCT04842864|Experimental|Young|10 healthy men and women 18-35 yo.
16276185|NCT04842864|Active Comparator|Older adults|10 healthy men and women 65-85 yo
16276186|NCT04842838|Experimental|DCB strategy|
16276187|NCT04842838|Active Comparator|DES strategy|
16276188|NCT04842825|Experimental|kidney-tonifying and blood-regulating herbs treatment group|the treatment group will receive sequential treatment with the Chinese herbal formula for tonifying the kidney, nourishing the blood, and activating the blood 2 months before the proposed ET to regulate menstruation and improve ovarian reserve function. Treatment with the Chinese herbal formula will continue on the 5th day of menstruation after entering the super-ovulation cycle.
16276189|NCT04842825|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
16276190|NCT04842812|Experimental|TILs/CAR-TILs treatment|Obtain TILs/CAR-TILs from advanced solid tumor patients and infuse them back to evaluate safety and clinical efficacy of the treatment.
16276191|NCT04842799|Experimental|Digital delivery of genetic pre-test information|Half of participants will be provided with genetic pre-test information via the BRCA-DIRECT digital platform.
16276192|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss genetic pre-test information|Half of participants will be provided with genetic pre-test information via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
16276193|NCT04842799|Experimental|Digital delivery of BRCA-gene testing results|97.5% of participant's with a negative (normal) result will receive their BRCA-gene testing result via the BRCA-DIRECT digital platform.
16276194|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss BRCA-gene testing results|2.5% of participants with a negative (normal) result and those with positive results will receive their BRCA-gene testing result via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
16276195|NCT04842786|Experimental|Coconut oil at 5 mg/Kg body weight twice daily|Coconut oil (Parachute Brand) is a marketed product that is routinely used for daily massage after birth for infants in India. An amount of 5 mg/Kg body weight will be applied twice daily by the health care provider from enrollment until discharge, or until day of life 28, whichever occurs first.
16276196|NCT04842786|No Intervention|No intervention|Subjects assigned to this arm will have their skin gently stroked twice daily for the time that would be required to apply an oil. This will simulate the stroking received by the intervention arm subjects. This will occur from enrollment until discharge, or until day of life 28, whichever occurs first.
16276197|NCT04842773|Experimental|US measurement of sarcopenia|
16276198|NCT04842760||No platelet disorders or no HIT|Patients without platelet disorders or without HIT, without anti-PF4/H antibodies, without anti-aggregant treatment.
16276199|NCT04842760||HIT patients with anti-PF4/H antibodies|patients with anti-PF4/H antibodies but for whom HIT was ruled out.
16276200|NCT04842760||platelet dysfunction or HIT|Patients with platelet dysfunction or suffering from HIT
16276203|NCT04842734|Experimental|Physical exercise and computerized cognitive stimulation|"Exercise sessions will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed.
~The cognitive stimulation program is planned for 12 weeks, 5 days a week, approximately 10 minutes, for a total of 40 sessions [42].
~Fisrtly, the use of Beynex will be demonstrated to the patients. Then, it will be given as home program. While the patients play the games in cognitive stimulation application (Beynex) via their smartphones, their caregivers will be informed in detail about accompanying the patients if they need it. The follow-up of cognitive stimulation will be made with the person accompanying the patient over the phone."
16276204|NCT04842734|Experimental|physical exercise|Exercise sessions will be demonstrated to individuals by a 6-year-experienced physiotherapist via videoconference (Zoom Inc.) and the exercises will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed.
16276205|NCT04842734|No Intervention|control|The individuals included in this group will be informed that they should continue their normal daily life activities.
16276206|NCT04842721|Active Comparator|Hypertonic Saturated Saline Mouth Rinse Active Arm|The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
16276209|NCT04842708|Experimental|Healthy Volunteers that are assigned to be vaccinated against COVID19|Healthy Volunteers that are eligible to be vaccinated against COVID19
16276210|NCT04842695|Active Comparator|kegel´s exercise (pelvic floor exercise)|A midwife/nurse works with the women according to the following protocol: 1.-identify anal sphincter, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2.- identify elevator ani muscle and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting, bent forward, elbows on knees; 3.- contract elevator ani muscle with a position of sitting, lying, and standing; 4.- contract anal sphincter with a position of sitting, lying, and standing. The sessions are conducted by the same midwife/nurse to women in both groups/arms to be performed by the women at home. .
16276211|NCT04842695|Experimental|Electroacupuncture group|"Acupuncture point called bilateral R7 receive acupuncture with 0.25*40 mm needle with a perpendicular puncture 1.5 cun. The electrical stimulator is applied to bilateral R7, with dilatation wave 50 Hz and direct electric current of 1 milliamperes.. Each session lasts 30 minutes per day. Participants are treated 1 time per week for 12 weeks, total 12 sessions for each patient.
~Equipment:
~Electroacupuncture device.
~device made in China"
16276212|NCT04842682|Experimental|Active intervention|"Solo groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)
~Combi groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml) and combined with DNA-HIV-PT123 HIV-1 vaccine (solution at 4.0 mg/ml)"
16276213|NCT04842682|Placebo Comparator|Placebo|Commercial Sodium Chloride at 0.9% (NaCl 0.9%)
16276214|NCT04842669|Experimental|Low level laser therapy|Low level laser therapy
16276215|NCT04842669|Active Comparator|Conservative treatment|Conservative treatment
16276216|NCT04842656|Experimental|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique. ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformis and direct pressure is applied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times(22).
16276217|NCT04842656|Experimental|Post isometric relaxation alongwith conventional treatment|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions(32)
16276218|NCT04842643|Experimental|Epoch 2 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 50 and 200 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once a week until the study drug becomes commercially available (approximately 2 years). All participants of this arm will have assigned Epoch 2 of previous study (TAK-664-3001). The dose of IGSC will be established in previous study.
16276219|NCT04842643|Experimental|Epoch 3 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 100 and 400 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once every 2 weeks until the study drug becomes commercially available (approximately 2 years). All participants of this arm will have assigned Epoch 3 of previous study (TAK-664-3001).The dose of IGSC will be established in previous study (TAK-664-3001).
16276220|NCT04842630|Experimental|SHR-1916|
16276221|NCT04842617|Experimental|Treatment group A|
16276222|NCT04842617|Placebo Comparator|Treatment group B|
16276223|NCT04842604|Experimental|Participants from B1371019 and B1371012|"Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed.
~The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study.
~Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study."
16276224|NCT04842591||kidney transplant candidates|Patients listed for first kidney transplantation
16276225|NCT04842578|Experimental|group of thin cross- section of CT|Anatomic Segmentectomy with the Guidance of Thin Cross- Section of CT
16276226|NCT04842578|Active Comparator|group of thin 3D simulation|Anatomic Segmentectomy with the Guidance of 3D simulation
16276227|NCT04842565|Experimental|TACE+Sintilimab|
16276228|NCT04842552|Active Comparator|Hydralazine hydrochloride 25mg|Hydralazine hydrochloride (25mg tablets) every eight hours (TDS)
16276229|NCT04842552|Placebo Comparator|Placebo|Placebo tablets (identical in shape to the active comparator) every eight hours (TDS)
16276230|NCT04842539|Experimental|FMT Arm|FMT Arm:30 grams stool homogenized with 100 mL normal saline and filtered administered a single time via nasojejunal tube.
16276231|NCT04842539|Other|Standard of care (SOC) Arm|Standard of care treatment with nutritional supplementation and other supportive care
16276232|NCT04842526|Experimental|Anlotinib and irinotecan combined with temozolomide|
16276233|NCT04842513|Experimental|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
16276234|NCT04842500|Experimental|"Cheap Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
16276266|NCT04842305||G4: COVID-19 infected and vaccinated|Individuals who have been infected with COVID-19 and subsequently been vaccinated
16276305|NCT04841954|Experimental|Prick-test|
16276235|NCT04842500|Experimental|"Cheap Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
16276236|NCT04842500|Experimental|"Expensive Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
16276237|NCT04842500|Experimental|"Expensive Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
16276238|NCT04842487|Experimental|Treatment arm|"Lenalidomide：25mg po QN,D1-10
~Rituximab: 375mg/m2, ivdrip, D1
~CTX: 750mg/m2, iv or ivdrip, D1
~THP: 50mg/m2, iv or ivdrip, D1
~VCR： 1.4 mg/m2 , iv（max：2mg）, D1
~Pred: 60mg/m2, po, D1-5"
16276239|NCT04842474|Experimental|Gaze stability and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
16276240|NCT04842448|Experimental|Hyperbaric oxygen treatment|HBO2 240 kPa, 90 min, maximum 10 treatments
16276241|NCT04842448|Placebo Comparator|Sham treatment|Air 134-120 kPa, 90 min, maximum 10 treatments
16276242|NCT04842435|Experimental|Stage 1. Group 1|Group 1 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 1 mL/kg in addition to standard therapy
16276243|NCT04842435|Experimental|Stage 1. Group 2|Group 2 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 2 mL/kg in addition to standard therapy
16276244|NCT04842435|Experimental|Stage 1. Group 3|Group 3 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 4 mL/kg in addition to standard therapy
16276245|NCT04842435|Placebo Comparator|Stage 1. Group 4|Group 4 - 39 subjects who will receive a single intravenous infusion of placebo at a dose of 1 mL/kg in addition to standard therapy
16276246|NCT04842435|Active Comparator|Stage 2. Group 1|Group 1 - 110 subjects who will receive a single intravenous infusion of COVID-globulin at a dose defined at Stage 1 in addition to standard therapy
16276247|NCT04842435|Placebo Comparator|Stage 2. Group 2|Group 2 - 110 subjects who will receive a single intravenous infusion of placebo at a dose equal to the COVID-globulin dose in addition to standard therapy
16276248|NCT04842422|Experimental|Earliest Stage Treatment of Aktinic Keratosis|
16276249|NCT04842396|Experimental|Experimental: Motorized cycle ergometer|"The exercise group cycles 20 minutes per session on the MOTOmed Muvi 3 days per week for 6 weeks at an intensity guided by the perception of effort.
~A cycling cadence is fixed between 25 and 30 rpm for all sessions since that cadence is comfortable for every participant. Researchers adjust resistance on the motorized cycle to increase the external load until it reached the level required to reach the intensity of effort programmed by the OMNI-RPE. The six weeks are programmed in the form of two intensity-differentiated training phases of three weeks. In the first training phase (i.e., the first three weeks), participants are requested to cycle simultaneously with the upper and lower limbs at an intensity equivalent to a perception of 3 (i.e., easy to somewhat moderate) on the OMNI-RPE (0-10)."
16276250|NCT04842396|No Intervention|Control group|Participants are evaluated the week before and the week after the experimental group finishes the training period (pre- vs. postintervention) to facilitate an examination of the changes in body composition, functional performance, and resting cardiovascular state.
16276251|NCT04842383|Active Comparator|Half strength Hemp Oil Preparation|The topical preparation contains only 500mg of cannabinoids per ounce. The other ingredients are the same in both arms.
16276252|NCT04842383|Active Comparator|Full strength Hemp Oil Preparation|The topical preparation contains 1000mg of cannabinoids per ounce. The other ingredients are the same in both arms.
16276253|NCT04842370|Experimental|Dose escalation and expansion of PHI-101|
16276254|NCT04842357|Other|video - then self-study|Group A will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group A will watch a standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group A will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
16276255|NCT04842357|Other|self-study, then video|Group B will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group B will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group B will watch the standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
16276256|NCT04842344|Experimental|Noninvasive ventilation and ECCO2R|
16276257|NCT04842344|No Intervention|Noninvasive ventilation|
16276258|NCT04842331|Experimental|RESP301 + Standard of Care (SOC)|
16276259|NCT04842331|Active Comparator|Standard of Care (SOC)|
16276260|NCT04842318|Experimental|BR+R|Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
16276261|NCT04842318|Experimental|RCHOP+R|Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
16276262|NCT04842318|Experimental|R2+R2|Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
16276263|NCT04842305||G1: Control group|SARS-CoV-2 naïve persons who have neither been vaccinated nor have had COVID-19 (controls)
16276264|NCT04842305||G2: COVID-19 infected|Persons who have had COVID-19
16276265|NCT04842305||G3: COVID-19 vaccinated|Persons who have been vaccinated with Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1-S
16276374|NCT04841551|Other|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
16276269|NCT04842266||Treatment of Impending and Actual Pathologic Fractures in the Pelvis from Metastatic Bone Disease|The patient will undergo surgery and will be treated with the IlluminOss implant. Patients will be evaluated and given questionnaires post operatively at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months
16276270|NCT04842266||Treatment of Geriatric Pelvic Fractures with IlluminOss Pelvic Implant|Geriatric pelvic fracture patients will be treated with the IlluminOss Pelvic Implant. Patients will be evaluated and given questionnaires post operatively at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months
16276271|NCT04842253|Experimental|High flow nasal cannula|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.
16276272|NCT04842253|No Intervention|Low flow nasal cannula|Participants in the current standard of care will receive low flow nasal cannula during deep sedation.
16276273|NCT04842240||Patients undergoing implant based immediate breast reconstruction.|Patients will undergo either pre- or sub-pectoral implant based immediate breast reconstruction.
16276274|NCT04842214||Oncologic disorders|"All patients assigned for oncological rehabilitation with the diagnosis Cancer are included to this cohort."
16276275|NCT04842201|Experimental|CM326|subcutaneous injection
16276276|NCT04842201|Placebo Comparator|Placebo|subcutaneous injection
16276277|NCT04842188|Active Comparator|L-PRF|Leukocyte platelet rich fibrin as a sole graft material in class II furcation
16276278|NCT04842188|Active Comparator|L-PRF with aPDT|Leukocyte platelet rich fibrin combined with antibacterial photodynamic therapy in class II furcation
16276279|NCT04842162|Experimental|Patients with head and neck cancer|
16276280|NCT04842149|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
16276281|NCT04842149|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
16276282|NCT04842136||Myofascial Temporomandibular Disorder (TMD) with Sleep Bruxism (SB)|Patients with Myofascial TMD and with sleep bruxism with the diagnosis of regular or frequent teeth grinding sounds during the sleep, and one or more following clinical signs, such as jaw muscle pain or fatigue on waking up in the morning, temporal headache, hypertrophy of the masseter muscle, abnormal tooth wear, and/or jaw locking were included in the group.
16276283|NCT04842136||Myofascial Temporomandibular Disorder (TMD) without Sleep Bruxism (SB)|Patients with Myofascial TMD without sleep bruxism were included in the group.
16276284|NCT04842123|Other|Atrial fibrillation (AF)|Patients with a known history of AF who are in AF at the time of study screening.
16276285|NCT04842123|Other|Normal Sinus Rhythm (SR)|Patients with no known diagnosis of AF or other arrhythmia
16276286|NCT04842110|Experimental|1064 Full Abdomen|eonTM FR 1064 nm device Patient will be treated with the eonTM FR 1064 nm device
16276287|NCT04842097|Experimental|Mindfulness-based stress reduction intervention|Online 8-week group program, once per week
16276288|NCT04842097|No Intervention|Waiting list|Controls will not receive any intervention during this time. They are on chronic pain clinics waiting list
16276289|NCT04842084||healthy volunteers|Healthy volunteers both sex aged between 18 and 50 without personal or family history of hemorrhage, thrombosis before 45 years old,
16276290|NCT04842071|Experimental|18F-NaF eligible patients|
16276291|NCT04842058||Orthostatic tolerant patients (OT)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
16276292|NCT04842058||Orthostatic intolerant patients (OI)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
16276293|NCT04842045|Experimental|Single Arm|Medically and psychiatrically healthy adults ages 21 to 60 years will receive a single 25 mg dose of psilocybin combined with repeated boluses of midazolam administered in a clinically supportive setting.
16276294|NCT04842032|Experimental|KRN23|KRN23 0.8 mg/kg starting dose, administered Q2W by SC injection up to Week 64. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
16276295|NCT04842019|Experimental|KRN23|KRN23 1 mg/kg administered subcutaneously (SC) every 4 weeks for 48 weeks. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
16276296|NCT04842006|Experimental|TNT + precision|
16276297|NCT04842006|Active Comparator|Conventional|
16276298|NCT04841993|Experimental|Oral formulation: Cannabis decoction|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%) ,cannabis decoction will be prepared at the moment by putting female inflorescences in cold water brought to a boil, boiling for 15 minutes and using 500 mg of medicinal cannabis for 500 ml of water.
16276299|NCT04841993|Experimental|Oral formulation: Cannabis oil|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), cannabis oil is prepared the day before the experimental session with 500 mg of female inflorescences in 5 ml of olive oil from the European Pharmacopoeia, heating in a water bath (approximately 98 ° C) for 120 minutes and cooling the oil samples. at room temperature.
16276300|NCT04841993|Experimental|Vaporized formulation: Cannabis vaporized|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), 100 mg of Cannabis inflorescences of FM2 standardized cannabis were administered through Volcano vaporizer .
16276301|NCT04841980|Active Comparator|Antibiotics|
16276302|NCT04841980|Active Comparator|Dietary based therapy|
16276303|NCT04841967|Experimental|TELL Tool Group|Parents in the TELL Tool group will complete a decision support aid that has four interactive, multimedia and multicomponent modules that will be administered digitally. It will take parents about 60 minutes to complete the TELL Tool.
16276304|NCT04841967|Active Comparator|eBook Attention-Control|Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.
16276306|NCT04841941|Experimental|single arm|G4 Multifocal soft contact lens with a 54% water content for presbyopia
16276307|NCT04841928|No Intervention|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
16276308|NCT04841928|Experimental|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
16276309|NCT04841928|Experimental|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
16276310|NCT04841928|Experimental|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
16276311|NCT04841928|Experimental|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).
16276312|NCT04841928|Experimental|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
16276313|NCT04841928|Experimental|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
16276314|NCT04841928|Experimental|Mindful attention + Decentering + Value-based action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).
16276315|NCT04841915|Experimental|Micellar Cassein Isolate High-Protein Diet|4weeks eucaloric intake on high-protein diet with micellar cassein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
16276316|NCT04841915|Experimental|Whey Protein High-Protein Diet|4weeks eucaloric intake on high-protein diet with whey protein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
16276317|NCT04841915|Placebo Comparator|Normal Diet|4weeks eucaloric diet with normal protein content (15E%) followed by 20weeks hypocaloric intake on equivalent diet.
16276318|NCT04841902|Experimental|Life Style Intervention Manual (Supervised)|Supervised Exercises with Life Style Intervention Manual (Dietary & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of alternating light to moderate intensity aerobic exercises including warm up and rest interval
16276319|NCT04841902|Experimental|Life Style Intervention Manual (Home Based)|Home Based- Life Style Intervention Manual (Exercise, Dietary & Educational Component for 16 weeks. Subject will be asked to maintain a regular exercise and dietary diary to ensure adherence to the program
16276320|NCT04841902|Placebo Comparator|Control|Age matched Control Group followed for 16 weeks with General Advise to stay healthy and active
16276321|NCT04841889|Other|Associated factors with decannulation|Collection of demographic, biological, ventilatory, respiratory and extra-respiratory parameters at the admission and the end of stay in the respiratory weaning center. Lung and diaphragm ultrasound, swallowing and muscles assessment will be performed.
16276322|NCT04841876||Group-1|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-1, participants will be asked to play three consecutive rugby matches, with 40 min for each match. The total duration will be 2 hours. There is no additional intervention on this group.
16276323|NCT04841876||Group 2|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-2, participants will be asked to only watch the rugby matches. They will not received any intervention.
16276324|NCT04841863|Active Comparator|Drug Code Active Patient o DCAP|"Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
16276325|NCT04841863|Placebo Comparator|Standard care|"Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
16276326|NCT04841850||Hazelnut allergic children under oral immunotherapy|"Children Under eighteen years of age
~Convincing clinical history of hazelnut allergy
~Positive hazelnut prick test or specific IgE
~Under IOT hazelnut protocol in pneumology and allergology-paediatric departement of the Mother and Child Hospital in Bron"
16276327|NCT04841837|Experimental|Time-restricted feeding|Restrict all calorie intake within a self-selected 10-hours window for 12 weeks, without necessarily altering diet quality and quantity
16276328|NCT04841824||Critically ill patients with sepsis|
16276329|NCT04841824||Critically ill patients without sepsis|
16276330|NCT04841811|Experimental|Postoperative Almonertinib continuous treatment group|Operable subjects were randomly assigned to groups A and B after surgery: Group A received 110 mg of Almonertinib once a day for 2 years.
16276331|NCT04841811|Experimental|Postoperative ctDNA dynamic monitoring guided the Almonertinib treatment group|Operable subjects were randomly assigned to groups A and B after surgery:Group B received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months Test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).
16276332|NCT04841811|Experimental|Almonertinib continuous treatment group after radical radiotherapy|Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy.Group C continued to receive Almonertinib 110 mg once a day for 2 years.
16276333|NCT04841811|Experimental|ctDNA dynamic monitoring guided the Almonertinib treatment group after radical radiotherapy|Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy.Group D received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months Test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).
16276334|NCT04841798|Other|Duloxetine|Assessment of MAO-B distribution volume in the prefrontal cortex before and after duloxetine at 60 mg daily.
16276335|NCT04841798|Other|Rasagiline|Assessment of regional MAO-B distribution volume before and after rasagiline at 1.0 mg daily.
16276336|NCT04841798|Other|Tranylcypromine|Assessment of regional MAO-B distribution volume before and after tranylcypromine at 30 to 60 mg daily.
16276337|NCT04841785||CKD4/5|Patients with chronic kidney disease stage G4-G5 without dialysis or with a kidney transplant
16276338|NCT04841785||Dialysis|Patients on hemodialysis and peritoneal dialysis
16276339|NCT04841785||Kidney transplant|Patients with a kidney transplant at least 6 weeks after transplantation
16276340|NCT04841772|Active Comparator|Vegan Protein|
16276341|NCT04841772|Placebo Comparator|Placebo|
16276342|NCT04841759|Experimental|"Post COVID-19 fatigue at baseline yes"|SARS-CoV2 survivor who attends the exercise program and suffers from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
16276343|NCT04841759|Active Comparator|"Post COVID-19 fatigue at baseline no"|SARS-CoV2 survivor who attends the exercise program and doesn't suffer from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
16276344|NCT04841746|Experimental|Cycling rehabilitation with functional electrical stimulation|
16276345|NCT04841746|Active Comparator|Cycling rehabilitation|
16276346|NCT04841733|Experimental|Protocol I: Foam Roller (FR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Cold-Water Immersion (CWI)
16276347|NCT04841733|Experimental|Protocol II: Stretching (STR) + Cold-Water Immersion (CWI)|Stretching (STR) Cold-Water Immersion (CWI)
16276348|NCT04841733|Experimental|Protocol III: Foam Roller (FR) + Stretching (STR)|Foam Roller (FR) Stretching (STR)
16276349|NCT04841733|Experimental|Protocol IV: Foam Roller (FR) + Stretching (STR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Stretching (STR) Cold-Water Immersion (CWI)
16276350|NCT04841720|Experimental|HSK16149|HSK16149（D1-D5）
16276351|NCT04841720|Experimental|Metformin|Metformin
16276352|NCT04841720|Experimental|HSK16149+Metformin|HSK16149+Metformin
16276353|NCT04841707|Experimental|COVID-19 patients|
16276354|NCT04841694|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day
16276355|NCT04841681|Experimental|Video-based Psychotherapy|The group received the intervention of video-based psychotherapy.
16276356|NCT04841668||Patients with recently diagnosed T2DM|This group will consist of 36 recently diagnosed T2DM, according to the World Health Organization (WHO) patients (last 6 months), who have not received treatment with metformin.
16276357|NCT04841668||Patients with long-term T2DM|The group will consist of 100 patients with long-term T2DM, according to the WHO classification, regardless of whether they take metformin or another treatment.
16276358|NCT04841642|Experimental|Manual therapy and a telerehabilitation program|"In the experimental group, an intervention based on manual therapy and a telerehabilitation program based on exercises will be carried out.
~The investigators will apply manual therapy for ten minutes a week based on cervical mobilizations and suboccipital inhibitions.
~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
16276359|NCT04841642|Active Comparator|Manual therapy and recommendations for home exercises|"In the control group, the same manual therapy intervention and recommendations for home exercises will be applied.
~This exercises recommendations will be based on a simulation of the exercise in the same session of the manual therapy of each week."
16276360|NCT04841629|Experimental|PreBioGyn Gel|Topical administration to forearm
16276361|NCT04841629|Active Comparator|Trimosan Gel|Topical administration to forearm
16276362|NCT04841629|Active Comparator|RepHresh Gel|Topical administration to forearm
16276363|NCT04841616|Experimental|Contrast-enhanced EUS (CH-EUS) Arm|After initial evaluation, 2.5ml of second-generation contrast media, SonoVue (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
16276364|NCT04841616|Active Comparator|Conventional EUS Arm|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed
16276365|NCT04841603|Active Comparator|Treatment as usual|Treatment as usual
16276366|NCT04841603|Experimental|Mindshift CBT|Treatment as usual + Access to Mindshift CBT app
16276367|NCT04841590|Experimental|Experimental Group|The experimental group (EG) will receive treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
16276368|NCT04841590|Sham Comparator|Control Group|The control group (CG) will not receive any treatment
16276369|NCT04841590|Placebo Comparator|Placebo Group|Subjects belonging to this group will receive the application of off ultrasound applied to the abdominal region for approximately 10 minutes.
16276372|NCT04841564|Active Comparator|ultrasound group|serratus anterior plane block will be done through ultrasound guidance
16276373|NCT04841564|Experimental|Open group|serratus anterior plane block will be done after mastectomy through the open wound
16309214|NCT04612465|Placebo Comparator|Fibringlue|Standard comparator
16276375|NCT04841538|Experimental|Cohort 1|ES101 is administered via intravenous infusion, 0.3mg/kg，once every 14 days, every 28 days as a treatment cycle.
16276376|NCT04841538|Experimental|Cohort 2|ES101 is administered via intravenous infusion, 1mg/kg，once every 14 days, every 28 days as a treatment cycle.
16276377|NCT04841538|Experimental|Cohort A1|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
16276378|NCT04841538|Experimental|Cohort A2|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
16276379|NCT04841538|Experimental|Cohort B|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
16276380|NCT04841538|Experimental|Cohort C|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
16276381|NCT04841525||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
16276382|NCT04841525||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
16276386|NCT04841499|Experimental|Treatment Arm|7 days of BASIS™ orally
16276387|NCT04841486||"with history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy with history of spontaneous termination of pregnancy
16276388|NCT04841486||"without history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy without history of spontaneous termination of pregnancy
16276389|NCT04841473|Active Comparator|Standard Concussion Education|Participants will receive standard concussion education materials (online training) focused on concussion prevention in youth sport.
16276390|NCT04841473|Experimental|TRAIN Concussion Education|After receiving the standard concussion education materials (online training), participants will receive an additional module, the TRAIN concussion education module.
16276391|NCT04841460|Experimental|Low-fat ground beef|Participants will consume 25 low-fat ground beef patties, 5 patties per week for 5 weeks.
16276392|NCT04841460|Experimental|High-fat ground beef|Participants will consume 25 high-fat ground beef patties, 5 patties per week for 5 weeks.
16276393|NCT04841434|Experimental|Dose escalation|Patients will receive up to 6 cycles of HD-MTX Treatment Dose escalation will be performed using three dose levels of MTX: 3.0 g/m2, 3.5 g/m2, 4.0 g/m2
16276394|NCT04841421|Experimental|89Zr-CD147 1mCi±10% 10mg dose group|The activity administered was 1mCi±10% and the mass of radiolabeled CD147 was 10 mg.
16276395|NCT04841421|Experimental|89Zr-CD147 3mCi±10% 10mg dose group|The activity administered was 3mCi±10% and the mass of radiolabeled CD147 was 10 mg.
16276396|NCT04841421|Experimental|89Zr-CD147 5mCi±10% 10mg dose group|The activity administered was 5mCi±10% and the mass of radiolabeled CD147 was 10 mg.
16276397|NCT04841408|Experimental|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
16276398|NCT04841395||PE|Premature ejaculation group
16276399|NCT04841395||CG|Control group (Healthy subjects)
16276400|NCT04841369|Experimental|1A|Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)
16276401|NCT04841369|Active Comparator|1B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)
16276402|NCT04841369|Experimental|2A|Subjects received four doses of PCV13i at 3 months of age
16276403|NCT04841369|Experimental|3A|Subject received three doses of PCV13i at 7 to 11 months of age
16276404|NCT04841369|Active Comparator|3B|Subject received three doses of PCV13 at 7 to 11 months of age
16276405|NCT04841369|Experimental|4A|Subjects received two doses of PCV13i at 12 to 23 months of age
16276406|NCT04841369|Active Comparator|4B|Subjects received two doses of PCV13 at 12 to 23 months of age
16276407|NCT04841369|Active Comparator|5A|Subjects received one dose of PCV13i at 2 to 5 years old.
16276408|NCT04841369|Active Comparator|5B|Subjects received one dose of PCV13 at 2 to 5 years old.
16276409|NCT04841356|Experimental|ICG|Immediate Compression Garment
16276410|NCT04841330||Healthy volunteers|A minimum of 100 healthy volunteer participants (14yo and older)
16276411|NCT04841317|Experimental|Single-arm: Blood pressure intervention|Participants will use a mobile technology system comprising of a remote home blood pressure monitoring cuff and a mobile application integrated with a clinician-facing component to view and manage remote blood pressures. Participants will use this for 12 weeks, with assessment of blood pressure outcomes and anonymous surveys regarding the technology at 12 weeks.
16276412|NCT04841304||Patients receiving hemodialysis with diabetes|Patients receiving chronic hemodialysis with a diagnose of Type 1 diabetes or Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) and receiving insulin treatment
16276413|NCT04841304||Patients receiving hemodialysis without diabetes|Patients receiving chronic hemodialysis without diabetes (no known diagnosis of diabetes, HbA1c < 48 mmol/mol and fasting blood glucose < 6.1 mmol/l at inclusion)
16276414|NCT04841291|Experimental|Virtual Simulation-Based Arm|Access virtual simulation-based diabetes foot care education once for 30 minutes plus the standard care.
16276415|NCT04841291|No Intervention|Standard Care Arm|Participants will continue utilizing the usual follow-up diabetes care which occurs every month.
16276416|NCT04841278|Experimental|EUS/ERCP|Patients with liver graft dysfunction enrolled sequentially for proposed protocol: EUS with possible interventions and possible ERCP
16276417|NCT04841265|Active Comparator|Vitamin D3|The Vitamin D3 (intervention) arm will receive a total of 800 IU vitamin D3 supplementation per day.
16276418|NCT04841265|No Intervention|Control|The control arm will receive 400 IU vitamin D3 per day from routine antenatal multivitamin supplementation.
16276419|NCT04841239|Experimental|Herbal topical formulation|
16276420|NCT04841239|No Intervention|Control|
16276421|NCT04841226|Active Comparator|Silq Cleartract™ 100% Silicone 2-Way Foley Catheter|Up to 82 subjects
16276422|NCT04841226|Active Comparator|Silver-coated Latex 2-Way Foley Catheter|Up to 82 subjects
16276423|NCT04841226|Active Comparator|Silicone-coated Latex 2-Way Foley catheter|Up to 82 subjects
16276424|NCT04841213|Active Comparator|Group after vitamin D3 level stabilization|Patients with loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who will undergo dental implant placement after stabilization of vitamin D3 levels
16276425|NCT04841213|Active Comparator|Group before vitamin D3 level stabilization|Patients with the loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who undergo the dental implantation during treatment by an endocrinologist
16276426|NCT04841200|Experimental|Chinese medicine compound combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound based on TCM syndrome differentiation in addition to symptomatic treatments.
16276427|NCT04841200|Placebo Comparator|Chinese medicine compound placebod combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound placebo based on TCM syndrome differentiation in addition to symptomatic treatments.
16276428|NCT04841174|Experimental|Abdominal Massage|"Participants in the experimental group will be given an abdominal massage twice a day for 15 minutes and three days in a row by the researcher. The massage will be done 2 hours after the child has been fed. Abdominal massage will be done using the I love u technique."
16276429|NCT04841174|No Intervention|Intraabdominal pressure|Intra-abdominal pressure measurements will be made twice a day before the abdominal massage is given to the participants. This measurement will be made in line with a protocol. The intraabdominal pressure will be measured using the bladder passage method. This measurement will be made in both control and experimental groups.
16276430|NCT04841174|No Intervention|Gastric measurements|In the experimental and control groups, the abdominal circumference will be measured by the researcher twice a day for three days in a row. The gastric residual volume will be checked during the nurses' care time. The presence of vomiting and defecation will be checked during the care time of the nurses.
16276431|NCT04841161|Other|Healthy subjects|The healthy adults who have not any neurological, musculoskeletal or rhematogical disease, a history of orthopedic surgery on spine or lower extremity. Their age should be ranged between 20 - 75 years.
16276432|NCT04841161|Experimental|Stroke subjects|Stroke patients were included if they were: (1) diagnosed with unilateral ischemic or hemorrhagic stroke; (2) a minimum of six months post stroke ; (2) able to stand without support for 1 minutes; (3) able to understand and follow verbal instructions. and (4) medically stable with physician release.
16276433|NCT04841148|Experimental|HCQ|Patients will receive HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
16276434|NCT04841148|Experimental|Avelumab|Patients will receive Avelumab, 10 mg/kg, IV, D1 and D15 of each 28-day cycle.
16276435|NCT04841148|Experimental|Palbociclib and Avelumab|Patients will receive Palbociclib 125 mg daily, by mouth on D1-21 concurrently with Avelumab, 10 mg/kg IV on D1 and D15 of each 28-day cycle
16276436|NCT04841148|Experimental|Palbociclib and HCQ|Patients will receive Palbociclib 75 mg daily, by mouth on D1-28 concurrently with HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
16276437|NCT04841135|Other|Alzheimer disease group|
16276438|NCT04841135|Other|Control|
16276439|NCT04841122|Active Comparator|Camera observation|Camera observation
16276440|NCT04841122|No Intervention|No camera observation|No intervention
16276441|NCT04841096|Experimental|Group A: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day
16276442|NCT04841096|Experimental|Group B: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day
16276443|NCT04841083|Experimental|Allay lamp (narrow band green light)|Subjects who purchased the Allay Lamp are asked to document the effects of spending time in the narrow band of green light it emits, on their headache or any of its associated symptoms.
16276444|NCT04841070|Experimental|Persistent pulmonary hypertension of the newborn.|Children aged 1 to 5 years who have been hospitalized in pediatric resuscitation service for the treatment of persistent pulmonary hypertension of the newborn.
16276448|NCT04841044|Experimental|Intervention ( Cetoleic acid)|"6x mackerel oil (cetoleic acid: 16A%, estimated: 135 mg/g (FFA)) capsules every morning for 4 weeks
~(A%= area percent)"
16276449|NCT04841044|Placebo Comparator|Control oil|"6x capsules control oil (Control oil= mix of anchovy oil, olive oil, high-oleic sunflower oil, rapeseed oil (cetoleic acid: 0,7 A% estimated: 6 mg/g (FFA)) every morning for 4 weeks
~(A%= area percent)"
16276450|NCT04841031|Experimental|NET Treatment|Narrative Exposure Therapy (NET) Treatment: Treatment group consists of eligible individuals who are randomly assigned to receive NET treatment and are part of the study sample. Within each health center, treated individuals are randomly selected over several cohorts. In every cohort, the treatment group contained 6 individuals who received NET.
16276451|NCT04841031|Other|Control|This group contains eligible individuals who are randomly assigned to the control group and are part of the study sample. In every cohort, the control group contained 6 individuals.
16276452|NCT04841018|Experimental|Control|Higher dose of dexamethasone (0.5mg/kg) that is known to enhance the analgesic quality of caudal block from previous study
16276453|NCT04841018|Experimental|Dexamethasone|Lower, antiemetic dose of dexamethasone (0.15mg/kg)
16276454|NCT04841005|Experimental|Square-Step Exercise group|Square-step exercise for 8 weeks will be applied under the supervision of a physiotherapist.
16276455|NCT04841005|Experimental|Strengthening Exercise Group|Strengthening exercise for 8 weeks will be applied under the supervision of a physiotherapist.
16276456|NCT04840992|Experimental|A1a Phase I low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
16276457|NCT04840992|Placebo Comparator|A1b Phase I placebo low 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
16276458|NCT04840992|Experimental|A2a Phase I medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
16276459|NCT04840992|Placebo Comparator|A2b Phase I placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
16276460|NCT04840992|Experimental|A3a Phase I high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
16276461|NCT04840992|Placebo Comparator|A3b Phase I placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
16276462|NCT04840992|Experimental|A4a Phase I combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
16276463|NCT04840992|Placebo Comparator|A4b Phase I placebo combine 2 doses|6 subjects, Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
16276464|NCT04840992|Experimental|A5a Phase I single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
16276465|NCT04840992|Placebo Comparator|A5b Phase I placebo single dose|6 subjects, Placebo containing 0 vp, 1 dose Aerogen Solo
16276466|NCT04840992|Experimental|B1a Phase II low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
16276467|NCT04840992|Placebo Comparator|B1b Phase II placebo low 2 doses (18-59)|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
16276468|NCT04840992|Experimental|B2a Phase II medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
16276469|NCT04840992|Placebo Comparator|B2b Phase II placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
16276470|NCT04840992|Experimental|B3a Phase II high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
16276471|NCT04840992|Placebo Comparator|B3b Phase II placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
16276472|NCT04840992|Experimental|B4a Phase II combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
16276473|NCT04840992|Placebo Comparator|B4b Phase II placebo combine 2 doses|Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
16276474|NCT04840992|Experimental|B5a Phase II intramuscular single dose|Ad5-nCoV containing 5E10 vp, 1 dose Intramuscular Injection
16276475|NCT04840992|Placebo Comparator|B5b Phase II placebo intramuscular single dose|placebo containing 0 vp, 1 dose Intramuscular Injection
16276476|NCT04840992|Experimental|B6a Phase II Aerogen Solo single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
16276477|NCT04840992|Placebo Comparator|B6b Phase II placebo Aerogen Solo single dose|placebo containing 0 vp, 1 dose Aerogen Solo
16276478|NCT04840979|Experimental|Cognitive Impairment|Subjects diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI) will have one PET scan with 11C-ER176, with arterial sampling. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
16276479|NCT04840979|Active Comparator|No Cognitive Impairment|Healthy volunteers who are cognitively normal will have one PET scan with 11C-ER176, with arterial sampling. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
16276480|NCT04840966||HOS: hospitalized COVID19 patients|Patients positive to COVID19 hospitalized
16276481|NCT04840966||HI: Home-isolated COVID19 patients|Home-isolated patients positive to COVID19
16276482|NCT04840966||CTRL: Healthy controls|Healthy COVID19 negative subjects
16276483|NCT04840927|Experimental|Cohort 1: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:
~Treatment sequence 1: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.
~Treatment sequence 2: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.
~Treatment sequence 3: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.
~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
16276484|NCT04840927|Experimental|Cohort 2: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:
~Treatment sequence 4: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.
~Treatment sequence 5: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.
~Treatment sequence 6: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.
~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
16276487|NCT04840901|Experimental|Lebrikizumab - Pre-Filled Syringe with Needle Safety Device|Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).
16276488|NCT04840901|Experimental|Lebrikizumab - Autoinjector|Lebrikizumab administered SC via autoinjector (AI).
16276489|NCT04840888|Experimental|LY3484356 (Cohort 1)|LY3484356 administered as single doses orally with (fed) or without food (fasted).
16276490|NCT04840888|Experimental|LY3484356 + Omeprazole (Cohort 2)|LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.
16276491|NCT04840888|Experimental|LY3484356 + Itraconazole (Cohort 3)|LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.
16276492|NCT04840888|Experimental|LY3484356 + Rifampicin (Cohort 4)|LY3484356 administered as single dose orally on Day 1 and rifampicin administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of rifampicin on Day 12 orally followed by single dose of rifampicin administered orally on Days 13 to 15.
16276493|NCT04840875|Experimental|chimeric antigen receptor T cell treatment|
16276494|NCT04840862|Experimental|rifabutin|Rifabutin PO [two 150mg capsules] ; Trikafta PO [one orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
16276495|NCT04840849|Experimental|Nirsevimab|Nirsevimab single dose IM injection
16276496|NCT04840849|Placebo Comparator|Placebo|Placebo single dose IM injection
16276497|NCT04840836||Telehealth-supported LARC provision|"Patients who receive care at the SBHC provide informed consent for care, as well as record review for quality assurance purposes. Analyses will include female patients who have a reproductive health visit, which includes contraceptive counseling, contraceptive management, or contraceptive method initiation, during the study period. Patients who have a telehealth consultation with a SBHC medical provider for LARC services (conservatively estimated n=113) will be considered enrolled patients once the data are extracted from the EHR."
16276498|NCT04840823|Experimental|Enoxacin 200mg twice daily|Enoxacin 200mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 1 active 200mg enoxacin tablet and 2 placebo tablets per dose.
16276499|NCT04840823|Experimental|Enoxacin 400mg twice daily|Enoxacin 400mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 2 active 200mg enoxacin tablets and 1 placebo tablet per dose.
16276500|NCT04840823|Experimental|Enoxacin 600mg twice daily|Enoxacin 600mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 3 active 200mg enoxacin tablets per dose.
16276501|NCT04840810|Active Comparator|Out of plane/ short axis central venous cannulation|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
16276502|NCT04840810|Active Comparator|In-plane/long axis central venous cannulation|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
16276503|NCT04840797||Suspected Sudden Cardiac Arrest|All subjects with suspected of a circulatory arrest of any cause.
16276504|NCT04840784|Experimental|ETH-155008|Dose level: 10mg/day, 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 3-6 subjects, taking ETH-155008 tablets once daily.
16276505|NCT04840758|Experimental|SABR+Sintilimab|Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and secondary lesions. Sintilimab was used 2 weeks after the end of SABR. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
16276506|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 3.75mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
16276507|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 1.88mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
16276508|NCT04840745|Experimental|CKD-841 D(=leuprorelin acetate 2.92mg)|Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
16276509|NCT04840745|Active Comparator|Leuplin Inj.(=leuprorelin acetate 3.75mg)|Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
16276510|NCT04840732|Experimental|Experimental: Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
16276511|NCT04840732|Placebo Comparator|No Intervention: usual care|Chemotherapy training as usual care (for training chemotherapy skill).
16276512|NCT04840706|Active Comparator|Airvo|Patients allocated to use Airvo device
16276513|NCT04840706|Placebo Comparator|Control|Patients not using Airvo, standard care
16276514|NCT04840693|Experimental|Excess of endogenous glucoglucocorticoids (group 1)|v
16276515|NCT04840693|Experimental|Exogenous hypercortisolisms (group 2)|a disease justifying the up-coming start of a glucocorticoid therapy
16276516|NCT04840693|Experimental|Adrenal insufficiency (group 3)|chronic adrenal insufficiency
16276517|NCT04840693|Other|Control (group 4)|without glucocorticoid excess
16276518|NCT04840680||Participants With MM|Participants with MM who are newly prescribed and will start treatment with ixazomib citrate in a real-world clinical practice setting will be observed prospectively for up to 6 years.
16276519|NCT04840667|Experimental|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion Every Other Week (EOW) for 104 weeks.
16276520|NCT04840654|Active Comparator|Caudal block|This group will receive the Caudal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
16276521|NCT04840654|Active Comparator|Pudendal Block|This group will receive the Pudendal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
16276522|NCT04840641|No Intervention|Baseline|The investigators measure the baseline of flucloxacillin and cocktaildrugs.
16276523|NCT04840641|Experimental|Flucloxacillin treatment|The investigators measure the concentration of flucloxacillin after 9 and 27 days and the concentration of cocktaildrugs after 10 and 28 days.
16276524|NCT04840628|Experimental|neural respiratory drive|neural respiratory drive assessed by EMGdi recorded from a multipair esophageal electrode
16276525|NCT04840615|Experimental|1/Intratumoral LMB-100 Administration|Those with pleural or peritoneal mesothelioma receiving intratumoral administration of LMB-100 + ipilimumab in for up to 4 cycles (cycles 1 and 2 include LMB-100 plus ipilimumab; cycles 3 and 4 consist of ipilimumab only)
16276558|NCT04840381||Nonagenarians and Centenarians|Nonagenarians and Centenarians borned and living for most of their life in the Abruzzo region.
16276530|NCT04840576|Placebo Comparator|Conventional Dressing|waterproof sterile dressing OPSITE Post-Op Visible, Smith & Nephew, UK
16276531|NCT04840576|Experimental|Prophylactic negative wound pressure dressing|PICO-7, Smith & Nephew, UK
16276532|NCT04840563|Experimental|Kalifilcon A lenses|Commercially available kalifilcon A lenses (Bausch + Lomb)
16276533|NCT04840563|Active Comparator|Dailies Total1|Dailies Total1 (Alcon)
16276534|NCT04840563|Active Comparator|Precision1|Precision1 (Alcon)
16276535|NCT04840550|Experimental|Tegoprazan 25mg|Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
16276536|NCT04840550|Active Comparator|Lansoprazole 15mg|Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.
16276537|NCT04840537|Active Comparator|cytological brushing followed by cholangioscopy in case of failure|
16276538|NCT04840537|Experimental|cholangioscopy from the start|
16276539|NCT04840524|Other|Conventional preparation design (Chamfer finish line with Butt joint incisal preparation design)|conventional treatment
16276540|NCT04840524|Experimental|New preparation design (Feather edge finish line with feather edge incisal preparation design)|New preparation design
16276541|NCT04840511|Experimental|lidocaine group|The study group receives perioperative lidocaine infusion with general anesthesia for robot-assisted prostatectomy
16276542|NCT04840511|Placebo Comparator|control group|The control group receives normal saline infusion with with general anesthesia for robot-assisted prostatectomy
16276543|NCT04840498||Magic Camp Session #1|Children ages 9-18
16276544|NCT04840498||Magic Camp Session #2|Children ages 9-18
16276545|NCT04840485|Experimental|Treatment group A|
16276546|NCT04840485|Experimental|Treatment group B|
16276547|NCT04840485|Placebo Comparator|Treatment group C|
16276549|NCT04840459|Experimental|BAMLANIVIMAB|The dosage of bamlanivimab in adults and pediatric patients 12 years of age and older weighing at least 40 kg is a single IV infusion of 700 mg bamlanivimab administered over at least 60 minutes
16276550|NCT04840459|Experimental|CASIRIVIMAB + IMDEVIMAB|10 mL of casirivimab and 10 mL of imdevimab from each respective vial using two separate syringes and dilute together in the infusion bag containing 0.9% Sodium Chloride Injection
16276551|NCT04840433|Experimental|MACE|Patients will receive MACE for IDA.
16276552|NCT04840420|Active Comparator|Intervention|"Inpatient
~The WBCs conducts approximately daily visits to:
~collect demographics and baseline data;
~co-develop personalised social prescription plan with the participant based on Social Determinants of Health (SDoH) using SBAR4;
~referring and accompanying the participant to attend inpatient activities that suit the participant's interests and preferences; and
~informing and seeking the participant's agreement with community assets identified for the participant together with CNS.
~About 1-week post-discharge, the WBCs will call to check his/her transition back to community and readiness to start attending community activities or receiving services. For community activities, the WBCs and CNS will visit the participant, accompanying him/her to the activity premise on the first day of the activity session and send the participant home after the session."
16276553|NCT04840420|Other|Control|"Usual Care
~Inpatient phase For the control group, the interviewer will conduct approximately 2 visits to collect demographics and baseline data. The duration of each visit will range from 15 to 30 minutes.
~Community phase For the control group, no intervention will be administered."
16276554|NCT04840407|Experimental|SHARP coach arm|The SHARP Peer Coach supports the direct care HHA and indirectly support the patient/family caregiver to enhance the patient's post-stroke recovery through two main pathways: 1) culturally sensitive, patient-centered reinforcement of rehabilitation regimens (prescribed physical/occupational exercises/training); and 2) early recognition and reporting of barriers to the rehabilitation therapist regarding adherence and recovery, including: a) environmental obstacles, b) family-related issues, c) psychological/clinical barriers (e.g., depression/anxiety).
16276555|NCT04840407|No Intervention|Usual care arm|
16276556|NCT04840394|Experimental|BDB018 in Monotherapy|"A single subject will be enrolled at each dose level in the single agent arm.
~Then dosage escalation will follow a traditional 3+3 dose escalation design.
~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB018 is reached."
16276557|NCT04840394|Experimental|BDB018 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.
~When the MTD or RP2D of single agent BDB018 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, approximately twenty additional subjects will be enrolled in the expansion phase of the study."
16276559|NCT04840368|Experimental|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
16276560|NCT04840368|Active Comparator|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min, and a cool down of 10 min (muscle stretching and relaxation). They will be performed individually, outside, at a self-selected intensity, with no supervision.
16276561|NCT04840355||Subjects with no irAEs|
16276562|NCT04840355||Subjects with degree 1-2 irAEs|
16276563|NCT04840355||Subjects with degree 3-4 irAEs|
16276564|NCT04840342|Experimental|Eplerenone Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
16276565|NCT04840342|Experimental|Amlodipine Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
16276566|NCT04840329|Experimental|Education Arm|
16276567|NCT04840329|No Intervention|Waitlist Control Arm|
16276568|NCT04840316||Post operative|Nil Intervention - observational cohort study
16276569|NCT04840303|Experimental|Hub user group|This group receives community-based mental wellness youth hub services for young people to enhance personal strengths and overall mental well-being.
16276570|NCT04840303|No Intervention|non-hub user active control group|This group does not receive the community-based mental wellness youth hub services but other generic youth services in the community.
16276571|NCT04840303|No Intervention|non-hub user community control group|This group does not receive any youth services in the community.
16276572|NCT04840290|Experimental|Sintilimab Plus Platinum Doublet Chemotherapy|Specified dose on specified days Sintilimab
16276573|NCT04840277|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
16276574|NCT04840277|No Intervention|Control group|Traditional hearing aid adjustment
16276575|NCT04840264|Experimental|3rd Line Therapy|Docetaxel 25mg/m, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m, ivdrip 180 min, D1, D15; 5Fu 1200mg/m, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
16276576|NCT04840264|Experimental|2nd Line Therapy|Docetaxel 25mg/m, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m, ivdrip 180 min, D1, D15; 5Fu 1200mg/m, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
16276577|NCT04840264|Experimental|1st Line Therapy|Docetaxel 25mg/m, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m, ivdrip 180 min, D1, D15; 5Fu 1200mg/m, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
16276578|NCT04840251|Experimental|Intervention|The treatment group will have a physiotherapy well-being review and be referred for rehabilitation. They will be seen after 6 months for follow-up
16276579|NCT04840251|No Intervention|Control|The control group will have initial assessments then receive brief advice on exercise. They will also be followed up after 6 months
16276580|NCT04840251|Other|Qualitative|to understand how it feels to take part in the well-being review, we will interview some participants who have already had this kind of treatment and ask questions about their experiences of it and how it was for them. We are also interested to know what differences they felt it made so that we can help to decide about the things we want to measure as outcomes in the interventional of the study.
16276581|NCT04840238|Experimental|Cholecalciferol|Cholecalciferol 30,000IU weekly orally
16276582|NCT04840238|Placebo Comparator|Placebo|Placebo tablets weekly orally
16276583|NCT04840225||Endocarditis|100 patients diagnosed with infectious endocarditis according to DUKE criteria. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 6 months after discharge.
16276584|NCT04840225||TAVI/TEVAR patietns|30 patients undergoing elektive TAVI/TEVAR procedures. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to procedure and followed undtill 3 months after discharge.
16276585|NCT04840225||Patients with bacterial infections without endocarditis|30 patients diagnosed with with bacterial infections, without endocarditis. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 3 months after discharge.
16276586|NCT04840225||Healthy blood donors|Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to blood donation and approximately 1 week after blood donations
16276610|NCT04840056||Atrophic gastritis|patient with history of histologically proven atrophic gastritis
16276611|NCT04840043|Experimental|Osteopathy Group|Stimulation on the sympathetic truncus and prevertebral ganglia
16276587|NCT04840212|Experimental|Study Group|Patients currently hospitalized in multiple service lines (surgical intensive care unite [SICU], surgical progressive care unit [SPCU], burns, trauma, plastics, general surgery, orthopedics, surgical specialties, and inpatient rehabilitation) will be included. Lavender-Sandalwood scented aromatherapy sticker will be used throughout the patient hospital stay.
16276588|NCT04840212|No Intervention|Control Group|The historical control group will be comprised of hospitalized patients in multiple service lines from the previous year with the same time period, demographic characteristics, service line, and relevant clinical information.
16276589|NCT04840199|Experimental|Arm A: letermovir|Two tablets taken once daily, with or without food for 48 weeks alongside combination ART (antiretroviral therapy); followed by 12 weeks of observation on ART alone.
16276590|NCT04840199|Placebo Comparator|Arm B: placebo|Two tablets taken once daily, with or without food for 48 weeks alongside combination ART; followed by 12 weeks of observation on ART alone.
16276591|NCT04840186|Active Comparator|2nd line chhemotherapy|Patients in this arm will be receiving the standard care which is 2nd line chemotherapy. Type of chemotherapy determined by treating oncologist.
16276592|NCT04840186|Active Comparator|2nd line chemotherapy + resection|Patients in this arm will be treated with liver resection and/or ablation at Oslo University Hospital followed by adjuvant 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist.
16276593|NCT04840173|Experimental|Music at home|Caregivers will use Singing, music listening, or moving with music twice a week for 30 minutes with their care recipient.
16276594|NCT04840160|Placebo Comparator|Placebo|Participants supplied with 30 ml of a low fruit (<1%) cordial mixed with maltodextrin and protein diluted in 100 ml water twice daily, once in the morning and evening.
16276595|NCT04840160|Experimental|Cherry juice|Participants supplied with 30 ml of a tart cherry juice concentrate (CherryActive, United Kingdom; (containing 36.8 mg of anthocyanins) diluted in 100 ml of water twice daily, once in the morning and evening.
16276598|NCT04840134|Experimental|From Hardship to Hope: Financial Wellness Intervention|"From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk
~Over the course of this study, the investigators will develop and pilot a financial wellness intervention to work in tandem with clinical treatment. The intervention will support individuals experiencing financial hardship and suicide risk to address their financial difficulties (e.g., debt, inability to meet basic needs) by coaching them on financial management techniques, facilitating a financial wellness plan, and connecting them with community-based financial supports (e.g., free financial counseling). The intervention will be facilitated by trained peer specialists, who are individuals with lived experience of financial hardship and suicidal ideation or suicidal behaviors who are state certified peer specialists (having met formal training and experience requirements)."
16276599|NCT04840121|Active Comparator|Study Group - AdhesioRT|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the study group will proceed with frozen embryo transfer cycle according window of implantation determined by AdhesioRT.
16276600|NCT04840121|Active Comparator|Control Group - Standard of Care|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the control group will proceed with the first frozen embryo transfer cycle as per standard of care. In the event of unsuccessful implantation (negative serum pregnancy test), participants will proceed with subsequent frozen embryo transfer cycle according to window of implantation determined by AdhesioRT.
16276601|NCT04840108|Experimental|Support Person Coaching Intervention|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail. Support persons in this arm will also complete a one-session coaching intervention (15-25 minutes) delivered virtually by research staff via phone.
16276602|NCT04840108|Active Comparator|Support Person Written Materials|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
16276603|NCT04840095|Experimental|Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
16276604|NCT04840095|Experimental|Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
16276605|NCT04840095|Experimental|Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, we will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while we simultaneously use MRS to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
16276606|NCT04840082|Experimental|Collecting of Clinical Specimens for COVID-19 Testing|Nasopharyngeal swab is performed on all participants to collect specimens for Rapid antigen COVID-19 Testing
16276607|NCT04840069|No Intervention|MRI-guided radiotherapy|Patients will undergo standard of care MRI-guided radiotherapy.
16276608|NCT04840069|Experimental|MRI + Fluciclovine PET-guided radiotherapy|Patients will undergo MRI + Fluciclovine PET-guided radiotherapy
16276609|NCT04840056||Intestinal Metaplasia|patient with history of histologically proven gastric intestinal metaplasia
16276612|NCT04840043|Sham Comparator|Control Group|Stimulation on similar areas with lighter touch and shorter duration
16276613|NCT04840030|No Intervention|Standard health advice (SHA-control)|"The participant will receive verbal information of risk factors and information, reassessment, and written materials regarding approved recommendations on active and healthy aging on topics such as diet, physical activity, cognitive training as well as risk factor control following the state of the art and published guidelines by the Department of Health of the Basque Government/ Basque Country Public Health System (Osakidetza) and the WHO (Guidelines for risk reduction of cognitive decline and Dementia and the Guidance on person-centered assessment and pathways in primary care - ICOPE). Participants in this group will receive the best standard health care from their primary care and specialist health teams according to already established routines as well as usual social services assessments and care as needed."
16276614|NCT04840030|Experimental|Multidomain intervention (MM-Int)|Participants in this group will receive the same verbal and written recommendations as to the ones in the SHA-Control group but then they will perform a 2 year structured program with periodic individual and group visits regarding 1) Risk factor control (vascular factors, polypharmacy); 2) Cognitive training, 3) Physical activity, 4) Dietary changing program and 5) emotional counseling and social engagement.
16276615|NCT04840017|Experimental|Study group I|excessive body weight and flat feet
16276616|NCT04840017|Experimental|Study group II|normal body weight and flat feet
16276617|NCT04840017|No Intervention|Study group III|control, healthy children
16276618|NCT04840004|Other|Aprepitant|One arm study.
16276619|NCT04839991|Experimental|Multi center open label Dose Escalation followed by cohort expansion|
16276620|NCT04839978|Experimental|Preventive Intervention|Students in schools assigned to the preventive intervention study condition will take part in the Connect school-based prevention program and the community-level Communities Mobilizing for Change and Action (CMCA) intervention.
16276621|NCT04839978|No Intervention|Delayed Intervention Control Group|Students in schools assigned to the control group will not receive the Connect and CMCA interventions. Schools in the control group will receive usual school and community prevention and be offered the trial's programs after this three-year study ends.
16276622|NCT04839965|Experimental|IV Ampion|Ampion administered via intravenous infusion
16276623|NCT04839965|Placebo Comparator|IV placebo|Placebo administered via intravenous infusion
16276624|NCT04839952|Experimental|Healthy Lifestyles Intervention Arm|Participants will receive the healthy lifestyles intervention.
16276625|NCT04839952|Active Comparator|Education-Only Control Arm|Participants will receive the education-only intervention.
16276626|NCT04839939|Active Comparator|Control Group|Children in this group received conventional physical therapy program in form of Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training were all part of the treatment plan, which was based on the neurodevelopmental approach.
16276627|NCT04839939|Experimental|AFO Group|Children in this group received the same conventional treatment plus they were provided with solid community-prescribed AFO with a wearing schedule of 6-12 hours per day. Parents were given a detailed demonstration about how to use the AFO probably and watching for areas of skin overpressure. AFO needs to be worn with a smooth, long sock underneath with the child's heel is right down in the AFO with the ankle strap and/or shoe fastened firmly.
16276628|NCT04839939|Experimental|Combination Taping Group|"Children in this group received the same conventional treatment plus the combination taping technique, which was performed by one qualified physical therapist with over five years of experience. The technique started with the application of two 5-cm wide Kinesio tape I straps. The first strap was applied from the lateral condyle of the tibia to the base of the first metatarsal bone with the ankle joint in plantar flexion. The tape was not stretched for 5 cm from the initial site and was then stretched up to 30% for the remaining parts15. The second I strap While the therapist holds the ankle in dorsiflexion, he applied the distal end of the tape 10 cm below the ankle joint. With almost 70% tension, the proximal end is applied 10 cm above the ankle joint. While one hand was holding each end of the tape, the child was asked to move the joint into plantar flexion. Finally, both hands moved towards the middle of the joint to apply the remaining tape."
16276629|NCT04839926|Experimental|0.5mg CY150112|single oral CY150112 while fasting on day 1.
16276630|NCT04839926|Experimental|1.5mg CY150112|single oral CY150112 while fasting on day 1.
16276631|NCT04839926|Experimental|4.5mg CY150112|single oral CY150112 while fasting on day 1.
16276632|NCT04839926|Experimental|10mg CY150112|single oral CY150112 while fasting on day 1.
16276633|NCT04839926|Experimental|18mg CY150112|single oral CY150112 while fasting on day 1.
16276634|NCT04839926|Experimental|24mg CY150112|single oral CY150112 while fasting on day 1.
16276635|NCT04839900|Active Comparator|Proactive iCCM|Community health workers (CHWs) will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. Weekly household visits will be conducted year round. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
16276636|NCT04839900|No Intervention|Standard Passive iCCM|Community health workers (CHWs) will provide case management per national iCCM policy to all who are brought for consultation, but will not conduct household visits to provide active case detection. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
16276637|NCT04839887||Validation study|Three hundred patients with ischemic stroke (18-65 years) will be enrolled for the validation of the Czech version of the the Stroke Impact Scale 3.0. The reliability and validity study will have a cross-sectional design.
16276638|NCT04839887||Prospective quantitative study|Two hundred enrolled IS patients (100 young IS patients < 50 years and 100 IS patients of 50-65 years) will undergo a serial of structured and standardized questionnaires during scheduled outpatients' controls three, six and 12 months after IS. In all enrolled patients, the functional outcome, neuropsychological status and quality of life will be assessed using standardized scales and tools.
16276639|NCT04839887||In-depth interview qualitative study|twenty young IS patients < 50 years will undergo an in-depth, semi-structured interview with explanatory questions that will allow a detailed understanding of the patient's experience. Interpretative phenomenological analysis (IPA) study design will be used.
16276642|NCT04839848||Permanent suture|Mesh fixation with permanent suture
16276643|NCT04839848||Long-term absorbable|Mesh fixation with long-term absorbable suture
16276644|NCT04839848||Short-term absorbable|Mesh fixation with short-term absorbable suture
16276645|NCT04839848||Fibrin glue|Biologic glue/sealant produced from human donor blood
16276646|NCT04839848||Progrip|Pre-fabricated absorbable fixation hooks, integrated in mesh. Progrip is a registered trademark owned by Medtronic
16276647|NCT04839835|No Intervention|standard waiting room|standard chemoterapy waiting room
16276648|NCT04839835|Experimental|waiting room enriched with art objects|waiting room enriched with music, paintings and artificial plants
16276649|NCT04839822|Experimental|Intervention Arm: Psychoeducation with elements of CBT & mood chart.|Patients will receive full access to edupression.com® immediately after inclusion. This intervention includes all medical mechanisms of action of edupression.com®: Psychoeducation with elements of CBT (learning content and exercises) and a mood chart (depression symptom monitoring).
16276650|NCT04839822|Active Comparator|Active control arm: (occupational) interventions and progress monitoring.|These patients will also receive an edupression.com® account with different content. This content will be limited to medically useful tips, that have have not been shown to be effective in improving depressive symptoms in RCTs. Patients of both arms will be instructed to use chat functions to contact study personnel and to fill out questionnaires and tests to collect outcome and additional measures.
16276651|NCT04839809|Experimental|CC-92480-02 (Formulation A) with Placebo|CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.
16276652|NCT04839809|Experimental|CC-92480 (Formulation B)- fasted condition|A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.
16276653|NCT04839809|Experimental|CC-92480-02 (Formulation A) - fasted condition|A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.
16276654|NCT04839809|Experimental|CC-92480 (Formulation B) - Low-fat meal|A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).
16276655|NCT04839809|Experimental|CC-92480-02 (Formulation A) - high-fat meal|A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).
16276656|NCT04839796||Participants residing in urban areas|Urban residents enjoy convenient transportation, have access to abundant medical resources, have more job opportunities, and are on average younger but are also exposed to more air pollution.
16276657|NCT04839796||Participants residing in rural areas|Rural residents have less access to transportation, medical resources, and job prospects comparatively and are comparatively older. However, Rural residents are exposed to less pollution in general.
16276658|NCT04839770|Experimental|Axonpen|Subjects will receive minimally invasive endoscopic surgery using the Axonpen™ system for early hematoma evacuation (within 48 hours post-ictus).
16276659|NCT04839744|Experimental|TG103 produced by the modified manufacturing process|A single dose of TG103 (15mg) produced by the modified manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
16276660|NCT04839744|Active Comparator|TG103 produced by the original manufacturing process original manufacturing process|A single dose of TG103 (15mg) produced by the original manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
16276661|NCT04839731|Placebo Comparator|Placebo group|10 patients will be divided into 7 and 14 day treatment groups with 5 patients each. They will apply Nourivan base cream from Pure Science Rx, twice per day for their designated time.
16276662|NCT04839731|Experimental|7 day medication group|The 7 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 7 days.
16276663|NCT04839731|Experimental|14 day medication group|The 14 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 14 days.
16276664|NCT04839718||Control|Patients receiving referral to specialty mental healthcare
16276665|NCT04839718||ADAPT|ADAPT
16276666|NCT04839705|Other|WEB Aneurysm Embolization Device|WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
16276667|NCT04839692|Other|Young Caucasian females (18-30 years old)|
16276668|NCT04839692|Other|Aged Caucasian females (>60 years old)|
16276669|NCT04839679|Active Comparator|Standard of Care Mayo Clinic booklet|Subjects will receive the standard Mayo Clinic educational booklet in preparation for clinically indicated radiation therapy treatment
16276670|NCT04839679|Experimental|Culturally Oriented Education|Subjects will receive a culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner in addition to the standard Mayo Clinic booklet
16276671|NCT04839666||Propofol|
16276672|NCT04839653|No Intervention|Control group: standard care|Patients in the standard care group will be prospectively evaluated to determine pre-defined clinical outcomes.
16276673|NCT04839653|Experimental|Selective digestive decontamination group|"Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B q6h
~In the NGT 10 ml of suspension containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B and 500 mg of vancomycin q6h
~A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd"
16276674|NCT04839640|Active Comparator|reinforced acrylic resin denture teeth|Shufo acrylic denture teeth
16276675|NCT04839640|Experimental|Composite resin denture teeth|Bredent denture teeth
16276676|NCT04839627||serum progesterone measurement|
16276932|NCT04837612||Subjects with dilated cardiomyopathy|Subjects diagnosed with dilated cardiomyopathy by medical history, physical examination and echocardiography.
16276677|NCT04839614|Experimental|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY|"Upon enrollment in the study at first appointment with gynecologic oncologist, referral to the BWH Center for Metabolic and Bariatric Surgery (CMBS).
~Schedule a series of appointments with a bariatric surgeon, nutritionist and psychologist, which is part of the approval process for weight loss surgery.
~Hysterectomy and weight loss surgery will then be scheduled on the same day within 8 weeks from first visit with the gynecologic oncologist for endometrial cancer or 12 weeks if you have endometrial pre-cancer.
~Series of post-operative visits with the bariatric surgeon and gynecologic oncologic surgeon as well as the nutritionist and psychologist."
16276678|NCT04839601|Experimental|Evaluation Group (stimulation ON)|Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
16276679|NCT04839588||Usability study, healthy volunteers and those with cognitive impairments following chemotherapy|"2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be
~Female Either healthy or breast cancer survivor;
~Age 20 to 65 years;
~Have st least 12 years of formal education;
~Be English speakers;"
16276680|NCT04839575|Active Comparator|Latiglutenase|IMGX003
16276681|NCT04839575|Placebo Comparator|Placebo|Placebo
16276682|NCT04839562|Experimental|solriamfetol|Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
16276683|NCT04839562|Placebo Comparator|placebo|Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
16276684|NCT04839549|Experimental|Dextenza (Intracanalicular ) 0.4mg|Dextenza for the treatment of Ocular Rosacea
16276685|NCT04839549|Active Comparator|Fluoromethalone .01%|Fluoromethalone .1% BID for 2 weeks then once daily for 2 weeks for the treatment of Ocular Rosacea
16276686|NCT04839536|Active Comparator|Target controlled infusion (TCI) propofol|For TCI propofol group, all patients will receive nasal CPAP mask and nasal breathing with oxygen of 3 litre/min. We will utilize the Schneider model to target effect-site (Cet) starting from 0.5 mcg/ml and with a gradual 0.5mcg/ml increment every 30s until OAAS score of 3 is achieved. For any patients with OAAS score < 3, Cet will be decreased by a decremental 0.5 mcg/ml. The deepest level of sedation will be recorded.
16276687|NCT04839536|Experimental|Sevoflurane sedation|Patients randomised to this arm will be given time to familiarise with the nasal continuous positive airway pressure (CPAP) mask and nasal breathing with oxygen 3 litre/min via a Bain anaesthetic circuit before the introduction of sevoflurane. Once the patient starts to adapt to nasal CPAP mask, sevoflurane will be delivered, starting with a concentration of 0.2% and increase stepwise by 0.2% every 30s until sedation score of OAAS of 3 is achieved. Anaesthetist in charge will assess and maintain sedation endpoint to OAAS 3. If patient is over sedated, sevoflurane concentration will be reduced by 0.2% until OAAS 3. The deepest level of sedation will be recorded.
16276688|NCT04839523|Experimental|Exufiber|Treatment with Exufiber gelling fiber dressing
16276689|NCT04839523|Experimental|Exufiber Ag+|Treatment with Exufiber Ag+ silver-coated, gelling fiber dressing
16276690|NCT04839510|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
16276691|NCT04839497|Experimental|Volar Fibroblast Treatment|Volar fibroblasts are injected in the affected area of the residual limb of transtibial amputees to treat skin problems
16276692|NCT04839497|No Intervention|Cryoprotectant|Vehicle Control. Interdermal injection of cryoprotectant
16276693|NCT04839484|Experimental|Lumina|Lumina Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
16276694|NCT04839484|Active Comparator|Restylane Defyne|Restylane Defyne Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
16276695|NCT04839471|Experimental|BI-754091 plus afatinib|BI-754091 plus afatinib
16276696|NCT04839458|Experimental|Dental Prescale II used|
16276697|NCT04839445|Active Comparator|General anesthesia + TAP block|Induction: remifentanil in total intravenous anesthesia (TIVA), Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Transversus abdominis plane (TAP) block: 20 minutes before surgery. Ropivacaine 0.37% 20ml + dexamethasone 2mg per side. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the bispectral index system (BIS) values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and train of four (TOF) monitoring. Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev. Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev.
16276698|NCT04839445|Active Comparator|General anesthesia + ESP block|"Erector spinae plane (ESP) block: 20 minutes before surgery. T8 level bilaterally, ropivacaine 0.37% 20ml + dexamethasone 2mg per side.
~Induction: Remifentanil in TIVA, Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the BIS values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and TOF monitoring.
~Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev.
~Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev."
16276699|NCT04839432||Crystalloids group|Patients had only a balanced crystalloid solution in the priming of the cardiopulmonary bypass (pre interventional group)
16276700|NCT04839432||albumin group|Patients had only a 4% albumin solution in addtion to a very low volume of a balanced crystalloid solution in the priming of the cardiopulmonary bypass (post interventional group)
16276933|NCT04837599|No Intervention|Pentax i 10|Patient gets normal colonoscopy without Endocuff or activation of artifical intelligence
16309215|NCT04612452||Lighthouse Trust in Lilongwe|
16276701|NCT04839406|Experimental|Intervention|"Structured follow up at the ICU
~1-3 days after admittance: Map caregivers' prioritized symptoms, needs and preferences with a digital assessment tool, followed by a meeting with a nurse to address these issues.
~Every 1-2 weeks: Repeat assessment of symptoms and needs with the assessment tool followed by a meeting with a nurse.
~At discharge: Structured conversation focusing on information and preparation for the transition to a regular ward or to another hospital including a card with information and support.
~Bereavement: Individualized support based on caregiver expressed needs, preferences and previous mapping, including a card with information and support.
~Follow up: Caregivers or bereaved will be contacted after 4-6 weeks, and will be offered a follow up conversation either on phone or at the unit."
16276702|NCT04839406|No Intervention|Follow up as usual (Control)|Follow up as usual at the ICU
16276703|NCT04839393|Experimental|Part A - Sequence 1|Treatment A - PF-06882961 single dose followed by Treatment B - PF-06882961 single dose and PF-06865571 single dose
16276704|NCT04839393|Experimental|Part A - Sequence 2|Treatment B - PF-06882961 single dose and PF-06865571 single dose followed by Treatment A - PF-06882961 single dose
16276705|NCT04839393|Experimental|Part B|Period 1: PF-06865571 single dose, Period 2: PF-06882961 twice daily dose titration, Period 3: PF-06865571 single dose and PF-06882961 twice daily dosing, Period 4: PF-06865571 twice daily dosing and PF-06882961 twice daily dosing
16276706|NCT04839380|Experimental|Treatment Group : Ruxolitinib|ruxolitinib cream 1.5% will be applied twice daily as a thin film.
16276707|NCT04839367|Experimental|Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 100 MBq 64Cu-SAR-bisPSMA.
16276708|NCT04839367|Experimental|Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 150 MBq 64Cu-SAR-bisPSMA.
16276709|NCT04839367|Experimental|Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 200 MBq 64Cu-SAR-bisPSMA.
16276712|NCT04839341|Experimental|A Phase I, open-labeled multicenter study|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)
16276713|NCT04839328|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
16276714|NCT04839328|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
16276715|NCT04839315|Other|mRNA COVID19 vaccines|mRNA-based COVID19 vaccines
16276716|NCT04839302||Patients with possible nectrotizing fascitis|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
16276717|NCT04839289|Experimental|A-B-A|"Participants will be fit with hearing instruments A and B in the following order:
~Hearing instrument A Hearing instrument B Hearing instrument A"
16276718|NCT04839289|Experimental|B-A-B|"Participants will be fit with hearing instruments A and B in the following order:
~Hearing instrument B Hearing instrument A Hearing instrument B"
16276719|NCT04839276|Experimental|Injection Laryngoplasty with PRF and Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is added to 4 mL of PRF and is smoothed by pushing it back and forth 15 times on a 2-tube 10 mL piston tube connected to a three-way connector. 3 mL of the mixture of fat and PRF is injected using a 12 G laryngoplasty syringe until medialization is achieved.
16276720|NCT04839276|Active Comparator|Injection Laryngoplasty with Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is mashed by pushing it back and forth 15 times in a container of 2 piston tubes (10 mL) connected to a three-way connector. The crushed fat is injected as much as 3 mL using a 12 G laryngoplasty syringe until medialization is achieved.
16276721|NCT04839263|Active Comparator|"FAST TRACK protocol"|"FAST TRACK protocol Preoperative evaluation and information
~Patient general health state optimization proposal prior to hospitalization:
~Preoperative strategy:
~Hospitalization on surgery day
~No prolonged fasting
~Perioperative strategy:
~Pain control based on limited systemic opioid therapy use
~Anti-nausea prophylaxis
~Anaesthesia via IV propofol / remifentanyl
~Bladder catheter removal postoperative
~Postoperative strategy:
~Pain control using balanced analgesia
~Gum chewing
~Early oral refeeding and rapid mobilization
~Venflon removal 6 hours post-op"
16276722|NCT04839263|No Intervention|"Conventional setting protocol"|"Conventional setting protocol
~Preoperative strategy:
~Hospitalization on surgery day
~Fasting as of midnight prior to the day of surgery
~Perioperative strategy:
~- Balanced anaesthesia via halogens gases
~Postoperative strategy:
~Same day refeeding and mobilization minimum 6 hours post operation
~Bladder catheter and Venflon removal on day 1"
16276723|NCT04839250|Experimental|cataract surgery performed by heads-up method|
16276724|NCT04839250|No Intervention|Traditional surgery|Traditional surgery was performed under a surgical microscope.
16276725|NCT04839237|Experimental|Liraglutide|Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
16276726|NCT04839237|Experimental|Liraglutide combined with metformin|Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.
16276727|NCT04839224|Experimental|Carbogen group|
16276728|NCT04839224|Active Comparator|Phenylephrine group|
16276729|NCT04839211|Experimental|Inspiratory muscle training|High-intensity inspiratory muscle training
16276730|NCT04839211|Sham Comparator|Sham inspiratory muscle training|Unloaded inspiratory muscle training
16276731|NCT04839198|Experimental|Adaptive Treatment plus usual care|
16276732|NCT04839198|Active Comparator|Usual care|
16276734|NCT04839159|Experimental|SCD Patient|
16276934|NCT04837599|Active Comparator|Pentax i 10 with artificial intelligence Discovery TM|Normal Pentax i 10 colonoscope with on the special monitor acitvated artificial intelligence
16309216|NCT04612452||CIDRZ in Lusaka|
16276735|NCT04839146|Experimental|Group 1: 6 microgram ABNCoV2 with/without MF59 adjuvant|In Group 1 (n=6), subjects will receive 6 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276736|NCT04839146|Experimental|Group 2: 12 microgram ABNCoV2 with/without MF59 adjuvant|In Group 2 (n=6), subjects will receive 12 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276737|NCT04839146|Experimental|Group 3: 25 microgram ABNCoV2 with/without MF59 adjuvant|In Group 3 (n=6), subjects will receive 25 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276738|NCT04839146|Experimental|Group 4: 50 microgram ABNCoV2 with/without MF59 adjuvant|In Group 4 (n=6), subjects will receive 50 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276739|NCT04839146|Experimental|Group 5: 70 microgram ABNCoV2 with/without MF59 adjuvant|In Group 5 (n=6), subjects will receive 70 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276740|NCT04839146|Experimental|Group 6: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 6 (n=6) will receive the next lower dosage of the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276741|NCT04839146|Experimental|Group 7: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 7 (n=6) will receive the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
16276742|NCT04839133|Other|Feasibility study group|
16276743|NCT04839120|Active Comparator|MDPK67b|
16276744|NCT04839120|Placebo Comparator|Placebo|
16276745|NCT04839081||RA patients|RA patients diagnosed according to the 1987 ACR Criteria
16276746|NCT04839081||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint other than in hand, lasting more than three months
16276747|NCT04839068||First is retrospective part|: by obtaining the data from the patients records in a period between January 1st 2019 to December 31st 2019, and from May 1st 2020 to December (excluding women conceived before April 1st 2020)
16276748|NCT04839068||Second is prospective part|the same data will be obtained from the patient records in the same way in a period from the January 1st 2021 to the December 31st to assess the pregnancy outcomes in pregnant women who conceived after occurrence of Covid 19 pandemic in Egypt.
16276749|NCT04839055|Experimental|Experimental: Coenzyme A 200U|Coenzyme A 200U per day
16276750|NCT04839055|Placebo Comparator|Placebo Comparator: Placebo|Abiraterone without coenzyme A
16276760|NCT04839029|Experimental|Bipolar En bloc TURBT|patient subjected to bipolar Needlescopic En bloc resection of NMIBC
16276761|NCT04839029|Active Comparator|Monopolar En bloc TURBT|patient subjected to Monopolar Needlescopic En bloc resection of NMIBC
16276762|NCT04839016|Experimental|Treatment group A|
16276763|NCT04839016|Placebo Comparator|Treatment group B|
16276767|NCT04838977|Experimental|RESET|Children will view 8 educational modules online and participate in 8 sessions with a therapist via telehealth.
16276768|NCT04838977|No Intervention|Control|Children will receive usual post-trauma care.
16276769|NCT04838964|Experimental|MRG003|MRG003 will be administrated via IV infusion at 2.0 mg/kg on Day 1 of every 3 weeks (21-day cycle).
16276770|NCT04838951|Experimental|Intervention arm|CADe system will be used during withdrawal phase of colonoscopy.
16276771|NCT04838951|No Intervention|Control arm|Colonoscopy will be performed according to hospital protocol.
16276772|NCT04838925|Experimental|Mobile Neurofeedback|Participants engage in the use of a mobile neurofeedback intervention, which involves using a mobile app paired with an EEG headset, to achieve a calm, relaxed state. Participants will be instructed to use the intervention at a minimum of 10 minutes a day, 4 times a week for a total of 12 weeks.
16276773|NCT04838912|Experimental|Cool Kids ASA|The Cool Kids ASA anxiety program
16276838|NCT04838262|Experimental|Assessment of Daily Stress Processes|Subjects will report cumulative exposure, perceived severity, and emotional responsiveness to commonly occurring everyday psychosocial stressors utilizing an ecological momentary assessment approach for 8 consecutive days.
16276935|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM|Endocuff cap is mounted on the tip of the endoscope a cheap assistance device proven in former studies to increase adenoma detection rate.
16276774|NCT04838899|Experimental|Treatment Arm|All metastases that fulfill the definition of oligoprogression seen on conventional imaging will be treated with standard SABR dose fractionation schemes routinely used at Sunnybrook Odette Cancer Centre. The prostate (if present and not previously treated) will be treated to a dose of 35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Spine metastases will be treated to a dose of 24 Gy in 2-3 fractions or 30-40 Gy in 5 fractions. Involved lymphadenopathy will be treated to a dose of 30-40 Gy in 5 fractions. Similarly, brain, lung, liver, and adrenal metastases will be treated with standard Sunnybrook SABR doses. Patients will remain on abiraterone during and after SABR treatments.
16276775|NCT04838886|Experimental|Exercise group|The intervention group will be received telerehabilitation-based pilates training three times a week for 6 weeks.
16276776|NCT04838886|No Intervention|Waitlist|The control group will be a wait-list group without any additional specific treatment.
16276777|NCT04838873|Active Comparator|Open Radical Cystectomy|Standard open radical cystectomy.
16276778|NCT04838873|Experimental|Laparoscopic-assisted radical cystectomy.|Laparoscopic-assisted radical cystectomy.
16276779|NCT04838860|Active Comparator|Parallel Arm of iMCD Patients|Enrolling in Stage 1a of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
16276780|NCT04838860|Active Comparator|Parallel Arm of TAFRO-iMCD Patients|Enrolling in Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
16276781|NCT04838847|Experimental|Participants / Healthy Participants Aged ≥65 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16276782|NCT04838847|Experimental|Participants / Healthy Participants Aged 18-45 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16276783|NCT04838821|Experimental|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
16276784|NCT04838821|Experimental|Placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
16276785|NCT04838808|Active Comparator|Rivaroxaban|Rivaroxaban 2.5mg oral twice daily for 90-days
16276786|NCT04838808|Placebo Comparator|Placebo|Oral placebo tablet twice daily for 90-days
16276787|NCT04838782|Experimental|Repeat Surgical Resection|Standard surgical operative management according to local practices.
16276788|NCT04838782|Active Comparator|Management Without Re-operation|Non-surgical management with standard care according to local practices.
16276791|NCT04838756|Experimental|Intervention arm|AI-integrated mammography screening
16276792|NCT04838756|Experimental|Control arm|Conventional mammography screening (standard of care)
16276793|NCT04838743||IDegLira|Real-world adult population with type 2 diabetes mellitus in Japan.
16276794|NCT04838730|Experimental|single-arm|Hanita CleaRing device (CE approved; AMAR Certificate)
16276795|NCT04838717|Active Comparator|BPG Arm|BPG injections will be performed at the participating center
16276796|NCT04838717|Experimental|Doxycycline Arm|Dispensing of Doxycycline 100 mg is carried out at one time at V0 - Inclusion visit.
16276797|NCT04838704|Experimental|RUX group|
16276798|NCT04838704|Active Comparator|Control group|
16276799|NCT04838691|Experimental|interpersonal relations counseling applied|8 sessions of interpersonal relations counseling, each lasting 40 minutes, were applied for 2.
16276800|NCT04838691|No Intervention|no application|No action taken.
16276801|NCT04838678|Experimental|Healthy Control|Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
16276802|NCT04838678|Experimental|Hypertensive|Hypertensive adults who are not obese
16276803|NCT04838678|Experimental|Obese|Obese adults who are not hypertensive
16276804|NCT04838678|Experimental|Obese-hypertensive|Obese adults who are being treated for hypertension
16276805|NCT04838665|Active Comparator|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)|20 infants were enrolled in Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)
16276806|NCT04838665|Experimental|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)
16276807|NCT04838665|Experimental|1 instillation of 0.5% tropicamide +0.5% phenylephrine w/a cotton wick placed in the inferior fornix|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick placed in the inferior fornix (SIW)
16276808|NCT04838652|Experimental|Pembrolizumab plus Chemotherapy|All patients will receive 1 dose of 200 mg pembrolizumab IV as single agent upfront, followed by 2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide) and a PET/CT-based restaging. Following a PET-guided treatment strategy, patients will then receive either another 2 cycles of IV P-ICE in case of a negative PET (i.e., Deauville score 1-3), or 2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin) in case of a positive PET (i.e., Deauville score > 3). After completion of treatment with P-ICE or P-DHAP, respectively, patients will receive a consolidation therapy with pembrolizumab for another 6 cycles. In case of non-CR after at least 4 cycles of combination therapy (4x P-ICE or 2x P-ICE + 2x P-DHAP), physicians may decide to go for HDCT or an alternative standard of care treatment option.
16276809|NCT04838639|Experimental|NO-13065, oral tablet|
16276810|NCT04838639|Placebo Comparator|Placebo matched to NO-13065, oral tablet|
16276813|NCT04838587||6750 Children <3 years ( 5 sites)|A total of 6750 children from the will be identified from the respective health facility catchment area during the Census stage of the study. Each of the 5 health facilities will identify 1350 children under 3 years of age in their respective catchment area. During the Surveillance stage, the participants will be enrolled into the study if and when they present with diarrhoea at the Health facility.
16276814|NCT04838548|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
16276815|NCT04838535|Other|PCOS follicular fluid|
16276816|NCT04838522||All Study Participants|Participants with chronic idiopathic constipation who are treated with prucalopride 2 milligrams (mg) oral tablets which was initiated prior to enrollment, and are breastfeeding their infant at the time of enrollment and sample collection will be observed prospectively.
16276817|NCT04838509||Patients with elevated creatine kinase|
16276818|NCT04838496|Experimental|Single-arm study|All patients will receive induction chemotherapy consisting of 4-6 cycles of FOLFOXIRI. Restaging will be performed after 4 cycles with a pelvic MRI and a thoraco-abdominal CT-scan. In case of stable or responsive disease, the remaining 2 cycles of FOLFOXIRI will be provided. In case of progressive, but still resectable disease, chemoradiation will be provided immediately, without the remaining 2 cycles of FOLFOXIRI. Restaging will be performed after chemoradiation. In case of resectable disease, surgery is performed.
16276819|NCT04838483|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.
~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
16276820|NCT04838457|Experimental|ACME-TM|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
16276822|NCT04838405|Experimental|CT-388|SC dose of CT-388
16276823|NCT04838405|Placebo Comparator|Placebo|SC dose of placebo matching CT-388 dose
16276824|NCT04838392|Experimental|CGM System|Blood draw and glucose challenge will be performed to evaluate performance of CGM system compared to reference measurement during in in-clinic visits.
16276825|NCT04838379|Placebo Comparator|group Bupivacaine|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
16276826|NCT04838379|Active Comparator|group bupivacaine&dex|2 will include 30 patients: each one will receive 2.5mg/kg of 0.25% bupivacaine plus 2 µ/kg of dexmedetomidine diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
16276827|NCT04838366|Experimental|Intervention|The study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). We will provide glucose-D.
16276828|NCT04838366|No Intervention|Usual care|The control group will be kept in fasting condition from midnight as a traditional practice in existence.
16276829|NCT04838340|Active Comparator|Standart care|Standart care group will leave in the hospital's usual care and no intervention will be applied.
16276830|NCT04838340|Experimental|Hypnobirthing group|Hypnobirthig training intervention will be applied to the Hypnobirthing group for 4 weeks and 3 hours a week and usual care will be provided by healthcare professionals.
16276831|NCT04838314|No Intervention|Standard of cares|Peri operative analgesia by opioids
16276832|NCT04838314|Experimental|regional analgesia|Peri operative analgesia by continuous bilateral ESP catheters
16276833|NCT04838301|Experimental|Allo group|Allopregnanolone 4mg IV 30-minute infusion once per week for 12 months.
16276834|NCT04838301|Placebo Comparator|Control group|Placebo (normal saline) IV 30-minute infusion once per week for 12 months.
16276835|NCT04838288|Experimental|Change from Prograf to Envarsus|All participants will be switched from Prograf to Envarsus
16276836|NCT04838275|Experimental|Exercise Arm|antifibrotic therapy + mHealth monitoring + 12-wk mHealth home exercise prescription
16276837|NCT04838275|No Intervention|Non-Exercise Arm|antifibrotic therapy + mHealth monitoring
16276839|NCT04838249||Female Control|"n = 20; Inclusion criteria
~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
16276840|NCT04838249||Male Control|"n = 20; Inclusion criteria
~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
16276841|NCT04838249||Female cross-sex hormone therapy|"n = 20; Inclusion criteria
~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²
~Exclusion criteria
~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
16276842|NCT04838249||Male cross-sex hormone therapy|"n = 20; Inclusion criteria
~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²
~Exclusion criteria
~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
16276843|NCT04838236|Experimental|MASP app|200 African American smokers with elevated AS will be enrolled and randomly assigned to either: (1) the smartphone-based National Cancer Institute (NCI) QuitGuide app for standard mobile smoking cessation treatment (2) the MASP smoking cessation app developed by our team targeting sensitivity to interoceptive stress.
16276844|NCT04838236|Other|QuitGuide app|200 African American smokers with elevated AS will be enrolled and randomly assigned to either: (1) the smartphone-based National Cancer Institute (NCI) QuitGuide app for standard mobile smoking cessation treatment (2) the MASP smoking cessation app developed by our team targeting sensitivity to interoceptive stress.
16276845|NCT04838223||Neuropathic Corneal Pain with Ocular Surface Discomfort|Participants diagnosed with neuropathic corneal pain with ocular surface discomfort
16276846|NCT04838223||Neuropathic Corneal Pain with Dry Eye Disease|Participants diagnosed with dry eye disease and neuropathic corneal pain
16276847|NCT04838223||NCP or Dry Eye in patients with ocular surface discomfort|Participants diagnosed with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort
16276848|NCT04838210|Experimental|Group Prenatal Care|Group prenatal care model
16276849|NCT04838210|Active Comparator|Individual Prenatal Care|Individual prenatal care
16276851|NCT04838184||Dental patients|Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible
16276852|NCT04838171||Specimen collection to support development of engineering Treg|
16276853|NCT04838158|Active Comparator|Intervention group|Those cases who underwent operative treatment and isokinetics evaluation.
16276854|NCT04838158|Other|Control group|Those who were control group of healthy subjects to compare to normative data
16276855|NCT04838145|Active Comparator|Active treatment|Pleconaril: 5 mg/kg x2 times a day for 26 weeks up to 40 kg. Max dose 300mg x2. Ribavirin:15 (7.5) mg/kg/day divided in two doses daily for 26 weeks: Max dose 1000mg/24h if body weight<75kg and 1200mg if body weight>75kg.
16276856|NCT04838145|Placebo Comparator|Placebo|Receives placebo, on a double blind basis
16276857|NCT04838132|Experimental|Transversus thoracis muscle plane and rectus sheath block with ropivacaine|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.3% ropivacaine respectively.
16276858|NCT04838132|Experimental|Transversus thoracis muscle plane and rectus sheath puncture with saline|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.9% saline respectively.
16276859|NCT04838119||Patients with a preoperative asymptomatic COVID screening test|
16276862|NCT04838093||Patient cohort:|all patients with vascular disorders consecutively admitted at our tertiary care hospital from March 16 to December 07, 2020
16276863|NCT04838093||Control cohort:|data of two nationwide PCR-based studies conducted in a representative random sample, from April 1-6, and November 12-14, 2020, collected by the Austrian Ministry of Science and the Austrian Red Cross to estimate the spread of SARS-CoV-2 infection among the non-hospitalized Austrian population.
16276864|NCT04838093||HCP cohort:|HCP worker data, including nurses, nurse technicians, physicians, surgical personal, physical therapists, nurse practitioners, environmental service workers, administrative staff, and dietitians, working in close proximity to admitted patients at our tertiary care hospital from March 16 to December 07, 2020.
16276865|NCT04838080|Experimental|Low dose vaccine|Inactivated COVID-19 Vaccine 4 µg/0.5 ml
16276866|NCT04838080|Experimental|High Dose Vaccine|Inactivated COVID-19 Vaccine 6 µg/0.5 ml
16276867|NCT04838080|Placebo Comparator|Placebo|0.9 % NaCl
16276868|NCT04838067|Experimental|Cefaly Intervention|Cefaly
16276869|NCT04838054|Experimental|Test - stabilized chlorine dioxide rinse|Subjects will receive CloSYS Ultra Sensitive Rinse
16276870|NCT04838054|Placebo Comparator|Control - oral rinse, no active ingredients|Subjects will receive oral rinse - no active ingredients
16276871|NCT04838041|Experimental|Combination Therapy and Remission Phase|All eligible patients will begin a combination of asciminib plus imatinib cycle 1 day 1 in the combination treatment phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their imatinib and be monitored off treatment.
16276872|NCT04838028||StdPPM|Standard pure polypropylene mesh
16276873|NCT04838028||LWM|Lightweight mesh
16276874|NCT04838028||Tacks, metal|Metal staples or tacks
16276875|NCT04838028||Tacks, absorbable|Absorbable synthetic staples or tacks
16276876|NCT04838028||Fibrin glue|Biologic glue/sealant produced from human donor blood
16276877|NCT04838028||Non-fixation|Mesh is deployed without fixation
16276878|NCT04838002|Active Comparator|Focus ESWT|
16276879|NCT04838002|Active Comparator|Radial ESWT|
16276880|NCT04838002|Sham Comparator|Sham ESWT|
16276881|NCT04837989|Experimental|Diabetes Body Project|Participants randomized to the experimental condition will receive virtual Diabetes Body Project groups immediately.
16276882|NCT04837989|Active Comparator|Educational|Participants randomized to the control condition will receive an education brochure and will be offered the Diabetes Body Project after 6 months.
16276883|NCT04837976||Individuals with Parkinson's Disease|
16276884|NCT04837976||Supportive individuals|For example carers, family members or any other individual providing regular support or care to the person with Parkinson's.
16276885|NCT04837976||Healthcare Professionals|
16276886|NCT04837950|Experimental|Before pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview before pulling diaphragmatic suture
16276887|NCT04837950|Experimental|After pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview after pulling diaphragmatic suture
16276888|NCT04837937|Experimental|Condition 1|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case
16276889|NCT04837937|Experimental|Condition 2|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Insurance' conflict negotiation/dispute resolution case
16276890|NCT04837937|Experimental|Condition 3|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution case
16276891|NCT04837937|Experimental|Condition 4|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution case; (3) 'Caregiver vs. Insurance' conflict negotiation/dispute resolution case
16276892|NCT04837937|Experimental|Condition 5|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution case
16276893|NCT04837937|Experimental|Condition 6|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution case; (3) 'Caregiver vs. Insurance' conflict negotiation/dispute resolution case
16276894|NCT04837937|Experimental|Condition 7|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution case; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution case
16276895|NCT04837937|Experimental|Condition 8|(1) 'Caregiver vs. Patient' conflict negotiation/dispute resolution case; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution case; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution case; (4) 'Caregiver vs. Insurance' conflict negotiation/dispute resolution case
16276896|NCT04837924|Experimental|B (FICB)|Participants receiving fascia iliaca compartment block (FICB)
16276897|NCT04837924|Sham Comparator|A (PLACEBO)|Participants receiving sham injection matching fascia iliaca compartment block (FICB)
16276898|NCT04837911|Other|Patients using the Spirobank Smart|Use of a portable spirometry
16276899|NCT04837898|Active Comparator|haskap berry|A commercially available haskap berry powder
16276900|NCT04837898|Placebo Comparator|Placebo|Black cherry KoolAid (Kraft Foods, USA) with added maltodextrin to match carbohydrate and calorie content
16276901|NCT04837885|Experimental|68Ga-DOTA-peptides PET/CT|68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
16276902|NCT04837885|Experimental|LUTATHERA® by intra-arterial hepatic injection (IAH)|One treatment dose of LUTATHERA® by intra-arterial hepatic injection after conventional treatment by 4 intravenous administrations
16276903|NCT04837872|Experimental|Multimodal Physical Therapy (MPT)|The multimodal physical therapy (MPT) program consisted of manual therapy, therapeutic exercise, and utilization of a static progressive splint (Joint Active Systems SPS Knee, Effingham, IL). Although the primary focus of this study was on improving knee flexion ROM, two protocols were developed: one to improve flexion deficits and one to improve extension deficits. Participants in the MPT group received physical therapy 2x per week for 4 weeks. They were instructed to use the static progressive splint(s) 3x per day for 30 minute sessions (90 minutes total per day) for each splint (e.g., 90 minutes for flexion splint, 90 minutes for extension splint).
16276931|NCT04837625||Myasthenic Crisis Cohort|
16276904|NCT04837859|Experimental|Arm A age 18-60|Patients at the age of 18-60 years at enrollment will receive 2 initial doses of 200 mg tislelizumab in 21-day intervals followed by an interim positron emission tomography (PET-2). Following a PET-guided approach, patients with a negative PET-2 (i.e. Deauville score 1-3) according to central review will continue receiving tislelizumab for another 4 doses of 300 mg in 28-day intervals. Patients with a positive PET-2 (i.e. Deauville score >3) will receive 4 cycles of combined 300 mg tislelizumab on day 1 and AVD chemotherapy on day 1 and 15 in 28-day cycles (4x T-AVD). For all patients, 30 Gy involved-site radiotherapy (IS-RT) will only be applied in case of PET positivity after completion of (chemo-) immunotherapy.
16276905|NCT04837859|Experimental|Arm B Age 60+|Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.
16276906|NCT04837846||Prospective CCTA Arm|
16276907|NCT04837833|Experimental|research ultrasound (rUS1)|Participants will undergo research ultrasound (rUS1) within two days of their routine contrast enhanced CT scan (CECT). A subset of participants will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT.
16276908|NCT04837820|Experimental|Acupuncture|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
16276909|NCT04837820|Placebo Comparator|Sham Acupuncture (SA)|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
16276910|NCT04837820|Experimental|Wait-List Control|During the 26-week waiting period, the CRC will contact patients in the WLC group at the same frequency as the acupuncture groups with respect to data collection. Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians. WLC patients will be compensated with real acupuncture treatments after Week 26 (end of study).
16276911|NCT04837807|Experimental|Unit Dose|Subjects randomized to this group will apply the unit-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
16276912|NCT04837807|Experimental|Multi Dose|Subjects randomized to this group will apply multi-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
16276913|NCT04837781|Experimental|Normal vitamin D|Include patients with normal vitamin D level (above 30ng/ml). Vitamin D level will be measured at the beginning of treatment if there is deficiency then the patient refer to specialized physician to be supplied with vitamin D supplement to optimized the level to normal then start orthodontic treatment
16276914|NCT04837781|Experimental|Vitamin D deficiency|Include patients with unknown vitamin D level until time of canine retraction where we measure level if deficiency exist (below 30ng/ml) then the patient will be referred to specialized physician to be supplied with vitamin D supplement.
16276915|NCT04837781|Experimental|Control|includes patients with unknown vitamin D level until the completion of canine retraction where we measure level. If deficiency exists (below 30ng/ml) then we will refer the patient to specialized physician to be supplied with vitamin D supplement
16276916|NCT04837768|Active Comparator|Serum Progesterone Levels >9.2 ng/ml|These patients will receive only twice-daily vaginal progesterone supplementation following embryo transfer
16276917|NCT04837768|Active Comparator|Serum Progesterone Levels <9.2 ng/ml|These patients will receive twice-weekly intramuscular progesterone supplementation in addition to the twice-daily vaginal supplementation following embryo transfer
16276918|NCT04837742|Experimental|ESPB group|ESPB injection at T8 region with levobupivacaine 100mg (20 ml)+ Iohexol 10 ml
16276919|NCT04837742|Sham Comparator|Control group|ESPB injection at T8 region with 0.9% normal saline 20ml + Iohexol 10ml
16276920|NCT04837729|Experimental|Experimental (acupressure) group|Acupressure (complementary and integrative medicine method) Acupressure will be applied individually to the experimental group for 20-25 minutes three times a week for four weeks. Data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
16276921|NCT04837729|No Intervention|Control group|No intervention will be made to women in the control group. However, data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
16276922|NCT04837716|Experimental|Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)|"INDUCTION THERAPY: Patients receive ensartinib PO QD on days 1-21, carboplatin IV over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
16276923|NCT04837690||UEMR|
16276924|NCT04837677|Experimental|PRT1419|PRT1419 will be administered by intravenous infusion
16276925|NCT04837664|Experimental|Rose Bengal-mediated Photodynamic therapy|Participants belonging to the rose bengal mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer rose bengal was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
16276926|NCT04837664|Experimental|Curcumin-mediated photodynamic therapy|Participants belonging to the curcumin mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer curcumin was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
16276927|NCT04837664|Active Comparator|Nystatin therapy|Participants belonging to the Nystatin group were administered the topical nystatin-based antifungal drug.
16276928|NCT04837651||Ocrelizumab Treated Multiple Sclerosis Patients|
16276929|NCT04837651||Natalizumab Treated Multiple Sclerosis Patients|
16276930|NCT04837638||Adults with HeFH|Adult men and women aged 18 to 65 years with genetically-defined HeFH.
16276936|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM and artificial intelligence Discovery TM|Endocuff cap is mounted on the tip of the endoscope and artificial intelligence is activated on the monitor. hypothesis is that probably artificial intelligence and Endocuff combined potentiate their effect.
16276937|NCT04837586|Active Comparator|Standard Care|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic
16276938|NCT04837586|Active Comparator|Simple Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a simple scale.
16276939|NCT04837586|Active Comparator|EHR-Connected Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a Smart scale that is connected to the Electronic Health Record (EHR).
16276940|NCT04837573|Experimental|Group 1 Intervention, Weeks 1-8|During Weeks 1-8, Group 1 receives the Intervention and Group 2 receives no treatment.
16276941|NCT04837573|Active Comparator|Group 2 Intervention, Weeks 9-16|During Weeks 9-16, Group 2 receives the Intervention and Group 1 receives no treatment.
16276942|NCT04837560|Experimental|Temporarily or permanently wheelchair users which suffer from Venous Edema|Temporarily or permanently wheelchair users which suffer from Venous Edema
16276943|NCT04837547|Experimental|Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:
~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg
~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
16276944|NCT04837547|Experimental|Arm 2: Relapsed/Refractory Neuroblastoma (NB)|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:
~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg
~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
16276945|NCT04837534|Experimental|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
16276946|NCT04837534|Experimental|SMS and phone call reminder group:|In this group after the children have been examined, treatment plan and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol
16276947|NCT04837534|No Intervention|Routine standard care group|In this group, the children will undergo ocular examination, and treatment plan. They will be discharged from the department and advised accordingly including a routine follow-up schedule as per hospital protocol.
16276948|NCT04837521|Experimental|Therapist Delivered Unified Protocol|This is a five session psychotherapy designed to help people with problems such as anxiety and depression.
16276949|NCT04837521|Experimental|Self-Guided Unified Protocol|This is a five session treatment that patients can complete independently.
16276950|NCT04837508|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
16276951|NCT04837495|Active Comparator|Stellate Ganglion block group|will include 20 patients: each one will receive 10 ml lidocaine 2% right stellate ganglion block (RSGB) under sonar guidance
16276952|NCT04837495|No Intervention|Control group|will include 20 patients: a control group
16276953|NCT04837482|Experimental|AGN-190584 Sequence 1|AGN-190584 Sequence 1 (Participants will receive AGN-190584 from Visit 2 through Visit 3 followed by Vehicle from Visit 4 through Visit 5).
16276954|NCT04837482|Experimental|AGN-190584 Sequence 2|AGN-190584 Sequence 2 (Participants will receive Vehicle from Visit 2 through Visit 3 followed by AGN-190584 from Visit 4 through Visit 5).
16276955|NCT04837469|Experimental|Universal Adhesive|universal adhesive
16276956|NCT04837469|Experimental|Etch-And-Rinse Adhesive|Etch-And-Rinse Adhesive
16276957|NCT04837456|Experimental|Calorie restricted diet and excecise intervention|a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement [36]. Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%[36].Each session was approximately 150 minutes one week for six months and consisted of aerobic exercises, resistance training, and exercises to improve flexibility and balance.
16276958|NCT04837456|Experimental|libitum diet and waiting list control group|participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
16276959|NCT04837456|Experimental|Early APM group|Early APM group participants received APM with syndrome within 3 to 6 months
16276960|NCT04837456|Experimental|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
16276961|NCT04837443|Experimental|Synchronous working group|
16276962|NCT04837443|Sham Comparator|Asynchronous working group|
16276963|NCT04837417||Pathologic group|At least 10 male participants who underwent anterior cruciate ligament arthroscopic reconstruction using semitendinosus and gracilis tendons graft, between 6 and 18 months before the tests
16276964|NCT04837404|Other|ultrasound guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.
16276965|NCT04837404|Other|fluoroscopy guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.
16276966|NCT04837391||Urologic oncology surgery in elderly|Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years
16283894|NCT04789057|Experimental|Statins|Atorvastatin 40 mg treatment, p.o., QD
16276967|NCT04837378|Experimental|Abdominal Massage Group|Abdominal massage process stage; After the preliminary test data were obtained, the hands were warmed and creamed with vaseline, abdominal massage was applied to the patient in the supine position for 15 minutes. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
16276968|NCT04837378|Experimental|In-bed Exercise Group|In-bed exercise process phase; After the pre-test data were obtained, the patient was applied passive in-bed exercises for approximately 15 minutes in all extremities in the supine position. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
16276969|NCT04837378|No Intervention|Control Group|Control group stage; Gastrointestinal complications and comfort parameters were recorded in this group at the same time as the experimental groups without any intervention.
16276972|NCT04837352||Multiple sclerosis patients|Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study
16276973|NCT04837339|Other|Patients with lung disease requiring transplantation or who have undergone lung transplantation|There is no intervention to be administered.
16276974|NCT04837326|Experimental|Heel Lance Blood Sampling in Facilitated Tucking Position|The infants were put in facilitated tucking position by an experienced newborn nurse. They were put in facilitated tucking position so that their arms and legs were in a flexed midline position close to their trunk in a side-lying position. They were positioned so that they could move their extremities freely. They were held in facilitated tucking position for 120 seconds before the procedure. They were kept in facilitated tucking position until the blood sample was taken from the right heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
16276975|NCT04837326|Experimental|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|The mother, whose privacy was protected, embraced the infant for 120 seconds before the procedure. The infant was embraced by the mother during the heel lance blood sampling from the left heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
16276976|NCT04837326|Experimental|Heel Lance Blood Sampling Using White Noise|The 'Don't Let Your Baby Cry, PT.2' track from the 'Colic' album by Orhan Osman using the 'The Happiest Baby' album by Dr. Harvery Karp which was composed only of intrauterine was made listened to the infants via Xperia Ultra Mp3 Player for 120 seconds before and 120 seconds after the heel lance blood sampling procedure. While white noise was made listened to the infants before, during and after the procedure, Digital Sound LeverMeter brand noise measurement device was put at a distance of 50 cm from the infant and the ambient noise level was adjusted as 55 dB. The blood samples were taken by the researcher after inserting the lancet in the first try.
16276977|NCT04837326|No Intervention|Control Group|Suitable environmental conditions (ambient temperature, silent environment, etc.) were ensured in the study room for the infant's comfort. A saturation probe was inserted to the right wrist of the infant to monitor him/her. A video record was taken for 120 seconds without any intervention to the infants before and after the heel lance blood sampling procedure. The blood samples were taken by the researcher after inserting the lancet in the first try. Heel lance was performed in clinical routine for preterm infants in the control group.
16276978|NCT04837313|Experimental|Parkinson's Disease with Constipation|Fecal microbiota transplantation will be performed.
16276979|NCT04837300|Experimental|Experimental-1|Resisted Sprint Training
16276980|NCT04837300|Experimental|Experimental-2|Plyometric Training
16276981|NCT04837300|No Intervention|Control|No Training
16276982|NCT04837287|Active Comparator|Static Stretching Exercise for 10 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
16276983|NCT04837287|Active Comparator|Static Stretching Exercise for 30 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
16276984|NCT04837274|Placebo Comparator|Placebo|Dextrose (480 mg)
16276985|NCT04837274|Experimental|Active|Tart Cherry (480 mg)
16276986|NCT04837248|Active Comparator|Group 1. Conventional treatment|Patients will be treated with a physiotherapy programme without digital support.
16276987|NCT04837248|Experimental|Group 2. Experimental treatment.|Patients will be treated using a digitally supported physiotherapy programme.
16276991|NCT04837222||Participants with CD30-positive Lymphoma|All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
16276992|NCT04837209|Experimental|Niraparib + Dostarlimab + Radiation therapy|"Study cycle length is 3 weeks. Participants will receive:
~Niraparib 1x daily during each study cycle
~Dostarlimab 1x every 3 weeks for 4 study cycles, then 1x every 6 weeks beginning on Cycle 5
~Radiation therapy will be given on Days 1, 2, and 3 of Cycle 1."
16283895|NCT04789057|Placebo Comparator|Placebo|Placebo tablet, p.o., QD
16276997|NCT04837170|Experimental|S (+)-Ketamine group|"Drug: Conventional therapy + S (+)-Ketamine In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection,but the recommended dosage is given, which is lower than the dosage specified in the instructions.
~Recommended use and dosage of S (+)-Ketamine:
~Bolus intravenous injection before skin incision, the dose is 0.1~0.5 mg/kg;
~Bolus intravenous injection (dose 0.1~0.5 mg/kg) before skin incision +continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation;
~Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h."
16276998|NCT04837170|Active Comparator|Control group|Drug: Conventional therapy Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
16276999|NCT04837157|Experimental|Intervention Group|9 treatment sessions will be performed with the ATLAS2030 exoskeleton. The rehabilitation sessions last approximately 90 minutes. Two sessions are scheduled per week, for two weeks.
16277000|NCT04837144|Experimental|Intervention Group|The Intervention Group will receive 9 physical rehabilitation sessions using the MAK device. Each session will consist of approximately 90 minutes.
16277001|NCT04837131|Experimental|Ixazomib in patients with scleroderma-interstitial lung disease (ILD)|Participants will be administered oral ixazomib for six cycles (each cycle is 28 days duration).
16277002|NCT04837118|Experimental|Supportive care (resistance training)|SEE DETAILED DESCRIPTION.
16277003|NCT04837105|Active Comparator|Control group|"Classic rehab (physio including strength rehab, fitness, motor activity...) + treadmill gait training 3*/week/4weeks:
~5 minutes of warm-up with gradual increase in treadmill speed, max 20 minutes of walking at 80% of maximum speed, 5 minutes of active recovery with gradual decrease in treadmill speed.
~(protocol from Grecco et al.)"
16277004|NCT04837105|Experimental|Test group|"Classic rehab - same as control group - (physio including strength rehab, fitness, motor activity...) + overground ARROW CP gait training 3*/week/4weeks:
~walking sprint session at maximal speed with gradual increase in number of repetitions over the weeks.
~(protocol from Verschuren et al.)"
16277005|NCT04837092|Experimental|FR104 Treatment|
16277006|NCT04837053|Experimental|Intervention cluster|EKIT tool
16277007|NCT04837053|Active Comparator|Control Cluster|routine care
16277008|NCT04837040|Experimental|Paltusotine|
16277009|NCT04837040|Placebo Comparator|Placebo|
16277010|NCT04837027|Experimental|Aerobic training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
16277011|NCT04837027|Active Comparator|Balance training|Balance Training A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance
16277012|NCT04837014|Experimental|Acetaminophen and naproxen only arm|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
16277013|NCT04837014|Active Comparator|Acetaminophen, naproxen and dilaudid arm|Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
16277016|NCT04836988||Digitally delivered osteoarthritis treatment|Participants enrolled in the digitally delivered osteoarthritis managament program (Joint Academy register)
16277017|NCT04836988||Face-to-face delivered osteoarthritis treatment|Participants enrolled in the face-to-face delivered osteoarthritis managament program (BOA-register)
16277018|NCT04836975||SCLC|Patient Diagnosed with Small Cell Lung Cancer- (extensive or limited)
16277019|NCT04836975||NSCLC|Patient diagnosed with primary stage III Non-Small cell lung Cancer
16277020|NCT04836962|Placebo Comparator|control|normal saline is administrated to patients.
16277021|NCT04836962|Experimental|dexamethasone|0.5mg/kg dexamethasone is administered to patients.
16277022|NCT04836949|Experimental|Shear Wave Elastography Group|
16277023|NCT04836949|Active Comparator|Conventional ultrasonography Group|
16277024|NCT04836936|Placebo Comparator|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using an empty cryopuncture device without nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
16277025|NCT04836936|Active Comparator|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using a cryopuncture device with nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
16278096|NCT04829656||Clinical Cohort|Enrolled via the 5 participating clinics at LBDA Research Centers of Excellence.
16277026|NCT04836923|Experimental|LIFT subgroup|PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
16277027|NCT04836923|Experimental|LIFT + REAP subgroup|"PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. We will also employ Realistic Effort Action Planning (REAP), a form of personality-informed motivational interviewing in a subset of patients to potentially enhance patient engagement and adherence to the home-exercise prescription."
16277028|NCT04836910||Study Group: Women with Polycystic Ovary Syndrome|Woen diagnosed with Polycystic Ovary Syndrome according to the Rotterdam Criteria (requires 2 out of 3 symptoms: 1. Hyperandrogenism or excess levels of androgen. 2. Oligo or anovulation. 3. Polycystic ovaries on ultrasound - over 12 follicles, 2-9 mm or increased ovarian volume),who haven't started any treatment
16277029|NCT04836910||Cohort Group: Women without Polycystic Ovary Syndrome|
16277030|NCT04836897|Experimental|Treatment|Transcatheter aortic valve replacement
16277031|NCT04836884|Experimental|Vascular anomaly/malformation biopsy|Subjects with a vascular anomaly will have a research percutaneous vascular anomaly/malformation biopsy completed at the time of the clinically indicated percutaneous sclerotherapy, embolization and/or ablation.
16277032|NCT04836871|Experimental|Double filtration plasmapheresis (DFPP) combined with chemotherapy|
16277033|NCT04836858|Experimental|CMK389 high dose|Active
16277034|NCT04836858|Placebo Comparator|Placebo high dose|Placebo
16277035|NCT04836858|Experimental|CMK389 low dose|Active
16277036|NCT04836858|Placebo Comparator|Placebo low dose|Placebo
16277037|NCT04836845|Active Comparator|Focus extracorporeal shock wave therapy|
16277038|NCT04836845|Active Comparator|Radial extracorporeal shock wave therapy|
16277039|NCT04836845|Sham Comparator|Sham extracorporeal shock wave therapy|
16277041|NCT04836819|Active Comparator|Group L|IV lidocaine infusion (1-2 mg/kg/h) up to postoperative 12 hours.
16277042|NCT04836819|Active Comparator|Group K|IV ketamine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
16277043|NCT04836819|Active Comparator|Group D|IV dexmedetomidine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
16277044|NCT04836806|Experimental|cetirizine and famotidine|Participants testing positive for COVID-19 who are randomized to take cetirizine and famotidine for 10 days.
16277045|NCT04836806|Placebo Comparator|Placebo|Participants testing positive for COVID-19 who are randomized to take a placebo to match cetirizine and famotidine for 10 days.
16277046|NCT04836793||Patients with cancer|"Patients with active treatment in adjuvant/induction setting,
~Patients with active treatment in metastatic/relapse setting,
~Patients without active treatment (last treatment above 6 months)."
16277047|NCT04836793||Patients without cancer but aged above 70 years|
16277048|NCT04836793||Healthy person|
16277049|NCT04836780|Experimental|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
16277050|NCT04836780|Active Comparator|Standard of care|Standard care therapy
16277051|NCT04836767||people with a history of COVID-19|"COVID-19 Group Inclusion Criteria
~Having been diagnosed with COVID-19 at least 12 weeks ago,
~Being literate,
~Being in the age range of 18-65,
~Volunteering to participate in research,
~To be clinically stable, to be under control if any accompanying comorbid conditions (such as hypertension, diabetes),
~Not having any orthopedic and neurological problems that might interfere with evaluating peripheral muscle strength, balance and exercise capacity.
~COVID-19 Group Exclusion Criteria
~Those with an ICU hospitalization history due to the diagnosis of COVID-19,
~Recent myocardial infarction and pulmonary embolism.
~Having accompanying chronic diseases,
~Those who have any orthopedic or neurological disorders that will prevent walking,
~Another COVID-19 PCR Test positivity in the last 12 weeks,
~Not being able to cooperate and adapt to exercise test due to neurological influences such as cerebrovascular disease or psychiatric disorders,"
16277052|NCT04836767||healthy people|"Healthy Group Inclusion Criteria
~Not having COVID-19,
~Being literate,
~Being in the age range of 18-65,
~Volunteering to participate in research. The Criteria for Not Including the Healthy Group in the Study
~Those who have any orthopedic or neuromuscular disorders that will prevent walking,
~Having any chronic illness or psychiatric conditions or mental afflictions that may interfere with cooperation or compliance with exercise tests."
16277053|NCT04836754||Case group|Pregnant women with Covid-19
16277054|NCT04836754||Control groups|Pregnant women who do not have Covid-19
16277055|NCT04836741|Experimental|Micro Hand S robot-assisted surgery|This group is consisted of 40 cases performed using the Micro Hand S robot by one single surgeon for rectal cancer
16277056|NCT04836741|Active Comparator|Laparoscopic surgery|This group is consisted of 65 cases performed using the laparoscope by one single surgeon for rectal cancer
16277057|NCT04836728|Experimental|arm 1|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.
16277058|NCT04836728|Active Comparator|arm 2|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2;
16277059|NCT04836715||Parkinson's Disease|Individuals with idiopathic Parkinson's Disease and no other neurological disease
16277060|NCT04836715||Other Neurological Disorders|Individuals with one neurological disorder other than Parkinson's Disease (e.g. Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Parkinsonism)
16277061|NCT04836715||Healthy|Individuals without any neurological disorder
16277062|NCT04836702||Left ventricular function|"Depressed LV function
~LV ejection fraction < 50%
~LV systolic function; defined as mild / mod / sev decreased
~LV diastolic function; defined as mild (g1 ) / mod (g2) / sev ( g3) decreased
~Normal LV function"
16277063|NCT04836702||Right ventricular function|"Depressed RV function
~a. RV systolic function defined as mild / mod / sev decreased
~Normal RV function"
16278097|NCT04829656||Virtual Cohort|Enrolled via the LBDA.
16277064|NCT04836702||Valvular lesions|"Moderate or severe valvular lesions
~Aortic stenosis
~Aortic regurgitation
~Mitral stenosis
~Mitral regurgitation
~Tricuspid regurgitation
~Clinically normal valvular lesions
~No valvular lesion
~Mild stenosis / regurgitation of above mentioned lesions"
16277065|NCT04836689|Other|30 breaths per minutes|Using NIPPV with rate of 30 for 1 hour. Measuring trans cutaneous CO2
16277066|NCT04836689|Other|10 breaths per minute|Using NIPPV with rate of 10 for 1 hour. Measuring trans cutaneous CO2
16277067|NCT04836676|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid Cath or C-REX RectoAid Cath.
16277068|NCT04836663|Experimental|TQ-B3525 tablet|
16277069|NCT04836650|Placebo Comparator|Flat Insole (no metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles.
16277070|NCT04836650|Experimental|Flat Insole (with 2 millimeters metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles with a 2 millimeters polyester resin metatarsal bar.
16277071|NCT04836637|Placebo Comparator|Product with placebo (no calcium supplementation).|Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.
16277072|NCT04836637|Active Comparator|Product with calcium-carbonate|800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.
16277073|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac"|800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.
16277074|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac and Inulin"|800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.
16277075|NCT04836624|Experimental|Co-designing personalised aids of daily living|Participants will be involved in up to 6 interactive sessions spread over 3 months with the researcher. Participants will work with the researcher to help develop their own assistive device to overcome challenges of daily living they experience.
16277076|NCT04836611|Other|regular cannabis consumer patients|
16277077|NCT04836598|Active Comparator|Multiport laparoscopic cholecystectomy|controlled group
16277078|NCT04836598|Active Comparator|Bikini line laparoscopic cholecystectomy|bikini line 2 ports
16277079|NCT04836585|No Intervention|Care As Usual|Participants in the control condition are followed by their RLS psychiatrists during the study as per usual care.
16277080|NCT04836585|Experimental|eMBC Intervention|Participants in the intervention arm are followed by their RLS psychiatrists during the study at clinically appropriate intervals with the addition of eMBC.
16277081|NCT04836572|Other|Wear Period|
16277084|NCT04836546|Experimental|Self monitoring of blood glucose, then CGM System|All participants will first manage their diabetes with SMBG for 6 months followed by managing their diabetes with Eversense CGM system for the next 6 months
16277085|NCT04836533|Experimental|Computerized Cognitive Training|Those assigned to the computerized cognitive training arm prior to antidepressant trial enrollment will receive computerized cognitive training that includes games that scale in difficulty.
16277086|NCT04836533|Active Comparator|Solitaire Training|Those assigned to the solitaire training arm prior to antidepressant trial enrollment will receive computerized solitaire games.
16277087|NCT04836533|Experimental|Open-label antidepressant treatment|Those assigned to receive open-label antidepressant treatment will begin with 10 mg of escitalopram. If the participant cannot tolerate or has an adverse reaction to escitalopram, duloxetine will be offered instead.
16277088|NCT04836533|Placebo Comparator|Placebo-controlled antidepressant treatment|Those assigned to the placebo-controlled group will be told that they have a 50/50 chance of receiving either escitalopram or placebo.
16277089|NCT04836520|Experimental|SHR6390+anatrozole|Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.
16277090|NCT04836507|Experimental|CRC01|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.
16277091|NCT04836494|Experimental|BBP-671 for SAD|The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
16277092|NCT04836494|Placebo Comparator|Placebo for SAD|The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
16277093|NCT04836494|Experimental|BBP-671 for MAD|The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
16277094|NCT04836494|Placebo Comparator|Placebo for MAD|The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
16277095|NCT04836494|Experimental|BBP-671 for SAD Food Effect|Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.
16277096|NCT04836494|Experimental|BBP-671 for PA and MMA Patients|Up to eight (8) PA patients and eight (8) MMA patients will receive BBP-671.
16277097|NCT04836481||LEV8|Levetiracetam 1000 mg every 8 hours
16277098|NCT04836481||LEV12|Levetiracetam 1000 mg every 12 hours
16277099|NCT04836468||Experimental group|Application of Magnetic Tape transversely over the vertebral levels of L4 and L5
16277100|NCT04836468||Placebo group|Application of kinesiology tape transversely over the vertebral levels of L4 and L5
16277101|NCT04836455|Experimental|The Real Cost vaping prevention ads - Health effects theme|
16277102|NCT04836455|Experimental|The Real Cost vaping prevention ads - Addiction theme|
16277103|NCT04836455|Other|Neutral vaping ads|
16278295|NCT04828278|Active Comparator|Treatment 2|1,500 mg of ASI (bonded arginine silicate) + 100 mg of inositol (nooLVL)
16277104|NCT04836442|Experimental|Alcohol-PTSD-PFI (AP-PFI)|Hazardous drinkers with at least subclinical PTSD and elevated AS (N=100) recruited from the community will be randomly assigned to receive Alcohol-PTSD-PFI (AP-PFI) or an attention information control condition (C-PFI).
16277105|NCT04836442|Other|Attention Information control condition (C-PFI).|Hazardous drinkers with at least subclinical PTSD and elevated AS (N=100) recruited from the community will be randomly assigned to receive Alcohol-PTSD-PFI (AP-PFI) or an attention information control condition (C-PFI).
16277106|NCT04836429|Experimental|Treatment (porfimer sodium, photodynamic therapy)|Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy
16277107|NCT04836416||Young Adult/Normal|Age 18-35, BMI 18.5-24.9
16277108|NCT04836416||Young Adult/Overweight and Obese|Age18-35, BMI greater than 25.0
16277109|NCT04836416||Adult/Normal|Age 36-50, BMI 18.5-24.9
16277110|NCT04836416||Adult/Overweight and Obese|Age 36-50, BMI greater than 25.0
16277111|NCT04836416||Older Adult/Nornal|Age 51-65, BMI 18.5-24.9
16277112|NCT04836416||Older Adult/Overweight and Obese|Age 51-65, BMI greater than 25.0
16277113|NCT04836403||Rhinosinusitis without treatment group|children aged 2 and 12 years with rhinosinusitis not receiving treatment
16277114|NCT04836403||Rhinosinusitis with treatment group|children aged 2 and 12 years with rhinosinusitis receiving treatment
16277115|NCT04836403||healthy volunteers|children aged 2 and 12 years without rhinosinusitis
16277117|NCT04836377||Subjects with Gaucher 1 Disease|This is a long-term follow-up study of subjects who previously received AVR-RD-02 (single dose administration) in the GuardOne (AVRO-RD-02-201) parent study. No investigational product will be administered in this study.
16277118|NCT04836364||Pediatric Cohort|Parents of children ages 2 to 15 years old will provide data using the APICHS.
16277119|NCT04836351|Experimental|Concentrated rehabilitation|3+ 1-2 day concentrated rehabilitation for patients with persistent symptoms post COVID-19.
16277120|NCT04836338||Participants|Anesthesia and emergency medicine providers who perform pediatric orotracheal intubations
16277121|NCT04836325|Experimental|Experimental: transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of Transcranial Static Magnetic Field Stimulation (tSMS) in the primary motor cortex with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
16277122|NCT04836325|Sham Comparator|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
16277123|NCT04836312|No Intervention|Attention Control|Patients will be instructed via text message and email to fast at least 16 hours per day every day. For the next 18 weeks, they will receive a daily text message via the Way to Health platform asking if they fasted for at least 16 hours over the past 24 hours. If they fail to respond, reminder text messages will be sent. Once per week, they will receive a text message asking them to weigh themselves and check their blood pressure, and reply with the results via text message
16277124|NCT04836312|Experimental|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
16277125|NCT04836299|Experimental|Ivermectin|Participants will receive a single 600 µg / kg dose of ivermectin.
16277126|NCT04836299|Placebo Comparator|Placebo Comparator|Participants will receive a single dose of placebo.
16277127|NCT04836286|Experimental|single group repeated design|The Emotive Intelligent Spaces (EIS) leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
16277128|NCT04836273|Experimental|120 µg dasiglucagon|Subcutaneous 120 µg dasiglucagon self-administration
16277129|NCT04836273|Placebo Comparator|Placebo|Subcutaneous placebo self-administration
16277132|NCT04836234|Experimental|intervention group|Participants will receive Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum. They will be instructed to chew the gum for pain relief after the separator and initial arch wire placement if required. Chew the gums for 10-12 minutes and as much as they want whenever they feel discomfort or pain. They are free to take any medication when necessary and respond to the questionnaires on the amount of chewing gum and analgesics used.
16277133|NCT04836234|No Intervention|Control group|Participants will not receive any prescription after the separators and initial arch wires placement. They will be specifically asked not to chew chewing gum. As in the intervention group, they can take any medication when they feel necessary and respond to the questionnaires on the amount of analgesics used.
16277134|NCT04836221|Experimental|Intervention|Will receive mHealth support for comorbidity and support from a Community Health Worker by phone
16277135|NCT04836195|Experimental|PCLX-001 intervention|"The Dose-Escalation phase will follow a standard 3+3 cohort design. Three patients will be treated at each dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level. Escalation will terminate as soon as two or more patients experience any DLT attributable to study drugs, at a given dose level.
~Oral PCLX-001 will be provided as continuous daily dosing on a 28-day cycle. The starting dose of PCLX-001 will be 20 mg daily Expansion Cohort Once the MTD has been defined, preliminary activity will be further evaluated in the expansion part of the study. The RP2D may be the MTD but not necessarily as not only safety data will be taken into account prior to its determination."
16277136|NCT04836182|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRX by subcutaneous injection once-weekly
16277137|NCT04836182|Placebo Comparator|Placebo|Matching placebo by subcutaneous injection once-weekly
16277138|NCT04836169|Experimental|InCaveo EOA System|InCaveo EOA System (including integrated CBT but without tapering) group
16277139|NCT04836169|No Intervention|Control Group-usual care with pill bottles|UCPB group-usual care with pill bottles
16277140|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for triple negative early breast cancer|Patients with triple negative subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
16277141|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for luminal like early breast cancer|Patients with luminal like subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
16277142|NCT04836130|Active Comparator|(ZMC) Fractures reduction Using Patient Specific Guide (PSG)|
16277143|NCT04836130|Active Comparator|(ZMC) Fractures reduction Using Conventional Technique|
16277144|NCT04836117|Experimental|Informed|"Blood draw for SomaSignal Test and laboratory assessments at baseline, and 6 months (±30 days); SomaSignal Test results to be sent to investigators as available. Review and discussion of results with the participant from baseline and 6 months within 30 days (2-4 weeks to get SomaSignal results) after blood draw. Initiation of changes in medical management as soon as test results are known and discussed with patient.
~Patients will have a blood draw performed at baseline and 6 months for lipid panel, hemoglobin A1C, CBC, and BMP."
16277145|NCT04836117|No Intervention|Uninformed|"Blood draw for SomaSignal Test at baseline and 6 months (+30 days). However, results will not be provided to clinician and participant until study conclusion. Patients contacted within 30 days (2-4 weeks) after baseline and 6-month visits to discuss treatment strategy (nothing, add/ remove medication, etc.) made at visit. Patients will have a blood draw performed at baseline and for lipid panel, hemoglobin A1C, CBC, and BMP
~SomaSignal Test results to be sent to investigators AFTER study conclusion. Patients will be provided with SomaSignal Test results after the 6 month post-test timepoint."
16277146|NCT04836091|Experimental|Immediate intervention|From baseline to 2-month post-test, participants in the intervention arm will have access to the OurPlan program app.
16277147|NCT04836091|Experimental|Waitlist-delayed intervention|Participants in this study arm will not have access to the OurPlan program in the app from baseline to day 30 (month 1) of the trial. From day 31 to day 60, participants in this study arm will be given access to the OurPlan program in the app.
16277148|NCT04836078|Placebo Comparator|Plain chitosan gel group|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement . Randomization will be performed and concealment from the assessors. For root conditioning purpose, Group (I) ; will be injected subgingivally with chitosan 2% gel .
16277149|NCT04836078|Active Comparator|Chitosan gels containing free Simvastatin|Will be injected subgingivally with simvastatin microsponges dispersed into chitosan 2% gel. .
16277150|NCT04836078|Experimental|Chitosan gels containing Simvastatin microsponges|This group will be injected subgingivally with free simvastatin dispersed into chitosan 2% gel containing .
16277151|NCT04836052|Experimental|omega-3-oil arm|patients admitted to ICU in HMC on any kind of oxygen support will get omega-3-oil 2 gm PO/NGT/OGT twice daily for 28 days or till ICU discharge or till death .
16277152|NCT04836052|No Intervention|standard of care arm ( no omega -3-oil )|patients admitted to ICU in HMC on any kind of oxygen support will get ( standard of care= No Omega-3-oil ) but their labs will be monitored
16277153|NCT04836039||Physiotherapists|Individuals between the ages of 22-65 who continue to work as a self-employed or employee physiotherapist.
16277154|NCT04836026||HF20™ for Pediatric CRRT|Pediatric patients in an intensive care unit requiring CRRT for acute kidney injury (AKI)
16277155|NCT04836013|Experimental|Probiotic group|Lactobacillus reuteri LMG P-27481 and Lactobacillus rhamnosus GG (ATCC 53103), sucralose and isomalt as an oral stick formulation of 1,6 g with a concentration of probiotic of 2x100bilion colony forming unit (CFU) per stick.
16277156|NCT04836013|Placebo Comparator|Placebo group|The placebo will contain 1.6 g per stick of sucralose and isomalt
16277157|NCT04836000|Placebo Comparator|Placebo Group|In addition to the conservative treatment of the control group, low-level laser therapy (turned off) will be applied for 12 weeks. In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions.
16277158|NCT04836000|Experimental|Experimental Group|In addition to the conservative treatment of the control group, low-level laser therapy will be applied for 12 weeks.
16277159|NCT04836000|Active Comparator|Control Group|For 12 weeks, all three groups will receive five sessions per week of a protocolised treatment based on therapeutic exercises, analgesic electrotherapy and cryotherapy.
16277160|NCT04835974|Experimental|diabetic patients with reflow phenomenon|All Assiut University heart Hospital patients ,and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their intervention procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis.
16277161|NCT04835948||Multiple doses of anti-thymocyte globulin (ATG)|Control group that received fractionated doses of 1.5 mg/kg adding up to a total of 6 mg/kg
16277162|NCT04835935||subject who developed atopic disease|
16277163|NCT04835935||subject who did not develop atopic disease|
16277201|NCT04835688|Sham Comparator|Sham-treatment|Sham-treatment. Manipulation of the tympanic membrane to simulate ventilation tube insertion without performing a ventilation tube insertion.
16277202|NCT04835675||Cancer Arm|Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected
16277164|NCT04835922|Experimental|Intercostal Nerve Block|• In Group I (ICBN group): Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine at the termination of PCNL under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each).
16277165|NCT04835922|Active Comparator|Peritract infiltration|In Group P (PTI): Single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given on completion of PCNL by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position). Then the surgical wound and intervention site will be covered with an occlusive dressing.
16277166|NCT04835909|Experimental|Behavioral: modern board and card games|Participants will play modern board and card games in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
16277167|NCT04835909|Active Comparator|Behavioral: paper and pencil tasks|Participants will do cognitive paper and pencil tasks in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
16277168|NCT04835909|No Intervention|Wait-list|Participants will be in a wait-list over a period of 16 weeks. Then, they received the board and card games' or paper and pencil tasks' intervention.
16277169|NCT04835896|Experimental|Study treatment|
16277170|NCT04835883|Experimental|Assigned interventions|Subjects enrolled into the CS20AT04 with corticosteroid taper regimen arm will receive two infusions of CS20AT04 (2.0×10^6cell/kg), on 0 day and on 12 weeks post-enrollment.
16277171|NCT04835870|Experimental|R-CHOP + Zanubrutinib|Zanubrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
16277172|NCT04835857||Experimental-Arm|"For the same subject,
~ViTrack wrist cuff is applied on one of the wrist
~Standard Oscillometric cuff is applied to the brachial artery / wrist of the same arm
~Auscultatory cuff is applied to the brachial artery of the same arm"
16277173|NCT04835844||Mapping with CARTO|CARTO (Biosense Webster) in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
16277174|NCT04835844||Mapping with RHYTHMIA|RHYTHMIA (Boston Scientific) in conjunction with the 64-electrodes ORION mini-basket catheter.
16277175|NCT04835831|Experimental|adapted physical activity + Dietetic advice|
16277176|NCT04835831|No Intervention|Dietetic advice only|
16277177|NCT04835818|Experimental|Reporting|check point-of-care Multiplex PCR for pneumonia pathogens and report results to primary care physician
16277178|NCT04835818|No Intervention|Usual Care|check point-of-care Multiplex PCR for pneumonia pathogens but do NOT report results to primary care physician. Let primary care physician provide usual standard care
16277179|NCT04835805|Experimental|Belvarafenib Monotherapy|Twice daily (BID), continuous dosing.
16277180|NCT04835805|Experimental|Belvarafenib Plus cobimetinib|Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.
16277181|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib Plus Atezolizumab|Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus atezolizumab IV infusion every 4 weeks (Q4W) followed by an expansion phase
16277182|NCT04835792||Previously Treated for Lyme Disease|
16277183|NCT04835792||Healthy Volunteers|
16277184|NCT04835779||SFN Patients|Patients with diagnosed Small Fibre Neuropathy
16277185|NCT04835779||Patients undergoing chemotherapy|Patients undergoing chemotherapy and are expected to develop SFN as a result
16277186|NCT04835779||Healthy Volunteer|Healthy test person
16277187|NCT04835766||Symptomatic group|These patients had bladder injury during PAS surgery and had Lower urinary tract symptoms
16277188|NCT04835766||Asymptomatic group|These patients had bladder injury during PAS surgery and had no Lower urinary tract symptoms
16277189|NCT04835753|Experimental|study group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training plus shock wave on the muscle belly of the planter flexor hypertonic muscles.
16277190|NCT04835753|Other|control group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training .these traditional therapy had been approved by previous studies its effectiveness in management cerebral palsy child
16277191|NCT04835740|Active Comparator|Conventional Rehabilitation|Based on the functional capacity of each participant, customized Aerobic exercise plan was designed by the on-site physiotherapist.
16277192|NCT04835740|Experimental|Combined Training (conventional rehabilitation plus high-intensity interval training):|The patients received 40 minutes of High intensity interval treadmill training in addition to their normal conventional rehabilitation.
16277193|NCT04835727|Experimental|Semi-vegetarian diet|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
16277194|NCT04835714|Experimental|Part A with Monotherapy dose escalation|
16277195|NCT04835714|Experimental|Part B with Combination therapy dose escalation|
16277196|NCT04835714|Experimental|Part C with Combination therapy dose confirmation|
16277197|NCT04835714|Experimental|Part D with Combination therapy dose expansion|
16277198|NCT04835701|Experimental|Music Intervention group|Subjects randomized to the music group will choose 10 songs, which will be played during the procedure, from the time of positioning through completion of IUD insertion and speculum removal. Participants will otherwise undergo standard protocol for IUD insertion in an outpatient clinic setting. Total participation is predicted to last approximately 30 minutes.
16277199|NCT04835701|No Intervention|Control group|Participants to undergo same standard protocol for IUD insertion in an outpatient clinic setting. No music will be played during the procedure.
16277200|NCT04835688|Experimental|Ventilation tube insertion|Ventilation tube insertion into the tympanic membrane.
16309217|NCT04612439|Experimental|VABB Elite 10G|Vacuum-assisted Elite 10G
16277203|NCT04835675||Benign Diseases Arm|Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected
16277204|NCT04835662|Other|Complementary feeding promotion|Intervention
16277205|NCT04835649|Experimental|Exercise group|The group that will receive task-oriented training via telerehabilitation
16277206|NCT04835649|Placebo Comparator|Control group|The control group only will be given a home program that includes walking and balance exercises
16277207|NCT04835623|Experimental|Cyclosporine|Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks
16277208|NCT04835610||PVI values|PVI values measured at the finger and forehead areas in pediatric patients
16277209|NCT04835610||no control group|no control group
16277210|NCT04835597||Observational (movement assessment, medical data collection)|Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
16277211|NCT04835584|Experimental|Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.
16277212|NCT04835584|Experimental|Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
16277213|NCT04835584|Experimental|Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.
16277214|NCT04835584|Experimental|Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
16277215|NCT04835571|Experimental|CARMA study participants|All patients in the study are in the same treatment arm: all were treated for 12 months according to routine care and international guidelines for cardiovascular disease prevention in patients with very high cardiovascular risk. Through study physicians patients received an individual assessment and optimized cardiovascular risk management, including life style advice and adjustments in their medical preventive treatment, based on drugs used in standard care (eg. lipid lowering medication, anti-hypertensive-treatment, anti-thrombotic treatment). All treatment goals were set in accordance with current guidelines at the time for study participation.
16277216|NCT04835558||Group I|Subjects with obesity hypoventilation sydrome (30 < body mass index < 40 kg/m2)
16277217|NCT04835558||Group II|Subjects with obesity hypoventilation sydrome (body mass index > 40 kg/m2)
16277218|NCT04835558||Control Group|Age and sex-matched obese subjects (30 < body mass index < 40 kg/m2) with low risk of obstructive sleep apnea (STOP-BANG score < 3)
16277219|NCT04835545|Experimental|Wet Perlite, 2L air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with 2L air pocket
16277220|NCT04835545|Experimental|Wet Perlite 2L air pocket with resistance compensation|Breathing in the simulated avalanche snow. Breathing into model of wet perlite 2L air pocket with resistance compensation
16277221|NCT04835545|Experimental|Wet Perlite, no air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with no air pocket
16277222|NCT04835532|Experimental|Control group|"Vertical alveolar bone augmentation was performed by GBR technique before implantation.
~BIO-OSS+ BIO-GIDE barrier membrane"
16277223|NCT04835532|Experimental|Treatment group 1|"Vertical alveolar bone augmentation was performed by GBR technique and tenting screws before implantation.
~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws"
16277224|NCT04835532|Experimental|Treatment group 2|"Vertical alveolar bone augmentation was performed by GBR technique in combination with tenting screws and A-PRF, I-PRF before implantation.
~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws+A-PRF, I-PRF"
16277225|NCT04835519|Experimental|chimeric antigen receptor T cell treatment|
16277226|NCT04835506|Experimental|iDose-infliximab dosing|infliximab dosing based on the iDose dashboard
16277227|NCT04835506|Active Comparator|SOC infliximab dosing|infliximab dosing based on standard-of-care
16277228|NCT04835493|Experimental|Intervention|Intervention individuals will receive the 12-month diabetes TIME program
16277229|NCT04835493|Other|Enhanced Usual Care (EUC)|We will define EUC as usual clinical care, which consists of diabetes management provider encounters (mean quarterly) plus monthly individual appointments with a pharm-Ds or nutritionists as clinically indicated. In addition, clinics offer multiple other individual and group opportunities. In addition for the EUC arm, we will provide three quarterly, 1-hour classes (nutrition medications, exercise). The classes will be led by a research-staff trained, bilingual healthcare professional e.g., nurse. EUC individuals will not have contact with CHWs.
16277230|NCT04835480|Experimental|OsrHSA Group|OsrHSA (10g or 20g), IV, qd
16277231|NCT04835480|Active Comparator|HSA Group1|HSA (10g or 20g), IV, qd
16277232|NCT04835467|Experimental|Intracoronary imaging|Intracoronary imaging during PCI
16277233|NCT04835454||control group|The control group consisted of healthy men with no cancer and no chronic diseases. They will be age-matched with patient group and recruited among men subjected to the routine periodic medical examination.
16277234|NCT04835454||Prostate cancer group|Patients who are confirmed to have prostate cancer based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue with no other coexisting cancers or prostate cancer treatment
16277235|NCT04835454||benign prostatic hyperplasia group|Patients who are confirmed to have benign prostatic hyperplasia based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue
16277238|NCT04835428|Experimental|Treatment with AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
16277239|NCT04835428|Active Comparator|Treatment with PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
16277240|NCT04835415|Active Comparator|group T|Group (T) (n=41): will receive ultrasound guided thoracic epidural analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
16277241|NCT04835415|Active Comparator|group R|Group (R) (n=41): will receive bilateral ultrasound guided retrolaminar block analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
16277242|NCT04835402|Experimental|Intervention|Day 1: Pembrolizumab 400mg Day 10: Irreversible electroporation Day 42/84/126/168: Pembrolizumab 400mg
16277243|NCT04835389|Experimental|AlloGen Liquid|A single-dose, intra-articular (IA) injection of 2.0 mL of AlloGen Liquid administered to the affected knee.
16277244|NCT04835389|Placebo Comparator|Saline|A single-dose, intra-articular (IA) injection of 2.0 mL of saline administered to the affected knee.
16277245|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 1|The standard percussor palm cups are made out of a soft vinyl material molded into shape. The outer diameter of the infant palm cup is 1-3/4 inches and there is a 1-inch diameter pocket inside this product similar to a suction cup.
16277246|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 2|This product was developed by MMRI personnel using a small custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
16277247|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 3|This product was developed by MMRI personnel using a large custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
16277248|NCT04835363|No Intervention|Control group|Usual care.
16277249|NCT04835363|Experimental|OT intervention.|Patients and their caregivers assigned to the experimental group are included in an early occupational therapy intervention program.
16277250|NCT04835350|No Intervention|Hybrid closed loop group|Patients using AID system Pancreas4ALL in mode hybrid closed loop.
16277251|NCT04835350|Experimental|Closed loop meal announcment|Patients using AID system Pancreas4ALL in mode meal announcment. They only announce what amout of carbs going to eat. They calculate no bolus
16277252|NCT04835350|Experimental|Full closed loop|Patients using AID system Pancreas4ALL in mode full closed loop. They eating with no permission and they do not calculate and sending bolus anymore.
16277253|NCT04835337|Experimental|Air purifier|Participants in this group receive an intervention of real air purifiers placed in the indoor environment.
16277254|NCT04835337|Sham Comparator|Control|Participants in this group receive an intervention of sham air purifiers, we just remove the filter in the purifiers, and the other treatments are the same as the real purification group.
16277255|NCT04835298||Myotonic dystrophy type 1|adult patients with myotonic dystrophy type 1
16277258|NCT04835259|Active Comparator|Group 1(treatment group)|"Topical application of a cream of a combination of antioxidants once daily at night for 6 months Name: Selenium ACE cream (Interpharma UK company, Egypt)
~Ingredients:
~Selenium (Selenium amino acid chelate) 0.5% Vitamin C (Sodium ascorbyl phosphate - stay C) %1 Vitamin E (Tocopheryl acetate) % 0.5 Vitamin A (Retinyl palmitate) %1 Emulsifiers ( Ceteareth 20 , Glycerol monostearate , Cetyl alcohol) Emollient(Caprylic capric triglycerides)"
16277259|NCT04835259|Active Comparator|Group 2 (positive control)|Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)
16277260|NCT04835259|Placebo Comparator|Group 3 (Negative control)|Topical application of a panthenol cream once daily at night for 6 months (panthenol 2% cream, El Nile company, Egypt)
16277261|NCT04835246|Experimental|Spectra IMDx|"The physician will be asked to give a diagnosis of the lesion under White light endoscopy (WLE) firstly and the endoscopic diagnosis result will be recorded on case report form. Then the physician will introduce the probe of Spectra IMDx system to contact and assess the lesion. The Spectra IMDx system will detect the scattering light signal from the lesion and assess the risk of the lesion being high-grade intraepithelial neoplasia or gastric cancer, and display the result on the Spectra IMDx screen. The Spectra IMDx assessment will be recorded on case report form. Both the patient and doctor will be blinded from the results from Spectra IMDx system.
~After Spectra IMDx system examination, the physician takes biopsy sample(s) in suspected lesion for further histopathological diagnosis."
16277262|NCT04835233|Experimental|methyldopa|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
16277263|NCT04835233|Active Comparator|captopril|postpartum exchange methyldopa for captopril 25 mg 01 tablet every 8 hours, doubling the dose depending on pressure levels, up to 15 days postpartum
16277264|NCT04835220|No Intervention|Control Group|Electronic pill bottle cap (MEMs bottle cap) with no Telehealth calls
16283925|NCT04788810|Experimental|Oral route|Volunteers receiving d12-Cl2BPA via oral route
16277265|NCT04835220|Other|Telehealth intervention group|Electronic pill bottle cap (MEMs bottle cap) with regular telehealth visits to the veterans at the VAMCs on the stewardship program. These visits will involve contacting the veterans by telephone, administering a questionnaire to review their medication-taking behavior for oral chemotherapy, and potentially contacting the treating oncologist in the event that the veterans are at risk of non-adherence (based on their responses).
16277266|NCT04835194||Lean/Elderly/Multimorbid (anticipated)|Lean/Elderly/Multimorbid phenotype of HFpEF patients with concurrent DM, HTN (anticipated from a multicentered HFpEF study in Vietnam: https://www.hindawi.com/journals/crp/2021/4587678/)
16277267|NCT04835194||Congestive/Metabolic (anticipated)|Congestive/Metabolic phenotype of HFpEF patients with concurrent DM, HTN (anticipated from a multicentered HFpEF study in Vietnam: https://www.hindawi.com/journals/crp/2021/4587678/)
16277268|NCT04835181|Experimental|Electroacupuncture combined with umbilical moxibustion|
16277269|NCT04835181|Active Comparator|Electroacupuncture|
16277270|NCT04835168|Experimental|BT-11 500mg|Oral
16277271|NCT04835168|Experimental|BT-11 1000mg|Oral
16277272|NCT04835168|Placebo Comparator|BT-11 Placebo|Oral
16277273|NCT04835155|Experimental|experimental group|The researcher applied Premature Infant Oral Motor Intervention to the experimental group for 5 minutes per day for 14 consecutive days, 15-20 minutes before a sheduled feeding at either the 09:00 or 12:00 feeding. On the first day, the baseline sucking capacity of babies in experimental group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials. Growth measures were collected on the 1st and 14th days and the day of disharge.
16277274|NCT04835155|No Intervention|control grup|The researcher did not apply any intervention. On the first day, the baseline sucking capacity of babies in control group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials.
16277275|NCT04835142|Experimental|Double blind control period|"experiment arm： All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.
~control arm: All eligible subjects will receive Erbitux in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks."
16277276|NCT04835142|Experimental|Open single period|All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.
16277277|NCT04835129|Experimental|Safety Run-in|Six subjects will be enrolled. Isatuximab (10 mg/kg) intravenous (IV) on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) by mouth (PO) days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
16277278|NCT04835129|Experimental|Expansion|"Forty-seven subjects with relapsed and/or refractory multiple myeloma will be enrolled.
~Isatuximab (10 mg/kg) IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) PO days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle."
16277279|NCT04835116|Other|Local Anesthesia|Group A patients received peri tract local anaesthesia infiltration with 0.25% Bupivacaine.
16277280|NCT04835116|Other|Intravenous Analgesics|Group B patients received postoperative intravenous analgesia.
16277281|NCT04835103|Other|Set a case management model for somatoform patients|Somatoform patients receiving case management, single group assignment, open label
16277282|NCT04835103|Other|Time-limited psychotherapy for somatoform patients|Somatoform patients receiving psychotherapy (based on cognitive-behavioral therapy and biofeedback therapy) vs treatment as usual, open label, non-randomized
16277283|NCT04835077|Experimental|Structured Aerobic Exercises|"Following the training on aerobic exercise content and effectiveness;
~First Week; participants 5 minutes warm-up, 20 minutes of aerobic exercise with 60-70% of maximum heart rate, and 5 minutes of cool down.
~In the following weeks, the aerobic exercise duration of all participants will be increased by 5 minutes compared to the previous week.
~The duration of the sessions in the 7th and 8th weeks will progressively progress to 40 minutes and the intensity to 75-80% of the maximum heart rate."
16277284|NCT04835077|Experimental|Postural Stabilization Exercises|"Exercises; It will consist of postural exercises to be done in prone, supine, side lying, crawling, sitting and standing positions. All exercises will be done in 2 sets per day, the number of repetitions will be determined individually and progressed.
~Breathing exercises
~Four-way stretching and strengthening of the neck muscles
~Shoulder girdle stretching and strengthening exercises
~Hip flexors, hamstring, itb, lumbar extensor stretching and strengthening
~Lying down exercises in the crawling position
~Shuttle movement
~Plank movement
~Toe taps
~Bridging
~Straight leg lift
~Straight leg raises in side-lying
~Prone knee flexion"
16277285|NCT04835077|No Intervention|Control|The individuals without any treatment will continue their normal lives and will be included in the study as a control group. Exercise will be given after 8 weeks.
16277286|NCT04835064|Experimental|Nab-paclitaxel and Gemcitabine|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15;Gemcitabine 1000 mg/m2 was given intravenously for more than 30min on days 1, 8, and 15, and repeated every 4 weeks.
16277287|NCT04835064|Experimental|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
16277288|NCT04835051|Other|Breastfeeding promotion|The breastfeeding promotion intervention included training for health workers, interpersonal communication (in person and digital) between providers and pregnant/breastfeeding women, and mass media.
16277289|NCT04835051|No Intervention|Comparison|
16277290|NCT04835038|Experimental|Sodium Bicarbonate Ringer's Injection group|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
16277291|NCT04835038|Active Comparator|Sodium Lactated Ringer's Injection group|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
16277335|NCT04834765|Active Comparator|Mindfulness based Art Therapy|Participants will engage in both mindfulness activities and art therapy twice per week and will learn techniques through the use of yoga, mediation, breathwork and art.
16277336|NCT04834765|No Intervention|Control Group|Participants will go about daily life as usual.
16277292|NCT04835025||Control group (radiotherapy group)|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesion (without limitation of dose and treatment method for radiotherapy) , but not receiving immunotherapy. Those patients would enter the control group. After patients experiencing disease progression(PD) in this group, follow-up treatment does not include immunotherapy until tumor progression again or death.
16277293|NCT04835012||Treatment|"Subjects in this treatment group had their medical debt forgiven by a non-profit charity, RIP Medical Debt. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
16277294|NCT04835012||Control|"No intervention was given to subjects in this control group. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
16277295|NCT04834986|Experimental|Tislelizumab combined with Lenvatinib|
16277296|NCT04834973|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2 given in combination with three weekly 200 mg intravenous doses of pembrolizumab.
16277297|NCT04834960|Other|MOV Intervention|Pre-intervention and post-intervention design
16277298|NCT04834947||Prone position in non-intubated COVID19 , before and after.|Patients with non-intubated COVID19 pneumoniae for whom the clinician has decided to try prone positioning to increase the PaO2 in a context of hypoxemia with O2 requirement.
16277299|NCT04834934||COVID-19 first wave patients|1700 patients retrospectively enrolled in 15 Italian hospitals from 16/2/2020 to 29/4/2020.
16277300|NCT04834934||COVID-19 second wave patients|300 patients prospectively enrolled in IRCCS San Raffaele Hospital from 19/10/2020 to 31/12/2020.
16277301|NCT04834921|Experimental|MCO-CVVHD|CVVHD with MCO filter for 24 hours
16277302|NCT04834921|Active Comparator|HFF-CVVHDF|CVVHDF with high flux filter for 24 hours
16277303|NCT04834908|Experimental|Equine COVID-19 Antiserum [F(ab')2] (BSVEQAb) Along with Standard of care|"Dose of BSVEQAb - 5 mg/kg or 10 mg/kg body weight. It is administered as a single dose intravenously after diluting in 100 -150 ml saline. The infusion will be done over 1 to 2 hours.
~Standard of care for treatment of COVID-19 positive patients"
16277304|NCT04834908|Active Comparator|Standard of care.|Treatment as per current treatment guidelines and institutional practice for COVID-19 positive patients will be administered
16277305|NCT04834895|Active Comparator|mhealth exercise group|home exercise program is given to patients via mobile application
16277306|NCT04834895|Experimental|brochure exercise group|home exercise program is given to patients via brochure
16277307|NCT04834882||Healthcare workers|Medical and paramedical staff in Reims University Hospital and EPSM Marne working in COVID-19 units and non COVID-19 units
16277308|NCT04834869||Pfizer-BioNTech COVID-19 Vaccine|Recently vaccinated individuals by Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
16277309|NCT04834869||Moderna COVID-19 Vaccine|Recently vaccinated individuals by Moderna COVID-19 Vaccine
16277310|NCT04834869||AstraZeneca-Oxford University COVID-19 Vaccine|Recently vaccinated individuals by AstraZeneca-Oxford University COVID-19 Vaccine (Vaxzevria)
16277311|NCT04834869||CoronaVac|Recently vaccinated individuals by CoronaVac (Sinovac COVID-19 Vaccine)
16277312|NCT04834869||Sinopharm|Recently vaccinated individuals by Vero Cells (Sinopharm COVID-19 Vaccine)
16277313|NCT04834869||Sputnik V|Recently vaccinated individuals by Sputnik V COVID-19 Vaccine
16277314|NCT04834869||Janssen|Recently vaccinated individuals by Janssen COVID-19 Vaccine
16277315|NCT04834869||CureVac|Recently vaccinated individuals by CureVac COVID-19 Vaccine
16277316|NCT04834869||Novavax|Recently vaccinated individuals by Novavax COVID-19 Vaccine
16277317|NCT04834869||Covaxin|Recently vaccinated individuals by Covaxin COVID-19 Vaccine
16277318|NCT04834869||CanSino|Recently vaccinated individuals by CanSino COVID-19 Vaccine
16277319|NCT04834856|Experimental|ensovibep dose 1|
16277320|NCT04834856|Experimental|ensovibep dose 2|
16277321|NCT04834830||Patients with pleural effusion|In patients with pleural effusion and indication for diagnostic and/or therapeutic procedures (thoracocentesis, drainage of fluid, indwelling pleural catheter (IPC) management, and/or video-assisted thoracoscopic surgery), pleural fluid will be examined for various cytokines and PD1-lymphoctyes.
16277322|NCT04834817|Experimental|LED treatment|LED treatment with Celluma POD device after laser test area
16277323|NCT04834817|No Intervention|Control|No treatment after laser test area
16277324|NCT04834804|Experimental|Suspension training group|
16277325|NCT04834804|Experimental|Free weight training group|
16277326|NCT04834804|No Intervention|Control group|
16277327|NCT04834791|Experimental|Letrozole|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles.
16277328|NCT04834791|Active Comparator|Gonadotropins|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
16277329|NCT04834778|Experimental|Cohort 1 - 25 mg|25 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
16277330|NCT04834778|Experimental|Cohort 2 - 50 mg|50 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
16277331|NCT04834778|Experimental|Cohort 3 - 100 mg|100 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
16277332|NCT04834778|Experimental|Cohort 4 - 200 mg|200 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
16277333|NCT04834765|Active Comparator|Mindfulness|Participants will be engaging in a mindfulness tasks twice per week for 5 weeks in which they will learn techniques through the use of yoga, meditation and breathwork.
16277334|NCT04834765|Active Comparator|Art Therapy|Participants will engage in art therapy with the use of clay twice per week through prompts.
16277337|NCT04834752||Patients tested for COVID-19|Patients who were tested for COVID-19 nasopharyngeal polymerase chain reaction (PCR)
16277338|NCT04834739|Active Comparator|Study group (30 volunteer healthcare workers who had Covid-19|30 volunteer healthcare workers who had Covid-19 and stayed in hospital or at home were included.
16277339|NCT04834739|Active Comparator|Control group (30 volunteer healthcare workers who had not have Covid-19)|In control group, 30 volunteer healthcare workers who were matched for age ande gender with study group were included and these persons had not have Covid-19.
16277340|NCT04834726|Active Comparator|1: Usual Care|Patients will receive a phone call to schedule their appointment from an Access Center representative. Access Center representatives will make up to 3 attempts to schedule an appointment with the patient. Patients randomized to this arm will not receive any text messaging.
16277341|NCT04834726|Experimental|2A: Call Back + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
16277342|NCT04834726|Experimental|2B: Call Back + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
16277343|NCT04834726|Experimental|2C: Call Back + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
16277344|NCT04834726|Experimental|2D: Call Back + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-outWill include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
16277345|NCT04834726|Experimental|3A: In-Bound Call + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
16277346|NCT04834726|Experimental|3B: In-Bound Call + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
16277347|NCT04834726|Experimental|3C: In-Bound Call + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
16277348|NCT04834726|Experimental|3D: In-Bound Call + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-out. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
16277349|NCT04834713||Mild patients|defined as patients who had kidney injury without oliguria and hypotension
16277350|NCT04834713||moderate patients|defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria
16277351|NCT04834713||severe patients|defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50-500 mL/day) for ≤ 5 days or anuria (urine output of < 100 mL/day) for ≤ 2 days
16277352|NCT04834713||critical patients|defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50-500 mL/day) for > 5 days or anuria (urine output of < 100 mL/day) for > 2 days
16277353|NCT04834713||healthy control|defined as people without HFRS
16277354|NCT04834700|No Intervention|hands-on group|The doctors who participated in the study will be educated ocular ultrasound scanning method by hands-on about 20 minutes, and perform ocular ultrasound scans on two standard patients.
16277355|NCT04834700|Other|online group|The doctors who participated in the study will be educated ocular ultrasound scanning method by online lecture about 20 minutes, and perform ocular ultrasound scans on two standard patients.
16277356|NCT04834687|Experimental|Rope-skipping group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
16277357|NCT04834687|Experimental|Diet intervention group|Participants would be required to take part in a diet plan , including a high-fiber diet and time-restricted eating.
16277358|NCT04834687|Experimental|Combined intervention group|Participants will receive both rope-skipping and diet interventions at the same time.
16277359|NCT04834687|No Intervention|Control group|Participants would be required to maintain existing diet patterns and physical activity levels.
16277360|NCT04834674|Experimental|DEB-TACE combined with apatinib and PD-1 antibody|The participants will receive the combined treatment of local therapy (DEB-TACE, oxaliplatin and gemcitabine), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
16277361|NCT04834661||inside group|laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
16277362|NCT04834661||outside group|laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
16277363|NCT04834648|Experimental|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor
~B. Telephonic Follow up:
~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
16277364|NCT04834648|No Intervention|Control Arm|General Counseling, which included saying you need to visit the hospital and you have involvement in the eyes due to diabetes, providing a health education leaflet.
16277365|NCT04834635|Experimental|FundoRingOAGB group|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia).
16277366|NCT04834635|Active Comparator|OAGB group|laparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia).
16277457|NCT04833959|Experimental|89Zr-Panitumumab|Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.
16277367|NCT04834622|Experimental|Melodies for Mums|Mothers will start a block of 10-week classes and continue with their group for the duration of the course. Classes will take place in Children's Centres (or online). Mothers will attend with their babies and will sit in a socially-distanced circle on the floor surrounded by soft play cushions and mats. Classes will start with welcome songs, introducing everyone to one another, and involve a range of singing and music activities. Mothers will be required to respect social distancing guidelines. Music activities will include learning songs from around the world and will be accompanied by instruments that the mothers and babies can play together. Instruments will not be shared and will be disinfected before and after the singing sessions. Mothers will also work to write some of their own songs over the weeks. Recordings of the group singing the songs together will be made for the mothers to listen to at home. Classes will be led by professional workshop leaders trained by Breathe.
16277368|NCT04834622|Active Comparator|Control (mother-baby community sessions)|Our control group will be a 'active' control. During the first 10 weeks (during the study period), mothers in the control group will receive details of other non-music classes available to them in the community (or online if necessary, depending on the programs available at the time and government guidelines) and will receive the same schedule of texts and phone calls to encourage them to join these activities. They will still be seen by the researchers to collect clinical measures and biological samples (including the pre-post saliva samples) and to monitor engagement in other activities. Following the first 10 weeks, the mothers in the control group will be offered a place on the singing programme, but these data will not be part of the study, and they will not join groups with women who are in the study
16277369|NCT04834609|Experimental|Injection with adipose tissue|Injection of freshly collected autologous adipose tissue
16277370|NCT04834596||patients without hepatic metastases|hepatic scanner of 100 patients with colorectal cancer without hepatic metastases will be analysed
16277371|NCT04834596||patients with synchronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with synchronous hepatic metastases will be analysed
16277372|NCT04834596||patients with metachronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with metachronous hepatic metastases will be analysed
16277373|NCT04834570||Breast Cancer Survivors|Women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment
16277374|NCT04834557|Placebo Comparator|Control|Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.
16277375|NCT04834557|Experimental|Digoxin|Participants in this arm will receive digoxin 0.25 mg every other day + DMARDs for 24 weeks.
16277376|NCT04834557|Experimental|Ursodeoxycholic acid (UDCA)|Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.
16277377|NCT04834544|Experimental|DCVAC/OvCa arm|
16277378|NCT04834544|Placebo Comparator|Placebo arm|
16277379|NCT04834531|Experimental|Zhuli capsule|Base on the standard medical treatment, the patients in this group will be used Zhuli capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
16277380|NCT04834531|Placebo Comparator|Placebo|Base on the standard medical treatment, the patients in this group will be used placebo capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
16277381|NCT04834518||Negative result at the first autoantibodies screening test|Participants will be invited to repeat the screening test at the age of 2-5 years old
16277382|NCT04834518||Positive result at the first or second autoantibodies screening test|"Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated)
~Families will attend diabetes-educational program emphasizing on DKA prevention
~Stress assessment for the families involved and stress alleviating interventions when required."
16277383|NCT04834505||Derivation sample|The patients conclusively diagnosed as FAIP or PC are retrospectively collected.
16277384|NCT04834505||Validation sample|The patients with difficulty in distinguishing between FAIP and PC are prospectively enrolled.
16277385|NCT04834427|Experimental|S (+)-Ketamine group|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.
16277386|NCT04834427|Active Comparator|Control group|Patients who undergo conventional therapy without S (+)-Ketamine hydrochloride injection during perioperative period.
16277389|NCT04834401||Natalizumab|Natalizumab (minimum of 6 doses at standard interval)
16277390|NCT04834401||Fumarates|Fumarates (dimethyl fumarate or diroximel fumarate)
16277391|NCT04834401||Interferon Beta 1a|Interferon Beta 1a (or pegylated Interferon Beta-1a)
16277392|NCT04834401||Ocrelizumab|Ocrelizumab (minimum of 2 full cycles of 600mg)
16277393|NCT04834388|Experimental|Anakinra High dose|500mg i.v. loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days
16277394|NCT04834388|Experimental|Anakinra Low dose|100mg s.c. loading dose, followed by subcuteanous administration of 100mg twice daily for 3 days.
16277395|NCT04834388|No Intervention|Standard care|Standard care group
16277396|NCT04834375|No Intervention|Standard dexamethasone dose|Dexamethasone 6 mg IV daily for 10 days
16277397|NCT04834375|Experimental|Weight-based dexamethasone dose|Dexamethasone 0.2 mg/kg/day IV (maximum 20 mg daily) for 10 days
16277398|NCT04834362|Experimental|Analog insulin arm|Patients treated with insulin analog regimen will receive 50% of total daily dose as basal insulin glargine at the same time of day and 50% as insulin aspart given in 3 equally divided doses at 6 am, 12 pm and 6 pm.
16277399|NCT04834362|Active Comparator|Human insulin arm|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm
16277400|NCT04834349|Experimental|Cohort I (NBTXR3, SBRT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo SBRT QOD on days 15-29. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16277458|NCT04833946|Active Comparator|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
16277401|NCT04834349|Experimental|Cohort II (NBTXR3, IMRT/IMPT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo IMRT/IMPT QD on days 15-50. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16277402|NCT04834336|Experimental|Physical training plus inspiratory muscle training|"Inspiratory Muscle Training (IMT) will be implemented by using the Power Breathe® device. IMT training will begin with mild to moderate intensity of maximal inspiratory pressure. It will be performed 6 to 10 breaths, 4 sets, and twice daily during the hospitalization when as soon as hemodynamic stability is provided.
~Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided."
16277403|NCT04834336|Active Comparator|Physical training|Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided.
16277404|NCT04834323|Active Comparator|group (1)|included 42 patients who were subjected to distal mesogastric fixation after laparoscopic sleeve gastrectomy
16277405|NCT04834323|No Intervention|group (2)|included 42 patients who were subjected to laparoscopic sleeve gastrectomy alone without distal mesogastric fixation
16277406|NCT04834310|Experimental|Intraoperative and Postoperative Antibiotics|The experimental group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by oral antibiotics for 5 days postoperatively.
16277407|NCT04834310|Placebo Comparator|Intraoperative Antibiotics and Placebo|The control group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by a placebo for 5 days postoperatively
16277408|NCT04834297|Experimental|SVS mattress|Infants randomized to the experimental arm will have the SVS mattress placed in their crib within 24 hours of birth and will continue till discharge home after the completion of monitoring phase of NOWS or till determination is made to initiate pharmacotherapy for NOWS.
16277409|NCT04834297|No Intervention|Standard mattress|Infants randomized to the no intervention arm will continue to be cared for using the standard hospital crib mattress throughout their birth hospitalization.
16277410|NCT04834284||Helicopter Emergency Medical Services (HEMS)|Patients transported to the comprehensive stroke centre at least in some part by a HEMS unit
16277411|NCT04834284||Ground Emergency Medical Services (GEMS)|Patients transported to the comprehensive stroke centre solely by an ambulance
16277412|NCT04834271|Active Comparator|Exercise without blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) without blood flow restriction.
16277413|NCT04834271|Experimental|Exercise with 40% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% of arterial occlusion pressure blood flow restriction.
16277414|NCT04834271|Experimental|Exercise with 80% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% of arterial occlusion pressure blood flow restriction.
16277415|NCT04834258|Experimental|Walking and respiratory muscle training group|"Walking and respiratory muscle training group (W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.
~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.
~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.
~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged."
16277416|NCT04834258|Active Comparator|Respiratory muscle training group|In the Respiratory muscle training group (RMT), Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged
16277417|NCT04834245|Experimental|hydrogel/nano silver-based dressing|hydrogel/nano silver-based dressing
16277418|NCT04834219||On-pump CABG|Patients with an on-pump indication by the cardiovascular surgery department will be included in the study.
16277419|NCT04834219||Off-pump CABG|Patients with an off-pump indication by the cardiovascular surgery department will be included in the study.
16277420|NCT04834206|Other|DNF-N|"Induction chemotherapy:
~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks
~Concurrent chemoradiotherapy:
~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy
~Radiotherapy: radical intense modulated radiation therapy"
16277421|NCT04834193|Experimental|WET-SUCTION|The stylet will be removed and the needle will be pre-flushed with 1-2mL of saline. The lesion will then be punctured, and suction will be applied using a 10-mL pre-vacuum syringe. The sample collected will be pushed into a formalin vial with saline.
16277422|NCT04834193|Active Comparator|SLOW-PULL|After puncturing the lesion, the stylet will be slowly and gradually withdrawn for at least 40cm. The sample will be pushed into formalin using the stylet.
16277459|NCT04833946|Placebo Comparator|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
16277460|NCT04833933||Control group|"Initially in DISCO trial : no intervention, usual care
~In DISCO-SET trial : survey (the same in the 4 groups)"
16277423|NCT04834180|Sham Comparator|Vaccaria seeds plus diet therapy|Vaccaria seeds at the exterior side of the ear area, standard points were selected according to clinical experience in traditional Chinese medicine: Shenmen (TF4), Stomach (CO4), Hunger, Mouth (CO1), Point Zero HX1) and Sanjiao (CO17). Mustard seeds (Vaccaria ear seeds, Beijing Zhongyan Taihe Medicine, Beijing, China) were used, plus diet therapy prescribed by a licensed nutritionist.
16277424|NCT04834180|Active Comparator|ASP needles plus diet therapy|ASP needles on the outside of the ear standard points were selected according to clinical experience in traditional Chinese medicine: ASP gold needles, strengthening the centre with point 0 (the umbilicus) in the dominant ear, Porta Fortunae in the non-dominant ear, Barbiturate in the non-dominant ear, Psychosomatique key point in the dominant ear and the point Aggression, plus diet therapy prescribed by a licensed nutritionist.
16277425|NCT04834180|No Intervention|only diet therapy|only diet therapy prescribed by a licensed nutritionist.
16277426|NCT04834167|Experimental|Treatment|Eligible patients will receive ten picopulse treatments for bi-monthly.
16277427|NCT04834154|Active Comparator|Mindfulness group visit|Participants will attend 6 weekly educational and mindfulness sessions
16277428|NCT04834154|Placebo Comparator|Wait list control|Participants will be placed on a wait list
16277429|NCT04834141||Kyphotic Group|"Participants with kyphosis angle ≥ 40 degrees joined the kyphosis group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.
~Static balance Assessment:
~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
16277430|NCT04834141||Control Group|"Participants with kyphosis angle < 40 degrees for the control group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.
~Static balance Assessment:
~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
16277431|NCT04834128|Experimental|γδ T cells (IMP, TCB008)|Patients will receive an infusion of γδ T cells (IMP, TCB008) following informed consent after admission to hospital for SARS-CoV-2 infection (COVID-19).
16277432|NCT04834115|Experimental|Ivermectin|Ivermectin 200mcg/kg single dose, maximum dose 18mg
16277433|NCT04834115|Placebo Comparator|Placebo|Inactive medication tablets indistinguishable from ivermectin tablets
16277434|NCT04834089|Experimental|Experimental product group (Stage A)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
16277435|NCT04834089|Placebo Comparator|Placebo group (Stage C)|Saline solution Administration Route: Intravenous
16277436|NCT04834089|Experimental|Experimental product group (Stage B)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
16277437|NCT04834089|Experimental|Experimental product group (Stage C)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
16277438|NCT04834076||Cancer patients|50 cancer patients referred to the Oncology Department, Faculty of medicine, Sohag University.
16277439|NCT04834076||Healthy controls|50 healthy controls will be recruited in the study.
16277440|NCT04834063||NAFLD Cases|Non- alcoholic fatty liver disease
16277441|NCT04834063||control|healthy individual with normal liver on abdominal ultrasound
16277442|NCT04834050|Experimental|Rheumatoid arthritis patients|
16277443|NCT04834050|Experimental|Knee Osteoarthritis patients|
16277444|NCT04834050|Experimental|Healthy patients|
16277445|NCT04834037|Experimental|Experimental|"Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs.
~As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service. An information pamphlet consisting of textual material about NIV treatment was developed."
16277446|NCT04834037|No Intervention|No intervention|Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
16277447|NCT04834024|Experimental|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|
16277448|NCT04834024|Active Comparator|lenalinomide|
16277449|NCT04833998|Placebo Comparator|Placebo|Placebo will be cream without the active ingredient. It will be matched in appearance, smell, consistency, and color to Extremecare topical cream. Patients will be instructed to apply the placebo cream to the hand and feet.
16277450|NCT04833998|Experimental|Extremecare|Extremecare is a moisturizing cream based on Thoitaine, Aloe Vera and Calendula for topical use. Patients will be instructed to apply the moisturizing cream to the hand and feet.
16277451|NCT04833985|Experimental|transesophageal echocardiography guidance|
16277452|NCT04833985|Experimental|intracardiac echocardiography guidance|
16277453|NCT04833985|Experimental|fluoroscopy only guidance|
16277454|NCT04833972|Experimental|Experimental: V1: Binary Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has binary (yes/no) response options."
16277455|NCT04833972|Experimental|Experimental: V2: Categorical Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has categorical response options: all or almost all; more than half, but fewer than 90%; fewer than half, but more than 10%; very few, or no one"
16277456|NCT04833972|Experimental|Experimental: V3: Open-Ended Numerical Estimate|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire permits the study participant to provide an open-ended numerical estimate."
16309218|NCT04612439|Active Comparator|BARD 14G CNB|BARD 14G Core needle
16277461|NCT04833933||Questionnaire|"Initially in DISCO trial : Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
~In DISCO-SET trial : survey (the same in the 4 groups)"
16277462|NCT04833933||Coordination|"Initially in DISCO trial : Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
~In DISCO-SET trial : survey (the same in the 4 groups)"
16277463|NCT04833933||Questionnaire + Coordination|"Initially in DISCO trial :
~Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
~Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
~In DISCO-SET trial : survey (the same in the 4 groups)"
16277464|NCT04833920|Active Comparator|active tDCS|tDCS targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days
16277465|NCT04833920|Sham Comparator|sham tDCS|tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds
16277466|NCT04833907|Experimental|3.7 x 10^13 v.g. rAAV-Olig001-ASPA|3.7 x 10^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 4 pre-defined intracerebroventricular sites
16277467|NCT04833894|Experimental|Efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
16277468|NCT04833881||The control group|
16277469|NCT04833881||Experimental group|
16277470|NCT04833868|Experimental|hippotherapy combined with Schroth Exercise|received hippotherapy combined with Schroth Exercise hippotherapy session for 30 minutes of walking and sitting trot training, 15 sessions split into 2 phases over ten weeks in addition to 60-minute session Schroth's intervention, 3 times/ week for 10 weeks
16277471|NCT04833868|Active Comparator|Schroth Exercise|received Schroth's intervention for a 60-minute session, 3 times/ week for 10 weeks
16277472|NCT04833855|Active Comparator|Group 1: Omalizumab|Participants naive to anti-IgE therapies will receive omalizumab.
16277473|NCT04833855|Placebo Comparator|Group 2: Placebo|Participants naive to anti-IgE therapies will receive a placebo.
16277474|NCT04833855|Experimental|Group 3: Tezepelumab Dose 1|Participants naive to anti-IgE therapies will receive tezepelumab.
16277475|NCT04833855|Experimental|Group 4: Tezepelumab Dose 2|Participants naive to anti-IgE therapies will receive tezepelumab.
16277476|NCT04833855|Placebo Comparator|Group 5: Placebo|Participants previously treated with anti-IgE therapies will receive a placebo.
16277477|NCT04833855|Experimental|Group 6: Tezepelumab Dose 1|Participants previously treated with anti-IgE therapies will receive tezepelumab.
16277478|NCT04833855|Experimental|Group 7: Tezepelumab Dose 2|Participants previously treated with anti-IgE therapies will receive tezepelumab.
16277479|NCT04833842|Experimental|Web-based birth preparation program supported by motivational interview|A web-based childbirth preparation program prepared based on the Health Belief Model and supported by motivational interviews will be applied to primigravida women in the initiative group.
16277480|NCT04833842|Experimental|web-based birth preparation program|A web-based birth preparation program based on the Health Belief Model will be applied to primigravida women in the control group.
16277481|NCT04833829|Active Comparator|Clinic Patients During the Pre-implementation Period|Patients visiting one of the study clinics prior to implementation of the CHIMES intervention. The Baseline time period consists of study Months 1 - 12. Data are retroactively abstracted from medical records of patients who had clinic visits that occurred between January 1, 2019 and December 31, 2019.
16277482|NCT04833829|Experimental|Clinic Patients During the Implementation Period|Patients visiting one of the study clinics during the Implementation period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 13 - 27.
16277483|NCT04833829|Experimental|Clinic Patients During the Maintenance Period|Patients visiting one of the study clinics during the Maintenance period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 28 - 33.
16277484|NCT04833816|Experimental|Ketamin|Patient will get a bolus of ketamine at 0.1 mg / kg followed by a continuous infusion of ketamine at a dose of 0.15 mg / kg / hour
16277485|NCT04833816|Placebo Comparator|Placebo|Patient will get a bolus of NaCL at 0.1 mg / kg followed by a continuous infusion of NaCl at a dose of 0.15 mg / kg / hour
16277486|NCT04833790|Experimental|Free distribution of ORS + standardized patient with ORS preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
16277487|NCT04833790|Experimental|Free distribution of ORS + standardized patient with Antibiotic preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
16277488|NCT04833790|Experimental|Free distribution of ORS + standardized patient with no preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
16277489|NCT04833790|Experimental|Free distribution of ORS + standardized patient with no preference + no financial incentive|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
16277490|NCT04833790|Experimental|Status quo ORS supply + standardized patient with ORS preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
16278324|NCT04828109|Active Comparator|VR Only|Daily VR only. Daily VR use every 3 hours up to 30 minutes at a time.
16277491|NCT04833790|Experimental|Status quo ORS supply + standardized patient with Antibiotic preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
16277492|NCT04833790|Experimental|Status quo ORS supply + standardized patient with no preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
16277493|NCT04833790|Experimental|Status quo ORS supply + standardized patient with no preference + no financial incentive|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
16277494|NCT04833777|Active Comparator|Lidocaine|Administration of subcutaneous lidocaine as local anesthetic prior to carpal tunnel release (lidocaine intervention)
16277495|NCT04833777|Experimental|Bupivacaine|Administration of subcutaneous bupivacaine + lidocaine as local anesthetic prior to carpal tunnel release (bupivacaine intervention)
16277496|NCT04833764|Experimental|Rosuvastatin|Subjects will receive 20 mg daily dose of rosuvastatin for at least 3 months
16277497|NCT04833751||Anesthesia for cardio/neurovascular surgery or procedure|Patients undergoing anesthesia in an operating room or hybrid room for cardio/neurovascular surgery or procedure.
16277498|NCT04833738|Active Comparator|Electrotherapy|
16277499|NCT04833738|Active Comparator|corticosteroid|
16277500|NCT04833738|Active Comparator|hyaluronic acid|
16277501|NCT04833725||COPD combined with OSA|All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc. This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
16277502|NCT04833712|Experimental|Stereotactic Radioablation|"Noninvasive Stereotactic Radioablation will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.
~Pulmonary vein isolation will be assessed by using Cardioinsight non-invasive mapping system"
16277503|NCT04833699|No Intervention|Control|Group A served as the control group who did not receive any intervention except our clinical standard postoperative care
16277504|NCT04833699|Experimental|Study|Group B served as the hot pack group that warm water (80 C) was put in a hot pack (Fig 1) and then placed on the patients umbilicus at 6, 12, and 18 h after the operation for 45 minutes in addition to clinical standard postoperative care.
16277505|NCT04833686|Active Comparator|Sonata for 2 pianos in D major, K.488 by Mozart|An Mp3 player, upload with music by Mozart. Music was played using headphones suitable and approved for use in children.
16277506|NCT04833686|Active Comparator|"Instrumental music (To the Point, by Dean Evenson & Tom Barabas)"|An Mp3 player, upload with instrumental music. Music was played using headphones suitable and approved for use in children.
16277507|NCT04833686|Active Comparator|Silence|An Mp3 player, upload with silence. Silence was played using headphones suitable and approved for use in children.
16277508|NCT04833673|Experimental|PMR|"The PMR intervention involving tensing and relaxing the body muscles accompanied with deep breathing. The researchers told each
~participant to sit in a soundless and breathable room and in a comfortable position before each session at their home. The participants performed tensing and relaxing for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed with deep breathing. The participants were instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Moreover, throughout this exercise, the participants imagined a wave of relaxation flowing over their body."
16277509|NCT04833673|Experimental|BRT|Within the scope of this technique, first of all, the participants were asked to focus on a word that relieves them such as love, health or well-being. And so, the participants were asked to be in comfortable position in a silent and breathable room with the closed eyes, relax their muscles from the sole of their feet and progressing up to their face gradually, keep them relaxed, accompanied with deep breathing, be aware of their breathing, exhale gently. They continue these practices for 20 minutes and try to relax their muscles. After finishing the duration, they sit quietly for several minutes with eyes closed and later with eye opened.
16277510|NCT04833673|No Intervention|CG|"Regarding CG, the participants were invited to the same room and received only a single time attention-matched education on Living with MS; including definition of MS, dietary advices for MS patients. The attention-matched education was performed face to face and lasted for 10 min. All participants in the three study groups also received usual treatment and care."
16277511|NCT04833660|Experimental|rTMS group|"Each patient will receive five consecutive sessions (Monday to Friday for 1 week).
~Patients in the rTMS group will administer rTMS over the optimal scalp site at 10 Hz, with an intensity of 90% of the MT and a duration of 5 seconds, for a total of 20 trains separated by 55-second intertrain pauses (a total of 1,000 pulses). The coil will be placed tangentially to the scalp at an approximate angle of 45° tilted backward and laterally. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods."
16277512|NCT04833660|Sham Comparator|sham group|Patients in the sham group will administer sham stimulation using the same protocol, except that the angle of the coil is 90° (i.e., perpendicular, rather than tangential) to the skull. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods.
16277513|NCT04833647|Other|Term|7-10 years old born at 37-42 weeks gestation
16277514|NCT04833647|Other|Late preterms|7-10 years old born at 34.0-36.6 weeks gestation
16277515|NCT04833647|Other|Preterms with BPD|7-10 years old born before 30 weeks gestation with the diagnosis of BPD: the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation
16277583|NCT04833179|Placebo Comparator|placebo|Placebo capsule that can not be differentiate from the focal transplant capsule will be given in the same interval as the fecal transplant procedure written above.
16277516|NCT04833647|Other|pretermas without BPD|7-10 years old born before 30 weeks gestation without the diagnosis of BPD (without the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation)
16277517|NCT04833621|Active Comparator|NMES GROUP|NMES TREATMENT AND PHYSICAL TREATMENT
16277518|NCT04833621|Active Comparator|CONTROL GROUP|JUST PHYSICAL TREATMENT
16277519|NCT04833608|Active Comparator|Vktory Carbon fiber insoles|VKTRY insoles were initially designed to increase ground force leading to a harder push off for faster running or higher jumping. To enable energy return the insole needed to be extremely rigid and therefore consists out of a full length Carbon-Fiber base. Unexpectedly the Carbon fiber base makes this a highly rigid construct which will likely benefit those patients with MTP arthritis as it will take away much movement of the MTP joint, without having an uncomfortable shape, i.e. patients can use this insole in their own shoes, possibly leading to a higher patient compliance and, simultaneously, to better outcome
16277520|NCT04833608|Active Comparator|Morton's extension insoles|Based on expert opinions, it seems the Morton extensions may alleviate pain but are also poorly tolerated by patients due to its uncomfortable shape, coincidently leading to a low patient compliance rate.
16277521|NCT04833595|Experimental|Mindfulness Arm|"A recommendation on healthy food intake will be sent to participants. At the end of each week, participants will be required 1) to submit THREE photos of the meals that they are most satisfied with in terms of healthiness and 2) using the photos to answer a questionnaire about their diet. The photos and completed questionnaire must be submitted to the research investigator each week for a total of 8 weeks. After 8 weeks, participants will be required to get tested for your fasting total cholesterol and blood glucose level in the appointed pharmacy for the second time. It is estimated to require 15-30 minutes of their time weekly.
~The questionnaire used for experimental group contains reflective questions as part of the mindfulness intervention."
16277522|NCT04833595|Active Comparator|Non-mindfulness Arm|Everything is similar to the experimental arm. However, the questionnaire used for control group does not contain reflective questions to serve as control group.
16277523|NCT04833582|Experimental|Combination ZN-c3 with Gemcitabine|
16277524|NCT04833569|Experimental|Indocyanine green mediated photodynamic therapy (ICG-PDT)|Delivery of ICG solution at a concentration of 1 mg/mL will be used. The photosensitizer will be applied until the bottom of the peri-implant pocket using a 1 ml syringe. An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J will be used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction.
16277525|NCT04833569|Placebo Comparator|Peri-implant mechanical debridement|Non-surgical peri-implant mechanical debridement (PIMD) through ultrasonic device with a carbon tip.
16277526|NCT04833556||Postpartum haemorrhage|Patients undergoing cesarean delivery with postpartum haemorrhage (blood loss more than or equal to 1,000 ml.)
16277527|NCT04833543|Active Comparator|Tilt Table|
16277528|NCT04833543|Experimental|Robotic Mobility Device (REX)|
16277529|NCT04833530||Woman undergoing an gastric ultrasound assessment.|Woman undergoing general anesthesia for oocyte retrieval during in vitro fertilization, will undergo an gastric ultrasound assessment.
16277530|NCT04833517||Lu177 PSMA RLT|Lutetium-177 prostate-specific membrane antigen (Lu177 PSMA) radioligand therapy (RLT) according to standard local protocol
16277531|NCT04833517||Ac225 PSMA RLT|Actinium-225 prostate-specific membrane antigen (Ac225 PSMA) radioligand therapy (RLT) according to standard local protocol
16277532|NCT04833517||Tandem Lu177 / Ac225 PSMA RLT|Combined Lu177 / Ac225 PSMA radioligand therapy according to standard local protocol
16277533|NCT04833517||Ra223 chloride|Bone-targeted Radium-223 (Ra223) radionuclide therapy in standard application
16277534|NCT04833517||Sm153 EDTMP|Bone-targeted Samarium-153 (Sm153) EDTMP radionuclide therapy in standard application
16277535|NCT04833517||Y90 microshperes|Radioembolization with yttrium-90 (Y90) microspheres, standard methodology
16277536|NCT04833491||Senile cataract|
16277537|NCT04833491||Traumatic cataract|
16277538|NCT04833491||Congenital cataract|
16277539|NCT04833491||Lens dislocation group|
16277540|NCT04833491||Complicated cataract|
16277541|NCT04833478|Experimental|Application|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
16277542|NCT04833478|Experimental|Dental Song|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
16277543|NCT04833478|Experimental|Tell Show Do|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
16277544|NCT04833465||JIA|Patients ages 5-21 with a diagnosis of JIA.
16277545|NCT04833465||SLE|Patients ages 5-21 with a diagnosis of SLE.
16277546|NCT04833465||FM|Patients ages 5-21 with a diagnosis of FM.
16277547|NCT04833452|Active Comparator|Wide fenstrum Endoscopic DCR|
16277548|NCT04833452|Active Comparator|Narrow Fenstrum Endoscopic DCR|
16277549|NCT04833439|Experimental|Fasting Mimicking Diet|2 cycles of 3-day fasting mimicking spaced by a 2 week interval
16277550|NCT04833426|Active Comparator|Testosterone therapy|Daily application of two pump auctions of 16.2mg/ml testosterone gel. Dosage may be altered depending on clinical response
16277551|NCT04833426|Placebo Comparator|Placebo therapy|Daily application of two pump auctions of placebo gel.
16277552|NCT04833413||Continue intensive treatment group|Patients with type 2 diabetes who continued intensive treatment within 6 months after hospital discharge
16277553|NCT04833413||Premixed insulin treatment group|Patients with type 2 diabetes who changed to premixed insulin within 6 months after hospital discharge
16277554|NCT04833413||Basic insulin treatment group|Patients with type 2 diabetes who changed to basic insulin treatment within 6 months after hospital discharge
16277555|NCT04833413||Oral hypoglycemic drug treatment group|Patients with type 2 diabetes who changed to oral hypoglycemic drug treatment within 6 months after hospital discharge
16277556|NCT04833400|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The ICRS is very likely to the conventional stationary biking, but with an algorithm that automatically controls the resistance of pedalling, considering the instant heart rate and cadence, to keep the heart rate within the targeted heart rate zone.
16277557|NCT04833400|Active Comparator|Traditional aerobic exercise training (TAET)|"The TAET is performed with stationary biking, with intensity being set as subjective rating of perceived exertion at a somewhat hard to hard level. The resistance of pedaling is ad-justed by the user or physical therapist."
16277558|NCT04833387|Experimental|PD-1 antibody + capecitabine + radiation|
16277559|NCT04833374|Experimental|1-2-3 Group|Patients in 1-2-3Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
16277560|NCT04833374|Active Comparator|1-3-5 Group|Patients in 1-3-5 Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-3rd-5th month ,then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
16277562|NCT04833348|Experimental|Patients|Infants with spinal muscular atrophy cared by the Neuromuscular Reference Center at Necker Hospital and eligible for innovative therapy (gene therapy or pharmacogenetics)
16277563|NCT04833335|Experimental|Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus|Inclusion visit, 1 month later, 6 month later
16277564|NCT04833322|Experimental|Single arm group|Galactose supplementation
16277565|NCT04833309|Experimental|Pharmacopuncture therapy|Pharmacopuncture will be administered to the subjects in the pharmacopuncture therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
16277566|NCT04833309|Active Comparator|Physical therapy|Physical therapy will be applied to the subjects in the physical therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
16277567|NCT04833283|Experimental|the intervention group intermittent hypoxic-hyperoxic training|"the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)
~Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s)."
16277568|NCT04833283|Placebo Comparator|the control group|intermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask
16277569|NCT04833270|Experimental|KM non-pharmacological treatment group|Non-pharmacological treatment including Korean medicine will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
16277570|NCT04833270|Active Comparator|Pharmacological treatment group|Pharmacological treatment will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
16277571|NCT04833257|Experimental|GP combine with Tislelizumab neoadjuvant therapy+CCRT|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
16277572|NCT04833244|Active Comparator|Interventional|Patients are taught to draw their shoulders away from their heads and necks, activating the subscapularis and pectoralis muscles. When asked immediately afterwards to abduct and flex their shoulders, these muscles perform the action that generally engages the injured supraspinatus muscle, causing significant pain. However, when these muscles are substituted for the injured supraspinatus, abduction and flexion subsequently occur painlessly.
16277573|NCT04833244|Placebo Comparator|Control|Patients are taught a sham maneuver that does little or nothing to alleviate the pain of abduction and flexion of the shoulders. Therefore their pain levels before and after learning the maneuver are likely to be similar.
16277574|NCT04833231||High eGFR group (eGFR ≥60 mL/ min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) ≥60 mL/ min/1.73 m2 as high eGFR group
16277575|NCT04833231||Low eGFR group (eGFR <60 mL/min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 as low eGFR group
16277576|NCT04833218|Active Comparator|propranolol group|we will give propranolol 40 milligram tablet twice daily in orogastric or nasogastric tube
16277577|NCT04833218|Active Comparator|propranolol clonidine|we will give propranolol 20 milligram tablet twice daily and clonidine 150 microgram tablet twice daily in orogatric or nasogastric tube
16277578|NCT04833218|No Intervention|control group|we will give conventional treatment, no propranolol nor clonidine
16277579|NCT04833205|Experimental|Leptomeningeal metastases received EGFR-TKI and Nimotuzumab|The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI
16277580|NCT04833192||experimental group|patients diagnosed with subclinical hypercortisolism as assessed by an endocrinologist.
16277581|NCT04833192||control grpup|patients diagnosed with nonfunctional adrenal adenoma as assessed by an endocrinologist.
16277582|NCT04833179|Experimental|fecal transplant|Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. The treatment will be given in the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment.
16277584|NCT04833166|Experimental|Full glottic view on CMAC- D blade|Deliberately obtaining a full glottis view is deﬁned as negotiation and advancement of CMAC D blade tip positioned at the vallecula. Occasionally, external laryngeal pressure may be needed to assist in obtaining a full glottic view. The full glottic view is defined as a percentage of glottic opening (POGO) approximate 100%.
16277585|NCT04833166|Active Comparator|Partial glottic view on CMAC- D blade|The partial glottis view is deﬁned as a percentage of glottic opening <50%. This is achieved by deliberately position the CMAC D-blade tip proximally away from the vallecular.
16277586|NCT04833153|Experimental|PFP intervention|PFP 10 week continuing education intervention
16277587|NCT04833153|No Intervention|Control arm|Usual care
16277588|NCT04833140|Active Comparator|Estradiol|"Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic).
~Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection"
16277589|NCT04833140|Placebo Comparator|Placebo|Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)
16277590|NCT04833127|Active Comparator|Masibambane - Gender-Enhanced|"A virtual (online) group-based interactive Gender-Enhanced (GE) Workshop (using the WhatsApp® platform). The intervention has components that are conducted by participants on their own time as well as a real-time live interactive session."
16277591|NCT04833127|Other|Individually accessed|In this condition women are given access to a PrEP video and to websites that provide information on PrEP and on contraception options.
16277592|NCT04833114|Experimental|Experimental Arm: Pola-R-ICE|combination of standard chemotherapy with polatuzumab vedotin (Pola-R-ICE) Application
16277593|NCT04833114|Active Comparator|Standard Arm: R-ICE|conventional treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)
16277594|NCT04833101|Experimental|"0-28 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 28, and a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
16277595|NCT04833101|Placebo Comparator|"0-28 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 28, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
16277596|NCT04833101|Experimental|"0-56 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
16277597|NCT04833101|Placebo Comparator|"0-56 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
16277598|NCT04833088|Other|Healthcare professionals|
16277599|NCT04833088|Other|Patients who suffer from spatial neglect|
16277600|NCT04833088|Other|Patients who have walking difficulties|
16277601|NCT04833088|Other|Patients who require long term use of an IV-stand|
16277602|NCT04833075|Other|Single arm|additional blood sampling (single arm)
16277603|NCT04833062||Diabetes mellitus group|Based on DM type, all women will be divided into four groups: prepregnancy/preexisting DM insulin-dependent or independent (types I and II; classes B, C, and D) and gestational DM (GDM) with or without the need for insulin therapy (DM classes A1 and A2). In the case of gestational DM, the gestational week at the time of diagnosis will be registered. We will consider whether women are diagnosed with another preexisting disease (endocrinological or another one) before or during pregnancy, in order to check the relationship of this disease and their DM and potential risks for pregnancy.
16277604|NCT04833062||Nondiabetic group|Nondiabetic women who received birth assistance at our referral centers and who agreed to participate in the study were included in the control group. A control of healthy (non-diabetic women) mothers so to compare characteristics and outcomes across diabetic groups will comprise the control group.
16277605|NCT04833049|Experimental|TAK-994 Dose 1 + [14C]TAK-994 Dose 2 + [14C]TAK-994 Dose 3|TAK-994 Dose 1, tablet, orally, on Day 1, followed by [14C]TAK-994 Dose 2, infusion, intravenously, on Day 1 of Part A, followed by a washout period of at least 8 days, further followed by [14C]TAK-994 Dose 3, suspension, orally, on Day 1 of Part B.
16277606|NCT04833036|Active Comparator|c-CetuIRI|Irinotecan combined with cetuximab
16277607|NCT04833036|Experimental|s-IRI-CetuIRI|single irinotecan first, then irinotecan plus cetuximab sequentially after PD
16277608|NCT04833023|Active Comparator|Haloperidol Arm|Haldol 2mg/ml oral solution
16277609|NCT04833023|Active Comparator|Olanzapine Arm|Olanzapine Actavis 5mg orodispersible tablet
16277610|NCT04833010|Active Comparator|No cloth face mask|Cross-over randomization. Participants randomized to this arm will not wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
16277611|NCT04833010|Experimental|Cloth face mask|Cross-over randomization. Participants randomized to this arm will wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
16277612|NCT04832997|Experimental|mpMRI plus Micro-US|Patients with a clinical suspicion of csPCa will receive mpMRI and Micro-US in two different visits (randomized sequence). The results of the diagnostic procedures will determine how many and which type of prostate biopsies patients will undergo.
16277613|NCT04832984|Experimental|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum over a period of 12 weeks and then the post-core curriculum for 12 weeks through the app. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the peer support, and regular care and follow up in community pharmacies for support.
16277614|NCT04832984|Active Comparator|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the educational curriculum."
16277660|NCT04832711||the low-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
16277617|NCT04832958|Experimental|Radioguided surgery|"68Ga-PSMA PET/MRI acquisition
~99mTc-PSMA-I&S intravenous injection the day before surgery
~99mTc-PSMA-I&S SPECT/CT imaging
~99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations
~Robot-assisted ePLND followed by RP
~99mTc-PSMA-RGS to detect an increased count rate in the prostatic fossa after removal of the primary tumor
~Histopathological examination
~Monitoring of adverse events and perioperative outcomes after surgery"
16277618|NCT04832945||Ivermectin Group|Healthcare personnel receiving Ivermectin weekly PrEP
16277619|NCT04832945||Control Group|Healthcare personnel not receiving Ivermectin
16277620|NCT04832932||75 years of age or older|individuals 75 years of age and older who received COVID-19 vaccine
16277621|NCT04832932||65-74 years of age|individuals 65-74 years of age who received COVID-19 vaccine
16277622|NCT04832932||16-64 years of age|Individuals in 16-64 age range who received COVID-19 vaccine
16277623|NCT04832932||MEBO/PATM|Individuals in 16-69 age range with present or past MEBO/PATM symptoms who received COVID-19 vaccine
16277624|NCT04832919|Experimental|Nurse-Community Health Worker-Family Partnership|The experimental arm will receive the Nurse-Community Health Worker-Family Partnership intervention
16277625|NCT04832919|No Intervention|Standard of Care|The control arm will receive standard access to NYC Department of Health COVID-19 testing sites and standard COVID-19 public health messaging
16277626|NCT04832906|Active Comparator|"Group A Ulipristal Acetate (UA) - Fibristal group (n=35)"|Patients within this group received oral Ulipristal Acetate (Fibristal ©) 5 mg / day starting from the first day of menstrual bleeding, and for 3 months (period of the study).
16277627|NCT04832906|Active Comparator|"Group B Uterine artery embolization (UAE) group (n=35)"|Patients within this group underwent bilateral selective uterine artery embolization, during which polyvinyl alcohol (PVA) particles was administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected. The gelatin sponge cap was thought to both complete the occlusion of the uterine artery and to prevent PVA particles from being drawn out of the uterine artery by the Venturi effect, which would result in non-target embolization.
16277628|NCT04832893|Active Comparator|Use of FFP2 respirator|Using of FFP2 respirator during the 30 minutes test
16277629|NCT04832893|Active Comparator|Use of surgical mask|Using of surgical mask during the 30 minutes test
16277630|NCT04832893|Sham Comparator|no mask|The 30 minutes test will be carried out without mask
16277631|NCT04832880|Experimental|Control arm (dexamethasone arm)|IV dexamethasone 6 mg for 10 days
16277632|NCT04832880|Experimental|Remdesivir arm|IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10
16277633|NCT04832880|Experimental|Baricitinib arm|IV dexamethasone 6 mg for 10 days + baricitinib 4 mg die for 10 days. For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days.
16277634|NCT04832880|Experimental|Remdesivir + baricitinib arm|"IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10 + baricitinib 4 mg die for 10 days.
~For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days."
16277635|NCT04832854|Experimental|Cohort A (PD-L1 High)|"Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A and receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgical resection and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles at the discretion of the investigator.
~Chemotherapy may include:
~cisplatin/carboplatin + pemetrexed (for non-squamous only)
~cisplatin/carboplatin + gemcitabine (for squamous only)
~carboplatin + paclitaxel"
16277636|NCT04832854|Experimental|Cohort B (PD-L1 All Comers)|"All comers, which are participants with any PD-L1 expression level, will be enrolled in Cohort B and receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgical resection and adjuvant atezolizumab plus tiragolumab for 16 cycles.
~Chemotherapy may include:
~cisplatin/carboplatin + pemetrexed (for non-squamous only)
~cisplatin/carboplatin + gemcitabine (for squamous only)
~carboplatin + paclitaxel"
16277637|NCT04832841||SARS-CoV-2 naive|Kidney transplant recipients without previous SARS-CoV-2 infection verified by absence of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
16277638|NCT04832841||SARS-Cov-2 exposed|Kidney transplant recipients with previous SARS-CoV-2 exposition verified by positivity of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
16277639|NCT04832841||Waiting list|Kidney transplant recipients who were vaccinated on waiting list (a) SARS-CoV-2 naive (b) SARS-Cov-2 exposed
16277640|NCT04832828||COVID+ Group|Patients diagnosed with Covid19 positive in last 7 days
16277641|NCT04832815|Experimental|Equine Therapy|
16277642|NCT04832815|No Intervention|Treatment as Usual (TAU)|
16277643|NCT04832815|Experimental|Therapeutic Horsemanship Program|
16277644|NCT04832802|Experimental|ACCESS-Vets Intervention Group|This group will receive ACCESS-Vets, a customized employment intervention adapted for use in VA healthcare.
16277645|NCT04832802|Active Comparator|IPS (Usual Care) Group|This group will receive IPS (Individual Placement and Support), the usual evidence-based supported employment program in VA.
16277646|NCT04832789|No Intervention|Best conventional ventilation|
16277647|NCT04832789|Experimental|Ultra-protective ventilation with ECMO|
16277648|NCT04832776|Experimental|FOLFOXIRI+C225|
16277649|NCT04832776|Active Comparator|FOLFOXIRI+BEV|
16277650|NCT04832763|Experimental|Physical function testing, questionnaire|Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.
16277651|NCT04832750||Major Depressive Episode|At least one failed pharmaco trial in current episode
16277652|NCT04832750||Major Depressive Episode with comorbid Borderline Personality Disorder|At least one failed pharmaco trial in current episode
16277653|NCT04832750||Healthy Controls|
16277654|NCT04832737|Experimental|Intervention|SDT theory-based psychotherapeutic treatment model
16277655|NCT04832737|No Intervention|Control|Wait List
16277661|NCT04832711||the high-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
16277662|NCT04832698||Observational (survey administration)|Participants complete a survey over 10 minutes before and after completing training and using the Mentice endovascular simulator device.
16277663|NCT04832685|Experimental|UP and DOWN-Modulation|All participants will receive UP- and DOWN-modulation of the posterior cingulate cortex (PCC).
16277664|NCT04832672||The upfront radiotherapy group|
16277665|NCT04832672||The upfront targeted-therapy group|
16277666|NCT04832659|Active Comparator|CEASE|Those assigned to the Active Comparator arm will receive the CEASE intervention.
16277667|NCT04832659|Experimental|CEASE + BIO|Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
16277668|NCT04832633|Experimental|test bolus(TB) I|We use the TB method with biphasic injection, followed by the saline flush. Initially, we inject the 10 ml of test contrast media with a velocity of 3ml/s and apply the ROI at the bifurcation of PA and descending aorta at the same level. The dynamic curve demonstrates the time to peak enhancement of P second and A second. The first phase of contrast media injection uses a velocity of 2ml/s and the volume of contrast is measured as 2ml/s multiply (A-P) second. The second phase of contrast media injection uses a velocity of 3ml/s and the volume of contrast media is 70ml minus the amount of first phase injection. The total volume of the contrast media is 80ml, including the 10ml for pre-diagnostic test bolus images. We performed the saline flush following the administration of the contrast media with 20 ml normal saline. The start time of the diagnostic scan is at the A second.
16277669|NCT04832633|Experimental|test bolus(TB) II|This group is similar to the TB I. However, we use the lesser contrast media in the second phase of injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus the amount of first phase injection. The total volume of the contrast media is 70 ml, also including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The start time of the diagnostic scan is at the A second as well.
16277670|NCT04832633|Experimental|bolus-tracking(BT) I|Initially, 10ml of test contrast media was administrated but no calculation was performed for these pre-diagnostic test bolus images in this group. Unlike the TB method, we use 10 seconds as the fixed interval of (A-P) in this group. The first phase of contrast media injection uses a velocity of 2ml/s and thus the volume of contrast is 20ml. The second phase of contrast media injection is administered with a velocity of 3ml/s and the volume of the contrast media is 70ml minus 20ml. The total volume of the contrast media is 80 ml. The following saline flush uses 20 ml of normal saline. The tracking scan started after contrast injection was initiated for 15 seconds. The ROI is placed in the descending aorta at the same level of PA bifurcation and the diagnostic CT scan is triggered when the density in the ROI achieves the baseline density plus 150HU.
16277671|NCT04832633|Experimental|bolus-tracking(BT) II|This group is similar to the BT I. The first phase of injection is the same as the BT I group. We use lesser contrast media in the second phase of contrast injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus 20ml. The total volume of the contrast media is 70 ml, including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The protocol for triggering diagnostic CT scan is the same as that in BT I.
16277672|NCT04832607|Experimental|Multivirus (CMV, EBV, AdV)-specific T cells|"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus
~Max dose:
~HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW
~HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW
~Min. dose:
~- 10 T cells/kg recipient BW"
16277673|NCT04832607|Placebo Comparator|Sodium chloride|Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA
16277674|NCT04832594|Experimental|Supplemental MRI|Women randomized to MRI will be examined using a shortened MRI protocol on a Signa Premier 3T MRI scanner. The MRI examination will be reviewed by two radiologists and assigned BI-RADS score. Appropriate clinical work-up will follow according to the BI-RADS score. BI-RADS 3 or higher at initial MRI will be recalled for a second look ultrasound.
16277675|NCT04832594|No Intervention|No MRI (standard-of-care)|"Standard-of-care. Both arms will have had a regular screening mammography examination prior to randomization. The No MRI arm will have no further intervention."
16277676|NCT04832581|Experimental|Experimental Group|The experimental group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. The experimental group was included in the program based on the Orem Self Care Model. The program includes anatomical, physiological and hormonal changes during pregnancy, urinary system infections and preventive measures. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. Both groups were informed that the study was concluded.
16277677|NCT04832581|No Intervention|Control Group|The control group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. After the research was completed, information was given in order to avoid bias and the brochure was delivered. Both groups were informed that the study was concluded.
16277678|NCT04832568||Delirium is determined by CAM or CAM-ICU score|
16277679|NCT04832568||No delirium is determined by CAM or CAM-ICU score|
16277680|NCT04832555|Experimental|Open: non elective irradiation|Patients within inclusion criteria will be enrolled in the experimental treatment: a radiation therapy addressed to non elective site of disease and with a simultaneous integrated boost
16277681|NCT04832529|Active Comparator|Perianal abscess cavity packing|
16277682|NCT04832529|Experimental|Perianal abscess cavity no packing|
16277683|NCT04832516|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
16277684|NCT04832516|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
16277769|NCT04831931|No Intervention|Control Group|No exercise application will be done in this group.Evaluation tests will be applied for 4 weeks only online.
16310085|NCT04606784|Experimental|Ampion|Ampion
16277685|NCT04832503||Group 1|The PROMPT-treated group will include 12 children with idiopathic CAS. The pre-treatment assessment is aimed at evaluating the baseline speech and language level and at treatment planning. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided in order to shape speech movements, to give information on sequencing and timing, and to introduce constraints for the reduction of the degrees of freedom at the articulators' level in favour of motor control. In a PROMPT session the syllables, words and phrases are produced within a communicative context in play. Speech motor goals are, as soon as possible, integrated in goals for language and functional communication.
16277686|NCT04832503||GROUP 2|The LNSOM-treated group will include 12 children with idiopathic CAS. The pre-treatment assessment is aimed at evaluating the baseline speech and language level and at the treatment planning. None of the SLTs treating this group are PROMPT trained. According to the standard care methods used in Italy, the intervention consists of a linguistic and articulatory approach that includes auditory discrimination of phonemic categories at the syllable and word level and non-speech oral motor exercises. Receptive and expressive lexicon and morphosyntax are targeted depending on the children's linguistic profile.Differently from the PROMPT, selection of speech sounds to be targeted, is based on developmental speech sounds acquisition rather than motor criteria. According to this treatment approach, the motor goal is usually identified with the placement of the main articulator involved in the production of a speech sound.
16277687|NCT04832477|Other|Stigma Counseling for PrEP Access|Behavioral counseling
16277688|NCT04832464|Active Comparator|Balance Training Home plan|"The Control group is undergoing balance training only, 3 days a week, and will be for 8 weeks. Balance training includes 10minutes of warm-up and 30 minutes of balance exercises. A force plate will be used to measure the postural sways. Measurements will be taken at a base-line, after the first session, at mid-level (4th week) and at the end (8th week).
~These exercises include Static Balance exercises(1-2weeks): Romberg with eyes open & close, Tandem standing with eyes open & close with alternate feet, Single leg stance.
~Static/ Dynamic/ Anticipatory Postural Control (3-4weeks): Sit to Stand, FRT( forward reach test) that is forward, sideways, cross reach, and timed up and go test.
~Static/ Dynamic/ Anticipatory? Reactive Postural Control (5-6weeks): Perturbations:
~Controlled by the therapist in sitting & standing, Throwing a ball, kicking a ball.
~(7-8weeks): Combination of All"
16277689|NCT04832464|Experimental|BRACE Protocol: Balance training along with resistance, aerobic and cognitive excercises|"BRACE protocol for balance training 3 days a week for 8 consecutive weeks on alternate days.
~These exercises include Static Balance exercises(1-2weeks) plus Chair rise 30 sec without using hands, 6-minute walk, count reverse from 50, push the wall, and reverse count from 20.
~Static, dynamic, anticipatory postural control (3-4weeks) plus Stair climbing without using rails, marching in space, remember 5 words, name 5 animals, repeat 5 words, spell the word like APPLE, spell backward again.
~Static, dynamic, anticipatory postural control (5-6weeks) plus Squatting, cycling, count even numbers from 1-50.
~calculation: Addition, subtraction, multiplication, division. (7-8weeks): Combination of all."
16277690|NCT04832451|Experimental|Intervention Group|"The Beck Depression Inventory[BDI] (inclusion criteria) was applied face to face to the students who constituted the population (n=385). After the BDI scores were evaluated, the students who met the inclusion criteria were randomly assigned to the intervention and control groups.
~In a preliminary interview held with the intervention group (n=10), they were informed about the subject of the research, the duration and content of the implementation process, session rules, and that sessions would be audio-recorded. Informed consent forms were obtained from them, and pre-tests (BDI, Coping Styles Inventory[CSI]) were applied.
~A total of 21 90-minute Interpersonal Relational Role Analysis (IRRA) sessions (two sessions a week) were held with the intervention group.
~21 sessions of IRRA were applied to the intervention group, once the sessions were completed, post-tests (BDI, CSI) were applied. Three months later, a follow-up test (BDI, CSI) was applied to intervention group."
16277691|NCT04832451|No Intervention|Control Group|The students in the control group were informed about the research, informed consents were obtained from them, and pre-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to them. No intervention was applied to the control group (n=10). Once the Interpersonal Relational Role Analysis sessions were completed, post-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to the control group. Three months later, a follow-up test (Beck Depression Inventory, Coping Styles Inventory) was applied to control groups. After the follow-up test, the participants in the control group were referred to the psychological support unit of the university.
16277692|NCT04832438|Experimental|9-ING-41 plus carboplatin|Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle
16277693|NCT04832425|Experimental|PRAX-114|40 mg PRAX-114 once daily
16277694|NCT04832425|Placebo Comparator|Placebo|Placebo once daily
16277695|NCT04832412|Experimental|BrainPhyt Low dose|220 mg BrainPhyt and 500 mg 100 % sunflower oil for 4 weeks, followed by 220 mg for 20 weeks
16277696|NCT04832412|Experimental|BrainPhyt high dose|440 mg BrainPhyt for 4 weeks, followed by 500 mg 100 % sunflower oil for 20 weeks
16277697|NCT04832412|Placebo Comparator|Placebo|1000 mg 100 % sunflower oil for 4 weeks, followed by 500 mg 100 % sunflower oil for 20 weeks
16277698|NCT04832399||Natalizumab|Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks.
16277699|NCT04832373|Other|Humanoid Robot|
16277700|NCT04832360|Experimental|Control (CTL)|Participants do not receive financial incentive intervention
16277701|NCT04832360|Experimental|Single Target (ST)|One member of each dyadic-smoking couple will receive financial incentive intervention
16277702|NCT04832360|Experimental|Dyadic Target (DT)|Both members of each dyadic-smoking couple will receive financial incentive intervention
16277703|NCT04832347|Experimental|Exercise group|Exercise group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
16277704|NCT04832347|Experimental|Vagus group|Vagus therapy will be applied to Group 2 for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
16277705|NCT04832347|No Intervention|Control group|Control group will be followed as a control group and no application will be made.
16277706|NCT04832334||Stroke Patients Group|Stroke patients with hemiplegia or chronic hemiparesis
16277707|NCT04832334||Control Group|Healthy control group age,sex, and level of education matched
16277708|NCT04832321|No Intervention|No intervention: V1: Control|This version of the survey questionnaire depicts a young man with no symptoms of alcohol use disorder
16277709|NCT04832321|Experimental|Experimental: V2: Alcohol Use Disorder|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder."
16277710|NCT04832321|Experimental|Experimental: V3: Alcohol Use Disorder + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with complete response."
16277711|NCT04832321|Experimental|Experimental: V4: Alcohol Use Disorder + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with partial relapse."
16277712|NCT04832321|Experimental|Experimental: V5: Alcohol Use Disorder + Economic Impact|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances."
16277713|NCT04832321|Experimental|Experimental: V6: Alcohol Use Disorder + Economic Impact + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with complete response."
16277714|NCT04832321|Experimental|Experimental: V7: Alcohol Use Disorder + Economic Impact + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with partial relapse and continued negative economic impact."
16277715|NCT04832308|Experimental|SVS SET Program|Participants enroll in SVS Program which includes 1) educational information on PAD, exercise and nutrition, 2) weekly health coaching, and 3) walking therapy prescription.
16277716|NCT04832308|No Intervention|Usual Care|This usual care arm will allow sites to direct patients as they usually do. This could include an in-person exercise therapy program or simply exercise instruction during an office visit.
16277717|NCT04832295|Experimental|Intervention|Photo-supported conversations about well-being, in addition to care as usual
16277718|NCT04832295|Active Comparator|Control|Care as usual
16277719|NCT04832282|Other|Roux-en-Y gastric bypass patients with weight regain|The study population is Roux-en-Y gastric bypass (RYGB) patients with weight regain undergoing an endoscopy at Bellevue Hospital Center or Brigham and Women's Hospital.
16277720|NCT04832269||MP exposed group|children and adolescents (aged 8 to 18 years) of mothers with prenatal exposition to MP in the context of an MS relapse therapy
16277721|NCT04832269||MP non-exposed group/control group|children and adolescents of mothers suffering from MS aged 8 to 18 years
16277722|NCT04832256||High Flow anesthesia|administered 4 L/min fresh gas flow during general anesthesia
16277723|NCT04832256||Low Flow Anesthesia|administered 1 L/min fresh gas flow during general anesthesia
16277724|NCT04832243|Experimental|Experimental: V1: List No. 1|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The first version of the questionnaire includes 6 sets of 3 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully. The statements on food and water insecurity that are included in the experimental version are omitted."
16277725|NCT04832243|Experimental|Experimental: V2: List No. 2|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The second version of the questionnaire includes 6 sets of 4 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully for 3 of the true-false statements. One statement in each set relates to food and water insecurity and is designed to determine the extent to which social desirability bias may influence responses to food and water insecurity questions."
16277726|NCT04832230||Healthy individuals|This group is composed of healthy individuals without previous noise exposure.
16277727|NCT04832230||Acute acoustic trauma patients|This group is composed of patients suffering from acute acoustic trauma.
16277728|NCT04832217|Experimental|Pyrenees' beef group|"In the first period, 24 participants were randomly assigned to a beef (Pyrenees' beef group).
~In the second period, 23 participants were randomly assigned to a beef (Pyrenees' beef group)."
16277729|NCT04832217|No Intervention|Conventional Chicken group|"In the first period, 23 participants were randomly assigned to a conventional chicken-based group (control group).
~In the second period, 24 participants were randomly assigned to a conventional chicken-based group (control group)."
16277730|NCT04832204|Experimental|solid tumor with only liver metastases after first line treatment|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
16277733|NCT04832165|Experimental|Muscle inspiratory strength training|An 8-week muscle inspiratory muscle strength training
16277734|NCT04832165|No Intervention|No training program|No intervention
16277735|NCT04832152|Other|Feasibility trial group|One group (arm) trial where all will receive treatment.
16277736|NCT04832139|Experimental|Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)|Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.
16277737|NCT04832139|Experimental|Marstacimab PFS, then marstacimab PFP|Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.
16277738|NCT04832126||Patient|patients with channelopathies
16277739|NCT04832126||Family|relatives of patients with channelopathies
16277740|NCT04832113|Experimental|Patient Therapeutics Education (PTE)|Educational diagnosis prior radiotherapy and participation to Patient Therapeutics Education (PTE) in Adapted Physical Activity (APA) and dietetic sessions. In addition to conventional support (dietary and hydration advice).
16277741|NCT04832113|Other|Conventional support|Dietary and hydration advices
16277742|NCT04832100||Patients with primary fibromyalgia|Adults with complaints of chronic widespread pain at the outpatient department of KMUH were consecutively enrolled over a 5-year period from July 2017 to June 2022. Participants were interviewed by experienced neurologists , and those who fulfilled the 2011 American College of Rheumatology (ACR) criteria for FM were recruited .
16277743|NCT04832100||Healthy controls|Age- and sex-matched subjects without pain and soreness were also prospectively recruited as healthy controls.
16277744|NCT04832087||Cohort A|Participants with SBS who started Teduglutide after FDA approval (May 2019)
16277745|NCT04832087||Cohort B|Participants with SBS receiving Teduglutide after FDA approval (May 2019) who initially received teduglutide prior to FDA approval (clinical trials)
16277746|NCT04832074|Experimental|Dry Needling|"Dry needling will be performed with 'solid filiform needles'. The procedure is as follows: The participant will lie in the prone position. The overlying skin will be cleaned with antiseptic spray. The taut band and MTrP, will be localized manually.
~After measuring the Pain Pressure Thresholds in this location and the control (located 3 cm lateral to the MTrP), the needle within its plastic guide tube will be placed over the MTrP. After a tapping movement to insert the needle, the needle will be moved to the muscle around the bundle and moved forward and backward to the tissue to elicit a small muscle twitch. After eliciting LTR, needling will be stopped. If no twitch were elicited, needling will stopped after two or three stellate movements"
16277747|NCT04832074|Sham Comparator|Sham Dry Needling|"The same approach will be used with the exception of piercing the skin. The guide tube will press against the tissue and the sham needle will be allowed to drop against the skin. The handle will be tapped briskly but not breaking the skin. The sham needle will stay within the guide tube and will be pressed against the skin twice so as to mimic the quick in and out technique."
16277748|NCT04832048|Experimental|High intensity training (HIT) group|The HIT group performed the exercises with loads at 80-90% of HRF.
16277749|NCT04832048|Experimental|Low-moderate intensity training (LMIT) group|The HIT group performed the exercises with the loads at 50-70% of the HRF
16277750|NCT04832048|Placebo Comparator|No training group|They did not perform any type of programmed physical exercise during the study.
16277751|NCT04832035|Experimental|"Standard psychotherapeutic care + coordinated and peer supported mental health care"|"Participants receive standard psychotherapeutic care in the public healthcare system. For participants and therapists in this group standard care and additional organisational support is available which is labeled coordinated and peer supported mental health care. This includes several additional organisational assistance components that are currently not part of the services of the public mental health care system, i.e. a coordination center, trained peers to support treatment utilisation, a support and training center for therapists, and an interpreter pool.This is Treatment as Usual plus coordination and peer support."
16277752|NCT04832035|Other|"Standard psychotherapeutic care"|Participants receive standard psychotherapeutic care in the public healthcare system. For participants in this group no additional organisational support is available. This is Treatment as Usual.
16277753|NCT04832022||Vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who accepted vaccination against SARS-CoV2
16277754|NCT04832022||Non vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who refused vaccination against SARS-CoV2
16277755|NCT04832009|Experimental|Glucose Infusion|Hyperglycemia (glucose infusion) will receive an I.V. Glucose infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
16277756|NCT04832009|Experimental|Lipid Infusion|Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
16277757|NCT04831996|Experimental|Treat Group 1 : Normal Renal Function|eGFR: ≥ 90 mL/min/1.73 m^2
16277758|NCT04831996|Experimental|Treat Group 2 : Mild Renal Impairment|eGFR: 60-89 mL/min/1.73 m^2
16277759|NCT04831996|Experimental|Treat Group 3 : Moderate Renal Impairment|eGFR: 30-59 mL/min/1.73 m^2
16277760|NCT04831996|Experimental|Treat Group 4 : Severe Renal Impairment|eGFR: ≤ 29 mL/min/1.73 m^2 and not on Hemo Dialysis
16277761|NCT04831996|Experimental|Treat Group 5 : Kidney Failure|eGFR: ≤ 29 mL/min/1.73 m^2 and on Hemo Dialysis
16277762|NCT04831957|Other|Patient underwent TAVI procedure|- Elderly patients who will undergo a TAVI procedure coming to the geriatric day hospital
16277763|NCT04831944|Experimental|Treatment Group 1 : Severe hepatic impairment|Child Pugh (CP) assessment score of 10-14 points
16277764|NCT04831944|Experimental|Treatment Group 2 : Moderate hepatic impairment|Child Pugh (CP) assessment score of 7-9 points
16277765|NCT04831944|Experimental|Treatment Group 3 : Mild hepatic impairment|Child Pugh (CP) assessment score of 5-6 points
16277766|NCT04831944|Experimental|Treatment Group 4 : Normal hepatic impairment|Normal hepatic function
16277767|NCT04831931|Experimental|Supervised Exercise Group|"Telerehabilitation will be applied in this group, which will last 4 weeks, and include the following processes
~Exercises that will be performed every Monday will be taught and applied face-to-face under the supervision of the therapist with online videoconferencing method. Then, videos of weekly exercises that will be prepared by the therapist will be transmitted online to patients.
~Patients will be asked to perform these exercises 4 days a week in the same week, on Wednesdays, Fridays and Sundays.
~Also, a video call will be made on Fridays to evaluate whether the movements are done effectively and correctly, and questions of patients (if any) will be answered.
~Patients will be informed by the physiotherapist that they should send messages on Wednesdays and Sundays to show that they are doing the exercises.
~The exercise program of new week will be taught every Monday for 4 weeks, the prepared video will be sent, and the program will be advanced and completed."
16277768|NCT04831931|Active Comparator|Exercise Group|Exercise recommendations will be made to this group. Videos and photographs of weekly exercises prepared by the therapist will be sent online to the patient every Monday for 4 weeks, patients will be advised to repeat these exercises 4 days a week.
16278325|NCT04828109|Active Comparator|Fitbit Only|Fitbit daily step goal of 2,000 steps.
16277770|NCT04831918|Experimental|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of the Mueller cemented cup as acetabular component.
16277771|NCT04831905|Experimental|Pilote study|Micro-wave ablation of index lesion identified on MRi on prostate cancer
16277772|NCT04831892|Experimental|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Topical lotion containing isosorbide diesters and colloidal oatmeal to be applied to the entire body once daily.
16277773|NCT04831892|Active Comparator|Moisturizer containing colloidal oatmeal|Topical moisturizer with colloidal oatmeal to be applied to the entire body once daily
16277774|NCT04831879|Experimental|Group A AMPS - sham|Treatment phase 1: AMPS Treatment phase 2: sham
16277775|NCT04831879|Experimental|Group B sham - AMPS|Treatment phase 1: sham Treatment phase 2: AMPS
16277776|NCT04831866||Surveillance Cohort|Surveillance Cohort: Schools participating in this cohort will be performing surveillance testing weekly on approximately 10-20% of students and 100% of staff.
16277777|NCT04831866||Exposure Cohort|Exposure Cohort: Schools participating in this cohort will be performing exposure testing on students and staff who have been identified as having close contact with school members diagnosed with SARS-CoV-2 infection.
16277778|NCT04831853|Experimental|Supervised self-swabbing followed by conventional swabbing|the subjects will first benefit from a 5 minutes explanation on how to perform self-swabbing and will then performed the swabbing under the supervision of a trained healthcare professional
16277779|NCT04831853|Experimental|Conventional swabbing followed by supervised self-swabbing|the subject will undergo conventional nasopharyngeal swabbing performed by a trained healthcare professional first.
16277780|NCT04831840||Female participants with recurrent urinary tract infections (RUTI).|Patients with RUTIs (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
16277781|NCT04831840||Female control patients without RUTIs|Patients without RUTIs (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
16277785|NCT04831814|Experimental|Near Focus NBI|Use of the Near Focus NBI to make optical diagnosis
16277786|NCT04831814|Active Comparator|Standard Focus NBI|Use of the Standard Focus NBI to make optical diagnosis
16277787|NCT04831801||Female patients with overactive bladder (OAB)|Patients with urgency and frequency syndrome with or without pelvic pain (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
16277788|NCT04831801||Female control patients without LUTS|Patients without LUTS (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
16277790|NCT04831775|Experimental|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice over 8 weeks. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on. The intervention group will be asked to practice 20 minutes, 7 days a week.
16277791|NCT04831775|Active Comparator|Brain Games Only|An active control group will be used. The differing variable between the two groups is the class sessions. Those randomized to the control group will only receive a link to the BrainHQ games site. A specific amount of practice will not be prescribed, but the frequency and duration of participant's practice will be obtained from BrainHQ. Participants will receive a weekly phone call to maintain connection to the study. Data collection will be on the same schedule as the intervention group.
16277792|NCT04831736|Experimental|Treatment|
16277793|NCT04831736|Placebo Comparator|Control|
16277794|NCT04831710|Experimental|Sintilimab+Chidamide|Participants will receive Sintilimab,200mg, ivd, d1; Chidamide,30mg,po,biw,d1-21; repeated every 3 weeks(up to 1 year) until disease progression, intolerable toxicity, death, or termination of the study for any reason.
16277795|NCT04831697|Experimental|Multi-Caregiving Intervention|The multi-caregiving intervention consists of group-based, peer support, and nurse-facilitation and includes: a. Storytelling/shared experiences (30 minutes); Peer support and problem solving (30 minutes); Coping strategies (30 minutes); and Structured Diabetes Education and Skills Training (30 minutes).
16277796|NCT04831697|Active Comparator|Diabetes Enhanced Usual Care Intervention|This is composed of group-based, nurse-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
16277797|NCT04831684|Placebo Comparator|Group A|
16277798|NCT04831684|Experimental|Group B|
16277799|NCT04831671|Active Comparator|Infra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an infra-patella approach.
16277800|NCT04831671|Experimental|Supra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an supra-patella approach.
16277886|NCT04831034|Experimental|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
16277801|NCT04831658|Experimental|Orelabrutinib combined with PD-1 and fotemustine|Orelabrutinib 200 mg,qd,Oral administration; PD-1 200mg D1 dissolved in 100mL 0.9% NS, intravenously ;Fotemustine 100mg/m2 D2 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light .
16277802|NCT04831632||people aged 50-75|men and women aged 50-75 who belong to Hospital El Cruce's coverage area and do not have personal history of colorectal cancer or inflammatory bowel disease, personal or family history of syndromes of predisposition to known cancers, or family history of colorectal cancer in a first-degree relative aged less than 60
16277803|NCT04831619|Experimental|PET scanner in addition to MRI|
16277804|NCT04831606|Active Comparator|Control Arm|Patients will receive a biweekly standard treatment at home according to the International Working Group on Diabetic Foot consisting of: Debridement of the lesion, unloading with a brace up to the calf, non-removable (except for contraindications), dressing of the wound with advanced dressings in use at the specialized center and in the home care network.
16277805|NCT04831606|Experimental|EmoLED Arm|Patients on top of the standard treatment of the control arm will receive EmoLED blue light irradiation for two minutes at each biweekly medication.
16277806|NCT04831593||Group Elective|In our clinic, pediatric patients who will undergo elective surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in elective pediatric patients before general anesthesia.
16277807|NCT04831593||Group Emergency|In our clinic, pediatric patients who will undergo emergency surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in emergency pediatric patients before general anesthesia.
16277808|NCT04831580|Active Comparator|Open radical hysterectomy|
16277809|NCT04831580|Experimental|Robotic radical hysterectomy|
16277810|NCT04831567|Experimental|Interventional|The participants will be submitted to metaiodobenzylguanidine 4 doses of 7.400 Mbq (million of Becquerels) (200 mCi). Each dose will be repeated with a minimum interval of 60 days.
16277813|NCT04831541|Experimental|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
16277814|NCT04831528||No secondary changes of drug resistance|
16277815|NCT04831528||Secondary mutations of RAS|
16277816|NCT04831528||Secondary mutation of BRAF|
16277817|NCT04831528||HER2 amplification|
16277818|NCT04831528||Other secondary mutations|
16277819|NCT04831515|Experimental|Lens A|"daily disposable soft contact lens - test lens
~Subjects will be randomized to wear test lenses for one week and then cross-over to control lenses for one week."
16277820|NCT04831515|Active Comparator|Lens B|"daily disposable soft contact lens - control lens
~Subjects will be randomized to wear control lenses for one week and then cross-over to test lenses for one week."
16277821|NCT04831502|Experimental|Sequence 1: TAK 906 50 mg (Treatment A+Treatment B+Treatment A+Treatment B+Treatment C)|Participants will receive TAK-906 50 milligram (mg) as Treatment A (TAK-906 capsule) and Treatment B (TAK-906 tablet) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
16277822|NCT04831502|Experimental|Sequence 2: TAK-906 50 mg (Treatment B+Treatment A+Treatment B+Treatment A+Treatment C)|Participants will receive TAK-906 50 mg as Treatment B (TAK-906 tablet) and Treatment A (TAK-906 capsule) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
16277823|NCT04831489||deep sedation|Anesthesia will be induced using titrated doses of propofol (0.5-1.5 mg/kg) and fentanyl (25-50 μg) initially to carefully maintain spontaneous breathing yet maintaining airway patency. Once adequate jaw relaxation is achieved, the endoscopy probe will be inserted. Maintenance of sedation will be carried out using propofol infusion between 80-120 mcg/kg/min. Additional dose 25-50 mg propofol will be given to the patient if spontaneous movement occurs
16277824|NCT04831489||Genral anesthesia|"After mask pre-oxygenation, anesthesia will be induced with (2 mg/kg) propofol and (1 μg /kg) fentanyl. The neuromuscular blockade will be achieved with (0.5 mg/kg) atracurium followed by tracheal intubation. Anesthesia will be maintained to keep the end-tidal anesthetic concentrations within 1 MAC for sevoflurane.
~The neuromuscular blockade will be maintained with intermittent doses of atracurium (0.1mg/kg). Mechanical ventilation is adjusted with fresh gas flow oxygen in air 30-40% at a rate of 2 L/min to maintain end-tidal carbon dioxide of 35-40 mm Hg. Reversal of neuromuscular blockade will be achieved by intravenous administration of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg."
16277825|NCT04831463|Experimental|experimental group|The experimental (N = 49) received a short-term IHAPIM program by one-on-one interview (5 week, 1 hr per week, 10 hr in total).
16277826|NCT04831463|No Intervention|control group|Firstly, Pre-tests were applied to the men in the control group. No intervention was applied to this group. Post-tests were made 3 months after finished intervention which applied to experimental group.
16277827|NCT04831450|Experimental|Cemiplimab After CRT in HNSCC|Participants will receive Cemiplimab for 6 consecutive months (a total of 8 cycles) 14-42 days after completion of standard of care CRT.
16277828|NCT04831437|Experimental|Hypofractionated|EBRT 40Gy/15fr
16277829|NCT04831437|Active Comparator|Control Group|EBRT 45Gy/ 25fr
16277830|NCT04831424|Experimental|Healthy controls|No diagnosis of mitochondrial disease
16277831|NCT04831424|Experimental|Mutation|Participants carrying the m.3243A>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
16277832|NCT04831424|Experimental|Mutation with MELAS|Participants carrying the m.3243A>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
16277833|NCT04831424|Experimental|Deletion|Participants carrying a single, large-scale mtDNA deletion
16277884|NCT04831047|Experimental|Upneeq Group|Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)
16278326|NCT04828109|No Intervention|Control|Standard of care
16277834|NCT04831411|Active Comparator|Whole Body Vibration|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive whole-body vibration training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
16277835|NCT04831411|Active Comparator|Progressive Resistance Training|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive resistance training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
16277836|NCT04831398|Active Comparator|Control|Time control experiment (CON). Nothing given to subject
16277837|NCT04831398|Placebo Comparator|Placebo|Placebo (PLA) is 10 sublingual sprays of a diluted (1 microliter/29ml filtered water) mint extract.
16277838|NCT04831398|Experimental|Melatonin|5mg commercially available melatonin (MEL) spray will be given sublingually.
16277839|NCT04831385|Experimental|CBT-i|
16277840|NCT04831385|No Intervention|Control (Usual Care)|Control
16277841|NCT04831372|Active Comparator|On Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.
~The control group will be using the first method, which is the on-table method, which uses a specialized surgical table, called a traction table. This table involves placing both feet in specialized boots that are then hooked up to the table, and allows for positioning of the operative leg with aid of the table.
~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
16277842|NCT04831372|Experimental|Off Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.
~The experimental group will be using the second method, which is the off-table method. In this method the patient is placed on a standard operating room table and the operative leg is manually positioned by the surgeon during the procedure . This obviates the need for the additional staff members or purchase of a specialized table.
~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
16277843|NCT04831346|Experimental|low level laser|"A low-level gallium arsenide diode (Biolase, USA) at a 940 nm wavelength with 0.2 W output power and 2 J energy. The device was calibrated, and the probe was disinfected prior to every treatment.
~The Masseter and Temporalis muscles will be bilaterally assessed with constant pressure to define tenderness.
~LLLT applied perpendicular to each tender point of the intended muscles for 10 seconds with an energy density of 2.5 J/cm2.
~Sessions are scheduled 3 days a week (every other day)"
16277844|NCT04831346|Experimental|Occlusive splint therapy|"A soft occlusal splint (vacuum-formed ) made from a 2-mm-thick elastic rubber sheets will be used.
~Splints were individually designed ( in the out patient clinic of the college of dentistry) for the upper arch of each patient. An alginate imprint of the maxillary arch will be taken to fabricate a master cast of the maxilla.
~A vacuum pressure device was utilized for molding the rubber sheets (13 x 13 cm /2-mm thickness).
~Sheets were removed after it has been appropriately adjusted to the mold in the vacuum former. Edges will be properly trimmed, and the palate part is detached to obtain the end shape.
~Participants are instructed to wear the splint at all times except during mealtimes and oral hygiene."
16277845|NCT04831346|No Intervention|Control|This group will be a wait list group recieving no intervention except for the regular analgesic prescribed by the reffering dentist
16277846|NCT04831333||Active CMVR|The UWF images of cytomegalovirus retinitis (CMVR) included various patterns: hemorrhagic necrotizing lesion, granular lesion, frosted branch angiitis, and optic neuropathy lesion. Active CMVR lesion was defined as obvious opacity (mild, moderate, severe, very severe)
16277847|NCT04831333||Inactive CMVR|Inactive CMVR lesion was defined as a lack of opacity or questionable/equivocal activity.
16277848|NCT04831333||Non-CMVR|The non-CMVR images included normal retina and other retinopathies such as HIV-related microvascular retinopathy, diabetic retinopathy, retinal detachment, vitreous hemorrhage.
16277849|NCT04831320|Experimental|nab-Paclitaxel + Nivolumab|"nab-Paclitaxel 125 mg/m^2 intravenous (IV) on days 1, 8 & 15 of each 28-day cycle.
~Nivolumab 480 mg IV Day 1 of each 28-day cycle."
16277850|NCT04831307|Experimental|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
16277851|NCT04831294|Experimental|Cannabidiol (CBD)|A tincture containing 125mg broad spectrum CBD oil (6.7%), 24mg sunflower lecithin (1.3%), 56mg peppermint oil (3.0%), and 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
16277852|NCT04831294|Placebo Comparator|Placebo|A tincture containing 149mg sunflower lecithin (8.0%), 56mg peppermint oil (3.0%), 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
16277853|NCT04831281|Experimental|Low Dose|Daily subcutaneous injection of Low Dose ATH-1017
16277854|NCT04831281|Experimental|High Dose|Daily subcutaneous injection of High Dose ATH-1017
16277855|NCT04831281|Placebo Comparator|Placebo|Daily subcutaneous injection of Placebo
16277856|NCT04831268|Experimental|Glucose as reference food|"Twelve healthy, normal weight subjects (male: 7, female:
~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
16277885|NCT04831047|Sham Comparator|Control Group|Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)
16277857|NCT04831268|Experimental|Lentils and lupins mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:
~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
16277858|NCT04831268|Experimental|Trahanas with tomato sauce mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:
~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
16277859|NCT04831268|Experimental|Halva with currants mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:
~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
16277860|NCT04831255|Experimental|ZILRETTA|Single injection of triamcinolone acetonide extended-release injectable suspension, injected in the glenohumeral joint under ultrasound guidance.
16277861|NCT04831229|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
16277862|NCT04831229|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
16277863|NCT04831216|Experimental|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
16277864|NCT04831203|Experimental|Protein-hydrolysate|Dietary supplement: an egg-protein hydrolysate (NWT-03) Study volunteers will receive a daily powder of 5 g of protein hydrolysate to mix with 200 mL of water for 36 weeks.
16277865|NCT04831203|Placebo Comparator|Control|Control: 5 g of maltodextrin powder mixed with 250 mL of water for 36 weeks.
16277866|NCT04831190|Experimental|Intervention|All participants will be involved in a tailored exercise intervention for 12 weeks.
16277867|NCT04831177|Active Comparator|Patients planned to undergo Femtosecond laser FS assisted LASIK|In FS group, Allegretto WaveLight FS-200 femtosecond laser was used to create flaps with flap thickness planned to be 100 um.
16277868|NCT04831177|Active Comparator|Patients planned to undergo Microkeratome MK assisted LASIK|In MK group, Moria 2 Microkeratome was used to create flaps with flap thickness planned to be 100 um.
16277869|NCT04831164||Case|Patients with MRI confirmed rotator cuff tears
16277870|NCT04831164||Control|Patients without rotator cuff tears
16277871|NCT04831151|Active Comparator|Drospirenone group: 0,03 mg ethinylestradiol + 3 mg drospirenone|generic name:yasmin dosage form:oral dosage: 0,03 mg ethinylestradiol + 3 mg drospirenone frequency: once a day duration: 3 months
16277872|NCT04831151|Active Comparator|cyproterone acetate group: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate|generic name:diane 35 dosage form:oral dosage: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate frequency: once a day duration: 3 months
16277873|NCT04831138|Experimental|RCC Patients|Patients with locally advanced or metastatic renal cell carcinoma
16277874|NCT04831125||Individuals receiving conduction system pacing|
16277875|NCT04831112|Experimental|Honey|Topical honey to be used for dressing 4ml per square inch.
16277876|NCT04831112|Active Comparator|EUSOL|EUSOL soaked gauze to be placed over the wound as dressing.
16277877|NCT04831099|Experimental|Testosterone|Testosterone gel (20 mg/day) for 8 weeks per period.
16277878|NCT04831099|Placebo Comparator|Placebo|Placebo gel (20 mg/day) for 8 weeks per period.
16277879|NCT04831086|Experimental|Intervention|"In the intervention arm, the management will be optimized according to the risk of the predictive model. The predictive model of intra-amniotic infection includes maternal C-reactive protein (CRP) (in mg/L) and amniotic fluid glucose (in mg/dL), and the predictive model of spontaneous preterm delivery within 7 days includes gestational age (in weeks), cervical length (in mm), amniotic fluid glucose (in mg/dL) and Interleukin (IL)-6 (in a log10 scale). High risk will be defined when the risk is > 10% in the predictive model of spontaneous delivery in 7 days and > 20% in the predictive model of intra-amniotic infection:
~If low-risk: we will optimize the standard management reducing the dose of steroids (e.g not administering second doses), tocolysis duration and facilitating discharge home.
~If high-risk: we will follow the standard management of each center and we will treat with antibiotics"
16277880|NCT04831086|No Intervention|Control|In the control arm the standard management of each center will be followed regarding doses of steroids, duration of tocolysis or maternal stay length duration.
16277881|NCT04831073||Acute type A aortic dissection|Patients who underwent surgery for acute type A aortic dissection
16277882|NCT04831060||Case (patients with stage 3 or 4 periodontitis)|
16277883|NCT04831060||Control (healthy periodontium)|Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries or aesthetic surgeries
16277888|NCT04831008|Active Comparator|Figure-of-eight|Using the figure-of-eight closure technique when closing access for structural heart therapies.
16277889|NCT04831008|Active Comparator|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
16277890|NCT04830995|Experimental|diet program|moderate restricted diet (1800-2000 kcal/day) for four weeks, 3 sessions weekly
16277891|NCT04830995|Experimental|high intensity interval training|high intensity interval training for four weeks, 3 sessions weekly
16277892|NCT04830982|Experimental|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
16277893|NCT04830982|Placebo Comparator|Placebo|Placebo as additive to hypothermic hyperkalemic cardioplegia.
16277894|NCT04830969|Experimental|A: Diabetic + SRP + SPT|The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
16277895|NCT04830969|Experimental|B: Non-Diabetic + SRP + SPT|The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
16277896|NCT04830969|Active Comparator|C: Diabetic + SRP|The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
16277897|NCT04830969|Active Comparator|D: Non-Diabetic + SRP|The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
16277898|NCT04830956|Experimental|Sequence 1|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
16277899|NCT04830956|Experimental|Sequence 2|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
16277900|NCT04830956|Experimental|Sequence 3|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
16277901|NCT04830956|Experimental|Sequence 4|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
16277902|NCT04830956|Experimental|Sequence 5|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
16277903|NCT04830943|Other|Olfactory and gustatory disorders after covid 19 infection|Cerebrolysin Dose:10 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 8 more weeks.
16277904|NCT04830930|Experimental|Sequence 1|Period 1: fasted condition/ Period 2: fed condition
16277905|NCT04830930|Experimental|Sequence 2|Period 1: fed condition/ Period 2: fasted condition
16277906|NCT04830917|Experimental|Treatment with Kinesiotape and Oval 8|
16277907|NCT04830917|Experimental|Treatment with quick cast|
16277908|NCT04830904|Experimental|Use of lycra garments|the subjects are assessed with and without wearing the device
16277909|NCT04830878|Experimental|Treatment|Methotrexate treatment
16277910|NCT04830852||Recovery Group|Participants aged 21 years and younger and enrolled within 12 weeks after acute infection or positive test. These participants will attend study visits at baseline, every 3 months for the first 6 months, and subsequently every 6 months for a total of 3 years.
16277911|NCT04830852||Convalescent Group|Participants aged 21 years and younger and enrolled more than 12 weeks after acute infection or positive test. These participants will attend study visits at baseline and subsequently every 6 months for a total of 3 years.
16277912|NCT04830852||Household contacts of infected patients|Household contacts of the infected patients will serve as a control group and will attend visits for evaluations and sample collection at baseline and every 12 months for a total of 3 years.
16277913|NCT04830852||Parents/guardians of participants|Parents or guardians of participants in all cohorts will also be enrolled for limited participation to complete questionnaires about how the family is impacted by the participant's health and SARS-CoV-2.
16277914|NCT04830839|Experimental|Recovery after Stress Toolkit (ReSeT)|"ReSeT is comprised of interactive web-based psychoeducational modules that are developmentally tailored for school age children (8-17 years) for use with synchronous e-health therapy sessions with a trained therapist.
~Participants in the ReSeT treatment will complete 8 modules and therapy sessions. Parents will also have access to 4 modules During the study, children/youth will be asked to complete all eight sessions of the online treatment together with the therapist over an 8 -12 week time period (to allow for scheduling/cancellations). For younger children, parents will participate in the beginning and end of each session. Sessions will last approximately 30-60 minutes and will occur approximately every week for an anticipated 4-8 hour time commitment. Parents of older children will be permitted to review the content independently and participate in feedback sessions."
16277915|NCT04830813|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
16277916|NCT04830813|Placebo Comparator|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
16277917|NCT04830800|Experimental|COVIVAC 1mcg|1mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
16277918|NCT04830800|Experimental|COVIVAC 3mcg|3mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
16277919|NCT04830800|Experimental|COVIVAC 10mcg|10mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
16277920|NCT04830800|Experimental|COVIVAC 1mcg + CpG1018 1.5mg|1mcg + CpG1018 IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
16277921|NCT04830800|Placebo Comparator|Placebo|Phosphate buffered saline (pH 7.2) for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
16277922|NCT04830787||hypertrophic cardiomyopathy|patients with hypertrophic cardiomyopathy
16277923|NCT04830787||control without hypertrophic cardiomyopathy|controls without hypertrophic cardiomyopathy
16277924|NCT04830774|Other|COVID-19 patients with new-onset AF|Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.
16277925|NCT04830761|Experimental|Habit - Motivation group|First: 2 weeks habit intervention; Second: 2 weeks motivation intervention
16277926|NCT04830761|Experimental|Habit - Social group|First: 2 weeks habit intervention; Second: 2 weeks social intervention
16277927|NCT04830761|Experimental|Habit - Habit group|4 weeks habit intervention
16277928|NCT04830761|Experimental|Motivation - Habit group|First: 2 weeks motivation intervention; Second: 2 weeks habit intervention
16277929|NCT04830761|Experimental|Motivation - Social group|First: 2 weeks motivation intervention; Second: 2 weeks social intervention
16277930|NCT04830761|Experimental|Motivation - Motivation group|4 weeks motivation intervention
16277931|NCT04830761|Experimental|Social - Habit group|First: 2 weeks social intervention; Second: 2 weeks habit intervention
16277932|NCT04830761|Experimental|Social - Motivation group|First: 2 weeks social intervention; Second: 2 weeks motivation intervention
16277933|NCT04830761|Experimental|Social - Social group|4 weeks social intervention
16277934|NCT04830748|Active Comparator|Therapeutic exercises group|The first group will receive therapeutic exercises in the form of stretching and strengthening exercises of the knee.
16277935|NCT04830748|Experimental|Therapeutic exercises and mechanical traction group|The experimental group will receive the same exercise program of the first group preceded by continuous mechanical traction of the knee.
16277938|NCT04830722|Active Comparator|Sculptra Aesthetic Side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.
16277939|NCT04830722|Placebo Comparator|Placebo side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side
16277943|NCT04830683||ICU Covid-19 patients|Covid-19 patients admitted for refractory respiratory failure despite conventional oxygen therapy requiring Intensive Care Unit (ICU) admission and oxygenation through either High Flow Nasal Cannula (HFNC) therapy or endotracheal intubation with mechanical ventilation
16277944|NCT04830683||non-ICU Covid-19 patients|Covid-19 patients admitted at hospital requiring conventional oxygen or continuous positive airways pressure (cpap)
16277945|NCT04830683||matched control subjects|Healthy subjects matched for similar cardiovascular risk factors than ICU Covid-19 patients
16277946|NCT04830683||ICU septic shock patients|Septic shock patients corresponded to refractory hypotension in response to an infection, in non Covid-19 patients, requiring ICU hospitalisation for vasopressors to maintain mean arterial pressure (MAP) > 65mm Hg despite adequate volume resuscitation according to the Surviving Sepsis Campaign
16277947|NCT04830670||Large sinus|same patient, sinus width > 12mm measured at 10mm from the alveolar crest at the planned implant site
16277948|NCT04830670||narrow sinus|same patient, sinus width < 12mm measured at 10mm from the alveolar crest at the planned implant site
16277949|NCT04830657|Experimental|Distant reiki group|The application will be carried out by the researcher who has received level 2 reiki training. Reiki energy will be sent to the individuals who have undergone hemodialysis with the intention of healing. The Reiki practitioner is enabled to send the Reiki remotely in a quiet and lonely room. The practitioner moves to the right side of the individual, imagining as if he is next to the individual, and his aura (the energy that exists around the body) is corrected 3 times from above and from the head to the feet. The practitioner's hands are held side by side. Starting from the beginning of the application, reiki energy is sent to the 7 main chakras in an average of 3 minutes, from top to bottom. Each session is approximately 21-25 minutes. After the session, the chakra equalization process is applied to help the frequencies of the chakras to work in harmony with each other. 15 minutes in total. Balancing is done.
16277950|NCT04830657|Other|Control|Patients will receive routine treatment in accordance with the institution policy without any intervention in the control group.
16277951|NCT04830644|Experimental|Iguratimod 1|orally 25mg twice a day
16277952|NCT04830644|Experimental|Iguratimod 2|orally 20mg twice a day
16277953|NCT04830644|Experimental|Iguratimod 3|orally 10mg twice a day
16277954|NCT04830644|Placebo Comparator|Placebo|orally twice a day
16277955|NCT04830605|Experimental|Intervention|Internet-delivered treatment for parents with health anxiety on behalf of their child. Eight weeks with therapist support.
16277956|NCT04830592|Experimental|Part A|NG-641 monotherapy
16277957|NCT04830592|Experimental|Part B|NG-641 and pembrolizumab
16277958|NCT04830579|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in Period 1 and a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16277959|NCT04830579|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in Period 1 and a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16277962|NCT04830553|Experimental|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
16277963|NCT04830553|No Intervention|Waiting list.|Each couple will go through an initial waiting period before the treatment phase. Duration of the waiting period: five weeks.
16277964|NCT04830540|No Intervention|Control|Participants assigned to the control group will be asked to continue wearing their typical shoes and to complete every two weeks the footwear and injury log provided
16277965|NCT04830540|Experimental|Intervention|Individuals assigned to the intervention group will be provided with 2 styles of the OOFOS recovery shoes, and will be asked to wear the OOFOS slide, sandal and/or closed toe shoes as their primary footwear outside training and competition for the 6 weeks between study visits. Intervention participants will also be asked to complete a daily shoe wear log and a shoe comfort assessment survey every other week.
16277966|NCT04830527|Experimental|Intervention group|Patients in experimental group will receive EMA prompts. Therapists in this group will receive a summarized PDF report before the beginning of the first psychotherapy session. The report will include graphic summarized data from the EMA prompts.
16277967|NCT04830527|Active Comparator|Control group|"Patients in control group will receive the EMA prompts in the same manner as patients in the experimental group.
~Therapists in this group will not receive the PDF reports, and instead will get raw scores from a screening evaluation conducted with patients in the recruitment phase of the study."
16277968|NCT04830514|Experimental|Recommended dietary allowance (RDA) for protein|(RDA; 0.8g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
16277969|NCT04830514|Experimental|Habitual protein intake consistent with population level norms|(NHANES; 1.0g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
16277970|NCT04830514|Experimental|Optimal protein intake (OPI)|(OPI; 1.5g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
16277972|NCT04830488|Experimental|Body Image after Head and Neck Cancer Treatment|
16277973|NCT04830475|Experimental|NIV Group|In poostoperative period, patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
16277974|NCT04830475|Active Comparator|Control Group|In the postoperative period, patients were offered VenturiMask with Fio2 60% at 15 l / m.
16277975|NCT04830462|Other|LTBI and DM|Participants with LTBI and DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
16277976|NCT04830462|Other|LTBI without DM|Participants with LTBI without DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
16277977|NCT04830449|Experimental|HCP1904-2|
16277978|NCT04830449|Active Comparator|RLD2001-2|
16277979|NCT04830423|Active Comparator|medikal ozone group|medical ozone group patients diagnosed with knee ostheoarthritis
16277980|NCT04830423|Other|steroid group|steroid group patients diagnosed with knee ostheoarthritis
16277981|NCT04830410|Experimental|Fructan powder|2 g of fructan powder 3 times per day for 7 days
16277982|NCT04830410|Placebo Comparator|Placebo|2g of placebo (maltodextrin) 3 times per day for 7 days.
16277983|NCT04830397|Experimental|QLS-101 0.5%|
16277984|NCT04830397|Experimental|QLS-101 1%|
16277985|NCT04830397|Experimental|QLS-101 2%|
16277986|NCT04830397|Active Comparator|Timolol Maleate 0.5% preservative free ophthalmic solution|
16277987|NCT04830384|Experimental|Fully Active|LLLT & Music Therapy
16277988|NCT04830384|Active Comparator|LLLT Only|LLLT Therapy
16277989|NCT04830384|Placebo Comparator|Music Only|Music Therapy
16277990|NCT04830384|Sham Comparator|Placebo|No Therapy
16277991|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #1)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
16277992|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #2)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
16277993|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #3)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
16277994|NCT04830371|Active Comparator|Arm D (Typbar-TCV)|Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.
16277995|NCT04830358|Experimental|EuPCV15|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
16277996|NCT04830358|Active Comparator|Prevenar13|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
16277997|NCT04830345|Experimental|ATGC-100 100U|ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
16277998|NCT04830345|Active Comparator|Botox 100U|Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
16277999|NCT04830332|Other|Study group|Women with endometrial carcinoma
16278035|NCT04830085|Active Comparator|Patients without adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was excluded with histopathological assessment.
16278036|NCT04830072|Experimental|AR group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support with AR pictures
16278037|NCT04830072|Active Comparator|Control group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support
16278038|NCT04830059|Experimental|High intensity intermittent training|HIIT exercise program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes.
16278418|NCT04827511||control group|81 healthy children, not known or diagnosed with a chronic disease of any kind
16278000|NCT04830319|Experimental|Test-control group (TCG)|The test-control group (TCG) will initiate the protocol with exercises of the Pilates method, which includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. The TCG group will then conduct 20 task-oriented training sessions
16278001|NCT04830319|Active Comparator|Control-test group (CTG)|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
16278002|NCT04830306|Active Comparator|6MST|Six minute step test
16278003|NCT04830306|Active Comparator|6MWT|Six minute walk test
16278004|NCT04830306|Active Comparator|CPET|Cardiopulmonary exercise test
16278005|NCT04830280|Active Comparator|Posterior quadratus lumborum block|
16278006|NCT04830280|Sham Comparator|control group|
16278007|NCT04830267|Active Comparator|Camrelizumab alone|Camrelizumab 200mg IV every 2 weeks
16278008|NCT04830267|Experimental|Stereotactic body radiotherapy plus Camrelizumab|Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks
16278009|NCT04830254|Active Comparator|study group(A)|Group (A) included 20 patients who received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs) for 45 min per session, three times per week, and for 12 weeks.
16278010|NCT04830254|Sham Comparator|Control group(B)|The control group(B) included 20 patients who received placebo TENS stimulation but with a voltage level falling to zero after 10 s of stimulation
16278011|NCT04830215|Other|Brexpiprazole|Brexpiprazole as a flexible dose; 0.5 to 2 mg/day and patient will continue on the stable dose of ADT that they were taking at screening.
16278012|NCT04830189|Experimental|shoulder slings|Patients were used shoulder sling in addition to conservative treatment.
16278013|NCT04830189|Active Comparator|forearm sling|Patients were used forearm sling in addition to conservative treatment.
16278014|NCT04830176|Active Comparator|moringa|First phase of subjects were given dentifrice for brushing
16278015|NCT04830176|Active Comparator|miswak|second phase of subjects were given dentifrice for brushing
16278016|NCT04830163|Experimental|Paired corticomotoneuronal stimulation during sensorimotor mu rhythm trough phases|
16278017|NCT04830163|Active Comparator|Paired corticomotoneuronal stimulation during random sensorimotor mu rhythm phases|
16278018|NCT04830150|Experimental|supportive interventions group|Supportive and educational nursing interventions about reducing maternal stress levels in the experimental group included the following: the NICU was physically described to mothers on the first day they visited their infants, mothers were introduced to team members, and given information about how to obtain information about their baby, visiting hours and conditions.
16278019|NCT04830150|No Intervention|control group|Mothers did not have any other intervention applied by the researchers during routine operation while their infants were in the unit.
16278026|NCT04830124|Experimental|Advanced Cutaneous Melanoma|Patients with unresectable and/or metastatic cutaneous melanoma
16278027|NCT04830124|Experimental|Advanced mucosal melanoma|Patients with unresectable and/or metastatic mucosal melanoma
16278028|NCT04830111|Experimental|heart rate variability biofeedback training group|The goal of heart rate variability biofeedback is to increase heart rate variability through paced breathing exercises, which have shown to be effective in reducing stress and anxiety in general adult populations.
16278029|NCT04830111|No Intervention|Care as usual|In this condition, all of this group take care by hospital routine and the questionnaires were completed over a period with similar intervals.
16278030|NCT04830098|Experimental|Stabilization group|Stabilization group will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
16278031|NCT04830098|Experimental|Manipulation group|Manipulation group be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
16278032|NCT04830098|Experimental|Stabilization and Manipulation group|Stabilization and Manipulation group will be given both stabilization exercises and manipulation exercises.
16278033|NCT04830098|No Intervention|Control group|No application will be made in the control group.
16278034|NCT04830085|Experimental|Patients with adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was diagnosed with histopathological assessment.
16310086|NCT04606784|Other|Standard of Care|Standard of Care
16278039|NCT04830059|Experimental|HIIT with pollution reduction|HIIT program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
16278040|NCT04830059|Experimental|Moderate intensity continuous training|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise.
16278041|NCT04830059|Experimental|MICT with pollution reduction|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
16278042|NCT04830059|Experimental|Stretch control group|Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.
16278043|NCT04830059|Experimental|Control with pollution reduction|"Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.
~Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10."
16278044|NCT04830046||Multiple Myeloma-MM patients|People with Multiple Myeloma-MM receiving covid 19 vaccine
16278045|NCT04830046||Waldenstrom's macroglobulinemia-WM patients|People with Waldenstrom's macroglobulinemia-WM receiving covid 19 vaccine categorized by treatment naïve, actively receiving BTK inhibitor,currently or previously treated.
16278046|NCT04830033|Experimental|ENO Breathe group|Participation in the online ENO Breathe programme for 6 weeks.
16278047|NCT04830033|No Intervention|Usual Care Group|Participants continue with usual care.
16278048|NCT04830020|Active Comparator|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
16278049|NCT04830020|Placebo Comparator|placebo|5 ml of saline via nebulizer b.i.d.
16278052|NCT04829955|No Intervention|Observation phase|After screening and randomization for either the eccentric orientated intervention group or the concentric orientated intervention group, all measurements will be made for the first time by investigators at point A1. An observational phase for six weeks will follow to achieve an intern acceptance sampling for the measurements which will be used.
16278053|NCT04829955|Active Comparator|Eccentric training group|"Subjects in the eccentric training group (GEC) will attend six weeks of eccentric orientated training. The eccentric orientated training will use the cadence 3-0-1 for eccentric - break - concentric.
~3 sessions/week
~60 minutes per session including a warming up and cool down phase
~6 exercises
~total of 18 sessions"
16278054|NCT04829955|Active Comparator|Concentric training group|"The concentric training group (GCO) will attend six weeks of concentric orientated training. Each group will perform a manual resistance/bodyweight resistance training accentuating the concentric phase of the movement. The concentric orientated training will use the cadence 1-0-3 for eccentric - break - concentric.
~3 sessions/week
~60 minutes per session including a warming up and cool down phase
~6 exercises
~total of 18 sessions"
16278055|NCT04829942|Experimental|experimental|A 12-week training program will be applied to the experimental group. Pre-tests will be applied before the trainings begin, and height and weight measurement, nutrition, health perception and behavior scale and physical activity scale will be applied to the experimental group and the control group within the 3rd and 6th month after the training program begins. Scale applications will be applied within 2 days, taking into account the attention span of the students.
16278056|NCT04829942|No Intervention|no intervention|Power point presentations will be given to the control group
16278057|NCT04829929|Experimental|One arm|Patients with Non-Valvular Atrial Fibrillation and High Bleeding Risk
16278058|NCT04829916|Experimental|RMC-035|Participants will receive RMC-035 intravenously
16278059|NCT04829916|Placebo Comparator|Placebo|Participants will receive matching placebo solution intravenously
16278060|NCT04829903|Active Comparator|Group DUL|Group taking Dulaglutide injections
16278061|NCT04829903|Placebo Comparator|Group LIR|Group taking Liraglutide injections
16278062|NCT04829877|Experimental|Web-based mind-body intervention with HRVB|Both standard usual care and the web-based mind-body intervention with HRV biofeedback (MBI-HRVB) will be provided to the participants. The web-based mind-body intervention with HRV biofeedback program consisted of 5-week training sessions and breathing training.
16278063|NCT04829877|Experimental|Web-based mind-body intervention|Both standard usual care and the web-based mind-body intervention will be provided to the participants. The web-based mind-body intervention program consisted of 5-week training sessions.
16278064|NCT04829877|No Intervention|Control|The women in the control group will receive the standard usual care provided at the fertility clinic. The standard care protocols encompass elements such as routine assessment and health education at each visit. Participants enrolled in the control group will be approached once a week by a nurse to provide health consultation about fertility treatment, medication, signs, and symptoms of discomfort for five weeks.
16278065|NCT04829864|Experimental|STEP|Participants will participate, online or in-person, to the 8-9 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities in relation to trauma and motherhood.
16278066|NCT04829864|No Intervention|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
16278067|NCT04829851||Health Care Professionals|Registered health care professional, such as a General Practitioner/ Dietitian/ Nutritionist/ Registered Exercise Professional (REPs) etc. who sees clients for assistance with weight management and / or iron deficiency or diet quality.
16278068|NCT04829851||Adults who are Overweight|Adults (> 18 years) who are considered to be overweight (25 - 30 kg/m2) but are otherwise in good physical health and a regular android smart phone/ tablet user.
16278069|NCT04829851||Adults with Iron Deficiency Anaemia|Adults (> 18 years) who have been diagnosed with Iron deficiency anaemia but are otherwise in good physical health and a regular android smart phone/ tablet user.
16278070|NCT04829851||Adults with Low- Fruit/ Vegetable Intake|Adults ( > 18 years) with a low fruit and vegetable intake (2-3 portions/ d) but are otherwise in good physical health and a regular android smart phone/ tablet user.
16278419|NCT04827498||Myocardial ischemia without obstructive coronary stenosis|
16278071|NCT04829838|Experimental|Intravenous levetireacetam|Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)
16278072|NCT04829838|Experimental|intravenous phenytoin|Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day
16278073|NCT04829812||Prospective cohort|Prospective cohort with inclusion of consecutive or pseudo-consecutive patients by vascular specialist at their place of practice. Patient follow-up to assess ulcer progression and compression tolerance.
16278074|NCT04829799|Active Comparator|Control Group|Subjects will receive intracameral 1% preservative-free lidocaine following paracentesis
16278075|NCT04829799|Experimental|Study Experimental Group|Subject will receive Omidria (phenylephrine and ketorolac (1.0%/0.3%) added to the ophthalmic irrigating solution during the cataract extraction procedure
16278076|NCT04829786|Experimental|Japanese group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
16278077|NCT04829786|Experimental|non-Asian group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
16278078|NCT04829773|Experimental|PK Cohort 1|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.
~Sequence A-B-C: Subjects received a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
16278079|NCT04829773|Experimental|PK Cohort 2|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.
~Sequence B-C-A: Subjects received a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast)."
16278080|NCT04829773|Experimental|PK Cohort 3|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.
~Sequence C-A-B: Subjects received a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); and then followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
16278081|NCT04829773|Experimental|Drug-Drug interaction (DDI) Cohort|On the morning of Day 1, subjects received a single dose of midazolam 30 minutes after the start of a standardized breakfast. On Day 2 (after the 24-hour midazolam blood draw) through Day 15, subjects received a daily, single dose of palovarotene in the morning 30 minutes after the start of a standardized breakfast. A second dose of midazolam was administered on Day 15 in the morning (immediately following the palovarotene dose) 30 minutes after the start of a standardized breakfast.
16278082|NCT04829760|Experimental|Psyllium|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to at least 8 ounces (240 mL) of cold water or a beverage that is typically consumed. Participants will ingest the intervention each morning and evening for eight weeks.
16278083|NCT04829760|Experimental|Coarse wheat bran|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to a food they normally eat.
16278084|NCT04829760|Placebo Comparator|Maltodextrin|Volume equivalent to the psyllium. Participants will be instructed to divide the daily dose into 2 doses and ingest by adding the product to a food or to 8 ounces (240 mL) of a beverage that is typically consumed.
16278085|NCT04829747|Experimental|Atogepant|Participants will receive fixed dose of Atogepant once daily for 12 weeks.
16278086|NCT04829734|Experimental|Active PBMT-sMF|Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
16278087|NCT04829734|Placebo Comparator|Placebo PBMT-sMF|Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
16278088|NCT04829721|Experimental|Educational Video Workshop|A single 20 minute video workshop on pelvic floor disorders.
16278089|NCT04829708|Active Comparator|PCI Arm|Patients received PCI (recommended hippocampal protection) within 6 weeks after first-line treatment, with a total dose of 25 Gy, 2.5 Gy each time, once a day, 5 times a week, a total of 10 times. Brain enhancement MRI examination is performed every 3 months in first two years, and then performed every 6 months until the brain metastasis occur.
16278090|NCT04829708|Experimental|MRI Arm|Patients undergo enhancement MRI examination every 3 months in first two years, and then performed every 6 months until the brain metastasis occur. Once brain metastases occur, brain radiotherapy and systemic treatment should be conducted with the follow-up observation of brain enhancement MRI continuing.
16278091|NCT04829695|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
16278092|NCT04829695|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
16278093|NCT04829682|Experimental|ACT for Life|ACT for Life + Treatment as Usual
16278094|NCT04829682|Active Comparator|Present Centered Therapy|Present Centered Therapy + Treatment as Usual
16278098|NCT04829643|Experimental|PET/MRI|Patients with early breast cancer up to 3 cm without overt nodal involvement who are candidates to upfront surgery
16278099|NCT04829630|Other|subjects who received three vs. four ID PEP at least two, five or 10 years earlier|"30 subjects who received three ID PEP at least two years earlier in Cambodia and Madagascar
~30 subjects who received three ID PEP at least five years earlier in Cambodia and Madagascar
~30 subjects who received three ID PEP at least 10 years earlier in Cambodia and Madagascar
~30 subjects who received four ID PEP at least two years earlier in Cambodia and Madagascar
~30 subjects who received four ID PEP at least five years earlier in Cambodia and Madagascar
~30 subjects who received four ID PEP at least 10 years earlier in Cambodia and Madagascar"
16278100|NCT04829617|Experimental|PP-MI Intervention|Participants will receive a 12-week, Positive Psychology-Motivational Interviewing (PP-MI) intervention. Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. Each weekly session will include PP and goal setting portions. In the PP portion, a study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. Additionally for the goal-setting portion, the trainer will (a) review their goals and health behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
16278101|NCT04829617|Active Comparator|MI-alone Intervention|This condition will mirror the MI component of the PP-MI intervention. During the first three sessions, participants will learn about the causes and types of HF, risk factors for cardiovascular disease, and methods for monitoring risk factors and symptoms. Then participants will complete nine sessions related to physical activity, a low sodium diet, and medication adherence. Weekly tasks (e.g., brainstorming barriers) will be assigned, completed between calls, and reviewed at the following call. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
16278102|NCT04829604|Experimental|HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory|"This global Phase 2 study is designed to assess anticancer activity and safety of ARX788 in HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
~The investigational medicinal product (IMP), ARX788, will be administered every 4 weeks (Q4W) by intravenous (IV) infusion."
16278103|NCT04829578|Other|Hypnosis|hyspnosis treatment
16278104|NCT04829565|Experimental|botulinum toxin|50 IU of botulinum toxin
16278105|NCT04829565|Placebo Comparator|placebo|50 IU of placebo
16278106|NCT04829552||Control group: low dose group.|patients treated with subcutaneous low molecular weight heparin 40 mg once daily or unfractionated heparin 5000 IU twice or three times daily for at least 5 days.
16278107|NCT04829552||Study group: high dose group.|Patients treated with subcutaneous low molecular weight heparin 1 mg/kg twice daily or 1.5 mg/kg daily or a continuous intravenous infusion of unfractionated heparin for at least 5 days.
16278108|NCT04829539|Experimental|Group I (BBT-CI)|Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
16278109|NCT04829539|Active Comparator|Group II (HEAL)|Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
16278110|NCT04829500|No Intervention|Pre-Intervention Baseline Collection Phase|All sites will start with a baseline collection phase without exposure to the intervention, consistent with the stepped wedge cluster randomized trial design. A sequential randomized crossover to the intervention (MAP-VA) will be assigned, which cannot be reversed once it has been introduced.
16278111|NCT04829500|Experimental|MAP-VA Intervention|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities such as implicit learning, procedural memory, reading abilities. Staff training provides practice with: 1) pre-developed activities and templates, 2) a simple reading assessment to inform development of external cues; and 3) identifying opportunities for increased independence and resident contribution to community routines. Staff are also introduced to concrete strategies that improve dignity, control, and independence.
16278112|NCT04829487|Experimental|Vitamin D|Vitamin D 50,000 IU orally weekly for 8 weeks
16278113|NCT04829487|Placebo Comparator|Placebo|Placebo capsules orally weekly for 8 weeks
16278114|NCT04829474||Women consulting for spouse abuse|The study focuses on women consulting a doctor as part of spouse abuse, whatever the context (at the request of the police or not) or their motivation (medical or social).
16278115|NCT04829461|Experimental|Ambu® aScope™ 4 Cysto|Ureteral stent removal procedure performed with Ambu® aScope™ 4 Cysto (single-use cystoscope).
16278116|NCT04829461|Active Comparator|Standard of Care (SOC)|Ureteral stent removal procedure performed with standard of care (reusable cystoscope).
16278117|NCT04829448|Experimental|Protein Intervention Group|Patients who receive the protein nutritional supplement as part of their prescribed exercise-based rehabilitation program.
16278118|NCT04829448|No Intervention|Control Group|Patients who receive the prescribed exercise-based rehabilitation program, without protein supplement.
16278119|NCT04829435|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
16278185|NCT04829123|Experimental|Multiple doses of 1.7 mg HEC88473|Healthy subjects, receiving a weekly dose of 1.7 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
16278120|NCT04829435|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
16278121|NCT04829409|Active Comparator|paravertebral block|Patients receive ultrasound-guided paravertebral block
16278122|NCT04829409|Active Comparator|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
16278123|NCT04829409|Experimental|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
16278124|NCT04829396|Experimental|Fibre mixture|"Dietary supplement. A mixture of fibres will be administered consisting of 10g of acacia gum powder and 3g of carrot powder.
~The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day."
16278125|NCT04829396|Placebo Comparator|Placebo for Fibre mixture|A placebo of the mixture of fibres will be administered.
16278127|NCT04829370|Active Comparator|PLT|All subjects are treated with fractional carbon dioxide laser, then applied 2 mL PLT solution (dissolved in normal saline) on the right face.
16278128|NCT04829370|Placebo Comparator|Saline|All subjects are treated with fractional carbon dioxide laser, the left face (control group) be applied 2 mL normal saline
16278129|NCT04829344|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
16278130|NCT04829344|Placebo Comparator|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
16278131|NCT04829331|Experimental|Restrata with a split-thickness skin graft|
16278132|NCT04829331|No Intervention|Split-thickness skin graft alone|
16278134|NCT04829305|Experimental|Low dose of SHR2285|The subjects will receive a single dose of SHR2285 (low dose).
16278135|NCT04829305|Experimental|Medium dose of SHR2285|The subjects will receive a single dose of SHR2285 (medium dose).
16278136|NCT04829305|Experimental|High dose of SHR2285|The subjects will receive a single dose of SHR2285 (high dose).
16278137|NCT04829292|Experimental|Open treatment|Supportive therapy followed by CBT
16278138|NCT04829279|Experimental|Case|Emergency patient transferred by CONNECT AI system
16278139|NCT04829279|No Intervention|Control|Emergency patient transferred by conventional EMS
16278140|NCT04829266|Experimental|process simulation group|an experimental group with process simulation with elements of relaxation
16278141|NCT04829266|Experimental|outcome simulation group|an experimental group with outcome simulation with elements of relaxation
16278142|NCT04829266|Other|control group|a control group with no process and outcome simulations, but with elements of relaxation
16278143|NCT04829253|Experimental|b-DBT (Brief Dialectical Behavioral Therapy)|3 months of and intensive modified DBT intervention.
16278144|NCT04829253|Active Comparator|s-DBT (standard Brief Dialectical Behavioral Therapy)|6 months of a standard DBT intervention (this is a shorter version of the original 12-month DBT, but includes all four active components delivered over 6 months)
16278145|NCT04829240|Experimental|Intervention condition|Modular cognitive-behavioral anxiety intervention tailored to and personalized for Veterans
16278146|NCT04829240|Active Comparator|Control condition|Usual care anxiety treatment
16278147|NCT04829227|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
16278148|NCT04829227|Experimental|"off the face areas"|"off the face areas: abdomen, or arms or thighs or Décolleté."
16278151|NCT04829201||Obstructive sleep apnea (OSA)|OSA patients who are eligible for either functional septorhinoplasty or oropharyngeal/orthognathic surgery
16278152|NCT04829188|Active Comparator|Structured Telephone Support (STS)|Post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care provider (PCP) within seven days post-discharge.
16278153|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Standard Response Team (RPM-Low, Standard Team)|Questions are pushed to members patients times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
16278186|NCT04829123|Experimental|Multiple doses of 5.1 mg HEC88473|Healthy subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
16278187|NCT04829123|Experimental|Multiple doses of 10.2 mg HEC88473|Healthy subjects, receiving a weekly dose of 10.2 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
16278154|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Standard Team (RPM-High, Standard Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
16278155|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Enhanced Team (RPM-Low, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives).
16278156|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Enhanced Team (RPM-High, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans.Team members (e.g., CRNP, social workers, nurses) address RPM triggers, meet with the patient three times, pharmacy review, develop care plans, and discuss advance directives).
16278157|NCT04829162|Experimental|Mother with obesity, daughter with obesity|Image of a mother with obesity and a daughter with obesity.
16278158|NCT04829162|Experimental|Mother with obesity, daughter without obesity|Image of a mother with obesity and a daughter without obesity.
16278159|NCT04829162|Experimental|Mother without obesity, daughter with obesity|Image of a mother without obesity and a daughter with obesity.
16278160|NCT04829162|Experimental|Mother without obesity, daughter without obesity|Image of a mother without obesity and a daughter without obesity.
16278161|NCT04829162|Experimental|Mother with obesity, son with obesity|Image of a mother with obesity and a son with obesity.
16278162|NCT04829162|Experimental|Mother with obesity, son without obesity|Image of a mother with obesity and a son without obesity.
16278163|NCT04829162|Experimental|Mother without obesity, son with obesity|Image of a mother without obesity and a son with obesity.
16278164|NCT04829162|Experimental|Mother without obesity, son without obesity|Image of a mother without obesity and a son without obesity.
16278165|NCT04829162|Experimental|Father with obesity, daughter with obesity|Image of a father with obesity and a daughter with obesity.
16278166|NCT04829162|Experimental|Father with obesity, daughter without obesity|Image of a father with obesity and a daughter without obesity.
16278167|NCT04829162|Experimental|Father without obesity, daughter with obesity|Image of a father without obesity and a daughter with obesity.
16278168|NCT04829162|Experimental|Father without obesity, daughter without obesity|Image of a father without obesity and a daughter without obesity.
16278169|NCT04829162|Experimental|Father with obesity, son with obesity|Image of a father with obesity and a son with obesity.
16278170|NCT04829162|Experimental|Father with obesity, son without obesity|Image of a father with obesity and a son without obesity.
16278171|NCT04829162|Experimental|Father without obesity, son with obesity|Image of a father without obesity and a son with obesity.
16278172|NCT04829162|Experimental|Father without obesity, son without obesity|Image of a father without obesity and a son without obesity.
16278173|NCT04829149||Statin therapy group (No interventional)|Observational. Statin therapy group: Once daily administered per the locally approved product information of rosuvastatin, simvastatin, atorvastatin, pitavastatin etc,. (except Rosuzet Tab.)
16278174|NCT04829149||Rosuzet tablet group (No interventional)|Observational. Rosuzet Tab.(ezetimibe/rosuvastatin) group: once daily administered per the locally approved product information of Rosuzet Tab. 10/5mg, 10/10mg, 10/20mg
16278175|NCT04829136|Experimental|Arm I (enteral nutrition)|Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
16278176|NCT04829136|Active Comparator|Arm II (standard of care)|Patients receive standard of care nutritional support.
16278177|NCT04829123|Experimental|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278178|NCT04829123|Experimental|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278179|NCT04829123|Experimental|Single dose of 5.1 mg HEC88473|Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278180|NCT04829123|Experimental|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278181|NCT04829123|Experimental|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278182|NCT04829123|Experimental|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278183|NCT04829123|Experimental|Single dose of 34.0 mg HEC88473|Healthy subjects, receiving a single dose of 34.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
16278184|NCT04829123|Experimental|Single dose of 44.2 mg HEC88473|Healthy subjects, receiving a single dose of 44.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
16314125|NCT04578938|Sham Comparator|Ketamine + Sham Training|
16278191|NCT04829097|Experimental|SIB-IMRT|1. New auxiliary TMZ period: oral TMZ 75mg/m2, qd, continued until the beginning of radiotherapy. 2. Concurrent radiotherapy and chemotherapy period: 4 weeks in total. Prior to treatment, radiotherapy positioning and planning were established, using SIB-IMRT technology, the irradiation range, the tumor residual area 60Gy/20f/4w, the tumor bed area 40Gy/20f/4w, 1 time/d, 5 times/w. During radiotherapy, TMZ will continue to be administered orally simultaneously, the specific dose: TMZ 75mg/m2 qd, until 42 days. 3. Intermediate rest period: 4 weeks in total. ;4. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; after cycles 3, 6, 9, and 12 of adjuvant chemotherapy Head functional magnetic resonance examination was performed to assess the size of residual lesions and edema.
16278192|NCT04829097|Active Comparator|CRT|1. Concurrent radiotherapy and chemotherapy period: 6 weeks in total. Radiotherapy positioning and planning before treatment, using CRT technology, irradiation range, tumor bed area, 60Gy/30f/6w, 1 time/d, 5 times/w, simultaneous TMZ oral administration on the first day of radiotherapy, specific dose: TMZ 75mg/m2 qd for 42 consecutive days; head functional magnetic resonance imaging was performed at the end of radiotherapy to assess the size of residual lesions and edema. 2. Intermediate rest period: 4 weeks in total. The patient will go to the hospital to recheck blood routine every week;3. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; head functional magnetic resonance imaging was performed after adjuvant chemotherapy in cycles 3, 6, 9, and 12 to assess the size of residual lesions and edema.
16278193|NCT04829084|Experimental|Intervention Arm|Health education
16278194|NCT04829084|No Intervention|Control Arm|No health education
16278195|NCT04829071|Experimental|Evaluating motor learning and brain structures post-stroke|We will use a single arm design to determine the impact of post-stroke cognitive impairment on two forms of motor learning (implicit and explicit) and evaluate the structural integrity of relevant brain structures in 65 individuals post stroke
16278196|NCT04829045|Experimental|Acupuncture plus diabetic routine care|Subjects will receive acupuncture treatment using press needles
16278197|NCT04829045|Placebo Comparator|Placebo plus diabetic routine care|Subjects are given placebo
16278198|NCT04829032||Hartmann's procedure|Evaluate the role of Hartmann's procedure in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
16278199|NCT04829032||Colonic resection with primary anastomosis|Evaluate the role of colonic resection with primary anastomosis in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
16278200|NCT04829019|Active Comparator|whole-brain irradiation (WBI) plus Osimertinib|Osimertinib plus WBI, with Osimertinib at a dose of 80 mg once per day.
16278201|NCT04829019|Active Comparator|Osimertinib|Osimertinib with WBI sequential therapy, with Osimertinib at a dose of 80 mg once per day.
16278202|NCT04829006|Other|Speakers|Participants will be recording sentences using a customized app, which is the focus of the current investigation. There is no arm per se, as the current investigation does not involve an intervention. The current investigation aims at developing and pilot testing an app.
16278203|NCT04828993|Experimental|Chinese participants treated with Tafamidis Meglumine|
16278204|NCT04828980|Active Comparator|Mindfulness Virtual Reality Experience|Patients will be provided with a mindfulness VR experience for use up to 15 minutes at bedside.
16278205|NCT04828980|Active Comparator|Gaming Virtual Reality Experience|Patients will be provided with an active gaming VR experience for use up to 15 minutes at bedside.
16278206|NCT04828967|Experimental|Hypnosis group|Hypnosis is added to the conventional group.
16278207|NCT04828967|No Intervention|conventional group|only conventional group
16278208|NCT04828954|Active Comparator|2 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint for 2 weeks following their thumb CMC arthroplasty
16278209|NCT04828954|Active Comparator|6 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint, transitioned to cast, for a total of 6 weeks following their thumb CMC arthroplasty
16278210|NCT04828941|Experimental|Electronic Headache Diary|The electronic headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
16278211|NCT04828941|Active Comparator|Paper Diary|The paper headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
16278212|NCT04828928|Experimental|proportion of patients with neuropathy|to prospectively study patients with a wild-type amyloid cardiopathy condition to identify and describe the associated neuropathy
16278213|NCT04828915||Training cohort|Randomly selection of 80% of the study population. The machine learning algorithm is trained on this dataset
16278214|NCT04828915||Validation cohort|Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.
16278268|NCT04828512||impaired glucose intolerance (IGT)|In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT.
16278491|NCT04827004|Experimental|Anlotinib Hydrochloride Capsules|This is a multi-target receptor tyrosine kinase inhibitor.
16278215|NCT04828889|Experimental|research|The subjects in the study group will undergo a series of 4 treatments by 2 certified physiotherapists for pelvic floor treatment that will include instruction in self-use of anal dilators once a week for four weeks. The anal dilation will be performed using Dilatan® anal dilators (Enterprises Sapimed, Alessandria) in varying sizes of 22, 23 and 27 mm. In the first week, a 20 mm dilator will be inserted twice a day for at least 10 minutes. In the second week, a 23 mm extender will be inserted into the anus, twice a day for at least 10 minutes. In the last two weeks, a 27 mm extender will be inserted twice a day for at least 10 minutes. To facilitate the insertion of the extender, patients will use lubricating cream. At the end of each week, patients will meet with a pelvic floor physiotherapist to make sure that the insertion is done properly, that there are no side effects and that it is possible to move on to the next step.
16278216|NCT04828889|No Intervention|waiting|The subjects in the waiting group will be able after a month to choose to undergo surgery or also receive treatment by extenders.
16278217|NCT04828889|Active Comparator|surgery|The subjects in the surgery group will undergo surgical treatment only.
16278218|NCT04828876|Experimental|Yoga practice|The yoga practice will be held 2 days a week for 6 weeks, a total of 12 sessions. Each session is set as one hour
16278219|NCT04828876|No Intervention|Control group|Routine maintenance will be applied
16278220|NCT04828863||Index subjects|25 young adults with MSUD who are between the ages of 21 and 35 years-old
16278221|NCT04828863||Control subjects|25 age-matched siblings or acquaintances who do not have MSUD and are between ages 21-35 years old
16278222|NCT04828850|Experimental|EBUS-TBNA procedure|Single arm protocol. Invasive mediastinal staging with EBUS-TBNA in clinical N0 NSCLC patients candidate to surgical resection with systematic lymphadenectomy.
16278223|NCT04828837|Experimental|Bubble positive expiratory pressure training|The experimental group receives the Bubble PEP training.
16278224|NCT04828837|No Intervention|general care|The control group receives the division of chest ward routine care.
16278225|NCT04828824|Experimental|COCR Arm|Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.
16278226|NCT04828824|No Intervention|SOC Arm|Participants in the SC arm will be offered care according to our standardized protocol, which may include STI testing, reassurance and monitoring, prescription of COCs if desired, or removal.
16278227|NCT04828798|Active Comparator|Directional deep brain stimulation|Deep brain stimulation delivered in a directional manner within an axial plane
16278228|NCT04828798|Active Comparator|Nondirectional deep brain stimulation|Deep brain stimulation delivered in a nondirectional manner within an axial plane
16278229|NCT04828785|Experimental|Medically Tailored Meal (MTM)|The Medically Tailored Meal (MTM) intervention consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
16278230|NCT04828785|Active Comparator|Food Subsidy|As a comparison group, those not randomized to receive the MTM intervention will receive usual care provided by their clinicians not associated with the study, plus a food subsidy ($30/month) for 6 months, along with healthy eating information to guide use of that subsidy.
16278231|NCT04828772||Cohort 1|COVID-19 participants receiving anticoagulants
16278232|NCT04828772||Cohort 2|COVID-19 participants not receiving anticoagulants
16278233|NCT04828759|Experimental|VR-treatment, then Treatment as usual|Participants will receive 8 weeks of VR-treatment. Participants are allowed to practice as much as they wish during the VR-intervention. However, they are given a recommendation of the amount of practice (5 h / week). Before the VR-intervention, the participants will receive a guidance for using the VR-devices (i.e. orientation period) by the SLT. Participants will be able to contact the SLT freely during the 8 weeks VR-intervention period. After the orientation period, the participants will be practicing at their homes independently. However, they will receive remote guidance by the SLT. The guidance includes weekly remote guidance sessions by SLT (8 x 45 min) to ensure that training is fluent and unproblematic. Additionally, the content of exercises can be modified during these sessions. The SLT is also able to monitor the training of participants with the system. Devices: VR headset and controller, Tablet computer.
16278234|NCT04828759|Experimental|Treatment as usual, then VR-treatment|Wait list control group: During the waitlist period the participants will receive the traditional speech and language therapy rehabilitation offered by (if offered) the general health care system in their own home municipality. The amount of rehabilitation is not controlled during the wait list period. However, the amount of received traditional speech and language rehabilitation in waitlist period will be documented. The waitlist control group will receive the same VR intervention period after the 8 weeks waitlist period.
16278235|NCT04828746|No Intervention|Control|Patients who will undergo lumbar puncture without pre-procedural ultrasound-guided skin marking
16278236|NCT04828746|Experimental|Experimental|Patients who will undergo lumbar puncture after pre-procedural ultrasound-guided skin marking
16278237|NCT04828733|Experimental|Antireflux OAGB group|Antireflux laparoscopic one anastomosis gastric bypass with suture cruroplasty and the total wrapping of the fundus of the gastric excluded part.
16278238|NCT04828733|Active Comparator|Standard OAGB group|laparoscopic one anastomosis gastric bypass with only suture cruroplasty.
16278239|NCT04828720|Active Comparator|PRF group|"The PRF was prepared according to Choukroun et al. [5] immediately before surgery, a 10 ml blood sample was taken by venipuncture of the antecubital vein without anticoagulant. The tubes were centrifuged immediately by a dedicated centrifuge at 3,000 rpm for 10 minutes.
~A structured fibrin clot was produced by such preparation protocol in the middle of the tube, with the erythrocytes at the bottom and acellular plasma at the top. Following elimination of acellular plasma, a sterile scissors was used to separate the PRF from the erythrocytes. A membrane of PRF was formed by squeezing it gently between two pieces of gauze. Folding of the membrane was performed to achieve the required thickness (1.0 mm) with accurate trimming to match the palatal wound. The obtained membrane was then placed at the palatal donor site and compressed with gauze. Then, it was secured with 3-0 black plaited silk and a stent was placed."
16278269|NCT04828512||newly diagnosed DM (subclinical DM)|In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM).
16278240|NCT04828720|Placebo Comparator|Control group|the palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in control group used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
16278241|NCT04828720|Experimental|ozonated group|the palatal wound in ozanaited group will be painted by ozainated oil 2ml daily for 1 week, Patients used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
16278242|NCT04828707|Active Comparator|Migraine prevention treatment with active Nerivio|Participants will treat with an active Nerivio device every other day for migraine prevention.
16278243|NCT04828707|Sham Comparator|Migraine prevention treatment with sham Nerivio|Participants will treat with a sham (placebo) Nerivio device every other day for migraine prevention.
16278244|NCT04828694|Experimental|BICX104|BICX104 is an eroding implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
16278245|NCT04828694|Active Comparator|Vivitrol|Vivitrol intramuscular injection containing 380 mg of naltrexone. Three consecutive doses will be administered once every 28 days for 84 days.
16278246|NCT04828681||Patients with Angio-IMR>40 Unit|Patients with angio-IMR>40U in the culprit vessel after successful primary PCI.
16278247|NCT04828681||Patients with Angio-IMR≤40 Unit|Patients with angio-IMR≤40U in the culprit vessel after successful primary PCI.
16278248|NCT04828668|Experimental|Formula C|30 participants will be randomized to masked active study product (Formula C) for 28-days; they will continue to the open label extension phase (with commercially available product for an additional 28-days when they will receive commercially available product.
16278249|NCT04828668|Placebo Comparator|Placebo|30 participants will be randomized to placebo for 28-days; they will roll-over to the open label extension phase of study product (Formula C) for an additional 28-days when they will receive commercially available product.
16278250|NCT04828655|No Intervention|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity. Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
16278251|NCT04828655|Experimental|EXPERIMENTAL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning. Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
16278252|NCT04828642|Active Comparator|Supplementation group|Antioxidant vitamins (Vitamin C (1000 mg) + Vitamine E (235 mg))
16278253|NCT04828642|Placebo Comparator|Placebo group|Placebo supplementation with the same aspect as supplementation
16278254|NCT04828629||Identification of prognostic factors in patients who have recovered from COVID-19|Selected prognosis factors will be analyzed in patients who have recovered from COVID-19
16278255|NCT04828616|Experimental|DP303c injection|"Part1:Patients with HER2-expressing advanced ovarian cancer will be treated with DP303c injection at 2.0 mg/kg or 3.0 mg/kg every 3 weeks (Q3W) to determine the recommended phase 2 dose (RP2D).
~Part2a:Patients with HER2-overexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D.
~Part2b:Patients with HER2-lowexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D."
16278256|NCT04828590||Patients with suspected CAD containing at least one 30%-90% coronary CTA stenosis|Patients' datasets with suspected CAD containing at least one 30%-90% coronary CTA stenosis; and ICA-FFR was measured on vessels with diameters greater than 2 mm will be analyzed. Diagnostic performance based on CT-derived FFR using DVFFR software will be compared with the diagnostic performance from ICA-FFR measurements.
16278257|NCT04828577|Experimental|Real Time Neurofeedback|Real time neurofeedback will be based on a classifier of increasing or decreasing delay discounting fMRI patterns. Participants will try to modulate their discounting rate based on neurofeedback via a visual dial, during an fMRI scan. Participants will be told they will be controlling the visual dial.
16278258|NCT04828577|Sham Comparator|"Idealized/Sham Neurofeedback"|"Rather than using the output of a classifier, the visual dial will display perfect modulation of increasing and decreasing delay discounting and participants will told that they will not be controlling the visual dial."
16278259|NCT04828564|Experimental|Ribavirin Arm|"Ribavirin dosage: 200 mg oral ribavirin capsules for 5 days
~Regimen: 1200 mg loading dose on day-1 (three capsules in the morning and three capsules in the evening) followed by 800 mg/day maintenance dose (two capsules in the morning and two capsules in the evening) on day-2 to day-5."
16278260|NCT04828564|Active Comparator|Favipiravir Arm|"Favipiravir dosage: 200 mg oral favipiravir tablets for 5 days
~Regimen: 2x1600 mg loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5."
16278261|NCT04828551|Other|MGH and UCSD Study subjects|"This study will enroll patients with suspected or confirmed diagnosis of NAFLD. Based on protocol-specified FIB-4 values, about one-third are expected to have low, one-third to have intermediate, and one-third to have high likelihood of advanced fibrosis.
~Sex: 50:50 - Note- no stratification will be done based on sex Age: ≥ 18 yrs Demographic group: Patients with a high probability of NAFLD based on the eligibility criteria General health status: Patients with suspected or confirmed diagnosis of NAFLD Geographic location: Boston, MA (greater metropolitan areas) and San Diego, CA (greater metropolitan areas)"
16278262|NCT04828538|Active Comparator|Vitamin D|Oral 4000 IU Vitamin D
16278263|NCT04828538|Active Comparator|Omega DHA / EPA|Oral 1000mg Omega DHA/EPA vs. placebo
16278264|NCT04828538|Active Comparator|Vitamin C, Vitamin B complex and Zinc Acetate|Combination of oral 1000 mg Vitamin C, Vitamin B complex and Zinc Acetate, 100 mg/day
16278265|NCT04828525|Experimental|Experimental|participants will be given corticosteroids in addition to conventional treatment
16278266|NCT04828525|Placebo Comparator|Placebo|participants will be given normal saline in addition to conventional treatment
16278267|NCT04828512||normal glucose tolerance (NGT)|In the 75-g OGTT, an FPG level of < 100 mg/dL or a 120-min PG level of < 140 was diagnosed as NGT.
16278270|NCT04828499|Experimental|Progressive Cracking Technique|Patients with hard nucleus cataract were treated with Progressive Cracking Technique.
16278271|NCT04828499|Experimental|Conventional Chop Technique|Patients with hard nucleus cataract were treated with Conventional Chop Technique.
16278272|NCT04828486|Experimental|Treatment (futibatinib, pembrolizumab)|Patients receive futibatinib PO QD on days 1-21 for cycles 1-9, and days 1-42 for subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-9 and every 42 days for subsequent cycles for up to 2 years in the absence of disease progression or unacceptable toxicity.
16278273|NCT04828460||Kidney transplant recipients who receive Covid-19 vaccine|
16278274|NCT04828447|Experimental|High Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet high in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
16278275|NCT04828447|Experimental|Low Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet low in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
16278276|NCT04828434|Experimental|Virtual Individual Cognitive Stimulation Therapy|"Virtual Cognitive Stimulation Therapy (viCST), a psychosocial intervention, is a modified version of CST for people with mild to moderate dementia. Like the original CST, each of the 14 sessions will begin with a warm-up activity, which includes an orientation task and discussion of current affairs, followed by a main themed activity.
~viCST will be prescribed to participants twice a week, for 7 weeks and each session is approx. 45 minutes. The intervention will be delivered by trained professionals, such as research staff, psychologists, and trainee clinical psychologists. All facilitators will have at least one year of experience in dementia care and completed the CST training."
16278277|NCT04828434|No Intervention|Treatment as usual|Standard care.
16278278|NCT04828421|Experimental|Probiotic group|Participants will be treated with a daily capsule of a multi-species probiotic (3.3 billion Lactobacillus rhamnosus and Bifidobacterium lactis) during 10 weeks.
16278279|NCT04828421|Placebo Comparator|Placebo group|Participants will receive a harmless substance (potato starch) during 10 weeks.
16278280|NCT04828369||EUS-guided coil and cyanoacrylate injection|Patients who received EUS-guided coil embolization combined with endoscopic cyanoacrylate injection
16278281|NCT04828369||BRTO|Patients who received balloon-occluded retrograde transvenous obliteration (BRTO)
16278282|NCT04828356|Experimental|Foot reflexology group|The first researcher received hands-on training about reflexology application before the study started. The researcher applied foot reflexology on the patients with liver transplantation in the experimental group in one session (30 minutes) after the operation. Patient confidentiality was maintained in all procedures. The patient identity form was implemented before reflexology application. Pain and comfort levels were assessed as the pre-test. Then, venous blood was taken to determine the plasma β-End level. Foot reflexology was first applied on the right foot, which is effective on the sympathetic nervous system, for 15 min and then, on the left foot, which is effective on the parasympathetic nervous system, for 15 min. Same process was performed on the left foot and the reflexology application was completed within 15 min. Venous blood was taken again to assess the β-End level as the post-test after the application, and the NPS and PCQ were implemented again.
16278283|NCT04828356|No Intervention|No treatment group|The patient identity form, NPS and PCQ were applied on the patients in the control group as the pre-test. After the questions were answered, venous blood was taken to determine the plasma β-End level. No intervention other than clinical protocol was applied on the control group, and after taking venous blood after 30 minutes to determine β-End level, the NPS and PCQ were re-applied as the post-test.
16278284|NCT04828343|Experimental|Cohort 1 <50 kg|Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
16278285|NCT04828343|Experimental|Cohort 2 <50 kg|Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
16278286|NCT04828343|Experimental|Cohort 3 >=50 kg|Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
16278287|NCT04828343|Experimental|Cohort 4 >=50 kg|Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
16278288|NCT04828330||Observational cohort|This is a case-crossover study nested within a cohort study.
16278289|NCT04828304|No Intervention|control group|
16278290|NCT04828304|Experimental|treatment group|
16278291|NCT04828291|Experimental|Online Mindfulness Intervention (OMI)|Before beginning the daily practices, this group will be introduced to the OMI via an online platform and answer any questions about the practice. Then, each day, this group will be guided through a series of mindfulness practices offered online (www.bemindfulonline.com) delivered on their smartphones or laptops.
16278292|NCT04828291|Experimental|OMI paired with peer support (OMI+)|Before beginning the daily OMI, in addition to being briefed, this group will be paired with a peer to be in touch with and guide and support each other in this process. Then they will start the OMI program and will follow parallel instructions as the OMI group. The peer support will include five brief (30-minute) weekly meetings to support and encourage each other to continue practicing mindfulness and to complete the online intervention. Each week we will provide prompts and topics for participants to discuss and at the end of each meeting, participants will then complete a short, 5-10 minute post-meeting survey to assess the well-being and attitudes of their partner (see additional materials for meeting prompts and post-meeting survey questions). The first of these meetings will occur on Day 8, and subsequent weekly meetings during the intervention period will be scheduled based on the shared availability of both participants in each pair.
16278293|NCT04828291|Active Comparator|Active control receiving cognitive exercises|Instead of the OMI, this group will be receiving cognitive exercises in the intervention period.
16278294|NCT04828278|Placebo Comparator|Treatment 1|1,600 mg of Placebo (maltodextrin)
16278296|NCT04828265|Experimental|Aldafermin 0.3mg|Subcutaneous injection of a single dose of aldafermin 0.3mg in healthy adult male Japanese or non-Japanese subjects
16278297|NCT04828265|Experimental|Aldafermin 1mg|Subcutaneous injection of a single dose of aldafermin 1mg in healthy adult male Japanese or non-Japanese subjects
16278298|NCT04828265|Experimental|Aldafermin 3mg|Subcutaneous injection of a single dose of aldafermin 3mg in healthy adult male Japanese or non-Japanese subjects
16278299|NCT04828252|Experimental|808nm|The wavelength of this experimental group was 808nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
16278300|NCT04828252|Active Comparator|660nm|The wavelength of this experimental group was 660nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
16278301|NCT04828252|Placebo Comparator|Control|The wavelength of control group, total power: 0.0072W, 15 minutes a session, 3 times a week for 8 weeks
16278302|NCT04828239|Experimental|Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
16278303|NCT04828239|Active Comparator|Manual Acupuncture Group|Acupuncture point: PC-6 and PC-7 Responses elicited: de qi sensation Manual: twirling with lifting-thrusting method stimulation Needles retained for 30 min Needle type: C&G, gauge and size: 0.25x40mm
16278304|NCT04828239|Sham Comparator|Sham Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 Sham laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
16278305|NCT04828226|Experimental|Intervention|"The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study.
~At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied.
~The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia.
~Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) > 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction."
16278306|NCT04828226|Placebo Comparator|Control|The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.
16278307|NCT04828213|Experimental|Tooth-borne RME appliance (Hyrax)|"In the Tooth-borne RME expander group, bands were placed to the maxillary right and left upper 1st premolar and 1st molar teeth. The impression of the upper jaw was obtained with the bands in mouth by using alginate impression material. In the laboratory process, a hyrax (Forestadent, Pforzheim, Germany; Forestadent USA, St Louis, Missouri, USA) expansion appliance with an expansion screw in the middle was prepared on the models by the same technician under standard conditions.
~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
16278308|NCT04828213|Experimental|Hybrid hyrax RME appliance|"Rapid Maxillary Expansion Treatment. In the Hybrid hyrax RME appliance group, mini-screws of 2 mm diameter and 9 mm length (Benefit mini-implants; PSM Medical Solutions; Tuttlingen, Germany) were placed 3 mm posterior and 1 to 5 mm paramedian to the incisive foramina.
~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
16278309|NCT04828200||sarcopenic patints with knee ostheoarthritis|12 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients with sarcopenia.All subjects were evaluated by the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria for the diagnosis of sarcopenia.
16278310|NCT04828200||non sarcopenic patients with knee ostheoarthritis|90 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients.
16278311|NCT04828200||control group|33 patients between the ages of 50-70, who have been followed up not being exposed to be sarcopenia or knee OA
16278312|NCT04828187||Study group|8 patients aged between 18 to 75 years with Uncorrected Distance Visual Acuity ≥ 5/10
16278313|NCT04828174|Experimental|anti-TRBC1 CAR-T cell|Administration with anti-TRBC1 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients.
16278318|NCT04828135|Experimental|subjects with diagnosis of COVID-19 (Long-hauler)|23 subjects with a confirmed diagnosis of COVID-19 infection, and after 60 days or longer
16278319|NCT04828122||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia
~Positive amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16278320|NCT04828122||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)
~Negative amyloid PET or amyloid CSF status.
~MMSE 23-30 (inclusive)"
16278321|NCT04828122||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Positive amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16278322|NCT04828122||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline
~Negative amyloid PET or amyloid CSF status.
~MMSE 26-30 (inclusive)"
16278323|NCT04828109|Active Comparator|VR and Fitbit|Daily VR use every 3 hours up to 30 minutes at a time and Fitbit daily step goal of 2,000 steps
16278327|NCT04828096|Active Comparator|Penta-one retainer|Penta-one retainer is one wire that is been in use for many years. Penta-one retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retainers are going to be bonded with sandblasted enamel and half without.
16278328|NCT04828096|Experimental|Ortho-FlexTech retainer|Ortho-Flextech chain wire is relatively new in the market and needs to be evaluated. Ortho-Flextech retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
16278329|NCT04828096|Experimental|Memotain retainer|Memotain wire is relatively new in the market. It requires digital scanning and the technique is said to be very exact. Memotain retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
16278330|NCT04828083|Active Comparator|Ultrasound-guided adductor canal block with local anesthetic|Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml
16278331|NCT04828083|Sham Comparator|Ultrasound-guided adductor canal block with saline|Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)
16278332|NCT04828070||Registry participant|Prospective collection of clinical information, completion of anxiety/depression, microaggressions, and quality of life questionnaires
16278333|NCT04828044||Microwave Ablation/ Coagulation Arm|These patients will receive microwave ablation using MedWaves Microwave Ablation/ Coagulation System.
16278334|NCT04828031|Experimental|Vitamin D 50,000 IU PO every week|Vitamin D 50,000 IU PO every week for 12 weeks
16278335|NCT04828018||Key Staff|Key Staff will take part in one interview lasting up to 60 minutes
16278336|NCT04828018||In-Pensioners|Royal Hospital Chelsea In-Pensioners will take part in one interview lasting up to 90 minutes and complete n=2 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF) at the start of their qualitative interview.
16278337|NCT04828018||New In-Pensioner|New In-Pensioners wil be asked to complete a total of n=4 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF), n=2 on admission to Royal Hospital Chelsea and n=2 six months after admission.
16278340|NCT04827992|Experimental|Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment|This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
16278341|NCT04827992|Active Comparator|Prescription Opioid Taper Support (POTS) treatment alone|This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
16278342|NCT04827979|Experimental|Cohort 1 (N=5 Subjects)|"Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:
~Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.
~Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%."
16278343|NCT04827979|Experimental|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects is dependent on the results in Cohort 1.
~Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:°
~Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.
~Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.
~May be modified based on the safety and efficacy analysis of Cohort 1."
16278344|NCT04827966|Active Comparator|Fluoride Varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride. 0.2-0.5ml of the varnish is applied onto the tooth surface after through cleaning. One coats of the varnish will be applied and patient will be instructed not to rinse with water or eat for 30 minutes. This is based on the manufacturer's instructions.
16278345|NCT04827966|Active Comparator|Tooth Mousse|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization. One tube of the Tooth Mousse will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
16278346|NCT04827966|Active Comparator|MI Paste|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes. Recent studies have investigated the remineralization potential of CPP-ACP combined with fluoride and have found a synergistic effect when these are administered together, which is the composition in MI paste. One tube of the MI Paste will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
16278347|NCT04827966|Active Comparator|Acidulated phosphate fluoride gel|A stable thixotropic gel providing 1.23% fluoride ion. This is only for professional use and applied by the dentist. The teeth is cleaned and polished and the gel is applied onto a tray. It is filled upto one third of the tray according to manufacturer's instructions. The tray is then inserted into the mouth and the patient is asked to gently bite down lightly for 1 to 4 minutes.The tray is then removed and patient is asked to expectorate any material in the mouth. The patient is instructed not to eat, rinse or drink for 30 minutes.
16278348|NCT04827966|Active Comparator|Fluoride Mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts.
16278350|NCT04827940|Experimental|intervention arm|"Data from the study was collected during the implementation of the Nursing Surgical Diseases class. Students who completed the 4-hour training program on sleep, relaxation exercises and survey practice have been pollsters of the study.
~Relaxing music for sleep, prepared by the Turkish Psychological Association, is uploaded to patients' mobile phones. Patients were asked to perform relaxation exercises for a week at bedtime, lasting an average of 30 minutes, and with music every day, taking advantage of nurse observation at the clinic with the patient's declaration in check. Students who took part in the practice served as reminders of patients' compliance with the exercises."
16278351|NCT04827940|Other|Control arm|Those who did not do progressive muscle relaxation exercises or did not practice regularly for a week constituted the control group.
16278352|NCT04827927|Experimental|INTELLiVENT-ASV|Use of INTELLiVENT-ASV during 3 hours with 30 minutes wash-out time before.
16278353|NCT04827927|Active Comparator|Conventional Ventilation|Use of conventional ventilation during 3 hours with 30 minutes wash-out time before.
16278354|NCT04827914|Experimental|Enhanced Care Condition|
16278355|NCT04827914|Active Comparator|Basic Care Condition|
16278356|NCT04827901|Active Comparator|XEN1101|Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
16278357|NCT04827901|Placebo Comparator|Placebo|Subjects will take a matching placebo daily for eight weeks.
16278358|NCT04827888||underweight|patients who underwent one of the 25 common orthopaedic surgeries and have a body mass index (BMI) of <18.5kg/m2
16278359|NCT04827888||normal-weight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 18.5kg/m2 and 24.9kg/m2
16278360|NCT04827888||overweight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 25kg/m2 and 29.9kg/m2
16278361|NCT04827888||mildly obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 30kg/m2 and 34.9kg/m2
16278362|NCT04827888||moderately-to-severely obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI ≥35kg/m2
16278363|NCT04827875|Experimental|AIV001 Treatment Dose 1|Intradermal, Dose 1
16278364|NCT04827875|Experimental|AIV001 Treatment Dose 2|Intradermal, Dose 2
16278365|NCT04827862|Experimental|Pembrolizumab and Radiation Therapy|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
16278366|NCT04827849|Experimental|Experiment group|The study group will be provided physical examination, pregnancy monitoring and training on transition to motherhood within the direction of nursing care based on Meleis's Transition Period Theory, in addition to the usual care provided by healthcare professionals.
16278367|NCT04827849|No Intervention|Control group|The control group continued to receive the routine care
16278368|NCT04827836|No Intervention|Cohort A - Room-temperature eye drops and povidone-iodine|Participants will receive a standardized topical anesthesia protocol of oxybuprocaine hydrogen chloride (HCl) 0.4% and lidocaine HCl 2% eye drops. Each drop will be instilled 3 times (one drop): At 10 minutes, 5 minutes, and just before the injection. Before the injection patients will receive cul-de-sac 5% povidone-iodine (3 drops) and the peri-ocular skin will be disinfected using a 10% povidone-iodine. A standard intravitreal injection of bevacizumab, 1.25 mg/0.05 ml will be performed through the pars plana with a 30-gauge needle, 3.5 mm from the corneal limbus, at the superior-temporal quadrant. Following the injection, a cotton swab absorbed with 5% povidone-iodine will be applied to the injection site.
16278369|NCT04827836|Experimental|Cohort B - Cooled eye drops and povidone-iodine|Participants will receive the same treatment as cohort A, using cooled eye drops and povidone-iodine (5 degree Celsius).
16278370|NCT04827823||Group 1- Amalgam restorations|Multi-surface amalgam restorations performed by dental students and are in function for about 5 years.
16278371|NCT04827823||Group 2- Composite restorations|Multi-surface composite restorations performed by dental students and are in function for about 5 years.
16278372|NCT04827810|Experimental|Dose -1|Accelerated Phase: - Standard Phase: 5 mg
16278373|NCT04827810|Experimental|Dose 1|Accelerated Phase: 10 mg Standard Phase: 10 mg
16278374|NCT04827810|Experimental|Dose 2|Accelerated Phase: 20 mg Standard Phase: 20 mg
16278375|NCT04827810|Experimental|Dose 3|Accelerated Phase: 40 mg Standard Phase: 35 mg
16278376|NCT04827810|Experimental|Dose 4|Accelerated Phase: 80 mg Standard Phase: 50 mg
16278377|NCT04827810|Experimental|Dose 5|Accelerated Phase: 160 mg Standard Phase: 65 mg
16278378|NCT04827810|Experimental|Dose 6|Accelerated Phase: 320 mg Standard Phase: 85 mg
16278379|NCT04827797|Experimental|birth ball|The positions and movements for birth ball in the active and latent phases: kneeling on the ground and leaning on the spherical birthing ball, sitting on the ball with front support, sitting positions on the spherical birthing ball, full rotation of hip, moving to the right/left, back and forth. Positions and movements were repeated every 30 minutes. The 30-minute intervals were interrupted in cases where the women were not feeling well.
16278380|NCT04827797|Experimental|peanut ball|The positions and movements for the pregnant women in peanut ball: upright sitting position, forward bending positions, with backward and forward movement and swaying right and left on the peanut ball
16278381|NCT04827784|Experimental|Auriculotemporal Nerve Block Administration|A total of 3 doses of Auriculotemporal Nerve Block (ATNB) were administered to involved participants. Local anesthetic solutions containing Articaine Hydrochloride (80 mg / 2 ml) and epinephrine bitartrate (0.02 mg / 2 ml) were used for ATNB application. The injections were repeated on follow-up visits in the first and fourth weeks. The maximal mouth opening amounts, pain intensity values (via VAS scale), and self-reported outcomes were evaluated at the pre-injection, first week, fourth week, and sixth-month follow-up controls.
16278382|NCT04827758|Other|Patients hospitalized in the follow-up care and rehabilitation units|
16278383|NCT04827745|Experimental|Subjects with R/R CD19-positive MPAL|Cohort A: Evaluate the efficacy of blinatumomab to achieve the best morphologic response after the first two cycles of therapy in subjects with morphologic R/R CD19-positive MPAL
16278384|NCT04827745|Experimental|Subjects with CD19-positive MPAL in complete remission and detectable MRD|"Cohort B: Evaluate the efficacy of blinatumomab to achieve MRD-negativity in subjects with CD19-positive MPAL in CR, or CRh, or CRi or CRp after receiving at least one chemotherapy block of standard ALL or AML treatment with MRD-positivity at a level of
~≥ 0.1% using an assay with a minimum sensitivity of 0.01%"
16278385|NCT04827732|Experimental|Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|-Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1
16278386|NCT04827732|Experimental|Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|-Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2
16278387|NCT04827732|Experimental|Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|-Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3
16278388|NCT04827719|Experimental|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
16278389|NCT04827693||Immediate|implants are placed immediately after tooth extraction
16278390|NCT04827693||Delayed|implants are placed months after the tooth has been extracted
16278391|NCT04827680|Experimental|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
16278392|NCT04827667||Patients with lung cancer|In lung cancer patients with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
16278393|NCT04827667||Patients wiht interstitial lung disease|In patients with interstitial lung disease with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
16278394|NCT04827667||Patients with asthma|In patients with asthma with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
16278395|NCT04827654|Experimental|Intervention group|Families in the intervention arm will receive a program of 4 weeks of access to fruit and vegetables through direct access (produce box) and a gift card to the grocery store for purchase of preferred produce.
16278396|NCT04827654|No Intervention|Control Group|Families in the control group will not receive any produce boxes or gift cards during the study period. At the end of the study period they will receive gift cards of equivalent amount.
16278397|NCT04827628|Experimental|Obese with Oryza sativa extract|The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract
16278398|NCT04827628|Active Comparator|Obese with control|The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture
16278399|NCT04827628|Active Comparator|Normal Body Mass Index|The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture
16278400|NCT04827615|Other|High Risk|"Group 2: Of all adults in (1), those at high risk of diabetes and hypertension, defined as having a score >4 based on the following criteria:
~Age 40-49 years (+1), age ≥50 years (+2)
~Used to smoke or use smokeless tobacco products or sometimes currently use (+1), currently use daily (+2)
~Currently consume alcohol daily (+1)
~Waist circumference 81-90 cm (women)/91-100 cm (men) (+1), >90 cm (women)/>100cm (men) (+2)
~Physical activity <150 minutes per week (+1)
~Parent and/or sibling with high blood pressure, diabetes, or heart disease (+2)"
16278401|NCT04827615|Other|Eligible adults|Group 1: All adults ≥30 years old living in the 12 target villages who meet eligibility criteria and provide informed consent
16278402|NCT04827602||Allergy tested group|Patients who have completed penicillin allergy testing
16278403|NCT04827589|Experimental|Tirabrutinib|Participant will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 8 weeks.
16278404|NCT04827589|Placebo Comparator|Placebo|Participants will receive placebo twice daily in addition to their standard-of-care therapy for up to 8 weeks.
16278405|NCT04827589|Experimental|Tirabrutinib, Open Label Extension|At Week 8, participants who have not discontinued the study drug will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 16 weeks.
16278410|NCT04827563||Participants with Normal Baseline Endothelial Function|
16278411|NCT04827563||Participants with Abnormal Baseline Endothelial Function|
16278412|NCT04827550||STUDY GROUP|diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
16278413|NCT04827550||CONTROL GROUP|90 healthy volunteers
16278414|NCT04827537||20-hydroxyecdysone group|water sports athletes with Giardia infection will receive 20-hydroxyecdysone (100 mg (one pill) x two times a day orally), 10 consecutive days
16278415|NCT04827537||metronidazole group|"water sports athletes with Giardia infection will receive metronidazole, 500 mg (one pill) x two times a day orally, 10 consecutive days
~, and placebo preparations, respectively"
16278416|NCT04827537||placebo group|water sports athletes with Giardia infection will receive placebo preparation, 100 mg (one pill) x two times a day orally, 10 consecutive days
16278417|NCT04827511||cohort group|80 children with disabilities like autism, ADHD, Down syndrome, deafness, phocomelia, dyslexia, different motor problems
16278422|NCT04827472|Experimental|Part1(Cohort1) : DWJ1521 Amg|
16278423|NCT04827472|Experimental|Part1(Cohort2) : DWJ1521 Bmg|
16278424|NCT04827472|Experimental|Part1(Cohort3) : DWJ1521 Cmg|
16278425|NCT04827472|Experimental|Part1(Cohort4) : DWJ1521 Dmg|
16278426|NCT04827472|Experimental|Part2 : DWJ1521 Xmg|
16278427|NCT04827472|Experimental|Part2 : DWP14012 Tablet|
16278428|NCT04827459|Experimental|MI Sleep Coach Mobile Application|The Sleep Coach app includes evidence-based CBT-I strategies, interactive activities and a computerized dialogue agent to engage users in the adoption of and adherence to CBT-I strategies.
16278429|NCT04827446|Experimental|Intervention Arm|Light intervention delivered through SYNC app + blue-light blocking glasses.
16278430|NCT04827446|Active Comparator|Control Arm|Placebo light intervention delivered through SYNC app + clear glasses.
16278431|NCT04827433||Women having a persistent low-lying placenta with an IOD between 6 and 20 mm|Women having a persistent low-lying placenta with an IOD between 6 and 20 mm who will be offered a vaginal birth, considering 3 subgroups: 1) 6-10 mm; 2) 11-20mm; 3) > 20 mm (resolution of previa or low-lying placenta)
16278432|NCT04827433||Women with normal located placenta|Women with a normally located placenta at the II trimester scan will represent the control group.
16278433|NCT04827420|Experimental|MiQuit Care|Intervention arm: Advise to quit + automatic linkage to quitline + patient navigation
16278434|NCT04827420|Active Comparator|Enhanced Standard of Care|Active Comparator: Advise to quit + written self-help materials
16278435|NCT04827407|Experimental|Basic therapy + Efferon LPS|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
16278436|NCT04827407|No Intervention|Baseline therapy|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis.
16278437|NCT04827394|Experimental|Intervention group|In the intervention group, the infant will be placed on the thermal mattress, then wrapped.
16278438|NCT04827394|No Intervention|Control group|In the non-intervention group, the infant will be delivered onto the sterile field as per standard of care.
16278439|NCT04827381|No Intervention|Usual care|Patients visiting their clinician will receive the normal, written after-visit-summary (available on paper or via the patient portal).
16278440|NCT04827381|Experimental|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
16278441|NCT04827381|Experimental|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
16278442|NCT04827368||Crohns Disease|
16278443|NCT04827368||Ulcerative Colitis|
16278444|NCT04827368||Non-IBD|
16278447|NCT04827329||Patients with a sleep disorder|Patients with a sleep disorder recording performed in the Sleep Unit in Montpellier University Hospital.
16278448|NCT04827329||Patients with a narcolepsy|Patients with a narcolepsy (type 1 or type 2) / a idiopathic hypersomnia or a restless legs syndrome.
16278449|NCT04827316||Patients undergoing clinically indicated CCTA|Patients undergoing clinically indicated CCTA
16278450|NCT04827290|Experimental|Normal-protein and low-AGE through raw or rare proteins diet|Normal-protein (0,8g/kg/day) and low-AGE through raw or rare proteins diet during 24 months
16278451|NCT04827290|Active Comparator|Normal-protein and AGE-rich diet|Normal-protein (0,8g/kg/day) and high-AGE through overcooked proteins diet during 24 months
16278452|NCT04827277|Active Comparator|Reverse total shoulder replacement|Participants will receive a reverse total shoulder arthroplasty
16278453|NCT04827277|Active Comparator|Anatomic total shoulder replacement|Participants will receive an anatomic total shoulder arthroplasty
16278454|NCT04827264||Return to Play Testing using Checklist|"Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with the Safe return to play following ACL reconstruction checklist"
16278455|NCT04827264||Return to Play Testing using Clinical Judgment|Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with clinical judgement
16278456|NCT04827251|Other|Caffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume caffeinated coffee during 28 days, followed by decaffeinated coffee during more 28 days.
16278457|NCT04827251|Other|Decaffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume decaffeinated coffee during 28 days, followed by caffeinated coffee during more 28 days.
16278458|NCT04827238||Patients with Elevated Gradients Post Transcatheter Aortic Valve Replacement|Patients who have an echocardiographic transaortic mean gradient ≥ 20mmHg OR VARC-3 criteria for ≥ moderate hemodynamic valve deterioration post TAVR on any TTE > 1 month post-TAVR
16278459|NCT04827225||PoPPY Group|Mother, Father and child born prematurely
16278460|NCT04827212|No Intervention|Control|Control group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks
16278527|NCT04826653|Experimental|Timing suture removal_1 week|
16278461|NCT04827212|Experimental|Treatment|Treatment group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks. In addition, the Companion will be deployed in the treatment group only.
16278462|NCT04827199|Experimental|ARTUS MONO AUS|The subjects will be implanted with the experimental medical device ARTUS MONO Artificial Urinary Sphincter (AUS) during the surgical procedure and will be trained to the use of the Remote Control to control themselves the micturition.
16278463|NCT04827186|Experimental|highly sensitized patients with either a positive FCXM, or positive CDC cross-match|highly sensitized patients that receive a donor offer and have either a positive FCXM (T or B cell positive) or positive CDC cross-match (B cell positive); a positive CDC cross-match (T cell positive) remains a contraindication at this time.
16278464|NCT04827186|No Intervention|historical cohort of highly sensitized patients with a positive FCXM, or positive CDC cross-match|The control group, as comparison, will be an historical cohort of highly sensitized patients with positive flow (B and T) or positive B standard crossmatch, which received kidney transplant alone or simultaneous kidney and pancreas transplant and followed our standard protocol
16278465|NCT04827173|Experimental|Healthy volunteers|
16278466|NCT04827160||COVID-19|Patients with COVID-19
16278467|NCT04827147|Experimental|MPP first, FPP second|Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period.
16278468|NCT04827147|Experimental|FPP first, MPP second|Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period.
16278469|NCT04827134|Experimental|Cohort 1: Treatment sequence AB|Participants will receive pediatric TRIUMEQ as a dispersion to be taken immediately after a high calorie meal (Treatment A) in Period 1 followed by pediatric TRIUMEQ administered as a dispersion under fasted conditions (Treatment B) in Period 2.
16278470|NCT04827134|Experimental|Cohort 1: Treatment sequence BA|Participants will receive pediatric TRIUMEQ as a dispersion under fasted conditions (Treatment B) in Period 1 followed by pediatric TRIUMEQ administered as a dispersion to be taken immediately after a high calorie meal (Treatment A) in Period 2.
16278471|NCT04827134|Experimental|Cohort 2: Treatment sequence CD|Participants will receive pediatric DOVATO as a dispersion to be taken immediately after a high calorie meal (Treatment C) in Period 1 followed by pediatric DOVATO administered as a dispersion under fasted conditions (Treatment D) in Period 2.
16278472|NCT04827134|Experimental|Cohort 2: Treatment sequence DC|Participants will receive pediatric DOVATO as a dispersion under fasted conditions (Treatment D) in Period 1 followed by pediatric DOVATO administered as a dispersion to be taken immediately after a high calorie meal (Treatment C) in Period 2.
16278473|NCT04827121|Active Comparator|Fascial iliac compartment block group|Patients in this group will recieve supra-inguinal fascial iliac compartment block after anesthesia induction.
16278474|NCT04827121|Active Comparator|Quadratus lumborum block group|Patients in this group will recieve quadratus lumborum block after anesthesia induction.
16278475|NCT04827095|Experimental|Web-Based Support and Education Program 1|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
16278476|NCT04827095|Experimental|Web-Based Education and Support Program 2|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
16278477|NCT04827082|Experimental|Diacutaneous fibrolysis group|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
16278478|NCT04827082|No Intervention|Control group|Participants will be used as their own controls, with one lower extremity randomly receiving intervention. The control extremity will not receive any intervention
16278479|NCT04827069|Experimental|Arm 1|Clifutinib Besylate:10 mg
16278480|NCT04827069|Experimental|Arm 2|Clifutinib Besylate:20 mg
16278481|NCT04827069|Experimental|Arm 3|Clifutinib Besylate:40 mg
16278482|NCT04827069|Experimental|Arm 4|Clifutinib Besylate:55 mg
16278483|NCT04827069|Experimental|Arm 5|Clifutinib Besylate:70 mg
16278484|NCT04827056|Experimental|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
16278485|NCT04827056|Experimental|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
16278486|NCT04827056|Placebo Comparator|Placebo|Placebo and study drug will look exactly the same in order to maintain the double-blind; study drug and placebo are administered exactly the same.
16278487|NCT04827043|Experimental|Quadratus lumborum block|QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg & 3mg/Kg with epinephrine), single injection sonar guided.
16278488|NCT04827043|Experimental|Thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
16278489|NCT04827030|Active Comparator|Ropivacaine hydrochloride injected by Erector Spinae block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
16278490|NCT04827030|Active Comparator|Ropivacaine hydrochloride injected by Paravertebral block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
16278492|NCT04826991|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
16278493|NCT04826991|Sham Comparator|Inactive UV Device|A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).
16278494|NCT04826965|Active Comparator|Wound vac application|Wound vac application for open upper/lower extremity open wound
16278495|NCT04826965|Active Comparator|Wound vac application including irrigation|Wound vac application WITH irrigation for upper/lower extremity open wound
16278496|NCT04826939|Experimental|Device usage|All participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device
16278497|NCT04826926|Experimental|Non-surgical periodontal treatment NSPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.
~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
16278498|NCT04826900|Experimental|Robotic Group|Training session included 45 minutes Robotic Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
16278499|NCT04826900|Experimental|Robotic Mirror Group|Training session included 45 minutes Robotic Mirror Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
16278500|NCT04826887||Solep Arm|Use of SOLTIVE Thulium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
16278501|NCT04826887||Control Arm|Use of Holmium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
16278502|NCT04826874|Experimental|Affect Labeling_direct|Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling
16278503|NCT04826874|No Intervention|Wait-list|Randomized to a two-week wait-list control
16278504|NCT04826861|Other|Intervention for overweight pregnant women|Intervention will be delivered during antenatal visits in maternity care
16278505|NCT04826835|Experimental|Prehabilitation intervention|Participants in the intervention group will follow a 2-week prehabilitation program before lung resection.
16278506|NCT04826835|Active Comparator|Health education control|Participants in the control group will receive health education classes during 2 weeks before lung resection.
16278507|NCT04826822|Experimental|Treatment|"After randomisation (Day 1): Spironolactone [100 mg 1x/day] + dexamethasone [2 mg 2x/day, 12/12h] Days 2-12*: Spironolactone [50 mg 2x/day, 12/12h] + dexamethasone [2 mg 2x/day, 12/12h] Days 13-20: Spironolactone [25 mg 2x/day, 12/12h] Days 21-28: Spironolactone [25 mg 1x/day] Standard treatment is according to the treatment protocol for 2019-nCoV infection.
~*In case of cortisol levels above 100 nmol/L on days 3 and 4, the dexamethasone dose should be increased to 3 mg in the morning and in the evening (total 6 mg per day)."
16278508|NCT04826822|Active Comparator|Control|Patients receiving standard-of-care treatment for SARS-CoV-2 infection as regulated by the relevant guidelines of the Ministry of Healthcare of the Russian Federation
16278509|NCT04826809|Experimental|Health care workers|Health care workers will complete a fit test while wearing the Nordell Single E-100 layer + (cotton layer) mask, Nordell Double E-100 layer mask and an N95 mask
16278510|NCT04826796|Experimental|Whatsapp intervention group|In addition to standard care, participants will be included into a peer support Whatsapp group on Whatsapp with other participants and trained peer supporters after study entry. Standard weekly prompt text messages will be sent to the group by peer supporters to encourage questions and discussion related to breastfeeding. Peer supporters will provide breastfeeding and emotional support. Intervention will last for 6 months after birth.
16278511|NCT04826796|No Intervention|Control group|Participants in the control group will continue to receive standard care.
16278512|NCT04826783|Experimental|Diode laser|
16278513|NCT04826783|Experimental|Er,Cr:YSGG laser|
16278514|NCT04826783|Experimental|Er:YAG LAser|
16278515|NCT04826757|No Intervention|standard care|standard care for low back pain management by general practioners (GPs). the physiotherapist and occupational health services can be solicited independently by the patient or GP.
16278516|NCT04826757|Experimental|coordinated care|"Coordinated care between general practioners, physiotherapist and occupational health services.
~An intervention training will be performed before the start of the study for any care professional's to elaborate coordination tools and have an active communication."
16278517|NCT04826744||Adults with palpebral involvement of atopic dermatitis|
16278518|NCT04826731||Incentive Spirometer Group|"Patients who would use an incentive spirometer, in addition to standard care provided to COVID-19 patients, will be categorized under Incentive Spirometer Group."
16278519|NCT04826731||Standard Care Group|"Patients who did not use an incentive spirometer despite being suggested to do so will be categorized under Standard Care Group."
16278520|NCT04826718||Cohort|All Health Care Worker (HCW) from Hospital in Santiago and S. Vicente islands, Cabo Verde
16278521|NCT04826718||Control|HCW who report no SARS-CoV-2 infection in the period prior to the interview and/or suspected COVID-19 in the period prior to the interview
16278522|NCT04826718||Cases|HCW who report positive SARS-CoV-2 infection confirmed by performing a positive PCR test and/or positive Rapid Antigen Test in the period prior to the interview
16278523|NCT04826692|Experimental|Metformin|Therapeutic group: Biguanidines (antidiabetic) Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
16278524|NCT04826692|Placebo Comparator|Placebo|Therapeutic group: NA Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
16278525|NCT04826679|Experimental|Experimental|"Camrelizumab + Cisplatin + Nab-paclitaxel
~Camrelizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Cisplatin (IV), dose=60mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
16278526|NCT04826666||Groups/Cohorts|The Principal Investigator propose to conduct a retrospective observational cohort study of all consecutive adult patients who underwent a liver transplantation between July 2008 and January 2021 at the Centre hospitalier de l'Université de Montréal (CHUM).
16278534|NCT04826588|Active Comparator|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
16278535|NCT04826588|Active Comparator|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
16278536|NCT04826588|No Intervention|Standard of care|Patient receives usual hospital care
16278537|NCT04826575|No Intervention|Control|No intervention will be done in this group.
16278538|NCT04826575|Experimental|Pre-Habilitation|Two weeks of high intensity respiratory muscle training, optional smoking cessation and psychological support.
16278539|NCT04826562|Experimental|dolutegravir/lamivudine|dolutegravir/lamivudine
16278540|NCT04826536||Cohort 1|Participants with psoriasis
16278541|NCT04826523||Participants treated with Venetoclax|Participants who were prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) will be enrolled for this study.
16278542|NCT04826510|Active Comparator|Lithium carbonate group|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
16278543|NCT04826510|Experimental|Perospirone hydrochloride group|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
16278544|NCT04826510|Experimental|Lithium carbonate + perospirone hydrochloride group|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
16278545|NCT04826497|Experimental|Nicorandil|Patients who received intracoronary and intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
16278546|NCT04826497|Placebo Comparator|Placebo （normal saline）|Patients who received intracoronary and intravenous placebo before and after reperfusion with primary percutaneous coronary intervention
16278549|NCT04826471|Experimental|DermoRelizema ecofoam|DermoReizema ecofoam for 42 days, 2 times per day
16278552|NCT04826445||Patients included in PENTOCLO protocol|We perform a prospective study with inclusions of all consecutive patients with osteoradionecrosis eligible for PENTOCLO.
16278553|NCT04826432|Experimental|Pasireotide|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
16278554|NCT04826432|Placebo Comparator|Placebo|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
16278555|NCT04826419|Active Comparator|Non-invazive ozone therapy in a group|ozone therapy
16278556|NCT04826419|No Intervention|Control group|control groups do not take ozone therapy
16278557|NCT04826406|Experimental|Camrelizumab+Apatinib|
16278558|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 1|"A 3+3 dose escalation design will be used to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when combined with cemiplimab.
~Participants will receive ASP8374 and Cemiplimab every 3 weeks for up to 2 years."
16278559|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 2|"Upon determination of the MTD/RP2D of ASP8374 plus cemiplimab in Cohort 1, a dose expansion will be performed in which eligible participants who are candidates for surgical resection will enroll to Cohort 2 and will be randomized into one of four treatment groups (2A-2D).
~Group 2A: IV ASP8374 within 14± 5 days prior to surgery.
~Group 2B: IV Cemiplimab within 14± 5 days prior to surgery.
~Group 2C: IV ASP8374 plus cemiplimab within 14± 5 days prior to surgery at the MTD/RP2D established in Cohort 1.
~Group 2D: No immune checkpoint therapy prior to surgery.
~Post-operatively, all Cohort 2 participants will receive ASP8374 plus cemiplimab every 3 weeks administered at the MTD/RP2D established by Cohort 1
~Per determination of treating clinician, participants will have 89Zr-Df-IAB22M2C administered prior to PET scans."
16278560|NCT04826380|Other|Trapeziectomy|Simple trapeziectomy for treating CMC I arthritis
16278561|NCT04826380|No Intervention|Conservative|Conservative measures (e.g. splint, NSAID, activation modification) for treating CMC I arthritis
16278562|NCT04826367|Experimental|Exercise Group (EG)|"The participants in the EG will perform relaxation exercises in groups of up to 8 people, 3 days a week for 6 weeks via WhatsApp (© 2020 WhatsApp, Inc.) or Zoom (© 2012-2020 Zoom Video Communications, Inc.) applications. Relaxation exercises will be performed with the Progressive Relaxation Exercises (PRE) technique defined by Jacobson et al.[11] Tele-rehabilitation sessions will last approximately 40 minutes of each, accompanied by a physiotherapist who has 8 years of experience in the field of oncological rehabilitation."
16278563|NCT04826367|No Intervention|Control Group (CG)|Participants in this group will have a brochure with simple exercises (relaxation exercises involving the upper and lower extremities) in sitting and lying positions. They will be advised to be as active as possible at home and to take mild walks at home. Any supervised exercise program will not apply to participants in the CG. If the participants apply any regular exercise program within 6 weeks, the participants in this group will be excluded from the study.
16278566|NCT04826341|Experimental|1/Phase I|Dose escalated Sacituzumab Govitecan and Berzosertib
16278567|NCT04826341|Experimental|2/Phase II|Sacituzumab Govitecan and Berzosertib treatment with identified MTD based on phase I.
16278568|NCT04826328|Experimental|FX301 Low Dose Low Volume|65 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
16278569|NCT04826328|Experimental|FX301 Low Dose High Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
16278570|NCT04826328|Experimental|FX301 High Dose Low Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
16278571|NCT04826328|Experimental|FX301 High Dose High Volume|260 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
16278572|NCT04826328|Placebo Comparator|Normal Saline|Low or high matching volume of preservative-free normal saline given as a single injection adjacent to the sciatic nerve of the popliteal fossa
16278573|NCT04826315|Experimental|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
16278574|NCT04826302|Experimental|Myofascial treatment|4 sessions of myofascial intervention, 40 minutes per session, 1 session per week
16278575|NCT04826302|Sham Comparator|Sham myofascial treatment|4 sessions of sham myofascial intervention, 40 minutes per session, 1 session per week
16278576|NCT04826276|Experimental|All Subjects|"for the abstinence intervention, 12+ hours after smoking will be assessed before assessments following smoking as normal
~For the satiated intervention, smoking as normal will be assessed first before assessments following 12+ hours of abstinence from smoking"
16278577|NCT04826263|Experimental|ESWT Group|The patients in the ESWT group will receive ESWT treatment and a home exercise program.
16278578|NCT04826263|Experimental|LLLT Group|The patients in the LLLT Group will receive LLLT treatment and a home exercise program.
16278579|NCT04826250|Experimental|Hypertensive patients - nighttime medication|Hypertensive patients will be instructed to take their medication in the evening for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the morning for four weeks.
16278580|NCT04826250|Experimental|Hypertensive patients - morning medication|Hypertensive patients will be instructed to take their medication in the morning for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the evening for four weeks.
16278581|NCT04826237|Experimental|Statin|"Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day;
~Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone:
~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
16278582|NCT04826237|Placebo Comparator|Placebo|"Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone
~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
16278583|NCT04826224|Experimental|Subjects with Osteoarthritis of the shoulders|Subjects diagnosed with Osteoarthritis of the shoulders will be injected with concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
16278584|NCT04826211|Experimental|Node positive BC patients undergoing PST|Patients with breast cancer of any size with positive axillary nodes and candidates to PST will undergo PET/MRI both prior to PST and after PST before surgery
16278585|NCT04826198|Experimental|AsiDNA in addition to Niraparib|Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
16278586|NCT04826185|Experimental|IMB-1018972 200mg|
16278587|NCT04826185|Placebo Comparator|Placebo|
16278588|NCT04826172|Experimental|IMB-1018972 200mg|
16278589|NCT04826172|Placebo Comparator|Placebo|
16278590|NCT04826159|Experimental|IMB-1018972 200 mg|
16278591|NCT04826146||CONOX|Patients are monitored with BIS and CONOX
16278592|NCT04826133|Active Comparator|Acute Pretreatment with Calcitriol|To explore the effects of acute pre-treatment with Calcitriol on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
16278593|NCT04826133|Placebo Comparator|Acute Pretreatment with Placebo|To explore the effects of acute pre-treatment with placebo on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
16278594|NCT04826120|Active Comparator|PCEA group|Patients of this group had intermittent epidural analgesia via PCEA associated to systematic 8 ml boluses every 60 min during the second stage of labor.
16278595|NCT04826120|Experimental|CEI Group|Patients of this group had continuous epidural infusion at the rate of 8 ml/h during the second stage of labor.
16278596|NCT04826107|Experimental|Part 1: Dose-finding stage|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg，2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.
16278597|NCT04826107|Experimental|Part 2: Cohort A|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.
16278598|NCT04826107|Experimental|Part 2: Cohort B|Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.
16278599|NCT04826107|Experimental|Part 2: Cohort C|Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.
16278600|NCT04826107|Experimental|Part 2: Cohort D|Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.
16278601|NCT04826094|Experimental|Group 1: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278602|NCT04826094|Experimental|Group 2: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278603|NCT04826094|Experimental|Group 3: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278604|NCT04826094|Experimental|Group 4: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278605|NCT04826094|Experimental|Group 5: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278606|NCT04826094|Experimental|Group 6: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278607|NCT04826094|Experimental|Group 7: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
16278608|NCT04826081||Case|women who contracted symptomatic dengue fever during pregnancy
16278609|NCT04826081||Control|women who did not contract symptomatic dengue fever during pregnancy
16278610|NCT04826068|Experimental|Emotional Processing|The intervention looks at emotional processing of face interpretation.
16278611|NCT04826068|Placebo Comparator|Control intervention|The control group is seeing the same faces and are asked questions regarding them.
16278612|NCT04826055|Active Comparator|loop bypass with fixed biliary limb length|in all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
16278613|NCT04826055|Experimental|loop bypass with a biliary limb is a percentage of the small intestine|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
16278614|NCT04826042|Active Comparator|contrast group|injection of contrast medium 6 cc during thoracic epidural catheterization
16278615|NCT04826042|Placebo Comparator|normal saline group|injection of normal saline 6 cc during thoracic epidural catheterization
16278616|NCT04826029|Other|Standard arm|
16278617|NCT04826029|Experimental|Interventional arm|
16278618|NCT04826016|Experimental|PHASE Ib - ARM A: POL6326 (balixafortide) + eribulin|On day 1 and 8 of each 21-day cycle (+/- 1 day) fixed eribulin dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) combined with increasing doses of POL6326 (balixafortide) starting at a dose of 11 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Eribulin will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 2 to 5 min. Up to 4 additional cohorts may be introduced
16278619|NCT04826016|Experimental|PHASE Ib - ARM B: POL6326 (balixafortide) + nab-paclitaxel|On day 1, 8 and 15 of each 28-day cycle (+/- 1 day) fixed nab-paclitaxel dose of 100 mg/m2 combined with increasing doses of POL6326 (balixafortide) starting at a dose of 5.5 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Nab-paclitaxel will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 30 min. Up to 5 additional cohorts may be introduced
16278620|NCT04826016|Experimental|PHASE 2 - ARM A: POL6326 (balixafortide) + eribulin|MTD/RDP2 POL6326 (balixafortide) (from arm A phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 1.4 mg/m2 eribulin over 5 min Intravenous infusion on days 1 and 8 in 21-day cycles (+/- 1 day).
16278621|NCT04826016|Experimental|PHASE 2 - ARM B: POL6326 (balixafortide) + nab-paclitaxel|MTD/RDP2 POL6326 (balixafortide) (from arm B phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 100 mg/m2 nab-paclitaxel over 30 min Intravenous infusion on days 1, 8 and 15 in 28-day cycles (+/- 1 day).
16278624|NCT04825990|Experimental|Single Arm Treatment|Patients will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week dosing cycle (Q3W) and olaparib 300 mg capsules twice a day (BID) every day starting from Day 1 of Cycle 1. Treatment with protocol therapy will continue until objective disease progression, any prohibitive toxicity or until a maximum of 35 treatment cycles (up to 2 years).
16278625|NCT04825964||Patients|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated at diagnosis and after 1-3 months.
16278626|NCT04825964||Healthy Controls|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated one time.
16278627|NCT04825951|Active Comparator|CS 2000 appliance|treating growing skeletal Class III patients
16278628|NCT04825951|Active Comparator|Reversed Forsus Fatigue resistant appliance|treating growing skeletal Class III patients
16278629|NCT04825951|No Intervention|Control|"A group of untreated skeletally growing class III patients will be recruited to account for the possible effects of growth in the treatment groups.
~This group matches the treated groups in malocclusion, stages of skeletal maturation, and mean observation period. Those patients will be treated after the period of the study."
16283926|NCT04788810|Experimental|Dermal route|Volunteers receiving d12-Cl2BPA via oral route
16278630|NCT04825938|Experimental|Toripalimab + Carboplatin + Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.
~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.
~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
16278631|NCT04825925|Experimental|DEB-BACE|
16278632|NCT04825912|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 10 weeks.
16278633|NCT04825899||NGS Panel|patients who had NGS 481 gene mutation detected
16278634|NCT04825873||Cohort 1|Participants with non-small cell lung cancer (NSCLC)
16278635|NCT04825873||Cohort 2|Participants with squamous cell carcinoma of head and neck (SCCHN)
16278636|NCT04825860|Experimental|SEP-363856 50 mg/day|Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.
16278637|NCT04825860|Experimental|SEP-363856 75 mg/day|Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.
16278638|NCT04825860|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.
16278639|NCT04825847|Active Comparator|Electroencephalographic (EEG)-guided group|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
16278640|NCT04825847|Active Comparator|Standard Care (SC) group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at [0.8-1.2] MAC.
16278641|NCT04825834||Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis|
16278642|NCT04825834||Individuals eligible for Lung Cancer screening with no cancer diagnosis|
16278643|NCT04825834||Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis|
16278644|NCT04825821||Low transverse hysterotomy closed by double-layer unidirectional barbed suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by double-layer unidirectional barbed suture
16278645|NCT04825821||Low transverse hysterotomy closed by conventional double-layer smooth suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by conventional double-layer smooth suture
16278646|NCT04825808||Patients|Consecutive elderly (≥55 years) patients, recruited and registered in the stroke database of two centres (Nîmes University Hospital and Montpellier University Hospital, France), presenting with cSAH with suspected, possible, or probable CAA.
16278647|NCT04825795||DPP4-inhibitor|Patients who were prescribed DPP4-inhibitor during the period between two coronary CT scan.
16278648|NCT04825795||No DPP4-inhibitor|Patients who were not prescribed DPP4-inhibitor during the period between two coronary CT scan.
16278649|NCT04825782||Pregnant Women exposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
16278650|NCT04825782||Pregnant Women unexposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
16278651|NCT04825769|Experimental|Intervention|Red light irradiation was conducted at school from Monday to Friday and at home everyday in summer and winter holiday twice a day for 3 minutes per time, with an interval of 4 hours
16278652|NCT04825769|No Intervention|Control|No intervention
16278653|NCT04825756|Experimental|Treatment Group|A total of up to 80 child/caregiver dyads will be enrolled in the study, anticipating that 40 dyads will complete the 10 week intervention. An equine assisted therapy called Reining in Anxiety for children with anxiety and their caregivers.
16278654|NCT04825743|Experimental|RUC-4 Dose 1 (0.110 mg/kg)|Subjects will receive a single subcutaneous injection containing RUC-4 Dose 1 (0.110 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
16278655|NCT04825743|Experimental|RUC-4 Dose 2 (0.130 mg/kg)|Subjects will receive a single subcutaneous injection containing RUC-4 Dose 2 (0.130 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
16278656|NCT04825743|Placebo Comparator|Placebo|Subjects will receive a single subcutaneous injection containing Placebo in the ambulance after diagnosis of STEMI and before hospital arrival
16278657|NCT04825730|Experimental|Long Term Follow-up after Jointstem Transplantation|
16278658|NCT04825717|Experimental|Intervention group|Patients in this group will be administered nutrition and fluid plans prepared by the department dietitian using calorimetry-based measurements
16278659|NCT04825717|No Intervention|Control group|Nutrition plans of patients in this group will be calculated by the department dietitian using the standard, currently accepted RDI (recommended dietary intake) formula.
16278662|NCT04825691||cases diagnosed as prostatic acinar adenocarcinoma|
16278663|NCT04825678|Experimental|Erenumab|
16278664|NCT04825665|Experimental|Continuous force|A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar on one side
16278665|NCT04825665|Experimental|Intermittent force|A buccally directed tipping force of 150 g removed every 21 days for a 7-day rest period applied to the maxillary first premolar on one side
16278721|NCT04825223|Active Comparator|Stage 4: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine or Bexsero vaccine and RVs in the respective dosing schedule at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
16314857|NCT04574063|Experimental|Lifestyle website only|
16278666|NCT04825639||Sepsis|"Patients admitted to PICU who are selected from registry based on primary diagnoses with codes for the following search codes were selected:
~Sepsis is defined as per the International Consensus Conference pediatric sepsis definition (2005) [citation 1].
~In silico analysis will be carried out in the sepsis cohort comparing admissions with Acute Kidney Injury (AKI) and those without AKI to identify factors associated with AKI.
~In those selected admissions to PICU, information on Renal Function, Chloride levels, clinical outcome and medication use as well as fluid resuscitation will be collected from hospital online resources such as discharge summaries, results portal and the PICANet database. In addition the Paediatric Index of Mortality 3 severity of illness scores will be reported for all admissions.
~Sepsis will be defined based on the International Pediatric Consensus Conference definition of sepsis (2005)"
16278667|NCT04825639||Diabetic Ketoacidosis (DKA)|"This group is defined based on the British Society of Paediatric Endocrinology and Diabetes.case definition for Diabetic Ketoacidosis [citation 2].
~The data collected will be similar to the sepsis cohort. In silico analysis will be carried comparing those with AKI and without AKI in the DKA cohort."
16278668|NCT04825587|Experimental|Concomitant ACL and ALL reconstruction|The participant will undergo both the ACL and ALL reconstruction surgery.
16278669|NCT04825587|Experimental|ACL reconstruction alone|The participant will undergo only ACL reconstruction surgery.
16278670|NCT04825574|Experimental|Patients with GIST previously enrolled in avapritinib clinical trials|
16278671|NCT04825561|Active Comparator|Active Comparator|AD-208 and Placebo of AD-2081
16278672|NCT04825561|Placebo Comparator|Placebo Comparator|Placebo of AD-208 and Placebo of AD-2081
16278673|NCT04825561|Experimental|Experimental Comparator|Placebo of AD-208 and AD-2081
16278674|NCT04825535|Experimental|Standard psychiatry and cognitive behavioural online intervention|The online group CBT-M program combines software-based workbooks with phone-based Navigator-Coaching that coordinates software interactions (e.g., secure text messaging, Fitbit tracked walking, food monitoring via photography). Navigation coaching is supplied by students who were pursuing graduate degrees (MSc, MA, PhD) in kinesiology and health science, education, and psychology.
16278675|NCT04825535|Active Comparator|Standard psychiatry and cognitive behavioural in-person intervention|The on-site, usual-care CBT group follows the structure of the Mind Over Mood workbook in reviewing CBT concepts and procedures. A series of work sheets assist participants in differentiating moods, and in differentiating moods from thoughts and situational influences, leading to modifications of thinking, behaviour, emotion and mood. Group leaders are standard leaders in the CAMH group-CBT program who have Masters-level degrees in psychology, social work and occupational therapists.
16278676|NCT04825522|No Intervention|Control|Participants will not be receiving vancomycin.
16278677|NCT04825522|Active Comparator|Vancomycin|For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
16278678|NCT04825509||Successful weaning group|Patients will be in this group according to primary outcome, if they will succeed spontaneous breathing trial for 120 minutes and will be extubated successfully without need for invasive or non-invasive ventilation for 48 hours
16278679|NCT04825509||Weaning failure group|"Patients will be in this group according to primary outcome, if they will fail spontaneous breathing trial or extubation within 48 hours
~Weaning failure will be considered if:
~Patients will need MV during spontaneous breathing trial within 120 minutes, or
~patients will need invasive or non-invasive ventilation within 48 hours"
16278680|NCT04825496|Experimental|ssCART-19 Cells|"Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16278683|NCT04825470|Experimental|Liver Transplantation|
16278684|NCT04825470|Active Comparator|Tyrosine kinase inhibitors therapy only|
16278685|NCT04825457|Active Comparator|Anchoring-tip EMR|AEMR, the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins.
16278686|NCT04825457|Active Comparator|Conventional EMR|After injection of normal saline solution mix, snaring was tried for CEMR.
16278687|NCT04825431|Experimental|TAS-205, [14C]TAS-205|
16278688|NCT04825418|Experimental|Therapeutic Hypothermia Group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Decompressive Hemicraniectomy care based on international guidelines except therapeutic hypothermia using surface cooling device.
16278689|NCT04825405|Active Comparator|The use of the active Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the active TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
16278690|NCT04825405|Placebo Comparator|The use of the passive Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the passive TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
16278691|NCT04825392|Experimental|HX008|
16278692|NCT04825379|Experimental|bioactive composite|Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN)
16278693|NCT04825379|Experimental|posterior resin composite|G-ænial Posterior (GC, Tokyo, Japan) (GP)
16278775|NCT04824833|Active Comparator|Serratus anterior plane block|
16278776|NCT04824833|No Intervention|control group|
16279051|NCT04822896|Active Comparator|Real Physical Movements|They will be asked to actually do the exercises shown in the video.
16278694|NCT04825366|Active Comparator|Standard educational program|Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.
16278695|NCT04825366|Active Comparator|Standard educational program combined with high intensity interval training|"Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.
~Each study participant will be asked to train 3 times per week following the home-based program that will be provided to them. Participants will be asked to perform at least 2 training sessions per week with the exercise specialist on a virtual platform. The training session will consist of a 3 to 5-minute low-intensity warm-up followed by 6 to 12 1-minute bouts of high-intensity exercise interspersed with 1-minute bouts of low-intensity exercise. Each session will end with a 3-minutes cool-down period."
16278696|NCT04825353|Experimental|ECIRS-Group|
16278697|NCT04825353|Active Comparator|SPCNL-GRoup|
16278698|NCT04825340|Experimental|Study vaccine|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
16278699|NCT04825340|Placebo Comparator|Placebo|commercial normal saline
16278700|NCT04825314|Active Comparator|Bactiguard urethral catheter|Group A: Fifty Patients with urethral catheter using noble metal alloy coated catheter (Bactiguard AB, Stockholm ,Sweden).
16278701|NCT04825314|Active Comparator|Silicone Foley urethral catheter|Group B: Fifty Patients with urethral catheter using silicone Foley catheter (Well Lead, Guangzhou, China).
16278702|NCT04825301||training cohort|data collection
16278703|NCT04825301||validation cohort|data collection
16278704|NCT04825288|Active Comparator|Arm 1|"XB2001 + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment
~• Arm 1 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: XB2001 MTD as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-Fluorouracil 2400mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
16278705|NCT04825288|Placebo Comparator|Arm 2|"Placebo + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment
~• Arm 2 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: Placebo as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
16278706|NCT04825275|Experimental|Posaconazole|Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
16278707|NCT04825275|No Intervention|Control|Participants will not undergo any intervention.
16278708|NCT04825262|Experimental|Intervention genotyping group|"Patients who are scheduled to receive renal transplant from a living donor between January 2021 to January 2023. They will be assigned to receive the initial CYP3A5 genotype-based tacrolimus (FK) dose as determined by their CYP3A5 genotype.
~CYP3A5 expresser (extensive or intermediate metabolizer) - 0.20mg/kg CYP3A5 non-expresser (poor metabolizer) - 0.15mg/kg
~The starting dose of the intervention arm will be reviewed for every 10 patients recruited based on the drug levels achieved."
16278709|NCT04825262|No Intervention|Historical Control Group|Patients who received renal transplant from a living donor between January 2016 - December 2020 and received standard weight-based dosing of tacrolimus
16278710|NCT04825249|Experimental|The traditional suture bridge technique group|For the TSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
16278711|NCT04825249|Experimental|The modified suture bridge technique group|For the MSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
16278712|NCT04825236|Experimental|Decision Aid Users|Patients with CF who are given access to the MyVoice:CF decision aid
16278713|NCT04825236|Experimental|CF Healthcare Providers|Members of the adult CF care team who interact with patients who have used the decision aid
16278714|NCT04825223|Experimental|Stage 1: MenB vaccine formulation(s)|Assigned MenB vaccine formulation or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
16278715|NCT04825223|Active Comparator|Stage 1: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
16278716|NCT04825223|Experimental|Stage 2: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, MenQuadfi vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of leading MenB vaccine formulation single injection at Day 366
16278717|NCT04825223|Active Comparator|Stage 2: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of Bexsero vaccine single injection at Day 366
16278718|NCT04825223|Experimental|Stage 3: Men B vaccine formulation(s)|Assigned MenB vaccine formulation and/or MenQuadfi vaccine single injection in the respective dosing schedule at Day 01 and Day 61
16278719|NCT04825223|Active Comparator|Stage 3: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine single injection at Day 01 or Bexsero vaccine single injection at Day 01 and Day 61
16278720|NCT04825223|Experimental|Stage 4: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, Routine Vaccines (RV)s and MenQuadfi vaccine single injection in the respective dosing at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
16278777|NCT04824820|Experimental|Vibrator|Participants will be using commercially available genital vibrator for at least 5 minutes and/or reaching an orgasm three times a week for 3-4 months.
16278722|NCT04825210|Experimental|Integrated Behavioral Health - Prevention (IBH-P)|The IBH-P intervention addresses four areas: 1) assessment of emotional and behavioral adjustment, 2) parental education on important supports for emotional and behavioral health, 3) modeling and guidance on nurturing and responsive parenting, and 4) addressing parental concerns about and promoting child self-regulation. The primary focus of IBH-P is promoting infant self-regulation by teaching mothers how to soothe and calm their baby. Trauma-informed and relationship building methods are emphasized to acknowledge maternal experiences with violence and adversity and the desire to establish a strong working alliance. IBH-P is distinguished from Bright Futures through its emphasis on experiential learning, modeling of effective parenting skills, in-session practice and feedback, and proactive problem-solving. Families in IBH-P will receive all standard care elements of the well-child visit including pediatrician implementation of Bright Futures curriculum.
16278723|NCT04825210|Active Comparator|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|The Bright Futures control condition consists of standard of care in addressing emotional and behavioral health as provided by pediatricians. Pediatricians will follow the 4th edition of the Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents [pocket guide]. Guidelines are provided for topics to discuss and anticipatory guidance at each well-child visit. In contrast to IBH-P, there is an emphasis on didactic presentation, teaching mothers about developmental milestones, and responding to questions and concerns. These include discussions of crying, soothing, and feeding, although self-regulation is not a unifying theme.
16278724|NCT04825197|Experimental|LRS Group|This arm will receive up to 4 doses (100 mg Kg) of Poractant alfa (Curosurf, Chiesi) every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV. Optimal recruitment is defined as adequate oxygenation using a fraction of inspired oxygen (FiO2) of 0.30 or less. The continuous distending pressure (CDP) will be increased stepwise (1 cmH2O every 2-3 min) as long as pulse oximetry (SpO2) improves. The FiO2 will be reduced stepwise, keeping SpO2 within the target range (87-94 %). The recruitment procedure will be stopped if oxygenation no longer improves or if the FiO2 is equal to or less than 0.30. The corresponding CDP will be called the opening pressure (CDPO). Next, the CDP will be reduced stepwise (1-2 cmH2O every 2-3 min) until the SpO2 deteriorates (by at least 2-3 points). The corresponding CDP will be called the closing pressure (CDPC). After a second recruitment maneuver at CDPO for 5 min, the optimal CDP (CDPOPT) will be set 2 cmH2O above the CDPC for at least 3 min.
16278725|NCT04825197|No Intervention|Standard Group|This arm will be managed following the ward standard ventilatory protocol which does not contemplate neither surfactant administration nor recruitment manoeuvre.
16278726|NCT04825184|Experimental|Body image chatbot|The artificial intelligence chatbot, Topity, is designed to target sociocultural risk and protective factors for body image using eight therapeutic techniques derived from several evidence-based theories, including media literacy, cognitive behaviour theory and positive body image. The intervention aims to engage users in techniques that teaches users how to 1) Critically analyse and evaluate media content to reduce vulnerability to negative media influences (i.e., media literacy theory; 10); 2) Identify and challenge unhelpful thinking styles and behaviours that perpetuate body image distress (i.e., cognitive behaviour theory; 11); and 3) Appreciating the features, functions and health of the body, beyond it's appearance (i.e., positive body image theory; 12). Users will be assessed on state body satisfaction and affect before and after engaging with a technique to assess the immediate impact of the micro-intervention.
16278727|NCT04825184|No Intervention|Assessment only|The comparison control condition will be assessment only. This is informed by a care as usual framework; whereby, Brazilian adolescents are not currently offered online body image prevention or intervention resources at school or within the community.
16278728|NCT04825171|Experimental|Bryophyllum pinnatum 50% chewing tablets|Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of chewing tablets, 350mg per tablet, 0-2-2-2/d: 2 tablets at midday, 2 tablets in the evening, 2 tablets before bedtime.
16278729|NCT04825145||Preeclamptic women|Pregnant women who is diagnosed with preeclampsia during anytime of pregnancy.
16278730|NCT04825145||Healthy pregnant women|Pregnant women without preeclampsia. Will be matched for body mass index, gestational age and age.
16278731|NCT04825132|Experimental|Bacteremia and/or acute respiratory infection|Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for with bacteraemia and/or acute respiratory infection
16278732|NCT04825132|Active Comparator|Without suspicion of infection|The control patient will undergo the exact same procedures as the case patient described before except for the blood and respiratory sample part. • The typical control patient will be of the same age (+/- 3 years, but aged above 65 years), same sex, without suspicion of infection and hospitalized during the past or upcoming month in the same centre. There will be 2 controls for one case.
16278733|NCT04825119||MND patients|Patients with ''clinically definite ALS'' or ''clinically probable ALS'' or ''clinically probable ALS - laboratory supported'' according to the revised El Escorial diagnostic criteria or with the diagnosis of PMA or PLS will be included.
16278734|NCT04825119||SMA patients|SMA patients type I, II, III, and IV will be included.
16278735|NCT04825106|Active Comparator|Expected|Anaphylactic shock occurs after the injection of a drug known to cause allergic reactions
16278736|NCT04825106|Active Comparator|Unexpected, no distractor|Anaphylactic shock occurs unexpectedly, but their is no medical distractor
16278737|NCT04825106|Active Comparator|Unexpected, with distractor|Anaphylactic shock occurs unexpectedly. Scenario is set up such, that a tension pneumothorax may be a likely explanation
16278738|NCT04825093|Experimental|Intervention group|Women allocated to this group will be supplemented with 2,000 UI of vitamin D3.
16278739|NCT04825093|Active Comparator|Control group|The control group will consist of pregnant women supplemented with 400 UI of vitamin D3.
16278740|NCT04825067|Experimental|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
16278741|NCT04825054|Experimental|A 60-min trial ventilated with NAVA|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
16278742|NCT04825054|Experimental|A 60-min trial ventilated with PCV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
16278743|NCT04825054|Experimental|A 60-min trial ventilated with PSV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
16278744|NCT04825041||Infertilite women|Subjected to three successive hysteroscopic tests
16278745|NCT04825028||Internal Diagnostic Accuracy Cohort|Consecutive patients with available CZT-SPECT within 3 months of measuring FFR in the left anterior descending coronary artery. In these patients, correlation between angiography-derived IMR and hyperemic microvascular resistance will be assessed.
16278746|NCT04825028||External Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (J Nucl Cardiol. 2020 Sep 30. doi: 10.1007/s12350-020-02252-8.), INOCA patients and normal controls confirmed by CZT-SPECT and angiography will be included for the assessment of angiography-derived IMR in diagnosing microvascular dysfunction.
16278747|NCT04825028||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the target vessel after successful revascularization. Those patients have follow-up data after 2 years from index procedure.
16278748|NCT04825015||OLTx|Liver insufficiency patients undergoing transplantation surgery
16278749|NCT04825002|Experimental|Urinary multimarker sensor arm|A urine of this group will be collected and measured using a newly developed urinary multimarker sensor (ANXA3, PSMA, ERG, ENG)
16278750|NCT04824989|Experimental|Sleep Health|Family receives the Sleep Health In Preschoolers parenting intervention to address toddler sleep problems.
16278751|NCT04824989|Experimental|Behavior Health|Family receives the Family Check-Up parenting intervention to address toddler behavior problems.
16278752|NCT04824989|Experimental|Choice|Family is given the opportunity to select either the Sleep Health in Preschoolers intervention to address toddler sleep problems or the Family Check-Up intervention to address toddler behavior problems.
16278753|NCT04824989|Active Comparator|Control|Family receives a safety and hygiene active control intervention.
16278754|NCT04824976|Active Comparator|Blueberry|Freeze-dried pure blueberry powder
16278755|NCT04824976|Placebo Comparator|Placebo|Maltodextrin powder.
16278756|NCT04824950|Other|Monitoring of Circulating Tumor DNA|
16278757|NCT04824937|Experimental|Telaglenastat + Talazoparib|"During 28 day study cycles, participants will receive:
~Telaglenastat 2x daily at a predetermined dose
~Talazoparib 1x daily at a predetermined dose"
16278758|NCT04824937|Experimental|Telaglenastat + Talazoparib Staggered|If a beneficial response is seen with the Arm 1 Telaglenastat + Talazoparib combination, participants will receive telaglenastat alone 2x daily at a predetermined dose with the addition of talazoparib at 1x daily at a predetermined dose if the disease gets worse.
16278759|NCT04824924|Experimental|HVAG regimen|
16278760|NCT04824911|Experimental|Intervention group|"This group will receive dual antiplatelet and high-intensity statin treatment.
~Dual antiplatelet treatment: loading of clopidogrel 300mg plus aspirin 300mg, followed by clopidogrel 75 mg/day and aspirin 100 mg/d from day 2 to day 21, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
~High-intensity statin treatment: Atorvastatin 40-80mg/day or Rosuvastatin 20 mg/day for 90 days."
16278761|NCT04824911|Active Comparator|Historical control|A historical control group of patients receiving single antiplatelet therapy but no high-intensity statin treatment will be drawn from previous prospective observation studies. Antiplatelet therapy includes aspirin(100-300mg/day) or Clopidopgrel (75mg/day).
16278762|NCT04824898|Experimental|simvastatin 1.2%gel|simvastatin 1.2%gel applied after open flap debridment in group I
16278763|NCT04824898|Experimental|I-prf|Injectable plasma rich fibrin will be collected from each patient in group II and the applied after open flap debridment
16278764|NCT04824885|Experimental|Acetate free then acetate containing dialysate|Patients in group 1 will first be treated with the acetate-free dialysate (A-D) for 6 months and then the acetate-containing dialysate (A + D) for 6 months.
16278765|NCT04824885|Experimental|Acetate containing dialysate then acetate free dialysate|Group 2 patients will continue on the usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months. Patients will be blinded from study treatment.
16278766|NCT04824872|Experimental|Sequence 1|Dasiglucagon high dose, followed by placebo, followed by dasiglucagon low dose
16278767|NCT04824872|Experimental|Sequence 2|Dasiglucagn low dose, followed by dasiglucagon high dose, followed by placebo
16278768|NCT04824872|Experimental|Sequence 3|Placebo, followed by dasiglucagon low dose, followed by dasiglucagon high dose
16278769|NCT04824872|Experimental|Sequence 4|Dasiglucagon high dose, followed by dasiglucagon low dose, followed by placebo
16278770|NCT04824872|Experimental|Sequence 5|Placebo, followed by dasiglucagon high dose, followed by dasiglucagn low dose
16278771|NCT04824872|Experimental|Sequence 6|Dasiglucagon low dose, followed by placebo, followed by dasiglucagon high dose
16278772|NCT04824859|Experimental|Experimental|The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided.
16278773|NCT04824846|Experimental|Ambulance drivers with received Integrated back pain module (IBPM)|Behavioral: Integrated back pain module (IBPM)
16278774|NCT04824846|Other|Ambulance drivers with received Health Educational Pamphlet.|Other: Health Educational Pamphlet.
16278778|NCT04824807|Experimental|Clinical Pilates Group|Individuals in the this group will receive 24 sessions of Clinical Pilates training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
16278779|NCT04824807|Experimental|Yoga Group|Individuals in the this group will be given 24 hours of yoga training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
16278780|NCT04824807|Other|Control Group|Individuals in the this group will not receive any treatment. Individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
16278781|NCT04824794|Experimental|Treatment|GEN3014
16278782|NCT04824768|Experimental|Experimental group|30 min session of CRet with functional massage on the rectus femoris, and gastrocnemius.
16278783|NCT04824768|Sham Comparator|Control group|30 min session of CRet with functional massage on the rectus femoris, and gastrocnemius. Sham stimulation was provided by only turn on the device but dose is 0.
16278784|NCT04824755|Experimental|Demographics and clinic characteristics of children in different ages|
16278785|NCT04824755|Experimental|PedEyeQ domain scores|
16278786|NCT04824755|Experimental|Boxes represent first, median, and third quartile values.|
16278787|NCT04824755|Experimental|Parent of kids aged 0-4y and 5-11y PedEyeQ domain scores|
16278788|NCT04824742|Experimental|neoadjuvant PDT + radical surgery|Photodynamic therapy for neoadjuvant treatment of cholangiocarcinoma
16278789|NCT04824742|Active Comparator|radical surgery|Patients with cholangiocarcinoma undergo radical surgical resection
16278792|NCT04824716|Experimental|postconditioning|Patients that underwent postconditioning after primary percutaneous coronary intervention.
16278793|NCT04824716|Other|control|Patients that underwent primary percutaneous coronary intervention.
16278794|NCT04824703|Active Comparator|Conservative oxygen therapy|"Spo2 alarm limit will be set as follow: - upper limit 94% and lower limit 88%
~If spo2 >94% Unless fio2 is 0.21%, decrease fio2 by 0.10% at intervals no longer than 5 minutes till spo2 = 94%
~If spo2 within target Decrease fio2 0.05% at intervals no longer than 30 min till fio2 0.21% reached or spo2 = 88 %
~If spo2 < 88 % return to previous spo2 that achieve target spo2.
~if an arterial blood gas demonstrate that the PaO2 is < 60 mmHg FiO2 will increased if clinically appropriate irrespective of the SpO2 reading ( target po2 60-100 mmhg )
~During intubation, airway suction, tracheostomy, bronchoscopy, transportation outside of the ICU for radiological or other investigations or for procedures or operations, other critical situations such as hemodynamic collapse, patients will receive standard (non-study)treatment.
~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
16278795|NCT04824703|Placebo Comparator|Liberal oxygen therapy|"Spo2 target > 95%
~No specific measures will be taken to avoid high fio2 or high po2
~Use of upper alarm limit for spo2 will be prohibited
~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
16278796|NCT04824690|Experimental|Virtual Reality Group|The virtual reality group watched a 1.5-minute VR video showing the operating theater and explaining the perioperative process. After the surgery, this group watched cartoons during the first standard nursing procedures after the effect of the anesthesia wore off.
16278797|NCT04824690|No Intervention|Control Group|The control group received conventional care and education regarding the perioperative process of surgery.
16278798|NCT04824651||Solid cancer|800 participants
16278799|NCT04824651||Solid organ transplantation|700 participants
16278800|NCT04824651||Allogeneic hematopoietic stem cell transplantation|350 participants
16278801|NCT04824651||Chronic renal failure|Patients with chronic renal failure stage 4, 5 who receive dialysis or not 350 participants
16278802|NCT04824651||Autoimmune and autoinflammatory systemic diseases|"Systemic lupus erythematosus ,Systemic Vasculitides,...
~750 participants"
16278803|NCT04824651||Multiple sclerosis/ Neuromyelitis optica diseases|MS defined by Mac Donald et al. 2017 and Neuromyelitis optica defined by Wingerchuk et al. 2015 ; 600 participants
16278804|NCT04824651||Chronic inflammatory rheumatism|"Ankylosing spondylitis and rheumatoid polyarthritis
~600 participants"
16278805|NCT04824651||Hypogammaglobulinemia|300 participants
16278806|NCT04824651||Obese non diabetic|BMI ≥ 30 1400 participants
16278807|NCT04824651||Diabetic (type I and II) obese or not|1400 participants
16278808|NCT04824651||People living with HIV-1|1400 participants
16278809|NCT04824651||Senior group (free from chronic conditions of interest listed above)|≥75 years 450 participants
16278810|NCT04824651||Control group (free from chronic conditions of interest listed above)|18 to 74 years 1400 participants
16278811|NCT04824651||Control AZ-PF group (free from chronic conditions of interest listed above)|Participants with first dose of Astra-Zeneca vaccine AZD1222 and second dose of Pfizer ARNm vaccine BNT162b2 200 participants
16278812|NCT04824638|Experimental|Group 1: SARS-CoV-2 naive participants|participants without antecedent of SARS-CoV-2 infection
16278813|NCT04824638|Experimental|Group 2: Previously SARS CoV-2 infected participants|participants with antecedent of SARS-CoV-2 infection (more than 5 months)
16278863|NCT04824274|Experimental|Transversus abdominis plane block and intrathecal fentanyl|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.
16278864|NCT04824274|Active Comparator|Intrathecal morphine|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.
16278865|NCT04824261|Active Comparator|group 1|randomized 50 otomycosis patients will receive Clotrimazol solution 1%
16278814|NCT04824612|Sham Comparator|Sham Group|"intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide (Triancil®, Apsen Farmacêutica S.A.) - two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
~Sham PBM in the preoperative and postoperative periods of keloid removal surgery: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month."
16278815|NCT04824612|Experimental|Experimental Group|"Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J). Frequency: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month.
~Intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide: two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies."
16278816|NCT04824599|Active Comparator|PECS+subcutaneus local anesthetic infiltration|Preoperative ultrasound-led PECS II blockade with ropivacaine 3,75mg/ml (2mg/kg). After surgery - wound infiltration by the surgeon with ropivacaine 2mg/ml (1mg/kg).
16278817|NCT04824599|Active Comparator|Local anesthetic infiltration|Prior to scrubbing surgeon infiltrates the thought incision area with ropivacaine 3,75/ml (1mg/kg). Perioperatively after removal of the tumor follows the deep infiltration of the wound with ropivacaine 3,75mg/ml (2mg/kg).
16278818|NCT04824586|Experimental|Insulin infusion regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin infusion regimen.
~Fast-acting human insulin (Actrapid®) was used in this group."
16278819|NCT04824586|Experimental|Insulin bolus regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin bolus regimen.
~Fast-acting human insulin (Actrapid®) was used in this group."
16278820|NCT04824573|Experimental|Inspiratory Muscle Training (IMT)|The program of the IMT group (n=16) consists of individual sessions of approximately 20 minutes and the Powerbreathe device (IMT Technologies Ltd., Birmingham) was used for training.
16278821|NCT04824573|Experimental|Manual Therapy|In the manual therapy group (n=19), in addition to the approaches applied to the individuals in the IMT group, a total of eight sessions of manual therapy (manipulation, joint mobilization, and soft tissue mobilization) approaches, two days a week for four weeks and at least two days between sessions, were applied by an experienced physiotherapist in manual therapy. Manual therapy applications; included techniques targeting the cervical and thoracic regions. Techniques for the thoracic region; while it consists of manual diaphragm release, thoracic mobilization and High Velocity Low Amplitude (HVLA) thrust manipulation; the techniques applied to the cervical region consisted of soft tissue and joint mobilization.
16278822|NCT04824560|Other|BP Education|All participants enrolled receive blood pressure education.
16278825|NCT04824534||Healthy subjects|
16278826|NCT04824534||Healthy subjects matching baseline characteristics with patients|
16278827|NCT04824534||Patients with sarociliac joint dysfunction|
16278828|NCT04824521|Experimental|Mindfulness-Oriented Recovery Enhancement via tele-health|Participants will be assigned to 8 weeks of Mindfulness-Oriented Recovery Enhancement delivered via tele-health.
16278829|NCT04824508|Active Comparator|Conventional position (head position)|Leaderposition at the patient's head
16278830|NCT04824508|Active Comparator|Remote position|Leaderposition remote from patient and hands-off
16278831|NCT04824495||Patients with acute COVID-19|
16278832|NCT04824482|Experimental|Robot-assisted gait training (RGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
16278833|NCT04824482|Active Comparator|Therapist-assisted gait training (TGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
16278834|NCT04824469|Experimental|web based training|"Patients on the first day; Patient Information Form (1st and 2nd part), Memorial Symptom Assessment Scale, Covid-19 Symptom Assessment Inventory, Morisky Compliance Scale, World Health Organization Quality of Life Scale Short Form Turkish Version, E-Health literacy scale on website or mobile devices Google via the form or by sending a phone link.
~Morisky Compliance Scale will be applied on the 7th day by sending a link to the website or mobile devices via google form.
~Patients in the intervention group will be asked to fill out the Covid-19 Symptom Assessment Inventory on the website when they experience changes in their symptoms.
~Patients in the intervention group will be provided with web-based training and telephone (SMS) reminder service for 4 weeks.
~All questionnaires and web site evaluation form will be filled in the pre-test after 4 weeks."
16278866|NCT04824261|Active Comparator|group 2|randomized 50 otomycosis patients will receive 4%boric acid in distilled water
16278867|NCT04824248|Experimental|Experimental intervention|10 weeks online therapy delivered using a blended approach. The online therapy consists of instructive video's, challenges to complete, 1-on-1 video calls with the therapist, online quizzes, online booklets, and online diaries/workbooks. . The experimental group will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. The combined therapy will adhere to guidelines for patient-centered care
16278835|NCT04824469|No Intervention|standard care|The scales applied to the intervention group on the first day, by sending the E-Health literacy scale form or phone link via Google on mobile devices. The symptoms of the patients in the control group will be evaluated at the end of the 1st day, 7th day, 14th day and 4th day. No intervention was planned for the patients in the control group during the follow-up. In the standard practice protocol, after patients are informed for follow-up and treatment at home, they are called by the Ministry of Health and family physicians for symptom follow-up. The standard hospital protocol does not include a scheduled training program, telephone monitoring, or web-based training. After collecting the data in the intervention group, the website will be opened to the use of the control group.
16278836|NCT04824456|Experimental|bilateral sagittal split osteotomy using chisels.|The final split is completed with Smith forceps and flag separators
16278837|NCT04824443|Experimental|Participants who were hospitalized for COVID-19|Participants will be post-cancer treatment patients who were hospitalized for COVID-19.
16278838|NCT04824430||SLH 3M|Second look hysteroscopy (SLH) performed 3 months post-ablation
16278839|NCT04824430||SLH 6M|Second look hysteroscopy (SLH) performed 6 months post-ablation
16278840|NCT04824430||SLH 12M|Second look hysteroscopy (SLH) performed 12 months post-ablation
16278841|NCT04824417|Active Comparator|Control|Oral itraconazole
16278842|NCT04824417|Experimental|Intervention|Oral voriconazole
16278843|NCT04824404|No Intervention|Standard Treatment As Usual (TAU)|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly or bi-weekly visits (at the discretion of the provider) to the clinic to meet with their provider and provide a sample of blood.
16278844|NCT04824404|Experimental|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professional
16278845|NCT04824391|Experimental|3 mcg/0.5 ml Vaccine|Low dose vaccine
16278846|NCT04824391|Experimental|6 mcg/0.5 ml Vaccine|Medium dose vaccine
16278847|NCT04824391|Placebo Comparator|Placebo|Placebo
16278848|NCT04824378||label 1|Baseline data measurement of this group of patients: arm circumference（positive） and ICG (positive).
16278849|NCT04824378||label 2|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (positive).
16278850|NCT04824378||label 3|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (negative).
16278851|NCT04824365|Experimental|treatment of COVID-19 or influenza infected patients with a sodium pyruvate nasal spray|In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVIV-19 and influenza infections.
16278852|NCT04824365|Placebo Comparator|Placebo control treatment of COVID-19 or influenza infected patients|In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVIV-19 and influenza infections.
16278853|NCT04824352|Experimental|apatinib+IE|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA < 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
16278854|NCT04824339|Experimental|Immediate Intervention Group|The intervention is an 8-week combined aerobic and resistance program, with virtual, group-based, supervised exercise sessions twice per week (60 min). The intervention also includes optional education on healthy eating.
16278855|NCT04824339|Experimental|Delayed Intervention Group|Usual lifestyle control for 8 weeks and then invited to participate in the exercise intervention.
16278856|NCT04824326|Experimental|Pythagorean Self Awareness Intervention for Children and Adolescence(PSAI-CA)|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
16278857|NCT04824313||COVID-CAVA PE|Patients with RT-PCR proven COVID-19 disease and CTA proven pulmonary embolism
16278858|NCT04824313||COVID-CAVA non-PE|Patients with RT-PCR proven COVID-19 disease and no evidence of pulmonary embolism on CT
16278859|NCT04824300|Active Comparator|erector spinae plane block group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.Group ESPB was applied before general anesthesia by the same anesthesiologist with block experience. In the sitting position, using an ultrasound-guided linear probe (6-13 MHz) on the side to be operated, T3 is marked 3 cm from the lateral of the spinous processes and with the in-plane technique, a 22G block needle (100mm, B-Braun, Germany) in the cranio-caudal direction first After it was observed that the erector spina muscle was separated from the transverse process with -2 ml normal saline, 20 ml 0.5% bupivacaine and 100 mg lidocaine were administered. And the drug was found to spread to the craniocaudal line at the ESP on ultrasound.Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
16278860|NCT04824300|No Intervention|non block control group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.15 minutes before the end of the surgery, 1 gr paracetamol and 100 mg tramadol were given to the control group. Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
16278861|NCT04824287|Experimental|Experimental|pelvic floor exercise
16278862|NCT04824287|No Intervention|control group|no intervention
16278891|NCT04824066||Cardiothoracic Surgery Cohort|Adults patients who are scheduled to undergo cardiothoracic surgery and meet the inclusion and exclusion criteria.
16278868|NCT04824248|Active Comparator|Control intervention|Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.
16278869|NCT04824235|Experimental|Amnoitic Chorion Membrane and xenograft|extraction sockets where ridge preservation will be performed using Chorion Membrane with Xenograft
16278870|NCT04824235|Active Comparator|Amnoitic Chorion Membrane only|extraction sockets where ridge preservation will be performed using Chorion Membrane Alone
16278871|NCT04824222|Experimental|A - SOC+IMP|The FMT (fecal microbiota transplantation) will be administered along with the standard COVID 19 pharmacological treatment (SOC- Standard of care). The FMT will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
16278872|NCT04824222|Placebo Comparator|B - SOC+placebo|Using standard COVID 19 pharmacological treatment (SOC- Standard of care). The placebo will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules).
16278873|NCT04824209||AP group|Healthy patients between 25-55 years with Apical Periodontitis
16278874|NCT04824209||Control Group|Healthy patients between 25-55 years without Apical Periodontitis
16278875|NCT04824196|Experimental|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirror.Anterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear movements were performed for five minutes
16278876|NCT04824196|Active Comparator|propriocetion therapy|"Alternate knee flexion-extension with extended trunk posture using both hands for support.
~Hip and knee flexion-extension with swiss ball between the back and wall.
~Hip aises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises.
~then perform all exercise on gym ball"
16278877|NCT04824183|Experimental|Music therapy|Music therapy that begins with patient education on WhatsApp will be delivered to participants 3 times a week before surgery followed by a telephone session and face-to-face monitoring of intervention usage.
16278878|NCT04824183|No Intervention|Usual care|Participants in the control group will receive preoperative pain education via a one-on-one WhatsApp chat. The pain education will focus mainly on the type of pain to expect after surgery, how to report pain and how to request for pain medication. MT will not be introduced to the participants in this group neither will there be any phone call for psychological support. Other preoperative care and postoperative care will be provided according to the hospital and ward practices.
16278879|NCT04824170|Experimental|Neural glide|Neural mobilization of median nerve which includes gliding and sliding was given
16278880|NCT04824170|Experimental|Rhythmic stabilization technique|Proprioceptive Neuromuscular Facilitation (Rhythmic stabilization technique will be Given)
16278881|NCT04824144|Experimental|Dexmedetomidine subcutaneous continuous infusion|Participants will receive 0.2mcg/kg/hr of dexmedetomidine, titrated up by 0.1 mcg/kg/hr every hour as required, up to a maximum dose of 0.7mcg/kg/hr by subcutaneous continuous infusion.
16278882|NCT04824131|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or join an open-label extension CAB study in their area, if available.
16278883|NCT04824118||Group 1: Gestation less than 10 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
16278884|NCT04824118||Group 2: Gestation 10-14 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
16278885|NCT04824118||Group 3: Gestation 14-20 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
16278886|NCT04824118||Group 4: Non-pregnant controls|Blood tests at baseline only.
16278887|NCT04824105|Experimental|Neurostimulation Group|"On one study day, participants will complete experimental tasks during functional magnetic resonance imaging. On two other study days, participants will complete tasks before and after receiving repetitive transcranial magnetic stimulation (rTMS). All participants will receive rTMS to ventromedial prefrontal cortex on one study day, and to pre-supplementary motor area on another study day.
~Two stimulation procedures will be used, one for ventromedial prefrontal cortex and one for pre-supplementary motor area. For both targets, 3 sessions of 600 pulses at 110% of resting motor threshold will be presented over 30 minutes. For ventromedial cortex, a session will involve intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. For pre-supplementary motor area, a session will involve continuous theta burst presented in 3-pulse bursts with 15 pulses/ sec."
16278888|NCT04824092|Experimental|Tafasitamab plus lenalidomide in addition to R-CHOP|"Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles:
~Tafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15.
~Lenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle
~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
16278889|NCT04824092|Placebo Comparator|Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP|"Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles:
~Tafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle
~Lenalidomide placebo: Days 1-10 of each 21-day cycle
~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
16278890|NCT04824079|Experimental|Keynatinib treatment group|All subjects shall be treated with Keynatinib twice a day (once every 12±3 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. Every 21 days is a treatment cycle .
16285394|NCT04778696|Experimental|PASO pace mapping|PASO pace mapping with visualisation in CARTO3
16278892|NCT04824053|Experimental|UNICLA-A2 milk and its subproducts|Participants (n=17) ingest milk and dairy products made from cows homozygous for beta casein A2 during 3 months. These products are also enriched in insaturated fatty acids and selenium. The daily intake reflects the habitual consumption habits. Recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day.
16278893|NCT04824053|Placebo Comparator|Placebo|"Participants (n=17) ingest conventional dairy products and milk daily during 3 months. As happens in the UNICLA-A2 arm, the daily intake reflects habitual dairy consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day."
16278894|NCT04824040||Study group|Patients with a genetically confirmed dysferlinopathy.
16278895|NCT04824040||Control group|Healthy Volunteers
16278896|NCT04824027|Experimental|HMI Group|Women undergoing standard neoadjuvant chemotherapy for breast cancer
16278897|NCT04824014|Experimental|4FMFES-PET imaging at 0, 6 and 18 months|Patients burdened with ER+ advanced breast cancers and recruited in the trial will undergo an experimental 4FMFES-PET imaging within a 4-week interval of a medically-prescribed FDG-PET. The 4FMFES-PET procedure will be repeated at 6 and 18 months following the initial scan.
16278898|NCT04824001||STEMI|ST-segment elevation myocardial infarction (STEMI) is defined by symptoms of myocardial ischemia accompanied by a persistent elevation of the ST segment on the electrocardiogram (ECG) and the subsequent release of biomarkers of myocardial necrosis.
16278899|NCT04824001||NSTEMI|If there is elevation of the blood markers suggesting heart damage, but no ST elevation seen on the EKG tracing, this is known as a non ST-elevation myocardial infarction (NSTEMI).
16278901|NCT04823975|Experimental|HIEP intervention|Participants will be given the health insurance intervention from Utah Health Policy Project staff, which includes four, 30 minute long, educational learning sessions.
16278902|NCT04823962|Experimental|GM-CSF|rhGM-CSF (molgramostim) + hydrogel
16278903|NCT04823962|Placebo Comparator|Placebo|Hydrogel
16278904|NCT04823949|No Intervention|Standard care|Patient will be scheduled for a blood pressure check in the office 7-10 days postpartum
16278905|NCT04823949|Experimental|Intervention|Patient will receive a Babyscripts blood pressure cuff(brand: A&D Medical) and Babyscripts MyJourney phone app with which to monitor their blood pressures twice daily for 16 days after discharge
16278906|NCT04823936|No Intervention|control group|received the selected physical therapy program for one hour, three times weekly for two successive months including facilitation of balance and protective reactions from kneeling, half kneeling and standing position, standing alone on balance board, standing on one leg, open gait training alone (walking on the balance beam, walking on the stepper and walking on wedges), training stair climbing, and strengthening of the back and abdominal muscles.
16278907|NCT04823936|Active Comparator|study group|received the selected physical therapy program for one hour, three times weekly in addition to core stability training program for 30 minutes
16278908|NCT04823923|Other|Patients without renal insufficiency under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
16278909|NCT04823923|Other|Patients without renal insufficiency under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
16278910|NCT04823923|Other|Patients with moderate renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
16278911|NCT04823923|Other|Patients with moderate renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
16278912|NCT04823923|Other|Patients with severe or terminal stage renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
16278913|NCT04823923|Other|Patients with severe or terminal stage renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
16278914|NCT04823897|Experimental|Dose Escalation and Expansion|"Dose escalation phase: CCI-001 will be administered at the starting dose to a cohort of patients with recurrent and/or metastatic solid tumours. The dose will be escalated sequentially in subsequent cohorts to determine the maximum tolerated dose, or recommended dose for the dose expansion cohort.
~Dose expansion phase: patients with the following tumour types will be permitted to enroll: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined during the dose escalation phase."
16278915|NCT04823884|Active Comparator|open distal chevron osteotomy|Hallux valgus correction is provided by using the traditional open distal v-shaped chevron osteotomy.
16278916|NCT04823884|Active Comparator|minimally invasive distal chevron osteotomy|Hallux valgus correction is provided by using a minimally invasive distal v-shaped chevron osteotomy.
16278917|NCT04823871|Other|High risk patients for breast and/or ovarian cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
16278918|NCT04823871|Other|Suspected Ovarian Epithelial Cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
16278919|NCT04823858||Examination Group|There will only be one arm of subjects in this study. The arm will include subjects who plan to undergo a single-level TLIF stabilized with pedicle screws and meet all of the eligibility criteria.
16278920|NCT04823845|Experimental|Plantar Wart Treatment Using Adapalene Gel 0.1%|patients treated for plantar warts with Adapalene 0.1% gel
16278921|NCT04823832|Active Comparator|ERCP group|endoscopic retrograde cholangiopancreaticography with plastic stent insertion
16278922|NCT04823832|Active Comparator|PTD group|ultrasound guided percutaneous transhepatic catheter insertion
16278923|NCT04823819|Active Comparator|rTMS stimulation|20 sessions of stimulation with increasing intensity, reaching maximum in the 4th session.
16278924|NCT04823819|Active Comparator|tDCS stimulation|The stimulation time will be 20 minutes, the current intensity will be 2mA.
16278925|NCT04823819|Sham Comparator|Sham rTMS stimulation|20 sessions of stimulation, but without current.
16278926|NCT04823819|Sham Comparator|Sham tDCS stimulation|The stimulation time will be 20 minutes, but without current.
16279125|NCT04822415|Experimental|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
16278927|NCT04823806|Experimental|Healthy participants and participants with depressive disorder: dietary spermidine supplementation|Dietary Supplement: Polyamine 21 days of spermidine supplementation (3 sachets/day = 6mg spermidine/day)
16278928|NCT04823806|Placebo Comparator|Healthy participants and participants with depressive disorder: dietary placebo supplementation|Dietary Supplement: Placebo 21 days of Placebo supplementation (3 sachets/day)
16278929|NCT04823793||Healthy group : Stool specimens from participants with healthy colon|"Stool specimens will be collected from participants before having a colonoscopy.
~If the participant's colon has a healthy colon without any cancerous lesion, the stool specimen will be included in the healthy group."
16278930|NCT04823793||Disease group : Stool specimens from participants with adenoma/colorectal cancer|"Stool specimens will be collected from participants before having a colonoscopy.
~If the participant's colon has precancerous lesion, such as adenoma, the stool specimen will be included in the disease group.
~Also, specimens from confirmed colorectal cancer patients are included in the disease group."
16278931|NCT04823780||early enteral nutrition support group|Nutrient solution is provided through oral nutrient solution within 4-48 hours after endoscopic treatment
16278932|NCT04823780||parenteral Nutrition Group|Intravenous nutrition is provided within 48 hours after endoscopic treatment
16278933|NCT04823767|Experimental|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
16278934|NCT04823741||PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
16278935|NCT04823728||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
16278936|NCT04823715||TACE- hypofractionated radiation therapy|Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
16278937|NCT04823715||Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma
16278938|NCT04823702|Experimental|Child-Pugh A (Mild Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
16278939|NCT04823702|Experimental|Child-Pugh B (Moderate Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
16278940|NCT04823702|Experimental|Child-Pugh C (Severe Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
16278941|NCT04823689|Sham Comparator|Dorsal decubitus|The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.
16278942|NCT04823689|Experimental|Ventral decubitus|The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.
16278943|NCT04823676|Active Comparator|Probiotic composition|A capsule containing a mix of probiotic strains (1.5 x 10^9 CFU/capsule ) administered once daily for 4 months
16278944|NCT04823676|Placebo Comparator|Placebo|A capsule containing placebo administered once daily for 4 months
16278945|NCT04823663||BSC Product Use|"Subject fulfilling one of the following conditions:
~a. prospectively scheduled for a procedure involving i. use of a BSC EP Ablation product or BSC Capital Equipment product or ii. a BSC CRM product implant or b. retrospectively enrolled no more than 10 days after the index procedure and and all data necessary for appropriate reporting of all past visits is available and complete including i. the procedure where being diagnosed or treated with at least 3 separate BSC EP Ablation products/components or BSC Capital Equipment products/components or ii.the BSC CRM product implant."
16278946|NCT04823650||Ages 3-5|
16278947|NCT04823650||Ages 6-11|
16278948|NCT04823650||Ages 12-17|
16278949|NCT04823624|Experimental|MG MBG453|Participants will be given MBG453 On Day 1 of each cycle 28 days (4 weeks) study cycle
16278950|NCT04823611|Placebo Comparator|Part A:Placebo|Placebo solution for subcutaneous injection.
16278951|NCT04823611|Experimental|Part A:AZD8233|AZD8233 for subcutaneous injection.
16278952|NCT04823611|Placebo Comparator|Part B:Placebo|Placebo solution for subcutaneous injection.
16278953|NCT04823611|Experimental|Part B:AZD8233 high dose|AZD8233 high dose for subcutaneous injection.
16278954|NCT04823611|Experimental|Part B:AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
16278955|NCT04823611|Experimental|Part B:AZD8233 low dose|AZD8233 low dose for subcutaneous injection.
16278956|NCT04823598|Active Comparator|Reference group|Coached pushing and Finnish manual perineal protection
16278957|NCT04823598|Experimental|Study group|Uncoached pushing and Hands-poised perineal protection
16278958|NCT04823585|Placebo Comparator|subcutaneous injections of placebo|Subcutaneous injections of placebo (physiological sodium chloride solution) once per month for 16 weeks. A total of 4 injections.
16278959|NCT04823585|Experimental|subcutaneous injections of Mepolizumab 100 mg|Subcutaneous injections of Mepolizumab 100 mg once per month for 16 weeks. A total of 4 injections.
16278960|NCT04823572|Active Comparator|A-PRF Advanced Platelet-Rich Fibrin|Comparing healing effect of an autologous product with open flap debridement.
16278961|NCT04823572|Active Comparator|OFD Open Flap Debridement|Comparing healing effect of an autologous product with open flap debridement.
16278962|NCT04823559|No Intervention|Usual practice|Usual practice
16278963|NCT04823559|Experimental|Intervention|Receives educational workshop
16279085|NCT04822675|Experimental|Percutaneous mitral repair|Percutaneous mitral repair +/- coronary artery bypass grafting within 14 days of mitral repair.
16314858|NCT04574063|Experimental|Lifestyle website PLUS SNPs|
16278964|NCT04823546|Experimental|Activity based therapy|"Activity based training was done in 2 phases. exercise involve
~Standing and reaching
~Sit-to-stand
~Stepping forward and backward Phase 2 Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise.
~(10) Walking on a treadmill;"
16278965|NCT04823546|Active Comparator|strength training|Strength training for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
16278966|NCT04823533|Experimental|Probiotic|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
16278967|NCT04823533|Placebo Comparator|Placebo|Placebo formulation containing only the excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
16278968|NCT04823520|Active Comparator|Group 15% concentration|30 patients MDA will be done to one half of the face then TCA 15% will be applied to the whole face.
16278969|NCT04823520|Active Comparator|Group 20 % concentration|30 patients will receive MDA to one side of the face , TCA 20% will then be applied to the whole face.
16278970|NCT04823507||Concussion patients treated with Photobiomodulation|"Patients between the ages of 15-65 years clinically diagnosed with a mild Traumatic Brain Injury by a health professional and currently not undergoing any treatment during a 1 year period from January 2018 to December 2018.
~Documentation of the history of a qualifying mild Traumatic Brain Injury within 3 months of traumatic incident and/or diagnosis with persistent symptomatology after 3 months. For reference, International Classification of Diseases, Tenth Revision (ICD-10) clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol4."
16278971|NCT04823494|Active Comparator|Pro-Fit|Hearing aids fit by a professional hearing care provider using best practices.
16278972|NCT04823494|Experimental|Self-Fit|Hearing aids fit by patient.
16278973|NCT04823468|Experimental|Experimental group|In addition to conventional dietary instruction and individualized nutritional counselling, patients were given additional ONS (Abbott®Ensure of 55.8 g tid) from the beginning to the end of radiotherapy.
16278974|NCT04823468|Other|Control group|Conventional dietary instruction and individualized nutritional counselling from the beginning to the end of radiotherapy.
16278975|NCT04823455|Experimental|Allo Omero 2020|Humeral allograft group 12 patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.Included patients were clinically and radiographically re-evaluated for the purpose of this study by examiners not involved in the primary treatment at a mean of 66 months postoperatively. The clinical examination consisted of a physical examination and structured interview. Computed tomography (CT) was carried out at the medium follow-up of 66 months in all patients to evaluate OA progression and allograft resorption.
16278976|NCT04823442|Active Comparator|Study A|Metabolic PET study with mirabegron
16278977|NCT04823442|Experimental|Study B|Metabolic PET study with mirabegron and bisoprolol
16278978|NCT04823429|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
16278979|NCT04823429|Experimental|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
16278980|NCT04823429|No Intervention|Control group|Without any exercise training
16278981|NCT04823416|Active Comparator|Stoma|
16278982|NCT04823416|Active Comparator|Resection and stoma|
16278983|NCT04823403|Experimental|Patients with heptaocellular carcinoma|"Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.
~Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels*.
~(D1) Starting dose : 50 mg; n=3 to 6
~(D2) 2nd dose-level : 100 mg; n=3 to 6
~(D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) *Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (>1/3 DLT at D1)"
16278984|NCT04823390|Other|Anesthetist controlled group|15 patients undergoing cataract surgery will receive sedation given by the anesthetist together with local anesthesia according to the depth of sedation in the form of intravenous Midazolam and Fentanyl.
16278985|NCT04823390|Other|Patient-controlled group|15 patients undergoing cataract surgery under local anesthesia will administer sedation to themselves through a pump.
16278986|NCT04823377|Other|Period A: Usual management|Period of end-of-life care as usual
16278987|NCT04823377|Other|Period B: Process of optimization of the medical decision|Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
16278988|NCT04823364|Active Comparator|Medically healthy adults diagnosed with ADHD|Medically healthy adults diagnosed with ADHD (men and women) ages 18-40 years (N= 35), treated with Amphetamines (Mixed Amphetamine salts (Attent) or short-acting methylphenidate (Ritalin)
16278989|NCT04823364|No Intervention|Control|HCS (N= 25) volunteers ages 18-40 years, who did not report ADHD or any other illness or medical conditions, and who do not take chronically medications, will be enrolled from the general population.
16278990|NCT04823351|Other|FFP2 Mask|Universal FFP2-masking for every healthcare worker with patient contact, compared to selective FFP2-masking, which means that FFP2 masks are worn only during aerosol-generating procedures such as tube manipulation;
16278991|NCT04823351|Other|Surgical Mask|Universal surgical mask IIR type masking for healthcare workers in contact with COVID-19 patients.
16279016|NCT04823156|Experimental|Low energy and adequate calcium|All dietary food and water will be provided for 19 days. The energy content of the diet will be prescribed, according to exercise levels, to elicit an energy availability of 45 kcal per kg of fat free mass per day for the first 7 days and 15 kcal per kg of fat free mass per day thereafter. Foods high in calcium will be removed and participants will be provided with a calcium and vitamin D food supplement (two daily 500 mg calcium and 400 IU vitamin D supplements) (total intake 1500 mg calcium per day and 800 IU vitamin D3 per day).
16279086|NCT04822675|Active Comparator|Mitral valve surgery|Surgical mitral valve surgery +/- coronary artery bypass grafting
16314859|NCT04574063|Experimental|Lifestyle website PLUS group coaching|
16278992|NCT04823338|Experimental|Conectar Jugando Online Program|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Sherlock Express (Kermarrec, 2019), Streams (Itsubaki, 2011) and Blurble (Bernard, 2013). The play sessions were carried out in groups of between 2 and 4 boys and girls of similar ages (same school stage) formed according to the availability of the participants. In the sessions, the physical games were projected on the videoconference tool by the researcher and the participating boys and girls carried out their actions using their voice and the platform tools. The program was gamified though a narrative about a space travel to different planets in discovering new games and get different mission badges and super team badges in their logbook.
16278993|NCT04823338|No Intervention|Wait-list group|Wait-list
16278994|NCT04823325||Surgery patients|Otherwise healthy patients with Skeletal Class III problem
16278995|NCT04823312|Experimental|Medtronic Duo Extended Set|These subjects will be using 4 Duo Extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
16278996|NCT04823299|Active Comparator|Cryoballoon ablation|Cryoballoon Pulmonary Vein Isolation-Wide area circumferential ablation (WACA)
16278997|NCT04823299|Experimental|RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation|Radiofrequency wide area circumferential ablation (WACA) ± electrophysiological testing guided ablation of non-pulmonary vein triggers of AF and low voltage area ablation
16278998|NCT04823286|Experimental|Virtual reality health platform during hemodialysis|During 12 weeks subjects will use a VR platform during hemodialysis. The intervention will be virtual reality exercise, nutritional advice and psychological wellbeing support plus cognitive training.
16278999|NCT04823286|No Intervention|Control group-usual care|During 12 weeks subjects will carry on with the usual care in the hemodialysis unit
16279000|NCT04823273|Experimental|General improvement|"Using the expertise of the study personnel, electronic-health record system architects working for UCHealth, and incorporating feedback from the users who participated in the user-centered design sessions we made changes to the blood transfusion order-set as well as the prepare and transfuse orders. The intention of the changes to the interface are to be more intuitive for ordering clinicians."
16279001|NCT04823273|Experimental|In-line help text|In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
16279002|NCT04823273|Experimental|Interruptive alert|In addition to general improvement changes, subjects exposed to the interruptive alert arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. In contrast to the in-line help text arm, this arm includes an interruptive alert that appears when the user selects the transfusion order. This alert offers users the option to remove the order which results in no-blood product ordered. Alternatively, users may continue to order blood and are asked to select the reason for proceeding with the intended order.
16279003|NCT04823260|Active Comparator|Arm A = 300 mg NMN supplement (n = 20)|Subjects who are assigned to 300 mg arm (NMN) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
16279004|NCT04823260|Placebo Comparator|Arm B = Placebo 300 mg (n=07)|Subjects who are assigned to 300 mg arm (placebo) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
16279005|NCT04823260|Active Comparator|Arm C = NMN Supplement 600 mg (n= 20)|Subjects who are assigned to 600 mg arm (NMN) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
16279006|NCT04823260|Placebo Comparator|Arm D = Placebo 600 mg (n=07)|Subjects who are assigned to 600 mg arm (Placebo) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
16279007|NCT04823260|Active Comparator|Arm E = NMN Supplement 900 mg (n=10)|Subjects who are assigned to 900 mg arm (NMN) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
16279008|NCT04823260|Placebo Comparator|Arm F = Placebo 900 mg (n=06)|Subjects who are assigned to 900 mg arm (Placebo) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
16279009|NCT04823247||Tildrakizumab|Patients diagnosed with moderate-to-severe plaque psoriasis who require systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor in real-world clinical practice, following the routine clinical practice on each patient country, will be observed for 24 months.
16279010|NCT04823221||Rezūm system|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
16279011|NCT04823208|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
16279012|NCT04823208|Placebo Comparator|Placebo|Placebo administered SC
16279013|NCT04823182||Cases|Cases - Recent COVID-19 infection ≥ 6 weeks and ≤ 12 months before enrolment, as evidenced by positive reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 swab
16279014|NCT04823169|Experimental|podobarometry|podobarometric measures at day7 and day 30
16279015|NCT04823156|Active Comparator|Adequate energy and adequate calcium|All dietary food and water will be provided for 19 days. The energy content of the diet will be prescribed, according to exercise levels, to elicit an energy availability of 45 kcal per kg of fat free mass per day. Foods high in calcium will be removed and participants will be provided with a calcium and vitamin D food supplement (two daily 500 mg calcium and 400 IU vitamin D3 supplements) (total calcium intake 1500 mg per day and 800 IU vitamin D3 per day).
16279050|NCT04822896|Experimental|Visual Motor Imagery|They will be asked to imagine the exercises visually from a third person perspective (as if they were watching from the mirror / from the mirror while doing it themselves).
16279017|NCT04823156|Active Comparator|Low energy and low calcium|All dietary food and water will be provided for 19 days. The energy content of the diet will be prescribed, according to exercise levels, to elicit an energy availability of 45 kcal per kg of fat free mass per day for the first 7 days and 15 kcal per kg of fat free mass per day thereafter. Foods high in calcium will be removed and participants will be provided with a vitamin D food supplement (two daily 400 IU vitamin D supplements) (total intake <500 mg calcium per day and 800 IU vitamin D3 per day).
16279018|NCT04823130|Experimental|Dupilumab|Double dose on Day 1 and followed by single dose every 2 weeks (Q2W).
16279019|NCT04823117||Music therapy group|Music therapy lasted 30 minutes every day for a total of 20 days.
16279020|NCT04823117||Control group|No treatment given.
16279021|NCT04823104|Experimental|Intervention group with home visitation|pregnant women who are included in this group will be assigned an intervention by home visitation for pregnancy follow-up
16279022|NCT04823104|No Intervention|control group without home visitation|pregnant women will be free to choose their pregnancy follow-up without home visitation
16279023|NCT04823091|Experimental|Fludarabine + Cyclophosphamide + anti-CD7 CAR-T Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (250 mg/kg) on day -5, -4, and -3, followed by the infusion of CAR7-T cells with the dose of 0.5×10^6/kg, 1×10^6/kg, 2×10^6/kg and 4×10^6/kg (with an allowance of ±20%) for 3 consecutive days. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
16279024|NCT04823078|Active Comparator|Activity base therapy|
16279025|NCT04823078|Other|Strength training|
16279026|NCT04823065|No Intervention|Control group|4FMFES injection is performed as usual, no supplemental medication is used.
16279027|NCT04823065|Experimental|Loperamide|Patients will receive 4 mg loperamide per os 15 minutes prior injection of the 4FMFES radiotracer dose. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
16279028|NCT04823065|Experimental|Hyoscine-N-butylbromide|In a similar fashion that what is used for some gastro-intestinal radiological examinations, repeated intravenous injection of 20 mg hyoscine-N-butylbromide will be applied at 0, 20 and 40 minutes following 4FMFES injection. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
16279029|NCT04823052|Placebo Comparator|Placebo|One capsule, once a day
16279030|NCT04823052|Active Comparator|Sulindac, dose strength 1|One capsule, once a day
16279031|NCT04823052|Active Comparator|Sulindac, dose strength 2|One capsule, once a day
16279032|NCT04823039|Other|Vaccination in patient with sepsis|
16279033|NCT04823026||Group 1|"70 young infants with proven bacterial infection.
~Interventions:
~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
16279034|NCT04823026||Group 2|"70 young infants with non-bacterial infection.
~Interventions:
~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
16279035|NCT04823026||Group 3|"30 young infants without infection.
~Interventions:
~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
16279036|NCT04823013|Experimental|high power pain threshold ultrasound which the dose was kept constant group (HPPT-US 1)|Participants in HPPT-US 1 group received one session of HPPT-US treatment which the dose was kept constant. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
16279037|NCT04823013|Experimental|high power pain threshold ultrasound which the dose reduced to one half group (HPPT-US 2)|Participants in HPPT-US 2 group received one session of HPPT-US treatment which the dose reduced to one half. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
16279038|NCT04823013|Experimental|ischemic compression group|Participants in IC group received one session of ischemic compression therapy. Ischemic compression is a therapy technique used in manual therapy, where blockage of blood in an area of the body is deliberately made, so that a resurgence of local blood flow will occur upon release.
16279039|NCT04823000|Experimental|Repeated MSCs treatment in MS patients|Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)
16279040|NCT04822974|Experimental|STUDY ARM|blood samples collection
16279041|NCT04822961|Experimental|Senaparib (IMP4297) 20 mg|During the treatment period, eligible patients will receive single agent of Senaparib at a dose of 100 mg once daily (QD), continuously on a 4-week cycle
16279042|NCT04822961|Placebo Comparator|Placebo|During the treatment period, eligible patients will receive placebo QD, continuously on a 4-week cycle
16279045|NCT04822922|Experimental|low dose|hUC-MSCs 4*10^5/kg/each time
16279046|NCT04822922|Experimental|middle dose|hUC-MSCs 8*10^5/kg/each time
16279047|NCT04822922|Experimental|high dose|hUC-MSCs 12*10^5/kg/each time
16279048|NCT04822909|Experimental|Apremilast group|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.
~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids."
16279049|NCT04822896|Experimental|Kinesthetic Motor Imagery|They will be asked to imagine the exercises kinesthetically from a first person perspective (as if they were doing it themselves).
16279052|NCT04822883|Experimental|Dose-escalation - RL-007|Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
16279053|NCT04822883|Placebo Comparator|Dose-escalation - matching Placebo|Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
16279054|NCT04822870|Experimental|quadratus lumborum block|Parturients receive ultrasound-guided quadratus lumborum block as post-operative analgesia.
16279055|NCT04822870|Experimental|iliohypogastric/ilioinguinal nerve block|Parturients receive ultrasound-guided iliohypogastric/ilioinguinal nerve block as post-operative analgesia.
16279056|NCT04822870|Active Comparator|epidural analgesia|Parturients receive epidural morphine via epidural catheter placed during anesthesia as post-operative analgesia.
16279057|NCT04822857||1|AMH > cut-off point
16279058|NCT04822857||2|AMH < cut-off point
16279059|NCT04822844|Experimental|Aromatherapy with Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
16279060|NCT04822831|Experimental|Long-term Ventilator-dependent Patients with intervention|45 Degree Semi-recumbent Position With Upper Limb Exercise Training on Long-term Ventilator-dependent Patients
16279061|NCT04822831|Experimental|Long-term Ventilator-dependent Patients without intervention|There is no intervention on Long-term Ventilator-dependent Patients ,and just keep routine treatment.
16279062|NCT04822818|Experimental|Bevacizumab + SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
16279063|NCT04822818|Active Comparator|SOC|SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
16279064|NCT04822805|Experimental|Treatment with Anlotinib|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
16279065|NCT04822792||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
16279066|NCT04822792||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
16279067|NCT04822792||Healthy Arm|Participants without known presence of malignancies or benign disease, from whom blood samples will be collected
16279068|NCT04822779|Active Comparator|Active Group|"This group will receive ultrasound therapy.
~Respondents will conduct individual medical-gymnastics: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
16279069|NCT04822779|Sham Comparator|Control Group|"This group will receive sham ultrasound therapy.
~Respondents will conduct the same individual medical-gymnastics, as in the active group: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
16279070|NCT04822766|Active Comparator|Chemotherapy|
16279071|NCT04822766|Experimental|Allogeneic Hematopoietic Cell Transplantation|Time of transplant procedure The best available treatments of AML
16279074|NCT04822740|Experimental|Novel strategy|"Inserting the CGMS device with use of the results of the device in real time by the health care team
~Insulin infusion according to the same local guidelines for insulin therapy in ACS
~Transmission of real-time data to the nurse and use of the alarms of the device
~Adaptation of insulin according to blood glucose measured by the CGMS device and according to the same protocol as the conventional arm
~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
16279075|NCT04822740|Active Comparator|Conventional strategy|"Inserting the CGMS device without the use of the results by the health care team: blinded CGMS (use of these results only at the end of the participation to analyze the main criterion)
~Insulin infusion according to the same local guidelines for insulin therapy in ACS
~Adaptation of insulin according to the capillary blood glucose levels performed every hourly if insulin dose change, every 2 hours if stable insulin dose according to local recommendations
~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
16279076|NCT04822714|Experimental|Mobile Career Competencies Intervention|The intervention protocol has five main components and is designed in English language. The first component consists of an educational session. The second component focuses on one's reflection on motivation and qualities. The third component assists users in working out strategies with others. The fourth component prompts users to reflect on and narrate their emerging career stories through goal-setting identification activities. The fifth component includes the government's human resource practices, training programs offered, and policies. The fourth and fifth component require users to reflect on their work exploration and career control career competencies.
16279077|NCT04822714|No Intervention|Waitlist control|Waitlist control group attended work and basic training from the organization as usual. They only receive the mobile intervention after the intervention group completing of the intervention.
16279078|NCT04822701|Placebo Comparator|Phase II, Arm 1: Placebo infusion with placebo inhalation|
16279079|NCT04822701|Experimental|Phase II, Arm 2: Low dose BI 767551 infusion with placebo inhalation|
16279080|NCT04822701|Experimental|Phase II, Arm 3: High dose BI 767551 infusion with placebo inhalation|
16279081|NCT04822701|Experimental|Phase II, Arm 4: Placebo infusion with BI 767551 inhalation|
16279082|NCT04822701|Experimental|Phase III, Arm 1: BI 767551 (medium or high dose infusion) or low dose inhalation|
16279083|NCT04822701|Placebo Comparator|Phase III, Arm 2: Placebo|
16279084|NCT04822688||Basic Science (Biospecimen collection)|Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
16286066|NCT04773678|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
16279087|NCT04822662|Experimental|Experimental Group: Epilepsy education program|The training prepared for epilepsy will be held in 3 main modules and 5 sessions with two weeks intervals. Each session will last 25 minutes. Trainings will be given to adolescents and their parents online.
16279088|NCT04822662|No Intervention|Control Group|The control group will receive standard epilepsy treatment without any training intervention. The group did not receive any other intervention.
16279089|NCT04822649|Other|Heart failure with preserved ejection fraction|Adenosine stress echocardiography, body composition, and cardiopulmonary exercise test will be done in all of the enrolled patients. Left ventricular end-diastolic pressure will be assessed during coronary angiography.
16279090|NCT04822636|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
16279091|NCT04822636|Active Comparator|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
16279092|NCT04822623||MS|
16279093|NCT04822623||NMOSD|
16279094|NCT04822623||Control|
16279098|NCT04822597|Active Comparator|Ice Pack|Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)
16279099|NCT04822597|Experimental|Lidocaine Patch|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection
16279100|NCT04822597|Experimental|Buzzy(R)|A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.
16279101|NCT04822597|Experimental|Lidocaine Patch and Buzzy(R)|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.
16279102|NCT04822584|Experimental|Phototherapy associated with active treatment|"Baricitinib 4 mg/day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.
~(Phototherapy will be started 12 weeks after the beginning of baricitinib)"
16279103|NCT04822584|Placebo Comparator|Phototherapy associated with placebo|"Placebo once a day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.
~(Phototherapy will be started 12 weeks after the beginning of placebo of baricitinib)."
16279104|NCT04822571|Other|Adolescent volunteers|Adolescent males aged 12-16 years old
16279105|NCT04822571|Other|Adult volunteers|Adult males aged 25-35 years old
16279106|NCT04822558|Other|Ankle and hindfoot reconstruction surgery|Patients who underwent an ankle- or hindfoot reconstruction surgery
16279107|NCT04822545|Other|Intervention Arm|"-Adult (≥ 18 years of age) hospitalized patients who have obesity (BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 if Asian/South Asian), as recorded in the medical chart, who have decision-making capacity and whose acute medical condition has been stabilized.
~we will exclude patients who are enrolling in hospice/comfort care and the patients who are already enrolled in the CWM clinic. Non-English speaking patients. Patients who have opted out of research in their Epic EHR will be excluded from consideration for participation."
16279108|NCT04822532|Experimental|Pharmacogenetic based-model (GSTA1)|
16279109|NCT04822532|Active Comparator|The most performing method based on age and weight - McCune's model|
16279110|NCT04822506|Experimental|Routine perioperative management and PEA|Routine perioperative management and perioperative electroacupuncture (preoperative, intraoperative, postoperative)；
16279111|NCT04822506|Active Comparator|Routine perioperative management and postEA|Routine perioperative management and postoperative electroacupuncture
16279112|NCT04822493|Experimental|Counseling Aid|"A. Complete the demographic questionnaire, the survey questions, and then complete the counseling aid. Receive standard counseling as part of routine prenatal care.
~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
16279113|NCT04822493|No Intervention|Standard Care|"A. Complete the demographic questionnaire and survey questions without watching the educational video. Receive standard counseling as part of routine prenatal care.
~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
16279114|NCT04822480||DPP Patients|UMMC Patients with prediabetes or risk for diabetes based on risk parameters referred to and enrolled in the DPP.
16279115|NCT04822480||Non-DPP Patients|Control matched UMMC patients with prediabetes or risk for diabetes based on risk parameters not enrolled in the DPP.
16279116|NCT04822467|Active Comparator|Standard Wipe|Participants will receive a supply of ethanol-based wipes for daily use
16279117|NCT04822467|Experimental|SQ53 Wipe|Participants will receive a supply of SQ53 wipes for daily use.
16279118|NCT04822454|Experimental|Night shift shadowing program|Medical students who participated in a night shift shadowing program prior to their first official night shifts
16279119|NCT04822454|No Intervention|No night shift shadowing program|Medical students who did not participate in the night shift shadowing program prior to their first official night shifts
16279120|NCT04822441||Patients who contracted dengue fever before 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy before 34 weeks outside the peri-partum period (more than 12 days before childbirth)
16279121|NCT04822441||Patients who contracted dengue fever after 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy after 34 weeks outside the peri-partum period (more than 12 days before childbirth)
16279122|NCT04822441||Patients who have contracted dengue during the peripartum period|Patients who have contracted dengue during the peripartum period or who have a suspicion of dengue (in the 12 days preceding childbirth)
16279123|NCT04822428|Experimental|study group(A)|Group (A): included Twenty patients who received osteopathic manipulative techniques, 1 session per week for 3 weeks.
16279124|NCT04822428|No Intervention|Control group(B)|Group (B): included twenty patients who received analgesic drugs only.
16279126|NCT04822415|Active Comparator|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
16279127|NCT04822389|Experimental|Home-based telerehabilitation exercise|Exercise training is conducted in the patient's home conditions using modern technology to transfer medical data remotely - the participants receive a heart rate monitor and sensor. To know what to do and how to exercise, the first (1-2) exercise training sessions will be controlled by the physiotherapist in a rehabilitation clinic in the hospital, who creates individual exercise training for each patient. The patient's training data will be downloaded and updated regularly via the internet platform and clinicians will evaluate these results and provide patients with telephone feedback.
16279128|NCT04822376|Experimental|High risk arm|Mabs at day 0 and vaccine at week 6
16279129|NCT04822376|Experimental|High risk arm (Immunological ancillary study)|Mabs at day 0 and vaccine at week 6
16279130|NCT04822376|Active Comparator|Control arm (Immunological ancillary study)|Vaccine at day 0 for contacts eligible for vaccination
16279131|NCT04822363|Experimental|Group A: Healthy|Low Dose Aspirin - 81mg daily for 7 days
16279132|NCT04822363|Experimental|Group B: Healthy|High Dose Aspirin - 325mg daily for 7 days
16279133|NCT04822363|Experimental|Group C: Healthy|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
16279134|NCT04822363|Experimental|Group D: Obese|Low Dose Aspirin - 81mg daily for 7 days
16279135|NCT04822363|Experimental|Group E: Obese|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
16279136|NCT04822350||Locally advanced or metastatic urothelial carcinoma patients treated with avelumab|
16279137|NCT04822337|Experimental|Phase I|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
16279138|NCT04822337|Experimental|Phase II|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
16279139|NCT04822324|Experimental|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion.
~shoulder flexion with elbow extension.
~circumduction with compression
~circumduction with distraction
~shoulder abduction and internal rotation with elbow flexion.
~shoulder adduction and external rotation with elbow flexion
~stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.
~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.
~conventional therapy Joint mobilization
~Exercise therapy:
~Self stretching and strengthening exercises"
16279140|NCT04822324|Active Comparator|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.
~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.
~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
16279141|NCT04822311|Experimental|Investigate the effects of an exercise intervention on retired APF players|20 retired APF players (≥ 18 years of age), who suffer from chronic pain, will be enrolled.
16279142|NCT04822298|Experimental|Part 1: Dose Exploration|The dose exploration part of the study will estimate the MTD and/or the RP2D.
16279143|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.
16279144|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 2 Squamous NSCLC|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.
16279145|NCT04822285|Experimental|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
16279146|NCT04822285|Active Comparator|Routine Psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
16279147|NCT04822272|Experimental|Thermometry MRI|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
16279148|NCT04822259|Experimental|JOURNEY II BCS TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
16279149|NCT04822259|Experimental|JOURNEY II CR TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
16279150|NCT04822246|Other|Control: Hand instrumentation for caries excavation|Hand instrumentation for caries excavation
16279151|NCT04822246|Experimental|Intervention 1: EMS Airflow device for caries excavation|Powder/water jet prophylaxis device (EMS Airflow) for caries excavation
16279152|NCT04822246|Experimental|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|Hand excavation and Powder/ jet prophylaxis device (EMS Airflow) for caries excavation
16279153|NCT04822233|Experimental|Hall Technique (HT)|
16279154|NCT04822233|Experimental|Modified Hall Technique (MHT)|
16279155|NCT04822233|Active Comparator|Conventional Technique (CT)|
16279156|NCT04822220|Experimental|Experimental|Fatigue Self-management Programme
16279157|NCT04822220|No Intervention|Controlled|The control group received routine treatment and nursing care
16279158|NCT04822207|Experimental|Acupuncture group|In the acupuncture group, those patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
16279159|NCT04822207|No Intervention|Control group|In the control group, these patients do not receive any treatments during embryo transfer cycle. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
16279185|NCT04821999|Experimental|group I|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
16279160|NCT04822194|Experimental|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
16279161|NCT04822194|Active Comparator|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
16279164|NCT04822168|Active Comparator|Standard Care|Standard Care through detox-based opioid treatment with B/N and weekly urine toxicology screening
16279165|NCT04822168|Experimental|MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure medication storage device, and a standardized protocol for supervising self-administration of medication via videoconferencing.
16279166|NCT04822155||Children|Children between 11-17 years of age will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect their physical, emotional, or mental well-being (BRIEF-II and CBCL questionnaires). The child will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality.
16279167|NCT04822155||Adults|Adults, 18 years and older will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect your physical, emotional, or mental well-being (BRIEF-A and ABCL questionnaires). The adult will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality. Additionally, the adult will need to take their blood pressure 3 times per day for 14 days and record measurements.
16279168|NCT04822129|Active Comparator|Treatment as usual|Intervention for TAU group: Actual participation in the intervention will begin with the first videoconference. The general format for each conference will be a brief presentation (10-15 minutes) by Dr. Ownby on a specific topic related to brain health, with the remainder of the time spent in discussion of the topic's importance and in answering participants' questions about the topic or about any other concerns they have related to developing a brain healthy lifestyle. The first videoconference will also provide participants with an overview of the daily log form, instructions for completing it and entering results every week in RedCap, and a reminder on the process of compensation for completion of the logs.
16279169|NCT04822129|Experimental|Cogtrastim model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model. Early videoconference sessions will also focus on strategies for behavior change, including realistic goal setting, problem solving about possible difficulties, and assistance in formulating a written plan to improve brain health. Participants will be encouraged to develop a written program for brain health and to also develop self-monitoring habits.
16279170|NCT04822116|No Intervention|standard of care|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol."
16279171|NCT04822116|Active Comparator|goal directed intraoperative haemodynamic optimization|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol. Additional application of a non-invasive haemodynamic optimization protocol in the post anaesthesia care unit."
16279172|NCT04822090||Group I|HHA patients with acute symptomatic HPV-B19 infection
16279173|NCT04822090||Group II|HHA patients without acute symptomatic HPV-B19 infection
16279174|NCT04822077|Experimental|Proton radiotherapy|"Proton radiotherapy with RBE doses:
~Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).
~Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)
~Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
16279175|NCT04822064|Experimental|intranasal dexmedetomdine and kemtaine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
16279176|NCT04822064|Active Comparator|oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
16279177|NCT04822051|Experimental|Psychoeducation Group|"Uncertainty Management Psychoeducation Program was given."
16279178|NCT04822051|No Intervention|Control Group|No attempt was made by the researcher during the study. Only data collection was carried out.
16279179|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and dietary recommendations|Patients with scleroderma and hypovitaminosis D who receive dietary recommendations
16279180|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and Vitamin D supplementation|Patients with scleroderma and hypovitaminosis D who receive Vitamin D supplementation
16279181|NCT04822025|Experimental|High Dose|High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16279182|NCT04822025|Experimental|Mid Dose|Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16279183|NCT04822012||Female|Female patients going through an egg retrival procedure and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
16279184|NCT04822012||Male|male patients going through an in vitro fertilization cycle and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
16279186|NCT04821999|No Intervention|group II|No treatment
16279189|NCT04821960|Active Comparator|Conventional Mindfulness Program|Routine mindfulness lessons and activities.
16279190|NCT04821960|Experimental|Tailored Mindfulness Program for Fear of Memory Loss|Tailored mindfulness lessons and activities for fear of memory loss.
16279191|NCT04821947|Active Comparator|RIB Group|Drug: Bupivacaine 0.25% patients will receive 20 ml of bupivacaine 0.25% in the rhomboid plane under rhomboid major muscle
16279192|NCT04821947|Active Comparator|LA Group|Drug: Bupivacaine 0.25% patients will receive wound infiltration of VATS incision, single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine .
16279193|NCT04821934|Experimental|Telerehabilitation (TR) at home + Telesurveillance program (TSu)|These COVID-19 patients will enter the usual telesurveillance program together with a specific remote rehabilitation program on exercise activity.
16279194|NCT04821934|Active Comparator|Telesurveillance (TSu) alone|These COVID-19 patients will enter the usual remote telesurveillance program
16279195|NCT04821921||Patients with diabetes mellitus|Approximately 750 patients with diabetes mellitus from 3 GP practices specialized on diabetes treatment
16279196|NCT04821908||Group 1|population included in the VIRASTHMA COVID G4 study
16279197|NCT04821908||Group 2|"population included in the previous studies VIRASTHMA, CHAMPIASTHMA (IRDCB No.: 2019-A03310-57), COBRAPED (NCT02114034), VIRASTHMA 2 (IRDCB No.: 2014 A01687 40, NCT: 03960359), INCOVPED (pediatric emergencies, NCT04336761)."
16279198|NCT04821882|No Intervention|Control|Healthy participant
16279199|NCT04821882|Experimental|Dextrose treatment|IC/PBS patients had been treated by intravesical instillations of hyaluronic acid and/or botox for more than 6 months
16279200|NCT04821856|Experimental|Cannabidiol 100mg/ml|"The starting dose of cannabidiol (CBD) will be 5 mg/kg/day and will be administered orally twice daily in doses of 2.5 mg/kg (up titration phase from day 1 to 7). After one week, the dose of CBD will be increased to 10 mg/kg/day in two daily doses of 5mg/kg (8-week maintenance phase from day 8 to 63). On completion of the maintenance phase the dose of CBD will be decreased to 5mg/kg/day for one week (day 64 to 70), after which the CBD administration will cease.
~A ceiling dose of 1000mg/day will be administered to all participants weighing 100kg or greater. These participants will receive a dose of 500mg/day during up- and down-titration.
~Doses will be rounded to the nearest 10mg (0.1mL)."
16279201|NCT04821856|Placebo Comparator|Placebo|"The control group will receive placebo medium-chain triglyceride (MCT) oil which is indistinguishable from the active medication in appearance, smell and taste.
~Dose will be matched for volume to the cannabidiol arm, and administered twice daily for 10 weeks (including up- and down-titration)."
16279202|NCT04821843|Experimental|(Neoadjuvant chemotherapy) nCT|This arm received chemotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
16279203|NCT04821843|Placebo Comparator|(Neoadjuvant Chemoradiation) nCRT|This arm received chemoradiotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
16279204|NCT04821830||Parkinson's disease patients who take levo-dopa as standard of care|Participants will undergo evaluation of the relationship between the LDR and movement vigor. All participants will undergo standard evaluation with standard clinical rating scales and three outcome measures: Tapping Speed Task - Measurement of Bradykinesia; Grip Strength Task - Measurement of Incentive-Outcome Coupling - Movement Vigor; Joystick Movement Task - Measurement of Incentive-Outcome Coupling - Movement Vigor. Some participants may opt in to an additional training and evaluation: Value Driven Attentional Oculomotor Capture.
16279205|NCT04821817|Placebo Comparator|Group C (Control group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
16279206|NCT04821817|Experimental|Group R (rocuronium group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
16279207|NCT04821804|Experimental|Experimental|local application of HYADENT BG on both donor and recipient sites
16279208|NCT04821804|Placebo Comparator|control|application of normal saline on both donor and recipient sites
16279209|NCT04821778|Placebo Comparator|Definitive Chemoradiation|This arm received chemoradiation without immunotherapy/targeting agents as definitive treatment.
16279210|NCT04821778|Experimental|Chemoradiation Combined With Immunotherapy/targeting agents|This arm received chemoradiation with immunotherapy/targeting agents as definitive treatment.
16279211|NCT04821765|Experimental|Chemoradiotherapy Combined With PD-1 Antibody|The arm received chemoradiotherapy, 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week) to recurrent sites combined with chemotherapy（Cisplatin 75 mg/m2/day 1, and albumin paclitaxel 150 mg/m2/day 1 , every 3 weeks, 2 cycles ).PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg，d1，every 3 weeks，2 cycles). After completion of chemoradiotherapy, PD-1 antibody was given continuously with 2-4 cycles of chemotherapy (the same regimen with concurrent chemotherapy) until 1 year or desease progression.
16279212|NCT04821752|Experimental|Toxicant avoidance and glucose dysregulation|To investigate whether or not the excretion of urinary toxicant metabolites is reduced by dietary modification and lifestyle intervention in people with glucose dysregulation; whether the participant's ranked glucose dysregulation correlates with the amount and/or type of toxic metabolites excreted at baseline; and whether the body's immediate response to glucose is improved by the reduction of toxicant burden.
16279213|NCT04821739|Experimental|Treatment with AGN1 LOEP SV Kit|VCF is treated with the AGN1 LOEP SV Kit
16279214|NCT04821726|Experimental|Drug eluting balloon (Vmoky)|A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.
16279215|NCT04821700||Patients with Carotid stenosis|Ischemic stroke patients with atrial fibrillation and carotid stenosis
16279216|NCT04821700||Patients without Carotid stenosis|Ischemic stroke patients with atrial fibrillation without carotid stenosis
16279217|NCT04821687|Experimental|Opicapone 50mg|
16279218|NCT04821687|Active Comparator|Levodopa 100mg|
16279219|NCT04821674|Experimental|Cohort A1: DS-5670a 10 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
16279220|NCT04821674|Experimental|Cohort A2: DS-5670a 30 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
16279221|NCT04821674|Experimental|Cohort A3: DS-5670a 60 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
16279222|NCT04821674|Experimental|Cohort A4: DS-5670a 100 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
16279223|NCT04821674|Placebo Comparator|Cohort A: Placebo|Healthy adults participants will be randomized to receive a intramuscular injection of placebo.
16279224|NCT04821674|Experimental|Cohort B1: DS-5670a 10 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
16279225|NCT04821674|Experimental|Cohort B2: DS-5670a 30 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
16279226|NCT04821674|Experimental|Cohort B3: DS-5670a 60 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
16279227|NCT04821674|Experimental|Cohort B4: DS-5670a 100 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
16279228|NCT04821674|Placebo Comparator|Cohort B: Placebo|Healthy elderly participants will be randomized to receive a intramuscular injection of placebo.
16279229|NCT04821648|Experimental|Dosage group A|"Dosage group A will consist of 6 subjects, 1:1:1 (A1:A2:A3 below):
~A1: 0.04 mg/injection; A2: 0.075 mg/injection; A3: 0.15 mg/injection Two subjects will be dosed in the area scheduled for resection with 5 injections of the lowest of the 3 RJV001 test article strengths (i.e., 0.04 mg/injection); the two subjects will also be dosed with a single injection of vehicle in the area scheduled for resection for a total of 6 injections. At the conclusion of a given test article dose group, if tolerated, enrollment will continue to the next higher dose after approval to advance based upon an interim safety review. This same process will be repeated for the 0.075 mg/injection dose with 2 additional subjects. Assuming the interim safety review for the mid dose (i.e., 0.075 mg/injection) is deemed acceptable, the 2 final subjects will be treated with the high dose (0.15 mg/injection)."
16279230|NCT04821648|Experimental|Dosage group B|"Dosage group B will consist of 3 subjects (if only 1 dose from Dosage group A is well tolerated) or 6 subjects (if 2 doses from Dosage group A are well tolerated), randomized 1:1 (B1:B2 below).
~B1: RJV001 Solution for Injection, Dose 1 B2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Dosage group A, referred to as Dose 1 and Dose 2). Up to 13 injections (12 active and 1 vehicle) will be administered in an open label manner in the area scheduled for resection. If tolerated, enrollment will continue to Dosage group C after approval to advance based upon an interim safety review."
16279231|NCT04821648|Experimental|Dosage group C|"Dosage group C will consist of 3 subjects (if only 1 dose from dosage group B is well tolerated) or 6 subjects (if 2 doses from Dosage group B are well tolerated), randomized 1:1 (C1:C2 below).
~C1: RJV001 Solution for Injection, Dose 1
~C2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Cohort B, referred to as Dose 1 and Dose 2). Up to 31 injections (30 active and 1 vehicle) will be administered in an open-label manner in the area scheduled for resection."
16279232|NCT04821635|Experimental|Rower|Single group of 35 traumatic paraplegic patients meeting the inclusion criteria will benefit from the FES-ROW protocol during 9 months
16279233|NCT04821622|Experimental|Arm 1|Talazoparib plus enzalutamide
16279234|NCT04821622|Active Comparator|Arm 2|Placebo plus enzalutamide
16279235|NCT04821609|Experimental|Resistance training group|Twice a week sessions supervised and group, during 12 weeks
16279236|NCT04821609|No Intervention|Control Group|The control group will follow the usual physical therapy management, which does not include resistance training
16279237|NCT04821596|Experimental|Multiple Sclerosis Patients|Multiple Sclerosis Patients usually followed by Dr. Bourre as part of his consultation at the Rouen University Hospital will be offered the opportunity to participate in this study if they meet the selection criteria.
16279238|NCT04821583|Experimental|Hydrocortisone|Hydrocortisone (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The hydrocortisone periods last 10 weeks per period. In total, there are two hydrocortisone periods.
16279239|NCT04821583|Placebo Comparator|Placebo|Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.
16279240|NCT04821570||Chemotherapy (IV and oral)|
16279241|NCT04821570||Immunotherapy|
16279242|NCT04821570||Chemotherapy + Immunotherapy|
16279243|NCT04821570||Cyclin- dependent kinase (CDK) 4/6 inhibitors|
16279244|NCT04821570||Stem Cell Transplant recipients|
16279245|NCT04821557|Experimental|Microbial Protease Supplement|A microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) is taken with a 25g pea protein beverage. The test article will be provided in 250mg capsule form. Capsules will be opened and mixed into protein shake 5 minutes before ingestion.
16279246|NCT04821557|Placebo Comparator|Placebo (Maltodextrin)|The placebo (maltodextrin) article will be provided in 250mg capsule form. Capsules will be opened and mixed into 25g pea protein shake 5 minutes before ingestion.
16279247|NCT04821544|No Intervention|Control|Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period.
16279248|NCT04821544|Experimental|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
16279287|NCT04821258|Experimental|MICODIGEST 2.0 supplement|Treatment with MICODIGEST 2.0 will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20mL/day (10mL before breakfast and 10 mL before dinner) for 4-6 weeks.
16279251|NCT04821518||The study group (post-stroke)|The study group consisted of 26 patients in whom ischaemic brain stroke occurred within 14 days before the admission to the Clinical Department, and were hospitalised at the Department of Neurological Rehabilitation of the Clinical Department of Rehabilitation in the Wiktor Dega Orthopaedic and Rehabilitation Clinical Hospital in Poznań
16279252|NCT04821518||The control group|The control group was composed of 26 healthy individuals recruited from the hospital staff who did not experience stroke.
16279253|NCT04821505|Experimental|Meditation|The Transcendental Meditation program is described as a simple natural technique practiced for 20 minutes twice daily for deep rest and relaxation. Previous studies have shown its feasibility, validity, and reliability in Blacks at risk for CVD.
16279254|NCT04821505|Active Comparator|Health Education|Health education program matched to the experimental intervention for time, attention, and other non-specific factors.
16279255|NCT04821492||Hyperhomocysteinemia|
16279256|NCT04821492||Normal Hcy levels|
16279257|NCT04821479|Experimental|Repeated MSCs treatment in ALS patients|Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline.
16279258|NCT04821466|Experimental|Virtual Reality Headset|VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing
16279259|NCT04821453|Placebo Comparator|Conventional Flow Triggered Mechanical Ventilation (CMV)|Subjects will be ventilated with conventional mechanical ventilation with data collected for the 5 day time frame to compare to the experimental arm
16279260|NCT04821453|Experimental|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be ventilated on neurally adjusted ventilatory assist (NAVA) mode with data collected for the 5 day time frame to compare with placebo arm
16279261|NCT04821440|Active Comparator|Lower Limb Lymphedema|Patients suffering from unilateral lower-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
16279262|NCT04821440|Active Comparator|Upper Limb Lymphedema|Patients suffering from unilateral upper-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
16279263|NCT04821427|Experimental|Brief mHealth Intervention + mobile messaging|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages
16279264|NCT04821427|No Intervention|Assessment Only|This is an assessment only condition. No intervention following completion of baseline surveys will be administered.
16279265|NCT04821414||trial group|anakinra canakinumab
16279266|NCT04821414||control group|conventional treatment
16279267|NCT04821401|Experimental|Males study product|25 men will be randomized to Rejuvant
16279268|NCT04821401|Placebo Comparator|Males placebo|25 man will be randomized to placebo
16279269|NCT04821401|Experimental|Females study product|25 women will be randomized to Rejuvant
16279270|NCT04821401|Placebo Comparator|Females placebo|25 women will be randomized to placebo
16279271|NCT04821388|Experimental|intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries.|
16279274|NCT04821362|No Intervention|Standard technique group|In this group, peripheral intravenous catheter insertion will be performed routinely.
16279275|NCT04821362|Active Comparator|Ultrasound group|In this group, peripheral intravenous catheter insertion will be performed with ultrasound. A linear probe will be used for procedures.
16279276|NCT04821362|Active Comparator|Near Infrared Device Group|In this group, peripheral intravenous catheter insertion will be performed with AccuVein AV 400.
16279277|NCT04821349|Other|Single arm study|Standard reading Group vs AI-assisted reading Group
16279278|NCT04821336||Thyroid tissue samples|from 30 patients, tissue samples , frozen and embedded paraffin have been collected and preserved for research. For this study, tumoral tissue and healthy tissue will be used;
16279279|NCT04821323|Experimental|Indomethacin Challenge|Participants will receive challenge agent as two single oral doses of Indomethacin, one on Day -1 and one on Day 1. In addition, participants will receive lactulose-mannitol solution on Day -4 (baseline) and on Day 1 (post Indomethacin challenge).
16279282|NCT04821297|Experimental|Supportive care (message)|Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy.
16279283|NCT04821284|Experimental|Arm I (sonazoid, ultrasound, chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients also receive sonazoid IV over 20 minutes and undergo CEUS.
16279284|NCT04821284|Active Comparator|Arm II (chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity.
16279285|NCT04821271|Experimental|1|Individuals in Arm 1 will receive daily double-blinded TS-161 for three weeks during Test Session 1 and daily double-blinded placebo for three weeks during Test Session 2.
16279286|NCT04821271|Experimental|2|Individuals in Arm 2 will receive daily double-blinded placebo for three weeks during Test Session 1 and daily double-blinded TS-161 for three weeks during Test Session 2.
16279321|NCT04821076|Active Comparator|Energy balance + exercise|
16279288|NCT04821258|Placebo Comparator|Placebo|Treatment with placebo will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20 mL/day (before breakfast and before dinner) for 4-6 weeks.
16279289|NCT04821232|Experimental|interventional|"Students in the intervention group will be given a total of 120 minutes out of 40 minutes, and 24 sessions of yoga for 8 weeks, 3 days a week. The researcher who will make yoga with each student will be sent videos on the online platform, including a yoga introduction and a full yoga session with the students after a yoga session. The students were asked to do yoga 3 times a week in accordance with the video and the researcher will be called twice a week to get information about the process. Content of education;
~Breath Awareness Training (10 minutes)
~Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose
~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
16279290|NCT04821232|Other|Control groups|No intervention will be applied to students in the control group.
16279291|NCT04821219|Experimental|Tumoroid generation|Single arm, including all the patients enrolled to generate tumor models
16279292|NCT04821206||Cases|Patients with diagnosis of RA, PsA and SpA
16279293|NCT04821206||Controls|Patients with diagnosis of RA, PsA and SpA
16279294|NCT04821193|Experimental|Experimental Group 1|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 5% NaHCO3 water solution group Grup number: 20
16279295|NCT04821193|Experimental|Experimental Group 2|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 2% Chlorhexidine Gluconate solution group Grup number: 21
16279296|NCT04821193|No Intervention|Control Group|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 70% Alcohol solution group Grup number: 21
16279297|NCT04821180||patients treated by angle stable plate PHILOS|
16279298|NCT04821180||patients treated by reverse total shoulder arthroplasty SMR|
16279299|NCT04821167|Other|Laparoscopic orchiopexy for intra-canalicular (emergent or peeping) testis|This is a prospective study conducted on male children with intermittent palpable (peeping) UDT to evaluate the safety and efficiency of laparoscopic orchiopexy of intra-canalicular (emergent or peeping) testis.
16279300|NCT04821154||1) Revision Splined CCK|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, constrained condylar knee (CCK) articular surface, Persona Revision femoral component, and splined femoral stem.
16279301|NCT04821154||2) Revision Cemented CCK|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
16279302|NCT04821154||3) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, posterior stabilized/constrained posterior stabilized (PS/CPS) articular surface, Persona Revision femoral component, and splined femoral stem.
16279303|NCT04821154||4) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
16279304|NCT04821154||5) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
16279305|NCT04821154||6) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
16279306|NCT04821154||7) Revision Cemented CCK with 5 Degree Primary Tibia|Patients who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
16279307|NCT04821154||8) Primary Splined CCK/CPS/PS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and splined femoral stem.
16279308|NCT04821154||9) Primary Cemented CCK/PS/CPS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
16279309|NCT04821154||10) Primary Cemented CCK/PS/CPS with 5 Degree Primary Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
16279312|NCT04821128||Patients who improved surgical treatment for oral cavity cancer|T1 T2 and T3 OSCC tumor, patients who have a recent evaluation cervico thoracic scanner in their medical files.
16279313|NCT04821115|Experimental|Low intensity choc waves therapy (Experimental group)|The patients will use the device with a real applicator.
16279314|NCT04821115|Sham Comparator|Sham group|The patients will use the device with a sham applicator. Instead of a focusing lens, the applicator will have an internal foam piece that will dissipate the energy of the shockwave. Hence, the sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted
16279315|NCT04821102|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
16279316|NCT04821102|Placebo Comparator|Saline|saline
16279317|NCT04821089|Experimental|IPN10200 group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
16279318|NCT04821089|Placebo Comparator|Placebo group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
16279319|NCT04821076|Active Comparator|Energy balance|
16279320|NCT04821076|Experimental|Energy restriction|
16279323|NCT04821063|Experimental|Therapeutic dose: ITF2357 100 mg|Participants will receive a single dose of ITF2357 100 mg administered as 10 milliliters (mL) of ITF2357 10 milligrams per milliliter (mg/mL) oral suspension and 20 mL of placebo matched to ITF2357 oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
16279324|NCT04821063|Experimental|Supratherapeutic dose: ITF2357 300 mg|Participants will receive a single dose of ITF2357 300 mg administered as 30 mL of ITF2357 10 mg/mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
16279325|NCT04821063|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matched to ITF2357 administered as 30 mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
16279326|NCT04821063|Active Comparator|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg tablet under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
16279327|NCT04821050|Experimental|Treatment|Sacral nerve stimulation
16279328|NCT04821050|Sham Comparator|Control|Sham stimulation
16279329|NCT04821037|Experimental|ACT|"A digitally-based ACT program will be conducted in two half-day workshops via meeting software (e.g. Zoom) consisting of:
~mindfulness exercises, for stress reduction and to guide nurses to observe their painful thoughts and feelings that they are attempting to avoid;
~ACT-metaphors, to let nurses realize the cost of struggling with psychological distress often create more distress;
~experiential exercises, to guide nurses to notice their own experiences in providing nursing care throughout their nursing career and explore any special qualities;
~explore the nurses' values with respect to different areas in their lives."
16279330|NCT04821024||mild-moderate disability|Those whose neck disability index value is 5-34
16279331|NCT04821024||high disability|Those whose neck disability index value is 35 and above
16279332|NCT04821011||Newborn birth between 28 and 40 Weeks of Gestational Age (wGA)|"Newborn birth between 28 and 40 Weeks of Gestational Age (wGA) will be included. The mother's newborn will be have a record of her heartbeats.
~The newborn will be have an acoustic listening of their mother's heartbeat and a record of their own heartbeats."
16279333|NCT04820985||Women undergoing IVF|
16279334|NCT04820972|Experimental|E-STAR group|
16279335|NCT04820972|No Intervention|traditional group|
16279336|NCT04820946||various episodic mood disturbances patient group|A group of patients with various episodic mood disturbances was used as a clinical case control group.
16279337|NCT04820946||Disruptive Mood Dysregulation Disorder (DMDD) patient group|DMDD patients referred to the hospital for suicidal behaviors between 2013 and 2018 in terms of diagnostic stability, psychiatric comorbidity, and psychosocial factors.
16279338|NCT04820933|Experimental|Doravirine plus emtricitabine and tenofovir alafenamide fumarate|PIFELTRO (doravirine) 100 mg tablet one daily for 3 months Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate) tablet one daily for 3 months
16279339|NCT04820920|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of 8-10 (mother-child pairs) participants per group in online group sessions (45-60 minutes per session) and will deliver one session every fortnight for 12 sessions.
16279340|NCT04820920|Placebo Comparator|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions. The placebo-effect sessions would last approximately 45-60 minutes per session for 12 sessions (8-10 participants per group). One session would be delivered every fortnight for 12 sessions.
16279341|NCT04820907|Experimental|HCP1904-1|
16279342|NCT04820907|Active Comparator|RLD2001-1|
16279343|NCT04820894||Observational (survey, medical records review)|Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.
16279344|NCT04820881||Case Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
16279345|NCT04820881||Control Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
16279346|NCT04820868||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
16279347|NCT04820868||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
16279348|NCT04820855|Experimental|Treatment|This is an individual treatment program devised by a pelvic floor physical therapist including a daily yoga series and mindfulness via a Smartphone app.
16279349|NCT04820855|Active Comparator|Control|These are participants undergoing regular treatment for interstitial cystitis with their providers
16279350|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 1|TAK-994 dose 1, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
16279351|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 2|TAK-994 dose 2, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
16279352|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 3|TAK-994 dose 3, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
16279353|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 1|Following the Active Drug Extension Period, participants randomized to active treatment Dose 1 will continue to receive same dose (TAK-994, dose 1, tablets, orally) from Day 57 to Day 84.
16279354|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 2|Following the Active Drug Extension Period, participants randomized to active treatment Dose 2 will continue to receive same dose (TAK-994, dose 2, tablets, orally) from Day 57 to Day 84.
16279355|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 3|Following the Active Drug Extension Period, participants randomized to active treatment Dose 3 will continue to receive same dose (TAK-994, dose 3, tablets, orally) from Day 57 to Day 84.
16279356|NCT04820842|Placebo Comparator|Double-blind Randomized Withdrawal Period: Placebo|Following the Active Drug Extension Period participants will receive placebo-matching tablets for 4 weeks (from Day 57 to Day 84).
16279357|NCT04820829|Active Comparator|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
16279358|NCT04820829|Active Comparator|Moderate RM, moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
16279359|NCT04820829|Active Comparator|Low RM, high NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
16279360|NCT04820816||Posterior pelvic tilt group|"patients with chronic low back pain or repeated non-specific back pain for more than three months.
~Both sex with posterior pelvic tilt (-0.7 ± 6.5°) and decreased lumbar lordosis
~Their ages were ranged from 20-35 years
~Body Mass Index from 18-25 Kg/m²"
16279361|NCT04820816||Normal anterior pelvic tilt group|"patients with chronic low back pain or repeated non-specific back pain for more than three months.
~Both sex with anterior pelvic tilt (5° and 13°) and normal lumbar lordosis
~Their ages were ranged from 20-35 years
~Body Mass Index from 18-25 Kg/m²"
16279362|NCT04820803|Experimental|Cetylpyridinium Chloride (CPC) 0,07%|patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds
16279363|NCT04820803|Placebo Comparator|Placebo: Distilled water with the same flavor and coloring as the product to be evaluated|patients who rinse with distilled water mouthwash for 60 seconds
16279364|NCT04820790|Experimental|Experimental Group 1|The efficiency of the mobile app in the follow-up of patients with home oxygen will be evaluated during 6 months
16279365|NCT04820790|No Intervention|Intervention Group 2:|Regular monitoring of the home oxygen without mobile app during 6 months
16279366|NCT04820777|Experimental|perturbation based training|External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
16279367|NCT04820777|Active Comparator|Conventional' balance training|"Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor.
~Rehash with your correct leg, exchanging to and fro between legs for a sum of 20 repitions (10 on every leg).
~Situated Marching Starting with a situated position, lift your effected leg towards your chest, making an honest effort to keep up controlled development."
16279368|NCT04820764|Experimental|CardioMech Mitral Valve Repair System (MVRS)|
16279369|NCT04820751|Experimental|Cyproheptadine and standard care|"Start Cyproheptadine 8mg three times a day during 5 days. Dose will be reduced to 4mg three times a day if GFR inferior to 30ml/min/1.73m²
~Standard management of COVID-19 infection according to current international guidelines"
16279370|NCT04820751|No Intervention|Standard care|Standard management of COVID-19 infection according to current international guidelines
16279371|NCT04820738|Experimental|Experimental group|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking).
16279372|NCT04820738|Active Comparator|Control group|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
16279373|NCT04820725|Experimental|Study group|Patients whose BASMI score is 2 will be included in the study
16279374|NCT04820725|Experimental|Control group|Patients whose BASMI score is 0 and 1 will be included in the study
16279375|NCT04820699|Experimental|post isometric relaxation|Group A received Post isometric relaxation technique (MET).The participants performed isometric contractions using 20% of their strength, 5 second holds with 5 seconds rest time in between each contraction
16279376|NCT04820699|Experimental|mulligan bent leg raise|Group B: Mulligan bent leg raise technique. Isometric contraction of hamstring muscle for progressively five greater position of hip flexion; three pain-free repetitions with 5 second hold was performed by participants
16279377|NCT04820686|Experimental|VBR + AB-729 + SOC NrtI|Participants with cHBV will receive VBR + AB-729 + SOC NrtI for 48 weeks followed by SOC NrtI alone for an additional 48 weeks.
16279378|NCT04820686|Other|VBR + SOC NrtI|Participants with cHBV will receive VBR + SOC NrtI for 48 weeks followed by SOC NrtI alone for an additional 48 weeks. This treatment will be used as a reference regimen.
16279379|NCT04820686|Other|AB-729 + SOC NrtI|Participants with cHBV will receive AB-729 + SOC NrtI for 48 weeks followed by SOC NrtI alone for an additional 48 weeks. This treatment will be used as a reference regimen.
16279380|NCT04820673||Sarecycline|Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.
16279381|NCT04820660|Experimental|Task oriented Strength training group|Standing and reaching in different directions Sit-to-stand Stepping forward and backward Stepping sideways onto blocks
16279382|NCT04820660|Experimental|Balance Training|Stepping forward, backward, and sideways on the exercise step; Stepping over blocks of various heights; Standing up from a chair, From a sitting position on a 65-cm Swiss ball, Arms; bending the trunk forward and side to side); Performing double-legged stance Performing tandem stance Rising from a chair without the use of the arms; Walking forward and backward with a tandem walking pattern Performing single- legged stance
16279385|NCT04820634|Experimental|VR-JIT|In this arm, participants would participate in simulated interviews utilizing a software program and virtual interviewer, once a week for 90 minutes.
16279386|NCT04820634|Placebo Comparator|Wonderworks|In this arm, participants would participate in a similar intervention, also once a week for 90 minutes. However, in this arm, the intervention would be in a virtual office environment completing office tasks.
16279387|NCT04820621|Experimental|Participants with mild hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
16279388|NCT04820621|Experimental|Participants with moderate hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
16279389|NCT04820621|Experimental|Participants with normal hepatic function|All participants will receive a single oral dose in the fasted state on Day 1.
16286067|NCT04773678|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
16279390|NCT04820608|Experimental|Customized, transepithelial cross-linking|All study patients will be treated according to the customized remodeled vision protocol
16279391|NCT04820595||Control group|Patients who have RASS < +2 and have not delirium according CAM-ICU immediately upon emergence from anesthesia
16279392|NCT04820595||Agitated non-delirious group|Patients who have RASS = +2 or more and have not delirium according CAM-ICU immediately upon emergence from anesthesia
16279393|NCT04820595||Agitated delirium group|Patients who have RASS = +2 or more and have delirium according CAM-ICU immediately upon emergence from anesthesia
16279394|NCT04820582||Delphi Panel|A group of international experts comprising patients experts, gynecologists, radiologist, psychologists, nurses and researchers, were identified based on their expertise in the field or due to your active role in an endometriosis patient association that have accepted to participate to this study.
16279395|NCT04820556||Arterial hypertension|
16279396|NCT04820556||Atherosclerosis occlusive disease|
16279397|NCT04820556||Heart failure with preserved ejection fraction|
16279398|NCT04820556||Heart failure with reduced ejection fraction|
16279399|NCT04820556||Diabetes mellitus, type 2|
16279400|NCT04820556||Chronic obstructive pulmonary disease and asthma|
16279401|NCT04820556||Nonalcoholic fatty liver disease|
16279402|NCT04820556||Control group|
16279403|NCT04820543|Experimental|Simplified Method|In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered. The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
16279404|NCT04820543|Experimental|Individualized Method|In this method, the patients were administered BTX-A after 8 months when the effect of the previous injection vanished. And A dosage and injection sites were individualized according to the degree of severity of anterior GE presented pretreatment. For mild GS (3 to< 5mm), 2 U BTX-A was injected at bilateral LLSAN. For moderate (5 to < 7mm) and severe GS (≥ 7mm), 3 U and 5 U of BTX-A were injected per side (total, 6 U and 10U). And The injection points located at both LLSAN and the Yonsei point, with half doses at each point.
16279406|NCT04820517|Experimental|Experimental Group|The Roy Adaptation Model Based Empowerment Program, which consists of 12 sessions that will create awareness of social media and its effects in students and contribute to students gaining and maintaining a healthy lifestyle by providing controlled and purposeful use of social media with behavioral change, will be held with online group sessions for 12 weeks to the students in the experimental group. .
16279407|NCT04820517|No Intervention|Control Group|No intervention will be made to the students in the control group. When the research is completed, student nurses in the control group will be informed about social media addiction and its effects.
16279408|NCT04820504|Placebo Comparator|Blinded to visual feedback from AIR device|Providers did not receive AIR device feedback during newborn mannequin ventilation
16279409|NCT04820504|Experimental|Not blinded to visual feedback from AIR device|Providers did receive AIR device feedback during newborn mannequin ventilation
16279410|NCT04820491|Active Comparator|X-Ray|
16279411|NCT04820491|Active Comparator|Ultrasound|
16279412|NCT04820478|Experimental|Beta Hydroxybutyrate|3 x 40 ml (= 3 x 15.6 g) beta hydroxybutyrate per day, mixed with acidic juice (e.g. orange juice), in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
16279413|NCT04820478|Placebo Comparator|Placebo|3 x 40 ml placebo per day, mixed with acidic juice (e.g. orange juice), in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
16279414|NCT04820452|Experimental|cohort 1 IBI302 treated with high dose level of IBI302|
16279415|NCT04820452|Active Comparator|Aflibercept|
16279416|NCT04820452|Experimental|cohort 1 IBI302 treated with low dose level of IBI302|
16279417|NCT04820439|Experimental|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|
16279418|NCT04820439|Active Comparator|Perjeta ®|
16279419|NCT04820426||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of neuropathic pain and its effect on the quality of life, at their admission.
16279420|NCT04820413|Experimental|FMT|
16279421|NCT04820400|Experimental|VR-360 group (VR-group)|Patients will watch a VR-360 distraction video during dressing change. The patient will be asked or helped to wear the HMD write in full at the onset of a procedure and watch the VR-360 video during the dressing change procedure. When experiencing pain, the patient may indicate the need for further analgesic medication during the procedure, the patient will be asked to push a button in their hand that will trigger a light-based signal for the nurse to provide further analgesic medication. Should their hands both be involved in the burn injury, the patient will indicate the same verbally.
16279422|NCT04820400|No Intervention|Control Group (standard treatment)|The patients will receive standard treatment and will be instructed to use the same button to indicate their pain.
16279423|NCT04820374|No Intervention|traditional extubation indications and traditional restoration indoor requirements|
16279424|NCT04820374|Experimental|Extubate the tube according to the pupil index and leave the recovery room|
16279425|NCT04820361|Placebo Comparator|Placebo|oral spray
16279426|NCT04820361|Active Comparator|Sativex®|.It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
16279427|NCT04820335|Experimental|Immediate Treatment Group|Participants will complete 7, 60-minute SEMAT sessions over 7 weeks with their group.
16279428|NCT04820335|No Intervention|Delayed Treatment Control|Participants will not receive the intervention immediately. After 8 weeks, participants in this arm will complete the SEMAT. This is not a crossover design, because the treatment effects from those in the immediate treatment group can not be taken away.
16279429|NCT04820322|Placebo Comparator|control cookie|a sugarsnap cookie baked specifically for this trial
16279430|NCT04820322|Active Comparator|Fibersym cookie|a sugarsnap cookie baked using the same methodology for the control cookie but with the resistants starch RS4, Fibersym, added
16279457|NCT04820075|Other|Process about performance of the preoperative shower|Implementation of a process aimed at improving the preoperative shower in programmed surgery
16279432|NCT04820296|Experimental|Experimental group|Pregnant women in the experimental group will be given 4 sessions Solution-Oriented Approach program, starting at the 32th week of pregnancy. Pregnants in the experimental group will be administered the Wijma Birth Expectation/Experience Scale (W-DEQ-A) and Pregnancy Psychosocial Health Assessment Scale (PPHAS) before the intervention. After the program is completed, a training booklet will be provided for pregnant women and (W-DEQ-A) and PPHAS will be applied again. With pregnant women, 37-40. between gestational weeks, they will be contacted again, face-to-face interview method (W-DEQ-A) and PPHAS again will be evaluated. The pregnant women will inform the researcher by phone after the delivery and the researcher will visit the hospital within the first 24 hours after the delivery to evaluate the mothers' birth fear levels Scale (W-DEQ-B). At the end of the first postpartum week, the postnatal senses of security of the mothers will be evaluated by telephone follow-up counseling.
16279433|NCT04820296|No Intervention|Control group|Pregnant women in the control group will only receive routine care. Pregnant women in the control group will be administered the same scales simultaneously with the experimental group.
16279434|NCT04820283|Experimental|Care manager intervention (nurse)|
16279435|NCT04820283|Active Comparator|Internet-based CBT|
16279436|NCT04820270|Experimental|Autologous Tregs in allogenic islet transplantation|Autologous Tregs are given simultaneously to the patient with the islets
16279437|NCT04820257|Experimental|Home based exercise|Home based exercise with health coaching
16279438|NCT04820257|No Intervention|Usual care|Usual care, waiting list
16279439|NCT04820244||No intervention|Otherwise healthy human volunteers, 16-55 years old, with a confirmed genetic diagnosis of Usher Syndrome type 2 or non-syndromal USH2A related retinitis pigmentosa
16279440|NCT04820231|Other|PRP injection group|"Intra-articular PRP injection with ultrasound guidance
~Three times PRP injections with an interval of one week"
16279441|NCT04820218|Other|Without Try-on glasses|Subjects will be asked to measure their visual acuity without their try-on glasses
16279442|NCT04820205|Experimental|intranasal dexmedetomdine and kemtaine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
16279443|NCT04820205|Active Comparator|oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
16279444|NCT04820192||Post-acute concussion (<6 months) or Post-Concussion Syndrome (PCS) (≥ 6 months)|Patients were divided into cohort groupings to compare outcomes of applying CranioSacral Therapy to their unique constellations of persistent symptoms attributed to their concussion injury. Symptoms less than 3-6 months duration may be part of the usually rate of injury resolution through rest along. Symptoms persisting after 6 months are considered PCS. Less than 6 months since injury were considered post-acute concussion stage of recovery.
16279445|NCT04820192||Athletes (A) or Non-athletes (NA)|Reporting of symptoms that exist and/or persist may differ between patients who are/were athletes and concussions were sustained during their sporting events. Non-athletes may report differently. The types of injuries involved in the concussion were also captured.
16279446|NCT04820192||Traditional gender.|Symptoms and response to rest has been reported to have differences between male and female patients. Age under 14 years was considered an exclusion due to immaturity in insight and reporting. Thus, young adult ages and older were included and observations between gender reporting was noted.
16279447|NCT04820179|Experimental|Cabozantinib 40mg + Atezolizumab 1200mg|Cabozantinib 40 mg, tablets, oral administration, once daily, continuously. Atezolizumab 1200 mg, administered intravenously, on Day 1 of every 21 day cycle.
16279448|NCT04820153|Other|Study Participants|Study participants will participate in both the Physical Activity Monitoring Device intervention and the Lifestyle Redesign Coaching intervention simultaneously. Both interventions are complementary to one another.
16279449|NCT04820140||muscle strengthening program|All patients will be receiving a muscle strengthening program consisting in both a training against resistance and an endurance training by elliptical bike during an observational period of 12 weeks for each treatment. Each training program will be preceded by a 4-week period of lymphatic drainage in order to improve neuromuscular sensitivity.
16279452|NCT04820114|Active Comparator|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life.
16279453|NCT04820114|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
16279454|NCT04820101|Experimental|Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy|Every preterm newborns 26+0-36+6 wGA who undergoes LISA procedure will receive sedation with dexmedetomidine in order to evaluate its efficacy in achieving pain control and comfort.
16279455|NCT04820088|Experimental|Intervention Arm|The educational intervention will be TTACS, the training program with simulated roleplays. Each participant will be asked to schedule 10 hours of time to utilize the simulation. In order to ensure all participants adhere to the minimum intervention requirements, each will be asked to schedule training time with a member of the research team. Participants will attend an initial training session where each participant will receive a short orientation about the product and its capabilities. Participants will attend an initial training session at one of two sites Psychology Department at Towson University or SIMmersion's office in Columbia, MD based on participant preference. Subsequent training sessions may be completed at Towson, SIMmersion or can be completed individually. Participants will receive confirmation emails the day before a scheduled session and a phone call to reschedule any missed sessions.
16279456|NCT04820088|No Intervention|Contro Arm|Students randomized to the control group will be given an electronic copy of the Guidelines for Psychological Practice with Transgender and Gender Non-Conforming People (APA, 2015) and asked to take notes in the pdf document. The amount of time students spend on the document and note-taking will be recorded and notes will be analyzed for content. As an incentive, the participants in the control group will be given access to TTACS after they complete the post-intervention assessment.
16279460|NCT04820036|Other|Patients with Obesity and NASH scheduled/recommended for P-ESG Procedure|We will perform a 12-month prospective, single-center, pilot observational study on patients with obesity and NASH with advanced fibrosis who are undergoing P-ESG. A total of 15 patients will undergo EUS-LB with EUS-PPG measurement in a single session prior to and at 12 months following P-ESG
16279461|NCT04820023|Experimental|BBT-176|
16279462|NCT04820023|Experimental|BBT-176 in combination with Cetuximab|
16279463|NCT04819997|Experimental|Supportive care (videoconference, questionnaire, survey)|Patients participate in 5 videoconference sessions over 30 minutes each over 6 weeks focused on worry management skills, values-based goal setting, and brief mindfulness-based practices, then complete patient workbook activities after each session over 15-20 minutes per day. Patients also complete a survey over 8 minutes at 6 weeks, an exit interview at 7 weeks, and questionnaires over 25 minutes each at baseline, 6 weeks, and 10 weeks.
16279464|NCT04819984|Experimental|Continuous PtC02 evaluation|Continuous PtC02 measured by TCM5 monitor during ventilatory weaning test of 30 minutes when available
16279465|NCT04819971|Experimental|TTC|
16279466|NCT04819945|Experimental|GATT-Patch|GATT-Patch will be used to control bleeding during open liver surgery. Each surgery will be performed according to the standard procedures at the hospital, with the exception of the use of GATT-Patch.
16279467|NCT04819932|Experimental|group1|subject take DWC202008 and DWC2020091 on a fasted condition, and after wash out period, take DWJ1451 with on a fasted condition
16279468|NCT04819932|Experimental|group2|subject take DWJ1451 on a fasted condition, and after wash out period, take DWC202008 and DWC202009 with on a fasted condition
16279469|NCT04819906|Experimental|T-ST-P-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279470|NCT04819906|Experimental|ST-M-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279471|NCT04819906|Experimental|P-T-M-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279472|NCT04819906|Experimental|M-P-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279473|NCT04819906|Experimental|ST-P-T-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279474|NCT04819906|Experimental|P-M-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279475|NCT04819906|Experimental|T-ST-M-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279476|NCT04819906|Experimental|M-T-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279477|NCT04819906|Experimental|P-T-ST-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279478|NCT04819906|Experimental|T-M-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279479|NCT04819906|Experimental|ST-P-M-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279480|NCT04819906|Experimental|M-ST-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets
~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets
~Treatment P: Placebo: five E4 placebo tablets
~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
16279481|NCT04819893||Women giving birth prematurely|Delivery before 29 WA
16279482|NCT04819893||Women giving birth at term|Childbirth between 39WA and 31WA+6 days
16279483|NCT04819867|Experimental|propolis|propolis will be applied to the affected teeth
16279484|NCT04819867|Active Comparator|gluma desensitizer|Gluma desensitizer will be applied to the affected teeth
16279485|NCT04819854|Experimental|EP395|EP395 in ascending doses. Orally, once daily.
16279486|NCT04819854|Placebo Comparator|Placebo|Placebo, weight matched in ascending doses. Orally, once daily.
16279487|NCT04819841|Experimental|GPH101 Drug Product|GPH101 Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.
16279488|NCT04819828|Experimental|Tamsulosin|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed plus oral tamsulosin (0.4 mg/day) for eight weeks.
16279489|NCT04819828|Active Comparator|Control|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed
16279490|NCT04819815||Type 1 diabetes mellitus|"Patients
~Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue (fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated."
16279491|NCT04819815||Healthy Controls|Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue ( fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated.
16279492|NCT04819802||Covid-19 patients|Adult Covid-19 patients admitted to intensive care units
16279493|NCT04819789|Experimental|Fermotein™ dry|Fermotein™ powder presented in the form of a porridge.
16279494|NCT04819789|Experimental|Fermotein™ wet|Fermotein™ wet presented in the form of a porridge.
16279495|NCT04819789|Experimental|Fermotein™ modified wet|Fermotein™ modified wet presented in the form of a porridge.
16279496|NCT04819789|Active Comparator|Mycoprotein|This mycoprotein product presented in the form of a porridge.
16279497|NCT04819776|Experimental|Iloperidone|
16279498|NCT04819776|Placebo Comparator|Placebo|
16279499|NCT04819763|Experimental|Physical training of the lateral pterygoid muscle|Static stretching and isometric contraction exercises of the lateral pterygoid muscle are used to strengthen and restore a physiological lateral movement of the mandible.
16279500|NCT04819763|Active Comparator|Stabilization appliance therapy|Hard acrylic splint with anterior canine guidance for the lower jaw.
16279501|NCT04819750|Active Comparator|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
16279502|NCT04819750|Placebo Comparator|Headphones with noise reduction|Headphones with noise reduction without music
16279503|NCT04819737|Experimental|Spinal Cord MRI|
16279504|NCT04819724|Other|Group 1: patient group (unilateral rotator cuff tear)|Group 1: 75 patients with unilateral rotator cuff tear
16279505|NCT04819724|Other|Group 2: (healthy volunteers)|Group 2: (healthy volunteers) 25 asymptomatic control subjects (age and sex distribution matching the patient group)
16279506|NCT04819711|Active Comparator|Intervention|Thinking Healthy group intervention integrated into antenatal pregnancy school classes
16279507|NCT04819711|No Intervention|Control|Participants randomized to the control arm will not be offered the THP intervention but will attend the 5 sessions of the routine group antenatal pregnancy school classes. The class provides education about pregnancy, birth and new-born care and offers support to women. The women will also be able to access all usual care and support offered by the participating hospitals
16279508|NCT04819685|Experimental|test group|Intervention:Anti-radiation spray (liquid dressing)
16279509|NCT04819685|No Intervention|control group|
16279510|NCT04819672|Experimental|Low Intensity Training associated with Partial Blood Flow|In the experimental group, a cuff with compression at 60% of the pressure required for total arterial occlusion will be placed, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff with partial blood flow restriction will be used during knee extension and squat exercises.
16279511|NCT04819672|Sham Comparator|Low Intensity Training associated with Partial Blood Flow-Sham|In the sham group, the cuff will be placed, but there will be no arterial occlusion pressure, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff without partial blood flow restriction will be used during knee extension and squat exercises.
16279512|NCT04819659|No Intervention|Group Control|Without pharyngeal pack insertion
16279513|NCT04819659|Experimental|Group Pharyngeal packing (Group PP)|Pharyngeal pack insertion after endotracheal intubation
16279514|NCT04819646|Experimental|Inflammation|Marine Lipid Oil concentrate softgel and dietary supplement capsule
16279515|NCT04819633||Study Group|30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
16279516|NCT04819633||Control Group|30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
16279517|NCT04819620|Experimental|Single Dose|Single dose administration
16279518|NCT04819620|Experimental|Multiple Dose|Multiple dose administration
16279519|NCT04819620|Experimental|Solid Dose Comparison|Solid dose administration
16279520|NCT04819607||BMFS patients|Patients with BMFS attending Peter MacCallum Cancer Centre haematology clinic.
16279521|NCT04819594|Experimental|Study Group|Nurses will wear the Elequil aromatabs ® (100% pure essential oil) over a four-hour period
16279522|NCT04819581|Experimental|SP-103 (1 topical system)|One topical system applied to the skin on the back for 12 hours.
16279523|NCT04819581|Experimental|SP-103 (2 topical systems)|Two topical systems applied to the skin on the back for 12 hours.
16279524|NCT04819581|Experimental|SP-103 (3 topical systems)|Three topical systems applied to the skin on the back for 12 hours.
16279525|NCT04819581|Active Comparator|ZTlido|Three topical systems applied to the skin on the back for 12 hours.
16279528|NCT04819555||adult patients with ALS|incident population of ALS patients followed in the FILSLAN centres.
16279531|NCT04819529|Experimental|Experimental Group - Early and intensive Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
16279865|NCT04817306||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
16279532|NCT04819529|No Intervention|Control group - Standard Analgesia,Sedation, Delirium and Mobilization (ASDM) Protocol|The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.
16279533|NCT04819516|Experimental|HIFU with REGOTORI|
16279534|NCT04819503|Other|Active and then sham repetitive transcranial magnetic stimulation|"Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
~Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS."
16279535|NCT04819503|Other|Sham and then active repetitive transcranial magnetic stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS.
16279536|NCT04819477|Other|Cate Plots|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The first group (Arm 1) receives a Cates plot and then another survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior.
16279537|NCT04819477|Other|Fact box only|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The second group (Arm 2) receives then a survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior
16279538|NCT04819464|Experimental|Group A: Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child-Pugh Score of 5 to 6).
16279539|NCT04819464|Experimental|Group B: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Score of 7 to 9).
16279540|NCT04819464|Experimental|Group C:Healthy participants|Healthy participants will be matched to the participants with hepatic impairment based on age and body weight.
16279541|NCT04819451|Experimental|MACSF group|In the experimental group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with non-aneurysmal subarachnoid hemorrhage were included in the stratified random method. Use Magnesium-Rich Artificial Cerebrospinal Fluid(MACSF) in the CSF replacement, and the remaining treatments should strictly follow the guidelines as same as the control group. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
16279542|NCT04819451|No Intervention|NS group|In the control group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with non-aneurysmal subarachnoid hemorrhage were included according to the stratified random method. Use the normal saline (0.9% Sodium Chloride Injection) in the CSF replacement, and the remaining treatments should strictly follow the guidelines. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
16279543|NCT04819438|Experimental|Riluzole orodispersible film (Test)|The subjects will be treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
16279544|NCT04819438|Active Comparator|Rilutek® (Reference)|The subjects will be treated with one film-coated table containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
16279545|NCT04819425|Experimental|Elastic Adhesive Strips|"Endotracheal tube fixed by elastic adhesive tape (Tensoplast type adhesive tape):
~The adhesive tape will be attached to the patient's face (opposite side to the endotracheal tube) and then two turns around the endotracheal tube will be made. The rest of the adhesive tape will be attached to the other side of the face (side of the endotracheal tube).
~The laminated tape will be kept on the adhesive tape until it passes over the neck in order to avoid adhering to the hair.
~Finally, the end of the adhesive tape will be replaced on the part already attached to the patient.
~It will be changed daily and after stain or examinations if necessary."
16279546|NCT04819425|Active Comparator|Lace in A Protective Sheath|"A loop is made with the lace then the endotracheal tube is passed through the loop. The loop is tightened by pulling each side on the remaining cords and a knot is made on one side of the fastener.
~It will be changed daily and after stain or examinations if necessary."
16279547|NCT04819412|Experimental|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
16279548|NCT04819412|Experimental|ROTAVAC 5C -F2|ROTAVAC5C formulation BBIL-R2014-2
16279549|NCT04819412|Active Comparator|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
16279550|NCT04819399|Experimental|Catumaxomab|intravesical Catumaxomab instillation
16279553|NCT04819373|Experimental|BDB001|BDB001 will be administered intravenously as monotherapy in subjects with histologically-confirmed unresectable or metastatic solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment either as monotherapy or in combination with other therapies.
16279554|NCT04819360|Active Comparator|Vesicare|Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
16279555|NCT04819360|Active Comparator|Botox|Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).
16279556|NCT04819347|Experimental|Early treatment of infection|"HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.
~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
16279611|NCT04818944|Placebo Comparator|Placebo Arm|Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
16279557|NCT04819347|Experimental|Chronic period of infection treatment|"Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.
~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
16279558|NCT04819334|Placebo Comparator|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
16279559|NCT04819334|Experimental|Commercially Available Sports Drink B|A commercially available flavored electrolyte solution, PepsiCo
16279560|NCT04819334|Experimental|Commercially Available Sports Drink A with added Amino Acids|he same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids (~2.6 g/100 ml).
16279561|NCT04819321|Experimental|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
16279562|NCT04819295||Latinx Adolescents|
16279563|NCT04819295||Parents of Latinx Adolescents|
16279564|NCT04819295||Healthproviders|
16279565|NCT04819282||One group|Physical performance was evaluated with the Senior Fitness Test in one group of geriatric individuals.
16279566|NCT04819269|Active Comparator|Tivanisiran sodium ophthalmic solution|
16279567|NCT04819269|Placebo Comparator|Vehicle ophthalmic solution|
16279568|NCT04819256|Experimental|Intervention arm|Providers use PACE-It mobile application as a care co-ordination platform
16279569|NCT04819256|No Intervention|Usual care|Providers use usual modes of communication (e.g., phone calls, emails)
16279570|NCT04819243|Experimental|Atezolizumab+Talazoparib|"st line treatment
~Palbociclib 125mg po D1-21
~AI : Prescribed as per local guideline
~GnRH agonist: Prescribed as per local guideline
~nd line treatment
~Talazoparib 1mg po
~Atezolizumab 1200mg IV (3week)"
16279571|NCT04819243|Experimental|Talazoparib|"st line treatment
~Palbociclib 125mg po D1-21
~AI : Prescribed as per local guideline
~GnRH agonist: Prescribed as per local guideline
~nd line treatment - Talazoparib 1mg po"
16279572|NCT04819230|Experimental|Bias Modification|Attention (ATT) and interpretation (ITT) bias training. Participants complete the ATT and ITT tasks twice per week for four weeks. The ATT trains attention toward neutral stimuli and away from negative stimuli. On trials with one neutral and one threat word, the probe will always follow the location of the neutral word. Therefore, there is a contingency between the valence of the word and the location of the probe. Participants will be asked to indicate which type of probe had appeared in each trial by pressing a corresponding button as rapidly and accurately as possible. The ITT trains participants to make benign (vs. threatening) interpretations of socially-ambiguous scenarios. For each trial, a word suggesting a socially threatening or benign interpretation is presented then replaced by a sentence describing a socially-ambiguous scenario. Participants indicate if they thought the word and sentence were related. Participants will receive corrective feedback after each trial.
16279573|NCT04819230|Placebo Comparator|Control Condition|"A combination of attention (ATT-C) and interpretation (ITT-C) control tasks
~These tasks are identical to the experimental tasks (ATT and ITT) with the exceptions that:
~ATT-C: It is designed to train attention toward neither neutral nor the threat stimuli. This will be achieved by having an equal number of probes follow the location of the threatening word and the neutral word.
~ITT-C: It is not designed to train benign interpretations of ambiguous social scenarios. Thus, no feedback will be given during the inter-trial interval, rather participants will see a blank screen between trials.
~Participants will complete both the ATT-C and ITT-C tasks twice per week for four weeks, totaling to eight experimental sessions."
16279574|NCT04819217|Other|Active bamboo charcoal|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
16279575|NCT04819217|Other|Probiotics|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
16279576|NCT04819204|Experimental|GnRH antagonist alone|Intervention: Cetrorelix acetate (Cetrotide)
16279577|NCT04819204|Experimental|GnRH antagonist + Testosterone add-back|Intervention: Cetrorelix acetate (Cetrotide) + Testosterone gel (Androgel)
16279578|NCT04819191|Experimental|SHARING Choices|"Components of SHARING Choices include:
~A letter from the clinic introducing an initiative to prepare persons and families for Advance Care Planning (ACP); Access to a facilitator trained to lead ACP discussions; Patient-family agenda-setting to align perspectives about the role of family and stimulate discussion about ACP; Facilitated registration to the patient portal (for patient and family) as desired; Education & resources about Alzheimer's Disease and Related Dementias (ADRD) for clinic staff."
16279579|NCT04819191|No Intervention|Usual care|Usual care
16279580|NCT04819165||COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with confirmed COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
16279581|NCT04819165||non COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with negative COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
16279582|NCT04819152||Exposed|Several studies will be performed based on this cohort. I each study the exposed group will be a group of tobacco users evaluatedin the relevant study. This could be a vulnarable group tobacco users such as: users without a job, with short or no education, without permanent housing, diagnosed with mental illness, diagnosed with chronic obstructive pulmonary disease (COPD), undergoing surgery, adolescents, elderly, migrants, or pregnant women.
16279583|NCT04819152||Unexposed|In each study the unexposed group will consist of tobacco user from the study cohort without the condition examined in the relevant study.
16279612|NCT04818931|Experimental|Antibiotics|Cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
16279613|NCT04818931|No Intervention|No antibiotics|
16279614|NCT04818918||STEMI group|"Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.
~Absolute coronary flow and microvascular resistance will be measured in the LAD."
16286068|NCT04773678|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
16279584|NCT04819139|Active Comparator|Thumb exercises +orthosis|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.
~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain."
16279585|NCT04819139|Experimental|Thumb exercises +orthosis+ proprioceptive program exercises|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.
~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain. In addiction, patients will received a proprioceptive program exercises using also a online program with a laptop."
16279586|NCT04819126|Experimental|Nintendo Wii Virtual Reality Application In Older People With Alzheimer's Dementia|"The study included a total of 32 volunteers between the ages of 65-80, who stayed in Karaman Ahmet Mete Nursing Home, Elderly Care and Rehabilitation Center, with mild or moderate Alzheimer's dementia diagnosed by a neurologist. As a result of the power analysis, it was calculated that at least 16 individuals could be included in each group (at least 32 individuals in total). Randomization was performed by the sealed-envelope method. According to this method, 4 females and 12 males were determined to be in the control group, while 5 females and 11 males were determined to be in the training group.
~The evaluation was completed before the intervention. The same evaluation was conducted after 6 weeks.
~The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes, and each patient was trained with the same games."
16279587|NCT04819126|No Intervention|Older People With Alzheimer's Dementia|In the control group, no application was performed during this period, and routine medical treatments were continued. The training group was evaluated before and after the training, while the control group was re-evaluated at the end of the 6th week after the first evaluation. After the study was completed, the volunteers from the control group were also given training.
16279588|NCT04819113|Experimental|Nimenrix|Nimenrix
16279591|NCT04819087|Experimental|Patients|Patients with Pelvic Floor Dysfunction Related Temporamandibular Joint Problems and Tinnitus
16279592|NCT04819074||Patients with unruptured brain aneurysms|"We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.
~No intervention."
16279593|NCT04819061|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training
16279594|NCT04819061|Sham Comparator|Sham group|In the group G2 will be administered: tDCS sham + dual-task motor training
16279595|NCT04819048|Experimental|Low-Level Laser Therapy+acupuncture|"The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.
~After LLLT irradiation,the following acupuncture points will be selected: Jiache,Xiaguan,Quanliao,Baihui,Fengchi, Hegu.The needles will be inserted and rotated manually with a frequency of about 100 turns per minute clockwise and counterclockwise ,as above vertically into a depth of 25-30 mm to achieve the proper feel called Deqi in every point on the affected side, and then the needles will be retained for 30 minutes."
16279596|NCT04819048|Active Comparator|Low-Level Laser Therapy|The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.
16279597|NCT04819035||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
16279598|NCT04819022||Musculoskeletal disorder|
16279599|NCT04819009||Central District|The ETMI method will be implemented in this group
16279600|NCT04819009||North District|control
16279601|NCT04819009||Hasharon District|control
16279602|NCT04819009||South District|control
16279603|NCT04819009||Jerusalem and Hasfhela District|control
16279604|NCT04818996|Experimental|Mediterranean Diet|In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.
16279605|NCT04818983||NSCLC cohort|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
16279606|NCT04818983||ED-SCLC cohort|Patients with extensive disease small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
16279607|NCT04818970|Experimental|Phototherapy of narrow band ultraviolet Light B-Band NB-UVB|Daavlin Series 1 Phototherapy Unit that emits UVB light between 280nm and 320nm.
16279608|NCT04818970|Placebo Comparator|Placebo - Light|Daavlin Series 1 Phototherapy Unit that does not emit UVB light between 280nm and 320 nm.
16279609|NCT04818957|Experimental|Vitamin D Oral Thin Film (OTF)|Study subjects will receive vitamin D OTF for a maximum of 12 weeks.
16279610|NCT04818944|Experimental|Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))|Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
16279615|NCT04818918||Control group|"Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions <90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value >0.8).
~Absolute coronary flow and microvascular resistance will be measured in the LAD."
16279616|NCT04818905|Experimental|Helichrysum italicum infusion|1 g of milled plant material (Helichrysum italicun) immersed in hot water (200 mL, 100 °C) for 10 minutes.
16279617|NCT04818905|Placebo Comparator|Hot water|The control beverage contained only hot water (200 mL, 100 ˚C).
16279618|NCT04818892||IBD and Non-Immunosuppressive Group|Clinical diagnosis of IBD, non-systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
16279619|NCT04818892||IBD and Immunosuppressive Group|Clinical diagnosis of IBD, treated with systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
16279620|NCT04818879|Experimental|Interventional group|
16279621|NCT04818879|Sham Comparator|Control group|
16279622|NCT04818866||Patients hospitalized for Covid-19|
16279623|NCT04818853||COVID Patients with Aspergillosis and Other fungal Infections|All patients have been diagnosed with COVID-19. The purpose of this study is to look at this group of patients in the potential to develop Aspergillosis and other fungal infections.
16279624|NCT04818840||Resurfaced/non patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
16279625|NCT04818840||un-resurfaced patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
16279626|NCT04818827||Ketamine group|This cohort includes patients who received ketamine as a sedative analgesic agent during mechanical ventilation
16279627|NCT04818827||Non Ketamine group|This cohort includes patients who received sedatives other than ketamine during mechanical ventilation
16279628|NCT04818814|Experimental|Mindfulness Meditation (MM) App|Participants randomized to the MM condition will be asked to download and use the free Mindfulness Coach app (available for iOS and Android platforms) developed by the Veteran Affairs National Center for PTSD. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes. Participants will attend a live videochat orientation to the study with the research coordinator (RC) to receive assistance in downloading and using the app. Participants will be asked to listen to at least one, and ideally two, audio-guided meditation exercises using the app daily for six weeks. The RC will ask participants to complete weekly logs of their MM app use via a Qualtrics survey sent via email.
16279629|NCT04818814|Active Comparator|Engagement and Distraction (ED) App|Participants randomized to the Engagement and Distraction condition will be asked to download and use the free TED Talk app (available for iOS and Android platforms). The app offers many videos of engaging and distracting presentations about technology, entertainment, and design. The research coordinator will work with the participant to create a customized list of Ted Talk videos, each lasting 6-12 minutes, based on participants' personal interests. Participants will be asked to listen to or watch at least one, and ideally two, presentations using the app daily for six weeks. The research coordinator will ask participants to complete weekly logs of their TED Talk app use via a Qualtrics survey sent via email.
16279630|NCT04818801|Experimental|Recombinant two-component COVID-19 vaccine (CHO cell)|Participants received Recombinant two-component COVID-19 vaccine (CHO cell) 0.5ml reconstituted by adjuvant solution, 2 shots at a interval 21 days, intramuscular injection
16279631|NCT04818801|Placebo Comparator|Placebo|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 2 shots at a interval 21 days, intramuscular injection
16279632|NCT04818775|Experimental|HemaClear|
16279633|NCT04818775|Active Comparator|Pneumatic Tourniquet|
16279634|NCT04818762||Preterm neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
16279635|NCT04818762||Preterm neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
16279636|NCT04818762||Term neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
16279637|NCT04818762||Term neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
16279638|NCT04818749|Placebo Comparator|Placebo|Participants allocated to this arm will have placebo administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
16279639|NCT04818749|Active Comparator|Dexamethasone 12 mg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
16279640|NCT04818749|Experimental|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and dexmedetomidine 1 mcg/kg administered intravenously after induction of general anaesthesia.
16279641|NCT04818736|Experimental|COVID-19|mRNA-1273 vaccine
16279642|NCT04818736|Experimental|Control|Usual care
16279643|NCT04818723|Experimental|Montelukast Group|53 in Case Group (given montelukast 5mg at bed time). All patients were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
16279673|NCT04818541|Experimental|Protected Percutaneous Coronary Intervention|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for PPCI. Duration of Impella use ≤ 6 hours if used for PPCI.
16279866|NCT04817306||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
16279644|NCT04818723|Placebo Comparator|Placebo Group|Patients in this groups were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
16279645|NCT04818710|Placebo Comparator|skin incision with a scalpel|In the scalpel group, the incision was made by the traditional method, with proper homeostasis by applying pressure to skin blood vessels and ligating the subcutaneous bleeding.
16279646|NCT04818710|Active Comparator|skin incision with diathermy|In the diathermy group, the incision made using a small flat blade pen electrode, set on cutting mode and delivering a 120 watt (maximum) sinusoidal current, electrosurgical cutting performed without pressure or mechanical displacement.
16279647|NCT04818697||Patients with heart rhythm disorders|Having been diagnosed with heart rhythm disorders such as atrial fibrillation, atrial tachycardia, ventricular tachycardia, and ventricular extrasystole
16279648|NCT04818697||Healthy individuals|Healthy individuals without chronic disease
16279649|NCT04818684||Physician|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
16279650|NCT04818684||Psychologists|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
16279651|NCT04818684||Caregivers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
16279652|NCT04818684||Nurses|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
16279653|NCT04818684||Social and Educational Assistants|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
16279654|NCT04818684||Volunteers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit. The representative participating in the study will preferably be the volunteer coordinator.
16279655|NCT04818684||Relatives|"Relative of a patient who died in the palliative care unit at least 6 months ago Person to trust or to prevent if not designated Relative understanding and speaking sufficient French Relative not a health professional
~Relative who visited the palliative care unit during the last 3 days of the patient's life and who met the care team:
~Traceability of the arrival of the loved one in the last 2/3 days of the patient's hospitalization
~Traceability of a meeting of the loved one with a member of the team over the last 3 days of his hospitalization or verification during telephone contact with the loved one after drawing lots Relative with an email address (to be verified during telephone contact with the loved one after drawing lots)"
16279656|NCT04818671|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
16279657|NCT04818658||Preformed Metal Crowns using Hall Technique|
16279658|NCT04818658||Compomer Restoration|
16279659|NCT04818645|Experimental|Confirm Rx insertable cardiac monitor|The Confirm RX implantable cardiac monitor (ICM) is an FDA-approved device that can be injected into the subcutaneous tissue and can provide automatic as well as patient triggered electrocardiographic recordings of symptomatic episodes during long term follow-up. This Implantable cardiac monitor is paired with a remote monitoring smartphone application called My Merlin that capable of rapid remote review of electrograms to be utilized in this study for arrhythmia detection. The Confirm Rx ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
16279660|NCT04818645|Active Comparator|Conventional Management|The conventional management arm will use arrhythmia signs and symptoms to determine occurrence of arrhythmias.
16279661|NCT04818632|Experimental|AZD9833 monotherapy dose escalation|
16279662|NCT04818632|Experimental|AZD9833 monotherapy dose expansion|
16279663|NCT04818632|Experimental|AZD9833 with palbociclib dose expansion|
16279664|NCT04818632|Experimental|AZD9833 with everolimus dose expansion|
16279665|NCT04818619||chronic myeloid leukemia patients|
16279666|NCT04818619||Healthy individuals|
16279667|NCT04818606|Experimental|Intervention (MORE) Group|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings. Pre-recorded guided meditations created by study personnel using scripts from the MORE manual will be provided to participants to facilitate their daily practice.
16279668|NCT04818606|No Intervention|Control Group|This group will undergo treatment as usual (TAU) over the course of the eight-week time period of parallel group comparison. This may or may not involve regularly scheduled, standard visits with other medical personnel, including primary care, specialized medical services, or complementary and integrative health practitioners (e.g., acupuncture). Participants will be asked to refrain from altering therapeutic approaches to pain management during this time unless medically necessary and will be asked to report any changes made to their treatment plan on a daily basis.
16279669|NCT04818593|Experimental|ZyMot Separation|Treatment
16279670|NCT04818593|Active Comparator|Density Gradient Centrifugation|Control
16279671|NCT04818580|Experimental|Right-Sided Progressive Tension Sutures|
16279672|NCT04818580|Active Comparator|Left-Sided Progressive Tension Sutures|
16279813|NCT04817670|Experimental|Cohort 1a|Subjects receive VIT-2763 30mg daily during the 8 weeks of treatment (Part A and Part B)
16279674|NCT04818541|Experimental|Cardiogenic shock|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for cardiogenic shock. Duration of Impella use > 8 hours and ≤ 4 days.
16279675|NCT04818528|Experimental|Constraint Induced Movement Therapy and Routine Physical Therapy|Patients received constrained induced movement therapy and routine physical therapy for up to 6 hrs/day, 5 days/week for 4 weeks.
16279676|NCT04818528|Active Comparator|Routine Physical Therapy|Patients received routine physical therapy for 5 days/week for 4 weeks.
16279677|NCT04818515|Experimental|Atogepant, Ubrogepant, and Coadministration|Participants will receive oral tablets of ubrogepant, followed be oral tablets of atogepant, followed by administration of oral tablets of atogepant and ubrogepant in combination, for a 30 day interventional period and a 7 day follow up period.
16279678|NCT04818489|Experimental|Colchicine group|Colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the local standard protocol of COVID19 management
16279679|NCT04818489|Placebo Comparator|Control group|the local standard protocol of COVID19 management
16279680|NCT04818476||HR-T1a|Patients who weretreated by radical endoscopic resection for a high-risk mucosal EAC (HR-T1a N0M0)
16279681|NCT04818476||LR-T1b|Patients who were treated by radical endoscopic resection for a low-risk submucosal EAC (LR-T1b N0M0)
16279682|NCT04818476||HR-T1b|Patients who were treated by radical endoscopic resection for a high-risk submucosal EAC (HR-T1b N0M0)
16279683|NCT04818450|Experimental|Gabapentin|Start gabapentin 100 mg at 9.00 PM on the second night of ICU admission and titrate gabapentin dose as needed. Maximum gabapentin dose in this study is 300 mg/day.
16279684|NCT04818450|No Intervention|Standard care|Not receiving gabapentin.
16279685|NCT04818437|Experimental|Balance training|"Balance training
~Trunk, head, and upper limbs rotation from kneeling.
~Upper limbs flexion and extension with simultaneous head movement from kneeling.
~Pelvic bridging followed by raising one lower limb and extending knee.
~Lifting opposite upper and lower limbs from Quadruped position.
~6-Heel and toe raises, alternate rising ofthe right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed"
16279686|NCT04818437|Active Comparator|Core stability exercise|"Core stability exercises:
~Abdominal bracing while lying in supine position.
~Abdominal bracing with heel slide while lying in supine position.
~Abdominal bracing with Leg lifts while lying in supine position.
~Abdominal bracing with bridging while lying in supine position.
~Abdominal bracing while Standing 6-Abdominal bracing while walking.
~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying."
16279687|NCT04818424|Experimental|REAL training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
16279688|NCT04818424|Active Comparator|Control training|Control training refers to similarly structured gait training as with REAL, with the only exception of using soft robotic exosuits. Control training is performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. Control training includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
16279689|NCT04818411|Active Comparator|Routine physical therapy treatment with the Stabilization exercises|Stabilization exercises
16279690|NCT04818411|Experimental|Routine physical therapy treatment + High-velocity thrust manipulation|High-velocity thrust manipulation
16279691|NCT04818398|Experimental|DS-6016a dose level 1|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
16279692|NCT04818398|Experimental|DS-6016a dose level 2|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
16279693|NCT04818398|Experimental|DS-6016a dose level 3|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
16279694|NCT04818398|Experimental|DS-6016a dose level 4|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
16279695|NCT04818398|Experimental|DS-6016a dose level 5|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
16279696|NCT04818398|Experimental|DS-6016a dose level 6|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
16279697|NCT04818398|Placebo Comparator|Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
16279698|NCT04818385||Participants Receiving Risankizumab|Participants will receive risankizumab as prescribed by their physician.
16279699|NCT04818385||Participants Receiving All Other Biologics|Participants will receive all other biologics as prescribed by their physician.
16279700|NCT04818372|Experimental|Dose escalation|"Subjects enrolled in this arm will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
~Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 4 dose levels (0.006mg/kg, 0.06mg/kg, 0.3mg/kg and 1.0mg/kg) and then traditional 3+3 dose escalation design will be used for the following levels (2.0mg/kg, 4.0mg/kg, 8.0mg/kg, 16mg/kg and 24mg/kg)."
16279701|NCT04818372|Experimental|Dose expansion _Cohort 1|This cohort will comprise subjects with RRMM. Subjects will receive the CM313 in combination with dexamethasone.
16279702|NCT04818372|Experimental|Dose expansion _Cohort 2|This cohort will comprise subjects with RRMM and NDMM. Subjects will receive the CM313 in combination with Rd regimen.
16279703|NCT04818359|Experimental|Interventional Arm|Supervised exercise program: MoviS Training. Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
16279704|NCT04818359|No Intervention|Control Arm|Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
16279709|NCT04818333|Experimental|SHR-A1811|SHR-A1811 was administered intravenously every 3 weeks (Q3W) until discontinuation treatment
16279710|NCT04818320|Experimental|Favipiravir|Favipiravir treatment group (with standard of care),
16279711|NCT04818320|No Intervention|Control|No favipiravir given. Standard of care only
16279712|NCT04818307|Experimental|Macquarie Injury Management group|
16279713|NCT04818307|Active Comparator|Mulligan Mobilization with Movement|
16279714|NCT04818281|Experimental|Low-Dose Group (Group A)|12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
16279715|NCT04818281|Experimental|High-Dose Group (Group B)|12 participants will receive 40 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
16279716|NCT04818281|Placebo Comparator|Placebo Group|12 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
16279717|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
16279718|NCT04818268|Experimental|Auditory Sensory Memory|Auditory Sensory Memory
16279719|NCT04818268|Experimental|Somatosensory Sensory Memory|Somatosensory Sensory Memory
16279720|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback + cTBS to 46v|Adaptation to Altered Auditory Feedback + cTBS to 46v
16279721|NCT04818268|Experimental|Sensory Memory + cTBS to 46v|Sensory Memory + cTBS to 46v
16279722|NCT04818255|Experimental|Disclosure|Participants who demonstrated decisional capacity for and interest in disclosure (or whose care partner is able to do so) will receive the participant's personalized PET amyloid and tau biomarker status, as well as information about the meaning and clinical utility of this information and recommendations for next steps (e.g., discussing findings with his/her provider).
16279723|NCT04818242|Active Comparator|POC testing with Blinded CGM Group (Standard of Care Group)|Patients in the standard of care group will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results.
16279724|NCT04818242|Experimental|Dexcom CGM with Glucose Telemetry System Group (CGM-GTS Group)|Patients in the intervention CGM group will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.
16279725|NCT04818229|Experimental|Investigational Group 1|Therapeutic and supratherapeutic multiple oral doses of CBP-307.
16279726|NCT04818229|Placebo Comparator|Investigational Group 2|Moxifloxacin (positive control for method validation) and Placebo oral administration.
16279727|NCT04818216|Placebo Comparator|Placebo Group|Placebo capsules will be administered 2 capsules twice daily for 10 days
16279728|NCT04818216|Experimental|Nicotinamide Riboside Group|Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
16279729|NCT04818203|Experimental|Test Group|Participants receive 1 mL of clusters of autologous dermal fibroblast to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
16279730|NCT04818203|Placebo Comparator|Placebo|Participants receive 1 mL of placebo solution to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
16279731|NCT04818190|No Intervention|DIEP reconstruction, no neurotization|DIEP reconstruction No sensory neurotization
16279732|NCT04818190|Experimental|DIEP reconstruction, neurotization|DIEP reconstruction With sensory neurotization
16279733|NCT04818177||Normal Weight|Normal weight is defined as BMI 18.5 - 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.
16279734|NCT04818177||Overweight or Obese|Overweight or obese is defined as BMI > 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.
16279735|NCT04818151||ESRD patients with VTE treated with warfarin|Warfarin as primary treatment of VTE
16279736|NCT04818151||ESRD patients with VTE treated with apixaban|Apixaban as primary treatment of VTE
16279737|NCT04818138|Active Comparator|Narrowband UVB|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
16279738|NCT04818138|Active Comparator|Broadband UVB|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
16279739|NCT04818125|Other|Patients with breast cancer|
16279740|NCT04818112|Experimental|Behavioral ATVV intervention|A multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
16279741|NCT04818112|Active Comparator|Attention control|An attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
16279742|NCT04818099|Experimental|routine supportive psychotherapy and votioxetine|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given votioxetine 10mg/tablet, one tablet each time, once a day, for 2 months.
16279743|NCT04818099|Placebo Comparator|routine supportive psychotherapy and control|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given placebo, one tablet each time, once a day, for 2 months.
16279744|NCT04818086|Active Comparator|Lemborexant Arm|Study Drug Dosage: 5 mg of lemborexant, and 10 mg of lemborexant, all subjects will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
16279745|NCT04818086|Placebo Comparator|Placebo Arm|Comparative placebo, all subjects will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
16279863|NCT04817332|Placebo Comparator|Placebo|Placebo oral tablet, 25mg once per day for 28 days
16279746|NCT04818073|Experimental|Group A|Participants with intact finger proprioception will undergo new FINGER robotic training with no physical assistance 3 times a week for a period of 3 weeks.
16279747|NCT04818073|Experimental|Group B|Participants with intact finger proprioception will undergo new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
16279748|NCT04818073|Experimental|Group C|Participants with poor finger proprioception will undergo intensive, robotic-assisted proprioceptive training for a 3-week period prior to new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
16279749|NCT04818073|Experimental|Group D|Participants with poor finger proprioception will undergo new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
16279750|NCT04818060||Low Risk of Motor Diagnosis|
16279751|NCT04818060||High Risk of Motor Diagnosis|
16279752|NCT04818060||Stage I or II Huntington's Disease|
16279753|NCT04818060||Healthy Controls|
16279754|NCT04818047|Experimental|Experimental: VID-KIDS Intervention Program Group|Experimental: VID-KIDS Intervention Program Group RN review photos of infant engagement/ disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
16279755|NCT04818034|Experimental|Study Drug|The study drug Dapagliflozin
16279756|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
16279757|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Forward Skin Stretch|Adaptation to Altered Auditory Feedback + Forward Skin Stretch
16279758|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Backward Skin Stretch|Adaptation to Altered Auditory Feedback + Backward Skin Stretch
16279759|NCT04818021|Experimental|Speech Repetition Control|Speech Repetition Control
16279760|NCT04818008|Experimental|Otago Exercise Program|Patients will receive the Otago Exercise Program for 8 weeks plus health awareness videos about topics related to MS.
16279761|NCT04818008|No Intervention|Control group|Patients will receive health awareness videos only about topics related to MS.
16279762|NCT04817995|Experimental|Intervention group|The intervention group will get a 6-week internet-based stress recovery intervention.
16279763|NCT04817995|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
16279764|NCT04817982|Experimental|Perineural dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Dexamethasone will be added perineurally in this arm on the same day as the 'systemic dexamethasone' group.
16279765|NCT04817982|Active Comparator|Systemic dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as the 'perineural dexamethasone' group. Thereby, this ulnar nerve block will only be affected by the perineurally added dexamethasone that is absorbed and redistributed systemically.
16279766|NCT04817982|Placebo Comparator|Placebo|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as lidocaine group. This will be the actual placebo group.
16279767|NCT04817982|Active Comparator|Perineural lidocaine|Bilateral ulnar nerve blocks with bupivacaine. Lidocaine will be added perineurally in this arm on the same day as the actual placebo group.
16279768|NCT04817969|Other|Persona Ti-Nidium|Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System
16279769|NCT04817956|Experimental|Atezolizumab|Atezolizumab used outside of current indication, based on biomarkers
16279770|NCT04817956|Experimental|Atezilizumab combined with bevacizumab|Atezilizumab combined with bevacizumab used outside of indication, based on biomarkers
16279771|NCT04817956|Experimental|Phesgo (trastuzumab og pertuzumab)|Phesgo used outside of indication, based on biomarkers.
16279772|NCT04817956|Experimental|Alectinib|Alectinib used outside of indication, based on biomarker
16279773|NCT04817956|Experimental|vismodegib|vismodegib used outside of indication, based on biomarker
16279774|NCT04817956|Experimental|entrectinib|entrectinib used outside of indication, based on biomarker
16279775|NCT04817956|Experimental|Zelboraf + Cotellic|Zelboraf + Cotellic used outside of indication, based on biomarker
16279776|NCT04817930|Experimental|Patient specific chin implant|A patient specific chin peek implant was used for chin augmentation
16279777|NCT04817930|Experimental|computer guided advancement genioplasty|Computer guided advancement genioplasty using patient specific cutting and positioning guides
16279778|NCT04817917|Experimental|3JEV-I (Group 1)|"Retrospective: 3 doses of JE vaccines. 2 doses of Inactivated JE Vaccine (JEV-I, 7-10 days apart) at 8 months of age and 1 dose of JEV-I at 2 years old.
~Prospective: 1 booster dose of JEV-I at 6 years old."
16279779|NCT04817917|Experimental|JEV-L+JEV-I (Group 2)|"Retrospective: 2 doses of JE vaccines.
~1 dose of JE attenuated live vaccine (JEV-L) at 8 months of age and 1 dose of JEV-I at 2 years old.
~Prospective: 1 booster dose of JEV-I at 6 years old."
16279780|NCT04817917|Experimental|JEV-L+2JEV-I (Group 3)|"Retrospective: 3 doses of JE vaccines.
~1 dose of JEV-L at 8 months of age and 2 dose (7-10 days apart) of JEV-I at 2 years old."
16279781|NCT04817917|Experimental|2JEV-I+JEV-L (Group 4)|Retrospective: 3 doses of JE vaccines. 2 doses of JEV-I (7-10 days apart) at 8 months of age and 1 dose of JEV-L at 2 years old.
16279782|NCT04817917|Experimental|2JEV-L (Group 5)|Retrospective: 2 doses of JE vaccines. 2 doses of JEV-L respectively administered at 8 months of age and 2 years old.
16279783|NCT04817904|Experimental|Statin-Treated|"This arm will be receiving:
~Cisplatin along with conventional nephroprotective interventions (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)
~Rosuvastatin 10 mg/day"
16279864|NCT04817319|Experimental|Major patients diagnosed with Covid + requiring oral care.|
16279784|NCT04817904|No Intervention|Statin-Free|"This arm will be receiving:
~-Cisplatin along with conventional nephroprotective interventions only (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)"
16279785|NCT04817891|Experimental|Experimental: HD-tDCS|Maximum 4 milliAmp (mA) per channel of HD-tDCS treatment for 20 minutes, for 10 sessions. Total mA dose determined by individualized computational models.
16279786|NCT04817878||Late preterm infant group|Gestational age 33 weeks-36 weeks
16279787|NCT04817878||Very premature infant group|Gestational age 28 weeks-32 weeks
16279788|NCT04817878||Super preterm infant group|Gestational age less than 28 weeks
16279789|NCT04817865||Standard Pre-Procedural Urine Culture|This is a control cohort that follows standard pre-procedural protocol by implementing antibiotic prophylaxis and treatment regimens based on dipstick urine analysis (UA) followed by reflexed traditional urine culture and sensitivity (C&S) methods performed before injection.
16279790|NCT04817865||Pre-Procedural M-PCR/P-AST|This is an experimental cohort that implements Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) for pre-procedural UTI screening. The cohort follows an antibiotic treatment regimen based on the results of M-PCR/P-AST.
16279791|NCT04817852|Experimental|CBCT data of C-shaped canal in mandibular second molar will Be assessed for age.|Detection of variation in root canal morphology by using CBCT.
16279792|NCT04817839|Experimental|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
16279793|NCT04817839|Experimental|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
16279794|NCT04817826|Experimental|Cohort 1|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
~Patients in Cohort 1 will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed by an active follow-up every 12 weeks for two years and then a standard follow-up every six months until the end of the fifth year from surgery."
16279795|NCT04817826|Experimental|Cohort 2|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
~In Cohort 2, patients with no evidence of complete clinical response will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed up. Patients with complete clinical response will undergo a non-operative management (NOM) with an active follow-up phase every 12 weeks for two years, followed by standard follow-up every six months until the end of the fifth year. At any time during follow-up, in case of clinical suspicion or confirmation of residual gastric cancer, patients will undergo standard surgery according to the clinical practice at their Centre."
16279796|NCT04817800|Experimental|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|
16279797|NCT04817800|Experimental|100 μg Beclomethasone dipropionate, Nasal Spray|
16279798|NCT04817800|Active Comparator|RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)|
16279799|NCT04817787|Placebo Comparator|LoEx+Placebo|"Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions while receiving placebo.
~Drug: Low Intensity Exercise + Placebo
~Low Intensity Exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo."
16279800|NCT04817787|Placebo Comparator|HiEx+Placebo|"Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions while receiving placebo.
~Drug: High Intensity Exercise + Placebo
~High Intensity Exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo."
16279801|NCT04817787|Active Comparator|LoEx+Metformin|"Subjects randomly assigned to this group will participate in the same 3 supervised training sessions and 2 unsupervised training sessions, but they will be provided Metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not find out whether or not they are on Metformin until after the study is complete. If their doctor needs to know, the people doing this study can find out.
~Drug: Low Intensity Exercise + Metformin
~Low Intensity Exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo."
16279802|NCT04817787|Active Comparator|HiEx+Metformin|"Subjects randomly assigned to this group will participate in the same HiEx 3 supervised training sessions and 2 unsupervised training sessions, but they will be provided Metformin.
~Drug: High Intensity Exercise + Metformin
~High Intensity Exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo."
16279803|NCT04817774|Experimental|Treatment group|Subjects undergo kidney transplant as per planned standard of care and are administered study drug post transplantation, up to 15 subjects.
16279804|NCT04817774|No Intervention|Control group and Transplant donors|"Control group: Subjects undergo kidney transplant as per planned standard of care with no study drug administered, up to 6 subjects.
~Transplant donors: Transplant donors for each subject in the treatment and control groups, up to 21 subjects."
16279805|NCT04817761|Experimental|Calaspargase pegol (S95015)|
16279806|NCT04817748||Acute ST segment elevation myocardial infarction（STEMI）|the patients' coronary and venous blood were drawn for metabolomics study
16279807|NCT04817748||Acute non ST segment elevation myocardial infarction（NSTEMI）|the patients' coronary and venous blood were drawn for metabolomics study
16279808|NCT04817748||Acute myocardial infarction with no obstructive coronary atherosclerosis（MINOCA）|the patients' coronary and venous blood were drawn for metabolomics study
16279809|NCT04817748||Patients with normal coronary artery（NCA)|the patients' coronary and venous blood were drawn for metabolomics study
16279810|NCT04817735|Other|Cohort|
16279811|NCT04817709||Arm 1|Patients view a video and read a workbook over 30 minutes about breast reconstruction surgery before their appointment. Patients also complete a questionnaire over 5-10 minutes before and after the video and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
16279812|NCT04817709||Arm 2|Patents receive an educational booklet about breast reconstruction surgery during appointment. Patients also complete a questionnaire over 5-10 minutes before and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
16279814|NCT04817670|Experimental|Cohort 1b|Subjects receive VIT-2763 30mg daily during the first 4 weeks of the treatment (Part A) followed by 60mg daily for other 4 weeks (Part B).
16279815|NCT04817670|Experimental|Cohort 2a|Subjects receive VIT-2763 60mg daily during the 8 weeks of treatment (Part A and Part B)
16279816|NCT04817670|Experimental|Cohort 2b|Subjects receive VIT-2763 60mg daily during the first 4 weeks of the treatment (Part A) followed by 120 mg daily for other 4 weeks (Part B).
16279817|NCT04817670|Placebo Comparator|Cohort 3|Subjects randomised to placebo during Part A continue unchanged during Part B.
16279818|NCT04817644|Experimental|Oral semaglutide|All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
16279821|NCT04817605|Experimental|Exercise Therapy|
16279822|NCT04817592||Age1(20-25)|The groups are divided as per age
16279823|NCT04817592||Age2(25-30)|
16279824|NCT04817592||Age3(30-35)|
16279825|NCT04817592||Age4(35-40)|
16279826|NCT04817592||Age5(40-45)|
16279827|NCT04817579|Active Comparator|Conventional visual shade matching|Patients requiring single crown in the esthetic zone treated with Conventional visual shade matching (Ivoclar Classic shade guide)
16279828|NCT04817579|Experimental|Spectrophotometer|Patients requiring single crown in the esthetic zone treated with Spectrophotometer (Vita Easy Shade)
16279829|NCT04817579|Experimental|Digital photography combined with eLABor_aid shade analyzing software.|Patients requiring single crown in the esthetic zone treated with Digital photography combined with eLABor_aid shade analyzing software.
16279830|NCT04817566|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
16279831|NCT04817566|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
16279832|NCT04817553||IgG4 pancreatobiliary|IgG4 patients with pancreatobiliary involvement
16279833|NCT04817540|Experimental|Single arm, Herzuma arm|
16279834|NCT04817527|Experimental|Edaravone Dexborneol|
16279835|NCT04817527|No Intervention|conventional therapy|conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy
16279836|NCT04817514|Experimental|specific shoulder rehabilitation protocol group (SRG);|
16279837|NCT04817514|Experimental|specific protocol of shoulder rehabilitation plus aerobic exercise group (ARG)|
16279838|NCT04817501||Breast cancer|At least eighty five subjects with breast cancer
16279839|NCT04817501||Ovarian cancer|At least 32 subjects with ovarian cancer
16279840|NCT04817501||Endometrial Cancer|At least 33 subjects with endometrial cancer
16279841|NCT04817501||Healthy control|30 healthy volunteers
16279842|NCT04817501||Suspected malignant tumor non-verified|Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined
16279843|NCT04817488||Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed with tele-supervision.
16279844|NCT04817488||Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed without tele-supervision.
16279845|NCT04817475||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
16279846|NCT04817462||Liver Biopsy|All patients undergo a liver biopsy only
16279847|NCT04817449||Suspected Ovarian Cancer|Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer.
16279848|NCT04817436|Active Comparator|Without adapted physical activity program (APA)|
16279849|NCT04817436|Experimental|With adapted physical activity program (APA)|
16279850|NCT04817423||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
16279851|NCT04817410|Experimental|Oral Naloxone|Oral Naltrexone initiation
16279852|NCT04817384|Experimental|Graston technique group|For Graston practice, instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
16279853|NCT04817384|Experimental|Classical massage group|The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
16279854|NCT04817371|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
16279855|NCT04817371|Other|Symptomatic patients with positive PCR for other respiratory virus|Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses
16279856|NCT04817371|Other|Asymptomatic patients or healthy volunteers|Patients or healthy volunteers with negative RT-PCR and negative serology
16279857|NCT04817371|Other|Volunteers or patients vaccinated against COVID-19|Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)
16279858|NCT04817358||Demirjian method|According to the Demirjian method, the development of the seven left mandibular permanent teeth (except the third molar) were rated on the eight-stage scale from A to H. Each stage of mineralization was given a score, total dental maturity score was evaluated according to standard tables for boys and girls
16279859|NCT04817358||Willems method|Willems' method was determined using the Demirjian calcification stages but scores were evaluated according to Willems' specific tables
16279860|NCT04817358||Nolla method|In the Nolla method, the development of seven left mandibular and maxillar teeth were defined on 10 stages. If the tooth was between stages an appropriate fraction (0.2, 0.5 or 0.7) was added. The total score was determined according to the tables prepared for girls and boys as recommended by Nolla
16279862|NCT04817332|Experimental|Brensocatib|Brensocatib oral tablet, 25mg once per day for 28 days
16286250|NCT04772287|Experimental|Toripalimab|
16279867|NCT04817306||Non-tumor (Healthy) Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
16279868|NCT04817293||COVID-19 positive|
16279869|NCT04817293||COVID-19 negative|
16279870|NCT04817280||Ice Swimmers Group.|No intervention. Data obtained from Polish ice swimmers reported by them retrospectively in the questionnaire.
16279871|NCT04817267|Experimental|reSET-O + Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU plus the reSET-O app.
16279872|NCT04817267|No Intervention|Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU only (no use of the reSET-O app).
16279878|NCT04817228|Experimental|EX-02 Gel|The powder of EX-02 (8.1 g in each unit) should be reconstituted with 20 g sterile water for injection (WFI) to obtain 5% EX-02. EX-02 5% gel will be topically applied on a wound surface of up to 80 cm2 for 24±3 hours, up to 8 consecutive applications
16279879|NCT04817215|Experimental|Patients who are Drug naïve or diet controlled|
16279880|NCT04817215|Experimental|Patients on Metformin only|
16279881|NCT04817215|Experimental|Patients on two or three oral glucose-lowering agents|
16279882|NCT04817202|Experimental|Group A1 (hzVSF-v13 50mg, intravenous, single dose)|Single administration (intravenous) of 50mg hzVSF-v13 on Day 1.
16279883|NCT04817202|Experimental|Group A2 (hzVSF-v13 100mg, intravenous, single dose)|Single administration (intravenous) of 100mg hzVSF-v13 on Day 1.
16279884|NCT04817202|Experimental|Group A3 (hzVSF-v13 200mg, intravenous, single dose)|Single administration (intravenous) of 200mg hzVSF-v13 on Day 1.
16279885|NCT04817202|Experimental|Group A4 (hzVSF-v13 400mg, intravenous, single dose)|Single administration (intravenous) of 400mg hzVSF-v13 on Day 1.
16279886|NCT04817202|Experimental|Group A5 (hzVSF-v13 800mg, intravenous, single dose)|Single administration (intravenous) of 800mg hzVSF-v13 on Day 1.
16279887|NCT04817202|Experimental|Group A6 (hzVSF-v13 1200mg, intravenous, single dose)|Single administration (intravenous) of 1200mg hzVSF-v13 on Day 1.
16279888|NCT04817202|Experimental|Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)|Single administration (subcutaneous) of 100mg hzVSF-v13 on Day 1.
16279889|NCT04817202|Experimental|Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)|Multiple administration (intravenous) of 100mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
16279890|NCT04817202|Experimental|Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)|Multiple administration (intravenous) of 400mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
16279891|NCT04817202|Placebo Comparator|Placebo (intravenous, single dose)|Single administration (intravenous) of placebo on Day 1.
16279892|NCT04817202|Placebo Comparator|Placebo (subcutaneous, single dose)|Single administration (subcutaneous) of placebo on Day 1.
16279893|NCT04817202|Placebo Comparator|Placebo (intravenous, multiple dose)|Multiple administration (intravenous) of placebo on Day 1, Day 15, Day 29, Day 43, Day 57.
16279894|NCT04817189|Experimental|NEPA (300mg netupitant/0.5mg palonosetron) + Dexamethasone 8 mg|"Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
~Dexamethasone (8 mg) will be administered on Day 1 of each cycle."
16279895|NCT04817189|Active Comparator|Standard of care + Dexamethasone 8 mg|"Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy and one of the 5-HT3-RAs recommended by European Society for Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC) guidelines (standard of care), i.e. either:
~Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)"
16279896|NCT04817176|Experimental|MI-CBT KNA Program|The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
16279897|NCT04817176|Active Comparator|KN Information-Only Program|6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
16279898|NCT04817163|Experimental|Stepped care CBT-I|
16279899|NCT04817150|Experimental|3D-laparoscopy|patients who underwent 3D laparoscopic ventral rectopexy
16279900|NCT04817150|Active Comparator|2D-laparoscopy|patients who underwent conventional 2D laparoscopic ventral rectopexy
16279901|NCT04817137|Other|All Enrolled Patients|Patients will wear the Caretaker Pulse Decomposition Analysis (PDA) Device, which will record the patient's blood pressure.
16279902|NCT04817124|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
16279903|NCT04817124|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
16279904|NCT04817111|Other|Open Label - MIB-626|MIB-626
16279905|NCT04817098|Experimental|Journey of Life Intervention Group|Community members (caregivers, teachers, and community leaders) will participate in group workshops for a period of 6 weeks.
16279906|NCT04817098|Other|Waitlist Control Group|The waitlist control group will not receive the intervention during the first 6 months of implementation in order to assess the effects of the intervention compared to the control group. However, following intervention completion in the experimental group, the control group will receive 6 months of the intervention.
16279907|NCT04817085|Experimental|Visant Medical Canalicular Plug|Bilateral placement of the Visant Canalicular Plug inserted on Day 1
16279908|NCT04817085|Active Comparator|Commercially available canalicular plug|Bilateral placement of commercially available canalicular plug inserted on Day 1
16279909|NCT04817072|Other|Chronic inflammatory rheumatic disease|Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
16279910|NCT04817059|Experimental|Head mold on|
16279911|NCT04817059|No Intervention|Head mold off|
16279912|NCT04817033|Active Comparator|High risk OSA Dexmedetomidine|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
16279913|NCT04817033|Active Comparator|High risk OSA Midazolam|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
16279914|NCT04817033|Active Comparator|Low&Medium OSA Dexmedetomidine|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
16279915|NCT04817033|Active Comparator|Low&Medium OSA Midazolam|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
16279916|NCT04817020|Other|Compare %2 klorheksidin and %70 Alchol on phlebitis|
16279917|NCT04817007|Experimental|Part 1A: BMS-986158 + Ruxolitinib|
16279918|NCT04817007|Experimental|Part 1B: BMS-986158 + Fedratinib|
16279919|NCT04817007|Experimental|Part 2A: BMS-986158 + Ruxolitinib|
16279920|NCT04817007|Experimental|Part 2B1: BMS-986158 + Fedratinib|
16279921|NCT04817007|Experimental|Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable|
16279922|NCT04816994|Experimental|High dose cannabis oil|Single-dose 20.0 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic.
16279923|NCT04816994|Experimental|Low dose cannabis oil|Single-dose 10 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
16279924|NCT04816994|Placebo Comparator|Control|Single-dose Olive oil that is similar in appearance and taste to cannabis oil
16279925|NCT04816981|Experimental|EBUS-Elastography|
16279926|NCT04816968|Experimental|Arm A - Cefepime|Continuous infusion of Cefepime at home.
16279927|NCT04816968|Experimental|Arm B - Piperacillin/tazobactam|Continuous infusion of Piperacillin/tazobactam at home.
16279928|NCT04816968|Experimental|Arm C - Meropenem|Continuous infusion of meropenem at home.
16279929|NCT04816968|Experimental|Arm D - Vancomycin|Continuous infusion of vancomycin at home.
16279930|NCT04816955|Experimental|Nutrient-based recommendations|Participants in this group will be given nutrient-based recommendations to reduce free sugar intakes.
16279931|NCT04816955|Experimental|Nutrient- and food-based recommendations|Participants in this group will be given nutrient- and food-based recommendations to reduce free sugar intakes.
16279932|NCT04816955|Experimental|Nutrient- and food-based recommendations with food swaps|Participants in this group will be given nutrient- and food-based recommendations and advice on food swaps to reduce free sugar intakes.
16279933|NCT04816955|Placebo Comparator|Control|Participants in this group will not be given any recommendations to reduce free sugar intakes.
16279934|NCT04816942|Experimental|Convalescent Plasma|Patients receiving Two units of ABO compatible COVID-19 convalescent plasma will be administered.P
16279935|NCT04816929|Experimental|Bobath Method Group|The Bobath based exercises for 60 minutes will be formed according to the needs of the individual and will involve trunk exercises such as placing, stretching, functional reach, rotations, functional strengthening and, balance and walking exercises etc. It will be performed 3 days a week for 8 weeks.
16279936|NCT04816929|Active Comparator|Task-Oriented Approach Group|The task-oriented approach for 60 minutes will be formed according to the needs of the individual and involve exercises targeting functional tasks determined. It will be performed 3 days a week for 8 weeks.
16279937|NCT04816916|Active Comparator|AXA1665 53.8 g per day|AXA1665 administered orally TID
16279938|NCT04816916|Placebo Comparator|Matching placebo|Placebo administered orally TID
16279939|NCT04816903|Experimental|Symptomatic vaginitis patients|All participants will be enrolled according to their complaints, All will be tested by the Gyni system, Only in the second group the physician will be unblinded to the Gyni results.
16279940|NCT04816890|Experimental|M1 Pram P037|Multi daily administration of M1 Pram P037 by subcutaneous injection
16279941|NCT04816890|Active Comparator|Insulin lispro|Multi daily administration of insulin lispro (Humalog®) by subcutaneous injection
16279942|NCT04816877||Patient controlled analgesia (PCA) group|Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids.
16279943|NCT04816877||Physician directed analgesia (PDA) group|Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician.
16279944|NCT04816864|Active Comparator|ECANS started from the right vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
16279945|NCT04816864|Active Comparator|ECANS started from the left vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
16279946|NCT04816851||Ozaki group|Patients undergoing aortic valve reconstruction using autologous pericardium (OZAKI technique) at Assiut University Hospitals in conjunction with Al-Nas hospital in cairo.
16279947|NCT04816838|Experimental|N/A(Single Arm)|
16279948|NCT04816825|Experimental|Exergaming|The combination of 1) game-console based exercise programs, 2) specifically designed by professional physiotherapists with focus on subjects with a chronic lung disease and 3) weekly distant monitoring with close supervision by a physiotherapist. Individually prescribed exercise program based on tests of patient's physical fitness.
16280155|NCT04815551|Experimental|AV-380 IV 4 mg/kg|IV infusion of AV-380 at dose level 4 mg/kg
16279949|NCT04816825|Active Comparator|Standard rehabilitation|Standard rehabilitation at the COPD-Center. This includes recommendations about physical activity according to the general guidelines, however, individualized after each subject's physical fitness level.
16279950|NCT04816812|Other|Exercise|In the intervention arm, a 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level.
16279951|NCT04816812|Other|Comparison|Comparison
16279952|NCT04816799|Experimental|START|START (startle adjuvant rehabilitation therapy) will be applied.
16279953|NCT04816799|No Intervention|Control|Subjects will train but without START
16279954|NCT04816786||Group 1: Admitted to ICU and died during the hospital stay.|
16279955|NCT04816786||Group 2: Admitted to ICU was were discharged.|
16279956|NCT04816773||Newly or previously implanted patients|Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert
16279957|NCT04816747|Experimental|Autologous PRP|Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.
16279961|NCT04816708|Active Comparator|Arm 1: Intervention group (access to LIFT mindfulness app)|Participants randomized to the intervention arm will be provided access to LIFT app's daily mobile mindfulness therapy for 30 days.
16279962|NCT04816708|No Intervention|Arm 2: Control waitlist group (delayed access to LIFT mindfulness app)|Control participants will not receive access to the LIFT app daily mobile mindfulness therapy during study period. They may have access to LIFT app daily mobile mindfulness therapy after completion of the study period.
16279963|NCT04816695|Experimental|VOC analysis|VOC analysis in exhaled air in patients hospitalised for COPD exacerbation
16279964|NCT04816682|Active Comparator|LAGOSA ARM|Consecutively admitted patients will be allocated silymarin tablets (150 mg each) T.I.D. 3-2-2
16279965|NCT04816682|No Intervention|Control arm|Consecutive patients with the same inclusion/exclusion criteria as in active arm, hospitalised at the same department before the initiation of the study (historical controls)
16279966|NCT04816669|Experimental|Lyophilized SDV|
16279967|NCT04816669|Experimental|Frozen liquid MDV (control for lyo SDV)|Control for lyophilized SDV
16279968|NCT04816669|Experimental|Frozen-liquid with LNP size at the upper end of specification|
16279969|NCT04816669|Experimental|RTU|
16279970|NCT04816656|Experimental|Experimental arm|All patients were presented the digital PROMs platform during their chemotherapy
16279971|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
16279972|NCT04816643|Experimental|Mid-Dose, ≥5 to <12 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
16279973|NCT04816643|Experimental|High-Dose, ≥5 to <12 Years|High-Dose (30mcg), 2 doses 21 days apart
16279974|NCT04816643|Experimental|Low/Mid-Dose, ≥2 to < 5 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
16279975|NCT04816643|Experimental|Mid-Dose, ≥2 to <5 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
16279976|NCT04816643|Experimental|High-Dose, ≥2 to <5 Years|High-Dose, (30mcg), 2 doses 21 days apart
16279977|NCT04816643|Experimental|Low/Mid-Dose, ≥6 Months to <2 Years|Low/Mid-Dose, (10mcg), doses 21 days apart
16279978|NCT04816643|Experimental|Mid-Dose, ≥6 Months to <2 Years|Mid-Dose, (20mcg), doses 21 days apart
16279979|NCT04816643|Experimental|High-Dose, ≥6 Months to <2 Years|High-Dose, (30mcg), 2 doses 21 days apart
16279980|NCT04816643|Experimental|Low-Dose, ≥5 to <12 Years|Low-Dose (3mcg), 2 doses 21 days apart
16279981|NCT04816643|Experimental|Low-Dose, 16 to <30 Years|Low-Dose (3mcg), 2 doses 21 days apart
16279982|NCT04816643|Experimental|Low/Mid-Dose, 16 to <30 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
16279983|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years|
16279984|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years|
16279985|NCT04816643|Placebo Comparator|Placebo, ≥5 to <12 Years|
16279986|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years|Low-Dose (3mcg), 2 doses 21 doses apart
16279987|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years|Low-Dose (3mcg), 2 doses 21 days apart
16279988|NCT04816643|Experimental|Low-dose, 12 to <16 Years|Low-Dose (3mcg), 2 doses 21 days apart
16279989|NCT04816643|Experimental|Low/Mid-Dose, 12 to <16 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
16279990|NCT04816630||CBC-Diff Monocyte Volume Width Distribution|Monocyte Distribution Width [MDW] is part of the CBC with Differential. No intervention
16279991|NCT04816617|Experimental|Aerobic Exercise|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
16279992|NCT04816617|Placebo Comparator|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
16279993|NCT04816604|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) over 72 weeks
16279998|NCT04816552|Experimental|CHoBI7 mHealth program Arm|The first arm will receive the CHoBI7 mHealth program and a general message on oral rehydration solution (ORS) (CHoBI7 mHealth program Arm) .
16279999|NCT04816552|Active Comparator|Standard Recommendation Arm|The second arm will serve as a Control Arm and only receive a general message on oral rehydration solution (ORS).
16280003|NCT04816500|Experimental|RIC group|Device: Remote ischemic conditioning RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
16280004|NCT04816500|Other|Regular treatment|
16280005|NCT04816487|Active Comparator|Silver Diamine Flouride|Discoloration of primary carious teeth treated by SDF
16280006|NCT04816487|Experimental|Glutathione|Discoloration rate of primary carious teeth treated by SDF + Glutathione
16280007|NCT04816487|Experimental|Potassium iodide|Discoloration rate of primary carious teeth treated by SDF + KI
16280008|NCT04816474|Experimental|Education and Phone Counseling Service|Patients in this group will be trained online for 6 weeks. After the online training is over, a telephone consultation service will be provided once a week for 6 weeks.
16280009|NCT04816474|No Intervention|Control|No application will be made to patients in this group for 12 weeks. Pre-test and post-test will be applied.
16280010|NCT04816461|Experimental|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive
16280011|NCT04816461|Experimental|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive
16280012|NCT04816461|Active Comparator|SMC alone|No roommates screening and treatment
16280013|NCT04816448|Experimental|Studygroup|cervical mobilization (Headache SNAG) with baseline treatment (Hot pack for 10 minutes, TENS 10 minutes, Neck isometrics and stretching).
16280014|NCT04816448|Active Comparator|Control Group|Sub-occipital myofascial release with baseline treatment (Hot pack for 10 minutes, TENS for 10 minutes, Neck isometrics and stretching
16280015|NCT04816422|Experimental|Proprioceptive neuromuscular facilitation|Bilateral upper extremity pattern for trunk by Chopping, Lifting 2. Bilateral lower extremity pattern for trunk. 3. Trunk lateral flexion. 4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion.
16280016|NCT04816422|Active Comparator|Conventional treatment|"Procedure Group 2 has received conventional trunk exercise program for 45 min/day, 4 days
~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
16280017|NCT04816409|Experimental|(Neurodevelopmental therapy)|"Starting Posture Start and evaluate the supreme effective posture to move from(usually straight) Reassemble to mid plane (head/trunk)
~•Neutral position of body Identify the Missing Components Detect starting posture and compare to normal.
~Neurodevelopmental therapy application :
~Tonic postural extensor muscle strengthening:
~Push-pull scooter board games contrary to resistive tubing strips.
~Developmental movement patterns training:
~Obstacle crawl, hold swing's ropes in kneeling anhalf kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of sustaining exercise positions in children.4. Ambulation training, suitable to the motor"
16280018|NCT04816409|Active Comparator|Conventional treatment|Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,
16280019|NCT04816396|Experimental|experimental|For 8 weeks, Reminiscence Therapy based on Roy Adaptation Model will be applied
16280020|NCT04816396|No Intervention|No İntervention|No intervention will be applied to this group.
16280021|NCT04816383|Experimental|Experimental Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the Apple breastfeeding application in the office once enrolled in the study between 32 to 36 weeks gestation. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
16280022|NCT04816383|No Intervention|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
16280023|NCT04816370|Experimental|pSS group|primary Sjögren's syndrome group
16280024|NCT04816370|Experimental|Control Group|Control group
16280025|NCT04816370|Experimental|pSS Premenopausal|primary Sjögren's syndrome premenopausal patients
16280026|NCT04816370|Experimental|pSS Postmenopausal|primary Sjögren's syndrome postmenopausal patients
16280156|NCT04815551|Experimental|AV-380 IV 8 mg/kg|IV infusion of AV-380 at dose level 8 mg/kg
16280157|NCT04815551|Experimental|AV-380 IV 13 mg/kg|IV infusion of AV-380 at dose level 13 mg/kg
16280027|NCT04816357||Endometriosis & Migraine|"Premenopausal women aged 18-55 years, at time of operation
~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)
~For the cases migraine needs to be confirmed during the interview according to the IHS criteria."
16280028|NCT04816357||Endometriosis|"Premenopausal women aged 18-55 years, at time of operation
~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)"
16280029|NCT04816344||Group MP (n=35)|"The patients were separated into four groups according to the anaesthetic agents given.
~Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage."
16280030|NCT04816344||Group MK (n=35)|Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg ketofol (10% ketamine + 10% propofol) iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg iv ketofol was given as additional dosage.
16280031|NCT04816344||Group DP (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage.
16280032|NCT04816344||Group DK (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg ketofol iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg ketofol iv was given as an additional dosage.
16280033|NCT04816331||Neonatal Encephalopathy (NE)|This study is a follow up of children at 2-3 years of age who were enrolled in the HRB-funded Neonatal Inflammation and Multiorgan dysfunction and Brain injUry reSearch group (NIMBUS) project. These babies had Neonatal Encephalopathy and required Therapeutic Hypothermia and are matched with controls. Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management were collected. In addition, details of Therapeutic Hypothermia treatment including initiation, duration and clinical examination, investigations including cranial USS, MRI, EEG and placental histology analysis performed as were recorded.
16280034|NCT04816331||Controls|The controls include age-matched normal children born at term with a normal delivery and postnatal course.
16280035|NCT04816318||Social and public health measures against COVID-19|Public Health and Social measures against COVID-19. This group refers to the population exposed to public health and social measures against COVID-19
16280036|NCT04816318||Control|The comparator is the pre-intervention period
16280037|NCT04816305|Experimental|rTMSc + physiotherapy|A conventional high-frequency rTMS (rTMSc) will be applied over the lesioned hemisphere over the motor cortex. After rTMSc, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
16280038|NCT04816305|Experimental|rTMSp + physiotherapy|A personalized high or low-frequency rTMS (rTMSp) will be applied to the lesioned or non-lesioned hemisphere depending on cortical biomarkers assessment guide a personalized stimulation for each patient in this group. After rTMSp, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
16280039|NCT04816305|Sham Comparator|tDCS sham + physiotherapy|The sham protocol will be delivered to each patient of this arm imitating the exat sound of the equipment and structure of the experimental arms. After rTMS sham, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
16280040|NCT04816292|Active Comparator|Hot Snare Polypectomy|If an eligible polyp 5-15 mm (as compared by the size of the snare) is found, according to the randomized group, HSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 2 biopsies (polyps 5-9mm) or 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
16280041|NCT04816292|Experimental|Cold Snare Polypectomy|If an eligible polyp 5-15 mm (as compared by the size of the snare) is found, according to the randomized group, CSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 2 biopsies (polyps 5-9mm) or 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
16280042|NCT04816279||First Audit cycle|
16280043|NCT04816279||Second Audit cycle|
16280044|NCT04816266||Myopic patients|
16280045|NCT04816266||Hypermetropic patients|
16280046|NCT04816266||Emmetropic people|
16280047|NCT04816253|Placebo Comparator|Normal saline|Normal saline irrigation after extraction and No drug placed in tooth socket
16280048|NCT04816253|Active Comparator|Gengigel|Gengigel (Hyaluronic acid) placed after extraction
16280049|NCT04816253|Active Comparator|Methylprednisolone|Methylprednisolone will be given intravenous to a patient half an hour before the surgery
16280050|NCT04816253|Active Comparator|Methylprednisolone and Gengigel|Methylprednisolone will be given intravenous to a patient half an hour before the surgery and Gengigel (Hyaluronic acid) placed after extraction
16280051|NCT04816240|Experimental|Midodrine + Albumin +Standard Medical Treatment|SMT + Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (>75 mm and <90).
16280052|NCT04816240|Active Comparator|Albumin + Standard Medical Treatment+ Placebo|80grams/week for 2 weeks followed by 40gram/week + Placebo
16280053|NCT04816227||Amyotrophic Lateral Sclerosis (ALS)|Blood draw
16280054|NCT04816227||asymptomatic carriers of ALS mutations|Blood draw
16280055|NCT04816227||patients with motor impairment other than ALS|Blood draw
16280056|NCT04816227||healthy controls|Blood draw
16280057|NCT04816214|Experimental|Combination of capmatinib + osimertinib (run-in part)|For run-in part: Up to 2 dose levels of capmatinib in combination with osimertinib may be investigated. The starting dose of combination is capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation is required, a lower dose level is defined as capmatinib 400 mg orally twice a day (b.i.d) and osimertinib 40 mg orally once per day (q.d.)
16280158|NCT04815551|Experimental|AV-380 IV 20 mg/kg|IV infusion of AV-380 at dose level 20 mg/kg
16280058|NCT04816214|Experimental|Combination of capmatinib + osimertinib (randomized part)|For randomized part: capmatinib in combination with osimertinib administered at the recommended Phase III regimen (defined in the safety run-in part).
16280059|NCT04816214|Active Comparator|platinum + pemetrexed based doublet chemotherapy|For randomized part: following local guidelines as per standard of care and products labels
16280060|NCT04816201|Experimental|Electroacupuncture|Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
16280061|NCT04816201|Sham Comparator|Sham electroacupuncture|Participants in the sham electroacupuncture group received sham electroacupuncture with a pragmatic placebo needle on sham acupoints. The sham Xuanji (CV21) point was 1 cun (≈20 mm) above to Xuanji (CV21), the sham Danzhong (CV27) point was 1 cun(≈20mm) above to Danzhong (CV27), the sham Qihai (CV06) point was 1 cun(≈20mm) above to Qihai (CV06), the sham Guanyuan (CV04) point was 1 cun(≈20mm) above to Guanyuan (CV04), the sham Liangmen (ST21) point was 1 cun(≈20mm) lateral to Liangmen (ST21), and the sham Zusanli (ST36) point was 1 cun(≈20mm) lateral to Zusanli (ST36). Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no skin penetration or electricity output.
16280062|NCT04816188|Experimental|Exercise and Activity Modification|
16280063|NCT04816175|Experimental|Treatment Intervention|All children will receive 3-5 weeks of intensive neuromotor Acquire therapy, an operant conditioning, play based therapy that maximizes therapeutic movements, attention, and engagement.
16280064|NCT04816162|Placebo Comparator|Control group|21 ml of normal saline 0.9% will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively.
16280065|NCT04816162|Active Comparator|ketofol group|21 ml of a mixture of (ketamine and propofol) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
16280066|NCT04816162|Active Comparator|dexmedetomidine group|21 ml of a mixture of (dexmedetomidine diluted with normal saline 0.9%) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
16280067|NCT04816149|Active Comparator|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
16280068|NCT04816149|Experimental|Treatment for Relationships and Safety Together (TR&ST)|"TR&ST consists of twelve 90-minute sessions delivered in four phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems. Finally, in phase four, couples engage in relapse prevention exercises and outline individual and couple values in order to create a life worth living moving forward."
16280069|NCT04816136||patients with a sleep recording performed|patients with a sleep recording performed in the sleep unit in Montpellier University Hospital, who had an ischemic stroke before the recording.
16280070|NCT04816123|Experimental|[14C]Donafenib|
16280071|NCT04816110|Experimental|mineralized plasmatic matrix with collagen membrane|
16280072|NCT04816110|Active Comparator|mineralized plasmatic matrix without collagen membrane|
16280073|NCT04816097|Active Comparator|Steroid Group|Participants will receive 4 doses of dexamethasone 6mg IM 48h before elective CS.
16280074|NCT04816097|No Intervention|No Steroid Group|Participants will receive No treatment before elective CS.
16280075|NCT04816084|Experimental|Population|Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne
16280076|NCT04816071|Experimental|EAA - non-vaccinated|18 g/day
16280077|NCT04816071|Placebo Comparator|Placebo - non-vaccinated|18 g/day
16280078|NCT04816071|Experimental|EAA - vaccinated|18 g/day
16280079|NCT04816071|Placebo Comparator|Placebo - vaccinated|18 g/day
16280080|NCT04816058||Ankle Instability Group|Patients with a history of ankle instability or injury.
16280081|NCT04816058||Healthy Group|Participants without a history of ankle injury
16280082|NCT04816045|Active Comparator|Intervention|Electrochemotherapy with bleomycin
16280083|NCT04816045|Active Comparator|Control|Electroporation with saline
16280084|NCT04816032|Experimental|Pennebaker's expressive writing|Three consecutive days for 20 minutes daily of expressive writing. The topic of the traumatic traveling experience, focalizing the attention on the deeper emotions, thoughts, and feelings.
16280085|NCT04816032|Active Comparator|Writing about different aspects of their knowledge|Three consecutive days for 20 minutes daily of neutral writing. Different topics of own knowledge Description of the city, their room, their place where they live, or easy procedure like, how to make a coffee (or something else), their population, trying to remain free from deep emotions, thoughts, or feelings.
16280086|NCT04816032|No Intervention|Control|No intervention
16280087|NCT04816019|Experimental|Group 1a: Low Dose|"A single, Covid-19 vaccine naive volunteer will receive a single dose of 5x10^9vp ChAdOx1 nCOV-19 IN.
~Volunteers in Group 1a & b will be randomized to receive booster dose of 5 x 10^9vp ChAdOx1 IN or no booster"
16280159|NCT04815551|Experimental|AV-380 SC 4 mg/kg|Subcutaneous injection of AV-380 at dose level 4 mg/kg
16280088|NCT04816019|Experimental|Group 1b: Low dose|"5 Covid-19 vaccine naive volunteers will receive a single dose of 5x10^9vp ChAdOx1 nCOV-19 IN.
~Volunteers in Group 1a & b will be randomized to receive booster dose of 5 x 10^9vp ChAdOx1 IN or no booster"
16280089|NCT04816019|Experimental|Group 2a: High Dose|"3 Covid-19 vaccine naivevolunteers will receive a single dose of 5x10^10vp ChAdOx1 nCOV-19 IN.
~Volunteers in Group 2a & b will be randomized to receive booster dose of 5 x 10^10vp ChAdOx1 IN or no booster"
16280090|NCT04816019|Experimental|Group 2b: High Dose|"Up to 15 Covid-19 vaccine naive volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCOV-19 IN.
~Volunteers in Group 2a & b will be randomized to receive booster dose of 5 x 10^10vp ChAdOx1 IN or no booster"
16280091|NCT04816019|Experimental|Group 3: Intermediate Dose|"Up to 18 Covid-19 vaccine naive volunteers will receive a single dose of 2x10^10vp ChAdOx1 nCOV-19 IN.
~Volunteers will be randomized to receive booster dose of 2 x 10^10vp ChAdOx1 IN or no booster"
16280092|NCT04816019|Experimental|Group 4: High Dose, vaccinated boost|6 volunteers, previously vaccinated with two doses of ChAdOx1 nCoV-19 IM will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 IN.
16280093|NCT04816019|Experimental|Group 5: High Dose, vaccinated boost|6 volunteers, previously vaccinated with two doses of BNT162b IM will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 IN.
16280094|NCT04816006|Experimental|Aerobic Exercise Training|Breast cancer survivors randomized to the intervention group will participate in a moderate-intensity aerobic exercise program for 24 weeks.
16280095|NCT04816006|Active Comparator|Health Education (Control)|Individuals randomized to Health Education will receive individual education and counseling related to general cancer-related health and support across 24 weeks.
16280096|NCT04815993|Experimental|SYN-020, 5 mg|6 subjects to receive a single 5 mg dose of SYN-020
16280097|NCT04815993|Experimental|SYN-020, 15 mg|6 subjects to receive a single 15 mg dose of SYN-020
16280098|NCT04815993|Experimental|SYN-020, 45 mg|6 subjects to receive a single 45 mg dose of SYN-020
16280099|NCT04815993|Experimental|SYN-020, 150 mg|6 subjects to receive a single 150 mg dose of SYN-020
16280100|NCT04815980|No Intervention|Control|The control group performed no Pilates intervention. They continued with their typical activities of daily living.
16280101|NCT04815980|Experimental|Pilates|Participants in this group performed a 30 minute mat-based Pilates intervention 3 times/week for 12 weeks.
16280102|NCT04815967|Experimental|Experimental: Phase 2: MYOBLOC 10,000 U, IM|"Phase 2 will compare the efficacy and safety of 2 doses of MYOBLOC versus volume-matched placebo in the treatment of upper limb spasticity. Ninety subjects will be randomized 1:1:1 to receive a total limb dose of 10,000 Units of MYOBLOC, 15,000 U of MYOBLOC.
~Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension."
16280103|NCT04815967|Experimental|Experimental: Phase 2: MYOBLOC 15,000 U, IM|"Phase 2 will compare the efficacy and safety of 2 doses of MYOBLOC versus volume-matched placebo in the treatment of upper limb spasticity. Ninety subjects will be randomized 1:1:1 to receive a total limb dose of 10,000 Units of MYOBLOC, 15,000 Units of MYOBLOC.
~Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension."
16280104|NCT04815967|Placebo Comparator|Placebo Comparator: Phase 2: Placebo|Volume-matched placebo via intramuscular (IM) injection into targeted muscles of the affected upper limb.
16280105|NCT04815967|Experimental|Experimental: Phase 3 -RP3D|Phase 3 will compare the efficacy and safety of the RP3D of MYOBLOC versus volume-matched placebo in the treatment of upper limb spasticity. Between 60 to 182 subjects will be randomized 1:1 to receive the RP3D of MYOBLOC.
16280106|NCT04815967|Placebo Comparator|Placebo Comparator: Phase 3: Placebo|Volume-matched placebo via IM injection into targeted muscles of the affected upper limb.
16280107|NCT04815954|Experimental|Early group|Early urinary catheter removal: 24±6 hours after completion of surgery.
16280108|NCT04815954|Active Comparator|Delayed group|Delayed urinary catheter removal: 72±6 hours after completion of surgery.
16280109|NCT04815941|Experimental|Soft ball tissue release exercises|
16280110|NCT04815915|Experimental|Study Group|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
16280111|NCT04815902|Experimental|Active Fisetin and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
16280112|NCT04815902|Active Comparator|Active Fisetin and Losartan Placebo|Losartan Placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
16280113|NCT04815902|Active Comparator|Fisetin Placebo and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
16280114|NCT04815902|Placebo Comparator|Control|Losartan placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
16280115|NCT04815889|No Intervention|Control group|Recruitment of the control group is done through the county parts that have not yet been included in the clinical trial of new methods. This means that children / families are not withheld from treatment they would otherwise receive.
16280116|NCT04815889|Active Comparator|PRIMUS parent training group and preschool teacher training group|The parents have undergone PRIMUS Group-based parent support program for 5 half days This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The preschool teachers may participate for half a day in education together with the parents as a practical implementation in the child's everyday life.
16280160|NCT04815551|Experimental|AV-380 SC 2 mg/kg|Subcutaneous injection of AV-380 at dose level 2 mg/kg
16280117|NCT04815889|Other|Demand-driven intervention|"The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:
~Support in the child's everyday environment home / preschool
~Targeted parent training group: toilet, sleep, food, everyday structure, handle behavioural problems
~Web Courses Each individual intervention is evaluated afterwards with the study questionnaire."
16280120|NCT04815863||Elderly|Over 60 years old
16280121|NCT04815863||Non-Elderly|Under 60 years old
16280122|NCT04815850||Patients on haemodialysis|Patients receiving haemodialysis
16280123|NCT04815850||Healthy controls|Participants with no chronic kidney disease or history of immunosuppression
16280124|NCT04815837|Experimental|Intervention|"Participants received the following interventions:
~Viewing a video promoting Human Papillomavirus (HPV) vaccination
~Receiving discount coupons
~Visiting the project webpage
~Receiving follow-up reminders"
16280127|NCT04815811|Experimental|Children suffering from acute inflammatory processes.|"The study population will consist of male and female children, aged from 6 months to 7 years old, admitted to the hospital for one of the three following types of acute inflammatory processes:
~Urinary tract infection caused by Escherichia coli
~Pneumonia with pleural effusion caused by Streptococcus pneumoniae
~Sepsis"
16280128|NCT04815811|Other|Control group|Male and female children, aged from 6 months to 7 years old, admitted to the hospital for a scheduled operation for a non-inflammatory pathology.
16280129|NCT04815798|Experimental|Bacteriophage-loaded Microcapsule Spray with Standard of Care|Phage therapy (Bacteriophage-loaded Microcapsule Spray) will be administered topically in conjunction with standard of care for pressure ulcers.
16280130|NCT04815798|Placebo Comparator|Placebo with Standard of Care|Placebo, analogous to the experimental arm, will be administered topically in conjunction with standard of care for pressure ulcers.
16280131|NCT04815785|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and loading system
16280132|NCT04815759||Pre pandemic|
16280133|NCT04815759||Post pandemic|
16280134|NCT04815746|Experimental|Psychosocial Symptom Management Intervention (PSMI) Experimental Condition Arm|Participants in this group will receive the Cognitive Behavioral Therapy (CBT)-based skills over a 10-week period.
16280135|NCT04815746|Active Comparator|Usual Clinical Care Control Arm|Participants in this group will receive standard education.
16280136|NCT04815733|Active Comparator|Mandatory ventilation|deep neuromuscular block and mandatory ventilation (PCV-VG);
16280137|NCT04815733|Experimental|Pressure support ventilation|partial neuromuscular block and pressure support ventilation (PSVpro).
16280139|NCT04815707|Other|Surgery|Occult hernia found will be repaired at the same time as the initial inguinal hernia
16280140|NCT04815707|No Intervention|Expectant Management|No surgery will be done if an occult hernia is found during the initial inguinal hernia surgery
16280141|NCT04815694|Experimental|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI > 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
16280142|NCT04815694|No Intervention|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI < 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
16280145|NCT04815668|Experimental|Acupuncture group|
16280146|NCT04815668|Placebo Comparator|Placebo acupuncture group|
16280147|NCT04815668|Other|Rescue medication|
16280148|NCT04815603|Experimental|BGE-117|BGE-117 Capsules (4mg or 12mg) to be taken by mouth once a day for 84 days.
16280149|NCT04815603|Placebo Comparator|Placebo|Placebo Capsules to be taken by mouth once a day for 84 days.
16280150|NCT04815590|Experimental|Sublocade|This consists of 2 once-monthly 300 mg followed by 4 once-monthly 100 mg subcutaneous injections.
16280151|NCT04815577||CHD group|The CHD group is made up of the children included in the first study. From these 496 children with CHD, children with a second CPET more than one year from the first referral CPET were included. If several CPETs were performed in the follow-up, we retain the most distant CPET from the first, excluding the CPETs that were performed after a cardiopulmonary rehabilitation program implemented in the region in 2018. The group corresponding to the first CPET was called. Among the initial 496 children, if patients had not had a second CPET, the cause was indicated. As a reminder, the patients included in the initial study were aged 5-18 years old and they were referred by their paediatric cardiologists to one of the two CPET laboratories after their annual medical check-up. The anatomical and clinical classification of congenital heart diseases was used to define the type of malformation. The demographic, clinical, echocardiographic data were collected during the first CPET.
16280152|NCT04815577||Controle|The controle Group consisted of children referred for nonsevere functional symptom linked to exercise (murmur, palpitations or dyspnea) or for a medical sports certificate. We included controlled children from 2015 to 2020 period who will be added to the controlled patients of the initial study. These patients only had one CPET.
16280153|NCT04815564|Experimental|Intervention|Subjects with a PAR score between 15 and 40 and fulfilling the other eligibility criteria will be offered participation in the trial.
16280154|NCT04815564|No Intervention|Natural History|Subjects with a PAR score outside of 15-40 will be offered the opportunity to remain on study for the Natural History arm.
16280163|NCT04815538||industrial workers|Active workers more than 1 year in petrochemical plant, fertilizer factory , electrical station and food industry
16280164|NCT04815538||control group|office work unexposed
16280165|NCT04815525||Normal finding|Colonoscopy finding normal
16280166|NCT04815525||Hyperplastic polyps|Colonoscopy finding of hyperplastic polyps
16280167|NCT04815525||Low-risk adenomas|Colonoscopy finding of low-risk adenomas
16280168|NCT04815525||High-risk adenomas|Colonoscopy finding of high-risk adenomas
16280169|NCT04815512||exposed group|workers in The Petroleum Pipelines Company who are occupationally exposed to petroleum products will be included in the study.
16280170|NCT04815512||Comparison group (control group)|healthy administrative workers in assiut university
16280171|NCT04815499|Experimental|Food supplement|One tablet a day, during 12 months
16280172|NCT04815499|Placebo Comparator|Placebo|One tablet a day, during 12 months
16280173|NCT04815486|Experimental|Bilateral rTMS combined with MI through a BCI training platform in VR with NeuRow|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks, and Motor Imagery (MI) treatment through the BCI training paradigm in VR (NeuRow) for 12 non-consecutive sessions (Monday, Wednesday and Friday) in four weeks.
16280174|NCT04815486|Active Comparator|Repetitive TMS in bilateral cortical primary motor area|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks.
16280175|NCT04815473|Other|Patients treated with AndraValvulotome|
16280176|NCT04815460|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
16280177|NCT04815460|Experimental|Ｍoderate intensity-continuous (MCT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
16280178|NCT04815460|No Intervention|Control group|Without any exercise training
16280179|NCT04815447||CCS group|Patients under 25 were recruited in the pediatric CPET laboratory of Montpellier University Hospital after a regular paediatric cardiology outpatient visit.
16280180|NCT04815447||Control|The control group consisted in children referred for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certificate. These children were classified in the control group only after a completely normal check-up, including physical examination, electrocardiogram, echocardiography, and spirometry.
16280181|NCT04815434||Adults with disabilities and complex health conditions|Interviews, experience of the mouth and oral health and function
16280182|NCT04815421|Experimental|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The therapy duration was 6 days.
16280183|NCT04815421|Experimental|the meridian group|Patients in the meridian group were treated with dredging the same side Hand yang meridian techniques
16280184|NCT04815408|Experimental|NIC|"Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)
~Interval debulking surgery and HIPEC
~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
16280185|NCT04815408|Active Comparator|NC|"Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)
~Interval debulking surgery and HIPEC
~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
16280186|NCT04815395|Experimental|Oral Oxytocin|Oxytocin (24IU) orally
16280187|NCT04815395|Experimental|Intranasal Oxytocin|Oxytocin (24IU) intranasally
16280188|NCT04815395|Placebo Comparator|Oral Placebo|Placebo orally
16280189|NCT04815382|Experimental|Dynamic Upper Limb Orthosis group|"The dynamic upper limb orthosis group will receive a treatment based on the use of a dynamic upper limb orthosis.
~Participants of this group will continue to receive their regular therapy"
16280190|NCT04815382|No Intervention|Control group|The control group will not receive any type of intervention Participants of this group will continue to receive their regular therapy
16280191|NCT04815369||Guidance Clinical Pathway|Facilities will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification to a central point person within the Nursing Home (NH) facility
16280192|NCT04815369||Traditional Clinical Pathway|Facilities will employ their current standard clinical care practices for suspected UTI, including SUC, UA, and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
16280195|NCT04815343|Experimental|Bilateral users|two implant systemswith two sound processors
16280196|NCT04815343|Experimental|Bimodal user|with one sound processor and one hearing aid
16280197|NCT04815330||Patient dyspnea under veno-arterial extracorporeal circulation|"Relief of dyspnea will be carried out by the clinician in charge of the patient. He will have complete control of his behaviour. He will carry out this test according to the practices in force in the department.
~If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
~In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved."
16280226|NCT04815148|Experimental|Phase Ib-2: MH004 (3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
16280227|NCT04815135||2020 group (COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the lockdown period due to the COVID19 pandemic
16280258|NCT04814875|Experimental|Part 1 - ACD (Safety)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
16280198|NCT04815317|Active Comparator|Basal|"The impact of these stimulations will be compared to that of a control stimulus.
~The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.
~The sensitive control condition will be achieved by administering fresh air on the calf.
~An pressure support (+5) increment will be performed to ensure comparability of subsequent experimental sequences and their effect on dyspnea."
16280199|NCT04815317|Experimental|Intervention|"Patients will be subjected to sensory stimuli that may be auditory or sensitive.
~The sensory stimulations will be administered by a research nurse. The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).
~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.
~Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes."
16280200|NCT04815291|Experimental|Device|Receives SCOUT at biopsy
16280201|NCT04815278|Experimental|Control Group|Participants will receive usual DSS employment services that include, but are not limited to, consultation with an employments specialist, resume writing guidance, educational classes and attendance at job fairs. Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
16280202|NCT04815278|Experimental|Employer Intervention Only|Participants will receive usual DSS employment services and an employer level workplace equity, job & health supports intervention. The employer intervention will include an implicit bias workshop and supervisor support training in addition to regular supervisor check-ins every other week.
16280203|NCT04815278|Experimental|CDPP Only|Participants will receive the individual level CDPP intervention and no employer intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions. Content for the program will include healthy lifestyle habits, managing stress and staying motivated.
16280204|NCT04815278|Experimental|CDPP and Employer Intervention|Participants will receive the individual level CDPP intervention and employer level workplace equity, job & health supports intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions and check-ins. Content for the program will include healthy lifestyle habits, managing stress and staying motivated. The employer intervention will include an implicit bias workshop and supervisor support training, in addition to regular supervisor check-ins every other week..
16280205|NCT04815265|Experimental|Experimental group|Participants in the experimental group received remimazolam for sedation
16280206|NCT04815265|Active Comparator|Control group|participants in the control group received dexmedetomidine for sedation
16280207|NCT04815252|Experimental|CHIME Intervention|Participants will complete an 8-week compassion and mindfulness-based intervention with a group facilitator. The curriculum focuses on providing mindfulness-based stress reduction techniques for use in the early childhood education environment.
16280208|NCT04815252|No Intervention|Waitlist control|Participants are placed on a wait-list to receive the intervention.
16280209|NCT04815239|Active Comparator|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) for at-risk offspring includes 8 sessions over 6 months delivered via secure telemedicine platform. The basis of the intervention is the treatment manual iteratively developed and tested in close consultation with content experts during our open pilot study and R34.The intervention focuses on education about BP risk, stabilizing sleep and daily routines and interpersonal relationships.
16280210|NCT04815239|Active Comparator|Healthy Lifestyle Intervention (HL)|HL is based on the treatment manual developed in a prior trial for adults and adolescents with BP. HL includes psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health. In HL, patients are taught to develop and maintain an individualized lifestyle plan and provided support and encouragement for making progress toward their goals. HL clinicians will deliver 8 sessions over 6 months via secure telehealth platform.
16280211|NCT04815226|Other|Using Peristeen Transanal Irrigation|All participants in the trial will use Peristeen Transanal Irrigation. Eligible volunteers will be those patients who have failed conventional supportive bowel care, have neurogenic bladder, and use CIC (ClC: Clean Intermittent Catheterization) daily.
16280212|NCT04815213|Experimental|Arm 1|Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
16280213|NCT04815200|Other|Nickel titanium NiTi arch wire (Gold Standard, control group)|Patient will receive 0.014 round Nickel titanium NiTi archwire and will be ligated using a ligature wire with Follow up for 2 months.
16280214|NCT04815187|Experimental|Montelukast 10 mg|Subjects will be instructed to take one pill at night for 90 days
16280215|NCT04815187|Placebo Comparator|Placebo|Subjects will be instructed to take one pill at night for 90 days
16280216|NCT04815161|Other|Pilloxa pillbox|Patients receiving the Pilloxa pillbox for drug administration
16280217|NCT04815148|Experimental|Phase Ia: MH004 (0.1%) in healthy volunteers|SAD and MAD
16280218|NCT04815148|Experimental|Phase Ia: MH004 (0.3%) in healthy volunteers|SAD and MAD
16280219|NCT04815148|Experimental|Phase Ia: MH004 (1%) in healthy volunteers|SAD and MAD
16280220|NCT04815148|Experimental|Phase Ia: MH004 (3%) in healthy volunteers|SAD and MAD
16280221|NCT04815148|Experimental|Phase Ib-1: MH004 (0.1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
16280222|NCT04815148|Experimental|Phase Ib-1: MH004 (0.3%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
16280223|NCT04815148|Experimental|Phase Ib-1: MH004 (1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
16280224|NCT04815148|Experimental|Phase Ib-2: MH004 (0.3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
16280225|NCT04815148|Experimental|Phase Ib-2: MH004 (1%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
16280228|NCT04815135||2019 group (pre COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the similar period in 2019
16280229|NCT04815122||Carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity carriers of the Met allele of the COMT Val158Met polymorphism
16280230|NCT04815122||Non-carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity non-carriers of the Met allele of the COMT Val158Met polymorphism
16280231|NCT04815109||critical ill COVID-19|Critically ill COVID-19 patients with need for ventilation and appropriate sedation
16280232|NCT04815096|Experimental|[18F]F-AraG|"Radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
~Trade name: VisAcT"
16280233|NCT04815083|Placebo Comparator|Standard of Care Arm|Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm.
16280234|NCT04815083|Experimental|PD G 506 A + Fluorescence-Guided Resection Arm|Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.
16280235|NCT04815070||Diabetic|A group of diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
16280236|NCT04815070||Non-Diabetic|A group of non-diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
16280237|NCT04815057|Experimental|Education|wellness education
16280238|NCT04815044||Women from the PED-t study|Women who participated in the PED-t study in 2016-2018 who report previous (or in future time) pregnancy.
16280240|NCT04815018||Patients with New Cases of SARS-CoV-2|Newly recruited residents who have been identified as positive through Ohio's Post-Acute Regional Rapid Testing (PARRT) Program will undergo at at least 4 weeks, but no more than 8 weeks, of nasal swab and exhaled breathe particles specimen collection for Covid testing. Previously enrolled residents will submit weekly collections of nasal swab specimens and exhaled breathe particles once they exhibit respiratory-related symptoms, or once a test is ordered by the provider for suspicion of exposure. Collection will continue until these subjects fulfill their 8 weeks of testing.
16280241|NCT04815018||Patients without SARS-CoV-2|This cohort will consist of previously enrolled residents who submitted nasal swabs and exhaled breathe particles for Covid testing once a week for 8 weeks. The patients will have been identified as negative for a SARS-CoV-2 infection each week.
16280242|NCT04815005||HoFH|Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.
16280243|NCT04814992|Active Comparator|Computer-Assisted Preoperative CBT Intervention|"Patients will receive the computer-assisted preoperative CBT intervention (n=75). A particularly promising internet-based CBT pain program for the population of interest, PAINTrainer, demonstrated improved pain, function, coping and global health in patients with chronic knee arthritic pain in comparison to an internet education control, with benefits persisting for up to 52 weeks. In addition to the PAINTrainer, there will be an integration of a motivational interviewing (MI) intervention delivered by a trained coach across the sessions about (1) the benefits of opioid tapering for post-operative pain control, (2) approaches for safely tapering, (3) identifying and managing withdrawal symptoms patients may experience."
16280244|NCT04814992|No Intervention|Treatment-as-usual (control)|Patients scheduled to undergo total joint arthroplasty at the study site are automatically enrolled in a mandatory 4-hour education class delivered by a nurse educator or physical therapist. Utilizing an in-person Powerpoint presentation format, patients are informed about pre-habilitation exercises to do prior to surgery; what to expect the day of surgery; the multimodal analgesia protocol used in the perioperative period; options for anesthesia and analgesia; and the expectation of physical therapy after surgery.
16280245|NCT04814979|Experimental|Experimental Group|Low-intensity pulsed ultrasound along with routine physical therapy
16280246|NCT04814979|Active Comparator|Control Group|Routine physical therapy alone
16280247|NCT04814953||Basal cell carinoma patients|Patients with basal cell carcinoma in history (up to 10 years before inclusion) with or without squamous cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
16280248|NCT04814953||Squamous cell carcinoma patients|Patients with squamous cell carcinoma in history (up to 10 years before inclusion) with or without basal cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
16280249|NCT04814953||Patients with actinic keratoses|Patients with actinic keratosis in history (up to 10 years before inclusion) with or without basal cell carcinoma or squamous cell carcinomas but no other skin cancers (melanoma or non-melanoma skin cancer)
16280250|NCT04814927|Active Comparator|Copper IUD|The copper IUD contains approximately 176 mg of copper wire wrapped around a vertical stem. It is FDA approved for pregnancy prevention for 10 years.
16280251|NCT04814927|Active Comparator|Etonogestrel Implant|The ETG implant is a single, radiopaque, rod shaped implant containing 68 mg of etonogestrel. It is FDA approved for pregnancy prevention for 3 years.
16280252|NCT04814927|Active Comparator|Levonorgestrel IUS|The LNG IUS contains approximately 52 mg. of LNG. It is FDA approved for pregnancy prevention for 5 - 6 years.
16280253|NCT04814927|Active Comparator|DMPA Sub-cutaneous|DMPA contains 104 mg of medroxyprogesterone acetate in 0.65 mL of fluid, administered by subcutaneous injection in the abdominal fat, thigh or skin over the deltoid muscle. It is FDA approved for pregnancy prevention for 14 weeks.
16280254|NCT04814914||KB109 + Self Supportive Care (SSC)|
16280255|NCT04814914||Self Supportive Care (SSC) Alone|
16280256|NCT04814901|Experimental|Study group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae using FAMM and assessment of success regarding patient satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection.
16280257|NCT04814901|Active Comparator|Comparator group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae and its effect on patient's satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection
16280259|NCT04814875|Experimental|Part 2 - ACD (Efficacy)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
16280260|NCT04814836|Other|Group I|Total-etch mode with 35% phosphoric acid
16280261|NCT04814836|Other|Group II|Selective-etch mode with 35% phosphoric acid
16280262|NCT04814836|Other|Group III|Total-etch mode with laser (Er,Cr:YSGG)
16280263|NCT04814836|Other|Group IV|Selective-etch mode with laser (Er,Cr:YSGG)
16280264|NCT04814836|Other|Group V|Self-etch mode
16280265|NCT04814823||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
16280266|NCT04814797||"CF children with gas trapping"|"CF children with gas trapping will be defined by a ratio between the difference of functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of >10%"
16280267|NCT04814797||"CF children without gas trapping"|"CF children without gas trapping will be defined by a ratio between the difference of the functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of ≤10%"
16280268|NCT04814771|Experimental|[14C] TS-142|Participants will receive oral [14C] TS-142 under fasted conditions
16280269|NCT04814745|Active Comparator|morphine|morphine 150 mcg will be administered intrathecally before surgery by using a 25 Gauge with acre spinal needle
16280270|NCT04814745|Active Comparator|tramadol|tramadol 400 mg will be administered by using an elastomeric pump for 24 hours after surgery
16280271|NCT04814745|Active Comparator|ropivacaine|at the end of surgery transversus abdominis plane block will be performed bilaterally and ropivacaine 80 mg will be used
16280272|NCT04814719|Experimental|Pentosan Polysulfate Sodium|Pentosan Polysulfate Sodium (PPS) at Dose and frequency selected in Stage 1 of Parent Study for 6 weeks
16280273|NCT04814719|Placebo Comparator|Placebo|Placebo for 6 weeks
16280274|NCT04814706||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
16280275|NCT04814693|Experimental|Interventional arm|Subjects randomized to the control device arm will undergo treatment with the EndoRotor System, which is a powered debridement tool intended for use in endoscopic procedures to resect and remove necrotic debris during direct endoscopic necrosectomy (DEN) for walled-off necrosis. The system consists of capital components including a power console, roll stand, vacuum pump, and foot control; as well as disposable components including a single-use catheter, purge kit, and suction bag. The EndoRotor System has CE-Mark 613797 and is cleared for use by the FDA in the United States.
16280276|NCT04814693|Active Comparator|Control arm|Subjects randomized to the control device arm will undergo conventional DEN as per the standard of care. Investigators will choose conventional DEN instruments according to their preference.
16280277|NCT04814654|Experimental|CHALO! 2.0|MSM randomized to this arm will receive twice weekly digital media messages for 12 weeks about HIV, HIV-testing, prevention, and treatment. Digital contents and components will target SEM/IMB domains. Digital media will combine text messages, infographics, and brief animated videos (<30 seconds), with each message containing a link to a study-specific webpage listing testing resources and MSM-specific services offered by HST. Participants will also be able to interact with online outreach workers.
16280278|NCT04814654|Active Comparator|Attention-matched control (AMC)|MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health. Digital media will contain a link to a study-specific webpage listing testing resources and MSM-specific services offered by HST. Participants will also be able to interact with online outreach workers.
16280279|NCT04814654|Active Comparator|Digital coupon only control (DCO)|MSM randomized to the DCO arm will receive, at study entry, a digital coupon for free HIV testing and a resource webpage link.
16280280|NCT04814641||Infants with hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, with hypophosphatemia in the first 5th days
16280281|NCT04814641||Infants without hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, without hypophosphatemia
16280283|NCT04814615|Experimental|CD38-positive multiple myeloma|Patients with CD38 positive multiple myeloma with be enrolled. Patients will undergo pretreatment evaluation with standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Patients will then undergo a course of standard of care therapy as defined by a medical oncologist. Following therapy, patients will repeat standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Data analysis will be performed to evaluate 89Zr-daratumumab against standard of care diagnostic tests for the detection and localization of active disease before and after therapy.
16280284|NCT04814602|Active Comparator|Control|Healthy controls Proglumide 400 mg given once by mouth
16280285|NCT04814602|Experimental|Hepatic Impaired|Cirrhosis Child-Pugh A and B Proglumide 400 mg given once by mouth
16280286|NCT04814589|Experimental|ezetimibe Tablets|ezetimibe tablets test formulation at a single dose of 10 mg
16280287|NCT04814589|Active Comparator|ezetimibe tablets(Ezetrol ®)|ezetimibe tablets reference formulation at a single dose of 10 mg
16280288|NCT04814576|Experimental|Group 1|Collaborative nursing care
16280289|NCT04814576|No Intervention|Group 2|Traditional nusing care
16280290|NCT04814537|Experimental|Dural Puncture Epidural Technique|Laboring women receiving the Dural Puncture Epidural (DPE) Technique with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
16280368|NCT04813991|Active Comparator|Arm 2 - Oxycodone Breakthrough|5 mg of Oxycodone for breakthrough pain.
16280369|NCT04813978|No Intervention|Group B (control)|Head phone will be placed and music will not be played, will get normal nursing care
16280291|NCT04814537|Active Comparator|Epidural Technique|Laboring women receiving the Conventional Epidural Technique (EPL) with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
16280292|NCT04814524|Experimental|Group 1 (VR, Fitbit)|Beginning postoperative day 0, patients use VR daily over 30 minutes every 3 hours, and wear Fitbit daily with a goal of 2,000 steps until the day of discharge, or until 14 days after surgery.
16280293|NCT04814524|Experimental|Group 2 (VR)|Beginning postoperative day 0, patients use VR daily over 30 minutes every 3 hours until the day of discharge or until 14 days after surgery.
16280294|NCT04814524|Experimental|Group 3 (Fitbit)|Beginning postoperative day 0, patients wear Fitbit daily with a goal of 2,000 steps until the day of discharge or until 14 days after surgery.
16280295|NCT04814524|Active Comparator|Group 4 (questionnaire)|Patients do not use VR or wear Fitbit.
16280296|NCT04814511|Other|Standard therapy with InfectoScab 5 % Creme|
16280297|NCT04814511|Experimental|Escalated therapy with InfectoScab 5 % Creme (arm E5)|
16280298|NCT04814511|Experimental|Escalated therapy with Permethrin 10 % Creme (arm E10)|
16280299|NCT04814511|Experimental|Escalated therapy with InfectoScab 5 % Creme in combination with Driponin 3 mg Tabletten (arm EK)|
16280300|NCT04814498|Experimental|Geneva cocktail (less fexofenadine) & BLD-0409|Following an overnight fast of at least 10 hours, subjects will be administered IP in a fixed sequence.
16280301|NCT04814485|Experimental|SHR-1020 combined with albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel
16280304|NCT04814459|Experimental|HOP-UP-PT Program|HOP-UP-PT Program group will participate in the 7-month HOP-UP-PT program
16280305|NCT04814459|No Intervention|Normal Level of Activity|Normal Level of Activity group will be instructed to continue their normal level of activity throughout the 7-months after which they will be offered the opportunity to receive the HOP-UP-PT program
16280306|NCT04814446|Experimental|Gardasil 9®|Nonavalent HPV vaccine
16280307|NCT04814446|Placebo Comparator|Placebo|NaCl 0.9 % solution for injection
16280308|NCT04814433|Experimental|Topical lidocaine and bupivacaine alone|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
16280309|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
16280310|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and tranexamic acid|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
16280311|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and aminocaproic acid;|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid
16280312|NCT04814420|Experimental|Experimental group|The group will include 15 patients with OSA 5 with mild OSA 5 with moderate OSA 5 with severe OSA
16280313|NCT04814420|Other|Control group|This group will include 5 patients with no OSA
16280314|NCT04814407||Lung cancer patients|Patients age over 20, with suspected or confirmed diagnosis of lung cancer.
16280315|NCT04814407||Indeterminate subjects|Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
16280316|NCT04814407||Control subjects|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
16280317|NCT04814381|Experimental|Ketamine + Magnesium|patients in the experimental group will receive 0.5mg/kg of ketamine over 2 hours, diluted in 50cc of NaCl 0.9% and 3g of magnesium sulfate over 30 minutes diluted in 250cc of NaCl 0.9%.
16280318|NCT04814381|Active Comparator|Control|patients in the control group will receive 25mg of hydroxyzine over 2 hours, diluted in 50cc of NaCl 0.9% and 250cc of NaCl 0.9% over 30 minutes
16280323|NCT04814355|Experimental|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
16280324|NCT04814329||effective group|After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
16280325|NCT04814329||stable group|After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
16280326|NCT04814329||Early progressed group|After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
16280327|NCT04814316||Study group|Patients with gastroesophageal reflux or gastroesophageal reflux disease who will use lansoprazole.
16280328|NCT04814316||Control group|Healty volunteers who will not use lansoprazole.
16280329|NCT04814303|Active Comparator|ITM|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added.
16280330|NCT04814303|Active Comparator|ACB|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, the short-bevel echogenic needle is advanced in-plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in this group received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
16280331|NCT04814303|Active Comparator|PAI|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. PAI intra-operatively will be performed with 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone.
16280332|NCT04814290||living liver donors|cases already underwent hepatectomy for living-donor liver transplantation.
16280333|NCT04814290||matched controls|healthy persons who attended the preoperative clinic while preparing for donation but were rejected because of an ABO blood group mismatch.
16280334|NCT04814277||MRI Data Collection|A group of 34 subjects will be scanned on a 3Tesla (3T) and on a 7T MRI scanner. The images will be compared.
16280337|NCT04814238||mini-David|
16280338|NCT04814238||mini-Yacoub|
16280339|NCT04814238||mini-Bentall|
16280340|NCT04814225|Experimental|Pea Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
16280341|NCT04814225|Experimental|Pea & Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
16280342|NCT04814225|Experimental|Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
16280343|NCT04814225|Active Comparator|Whey Protein Isolate|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
16280344|NCT04814212|Experimental|Drug-coated balloon (DCB)|The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
16280345|NCT04814212|Active Comparator|Drug-eluting stent (DES)|The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
16280346|NCT04814199||Patients using epidural management algorithm|Patients will be educated and given an algorithm to follow while in labour and after having an epidural catheter placed.
16280347|NCT04814186|Experimental|Chinese participants treated with Tafamidis|treatment group with tafamidis
16280348|NCT04814173|Experimental|One jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a one-jaw mechanic (mini-implants in the maxillary arch).
16280349|NCT04814173|Experimental|Two-jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a two-jaw mechanic (mini-implants in the mandibular arch with class II elastics).
16280350|NCT04814173|Experimental|Traditional treatment|traditional en-mass retraction with first premolars extraction with mini-implants in the maxillary arch.
16280351|NCT04814160|Active Comparator|autogenous bone graft|autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
16280352|NCT04814160|Experimental|mix of bioactive glass and autogenous bone graft|1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
16280353|NCT04814134|Experimental|CPNS Therapy|Treatment with CPNS system: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
16280354|NCT04814134|Other|Standard of Care|Available standard treatment
16280355|NCT04814121|Experimental|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
16280356|NCT04814121|Placebo Comparator|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
16280357|NCT04814108|Experimental|ZN-c3 Single Agent|
16280358|NCT04814095|Experimental|Targeted therapy|
16280359|NCT04814082|Active Comparator|Medial-Pivot Knee System|Total Knee Arthroplasty will be done by implanting the MicroPort Medial Pivot Knee System into subjects.
16280360|NCT04814082|Active Comparator|Single Radius Design Total Knee System|Total Knee Arthroplasty will be done by implanting the Stryker Triathlon Tritanium Knee System into subjects.
16280361|NCT04814056|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
16280362|NCT04814043|Experimental|PD-1 antibody and lenvatinib plus TACE-HAIC|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
16280363|NCT04814030|Experimental|AIPD-1|Trans hepatic artery infusion of PD-1 antibody, chemoembolization, FOLFOX-based infusion chemotherapy
16280364|NCT04814017|Experimental|Radial shock-wave group|Group I (15 subjects) received radial shock-wave application one times a week for six weeks and home based stretching exercises.
16280365|NCT04814017|Experimental|Control|Group II (15 subjects) received home based stretching exercises for six weeks.
16280366|NCT04814004|Experimental|hCD19.IL15.CAR-iNKT cells|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16280367|NCT04813991|Experimental|Arm 1 - Ibuprofen Breakthrough|600 mg Ibuprofen for breakthrough pain.
16286251|NCT04772287|Placebo Comparator|Placebo|
16280370|NCT04813978|Experimental|Group A (music intervention)|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
16280371|NCT04813965|No Intervention|Control|Participants in the control group received standard information on treatment side-effects.
16280372|NCT04813965|Experimental|Information without self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information group received standard information with additional written information about potential chemotherapy-related cognitive symptoms.
16280373|NCT04813965|Experimental|Information with self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information+SA group (SA=self-affirmation) received standard and additional written information about potential chemotherapy-related cognitive symptoms with a subsequent self-affirmative text.
16280374|NCT04813952|Active Comparator|Group M|Group M is minimal flow anesthesia group with fresh gas flow 0,5 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 0,5 L.min-1 flow under general anesthesia.
16280375|NCT04813952|Active Comparator|Group H|Group H is high flow anesthesia group with fresh gas flow 4 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 4 L.min-1 flow under general anesthesia.
16280376|NCT04813926||Patients diagnosed with PAH|
16280377|NCT04813913|Experimental|bevacizumab|bevacizumab in combination with IV fluoropyrimidine chemotherapy.
16280378|NCT04813900|Experimental|Patient suspected to suffer from interstitial syndrome needing an arterial blood gas analysis|
16280379|NCT04813874||neuraxial analgesia only|Receiving neuraxial analgesia only for labor
16280380|NCT04813874||NO2 and neuraxial analgesia|Receiving nitrous oxide and neuraxial analgesia for labor
16280381|NCT04813848|Experimental|Varnish fluoride|Varnish fluoride to be applied on the surface of exposed dentin
16280382|NCT04813848|Active Comparator|Bonding agent|Bonding agent to be applied on the surface of exposed dentin
16280383|NCT04813835||suicidal depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
16280384|NCT04813835||depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
16280385|NCT04813835||control|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
16280386|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
16280387|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
16280388|NCT04813822|Active Comparator|Gyno-Daktarin® Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
16280389|NCT04813809|Experimental|BARRIER EasyWarm|This is an open, non randomised, single arm study
16280390|NCT04813796|Experimental|mRNA-1283 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1283 at Dose Level 1 on Day 1 and Day 29.
16280391|NCT04813796|Experimental|mRNA-1283 Dose Level 2|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 2 on Day 1 and Day 29.
16280392|NCT04813796|Experimental|mRNA-1283 Dose Level 3|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 3 on Day 1 and Day 29.
16280393|NCT04813796|Experimental|mRNA-1273|Participants will receive 2 IM injections of mRNA-1273 at a pre-specified dose for this study on Day 1 and Day 29.
16280394|NCT04813796|Experimental|Placebo / mRNA-1283|Participants will receive 1 IM injection of study drug-matching placebo on Day 1 and 1 IM injection of mRNA-1283 at a pre-specified dose on Day 29.
16280395|NCT04813783||Control group|The first group of 26 volunteers who meet the inclusion criteria of the study will form the control group. These participants will be given clinical routine training about mucositis care.
16280396|NCT04813783||Intervention Group|In the study, in order to prevent/minimize the flow of information between the control and intervention groups, the data of the control group will be collected first. Data collection will be suspended in the clinic for three months after the control group data is completed. After this period, data of the enterprise group will be collected. Participants in the intervention group will be provided with mucositis training within the scope of the Mucositis Care Protocol in line with the MASCC / ISOO 2019 Recommendations.
16280397|NCT04813770|Experimental|Theory-based messages|Theory-based health messages about COVID-19 and COVID-19 vaccination, the necessity of COVID-19 vaccination to oneself and others, and COVID-19 vaccine regulatory approval processes. These messages are based on publicly available information and are hypothesised to increase perceived necessity and reduce concerns about vaccination, and target known barriers to vaccine uptake.
16280398|NCT04813770|Active Comparator|General messages|General messages about the COVID-19 virus and the vaccination programme. These messages do not target necessity and concerns, but are anticipated to promote understanding of the pandemic.
16280399|NCT04813757|Experimental|intervention group|Participants in the intervention group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy. The exercise program will include 2 scapular and rotator cuff strengthening exercises emphasizing scapular upward rotation and posterior tilt and one additional flexibility exercise. These exercise will be repeated at home on the days in between the therapy sessions.
16280422|NCT04813575|No Intervention|control group|This arm will be control group and will be observed prospectively
16280423|NCT04813562|Experimental|Middle-dose vaccine (18-59 years)|Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
16280424|NCT04813562|Experimental|High-dose vaccine (18-59 years)|Two doses of High-dose vaccine at the schedule of day 0, 28, 56
16280400|NCT04813757|Active Comparator|control group|Participants in the control group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy, posterior shoulder stretching, and mobilization-with-movement into shoulder elevation. The exercise program will include 2 exercises focusing on scapular and rotator cuff strengthening without a special emphasis on scapular upward rotation as well as one additional flexibility exercise. These exercises will be performed at home on the days on between the therapy sessions.
16280401|NCT04813744|Experimental|Investigation of atraumatic restorative treatment in adults with a high risk of caries|The study group included a total of 25 healthy individuals with high caries risk who had molar teeth in their mouth with 3-4 mm depth occlusal dentin caries. In the clinical study, the infected and demineralized dentin was cleaned manually with a sterile excavator. The dentin sample was taken from the last removable and affected dentin layer at the cavity floor by one excavation for microbiological assessment. The teeth were restored with a conventional glass ionomer cement. In the 6th month, restorations were removed by using low-speed round steel bur, and the dentin samples were removed with an excavator from the cavity floor to repeat the microbiological assessment. In the first week and 6th month of atraumatic restorative treatment, the impressions were taken from the restored teeth to prepare replicas. The replicas of the twenty teeth out of 25 were randomly selected to evaluate of marginal adaptation under scanning electron microscopy.
16280402|NCT04813718|Active Comparator|Synbiotic|Omni-Biotic Pro Vi 5
16280403|NCT04813718|Placebo Comparator|Placebo|similar looking and tasting
16280404|NCT04813705|Experimental|Reduced dose group|The patients achieving CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
16280405|NCT04813705|Active Comparator|Conventional dose group|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
16280406|NCT04813679||Neutropenic Enterocolite patients assessed with bed side ultrasound sonography|"From March 2007 through the entire study period all patients admitted eighter in our chemotherapy-ward or BMT-ward to receive intensive chemotherapy (chemo) for any hematological malignancies, or chemotherapy (CHT) for both auto transplant (ASTC) and allogeneic transplant (AlloTx), were prospectively enrolled in the study. When the patient received more than one chemo cycle, each ward access was considered a new observational period.
~Patients who received CHT and experienced CHT-induced neutropenia (CHTNP) were enrolled in the study. We defined one observational period each admission on the ward to receive CHT, in which CHT and length of stay could vary from the previous admission. One observational period ended with the discharge of the pts form the ward. If a pts experienced a new chemo related NECe during another admission, it was considered as e new NECe."
16280407|NCT04813679||Neutropenic Enterocolite negative patients assessed with bed side ultrasound sonography|NEC negative patients received bed-side ultrasound sonography after three days of neutropenia.
16280408|NCT04813666|Active Comparator|TB group|
16280409|NCT04813666|Placebo Comparator|Non TB group|
16280410|NCT04813653|Experimental|cyclosporine in combination with carfilzomib and dexamethasone|cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed multiple myeloma refractory to carfilzomib with high expression of the PPIA gene in myeloma cells
16280411|NCT04813640|Placebo Comparator|Single Vision Spectacles|Commercially available conventional single vision spectacles
16280412|NCT04813640|Active Comparator|Commercially available myopia control spectacles|Commercially available myopia control spectacles
16280413|NCT04813640|Experimental|Novel Myopia control spectacles - Prototype I|Experimental myopia control spectacles
16280414|NCT04813640|Experimental|Novel Myopia control spectacles - Prototype II|Experimental myopia control spectacles
16280415|NCT04813627||Participants with R0 resected Stage II (high risk) or Stage III CRC|The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.
16280416|NCT04813614|Experimental|STYLAGE M Lidocaine|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into and/or around the lip mucosa by linear threading injection, multipoint injection, or a combination of both techniques with needle or cannula.
~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.
~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
16280417|NCT04813614|Active Comparator|Active control group|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into the submucosal layer of the lip by linear threading injection or serial puncture techniques injection with needle or cannula.
~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.
~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
16280418|NCT04813601|Experimental|Robot Asissted Gait Training|The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton and will also have the technical supervision of personnel specialised in the handling of the laboratory and the robotic device.
16280419|NCT04813588|Experimental|Pantomimng|In experimental group pantomiming treatment will be administered
16280420|NCT04813588|Active Comparator|Easy onset|In active comparator group easy onset method will be administered
16280421|NCT04813575|Experimental|Intervention arm|Experimental arm patients will have cryobiopsies for histological analysis of the ongoing pathology
16316181|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
16280425|NCT04813562|Experimental|Middle-dose vaccine (60-85 years)|Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
16280426|NCT04813562|Experimental|High-dose vaccine (60-85 years)|Two doses of High-dose experimental vaccine at the schedule of day 0, 28, 56
16280427|NCT04813562|Placebo Comparator|Middle-dose placebo (18-59 years)|Three doses of middle-dose placebo at the schedule of day 0, 28, 56
16280428|NCT04813562|Placebo Comparator|High-dose placebo (18-59 years)|Two doses of High-dose placebo at the schedule of day 0, 28, 56
16280429|NCT04813562|Placebo Comparator|Middle-dose placebo (60-85 years)|Three doses of middle-dose placebo at the schedule of day 0, 28, 56
16280430|NCT04813562|Placebo Comparator|High-dose placebo (60-85 years)|Two doses of High-dose placebo at the schedule of day 0, 28, 56
16280431|NCT04813549||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of secondary fibromyalgia and its effect on the quality of life, at their admission.
16280432|NCT04813536||nurses in Assiut university hospitals|currently working nurses exposed to shift work
16280433|NCT04813536||control group|currently working nurses not exposed to shift work
16280434|NCT04813523|Experimental|Experimental: Pembrolizumab+Cisplatin+5-FU|Participants receive preoperative pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 600 mg/m^2/day IV infusion on Days 1 to 5. There are 3 cycels of preoprative therapy and 3 cycles of postoperative therapy.
16280435|NCT04813510|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment."
16280436|NCT04813510|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
16280437|NCT04813497|Other|Participants who refuse the SARS-CoV-2 vaccine|Participant who does not wish to be vaccinated against the SARS-CoV-2 virus and who wishes to perform the serological test during the vaccination campaign and the second 12-14 weeks after the first serological test.
16280438|NCT04813497|Other|Participants who received the first dose of SARS-CoV-2 vaccine before the first serological test|Participant who has received his first dose of vaccine and who performs his serological test when he receives the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity. The second serological test will be done 12 to 14 weeks after the second dose of the SARS-CoV-2 vaccine to determine its immunity.
16280439|NCT04813497|Other|Participants who start whit the serological test before SARS-CoV-2 vaccine|Participant who performed the serological test before the first dose of vaccine and 12 to 14 weeks after the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
16280440|NCT04813484|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
16280441|NCT04813471|Experimental|Endothelial Dysfunction Protocol|"Experimental: Endothelial Dysfunction Protocol
~Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin(or home statin), nicorandil, l-arginine, folic acid and vitamin B complex) in critically Ill patients already on optimal medical therapy for the treatment of COVID-19 virus. Protocol will be given for a total of 14 days or until discharge from the hospital
~Patients already on home statin will continue their medication or if the are eligible for statins they will recieve 40 mg tablet to be given PO once daily.
~Nicorandil Nicorandil 10 mg PO BID for the first 7 days and then if no contraindications escalated to 20 mg PO BID for the remaining 7 days
~Folic Acid Folic Acid 5 mg po once daily
~L-Arginine L-Arginine 1 g po TID
~Vitamin B complex (Becozyme) 1 ampoule IV daily"
16280442|NCT04813471|No Intervention|Standard of care|Standard of Care
16280443|NCT04813445|Experimental|Xingnaojing injection|"Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
~Interventions:
~Drug: Xingnaojing injection Other: Standard care"
16280444|NCT04813445|No Intervention|Standard care|"Subjects will receive guidelines-based standard care.
~Interventions:
~Other: Standard care"
16280445|NCT04813419|Active Comparator|right face|The right side of face of subjects
16280446|NCT04813419|Experimental|left face|The left side of face of subjects
16280447|NCT04813406|Experimental|Anlotinib + Sintilimab|
16280448|NCT04813393||Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire Group|The CPHP-Q was administered as a caregiver-report questionnaire. It aims to measure home program adherence of parents of children with CP. Parents applied this instrument in the study.
16280449|NCT04813380|Active Comparator|Sublingual immunotherapy group|one drops under tongue for ten days then three Drops for another ten days then five drops for another ten days for three successive months then five drops every two days per week for two months then five drops one day per week for one months
16280450|NCT04813380|Placebo Comparator|Placebo|one drops under the tongue then three drops then five drops for three successive months then five drops every two days per week for two months then five drops one day per week for one months
16280451|NCT04813367||Twisted fallopian tubes cohort|Description of girls who went through surgery for twisted fallopian tubes
16280452|NCT04813354|Experimental|Sequence arm A: ELLIPTA followed by BREEZHALER/ Questionnaire version 1|
16280453|NCT04813354|Experimental|Sequence arm B: ELLIPTA followed by BREEZHALER/ Questionnaire version 2|
16280454|NCT04813354|Experimental|Sequence arm C: BREEZHALER followed by ELLIPTA/ Questionnaire version 1|
16280455|NCT04813354|Experimental|Sequence arm D: BREEZHALER followed by ELLIPTA/ Questionnaire version 2|
16280456|NCT04813341|Experimental|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles
16280480|NCT04813159|Sham Comparator|Sham-control|Consented STEMI participants presenting < 24 hours who are randomised to the sham protocol will receive low-pressure cuff inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff. The sham control protocol will be repeated daily for the next 2 days.
16280457|NCT04813341|Active Comparator|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week
~SITTING EERCISES:
~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times
~BALANCE EXERCISES:
~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.
~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
16280458|NCT04813315|Experimental|Kendall exercise|Experimental group 1 got this intervention containing Kendall exercise for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
16280459|NCT04813315|Experimental|Gong's mobilization|Experimental group 1 got this intervention containing Gong's mobilization for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
16280460|NCT04813302|Experimental|Gingival recession treatment|Gingival recession treatment by means of a coronally advanced flap and a connective tissue graft
16280461|NCT04813289||Anaesthesia type|"Inhalational anaesthesia without Remifentanil use
~Inhalational anaesthesia with Remifentanil use
~Total intravenous anaesthesia"
16280462|NCT04813289||Blood pressure monitoring|"Intraarterial line use
~Non-invasive blood pressure monitoring"
16280463|NCT04813276|Experimental|Serious game intervention|Participants receive the Strong Together serious game program on a tablet computer.
16280464|NCT04813276|Active Comparator|Enhanced care as usual|Participants receive a paper-based self-advocacy guide.
16280466|NCT04813250|Sham Comparator|Group R|IMV(intermittent mandatory ventilation) Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight)
16280467|NCT04813250|Experimental|Group RP|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O
16280468|NCT04813250|Experimental|Group RI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + Reverse IE ratio ventilation( I:E=1:1)
16280469|NCT04813250|Experimental|Group RPI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O + Reverse IE ratio ventilation( I:E=1:1)
16280470|NCT04813224|Experimental|TRAUMA CENTERED EMDR-BASED TREATMENT|"Phase 1) Client history before session 1 Phase 2) Preparation for the treatment of the traumatic event, with psycho education and regulation strategies.
~Phases 3 to 6) Gives the sense of Safety (safe place, past resource, desired future-PC, timeline) control structure, order, differentiation of past & present (move concretely between past danger to present safety) EMD strategy gives containment boundaries to current T-Episode.
~Phase 7) Session closure A group debriefing of the experience will take place, and some of the stabilization exercises Phase 8) Re-Evaluation This phase will take place immediately after the group intervention. It assesses which participants may need individual attention and which may need further evaluation to identify the nature and extent of their symptoms."
16280471|NCT04813224|Active Comparator|TRAUMA-FOCUSED CBT-BASED TREATMENT|TF-CBT is an evidence-based therapeutic approach to improve symptoms of PTSD as well as affective or cognitive and behavioral problems. The treatment will consist of three phases that will include: Psychoeducation, Relaxation-Mindfulness, Emotional regulation skills, Cognitive coping skills, Narration and processing of trauma, Exposure / Desensitization of memories of the trauma, Self-esteem and future goals. The treatment is composed by 3 phases: 1) Phase 1: TF-CBT Coping Skills for Complex Traumas. Phase 2: Narration of trauma and processing of complicated trauma. Phase 3: Consolidation and closure of the treatment. Each case is delivered to the participants in a maximum of 3 sessions per phase.
16280472|NCT04813211|Experimental|Trial group|20 patients with cervical spondylosis undergoing mobile artificial cervical vertebrae replacement
16280473|NCT04813211|Experimental|Control group|20 patients with cervical spondylosis undergoing anterior cervical corpectomy and fusion
16280474|NCT04813198|Active Comparator|TIPSTART|Following baseline testing, the study orientation and randomization, the TIPSTART group will engage in 5.5 hours (30 minutes, on 11 separate occasions, over 10 weeks) of training delivered through Zoom and supported by instructional and communication apps, and that is further supervised by our TIPSTART study navigators who will provide motivational support and detailed lifestyle behavioral prescriptions (150 to 300 minutes per week of aerobic and strength training, with mental practice of material discussed each week). Participants will also be asked to complete approximately 3 total hours of repeated testing that occurs online via surveys and face-to-face interviews for the 12-week study.
16280475|NCT04813198|No Intervention|Wait-list Control|Following baseline testing, the study orientation and randomization, the wait-list control group will be asked to continue living life as usual until their delayed TIPSTART program is initiated. Participants will be asked to complete repeated online surveys and face-to-face interviews during the first 12 weeks, concurrently, with participants assigned to the TIPSTART intervention.
16280476|NCT04813185|No Intervention|Treatment as usual|Adults who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
16280477|NCT04813185|Experimental|In-hospital intervention|Adults randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 6-months of community case management and a firearm counseling program.
16280478|NCT04813172|Experimental|Head and neck cancer patients|Patients from the Eye and Ear Institute Survivorship Clinic who are diagnosed with head and neck cancer.
16280479|NCT04813159|Active Comparator|Remote Ischaemic Conditioning (RIC)|Consented STEMI participants presenting < 24 hours who are randomised to the RIC protocol, will receive blood pressure cuff inflation by the automated RIC blood pressure device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
16280546|NCT04812730|Other|Control group|Asymptomatic adults not suffering from a spinal deformity
16280481|NCT04813159|No Intervention|Observational|Consented STEMI participants presenting > 24 hours but within 72 hours of MI onset will be recruited into the observational arm of the study which will have the same study endpoints as the RCT. These participants will not be randomised or receive any trial intervention.
16280482|NCT04813146|Experimental|Synchronized Lifestyle Modification Program (SLP)|Synchronized Lifestyle Modification Program ( Synchronization of dietary intake with the natural circadian rhythm of the body)
16280483|NCT04813146|Experimental|Synchronized Lifestyle Modification Program along with Physiotherapy|Synchronized Lifestyle Modification Program along with Physiotherapy (Synchronization of dietary intake and Physiotherapy including aerobic, resistance, flexibility and balance exercises)
16280484|NCT04813146|Experimental|Physiotherapy|Physiotherapy (aerobics, resistance, flexibility and balance exercises)
16280485|NCT04813146|No Intervention|Control Group|No Intervention will be given to this group ( conventional medicine will be given to these patient )
16280486|NCT04813133|Experimental|Synchronized Lifestyle Modification Program|Synchronized Lifestyle Modification Program
16280487|NCT04813133|Experimental|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronized Lifestyle Modification Program and Physiotherapy
16280488|NCT04813133|Experimental|Physiotherapy|Physiotherapy included Aerobics, Resistance exercise, Flexibility exercise, and Balance exercise.
16280489|NCT04813133|No Intervention|Control Group|No intervention will be given to this Group
16280490|NCT04813120|Experimental|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
16280491|NCT04813120|Experimental|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
16280492|NCT04813120|Experimental|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
16280493|NCT04813120|Active Comparator|Traditional MT using a mirror box|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
16280494|NCT04813107|Active Comparator|APL-1202 in combination with tislelizumab|
16280495|NCT04813107|Placebo Comparator|Tislelizumab alone|
16280496|NCT04813094|Experimental|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Participants will have their own account and passwords to log in to the system via mobile phones or computers. Everyone will have their own area to ensure the privacy of participants. The research nurse will have sent messages every day to care about the participant's condition.
16280497|NCT04813094|Active Comparator|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
16280498|NCT04813081|Active Comparator|Free gingival graft around dental implant patients|Test Group (TG) consists of patients have free gingival graft around dental implant patients
16280499|NCT04813081|Active Comparator|Free gingival graft around the teeth|Control Group (CG) consists of patients have free gingival graft around the teeth.
16280500|NCT04813068||Interview arm|Group of patients who have agreed to have a qualitative interview on the topic of recurrence of lung cancer
16280501|NCT04813055||Therapeutic EUS|Procedures involving Linear Echoendoscopes to create a communication between the gastrointestinal tract and a target organ (biliary tree, pancreatic duct, fluid collection, gallbladder, downstream gastrointestinal tract) through plastic or metal stents.
16280502|NCT04813055||Controls|Patients eligible for T-EUS procedures, but undergoing alternative surgical interventions, percutaneous interventions (e.g. Percutaneous Biliary Drainage) or non-EUS based endoscopic procedures (e.g. enteral stenting)
16280503|NCT04813042|Experimental|Working Out Dads|Fathers allocated to the Working Out Dads (WOD) arm will receive the intervention program. WOD is a 6-week manualised program. The weekly 90 minute sessions combine a one hour facilitated discussion by a male facilitator trained in delivery of WOD and a 30-minute gym workout provided by a personal trainer. The group size ranges from 6-10 fathers, with 14 groups running over the study period. The weekly sessions are provided in the evenings, in local gyms or a community setting (e.g., maternal child health centre, local council rooms, local hall, local park, Tweddle Child & Family Health Service).
16280504|NCT04813042|Active Comparator|Usual Care|Fathers allocated to the Usual Care arm will receive the clinical care typically provided to parents experiencing mental health difficulties by an Early Parenting Centre or community health service. Within 2 weeks of baseline assessment, Usual Care participants will receive a brief psychological consultation from Tweddle's Clinical Manager.
16280505|NCT04813029|Experimental|Straight Leg Raise|Patients perform straight leg raise maneuver at the end of High-resolution Manometry test
16280506|NCT04813016|Active Comparator|Early tramal/bupivacaine|patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of the first two trocars before starting the surgery.
16280507|NCT04813016|Active Comparator|Late tramal/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
16280508|NCT04813016|Active Comparator|Early dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% before creation of a pneumoperitoneum and placement of the first two trocars before the start of surgery.
16280509|NCT04813016|Active Comparator|Late dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
16280547|NCT04812717|Active Comparator|CytoSorb-Yes|Heart failure patients that will receive intraoperative treatment with CytoSorb.
16280510|NCT04813003||Surgery group (group 1)|5 adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery will undergo functional imaging and neurobehavioural tasks before and six months after bariatric surgery.
16280511|NCT04813003||Control group (group 2)|5 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age-, sex- and education will serve as a control group and undergo the same experiment on a single occasion.
16280512|NCT04812990||hepatitis c patients|50 patients will be recruited for study group from consecutive patients previously diagnosed by hepatitis C regardless of the etiology of the condition and regularly attending at Soad Kafay hospital. Participants with history of smoking and alcoholism that could affect their oral health status were excluded.
16280513|NCT04812990||clinically healthy patients|populations will be randomly recruited from the out-patient of dental diagnosis clinic in Misr University For science & technology university to include total 50 clinically healthy participants, with no history of liver disease, or any other chronic debilitating illness, or habit of smoking or drinking, , as well as history of an intervention or condition that could affect the oral mucosa (e.g., history of radiotherapy and/or not receiving any medication that could affect oral health.
16280514|NCT04812977|Experimental|Group A|A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
16280515|NCT04812977|Active Comparator|Group B|Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
16280516|NCT04812964|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
16280517|NCT04812964|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
16280518|NCT04812951|No Intervention|young control|25 patients < 65 years old without any prophylactic anti-inflammatory preoperative treatment
16280519|NCT04812951|No Intervention|control|25 patients > 75 years old without any prophylactic anti-inflammatory preoperative treatment
16280520|NCT04812951|Experimental|Study group|25 patients > 75 years old with prophylactic anti-inflammatory preoperative treatment
16280521|NCT04812951|Active Comparator|Vehicle group|25 patients > 75 years old with vehicle preoperative treatment
16280522|NCT04812925|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
16280523|NCT04812912||Participants with Colon Cancer|This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis
16280524|NCT04812912||Participants with Rectal Cancer|This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis
16280525|NCT04812899|Experimental|Parents who have a child/adolescent with an eating disorder on waitlist|"Each participant will receive a series of pre-recorded videos and book -(10 videos of about 10 minutes each, along with the book Help Your Teenager Beat an Eating Disorder). This will include content on empowering parents to renourish their child and interrupt binge/purge behaviors."
16280526|NCT04812886|Experimental|Epidemiological study|
16280527|NCT04812860|Experimental|HR18042 100mg|
16280528|NCT04812860|Experimental|HR18042 125mg|
16280529|NCT04812860|Experimental|HR18042 200mg|
16280530|NCT04812860|Active Comparator|Tramadol hydrochloride ER 100mg|
16280531|NCT04812860|Placebo Comparator|Placebo to match HR18042 and Tramadol hydrochloride ER|
16280532|NCT04812847||Gram negative infection, MDR present|Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
16280533|NCT04812847||Gram negative infection, MDR absent|Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
16280535|NCT04812795|Experimental|Culturally tailored|The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.
16280536|NCT04812795|Active Comparator|Non-culturally tailored|The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.
16280537|NCT04812782|Experimental|EVOO-Butter|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with EVOO and the second with butter.
16280538|NCT04812782|Experimental|Butter-EVOO|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with Butter and the second with EVOO
16280539|NCT04812769|Experimental|Intervention|Two nursing homes will receive the eCARE-ID intervention
16280540|NCT04812769|Placebo Comparator|Control|One control nursing home will receive infectious disease consultations and antibiotic stewardship services per routine practice.
16280541|NCT04812756|Experimental|Texting intervention|This is a single arm study in which all participants received a pedometer and text messages for the 12 week intervention period. Participants received a content message and a message requesting them to report the number of steps from their pedometer daily.
16280542|NCT04812743|Experimental|Colorectal Health Research Champion trainees|Colorectal Health Research Champion (CHRC) trainees receive 5 education sessions on colorectal cancer, clinical research, biospecimen donation, ethics, and presentation skills. The CHRCs will invite others in their social networks to present to them this educational information, following the train the trainer model of health education.
16280543|NCT04812730|Other|ASD with decompensated sagittal misalignment|Adults suffering from a spinal deformity with a decompensated sagittal misalignment
16280544|NCT04812730|Other|ASD with compensated sagittal misalignment|Adults suffering from a spinal deformity with a compensated sagittal misalignment
16280545|NCT04812730|Other|ASD without sagittal misalignment|Adults suffering from a spinal deformity without a sagittal misalignment
16280548|NCT04812717|No Intervention|CytoSorb-No|Heart failure patients that will not receive intraoperative treatment with CytoSorb.
16280549|NCT04812704|Experimental|Nutritional complement|"A prospective study will be carried out including adult patients with neoplasia who should benefit in their therapeutic strategy from oncological surgery. About fifty patients will be recruited in the oncology / surgery department at the Saint-Luc University Clinics in Brussels. Patients will be assessed at the initial consultation and after the pre-habilitation period, ie the day before the operation.
~Dietary monitoring will be carried out in parallel with a physical and respiratory preparation program (prehabilitation) and the intake of protein nutritional supplements in the form of powder to be diluted will be carried out after each exercise session."
16280550|NCT04812691|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in 1 x 10^8 CAR+T cells dose level
16280551|NCT04812678|Active Comparator|Physiotherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines"
16280552|NCT04812678|Experimental|Physiotherapy and Fasciatherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines, associated with Fasciatherapy Danis Bois Method"
16280553|NCT04812678|Experimental|Fasciatherapy|Fasciatherapy Danis Bois Method
16280554|NCT04812665||Qualitative sub-study (SS1)|One group of caregivers (n = 10) will engage with the mHealth solution during 1 month. Subsequently, an individual semi-structured interview with each of the participants will proceed to gather user experience qualitative information.
16280555|NCT04812665||Quantitative sub-study (SS2)|A different group of caregivers (n = 55) will engage with the mHealth solution during 3 months. As elaborated in the following sections, a quantitative approach will be adopted to assess different emotional and behavioral parameters before and after engaging with the mHealth solution (pre-post design).
16280556|NCT04812652|Experimental|Intervention group: Digitally distributed yoga|"Type of yoga: Physical yoga sequences that through scientific evaluation have proven to be effective and relevant for the target group. There will be 3 different programs during the 10-week-intervention Dose: twice weekly for 10 weeks; one yoga class live broadcasted and digitally distributed to the patient's computer or mobile device, and one class pre-recorded video for self-training.
~Sequences: The yoga class will be 60 minutes including 10 minutes of final relaxation. Thereafter, a 5 minutes reflection will be offered.
~Home Training: Instructions for yoga home practice will be standardized. The three yoga programs will be distributed in video-links for the participants to view at a time-point that suits them during the week. The recommendation will be to yoga at home once a week in addition to the digital yoga class in real time.
~Participants are expected to use their own computer or mobile device."
16280557|NCT04812652|No Intervention|Control group: Regulare care|Receive regular care, including written standardized information about the importance of physical activity by their contact nurse or physiotherapist, when discharged from the hospital accordingly to the routines at the clinic.
16280558|NCT04812639|Experimental|buccal infiltartion technique|
16280559|NCT04812639|Active Comparator|Inferior alveolar nerve block technique|
16280560|NCT04812626|Experimental|Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;|Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
16280561|NCT04812626|Experimental|Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination|"Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU.
~Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks."
16280562|NCT04812613|Other|Phase 2 Intervention|This study will utilize a mixed methods CBPAR approach. A peer-driven recruitment strategy will be implemented to enroll 20 at-risk youth who attend alternative schooling and drop-in activities at OCH. The investigators will select with the help of OCH staff, youth peer researchers that will be rigorously trained, similar to the PROMPT project. Peer researchers will be paid honoraria ($15/hr) to compensate for the time spent on research activities. Qualitative data through focus groups will also be collected from youth and key informants at OCH. This information will be used to design an individualized and focused social support intervention for youth. All youth in this arm will also have option to meet with a licensed mental health and substance use nurse to discuss treatment options. Youth's progress in the intervention will be followed with monthly interviews. The involvement of the research team will be limited to referring interested youth to said licensed health professional.
16280563|NCT04812600||Cardiac Rehabilitation|Individuals assigned to phase II (outpatient) cardiac rehabilitation program will undergo their normal exercise routines while the investigators make the measurements pre and post exercise at 0 week, and following 1 and 4 weeks of exercise.
16280564|NCT04812587|Experimental|Experimental group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
16280565|NCT04812587|No Intervention|Comparison group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
16280566|NCT04812574|Experimental|Hypertonic Saline (10%) Injection|Periurethral hypertonic saline (10%) injection was performed in female patients with Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.
16280567|NCT04812561|Experimental|Bronch™ group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day, 800 mg/day as Bronch™)
16280568|NCT04812561|Placebo Comparator|Placebo group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day)
16280569|NCT04812548|Experimental|sabatolimab + azacitidine + venetoclax|"Part 1: Safety run-in consists of 2 subsequent cohorts of a lower dose (cohort 1) and s higher dose (cohort 2) of sabatolimab in combination with fixed dose of venetoclax and azacitidine. Cohort 2 will be open only after the review of safety data from cohort 1 indicates the regimen is safe. If the regimen using sabatolimab at the lower dose is not safe, the study will be stopped. Subsequently, if the review of safety data from participants enrolled in cohort 2 indicates that the regimen is safe, then Part 2 will be opened. Otherwise, if the regimen at the higher dose is not safe, the study will be also stopped.
~Part 2: Expansion will enroll additional participants to further investigate the regimen including sabatolimab at the higher dose, azacitidine and venetoclax. Participants data from Part 1 and Part 2 treated with the higher dose will be combined to determine the complete remission rate."
16280570|NCT04812535|Experimental|Arm A: IFX-1 monotherapy|IFX-1 monotherapy
16280571|NCT04812535|Experimental|Arm B: IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
16280572|NCT04812522|Other|Clean Cut intervention - Cluster 1|"Cluster 1 will receive the Clean Cut infection prevention intervention at random time point A"
16280573|NCT04812522|Other|Clean Cut intervention - Cluster 2|"Cluster 2 will receive the Clean Cut infection prevention intervention at random time point B"
16280574|NCT04812522|Other|Clean Cut intervention - Cluster 3|"Cluster 3 will receive the Clean Cut infection prevention intervention at random time point C"
16280575|NCT04812522|Other|Clean Cut intervention - Cluster 4|"Cluster 4 will receive the Clean Cut infection prevention intervention at random time point D"
16280576|NCT04812522|Other|Clean Cut intervention - Cluster 5|"Cluster 5 will receive the Clean Cut infection prevention intervention at random time point E"
16280577|NCT04812509|Experimental|MW032|MW032 injection(120mg) was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
16280578|NCT04812509|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
16280581|NCT04812470|Experimental|Autologous tumor infiltrating lymphocytes (TIL)|Autologous TIL administered via hepatic arterial infusion followed by low dose Interleukin-2 after preconditioning chemotherapy with Melphalan.
16280582|NCT04812457|Experimental|Physiological cures using pure hyaluronic acid (Hialucic®)|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding
16280583|NCT04812457|Active Comparator|Control group using traditional cure (Betadine Gel).|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to Povidone Iodine Gel (Betadine Gel®) will be applied following the same procedure.
16280584|NCT04812444|Experimental|Zylox Peripheral Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
16280585|NCT04812444|Active Comparator|Zilver Vena Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
16280586|NCT04812431|Experimental|PSA-NCAM(+) NPC|Cells are administered through intrathecal injection. Injection is administered to a total of five areas.
16280587|NCT04812418|Experimental|Group (A)|120 mg of eschscholtzia extract and 50 mg of valerian extract by tablet, without support 28 days
16280588|NCT04812418|Placebo Comparator|Group (B)|Placebo 28 days
16280589|NCT04812405|Other|Teeth|Occlusal examination
16280590|NCT04812392|Experimental|Acute Physical Inactivity|Subjects will undergo 5 days of reduced physical activity.
16280591|NCT04812366|Active Comparator|Group 1a|LHRHa plus apalutamide.
16280592|NCT04812366|Active Comparator|Group 1b|LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
16280593|NCT04812366|Active Comparator|Group 2a|LHRHa plus abiraterone acetate plus prednisone.
16280594|NCT04812366|Active Comparator|Group 2b|LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
16280595|NCT04812366|Active Comparator|Group 3|LHRHa plus abiraterone acetate plus prednisone plus niraparib
16280596|NCT04812353|Other|Foot and ankle arthrodesis or osteotomy|Patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
16280597|NCT04812340|Active Comparator|High intensity Circuit training|Intervention will consist of 6 series with 3 minutes rest period between the series. The series will consist of burpees, skipping, 1 legged squats, leg levers, and push-ups. the exercise volume will be increased progressively over 8 weeks.
16280598|NCT04812340|Active Comparator|Low intensity interval training|the intervention will consist of 4 series of Low-intensity exercises with 3 minutes of rest. the series will comprise of jogging and walking. the Exercise volume will be increased gradually.
16280599|NCT04812327||Prospective Observational Diagnostic Evaluation|Potential participants will be recruited at study sites where they are admitted/held for COVID-19 isolation. On the first day of isolation (ideally on the day they first test positive for SARS-CoV-2), potential participants will be asked to participate in the study. After consent (Study Day 0), two nasopharyngeal swabs (NP swabs) and one nasal swab will be collected. One NP swab will be tested via viral culture and the other nasal swab will be tested by RT-PCR for SARS-CoV-2. The nasal swab will be tested on the BD Veritor System. Specimen collection and testing will be repeated every 2 days for 6 days (Study Day 2, Day 4, and Day 6) or until the RT-PCR Ct value is >30, whichever comes first. Participants will be monitored for symptoms of COVID-19 throughout the study.
16280600|NCT04812314|Experimental|Exercise|"This exercise prescription represents a common or conventional form of physical activity (e.g., moderate/brisk walking). If assigned to this group, participants will perform 45 minutes of moderate intensity continuous steady-state exercise at 70% maximal heart rate (HRmax) to expend 250 calories 4 days per week."
16280601|NCT04812314|Experimental|No exercise|Subjects assigned to this group are to remain sedentary (no planned physical exercise) throughout the duration of the study.
16280602|NCT04812301||Group 1|Egg-white sandwich is added with 1 mCi Tc-99m sodium phytate, then Abbott Vital® added with 1 mCi Tc-99m sodium phytate
16280603|NCT04812301||Group 2|Abbott Vital® is added with 1 mCi Tc-99m sodium phytate, then egg-white sandwich added with 1 mCi Tc-99m sodium phytate
16280604|NCT04812275|Active Comparator|Non absorbable suture|Wound closure with non absorbale suture. Dimension and brand at the discretion of the surgeon.
16280605|NCT04812275|Experimental|Absorbable suture|Wound closure with absorbale suture. Dimension and brand at the discretion of the surgeon.
16280606|NCT04812262|Experimental|Group A1 - Single Ascending Dose|DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
16280607|NCT04812262|Experimental|Group A2, Single Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
16280608|NCT04812262|Experimental|Group A3, Single Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
16280609|NCT04812262|Experimental|Group A4, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
16280610|NCT04812262|Experimental|Group B1 - Multiple Ascending Dose|DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
16280611|NCT04812262|Experimental|Group B2 - Multiple Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
16280612|NCT04812262|Experimental|Group B3 - Multiple Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
16280613|NCT04812262|Experimental|Group B4 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
16280614|NCT04812236|Experimental|Single decoction group: Wulingsan single decoction granules|Wulingsan single decoction granules, Alisma orientalis (15g), Polyporus (10g), Baizhu (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
16280615|NCT04812236|Other|Co-decocting group: Wulingsan co-decocting granules|Wulingsan co-decoction granules, Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
16280616|NCT04812236|Other|Powder group: Wuling powder powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. Take 5g each time with warm water twice a day.Take 12 weeks as a course of treatment.
16280617|NCT04812236|Placebo Comparator|Simulant group: Simulant of granular dosage form|Granule simulant, the composition is Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day. Take 12 weeks as a course of treatment.
16280618|NCT04812223|Active Comparator|Delayed Clamping|In this group, the umbilical cord will be clamped 60 seconds after the baby is born.
16280619|NCT04812223|Active Comparator|Early Clamping|In this group, the umbilical cord will be clamped 15 seconds after the baby is born.
16280620|NCT04812223|Active Comparator|Milking Clamping|In this group in which the umbilical cord will be milked, the cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
16280621|NCT04812210||case: children with congenital heart disease aged 2 to 4 years.|case: children with congenital heart disease aged 2 to 4 years.
16280622|NCT04812210||control children recruited in kindergartens and schools aged 2 to 4 years|control children recruited in kindergartens and schools aged 2 to 4 years
16280623|NCT04812197|Other|Skin Biopsies|Patients undergo punch biopsies of inflamed and non-inflamed skin and a blood sample collection.
16280624|NCT04812184|Experimental|Surgical Tape to bridge of nose|placed a piece of tape to the bridge of the nose, adhering a face mask to the patient's face
16280625|NCT04812184|No Intervention|Standard of care|Patients given a mask with no intervention to the mask
16280626|NCT04812171||smoker participants|
16280627|NCT04812171||non-smoker participants|
16280628|NCT04812171||diabetic participants|
16280629|NCT04812171||non-diabetic participants|
16280630|NCT04812158|Active Comparator|Control group|participants in the control group receive gold standard physiotherapy intervention 5 times a week for 6 weeks
16280631|NCT04812158|Experimental|Experimental group|3 min video-aided mindful deep breathing (VAMDB) or visual guiding on deep breathing with 6 deep breath per minute along with standard physiotherapy (SP) protocol and the control group was given standard physiotherapy (SP) protocol 5 times a week for 6 weeks
16280632|NCT04812158|No Intervention|Healthy control|Active healthy participants who engaged in regular collegial sports
16280633|NCT04812132|Active Comparator|Women|
16280634|NCT04812132|Active Comparator|Men|
16280635|NCT04812119||Patients with the CTNNB1 mutation|Patient with a diagnosed CTNNB1 mutation.
16280636|NCT04812106||Participants with LC-FAOD|
16280637|NCT04812093||Medical Tool|Spectroscopic otoscope
16280638|NCT04812080|Experimental|EXPLORER PET/CT Imaging|Study participants will be injected with 10 +/- 2 mCi of 18F-FDG using and IV line and a 60 minute PET scan will begin on EXPLORER. Prior to the PET scan, an ultra-low-dose CT scan (less than 1 minute ) will be acquired for attenuation correction purposes only. Ninety (90) minutes after being injected with FDG, participants will have another ultra-low dose CT scan (less than 1 minute) which will be acquired for attenuation correction purposes only. This will be followed by a 20 minute PET scan on EXPLORER. One-hundred and twenty (120) minutes after being injected with FDG, participants will be positioned supine on the scanner table for the last time. At this time, a low dose CT scan (less than 1 minute) will be acquired once again for attenuation correction purposes. This will be followed by one last 20 minute PET scan on EXPLORER. The IV line will be removed after completion of the study.
16280639|NCT04812067|Experimental|TTHX1114 weekly x 5|TTHX1114 via IC injection weekly x 5
16280640|NCT04812054|Experimental|Hypothermic oxygenated machine perfusion|Allografts will be subject to end-ischemic hypothermic oxygenated perfusion at 12 degrees Celsius through both hepatic artery and portal vein after a period of simple cold storage at 4 degrees Celsius and immediately prior to implantation. The perfusion will last at least 2 hours and the period will be prolonged in case of ongoing hepatectomy, in order to perform graft implantation immediately after perfusion.
16280641|NCT04812054|Active Comparator|Simple cold storage|Allografts will be stored in perfusate at 4 degrees Celsius from the procurement until implantation.
16280642|NCT04812041||Intensive care unit delirium|Covid-19 patients in ICU are screened for delirium and rated the severity with CAM-ICU 7 scores.
16280643|NCT04812028|Experimental|Prospective Experimental Group|Participants in this group will prospectively receive the intervention.
16280644|NCT04812028|No Intervention|Retrospective Review Group|Participants in this group will have their medical records retrospectively reviewed.
16280645|NCT04812015|Other|Dose Group 1|
16280646|NCT04812015|Other|Dose Group 2|
16280647|NCT04812015|Other|Dose Group 3|
16280648|NCT04812015|Other|Dose Group 4|
16280649|NCT04812015|Other|Dose Group 5|
16280650|NCT04812015|Other|Dose Group 6|
16280651|NCT04812015|Other|Dose Group 7|
16280652|NCT04812015|Other|Dose Group 8|
16280653|NCT04812015|Other|Dose Group 9|
16280654|NCT04812002|Experimental|Double medicine combined|participants received 200mg of PD-1 inhibitors combined 15mg of bevacizumab per square body surface area intravenously every 3 weeks
16280655|NCT04811989|Experimental|Video Watching Group|Participants will watch an instructive video on diabetic foot care and will receive face-to-face teaching on diabetic foot care.
16280656|NCT04811989|Experimental|Real-time Leaflet Reading Group|Participants will receive a leaflet with diabetic foot care information, whose reading will be guided in real-time by the Researcher, and will also receive face-to-face teaching on diabetic foot care.
16280657|NCT04811989|Active Comparator|Standard Care Group|Participants will receive the standard care that includes face-to-face teaching about diabetic foot care and will take a leaflet on diabetic foot care to read at home.
16280658|NCT04811937|Experimental|Artificial intelligence for real-time Computer decision support of resection of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information about polypectomy procedures.
16280659|NCT04811924|Active Comparator|CXL with MMC|Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
16280660|NCT04811924|Placebo Comparator|CXL without MMC|Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).
16280661|NCT04811911|Active Comparator|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
16280662|NCT04811911|Active Comparator|Methotrexate group|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
16280663|NCT04811911|No Intervention|healthy individuals as control group|
16280664|NCT04811898|Experimental|Experimental single arm|Single group with 5 dose escalation for each cohort (0,5 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg; 5 mg/kg)
16280665|NCT04811885||child with ASD of school going age|Questionnaire complete by parent with children with ASD semi structure interview complete by parent with children
16280666|NCT04811872|Experimental|Intact umbilical cord milking (I-UCM)|
16280667|NCT04811872|Experimental|Cut-umbilical cord milking(C-UCM)|
16280668|NCT04811872|Experimental|Delayed Cord Clamping (DCC )|
16280669|NCT04811859|Experimental|Study Group|In the study group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 40% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The patients will come for a control once a week, the maximum inspiratory pressure will be measured again and the new training intensity will be determined at 40% of the new maximum inspiratory pressure.
16280670|NCT04811859|Sham Comparator|Control group|In the control group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 10% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The exercise workload will not be increased and will remain the same. It will run at 10% of maximum inspiratory pressure for eight weeks.
16280671|NCT04811846|Active Comparator|TURBT (Transurethral Resection of Bladder Tumor)|For patients undergoing bipolar transurethral resection, bladder tumor is resected in a piecemeal manner.
16280672|NCT04811846|Active Comparator|PKVB (Plasma Kinetic Vaporization of Bladder Tumor)|For patients undergoing bipolar plasma kinetic vaporization of bladder tumor, bladder tumor is vaporized.
16280673|NCT04811833||Monoplus®|Adult patients undergoing an elective, primary surgery within the gastrointestinal tract with the need for anastomosis.
16280674|NCT04811794||Group A (largest part of the cohort)|Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
16280675|NCT04811794||Group B (very small part of the cohort)|Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)
16280676|NCT04811781||Cancer Patients with SARS-COV-2 infection.|
16280677|NCT04811768|Experimental|Bony wall group|In the bony wall group, following piezosurgery the retrieved bony wall was repositioned.
16280678|NCT04811768|Experimental|Collagen membrane group|In the collagen membrane group, the lateral window was created by rotary instruments, covered via a native collagen membrane (collprotect, botiss biomaterials GmbH, Zossen, Germany).
16280679|NCT04811742|Experimental|immersion bathing group|Immersion bathing was started by placing the baby's whole body, except for the head and neck, into a bathtub of warm water with a depth of 13-14 cm. The baby was shampooed and cleaned in the tub. Then, the baby was taken out of the water and rinsed over the tub. Finally, the baby was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
16280680|NCT04811742|Experimental|showering group|Shower was started by keeping the baby's face down and firmly gripping the baby from his/her armpit and head by one of the nurse's hands. The baby was washed under running water with the other hand. The second nurse assisted to ensure the flow of water. After the baby was rinsed, he/she was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
16280681|NCT04811729|Experimental|Experimental Group|Intervention based on the Motivational Interview, previously receiving a training program
16280682|NCT04811729|Active Comparator|Control Group|Usual care based on a health counci
16280683|NCT04811716|Experimental|Pozelimab Q4W + Cemdisiran|
16280684|NCT04811716|Experimental|Pozelimab Q2W + Cemdisiran|
16280685|NCT04811703|Experimental|Combined PIPAC / IV chemotherapy treatment|Patients will undergo 3 cycles of combined chemotherapy, consisting of PIPAC (cisplatin-doxorubicin, escalating doses) and systemic chemotherapy (paclitaxel-carboplatine, standard doses). First patient will be treated at the lowest dose: doxorubicin 2.1 mg/m² and cisplatin 10.5 mg/m². Subsequent patients will be treated at the dose recommended by the CRM algorithm in the absence of dose-limiting toxicity. A total of 6 dose levels with a factor between 1 and 3 are considered. The maximum dose considered will be doxorubicin, 6.3 mg/m² and cisplatin, 31.5 mg/m². The doses of intravenous chemotherapy will be defined in a standard way, according to the habits of the investigating clinicians and in accordance with the doses received previously. Each cycle will last 28 days and will begin at day 1 with PIPAC procedure and will be completed at day 8 with systemic chemotherapy. Combined chemotherapy will be repeated every 4 weeks for up to 3 cycles in the absence of unacceptable toxicity.
16280686|NCT04811690|Experimental|claim and imagery|control condition (status quo) showing a front-of-package (FOP) vitamin C claim and fruit imagery on all fruit-flavored drinks.
16280687|NCT04811690|Experimental|imagery only|FOP fruit imagery on all fruit-flavored drinks, no vitamin C claim on drinks high in added sugars (>=20 %DV)
16280688|NCT04811690|Experimental|claim only|FOP vitamin C claim on all fruit-flavored drinks, no fruit imagery on drinks high in added sugars
16280689|NCT04811690|Experimental|no claim or imagery|No FOP vitamin C claim or fruit imagery on drinks high in added sugars
16280690|NCT04811690|Experimental|claim, imagery, and % juice disclosure|FOP fruit imagery, vitamin C claim, and % juice disclosure on all fruit-flavored drinks
16280691|NCT04811690|Experimental|claim, imagery, and added sugar warning|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning on drinks high in added sugar
16280692|NCT04811690|Experimental|claim, imagery, and added sugar warning with teaspoons of added sugar disclosure|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning with teaspoons of added sugar disclosure on drinks high in added sugar
16280693|NCT04811664|Experimental|Immediate Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 1 and Day 29.
16280694|NCT04811664|Experimental|Delayed Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 113 and Day 141.
16280695|NCT04811664|No Intervention|Vaccine Declined|Participants who prefer not to be vaccinated, If requested, participant will be offered vaccine if they have not received vaccine outside of the study
16280696|NCT04811651|Experimental|Treatment group|intravenous umbilical cord derived mesenchymal stem cells
16280697|NCT04811651|Placebo Comparator|Placebo Comparator|intravenous placebo solution with the same appearance as the treatment group.
16280698|NCT04811625|Other|PL-ASA capsule, then EC-ASA tablet|PL-ASA capsule 81 mg, then crossover to EC-ASA tablet 81 mg
16280699|NCT04811625|Active Comparator|EC-ASA tablet, then PL-ASA capsule|EC-ASA tablet 81 mg, then crossover to PL-ASA capsule 81 mg
16280700|NCT04811612|Experimental|Infants sampled for warmed and unwarmed heel stick glucose measurements|This single study arm will be samples for blood glucose measurement using both a warmed and unwarmed heel.
16280701|NCT04811599||deep learning algorithm group|Before patients going through colonoscopy or gastroscopy ,taking them tongue images and collecting basic information by mobile phone with Anymed.After examination,endoscopic report and histology analysis is collected .Categorizing the images by gastrointestinal diseases，developing and validating a deep learning algorithm for the diagnosis of digestive tract diseases depending on tongue images.Extracting tougue coating,gastric mucosa and stool DNA by high-throughput sequencing,and analyzing their composation,adundance and diversity.
16280702|NCT04811586|Experimental|one-step Hybrid Coronary Revascularization (HCR)|One-step HCR is defined as off-pump MIDCAB LIMA-LAD revascularization immediately followed by PCI for at-least one non-LAD lesion(or LAD-diagonal lesion) with DES implantation in a hybrid operating room.
16280703|NCT04811586|Active Comparator|Percutaneous Coronary Intervention (PCI)|PCI will be performed using standard technique at the discretion of interventional cardiologist with DES implantation in a routine catheter lab.
16280704|NCT04811573|Experimental|Tfasted|T: Test Treatment fasted: under fasted conditions
16280705|NCT04811573|Experimental|R1fasted|R1: Reference 1 Treatment fasted: under fasted conditions
16280706|NCT04811573|Experimental|R2fasted|R2: Reference 2 Treatment fasted: under fasted conditions
16280707|NCT04811573|Experimental|Tfed|T: Test Treatment fed: under fed conditions
16280708|NCT04811573|Experimental|R1fed|R1: Reference 1 Treatment fed: under fed conditions
16280709|NCT04811560|Experimental|JNJ-75276617|Participants in Part 1 (dose escalation) will receive JNJ-75276617 orally on a 28-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Food effect cohort participants in Part 1 will receive JNJ-75276617 orally on Cycle 2 Day 1 under fasted condition and on Cycle 2 Day 2 under fed condition. Participants in Part 2 (dose expansion) will receive JNJ-75276617 orally at one of the RP2D(s) determined in Part 1.
16280710|NCT04811547||Ankle-Brachial Index value|Valid participants were separated into 0-0.60, 0.61-0.90, 0.91-0.99, and 1.00-1.40 four ABI subgroups.
16280711|NCT04811521|Active Comparator|Primary care follow-up|Enhanced primary care coordination
16280712|NCT04811521|Active Comparator|Online Cognitive Behavioral Therapy|Online Self-Administered Anxiety Management Program plus Peer Support Guidance
16280713|NCT04811521|Active Comparator|Therapist-Administered Cognitive Behavioral Therapy|Telehealth 8 one-hour sessions over the course of 8 to 10 weeks
16280714|NCT04811495|Experimental|patient with temporomandibular joint disorders|
16280715|NCT04811482|Experimental|Intervention Group|This study consists of one arm, an intervention group.
16280716|NCT04811469|Experimental|Cohort 1|CBP-174 dosage 1/Placebo in a 3:1 ratio
16280717|NCT04811469|Experimental|Cohort 2|CBP-174 dosage 2/Placebo in a 3:1 ratio
16280718|NCT04811469|Experimental|Cohort 3|CBP-174 dosage 3/Placebo in a 3:1 ratio
16280719|NCT04811469|Experimental|Cohort 4|CBP-174 dosage 4/Placebo in a 3:1 ratio
16280720|NCT04811469|Experimental|Cohort 5|CBP-174 dosage 5/Placebo in a 3:1 ratio
16280721|NCT04811469|Experimental|Cohort 6|CBP-174 dosage 6/Placebo in a 3:1 ratio
16286252|NCT04772274|Experimental|SB17|SB17 (proposed ustekinumab biosimilar)
16280722|NCT04811456||MIS-C|"Cases fulfilling following criteria:
~fever ≥3 days
~at least two of the following:
~rash or bilateral conjunctivitis or mucocutaneous inflammation signs
~hypotension
~features of myocardial dysfunction, pericarditis, or coronary artery abnormality, based on echocardiographic findings or elevated B-type natriuretic peptide (BNP)/N-terminal-pro-BNP (NT-proBNP) or troponin
~evidence of coagulopathy
~acute gastrointestinal problems
~elevated inflammatory markers AND
~no other apparent microbial cause
~evidence of COVID-19 (positive real-time polymerase chain reaction, antigen test or serology), or personal history of COVID-19 or contact with a proven COVID-19 case"
16280723|NCT04811443||Patients with solid tumors who have received myelosupressive therapy|
16280724|NCT04811430||Randomized Traditional|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
16280725|NCT04811430||Radomized Cue Needle Tracking technology|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
16280726|NCT04811404|Experimental|Ethyl eicosapentaenoic acid|Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day
16280727|NCT04811391||Vaccinated participants|Participants who have received 2 doses of the pfizer Covid-19 vaccine or 1 or dose of the Astra Zeneca Covid-19 Vaccine
16280728|NCT04811391||Unvaccinated participants|Have not received any doses of any form of COVID-19 vaccine
16280729|NCT04811378|Active Comparator|HaemoCer|
16280730|NCT04811378|No Intervention|No HaemoCer|
16280731|NCT04811339|Experimental|BSS&PBO|All patients will be assigned to the treatment group for the first 10 patients treated with open label BSS.
16280732|NCT04811339|Placebo Comparator|SOC control group|The Subsequent 25 patients will be randomized to either placebo or BSS. The patients will be assigned by envelope containing a symbol for either active drug or placebo (or other suitable randomization event) by a member of the research team not directly involved in the clinical trial.
16280733|NCT04811326|Active Comparator|NB-UVB radiation|will expose to 2 sessions/week of NB-UVB radiation, for 3 months.
16280734|NCT04811326|Active Comparator|Latanoprost|latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).
16280735|NCT04811326|Active Comparator|latanoprost + NB-UVB|(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.
16280736|NCT04811326|No Intervention|healthy individuals|healthy individuals as control group
16280737|NCT04811313|Active Comparator|T group|each participant will receive 15 mg/kg of tranexamic acid diluted in a 10 mL syringe slowly over 10-15 minutes, 15 minutes before skin incision.
16280738|NCT04811313|Active Comparator|TC group|each participant will receive 10 mg/kg of tranexamic acid diluted in a 5 mL syringe slowly over 5 minutes, 15 minutes before skin incision, and A caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
16280739|NCT04811313|Active Comparator|C group|each participant will receive a caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
16280740|NCT04811313|Placebo Comparator|P group|participants will receive the regular standard care without adding tranexamic acid or caudal epidural block
16280741|NCT04811287|Active Comparator|CTR with PRP|Carpal tunnel release with adjuvant platelet-rich plasma.
16280742|NCT04811287|Placebo Comparator|CTR without PRP|Carpal tunnel release without adjuvant platelet-rich plasma.
16280743|NCT04811274||Patients|Minor patients with alveolar proteinosis by mutations of the MARS gene.
16280744|NCT04811274||Controls|Minors patients without alveolar proteinosis.
16280745|NCT04811261|Experimental|3+3 dose escalation|The first 3 subjects' patients will be administered 50 x 10^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
16280746|NCT04811235|Experimental|Arm 1|NIRS monitoring of spinal cord oxygenation and hemodynamics
16280747|NCT04811222|Experimental|Ga-DOTATATE PET/MRI scan|Patients with abdominal aortic aneurysm will undergo Ga-DOTATATE PET/MRI scan
16280748|NCT04811209||single group, open labelled observational study with no blinding.|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
16280749|NCT04811196|Experimental|Metronomic dosing|"This Arm is an open-label, non-randomized, phase 1 study of metronomic dosing of selinexor in patients with locally advanced or metastatic MPNST, ESS, LMS. Up to seven dose levels of Selinexor will be investigated.
~Patients will undergo 3+3 based dose escalation to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Selinexor.
~Escalating doses of selinexor will be given starting with 2.5 mg (taken orally 4 days in a row followed by 3 days break from treatment, repeating this weekly as part of a 28-day cycle). The first dose for the first 2 patients at each dose level will be staggered by 7 days. Minimum number of patients treated in this trial arm is 18 patients, and maximum 36 patients.
~Schedule:
~Selinexor flat dosing with dose levels (DLs) of 2.5mg (DL1), 5mg (DL2), 7.5mg (DL3), 10mg (DL4), 12.5mg (DL5), 15mg (DL6), 17.5mg (DL7). A DL-1 (1.25 mg) is also incorporated."
16280750|NCT04811196|Experimental|Split dosing|The second arm of the study is an open-label, non randomized, phase 1b study of selinexor in patients with any histological subtype of STS administered orally one day per week, 40mg in the morning, 20mg in the afternoon and 20mg at night as part of a 28 day cycle. Twenty patients will be accrued to this arm.
16280751|NCT04811183||Experimental group|Adult patients hospitalized with diabetes and polymedicated. Selected to benefit from a pharmaceutical consultation before their return home.
16280752|NCT04811170|Experimental|Counselling group|Counselling sessions will be conducted at the designated centers operated by the Zubin foundation. According to the level of the DASS score, 6 to 10 sessions (based on the algorithm) of counselling service will be provided to the participants by three registered counsellors. A lead counsellor will oversee all cases and services. The counselling program consists of 6-10 60-minute sessions, and the sessions can be flexibly delivered over 1 to 2 weeks, ranging from one 60-minute session biweekly or weekly.
16280753|NCT04811170|Other|Waiting group|For participants in the waiting list control group, they will receive monitoring service over phone calls during the 8-12 weeks wait period. Counselling service will be offered after the post-treatment assessment.
16280754|NCT04811157|Experimental|Test group|Healthy adults consuming test product
16280755|NCT04811157|Placebo Comparator|Control group|Healthy adults consuming control product
16280756|NCT04811144|Experimental|Cavity group|The 35 participants accepted Er:YAG laser treatment for dental cavity. Each participant was collected their data including history records, affected range check, X-ray&photo, treatment, pain index check, return visit check after two weeks by researchers.
16280757|NCT04811144|Experimental|Sensitive Teeth group|The 35 participants accepted Er:YAG laser treatment for sensitive teeth. Each participant was collected their data including history records, sensitive check, X-ray&photo, treatment, pain index and effectiveness check, return visit check after two weeks by researchers.
16280758|NCT04811144|Experimental|Abnormal Frenum Attachment group|The 35 participants accepted Er:YAG laser treatment for Abnormal Frenum Attachment. Each participant was collected their data including history records, abnormal position check, photo, cutting, pain index check, return visit check after three, five and seven days. by researchers.
16280759|NCT04811144|Experimental|Peri-implantitis intervention group|The 12 participants accepted Er:YAG laser treatment for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
16280760|NCT04811144|No Intervention|Peri-implantitis control group|The 12 participants accepted mechanical debridement for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
16280761|NCT04811131|Active Comparator|Active IP and Active Phototherapy|ARQ-252 cream 0.3% BID with phototherapy.
16280762|NCT04811131|Active Comparator|Active IP and Sham Phototherapy|ARQ-252 cream 0.3% BID with sham phototherapy
16280763|NCT04811131|Placebo Comparator|Vehicle and Active Phototherapy|ARQ-252 Vehicle cream BID with active phototherapy
16280764|NCT04811131|Placebo Comparator|Vehicle and Sham Phototherapy|ARQ-252 Vehicle cream BID with sham phototherapy
16280765|NCT04811118|Experimental|Albumin-bound docetaxel|Subjects will receive albumin-bound docetaxel via intravenous infusion (IV) once every three weeks (a cycle), at the dose of 75mg/m2
16280766|NCT04811118|Experimental|Taxotere|Subjects will receive Taxotere via intravenous infusion once every three weeks (a cycle), at the dose of 75mg/m2.
16280767|NCT04811105|Active Comparator|steam ablation|The fistula tract which treated with steam ablation
16280768|NCT04811105|Active Comparator|control group|The fistula tract which do not take any treatment
16280771|NCT04811079|Experimental|Spectacle Filter Sequence 1|(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
16280772|NCT04811079|Experimental|Spectacle Filter Sequence 2|(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
16280773|NCT04811079|Experimental|Spectacle Filter Sequence 3|(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
16280774|NCT04811079|Experimental|Spectacle Filter Sequence 4|(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
16280775|NCT04811079|Experimental|Spectacle Filter Sequence 5|(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
16280776|NCT04811079|Experimental|Spectacle Filter Sequence 6|(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
16280777|NCT04811079|Experimental|Spectacle Filter Sequence 7|(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
16280778|NCT04811079|Experimental|Spectacle Filter Sequence 8|(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
16280779|NCT04811079|Experimental|Spectacle Filter Sequence 9|(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
16280780|NCT04811079|Experimental|Spectacle Filter Sequence 10|(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
16280781|NCT04811066|Experimental|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
16280782|NCT04811066|Experimental|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
16280783|NCT04811066|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
16280784|NCT04811053|Experimental|Treatment group A|
16280785|NCT04811053|Placebo Comparator|Treatment group B|
16280788|NCT04811027|Experimental|(CPS ≥1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).
~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
16280789|NCT04811027|Active Comparator|(CPS ≥1): Pembro|Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).
16281049|NCT04809064|Experimental|Latarjet/rehabilitation|Latarjet surgical procedure and post-operative rehabilitation.
16280790|NCT04811027|Experimental|(CPS <1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).
~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
16280791|NCT04811014|Experimental|MOUD induction and behavioral interventions among opioid-dependent youths|Induction into medication for opioid use disorder (MOUD) treatment and behavioral interventions
16280792|NCT04811001|Experimental|Arm A (Osimertinib->Dacomitinib)|"Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal.
~At treatment discontinuation patients maintaining the original EGFR mutation will switch to Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal."
16280793|NCT04811001|Experimental|Arm B (Dacomitinib->Osimertinib)|"Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal.
~At treatment discontinuation, patients harboring the EGFR-T790M will receive Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal."
16280794|NCT04810988|Active Comparator|Unsupported|"Participants in this arm will receive a 12-week Unified Protocol intervention delivered via the same web platform. Each week, participants will complete the following content:
~depression survey,
~anxiety survey,
~information about their symptom change over time,
~psychoeducational text
~practice exercises,
~home practice instructions,
~writing exercise,
~home practice worksheets.
~In the first week, participants will receive an emailed welcome message followed by a link to the first week's content. For every following week, participants will receive an email at the start of the week with automatically generated feedback on intervention usage, behavior change, and symptom change, as well as the link to the new week's intervention content."
16280795|NCT04810988|Experimental|Partially Supported|Participants in the partially supported arm will receive all aspects of the intervention described above, with no differences between arms for the first seven weeks of the intervention (Modules 1-6). Participants will be introduced to their study therapist in week 8, at the start of Module 7 via email. During Module 7 (exposure; weeks 8-11), participants will receive four video therapy sessions. Session content will be based on principles of exposure therapy (developing a personalized exposure hierarchy, live demonstrations of exposure exercises, in-session exposure practices, post-exposure processing, home practice assignments, and therapist feedback).
16280796|NCT04810975|Placebo Comparator|The effect of exercise A on musculoskeletal health|
16280797|NCT04810975|Active Comparator|The effect of exercise B on musculoskeletal health|
16280800|NCT04810949|Active Comparator|serum vitamin D levels +/- 20ng/ml (Group 1)|Patients with serum vitamin D levels +/- 20ng/ml
16280801|NCT04810949|Placebo Comparator|serum vitamin D levels +/- 20ng/ml ( Group 2)|Patients with vitamin D levels +/- 20ng/ml
16280802|NCT04810936|Experimental|Early ONS intervention group|Patients in early ONS intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy) and ONS intervention in the beginning of radiotherapy. The ONS is prescribed to increase oral intake of patients and to ensure total energy supply is more than 30 kcal/kg/day and protein intake more than 1.2 g/kg/day.
16280803|NCT04810936|No Intervention|Standard nutrition intervention group|Patients in standard nutrition intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy).
16280804|NCT04810923|Experimental|i-PRF group|arthrocentesis procedure plus four consecutive intra-articular injection of i-PRF.
16280805|NCT04810923|Experimental|Control group|arthrocentesis procedure alone.
16280806|NCT04810910|Experimental|Personalized neoantigen vaccines|"iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses"
16280807|NCT04810897||Parkinson's disease|The neurologists will inform the individuals with PD that we are doing this research and we will attach the research advertisement at Movement Disorder Clinic, Division of Neurology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Only individuals with PD who meet the inclusion and exclusion criteria will be invited to participate in the study. The researcher will inform participants about the purpose, procedure, and advantage of the study prior to participation in the study. Individuals with PD will be asked to sign an informed consent if they agree to participate in the study.
16280808|NCT04810884||Living kidney donors|"Aim 1: A survey about fractures and general bone health will be sent to 3000 prior living kidney donors.
~Aim 2: Out of these 3000 subjects, 200 prior living kidney donors who are ≥10 years post kidney donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
16280809|NCT04810884||Matched Controls|"Aim 1: A survey about fractures and general bone health will be sent to 3000 age, sex, race, and comorbidity-matched subjects who would have been eligible to donate but did not donate a kidney.
~Aim 2: Out of these 3000 subjects, 200 control subjects who would be eligible to donate, but have not donated, and are matched by age, sex, race, and comorbidity to donors at the time of donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
16280810|NCT04810871|Experimental|Treatment (surgery)|Patients undergo surgery as indicated clinically when applicable.
16280811|NCT04810858|Other|HIV+ marijuana user|Participants with HIV who report marijuana use
16280812|NCT04810858|Other|HIV+ non-drug user|Participants with HIV who report no drug use
16280813|NCT04810858|Other|HIV- marijuana user|Participants without HIV who report marijuana use
16280814|NCT04810858|Other|HIV- non-drug user|Participants without HIV who report no drug use
16280981|NCT04809558|Active Comparator|Progressive intensity with no visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with no visual biofeedback.
16280815|NCT04810845|Experimental|Patients undergoing coronary angiography with planned PCI|Patients with a known coronary artery disease admitted for elective coronary angiography with planned PCI would be enrolled
16280816|NCT04810832|Experimental|Whole group|"The whole group undergo the two phases of the study:
~1/ They listen successively the 3 oddball paradigms in the department of neurophysiology : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice
~2/ They listen successively the same 3 oddball paradigms in the neurosurgical department, during their intractable epilepsy presurgical evaluation : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice"
16280817|NCT04810819|Experimental|Experimental group|
16280818|NCT04810819|Placebo Comparator|control group|
16280819|NCT04810806|Experimental|Immediate coronary angiography group|Immediate coronary angiography group will routinely receive coronary angiography within 2 hours after randomization.
16280820|NCT04810806|Active Comparator|Delayed coronary angiography group|Delayed coronary angiography group will receive coronary angiography during hospitalization after stabilization of symptoms and signs of heart failure.
16280824|NCT04810754|Experimental|Daratumumab subcutaneous|open label daratumumab s.c., unblinded
16280825|NCT04810728|Experimental|Extract Psidii guava|2 Capsule of extract Psidii guava, three times daily
16280826|NCT04810728|Active Comparator|Standard therapy|Standard therapy for Covid-19 patient (vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
16280827|NCT04810715||Patient Group|Anklyosing Spondilitis
16280828|NCT04810702||patients with von Willebrand disease|
16280829|NCT04810702||case control|
16280830|NCT04810689|Experimental|XFBD Arm|XFBD (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
16280831|NCT04810689|Placebo Comparator|Placebo Arm|Placebo (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
16280832|NCT04810676|Experimental|Sequence 1|"Peroid 1: CKD-501, D745, D150 -PO
~Peroid 2: CKD-383- PO"
16280833|NCT04810676|Experimental|Sequence 2|"Peroid 1: CKD-383- PO
~Peroid 2: CKD-501, D745, D150 -PO"
16280834|NCT04810650|Experimental|Dynamic Prevention Intervention|
16280835|NCT04810650|Experimental|Dynamic Treatment Intervention|
16280836|NCT04810650|Active Comparator|Control|
16280837|NCT04810637|Experimental|GX-I7|Patients randomised on experimental arm will receive GX-I7 drug
16280838|NCT04810637|Placebo Comparator|GX-I7 vehicle|Patients randomised on comparator arm will receive placebo
16280839|NCT04810624|Experimental|Relapse Prevention and Changing Habits +|Treatment consists of 5 carefully selected components that can reasonably be expected to reduce the rate of weight loss following acute weight restoration: behavioral, cognitive, motivation, monitoring, and skill consolidation. The manualized treatment is provided by a clinician via telehealth. Treatment consists of an orientation to treatment session prior to discharge, followed by 45-minute video telehealth sessions, twice weekly for 6 weeks and then once weekly.
16280840|NCT04810611|Experimental|Arm 1: MBG453 single agent|Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.
16280841|NCT04810611|Experimental|Arm 2: NIS793 single agent|Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.
16280842|NCT04810611|Experimental|Arm 3: canakinumab single agent|Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.
16280843|NCT04810611|Experimental|Arm 4: MBG453 + NIS793 combination|Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.
16280844|NCT04810611|Experimental|Arm 5: MBG453 + canakinumab combination|Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.
16280845|NCT04810598|Experimental|Group 1: Participants With Normal Renal Function|Participants with normal renal function will receive single dose of venetoclax on Day 1.
16280846|NCT04810598|Experimental|Group 2: Participants With End Stage Renal Disease|Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).
16280847|NCT04810585|Experimental|Treatment|
16280848|NCT04810572|Active Comparator|Group 1 - composition with Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition with Silymarin (Silybum marianum), in a diary dose of 140 mg for 90 days.
~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
16280849|NCT04810572|Active Comparator|Group 2 - composition without Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 90 days.
~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
16280850|NCT04810572|Active Comparator|Group3 - Low-mineral composition without Silymarin (L5)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 90 days.
~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
16280877|NCT04810377|Experimental|EUS-guided gastroenterostomy in malignant gastric outlet obstruction|The patients with malignant gastric outlet obstruction will be confirmed as follows: Histopathological report of cancer, thoracoabdominal tomography and impaired tolerance to oral feeding (tolerance to liquids only or null).
16280851|NCT04810546|Experimental|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
16280852|NCT04810546|No Intervention|Usual care|Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
16280853|NCT04810533|Experimental|[14C] SH-1028|Volunteers will receive 200 mg [14C] SH-1028 containing a nominal 88 μCi activity, administered by mouth, as a solution.
16280854|NCT04810520||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
16280855|NCT04810520||Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed without tele-supervision.
16280856|NCT04810507|Experimental|Anagliptin arm|Anagliptin 100 mg twice a day
16280857|NCT04810507|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg once a day
16280858|NCT04810494|Experimental|test drug|2% Lidocaine
16280859|NCT04810494|Placebo Comparator|Placebo|0.9% Normal Saline
16280860|NCT04810481|No Intervention|Standard Practice|Anesthesia will be provided at the discretion of the anesthesiologist following cardiovascular variables in accordance with usual clinical indications.
16280861|NCT04810481|Active Comparator|BIS Group|Anesthesia will be titrated to achieve a BIS value of 45-60 during maintenance of anesthesia. Additional intervention will be provided only if the subject is in distress.
16280862|NCT04810468|Other|Children in primary school|anthropometric measurment will take from each participiant in study to asses wheight ,height ,BMl and also use aquestionnaire yo asses the Sociodemographic data,dietary habits ,hygiene information
16280863|NCT04810455|Experimental|Purrble -- Intervention design and logic model|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing; see (Theofanopoulou et al 2019, Slovak et al 2018) for the design and data from previous deployments.
~The toy is introduced to the child as an anxious creature that needs kind attention from humans. When picked up, the toy emits a frantic heartbeat that slows down if the child uses calm stroking movements. If the toy is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.
~Logic model underlying the intervention:
~Level 1: in-the-moment soothing support to children in emotional moments when they would attempt to calm down.
~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.
~Level 3: shift in children's ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
16280864|NCT04810455|Active Comparator|Non-interactive plush toy -- active control group|"The investigators argue that a comparison with a non-active control-such as waiting list / treatment-as-usual (i.e., nothing)-would not allow us to distinguish the hypothesised impact on in-the-moment soothing of interactivity vs. the emergence of new family routines; and would be also open to unequal social desirability bias.
~However, from the perspective of the hypothesised logic model (Levels 1-3), it is not necessary for the active control to have exactly the same form factor as the active toy, as long as it is comparable in size, shape, and appeal. In fact, the investigators have explicitly decided not to use deactivated Purrble units as active controls due to the increased risk of unblinding, whereby the participants search for or come across Purrble online (or notice the plastic enclosure with electronics inside the toy), and assume their unit is malfunctioning."
16280865|NCT04810442|Experimental|Nap Group|This group will be involved with taking a nap in between the two scanning procedures.
16280866|NCT04810442|No Intervention|No-Nap Group|This group will not be taking a nap in between the two scanning procedures, and instead will be silently watching a film for the 45 minute period.
16280867|NCT04810429|Placebo Comparator|Placebo|TMJ arthroscopy and Saline solution NaCl 0,9% in 2 syringes with 1 ml each. Injected in Right Masseter (0.5ml), Left Masseter (0.5ml), Right Temporalis (0.5ml) and Left Temporalis (0.5ml).
16280868|NCT04810429|Active Comparator|IncobotulinumoxinA|TMJ arthroscopy and Dose of IncobotulinumoxinA to be injected 100 U distributed in 2 syringes with 1 ml each: 25U (0.5ml) in Right Masseter / 25U (0.5ml) in Left Masseter / 25U (0.5ml) in Right Temporalis / 25U in Left Temporalis.
16280869|NCT04810416|Experimental|Texting- 10 minutes|Assigned participants will do texting for 10 minutes.
16280870|NCT04810416|Experimental|Writing- 10 minutes|Assigned participants will do writing for 10 minutes.
16280871|NCT04810416|Experimental|Texting- 15 minutes|Assigned participants will do texting for 15 minutes.
16280872|NCT04810416|Experimental|Writing-15 minutes|Assigned participants will do writing for 15 minutes.
16280873|NCT04810416|No Intervention|Control group|No hand activities.
16280874|NCT04810403|Experimental|SOMEBODY Eating Disorder Prevention Program|All participants will be recruited to participate in the SOcial MEdia (SOME) adaptation of activities from the BODY Project (SOMEBODY).
16280935|NCT04809935|Active Comparator|EUS-CPA|Radiofrequency ablation of the coeliac plexus
16281048|NCT04809064|Experimental|Open Bankart/rehabilitation|Open Bankart surgery and post-operative rehabilitation.
16280878|NCT04810364||All HIV-positive patients with chronic coronary syndrome|The Group includes all HIV-positive patients with stable chest pain. The progression of atherosclerosis will be quantitatively characterized by the parameters of the lesions (e.g. plaque burden, cap thickness, arterial remodeling, presence of erosions or rupture, malaposition of the stent, a vessel injury score, etc.). The imaging data will be handled with expert-level post-processing software.
16280879|NCT04810351||Younger 1|young patients ( 18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 and CRP > 30 mg/dl during more than one week out of hospital with appropriate intelligent standard inpatient or outpatient workup in hospital to rule out usual causes of fever
16280880|NCT04810351||Older 1|old patients ( > 70 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week out of hospital with appropriate intelligent standard inpatient or outpatient workup in hospital to rule out usual causes of fever
16280881|NCT04810351||Young 2|young patients (18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 and CRP > 30 mg/dl during more than 3 weeks with 3 out/in (hospital) visits or 3 days inhospital visits with appropriate intelligent standard inpatient or outpatient workup in hospital to rule out usual causes of fever.
16280882|NCT04810351||Older 2|old patients ( > 70 years old) with oral or rectal fever fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during 3 weeks with 3 out (hospital) visits of 3 days inhospital with appropriate intelligent standard inpatient or outpatient workup in hospital to rule out usual causes of fever
16280883|NCT04810338||All patients received conventional dialysis treatment|All patients received conventional dialysis treatment during an observational period of 3 years
16280884|NCT04810312|Experimental|Intervention group|Back extensor strengthening with oral protein supplementation
16280885|NCT04810299|Experimental|Aromatherapy Massage Group|According to this Tisserand Institute guide chart, for a 2% dilution process, dilution will be provided with a total of 12 drops by adding 4:4:4 drops of lavender, Roman chamomile and ginger essential oils in 20 ml of sweet almond oil. Expert opinion was obtained from a phytotherapy and aromatherapy specialist physician that the oils and dilution rates used were appropriate. Foot massage will be applied on the 1st, 2nd and 3rd postoperative days by dropping 5 drops of the prepared oil mixture for each foot. State Anxiety Scale, Richard-Campbell Sleep Quality Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and 30 minutes after the application. Foot massage will be applied for 20 minutes.
16280886|NCT04810299|Experimental|Classical Foot Massage Group|Baby oil will be applied as massage oil to patients who are assigned to the classical foot massage group before the surgery. 5 drops of baby oil for each foot are applied after the surgery. Foot massage will be applied for 20 minutes on the 1st,2nd and 3rd days. State Anxiety Scale, Richard-Campbell Sleep Quality Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and 30 minutes after the application.
16280887|NCT04810299|No Intervention|Control Group|Except for routine care practices, no attempt will be made to the patients assigned to the pre-operative control group. State Anxiety Scale, Richard-Campbell Sleep Quality Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied on postoperative 1st, 2nd and 3rd days. The same scales will be re-evaluated 60 minutes after the first measurement.
16280888|NCT04810286|Experimental|Experimental Group|3D-print myofunctional appliance
16280889|NCT04810286|Active Comparator|Control Group|Prefabricated myfunctional appliance
16280890|NCT04810273|Experimental|early mobilization (ER) group|Participants in the EM group will undergo the progressive early mobilization protocol in the trauma ICU in a manner consistent with the our hospital practice guidelines indicated by the Modified Trauma ICU Mobility Scale for progressive mobilization during the ICU stay. The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay
16280891|NCT04810273|Active Comparator|standard early rehabilitation (SER) group|Patients in the SER group will receive standard physiotherapy including passive range of motion exercises, active exercises, bed mobility, and respiratory therapy during their ICU stays. In the SER group, out-of-bed mobilization (>=Level III in the Modified Trauma ICU Mobility Scale) will be started as soon as possible after ICU discharge.
16280892|NCT04810260|Active Comparator|HIV +|Patients will have the application and use it to increase their awareness about their medical condition.
16280893|NCT04810260|Active Comparator|HIV -|Patients will have the application and use it to increase their awareness about their medical condition.
16280894|NCT04810247|Experimental|Body Project intervention|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised.
16280895|NCT04810221|Experimental|Experimental|Measure of SpO2 and heart rate (HR) measurements obtained with BrOxy M with that obtained with the reference pulse oximeter in paired observations
16280896|NCT04810208|Experimental|NZ-DTX Depot|
16280897|NCT04810182||Glioblastoma Patients treated with Regorafenib|Patients with a confirmed diagnosis of Glioblastoma for whom a decision to treat with regorafenib has been made (by the treating physician).
16280898|NCT04810169||Smart inhaler|Children with smart inhaler
16280899|NCT04810156|Active Comparator|Mycophenolate mofetil|"If less than 20 percent reduction in ALT/AST or bilirubin during treatment with corticosteroids or corticosteroids plus UDCA at day 4 or at day 7 respectively, the patient will undergo block-randomized to an add on of MMF or tacrolimus Meanwhile tapering of corticosteroids in patients with sufficient response.
~MMF will be stopped 8 weeks after treatment stop of corticosteroids."
16280900|NCT04810156|Active Comparator|Tacrolimus|"If less than 20 percent reduction in ALT/AST or bilirubin during treatment with corticosteroids or corticosteroids plus UDCA at day 4 or at day 7 respectively, the patient will undergo block-randomized to an add on of MMF or tacrolimus Meanwhile tapering of corticosteroids in patients with sufficient response.
~Tacrolimus will be stopped 8 weeks after treatment stop of corticosteroids."
16280936|NCT04809909|Experimental|Peripheral stimulation of acupuncture points (PSAP)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of acupuncture points.
16280937|NCT04809909|Active Comparator|Peripheral nerve field stimulation (PNFS)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of the painful area.
16280901|NCT04810143|Experimental|Aim 1|"All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits. A convenience sample of 25 inpatient samples will be collected for Aim 1. Although the assay developed by the MSCF will be validated for accuracy, the purpose of Aim 1 is to test real world application of the Mitra Microsampler tubes against the gold standard of blood collected by venipuncture in a controlled setting. To accomplish this, consecutive inpatient heart transplant patients will be enrolled. That sample will be collected at the same time (+/- 15 minutes) as a clinically-indicated, appropriately-timed venipuncture for measurement of a tacrolimus trough and prior to the subject taking tacrolimus so as to represent a trough."
16280902|NCT04810143|Experimental|Aim 2|Outpatient. A convenience sample of 25 outpatients collecting 1-2 samples will be collected for Aim 2. For those who agree to participate, the parent/patient will be taught by a member of the team on how to use the Microsampler to collect blood from a finger stick. They will be provided with a kit for collection of up to 2 samples and will also be provided with appropriate shipping materials to return samples to CCHMC. Participants will then be instructed to collect a sample in the Mitra Microsampler via fingerstick. In addition to the process of collecting the sample in Aim 2, appropriately-aged participants and/or families will be asked to fill out a brief survey regarding sample collection. This will include questions about the ease or difficulty of performing the steps and tolerability of the procedure relative to past experiences with values obtained by venipuncture.
16280903|NCT04810130|Sham Comparator|Kicking|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer kicking intervention).
16280904|NCT04810130|Experimental|Soccer Heading (Frontal)|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer heading intervention).
16280905|NCT04810130|Experimental|Soccer Heading (Oblique)|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer heading intervention).
16280906|NCT04810117||COVID-19 PCR positive patients who are not yet vaccinated|Patients test positive with PCR and recovered from COVID-19
16280907|NCT04810117||COVID-19 patients with obvious symptoms who are not yet vaccinated|COVID-19 patients with obvious symptoms but PCR test was not conducted for them
16280908|NCT04810117||COVID-19 suspected patients with no symptoms who are not yet vaccinated|COVID-19 suspected patients with no symptoms but came in obvious contact with infected environmental/biological samples
16280909|NCT04810117||COVID-19 PCR positive patients who are vaccinated|COVID-19 suspected patients who have got either one or two doses of vaccine
16280910|NCT04810117||Healthy Individuals who are vaccinated|Control group
16280911|NCT04810117||Healthy Individuals who are not vaccinated|Control group
16280912|NCT04810104|Experimental|Active drug: AZD0328|Participants will receive AZD0328 capsules for oral administration.AZD0328 is a selective α7 nicotinic receptor agonist, The total daily dosage of AZD0328 is 1mg per day; administered as 0.5mg twice daily / BID. The study treatment period is 12-weeks.
16280913|NCT04810104|Placebo Comparator|Placebo|Participants will receive identical-appearing placebo capsules for oral administration.Participants will be instructed to take 2 capsules in the morning and 2 capsules in the evening for a 12-week period.
16280914|NCT04810091|Experimental|Arm A (telotristat ethyl, SSA)|Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
16280915|NCT04810091|Active Comparator|Arm B (placebo, SSA)|Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
16280916|NCT04810078|Experimental|Arm A: Subcutaneous Nivolumab|
16280917|NCT04810078|Active Comparator|Arm B: Intravenous Nivolumab|
16280918|NCT04810065|Other|SingStrong for Pulmonary Fibrosis|"This arm of the project explores Singing as an intervention for people suffering from Pulmonary Fibrosis specifically.
~It is a 10 week programme. All other aspects of the intervention are the same in terms of delivery and length of classes.
~Different outcome measures, namely the St Georges Respiratory Questionnaire is used in this trial. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations."
16280919|NCT04810052|Experimental|Condition I (contribution)|Patients do 1 nice thing (can be as large or as small as they wish) BIW for 4 weeks for their caregivers while at home.
16280920|NCT04810052|Experimental|Condition II (gratitude)|Patients write a letter or note of gratitude BIW for 4 weeks to their caregivers who have helped with their treatment or recovery.
16280921|NCT04810052|Active Comparator|Condition III (daily activities tracking)|Participants keep track of their daily activities.
16280922|NCT04810039||doctor working in neuro-intensive unite care|doctor predicting the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
16280923|NCT04810026|Active Comparator|Group 1: Education only|Push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
16280924|NCT04810026|Experimental|Group 2: Education and Meals|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
16280925|NCT04810026|Experimental|Group 3: Education, Meals, Coaching|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, coaching program (e.g., diabetes-specific coaching and education, push notifications for lifestyle education modules, community support) for 12 weeks, and passive access to lifestyle education for final 4 weeks
16280926|NCT04810000||Group A|Group A ( Tourniquet release before wound closure and hemostasis ensured )
16280927|NCT04810000||Group B|Group B ( Tourniquet release after wound closure )
16280928|NCT04809987|Experimental|Virtual Gait and Physical Exercise|
16280929|NCT04809987|Sham Comparator|Documental projection and Physical Exercise|
16280930|NCT04809987|Experimental|Virtual Gait|
16280931|NCT04809987|Sham Comparator|Documental Projection|
16280932|NCT04809974|Placebo Comparator|Placebo|Placebo: 40 participants will take placebo in the form of a capsule.
16280933|NCT04809974|Experimental|Niagen|Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
16280934|NCT04809935|Active Comparator|EUS-CPB|Chemical ablation of the coeliac plexus
16280938|NCT04809883||observational study of gastric and pyloric motor function measured with Endoflip|observational study of gastric and pyloric motor function measured with Endoflip during fasting and postprandial periods There is NO intervention
16280939|NCT04809870||LC (liver cirrhotic patients)|Patients with concomitant liver cirrhosis
16280940|NCT04809870||Non-LC (non liver cirrhotic patients)|Patients without concomitant liver cirrhosis
16280941|NCT04809857|Experimental|Plyometric Exercise Group|Plyometric exercise training 3 days a week for 6 weeks
16280942|NCT04809857|Active Comparator|Isokinetic Exercise Group|Isokinetic exercise training 3 days a week for 6 weeks
16280943|NCT04809857|No Intervention|Control Group|no exercise intervention
16280944|NCT04809831|Active Comparator|Trial Group - Biorepair Peribioma Toothpaste + Mousse|Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.
16280945|NCT04809831|Active Comparator|Control Group - Curasept Toothpaste (chlorhexidine 0,2%)|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.
16280946|NCT04809818|Experimental|Part A - LT3001 Drug Product|Multiple doses of LT3001 administered by intravenous infusion
16280947|NCT04809818|Placebo Comparator|Part A - Placebo|Multiple doses of Placebo administered by intravenous infusion
16280948|NCT04809818|Experimental|Part B - LT3001 and Aspirin|Multiple doses of LT3001 and Aspirin administered
16280949|NCT04809818|Experimental|Part B - LT3001 and Clopidogrel|Multiple doses of LT3001 and Clopidogrel administered
16280950|NCT04809818|Experimental|Part B - LT3001 and Apixaban|Multiple doses of LT3001 and Apixaban administered
16280951|NCT04809818|Experimental|Part B - LT3001 and Dabigatran|Multiple doses of LT3001 and Dabigatran administered
16280954|NCT04809792|Experimental|Head and neck cancer|In this arm patients with head and neck cancers treated with SBRT are recruited.
16280955|NCT04809779|Experimental|Sintilimab|
16280959|NCT04809753|Experimental|Eustachian tube dilation|Eustachian tube dilation with an endovascular balloon
16280960|NCT04809740||Patient Group 1|Initial chart review - Component 2 - 15,000 Patients
16280961|NCT04809740||Providers Group 1|Initial chart review-Component 2 - 300 Providers
16280962|NCT04809740||Patient Group 2|Initial chart review-Component 3 - 35,000 Patients
16280963|NCT04809740||Providers Group 2|Provider Interview-Component 4 - 15 Providers
16280964|NCT04809740||Patient Group 3|Patient Interview-Component 4 - 15-60 Patients
16280965|NCT04809727|Experimental|Biopsy|four quadrant biopsy
16280966|NCT04809714|Active Comparator|Routine Post-operative Physical Therapy|The control group will undergo routine post-op and undergo a modified version of the graduated therapy protocol.
16280967|NCT04809714|Experimental|Routine Physical Therapy + Blood Flow Restriction and Neuromuscular Electrical Stimulation (NMES)|The intervention group will start with a Delfi tourniquet system cuff set on a limb occlusion pressure (LOP) of 60-100%. The intervention group will also use a neuromuscular electrical stimulation device at therapeutic level in addition to BFR.
16280968|NCT04809701|Experimental|Configuration A first|Subjects receive the test of Configuration A first and Configuration B second.
16280969|NCT04809701|Experimental|Configuration B first|Subjects receive the test of Configuration B first and Configuration A second.
16280970|NCT04809688|Experimental|Single arm|Single arm
16280971|NCT04809675|Active Comparator|HOS-HOS-FCM-FCM sequence|Use of a hard occlusal splint (HOS) for the first two weeks, followed by a week off, and a flexible customized mouthguard (FCM) for the fourth and fifth week.
16280972|NCT04809675|Active Comparator|FCM-FCM-HOS-HOS sequence|Use of a flexible customized mouthguard (FCM) for the first two weeks, followed by a week off, and a hard occlusal splint (HOS) for the fourth and fifth week.
16280973|NCT04809662||Main cohort|This is a split-body study, with patients acting as their own controls between lesional and nonlesional skin. All patients will apply imiquimod.
16280974|NCT04809649|Experimental|SUBA-itraconazole|Drug: SUBA-itraconazole Dosage Form: 65 mg capsules Dosage: 260 mg/day Frequency: 130 mg twice daily (BID) Duration: Up to 180 days
16280977|NCT04809610|Experimental|Intervention group: Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises, and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
16280978|NCT04809610|No Intervention|Control group: Waiting list control group.|Participants in this condition will be informed that they will have access to the intervention at 3 months (after the intervention group).
16280979|NCT04809571|Experimental|Photoacoustic imaging and Confocal Raman spectroscopy measurement|
16280980|NCT04809558|Active Comparator|Max intensity with no visual biofeedback|Tongue resistance exercises completed at maximum intensity with no visual biofeedback.
16280982|NCT04809558|Active Comparator|Max intensity with visual biofeedback|Tongue resistance exercises completed at maximum intensity with visual biofeedback of performance.
16280983|NCT04809558|Active Comparator|Progressive intensity with visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with visual biofeedback of performance.
16280984|NCT04809545|Experimental|Intervention|The study intervention consists of the delivery of a soundscape in the private rooms of the participant during the morning and evening. The soundscape is personalized and consists of a collection of natural sounds, birdsongs, kitchen sounds, music, bell sound, outdoor sounds, water/rain sounds, and similar.
16280985|NCT04809545|Active Comparator|Treatment as Usual|As part of usual care, patients on the Specialized Dementia Unit receive a comprehensive assessment of their health and symptoms of dementia involving consultation by a geriatric psychiatrist, geriatrician, physical therapist, occupational therapist, and recreation therapist, and pharmacological and non-pharmacological treatment plans are developed and executed. All participants in the study will receive this standard of care
16280986|NCT04809532|Experimental|Group A|Transverse abdominis plane (TAP ) block via 20ml 0.25% bupvicaine on both sides of midline will be given at end of surgery
16280987|NCT04809532|No Intervention|Group B|At the end of surgery, no additional intervention will be done.
16280988|NCT04809519|Experimental|UHTINuM|UHTINuM is an acronym that defines multimodal interventions consisting of three components. These interventions are as follows: (1) Structured yoga program including meditation and breathing techniques (2) Hypertensive Treatment Compliance Training (3) Teaching blood pressure measurement and monitoring at home.
16280989|NCT04809519|Active Comparator|Control group|Control group will be receive information notes and standard brochures related to physical activity, healthy lifestyle behaviors advice, stop smoking etc. and will be referred to a specialist physician.
16280990|NCT04809506||Patient consulting the Centre for Screening and Prevention of Atherosclerosis|2 additional blood samples (2 x 7ml) at every visit
16280991|NCT04809493||patients will be receiving conventional dialysis|Patients will be receiving conventional dialysis treatment followed by isonatremic dialysis treatment during an observational period of 2 months for each treatment
16280992|NCT04809480||Non-COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from January 2017 up to February 2020
16280993|NCT04809480||COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from February 2020 up to December 2020 with positive COVID19 PCR test
16280994|NCT04809467|Experimental|tafasitamab + parsaclisib|"Participants will be assigned to disease specific cohorts based on the histology of their underlying disease.
~Cohort 1: R/R DLBCL Cohort 2: R/R MCL Cohort 3: R/R FL Cohort 4: R/R MZL Cohort 5: R/R CLL/SLL"
16280995|NCT04809441|Experimental|Weight loss group|Participants were rigorously evaluated by the same endocrine doctor and podiatrist at baseline (Session 1) and at the end of the study after weight loss intervention (Session 2), when each participant had lost between 11-12% of its corporal weight. Therefore, we obtained 2 weight related with the two sessions: Session 1 - Weight 1; Session 2 - Weight 2.
16280996|NCT04809428||vNOTES Salpingectomy|Elective bilateral salpingectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
16280997|NCT04809428||LS Salpingectomy|Elective bilateral salpingectomy by conventional laparoscopy
16280998|NCT04809415|Sham Comparator|Sham Group (G-S)|The LED blanket will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
16280999|NCT04809415|Experimental|300J Infrared Blanket LED Group (Blanket-300J)|The LED blanket with a wavelength of 940nm, energy of 300J, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
16281000|NCT04809415|Experimental|300J Infrared Cluster LED Group (Cluster-300J)|The LED Cluster with a wavelength of 850 nm, energy of 300 J, will be applied to the quadriceps (5 points) and hamstrings (5 points), bilaterally, just before the strength training protocol.
16281001|NCT04809402|Other|Telemonitoring|Subjects in the telemonitoring group will have post-operative follow-up measurements involving teleconsultations, remote eye exams and health questionnaires.
16281002|NCT04809402|No Intervention|Usual care|Subjects in the usual care group will receive regular post-operative care, mostly involving in-hospital consultations.
16281003|NCT04809389|Experimental|Test Product|DelNS1-nCoV-RBD LAIV at 1×107 EID50 and 1×107.7 EID50, 2 doses 4 weeks apart, intranasal administration
16281004|NCT04809389|Placebo Comparator|Reference Product|Matching placebo, 2 doses 4 weeks apart, intranasal administration
16281005|NCT04809376|Experimental|PPS Twice Weekly|Pentosan Polysulfate Sodium (PPS) twice weekly for 6 weeks
16281006|NCT04809376|Experimental|PPS Once Weekly|Pentosan Polysulfate Sodium (PPS) + placebo once weekly for 6 weeks
16281007|NCT04809376|Experimental|PPS Fixed Dose Once Weekly|Pentosan Polysulfate Sodium (PPS) Fixed dose (100mg or 150mg) once weekly + placebo once weekly for 6 weeks
16281008|NCT04809376|Placebo Comparator|Placebo|Placebo twice weekly for 6 weeks
16281009|NCT04809363|Experimental|CDPATH™|Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.
16281010|NCT04809350|Active Comparator|Adjustable Human Milk Fortification|Human milk fortification based on blood urea levels
16281011|NCT04809350|Experimental|Targeted Human Milk Fortification|Human milk fortification based on milk analysis
16281012|NCT04809337|Experimental|Stabilization Exercise Group|
16281013|NCT04809337|Experimental|Therapeutic Exercise Group|
16281014|NCT04809324|Experimental|Gross examination|measurement of the surgical margins will be done by the surgeon in the operating room using sterile scale after resection of the primary tumor .
16281015|NCT04809324|Active Comparator|Frozen section|frozen section examination of surgical margins will be done by the pathologist.
16281016|NCT04809311||Lifestyle intervention ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician.
16286253|NCT04772274|Active Comparator|EU Stelara|EU sourced Stelara (ustekinumab)
16281017|NCT04809311||Other oral antidiabetic drugs (OADs) ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
16281018|NCT04809311||Basal insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
16281019|NCT04809311||Glucagon-like peptide-1 (GLP-1) ± Basal insulin (loose and fixed combination) ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
16281020|NCT04809311||Basal + Bolus or premixed insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
16281021|NCT04809298|Other|Free-hand lumbar punction|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the free-hand method.
16281022|NCT04809298|Active Comparator|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
16281024|NCT04809272|Experimental|ParentChat for parents of children ages 2-17|The ePLH parent support groups will be delivered over a 8 week period (i.e., 7-8 short online interactive group sessions, two per week). ePLH facilitators will moderate discussions around the parenting theme, support parents on an individual basis, and encourage them to apply the parenting skills at home. The facilitators will begin the next group engagement with a brief voice summary of the feedback and address possible solutions to 2-3 key challenges. Facilitators will also be provided with weekly supervision by an ePLH coach or trainer. A designated research assistant will provide parent support groups with needed technical support during the implementation - including IT-related support. Data bundles will be provided for internet access and to incentivise engagement.
16281025|NCT04809259|Experimental|Continuous infusion of meropenem|The meropenem solution will be administered continuously using elastomeric pumps which will be changed every 24 hours and which will be inserted in an isothermal pouch to ensure that the antibiotic solution is maintained at a temperature between 10° and 15°
16281026|NCT04809246|No Intervention|Standard of care|The first group (n=240) of participants enrolled in the study will be assigned to the control period to receive the standard of care.
16281027|NCT04809246|Experimental|'One-stop-shop' intervention|Following the control period, the second group (n=480) of participants enrolled in the study will be assigned to the intervention period to receive the 'one-stop-shop' intervention.
16281028|NCT04809220|Experimental|1.5 mg Dulaglutide|"1.5 mg Dulaglutide given subcutaneously (SC).
~Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medications (OAM).
~Participants taking DPP-4 inhibitors (DPP-4i) to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period."
16281029|NCT04809220|Active Comparator|0.75 mg Dulaglutide|"0.75 mg Dulaglutide given SC.
~Dulaglutide will be given alone or in combination with 1 OAM.
~Participants taking DPP-4i to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period."
16281030|NCT04809207|Experimental|CF Wellness Program|Participants will receive CF Wellness Program sessions.
16281031|NCT04809181|Experimental|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
16281032|NCT04809168||AS patients|AS patients diagnosed according to the modified New York criteria
16281033|NCT04809168||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint lasting more than three months
16281034|NCT04809155|Experimental|Girl2Girl|Girls receive text messages that address the information, motivation, and behavioral skills components need to prevent unwanted pregnancy.
16281035|NCT04809155|No Intervention|Control - Healthy lifestyle|Girls receive text messages about a 'healthy lifestyle', including healthy social media use and self-esteem.
16281036|NCT04809142|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16281037|NCT04809142|Active Comparator|Chemotherapy|Capecitabine tablets combined with oxaliplatin injection or gemcitabine hydrochloride injection. Each cycle is 3 weeks.
16281038|NCT04809129|Experimental|External mechanical loading|"Following bariatric surgery (RYGB or SG) patients will be asked to wear a weighted vest for a minimum of 8 hours daily and during physical exercise for three months postoperatively.
~Weight will be incrementally added on a weekly basis to maintain the baseline weight as patients lose weight following surgery up to a maximum of 15%."
16281039|NCT04809129|No Intervention|Standard postoperative care|Patients following bariatric surgery (RYGB or SG) will receive standard postoperative care.
16281040|NCT04809116|Experimental|open-label pimavanserin 34mg at bedtime for 6 weeks|Subjects enrolled into treatment with open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
16281041|NCT04809103|Experimental|Intratumoral Cisplatin Arm|Single arm approach. There is no comparator or placebo group. Cisplatin will be administered directly into a non-small cell lung cancer, following imaging verification and pathologic diagnosis, during a single bronchoscopic procedure.
16281042|NCT04809090|Active Comparator|SMT Group|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews
16281043|NCT04809090|Experimental|SMT+CA|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews and subjects will use an APP together a CA (Conversational Agent) an Artificial Intelligence.
16281044|NCT04809090|Experimental|Only CA|This group will receive only an APP together a CA (Conversational Agent) an Artificial Intelligence.
16281045|NCT04809090|No Intervention|Waiting-List|This group will not receive any intervention
16281046|NCT04809077|Other|Reverse total shoulder replacement|Patients who underwent a total shoulder replacement using a reverse type implant (Delta Xtend or Zimmer TM)
16281047|NCT04809064|Experimental|Arthroscopic Bankart repair with remplissage of Hill-Sachs lesion/rehabilitation|Arthroscopic Bankart repair surgery with remplissage of Hill-Sachs lesion and post-operative rehabilitation.
16281050|NCT04809051|No Intervention|Condition 1: Combined Transplant Pictograph|"Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a survival rate pictograph corresponding to all patients at the center who received transplants."
16281051|NCT04809051|Experimental|Condition 2: Stratified Transplant Pictograph|"Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of survival rate pictographs corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
16281052|NCT04809051|Experimental|Condition 3: Combined Transplant SRTR|"Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a quintile score corresponding to all patients at the center who received transplants."
16281053|NCT04809051|Experimental|Condition 4: Stratified Transplant SRTR|"Participants randomized to Condition 4 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of quintile scores corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
16281054|NCT04809038|Experimental|dry needling|dry needling will be received twice a week for four weeks
16281055|NCT04809038|Experimental|magnesium sulphate iontophoresis|magnesium sulphate iontophoresis will be received twice a week for four weeks
16281056|NCT04809038|Active Comparator|stretching exercise|stretching will be received twice a week for four weeks
16281057|NCT04809025||the pathology of endoscopic biopsy|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on endoscopic biopsies
16281058|NCT04809025||the pathology of surgical resection specimen|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on surgical resection specimens
16281059|NCT04809012|Experimental|STI-3031|20 mg/kg STI-3031 administered intravenously Q2W
16281060|NCT04808999|Experimental|Pembrolizumab|Neoadjuvant Phase: 200 mg IV infusion, every 3 weeks (Day 1 of each 3-week cycle, 2 cycles) Adjuvant Phase: Day 1 of each 3-week cycle, 15 cycles
16281061|NCT04808986|Other|serology COVID-19|Serology of COVID-19 will be proposed to all health professionels and household members included in the study
16281062|NCT04808973|Experimental|Lamivudine plus Dolutegravir in FDC|Single arm of 3TC+DTG for treatment of pregnant women with HIV infection
16281065|NCT04808934||Non-Valvular Atrial Fibrillation (NVAF) Adults|Adult patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban or VKAs between June 16, 2014 and December 31, 2018.
16281066|NCT04808921|Experimental|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
16281067|NCT04808908|Experimental|N-803|All participants will receive the intervention, N-803 treatment.
16281068|NCT04808895|Active Comparator|Acetylsalicylic acid|Tablets of 100 mg acetylsalicylic acid (one 100 mg daily dose. On the first day a loading dose of 300 mg will be administered)
16281069|NCT04808895|Placebo Comparator|Placebo|Tablets of placebo, identical to active comparator (one tablet daily dose. On the first day 3 tablets will be administered)
16281070|NCT04808882|Experimental|Low dose prophylactic anticoagulation|LD-PA : 3500 IU/24h
16281071|NCT04808882|Experimental|High dose prophylactic anticoagulation|HD-PA : 7000 IU/24h.
16281072|NCT04808882|Experimental|Therapeutic anticoagulation|TA : 175 IU/kg/24h.
16281073|NCT04808869|Sham Comparator|Control|Cycling at 70 rpm 3 times/week without any blood flow restriction cuffs
16281074|NCT04808869|Experimental|BRF 60% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in one leg.
16281075|NCT04808869|Experimental|BFR 80% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in one leg.
16281076|NCT04808869|Experimental|BFR Bilateral 60%|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in both legs.
16281077|NCT04808869|Experimental|BFR 80% Bilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in both legs.
16281078|NCT04808856|Experimental|ACTH|Adrenocorticotropic Hormone
16281079|NCT04808856|Active Comparator|Methylprednisolone|Methylprednisolone
16281081|NCT04808830||Pulmonary arterial hypertension|Adult patients with pulmonary arterial hypertension
16281082|NCT04808817|Experimental|patients|
16281083|NCT04808804||DM|Patients With Type 2 Diabetes Mellitus without any signs of diabetic retinopathy or with mild non proliferative diabetic retinopathy
16281084|NCT04808804||Healthy|healthy controls
16281085|NCT04808791|Experimental|Single Arm iTTO treatment|"Patients will receive the combination of irinotecan, TAS-102, and Oxaliplatin on a 28 day cycle with the following doses;
~Irinotecan 160mg/m2 IV infusion over 60-90 mins on day 1
~Oxaliplatin 100mg/m2 IV infusion over 2 hours on day 1
~TAS-102 (Trifluridine/Tipiracil) 25mg/m2 twice a day, on days 1-5 and 8-12 every 28days."
16281181|NCT04808089|Active Comparator|Usual care|The research assistant assess/ teach inhaler technique, offering the asthma education as the regular clinical service.
16281086|NCT04808778||Participants with sickle cell anemia identified with neurological morbidity|"Successful completion of screening procedures inclusive of 1.) Cerebral blood flow velocity greater than or equal to 200 cm/sec measured twice or 2.) At least one measurement greater than or equal to 220 cm/sec in the middle cerebral artery or 3.) Two TCD measurements above 190 cm/sec within a three-month interval;
~MRI showing cerebral infarcts with or without (based on Silent Cerebral Infarct Trial (SIT) criteria) neurological deficits on standard neurological examination;
~Informed consent from a participant (> 18 years) or parent/legal guardian for participants (< 18 years) and assent of the participant completed;
~Acceptance of hydroxyurea therapy for one year as standard care. After one year of therapy, the participant will have the option to continue therapy with follow-up visits to monitor adherence to therapy with his or her care provider."
16281087|NCT04808778||Participants with sickle cell anemia identified to be without neurological morbidity|"Successful completion of screening procedures inclusive of cerebral blood flow velocity less than or equal to 199 cm/sec in the middle cerebral artery;
~Normal MRI and MRA;
~No focal neurological deficit on standard neurological examination;
~Informed consent from a participant (> 18 years), or parent/legal guardian for participants (< 18 years) and assent from the participant;
~Agreement to be followed for at least one year in the study."
16281088|NCT04808765|Experimental|VAC group|A randomized group of patients receiving negative pressure wound therapy dressing (Avelle-ConvaTec) on closed incision
16281089|NCT04808765|Active Comparator|ST group|A randomized group of patients receiving standard dressing (sterile gauze and medical tape) on closed incision
16281090|NCT04808752|Experimental|Almonertinib high-dose group|Patients who meet the criteria for inclusion and exclusion will be included in the high-dose almonertinib treatment group and receive oral almonertinib 165 mg once a day
16281091|NCT04808726|Other|Control Group|standard breastfeeding education and counseling service to another group
16281092|NCT04808713|Experimental|Treatment condition|
16281093|NCT04808713|No Intervention|Waitlist condition|
16281094|NCT04808700|Other|Focal cartilage lesion|Patients with focal cartilage lesions who underwent a knee surgery using the Episealer implant
16281095|NCT04808687|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles
16281096|NCT04808674|Experimental|Group-based cognitive remediation program|Patients are admitted to the day hospital 2 days a week for 6 weeks and participate in a group-based (4 patients per group) rehabilitation program conducted by a multidisciplinary team including a PMR doctor, a neuropsychologist, an occupational therapist, and a physical activity monitor).
16281097|NCT04808674|Experimental|One-on-one cognitive remediation program|Patients are admitted to the day hospital 5 days a week for 6 weeks and participate in a one-on-one intensive rehabilitation program conducted by a multidisciplinary team including a speech therapist, neuropsychologist, occupational therapist, physiotherapist, physical activity monitor and a psychologist.
16281098|NCT04808661|Experimental|Intervention group|Thoracic endovascular aortic repair plus optimal medical therapy
16281099|NCT04808661|Active Comparator|Conservative group|Optimal medical therapy
16281100|NCT04808648|Experimental|Itraconazole and SH-1028|In the itraconazole study, patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.
16281101|NCT04808648|Experimental|Rifampicin and SH-1028|In the rifampicin study, patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16
16281102|NCT04808635||general surgery residents|
16281103|NCT04808635||orthopedic surgery residents|
16281104|NCT04808635||urology residents|
16281105|NCT04808635||OBGYN residents|
16281106|NCT04808622|Experimental|TSC 0.5 mg/kg|TSC 0.5 mg/kg given as a one-time IV bolus injection
16281107|NCT04808622|Experimental|TSC 1.0 mg/kg|TSC 1.0 mg/kg given as a one-time IV bolus injection
16281108|NCT04808622|Experimental|TSC 1.5 mg/kg|TSC 1.5 mg/kg given as a one-time IV bolus injection
16281109|NCT04808622|Experimental|TSC 2.0 mg/kg|TSC 2.0 mg/kg given as a one-time IV bolus injection
16281110|NCT04808622|Experimental|TSC 2.5 mg/kg|TSC 2.5 mg/kg given as a one-time IV bolus injection
16281111|NCT04808622|Placebo Comparator|Placebo|7 mL normal saline given as a one-time IV bolus injection
16281112|NCT04808609|Experimental|Intervention|The Intervention group receives standard smoking cessation counseling and nicotine replacement therapy AND access to the Lumme app that tracks smoking behaviors and provides cessation support.
16281113|NCT04808609|Other|Control|The Control group receives standard smoking cessation counseling and nicotine replacement therapy
16281114|NCT04808583|Active Comparator|Group (A)|conventional TLH with uterine artery ligation after the cornual pedicles
16281115|NCT04808583|Experimental|Group (B)|TLH with uterine artery ligation at its origin at the beginning of the operation
16281116|NCT04808570|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
16281117|NCT04808557|Active Comparator|Trial Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Biorepair Total Protection for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
16281118|NCT04808557|Active Comparator|Control Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Sensodyne Repair & Protect for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
16281119|NCT04808544|Placebo Comparator|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
16281120|NCT04808544|Active Comparator|Naldebain group|Patients assigned to Naldebain group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
16281145|NCT04808336|Active Comparator|PRP injection group|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
16281146|NCT04808336|Active Comparator|surgical group..|Group 2: thirty patients underwent surgery
16281182|NCT04808076|Active Comparator|iNPH patients|Shunt operation
16281121|NCT04808531|Placebo Comparator|Double Placebo Arm|"Spray Placebo + Tablet Placebo Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian Office of Drug Control (ODC) (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.
~Tablet Placebo will be identical to the Oxycontin tablets."
16281122|NCT04808531|Experimental|Treatment NanaBis™ Arm|NanaBis™ + Tablet Placebo NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC and CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD. The dose administered will be 2 - 3 doses per 4 hours unless asleep.
16281123|NCT04808531|Active Comparator|Comparator (Oxycodone) Arm|"Spray Placebo + Oxycodone CR Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian ODC (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.
~Oxycodone controlled release (CR) used as a comparator will be Oxycontin tablets 10 mg - 70 mg po bd."
16281124|NCT04808518||Bx reg group|
16281125|NCT04808518||non-Bx reg group|
16281129|NCT04808492|Experimental|CureWave High Intensity Laser|The participant will lie prone and the HILT will be administered in two preliminary test locations. In order to evaluate any possible adverse reactions, the initial treatment location will be delivered at a decreased intensity at two separate locations above the target treatment areas. The Power for these two locations will be at a half dose (22 W) for one minute each. The initial, half dose treatment area is indicated by the Blue circles in the image below. Upon conclusion of the initial test treatments (at half dose), the skin with be evaluated for excessive redness or any other changes in skin appearance. Also, the participant will be asked about any discomfort. Should no unanticipated changes in skin appearance occur and the participant reports no discomfort, the treatment will be administered. The process of applying the laser at half dosage will occur prior to each treatment.
16281130|NCT04808492|Placebo Comparator|Control|The participant will lie prone and the Placebo HILT will be administered is the same capacity as the treatment group however no Laser treatment will be administered. Upon conclusion of the placebo treatment, the skin with be evaluated for excessive redness or any other changes in skin appearance. Also, the participant will be asked about any discomfort.
16281131|NCT04808479|Experimental|UC imFREE Smartphone application intervention|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
16281132|NCT04808479|Active Comparator|Health Education and pamphlet|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
16281133|NCT04808466|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with paclitaxel): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.
~Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
16281134|NCT04808466|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.
~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
16281135|NCT04808466|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.
~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
16281136|NCT04808453|Experimental|CPI-300|Dose Escalation Group: CPI-300 will be administered via intravenous infusion once every 2 weeks for up to 6 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
16281138|NCT04808414|Experimental|QPX9003 for IV infusion|IV novel polymyxin antibiotic Single and Multiple IV doses x 7 days via IV infusion q6hrs
16281139|NCT04808414|Placebo Comparator|Placebo for Infusion|IV saline Single and Multiple IV doses x 7 days via IV infusion q6hrs
16281140|NCT04808401|Experimental|Normoxaemia First + Hyperoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
16281141|NCT04808401|Experimental|Normoxaemia First + Normoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive normoxic concentrations.
16281142|NCT04808401|Experimental|Hyperoxia First + Hyperoxia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
16281143|NCT04808401|Experimental|Hyperoxia First + Normoxaemia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive normoxic concentrations.
16281144|NCT04808362|Experimental|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
16281147|NCT04808323|Experimental|Cohort A|Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
16281148|NCT04808323|Experimental|Cohort B|Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
16281149|NCT04808323|Experimental|Cohort C|Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
16281150|NCT04808310|Active Comparator|Angiography|The indication to further coronary intervention will be based on angiographic diameter stenosis.
16281151|NCT04808310|Experimental|Quantitative flow ratio (QFR)|The indication to further coronary intervention will be based on QFR.
16281152|NCT04808284|Experimental|tDCS-SMA|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the supplementary motor area (SMA) for 30 minutes.
16281153|NCT04808284|Experimental|tDCS- DLPFC|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC) for 30 minutes.
16281154|NCT04808284|Sham Comparator|tDCS- SHAM|Participants randomized to this arm will receive a single session of Sham tDCS for 30 minutes, delivered to supplementary motor area (SMA) or to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC).
16281155|NCT04808271|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
16281156|NCT04808271|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
16281157|NCT04808245|Experimental|Standard patient cohort|"All fifteen patients will receive in total 11 doses of H3K27M peptide vaccine starting with standard radiotherapy (RT) and 14 doses of the human anti-PD-L1 antibody Atezolizumab/ Tecentriq® (every three weeks, q3w) starting four weeks after completion of RT. The first 3 vaccines will be given bi-weekly (q2w) in combination with RT. One dose of vaccination will be given at the beginning of recovery (RE) period following RT. Vaccines 5-11 (q6w) will be initiated with Atezolizumab after completion of RE. The H3K27M peptide vaccine is administered in combination with topical Imiquimod that serves as an adjuvant.
~For safety reasons, the first three patients will be enrolled sequentially: Each patient will receive the first vaccination at the earliest 28 days after the previous patient has received the first vaccination."
16281158|NCT04808232|Experimental|health education and progressive muscle relaxation exercise|Health education and progressive muscle relaxation exercise training was given to women in this group.
16281159|NCT04808232|Experimental|progressive muscle relaxation exercise|Progressive muscle relaxation exercise training was given to women in this group.
16281160|NCT04808232|No Intervention|Control group|women in this group were not intervened.
16281161|NCT04808219||Driver|Ambulance driver who was involved in a traffic collision - video analysis of the collision records and in-depth interview aiming to find the cause of the collision.
16281162|NCT04808206||Obese patients eligible for laparoscopic bariatric surgery|
16281163|NCT04808193|Experimental|Brugada Survey|Survey will be answered by all participants
16281164|NCT04808180|Experimental|Trial Group|Patients from this group have teeth afflicted with MIH. They will be evaluated after home oral care with BioRepair toothpaste containing microRepair®.
16281165|NCT04808180|Active Comparator|Control Group|Patients from this group do not have teeth with demineralizations. The same teeth of Trial Group will be evaluated after home oral care with toothpaste containing microRepair®; if also those teeth are afflicted with MIH, the adjacent teeth will be considered.
16281166|NCT04808167|Experimental|Therapeutic Group|Therapeutic group receives remote ischemic conditioning.
16281167|NCT04808167|No Intervention|Control Group|Control group does not receive remote ischemic conditioning.
16281168|NCT04808154|Experimental|test drug|Powder for oral solution of SNP-630.
16281169|NCT04808141|Experimental|Digital Rehabilitation|Home-based rehabilitation with a digital biofeedback system
16281170|NCT04808141|Active Comparator|Conventional rehabilitation at an outpatient clinic|
16281171|NCT04808128|Experimental|Drink A + SC|In t0 the group will receive 250 ml XL energy drink + 20 gr sucrose.
16281172|NCT04808128|Active Comparator|Drink B + SC|In t0 the group will receive 250 ml Fanta soft drink + 20 gr sucrose.
16281173|NCT04808128|Active Comparator|Drink C + SC|In t0 the group will receive 250 ml soda water + 47 gr sucrose.
16281174|NCT04808128|Experimental|Drink A + CC|In t0 the group will receive 250 ml XL energy drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
16281175|NCT04808128|Active Comparator|Drink B + CC|In t0 the group will receive 250 ml Fanta soft drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
16281176|NCT04808128|Active Comparator|Drink C + CC|In t0 the group will receive 250 ml soda water + 27gr sucrose + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
16281177|NCT04808115|Experimental|KDS-1001|KDS-1001 is infused on Day 1 of each 14 day cycle. Patients will receive 6 cycles of KDS-1001 treatment.
16281178|NCT04808102|Experimental|IER serious game|A serious game training interpersonal emotion regulation strategies.
16281179|NCT04808102|Sham Comparator|control game|A control puzzle game without psychoeducational content.
16281180|NCT04808089|Experimental|Health Lung App. +ezOxygen|"Health Lung App. (AstraZeneca Pharmaceuticals LP) is the application for mobile phone to help asthma care and is available freely in Google Play. Health Lung can be connected to the mobile spirometry, ezOxygen (Genius Holding Co.,Ltd Taiwan Branch).
~The functions of Health Lung App. include asthma control monitor, lung function monitor, controller and reliver inhaler reminder and recording, asthma educational topics in brief and information of air quality
~Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.
~he physicians in charge will get the information about control status score by ACT, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
16281183|NCT04808076|No Intervention|Healthy Individuals|Healthy individuals without any neurological disease.
16281184|NCT04808063|Experimental|Algorithm use for prphylactic mesh after emergency laparotomy|Patients with emergency surgery in whom algorithm for prophylactic mesh is use to help decide abdominal wall mesh reinforcement or not.
16281185|NCT04808037|Experimental|Cohort 1, First Part|12 patients are anticipated to receive Belantamab Mafodotin 2.5 Q8W = 2.5 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
16281186|NCT04808037|Experimental|Cohort 2, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
16281187|NCT04808037|Experimental|Cohort 3, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
16281188|NCT04808037|Experimental|Group A, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.
~In this Arm the ocular toxicity will be graded according to the Dose Modification Guidelines for Corneal-Related Adverse Events Associated with belantamab mafodotin"
16281189|NCT04808037|Experimental|Group B, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.
~In this Arm the ocular toxicity will be graded according to the Dose modification guidance based on visual acuity"
16281190|NCT04808024|Experimental|Players of amateur football leagues|The players of amateur football leagues who will receive SelfMyofascial Release intervention
16281191|NCT04808024|No Intervention|Control group|The players of amateur football leagues who will receive no intervention
16281192|NCT04808011|Experimental|Treatment|Each subjects will be treated with his prescribed dialysis device for 14 days, followed by a treatment period of 30 days with the investigational IDA system, and concluding with additional 14 days of treatment with the prescribed dialysis device.
16281193|NCT04807998||Group EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score of 12 or greater was defined as EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
16281194|NCT04807998||Group non-EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score less than 12 was defined as non-EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
16281195|NCT04807985||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
16281200|NCT04807959||20Lighter Program Participants|All enrolled subjects will have completed a 20Lighter anti-obesity program prior to enrollment.
16281201|NCT04807933|Experimental|Experimental group (BFB training)|The participants assigned to the experimental group will do the biofeedback training using the Emwave software during the intervention period (T2-T3). The biofeedback software (Emwave Pro®) includes a photoplethysmography sensor that can be positioned on the earlobe. The installation of the program and the explanations needed for using it, will be done during the second session (T2). According to the guidelines, a fractional training is proposed 5 minutes, 3 times a day for 24 days (T2-T3).
16281202|NCT04807933|No Intervention|Control group (no BFB training)|The participants assigned to the experimental group will not do a specific exercise during the intervention period (T2-T3).
16281203|NCT04807920|Experimental|Intravesical OnabotulinumtoxinA|The treatment group will receive 100 units of BOTOX® reconstituted in 10mL of injectable preservative-free normal saline at the time of cystoscopy. An injection cystoscopy needle will be set to 3mm and used to inject 0.5mL reconstituted OnabotulinumtoxinA at each injection site, approximately 1cm apart along the posterior bladder wall, for a total of 20 injection sites (4 rows of 5 injection sites). This will be the only treatment.
16281204|NCT04807920|Placebo Comparator|Placebo|Subjects randomized to the placebo group will undergo the same procedure but will only receive 10mL of injectable preservative-free normal saline. This will be the only treatment.
16281205|NCT04807907|Experimental|Infant Directed Speech (IDS) Video + IDS Calendar|The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.
16281206|NCT04807907|No Intervention|Control|No intervention. The participant will receive a regular wall calendar with an image of Stanford.
16281207|NCT04807894|Experimental|Vaginal Testosterone Cream Arm|Women enrolled in this arm will receive vaginal testosterone cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
16281208|NCT04807894|Placebo Comparator|Vaginal Placebo Cream Arm|Women enrolled in this arm will receive vaginal placebo cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
16281209|NCT04807881|Experimental|Keynatinib treatment group|Keynatinib, 20 mg，BID
16281210|NCT04807868||Biopsy Group|Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
16281211|NCT04807868||Non-Biopsy Group|Adults without any history of NAFLD
16281212|NCT04807855|Experimental|the experimental arm|All subjects, the ptosis group and the normal group receive the same intervention.
16281215|NCT04807829|Experimental|Nabilone|Patients in the treatment group will be administered oral Nabilone 2 mg once daily for 3 days in addition to treatment as usual according to current clinical guidelines and standard of care.
16281216|NCT04807829|Placebo Comparator|Placebo Comparator|Patients in the Placebo Comparator group will receive placebo once daily for 3 days plus treatment as usual.
16281217|NCT04807816|Experimental|Experimental Arm A: treatment by berzosertib combined with gemcitabine|Patients with advanced leiomyosarcomas will be treated with berzosertib combined with gemcitabine
16281218|NCT04807816|Other|Standard Arm B: treatment by gemcitabine alone|Patients with advanced leiomyosarcomas will be treated with with gemcitabine alone (control arm)
16281219|NCT04807803|Experimental|Patients with compensated cirrhosis and portal hypertension|
16281220|NCT04807790|Experimental|Telerehabilitation based structured home program group|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.
~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
16281221|NCT04807790|No Intervention|Routine physiotherapy and rehabilitation group|Routine physiotherapy and rehabilitation practices, consist of activities organized by physiotherapists as one or two sessions per week according to the functional levels of children with CP. Routine physiotherapy and rehabilitation applications include increasing postural control, gaining motor development steps, strengthening training, balance training, long-term stretching training, manual therapy, hydrotherapy, hippotherapy and neurodevelopmental therapy approaches.
16281222|NCT04807777|Experimental|Ruxolitinib|"In a safety lead-in of 6 patients, subjects will receive 15mg of ruxolitinib twice daily (BID). After 4 weeks, if dose-limiting toxicities (DLT) are observed in 1 or fewer patients, the study will enter stage 1 of the Simon two-stage design where all subsequent patients will receive a starting dose of ruxolitinib 15mg BID.
~Subjects will have regularly scheduled study visits at the clinical site on Day 1 and Day 15 (± 3 days) of the first 2 cycles, then on Day 1 (± 3 days) of every subsequent cycle (starting cycle 3), where safety assessments, including laboratory assessments, vital signs, and physical examinations will be performed."
16281223|NCT04807764|Experimental|Real transspinal stimulation delivered during standing followed by locomotor training|Transspinal tonic stimulation of the thoracolumbar region will be delivered at a frequency of 30 Hz during standing with as needed body weight support (BWS) in a standing frame or in the Lokomat to ensure safety.
16281224|NCT04807764|Experimental|Real transspinal stimulation delivered while lying supine followed by locomotor training|Transspinal tonic stimulation will be delivered at a frequency of 30 Hz while lying supine.
16281225|NCT04807764|Sham Comparator|Sham transspinal stimulation delivered during standing followed by locomotor training|One sham group will be receiving transspinal stimulation during standing at an intensity where sensation is absent.
16281226|NCT04807751|Experimental|Delgocitinib cream 20 mg/g|topical occlusive administration
16281227|NCT04807751|Placebo Comparator|Delgocitinib cream vehicle|topical occlusive administration
16281228|NCT04807751|No Intervention|Untreated skin|topical occlusive administration
16281229|NCT04807738|Active Comparator|"Neuroproprioceptive facilitation and inhibition"|"ARM 1 - Neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT), with former positive probative evidence on MS and are recommended for MS intervention."
16281230|NCT04807738|Experimental|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"ARM 2. Experimental group, neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) through virtual reality and software inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). We believe that the VR environment might lead to better results due to greater motivation effect, novelty effect, entertainment effect, as well as activating the reward system. We believe the VR might enhance the activation of mirror neurons, it might also activate proprioception. The present physiotherapist is to ensure proper execution of the tasks. The correlation of the two arms of the study should indicate, whether virtual reality and the software used are as effective, or more effective in sustaining the hand motor function and axial stability, than traditionally led therapy."
16281231|NCT04807725||Peri-implant health|Includes patients with peri implant mucosa without inflammatory signs and absence of peri-implant bone loss.
16281232|NCT04807725||Peri-implantitis|Includes patients with bleeding and / or suppuration on probing, probing depth equal or greater than 6mm and bone loss equal to or greater than 3mm.
16281233|NCT04807699||Total participants|3500 participants that will have their medical forms checked
16281234|NCT04807686|Active Comparator|traditional algorithm|
16281235|NCT04807686|Experimental|notched-type algorithm|
16281236|NCT04807673|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m^2 IV on Day 2 Q3W, and cisplatin 80 mg/m^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year.
~Surgery: McKeown esophagectomy"
16281237|NCT04807673|Experimental|neoadjuvant chemoradiotherapy+ Surgery (114)|"neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment.
~Surgery: McKeown esophagectomy"
16281238|NCT04807660||Prospective cohort|Middle ear fluid sample for each enrrolled children
16281239|NCT04807647|Experimental|music band|"The starting person will first talk about white noise and explain how he can direct breastfeeding, and fill the Informed Volunteer Form, Patient Identification Form and Application Registration Form. The mother and baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. During the second breastfeeding, 30 newborn group Orhan OSMAN's Kolik album will be played on the music player Your Baby Don't Cry. After the process is completed, a written response will be received for the data Premature Baby Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form."
16281303|NCT04807140|Experimental|Toripalimab|Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days
16281240|NCT04807647|No Intervention|control|First, the mother will be informed about the study. Then the appropriate position will be given. The informed volunteer form, the Patient Identification Form and the Application Registration Form will be filled. The mother and the baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. No intervention will be applied during the second breastfeeding. After the procedure is completed, a written response will be received with the data Premature Infant Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form.
16281241|NCT04807634|Other|Group A (control)|Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose
16281242|NCT04807634|Other|Group B (case)|that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes
16281243|NCT04807621|Active Comparator|Platelets|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, a platelet transfusion.
16281244|NCT04807621|Experimental|Fibrinogen|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, fibrinogen concentrate.
16281245|NCT04807608||Healthy Users|Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
16281246|NCT04807595||Retrospective cohort|Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.
16281247|NCT04807569|Experimental|Experimental group|"10 sessions of non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation."
16281248|NCT04807569|Experimental|Control group|one-month course of drug therapy with alpha-1-adrenoblocker according to the standard scheme
16281249|NCT04807543|Active Comparator|study group|17-hydroxyprogesterone caproate (17P) (250 mg in castor oil, 1 mL total volume)intramuscular injection
16281250|NCT04807543|Placebo Comparator|control group|castor oil, 1 mL total volume intramuscular injection
16281251|NCT04807530|Active Comparator|Medial Prefrontal TMS|10 Hz High frequency TMS applied to the mPFC
16281252|NCT04807530|Placebo Comparator|Posterior Superior Temporal TMS|10 Hz high frequency TMS applied to the pSTS
16281253|NCT04807517|Experimental|Buspirone|Subjects will receive buspirone 2.5 mg each morning at the start of the trial. The dose will be increased by 2.5 mg per week in two divided doses daily depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 2.5 mg and the maximum total daily dose will be 30 mg. Medication will be dosed twice daily due to the short half-life (2-3 hours) of this medication.
16281254|NCT04807491|Active Comparator|Kabat Technique's|Kabat exercises on Upper fulcrum, Intermediate fulcrum and lower fulcrum
16281255|NCT04807491|Experimental|Neuromuscular Re-Education:|For initiation, Facilitation, Movement control and movement control
16281256|NCT04807478||Pediatric patients|Pediatric patients with new-onset PNAC
16281257|NCT04807465|Other|G-Premio universal adhesive used in smoker participants|Participants who smoke at least 10 cigarettes per day
16281258|NCT04807465|Other|G-Premio universal adhesive used in non-smoker participants|participants who non-smoke have never smoked before
16281259|NCT04807452|Active Comparator|Strength and balance training|Exercises like ROMS, stretching, static balance and dynamic balance
16281260|NCT04807452|Experimental|Aerobics training|Control Group received aerobic training.
16281262|NCT04807426|Active Comparator|Multi Sensory stimulation exercises|only Multisensory stimulation Exercises
16281263|NCT04807426|Experimental|Task Oriented Exercises|Task-oriented exercises without Multisensory stimulation Exercises
16281264|NCT04807426|Experimental|Task oriented exercises and Multisensory stimulation exercises.|Task-oriented exercises with Multisensory stimulation Exercises
16281265|NCT04807413|Experimental|Study Arm: The balloon will be opened to deliver nitric oxide at 40 ppm.|Nitric oxide balloon will be connected to the CPB machine. Participants randomized to this group will receive 40 ppm nitric oxide through the pump.
16281266|NCT04807413|Active Comparator|Control Arm: The balloon will be closed and no nitric oxide will be delivered.|Participants in this group will receive standard of care treatment. Participation in the trial will not affect surgery management in any way.
16281267|NCT04807400|Experimental|Background Therapy + Behavioural Support|Participants will continue to receive their background lipid lowering therapy plus behavioural support.
16281268|NCT04807400|Experimental|Backgroud Therapy + Inclisiran|Participants will continue to receive their background lipid lowering therapy plus inclisiran for injection.
16281269|NCT04807400|Experimental|Background Therapy + Inclisiran + Behavioral Support|Participants will continue to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.
16281274|NCT04807374|Experimental|Single arm- HCL Therapy|Single arm study with all participants being treated with HCL for 6 months given the non-randomized interrupted time series study design.
16281275|NCT04807361||Subjects|
16281276|NCT04807348|Experimental|Chiglitazar sodium 32mg QD+metformin|Chiglitazar 32mg qd+metformin
16281277|NCT04807348|Experimental|Chiglitazar sodium 48 mg QD+metformin|Chiglitazar 48 mg qd+metformin
16281278|NCT04807348|Placebo Comparator|placebo+metformin|placebo+metformin
16281279|NCT04807335|Experimental|Investigational medicinal product CT001|intranasal dosage of CT001
16281280|NCT04807335|Active Comparator|Comparator 1|Ketamine 10mg iv
16281281|NCT04807335|Active Comparator|Comparator 2|Sufentanil 10mcg iv
16281282|NCT04807322||Elective cases|Patients, who received a RTSA for degenerative reasons like cuff arthropathy or osteoarthritis
16281283|NCT04807322||Fracture cases|Patients, who received a RTSA for a proximal humerus fracture
16281284|NCT04807309|Placebo Comparator|Placebo|Placebo comparison
16281285|NCT04807309|Active Comparator|Danazol Pill|Danazol 200mg orally twice a day
16281286|NCT04807296|Active Comparator|TFLEP|Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.
16281287|NCT04807296|Active Comparator|m-HoLEP|The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.
16281288|NCT04807283|Experimental|Treatment|
16281289|NCT04807270|Active Comparator|T-LAB / PRP KIT|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP KIT injection in 3 sessions will be applied.
16281290|NCT04807270|Active Comparator|T-LAB / PRP INJECTION SYRINGE|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied.
16281291|NCT04807270|Active Comparator|SALINE|In the first group, Platelet-rich plasma (PRP) prepared with SALINE injection in 3 sessions will be applied.
16281292|NCT04807244|Other|Treatment of deep carious lesions: Randomized-controlled trail|Teeth with reversible pulpitis will be included accordingly to the inclusion criteria (see below). After randomization, teeth will be treated either with selective caries removal (indirect pulp capping) or partial pulpotomy pursuant to the below described clinical protocol. The intention of this study arm is to evaluate both therapies.
16281293|NCT04807244|Other|Treatment of deep carious lesions: Prospective non-controlled intervention trial|Teeth with reversible pulpitis according to the inclusion criteria (see below) will be included. Depending on the clinical situation, a partial or full pulpotomy will be conducted accordingly to the defined clinical protocols (see below). In this study arm, we want to evaluate 1) different times of pulpal bleeding before pulp capping and 2) partial versus full pulpotomy on the clinical outcome in teeth with irreversible pulpitis.
16281294|NCT04807218|Active Comparator|Nutritional Ketosis Intervention Referral|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
16281295|NCT04807218|Active Comparator|CHHS Standard Care - Delayed Referral to Nutritional Ketosis Intervention|All subjects will be enrolled in Colorado Heart Healthy Solutions (CHHS), which consists of community health worker (CHW) contact and sessions on: 1) cardiovascular disease knowledge; 2) Health behavior change through skill building to improve diet (e.g., portion sizes, increasing fruit/vegetable intake, reducing intake of sugar sweetened beverages, decreasing fast food meals, etc.), increase physical activity, and improve well-being, tailored to individual subjects' risk profile and self-identified goals; and 3) Connection to services including primary care, mental health services if needed, and relevant community programs to address barriers (e.g. food insecurity, need for legal help) or to promote behavior change (e.g. free/low cost exercise programs).
16281296|NCT04807205|Experimental|Elite IQ Laser|The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.
16281297|NCT04807192|Experimental|Arm 1: SBRT|
16281298|NCT04807192|Experimental|Arm 2: CMP-001 + SBRT|
16281299|NCT04807179|Experimental|Alexandrite Laser|Single arm, self-controlled
16281300|NCT04807166|Experimental|Anlotinib Combined With Carboplatin/Paclitaxel|Anlotinib Combined With Carboplatin/Paclitaxel
16281301|NCT04807153||Patients|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
16281302|NCT04807153||Healthy Controls|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
16281304|NCT04807140|Experimental|Toripalimab + Carboplatin+ Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.
~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.
~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
16281305|NCT04807127||ICI-pneumonitis|Cancer patients experiencing ICI-pneumonitis
16281306|NCT04807127||Radiotherapy induced pneumonitis|Cancer patients experiencing RT-pneumonitis
16281307|NCT04807127||TKI-induced pneumonitis|Cancer patients experiencing TKI-induced pneumonitis
16281308|NCT04807114||NSCLC st.IV (PD-L1 > 50%)|Anti-PD-1 monotherapy
16281309|NCT04807114||NSCLC st.IV (PD-L1 < 50%)|Combination anti-PD-1 + chemotherapy
16281310|NCT04807101|No Intervention|midazolam and fentanyl|Patients in this arm will receive standard conscious sedation with midazolam and fentanyl
16281311|NCT04807101|Experimental|midazolam alone|Patients in this arm will receive conscious sedation with medazepam alone
16281312|NCT04807088|Experimental|Intervention Group|Tactile-kinesthetic stimulation (TKS) was performed with a specific baby oil provided by the investigator. Tactile stimulation was performed while the neonate was in prone position. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Every massage was performed for 2 × 5 seconds, with a total duration of 5 minutes. Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 2 × 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 10 consecutive days.
16281313|NCT04807088|Placebo Comparator|Control Group|Control group was not given TKS.
16281314|NCT04807062|Experimental|DTPFs treated with structural bicortical autologous ICBG combined with TBTM|
16281315|NCT04807010|Active Comparator|Prostate artery embolization|
16281316|NCT04807010|Sham Comparator|Sham|
16281317|NCT04806984||Call center phone call|Participants randomized to this arm will receive a phone call from the call center reminding them to schedule their appointments.
16281318|NCT04806984||No call center phone call|Participants randomized to this arm will not receive a phone call from the call center reminding them to schedule their appointments.
16281319|NCT04806984||MyChart message|Participants randomized to this arm will receive an automated MyChart message reminding them to schedule their appointments.
16281320|NCT04806984||No MyChart message|Participants randomized to this arm will not receive an automated MyChart message reminding them to schedule their appointments.
16281321|NCT04806971||Periodontitis|Patients with stage III, grade B / C periodontitis were diagnosed based on the new classification criteria. [2, 24] Clinical attachment loss ≥5 mm, probing depth (PD) ≥6 mm, ≥20 teeth and radiographic bone loss extending to the middle third of the root. Grade B was evaluated indirectly considering radiographic bone loss in the most affected tooth in the dentition as a function of age (0.25-1.0). Grade C was assessed considering the radiographic bone loss in the most affected tooth in the dentition as a function of age (>1.0).
16281322|NCT04806971||Healthy|The periodontally healthy subjects without any clinical sign of inflammation,not showing a history of periodontitis; PD ≤3 mm; <10% of sites with bleeding on probing (BOP); an absence of detectable attachment and/or bone loss; without extensive caries or restorations and presence of at least 28 permanent teeth. In addition, all the control subjects showed the absence of any local or systemic pathology.
16281323|NCT04806958|Experimental|Conventional Emergency Dispatch PLUS PulsePoint notification|Eligible 911 calls randomized to the experimental arm of the study will undergo usual dispatch of emergency services personnel as per pre-existing local protocols and activation of the PulsePoint system. When triggered, the system will push location data to all PulsePoint mobile application users within 400 meters of the emergency. Devices receiving the alerts from the PulsePoint system will alarm with auditory, tactile and visual stimuli. The application will present a map showing the exact location of the emergency and the closest public access defibrillator.
16281324|NCT04806958|No Intervention|Conventional Emergency Dispatch|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures as per pre-existing local protocols (e.g. dispatch of emergency vehicles, attempted dispatch-assisted CPR) without activation of the PulsePoint system. 911 calls randomized to the control arm will not be associated with any PulsePoint alerts.
16281325|NCT04806945|Experimental|HLX10|HLX10 + chemotherapy
16281326|NCT04806945|Placebo Comparator|Placebo|Placebo + chemotherapy
16281327|NCT04806932|Active Comparator|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
16281328|NCT04806932|Placebo Comparator|The conventional approach|The first three attempts via the conventional approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
16281329|NCT04806919|No Intervention|Control group: Amelgen ® 400 mg BID|Continue daily dose progesteron
16281330|NCT04806919|Experimental|Intervention group: Amelgen ® 400 mg TID|Increase daily progesteron dose
16281331|NCT04806906|Experimental|CC-486|subjects will receive 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
16281332|NCT04806893|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
16281333|NCT04806893|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
16281334|NCT04806880||users|Users of web-application
16281335|NCT04806854|Experimental|LUM-201 (1.6 mg/kg/day)|
16281336|NCT04806854|Experimental|LUM-201 (3.2 mg/kg/day)|
16281337|NCT04806841|Experimental|Intervention group|Participants will have access to 4 weekly supervised training sessions for 3 months. The intervention group will also take part in 3 group meetings (behavioral intervention) and will receive follow-up phone calls from month 4 to 6.
16281338|NCT04806841|Experimental|Control group|Participants will have access to 4 weekly supervised training sessions for 3 months without any behavioral intervention.
16281339|NCT04806828||HF|Preoperative classification of inguinal hernia
16281340|NCT04806802|Experimental|APIOC Sphere or Astigmatism|Single Vision Spherical or Toric Contact Lens
16281434|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing|
16281341|NCT04806789||Children with suspected acute appendicitis|"Cohort: Children with suspected acute appendicitis. Clinical examination (including history of nausea, vomiting, temperature, information of rebound tenderness, right iliac fossa pain, duration of symptoms, gender and weight) and blood samples will be obtained at the emergency department (blood gas, C-reactive protein, neutrophiles and white blood cell count). Radiology (ultrasound and/or computed tomography) will be performed thereafter.
~Outcome measures
~Primary outcome measure: Plasma sodium. To investigate if plasma sodium is an independent predictor of perforation in children with acute appendicitis. In advance, five variables (Plasma sodium, C-reactive protein, symptom duration, age and temperature) will be included in the final multivariable analysis"
16281342|NCT04806776|Active Comparator|24hrs dressing change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
16281343|NCT04806776|Experimental|7d change dressing|Dressing change and sampling were completed 7days after catheterization in the operating room or PICU.(if there is no clinical indication occur,such leaking,blood).
16281344|NCT04806763|Experimental|Menicon Z Night|The experimental group is allocated to wear Menicon Z Night orthokeratology contact lenses for two years
16281345|NCT04806763|Active Comparator|Glasses|The active comparator includes a group that was allocated to wear distance, single-vision glasses for two years
16281346|NCT04806737|Active Comparator|IMP|Teriflunomide 14 mg tablets, first 7 days 5 tablets once pr day, thereafter 1 pr day for another 6 days.
16281347|NCT04806737|Placebo Comparator|Placebo|Sham tablets
16281348|NCT04806724|Experimental|Program #1|Participants attend 5 sessions (1.5 hours each) consisting of education and skills training to address cancer-related reproductive and sexual health concerns. Sessions occur via videoconference.
16281349|NCT04806724|Active Comparator|Program #2|Participants attend 4 sessions (1.5 hours each) consisting of education and skills training to address cancer-related concerns. Sessions occur via videoconference.
16281350|NCT04806711|Experimental|Menicon Z Night|The experimental arm consist of a group of Menicon Z Night orthokeratology contact lens wearers
16281351|NCT04806711|Active Comparator|Control|The active comparator arm consist of a control group of distance, single-vision glasses and contact lens wearers
16281352|NCT04806698|Experimental|Menicon Z Night|The experimental arm includes a group of children wearing Menicon Z Night orthokeratology contact lenses for 7 years
16281353|NCT04806698|Active Comparator|Control|The active comparator arm includes a control group of children wearing distance, single-vision glasses or soft contact lenses
16281354|NCT04806685|Experimental|Intervention|Diet therapy plus sleep education
16281355|NCT04806685|Other|Control|Diet therapy
16281356|NCT04806659|Experimental|SH1573 Capsules|SH1573 capsules administered orally. Multiple doses will be administered by effiacy and safety to determine the RP2D.
16281357|NCT04806646|Experimental|Single Arm Treatment|"One cycle of therapy is defined as 28 days of sonidegib. The patient will start with TS1 schedule.
~TS1: assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.
~TS2: assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.
~If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study."
16281358|NCT04806633|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following cardiac catheterization and PCI
16281359|NCT04806633|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following cardiac catheterization and PCI
16281360|NCT04806620||People with ME/CFS|No intervention will be administered.
16281361|NCT04806620||People with Long-COVID|No intervention will be administered.
16281362|NCT04806620||Healthy Controls|No intervention will be administered.
16281363|NCT04806607|Active Comparator|19Gauge Fine Needle Biopsy|19Gauge Fine Needle
16281364|NCT04806607|Active Comparator|22 Gauge Fine Needle Biopsy|22Gauge Fine Needle
16281365|NCT04806594|Experimental|Papix acne scar|Papix acne scar gel for 8 consecutive weeks, 2 times per day
16281366|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 1|"Participants will each be administered L dose for one time. With 28days follow-up after the cells infusion.
~Allogeneic hepatocyte cell numbers: L"
16281367|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 2|"Participants will each be administered M dose for one time. With 28days follow-up after the cells infusion.
~Allogeneic hepatocyte cell numbers: M"
16281368|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 3|"Participants will each be administered H dose for one time. With 28days follow-up after the cells infusion.
~Allogeneic hepatocyte cell numbers: H"
16281369|NCT04806568|Experimental|PwMS-CogTr|Adult individuals with Multiple Sclerosis that will follow a cognitive training intervention.
16281370|NCT04806568|No Intervention|PwMS-Con|Adult individuals with Multiple Sclerosis serving as passive controls.
16281371|NCT04806555|Experimental|Compression ultrasound|All recruited patients
16281372|NCT04806542|Experimental|TMR-group|8-week program for schoolchildren called TMR (Training for Resilience and Mindfulness).
16281373|NCT04806542|Active Comparator|Treatment as Usual|Individual counselling.
16281374|NCT04806529|Experimental|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|The experimental group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
16281375|NCT04806529|Placebo Comparator|The Comparator Group - Placebo|The comparator group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
16281376|NCT04806516|Experimental|Summit RC+S DBS Implant for OCD|All subjects will receive surgical implantation of RC+S DBS system with ECoG paddles
16281435|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing, Personalized Recommendation|
16281436|NCT04806165|Experimental|Psychoeducation, Personalized Recommendation, Repeated Administration|
16281377|NCT04806516|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
16281378|NCT04806503|Experimental|UNR844 Low|UNR844 Low ophthalmic solution; one drop twice-a-day for three months
16281379|NCT04806503|Experimental|UNR844 Medium 1|UNR844 Medium 1 ophthalmic solution; one drop twice-a-day for three months
16281380|NCT04806503|Experimental|UNR844 Medium 2|UNR844 Medium 2 ophthalmic solution; one drop twice-a-day for three months
16281381|NCT04806503|Experimental|UNR844 High|UNR844 High ophthalmic solution; one drop twice-a-day for three months
16281382|NCT04806503|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution; one drop twice-a-day for three months
16281383|NCT04806490||Chinese participants with Yin Deficiency Syndrome|"The participants with Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.
~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
16281384|NCT04806490||Chinese participants without Yin Deficiency Syndrome|"The participants without Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.
~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
16281385|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - telemedicine before face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone telemedicine consultation before face-to-face evaluation
16281386|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - only face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone only face-to-face evaluation
16281387|NCT04806464|Experimental|Single Arm|"Part1:
~1.0*10^8 PFU on Day 1
~1.0*10^8 PFU on Days 1 to 2
~1.0*10^8 PFU on Days 1 to 3
~1.0*10^8 PFU on Days 1 to 4
~1.0*10^8 PFU on Days 1 to 5
~Part2:
~Depends on the recommended dose in Part1"
16281388|NCT04806451|Experimental|Crinecerfont|Solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment for 24 weeks.
16281389|NCT04806451|Placebo Comparator|Placebo|Solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment for 24 weeks.
16281390|NCT04806438|Active Comparator|Group A (nebulized lignocaine group)|Patients will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
16281391|NCT04806438|Active Comparator|Group B (nerve block group)|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice.
16281392|NCT04806425|Active Comparator|IL group|receive 1.5 ml /kg intralipid 20% through Central venous line after sternotomy over 1 hour
16281393|NCT04806425|Placebo Comparator|NS group|recieve 1.5 ml /kg normal saline 0.9% through central venous line after sternotomy over 1 hour
16281394|NCT04806399|No Intervention|Usual Care Control Group|
16281395|NCT04806399|Active Comparator|Outreach Contact with Decision Counseling Group|
16281396|NCT04806386|Experimental|Psyllium fiber supplement treatment|All patients will receive psyllium fiber in the form of edible bars, 7g, twice a day to total 14g per day.
16281397|NCT04806373|Placebo Comparator|Talc Slurry Pleurodesis (TSP) plus placebo|Patients who sign informed consent may be randomized to receive TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml Normal saline (NS)) through the chest pleural catheter.
16281398|NCT04806373|Experimental|Talc Slurry Pleurodesis (TSP) plus Cathflo Activase|Patients who sign informed consent may be randomized to receive TSP (Talc, 5mg in 50ml Normal saline (NS)) with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter
16281399|NCT04806360|Experimental|ACRF group|ACRF is a new surgical procedure that previously proposed by our team, it combines the advantages of both the conventional anterior and posterior approach. Eligible patients in this group will receive ACRF surgery.
16281400|NCT04806360|Active Comparator|conventional anterior surgery group|Eligible patients in this group will receive conventional anterior surgery, including anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
16281401|NCT04806360|Active Comparator|conventional posterior surgery group|Eligible patients in this group will receive conventional posterior surgery, including laminectomy and fusion surgery or laminoplasty surgery.
16281437|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing, Repeated Administration|
16281438|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|
16281471|NCT04805931|No Intervention|Control|Will receive a text message with standard messaging used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
16281976|NCT04802525|Experimental|Moderate-intensity aerobic exercise training plus a low-fat diet program group|
16281403|NCT04806334|Experimental|4D MRI of pelvis/bladder with genomic analysis of bladder tumor|Patients with sessile appearing bladder masses who are destined to undergo transurethral resection of the bladder tumor (TURBT) and are felt by the treating physician to harbor MIBC will be enrolled. Prior to TURBT, ALL subjects will undergo axial imaging for clinical staging in the form of contrast enhanced MRI of the abdomen and pelvis (standard of care). The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI). Both the abdominal and pelvic MRI will have an official interpretation by a radiologist, thus both can be used in the care of the subject. Next, ALL subjects will undergo TURBT at which time, voided urine, blood and fresh frozen bladder tumor will be collected. Follow-up pathology will be collected.
16281404|NCT04806321|Experimental|Project SOLVE|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents solve, rather than be overwhelmed by, everyday problems. The program includes: (1) An introduction to problem solving; (2) Testimonials from valued others (older adolescents; celebrities) describing their use of problem solving skills; (3) Evidence from studies that our brains are capable of problem solving and that problem solving can be helpful; and (4) Activities designed to enable adolescents to practice sequential problem solving using a few steps (SOLVE Steps)."
16281405|NCT04806321|Active Comparator|Project SUCCESS|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents improve their study skills. This program includes: (1) An introduction to study skills; (2) Testimonials from valued others describing their use of study skills; (3) Description of helpful and commonly used study skills (e.g., note-taking); and (4) Activities designed to encourage adolescents to practice these skills in their daily lives."
16281406|NCT04806308|Experimental|Intervention group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
16281407|NCT04806308|No Intervention|Control group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
16281409|NCT04806269||Thyroid dysfunction group|"Subjects with thyroid dysfunction including thyrotoxicosis and hypothyroidism Subjects who were newly diagnosed or undergoing treatment for thyroid dysfunction can be included in the study.
~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
16281410|NCT04806269||Control group|"Subjects without thyroid dysfunction including thyrotoxicosis and hypothyroidism.
~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
16281411|NCT04806256|Experimental|CDSS group|Subjects' treatment regimens were influenced by the CDSS, which was the recommended system for Tradictional Chinese Medicine treatment of dry eye.
16281412|NCT04806256|Active Comparator|non-CDSS group|The treatment of the subjects was routine and not affected by the CDSS for Tradictional Chinese Medicine.
16281413|NCT04806243|Experimental|Carelizumab Combined With Regorafenib arm|
16281414|NCT04806230||Observed|
16281415|NCT04806217|Experimental|¨Patients with multiple sclerosis|"Patients :
~With multiple sclerosis
~Aged of 18 and over
~Recruited during their consultation in the adult outpatient unit or neurological unit or during a hospitalization."
16281416|NCT04806204|Experimental|music therapy before the angiography|Patients in the Intervention 1 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes before the CAG procedure. Since individuals are in the CAG unit collectively before the procedure, headphones will be used in order not to disturb other individuals. After the interviews, musical types will be arranged as instrumental, non-verbal, at 70 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice. Instrumental works will be uploaded to the portable MP3 player provided by the researchers.
16281417|NCT04806204|Experimental|music therapy during the angiography|Patients in the Intervention 2 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the CAG hall during the CAG procedure. After the interviews, musical types will be arranged as instrumental, non-verbal, 75 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice.
16281418|NCT04806204|No Intervention|control group|After the polyclinic controls of the patients, on the day of the CAG procedure, data collection forms will be applied in the CAG unit 30 minutes before the procedure. Routine care will be applied to patients in this group and music therapy will not be applied. The physiological parameters of the patient will be measured by the clinical nurse 15 minutes after the procedure, and data collection forms will be applied again 20 minutes later.
16281419|NCT04806191|Experimental|Intervention|Patients will be assessed by GPs who have attended an outreach workshop and trained at using an evidence based strategy for shoulder examination and treatment. GPs will have access to a decision support tool and patients is offered a tailored information package for self management.
16281420|NCT04806191|Active Comparator|Treatment as usual (TAU)|The participants enrolled in the control period will receive treatment as offered in general practice.
16281421|NCT04806178|Active Comparator|BCG intradermal vaccine|Intradermal BCG Group (n=16): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
16281422|NCT04806178|Placebo Comparator|Placebo|Placebo group (n = 16): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
16281423|NCT04806165|Experimental|Repeated Administration|
16281424|NCT04806165|Experimental|Personalized Recommendation|
16281425|NCT04806165|Experimental|Motivational Interviewing|
16281426|NCT04806165|Experimental|Core Modules Only|
16281427|NCT04806165|Experimental|Motivational Interviewing, Personalized Recommendation, Repeated Administration|
16281428|NCT04806165|Experimental|Motivational Interviewing, Repeated Administration|
16281429|NCT04806165|Experimental|Motivational Interviewing, Personalized Recommendation|
16281430|NCT04806165|Experimental|Personalized Recommendation, Repeated Administration|
16281431|NCT04806165|Experimental|Psychoeducation|
16281432|NCT04806165|Experimental|Psychoeducation, Repeated Administration|
16281433|NCT04806165|Experimental|Psychoeducation, Personalized Recommendation|
16281439|NCT04806152|Experimental|Sarcopenia and combined-modality high intensity supervised exercise training|Participants were given Treadmill exercise training, lower extremity progressive resistance training using a Cybex leg press machine, and a 1-hour adaptive physical activity (APA) programme in which participants were required to walk for 12 minutes through an obstacle course in which they must clear 10 cm high boards, climb 3 steps and walk sideways through hula-hoops placed on the floor all the while dual-tasking i.e. waving at strategically placed signs, conversing while walking and picking up objects. Participants also performed exercises at the parallel bars which included weight-shifting from leg to leg and half-squatting; they were also guided through seated upper- and lower-limb stretching exercises for range of motion and trunk mobility. All exercise sessions were supervised by physiotherapists. For two of the weekdays on which participants did not attend supervised training, they were asked to walk for 30 minutes at home and perform the APA exercises described above.
16281440|NCT04806152|Active Comparator|Sarcopenia and 'usual care' unsupervised exercise|Participants were required to do 5-12 chair rises and also 30-minutes walking 5 days per week. Upper limb and trunk flexibility exercises were also taught.
16281441|NCT04806139|Experimental|Intervention Group - Remote Enhance Fitness|Participants assigned to the intervention group will participated in a 16-week remote exercise intervention. Following a home/space environment and technology needs assessment, participants will attend a one-on-one orientation and practice class with a research assistant. Participants will join a live-streamed, instructor-led group Enhance Fitness exercise session for 1-hour, 3 days/week for 4 months (16-weeks).
16281442|NCT04806139|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will be offered the opportunity to participate in the Remote Enhance Fitness class after study measures are completed. Cuff weights will be provided along with technical orientation, support, and equipment as needed.
16281443|NCT04806126||Virtual Mentoring Program Participants|Physicians credentialed at Satellite Healthcare will be eligible to participate along with nephrology fellows from training programs affiliated with credentialed physicians.
16281444|NCT04806113|Other|Vaccine|Study participants (People with rheumatic diseases and age matched controls).
16281450|NCT04806061|Experimental|sodium bicarbonate|iv sodium bicarbonate 8.4%
16281451|NCT04806061|Experimental|control|standard care
16281452|NCT04806048||Hospitalized patients and outpatients|There may be different types of patients with differing follow-up plan but all will bie considered one group regarding on whether they receive their recommended follow-up plan
16281453|NCT04806035|Experimental|TG-1801|TG-1801 Single Agent
16281454|NCT04806035|Experimental|TG-1801 + Ublituximab|TG-1801 in combination with ublituximab
16281455|NCT04806022|Experimental|Mental Fatigue Task first|"First appointment :
~Pre-fatigue assessment
~mental fatigue task
~post-fatigue assessment
~7 resting days
~second appointment
~Pre-fatigue assessment
~Muscle fatigue task
~post-fatigue assessment"
16281456|NCT04806022|Experimental|Muscle fatigue task first|"First appointment :
~Pre-fatigue assessment
~Muscle fatigue task
~post-fatigue assessment
~7 resting days
~second appointment
~Pre-fatigue assessment
~mental fatigue task
~post-fatigue assessment"
16281457|NCT04806009|Experimental|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program. The MLWI Intervention was developed and presented by the Principle Investigator (PI) who is a psychiatrist and have completed the Training of Mindfulness Facilitation (TMF) program at the Mindful Awareness Research Center of University of California, Los Angeles.
16281458|NCT04806009|Active Comparator|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|Participants in the Control Group will receive CBT-I after follow the WeChat mini-program. The CBT-I was developed and presented by a researcher who is a psychiatrist/psychologist and have many years' experiences in CBT.
16281459|NCT04805996|Experimental|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|This study has only one arm and no comparator.
16281460|NCT04805983|Experimental|10 mg BMS-984923|
16281461|NCT04805983|Experimental|40 mg BMS-984923|
16281462|NCT04805983|Experimental|70 mg BMS-984923|
16281463|NCT04805983|Experimental|100 mg BMS-984923|
16281464|NCT04805970||Patients with and without diabetes who were previously diagnosed with COVID-19|
16281465|NCT04805957|Experimental|Treatment|All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
16281466|NCT04805944||DTG treated (A)|80 HIV-infected adults treated with dolutegravir (as a component of their usual provider-prescribed antiretroviral regimen)
16281467|NCT04805944||BIC treated (B)|30 HIV-infected adults treated with bictegravir (as a component of their usual provider-prescribed antiretroviral regimen)
16281468|NCT04805944||DTG discontinued due to neuropsychiatric adverse event (C)|50 HIV-infected adults having stopped dolutegravir due to neuropsychiatric adverse effects (insomnia, depression, anxiety)
16281469|NCT04805944||Shifting to DTG (D)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing dolutegravir
16281470|NCT04805944||Shifting to BIC (E)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing bictegravir
16281472|NCT04805931|Experimental|Scarcity|Will receive a text message with a behavioral scarcity message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
16281473|NCT04805931|Experimental|Social good|Will receive a text message with a behavioral social good message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
16281474|NCT04805918|Experimental|VIPP-SD (Video-feedback Intervention to Promote Positive Parenting and Sensitive Discipline).|The VIPP-SD includes seven sessions of 1½-2 hours each with an 2-4 weeks interval VIPP-SD is delivered by a VIPP-SD trained pedagogue and takes place in the family home and the targeted parent and child are videotaped during daily interactions. The intervener studies the video and prepares feedback. During the sessions, the intervener and parent review the video together and the intervener provides their feedback according to the VIPP-SD protocol.
16281475|NCT04805918|Active Comparator|Care as ususl|The existing standard practices for parents of 2-6 year old children identified to be at risk for developing externalizing problems in the participating municipalities will be the active control condition. These vary in content and duration in the municipalities. Likewise, CAU may change during the project period. The exact content and duration of CAU interventions as well as participants' adherence to treatment will be described as precisely as possible.
16281476|NCT04805905||Skin graft|
16281477|NCT04805905||Local flap|
16281478|NCT04805879|Active Comparator|FMT capsules|"Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool and each containing 0.67 ml of pelleted intestinal microbes.
~PArticipants will recieve a loading dose of 60 capsules over 3 consecutive days followed by a booster dose of 20 caspules 1 month after and a second similar booster dose a month after that"
16281479|NCT04805879|Placebo Comparator|Placebo oral Capsules|Placebo casules are inactive capsules that look and weigh the same as the Active FMT caspules. Participants will follow the same schedule as the Active arm.
16281480|NCT04805866||Healthy Age-matched controls|Healthy individuals ages 18-85
16281481|NCT04805866||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-85
16281482|NCT04805853||type 2 diabetes without polycystic ovary syndrome|The treatment of type 2 diabetes is based on the Chinese Medical Association Diabetes Branch '2017 China Type 2 Diabetes Prevention Guidelines' for lifestyle adjustment and diabetes drug treatment.The research physician decides the diabetes treatment measures of the research object; the blood sugar control goal is that glycosylated hemoglobin is less than 7%.
16281483|NCT04805853||polycystic ovary syndrome without type 2 diabetes|The treatment of polycystic ovary syndrome is based on the '2018 Polycystic Ovary Syndrome Chinese Diagnosis and Treatment Guidelines' by the Endocrinology Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association and the Guide Expert Group '2018 Polycystic Ovary Syndrome Expert consensus on diagnosis and treatment of endocrinology' for lifestyle and drug treatment.
16281484|NCT04805853||polycystic ovary syndrome with type 2 diabetes|Treatment is as above.
16281485|NCT04805827|Experimental|Gabapentin|1 tablet contains 600 mg Gabapentin
16281486|NCT04805827|Active Comparator|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
16281487|NCT04805814|Active Comparator|Intervention Group|All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.
16281488|NCT04805814|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.
16281489|NCT04805801||Hemophilia A with FVIII inhibitors|Hemophilia A patients with FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
16281490|NCT04805801||Hemophilia A without FVIII inhibitors|Hemophilia A patients without FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
16281491|NCT04805788|Experimental|Treatment (SBPT)|Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
16281492|NCT04805775|Active Comparator|Desflurane Inhalant Product Group|Anesthesia maintenance: desflurane inhalation (mac1.0-1.2) sufentanil 0.3-0.5 μ g / (kg · h) atracurium CIS benzenesulfonate 1-3 μ g / (kg · min)
16281493|NCT04805775|Experimental|Propofol Group|Anesthesia maintenance: propofol TCI: 3-4ug / ml sufentanil 0.3-0.5 μ g / (kg · h) cisatracurium besylate 1-3 μ g / (kg · min)
16281494|NCT04805762||Children with overweight or obesity following the lifestyle intervention YCND|Children with overweight or obesity that are participant of the lifestyle intervention YCND
16281495|NCT04805749|Experimental|Osteopathic manipulation|Spinal Mobilisation / Cranial Osteopathy therapy / Circulatory Techniques / Visceral osteopathic therapy
16281496|NCT04805736|Experimental|Microwave Ablation alone|Microwave Ablation+ Breast Surgery
16281497|NCT04805736|Experimental|Camrelizumab alone|Camrelizumab+ Breast Surgery
16281498|NCT04805736|Experimental|Microwave Ablation & Camrelizumab|Microwave Ablation + Camrelizumab + Breast Surgery
16281556|NCT04805359|Experimental|Hypoxic exercise (HE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 15%O2 in air (HE) for 30 minutes per day, 5 days per week for 6 weeks
16281557|NCT04805359|No Intervention|Normoxic control|Without any exercise training
16281977|NCT04802512||patients|patients who were used telehealth
16281499|NCT04805723|Experimental|Patients with pulmonary nodule scheduled VATS|"Patients with pulmonary nodule scheduled VATS were included in this study. Inclusion and exclusion criteria were considered.
~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
16281500|NCT04805723|Experimental|Patients with pulmonary nodule scheduled thoracotomy|"Patients with pulmonary nodule scheduled thoracotomy were included in this study. Inclusion and exclusion criteria were considered.
~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
16281501|NCT04805710|No Intervention|clopidogrel combined with aspirin arm|Patients selected in the clopidogrel combined with aspirin arm will receive clopidogrel 75 mg once daily and aspirin 100 mg once daily.
16281502|NCT04805710|Experimental|clopidogrel combined with rivaroxaban arm|Patients selected in the clopidogrel combined with rivaroxaban arm will receive clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily.
16281503|NCT04805697|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
16281504|NCT04805697|Experimental|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
16281505|NCT04805684|Active Comparator|lung ultrasound 12|12 zone lung ultrasonography protocol
16281506|NCT04805684|Active Comparator|lung ultrasound 14|14 zone lung ultrasonography protocol
16281509|NCT04805645||Non-Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit which died before or on day 28 post ICU admission
16281510|NCT04805645||Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit whom are still alive on day 28 post ICU admission
16281511|NCT04805632||Dialysis|Patients on hemodialysis or peritoneal dialysis who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
16281512|NCT04805632||Healthy|Medical staff who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
16281513|NCT04805619|Experimental|Arm 1|Patients with long or very long lesions (≥ 30 mm) in native coronary arteries.
16281514|NCT04805606|Experimental|Sequence 1|CKD-843 A - 27mg, Single Dose
16281515|NCT04805606|Experimental|Sequence 2|CKD-843 A - 45mg, Single Dose
16281516|NCT04805606|Experimental|Sequence 3|CKD-843 A - 56mg, Single Dose
16281517|NCT04805606|Experimental|Sequence 4|CKD-843 B - 45mg, Single Dose
16281518|NCT04805606|Active Comparator|Sequence 5|CKD-843-R
16281519|NCT04805593|Experimental|WaveLight EX500 excimer laser system|Laser-assisted in situ keratomileusis (LASIK) surgery using the WaveLight EX500 excimer laser system
16281520|NCT04805580|Active Comparator|intrathecal block|patients (25) will receive unilateral intrathecal block using 1.5 ml of hyperbaric bupivacaine
16281521|NCT04805580|Active Comparator|Quadratus lumborum block|patients (25) will receive quadratus lumborum block by an anterior approach using 30 ml of bupivacaine 0.25%
16281522|NCT04805567||Patients with polyps and adenomas|The inclusion criteria are: (i) CRC screening; (ii) post-polypectomy surveillance; (iii) diagnostic assessment (anemia, lower gastrointestinal bleeding, abdominal pain, recent change in bowel habits); and (iv) age over 50 years.
16281523|NCT04805554|Experimental|Joint Insights Decision Aid|Participants view the entire Joint Insights decision aid for knee osteoarthritis including: Education Module with information about knee osteoarthritis and risks and benefits of various treatment options, Preferences and Values elicitation questions, and Personalized Risk/Benefit Report.
16281524|NCT04805554|Active Comparator|Education Module Only|Participants view the Joint Insights Education Module only
16281525|NCT04805528|Experimental|Experimental: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS) Therapy|Six (6) small electrodes will be placed on specific points of the body using adhesive pads. These electrodes are connected to the ALTENS device, which will send controlled, low-level electrical impulses through the skin and into the tissue underneath.
16281526|NCT04805515|Experimental|Nicotine Corrective Messages|Participants in the nicotine corrective messages condition will receive 8 brief nicotine corrective public education messages delivered online during 4 waves of the 12 week study. The messages will communicate misperceptions about nicotine's role in health harms as well as misperceptions that reduced nicotine content cigarettes are less harmful than tobacco cigarettes and that e-cigarettes contain less nicotine than tobacco cigarettes.
16281527|NCT04805515|No Intervention|Delayed Message Control|Participants in the control condition will be exposed to the nicotine corrective messages after the completion of the final assessment at the end of the 12 week study.
16281528|NCT04805502|Experimental|Aerobic Exercise (AE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.
~The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle) for all of their sessions."
16281713|NCT04804215|Experimental|The controled group in non-Intraductal transanastomotic stent|"Inclusion criteria
~19 years old or older ~ under 70 years old
~Patients eligible for liver transplantation ③ Patients who have consented to written consent
~No stent was used during biliary reconstruction"
16281529|NCT04805502|Experimental|Resistance Exercise (RE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.
~The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets with rest period of 30-60 seconds between sets as needed.[100] Seated isokinetic exercise using Cybex machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on Cybex machines. Core exercises will be performed at the end of the session (i.e. seated side bends)."
16281530|NCT04805502|Experimental|Combination Exercise (AERE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.
~The AERE group will switch between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeated repeat with different exercises.[106-108] The investigators will also calculate the metabolic minutes per week (METmin/wk) of all participants in order to account for potential differences in energy expenditure based on activity, though the dose of 150 min/wk at moderate intensity is held constant between exercise groups."
16281531|NCT04805502|No Intervention|Control (no exercise)|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
16281532|NCT04805489|Experimental|stress test with masks|Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
16281533|NCT04805476|Experimental|Non invasive mechanical ventilation|The subjects in the immediate intervention group (GI) will be extubated and placed in NIV the moment they enter the recovery room through a portable ventilator (Esprit ® or BiPAP Vision ®, Respironics) in face mask. The parameters will be adjusted as follows: FiO2 = 50%, positive expiratory pressure (EPAP, starting at 4-6 cmH2O and adjusting 1-2 cmH2O to avoid snoring, apnea, paradoxical breathing and desaturations) and adjusted inspiratory positive pressure (IPAP) to maintain a tidal volume of 400 to 500 ml, maintaining IPAP <15cmH2O17. Individuals will receive this ventilatory support for 1 hour. After this period the patients will be submitted to the same care of GP patients.
16281534|NCT04805476|Active Comparator|Usual care|Subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to the team routine and patient need.
16281535|NCT04805463|Experimental|control group|After gingivectomy and released into the secondary wound healing gingivoplasty group.
16281536|NCT04805463|Experimental|PRF group|The group in which PRF was applied to the wound surface after gingivectomy and gingivoplasty.
16281537|NCT04805463|Experimental|CGF group|The group in which CGF was applied to the wound surface after gingivectomy and gingivoplasty.
16281538|NCT04805463|Experimental|AFG group|The group in which AFG was applied to the wound surface after gingivectomy and gingivoplasty.
16281539|NCT04805450|Active Comparator|ES before SEMS placement|ERCP with ES before biliary fully covered SEMS placement.
16281540|NCT04805450|Active Comparator|no ES before SEMS placement|ERCP without ES before biliary fully covered SEMS placement.
16281541|NCT04805437|Experimental|3D TLSO|A 3-dimensional Boston brace will be designed to the patient's individual type of scoliosis. In-brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
16281542|NCT04805437|Active Comparator|Standard TLSO|A standard Boston brace will be designed to the patient's individual type of scoliosis. In brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
16281543|NCT04805424|Active Comparator|Abdominoplasty|Standard abdominoplasty
16281544|NCT04805424|Experimental|Lipo-abdominoplasty|Abdominoplasty plus liposuction
16281545|NCT04805411|Experimental|High-dose arm|600mg for 1st dose, and then 300 mg for 2-8nd doses, every 2 weeks, SC
16281546|NCT04805411|Experimental|low-dose arm|300mg for 1st dose, and then 150 mg for 2-8nd doses, every 2 weeks, SC
16281547|NCT04805411|Placebo Comparator|placebo|placebo for 1-8 doses, every 2 weeks, SC
16281548|NCT04805398|Experimental|CM310|CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
16281549|NCT04805398|Placebo Comparator|Placebo|Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.
16281550|NCT04805385|Experimental|PS128|Subjects will consume the PS128 capsules every day, 2 capsules at a time, for 12 weeks.
16281551|NCT04805385|Placebo Comparator|Placebo|Subjects will consume the placebo capsules every day, 2 capsules at a time, for 12 weeks.
16281552|NCT04805385|No Intervention|Healthy Control|
16281553|NCT04805372|Experimental|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
16281554|NCT04805372|Placebo Comparator|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
16281555|NCT04805359|Experimental|Normoxic exercise (NE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 21%O2 in air (NE) for 30 minutes per day, 5 days per week for 6 weeks
16281714|NCT04804202|Other|Virtual Reality|This is a single arm study in which all participants will execute the same tasks over two sessions.
16281558|NCT04805346|Experimental|Therapeutic Group|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada). The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol).
16281559|NCT04805346|No Intervention|Control Group|A control group will undergo a similar procedure, but the cuff will not be inflated.
16281560|NCT04805333|Experimental|Dose 1 - 450mg Artemisia annua|Participants in this group will consume 1 cup of decaffeinated coffee (450 mg Artemisia annua).
16281561|NCT04805333|Experimental|Dose 2 - 900mg Artemisia annua|Participants in this group will consume 2 cups of decaffeinated coffee (900 mg Artemisia annua).
16281562|NCT04805333|Experimental|Dose 3 - 1350mg Artemisia annua|Participants in this group will consume 3 cups of decaffeinated coffee (1350 mg Artemisia annua).
16281563|NCT04805333|Experimental|Dose 5 - 1800mg Artemisia annua|Participants in this group will consume 4 cups of decaffeinated coffee (1800 mg Artemisia annua).
16281564|NCT04805333|Experimental|Dose Expansion - Recommended Phase II Dose|This cohort will be an expansion of 6 patients for further tolerability and secondary endpoints analysis. They will consume the recommended phase II dose (dependent on prior analysis).
16281565|NCT04805307|Experimental|Part A, Dose escalation|CMG901 will be administered in treatment cycles once every 3 weeks (Q3W). Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.3mg/kg and 0.6mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (1.2mg/kg, 1.8mg/kg, 2.2mg/kg, 2.6mg/kg and 3.0mg/kg).
16281566|NCT04805307|Experimental|Part B, Dose expansion _GC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.
~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
16281567|NCT04805307|Experimental|Part B, Dose expansion _PC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.
~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
16281568|NCT04805307|Experimental|Part B, Dose expansion _GC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.
~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
16281569|NCT04805307|Experimental|Part B, Dose expansion _PC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.
~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
16281570|NCT04805281|Active Comparator|Lithium Disilicate IPS e.max crowns in posterior teeth|
16281571|NCT04805281|Experimental|Monolithic Zirconia (5Y-TZP/3-YTZP) crowns in posterior teeth|
16281572|NCT04805268|Experimental|One subject with possible Luft's disease|18F-FDG will be administered I.V., approximately 1 hour prior to PET/CT scan.
16281573|NCT04805255||Hypofractionated Stereotactic Radiotherapy (HF-SRT)|"A prospective cohort study addressing both neurocognitive outcome measures and oncological endpoints will be carried out for treating newly-diagnosed brain oligometastases with a pre-defined course of hypofractionated stereotactic radiotherapy (HF-SRT) in cancer patients with a fair/satisfactory performance status.
~Either a limited number of brain metastases or oligometastatic brain disease refers to that the number of brain metastatic lesions (both post-resected and intact) at enrollment should be limited to three or fewer and that the greatest diameter of any metastatic lesion (either a tumor bed post-surgical resection or an intact brain metastasis) should be no more than 4 cm."
16281574|NCT04805242|Active Comparator|Dextrose prolotherapy groups|In the first group, dextrose prolotherapy injection will be applied.
16281575|NCT04805242|Sham Comparator|Saline groups|In the second group, physiological saline injection will be applied.
16281576|NCT04805229||Patients undergoing surgery|Retrospective cohort of patients who underwent surgery between 1/1/13 to 12/31/19 and were sampled from the Truven Health MarketScan Database.
16281577|NCT04805216||Immunocompromised patients (study group)|People who are likely to have a suppressed immunity due to their haematological disorder or its treatment
16281578|NCT04805216||Immunocompetent volunteers (control group)|People without suppressed immunity
16281579|NCT04805203|Other|blood samples|4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
16281582|NCT04805177|Experimental|hematoma evacuation|Early minimally invasive image guided hematoma evacuation
16281583|NCT04805164|Experimental|Innovative strategy|usual medical and surgical care with corticotomy and use of a bone substitute (Cerament-G) delivering gentamicin locally (± skin and soft-tissue/muscle flap) and antibiotic therapy.
16281584|NCT04805164|Active Comparator|Reference strategy|Medico-surgical usual care with corticotomy (± skin and soft-tissue/muscle flap), and antibiotic therapy.
16281585|NCT04805125|Active Comparator|Moderna mRNA COVID-19 vaccine|The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart.
16281586|NCT04805125|Active Comparator|Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine|"Active:
~The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland.
~Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later."
16281715|NCT04804189|No Intervention|Control Group|25 4-H Shooting Sport Clubs that will not receive The Reframe intervention.
16319851|NCT04539782|No Intervention|No intervention|Standard care
16281587|NCT04805112|Experimental|Provision of multiple self-tests|Participants randomized to the intervention group will be given 2-3 HIV oral self-tests to offer to their sexual partner(s). The participant will be instructed to encourage their partner to test himself alone [partner testing] or with the participant [couple testing]; the partner will also be given a card with information on testing and a list of facilities where he can go for confirmatory testing. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
16281588|NCT04805112|No Intervention|Referral vouchers for clinic testing|Participants randomized to the control group will be given multiple referral coupons for HIV testing at pre-selected HIV testing services (HTS) sites. The participant will be instructed to give the coupon to their sexual partner(s) and encourage him to go for HIV testing at pre-selected HTS sites, either alone [partner testing] or together with the participant [couple testing]. The coupon will also have information on testing and a list of facilities where he can go for HTS. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
16281589|NCT04805086|Experimental|MON002|Minimum of 1x10~7 cells to maximum of 2x10~6 cells/kg. Single infusion.
16281590|NCT04805073|Experimental|Promethazine|The treatment will consist of a blinded syringe of 1cc clear liquid 25mg/ml Promethazine
16281591|NCT04805073|Placebo Comparator|Placebo|The treatment will consist of a blinded syringe of 1cc 0.9% Sodium Chloride
16281592|NCT04805060|Experimental|TQB2858 injection|TQB2858 administered intravenously (IV) once every 3 week
16281593|NCT04805047|Experimental|Intervention:education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
16281594|NCT04805047|No Intervention|control|regular care
16281595|NCT04805034||HBeAg positive/HBsAg positive|
16281596|NCT04805034||HBeAg seroconversion /HBsAg loss|
16281597|NCT04805021||Patients in the Acquired Hemophilia A group.|
16281598|NCT04805021||patients in the constitutional hemophilia A group.|
16281599|NCT04805021||patients in the control subjects group.|
16281600|NCT04805021||patients in the group of patients with inflammatory pathology.|
16281601|NCT04805008|Experimental|Intervention|Lactation cookies
16281602|NCT04805008|Placebo Comparator|Control|Control cookies
16281603|NCT04804995||Heathy participants|
16281604|NCT04804995||migraine patients|
16281605|NCT04804969||At Risk Echo Referrals|Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.
16281606|NCT04804956||Early-rectal cancer|The patients to be included in this group will be those with Stage I (initial tumor stage). The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur. This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.
16281607|NCT04804956||Advanced-rectal cancer|The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis. Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures. In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.
16281608|NCT04804956||Synchronous metastasis -rectal cancer|The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease. Patients with distant metastases in one organ or more than one organ will be included.
16281609|NCT04804943|Experimental|NOA-001 group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
16281610|NCT04804943|No Intervention|Standard treatment group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard therapy.
16281611|NCT04804943|Experimental|NOA-001 group (ARDS caused by COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
16281612|NCT04804930||patients with systemic scleroderma|
16281613|NCT04804930||healthy subject|healthy subject without systemic scleroderma or known hair or scalp disease
16281614|NCT04804917||Participants in the MindMyMind RCT|"The study participants comprise the 396 youths (and their parents) who participated in the Mind My Mind RCT. The study participants were randomized to the experimental MMM intervention (n=197) or MAU (n=199) and followed in the trial until 26 weeks after randomization, from September 7, 2017, to August 28, 2019.
~The MMM consisted of 9-13 weekly, individual therapy sessions. The CBT methods were organized in modules for anxiety, depression and behavioral problems. Flowcharts described the sequencing and dosing of modules to match the problems at hand. The therapy was completed within 17 weeks, followed by a booster session after four weeks.
~The MAU was enhanced by two care-coordination visits (week 2 and 17). The MAU interventions included anonymous counseling, pedagogical advice, network meetings, educational support, psychological treatment, or no treatment."
16281615|NCT04804904|Experimental|TQ-B3101: Fed + Fast|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fed condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fasted condition on Day 1 of treatment period 2.
16281616|NCT04804904|Experimental|TQ-B3101: Fast+Fed|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fed condition on Day 1 of treatment period 2.
16281617|NCT04804891|Experimental|Cell Therapy|Patients will receive an infusion containing 1x106/kg CD34+ cells. No more than 104 CD34+ T cells per kg recipient weight will be included in the infusion. Cadaveric donor CD34 cell infusion will occur at any time between post-operative day 11 to day 13 following transplantation.
16281618|NCT04804891|No Intervention|Control|Patients who do not consent to receive donor CD34 cell infusion or whose donor family declines consent for research use of donor bone marrow will receive their usual standard of care.
16281619|NCT04804878||Biospeciman Repository and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
16281620|NCT04804865||population|"The population includes adult patients.
~Patients died from refractory or relapsed diffuse large-cell lymphoma.
~Patients <65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.
~Patients >65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles)."
16281621|NCT04804852||study population|Patient diagnosed with head & neck carcinoma at diagnosis
16281622|NCT04804839|Experimental|First research arm (Combined group)|Combined group with 8 weeks of pelvic floor muscle training, knack maneuver and lifestyle recommendations.
16281623|NCT04804839|Experimental|Second research arm [PFMT (including knack maneuver) group]|Only 8-week PFMT (including knack maneuver)
16281624|NCT04804839|Active Comparator|Third research arm (PFMT alone group)|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
16281625|NCT04804813||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 26 weeks. Participants received interventions as part of routine medical care.
16281626|NCT04804800|No Intervention|Control group|The patients benefit from the care recommended by the HAS. They benefit from psychological interviews, psychiatric follow-up, dietetic follow-up, family interviews and therapy. Body therapies (physiotherapy, massage, fascia therapy, psychomotor skills, dance therapy, etc.) may also take place. Patients will also benefit from relaxation and body scan.
16281627|NCT04804800|Experimental|Experimental group 1 : Virtual Reality|The patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan (1 hour).
16281628|NCT04804800|Experimental|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|The patients benefit from the care recommended by the HAS, the virtual reality and the multisensory remediation programs, and also the body scan.
16281631|NCT04804774|Experimental|WW program modified for people with Type 2 diabetes|Includes weekly Virtual Workshops and use of the WW App.
16281632|NCT04804761|Experimental|Real EA group|
16281633|NCT04804761|Sham Comparator|Sham EA group|
16281634|NCT04804748||Phase A|"Approximately 150 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery)
~Data regarding standard of care post-operative pacing and treatment of POAF, if applicable, will be collected from time of surgery until discharge
~No use of an external bi-atrial pacing device
~No use of Defipace
~In-hospital data will be collected for all patients
~Patients that developed POAF (n=50) will be followed-up with a phone call 30 days after surgery"
16281635|NCT04804748||Phase B|"Approximately 300 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery) with planned TMA implantation
~In-hospital data will be collected for all patients
~Use of the DefiPace system for the treatment (low-energy cardioversion) and post-operative prevention (bi-atrial pacing) of POAF will be documented (n=100). These patients will be followed-up with a phone call 30 days after surgery"
16281636|NCT04804735|Experimental|REV : local anesthesia and virtual reality|Use of virtual reality device in Implanted Venous Access Device (IVAD) procedure under local anesthesia
16281637|NCT04804735|Experimental|MUS : local anesthesia and music therapy|Use of musicotherapy tool in Implanted Venous Access Device (IVAD) procedure under local anesthesia
16281638|NCT04804735|No Intervention|CONTROL : standard local anesthesia|Implanted Venous Access Device (IVAD) procedure under local anesthesia as standard of care
16281639|NCT04804709|Experimental|FUS using Oral Panobinostat|All patients enrolled in the study will be treated with oral Panobinostat after receiving Focused Ultrasound treatment (FUS) with microbubbles and neuro-navigator-controlled sonication.
16281640|NCT04804696|Experimental|TPC treatment|Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
16281641|NCT04804683|Other|Cohort of patients with Fibromuscular Dysplasia|Intervention consists in blood/urine sampling
16281642|NCT04804670|Experimental|Sonic-Floss toothbrush and small brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
16281643|NCT04804670|Experimental|Sonic-Floss toothbrush and full size brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
16281644|NCT04804670|Active Comparator|Manual brushing and flossing|American Dental Association standard manual toothbrush used for 2 minutes and dental floss all teeth
16281645|NCT04804657|Active Comparator|Sage extract|Two hours before the endurance test, participants were asked to absorb two capsules of sage extracts (600mg each - cognivia™)
16281646|NCT04804657|Placebo Comparator|placebo|Two hours before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance than active comparator).
16281647|NCT04804644|Experimental|Arm I (SRS)|Patients undergo SRS over 1 day (in some cases several days).
16281648|NCT04804644|Active Comparator|Arm II (HA-WBRT, memantine)|Patients also undergo HA-WBRT QD for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients will also receive memantine PO QD or BID for up to 24 weeks in the absence of disease progression or unacceptable toxicity.
16281649|NCT04804631||Gastrostomy tube|Prophylactic gastrostomy placed prior to bone marrow transplant.
16281650|NCT04804631||Nasogastric tube|Nasogastric tube placed during admission.
16281651|NCT04804618||Healthy control group|aged ≥55 years old, no dementia, MCI or no family history of AD.
16281652|NCT04804618||Alzheimer's disease high-risk group|aged ≥55 years old, immediate family members of AD patients
16281653|NCT04804618||Alzheimer's disease group|aged ≥55 years old, diagnosed as AD patients
16281654|NCT04804618||Mild cognitive impairment group|patients ≥55 years of age, diagnosed with MCI
16281655|NCT04804605|Experimental|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
16281656|NCT04804592|Experimental|Group A: SiHy CL|Silicone hydrogel (SiHy) CL wear at least 3 days per week and at least 8 hours per day;
16281657|NCT04804592|Experimental|Group B: RGP CL|Rigid gas permeable (RGP) CL wear at least 3 days per week and at least 8 hours per day;
16281658|NCT04804592|Experimental|Group C: no CL wear|No current CL wear for at least 3 months;
16281659|NCT04804579|Experimental|Fall Prevention Intervention|"The Intervention involves 3 primary components: virtual group sessions, at-home exercises, and weekly phone check-ins.
~Virtual Group Session will be held via phone/video call for approximately 30 minutes per week for 10 weeks.
~At-Home Exercises will be assigned by a registered occupational therapist member of the study team, and participants will be instructed to complete them independently at home 3 times per week. Participants will record the exercises that they complete.
~Weekly Phone Check-Ins will occur once per week. These check-ins will be used to provide support and problem solving as needed, and individualized reminder systems will be set up to prompt the participant to engage in their weekly exercises (e.g., set up alarm on phone, notifications through calendar app)."
16281660|NCT04804579|No Intervention|Control Group|Participants will be provided with an educational pamphlet that includes resources related to falls and alcohol use.
16281661|NCT04804566||ERT User- Did Not Switch to Galafold|ERT users with mutation amenable to Galafold who did not switch
16281662|NCT04804566||ERT User- Switched and Stayed on Galafold|ERT users with the mutation amenable to Galafold who switched and stayed on Galafold
16281663|NCT04804566||No Previous Therapy- Started Galafold and Stayed On|Those naïve to therapy with the mutation amenable to Galafold who went on and stayed on Galafold
16281664|NCT04804566||No Previous Therapy- No Current Therapy|Those who were naïve to therapy with the mutation amenable to Galafold and have never been on any therapy.
16281665|NCT04804566||ERT Users- Switched and Discontinued Galafold|Participants who are ERT users with an amenable mutation who switched to and later discontinued Galafold
16281666|NCT04804566||No Previous Therapy- Started Galafold and Discontinued|Participants who are naïve to therapy with an amenable mutation, went on Galafold, and discontinued
16281669|NCT04804540|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2 and 6 during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.
16281670|NCT04804527|Experimental|Intensified physiotherapy|In addition to usual care physiotherapy patients in the intensified physiotherapy group will receive an extra physiotherapy session of up to 30 minutes on every weekday starting on the first postoperative day. The session will include progressive functional training of basic mobility and walking in the ward delivered by an experienced physiotherapist affiliated with the trial. The aim of this additional session is to improve the functional advances achieved during the earlier physiotherapy session.
16281671|NCT04804527|Active Comparator|Usual care physiotherapy|Patients will receive approximately 30 minutes physiotherapy once daily in the ward delivered by the ward's usual physiotherapists i.e. starting on the first postoperative day and thereafter primarily on weekdays until discharge (a mean of 8.82 days after admission). Usual care physiotherapy is individualized taking the patients ability and previous level of functioning into account and includes 1) progressive functional training of basic mobility e.g. in-out of bed, sit-to-stand and walking including progression in walking aid, stair training if possible, and advices toward better physical functional level, 2) basic bed exercises with progression to standing exercises according to a hand-out training program and recommendations on doing exercises daily and being as physical active as possible during the day.
16281672|NCT04804514|Experimental|KH001|
16281673|NCT04804514|Placebo Comparator|Placebo|
16281674|NCT04804501|Experimental|Blue Light Glasses (experimental)|These subjects will wear the device (glasses) while performing a reading task.
16281675|NCT04804501|Other|No Glasses (control)|These subjects will not wear the device (glasses) while performing a reading task.
16281676|NCT04804475|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
16281677|NCT04804475|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
16281678|NCT04804462|Experimental|Virtual Reality Meditation for Fatigue|Participants will experience Virtual Reality Meditation in the comfort of their own home.
16281679|NCT04804449||Rheumatoid arthritis and psoriatic arthritis|Patients with rheumatoid arthritis or psoriatic arthritis, who require an intra-articular corticosteroid injection
16281680|NCT04804436|Experimental|Patients with nephrolithiasis|The real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
16281681|NCT04804436|Experimental|Healthy control group|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
16281682|NCT04804423|Active Comparator|Fluoride varnish (Duraphat®)|Fluoride varnish application is recommended by the German National Health System for managing hypersensitivity and dental caries. Sodium fluoride varnish (Duraphat®) will be applied on hypersensitive active carious lesions (ICDAS 5).
16281683|NCT04804423|Experimental|Silver fluoride and potassium iodide (Riva Star®)|Silver fluoride and potassium iodide (Riva Star®) is primarily indicated for relieving hypersensitivity will be applied on hypersensitive active carious lesions (ICDAS 5) following isolation of the affected teeth and according to manufacturer's instructions.
16281712|NCT04804215|Experimental|The experimental group in Intraductal transanastomotic stent|"Inclusion criteria
~19 years old or older ~ under 70 years old
~Patients eligible for liver transplantation ③ Patients who have consented to written consent
~Intraductal transanastomotic stent was used during biliary reconstruction"
16281716|NCT04804189|Experimental|Intervention Group|25 Randomized 4-H Shooting Sport Clubs that will receive The Reframe intervention.
16281684|NCT04804410|Experimental|Dielectric Properties of Tissue Samples from Thoracic Malignancies and Corresponding Normal Tissues|Our plan is to analyze 3-5 tissue probes acquired from 30 patients with a variety of thoracic malignancies. The investigators will plan to acquire tissue from each type of malignancy including: lung cancer, esophageal cancer and pleural based tumors. Tissue will be acquired in the operating room. Impedance measurements will be collected on multiple sections of excised tissue and will be translated into dielectric properties. After acquisition of data, the investigators will assess the data and continue to acquire patients to obtain significant estimates of overall tissue properties in each type of tumor. After undergoing an informed consent process in accordance with IRB approval, patients with be formally enrolled. All tumor electric property data will be stored securely and remain anonymous of patient identifying data.
16281685|NCT04804397|Experimental|Sucrose|Sucrose: 1l sucrose sweetened soft drink per day for 8 weeks (1650 KJ, 97g carbohydrate per day) as 4 25cl drinks
16281686|NCT04804397|Placebo Comparator|Aspartame|Aspartame: 1l aspartame sweetened soft drink per day for 8 weeks as 4 25cl drinks
16281687|NCT04804384|Experimental|Experimental|
16281688|NCT04804371|Other|18F-FDG PETCT scan|18F-FDG tracer (5 MBq/kg body weight of FDG; up to 550 MBq) will be injected into the intravenous
16281689|NCT04804358|Other|Anorexic women|Anorexic women with or without history of psychological trauma will perform study procedure : sociodemographic and clinical assessments, measurement of cardiac variability and salivary cortisol changes, before, during and after the exposition test.
16281690|NCT04804345||The aprotinin group,|all patients receiving a first infusion 1M KIU before surgical incision followed by a steady dose of 250 000 KIU/h with an additional dose of 1M KIU added to the cardiopulmonary bypass unit.
16281691|NCT04804345||The tranexamic acid group|all patient receiving tranexamic acid following each local center standarded protocol
16281692|NCT04804332|Experimental|EXPECTANT MANAGEMENT|No treatment will be offered.
16281693|NCT04804332|Experimental|OPERATIVE HYSTEROSCOPY|Operative hysteroscopy using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) is performed.
16281694|NCT04804306||Diagnostic Test: CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis as part of the CBC-Diff ordered by ED Physician as part of the Institution's Standard of Care. Results will not be used to manage patients
16281695|NCT04804293|Experimental|Operative treatment (surgical decompression) for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated at 3 and 6 months post-operatively. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. This imaging will be done before the treatment. We will repeat the imaging study at 3 and 6 months after the treatment. Each ultrasound imaging session will take about less than 10 min. The investigators do not expect any discomfort during the imaging.
16281696|NCT04804293|Experimental|Corticosteroid injection treatment for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated after 6 weeks following corticosteroid injection. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. The investigators do not expect any discomfort during the imaging.
16281697|NCT04804280||Preterm children (PT)|"gestational age at birth: 26+0 to 31+6 weeks;
~absence of documented neurological pathology;
~absence of sensory deficits;
~absence of malformative syndromes and/or major malformations."
16281698|NCT04804280||Full-term children (FT)|"gestational age at birth ≥ 37 weeks;
~birth weight ≥ 2,500g;
~APGAR 5' ≥ 7
~delivery without any complications for baby and/or mother;
~no prenatal and/or postnatal clinical conditions;
~no hospitalizations at the time of birth or postpartum;
~absence of malformative syndromes and/or major malformations."
16281699|NCT04804267|Experimental|Experimental|Linaclotide Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
16281700|NCT04804267|Active Comparator|Active Comparator|LINZESS® Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
16281701|NCT04804267|Placebo Comparator|Placebo Comparator|Placebo Drug: Placebo orally once daily
16281708|NCT04804241|Experimental|10 mg daily Senicapoc|10 mg daily Senicapoc for 52 weeks
16281709|NCT04804241|Placebo Comparator|Placebo Group|Placebo daily for 52 weeks
16281710|NCT04804228|Experimental|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis, following the PGM maps described by Travell and Simons. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 3 weeks.
16281711|NCT04804228|Active Comparator|Ischemic compression, analytical stretching and postural habits educational dossier|The control group consisting of 40 subjects will undergo an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifid and iliocostal, 1 weekly session for 3 weeks providing a training dossier of postural education in their activities of daily life.
16281978|NCT04802512||health professional|health professional who were used telehealth.
16281717|NCT04804176|Active Comparator|5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation|The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
16281718|NCT04804176|Active Comparator|GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation|The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
16281719|NCT04804176|Sham Comparator|the control group|The instrument is not working, only in exhaust mode.
16281720|NCT04804163|Experimental|Upper urinary tract disease group|Patients with upper urinary diseases (renal cell carcinoma, adrenal tumor and nonfunctioning kidney) will be treated by telesurgery.
16281721|NCT04804150|Experimental|Medical Device active or inactive|The medical device will be active, or inactive. Randomization will define when and how long time the medical device will plugged and active, and when and how long time the medical device will be unplugged and inactive. The patient won't know if the medical device is active or not
16281722|NCT04804137||Group|adult patients with adenocarcinoma type non-small cell lung cancer
16281723|NCT04804124|Experimental|Short Sleepers|Reported nightly sleep time of ≤6 hours
16281724|NCT04804124|Experimental|Long Sleepers|Reported nightly sleep time of ≥9 hours
16281725|NCT04804124|Experimental|Average Duration Sleepers|Reported nightly sleep time of 7-8 hours
16281726|NCT04804111|Placebo Comparator|Placebo|maintain the initial dose, without increasing the dose.
16281727|NCT04804111|Active Comparator|URC102 3mg|Administer 3 mg of URC102 for 12 weeks
16281728|NCT04804111|Active Comparator|URC102 6mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 11 Weeks.
16281729|NCT04804111|Active Comparator|URC102 9mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 1 Weeks, maintain 9 mg of URC102 dose
16281730|NCT04804111|Other|Febuxostat 80 mg|maintain the initial dose, without increasing the dose.
16281731|NCT04804098|Active Comparator|15 Minute Non-linear Compression Profile|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
16281732|NCT04804098|Active Comparator|15 Minute Linear Compression Profile|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
16281733|NCT04804072|Experimental|Integrated health services delivered in the mobile unit and peer navigation|Participants in the intervention arm will be provided integrated health services delivered in the mobile unit and peer navigation for 26 weeks.
16281734|NCT04804072|Active Comparator|Peer navigation to connect them to health services available at community-based agencies|Participants in the active control arm will be provided 26 weeks of peer navigation to connect them to health services available at community-based agencies.
16281735|NCT04804059|Experimental|Cohort A|[14C]-APX001 Oral Solution
16281736|NCT04804059|Experimental|Cohort B|[14C]-APX001 Solution for Infusion
16281737|NCT04804046|Experimental|Synbiotic|Bifidobacterium longum spp. longum R0175, Bifidobacterium animalis spp. Lafti B94, Bifidobacterium bifidum R0071 at 3x10^9 CFU/d plus resistant starch type 2, arabinoxylan, and galactooligosaccharide at 24 g/d will serve as the treatment.
16281738|NCT04804046|Placebo Comparator|Digestible Maltodextrin|Digestible maltodextrin will serve as the placebo.
16281739|NCT04804033|Active Comparator|BHV-3500 200mg|Zavegepant 200mg oral soft gel capsule.
16281740|NCT04804033|Placebo Comparator|Placebo 200mg|Matching placebo 200mg oral soft gel capsule.
16281741|NCT04804033|Active Comparator|BHV-3500 100mg|Zavegepant 100mg oral soft gel capsule.
16281742|NCT04804033|Placebo Comparator|Placebo 100mg|Matching placebo 100mg oral soft gel capsule.
16281743|NCT04804020|Active Comparator|NC (Natural cycle)|Performing the first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
16281744|NCT04804020|Active Comparator|mMC (modified Natural cycle)|Performing the first ultrasound scan on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
16281745|NCT04804020|Active Comparator|AC (Artificial cycle)|Preparing the endometrium by using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
16281746|NCT04804007|Experimental|Maintenance Oral Etoposide|Maintenance daily oral Etoposide.
16281747|NCT04804007|No Intervention|Observation|If randomized to Observation, subjects will jump to follow-up.
16281748|NCT04803994|Experimental|Systemic therapy with atezolizumab + bevacizumab|"Patients receive atezolizumab 1200 mg flat dose plus bevacizumab 15 mg/kg given intravenously every 3 weeks until failure of strategy, participant request, or withdrawal of consent for a maximum of up to 24 months.
~The discontinuation of one of the study drugs for toxicity reasons does not qualify as failure of treatment strategy as long as the other drug can be continued according to protocol."
16281979|NCT04802499||persons who using telehealth (patients)|patients who have received telehealth
16281749|NCT04803994|Active Comparator|Locoregional therapy with TACE|"Patients will receive initial TACE and - if required to achieve or improve an objective response - a second TACE after 8 weeks (±7 days window). Thereafter, additional TACE can be applied on demand until failure of strategy, participant request, or withdrawal of consent for a maximum of up to 24 months.
~TACE must be discontinued in cases of technical difficulties making additional TACE impossible.
~Only conventional TACE (cTACE) and drug-eluting bead TACE (DEB-TACE) approaches are accepted as TACE therapy. However, consistency in the TACE procedure and the use of the chemotherapeutic agent has to be maintained for each individual patient."
16281750|NCT04803981|Experimental|Standard diet with daily SpoonfulONE|Participants will receive one serving of SO (one of three possible forms of SO: mix-ins, puffs, or crackers) daily in addition to a standard diet. The SO form fed on a given day will be at the discretion of the parent/guardian.
16281751|NCT04803981|No Intervention|Standard diet|Participants will feed on a standard diet only, with no intervention, and complete questionnaires
16281752|NCT04803968|Experimental|control group|"After the evaluations are completed, the participants will be randomly divided into two groups using a computer-assisted randomization program.
~The cardiac rehabilitation program will be a total of 30 sessions, 5 days a week x 6 weeks. All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training"
16281753|NCT04803968|Experimental|intervention group|The combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.
16281754|NCT04803955|Experimental|16mg,KB|Group A:16mg,Q8h±3min,Day1-Day7
16281755|NCT04803955|Placebo Comparator|Placebos|Group B:Placebos,Q8h±3min,Day1-Day7
16281756|NCT04803929|Experimental|Anti-ILT3 CAR-T cells|All subjects were intravenous administrated with anti-ILT3 CAR-T cells
16281757|NCT04803903||HPI + GDHT treatment|HPI + GDHT treatment using the FlowTraQ sensor and EV1000 monitor with the HPI algorithm incorporated following our protocol for hemodynamic treatment (fluids, vasopressors and inotropes) administered
16281758|NCT04803903||Control|Conventional treatment with invasive blood pressure monitoring. Administration of fluids and/or vasopressors are guided by standard hemodynamic parameters at the discretion of the attending physician.
16281759|NCT04803890|Experimental|No touch radiofrequency ablation|A total of 150 patients who have decided to participate in the study will be included, and prospective study will be performed to these patients for radio-frequency ablation using octopus electrodes, combined high-frequency transmission mode, and the 'No touch' technique.
16281760|NCT04803877|Experimental|Regorafenib and Nivolumab|
16281761|NCT04803864|Experimental|Roxadustat|Early and short-term Roxadustat treatment
16281762|NCT04803864|No Intervention|Control|Patients only receive conventional therapies as recommended by guidelines.
16281763|NCT04803851|Experimental|Treatment group|Anlotinib plus AK105
16281764|NCT04803838||Patiens|Patients With symptomatic or asymptomatic carotid stenosis (> 50%, NASCET criteria)
16281765|NCT04803838||Controls|For study 1: Healthy Controls, volunters (mostly blood donors) For study 2 and 3: Spouses/someone living in the same household as the patient.
16281766|NCT04803825|Experimental|Heavy Slow Exercise|One dedicated physiotherapist will supervise and instruct the exercise program on an individual basis. If the patient doesn't have access to a dumbbell, it will be offered free rental from the physiotherapy ward. Follow-up on the exercises will be scheduled as needed and tele rehabilitation will be offered as an option. Additionally to HSR exercises, participants will be instructed to perform daily stretches of the forearm.
16281767|NCT04803825|Active Comparator|Extracorporeal Shock wave therapy|The patients will receive rESWT (SwissDolodClast/EMS) once a week for three sessions. The treatment will be given by a physiotherapist trained in using rESWT. The rESWT is given on the ECRB tendon insertion area.
16281768|NCT04803825|Active Comparator|Information and advice|The information and advice group are given a single face-to-face session with a physiotherapist, lasting up to 60 minutes.
16281769|NCT04803812|Experimental|Receive weekly SMS containing wellness stories shared by other Ontario physicians|
16281770|NCT04803812|Experimental|Receive weekly SMS containing aim wellness resources/strategies.|
16281771|NCT04803812|Experimental|Receive weekly SMS combining wellness stories & resources/strategies|
16281772|NCT04803799|Experimental|Experimental Arm|Training programme using Exergame as a support over a 12 week period
16281773|NCT04803786||Transition from Xyrem to Xywav|
16281774|NCT04803773|Experimental|Experimental Arm|
16281775|NCT04803760||mild disability|Those whose neck disability index value is 25 and below
16281776|NCT04803760||high disability|Those whose neck disability index value is 25 and above
16281777|NCT04803747|Active Comparator|Tranexamic acid (TXAl Arm|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
16281778|NCT04803747|Placebo Comparator|Placebo Arm|Placebo 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
16281779|NCT04803734|Experimental|Test|Albuterol Sulfate inhalation aerosol
16281780|NCT04803734|Active Comparator|Reference|Proair HFA (albuterol sulfate) Inhalation Aerosol
16281781|NCT04803721||Patient with a myelodysplastic syndrome|Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR=IPSS-R<4.5) or high risk (HR=Revised International P rognostic Scoring System>4.5)
16281782|NCT04803721||Control patient|Healthy blood donor (regardless of age) Or Patient >60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse), having expressed his non opposition to participate in the study
16281783|NCT04803708|Experimental|Part A- Cohort 1|8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.
16281784|NCT04803708|Experimental|Part B- Cohort 2|"18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either:
~TP-102 q.d 3x weekly up to four weeks (n=12)
~Placebo q.d. 3x weekly up to four weeks (n=6)
~Subjects will be followed-up for 7 days."
16281785|NCT04803682|Experimental|Prevention (ASPIRE, mentorship)|"Participants complete online ASPIRE course over 3.5-4 hours.
~HIGH SCHOOL MENTORS: Eleventh grade high school students receive mentor training over 4-5 hours on how to mentor ninth grade students.
~ALL STUDENTS: Mentors and mentees are paired up so that eleventh grade high school students mentor the ninth grade high school students over 30 minutes for 7 sessions about the different types of tobacco products (such as cigarettes, cigars, hookah, and so on) and the dangers of these products."
16281786|NCT04803669|Active Comparator|Conventional Treatment Group|Includes Hotpack, TENS, Ultrasound and Exercise programs.
16281787|NCT04803669|Experimental|IASTM Group|Inludes Hotpack, TENS, Ultrasound, Exercise program and Instrument-assisted Soft Tissue Mobilization Technique
16281788|NCT04803656|Other|Assesment|Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), clinical (diagnosis period) and medical status, personal history and family history, COPD stage, COPD Assessment Test (CAT) score, emergency and hospital admissions numbers in the last 3 months, exacerbation and hospitalization numbers in the last one year were recorded. Respiratory and peripheral muscle strengths are evaluated. Also pulmonary functions test results obtained.
16281789|NCT04803643||Patients|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
16281790|NCT04803643||Healthy controls|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
16281791|NCT04803630|Experimental|Treatment of depression (thermal therapy)|Patients undergo thermal therapy over 2.5 hours.
16281792|NCT04803617||Patient's group|geriatric patients with interstitial lung disease
16281793|NCT04803617||Control group|healthy volunteers selected from the geriatric population
16281794|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
16281795|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6 months
16281796|NCT04803604|Experimental|Basic social support + communication + 1 monthly follow up call|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
16281797|NCT04803604|Experimental|Basic social support + communication + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
16281798|NCT04803604|Experimental|Basic social support + Ottawa guide + 1 monthly follow up call|2 in-person/telephone weekly sessions on 1 coaching session on providing social support, decision support tools, and a single monthly follow-up call
16281799|NCT04803604|Experimental|Basic social support + Ottawa guide + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
16281800|NCT04803604|Experimental|Basic social support + 1 monthly follow up call|1 in-person/telephone weekly sessions on providing social support and a single monthly follow-up call
16281801|NCT04803604|Experimental|Basic social support + monthly follow up calls for 24 weeks|1 in-person/telephone weekly sessions on providing social support and monthly follow-up calls for 6 months
16281802|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + 1 monthly follow up call|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
16281803|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6
16281804|NCT04803604|Experimental|Advanced social support + communication + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
16281805|NCT04803604|Experimental|Advanced social support + communication + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
16281806|NCT04803604|Experimental|Advanced social support + Ottawa guide + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, decision support tools, and a single monthly follow-up call
16281807|NCT04803604|Experimental|Advanced social support + Ottawa guide + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
16281808|NCT04803604|Experimental|Advanced social support + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, and a single monthly follow-up call
16281809|NCT04803604|Experimental|Advanced social support + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, and monthly follow-up calls for 6 months
16281980|NCT04802499||caregivers|family member of the patients who recieved telehealth
16281810|NCT04803591|Experimental|A: Tranexamic Acid group|Patients in the Tranexamic Acid (TXA) group (arm-A) will be administered with 2 doses of intravenous tranexamic acid (cumulative dose 10ml=1g) as follows: the first dose 10 minutes before the surgical incision (1 vial of 5 ml = 0,5g by slow intravenous injection(=1ml/minute)), and the second 3 hours after the start of surgery (1 vial of 5 ml = 0,5g, by slow intravenous injection).
16281811|NCT04803591|No Intervention|B : No treatment group|In the control group, will not be administered TXA or any other drugs.
16281812|NCT04803578||Knee Arthroplasty Group|Subjects that received knee arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
16281813|NCT04803578||Hip Arthroplasty Group|Subjects that received hip arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
16281814|NCT04803578||Age-Matched healthy Group|Subjects age-matched with those included in the knee and hip group. Subjects are asked to walk at their self-selected speed and at low speed matchable with those of the knee and hip group
16281815|NCT04803565|Experimental|Custom-Made Insole|"This Group will receive a custom-made shoe insole designed on the foot shape of the subjects.
~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
16281816|NCT04803565|Sham Comparator|Sham Insole|"This group will receive a Sham shoe insole without any specific custom-made design.
~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
16281817|NCT04803552|Experimental|Contactless sleep apnea screening vs respiratory polygraphy|
16281818|NCT04803539|Active Comparator|Capecitabine|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
16281819|NCT04803539|Experimental|Capecitabine + Apatinib + Camrelizumab|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
16281820|NCT04803500|Active Comparator|Simvastatin group|simvastatin gel (1.2 mg/0.1 ml of solid lipid nanoparticles) was locally applied to fill the jumping distance.
16281821|NCT04803500|Placebo Comparator|Control group|the solid lipid nanoparticles carrier was injected into the jumping distance.
16281822|NCT04803487|Experimental|the Micro Hand S robot group|41 patients were randomly allocated in the Micro Hand S robot group and cholecystectomy was performed using the Micro Hand S robot.
16281823|NCT04803487|Other|the da Vinci robot group|41 patients were randomly allocated in the da Vinci robot group and cholecystectomy was performed using the da Vinci robot.
16281824|NCT04803474||Klinefelter|Patients with Klinefelter syndrome
16281825|NCT04803474||Turner|Patient with Turner syndrome
16281826|NCT04803448|No Intervention|Control|No statement is provided before asking the health care question. Example: What is your weight in pounds?
16281827|NCT04803448|Experimental|Benefit Statement|A statement of benefit will be given (see intervention) after the health question.
16281828|NCT04803448|Experimental|Risk Statement|A statement of risk will be given (see intervention) after the health question.
16281829|NCT04803448|Experimental|Privacy Statement|A statement of privacy will be given (see intervention) after the health question.
16281830|NCT04803448|Experimental|Benefit + Privacy statement|A statement of benefit and privacy will be given (see intervention) after the health question.
16281831|NCT04803448|Experimental|Risk + privacy statement|A statement of risk and privacy will be given (see intervention) after the health question.
16281832|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation
16281833|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - only face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation
16281834|NCT04803422|Active Comparator|Arm 1- Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.
~First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.
~Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim."
16281835|NCT04803422|Active Comparator|Arm 2 - Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.
~First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.
~Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin."
16281836|NCT04803409|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
16281837|NCT04803409|No Intervention|Control Group|Control Group
16281838|NCT04803396|Placebo Comparator|Placebo|Placebo was administered once a day (oad) as matching oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
16281839|NCT04803396|Experimental|50 mg DF2755A|"The experimental drug was administered once a day (oad) as one oral capsule of 50 mg.
~The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions."
16281840|NCT04803396|Experimental|150 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
16281841|NCT04803396|Experimental|300 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
16281981|NCT04802499||health professions|persons who use the telehealth.
16281842|NCT04803396|Experimental|600 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
16281843|NCT04803383|Experimental|Tele-Yoga Group|Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program
16281844|NCT04803383|No Intervention|Control group|Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
16281845|NCT04803370|Other|Control group|Standard treatment for COVID-19 (according to clinical guidelines for COVID-19).
16281846|NCT04803370|Experimental|Intervention group|Convalescent patient plasma 300 ml given in 2 consecutive days, plus standard treatment for COVID-19 (according to clinical guidelines).
16281847|NCT04803357|Experimental|Blinded Continuous Glucose Monitoring Devise|If you are in the control group, you will wear a continuous glucose monitor with the read out screen covered so you can not see your continuous glucose level. You will be taught how to test your blood sugar by pricking your finger and using a standard blood glucose meter as per the standard of care used by your provider in the obstetrics clinic.
16281848|NCT04803344|Experimental|Experimental Group|After the childbirth, writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the pregnancy.
16281849|NCT04803344|Active Comparator|Control Group|
16281850|NCT04803331|Experimental|cT1-2N0M0 oral cancer patients|Patients undergo routine sentinel lymph node procedure (99mTc injection, planar imaging, SPECT-CT and surgery) for clinical purposes. After 99mTc injections and imaging has been executed peritumoral SPIO injections are performed by a medical doctor. A T2*-weighted iron sensitive MRI scan is made 1 hour later.
16281851|NCT04803318|Experimental|Combination treatment of 3 inhibitors|Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
16281852|NCT04803305|Experimental|Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 Treatment|subcutaneous injection
16281853|NCT04803305|Placebo Comparator|Double-Blind Placebo Treatment followed by Open-Label PF-06946860 Treatment|subcutaneous injection
16281854|NCT04803292||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
16281855|NCT04803292||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
16281856|NCT04803292||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
16281857|NCT04803279||Ponto 3 SuperPower users|"Patients who are fitted either unilaterlaly or bilatterally on abutment since the device came to the market in 2016, and who have follwoed the clinics normal routine fitting and follow up visits.
~They must also have undergone the normal procedures performed as part of the clinics routine for fitting and following up. Data will be collected from these routine visits."
16281858|NCT04803266|Experimental|Internal mammary node irradiation|
16281859|NCT04803266|Active Comparator|No internal mammary node irradiation|
16281860|NCT04803253|Experimental|Participants using the ORTHOPUS set of prosthetic solution|
16281861|NCT04803227|Active Comparator|Emricasan|Emricasan
16281862|NCT04803227|Placebo Comparator|Placebo|Placebo
16281863|NCT04803214|Other|Treatment (ReActiv8)|Market-approved ReActiv8 device
16281864|NCT04803214|No Intervention|Control (OMM)|Standard of Care
16281865|NCT04803201|Experimental|Arm A (duvelisib, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive duvelisib PO BID on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16281866|NCT04803201|Experimental|Arm B (CC-486, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive CC-486 PO QD on days -6 to 0 of cycle -1 and days 8-21 of cycles 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16281867|NCT04803201|Active Comparator|Arm C (CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16281868|NCT04803188|Experimental|A: patients will perform non-contrast MRI|A: 355 patients will perform non-contrast MRI regardless their serum PSA value
16281869|NCT04803188|Experimental|B: patients will perform non-contrast MRI|B: 355 patients will perform non-contrast MRI when serum PSA value is increased (>4 ng/ml or 2.5 ng/ml if positive family history)
16281870|NCT04803175||Sacubitril/valsartan|Patients undergoing continued treatment with sacubitril/valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
16281871|NCT04803175||Valsartan|Patients undergoing continued treatment with valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
16281901|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 80 years and older|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older
16281902|NCT04802980|Experimental|HB002.1T + Oxaliplatin+ Capecitabine|21-24 patients with advanced gastric cancer administeredHB002.1T+ Oxaliplatin+ Capecitabine combination every 3 weeks in a 21-day cycle, total 18cycles
16281872|NCT04803162||patients with eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group. EoE patients were then treated for 8 weeks with PPs - omeprazole in the dose of 20 mg twice daily. After 8 weeks, each patient in the EoE group again passed all the tests (the protocols were identical to those used for qualifying patients to the project).
16281873|NCT04803162||patients without eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group.
16281874|NCT04803149|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
16281875|NCT04803149|Active Comparator|Conventional Radiofrequency|Conventional radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
16281876|NCT04803136|Other|Bone SPECT/CT|Gamma Camera with computed tomography
16281877|NCT04803136|Other|Spine surgeries|spine stabilization and fusion surgeries
16281878|NCT04803123|Experimental|Copanilisib|
16281879|NCT04803110|Experimental|Immediate Implant with SST (SST)|Patients who will receive immediate implant placement using the Socket-Shield Technique.
16281880|NCT04803110|Active Comparator|Immediate Implant with biomaterial (GAP)|Patients who will receive immediate implant placement using bone biomaterials to fill the gap after complete extraction of the tooth.
16281881|NCT04803097||pediatric cataract group|Children who underwent cataract surgery and primary IOL implantation at the Eye Hospital of Wenzhou Medical University (Hangzhou, China) between 2016 and 2019 were included in the study. Every surgery included posterior capsulorhexis or capsulotomy and anterior vitrectomy. Patients accept slit-lamp-adapted anterior segmental photography at 1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
16281882|NCT04803084||Advanced Pathology|Breast magnetic resonance imaging (MRI) as a preliminary predictive biomarker for breast cancer treatment response.
16281883|NCT04803071|Experimental|Adjuvant therapy trial group|N-3pufas improved cognitive formula adjuvant therapy intervention group
16281884|NCT04803071|Active Comparator|Adjuvant treatment control group|General fish oil formula product adjuvant treatment control group
16281885|NCT04803071|Placebo Comparator|Placebo assisted treatment control group|
16281886|NCT04803071|No Intervention|Healthy group|
16281887|NCT04803058|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
16281888|NCT04803045||Follow Up Email|Patients received a follow up email 3 months after an initial consult with a physician but did not return to care.
16281889|NCT04803045||No follow up|Patients who did not receive any follow up after their initial consult, following clinic standard of care.
16281890|NCT04803032|Experimental|Superficial parotidectomy using trident landmark technique|A modified Blair incision was made along the preauricular skin crease with the same steps of the routine parotid surgery. Dissection was performed using bipolar cautery and blunt instrument; from the tragal cartilage (the anterior surface) until the bony anterior wall of the external auditory canal (EAC); from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle; it is the lower point of the landmark. The facial nerve is located in the region between these two structures.
16281891|NCT04803019|Active Comparator|DEB-TACE or chemoembolization with microspheres|The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F)
16281892|NCT04803019|Active Comparator|TAE or embolization with microspheres|The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F)
16281893|NCT04803006|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
16281894|NCT04803006|Experimental|Arm 2|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
16281895|NCT04803006|Experimental|Arm 3|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
16281896|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70 years and older|All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma
16281897|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70-79 years|All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma
16281898|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 80 years and older|All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma
16281899|NCT04802993||All patients resected with pancreaticoduodenectomy, all ages|All patients in the registry resected with pancreaticoduodenectomy during the study period
16281900|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 70-79 years|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years
16281903|NCT04802980|Experimental|HB002.1T + Paclitaxel + Carboplatin|21-24 patients with advanced ovarian cancer, cervical cancer, head and neck cancer or lung cancer (not limited to the above tumor types) administered HB002.1T + Paclitaxel + Carboplatin combination every 3 weeks in a 21-day cycle, total 18cycles
16281904|NCT04802980|Experimental|HB002.1T + Gemcitabine + Cisplatin|21-24 patients with advanced biliary tract tumor, pancreatic cancer, bladder cancer or nasopharyngeal carcinoma (not limited to the above tumor types) administered HB002.1T + Gemcitabine + Cisplatin combination every 3 weeks in a 21-day cycle, total 18cycles
16281905|NCT04802967|Experimental|KLS-GABA (part A and B)|"KLS-GABA 80 mg-34 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules are administered with 240 mL of water.
~KLS-GABA (40 mg-17mg, 80 mg-34 mg, or 160 mg-68 mg) in Part B are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.
~To maintain he blind, subjects assigned to receive 160 mg-68 mg KLS-GABA are administered two co-crystal KLS-GABA 114 mg (80 mg-34 mg) capsules, and subject assigned to receive 40 mg-17 mg KLS-GABA or 80 mg-34 mg KLS-GABA also receive a placebo capsule (dummy placebo)."
16281906|NCT04802967|Active Comparator|KLS (part A and B)|"KLS 80 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules will be administered with 240 mL of water.
~In the part B KLS (40 mg, 80 mg or 160 mg) are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water. To maintain the blind, subjects assigned to receive 160 mg KLS alone are administered two KLS 80 mg capsules and subjects assigned to receive either 40 mg KLS alone or 80 mg KLS alone also receive a placebo capsule (dummy placebo)."
16281907|NCT04802967|Active Comparator|Gabapentin (part B)|Gabapentin 300 mg are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.To maintain the blind, subjects assigned to receive 300 mg gabapentin also receive a placebo capsule (dummy placebo).
16281908|NCT04802967|Placebo Comparator|Placebo (part B)|To maintain the blind subjects assigned to receive placebo receive 2 placebo capsules. Capsules will be administered with 240 mL of water.
16281909|NCT04802954|Experimental|High risk group|Patients with hepatocellular carcinoma greater than 1 cm in size. All patients from an ultrasound screening programme who have been diagnosed with a nodule larger than 1 cm and referred to our centres will be included in this group. They will then be excluded of this group if the diagnosis of hepatocellular carcinoma is not retained according to the radiological or histological reference diagnostic standards (gold standard).
16281910|NCT04802954|Experimental|Low risk group|Patients without hepatocellular carcinoma. A 1-year interval ultrasound will be performed to confirm the absence of new nodule in the year following inclusion.
16281911|NCT04802941|Experimental|Neoadjuvant Chemotherapy by CDSS|
16281912|NCT04802941|Active Comparator|Neoadjuvant Chemotherapy in General practice|
16281913|NCT04802928|Placebo Comparator|A|Placebo tablets.
16281914|NCT04802928|Experimental|B|
16281915|NCT04802915|Other|epiretinal membrane group|Patient with epiretinal fibrosis confirmed by OCT with BCVA< 0,6 and complaints of metamorphopsies
16281916|NCT04802889|Experimental|cadaver eyes|The Central region of the retina and preretinal structures of cadaver eyes are examined
16281917|NCT04802876|Experimental|Spartalizumab (PDR001)|400mg/intravenous every 28 days
16281918|NCT04802863|Experimental|Five doses of XNW4107 with imipenem/cilastatin|Each subject will receive a total of five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin via IV infusion administered every 6 hours with each administration infused over 60 minutes.
16281919|NCT04802850|Experimental|Real MWM|Real mobilization with movement
16281920|NCT04802850|Sham Comparator|Sham MWM|sham or placebo mobilization with movement
16281929|NCT04802798|Experimental|Placebo, Fibre 1, Fibre 2|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
16281930|NCT04802798|Experimental|Placebo, Fibre 2, Fibre 1|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
16281931|NCT04802785|Experimental|The study Group|"Before the flight in the conditions of the clinic's medical treatment room: Citicoline 500 mg(Vitaae®) and Cytochrome10 mg (Cytochrome C®) per os.
~30 minutes before the flight: dilute 1 sachet of ORS® (Sodium Chloride 2.6 g+Potassium Chloride 1.5 g+Sodium Citrate 2.90 g+Dextrose 13.5 g) in 1 liter of water. Drink half of the solution (0.5 l) 30 minutes before the flight (at the airport). Also, 0.5 L of the solution will be provided on the plane during landing. If the flight lasts more than 1.5 hours, then dilute the second sachet of ORS® with 0.5-1 liters of water.
~30 minutes before the flight (per os): Domperidone (Motilium ®) (1 tablet), Simethicone (Gas-X®) (3-4 capsules), Acetylsalicylic acid 150 mg and magnesium hydroxide 30,39 mg (Cardiomagnyl®)(1 tablet), probiotic (Bactistatin®) (1 capsule) per os."
16281932|NCT04802785|Active Comparator|Control group|Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
16281933|NCT04802785|No Intervention|Explanatory group:|12 participants without any intervention.
16281940|NCT04802746|Experimental|Sequence ABC in Part A|Study participants randomized to this arm will receive Staccato Placebo (A) and two fixed doses of Staccato alprazolam Dose 1 (B) and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
16281941|NCT04802746|Experimental|Sequence BCA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato alprazolam Dose 2 (C), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
16281942|NCT04802746|Experimental|Sequence CAB in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato Placebo (A), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
16281943|NCT04802746|Experimental|Sequence ACB in Part A|Study participants randomized to this arm will receive Staccato Placebo (A), Staccato alprazolam Dose 2 (C), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
16281944|NCT04802746|Experimental|Sequence BAC in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato Placebo (A), and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
16281945|NCT04802746|Experimental|Sequence CBA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato alprazolam Dose 1 (B), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
16281946|NCT04802746|Experimental|Staccato alprazolam in Part B|Study participants randomized to this arm will receive Staccato alprazolam at pre-specified time points in Part B.
16281947|NCT04802746|Placebo Comparator|Staccato placebo in Part B|Study participants randomized to this arm will receive Staccato placebo at pre-specified time points in Part B.
16281952|NCT04802707|Experimental|dC/dT100-400 Arm|Children 0-18 Y who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.
16281953|NCT04802694|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
16281954|NCT04802694|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube.
16281955|NCT04802694|Active Comparator|Adhesive product|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube.
16281956|NCT04802681|Other|Wirecath - PressureWire X|Patients will undergo simultaneous FFR measurements with the Wirecath and PressureWire X simultaneously.
16281957|NCT04802668||Circulatory failure patients|Circulatory failure patients requiring fluid responsiveness evaluation
16281958|NCT04802655|Experimental|Exergame Group (EG)|In addition to routine NDT training, Structured Exergame Program for upper extremity and trunk control will be applied in this group. Xbox one - Kinect supported video games will be selected for video-game based exergame program. The Video games to be included in the Exergame program will be selected by Analytical Hierarchy Process. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
16281959|NCT04802655|Active Comparator|Activity Based Exercise Group (AG)|In addition to routine NDT training, Goal Directed Activity Based Exercises for upper extremity and trunk will be applied to this group. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
16281960|NCT04802629||Term neonates|≥ 37+0 weeks of gestation
16281961|NCT04802629||Preterm neonates|≤ 36+6 weeks of gestation
16281962|NCT04802616|Experimental|Polyvalent mechanical bacterial lysate|Treatment over 3 successive months with one daily sublingual tablet (7 mg of bacterial lysate) over 10 days followed by 20 days of rest.
16281963|NCT04802616|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily sublingual tablet over 10 days followed by 20 days of rest.
16281964|NCT04802603|Other|Radiotherapy|Cohort 1 (De novo) No Prior radiotherapy Cohort 2 (Prior radiotherapy) Prior radiotherapy
16281965|NCT04802590|Experimental|Arm A|Ibrutinib (+ CD20Ab)
16281966|NCT04802590|Experimental|Arm B|Ibrutinib + Venetoclax (+CD20Ab)
16281967|NCT04802577||Primary Sjögren's syndrome|The patient's diagnosed with Primary Sjögren's according to 2016 ACR/EULAR classification criteria
16281968|NCT04802577||Healthy Controls|Healthy hospital workers without any chronic disease
16281969|NCT04802564|Experimental|Multisensory-based music treatment|Using a multisensory-based music treatment synchronizing with vibrotactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
16281970|NCT04802564|Active Comparator|Traditional sensory reeducation intervention|Using constant and moving tactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
16281971|NCT04802551|Experimental|Intervention group|
16281972|NCT04802551|No Intervention|Control group|
16281973|NCT04802538|Experimental|Study Group|All patients will begin the study by using their normal ostomy pouching equipment for 28 days. This will be followed by a transition to using the OstoRing® for 28-47 days.
16281974|NCT04802525|Experimental|Moderate-intensity aerobic exercise training without dietary control group|
16281975|NCT04802525|Experimental|Low-fat diet program without exercise intervention group|
16281982|NCT04802486|Experimental|Arm 1: Exercise Intervention and Standard Care|A home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
16281983|NCT04802486|No Intervention|Arm 2: Standard Care|Standard care for your cancer as prescribed by your oncologist
16281984|NCT04802473|Experimental|Gingival recession treatment|Gingival recession treatment by means of tunnel technique and OrACell dermal matrix.
16281985|NCT04802460|Experimental|virtual reality|Patients assigned to the VR group will be engaged with the VR using a publicly available VR set. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
16281986|NCT04802460|No Intervention|control arm|Patients in the control arm will undergo standard of care office hysteroscopy. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
16281987|NCT04802434|Experimental|Strengthening Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member, or friend) will attend weekly 3 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach cognitive compensation and mindfulness-based emotion regulation skills. Strategies from the PEERS Social Skills Program will also be taught. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
16281988|NCT04802434|Active Comparator|PEERS Social Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member or friend) will attend weekly 1.5 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach skills for improving social relationships and handling social rejection. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
16281989|NCT04802434|No Intervention|Delayed Treatment Control Group|Participants in the delayed treatment control group will participate in a 10-month wait period, during which they will complete data collection procedures at three time points (Baseline, Post, and 6-month follow-up).
16281990|NCT04802421|Active Comparator|CPAP30|a 30 secondes 30 cmH2O continuous positive airway pressure applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
16281991|NCT04802421|Active Comparator|STEP30|a stepwise increase (+5 cmH2O) in postivie airway pressure from +5 cmH2O to +30 cmH2O and decrease (-5 cmH2O) from +30 cmH2O to +5 cmH2O applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
16281992|NCT04802408|Active Comparator|Baby Shampoo Nasal Wash|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
16281993|NCT04802408|Active Comparator|Listerine Gargle|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
16281994|NCT04802408|Experimental|Combination of Baby Shampoo Nasal Wash and Listerine Gargle|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
16281995|NCT04802408|Placebo Comparator|Saline Wash and Gargles|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
16281996|NCT04802382|Experimental|Arm 1 - CimetrA-1|a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
16281997|NCT04802382|Experimental|Arm 2 - CimetrA-2|a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
16281998|NCT04802382|Placebo Comparator|Arm 3 - Placebo|composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
16281999|NCT04802369|Active Comparator|Identyfication of prognostic factors in VO2max<17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max<17 ml/kg/min
16282000|NCT04802369|Sham Comparator|Identyfication of prognostic factors in VO2max>17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max>17 ml/kg/min
16282002|NCT04802343|Experimental|BAY1817080 dose escalation|Healthy male subjects will receive BAY1817080 dose 1 and dose 2 as a single oral dose and BAY1817080 dose 3 as a single oral dose on Day 1 and twice daily (BID) from Day 7 to Day 16 followed by a last dose in the morning of Day 17.
16282003|NCT04802343|Placebo Comparator|Placebo|Healthy male subjects will received corresponding placebo.
16282004|NCT04802330||Female genital mutilation|Assessment of FGM prevalence in Beni Suef localities and its impact on studied women.
16282005|NCT04802317||Control|Health people without any respiratory diseases
16282006|NCT04802317||Bronchial asthma|Patients with asthma
16282007|NCT04802317||COPD|Patients with chronic obstructive pulmonary disease
16282008|NCT04802304|Experimental|Treatment|
16282009|NCT04802304|No Intervention|Control|
16282010|NCT04802291|Experimental|Healthy HomeStyles|Online educational intervention addressing salient factors affecting school-age children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, irregular breakfast consumption, limited physical activity, and inadequate sleep as well as children's limited food preparation skills.
16282011|NCT04802291|Active Comparator|Safe HomeStyles|Online educational intervention addressing aspects of home safety issues, such as indoor air quality, mold & moisture, hazardous household products, carbon monoxide, home safety, foodborne illness, and refrigerator temperatures.
16282012|NCT04802278||Babies born to mothers convalescent from antenatal COVID-19|
16282013|NCT04802278||Babies born to healthy mothers|
16282014|NCT04802278||Vaccinated mothers|Lactating mothers who received COVID-19 vaccination
16282015|NCT04802265||ILM peeling|ILM is peeled during epiretinal membrane surgery
16282016|NCT04802265||without ILM peeling|ILM is not peeled during epiretinal membrane surgery
16282017|NCT04802252||62 patients with benign prostatic hyperplasia in the experimental group|The pulse sound waves of three parts and five layers of each of the two hands of 62 patients with benign prostatic hyperplasia were collected by acoustic pulse detection system.
16282018|NCT04802252||62 relatively healthy men without benign prostatic hyperplasia in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 62 relatively healthy men without benign prostatic hyperplasia were collected by acoustic pulse detection system.
16282019|NCT04802239|Active Comparator|calm waking group|calm waking state group
16282020|NCT04802239|Experimental|hypnosis session|hypnosis session group
16282021|NCT04802226|Experimental|optimized self-exclusion procedure A|optimized self-exclusion procedure including content optimization with brief intervention, normative feedback, motivational approach, a personal story of a peer who had a positive experience using the tool, re-contact before the end of the self-exclusion period to propose an extension of the period outside the gambling plateform
16282022|NCT04802226|Other|standard self-exclusion B|standard self-exclusion with a single neutral notification email
16282023|NCT04802213|Active Comparator|Rehabilitation exercise|1.perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
16282024|NCT04802213|Experimental|Rehabilitation exercise + joint mobilization device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)"
16282025|NCT04802213|Experimental|Rehabilitation exercise +joint mobilization device treatment + laser acupuncture device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)
~perform laser acupuncture device treatment for patients with frozen shoulders ( three sessions per week for 8 consecutive weeks. patients in each treatment session received laser at a dosage of 4 joules/cm2 for the eight chosen position. )"
16282026|NCT04802200||Patients operated from minimally invasive cardiac surgery|Patients operated between December 16, 2019 and june 30, 2021 from minimally invasive cardiac surgery with femoral cannulation for cardiopulmonary bypass in Dijon University hospital and in whom the MANTA device has been used for femoral artery closure
16282027|NCT04802187|Other|RADx CHCs testing intervention strategy|Six Massachusetts community health center partnerships implementing both a common testing expansion implementation strategy plus tailored strategies designed for community partner needs.
16282028|NCT04802187|Other|Usual care control|
16282029|NCT04802174|Experimental|1/ Phase I|Dose escalation of Berzosertib + lurbinectedin
16282030|NCT04802174|Experimental|2/ Phase II|Berzosertib + lurbinectedin at MTD
16282031|NCT04802161|Experimental|Arm A (CPX-351, pomalidomide)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 21 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity."
16282032|NCT04802161|Active Comparator|Arm B (CPX-351)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine intravenously (IV) over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity."
16282033|NCT04802148|No Intervention|control (natural healing)|Extraction socket is naturally healed
16282034|NCT04802148|Experimental|Test 1 (membrane guided regeneration)|Extraction socket is filled with graft (FDBA) and covered with collagen membrane
16282035|NCT04802148|Active Comparator|Test 2 (collagen plug)|Extraction socket is filled with a collagen plug
16282036|NCT04802122|Experimental|Sevoflurane group|Patients in this group will receive Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) for induction to anesthesia and to facilitate endotracheal intubation (without the use of muscle relaxant) and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia plus muscle relaxant until study completion.
16282037|NCT04802122|Active Comparator|Propofol group|Patients in this group will receive a standard anesthesia induction involving Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% for induction to anesthesia and to facilitate endotracheal intubation and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia.
16282038|NCT04802109|Placebo Comparator|CPR with level D PPE|The participant doing CPR for 5 minutes with wearing level D personal protective equipment with surgical face mask
16282039|NCT04802109|Experimental|CPR with level C PPE|The participant doing CPR for 5 minutes with Level C personal protective equipment with N-95 face mask
16282040|NCT04802109|Experimental|CPR with Level C PPE + PAPR|The participant doing CPR for 5 minutes with Level C personal protective equipment with Powered Air-Purifying Respiratory.
16282041|NCT04802096|Experimental|Inspiratory muscle training combined pulmonary rehabilitation|
16282042|NCT04802096|Sham Comparator|Sham inspiratory muscle training combined pulmonary rehabilitation|
16282043|NCT04802070|Experimental|CIK|
16282044|NCT04802057|Experimental|BIVV020|Repeat dose of BIVV020
16282045|NCT04802031|Experimental|Treatment (isatuximab)|Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a >=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.
16282046|NCT04802018|Experimental|Monitored group|Monitoring of vital signs and following with the conventional telephone protocol
16282047|NCT04802018|No Intervention|Control group|Conventional telephone follow-up by health staff
16282048|NCT04802005|Experimental|Aerobic interval|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure (target expenditure ~450-500kcal/session). Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity at 70-85% of predicted HRmax, and for the second period the intensity will be reduced to 60-65% of predicted HRmax for 2 minutes. The training sessions will be carried out outdoors at the trails located on campus. The activity will consist of walking and/or light jogging. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion (RPE) as needed. The RPE for the first period range will be 13-17 (15-17 at the end of the period) and 10-12 for the second period.
16282049|NCT04802005|No Intervention|Control group|Participants in the control group will not participate in the training programs.
16282050|NCT04801992||MINI WELL Ready (SIFI SpA, Italy)|Extended depth of focus intraocular lens implantation
16282051|NCT04801966|Experimental|Treatment|"All participants will have an individualised treatment plan. The possible treatments that can be prescribed are as follows, they may be given as a single agent or in combination
~Trametinib 2 mg/day
~Cobimetinib 60 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)
~Binimetinib 45 mg/ twice a day
~Alpelisib 300 mg/day
~Vemurafenib 960 mg twice a day
~Dabrafenib 150 mg twice a day
~Encorafenib 450 mg/day
~Palbociclib 125 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)
~Ribociclib 600 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off
~Abemaciclib 150 mg twice a day
~Olaparib 300 mg twice a day
~Talazoparib 1 mg/day
~Nivolumab 240 mg IV once every two weeks
~Atezolizumab 1200 mg IV on day 1 of a 21 day cycle
~Pembrolizumab 200 mg IV on day 1 of a 21 day cycle"
16282052|NCT04801953|Active Comparator|Nimodipine|During surgery a nimodipine soaked gel foam pad is administered to the cranial nerves VII and VIII
16282053|NCT04801953|Placebo Comparator|Placebo|During surgery a sodium chloride soaked gel foam pad is administered to the cranial nerves VII and VIII
16282054|NCT04801940|No Intervention|Standard Care|Participant receives usual post-hospital care.
16282055|NCT04801940|Active Comparator|Apixaban|Intervention: Drug: Apixaban.
16282056|NCT04801940|Active Comparator|Atorvastatin|Intervention: Drug: Atorvastatin.
16282057|NCT04801914||Matrix Metalloproteinases|Value of serum matrix metalloproteinase activity before and one month after PTBD
16282058|NCT04801901|Experimental|Distal transradial access (dTRA)|Subjects randomized to the experimental arm will undergo cardiac catheterization using distal transradial access (dTRA) to facilitate coronary angiography and percutaneous coronary intervention.
16282059|NCT04801901|Active Comparator|Forearm radial access (fTRA)|Cardiac catheterization to facilitate coronary angiography and percutaneous coronary intervention using the standard forearm radial artery which is the current standard of care in interventional cardiology.
16282060|NCT04801888|Experimental|Combined immunization group|The combined immunization group is randomly divided into two subgroups, 120 subjects in each group. The combined immunization subgroup Ⅰ receive SARS-CoV-2 inactivated vaccine (Vero cell)&Quadrivalent Influenza Vaccine on day0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) on day 28.The combined immunization subgroup Ⅱ receive SARS-CoV-2 inactivated vaccine (Vero cell) on day 0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) & Quadrivalent Influenza Vaccine on day 28.
16282061|NCT04801888|Experimental|Non combined immunization group|The non combined immunization group receive SARS-CoV-2 inactivated vaccine (Vero cell)(first dose) on day 0, Quadrivalent Influenza Vaccine on day 14 and SARS-CoV-2 inactivated vaccine (Vero cell)(second dose) on day 28.
16282062|NCT04801875|Experimental|Violin Performers|Violin performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
16282063|NCT04801875|Experimental|Ney Performers|Ney performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
16282064|NCT04801862||Patients diagnosed of C.difficile infection|Open cohort of consecutive patients diagnosed of Clostridioides difficile infection
16282065|NCT04801849|Active Comparator|Vitamin E, 200 IU|200 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
16282066|NCT04801849|Active Comparator|Vitamin E, 400 IU|400 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
16282067|NCT04801849|Active Comparator|Vitamin E, 800 IU|800 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
16282068|NCT04801849|Placebo Comparator|Placebo|matching placebo taken once daily with breakfast
16282069|NCT04801836|Experimental|Treatment Arm|Subjects will receive 15 mg E4 orally once daily for 21 consecutive days
16282070|NCT04801836|Placebo Comparator|Placebo Arm|Subjects will receive matching placebo orally once daily for 21 consecutive days.
16282071|NCT04801823|Active Comparator|Home Introduction of Individual tree nuts|Current standard of care which is to advise families of infants diagnosed with peanut allergy to introduce tree nuts individually via a standardized, graded and cautious home introduction protocol. Day 1: smear of nut paste to the inside of lip; Day 2: 1/8 teaspoon; Day 3: 1/4 teaspoon; Day 4: 1/2 teaspoon; Day 5: 1 teaspoon. Repeat process with each individual tree nut.
16282072|NCT04801823|Experimental|In hospital multi-tree nut (almond, cashew hazelnut and walnut) oral food challenge (OFC)|Infant will be booked for a 4-nut butter (Almond, Hazelnut, Walnut, and Cashew) graded and supervised OFC in the allergy clinical trials unit at the Murdoch Children's Research Institute. The nut butter contains a 1g dose of each nut protein in a total weight of 20g. Doses will be administered every 15minutes (1. Smear to inside of lip, 2.1/8 teaspoon, 3.1/4 teaspoon, 4.1/2 teaspoon, 5.1 teaspoon, 6.remainder of 20g nut butter paste) If challenge negative, infants continue home introduction of tree nuts as per written instructions provided. If challenge positive, infants will have additional SPT (for full tree nut panel) and single tree nut OFC as per protocol to determine tolerance/allergic status (and +/- home introduction recommendation) for each tree nut.
16282073|NCT04801810|Experimental|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
16282074|NCT04801810|Sham Comparator|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
16282075|NCT04801797|Experimental|Standard of Care (Conventional Induction)|"Randomized participants will receive cytarabine and idarubicin [or daunorubicin) per standard of care as follows:
~Induction: cytarabine on days 1-7 and idarubicin (or daunorubicin) on days 1-3 of induction.
~Second Induction (if needed): Cytarabine on days 1-5 and idarubicin (or daunorubicin) on days 1-2 of re-induction.
~Consolidation (if needed): If < 60 years, cytarabine days 1,3,5 of consolidation cycles, and if ≥60 years, cytarabine days 1-5 of consolidation cycles
~Those with secondary or therapy-related AML can receive liposomal daunorubicin and cytarabine (Vyxeos) per standard of care as follows:
~Induction: Liposomal daunorubicin and cytarabine (Vyxeos) on Days 1,3, 5 of induction.
~Second Induction (if needed): Liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of re-induction Consolidation (if needed): liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of consolidation cycles"
16282076|NCT04801797|Experimental|Investigational (Venetoclax and Azacitidine)|Participants will receive azacitidine on days 1-7 and venetoclax daily for up to (3) three 28-day study cycles and evaluated for response or benefit. If benefit/response is achieved, azacitidine on days 1-7 and venetoclax on days 1-28 (or less if deemed necessary per protocol) will be given in repeating 28-day cycles until benefit/response is no longer achieved or until patient proceeds to transplantation.
16282077|NCT04801784|Experimental|Fluid balance neutralization|Fluid balance neutralization using increased net ultrafiltration, aiming to neutralize the cumulative fluid input received over the first 72 hours of study participation.
16282078|NCT04801784|Active Comparator|Standard care|Active control group of positive fluid balance during the first 72 hours of study participation with zero or near-zero net ultrafiltration.
16282079|NCT04801771|Experimental|Subjects implanted with Inspire UAS System|Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.
16282080|NCT04801758|Experimental|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 704/HPTN 085 (NCT02716675).
16282081|NCT04801745|Experimental|Healthy Vegan Diet|Education on healthy vegan diet
16282082|NCT04801745|Experimental|Healthy Vegan Diet with Amla fruits|Education on healthy vegan diet, 3g of powdered amla fruits per day
16282083|NCT04801745|Active Comparator|My Plate - Low Purine|"Education on My Plate diet with emphasis on choosing low purine protein options."
16282084|NCT04801745|Experimental|My Plate - Low Purine with Amla Fruits.|"Education on My Plate diet with emphasis on choosing low purine protein options and with an addition of 3g of amla powder per day."
16282085|NCT04801732|Experimental|mulligan group|Patients in the study group will treated with SNAGS techniques on thoracic spine with traditional treatment consist of ice application, supervised exercises (stretching and strengthening exercise) for 3 times/week for one month.
16282086|NCT04801732|Active Comparator|exercising group|will receive only traditional treatment (ice application and supervised exercise ) for 3 times/week for one month.
16282087|NCT04801719|Experimental|Experimental arm - endoluminal RFA|standard treatment protocol for malignant biliary stenosis + endoluminal RFA prior metal stent insertion
16282088|NCT04801719|No Intervention|Control arm|standard treatment protocol for malignant biliary stenosis which includes metal stent insertion
16282089|NCT04801693|Experimental|BI 1819479|single rising doses (SRD) part
16282090|NCT04801693|Placebo Comparator|Placebo|Single rising doses (SRD) part
16282091|NCT04801693|Experimental|BI 1819479 fed - fasted arm|Food effect part
16282092|NCT04801693|Experimental|BI 1819479 fasted - fed arm|Food effect part
16282093|NCT04801680||Mpact 3d metal|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. The
16282094|NCT04801667|Experimental|Coronavac vaccine|Kidney transplant recipients receiving the coronavac vaccine
16282095|NCT04801654||Ion released group|First 30 patients will be assessed for metalic ion released by blood sample. the patients will be monitored until 10 years follow-up for long term performance of the device
16282096|NCT04801654||Other group|The remaining 125 patients will be not assessed for metalic ion released; they will be monitored until 10 years follow-up for long term performance of the device
16282097|NCT04801641|Placebo Comparator|Placebo|Placebo
16282098|NCT04801641|Experimental|Low-Dose Nabilone|pms-nabilone titrated to 2 mg daily
16282099|NCT04801641|Experimental|High-Dose Nabilone|pms-nabilone titrated to 6 mg daily
16282100|NCT04801628|Active Comparator|Active Tecar|"Transfer Electrode Capacitive and Resistive (TECAR) Therapy (radio frequency therapy; INDIBA, Spain) will be used. In CET mode, heat transfer is concentrated on the skin and superficial muscles, which are tissue with high electrolytes, while the RET mode focuses heat transfer on bones, tendons, joints, and deep muscles. In this study, both CET and RET modes will be applied to the participant' quadriceps for 15-20 minutes at stable frequency of 448 KHz. According to the manufacturer's guidelines for safety, the CET mode will be first implemented for 5 minutes. Then will be continued in RET mode using for the rest of the treatment. Participants will be asked to lie down comfortably, and treatment will be beginning.
~The intensity of the current will be set at the level of comfort between 0%-100%, averaging about 40%. TECAR therapy will be applied by a physical therapist for all participants."
16282101|NCT04801628|Placebo Comparator|Placebo Tecar|the same procedure as in active Tecar but the device not provide any radio frequency
16282102|NCT04801589|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 4 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.
~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr."
16282103|NCT04801589|Active Comparator|Midazolam|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 0.5 mg/mL midazolam. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.
~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr."
16282104|NCT04801576|Placebo Comparator|Placebo mouthrinse|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse without flouride for 28 days; toothpaste with 1050 ppm F and mouthrinse without flouride for 28 days; toothpaste with 1450 ppm F and mouthrinse without flouride for 28 days.
16282105|NCT04801576|Experimental|Fluoride in mouthrinses|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse with 450 ppm F for 28 days; toothpaste with 1050 ppm F and mouthrinse with 450 ppm F for 28 days; toothpaste with 1450 ppm F and mouthrinse with 450 ppm F for 28 days.
16282106|NCT04801563|Other|SINGLE ARM|
16282107|NCT04801550|Active Comparator|Millimeter wave emitter status 1|Somatosensory stimulus during Magnetoencephalography (MEG) records
16282108|NCT04801550|Sham Comparator|Millimeter wave emitter status 2|Somatosensory stimulus during Magnetoencephalography (MEG) records
16282109|NCT04801537||normal body temperature and warm extremities|standard set of environmental temperature is done, and the infant's body temperature is normal and extremities are warm
16282110|NCT04801537||normal body temperature and cold extremities|standard set of environmental temperature is done, and infant's body temperature is normal and extremities are cold
16282111|NCT04801524|No Intervention|Holdout Arm|In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
16282112|NCT04801524|Experimental|Self-benefit sub-arm|In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
16282113|NCT04801524|Experimental|Prosocial-benefit sub-arm|In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
16282114|NCT04801524|Experimental|Early-access and self-benefit sub-arm|In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
16282115|NCT04801524|Experimental|Early-access and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
16282116|NCT04801524|Experimental|Fresh start and self-benefit sub-arm|In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
16282117|NCT04801524|Experimental|Fresh start and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
16282118|NCT04801511|Experimental|Experimental|"Preoperative concurrent chemoradiotherapy and high-dose intravenous vitamin C :
~The eligible subjects will be treated with concurrent chemoradiotherapy and high-dose intravenous vitamin C preoperatively. IMRT will be delivered to PTV-CTV (plan target volume-clinical target volume) with a dose of 45Gy/25fraction/5weeks. If necessary. During IMRT, 2-3 cycles of concurrent chemotherapy (mFOLFOX6) will be delivered. High-dose intravenous vitamin C ( 24g/d，QD ) will be delivered on the day of radiotherapy from the beginning to the end of IMRT.
~preoperative consolidation chemotherapy: Three additional cycles of neoadjuvant chemotherapy (mFOLFOX6) will be given after the end of IMRT.
~TME （total mesorectal excision）or sphincter preserving surgery will be performed approximately the 10th-12th weeks after the end of IMRT. Whether or not to select watch and wait needs to refer to the tumor location, tumor regression, surgeon's opinion and patient's will."
16282119|NCT04801498||Healthy controls|Men and women ages 18-65 years old with no major medical problems and no history of chronic pain or opioid use.
16282120|NCT04801498||Chronic pain patients not taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) that have not used any opioid medication within the past one year.
16282121|NCT04801498||Chronic pain patients taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) using chronic daily opioid use for longer than 3 months duration and taking stable doses of opioid medications for at least 30 days prior to study visit.
16282122|NCT04801485|Active Comparator|Myo-inositol|
16282123|NCT04801485|Placebo Comparator|Placebo|
16282124|NCT04801472|Other|Patients with oral cavity or oropharyngeal squamous cell carcinoma|
16282125|NCT04801459|Experimental|Antiperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|
16282126|NCT04801459|Other|Isoperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|
16282127|NCT04801446|Active Comparator|Transcranial Direct Current Stimulation|
16282128|NCT04801446|Sham Comparator|Sham Stimulation|
16282129|NCT04801433|Experimental|Boleda Supramolecular Active Zinc|Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
16282130|NCT04801433|Active Comparator|Capotetriol scalp solution|30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
16282131|NCT04801433|Placebo Comparator|Supramolecular Hydrogel|30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
16282132|NCT04801420|Experimental|Part A+B - Group 1|Part A: VLA15 at Month 0, 2 and 6 - Part B: VLA15 or placebo depending on schedule selection
16282133|NCT04801420|Experimental|Part A+B - Group 2|Part A: VLA15 at Month 0 and 6, placebo at Month 2 - Part B: VLA15 or placebo depending on schedule selection
16282134|NCT04801420|Placebo Comparator|Part A+B - Group 3|Placebo
16282135|NCT04801407|Active Comparator|radiofrequency group|it is the group that will be treated with Percutaneous Radiofrequency Rhizotomy
16282136|NCT04801407|Active Comparator|Microvascular decompression group|it is the group that will be treated with Microvascular decompression
16282137|NCT04801394|Experimental|Mesh Group|Patient with large incisional hernia treated with FLaPp® mesh as neoperineium
16282138|NCT04801381|Active Comparator|Aquablation therapy|Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR).
16321241|NCT04530266|Placebo Comparator|Healthy controls|
16282139|NCT04801381|Active Comparator|Transurethral laser enucleation|Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP).
16282142|NCT04801355|Other|laparoscopic resection|patients with colonic adenomas who will undergo to laparoscopic segmental resection
16282143|NCT04801355|Experimental|full-thickness laparo-endoscopic colon adenomas excision|patients with colonic adenomas who will undergo to laparo-endoscopic full-thickness colon resection
16282144|NCT04801342|Experimental|Unilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with unilateral hippocampal avoidance and Concurrent use of Memantine HCL
16282145|NCT04801342|Active Comparator|Bilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with bilateral hippocampal avoidance and Concurrent use of Memantine HCL
16282146|NCT04801329||Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)|
16282147|NCT04801316|Other|Part 1: Video training|"Participants will undergo the following procedures:
~Community instructors (involved in the training itself):
~Attend a video-facilitated training
~Be assessed for competency level of class execution before and after the video-facilitated training
~Might need to conduct or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)
~Might need to participate in one interview/discussion which will last up to 2 hours
~Community-dwelling older adult or community providers (individuals involved in the programme implementation but not the training itself):
~Attend or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)
~Participate in one interview/discussion which will last up to 2 hours"
16282148|NCT04801316|Experimental|Part 2: Exercise Intervention|"Participants will participate in 6 months of exercises, and be provided with education and advice on how to reduce their risk of falls.
~The exercises are divided into 2 phases:
~The Steady Feet (SF) exercise programme phase. A twice-weekly tailored structured group exercise class will be conducted for 3 months with community instructors and exercise video.
~A 3 months maintenance exercise phase. A once-weekly structured community group exercise class."
16282149|NCT04801316|No Intervention|Part 2: Control|Participants will be provided with the usual education and advice on how to reduce their risk of falls.
16282150|NCT04801303|Experimental|Friedreich's Ataxia patients|"Friedreich's Ataxia patients that will receive treatment with Calcitrol 0.25mcg/24h for a year.
~During the clinical trial:
~The effects of Calcitriol in the neurological symptoms of Friedreich's Ataxia patients will be evaluated before starting the treatment and after a year. The following scales will be used: SARA scale, 9-Hole Peg test, 8 meters walking test, PATA velocity test and Quality of life test with the SF36 questionnaire.
~The changes in the Frataxin's levels during the treatment with Calcitriol will be measured: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment."
16282151|NCT04801290||TIPS insertion|
16282152|NCT04801277|Active Comparator|Acupuncture on PC6 and LI4|Acupuncture on bilateral acupoints, that are PC6 and LI4. The pericardium meridian PC6 point (Neiguan) is defined as follows. The patient's four fingerbreadths will be placed on the medial aspect of their forearm with the edge of the 4th finger on the wrist crease. This is then subtracted from the width of the interphalangeal joint of her thumb. The point between the tendons of extensor carpi radialis and palmaris longus was the pericardium meridian PC6 point (Neiguan). The large intestine LI4 point (Hegu) located on the dorsum of the hand, between the first and second metacarpal bones, at the midpoint of the second metacarpal bone and close to its radial border.
16282153|NCT04801277|Sham Comparator|Acupuncture on Sham acupoints|Acupuncture on bilateral non acupoints. In sham/placebo group, patient will have the acupuncture needles inserted at non-acupoint 2cm radial to PC6 and between 2nd and 3rd metacarpal bone bilaterally, superficial skin piercing (adequate depth to let patient feels needle is inserted)
16282154|NCT04801264|Experimental|68Ga-PSMA, PET/CT and 177Lu-EB-PSMA-617 therapy|All patients diagnosed with ACC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
16282155|NCT04801251|Other|Resident|Full history.complete systemic and cardiac physical examination
16282156|NCT04801251|Other|Assistant Lecturer|Echocardiographic examination
16282157|NCT04801238|Active Comparator|LCBDE + LC|Laparoscopic common bile duct exploration with laparoscopic cholecystectomy
16282158|NCT04801238|Active Comparator|ERC + LC|Endoscopic retrograde cholangiography with laparoscopic cholecystectomy
16282159|NCT04801225|Experimental|VItalFlow Stimulation Treatment|"Enrolled subjects shall receive a VitalFlow stimulation after other standard-of-care treatments are initiated. VitalFlow treatment is initiated by powering on the System and positioning the two (Left and Right) VItalFlow coils on each side of the head (by the ear).
~The operator controls the VItalFlow Stimulation through the accompanying console with simple button operation. Once treatment is initiated, the VitalFlow provides continuous, biphasic pulses at a preset power cycle with the total treatment time under 5 min (fixed time). After treatment is completed, the coils are removed and replaced on the VitalFlow System."
16282160|NCT04801212|Experimental|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
16282161|NCT04801212|Active Comparator|core stability exercises alone|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
16282162|NCT04801199|Experimental|CPL-2009-0031 140 mg|Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks
16282163|NCT04801199|Active Comparator|Sitagliptin 100 mg|Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks
16282164|NCT04801173|Experimental|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
16282165|NCT04801173|Active Comparator|Low calorie diet|Control treatment with a low calorie standard diet
16282166|NCT04801160|Experimental|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
16282167|NCT04801160|Active Comparator|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
16282168|NCT04801147|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
16282169|NCT04801134|Other|Food insecurity|Food insecure families will be assigned education and community resources needed.
16282170|NCT04801121||Pregestational diabetic pregnant|Cases: Women with type 1 or type 2 diabetes before start of pregnancy
16282171|NCT04801121||Non-diabetic pregnant|Controls: Women without metabolic disease before start of pregnancy
16282172|NCT04801108|No Intervention|Medical management group|COPD patients with severe emphysema and incomplete lobar fissures will be placed on maximal medical therapy for 3 months. At the end of this 3 month period, patients will fill in an additional set of quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. New pulmonary function testing will be performed and crossover to the intervention group will be offered.
16282173|NCT04801108|Experimental|Intervention group|COPD patients with severe emphysema and incomplete lobar fissures will undergo video-assisted thoracic surgery fissure completion and valves placement. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
16282174|NCT04801108|Experimental|Crossover group|Subjects allocated to the medical management group will be offered to crossover after the 3 months follow-up period. The same procedure as in the intervention group will be performed. Follow-up after surgery will be the same as in the intervention group.
16282175|NCT04801095|Experimental|WM-S1-030|Dose escalation (part 1) and Dose expansion (part 2)
16282176|NCT04801082|Active Comparator|EUS-CPB|Endoscopic Ultrasound Guided Coeliac Plexus Block
16282177|NCT04801082|Active Comparator|EUS-CPA|Endoscopic Ultrasound Guided Coeliac Plexus Radiofrequency Ablation
16282178|NCT04801069|Experimental|Auto-Adaptative Servo-Ventilation|
16282179|NCT04801069|No Intervention|Control|
16282180|NCT04801056|Experimental|TB006|"During the SAD study, subjects will receive a single dose of TB006 (at the dosage level of 10 ~ 50 mg/kg) administered via i.v. infusion for 60 mins.
~In addition, a sentinel cohort of 5 mg/kg will be open for enrollment and double-blinded randomization first, with 2 patients randomized to active/TB006 arm, to assess preliminary safety and tolerability of study drug, and to determine cohort expansion and dose escalation. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
16282181|NCT04801056|Placebo Comparator|Placebo|"During the SAD study, subjects will receive a single dose of the placebo administered via i.v. infusion for 60 mins.
~In addition, the corresponding sentinel placebo group will include 1 patient to placebo arm. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
16282182|NCT04801043|Experimental|Cohort 1: Healthy young females|Healthy young females participants, ≥ 18 to ≤ 45 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
16282183|NCT04801043|Experimental|Cohort 2: Healthy elderly males|Healthy elderly male participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
16282184|NCT04801043|Experimental|Cohort 3: Healthy elderly females|Healthy elderly female participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
16282185|NCT04801043|Placebo Comparator|Placebo to XNW 4107 & imipenem/cilastatin|Matching placebo for XNW4107 and imipenem/cilastatin
16282186|NCT04801030|Experimental|Culturally-appropriate social marketing campaign|Participants will receive a multi-layered, social marketing campaign which is deemed culturally appropriate. This will occur over a 6 month -time period. Rates will be observed at 0, 6, and 12 months.
16282187|NCT04801030|No Intervention|Control Arm 1|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
16282188|NCT04801030|No Intervention|Control Arm 2|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
16282189|NCT04801017|Experimental|OT-101 + Artemisinin + Standard of Care|"OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days.
~Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral"
16282190|NCT04801017|Placebo Comparator|Placebo + Artemisinin + Standard of Care|Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral
16282192|NCT04800978|Experimental|BVAC-C+Durvalumab|"• Part A: The primary objective of the part A is to assess the maximum tolerable dose of BVAC-C combined with durvalumab 1500 mg as defined by dose-limiting toxicities (DLTs), and to find the maximum tolerated dose (MTD) that can be safely used for Part B (single arm phase II).
~• Part B: The primary objective of the part B is to evaluate the safety and clinical efficacy, as measured by 6-month PFS rate, of the combination therapy of durvalumab and BVAC-C in patients with HPV 16 or 18 positive cervical cancer recurrent after or refractory to first-line platinum-based chemotherapy +/-bevacizumab."
16282193|NCT04800965|No Intervention|Holdout Arm|In the Holdout arm, patients will not receive text messages about COVID-vaccine.
16282194|NCT04800965|Experimental|Simple Text Sub-arm|In the Simple Text sub-arm, participants will not receive any additional information.
16282297|NCT04800484|Experimental|Arm 17:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Soft, Tall Firm, NoAFO
16282195|NCT04800965|Experimental|Simple Text + Video Sub-arm|In the Simple Text+Video sub-arm, together with the appointment link, participants will also receive a link to a 2-minute video in the text message. The video contains information about the prevalence of COVID-19 and the effectiveness and safety of the COVID-19 vaccine.
16282196|NCT04800965|Experimental|Enhanced Text sub-Arm|In the Enhanced Text sub-arm, in addition to the appointment link, the text message will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
16282197|NCT04800965|Experimental|Enhanced Text + Video Sub-arm|In the Enhanced Text+Video sub-arm, in addition to the appointment link, the text message will encourage patients to watch a 2-minute video (the same as in the Simple Text+Video sub-arm) and use enhanced language aimed at reducing patients' psychological barriers of following through on scheduling an appointment.
16282198|NCT04800952|Other|To establish the appropriate dosing regimens of newly available antibiotics during CRRT|High dose (world standard dose) and low dose CRRT (Japan local) CRRT protocol Vascular access will be obtained by inserting a double-lumen dialysis catheter into the internal jugular or femoral veins. High dose CRRT in Australia, Blood flow through the extracorporeal circuit will be maintained at 150 ml/min. The CVVHF replacement volume will be set at 25ml/kg/hour and bicarbonate-buffered replacement fluids will be added in post-dilutional mode. Low dose CRRT in Japan, Blood flow through the extracorporeal circuit will be maintained at 80 ml/min. CVVHF replacement volume will be set at 15ml/kg/hour and bicarbonate-buffered replacement fluids will be added in the post-dilutional mode. Fluid balance, volume removal and the duration of CVVHF will be determined by the ICU physician based on the patient's individual clinical status.
16282199|NCT04800939|Experimental|Acupressure Group|The experimental group will be given acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
16282200|NCT04800939|Other|Placebo Acupressure Group|The control group will be given plasebo acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
16282201|NCT04800926|Experimental|Xavier wheelchair controller|Surface electromyography control of wheelchair
16282202|NCT04800913|Experimental|Multimodal imaging|"Preoperative 2D/3D TOE AND MDCT for appendage characterisation and sizing
~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success
~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
16282203|NCT04800913|Experimental|Standard imaging|"Preoperative 2D/3D TOE OR MDCT for appendage characterisation and sizing
~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success
~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
16282204|NCT04800900|Experimental|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors
16282205|NCT04800887|Active Comparator|Extended depth of focus intraocular lens|Eyes of patients implanted with extended depth of focus lens Tecnis Eyhance
16282206|NCT04800887|Active Comparator|Monofocal intraocular lens|Eyes of patients implanted with monofocal lens Tecnis ZCB00
16282207|NCT04800874|Experimental|Cohort 1|Subjects will receive 6 grams of BBP-418 once daily x 90 days, then 12 grams twice daily (BID, a least 8 hours apart) of BBP-418 daily until study completion.
16282208|NCT04800874|Experimental|Cohort 2|Subjects will receive 6 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
16282209|NCT04800874|Experimental|Cohort 3|Subjects will receive 12 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
16282210|NCT04800848||Mask/No Mask|"The group will perform both situations in a randomized cross-over design:
~1. Scholars will perform the fitness test with the use of a N95/FFP2 face mask
~2. Scholars will perform the fitness test without the use of a N95/FFP2 face mask"
16282211|NCT04800835|Active Comparator|Group 1- Spatz3 adjustable balloon 12-month implantation;|A 12 month adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
16282212|NCT04800835|Active Comparator|Group 2- 6-month non adjustable balloon implantation with additional 6 months follow-up|A 6-month non adjustable intragastric balloon for weight loss
16282213|NCT04800822|Experimental|PF-07284892 monotherapy|Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
16282214|NCT04800822|Experimental|PF-07284892 in combination with lorlatinib (Part 2)|Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
16282215|NCT04800822|Experimental|Expansion Phase (Cohort 1)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib without prior platinum-based chemotherapy
16282216|NCT04800822|Experimental|Expansion Phase (Cohort 2)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib with prior platinum-based chemotherapy
16282217|NCT04800822|Experimental|Expansion Phase (Cohort 3)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
16282218|NCT04800822|Experimental|Expansion Phase (Cohort 4)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC resistant to BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
16282219|NCT04800822|Experimental|Expansion Phase (Cohort 5)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC refractory to BRAFi plus EGFRi
16282220|NCT04800822|Experimental|Expansion Phase (Cohort 6)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
16282221|NCT04800822|Experimental|Expansion Phase (Cohort 7)|PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
16282222|NCT04800822|Experimental|PF-07284892 in combination with encorafenib and cetuximab (Part 2)|Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
16282223|NCT04800822|Experimental|PF-07284892 in combination with binimetinib (Part 2)|Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors
16282298|NCT04800484|Experimental|Arm 18:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Firm, Tall Soft, NoAFO
16282224|NCT04800809||Children and young adults with SCD and stroke|"Participants with SCD confirmed with hemoglobin electrophoresis or high pressure liquid chromatography (HPLC)
~Age 5 to 26 years old
~Present within three months of stroke event that is diagnosed as a stroke by the local health care provider
~Medical records are available for review for the stroke event that occurred within 3 months"
16282225|NCT04800809||The participants in SPIN and SPRING and SPRINT Trials|The participants enrolled in our previous primary and secondary stroke prevention trials in northern Nigeria; SPIN and SPRING (children with SCD with normal and abnormal TCD measurements; NCT02560935 and NCT01801423), SPRINT (children with SCD and strokes; NCT02675790) Trials for ascertainment of incidences rates of strokes in children and young adults receiving standard care after completion of primary stroke prevention trials. For this purpose, we will enroll these participants to follow their progress after completion of the trials. No intervention is planned, only to follow the participants with and without abnormal TCD measurements and with and without strokes.
16282226|NCT04800796||Intervention Group|Intervention Group with audiovisually blended learning concept
16282227|NCT04800796||Standard group|Standard Group receiving the Standard operating procedures via E-Mail and Confirmation when reading.
16282228|NCT04800783|Other|Swallowing disorders cohort|All included patients will undergo an ultrasound assessment of the oral and laryngeal structures involved in the swallowing process.
16282229|NCT04800757|Experimental|individual (Brief Motivational Intervention)|
16282230|NCT04800757|Experimental|Group (Group Problem Solving)|
16282231|NCT04800757|Placebo Comparator|Standard of Care|
16282232|NCT04800744|Experimental|Lavender Peppermint Elequil Aromatab|Participants will have a lavender peppermint elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new treatment elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
16282233|NCT04800744|Active Comparator|Sweet Almond Oil Elequil Aromatab|Participants will have a sweet almond oil active comparator elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new active comparator elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
16282234|NCT04800731||Group 1|Group 1 will consist of 100 patients COVID-19 positive patients older than 70 years old hospitalized in UZ Brussel from February 2020 until September 2020 with a positive RT-PCR test for SARS-CoV-2.
16282235|NCT04800731||Group 2|Group 2 will consist of 100 patients older than 70 years old hospitalized in UZ Brussel for acute infections other than COVID-19.
16282236|NCT04800731||Group 3|Group 3 will consist of healthy aged people defined as in the modified SENIEUR protocol (12, 13). This group is recruited from a previously conducted study. These are community dwelling individuals above the age of 70 and considered as almost healthy with some conditions that are present in the majority of old people such as osteoporosis, osteoarthritis or atherosclerosis.
16282237|NCT04800718|Experimental|Door-to-door screening|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
16282238|NCT04800718|No Intervention|Routine awareness activities,Control Arm|The control arm VC will continue its routine awareness activities & health talk sessions in the community.
16282239|NCT04800705||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
16282240|NCT04800705||Control group|The study population will be consisted of 70 women with POI as the study group and 70 patients with normal healthy women as the control group. A volunteer group of healthy women who will be visited the gynaecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
16282243|NCT04800679|Active Comparator|intravitreal bevacizumab injections and then rescue|
16282244|NCT04800679|Active Comparator|PRP group|
16282245|NCT04800679|Active Comparator|IVB injections and a modified laser|
16282246|NCT04800666|Experimental|Facial Nerve Block Group|Facial Nerve Block and oral Mecobalamin Tablets
16282247|NCT04800666|Experimental|Stellate Ganglion Block Group|Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
16282248|NCT04800666|Experimental|D Group|Facial Nerve Block
16282249|NCT04800666|Other|C Group|control
16282250|NCT04800653|Experimental|Stellate ganglion block|Before the operation, the right stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
16282251|NCT04800653|No Intervention|Control|Do nothing
16282252|NCT04800640|No Intervention|No Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
16282253|NCT04800640|Experimental|Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
16282254|NCT04800627|Experimental|Treatment (pevonedistat, pembrolizumab)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16282255|NCT04800614|Experimental|Fasted dosing followed by fed dosing (high-fat meal) followed by fed dosing (low-fat meal)|Dosing in the fasted state followed by fed dosing after high and low fat meals
16282256|NCT04800614|Experimental|Fasted dosing followed by fed dosing (low-fat meal) followed by fed dosing (high-fat meal)|Dosing in the fasted state followed by fed dosing after low and high fat meals
16282299|NCT04800484|Experimental|Arm 19:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Tall Firm, Short Soft, NoAFO
16282257|NCT04800614|Experimental|Fed dosing (high-fat meal) followed by fasted dosing followed by fed dosing (low-fat meal)|Dosing after a high-fat meal followed by doing in the fasted sate followed by dosing after a low-fat meal
16282258|NCT04800614|Experimental|Fed dosing (high-fat) followed by fed dosing (low-fat) followed by dosing in the fasted state|Fed dosing (high-fate meal) followed by fed dosing (low-fate meal) followed by dosing in the fasted state
16282259|NCT04800614|Experimental|Fed dosing (low-fat) followed dosing in the fasted state followed by fed dosing (high fat)|Fed dosing (low-fat) meal followed dosing in the fasted state followed by fed dosing (high-fat meal)
16282260|NCT04800614|Experimental|Fed dosing (low-fat) followed by fed dosing (high-fat) followed by dosing in the fasted state|Fed dosing after a low-fat and high-fate meals followed by dosing in the fasted state
16282261|NCT04800601|Experimental|Experimental group|
16282262|NCT04800601|Active Comparator|Control group|
16282263|NCT04800588|Experimental|Older participant group|We will evaluate the performance of healthy older participants (N = 500, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. The goal is to characterize changes in performance to aging and task experience in a group of older subjects. Subjects will undergo APOE genetic testing with saliva samples.
16282264|NCT04800588|Experimental|CCAB vs. manual test group|We will compare the performance of normal participants (N = 100, age range 18 to 89) on computerized and manually administered cognitive tasks.
16282265|NCT04800588|Experimental|Younger participant group|We will gather normative data from younger participants (N = 400, ages 18 to 59) for three days at enrollment. A subset of these subjects (N=150) will undergo longitudinal testing at 6-month intervals for three years thereafter.
16282266|NCT04800588|Experimental|Screening test group|We will examine the performance of participants (N=1000, ages 18 to 89) on a 30-min computerized cognitive screening test. Testing may be repeated at 6-month or 1-year intervals.
16282267|NCT04800575|Experimental|Semi-permeable film dressing|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
16282268|NCT04800575|Other|sterile gauze and tape dressing|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
16282269|NCT04800562|Experimental|PCS499 900mg BID|PCS499 900mg twice a day with food
16282270|NCT04800562|Placebo Comparator|Placebo|similar in appearance to active study drug
16282271|NCT04800549|Experimental|METHOD|The power of the test in the study was calculated by using G*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.
16282272|NCT04800536|Experimental|Cardiovascular effects of rapidly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with a rapidly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
16282273|NCT04800536|Experimental|Cardiovascular effects of slowly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with slowly declining plasma glucose (<0.085 mmol/l/min). A combined hyperglycaemic and euglycaemic clamp with a slowly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
16282275|NCT04800510|No Intervention|NoCDO|Participants will be evaluated without a CDO.
16282276|NCT04800510|Experimental|CDO-A|The first design variant will be designated CDO-A.
16282277|NCT04800510|Experimental|CDO-B|The second design variant will be designated CDO-B.
16282278|NCT04800510|Experimental|CDO-C|The third design variant will be designated CDO-C.
16282279|NCT04800497||Patients resected for hepatocellular carcinoma|
16282280|NCT04800497||Patients who underwent surgery for benign diseases|
16282281|NCT04800484|Experimental|Arm 1:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Soft, Short Firm, NoAFO
16282282|NCT04800484|Experimental|Arm 2:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Firm, Short Soft, NoAFO
16282283|NCT04800484|Experimental|Arm 3:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Tall Firm, Short Firm, NoAFO
16282284|NCT04800484|Experimental|Arm 4:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Short Firm, Tall Firm, NoAFO
16282285|NCT04800484|Experimental|Arm 5:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Tall Firm, Short Soft, NoAFO
16282286|NCT04800484|Experimental|Arm 6:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Short Soft, Tall Firm, NoAFO
16282287|NCT04800484|Experimental|Arm 7:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Soft, Short Firm, NoAFO
16282288|NCT04800484|Experimental|Arm 8:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Firm, Short Soft, NoAFO
16282289|NCT04800484|Experimental|Arm 9:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Tall Soft, Short Firm, NoAFO
16282290|NCT04800484|Experimental|Arm 10:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Short Firm, Tall Soft, NoAFO
16282291|NCT04800484|Experimental|Arm 11:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Tall Soft, Short Soft, NoAFO
16282292|NCT04800484|Experimental|Arm 12:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Short Soft, Tall Soft, NoAFO
16282293|NCT04800484|Experimental|Arm 13:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Short Firm, Tall Firm, NoAFO
16282294|NCT04800484|Experimental|Arm 14:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Tall Firm, Short Firm, NoAFO
16282295|NCT04800484|Experimental|Arm 15:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Short Firm, Tall Soft, NoAFO
16282296|NCT04800484|Experimental|Arm 16:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Tall Soft, Short Firm, NoAFO
16282300|NCT04800484|Experimental|Arm 20:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Short Soft, Tall Firm, NoAFO
16282301|NCT04800484|Experimental|Arm 21:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Short Soft, Tall Soft, NoAFO
16282302|NCT04800484|Experimental|Arm 22:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Tall Soft, Short Soft, NoAFO
16282303|NCT04800484|Experimental|Arm 23:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Firm, Tall Soft, NoAFO
16282304|NCT04800484|Experimental|Arm 24:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Soft, Tall Firm, NoAFO
16282305|NCT04800471|Active Comparator|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
16282306|NCT04800471|Placebo Comparator|Point of Care Glucose Group|Participants in this group will be monitored by point of care glucose values
16282307|NCT04800458|Experimental|thrombocytopenic patients|
16282308|NCT04800445||Case group of fullterm neonates with neonatal sepsis|
16282309|NCT04800445||Healthy fullterm neonates|
16282310|NCT04800432|Experimental|Feasibility and acceptability of ADAPT+|ADAPT+ is a family-based obesity intervention for high-risk Latino youth and their parents living in rural communities that incorporates culture-specific components and mindfulness-based approaches to promote adaptive health behaviors in a high-risk and underserved population.
16282311|NCT04800432|Active Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) provides publicly available material in both English and Spanish on the role of diet and exercise in pediatric obesity in a one-time information session.
16282312|NCT04800419|Experimental|Acceptance and Commitment Therapy (ACT)|ACT will be conducted in a group of 10 for each session. The ACT modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
16282313|NCT04800419|Experimental|Mindfulness-based Stress Reduction (MBSR)|MBSR will be conducted in a group of 10 for each session. The MBSR modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
16282314|NCT04800419|No Intervention|Control|The subjects in the control group will be assigned in the wait-list where either ACT or MBSR will be provided after the study has been completed.
16282315|NCT04800393|Experimental|Inhalation anesthesia|
16282316|NCT04800393|Active Comparator|Total intravenous anesthesia|
16282317|NCT04800380|No Intervention|Routine training|Nursing students in the control group will receive training in routine metric and drug dose calculation in virtual environment.
16282318|NCT04800380|Experimental|Edpuzzle application|Students in the intervention group will watch the routine metric and drug dose calculation training in virtual environment, as well as interactive videos prepared by the first researcher and uploaded to the Edpuzzle application.
16282319|NCT04800367|Experimental|Romosozumab followed by denosumab|Romosozumab 210 mg subcutaneous injection, once a month for 12 months followed by denosumab 60 mg subcutaneous injection, once every six months for 12 months.
16282320|NCT04800354|Experimental|Nurse-led Mindfulness Based Intervention|
16282321|NCT04800354|Active Comparator|Nurse-led Pain Psychoeducation|
16282322|NCT04800341||Patients ESADA follow-up|Patients included in the ESADA European database and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire.
16282323|NCT04800315|Experimental|Dose 1: CC-93538 SC QW|Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.
16282324|NCT04800315|Experimental|Dose 2: CC-93538 and Placebo SC Q2W|Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.
16282325|NCT04800315|Experimental|Dose 3: CC-93538 and Placebo SC Q2W|"Starting at the baseline visit, active IP and matching placebo will be administered.
~On the alternate weeks, placebo will be administered weekly to maintain the blind."
16282326|NCT04800315|Placebo Comparator|Placebo SC QW|Administration of placebo each week.
16282327|NCT04800302|Experimental|Continuous QLB group|U/S-guided continous QLB III
16282328|NCT04800302|Active Comparator|Single dose QLB group|U/S-guided single dose QLB III
16282329|NCT04800302|Active Comparator|Morphine group|IV Morphine
16282330|NCT04800276|Experimental|APA with consideration of ischemia localization|
16282331|NCT04800276|Experimental|APA without consideration of ischemia localization|
16282332|NCT04800263|Experimental|SHR-1905 Dose Level 1|SHR-1905 Dose level 1
16282333|NCT04800263|Experimental|SHR-1905 Dose Level 2|SHR-1905 Dose level 2
16282334|NCT04800263|Experimental|SHR-1905 Dose Level 3|SHR-1905 Dose level 3
16282335|NCT04800263|Experimental|SHR-1905 Dose Level 4|SHR-1905 Dose level 4
16282336|NCT04800263|Experimental|SHR-1905 Dose Level 5|SHR-1905 Dose level 5
16282337|NCT04800250|Experimental|A - Mucogain matrix on right|The patient will receive mucogain matrix on right side and connective tissue graft on left side.
16282338|NCT04800250|Experimental|B - Mucogain matrix on left|The patient will receive mucogain matrix on left side and connective tissue graft on right side.
16282341|NCT04800224|Placebo Comparator|Placebo|Patients in the Placebo group will receive an identical number of capsules containing 900 mg / day of placebo (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
16282342|NCT04800224|Active Comparator|Propolis|Participants in the Propolis group will receive propolis EPP-AF at a dose of 900 mg / day (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
16282343|NCT04800211|No Intervention|Control|Continue smoking under ad libitum use of subjects' own brand of conventional lit-end cigarettes, without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
16282344|NCT04800211|Experimental|Test 1|"Exclusive ad libitum use of test e-Vapor Product NuMark LLC, MarkTen® XL Bold CLASSIC* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
~*Product no longer sold commercially"
16282410|NCT04799743|Experimental|Resveratrol group|Resveratrol group (treatment group) will be instructed to consume with capsules (1.0 g, orally once a day) for six months.
16321858|NCT04526314||Stage 3 with adjuvant chemotherapy|
16282345|NCT04800211|Experimental|Test 2|"Exclusive ad libitum use of test e-Vapor Product Nu Mark LLC, MarkTen® XL Bold MENTHOL* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
~*Product no longer sold commercially"
16282346|NCT04800185|Other|Treatment group|
16282347|NCT04800172|Active Comparator|Roflumilast arm|
16282348|NCT04800172|Placebo Comparator|Placebo arm|
16282349|NCT04800159|Active Comparator|THC Cannabis|13.03% THC/ 0.13% CBD
16282350|NCT04800159|Active Comparator|CBD Cannabis|0.44% THC/ 12.32% CBD
16282351|NCT04800159|Placebo Comparator|Placebo|≤ 0.01% THC/ ≤ 0.01% CBD
16282352|NCT04800146||Cohort 1|patients with solid tumors treated with chemotherapy (ongoing or completed no more than 6 months before enrollment). Specific type of chemotherapy inducing similar immunosuppression will be selected (including but not limited to platinum-based combinations, anthracycline combinations, triweekly docetaxel).
16282353|NCT04800146||Cohort 2|patients with solid tumors treated with single agent immune-check points inhibitors (ongoing or completed no more than 6 months before the enrollment
16282354|NCT04800146||Cohort 3|patients with solid tumors treated with hormonal agents (ongoing or completed no more than 6 months before enrollment): any anti-androgen for prostate cancer and any anti-estrogen for breast cancer patients.
16282355|NCT04800146||Cohort 4|patients with previously untreated mature B cell tumors in watch and wait
16282356|NCT04800146||Cohort 5|patients with mature B cell tumors treated with anti-CD20 monoclonal antibody either alone or in combination with chemotherapy (ongoing or completed no more than 12 months before enrollment
16282357|NCT04800146||Cohort 6|patients with hematological malignancies treated with pathway inhibitors (ongoing or completed no more than 12 months before enrollment). Different type of targeted agents can be considered, including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors or phosphoinositide-3 kinase (PI3K) inhibitors
16282358|NCT04800146||Cohort 7|patients with hematological malignancies who have received autologous stem cell or allogenic transplant within 12 months
16282359|NCT04800146||Cohort 8|non-cancer subjects (age and gender matched) referred to the Division of Infectious Diseases, Lugano, EOC for vaccination against SARS-CoV-2.
16282360|NCT04800133|Experimental|BNT162b2|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (or intradermal for immunocompromised patients; or by graded challenge with history of non-severe allergy to PEG-containing drugs) 30ug/0.3ml per dose 2 doses given 21 days apart; or 3 doses for immunocompromised patients; or 1 dose for patients with prior COVID-19
16282361|NCT04800133|Experimental|CoronaVac|CoronaVac by SinoVac Intramuscular injection (or intradermal for immunocompromised patients) 3ug/0.5ml per dose 2 doses given 28 days apart; with 3rd dose optional; or 1 dose for patients with prior COVID-19
16282362|NCT04800120|Active Comparator|Study Group|Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy
16282363|NCT04800120|No Intervention|Control Group|Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy
16282364|NCT04800107|Experimental|Treatment Group|Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.
16282365|NCT04800107|Placebo Comparator|Placebo Group|Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.
16282366|NCT04800094|Experimental|Investigational Ultrasound Imaging for Liver Fat Quantification|
16282367|NCT04800081|Experimental|Sacubitril/Valsartan|receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan
16282368|NCT04800081|Active Comparator|Valsartan|receive once-daily treatment with 80-320 mg of Valsartan
16282369|NCT04800055|Experimental|ATSB + VC intervention|Arm 1 will receive ATSBs for up to two years.
16282370|NCT04800055|No Intervention|VC only|Arm 2 will receive the standard of care of universal vector control coverage.
16282371|NCT04800042|Other|Patients with scheduled major surgery|Patients with scheduled major surgery
16282372|NCT04800029|Experimental|TIPS Alone|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
16282373|NCT04800029|Experimental|TIPS and ED-SAFE|"Half of the ED discharged patients with suicide risk will also be invited to receive post-discharge telephone counseling originally developed by Principal Investigator in a previous study, Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE). The participant will receive three calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
16282374|NCT04800029|Active Comparator|No intervention, Treatment as Usual|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
16282375|NCT04800016|Experimental|Vivity IOL|AcrySof IQ Vivity Extended Vision IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
16282405|NCT04799795||healthy subjects|Age-matched healthy participants will be recruited via flyers at public education facilities and online advertisement. Participants need to be healthy and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
16282406|NCT04799795||patients with absence epilepsy|Apart from the diagnosis of epilepsy, patients need to be of good health and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
16282407|NCT04799782|Active Comparator|Mirtazapine|The drug will be taken for a one week peroid.
16282408|NCT04799782|Placebo Comparator|Placebo|The drug will be taken for a one week peroid.
16282376|NCT04800003||Dry human mandibles, selected for evaluation|51 dry mandibles with posterior region endetulism and sufficient bone integrity to make the necessary measurements were evaluated. CBCT images of the 51 dry human mandibles included in the study were obtained using the Planmeca Promex-3D (Helsinki, Finland) device in our faculty Dentomaxillofacial Radiology department. Gonial angle was measured on CBCT images as the angle between the tangent line drawn posterior to the border of the ramus of the mandible and the tangent line drawn to the lower border of the mandible. While determining the depth of the submandibular fossa, a line was drawn to connect the most dislocated upper and lower points on the inner surface of the mandible in the coronal plane sections obtained with CBCT, and the length of the line drawn at a right angle from the deepest point of the fossa to this line was measured as the depth of the submandibular fossa.
16282377|NCT04799990||Risankizumab|Participants will receive risankizumab as prescribed by their physician.
16282378|NCT04799990||Comparator Group 1|Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.
16282379|NCT04799990||Comparator Group 2|Participants will receive non-biologic systemic small molecules as prescribed by their physician.
16282380|NCT04799977||COVID19 infection with olfaction disorder|Patients, ≥18 ans, who suffered from an olfaction disorder while going through a COVID19 infection
16282381|NCT04799977||COVID19 infection without olfaction disorder|Patients, ≥18 ans, who suffered from a COVID19 infection without any olfaction disorders
16282382|NCT04799964|Experimental|Group A|Flow diverter(Ton-bridgeMT, China)
16282383|NCT04799964|Active Comparator|Group B|Tubridge(Microport, China)
16282384|NCT04799951||Breast Surgeon|surgeons having experience in and regularly conducting breast conservation surgery and mastectomy surgeries
16282385|NCT04799938|Active Comparator|İntevention group|Prediabetic patients with age 30-50 and overweight Standart recommendations Exercise intervention will be made.
16282386|NCT04799938|No Intervention|Control group|Prediabetic patients with age 30-50 and overweight Only Standart recommendations
16282387|NCT04799938|No Intervention|Metformin Group|Prediabetic patients who received metformin Standart recommendations
16282388|NCT04799925||Intervention group|Hyperuricemic group will be treated with uric acid lowering drug (febuxostat 80 mg once daily for 6 months).
16282389|NCT04799925||Placebo group|Hyperuricemic group will take placebo pills.
16282390|NCT04799912|Experimental|Elective labor induction|Elective labor induction via oxytocin between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days for women with favorable cervix. Those with an unfavorable cervix (Bishop score < 6) will first undergo cervical ripening (method left to the discretion of the practitioner) in conjunction with or followed by oxytocin stimulation unless a contraindication arises. Except for elective induction of labor between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days, the obstetrical management will not be modified compared to routine obstetrical management.
16282391|NCT04799912|No Intervention|Expectant management|Standard follow-up visits until at least 41 weeks of gestation and 0 day without elective labor induction unless a medical indication is present. Antepartum fetal testing will be initiated no later than 41 weeks of gestation and 1 day according to policies at each center (according to the French guidelines). If still pregnant, women will undergo induction at 41 weeks of gestation and 6 days (according to the French guidelines)
16282392|NCT04799899|Experimental|Virtual MBCT Intervention|Participants will participate in 8 weekly virtual group sessions of MBCT. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
16282393|NCT04799899|Experimental|Virtual Health Enhancement Control|Participants will participate in 8 weekly virtual group sessions that focus on cardiac health and depression education. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
16282394|NCT04799886||Child and adolescent psychiatrist|
16282395|NCT04799860|Experimental|health promotive work-way|Six primary care units that voluntarily enrolls as experimental units. The units will receive implementation support based on previous research and tailored to the specific prerequisits and context for each unit. Strategies includes involvement of target groups; informationa and interactive education;use of external and internal facilitators tarined for the purpose; systematic feedback and learning dialogs during the project. The implementation support will take approximately 12 months.
16282396|NCT04799860|No Intervention|Control|Six primary care centers of similar size and socioeconomic background in the population listed to each center.
16282397|NCT04799847|Experimental|Catumaxomab|In the dose escalation phase, 3 dose levels of catumaxomab will be explored.
16282398|NCT04799834||CASES|Subjects who have had a severe form of COVID-19 and developed respiratory failure requiring oxygen supplementation or CPAP mechanical ventilation or intubation
16282399|NCT04799834||CONTROLS 1|Subjects, comparable in age, sex and risk factors (such as concomitant diseases) with the CASES, who contracted the virus but either did not fall ill or had mild symptoms
16282400|NCT04799834||CONTROLS 2|Subjects, comparable in age, sex and risk factors (such as concomitant pathologies) with the CASES, who did not contract the virus
16282401|NCT04799821|Experimental|Intervention|Daily walnut consumption
16282402|NCT04799821|Other|Control|No walnut consumption
16282403|NCT04799808||BioNTech cohort|The BioNTech cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by comirnaty vaccine from BioNTech. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised solid organ transplant recipients, and the staff caring for them in the nephrology dispensaries.
16282404|NCT04799808||Moderna cohort|The Moderna cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by Moderna Biotech vaccine. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised kidney transplant recipients, and the staff caring for them in the nephrology dispensaries.
16282409|NCT04799769|Experimental|Test Device|Investigational Device Arm
16282411|NCT04799743|Placebo Comparator|Placebo group|Placebo group (control group) will be instructed to orally take placebo (edible paraffin, 1.0) once a day.
16282412|NCT04799730||SLE cases in remission|according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI <5
16282413|NCT04799730||SLE cases in activity|according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5
16282414|NCT04799730||Control group|Healthy age and sex matched subjects.
16282415|NCT04799704||symptomatic patient|The first part of our study is to confirm the detectability of the SARS-nCoV-2 in the tear film of symptomatic patients.
16282416|NCT04799691||Invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 first period.
16282417|NCT04799691||Non-invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 second period.
16282418|NCT04799678||Participants|Current user of the Smart Asthma app
16282419|NCT04799665||All Participants|
16282420|NCT04799652||Doctors within Belgian Hospitals|
16282421|NCT04799639|Experimental|paclitaxel + cisplantin + Sindilimab|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles paclitaxel 150mg/m2，ivdrip,>3 hours cisplantin 70mg/m2，ivdrip，>1 hours Sindilimab 200mg，ivdrip, >0.5 hours
16282422|NCT04799626||Treatment|The use of antimicrobial agents depends on the clinical practice.
16282423|NCT04799613|No Intervention|Natural walking|
16282424|NCT04799613|Experimental|fast walking|
16282425|NCT04799613|Experimental|normal walking passing through narrow pathway|
16282426|NCT04799613|Experimental|fast walking passing through narrow pathway|
16282427|NCT04799613|Experimental|Natural walking with dual task|
16282428|NCT04799613|Experimental|fast walking with dual task|
16282429|NCT04799613|Experimental|Natural walking passing through narrow pathway and during cognitive dual task|
16282430|NCT04799613|Experimental|fast walking passing through narrow pathway and during cognitive dual task|
16282431|NCT04799613|Experimental|Natural walking reducing the best side|
16282432|NCT04799613|Experimental|fast walking reducing the best side|
16282433|NCT04799613|Experimental|Natural walking reducing the best side passing through narrow pathway|
16282434|NCT04799613|Experimental|fast walking reducing the best side passing through narrow pathway|
16282435|NCT04799613|Experimental|Natural walking reducing the best side with cognitive dual task|
16282436|NCT04799613|Experimental|fast walking reducing the best side with cognitive dual task|
16282437|NCT04799613|Experimental|Natural walking reducing the best side passing through narrow pathway and during cognitive dual task|
16282438|NCT04799613|Experimental|fast walking reducing the best side passing through narrow pathway and during cognitive dual task|
16282439|NCT04799600||Acute Renal Failure in ICU|COVID-19 Patients with Acute Renal Failure in ICU
16282440|NCT04799587|Active Comparator|P6 Accupressure Group|The pressure point will be stimulated by the presence of the magnet when positioned properly on the P6 acupressure point. Additional pressure may be applied as desired by the study subject but is not necessary for P6 stimulation.
16282441|NCT04799587|Sham Comparator|Sham Pressure Point|The sham pressure point (distal to the P6 acupressure point).
16282442|NCT04799574|Experimental|music therapy activity|The music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle.
16282443|NCT04799574|Placebo Comparator|Health education lecture|routine activities of community
16282444|NCT04799561|Experimental|Teleprehabilitation cohort|Patients in this single-arm study will receive multimodal teleprehabilitation.
16282445|NCT04799548|Experimental|neoadjuvant TACE plus Tislelizumab|
16282446|NCT04799535||Observational (ultrasound)|"AIM 1: Participants undergo a breast ultrasound over 15 minutes.
~AIM 2: Participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy, 2 months after start of chemotherapy, and after the completion of chemotherapy before surgery. Participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and 1 month after start of chemotherapy.
~AIM 3: Patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study."
16282447|NCT04799496||Vedolizumab|Participants with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-α) antagonist and have initiated vedolizumab treatment in a routine clinical practical setting in South Korea, will be observed prospectively.
16282448|NCT04799470|Experimental|PD with DBS|Patients with Parkinson's Disease who were implanted with Medtronic Percept PC for DBS and consent to participate in the study.
16282449|NCT04799457|No Intervention|Classical caesarean group|Care providers are applying standard caesarean procedure for participants.
16282450|NCT04799457|Experimental|Study caesarean group|Care providers are applying additional sutures to standard caesarean procedure for participants.
16282451|NCT04799444||Adult patients with complications post COVID-19|
16282452|NCT04799444||Children with complications post COVID-19|
16282453|NCT04799431|Experimental|Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab|All participants receive this intervention.
16282454|NCT04799418|Experimental|Experimental Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
16282455|NCT04799405|Experimental|tDCS MDD|"A group of 50 participants with major depressive disorder (MDD).
~tDCS, as a relatively simple and portable technology, is particularly well suited for remotely-supervised, home-based treatment, which would facilitate longer periods of treatment as well as offer a suitable therapeutic option at the present time as the investigators aim to deal with the COVID-19 pandemic."
16282456|NCT04799392|Experimental|Persons tested with investigational device following PCR test|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
16321859|NCT04526314||Stage 3 without adjuvant chemotherapy|
16282457|NCT04799392|Experimental|Persons tested with investigational device following vaccination|Persons tested with investigational device who previously were vaccinated for COVID-19 with an emergency use authorized or FDA cleared COVID-19 vaccine
16282458|NCT04799366||MC|MC patients with either dominant (Thomsens) or recessive (Becker) myotonia.
16282459|NCT04799366||Healthy Controls|Healthy controls age- and gender matched.
16282460|NCT04799353|Experimental|Group 1: Placebo SC + Placebo IV|Participants will receive Subcutaneous (SC) Placebo, followed by Intravenous (IV) Placebo.
16282461|NCT04799353|Experimental|Group 2: Budigalimab (SC) + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
16282462|NCT04799353|Experimental|Group 3: Budigalimab SC + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
16282463|NCT04799353|Experimental|Group 4: Placebo SC + Budigalimab IV|Participants will receive Subcutaneous (SC) Placebo, followed by IV Budigalimab.
16282464|NCT04799340|Experimental|holistic face training|
16282465|NCT04799340|Experimental|holistic face training + repetition lag training|
16282466|NCT04799340|No Intervention|waitlist control|
16282467|NCT04799327|Experimental|Treatment group A|
16282468|NCT04799327|Experimental|Treatment group B|
16282469|NCT04799327|Experimental|Treatment group C|
16282470|NCT04799327|Placebo Comparator|Treatment group D|
16282471|NCT04799314|Experimental|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose 200mg frequency 1 time for 2 months duration 2 years
16282472|NCT04799314|No Intervention|No intervention|No intervention
16282476|NCT04799288|Experimental|Teriflunomide|Teriflunomide 14 mg daily
16282479|NCT04799262|Experimental|Tofacitinib+Prednisone|Tofacitinib was given at the dose of 10mg daily through the 24 weeks. Patients were to receive prednisone in a dosage of 15mg daily at baseline and decreased to 10mg daily at week 2. The PMR-AS was determined every two weeks; if ≤10, the prednisone dosage was decreased by 2.5 mg every two weeks; and if >17 the dosage was increased to previous dosage; if 10≤PMR-AS ≤17, the dosage was maintained at previous stable dose.
16282482|NCT04799236|Active Comparator|Group 1: Oral Miltefosine|Miltefosine will be administered per os at 150 mg/day [50 mg tid] for 28 days. This is the standard regimen of miltefosine for persons >45 kg.
16282483|NCT04799236|Active Comparator|Group 2: Intravenous pentavalent antimony|IV pentavalent antimony (meglumine antimoniate) will be administrated at 20 mg x kg x d during 20 consecutive days. Antimony will be diluted in 10 times its volume in 5%Dextrose in destilled water and injected IV in 20 minutes
16282484|NCT04799236|Experimental|Group 3: Intravenous liposomal amphotericin B|LAMB will be administered IV at 3 ampules [150 mg] on each of days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Three ampules is the individual dose suggested by Aronson et al [2016] and equals 2.5 mg/kg/dose for a 60 kg person. 15 doses of 3 ampules (total of 2250 mg) equals 37.5 mg/kg for a 60 kg person.
16282485|NCT04799223|Experimental|Group receiving the 4 designed foods|The experimental group consumes the 4 foods designed for the study and will follow healthy eating guidelines.
16282486|NCT04799223|Active Comparator|Group with no designed foods|The control group follows healthy eating guidelines.
16282487|NCT04799210|Experimental|Human Factors Actual Use|Confirm device use safety and effectiveness of the Eximis CS (Contained Segmentation) System in actual use
16282488|NCT04799197|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
16282489|NCT04799184|Experimental|Group I Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.
~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug/ml completing a volume of 20 ml."
16282490|NCT04799184|Active Comparator|Group II no Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.
~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine completing a volume of 20 ml."
16282491|NCT04799171|Active Comparator|Young Adults (Age group 18-39)|31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
16282492|NCT04799171|Active Comparator|Middle Aged Adults (Age group 40-59)|31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
16282493|NCT04799171|Active Comparator|Old Adults (Age group >60)|31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
16282494|NCT04799158|Experimental|Run-In Period|Participants will receive vonoprazan 20 mg once daily for up to 4 weeks.
16282495|NCT04799158|Experimental|Vonoprazan 10 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 10 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
16282496|NCT04799158|Experimental|Vonoprazan 20 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 20 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
16282497|NCT04799158|Experimental|Vonoprazan 40 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 40 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
16282498|NCT04799158|Placebo Comparator|Placebo: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take a placebo when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
16282499|NCT04799119|Experimental|DAID dog training|'Do As I Do' (DAID) dog training employs operant conditioning to train dogs to copy the behavior of their owner upon hearing the verbal cue 'Do it', similar to teaching a dog the rules behind the game 'Simon Says'. Once this rule has been established and generalized, something that can be achieved in dogs by practicing with only 3-6 initially learned behaviors, owners can demonstrate new actions and use the cue 'Do it' to prompt a matched, imitative, behavioral response.
16282500|NCT04799119|No Intervention|Control|No intervention (waitlisted and will be provided with the experimental condition post-study completion).
16282501|NCT04799093||Cannabis users|
16282502|NCT04799093||Normals|
16282503|NCT04799054|Experimental|Part 1 Dose Escalation: TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.
16282504|NCT04799054|Experimental|Part 2 Dose Escalation: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.
16282505|NCT04799054|Experimental|Part 3 Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination.
16282506|NCT04799041|Active Comparator|GTX 2/3|Dose level administered of GTX 2/3 was 80 mcg. Dose was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of GTX 2/3 was injected. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 40 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
16282507|NCT04799041|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of placebo was injected.
16282508|NCT04799028|Active Comparator|Traditional children's fortified cow's milk|
16282509|NCT04799028|Experimental|New toddler milk with synbiotics and fat blend|
16282510|NCT04799028|Other|Toddlers consuming habitual diet|
16282511|NCT04799015|Experimental|Dexamethasone|Dexamethasone 10mg IV + metoclopramide 10mg IV
16282512|NCT04799015|Placebo Comparator|Placebo|Placebo IV + metoclopramide 10mg IV
16282513|NCT04799002|Active Comparator|Topotecan|Topotecan intraocular injection during chemotherapy
16282514|NCT04799002|Experimental|Melphalan|Melphalan intraocular injection during chemotherapy
16282517|NCT04798976||CDSS (MedicBK) Analysis|
16282518|NCT04798976||Core Laboratory Analysis|
16282519|NCT04798963|Other|On-clamp partial nephrectomy|Patients who are assigned to on-clamp partial nephrectomy.
16282520|NCT04798963|Other|Off-clamp partial nephrectomy|Patients who are assigned to off-clamp partial nephrectomy.
16282521|NCT04798937|Experimental|Intervention group|Youth in this group received usual care, consisting of medical consultations, in combination with a health education program based on motivational interviewing provided by a nurse
16282522|NCT04798937|No Intervention|Control group|Youth in this group received usual care only consisting of medical consultations
16282525|NCT04798911||Observational - phase 1|"Determination of Informational Needs (Months 0- 9)
~Qualitative interviews with patients with SS
~Interview transcriptions and thematic analysis"
16282526|NCT04798911||Observational - phase 2|"Phase 2 Development of the informational need instrument for SS [SS-INQ] (Months 9-32)
~Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group
~Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis
~Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability"
16282527|NCT04798898|Experimental|Intervention (+RFA) arm|Preoperative partial RFA necrosis in the liver metastasis followed by liver resection
16282528|NCT04798898|No Intervention|Control (-RFA) arm|Liver resection
16282529|NCT04798885|No Intervention|Enhanced usual care|Participants will be informed about typical Post Concussion Symptoms and the process of typical recovery as well as given reassurance concerning the prognosis. Advice concerning the use of pain relief medication will also be provided.
16282530|NCT04798885|Experimental|GAIN 2.0 intervention|An eight-week, interdisciplinary intervention program based on principles from cognitive behavioural therapy (CBT) and gradual return to activities.
16282531|NCT04798872|Experimental|web-based educational program|Consist of 6 education session during 1 month and will be followed up by telephone counselling at 2, 4, and 6 weeks postpartum.
16283059|NCT04795180|No Intervention|Non-irrigations|No irrigations trough the efferent limb of loop ileostomy
16282532|NCT04798872|No Intervention|control (usual care)|Mothers in the control group will receive standard treatment with pamphlets during the prenatal period. After delivery, standard postpartum care will be provided by the midwife, including pamphlets, rooming in and encourage mothers to breastfeed the baby.
16282533|NCT04798859|Experimental|Family-centered in home rehabilitation|"Seven individualized meetings with the family (7 sessions whereof most will be videoconferences, with the possibility of 1-2 of the sessions being home visits), one parent group seminar and 4 meetings (three videoconferences and one phone call) with school and local care providers during a period of 4-5 months.
~Based on target outcomes areas noted by children and parents, individual goals will be established (2-5 per family). Strategies to meet goals will be established for each goal, and goal attainment scaling will be used to quantify goal attainment."
16282534|NCT04798859|Active Comparator|Control group|Usual health care and rehabilitation services provided in the municipality, including school.
16282535|NCT04798846|Active Comparator|External fixator|patient treated by external fixator
16282536|NCT04798846|Active Comparator|Dorsal plate|patient treated by dorsal spanning plate
16282537|NCT04798833|Experimental|Integrated Newborn Care Kit|"The integrated newborn care kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, three misoprostol tablets (200ug each), 4% chlorhexidine solution, sunflower oil emollient, temperature monitoring strip or sticker, a fleece blanket, a reusable, non-electric, heating device, and a pictorial instruction guide. Lady Health Workers will be equipped with a hand-held electronic scale to identify low birth weight newborns.
~Participants in this arm will receive the same local standard of care as the no intervention arm."
16282538|NCT04798833|No Intervention|Control (Local Standard of Care)|"In the control arm, LHWs will deliver the local standard of care, which entails both anti-natal and post-natal LHW home visits. As part of standard practice, LHWs visit pregnant women in their homes during the 3rd trimester, at which time these health workers:
~Provide instructions regarding proper nutrition during pregnancy
~Encourage that delivery take place in a facility
~Discuss the fundamentals of safe water, sanitation, and hygiene behavior
~Encourage exclusive breastfeeding
~These community health workers will identify early danger signs in newborns such as infections and teach caregivers to identify the same symptoms, so that early interventions can be made. If danger signs are identified, the LHW will refer newborns to the appropriate level of health care."
16282539|NCT04798820|Active Comparator|SE-STG|simplified dietary education arm in subtotal gastrectomy group.
16282540|NCT04798820|Active Comparator|IE-STG|intensive dietary education arm in subtotal gastrectomy group
16282541|NCT04798820|Active Comparator|SE-TG|simplified dietary education arm in total gastrectomy group.
16282542|NCT04798820|Active Comparator|IE-TG|intensive dietary education arm in total gastrectomy group
16282543|NCT04798807||Hospitalized non-critical services patients|"Patients, who were hospitalized in the clinics (hematology, neurology, gastroenterology, nephrology, endocrine, pulmonary disease and cardiology) of Malatya Training and Research Hospital, were screened both Nutritional Risk Screening 2002 (NRS-2002) and Subjective Global Assessment (SGA) tools within the first days of admission to the patients.
~The nutritional status of patients categorized according the screening tools.
~Nutritional Risk Screening 2002 (NRS-2002) : The patients were classified as being nutritionally risk (NRS+): total score ≥ 3 or nutritionally risk-free (NRS-): total score < 3 according to NRS 2002 results.
~Subjective Global Assessment (SGA) The SGA screening provides three alternative categories for nutritional classification: well nourished (A); mild-to-moderately malnourished (B); or severely malnourished (C)."
16282544|NCT04798781|Experimental|telatinib + Keytruda|
16282545|NCT04798768|Experimental|Patients implanted with S-ICD and leadless cardiac pacemaker|Patients implanted with an S-ICD and leadless cardiac pacemaker that complete intended testing based on the study protocol
16282546|NCT04798755|Active Comparator|Adalimumab|
16282547|NCT04798755|Active Comparator|Methotrexate|
16282548|NCT04798755|Experimental|Adalimumab+Methotrexate|
16282549|NCT04798742|Experimental|Gait performance preop vs postop|Pre and postop
16282550|NCT04798742|Experimental|Gait performance postop vs controls|Postop vs controls
16282551|NCT04798716|Experimental|Escalating Dose First Cohort|"First Cohort:
~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 2 x 10^9 exosomes"
16282552|NCT04798716|Experimental|Escalating Dose Second Cohort|"Second Cohort:
~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 4 x 10^9 exosomes."
16282553|NCT04798716|Experimental|Escalating Dose Third Cohort|Five patients will receive a treatment dose of 8 X 10^9 exosomes every other day for a period of 5 days, with a minimum of 24 hours between doses recorded.
16282554|NCT04798716|Placebo Comparator|Treatment Dose Fourth Cohort Randomized control ratio 1:3|"Fourth Cohort:
~Randomized Cohort Up to 40 patients may be enrolled in this phase of the trial. For those receiving the placebo (~25%), 3 doses will be given over the 5 day period, dispensed from identical vials with physician and patient blinded. The full dose of 8 X 10^9 exosomes will be given to 75% of the patients in 3 doses over the course of 5 days, with one dose occurring every other day."
16282555|NCT04798703|Experimental|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|
16282556|NCT04798690||Growth hormone|Growtropin®-II
16282557|NCT04798677|Experimental|Influenza vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Influenza vaccine followed by 30 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
16282558|NCT04798677|Placebo Comparator|Influenza vaccine + placebo|Influenza vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
16282559|NCT04798677|Experimental|Covid-19 vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Covid-19 vaccine followed by 35 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
16282560|NCT04798677|Placebo Comparator|Covid-19 vaccine + placebo|Covid-19 vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
16282628|NCT04798222|Experimental|Group 2: Treatment Sequence AFHG|Participants will receive a single oral dose of Treatments A, F, H, and G in Treatment periods 1 to 4 on Day 1 of the study.
16322069|NCT04524780|Experimental|intracardiac echocardiography guidance|
16282561|NCT04798664|No Intervention|Basic Usual Care|Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
16282562|NCT04798664|Active Comparator|Enhanced Usual Care|Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
16282563|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives|Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
16282564|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives plus Mobile Health Application|"Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the future is now between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner."
16282565|NCT04798651|Experimental|patients with multiple sclerosis or clinically isolated syndrome|subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome
16282566|NCT04798638|Experimental|Arm1: TY-9591 + Osimertinib + TY-9591|Participants will receive TY-9591 tablets under fasted condition in period 1 , followed by Osimeritinib Mesylate tablet under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
16282567|NCT04798638|Experimental|Arm2: Osimertinib + TY-9591 + TY-9591|Participants will receive Osimeritinib Mesylate tablet under fasted condition in period 1 , followed by TY-9591 tablets under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
16282575|NCT04798612|Experimental|Intervention arm|Two 45 mikrogram doses of interferon-alfa2a (Pegasys). Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
16282576|NCT04798612|Placebo Comparator|Placebo|Two 1 ml doses of saline liquid. Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
16282577|NCT04798599|Experimental|Intervention|In the intervention group there will be the application of the intervention - use of telemonitoring and teleorientation applied to children in primary care in Dentistry.
16282578|NCT04798599|Active Comparator|Waiting list|In the control group, children waiting to be booked to the intervention (in implementation in the unit because of the pandemic) will be evaluated for the outcomes. Only after the evaluation, the control group's children will be invited to perform the teleconsultation (proposed intervention).
16282579|NCT04798586|Experimental|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
16282580|NCT04798560||Patients undergoing Whipple operation|After Whipple operation patients will be observed for complications and emphasis will be given on the presence of postoperative pancreatic fistula (POPF) according to the ISGPF 2016 definition. There will be to arms of patients. The first will include patients that do not develop POPF or either develop Biochemical Leak (Grade A). The second group consist of patients that develop either Grade B or Grade C POPF
16282581|NCT04798547|Placebo Comparator|Standard Length Myotomy|Patients randomized to received 8 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
16282582|NCT04798547|Experimental|Short Length Myotomy|Patients randomized to received 4 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
16282583|NCT04798534|Experimental|Intervention group|CHW in the intervention arm will receive intervention through a combination of in-person training sessions and internet support. MMT patients in the intervention arm can use a specially designed online platform to communicate with their CHW.
16282584|NCT04798534|No Intervention|Control group|The control group CHW will perform business as usual. Both control group CHW and MMT patients do not have access to the online platform.
16282585|NCT04798521|Experimental|Tele-HCV Treatment|Participants allocated to telemedicine intervention arm are scheduled for treatment assessment by a study clinician. For a majority of participants, this will also be the treatment initiation visit. If additional studies are necessary for routine treatment decision making, peers will assist participants in navigating health system barriers and arrangement of second telemedicine visit.
16282586|NCT04798521|Active Comparator|Community Linkage to Care|Participants allocated to the community linkage-to-care arm will complete screening, be offered enrollment, and undergo informed consent as in the telemedicine arm. Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment.
16282587|NCT04798508|Other|Whole group|"The whole group listen successively the 3 paradigms :
~P3 own-name recorded by listening to a smiling voice
~P3 own-name recorded by listening to a neutral voice
~P3 own-name recorded by listening to a rough voice"
16282629|NCT04798222|Experimental|Group 2: Treatment Sequence FGAH|Participants will receive a single oral dose of Treatments F, G, A, and H in Treatment periods 1 to 4 on Day 1 of the study.
16322719|NCT04520256|Experimental|Social Support, Exercise|
16282588|NCT04798495|Experimental|HAPPY|A 6-month multimodal interdisciplinary rehabilitation programme was tested; We used motivating interviewing technique, individual supervised physical exercise training, relaxation exercises, nutritional counselling and lessons for patients and relatives in small groups. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and an interactive physical exercise programme. Feasibility parameters were acceptability, practicality, safety and programme adherence.
16282589|NCT04798482|Experimental|Dexmedetomidine|This is a single arm, open label, interventional study examining the effects of dexmedetomidine on anal manometry. All subjects will be administered dexmedetomidine following their baseline manometry measurements. Following dexmedetomidine administration, anal manometry measurements will be observed for 15 minutes.
16282590|NCT04798469|Experimental|Testosterone|Weekly injections of testosterone 125 mg.
16282591|NCT04798469|Placebo Comparator|Placebo|Weekly injections of placebo.
16282592|NCT04798456||Patients with DoC|
16282593|NCT04798456||Caregivers/ legal guardian of patients with DoC|
16282594|NCT04798443|Active Comparator|Subureteral endoscopic injection|The endoscopic procedure was done under general anesthesia, and all patients received antibiotic prophylaxis. We used the subureteral injection technique (STING), as described by O'Donnell and Puri (1984). The volume of Dx/HA was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
16282595|NCT04798443|Active Comparator|open ureteral reimplantation (lich-gregoir)|extravesical ureteral reimplantation (lich-gregoir) by open surgery
16282596|NCT04798430|Experimental|LIB003 (lerodalcibep)|300 mg monthly (Q4W) by subcutaneous injection
16282597|NCT04798417|Experimental|Probiotic|
16282598|NCT04798417|Experimental|Prebiotic|
16282599|NCT04798417|Placebo Comparator|Maltodextrin|
16282600|NCT04798404||Exercise Intervention in 20 collective sessions|104 elders recruited among the community (mean age: 82.1 ± 5.7, 72 women and 32 men), diagnosed in initial consultation with mobility disability risk (sedentary or/and pre-frail/frail or/and sarcopenia at least probable) who participated in 20 collective sessions twice a week and two hours per week, and have been seen for reassessment in final consultation.
16282601|NCT04798391|Experimental|Dexamethasone with lignocaine|
16282602|NCT04798378|Experimental|Treatment Arm|Participants will received a customized NuroSleeve and undergo 8 weeks of occupational therapy using the NuroSleeve (45 minutes three times per week).
16282603|NCT04798365|Experimental|Intervention group|The main components of the intervention are 1) two sessions of voluntary continuing medical education on the urinary tract infection program in each LTCF for physicians and nursing staff, 2) distribution of educations materials such as written guidelines on antibiotic prescribing including a smart phone friendly version, 3) implementation of the project homepage as a platform to distribute guidelines and educational videos and to enable physicians to ask questions which will be answered by an infectious disease physician.
16282604|NCT04798365|No Intervention|Control group|No intervention until end of the stuy.
16282605|NCT04798352|Experimental|LUTONIX(R)035 drug-coated balloon catheter|
16282606|NCT04798352|Experimental|RANGER TM drug-coated balloon catheter|
16282607|NCT04798339|Experimental|Phase 1b: Dose Level 1|Patients will be treated at dose level 1: Canakinumab 150 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
16282608|NCT04798339|Experimental|Phase 1b: Dose Level 2|Patients will be treated at dose level 2: Canakinumab 300 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
16282609|NCT04798339|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Patients will be treated with Darbepoetin alfa subcutaneously at a dose of 300 mg on days 1 and 15 of each cycle plus the maximum tolerated dose of Canakinumab.
16282610|NCT04798326|Experimental|MW032|MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.
16282611|NCT04798326|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.
16282612|NCT04798313|Experimental|MW031|MW031 injection (60mg) by subcutaneous injection once on the first day of treatment.
16282613|NCT04798313|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day of treatment.
16282614|NCT04798300|Other|tested material|Newly Introduced Gradient Monolithic Zirconia (Intervention)
16282615|NCT04798300|Active Comparator|comparator material|Full Strength Monolithic Zirconia (Comparator)
16282616|NCT04798287||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
16282617|NCT04798287||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
16282620|NCT04798261||Patients with acute pulmonary embolism|
16282621|NCT04798248|Experimental|Momentary Affect Regulation - Safer Sex Intervention|Momentary Affect Regulation - Safer Sex Intervention (MARSSI) is the treatment condition. MARSSI aims to enhance an individual's motivation to change risk behaviors, provides skills to address depression's effects on behavior, and prompts and reinforces healthy affect regulation, cognitive behavioral skill use, and behavior change in daily life.
16282622|NCT04798248|Sham Comparator|Podcast Health Group|The Podcast Health Group is the control counterfactual condition.
16282623|NCT04798235|Experimental|TSHA-101|Subjects who will receive one-time intrathecal TSHA-101, brain volume based sliding scale for dosage
16282624|NCT04798222|Experimental|Group 1: Treatment Sequence ABECD|Participants will receive a single oral dose of Treatments A, B, E, C, and D in Treatment periods 1 to 5 on Day 1 of the study.
16282625|NCT04798222|Experimental|Group 1: Treatment Sequence BACED|Participants will receive a single oral dose of Treatments B, A, C, E, and D in Treatment periods 1 to 5 on Day 1 of the study.
16282626|NCT04798222|Experimental|Group 1: Treatment Sequence CDBEA|Participants will receive a single oral dose of Treatments C, D, B, E, and A in Treatment periods 1 to 5 on Day 1 of the study.
16282627|NCT04798222|Experimental|Group 1: Treatment Sequence EADBC|Participants will receive a single oral dose of Treatments E, A, D, B, and C in Treatment periods 1 to 5 on Day 1 of the study.
16282630|NCT04798222|Experimental|Group 2: Treatment Sequence GHFA|Participants will receive a single oral dose of Treatments G, H, F, and A in Treatment periods 1 to 4 on Day 1 of the study.
16282631|NCT04798222|Experimental|Group 2: Treatment Sequence HAGF|Participants will receive a single oral dose of Treatments H, A, G, and F in Treatment periods 1 to 4 on Day 1 of the study.
16282632|NCT04798209|Experimental|Part A (single ascending dose) Dose A1|Single dose A1 of ACT-777991.
16282633|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A2|Single dose A2 of ACT-777991.
16282634|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A3|Single dose A3 of ACT-777991.
16282635|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A4|Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.
16282636|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A5|Single dose A5 of ACT-777991.
16282637|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A6|Single dose A6 of ACT-777991.
16282638|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A7|Single dose A7 of ACT-777991.
16282639|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A8|Single dose A8 of ACT-777991.
16282640|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B1|Multiple doses B1 of ACT-777991.
16282641|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B2|Multiple doses B2 of ACT-777991.
16282642|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B3|Multiple doses B3 of ACT-777991.
16282643|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B4|Multiple doses B4 of ACT-777991.
16282644|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B5|Multiple doses B5 of ACT-777991.
16282645|NCT04798209|Experimental|Part A (single ascending dose) Absolute Bioavailability|Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.
16282646|NCT04798209|Experimental|Part B (multiple ascending dose) ADME|Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.
16282647|NCT04798196|Placebo Comparator|Control group|Participants will receive treatment as usual (TAU).
16282648|NCT04798196|Experimental|ElderTree on laptop (ET- LT)|Participants will receive ElderTree on a laptop.
16282649|NCT04798196|Experimental|ElderTree on smart system (ET- SS)|Participants will receive ElderTree on a smart system.
16282650|NCT04798183||Healthy participants|
16282651|NCT04798183||Amyotrophic Lateral Sclerosis with bulbar involvement patients|
16282652|NCT04798157|Experimental|Children with Hemoglobinopathies|children from 2-18 years old , diagnosed to have hemoglobinopathy disease
16282653|NCT04798144|Experimental|Cryotherapy group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at 2.5°C in the refrigerator using EndoVac negative pressure irrigation system.
16282654|NCT04798144|Placebo Comparator|Control group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at room temperature in the refrigerator using EndoVac negative pressure irrigation system.
16282655|NCT04798131|Experimental|Active|The visual feedback will correspond to instructions, adapted to the current hallucinatory state and decoded online from the fMRI signal.
16282656|NCT04798131|Sham Comparator|Sham|The visual feedback will correspond to random instructions independently of the fMRI signal.
16282657|NCT04798118|Experimental|group treated with toilet bronchoscope|"Toilet bronchoscopy will be done as supportive care to sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :
~Copious secretion
~Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
16282658|NCT04798118|Active Comparator|group treated with standered care|"sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :
~Copious secretion
~Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
16282659|NCT04798105|Sham Comparator|tDCS sham|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in sham mode.
16282660|NCT04798105|Active Comparator|tDCS anodal|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in anodal/excitatory mode.
16282661|NCT04798053|Experimental|Patient affected by a chronic inflammatory rheumatism|patient affected by a chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Systemic lupus, Still disease, scleroderma…),
16282662|NCT04798053|Active Comparator|Controls|patient affected by a non-inflammatory or degenerative musculo-skeletal disease during the containment period
16282663|NCT04798040|No Intervention|Control group|"Routine treatment and nursing care of the clinic will be applied to the patients without any application.
~Routine interventions applied to the control group during silicone drain removal in the clinic:
~The patient will be informed about the procedure.
~The consent of the patient who agrees to participate in the study will be obtained.
~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale .
~The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.
~The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
16282664|NCT04798040|Experimental|Cold application group|The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale. A gel pad with a temperature of -10 ° C and a homogeneous distribution when cooled will be placed so that the patient is in full contact with the silicone drain.Since the skin temperature must fall below 13.6 ° C for cold application to have a local analgesic effect, the application will be terminated when the patient's skin temperature is 13.6 ° C by measuring every one minute during the cold application and the physician will be informed that the patient is ready.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale15 minutes after the removal of the silicone drain.
16282708|NCT04797806|Other|monotherapy|Icotinib
16282709|NCT04797793|Experimental|Adapalene gel 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16283060|NCT04795180|Experimental|Butyrate irrigations|Butyrate irrigations trough the efferent limb of loop ileostomy
16282665|NCT04798040|Experimental|Lavender oil group|"All patients who accept the study will be tested for lavender oil before the procedure to exclude sensitivity to lavender. Patients in the lavender group will be given oxygen with a lavender oil covered face mask 15 minutes before the silicone drain is removed. Two drops of 2% lavender oil will be applied with a cotton swab inside the oxygen face mask.
~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
16282666|NCT04798027|Experimental|Group 1|1 injection of SARS-CoV-2 mRNA vaccine formulation 1 at Day 1
16282667|NCT04798027|Experimental|Group 2|1 injection of SARS-CoV-2 mRNA vaccine formulation 2 at Day 1
16282668|NCT04798027|Experimental|Group 3|1 injection of SARS-CoV-2 mRNA vaccine formulation 3 at Day 1
16282669|NCT04798027|Placebo Comparator|Group 4|1 injection of placebo at Day 1
16282670|NCT04798027|Experimental|Group 5|2 injections of SARS-CoV-2 mRNA vaccine formulation 1 at Day 1 and Day 22
16282671|NCT04798027|Experimental|Group 6|2 injections of SARS-CoV-2 mRNA vaccine formulation 2 at Day 1 and Day 22
16282672|NCT04798027|Experimental|Group 7|2 injections of SARS-CoV-2 mRNA vaccine formulation 3 at Day 1 and Day 22
16282673|NCT04798027|Placebo Comparator|Group 8|2 injections of placebo at Day 1 and Day 22
16282674|NCT04798001|Experimental|Cohort A / Dosage Group 1 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
16282675|NCT04798001|Experimental|Cohort A / Dosage Group 2 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
16282676|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
16282677|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Two Doses|Participants in this arm (18-55 years) will receive an intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1. These participants will receive a second, identical dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 36.
16282678|NCT04798001|Experimental|Cohort A / Dosage Group 3b (intranasal spray) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of a nasal spray on Day 1.
16282679|NCT04798001|Experimental|Cohort B / Dosage Group 4 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
16282680|NCT04798001|Experimental|Cohort B / Dosage Group 5 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
16282681|NCT04798001|Experimental|Cohort B / Dosage Group 6 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
16282682|NCT04797988|Experimental|eon FR 1064 nm Device|Patient will be treated with the eon FR 1064 nm device.
16282683|NCT04797975|Experimental|KDS-1000|NK cells expanded ex vivo using PM21 membrane particles:
16282684|NCT04797975|Placebo Comparator|Control|0.9% Normal Saline
16282685|NCT04797962|Experimental|Intervention|dedicated case management
16282686|NCT04797962|No Intervention|Usual care|usual care
16282687|NCT04797949|Active Comparator|Randomized to USPSTF Criteria|Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
16282688|NCT04797949|Active Comparator|Randomized to Universal aspirin receipt|Women randomized to receiving low dose aspirin without knowing their risk status.
16282689|NCT04797936|Active Comparator|Treatment group BNO 1030|BNO 1030
16282690|NCT04797936|Other|Control group|Standard care
16282691|NCT04797923|Experimental|Intraperitoneal paclitaxel with systemic chemotherapy|
16282692|NCT04797897|Experimental|CORI UKA|Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with CORI.
16282693|NCT04797897|Active Comparator|Conventional UKA|Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.
16282694|NCT04797884|Experimental|TheraBionic Arm - Active Arm|For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
16282695|NCT04797884|Placebo Comparator|Placebo Arm|For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
16282696|NCT04797871|Experimental|Exercise|Resistance training
16282697|NCT04797871|Active Comparator|Standard care|Non-supervised ACSM exercise guidelines
16282698|NCT04797858|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.
16282699|NCT04797858|Active Comparator|Test referral distribution|Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.
16282700|NCT04797845|Experimental|telemonitoring of non invasive ventilation at home|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months. Ventilation machines make it possible to carry out remote monitoring, with the help of healthcare providers.
16282701|NCT04797832|Active Comparator|Treatment|100 patients receiving IV Iron during index hospitalisation.
16282702|NCT04797832|No Intervention|No treatment|100 patients not receiving IV Iron above standout treatment.
16282703|NCT04797819||Serum sST2 level < 14.5 ng/mL|
16282704|NCT04797819||14.5 ng/mL ≤ Serum sST2 level < 20.5 ng/mL|
16282705|NCT04797819||20.5 ng/mL ≤ Serum sST2 level < 25.9 ng/mL|
16282706|NCT04797819||Serum sST2 level ≥ 25.9 ng/mL|
16282707|NCT04797806|Experimental|combination therapy|Anlotinib Combined With Icotinib
16282710|NCT04797793|Active Comparator|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16282711|NCT04797793|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16282712|NCT04797780|Experimental|SY-1425 + Azacitidine|"SY-1425: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle.
~Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
16282713|NCT04797780|Placebo Comparator|SY-1425 Matched Placebo + Azacitidine|"Placebo: SY-1425-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle.
~Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
16282714|NCT04797767|Experimental|Treatment (CLAG-M, venetoclax)|Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.
16282715|NCT04797741|Experimental|IDEA3 Intervention|
16282716|NCT04797728|Experimental|Elacestrant|400 mg given orally (PO), once a day, in a continuous schedule (QD). 4 weeks (+/- 2 days) of elacestrant treatment
16282717|NCT04797715|Experimental|AXS-05|Up to 26 weeks in double-blind period
16282718|NCT04797715|Placebo Comparator|Placebo|Up to 26 weeks in double-blind period
16282719|NCT04797702|Experimental|Experimental group|Glumetinib combined with Toripalimab
16282720|NCT04797689|Experimental|Trauma Informed Yoga|Participants will receive 12 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
16282721|NCT04797689|Experimental|Trauma Informed Psychotherapy|Participants will receive 12 x 120 min group-based psychotherapy sessions, delivered synchronously over Zoom.
16282722|NCT04797689|No Intervention|Control|These participants will not receive an intervention.
16282723|NCT04797676||EUS-FNB group|Each patient participated in the EUS-FNB group and the surgery group. The procedure of EUS-FNB with wet suction technique is as follow: before the needle was inserted into the biopsy channel, the stylet was removed, and the needle was flushed with saline solution until the fluid dripped out of the needle tip. The air column was replaced with the fluid. A 10-mL syringe was prefilled with 2 mL of saline solution, and the valve was closed. The syringe was loaded to the 5-mL position (i.e. a 3-mL vacuum) and then attached to the proximal port and used for biopsy after inserting into the biopsy channel and puncturing the lesion. Each patient was performed 1-2 passes to obtain specimens for subsequent experiments.
16282724|NCT04797676||surgery group|Each patient participated in the EUS-FNB group and the surgery group. The patient underwent EUS-FNB with wet suction technique first, followed by surgery (palliative surgery without excising tumor is not included) for pancreatic cancer. According to the size of the specimen, 0.5cm3-1cm3 tumor specimen was used for subsequent experiments.
16282725|NCT04797663|Active Comparator|Nd-YAG laser|laser hair removal
16282726|NCT04797663|Experimental|TCA 20%|chemical peel
16282727|NCT04797650|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
16282728|NCT04797650|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
16282729|NCT04797650|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
16282730|NCT04797637|Experimental|Treatment Group|Patients randomized to the treatment group will have the ABBy device applied by study personnel at the time of randomization, followed by a continuation of usual postoperative care.
16282731|NCT04797637|No Intervention|Standard of Care|The control group will have postoperative care per usual care
16282732|NCT04797624||Baseline group|The baseline group included the patients diagnosed with gastric cancer between January 1, 2019, and December 31, 2019, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
16282733|NCT04797624||Pandemic group|The pandemic group included the patients diagnosed with gastric cancer during the period between March 1, 2020, and December 31, 2020, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
16282734|NCT04797611|Other|Investigational Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
16282735|NCT04797611|Other|Investigational Treatment 2|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
16282736|NCT04797598|Active Comparator|Virtual Reality group|In this group patients will be treated with virtual reality . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The virtual reality group will receive 30 minutes virtual reality training and 30 minutes conventional treatment.
16282737|NCT04797598|Active Comparator|Cyclic training group|In this group patients will be treated with cyclic training . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The cyclic training group will receive 30 minutes cyclic training and 30 minutes conventional treatment
16282738|NCT04797585|Active Comparator|Laparoscopic supracervical hysterectomy|Minimally invasive procedure to remove a woman's uterus
16282739|NCT04797585|Experimental|Vaginal hysterectomy|Surgical procedure to remove the uterus
16282740|NCT04797572|Other|Treated group|Patients in whom the free margin cusp sizer will be used to measure the free margin of the three leaflets of the aortic valve during aortic valve repair.
16282804|NCT04797104|Experimental|LIB003 (lerodalcibep)|300 mg (1.2 mL) SC Q4W
16282805|NCT04797104|Placebo Comparator|Placebo|1.2 mL SC Q4W
16282741|NCT04797559|Experimental|SZaMN Treatment Group|Patients randomized into the SZaMN-treatment group will receive a bilateral single injection SZaMN block under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthestic per side.
16282742|NCT04797559|No Intervention|Control Group|Patients in this group will receive the standard of care for T&A procedures within the pediatric population.
16282743|NCT04797546|Experimental|Adductor Canal Block|With mild sedation, a continous bupivacaine 0.1% infusion catheter is placed in the adductor canal. Afterwards, patients are placed under General Anesthesia, and surgery starts. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
16282744|NCT04797546|Active Comparator|Patient Controlled Morphine Analgesia|Patients are placed under General Anesthesia, and after surgery, a Morphine patient controlled analgesia delivery system is installed. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
16282745|NCT04797520|Other|Treatment|All participants will have placement of ETT confirmed using both Core stethoscope and point-of-care ultrasound
16282746|NCT04797507|Experimental|Treatment Group|SHR-1210 plus Anlotinib
16282747|NCT04797494|No Intervention|Control Group|No acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear.
16282748|NCT04797494|Experimental|Experimental Group|A acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear. Patients were asked to wear the RA 3 weeks prior to restorative treatment for 24h per day, except for when eating.
16282749|NCT04797481|Experimental|Novel Intervention|Novel Intervention Exercise group.
16282750|NCT04797481|Active Comparator|Control|Self-managed Exercise group.
16282751|NCT04797468|Experimental|HLX23|HLX23 administered IV.
16282752|NCT04797455|Experimental|PI+ Inpatient Treatment as Usual|"Standard inpatient treatment delivered in the context of an adolescent psychaitric inpatient unit plus an 4 session DBT-based parenting intervention PI)
~Intervention: Behavioral: DBT-Based Parenting Intervention"
16282753|NCT04797455|Active Comparator|Inpatient Treatment alone|"No parenting intervention provided beyond what is part of the inpatient treatment as usual.
~Intervention: Behavioral: Treatment as Usual"
16282756|NCT04797429|Experimental|intervention group|The intervention group will receive antidiabetic therapy according to the current guidelines but with the additional opportunity to use the peer support IMS tool. Peer support and moderation of the intervention group will be provided by moderators. Moderators will be supervised by a dietitian.
16282757|NCT04797429|Active Comparator|control group|The control group receives the antidiabetic therapy according to the current guidelines, but without having access to the IMS tool. This means that participants receive medical treatment by their practitioner according to the Austrian recommendations.
16282758|NCT04797416|Active Comparator|1-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 1 hour.
16282759|NCT04797416|Experimental|6-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 6 hours.
16282760|NCT04797416|Experimental|12-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 12 hours.
16282761|NCT04797403|Experimental|Intervention|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
16282762|NCT04797403|No Intervention|Enhanced Usual Care|Enhanced usual care will include an education session on the ACC/AHA hypertension guideline to providers and proper BP measurement to providers and staff at enhanced usual care clinics.Otherwise, no active intervention will take place, and all usual care clinics will follow their routine clinic practice.
16282763|NCT04797390|Active Comparator|Advanced Pneumatic Compression Device (APCD)|Daily self-administered treatment with the Flexitouch® Plus system (FT)
16282764|NCT04797390|Active Comparator|Usual Care|Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
16282765|NCT04797377|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
16282766|NCT04797364|Experimental|Pharmacogenetic Testing|Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)
16282767|NCT04797351|Experimental|Condition 1 - Experimental Group|"Pre-treatment session + 12 Sessions Group Intervention
~TAU - Treatment as usual (Psychiatric support through Public health system)"
16282768|NCT04797351|No Intervention|Condition 1 - Control Group|"TAU - Treatment as usual (Psychiatric support through Public health system)
~Waiting list (will have access to the intervention program BI-REAL after the 3 month follow up assessment)"
16282769|NCT04797351|Experimental|Condition 2 - Experimental Group|"Pre-treatment session + 12 Sessions Group Intervention
~TAU - Treatment as usual (Psychiatric support through Public health system)
~Specialized support for Bipolar Disorder (members of an association - ADEB - that provides psychoeducation about BD, and psychological support)"
16282770|NCT04797351|No Intervention|Condition 2 - Control Group|"TAU - Treatment as usual (Psychiatric support through Public health system)
~Specialized support for Bipolar Disorder (members of an association - ADEB - that provides psychoeducation about BD, and psychological individual support)
~Waiting list (will have access to the intervention program BI-REAL after the 3 month follow up assessment)"
16282771|NCT04797338|Active Comparator|GnRHa treatment based luteal support|Patients will initiate intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be stopped.
16282806|NCT04797091||Patients with SARS-CoV-2-infection|Patients with evidence of SARS-CoV-2-infection
16282807|NCT04797091||Control group|Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.
16283134|NCT04794634|Experimental|Alzheimer Disease|
16282772|NCT04797338|Active Comparator|Estrogen and progesterone supplementation|Patients will start treatment with a combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of progesterone retard 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
16282773|NCT04797325|Active Comparator|vedolizumab|
16282774|NCT04797325|Active Comparator|Standard treatment|
16282775|NCT04797312|Experimental|Opioid free anesthesia (OFA) protocol|
16282776|NCT04797312|Sham Comparator|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|
16282777|NCT04797299||Single Arm Cohort|Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score.
16282778|NCT04797286|Experimental|Sildenafil|Sildenafil 20 mg by mouth three(3) times each day
16282779|NCT04797286|Placebo Comparator|Placebo|Placebo by mouth three(3) times each day
16282780|NCT04797273|Experimental|Internet-based cognitive behavior therapy|
16282781|NCT04797273|Active Comparator|Internet-based structured treatment-as-usual|
16282782|NCT04797260|Experimental|Gene therapy|In this arm, 5 patients will be included for gene therarpy
16282783|NCT04797247|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
16282784|NCT04797247|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
16282785|NCT04797234|Experimental|Control|There will be no intervention to the control group.
16282786|NCT04797234|Experimental|Experiment|The experimental group will be trained for 6 weeks.
16282787|NCT04797221||Veteran study group|The investigators will recruit approximately 20 Veterans who were identified as having elevated suicide risk while being treated in a VA Emergency Department.
16282788|NCT04797208|Experimental|Real-Time CGM|This group will have a subcutaneous RT-CGM inserted by a member of the research team. CGM's low and high glucose alerts will be activated. The treating clinical team will be able to remotely monitor glucose data and be notified of low glucose alerts through the linked handset. Hyper- and hypo-glycemia management including insulin dose adjustments by the treating clinical team, will be guided by sensor glucose levels and trends according to written guidelines during the study. Glucose level during and post-hypoglycaemia treatment will be confirmed by capillary blood glucose (CBG) measurements (using the NovaStat® glucometer or similar CE-marked glucose meter).
16282789|NCT04797208|Active Comparator|Capillary blood glucose with masked CGM|This group will have their glucose monitored in hospital using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted by a member of the research team to collect glucose values (glucose values will not be displayed and no glucose alerts will be available). This will removed at the end of the study by the research team.
16282790|NCT04797195|Experimental|CKD-PD app user group|Patients on peritoneal dialysis using the CKD-PD app and home monitoring equipment to measure and record blood pressure, body weight, and dialysis fluid removed
16282791|NCT04797195|No Intervention|Usual care group|Patients on peritoneal dialysis using handwritten notebook to record record blood pressure, body weight, and dialysis fluid removed; measurements obtained through usual method
16282792|NCT04797182|Experimental|blank control|No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.
16282793|NCT04797182|Experimental|primary prevention|"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.
~Drug-withdrawal indications:
~PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.
~When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued"
16282794|NCT04797169|Experimental|Noom Health|
16282795|NCT04797169|Active Comparator|Noom Digital Health|
16282796|NCT04797156|Experimental|High Dose Intravenous TXA (hTXA group)|Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
16282797|NCT04797156|Experimental|Low Dose Intravenous TXA (lTXA group)|Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
16282798|NCT04797156|Placebo Comparator|Combined Intravenous and Topical TXA group (cTXA group)|Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure
16282799|NCT04797143||control group|patients in control group receive standard care
16282800|NCT04797143||intervention group|intervention group after implementation of a MCP
16282801|NCT04797130|No Intervention|Control group|All subjects eligible for inclusion in this study receive usual care physiotherapy as prescribed by the physician. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Patients in the control group will receive an accelerometer, measuring PA, which is applied by the physiotherapist during the first treatment. They receive no other additional intervention. Usual care physiotherapy sessions will take approximately 20-30 minutes per session.
16282802|NCT04797130|Experimental|Intervention group|Patients in the intervention group will receive usual care physiotherapy and use Hospital Fit 2.0 (HF) additionally. After the last treatment session (max. 7 days), the therapist will remove the accelerometer and participation in the study will end.
16282803|NCT04797117|Other|blood sample|The blood samples for the study for each patient will be collected in the form of additional tubes.
16282808|NCT04797078|Active Comparator|Transrectal fusion biopsies of the prostate|"Transrectal approach, patient in left lateral position, local anestesia 10ml lidocaine 1% at prostate base laterally and apex if indicated.
~MRI-ultrasound fusion-guided biopsies with 4 biopsy cores per lesion, where clinically indicated. 18G biopsy needle.
~Standard 12-core template for systematic biopsies. 18G biopsy needle.
~Antibiotic prophylaxis with 750mg ciprofloxaicin, single dose p.o."
16282809|NCT04797078|Experimental|Transperineal free hand fusion biopsies of the prostate|"Men randomized to the experimental arm undergoes free-hand targeted transperineal fusion biopsies as defined below.
~Patient is placed supine in the lithotomy-position. The perineal area is prepared with chlorhexidine 0,5ml/ml.
~Ropivacain 7,5mg/ml is used as an anesthetic agent. Up to 40ml's (equivalent to 300mg) can be used to anestitize the skin, caudal and cranial part of the urogenital diaphragm and periprostatic tissue.
~Free-hand MRI-ultrasound fusion-guided biopsies with at least 4 biopsy cores per lesion. Coaxial technique with 18G biopsy needle.
~10-12 Systematic biopsies according to the modified Barzell 12-core template.
~No antibiotic profylaxis unless warranted by immunosuppression, previous sepsis or urinary tract infection."
16282810|NCT04797065|Experimental|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 6 minutes then in 9 minutes during the colonoscopy withdrawal.
~At 6-minute withdrawal, the left colon, transverse colon and right colon will take 2 minutes each. Then at 9-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 3 minutes each.
~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
16282811|NCT04797065|Active Comparator|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 9 minutes then in 6 minutes during the colonoscopy withdrawal.
~At 9-minute withdrawal, the left colon, transverse colon and right colon will take 3 minutes each. Then at 6-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 2 minutes each.
~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
16282812|NCT04797052|Experimental|Post operative patients|Post operative patient in orthopedic and digestive surgery
16282813|NCT04797039||MR guided cryoablation|Focal MR guided cryoablation for low- to intermediate-grade prostate cancer
16282814|NCT04797026|Experimental|Penpal Program to Alleviate Loneliness|A social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitative measures of loneliness
16282815|NCT04797013|Active Comparator|rhTNK-tPA (0.25mg/kg)|rhTNK-tPA (0.25mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
16282816|NCT04797013|Active Comparator|rt-PA (0.9mg/kg)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the remainder in 1 hour. Maximum dose 90mg.
16282817|NCT04797000|Experimental|Eltrombopag Arm|Participants randomized to a 1: 1 ratio will take eltrombopag.
16282818|NCT04797000|Placebo Comparator|Placebo Arm|Participants randomized to a 1: 1 ratio will take Placebo.
16282819|NCT04796987||cervical myelopathy|MR images of patients with cervical myelopathy
16282820|NCT04796987||normal|normal section of the MRI of patients with cervical myelopathy
16282821|NCT04796974|Experimental|Cention|Alcasite restorative material
16282822|NCT04796961|Other|Implementation Intervention|All participants will receive the implementation intervention.
16282823|NCT04796948|Experimental|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|"irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.
~oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.
~5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.
~LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution."
16282824|NCT04796935|Experimental|Experimental Group 1: Tactile Imaging (VerTouch)|VerTouch used to identify and mark, or begin placement of a needle, at an insertion site.
16282825|NCT04796935|Active Comparator|Group 2: Control (palpation)|Palpation used to identify and mark an insertion site.
16282828|NCT04796909|Experimental|Parent coaching|The parent-coaching intervention consists of up to 8 weekly/fortnightly sessions, and each session will last up to one hour.
16282829|NCT04796909|Active Comparator|Parent consultation|The parent consultations are given for up to 8 weekly/fortnightly sessions, and each session may last up to one hour.
16282830|NCT04796896|Experimental|mRNA-1273|"Part 1: Participants will receive 2 intramuscular (IM) injections of mRNA-1273 at up to 3 doses pre-specified for this study, 28 days apart, on Day 1 and Day 29.
~Part 2: Participants will receive 2 IM injections of mRNA-1273 at the dose selected from Part 1, 28 days apart, on Day 1 and Day 29."
16282831|NCT04796896|Placebo Comparator|Placebo|Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo 28 days apart, on Day 1 and Day 29.
16282832|NCT04796883|Experimental|single arm|Hanita Glaucoma shunt Ver.3.2
16282834|NCT04796857|Experimental|Tislelizumab in Combination With Lenalidomide|On the day of tislelizumab infusion, lenalidomide should be taken 30 minutes after the end of tislelizumab infusion
16282835|NCT04796831|Experimental|All Participants|Participants who will receive a single, oral dose of 60 mg quizartinib and a single, IV administration of 50 μg 14C-quizartinib solution for infusion at 4 hours post-oral dosing.
16282836|NCT04796818|Experimental|Diagnostic (IVIM DWI)|Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.
16282853|NCT04796649|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
16282837|NCT04796805|Experimental|Essential oil application group|The experimental group received 20% black pepper essential oil in a base of aloe vera gel applied topically to the forearm using a rollerball 10 min before venipuncture. Twelve swipes were applied using the rollerball applicator. The maximum dose of the black pepper/aloe vera gel mixture was 3 mL. Sphygmomanometer cuff was placed on the right arm, and the cuff was inflated until it reached the patient's diastolic blood pressure level. When the pointer reached the desired value, the period was commenced by the researcher. The nurse determined the right vein. After selecting the right vein, the period was ended as the nurse successfully placed a catheter.
16282838|NCT04796805|No Intervention|Control group|Diastolic blood pressure and body temperature of the patients in the control group were measured. A sphygmomanometer cuff was placed on the arm that was not actively used by the patient. Until the cuff's pointer reached the diastolic blood pressure level of the patient, it was inflated. When the tip came to the desired value, the period was noted by the researcher. Without any extra attempts being made, the catheter was placed by the nurse. The period ended with the successful catheter placement by the nurse. Period of appropriate vein selection, the period of placing the catheter successfully, patient and nurse satisfaction were recorded.
16282839|NCT04796792|Experimental|Treatment group|This study is currently in Phase 1 where all subjects undergo the investigational study.
16282840|NCT04796779|Experimental|CLC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the intervention group will use the Tandem t:slim X2 with Control-IQ Technology v1.0 during the first 13 weeks of the study (RCT phase, weeks 1-13) and then use Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 for the remaining 13 weeks of the study (extension phase, weeks 14-26).
16282841|NCT04796779|Active Comparator|SC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the SC group will use their existing insulin therapy in conjunction with study Dexcom G6 CGM during the first 13 weeks of the study (RCT phase, weeks 1-13). The SC group will then transition to using the Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 and study Dexcom G6 CGM for the remaining 13 weeks of the study (weeks 14-26).
16282842|NCT04796766|Experimental|Healthy volunteers|HFS / LFS in healthy volunteers at two different points in time
16282843|NCT04796766|Experimental|Migraine patients|HFS / LFS in migraine patients at a single point in time
16282844|NCT04796766|Experimental|Patients with Botulinum toxin or CGRP-targeted therapy|HFS / LFS before and under treatment with Botulinum toxin or CGRP-targeted therapy
16282845|NCT04796753||Youth basketball players who belonged to basketball developmental teams (U12, U14,U16,U17).|All participants completed the same ten-minute neuromuscular warm-up consisting of the following exercises: joint mobility exercises, dynamic stretching exercises, jumps, multidirectional displacements and changes of direction. Following, subjects were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. The performance of each test was recorded using two cameras (Iphone XS, Apple). To allow visible tracking of the different joints, participants were required to wear shorts with the hem at approximately mid-thigh. When scoring performance, each test was viewed in both planes (sagittal and frontal views).
16282846|NCT04796727||OHCA|300 OHCA admitted directly to the cathlab and alive at discharge during a 2 years period of enrolement.
16282847|NCT04796714|Sham Comparator|Double antiplatelet therapy group|Patient randomized in this group will receive 1 tablet containing clopidogrel 75 mg and 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
16282848|NCT04796714|Experimental|Aspirin group|Patients randomized in this group: will receive 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
16282849|NCT04796701|Experimental|Follow Home Intervention|If possible, all included participants are physically followed home by a hospital-based project worker on the day of discharge. During the visit, the focus is on: basic human needs, medication review reconciliation, and a comprehensive geriatric assessment. Problems, challenges and concerns are discussed. Finally, a conference for the following working day is arranged either as a physical visit or a video conference. The patient, relatives, community-based nurse and project worker are invited to participate and health status and challenges are discussed They are recommended to contact the project worker about health and practical issues up to 7 days after discharge where the intervention ends. Subsequently, the responsibility for treatment and care is assigned to the GP and home healthcare provider.
16282850|NCT04796701|No Intervention|Control|On the day of discharge, the hospital-based nurse digitally sends a summary of the hospital stay and a treatment and care plan to the community-based nurse. If needed, the hospital-based nurse contacts the community-based nurse by phone as a supplement to the plan. Finally, a discharge letter conducted by the hospital-based doctor is digitally sent to the GP
16282851|NCT04796688|Experimental|Fludarabine + Cyclophosphamide + AT19 cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on days -5, -4, and -3, followed by the infusions of AT19 cells on day 0-2. The study will be divided into three groups: B-ALL, B-CLL, and B-cell lymphoma. Doses of 0.5×10^7, 1.0×10^7, and 2.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.
16282852|NCT04796675|Experimental|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by one infusion of CAR-NK-CD19 cells on day 0. The study will be divided into three groups: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Non Hodgkin's Lymphoma. Doses of 0.01×10^7, 0.1×10^7, 1.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
16282999|NCT04795570||Controls. Patients who DO NOT develop urethral stricture|Patients who DO NOT develop urethral stricture within 6 months after TUR P/B
16282854|NCT04796649|Active Comparator|Standard treatment + Sham laser|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
16282858|NCT04796623|Experimental|TQB3616 capsules combined with fulvestrant injection|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
16282859|NCT04796610|Experimental|Intervention|Unsuppressed HIV patients at the intervention clinic will receive guidance from their health care provider on the selection of a treatment partner. The patient and treatment partner will receive education on HIV treatment and how treatment partners can support patients in treatment adherence.
16282860|NCT04796610|No Intervention|Control|Patients at the control clinic will receive standard of care at the clinic during the intervention assessment period.
16282861|NCT04796597|Experimental|Single-arm|Implantation of subcutaneous leads and connection to an external EEG amplifier
16282862|NCT04796584||MS subjects who are being treated with ocrelizumab|Ocrelizumab's immunomodulating mechanisms of action is B-cell lytic. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection.
16282863|NCT04796584||MS subjects who are being treated with fingolimod|Fingolimod's immunomodulating mechanisms of action is to prevent mobilization of B and T cells from peripheral lymphoid organs. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection.
16282864|NCT04796584||MS subjects who are being treated with natalizumab|Natalizumab's immunomodulating mechanisms of action is to block transmigration of monocytes, and lymphocytes into the central nervous system. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection.
16282865|NCT04796584||MS subjects who are being treated with dimethyl fumarate/diroximel fumarate|Dimethyl Fumarate's immunomodulating mechanisms of action is to reduce inflammation-induced oxidative stress. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection.
16282866|NCT04796571|Experimental|Care Coordination Arm|Patients were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care.
16282867|NCT04796571|No Intervention|Usual Care|Participants in the usual care arm underwent symptom monitoring through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. Results of the monthly PRO instrument were available to their treating IBD doctor with interventions at their discretion.
16282868|NCT04796571|No Intervention|passive control arn|To explore whether our usual care arm was influenced by the monthly PRO measurements required for examination of our primary outcome, we compared IBD charges, total charges, ED visits, hospitalizations, and medication utilization at 12 months in the usual care arm to a passive control arm consisting of patients who met eligibility criteria, but were not enrolled in the intervention or usual care arms.
16282869|NCT04796545|Experimental|Tsert SI System model NG SI IMT 3X|All participants will be implanted with the Tsert SI System model NG SI IMT 3X.
16282870|NCT04796532|No Intervention|Control|No intervention. The control group will maintain their normal physical and dietary activity.
16282871|NCT04796532|Experimental|Homebased HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Homebased HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. This group will have 16 week follow-up.
16282872|NCT04796532|Experimental|Traditional HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional-HIIT group participants will attend presential HIIT workout sessions supervised. This group will have 16 week follow-up.
16282873|NCT04796519|Experimental|Unilateral TKA|Unilateral total knee arthroplasty group (UTKA) consisted of patients who did not undergo a second TKA within 3 months of the first TKA
16282874|NCT04796519|Experimental|Bilateral TKA|bilateral total knee arthroplasty group (BTKA) were those who had a second TKA within 12 months after initial TKA
16282875|NCT04796506|Active Comparator|Exercise Group|PD participants randomized to progressive resistance training PRT) will have 12 weeks of supervised PRT 3 times per week. After the 1st 12 weeks, responders to PRT (increase in slow wave sleep) will continue PRT for an additional 12 weeks, non-responders to PRT will transition to endurance training (ET).
16282876|NCT04796506|Placebo Comparator|Delayed Exercise Group|PD participants randomized to the delayed exercise control group will not exercise for the 1st 12 weeks of the study. After the 1st 12 weeks, participants in the delayed exercise group will transition to PRT for the 2nd 12 weeks.
16282877|NCT04796480|Active Comparator|YOGURT|Group 1 children were given home made plain yogurt in treatment of acute diarrhea
16282878|NCT04796480|Active Comparator|LACTOSE FREE FORMULA MILK|Group 2 children were given lactose free formula milk in treatment of acute diarrhea
16282879|NCT04796467|Experimental|68Ga-PSMA617 and 68Ga-P16-093 PET/CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of 68Ga-PSMA617 and 68Ga-P16-093, respectively.
16282880|NCT04796454|Active Comparator|CisGem/GemOx|"Cisplatin/Gemcitabine (3-week cycle):
~Cisplatin IV 25 mg/m² d1 and day8
~Gemcitabine 1000 mg/m² d1 and d8
~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years.
~In case of unacceptable toxicity the CisGem regimen can also be switched to a GemOx regimen (4-week cycle):
~Oxaliplatin IV 100 mg/m² d1 and day15
~Gemcitabine 1000 mg/m² d1 and d15"
16282881|NCT04796454|Experimental|PamTMZ|"Pamiparib + temozolomide (4-week cycle):
~Pamiparib 60 mg PO twice a day d1-d28 Temozolomide 60 mg PO daily d1-d7
~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years."
16282882|NCT04796441|Experimental|CAR--γδT|Patients will be treated with CAR--γδT cells
16282883|NCT04796428|Active Comparator|canagliflozin|100 mg (or 50/850 mg and 50/1000 mg of the fixed association with metformin) or 300 mg (or the 150/850 mg and the 150/1000 mg fixed association with metformin).
16282884|NCT04796428|Active Comparator|dapagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 10/5 mg of the fixed dapagliflozin / saxagliptin combination)
16282885|NCT04796428|Active Comparator|empagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 5/5 mg of the empagliflozin / linagliptin combination) or 25 mg (or the 12.5/850 mg and the 12.5/1000 mg fixed association with metformin; or the 12.5/5 mg empagliflozin / linagliptin combination).
16282886|NCT04796415|Experimental|DEMA-Pro|The DEMA-Pro intervention will be administrated. Subjects will attend six weekly, 1-hour telephone sessions.
16282887|NCT04796402|Active Comparator|Control|Standard of care
16282888|NCT04796402|Experimental|Intervention|Administration of Bamlanivimab
16282889|NCT04796389|Experimental|Recorded music|Recorded music intervention
16282890|NCT04796389|No Intervention|Control|Standard of care
16282891|NCT04796376|Other|Cutting seton|A piece of surgical thread that's left in the fistula for several weeks to keep it open. This allow it to drain and help its heal.
16282892|NCT04796363|Experimental|ESPB Bubivacaine 0.25%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 20 ml bupivacaine 0.25 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
16282893|NCT04796363|Active Comparator|ESPB Bubivacaine 0.125%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 40 ml bupivacaine 0.125 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
16282894|NCT04796363|Placebo Comparator|No ESPB|20 patients will undergo standard general anaesthesia as a control group and postoperative analgesia with intravenous morphine patient controlled analgesia (PCA) and rescue analgesia if required.
16282895|NCT04796350|Experimental|Treated group|Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
16282896|NCT04796350|No Intervention|Control group|Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip
16282898|NCT04796324|Experimental|Ixabepilone|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
16282899|NCT04796298|Experimental|Ballistic Hamstring Stretching Group|Ballistic Hamstring Stretching
16282900|NCT04796298|Experimental|Hamstring Extender Exercise Group|Hamstring Extender Exercise
16282901|NCT04796298|Experimental|Kinesiotape Group|Kinesiotape
16282902|NCT04796285|Experimental|Lab Clasp|A finger based device to assay interstitial fluid lactate
16282903|NCT04796272|Active Comparator|Traditional exercise|fatigued multiple sclerosis patients with a traditional training program
16282904|NCT04796272|Experimental|Individual exercise|tired multiple sclerosis patients with an adapted and individualized training program
16282905|NCT04796259|No Intervention|Negative control|Water
16282906|NCT04796259|Active Comparator|Positive control|Non-alcoholic beer solids
16282907|NCT04796259|Experimental|Intervention 1|Malt ingredient I
16282908|NCT04796259|Experimental|Intervention 2|Malt ingredient II
16282909|NCT04796246|Experimental|Leap Motion Controller|Intervention Group: which will receive treatment with Leap Motion Controller
16282910|NCT04796246|Active Comparator|Conventional Physiotherapy|Control Group: who will receive treatment with conventional physiotherapy.
16282911|NCT04796220|Experimental|Arm A: GEM|
16282912|NCT04796220|Experimental|Arm B: FUS|
16282913|NCT04796220|Experimental|Arm C: GEM/FUS|
16282914|NCT04796207|Experimental|Fish Oil Capsules|Participants in the treatment arm will receive 3 grams of DHA and EPA (2:1 weight ratio) 3 times a week for 25-weeks during regular football season.
16282915|NCT04796207|Placebo Comparator|Safflower Oil Capsules|Participants in the treatment arm will receive 3 grams of high-oleic safflower oil) in a 1:1 allocation ratio for 25-weeks during regular football season.
16282916|NCT04796194|Experimental|LTX-315 in combination with pembrolizumab|"LTX-315 will be injected directly into the selected tumor lesion(s) at Days 1, 2, 3, 8, 15, 22, and 29. The maximum number of injections given per dosing day is 8 (5 mg each for a maximum total of 40 mg per day); the number of injections required per lesion depends on lesion size. The maximum total number of LTX-315 injections during the study will be 56 (up to 8 injections per day on each of 7 dosing days).
~Pembrolizumab will be dispensed and administered as an IV infusion."
16282917|NCT04796168|Active Comparator|post operative Ankle fractures with splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive splint post operative
16282918|NCT04796168|No Intervention|post operative Ankle fractures without splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive NO splint post operative
16282919|NCT04796155||labour arrest|Pregnant women whose labour progress is delayed and suspected or diagnosed as labour arrest according to the NICE guidelines. Intrapartum ultrasound will be performed at the suspicion of labour arrest in the active phase of the first and second stage of labour. Amniotomy will be performed as routine obstetric care according to the local clinical protocols in accordance with the NICE guideline. Later, diagnosis of labour arrest will be made in slow progress following amniotomy (<1cm cervical dilatation in 2 hours) where a sonographic examination will be repeated.
16282920|NCT04796142|Experimental|Reconciliation|Interventional trial without drugs
16283025|NCT04795466|Placebo Comparator|Placebo|Matching placebo sub-cutaneous injections
16282921|NCT04796129||patients with hip osteoarthritis|the patients who aged 45 and older and have paint in the hips. and also without having any other comorbidities about inflammatory status.
16282922|NCT04796129||control|the participants who have any other comorbidities for impact on the inflammatory status and also no hip pain.
16282925|NCT04796090||Adolescents with genital warts (Study Group)|The Study group included adolescents who was diagnosed as positive for genital warts during the examination.
16282926|NCT04796090||Healthy adolescents (Control Group)|The Control group was composed of healthy adolescents who admitted for only contraceptive counselling.
16282927|NCT04796077|Experimental|Pop-Up Book|Patients read an interactive pop-up book about general anesthesia induction in addition to standard consultation with an anesthesia provider.
16282928|NCT04796077|No Intervention|Standard Care|Patients received standard consultation with an anesthesia provider (standard care).
16282929|NCT04796064|Experimental|low-intensity aerobic training group|
16282930|NCT04796064|Experimental|high-intensity aerobic training group|
16282931|NCT04796051|Experimental|Neck orthosis group, posterior cervical weight orthosis|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull. Neck orthosis group will use a cervical orthosis (with the posterior cervical neck weight) for 10 minutes / 3 times a day, for a total of 30 minutes a day
16282932|NCT04796051|Active Comparator|Deep cervical flexors exercise|Deep cervical flexors exercise group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
16282933|NCT04796038|Experimental|Rise SC|All patients will receive the Rise semi-compliant balloon catheter as per treatment.
16282934|NCT04796025|Experimental|T-Double|TACE Combined With Sintilimab Plus Bevacizumab Biosimilar
16282935|NCT04796012|Experimental|Atezolizumab with vincristine, irinotecan and temozolomide|Atezolizumab will be administered by intravenous (IV) infusion at a dose of 15 mg/kg (maximum 1200 mg) on Day 1 of each 21-day cycle, along with vincristine, irinotecan, and temozolomide at the above doses. Treatment will continue for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
16282936|NCT04795999|Experimental|Project With program|Project With is a 12-lesson literary-based curriculum, delivered by Youth Advocates to youth in juvenile justice facilities and group homes in Southern California either in person or virtually, under COVID-19 contingencies. Program schedule is determined by the facility. The goals of Project With are to promote optimal health and reduce teen pregnancy and sexually transmitted infections (STIs).
16282937|NCT04795999|No Intervention|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition.
16282938|NCT04795973|Experimental|IF group|intermittent fasting intervention for 4 weeks
16282939|NCT04795960|Experimental|Low serine diet|
16282940|NCT04795960|Experimental|High serine diet|
16282941|NCT04795934|Active Comparator|Laparoscopic Nissen Fundoplication (LNF)|Control
16282942|NCT04795934|Active Comparator|Combo Transoral Incisionless Fundoplication (CTIF)|Treatment
16282945|NCT04795908|Experimental|Active rTMS Group|Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
16282946|NCT04795908|Sham Comparator|Sham rTMS Group|Participants will undergo the same procedure for identifying target location and RMT used in patients receiving real rTMS. Simulated rTMS will be administered using a MagStim sham coil, which produces discharge noise and vibration without stimulating the cerebral cortex
16282947|NCT04795895|Experimental|ultrasonography (US)|
16282948|NCT04795895|Active Comparator|Standard routine (SR)|
16282949|NCT04795882|Experimental|Cohort 1: BCMA CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA CAR T-cells
16282950|NCT04795882|Experimental|Cohort 2: BCMA/CD19 CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA/CD19 CAR T-cells
16282951|NCT04795869|Experimental|Treatment (brentuximab vedotin, pembrolizumab)|Patients receive brentuximab vedotin IV over 30 minutes on day 1, and pembrolizumab IV over 30 minutes on day 3 of cycle 1, day 1 of subsequent cycles. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles of treatment, patients may discontinue treatment if they experience disease progression, are eligible for stem cell transplant, or if they elect to not undergo SCT.
16282954|NCT04795843|Experimental|Progressive exercise therapy and patient education|6-months
16282955|NCT04795843|Active Comparator|Usual Care|6-months
16282956|NCT04795830|Active Comparator|Control group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.
~Using a glass ionomer gun, a capsule of GC Corporation's EQUIA Forte High Translucency glass ionomer restorative (GC EQUIA Forte HT Fil Capsule) will be injected to fill the pulp chamber.
~Finally, the tooth will be restored with a stainless steel crown."
16283026|NCT04795453||assessment of usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
16283135|NCT04794634|Experimental|Lewy body disease|
16282957|NCT04795830|Active Comparator|Control group with Restoration|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.
~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
16282958|NCT04795830|Experimental|Study group with Restoration|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.
~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
16282959|NCT04795830|Experimental|Study group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.
~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber.
~Finally, the tooth will be restored with a stainless steel crown."
16282960|NCT04795817||Single arm|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA
16282961|NCT04795804|Placebo Comparator|Placebo|11.43 g (3 x 3.81 g) maltodextrin the day before the clinical investigation day
16282962|NCT04795804|Active Comparator|Human milk-like oligosaccharide alone|12 g (3 x 4 g) of the human milk-like oligosaccharide the day before the clinical investigation day
16282963|NCT04795804|Experimental|Human milk-like oligosaccharide and resistant starch|12 g (3 x 4 g) of the human milk-like oligosaccharide and 7.5g resistant starch (3 x 2.5 g) the day before the clinical investigation day
16282964|NCT04795778||Patients with breast cancer|Breast cancer patients with or without breast cancer surgery, with or without mastectomy, with or without lymphedema
16282965|NCT04795778||Control group|Healty individuals with no disease
16282966|NCT04795765||Patients treated with SpineJack system|SpineJack system procedure
16282967|NCT04795765||Patients treated with vertebral augmentation|Vertebral augmentation procedures may include either balloon kyphoplasty (BKP) or vertebroplasty (VP).
16282968|NCT04795752|Experimental|TearCare Group (Study Device)|
16282969|NCT04795752|Active Comparator|Restasis Group (Control)|
16282970|NCT04795726|Experimental|Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
16282971|NCT04795726|Placebo Comparator|Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
16282972|NCT04795713|Experimental|PD-L1 Positive NSCLC|Subjects with PD-L1 Positive Lung Carcinoma (NSCLC) who received prior PD-1/PD-L1 treatment
16282973|NCT04795713|Experimental|PD-L1 Positive SCCHN|Subjects with PD-L1 Positive Squamous Cell Carcinoma of the head and neck (SCCHN), refractory to or ineligible for platinum-based therapy, who received prior PD-1/PD-L1 treatment
16282974|NCT04795713|Experimental|Other relapsed/refractory PD-L1 positive solid tumors|Subjects with any other relapsed or refractory PD-L1 positive solid tumor who received PD-1/PD-L1 treatment.
16282975|NCT04795713|Experimental|PD-L1 positive advanced cancer|Subjects with PD-L1 positive advanced cancer (solid tumors)
16282976|NCT04795700|Experimental|The intervention group|Patients in the intervention group receiving the 8 weeks MSC intervention sessions.
16282977|NCT04795700|No Intervention|The control group|No interventions except conventional care were performed for the control group.
16282978|NCT04795687||Ischemic stroke patients|
16282979|NCT04795687||Control|
16282980|NCT04795674|Experimental|ADHD EWM|Participants will receive EWM training sessions.
16282981|NCT04795674|Placebo Comparator|ADHD Placebo|Participants will receive placebo training sessions.
16282982|NCT04795661|Experimental|Cohort Colorectal cancer (CRC)|Pembrolizumab prior to surgery
16282983|NCT04795661|Experimental|Cohort Oesogastric cancer|Pembrolizumab prior to surgery
16282984|NCT04795661|Experimental|Cohort Endometrial cancer|Pembrolizumab prior to surgery
16282985|NCT04795661|Experimental|Cohort Other cancer|Pembrolizumab prior to surgery
16282986|NCT04795648|Experimental|Spatial Repellent|Transfluthrin
16282987|NCT04795648|Placebo Comparator|Placebo|Inert ingredients
16282988|NCT04795635|Experimental|CMM + Axon Therapy|"Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days). Participants randomized to the CMM plus Axon Therapy group will return to the clinic for Axon Therapy treatments as follows:
~Month 1: 6 treatments
~WEEK 1: 3 treatments (consecutive treatments are best)
~WEEK 2-4: Weekly treatments
~Month 2: Bi-monthly treatment
~Months 3-12: Treatments every 2-4 weeks
~In addition to in-clinic assessments and treatments, all participants will a receive weekly phone follow-up to assess pain intensity and occurrence of adverse events after treatment starts. Weekly phone follow-ups will only occur during weeks when the participant is not in clinic for treatment."
16282989|NCT04795635|No Intervention|CMM Only|Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days)
16282992|NCT04795609|Active Comparator|Interventional group|Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training or to standard rehabilitation care
16282993|NCT04795609|No Intervention|Control group|Bed restriction strategy for 5 days
16282994|NCT04795596|Experimental|surgery + chemotherapy|surgical resection for recurrent platinum resistant ovarian cancer followed by second line chemotherapy as per the investigator's choice
16282995|NCT04795596|Active Comparator|chemotherapy alone|second line chemotherapy according to investigator's choice
16282996|NCT04795583|Experimental|Prednisone|"Treatment adjusted by weight. Prednisone 25 mg capsules:
~≤ 50kg = 2 capsules QD x 7 days (maximum dose = 50mg/day)
~50 - 80kg = 3 capsules QD x 7 days (maximum dose = 75mg/day)
~> 80kg = 4 capsules QD x 7 days (maximum dose = 100mg/day)"
16282997|NCT04795583|Placebo Comparator|Placebo|Capsules with the same appearance as Prednisone
16282998|NCT04795570||Cases. Patients who develop urethral stricture|Patients who develop urethral stricture within 6 months after TUR P/B
16283000|NCT04795557|Experimental|ADAPT232|"50 patients take ADAPT-232® oral solution in the daily dose of 60 ml ( 30 ml two times daily) for 14 days.
~One mL of oral solution contains:
~Schisandra chin. fructus native extract 10,0 mg DERnative 2,0-5,0:1 Eleutherococcus sent. radix native extract 2,6 mg DERnative 17-30:1 Rhodiola rosea radix native extract. 3,0 mg DERnative 2,0-5,0:1 Inactive excipients,"
16283001|NCT04795557|Placebo Comparator|Placebo|50 patients take Placebo oral solution in the daily dose of 60 ml ( 30 ml two times daily) for 14 days.
16283002|NCT04795544|Experimental|cuff inflation by the residual volume|"LMA will be inserted with the initial inflating volume correspondent to residual volume group (RV group):
~volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 mL syringe without plunger is connected to the laryngeal cuff for 5 minutes"
16283003|NCT04795544|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group)
16283004|NCT04795544|Placebo Comparator|unchanged cuff inflation volume|LMA will be inserted unchanged (NV group): LMA is unpacked and used without inflating or deflating the cuff.
16283005|NCT04795531|Experimental|Once weekly insulin icodec + once daily placebo|Participants will get once daily and once weekly injections
16283006|NCT04795531|Experimental|Once weekly placebo and once daily insulin degludec|Participants will get once daily and once weekly injections
16283007|NCT04795518||Cross sectional study by questionnaire among group of pediatric dentistry|"An interviewed questionnaire is divided into two parts. The first part of the questionnaire will investigate the socio-demographic characteristics of the respondents. The second part of the questionnaire is divided into five sections to cover the following items:
~Use of antibiotics pattern
~Knowledge about antibiotics
~Sources of information"
16283008|NCT04795505||Intervention group|A tertiary A-level hospital WeChat-based intervention
16283009|NCT04795505||Control group|Traditional community hospital intervention
16283010|NCT04795492|Experimental|Intervention group|Remote intervention
16283011|NCT04795492|Active Comparator|Control group|Routine outpatient follow-up
16283012|NCT04795479|Experimental|Treatment Sequence 1|Participants will receive relacorilant 400 mg once daily (QD) for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283013|NCT04795479|Experimental|Treatment Sequence 2|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283014|NCT04795479|Experimental|Treatment Sequence 3|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283015|NCT04795479|Experimental|Treatment Sequence 4|Participants will receive relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283016|NCT04795479|Experimental|Treatment Sequence 5|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283017|NCT04795479|Experimental|Treatment Sequence 6|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283018|NCT04795479|Experimental|Treatment Sequence 7|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283019|NCT04795479|Experimental|Treatment Sequence 8|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283020|NCT04795479|Experimental|Treatment Sequence 9|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283021|NCT04795479|Experimental|Treatment Sequence 10|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283022|NCT04795479|Experimental|Treatment Sequence 11|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283023|NCT04795479|Experimental|Treatment Sequence 12|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
16283024|NCT04795466|Experimental|Canakinumab|increasing doses of sub-cutaneous injections
16283027|NCT04795453||assessment of score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
16283028|NCT04795440|No Intervention|Eya-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the ejaculate (control group).
16283029|NCT04795440|Experimental|Test-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the testicle (study group).
16283030|NCT04795427|Experimental|asciminb arm|Patients will receive asciminib (40 mg BID continuous)
16283031|NCT04795427|Experimental|best available treatment arm|Patients will receive best available therapy chosen by investigator
16283032|NCT04795414||Vaccination Group|Participants vaccinated with inactivated SARS-CoV-2 vaccine are studied for safety and antibody response.
16283033|NCT04795401|Experimental|FRAME Group|"Patients will be enrolled during their hospitalization/consultation in vascular surgery department. After asking questions, his given free, informed and written consent will be collected, and recorded in his medical file by the investigator.
~During this hospitalization, the pre-procedure forming part of the usual care is carried out. The specific acts of research are: Cardiac echocardiography and Quality of life survey SF-36 The plication procedure will be performed according to the FRAME FR. All pre-, peri-, and post- operative routine patient management will be carried out as usual.
~Follow up visits will be held at 6, 12 months post procedure. All follow up visits will include the assessments as usual.
~The specific acts of research are as follows: Cardiac echocardiography at 12 months and quality of life survey SF-36."
16283034|NCT04795401|No Intervention|Control Group|"Control group corresponds to the historical patients over a period of time sufficient to have at least 20 patients according to inclusion criteria. The information form will be sent to each patient eligible for the study by post. Without any feedback from him within 30 days, it is considered that the patient does not object to the use of its data.
~As part of this research, no additional examination will be performed. The data used correspond to the data collected in the usual care of patients."
16283035|NCT04795375|Experimental|Intervention|The intervention group will receive Physical activity counseling and guidance by a certified Nurse during the six months after the surgery, additional to the routine follow-up after bariatric surgery at Hadassah-Ein Kerem Hospital.
16283036|NCT04795375|No Intervention|Control|"The control group will receive the routine follow-up followed at Hadassah-Ein Kerem Hospital after bariatric surgery, which includes long term follow-up with the surgeon and a dietitian.
~Participants at the Control group will receive Physical activity counseling by a certified nurse at the end of trial."
16283037|NCT04795362||patients with Delayed cerebral ischemia|50 adult patients hospitalized in neurological intensive care unit for subarachnoid hemorrhage, in whom the onset of delayed cerebral ischemia is suspected will be included.
16283038|NCT04795349|Experimental|NAC Patients.|Breast cancer patients after NAC completion, prior to surgery
16283039|NCT04795336|Active Comparator|Knee cohort|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
16283040|NCT04795336|Placebo Comparator|Knee cohort control|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
16283041|NCT04795336|Active Comparator|Hip cohort|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
16283042|NCT04795336|Placebo Comparator|Hip cohort control|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
16283043|NCT04795323|Experimental|Non-pharmacological followed by addition of pharmacological self-management support|
16283044|NCT04795310|Experimental|Pulsed Dye Laser|PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD)
16283045|NCT04795310|Active Comparator|Intense Pulsed Light|Vascular wavelength bands of 530-650nm and 900-1200nm
16283046|NCT04795297||recurrent BCC|recurrent BCC
16283047|NCT04795297||resected BCC|resected BCC
16283048|NCT04795284||Patients with symptomatic lumbar spinal stenosis|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
16283049|NCT04795284||Healthy elderly|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
16283050|NCT04795271|Experimental|Orthopedic treatment|"Participants who are referred for orthopedic treatment as indicated by the treating traumatologist or rehabilitating doctor will be evaluated and treated by one of the three orthopedists participating in this study.
~After the orthopedic evaluation, the professional will determine the most suitable insole according to the plantar discharge needs required by the patient. The intervention in the insole can include modifications or corrections at the forefoot, midfoot, or hindfoot. The material used in each insole will also be specified. When the insole requires many modifications and raises the height of the subject's foot, the use of orthopedic footwear will also be added to prevent pressure on the dorsum of the foot that could be caused by normal footwear."
16283052|NCT04795232|No Intervention|Control|Participants in this arm will receive no intervention
16283053|NCT04795232|Experimental|COD45|Participants in this arm will participate in a COD training session consisted of 45 degrees changes of direction
16283054|NCT04795232|Experimental|COD90|Participants in this arm will participate in a COD training session consisted of 90 degrees changes of direction
16283055|NCT04795206||Cohort 1: Main Cohort|All eligible participants with CHM in IRIS Registry will be included.
16283056|NCT04795206||Cohort 2: Trial-Matched Cohort|Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.
16283061|NCT04795180|Sham Comparator|Saline irrigations|Saline irrigations trough the efferent limb of loop ileostomy
16283062|NCT04795167||FlowTriever Arm|
16283063|NCT04795167||Context Arm|
16283064|NCT04795167||Prior Therapy Arm|
16283065|NCT04795154|No Intervention|Pre-test group|pregnant women> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg without treatment.
16283066|NCT04795154|Experimental|Post-test group|pregnant women > 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg got yoga exercise, and post group was got yoga exercise was 30 minutes every 2 weeks for two months (4 times treatment). Yoga exercises technique used stretching and posture exercises (asanas) combined with deep breathing (pranayama) and meditation, to unify body, mind, and spirit (Babbar S, Parks-Savage AC, Chauhan SP, 2012).
16283067|NCT04795141|Active Comparator|Group A|80mg ABY-035 Q2W SC injection
16283068|NCT04795141|Active Comparator|Group B|160mg ABY-035 Q4W SC injection
16283069|NCT04795141|Active Comparator|Group C|40mg ABY-035 Q2W SC injection
16283070|NCT04795141|Placebo Comparator|Group D|Placebo Q2W SC injection
16283071|NCT04795128|Other|IBI322|Single arm
16283072|NCT04795102|Experimental|L-PRF with ATBG around implant|L-PRF clots to cover ATBG around immediately placed dental implants in the extraction sockets
16283073|NCT04795102|Active Comparator|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
16283074|NCT04795089||Patients|Patients with iNPH and shunt surgery.
16283075|NCT04795089||Healthy individuals|Healthy controls with similar gender and age distribution as the patients.
16283076|NCT04795076|Placebo Comparator|Standard formula|Feeding the infant or child with the regular formula which is prepared with standard concentrations
16283077|NCT04795076|Active Comparator|Nutrient-dense formula|Feeding the infant or child with the nutrient-dense formula which is prepared by concentrating regular formula.
16283078|NCT04795063|Experimental|Total Robotic Distal Gastrectomy|After exploration and randomization, patients received total robotic distal gastrectomy
16283079|NCT04795063|Active Comparator|Robotic-Assisted Distal Gastrectomy|After exploration and randomization, patients received robotic-assisted distal gastrectomy.
16283080|NCT04795050|Experimental|Intervention|
16283081|NCT04795050|No Intervention|Control|
16283082|NCT04795037|Experimental|CU06-1004 for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts
~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
16283083|NCT04795037|Placebo Comparator|Placebo for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts
~2 of out 8 subjects per cohort will be randomized to receive placebo"
16283084|NCT04795037|Experimental|CU06-1004 for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts
~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
16283085|NCT04795037|Placebo Comparator|Placebo for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts
~2 of out 8 subjects per cohort will be randomized to receive placebo"
16283086|NCT04795011|Active Comparator|control group|Standard rehabilitation protocol will be administered to the control group. In the standard rehabilitation protocol for the first three days after surgery, 3 sets of exercises will be applied as 10 repetitions. The treatment will be initiated for the patients with tolerable coughing and deep breathing exercises. Active dorsi-plantar flexion of the ankle, isometric contraction for the quadriceps, hamstrings and gluteus maximus, for the knee in the supine position on the bed; active heel shift exercises, straight leg raising and standing knee and hip flexion, active hamstring curling, and self-hamstring stretching will be performed. After the exercise, the morning treatment protocol will be completed with a walker at a tolerable distance. The patient will be given assignment in the form of walking and repetition of morning exercises at a tolerable level at least twice during the day.
16283087|NCT04795011|Experimental|manual lymphatic drainage group|manual lymphatic drainage (MLD) will be applied to the second group (MLD group) in addition to the standard rehabilitation protocol
16283088|NCT04794998||"Recommended schedule cohort"|COVID-19 patients who have applied the proposed treatment recommendation algorithm at the onset of or within few days from the beginning of symptoms.
16283089|NCT04794998||"control cohort"|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, and treated at home by their family doctors with drug regimens other than those proposed in the recommendations
16283090|NCT04794972|Experimental|Study treatment|Patients receive GNC-039 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another two cycles at the same dose level.
16283091|NCT04794946|Experimental|Liver Cirrhosis|Evidence of liver cirrhosis established during the clinical investigations and/or hospital stay, as evidenced by clinical, endoscopic, radiological and/or histological criteria.
16283092|NCT04794946|Active Comparator|Non Liver Cirrhosis (Healthy Control)|No major respiratory, cardiac comorbid illnesses or malignancy or immunosuppressed state
16283093|NCT04794933|Active Comparator|Conventional therapy (CT)|Cold pack (15 minutes); pulsed ultrasound therapy (1 watt/cm², 3 MHz, 1:2 pulsed mode; 3 minutes); transcutaneous electrical nerve stimulation (60-120 Hz; 20 minutes) and exercises (20 minutes). The exercises included stretching, strengthening and posture exercises.
16283094|NCT04794933|Experimental|CT+ PNF in extremity pattern|PNF in the extremity pattern, were instructed to actively move through the PNF flexion-abduction-external rotation diagonal pattern for 10 repetitions with manual facilitation and the treatment was performed within the range in which pain did not occur. Rhythmic stabilization and repeated contractions were applied from the PNF techniques.
16283095|NCT04794933|Experimental|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|PNF in scapula and upper trunk patterns in addition to PNF in the extremity pattern. The scapular pattern application was performed by positioning the affected extremity in a relaxed position above the stable side in the side-lying position. Rhythmic stabilization and repeated contractions were applied from the anterior-elevation position in the direction of posterior-depression. Extension, lateral flexion and rotation to the affected side were performed in the trunk patterns in rhythmic stabilization and repeated contractions.
16283096|NCT04794907||DR|Patients with diabetes
16283097|NCT04794907||AMD|Patients age 55 and older
16283098|NCT04794894||Telerehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at home via telecommunication technologies.
16283099|NCT04794894||Clinic-based rehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at a local facility.
16283100|NCT04794881|Experimental|24 hours|Newborn infants in this group will undergo repeat lumbar puncture at 24 hours after a traumatic lumbar puncture
16283101|NCT04794881|Active Comparator|48 hours|Newborn infants in this group will undergo repeat lumbar puncture at 48 hours after a traumatic lumbar puncture
16283102|NCT04794868||Culprit vessel of acute coronary syndrome|Culprit vessel of acute coronary syndrome
16283103|NCT04794868||Non-culprit vessel of acute coronary syndrome|Non-culprit vessel of acute coronary syndrome
16283104|NCT04794855||preganant women|observation from 6-8 weeks.
16283105|NCT04794842|Active Comparator|Tetracaine|Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.
16283106|NCT04794842|Active Comparator|Phenol|Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).
16283107|NCT04794829||NIH staff|NIH staff who are 18 years and older. NIH staff may include employees and contractors, fellows and volunteers.
16283108|NCT04794816||Observational (questionnaire administration)|Participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.
16283109|NCT04794803|Experimental|Reparixin|Reparixin oral tablets 1200 mg TID for 7 days
16283110|NCT04794803|Active Comparator|Standard of care|Standard of care
16283111|NCT04794790|No Intervention|Standard Dose|Standard dose induction Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study.
16283112|NCT04794790|Experimental|Macro or High Dose|Macro or High Dosing Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
16283113|NCT04794790|Experimental|Micro or Low Dose|Micro or Low Dose Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
16283114|NCT04794777|Experimental|Experimental arm|Individualised therapy based on results of the PSMA PET/CT.
16283115|NCT04794777|Active Comparator|Control arm|Standard salvage therapy. Results of PSMA PET/CT blinded.
16283116|NCT04794764|Experimental|McGrath MAC|First pass success rate using the McGrath Mac
16283117|NCT04794764|Experimental|Macintosh Laryngoscope|First pass success rate using the Macintosh laryngoscope
16283118|NCT04794738|Experimental|Treatment group A|
16283119|NCT04794738|Experimental|Treatment group B|
16283120|NCT04794738|Placebo Comparator|Treatment group C|
16283121|NCT04794738|Active Comparator|Treatment group D|
16283122|NCT04794725|Other|Blood Sampling|blood samples from venepuncture (10mL)
16283123|NCT04794712||Study group A|"Participants group: Group A : 20 participants with chronic venous insufficiency
~3 months exercise pre surgery
~Pre-surgery evaluation
~Venous reflux assessment by ultrasound and PPG
~Pain assessment by CHEPS,VAS QS MCGILL
~3 months exercise post surgery
~Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
16283124|NCT04794712||Study group B|"Participants group: Group B : 20 participants with chronic venous insufficiency
~Pre-surgery evaluation
~Venous reflux assessment by ultrasound and PPG
~Pain assessment by CHEPS,VAS QS MCGILL
~Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
16283125|NCT04794712||Study Group C|"Participants group: Control Group C : 40 participants with chronic venous insufficiency SUBGROUP 1: WITHOUT EXERCISE 20 PARTICIPANTS
~VENOUS ASSESSMENT TOOLS( U/S, PPG )
~PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)
~SUBGROUP 2: 3 MONTHS EXERCISE 20 PARTICIPANTS
~VENOUS ASSESSMENT TOOLS ( U/S, PPG )
~PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)"
16283127|NCT04794673||Left damage|Have the brain damage and the location of the damage in the left brain
16283128|NCT04794673||Right damage|Have the brain damage and the location of the damage in the right brain
16283129|NCT04794673||Nomal control|Not have the brain damage
16283130|NCT04794660|Active Comparator|Arm 1|In this arm, HPV-positive women will undergo a Visual Inspection with Acetic Acid (VIA) triage test followed by biopsies. Treatment by thermal ablation (or cryotherapy in South Africa) will be applied to VIA positive women eligible for ablative treatment. Non eligible women will be referred to colposcopy.
16283131|NCT04794660|Active Comparator|Arm 2|In this arm, HPV positive women will get biopsies and receive an ablative treatment by thermal ablation (or cryotherapy in South Africa) if they are eligible to ablative treatment. Non eligible women will be referred to colposcopy
16283132|NCT04794647|Experimental|cervical mobilization|'Rotation mobilization' was applied to the symptomatic segment / segments after the detailed evaluation (symptom localization tests, cervical region safety tests, joint play tests, pain provocation/alleviation tests) in accordance with the Kaltenborn-Evjenth system in cervical region. Five series of 45-s mobilizations were performed with 15 s of rest. Each patient received 6 treatment sessions over a period of 3 week.
16283133|NCT04794647|Placebo Comparator|placebo mobilization|Placebo mobilization was applied to the cervical region in the same position and the same grip with the mobilization group. The physiotherapist put her hand on a randomly selected faset without any pushing or pulling, The duration of placebo mobilization was the same as the duration of the other group. Each patient received 6 treatment sessions over a period of 3 week.
16283138|NCT04794621|Experimental|SOC and PED-10 +Procellera|In group 2, in addition to SoC, the patients will apply the EDThi dressing (PED-10) on the wound(s) for the first 3 weeks following enrollment followed by Procellera® or EDTlo for additional 3 weeks. The use of dressings will be discontinued anytime if complete wound closure is achieved.
16283139|NCT04794608|Experimental|HypnoVR Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
16283140|NCT04794608|No Intervention|Control Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of activity among those currently proposed in the service of hematology (reading, music, television).
16283141|NCT04794595||sepsis group with CBP|The child with sepsis should be treated with CBP， but could not receive this treatment for various reasons
16283142|NCT04794595||sepsis group without CBP|The child with sepsis should be treated with CBP and received this treatment
16283143|NCT04794582|Active Comparator|ProGrip® Mesh reinforcement|Once the closure has been completed in 2 muscle-aponeurotic planes with continuous synthetic suture (Monomax® USP 0), the closure will be completed by placing the ProGrip® macroporous polypropylene monofilament mesh in supra-aponeurotic position using the surface with the polylactic acid microgrips, which act as Velcro, in direct contact with the superficial aponeurotic plane constituted by the aponeuroses of the greater oblique muscle and the crescentic line of the anterior rectus abdominis muscle. The polylactic acid microgrips provide immediate fixation, making additional fixation with stitches unnecessary, which makes the technique very easy to use and systematize among the different surgeons of the transplant team. The procedure is completed with the placement of a low caliber round Jackson-Pratt subcutaneous drain (10F) connected to a vacuum system that will be removed on post-transplant day 2 or 3
16283144|NCT04794582|No Intervention|Monomax® USP 0 2 planes closure|The control group will proceed according to standard clinical practice with closure using the technique in 2 muscle-aponeurotic planes with very long-term (3 months) absorbable synthetic continuous suture of poly(4-hydroxybutyrate), monofilament, elastic (Monomax® USP 0) according to the small-bites technique. In order to achieve masking of the participating subject, a small-bore (10F) Jackson-Pratt drain connected to a vacuum system will be placed in the subcutaneous space at the end of the procedure in a manner similar to the intervention group. In both treatment groups, the subcutaneous drain will be removed on post-transplant day 2 or 3.
16283145|NCT04794569|Experimental|Tinzaparin|initial 3-week lead-in course of low molecular weight heparin (tinzaparin 175 units/Kg sc daily) followed by a direct oral anticoagulant (rivaroxaban 20mg po daily) for at least 3 months
16283146|NCT04794569|Active Comparator|Rivaroxaban|Direct oral anticoagulant only (rivaroxaban 15mg po BID for 3 weeks followed by rivaroxaban 20mg po daily ) for at least 3 months
16283147|NCT04794556|Experimental|Group A|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
16283148|NCT04794556|Experimental|Group B|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
16283149|NCT04794556|Experimental|Group C|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
16283152|NCT04794517|Experimental|IMP|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
16283153|NCT04794517|Placebo Comparator|Placebo|Placebo, one tablet/die will be administered orally for six-weeks.
16283154|NCT04794504|Experimental|Botox Injection Group|Two weeks pre-operatively, patients in the Botox injection group will receive intramuscular injections of Botox totaling 100U bilaterally (50U/side). 10 U will be injected into the temporalis (over 5 sites) and 40 U will be injected into the masseter muscle (over 4 sites). Botox will be reconstituted from a powdered form in 2cc of 0.9% sterile saline, and appropriate volumes will be administered.
16283155|NCT04794504|Placebo Comparator|Saline Injection Group|Two weeks pre-operatively, patients in the saline injection group will receive intramuscular injections of Botox totaling the same volumes administered for Botox patients above, across the same number of sites in the temporalis and masseter muscles bilaterally.
16283156|NCT04794491|Experimental|Open-Label Conversion and Treatment Optimization|Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.
16283157|NCT04794478|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
16283158|NCT04794465||Asymptomatic IBD diagnosed during the colorectal cancer screening|
16283159|NCT04794452|Active Comparator|Battery operated toothbrush|battery operated toothbrush
16283160|NCT04794452|Active Comparator|Manual toothbrush|Manual toothbrush
16283161|NCT04794439|Active Comparator|Toothpaste 1 with Stannous Fluoride|Toothpaste with Stannous Fluoride
16283162|NCT04794439|Active Comparator|Toothpaste 1 with Sodium Fluoride and sodium bicarbonate|Toothpaste with Sodium Fluoride and sodium bicarbonate
16283163|NCT04794439|Active Comparator|Toothpaste 2 with Stannous Fluoride|Toothpaste with Stannous Fluoride
16283164|NCT04794439|Active Comparator|Toothpaste 2 with sodium Fluoride and sodium bicarbonate|Toothpaste with sodium Fluoride and sodium bicarbonate
16283165|NCT04794426|Active Comparator|control group|The group that have caries in primary molars and treat them with Hall Technique
16283166|NCT04794426|Experimental|experimental group|The group that have caries in primary molars and treat them with Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC.
16283167|NCT04794413|Experimental|Pimavanserin|All participants will receive pimavanserin 17mg once daily for 1 week and, if the tics are deemed to be inadequately controlled then increase to 34 mg once daily, taken orally as two 17 mg tablets once daily.
16283168|NCT04794400|Experimental|Intervention|An additional oxygen mask was applied for 30 minutes, in patients with ongoing HFNC treatment.
16283169|NCT04794374|Experimental|Discharged COVID-19 survivors|"Telerehabilitation will be provided by physiotherapists including audio, video visits.
~A brochure designed by physiotherapists for COVID-19 survivors will be used. Physiotherapists will call patients weekly and guide, design, modify the exercises accordingly to the patients."
16283282|NCT04793555|Experimental|Experimental_Arm|Assessment of behavior during day and night by unobtrusive sensors
16283283|NCT04793542|No Intervention|Control|
16283170|NCT04794348|Active Comparator|Fresh Frozen Plasma (FFP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL of fresh frozen plasma. After completion of warfarin dosing, approximately 810 mL of fresh frozen plasma will be intravenously administered to the subject.
16283171|NCT04794348|Experimental|Freeze Dried Plasma (FDP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL, that will be manufactured into freeze dried plasma units. After completion of warfarin dosing, approximately 810 mL of freeze dried plasma will be intravenously administered to the subject.
16283172|NCT04794335||Patients undergoing resection of intestine for therapeutic purposes|Tissue will be accepted from all eligible donors who consent to having their intestine removed for therapeutic purposes. This tissue would normally be disposed of as medical waste, used for research purposes. The tissue will be studied in the lab in a series of experiments involving GABA agonists and antagonists. Each GABA agonist and/or agonists/antagonist combination will be studied on intestine tissue randomly assigned to one of four groups defined by patient sex (m/f) and the application of inflammatory mediators (+/-). Thus, four groups are needed per GABA agonist and agonist/antagonist combination and seven agonist/antagonist combinations will be tested for a total of 28 experimental groups. But all of these groups will be generated from all patients recruited for the study.
16283173|NCT04794322||Pelvic Mass Cohort (cohort #1)|200 participants scheduled for surgery for suspected ovarian cancer due to a pelvic mass but without a confirmed tissue or cytology diagnosis.
16283174|NCT04794322||BRCA1/2 Carriers Cohort (cohort #2)|50 participants with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingo-oophorectomy (RRSO) to remove ovaries and fallopian tubes.
16283175|NCT04794309|Experimental|Experimental Group|The participants will receive circuit training exercise and dietary intervention.
16283176|NCT04794309|Active Comparator|Control group|The participants will be only involved in dietary intervention.
16283177|NCT04794283||Hand milking with Diabetes|93 women with DM1, DM2 and medically treated GDM who are patients in specialist maternity care at Soderhospital in Stockholm and who plan to hand milk are part of this group.
16283178|NCT04794283||Not hand milking with diabetes|A group of 93 women are then selected from 1 April 2021and back in the same number as the group1 (n=93) this group only gave milk substitute the first 24h.
16283179|NCT04794270|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
16283180|NCT04794270|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
16283181|NCT04794257|Active Comparator|i-IONM|In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
16283182|NCT04794257|Experimental|NerveTrend|In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
16283183|NCT04794244|Experimental|Experimental|group in which the experimental group training program is applied
16283184|NCT04794244|No Intervention|No Intervention|group without control group training program
16283185|NCT04794231|Active Comparator|Standard dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
16283186|NCT04794231|Active Comparator|Chlorhexidine gluconate -impregnated dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
16283187|NCT04794218|Experimental|Study Group 1|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^4 or Placebo
16283188|NCT04794218|Experimental|Study Group 2|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
16283189|NCT04794218|Experimental|Study Group 3|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
16283190|NCT04794218|Experimental|Study Group 4|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
16283191|NCT04794218|Experimental|Study Group 5|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
16283192|NCT04794218|Experimental|Study Group 6|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
16283193|NCT04794218|Experimental|Study Group 7|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
16283194|NCT04794205|Experimental|Low Dose BCP|Subjects will receive low dose of BCP.
16283195|NCT04794205|Experimental|Medium Dose BCP|Subjects will receive a medium dose of BCP
16283196|NCT04794205|Experimental|High Dose BCP|Subjects will receive high dose of BCP.
16283197|NCT04794205|Experimental|Placebo|Subjects will receive placebo drug.
16283198|NCT04794179|Other|Naida Link CROS device|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
16283199|NCT04794153|Experimental|Pork|Locally sourced
16283200|NCT04794153|Experimental|Salmon|Locally sourced
16283201|NCT04794153|Experimental|Mycoprotein|Provided by Marlow Foods
16283202|NCT04794153|Experimental|Lentils|Red
16283203|NCT04794153|Experimental|Egg|Local supplier
16283204|NCT04794153|Active Comparator|Egg whites|Local Supplier
16283284|NCT04793542|Sham Comparator|Lukewarm Water|
16283205|NCT04794140|Experimental|one pass group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from a single pass for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
16283206|NCT04794140|Experimental|two passes group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from two passes for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
16283207|NCT04794127|Experimental|Trabectedin in combination with Pioglitazone|Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
16283208|NCT04794114|Experimental|orthosis in hemiplegia|
16283209|NCT04794101|Experimental|Deferred treatment from MGT-RPGR-021 4e11|Deferred treatment
16283210|NCT04794101|Active Comparator|Already treated in MGT-RPGR-021|Already treated
16283211|NCT04794101|Experimental|Deferred treatment from MGT-RPGR-021 2e11|Deferred treatment
16283212|NCT04794088|Active Comparator|Intravenous imatinib mesylate (Impentri®)|Patients receiving the active investigational medicinal product will be receiving imatinib 200mg b.i.d. (administered as an 8 mg/mL solution for i.v. infusion) for 7 days.
16283213|NCT04794088|Placebo Comparator|Placebo solution|Patients receiving the placebo comparator will be receiving the same amount of intravenous solution, however containing 0.01M acetate buffer with 1.9% glycerol.
16283216|NCT04794049|Experimental|Experiment cohort|4-6 hours before colonoscopy, patients in experiment cohort began to drink the first 150ml lactulose and half hour later, drink other 150ml lactulose dissolved in 1.5 L of water at a rate of 250ml every 15 minutes.
16283217|NCT04794049|Active Comparator|Control cohort|The participants in control cohort began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
16283218|NCT04794036|Experimental|Experimental Group|Telerehabilitation asynchronous programme at home
16283219|NCT04794036|Active Comparator|Control Group|Rehabilitation programme with an explanatory booklet at home
16283220|NCT04794023|Experimental|Intervention_Corneal Ablation|
16283221|NCT04794010||Cohort 1|Participants with Metastatic Non-Small Cell Lung Cancer
16283222|NCT04793997|Active Comparator|Verum Microbiome spray group|Daily use of microbiome spray for two weeks
16283223|NCT04793997|Placebo Comparator|Placebo spray group|Daily use of placebo spray for two weeks
16283224|NCT04793997|No Intervention|Household member group|No use of spray
16283225|NCT04793984|Experimental|Inhaleen|Iota-Carrageenan inhalation
16283226|NCT04793984|Placebo Comparator|Placebo|NaCl inhalation
16283227|NCT04793971||postoperative cases|patients that underwent percutaneous release of the paratenon for chronic midportion Achilles tendinopathy
16283228|NCT04793958|Experimental|MRTX849 + Cetuximab|
16283229|NCT04793958|Active Comparator|mFOLFOX6 or FOLFIRI|
16283230|NCT04793945|Active Comparator|light therapy twice weekly|15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light twice weekly and topical steroid twice daily the second patch will be treated by topical steroid twice daily. the third patch will be left as a control.
16283231|NCT04793945|Active Comparator|light therapy once weekly|"15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light once weekly and topical steroid twice daily.
~the second patch will be treated by topical steroid twice daily. the third patch will be left as a control."
16283232|NCT04793932|Active Comparator|PAXG Arm A|cisplatin 30 mg/m2 every 2 weeks, nab-paclitaxel 150 mg/m2 every 2 weeks, gemcitabine 800 mg/m2 every 2 weeks, capecitabine 1250 mg/m2/day (for 28 consecutive days) in 28-day cycles administered for 4 cycles (4 months).
16283233|NCT04793932|Active Comparator|mFOLFIRINOX Arm B|irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, folinic acid at a fixed dose of 400 mg/m2, fluorouracil continuous IV infusion 2.4 g/m2 over 46 hours in 14-day cycles administered for 8 cycles (4 months).
16283234|NCT04793932|Active Comparator|short-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive immediate surgery followed by 2 further months of the same chemotherapy
16283235|NCT04793932|Active Comparator|long-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive 2 further months of the same chemotherapy followed by surgery
16283236|NCT04793919|Active Comparator|Standard Risk (SR)|Patient with APL and WBC less than 10x10e9/L at presentation before start treatment
16283237|NCT04793919|Experimental|High Risk (HR)|Patient with APL, with the highest pre-treatment WBC count equal to or greater than 10x10e9/L at presentation
16283238|NCT04793906|Experimental|Beef|
16283239|NCT04793906|Experimental|Plant-based alternative|
16283240|NCT04793893|Experimental|Treatment of residual hypermetropia refraction after LASIK|"The main problem at young patients post - LASIK after one year is residual hypermetropic refractive errors (especially accommodation problem) The method used in Eye Hospital is treatment with implantation of human fresh corneal lenticule (min. -1.50D) taken from myopic patients in post - LASIK patients with residual hypermetropic refractive error (min. +1.0D).
~The flap of LASIk is lifted,cleaned and then the lenticule gently inserted.The lenticule was positioned according the K2 values when is astigmatism residual refractive error.In cases where is not astigmatism the lenticule was positioned in central position under the flap."
16283285|NCT04793542|Active Comparator|Hot Water|
16283286|NCT04793529|Experimental|Cholecalciferol injection|
16322720|NCT04520256|Experimental|Dysregulated Eating, Exercise|
16283241|NCT04793880|Experimental|Medication checklist with cost information|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist with cost information intervention.
16283242|NCT04793880|Active Comparator|Medication checklist|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist without cost information.
16283243|NCT04793867||CF and Non-CF Bronchiectasis|In the first arm (Aims 1 & 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement.
16283244|NCT04793867||Healthy Subjects|Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.
16283245|NCT04793854||Case|Children with sickle cell anemia attending the centre of reference for sickle cell disease in Guadeloupe.
16283246|NCT04793854||Control|Control children without chronical disease
16283247|NCT04793841||General population|sexually experienced adults (aged 18 or above) of the randomly selected household
16283248|NCT04793841||men who have sex with men|men who have sex with men aged 18 or above and normally living in Hong Kong
16283249|NCT04793828|Experimental|Intervention (velibra)|Arm consisting of participants who receive velibra, an internet-based cognitive behavioral therapy program.
16283250|NCT04793815|Experimental|Cryo-activation and anti-PD-1 monotherapy combination|
16283251|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION + NONINVASIVE VENTILATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session with non-invasive ventilation.
16283252|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session without non-invasive ventilation.
16283253|NCT04793776|Experimental|Manage Emotions to Reduce Aggression (MERA)|MERA is 3 individual 90-minute sessions delivered over 3 weeks.
16283254|NCT04793776|Active Comparator|Present Centered Psychotherapy (PCT)|PCT delivered in 3 individual 90-minute sessions over 3 weeks.
16283255|NCT04793763|Placebo Comparator|group A|"placebo Comparator Group A
~: twenty patients were received traditional Physical Therapy agents"
16283256|NCT04793763|Experimental|group B|experimental Group B Group B: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and deep neck flexors exercises;
16283257|NCT04793763|Experimental|group C|"Experimental Group C
~Group C: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and Mckenzie technique."
16283258|NCT04793750|Experimental|POC HIV VL Testing|Participants will receive the standard of care tests (DPP HIV-Syphilis Test System, OraQuick) plus the HIV POC VL test.
16283259|NCT04793750|Active Comparator|SOC HIV Testing|Participants will receive routine standard of care HIV testing.
16283260|NCT04793737|Experimental|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
16283261|NCT04793724|Experimental|Simeox first|Patients who will undergo Simeox intervention first. After three months cross-over to PARI O PEP intervention.
16283262|NCT04793724|Active Comparator|PARI O PEP first|Patients who will undergo PARI O PEP intervention first. After three months cross-over to Simeox intervention.
16283263|NCT04793711|Experimental|EpiCeram|Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.
16283264|NCT04793698|Experimental|Compassion meditation|Compassion meditation is a contemplative meditation practice that fosters compassion through contemplation of common humanity.
16283265|NCT04793698|Active Comparator|Applied relaxation|Veteran.calm is an applied relaxation program that exposes participants to a variety of relaxation strategies and their application.
16283266|NCT04793685|Experimental|Active Drug|Prazosin (16mg/day) versus Placebo comparator, administered in t.i.d schedule, in capsules, over a 12 week period, with 2 weeks titration in weeks 1-2 and a 5-day taper in week 12.
16283267|NCT04793685|Placebo Comparator|Placebo Drug|Placebo for 12 weeks.
16283268|NCT04793672||Patients with malignant tumors and healthy people|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
16283269|NCT04793659|Experimental|Oral Fasudil 90 mg/day|Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
16283270|NCT04793659|Experimental|Oral Fasudil 180 mg/day|If the subject is a not a responder in the open-label period 1 but tolerated Fasudil 90 mg/day, they will be escalated to Fasudil 180 mg/day (open-label period 2) for 42 days. If the subject is a responder to Fasudil 180 mg/day, they are randomized to either Fasudil 180 mg/day for 42 days or a placebo (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
16283271|NCT04793659|Placebo Comparator|Oral Placebo|Placebo comparator arm to investigational drug (Fasudil 90 mg/day or 180 mg/day).
16283274|NCT04793633|Experimental|LINFU™ to increase sensitivity of pancreatic juice cytology|LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
16283275|NCT04793620|Experimental|TQL1055|TQL1055 + acellular pertussis vaccine
16283276|NCT04793620|Active Comparator|Acellular pertussis vaccine|Acellular pertussis vaccine
16283277|NCT04793594||Tele- Assessment Group|Balance Assessment
16283278|NCT04793594||Face To Face (Clinic) Group|Balance Assessment
16283279|NCT04793581|Other|Single Arm|Single-arm study
16283280|NCT04793568|Experimental|Recombinant Interferon gamma 1b (IMUKIN®)|
16283281|NCT04793568|Placebo Comparator|Recombinant Interferon gamma 1b placebo|
16283402|NCT04792606||Hip reconstructive surgery|
16283287|NCT04793516|Experimental|VR-based spatial retraining|Game-like therapy activities will be taken place in a virtual environment, provided through an immersive head-mounted display.
16283288|NCT04793503|Active Comparator|conventional complete denture|the patients receive conventional complete denture constructed from heat cure acrylic resin
16283289|NCT04793503|Active Comparator|CADCAM 3D printed denture|the patients receiveCADCAM 3D printed denture constructed by using printing machine
16283290|NCT04793503|Active Comparator|CAD/CAM milled denture|the patients receiveCADCAM 3D printed denture constructed by using milling machine
16283291|NCT04793490|Other|Group A (Control group)|Patients will receive paracetamol 1 g thrice daily intravenously
16283292|NCT04793490|Active Comparator|Group B (Sphenopalatine ganglion block group)|patients will receive sphenopalatine ganglion block via transnasal approache by a cotton tipped applicator soaked in 2%lignocaine with 4 mg dexamethasone
16283293|NCT04793477|Experimental|K files (Dentsply Caulk, Milfors, DE, USA)|Instrumentation with manual files shall be performed with balanced forces (Roane) technique consist of placing the instrument as apically as it can go and then turning it clockwise (less than 180º). This is followed by a counterclockwise rotation (of at least 120º) with slight apical pressure. This is repeated until the desired working length is obtained.
16283294|NCT04793477|Experimental|VDW.ROTATE (VDW, Munich, Germany).|Instrumentation with VDW.ROTATE files shall be performed with a glide path to WL using VDW.ROTATETM 15.04 until reaching working length (1.3cNm and 300-400 rpm), the next instrument in the sequence is VDW.ROTATETM 20.05 until reaching working length (2.1cNm and 300-400rpm). and finally instrument with VDW.ROTATETM 25.04 (2.3cNm and 300-400rpm)
16283295|NCT04793477|Experimental|Reciproc® blue (RCP, VDW, Munich, Germany)|Instrumentation with Reciproc blue files shall be performed with only one file and move it in a pecking motion (the amplitude will not exceed 3mm). All the instruments shall be cleaned after 3 pecks.
16283296|NCT04793464|Experimental|Promotores|The Promotores de Salud intervention involves specified outreach and psychoeducation on SARS-CoV-2 health related behaviors.
16283297|NCT04793464|Active Comparator|Control|Services as usual includes outreach as usual strategies and pamphlets on site at events.
16283298|NCT04793451|Experimental|Group A|Endurance training
16283299|NCT04793451|Experimental|Group B|Endurance-strength training
16283300|NCT04793438|Experimental|Intervention group|Motive-specific intervention; three appointments within two weeks, 30-45 minutes per session.
16283301|NCT04793438|Active Comparator|Control group|Supportive conversations; three appointments within two weeks; 30-45 minutes per session.
16283302|NCT04793425|No Intervention|Standard care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI.
16283303|NCT04793425|Experimental|Mobile app care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI. On top of that every patient will be given an access to mobile application, which will support rehab process. The application stands as a educational and coordination tool.
16283305|NCT04793399|Experimental|Bosutinib-Atezolizumab Combination|"Drugs to be administered:
~Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year"
16283306|NCT04793386|Experimental|Carotid ultrasound|When stopping chest compressions to check manual palpation every 2 minutes, an ultrasound scan of the carotid artery is performed. Whether or not return of spontaneous circulation is determined based on the compressibility and pulsatility of the carotid artery, and the time taken from the start of the ultrasound scan to the determination is recorded.
16283307|NCT04793373|Experimental|EpiFaith® group|Study subject will have the epidural placement with an EpiFaith® syringe.
16283308|NCT04793373|Active Comparator|Conventional group|Study subject will have the epidural placement with a conventional glass syringe.
16283309|NCT04793360||LiverCare Surveillance|Participants undergoing orthotopic liver transplant (de-novo or re-transplant) will be considered for this study
16283310|NCT04793347|Experimental|shock waves|group of patients with anal fissure will be treated with shock waves
16283311|NCT04793334||Obese + OSA|"Inclusion Criteria:
~Men and women
~Ages >= 30-65 years old
~BMI 35-40 kg/m2
~Scheduled for sleeve gastrectomy (bariatric surgery)
~OSA identified by PSG
~Exclusion Criteria:
~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.
~Pregnancy
~Currently smoking
~Any respiratory disorder other than OSA or well controlled asthma
~contraindication to MRI"
16283312|NCT04793334||Obese without OSA|"Inclusion Criteria:
~Men and women
~Ages >= 30-65 years old
~BMI 35-40 kg/m2
~Scheduled for sleeve gastrectomy (bariatric surgery)
~No OSA identified by PSG
~Exclusion Criteria:
~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.
~Pregnancy
~Currently smoking
~Any respiratory disorder other than OSA or well controlled asthma
~contraindication to MRI"
16283313|NCT04793321|Other|healty nulliparous females|"each participant did three conditions:
~holding nothing (unloaded).
~holding an infant mannequin in arms(arms).
~holding an infant mannequin in the baby carrier(carriers)."
16283314|NCT04793308|Experimental|Group (1); (ProTaper Next, Rotary system).|Group I teeth were prepared with rotary instrumentation using ProTaper Next (Dentsply, Switzerland)
16283315|NCT04793308|Experimental|Group (2); K- files, Manual instruments.|Group II root canals were prepared by manual instrumentation using K type files Mani, Japan).
16283316|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 1 and test drug 2|
16283317|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 3 and test drug 4|
16283318|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 5 and test drug 6|
16283319|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 7|
16283320|NCT04793282|Placebo Comparator|Control|Post-test satisfaction
16283321|NCT04793282|Experimental|Experimental|Treatment and satisfaction
16283322|NCT04793269||Long COVID|Patients with long COVID syndrome
16283323|NCT04793256|Experimental|intervention|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
16283403|NCT04792606||Salvage hip surgery|
16283324|NCT04793256|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
16283325|NCT04793243|Experimental|Intervention group|Formed by 22 patients that received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
16283326|NCT04793243|No Intervention|Control group|Formed by 20 patients that did not receive supplementation
16283327|NCT04793217|Experimental|Improving AIDS Care after Trauma+|ImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. The ImpACT+ individual sessions will focus on coping skills and care engagement during an early critical period, while maintenance check-ins will serve to reinforce positive change and support the ongoing implementation of skills as new challenges arise.
16283328|NCT04793217|Active Comparator|Adapted Problem-Solving Therapy|Participants randomly assigned to the control condition will receive a brief adapted version of problem-solving therapy (PST), based on Problem Management Plus, a component of the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP). PST is a psychoeducational treatment focused on managing the negative effects of stressful life events. PST has been found to be effective for a range of problems, such as depression, and is recommended for implementation in low-resource settings.
16283329|NCT04793204|Experimental|fezolinetant|A single oral dose of fezolinetant will be administered with water under fasting conditions on day 1 (low dose), day 4 (medium dose) and day 7 (high dose). From day 10 to day 15, the medium dose of fezolinetant will be administered with water after breakfast once daily. On day 16, the medium dose of fezolinetant will be administered with water under fasting conditions.
16283330|NCT04793178|Active Comparator|Oxygen Reserve Index Blinded Group|Aneshesist will be blinded for oxygen reserve index monitoring (ORI, Masimo Corporation), but he will be allowed to use pulse oxymetry and end-tidal carbon dioxide monitoring to manage the respiratory conditions and depth of sedation.
16283331|NCT04793178|Experimental|Oxygen Reserve Index Group|Aneshesist will be allowed to use pulse oxymetry, end-tidal carbon dioxide and oxygen reserve index (ORI) monitoring. He will manage the depth of sedation, respiaratory conditions.
16283332|NCT04793165|Experimental|Non-hybrid closed-loop system|"To compare two types of treatments:
~During the first 3 days: Previous or conventional, with CSII plus CGM in open loop.
~During the second 3 day period: AP with CSII plus CGM in a closed-loop system, through the ARG algorithm."
16283333|NCT04793152|Experimental|Vancomycin continuous infusion|A loading dose of 15-20mg/kg will be given followed by continuous infusion dose of 30mg/kg over 24 hours if normal renal function. Dose will be adjusted based on creatinine clearance. A random vancomycin level will be done with routine morning blood work until target level have been achieved. The dose is adjusted to target of 17-21mg/L based on target area under the curve of 400-500.
16283334|NCT04793152|Active Comparator|Vancomycin intermittent dosing|A loading dose of 25mg/kg (maximum 2g) will be given to severely ill patients at the discretion of physician and pharmacist. The intermittent dose will be 15mg/kg every 12 hours if normal renal function. The frequency of dosing will be adjusted based on creatinine clearance. Trough level will be done before the fourth dose and adjusted to target trough level of 15-20mg/L.
16283335|NCT04793113|Experimental|Intervention|Low carbohydrate, high protein meals
16283337|NCT04793074|Experimental|Transforming nanoparticle dressing|Patients in the treatment group (n=30) had transforming nanoparticle dressing
16283338|NCT04793074|Active Comparator|Conventional compression dressing|The control group (n=30) received conventional compression dressing.
16283339|NCT04793048|Active Comparator|Active group received an active device and a scaling and root planing (SRP) at baseline|
16283340|NCT04793048|Sham Comparator|Sham group received a sham device and a scaling and root planing (SRP) at baseline|
16283341|NCT04793035|Experimental|Enrolled patients|Single-arm study for enrolled GERD patients to be treated with an Omega-Cuff device
16283342|NCT04793022|Experimental|TIVA-Propofol|Intravenous anesthesia with Propofol
16283343|NCT04793022|Active Comparator|Inhaled Anesthesia|General Inhaled Anesthesia
16283344|NCT04793009||mesh group|patients undergoing abdominoperineal resection with end colostomy and implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
16283345|NCT04793009||no-mesh group|patients undergoing abdominoperineal resection with end colostomy without implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
16283346|NCT04792996||Gilbert´s Syndrome|Subjects with mild hyperbilirubinaemia and a plasma level of unconjugated bilirubin of 17.1 µmol.
16283347|NCT04792996||Control group|Healthy controls with lower plasma level of unconjugated bilirubin of 17.1 µmol, aen and gender matched.
16283348|NCT04792983||Older (≥ 65 years of age)|Older surgical patients presenting for elective spine surgery.
16283349|NCT04792970|Active Comparator|Talc instilled via tunneled pleural catheter combined with standard daily drainage|This arm consists of eligible participants who are randomized to the Talc arm and would receive Talc therapy instilled into the pleural catheter.
16283350|NCT04792970|No Intervention|Standard daily drainage|This arm consists of eligible participants who are randomized to control group and would not receive any intervention.
16283351|NCT04792957||Pyoderma Gangrenosum|Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.
16283352|NCT04792957||Hidradenitis Suppurativa|Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
16283353|NCT04792957||Psoriasis|Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
16283354|NCT04792957||Healthy Subjects|Skin biopsies obtained from patients with healthy subjects, will be used to control group.
16283355|NCT04792944||No treatment|Those are the patients that do not receive any treatment for the aneurysm, neither endovascular nor surgical
16283356|NCT04792944||External ventricular drain only with neither embolization nor clipping|These patients will be treated with an external ventricular drain only with neither embolization nor clipping
16283357|NCT04792944||Embolization|These patients will be treated endovascularly
16283358|NCT04792944||Programmed surgical clipping|These patients will be treated no on an emergency basis with surgical clipping of an aneurysm that has bled
16283359|NCT04792944||Emergency surgical clipping with cisternal urokinase administration|These patients with undergo emergency surgical clipping with cisternal urokinase administration
16283360|NCT04792944||Patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping|This group will include patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping
16283361|NCT04792931|Other|Adult Autoimmune Myopathies|It is a description Autoimmune Myopathie cohort
16283362|NCT04792918||NEC/LOS preterm infants|Collection of biological samples (stool, stomach fluid, blood, urine) and health-related data over the first few weeks of life, additional stool samples after onset of NEC/LOS
16283363|NCT04792918||Preterm infants not developing NEC/LOS|Collection of biological samples (stool, stomach fluid, blood, urine) and health-related data over the first few weeks of life
16283364|NCT04792918||Family members of preterm infants|Collection of biological samples (stool, breastmilk, vaginal swab) and health-related data at one timepoint after the birth of the preterm infant from members of the family (mother, father)
16283366|NCT04792879|Experimental|Peripheral veins Doppler ultrasound|
16283367|NCT04792853|Experimental|Tab-G (tablet-based group CBT education)|Tab-G participants will receive 4 weekly CBT(cognitive behavioral therapy)-based group learning sessions to encourage a simple walking activity through videoconferencing meetings in a group of 5 members. The educational materials emphasize shared goal setting and mutual reinforcement.
16283368|NCT04792853|Experimental|Tab-I (tablet-based individual CBT education)|Tab-I participants will receive 4 weekly CBT(cognitive behavioral therapy)-based individual learning sessions to encourage a simple walking activity through videoconferencing meetings.
16283369|NCT04792853|No Intervention|Usual care group|A usual care group will receive general arthritis management education. Participant are instructed to maintain usual activity during the study period.
16283370|NCT04792827||analgosedation group|analgosedation concept
16283371|NCT04792827||historical group|standard historical concept
16283372|NCT04792814||MAT-RAP group|MAT and RAP
16283373|NCT04792814||historical group|standard procedure
16283374|NCT04792801||Patients with HCC and whose liver transplant plan has been validated|"Prospective inclusion of patients who are candidates for a transplant for CHC at the University Hospital of Lille and Rouen whose transplant project has been validated with a AFP score ≤ 2.
~The systematic performance of a PET-CT with FDG and a PET-CT with Choline in all patients. At the end of the entire assessment, the patients will be (or not) registered on the transplant list and, for the patients registered on the list, a follow-up will be carried out at the level of a specialized transplant consultation every 3 months at during which the alphafoetoprotein dosage and abdominal imaging will be updated, until liver transplantation."
16283377|NCT04792775|Experimental|Prolonged Exposure + Emotion Regulation Skills Training|Twelve, 90-minute sessions of Prolonged Exposure (PE) with Dialectical Behavior Therapy (DBT) Emotion Regulation Skills Training.
16283378|NCT04792762|Experimental|GIP(1-42)|
16283379|NCT04792762|Experimental|GIP(1-30)NH2|
16283380|NCT04792762|Placebo Comparator|Placebo|
16283381|NCT04792749|Experimental|Metformin treatment|Patients who receive metformin in addition to progestin therapy
16283382|NCT04792749|No Intervention|Conventional treatment|Patients who receive progestin therapy only
16283383|NCT04792736||Survivors|Patients discharged alive from intensive care unit
16283384|NCT04792736||non survivors|Patients who succumbed during their ICU stay
16283385|NCT04792723|Experimental|Healthy volunteer|Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks
16283386|NCT04792710|Experimental|Intervention arm|This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose
16283387|NCT04792710|Placebo Comparator|Control arm|This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose
16283388|NCT04792697|Experimental|Advance/Extend Manipulation|"For ~2 weeks, Advance/Extend participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days will be instructed to:
~Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)
~Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)
~Increase morning bright light exposure via bright light goggles (30 min after rise)
~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
16283389|NCT04792697|Active Comparator|Control|Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 13 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments, thereby controlling for effort.
16283390|NCT04792684||Arm A.|Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery
16283391|NCT04792684||Arm B|Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy
16283392|NCT04792671||Perinatal group|females who are pregnancy
16283393|NCT04792671||postpartum group|female who get delivery(from day 1 up to 1 year)
16283394|NCT04792645|Placebo Comparator|Placebo|10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks
16283395|NCT04792645|Experimental|Memantine|10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks
16283396|NCT04792632||Intervention|Intervention is the use of Veye Lung Nodules during the reading of the CT scans
16283397|NCT04792619|Experimental|Control|
16283398|NCT04792619|Active Comparator|Study|
16283399|NCT04792606||"Natural History or watchful waiting"|
16283400|NCT04792606||Serial botulinum toxin injections|
16283401|NCT04792606||Adductor (+/- psoas) muscle releases alone|
16283405|NCT04792580|Experimental|Treatment|Subjects receive lifitegrast 5% ophthalmic solution twice a day for 4 weeks after a 2 week washout.
16283406|NCT04792580|Active Comparator|Standard of Care|Subjects receive Systane Preservative Free Tears twice a day for 4 weeks after a 2 week washout.
16283407|NCT04792567|Experimental|Siponimod - continuous|Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination
16283408|NCT04792567|Experimental|Siponimod- interrupted|Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination
16283409|NCT04792567|Active Comparator|Comparator|Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination
16283410|NCT04792554||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
16283411|NCT04792541|Placebo Comparator|control group|saline solution
16283412|NCT04792541|Experimental|test group|HY containing gel; GUM® Afta Clear Gel, Sunstar
16283413|NCT04792528|Experimental|One training period|One training period of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
16283414|NCT04792528|Experimental|Two training periods|Two training periods of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
16283415|NCT04792528|Active Comparator|Active control|The generalized brain training group (Active control) will play solitaire 30 minutes daily for 25 sessions
16283416|NCT04792515|Experimental|treatment group|Patients were treated with camrelizumab combined with SOX/ or apatinib
16283417|NCT04792502|Experimental|Planned Therapy|
16283418|NCT04792489|Experimental|Single, open label|
16283419|NCT04792476|Active Comparator|Active Comparator: Experimental group|The experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
16283420|NCT04792476|No Intervention|No Intervention: Control group|"The control group will only receive the conventional treatment offered in the clinical program. For 12 weeks, parients will attend 8 visits with mental health specialist nurse, where they will receive information, oral and written, to comply with the recommendations for physical exercise: 150-300 min/week of moderate physical activity or 75-150 min/week of vigorous physical activity.
~In both groups (experimental and control), patients will be informed of the risk of weight gain, and they will be advised, regardless of the group assigned, to watch their diet and increase physical exercise until they meet the weekly recommendations."
16283421|NCT04792463||Patients with personal and/or family history suggestive of hereditary BAP1|Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma
16283422|NCT04792463||Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance|"Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members
~Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1"
16283423|NCT04792450||ED Patients|Patients presenting in Emergency Department
16283424|NCT04792450||ED Staff|Staff working within the Emergency Department
16283425|NCT04792437||glioma patients|glioma patients with routine surgery
16283426|NCT04792424|Experimental|No monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.
~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.
~Citrate dose start at 4 mmol/L and no adjustment of citrate dose. Post-filter ionized calcium result will blind for physician.
~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
16283427|NCT04792424|Placebo Comparator|Monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.
~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.
~Citrate dose start at 4 mmol/L with adjustment of citrate dose to acheive post-filter ionized calcium at 0.25-0.35 mmol/L.
~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
16283428|NCT04792411|Experimental|Prehabilitation group|This arm will be subject to at least 6 weeks of a tailored prehabilitation programme
16283429|NCT04792398|Experimental|Sleep Bruxism Subjects|"Ultrasound guided BTX-A injection: 25 units (divided in two injections) in each masseter muscle.
~One-time intervention. Effect observation by measuring various biosignals (EMG, EOG, EEG), bite force, chewing efficiency, psychometric assessments."
16283430|NCT04792385|Experimental|E4/DRSP 15/3 mg|Single treatment arm will receive E4/DRSP 15/3 mg
16283431|NCT04792372|Other|Periodontitis patients|Single-group receiving periodontal treatment. The data will be evaluated according to the healing potential of individuals in the group and also site-specifically.
16283432|NCT04792359|Experimental|Equinometer|Measurement with Equinometer
16283433|NCT04792333|Experimental|Treatment|500 mg (2 capsules of 250 mg)
16283434|NCT04792320|Experimental|Active bamboo charcoal|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The participants will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.
~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.
~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
16283460|NCT04792125|Experimental|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed external electrical stimulation (EES) added to pelvic floor muscle training (PFMT).
16283435|NCT04792320|Experimental|Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.
~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.
~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
16283436|NCT04792320|Experimental|Active bamboo charcoal+Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.
~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.
~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
16283437|NCT04792320|No Intervention|No invervention|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.
~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.
~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
16283438|NCT04792307|Other|Neuromuscular electrical stimulation (NMES) to one leg|"NMES left leg, no high protein ice cream supplementation
~NMES right leg, no high protein ice cream supplementation"
16283439|NCT04792307|Other|High protein ice cream supplementation|"NMES left leg, high protein ice cream supplementation
~NMES right leg, high protein ice cream supplementation"
16283440|NCT04792294||Lung transplant recipients with chronic lung allograft dysfunction|Lung transplant recipients with chronic lung allograft dysfunction, who underwent extracorporeal photopheresis
16283441|NCT04792281||Patients with suspected native valve endocarditis|
16283442|NCT04792268|Experimental|Electronic clinical decision support|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm. An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.
~Automated electronic decision support will be provided as a combination of visual prompts on the individual patient's dashboard, accessed by clinicians when they view a patient record on the electronic health record supplemented by an email sent to the NHS Trust email account addresses of the participating ward clinician(s).
~Alerts will include locally approved guideline-based recommendations for clinician-led monitoring and management of dysglycaemia and known diabetes, tailored to the individual patient based upon reported HbA1c values."
16283443|NCT04792268|No Intervention|Treatment as usual|Clinicians will not have access to eCDSS on wards recruited to this arm and will deliver care as usual.
16283444|NCT04792255|Experimental|Group A: Reduced contrast media dose group|"Reduced contrast media protocol: extracranial carotid artery intervention (2-4 fps with institutional protocol).
~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 3 ml iodined contrast media with a 3 ml/s flow rate.
~DSA and DVA images will be calculated; DVA images will be used for diagnosis and interventions."
16283445|NCT04792255|Active Comparator|Group B: Standard contrast media dose group|"Standard contrast media protocol: extracranial carotid artery intervention (2-4 fps with institutional protocol).
~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 6 ml iodined contrast media with a 3 ml/s flow rate.
~DSA and DVA images will be calculated; DSA images will be used for diagnosis and interventions."
16283446|NCT04792242|Active Comparator|goal directed therapy|svo2,haematocrite value,urine output,mean arterial pressure and central venous pressure
16283447|NCT04792242|Active Comparator|PCO2 gap algorithm|PCO2 gap,haematocrite value,Spo2,cardiac index
16283448|NCT04792229|Experimental|Experimental Group|"Standing on WBV device (frequency of 40 Hz); 3 Minute vibration with 3 minute rest.
~Three times repetition . Total 18-minute vibrational therapy protocol. 3 days session per week"
16283449|NCT04792229|Active Comparator|Control Group|"Stretching exercise (hip adductors ,plantar flexors, external rotators of hip & knee flexors).
~Active and passive ROMS to lower extremities. Strengthening exercises (hip and knee extensors, ankle dorsiflexes) 3 Repetitions into 3 day session per week"
16283450|NCT04792216|Experimental|Wild Salmon|Wild salmon fillets in a raw form
16283451|NCT04792216|Experimental|Farmed Salmon|Farmed salmon fillets in a raw form
16283452|NCT04792190|Active Comparator|Intervention Management Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
16283453|NCT04792190|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
16283454|NCT04792177|Experimental|Intervention group|Emotion regulation skills training group
16283455|NCT04792177|No Intervention|waitlist control group|The control group will not receive any intervention during the trial but will be offered the same treatment at the end of the six-months follow-up assessment.
16283456|NCT04792164|Experimental|The experimental group will receive US guided nerve block|The experimental group will receive US guided nerve block by lidocaine before open inguinal hernia repair.
16283457|NCT04792164|Other|The control group will receive usual infiltration|The control group will receive usual infiltration by lidocaine before open inguinal hernia repair.
16283458|NCT04792151||PHP Youth|Youth ages 6-17 receiving standard of care treatment (i.e., transdiagnostic intervention for emotional disorders) in a partial hospitalization program
16283459|NCT04792138||Men suspected of Prostate Cancer|
16286254|NCT04772274|Active Comparator|US Stelara|US sourced Stelara (ustekinumab)
16283461|NCT04792125|Other|External electrical stimulation (EES) group|This arm is going to include the patients who are performed external electrical stimulation (EES).
16283462|NCT04792125|Active Comparator|Pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed pelvic floor muscle training (PFMT).
16283463|NCT04792112|Experimental|Guideline + decision support tool|A decision support tool summarizing harms and benefits of late preterm antenatal corticosteroids will be integrated into the clinical practice guideline available to clinicians in the hospitals in the experimental arm.
16283464|NCT04792112|No Intervention|Guideline only|Clinicians in the hospitals in the 'no-intervention' arm will have access to the standard guideline only (without the integrated decision support tool).
16283465|NCT04792099|Experimental|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) with blended oxygen delivered by binasal prongs or nasal mask.
16283466|NCT04792099|Active Comparator|Nasal Cannula|Blended oxygen delivered by nasal cannula (NC).
16283467|NCT04792086||Inhabitants in Nord-Trøndelag 70 years of age and older|All inhabitants in Nord-Trøndelag 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
16283468|NCT04792086||Inhabitants in one area in Trondheim, 70 years of age and older|All inhabitants one area in Trondheim, 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
16283469|NCT04792073|Experimental|Avelumab and Radiation Therapy|Will receive avelumab at the FDA approved dose and schedule of 800 mg IV over 60 minutes every 2 weeks (+/- 3 days) until treatment intolerance or disease progression occurs.Comprehensive Ablative Radiation Therapy (CART) will be initiated between the first and second dose of avelumab. Comprehensive ablative radiation therapy will be given according to guidelines
16283470|NCT04792073|Experimental|Radiation Therapy alone|Will receive Comprehensive Ablative Radiation Therapy (CART) alone
16283471|NCT04792060|Experimental|adult patients with distal ulna fractures|adult patients with distal ulna fractures
16283472|NCT04792047||Lesions with perivasular FAI greater than ≥-70.1|
16283473|NCT04792047||Lesions with perivasular FAI greater than <-70.1|
16283474|NCT04792034|Experimental|Active|Active: FDA Approved Golprelto (Cocaine Hydrochloride Topical Solution)
16283475|NCT04792021|Active Comparator|N-acetylcysteine (NAC)|Patients receiving N-acetylcysteine (NAC)
16283476|NCT04792021|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
16283477|NCT04792008|Experimental|YQ23 Single dose|Two-third of randomized patients will receive YQ23 as active treatment
16283478|NCT04792008|Placebo Comparator|Placebo Single dose|One-third of randomized patients will receive matching placebo
16283479|NCT04791982|Experimental|Experimental group|
16283480|NCT04791982|No Intervention|Control group|
16283481|NCT04791969|Experimental|Naltrexone with ecological momentary intervention|Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)
16283482|NCT04791969|Placebo Comparator|Placebo with ecological momentary intervention|Placebo, intermittent with ecological momentary assessment (EMA)
16283483|NCT04791956|Experimental|Prebiotic|Inulin-type fructans
16283484|NCT04791956|Placebo Comparator|Placebo|Maltodextrin
16283485|NCT04791943|Experimental|Experimental Treatment - Melatonin|Premedication for three nights with 10mg melatonin
16283486|NCT04791943|Placebo Comparator|Control Treatment - Lactose|Premedication for three nights with lactose capsules
16283487|NCT04791917|Experimental|Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
16283488|NCT04791917|Sham Comparator|Sham Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
16283489|NCT04791891||Low Back Pain (LBP)|"Adult women and men with self-reported LBP.
~Inclusion Criteria for potential LBP participants
~At least 18 years old;
~Internet access;
~Fluent in English or French;
~Self-reported LBP.
~Exclusion Criteria: No exclusion criteria will be adopted in this study.
~Note: While our recruitment efforts will focus on the acute or subacute phases, previous experience suggests that individuals with chronic LBP (cLBP) will also respond. While not the focus of the Study, their longitudinal data will be valuable and affiliated projects may be interested in also recruiting cLBP participants. We will therefore accept all individuals who self-register for the study and will then filter the data based on specific research questions."
16283490|NCT04791878|Experimental|Mesenchymal stem cells|allogeneic bone marrow derived mesenchymal stem cells
16283491|NCT04791865|Active Comparator|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
16283492|NCT04791865|Experimental|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
16283493|NCT04791839|Experimental|Cohort A: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.
~Cohort A participants are those that have PD-L1 1-49%"
16283494|NCT04791839|Experimental|Cohort B: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.
~Cohort B participants are those that have PD-L1 ≥ 50%."
16283495|NCT04791826|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of HF in diabetes and the lack of an active order for SGLT2i therapy.
16283496|NCT04791826|No Intervention|No Alert|The CDS will not issue an on-screen alert.
16283497|NCT04791813||Exposure group|group of surgically treated unilateral cleft lip and palate Egyptian children aged 9_12years
16283498|NCT04791813||Control group|group of healthy Egyptian children aged 9_12years
16283499|NCT04791787|Active Comparator|Standard Weight Maintenance|Standard weight maintenance diet will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
16322834|NCT04519632||Parents|Qualitative interviews
16283500|NCT04791787|Active Comparator|Isocaloric Diet|Isocaloric diet will be provided for 10 days for subjects who are currently treated with a T2DM medication included in the inclusion criteria
16283501|NCT04791787|Active Comparator|Isocaloric Diet with Beta-hydroxy butyrate|Isocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
16283502|NCT04791774|Active Comparator|Protein group|Patients receive 20 grams of Intrinsically labelled milk protein.
16283503|NCT04791774|Experimental|Free amino acid group|Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine
16283504|NCT04791761|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Families will receive an opioid disposal education document.
16283505|NCT04791761|Experimental|Opioid pain control + Disposal Pouch|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Half of the families randomized to the opioid group will be further randomized to receive an opioid disposal bag + an opioid disposal education document. The pouch is a drug deactivation disposal pouch to dispose the opioid at home.
16283506|NCT04791761|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary or by email/mail if no appointment was scheduled.
16283507|NCT04791748|Experimental|Patients with chronic vestibular deficits|Patients aged 7 to 17 years with chronic vestibular deficits
16283508|NCT04791748|Active Comparator|Controls|Patients aged 7 to 17 years without chronic vestibular deficits
16283511|NCT04791722|Active Comparator|Wave 1|Properties in Wave 1 (n=4) will implement a smoke-free policy on January 1, 2020.
16283512|NCT04791722|Experimental|Wave 2|Properties in Wave 2 (n=4) will implement a smoke-free policy on May 1, 2020.
16283513|NCT04791722|Experimental|Wave 3|Properties in Wave 3 (n=4) will implement a smoke-free policy on October 1, 2020.
16283514|NCT04791709|Experimental|HOLA Group|Participants in this group will receive a multicomponent intervention for 16 weeks.
16283515|NCT04791683|No Intervention|Control|Infertile couples in the control group were selected by randomization, routine protocols in the clinic were applied
16283516|NCT04791683|Experimental|Experimental|"st interview: Application of data collection tools
~nd meeting: Sexual counseling (1 week after the first interview)
~rd interview: Sexual counseling (1 week after the first session)
~th meeting: Sexual counseling (1 week after the second session)
~th interview: Telephone interview (2 months after the first assessment)
~th interview: re-application of data collection tools, including the final evaluation"
16283517|NCT04791657||Patients without complications|Patients with uneventful recovery
16283518|NCT04791657||Patients with complications|Patients experiencing complications within 30 days postoperatively
16283519|NCT04791618|Active Comparator|Health360x only (High tech)|"Access to Health360x technology only for 6 months Behavioral: Health360x Participants will receive Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self- management skills. Every participant will view an orientation video which will include information on how to access Health360 from home and other internet connected devices; how to use activity monitors provided by the study and sphygmomanometer. They will receive an introduction to heart health curriculum, quizzes and discussion forums. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the Helath360x application will be available online and by phone.
~The Health360x application will send messages to participants in this arm reminding them to perform study related activities."
16283520|NCT04791618|Experimental|Health360x plus Coach (High tech High touch)|"Health360x technology plus health coach Behavioral: Health360x plus health coach Participants will receive all of the resources in Arm A and Health coach interactions.
~The Health coach will send messages to participants in this arm reminding them to perform study related activities. The coach interactions will be focused on helping with attainment of self- management behaviors"
16283521|NCT04791605|Experimental|Gait analysis of cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to cemented stem
16283522|NCT04791605|Experimental|Gait analysis of non-cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to non-cemented stem
16283523|NCT04791592|Active Comparator|Group PIFB|PIF block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
16283524|NCT04791592|Active Comparator|Group TTMPB|TTMP block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
16283525|NCT04791579|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
16283526|NCT04791579|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
16283527|NCT04791566|Active Comparator|Intestinal obstruction, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
16283528|NCT04791566|Placebo Comparator|Intestinal obstruction, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
16283529|NCT04791566|Active Comparator|Perforated viscus, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
16283530|NCT04791566|Placebo Comparator|Perforated viscus, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
16322835|NCT04519632||Healthcare Professionals|Qualitative interviews
16283531|NCT04791553|Experimental|Normal Hepatic Function|Group 1 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to Matching healthy subjects with normal hepatic function
16283532|NCT04791553|Experimental|Hepatic Impairment|Group 2 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to subjects with severe hepatic impairment
16283533|NCT04791540||Patients with trachestomy|Patients, attending a respiratory rehabilitation program, who underwent tracheostomy decannulation
16283534|NCT04791527|Experimental|Mind-body Intervention arm|Online yoga, meditation, behavior change tips, and nutrition tips
16283535|NCT04791514|Experimental|Treprostinil Palmitil Inhalation Powder - Dose Exploration|Participants will be administered a single dose of trepreostinil palmitil inhalation powder (TPIP). The first participant will be administered TPIP 112.5 μg. Dose levels for subsequent participants will be determined based on information collected for the previous participant(s) by a Safety Review Committee.
16283536|NCT04791501||Hypoxemic Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more and FiO2 of 0.3 or more.
16283539|NCT04791475|Experimental|Dexmedetomidne with 0.5% bupivacaine|1mcg/kg dexmedetomidine as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
16283540|NCT04791475|Active Comparator|Dexamethasone with 0.5% bupivacaine|4mg dexamethasone as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
16283541|NCT04791449|Experimental|Treatment-as-usual plus medically-supervised exercise (TAU-EX)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. Coincident with these appointments, ideally, they will also attend a medically-supervised exercise program supervised by the exercise physiologists of the Cardiac Rehabilitation facility. The exercise sessions will last no more than 1-hr per session. The maximum number of sessions possibly attended over the 12-wk intervention period is 36. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
16283542|NCT04791449|No Intervention|Treat-as-usual (TAU)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
16283543|NCT04791436||Mild Illness|Recovered COVID-19 patients who experienced a mild clinical course
16283544|NCT04791436||Moderate Illness|Recovered COVID-19 patients who experienced a moderate clinical course
16283545|NCT04791436||Severe Illness|Recovered COVID-19 patients who experienced a severe clinical course
16283546|NCT04791423|Experimental|Single dose of GRAd-COV2|1 single IM dose of GRAd-COV2 2 x 10^11 vp plus 1 dose of saline placebo after 21 days
16283547|NCT04791423|Experimental|Double dose of GRAd-COV2|2 repeated (21 days apart) IM dose of GRAd-COV2 1 x 10^11
16283548|NCT04791423|Placebo Comparator|Placebo|Two doses of saline placebo on day 1 and day 22
16283549|NCT04791410||Experimental group|patients who met the inclusion criteria were treated with RVLM decompression at the same time of facial nerve decompression.
16283550|NCT04791410||control group|Patients who met the inclusion criteria were followed up for 3 months before surgery
16283551|NCT04791397|Experimental|Group trial|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
16283552|NCT04791397|Experimental|Group control|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
16283553|NCT04791384|Experimental|Abemaciclib/Elacestrant|Abemaciclib and Elacestrant combination
16283556|NCT04791345|Experimental|Methylprednisone single-dose|Subjects receive a single dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
16283557|NCT04791345|Experimental|Methylprednisone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 7 days after administration in 20 fractions.
16283558|NCT04791345|Experimental|Deflazacort single-dose|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
16283559|NCT04791345|Experimental|Dexamethasone single-dose|"Subjects receive a single-dose treatment. Urine samples will be collected until 13 days after administration in 11 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration.
~Blood samples will be collected until 9 days after administration in 6 fractions: pre-administration and 24h, 48h, 72h, 120h and 192h post-administration."
16283560|NCT04791345|Experimental|Dexamethasone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 10 days after administration in 34 fractions. Blood samples will be collected until 13 days after the first administration.
16283561|NCT04791332|Experimental|Single Dose Cohort: Cohort 1 and 2|Participants will receive a single oral dose of JNJ-67953964 or a matching placebo on Day 1.
16283562|NCT04791332|Experimental|Multiple Dose Cohort: Cohort 3|Participants will receive multiple oral dose of JNJ-67953964 once daily or a matching placebo up to Day 14.
16283590|NCT04791137|Experimental|Standard imagery cognitive bias modification|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention derived from that implemented in previous studies.
16283833|NCT04789499|Experimental|Theophylline|400mg theophylline capsule diluted in 240 mL isotonic nasal saline lavage twice daily.
16283567|NCT04791306|Experimental|Exercise Training|All participants should increase their physical activity level to at least 150 min per week, guided with once a week supervised in-house training as well as an application for planning and documentation for home-based physical activity
16283568|NCT04791293||Group 1|Patients with postoperative complications
16283569|NCT04791293||Group 2|Patients without postoperative complications
16283570|NCT04791280||patients with systemic sclerosis|"On the day of inclusion, the faeces collection will be carried out by the patient using adapted equipment, either at the hospital or at home. In the case of a home collection, it will be carried out on the day of a planned hospital and preserved using equipment provided and tested to maintain the quality of the collection before storage.
~6 months after inclusion (+/- 2 months) a follow-up visit will be carried out and the patient will perform a second faecal sample.
~At the inclusion visit and at M6 the UCLA SCTC GIT 2.0 questionnaire will be completed by the patient."
16283571|NCT04791267|Experimental|Intervention|Community health navigator program for six months
16283572|NCT04791267|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program
16283573|NCT04791254||A - main study cohort|"This is the main study cohort. All patients with upper gastrointestinal (gastric, oesophageal and gastro-oesophageal) cancers attending the medical oncology clinic and commencing systemic therapy will be invited to participate.
~They will receive dietician support as part of their standard treatment. They will undergo assessments of body composition as part of this assessment"
16283574|NCT04791254||Sub-cohort B|This sub-cohort will be invited to undergo more detailed fitness testing in the form of cardio-pulmonary exercise testing in addition to their routine care in the main cohort
16283575|NCT04791254||sub-cohort C|This sub-cohort will be invited to undergo an assessment of gut hormone and cytokine levels in addition to their routine care in the main cohort
16283576|NCT04791254||Cohort D|This is a cohort of healthy volunteers invited to act as a control to cohort C and undergo the gut hormone assessment
16283577|NCT04791241|Experimental|check-list with ultrasound|check-list including lung ultrasound for the management of patients with acute respiratory failure at the emergency department during the COVID-19 era
16283579|NCT04791215||Prospective Sample Collection|Prospective sample collection from participants treated with pembrolizumab monotherapy at Columbia University Irving Medical Center under standard of care treatment. Prospective cohort subjects must consent to provide available archived tumor and blood for whole exome sequencing (WES) (matched tumor and normal) for creation of plasma ctDNA panels. The tumor sample must be from a site that was not previously irradiated or has progressed after radiation.
16283580|NCT04791215||Retrospective Sample Collection|Retrospective sample collection from participants that consent to provide genetic data from previous whole exome sequencing (WES) in the form of files for creation of plasma ctDNA panels.
16283581|NCT04791202|Experimental|Dextrose Group|Injection for Group A: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 15% dextrose mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
16283582|NCT04791202|Active Comparator|Methylprednisolone Acetate Group|Injection for Group B: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 40mg methylprednisolone acetate mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
16283583|NCT04791189||Patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Major male or female patient [18 to 45 years of age] with juvenile idiopathic arthritis reported before the age of 16.
~- Able to understand and complete the questionnaire online (speaking and reading French, with an internet connection for completion via RedCap°). ¬
~- Able to give informed consent to participate
~- Involving one's parents in the survey is not a prerequisite for inclusion."
16283584|NCT04791189||Parents of patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Parents of adult patients with JIA
~- Parents able to understand and complete the questionnaire online (speaking and reading French, having an internet connection for completion via Red Cap°).
~- Able to give informed consent to participate
~- The parents must have been in charge of the patient as a teenager."
16283585|NCT04791176|Experimental|Lenvatinib and IMRT|Concurrent Lenvatinib and IMRT, followed Lenvatinib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
16283586|NCT04791163|Experimental|Sub-ischial socket|Start using the sub-ischial socket for four weeks and be tested with this socket.
16283587|NCT04791163|Active Comparator|Ischial containment socket|Start using the ischial containment socket for four weeks and be tested with this socket.
16283588|NCT04791150|Experimental|Patient with cancer immunotherapy treatment|All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment.
16283589|NCT04791137|No Intervention|Monitoring|Participants complete weekly questionnaires (QIDS-SR, PMH, GAD-7) on a weekly basis but receive no intervention.
16283591|NCT04791137|Experimental|Standard imagery cognitive bias modification plus additional rationale and transfer instructions|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, but in addition are first presented with a more extended rationale for completing the training, and during each training session are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions.
16283592|NCT04791137|Experimental|Standard imagery cognitive bias modification with frequent brief sessions|"Participants are scheduled to complete a first introductory session then 40 brief (~5 min) sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 2 per day five days per week for each of the four training weeks. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 30.05.21."
16283593|NCT04791137|Experimental|Standard imagery cognitive bias modification with a less intensive schedule|"Participants are scheduled to complete a first introductory session then 11 further sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 3 sessions scheduled for each of the four training weeks. Sessions have fewer training scenarios than the Standard imagery cognitive bias modification condition and more varied task instructions. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 09.06.21."
16283594|NCT04791124||Typical Developing Subjects|EEG evaluation of typical developing subjects
16283595|NCT04791124||Down Syndrome Subjects|EEG evaluation of DS subjects
16283596|NCT04791098|Experimental|Stronger pre-transplant check-up|routine patient management + specific infectious diseases consultation
16283597|NCT04791098|No Intervention|Standard pre-transplant check-up|routine patient management + letter sent to nephrologist
16283598|NCT04791085||general surgeons|General surgeons who work at general or private hospitals in Greece
16283599|NCT04791072|Experimental|Telecoaching group|They will be given breathing exercise training and will be asked to do it every day for 8 weeks. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. They will be called by phone once a week and encouraging speeches will be made.
16283600|NCT04791072|Active Comparator|Control Group|They will be given breathing exercise training and will be asked to do it every day. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. There will be no interviews in the control group.
16283601|NCT04791059|Experimental|Combined analgesia group|Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
16283602|NCT04791059|Placebo Comparator|Control group|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
16283603|NCT04791046||By CDSS (MedicBK) Analysis|
16283604|NCT04791046||General practice|
16283605|NCT04791033||Adenomyosis|Patients with adenomyosis
16283606|NCT04791033||Other benign gynecological conditions|Patients with other benign gynecological conditions (i.e: myomas, endometriosis).
16283607|NCT04791020|Active Comparator|Lidocaine + paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
16283608|NCT04791020|Experimental|Lidocaine|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied.
16283609|NCT04791007|Experimental|Single dose administration (Part 1)|the dose of the drug (4g OB-002H (8.0 mg/g)) administrated once vaginally or rectally
16283610|NCT04791007|Experimental|Multidose administration (Part 2)|the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
16283611|NCT04790981|Active Comparator|selected physical therapy program group|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
16283612|NCT04790981|Active Comparator|motor imaginary training and selected physical therapy program group|"The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following.
~Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise"
16283613|NCT04790968|Experimental|PSMA-PET/MRI and PET/CT for detection of lymph node metastases.|"Each patients will undergo an MRI-, PET/MRI- and PET/CT-examination (on the same day) prior to treatment.
~Patients in the radiotherapy cohort will additionally undergo an MRI examination after hormonal treatment, before radiotherapy."
16283614|NCT04790942|Experimental|berberine hydrochloride group|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets
16283615|NCT04790942|Placebo Comparator|lifestyle intervention group|Lifestyle intervention group (CON) refers to healthy lifestyle education
16283639|NCT04790838||Reference Product|ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK
16283834|NCT04789499|Placebo Comparator|Placebo|500mg lactose capsule diluted in 240 mL isotonic nasal saline lavage twice daily.
16283616|NCT04790929|Experimental|Regular Muse Meditation System - No Coaching|Participants will join a 1.5-hour virtual onboarding session where they will complete their first Muse session. Participants will then be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks. If they wish to use the system more frequently within the 6 weeks, they will be encouraged to do so and will be able to choose between all the styles of meditation available in the Muse Meditation System (Mind, Heart, Breath, Body, Guided or Sleep Journeys). For any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
16283617|NCT04790929|Experimental|Regular Muse Meditation System - Additional Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 8 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
16283618|NCT04790929|No Intervention|Controls|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness, anxiety and depression and sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
16283619|NCT04790916|Experimental|RO7049665 3.5 mg|Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed.
16283620|NCT04790916|Experimental|RO7049665 7.5 mg|Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed.
16283621|NCT04790916|Placebo Comparator|Placebo|Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.
16283622|NCT04790903|Experimental|Venetoclax (Schedule A)|"Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below:
~Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows:
~Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5."
16283623|NCT04790903|Experimental|Venetoclax (Schedule B)|"Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below:
~Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows:
~Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10."
16283624|NCT04790877|Active Comparator|First sub-study: Glucose beverage|This intervention entails the intake of a beverage including 25 g of glucose.
16283625|NCT04790877|Experimental|First sub-study: Regular alcohol-free beer|This intervention entails the intake of regular alcohol-free beer including 25 of carbohydrates.
16283626|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (isomaltulose + maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 25 g of carbohydrates.
16283627|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (++ maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 25 g of carbohydrates.
16283628|NCT04790877|Active Comparator|Second sub-study: White bread + Water|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and water.
16283629|NCT04790877|Experimental|Second sub-study: White bread + Regular alcohol-free beer|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and regular alcohol-free beer (providing 14.3 g of carbohydrates).
16283630|NCT04790877|Experimental|Second sub-study: White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin)|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 14.3 g of carbohydrates.
16283631|NCT04790877|Experimental|Second sub-study: White bread + Alcohol-free beer enriched with ++ maltodextrin|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 14.3 g of carbohydrates.
16283632|NCT04790877|Active Comparator|Second sub-study: Extra-White bread + Water|This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
16283633|NCT04790864|Experimental|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|
16283634|NCT04790864|Active Comparator|Online large-group one-session treatment with post-treatment control exercise|
16283638|NCT04790838||Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
16283640|NCT04790825|Experimental|Intensive periodontal treatment|Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia.
16283641|NCT04790825|Active Comparator|Community-based periodontal care|Standard cycle of supragingival mechanical scaling and polishing.
16283642|NCT04790812|Placebo Comparator|Celecoxib plus Placebo|Single oral dose of celecoxib 200 mg with placebo 30 to 60 minutes prior to the dental procedure
16283643|NCT04790812|Active Comparator|Celecoxib plus Acetaminophen|Single oral dose of celecoxib 200 mg in combination with acetaminophen 1000 mg 30 to 60 minutes prior to the dental procedure.
16283644|NCT04790799|Experimental|Intervention group|Treatment in a hospital setting at Gentofte Hospital skin department with patient education, glove counselling, personal product screening by a chemistry engineer, extended allergy testing and the standard treatment of hand eczema.
16283645|NCT04790799|No Intervention|Control group|Treatment as usual (at a dermatologist office).
16283646|NCT04790786|Experimental|Lilly Bamlanivimab|The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset.
16283647|NCT04790786|Experimental|Regeneron Casirivimab + Imdevimab|The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
16283648|NCT04790786|Experimental|Lilly Bamlanivimab + Etesevimab|The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
16283649|NCT04790786|Experimental|Sotrovimab|The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
16283650|NCT04790773|No Intervention|Standard of care|Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
16283651|NCT04790773|Active Comparator|Alexa Education|Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.
16283652|NCT04790760|Experimental|Continuous Glucose Monitoring|Participants will wear a CGM device on the back of both their left and right arm for 6 weeks.
16283653|NCT04790747|Experimental|radiotherapy and CAR-T therapy|sequential radiotherapy and CAR-T cell therapy
16283654|NCT04790734|Experimental|Remimazolam Besylate|"Remimazolam continuous infusion of 0.1 to 0.2 mg/kg/h to reach a RASS score of -3 to 0.
~remifentanil continuous infusion of 4 to 9 ug/kg/h to reach a CPOT score of 0 to 2.
~The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician."
16283655|NCT04790734|Active Comparator|Propofol|"Propofol continuous infusion of 0.5 to 4 mg/kg/h to reach a RASS score of -3 to 0.
~remifentanil continuous infusion of 4 to 9 ug/kg/h to reach a CPOT score of 0 to 2.
~The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician."
16283656|NCT04790708|Experimental|Midgut NETs|75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
16283657|NCT04790708|Experimental|Pancreatic NETs|75 patients affected by non-functional and functional NETs arising from Pancreas.
16283658|NCT04790708|Experimental|Bronchial NETs|25 patients affected by non-functional and functional Bronchial NETs.
16283659|NCT04790708|Experimental|Sympathetic-Adrenergic axis NEts|25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
16283660|NCT04790708|Experimental|Other Nets|25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
16283661|NCT04790708|Experimental|Cancers of Unknown Primary Origin (CUP) NETs|25 patients affected by non-functional and functional unknown primary NETs
16283662|NCT04790695|Experimental|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
16283663|NCT04790682|Experimental|NSCLC patient in a metastatic stage eligible for 1st-line TT with immune checkpoint inhibitor.|
16283664|NCT04790669|Experimental|Daily adjustable progressive resistance exercises (DAPRE)|DAPRE technique, hot pack, stretching exercises.
16283665|NCT04790669|Experimental|Close kinetic chain exercises (CKC).|CKC exercises, hot pack, stretching exercises
16283666|NCT04790656|Active Comparator|Conventional Therapy|The control program will consist of progressive exercises according to each postoperative day. Two daily sessions with an average duration of 25 min will be performed. In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
16283667|NCT04790656|Experimental|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days
16283668|NCT04790643||Stage 1 - Development of the new cardiac risk stratification protocol|This will be a prospective cohort study, in which individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables that will be used to guide the elaboration of the cardiac risk stratification protocol. After this initial evaluation, the volunteers will be followed for 2 months during their habitual cardiac rehabilitation routine for the evaluation and registry of the occurrence of minor adverse events, defined as signs and symptoms (arrhythmias, blood pressure alterations, tachypnea, pallor, chest pain, cramps, muscle pain, fatigue, and nausea). The cardiac rehabilitation program in which the volunteers will be recruited is based on moderate-intensity aerobic exercise.
16283699|NCT04790461|Experimental|1. experimental group: face to face education+PMR exercise|The education and PMR exercises prepared in line with the face-to-face Roy adaptation model will be applied. In groups of 8-10 people, the first 4 sessions in rehabilitation centers will last for the first 4 sessions, and then PMR exercises will be taught and applied (between the 2nd and the 5th weeks, they will be encouraged to do PGE twice at home). The next 4 weeks will be provided with PMR consultancy (3 times a week application / total 24 sessions of PMR application). PMR exercises will be given a follow-up schedule and the caregivers will be followed up by the caregivers themselves and the researchers.
16283669|NCT04790643||Stage 2 - Reproducibility and efficiency of the new protocol|"This will be a prospective cohort study, in which a new sample of individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables and stratified in one of the three following risk classes: low risk, moderate risk, and high risk accordingly to the new risk stratification protocol. After that, the sample will be followed for 2 months of rehabilitation to the evaluation of the occurrence of signs and symptoms. The cardiac rehabilitation program from where the volunteers will be recruited is based on moderate-intensity aerobic exercise and resistance training. With these data, the reproducibility and efficiency of the protocol will be evaluated."
16283670|NCT04790643||Stage 3 - Protocols´ agreement between evaluators|This will be a cross-sectional observational study in which a new sample of participants will be evaluated by two independent physiotherapists for clinical and physical variables, and based on these data will be stratified by the new protocol by the same evaluators independently. After these procedures, the protocol´s agreement between evaluators will be analyzed.
16283671|NCT04790630|Experimental|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|
16283672|NCT04790630|Active Comparator|Active Control|
16283673|NCT04790617|Experimental|Intervention|Community health navigator program for six months.
16283674|NCT04790617|No Intervention|Control|Usual health care.
16283675|NCT04790604|Experimental|Intervention|Community health navigator program for six months.
16283676|NCT04790604|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program.
16283677|NCT04790591|Active Comparator|Age <80 yrs. and ASA class <3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
16283678|NCT04790591|Active Comparator|Age ≥80 yrs. and/or ASA class ≥3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
16283679|NCT04790578|Experimental|ZoeInsights Application Arm|Participants will receive free access to the ZI app for the 12-week intervention. After completing initial set-up, participants will be asked to record physical activity and symptoms regularly via scheduled in-app routines. Further use of ZI (eg. Custom daily routines, additional graphing, medication tracking, accessing linked health resources) during the intervention will be possible ad libitum. After the initial 12-weeks of the EXCEL+ZI intervention, participants have continued free access to the ZI app for up to 1 year.
16283680|NCT04790578|Active Comparator|Waitlist control|During the 12-week intervention the participants will only take part in an online delivered EXCEL exercise class and will not have access to the ZI app. After completion of the 24-week test, the participants will be granted access to the ZI app.
16283681|NCT04790565|Experimental|Fecal microbiota transplantation (FMT)|Patients will be given capsulized FMT, 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Patients will continue fasting for 2 hours after the intervention. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
16283682|NCT04790552|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
16283683|NCT04790552|Experimental|Night Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will consume a Fast Bar 3 hours after the dinner and then fast overnight. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
16283684|NCT04790552|Experimental|Bar + Coffee Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
16283685|NCT04790552|Experimental|Bar + Tea Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with tea on day 2.
16283686|NCT04790539|Experimental|SHR-1210+Paclitaxel-albumin+Carboplatin|SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first day of each cycle, with intravenous drip.
16283687|NCT04790526|Experimental|Group A|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
16283688|NCT04790526|Experimental|Group B|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
16283689|NCT04790526|Experimental|Group C|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
16283690|NCT04790526|Experimental|Group D|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
16283691|NCT04790513|Experimental|LIB003 (lerodalcibep)|300 mg SC Q4W
16283692|NCT04790513|Active Comparator|evolocumab|420 mg SC Q4W
16283693|NCT04790513|Active Comparator|alirocumab|300 mg SC Q4W
16283694|NCT04790500|Active Comparator|Group A|mobilization technique
16283695|NCT04790500|Experimental|Group B|muscle energy technique
16283696|NCT04790487|Experimental|Chlorpheniramine|Chlorpheniramine (CPM)
16283697|NCT04790487|Placebo Comparator|Control|Saline
16283698|NCT04790474|Experimental|ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment|Prospective study of ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment for patients with relapsed and refractory multiple myeloma (RRMM) previously treated with daratumumab, lenalidomide and bortezomib
16283700|NCT04790461|Experimental|2. experimental group: mobile health education + PMR exercise|Access to mobile applications will be provided for 8 weeks, including the Roy adaptation model-based training and PMR exercises, which include video and training presentations prepared by the consultant and researcher, as a power point presentation. PMR exercises will be uploaded to the system by uploading a follow-up schedule to the system, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers can follow the participants.
16283701|NCT04790461|Experimental|3rd experimental group: face to face and mobile health education + PMR exercise|4 sessions prepared in line with the Roy adaptation model face to face and held in rehabilitation centers, training in groups of 8-10 people, teaching PMR exercises and installing phone applications that can be accessed for 8 weeks), 8-week intervention including training (enabling them to do progressive relaxation exercises and access to training content) will be provided. . The PMR exercises will be uploaded to the system / given as a printout according to the caregiver's preference, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers watch the participant.
16283702|NCT04790461|Other|Control group|Without applying any intervention, the post-test YBYKA, ASÖ and SBÇYA scales will be applied in the 10th week of the study. After all the tests for the study are measured and finished, they will be provided with training and relaxation exercises.
16283703|NCT04790448|Experimental|VIC regimen|"Patients will receive VIC regimen every 2 weeks:
~Cetuximab 500mg/m2 IV on Day 1; Irinotecan 180mg/m2 IV on Day 1 (If patient carries UGT*28 7/7 or UGT*6 A/A or UGT*28 6/7 and UGT*6 A/G variants, use Irinotecan IV 150mg/m2 instead); Vemurafenib PO BID on Days 1 to 14 (Dosage: 480mg; 720mg; 960mg, determined by the maximum tolerated dose (MTD) in Phase Ia trial)."
16283704|NCT04790422|Experimental|Dietary fiber 1|
16283705|NCT04790422|Experimental|Dietary fiber 2|
16283706|NCT04790422|Experimental|dietary fiber 3|
16283707|NCT04790422|Experimental|caseine protein hydrolisate|
16283708|NCT04790422|Placebo Comparator|Maltodextrine|
16283709|NCT04790409|Experimental|Sintilimab with anlotinib|
16283710|NCT04790396||Patient presenting at emergent department with cardiac arrest|
16283711|NCT04790383|Experimental|Advanced Self-Adhesive resin composite hybrid restorations|(Surefil one (Dentsply Sirona)).
16283712|NCT04790383|Active Comparator|Conventional resin composite restoration.|Sphere Tec, (Dentsply Sirona)
16283713|NCT04790370|Active Comparator|Anticoagulation|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
16283714|NCT04790370|Active Comparator|Anticoagulation and EkoSonicTM Endovascular System|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
16283715|NCT04790357|Other|Reference strategy|correspond to the reference techniques according to the current guidelines in the etiological work up of ischemic strokes and TIA
16283716|NCT04790357|Other|Evaluated strategy|correspond to perform the cci-MR: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
16283717|NCT04790344|Experimental|Treatment Arm|All study subjects belong to Treatment Arm, which is receiving investigational LUX-Dx ICM device.
16283718|NCT04790331|Experimental|verapamil group|verapamil group who will receive verapamil 80 mg PO 3 hours preoperative
16283719|NCT04790331|Experimental|Ditiazim|Diltiazim group will receive Diltiazim 90mg PO 3 hours preoperative
16283720|NCT04790331|Experimental|placebo group|Placebo oral tablet
16283721|NCT04790318|Active Comparator|General Anesthesia +TiQLB|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume limited to 20 ml
16283722|NCT04790318|Active Comparator|General Anesthesia+ Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
16283723|NCT04790305|Experimental|Huaier Granule + Conventional Treatment/visit|"Huaier Granule: oral administration, 20g each time, 3 times a day. The starting time of Huaier granule: from the beginning of adjuvant therapy to the end of adjuvant therapy, and within 60 days after the end of adjuvant therapy is also acceptable.
~Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine."
16283724|NCT04790305|No Intervention|Conventional Treatment/visit|Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine.
16283725|NCT04790292|Active Comparator|group M|group M 10mg morphine +0.25% bupivacaine
16283726|NCT04790292|Active Comparator|group MD|group MD 10mg morphine + 8mg dexamethasone +0.25% bupivacaine
16283727|NCT04790279|Experimental|Amlodipine|
16283728|NCT04790279|Active Comparator|Nifedipine ER|
16283729|NCT04790253|Active Comparator|PCI followed by brain MR surveillance|"Prophylactic cranial irradiation will be delivered at the dose of 25 Gy in 10 fractions to the whole brain.
~Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 months.
~Extracranial imaging is recommended and will be performed per institutional standards at the discretion of the treating physician."
16283730|NCT04790253|No Intervention|MRI Active Surveillance|Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 month. Clinical evaluation will be performed every 3 months.
16283731|NCT04790240|Active Comparator|Inflammation (I)|"Upper respiratory inflammation.
~Fever.
~Lower respiration inflammation."
16283732|NCT04790240|Active Comparator|Inflammation (II)|Cough, chest pain
16283733|NCT04790240|Active Comparator|Inflammation (III)|"Metabolites
~Clots"
16283734|NCT04790214|Experimental|Stable CHF patients|Stable CHF patients on stage II/III based on the New York Heart Failure classification
16283735|NCT04790201|Experimental|Friendship Bench Delivered by Professional Counselor|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a professional counselor. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the adapted FB protocol (Aim 1).
16283827|NCT04789551||Control patients|Patients without any immunological diseases who present for elective surgery.
16283828|NCT04789538||Monofocal IOL|
16283736|NCT04790201|Experimental|Friendship Bench Delivered by Lay Counselor|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a trained lay counselor. Individuals enrolled in this arm arm will receive 6 weekly counselling sessions per the adapted FB protocol (Aim 1).
16283737|NCT04790201|Active Comparator|Enhanced Usual Care|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care.
16283738|NCT04790188|Experimental|Experimental intervention first.|Participants randomized to receive the nootropic first.
16283739|NCT04790188|Placebo Comparator|Experimental intervention second.|Participants randomized to receive the placebo first
16283740|NCT04790162|Active Comparator|Meditation Intervention|Heartfulness meditation
16283741|NCT04790162|No Intervention|Control|Wait listed control group
16283742|NCT04790149|Sham Comparator|Conventional Group|Conventional usual Rehabilitation is administered to a group of patients without any effect on their recovery
16283743|NCT04790149|Experimental|NEUROM|participants received the new protocol of a method called NEUROM consisting of 3 phases of treatment : Motor Imagery training, active rehabilitation and functional rehabilitation
16283744|NCT04790149|Experimental|NEUROM combined with tDCS|same as the second arm of NEUROM combined with transcranial direct stimulation
16283745|NCT04790136|Experimental|GLA-015|GLA-015 (Glatt Pharmaceutical Services GmbH & Co. KG, Germany); 5.051 g granules containing 1500 mg cannabidiol to be dispersed in water; oral multiple dose administration twice daily over 7 consecutive days after a light meal
16283746|NCT04790136|Active Comparator|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|"DAC C-052 Cannabidiol / NRF 22.10 Ölige Cannabidiol-Lösung 100 mg/ml (Oily cannabidiol solution 100 mg/ml) (Glatt Pharmaceutical Services GmbH & Co. KG, Germany; according to DAC/NRF specifications); 15 ml solution containing 1500 mg cannabidiol; oral multiple dose administration twice daily over 7 consecutive days after a light meal"
16283747|NCT04790123|Sham Comparator|Control group|
16283748|NCT04790123|Experimental|Experimental group|
16283749|NCT04790110||Studie A ESO - monitoring|Patients that present themselves at the clinic through referral from their dentist with tooth wear, who have no request for help, receive a non-restorative 'counseling & monitoring' strategy , in which appropriate preventive measures are recommended and wear and tear is monitored and recorded by periodically taking intra-oral photographs and 3D scans
16283750|NCT04790097|Experimental|Simultaneous In-Field Boost on FET-PET positive target volumes|
16283751|NCT04790084||Healthy-Myopia-CSC|Cross-sectional study, no intervention, only collecting OCT,OCTA images and other eye parameters of patients.
16283752|NCT04790071|Active Comparator|Conventional therapy|It covers the classical physical therapy modalities that patients will take for shoulder pain.
16283753|NCT04790071|Active Comparator|Conventional therapy plus dry needling|It covers the classical physical therapy modalities that patients will take for shoulder pain. It also refers to the dry needling treatment to be applied.
16283754|NCT04790058||Physicians using CSRS practice recommendation to treat syncope patients in ED.|During the control period, there will be no interventions. The intervention is the knowledge translation of the CSRS practice recommendations.The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. The ED physician or non-ED physician performing consultation on the patient can apply all the components of the practice recommendation and decide disposition of the patients who are eligible to be studied.
16283755|NCT04790045|Other|Venetoclax-based treatment|Single-arm study Patients enrolled will be receiving venetoclax-based regimens according to the standard of care
16283756|NCT04790019|Experimental|Low energy availability|Intervention involves three of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day.
16283757|NCT04790019|Experimental|Low energy availability and high impact jumping|Intervention involves three days of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day and brief high impact jumping exercise performed daily in the morning and in the evening.
16283758|NCT04790006|Experimental|TG103|TG103 will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
16283759|NCT04790006|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
16283760|NCT04789980||Patients|Patients with locally advanced or metastatic pancreatic cancer who plan to receive palliative chemotherapy
16283761|NCT04789967|Active Comparator|Guided Imagery (GI)|A 8 minute audio that focuses on evoking mental images in reducing the abdominal bloating sensation in patients
16283762|NCT04789967|Active Comparator|Progressive Muscle Relaxation (PMR)|A 8 minute audio that focuses on contracting certain muscle groups and relaxing it progressively in reducing the abdominal bloating sensation in patients
16283763|NCT04789967|Placebo Comparator|Audiobook|A 8 minute audio that focuses on providing educational information regarding functional gastrointestinal disorders and related knowledge.
16283764|NCT04789954|Experimental|AryoSeven 10 μg/kg|Single dose, intravenously
16283765|NCT04789954|Experimental|AryoSeven 30 μg/kg|Single dose, intravenously
16283766|NCT04789954|Experimental|AryoSeven 90 μg/kg|Single dose, intravenously
16283767|NCT04789954|Experimental|AryoSeven 270 μg/kg|Single dose, intravenously
16283768|NCT04789954|Active Comparator|NovoSeven 30 μg/kg|Single dose, intravenously
16283829|NCT04789525|Experimental|Group A (high-intensity aerobic training with high protein diet )|
16283830|NCT04789525|Experimental|Group B(regular physical activities and taken regular diet)|
16283831|NCT04789512||Covid-19 players|Female volleyball players with Covid-19
16283769|NCT04789941|Experimental|Single arm of patients with locally advanced cancer cervix|"Single arm study to assess the efficacy and safety of use of neoadjuvant cisplatin and irinotecan in treatment of patients with locally advanced cancer cervix.
~A combined regimen of intravenous infusion of cisplatin 80mg/m2 on day 1 with irinotecan 60mg/m2 on day 1 and day 8 of every 21- day cycle for 3 cycles.
~Then, MRI pelvis will be used for assessment of disease response. According to RECIST criteria, patients who will develop at least stable disease, will be sent for radical hysterectomy. Afterwards, 6 weeks after the surgery, another 3 cycles of the same regimen will be given to the participants as adjuvant treatment."
16283770|NCT04789928|Experimental|Patients with uncomplicated LTIVC-related BSI and eligible|Patients included in this study will receive daily injection of genta-EDTA-Na2 lock associated with systemic antibiotics.
16283771|NCT04789915|Active Comparator|Memantine + amisulpride|"Tablet memantine or placebo will be initiated at 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. The tablets will be identical and be provided in 10mg tablets or 20 mg tablets. (12 weeks of treatment).
~Tablet amisulpride will be administered in doses starting at 50-100mg/day. Doses will be increased slowly according to effect and side effects up to 800mg/day."
16283772|NCT04789915|Placebo Comparator|Placebo + amisulpride|"Coated placebo tablets will be provided to match memantine. Placebo equivalent of 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. (12 weeks of treatment).
~Tablet amisulpride will be administered in doses starting at 50-100mg/day. Doses will be increased slowly according to effect and side effects up to 800mg/day."
16283773|NCT04789902|Experimental|Hospital site 1|This site will provide usual ED care during the control period which will last for the first six months of the study. After six months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
16283774|NCT04789902|Experimental|Hospital site 2|This site will provide usual ED care during the control period which will last for the first 12 months of the study. After 12 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
16283775|NCT04789902|Experimental|Hospital site 3|This site will provide usual ED care during the control period which will last for the first 18 months of the study. After 18 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
16283776|NCT04789902|Experimental|Hospital site 4|This site will provide usual ED care during the control period which will last for the first 24 months of the study. After 24 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
16283777|NCT04789889|Experimental|IORT|intraoperative radiotherapy(IORT) in BCS.
16283778|NCT04789889|Active Comparator|PORT|traditional postoperative radiotherapy following BCS.
16283779|NCT04789876|Experimental|App Intervention Group (AIG)|Phosphate mobile app for 12 weeks.
16283780|NCT04789876|Active Comparator|Dietitian Intervention Group (DIG)|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study.
16283781|NCT04789863|Other|Intervention group|Intervention group (IG) patients will receive usual care plus the SMILe-ICM (see below) when they come to their planned follow-up appointments at the University Hospital Basel. Thus, while IG participants will receive the same number of follow-up appointments as CG participants (depending on their state of health), they will also receive the SMILe-ICM, i.e., tailored self-management and behavioural support delivered by the combination of totally 12 face-to-face meetings with a Care Coordinator (CC) and the SMILeApp. The personal meetings with the CC will last around 40-90 minutes. The first three of them will occur during the initial alloSCT hospitalization, and the other nine will occur in the outpatient setting, beginning with biweekly and expanding to bi-monthly intervals until one year post-alloSCT.
16283782|NCT04789863|Other|Control group|"see Intervention section"
16283783|NCT04789850|Experimental|Itacitinib|200mg of oral Itacitinib everyday for 360 days.
16283784|NCT04789850|Placebo Comparator|Placebo|Oral placebo everyday for 360 days.
16283785|NCT04789837|Experimental|Cilostazol|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
16283786|NCT04789837|Placebo Comparator|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
16283787|NCT04789824|Experimental|Investigation group|Eye Hygiene (warm compress, eyelid massage, and eyelid cleaning)
16283788|NCT04789824|No Intervention|Control Group|No intervention
16283789|NCT04789811|Experimental|Exercise Group|It describes the exercise protocol that the patients will do.
16283790|NCT04789811|Experimental|Exercise plus Dry Needling Group|It describes the exercise protocol to be performed by the patients and the methodology of dry needling to be applied.
16283791|NCT04789798|Experimental|TeleDiab (Telemedicine)|"TeleDiab program components consist of:
~Electronic transmission of capillary blood glucose measurement results
~Electronic transmission of blood pressure measurements
~Synchronized video-conferencing, secure messaging
~Access to clinical data from patient files when necessary
~Reminding of routine follow-up tests and examinations
~Providing web-based educational materials to patients."
16283792|NCT04789798|Active Comparator|Usual Care|usual diabetes care, as provided by primary care providers in the hospital
16283793|NCT04789772|Experimental|Laser acupuncture group|Laser acupuncture group receive laser acupuncture treatment with cognitive behavioral therapy.
16283794|NCT04789759|Experimental|Socket Preservation Alloplastic Material|"10 Consecutive Patients with hopeless teeth and 1/3 or more buccal bone resorption will be placed in a therapy go bone regeneration called socket preservation technique.
~The surgery will include placement of 2/3 biphasic calcium sulfate cement matrix's with hydroxyapatite (HA granules) to fill the alveolar defects, and place a resorbable membrane sutured to adjacent tissue, to avoid material leakage.
~No flap retraction. 3 Month later an implant will be placed, and a bone biopsy of the healed socket harvested. 2 Month later a final Zirconia ceramic crown screw retained to the osseointegrated implant.
~Primary (T0) and Secondary (T1) stability measured with ISQ values.
~Intraoral Scanner and an STL File will be taken at T0 , T1 and T2 for volumetric alteration evaluation."
16283795|NCT04789759|Active Comparator|Extraction Socket Spontaneous Healing|10 Consecutive patients with a tooth extraction without the aim of placing a future implant and without Biomaterial filler placed in the socket. Spontaneous healing
16283796|NCT04789746|Experimental|Running group|Participants that will join the running program.
16283832|NCT04789512||non-Covid-19 players|Female volleyball players with non Covid-19
16283797|NCT04789733|Experimental|Tight pressure management|"Patients assigned to tight blood pressure control angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.
~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.
~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
16283798|NCT04789733|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
16283799|NCT04789720|Experimental|SyMon-SAYS Intervention (Group A)|Group A participants will receive the SyMon-SAYS intervention every week for 16 weeks.
16283800|NCT04789720|Other|SyMon-SAYS Waitlist Control (Group B)|The waitlist control group participants (Group B) will receive their usual care during weeks 1-8 and will receive the SyMon-SAYS intervention every week during weeks 9-16.
16283801|NCT04789707||KERATOCONUS group|"All workers with keratoconus all stages followed at the service of ophthalmology in CHU Gabriel Montpied, Clermont-Ferrand, Auvergne.
~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
16283802|NCT04789707||CONTROL group|"workers with good visual acuity consulting in ophthalmology service of Clermont-Ferrand.
~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
16283803|NCT04789694|No Intervention|A|Standard care support
16283804|NCT04789694|Experimental|B|Low intensity support
16283805|NCT04789694|Experimental|C|High intensity support
16283806|NCT04789681|Experimental|Prevention (canakinumab)|Patients receive canakinumab SC on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16283807|NCT04789668|Experimental|Treatment (bintrafusp alfa, pimasertib)|Patients receive bintrafusp alfa IV over 1 hour every 2 weeks and pimasertib PO BID on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16283808|NCT04789655|Experimental|CC-96191|CC-96191 will be administered intravenously on a 28-day Cycle
16283809|NCT04789642|Experimental|study group|A social group will be created on whatsapp for subjects of the intervention group and they will receive education about blood pressure measurement guidelines in 24 sessions, once per day in the form of text, image and video clips. In addition to British and Irish Hypertension Society (BIHS) blood pressure measurement auscultatory tutorials.
16283810|NCT04789642|No Intervention|control group|The control group will not receive any intervention only their routine education that is provided by the continuous staff development team of the hospital.
16283811|NCT04789629|Active Comparator|low level laser , physiotherapy|Instrumentation Diode laser device will use for biostimulation of the muscle fiber . The device has a wavelength of 808 nm and a power output 0-250 mW. parameters of laser : Wavelength 808 nm Power output 100 mW Spot size 0.0314 cm2 Power density 3,18 W/cm2 Treatment time per point 40 s Energy density per point 4,77 J/cm2 Energy per point 4 J 12 sessions for one month with traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training .)
16283812|NCT04789629|Active Comparator|physiotherapy|traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training ) for one hour
16283813|NCT04789616|Experimental|Maraviroc (Celsentri)|Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).
16283814|NCT04789616|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks)."
16283815|NCT04789603|Active Comparator|Without Mask Group|Patients who will perform the 6-min walk test without mask
16283816|NCT04789603|Active Comparator|Surgical Mask|Patients who will perform the 6-min walk test with surgical mask
16283817|NCT04789603|Experimental|Fpp2 Mask|Patients who will perform the 6-min walk test with Fpp2 mask
16283818|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 1_B Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03B adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
16283819|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 1_A Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03A adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
16283820|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 2_B Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03B adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
16283821|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 2_A Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03A adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
16283822|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 3_B Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03B adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
16283823|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 3_A Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03A adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
16283824|NCT04789577|Placebo Comparator|Placebo Group|Healthy male and female participants who will receive two doses of placebo, the first dose at Day 1 and the second dose at Day 22
16283825|NCT04789551||Multiple Sclerosis Stable Conditions|Multiple sclerosis patients presenting for a routine clinic visit.
16283826|NCT04789551||Multiple Sclerosis Acute Flare Up|Multiple sclerosis patients admitted to the hospital with acute symptoms.
16283835|NCT04789486|Experimental|AGUIX + SMART Phase 1|"Dose escalation of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
~Central non-small cell lung cancer-NSCLC cohort will receive:
~five fractions of stereotactic body radiation therapy (SBRT)
~AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation and for patients receiving radiation over a two (2) week period with the 4th fraction of radiation .
~Locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC cohort, will receive:
~five fractions of stereotactic body radiation therapy (SBRT)
~AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation."
16283836|NCT04789486|Experimental|AGUIX + SMART Phase 2|Randomized participants will receive recommended phase 1 dose established for their disease group (central non-small cell lung cancer-NSCLC or locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC) of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
16283837|NCT04789486|Experimental|SMART Phase 2|Randomized participants will receive standard of care SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
16283838|NCT04789473||Control Normal Glycemic Pregnancy|Cohort of control adults who are currently pregnant or have been pregnant within the last year, but were not diagnosed with gestational diabetes.
16283839|NCT04789473||Gestational Diabetic Cohort|Cohort of adults who are currently pregnant or have been pregnant within the last year, but were diagnosed with gestational diabetes.
16283840|NCT04789460||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT in two tertier hospital in Istanbul
16283841|NCT04789447||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT
16283842|NCT04789434|Experimental|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose：200mg frequency：1 time for 2 months duration：2 years
16283843|NCT04789434|No Intervention|No intervention|No intervention
16283844|NCT04789421|Active Comparator|Arm 1 (interventional)|Patients with equivocal skin lesions suspicious for melanoma, randomised to adjunctive RCM evaluation, following clinical and dermoscopy evaluation.
16283845|NCT04789421|Placebo Comparator|Arm 2 (control)|Patients with equivocal skin lesions suspicious for melanoma, randomised to clinical and dermoscopy evaluation only; adjunctive RCM evaluation refused.
16283846|NCT04789408|Experimental|KITE-222|"Dose Escalation: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-222 to determine the maximum tolerated dose (MTD) of KITE-222.
~Dose Expansion: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose (at the MTD determined) of KITE-222."
16283847|NCT04789382|Other|Sequence 1|LID018869+RepleniSH in the right eye and Biofinity+RepleniSH in the left eye (first wear period), followed by PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
16283848|NCT04789382|Other|Sequence 2|Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (first wear period), followed by LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
16283849|NCT04789382|Other|Sequence 3|LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (first wear period), followed by Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
16283850|NCT04789382|Other|Sequence 4|PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (first wear period), followed by LID018869+RepleniSH in the right eye and Biofinity+RepleniSH the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
16283851|NCT04789356|Active Comparator|High-risk individuals (with comorbidities)|Public safety and security (police officers and law enforcement, fire department), and high school and college/university professionals of the state government public education network who present at least one of the comorbidities included in the National Plan for the Operationalization of Vaccination Against COVID-19 will be invited to receive the CoronaVac vaccine
16283852|NCT04789356|No Intervention|Low-risk individuals (without comorbidities)|Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project.
16283853|NCT04789343|Experimental|hand files with lateral condensation technique|Previously done root canal filling removed by hand files (Hedstrom file,VDW, Munich,Germany ) and shaped with the same files and after instrumentation, all canals were filled by AH Plus sealer (Dentsply De Tray, Costanz, Germany) and lateral condensation technique of gutta-percha.
16283854|NCT04789343|Experimental|Reciproc instrument with lateral condensation technique|Previous root canal filling removed by Reciproc instrument (VDW ,Munich, Germany )using Endomotor (VDW, Munich, Germany). After removal, root canal instrumented with the same instrument and obturated using AHPlus sealer with lateral condensation technique of gutta-percha.
16283855|NCT04789343|Experimental|Reciporoc instrument with continuous warmed condensation technique|Previous root canal removed by Reciproc instrument using Endomotor, shaped and obturated by AhPlus sealer with continuous gutta-percha technique (Diadent Dia-Duo (Diadent, Chongju, Korea).
16283856|NCT04789330|Active Comparator|Norepinephrine|Norepinephrine continuous infusion as the first line vasopressor
16283857|NCT04789330|Active Comparator|Phenylephrine|Phenylephrine continuous infusion as the first line vasopressor
16283888|NCT04789096|Experimental|PD-L1 negative|"Participants will receive:
~Tucatinib (oral) at a dose of 300 mg BD on day 1-21
~Capecitabine (oral) at a dose of 1000 mg/m^2 BD on day 1-14 of each 21-day cycle
~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle (or 400 mg IV every 6 weeks)
~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle."
16283889|NCT04789083|Experimental|Group 1 (Propolis)|Medical therapy and propolis
16283858|NCT04789317||Stable CAD or stabilized NSTEMI (ACS) with significant epicardial lesions defined as FFR≤0.80.|The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.
16283861|NCT04789291|Experimental|Fed state (Test, T) - Fasted state (Reference, R)|
16283862|NCT04789291|Experimental|Fasted state (Reference, R) - Fed state (Test, T)|
16283863|NCT04789278|Experimental|Notification|"Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or postal mail that will inform them of the CAC identified on their previous chest CT. It will provide an overview of CAC, an image of their chest CT, and a recommendation that they discuss this finding with their clinician. These clinicians will be notified of these findings via an earlier EHR message. Any treatment decisions will be made by the patient and their clinician.
~Patients randomized to notification who are not prescribed a statin medication and do not have a documented discussion regarding statin therapy within three months will be sent a second message at that time. Their primary care providers will receive a second EHR message concurrently."
16283864|NCT04789278|No Intervention|Usual Care|Both arms have previously had their CT scans reported according to standard clinical practice. This may include notification of the CAC in the imaging report. The usual care arm will not receive any additional notification beyond this standard of care during the project.
16283865|NCT04789265|Experimental|Combined Therapy (Instrumented Soft Tissue Mobilization)|
16283866|NCT04789265|No Intervention|Control Group (Exercise Therapy)|
16283867|NCT04789252||Patients with NSCLC or with colon cancer|"The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent.
~The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice.
~It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes"
16283868|NCT04789239|Experimental|SZC + MRA treated heart failure patients|"Optimal dose of SZC, which is an approved drug for hyperkalemia in Sweden.
~The subject is treat with 5 mg daily however it can be reduced to once every second day, or inreased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with a mineralcorticoid receptor antagonist (spironolacton or eplerenon), 25 mg or 50 mg depending on what dose they could tolerate."
16283869|NCT04789239|Placebo Comparator|Placebo + MRA treated heart failure patients|The subject is treat with placebo drug, 5 mg once daily, however it can be reduced to once every second day, or increased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with the dose of mineralcorticoid receptor antagonist (spironolacton or eplerenon) 25 mg or 50 mg depending on what dose they could tolerate.
16283870|NCT04789213||Patients with Living Donor Liver Transplantation|
16283871|NCT04789213||Patients with Deceased Donor Liver Transplantation|
16283872|NCT04789200|Experimental|NX9 oral contrast agent|Subjects will be given a 9% w/w HBGM concentration of NX9 provided as 1.2L of liquid.
16283873|NCT04789187|Active Comparator|Arm A: Exercise intervention arm|
16283874|NCT04789187|Placebo Comparator|Arm B: Control arm|
16283877|NCT04789161||double kissing crush stenting|patients with true bifurcation lesion undergoing double kissing crush stenting
16283878|NCT04789161||double kissing culotte stenting|patients with true bifurcation lesion undergoing double kissing culotte stenting
16283879|NCT04789148|Experimental|4 IU oxytocin - 24 IU oxytocin - placebo|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: intranasal placebo
16283880|NCT04789148|Experimental|4 IU oxytocin - placebo - 24 IU oxytocin|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 24 IU intranasal oxytocin
16283881|NCT04789148|Experimental|24 IU oxytocin - 4 IU oxytocin - placebo|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: intranasal placebo
16283882|NCT04789148|Experimental|24 IU oxytocin - placebo - 4 IU oxytocin|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 4 IU intranasal oxytocin
16283883|NCT04789148|Experimental|Placebo - 4 IU oxytocin - 24 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: 24 IU intranasal oxytocin
16283884|NCT04789148|Experimental|Placebo - 24 IU oxytocin - 4 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: 4 IU intranasal oxytocin
16283885|NCT04789135|Experimental|Ozone Therapy|Administration of intravesical ozone gas in patients with Interstitial cystitis/bladder pain sydrome
16283886|NCT04789109|Experimental|CapTemY90|"Capecitabine 600 mg/m2 twice daily for 14 days and temozolomide 150-200 mg/m2 in two divided doses on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities.
~During the initial cycle of CapTem, simulation angiography for Y-90 radioembolization planning will be performed. Once the patient has successfully completed the first cycle of CapTem and undergone simulation demonstrating eligibility for Y-90 radioembolization, the dominant lobe will be treated on Day 7 of the 2nd cycle of CapTem. Resin microspheres will be prescribed according to the BSA method per the manufacturer's Instructions for Use. If the other hepatic lobe needs to be treated, this will be done on Day 7 of the 3rd or 4th cycle of CapTem."
16283887|NCT04789096|Experimental|PD-L1 positive|"Participants will receive:
~Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle
~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle (or 400 mg IV every 6 weeks)
~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle."
16283890|NCT04789083|Experimental|Group 2 (Nurse Coaching/ Nursing education)|Medical treatment and nurse coaching
16283896|NCT04789044|Experimental|PEG fusion mediated repair|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
16283897|NCT04789044|Experimental|PEG mediated reconstruction|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
16283898|NCT04789044|No Intervention|conventional nerve repair|Standard nerve repair
16283899|NCT04789044|No Intervention|conventional nerve reconstruction|standard nerve reconstruction
16283900|NCT04789031|Experimental|Intervention group|Patients received oral nutritional supplementation and standard nutritional counseling for 6 months.
16283901|NCT04789031|No Intervention|Control group|Patients received standard nutritional counseling for 6 months.
16283902|NCT04789018||Observational (survey, virtual genetic board, interview)|Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
16283903|NCT04789005|Active Comparator|Phenylephrine group|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
16283904|NCT04789005|Experimental|Norepinephrine group|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
16283905|NCT04788992|Experimental|Intervention group|receive dementia care training
16283906|NCT04788992|Active Comparator|Control group|receive dementia care training without virtual reality activity
16283907|NCT04788953|Experimental|Solriamfetol (Sunosi)|"Participants will start at 75 mg and take that dose for 3 consecutive days. Participants will take their first 75mg dose on an early morning work day and take the next two 75 mg doses upon awakening regardless of their work schedule.
~They will then move to 150mg on the next early morning work day and for all subsequent early morning shift work days. The drug/placebo will be taken orally within 30 minutes after awakening, before the start of each early morning shift. Prior to the end of study of visit (Visit 5), drug will be taken at home within 30 minutes of awakening."
16283908|NCT04788953|Placebo Comparator|Control|Participants randomized into the Control arm will receive a placebo
16283909|NCT04788940||AMI patients treated with PCI|Acute myocardial infarction patients who underwent percutaneous coronary intervention and cardiac magnetic resonance imaging
16283910|NCT04788914|Other|Active bamboo charcoal|In this proposal, investigators aim to determine the therapeutic impact of a carbonaceous oral adsorbent made of activated bamboo charcoal (ABC) with/without probiotics on the endothelial/vascular function, CV outcome and mortality in CKD patients with PAD. In addition, investigators hypothesize that circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota. Investigators also hypothesize that the administration of ABC could normalize the dysbiosis of gut microbiota, dysregulated circulating lncRNAs and metabolome that are linked to adverse CV/limb outcomes in CKD patients with PAD.
16283911|NCT04788914|Other|Probiotics|The therapeutic impact of probiotics on circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota.
16283912|NCT04788901|Experimental|Online therapeutic game|Participants in this group will have access to the evaluation module of the REThink game.
16283913|NCT04788888|Experimental|Navitor Transcatheter Aortic Valve, FlexNav Delivery System|Navitor valve implantation, FlexNav Delivery system (small and large) and and Navitor Loading System (small and large)
16283914|NCT04788875|Active Comparator|Small Bite Technique Group|closure of laparotomy by small bites technique using PDS 2.0
16283915|NCT04788875|Other|Standardised Large Bites Technique Group|usual practice closure of laparotomy by standardised large bites technique using PDS 2.0
16283916|NCT04788862|Experimental|Group 1: High prior P. falciparum exposure|6 participants with high previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
16283917|NCT04788862|Experimental|Group 2: Low prior P. falciparum exposure|6 participants with no or low previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
16283918|NCT04788849||Women referred to colposcopy|Three sample types (urine, vaginal and cervical) will be collected from all enrolled women.
16283919|NCT04788836||Surgery Group|60 (minimum) to 150 (maximum) adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery or who had bariatric surgery in the last six months.
16283920|NCT04788836||Control Group|Comparison of food purchase behaviour with control subjects will be performed using an already existing cohort from a previous study. This does not required recruiting control subjects.
16283921|NCT04788823|No Intervention|Control|Group 1 will represent controls and will not receive prednisone in the 3-year post-op period.
16283922|NCT04788823|Experimental|Prednisone Monthly - Scheduled|Group 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered.
16283923|NCT04788823|Experimental|Prednisone Monthly - As Needed|Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
16283924|NCT04788823|Experimental|Prednisone Every Other Week|Group 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks
16283927|NCT04788797|Active Comparator|Prolyl Endopeptidase|Patients blinded-receive active AN-PEP at a dose of 2 capsules/breakfast, lunch and dinner during 8 weeks (study arm)
16283928|NCT04788797|Placebo Comparator|Placebo|Patients blinded-receive 2 capsules of a placebo (specially designed and prepared for the study) at breakfast, lunch and dinner during 8 weeks (Placebo arm).
16283929|NCT04788771|Sham Comparator|Tracheal intubation in laparoscopic extraperitoneal hernia repair|
16283930|NCT04788771|Active Comparator|laryngeal mask airway in laparoscopic extraperitoneal hernia repair|
16283931|NCT04788758|Experimental|Health Services Research (G8 screening tool, referral)|"PHASE I: Registered Nurses receive training on how to administer the G8 screening tool utilizing an Epic flowsheet to patients using a self-directed education module and by direct assessment by a geriatrician.
~PHASE II: Patients complete the G8 screening tool questionnaire over 10 minutes as part of their standard initial assessment, and their answers are entered into their EHR flowsheet. Patients who score =< 14 on the G8 are referred for a CGA at SAOC, and these patients and their medical oncologists are made aware. Within 2 weeks of the initial screening, the results are communicated with the patient and medical oncologist at a 2-hour SAOC visit. Patients with a score of > 15 on the G8 are made aware of their results without any referral generated."
16283932|NCT04788745|Experimental|Experimental|Trimetazidine 35mg
16283933|NCT04788732||1-Inhalation Anesthesia|patients in this group will be anesthetized only with an inhaled anesthetic ( Sevoflurane ).
16283934|NCT04788732||2-Total Intravenous Anesthesia|the patients in this group will be anesthetized with only intravenous drugs such as benzodiazepícos (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not to relaxing neuromuscular (nondepolarizing/depolarizing), and adjuvant drugs such as dextrocetamina, dexmedetomidine, lidocaine, and magnesium sulfate.
16283935|NCT04788732||3-Balanced anesthesia|the patients in this group will be anesthetized with blends of anesthetic inhaled (Sevoflurane) and intravenous drugs such as benzodiazepine (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not with neuromuscular relaxants (nonpolarizing/depolarizing) and adjuvant drugs such as dextrocetamine, dexmedetomidine, lidocaine, and magnesium sulfate.
16283936|NCT04788719|Experimental|Preoperative|Gait analysis kinematics and kinetics
16283937|NCT04788719|Experimental|Postoperative|Gait analysis kinematics and kinetics
16283938|NCT04788706|Active Comparator|Group I|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
16283939|NCT04788706|Placebo Comparator|Group II|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
16283940|NCT04788706|Active Comparator|Group III|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
16283941|NCT04788706|Placebo Comparator|Group IV|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
16283942|NCT04788693|Experimental|Motor imagery and gait training group|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.
~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise. In an interspersed way, motor imagery exercises will be carried out where participants must rehearse or simulate mentally each gait exercise that will be developed in the session."
16283943|NCT04788693|Active Comparator|Gait training group without motor imagery|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.
~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise. In the periods that the experimental group performs the motor imagery exercises, the control group will take breaks."
16283944|NCT04788680|Experimental|Experimental: Beverage 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
16283945|NCT04788680|Experimental|Experimental: Beverage 2|Participants receive a beverage with a defined amount of non-nutritive sweetener.
16283946|NCT04788680|Experimental|Experimental: Beverage 3|Participants receive a beverage with a defined amount of monosaccharide.
16283947|NCT04788680|Experimental|Experimental: Beverage 4|Participants receive a beverage with a defined amount of disaccharide.
16283948|NCT04788667|Experimental|Experimental Group|A health education programme using a telerehabilitation platform
16283949|NCT04788667|Active Comparator|Control Group|General recommendations using a telerehabilitation platform
16283950|NCT04788654|Active Comparator|Pharmacological group|Pharmacological analgesia will be performed
16283951|NCT04788654|Experimental|Pharmacologican and surgical group|Pharmacological and surgical analgesia will be performed.
16283952|NCT04788641|Experimental|Cohort 1|Subjects in Cohort 1 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: tacrolimus alone (treatment A) followed by the combination treatment of tacrolimus and SZC (treatment B) or vice versa.
16283953|NCT04788641|Experimental|Cohort 2|Subjects in Cohort 2 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: cyclosporin alone (treatment C) followed by the combination treatment of cyclosporin and SZC (treatment D) or vice versa.
16283954|NCT04788628|Experimental|Epilepsy inpatients|Epilepsy inpatients with implanted hippocampal electrodes and continuous scalp EEG monitoring
16283955|NCT04788615|Experimental|ofatumumab|Oftatumumab 20mg auto injector syringes for subcutaneous injection on Day 1, Week 1 and 2, followed by subsequent monthly dosing, starting at Month 1.
16283956|NCT04788615|Active Comparator|First line DMT|"Glatiramer acetate minimum dose 20mg or maximum dose 40mg twice a day or three times a week or
~Interferon minimum dose 22µg or maximum dose of 0.25mg 3 times a week or once a week or Every second week depending on preparation or
~Teriflunomide 14 mg once a day or
~Dimethyl fumarate minimum dose of 240mg or maximum dose of 480mh twice a day"
16283957|NCT04788589|Experimental|Sedation and Ventilator Weaning Protocol|"Sedation: start midazolam 5-10 mins (max 3x). If MV 12 hrs-2d: Pain: morphine @2 hrs if needed (max 10mg/x). Sedation: midazolam @ 1-2 hrs if needed (max 10mg/x). If MV >2 d: morphine & midazolam drip (max 10mg/hr). MV weaning checklist @morning. Pass if no incr of sedation dose due to agitation, NMBAs, incr in ICP. Fail: reassessed tomorrow. Pain and SBS scores assessed @morning until extubation. Stop all sedation and analgetic for sedation. Continue analgetics for pain. Subjects monitored for 4 hrs. Assess pain and WAT-1 score. Pass (GCS of E3, tolerate sedation interruption for > 4 hrs): MV weaning protocol. Fail (Persistent anxiety/agitation, incr pain score, incr RR > 5 mins, SpO2 <88% >5 mins, acute heart dysrhythmia, >=2 signs of ARDS): sedation resumed ½ dose, up titrated.
~MV weaning: CPAP 5/PS < 7. Pass: No failure criteria for 2 hrs. Fail (Incr RR > 5 mins, SpO2 <88% > 5 mins, acute decr in GCS/acute heart dysrhythmia, >=2 signs of ARDS): previous MV setting."
16283958|NCT04788589|No Intervention|Control|"Informed consent
~Randomization into groups
~Sedation and ventilator weaning according to attending physicians
~Pain scores and SBS score is noted every 6 hours for the first 24 hours, and every day for the next 24 hours until extubation.
~Attending physicians assessed that subject could be weaned: pain scores, SBS score, WAT-1 score
~Extubation. Researcher did not take part in the judgement of extubation."
16283959|NCT04788576||Patients with heart failure with preserved ejection fraction (HFpEF)|Subject with preserved ejection fraction (ejection fraction > 50%) and with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF ≥5 or 2-4 with abnormal stress test or invasive hemodynamic test)
16283960|NCT04788563|Experimental|Heat-sensitive moxibustion group A|In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
16283961|NCT04788563|Active Comparator|Control group A|In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
16283962|NCT04788563|Experimental|Heat-sensitive moxibustion group B|Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
16283963|NCT04788563|Active Comparator|Control group B|Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
16283964|NCT04788563|Experimental|Heat-sensitive moxibustion group C|Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
16283965|NCT04788563|Active Comparator|Control group C|Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
16283969|NCT04788537|Experimental|Intervention Group|
16283970|NCT04788537|No Intervention|Nonintervention Group|
16283971|NCT04788524|Experimental|Computer Task Manipulation|Participants will complete computer tasks while undergoing an fMRI brain scan
16283974|NCT04788498|Experimental|Laparoendoscpoic single site surgery LESS|35 patients undergoing laparoscopic ovarian cystectomy A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
16283975|NCT04788498|Active Comparator|Conventional multiport laparoscopy|35 patients undergoing laparoscopic ovarian cystectomy It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
16283976|NCT04788485|Active Comparator|Neonates before adding smectite|neonates will receive diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
16283977|NCT04788485|Active Comparator|neonates after adding smectite|neonates after they received diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
16283978|NCT04788472|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
16283979|NCT04788459|Experimental|0.5 mg PB|"0.5 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 1 mg
~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
16283980|NCT04788459|Experimental|1 mg PB|"1 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 2 mg
~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
16283981|NCT04788459|Experimental|2 mg PB|"2 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 4 mg
~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
16283982|NCT04788459|Experimental|2 mg P|"2 mg P (Prime) - Total dose: 2 mg
~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1"
16283983|NCT04788446|Experimental|Mini-flipped Game-based Learning|"20 minutes for the Mediterranean food table game, 20 minutes for the Mediterranean diet nutrition course.
~1 time a week (40 mins/ each time)
~Lasts for 8 weeks"
16283984|NCT04788446|Placebo Comparator|Balanced diet|"Given a balanced diet nutrition health education manual for the aged.
~Lasts for 8 weeks"
16283985|NCT04788433||ROCCO-A (A-symptomatic)|Patients with documented COVID-19 infection and NO symptoms
16283986|NCT04788433||ROCCO-P (Pauci-symptomatic)|Patients with documented COVID-19 infection and mild symptoms but NO oxygen support)
16283987|NCT04788433||ROCCO-L (mild)|Patients with documented COVID-19 infection and mild severity - requiring OXIGEN SUPPORT
16283988|NCT04788433||ROCCO-M (moderate)|Patients with documented COVID-19 infection and moderate severity - requiring OXIGEN SUPPORT by NON-INVASIVE modalities
16283989|NCT04788433||ROCCO-S(severe)|Patients with documented COVID-19 infection and severe disease requiring INVASIVE VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION
16283990|NCT04788420||Sorafenib group|Patients assigned to this group received sorafenib post-transplantation.
16283991|NCT04788420||Control group|Patients assigned to this group did not receive sorafenib or any other FLT3 inhibitor post-transplantation until reaching the primary outcome.
16283992|NCT04788407|Experimental|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID.
16283993|NCT04788407|Placebo Comparator|Placebo|Subjects will receive placebo TID.
16283994|NCT04788381||Participants with CRC or lung cancer was performed unexpected operation|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
16283995|NCT04788368||Patients treated with TEM - transanala microsurgery|Early rectal cancer treated with TEM - full thickness resection
16283996|NCT04788368||Patients treated with ESD|Early rectal cancer treated with the endoscopic treatment ESD - endoscopic submucosal resection
16283997|NCT04788368||Patients treated with EMR|Early rectal cancer treated with the endoscopic treatment EMR - endoscopic mucosal resection
16283998|NCT04788355|Active Comparator|Control Group standard treatment|Patients will be treated only with standard hospital treatment
16283999|NCT04788355|Experimental|Group Hydroxychloroquine|Patients will be treated with Hydroxychloroquine associated with standard hospital treatment
16284000|NCT04788355|Experimental|Group Hydroxychloroquine e Apixaban|Patients will be treated with Hydroxychloroquine associated with apixaban and standard hospital treatment
16284001|NCT04788355|Experimental|Group Apixabana|Patients will be treated with apixaban associated with standard hospital treatment
16284002|NCT04788342||Patients with and without left ventricular systolic dysfunction|Patients with different pathologies of the cardiovascular system (coronary artery disease, hypertension, valvular heart disease, heart failure) will be performed pulse wave recording using a CardioQvark cardiomonitor and echocardiography.
16284003|NCT04788329|Experimental|Relaxation Group|This program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel.
16284004|NCT04788329|Experimental|Meditation Group|"This treatment group will be enrolled in Wim Hof Method, a meditation program. Patients in this group will take the online The Fundamentals Course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively"
16284005|NCT04788329|No Intervention|Standard Care Group|The control group will get the standard of care therapy after surgery.
16284006|NCT04788316|Experimental|Intervention|A computerized brief intervention (CBI) followed by six months of personalized text messaging
16284007|NCT04788316|No Intervention|Control|Treatment as usual
16284011|NCT04788290||Single group(No interventional)|Other Name: Observational Rabone D®, Once daily administered per the locally approved product information
16284012|NCT04788277||Diagnostic (biospecimen collection)|Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
16284013|NCT04788264|Experimental|Arm I (exercise training, behavior modification)|Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11.
16284014|NCT04788264|Active Comparator|Arm II (Fitbit, consultation)|Patients receive a Fitbit to monitor physical activity for 12 weeks. Patients also receive consultation from a physical therapist to assess physical performance at weeks 1, 6, and 12.
16284017|NCT04788238|Experimental|Intervention group|Participants in the intervention arm will participate in the dual-task Zumba Gold (DTZ) program. They will be grouped into 10 participants per class.
16284018|NCT04788238|No Intervention|Control group|Participants in the control group will receive health education about dementia risk reduction provided by community health nurses.
16284019|NCT04788225||Patients with ATFL repair by arthroscopic method|Patients who have passed at least 1 year after the operation Unilateral arthroscopic ATFL repair Between the ages of 18-65 Volunteer to participate in the study Without any orthopedic conditions, neuromuscular disease, balance disorder, cognitive disorder No history of fracture and surgical operation of the lower extremity
16284020|NCT04788225||Control group|Between the ages of 18-65 Volunteer to participate in the study Healthy individuals with no disease
16284021|NCT04788212|Experimental|GBAT|10-week behavioral activation treatment group.
16284022|NCT04788199||Non-closure group|Group in which mesenteric defects were not closed after laparoscopic Roux-en-Y gastric bypass.
16284023|NCT04788199||Closure group|Group in which mesenteric defects were closed using cyano-acrylate glue after laparoscopic Roux-en-Y gastric bypass.
16284024|NCT04788186|No Intervention|Continue beta blocker therapy|Participants in this arm will continue their beta blocker therapy as per their usual clinical care
16284025|NCT04788186|Experimental|De-prescribe beta blocker therapy|Beta blocker therapy will be de-prescribed in this arm
16284026|NCT04788160|Experimental|Cervical SNAGs along with conventional therapy|patient will receive Cervical SNAGs along with conventional therapy (Group A)
16284027|NCT04788160|Other|Conventional Therapy|patient will receive only conventional therapy (Group B)
16284028|NCT04788121|Active Comparator|Treatment/Tranexamic Acid Group|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS.
16284029|NCT04788121|Placebo Comparator|Control Group|The control group will receive injection 100 ml NS over 15 minutes infusion, followed by injection 500 ml NS over 12 hours infusion.
16284030|NCT04788108|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
16284031|NCT04788108|Placebo Comparator|Placebo|placebo by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
16284032|NCT04788095|Experimental|App-based mindfulness program|Patients participate in a mindfulness-based program by using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks.
16284033|NCT04788082|No Intervention|Control|Standard of care (not involving 3D printing)
16284034|NCT04788082|Experimental|3D Model|3D printed models (at least one rigid blood volume model and one flexible shell model) will be used for surgical planning.
16284035|NCT04788069|Active Comparator|Wholemeal bread|Treatment with wholemeal bread
16284036|NCT04788069|Active Comparator|Sourdough bread|Treatment with sourdough bread
16284037|NCT04788069|Active Comparator|Bread with sourdough|Treatment with bread with sourdough
16284038|NCT04788056|Experimental|Bupivacaine|PSPB catheters will be placed with 60mL of 0.2% bupivacaine and continue to infuse bupivacaine 0.125% at 10mL/hr through the catheter
16284039|NCT04788056|Placebo Comparator|Saline|PSPB catheters will be placed with 60mL of saline and continue to infuse saline through the catheters.
16284040|NCT04788043|Experimental|Magrolimab (Hu5F9 G4) and pembrolizumab|All subjects will have a baseline PET CT and excisional or core needle biopsy within 1 month of study enrollment and baseline electrocardiogram and laboratory studies within 1 week of study enrollment. All subjects will receive treatment with magrolimab and pembrolizumab according to the dosing schedule. Magrolimab IV given on cycle 1, 2 and 3. Pembrolizumab 200 mg IV given on Cycle 1, 2 and 3. Patients may continue to receive treatment on the study for a maximum of 24 months or until progression of disease, unacceptable toxicity, or bridge to stem cell transplantation (SCT).
16284041|NCT04788030||Digital nerve reconstruction with muscle-in-vein conduits|
16284042|NCT04788017|Active Comparator|ziresovir|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.
~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:
~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.
~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.
~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
16284043|NCT04788017|Placebo Comparator|placebo|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.
~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:
~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.
~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.
~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
16284054|NCT04787991|Experimental|Cohort A: Nivolumab + Ipilimumab + nP/gem|
16284055|NCT04787991|Experimental|Cohort B: Hydroxychloroquine + Ipilimumab + nP/gem|
16284056|NCT04787978|Experimental|AAMWI-OSU Intervention|In this single-arm pilot program, 100 African American male participants will be enrolled who have poor or average cardiovascular health (< 4 life's simple 7 metrics in the ideal range) to a physical activity, education and patient activation intervention.
16284057|NCT04787965||ONGENTYS|Opicapone 50 mg capsule once daily for 6 months
16284058|NCT04787952||Group 1= healthy subjects|"Inclusion criteria to the group 1 (healthy males) N=20:
~BMI <25 kg/m2;
~RR<140/90mmHg;
~age 21-43 years
~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;
~no chronic disease"
16284059|NCT04787952||Group 2 = overweight/obese subjects|"Inclusion criteria to the group 2 ( overweight/obese males ) N=20:
~Blood pressure < 140/90 mmHg (well controlled by inh ACE; no beta-blockers)
~No chronic disease
~BMI > 25 <35kg/m²
~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;
~age 21-43 years"
16284060|NCT04787939|Experimental|Early Feeding Arm|Early Feeding Group
16284061|NCT04787926||Duralock-C 4%|DuraLock-C 4.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 40 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
16284062|NCT04787926||Duralock-C 30%|DuraLock-C 30.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 300 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
16284063|NCT04787926||Duralock-C 46.7%|DuraLock-C 46.7%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 467 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
16284064|NCT04787913|No Intervention|controlgeneric|No intervention provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
16284065|NCT04787913|No Intervention|controlmeasles|No intervention provided. Participant answers outcome questions about measles. English and French.
16284066|NCT04787913|No Intervention|controlpertussis|No intervention provided. Participant answers outcome questions about pertussis. English and French.
16284067|NCT04787913|No Intervention|controlflu|No intervention provided. Participant answers outcome questions about flu. English and French.
16284068|NCT04787913|Experimental|herdimmgeneric|Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
16284069|NCT04787913|Experimental|herdimmmeasles|Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French.
16284070|NCT04787913|Experimental|herdimmpertussis|Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French.
16284071|NCT04787913|Experimental|herdimmflu|Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French.
16284072|NCT04787913|Active Comparator|robertkochgeneric|Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
16284073|NCT04787913|Active Comparator|sbsnewsgeneric|Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
16284074|NCT04787913|Active Comparator|guardianmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
16284075|NCT04787913|Active Comparator|theotheredmundmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
16284076|NCT04787913|Active Comparator|publichealthagencycanadaflu|Video (comparator) provided. Participant answers outcome questions about flu. English and French.
16284077|NCT04787900|Experimental|iPhone measurement application|For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
16284078|NCT04787900|Active Comparator|Bubble inclinometer|measurement will be done by the same method. For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
16284079|NCT04787887|Active Comparator|Abcertin|Abcertin 60IU/kg
16284080|NCT04787887|Active Comparator|Cerezyme|EU-sourced Cerezyme
16284081|NCT04787874|No Intervention|Control|The control arm will receive no additional prehabilitation material prior to material. Rather, they will receive standard preoperative care in which they will be given standard advice on nutrition and fitness. REDcap surveys will be administered.
16284082|NCT04787874|Experimental|Prehab Intervention Arm|The intervention arm will receive access to the prehab program (abdominal workout videos) and surveys via RedCAP.The program will start no less than 14 days before the date of surgery.
16284083|NCT04787861|Active Comparator|Control group|Control group treatment is identical to treatment of the study group but without a motorized movement device.Childen in this group received chest physical therapy program including positioning, breathing exercises, and postural drainage in addition to incentive spirometer training for 20 minutes, 3 times/week for 12 weeks.
16284084|NCT04787861|Experimental|study group|This group received the same program given to the control group in addition to an aerobic training regimen for 25 minutes 3 times/week for 12 weeks using a motorized movement device.
16284085|NCT04787848|Experimental|HIV negative without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
16284086|NCT04787848|Experimental|HIV negative with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
16284087|NCT04787848|Experimental|HIV positive without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
16284088|NCT04787848|Experimental|HIV positive with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
16284089|NCT04787835|Experimental|Forearm Nerve Block|Patients will receive a nerve block of the radial, median, and ulnar nerves at the level of the forearm using 1% lidocaine with epinephrine. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
16284090|NCT04787835|Active Comparator|Local Anesthetic Infiltration|Patients will receive local anesthetic infiltration, using 1% lidocaine with epinephrine, to the fracture site and surrounding tissue. No nerve blocks will be performed. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
16284091|NCT04787809|Experimental|Living Well Intervention Group|Participants in the Living Well treatment group will receive a brief digital intervention informed by Acceptance and Commitment Therapy.
16284092|NCT04787809|No Intervention|Control Group|Participants in the control group will not receive any intervention. These individuals will have the option to access the intervention at the conclusion of their study participation.
16284093|NCT04787796|Experimental|The Self-built-in M-ECG recorders have passed the electrical.|We shall conduct this prospective clinical study to define the specific patterns of multichannel ECG change in adults with suspected CAD or ACS. For multichannel ECG (M-ECG) examination, the signal will be recorded with a Self-built-in ECG recorder.
16284094|NCT04787783|Experimental|Web based assessment|Participants will be leaded through preoperative period on a web based application. Participants will be addressed to either virtual or traditional face to face outpatient consultation on the basis of the information registered in the web based preoperative questionnaire that the application incorporates. Virtual assessment will be the performed by evaluating both the filled web based questionnaire together with participants´ electronic records. Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records.
16284095|NCT04787783|No Intervention|Traditional face to face assessment|"Participants will be leaded through preoperative period following traditional institutional standards of care.
~Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records."
16284096|NCT04787770||diabetes without complications|diabetes without complications
16284097|NCT04787770||diabetes with Peripheral Arterial Disease|diabetes with Peripheral Arterial Disease
16284098|NCT04787770||diabetic foot group|diabetic foot group
16284099|NCT04787757||Percutaneous cardiac procedures|Patients undergoing percutaneous cardiac procedures
16284100|NCT04787744|Active Comparator|Standard Systemic Therapy (SST)|All Veterans will receive SST
16284101|NCT04787744|Experimental|SST + PET-directed local therapy|"In addition to SST, all Veterans will receive PET-directed local therapy to all metastases using surgery or radiation. The selection of surgery or radiation to each metastasis will be determined using shared decision-making between the physician and Veteran.
~For Veterans with a local recurrence, this will be treated with salvage local therapy."
16284102|NCT04787731|Active Comparator|Lidocaine|Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent. It exists in liquid form in cartridges. Lidocaine is a FDA approved marketed anesthetic drug.
16284103|NCT04787731|Active Comparator|Bupivacaine|Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product. It exists in liquid form in cartridges. Bupivacaine is a FDA approved marketed anesthetic drug and meets IND Exemption.
16284104|NCT04787718|Experimental|Almond|Participants will consume 2.0 oz of raw, shelled, unsalted almonds.
16284105|NCT04787718|Active Comparator|Control group|an isocaloric (2.0 oz raw almonds) amount of unsalted pretzels daily.
16284106|NCT04787692|Experimental|Opioid and Benzodiazepine Naive-patients|Opioid and Benzodiazepine Naive-patients, defined as no medications 30 days prior to surgery
16284107|NCT04787692|Experimental|Opioid and Benzodiazepine Tolerant-patients|Opioid and Benzodiazepine Tolerant-patients, defined as use of medications on most days for 1 or more months (>30 days) prior to surgery
16284108|NCT04787679||Osteoporotic patients|Osteoporotic patients, age > 18 years old
16284109|NCT04787679||Non osteoporotic patients|Non osteoporotic patients, age > 18 years old
16284110|NCT04787666|Experimental|respiratory failure after cardiac surgery.|Dinamika of the indicator p/F Ratio
16284111|NCT04787653|Active Comparator|Otoband efficacy on Tinnitus|"Participants will wear the Otoband on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Each participant will select his/her preferred stimulation level. The OtoBand will be programmed to operate at one of three power levels that are thought to be effective. The OtoBand will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
16284112|NCT04787653|Placebo Comparator|Placebo device efficacy on Tinnitus|"The placebo device will use the same case, headband and battery as the OtoBand. The transducer in the OtoBand will be rotated 90 degrees, so that the placebo device will vibrate in a direction ineffectual at providing bone conducted vibrations. The vibrations will be in the horizontal plane, parallel to the skull, and will not have their energy penetrating the skull all the way to the vestibular system. Each participant will select his/her preferred stimulation level. The placebo devices will be made to vibrate at one of three power levels, none of which are thought to be effective. The placebo will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
16284113|NCT04787614||Home-based providers|Individuals who provided paid care for children under the age of 13 in a residential setting as of 2019
16284114|NCT04787614||Center-based providers|Providers who cared to children ages 0 through 5 years of age (not yet in kindergarten) in a non-residential setting as of 2019
16284115|NCT04787614||Center-based workforce|Individuals employed in center-based child care programs working directly with children in classrooms as of 2019
16284116|NCT04787601|Experimental|Cognitive training|Cognitive-based neuromuscular exercises will be applied to the experimental group for a total of 8 weeks.
16284117|NCT04787601|Other|Control|The control group will only do the classic training.
16284118|NCT04787588||Hospitalized patients|100 patients hospitalized with Covid-19, and 100 hospitalized controls without Covid-19
16284119|NCT04787588||Mild/Moderate asthma and health controls|20 asthmatic patients, 10 patients with asthma and allergic rhinitis, and 5 healthy controls.
16284120|NCT04787575|Experimental|Arm A|Oxygen-ozone therapy plus antibiotic therapy
16284121|NCT04787575|Other|Arm B|Antibiotic therapy
16284122|NCT04787562|Experimental|Cohort 1: normal renal function|Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
16284123|NCT04787562|Experimental|Cohort 2: Mild renal insufficiency|Participants with an eGFR 60 to <90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
16284124|NCT04787562|Experimental|Cohort 3: Moderate renal insufficiency|Participants with an eGFR 30 to <60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
16284125|NCT04787562|Experimental|Cohort 4: Severe renal insufficiency|Participants with an eGFR 15 to <30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
16284126|NCT04787562|Experimental|Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy|Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
16284127|NCT04787549|Experimental|Virtual reality exergames|Cognitively challenging exergames using fully immersive virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
16284128|NCT04787536||Study cohort|Patients aged 65 years or greater; scheduled to perform noncardiac elective surgery expected to require at least an overnight stay in hospital after surgery; surgery deferred, with a known or probable surgery date in ≥6 weeks
16284129|NCT04787523||Patients with pathological response to treatment|Response evaluated using the pathology report
16284130|NCT04787497|Experimental|Experimental Group|
16284131|NCT04787497|No Intervention|Control Group|
16284132|NCT04787471|Active Comparator|30 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
16284133|NCT04787471|Active Comparator|10 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
16284134|NCT04787458|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
16284135|NCT04787458|No Intervention|Control group|subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
16284136|NCT04787432|Experimental|Intervention|"Experimental: SAFRAPP Intervention
~Participants in this group will receive a 6-week SAFRAPP intervention, comprising of laughter yoga, health education and case management. SAFRAPP will be conducted on social media (Facebook and WhatsApp)."
16284137|NCT04787432|No Intervention|Control Grup|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is completed.
16284138|NCT04787419|Experimental|probiotics|"2 sachets per day for 4 weeks.
~1 sachet of probiotics (1gram) contains: Viable Counts 1 x 107 CFU/g living bacteria in dual pH dependent release coated (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), Vitamin C 10 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Niacin 2 mg."
16284139|NCT04787419|Placebo Comparator|placebo|"2 sachets per day for 4 weeks.
~1 sachet of placebo (1gram) contains: saccharum lactis"
16284140|NCT04787406|Active Comparator|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
16284141|NCT04787406|Active Comparator|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
16284142|NCT04787406|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
16284143|NCT04787393|Experimental|LOVE-HF-2 Arm A (Full data analysis mode of Heartfelt + symptoms reporting)|"Participants in LOVE-HF-2 Arm A (Heartfelt device + Symptoms reporting) will follow standard advice about symptom reporting but will be asked not to weigh themselves for the 30 days that they are in that arm. The Heartfelt device will be in the full data analysis mode which means that the device will be fully operational and will be detecting and reporting changes in foot volume over time."
16284144|NCT04787393|Other|LOVE-HF-2 Arm B (Technical checks only mode of Heartfelt + weighing + symptom reporting)|"Participants in LOVE-HF-2 Arm B (Weight + Symptoms reporting) will follow standard advice for the 30 days that they are in that arm. They will have the device installed, however the device will not report any alerts ( technical checks only mode ) during the time participants are on that arm. The Heartfelt device will be in 'technical checks' where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour."
16284145|NCT04787380|Experimental|LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
16284146|NCT04787380|No Intervention|LOVE-HF Arm B (Technical checks only mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
16284147|NCT04787367|Experimental|Early-operative TAP block|The TAP block will be administered after the placement of the camera port.
16284148|NCT04787367|Experimental|Late-operative TAP block|The TAP block will be administered at the completion of the case just before removing the camera port.
16284149|NCT04787354|Active Comparator|Control arm|"Standard adjuvant XELOX 8 cycles
~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, total 8 cycles"
16284150|NCT04787354|Experimental|Study arm|"Adjuvant XELOX 4 cycles followed by capecitabine monotherapy 4 cycles
~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles
~followed by
~Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles"
16284151|NCT04787341|Active Comparator|Panitumumab followed by Regorafenib|
16284152|NCT04787341|Experimental|Regorafenib followed by Panitumumab|
16326016|NCT04497402||male matched COVID19-free patients|
16284153|NCT04787328|Experimental|HA121-28 tablets|Patients will receive HA121-28 tablets at 600 mg once daily (QD) for 21 days on a 28-day treatment cycle.
16284154|NCT04787315|Active Comparator|Intensive rehabilitation without workstation|
16284155|NCT04787315|Experimental|Intensive rehabilitation with workstations|
16284157|NCT04787289|Active Comparator|Higher Standard dosing as per standard regimen|bevacizumab 15mg/kg + chemotherapy
16284158|NCT04787289|Experimental|Lower standard dosing bevacizumab plus chemotherapy|bevacizumab 7.5mg/kg + chemotherapy
16284159|NCT04787276|Experimental|E.coli Nissle 1917|probiotic, oral, for the first 4 days, 1 capsule, and then 2 capsules per day for 1 month treatment
16284160|NCT04787276|Active Comparator|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
16284161|NCT04787276|Active Comparator|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
16284162|NCT04787263|Experimental|CD19-CAR_Lenti|Following lymphodepletion with chemotherapy (fludarabine + cyclophosphamide), patients will be treated with 1.0 to 3.0 x 10^6/kg CD19-Chimeric Antigen Receptor (CAR)_Lenti positive cells as a single dose. The product will be infused fresh, at the end of manufacturing.
16284163|NCT04787250|Experimental|Arm 1, Phage Therapy with Antibiotic Treatment|Phage therapy will be administered in conjunction with antibiotic treatment.
16284164|NCT04787250|Active Comparator|Arm 2, Standard of Care|Two-stage exchange arthroplasty entails resection arthroplasty and placement of an antibiotic-loaded spacer, antibiotic therapy, an antibiotic-free observation period, and re-implantation of a new prosthesis.
16284165|NCT04787237|Experimental|Vestibulart socket therapy and immediate implants|A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted . A flexible cortical membrane shield that is made of cortical bone of heterologous origin was introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a membrane tack or a micro screw to the alveolar bone apical to the base of the socket . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
16284166|NCT04787237|Active Comparator|Buser's technique and early implant placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 8-12 weeks was followed. Then an open flap implant surgery using a triangular flap design was cut. Implant was then placed under the crest of the palatal bone. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone conditioned medium (BCM) added to bioss bone granules to activate it.
16284167|NCT04787224||infected sockets|Signs of infection were periapical radiolucency only in 3 sites (2 patients), fistula in 2 sites (2 patients), sinus in 11 sites (7 patients) and finally swelling in 3 sites (2 patients)
16284168|NCT04787224||Non infected sockets|This is ensured by the absence of any clinical signs and symptoms of infection in addition to negative radiographic findings
16284169|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
16284170|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
16284171|NCT04787211|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
16284172|NCT04787198|Experimental|hypertonic saline|
16284173|NCT04787198|Placebo Comparator|isotonic saline|
16284174|NCT04787146||Patients|"From Monday to Friday, the study will be offered to patients selected consecutively and who have fallen within the previous 24 hours (between 7.55 a.m. the day before and 7.55 a.m. the next day).
~After delivery of the written information note to the patient, the investigating physician answers the patient's questions and accepts his non-objection. The patient should be given sufficient time to think things through to make the decision to participate in the study.
~Its non-opposition will be traced in the computerized medical file created on the day of its inclusion in the protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
16284175|NCT04787120||Individuals with arterial abdominopelvic bleeding|Arterial abdominopelvic bleeding or imminent risk of bleeding
16284176|NCT04787107|Experimental|10 Minute Chair Massage|Chair massage for 10 minutes once a week for 5 weeks
16284177|NCT04787107|Experimental|10 Minute Scheduled Break|Scheduled 10-minute break once a week for 5 weeks
16284180|NCT04787081|Experimental|Sleep Care Positioning Training Program GRP1|A sleep care positioning lesson created by a University's postural-care scholars using Camtasia® video creation software with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of interactive videos embedded with learning checkpoints. All videos included narration and closed captioning. The following link contains the videos which were modified post-study to reflect some of the participant's feedback: https://stkatentpc.weebly.com/
16284181|NCT04787081|Active Comparator|Sleep Care Positioning Training Program GRP2|A sleep care positioning lesson created by a research assistant along with the principal investigator with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of primarily written summary statements and links to freely available web-based information. Most of this lesson's modules included written information that the participant would need to read with the exception of the positioning methods modules. For the positioning module, participants were provided with links to manufacturers' websites which contained video clips on how to place postural supports.
16284182|NCT04787068|Experimental|Treatment group|Intervention is occupational therapy support
16284183|NCT04787068|No Intervention|Control group|No intervention was provided, only educational material was given.
16284184|NCT04787055|Experimental|Receiver in the canal hearing instrument|Group of subjects who will get the receiver in the canal hearing instrument for a 6 month period.
16284185|NCT04787042|Experimental|Phase 1a, Dose Escalation|In phase 1 dose escalation will start at a dose level of 30ug/kg . Patients will be treated every week and the DLT evaluation period is 28 days. According to the mTPI schema initially there will be 2 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D
16284186|NCT04787042|Experimental|Phase 2, Expansion|Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.
16284187|NCT04787029|Experimental|prophylactic medical compression therapy group|"This study provides medical compression stockings from the start date of Docetaxel administration for patients who have undergone mastectomy and axillary lymphectomy for breast cancer, and who are planning to receive Docetaxel adjuvant chemotherapy. The intervention group wears medical compression stockings for upper limbs with a pressure level of 1 (15-21mmHg) during the day from the start of docetaxel administration to 3 months after the end of administration.
~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
16284188|NCT04787029|No Intervention|control group|"The control group proceeds as an observation, but interventions such as providing stockings in the event of lymphedema are performed.
~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
16284189|NCT04787016|Experimental|Pilate training|The participants of this group perform pilate training along with conventional cricket training.
16284190|NCT04787016|No Intervention|Conventional training|The participants perform only conventional cricket training.
16284191|NCT04787003|Experimental|Oncolytic virus (OVV-01) injection for patients with advanced solid tumors|Oncolytic virus (OVV-01) injection combined with or without immune checkpoint inhibitors in the treatment of patients with advanced solid tumors.
16284192|NCT04786990|Experimental|Open-Label Treatment|"Subjects 6-11 years of age: 100 to 400mg SPN-812 (100 mg capsule)
~Subjects 12-17 years of age: 100 to 600mg SPN-812 (100, 200 mg capsule)"
16284193|NCT04786977||VIPN Patients|
16284194|NCT04786977||Healthy Volunteers|
16284195|NCT04786964|Experimental|Cosibelimab|Participants receive cosibelimab 1200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by cosibelimab 1200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
16284196|NCT04786964|Active Comparator|Control|Participants receive pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pemetrexed 500 mg/m^2 IV Q3W until progression.
16284200|NCT04786938|Experimental|Saccharomyces boulardii|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34) plus S. boulardii CNCM I-745 (approximately 22.5 x109 CFU
16284201|NCT04786938|No Intervention|No intervention|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34)
16284202|NCT04786925|Placebo Comparator|Control diet|A conventional diet based on the current Spanish Mediterranean dietary guidelines: Spanish Society of Community Nutrition (SENC).
16284203|NCT04786925|Experimental|Nutriprecision diet|A Mediterranean, balanced diet based on the inclusion of precision foods designed and developed within the framework of Nutriprecision project. A mobile application to empower and support the management of the dietary prescription. A digital tool for cognitive stimulation.
16284204|NCT04786899||Hispanic/Latino patients undergoing cardiothoracic surgery|Observational study of patients scheduled for cardiothoracic surgery as part of standard of care. Patients will be followed up to 30 days prior to surgery and up to 7 days after surgery or hospital discharge, whichever is sooner. Patients preoperative sleep patterns and postoperative delirium will be followed.
16284205|NCT04786886|Experimental|Virtual Reality Visual Field Group|Participants in this group will have virtual reality visual field testing during standard of care follow-up visit.
16284231|NCT04786665|Experimental|Strawberry powder|Participants consume 1 package of standard strawberry powder (26 g) daily for 8 weeks
16284206|NCT04786873|Active Comparator|standard GHST order randomized: arginine - clonidine|"At visit 2 (V2), all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at visit 3 (V3) and visit 4 (V4).
~In this arm, those subjects will be presented which will have been randomized to the arginine GHST at V3 and the clonidine GHST at V4.
~At visit 5 (V5) all subjects will perform the macimorelin GHST."
16284207|NCT04786873|Active Comparator|standard GHST order randomized: clonidine - arginine|"At V2, all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at V3 and V4.
~In this arm, those subjects will be presented which will have been randomized to the clonidine GHST at V3 and to the arginine GHST at V4.
~At V5 all subjects will perform the macimorelin GHST."
16284209|NCT04786834|Active Comparator|Traditional training group|Trainees in the Traditional trained group will be trained according to the traditional approach of 'See one, do one, teach one' principle. Trainees will have an e-learning didactic component (specifically on the anatomy & physiology of the procedure, clinical aspects of the procedure, published evidence etc) which they must complete before training by a procedure expert. On completion of the e-learning module they will complete a summative assessment of their knowledge. They will then be shown how and then trained to suture and tie knots using the robot. The VUA will be demonstrated initially by an expert and who will then proctor the trainees in the same technique for repeated training trials., i.e., repeated practice for a period of time matched to the PBP group.
16284210|NCT04786834|Experimental|Proficiency based progression (PBP) training group: a new training methodology|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge before continuing to the surgical training. Their knowledge will be assessed in a formative and summative fashion. After their initial VUA assessment, procedure-specific and validated procedure metrics will be used to teach the students the steps of the procedure, as well as the correct (and incorrect) way to perform the procedure. The metrics will be used to give them performance feedback with specific advice on how they might improve their performance, i.e., deliberate practice.
16284211|NCT04786821|Placebo Comparator|Standard Exercise Training Programme|Participants will receive interventions by an exercise specialist based on the participant's tolerance. These sessions will be delivered by a exercise specialist.
16284212|NCT04786821|Active Comparator|Exoskeleton Exercise Programme|The Phoenix Exoskeleton suit will be used in this study. It is a powered Exoskeleton, with a modular design. Participants will receive interventions by an research physiotherapist based on the participant's tolerance.
16284213|NCT04786795|Experimental|Compound Azintamide Enteric-coated Tablets|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the experimental group takes Compound Azintamide Enteric-coated Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
16284214|NCT04786795|Placebo Comparator|Oryz-aspergillus Enzyme|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
16284215|NCT04786782||Three-dimensional reconstruction group|Portal hypertension is controlled with upper endoscopic screening and vPPG was detected by the noninvasive PPG-detecting software
16284216|NCT04786782||Natural follow-up group|Portal hypertension is controlled with the most updated guideline for clinical practice, namely, cirrhotic patients with either liver stiffness measurement >15kPa or PLT<150*10^9 should be screened with upper GI endoscopy and treated according to endoscopic results
16284217|NCT04786769|Experimental|Iron supplementation|"Intravenous ferric carboxymaltose will be administered according to weight and hemoglobin values at randomization as follows:
~2-4 weeks before valve intervention On the day of admission to valve intervention (if determined by dose calculation, otherwise placebo) 12 weeks after valve intervention (if iron deficiency persists, otherwise placebo)"
16284218|NCT04786769|Placebo Comparator|Placebo|"Intravenous 0.9% NaCl (placebo) will be administered as follows:
~2-4 weeks before valve intervention On the day of admission to valve intervention 12 weeks after valve intervention"
16284219|NCT04786756|Active Comparator|Lateral Approach of Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
16284220|NCT04786756|Active Comparator|Medial Approach of Costoclavicular Block|US-guided medial approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
16284221|NCT04786743|Experimental|non-urgent endoscopy group|undergo endoscopy between 6 and 24 hours after gastroenterological consultation
16284222|NCT04786743|Other|urgent endoscopy group|undergo endoscopy within 6 hours after gastroenterological consultation
16284223|NCT04786730|Experimental|Open-label centanafadine|There will be multiple cohorts dosed with open-label centanafadine.
16284224|NCT04786717|Experimental|core muscle training|Training the endurance of the core muscle.
16284225|NCT04786717|Experimental|movement control training|Based from the initial test, the subjects will receive lumbar movement control exercise. They will perform each lumbar movement control exercise in different position.
16284226|NCT04786717|Experimental|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, and the subjects will practice the real movement in the rest of 7 times.
16284227|NCT04786691|Placebo Comparator|Black coffee first|12 oz of black coffee with no additives is the first intervention tested
16284228|NCT04786691|Active Comparator|Coffee with half and half first|12 oz of black coffee with 1 oz of half and half is the first intervention tested
16284229|NCT04786691|Active Comparator|Coffee with non-dairy creamer first|12 oz of black coffee with 1 oz of liquid non-dairy creamer is the first intervention tested
16284230|NCT04786678|Experimental|All participants|All participants will have a baseline before all participants undergo intervention. The purpose is to pilot the intervention to establish possible effects, as well as to determine if there are any usability or other issues.
16284232|NCT04786665|Placebo Comparator|Placebo group|Participants consume 1 package of placebo powder (26 g) daily for 8 weeks
16284233|NCT04786652|Experimental|Assessment of fluid responsiveness|
16284234|NCT04786639||Surgical Fixation Group|Open reduction with deltopectoral incision and humeral osteosynthesis with anatomic plates and screws will be performed for surgical fixation.
16284235|NCT04786639||Non-Operative Group|Non-surgical treatment will be performed with sling immobilization.
16284236|NCT04786613|Active Comparator|20 mg, 1.0% hyaluronic acid injection groups|In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.
16284237|NCT04786613|Active Comparator|32 mg, 1.6% hyaluronic acid injection groups|In the second group, 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.
16284238|NCT04786613|Active Comparator|48 mg, 2.0% hyaluronic acid injection groups|In the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied.
16284241|NCT04786587||Pregnant woman|
16284242|NCT04786574|Experimental|Tolvaptan (OPC-41061)|
16284243|NCT04786561||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years or older were invated to participate in HUNT 4 70+
16284244|NCT04786561||HUNT4 70+ Trondheim|All inhabitants of one district in Trondheim 70 years or older were invated to participate in HUNT 4 70+
16284245|NCT04786548|Experimental|Celecoxib Treatment|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment
16284246|NCT04786535|Active Comparator|Hemodiafiltration|
16284247|NCT04786535|Experimental|Expanded hemodialysis|
16284248|NCT04786535|Experimental|Conventional high-flux hemodialysis|
16284249|NCT04786509||ECG sensor|All subjects performed shuttle run (SR), Cooper 2400 m (C), and 100 m sprint test (S), once wearing the sensor attached to self-adhesive skin electrodes, additionally fixed with self-adhesive tapes, and secondly with the sensor attached to Polar belt and strapped around the chests.
16284250|NCT04786496|Experimental|ITP+SA Wise intervention (Incremental Theory of Personality Intervention with Self-affirmations)|Wise intervention (based on ITP and SA) consisting on several tasks to be completed individually. 30 minutes
16284251|NCT04786496|Experimental|ITP Wise intervention (Incremental Theory of Personality Intervention)|Wise intervention (based on ITP) consisting on several tasks to be completed individually. 30 minutes
16284252|NCT04786496|Other|Control Intervention|Educational intervention (about heritage conservation) consisting on several tasks to be completed individually. 30 minutes
16284253|NCT04786483|Experimental|Laughter Therapy group|All students enrolled in the laughter therapy group will receive a total of 10 sessions of laughter therapy, 60 minutes, 2 days a week.
16284254|NCT04786483|No Intervention|Control|No attempt will be made to students in this group.
16284255|NCT04786470|Active Comparator|Local Anaesthetic Infusion|
16284256|NCT04786470|Sham Comparator|Saline Infusion|
16284258|NCT04786444|Active Comparator|VLA1553 Lot 1|
16284259|NCT04786444|Active Comparator|VLA1553 Lot 2|
16284260|NCT04786444|Active Comparator|VLA1553 Lot 3|
16284261|NCT04786431||Controls, CVD, IS, SLE|"Control (n = 85) were taken from the population of the Coimbra and Lisbon, Portugal, regions. They satisfied the criterion that they had never had any CVD- or SLE-related health complaints.
~The CVD patients (n = 238) were divided into 6 groups. CVD1 (n = 61) contains individuals who went to the hospital with chest pain but had no indicators for stable angina pectoris, unstable angina pectoris or myocardial infarction.
~Acute ischemic stroke (IS) (n = 21) were patients admitted at the emergency room of the Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, who suffered from acute ischemic stroke.
~The SLE cohort (n = 104) were patients from Hospital Dr. Fernando Fonseca, Amadora, Portugal."
16284262|NCT04786418|Active Comparator|Control group|Participants will be given standard advice about healthy eating, physical activity and management of weight during the study visit, in line with current NHS practice. There will be a total of 9 study visits for this group.
16284263|NCT04786418|Experimental|Low-calorie diet intervention group|Participants will received a special diet involving 25 regular visits and intensive management. Participants will be given a supply of especially formulated soups and shakes, a special diet in a form of powder that need to be mixed with 200 ml water.
16284264|NCT04786405|Experimental|Mindfulness Meditation|Participants in this arm will complete five, 20-minute mindfulness meditation sessions delivered over consecutive days.
16284265|NCT04786405|Active Comparator|Clinical Hypnosis|Participants in this arm will complete five, 20-minute clinical hypnosis sessions delivered over consecutive days.
16284266|NCT04786392|Active Comparator|Lutein supplement|"Supplement containing 5 mg powdered lutein, capsule filler microcrystalline cellulose.
~To be administered once."
16284334|NCT04785807|Experimental|Evaluation arm|
16284267|NCT04786392|Experimental|Blended food beverage|Blended food beverage containing 5 mg lutein from baby spinach. To be administered/consumed once.
16284268|NCT04786392|Experimental|Whole food|Consumption of 5 mg of lutein from baby spinach. To be administered/consumed once.
16284269|NCT04786379|Experimental|Patients with confirmed septic arthritis of the native knee|
16284270|NCT04786353||COVID positive kids|Kids with at least one positive COVID test.
16284271|NCT04786353||COVID negative kids|Kids with negative COVID test.
16284272|NCT04786353||COVID positive adults|Adults with at least one positive COVID test
16284273|NCT04786353||COVID negative adults|Adults with negative COVID test
16284274|NCT04786340|Placebo Comparator|Placebo: 4 mL of matching placebo topical solution.|The placebo solution contains the same ingredients as the active solution with the exception of the active WST-057. It is dispensed with a pump to deliver 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
16284275|NCT04786340|Experimental|WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution|The WST-057 is the active topical solution and contains pirenzepine free base monohydrate. It is dispensed with a pump to deliver (with 4 pumps) 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
16284276|NCT04786327|Placebo Comparator|treated by using Minimally invasive flap only.|7 sites treated with Minimally invasive flap only
16284277|NCT04786327|Experimental|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft
16284278|NCT04786327|Experimental|MIST with root conditioning (EDTA) and GEM 21S .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S
16284279|NCT04786314|Experimental|Hot Water Application Group|Pregnant women will apply hot water to their legs before going to sleep for a week, depending on the groups they are in.
16284280|NCT04786314|Experimental|Cold Water Application Group|Pregnant women will apply cold water to their legs before going to sleep for a week, depending on the groups they are in.
16284281|NCT04786314|No Intervention|Control Group|There will be no intervention other than routine follow-up and maintenance.
16284282|NCT04786288|Experimental|Aromatherapy|"22 elderly participants received M technique hand massage that lasted for 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the hand massage.
~Intervention: massage with lavender essential oil mixed in a carrier oil"
16284283|NCT04786288|Placebo Comparator|Placebo|"odourless baby oil was used for the application of the M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
~Intervention: other: massage with no fragrance baby oil"
16284284|NCT04786288|No Intervention|Control|Participants in this group didn't receive any type of intervention from the researcher except the routine hospital management.
16284285|NCT04786275||Tetanic stimulation|Single arm study
16284286|NCT04786262|Experimental|VX-880|
16284287|NCT04786223|Other|C-11 ER176 PET/CT|C-11 ER176 is an investigational radiopharmaceutical that will be produced under cGMP in the Mayo Clinic Cyclotron Facility. The imaging agent (C-11 ER176) will be administered on an outpatient basis. It will be administered at a single time IV prior to the PET imaging.
16284288|NCT04786210|Experimental|Site A of keloid scar|One half of keloid scarring on a single subject
16284289|NCT04786210|Experimental|Site B of keloid scar|One half of keloid scarring on a single subject
16284290|NCT04786184|Experimental|CALM Breathing|
16284291|NCT04786184|Active Comparator|Wait-List Control|
16284292|NCT04786145|Active Comparator|Cryoneurolysis|40 patients are randomized to receive one treatment of cryoneurolysis on the facet joints of three lumbar level corresponding to their facet joint pain generator
16284293|NCT04786145|Active Comparator|Radiofrequency ablation|40 patients are randomized to receive one treatment of radiofrequency ablation on the facet joints of three lumbar level corresponding to their facet joint pain generator
16284294|NCT04786145|Sham Comparator|Placebo|40 patients are randomized to receive sham treatment. Subjected to similar procedures as cryoneurolysis and radiofrequency ablation, but without active treatment.
16284295|NCT04786132|Experimental|Dual Task (proprioception, balance and cognitive) training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.
~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
16284296|NCT04786132|Active Comparator|Proprioception and balance training|"The control group training protocol is the same as the experimental group, whit the same duration and the same sessions, the unique difference is that there was no music included in the sessions, and therefore cognitive ability was not worked.
~The sessions were carried out by the main researcher who controlled the technique of the exercises and motivated the participant."
16284297|NCT04786119|Experimental|CORI Robotics|Subjects having robotic assisted knee arthroplasty as decided by their doctor and treated with CORI Robotics.
16284298|NCT04786106|Active Comparator|CCH+PTT|Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.
16284299|NCT04786106|Active Comparator|Surgery+PTT|Men will undergo either penile plication or I&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
16284300|NCT04786093|Active Comparator|Stereotactic Ablative Radiotherapy (SAbR) Arm plus Durvalumab arm|SAbR with each radiation treatment fraction delivered every other day
16284301|NCT04786093|Experimental|Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus Durvalumab arm|PULSAR with each radiation treatment fraction delivered every 4 weeks
16284302|NCT04786080|Experimental|Parent Positive|This is an app developed for use on a smartphone providing a flexible digital space where parents can get support and advice to help them manage their children's behaviour. The app will be free and parents will be able to access the information when needed and in the order they choose. Parents in the intervention group will receive access during the immediate post-randomisation period.
16284303|NCT04786080|No Intervention|Follow-Up as Usual|FAU was selected as a comparator because of the pragmatic nature of the trial. Individuals randomised to FAU will receive no intervention for the first 10 weeks while the data for baseline (T1), T2 and T3 are collected. They will then be given access to all three zones of the app.
16284304|NCT04786067|Experimental|Immunosuppression Taper|Patients included in this arm are kidney transplant recipients with stable kidney function currently on or are converting to a Belatacept based immunosuppression regimen. Eligible patients who are deemed immune quiescent after a 3 month monitoring period will undergo sequential withdrawal of immunosuppression medications over a 12 month period from a three drug regimen to a Belatacept only immunosuppression regimen. During the total 15 month period patients will be monitored with monthly clinic visits, blood draws for routine monitoring as well as donor derived cell free DNA and genetic testing through KidneyCare to monitor immune suppression.
16284305|NCT04786054|Active Comparator|Group BED|Those who are diagnosed with having Binge Eating disorder. These individuals qualified after the questionnaire was administered.
16284306|NCT04786054|No Intervention|Group Non-BED|Those who are not diagnosed with having Binge Eating disorder
16284307|NCT04786041||underwent Appendectomy during march-april of 2019|all patients who underwent Appendectomy during the period of march-april of 2019
16284308|NCT04786041||underwent Appendectomy during march-april of 2020 (during covid pandemic)|all patients who underwent Appendectomy during the period of march-april of 2020 (during the COVID19 pandemic lockdown)
16284309|NCT04786028|Experimental|Isatuximab with CyBorD and Lenalidomide Maintenance|This is a single arm study of Isatuximab administered intravenously in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD), and Lenalidomide maintenance treatment
16284310|NCT04785989|Active Comparator|Group A: Healthy volunteers|Healthy volunteers are defined as people without a history of cancer
16284311|NCT04785989|Experimental|Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
16284312|NCT04785989|Experimental|Group B subset-2: Treatment naïve CLL patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
16284313|NCT04785989|Experimental|Group C:Treatment naïve CLL patients with high systemic disease burden|Treatment naïve CLL patients with high systemic disease burden
16284314|NCT04785976||Surgical clipping|
16284315|NCT04785976||Endovascular coiling|
16284316|NCT04785963|Experimental|Music with Suggestion|Active condition where participants will be provided with recordings of pre-determined music in addition to recorded suggestions instructing the participant on how to listen to the music.
16284317|NCT04785963|Active Comparator|Music|Control group where participants will be provided recordings of pre-determined music
16284318|NCT04785963|Active Comparator|Pain Information|Non-arts group receiving structured attention and standard care
16284319|NCT04785950||Women with IUS|Women aged 18 to 35 years from Spain who chose to use any low-dose LNG-IUS marketed in Spain for the first time during routine clinical practice
16284320|NCT04785937|Experimental|Imaging and Biopsy|All patients undergo both liver biopsy and liver imaging (US and MR) to assess the diagnostic performance of imaging compared to histopathological examination in the diagnosis of NASH and fibrosis.
16284321|NCT04785924|Other|Observation Treatment Group|All patients observed while treated with IMI/REL.
16284322|NCT04785898|Other|Screening patients COVID-19 test|"As part of the patient's management, two nasopharyngeal swabs will be taken from the same nostril:
~The first swab will be sent to the microbiology laboratory for analysis with the Simplexa ™ COVID-19 Direct assay so as not to impact the patient's diagnostic result.
~The second swab taken as part of the research will be analyzed with the ID NowTM COVID-19 test located in the UAS by one of the nurses trained and authorized to use it. The choice to perform the ID Now ™ COVID-19 test in the emergency room and not in the laboratory is based on the supplier's instructions. Indeed, the nasopharyngeal swab is intended to be analyzed directly and not to be transported in a container which could hinder the quality of the sample.
~The discomfort or pain felt by the patient during the first sample can possibly influence the quality of the second. This could induce a bias. To minimize this bias, staff will be specifically trained in sampling."
16284323|NCT04785885||Transcatheter Aortic Valve Replacement|Patients receive 100U/Kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
16284324|NCT04785885||Cardiac Valve Annuloplasty|Patients receive 300U/kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
16284325|NCT04785872|Experimental|Intervention group|
16284326|NCT04785872|No Intervention|Control group|
16284327|NCT04785859||Moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, with the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
16284328|NCT04785859||no moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, without the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
16284329|NCT04785846||Single Group|Adult patients with coronary artery disease undergoing percutaneous coronary intervention on vessels with a diameter less than or equal to 2.5 mm.
16284330|NCT04785833|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
16284331|NCT04785820|Experimental|RO7121661|
16284332|NCT04785820|Experimental|RO7247669|
16284333|NCT04785820|Active Comparator|Nivolumab|
16284335|NCT04785794|Experimental|M2SR dose, 50-64 years of age|Intranasal M2SR vaccine followed by standard, licensed IIV
16284336|NCT04785794|Placebo Comparator|Placebo dose, 50-64 years of age|Intranasal physiological saline followed by standard, licensed IIV
16284337|NCT04785794|Experimental|M2SR dose, 65-85 years of age|Intranasal M2SR vaccine followed by licensed IIV recommended for people 65 years and older
16284338|NCT04785794|Placebo Comparator|Placebo dose, 65-85 years of age|Intranasal physiological saline followed by licensed IIV recommended for people 65 years and older
16284339|NCT04785781|Other|no mask|individuals perform cardiopulmonary test via cycle ergometer without mask till voluntary exhaustion
16284340|NCT04785781|Other|surgical mask|individuals perform cardiopulmonary test via cycle ergometer with surgical mask till voluntary exhaustion
16284341|NCT04785781|Other|N95/fpp2|individuals perform cardiopulmonary test via cycle ergometer with N95 mask till voluntary exhaustion
16284342|NCT04785768|Experimental|PCA with continuous + bolus dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours;（2）PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h；lockout time = 10 minutes；（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
16284343|NCT04785768|Experimental|PCA with bolus-only dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
16284344|NCT04785768|Active Comparator|Oral opioid|（1）Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours；(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h； (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；(4)The treatment regimen was continued for 7 days.
16284345|NCT04785755|Active Comparator|Group I|The control group (n=15) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
16284346|NCT04785755|Experimental|Group II|The hypertonic saline solution (HSS) group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the start of the study to the end of the study) with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
16284347|NCT04785755|Experimental|Group III|The etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
16284348|NCT04785755|Experimental|Group IV|The hypertonic saline solution (HSS) + Etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg100mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days, and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
16284349|NCT04785742|Experimental|20 exon (20INS) mutation|
16284350|NCT04785742|Experimental|Rare mutations except for 20INS|
16284351|NCT04785729|Experimental|almonertinib|
16284352|NCT04785703||oral lichen planus group|patients with chronic bollus erosive lichen planus
16284353|NCT04785690|Experimental|CureSight|eye-tracking-based
16284354|NCT04785690|Active Comparator|Patching|occlusive deprivation
16284355|NCT04785677|Experimental|Comprehensive Trauma-Based Reentry Program|Participants will complete up to19 session comprehensive trauma-based reentry program.
16284356|NCT04785677|No Intervention|Treatment as usual (TAU)|Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.
16284357|NCT04785664|Experimental|LLE- Long Live the Elderly!|"The group has been randomized among the Long Live the Elderly! (LLE) clients in two cities: Rome and Naples. The LLE central database includes all the participants to the program in Naples and Rome who have been administered the Functional Geriatric Evaluation (FGE) questionnaire."
16284358|NCT04785664|No Intervention|SoC- Standard of Care|No intervention will be carried out. The control group is selected by randomization from a pool of over-80s followed up by General Practitioners in the same cities who have been available to be involved in the study. Each GP provided a list of patients which 10 names have been selected from by randomization. The total pool consisted of approximately 8500 individuals. The sample was made up of 690 selected patients of which 83 (12.02%) refused to participate in the study.
16284359|NCT04785651|Experimental|Tranexamic arm|Patients in this arm will undergo to a tibial osteotomy in combination with the anti-fibrinolytic agent Tranexamic acid.
16284360|NCT04785651|Other|control arm|Patients in this arm will undergo to a tibial osteotomy without the use of Tranexamic acid
16284361|NCT04785638|Experimental|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
16284362|NCT04785625|Experimental|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
16284363|NCT04785625|Placebo Comparator|Placebo implant|Placebo collagen-matrix implant
16284364|NCT04785612|Experimental|RSVPreF|A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume
16284365|NCT04785612|Placebo Comparator|Placebo|A single intramuscular injection of Placebo to match active vaccine
16284366|NCT04785599|Experimental|Group EC1: Exercices, informative talk|Group EC1 carried out the conventional prevention program consisting of an informative talk and an exercise program
16284367|NCT04785599|Experimental|Group ECCP2: Exercices, informative talk, compression garment|Group ECCP2 carried out the same program but with the addition of a prophylactic compression garment
16284368|NCT04785586|Experimental|Individual|"HWC protocol + three individual face-to-face sessions via video"
16284369|NCT04785586|Experimental|Group|"HWC protocol + three face-to-face group sessions via video"
16284370|NCT04785586|Active Comparator|Control|Standard HWC protocol
16284371|NCT04785573|Active Comparator|Intervention group|
16284372|NCT04785573|No Intervention|Control group|
16284373|NCT04785560|Active Comparator|Shunt setting 4 (=110 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 4 (110 mm H20), our standard setting.
16284374|NCT04785560|Active Comparator|Shunt setting 8 (=400 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 8 (400 mm H20 a k a virtual off), in practice a closed non-functional shunt.
16284375|NCT04785547|Experimental|Blincyto|Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.
16284376|NCT04785534|Experimental|Screening (survey, biomarker analysis, fibroscan)|Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.
16284377|NCT04785521||BM patients|Adult patients carrying new diagnosed BM confirmed by MRI
16284378|NCT04785521||No BM patients|Adult patients carrying extracranial tumor without BM as confirmed by MRI
16284379|NCT04785521||Benign lesion patients|Adult patients carrying intracranial extra-axial tumor as as confirmed by MRI
16284380|NCT04785508|Experimental|treated group|neuromuscolar tape application
16284381|NCT04785508|Active Comparator|control group|antigravity position
16284382|NCT04785495||Cancer Patients Exposed to Highly Emetogenic Chemotherapy|Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.
16284383|NCT04785482||Parents of infants with single ventricle heart disease|All participants
16284384|NCT04785469|Experimental|Eccentric training group|
16284385|NCT04785469|Active Comparator|Control group|
16284386|NCT04785456|Experimental|Active TBS|"Daily, 4-week, 5-days per week treatment sessions, each consisting of:
~First, intermittent TBS (iTBS) over the L-DLPFC: triplet 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, (600 pulses per session, total duration of 3 min 9 s), then continuous TBS (cTBS) over the R-DLPFC as 40 s uninterrupted bursts (600 pulses). Intensity at 120% resting motor threshold (RMT)."
16284387|NCT04785456|Sham Comparator|Sham TBS|Daily, 4-week, 5-days per week treatment sessions. The sham coil will generate auditory and somatosensory (vibratory) stimuli identical to the active stimulation.
16284388|NCT04785443|Experimental|ICG group|Patient receiving 3 intraoperative injections of indocyanine green.
16284389|NCT04785443|Other|Control group|Patient benefiting from the traditional surgical act
16284390|NCT04785430||Patients who underwent elective inguinal hernia surgery|Patients who have applied to the general surgery outpatient clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with inguinal hernia and underwent hernia repair surgery.
16284391|NCT04785430||Patients who underwent emergency inguinal hernia surgery|Patients who have applied to the emergency clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with incarcerated inguinal hernia and underwent hernia repair surgery.
16284392|NCT04785417|No Intervention|CONTROL GROUP|received conventional occupational therapy program
16284393|NCT04785417|Experimental|STUDY GROUP|received conventional occupational therapy program in addition to using tablet
16284394|NCT04785404|Experimental|primary skin closure|in this group, skin wound will be primarily closed
16284395|NCT04785404|No Intervention|secondary skin closure|skin will be left open to heal by secondary intention
16284396|NCT04785391||Patients with KDIGO stage 2 or 3 AKI|
16284397|NCT04785378|Experimental|Study Group|
16284398|NCT04785365|Other|Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001|
16284399|NCT04785352|No Intervention|Standard well-baby care|Children in this arm (control group), as well as children in the two intervention groups, will receive standard care as outlined in the Essential Package of Health Services by Haiti's Ministry of Public Health and Population (MSPP). This includes a World Health Organization (WHO) immunization schedule of vaccines, high dose vitamin A supplements, and growth monitoring and promotion.
16284400|NCT04785352|Experimental|Nutrition Intervention|Children in this arm will receive one egg per day for six months.
16284401|NCT04785352|Experimental|Grandi Byen|This arm comprises a multicomponent intervention on responsive parenting, nutrition, hygiene, and one egg per day for six months for children.
16284402|NCT04785339|Experimental|one-arm, pre-post design|This study will test an intervention in adult Latinx immigrants. There will be no control condition or other comparators. One condition will only provide data at pre (baseline) and post. The only comparison will be across time, but not across conditions as this will be the only condition and all participants will receive the same intervention.
16284403|NCT04785326|Experimental|DMB-3115|Patients randomized to receive DMB-3115 at the beginning of the study will continue to receive the same treatment
16284404|NCT04785326|Active Comparator|Stelara|Patients randomized to receive Stelara at the beginning of the study will be re-randomized at Week 28 in a 1:1 ratio to either continue on Stelara or will be transitioned to receive DMB-3115
16284405|NCT04785313||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) placed because of temporary contraindication to curative anticoagulation and that was been removed by the radiology department at the University Hospital of Saint-Etienne, between January 1, 2010 and December 31, 2014. All the Inferior Vena Cava Filters (IVCF) were been sent for histological examination.
16284406|NCT04785300|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
16284446|NCT04785079|Experimental|Graston effect medial arch, plantar fascia, and trapezius|Pre and post Graston change in blood flow at the medial arch foot, plantar fascia, and the trapezius region
16284407|NCT04785287|Experimental|Arm I (BMS-986218, SBRT)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 IV over 30 minutes on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT on days 36-39 (days 8-11 of cycle 2).
16284408|NCT04785287|Experimental|Arm II (BMS-986218, SBRT, nivolumab)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 and SBRT as in Arm 1. Beginning cycle 2, patients also receive nivolumab IV over 30 minutes starting on day 1. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16284409|NCT04785274||SpHb|
16284410|NCT04785274||Control|
16284411|NCT04785261|Active Comparator|conventional treatment|Patients in this group will be given conventional treatment including Artelac® Eye Drops (1-2 drips each time, every 4 hours) and Vidisic® Gel (1 drip each time, at bedtime) for 12 weeks.
16284412|NCT04785261|Experimental|conventional treatment + TCM|Patients in this group will be given conventional treatment and traditional Chinese medicine (6.0g twice daily) for 12 weeks.
16284413|NCT04785248|No Intervention|Controlled group|the routine preoperative disinfection method
16284414|NCT04785248|Experimental|Three-step disinfection|new developed method of preoperative disinfection
16284415|NCT04785235||ACS|Group ACS: Acute Coronary Syndrome
16284416|NCT04785235||Periodontitis|Group P :Periodontitis
16284417|NCT04785222|Experimental|DB|Group DB: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
16284418|NCT04785222|Active Comparator|BP|Group BP: Bilateral infraorbital nerve block with 0.5% plain bupivacaine, a volume of 2 ml per side
16284419|NCT04785222|Placebo Comparator|NS|Group NS (control): Bilateral infraorbital nerve block with normal saline 2 ml per side
16284420|NCT04785209||No complication|Thrombolysis in myocardial infarction flow grade III flow after PPCI, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
16284421|NCT04785209||No reflow|No reflow phenomenon after pci on STEMI patients, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
16284422|NCT04785196|Experimental|APG-115+Toripalimab|
16284423|NCT04785183|Experimental|Melatonin Group|
16284424|NCT04785183|Placebo Comparator|Control Group|
16284425|NCT04785170|Experimental|amino acid|"Dose: 1000 mg/day (500 mg/Capsule) Regimen: One capsule after breakfast & one capsule after dinner to be taken with a glass of water.
~Duration: 14 Days"
16284426|NCT04785157||severe COVID-19 patients with delirium|i) SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF) ii) systemic and central immune response characterization, associated to the assessment of CNS damage biomarkers (peripheral blood and CSF) iii) in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia) iv) structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity) v) multi-domains neurocognitive assessment.
16284427|NCT04785144|Experimental|Arm 1A|50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
16284428|NCT04785144|Experimental|Arm 1B|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
16284429|NCT04785144|Experimental|Arm 2A|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
16284430|NCT04785144|Experimental|Arm 2B|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
16284431|NCT04785144|Experimental|Arm 2C|100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
16284432|NCT04785144|Experimental|Arm 2D|50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
16284433|NCT04785144|Experimental|Arm 2E|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
16284434|NCT04785144|Experimental|Arm 2F|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
16284435|NCT04785144|Experimental|Arm 2G|50 mcg of mRNA-1273 and 50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
16284436|NCT04785144|Experimental|Arm 2H|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
16284437|NCT04785131|Experimental|Prune group|Oral contraceptive users will consume 50 grams prunes daily.
16284438|NCT04785131|No Intervention|Oral contraceptive users|Oral contraceptive users will be monitored throughout the study period.
16284439|NCT04785131|No Intervention|Non oral contraceptive users|Non oral contraceptive users will be monitored throughout the study period.
16284440|NCT04785118|Active Comparator|buscopan|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
16284441|NCT04785118|Active Comparator|ondansetron|Patients will receive IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
16284442|NCT04785118|Placebo Comparator|control|Patients will receive 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
16284443|NCT04785105||patient with isolated SMA stenosis|patient with isolated SMA stenosis on initial scanner
16284444|NCT04785105||patient with both SMA stenosis and CA or/and IMA stenosis|patient with both SMA stenosis and CA or/and IMA stenosis on initial scanner
16284445|NCT04785092|Experimental|Treatment - All Autologous Cartilage Regeneration|
16284447|NCT04785066|Experimental|Study treatment|Administration of dornase alfa during intervention of thrombectomy
16284448|NCT04785053|Active Comparator|Healthy young participants|a group of 20 cognitively intact younger participants (age 21-35)
16284449|NCT04785053|Active Comparator|Healthy older participants|A group of 20 cognitively intact older participants (age 55+)
16284450|NCT04785053|Active Comparator|Older MCI/mild AD participants|A group of 20 cognitively impaired older participants (age 55+)
16284451|NCT04785040||1|
16284452|NCT04785027|Other|PSORI-CM01 group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.
~PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
16284453|NCT04785027|Experimental|Gu Ben Hua Yu group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.
~Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
16284454|NCT04785014|Experimental|aspiration group|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
16284455|NCT04785014|Active Comparator|control group|no aspiration was performed in the control group. Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
16284456|NCT04784988|Experimental|PROPEL-like arm|Adynovate prophylaxis targeting a 12% FVIII through level based on PK assessment with my-PK-fit
16284457|NCT04784988|Active Comparator|Control arm|standard treatment with plasma derived or recombinant products containing FVIII according to current guidelines
16284458|NCT04784975||Preclinical Type 1 Diabetes|"Adolescents and young adults with preclinical diabetes (having at least 2 positive diabetes autoantibodies but who do not meet criteria for clinical diagnosis of type 1 diabetes).
~There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health."
16284459|NCT04784975||New Onset Type 1 Diabetes|Adolescents and young adults with a diagnosis of clinical type 1 diabetes. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
16284460|NCT04784975||Long standing Type 1 Diabetes|Adolescents and young adults with type 1 diabetes for at least 2 years. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
16284461|NCT04784975||Control|Adolescents and young adults without any evidence of diabetes or hyperglycemia. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
16284462|NCT04784962|No Intervention|Control Arm|Standard rehabilitation care including physiotherapy
16284463|NCT04784962|Experimental|Intervention Arm|Standard rehabilitation care including physiotherapy + Adjunctive Neuromuscular Stimulation Device Usage
16284464|NCT04784949|Experimental|Portland cement|pulpotomy with PRF and white Portland cement
16284465|NCT04784949|Experimental|Mineral trioxide aggregate|pulpotomy with PRF and Mineral trioxide aggregate
16284466|NCT04784949|Experimental|Biodentine|pulpotomy with PRF and Biodentine
16284467|NCT04784923||Instrumentation patients|Instrumentation patients
16284468|NCT04784910|Experimental|DWP14012 20mg|orally, once daily
16284469|NCT04784910|Active Comparator|Lansoprazole 15mg|orally, once daily
16284470|NCT04784897|Experimental|Brilacidin + SoC|Brilacidin IV infusion, 3 days and up to 5 days, in addition to Standard of Care
16284471|NCT04784897|Placebo Comparator|Placebo + SoC|Placebo IV infusion, 3 days and up to 5 days, in addition to Standard of Care
16284472|NCT04784884|Experimental|HSI-Pilot|Diagnostic hyperspectral imaging of the bronchus stump or bronchus anastomosis after lung resection and calculating the stump or anastomotic Perfusion measures, respectively
16284473|NCT04784871|Experimental|5waysA Intervention|The intervention, 5WaysA, is a 10 week modified web-based version of the original Five Ways to Wellbeing course. The intervention consists of a two-hour main webinar with live lecturing from a facilitator introducing the Five Ways to Wellbeing framework and teaching the participants how to implement the five health promotive activities in life, a booster session webinar four weeks later, as well as an SMS message twice a week in the six following weeks. Each SMS encourages participants to engage in one of the five activities, register activities/goals and queries about the degree of participation in the activity introduced in the previous SMS.
16284474|NCT04784871|Other|5waysA Active wait-list control|The active wait-list control group will get the same intervention as the interventions group, five months later. The active wait-list control group will be encouraged (in SMS messages) to write down an activity log once a week in ten weeks, while waiting. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
16284475|NCT04784871|Other|5waysA Inactive wait-list control|The inactive wait-list control group will get the same intervention as the interventions group, five months later. The inactive wait-list control group will not do anything specific while waiting for the intervention. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
16284477|NCT04784832|Placebo Comparator|Sequence 1 - Control|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation No mental training
16329632|NCT04472390||Discontinuing|TNF-α inhibitors
16284478|NCT04784832|Experimental|Sequence 1 - Training (same Task)|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
16284479|NCT04784832|Experimental|Sequence 1 - Training (similar task)|Motor task (Pretest and Posttests with a similar task in immediate post test) Transcranial magnetic stimulation Mental training
16284480|NCT04784832|Experimental|Sequence 1 - Training (different task)|Motor task (Pretest and Posttests with a different task in immediate post test) Transcranial magnetic stimulation Mental training
16284481|NCT04784832|Experimental|Sequence 2 - Mental|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
16284482|NCT04784832|Experimental|Sequence 2 - Physical|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
16284483|NCT04784832|Sham Comparator|Sequence 3 - Control 1|Mental Training Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
16284484|NCT04784832|Active Comparator|Sequence 3 - Control 2|Paired Associative Stimulation Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
16284485|NCT04784832|Experimental|Sequence 3 - Training (same task)|Paired Associative Stimulation Mental training (one task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
16284486|NCT04784832|Experimental|Sequence 3 - Training (different task)|Paired Associative Stimulation Mental training (two tasks) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
16284487|NCT04784832|Sham Comparator|Sequence 4 - Control|Transcranial magnetic stimulation Motor task Mental training
16284488|NCT04784832|Experimental|Sequence 4 - Cathodal|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
16284489|NCT04784832|Experimental|Sequence 4 - Anodal|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
16284490|NCT04784832|Experimental|Sequence 4 - Immobilization|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
16284491|NCT04784806|Experimental|Consumption of ground beef|Consuming 106g of cooked ground beef (85% lean) to deliver 20g of protein.
16284492|NCT04784806|Experimental|Consumption of ground pork|Consuming 118g of cooked ground pork (72% lean) to deliver 20g of protein.
16284493|NCT04784806|Experimental|Consumption of tofu burger|Consuming 113g of cooked tofu to deliver 20g of protein.
16284494|NCT04784806|Experimental|Consumption of Beyond Meat burger|Consuming 113g of Beyond Meat burger to deliver 20g of protein.
16284495|NCT04784793|No Intervention|Phase1: Design and development|"We conducted focus group meetings to discuss the content, features and design of the app.
~The focus group consisted of physiotherapists and young adults. The focus group members discussed the variety of topics in subgroups (login parameters, self-monitoring, exercises content, video or animation types, exercise diary, reminders, encouragement, method, etc)."
16284496|NCT04784793|No Intervention|Phase 2: Testing the app|We tested the prototype version app interface in the 2nd phase. All participants downloaded the prototype app and used the app for one week.
16284497|NCT04784793|No Intervention|Phase 3: Usability evaluation|"We conduct a think-aloud interview and evaluate the quantitative usability in the third phase.
~The quantitative usability was assessed by the System Usability Scale (SUS), and the adapted Usability, Satisfaction and Ease to Use (USE) Questionnaire."
16284498|NCT04784793|Active Comparator|Phase 4: Pilot randomized controlled trial/ The app-based group|"The app-based group:
~Participants in the intervention group received their smartphone-based- home exercise program."
16284499|NCT04784793|Experimental|Phase 4: Pilot randomized controlled trial/ The control group|"The control group:
~Participants in the control group received their home exercise programs as a paper handout."
16284500|NCT04784780|Experimental|Elobixibat|AJG533 (elobixibat) 10 mg orally once a day before meals for 12 weeks
16284501|NCT04784780|Placebo Comparator|Placebo|AJG533 placebo orally once a day before meals for 12 weeks
16284502|NCT04784767|Experimental|1A: 25 µg of SpFN + ALFQ on Days 1, 29 and 181.|Up to 20 participants will receive 25 µg of SpFN_1B-06-PL vaccine with 0.5 mL ALFQ adjuvant in a total 1.0 mL injection volume.
16284503|NCT04784767|Placebo Comparator|1B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
16284504|NCT04784767|Experimental|2A: 50 µg of SpFN + ALFQ on Days 1, 29, and 181.|Up to 20 participants will receive 3 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
16284505|NCT04784767|Placebo Comparator|2B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29, and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
16284506|NCT04784767|Experimental|3A: 50 µg of SpFN + ALFQ on Days 1 and 181.|Up to 20 participants will receive 2 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
16284507|NCT04784767|Placebo Comparator|3B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1 and 181.
16284508|NCT04784754|Placebo Comparator|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
16284509|NCT04784754|Experimental|Melatonin 3 mg|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
16284510|NCT04784754|Experimental|Melatonin 30 mg|Melatonin capsules will be prepared using hypromellose capsules containing 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
16284511|NCT04784741|Other|Control group|The control group was given the static hamstring muscle stretches, five sessions on alternative days according to the set protocols.
16284512|NCT04784741|Experimental|Experimental Group|Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.
16284513|NCT04784728|Experimental|Lidocaine topical system with swimming (Treatment A)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects swim for 15 minutes in a heated pool 4 hours after topical system application.
16284514|NCT04784728|Experimental|Lidocaine topical system with showering (Treatment B)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects take a 10-minute shower 8 hours after topical system application.
16284515|NCT04784728|Experimental|Lidocaine topical system under normal conditions (Treatment C)|One topical system is applied to the mid- to upper-back for 12 hours. Topical systems are not exposed to water during this period.
16284519|NCT04784689||Prospective - Cancer Patients that have received COVID-19 Vaccination|
16284520|NCT04784676|Experimental|nanohybrid composite blocks|nanohybrid composite CAD/CAM blocks
16284521|NCT04784676|Active Comparator|ceramic blocks|ceramic CAD/CAM blocks emax
16284522|NCT04784663|Experimental|Message Exposure|Participants exposed to 4 study videos over a one-month period and complete telephone-based assessments at baseline, 1- and 2-month follow up. Study videos are delivered by study's mobile app downloaded to participants' own Smartphone.
16284523|NCT04784663|Placebo Comparator|Wait List Control|While wait-listed, participants will receive one push notification each week thanking them for participation, informing them that they will receive messages in the near future or reminding them of the length of the study. Telephone-based assessments are completed at baseline, 1- and 2-month follow up. Push notifications are delivered by study's mobile app downloaded to participants' own Smartphone.
16284524|NCT04784650|Other|Pre-dialysis population|Pre-dialysis population, consisting both Diabetes Mellitus (DM) and non-DM patients
16284525|NCT04784637|Experimental|Group 1|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) for 6 weeks
16284526|NCT04784637|Experimental|Group 2|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) +Behavioral Adaptation Module (BAM) for 6 weeks
16284527|NCT04784611|Experimental|Group 1 - OP-ENS Intervention|Participants will be matched with a peer health navigator. As part of this complex behavioral intervention, participants and peer health navigators will engage in a systematic process of barrier and strength identification, goal setting and action planning related to issues of healthcare access and quality. Participants and peers will meet at least monthly over the course of the 12-month study period (but frequency is determined by participant need). Given the nature of the disability and healthcare experience, we anticipate the needs and therefore frequency will fluctuate over the duration of the study period. Beginning in month 10, participants and peers will engage in a period of transition planning to ensure that participants have the strategies and supports in place to assume the role of their own health navigator.
16284528|NCT04784611|No Intervention|Group 2 - Usual Care|Participants randomized to the usual care group will continue with their usual health and healthcare routines. Participants in the usual care group will receive a monthly newsletter with general interest information relevant to the disability community.
16284529|NCT04784598|Experimental|horseshoe piece group|Group 1- The intervention group I (n = 27) will receive a customized strip slipper with a 3mm EVA horseshoe piece (Shore A 28). And 2.5mm EVA cover (Shore A 28).
16284530|NCT04784598|Experimental|medial / lateral wedge piece group|Group 2- Intervention group II (n = 27) will receive a customized slipper with a 3mm EVA medial / lateral wedge piece (Shore A 42). And 2.5mm EVA cover (Shore A 28).
16284531|NCT04784598|Sham Comparator|Sham group|Group 3- The control group (n = 27 ) will receive a slipper with a 2.5mm EVA cover (Shore A 28) identical to the one used by the intervention group, but without corrective par
16284532|NCT04784585|Experimental|Enhanced Education|Theory-driven intervention focused on providing information about dietary quality and goals
16284533|NCT04784585|Experimental|Self-efficacy|Theory-driven intervention focused on providing skills to increase self-efficacy for following dietary goals
16284534|NCT04784585|Experimental|Motivation|Theory-driven intervention focused on providing skills to increase motivation for following dietary goals
16284535|NCT04784585|Experimental|Self-regulation|Theory-driven intervention focused on providing skills to increase self-regulation
16284536|NCT04784585|Active Comparator|Generic Risk Alert|A notification to alert participant of lapse risk, no additional intervention provided
16284537|NCT04784585|Sham Comparator|No Intervention|No notification or intervention is delivered to the participant during lapse risk
16284538|NCT04784572|Other|First injection delay and second injection delay|"During the first injection, the patient will make 3 scales: END, EVAF and insight and there will be an assessment of induration, redness and swelling done with nurses.
~During the second injection, the patient will perform the END and EVAF scale and then follow up with a maintenance"
16284596|NCT04784234|Placebo Comparator|Placebo Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
16284542|NCT04784546||Mild COVID-19 Infection Group|Mild cases present with acute symptoms of respiratory tract infection and gastrointestinal complaints.
16284543|NCT04784546||Moderate COVID-19 Infection Group|Moderate patients experience pneumonia, they don't have clinically aberrant hypoxemia(O2 saturation is more than 90%) but they have positive findings on chest computerized tomography (CT) scans.
16284544|NCT04784546||Severe COVID-19 Infection Group|Severe patients present with pneumonia, they have hypoxemia (O2 saturation is less than 90%) and have positive findings on chest computerized tomography (CT) scans.
16284545|NCT04784533|Experimental|Part A, Period 1 - Low dose|8 mg BID CTP-543 for 24 weeks
16284546|NCT04784533|Experimental|Part A, Period 1 - High dose|12 mg BID CTP-543 for 24 weeks
16284547|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from low dose|Dose reduction for a maximum of 24 weeks for those previously receiving 8 mg BID
16284548|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from low dose|Placebo for a maximum of 24 weeks for those previously receiving 8 mg BID
16284549|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from high dose|Dose reduction for a maximum of 24 weeks for those previously receiving 12 mg BID
16284550|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from high dose|Placebo for a maximum of 24 weeks for those previously receiving 12 mg BID
16284551|NCT04784533|Experimental|Part B - Low dose|8 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
16284552|NCT04784533|Experimental|Part B - High dose|12 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
16284553|NCT04784520|Experimental|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
16284554|NCT04784507|Experimental|En Bloc Resection Bladder Tumor (Any energy source)|Patients with suspicion of NMIBC (primary or recurrent) that underwent en bloc resection (EBRT
16284555|NCT04784507|Active Comparator|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Patients with suspicion of NMIBC (primary or recurrent) that underwent conventional TURBT
16284556|NCT04784494|Experimental|Magnetic Seizure Therapy|MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.
16284557|NCT04784481|Experimental|Experimental Group|"The EG received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
~All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol"
16284558|NCT04784481|No Intervention|Control Group|Conventional treatment. All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol
16284559|NCT04784468||Covid-19|Covid-19 patients
16284560|NCT04784468||Influenza|Influenza patients
16284561|NCT04784468||Cotrol|Control group
16284562|NCT04784455|Experimental|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within 100 days of HSCT
16284563|NCT04784442|Experimental|ETC-1002 180mg|
16284564|NCT04784442|Experimental|ETC-1002 120mg|
16284565|NCT04784442|Experimental|ETC-1002 60mg|
16284566|NCT04784442|Placebo Comparator|Placebo|
16284569|NCT04784416|Experimental|Transcranial Photobiomodulation (t-PBM)|
16284570|NCT04784416|Sham Comparator|Sham|
16284571|NCT04784403||Students and workers at the University of Barcelona|"The study population will be randomly selected from the different groups of the University:
~Students from the different centers and type of studies (undergraduate / graduate).
~Administrative and service personnel.
~Teaching and Research Staff."
16284572|NCT04784390|Active Comparator|Patching|Patching of the sound eye (fellow eye) - patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
16284573|NCT04784390|Experimental|Binocular video games|Binocular video games - patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
16284574|NCT04784377|Experimental|High laser group|
16284575|NCT04784377|Experimental|low laser group|
16284576|NCT04784377|Other|control group|
16284577|NCT04784351||Training|A subset of patients that are used to train the machine learning algorithm.
16284578|NCT04784351||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
16284579|NCT04784338|Experimental|Virtual shared teaching kitchen program|Participants will participate in virtual shared medical appointments that utilize the teaching kitchen
16284580|NCT04784325|Experimental|Women recruited from a general population subject to I/E criteria|All study participants will administer three blood collection modalities (2 TAP II, 1 ADx card, and phlebotomist-performed venipuncture).
16284581|NCT04784312|Experimental|9MW1411 injection|
16284582|NCT04784312|Experimental|9MW1411 injection placebo|
16284583|NCT04784299|Experimental|YVOIRE volume plus|Hyaluronic acid dermal filler
16284584|NCT04784299|Active Comparator|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
16284597|NCT04784234|Active Comparator|GlaucoCetin Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
16285160|NCT04780308||1 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 1 lateral K-wire
16284585|NCT04784286|Active Comparator|Telemedicine 30-day follow-up visit|"The Center for Connected Care will arrange for 30-day post-op telemedicine visits via a secured video application. When there is a telemedicine visit, the Center of Connected Care will connect the patient and then page the midlevel provider and dietitian after the electronic rooming process is complete & the patient is ready.
~A survey about post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-op care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for care outside of the direct medical costs, along with an open question asking for comments & feedback about their overall experience with their follow-up appointment."
16284586|NCT04784286|Active Comparator|In-person 30-day follow-up visit|"Standard practice of having bariatric surgery patients follow up with the bariatric surgery midlevel providers as well as with dietitians within 30-days after their bariatric procedure. The bariatric surgery midlevel providers are staffed and supported by our bariatric surgeons in case if they have questions or concerns.
~Participants will be contacted via telephone and will be surveyed about their post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-operative care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for their care outside of the direct medical costs, along with an open question that will ask patients to provide comments and feedback about their overall experience with their follow-up appointment."
16284587|NCT04784273||All study patients|Device - DynaNail - Utilization of a novel dynamic compression pseudoelastic intramedullary nail
16284588|NCT04784260||Group A (normozoospermic): >15 mill/ml and >32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing, library preparation and bioinformatic analysis.
16284589|NCT04784260||Group B (normozoospérmic): <15 mill/ml and <32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing,library preparation and bioinformatic analysis.
16284590|NCT04784247|Experimental|Leiomyosarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
16284591|NCT04784247|Experimental|High grade undifferentiated pleomorphic sarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal . Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
16284592|NCT04784247|Experimental|Vascular sarcomas (including angiosarcoma and epithelioid hemangioendothelioma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
16284593|NCT04784247|Experimental|Other soft tissue sarcomas (including synovial sarcoma and malignant peripheral nerve sheath tumor|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
16284594|NCT04784247|Experimental|Bone sarcomas (including osteosarcoma and chondrosarcoma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
16284595|NCT04784234|Active Comparator|GlaucoCetin Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
16284643|NCT04783909||PEX|42 eyes with PEX syndrome and coexisting cataract
16284598|NCT04784234|Placebo Comparator|Placebo Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
16284599|NCT04784221|Experimental|Radiation by protontherapy associated to nanoparticles injection|
16284600|NCT04784208||Arm 1-Healthy Volunteers|"Arm 1: Subjects from the general population who are naïve to their hypothyroid status.
~The Subjects will be randomly selected and will be equally stratified between genders and socio-economics statuses from places where groups of general populations are located"
16284601|NCT04784208||Arm 2- Hypothyroid treatment naïve patients|The subjects will be identified and selected from clinical settings such as hospitals, clinics and certified laboratories.
16284602|NCT04784195||Profesional acrobatics|Profesional Acrobatic Skyedivers as the cort group
16284603|NCT04784195||General active participations|Adults with meched caracteristics with the profesional acrobatics
16284604|NCT04784182|Experimental|Synbiotic supplement group|Daily consumption of pills containing prebiotics and probiotics
16284605|NCT04784182|Placebo Comparator|Placebo group|Daily consumption of pills containing maltodextrin
16284606|NCT04784169|Experimental|free middle turbinate flap group|A free middle turbinate flap is used to repair the leakage
16284607|NCT04784169|Active Comparator|vascularized nasoseptal flap|A vascularized nasoseptal flap is used to repair the leakage
16284608|NCT04784156||All study patients|"All study patients will be in one group.
~Interventions:
~Procedure: Subtalar (Talocalcaneal) arthrodesis Device: DynaNail Mini"
16284609|NCT04784143|Active Comparator|Two MDMA-assisted Psychotherapy Sessions|Two Experimental Sessions of MDMA-assisted Psychotherapy
16284610|NCT04784143|Active Comparator|Three MDMA-assisted Psychotherapy Sessions|Three Experimental Sessions of MDMA-assisted Psychotherapy
16284611|NCT04784130|Experimental|DHSMP core|Dietary Modification and Physical Activity
16284612|NCT04784130|Experimental|DHSMP core plus|Dietary Modification, physical activity and medication adherence
16284613|NCT04784130|Active Comparator|DHSMP control|enhanced usual care-3 hours of education plus materials.
16284614|NCT04784117||Subgroup 2016-2018|Subgroup before change of dispatcher protocol
16284615|NCT04784117||Subgroup 2019-2021|Subgroup after change of dispatcher protocol
16284616|NCT04784104|Experimental|Supraclaviculer block|The coronal oblique supraclavicular block will be applied to the first group with ultrasound guidance using a 22G 50 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.) Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
16284617|NCT04784104|Experimental|Infraclaviculer block|The lateral sagittal infraclavicular block will be applied to the second group with ultrasound guidance using a 22G 100 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.). Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
16284618|NCT04784091|Experimental|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
16284619|NCT04784091|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
16284620|NCT04784078|Experimental|dTRA group|
16284621|NCT04784078|Active Comparator|cTRA group|
16284622|NCT04784065|Active Comparator|Treatment arm with control orthosis|
16284623|NCT04784065|Experimental|Treatment arm with experimental orthosis|
16284624|NCT04784052|Experimental|Depleted Stem Cell Transplant with JSP-191 Conditioning|Participants will receive an infusion of donor stem cells which have been depleted of αβ+T cells using the CliniMACS System device. Before the stem cell transplant, they will receive a reduced-intensity preparative regimen containing JSP191 in combination with rATG, cyclophosphamide, fludarabine and rituximab.
16284625|NCT04784039|Active Comparator|TEE-group|
16284626|NCT04784039|Active Comparator|DD-group|
16284627|NCT04784026||Healthy Control Group|Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association for the purpose of sports, newly registered and between the ages of 6-18 will constitute the control group of the study.
16284628|NCT04784026||Case Group|The sample of the study will be inpatient and outpatient pediatric patients between the ages of 6-18 who have been diagnosed with cancer in the Pediatric Hematology-Oncology Clinics of Afyonkarahisar Health Sciences University Health Application and Research Center Department of Pediatrics.
16284629|NCT04784013|Active Comparator|Conventional group|
16284630|NCT04784013|Active Comparator|90W-group|
16284631|NCT04784000|Experimental|AT-527 550 mg + carbamezepine|
16284632|NCT04784000|Experimental|AT-527 1100 mg + carbamezepine|
16284633|NCT04783987||Healthy Control Group|Walking Assessments will be practised under dual and single task conditions.
16284634|NCT04783987||Case Group|Walking Assessments will be practised under dual and single task conditions.
16284635|NCT04783974||Patients assuming SSRI|Patients treated with dental implants and assuming selective serotonin reuptake inhibitors
16284636|NCT04783974||Patients assuming PPI|Patients treated with dental implants and assuming proton pump blockers
16284637|NCT04783974||Patients assuming Anti-inflammatory drugs|Patients treated with dental implants and assuming anti-inflammatory drugs
16284638|NCT04783974||Patients assuming Anti-hypertensive drugs|Patients treated with dental implants and assuming anti-hypertensive drugs
16284639|NCT04783974||Control group - Patients not assuming the studied drugs|Patients treated with dental implants and not assuming any of the following drugs: selective serotonin reuptake inhibitors, proton pump blockers, anti-inflammatory drugs, anti-hypertensive drugs
16284640|NCT04783935|Experimental|Mavenclad®|
16284641|NCT04783922||Benign Hematoma|Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand.
16284642|NCT04783922||Malignant Hematoma|Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome.
16284647|NCT04783857|Experimental|Progesterone + DMPA|Participants in this group will receive progesterone plus depot medroxyprogesterone acetate (DMPA)
16284648|NCT04783857|Active Comparator|Progesterone + Placebo|Participants in this group will receive progesterone plus the placebo injection treatment
16284649|NCT04783857|Active Comparator|Placebo + DMPA|Participants in this group will receive the placebo oral pill treatment plus depot medroxyprogesterone acetate (DMPA)
16284650|NCT04783857|Sham Comparator|Placebo + Placebo|Participants in this group will receive the placebo oral pill and injection treatments
16284651|NCT04783831||Biodegradable stent|
16284652|NCT04783831||Non-biodegradable stent|
16284653|NCT04783818||One Stage Reconstruction With Adjuvant Radiotherapy|
16284654|NCT04783818||Two Stage Reconstruction With Adjuvant Radiotherapy|
16284655|NCT04783818||Autologous Reconstruction With Adjuvant Radiotherapy|
16284656|NCT04783818||One Stage Reconstruction Without Adjuvant Radiotherapy|
16284657|NCT04783818||Two Stage Reconstruction Without Adjuvant Radiotherapy|
16284658|NCT04783818||Autologous Reconstruction Without Adjuvant Radiotherapy|
16284659|NCT04783805||Spontaneous HSIL regression|Patients that have spontaneous regression of HSIL throughout follow-up. Patients in this group will be further classified into 3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and cytology, and negative HPV for the HPV type initially detected); partial resolution (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL in either cytology, histology or colposcopy).
16284660|NCT04783805||Conization|Women who have cervical conization for any reason during follow-up. Patients in this group will be further classified according to indication criteria: failure to meet criteria for conservative management or persistence of HSIL after 24 months of follow-up.
16284661|NCT04783792|Experimental|ascorbic acid / phytochemical supplement|A mixture of active phenolic compounds with ascorbic acid
16284662|NCT04783792|Experimental|ascorbic acid|Ascorbic acid group
16284663|NCT04783779|Experimental|STARgraft-2|Participants will be implanted with 6mm diameter STARgraft-2 grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
16284664|NCT04783766|Experimental|CK-3773274 for Single Ascending Dose (SAD) Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274
16284665|NCT04783766|Placebo Comparator|Placebo comparator for SAD Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator
16284666|NCT04783766|Experimental|CK-3773274 for Multiple Dose (MD) Cohort|Subjects will receive multiple doses of CK-3773274
16284667|NCT04783766|Placebo Comparator|Placebo comparator for MD Cohort|Subjects will receive multiple doses of placebo comparator
16284668|NCT04783753|Experimental|EDP-514 and Itraconazole interaction (Part 1)|
16284669|NCT04783753|Experimental|EDP-514 and Carbamazepine interaction (Part 2)|
16284670|NCT04783753|Experimental|EDP-514 and Quinidine interaction (Part 3)|
16284671|NCT04783727|Experimental|Experimental arm|The individualised treatment durations defined by the RNA transcriptomic signature-based model
16284672|NCT04783727|No Intervention|Control arm|The locally accepted standard duration of treatment based on the WHO recommendation for treatment of MDR-TB patients
16284673|NCT04783714|Experimental|Active Group|"Active treatment comprises of 3 soft gel capsules daily (with food) of Swisse Nutra+ Cholesterol Balance, a novel combination nutraceutical containing bergamot juice extract, artichoke leaf extract, hydroxytyrosol and plant sterols, totaling a daily dose of 375 mg bergamot juice extract, 150 mg artichoke leaf extract, 50 mg hydroxytyrosol and 1.8 g sunflower phytosterols.
~Each capsule contains 125mg of bergamot juice extract, 50mg artichoke leaf extract, 16.67mg hydroxytyrosol and 600mg plant sterols.
~The intervention will be administered for 4 months (112 days)."
16284674|NCT04783714|Placebo Comparator|Placebo|3 soft gel capsules of matching placebo daily (total daily dose of 696 mg palm olein and 232 mg olive oil).
16284675|NCT04783688|Experimental|Experimental Group|All subjects will snorkel using the same FFSMs.
16284676|NCT04783675|Experimental|Intervention/treatment|
16284677|NCT04783662||Robust|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal to 0
16284678|NCT04783662||Pre Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is 1 or 2
16284679|NCT04783662||Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal or greater than 3
16284680|NCT04783649||High risk group|Women in the age group between 25 and 65 years old without prior history of malignancy referred to colposcopy
16284681|NCT04783649||Population sample|A population sample of women in the age group between 25 and 65 years old from several primary healthcare facilities to primary cervical screening
16284682|NCT04783636|Other|A|After a single administration of PT105R (leuprorelin acetate 3.75mg), a single administration of PT105 (leuprorelin acetate 3.75mg)
16284683|NCT04783636|Other|B|After a single administration of PT105 (leuprorelin acetate 3.75mg), a single administration of PT105R (leuprorelin acetate 3.75mg)
16284684|NCT04783623||Non-recurrence group|
16284685|NCT04783623||Recurrence group|
16284686|NCT04783610|Experimental|Study subjects for vHIT- and VOG-measurements|Each study subject is his/hers own comparator at different phases of ethanol consumption.
16284687|NCT04783571|Experimental|Schizophrenia|Adult outpatients with a diagnosis of schizophrenia.
16284688|NCT04783571|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use.
16284689|NCT04783558|Experimental|Adapted NAS tool Intervention|Pregnant women in this condition will receive the adapted mobile-based NAS instructional tool and TAU. Women in this condition will go through the NAS instructional tool at least once during pregnancy, with their choice of going through the modules gradually while waiting at the OAT clinic to receive their dose, or by scheduling a time to review the modules. Participants will have free online access to the tool throughout their third trimester as well as through 12-weeks postpartum so they can access the modules at any time, and as many times as desired, including after giving birth.
16284987|NCT04781517||Short-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments less than 3 was divided into Short-segment group(200).
16284690|NCT04783558|No Intervention|Treatment-as-Usual (TAU)|Pregnant women in this condition will receive care as usual that involves continued enrollment in OAT and continued obstetric care. We will also provide them with a printed handout containing information on NAS and local resources. Participants in the TAU condition will not receive iPads with accompanying modules, however the handout constitutes more information than they normally receive.
16284691|NCT04783545|Experimental|Single Ascending Dose Cohorts 1-6|Drug: VLX-1005
16284692|NCT04783545|Placebo Comparator|Single Ascending Dose Cohorts 1-6, Placebo|Drug: Placebo
16284693|NCT04783545|Experimental|Multiple Ascending Dose Cohorts 7-9|Drug: VLX-1005
16284694|NCT04783545|Placebo Comparator|Multiple Ascending Dose Cohorts 7-9, Placebo|Drug: Placebo
16284695|NCT04783532|Experimental|Telehealth Mindfulness Program|Telehealth mindfulness sessions
16284696|NCT04783519|Experimental|BASICS + SLEEP|The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
16284697|NCT04783519|Active Comparator|BASICS|The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
16284698|NCT04783519|No Intervention|Assessment Only Control|Participants in Assessment Only Control (AOC) condition will complete all assessments (including survey, daily, actigraphy) at the same time as participants in the 2 active interventions. AOC will also attend an in-person meeting to verify identity, provide rationale for daily monitoring, control for time/attention, and participants in all conditions including AOC will receive referrals for community services to address alcohol and MJ use, sleep, and other mental health concerns. No participants will be deprived of services; use of outside services will be tracked to assist with interpretation of outcomes. AOC condition will be offered BASICS + SLEEP after 3-month follow-up.
16284699|NCT04783506||Suicidal Behavior|Adolescents who have suicidal behavior, which for this study, is defined by a recent (within 3 months of enrollment) suicide attempt or suicidal ideation warranting urgent evaluation.
16284700|NCT04783506||At Risk for Mood Disorders|Adolescents at risk for mood disorders, which for this study, is defined by either personal history of anxiety disorder or substance use disorder or a history of trauma, or a first degree relative with a history of a mood disorder or suicidal history.
16284701|NCT04783506||Healthy Control|Healthy adolescents with no lifetime history of any psychiatric or substance use disorders or a history of trauma. Additionally, no first-degree family member with a history of a mood disorder or suicidal history.
16284702|NCT04783493|Active Comparator|ACTIVE|In the active group, non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold, this determined by abdominal muscle contractions, found from single pulses, applied gradually every 10 seconds until the contractions appear. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds.
16284703|NCT04783493|Placebo Comparator|PLACEBO|In the placebo group, a coil will be allocated in the T2-T3 thoracic region, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated. To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS).
16284704|NCT04783480|Active Comparator|Birthly plus standard of care|Women will receive a code to sign up for childbirth education classes through the Birthly platform. They will also participate in childbirth education at their own discretion.
16284705|NCT04783480|Placebo Comparator|Standard of Care|Women will not receive a code for the 3 Birthly courses. They will participate in childbirth education at their own discretion.
16284708|NCT04783454|Experimental|Intervention|"single (online) educational video on how the prevention program is designed and general advice on (how to adopt) a healthy lifestyle
~12-week training program: 2 sessions of 60 minutes per week, with the focus of the first session on cardiovascular exercises, and the focus of the second session on mobility and strengthening exercises"
16284709|NCT04783454|No Intervention|control|no intervention (wait and see approach)
16331811|NCT04456946|Experimental|Group of Low Level Laser Therapy|
16284710|NCT04783441|Active Comparator|Continuous glucose monitoring (CGM)|Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
16284711|NCT04783441|Placebo Comparator|Self monitoring of blood glucose (fingersticks)|The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
16284712|NCT04783428||Prior TIO Burosumab Clinical Trial Participants|
16284713|NCT04783428||Adults Who Have Not Participated In Prior Burosumab Clinical Trials|
16284714|NCT04783428||Pediatrics Who Have Not Participated In Prior Burosumab Clinical Trials|
16284715|NCT04783415|Experimental|Treatment (ublituximab, acalabrutinib, umbralisib)|"Patients receive ublituximab IV over 90 minutes-4 hours on days 1, 8, and 15 of cycle 1 and days 1 of cycles 2-6. Patients also receive acalabrutinib PO BID and umbralisib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ublituximab IV on day 1 on cycles 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30. Patients also receive acalabrutinib Po BID and umbralisib PO QD on day 1-28. Treatment repeats every 28 days for 24 cycles in the absence of disease progression of unacceptable toxicity."
16284716|NCT04783402|Experimental|e-OTCAT|The experimental group will receive the e-OTCAT program that consists of a 12-week videoconference-based occupational therapy intervention at the same time women with breast cancer receive chemotherapy.
16284717|NCT04783402|Other|Control Group|At the beginning of chemotherapy, the participants allocated to the control group will only receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care for these patients.
16284721|NCT04783376|Active Comparator|Arm 1 (usual treatment)|intervention A
16284722|NCT04783376|Active Comparator|Arm 2(splitted bolus dose, fast-acting insulin only)|intervention B
16284723|NCT04783376|Active Comparator|Arm 3 (splitted bolus dose, fast acting insulin before the meal and regular insulin after the meal)|intervention C
16284724|NCT04783363|Experimental|Arm A|"Visit 1: with Snoezelen session before invasive care
~Visit 2: standard care (=without Snoezelen session) before invasive care"
16284725|NCT04783363|Experimental|Arm B|"Visit 1: standard care (=without Snoezelen session) before invasive care
~Visit 2: with Snoezelen session before invasive care"
16284726|NCT04783350|Experimental|Transcranial alternating current stimulation (tACS)|Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.
16284727|NCT04783337|Experimental|HR-pQCT (high resolution computertomograph)|"This arm is the inverventional group for all collected cases. No other arms are available as comparator or control. All patients are treated the same.
~Description of the intervention in the section Intervention."
16284728|NCT04783324|Experimental|Experimental Group|Pregnant women in the intervention group will use the e-mobile health application developed by the researcher.
16284729|NCT04783324|No Intervention|Control Group|Pregnant women in the control group will not be intervened and standard care will be applied.
16284730|NCT04783311|Experimental|Phase 1 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
16284731|NCT04783311|Experimental|Phase 1 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
16284732|NCT04783311|Experimental|Phase 2 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
16284733|NCT04783311|Experimental|Phase 2 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
16284734|NCT04783311|Active Comparator|Phase 2 - Placebo comparator group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
16284735|NCT04783285|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.
16284736|NCT04783285|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed psychotic-specific medication.
16284737|NCT04783272|Experimental|Treatment|Photoacoustic Computed Tomography (PACT) Imaging
16284738|NCT04783246|Experimental|Group A- Intervention/Non-Intervention|Participants in this arm will initially be randomized to the intervention period and will receive the interventions for 11 weeks followed by no interventions for 11 weeks.
16284739|NCT04783246|Active Comparator|Group B- Non-Intervention/Intervention|Participants in this arm will initially be randomized to the non-intervention period for 11 weeks followed by the intervention period for 11 weeks.
16284740|NCT04783233||Packing with Gelfoam|Tympanoplasty surgery with fascia graft (either transcanal or post-auricular) will be preformed. The middle ear and external canal will then be packed with Gelfoam.
16284741|NCT04783233||Packing with Chitosan succinamide|The surgical intervention and tympanoplasty will be performed as normal. The middle ear and external canal will be packed Chitosan succinamide.
16284742|NCT04783220|Experimental|Intervention|The parents of babies in this group will receive an educational and intervention program
16284743|NCT04783220|No Intervention|Control|The parents of babies in this group will receive the standard parent education and follow-up.
16331812|NCT04456946|Experimental|Group of Occlusal Splint Treatment|
16284746|NCT04783194|Active Comparator|Dexamethasone + bupivacaine in bilateral TiPVB in lumbar spine surgery|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
16284747|NCT04783194|Active Comparator|Bupivacaine in bilateral TiPVB in lumbar spine surgery|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
16284748|NCT04783181|Experimental|Dose Level 1|BBP-631 lowest dose, administered once, intravenously (IV)
16284749|NCT04783181|Experimental|Dose Level 2|BBP-631 middle dose, administered once, IV
16284750|NCT04783181|Experimental|Dose Level 3|BBP-631, highest dose, administered once, IV
16284751|NCT04783168|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.
16284752|NCT04783168|Active Comparator|Arm II (usual care, Fitbit)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count
16284753|NCT04783168|Experimental|Arm III (usual care, Fitbit, Fitbit app)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device, install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.
16284754|NCT04783155|Experimental|12-weeks pulmonary rehabilitation training plus inspiratory muscle training|To assess maximum inspiratory pressure, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home.
16284755|NCT04783155|Placebo Comparator|12-weeks pulmonary rehabilitation plus placebo (inactive) inspiratory muscle|To assess maximum inspiratory pressure with placebo, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home. The resistance will be set to about 5% throughout the study.
16284756|NCT04783142|Other|High-fiber, low-protein diet|Participants will consume a high-fiber, low-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
16284757|NCT04783142|Other|Low-fiber, high-protein diet|Participants will consume a low-fiber, high-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
16284758|NCT04783129|Experimental|Face-to-face group|Face-to-face group (FFG), in which participants, in groups of 10 persons, followed a multidisciplinary health education program composed of 10 monthly face-to-face lectures
16284759|NCT04783129|Active Comparator|Remote group|Remote group (RG), in which individuals followed 10 monthly remote lectures
16284760|NCT04783129|Sham Comparator|Control group|Control group (CG), in which participants followed no education program (lectures)
16284761|NCT04783116|Experimental|Plant stanols (3g/day)|Consumption of plant stanol chews
16284762|NCT04783116|Placebo Comparator|Control|Consumption of placebo chews (without plant stanols)
16284763|NCT04783103|Active Comparator|Active adTMS|Subjects in the treatment arm receive 20 sessions of real adTMS . The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
16284764|NCT04783103|Sham Comparator|Sham adTMS|Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
16284765|NCT04783090|Experimental|1st cohort|MT1013 injection at 2.5 mg.
16284766|NCT04783090|Experimental|2nd cohort|MT1013 injection at 5 mg.
16284767|NCT04783090|Experimental|3rd cohort|MT1013 injection at 10 mg.
16284768|NCT04783090|Experimental|4th cohort|MT1013 injection at 15 mg.
16284769|NCT04783090|Experimental|5th cohort|MT1013 injection at 20 mg.
16284770|NCT04783077|Experimental|WhatsApp|
16284771|NCT04783077|Active Comparator|Control|
16284772|NCT04783051|Active Comparator|IPTp-SP|The IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy
16284773|NCT04783051|Experimental|ISTp-US-Py|The ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive
16284774|NCT04783038|Active Comparator|Distance Reiki|Subjects will be scheduled for once a week session of distance Reiki for 4 weeks.
16284775|NCT04783038|Sham Comparator|Sham Reiki|Subjects will be scheduled for once a week session of Sham distance Reiki for 4 weeks.
16284776|NCT04783038|No Intervention|Standard of Care|Subjects will not receive any Reiki treatment
16284777|NCT04783025|Experimental|Intervention Group (IG)|The participants in the IG will receive BGCTS, a blended training programme
16284778|NCT04783025|Active Comparator|Control Group (CG)|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staff.
16284779|NCT04783012|Experimental|Home removal of catheter after surgery|Patients randomized to home removal will be assigned to remove their catheters on postoperative day (POD) 2 (or if Th/F surgery, POD 4 or POD 3, respectively). They will be handed an instructional packed with visual, written and video instructions for catheter removal.
16284780|NCT04783012|Active Comparator|Office removal of catheter after surgery|Patients randomized to office removal will be assigned to return to the office on POD 2 (or if Th/F surgery, POD 4 or POD 3, respectively) for standard nurse visit with backfill, catheter removal and voiding trial in the office.
16284781|NCT04782999|Active Comparator|Oral glucose tolerance test|"Oral glucose tolerance test with ingestion of 75 g glucose and blood sampling.
~This test will be performed before and 3 months after RYGB."
16284782|NCT04782999|Active Comparator|Hyperglycemic clamp with saline infusion combined with arginine test|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 120 min with co-infusion of saline.
~After 120 min an arginine test with infusion of 50 g Arginine is performed.
~This test will be performed before, 1 week and 3 months after RYGB."
16284783|NCT04782999|Active Comparator|Hyperglycemic clamp with GLP-1 infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusion of intraveneous glucose for 90 min with co-infusion of GLP-1.
~This test will be performed before, 1 week and 3 months after RYGB."
16284784|NCT04782999|Active Comparator|Hyperglycemic clamp with GIP infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 90 minutes with co-infusion of GIP.
~This test will be performed before, 1 week and 3 months after RYGB."
16284785|NCT04782986|Experimental|Pan-intestinal capsule endoscopy|PillCam Crohn's capsule protocol
16284786|NCT04782986|Active Comparator|Conventional colonoscopy|Same-day colonoscopy under propofol sedation
16284787|NCT04782960|Active Comparator|20 patients receive Subconjunctival bupivacaine of the end of the surgery|20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score
16284788|NCT04782960|Placebo Comparator|20 patients receive Subconjunctival placebo in the end of operation|20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score
16284789|NCT04782934|Experimental|YANG system group|
16284790|NCT04782921|Experimental|Gel 40|Application of Gel 40
16284791|NCT04782921|Active Comparator|Gen-Os|Application of Gen-Os
16284792|NCT04782908|Experimental|Transcatheter tricuspid valve edge-to-edge repair|Patients will undergo transcatheter tricuspid valve edge-to-edge repair (TTVR) and hemodynamic characteristics will be analysed on a multimodal approach using cardiac magnetic resonance imaging and pressure volume loop analysis before and after TTVR.
16284793|NCT04782895|Experimental|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group|Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
16284794|NCT04782895|Active Comparator|Gardasil®9 group|Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9 .
16284795|NCT04782882|Experimental|intervention group|In the first session of the researcher (S.K.), the participants were explained the effects of anxiety and stress on the treatment in simple terms for 5 min. Then, information was given about the effects of laughter therapy and progressive muscle relaxation on the body. Laughter therapy was applied for 15-20 min. Then, the lights were turned off and progressive muscle relaxation exercises were performed for 15-20 min under candlelight and accompanied by music. The procedures were received as a group (2-6 people) in 3-4 face-to-face sessions.
16284796|NCT04782882|No Intervention|Control group|The control group then received routine care
16284797|NCT04782869|Experimental|tDCS (transcranial direct current stimulation)|Patient will be treated for 3 cycles. A cycle is composed of 5 bi-sessions (one per day) of 20 minutes each.
16284798|NCT04782856|Active Comparator|Single therapy|"Levothyroxine (LT4) and placebo (a look-alike inactive substance, a sugar pill) Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation."
16284799|NCT04782856|Experimental|Combination therapy|"Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3."
16284800|NCT04782843||Cohort|"he retrospective cohort studied includes all the patients included in a previous study carried out in our center, the objective of which was to study the diagnostic performance of the HEP score in surgical intensive care.
~The cohort studied is made up of all patients admitted for surgical resuscitation between October 2011 and October 2013 and validating the following criteria:
~Inclusion criteria: any adult patient (age ≥ 18 years), admitted to surgical intensive care, treated with heparin (UFH or LMWH), and suspected of TIH by a clinician in the department according to the criteria of the SFAR 2002.
~Non-inclusion criteria: minor patients, pregnant women and adults incapable."
16284801|NCT04782830|Experimental|placebo|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
16284802|NCT04782830|Active Comparator|Standard treatment|Either midodrine or atomoxetine at their regular dose.
16284803|NCT04782817|Experimental|High Flow Nasal Canula Oxygen Therapy|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
16284804|NCT04782817|Active Comparator|Provider Choice Standard Care|Participants be assigned standard provider choice of standard care therapy physician order set.
16284805|NCT04782804|Active Comparator|Capecitabine|Capecitabine as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
16284874|NCT04782310|Experimental|Group Pregabalin|Patients will receive oral Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
16284806|NCT04782804|Experimental|Capecitabine+PD-1 Antibody（Tislelizumab）|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery. PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
16284807|NCT04782791|Experimental|Nivo + SOX|Nivolumab plus SOX
16284808|NCT04782791|Active Comparator|Nivo|Nivolumab
16284809|NCT04782778|Active Comparator|Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
16284810|NCT04782778|Active Comparator|Ultrasound Guided Supraclavicular Block|US-guided supraclavicular block with 1 mg/kg Bupivacaine (%0,25)
16284811|NCT04782765|Experimental|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
16284812|NCT04782752|Experimental|Experimental: Radiation|"Patients will be differentiated into 4 groups:
~Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer
~Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer
~Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis.
~Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic).
~For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached."
16284813|NCT04782739||Description of PMTCT service provision and uptake at healthcare facilities|Aggregated data will be collected from all 1560 public healthcare facilities in Zimbabwe on key indicators including antenatal testing and treatment of HIV and syphilis, and management of HIV-exposed and HIV-positive infants. Data will be collected from March 2015 (5 years prior to the pandemic) to the end of the study, to explore trends over time.
16284814|NCT04782739||Neonatal admissions at Harare Children's Hospital|Individual-level patient data will be collected on all neonates admitted for care at Harare Children's Hospital, including on patient characteristics, clinical status at presentation and outcomes. Data will be collected from February 2019 to the end of the study, to explore trends over time.
16284815|NCT04782739||Qualitative study|Qualitative study of 20 pregnant/lactating women accessing routine PMTCT services and 10 community healthcare workers from the Mabvuku and Kuwadzana Polyclinics. The estimated enrolment of 30 participants given in the study design section above refers to participants from this group only.
16284816|NCT04782726|Placebo Comparator|Control Arm|After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the control arm, the radiation treatment planning will proceed as normal. Treatment planning is performed on Pinnacle. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
16284817|NCT04782726|Experimental|Research Arm|After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the research arm, a theoretical plan will be created after physician's segmentation and will be used as a guide for the final plan. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
16284818|NCT04782713|Other|PCP Evaluation of Smart PSA Screening Guidelines|Completing surveys at baseline, 3, 6, 9 and 12 months
16284819|NCT04782700|No Intervention|Watchful Waiting|The patients randomized to the watchful waiting group will not be prescribed any steroids at the time of randomization.
16284820|NCT04782700|Experimental|Prednisone (Steroid) Taper|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
16284875|NCT04782310|Experimental|Group Duloxetine|Patients will receive oral duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
16284876|NCT04782310|Experimental|Group Pregabalin& Duloxetine|Patients will receive single dose of Pregabalin 75mg + duloxetine 30mg two hour preoperatively, 75mg pregabalin 12 hour postoperative and then will continue pregabalin twice per day +duloxetine once after breakfast for one week.
16284985|NCT04781530|Experimental|Intervention (Device)|"Diagnostic Test: BioFire
~A molecular rapid syndromic testing platform, using the following panel:
~BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) In addition to standard of care"
16284825|NCT04782635|Experimental|AI group|"Care givers will be selected through permuted block.
~They will be explained the procedure of intervention and written consent will be asked.
~Mobile application will be installed in their mobile.
~They will be explained the working of mobile application
~Application will make a standard diet plan for the child according to the requirements of the child
~Then the child will use the application for one month.
~After one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application.
~Nutritional status of the patient will be monitored including weight, height, clinical signs, dietary history and will be updated in application.
~Then patient will follow the application for one month
~After another one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application and nutritional status will be measured"
16284826|NCT04782635|Other|usual care group|"Caregivers (Mothers/fathers/guardians) will be selected through permuted block.
~Patient weight, height, clinical signs will be noted.
~Caregivers will be handed over pamphlet regarding dietary instructions on discharge.
~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted including weight, height, clinical signs and dietary history.
~Patient will leave hospital with no added dietary instruction.
~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted weight, height, clinical sign, and dietary history."
16284827|NCT04782622||Apatinib+Camrelizumab|treated with apatinib+camrelizumab
16284828|NCT04782609|Experimental|20 mg Icapamespib cohort|Icapamespib will be administered orally once daily for each 28-day cycle. The initial dose in this trial will be 20 mg
16284829|NCT04782609|Experimental|dose expansion cohort|dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D)
16284830|NCT04782596|Experimental|One-centimeter resection|In the study subjects enrolled into this study arm, one-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
16284831|NCT04782596|Experimental|Two-centimeter resection|In the study subjects enrolled into this study arm, two-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
16284832|NCT04782583||CAS|
16284833|NCT04782583||TEMOIN|
16284834|NCT04782570|Experimental|Verum TMS|ITBS (intermittent Theta Burst Stimulation) over left frontal cortex
16284835|NCT04782570|Sham Comparator|Sham TMS|Sham TMS over left frontal cortex
16284836|NCT04782557|Experimental|EUS-guided PVA and HVA|Patient will undergo EUS-guided PVA and HVA
16284837|NCT04782544|Active Comparator|Treatment|5 grams of buttermilk powder daily for 10 weeks, oral.
16284838|NCT04782544|Placebo Comparator|Placebo|5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.
16284839|NCT04782518||Participants with PD|Adults with Parkinson Disease. This is an observational study without an intervention.
16284840|NCT04782505|Experimental|Cohort 1 (Part 1)|DWJ1248 100mg (100mg 1tab) PO
16284841|NCT04782505|Experimental|Cohort 2 (Part 1)|DWJ1248 200mg (100mg 2tab) PO
16284842|NCT04782505|Experimental|Cohort 3 (Part 1)|DWJ1248 300mg (100mg 3tab) PO
16284843|NCT04782505|Experimental|Group A (Part 2)|DWJ1248 100mg 2tab PO - Wash out - DWJ1248 200mg 1tab PO
16284844|NCT04782505|Experimental|Group B (Part 2)|DWJ1248 200mg 1tab PO - Wash out - DWJ1248 100mg 2tab PO
16284845|NCT04782492|Experimental|Y-composite graft|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
16284846|NCT04782492|Active Comparator|aortocoronary conduit|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
16284847|NCT04782479||in the air|the position of the practitioner's hand holding the tube was placed in the air while the assistant pulling back the stylet.
16284848|NCT04782479||on the cheek of a manikin|the position of the practitioner's hand holding the tube was placed on the cheek of a manikin while the assistant pulling back the stylet.
16284849|NCT04782466|Experimental|Intervention|The participant receives the intervention immediately following baseline measurements.
16284850|NCT04782466|Other|Waitlist attention-control|The participant receives the control condition for 6 months following baseline measurements. After 6 months, the baseline measurements are repeated and then the participant receives the intervention.
16284851|NCT04782453|Experimental|ToQuit|Participants from the ToQuit intervention arm will receive the messages on their mobile phones for 8 weeks. The messages will be sent for 3-4 days a week.
16284852|NCT04782453|Other|Control|Participants from the control group will be sent the details of other functional tobacco helplines in India.
16284853|NCT04782440|Experimental|Telerehabilitation|
16284854|NCT04782440|Active Comparator|Home exercise|
16284855|NCT04782401|Active Comparator|Genicular Nerve Block|
16284856|NCT04782401|Active Comparator|Physical Therapy|
16284857|NCT04782388|Experimental|Staccato alprazolam|Study participants will receive Single dose of Staccato alprazolam on Day 1 of the Treatment Period.
16284858|NCT04782388|Placebo Comparator|Staccato placebo|Study participants will receive placebo on Day 1 of the Treatment Period.
16284859|NCT04782375|Experimental|Treatment Arm A|discontinue antiviral treatment
16284860|NCT04782375|Active Comparator|Treatment Arm B|continue antiviral treatment
16284861|NCT04782349|Experimental|study group (A)|
16284862|NCT04782349|Experimental|study group (B)|
16284863|NCT04782349|Other|control group|
16284864|NCT04782336|Experimental|Group A (Sample Collection - Symptomatic Patients)|The patient will be completing or has completed a SOC Influenza A/B and/or COVID-19 and/or RSV test on the day of study.
16284865|NCT04782336|Experimental|Group B (Sample Collection - Asymptomatic Patients)|To enable the participation of site's who do not routinely providing SOC testing.
16284866|NCT04782323|Experimental|Group A aQII-1 Investigational|
16284867|NCT04782323|Experimental|Group B aQII-3 Investigational|
16284868|NCT04782323|Experimental|Group C aQII-6 Investigational|
16284869|NCT04782323|Experimental|Group D aQII-7 Investigational|
16284877|NCT04782297||Titan HD Catheter|The Titan HD Catheter is a double lumen catheter that provides 2 dedicated (arterial/venous) access lumens. Each lumen is connected through an extension line with female luer connectors. The arterial and venous catheter lumens connect to a hub to facilitate connection of extension tubes with clamps intended to prevent air/fluid communication and control fluid flow through the catheter. At the proximal end of the extension tubes are female Luer fittings to provide a needleless connection. The clamps and the sleeves are color-coded red for the arterial lumen and blue for the venous lumen. Each catheter has a cuff which is intended to be positioned underneath the skin at the skin exit to aid in securing the catheter and to provide a barrier to minimize the risk of infection. Each lumen is connected through an extension line with female Luer connectors. The transition between lumen and extension is housed within a molded hub.
16284878|NCT04782297||Hemo-Flow Catheter|The Hemo-Flow® Catheter has two lumens (one arterial lumen, one venous lumen) comprised of a biocompatible polymeric material that contains radiopaque filler to allow radiographic imaging of the distal tips to ensure proper placement into the superior vena cava. The arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment
16284879|NCT04782297||Hemo-Cath LT Catheter|"The Hemo-Cath® LT Catheter is designed for continuous extraction of a patient's blood and reinfusion of filtered blood. It has two lumens: the arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment. In order to increase filtering efficiency, the tip of the extraction (inflow) lumen is separated from the reinfusion (outflow) lumen, minimizing the reentry of dialyzed blood from the venous return into the arterial inflow (recirculation). This separation is achieved with a step-tip design."
16284880|NCT04782284|Experimental|Comprehensive swallowing rehabilitation|
16284881|NCT04782284|Active Comparator|Swallowing education|
16284882|NCT04782271|Experimental|Single administration Low Dose once daily|1 treatment day
16284883|NCT04782271|Experimental|Single administration Middle Dose once daily|1 treatment day
16284884|NCT04782271|Experimental|Single administration High Dose once daily|1 treatment day
16284885|NCT04782271|Experimental|Single administration High Dose twice daily|1 treatment day
16284886|NCT04782271|Experimental|Multiple administrations Low Dose once daily|7 treatment days
16284887|NCT04782271|Experimental|Multiple administrations Middle Dose once daily|7 treatment days
16284888|NCT04782271|Experimental|Multiple administrations High Dose once daily|7 treatment days
16284889|NCT04782271|Experimental|Multiple administrations High Dose twice daily|7 treatment days
16284890|NCT04782258|Experimental|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
16284891|NCT04782258|Experimental|Tolvaptan Tablets|Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later based on weight if able to swallow tablets.
16284892|NCT04782245|Experimental|Treatment group Daplagliflozin|
16284893|NCT04782245|Placebo Comparator|Control group|
16284894|NCT04782232||Patients with failing/absence of the right heart|Patients with acute or chronic, conservatively uncontrollable heart failure of varying pathogenesis, graded as stage III or IV according to NYHA, with an anticipated need for short-term to long-term right ventricular or biventricular support.
16284895|NCT04782206|Active Comparator|group 1|superior hypogastric plexus block
16284896|NCT04782206|Active Comparator|group 2|pulsed radiofrequency at S3 nerve root + superior hypogastric plexus block
16284897|NCT04782193|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
16284898|NCT04782180|Experimental|Rapid PrEP group|Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.
16284899|NCT04782167|Experimental|BRACE protocol|Researcher give Brace protocol to one group
16284900|NCT04782167|Experimental|Proprioception training|Researcher give proprioception protocol to one group
16284901|NCT04782141|Experimental|Positioning the trunk and upper limb to improve the coordination the hand.|The study investigated the effects of the trunk and upper limb positioning on improving wrist and hand coordination.
16284902|NCT04782128|Experimental|intravitreal 1.0mg RC28-E injection Q8|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
16284903|NCT04782128|Experimental|Experimental: intravitreal 1.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
16284904|NCT04782128|Experimental|Experimental: intravitreal 2.0mg RC28-E injection Q8|Subjects received 2.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
16284905|NCT04782128|Experimental|Experimental: intravitreal 2.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
16284906|NCT04782115|Experimental|1.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
16284907|NCT04782115|Experimental|1.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 1.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
16284908|NCT04782115|Experimental|2.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
16284986|NCT04781530|No Intervention|Control (Standard of Care)|Standard of Care
16285161|NCT04780308||1 medial 2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 2 lateral K-wire
16284909|NCT04782115|Experimental|2.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
16284910|NCT04782115|Experimental|control group|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of Conbercept every 4 weeks, for 3 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
16284911|NCT04782102|Experimental|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
16284912|NCT04782102|No Intervention|Care-as-usual|Care-As-Usual: all other kinds of interventions are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory (Chisholm et al., 2000; Roick et al., 2001)
16284913|NCT04782089|Experimental|Camrelizumab+Fluzoparib|
16284914|NCT04782076|Experimental|Dabigatran + Selpercatinib|Dabigatran as single dose administered orally on Day 1 followed by a single dose of dabigatran coadministered with a single dose of selpercatinib on Day 8 orally.
16284915|NCT04782063|No Intervention|No Intervention: Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
16284916|NCT04782063|Other|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
16284917|NCT04782050|Experimental|Study arm|
16284918|NCT04782037|Experimental|L-methylfolate supplementation|Children under 1 year of age in group A will receive 3 drops (90mcg) of L-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg) daily fior 5 days
16284919|NCT04782037|Placebo Comparator|distilled water|Subjects in Group B will receive equal amount of distilled water as placebo (i.e. 3 drops to <1yr age and 5 drops to >1 yr.
16284920|NCT04782024|Placebo Comparator|Placebo|
16284921|NCT04782024|Experimental|7-Keto 50mg|
16284922|NCT04782024|Experimental|7-Keto 25mg|
16284923|NCT04782011|Experimental|ATC/DDD arm|The intervention is the introduction of the ATC/DDD including the training of healthcare workers on its importance and usage in monitoring antibiotic use. The unit of intervention will be a health facility. Antibiotic prescriptions and antibiotic utilization records for adult patients (in-patients and ambulatory) from the selected facilities will be enrolled in the study.
16284924|NCT04782011|No Intervention|Control arm|The health care workers will continue with standard practice. However, the research team will collect data on antibiotic prescriptions and antibiotic utilization for adult patients (in-patients and ambulatory) from the selected facilities. The data will be compared with that of the intervention arm.
16284925|NCT04781998|Experimental|liraglutide 3 mg (Saxenda®) once-daily|
16284926|NCT04781985|Experimental|suprapubic cystolithotomy|Extraction of the vesical stone via open exploration of the bladder.
16284927|NCT04781972|Experimental|Methylphenidate first|Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.
16284928|NCT04781972|Placebo Comparator|Placebo first|Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.
16284929|NCT04781959|Active Comparator|5 Days of Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy.
16284930|NCT04781959|Active Comparator|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
16284931|NCT04781946|Experimental|Treatment Arm|Endoscopic pneumatic balloon dilation (PBD), gastric peroral endoscopic myotomy (G-POEM) and Roux-en-Y gastric bypass (RYGB) will be used for the management of post-LSG GSS using a predefined treatment algorithm.
16284932|NCT04781933|Active Comparator|Treatment with Combo|3 dietary supplements will be given
16284933|NCT04781933|Placebo Comparator|Treatment with Placebo|3 placebos will be given
16284934|NCT04781920||Patients having undergone an Anterior Cruciate Ligament (ACL) reconstruction|Patients having undergone an ACL reconstruction will be included.
16284937|NCT04781881||Entresto|Patients administered Entresto by prescription
16284938|NCT04781868|Experimental|Multi-nutrient supplement|
16284939|NCT04781868|Placebo Comparator|Placebo supplement|
16284940|NCT04781855|Experimental|Part A (ipilimumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks for up to a total of 2 years.
16284979|NCT04781582|Active Comparator|Bronchoscopic lung volume reduction arm|Primarily unilateral bronchoscopic lung volume reduction by endobronchial valves. If a bilateral procedure is feasible it must be performed within 3 months after the first intervention.
16284980|NCT04781569||Patients with S. aureus infection|
16284981|NCT04781569||healthy participants|
16284982|NCT04781543|Experimental|HZN-825 300 mg once daily (QD)|300mg oral tablets given in the morning and placebo in the evening
16284941|NCT04781855|Experimental|Part B (ipilimumab, nivolumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 7 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and nivolumab, and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks and nivolumab every 4 weeks for up to a total of 2 years.
16284942|NCT04781842|Experimental|Boxing Club Group|Participation in a weekly boxing program designed for people with Parkinson Disease
16284943|NCT04781842|No Intervention|Control group|No changes to regular physical activity during the study period
16284944|NCT04781829|No Intervention|Control|Critically ill patients with pneumonia will be treated with an antibiotic strategy at the discretion of the treating clinician
16284945|NCT04781829|Experimental|Interventional|Critically ill patients with pneumonia will be treated with an antibiotic strategy based on results from the BioFire Pneumonia Panel
16284946|NCT04781816|Experimental|SAR443122|SAR443122 for 12 weeks
16284947|NCT04781816|Placebo Comparator|Placebo|Matching placebo
16284948|NCT04781803|Experimental|Arm 1|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.
16284949|NCT04781803|No Intervention|Arm 2|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2 tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY) at 50 mg/kg per day on days +3 and +4
16284950|NCT04781790||Patients with Bone marrow failure|Standard of care of patients with bone marrow failure
16284951|NCT04781777|No Intervention|Control group|Dexmehtasone and local anesthetics in carpal tunnel syndrome
16284952|NCT04781777|Active Comparator|Insulin group|insulin added to dexamehtasone and local anesthetics
16284953|NCT04781764||glioma patients|glioma patients with routine surgery
16284954|NCT04781751|No Intervention|dexamethasone|dexamethasone with local anesthetics injected for carpal tunnel relief
16284955|NCT04781751|Active Comparator|Insulin group|insulin with local anesthetics and dexamehtasone injected for carpal tunnel relief
16284956|NCT04781738||patients with history of vascular ring who didn't have corrective surgery|patients with history of vascular ring who didn't have corrective surgery
16284957|NCT04781738||patients with history of vascular ring who underwent corrective surgery|patients with history of vascular ring who underwent corrective surgery
16284958|NCT04781725|Experimental|INT230-6 Treated Arm|Patients will receive INT230-6 injections for a total of 3 intratumoral doses (Days 1,8,15 over a 15-day period) prior to breast surgery.
16284959|NCT04781725|No Intervention|Control Arm|No intervention while awaiting surgery (as per standard of care)
16284960|NCT04781712|Experimental|Self-management using mHealth|Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
16284961|NCT04781712|No Intervention|Exercise using brochure|Only exercise using brochure
16284962|NCT04781686|Experimental|First-line treatment|"First-line treatment: Apatinib plus Camrelizumab combined with Docetaxel and S1 for six cycles.
~Maintenance treatment: Apatinib and Camrelizumab"
16284963|NCT04781673|Active Comparator|Ketamine|"Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order
~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
16284964|NCT04781673|Active Comparator|Lidocaine|"Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order
~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
16284965|NCT04781660|Experimental|Implantable Alginate Hydrogel|All patients will be treated with Implantable Alginate Hydrogel
16284966|NCT04781647|Active Comparator|ABI-H0731 + ETV|Participants with cHBV will receive ABI-H0731 with ETV for 48 weeks, followed by ETV alone for 12 weeks
16284967|NCT04781647|Experimental|ABI-H0731 + ETV + Peg-IFNα|Participants with cHBV will receive ABI-H0731 with ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
16284968|NCT04781647|Active Comparator|ETV + Peg-IFNα|Participants with cHBV will receive ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
16284969|NCT04781634|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
16284970|NCT04781621|Experimental|Robotic Gait Training|Patients in the Robotic Gait Training (RGT) group will receive 90 minutes per week of RGT once patients are deemed clinically appropriate as defined by being able to tolerate standing for 15 minutes without orthostatic intolerance. The duration of treatment will span the patient's length of stay in inpatient rehabilitation. The Ekso Bionics Ekso GT™ robotic exoskeleton will be used for RGT.
16284971|NCT04781621|Active Comparator|Usual Care Gait Training|Usual Care (UC) gait training including body weight-supported treadmill training (BWSTT) and conventional overground walking.
16284972|NCT04781608|Experimental|Intervention group|Gains access to the digital intervention program
16284973|NCT04781608|No Intervention|Wait-list- control group|Does not gain access to the intervention (until end of study)
16284974|NCT04781595|Active Comparator|Watermelon|Watermelon powder containing 3 g of L-citrulline.
16284975|NCT04781595|Active Comparator|Beetroot|Beetroot powder containing 8 mmol of nitrate.
16284976|NCT04781595|Active Comparator|Watermelon + beetroot|Watermelon powder containing 3 g of L-citrulline and Beetroot powder containing 8 mmol of nitrate.
16284977|NCT04781595|Placebo Comparator|Placebo|Maltodextrin
16284978|NCT04781582|Active Comparator|Lung volume reduction surgery arm|Bilateral videothoracoscopic lung volume reduction surgery by wedge resection. Unilateral procedures are possible in case of severe adhesions or intraoperative instability. In these cases a staged approach with contralateral LVRS within 3 months is possible.
16284983|NCT04781543|Experimental|HZN-825 300 mg twice daily (BID)|300mg oral tablets given in the morning and evening
16284984|NCT04781543|Placebo Comparator|Placebo|Placebo will be given orally in the morning and evening
16284988|NCT04781517||Long-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments no less than 3 was divided into Long-segment group(200).
16284989|NCT04781504|Experimental|standard care + moderate-intensity continuous exercise training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
16284990|NCT04781504|Experimental|standard care + high-intensity interval training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
16284991|NCT04781491|Experimental|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Subjects receive a 90-minute Forest Therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
16284992|NCT04781491|No Intervention|Waiting list|Subjects don't receive any therapy but are offered the same treatment after trial is finished.
16284995|NCT04781465|Experimental|Immersive Virtual Reality|"The patients are divided into groups of 3. Each group of patients will attend 2 days of care per week (for 4 weeks) Group N ° 1: Monday and Thursday. Group N ° 2: Tuesday and Friday.
~At each visit, the patient will participate in:
~[a Kinesitherapy treatment and a Virtual Immersion treatment] + [a Balneotherapy treatment or an Adapted Physical Activity treatment). Each treatment lasts 1 hour 10 minutes.
~Each patient will therefore come to the center 8 times over 1 month, or 4 hours 40 minutes a week, not counting virtual reality.
~If the groups are not full or according to the advice of the healthcare team, only one group will be selected (always 3 patients) and will attend 3 days per week."
16284996|NCT04781439|No Intervention|non-switching|control group
16284997|NCT04781439|Experimental|IV-to-PO conversion within 48-72 hours|early switching
16284998|NCT04781439|Experimental|IV-to-PO conversion after 72 hours|late switching
16284999|NCT04781426||HIV-negative MSM/TG|Oral pre-exposure prophylaxis (PrEP) will be offered to HIV negative MSM, TG identified to be at substantial risk for HIV infection and those motivated to take daily PrEP.
16285000|NCT04781413|Experimental|Experimental|"The phase I trial is a dose escalation design with standard 3+3 followed by expansion cohorts.
~Level Nab-PTX S-1 Sintilimab
~80 mg/m2 80mg/m2 200mg
~100 mg/m2 80mg/m2 200mg
~120 mg/m2 80mg/m2 200mg
~We start at level 1. The recommended dose (RD) is defined as dose equal to the maximum tolerated dose (MTD). If 1 of three patients experiences dose-limiting toxicities (DLT), three more patients will be enrolled at the same dose level. The MTD is defined as the dose level at which two or more of three patients, or at least two of 4-6 patients, have DLTs during one cycle."
16285001|NCT04781400|Experimental|Remote service delivery model PLUS mobile phone support|Remote service delivery plus mobile intervention via SMS will include weekly check-ins from study staff, calls from a trained counsellor on request, and access to a two-way messaging feature.
16285002|NCT04781400|Active Comparator|Remote service delivery model|Remote service delivery model.
16285003|NCT04781387|Experimental|CRS3123 200 milligram|"CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.
~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
16285004|NCT04781387|Experimental|CRS3123 400 milligram|"CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.
~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
16285005|NCT04781387|Active Comparator|Vancomycin 125 milligram|Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.
16285006|NCT04781374|Experimental|Neratinib|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.
~- Neratinib-once daily with 28 consecutive days defined as a treatment cycle"
16285007|NCT04781361||Isotonic fluid|"Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:
~Dextrose 5% in 0.9% NaCl,
~Intravenous fluid containing NaCl between 131 to 154 mmol/L"
16285008|NCT04781361||Hypotonic fluid|"Group, received hypotonic maintenance fluid containing NaCl < 130 mmol/L such as:
~Dextrose 5 % in 0.02 % NaCl,
~Dextrose 5% in 0.033 % NaCl
~Dextrose 5% in 0.045 % NaCl
~Intravenous fluid containing NaCl < 130 mmol/L"
16285009|NCT04781348|Experimental|Platelet Rich Plasma plus fat grafting|Group will receive Platelet Rich Plasma plus fat grafting
16285010|NCT04781348|Experimental|Fat grafting|Group will receive only fat grafting
16285011|NCT04781335|Active Comparator|Dexycu|
16285012|NCT04781335|Active Comparator|Standard Care Post operative drops|
16285015|NCT04781309|Experimental|NT-I7|480 microgram/kg IM (initial dose)
16285016|NCT04781296|Experimental|Subject's Scanned with Investigational Device|
16285017|NCT04781283|Experimental|specular microscopy|The density measurement is a painless and very brief examination (less than a minute) during which the patient places his head on a chin rest while maintaining his forehead on a bar provided for this purpose while looking straight ahead. The measurements are then taken without contact with the patient's eye.
16285018|NCT04781270|Experimental|mFOLFOXIRI+Bev|"Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks as the first-line treatment.
~Drug: mFOLFOXIRI plus Bevacizumab Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
16285052|NCT04781049|Active Comparator|TURP (Trans-Urethral Resection of Prostate)|Participants who undergo the standard treatment, namely Trans-Urethral Resection of Prostate
16285019|NCT04781270|Active Comparator|mFOLFOX6+Bev|"Patients will receive mFOLFOX6 plus bevacizumab once every two weeks as the first-line treatment.
~Drug: mFOLFOX6 Plus Bevacizumab mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
16285020|NCT04781257||Household contacts with co-prevalent/incipient TB|Household contacts diagnosed with active TB at baseline/during the study period
16285021|NCT04781257||Household contacts staying healthy|Household contacts without active TB who remain healthy throughout the study
16285022|NCT04781244|Active Comparator|EndWarts® FREEZE in Soft keratin|EndWarts® FREEZE were treated to 11 patients with wart at soft keratin
16285023|NCT04781244|Active Comparator|EndWarts® FREEZE in Hard keratin|EndWarts® FREEZE were treated to 11 patients with wart at hard keratin
16285024|NCT04781244|Active Comparator|Liquid nitrogen in Soft keratin|Liquid nitrogen were treated to 11 patients with wart at soft keratin
16285025|NCT04781244|Active Comparator|Liquid nitrogen in Hard keratin|Liquid nitrogen were treated to 11 patients with wart at hard keratin
16285026|NCT04781231|Experimental|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
16285027|NCT04781231|Active Comparator|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
16285028|NCT04781231|Other|Usual management of anxiety|
16285029|NCT04781218||Participants enrolled in the registry|Participants enrolled in the registry will include school community members including students, parents, staff, etc.
16285030|NCT04781205|Experimental|Intervention|Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function
16285031|NCT04781205|No Intervention|Usual care|No intervention at all
16285032|NCT04781192|Experimental|Dose Finding Regorafenib|We will use a 3 + 3 design with two dose levels of 80 mg and 120 mg to discover the Maximum Tolerated Dose (MTD) for regorafenib
16285033|NCT04781179|Experimental|CM-II Technique|
16285034|NCT04781179|Placebo Comparator|Psychoeducation|
16285035|NCT04781166|Experimental|Intervention|Participants will be immediately assigned to the intervention.
16285036|NCT04781166|Other|Waitlist control|Participants will complete measures before and after a waitlist equivalent to the duration of the intervention, to assess whether change is observed with time and repeated assessment. After the waitlist control, participants will be provided the opportunity to take part in the intervention. In this RDICT design, the pre- post- treatment data will be included in analyses.
16285037|NCT04781153|Experimental|Immediate intervention (A)|Subjects will receive the full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) immediately after baseline.
16285038|NCT04781153|Experimental|Delayed intervention (B)|"Subjects will receive a full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) 3-4 weeks after baseline. The delayed intervention will enable the study team to explore the effect of the participants change in behavior due to participation in a research project, and furthermore how change in oral hygiene habits might affect the lung function."
16285039|NCT04781140|Placebo Comparator|Placebo|Placebo, qd
16285040|NCT04781140|Experimental|SPN-812|SPN-812, qd
16285041|NCT04781127|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
16285042|NCT04781114|Experimental|JS002|Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
16285043|NCT04781114|Placebo Comparator|Placebo|Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);
16285044|NCT04781101|Experimental|conventional therapy|conventional therapy
16285045|NCT04781101|Experimental|RoboGait®|Group 1 (n = 13) received conventional therapy (65 min, 2 days/week ×8) and group 2 (n = 13) received 25 minutes of robot-assisted gait training (RoboGait®) in addition to conventional therapy (40 min, 2 days/week ×8).
16285046|NCT04781088|Experimental|Treatment (paclitaxel, lenvatinib, pembrolizumab)|Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
16285047|NCT04781075|Experimental|TAP Block with Exparel|TAP Block with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline
16285048|NCT04781075|Active Comparator|TAP Block with bupivicaine|TAP Block with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline
16285049|NCT04781062|Experimental|Breast Cancer Stage T1 Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.
~If bioptically confirmed T1 breast cancer, patients will undergo a second peripheral blood and urine collection after primary breast cancer surgery."
16285050|NCT04781062|Active Comparator|Benign Breast Lesion Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.
~If bioptically confirmed benign lesion, no other samples will be collected."
16285051|NCT04781049|Experimental|TPLA (Trans-Perineal Laser Ablation of Prostate)|Participants who undergo Trans-Perineal Laser Ablation of Prostate
16285227|NCT04779814||Cohort 6|SenTiva® (30 pediatric subjects)
16285053|NCT04781036|No Intervention|Normal feet|"Swab their feet to analyze foot microbiome via 16s DNA sequencing
~Collect their socks to analyze metabolomics via gas chromatography"
16285054|NCT04781036|Experimental|Foot odor without pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing
~Collect their socks to analyze metabolomics via gas chromatography
~Apply 4% chlorhexidine for 1 month
~Re-evaluate their feet at time of treatment finish and 2 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.
~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
16285055|NCT04781036|Experimental|Foot odor with pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing
~Collect their socks to analyze metabolomics via gas chromatography
~Apply 4% chlorhexidine for 1 month
~Re-evaluate their feet at time of treatment finish and 2 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.
~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
16285056|NCT04781023|Experimental|Intervention (Colpofix)|intravaginal gel with carboxymtheyl beta-glucan and polycabophil
16285057|NCT04781023|No Intervention|Control|No intervention (standard of care)
16285058|NCT04780997|Experimental|Virtual Realty|Microsoft Xbox Kinect® was used for virtual reality exercises
16285059|NCT04780984|Placebo Comparator|Placebo|Placebo, 2mL
16285060|NCT04780984|Experimental|Group 1 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)
~8 µg, 2.0 mL, 4 µg/mL"
16285061|NCT04780984|Experimental|Group 2 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)
~16 µg, 2.0 mL, 8 µg/mL"
16285062|NCT04780984|Experimental|Group 3 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)
~24 µg, 2.0 mL, 12 µg/mL"
16285063|NCT04780984|Active Comparator|Spiriva Respimat|5 ug, 2 actuations, 2.5 µg/actuation
16285064|NCT04780971|Other|Post-PCI intra-coronary physiological and OCT measurements|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
16285065|NCT04780958|Other|Study population|During the study period, babies born at this hospital with a gestational week of <30 were included .
16285066|NCT04780945|Experimental|Olaparib monotherapy|Patients, irrespective of BRCA status, will be treated with olaparib tablet 300 mg bid
16285067|NCT04780932|Placebo Comparator|Control Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Placebo 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
16285068|NCT04780932|Experimental|Experimental Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Macitentan 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
16285069|NCT04780919|Experimental|Treatment Group (A)|Group of patients with Achilles tendinopathy which are treated by focused extracorporeal shockwave therapy once a week for 5 weeks. ESWT parameters: 0,12 mJ/mm2, 10 Hz, 1300 shocks.
16285070|NCT04780919|Sham Comparator|Sham Group (B)|Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.
16285071|NCT04780906|Sham Comparator|Sham first (group 1)|Performs the first round of test with the sham comparator than with the experimental wrist taping
16285072|NCT04780906|Experimental|Wrist taping first (group 2)|Performs the first round of test with the experimental wrist taping than with the sham comparator
16285073|NCT04780893|Active Comparator|Active VeNS|
16285074|NCT04780893|Sham Comparator|Sham VeNS|
16285075|NCT04780880||Youth football players|Young footballers aged 10-16 training and playing for a Polish football club.
16285076|NCT04780867|No Intervention|Routine vaccination (Control)|
16285077|NCT04780867|Experimental|Delay vaccination (Experimental)|
16285078|NCT04780854|Active Comparator|Metformin group|1 gm metformin tablet administered twice daily for 3 months
16285079|NCT04780854|Placebo Comparator|Metformin-free|1 placebo tablet administered twice daily for 3 months
16285080|NCT04780841|Experimental|RDX013 Cohort 1|RDX013 low dose oral dosage, twice daily
16285081|NCT04780841|Experimental|RDX013 Cohort 2|RDX013 low, mid dose oral dosage, twice daily
16285082|NCT04780841|Experimental|RDX013 Cohort 3|RDX013 high, mid dose oral dosage, twice daily
16285083|NCT04780841|Experimental|RDX013 Cohort 4|RDX013 high dose oral dosage, twice daily
16285084|NCT04780841|Experimental|RDX013 Part B|RDX013 dose from Part A oral dosage, twice daily
16285085|NCT04780841|Placebo Comparator|Placebo Part B|oral dosage, twice daily
16285086|NCT04780828||GROUP I|Group I will include cases classified as normal weight (healthy) with a body mass index of 18.5-24.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined for this group will be made. Since this group was not considered as obese, it was determined as the control group.
16285087|NCT04780828||GROUP II|Group II will include cases classified as overweight and having a body mass index of 25.0-29.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
16285088|NCT04780828||GROUP III|Group III will include cases classified as class I obese, with a body mass index of 30.0-34.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
16285089|NCT04780828||GROUP IV|Group IV will include cases classified as class II obese, with a body mass index of 35.0-39.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
16285090|NCT04780828||GROUP V|Group V will include cases classified as class III (morbid) obese, with a body mass index of 40 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
16285091|NCT04780815|Experimental|myBluTM Formulation 1|
16285092|NCT04780815|Experimental|myBluTM Formulation 2|
16285093|NCT04780802|Other|Ballloon catheter|Balloon-assisted transarterial therapy will be performed in the first treatment session only
16285094|NCT04780776|Experimental|UVB treatment arm|The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 16-week study where they will be exposed to their individualized titration evaluation.
16285095|NCT04780776|Sham Comparator|Sham comparator arm|The sham comparator group will undergo the procedures as the treatment group with the exception that the Solius Photobiological System will only be turned on to emit visible radiation.
16285096|NCT04780763|Active Comparator|Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690|
16285097|NCT04780763|Placebo Comparator|Arm 2, Control: Milk-based non-fermented dairy product|
16285098|NCT04780750|Active Comparator|Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
16285099|NCT04780750|Active Comparator|Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks|Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\m2 every 3 weeks)
16285100|NCT04780737||Prophylactic cholecystectomy|Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy
16285101|NCT04780737||On-demand cholecystectomy|Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease
16285102|NCT04780724|Experimental|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
16285103|NCT04780724|Experimental|Hypercapnic|Participants inhale ambient air, the hypercapnic and hypoxic gas mixture, and the ambient air.
16285104|NCT04780711||Diagnostic Group|Demographic data, symptoms for TMJ of the students will be recorded. Physical examination will be included range of motion of temporomandibular joint, right and left TMJ lateral range of motion, whether there is a gradual opening, during deflection and deviation during the opening and subluxation for palpation and measurements. Opening and closing clicks, crepitation and popping will be recorded during palpation. Deep palpation of the skin, masseter and temporal muscles will be determined, posture analysis will be recorded and dental interventions, missing teeth, orthodontic treatments and bruxism histories will be taken. An appropriate diagnosis will be determined for students who are found to have pathology as a result of all these examinations and information about this diagnosis will be provided.
16285105|NCT04780698|Experimental|Study Cohort|
16285106|NCT04780685|Experimental|hMSCs|hMSCs will be given via IV administration.
16285107|NCT04780685|Placebo Comparator|Lactated Ringer's Solution|Lactated Ringer's Solution will be given via IV administration.
16285108|NCT04780672|Active Comparator|Molixan|30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products
16285109|NCT04780672|Placebo Comparator|Placebo|"Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance.
~ATC: B05CB01 Sodium chloride"
16285110|NCT04780659|Experimental|Vaccination with Comirnaty according to standard of care treatment|All study participants will receive Comirnaty according to current approval.
16285111|NCT04780646|Experimental|Nature therapy in urban nature|Subjects receive a 90-minute nature therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
16285112|NCT04780646|Active Comparator|City Walk|Subjects receive a 90-minute city walk through urban sourroundings once per week for 8 weeks with a city guide, who talks about city architecture and gives information about the history of the surroundings.
16285113|NCT04780646|No Intervention|Waiting List|Subjects don't receive any therapy.
16285114|NCT04780633|Experimental|Precede-Proceed based Training Program|The experimental group is the group in which five training sessions interventions are applied.
16285115|NCT04780633|No Intervention|Control group|The control group is the group in which have no educational intervention.
16285116|NCT04780620|Experimental|Parent Intervention Group|The parent intervention group will undergo 8 weekly, manualized group sessions, with between 6 and 10 parent participants. Sessions are structured and follow an agenda including check-in and review of home practice, discussion of a skill or strategy, and review and assignment of home practice. Group sessions are held weekly for 1.5 hours and include both didactic, discussion, and practice elements, as well as assigned home practice.
16285117|NCT04780620|No Intervention|Usual Care Group|Parents in the usual care condition will be involved in their adolescent's care as is standard in our clinical program. With adolescent consent, parents are invited to participate in a single, 2-hour orientation session for parents/caregivers that provides information about depression, as well as the role of sleep, diet, and exercise in improving mood. Based on adolescent preference, parents can also attend regular psychiatric appointments with their adolescent, in which they will receive further information about depression and may receive and provide information about their adolescent's depression symptoms and response to psychosocial and pharmacological interventions. This control condition will allow us to determine whether the parent intervention is more effective than a relevant clinical alternative.
16285118|NCT04780594||Pre-pandemic COVID-19 group (PreCOVID)|All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.
16285119|NCT04780594||Pandemic COVID-19 group (COVID)|All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis.
16285120|NCT04780581|Active Comparator|RECOVERY|intermediate-dose dexamethasone (6mg/24h - 10 days)
16285121|NCT04780581|Experimental|BOLUS|high-dose methylprednisolone bolus (250mg/4h - 3 days)
16285158|NCT04780321|Active Comparator|Anti-SARS-CoV-2 Monoclonal Antibody dose 1/2/3|use Anti-SARS-CoV-2 Monoclonal Antibody,dose 1/2/3 to treat COVID-19
16285122|NCT04780568|Experimental|Treatment (osimertinib, tegavivint)|Patients receive osimertinib PO QD on days 1-28 and tegavivint IV on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16285123|NCT04780542|Experimental|Clinician-Guided iCBT|Both help-seeking students recruited from university clinics and non-help-seeking students recruited from needs assessment survey and outreach will receive internet delivered cognitive behavioral therapy guided by clinicians
16285124|NCT04780542|Active Comparator|Treatment as usual|Help-seeking students recruited from university clinics will remain on waitlist until they receive treatment as usual. Non-help-seeking students recruited from needs assessment survey and outreach will be referred to university health clinic.
16285125|NCT04780542|Active Comparator|Self-guided iCBT|Help-seeking students recruited from university clinics will receive self-guided internet delivered cognitive behavioral therapy while on waitlist. Non-help seeking students recruited from needs assessment survey and outreach will receive the self-guided version of internet delivered cognitive behavioral therapy.
16285126|NCT04780529|Experimental|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
16285127|NCT04780516||Participants Treated With Risankizumab|Participants will receive risankizumab (Skyrizi) as prescribed by the physician according to the local label.
16285128|NCT04780503||Intubation Group/ Non-Intubation Group|Intubation group: Patients who failed noninvasive mechanical ventilation and who underwent endotracheal intubation Non-Intubation Group: Patients whose noninvasive mechanical ventilation is successful and endotracheal intubation is not applied
16285129|NCT04780503||Dying patients / Surviving patients|Dying patients :Patients with in-hospital mortality presenting with acute respiratory failure Surviving patients: Patients presenting and surviving due to acute respiratory failure
16285130|NCT04780490|Active Comparator|liberal fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine (No medication from the epidural catheter will be administered during surgery).
~Standard anesthesia induction will be applied (fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ), and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.
~Fluid resuscitation will be started with 10 ml / kg / hr Ringer's lactate solution.
~In patients with MAP <65 mmHg, 250 ml of Ringer's lactate solution will be given as a bolus.
~If the hypotension persists, the bolus 250 ml Ringer's lactate solution will be repeated up to 10 times."
16285131|NCT04780490|Active Comparator|restrictive fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine ( No medication from the epidural catheter will be administered during surgery. ) Standard anesthesia induction will be applied ( fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ) and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.
~Fluid resuscitation will be started with 2 ml / kg / hr Ringer's lactate solution and norepinephrine infusion at a dose of 2 mcg / kg / hr.
~In patients with MAP<65 mmHg, norepinephrine dose will be increased up to 8 mcg / kg / hr.
~If the hypotension persists although the norepinephrine dose is 8 mcg / kg / hr, 250 ml bolus Ringer's lactate solution will be given."
16285132|NCT04780477|Experimental|High Fiber Diet (HFD)|High Fiber Diet (HFD) will add approximately 25-30 grams of dietary fiber/d from legume dishes.
16285133|NCT04780477|Active Comparator|Healthy American Diet|Healthy American Diet pre-portioned meal replacement entrées with legumes replaced by lean chicken/meat.
16285134|NCT04780464|Active Comparator|Standard doxorubicin|
16285135|NCT04780464|Experimental|Metronomic doxorubicin|
16285136|NCT04780464|Experimental|Metronomic oral cyclophosphamide + prednisolone|
16285137|NCT04780451|Experimental|Omega|
16285138|NCT04780451|Placebo Comparator|Placebo|
16285139|NCT04780438|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following catheter ablation.
16285140|NCT04780438|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following catheter ablation.
16285141|NCT04780425|Experimental|DESMOND|receive usual care plus a structured diabetes self-management education program delivered once over 6hours
16285142|NCT04780425|Active Comparator|USUAL CARE|Receive usual care as per standard treatment guidelines of ghana unstructured education during clinic visits for routine care
16285143|NCT04780412|Active Comparator|Misoprostol Group|
16285144|NCT04780412|Placebo Comparator|Placebo Group|
16285145|NCT04780399|Experimental|Yangxue Qingnao pills high dose group|Yangxue Qingnao pills 7.5 g per time,2 times per day.
16285146|NCT04780399|Experimental|Yangxue Qingnao pills lower dose group|Yangxue Qingnao pills 5 g per time,2 times per day, and placebo identified to Yangxue Qingnao pills 2.5 g per time, 2 times per day.
16285147|NCT04780399|Placebo Comparator|Placebo group|Placebo identified to Yangxue Qingnao pills 7.5 g per time,2 times per day
16285148|NCT04780386|Experimental|NVP-1805|NVP-1805
16285149|NCT04780386|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1 and NVP-1805-R2
16285150|NCT04780373||Development cohort|
16285151|NCT04780373||Validation cohort|
16285152|NCT04780360|Experimental|Cayanoacrylate tissue adhesives|thin layers of high viscosity blend of n-butyl and 2-octyl cayanoacrylate tissue adhesive will be applied and rinsed with saline at least three times with interval of at least 30 seconds
16285153|NCT04780360|Active Comparator|Silk suture material|interrupted knots
16285154|NCT04780347|Experimental|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel combined with capecitabine
16285155|NCT04780347|Active Comparator|Capecitabine|Capecitabine
16285156|NCT04780334||Positive diagnosis of SARS-CoV-2|100 patients with a positive diagnosis of SARS-CoV-2
16285157|NCT04780334||Negative diagnosis of SARS-CoV-2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
16285159|NCT04780321|Placebo Comparator|Placebo|use placebo to treat COVID-19
16285162|NCT04780308||2 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 medial 1 lateral K-wire
16285163|NCT04780308||2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 lateral K-wire
16285164|NCT04780308||3 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 3 lateral K-wire
16285165|NCT04780282|Experimental|Scapular Stabilization Group|In the study, Adalar Water Sports Club (AWSK) takes places with its A team players; 15 players aged from 16-25 as the scapular stabilization group. The players in the scapular stabilization group will be applied scapular stabilization exercises for 8 weeks, 3 days a week in company with a physiotherapist. As stabilization exercises for the players; 1)Squatting while sliding a towel on the wall, 2)Wall push-ups with one leg extension, 3)Cross squat, 4)Pulling elastic band while squatting on one leg, 5)Double-leg squatting
16285166|NCT04780282|No Intervention|Control group|
16285167|NCT04780269|Experimental|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group.
16285168|NCT04780269|Experimental|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix.
16285169|NCT04780243|No Intervention|Pre-intervention group|Pre-intervention group: women participated during the base line assessment will be labeled as Pre-intervention group
16285170|NCT04780243|Experimental|postintervention group|Postintervention group: women participated after the intervention was initiated will be labeled as postintervention group.
16285171|NCT04780230|Experimental|real tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
16285172|NCT04780230|Sham Comparator|sham tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
16285173|NCT04780217|Experimental|Phase 1 Part A|T3011 Single Agent Dose Escalation in participants with solid tumors
16285174|NCT04780217|Experimental|Phase 1 Part B|Dose Escalation of Combination T3011 + pembrolizumab in participants with solid tumors
16285175|NCT04780217|Experimental|Phase 2a Arm A|RP2D T3011 + pembrolizumab in participants with NSCLC
16285176|NCT04780217|Experimental|Phase 2a Arm B|RP2D T3011 + pembrolizumab in participants with advanced solid tumors with metastasis in either liver and/or lung
16285177|NCT04780204|Experimental|Antiviral Treatment|Tenofovir Alafenamide 25mg once daily , Oral
16285178|NCT04780204|Other|Observation|Best supportive care
16285179|NCT04780191|Experimental|Active MyoRegulator® treatment|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
16285180|NCT04780191|Sham Comparator|Sham MyoRegulator® treatment|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
16285181|NCT04780178|Experimental|TACTICs|Our ACT intervention will include 6 weekly 1-hour telephone sessions and 1 booster session offered 1 month after session 6 designed to increase psychological flexibility through practice of one or more of the six skills in each session. Although these are ideally spaced 1 week apart, participants will have up to 12 weeks to complete the 6 sessions. Each session will include guided mindfulness practice that encourages non-judgmental awareness of the present moment to increase psychological flexibility; brief (10-minute) study-provided audio recordings will enable participants to practice mindfulness at home. Caregivers will also identify deeply-held values to serve as a guide when choosing how to spend limited time or energy and will set values-based action goals each week. A booster session will be provided one month after session 6 to reinforce skills learned.
16285182|NCT04780178|No Intervention|Minimally Enhanced Usual Care|All caregivers randomized to the mEUC group will receive a mailed packet containing 1) a letter from the Co-PIs thanking them for participating, 2) printed selections from of the NIH Alzheimer's caregiving website (https://www.nia.nih.gov/health/alzheimers/caregiving), and 3) a listing of Alzheimer's Association sponsored support groups closest to the caregiver's home address. Caregivers will also receive a brief phone call from the research coordinator to verify receipt of the packet. Since this is a usual care group with a minimally-enhanced component, it will be up to the mEUC participants to decide whether or not to engage with these intervention materials.
16285183|NCT04780165|Experimental|Single-arm|
16285184|NCT04780152|Experimental|tDCS arm|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
16285185|NCT04780152|Placebo Comparator|Control arm|Participant receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
16285186|NCT04780126||COVID-19 pneumonia patients|Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.
16285187|NCT04780087||Weight lifting women|Experienced resistance exercise trained and pregnant women
16285188|NCT04780087||Reference women|Physically active pregnant women (not experienced with free weight lifting)
16285189|NCT04780074|Active Comparator|Standard product (SP): USP CoQ10 powder, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
16285190|NCT04780074|Experimental|Investigational product 1 (IP1): CoQ10 in soybean oil, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
16285191|NCT04780074|Experimental|Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
16285192|NCT04780074|Experimental|Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
16285193|NCT04780074|Experimental|Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
16285194|NCT04780061|Experimental|Treatment|"Specific Product: Vitamin D3 50,000 IU
~Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period
~Specific Product: Vitamin K2/D
~Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3).
~Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day.
~Specific Product: Vitamin C/Zinc
~Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day."
16285195|NCT04780061|Placebo Comparator|Control|"Specific Product: Vitamin D3 50,000 IU
~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg
~Specific Product: Vitamin K2/D
~Placebo Equivalent: Medium chain triglyceride oil
~Specific Product: Vitamin C/Zinc
~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg"
16285196|NCT04780035|Experimental|"Group Vaccine"|2,250 volunteers who will be vaccinated with the EpiVacCorona vaccine, twice intramuscularly at a dose of 0.5 ml.
16285197|NCT04780035|Placebo Comparator|"Control Group"|750 volunteers who will be vaccinated with a placebo, twice intramuscularly at a dose of 0.5 ml.
16285198|NCT04780022||Older patients with cryptogenic embolism and PFO closure|Data (clinical events at last follow-up) on patients older than 60 years who have experienced a previous paradoxical embolism of unknown origin and underwent transcatheter PFO closure will be collected.
16285199|NCT04779970|Experimental|Caucasian patients|Cessation of treatment
16285200|NCT04779970|Active Comparator|non-Caucasian patients|Cessation of treatment
16285202|NCT04779931|Experimental|Convoy-Pal Intervention|Intervention participants will be sent Convoy-Pal equipment and materials. The equipment can simply be removed from the box, plugged in, and turned on to start. Research staff will provide technical support as needed during the trial. Convoy-Pal is 12-week intervention that uses the Routinify platform to deliver self-management tools and palliative care resources in the participants' home. The platform includes a tablet, charging stand, and smart watch, with additional options for mobile phone access and a website portal.
16285203|NCT04779931|Active Comparator|Waitlist Control|Participants will complete baseline assessments and will be recontacted at 11 weeks to complete follow up assessments at week 12. Participants will receive a $25 gift card for each assessment ($50 total). If they would like to try the intervention at that time, we will send them Convoy-Pal equipment and materials. They will then have 12 weeks to use the tool.
16285204|NCT04779918|Other|OviTex Reinforced Tissue Matrix|This is a single-arm study. All study subjects will receive OviTex.
16285205|NCT04779905||Non-alcoholic Fatty Liver Diseases|patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital
16285206|NCT04779905||control|healthy volunteers who looks normal on ultrasonography
16285207|NCT04779892|Experimental|CMAB008|
16285208|NCT04779892|Active Comparator|Remicade|
16285209|NCT04779879|Active Comparator|Sotrovimab (Gen1)|Part A (double-blinded) participants will be randomized to receive 500 mg of an IV infusion of Sotrovimab Gen 1 material or 500 mg of an IV infusion of VIR-7831 Gen 2 material
16285210|NCT04779879|Active Comparator|Sotrovimab (Gen2)|"Part B (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or by IM injection
~Part C (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or 250 mg by IM injection"
16285211|NCT04779866|Experimental|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
16285212|NCT04779866|Active Comparator|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
16285213|NCT04779853||Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM|serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).
16285214|NCT04779840||period 2011|
16285215|NCT04779840||period 2018|
16285216|NCT04779827|Experimental|Egalitarian Networks of Homogeneous Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
16285217|NCT04779827|Experimental|Egalitarian Networks of Diverse Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
16285218|NCT04779827|Experimental|Centralized Networks of Homogeneous Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices."
16285219|NCT04779827|Experimental|Centralized Networks of Diverse Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices."
16285220|NCT04779827|Experimental|Independent Control of Homogeneous Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
16285221|NCT04779827|Experimental|Independent Control of Diverse Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
16285222|NCT04779814||Cohort 1|Demipulse®/Aspire HC® (30 adult subjects)
16285223|NCT04779814||Cohort 2|Demipulse®/Aspire HC® (30 pediatric subjects)
16285224|NCT04779814||Cohort 3|Aspire SR® (30 adult subjects)
16285225|NCT04779814||Cohort 4|Aspire SR® (30 pediatric subjects)
16285226|NCT04779814||Cohort 5|SenTiva® (30 adult subjects)
16285228|NCT04779801|Experimental|ABFT|Adolescents and one or both parents will complete 16 weeks of Attachment-Based Family Therapy treatment.
16285229|NCT04779788|Experimental|I-125 seeds loaded stent group|Patients who receive the I-125 seeds loaded stent insertion
16285230|NCT04779788|Active Comparator|Normal stent group|Patients who receive the normal stent insertion
16285231|NCT04779762|Experimental|Group 1|Standard induction regimen of Ustekinumab with the Crohn's disease exclusion diet (CDED)
16285232|NCT04779762|Active Comparator|Group 2|Standard induction regimen of Ustekinumab as above without diet
16285233|NCT04779749||COVID positive <20 weeks|Case groups 1 will include pregnant patients infected by SARS-CoV2 before 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
16285234|NCT04779749||COVID positive >20 weeks|Case groups 2 will include pregnant patients infected by SARS-CoV2 after 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
16285235|NCT04779749||Control|Patients not infected by SARS-CoV2 during pregnancy during the period starting on February 1st 2020 and ending on November 30th 2020
16285236|NCT04779736|Other|Stepped Wedge Trial|The pilot intervention will be evaluated using a stepped wedge design, with participants serving as their own controls within each region and clinical site.
16285237|NCT04779723|Active Comparator|LRYGB Procedure|LRYGB technique was performed by placing 4 to 6 trocars, a 150 cm ante-colic Roux-limb gastric pouch (30 to 50 ml) was created with linear stapled or circular stapled gastro-jejunostomy, a 50-cm long biliopancreatic limb was chosen. A passive drainage was kept near to the gastro-jejunostomy.
16285238|NCT04779723|Active Comparator|LSG Procedure|35 Fr bougie was used for the calibration of a gastric tube. 3 to 6 cm of longitudinal incision of the stomach was done at pylorus to the angle of His. Using of absorbable suture, the staple line was sewn.
16285239|NCT04779697|Experimental|GLP-1a|GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
16285240|NCT04779697|Placebo Comparator|Placebo|Placebo pen administered weekly over 12 weeks
16285241|NCT04779684|Experimental|ACP by proxy pilot intervention group|All participants are included in the intervention group
16285242|NCT04779671|Experimental|VR group|
16285243|NCT04779671|Active Comparator|control group|
16285244|NCT04779645|Experimental|GRA (REMD-477) Group|Once weekly, subcutaneous injection of 70mg REMD-477 (in 1 mL solution) for up to 12 weeks.
16285245|NCT04779645|Placebo Comparator|Placebo Group|Once weekly, subcutaneous injection of 1mL saline solution for up to 12 weeks.
16285246|NCT04779632|Other|Crossover study: Fish Oil --> Safflower Oil|4 weeks of fish oil supplementation followed by 4 weeks of safflower oil supplementation
16285247|NCT04779632|Other|Crossover study: Safflower Oil --> Fish Oil|4 weeks of safflower oil supplementation followed by 4 weeks of fish oil supplementation
16285248|NCT04779619||Non-clinical Control|people who score below clinical cut off on measures of anxiety and depression (scoring <10 on PHQ-9 and <8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services
16285249|NCT04779619||Clinical Group A|people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (>9 on PHQ-9 and/or >7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23)
16285250|NCT04779619||Clinical Group B|people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7)
16285251|NCT04779606|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel (30 mg/mL), 3 drops instilled at a 1 min ± 15 sec interval.
16285252|NCT04779606|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel, 3 drops instilled at a 1 min ± 15 sec interval.
16285253|NCT04779593|Experimental|experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin."
16285254|NCT04779593|Active Comparator|control group|"Patients treated with bloodletting according to current guidelines ferritin alone"
16285255|NCT04779580|Experimental|Intervention Group (Only Group)|"Only one group in this study. 10 participants to have intervention.
~Lateral femoral cutaneous nerve block and evaluation:
~Routine ECG, pulse oximetry and blood pressure monitoring will be available. Using a sterile technique, the lateral femoral nerve will be approached using an in-plane ultrasound-guided technique, using a Stimuplex Ultra 360 50mm needle (B Braun, UK). Following negative aspiration, a one off STAT injection of 5mls lidocaine 1% will be administered subcutaneously.
~After 10 minutes, any altered sensation will be assessed using ice to differentiate normal and altered sensation. This area will be marked on the skin using a black marker pen. Photographs will be taken and images of the procedure will be recorded.
~The above will then be repeated for the subcostal nerve block.
~The total area of anaesthesia will then be compared to the standard surgical incision for hip surgery to assess whether the subcostal nerve block will offer any further analgesia."
16285256|NCT04779567|Experimental|Acetaminophen|Acetaminophen 1 gr in 100 ml saline 0,9% iv 4 times a day
16285257|NCT04779567|Placebo Comparator|Placebo|100 ml saline 0.9% iv 4 times a day
16285258|NCT04779554|Experimental|Flat Dose Mitomycin C|Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
16285259|NCT04779554|Experimental|Weight-Based Mitomycin C|Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
16285260|NCT04779528|Experimental|Group S|Patients will undergo fiberoptic intubation in supine position.
16285261|NCT04779528|Experimental|Group L|Patients will undergo fiberoptic intubation in lateral position.
16285262|NCT04779515|Experimental|Low-pressure|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
16285263|NCT04779515|Active Comparator|Standard-pressure|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
16285264|NCT04779502|Experimental|oregano|oregawash mouthwash was used twice times daily for 7 days
16285265|NCT04779502|Placebo Comparator|placebo|distilled water was used twice times daily for 7 days
16285320|NCT04779177|Experimental|Lumateperone 42 mg once daily for 5 days|
16285266|NCT04779502|Active Comparator|chlorhexidine|Corsodyl with 0.2%CHX mouthwash was used twice times daily for 7 days
16285267|NCT04779489|Experimental|PULSAR|Eligible patients will receive next-generation stereotactic radiotherapy (PULSAR) 30-36 Gy in 3 fractions to the bladder and targetable, pathologically enlarged lymph nodes
16285268|NCT04779476||Control Group|No dressing material will be used post dental extraction
16285269|NCT04779476||Alveogyl Group|Alveogyl will be placed in the dental socket after extraction
16285270|NCT04779476||Cutanplast Group|Absorbable gelatin sponges contain will be placed in the dental socket after extraction
16285271|NCT04779463||Mechanical Ventilated patients|All patients are invasively mechanically ventilated at least 24 hours, and are clinically stable as ready to undergo a spontaneous breathing trial.
16285272|NCT04779450|Experimental|Synchronous Telemonitoring|The sessions will be supervised by a therapist and conducted via video call using the WhatsApp® application, lasting 50 minutes, 3 times a week, for 6 consecutive weeks, the exercises will basically consist of active stretching, mobilization and scapular stabilization, and active shoulder exercises with gradual range of motion.
16285273|NCT04779450|Experimental|Asynchronous Telemonitoring|An explicative schedule with the exercises to be performed asynchronously during the week will be delivered weekly via e-mail and WhatsApp®. The exercises will be the same as those performed by the synchronous telemonitoring group, and the participant will be free to ask any questions about the protocol to the therapist at any time via text message or e-mail.
16285274|NCT04779450|Active Comparator|Control Group|Will receive only a booklet of usual guidelines for women after breast cancer, such as skin care, return to activities, upper limb functionality, self-care, lymphedema and physical activity practice.
16285275|NCT04779437|Experimental|Imagery Cognitive Bias Modification First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of imagery cognitive bias modification followed by two weeks of cognitive control training. Daily QIDS will be completed throughout the intervention phases.
16285276|NCT04779437|Experimental|Cognitive Control Training First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of cognitive control training followed by two weeks of imagery cognitive bias modification. Daily QIDS will be completed throughout the intervention phases.
16285277|NCT04779424||Primary Health Care Providers (PHCPs)|Any Belgian general practitioner (GP) (including those in professional training) currently working in primary care and any other primary health care providers (PHCPs) from the same GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP).
16285278|NCT04779411||Food Frequency Questionnaire Validation Group|"The validation procedure will span over four weeks, consisting of administering the Lutein and Zeaxanthin Food Frequency Questionnaire (FFQ L/Z) and 24-hour diet recalls at multiple timepoints. Timepoints for the eight 24-hour diet recalls will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on week days.
~The weekly L/Z FFQ will be completed at the conclusion of each of the four weeks.
~The monthly L/Z FFQ will be completed at baseline and at the conclusion of week four."
16285279|NCT04779411||Electronic Device Use Questionnaire Validation Group|The validation procedure will occur over eight weeks consisting of administering eight 24-hour diary of electronic device use (24-hour ED use diary) and the Electronic Device Use Questionnaire (EDUQ) at three time points. The time points for the eight 24-hour ED use diaries will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on weekdays. The EDUQ will be completed at baseline and at the conclusion of weeks four and eight.
16285280|NCT04779372|Experimental|Group of dCBT-I|participants will receive 6-week smartphone-based dCBT-I from a Wechat applet
16285281|NCT04779372|Sham Comparator|Group of sleep education|Patients will receive sleep health education like the advices getting from common sleep clinic by the same applet as the group of CBT-I in smartphone
16285282|NCT04779346||Outpatient cancer patients|Cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)
16285283|NCT04779333|Experimental|LEAP Group|In addition to the components of the BMT group, the LEAP program includes an emphasis on supporting optimal physical activity, limiting screen time, and encouraging adequate sleep. The child and caregiver are also given a wrist-worn activity tracker and caregivers participate in a motivational Facebook group.
16285284|NCT04779333|Active Comparator|BMT Group|The BMT Group will take part in a family-based intervention within the context of evidence-based behavioral management training (BMT) for caregivers. Standard BMT represents the current standard of care for childhood ADHD.
16285285|NCT04779320|Experimental|Induction Period, ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of ≥30 kg will be included in this arm group.
16285286|NCT04779320|Experimental|Induction Period, >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having baseline weight of >15 to <30 kg will be included in this arm group.
16285287|NCT04779320|Experimental|Induction Period, 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having baseline weight of 10 to 15 kg will be included in this arm group.
16285288|NCT04779320|Experimental|Maintenance Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
16285289|NCT04779320|Experimental|Maintenance Period: ≥30 kg: Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
16285290|NCT04779320|Experimental|Maintenance Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
16285321|NCT04779177|Experimental|Lumateperone 28 mg once daily for 5 days|
16334213|NCT04440592|Experimental|MT-7117|Oral tablet of MT-7117 once a day.
16285291|NCT04779320|Experimental|Maintenance Period: >15 to <30 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
16285292|NCT04779320|Experimental|Maintenance Period: 10 to 15 kg Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
16285293|NCT04779320|Experimental|Maintenance Period: 10 to 15 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
16285294|NCT04779307|Experimental|Induction Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of ≥30 kg were included in this arm.
16285295|NCT04779307|Experimental|Induction Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of >15 to <30 kg were included in this arm.
16285296|NCT04779307|Experimental|Induction Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of 10 to 15 kg were included in this arm.
16285297|NCT04779307|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
16285298|NCT04779307|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
16285299|NCT04779307|Experimental|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
16285300|NCT04779307|Experimental|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
16285301|NCT04779307|Experimental|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
16285302|NCT04779307|Experimental|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Baseline weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
16285303|NCT04779294||Fetus in labour at risk of acedimia|The Group of patients studied are fetuses in labour at risk of hypoxia with internal fetal monitoring and scalp lactate bloodsamples ( standard monitoring).
16285304|NCT04779294||Fetus in labour at risk of acedemia with STAN analysis|Same group of fetuses in labour at risk of hypoxia with internal fetal monitoring and STAN analysis(ST waveform analysis of the fetal electrocardiogram, opened after study inclusion finished)
16285305|NCT04779281|Experimental|Oral Rehydration Salts supplemented with L. Rhamnosus GG|a supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
16285306|NCT04779281|Experimental|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
16285307|NCT04779255|Experimental|Tumescent anesthesia|Patient who will receive tumescent anesthesia as analgesic treatment
16285308|NCT04779255|Active Comparator|Painkillers and cold water|Patient who will receive painkillers 1 hour before photodynamic therapy and cold water during session as analgesic treatment
16285309|NCT04779242|Experimental|Omadacycline|Omadacycline 100 mg IV; Omadacycline 300 mg PO (2 x 150 mg tablets); QD Dosing; 7-10 day duration.
16285310|NCT04779242|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg IV; Moxifloxacin 400 mg tablets; QD Dosing; 7-10 day duration
16285311|NCT04779229|Experimental|Parent Activation|This group of JPOs will deliver Parent Activation as a service to the juveniles and families on their caseloads.
16285312|NCT04779229|Active Comparator|Usual Services|This group of JPOs will deliver services as usual to the juveniles and families on their caseloads.
16285313|NCT04779216|Experimental|Active Romosozumab 210mg Injection|Romosozumab 210mg injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
16285314|NCT04779216|Placebo Comparator|Placebo|Placebo injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
16285315|NCT04779203||Osseodensification|Osseodensification is a novel, biomechanical osteotomy preparation technique that preserves bone through a non-excavating drilling process utilizing specially designed burs with a tapered geometry and specially designed flutes progressively expand the osteotomy whilst compacting bone into its walls and apex.
16285316|NCT04779203||Standard Drilling|Utilizing conventional drilling technique with standard bone drilling techniques.
16285317|NCT04779190|Experimental|Low-level laser therapy|In the low-level laser therapy group, each patient are going to receive low-level laser therapy and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
16285318|NCT04779190|Experimental|Therapeutic ultrasound|In the therapeutic ultrasound group, each patient are going to receive therapeutic ultrasound and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
16285319|NCT04779190|Active Comparator|Control|Participants are going to perform a home-based exercise program and receive cold-pack therapy 5 times a week, once a day for 15 sessions.
16285322|NCT04779164|Experimental|Patients with type 2 diabetes|Patients with diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
16285323|NCT04779164|Other|Patients without type 2 diabetes|Patients without diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
16285324|NCT04779151|Experimental|1.A - Urothelial Bladder Cancer|
16285325|NCT04779151|Experimental|1.B - Gastric or gastro-esophageal junction adenocarcinoma|
16285326|NCT04779151|Experimental|1.C - Head and Neck Cancer|
16285327|NCT04779151|Experimental|1.D - Biliary Tract Cancer|
16285328|NCT04779151|Experimental|1.E - Others: any histology, excepted breast cancer, prostate cancer or serous ovarian cancer|
16285329|NCT04779151|Experimental|Cohort 2 - Platinum-sensitive urothelial bladder cancer|
16285330|NCT04779151|Experimental|Cohort 3 - Clear Cell Renal Cell Carcinoma|
16285331|NCT04779138|Experimental|Increasing Uptake of COVID-19 Vaccination|"This is a pre-experimental one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
16285332|NCT04779125|Experimental|Gluteus plasty enhanced with Progrip self gripping mesh|All study patietns will have a gluteus enhanced plasty after abdominoperineal reconstruction.
16285333|NCT04779099|Experimental|4-session intervention|
16285334|NCT04779099|Active Comparator|Treatment as usual|
16285335|NCT04779086||1. group|Scale score results of first year physiotherapy and rehabilitation department students
16285336|NCT04779086||2. group|Scale score results of 2nd year physiotherapy and rehabilitation department students
16285337|NCT04779086||3. group|Scale score results of 3rd year physiotherapy and rehabilitation department students
16285338|NCT04779086||4. group|Scale score results of 4th year physiotherapy and rehabilitation department students
16285339|NCT04779060|Active Comparator|fentanyle group|
16285340|NCT04779060|Active Comparator|dexamethasone group|
16285341|NCT04779060|Placebo Comparator|control group|
16285342|NCT04779047|Active Comparator|group 1|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once
16285343|NCT04779047|Active Comparator|group 2|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.
16285344|NCT04779034|Experimental|Group 1|Basketball players
16285345|NCT04779008|Experimental|Experimental Group 1|Routine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.
16285346|NCT04779008|Experimental|Experimental Group 2|Routine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.
16285347|NCT04779008|No Intervention|Control group|routine treatment, no RIPC
16285348|NCT04778995|Experimental|Manager nurses (Experimental group)|Manager nurses who participated in the structured training program based on qualitative data. Web based training program was the intervention for this group.
16285349|NCT04778995|No Intervention|Manager nurses (Control group)|Manager nurses who were not included to the structured training program based on qualitative data. No intervention was performed for this group.
16285350|NCT04778982||dose-escalation Phase|KN026 20 mg/kg + palbociclib 100 /125 mg/day (Patients with HR-/HER2-positive MBC) or KN026 20 mg/kg + palbociclib 100 /125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
16285351|NCT04778982||parallel-group expansion Phase|KN026 20 mg/kg + palbociclib RP2D(Patients with HR-/HER2-positive MBC ) or KN026 20 mg/kg + palbociclib RP2D+Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )
16285352|NCT04778956|Experimental|Toripalimab plus salvage surgery|"Toripalimab: Toripalimab treatment before and after salvage surgery.
~Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node."
16285353|NCT04778956|Active Comparator|Salvage surgery alone|1. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.
16285354|NCT04778943||oblique lateral interbody fusion (OLIF)|Patients with lumbar spinal stenosis undergoing oblique lateral interbody fusion (OLIF)
16285355|NCT04778943||minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)|Patients with lumbar spinal stenosis undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
16285356|NCT04778930|Experimental|Group A_Intervention Group|It will consist of 18 sessions, 3 times a week, for 6 consecutive weeks; on the one hand, 12 face-to-face sessions of approximately 90 minutes duration, in which the Physical Therapy treatment will be carried out based on training of specific tasks directed to objectives and training of gait with a treadmill; In addition, a therapeutic education program will be carried out, with 6 telehealth sessions lasting approximately 60 minutes, which will include action observation activities. The face-to-face sessions will be held at the Physical Therapy Teaching Unit at University of Alcalá, and the telehealth sessions of the Therapeutic Education program will be carried out by remote assistance through a digital platform. All will be carried out by specialist Physical Therapists, members of the research team.
16285357|NCT04778930|Experimental|Group B_Control Group|The subjects in this group will receive their usual Physical Therapy intervention regimen for 6 weeks at their referral center and the same telehealth Therapeutic Education program of the intervention group.
16285358|NCT04778917|Experimental|Small dose low molecular weight heparin|Low molecular weight heparin calcium 100 units / kg/day, subcutaneous injection, 5-10 days of treatment or D-dimer recovery normal.
16285359|NCT04778917|Experimental|High dose of low molecular weight heparin|low molecular weight heparin calcium 200 units /kg/day, subcutaneous injection, treatment for 7 days or D-dimer return to normal.
16285360|NCT04778917|Placebo Comparator|Vacuity contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
16285361|NCT04778917|No Intervention|contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
16285362|NCT04778904|Experimental|Group 1 (MVA-HBV)|Day 0: MVA-HBV 1 x 10^8 pfu IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection
16285363|NCT04778904|Experimental|Group 2 (ChAdOx1-HBV, MVA-HBV)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection
16285364|NCT04778904|Experimental|Group 3 (ChAdOx1-HBV, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
16285365|NCT04778904|Experimental|Group 4 (ChAdOx1-HBV and nivolumab, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection + nivolumab 0.3 mg/kg IV infusion Day 28: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
16285366|NCT04778891|Experimental|Intervention group|In addition to usual care provided by general practitioner (GP) and other health care providers, a pharmacist-practitioner in collaboration with GPs from the study setting provided CMM services to patients in the intervention group. Based on the pre-defined inclusion criteria, GPs were selecting patients and referring them to the pharmacist. The individual consultation with the patient was held at the private counselling area where pharmacist and patient were able to talk face-to-face apart from the other patients. The initial assessment lasted 60-90 minutes and the follow-up evaluations 30-60 minutes. Alternatively, patients were followed-up by telephone. Communication with GPs took place in a written (electronic consultation system Health net. PRO; e-mail) and, if needed by face-to-face conversation. Each patient in the intervention group needed to agree to participate in the study by signing an Informed consent form.
16285367|NCT04778891|No Intervention|Control group|Patients in the control group received the usual care which includes GP and other health care provider visits. Data for the patients pertaining to the control group were provided by the 'control' GP and collected parallel with the intervention group. 'Control' GP profile corresponded to the profile of GPs included in the intervention group - the number of years of professional experience in the primary health care less than ten.
16285368|NCT04778865|Experimental|Vitamin D-correction|Subjects will receive one capsule with 50.000 IU cholecalciferol weekly for 3 months.
16285369|NCT04778865|Active Comparator|Vitamin D-RDA|Subjects will receive one capsule with 4.200 IU cholecalciferol weekly for 3 months.
16285370|NCT04778852|Experimental|EksoGT|Device: EksoGT. EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
16285371|NCT04778852|Active Comparator|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
16285372|NCT04778839|Experimental|Paclitaxel Micelles for Injection|In the First Period, Only three Participants in the first dose group were randomly assigned to 175 mg/m2 paclitaxel micelle for injection at a 1:1 rate.175 mg/m2, 260 mg/m2, 320 mg/m2, and 390 mg/m2 of paclitaxel micelle for Injection was intravenously administrated for three hours,three weeks constituted one course of treatment.
16285373|NCT04778839|Active Comparator|Paclitaxel Injection|three Participants were randomly assigned to 175 mg/m2 paclitaxel Injection,175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
16285374|NCT04778826|Active Comparator|Lung Lobectomy with standard ipsilateral lymphadenectomy|Lung lobectomy with ipsilateral lymphadenectomy
16285375|NCT04778826|Active Comparator|Lung Lobectomy with VAMLA|Lung lobectomy combined with video-assisted mediastinal lymphadenectomy through the neck (VAMLA). The approach is similar to transcervical mediastinoscopy and allows for a radical bloc dissection of all mediastinal lymph node stations. Besides the benefit of bilateral lung ventilation during this phase of the operation a bilateral mediastinal lymphadenectomy offers improved surgical radicality.
16285376|NCT04778813|Experimental|Artemether-lumefantrin (AL)|"The tablets will be given orally according to patients' age and under supervision of study team as follows:
~Day 0: H0 and H8
~Day 1: H24 and H36
~Day 2: H48 and H60"
16285377|NCT04778813|Experimental|Dihydro-artemisinin-piperaquin (DHA-PPQ)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
16285378|NCT04778813|Experimental|Artesunate-Pyronaridin (As-Pyr)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
16285379|NCT04778800|Experimental|almonertinib 110mg PO once daily|
16285380|NCT04778800|Experimental|almonertinib 160mg PO once daily|
16285381|NCT04778800|Experimental|almonertinib 220mg PO once daily|
16285382|NCT04778787|Experimental|the intervention group|The intervention group includes patients with decompensated chronic heart failure. The diagnosis will be made according to the criteria described above
16285383|NCT04778787|Experimental|the control group|The control group will be identical to the main group.
16285384|NCT04778774|Experimental|Adductor canal block group|Adductor canal block group
16285385|NCT04778774|Experimental|Femoral nerve block group|Femoral nerve block group
16285386|NCT04778761|No Intervention|Usual Care|Usual care entails receiving usual medical care by the home-based care team.
16285387|NCT04778761|Experimental|Video intervention|In addition to usual care, the intervention will entail having a visit by a trained study clinician to provide access to the ACP video. The study clinician will discuss the content of the video and answer any questions.
16285388|NCT04778748||Obstructive Sleep Apnea|Participants will be provided with a Withings sleep monitor and instructed to begin using it. Effective data collection via the Withings unit should be confirmed for at least 7 consecutive nights, and the WatchPAT device will be used during one of those same 7 nights.
16285389|NCT04778735|Other|Pediatric Patients with Liver Transplantation|
16285390|NCT04778722|Experimental|Probiotic group|pilot study with one interventional group
16285391|NCT04778709|Experimental|Bone Graft A|Bone Graft A: Mixture of 25% small-particle cortical, 25% large particle cortical, 25% small particle cancellous, 25% large particle cancellous allograft
16285392|NCT04778709|Active Comparator|Bone Graft B|Bone Graft B: 100% large particle cancellous allograft
16285393|NCT04778696|Active Comparator|conventional pace mapping|Conventional PVC pace mapping without visual guidance of PASO
16285395|NCT04778683|Experimental|VR Group|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing.
16285396|NCT04778683|No Intervention|Control Group|The same evaluations were performed in children in the control group who received routine clinical care.
16285397|NCT04778670|Active Comparator|Standard of Care|Standard of Care means all examinations will receive a flagging decision by: first reader and second reader radiologist as usual. However, in this paired design all participants will belong to both arms.
16285398|NCT04778670|Experimental|AI CAD combination|AI CAD combination in the primary end-point means the combination of the flagging decision of the first reader and AI CAD; in the secondary end-points it means any combination of AI alone, or AI in combination with first, second and both readers.
16285401|NCT04778631|Experimental|Heat therapy|Local perineal heat therapy during active second stage of labor
16285402|NCT04778631|Experimental|Cryotherapy|Local perineal cryotherapy during the immediate postpartum period
16285403|NCT04778631|No Intervention|Active second stage usual car|Standard obstetrical care and perineal protection during active second stage of labor
16285404|NCT04778631|No Intervention|Postpartum usual care|Standard immediate (<2 hours) postpartum care
16285405|NCT04778618|Experimental|Individual dose of Thymoglobulin|Individual dose of Thymoglobulin (r-ATG) : Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 7 mg/kg to10mg/kg)
16285406|NCT04778605||Patients with septic shock stabilized between H6 and H24 of treatment under noradrenaline.|
16285407|NCT04778592|Experimental|ETX-018810|Drug: ETX-018810 bid
16285408|NCT04778592|Placebo Comparator|Placebo|Matching Placebo bid
16285409|NCT04778579|Experimental|ARI-0001|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
16285410|NCT04778566||Cologuard Study Group|Within 60 days of their already scheduled screening colonoscopy, participants will provide a stool sample to be tested by a Cologuard screening test kit. Participants will also complete surveys prior to their colonoscopy as well as post colonoscopy.
16285411|NCT04778527|Experimental|Over-encapsulated DPP|A single, over-encapsulated DPP taken once daily for three 28-day cycles (Regimen A) followed by two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles (Regimen B)
16285412|NCT04778527|Experimental|Two Separate Tablets|Two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles followed by a single, over-encapsulated DPP taken once daily for three 28-day cycles
16285413|NCT04778514|Experimental|Over-encapsulated DPP|This arm is a single, over-encapsulated DPP containing PrEP and a COC taken once daily for three 28-day cycles.
16285414|NCT04778514|Experimental|Two Separate Tablets|This arm is two separate tablets (PrEP and COC) taken once daily for three 28-day cycles.
16285415|NCT04778501|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
16285416|NCT04778488|Other|NIRS diagnostics|NIRS measurement
16285417|NCT04778475|Experimental|Group A|The treatment group will receive increased frequency of PT services within the first 3-5 days of admission, followed by daily PT services for the duration of their inpatient stay.
16285418|NCT04778475|Active Comparator|Group B|The control group will receive standard care of PT services 3-5 times per week during their hospitalization.
16285419|NCT04778462|Experimental|Extracorporeal shock wave|Extracorporeal shock wave group A consist of 15 subject will receive extracorporeal shock wave and conventional treatment for trigger points for two weeks four treatment sessions
16285420|NCT04778462|Experimental|High-power pain thershold ultrasound|High -power pain thershold group b consist of 15 subject will receive high power pain threshold ultrasound and conventional treatment for upper trapezius trigger points for two weeks four treatment session
16285421|NCT04778462|Other|Controlled group|controlled group consist of 15 subjects will receive conventional treatment for trigger point for two weeks
16285422|NCT04778449||Observational (questionnaire, medical chart review)|Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
16285423|NCT04778436|Experimental|T7082|After inclusion, the patients will consume an association of 4 food supplements including Nutrof Total.
16285424|NCT04778423|Experimental|Avatar Therapy|AVATAR therapy for eating disorders
16285434|NCT04778384|Experimental|Intervention Group|30 patients receive micro-training based on a checklist & targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire)
16285435|NCT04778384|Sham Comparator|Control Group|30 patients receive a sham intervention: an unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
16285436|NCT04778371|Experimental|Almond supplement|Participants will consume 32 g dry roasted, unsalted almonds twice a day for 12 weeks
16285437|NCT04778371|Placebo Comparator|Placebo matched supplement|Participants will consume 100 g granola bar, calorie matched to Almond, twice a day for 12 weeks
16285438|NCT04778358|Experimental|OOCYTE DONORS|Administration of a higher dose of Rekovelle (follitropin delta) to increase the ovarian response to 17 oocytes (the optimal range being 15 to 25 oocytes) in an oocyte donor population without compromising safety and efficacy.
16285439|NCT04778345|Experimental|18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT|After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.
16285440|NCT04778319|Active Comparator|tubal occlusion|occlusion of tubes
16285441|NCT04778319|Sham Comparator|non occlusion of tube|non occlusion of tubes
16285442|NCT04778306|Active Comparator|Trans Oral Laser Surgery (Group 1)|In TOLS, the tumor tissue was removed en bloc and in one piece. The removed specimen was marked on a card with the help of pins. Permanent surgical margins were taken from the anterior, posterior, superior, inferior and deep areas of the tumor area.
16285443|NCT04778306|Active Comparator|Radiotherapy (Group 2).|. In RT; the head was routinely stabilized with the help of a thermoplastic mask and subsequently covered the primary area with a size varying from 4x4 cm to 6x6 cm. Total 63-70 Gy radiotherapy was applied 2.0-2.3 Gy/ day,5 days a week, for 6-7 weeks.
16285444|NCT04778293|Experimental|Experimental Group|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized (random.org), in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
16285445|NCT04778293|No Intervention|Control Group|No intervention
16285446|NCT04778280||Group A|1-Group A(Healty group with negative Giardia lamblia or control group) 96 samples
16285447|NCT04778280||Group B|2- Group B(Cases group with positive Giardia lamblia )96 sample
16285448|NCT04778267|Active Comparator|TPVB (thoracic paravertebral block)|TPVB will be performed in the sitting position A high frequency linear ultrasound probe will be applied in the parasagittal plane approximately 2-3 cm lateral to the midline till identification of the 3rd thoracic vertebra (T3) in the same side of surgery. Then the transducer will be moved progressively more medially until transverse processes are identified.The image acquired will have the transverse process located superiorly and an image of lower rib located inferiorly on the screen.The needle tip is to be observed to enter through the superior costotransverse ligament and loss of resistance sensation will be experienced. After confirming the anterior displacement of pleura with 2-3 mL of local anesthetic (LA), 30 ml of 0.25% bupivacaine and 4 mg dexamethasone will be administered for the block.
16285449|NCT04778267|Experimental|ES-PI (erector spinae-pectointercostal block)|"ESPB In the second group (ES-PI) Using a high frequency linear ultrasound probe, it will be located in a longitudinal orientation at the level of T3 spinous process and then will be placed 3 cm laterally from the midline to the side involved in the surgery. .a 22-gauge block needle will be inserted in-plane at an angle of 30-40°. 20 mL of 0.25% bupivacaine hydrochloride and 3 mg dexamethasone will be injected in the plane deeper to the erector spinae muscle.
~PIPB While the patient is in the supine position, a high frequency linear probe will be placed parallel to the long axis of the sternum at a distance 2-3 cm from the attachment of the second rib and sternum to identify the Pectoralis major muscle, external intercostal muscles and the second rib in the superficial plane. by separation of fascial layers of between the external intercostal and the pectoralis muscles, a total of 10 ml of 0.25% bupivacaine and 1 mg dexamethasone will be injected."
16285450|NCT04778254|Active Comparator|conventional obturator|conventional group received conventional clasp-retained obturators with metallic framework (Control group).
16285451|NCT04778254|Experimental|metallic attachment retained obturator|metal group received an attachment-retained obturator with metallic framework
16285452|NCT04778254|Experimental|PEEk attachment retained obturator|PEEK group received attachment-retained obturators with milled PEEK framework,
16285453|NCT04778241|Experimental|Micro-Osteoperforation group|All the participants bonded by the care provider with 0.022 inch MBT prescription appliance (Ortho TechanologyTM,USA). Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
16285454|NCT04778241|No Intervention|Control group|All the participants in this group bonded by the principal investigator with 0.022-inch slot MBT prescription appliance (Ortho TechanologyTM,USA). No micro-osteoperforation was used in this group.
16285455|NCT04778215|Experimental|Intervention group|progressive, 8 week lumbar stabilizing program
16285456|NCT04778215|No Intervention|Control group|Continue as usual
16285457|NCT04778202||first group (control group)|25 normal health control women apparently healthy. blood samples will be obtained after getting informed consent
16285458|NCT04778202||Second group (breast cancer patient group)|25 female patients referred to radiology departement at South Egypt Cancer Institute or Assiut University Hospital diagnosed as breast cancer patients as evidenced by clinical examination , mammography and histopathology
16285459|NCT04778189|Placebo Comparator|normal saline group (NS)|patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia
16285460|NCT04778189|Active Comparator|dexamethasone group (SD)|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia
16285461|NCT04778176|Experimental|DopaFuse Delivery System 50mg LD/hr or 68mg LD/hr flow rate|Either 50mg/13mg LD/CD per hour or 68mg/17mg LD/CD per hour flow rate based upon Subject's standard levodopa (LD) dose. Subjects will routinely wear each container for approximately 5 hours (3 containers per day).
16285462|NCT04778163|Experimental|Humor group 1|"Group 1 - experimental - will participate in a humor group with a one-hour group session per week for 6 weeks."
16285463|NCT04778163|No Intervention|Control group 2|"Group 2 - the control group - will follow an usual treatment regimen for 6 weeks. At the end of the Humor Group of group 1, the 2 groups of patients will undergo a second series of tests identical to those of the pregroup. The paired patients should be randomly assigned. The control group will do the Humor Group after 6 weeks."
16285464|NCT04778137|Experimental|CMAB007|75mg×2
16285465|NCT04778137|Active Comparator|Xolair|150mg
16285466|NCT04778124|Other|Patients with hemorrhoidal disease undergoing HAL-RAR|This is a single-arm trial, in which all patients with grade II hemorrhoidal disease resistant to conservative treatment, grade III and IV hemorrhoidal disease underwent HAL RAR surgery.
16285467|NCT04778111||Patients with exclusion|
16285468|NCT04778111||Control|
16285469|NCT04778098|Experimental|SMS group|"After postoperative standard discharge education was provided to the patients in the SMS group, they were given an individualized written Postoperative Medication Reference Chart. The patient/relative, whose contact information was received, was informed that they would be reminded via text message (SMS). SMS reminders which were individualized according to the patient based on the doctor's directive, were sent to the patients in the SMS group by the researcher clinical nurse (A. Ş). SMS sending started on postoperative day 1 and ended on day seven.
~SAI was applied again to all patients who came to the outpatient clinic for control on postoperative day seven. Unlike the control group, the Patient Satisfaction Form, which was prepared for the use of SMS reminders, was applied to the patients in the SMS group. Confirmation was obtained from the patients and their relatives that SMS reminders were received every day."
16285470|NCT04778098|No Intervention|Control group|the Patient Identification Form and SAI were applied to patients in the control on the day of surgery (postoperative day 0). Routine discharge education was provided to all patients by clinical nurses. During the discharge of the patients in the control group, they were informed about the change of dressing on the next day (postoperative day one) and control in the outpatient clinic on postoperative day seven. The patients were given an individualized written Postoperative Medication Reference Chart indicating the dosage and application time of eye drops they must follow for seven days at home.
16285471|NCT04778085||IMR patients|Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
16285472|NCT04778085||IMR therapists and other staff|Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
16285473|NCT04778072|Experimental|Group 1|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
16285474|NCT04778072|Experimental|Group 2|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
16285475|NCT04778072|Experimental|Group 3|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily with matching placebo
16285476|NCT04778059|Experimental|USB002|
16285477|NCT04778059|Placebo Comparator|Placebo|
16285483|NCT04778033||Vaccinated Men|Fertile men who were vaccinated with the BNT162b2 COVID-19 Vaccine
16285484|NCT04778007||Globus pharyngeus patients|The first group consists of 80 globus pharyngeus patients who have at least a year of globus sensation complaints. The participants will given the Turkish Version of the Laryngopharyngeal Measure of Perceived Sensation Questionnaire (T-LUMP), consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale. After the two weeks, 80 participants will given the T-LUMP and Visual analog scale for sampling.
16285485|NCT04778007||Healty subjects|The second group consists of 80 healty participants will given the T-LUMP consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale
16285486|NCT04777994|Experimental|Monotherapy Dose Escalation|ABBV-CLS-484 will be administered as a monotherapy in subjects with solid tumors
16285487|NCT04777994|Experimental|Combination Dose Escalation|ABBV-CLS-484 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
16285488|NCT04777994|Experimental|Monotherapy Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC)
16285588|NCT04777305|No Intervention|The control group|The control group will receive routine health care without exercise supervision (clinical and nutritional follow up).
16285489|NCT04777994|Experimental|Combination Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in combination with Programmed Cell Death-1 Inhibitor in subjects with locally advanced or metastatic, relapsed or refractory gastric or GEJ adenocarcinoma
16285490|NCT04777981|Experimental|CBDRA60 supplement|Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
16285491|NCT04777981|Placebo Comparator|Placebo|Control subjects will receive daily oral placebo tablets of identical appearance and taste containing no CBDRA60.
16285492|NCT04777968|No Intervention|Control Group (A) : RMGI restoration without SDF and KI.|• RMGI restoration without SDF and KI.
16285493|NCT04777968|Experimental|Intervention Group (B): Pretreatment with SDF and KI prior to RMGI restoration.|• Pretreatment with SDF and KI prior to RMGI restoration.
16285494|NCT04777955|Experimental|Group 1, core stabilization exercises group|core stabilization exercises will be performed using swissball. Program: Sitting on the ball will include (weight shifts, forward, backward and lateral sides), (pelvic bridge), (curl-up), (curlsup with diagonal reaching), (bird-dog exercise), (push-up) exercises. The application will be carried out for 6 weeks, 3 days a week for 30-45 minutes daily.
16285495|NCT04777955|Experimental|Group 2, electrical stimulation|"An adaptation of a pre-designed protocol will be used for the application of the Normocular Electrical Stimulation in the diaphragm. Current to be applied; Synchronous impulse at 30 Hz frequency, 1 sec beat increase time, 1 sec on (muscle contraction), 1 sec beat reduction time and 20 sec off (no warning) time. Two channels, each with two electrodes, will be placed in the seventh and eighth anterior intercostal space above and below the right and left sides of the xiphoid protrusion. The other two channels, each with two electrodes, will be placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
16285496|NCT04777955|Experimental|group 3, kinesiotape|"For anterior diaphragm banding, the patient will stand with arms raised. Next, the central part of the tape will be applied to the xiphoid protrusion with a tension of 50% to 70% after the maximum inhalation. While the patient is breathing, the ends of the tape will be pulled with 10 to 15% tension towards the lower ribs. To tape the rear diaphragm, the patient's body will bend forward, and the arms will be joined crosswise over the chest. After the maximum inhalation, the central part of the tape will be applied over the T10 with a tension of 50% to 70%. As the patient exhales and stretches the trunk, the ends of the tape will be attached to the lower ribs with a tension of 10 to 15%.
~The supine position will be used in the Kinesiological taping of the right and left external oblique and internal oblique muscles. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
16285497|NCT04777942|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
16285498|NCT04777942|Active Comparator|surgery alone|hepatic resection remove the liver tumors
16285499|NCT04777929||healthy pregnant woman|pregnant woman without any disease of pregnancy
16285500|NCT04777929||pregnant woman with preeclampia|pregnant woman with preeclampia but without any other disease of pregnancy
16285501|NCT04777916||Standard intensive 3+7 YOUNG OR ELDERLY|Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
16285502|NCT04777916||GO, Mylotarg®) with 3+7|Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
16285503|NCT04777916||CPX-351, Vyxeos®)|Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
16285504|NCT04777916||Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC)|Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
16285505|NCT04777916||Refractory or relapsed AML|"Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation).
~In the real life, because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients."
16285506|NCT04777903||underweight woman with twin pregnancy|underweight (BMI < 18.5 kg/m2)
16285507|NCT04777903||normal weight woman with twin pregnancy|normal (BMI: 18.5-23.9 kg/m2)
16285508|NCT04777903||overweight and obese woman with twin pregnancy|overweight and obese (BMI ≥24 kg/m2)
16285509|NCT04777890|Active Comparator|suboccipital inhibition technique group|
16285510|NCT04777890|Experimental|INYBI group|Participants in this group will be treated with the INYBI, an instrument designed for treating the suboccipital area, in a more precise way than the manual technique.
16285511|NCT04777890|Experimental|combined treatment group|Participants in this group will be first treated with the INYBI and then receive an upper cervical manipulation
16285512|NCT04777864|No Intervention|Usual Care|
16285513|NCT04777864|Experimental|Decision Aid|Usual care, plus introduction of a decision aid
16285514|NCT04777851|Experimental|Regorafenib + Nivolumab|Investigational arm: regorafenib at a dose of 90 mg orally once per day (on days 1 to 21 of a 28-day cycle), in combination with nivolumab 480 mg using 30-minutes intravenous infusion (on day 1 of a 28-day cycle, every 4 weeks).
16285515|NCT04777851|Active Comparator|Transarterial Chemoembolization (TACE)|"Control arm: Patients will be treated with transarterial chemoembolization (TACE) on-demand according to the clinical site's standards, with the goal of controlling all known liver lesions. Either conventional TACE (cTACE) or drug-eluting bead transarterial chemoembolization (DEB-TACE) may be used (as long as it is consistently applied for all patients at a given clinical site)."
16285516|NCT04777838|Active Comparator|Citalopram|Citalopram 10mg
16285517|NCT04777838|Active Comparator|Amitriptyline|Amitritptyline 25 mg
16285518|NCT04777838|Active Comparator|Bite Splint|Michigan Splint, nocturnal use
16335663|NCT04430569|Placebo Comparator|Placebo|
16285519|NCT04777825|Experimental|HRV biofeedback training|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist. This group of patients will also benefit from the HRV biofeedback training.
16285520|NCT04777825|Other|control|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist.
16285521|NCT04777799|Experimental|URGOnight|Use of the URGOnight neurofeedback training headband and its associated application
16285522|NCT04777786|Experimental|Physical Therapy Intervention|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning ~4 weeks after surgery (x̄=10 visits).
16285523|NCT04777786|No Intervention|Usual Care|The usual care group will be instructed to continue with their typical daily activities.
16285524|NCT04777773|Other|control group|classical physical therapy+ classical physical therapy
16285525|NCT04777773|Other|study group|classical physical therapy+ dual-task training
16285526|NCT04777760||one dose of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
16285527|NCT04777760||two and more doses of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
16285528|NCT04777747||viral infection|a child is infected by virus only
16285529|NCT04777747||viral and bacterial infection|a child is infected by virus and progress to bacterial infection
16285534|NCT04777708|Experimental|Treatment (pembrolizumab, BO-112)|Patients receive pembrolizumab IV over 30 minutes on day 1 of odd number cycles. Patients also receive BO-112 by intratumoral injection on day 1, 8, and 15 of cycle 1, and day 15 of subsequent cycles. Treatment repeats every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
16285535|NCT04777695||CICU Inpatients|This is a prospective observational study of all children admitted to the pediatric CICU during a one month period of time for patients aged 0 to less than or equal to 22 years of age, as per the World Health Organization definition of a pediatric patient.
16285536|NCT04777682|Other|single arm|A single-arm, open, single-center (hospital-based) prospective interventional study to compare intestinal ultrasound versus double balloon enteroscopy in diagnosis of malabsorption syndrome
16285537|NCT04777669|Experimental|Experiment|Subjects will be tested for their ability to understand speech with and without noise reduction
16285538|NCT04777656|Experimental|CDED/Modulen™IBD®|Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
16285539|NCT04777656|Active Comparator|Unrestricted food access|Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
16285540|NCT04777656|Other|Not randomized|Patient not in remission at M2 or refusing randomisation
16285541|NCT04777643|Experimental|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
16285542|NCT04777643|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
16285543|NCT04777630||Patients with low vision who experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
16285544|NCT04777630||Patients with low vision who do not experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
16285545|NCT04777617||WU/Barnes cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
16285546|NCT04777617||UT Southwestern cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
16285547|NCT04777604||Patients with resectable pancreatic cancer after neoadjuvant chemotherapy|
16285548|NCT04777591|Active Comparator|Control - plain bupivacaine|Receives plain bupivacaine TAP block as part of multi-modal pain control intraoperatively
16285549|NCT04777591|Experimental|Experimental - Liposomal bupivacaine|Receives plain bupivacaine + liposomal bupivacaine TAP block as part of multi-modal pain control intraoperatively
16285550|NCT04777578|Experimental|DN|
16285551|NCT04777578|No Intervention|Control|
16285552|NCT04777565|Experimental|CI surgery|cochlear implant surgery
16285553|NCT04777552||Fixed-schedule|Untill mid 2013 patients with individually determined fixed-schedule dosage of benzodiazepines in the case of alcoholdependence.
16285554|NCT04777552||CIWA-Ar|Halfway through the year 2013 the department of psychiatry changed the protocol in alcohol withdrawal treatment and changed it to a symptom-triggered therapy with the use of CIWA-Ar to assess the severity of the alcohol withdrawal syndrome.
16285555|NCT04777526|Active Comparator|Control group|"Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active
~- resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle."
16285556|NCT04777526|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
16285557|NCT04777513||Standard of care: FFR, ICA, CCTA|Patients with medical history for ischaemic heart disease will take part in non-invasive determination of haemodynamic parameters in coronary arteries with iSIL-FFR (in SILico FFR) technology.
16285558|NCT04777500|Experimental|taVNS Group1|This group will receive taVNS for 4 weeks.
16285559|NCT04777500|Experimental|taVNS Group 2|This group will receive taVNS for 4 weeks.
16285560|NCT04777487|Experimental|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and GCF obtained.
16285561|NCT04777487|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
16285562|NCT04777487|Experimental|Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
16285563|NCT04777474|Experimental|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy
16285564|NCT04777461|Experimental|Group 1|Pilot the structured education in women with PCOS
16285565|NCT04777448|No Intervention|Control|Simple physical activity advices will be given to the 27 patients of the control arm
16285566|NCT04777448|Experimental|telerehabilitation|Patients in the tele rehabilitation arm will perform 24 1h-telerehabilition sessions (dance, gym, cardio training, yoga, ...)
16285567|NCT04777435|Experimental|Patients with Thrombotic micro-angiopathy|
16285568|NCT04777422|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
16285573|NCT04777383|Experimental|Vascular effects of iontophoresed vasoactive substances|"Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period.
~Vasoactive substances:
~Miochol-E (Acetylcholine),10 mg/ml, Bausch & Lomb
~Methacholine chloride, 100 mg/ml, APL
~Norepinephrine, 1 mg/ml, Pfizer
~Phenylephrine, 10 mg/ml, Unimedic
~Atropine, 10 mg/ml, Bausch & Lomb
~Neostigmine, 2.5 mg/ml, Unimedic Pharma
~Sterile water, 100 ml, Braun"
16285574|NCT04777370|Experimental|sleeper stretch + thoracic manipulation|The group will receive the sleeper stretch at session #1, and a thoracic manipulation followed by the sleeper stretch at session #2.
16285575|NCT04777370|Experimental|posterior glenohumeral (PG) mobilization + thoracic manipulation|The group will receive a posterior glide mobilization at session #1, and a thoracic manipulation followed by posterior glide mobilization at session #2.
16285578|NCT04777344|Experimental|Intervention group|The intervention group will receive the multi-component intervention (counseling with intake assessment, follow-up, help obtaining nicotine replacement therapy, and CF-specific smoke exposure education)
16285579|NCT04777344|No Intervention|Control group|The control group will receive usual care plus CF-specific smoke exposure education.
16285580|NCT04777331|Experimental|Prasinezumab|Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W).
16285581|NCT04777331|Placebo Comparator|Placebo|Participants will receive placebo as an IV infusion Q4W.
16285582|NCT04777318|Experimental|Conventional physiotherapy|The individuals in the control group will be included in a total of 12 sessions of conventional physiotherapy program for 4 weeks, 3 days a week.
16285583|NCT04777318|Experimental|Muscle Energy Technique (MET)|In addition to the conventional physiotherapy program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the second group.
16285584|NCT04777318|Experimental|Cervical Mobilization Techniques (CMT)|In the third group, cervical mobilization techniques will be applied in addition to the conventional physiotherapy program for a total of 12 sessions for 4 weeks, 3 days a month.
16285585|NCT04777305|Experimental|Aerobic exercise training|"The aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on the Borg scale.
~Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training."
16285586|NCT04777305|Experimental|Resistance exercise training|Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and body weight exercises.
16285587|NCT04777305|Experimental|Combination exercise training|"The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterwards the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale.
~The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale."
16285589|NCT04777292|Experimental|Immediate-use|Immediate use of ESTOCMA mobile app. Participants will use the mobile application immediately after the baseline assessment (T1) during approximately 10 days or until app completion.
16285590|NCT04777292|Active Comparator|Delayed use|Delayed use of ESTOCMA mobile app. Participants will start using the app 15 days after the first assessment (T1), and immediately after the T2 assessment.
16285591|NCT04777279|Experimental|Individual physical exercise group|a 12-weeks physical exercise program (60 minutes/ three times weekly)
16285592|NCT04777279|Experimental|Individual Branched-Chain Amino Acids supplements group|a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
16285593|NCT04777279|Experimental|Combination of physical exercise and Branched-Chain Amino Acids supplements group|a 12-weeks physical exercise program (60 minutes/ three times weekly) and a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
16285594|NCT04777279|No Intervention|Control group|no intervention
16285595|NCT04777266|Experimental|Experimental Musictherapy Group|experimental group receiving the MT programme in addition to their usual treatment (pharmacological and psychosocial) (TAU + MT)
16285596|NCT04777266|Active Comparator|Control Non Musictherapy Group|Group with usual treatment only (TAU).
16285597|NCT04777253|Experimental|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
16285598|NCT04777253|Other|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
16285599|NCT04777227|Active Comparator|Debridement|A debridement (procedure involving cleaning and removing all hyperkeratotic tissue) was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr
16285600|NCT04777227|Sham Comparator|Debridement with needle insertion|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
16285601|NCT04777227|Placebo Comparator|Debridement with physiological water injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 0.9% sterile sodium chloride water. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
16285602|NCT04777227|Experimental|Debridement with lidocaine injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 2% lidocaine solution. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
16285603|NCT04777214|Active Comparator|Active TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS are delivered to a previously determined optimal response site in right frontal lobe.
16285604|NCT04777214|Sham Comparator|Sham TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS are delivered, however, the coil will be rotated 90 degrees during stimulation.
16285605|NCT04777201|Experimental|Faricimab|
16285606|NCT04777188|Experimental|Hypertrophic Obstructive Cardiomyopathy|Left ventricular systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy.
16285607|NCT04777175||KRAS mutation|patients carry with KRAS mutation
16285608|NCT04777175||ALK fusion|patients carry with ALK fusion
16285609|NCT04777175||ERBB2 mutation|patients carry with ERBB2 mutation
16285610|NCT04777175||MET skipping/amplication|patients carry with MET skipping/amplication
16285611|NCT04777175||RET fusion|patients carry with RET fusion
16285612|NCT04777175||BRAF mutation|patients carry with BRAF mutation
16285613|NCT04777162|Experimental|tislelizumab+anlotinib|patients will be administrate with dual drugs, tislelizumab plus anlotinib.
16285614|NCT04777149|Experimental|transcranial Random Noise Stimulation (tRNS)|Participants in this group will receive a combined intervention (3 days of tRNS during functional task practice and 3 days of sham-stimulation during functional task practice).
16285615|NCT04777149|Active Comparator|transcranial Direct Current Stimulation (tDCS)|Participants in this group will receive a combined intervention (3 days of tDCS during functional task practice and 3 days of sham-stimulation during functional task practice).
16285616|NCT04777136|Experimental|Geriatric home visit|Home-visit where a comprehensive geriatric assessment will be performed
16285617|NCT04777136|Active Comparator|Standard care|No follow-up.
16285618|NCT04777123|Active Comparator|sitting position|patients will be left in the sitting position
16285619|NCT04777123|No Intervention|supine position|patients will lie down immediately after injection
16285620|NCT04777110|Experimental|Esketamine injection group (0.25mg/kg)|The main anesthesiologist standing on the right side of the patient gave successive injections of esketamine (0.25 mg/kg), and 1 minute later, injected propofol (1.5 mg/kg) for 30 s
16285621|NCT04777110|Sham Comparator|Saline injection group(0.05ml/kg)|The main anesthesiologist standing on the right side of the patient sequentially injects normal saline (0.05ml/kg), and 1 minute later injects propofol (1.5 mg/kg), the injection time is 30 seconds
16285622|NCT04777097||healthy pregnant women|Healthy patients who receive a cesarean operation
16285623|NCT04777097||Pre-eclampsia|Patients with pre-eclampsia who receive a caesarean operation
16285624|NCT04777084|Experimental|IBI318|IBI318, 300mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 20mg, orally
16285625|NCT04777071|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV then undergo PET/CT over 2-3 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT scan 6 weeks after initiating therapy.
16285626|NCT04777058||Patients|Patients admitted to the intensive care unit, treated with isavuconazole intravenously for treatment of invasive fungal infections
16285627|NCT04777045|Experimental|Diltiazem|When signs of vascular dysfunction with the coronary function test.
16335913|NCT04428827||Surgery|Patients treated with surgery
16285628|NCT04777045|Placebo Comparator|Placebo|When signs of vascular dysfunction with the coronary function test.
16285629|NCT04777032||Liver transplant recipients|All liver transplant recipient in Denmark aged 18-100 years will be eligible for inclusion in the DACOLT study. Inclusion requires the individual to be able to understand the study information in either Danish or English and to be able to provide an informed consent.
16285630|NCT04777032||Control group 1_CGPS|The Copenhagen General Population Study (CGPS) is an ongoing observational population study with more than 110.000 participants from the greater Copenhagen area. All residents in the greater Copenhagen area > 40 years and 25% of 20-40 years old are invited to participate in the study and in follow-up examinations every decade. A random sample of 10.000 participants aged ≥ 40 years had a contrast enhanced CT of the chest including CT angiography of the heart performed. Of these, 6500 had a contrast enhanced CT of the abdomen.
16285631|NCT04777032||Control group 1_CCHS|The Copenhagen City Heart Study (CCHS) includes a random population sample included from the greater Copenhagen area. Health surveys have been repeated 5 times between 1976 and 2015. Almost 4000 participants were randomly selected for echocardiography.
16285632|NCT04777006|Experimental|Cluster 1 (First Cluster of Clinics Randomized to Receive Care)|Arm 1 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 3 of the trial
16285633|NCT04777006|Experimental|Cluster 2 (Second Cluster of Clinics Randomized to Receive Care)|Arm 2 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 6 of the trial
16285634|NCT04777006|Experimental|Cluster 3 (Third Cluster of Clinics Randomized to Receive Care)|Arm 3 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 9 of the trial
16285635|NCT04777006|Experimental|Cluster 4 (Fourth Cluster of Clinics Randomized to Receive Care)|Arm 4 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 12 of the trial
16285636|NCT04777006|Experimental|Cluster 5 (Fifth Cluster of Clinics Randomized to Receive Care)|Arm 5 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 15 of the trial
16285637|NCT04776993|Experimental|Methimazole|Antithyroid drugs (at individualized dosage) for 72 weeks and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
16285638|NCT04776993|Active Comparator|Thyroid ablation|Radioiodine therapy or total thyroidectomy (according to ultrasound thyroid volume) and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
16285639|NCT04776980|Experimental|Ferumoxytol Infused MRI|Ferumoxytol is an iron replacement product that is FDA approved to treat iron deficiency anemia in patients with chronic kidney disease (CKD). In this study, ferumoxytol is used to quantify tumor-associated macrophages. The infused dose would be 5mg/kg.
16285640|NCT04776967|Active Comparator|Compression Profile 4|Compression Profile/Schedule 4 = 10 minute linear, Total Time Interval of Compression to treatment depth = 10 minutes, Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at treatment depth 45 fsw
16285641|NCT04776967|Active Comparator|Compression Profile 3|Compression Profile/Schedule 3 = 10 minute non-linear, Total Time Interval of Compression to treatment depth = 10 minutes Rate (slope) of compression = Non-Linear rate of compression = 3 fsw/min to a depth of 17 fsw, then 5 fsw/min up to a depth of 38.5 fsw, then 6.5 fsw/min to arrival at the treatment depth of 45 fsw
16285642|NCT04776967|Active Comparator|Compression Profile 2|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
16285643|NCT04776967|Active Comparator|Compression Profile 1|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
16285644|NCT04776954|Active Comparator|Forced Air Warming System|Participants in this arm will receive warming using a forced air warming system.
16285645|NCT04776954|Active Comparator|Resistive Blanket Warming System|Participants in this arm will receive warming using a resistive blanket warming system.
16285646|NCT04776941|Experimental|Arm I (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive messages and write essays about their experiences over 30 minutes (non-stop) QW for 3 weeks.
16285647|NCT04776941|Active Comparator|Arm II (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.
16285648|NCT04776928|Experimental|Provider-level push report notifications|Push reports will be sent via using a secure email client. The email will be sent to the email address provided to the study team by the surgeon or site.
16285649|NCT04776928|No Intervention|Control group|This control group will consist of surgeons belonging to sites that signed the Exhibit B-1. Surgeons in this group will not receive the push reports.
16285650|NCT04776928|No Intervention|No intervention|Sites who did not sign Exhibit B-1.
16285651|NCT04776915||Study Group|Infertile patients due to polycystic ovarian syndrome
16285652|NCT04776915||Control Group|Infertile patients due to unexplained infertility
16285653|NCT04776902|Other|Study Group|All patients will be enrolled in one arm
16285654|NCT04776889|Active Comparator|Control/statin non-users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy.
16285655|NCT04776889|Experimental|Interventional/statin users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy and administered rosuvastatin 20 mg/day for 6 months
16285656|NCT04776876|Experimental|Treatment (retifanlimab, telotristat ethyl)|Patients receive retifanlimab IV over 30-60 minutes on day 1 and telotristat ethyl PO TID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16285657|NCT04776863||Smokeless tobacco|Individuals using smokeless tobacco
16285658|NCT04776863||No smokeless tobacco|Individuals who do not use smokeless tobacco
16285659|NCT04776850|Experimental|Treatment (PTIS, HCT)|See Detailed Description.
16285660|NCT04776837||Main Cohort|"Patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival)
~Prior to starting anti-cancer therapy and at subsequent designated visits (every one month)
~Collections include:
~Blood sample
~Questionnaires quality of life, mood, and symptoms
~Tissue may be obtained for next-generation sequencing."
16285661|NCT04776824||Patients with confirmed amyloidosis|Confirmed diagnosis of amyloidosis w/wo cardiac involvement
16285662|NCT04776798|Experimental|Biomechanical Taping|"Anti pronation taping will apply bilaterally with Dynamic Tape®. The tape will attach to the dorsal aspect of the foot.
~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
16285663|NCT04776798|Placebo Comparator|Placebo Taping|"Placebo Taping will apply bilaterally to each individual in the control group by the same physiotherapist, without any effect on increased pronation.
~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
16285664|NCT04776785|Experimental|Group 1|"In Group 1, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).
~At the 6th and 12th months after the clinical applications, Profluorid® Varnish application will be repeated for test 1 and control lesions."
16285665|NCT04776785|Experimental|Group 2|"In Group 2, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2).
~At the 6th and 12th months after the clinical applications; Profluorid® Varnish application will be repeated for test 1 lesions, and MI Varnish™ application will be repeated for test 2 lesions."
16285666|NCT04776785|Active Comparator|Group 3|"In Group 3, one lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).
~At the 6th and 12th months after the clinical applications; MI Varnish™ application will be repeated for test 2 lesions, and Profluorid® Varnish application will be repeated for control lesions."
16285667|NCT04776772|Placebo Comparator|Soccer player placebo|Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin
16285668|NCT04776772|Experimental|Soccer player synbiotic|Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
16285669|NCT04776772|Placebo Comparator|Sedentary individuals placebo|Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin
16285670|NCT04776772|Experimental|Sedentary individuals synbiotic|Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
16285672|NCT04776733|Experimental|prepackaged group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.
~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
16285673|NCT04776733|Active Comparator|restricted diet group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.
~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
16285674|NCT04776720|Experimental|Yoga Program|The 3-month yoga intervention provides instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
16285675|NCT04776720|Active Comparator|Physical Conditioning Program|The 3-month physical conditioning program provides instruction and practice in a variety of exercises and stretches that have been designed by the study physical therapist.
16285676|NCT04776655|Experimental|Bevacizumab in combination with FOLFIRI chemotherapy|"Bevacizumab will be administrered at a dose of 5 mg/kg iv every 2 weeks. The first dose of Bevacizumab will be administered over 90 minutes. Then, if the first infusion is well tolerated without infusion-related reaction, the second dose will be administered over 60 minutes. Then, if the second dose is also well tolerated without an infusion reaction, all subsequent doses will be administered over 30 minutes.
~Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
16285677|NCT04776655|Active Comparator|Cetuximab in combination with FOLFIRI chemotherapy|Cetuximab will be administered at a dose of 500 mg/m² iv every 2 week (14 days/cycle) Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
16285678|NCT04776642||MARK_AF|MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery
16285679|NCT04776642||INDICO AF|Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.
16285680|NCT04776642||PREDICT AF|PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery
16285681|NCT04776642||WEIGHTLOSS AF|The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.
16285682|NCT04776642||MAD AF|(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.
16285683|NCT04776642||Adapt Biobank - AF surgery|Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.
16285684|NCT04776642||Adapt Biobank - blood|Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.
16285685|NCT04776629|Active Comparator|Active Treatment|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.
~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
16285686|NCT04776629|Placebo Comparator|Placebo|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.
~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
16285687|NCT04776616|Sham Comparator|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
16285688|NCT04776616|Experimental|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
16285689|NCT04776603||Group 1|group 1 includes patients who axial length(AL)<26mm
16285690|NCT04776603||Group 2|group 2 includes patients who axial length（AL）≥26mm
16285691|NCT04776590|Experimental|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg per square meter of body-surface area weekly) and Caboplatin (area under the curve of 2 mg per milliliter per minute weekly) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
16285692|NCT04776577|Other|Study arm|"Group 1 and group 2 will be recruited and assessed in parallel at the discretion of the treating physician, based on the characteristics of the patient. Group 3 will be recruited from suitable patients in group 1 and 2.
~Simultaneous measurements study (group 1) Regular study group (group 2) Echocardiography-CFR group (group 3)"
16285693|NCT04776564||Intensive courses|Participants on courses delivered within four days
16285694|NCT04776564||Long courses|Participants on courses delivered over minimum four weeks
16285695|NCT04776564||Clinical|Participants attending G7P courses delivered within the specialist health care setting
16285696|NCT04776564||Internett|Participants attending G7P courses delivered as an online course
16285697|NCT04776564||Professional|Participants attending G7P courses wihere professional health care personell are delivering the teaching
16285698|NCT04776564||Non-professional|Participants attending G7P courses wihere no professional health care personell are delivering the teaching
16285699|NCT04776564||Control group|A sample of couples from the public that do not at the moment participate in couple therapy or any couple enhancement programs
16285700|NCT04776551|Other|group (1)|group (1) who are complaining of acute scaphoid fractures,we will do percutaneous trans trapezial fixation of scaphoid by Herbert screw.Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start.
16285701|NCT04776538|Experimental|Stem cell group|60 patients will be randomized to receive adipose-derived allogeneic stem cells
16285702|NCT04776538|Placebo Comparator|Placebo group|60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
16285703|NCT04776525|Experimental|Sequential ifosfamide and doxorubicin|Four cycles ifosfamide 9 g/m2 and four cycles doxorubicin 80 mg/m2. Each cycle has a duration of 14 days.
16285704|NCT04776512|Experimental|Epidural Analgesia|Patients of this group Will receive an epidural analgesia through a lumbar epidural catheter
16285705|NCT04776512|Experimental|ESP Block|Bilateral ESP block performed at the level of the 3 rd Lumbar transverse process.
16285706|NCT04776499|Experimental|Healthy volunteers receiving propylthiouracil, riociguat, and perphenazine|Eight healthy volunteers will be included. Up to 15 healthy volunteers will be screened to reach the goal of 8 exposed volunteers. Sex is not expected to have an impact on the short-term evaluation of the potential drug-drug interactions. Therefore female and male participants will be included in an undefined proportion.
16285707|NCT04776486|Experimental|Critically ill patients with augmented renal clearance|ICU patients with estimated renal clearance over 130ml/min/1.73m2
16285708|NCT04776473|Experimental|Open (i.e. surgical) treatment|"This includes reduction and internal fixation of the fracture (ORIF) performed using the preferred surgical approach and bone implants of the including centre that could be associated with one or several items among the following:
~physical therapy based on exercises done by the patient himself
~physical therapy performed by a specialized/non-specialized physical therapist
~arch bars / screws / splint use for transient MMF
~arch bars / screws / splint use for passive mobilization of the mandible"
16285709|NCT04776473|Other|Closed (i.e. conservative) treatment|"To date, there is no consensus on which procedures should be used in case of conservative treatment, which may vary between centres and, for a same centre, between patients. This includes one or several items among the following:
~physical therapy based on exercises done by the patient himself
~physical therapy performed by a specialized/non-specialized physical therapist
~arch bars / screws / splint use for transient maxillo-mandibular fixation (MMF) (15 days max)
~arch bars / screws / splint use for passive mobilization of the mandible"
16285710|NCT04776447|Experimental|Experimental: Atezolizumab plus induction chemotherapy plus CT-radiotherapy|"Induction Treatment:
~Atezolizumab: 1200mg, IV infusion Carboplatin: AUC5, IV infusion Paclitaxel: 200 mg/m2 The treatment will start within 1-5 days from enrollment. The treatment will be 3 cycles administered at 21-day intervals.
~Concurrent Chemotherapy (CT)-Radiotherapy Treatment:
~Chemotherapy and radiotherapy treatment will be at the discretion of the principal investigator of each site. It is recommended to use as concurrent chemotherapy treatment a platinum based doublet.
~After the 3rd cycle of the induction treatment, concurrent treatment will start, 1st concurrent cycle will be administered from day 1 of cycle 3 of induction treatment.
~Concurrent chest radiotherapy will be administered starting at day 1 of cycle 1 of concurrent chemo-radiotherapy.
~Maintenance with Atezolizumab:
~Atezolizumab: 1200mg, IV infusion After the 3rd cycle of the concurrent treatment, Atezolizumab maintenance treatment will start from day 1 of cycle 6 and will be administered for 12 months."
16285711|NCT04776421||ileostomy group|
16285712|NCT04776408|Active Comparator|Control group_Use Lung recruitment|Use the Lung recruitment,
16285769|NCT04776122|Experimental|Therapy - device assisted breathing|Breathing performed with device
16285713|NCT04776408|Experimental|Study group_Use Lung recruitment combined inhaled Nitric oxide|Use the Lung recruitment combined inhaled Nitric oxide,
16285714|NCT04776395|Experimental|Arm A (iberdomide hydrochloride, dexamethasone)|Patients receive iberdomide hydrochloride PO QD on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16285715|NCT04776395|Active Comparator|Arm B (iberdomide hydrochloride)|Patients receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16285716|NCT04776382|Experimental|Study Group|Trainees of this group will watch an EMME (Eye Movement Modeling Examples) pre-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
16285717|NCT04776382|No Intervention|Control Group|Trainees of this group will not watch the pre-recorded video
16285718|NCT04776369|Active Comparator|Lidocaine group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
16285719|NCT04776369|Active Comparator|Magnesium group|30 patients will receive IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
16285720|NCT04776369|Active Comparator|Combination group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. after induction of anesthesia.
16285721|NCT04776369|Placebo Comparator|control group|30 patients will receive IV saline 50 ml plus IV saline 50 ml over 30 min. after induction of anesthesia.
16285722|NCT04776356||QuickFix Small Staple|The QuickFix Small Staple will be used for an Akin osteotomy to correct hallux valgus interphalangeus.
16285723|NCT04776343|Experimental|Telemedecine follow-up|
16285724|NCT04776343|No Intervention|Hospital follow-up|
16285725|NCT04776330|Experimental|BCMA targeted prime CAR-T cells treat|Patients will be be treated with BCMA targeted prime CAR-T cells
16285726|NCT04776317|Experimental|Stage 1 (Naïve) Group 1|5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
16285727|NCT04776317|Experimental|Stage 1 (Naïve) Group 3A|30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
16285728|NCT04776317|Experimental|Stage 1 (Naïve) Group 3B|30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
16285729|NCT04776317|Experimental|Stage 1 (Naïve) Group 4|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
16285730|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 13|5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=10
16285731|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 14|1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
16285732|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 15|5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
16285733|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after Ad26 COVID-19 EUA Vaccinated) Group 8|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=10
16285734|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after Ad26 COVID-19 EUA Vaccines) Group 12|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=10
16285735|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccinated) Group 5|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
16285736|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccinated) Group 6|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
16285737|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccinated) Group 7|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
16285738|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 10|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
16285739|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 11|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10.
16285740|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 9|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
16285741|NCT04776317|Experimental|Stage 2 Dose de-escalation (SAM-S TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 16|1 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
16285837|NCT04775628|Experimental|inferior glide|Inferior glide of the right humerus till no motion is visual on the imaging
16285742|NCT04776317|Experimental|Stage 2 Dose de-escalation (SAM-S TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 17|1 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
16285743|NCT04776304|Other|qEEG Art Therapy|Participants will receive art therapy while a noninvasive, mobile qEEG measures brain activity. There is no comparison as this is an exploratory pilot study.
16285744|NCT04776291|Experimental|Recruitment and image processing|
16285745|NCT04776278|Experimental|Brief Alcohol Intervention (BAI) + Substance Free Activity Session (SFAS)|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the Substance-free activity session (SFAS), a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
16285746|NCT04776278|Experimental|Relaxation Training (RT) + Substance Free Activity Session (SFAS)|Participants will complete a relaxation training session that will include a clinician leading them through a diaphragmatic breathing exercise, a progressive muscle relaxation protocol, and then a brief breath-counting (mindfulness) exercise. A week later, the participant will receive the SFAS, a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
16285747|NCT04776278|Active Comparator|Education Control|This minimal contact control condition will include a brief (2-3 minute) discussion where the research assistant (RA) who completed the assessment session will describe the educational handout. This condition is meant to approximate a public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or motivational interviewing. Participants will receive information on risks associated with alcohol/drug misuse, strategies for reducing alcohol problems, managing stress, and goal-setting. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact
16285748|NCT04776265||RR HL Who Receive Salvage Chemotherapy and ASCT|Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
16285750|NCT04776239|Experimental|Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group|Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
16285751|NCT04776239|Experimental|Group 2: Placebo Group|Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
16285752|NCT04776226|No Intervention|Patients without depression|This group included patients without depression during enrollment of the cases.
16285753|NCT04776226|Experimental|Depressive patients with treatment|This group included patients wit depression but with treatment during enrollment of the cases.
16285754|NCT04776226|No Intervention|Depressive patients wihout treatment|This group included patients without depression but withou treatment during enrollment of the cases.
16285755|NCT04776213|Experimental|Mavenclad®|
16285756|NCT04776200||Ballet Groups|It was invited the individuals, who were ongoing for at least 3 months in classical ballet dance activity in the dance studio, between December 2019 and March 2020.
16285757|NCT04776200||Control Groups|It was invited the individuals, who have just registered for classical ballet dance activity.
16285758|NCT04776187|Active Comparator|Gadodiamide|"Patients who have undergone contrast-enhanced MRI using Gadodiamide contrast agent for clinical purposes.
~Generic name: Gadodiamide Injection; Product name: OMNISCAN; Sample specifications: 15ml: 4.305g (a sterile solution containing 287mg/ml gadodiamide)."
16285759|NCT04776187|Experimental|Gadoteric Acid Meglumine Salt|"Patients who have undergone contrast-enhanced MRI using Gadoteric Acid Meglumine Salt contrast agent for clinical purposes.
~Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid meglumine salt)."
16285760|NCT04776174|Experimental|standard and telerobotic ultrasound|Included patients will have both ultrasound examination: standard ultraosound (abdominal, cardiac or pulmonary depending on the prescription and telerobotic ultrasound
16285761|NCT04776161|No Intervention|Control|Patients in the control arm will not receive any intervention (but will receive electronic pill bottles to monitor their adherence).
16285762|NCT04776161|Experimental|Cue-Reward Intervention|Patients in this intervention arm will choose an event-based cue and receive reminder text messages reminding them of their cue. Additionally, a donation will be made to a local charity every time they take their medication.
16285763|NCT04776161|Experimental|Cue-Reward Intervention with possible intensification.|Patients in this intervention arm will choose an event-based cue. Additionally, a donation will be made to a local charity every time they take their medication. Those who show no improvement in adherence after 6 weeks will start receiving reminder text messages reminding them of their cue.
16285766|NCT04776135|Experimental|MT-1186 orally|Subjects receive the edaravone oral suspension orally.
16285767|NCT04776135|Experimental|MT-1186 via a nasogastric tube|Subjects receive the edaravone oral suspension via a nasogastric tube
16285768|NCT04776122|Active Comparator|Control with no device|Breathing performed with no device
16285770|NCT04776109|Active Comparator|(Group of continous thoracic epidural bupivacaine infusion [CEI])|Group I : An epidural catheter will be inserted via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T8 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine (sunny-bupivacaine) infusion. Proper placement of the catheter will be verified through an aspiration test and a test dose (2 ml) of lidocaine 2% with adrenaline. At the end of surgery, a 0.2 ml/kg bolus of bupivacaine 0.25% will be administered through the catheter and then an infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h will be administered immediately postoperative and continued for 48 hours.
16285771|NCT04776109|Active Comparator|(Group of continous bilateral erector spinae bupivacaine infusions[CESI])|Group II : Bilateral erector spinae catheters will be placed at T8 level. Surface anatomy or ultrasound (counting up from the 12th rib) will be used to identify the level of T8 after skin sterilization with the patient on the lateral position. Then a high frequency linear-array ultrasound transducer (Sono Site MW, Bothell, WA, USA) covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine will be infiltrated .
16285772|NCT04776096|Experimental|Bepotastine besilate 1,5% preservative free|Bepotastine besilate 1,5% in preservative-free bottle, administered once a day during the morning.
16285773|NCT04776096|Active Comparator|Olopatadine hydrochloride 0,2% with BAK|Olopatadine hydrochloride 0,2% with BAK as preservative, administered once a day during the morning.
16285774|NCT04776083|Experimental|radiotherapy arm|after first line systemic therapy, patients will receive radiotherapy to the primary lesion, hypo-fractionated regimen 45gy will be given over 15 fractions
16285775|NCT04776083|Active Comparator|no intervention arm|after first line systemic therapy, patients will be kept under follow up
16285776|NCT04776057|Other|lying|after cataract lying for 1 hour
16285777|NCT04776057|Other|sitting, walkin|after cataract sitting or walking for 1 hour
16285778|NCT04776044|Experimental|ATR-002|Participants will receive 900mg ATR-002 on day 1 (6 tablets with 150mg ATR-002; once daily), and 600mg ATR-002 on days 2 - 6 (4 tablets; once daily)
16285779|NCT04776044|Placebo Comparator|Placebo|Participants will receive matching tablets placebo on day 1 (6 tablets, once daily), and matching tablets placebo on days 2 - 6 (4 tablets per day, once daily)
16285780|NCT04776031|Experimental|Laser Treatment|Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
16285781|NCT04776018|Experimental|Phase 1, Part 1 - Dose Escalation: Arm A - TAK-981 Twice Weekly (BIW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg subcutaneous (SC) injection once weekly x 8 doses, then once every 2 weeks for 8 doses, then monthly up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
~TAK-981: Escalating doses of TAK-981 BIW intravenous (IV) infusion on Days 1, 4, 8, 11 and 15 in Cycle 1 and 2 (each Cycle is of 28 days) followed by every 2 weeks for 8 doses, then monthly up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
16285782|NCT04776018|Experimental|Phase 1, Part 1 - Dose Escalation: Arm B - TAK-981 Weekly (QW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg SC injection once weekly x 8 doses, then once every 2 weeks for 8 doses, then monthly up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
~TAK-981: Escalating doses of TAK-981 QW IV infusion once weekly x 8 doses, then once every 2 weeks x 8 doses, then monthly up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
16285783|NCT04776018|Experimental|Phase 1, Part 2 - Lead-in Cohort: TAK-981 + Daratumumab and Hyaluronidase-fihj|"Daratumumab and hyaluronidase-fihj: 1800 mg SC injection QW once weekly x 8 doses, then every 2 weeks x 8 doses, then monthly until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
~TAK-981: As per dose and schedule of TAK-981 defined in Phase 1b Part 1."
16285784|NCT04776018|Experimental|Phase 2 - Dose Expansion: TAK-981 + Daratumumab and Hyaluronidase-fihj or Mezagitamab|TAK-981 at RP2D as determined in Phase 1b Mezagitamab at a fixed dose of 600 mg SC injection or Daratumumab and Hyaluronidase-fihj at a fixed dose of 1800 mg weekly x 8 doses, then every 2 weeks x 8 doses, then monthly up to Cycle 24 or until disease progression unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
16285785|NCT04776005||Patients with malignant disease undergoing chemotherapy|Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
16285786|NCT04776005||Patients with malignant disease undergoing chemotherapy + immunotherapy|Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
16285787|NCT04776005||Patients with malignant disease undergoing immunotherapy|Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
16285788|NCT04776005||Patients with malignant disease treated with targeted therapies|Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
16285789|NCT04776005||Patients with malignant disease undergoing radiotherapy|Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
16285790|NCT04775992||preemptive group|patients in this group will receive preoperative gabapentoids
16285791|NCT04775992||control group|patients in this group will not receive gabapentoids
16285792|NCT04775979|Experimental|Diphenylcyclopropenone (DPCP)|Applying DPCP topically
16285793|NCT04775966||The study population|Patients meeting eligibility criteria (see appropriate section).
16285794|NCT04775953|Experimental|Arm 1 (Dalbavancin)|Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) <30 and not on dialysis. N=100
16285795|NCT04775953|Active Comparator|Arm 2 (Standard of Care)|For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100
16285796|NCT04775940|Experimental|Perforated collagen membrane|
16285797|NCT04775940|Active Comparator|Occlusive collagen membrane|
16285798|NCT04775927|Experimental|education group|marriage preparation training
16285799|NCT04775927|No Intervention|control group|No intervention
16285800|NCT04775914|Active Comparator|PCI standard|
16285801|NCT04775914|Experimental|PCI standard + ischemic conditioning|
16285802|NCT04775914|Experimental|Stent with ultrasound|
16285803|NCT04775914|Active Comparator|Stent without ultrasound|
16285804|NCT04775901|Other|CT-guided lung biopsy|Participants in this arm received conventional CT-guided percutaneous transthoracic lung biopsy.
16285805|NCT04775901|Experimental|Template-guided lung biopsy|Three-dimensionally printed navigational template was designed based on the CT scan images acquired before the biopsy. Under the guidance of navigational template, percutaneous transthoracic lung biopsy was conducted.
16285806|NCT04775875|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the caudate. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
16285807|NCT04775862|Experimental|RAS wild type; investigator choice re-challenge with anti EGFR Rx|
16285808|NCT04775862|Active Comparator|RAS mutant; investigator choice of SOC third line Rx|
16285809|NCT04775849|Experimental|Intraoperative Berger Space Imaging|Intraoperative OCT imaging of the space between the posterior capsule and the anterior hyaloid
16285810|NCT04775823|Experimental|Hybrid composite nano-ceramic|
16285811|NCT04775797|Experimental|Part 1 (Healthy Subjects): Single Ascending Dose (SAD)|Two cohorts (Cohorts A and B) of healthy subjects will receive single doses of AB-836/placebo in an alternating cohort design under fasted conditions. One additional treatment will be administered under fed conditions.
16285812|NCT04775797|Experimental|Part 2 (Healthy Subjects): Multiple Ascending Dose (MAD)|Participants in Cohorts C, D and E will receive a once daily dose of AB-836/placebo for 10 days
16285813|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H|Participants in Cohorts F, G, and H will receive multiple doses of AB-836/placebo once daily for 28 days.
16285814|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I|Participants in Cohort I will receive multiple doses of AB-836/placebo once daily for 28 days in combination with ongoing nucleos(t)ide analog (NA) therapy.
16285815|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort J|Participants in Cohort J will receive AB-836/placebo and TDF in combination once daily for 28 days.
16285816|NCT04775784||Adult neurosurgical patients|Adult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.
16285817|NCT04775771|Experimental|Animal Assisted Practice (Experimental) Group|
16285818|NCT04775771|No Intervention|Control Group|
16285819|NCT04775758|Experimental|Atypical facial pain group|Patients with clinally diagnosed G50.1 - atypical pain condition after all necessary diagnostic measures are taken to exclude a clear organic pathology (multiple diagnostic tests including MRI, CT and consultations from other specialists). Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
16285820|NCT04775758|Active Comparator|Maxillofacial fracture pain group|Patients with maxillofacial fracture (S02.3, S02.4, S02.6.) will be subjected into control group. Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
16285821|NCT04775745|Experimental|Dose Escalation Phase|Three to six subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-168 on a once or twice daily schedule for 28 days, starting at a dose of 100 mg/day.
16285822|NCT04775745|Experimental|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups.
16285823|NCT04775732|Experimental|ultra proactive arm|
16285824|NCT04775732|Active Comparator|reactive arm|
16285825|NCT04775719|Other|Outcome Prediction Group|Patient-Specific Prediction of Functional Outcome and Standard Pre-Operative Total Knee Arthroplasty Information
16285826|NCT04775719|Other|Standard Care Group|Standard Pre-Operative Total Knee Arthroplasty Information
16285827|NCT04775706|Experimental|HM15912 0.5 mg/kg Active|
16285828|NCT04775706|Placebo Comparator|Placebo|
16285829|NCT04775693|Experimental|RE|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as both an inpatient (2 days a week RE) and an outpatient (3 days a week RE).
16285830|NCT04775693|Active Comparator|SOC|Participants receive standard of care gait training only as both an inpatient (at least 2 days a week) and an outpatient (at least 3 days a week).
16285831|NCT04775693|Experimental|RE/SOC|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as an inpatient (2 days a week RE) and standard of care only as an outpatient (at least 3 days a week).
16285832|NCT04775680|Experimental|ADG106 combined with PD-1 antibody Dose Escalation Level 1|
16285833|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Dose Escalation Level 2|
16285834|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Expansion Phase|
16285835|NCT04775654|Experimental|Supplement|Participants consume 455mg of blackcurrant extract standardized to contain 50mg anthocyanins in a 2-capsule dose for 70 days.
16285836|NCT04775654|Placebo Comparator|Placebo|Participants consume 2 capsules of microcrystalline cellulose for 70 days.
16285838|NCT04775615|Experimental|Treatment group A|
16285841|NCT04775602|Experimental|18F-PSMA PET/CT|Patients with evidence of biochemical recurrence of prostate cancer radically treated, with negative results to traditional diagnostic methods or doubtful imaging of 18F- Fluoro Methyl Choline (18F-FMC) PET/CT will perform a 18F-PSMA PET/CT as a tool for searching and location of recurrence.
16285842|NCT04775589|Experimental|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps.
16285843|NCT04775576|Active Comparator|Group 1|This group will have fluid theraphy due to conventional methods. The participants in this group will have 8-10 ml/kg/hour cristalloid infusion. If the mean arterial pressure (MAP) is <65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
16285844|NCT04775576|Active Comparator|Group 2|Patients in the PVI group will be started on maintenance fluid therapy at 2-3 ml / kg / hour. In addition to standard monitoring, if PVI is <13% and OAB≥65mmHg in measurements made with PVI, current fluid therapy will continue. If PVI is <13% and MAP <65 mmHg, noradrenaline infusion will be started. If PVI is> 13% and OAB≥65 mmHg, 250 ml iv colloid bolus will be administered, and iv colloid bolus will be continued until the PVI is <13% in the 5-minute follow-ups. If PVI> 13% and MAP <65 mmHg, patients should receive 250 ml i.v. colloid infusion will be given, if MAP <65mmHg continues in 5 minutes follow-up, 250 ml i.v. Colloid and noradrenaline infusion will be started and repeated until the OAB≥65 mmHg and PVI <13%.
16285845|NCT04775563||Rheumatic diseases outpatients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences and General Hospital.
16285847|NCT04775537||OssiMend™ Bioactive Moldable|Patients undergoing Lumber Spine Fusion
16285848|NCT04775524|Experimental|Storytelling Through Music (STM)|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)
~Storytelling Through Music (STM) group will participate in the study for a total of 19 weeks with 6 weeks of the STM program and 3 months follow up.
~Storytelling Through Music (STM) utilizes multiple modalities including storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting.
~Weeks 1-4: participants are led through weekly writing workshop over an online platform (i.e., Zoom or an equivalent) to develop their stories. Simultaneous with the writing sessions are 10-minute self-care lessons
~Week 5: Participants will be paired with a professional songwriter who will put their story into a song.
~Week 6: During the last week, participants will have one more writing workshop to debrief about the intervention."
16285849|NCT04775524|Experimental|Wait List / Storytelling Through Music-Hybrid|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)
~Waitlist control group (Storytelling Through Music-Hybrid) will participate in the study for a total of 13 weeks with 2 weeks of Storytelling Through Music-Hybrid program and 11 weeks of follow up .
~Storytelling Through Music-Hybrid involves participants listening to songs created for other healthcare professionals for 2 weeks."
16285850|NCT04775511|Experimental|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
16285851|NCT04775511|Experimental|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
16285852|NCT04775511|Other|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
16285853|NCT04775498|Active Comparator|Face-to-face psychoeducation group|The group of face-to-face psychoeducation or standard intervention will consist of the participation by the patients include in all the sessions of a therapeutic education programme of the investigator center.
16285854|NCT04775498|Experimental|SIMPLe mobile application|The experimental intervention consists of the use of the SIMPLe application during 1 year: answers of 5 daily questions and to the weekly questions. Moreover, daily and personalized psychoeducation messages (adapted to the answers to the tests carried out) will be sent to user by notifications.
16285855|NCT04775485|Experimental|Single Arm|DAY101, an oral pan-RAF inhibitor in immediate-release tablet form in 2 strengths, 20 mg and 100 mg.
16285856|NCT04775472|Experimental|Early left atrial septostomy group|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation.
16285857|NCT04775472|Active Comparator|Conventional approach group|Conventional approach group will receive left atrial septostomy in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
16285858|NCT04775459||Surfactant administration without using score LUS|"It is a retrospective cohort : preterm newborns from august 2019 to december 2019 needed a surfactant administration.
~The surfactant was administrated only if the fraction of inspired oxygen (FiO2) >30% among the Guidelines of 2019"
16285859|NCT04775459||Surfactant administration using score LUS|"It is a prospective cohort : preterm newborns from january 2021 to juin 2020 needed a surfactant administration.
~The surfactant is administrated if FiO2 >30% OR if score LUS >8/18 among the literature"
16285860|NCT04775446||Patients with malignant pleural mesothelioma treated with Nivolumab.|Patients with malignant pleural mesothelioma treated with Nivolumab.
16285861|NCT04775420||Group 1|Ascetic patients without spontaneous bacterial peritonitis
16285862|NCT04775420||Group 2|Ascetic patients with spontaneous bacterial peritonitis
16285864|NCT04775394|Experimental|Pilot Part: Healthy subjects|3-5 healthy ex-smokers with normal lung function to establish methods
16285865|NCT04775394|Experimental|Main Part: COPD patients and Healthy Controls|8 subjects with COPD stage II and III who are ex-smokers and have a history of chronic cough and sputum production and 5-8 healthy, age-matched controls
16285866|NCT04775381|Experimental|Vitamin D|During preoperative visit (Month -2) patients will receive a cholecalciferol supplementation added to a fruit juice.
16285867|NCT04775381|No Intervention|Fruit juice|During preoperative visit (Month -2) patients will receive only fruit juice.
16285868|NCT04775368|Experimental|Diagnosis orientation group|For this study, there is only one arm. Each patient complete diagnosis questionnaires.
16285869|NCT04775355||Observational (biospecimen collection, questionnaire)|Patients undergo collection of stool and urine samples within 2 weeks before hormone therapy or radiation therapy, after hormone therapy but before start of radiation therapy, and after completion of radiation therapy. Patients also complete a series of questionnaires prior to starting radiation therapy, mid-way through radiation therapy, and after completion of radiation therapy (within 1-3 weeks, at 3 months, and then every 6 months until 3 years from radiation completion). Patients' medical records are also reviewed.
16285870|NCT04775342||1 group|1 group will be assessed then will be given smartphone to use and assessed
16285871|NCT04775329|No Intervention|Control arm|Standard of care
16285872|NCT04775329|Active Comparator|Treatment arm|
16285873|NCT04775316||Patients with fragile skin|Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.
16285874|NCT04775303|Experimental|experimental group|Cyclosporine 0.1% (Ikervis®) eye drop - one drop once daily
16285875|NCT04775290|Experimental|Arm Yoga (YG)|Patients assigned to the YG arm participate in yoga classes
16285876|NCT04775290|No Intervention|Arm control (CG)|Patients assigned to the CG arm will follow the normal course of radiotherapy.
16285877|NCT04775277||cases|pregnant female with idiopathic pulmonary fibrosis
16285878|NCT04775277||control group|pregnant female with bronchial asthma
16285879|NCT04775264|Experimental|Pulsed Electric Field Energy Ablation|ablation of ganglionated plexi structures on the epicardial surface of the heart delivered as a concomitant procedure during open heart surgery to eliminate atrial fibrillation
16285880|NCT04775251|Experimental|one group|The treatment program consisted of upward rotation exercises for 3 sessions/week, for 6 weeks.
16285881|NCT04775238|Active Comparator|Group 1 (Staphylococcus aureus)|Staphylococcus aureus is an example of gram positive bacteria which is a strong biofilm producer and highly resistant to antibiotics. Staphylococcus aureus will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
16285882|NCT04775238|Active Comparator|Group 2 (Pseudomonas aeruginosa )|Pseudomonas aeruginosa is an example of gram negative bacteria which is a strong biofilm producer and highly resistant to antibiotics. Pseudomonas aeruginosa will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
16285883|NCT04775225|Active Comparator|Hip denervation group|This group will receive Lidocaine 2% block of the femoral and obturator genicular branches.
16285884|NCT04775225|Placebo Comparator|control group|this group will receive saline injection subcutaneously at the same places.
16285885|NCT04775212|Active Comparator|desflurane|patients to be anesthetized with desflurane
16285886|NCT04775212|Active Comparator|sevoflurane|patients to be anesthetized with sevoflurane
16285887|NCT04775199|No Intervention|Control|Control: In all conditions, we will teach science using the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) a visual Journal/Reflection, and 4) a pre-recorded reading centered around a given theme such as sound. A research speech-language pathologist will provide two 30-minute interactive science lessons per week for six weeks to children with language learning challenges recruited nationwide. Children will participate in groups of three. Families will log on five additional times during each week to view the science book reading. In the control condition, children will receive these science lessons but no language intervention. Therefore, this intervention constitutes a nonintervention.
16285888|NCT04775199|Experimental|Science + Grammar Intervention|"Grammar: In the science + grammar condition, focused stimulation plus explicit instruction will be employed. Focused stimulation an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities.. The active ingredients are models (30) and recasts (5 per child) of the target structure (e.g., You measured how long the ramp is). Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Focused stimulation will be supplemented with explicit instruction using choral production and visual supports (3x per lesson) and a definition of the meaning of the structure (1 per lesson)."
16285889|NCT04775199|Experimental|Science + Vocabulary Intervention|Vocabulary: We will provide Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 12 words that pertain to scientific practices applicable to the FOSS lessons. The words are: compare, diagram, evidence, explanation, hypothesis, materials, model, multiple, pattern, problem, scientist, search. Two words will be targets in each session. We will ensure that for each target word per session there will be at least one definition model and 3 other models directed to the triad of participants and at least 2 elicitations per child. The recorded books also include 6 additional exposures to the words, for a cumulative exposure of 12.
16285890|NCT04775186|Experimental|Laparoscopic Burch colposuspension|
16285891|NCT04775186|Experimental|midurethral sling|
16285892|NCT04775173|Experimental|Low dose of sirolimus|Sirolimus In the first 6 months, the plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose; then in the next 6 months, the plasma trough concentration of sirolimus is maintained within the range of 3-5 ng/ml by adjusting sirolimus dose.
16285893|NCT04775173|Active Comparator|Regular dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
16285894|NCT04775160|No Intervention|Control group|The control group will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and will receive treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
16285895|NCT04775160|Experimental|Intervention group|The intervention group will receive an Ecological Momentary Intervention called SmartSafe, will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and their treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
16285896|NCT04775147|Experimental|Intervention group|Achieving SBP level of <120mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
16285897|NCT04775147|No Intervention|Control group|Maintaining SBP level of <140mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
16285898|NCT04775134||Subjects with earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
16285899|NCT04775134||Subjects WITHOUT earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
16285900|NCT04775121|Experimental|Experimental|Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time
16285901|NCT04775108|Experimental|Implanted patients|Implantation of Epygon mitral valve prosthesis
16285904|NCT04775069|Active Comparator|mRNA Group|The subjects will be vaccinated with the mRNA vaccine (Pfizer-Biontech).
16285905|NCT04775069|Active Comparator|Inactivated Virus Group|The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).
16285906|NCT04775069|Active Comparator|Adenovirus-vector Group|The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).
16285907|NCT04775043||Control population|First part of the study for the HFRDIS Questionnaire French validation
16285908|NCT04775043||Patients on hormone therapy for breast cancer|Second par of the study for the HFRDIS questionnaire use on patients on hormone therapy for breast cancer
16285909|NCT04775030|Experimental|CBD occlusal appliance|CBD occlusal appliance
16285910|NCT04775030|Placebo Comparator|occlusal appliance|Traditional material occlusal appliance
16285911|NCT04775004|Active Comparator|Bone marrow venting procedure (BMVP)|Subjects randomized in the OR to undergo BMVP surgical augmentation
16285912|NCT04775004|Active Comparator|Platelet rich plasma (PRP)|Subjects randomized in the OR to undergo PRP surgical augmentation
16285913|NCT04774991|Active Comparator|Azithro 1-59 fixed point|Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
16285914|NCT04774991|Active Comparator|Azithro 1-59 door-to-door|Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
16285915|NCT04774978|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE continuously with ProbeFix
16285916|NCT04774965|Experimental|Slumber Curve Group|Patients receiving Slumber Curve sleep aid for management of pain and sleep quality following rotator cuff repair.
16285917|NCT04774965|No Intervention|Normal Sleep Routine Group|Patients not receiving sleep aid.
16285918|NCT04774952|Experimental|RMC-5552|RMC-5552 for IV administration
16285919|NCT04774939|Active Comparator|EVLA only|Only main trunk/trunks with venous reflux will be treated
16285920|NCT04774939|Active Comparator|EVLA and sclerotherapy of tributaries|Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy
16285921|NCT04774926|Experimental|Brolucizumab 6 mg|Participants will receive 3 monthly ocular injections followed by a q12w or q8w maintenance phase based on patient's disease activity (DA).
16285922|NCT04774913|Experimental|Invest CTO PCI|A pre-planned two staged procedure in high-risk CTO PCI
16285923|NCT04774900||Standardised|The procedures will be observed with standardized equipment placement.
16285924|NCT04774900||Modified|The procedures will be observed with modified equipment placement - placement according to older methodology or custom.
16285925|NCT04774887|Experimental|HPV vaccination|Children receiving HPV vaccine will be studies for seroconversion to HPV types, and aflatoxin levels in blood will be measured and compared to seroconversion.
16285926|NCT04774874|Experimental|FOL- 005 (0.1 %)|topical formulation
16285927|NCT04774874|Experimental|FOL -005 (0.5 %)|topical formulation
16285928|NCT04774874|Experimental|FOL -005 (1.5 %)|topical formulation
16285929|NCT04774874|Placebo Comparator|Vehicle|topical formulation
16285930|NCT04774861||CCTA Group|This is an all-comers group, of all ages and ethnicities who have been evaluated with a CCTA from 2017-2020.
16285931|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to high frequency oscillating ventilator.
16285932|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to high frequency oscillating ventilator.
16285933|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to HFJV.
16285934|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to HFJV.
16285935|NCT04774835|Active Comparator|Standard aPS|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor.
16285936|NCT04774835|Experimental|aPS + HIVST|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor as well as the option to do HIV self-testing (HIVST) instead of testing at the local HTS location.
16285937|NCT04774822||Sequential Enrollment|Enrollment based on default inclusion criteria listed below
16285938|NCT04774822||Enrichment Enrollment|Enrollment based periodic statistician-activated inclusion criteria adjustment to attain statistically adequate distribution
16285939|NCT04774809|Active Comparator|SHR0302 Low Dose|Drug: SHR0302 SHR0302 Ointment BID Low Dose
16285940|NCT04774809|Active Comparator|SHR0302 High Dose|Drug: SHR0302 SHR0302 Ointment BID High Dose
16285941|NCT04774809|Placebo Comparator|Placebo Comparator: Vehicle|Drug: vehicle Vehicle BID Placebo
16285942|NCT04774796|Experimental|Cognitive Behavioural Therapy|Participants in this group will take part in a group CBT workshop for parents of children with food allergy. They will also have access to a self-help booklet in order to reinforce the learning that has taken place during the workshop.
16285943|NCT04774796|No Intervention|Treatment as usual|Participants in the control group will not take part in the group CBT workshop, but will have access to any treatment as usual relating to their child's food allergy. They will have access to the CBT self-help booklet after the all data collection has been finalised.
16285944|NCT04774783|Experimental|Low-Level Laser Therapy|Over the course of the study, participants within this group will receive 12 sessions of Low-Level Laser Therapy (LLLT) treatment over a duration of 4 weeks using the Richmar TheraTouch LX2 device. Treatment location will be determined through assessment of each qualifying participant. Treatment sessions will be limited to a single area of the body associated with the qualifying participant's primary pain complaint.
16285945|NCT04774770|Experimental|HED-Start Intervention arm|Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.
16285946|NCT04774770|No Intervention|Standard care arm|Participants assigned to the standard care arm will proceed with routine standard care.
16285947|NCT04774757|Experimental|Systemic therapy sequenced PALND|All received systemtic therapy (at most two lines).
16285948|NCT04774744|Experimental|Group I (digital health coaching program)|Patients receive the PACK Health digital health coaching program over 3 months consisting of communication initiated by either the PACK Health coach or the patient through either text, e-mail, or phone call, to provide education and support related to a specific topic such as fatigue, nutrition, or exercise.
16285949|NCT04774744|Active Comparator|Group II (standard of care support services)|Patients receive standard of care support services consisting of a telephone triage line that patients may call when experiencing physical or psychological concerns, or with any other questions related to their disease or treatment.
16285950|NCT04774731|Experimental|Whole Body Vibration|
16285951|NCT04774731|No Intervention|Control|
16285953|NCT04774705|Experimental|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|
16285954|NCT04774705|Placebo Comparator|Control group|For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
16285955|NCT04774679|Experimental|Biopsy Arm|All patients who underwent EUS Guided biopsy
16285956|NCT04774653||MIH Group in short stature from 6-8 years old|Molar Incisor Hypomineralization in stunted children aged from 6-8 years
16285957|NCT04774653||HSPM Group in short stature from 5-8 years old|Hypomineralization of Second Primary Molars in stunted children aged from 5-8 years
16285958|NCT04774653||Both MIH &HSPM Group in stunted (from 5-8) years old|When both primary molars and permanent teeth( First permanent molars & permanent incisors) are hypo-mineralized in children with short stature with age range from 5-8 years old
16285959|NCT04774614|Experimental|VITA ENAMIC multiColor anterior laminate veneers|
16285960|NCT04774614|Active Comparator|IPS e.max CAD anterior laminate veneers|
16285961|NCT04774588|Other|Using VSI Streamer and Telemedicine Study|Using the real time streaming of input from video capture devices to a head mounted display during interventional radiology procedures
16285962|NCT04774588|Placebo Comparator|Not using VSI Streamer and Telemedicine Study|Not using real time streaming of input from video capture devices to a head mounted display and just using current standard imaging in the Interventional Suite.
16285987|NCT04774367|Other|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|
16285988|NCT04774354||Abdominal surgery|POSSUM, the P-POSSUM and the Charlson comorbidity index will be calculated and compared to the outcomes obtained in our center.
16285989|NCT04774341||CDSS (MedicBK) Analysis|
16285990|NCT04774341||Core Laboratory Analysis|
16285991|NCT04774328|Active Comparator|CA-008 (vocacapsaicin)|Single administration
16285992|NCT04774328|Placebo Comparator|Placebo|Single administration
16285993|NCT04774315|Experimental|Omalizumab|
16285994|NCT04774289||1|Participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020
16285965|NCT04774562|Experimental|Video-Assisted Discharge Education (VADE) Group|VADE group received video-assisted discharge education in addition to the physiotherapy program given to the PT group on the same day by the same physiotherapist. The VADE program included information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities, home settings. VADE was prepared as a presentation of written information and videos which is shown this information by a professional model. Video shoots were done by a physiotherapist experienced in the field of physiotherapy and rehabilitation after THR surgery. The presentation was stopped when participants have questions or have points were not understood and the necessary explanations were shown verbally and practically. Along with the physiotherapy booklet, the participants were given an educational booklet containing written and visual information prepared in the same content as VADE.
16285966|NCT04774562|Experimental|Physiotherapy (PT) Group|The physiotherapy program given to the PT group after THR surgery. The physiotherapy program included breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation. The whole program was taught verbally and practically to participants and their relatives. Information was given about the exercises to be added at the end of the first week and in the 4th week. A physiotherapy booklet prepared with the same content was given to the participants. The booklet was examined by the patient and relatives, and the questions they asked were answered by the same physiotherapist. The participants were informed that they should continue the exercises for 12 weeks.
16285967|NCT04774549||Patients with inflammatory cardiomyopathy|Patients referred to CMR for suspected/known inflammatory cardiomyopathy and/or diagnosed inflammatory cardiomyopathy from CMR findings
16285968|NCT04774536|Experimental|CRISPR_SCD001 Drug Product|CRISPR_SCD001 Drug Product (autologous CD34+ cell-enriched population that contains cells modified by the CRISPR-Cas9 ribonucleoprotein) dose will be ≥3.0×106 CD34+ cells/kg recipient weight for each subject and the upper limit cell dose is 20 ×106 CD34+ cells/kg.
16285971|NCT04774510|Other|Optimized C-ARM CBCT|An optimized C-arm CBCT evaluation with a different acquisition geometry and a novel software for the rapid, quality improved and less-artefacts assessment of brain parenchyma and angiogram.
16285975|NCT04774471||Women with breast lesions|Women with an identified breast lesion have a non-invasive non-contrast MRI scan prior to biopsy.
16285976|NCT04774458|Experimental|Fluoroscopic-guided cervical epidural access|Cervical epidural access with loss of resistance technique using CLO view at 50 degree under fluoroscopic guidance.
16285977|NCT04774445|Experimental|Intervention Group|Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.
16285978|NCT04774445|No Intervention|Usual Care Group|Individuals randomized to this arm will receive the standard clinical practice.
16285979|NCT04774432|Active Comparator|GM-CSF group|"Patients will be randomly allocated to intervention group with GM-CSF added to CAPA and maturation medium.
~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.
~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
16285980|NCT04774432|Active Comparator|Control group|"Patients will be randomly allocated to control group without the addition of GM-CSF to CAPA and maturation medium.
~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.
~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
16285981|NCT04774419|Experimental|Radiation and TSR-042|Patients will undergo standard intensity modulated radiation therapy (IMRT) to the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks82 and receive IV TSR-042 every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of TSR-042.
16285982|NCT04774406||parp inhibitors|All patients treated at least with 1 PARPi
16285983|NCT04774393|Experimental|Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
16285984|NCT04774393|Experimental|Arm B (decitabine/cedazuridine, venetoclax, enasidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and enasidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
16285985|NCT04774380|Experimental|Durvalumab - (cisplatin or carboplatin) - Etoposide|Participants will receive durvalumab 1500 mg administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w) starting on Week 0 for 4 to 6 cycles. Thereafter, durvalumab monotherapy will be continued q4w post-chemotherapy unless specific treatment discontinuation criteria are met.
16285986|NCT04774367|Other|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|
16285995|NCT04774276||Group with occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They will have the cardiac rehabilitation protocol (4 weeks) with occupational therapist as usual practice. The inclusion in this group will be prospective, from January 2021.
16285996|NCT04774276||Group without occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They have done the cardiac rehabilitation protocol (4 weeks) without occupational therapist until december 2020. The inclusion in this group will be retrospective,
16285997|NCT04774263||General population|general population
16285998|NCT04774263||emergency caregivers|emergency caregivers
16285999|NCT04774250|Experimental|Zonisamide|For subjects randomized to zonisamide, the package will contain one zonisamide capsule (100 mg PO).
16286000|NCT04774250|Placebo Comparator|Placebo|For the subjects randomized to placebo, the package will contain one placebo capsule that looks, smells, and taste the same as zonisamide capsule.
16286004|NCT04774224|Active Comparator|Baricitinib|Baricitinib is an oral JAK1/JAK2-selective inhibitor. Dosage: The dose of baricitinib is 1 x 4mg tablet once daily Duration of administration: 48 weeks Mode of administration: Orally, with or without food
16286005|NCT04774224|Placebo Comparator|Placebo|One placebo tablet once daily for a duration of 48 weeks. Placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
16286006|NCT04774198||Occurrence of persistent postoperative hypotension|Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
16286007|NCT04774198||No occurrence of persistent postoperative hypotension|Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
16286008|NCT04774185|Experimental|New hearing aid loudspeaker|The new hearing aid loudspeaker is a loudspeaker system with a modified acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
16286009|NCT04774185|Active Comparator|Standard hearing aid loudspeaker|The hearing aid loudspeaker is a loudspeaker system with the existing acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
16286010|NCT04774159|Active Comparator|Colchicine|Colchicine 0.5mg daily for the duration of the trial
16286011|NCT04774159|Placebo Comparator|Colchicine-Placebo|Colchicine-Placebo daily
16286014|NCT04774120||Young Patients (Patients aged 18 to 65 years.)|Propofol infusion rate will be started at 20-25 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
16286015|NCT04774120||Elderly patients (Patients aged 65 to 85 years. )|Propofol infusion rate will be started at 15-20 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
16286016|NCT04774107|Experimental|P1101 + Ribavirin|P1101 400 µg SC Ribavirin 800-1400 mg PO
16286018|NCT04774081||Study group|Participants will be recruited among those whose insulin sensitivity has been previously measured by a high-dose euglycemic-hyperinsulinemic clamp at Pennington Biomedical during the last 5 years and indicated their wiliness to be re-contacted for future research
16286019|NCT04774068|Experimental|Treatment (romidepsin, parsaclisib)|"PRE-PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~INDUCTION PHASE: Patients receive romidepsin IV over 4 hours on days 1,8, and 15 and parsaclisib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and parsaclisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16286020|NCT04774042|Placebo Comparator|Placebo|Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
16286021|NCT04774042|Experimental|HAC|Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
16286022|NCT04774042|Experimental|Infloran|Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
16286023|NCT04774029|Experimental|BVN Block|Patients will receive temporary basivertebral nerve block using lidocaine during the vertebral augmentation procedure for osteoporotic compression fracture.
16286024|NCT04774016|Experimental|Test formula C|
16286025|NCT04774016|Experimental|Test formula B|
16286026|NCT04774016|Placebo Comparator|Test formula A|
16286027|NCT04774003|Experimental|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
16286028|NCT04774003|Experimental|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
16286029|NCT04774003|Placebo Comparator|Placebo|Placebo x 1 dose (n=10) at Day 1
16286030|NCT04773990|Other|Experimental Group|Group (A) twenty-five patients will receive biodex balance training
16286031|NCT04773990|Other|Controlled Group|twenty-five patients will receive a physical therapy exercise protocol
16286032|NCT04773977|Experimental|IBI362 liquid formulation|Participants received single subcutaneous injection of IBI362 liquid formulation
16286033|NCT04773977|Experimental|IBI362 lyophilized powder|Participants received single subcutaneous injection of IBI362 lyophilized powder
16286034|NCT04773964|Experimental|MET642 high dose|
16286035|NCT04773964|Experimental|MET642 low dose|
16286037|NCT04773951|Experimental|Dose escalation and extension group|"JS004 dose escalation: 1mg/kg, IV Q3W; 3mg/kg, IV Q3W; 10mg/kg, IV Q3W;
~JS004 dose extension: 3mg/kg, IV Q3W; 200mg, IV Q3W;
~JS004+Toripalimab Injection dose escalation: JS004 100mg+Toripalimab Injection 240mg, IV Q3W; JS004 200mg+Toripalimab Injection 240mg, IV Q3W;
~JS004+Toripalimab Injection dose extension: JS004 100mg+Toripalimab Injection 240mg, IV Q3W or JS004 200mg+Toripalimab Injection 240mg, IV Q3W，to be determined."
16286038|NCT04773925|Experimental|Mindfulness group|As this is a pilot feasibility trial, there is only one arm. All subjects will receive the mindfulness intervention if they consent to participate in the study.
16286039|NCT04773899|Other|Cohort C1|COVID19 (+) ICU patients with COVID19 pneumonia.
16286040|NCT04773899|Other|Cohort C2|COVID19 (-) matched ICU patients
16286041|NCT04773899|Other|Cohort C3|COVID19 (-) ASA 1 non-hospitalized patients
16286042|NCT04773886|Sham Comparator|MTA GROUP|Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.
16286043|NCT04773886|Sham Comparator|BIODENTINE GROUP|Vital Pulpotomy will be done using Biodentine as pulp capping agent.
16286044|NCT04773886|Active Comparator|PRF + MTA GROUP|Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
16286045|NCT04773886|Active Comparator|PRF+ BIODENTINE GROUP|Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
16286046|NCT04773873|Active Comparator|Arm 1: Porcelain fused to metal (PFM)|Implant screw-retained PFM crown fabricated by a laboratory using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
16286047|NCT04773873|Experimental|Arm 2: Hybrid abutment Lithium disilicate (e.max CAD)|Hybrid crown abutment: chairside-made perforated CAD-CAM Lithium disilicate crown (IPS e.max CAD LT A16) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
16286048|NCT04773873|Experimental|Arm 3:Hybrid abutment ceramic polymer infiltrated (Enamic)|Hybrid crown abutment: chairside-made perforated CAD-CAM ceramic-polymer infiltrated crown (Enamic) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
16286049|NCT04773860|Experimental|Experimental|The experimental group shall be receiving a 4 week programme of Muscle Energy Techniques on the following accessory muscles; Sternocleidomastoid, Pectoralis Minor, Trapezius, Scalene muscles and Latissimus Dorsi
16286050|NCT04773860|No Intervention|Control group|The control group will be taking their prescribed medication and continue with any conventional physiotherapy recommended for the individual.
16286051|NCT04773847|Experimental|MimetikOss 3D|
16286054|NCT04773821|Experimental|Experimental Arm|All men patients with low and intermediate risk prostate cancer (ISUP 1 and 2) who has already chosen to undergo focal treatment, in the referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. Follow-up visits are planned at 3, 6,12 and 13 month from the date of the focal treatment consistently with usual care. All patients will have a MpMRI and MpMRI targeted biopsy in the presence of a lesion suggestive of recurrence at 12 months. The subject will be his own control
16286055|NCT04773795|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.
~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
16286056|NCT04773782|Experimental|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
16286057|NCT04773769|Experimental|Overall Statistical design|We will treat 9 patients of each tumor type with a tea made of Graviola Leaves. If no responses are observed then the trial will be closed for that particular histological type. Should a response occur, then the trial will continue to the second stage for that cell type until 24 patients are accrued. If 3 or more responses are observed out of 24 cases, then the result will be considered promising.
16286058|NCT04773756|Other|Sofosbuvir / Daclatsvir|A drug used in the treatment of HCV infection, given in the same dose 400mg and 60 mg respectively once daily for 14 days
16286059|NCT04773743|Experimental|chronic nonspecific low back pain|Remotely delivered yoga intervention
16286060|NCT04773730|Active Comparator|Posterior transversus abdominus block|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated
~A 12-14 MHz linear array transducer will be placed transversely between the iliac crest and costal margin then slided from medial-lateral to visualize the posterior most part of the external oblique, internal oblique, and transversus abdominus muscles
~Then 20 mL of bupivacaine0.25% will be injected between the transverses abdominus muscle and the fascia deep to the internal oblique muscle
~The same steps will be repeated on the other side"
16286061|NCT04773730|Active Comparator|Quadratus lumborum block type 2|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated
~A2-5 MHz curved array transducer will be placed at the level of the antero-superior iliac spine then the external oblique muscle will be followed posterolaterally until its posterior border will be visualized The probe will be tilted down to identify a bright hyperechoic line After that 20 mL of bupivacaine 0.25% will be injected under direct visualization on the posterior surface of quadrates lumborum muscle
~The same steps will be repeated on the other side"
16286062|NCT04773717|Experimental|Ascorbic acid|"Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.
~Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours."
16286063|NCT04773717|Placebo Comparator|Placebo|Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.
16286064|NCT04773691|Experimental|test group|
16286065|NCT04773691|Placebo Comparator|control group|
16336812|NCT04422405|Experimental|Patients undergoing OAGB|
16286069|NCT04773665|Experimental|Phase 1a, Group G1|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Day 1 and placebo at Day 28
16286070|NCT04773665|Experimental|Phase 1a, Group G2|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Days 1 and 28
16286071|NCT04773665|Placebo Comparator|Phase 1a, Group G3|20 participants age 18-54 will receive placebo at Days 1 and 28
16286072|NCT04773665|Experimental|Phase 1b, Group G4|27 participants age 18-54 will receive VBI-2905a at a dose of 5 μg of S protein at Day 1
16286073|NCT04773665|Placebo Comparator|Phase 1b, Group G5|27 participants age 18-54 will receive placebo at Day 1
16286074|NCT04773665|Experimental|Phase 1b, Group G6|27 previously unvaccinated participants age 18-54 will receive VBI-2905a at a dose of 5 µg of S protein at Day 1 and Day 28
16286075|NCT04773639|Experimental|Multi-Modal Acceptance and Commitment Therapy (M-ACT)|M-ACT consists of five 2-hour group sessions (plus booster) that alternate with self-paced online modules and check-ins that participants complete on their own, between the group sessions. The intervention addresses distress associated with coping with metastatic cancer and supports engagement in advance care planning. The intervention is based on Acceptance and Commitment Therapy, an intervention model that aims to help people cope with life challenges and difficult thoughts/feelings in a manner that helps them to live fuller and more meaningful lives.
16286076|NCT04773639|Other|Control: Usual Care|Patients in the control arm will have access to usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request. After completion of study procedures, including FU, the UC participants will be offered M-ACT free of cost.
16286077|NCT04773613|Experimental|Experimental SLP|Infant placed in a SLP on the researcher's lap. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
16286078|NCT04773613|Other|Experimental SEP|Infant placed in a SEP on the researcher's lap. The head rests on the researcher's hand. Shoulder girdle higher than the pelvic girdle, head and back in a straight line at an angle of 30-45° to the ground - slight, natural body bend is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
16286079|NCT04773600|Active Comparator|ARQ-151 Cream 0.15%|Active comparator
16286080|NCT04773600|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
16286081|NCT04773587|Experimental|ARQ-151 Cream 0.15%|Active comparator
16286082|NCT04773587|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
16286083|NCT04773574|Experimental|Normal pregnant women with high myopia|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA) were performed in each trimesters and at 6 weeks after childbirth.
16286084|NCT04773561|Experimental|multifetal pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
16286085|NCT04773561|Active Comparator|singleton pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
16286086|NCT04773561|Active Comparator|age-stratified healthy non-pregnant women|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed.
16286087|NCT04773548|Experimental|VR-JIT|
16286088|NCT04773535||healthy Volunteers|Adult (>18y) healthy volunteers without previous injuries or pathologies of the hand and upper extremity
16286089|NCT04773522|Experimental|Talquetamab|Participants will receive talquetamab injection subcutaneously (SC) in 3 cohorts: Cohort 1 and Cohort 2 as 2 step-up doses and Cohort 3 as 3 step-up doses followed by a treatment dose.
16286090|NCT04773509|Active Comparator|PVB group|Patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides
16286091|NCT04773509|No Intervention|Control group|PVB are not performed in the control group.
16286092|NCT04773496||Balance evaluation|patient's balance is evaluated with instrumental posturography
16286093|NCT04773483|Active Comparator|Quorn Food products|
16286094|NCT04773483|Active Comparator|Meat/fish products|
16286095|NCT04773470|Experimental|Spinal Muscle Atrophy|All patients with Spinal Muscle Atrophy type 1 to 4
16286096|NCT04773457||Spine Surgery|Pediatric patients presenting for elective spine fusion surgery at Boston Children's Hospital
16286097|NCT04773457||Abdominal Surgery|Pediatric patients presenting for elective abdominal surgery at Boston Children's Hospital
16286098|NCT04773444|Experimental|Eccentric cycling training|Moderate intensity cycling training in eccentric type
16286099|NCT04773444|Experimental|Concentric cycling training|Moderate intensity cycling training in concentric type (intensity matched the eccentric training)
16286100|NCT04773444|No Intervention|Control group|without receiving any exercise training
16286101|NCT04773431|Experimental|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
16286102|NCT04773405|Other|Selective Trunk Block|Selective trunk block will be done under ultrasound guidance to patients scheduled for upper extremities surgeries. Local anaesthetic agents (a 1:1 mixture of 2% lidocaine with 5ug/ml of epinephrine and 0.5% levobupivacaine) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anaesthetize the whole upper limb.
16286103|NCT04773392|Active Comparator|Twice-daily Regimen|Twice-daily regimen of immediate release tacrolimus, mycophenolate mofetil (MMF)/mycophenolic acid (MPA) plus daily methylprednisolone or prednisone.
16286104|NCT04773392|Active Comparator|Once-daily Regimen|Once-daily regimen of Envarsus, azathioprine plus methylprednisolone or prednisone.
16286105|NCT04773366|Experimental|Group 1|"Multisystem patients (≥2 organs/systems) with involvement of one or more Risk organs, i.e. hematopoietic system, liver or spleen.
~All patients in this group receive an initial therapy (Week 1~6) followed by a consolidation continuation therapy (Week 7~22) and maintenance continuation therapy (Week 25~52)."
16286106|NCT04773366|Experimental|Group 2|"Multisystem patients, but without involvement of Risk organs.
~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
16286107|NCT04773366|Experimental|Group 3|"Includes patients with single system, multifocal or with single system, unifocal and special site (Isolated lesion of special site) or with single system, unifocal and CNS risk or with single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary or with single system, unifocal and other functionally critical anatomical sites.
~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
16286108|NCT04773366|Experimental|Group 4|"Patients with single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion).
~All patients in this group enter into observation after local therapy. Chemotherapy only apply to patients with disease reactivation during observation."
16286111|NCT04773340||DBT intervention|Adaptation of Dialectical Behavior Therapy designed for repeat criminal offenders at high risk of reoffense.
16286112|NCT04773327|Experimental|PEG-rhG-CSF prevention|Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle,
16286113|NCT04773327|No Intervention|non-prevention|Only close monitoring after chemotherapy
16286114|NCT04773301|Experimental|LEVOBUPIVACAINE|Patients treated with Levobupivacaine Altan 7.5 mg / ml solution for injection and infusion
16286115|NCT04773301|Experimental|ROPIVACAINE|Patients treated with Ropivacaine Altan 2 mg / ml solution for infusion
16286116|NCT04773288|Experimental|Live feedback provided on display during handwashing|
16286117|NCT04773288|No Intervention|No live feedback provided during handwashing|
16286118|NCT04773249|Experimental|Lateral Epicondylitis Bandage|A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
16286119|NCT04773249|Experimental|Wrist Extension Splint|A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
16286120|NCT04773249|No Intervention|Wait-and-see Policy|These patients will be monitored with a wait-and-see policy. No splint or band will be given to the patient.
16286121|NCT04773236|Active Comparator|Buffered Local anesthesia|Sodium bicarbonate with 2% lidocaine and 1:80.000 epinphrine
16286122|NCT04773236|Placebo Comparator|Non Buffered Local anesthesia|2%lidocaine with 1:80.000 epinphrine.
16286123|NCT04773223||Open surgery group|Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
16286124|NCT04773223||Endovascular group|Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
16286125|NCT04773210|Experimental|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment.
16286126|NCT04773210|Active Comparator|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment.
16286127|NCT04773197|Experimental|Coach-assisted C-CBT with BtB|Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
16286128|NCT04773197|Active Comparator|Coach-assisted animated C-CBT with EMW|Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
16286129|NCT04773197|Active Comparator|Standard stand-alone C-CBT with BtB|Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.
16286130|NCT04773184||Healthy adults|132 individuals with no history of swallowing impairment or any health conditions known to impact swallowing function will be included in this study to serve as a comparative control group or reference standard group here and in future studies.
16286131|NCT04773184||Adults at risk for swallowing impairment.|132 individuals with an underlying condition documented to lead to dysphagia will be enrolled in this study. 2) Confirmed medical diagnosis associated with an increased risk of dysphagia including but are not limited to: head and neck cancer, neurologic (e.g., stroke, traumatic brain impairment), neurodegenerative (e.g., Parkinson's disease, amyotrophic lateral sclerosis), neuromuscular disorders (e.g., myotonic dystrophy, Pompe disease, inclusion body myositis) rheumatologic diseases (e.g., dermatomyositis, inclusion body myositis, scleroderma), chronic respiratory illnesses (e.g., chronic obstructive pulmonary disease), structural (e.g., mass or trauma to the upper aerodigestive tract) and iatrogenic conditions (e.g., post-surgical such as anterior cervical discectomy/fusion or cardiac, post-radiation treatment to the upper aerodigestive tract).
16286132|NCT04773171|Experimental|CACR Group|Participants of CACR group will attend individual computer-assisted cognitive remediation sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
16286133|NCT04773171|Active Comparator|TAU Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CACR training.
16286134|NCT04773158|Experimental|Intervention Arm|The intervention clinic sites will be provided access to both the Functional gastrointestinal disorders (FGIDs) Screening Module and the Treatment Module
16286135|NCT04773158|No Intervention|Control Arm|The control clinics will have the Functional gastrointestinal disorders (FGIDs) Screening Module. However, control clinics will not have access to the FGIDs Treatment Module. These clinic sites will be given access to the pre-screener form section of the module, so that providers are made aware of a positive screen for a FGID.
16286136|NCT04773145||Femoral neck fracture|Patients over 80 years when suffering of femoral neck fracture with at least one year follow-up.
16286137|NCT04773132|Experimental|Low Protein Diet|All subjects will be given a low protein/protein-free diet in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
16286138|NCT04773119|Active Comparator|Pulmonary vein isolation (PVI) only|
16286139|NCT04773119|Active Comparator|PVI with substrate|
16286140|NCT04773093|Active Comparator|Continous Intravenous Lidocaine Infusion|Patient will recieve Continous Intravenous Lidocaine Infusion
16286141|NCT04773093|Placebo Comparator|Placebo|Patient will recieve placebo (NaCl 0.9% infusion)
16286142|NCT04773080||esophageal cancer surgery|patients undergoing elective esophageal surgery for cancer
16286145|NCT04773041||Patients with DLB|Patients diagnosed with DLB enrolled from the HealthPartners Neuroscience Center.
16286146|NCT04773041||Patients with Alzheimer's disease (AD)|Patients diagnosed with AD age and sex-matched, selected from the ADNI database.
16286147|NCT04773041||Patients with normal cognition (CN)|Patients diagnosed with normal cognition age and sex-matched, selected from the ADNI database.
16286148|NCT04773028||PATİENT GROUP(GROUP 1)|This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
16286149|NCT04773028||CONTROL GROUP(GROUP 2)|This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
16286150|NCT04773002||Group P|Total intravenous anesthesia (TIVA)
16286151|NCT04773002||Group S|Volatile anestesia
16286152|NCT04772989|Experimental|Dose Escalation Q3W Cohorts|Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
16286153|NCT04772989|Experimental|Dose Escalation Q4W Cohorts|Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
16286154|NCT04772989|Experimental|Dose Expansion Cohort 1|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
16286155|NCT04772989|Experimental|Dose Expansion Cohort 2|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
16286156|NCT04772989|Experimental|Dose Expansion Cohort 3|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
16286157|NCT04772989|Experimental|Dose Expansion Cohort 4|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
16286158|NCT04772989|Experimental|Dose Expansion Cohort 5|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
16286159|NCT04772976||Patient group|Patients with Ankylosing Spondylitis
16286160|NCT04772976||Healthy controls|Healthy controls
16286161|NCT04772950||Healthy adults|
16286162|NCT04772950||Patients with non-specific low back pain|
16286163|NCT04772937|Other|LLETZ group|LLETZ (large loop excision of the transformation zone) is one of several possible surgical interventions for treating cervical dysplasia.
16286164|NCT04772937|Other|LEEP group|LEEP (loop electrosurgical excision procedure) is one of several possible surgical interventions for treating cervical dysplasia.
16286165|NCT04772924|Experimental|fasting group|those preferred to take long time fasting
16286166|NCT04772924|Active Comparator|non fasting|those preferred not to take fasting
16286167|NCT04772911||Strata A: One-time OCT Measurements|The indication for Strata A is that some participants will elect not to undergo laser treatment, particularly if they have been extensively treated with laser previously, or have a light pink vascular stain that has been stable.
16286168|NCT04772911||Strata B: Serial OCT Measurements|Participants will have serial OCT measurements of their vascular stain performed prior to the start of standard of care laser treatment. OCT will be performed prior to each standard of care laser treatment if the participant has elected to have standard of care laser treatment as treatment of their vascular stain at the time of enrollment.
16286169|NCT04772898|Experimental|Hippotherapy|Both children with autism spectrum disorder and with typical development will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
16286170|NCT04772885|Experimental|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
16286171|NCT04772885|Experimental|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
16286172|NCT04772885|Experimental|Food Effect Cohort in healthy subjects|Healthy Volunteer SAD subject cohorts (up to 2) will return for a second treatment period and will receive the same treatment which was originally allocated, but in the fed state.
16337771|NCT04415775|Active Comparator|Conventional Gait Rehabilitation|
16286173|NCT04772885|Experimental|Multiple dose cohort in HS and AD patients|A single cohort of up to 20 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 14 days.
16286174|NCT04772872||Group A:Naturally conceived singleton|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
~Apgar score will be represented by the variance of degree of scores.
~Birth weight will be measured in grams."
16286175|NCT04772872||Group B: Singleton conceived from fresh embryo transfer(IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
~Apgar score will be represented by the variance of degree of scores.
~Birth weight will be measured in grams."
16286176|NCT04772872||Group C: Singleton conceived from frozen embryo transfer (IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
~Apgar score will be represented by the variance of degree of scores.
~Birth weight will be measured in grams."
16286177|NCT04772859|Experimental|Online Lifestyle Intervention|Online sessions of nutrition education, physical activity, and family participation.
16286178|NCT04772859|Other|Control Group|General nutrition recommendations
16286179|NCT04772846|Experimental|Chloroquine group|
16286180|NCT04772846|Placebo Comparator|Placebo drug group|
16286181|NCT04772833||Autopsy group|Patients with COVID-19 infection confirmed by PCR, whose death is related to active COVID-19 infection or its complications.
16286182|NCT04772820|Other|Primary Aim|Brief Behavioral Activation coaching will be delivered by telephone and other remote technology by trained coaches. Over 10 sessions, the coaches will help people to find meaningful activities to decrease loneliness, increase physical activity and improve nutrition.
16286183|NCT04772807||Healthy|
16286184|NCT04772807||Patients infected by COVID- 19 with no symptoms|
16286185|NCT04772807||Patients infected by COVID- 19 with symptoms|
16286186|NCT04772807||Patients diagnosed with atrial fibrillation|
16286187|NCT04772807||Hypertensive patients|
16286188|NCT04772807||Heart failure patients, EF < 40%|
16286189|NCT04772807||Heart failure patients, EF > 40% and < 60%|
16286190|NCT04772807||Heart failure patients, EF > 60%|
16286191|NCT04772794|Active Comparator|hyperoxygenation group|Intraoperative administration of a mixture of 80% oxygen and 20% air
16286192|NCT04772794|Placebo Comparator|control group|intraoperative administration of 30% oxygen and 70% air
16286193|NCT04772781|Experimental|S (+) - Ibuprofen|
16286194|NCT04772781|Active Comparator|Ibuliv® - ibuprofen|
16286195|NCT04772755|No Intervention|Usual Care|Participants will receive usual care that follows administration of a vaccine and will have a 20 minute post vaccination observation period.
16286196|NCT04772755|Experimental|Buzzy ® and Electronic Game|Buzzy® will be applied to arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants will be instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then play that game for a specified amount of time before, during and after the vaccination administration.
16286197|NCT04772742|Experimental|Eptinezumab|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion
~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
16286198|NCT04772742|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion
~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
16286199|NCT04772729|Active Comparator|Insulin Aspart|Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.
16286200|NCT04772729|Experimental|Insulin Fiasp|Patients will use the continuous subcutaneous insulin infusion of insulin faster aspart (Fiasp, Novo Nordisk) and RT-CGM for 4 weeks.
16286201|NCT04772690|Experimental|BAL|A resource-orientered, individual and group-based intervention addressing balance in everyday life, activities and QoL among people with chronic or advanced cancer.
16286202|NCT04772677|Experimental|BEAM - Infant|BEAM Infant will be delivered via mobile application to mothers with a 6-17 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
16286203|NCT04772677|Experimental|BEAM - Preschool|BEAM Preschool will be delivered via mobile application to mothers with a 18-36 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting Videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
16286204|NCT04772664|Experimental|Participants with Major Depression receiving a multi-strain probiotic|Participants with Major Depression receiving a multi-strain probiotic
16286205|NCT04772664|Placebo Comparator|Participants mit Major Depression receiving a placebo|Participants mit Major Depression receiving a placebo
16286206|NCT04772664|Experimental|Healthy volunteers receiving a multi-strain probiotic|Healthy volunteers receiving a multi-strain probiotic
16286207|NCT04772664|Placebo Comparator|Healthy volunteers receiving a placebo|Healthy volunteers receiving a placebo
16287774|NCT04761705|Experimental|Randomized Part 2, Arm 1|Dose 1 selected in Part I
16286208|NCT04772651|Experimental|Mediterranean Diet and dietary coaching|Patients receive 3 Mediterranean meals a day for 4 weeks and dietary coaching sessions (á 50 minutes once a week for 4 weeks)
16286209|NCT04772651|Placebo Comparator|Diet as usual and psychoeducation for depression|Patients receive normal hospital diet with 3 meals a day for 4 weeks and psychoeducation sessions (á 50 minutes once a week for 4 weeks)
16286210|NCT04772638|Experimental|PLAY intervention|The PLAY intervention with educators, parents and children
16286211|NCT04772638|Placebo Comparator|Wait list control|
16286212|NCT04772625||PFA|The cohort consists of all patients operated with patellofemoral arthroplasty for isolated patellofemoral osteoarthritis in Denmark from Jan 1 2008 to Dec 31 2015. The number of patients is expected to be around 500. A patellofemoral arthroplasty is defined as an arthroplasty consisting of a metal trochlear component and a polyethylene patella component. The definition of isolated patellofemoral osteoarthritis in the study is pragmatic and given by the operating surgeon.
16286213|NCT04772612|Experimental|Sitravatinib in healthy subjects|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in healthy subjects.
16286214|NCT04772612|Experimental|Sitravatinib in subjects with mild hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with mild hepatic impairment
16286215|NCT04772612|Experimental|Sitravatinib in subjects with moderate hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with moderate hepatic impairment
16286216|NCT04772612|Experimental|Sitravatinib in subjects with severe hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with severe hepatic impairment
16286217|NCT04772560|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
16286218|NCT04772560|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
16286219|NCT04772547|Experimental|Open label|4500 mg of vigabatrin administered enterally
16286220|NCT04772534|Experimental|3-dose in 9 to 15 year old boys|9 to 15 year old boys will receive a 3-dose regimen of 9-valent human papillomavirus (9vHPV) vaccine (Day 1, Month 2 and Month 6).
16286221|NCT04772534|Experimental|2-dose in 9 to 14 year old boys|9 to 14 year old boys receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
16286222|NCT04772534|Experimental|2-dose in 9 to 14 year old girls|9 to 14 year old girls receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
16286223|NCT04772521|Experimental|Intervention|Personalized chat-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for intervention group
16286224|NCT04772521|Placebo Comparator|Control|Regular text-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for control group
16286225|NCT04772508|Sham Comparator|Group A|15 sites received only scaling and root planing
16286226|NCT04772508|Active Comparator|Group B|15 sites received scaling and root planing with subgingival placement of amnion membrane
16286227|NCT04772508|Active Comparator|Group C|15 sites received scaling and root planing with subgingival placement of amnion membrane hydrated with Taurine
16286228|NCT04772495||Study group|with Multiple sclerosis
16286229|NCT04772495||Control group|not Multiple sclerosis
16286230|NCT04772482||All Participants|All participants will undergo path testing to determine skin sensitivity to certain compounds.
16286231|NCT04772469|Experimental|Promoter training, multiple self-test kits, and incentives|Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks.
16286232|NCT04772469|No Intervention|Short training and referral for testing|Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available.
16286233|NCT04772456|Experimental|metabolic MRI|Single-arm study in patients who have Glioma Perform metabolic magnetic resonance imaging on patient have a Glioma cancer to understand if metabolic MRI can be safely performed on this population
16286234|NCT04772443|Experimental|DWJ1506|
16286235|NCT04772443|Experimental|DWJ1507|
16286236|NCT04772443|Active Comparator|DWC202011|
16286237|NCT04772443|Active Comparator|DWJ1177|
16286238|NCT04772430|No Intervention|Control group|The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure
16286239|NCT04772430|Experimental|Experimental group|The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
16286240|NCT04772391|Other|Exercise Treatment Group|Exercise Sessions
16286241|NCT04772365|Experimental|Treatment group A|
16286242|NCT04772365|Placebo Comparator|Treatment group B|
16286243|NCT04772352|Experimental|Experimental group: Lifestyle intervention + febuxostat (40mg, once a day, orally)|participants accept febuxostat treatment in addition to lifestyle intervention for 0-48 week.
16286244|NCT04772352|Active Comparator|Control group: Lifestyle intervention|participants receive lifestyle intervention for 0-24 week. If the results of the 0-24 week study showed that the liver fat content of subjects in the experimental group was significantly lower than that in the control group, control group will accept febuxostat treatment in addition to lifestyle intervention in the next 25-48 week.
16286245|NCT04772339||Healthy Adults|Healthy adults aged between 18-30
16286246|NCT04772326||PrEP patients undergoing follow-up at Tourcoing hospital|
16286247|NCT04772313|Experimental|Pegloticase plus Methotrexate (MTX)|Pegloticase (8mg) intravenous (IV every two weeks). Methotrexate (15 or 25 mg weekly) subcutaneous (SC).
16286248|NCT04772300|Experimental|Sirolimus DCB group|Intervention with Sirolimus-coated balloon catheter
16286249|NCT04772300|Active Comparator|POBA group|Intervention with non-coated balloon catheter (POBA)
16286255|NCT04772261|Experimental|Lot-to-Lot Variability|Participants will be administered up to six different 13C-Spirulina test meal lots
16286256|NCT04772261|Experimental|Biological Variability|Participants will be administered the same 13C-Spirulina test meal lot on two different occasions
16286257|NCT04772248||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
16286258|NCT04772248||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
16286259|NCT04772235|Experimental|Advanced and/or metastatic EGFR mutant NSCLC|Eligible advanced and/or metastatic EGFR mutant NSCLC patients will receive the combination of osimertinib and repotrectinib.
16286260|NCT04772222|Experimental|Dexmedetomidine (DMT)|Subjects randomized to DMT arm in a 1:1 ratio. A loading dose of 1 mcg/kg will be given followed by 0.1 to 0.5 mcg/kg/h continuous infusion. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) will be used to determine infusion rate.
16286261|NCT04772222|Active Comparator|Morphine|Subjects randomized to morphine in a 1:1 ratio. Intermittent dosing every 3-4 hours of 0.02-0.05 mg/kg/dose or continuous infusion of 0.005 to 0.01 mg/kg/hr. The N-PASS will be used to determine dosing and frequency.
16286262|NCT04772209|Active Comparator|Sodium bicarbonate Arm|In this arm, the catheter lock solution is sodium bicarbonate
16286263|NCT04772209|Active Comparator|Heparin arm|In this arm, classic heparin will be used as a reference catheter lock solution (standard lock solution)
16286264|NCT04772196|No Intervention|Control Group|Patients enrolled in the control group will receive standard of care.
16286265|NCT04772196|Experimental|Vitamin D Supplementation Group|Patients enrolled in the Vitamin D Supplementation Group will receive 50,000 IU Vitamin D3 weekly for 8 weeks.
16286267|NCT04772157||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
16286268|NCT04772144|Experimental|Intervention group|
16286269|NCT04772144|No Intervention|Control group|
16286270|NCT04772131|Experimental|Desara® One|Single Incision Sling
16286271|NCT04772131|Active Comparator|Desara® Blue|Transobturator Sling
16286272|NCT04772105|Experimental|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route of administration: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: once every 4 weeks, 6 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
16286273|NCT04772105|Experimental|4mg of BAT5906|Specification: 16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4mg/eye/time, 50μl; medication duration: once every 4 weeks, 3 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
16286274|NCT04772092||Seniors|70 years of age and over, inpatients or outpatients
16286275|NCT04772079|Experimental|Active treatment (BMS-986165) standard dose|
16286276|NCT04772079|Experimental|Active treatment (BMS-986165) half-standard dose|
16286277|NCT04772079|Placebo Comparator|Placebo|
16286278|NCT04772066||Non adherent patients|Non adherent patients
16286279|NCT04772066||Adherent patients|Adherent patients
16286280|NCT04772053|Experimental|Participants undergoing tumor biopsy|
16286281|NCT04772040|Experimental|Young loading dose group|Participants (18-35) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the old group.
16286282|NCT04772040|Experimental|Old loading dose group|Participants (60y+) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the young group.
16286283|NCT04772040|Experimental|Young constant dose group|Participants (18-35y) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
16286284|NCT04772040|Experimental|Old constant dose group|Participants (60y+) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
16286285|NCT04772027||Muscular dystrophies group|40 patients with limb girdle muscular dystrophie
16286286|NCT04772027||Comparator group|40 healthy volunteers without neuromuscular or squeletic disorder
16286287|NCT04772014||e-cigarette users|daily e-cigarette use (additional smoking of traditional tobacco cigarettes is not an exclusion criterion)
16286288|NCT04772014||nicotine-naïve|lifetime consumption of less than 20 cigarettes or e-cigarettes
16286289|NCT04772001|Experimental|CCRT+Anlotinib|Classical chemoradiotherapy will be conducted by clinical routine method. Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks. Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime and for patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug. Hydrochloride anlotinib will be orally taken daily at a dose level of 12mg for 14 days. Then rest for 7 days and start a new cycles for a total of 3 cycles. First capsule of anlotinib will be taken 7 days before the first radiation.
16286321|NCT04771741||Multimodal Pain Pathway|"This group will receive the multimodal pain pathway cocktail of medications. This cocktail includes:
~Tylenol (acetominophen), 1000 mg, every 6 hours as needed for pain
~Ketorolac (Toradol), 10 mg, every 6 hours as needed for pain until post-op day 3
~Mobic (Meloxicam), 15 mg once daily, beginning on post-op day 4
~Flexeril (Cyclobenzaprine), 10 mg every 8 hours as needed for pain
~Pregabalin (Lyrica), 75 mg every 12 hours as needed for pain"
16286322|NCT04771728|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
16286290|NCT04771975|Experimental|MatchQEP group|"All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors [16-18]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.
~Participants in the MatchQEP group will receive exercise information and program sessions tailored by a qualified exercise professional (QEP) specifically for each BCS in the dyad. Dyads will meet with the QEP via Zoom once per week for 10 weeks for up to 60 minutes. For four weeks following the 10-week intervention period, the QEP will be available for consultation (i.e., a post-intervention tapering period) as needed by the MatchQEP group participants."
16286291|NCT04771975|Active Comparator|Match group|"All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors [16-18]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.
~Participants in the Match (control) group will independently communicate and support each other around exercise for 10 weeks. They will not have any contact with a QEP during this time."
16286294|NCT04771949||All patients coming to the University Clinic of Dentistry|All patients coming to the dental University Clinic will be screened for the inclusion in the study.
16286295|NCT04771936|No Intervention|Control Group|The control group who shall be awaiting surgery and not receiving a regular physiotherapy exercise intervention
16286296|NCT04771936|Active Comparator|Conventional Exercise Group|The conventional exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000).
16286297|NCT04771936|Experimental|Conventional Exercise Group with added core exercises|This exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000) and core exercises aimed at the activation of the core muscles as adapted from Imai et al (2010).
16286298|NCT04771923|Experimental|Tranexamic acid|
16286299|NCT04771923|Experimental|Adrenaline|
16286300|NCT04771910|Experimental|Topical cream with live probiotic bacteria (YUN)|Patients with atopic dermatitis using topical cream with live probiotic bacteria
16286301|NCT04771910|Placebo Comparator|Placebo cream (YUN)|Patients with atopic dermatitis using placebo cream (same formulation as probiotic cream except live probiotic bacteria)
16286302|NCT04771897|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with newly diagnosed DIPG or DMG will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level is reached and radiation therapy.
16286303|NCT04771897|Experimental|Part 2 BXQ-350 Tumor and Plasma Concentrations|Newly diagnosed DIPG or DMG patients undergoing neurosurgical biopsy prior to receiving radiation therapy will receive BXQ-350 at the MTD established in Part 1, or the highest planned dose level, and radiation therapy. Excised tumor tissue and plasma samples will be evaluated for SapC levels and pharmacodynamic effects.
16286304|NCT04771884||Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)|The use of antimicrobial agents depends on the clinical practice.
16286305|NCT04771871|Experimental|Epirubicin-Cyclophosphamide plus Paclitaxel- Carboplatin|Epirubicin 60mg/m2 with cyclophosphamide 600/m2 every three weeks for four courses followed by paclitaxel 120mg/m2 and carboplatin 6 AUC every three weeks for four courses
16286306|NCT04771858||Study Group|No intervention
16286307|NCT04771845||EEG-grid-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using electroencephalogram grid guided navigation
16286308|NCT04771845||MRI-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using MRI guided navigation
16286309|NCT04771845||NACC controls|National Alzheimer's Coordinating Center matched controls
16286310|NCT04771832||ERAS|Perioperative care with Enhanced Recovery After Surgery (ERAS) protocol
16286313|NCT04771806||Observational (MRI)|Patients undergo MRI with and without contrast immediately before radiotherapy (for radiation planning) and at mid treatment (week 3). Patients also undergo MRI without contrast on weeks 1, 2, 4, 5, and 6 of radiotherapy. Patients may also undergo neurocognitive function testing over 70 minutes before treatment, at the end of each week of treatment, and at 3 and 6 months after completion of treatment.
16286314|NCT04771793||Group A- before implentation of physical restraint protocols|
16286315|NCT04771793||Group B- after implentation of physical restraint protocols|
16286316|NCT04771780|Experimental|KHK7791|"During the dosing period, subjects administer KHK7791 twice daily just before meals.Subjects will be underwent tests at scheduled visits at least weekly until Week 12, at least once every 2 weeks after completion of Week 12 test.
~KHK7791 and phosphate binders are adjusted with the goal of controlling serum phosphorus concentration within a certain range based on the dose adjustment criteria described in the study protocol.It should be considered that phosphorus adsorbent should be switched to KHK7791 whenever feasible."
16286317|NCT04771767|Experimental|Ketamine + eCBT|Over 14 weeks, participants receive weekly sessions of asynchronous online cognitive-behavioural therapy as well as 6 sub-anesthetic infusions of Ketamine
16286318|NCT04771767|No Intervention|Waitlist-Control|Participants are on a waitlist during which time they will not receive the experimental treatment and will have no change in their treatment regimen. These patients will receive the experimental treatment after their participation in the experiment is complete.
16286319|NCT04771754|Experimental|Arm 1|"Dolutegravir - 50 mg once daily, orally administered for the first 28 days of the study.
~No treatment for the last 44 days of the study."
16286320|NCT04771754|Experimental|Arm 2|"No treatment for the first 28 days of the study.
~Dolutegravir - 50 mg once daily, orally administered for the last 28 days of the study (day 44-72)."
16286360|NCT04771455|Experimental|Condition 3|Behavioral weight loss intervention and decrease unhealthy weight control practices
16286323|NCT04771728|Experimental|Metronidazole vagianl and Probiotics(Umeta-mimi)|Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days）
16286324|NCT04771702|Experimental|Edmon arm|
16286325|NCT04771689|Active Comparator|Buprenorphine/Naloxone|Subjects will take a maximum dose of 4 mg buprenorphine and 1 mg naloxone with concurrent administration of other intravenous or oral opioids needed.
16286326|NCT04771689|No Intervention|Standard Medication Regiment|Subjects will take conventional intravenous or oral opioid management.
16286327|NCT04771676|Experimental|Oncorine (H101)|H101 diluted in 5ml 0.9% sodium chloride solution in was then intraperitoneally injected through the drainage catheter, the injection dose of H101 was determined by the ascites volume [5.0×10^11 vp for a small amount, 1×10^12 vp - 1.5×10^12 vp for medium amount, and 2×10^12 vp for the massive amount (classification of the ascites amount was described in response evaluation)]. H101 was injected at day 1 and 3.
16286328|NCT04771663|Experimental|Hypoxic|In this phase, participants inhale the hypoxic mixture for five minutes.
16286329|NCT04771663|Experimental|Hypoxic and Hypercapnic|In this phase, participants inhale the hypoxic and hypercapnic mixture for five minutes.
16286330|NCT04771650|Experimental|CAMI/CAMI booster|Culturally Adapted Motivational Interview. Participants will receive a single session, 75 minute addiction counseling discussion that focuses on the causes of addictive behavior. They will receive a CAMI booster session at 2 months and standard care in a primary care setting.
16286331|NCT04771650|No Intervention|Control|Assessment plus standard care. Participants will complete an assessment, including measures on drinking and drug use. They will also receive standard care in a primary care setting.
16286332|NCT04771637|Placebo Comparator|control with normal saline|
16286333|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h|
16286334|NCT04771637|Experimental|dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h|
16286335|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h|
16286336|NCT04771624||Patients|Subjects who have been Covid positive by RT-PCR at least 60 days ago and not having any symptoms of Covid-19 at the moment
16286337|NCT04771624||Healthy|Subjects who do not have any general medical, neurological or psychiatric disorder
16286338|NCT04771611|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
16286339|NCT04771611|Placebo Comparator|Placebo|Subjects will receive placebo
16286340|NCT04771598|Experimental|İntervention|Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
16286341|NCT04771598|Other|Control|Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
16286342|NCT04771585|No Intervention|Study Part A|Aerosol number and size spectrum characterization of 30 subjects, stratified by age groups, including 10 professional singers. Subjects will be examined twice within 14 days to assess reproducibility of aerosol emission.
16286343|NCT04771585|Experimental|Study Part B|From the 30 subjects of Part A, the 10 highest-emitting subjects will be assessed a third time, wearing four different classes of face masks consecutively with increasing aerosol filtering capacity.
16286344|NCT04771572|Experimental|Dose Escalation Phase|Phase 1a dose-escalation will begin with group 1 and proceed until DLT is observed and MTD is established, or until an RP2D is established. Subjects enrolled in the 10 mg dose cohort will receive 10 mg LP-118 once daily. Subjects enrolled in the 20 mg dose cohort will receive 10 mg LP-118 for the first day, followed by 20 mg LP-118 once daily thereafter. Subjects enrolled in the rest of the dose cohorts will follow 3+3 study design, starting with an accelerated step-up dosing schedule until they reach the designated target dose (50 mg, 100 mg, 200 mg, 300 mg, or 400 mg). Once the MTD or RP2D is established for group 1, the phase 1a dose escalation can proceed for group 2. The starting dose level for group 2 will be one dose level below the MTD or RP2D established for group 1.
16286345|NCT04771572|Experimental|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups. One or more RP2D may be explored. Definition of these cohorts will be accomplished by protocol amendment, and in light of emerging data from Phase 1a.
16286346|NCT04771559|Other|Cancer patients|Covid-19 antibody levels of patients will be measured
16286347|NCT04771559|Other|Healthy control|Covid-19 antibody levels of healthy controls will be measured
16286348|NCT04771546|Experimental|Intervention (Colpofix)|Intravaginal gel with Carboxymethyl-β-glucan and Polycarbophil
16286349|NCT04771546|No Intervention|Control|No intervention (standard of care)
16286350|NCT04771533|Experimental|Passive stabilization of the trunk and the upper extremity|The intervention (passive stabilization of the trunk and the upper arm) was tested in post-stroke patients (study group) and in patients with back pain, but without neurological deficits (control group)
16286351|NCT04771520|Experimental|Treatment (avapritinib)|Patients receive avapritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16286352|NCT04771507|Experimental|Intermittent ibrutinib|Intermittent treatment with ibrutinib.
16286353|NCT04771494|Experimental|Trained|Participants with at least 6 months of training with unstable devices
16286354|NCT04771494|Experimental|Untrained|Participants with no previous instability experience
16286355|NCT04771481|Experimental|metoclopramide|Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.
16286356|NCT04771481|Placebo Comparator|placebo|Normal saline 10 ml IV slowly push in 5 minutes.
16286357|NCT04771468||Sovratentorial ischemic stroke|
16286358|NCT04771455|Experimental|Condition 1|Behavioral weight loss intervention
16286359|NCT04771455|Experimental|Condition 2|Behavioral weight loss intervention and decrease negative affect
16286361|NCT04771455|Experimental|Condition 4|Behavioral weight loss intervention, decrease unhealthy weight control practices, and decrease negative affect
16286362|NCT04771455|Experimental|Condition 5|Behavioral weight loss intervention and decrease overvaluation of weight and shape
16286363|NCT04771455|Experimental|Condition 6|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease negative affect
16286364|NCT04771455|Experimental|Condition 7|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease unhealthy weight control practices
16286365|NCT04771455|Experimental|Condition 8|Behavioral weight loss intervention, decrease overvaluation of weight and shape, decrease unhealthy weight control practices, and decrease negative affect
16286366|NCT04771442|Experimental|Stromal vascular fraction injection|"Intervention:
~Single injection with autologous adipose tissue-derived stromal vascular fraction cells in and around the plaque."
16286367|NCT04771416|Experimental|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBKR03|"Cohort 1: Subjects aged >4 to <9 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna
~Cohort 2: Subjects aged >4 to <9 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna
~Cohort 3: Subjects aged >1 to <4 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna
~Cohort 4: Subjects aged >1 to <4 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna
~*GC/g: genome copiesy per gram of estimated brain weight"
16286368|NCT04771416|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBKR03|"Cohort 5: Subjects aged >1 to <9 months Drug: PBKR03 Single dose of PBKR03, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.
~*GC/g: genome copiesy per gram of estimated brain weight"
16286369|NCT04771403|Experimental|FMPD AP system|Participants will use the FMPD AP system for automated insulin delivery for a 76 hour study visit.
16286370|NCT04771403|Experimental|MPC AP System|Participants will use the MPC AP system for automated insulin delivery for a 76 hour study visit.
16286371|NCT04771390|Experimental|Part 1: Group A|Participants will receive 3 single doses of selitrectinib in adult tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
16286372|NCT04771390|Experimental|Part 1: Group B|Participants will receive 3 single doses of selitrectinib in pediatric tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
16286373|NCT04771390|Experimental|Part 2 (Group A): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
16286374|NCT04771390|Experimental|Part 2 (Group A): Dose B-C-A-D|Participants will receive dose B, C, A and D sequentially. The washing-out period between each dose is at least 3 days
16286375|NCT04771390|Experimental|Part 2 (Group A): Dose C-A-B-D|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
16286376|NCT04771390|Experimental|Part 2 (Group B): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
16286377|NCT04771390|Experimental|Part 2 (Group B): Dose B-D-A-C|Participants will receive dose B, D, A and C sequentially. The washing-out period between each dose is at least 3 days
16286378|NCT04771390|Experimental|Part 2 (Group B): Dose C-A-D-B|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
16286379|NCT04771390|Experimental|Part 2 (Group B): Dose D-C-B-A|Participants will receive dose D, C, B and A sequentially. The washing-out period between each dose is at least 3 days
16286380|NCT04771377|Experimental|standard protein supplementation (SPS)|0.8g protein/ IBW/ day
16286381|NCT04771377|Experimental|High protein supplementation (HPS)|1.2g protein/ IBW/ day
16286382|NCT04771377|Experimental|HPS + PA|1.2g protein/ IBW/ day + PA 3 times a week/ 12 weeks
16286383|NCT04771364||Standard care|"Patients aged >65 years old scheduled for hip fracture between January 1st 2019 and December 31th 2019.
~Standard anesthesiology cares were performed, as usual in our hospital institution."
16286384|NCT04771364||ASAP cohort|"Patients aged >65 years old scheduled for hip fracture between January 1st 2020 and December 31th 2020.
~Standard anesthesiology cares were performed, as usual in our hospital institution, but the investigator focused the attention on these cares' adaptation: early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic therapy."
16286385|NCT04771351|Experimental|COVI-AMG 100 mg|A single injection of 100 mg of COVI-AMG will be administered.
16286386|NCT04771351|Experimental|COVI-AMG 200 mg|A single injection of 200 mg of COVI-AMG will be administered.
16286387|NCT04771351|Placebo Comparator|Placebo|A single injection of placebo will be administered.
16286388|NCT04771338|Experimental|Treatment group|Job interview training protocol for 12 sessions
16286389|NCT04771338|No Intervention|Control group|No participation in any intervention protocol
16286390|NCT04771325|Other|Arm 1|Women are normally escorted to the health facilities by one or more family members and or friends. Women usually labor in an open first stage room where more than one woman is admitted sometimes with curtains to separate the beds with one person allowed besides her to provide support. The support persons do not have designated roles to play during this process. Routine analgesia is not given neither is continuous fetal monitoring. Midwives,
16286391|NCT04771325|Experimental|Arm 2|One session of training on admission in labor. The training will focus on emotional and physical support; emotional support including being Present, demonstrating a caring and positive attitude, saying calming verbal expressions, using humor, praise, encouraging and acknowledging efforts during the process of pushing the baby. Physical support including supporting her to change position favoring upright positions, walking with her, giving her drinks and food, massage, reminding her to go and pass urine, helping her find a comfortable position for pushing, wipe her face with cool cloth and help her breast feed
16286392|NCT04771312|Active Comparator|Information-only intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the information-only condition could respond to daily questions in a diary.
16286393|NCT04771312|Experimental|Social support network intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the social support condition could use an online chatting tool where they can send messages to their own network.
16286394|NCT04771299|Active Comparator|Cariprazine|1.5mg of Cariprazine added to their current treatment for 6 week period
16286395|NCT04771299|Placebo Comparator|Placebo|Matching placebo added to their current treatment for 6 week period.
16286396|NCT04771286|Experimental|BI 1015550 (C-14)|
16286401|NCT04771260||Case study #1|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286402|NCT04771260||Case study #2|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286403|NCT04771260||Case study #3|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286404|NCT04771260||Case study #4|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286405|NCT04771260||Case study #5|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286406|NCT04771260||Case study #6|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286407|NCT04771260||Case study #7|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286408|NCT04771260||Case study #8|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286409|NCT04771260||Case study #9|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286410|NCT04771260||Case study #10|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
16286411|NCT04771247|Experimental|CLEAR|Patients with GERD post LSG will undergo CLEAR (cardia band ligation).
16286412|NCT04771234|Experimental|Treatment group|The intervention consists of a self-guided digital tool to guide participants with chronic insomnia through sleep restriction and stimulus control procedures.
16286413|NCT04771221|Experimental|Main group|Patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
16286414|NCT04771221|Experimental|Control group 1|Patients with an early diagnosis of Gastroesophageal reflux disease
16286415|NCT04771221|Experimental|Control group 2|Patients without complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
16286416|NCT04771208|Other|Pre-Post Trial|Native Hawaiian participants from Homestead and Group Assisted Living (N=110) will partake in a pre-post study design. Participants will receive a baseline survey (as described below), view the ACP video intervention, and receive a post-intervention survey, which includes the same items as the baseline survey. In-person or phone interviews will be done at three and six months.
16286417|NCT04771208|No Intervention|Randomized Clinical Trial: Control Group|In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) to either the video (intervention) or usual care (control) arm. The control group will receive usual care. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey. Follow-up in person or by phone interviews will be done at three and six months.
16286418|NCT04771208|Experimental|Randomized Clinical Trial: Intervention Group|In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) to either the video (intervention) or usual care (control) arm. The intervention group will use the ACP video decision aid. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey. Follow-up in person or by phone interviews will be done at three and six months.
16286419|NCT04771195||Class of 2023|Stanford undergraduate students who are expected to graduate in Spring of 2023
16286420|NCT04771195||Class of 2024|Stanford undergraduate students who are expected to graduate in Spring of 2024
16286421|NCT04771169|Experimental|Vestibular Training Group|This Group will receive vestibular Adaptation and Balance exercises
16286422|NCT04771169|Active Comparator|Virtual Reality Group|This Group will receive virtual reality training by using exergaming.
16286423|NCT04771156|Experimental|Experimental group (Ketorolac)|
16286424|NCT04771156|Placebo Comparator|Control Group|
16286425|NCT04771143|Experimental|AFQ056|Experimental study drug
16286426|NCT04771143|Placebo Comparator|Placebo|Matching placebo
16286427|NCT04771130|Experimental|Parts 1 and 2: AML Cohorts|"Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
~BGB-11417: Oral administration of 80 mg for 10 days, with a 4-day ramp-up for the first cycle.
~BGB-11417: Oral administration of 160 mg for 10 days, with a 4-day ramp-up for the first cycle.
~BGB-11417: Oral administration of 160 mg for 28 days, with a 4-day ramp-up for the first cycle.
~Azacitidine: Intravenous or subcutaneous administration for 7 days."
16286428|NCT04771130|Experimental|Experimental: Parts 1 and 2: MDS Cohorts|"Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
~BGB-11417: Oral administration of 160 mg for 10 days, with a 4-day ramp-up for the first cycle.
~Azacitidine: Intravenous or subcutaneous administration for 7 days."
16286462|NCT04770844||premature child|300 premature child will be included. They will have three acquisitions during hospitalization.
16286463|NCT04770831||Single Arm|QOL following MIBG
16287775|NCT04761705|Experimental|Randomized Part 2, Arm 2|Dose 2 selected in Part I
16286429|NCT04771130|Experimental|Part 3: AML Cohort|"Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle (or 10-day cycle as determined after Parts 1 and 2). A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
~BGB-11417: Oral administration at the RP2D determined in Part 2, with a 4-day ramp-up for the first cycle.
~Azacitidine: Intravenous or subcutaneous administration for 7 days. Posaconazole: Oral administration for 10 days on second cycle only."
16286430|NCT04771130|Experimental|Part 3: MDS Cohort|"Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
~BGB-11417: Oral administration at the RP2D determined in Part 2 for 10 days, with a 4-day ramp-up for the first cycle.
~Azacitidine: Intravenous or subcutaneous administration for 7 days."
16286431|NCT04771104|Active Comparator|Allocated to intervention at first experimental day|
16286432|NCT04771104|Placebo Comparator|Allocated to intervention at second experimental day|
16286433|NCT04771091|Experimental|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist.
16286434|NCT04771052||CORE program|Patients admitted to a dedicated COVID-19 units (CHUS Hôtel-Dieu de Sherbrooke - CIUSSS de L'Estrie - CHUS) with medical clearance (physical deconditioning; hemodynamically stable; oxygen therapy by nasal cannula < 4 L/min for saturation > 92%; resting respiratory rate < 24; and heart rate between 50 and 120 beats per minute).
16286435|NCT04771052||Control|Patients admitted to a dedicated COVID-19 units (CHAUR de Trois-Rivières, CIUSSS de la Mauricie-et-du-Centre-du-Québec) receiving usual care, matched to CORE a patient with similar characteristics (sex, age, preadmission provenance).
16286436|NCT04771039||patients with chronic inflammatory bowel disease who consulted in ophthalmology|
16286437|NCT04771026|No Intervention|Control|Receiving routine conduct of general anaesthesia for supraglottic airway device
16286438|NCT04771026|Experimental|Dexamethasone|Receiving pre-operatively single dose nebulised dexamethasone 8mg prior to induction of general anaesthesia
16286439|NCT04771013|Experimental|Daily oral dose of thymic peptides|Patients will receive a daily oral dose of 250 mg of lyophilized thymic peptides dissolved in 50 mL of water (one hour before or two hours after a meal) in addition to the standard treatment, for up to 20 days or until medical discharge.
16286440|NCT04771000|Experimental|Ambrisentan|Ambrisentan, reconstituted oral solution, 125µg twice a day for up to 28 days
16286441|NCT04771000|Placebo Comparator|Placebo|Placebo, oral solution, twice a day for up to 28 days
16286442|NCT04770987||hyperlaxity|30 individuals with systemic hyperlaxity as defined by a score of 5 or greater on the Beighton Hypermobility Scale
16286443|NCT04770987||control|30 healthy, age and gender matched individuals without hyperlaxity
16286444|NCT04770974||Urothelial Carcinoma|"Patients over the age of 18 known for urological interventions for the following pathologies will be considered for enrollment in the group of cases:
~- Bladder cancer
~The exclusion criteria will be:
~Age under 18
~Pregnancy
~Lack of informed consent
~Inability to provide informed consent
~Patients included in the study, who meet the inclusion criteria, have an operative note for:
~Transurethral Resection of Bladder Neoplasia (TURBT)
~Radical Cystectomy for Bladder Neoplasia"
16286445|NCT04770961|Sham Comparator|Cryoablation|1. Cryoablation of intercostal nerves + Sham ESP catheter with saline infusion.
16286446|NCT04770961|Experimental|ESP + Cryoablation|2. Cryoablation of intercostal nerves + ESP catheter with local anesthetic infusion.
16286447|NCT04770948|Experimental|19G|19 gauge EBUS-TBNA needle
16286448|NCT04770948|Active Comparator|22G|22 gauge EBUS-TBNA needle
16286449|NCT04770935|Experimental|efanesoctocog alfa (BIVV001)|A single IV dose of BIVV001 will be administered to each patient
16286450|NCT04770922||Pediatric ALL patients on 6-mercaptopurine|Pediatric ALL patients treated with 6-mercaptopurine who did not experience neutropenia.
16286451|NCT04770922||Pediatric ALL patients on 6-mercaptopurine with neutropenia|Pediatric ALL patients treated with 6-mercaptopurine who experienced neutropenia.
16286452|NCT04770909|Experimental|Combined|Weekly incentives for dietary self-monitoring and weight loss
16286453|NCT04770909|Experimental|Dietary self-monitoring|Weekly incentives for dietary self-monitoring
16286454|NCT04770909|Experimental|Weight loss|Weekly incentives for weight loss
16286455|NCT04770909|No Intervention|Control|
16286456|NCT04770896|Experimental|Atezolizumab + Lenvatinib or Sorafenib|Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16286457|NCT04770896|Active Comparator|Lenvatinib or Sorafenib|Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16286458|NCT04770883|Experimental|Internet based cognitive behavioral therapy group|80 patients will be randomized to receive iCBT. Psychological therapy is effective in IBS patients. The treatment takes 10 weeks and is divided into five successive steps. Patients have to report that they have worked through a treatment step to get access to the next. The patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half of the treatment on step 5, in which exposure exercises are introduced. A psychologist/CBT therapist will manage the online therapeutic contact with the patients.
16286459|NCT04770883|Experimental|Low FODMAP group|80 patients will then be randomized to receive Low FODMAP diet. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) are poorly absorbed short-chain carbohydrates including fructose (in excess of glucose), lactose, polyols, fructans and galacto-oligosaccharides. The concept of considering all these molecules collectively as a treatment for IBS is relatively new. Understanding of FODMAPs comprises mechanisms of action such as luminal distension from their osmotic effect and rapid fermentation to hydrogen. These findings have led to increased application of the low FODMAP diet to manage IBS symptoms. Treatment will undergo 10 weeks supervised monotherapy with low FODMAP diet. This will be done with the help of professional dieticians in Örebro region, who will meet the patients and inform them how this diet works as well as follow up.
16286460|NCT04770883|Active Comparator|Control group|The control Group (40 patients) will wait for 10 weeks before being randomised to treatment with either iCBT or low FODMAP diet.
16286461|NCT04770870|Other|Treatment Arm|All subjects who meet eligibility, consented, and enrolled into the study will receive treatment.
16287776|NCT04761705|Active Comparator|Randomized Part 2, Arm 3|
16286464|NCT04770818|Active Comparator|Modified Brostrum procedure|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL (anterior talo-fibular ligament), CFL (calcanealfibular ligament), lateral ankle capsule and extensor retinaculum.
16286465|NCT04770818|Active Comparator|Modified Brostrum procedure with InternalBrace ligament augmentation|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL, CFL, lateral ankle capsule and extensor retinaculum with InternalBrace fixation using a 4.75mm BioComposite SwiveLock.
16286467|NCT04770792|Experimental|Experimental group|2% chlorhexidine gluconate with mineral trioxide aggregate.
16286468|NCT04770792|Active Comparator|Control group|Mineral trioxide aggregate.
16286469|NCT04770779|Experimental|Mitapivat|"Double-Blind Period: Participants will receive mitapivat 100 milligrams (mg) orally, twice daily (BID) for 48 weeks.
~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
16286470|NCT04770779|Placebo Comparator|Placebo|"Double-Blind Period: Participants will receive placebo matching mitapivat orally, BID for 48 weeks.
~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
16286471|NCT04770766||Staff observation|Doctor-in-training and non-medical practitioner volunteers
16286472|NCT04770766||Patient questionnaires|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study
16286473|NCT04770766||Case study NHS Trusts|NHS organisations with an Emergency Department participating as a case study site
16286474|NCT04770766||All England NHS Trusts|NHS Trusts whose Emergency Department (n=183) records data is held by NHS Digital and will be provided anonymously/without individual patient consent (these anticipated hundreds of thousands of records are not included in the enrolled patient numbers)
16286475|NCT04770766||Patient interviews|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview following completion of the patient questionnaire
16286476|NCT04770766||Staff interviews|Staff working in the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview
16286477|NCT04770766||Stakeholder interviews|Senior NHS clinicians, managers, commissioners and lay representatives with roles and interests in the non-medical practitioner workforce
16286478|NCT04770753|Experimental|Mitapivat|"Double-blind Period: Participants will receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks.
~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
16286479|NCT04770753|Placebo Comparator|Placebo|"Double-blind Period: Participants will receive placebo matching mitapivat, orally, BID for 24 weeks.
~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
16286480|NCT04770740|Active Comparator|Experimental: Vitamin K2|Patients with COVID-19 who get our dietary supplement vitamin K2, three tablets of 333mcg a day, for 14 days or until discharge, whichever occurs earlier.
16286481|NCT04770740|Placebo Comparator|Control: Placebo|Patients with COVID-19 who get placebo as control, three tablets a day, for 14 days or until discharge, whichever occurs earlier.
16286482|NCT04770727|Experimental|Workshop Intervention|A psychoeducation workshop will be provided alongside a workbook containing the content to review and refresh skills learnt. The psychoeducational intervention will be delivered by trainee clinical psychologists with interests in food allergy and delivered in line with a protocol.
16286483|NCT04770727|No Intervention|Treatment as usual|Adolescents randomised to the control arm will continue treatment as usual and receive the workshop materials after the active treatment group have completed their final follow-up at 3 months.
16286484|NCT04770714|Other|Breast MRI|Patients in this arm will be randomized to receive a Breast MRI in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
16286485|NCT04770714|Other|Contrast Enhanced Mammography|Patients in this arm will be randomized to receive a Contrast Enhanced Mammograph in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
16286486|NCT04770701|Experimental|Ahah drug|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.
~Characterized by rapid loss of resistance: AIDS
~Dermatitis, mouth ulcers, skin rash, itching, weight loss
~Hepatitis C virus (HCV) (+), Hepatitis B virus (HBV) (+), Tuberculosis (+)
~Ahah composition contains the following ingredients (concentrated extracts of plants):
~Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg"
16286487|NCT04770701|Experimental|Ahah Placebo|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.
~Characterized by rapid loss of resistance: AIDS
~Dermatitis, mouth ulcers, skin rash, itching, weight loss
~Hepatitis C virus (HCV)(+), Hepatitis B virus (HBV)(+), Tuberculosis (+)
~Ahah composition placebo (Ahah not containing concentrated extracts of plants Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)"
16286488|NCT04770688|Experimental|Osimertinib + Anlotiib|Escalating doses and expanding doses of Anlotinib administered with Osimertinib
16286489|NCT04770675||Treatment group|Any subject who is scheduled to undergo bronchoscopy as per routine clinical practice
16286490|NCT04770662|Other|research group|patients who are willing to participate in the study
16286491|NCT04770649||COVID-19 vaccine recipients|Subjects who have an appointment to receive a COVID-19 vaccine, and are able to provide samples prior to and after their first vaccine dose.
16286492|NCT04770623|Experimental|Chemotherapy|"Second line treatment will be as follows
~Docetaxel at 30 mg/m2 over 500 cc normal saline over 1 hour infusion
~Irinotecan at 185 mg/m2 with a maximum of 300 mg given over 500 cc normal saline over 2 hours infusion
~The whole regimen is to be cycled every 2 weeks for a maximum of 6 months with interim and end of treatment evaluation"
16286493|NCT04770610|Experimental|OT-101 alone|Atropine Sulfate 0.01% Ophthalmic Solution through year 4
16286494|NCT04770610|Experimental|OT-101 plus vehicle|Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year
16286495|NCT04770610|Placebo Comparator|Vehicle|Vehicle (Investigational Product minus active ingredient) through year 4
16286496|NCT04770597|Experimental|Intervention|CO2 values on sensor visible to staff
16286497|NCT04770597|Sham Comparator|Sham control|CO2 values on sensor not visible to staff
16286498|NCT04770584|Experimental|PTSD group|After the initial screening / baseline assessment visit, Post Traumatic Stress Disorder participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
16286499|NCT04770584|Other|Trauma-exposed healthy controls (TEHC)|After the initial screening / baseline assessment visit, trauma-exposed healthy participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
16286500|NCT04770571||Vuepoint II OCT|
16286501|NCT04770571||Reline-C|
16286502|NCT04770558|Experimental|Exergame group|The exergame group will receive exergame training for 12 weeks, 2 times a week and 60 min per session.
16286503|NCT04770558|No Intervention|Control group|The control group will not receive any intervention and maintain their lifestyle for 12 weeks.
16286504|NCT04770545|Experimental|Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered monthly intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or monthly sham will receive IVT pegcetacoplan (15 mg/100 μL) monthly for up to approximately 36 months.
16286505|NCT04770545|Experimental|Pegcetacoplan, 15 mg/100 μL, every other month (EOM) for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered every other month (EOM) intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or EOM sham will receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to approximately 36 months.
16286506|NCT04770532|Experimental|Insulin icodec|Insulin icodeg + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
16286507|NCT04770532|Active Comparator|Insulin degludec|Insulin degludec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
16286508|NCT04770506||Lithiasis patients|Lithiasis patients: diagnosis of recurrent NL confirmed by URO CT with presence of idiopathic hypercalciuria and metabolic workup available.
16286509|NCT04770506||Control group|Control group: patients without NL matched for age and sex and who had a bone mineral densitometry or abdominal CT.
16286512|NCT04770480|Active Comparator|Standard Care (SC)|Standard Post-Surgical Care utilizing opioids.
16286513|NCT04770480|Active Comparator|Enriched Surgical Management Pathway (EMP)|Enriched Surgical Management Pathway utilizing Physical Therapy and Mindfulness in addition to Standard Protocol.
16286514|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
16286515|NCT04770467|Placebo Comparator|Placebo in adult subjects with severe COVID-19|
16286516|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
16286517|NCT04770467|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
16286518|NCT04770428|Experimental|Cohort 1: Japanese MEDI7352|Randomized Japanese participants will receive single doses of MEDI7352 subcutaneously.
16286519|NCT04770428|Placebo Comparator|Cohort 1: Japanese Placebo|Randomized Japanese participants will receive matching placebo subcutaneously.
16286520|NCT04770428|Experimental|Cohort 2: Caucasian MEDI7352|Randomized Caucasian participants will receive single doses of MEDI7352 subcutaneously.
16286521|NCT04770428|Placebo Comparator|Cohort 2: Caucasian Placebo|Randomized Caucasian participants will receive matching placebo subcutaneously.
16286522|NCT04770402|Experimental|Acupuncture|
16286523|NCT04770402|Active Comparator|Standard of Care|
16286524|NCT04770389|Placebo Comparator|Placebo|placebo obicetrapib + placebo ezetimibe; once daily
16286525|NCT04770389|Experimental|Combination therapy|5 mg obicetrapib + 10 mg ezetimibe; once daily
16286526|NCT04770389|Experimental|Obicetrapib monotherapy|5 mg obicetrapib + placebo ezetimibe; once daily
16286527|NCT04770389|Experimental|Ezetimibe monotherapy|placebo obicetrapib + 10 mg ezetimibe; once daily
16286528|NCT04770376||Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab|Quantification of biomarkers will be performed on 100 patients treated with bevacizumab through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
16286556|NCT04770207|Experimental|Tumor diameter|Comparison of tumor diameter one month after injection of drug-eluting microspheres
16337772|NCT04415775|No Intervention|Healthy Controls|
16286529|NCT04770376||Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)|Quantification of biomarkers will be performed on 50 patients treated with chemotherapy through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
16286530|NCT04770363|Experimental|Bihemispheric Stimulation Group|The first group tDCS bihemispheric stimulation consisted of 20 minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex M1 (C3 and C4 of the international 10 -20 EEG electrode system).
16286531|NCT04770363|Experimental|Unihemispheric Stimulation Group|The second group unilateral stimulation, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone.
16286532|NCT04770363|Sham Comparator|Sham Group|The third sham group, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone, but delivering no current.
16286533|NCT04770350|Experimental|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
16286534|NCT04770337|Sham Comparator|Sham treatment|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.
16286535|NCT04770337|Experimental|STARSTIM device treatment|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.
16286536|NCT04770324|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
16286537|NCT04770311|No Intervention|Control|In a typical Healthy Lifestyless Nutrition visit, dietitians provide medical nutrition therapy to patients and their families. This includes addressing abnormal, nutrition-related lab values and providing targeted nutrition advice (foods to include, foods to limit) in order to resolve said labs. Motivational interviewing techniques will be used to help families identify barriers to Lifestyles change and provide strategies to help overcome these barriers. Families will receive compensation per each nutritional visit.
16286538|NCT04770311|Other|Intervention|Besides the usual standard of care during the nutrition visits, participants will have guidance on a microbiome-friendly diet and will receive groceries 1 time per week for 4 weeks.
16286539|NCT04770298|Experimental|Halliwick Assessment Group|8 children with GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM (GMFCS) I, 13 children with GMFCS II, 7 GMFCS III children, 8 GMFCS IV children and 4 children with GMFCS V. Intervention in water environment (Halliwick Concept), 1 times/week- 1 intervention on land/week, 9 months duration.
16286540|NCT04770298|Experimental|Bobath Assessment Group|7 children with GMFCS I, 12 children with GMFCS II, 8 children with GMFCS III, 6 children with GMFCS IV and 2 children with GMFCS V. Intervention on land ( Bobath), 2 times/week, 9 months duration.
16286541|NCT04770298|No Intervention|No intervention group|1 children with GMFCS I, 1 child with GMFCS III, 1 child with GMFCS IV and 2 GMFCS V children. No intervention.
16286542|NCT04770285|Other|Digital Therapeutic A|Digital Therapeutic Version A
16286543|NCT04770285|Other|Digital Therapeutic B|Digital Therapeutic Version B
16286544|NCT04770272|Experimental|Arm A|2 weeks Atezolizumab monotherapy before biopsy, followed by a 12-week therapy with Paclitaxel + Carboplatin+ Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
16286545|NCT04770272|Active Comparator|Arm B|12-week therapy with Paclitaxel + Carboplatin + Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
16286546|NCT04770259|No Intervention|Control|The control group will have a nursing evaluation and then follow the surgeon's instructions in the current standard way until de surgery day. In that day the RN will be evaluate again these group. Then, this group will be followed within the hospital and the first, second and third month after discharge.
16286547|NCT04770259|Experimental|Intervention|The intervention group will have a nursing evaluation and then will attend an evaluation by geriatarics team, kinesiology and nutrition, where a plan of physical cardiovascular, nutritional and metabolic prehabilitation is delivered. On the day of surgery, the RN will evaluate this group again. Then, this group will be followed within the hospital and the first, second and third month after discharge.
16286552|NCT04770233|Active Comparator|Early ACL reconstruction|Early ACL reconstruction is performed within 12 weeks after ACL injury and is followed by rehabilitation led by a physiotherapist. ACL surgical technique and rehabilitation is pragmatic according to the routines at the including centre.
16286553|NCT04770233|Active Comparator|Primary ACL rehabilitation|"Primary ACL rehabilitation is active rehabilitaion led by a physiotherapist. Active rehabilitation will begin as early as possible after the ACL injury. The goal of rehabilitation is to stabilized the knee without an operation.
~ACL reconstruciton is still an option after 6 months if the knee is unstable or do not allow adequat return to physical activity. If the patient sustain new knee injuries secondary to the ACL injury or has major instability, ACL reconstruction may be necessary before 6 months. The patients randomized to active rehabilitation will be routinely followed-up at his/her local hospital at 6 months."
16286557|NCT04770194|Experimental|Cohort 1: 200mg SP-8008 Prototype Capsule A|Treat 200 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
16286558|NCT04770194|Experimental|Cohort 2: 400mg SP-8008 Prototype Capsule A|Treat 400 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
16286559|NCT04770194|Experimental|Cohort 3: 800mg SP-8008 Prototype Capsule A|Treat 800 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
16286560|NCT04770194|Experimental|Cohort 4: 800 mg SP-8008 Prototype Capsule B|Treat 800 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
16286561|NCT04770194|Experimental|Cohort 5: 1200 mg SP-8008 Prototype Capsule B|Treat 1200 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
16286562|NCT04770194|Experimental|Cohort 6: 1800 mg SP-8008 Prototype Capsule B|Treat 1600 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
16286563|NCT04770181|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
16286564|NCT04770181|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
16286565|NCT04770168|Experimental|CBT Curriculum - First Cohort|Students will receive the 3-month cognitive behavioral therapy curriculum in the first half of the academic year.
16286566|NCT04770168|Experimental|CBT Curriculum - Second Cohort (Waitlist Controls)|Students will receive the current school board curriculum as usual for the first half of the academic year, serving as wait-list controls. Since this is a stepped wedge trial, the winter cohort will receive the identical intervention as the fall cohort in the second half of academic year.
16286567|NCT04770155|Active Comparator|Beetroot juice (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
16286568|NCT04770155|Placebo Comparator|Placebo (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
16286569|NCT04770155|Active Comparator|L-citrulline (Aim 1b)|Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
16286570|NCT04770155|Placebo Comparator|Placebo (Aim 1b)|Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
16286571|NCT04770155|Active Comparator|Sildenafil (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
16286572|NCT04770155|Placebo Comparator|Placebo (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
16286573|NCT04770155|Active Comparator|Bosentan (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
16286574|NCT04770155|Placebo Comparator|Placebo (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
16286575|NCT04770142|Experimental|TIRA|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
16286576|NCT04770129||Time period 2010-2014|Data from Turkish participants with metastatic breast cancer diagnosed January 2010-December 2014 will be retrospectively collected.
16286577|NCT04770129||Time period 2015-2019|Data from Turkish participants with metastatic breast cancer diagnosed January 2015-December 2019 will be retrospectively collected.
16286578|NCT04770116|Experimental|Intervention group|Participants in this group will receive all-night auditory stimulation during sleep over one week using a portable, in-home device (MHSL-SleepBand).
16286579|NCT04770116|Sham Comparator|Control group|Participants in this group will receive sham-stimulation, i.e. the device will be applied (biosignals will be recorded), but no tones will be played.
16286580|NCT04770103|Experimental|Dynamic|Participants within the dynamic arm will receive either traditional balance training within ACSM guidelines or Dynamic Step training known as Perturbation based training (PBT). Outcome measures assessed will be Margin of Stability during dynamic step recovery when subjected to a forward loss of balance, along with static postural sway ( a measure of postural control not requiring a step recovery). Participants motivation, mental wellness, attitudes to exercise and fear of falling will be assessed prior to the intervention and 6 months following the intervention.
16286581|NCT04770103|Experimental|Static|Participants within the static arm will receive only traditional balance training within ACSM guidelines. The outcome measure within the static arm is limited to static postural sway. Participants motivation, mental wellness, attitudes to exercise and fear of falling will be assessed prior to the intervention and 6 months following the intervention.
16286582|NCT04770090|Experimental|Early stage cervical cancer|Patients with cervical cancer eligible for surgery, stage IA1 to IB2
16286583|NCT04770077||Group S|Spray before intubation
16286584|NCT04770077||Group C|Intubation directly
16286585|NCT04770064|Experimental|High-dose/short-duration Fisetin (FIS-hi)|
16286586|NCT04770064|Experimental|Low-dose/sustained duration Fisetin (FIS-lo)|
16286587|NCT04770064|Placebo Comparator|Placebo|
16286618|NCT04769869|Placebo Comparator|Part 1a (SAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
16286619|NCT04769869|Experimental|Part 1b: AZD4604 for intravenous administration|Healthy volunteers will receive a single IV dose of AZD4604 administered as a 20 minute infusion.
16286620|NCT04769869|Experimental|Part 1b: AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604.
16286720|NCT04769167|Placebo Comparator|Healthy Pregnant Women (HPW)|HNPW are healthy women and currently pregnant
16286588|NCT04770051|Experimental|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
16286589|NCT04770038||Patient Group|60 BPD patients
16286590|NCT04770038||Control Group|30 Healthy participants
16286591|NCT04770025|Experimental|MI with tACS|Motivational interviewing with concurrent active stimulation
16286592|NCT04770025|Sham Comparator|MI with sham|Motivational interviewing with concurrent sham stimulation
16286593|NCT04770025|Active Comparator|MI-only|Motivational interviewing only, delayed treatment control
16286594|NCT04770012|Placebo Comparator|placebo|
16286595|NCT04770012|Active Comparator|clopidogrel|
16286596|NCT04770012|Active Comparator|aspirin|
16286597|NCT04769999|Experimental|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
16286598|NCT04769986|Experimental|Mobile Mindfulness-Based Relapse Prevention (mMBRP)|Participants will complete the Mindfulness Coach app program that is enhanced with additional modules containing MBRP content.
16286599|NCT04769986|Active Comparator|Active control|Participants will complete a course of an exercise/healthy eating app program that is matched in time and effort to the intervention condition app.
16286600|NCT04769973||Work Packages 1 - 3|"Work Package 1: Interviews with 15-20 people with Parkinson's and 15-20 caregivers.
~Work Package 2: National Survey with up to 2000 participants
~Work Package 3: Two to four Focus Groups with key stakeholders (6-10 participants per focus group)"
16286601|NCT04769960||Participants with breast tissue expanders|Participants with breast tissue expanders that require an MRI for clinical purposes are eligible for this study.
16286602|NCT04769947||Cohort 1|Cohort 1 retrospective/prospective study: 293 patients enrolled and reported in Fava et al 2019 (1) with at least 1 year of follow up at the end of the study (February 2017) and 107 patients enrolled but not reported in Fava et al 2019 since their follow-up was shorter than 1 year. The data for these patients will be collected since the end of previous study.
16286603|NCT04769947||Cohort 2|Cohort 2 retrospective/prospective study: patient not enrolled in the previous study (Fava et al 2019). The data for these patients will be collected since patient diagnosis to the end of the study.
16286604|NCT04769947||Cohort 3|Cohort 3 prospective study: patients who have discontinued TKI therapy after the study approval in each center. These patients will also participate in the validation process of Phase 2 of a questionnaire developed by an expert panel of eight CML patients with the purpose of capturing the experiences of people along all phases of the TFR.
16286605|NCT04769921||All-on-4 TiUltra and Xeal|Patients rehabilitated in the edentulous maxilla or mandible with an implant supported prosthesis through the All-on-4 Concept (2 anterior implants in the axial position and 2 posterior implants inserted with distal tilting). The implants used will be NobelParallel Conical Connection, with TiUltra surface. The abutments used will be Multi-unit abutments of internal connection with Xeal surface. The immediate prosthesis will be a high-density acrylic and 4 titanium cylinders. The definitive prosthesis will be a Titanium infrastructure with acrylic resin artificial gingiva and either acrylic or ceramic crowns.
16286606|NCT04769908|Experimental|Systemic Chemotherapy, Lenvatinib Plus Sintilimab|
16286607|NCT04769895|Experimental|MaaT013|"Route of administration: rectal (enema)
~Study drug dose: 4 enemas in total:
~Week 1:
~D0-D1: vancomycin pre-treatment (250mg per os, 4 times a day for 2 days)
~D2: 1 dose
~Between D3 to D5: 1 dose Week 2: 1 dose (7 +/- 2 days after the last dose) Week 3: 1 dose (7 +/- 2 days after the last dose) A supplementary dose can be prescribed in case of GvHD relapse or massive antibiotic use during the study."
16286608|NCT04769882|Active Comparator|Er:YAG laser therapy group|The removal of caries was performed with Er:YAG laser (Doctor Smile, Lambda SRL,Italy) with BOOST handpiece to cut the enamel and open the cavity, and 90° handpiece to remove the carious dentin with tips of 800 µ in diameter and 8 mm or 12 mm in length, in relation to the depth and distance of the lesion.
16286609|NCT04769882|No Intervention|Traditional therapy group|The removal of caries was performed with manual and rotating instruments, such as dentin spoon (ASA Dental S.p.a.), turbine (NSK Dental Italy S.r.l.) with diamond burs (Kerr Dental Italia S.r.l.) to cut the enamel and open the cavity and drill handpiece (KaVo Dental Italia S.r.l.) with tungsten carbide burs (Kerr Dental Italia S.r.l.) to remove the infected dentin.
16286610|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 1)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 1 administered with a DPI.
16286611|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 2)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 2 administered with a DPI.
16286612|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI(Dose 3)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 3 administered with a DPI.
16286613|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 4)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 4 administered with a DPI.
16286614|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 5)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 5 administered with a DPI.
16286615|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 6)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 6 administered with a DPI.
16286616|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 7)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 7 administered with a DPI.
16286617|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI|An additional cohort of healthy volunteers will receive a single inhaled dose of AZD4604 administered with a DPI.
16286621|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 8)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
16286622|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 9)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
16286623|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 10)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
16286624|NCT04769869|Placebo Comparator|Part 2 (MAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
16286625|NCT04769856|Experimental|Non-fasting group|
16286626|NCT04769856|Experimental|Fasting group|
16286627|NCT04769830||AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
16286628|NCT04769830||non-AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
16286629|NCT04769804||Patients with recurrent pityriasis versicolor|
16286630|NCT04769804||Healthy age and sex-matched controls|
16286631|NCT04769791|Experimental|cuff inflation by the residual volume|LMA will be inserted with the initial inflating volume correspondent to residual volume group ( RV group): volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 ml syringe without plunger is connected to the laryngeal cuff for 5 minutes.
16286632|NCT04769791|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group):
16286633|NCT04769791|Experimental|unchanged cuff inflation volume|LMA will be inserted with the initial inflating volume correspondent to unchanged volume group (NV group): LMA is unpacked and used without inflating or deflating the cuff.
16286634|NCT04769778|Experimental|Valsartan|Treatment with valsartan
16286635|NCT04769778|No Intervention|no treatment|no treatment received
16286636|NCT04769765|Experimental|All patients on the basic diabetic program, eligible for an individualized care pathway.|This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.
16286637|NCT04769752||No beta-blocker|Patient do no treat with beta-blocker before the surgery
16286638|NCT04769752||Beta blocker|Patient treat with beta-blocker in accordance to international guidelines
16286639|NCT04769752||Beta blocker2|Patient treat with beta-blocker without respect of international guidelines
16286640|NCT04769739|Active Comparator|CO2 insufflation|Colonoscopy will be performed in the traditional fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal.
16286641|NCT04769739|Active Comparator|WE with water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual decal debris, predominantly during insertion.
16286642|NCT04769739|Experimental|WE with 50% saline|Residual air in the colon will be removed, 50% salline (1:1 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
16286643|NCT04769739|Experimental|WE with 25% saline|Residual air in the colon will be removed, 25% saline (1:3 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
16286644|NCT04769726|Experimental|treatment|
16286645|NCT04769726|No Intervention|control|
16286646|NCT04769713|Experimental|Hepatic hilar nerve block in ablation patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
16286647|NCT04769713|Placebo Comparator|Placebo procedure in ablation patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
16286648|NCT04769713|Experimental|Hepatic hilar nerve block in chemoembolization patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
16286649|NCT04769713|Placebo Comparator|Placebo procedure in chemoembolization patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
16286650|NCT04769687|Experimental|Symbiotic Treatment : probiotic Vivomixx® + prebiotic Orafti®Synergy1|"The prebiotic, Orafti®Synergy1, is made from a volume-to-volume mixture of oligofructoses and Raftiline HP. Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets that can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
~The probiotic, Vivomixx®, consists of 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. Bulgaricus) from 3 strains of Bifidobacterium (B. longum, B. breve, and B. infantis) and a strain of streptococcus (S. salivarius subsp thermophilus). Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria which can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
~For the study, the symbiotics will be packaged by the probiotic manufacturer in the same sachet (at the same doses as mentioned above) whether for the symbiotics or for the placebo."
16286651|NCT04769687|Placebo Comparator|Placebo|
16286652|NCT04769674|Experimental|STAR intervention|Each research participant will receive individual 30-minute therapy sessions two times per week for fifteen weeks. Fifteen weekly ten-minute consultations with the teacher will also be conducted for each participant.
16286653|NCT04769648|Placebo Comparator|Vehicle|
16286656|NCT04769622||patients affected by untreated Periodontitis|patients coming to the Unit of Periodontics at the University of Siena will be screened for the inclusion in the study. All patients eligible for the inclusion in the study will undergo non-surgical periodontal treatment and will be administered a questionnaire about lifestyles (adherence to mediterranean diet, sleep quality, physical activity, perceived stress). Patients will be then reevaluated at 3 months after the completion on non-surgical periodontal therapy.
16286657|NCT04769609||Concentrated growth factor (CGF) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CGF
16286658|NCT04769609||Collagen membrane (CM) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CM
16286659|NCT04769583|Active Comparator|concomitant quadruple therapy (QC)|PPI (esomeprazole: 40 mg x 2 per day) with the amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day) for 14 days
16286660|NCT04769583|Placebo Comparator|triple therapy (TT)|PPI (esomeprazole: 40 mg x 2 per day) with amoxicillin (1 g x 2 per day) and clarithromycin (500 mg x 2 per day) AND PLACEBO for 14 days.
16286661|NCT04769570|Active Comparator|Group IPSB|In the first group of patients (Group IPSB), ultrasound-guided interscalene brachial plexus block will be applied 30 minutes before surgery.
16286662|NCT04769570|Active Comparator|Group SSNB|In the second group of patients, ultrasound-guided interscalene brachial plexus block and suprascapular nerve block will be applied 30 minutes before surgery.
16286663|NCT04769570|Active Comparator|Group Control|Patients in the third group (Group C), will be considered the control group and no block will be performed.
16286664|NCT04769557|Experimental|Paracetamol|Paracetamol
16286665|NCT04769557|Placebo Comparator|Placebo|placebo
16286666|NCT04769544|Active Comparator|Medial pivot group|Device used: medial pivot total knee arthroplasty design
16286667|NCT04769544|Active Comparator|Conventional group|Device used: conventional total knee arthroplasty design
16286668|NCT04769531|Experimental|Hip Joint Mobilizations|Hip joint mobilizations Hip strength training Knee exercises
16286669|NCT04769531|Experimental|Hip & Knee Muscles strength training|Hip strength training Knee exercises
16286670|NCT04769531|Active Comparator|Knee Muscles strength training|Knee exercises
16286671|NCT04769518|Active Comparator|Advanced Recovery Room Care (ARRC)|Patients are provided with high acuity care from arrival in Recovery (PACU) until the morning after surgery. This includes higher than normal nursing ratios (1:2), regular frequent rounds by specialist anaesthetic staff, and access to monitoring and medicines (eg vasopressor infusions) not available on normal postoperative surgical wards.
16286672|NCT04769518|Placebo Comparator|Usual care|Patients are managed in Recovery (PACU), then normal postoperative surgical wards, as per usual care.
16286673|NCT04769505|Experimental|Intervention group|Participants receive a digital mindfulness-based intervention (MBI) + treatment as usual.
16286674|NCT04769505|No Intervention|Wait list control group|Participants receive treatment as usual during the intervention period. They are provided with the digital mindfulness-based intervention (MBI) after their study completion.
16286675|NCT04769492|Other|Pilot Intervention|Tailored violence prevention intervention (#ChopViolence/#ChopHIV) for B-YGBMSM and B-TW in the Chicago HBC.
16286676|NCT04769479|Experimental|acoramidis|
16286677|NCT04769466|Experimental|Staff|Staff will be trained in the platform, and complete life story interviews with residents at their facilities. Upon completion of training, staff will complete surveys regarding it's effectiveness and utility, and following the completion of the interview, the resident's life story books, summary materials, and staff tools will be delivered four weeks later. Life story materials are meant to assist staff in providing more personalized care and a mechanism for residents to feel more deeply understood.
16286678|NCT04769466|Experimental|Residents|Residents will be screened for their cognitive status and compete interviews with a researcher prior to participation in the life story interview. Residents will then be interviewed again at T3 about four weeks after the life story books, summaries, and staff materials have been delivered.
16286679|NCT04769453|Active Comparator|iTrack surgical system with Healon GV Pro|Patients will be randomized to the iTrack surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
16286680|NCT04769453|Active Comparator|OMNI surgical system with Healon GV Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
16286681|NCT04769453|Active Comparator|iTrack surgical system with Healon Pro|Patients will be randomized to the iTrack surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
16286682|NCT04769453|Active Comparator|OMNI surgical system with Healon Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
16286683|NCT04769440|Active Comparator|M group (Mg sulphate )|patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes
16286684|NCT04769440|No Intervention|C group (control )|patients will receive 100 ml of normal saline intravenously over 30 minutes followed by saline infusion for 90 minutes
16286685|NCT04769427|Experimental|PDO Max thread injection to nose|
16286686|NCT04769414|Experimental|Chemotherapy|"Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation
~Doses as follows:
~Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15"
16286687|NCT04769401|Experimental|Effects of E2, P4 and LH Levels on implantation success|HRT was started with oral estradiol valerate (Estrofem®, Bayer Hispania, Barcelona, Spain) in a stepwise manner up to 8 mg/day. After 14 days on estrogen supplementation, endometrial thickness was measured by a vaginal 2D ultrasound and serum estradiol, LH and progesterone levels were also measured. If endometrial thickness was >7 mm with a triple layer pattern and quiescent ovaries, serum E2 was >100 pg/ml and the serum P level was <1.5 ng/ml, progesterone supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) or 25 mg/d of SC progesterone daily (Prolutex) as luteal phase support (referred to as day 0 of progesterone administration).
16286721|NCT04769167|Active Comparator|Diabetic Pregnant Women (DPW)|DNPW are diabetic and currently pregnant
16286688|NCT04769388|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
16286689|NCT04769388|Active Comparator|Osimertinib 80mg QD|All patients randomized into this will only receive Osimertinib 80mg.
16286690|NCT04769375||Group 1: Pregnant women diagnosed with GDM (first pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their first pregnancy.
16286691|NCT04769375||Group 2:Pregnant women diagnosed with GDM (2nd or 3rd pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
16286692|NCT04769375||Group 3: Healthy pregnant women (first pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their first pregnancy.
16286693|NCT04769375||Group 4:Healthy pregnant women (2nd or 3rd pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
16286694|NCT04769362|Experimental|β-blocker discontinuation arm|Discontinuation of β-blocker therapy after at least 1 year of β-blocker therapy after acute myocardial infarction
16286695|NCT04769362|No Intervention|β-blocker maintenance arm|Continuation of β-blocker therapy after acute myocardial infarction
16286696|NCT04769336||Patient|Each patient will undergo simultaneous testing with two different CBC analyzers.
16286697|NCT04769323|Experimental|Group 1|Group 1 use virtual reality.
16286698|NCT04769323|Experimental|Group 2|Group 2 do traditional home exercises.
16286699|NCT04769323|Experimental|Group 3|Group 3 do traditional home exercises and virtual reality.
16286700|NCT04769310|Other|Patient arm|"All patients will undergo a CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.
~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
16286701|NCT04769297|Experimental|Sublingual Micro-Dose Ketamine|Ketamine micro-dose 37.5mg compounded sublingual daily administration
16286702|NCT04769271|Active Comparator|Scaling and Root Planing (SRP)|
16286703|NCT04769271|Experimental|Scaling and Root Planing with tea tree oil|
16286704|NCT04769258||Patients with IBD treated with immunomodulatory drugs|
16286705|NCT04769258||Patients with IBD not treated with the immunomodulatory drugs|
16286706|NCT04769245||Single donor convalescent plasma|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
16286707|NCT04769245||ACB- IP 1.0|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
16286708|NCT04769232|Active Comparator|Standard Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by standard imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (estimation of the number of eosinophilic neutrophils according to the following categories 1: 0, 2: 1-6, 3. 7-14, 4. 15-50, 5. :50-100, 6. > 100, together with an estimation of an absolute number of eosinophilic neutrophils) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently for all other 10 biopsies using this imaging modality by endoscopist.
16286709|NCT04769232|Experimental|High Magnification Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by high magnification imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (see above) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently all other 10 biopsies using this imaging modality by endoscopist.
16286710|NCT04769219|Experimental|intervention group|Secondary prevention training will be given to 43 randomly selected patients between the fourth and sixth hours after AMI (in accordance with the patient's request). Secondary protection training will be carried out in two parts. First of all, the anatomical structure and functions of the heart, the definition of AMI, its causes, symptoms and risk factors will be explained, and then the issues to be considered after AMI will be explained. The content of the training will also be given to the participants in a written booklet.
16286711|NCT04769219|No Intervention|nursing care|43 randomly selected patients will form the control group and this group will be provided with routine care and follow-up in the clinic. No intervention will be made.
16286712|NCT04769206|Experimental|Galantamine|"Galantamine 16mg/day
~- titrating: 4mg once a day for 2 weeks, titrate to 8mg once a day for 2 weeks, then 8mg twice a day for 8 more weeks"
16286713|NCT04769206|Placebo Comparator|Placebo|"placebo (micro crystalline cellulose)
~- 1 pill once daily for 4 weeks, then 2 pills daily for 8 weeks"
16286714|NCT04769193|Experimental|Adipeau face cream|Cosmetic cream
16286715|NCT04769180||Patients affected with NCWS|100 patients with a definitive diagnosis of NCWS, based on DBPC gluten/wheat challenge.
16286716|NCT04769180||Patients affected with CD|50 patients affected with CD, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
16286717|NCT04769180||Patients affected with IBS not related to NCWS or other food allergies/intolerances|50 patients affected with IBS, according to the Rome IV criteria, not related to NCWS or other food allergies/intolerances, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
16286718|NCT04769167|Placebo Comparator|Healthy Non Pregnant Women (HNPW)|HNPW are healthy women and not pregnant
16286719|NCT04769167|Active Comparator|Diabetic Non Pregnant Women (DNPW)|DNPW are diabetic and not pregnant
16286722|NCT04769141||Hypertension patients|a prospective 4-month, cohort feasibility study will evaluate blood pressure (n=20) using the CURATE.AI platform.
16286723|NCT04769141||Diabetic patients|a prospective 4-month, cohort feasibility study will evaluate glycaemic (n=20) control using the CURATE.AI platform.
16286724|NCT04769128|Active Comparator|Group (A) (control group)(traditional physical therapy programme)|Group (A) (control group): Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training. 3 sessions/ week for 12 weeks.
16286725|NCT04769128|Experimental|Group (B) (experimental or manipulative group)|"Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training in addition to T3-T4 thoracic manipulation (Maitland screw technique grade V) 3 sessions/ week for 12 weeks."
16286726|NCT04769115|Other|Response to Alerts|Monitor patients daily for response to temperature changes and provide referral to doctor as needed
16286727|NCT04769102|Experimental|Spastic Cerebral Palsy|spastic Cerebral palsy children will be adapted in adaptive seat with flat and then Contoured cushions while kinematic changes of upper limb reaching movement are monitored through video capture with kinovea 2D software motion analysis system.
16286728|NCT04769089|Experimental|Pulse Dye Laser|Treatment with PDL alone.
16286729|NCT04769089|Experimental|CO2 Laser|Treatment with CO2 alone.
16286730|NCT04769089|Experimental|Combination|Treatment with both PDL and CO2 laser.
16286731|NCT04769089|Active Comparator|No treatment|No laser treatment.
16286732|NCT04769076|Experimental|Paclitaxel(Album-bound)|Subjects will receive neoadjuvant therapy with paclitaxel (albumin-bound) combined with cisplatin and PD-1 inhibitor (sintilimab) as well as radical concurrent radiotherapy and chemotherapy.
16286733|NCT04769063|Experimental|Hip|
16286734|NCT04769063|Experimental|Knee|
16286735|NCT04769063|No Intervention|Control|
16286736|NCT04769050||First-line patients|First-line treatment of HER2-positive metastatic breast cancer patients
16286737|NCT04769050||Second-line patients|Second-line treatment of HER2-positive metastatic breast cancer patients
16286738|NCT04769037|Active Comparator|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
16286739|NCT04769037|Placebo Comparator|Placebo|Lactose identical in appearance and taste to the active supplement
16286740|NCT04769024|Active Comparator|LUMEEN activities|Participants will benefit from LUMEEN activities for 8 weeks (2 session/week)
16286741|NCT04769024|Sham Comparator|USUAL activities|Participants will benefit from the thematic group workshops for 8 weeks (2 sessions/week)
16286742|NCT04769011|Experimental|Clinical, neuropsychological, neurophysiological, and genetic evaluations|Clinical, neuropsychological, neurophysiological, and genetic evaluations
16286743|NCT04768998||Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, POP).
16286744|NCT04768998||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, SUEP).
16286745|NCT04768998||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (POP, SUEP).
16286746|NCT04768985|Experimental|Treatment sequence 1: Treatment AB|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
16286747|NCT04768985|Experimental|Treament sequence 2: Treatment BA|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
16286750|NCT04768959|No Intervention|No Intervention: TAU + waiting list|This control group is a waiting list group. Participants received treatment as usual (TAU). Once the RCT is finished, participants have the chance to participate in the intervention group.
16286751|NCT04768959|Experimental|Experimental: TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
16286819|NCT04768530|Experimental|Scaling and Root Planing with Nitazoxanide hydrogel|
16286820|NCT04768504|Experimental|Treatment Arm|Tofacitinib 10 mg PO BID for 30 days
16286885|NCT04767984|Experimental|Arm I (atorvastatin, biospecimen collection)|Patients receive atorvastatin PO QD for 12 months.
16286752|NCT04768946||Adolescents with Acquired Brain Injury|Adolescents with traumatic brain injury, stroke, and other acquired brain injury ages 12 - 17 will participate in interviews about home safety. They also will have the opportunity to look at and, if desired, try the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
16286753|NCT04768946||Caregivers of Adolescents with Acquired Brain Injury|Caregivers of adolescents with traumatic brain injury, stroke, and other acquired brain injury will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
16286754|NCT04768946||Healthcare Workers|This cohort includes health professionals involved in discharge planning and community re-integration of adolescents with ABI. Healthcare workers will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
16286755|NCT04768933|Experimental|Toddler Milk Group|All enrolled subjects with be provided a new toddler milk for 28 days. Aligned with clinical and label recommendations, they will be required to intake at least 3 servings of 130 ml per day.
16286756|NCT04768920|Experimental|Teletx|The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 ~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc).
16286757|NCT04768894|Active Comparator|14-28 days|In group 1,the time interval between initial and re-TUR was 14-28 days,
16286758|NCT04768894|Active Comparator|29-42 days|In group 2, the time interval between initial and re-TUR was 29-42 days
16286759|NCT04768894|Active Comparator|43-56 days|In group 3, the time interval between initial and re-TUR was 43-56 days
16286762|NCT04768868|Other|IMP7068|"Part 1: Dose Escalation
~The study will begin with open-label dose escalation in IMP7068 monotherapy treatment to determine the Maximum tolerated dose (MTD)
~Part 2: Dose Expansion The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. A total of 100 patients each with advanced solid tumor who has exhausted available treatment options will be evaluated."
16286763|NCT04768855|Experimental|LY3540378 (Part A)|Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).
16286764|NCT04768855|Experimental|LY3540378 (Part B)|Multiple ascending doses of LY3540378 administered SC.
16286765|NCT04768855|Experimental|LY3540378 (Part C)|Multiple ascending doses of LY3540378 administered SC in Japanese Participants.
16286766|NCT04768855|Placebo Comparator|Placebo (Part A, B & C)|Placebo administered either IV or SC.
16286767|NCT04768842|Experimental|LY3209590 Lyophilized Formulation|LY3209590 as lyophilized formulation administered subcutaneously (SC) in one of the two study periods.
16286768|NCT04768842|Experimental|LY3209590 Solution Formulation|LY3209590 as solution formulation administered SC in one of the two study periods.
16286771|NCT04768816|Placebo Comparator|Placebo Comparator|Placebo 0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
16286772|NCT04768816|Experimental|Experimental|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells#1*10^7/kg). The infusion speed is 1ml/min.
16286773|NCT04768790|Experimental|Multidisciplinary Group|Description of the interventions of the multidisciplinary program: multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
16286774|NCT04768790|Active Comparator|General Group|Description of the interventions of the general program: exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
16286775|NCT04768777|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
16286776|NCT04768777|No Intervention|waitlist control condition|Participants will have 16-weeks of no intervention or interaction.
16286777|NCT04768764|Active Comparator|Group 1 Middle Adductor Canal Block|"Ultrasound Guided Middle Adductor Canal Block:
~20 ml Bupivacaine 0.25% Injectable Solution will be administered for middle adductor canal block.
~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
16286778|NCT04768764|Active Comparator|Group 2 Femoral Nerve Block.|"Ultrasound Guided Femoral Nerve Block:
~20 ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.
~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
16286821|NCT04768491||dacomitinib treatment|Sequential Therapy with Dacomitinib as First-line Treatment Followed by 3rd generation EGFR-TKI in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
16286822|NCT04768478|Active Comparator|Cannabidiol (CBD)|
16286779|NCT04768738|Experimental|Above Threshold Group|In the above threshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
16286780|NCT04768738|Experimental|Subthreshold Group|In the subthreshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
16286781|NCT04768738|Sham Comparator|Control Group|In the control group, bicycle exercise was performed under the same load with the current-free headset produced for sham applications for 5 minutes. Participants were shown that the device was working, but no current was given.
16286782|NCT04768725|Active Comparator|Dietary intervention|Participants will consume a self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day).
16286783|NCT04768725|Active Comparator|Physical-cognitive intervention|Participants will perform home-based physical-cognitive training for 60 minutes per session, 3 session a week.
16286784|NCT04768725|Experimental|Physical-cognitive with dietary intervention|Participants will receive both dietary intervention and physical-cognitive training same as those in the dietary and physical-cognitive intervention groups.
16286785|NCT04768725|No Intervention|Control|Participants in the control group will be encouraged to continue their activities and calorie intakes as they usually would.
16286786|NCT04768712|Experimental|Weight bearing aerobic exercise|
16286787|NCT04768712|No Intervention|Lifestyle counseling|
16286788|NCT04768699|Experimental|TQG203(30µg/kg)|
16286789|NCT04768699|Experimental|TQG203(90µg/kg)|
16286790|NCT04768699|Active Comparator|NovoSeven®(90µg/kg)|NovoSeven®,manufactured by Novo Nordisk Inc.
16286791|NCT04768699|Experimental|TQG203(180µg/kg)|
16286792|NCT04768686|Experimental|FLX475 and pembrolizumab combination therapy|"Cohort 1: EBV negative / CPI naïve gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer
~Cohort 2: EBV positive / CPI naïve gastric cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer"
16286793|NCT04768673|Experimental|Group 1|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II
16286794|NCT04768673|Experimental|Group 2|Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053
16286795|NCT04768673|Experimental|Group 3|Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I
16286796|NCT04768673|Experimental|Group 4|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I
16286797|NCT04768673|Experimental|Group 5|Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II
16286798|NCT04768673|Experimental|Group 6|Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053
16286799|NCT04768660|Other|normal|people will not use chewing gums after whipple operation
16286800|NCT04768647||Main cohort|Main cohort of all patients
16286801|NCT04768647||Subgroup of patients with imbalance|Subgroup of patients with imbalance
16286802|NCT04768634|No Intervention|Observation|Patients will be observed for arrhythmias and treated if they occur.
16286803|NCT04768634|Experimental|Testing|Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.
16286804|NCT04768621|Experimental|Winter residents of Southern and Antartic French Lands,|people exposed to stressors over long periods including winter
16286805|NCT04768621|Active Comparator|Country people going to Southern and Antartic French Lands|people going to Southern and Antarctic French Lands who benefit from milder conditions and only make short stays
16286806|NCT04768608|Experimental|PD1-PSMA-CART|Patients undergo leukapheresis by receiving cyclophosphamide and fludarabine on days -6 to -4, and then receive PD1-PSMA-CART intravenous injection (IV) at split doses from day 0 on.
16286807|NCT04768595|Placebo Comparator|Placebo|1g corn oil capsules
16286808|NCT04768595|Experimental|Ceto 10|1g capsules containing oil from north atlantic fish containing broad spectrum marine oil.
16286809|NCT04768595|Active Comparator|Omega-3|1 g capsules containing traditional, commericially available omega-3 marine oil.
16286810|NCT04768582|Experimental|Efient group|ACS patients who received oral Prasugrel after coronary angiography been done
16286811|NCT04768569|Active Comparator|Zonisamide Pre-op + Placebo Post-op|For subjects randomized to zonisamide pre-op, the pre-op package will contain one zonisamide capsule (100 mg PO) and the post-op package will contain one placebo capsule that looks, smells, and tastes the same as zonisamide capsules.
16286812|NCT04768569|Placebo Comparator|Placebo Pre-op + Placebo Post-op|For the subjects randomized to placebo, both pre- and post-op packages will contain placebo capsules that looks, smells, and taste the same as zonisamide capsules.
16286813|NCT04768569|Active Comparator|Placebo Pre-op + Zonisamide Post-op|For subjects randomized to zonisamide post-op, the pre-op package will contain one placebo capsule and the post-op package will contain one zonisamide capsule (100 mg PO).
16286814|NCT04768556|Experimental|ADHD group|ADHD group: 20 participants having received a positive diagnosis of ADHD
16286815|NCT04768556|Other|Control group 1|Control group 1: 20 participants having received a negative diagnosis of ADHD
16286816|NCT04768556|Other|Control group 2|Control group 2: 20 participants as healthy volunteers
16286817|NCT04768543||Exposure|Patients with moderate to severe OSA treated with UAS (Inspire Medical Systems, Inc)
16286818|NCT04768530|Active Comparator|Scaling and Root Planing (SRP)|
16286824|NCT04768465||Combined Immunotherapy|"MG patients are treated with tacrolimus combined with low-dose prednisone (0.25mg/kg/d).
~Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d)."
16286825|NCT04768465||Tacrolimus monotherapy|MG patients are treated with tacrolimus as initial immune monotherapy. Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d).
16286826|NCT04768439|Experimental|200 IU/d vitamin D|Patients will receive low-dose vitamin D (200 IU/d)
16286827|NCT04768439|Experimental|1600 IU/d vitamin D|Patients will receive high-dose vitamin D (1600 IU/d)
16286828|NCT04768426|Experimental|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day cycles
16286829|NCT04768413||Group A|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
16286830|NCT04768413||Group B|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
16286831|NCT04768400|Experimental|rocuronium|Neuromuscular blockade will be performed using rocuronium.
16286832|NCT04768387|Experimental|Personalized microbiome diet|Six weeks of AI-based microbiome diet was introduced.
16286833|NCT04768387|Active Comparator|Standard IBS diet|Six weeks of standard IBS diet was introduced.
16286834|NCT04768374|Experimental|VR group|Enrolled into 12 week VR intervention with Microsoft Kinect (twice a week, for 45 minutes) and conventional occupational therapy.
16286835|NCT04768374|Active Comparator|Control group|Control group only received conventional occupational therapy for 12 weeks
16286836|NCT04768361|Experimental|Behavioral Activation without Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and excludes terms and interventions from Third Generation Therapies.
16286837|NCT04768361|Experimental|Behavioral Activation with Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and include mindfulness practices.
16286838|NCT04768335|Active Comparator|Patient group with schizophrenia|The schizophrenic subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
16286839|NCT04768335|Active Comparator|Healthy control subjects|Healthy control subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
16286840|NCT04768322|Experimental|Early Left Ventricular Assist Device and Guideline Directed Medical Therapy|The intervention group will receive an early left ventricular assist device implantation (bridge to transplantation, bridge to candidacy or destination therapy) in addition to guideline directed medical therapy within 21 days of randomization.
16286841|NCT04768322|Other|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists if tolerated.
16286842|NCT04768309|Experimental|CKD group|CKD adult patients stage 4-5 Without diabetes BMI between 18 and 30 kg/m2
16286843|NCT04768309|Other|Healthy volunteers group|Adult without chronic treatment, without renal dysfunction
16286845|NCT04768283|No Intervention|Control group|Cardiac rehabilitation physical training program included: respiratory muscle training (7 days/week, for 15 minutes) and aerobic exercises on cycle ergometers (6 days/week, for 10-30 minutes, 30-50% watts or 30-50% HRmax).
16286846|NCT04768283|Experimental|Intervention group 1|"Combinated physical training program:
~Respiratory exercises, aerobic training will be the same as in the control group.
~Additional exercises: balance training and strength exercises with weights, elastic resistance rubbers."
16286847|NCT04768283|Experimental|Intervention group 2|"Combinated physical training program:
~Respiratory exercises, aerobic training will be the same as in the control group.
~Additional exercises: balance training with static and dynamic balance training device Biodex Balance System TM SD and strength exercises with HUR strength training machines."
16286848|NCT04768257||Patients with COVID-19, treated in intensive care|
16286849|NCT04768257||Patients with COVID-19, treated in hospital ward|
16286850|NCT04768257||Patients with COVID-19, treated at home|
16286851|NCT04768244||COVID19|- Women with SARS-CoV-2 infections
16286852|NCT04768231|Experimental|R35HZE|Participants treated with rifampicin at a dose of 35 mg per kilogram of body weight per day, added to the standard doses of isoniazid, pyrazinamide and ethambutol.
16286853|NCT04768205|Active Comparator|Study group|The therapy and Kinesio tex gold tape that was affixed to stretched and neck localised were applied
16286854|NCT04768205|Placebo Comparator|Sham control group|The therapy and Kinesio tex gold tape that was affixed to different neck localised as no-stretched were applied
16286855|NCT04768192||Pediatric patients with acquired brain injury|Subjects with a acquired brain injury occurred in the last 10 months prior the beginning of the treatment
16286856|NCT04768179|No Intervention|Arm1 (Control group)|standard of care
16286857|NCT04768179|Experimental|Arm 2|Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
16286858|NCT04768179|Experimental|Arm 3|3-day Ivermectin 600 mcg/kg/day/14-day 75mgASA/day + standard of care (Intervention 2)
16286859|NCT04768166|Experimental|Evaluate the safety of Miglustat administration in subjects with Spastic Paraplegia 11|100 mg of Miglustat, 3 caps per day for first 4 weeks; 100 mg of Miglustat, 6 caps per day for 8 weeks
16286860|NCT04768153||Patients|
16286886|NCT04767984|Placebo Comparator|Arm II (placebo, biospecimen collection)|Patients receive placebo PO QD for 12 months.
16286861|NCT04768140|Experimental|Bobath group|A conventional physiotherapy program was applied to this group. Additionally, Bobath treatment approach was applied for 10 repetitions during a 30-min session in the experimental group, in addition to the conventional physiotherapy program.
16286862|NCT04768140|Active Comparator|Conventional physiotherapy group|Only conventional physiotherapy program was applied to this group.
16286863|NCT04768127|Experimental|Early aftercare (intervention group 1)|Patients in this group will begin the ACHT program immediately after their bariatric metabolic operation. 3 weeks post surgery, they will attend the initial examination and meet their case manager. The obesity guide will then set up an electronic case file for the patient and introduce the patient to the obesity app. Through the next 18 months the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 2 patients visit a sports physician who assesses their mobility and physical capacity to compile a personal training plan, which will be uploaded onto the patient's case file and thus be available to the patient via the app. In months 3,6,9.12 and 18, patients will attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined by a physician and receive tailored dietary advice from a nutritional advisor. In month 18 patients revisit the surgical centre for the follow-up examination
16286864|NCT04768127|Experimental|Mid-term to long-term aftercare (intervention group 2)|Patients in this group first visit the study center 18 months after their bariatric surgery for the initial examination and start the program in month 19 post-op. At the center, they will meet their obesity guide who will set up an electronic case file for the patient and introduce the patient to the obesity app. Throughout the next 18 months, the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 19 post-surgery, patients visit a sports physician who assesses their mobility and devises a personal training plan. This plan will be uploaded onto the patient's case file and made available to the patient via the app. In months 19,21,24, 30 and 36, patients attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined and receive tailored dietary advice. In month 36, patients will be reexamined at the study center.
16286865|NCT04768127|No Intervention|control group 1 (early aftercare)|"Analogous to intervention group I, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination (18 months after the operation) at the obesity centre.
~If interested, patients in this group can be included in intervention group II until the required number of cases (140 patients) has been reached."
16286866|NCT04768127|No Intervention|control group 2 (mid-term to long-term aftercare)|Analogous to intervention group II, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination at the study center 36 months after the operation.
16286867|NCT04768114|Experimental|Genetically-Informed RiskProfile|
16286868|NCT04768114|Active Comparator|Brief Cessation Advice|
16286870|NCT04768088|Experimental|One-week training of falling techniques on landing biomechanics associated with ACL loading|Participants will perform one-week training of single-leg falling techniques, a post-training assessment, a two-week break, and a retention assessment.
16286871|NCT04768075|Experimental|Camrelizumab group|"subject will receive Camrelizumab intravenously(IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by Camrelizumab ± pemetrexed IV Q3W until progression (up to approximately 2 years).
~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
16286872|NCT04768075|Placebo Comparator|placebo group|"subject will receive placebo intravenously (IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by placebo ± pemetrexed IV Q3W until progression (up to approximately 2 years).
~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
16286873|NCT04768062|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 96 weeks.
16286874|NCT04768036|No Intervention|Usual Medical Care|As per standard of care
16286875|NCT04768036|Experimental|"SMART on FHIR application of the IMPROVE DD VTE CPR"|"This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients.
~Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records.
~2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm."
16286876|NCT04768023|Other|Control group|The group after 6 weeks of the research will receive placebo treatment.
16286877|NCT04768023|Active Comparator|Control group with physical activity|The group after 6 weeks of the research will receive placebo treatment. The group will be prompt to do 3500-8000 steps per day.
16286878|NCT04768023|Placebo Comparator|Placebo group|The group will receive placebo treatment for all the time of the research.
16286879|NCT04768023|Placebo Comparator|Placebo group with physical activity|The group will receive placebo treatment for all the time of the research. The group will be prompt to do 3500-8000 steps per day.
16286880|NCT04768023|Experimental|Vitamin D3 group|The group will receive vitamin D3 supplementation.
16286881|NCT04768023|Experimental|Vitamin D3 group with physical activity|The group will receive vitamin D3 supplementation. The group will be prompt to do 3500-8000 steps per day.
16286882|NCT04768010|Experimental|Misoprostol|Participants will receive 100-200 micrograms of oral misoprostol twice daily.
16286883|NCT04767997|Experimental|Experimental group|Participants in this group will be randomized to receive probiotic formulation for the following 12 weeks.
16286884|NCT04767997|Placebo Comparator|Control group|Participants in this group will be randomized to receive placebo for the following 12 weeks.
16286889|NCT04767958|Experimental|Patients consulted upon by ICU, internal medicine, or cardiology for hospital admission|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
16286890|NCT04767958|Experimental|patients undergoing cardiac testing/procedures|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
16286891|NCT04767958|Experimental|patients awaiting surgery|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
16286892|NCT04767958|Experimental|Health Care Workers|Health Care Workers who are being screened for COVID-19 will have both standard care and point-of-care NP swabs performed.
16286893|NCT04767945||Adults with liver cirrhosis admitted to hospital liver unit|Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data
16286894|NCT04767932|Experimental|control group|the control group will receive regular exercise training at same time.
16286895|NCT04767919|Active Comparator|Standard Percutaneous Nephrolithotomy (sPCNL)|The first arm will consist of a Standard of Care standard percutaneous nephrolithotomy (sPCNL)- performed using a 30 Fr access sheath following balloon dilation.
16286896|NCT04767919|Active Comparator|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|The second arm will consist of a Standard of Care mini percutaneous nephrolithotomy (mPCNL)- performed using an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
16286897|NCT04767906|Other|Cabozantinib|Enrolled patients start with 60mg of Cabozantinib. The maximum duration of treatment is 336 days. The dose can be adjusted by the physician to 40mg or 20mg.
16286898|NCT04767880|Experimental|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast in the women's own environment.
16286899|NCT04767880|Placebo Comparator|Placebo|The placebo will be ingested 30 min. prior to an OGTT (3 hours). The placebo will also be ingested 30 min prior to breakfast in the women's own environment.
16286900|NCT04767867|Experimental|Facemask oxygen (FM)|100% oxygen administered via facemask through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'breathe normally'
16286901|NCT04767867|Active Comparator|High-flow nasal oxygen (HFNO)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Participant instructed to 'keep the mouth closed and breathe normally'
16286902|NCT04767867|Active Comparator|High-flow nasal oxygen plus mouthpiece oxygen (HFNO+MP)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Additionally, 100% oxygen administered via mouthpice through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'keep the mouth closed and breathe normally'.
16286905|NCT04767841|Experimental|Metformin|Metformin 1000 mg daily plus Celecoxib 200mg capsule
16286906|NCT04767841|Experimental|Placebo|Placebo tablet daily plus Celecoxib 200mg capsule
16286907|NCT04767828|Experimental|One arm exploratory research|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition. Pyrrotini: 400 mg once a day, oral within 30 minutes after breakfast for 21 days. Cassitabine: twice a day, 800 mg / m2 orally within 30 minutes after each meal (one morning and one night, 12 hours apart, equivalent to a daily dose of 1600 mg / m2, one dose in the morning and one dose in the morning)
16286908|NCT04767815|Experimental|Sequence 1|"Period 1: A (Fasting)
~Period 2: B (30 minutes after a High-fat meal)
~Period 3: C (2 hours after a High-fat meal)"
16286909|NCT04767815|Experimental|Sequence 2|"Period 1: B (30 minutes after a High-fat meal)
~Period 2: C (2 hours after a High-fat meal)
~Period 3: A (Fasting)"
16286910|NCT04767815|Experimental|Sequence 3|"Period 1: C (2 hours after a High-fat meal)
~Period 2: A (Fasting)
~Period 3: B (30 minutes after a High-fat meal)"
16286911|NCT04767815|Experimental|Sequence 4|"Period 1: A (Fasting)
~Period 2: C (2 hours after a High-fat meal)
~Period 3: B (30 minutes after a High-fat meal)"
16286912|NCT04767815|Experimental|Sequence 5|"Period 1: C (2 hours after a High-fat meal)
~Period 2: B (30 minutes after a High-fat meal)
~Period 3: A (Fasting)"
16286913|NCT04767815|Experimental|Sequence 6|"Period 1: B (30 minutes after a High-fat meal)
~Period 2: A (Fasting)
~Period 3: C (2 hours after a High-fat meal)"
16286914|NCT04767802|Experimental|PTG-300|Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.
16286915|NCT04767789|Experimental|NZ-GHMH-01|Dietary supplement in shape of capsule to be taken once per day in the evening.
16286916|NCT04767789|Placebo Comparator|Placebo|The placebo is in shape of capsule to be taken once per day in the evening and in which only the active ingredients are not present.
16286917|NCT04767776|Experimental|Arm A|"Period  rivaroxaban and 6 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 12 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 50 milligram of activated charcoal 
~Washout period (6 days)"
16286918|NCT04767776|Experimental|Arm B|"Period  rivaroxaban and 12 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 6 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 24 milligram of activated charcoal 
~Washout period (6 days)"
16287158|NCT04766034|Active Comparator|Bundles|The grocery shopping simulation will include healthy bundle defaults with no discount
16286919|NCT04767776|Experimental|Arm C|"Period  rivaroxaban and 50 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 24 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 6 milligram of activated charcoal 
~Washout period (6 days)"
16286920|NCT04767776|Experimental|Arm D|"Period  rivaroxaban and 24 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 50 milligram of activated charcoal 
~Washout period (6 days)
~Period  rivaroxaban and 12 milligram of activated charcoal 
~Washout period (6 days)"
16286921|NCT04767763||Patients with Acute Kidney Injury|Patients with acute kidney injury and indications for initiation of continuous renal replacement therapy (CRRT) were included to this study irrespective of their gender, race and age.
16286922|NCT04767750||HCC patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
16286923|NCT04767750||T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
16286924|NCT04767750||HCC & T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
16286925|NCT04767750||Controls|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
16286926|NCT04767737|Experimental|Topical lavender oil group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
16286927|NCT04767737|Placebo Comparator|Placebo group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients. No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
16286928|NCT04767737|No Intervention|Control groups|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured.No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
16286929|NCT04767724|Experimental|Extracorporeal shock wave|Participants received three ESWT sessions once per week for three consecutive weeks. The probe of the ESWT machine (FT-174; Swiss Dolor Class; Switzerland) was placed perpendicularly on the patient's palm over the median nerve on the carpal tunnel after application of the ultrasound gel as a coupling agent. Afterward, the ESWT was administered with 1000 shots, 1.5 bar of pressure, and a frequency of 6 Hz
16286930|NCT04767724|Active Comparator|Local corticosteroid injection|A single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
16286931|NCT04767711|Active Comparator|L. reuteri Low Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E8 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 30 days, yielding a total dose of 1x10E9 L.reuteri CFU and 400 IU of cholecalciferol per day. Oral glucocorticoid 25 mg daily for 7 days.
16286932|NCT04767711|Active Comparator|L. reuteri High Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 30 days, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day. Oral glucocorticoid 25 mg daily for 7 days.
16286933|NCT04767711|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 30 days.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day. Oral glucocorticoid 25 mg daily for 7 days.
16286934|NCT04767698|Experimental|Belimumab + short-term Ocrelizumab|Participants will receive Belimumab and Ocrelizumab.
16286935|NCT04767698|Active Comparator|Continued Ocrelizumab|Participants will receive Ocrelizumab only.
16286936|NCT04767685||All patients|Consenting patients undergoing non-emergency surgery with anesthesia
16286937|NCT04767672|Experimental|Test product|Food ingredient containing non digestible carbohydrates, in shape of powder
16286938|NCT04767672|Placebo Comparator|Placebo|Food ingredient containing containing 95% of maltodextrin
16286939|NCT04767659|Experimental|Women candidate for clinical trial|Twenty adult women with a recent diagnosis of breast cancer, candidate for NAC, besides assessing the response to neoadjuvant chemotherapy using standard imaging evaluation, will undergo optical imaging at six selected time points from prior to commencement of NAC/baseline to the completion of NAC treatment (prior to surgery).
16286940|NCT04767646|Experimental|C-BNP with intensive rehabilitation program|
16286941|NCT04767633|Active Comparator|group A (PMC standard-dose)|Group A (PMC standard-dose): patients will receive two oral doses of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 17:00 and 4 hours later in the evening prior to the colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
16286994|NCT04767204|Experimental|Peer support service|Peer support workers co-lead and assist workplace problem-solving and care skills training in an extended vocational rehabilitation program
16286942|NCT04767633|Active Comparator|Group B (PMC split-dose)|Group B (PMC split-dose): patients will receive the first oral doses of PMC diluted in 150 ml of water (Picoprep; Ferring Italia, Milan, Italy) at 19:00 of the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
16286943|NCT04767620|Experimental|study groups|The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses.
16286944|NCT04767620|No Intervention|control groups|The control group was treated with observational treatment and follow-up in outpatient clinic.
16286945|NCT04767607||Breast cancer plus chemotherapy|Patients of the group will receive chemotherapy treatment.
16286946|NCT04767607||Breast cancer without chemotherapy|Patients of the group will not receive chemotherapy treatment.
16286947|NCT04767594||First-line Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy
16286948|NCT04767581|Active Comparator|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
16286949|NCT04767581|Placebo Comparator|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
16286950|NCT04767568|Experimental|Blood test|"In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding
~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor"
16286951|NCT04767555|Experimental|ILM (inner limiting membrane) peeling|ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment
16286952|NCT04767555|No Intervention|No Peeling|standard vitreous surgery without ILM peeling in patients suffering from retinal detachment
16286953|NCT04767542|Sham Comparator|Paracetamol|Patients with emergency LC will be administered intravenously 1 gr vial of paracetemol in 30 minutes during the awakening phase.
16286954|NCT04767542|Active Comparator|Transversus Abdominis Plane Block|With USG, the lateral part of the latissumus dorsi muscle attaches to the external lip of the iliac crest, just behind the middle axillary line and the end is directed slightly cranially, first through the external oblique muscle and fascia, then the internal oblique muscle and fascia, and after hydrodissection with saline for about 15-20 ml of local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally
16286955|NCT04767529|Experimental|EFX 28 mg|
16286956|NCT04767529|Experimental|EFX 50 mg|
16286957|NCT04767529|Placebo Comparator|Placebo|
16286958|NCT04767503|Active Comparator|Propofol|Maintence of anesthesia during the operation using target control infusion with propofol 1mg/ml with bispetral index(BIS) in the range 40-60.
16286959|NCT04767503|Sham Comparator|Desflurane|Maintence of anesthesia during the operation using inhalational agent desflurane with 0.5 to 1.5 minimal alveolar concentration (MAC) with bispetral index(BIS) in the range 40-60.
16286960|NCT04767490|Active Comparator|BPD-DS|Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb
16286961|NCT04767490|Experimental|SADI|Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel
16286962|NCT04767477|Other|Face-to-face rehabilitation and Telerehabilitation|The Face-to-face rehabilitation and Telerehabilitation protocol will consist of flexibility exercises, aerobic and resistance training, with two sessions per week.
16286963|NCT04767464|Other|Compass Course|Virtual Compass Course
16286964|NCT04767451||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
16286965|NCT04767451||Control group|The study population will consist of 50 women with POI as a study group and 50 patients with normal healthy women as a control group. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
16286966|NCT04767438||Pregnant women|All singleton pregnancies that present to the 12-week scan in the Obstetrics Unit of the participant hospitals. Singleton pregnancies; Gestational age less than 14 weeks, estimated according to Crown-Rump Length (CRL); Blood sample between 8 and 14 weeks of pregnancy; Patients who accept to participate in the study and sign the informed consent.
16286967|NCT04767425|Experimental|Experimental|
16286968|NCT04767412|Active Comparator|aerobic exercise|
16286969|NCT04767412|Active Comparator|aerobic exercise and inspiratory muscle training|
16286970|NCT04767399|Experimental|Single visit|root canal treatment will be done in one visit
16286971|NCT04767399|Experimental|multiple visit|root canal treatment will be done in multiple visit
16286974|NCT04767360|Other|Open labele BIONESS-Training|Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
16286995|NCT04767191|Active Comparator|artemether lumefantrine|The drug is approved and in use by the Kenya Ministry of Health as the 1st line treatment for malaria. The study is to assess the continued efficacy of the drug.
16287159|NCT04766034|Active Comparator|Bundles and Discount|The grocery shopping simulation will include healthy bundle defaults plus a discount
16286975|NCT04767347|Experimental|Fixed Work Rate|Participants will walk on a treadmill at 3 mph and the grade will be adjusted to elicit 430 W of metabolic heat production (the most common work intensity). This study will systematically examine the NIOSH recommendations for prescribing work-to-rest ratios with increasing environmental heat stress (defined as Wet Bulb Globe Temperature, WBGT) at this fixed rate of metabolic heat production on kidney function.
16286976|NCT04767347|Experimental|Fixed work-to-rest ratio|This study will systematically examine the NIOSH recommendations on changes in kidney function when the work-to-rest ratio is fixed at 30 min per hour (the most commonly prescribed work-to-rest ratio), but the rate of metabolic heat production and environmental heat stress differs (Figure 2). As described in Study 1, the appropriate rate of metabolic heat production will be elicited by having participants walk on a treadmill at 3 mph and the grade will be adjusted accordingly.
16286977|NCT04767334|Experimental|Gait training on Lower body positive pressure|"All participants will have gait training for 40 minutes a day, for three days a week, for six weeks. On session one, the lower body positive pressure chamber will be set to unload 50% of patient's body weight.On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.
~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
16286978|NCT04767321|Experimental|LTX-109 treatment|Nasal application of LTX-109 gel 3% (w/w), 250 mikroliters in each nostril, 4 times in one day, every two hours.
16286979|NCT04767321|Experimental|Placebo|Nasal application of placebo, 250 mikroliters in each nostril, 4 times in one day, every two hours.
16286980|NCT04767308|Experimental|Arm 1|"The tolerability and safety of CT125A cells will be assessed according to the 3+3 dose escalation design. There will be three dose levels, 1×10^6, 2×10^6, and 3×10^6, CAR+T cells/kg. For each level, 1-3 subjects will be enrolled. If no dose limited toxicity (DLT) occurs, next level will be assessed for DLT. If DLT occurs in one subject, 3 more subjects will be enrolled in this cohort for the evaluation of DLT. If DLT occurs in ≤ 1/6 subjects, next level will be assessed for DLT. If DLT occurs in ≥ 2 subjects, no more subjects will be enrolled in this cohort and dose escalation will be canceled. For each cohort, following subjects can only receive CT125A infusion at least 14 days after the first subject received CT125A infusion. If DLT occurs in 2 subjects at Dose Level 1, whether to explore a lower dose will be determined by the investigator. After dose escalation phase is completed, the dose for extension phase will be determined based on safety and PK data."
16286981|NCT04767295|Experimental|Camrelizumab, Albumin Paclitaxel, Carboplatin|"ESCC participants in this study will be given intravenous administration of Camrelizumab (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration.
~Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment."
16286982|NCT04767282|Other|Fruit and Vegetable Prescription|Each program participant will receive a fruit and vegetable prescription that is written by pediatricians to exchange for $15 of fresh produce. Prescriptions will be distributed during pediatric office visits and are redeemable at a local farmers' market and mobile market.
16286983|NCT04767269|Experimental|cuminum cyminum mouthwash|cuminum cyminum mouthwash in chronic gingivitis patients
16286984|NCT04767269|Active Comparator|herbal mouthwash|herbal mouthwash in chronic gingivitis patients
16286985|NCT04767256|Experimental|DD group|co-administered intravenous dexamethasone 10 mg and dexmedetomidine 1 ug/kg
16286986|NCT04767256|Placebo Comparator|D group|intravenous dexmedetomidine 1 ug/kg
16286987|NCT04767243|Sham Comparator|open flap debridement and filled with A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
16286988|NCT04767243|Active Comparator|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
16286989|NCT04767243|Active Comparator|with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF.|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) along with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
16286990|NCT04767230|Active Comparator|A heart-healthy diet + Flaxseed + Olive oil|A heart-healthy diet with a specified number of food servings from different food groups (including vegetables, fruits, grains, dairy products, meats) + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil (equivalent to 4 tablespoons; 2 tablespoons for lunch and 2 tablespoons for dinner) for 3 months
16286991|NCT04767230|Placebo Comparator|A heart-healthy diet|Recommendations for a heart-healthy diet, such as those of the American Heart Association for 3 months. These include eating at least 5 servings of vegetables and fruits daily, reduction in the consumption of sources of saturated and trans fats by avoiding the consumption of high-fat red meats and replacing them with low-fat meat or with poultry and fish, replacing low-fat dairy sources with regular or high-fat ones; consumption of regular vegetable oils such as canola and sunflower; reduction in salt consumption; and reduction in the consumption of simple sugars for 3 months
16286992|NCT04767217|Active Comparator|artemether-lumefantrine (ALN)|
16286993|NCT04767217|Active Comparator|dihydroartemisinin-piperaquine (DHA-PPQ)|
16287157|NCT04766034|Active Comparator|Discount|The grocery shopping simulation will include discount on eligible fruits and vegetables
16286996|NCT04767191|Active Comparator|dihydroartemisinin piperaquine|The drug is approved and in use by the Kenya Ministry of Health as the 2nd line treatment for malaria. The study is to assess the continued efficacy of the drug.
16286997|NCT04767178||Ibuprofen group|Infants that received oral ibuprofen were categorized into the ibuprofen group
16286998|NCT04767178||Paracetamol group|Infants that received oral paracetamol were categorized into the paracetamol group
16286999|NCT04767139||pre-intervention group|mothers included for the pre-intervention assessment of contraceptive prevalence rate in the selected health centers
16287000|NCT04767139||post intervention group|mothers included for the post-intervention assessment of contraceptive prevalence rate in the selected health centers
16287001|NCT04767113|Experimental|Heparin group|Continuous infusion of heparin was used to maintain the patency of CVC.
16287002|NCT04767113|Placebo Comparator|Control group|Continuous infusion of heparin was used at the corresponding speed.
16287003|NCT04767087|Active Comparator|Honey and Nigella sativa Arm|0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
16287004|NCT04767087|Placebo Comparator|Placebo Arm|empty capsule with sugar water
16287005|NCT04767074|Experimental|Non-pharmacological Cough control therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Sessions will be designed to target participants' needs and expectations according to the semi-structured theme.
~Session 1 General assessment Prescription of cough technique
~Session 2 Cough principles of cough Cough control
~Session 3 Breathing pattern retraining and laryngeal hygiene
~Session 4 Reinforcement of cough control therapies"
16287006|NCT04767061|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during period 4, we will again conduct a dose reduction until off of beta blockers."
16287007|NCT04767061|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
16287008|NCT04767048|Experimental|Experimental Arm|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
16287009|NCT04767048|Active Comparator|Control Arm|Tonsillectomy alone (unilateral or bilateral at the choice of the investigator)
16287010|NCT04767035|Active Comparator|MELT-100 3/25|MELT-100 3mg midazolam / 25 mg ketamine
16287011|NCT04767035|Active Comparator|MELT-100 2 x 3/25|MELT-100 2 doses of 3mg midazolam / 25mg ketamine
16287012|NCT04767035|Active Comparator|ketamine IV 18mg|
16287013|NCT04767035|Active Comparator|Midazolam IV 3.5mg|
16287016|NCT04767009|Experimental|SBRT for oligoprogressive NSCLC|
16287017|NCT04766996|Experimental|Prospective cases undergoing non-opioid drug regimen|Prospective study participants undergoing unilateral total hip replacement surgery and non-opioid drug regimen perioperatively
16287018|NCT04766996|No Intervention|Retrospective control underwent opioid drug regimen|Retrospective controls that underwent unilateral total hip replacement surgery and used opioid drug regimen perioperatively
16287019|NCT04766996|No Intervention|Professional Staff|Staff that participate in the implementation of the opioid free surgical protocol will be completing team assessment surveys seeking their opinion about interprofessional teamwork and communication.
16287020|NCT04766983||VAP - BAL positive|Clinically suspected VAP, microbiologically confirmed by BAL
16287021|NCT04766983||VAP - BAL negative|Clinically suspected VAP, not microbiologically confirmed by BAL
16287022|NCT04766983||NO VAP|No clinically suspected VAP during mechanical ventilation
16287023|NCT04766970|Active Comparator|Standardized assessment|
16287024|NCT04766970|Experimental|Telehealth assessment|
16287025|NCT04766957|Experimental|Idracare|The treatment will be applied 2 times a week, preferably at night before going to bed.
16287026|NCT04766944||Critically ill trauma patients of 50 years old and above|Patients of 50 years old and above admitted to the Montreal General Hospital intensive care unit for trauma
16287027|NCT04766931|Experimental|A1 FB2001 or Placebo|single dose
16287028|NCT04766931|Experimental|A2 FB2001 or Placebo|single dose
16287029|NCT04766931|Experimental|A3 FB2001 or Placebo|single dose
16287030|NCT04766931|Experimental|A4 FB2001 or Placebo|single dose
16287031|NCT04766931|Experimental|A5 FB2001 or Placebo|single dose
16287032|NCT04766931|Experimental|A6 FB2001 or Placebo|single dose
16287033|NCT04766931|Experimental|A7 FB2001 or Placebo|single dose
16287034|NCT04766931|Experimental|B1 FB2001 or Placebo|Once daily for 5 days
16287035|NCT04766931|Experimental|B2 FB2001 or Placebo|Once daily for 5 days
16287036|NCT04766918|Experimental|High molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with high molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
16287037|NCT04766918|Active Comparator|Low molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with low molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
16287038|NCT04766905|Experimental|Issa1|Dr.A.Sayed Issa and his team
16287039|NCT04766892|Experimental|Mavacamten (MYK-461)|
16287040|NCT04766879|Experimental|Spatial Repellent|Transfluthrin
16287041|NCT04766879|Placebo Comparator|Placebo|Inert ingredients
16287042|NCT04766866|No Intervention|Non-intervention or non-reveal group|Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery
16338095|NCT04413344|Active Comparator|Active|
16287043|NCT04766866|Experimental|Intervention group or reveal group|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
16287044|NCT04766853|Active Comparator|Dexamethasone|
16287045|NCT04766853|Experimental|Dexamethasone+Hyaluronic Acid|
16287046|NCT04766840|Experimental|IM73 CAR-T|"Drug: IM73 CAR-T Cells
~Fludarabine
~Cyclophosphamide"
16287047|NCT04766827|Experimental|albumin-bound paclitaxel combined with cisplatin (AP regimen)|Paclitaxel (albumin combined type) 260 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; Cisplatin: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles;
16287048|NCT04766827|Active Comparator|docetaxel combined with cisplatin (TP regimen)|docetaxel: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; cisplatin: 75 mg/m2, d1 every three weeks for a cycle, a total of dosing 2 cycles;
16287049|NCT04766814||Patient Group|40 women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
16287050|NCT04766814||Control Group 1|40 healthy women subjects between the ages of 50-80 year
16287051|NCT04766814||Control Group 2|40 healthy women subjects between the ages of 20-30 years
16287052|NCT04766775|Other|Application of Silver Diamine Fluoride onto the carious teeth surfaces|The patients will receive Silver Diamine Fluoride (SDF) treatment to the carious primary teeth. These are teeth with no sign or symptom, radiographically the deepest layer of the caries lesion does not involve the pulp, the inter-radicular area appears normal). Procedure: apply vaseline, isolate the tooth with a cotton roll, remove the food debris, and gross plaque on the tooth cavity with a spoon excavator, dry the tooth, apply the SDF (a clear, colorless solution) onto the tooth cavity. This application lasts for one minute. Take the urine and hair sample to assess the silver and fluoride levels. Take the urine sample before the SDF treatment, in the first and second 24 hours after the SDF treatment. Take the hair samples before the SDF treatment, followed by days 7,14,30,60,75, and 90 after the SDF treatment. Send the hair and urine samples to the laboratory to assess the silver and fluoride levels. If caries remains active, restore the SDF treated after the day 90 review.
16287053|NCT04766762|Experimental|Acupuncture combined with placebo group|Patients in this group will receive acupuncture combined with placebo.
16287054|NCT04766762|Other|Sham acupuncture combined with medication group|Participants in this group will receive sham acupuncture plus flunarizine hydrochloride.
16287055|NCT04766749|Experimental|Experimental|40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
16287056|NCT04766749|No Intervention|Control|A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
16287057|NCT04766736||Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
16287058|NCT04766736||Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
16287061|NCT04766710|Experimental|Community-based ART delivery (CAD)|The CAD model intervention will take place for 24 months. A total of 2000 registered stable people living with HIV will form into the CAD group. The investigators have developed the implementation guide, monitoring tools, quality assurance checklist, and lists of people living with HIV in selected ART clinics for the CAD model intervention. The first step will be to extract the data disaggregated by gender, age, and type of sub-populations, including adolescents, female entertainment workers, men who have sex with men, transgender women, and people who use drugs from the national database using the definitions introduced by the WHO. Once the list is completed with patient ART codes, a consultative meeting combined with the project orientation will be convened. Providers from the selected ART clinics and implementing partners at each site will divide stable people living with HIV into their respective groups based on the ART sites.
16287062|NCT04766710|Active Comparator|ART multi-month dispensing (MMD)|A total of 2000 registered stable people living with HIV will form into the control group and received standard services under the MDD model. The control-arm participants will visit the ART clinics and collect their ARVs from the facility-based staff.
16287063|NCT04766697|Experimental|Receive Intervention|All 20 couples will receive the 8-session adapted intervention.
16287064|NCT04766684|Experimental|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream|
16287065|NCT04766684|Active Comparator|L.M.X.4 cream with J-Tip saline injection|
16287066|NCT04766658|Other|Water Swallow Intervention First|Subjects will complete voice recordings after water swallows and then perform voice recordings after gargle phonation.
16287067|NCT04766658|Other|Gargle Phonation Intervention First|Subjects will complete voice recordings after gargle phonation and then perform voice recordings after gargle phonation.
16287068|NCT04766645||Covid patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with covid symptoms
16287069|NCT04766632|Experimental|one group|patients with high grade glioma
16287070|NCT04766619||Staff and stakeholders|For the longitudinal process evaluation - staff and stakeholders who have had direct contact or involvement with and have an understanding of OptmiseRx and/or PINCER will be invited to take part in an interview or focus group, an observation and/or complete a questionnaire. For the consolidated learning exercise - those who are in a position to influence the wider adoption of these interventions will be invited to take part in an interview or development workshop.
16287071|NCT04766619||Patients|Patients registered with a practice who have attended a consultation (or other related activity) for the PINCER intervention OR selected by their clinical care team OR attached to a patient group within a Clinical Commissioning Group (CCG) or practice OR patients identified through social media who have a long-term health condition and/or are taking any medication that requires them to have regular blood tests and have had a medication review in the past six month will be invited to take part in an interview or focus group.
16287072|NCT04766619||Public and patient representatives|For the consolidated learning exercise - patient and public representatives who have an understanding of the related medicines management issues in primary care will be invited to take part in an interview or workshop.
16287073|NCT04766593|Experimental|Oncological functional reeducation program|"It will consist of the following actions:
~Prescription of multimodal physical exercise: This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).
~Retraining in activities of daily living: Gradation and simplification of activities and training in energy saving techniques (EAT).
~Finally, an exhaustive daily record of the activity carried out by the patient will be carried out, from which it will be modified, adapting it to the clinical situation of the patient."
16287074|NCT04766593|Active Comparator|Prescription of multimodal physical exercise|This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The guideline will be to maintain a multimodal exercise to perform exercises of different characteristics, including aerobic exercises, balance exercises and low-load strength exercises for muscle groups, both in the upper quadrant and the lower quadrant. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).
16287075|NCT04766580|Experimental|Children with ADHD group|The same protocol is used for both groups
16287076|NCT04766580|Active Comparator|Children with no ADHD group|The same protocol is used for both groups
16287077|NCT04766567|Experimental|Serosal myomectomy|Patients with singleton pregnancy, who had serosal myomectomy during cesarean section
16287078|NCT04766567|Experimental|Endometrial myomectomy|Patients with singleton pregnancy, who had endometrial myomectomy during cesarean section
16287079|NCT04766567|Placebo Comparator|Control group|Patients with singleton pregnancy, who did not have myomectomy during cesarean section
16287080|NCT04766554|Active Comparator|Cerebral Oxymetry Monitoring|"The following procedures should be performed sequentially in the event of cerebral desaturation after 30 seconds:
~The positioning of the head, the presence of facial plethora, and bad position of catheters should be corrected;
~In case of arterial hypotension, the causal factors should be assessed and treated;
~In the presence of arterial hypoxemia, the causal factors should be assessed and treated to maintain a PaO2 > 150 mmHg;
~In the presence of hypercapnia, adjust the ventilation parameters avoiding hyperventilation;
~In the presence of anemia, the causal factors should be assessed, and the decision to undergo transfusion should also take into consideration the presence of tissue hypoperfusion;
~In cases of SvO2 below 70% and signs of hemodynamic instability, optimize fluid replacement and ventricular global contractility;
~Assess the increase of brain consumption of O2, avoiding the superficial level of anesthesia, hyperthermia, and tremors."
16287081|NCT04766554|No Intervention|Control Group|Patients will be treated according to the attending anesthesiologist, without the monitoring of cerebral oximetry, but to maintain a heart rate between 70 - 100 bpm, lactate levels <3 mmol/L and urine output> 0.5mL/Kg/h. In case of arterial hypotension the causal factors should be assessed and treated; in case of SvO2 below 70% and signs of hemodynamic instability, optimize volume replacement and global ventricular contractility through inotropic agents (epinephrine, dobutamine or milrinone); in the presence of anemia (Hb <6 to 7g/dL during CPB or Hb <8g/dL in the pre-CPB or post-CPB period), the causal factors should be assessed and the decision to transfuse should also take into account the presence of hypoperfusion tissue (increased lactate, low SvO2, acidosis); in episodes of bradycardia with hemodynamic instability, atropine may be used.
16287082|NCT04766528|Experimental|Mediterannen diet|The MED diet was abundant in fiber, micronutrients and plant-based proteins. The diet was rich in essential FA like monounsaturated fatty acids (MUFA) and n-3.
16287083|NCT04766528|Experimental|Canadian diet|The NAM diet had a high content in saturated fatty acids (SFA) and simple sugar and was low in fiber.
16287084|NCT04766502|Experimental|Blood sample (20ml) and Quality of Life Survey|
16287085|NCT04766489|Experimental|Complete Deongestive Therapy|Patients will be given complete decongestive therapy for 5 days a week and for a mean of 20 sessions. Each session will be of approximately 2 hours and 15 minutes in duration, although short stretch bandaging will be left on for 23 hours a day.
16287086|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 1|
16287087|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 2|
16287088|NCT04766476|Placebo Comparator|Placebo|
16287089|NCT04766463|Experimental|Treatment group A|
16287090|NCT04766463|Experimental|Treatment group B|
16287091|NCT04766463|Placebo Comparator|Treatment group C|
16287092|NCT04766463|Active Comparator|Treatment group D|
16287093|NCT04766450|Active Comparator|Group 1, NAC group|Group 1, NAC group (n=30): Patients will receive conventional therapy for diabetic neuropathy in addition to High Dose N-acetyl cysteine (2400 mg/day divided into two doses) daily for 3 months
16287094|NCT04766450|No Intervention|Group 2, Control group|Group 2, Control group (n= 30): Patients will receive conventional therapy for diabetic neuropathy alone for 3 months.
16287095|NCT04766437|Experimental|Prasugrel monotherapy|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
16287096|NCT04766424|Experimental|Behavioral sleep extension group|Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.
16338096|NCT04413344|Placebo Comparator|Placebo|
16287097|NCT04766424|Other|Health education|Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.
16287098|NCT04766411|Experimental|Unresisted sprint training|Participants will perform an acute training bout of unresisted sprints.
16287099|NCT04766411|Experimental|Resisted sprint training with load equal to 10% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 10% of body weight.
16287100|NCT04766411|Experimental|Resisted sprint training with load equal to 20% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 20% of body weight.
16287101|NCT04766411|Experimental|Control trial|Participants will perform no training protocol. They will only perform all the measurements.
16287104|NCT04766385|Experimental|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
16287105|NCT04766372|Experimental|Menu of physical activity options|"Participants in all 4 groups will receive this booklet with suggestions of ways to be physically active, e.g. YouTube workouts, cycling or jogging, sports, or design their own using a home-based exercise booklet. Participants are asked to do 3 exercise sessions of 30 minutes per week. Participants are asked to record what activity they did and the duration of the session using a method most convenient for them, e.g. notes on their phone, wall calendar or using an activity log template which we will provide.
~."
16287106|NCT04766372|Experimental|Physical activity programme|Participants in the second group with receive the activity menu (as described above) as well as a detailed physical activity programme. This programme includes supportive weekly text messages, access to live workouts and access to an online social community.
16287107|NCT04766372|Experimental|Individual behaviour change support|"Participants in the third group with receive the activity menu (as described above) as well as individual behaviour change support. Each participant is partnered with a trainee sport psychology (Activity Mentor) who they have weekly video calls with to support their health behaviour change."
16287108|NCT04766372|Experimental|Activity Programme & Behaviour Change Support|Participants in the fourth group will receive all of the above (exercise menu, live workouts, social community, support texts and weekly calls with an Activity Mentor).
16287109|NCT04766359|Experimental|Albumin-Bound paclitaxel combined with radiotherapy|"Albumin paclitaxel (100mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.
~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
16287110|NCT04766359|Experimental|Cisplatin combined with radiotherapy|"Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.
~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
16287111|NCT04766346|Experimental|Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form.
16287112|NCT04766333|Active Comparator|Healthcare Worker Focused Outreach Intervention Strategy|Healthcare Worker Focused Outreach Intervention Strategy
16287113|NCT04766333|Active Comparator|Community Organization Led Outreach|Community Organization Led Outreach
16287114|NCT04766320|Experimental|Tumor Infiltrating Lymphocytes (TIL)|1x10^9-3x10^11 in vitro expanded autologous TILs will be infused i.v. to patients with relapsed/refractory malignant gynecological tumors after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
16287115|NCT04766307|Experimental|experimental group|"Experimental group regimen:2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month）
~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
16287116|NCT04766307|Active Comparator|Control regimen group|"The control group regimen: 2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR
~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
16287117|NCT04766281|Active Comparator|MLC901 (NeuroAiD II)|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
16287118|NCT04766281|Placebo Comparator|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
16287119|NCT04766268|Experimental|PAE group|Patients with BPH with moderate lower urinary tract symptoms fulfilling the inclusion criteria and exclusion criteria will be enrolled in the trial to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
16287120|NCT04766255|Active Comparator|Control Group|Implant placement and prosthetic rehabilitation of the missing tooth
16287121|NCT04766255|Experimental|SCTG group|Implant placement, soft tissue augumentation of Connective Tissue Graft (from the palate) (SCTG) at the implant site and prosthetic rehabilitation of the missing tooth.
16287122|NCT04766255|Experimental|CM group|Implant placement, soft tissue augumentation of porcine collagen matrix (CM) at the implant site and prosthetic rehabilitation of the missing tooth.
16287123|NCT04766255|Experimental|PADM group|Implant placement, soft tissue augumentation of Porcine acellular dermal matrix (PADM) at the implant site and prosthetic rehabilitation of the missing tooth.
16287124|NCT04766242|Experimental|Intervention group|The intervention group will receive 10 healing session of 45-60 minutes as an adjunct to usual care, approximately once a week.The usual care will consist of the treatment plan made by their GP when they were diagnosed with moderate depression.
16287125|NCT04766242|Other|Control group|The control group will receive usual care as prescribed by their GP when they were diagnosed with moderate depression.
16287126|NCT04766229|Experimental|Single Arm|All participants in single arm study
16287127|NCT04766216|Experimental|Warfarin Patient Self-Management|Patients managing decisions relating to warfarin dose and next INR test based on the results of current INR test
16287128|NCT04766216|Active Comparator|Historical Control|Patients managed by anticoagulation providers prior to transitioning to warfarin patient self-management
16287129|NCT04766203|No Intervention|Global screening of high-performance athletes for REDS|This arm collects data with an online survey to assess prevalence and signs and symptoms of REDS in elite female and male elite and recreational athletes and para-athletes over the age of 15 years across the world.
16287130|NCT04766203|No Intervention|Basic screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline blood sample and potentially (where abnormalities are present) a follow-up 6 months later.
16287131|NCT04766203|No Intervention|Advanced screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline test for bone density (DXA scans), resting metabolic rate and exercise testing. Potentially (where abnormalities are present) a follow-up 6 months later.
16287132|NCT04766203|Experimental|Treatment of Canadian athletes with REDS: a holistic intervention arm|In this arm, varsity level to elite Canadian athletes and para-athletes with REDS will participate in a nutritional intervention aiming to improve energy availability and thus, REDS status.
16287133|NCT04766190|Other|Group 1: Usual Care|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.
~The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study."
16287134|NCT04766190|Other|Group 2: The DISCO App|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.
~The patient will be shown an iPad with an app while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study."
16287135|NCT04766190|Other|Group 3: The DISCO App + Booster|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.
~The patient will be shown an iPad with an app while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app."
16287136|NCT04766177|Experimental|bumetanide group|Bumetanide a dose of 0.5 mg twice per day
16287137|NCT04766177|Placebo Comparator|Placebo|Placebo twice daily
16287138|NCT04766164||Males and Females ages 18-26|Participants between the ages of 18-26 will complete a survey
16287139|NCT04766164||Males and Females ages 27-45|Participants between the ages of 27-45 will complete a survey
16287140|NCT04766151|Experimental|Transdermal glyceryl trinitrate patches|
16287141|NCT04766151|Placebo Comparator|Transdermal placebo patches|
16287142|NCT04766138|Experimental|Fecobionics studies|Single-arm study
16287143|NCT04766125|Other|Standard adverse event information|
16287144|NCT04766125|Other|Elaborated adverse event information|
16287145|NCT04766112|Experimental|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training which consist of 10 positions
16287146|NCT04766112|Active Comparator|Group II|Group B will receive yang style Tai chi exercise which consist of 10 positions
16287147|NCT04766099|No Intervention|Standard Treatment|Standard bedside coaching by labor and delivery staff
16287148|NCT04766099|Experimental|Educational Video|Patients will watch the provided coaching video in addition to standard bedside coaching by labor and delivery staff
16287149|NCT04766086|Experimental|GBS6 and Tdap|Hexavalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
16287150|NCT04766086|Experimental|GBS6 and Placebo|Hexavalent group B streptococcus vaccine and Placebo
16287151|NCT04766086|Experimental|Placebo and Tdap|Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
16287154|NCT04766047|Active Comparator|DEXMEDETOMIDINE AND AKI|The patients of the group undergoing EVAR under general anesthesia will receive dexmedetomidine intraoperatively.
16287155|NCT04766047|No Intervention|CONTROL AND AKI|The patients of the group undergoing EVAR under general anesthesia will not receive dexmedetomidine intraoperatively.
16287156|NCT04766034|Sham Comparator|Control|The grocery shopping simulation will not include any discounts or bundles
16287160|NCT04766021|Placebo Comparator|Placebo|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
16287161|NCT04766021|Experimental|100 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
16287162|NCT04766021|Experimental|150 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
16287163|NCT04766021|Experimental|200 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
16287164|NCT04766008|Experimental|Metformin continuation|
16287165|NCT04765995|Experimental|HZBio1 0.96mg/kg|Participants will receive intramuscularly 0.96 milligram per kilogram (mg/kg) of HZBio1.
16287166|NCT04765995|Experimental|HZBio1 3mg/kg|Participants will receive intramuscularly 3 milligram per kilogram (mg/kg) of HZBio1.
16287167|NCT04765995|Experimental|HZBio1 6mg/kg|Participants will receive intramuscularly 6 milligram per kilogram (mg/kg) of HZBio1.
16287168|NCT04765995|Experimental|HZBio1 9mg/kg|Participants will receive intramuscularly 9milligram per kilogram (mg/kg) of HZBio1.
16287169|NCT04765995|Experimental|HZBio1 12mg/kg|Participants will receive intramuscularly 12 milligram per kilogram (mg/kg) of HZBio1.
16287170|NCT04765982|Active Comparator|patients with less than 80% time in range|Better control group
16287171|NCT04765982|Placebo Comparator|patients with more than 80% time in range|poor control group
16287172|NCT04765969||Severe COPD patients|GOLD C and D group patients
16287173|NCT04765956|Experimental|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
16287174|NCT04765943||Study population|Patients with LVEF equal to or less than 40% determined by echocardiogram on the 4th day after acute myocardial infarction.
16287175|NCT04765930|Active Comparator|PRP Injection|Half of the face
16287176|NCT04765930|Placebo Comparator|Saline injection|Other half of the face
16287177|NCT04765917|Active Comparator|Selected Physical Therapy group|The Control group will receive a selected physical therapy program for 60 minutes, 3 times/week for 3 successive months including the following exercises
16287178|NCT04765917|Experimental|Motor imagery training|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 30 min in addition to 30 minutes motor imagery training program
16287179|NCT04765904|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding drilling
16287180|NCT04765904|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a topical therapeutic agent for managing caries lesions in young children
16287181|NCT04765891|Experimental|Positional Release Therapy|Participants were randomly assigned the positional release therapy treatment group. The participants underwent the treatment.
16287182|NCT04765891|Experimental|Therapeutic Massage|Participants were randomly assigned the therapeutic massage treatment group. The participants underwent the treatment.
16287183|NCT04765878|Experimental|Humidification|
16287184|NCT04765865||Baseline (Years 1-2)|Participants(n=3060) will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a baseline STEPs survey(n=2160) , 24-hour and spot urine assessments(n=450) , and 24-hour dietary recall assessment(n=450) .
16287185|NCT04765865||Interim (Year 3-4)|Participants(n=2610) will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a baseline STEPs survey(n=2160) and 24-hour and spot urine assessments(n=450).
16287186|NCT04765865||Final (Years 5-6)|Participants(n=3060) will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a baseline STEPs survey(n=2160) , 24-hour and spot urine assessments(n=450) , and 24-hour dietary recall assessment(n=450) .
16287187|NCT04765852|Experimental|Experimental Group 1|High dose probiotic supplement and maltodextrin as the excipient
16287188|NCT04765852|Experimental|Experimental Group 2|Low dose probiotic supplement and maltodextrin as the excipient
16287189|NCT04765852|Placebo Comparator|Control Group|Placebo supplement containing only maltodextrin but having the same appearance as the probiotic supplements
16287190|NCT04765839|Experimental|Intervention Arm - Receives COVID-19 Vaccine messages|Group to receive COVID-19 Vaccine messages during the first two weeks of the study.
16287191|NCT04765839|Experimental|Delayed Intervention Arm|Group to receive COVID-19 Vaccine messages during the last two weeks of the study.
16287192|NCT04765826|Experimental|high dose oral steroids|(20 patients) will receive high dose oral mini pulse steroids (dexamethasone 5 mg on two consecutive weekly days for 3 months).
16287193|NCT04765826|Experimental|low dose oral steroids|(20 patients) will receive low dose oral mini pulse steroids (2.5mg dexamethasone on two consecutive weekly days for 3 months
16287194|NCT04765826|Experimental|topical treatment|(20 patients) chosen lesions of comparable size and location in each patient in this group will receive either; super potent topical steroids once every other day, Tacrolimus ointment twice daily for 3 months, or nothing to serve as a control.
16287195|NCT04765813|Experimental|CBT and active smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
16287196|NCT04765813|Active Comparator|CBT and control smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with a control App
16287197|NCT04765800|Active Comparator|Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)|focus on core psychodynamic treatment principles (Leichsenring & Steinert, 2018); no use of imagery-based interventions
16287198|NCT04765800|Experimental|Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)|regular sessions with and focus on work with guided affectice imagery
16287199|NCT04765787||Painful musculoskeletal disorders in random order|Nuberol Forte® (Paracetamol 650 mg + Orphenadrine 50 mg) for the symptomatic management of the painful musculoskeletal disorders one tablet three times a day or as per physician discretion or as per severity of pain and treatment duration is 7-10 days
16287200|NCT04765774|Experimental|The Effect of Expressive Touch and Music Applied After Lumbar Disc Herniation Surgery|
16288007|NCT04760145|Active Comparator|Control Group|Multicomponent exercise without blood flow restriction
16287201|NCT04765761|Active Comparator|PLMA with Introducer'|PLMA placed in position with the help of the introducer-tool and then the introducer-tool retained in place throughout the institution and duration of positive pressure ventilation.
16287202|NCT04765761|Active Comparator|PLMA without Introducer|PLMA placed in position with the help of the introducer-tool and then the introducer-tool removed before institution of positive pressure ventilation.
16287203|NCT04765748||TAAA patients with Cytosorb|Patients suffering from a TAAA larger than 55mm
16287204|NCT04765748||TAAA patients without Cytosorb|Patients suffering from a TAAA larger than 55mm
16287205|NCT04765735|Experimental|Open-loop testing, then Closed-loop testing|Subjects receive Open-loop testing, then Closed-loop testing (Spinal Cord Stimulation - SCS Therapy)
16287206|NCT04765735|Experimental|Closed-loop testing, then Open-loop testing|Subjects receive Closed-loop testing, then Open-loop testing (Spinal Cord Stimulation - SCS Therapy)
16287207|NCT04765722|Experimental|Mepolizumab arm|Mepolizumab Dosage form: 1ml pre-filled syringe Dosage: 100mg Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
16287208|NCT04765722|Placebo Comparator|Placebo arm|Normal Saline (0.09% normal saline) Dosage form: 1ml pre-filled syringe Dosage: n/a Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
16287209|NCT04765709|Experimental|BRIDGE single arm|"Treatment plan:
~Part 1: induction with durvalumab plus histology-based chemotherapy regimen.
~Part 2: patients with a sufficient tumor shrinkage to be considered eligible for part 2 and they will be treated concomitantly with durvalumab and radiotherapy.
~Part 3: patients with partial response or stable disease after part 2 will be eligible for durvalumab maintenance, for up to 2 years or until disease progression or unacceptable toxicity."
16287210|NCT04765696||Persons 55 years or older considering relocation|No intervention is administered.
16287211|NCT04765683||Patients|Attending surgical outpatients
16287212|NCT04765683||Surgeons|Running surgical outpatients
16287213|NCT04765670|Experimental|Instrument Assisted Soft Tissue Mobilization|"The instruments will be applied to the soft tissue at 30º-60º angles, with multi-directional stroking movements. Instrument Assisted Soft Tissue Mobilization will be applied to the trapezius and sternocleidomastoideus muscles of the participants for 90 seconds."
16287214|NCT04765670|Experimental|Kinesiotape Application|The application will be made from the insertion of the upper trapezoidal muscle to its origo . During taping, the patient will be allowed to sit in an upright position in a chair with a back, with the scapula fixed, without supporting the arms. Before taping, the patient will be positioned with the shoulder in adduction and the head in lateral flexion towards the contralateral side. The patient will be asked to perform shoulder abduction against resistance, and the insertion area of the upper trapezius fibers will be palpated. The initial 2-3 cm part of the band will be glued to the lateral of the acromion without stretching, after full (100%) stretching is applied to the 2-3 cm part of the band from the insertion area of the upper trapezoid fibers, the patient's head is rotated to the affected side and the arm part of the band is stretched along the muscle fibers. it will be glued up to the hairline without doing it.
16287215|NCT04765657|Experimental|inclisiran sodium 300 mg|Subcutaneous injection
16287216|NCT04765657|Placebo Comparator|Placebo|Subcutaneous injection
16287217|NCT04765644|Active Comparator|Celecoxib|"Phase 1: Twenty volunteers will receive celecoxib 200 mg, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.
~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
16287218|NCT04765644|Placebo Comparator|Placebo|"Phase 1: Twenty volunteers will receive a placebo capsule, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.
~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
16287219|NCT04765631||Patients with Type 2 diabetes|Subjects from 3 cohorts (QUALYOR, OFELY, STRAMBO) presenting type 2 diabetes
16287220|NCT04765631||Control subjects without Type 2 diabetes|Controls patients from 3 cohorts (QUALYOR, OFELY, STRAMBO) without type 2 diabetes
16287221|NCT04765605|Experimental|WeFlow-Tbranch Stent Graft System|Participants will be treated with WeFlow-Tbranch Stent Graft System
16287222|NCT04765592|Experimental|WeFlow-Arch Modeler Embedded Branch Stent Graft System|Participants will be treated with WeFlow-Arch Modeler Embedded Branch Stent Graft System
16287223|NCT04765579||4in1|4in1 block will be applied in the operation room
16287224|NCT04765579||medical|medical analgesics will be applied in the service
16287225|NCT04765553|Active Comparator|Emapalumab|Emapalumab i.v infusion
16287226|NCT04765553|Placebo Comparator|Placebo|Saline i.v. infusion
16287227|NCT04765540|Active Comparator|T1: Business as Usual (BAU)|Handwashing station plus standard BRAC programming, i.e. in-person community WASH (water, sanitation and hygiene) demonstrations conducted in households/communal areas, and sticker signs/posters placed on walls in the 'catchment area' of the handwashing station, alerting people to the stations and roughly pointing the way.
16287228|NCT04765540|Experimental|T2: BAU + Low Intensity Nudges|"T1 plus a bundle of 'low-intensity' passive interventions, including:
~Large mirrors installed above handwashing station sinks to attract more people to the station
~7 to 8 large hand-shaped signposts pointing to the station and leading up to the station, placed on the ground in the vicinity of the station, starting from the nearest 'busy spot'"
16288121|NCT04759378|Experimental|IBS patients who have upper GIT symptoms|
16287229|NCT04765540|Experimental|T3: BAU + High Intensity Activities|"T1 plus an additional bundle of 'high-intensity' active interventions delivered for three weeks, including:
~Free soap and free facemasks provided to handwashing station users in regular giveaways at key times, along with encouragement to return to the station and to spread the word.
~A 'community message board' along with encouragement to make a mark on a scoreboard at the top of the board before/after use of the station to increase commitment and as an additional social cue. This will also visually show cumulative number of uses as a persistent cue of the social norm.
~General encouragement to use the stations, provided by the intervention delivery team while they are at the station. Intervention team members are equipped with a loudhailer to assist this.
~In addition, village handwashing station committees will be encouraged to try out their own ideas for encouraging more people to use the stations."
16287230|NCT04765527|Experimental|Turmeric|Dietary supplement, Turmeric Strength for Joint, containing turmeric root extract (with 350 mg curcumin), black pepper extract, boswellia gum resin extract, devil's claw root extract, and ginger root; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
16287231|NCT04765527|Placebo Comparator|Placebo|Placebo tablets; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
16287232|NCT04765514|Active Comparator|Standard Arm: TMZ with concurrent RT (combined modality arm)|"Patients will receive a total of 21 days of Temozolomide (TMZ), with 15 days of TMZ administered daily with concurrent RT. TMZ will be delivered at a dose of 75 mg/m2, given daily with RT for 15 days, one hour before each session of RT.
~After a 4-week break, patients will receive six cycles of adjuvant TMZ according to the standard 5-day schedule (days 1-5) every 28 days, up to 6 cycles as tolerated by the patient. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events, intractable nausea or fatigue."
16287233|NCT04765514|Experimental|Biomarker based treatment|"MGMT (+) Temozolomide monotherapy: Patients will receive Temozolomide (TMZ) at a dose of 75 mg/m2 daily for 21 consecutive days. This will be followed by six cycles of TMZ according to the standard 5-day schedule (days 1-5) every 28 days. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events. Dose will be determined using body surface area (BSA) calculation.
~MGMT methylation (-) RT monotherapy: Participants will receive radiation treatment with 40Gy / 15 fractions over a period of 21 days (3 weeks)."
16287234|NCT04765501||Patients group|Individuals with headache
16287235|NCT04765488|Experimental|Study group|"A group of patients in relation to whom the Wash In / WashOut procedure will be applied. In this group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
16287236|NCT04765488|No Intervention|Control group|A group of patients in relation to whom will be applied the traditional method of recovery from anesthesia. In this group during the period of awakening we stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness.
16287237|NCT04765475|Experimental|MotivationaI Interviewing Group|Participants in this study group will receive a brief, culturally appropriate, and age-tailored motivational interviewing (MI) intervention targeting facilitators and barriers to appropriate testing, isolation, and care-seeking among young adults and elders. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental, or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
16287238|NCT04765475|Experimental|COVID-19 Symptom Monitoring System Group|Participants in this study group will receive daily COVID-19 symptom (CS) text-based monitoring system to prompt more rapid testing at the onset of symptoms. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
16287239|NCT04765475|Experimental|MotivationaI Interviewing and COVID-19 Symptom Monitoring System Group|Participants in this group will receive both motivational interviewing and daily COVID-19 symptom (CS) text-based monitoring system. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
16287240|NCT04765475|Other|Control Group|Participants in this group will only receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19
16287241|NCT04765462|Experimental|Allogeneic γδ T cell Group|Subjects will receive allogeneic γδ T cells with/without chemotherapy.
16287242|NCT04765449|Experimental|ARM A: Covid-19 Patients Receiving CTLs|Patients who have an HLA antigen in common with COVID-19 fighting T cells will be admitted to the hospital and receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. The patients will be monitored for side effects for at least 4 days prior to discharge. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
16287741|NCT04762017|Experimental|Multidose ACT-01|Once daily IV infusions of ACT-01 (n=18) for 5 consecutive days
16287243|NCT04765449|No Intervention|ARM B: Covid-19 Patients Not Receiving CTLs|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.
16287244|NCT04765436|Experimental|PTX-COVID19-B|Participants, 45 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of PTX-COVID19-B vaccine in doses of 16 μg, 40 μg and 100 μg on Day 1, followed by a second dose on Day 28, respectively.
16287245|NCT04765436|Placebo Comparator|Placebo|Participants, 15 healthy adults 18 to 64 years of age, will receive 1 IM injection of matching placebo on Day 1, followed by a second dose on Day 28.
16287246|NCT04765423|Experimental|NaF PET/CT scan and F-18 fluciclovine PET/CT|"Visit 1: Participant receives a whole body [F-18] NaF PET/CT (diagnostic study)
~Visit 2: Participant receives a whole body [F-18] fluciclovine PET/CT within 3 weeks of Visit 1"
16287247|NCT04765410||Patients with solid pancreatic masses|Patients with solid pancreatic masses
16287248|NCT04765397|Active Comparator|Group M|Patients are in this group with monopolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
16287249|NCT04765397|Active Comparator|Group B|Patients are in this group with bipolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
16287252|NCT04765371|Active Comparator|DEXAMETHASONE Arm|Patients will take 6 mg per day of Dexamethasone during 10 days
16287253|NCT04765371|Active Comparator|PREDNISOLONE Arm|Patients will take 60 mg per day of Prednisolone during 10 days
16287254|NCT04765358|Other|All Participants|All participants will be provided with a commercially available CGM system. Training and data collection for the study will be completed remotely. After initial CGM training (initiation of unblinded CGM use or initial training with virtual clinic) has been completed, participants will continue to be followed by the virtual clinic team for approximately six months. Psychosocial screening questionnaires are administered at enrollment and during follow up. The virtual clinical team member will follow up with the study participant if there is an elevated score on the psychosocial screening questionnaires. After the initial six months of follow up, participants who decide to continue to use CGM will be asked to extend follow up and complete questionnaires, submit HbA1c samples, and share data. During the extended follow up phase, participants will be able to contact the virtual clinic with questions or to request assistance as needed.
16287257|NCT04765332||Included patients|Fill patient questionnaires at inclusion visit, around 3 months and 12 months
16287258|NCT04765319||Vets|Veterans receiving care from the PTSD Clinical Team at the Salt Lake City VAMC. All participants are adults with a diagnosis of PTSD. This study plans on reviewing data collected as part of standard clinical practices. The study will have no impact on the treatment provided to the patient.
16287259|NCT04765306|Active Comparator|Traditional Direct Fascial Closure|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed under traditional direct visualization without laparoscopic guidance using a single interrupted suture of 0-vicryl.
16287260|NCT04765306|Active Comparator|Fascial Closure Device|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.
16288122|NCT04759365|Experimental|ASN51|ASN51 will be administered as an oral capsule
16287261|NCT04765293|Experimental|Gravity group|"GRAVITY® system exercise is conducted on a machine. The tasks were non-weight bearing, and the only external load was the body mass of the trainee. The degree of unloading (the level of exercise) was chosen depending on the patient's body mass, their current health and the difficulty of the exercise. The machine allowed for exercising any chosen muscle group at chosen setting of the bench, platform and ropes. GRAVITY® system exercise aimed at general posture improvement and at strengthening the desired movement path, along with strengthening the deep spinal and abdominal muscles.
~GRAVITY therapy group had therapy twice a week for 4 weeks for 40 minutes that made 2x40 minx 4 weeks=320 minutes."
16287262|NCT04765293|Active Comparator|Control group|Control group had standard, two weeks ambulant every day physical therapy sessions ( laser therapy, cryotherapy, magnetotherpy, TENS and interference currents), 5 times a week 30 min, that is 10 sessions 30 min x10=300 min.
16287263|NCT04765280||Patients with chronic musculoskeletal pain|Patients with any musculoskeletal pain for at least 3 months
16287264|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Zinc.|Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma
16287265|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Vitamin D|Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals
16287266|NCT04765267|Other|Topical Corticosteroid|Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm
16287267|NCT04765254||control group|COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health
16287268|NCT04765254||diabetic group|COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs
16287269|NCT04765241|Experimental|mHealth Physical Activity Intervention|The intervention arm will receive a 12 month mobile health (mHealth) physical activity intervention with a goal of increasing their moderate-vigorous intensity physical activity levels by 90 minutes per week above baseline
16287270|NCT04765241|No Intervention|Control|Controls will receive general health education materials
16287271|NCT04765228|Experimental|Pegylated liposomal doxorubicin + Anlotinib|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
16287272|NCT04765215||Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine|
16287273|NCT04765215||Healthy volunteers who received two doses of coronavac vaccine|
16287274|NCT04765202|Experimental|All participants|"Each participant will receive both treatments.
~On each participant, similar wounds will be identified as treatment sites.
~Treatment sites will be randomized to receive either AG Tx (control) or SOMA Tx (experimental)."
16287275|NCT04765189|Placebo Comparator|Placebo|
16287276|NCT04765189|Experimental|Verum A|
16287277|NCT04765189|Experimental|Verum B|
16287278|NCT04765189|Experimental|Verum C|
16287279|NCT04765163||physician group with assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group using assistive equipment
16287280|NCT04765163||Physician group without assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group without assistive equipment
16287281|NCT04765150||Observational (electronic health record review, 3 T MRI)|"RETROSPECTIVE: Patients' medical records are reviewed.
~PROSPECTIVE: Patients undergo additional 3T MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours."
16287282|NCT04765137|Experimental|Atorvastatin 40 mg|Participants receive 40 mg atorvastatin orally daily in the evening.
16287283|NCT04765111|Experimental|Treatment (acalabrutinib, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 3-4 hours on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2-12, 14, 18, 20, 22, and 24. Cycles repeats every 28 days for up to 24 months or until complete remission is achieved in the absence of disease progression or unacceptable toxicity.
16287284|NCT04765098|Active Comparator|Etoposide|
16287285|NCT04765098|Experimental|Tamoxifen|
16287286|NCT04765085|Experimental|CBIT Group|Patients in this group would only receive the CBIT treatment.
16287287|NCT04765085|Experimental|Drug therapy Group|Patients in this group would only receive the drug therapy.
16287288|NCT04765072|Experimental|Survivorship care|Participants in rural areas will receive a telehealth (providing health-related services through electronic communication technologies) survivorship care plan in combination with assistance from a patient navigator.
16287289|NCT04765059|Experimental|Treatment Arm A|All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
16287290|NCT04765059|Placebo Comparator|Treatment Arm B|All randomized patients will receive placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
16287291|NCT04765046|Other|BIS™ System|Enrolled subjects who are undergoing a standard of care elective surgery under general anesthesia, will be equipped with the BIS system to non-invasively measure and interpret brain waive activity directly related to the effects of anesthetic agents during the surgery duration.
16287292|NCT04765033|Active Comparator|5% Hypertonic saline|5% hypertonic saline nebuliser 4 mls twice in a day for 3 months
16287293|NCT04765033|Placebo Comparator|Placebo|0.9% saline nebuliser 4 mls twice in a day for 3 months
16287294|NCT04765020|Experimental|Intervention group|12 weeks moderate to high-intensity exercise program
16287295|NCT04765020|No Intervention|Control group|exercise recommendations
16287296|NCT04765007|Experimental|Mindfulness group|This arm will be treated with a mindfulness-based stress reduction therapy.
16287297|NCT04765007|Other|Control group|This arm will be treated with a minimal intervention.
16287351|NCT04764630|Experimental|B. Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
16287298|NCT04764994|Active Comparator|Control Group|"Participants who will participated in the control group will receive a conventional physical therapy program for two hours. It will include two parts, each of them will be one hour and 15 minutes rest in between. The first part will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises. The second part will include: arm-reaching tasks, arm-hand tasks, manipulative tasks (grasping and release activities) and upper limb self-dependent tasks and the inclusion of the more affected upper limb in functional tasks of daily living activities.
~The conventional treatment program will be applied for both groups by therapists, experienced in stroke rehabilitation.
~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
16287299|NCT04764994|Experimental|Study Group|"Participants of study group will receive two hours treatment program that will include three parts, the first and the second parts (similar to that will be applied for participants in control group) will be together for one hour following by 15 minutes rest, then the third part will apply for one hour. The third part of the program will be one hour virtual reality intervention program by using Armeo Spring to simulate a range of upper limb tasks related to arm-reaching to target, reach and grasp (arm-hand activities) and manipulative tasks through using different games and soft-wares.
~The conventional treatment part of the program will be applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program will be applied by another experienced physiotherapists, who are well trained in using Armeo Spring System.
~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
16287300|NCT04764981|Experimental|Experimental Group 1: Essences Oils|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19 that will be submitted to clinical exams, olfactory test and MRI imaging, after that, participants will undergo an olfactory training with essences oils. Each participant in this group will receive a kit with four 30 ml bottles, each containing a circular piece of watercolor paper soaked in one of the four essences oils (rose, eucalyptus, lemon and cloves) used in olfactory training, a manual to make the olfactory training at home and a self-assessment diary which should be filled weekly. Each participant of this group will use the training kit for three months, the olfactory training consists of inhaling each of the substances for 30 seconds, with an interval of 30 seconds between them, twice a day, upon waking up and before bed, the participants will be reassessed with CCCRT after each month of training. The results of this group will be compared with the other groups.
16287301|NCT04764981|No Intervention|Experimental Group 2: Clinical follow-up|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19. that will be submitted to clinical exams, olfactory test and MRI imaging, after three months they will be reassessed.
16287302|NCT04764981|No Intervention|Control Group|The individuals of this group are 50 healthy individuals, without previous COVID-19 infection, that will be submitted to clinical exams, olfactory test, MRI imaging and the participants will be tested for the ability to identification of the essence oils utilized by Experimental group 1.
16287303|NCT04764968|No Intervention|Usual care|During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
16287304|NCT04764968|Experimental|Dasiglucagon|During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.
16287305|NCT04764955|Placebo Comparator|Group A (Placebo)|Prenatal Period 0 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
16287306|NCT04764955|Experimental|Group B (4200:0 IU/week)|Prenatal Period 4200 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
16287307|NCT04764955|Experimental|16800:0 IU/week|Prenatal Period 16800 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
16287308|NCT04764955|Experimental|28000:0 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
16287309|NCT04764955|Experimental|28000:28000 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 28000 IU/week (delivery-6 months postpartum)
16287310|NCT04764942|Experimental|Arm A (pomalidomide, selinexor, dexamethasone, carfilzomib, carfilzomib)|Patients receive selinexor PO and dexamethasone PO on days 1, 8 15, and 22, carfilzomib IV on days 1, 8, and 15, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
16287311|NCT04764942|Experimental|Arm B (selinexor, dexamethasone, pomalidomide)|Patients receive selinexor PO and dexamethasone PO on days 1, 8, 15, and 22, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
16287312|NCT04764929|Experimental|Helmet CPAP|Patients in the Pediatric Intensive Care Unit (PICU) already receiving CPAP through a facemask or nasal prongs or mask for at least four hours but no more than 48 hours will be transitioned to the Vyatil nonpowered oxygen tent system (Rochester, NY) by trained respiratory therapists per the manufacture's instructions: patient's neck circumference will be measured with a soft tape measure to ensure appropriate sizing. The helmet will be connected to at least 30 liters per minute of high flow medical air with an oxygen blender. The expiratory limb will be attached to the positive end expiratory pressure (PEEP) valve (initially set at 5 centimeters of water pressure) connected to a high-efficiency particulate air (HEPA) filter to prevent any viral particles from being released into the environment. A disposable manometer will be used to measure the pressure within the helmet. Once the flow to the helmet interface is on, the helmet will be sealed and secured with the system's arm straps.
16287313|NCT04764916|Experimental|Exparel/Intervention group|Will receive 10mL of standard 0.5% bupivacaine followed by 10mL of liposomal bupivacaine as adductor canal field block preoperatively
16287314|NCT04764916|Active Comparator|Standard of Care group|Will receive 20mL of standard 0.5% bupivacaine as adductor canal field block preoperatively
16287315|NCT04764903||LUTS/Nocturia|Patients with LUTS / Nocturia
16287316|NCT04764890|Experimental|Electroacupuncture and manual therapy|Electroacupuncture in several points and manual therapy in the lumbar spine
16287317|NCT04764890|Active Comparator|Manual therapy|Manual therapy in the lumbar spina
16287409|NCT04764253|Active Comparator|Usual care + Digital Self-Monitoring|
16287318|NCT04764877|No Intervention|Standard Care|Standard teaching and physical exam for any patient that would be seen at our Hilltop Primary Care center asthma clinic. This included baseline PFTs. FOR THIS STUDY a second set of PFTs were obtained at the end of the visit
16287319|NCT04764877|Experimental|OMT arm|As above BUT with the addition of standardized OMT focusing on lung functionality. OMT provided by either our OMM attending at that time (Dr Wolf) or residents trained by her for this study (Drs. Regan, Jones, Pe and Bryant)
16287320|NCT04764864|Active Comparator|Angioembolization|
16287321|NCT04764864|Active Comparator|Preperitoneal Pelvic Packing|
16287322|NCT04764851|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days
~Cohort 1 Probe Cocktail given on 2 separate days:
~midazolam: 1 µg infused IV
~caffeine: 200 mg oral tablet
~omeprazole: two 20 mg oral tablets
~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
16287323|NCT04764851|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days
~Cohort 2 Probe Cocktail given on 3 separate days:
~midazolam: 10 µg/mL given as 1mL oral solution.
~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution
~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
16287324|NCT04764851|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days
~Cohort 3 Probe Cocktail given on 2 separate days:
~- bupropion: 100mg oral tablet"
16287325|NCT04764838|Experimental|Intervantion|Pregnant Yoga
16287326|NCT04764838|No Intervention|Control|The clinic will receive routine care
16287327|NCT04764825|Experimental|Methadone, induction|"Patients receive methadone 0.15-0.2 mg/kg ideal bodyweight 10 minutes prior to surgery start (Syringe A).
~45 minutes before expected extubation patients will receive saline (syringe B)."
16287328|NCT04764825|Experimental|Methadone, end of surgery|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive methadone 0.15-0.2 mg/kg ideal bodyweight (syringe B).
16287329|NCT04764825|Active Comparator|Morphine|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive morphine 0.15-0.2 mg/kg ideal bodyweight (syringe B).
16287332|NCT04764786|Experimental|EVOO+POLY|Acute test meal
16287333|NCT04764786|Active Comparator|OO-POLY|Acute test meal
16287334|NCT04764773||Case|Patient who had COVID19 infection
16287335|NCT04764773||control|healthy volunteer who were age and sex matched with our patients
16287336|NCT04764760|Other|Phase 1:Study role tissue tensile strength|The tensile strength of the orifice of Frauchad was augmented by implantation of a Accordion fold shaped prosthesis.
16287337|NCT04764760|Other|Phase 2:Curative implantation of a custom designed bio-mechanically compatible Tensiflex prosthesis|The wing shaped custom designed tensiflex prosthesis in the groin was impanted as a curative technique since it provided seamless augmenation of the tensile tissue strength.
16287338|NCT04764734|Experimental|PSG and NightOwl|During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with the informed consent form. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
16287339|NCT04764721|Experimental|Patients enrolled in Neurocog-Covid study in Nancy hospital|Young patients (< 65 year old) who contracted VIDOC 19 and were hospitalized for less than 7 days during the first wave, and who present cognitive disorders may be definitively included in the Neurocog-Covid study if their neuropsychological assessment is abnormal. They will then have a prescription for a cerebral MRI and will be enrolled in the TEP-Covid study. If they accept, they will receive a 18F-FDG PET-CT .
16287340|NCT04764708|Active Comparator|Control Group|Cognitive behavioral therapy plus standard psychopharmacological treatment.
16287341|NCT04764708|Experimental|Experimental Group|A Third Wave Cognitive Therapy that integrates Compassion Focused Therapy and Metacognitively Oriented Psychotherapy.
16287342|NCT04764695|Experimental|Patients diagnosed with ALL with individualized nutritional treatment|As it is a pre-test / post-test design, the child himself will be the control at the end of the intervention. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
16287343|NCT04764669|Experimental|DLB Without Amyloid Copathology|Participants with DLB (without amyloid copathology) will receive E2027 50 milligram (mg) capsules, orally, once daily up to 12 weeks.
16287344|NCT04764669|Experimental|DLB With Amyloid Copathology|Participants with DLB (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
16287345|NCT04764669|Experimental|PDD Without Amyloid Copathology|Participants with PDD (without amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
16287346|NCT04764669|Experimental|PDD With Amyloid Copathology|Participants with PDD (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
16287347|NCT04764656||Brolucizumab|Naïve (Patients being the first time treated) and pre-treated patients
16287348|NCT04764643|Active Comparator|sodium thiosulfate solution arm|20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe
16287349|NCT04764643|Experimental|N-acetylcysteine solution arm|20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe
16287350|NCT04764630|Experimental|A. Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min)
16287352|NCT04764630|Active Comparator|C. Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
16287353|NCT04764604|Experimental|Muscle Tension Group|"10 participants with a diagnosis of muscle tension dysphonia will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:
~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice
~Three minutes of tube-in-water semi-occluded vocal tract exercise.
~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.
~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.
~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
16287354|NCT04764604|Experimental|Vocal Fold Palsy Group|"10 participants with a diagnosis of (unilateral) vocal fold palsy will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:
~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice
~Three minutes of tube-in-water semi-occluded vocal tract exercise.
~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.
~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.
~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
16287355|NCT04764604|Experimental|Presbylaryngis Group|"10 participants with a diagnosis of presbylaryngis will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:
~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice
~Three minutes of tube-in-water semi-occluded vocal tract exercise.
~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.
~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.
~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
16287356|NCT04764591|Active Comparator|Lateral sagittal approach|Patients in this group will be randomized to receive a lateral sagittal approach for Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
16287357|NCT04764591|Active Comparator|Costoclavicular approach|Patients in this group will be randomized to receive a costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
16287358|NCT04764565|Experimental|Nuun Instant|2 servings of Nuun instant in 1 liter water
16287359|NCT04764565|Placebo Comparator|Control|1 liter of water
16287360|NCT04764565|Experimental|Nuun Electrolyte|2.1 servings of Nuun Electrolyte in 1 liter water
16287361|NCT04764552|Experimental|Yeahhh Baby Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
16287362|NCT04764552|Placebo Comparator|Placebo Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
16287363|NCT04764539|Active Comparator|Stimuli administered via 2D format on an iPad Pro|50% of participants were given the video modeling stimuli in a 2D format (iPad Pro).
16287364|NCT04764539|Active Comparator|Stimuli administered in 3D format via VR goggles and bone conduction headphones|50% of participants were given the video modeling stimuli in 3D format via VR goggles with integrated bone conduction headphones.
16287365|NCT04764526|Experimental|Protein-enriched ice cream|Two protein-enriched ice cream daily (afternoon and evening) in two days in addition to the normal menu
16287366|NCT04764526|No Intervention|Control|Standard menu in two days
16287367|NCT04764513|Experimental|Patients with hematological malignancies after allo-HSCT|"Patients with negative minimal residual disease or stable disease:
~After inclusion, patients will receive or not receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.
~Patients with positive minimal residual disease but not hematologic relapse:
~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.
~Patients with hematologic relapse:
~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell."
16287368|NCT04764500||travellers to Southeast Asia|Clients planning to travel to Southeast Asia will be recruited
16287369|NCT04764487|Other|Standard follow-up|Patients will have no intervention. It is the comparator group. Patients will have the usual follow-up for clinical, biological and imaging exams.
16287370|NCT04764487|Experimental|KidneyPRO web-application follow up|"Patients will have to connect to the KidneyPRO web-application weekly to complete a questionnaire about their symptoms in addition to usual follow-up.
~Appropriate care will be offered if necessary (depending on the symptoms assessment)"
16287371|NCT04764474|Experimental|Part 1 Dose Escalation Cohorts|Patients from each cohort will be administered HMPL-306 orally QD
16287372|NCT04764474|Experimental|Part 2 Dose Expansion Cohorts|Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
16287373|NCT04764461|No Intervention|Control Group|The control group will continue with the standard practice of antenatal care using Mc Donald's rule for fundal heights measurements.
16287374|NCT04764461|Experimental|Intervention Group|Intervention group will follow the same antenatal visit plan as the control group with the use of customised GROW Charts for fundal height measurements.
16287377|NCT04764435||Patients receiving dialysis at a physician-owned dialysis facility|All adults with Medicare fee-for-service in 2017 who received dialysis at a physician-owned dialysis facility. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
16287378|NCT04764435||Patients receiving dialysis at a dialysis facility not owned by a physician|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility not owned by a physician. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
16287379|NCT04764435||Patients receiving dialysis at a facility owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
16287380|NCT04764435||Patients receiving dialysis at a facility NOT owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility NOT owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
16287381|NCT04764422|Placebo Comparator|Placebo|0.9% Normal Saline for injection
16287382|NCT04764422|Active Comparator|NDV-HXP-S 1 µg|35 subjects age 18-59 will receive NDV-HXP-S 1 µg study vacine administered 0.5 mL IM
16287383|NCT04764422|Active Comparator|NDV-HXP-S 3 µg|35 subjects age 18-59 will receive NDV-HXP-S 3 µg study vacine administered 0.5 mL IM
16287384|NCT04764422|Active Comparator|NDV-HXP-S 10 µg|35 subjects age 18-59 will receive NDV-HXP-S 10 µg study vacine administered 0.5 mL IM
16287385|NCT04764422|Active Comparator|NDV-HXP-S 1 µg + CpG1018 1.5 mg|35 subjects age 18-59 will receive NDV-HXP-S 1 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM
16287386|NCT04764422|Active Comparator|NDV-HXP-S 3 µg + CpG1018 1.5 mg|35 subjects age 18-59 will receive NDV-HXP-S 3 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM
16287387|NCT04764409||Group 1|This group includes patients who underwent chemoembolization of hepatic arteria
16287388|NCT04764409||Group 2|This group includes patients who underwent chemoinfusion of hepatic arteria
16287389|NCT04764396|Experimental|Heparin priming biopsies|
16287390|NCT04764396|Active Comparator|Standard of care (saline)|
16287391|NCT04764383|Experimental|PK/PD Group|Participants in the Pharmacokinetic (PK)/pharmacodynamic (PD) Group will receive L-Histidine and Lodosyn daily for 7 consecutive days.
16287392|NCT04764383|Placebo Comparator|L-Histidine and Lodosyn followed by Placebo Group|Participants in this group will receive L-Histidine and Lodosyn daily for 2 consecutive weeks followed by Placebo for an additional 2 consecutive weeks with a 1-week wash-out period in between.
16287393|NCT04764383|Experimental|Placebo followed by L-Histidine and Lodosyn Group|Participants in this group will receive Placebo daily for 2 consecutive weeks followed by L-Histidine and Lodosyn for an additional 2 consecutive weeks with a 1 week wash out period in between.
16287394|NCT04764370|Experimental|WeFlow-Arch Moduler Embedded Branch Stent Graft System|
16287395|NCT04764357||Cooling Cap Therapy|Participants receiving cooling cap therapy
16287396|NCT04764344|Experimental|Haloperidol|2.5 mg of IV haloperidol diluted to a final concentration of 5 mL with 0.9% sodium chloride
16287397|NCT04764344|Active Comparator|Ondansetron|4 mg of IV ondansetron diluted to a final concentration of 5 mL with 0.9% sodium chloride
16287398|NCT04764331|Other|Intervention|Caps will be provided for each subjects will use the cap once daily for10-minute treatment regimen
16287399|NCT04764318||Remote patient monitoring for hypertension|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
16287400|NCT04764318||Remote patient monitoring with care management|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM. In addition, PCPs will receive lists of candidate patients. Care managers will assist with the outreach to patients to offer RPM when recommended by the PCP, will monitor and support patient use of the remote monitor, and will promote action on the part of the patient or PCP when uncontrolled hypertension is present.
16287401|NCT04764318||Usual care|Medicare patients from non-intervention primary care practices in Northwestern Medical Group will contribute EHR data but will not have any new procedures put in place.
16287402|NCT04764305||Patients|Patients with Fontan circulation. No intervention planned (observational study)
16287403|NCT04764305||Controls|Healthy, biventricular controls. No intervention planned (observational study)
16287404|NCT04764292|Experimental|Contrast-enhanced mammography|Women who meet criteria for supplemental screening MRI, but who are unable to have MRI for medical/access/cost reasons, will be invited to have screening with contrast-enhanced mammography. Women will also have standard-of-care mammography/tomosynthesis per usual clinical practice.
16287405|NCT04764279|Experimental|OPTIFAST Arm|Participants in the intervention group will be given OPTIFAST® meal replacement shakes, 4 per day to achieve 900kcal/day, for the first 12 weeks of the study. The second phase will consist of partial meal replacement and food reintroduction over a 4 week period. When the intervention group begins to reintroduce foods, all study participants will be provided a workbook, created for the study, to explain optimal lifestyle changes for DMII management. The third phase will be a 8-month follow-up of participants on continued healthy lifestyle as described in the workbook.
16287406|NCT04764279|No Intervention|Control/Usual Care Arm|Usual Care : A gift card will be offered to participants in the control group to stabilize the incentive of the intervention. Participants in the control group will receive usual diabetes care based on the current Canadian Diabetes Association guidelines by their family physician. Participants in the control group will receive the same workbook as the intervention group at 16 weeks into the study.
16287407|NCT04764266|Experimental|Normothermic Machine Perfusion|Blood sampling at 5 time points after transplantation Perfusate collection at 3 time points during normothermic machine perfusion prior to transplantation
16287408|NCT04764253|Experimental|Modified Sodium Watcher Program + Digital Self-Monitoring|
16287410|NCT04764227|Experimental|Concurrent chemoradiotherapy group|"Interventions:
~Chemotherapy: Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5
~Radiotherapy: A total dose of 50.4Gy will be delivered in 28 fractions at 1.8Gy/fraction, 5 fractions per week in 6 weeks. The CTV encompassed the bilateral supraclavicular, superior mediastinal, and subcarinal regions."
16287411|NCT04764214|Experimental|3rd generation EGFR-TKI+ SBRT|
16287412|NCT04764201|Other|Sequence 1|Period 1: HGP2001, Period 2: HIP2001
16287413|NCT04764201|Other|Sequence 2|Period 1: HIP2001, Period 2: HGP2001
16287416|NCT04764175|Experimental|Telephone All Nations Breath of Life|This is a culturally targeted smoking cessation program developed for American Indian communities. It includes individual telephone counseling, text messaging, and educational materials.
16287417|NCT04764175|Active Comparator|Comparison Program|This is a non-culturally targeted smoking cessation program. It includes individual counseling, text messaging, and educational materials.
16287418|NCT04764162|Active Comparator|Choline supplementation|Participants will consume 1000 mg of choline per day for 4 weeks.
16287419|NCT04764162|Placebo Comparator|Placebo supplementation|Participants will consume 1000 mg of placebo per day for 4 weeks.
16287420|NCT04764149||PFll Group|Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/ m2) on day 1 and day 28, every 60 days. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
16287421|NCT04764149||Non-PFLL Group|Patients were treated with other platinum-based chemotherapy every 21 days including: PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1. TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
16287422|NCT04764123||AVNRT Cohort|"Patients admitted for electrophysiological study and ablation due to AVNRT tachycardia.
~During the study and before the ablation high density electroanatomical mapping will be performed."
16287423|NCT04764110|Experimental|Cyplexinol|900 mg daily (2 capsules) for 15 days
16287424|NCT04764110|Placebo Comparator|Placebo|2 capsules daily for 15 days
16287427|NCT04764084|Experimental|Treatment group|Niraparib-Anlotinib combination therapy
16287428|NCT04764071|Active Comparator|percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F. Pneumatic lithotripter is used for fragmentation and stone removal is accomplished with retrieval graspers through a rigid 22F nephroscope. An 18-24 F nephrostomy tube is placed at the end of the operation.
16287429|NCT04764071|Experimental|ultra-mini percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6 F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath. Then, a 9.5-F, rigid ureteroscope (KARL STORZ Medical Instruments) was introduced to the sheath. The renal stones were broken into pieces using holmium laser lithotripsy. Finally, the ureteroscope and sheath were removed and the tract site was packed for 2-3 min. then placement of double J stent will be done according to the decision of the operating surgeon for 3 to 4 weeks.
16287430|NCT04764058|Other|Montherapy|Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every 6 hours
16287431|NCT04764058|Other|Combination|Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU per vial.
16287432|NCT04764045|Active Comparator|Ropivacaine injection in trigger points|Ropivacaine injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
16287433|NCT04764045|Placebo Comparator|Placebo injection in trigger points|Saline injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
16287434|NCT04764019|Experimental|Patients|Patients with chronic digestive symptoms in whom intestinal dysmotility is suspected
16287435|NCT04764006|Experimental|Surufatinib plus Sintilimab|Drug: Surufatinib plus Sintilimab Surufatinib will be given orally. Sintilimab will be given intravenously
16287436|NCT04763993|Active Comparator|RYGBP|RYGBP: Roun-en-Y Gastric Bypass
16287437|NCT04763993|Experimental|SG|SG: Sleeve Gastrectomy
16287438|NCT04763980|Active Comparator|Cohort A (survey, genetic testing)|Patients complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may also undergo genetic testing.
16287499|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness in patients with type 2 diabetes|N=21 patients with type 2 diabetes
16288123|NCT04759365|Placebo Comparator|Placebo|Placebo will be administered as an oral capsule
16287439|NCT04763980|Experimental|Cohort B (educational session, survey, genetic testing)|Patients participate in educational session with health coach over 60 minutes. Patients also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may undergo genetic testing.
16287440|NCT04763967||PedSCath|Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.
16287441|NCT04763967||Retrospective Control|Generated from 2016 and 2018 anonymized subject data from the clinical sites.
16287442|NCT04763954|Experimental|Game|Group that receives the game intervention (the trial version and the access to level 2 and level 7
16287443|NCT04763954|No Intervention|Control|Group without intervention
16287444|NCT04763954|Experimental|Guidance|Group that receives the game (the same levels as group 1) and email coaching one day after completing the game.
16287446|NCT04763928|Experimental|VenDec|Patients will receive a combination of VENETOCLAX (400 mg per day orally on days 1 to 28 of 28-days courses) and DECITABINE (20 mg/sqm intravenously on days 1 to 5 of 28-days courses)
16287447|NCT04763915|Experimental|GeneSHARE|Access to GeneSHARE, a web-based toolkit including interactive and narrative components to enhance FC of genetic test results.
16287448|NCT04763915|Experimental|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
16287449|NCT04763915|Active Comparator|Standard-of-care|Receive standard-of-care from their treating healthcare provider.
16287452|NCT04763889|Experimental|CBT workshop|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. In the intervention group participants will attend a day workshop or two half day workshops focused on using CBT to manage their anxiety and stress.
16287453|NCT04763889|No Intervention|Self-help control treatment as usual group|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. Participants in the treatment as usual group will receive the workshop materials after the active treatment group have completed their final follow-up at 3 months
16287454|NCT04763876|Active Comparator|15 mg ketorolac intramuscular|Patients who received a single 15 mg dose of ketorolac administered intramuscularly
16287455|NCT04763876|Active Comparator|60 mg ketorolac intramuscular|Patients who received a single 60 mg dose of ketorolac administered intramuscularly
16287456|NCT04763863||Ostomates|Ostomates with leakage issues and stoma created at least 3 months ago
16287457|NCT04763850|Experimental|Walking decline|Walking decline on an instrumented treadmill under 3 different conditions
16287458|NCT04763837|Experimental|Intraureteral stent group|Patients assigned to this group will undergo placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in only in the kidney and NOT in the bladder. This group will be the experimental group.
16287459|NCT04763837|Active Comparator|Conventional Double-J stent|Patients assigned to this group will undergo placement of a double-J ureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and the bladder. This group will serve as the control.
16287460|NCT04763824|Active Comparator|cluster-randomized controlled trial, with delayed start control arm|Control arm/Delayed Onset
16287461|NCT04763824|Experimental|cluster-randomized controlled trial, intervention|Intervention arm
16287462|NCT04763811||Older 65 people|Older 65 people who live alone in their house will be included. They will have focus groups and Individual interviews.
16287463|NCT04763798|Experimental|Dominant|All subjects will receive the three stretching techniques on dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will be one week. Stretching exercises will be perform in a random order. A random-number generator will be used for randomization
16287464|NCT04763798|Active Comparator|Non dominant|All subjects will receive the three stretching techniques on non dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will bé one week. Stretching exercises will be perform in a random order. A random-number generator will bé used for randomization
16287465|NCT04763785||Patients with keratoconus corneas|Corneal tomography on patients with keratoconus diagnosis
16287466|NCT04763785||participants with healthy corneas|Corneal tomography on healthy participants
16287467|NCT04763785||retrospective part|fully anonymised Picture data of existing 4500 patients
16287468|NCT04763772|Experimental|Detailed Report|A detailed body composition profile report that consists of the following elements: basic demographic data, percent body fat, weight to muscle ratio, visceral fat and abdominal subcutaneous fat volume, visceral fat ratio (the fraction of visceral divided by total abdominal fat), muscle fat infiltration and liver fat (%), and thigh muscle volumes (also separated into right and left, anterior and posterior compartments). Each parameter is presented on a visual scale in the context of the individual value, general population defined by reference data (from United Kingdom (UK) Biobank population), a metabolic disease-free population (also from UK Biobank), low/high and very low/very high, corresponding to 15th and 5th percentiles, respectively. There are also descriptions of each biomarker and how they are derived to provide context for the recipient.
16287500|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness for healthy individuals|N=27 healthy individuals
16287469|NCT04763772|Placebo Comparator|Basic Weight Information|A simple informational report consisting of weight, BMI, and a visual representation of their BMI. This report also categorizes their BMI into underweight, normal weight, overweight, or obese categories according to the World Health Organization categorization schema.
16287470|NCT04763772|Experimental|Patient Provided|Report provided directly to the patient.
16287471|NCT04763772|Placebo Comparator|Physician Provided|Report provided directly to the provider to translate/counsel the patient.
16287472|NCT04763759|Experimental|Dose Level 1- 6mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
16287473|NCT04763759|Experimental|Dose Level 2- 15mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
16287474|NCT04763759|Experimental|Dose Level 3- 30 mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
16287475|NCT04763746||Sub-protocol 1|"Blood pressure, oxygen saturation and heart rate measured from participants selected because of their blood pressure.
~Within each study session, participants will have their blood pressure, oxygen saturation and heart rate measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
16287476|NCT04763746||Sub-protocol 2|"Respiratory rate and oxygen saturation measured from any participant.
~Within each study session, participants will have their respiratory rate and oxygen saturation measured twice using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
16287477|NCT04763746||Sub-protocol 3|"Oxygen saturation measured from participants expected to have low oxygen saturation.
~Within each study session, participants will have their oxygen saturation measured twice using standard-of-care equipment. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
16287478|NCT04763746||Sub-protocol 4|"Blood pressure, heart rate, respiratory rate and oxygen saturation measured from adults lacking capacity.
~Within each study session, participants will have their blood pressure, heart rate, respiratory rate and oxygen saturation measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
16287479|NCT04763720||Dyadic Developmental Psychotherapy|Families being treated with DDP at either of the centres
16287480|NCT04763707||Group 1 : Hepatocellular carcinoma HCC patients with HCV|40 HCV-related liver cirrhosis patients with HCC on top (Group 1).
16287481|NCT04763707||Group 2 : Cirrhotic patients with HCV|30 HCV-related liver cirrhosis patients(Group 2).
16287482|NCT04763707||Group 3 : Healthy control|20 healthy volunteers will be included as controls(Group 3).
16287483|NCT04763694|Experimental|Treatment arm|Subjects wore multifocal soft contact lenses for 12 months.
16287484|NCT04763681|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
16287485|NCT04763681|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
16287486|NCT04763668||Pregnant HIV positive women on ART|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV positive and have been on ARTs for at least four months before pregnancy. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
16287487|NCT04763668||Pregnant HIV negative women|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV negative. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
16287488|NCT04763668||Babies born to HIV positive mothers on ARTs|All babies born to pregnant HIV positive women on ARTs who were in the first arm of the study
16287489|NCT04763668||Babies born to HIV negative mothers|All babies born to pregnant HIV negative women who were in the first arm of the study.
16287490|NCT04763642|Active Comparator|Laparoscopic Pancreaticoduodenectomy (LPD)|
16287491|NCT04763642|Active Comparator|Robotic Pancreaticoduodenectomy (RPD)|
16287492|NCT04763642|Placebo Comparator|Open Pancreaticoduodenectomy (OPD)|
16287493|NCT04763629|Experimental|Interval Training (IT)|Patients randomized to this group will perform 45 minutes of exercise on treadmill, alternating intervals of ten minutes at 50-60% of VO2 peak and two intervals five miutes at 85-90% of VO2 peak
16287494|NCT04763629|Experimental|Compbined Training (CT)|Patients randomized to this group will perform 45 minutes of exercise in which they will perform aerobic continuous training on tradmill (20 minutes) and resistance training (25 minutes)
16287495|NCT04763616|Experimental|Isatuximab and Cemiplimab combined therapy|"Drug : Isatuximab
~1 cycle : 10mg/kg IV every week. It is administered on Day 2, Day 9, Day 16, Day 23.
~2~6 cycle : 10mg/kg every 2 weeks . It is administered on Day 2, Day 16.
~7th cycle and beyond : 10mg/kg IV every 3 weeks. It is administered on Day 2.
~Drug : Cemiplimab
~1st - 6th cycle : 250mg IV every 2 weeks. It is administered on Day 1, Day 15.
~7th cycle and beyond : 350mg every 3 weeks. It is administered on Day 1."
16287496|NCT04763590|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) had 3 principal components: (1) psychoeducation, (2) cognitive restructuring, and (3) exposure. In this treatment, derived from an empirically-supported treatment for panic disorder, psychoeducation consisted of teaching about the interrelationship between thoughts, feelings, and physical sensations during weaning. The cognitive component taught patients how to challenge their thoughts, with a particular focus on identifying thoughts that over-estimated the probability of negative medical events. The behavioral component consisted of reducing the need for mechanical ventilation in a step-wise, graduated, manner.
16287497|NCT04763564|Experimental|Liraglutide then Placebo|Participants will be randomly assigned to 6-week Liraglutide treatment. Then after a 5-day washout, treatment will continue with 6 weeks of placebo.
16287498|NCT04763564|Experimental|Placebo then Liraglutide|Participants will be randomly assigned to 6-week placebo treatment. Then after a 5-day washout, treatment will continue with 6 weeks of Liraglutide.
16288249|NCT04758507|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
16287501|NCT04763512|Experimental|Intact Cow's Milk Protein Formula Group (CMFG)|All enrolled subjects will be fed Stage 1 CMF libitum for 4 months. Thereafter, they will discontinue study formula and complete the study.
16287502|NCT04763512|Experimental|Partially Hydrolysed Whey Formula Group (pHFG)|All enrolled subjects will be fed Stage 1 pHF libitum for 4 months. Thereafter, they will switch to Stage 2 pHF at age 6 months (Study Month 4) and to Stage 3 pHF at age 12 months (Study Month 10). At age 18 months (Study Month 16), they will discontinue study formula and complete the study.
16287503|NCT04763499|Experimental|Freeze dried strawberry powder|"39g of freeze dried strawberry powder, which represents three daily servings of strawberries.
~The powder will be mixed in one cup of water."
16287504|NCT04763499|Placebo Comparator|control powder|39 g of a powder that matches the sugar and caloric content of the experimental powder. The powder will be mixed in one cup of water.
16287505|NCT04763486|Experimental|Prophylactic antibiotic treatment|Will be given Cefamezin antibiotic within 6 hours of delivery
16287506|NCT04763486|No Intervention|No intervention|Will not get antibiotic prophylactics
16287507|NCT04763473|Placebo Comparator|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
16287508|NCT04763473|Experimental|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
16287509|NCT04763460|Active Comparator|Baseline CRT programming|The comparator arm patients will remain at baseline CRT programming for the first 6 months, and then will crossover to the experimental arm and CRT device will be programmed to optimal settings derived from the electrocardiographic assessment for the following 6 months.
16287510|NCT04763460|Experimental|Electrocardiography-guided optimal CRT programming|The experimental arm patients will have CRT device programmed based on the electrocardiographic assessment for 12 months.
16287511|NCT04763447|Experimental|OMA withdrawal attempt|
16287512|NCT04763447|Active Comparator|OMA continuation|
16287513|NCT04763434|Active Comparator|RS group|20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone
16287514|NCT04763434|Active Comparator|RM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine
16287515|NCT04763434|Experimental|RSM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group)
16287516|NCT04763421|Experimental|Upper Gastrointestinal/Lower Gastrointestinal/Gynecological|Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
16287517|NCT04763408||Lenvatinib|Participants with advanced or unresectable HCC will initiate treatment with lenvatinib capsules based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
16287518|NCT04763408||Sorafenib|Participants with advanced or unresectable HCC will initiate treatment with sorafenib tablets based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
16287519|NCT04763395||non-severe COVID19|"Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types.
~A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura."
16287520|NCT04763395||Severe Covid19|Severe COVID19 was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR >-30 times/minute; ii) hypoxia: oxygen saturation (resting state) <-93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) <- 300 mmHg (millimeters of Mercury), or iv) the occurrence of respiratory or another organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
16287521|NCT04763382|Other|Experimental grups: Training of caregivers|"Application of data collection:
~Tools as pre-test, post-test and retention test to participants in the experimental group,
~Education:It includes the training given to the caregivers in the experimental group, delivery of the guide booklet at the end of the training
~Android phone application: Installing on the phones of the caregivers in the experimental group of the android application, which includes the frequency of CIC application, the CIC application process steps and hospital appointments, created by the nurse for the caregivers in the experimental group and the software is made by the computer engineer.
~One home visit and three phone calls were made in order to solve the problems that the caregivers in the experimental group experienced with the use of CIC or android use.
~Urinalysis for children who are inserted and put into the study:All participants in the study were asked to give urine tests three times with an interval of one month after discharge."
16287522|NCT04763382|Other|Control: Control grups|"As in the experimental group, the caregivers in the control group were pre-tested and post-tested using data collection tools.
~No intervention was made to the caregivers in the control group.
~However, caregivers in the control group performed urinalysis three times with an interval of one month after discharge."
16287523|NCT04763369|Experimental|Sub-tenon injection group|In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.
16287524|NCT04763369|Experimental|Suprachoroidal injection group|A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.
16287556|NCT04763161||Control group|"Patients not suffering from AIC, hospitalised in neurosurgery for another reason,
~Patients to be opered on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach."
16287742|NCT04762017|Placebo Comparator|Placebo|Once daily IV infusions of Placebo (n=18) for 5 consecutive days
16287527|NCT04763343|Experimental|Ketamine Treatment + CAMS Therapy|
16287528|NCT04763343|Placebo Comparator|Saline Placebo Treatment + CAMS Therapy|
16287531|NCT04763317||AFFECTED|"Affected with PrCa < 70 years
~Affected with metastatic castration resistant PrCa (mCRPC) at any age
~Affected with PrCa and a family history defined as
~two or more cases in family with one case < 70
~three or more cases any age (FDR or SDR)"
16287532|NCT04763317||UNAFFECTED|"- Aged >30 and with a family history defined as::
~FDR diagnosed < 70
~2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed < 70 years
~3 or more cases at any age (on same side of family)"
16287533|NCT04763304|Active Comparator|PPE-G (gown) followed by PPE-C (coverall)|"Placement of PPE-G (personal protective equipment including a gown for body protection) fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning.
~Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning."
16287534|NCT04763304|Active Comparator|PPE-C (coverall) followed by PPE-G (gown)|"Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning.
~Placement of PPE-G (personal protective equipment including a gown for body protection), fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning."
16287535|NCT04763291|No Intervention|Control group|Continue habitual diet and lifestyle.
16287536|NCT04763291|Experimental|Fruit, Vegetable and Berry (FVB) group|Participants have to ingest an encapsulated juice powder concentrate, otherwise continue their habitual diet and lifestyle.
16287537|NCT04763291|Experimental|Omega group|Participants have to ingest a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
16287538|NCT04763291|Experimental|Fruit, Vegetable, Berry and Omega (FVBO) group|Participants have to ingest an encapsulated juice powder concentrate along with a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
16287539|NCT04763278|Experimental|Prosthesis|Patient is temporarily fit with Point Digit partial hand prosthetic system
16287540|NCT04763265|Active Comparator|Group A (n=100): BoNT/A-DP (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures..
~A volume of 0.5 mL of the properly reconstituted BoNT/A-DP should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.
~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
16287541|NCT04763265|Active Comparator|Group B (n=100): Botox Cosmetic (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures.
~A volume of 0.5 mL of the properly reconstituted Botox Cosmetic should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.
~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
16287542|NCT04763252||Canadian|
16287543|NCT04763252||Non-Canadian|
16287544|NCT04763226|Experimental|Part A Furosemide|
16287545|NCT04763226|Experimental|Part B (SAD)|Single Ascending Dose (SAD)
16287546|NCT04763213||Invasive treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
16287547|NCT04763213||Medically treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
16287548|NCT04763200|Experimental|Impella Arm|Impella CP® or Impella 2.5 placement prior to high-risk PCI
16287549|NCT04763200|Active Comparator|Control Arm|Subjects randomized to the Control group will be treated per standard of care PCI with or without an intra-aortic balloon pump (IABP).
16287550|NCT04763187|Active Comparator|Control group|Lower molar extraction and filling of post-extraction alveolus with hemostatic sponge containing gentamicin.
16287551|NCT04763187|Experimental|PRGF group|Post-extraction alveolus is filled with PRGF.
16287552|NCT04763187|Experimental|PRF group|Post-extraction alveolus is filled with PRF.
16287553|NCT04763174|Experimental|mHealth Coping Skills Training for Symptom Management (mCOPE)|mHealth Coping Skills Training for Symptom Management (mCOPE) protocol tests the efficacy of a theory-based symptom management intervention designed to target multiple interrelated symptoms (pain, fatigue, psychological distress) with content uniquely relevant for young and middle-aged colorectal cancer patients. Addressing the co-morbid consequences of cancer while providing support in the context of age-related challenges (e.g., caring for children and parents, career) has the potential to significantly improve overall quality of life in young and middle-aged patients with cancer.
16287554|NCT04763174|No Intervention|Standard Care|Standard Care group will complete assessment questionnaires at the same time points as mCOPE, but will not receive mCOPE protocol.
16287555|NCT04763161||Experimental group|"Patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy.
~Intervention is decompressive hemicraniectomy in the context of a malignant sylvian ischaemic cerebral"
16287623|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 2|2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
16287557|NCT04763135|Experimental|Oral mirtazapine|Arm 1 patients will be treated using a daily mirtazapine treatment. Treatment will be taken on the evening. Treatment will be initiated at 15 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for old patients and those with liver failure.
16287558|NCT04763135|Active Comparator|Oral escitalopram|Arm 2 patients will be treated using a daily escitalopram treatment. Treatment will be taken in the morning. Treatment will be initiated at 10 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for 5 mg for old patients.
16287559|NCT04763122||Thyroid Cancer Cases|
16287560|NCT04763109|Experimental|Whole-Body Magnetic Resonance Imaging|
16287561|NCT04763096|Experimental|tacrolimus|conversion to Advagraf
16287562|NCT04763083|Experimental|Phase 1 Dose escalation|Up to 9 sequential cohorts including both CLL/SLL and MCL patients
16287563|NCT04763083|Experimental|Phase 2|CLL/SLL and MCL cohorts
16287564|NCT04763070|Other|Ciprofloxacin|
16287565|NCT04763057|Experimental|indirect pulp treatment with NeoPUTTY MTA|
16287566|NCT04763057|Active Comparator|indirect pulp treatment with calcium hydroxide|
16287567|NCT04763044|Other|Period 1|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
16287568|NCT04763044|Other|Period 2|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
16287569|NCT04763044|Other|Period 3|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
16287570|NCT04763044|Other|Period 4|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
16287571|NCT04763044|Other|Period 5|1100 ppm SnF2 toothpaste only
16287572|NCT04763031|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy - IORT
16287573|NCT04763018|Active Comparator|Treatment|This arm will receive a function iTEAR
16287574|NCT04763018|Sham Comparator|Sham|This arm will receive sham treatment device
16287575|NCT04763005|No Intervention|Healthy controls|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry.
16287576|NCT04763005|Experimental|Hypertensive Patients|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry. In addition, randomization to an eight-week high-intensity interval intervention or control condition with physical activity recommendations.
16287577|NCT04762992|Experimental|Intervention group, enoxaparin|Enoxaparin subcutaneous injections
16287578|NCT04762992|Placebo Comparator|Placebo, normal saline|Normal saline subcutaneous injections
16287580|NCT04762966||Therapeutic|Patients with metformin blood concentration in the therapeutic ranges.
16287581|NCT04762966||Supratherapeutic|Patients with metformin blood concentration above the therapeutic ranges.
16287582|NCT04762953|Experimental|SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis|Patients will receive sequential intraperitoneal paclitaxel along with intravenous paclitaxel, 5-FU, and leucovorin on Days 1 and 8 of every 21 day cycle for 3 months.
16287583|NCT04762940|Active Comparator|Control group|They will receive 24 robotics sessions with Amadeo robot three times a week for movement, but without specifically receiving vibration therapy.
16287584|NCT04762940|Experimental|Experimental group|They will recieve three times a week with 24 sessions plus vibration duration of approximately 20 minutes with a high vibration frequency. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible will be conducted prior to robotic treatments with Amadeo.
16287585|NCT04762914||Prehabilitation (PH)|Patients who underwent prehabilitation prior to colorectal cancer resection
16287586|NCT04762914||Non-Prehabilitation (NPH)|Patients who did not undergo prehabilitation prior to colorectal cancer resection
16287587|NCT04762901|Experimental|Stage 1 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
16287588|NCT04762901|Experimental|Stage 1 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
16287589|NCT04762901|Experimental|Stage 1 Arm 3|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
16287590|NCT04762901|Experimental|Stage 1 Arm 4|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
16287591|NCT04762901|Experimental|Stage 2 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
16287592|NCT04762901|Experimental|Stage 2 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
16287593|NCT04762888|Experimental|Diagnostic (68Ga-PSMA PET/MRI or PET/CT)|Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.
16287594|NCT04762875|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
16287595|NCT04762849|Experimental|laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR)|Laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. A ring with shape memory put on the gastric pouch
16287596|NCT04762849|Active Comparator|laparoscopic one anastomosis gastric bypass (MGB/OAGB) without band: standard surgery|Laparoscopic one anastomosis gastric bypass (MGB/OAGB) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
16287624|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 3|2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22
16287597|NCT04762836|Experimental|Augmented learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of DCS two hours prior to conditioning and fMRI
16287598|NCT04762836|Placebo Comparator|Baseline learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of placebo two hours prior to conditioning and fMRI
16287599|NCT04762823|Experimental|PD-ctDCS|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16287600|NCT04762823|Sham Comparator|PD-sham|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
16287601|NCT04762823|Active Comparator|NH-ctDCS|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16287602|NCT04762823|Sham Comparator|NH-sham|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
16287603|NCT04762810|Experimental|Cyclophosphamide and Glucocorticoids|Through the selective depletion of proliferating lymphocytes, cyclophosphamide has an inhibitory effect on both humoral and cellular immunity. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
16287604|NCT04762810|Active Comparator|Glucocorticoids monotherapy|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
16287605|NCT04762797||Non-neoplastic group|"Gallbladder polyps with pathological diagnosis of cholesterol polyps or inflammatory polyps are classified into Non-neoplastic group."
16287606|NCT04762797||Neoplastic group|"Gallbladder polyps pathologically diagnosed as adenocarcinoma, adenoma, adenomyosis, or other malignancies are classified into Neoplastic group."
16287607|NCT04762784|Experimental|Tocilizumab treatment|Tocilizumab is a recombinant humanized monoclonal antibody against human interleukin-6 (IL-6) receptor. Tocilizumab acts by inhibiting the activity of IL-6 receptor. IL-6 is a pro-inflammatory cytokine whose release can trigger a series of downstream pro-inflammatory responses. Tocilizumab inhibits IL-6 signal transduction by blocking the binding of IL-6 to soluble and membrane-bound IL-6 receptors, thereby reducing pathological inflammatory responses.
16287608|NCT04762784|Active Comparator|Glucocorticoids monotherapy|Glucocorticoids has fast onset of action and multiple anti-inflammatory effects.The conventional protocol is oral prednisone, followed by a slow tapering over 4 weeks. Besides, precautionary measures need to be taken against possible complications brought by the application of corticosteroids such as infections, diabetes mellitus, hypertension, Cushing's syndrome and osteoporosis, etc.
16287609|NCT04762771|Active Comparator|Active|Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.
16287610|NCT04762771|No Intervention|Control|Hospitalized covid-19 patients treated with current standard of care (per institution treating physicians) alone.
16287613|NCT04762745|Experimental|Phase I, Cohort 1|The combination of bendamustine, 60mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
16287614|NCT04762745|Experimental|Phase I, Cohort 2|The combination of bendamustine, 70mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
16287615|NCT04762745|Experimental|Phase I, Cohort 3|The combination of bendamustine, 80mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
16287616|NCT04762745|Experimental|Phase II|The combination of MTD dosage of bendamustine with pomalidomide and dexamethasone will be administrated in an expanded relapsed or refractory multiple myeloma cohorts for 8 cycles, then under the combination of pomalidomide and dexamethasone as maintenance therapy until progression or intolerable toxicities.
16287617|NCT04762732|Experimental|Experimental: negative pressure wound therapy (PREVENA™ Incision Management System)|Wound of ALT donor site will be cared under PREVENA™ Incision Management System
16287618|NCT04762732|Placebo Comparator|Placebo Comparator: conventional dressing|Wound of ALT donor site will be cared by traditional dressing and care.
16287619|NCT04762719|Other|PET/CT Scan with 11C-ER176|
16287621|NCT04762693||Cough monitoring|All enrolled participants will be asked to install the acoustic surveillance software in their smartphones and use it to record night-time coughs for a minimum 30-day period.
16287622|NCT04762680|Experimental|Phase 2 Cohort -SARS-CoV-2 vaccine Formulation 1|2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
16287625|NCT04762680|Experimental|Supplemental Cohort 1 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were previously vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
16287626|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
16287627|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine
16287628|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
16287629|NCT04762680|Active Comparator|Supplemental Comparator for Cohort 1 and 2 Boosters - Monovalent (D614)-AS03 SARS-CoV-2 vaccine|2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
16287630|NCT04762680|Active Comparator|Supplemental Cohort 3 - Monovalent (D614)-AS03 SARS-CoV-2 vaccine|2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
16287631|NCT04762680|Experimental|Supplemental Cohort 3 - Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine|2 injections of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
16287632|NCT04762680|Experimental|Supplemental Cohort 3 - Monovalent (B.1.351)-AS03|2 injections of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
16287633|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 1|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
16287634|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 2|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
16287635|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 3|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
16287636|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 4|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
16287637|NCT04762667|Experimental|Patients will undergo reverse shoulder arthroplasty with patient-specific instrumentation.|The patients underwent preoperative planning. A 3D model was made based on CT. The optimal position of the components of the endoprosthesis has been calculated. patient-specific instrumentation were created for each scapula and humerus using 3D modeling software. Individual guides use during operation for exact position of the components of the endoprosthesis.
16287638|NCT04762667|Other|Patients will undergo conventional reverse shoulder arthroplasty.|This group of patients was examined according to the standard method, Rg and CT of the shoulder joint were performed. According to the study, the sizes of the endoprosthesis were selected. Installation of the components of the endoprosthesis during the operation was carried out using standard (included in the set) guides. Orientation was performed according to the anatomical landmarks of the glenoid and the neck of the humerus, without taking into account the individual characteristics of the bones.
16287639|NCT04762641|Experimental|ABL503|ABL503 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
16287640|NCT04762628|Experimental|MAF capsules|MAF capsules 148 mg TID for 14 days + Standard of care
16287641|NCT04762628|Experimental|M capsules|M capsules 148 mg TID for 14 days + Standard of care
16287642|NCT04762628|Active Comparator|Comparison|Standard of care
16287643|NCT04762615||Patients with renal pathology treated with immunosuppressive drugs|Female in reproductive age suffering from renal disease that is or was previously treated with immunosuppressive drugs
16287644|NCT04762615||Patients with renal pathology without treatment|Control group
16287645|NCT04762615||Patients after renal transplantation taking immunosuppressive drugs|Female in reproductive age after renal transplantation taking immunosuppressive drugs
16287646|NCT04762602|Experimental|Part 1 Dose Escalation Cohorts|Patients from each cohort will be administered HMPL-306 orally QD
16287647|NCT04762602|Experimental|Part 2 Dose Expansion Cohorts|Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
16287648|NCT04762589|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
16287649|NCT04762589|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
16287650|NCT04762576||Cardiac Surgical Patients|All consenting adults undergoing cardiac surgery at Toronto General Hospital.
16287651|NCT04762563|Experimental|Experimental: Study Group|Patients in the IASTM group were asked to lie face down on a stretcher, exposing the entire lumbar region. IASTM was applied to all paraspinal muscles for a total of 5 minutes after massage cream was applied. Immediately afterwards, the same application was performed for the right and left hamstring muscles from the gluteal line to the bottom of the popliteal fossa for 3 minutes after massage cream was applied. IASTM application was performed vertically, horizontally and diagonally using instruments of different sizes and shapes at an angle of 45 degrees to the skin surface.
16287652|NCT04762563|Active Comparator|Active Comparator|"KT application (Kinesio Tape® Tex Gold) was performed using the muscle technique. In lumbar region application, while the patient was standing, the tape was cut as a Y-strip with a base of 5 cm."
16287686|NCT04762355|Experimental|Dose 1|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
16287653|NCT04762550||Patients undergoing Liver Transplantation|This is a prospective observational study that intends to offer participation to all patients undergoing liver transplantation at Toronto General Hospital. Parameters that will be measured include Thrombin generation, viscoelastic testing utilizing ROTEM, and conventional laboratory testing (INR, aPTT and Fibrinogen level) at five time points: (a) Prior to cross-clamp application; (b) within the first 30 minutes of venous cross clamp removal; (c) after 30 minutes of reperfusion; (d) On arrival in the intensive care unit (ICU) or post-anesthesia recovery unit; and (5) 12 hours post-operatively.
16287654|NCT04762537|Active Comparator|Standard Induction Method|The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period
16287655|NCT04762537|Experimental|Rapid Induction Method|The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
16287656|NCT04762524|Experimental|Initiation on CVVH|Patients in this arm were initiated on CVVH, rather than CVVHD
16287657|NCT04762524|Active Comparator|Initiation on CVVHD|Patients in this arm were initiated on CVVHD, rather than CVVHDH
16287658|NCT04762511|Experimental|HSV lower dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
16287659|NCT04762511|Placebo Comparator|Placebo Step 1 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
16287660|NCT04762511|Experimental|HSV low dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
16287661|NCT04762511|Placebo Comparator|Placebo Step 2 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
16287662|NCT04762511|Experimental|HSV medium dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
16287663|NCT04762511|Placebo Comparator|Placebo Step 3 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
16287664|NCT04762511|Experimental|HSV high dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
16287665|NCT04762511|Placebo Comparator|Placebo Step 4 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
16287666|NCT04762498|Experimental|Pegloticase 16mg cohort|16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly
16287667|NCT04762498|Experimental|Pegloticase 24/32mg cohort|24 or 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly
16287668|NCT04762485|Experimental|CD38 positive relapsed or refractory acute leukemia|Biological/Vaccine: Humanized CD7 CAR-T cells Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5- 10)x10^6 CD7 CAR-T cells/kg
16287669|NCT04762472|Active Comparator|Montelukast|Montelukast 10mg daily (tablet) orally x 26 weeks
16287670|NCT04762472|Placebo Comparator|Montelukast-matched placebo|Placebo (Montelukast identical) tablet 1 daily orally x 26 weeks
16287671|NCT04762459|Active Comparator|Almonertinib|Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.
16287672|NCT04762459|Experimental|Almonertinib/Pemetrexed/Cisplatin|"Drug: Almonertinib 110 mg Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years."
16287673|NCT04762459|Active Comparator|Pemetrexed/Cisplatin|"Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. If disease progresses during the treatment period and conditions required for the cross-treatment are met according to the assessment process, the patient can start to receive the open cross-treatment of Almonertinib. The overall treatment last for 3 years."
16287674|NCT04762446||SSI group|Participants who developed surgical site infection (SSI) based on the definition of Centre for Disease Control and Prevention.
16287675|NCT04762446||Non-SSI group|Participants who did not develop SSI.
16287676|NCT04762433|Experimental|Kegel Exercise Pregnancy Training - App|The intervention arm will be given a mHealth app for two months duration with the usual antenatal follow-up.
16287677|NCT04762433|No Intervention|Waitlist control|The control (waitlist) group will continue their usual antenatal follow-up and the KEPT-app will be given after the study ends.
16287678|NCT04762420||Sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience.|
16287679|NCT04762420||Dose of Sugammadex determined by quantitative monitoring (QSD).|
16287680|NCT04762407|Experimental|Sequence 1|Period 1 : Fasted state + HGP1910 + HGP1909, Period 2 : Fasted state + HCP1903
16287681|NCT04762407|Experimental|Sequence 2|Period 1 :Fasted state + HCP1903, Period 2 : Fasted state + HGP1910 + HGP1909
16287682|NCT04762381|Active Comparator|Dexamethasone|24 mg dexamethasone as single dose intravenously peroperatively
16287683|NCT04762381|Placebo Comparator|Placebo|saline infusion intravenously in a single dose
16287684|NCT04762368|Active Comparator|Active + Training|Participants in this arm will be exposed to active stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
16287685|NCT04762368|Sham Comparator|Sham + Training|Participants in this arm will be exposed to sham stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
16287687|NCT04762355|Experimental|Dose 2|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
16287688|NCT04762355|Experimental|Dose 3|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
16287689|NCT04762342|Experimental|Training Group Multiple Sclerosis|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.
~Balance- and functional exercises are included from week 10."
16287690|NCT04762342|No Intervention|Control Group Multiple Sclerosis|Habitual lifestyle including standard care.
16287691|NCT04762342|Experimental|Training Group Healty Control|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.
~Balance and functional exercises are included from week 10."
16287692|NCT04762342|No Intervention|Control Group Healthy Control|Habitual lifestyle
16287693|NCT04762329|Experimental|Patient group using Manage My Pain (MMP) digital application for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits, on the Manage My Pain (MMP) digital application
16287694|NCT04762329|No Intervention|Patient group using paper format for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits on paper format or phone interviews.
16287695|NCT04762316|Experimental|PP6 Drug|Use PP6 drugs to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
16287696|NCT04762316|Placebo Comparator|PP6 Placebo|Use PP6 placebo to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
16287697|NCT04762303|Experimental|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
16287698|NCT04762303|No Intervention|No MedReviewRx|During the control phase, MedReviewRx will not be accessible to health care professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home.
16287699|NCT04762290|Active Comparator|Active Group|This group will receive the intervention in the first 10 weeks of the study. The intervention is a dance intervention that consists of a series of expressive movements.
16287700|NCT04762290|Other|Waitlist Control|This group will receive the intervention in the second 10 weeks of the study (after the active group and after pre-post assessments in the first 10 weeks during the time of no intervention).
16287703|NCT04762264|Active Comparator|Short term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 1 to 3 months before to assess tissue incorporation into the 3D scaffold
16287704|NCT04762264|Active Comparator|Mid term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 4 to 7 months before to assess tissue incorporation into the 3D scaffold
16287705|NCT04762264|Active Comparator|Long term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor after 8 months and beyond to assess tissue incorporation into the 3D scaffold
16287706|NCT04762251|Experimental|Time-restricted eating (TRE)|The TRE group will be instructed to follow TRE (9 h/day) every day for 12 months with no other dietary instructions or advice provided. The TRE group will attend the same consult schedule as the CP group, but consultations will focus on timing of dietary intake and strategies to promote adherence. No dietary guidance regarding quantity or quality will be provided. Participants will be able to self-select the precise 9-h schedule that will best suit their lifestyles, with the caveat that the latest time of eating will be set at 7:00 pm. Outside of the elected eating window, participants will be allowed to consume water and black coffee and/or tea.
16287707|NCT04762251|Active Comparator|Current Best Practice (CP)|This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. No specific advice will be provided regarding time of day to start and finish eating and/or drinking (since this information is not outlined in current practice guidelines).
16287708|NCT04762238|Experimental|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
16287709|NCT04762238|Sham Comparator|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
16287710|NCT04762225|Experimental|RPTR-168|Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
16287711|NCT04762212|Active Comparator|Hip with the greatest limitation in flexion range of motion|Participants that have limited hip flexion of less than 101 degrees will be randomly assigned to one of two groups: one intervention group will receive Mobilization with Movement and home program of stretching with over-pressure one group will receive only a home program of stretching with over-pressure.
16287712|NCT04762212|Active Comparator|Hip with the least limitation in flexion range of motion|Participants least limited hip in flexion range of motion will serve as the control group. This limb will not receive an intervention.
16287714|NCT04762186|Experimental|Phase I dose level 1|Dose level one consists of 3 study patients receiving 1,000 adoptive SARS-CoV-2 specific T cells (IMP) per kg BW. If the first recipient does not experience a DLT associated with the dose level one therapeutic cells within 28 days, the second and third patient will receive 1.000 SARS-CoV-2 adoptive SARS-CoV-2 specific T cells per kg BW. If patient second and third do not experience a DLT within 14 days after treatment, the dose level two will be initiated.
16287715|NCT04762186|Experimental|Phase I dose level 2|Dose level two consists of 3 study patients receiving 5.000 adoptive SARS-CoV-2 specific T cells (IMP) per kg BW. If the fourth patient does not experience a DLT associated with the dose level two within 28 days, the fifth and sixth patient will receive 5.000 adoptive SARS-CoV-2 specific T cells per kg BW.
16287716|NCT04762186|Experimental|Phase II SoC plus IMP at the RP2D|Phase II SoC plus IMP at the RP2D consists of 26 patients treated with SoC plus adoptive SARS-CoV-2-specific T cells at the RP2D (Recommended Phase II Dose).
16287717|NCT04762186|Active Comparator|Phase II SoC|Phase II SoC consists of 13 patients treated with SoC.
16287718|NCT04762173|Experimental|Online self-help intervention|Participants are provided access to two online self-help programs provided by SilverCloud Health. One program is designed to support general stress resilience using principles and techniques from positive psychology and cognitive-behavioral therapy. The other program is designed to support coping with pandemic-related stressors using psychoeducation and cognitive-behavioral therapy and grief therapy principles. Participants have access to both programs and can proceed through them in the order and pace of their choosing. The online self-help intervention is fully self-guided.
16287719|NCT04762173|No Intervention|Care as usual|Participants are provided information about how to contact the counseling center at their college and/or in the local community using the phone number and website of their counseling center (if available), as well as the Substance Abuse and Mental Health Services Administration treatment locator.
16287720|NCT04762160|Experimental|Tazmetostat in combination with rituximab|Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1 (C1D1). Tazemetostat is supplied by Epizyme in pre-counted, appropriately labeled bottles. Tazemetostat will be administered from C1D1 to the end of Cycle 24, for a total of 24 months of therapy. Rituximab will be administered by either subcutaneous injection or IV infusion according to the regional product prescribing information and labeling. Rituximab will be administered at a dose of 375 mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles. Rituximab will be procured by the clinical sites from commercial sources. Disease Assessments will be performed at screening, C3D1, C6D1, C12D1, C18D1, C24D1
16287721|NCT04762147|Experimental|Paracetamol group-P|Paracetamol 15mg/Kg was dministered 30 minutes before the start of surgery
16287722|NCT04762147|Active Comparator|Fentanyl group-F|Fentanyl 2mcg/kg was administered at the time induction of anaesthesia
16287723|NCT04762134|Experimental|STI PrEP arm|doxycycline capsules 100mg orally daily for 12 months. Though the usual treatment dose of doxycycline is 100mg twice daily
16287724|NCT04762134|Experimental|STI PEP arm|doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
16287725|NCT04762134|No Intervention|Control/Standard of care arm|routine STI screening and care, which for sexually active gbMSM would not include any chemoprophylaxis for STI, as no clinical guidelines currently recommend its use
16287726|NCT04762121||Patients requiring intravenous catheter insertion|Adults (>18 years old) who require intravenous catheter insertion for their operation/procedure
16287727|NCT04762108||Sjögren's syndrome|Sjögren's syndrome with childhood-onset
16287728|NCT04762108||Healthy control|Age matched healthy control
16287729|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Quality of Life|mindfulness stress reduction program reduces menopausal complaints.
16287730|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Menopausal Symptoms|mindfulness stress reduction program improves the quality of life of women in the menopausal period.
16287731|NCT04762082|Experimental|Treatment A: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
16287732|NCT04762082|Active Comparator|Treatment B: Reference|Single oral dose of tadalafil oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
16287733|NCT04762082|Experimental|Treatment C: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
16287734|NCT04762082|Experimental|Treatment D: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with no water, under fasted conditions
16287735|NCT04762082|Experimental|Treatment E: Test|Single oral dose of tadalafil gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
16287738|NCT04762056||COVID-19 patients after ICU discharge|Patients who suffered COVID-19 pneumonia and stayed in ICU and discharged
16287739|NCT04762043|Experimental|MyoVoice Device|MyoVoice Device for individuals with total laryngectomy
16287740|NCT04762030|Experimental|Experimental Group|
16287743|NCT04762004|Experimental|Maternal speech|During the intervention, mothers were asked to speak to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
16287744|NCT04762004|Experimental|Maternal singing|During the intervention, mothers were asked to sing to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
16287745|NCT04762004|Active Comparator|Standard care|During the control condition (without the mother), the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
16287746|NCT04761952|Experimental|n-3PUFA treatment group|On the basis of routine treatment, oral supplement of n-3PUFA was given to CD patients since 2-week-postoperative till 1-year-postoperative.
16287747|NCT04761952|Placebo Comparator|Conventional treatment group|Treatment of azathioprine (daily orally) or infliximab (intravenously, at 0, 2,6 weeks with every 8-week-interval later) was given since 2-week-postoperative till 1-year-postoperative.
16287748|NCT04761926|Experimental|single arm|Asessments for the hearing with Ponto 4 sound processor on the implanted ear(s).
16287749|NCT04761900||participants were followed for the incidence of T2DM in a cohort study|performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.
16287750|NCT04761900||participants were followed for the incidence of hypertension in a cohort study|performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.
16287751|NCT04761900||participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study|performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.
16287752|NCT04761887|Experimental|Cool Block|Ropivacaine administered at approximately 4C, via a TAP block.
16287753|NCT04761887|Active Comparator|Room Temp Block|Ropivacaine administered at approximately 20-25C, via a TAP block.
16287754|NCT04761874|No Intervention|In-Person (Conventional) Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from December 1, 2019-March 15, 2020 that were evaluated, managed, and treated by the stroke care team in person.
16287755|NCT04761874|Experimental|Telestroke Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from March 16, 2020-June 29, 2020 that were evaluated, managed, and treated by the stroke care team remotely via telestroke.
16287758|NCT04761848|Experimental|Cilostazol|
16287759|NCT04761848|Placebo Comparator|Placebo|
16287760|NCT04761835|Active Comparator|Dietary Peanut|Participants in this group will be asked to continue peanut in their diet for 1 year at a dose determined from the double blind placebo controlled food challenge at baseline. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine their current peanut threshold. The current peanut threshold will be used to determine which participants will go into clinical care and which will get sustained unresponsiveness food challenges to peanut.
16287761|NCT04761835|No Intervention|Strict avoidance|Participants in this group will be asked to strictly avoid any peanut in their diet for 1 year. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine whether they will transition to daily dietary peanut or continue with clinical care.
16287762|NCT04761822|Experimental|Moderna COVID-19 Vaccine|The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.
16287763|NCT04761822|Experimental|Pfizer-BioNTech COVID-19 Vaccine|The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.
16287764|NCT04761822|Experimental|Placebo +Moderna COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.5 mL of placebo will be administered intramuscularly in the deltoid.
~The placebo dose will be followed by two doses of Moderna COVID-19 Vaccine, with the first dose administered 1 month later. The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart."
16287765|NCT04761822|Experimental|Placebo+Pfizer-BioNTech COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.3 mL of placebo will be administered intramuscularly in the deltoid.
~The placebo dose will be followed by two doses of Pfizer-BioNTech COVID-19 Vaccine, with the first dose administered 1 month later. The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart."
16287766|NCT04761796|Other|Professional flight members|
16287767|NCT04761783||Prospective arm|Patients will receive SIGNATERA™ test results and the immunotherapy treatment regimen, dosing schedule, duration of treatment, number of cycles, and modifications during treatment will be at the discretion of the HCP. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
16287768|NCT04761783||Control arm|Control cases must have undergone immunotherapy treatment and have follow-up data available in their medical record at the participating site for two years following initiation of immunotherapy or death.
16287769|NCT04761770|Experimental|Geriatric participants with various blood disorders|"Geriatric assessment (GA) pre-transplant
~Risk-adapted allocation of conditioning intensity based on GA
~GA-directed, longitudinal supportive care management"
16287770|NCT04761757|Active Comparator|Control Arm|
16287771|NCT04761757|Active Comparator|Intervention Arm|
16287772|NCT04761744|Experimental|Nivolumab|
16287773|NCT04761731|Experimental|ADVAGRAF®|One arm: Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
16287777|NCT04761692|Experimental|Arm 1|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan
16287778|NCT04761692|Experimental|Arm 2|This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan
16287779|NCT04761692|Experimental|Arm 3|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.
16287780|NCT04761679|Experimental|Intervention Group|
16287781|NCT04761679|No Intervention|Control Group|
16287782|NCT04761666||static verticalization device|children with severe cerebral palsy (GMFCS IV & V) with static verticalization device
16287783|NCT04761666||non verticalization device|children with severe cerebral palsy (GMFCS IV & V) without static verticalization device
16287786|NCT04761614|Experimental|Treatment (riluzole, mFOLFOX6, bevacizumab)|Patients receive riluzole PO BID on days 1-14. Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16287787|NCT04761601|Experimental|Dose Finding as Monotherapy - Part 1|
16287788|NCT04761601|Experimental|Expansion as Monotherapy - Part 2|
16287789|NCT04761601|Experimental|Dose Finding in Combination - Part 3|
16287790|NCT04761588|Experimental|Tyr sphere|All patients to receive Tyr sphere as part of their dietary management for tyrosinaemia or alkaptonuria (AKU).
16287791|NCT04761575||FFQ validation|All participants to complete all aspects of the study.
16287792|NCT04761562|Active Comparator|Control group|Patients will be treated with a standard surgical procedure - tympanoplasty.
16287793|NCT04761562|Experimental|PVRP group|Patients will be treated with a standard surgical procedure - tympanoplasty combined with PVRP. PVRP will be applied to the reconstructed tympanic membrane.
16287794|NCT04761549|Other|Adolescent Idiopathic Scoliosis|
16287795|NCT04761536||A|patients undergoing ARR with primary anastomosis between November 2016 and December 2020 after centralization of rectal cancer cases
16287796|NCT04761536||B|patients undergoing ARR with primary anastomosis between January 2006 and October 2016
16287797|NCT04761523|Active Comparator|Reduced fat arm|Daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% proteins
16287798|NCT04761523|Active Comparator|Standard healthy diet arm|Daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% proteins.
16287799|NCT04761497|Experimental|active music therapy|Each session consisted of: song of welcome (patients had to greet and introduce themselves), rhythmic exercise (three songs were used; therapist and patients kept rhythm by clapping their hands), dance exercises (three songs were used; patients should make free body movements in response to music), game of recognition of songs and interpreters (four songs were used) and song of goodbye.
16287800|NCT04761497|Experimental|passive music therapy|The therapist and the patients were seat listening to the music recorded in a CD. The therapist told patients which the name and the interpreter of each song of the list.
16287801|NCT04761497|Placebo Comparator|control|Patients were watching nature videos for the same duration than the interventions. A therapist was with them facilitating the activity.
16287802|NCT04761484|Experimental|Intervention|Insertion of peripheral venous catheter on admission to the NICU
16287803|NCT04761484|No Intervention|Control|Insertion of and umbilical venous catheter on admission
16287804|NCT04761471|Experimental|TI stimulation|Temporal interference (TI) stimulation is a type of low-intensity transcranial electrical stimulation with alternating current (tACS). In case of TI stimulation, 2 electric fields in kHz range are delivered to 4 electrodes, which are placed on the surface of the skull, to modulate neural oscillations.
16287805|NCT04761458|Experimental|Patients scheduled for elective surgery aged 65 and +|
16287806|NCT04761445|Experimental|Straumann Standard Plus (SP)|Patients receiving Straumann SP implants of 4.1 mm in diameter and length of 10 mm.
16287807|NCT04761445|Experimental|JDental care Octa (JD Octa)|Patients receiving JD Octa implants of 4.3 mm in diameter and 10 mm in length.
16287808|NCT04761432|Experimental|Intervention arm|Thirty (30) adult patients will be enrolled in this study. Each patient will be monitored simultaneously with the neoGuard device and a conventional patient monitor. Paired readings for temperature, respiratory rate, pulse rate and oxygen saturation will be captured every second for a maximum observation period of 1 hour.
16287809|NCT04761406|Experimental|Phaeosol group|Daily supplementation of Phaeosol softgel capsule (218mg/d), active ingredients of Microphyt. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
16287810|NCT04761406|Placebo Comparator|Placebo group|Daily supplementation of placebo softgel capsule (218mg/d of 100% sunflower oil) with the same appearance and packaging than experimental product. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
16287811|NCT04761393||Patients with emphysema and eosinophilia in blood and sputum|blood eosinophils ≥300 cells/μL and sputum eosinophils >3%
16287812|NCT04761393||Patients with emphysema and paucicellular inflammation|sputum neutrophils <65% and eosinophils <3%
16287813|NCT04761393||Patients with emphysema and sputum neutrophilia|sputum neutrophils >65% and sputum eosinophils < 3%
16287814|NCT04761380||stable COPD subjects|
16287815|NCT04761380||age-matched control subjects subjects who did not have any pulmonary disease|
16287816|NCT04761367|Other|INTERVENTION GROUP|The IG will participate in a 6-month exercise program based on the PAIR exercise protocol and will receive educational sessions and material on the importance of maintaining an active life style after THR or TKR
16287817|NCT04761367|No Intervention|CONTROL GROUP|The CG will receive only educational sessions and material on the importance of maintaining an active life style after THR or TKR
16289235|NCT04751474|No Intervention|Control group|The control group did not receive any intervention.
16287818|NCT04761354||University Medical Center Utrecht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287819|NCT04761354||University Medical Center Groningen|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287820|NCT04761354||Vu University Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287821|NCT04761354||University Medical Center Maastricht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287822|NCT04761354||Academic Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287823|NCT04761354||Istituto di Semeiotica Chirurgica Roma|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287824|NCT04761354||University of California San Francisco|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287825|NCT04761354||Northwestern Memorial Hospital|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287826|NCT04761354||Weill Cornell Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287827|NCT04761354||Columbia University Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287828|NCT04761354||University of Chicago Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287829|NCT04761354||M.D. Anderson Cancer Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287830|NCT04761354||Boston Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287831|NCT04761354||University Health Network Toronto|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287832|NCT04761354||Montreal General Hospital - McGill University|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287833|NCT04761354||University of Sydney|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
16287834|NCT04761341|Experimental|AMD|
16287835|NCT04761341|Active Comparator|healthy control|
16287836|NCT04761328|Experimental|Cessation of treatment|
16287837|NCT04761302|Experimental|Group 1: Intravenous Ketorolac and oral acetaminophen|Group 1 will be composed of patients receiving the following standard pain control protocol: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group. Patients who determine pain to be unbearable and wish to opt out of the non-opioid group will receive may do so.
16287838|NCT04761302|Active Comparator|Group 2: Intravenous Morphine and oral oxycodone|Group 2 will be composed of patients receiving the following pain control protocol: morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
16287839|NCT04761289|Active Comparator|Control group. Health education program|The participants in this group will undergo the usual clinical practice: compliance and adherence to the prescribed drug treatment will be explained, as well as the established guidelines for individualized health care. A Health Education Program will also be added at discharge, mainly aimed at reinforcing and promoting an active and healthy life.
16287840|NCT04761289|Experimental|Experimental Group. Multimodal Exercise and Functional Rehabilitation Program|"Prescription of multimodal physical exercise. A supervised and structured home program will be carried out for one month. It will be carried out daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. Each session will be structured in a warm-up, a main part and a cool-down and relaxation (14).
~Reeducation of Activities of Daily Living (ADL). Specific training will be carried out after the evaluation and before the discharge of the patients from the university healthcare complex. It is intended to identify the factors that are interfering with the performance of activities of daily living. The intervention will consist of three parts: Direct intervention on Activities of Daily Living (ADL), carried out in situ in the hospitalization and generalizable to their daily environment; teaching in Energy Saving Techniques (APR).
~Prescription of support products and adaptations of the environment."
16287841|NCT04761276||Lucidis Intra-ocular lens (IOL)|Adult patients with significant reduction in visual acuity and/or visual comfort from cataract who will receive Lucidis Intra-ocular lens
16287842|NCT04761263|Active Comparator|Selected Physical Therapy group|will receive a selected physical therapy program for 90 minutes, 3 times/week for 3 successive months.
16287843|NCT04761263|Experimental|Task-oriented circuit training group|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 45 minutes in addition to 45 minutes task-oriented circuit training program. The frequency of the whole program will be three times per week, for three months.
16287844|NCT04761250|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
16287845|NCT04761237|Experimental|Group 1|(H-P) : Pcv-aCO2≥6mmHg between T base and T 0h.;
16287846|NCT04761237|Experimental|Group 2|(L-P) : Pcv-aco2< 6mmHg at T base and≥6mmHg at T 0h
16287847|NCT04761224|No Intervention|control group|heated blanket + unheated NaCL instillation (operating room ambient temperature: around 17°C).
16287848|NCT04761224|Experimental|Heated group|heating blanket + instillation of NaCl at 38-39°C by Fluido® Irrigation fluid heating system
16287850|NCT04761198|Experimental|Squamous cell carcinoma of the head and neck|Advanced and/or recurrent or metastatic squamous cell carcinoma of the head and neck
16287851|NCT04761198|Experimental|Cervical cancer on or after chemotherapy|Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
16287852|NCT04761198|Experimental|Gastric or gastroesophageal junction adenocarcinoma|Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
16287853|NCT04761198|Experimental|Endometrial carcinoma post-platinum <3L treatment|Advanced and/or metastatic endometrial carcinoma
16287854|NCT04761198|Experimental|Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors|Advanced or metastatic tumor mutational burden-high (TMB-H)
16287855|NCT04761198|Experimental|Rare disease with high prevalence of TIGIT expression|Select rare tumors
16287856|NCT04761198|Experimental|Ovarian cancer|Recurrent high grade serous and endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line platinum-based therapy
16287857|NCT04761198|Experimental|Endometrial carcinoma post standard of care therapy|Advanced and/or metastatic endometrial carcinoma
16287858|NCT04761185|Experimental|HIPEC using Raltitrexed|
16287859|NCT04761159|Active Comparator|Ketofol1/1|Propofol 1 mg/kg + ketamin1 mg/kg (1/1 ratio) for group I to anesthesia induction.
16287860|NCT04761159|Active Comparator|Ketofol1/2|propofol 1,5 mg/kg + ketamin 0,75 mg/kg (2/1 ratio) for group II to anesthesia induction
16287861|NCT04761159|Active Comparator|Ketofol1/3|propofol 2 mg/kg +ketamin 0,66 mg/kg (3/1 ratio) for group III to anesthesia induction
16287862|NCT04761159|Active Comparator|propofol|propofol 3 mg/kg will perform for anesthesia induction
16287863|NCT04761146|Experimental|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT Diffusing Alpha-emitters Radiation Therapy using the DaRT applicator and seeds, inserted for 14 days prior to removal.
16287864|NCT04761133|Experimental|Pleural irrigation with antiseptic|Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.
16287865|NCT04761133|No Intervention|No pleural irrigation|Standard care
16287866|NCT04761120||Group 1: Primary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 1 will enroll 200 subjects undergoing surgical repair of primary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In primary mitral regurgitation, backflow through the closed valve is caused by disease intrinsic to the mitral valve tissue itself.
16287867|NCT04761120||Group 2: Secondary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 2 will enroll 200 subjects undergoing surgical repair of secondary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In secondary mitral regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
16287868|NCT04761120||Group 3: Primary tricuspid disease repair surgery with a full Tailor Ring implant|Group 3 will enroll up to 50 subjects undergoing surgical repair of primary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
16287869|NCT04761120||Group 4: Secondary tricuspid disease repair surgery with a full Tailor Ring implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In secondary tricuspid regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
16287870|NCT04761120||Group 5: Primary tricuspid disease repair surgery with a partial Tailor Ring or Tailor Band implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes posterior annuloplasty with either a partial Abbott SJM Tailor Ring with cut zone removed or an Abbott SJM Tailor Band. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
16287871|NCT04761107||GU participants with active or past infection of SARS-Co-V-2|GU patients from medical records with active or past infection of SARS-Co-V-2
16287872|NCT04761094||Insulin pump|All patient treated with insulin pump.
16287873|NCT04761081||South Asians who are lean|"The south Asian group who are lean will be of south Asian ethnicity and a waist circumference <90cm.
~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.
~Metabolic markers will be analysed and presented in a participant characteristics table."
16287874|NCT04761081||South Asians with central obesity|"The south Asian group with central obesity will be of south Asian ethnicity and a waist circumference of 90cm or greater.
~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.
~Metabolic markers will be analysed and presented in a participant characteristics table."
16287875|NCT04761081||White Europeans who are lean|"The white European group who are lean will be of white European ethnicity and a waist circumference <94cm.
~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.
~Metabolic markers will be analysed and presented in a participant characteristics table."
16289517|NCT04749524||Newborns|Otoacoustic Emissions to be measured with and without suppression noise
16287876|NCT04761081||White Europeans with central obesity|"The white European group with central obesity will be of white European ethnicity and a waist circumference of 94cm or greater.
~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.
~Metabolic markers will be analysed and presented in a participant characteristics table."
16287877|NCT04761055|Experimental|Screening Visits for Breast Cancer|Consenting patients will receive their already scheduled standard CBE and mammogram and in addition will receive a breast exam utilizing the iBreast Exam (iBE).
16287878|NCT04761042|Experimental|Wilderness program|A one-week (8 days) wilderness program, 3-month online support, and a follow-up visit for four days.
16287879|NCT04761042|Other|Holiday program (Attention control)|A one-week (8 days) holiday program, 3-month online contact, and a follow-up visit for four days.
16287880|NCT04761029|Active Comparator|grup R|Unilateral Rhomboid intercostal and subserratus block + intravenous patient-controlled analgesia
16287881|NCT04761029|Placebo Comparator|Group P|intravenous patient-controlled analgesia
16287882|NCT04761016|Active Comparator|Control|Control group participants will receive access to the same I-POP Health resources without CHW navigation until the end of 10-months (delayed CHW navigation). The current usual care model is outlined. Participants will complete study measures at baseline, 6-months, and 10-months timepoints. Upon completion of 10-months measures, these individuals will be assigned a CHW and receive delayed navigation.
16287883|NCT04761016|Experimental|I-POP CHW Intervention|I-POP+CHW participants will be paired with a CHW at baseline to assist with navigation for 10-months between health and wellness services in the selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227. Participants will receive a multi-level intervention utilizing the current I-POP Health model that includes: 1) Access to health services (including oral health), 2) Access to clinical prevention services, 3) Access to education and facilities to increase physical activity and improved nutrition choices, and 4) Scheduled visits with CHWs for education and navigation. Individuals will complete study measures at baseline, 6-months, and 10-months.
16287884|NCT04761003|Active Comparator|Group I (Cryobiopsy group):|patients where patients will be subjected to thoracoscopic cryobiopsy.
16287885|NCT04761003|Active Comparator|Group II (Forceps group)|patients where patients will be subjected to thoracoscopic forceps biopsy.
16287886|NCT04760977||Trauma patients in shock|The study focuses on hypotensive trauma patients assisted by HEMS teams
16287887|NCT04760951|Experimental|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
16287888|NCT04760951|Placebo Comparator|Placebo|Placebo comparator taken 2 times per day
16287889|NCT04760938|Experimental|Outdoor Behavioral Healthcare (OBH)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
16287890|NCT04760938|Experimental|Cognitive Behavioral Therapy (CBT)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
16287891|NCT04760912|Experimental|Experimental group general anesthesia without rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring. After induction with Propofol and Sufentanil ( doses adjusted according to weight and age) anesthesia was maintained with sevorane. Muscle strength measured on three occasions with Yamar dinamometar for hand grip strength, before induciran to anesthesia and immediate after Salingeru from anesthesia, then again measured in first 24 hours.
16287892|NCT04760912|Active Comparator|Active comparator: general anesthesia with rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring with train-of-four (TOF). After induction with Propofol and Sufentanil (doses adjusted according to weight and age) and rocuronium 0,6 mg per kg, anesthesia maintained with sevorane. Muscle strength neasured with Yamar dinamometar for hand grip strength before induction to anesthesia and immediate after awakening from anesthesia, then again measured in first 24 hours.
16287893|NCT04760899|Active Comparator|Active Group|This group will receive the active form of tDCS. The tDCS will be administered with the anode over the right lobule of the cerebellum, and the cathode over the left lobule of the cerebellum. Stimulation will be administered for a twenty minute period that does not include the 30 second ramp up at the beginning and end of the stimulation.
16287894|NCT04760899|Sham Comparator|Sham Group|This group will receive the sham form of tDCS. The electrodes will be placed in the same montage as in the Active group, however the stimulation parameters are different. For this group, the stimulation will be ramped up to the target intensity over thirty seconds at the beginning, then immediately ramp down over thirty seconds. The stimulation will then remain off for the next twenty minutes. After twenty minutes the stimulation will ramp up to the target intensity and then back down over thirty seconds.
16287895|NCT04760899|No Intervention|Healthy Controls|These will be age and sex-matched healthy controls who only come in for the baseline visit in order to provide comparative values with which to confirm adequate impairment in our diseased population.
16287896|NCT04760886||Urban trauma cohort|All paediatric trauma admissions in an urban, MTC treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
16287897|NCT04760886||Rural trauma cohort|All paediatric trauma admissions in a rural district general, treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
16287898|NCT04760873|Experimental|Cryotherapy for GAVE|Subjects will undergo cryotherapy for GAVE
16287899|NCT04760860|Placebo Comparator|Placebo Control Arm|Participants in this arm will receive placebo during the trial for 15 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
16287900|NCT04760860|Experimental|Terazosin Arm|Participants in this arm will receive Terazosin during the trial for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
16338097|NCT04413331||Vasculitis|Those with systemic vasculitis
16287901|NCT04760847|Experimental|Intermittent Fasting|Patients in Group A will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day.
16287902|NCT04760847|Active Comparator|Control|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast.
16287903|NCT04760821|No Intervention|Usual Care|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2. Usual Care means the clinical protocol approved by the enrolling center.
16287904|NCT04760821|Experimental|Trimetazidine|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2 plus trimetazidine.Usual Care means the clinical protocol approved by the enrolling center.
16287905|NCT04760808||AIS group|
16287906|NCT04760808||Control Group|
16287907|NCT04760795||coping strategy based on problem|59 geriatric patients will be included on the group: coping strategy based on problem
16287908|NCT04760795||coping strategy based on emotion|59 geriatric patients will be included on the group: coping strategy based on emotion
16287909|NCT04760782|Experimental|Treatment group|Daily self-administered injection of 80 mcg abaloparatide (8 weeks) + hard collar immobilization (12 weeks)
16287910|NCT04760782|Active Comparator|Historical control group|Patients who received only 12 weeks of hard collar immobilization
16287912|NCT04760756|Experimental|This refers to Fragility Fracture Integrated Rehabilitation Management|This refers to Fragility Fracture Integrated Rehabilitation Management and will include comprehensive rehabilitation program and assessment
16287913|NCT04760743|Experimental|low dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 30μg/dose), 1 dose each on Day 0 and 28
16287914|NCT04760743|Experimental|high dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 50μg/dose), 1 dose each on Day 0 and 28
16287915|NCT04760743|Placebo Comparator|Placebo group|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16287916|NCT04760730|Experimental|Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29|Subjects will receive 1 intramuscular (IM) injection of 5 × 10^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 29
16287917|NCT04760730|Experimental|Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29|Subjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10^10 vp (nominal) on Day 29.
16287918|NCT04760717|Experimental|Spironolactone|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
16287919|NCT04760717|No Intervention|Standard Care|Participants randomized to the Standard care arm will be receiving their normal routine blood pressure treatment.
16287920|NCT04760704||Experimental group|Persons aged 65 and over, residing in an institution for dependant elderly or in a long-term care unit
16287921|NCT04760704||control group|Health and medico-social professionals between 40 and 65 years of age
16287922|NCT04760691|Active Comparator|Pre-Exposure Prophylaxis (PrEP) only|Truvada one tablet by mouth daily
16287923|NCT04760691|Experimental|PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist|Truvada one tablet by mouth daily Leuprolide 11.25 milligrams (mg) intramuscular (im) injection once
16287924|NCT04760691|Experimental|PrEP plus Low Dose Estrogen|Truvada one tablet by mouth daily Estradiol 1 milligram by mouth daily x 2 weeks
16287925|NCT04760691|Experimental|PrEP plus High Dose Estrogen|Truvada one tablet by mouth daily Estradiol 6 milligrams (mg) by mouth daily x 2 weeks
16287926|NCT04760691|Experimental|High Dose Estrogen|Estradiol 6 mg by mouth daily x 2 weeks
16287927|NCT04760665|Experimental|Fecal microbiota transplantation|
16287928|NCT04760665|Placebo Comparator|Placebo|
16287929|NCT04760652|Active Comparator|CBT Cognitive Behavioral Therapy|Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.
16287930|NCT04760652|Other|TAU Treatment As Usual|Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).
16287931|NCT04760639||Test group|Participants who have a positive Covid-19 Test or negative Covid-19 test who provide a breath sample.
16287932|NCT04760626|Experimental|Insulin icodec with DoseGuide|Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.
16287933|NCT04760626|Active Comparator|Once daily basal insulin analogues|Participants randomised to basal insulin analogue injections once daily
16287934|NCT04760613|Active Comparator|Cannabidiol (CBD)|
16287935|NCT04760613|Placebo Comparator|Placebo (PCB)|
16287936|NCT04760600||IBD GROUPS|PATIENT WITH IBD DISEASE
16287937|NCT04760600||IBS GROUP|PATIENT WIT IBS DISEASE
16287938|NCT04760600||CONTROL 1|CONTROL WITH POSITIVE PARASITIC INFECTION AN POSITIVE GIT SYMTOMS
16287939|NCT04760600||CONTROL2|HEALTHY VOLUNTEARS
16287940|NCT04760587||study group|smart devices in adolescent
16287941|NCT04760574||Case group|HIV infected men who have sex with men
16287942|NCT04760574||Control group|HIV non-infected men
16287943|NCT04760561|No Intervention|Control group (conventional care)|Patients randomized to this arm will receive the conventional positioning interventions provided by the critical care nurses, which will not include self-prone positioning.
16287944|NCT04760561|Experimental|Intervention group (prone position group)|Patients randomized to this arm will receive self-prone positioning.
16287945|NCT04760548||Train dataset|This group is dedicated to developing an automated algorithm
16287946|NCT04760548||Test dataset|This group is dedicated to testing the performance of an automated algorithm
16287947|NCT04760548||Clinical Validation|This group is dedicated to assessing the clinical validity of the measurement in an independent validation cohort
16287948|NCT04760535|Experimental|Arm A: Invisalign® First clear aligners|"The Invisalign® First aligners are fabricated in a multilayer aromatic thermoplastic polyurethane/co-polyester 0.75mm (.030)-thick with a fine 3D manufacturing process."
16287949|NCT04760535|Active Comparator|Arm B: tooth-borne Hyrax-type maxillary expander|The Hyrax-type maxillary expander is a tooth-borne expansion appliance that is fixed to the upper second deciduous molars (or to the first permanent molars) using bands and includes a midline 12-mm self-locking screw (Forestadent, Pforzheim, Germany; 0.9 mm, complete turn). The expansion screw is connected to the conventional molar bands or printed clasps, modeled surrounding the molars, via a framework of 0.9mm stainless-steel wire. The framework is soldered to the bands and extending on the palatal side to the deciduous canines. The expander will be fabricated by qualified laboratory technician.
16287950|NCT04760522|Experimental|WGS Diagnostic|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease.
~Study related procedures: Blood sampling, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
16287951|NCT04760496|Experimental|Experimental group|The experimental group will receive oxytocin at 4 mIU/mL
16287952|NCT04760496|Active Comparator|Control group|The control group will receive oxytocin at 2 mIU/mL
16287953|NCT04760483|Experimental|Transperineal Laser Ablation for BPH|"Ceftriaxone 250 mg IM as antibiotic prophylaxis. Local Anesthesia: perineal skin will be infiltrated with 10 cc of Lidocaine 2% and then each neurovascular bundle will be infiltrated with 5 - 10 cc. Nitrous self-administered anesthesia will be available.
~One or two laser fibers from Echolaser x4 will be placed in each of the two prostate lobes using the plan. Treatment will be executed following Echolaser smart Interface planning, needles will follow targeted location using stepper grid under a transperineal approach in a sagittal plane. Ablation with 5 watts power per fiber, a total of ~ 1800 J will be delivered. We will evaluate pain measures and procedure tolerance using visual analog pain scale Upon completion we will measure coagulation zone with TRUS. Before discharge, trial of void will be conducted. Patients with a residual greater than 200 cc will have an indwelling catheter placed and will be discharged with it."
16287954|NCT04760470|Experimental|Technological-assisted upper extremity rehabilitation|Technological-assisted upper extremity rehabilitation.
16287955|NCT04760470|No Intervention|Wait list control|Continue their normal lives.
16287956|NCT04760457|Active Comparator|IL-FLS|Immediate loading (IL) and Flapless surgery (FLS)
16287957|NCT04760457|Active Comparator|IL-FPS|Immediate loading (IL) and Flapped surgery (FPS)
16287958|NCT04760457|Active Comparator|DL-FLS|Delayed loading (DL) and Flapless surgery (FLS)
16287959|NCT04760457|Active Comparator|DL-FPS|Delayed loading (DL) and Flapped surgery (FPS)
16287960|NCT04760444|Experimental|Peer Leader Diabetes Self-Management Support (PLDSMS)|Participants in the PLDSMS arm will receive 10 hours of group diabetes self-management education (DSME) with a certified diabetes care and education specialist. After the DSME group sessions, the group will complete 6 1-hour weekly diabetes self-management support (DSMS) session led by two peer leaders.
16287961|NCT04760444|Active Comparator|Control Group|Participants in the control group will receive 10 hours of group diabetes self-management education (DSME) with a certified diabetes care and education specialist.
16287962|NCT04760431|Active Comparator|Group A|Trastuzumab, Taxanes and Pertuzumab
16287963|NCT04760431|Experimental|Group B|Trastuzumab, Taxanes and TKIs
16287964|NCT04760418|Experimental|4 week baseline|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
16287965|NCT04760418|Experimental|6 week baseline|Participants in this arm are randomized to a 6-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
16287966|NCT04760405|Experimental|Tai Chi Easy Intervention|Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
16287967|NCT04760392|Experimental|GDM|Goal-directed mobilization
16287968|NCT04760392|No Intervention|Control|Standard of care
16287969|NCT04760379|Active Comparator|Conventional Therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
16287970|NCT04760379|Experimental|Vibration Therapy|Focal muscle vibrator (FMV) (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
16287971|NCT04760366|Experimental|Group A (Experimental)|Patients in this group will receive interventional therapy through fascial- muscular lengthening therapy .Patients in this group will also receive the conventional therapy
16287972|NCT04760366|Other|Group B: Conventional treatment|Patients in this group will receive the conventional therapy
16287973|NCT04760353|Experimental|Probiotic|one powder portion bag of the probiotic mixture (OMNi-BiOTiC STRESS) containing 9 human bacterial strains [Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51 Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)] and vitamin B (B2, B6, B12), self-administered orally twice a day for 8 weeks
16288004|NCT04760158|Sham Comparator|Sham Taping Group|Sham patellar taping and exercises were applied to participants.
16288005|NCT04760158|Other|control group|Only exercises were applied to participants.
16288006|NCT04760145|Experimental|Intervention Group|Multicomponent exercise with blood flow restriction
16287974|NCT04760353|Placebo Comparator|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.
~Powder portion bags are suitable for participants with intolerance to yeasts or lactose
~Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
16287975|NCT04760327|Experimental|Electrochemotherapy of gynecological cancers|
16287976|NCT04760314|Experimental|Lebrikizumab Regimen A + Topical Corticosteroid|Lebrikizumab Regimen A administered by subcutaneous (SC) injection in combination with topical corticosteroid
16287977|NCT04760314|Experimental|Lebrikizumab Regimen B + Topical Corticosteroid|Lebrikizumab Regimen B administered by SC injection in combination with topical corticosteroid
16287978|NCT04760314|Placebo Comparator|Placebo + Topical Corticosteroid|Placebo administered by SC injection in combination with topical corticosteroid
16287979|NCT04760301|Experimental|local tranexamic acid injection to cervix|1 gr of Tranexamic acid diluted in 10 ml saline
16287980|NCT04760301|Placebo Comparator|local normal saline injection to cervix|20 ml of saline
16287981|NCT04760301|Experimental|IV 1 g tranexamic acid|1 gr of Tranexamic acid diluted in 100 ml saline- IV
16287982|NCT04760301|Placebo Comparator|IV 1 g normal saline|100 ml saline- IV
16287983|NCT04760288|Experimental|Arm A (Pralsetinib)|Participants will receive Pralsetinib at a dose of 400mg orally once daily (PO QD) in 28-day cycles.
16287984|NCT04760288|Active Comparator|Arm B (SOC: Cabozantinib/Vandetanib)|Participants will receive either one of the following SOC therapies, as determined by the treating investigator: Cabozantinib: 140mg PO QD in 28-day cycles; Vandetanib: 300mg PO QD in 28-day cycles.
16287985|NCT04760275|Active Comparator|Medication - Fluoxetine|"Approved medication by the U.S. Food and Drug Administration (FDA) for treating anxiety disorders in children.
~The study's starting dose, and minimum permitted, will be 10 mg/day; should that not be tolerated, the patient will be withdrawn from active treatment (but not from study follow-up). After 1 week at 10 mg/day, the dose will increase to 20 mg/day. After completion of week 4, 10 mg/day dose increases will be permitted every other week as tolerated, up to a maximum daily dose of 80 mg/day. If patients are on doses >20mg/day, the total daily dose can be prescribed either once daily or split into twice daily administrations."
16287986|NCT04760275|Active Comparator|Cognitive Behavioral Therapy (CBT)|"Type of talk therapy that aims to identify and replace negative thoughts, using positive behavioral skills to create and maintain positive moods and healthy relationships.
~The Coping Cat (CC) program will be used as the behavioral intervention for this study.CC is an established evidence-based CBT treatment for pediatric anxiety. It is delivered in individual therapy sessions with anxious children."
16287987|NCT04760262||Group Propofol|anesthesia was maintained with TIVA (intravenous 125-250 µg/kg/min propofol + 0.1-0.25 µg/kg/min remifentanil infusion)
16287988|NCT04760262||Group Sevoflurane|anesthesia was maintained with inhalation (sevoflurane concentration of 1-2% in 50-50% O2-air mixture).
16287989|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 1)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 1) according to 0.2-week schedule.
16287990|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 2)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 2) according to 0.2-week schedule.
16287991|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 3)|Participants (n=935) aged 1-40 years old will received OCV-S (Lot 3) according to 0.2-week schedule.
16287992|NCT04760236|Active Comparator|Shanchol™ group|Participants (n=935) aged 1-40 years old will received Shanchol™ according to 0.2-week schedule.
16287993|NCT04760223|Experimental|Video intervention 1|We presented a 100-second video to study participants to reduce stigma towards depression (a boy presenter). The protagonist discussed his own depression and how getting help assist him.
16287994|NCT04760223|Experimental|Video intervention 2|We presented a 100-second video to study participants to reduce stigma towards depression (a girl presenter). The protagonist discussed his own depression and how getting help assist her.
16287995|NCT04760223|Placebo Comparator|control video 1|A 100-second video presenting a boy without depression
16287996|NCT04760223|Placebo Comparator|control video 2|A 100-second video presenting a girl without depression
16287997|NCT04760210|Active Comparator|Control Group|"Pre-physiotherapy session:
~Tens
~Infrared/Moist Heat heat for 10 minutes at the low back region.
~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps
~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps
~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps
~Postural Education
~Home Plan with lumbar Sacral Support
~Bed rest after the controlled treatment is recommended for this group."
16287998|NCT04760210|Active Comparator|Decompression|"Pre-physiotherapy session:
~Tens
~Infrared/Moist Heat heat for 10 minutes at the low back region.
~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps
~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps
~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps
~Postural Education
~Home Plan
~Decompression therapy session after the controlled treatment is recommended for this group."
16287999|NCT04760210|Active Comparator|ELDOA|"Pre-physiotherapy session:
~Tens
~Infrared/Moist Heat heat for 10 minutes at low back region.
~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps
~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps
~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps
~Postural Education
~Home Plan
~Segmental Spinal ELDOA Exercise after the controlled treatment is recommended for this group."
16288000|NCT04760197||patient under cancer immunotherapy with inflammatory ophthalmological manifestations|patient(>18 years old) under cancer immunotherapy with inflammatory ophthalmological manifestations
16288001|NCT04760184||COVID19 positives after autologous stem cell transplantation|All Swedish citizens treated with ASCT for malignant disease in Sweden from 1st January 2020 until 31st December 2020 who has tested positive for SARS-CoV-2 from start of conditioning until the end of the study period 31st March 2021.
16288002|NCT04760171||Group 1|Patients diagnosed with medullary thyroid cancer (MTC) who are undergoing standard surgical treatment for their disease. This will be either hemithyroidectomy or total thyroidectomy. Patients with laryngeal amyloidosis (LA) who are undergoing standard surgical treatment of this disease. This will be microlaryngoscopy & biopsy/debulking
16288003|NCT04760158|Experimental|Taping group|A new star taping technique and exercises were applied to participants.
16288008|NCT04760132|Active Comparator|Vaccine A - COMIRNATY COVID-19 vaccine|COMIRNATY (COVID-19, mRNA Vaccine) by BioNTech Manufacturing GmbH Marketing Authorisation EU/1/20/1528
16288009|NCT04760132|Active Comparator|Vaccine B - Moderna COVID-19 vaccine|"COVID-19 Vaccine Moderna dispersion for injection (COVID-19, mRNA Vaccine) by MODERNA BIOTECH SPAIN S.L.
~Marketing Authorisation EU/1/20/1507/001"
16288010|NCT04760132|Active Comparator|Vaccine C - Astra-Zeneca COVID-19 vaccine|COVID-19 Vaccine AstraZeneca suspension for injection (ChAdOx1-S [recombinant]) by AstraZeneca AB Marketing Authorisation EU/1/21/1529/001 and /002
16288011|NCT04760119|Active Comparator|Vein bypass surgery first strategy|
16288012|NCT04760119|Active Comparator|Endovascular treatment first (drug coated balloon angioplasty) strategy|
16288013|NCT04760093|Other|Low-to-High group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 1 will first receive low polyphenol concentration EVOO for consumption, followed by high polyphenol concentration EVOO for consumption following a 14- day washout phase.
16288014|NCT04760093|Other|High-to-Low group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 2 will first receive high polyphenol concentration EVOO for consumption, followed by low polyphenol concentration EVOO for consumption following a 14- day washout phase.
16288015|NCT04760080||Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine.|"Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine after acquired resistance to dabrafenib/trametinib.
~Patients treated
~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,
~From January 2008 to June 2020
~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib
~who became resistant to dabrafeib/trametinib
~and received after disease progression a treatment by dabrafenib/trametinib and hydroxychloroquine"
16288016|NCT04760080||Patients with a metastatic melanoma treated by cytotoxic chemotherapy.|"Patients with a metastatic melanoma treated by cytotoxic chemotherapy after acquired resistance to dabrafenib/trametinib.
~Patients treated
~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,
~From January 2008 to June 2020
~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib
~who became resistant to dabrafeib/trametinib
~and received after disease progression under dabrafenib/trametinib a treatment by cytotoxic chemotherapy"
16288017|NCT04760067||Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
16288018|NCT04760067||Artificial Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
16288019|NCT04760067||Wood Parquet|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
16288020|NCT04760054|Experimental|HUBOD martial arts practice|Participants will be trained in the Hubod exercise over 5 separate training sessions. Sessions will last approximately 30 minutes, involving a warm up, review of material from the previous session and the learning of the next movement in the HUBOD sequence. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
16288021|NCT04760054|Active Comparator|Active Comparator - Stationary Bicycle|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of mild to moderate intensity cardiovascular training on a stationary bicycle. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate exercise as in the Experimental group.
16288022|NCT04760054|Placebo Comparator|Attentional Control Group|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of watching videos on martial arts training methods and techniques. These sessions will be completely sedentary.
16288023|NCT04760041|Active Comparator|nebulized midazolam group|36 children will receive nebulized midazolam 0.2 mg/kg in 3 ml normal saline plus 5 ml clear juice 30 min before undergoing general anesthesia
16288024|NCT04760041|Active Comparator|oral midazolam group|36 children will receive oral midazolam 0.5 mg/kg in 5 ml clear juice plus nebulizer of 3 ml normal saline 30 min before undergoing anesthesia
16288026|NCT04760002||Atrial Fibrillation Patients|"Atrial fibrillation patients are to be investigated for sleep apnea by the a home-monitoring device.
~Other inclusion criteria are:
~>18 years <90 years"
16288027|NCT04759989|Active Comparator|30cc/kg ideal body weight (IBW)|"30cc/kg intravenous fluids based on the patients calculated ideal body weight will be administered when randomized to this arm
~Using Devine's formula. (men: 50kg + 2.3kg * (height(in) - 60); women: 45.5kg + 2.3kg * (height(in) - 60)"
16288028|NCT04759989|Active Comparator|30cc/kg adjusted body weight (AdjBW)|"30cc/kg intravenous fluids based on the patients calculated adjusted body weight will be administered when randomized to this arm
~Calculated by the following formula: AdjBW = IBW + 0.4(ABW - IBW)."
16288029|NCT04759989|Active Comparator|30cc/kg actual body weight (ABW)|"30cc/kg intravenous fluids based on the patients actual body weight will be administered when randomized to this arm
~Patients will receive an initial fluid bolus of 30 cc/kg of actual body weight"
16288030|NCT04759976|Experimental|Robotic motor training|Participants will perform motor tasks (i.e. movements) with upper limb robotic devices applying different strategies (e.g. supporting or challenging the subject, or being fully compliant).
16288031|NCT04759963||Group A|follow up for 6 women who gave birth through a cesarean delivery with Midline approach epidural anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
16288032|NCT04759963||Group B|follow up for 13 women who gave birth through a cesarean delivery with Midline approach spinal anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
16288033|NCT04759963||Group C|follow up for 7 women who gave birth through a cesarean delivery with general anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
16288124|NCT04759352|Experimental|Telephone post-test genetic counseling|Post-test genetic counseling delivered by telephone
16288034|NCT04759963||Group D|follow up for 12 women who are the control group (who did not experience any pregnancy or anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
16288035|NCT04759950|Experimental|Physical exercise & cognitive training group|The Physical exercise & cognitive training group receives a multicomponent physical exercise program combined with computer-based cognitive training.
16288036|NCT04759950|Experimental|Mindfulness & cognitive training group|The Mindfulness & cognitive training group receives mindfulness-based stress reduction therapy combined with computer-based cognitive training.
16288037|NCT04759950|Active Comparator|Cognitive training group|The Cognitive training group, as an active control group, receives only computer-based cognitive training.
16288038|NCT04759911|Experimental|Treatment (selpercatinib)|Patients receive selpercatinb PO BID on days 1-28. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
16288039|NCT04759898|Active Comparator|Stimulation (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and transcranial direct current stimulation.
16288040|NCT04759898|Sham Comparator|Sham (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and sham transcranial direct current stimulation.
16288041|NCT04759898|Experimental|Stimulation (invasive recording)|Patients with Parkinson's disease undergoing surgery for deep brain stimulation will be studied using electrocorticography combined with transcranial direct current stimulation
16288042|NCT04759885|Experimental|NTC015 low dose|One day single dose preparation same day of colonoscopy
16288043|NCT04759885|Experimental|NTC015 medium dose|One day single dose preparation same day of colonoscopy
16288044|NCT04759885|Experimental|NTC015 high dose|One day single dose preparation same day of colonoscopy
16288045|NCT04759885|Active Comparator|Polyethylene glycol plus ascorbate solution (2L PEG ASC) (Moviprep®)|Two litres of Moviprep® taken according to split-dose regimen (to commence in the evening before colonoscopy)
16288046|NCT04759872|Experimental|Metabolic Study Visit|Participants will complete a study visit for metabolic phenotyping and determination of the impact of hyperinsulinemia on outcomes of interest.
16288047|NCT04759859||Carotid Endarterectomy (CEA)|70 participants undergoing CEA
16288048|NCT04759859||Other Peripheral Vascular Surgery|30 participants undergoing other peripheral vascular surgical procedures
16288049|NCT04759846|Experimental|Group with normal hepatic function|Normal hepatic function
16288050|NCT04759846|Experimental|Group with moderate hepatic impairment|Moderate hepatic impairment (Child-Pugh Class B)
16288051|NCT04759846|Experimental|Group with severe impairment|Severe impairment (Child-Pugh Class C)
16288052|NCT04759833|Experimental|Part A: Low Dose Group|Participants weighing less than (<) 50 kilograms (kg) will receive a daily dose of 0.04 milligrams per kilogram (mg/kg) prucalopride oral solution (will draw the required volume from one bottle of 0.4 milligram per milliliter [mg/mL] and one bottle of placebo oral solution to account for the daily dose assigned) once daily (QD) or participants weighing greater than or equal to (>=) 50 kg will receive a single dose of 2 milligram (mg) prucalopride oral tablet during 12 weeks of treatment period. Volume of the oral solution will be based on the participants body weight (BW) at the randomization visit.
16288053|NCT04759833|Experimental|Part A: High Dose Group|Participants weighing < 50 kg will receive a daily dose of 0.08 mg/kg prucalopride oral solution (will draw the required volume from two bottle of 0.4 mg/mL to account for the daily dose assigned) QD or participants weighing >= 50 kg will receive a two dose of 2 mg prucalopride oral tablet during 12 weeks of treatment period. Volume of the oral solution will be based on the participants BW at the randomization visit.
16288054|NCT04759833|Placebo Comparator|Part A: Placebo|Participants weighing < 50 kg will draw equal volumes from two bottles of matching placebo oral solution to account for the daily dose assigned or participants weighing >= 50 kg will receive two daily dose of matching placebo oral tablet during 12 weeks of treatment period.
16288055|NCT04759833|Experimental|Part B: Low Dose Group|Participants weighing < 50 kg will receive a daily dose of 0.04 mg/kg prucalopride oral solution (will draw the required volume from one bottle of 0.4 mg/mL and one bottle of placebo oral solution to account for the daily dose assigned) QD or participants weighing >= 50 kg will receive a single dose of 2 mg prucalopride oral tablet during 36 weeks of treatment period. Volume of the oral solution will be based on the participants BW at the randomization visit.
16288056|NCT04759833|Experimental|Part B: High Dose Group|Participants weighing < 50 kg will receive a daily dose of 0.08 mg/kg prucalopride oral solution (will draw the required volume from two bottle of 0.4 mg/mL to account for the daily dose assigned) QD or participants weighing >= 50 kg will receive two dose of 2 mg prucalopride oral tablet during 36 weeks of treatment period. Volume of the oral solution will be based on the participants BW at the randomization visit.
16288057|NCT04759820|Experimental|Nano carbon group|Injection of carbon nanoparticle
16288058|NCT04759820|Active Comparator|Indocyanine green group|Injection of indocyanine green
16288059|NCT04759807|Placebo Comparator|Placebo|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
16288060|NCT04759807|Active Comparator|PUR1800 250 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
16288061|NCT04759807|Active Comparator|PUR1800 500 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
16288125|NCT04759352|No Intervention|In-person post-test genetic counseling|Post-test genetic counseling delivered in-person
16288705|NCT04755400|Placebo Comparator|Potassium Chloride|4 days treatment 24 mmol potassium chloride capsules
16288062|NCT04759794|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
16288065|NCT04759755||Study participants|25-60 year olds who demonstrate habitual sleep onset time between 10:00 pm-3:00 am and BMI 25-39.9.
16288066|NCT04759742|Experimental|group Ropivacaine|The recommended administration concentration of ropivacaine in the subarachnoid space was 0.5% and the dose was 2-3ml (practical clinical anesthesiology). Based on previous clinical experience, the starting dose of ropivacaine was set at 12.5mg (2.5ml) and Dixon's up-and down method was adopted (Dixon WJ, Massey FJ Jr. Introduction to Statistical Analysis. NY: McGraw-Hill;1969. P. 344.) The dose of ropivacaine in the next patient was adjusted to 0.5mg (0.1 mL) according to the results of the previous patient's trial.
16288067|NCT04759729|Experimental|PRO+D group|Participants will receive probiotic as well as vitamin D supplementation.
16288068|NCT04759729|Experimental|PL+D group|Participants will receive placebo instead of probiotics and vitamin D supplementation.
16288069|NCT04759716|Experimental|intervention arm|intervention arm will receive weight control program
16288070|NCT04759716|No Intervention|control arm|routine care
16288071|NCT04759703|Experimental|Pramipexole|Medication arm; 0.25 or 0.5 mg of pramipexole
16288072|NCT04759703|Placebo Comparator|Placebo|Placebo arm; 0.25 or 0.5 mg of placebo
16288073|NCT04759690|Experimental|Action observation group|Action observation group consist of 19 randomly selected participants.Action observation + conventional balance exercise group
16288074|NCT04759690|Active Comparator|Exercise group|Exercise group is the control group.Consist of 19 randomly selected participants. the The participants will only do the conventional balance exercise.
16288075|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the wrist during active video games playing|In one session the accelerometer will place on the dominant wrist Individuals will instructed not to remove and instruct them to wear the device during the session.
16288076|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the hip during active video games playing|"In one session the accelerometer will place on a flexible belt by attaching to the hip area at the intersection of the dominant wrist and axillary line.
~Individuals will instructed not to remove and instruct them to wear the device during the session."
16288077|NCT04759664|Experimental|LUT014 Gel (Dose 1)|
16288078|NCT04759664|Experimental|LUT014 Gel (Dose 2)|
16288079|NCT04759664|Placebo Comparator|Placebo|
16288080|NCT04759638||Rectal Cancer|Rectal Cancer
16288081|NCT04759625|Experimental|Biscuit enriched with mushroom powder|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
16288082|NCT04759625|Placebo Comparator|Placebo biscuit|Daily consumption of a placebo biscuit
16288083|NCT04759612|Experimental|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
16288084|NCT04759612|Experimental|Action Observation (AO Group)|Participants will watch another person's actions during an upper extremity functionality test.
16288085|NCT04759599|Active Comparator|Group 1|Group 1 will undergo Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks
16288086|NCT04759599|Active Comparator|Group 2|Group 2 will undergo Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
16288126|NCT04759339|Experimental|AG-920|Subjects will receive a single dose of articaine sterile topical ophthalmic solution in one eye only. The study eye will be randomized. The single dose will be administered by the clinic staff as two drops in study eye 30 seconds apart.
16288153|NCT04759131|Experimental|Prophylaxis|Participants will receive weekly dose of BIVV001 for 52 weeks.
16288706|NCT04755387|Other|Ticagrelor 90mg|Standard strategy group receive ticagrelor 90mg twice daily
16288093|NCT04759573|Experimental|Early Vocal Contact|"The EVC will take place in the hospital room while infants are in their individual incubators or open cribs. In the intervention group, mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
~Early Vocal Contact will be performed by mothers three times a week for 2 weeks, more than one hour after afternoon feeding. It will begin when the newborns are in an active sleep state, in calm awake state or in active awake state, but not in deep sleep or crying. Preterm infants will be enrolled from 25+0 to 32+6 weeks of GA, following the established inclusion criteria."
16288094|NCT04759573|Active Comparator|Behavioral observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
16288095|NCT04759547|Experimental|Handheld ultrasound-assisted technique|Participants will be received labor combined epidural-spinal analgesia using handheld ultrasound
16288096|NCT04759547|Active Comparator|Conventional palpation-guided technique|Participants will be received labor combined epidural-spinal analgesia using conventional landmark-guided technique
16288097|NCT04759534|Experimental|Treatment group 1|Received abdominal subcutaneous injection of IBI306 150 mg Q2W
16288098|NCT04759534|Experimental|Treatment group 2|Received abdominal subcutaneous injection of IBI306 150 mg Q4W
16288099|NCT04759534|Placebo Comparator|Placebo Group 1|Received a subcutaneous injection of placebo Q2W in the abdomen
16288100|NCT04759534|Placebo Comparator|Placebo Group 2|Received a subcutaneous injection of placebo Q4W in the abdomen
16288101|NCT04759521||Group 1|Inactive HBsAg carriers were patients with HBsAg positivity for more than 6 months
16288102|NCT04759521||Group 2|Patients diagnosed with chronic hepatitis B were patients with HBsAg positivity for more than 6 months
16288103|NCT04759521||Group 3|The control group was composed of healthy individuals who were not infected with hepatitis B virus and did not fit any exclusion criteria.
16288104|NCT04759508|Active Comparator|500 mg BD Flax Oil Capsule with Antihypertensive drug|Flax Oil Capsule 500 mg twice a day will be administered alongside antihypertensive drug in newly diagnosed hypertensive subjects
16288105|NCT04759508|Placebo Comparator|Placebo(Soya Oil) Capsule with Antihypertensive drug|No flax oil capsule,only placebo(soya oil) capsule will be administered alongside equivalent antihypertensive drug in newly diagnosed hypertensive subjects.
16288106|NCT04759495|Experimental|rtCGM|Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).
16288107|NCT04759495|Experimental|FGM|Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
16288108|NCT04759482||Patients with sleep apnea|We selected 150 patients recorded by polysomnography between january 2019 and june 2020 in the Center for Sleep Medecine and Research in Nancy.
16288109|NCT04759469|Experimental|High-intensity interval training (HIIT)|A high-intensity interval training program for 3 days/week (day after day) for 12 weeks on atreadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program intensity.
16288110|NCT04759469|Active Comparator|Moderate intensity interval training (MIIT)|A moderate intensity interval training program for 3 days/week (alternate days) on a treadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program.
16288111|NCT04759456|Experimental|Intervention group|Participants will undergo 12-week comprehensive remotely-supervised rehabilitation program along with individually titrated CPAP therapy.
16288112|NCT04759456|No Intervention|Control group|Participants will undergo individually titrated CPAP therapy.
16288113|NCT04759430|Active Comparator|Supervised Group|24 individuals will participate in the Supervised group. Patients in the supervised group will be treated individually by the researcher at the hospital. During the application, individuals will apply ten different stabilization exercises in company with a physiotherapist. Exercises will be applied under the supervision of a physiotherapist in the center where the work will be done for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks. The exercises program to be applied to the participants in the group is listed below: Supine position; Abdominal bracing, while continuing the abdominal bracing; heel slides, bridging, 90 degrees hip flexion. Quadruped position; Abdominal bracing while continuing the abdominal bracing; single arm lift, single leg lift, cross-arm leg raises activities. Standing position; Abdominal bracing.
16288114|NCT04759430|Experimental|Telerehabilitation Group|24 individuals will participate in the Telerehabilitation group. Patients in the telerehabilitation group will attend the treatment from their homes. The exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone. The same stabilization exercises will be applied to the participants in the supervised group. Exercises will be applied for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks.
16288115|NCT04759430|No Intervention|Control Group|
16288116|NCT04759404|Active Comparator|Deep Oscillation Group|Individuals in the deep oscillation group will be treated by the researcher. During the application, individuals will be positioned face down on the stretcher. After the powder is applied to the lumbar region, deep oscillation treatment with a frequency of 80% -100% with a frequency of 150 Hz for the first 10 minutes and 60 Hz for 5 minutes will be applied with the Physiomed Deep Oscilation device. Each individual will be given a home exercise program (stretching and strengthening for waist, back and abdominal) consisting of stretching and strengthening. Individuals will be asked to come to the center where the research will take place, for a total of six sessions for two weeks, three times a week.
16288117|NCT04759404|Active Comparator|Myofascial Release Group|Individuals in the myofascial relaxation group will be treated by the researcher. During the application, individuals will lie face down on the stretcher. Myofascial release therapy will be applied in the lumbar region and each individual will be given home exercise (stretching and strengthening for waist, back and abdominal). Individuals will be asked to come to the center where the research will be conducted for a total of six sessions for two weeks, three times a week.
16288118|NCT04759404|No Intervention|Control Group|
16288119|NCT04759391|Experimental|Exercise group|Lifestyle recommendations as well as digital pelvic floor muscle training to the exercise group
16288120|NCT04759391|Active Comparator|Control group|Lifestyle recommendations will be given to the control group
16288127|NCT04759326|Active Comparator|Hippotherapy treated group|The hippotherapy protocol will comprise three cycles. The first one consists of one session per day for 2 weeks allowing (i) to evaluate the patient and his neuro-functional skills, and (ii) to determine and carry out the treatment taking into account the silent barriers that may exist (PSTD, fatigue, pain, fear...) and strongly interfere with functional outcome (developing ways to overcome them). After a 9-week 'wash out' period (during which the patient consolidates the new patterns, translates them into daily activities and identifies new needs) where the patient continues his or her outpatient neurorehabilitation care, a further intermediate 1-week daily capacity building hippotherapy cycle follows. Then, after a second 9-week 'wash out' period (where the patient once again consolidates the new patterns, translates them into daily activities and identifies new needs), a final 1-week daily capacity building hippotherapy cycle will be carried out. Protocol will last 22 weeks.
16288128|NCT04759326|Placebo Comparator|Conventional neurorehabilitation treated group|Patients in the control group will receive standard outpatient rehabilitation treatment consisting of a program of physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support per week corresponding to the four weeks in which the treated group will be in hippotherapy. For the remaining 18 weeks, the treatment options for each patient, regardless of the group, will also include physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support.
16288129|NCT04759313|Experimental|Imagenarrative treatment group|INI Sessions: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
16288130|NCT04759313|Experimental|Wait List Control Group|In weeks 6 through 10, the same program will be delivered to the wait list control group.
16288131|NCT04759300|Active Comparator|Group C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS.
16288132|NCT04759300|Placebo Comparator|Group C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
16288133|NCT04759287|Active Comparator|VS group|include patients undergoing awake intubation using the C-MAC VS
16288134|NCT04759287|Placebo Comparator|FOB group|will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
16288136|NCT04759261|Other|Study group|
16288137|NCT04759248|Experimental|Atezolizumab in combination with Trastuzumab and Vinorelbine|
16288138|NCT04759235||neoadjuvant chemoradiotherapy of local advanced ESCC|All the patients receive paclitaxel/cisplatin chemotherapy and concurrent radiotherapy. Each patient receives radiation of 41.4 Gy / 23 fractions complied by intensity modulated radiotherapy or volumetric modulated arc therapy. Patients without disease progression after nCRT will be scheduled for surgery and patients with disease progression (PD) will continue to receive chemoradiation or additional treatments. Surgery will be performed 6 to 8 weeks after completion of chemoradiotherapy.
16288139|NCT04759196|Active Comparator|NESIS - Levetiracetam|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).
~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator."
16288140|NCT04759196|Experimental|NESIS - Topiramate|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).
~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression."
16288141|NCT04759196|Active Comparator|Non NESIS - Levetiracetam|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).
~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator.
~Levetiracetam should be as efficient as Topiramate in a group a participant with epileptic discharges."
16288142|NCT04759196|Experimental|Non-NESIS - Topiramate|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).
~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression.
~Topiramate should be as efficient as Levetiracetam in a group a participant with epileptic discharges."
16288143|NCT04759183|Experimental|Arm I (Angry Birds, TRIPP)|Patients participate in a VR intervention (Angry Birds) over 15 minutes before standard of care surgery and then participate in a VR intervention (TRIPP) over 15 minutes after surgery.
16288144|NCT04759183|Experimental|Arm II (TRIPP, Angry Birds)|Patients participate in a VR intervention (TRIPP) over 15 minutes before standard of care surgery and then participate in a VR intervention (Angry Birds) over 15 minutes after surgery.
16288145|NCT04759170|Other|Mother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
16288146|NCT04759170|Other|Fother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
16288147|NCT04759170|Other|Music therapist Recorded Receptive Music therapy intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
16288148|NCT04759170|Other|No singing|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
16288149|NCT04759157|Active Comparator|Couples-based treatment|Participants will attend 3, sessions (75, 50, 50 min) over video with a study therapist to discuss education about OSA and CPAP, strategies adjust to CPAP as a couple and techniques to improve sleep health.
16288150|NCT04759157|Other|Standard Information Control|Participants will receive treatment as usual and also standardized information about OSA and CPAP.
16288740|NCT04755166|Experimental|90:10|90% bone substitute, 10% autogenous bone
16288154|NCT04759118|No Intervention|Control group|The participant in his group is a pregnant woman. The facilitators of the control groups were midwives who are already providing prenatal education classes at the clinics. The classes followed the government curriculum, which consists of three classes per month and does not invite husbands to participate. However, in this study, participants in the control group have four classes over a one-month period to better match the program of the intervention group. The material for the standard curriculum includes anatomical and physiological changes during pregnancy, pregnancy care, birth, and postpartum care. The classes also address family planning after giving birth, newborn care, preventing infectious disease, and procedures for obtaining a birth certificate. The midwives also discuss and debunk unhealthy local myths, beliefs, and cultural practices surrounding pregnancy, childbirth and the postpartum period
16288155|NCT04759118|Experimental|Experimental group|The modified childbirth education program was applied in the experimental group. the intervention covered modification of content material, learning methods, and involving husband or other relatives during the class.
16288156|NCT04759105|Experimental|Autologous BM-MSC injection|"Two interventions:
~Bone marrow harvesting from the posterior superior iliac crest region
~Single injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control"
16288157|NCT04759105|Sham Comparator|Sham Procedure|"Two sham procedures:
~Simulated bone marrow harvesting without insertion into the posterior iliac crest region
~Simulated injection under only local anaesthesia without disc injection, without placebo injection."
16288158|NCT04759092|Experimental|Treatment with tDCS|Home based treatment with tDCS for four months
16288159|NCT04759079|Experimental|Acupuncture Needles and Antiemetic Drug|
16288160|NCT04759079|Active Comparator|Antiemetic Drug|
16288161|NCT04759066|Experimental|Experimental|Participants will wear HEALiX device
16288162|NCT04759053|Active Comparator|FNB|
16288163|NCT04759053|Active Comparator|Core biopsy|
16288164|NCT04759040|Active Comparator|MigraineGuard|Active supplement treatment , MigraineGuard capsule containing Coq10 , Magnesium ,Vit B2 , Skullcap Extract , Feverfew Extract , Piperine
16288165|NCT04759040|Placebo Comparator|Placebo for MigraineGuard|Placebo capsules non identifiable from Migraineguard capsules were used as control comparator
16288166|NCT04759027||X-ray|Measurements of subacromial distance on standardized direct radiography
16288167|NCT04759027||ultrasound|Measurements of subacromial distance on ultrasound
16288168|NCT04759014||Group 1|21 patients using non-articulated dynamic foot (non-articulating ankle, NAA)
16288169|NCT04759014||Group 2|21 patients using dynamic foot with hydraulic ankle (articulating hydraulic ankle, AHA)
16288170|NCT04759001|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
16288171|NCT04759001|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
16288172|NCT04758988|Other|Group A|This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
16288173|NCT04758988|No Intervention|Group B|"This group is withheld their access to the AI augmented digital online educational system for 2 months.
~After the 2 months delay, the subjects in the group are given the same access as the participants in Group A."
16288174|NCT04758975|Experimental|Venetoclax + Rituximab +/- Ibrutinib|"VENETOCLAX: Cycle 1 Day 1-Cycle 1 Day 28 Ramp-up with weekly dose escalation; Cycles 2-12: 400 mg QD RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
~At the end of Cycle 12 the MRD status is checked:
~3 consecutive uMRD in PB + 1 uMRD in BM at last assessment treatment discontinuation and follow-up At least 1 MRD+ sample in the last 3 assessments venetoclax 400 mg QD until uMRD or up to 24 months or unacceptable toxicity (whichever occurs first) in combination with IBRUTINIB 420 mg QD until uMRD or PD or unacceptable toxicity"
16288175|NCT04758962|Experimental|1 µg CoV2 SAM (LNP) Group|Participants aged 18-50 years, allocated in the 1 µg COV2 SAM (LNP) Group receive 2 doses of 1 µg CoV2 SAM (LNP) vaccine 30 days apart, at day 1 and day 31 and are followed up until the study end.
16288176|NCT04758949|Experimental|FL-101 Monotherapy|30 patients will receive FL-101 prior to surgery.
16288177|NCT04758949|Experimental|FL-101 + Nivolumab|30 patients will receive FL-101 and Nivolumab prior to surgery.
16288178|NCT04758949|Active Comparator|Nivolumab + Placebo|30 patients will receive Nivolumab and placebo prior to surgery.
16288179|NCT04758936|Experimental|Clonidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (clonidine) will be administered as soon as possible, The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
16288180|NCT04758936|Experimental|Dexmedetomidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (dexmedetomidine) will be administered as soon as possible. The α-2 agonist treatment that will be started will depend on the allocation of the previously randomized unit. The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
16288181|NCT04758923|Active Comparator|Two-Stage|Two-stage approach The treatment process commenced with an intial treatment phase. This will be udertaken Under General anaesthesia and entailed ERCP and endoscopic sphincterectomy
16288216|NCT04758728|Sham Comparator|Group C|Group C - great saphenous vein stripping with traditional hemostatic practice
16288217|NCT04758715|Other|Food provided|Food provided from a commercial meal service provider for a week
16288741|NCT04755153|Experimental|Kaiser Blood Pressure Control Bundle|
16288182|NCT04758923|Active Comparator|Single stage|Single stage approach Under General anaesthesia a5 trocar method will be used to access the abdominal cavity. Aconventional approach to laparoscopic cholecystectomy will be first udertaken with dissection of calot's triangle. The cystic duct will be pulled laterally to facilitate exposure of the anterior wall of the CBD, and the CBD will be opened longitudinally for a distance of approximately 1 to 1.5 cm using laparoscopic scissors. A5 mm flexible choledoscope will be used to identify the cbd stone which will be removed by flushing with sterile saline, passing a stone basket or electrohydroulic lithotripsy as neccesary to clear the CBD. A T-tube will be inserted into the CBD via the choledochotomy which will be closed by interrupted resorbable sutures before completing the cholecystectomy.
16288183|NCT04758910|Active Comparator|High Flow Oxygen Therapy|Tracheostomized patients will undergo a spontaneous breathing trial with high flow oxygen therapy.
16288184|NCT04758910|Active Comparator|T-piece|Tracheostomized patients will undergo a spontaneous breathing trial with T-piece as a standard of care.
16288185|NCT04758897|Experimental|Single Arm|"5.0*10^7 on D1
~1.0*10^8 on D1
~2.0*10^8 on D1
~2.0*10^8 on D1 and D2
~2.0*10^8 on Days 1 to 3
~2.0*10^8 on Days 1 to 4
~2.0*10^8 on Days 1 to 5"
16288186|NCT04758884|Experimental|Telemedicine group|"Visits by videoconference in months 0, 1, 2, 3, 4 and 6. Additionally, availability to send intermediate messages with a response from the endocrine in less than 72 hours.
~The videoconference will be held safely through the SocialDiabetes® App. Patients will be provided with a glucometer that transfers the data directly to the App without the patient having to enter it to avoid bias in time and value. Videoconferences will NOT be recorded.
~Patients with CGM will additionally have all their values on the platform that corresponds to their sensor (Libreview® for the Freesyle libre® sensor and Clarity® for the Dexcom G5 sensor)."
16288187|NCT04758884|No Intervention|Conventional management group|Initial visit, 3 and 6 months.
16288188|NCT04758871|Experimental|Dydrogesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using dydrogesterone 10 mg 3 times daily
16288189|NCT04758871|Active Comparator|Micronized progesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using micronized progesterone 2x200 mg twice daily vaginally
16288190|NCT04758858|Active Comparator|VLCHF (Very Low CHO High Fat) Diet|10% of energy from CHO, 15% proteins, and 75% lipids
16288191|NCT04758858|Active Comparator|Low-CHO Diet|30% of energy from CHO, 15% proteins and 55% lipids
16288192|NCT04758858|Placebo Comparator|Control Diet|50% of energy from CHO, 15% proteins and 35% lipids
16288193|NCT04758845|Experimental|Cocktail|Subjects will consume 1 capsule containing 2B CFU containing .5B CFU Bacillus subtilis DE111, .5B CFU Bacillus coagulans CGI314, .5B CFU Bacillus megaterium MIT411, and .5B CFU Bacillus clausii CSI08 for 45 days.
16288194|NCT04758845|Experimental|CGI314|Subjects will consume 1 capsule containing 1B CFU of Bacillus coagulans CGI314 for 45 days.
16288195|NCT04758845|Experimental|CSI08|Subjects will consume 1 capsule containing 1B CFU of Bacillus clausiiCSI08 for 45 days.
16288196|NCT04758845|Experimental|MIT411|Subjects will consume 1 capsule containing 1B CFU of Bacillus megaterium MIT411 for 45 days.
16288197|NCT04758845|No Intervention|Placebo|Subjects will consume 1 capsule containing maltodextrin for 45 days.
16288198|NCT04758819|No Intervention|Control group|Embryo selection according to Day 5/6 usual morphological criteria (Istanbul consensus)
16288199|NCT04758819|Experimental|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts: CTTEB group|Trophectoderm cells will be analyzed by NGS. Culture media will also be stored for further non-invasive chromosomal testing. Embryo selection will be done according to international guidelines (www.pgdis.org; Newsletter May 27, 2019).
16288200|NCT04758806|Experimental|Fecal microbial transplantation from unrelated donor|Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days
16288201|NCT04758793|Other|patients without liver disease,|taking blood samples and biopsy of muscular wall
16288202|NCT04758793|Other|patient with chronic liver disease without cirrhosis,|taking blood samples and biopsy of muscular wall
16288203|NCT04758793|Other|patients with compensated cirrhosis,|taking blood samples and biopsy of muscular wall
16288204|NCT04758793|Other|patient with severe cirrhosis|taking blood samples and biopsy of muscular wall
16288206|NCT04758767|Experimental|Dose escalation cohort|Monotherapy CID-103. Priming dose will be given for first dose. Dose and duration of infusion dependent on dose cohort and tolerability.
16288207|NCT04758767|Experimental|Dose expansion cohort - pretreated|CID-103 monotherapy at the recommended phase 2 dose
16288208|NCT04758767|Experimental|Dose expansion cohort - Naïve|CID-103 monotherapy at the recommended phase 2 dose
16288209|NCT04758754|Experimental|Single leg knee extension training (SLKE)|Active 8-week training involving lower limbs. SLKE participants will be involved in a 8-week aerobic training protocol involving the knee extensor muscles. The training will be held on an Anderson and Saltin ergometer, 3 times per week, with a single session duration of 33.3 min. Total weekly duration: 100 min.
16288210|NCT04758754|Active Comparator|Passive static stretching training (PST)|Passive 8-week training involving lower limbs. PST participants will be involved in a 8-week passive static training training involving the knee extensor muscles. The training will have a frequency of 5 times per week, with a single duration of 20 min. Total weekly duration: 100 min
16288211|NCT04758754|No Intervention|Control (CTRL)|CTRL will not receive any intervention.
16288212|NCT04758741|Experimental|Acceptance and commitment treatment|The members of the intervention group receive one session of acceptance and commitment treatment per week according to Hayes (2006) approach in groups of 10 in 8 sessions of 90 minutes by a trained counselor (researcher) in Mashhadalkoubeh Health Center.
16288213|NCT04758741|Sham Comparator|Health Education|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience.
16288214|NCT04758728|Active Comparator|Group A|Group A - great saphenous vein stripping with local adrenaline use for hemostasis
16288215|NCT04758728|Sham Comparator|Group B|Group B - great saphenous vein stripping with local normal saline use for hemostasis
16288742|NCT04755140||Endoprosthesis|Patients with a endoprosthesis
16288218|NCT04758702|Experimental|GROUP 1|L-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
16288219|NCT04758702|Experimental|GROUP 2|H-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
16288220|NCT04758702|Experimental|GROUP 3|A surgical stent will be delivered to cover the surgical site and apply pressure on the wound site.
16288221|NCT04758689|Experimental|Laser acupuncture and aerobic exercise|
16288222|NCT04758689|Experimental|Aerobic exercise|
16288223|NCT04758676|Experimental|Nutritional and physiotherapy protocol, BIA|Study subjects randomized into this study arm will be indicated for nutritional and physiotherapy protocol, based upon the obtained results of the measurements, using bioimpedance analysis.
16288224|NCT04758676|Active Comparator|Standard of care|Study subjects randomized into this study arm will be provided the current standard of care.
16288225|NCT04758663|Experimental|Declarative memory|Napping v. wake effect on declarative memory in habitual and non-habitual nappers.
16288226|NCT04758663|Experimental|Overnight Physiology|Napping v. wake effect on overnight physiology in habitual and non-habitual nappers.
16288227|NCT04758650|Experimental|Head and neck cancer|Patients diagnosed with pathology-proven squamous cell carcinomas of the head and neck in need of a non-surgical therapy.
16288228|NCT04758650|Experimental|Immune checkpoint inhibition|Patients diagnosed with any malignancy with a solid component in need of immune checkpoint inhibitor-type immunotherapy.
16288229|NCT04758650|Experimental|Carotid plaque|Patients diagnosed with carotid plaque, planned for standard of care carotid endarterectomy.
16288230|NCT04758637|No Intervention|Control Group|Physicians in the control group will receive no notification of their patient's fatal or nonfatal overdose.
16288231|NCT04758637|Experimental|Overdose Notification Group|The overdose notifications will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses.
16288232|NCT04758624|Experimental|Deep Brain Stimulation(DBS)|
16288233|NCT04758611|Experimental|Treatment Arm|The Treatment Arm receives the eShunt implant
16288234|NCT04758598|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Direct Selective Laser Trabeculoplasty (DSLT): employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
16288235|NCT04758598|Active Comparator|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
16288236|NCT04758585|Active Comparator|Study Group|
16288237|NCT04758585|No Intervention|Control Group|
16288238|NCT04758572|Experimental|Manual Therapy|"Mobilization. Axial decoaptation, talar mobilization, global and specific articulatory mobilization of the foot, mobilization of the fibular head, femorotibial mobilization, hip mobilization. In addition, lumbar joint mobilization is applied. The articulatory techniques last 15 minutes. Subsequently, Trigger Point Inhibition is applied. in the medial gastrocnemius, soleus, and square plantar muscles. The application of this technique lasted 15 minutes.
~Plantar fascia massage. A deep friction technique was applied longitudinally and transversely to the plantar fascia and the triceps surae. It lasted 15 minutes.
~Passive stretching. Stretches were applied to the plantar fascia, the gastrocnemius muscles and the soleus muscles in order to relax these muscles. The duration was 5/10 minutes."
16288239|NCT04758572|Sham Comparator|Placebo massage|Consist of gentle kneading and rubbing without intention to treat for 15 minutes.
16288240|NCT04758559|Placebo Comparator|Usual care|Patients receive usual care concerning dietary advice.
16288241|NCT04758559|Experimental|myfood24|Patients receive myfood24 a new online app to support tracking of food and nutrient intakes, and allows patients and healthcare professionals to communicate, seeing results of intakes to promote healthy dietary behaviour changes.
16288242|NCT04758559|Experimental|myfood24 + diet optimisation|Personalised feedback. Patients use myfood24 with an additional feature of new technology providing guidance of how to optimise their diets against targets, using information they provide about current intakes.
16288243|NCT04758546|Experimental|Aggressive screening criteria + high minimal ventilatory settings|
16288244|NCT04758546|Experimental|Aggressive screening criteria + low minimal ventilatory settings|
16288245|NCT04758546|Experimental|Conservative screening criteria + high minimal ventilatory settings|
16288246|NCT04758546|Active Comparator|Conservative screening criteria + low minimal ventilatory settings|
16288247|NCT04758533|Experimental|AloCELYVIR|Patients will received weekly infusion of AloCELYVIR during 8 weeks.
16288248|NCT04758520|Experimental|Experimental|"Six subjects are involved in a single session of upper limb robotic-assisted therapy lasting about 3 hours and including:
~passive mobilization of patient's upper arm along elementary shoulder movements:shoulder flexion/extension, adduction/ abduction in the frontal plane, horizontal adduction/ abduction, intra/extrarotation (Passive Mode);
~passive mobilization of patient's upper arm along complex trajectories recorded from manual mobilization of the therapist (Learn&Replay Mode);
~active mobilization, performed by the patient during rehabilitative functional tasks, relying only on gravity and friction compensations and tuneable assistance from the exoskeleton (Transparency Mode)."
16342523|NCT04381611||Glaucoma Surgery Combined|
16288250|NCT04758507|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of saline solution)
16288251|NCT04758494||Stroke1-hemiparesis|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis.
16288252|NCT04758494||Stroke 2-mild stroke|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a mild stroke.
16288253|NCT04758494||Stroke 3-speech disorder|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a speech disorder.
16288254|NCT04758494||Stroke 4-hemiparesis mainly of upper limb|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis mainly of upper limb.
16288255|NCT04758494||Stroke 5-memory loss and depression|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of memory loss and depression.
16288256|NCT04758494||Multiple Sclerosis|Patients diagnosed with multiple sclerosis.
16288257|NCT04758481|Experimental|Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy|The patients, in whom disease stabilisation/partial regression will be achieved, will undergo primary tumour radiotherapy and stereotactic body radiotherapy, followed with maintenance radiotherapy.
16288258|NCT04758468|Experimental|Telerehabilitation-based pelvic floor muscle training|
16288259|NCT04758468|Active Comparator|Home-based pelvic floor muscle training|
16288260|NCT04758468|No Intervention|Control (no specific intervention)|
16288261|NCT04758455|Experimental|P53 IHC|P53 staining density and intensity will be calculated. To assess P53 density in a semiquantitative way, a score of 0 will be given assigned if less than 5% of tumour cells expressed p53, 1 if 5% to 50% expressed p53 and 2 if more than 50% stained positive for p53. To evaluate P53 intensity, a score of 0 means weak or absent staining, 1 refers to the intermediate intensity and 2 stands for strong intensity.
16288262|NCT04758455|Experimental|Ki67 IHC|Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
16288263|NCT04758455|Experimental|Cyclin A IHC|Regarding Cyclin A, a standard peroxidase-conjugated streptavidin-biotin labelling was used for visualization, with 3,3 diaminobenzidine as chromogen. Level of cyclin A expression will be classified as absent (-), focal (+), moderate (++) diffuse (+++).
16288264|NCT04758442|Experimental|Vancomycin|Subjects with hematologic cancer who received intravenous vancomycin for a suspected or confirmed infection.
16288265|NCT04758429||Development or Training Cohort|will provide the data to be used for algorithm development and training.
16288266|NCT04758429||Test or Validation Cohort|will provide data to be used for algorithm validation.
16288267|NCT04758416||Metastatic breast cancer patients|50 metastatic breast cancer patients
16288268|NCT04758403|Experimental|Navigation Bronchoscopy ALONE|"This research study involves a screening period, a procedure and follow up visits
~Procedure Visit Navigation Bronchoscopy Alone
~Follow-Up Visits at Week 1, 4 and 12"
16288269|NCT04758403|Experimental|CBCT-GUIDED Navigation Bronchoscopy|"This research study involves a screening period, a procedure and follow up visits Procedure Visit- Cone Beam Computed Tomography - Guided Navigation Bronchoscopy for Peripheral Pulmonary Nodules
~-Follow-Up Visits at Week 1, 4 and 12"
16288270|NCT04758390|Experimental|IMARA intervention arm|Participants randomized to the IMARA arm will receive the IMARA intervention (i.e., the intervention group).
16288271|NCT04758390|Experimental|Health promotion control arm|Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
16288272|NCT04758377|Experimental|Arm 1|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
16288273|NCT04758351||Cases - Patients with chronic cough|Patients referred to secondary care clinic for investigation and treatment for explained chronic cough, refractory chronic cough, and unexplained chronic.
16288274|NCT04758338|Experimental|CTS Program Arm|6-week intervention delivered via telehealth using the VUMC telehealth services.
16288275|NCT04758338|Active Comparator|Education Attention Control Arm|Receive educational materials either online, by email, or in print form.
16288276|NCT04758312|Experimental|MY-Skills Mobile Intervention|MY-Skills Mobile is an 8-week intervention merging yoga and self-management offered via remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. The self-management content is delivered primarily through asynchronous tools that include educational videos and interactive activities for goal setting, action plan, monitoring goals, and problem-solving practice. Yoga is offered synchronously via Zoom two-times per week for 60 minutes (120 minutes per week). The synchronous yoga sessions will be offered at a time that best accommodates participants' schedules. Yoga will become progressively challenging over the eight weeks and will include seated and standing postures.
16288277|NCT04758299|No Intervention|Standard care|information from an FDA authorized home test kit for what actions to take for a negative or positive COVID-19 test
16288278|NCT04758299|Experimental|Decision science-based design|Information from a decision science-based design (of similar length to the FDA authorized home test kit information) for what actions to take for a negative or positive COVID-19 test
16288279|NCT04758286|Active Comparator|Successful outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
16288280|NCT04758286|Active Comparator|Complicated outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
16288281|NCT04758273|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
16288282|NCT04758273|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
16288283|NCT04758273|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
16288284|NCT04758273|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288285|NCT04758273|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288286|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
16342524|NCT04381611||Glaucoma treatment|
16288287|NCT04758273|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288288|NCT04758273|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288289|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
16288290|NCT04758260|Experimental|Antioxidant Treatment|Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men
16288291|NCT04758247|Active Comparator|Active|
16288292|NCT04758247|Sham Comparator|Sham|
16288293|NCT04758234|Experimental|LY3549492 (Part A)|LY3549492 administered orally as single ascending doses.
16288294|NCT04758234|Experimental|LY3549492 (Part B)|LY3549492 administered orally as multiple ascending doses.
16288295|NCT04758234|Placebo Comparator|Placebo|Placebo administered orally.
16288296|NCT04758221|Experimental|Single arm : Composite coronal build up strip crown|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
16288297|NCT04758208||Healthy CALIPER Participants|Healthy community children and adolescents recruited through the CALIPER initiative as well as healthy children and adolescents recruited from outpatient clinics at the Hospital for Sick Children through the CALIPER initiative. Blood samples from these participants will be tested on the Mindray BC-6800Plus device to measure hematology parameters and establish reference intervals.
16288298|NCT04758195|Experimental|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
16288299|NCT04758195|Active Comparator|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
16288300|NCT04758182|Experimental|Experimental group|Experimental group: HILT + sham ultrasound therapy In the experimental group, participants received HILT treatment 1 session per day over a period of 2 consecutive weeks (5 days/week); total 10 sessions. In this study we used HIRO 3.0 device applied to the hemiplegic shoulder and the area of following muscles include upper trapezius, supraspinatus, deltoid, pectoralis minor muscles and the tender points. The treatment consisted of high peak power (3kW), a wavelength of 1064 nm. Two phases of treatment were performed according to Rotator cuff tendinopathy protocol of the device. The total energy administered will be approximately 2500 J. The total treatment time was approximately 10 minutes. They also received sham ultrasound therapy, which performed by applying probe with gel without turning on the device, for 10 minutes.
16288301|NCT04758182|Active Comparator|Control group|"Control group: sham HILT + ultrasound therapy In control group, participants received continuous ultrasound therapy for 10 minutes in the same area as an experimental group with Chattanooga intellect mobile ultrasound device. The device was operated at the frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100% in the same area of the HILT group. They also received sham HILT, by applying the applicator with pre-recorded sound without starting the device, for 10 minutes. Ultrasound therapy and sham ultrasound were delivered according to the predefined protocol by the physiotherapists.
~Both groups received 3 ROM exercise sessions per day. Participants and their caregiver were educated about proper positioning and manual handling"
16288302|NCT04758169|Experimental|Enhanced Homestead Food Production|Participant in this arm will receive the Helen Keller's EHFP model which involves homestead food production, nutrition and WASH education and gender transformative sessions (intervention group). Participants will also receive interventions related to parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH and basic life-skill trainings.
16288303|NCT04758169|Experimental|Control|Participants in this arm will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings. This particular arm will not receive any homestead food production intervention over the course of the implementation.
16288304|NCT04758156|Experimental|CleanViewAL|1L polyethylene glycol+ascorbic acid split dose
16288305|NCT04758156|Placebo Comparator|SUPREP|Oral sulfate solutiom
16288306|NCT04758130|Experimental|App Group|Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.
16288307|NCT04758130|Placebo Comparator|Placebo Group|Patients in this group are not provided with the clinic link to the application.
16288309|NCT04758104|Experimental|Yttrium90|Intracystic application of yttrium90
16288310|NCT04758078|Experimental|Corticosteroids|Patients will receive inhaled corticosteroids (Budesonide 2 mL = 1000 microgram)
16288311|NCT04758078|Placebo Comparator|Placebo|Patients will receive nebulized 0.9% saline
16288312|NCT04758065|Active Comparator|1-Goup: Control group|Home-based cervical therapeutic exercise and manual therapy.
16288313|NCT04758065|Experimental|2-Group: Radial pressure waves Group|Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves.
16288314|NCT04758052|Experimental|simultaneous tracheostomy with gastrostomy (TSG)|This arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.
16288315|NCT04758052|No Intervention|non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)|"This arm include the patients who proceed with usual care placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard."
16288316|NCT04758013|Experimental|Laparoscopic gastric surgery with Epidural injection|Patients with laparoscopic gastric surgery who received epidural injection through an thoracic epidural catheter.
16288317|NCT04758013|Experimental|Laparoscopic gastric surgery without Epidural injection|Patients with laparoscopic gastric surgery who don't received epidural injection through an thoracic epidural catheter.
16288318|NCT04758013|No Intervention|Open gastric surgery|Patients with open gastric surgery.
16288319|NCT04758000|Experimental|Metformin|"Metformin will be administrated according with patients body mass index (BMI). The study is divided into 2 groups.
~Group 1: Localized osteosarcoma that have presented a response ≤ 60% to the pre-operatory chemotherapy).
~Group 2: Osteosarcoma and Ewing sarcoma patients with complete remission after the first relapse."
16288320|NCT04757987||Pain-free|Report persistent pain at enrolment
16288321|NCT04757987||Persistent pain|Report no pain at enrolment
16288322|NCT04757974|Experimental|Part 1: Treatment sequence ABC|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
16288323|NCT04757974|Experimental|Part 1: Treatment sequence BCA|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
16288324|NCT04757974|Experimental|Part 1: Treatment sequence CAB|Participants will receive FTR 600 mg ER tablet in Period 1 (Treatment C, reference) followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
16288325|NCT04757974|Experimental|Part 1: Treatment sequence ACB|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
16288326|NCT04757974|Experimental|Part 1: Treatment sequence BAC|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
16288327|NCT04757974|Experimental|Part 1: Treatment sequence CBA|Participants will receive FTR 600 mg ER tablet (Treatment C, reference) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
16288328|NCT04757974|Experimental|Part 2: Treatment sequence DE|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets in a fasted state (Treatment D) in Period 1 and following a high fat high calorie meal (Treatment E) in Period 2.
16288329|NCT04757974|Experimental|Part 2: Treatment sequence ED|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets following a high fat high calorie meal (Treatment E) in Period 1 and in a fasted state (Treatment D) in Period 2.
16288330|NCT04757961|Experimental|Lifestories|Participants in this condition will be actively participating in the online intervention for 4 weeks.
16288331|NCT04757961|No Intervention|Waitlist Control Condition|Participant in the waitlist group will be asked to not use other self-help websites or books for four weeks, after which they will be given weekly access to LifeStories modules. All participants will be asked to continue their antidepressant treatment as usual as directed by their primary care provider.
16288332|NCT04757948|Experimental|Acupuncture|Sterile needles are inserted into acupuncture points P-6 and St-36 bilaterally and retained for a total of 20 minutes. Halfway through the treatment, the needles are manipulated in order to re-create the acupuncture sensation. The needles are removed after 20 minutes of treatment prior to the second gag measurement.
16288333|NCT04757948|Experimental|TENS|Gel pads are affixed to the acupuncture points P-6 and St-36, bilaterally. The amplitude of the TENS device will be gradually increased up to a maximum setting of 8/10, with the subject asked to notify the examiner as soon as any sensation is noticed. Once a gentle buzzing sensation is noticed, the amplitude will be reduced slightly for comfort and then the device will remain for the duration of 20 minutes. The pads are then removed prior to the second gag reflex measurement.
16288334|NCT04757948|Placebo Comparator|Sham-TENS|For the sham-TENS group, the protocol is identical to the TENS group, however the electrical wires have been severed and re-attached in the control unit. As such, the unit will flash a light but there will be no current delivered. The subject is told that no sensation is required. The amplitude will be turned up to a maximum setting of 8/10 and left there for 20 minutes, then the device turned off and pads removed.
16288335|NCT04757922||Intervention: bilateral salpingectomy|Premenopausal women between 35 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.
16288336|NCT04757922||Control: tubal ligation or no sterilization|The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.
16288337|NCT04757909|Experimental|Monthly Haemoglobinometry|
16288338|NCT04757909|No Intervention|Routine monitoring|
16288339|NCT04757896|Active Comparator|Costoclavicular block lateral aproach|An 80-100 mm needle will be directed from the lateral to the medial with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
16288340|NCT04757896|Active Comparator|Costoclavicular block medial aproach|An 80-100 mm needle will be directed from the medial to the lateral with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
16288341|NCT04757857|Active Comparator|Rivaroxaban 10 mg|Participants will receive, from the 1st to the 14th day, a dose of 10 mg of rivaroxaban - OA (Oral Administration).
16288342|NCT04757857|No Intervention|Best locally standardized care|According to the study protocol, participating investigators are advised to follow the best available local practice in each participating site. There is no formal recommendation for any particular COVID-19 treatment, except symptomatic therapies.
16288343|NCT04757844|Experimental|Young healthy voluntary adults|30 young healthy voluntary adults
16288344|NCT04757818|Experimental|0.07% cetylpyridinium chloride (CPC) in mouthwash|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
16288345|NCT04757818|Placebo Comparator|Distilled water with the same colorant as the experimental product|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
16288346|NCT04757805|Experimental|Spinal anesthesia|Infants receiving spinal anesthesia for standard of care procedure
16288347|NCT04757792||No NSAID|included patients who did not receive NSAID prior to having COVID-19 disease
16288348|NCT04757792||Apsirin|included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease
16288349|NCT04757792||Celecoxib|included patients who received celecoxib (CEL) prior to having COVID-19 disease
16288350|NCT04757792||Miscellaneous|included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease
16288351|NCT04757779|Experimental|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach. Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle). On Day1 and Day8, subjects are required to inject irinotecan(65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
16288352|NCT04757753|Experimental|ready-to-use root canal sealer: PA1704|PA1704 is used in combination with gutta percha points for the permanent obturation of root canals.
16288353|NCT04757753|Other|root canal sealer: BioRoot™ RCS|BioRoot™ RCS is used in combination with gutta percha points for the permanent obturation of root canals.
16288354|NCT04757740|Active Comparator|Platelet rich fibrin Group|Platelet rich fibrin. Group P
16288355|NCT04757740|Active Comparator|Methylprednisolone acetate|Group S
16288356|NCT04757727||EDB|Adult women (> 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP
16288357|NCT04757714|Other|COPD Patients|"Patients agreeing to participate in the study and meeting the inclusion and non-inclusion criteria will have:
~The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
~a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
~to complete:
~a physical activity questionnaire (PHAS instrument)
~a COPD quality of life questionnaire (St George Hospital)
~A search for sarcopenia by studying the strength of the grip (dynamometer)"
16288358|NCT04757701||General dentists and dental hygienists in North Carolina|This objective will be met by administering a quantitative survey to active and licensed NC dentists and dental hygienists.
16288359|NCT04757701||Directors of Service-Learning Centers and their partnering FQHCs|This objective will be met by conducting qualitative assessments with ECU's SoDM's CSLCs and their partnering community clinic/FQHCs. The investigators will interview the Directors of the eight existing CSLCs and focus groups with clinical staff at each CSLC. In collaboration with the Directors of the CSLCs, the investigators will identify key stakeholders in the co-located/partnering medical clinics, and conduct interviews with the administrators and focus groups with medical clinic staff.
16288360|NCT04757688|Experimental|Cardiac radioablation (CRA)|CRA delivered via linear accelerator (stereotactic body radiotherapy) to the suspected arrhythmogenic substrate to a dose of 25 Gy in 1 fraction.
16288361|NCT04757675|Experimental|0.3 SK iv|0.3 μg/kg intravenous injection s-ketamin
16288362|NCT04757675|Experimental|0.5 SK iv|0.5 μg/kg intravenous injection s-ketamin
16288363|NCT04757675|Experimental|2 SK in|2 μg/kg intranasal s-ketamin
16288364|NCT04757675|Experimental|1 SK in + 1 DEX in|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
16288365|NCT04757675|Experimental|0.5 SK in + 2 DEX in|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
16288366|NCT04757662|Experimental|Tadalafil|"Tadalafil will be given orally once daily for a total of 60 days at a weight-normalized dose as follows:
~10 mg/day if weight ≤63.5 kg
~15 mg/day if weight >63.5 kg and ≤104.3 kg
~20 mg/day for weight >104.3 kg
~Standard of care fractionated radiation therapy (RT) to 60 Gy in 30 daily fractions will be administered in this study.
~Concurrent temozolomide (TMZ) will be administered as per standard of care, i.e., continuously (Monday through Sunday) from Day 1 of RT to the last day of RT at a daily oral dose of 75 mg/m^2 at the discretion of treating medical oncologist.
~Adjuvant therapy will administered as per standard of care. Typically, this consists of adjuvant TMZ initiated 4 to 6 weeks after completion of RT for 6 cycles at 150-200 mg/m^2 PO per day on Days 1-5 of every 28-day cycle. Tumor-treating fields or Optune device (Novocure) as per routine clinical care during adjuvant TMZ is permitted at the discretion of the treating physician."
16288371|NCT04757623|No Intervention|Group B : conventional primary closure|allileostomies are reversed with conventional method
16288372|NCT04757623|Experimental|Group A: Purse string closure|the ileostomy reversal circular incision used with stitches of continuous and non-absorbable. The wound of skin was closed by using (Proline No. 1) that leaving 0.5 cm defect on middle in the skin.
16288376|NCT04757597|Experimental|RIC group|RIC treatment and regular treatment.
16288377|NCT04757597|No Intervention|Regular treatment|Regular treatment alone.
16288378|NCT04757584|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during period 4, we will again conduct a dose reduction until off of beta blockers."
16288379|NCT04757584|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
16288380|NCT04757571|Experimental|Paroxetine|Paroxetine 20 mg daily plus standard therapy
16288381|NCT04757571|Placebo Comparator|Placebo|Placebo tablet daily plus standard therapy
16288382|NCT04757558|Active Comparator|C-MAC-VS group|C-MAC-VS will be used to facilitate intubation
16288383|NCT04757558|Placebo Comparator|control group|direct laryngoscopy using Macintosh laryngoscope will be done for DLT insertion.
16288384|NCT04757545|Active Comparator|HM-PRO intervention|The intervention group will have a predetermined nurseled consultation planned to assess medical status and symptom control at 0, 6 and 12 months. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients.
16288385|NCT04757545|No Intervention|Standard outpatient follow-up care|The control group will receive standard care in the outpatient clinic. The patient has a predetermined consultation appointment at the hospital one time a year with a doctor to evaluate medical status and symptom control.
16288386|NCT04757532|Experimental|Bupropion|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h post-administration.
16288387|NCT04757532|Experimental|Anastrozole|Subjects receive a single-dose treatment. Urine samples will be collected until 7 days after administration in 7 fractions: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h post-administration.
16288388|NCT04757532|Experimental|Testosterone cyclopentylpropionate|Subjects receive a single-dose treatment. Urine samples will be collected until 20 days after administration in 20 fractions: first urine of the day, every day.
16288389|NCT04757532|Experimental|Danazol|Subjects receive a single-dose treatment. Urine samples will be collected until 2 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h post-administration.
16288390|NCT04757532|Experimental|Chlorthalidone|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 4 fractions: 0-12h, 12-24h, 24-48h y 48-72h post-administration.
16288391|NCT04757519|Experimental|DPP-GLB Standard|Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
16288392|NCT04757519|Experimental|DPP-GLB Enhanced|Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
16288393|NCT04757506|Placebo Comparator|Placebo|cellulose-filled capsule
16288394|NCT04757506|Experimental|Naltrexone|single 50 mg oral dose naltrexone (capsule)
16288397|NCT04757480|Experimental|Thoracolumbar Interfascial Plane Block (TLIP)|
16288398|NCT04757480|Experimental|Bilateral Erector Spinae plane Block (ESB)|
16288399|NCT04757467|Active Comparator|Standard physiotherapy neuro-rehabilitation|Control Group: Patients included in the control group will receive standard physiotherapy neurorehabilitation protocols.
16288400|NCT04757467|Experimental|Repetition-CIMT|In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr
16288401|NCT04757467|Experimental|Hour-CIMT|The task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours.
16288402|NCT04757441|Experimental|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire (ELDOA)|Participants will receive conventional treatment along with ELDOA stretching exercises protocol at L5, S1.
16288403|NCT04757441|Other|Group B: Conventional treatment|Participants will receive only conventional treatment (Control)
16288404|NCT04757428|Active Comparator|Lithium disilicate|The intervention will be: Prosthetic endocrown
16288405|NCT04757428|Active Comparator|Hybrid nanoceramic|The intervention will be: Prosthetic endocrown
16288406|NCT04757415|Experimental|Traction straight leg raise technique for hamstring.|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions along with traction straight leg raise technique. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
16288407|NCT04757415|Experimental|Gluteal activation exercises|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
16342525|NCT04381611||Glaucoma imaging|
16288408|NCT04757402|Active Comparator|Control arm|All eligible candidates will be receiving standard preoperative counselling as per the hospital standards and protocols. The patient will fill five-points Amsterdam Preoperative Anxiety and Information Scale (APAIS) form for anxiety evaluation and Seven-points Likert Scale form for satisfaction regarding the counselling.
16288409|NCT04757402|Experimental|NSQIP Arm|All eligible candidates will be receiving standard preoperative counselling as per the control arm PLUS the risk will be explained using the scores from the NSQIP surgical risk calculator. The anxiety and the satisfaction scores will be recorded as in the control arm.
16288410|NCT04757376|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
16288411|NCT04757376|Active Comparator|US-licensed Prolia|60 mg/mL single dose administration, Solution for injection in PFS
16288412|NCT04757363|Experimental|Nivolumab Combined With FOLFOX and Regorafenib|Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
16288413|NCT04757350||cataract|Research subjects should meet the following criteria: Signed and dated informed consent form Commitment to abide by the research procedures and cooperate with the implementation of the whole process of research 18-90-year-old cataract patients or patients after cataract surgery
16288414|NCT04757337|Active Comparator|Doxorubicin|Intravenous Doxorubicin 60 mg/m² Cycle 1 then 75 mg/m² Cycle 2 to Cycle 6 D1-D21 with granulocyte-colony stimulating factor (G-CSF) and dexrazoxane.
16288415|NCT04757337|Experimental|Cyclophosphamide|Cyclophosphamide per os 100 mg twice a day, 1 week on, 1 week off until 2 years, or unacceptable toxicity, disease progression, withdrawn of consent or death.
16288416|NCT04757324|Experimental|education arm|Breastfeeding training was given to the training arm
16288417|NCT04757324|No Intervention|control arm|Breastfeeding training not given to control arm
16288419|NCT04757298|Other|Navigation/tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will continue receiving NS.
16288420|NCT04757298|Other|Navigation/tested/brief counseling|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC)
16288421|NCT04757298|Other|Navigation/not tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will continue receiving NS.
16288422|NCT04757298|Other|Navigation/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD)
16288423|NCT04757298|Other|Referral/tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
16288424|NCT04757298|Other|Referral/tested/brief counseling|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC).
16288425|NCT04757298|Other|Referral/not tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
16288426|NCT04757298|Other|Referral/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD).
16288427|NCT04757285||control group|25 healthcare personnel volunteers not working in quarantine hospitals of matched age
16288428|NCT04757285||healthcare providers worked in Intensive Care Units|"35 physicians (28 males and 7 females) and 35 nurses (10 males and 25 females). All volunteers were in good physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving contraceptive pills.
~Assigned participants were clinically evaluated for as hypertension, DM, dyslipidemia, renal function."
16288429|NCT04757246|Other|Cohort 1|Stable outpatients without implantable devices
16288430|NCT04757246|Other|Cohort 2|Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability
16288431|NCT04757246|Other|Cohort 3|Stable outpatients with implantable CardioMEMS devices
16288432|NCT04757233|Other|Single arm|Intervention: GlucoType Single arm study; all participants assigned to use the intervention
16288433|NCT04757220|Experimental|Patients with schizophrenia|"5 subjective questionnaires
~4 cognitive tasks with EEG recordings"
16288434|NCT04757220|Experimental|Patients with depression|"5 subjective questionnaires
~4 cognitive tasks with EEG recordings"
16288435|NCT04757220|Active Comparator|Healthy controls|"5 subjective questionnaires
~4 cognitive tasks with EEG recordings"
16288436|NCT04757194|Experimental|Intervention|Calculation of risk assessment score by machine learning algorithm and display of risk assessment information to dispatch nurses. Staff encouraged but not required to comply with suggested ranking.
16288437|NCT04757194|No Intervention|Control|Ambulance dispatch per standard of care
16288438|NCT04757181|Experimental|IBD patients|IBD patients will be used as their own control. Participants will start the study in a baseline phase (4 weeks) and intervention phase (8 weeks)
16288439|NCT04757168|Experimental|NOGA TM probe|
16289509|NCT04749589||iron replete|opposite of the other group
16288440|NCT04757155|Experimental|iCALM Intervention Group|iCALM is a brief, online psychotherapeutic intervention for patients with advanced and metastatic cancer. It consists of one introductory module and four therapeutic modules composed of written psychoeducational material, videos, and exercises. The intervention is designed to be completed in 9 weeks.
16288441|NCT04757155|No Intervention|Care as usual|Participants in the usual care group (UC) will receive routine care. At Princess Margaret Cancer Centre, routine care includes a referral to Psychiatry, Psychology, or Social Work, based on patients' needs.
16288442|NCT04757129||thrombolysis success group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
16288443|NCT04757129||thrombolysis failure group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
16288444|NCT04757116|Experimental|iTind arm|The iTind is a minimally invasive temporary implant
16288445|NCT04757116|Experimental|TURP arm|Transurethral Resection of the Prostate
16288446|NCT04757103||Above S3|Lesion located above the third sacral vertebra
16288447|NCT04757103||Below S3|Lesion located below the third sacral vertebra
16288448|NCT04757090|Experimental|89Zr-trastuzumab PET/CT imaging|"Enrolled subjects will be asked to undergo 18F-FDG PET/CT imaging (if not performed within the previous 90 days) and 89Zr-trastuzumab PET/CT imaging at baseline prior to the start of monotherapy MT-5111 treatment. Standard of care 18F-FDG PET/CT examinations performed within 90 days of 89Zr-trastuzumab administration can be used in place of a study specific 18F-FDG PET/CT scan. Baseline 89Zr-trastuzumab imaging should be completed no more than 30 days prior to initiating treatment with MT-5111.
~Cold trastuzumab and 89Zr-trastuzumab will be administered at Visit 1 and the 89Zr-trastuzumab PET/CT (Visit 2) will take place 4 days (+/-1 day) after administration of 89Zr-trastuzumab."
16288449|NCT04757077||GROUP 1|Patients 6-24 weeks after delivery with postpartum PGP (Patients with symptoms and signs of PGP, PGP confirmed with dedicated functional tests).
16288450|NCT04757077||GROUP 2|Patients 6-24 weeks after delivery, with no symptoms and signs of PGP.
16288451|NCT04757064|Experimental|Standard Rehabilitation Group|"Standard Rehabilitation Group: will receive the standard protocol of king Hussein hospital 6 weeks post-operative which is:
~Start aggressive knee flexion exercises and increase the extensor strength. Consider CPM/dynasplint if flexion <60_ MUA contraindicated.
~Examination under anesthesia can be done to assess the cause of limited knee flexion. Surgical release is indicated if knee flexion is < 60 degrees at six months after surgery."
16288452|NCT04757064|Experimental|Supervised Rehabilitation Group|Supervised Rehabilitation Group: will receive supervised rehabilitation program 1 session / week for 45 minutes-1 hour.
16288453|NCT04757038|Experimental|Hyalodisc injection|"• Group 1: One single X-ray-guided intradiscal injection (25 gauge) of 8 mg/mL of HYALODISC combined with PEP. The investigator will use one syringe for each involved disc, up to a maximum of three discs.
~The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided. Both groups (Group 1 and Group 2) will be treated with PEP according to a standardized protocol."
16288454|NCT04757038|No Intervention|Physical exercise program (PEP)|Group 2: PEP alone
16288455|NCT04757025|Experimental|Electrical Impedance Tomography|patient monitored by Electrical Impedance Tomography
16288456|NCT04757025|Active Comparator|Peripheral arterial Saturation|patient monitored by Peripheral arterial Saturation alone
16288457|NCT04756999|Experimental|Intervention|informed consent forms, nine sessions of foot reflexology massage will be given to reflex points including the solar plexus, brain, pituitary, thyroid, diaphragm, upper lymphs, lung, spinal cord and adrenal glands for 3 weeks. Then data collection tools were applied.
16288458|NCT04756999|Placebo Comparator|Control|informed consent forms, foot massage were performed. Then data collection tools were applied.
16288459|NCT04756986|Experimental|malic acid group|patients will receive a topical spray containing 1% malic acid
16288460|NCT04756986|No Intervention|placebo group|patients will receive a topical placebo spray
16288461|NCT04756973|Active Comparator|Standard weight loss|A 12 week small group weight loss intervention delivered via video teleconference technology.
16288462|NCT04756973|Experimental|Standard weight loss plus self-compassion skills training|A 12 week small group weight loss intervention delivered via video teleconference technology.
16288463|NCT04756960|Experimental|CHF6001|single dose of CHF6001 DPI co-administered with an intravenous microdose of [14C]-labelled CHF6001
16288464|NCT04756947||Pelvic injury|Paediatric patients (age ≤ 18 years) with a single pelvic bone fracture or pelvic ring injury, excluding pathological fractures.
16288465|NCT04756947||Pelvic and acetabular injury|Paediatric patients (age ≤ 18 years) with a combined pelvic and acetabular injury or an isolated acetabular fracture, excluding pathological fractures.
16288466|NCT04756934|Experimental|Ia: LP002 dose escalation-1mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 1mg/kg, Q3W for up to 1 year.
16288467|NCT04756934|Experimental|Ia: LP002 dose escalation-3mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 3mg/kg, Q3W for up to 1 year.
16288468|NCT04756934|Experimental|Ia: LP002 dose escalation-5mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 5mg/kg, Q3W for up to 1 year.
16288469|NCT04756934|Experimental|Ib: Expansion|Approximately 30 participants will receive HX008 of 200mg, Q3W plus LP002 of the recommended dose, Q3W for up to 1 year.
16288470|NCT04756934|Experimental|Ib: Control|Approximately 15 participants will receive LP002 of recommended dose, Q3W for up to 1 year.
16288471|NCT04756921||Patients cohort|Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.
16288472|NCT04756908|Experimental|Opira AIOL|
16288473|NCT04756908|Active Comparator|Monofocal AIOL|
16288474|NCT04756908|Active Comparator|Multifocal AIOL|
16288475|NCT04756895|Experimental|Bayesian method|Pharmacists will perform vancomycin dose adjustments according to AUC0-24h/MIC using the Bayesian method with a web application
16288476|NCT04756895|Active Comparator|Standard method|Pharmacists will perform vancomycin dose adjustments according to trough levels of vancomycin.
16288579|NCT04756219|Placebo Comparator|Control Contact|Participants randomized to this group will read a personal story of a person who survived a heart attack.
16288477|NCT04756882|Experimental|study group|6 patients received 12.5 speywood unit/cm (SU/cm) Dysport intramuscular & intradermal injections, within the first 5 postoperative days of the trauma
16288478|NCT04756882|No Intervention|control group|of 6 patients that acted as the control group and received no treatment
16288479|NCT04756869||Health Care Workers at Risk for COVID-19|Health care workers at risk for COVID-19 will be monitored using wearing sensors and smartphone technology.
16288480|NCT04756856|Experimental|Muscle-target oral nutritional supplementation|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D
16288481|NCT04756843|Experimental|Early treatment|Treatment started in the early mixed dentition phase
16288482|NCT04756843|Experimental|Late treatment|Treatment started in the late mixed dentition phase
16288483|NCT04756830|Other|Vaccination|All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
16288484|NCT04756804|Experimental|70% Isopropyl Alcohol novel preoperative skin antiseptic|70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation
16288485|NCT04756804|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation
16288486|NCT04756791|Active Comparator|Local infiltration anesthesia|Patients will receive local infiltration anesthesia with ropivacaine placed by surgeon.
16288487|NCT04756791|Experimental|Serratus anterior plane block|Patients receive a SAPB with ropivacaine placed by anesthesiologist.
16288488|NCT04756765|Experimental|Talazoparib Arm|Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.
16288489|NCT04756752||Fit and Vitaal program|People with a lower-limb amputation participating in the Fit and Vitaal rehabilitation program
16288490|NCT04756726|Experimental|Phase 1: Arm A - CFT7455|Participants with r/r NHL or r/r MM will be treated with oral CFT7455 QD
16288491|NCT04756726|Experimental|Phase 1: Arm B1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455 QD until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
16288492|NCT04756726|Experimental|Phase 1: Arm B2 - CFT7455 in combination with dexamethasone|Participants with r/r MM will be treated with oral CFT7455 in combination with a fixed dose of oral dexamethasone in each cohort
16288493|NCT04756726|Experimental|Phase 1: Arm C - CFT7455|Participants with r/r NHL will be treated with oral CFT7455 QD in each cohort until determination of MTD/RP2D
16288494|NCT04756726|Experimental|Phase 2: Arm 1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455
16288495|NCT04756726|Experimental|Phase 2: Arm 2 - CFT7455 in combination with dexamethasone|Participants with r/r MM treated with oral CFT7455 in combination with oral dexamethasone
16288496|NCT04756726|Experimental|Phase 2: Arm 3 - CFT7455|Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455
16288497|NCT04756726|Experimental|Phase 2: Arm 4 - CFT7455|Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral CFT7455
16288498|NCT04756713|Active Comparator|Chemotherapy|Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
16288499|NCT04756713|Experimental|Uterine evacuation|Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return to weekly hCG monitoring. If hCG levels are decreasing, patients will remain on weekly hCG follow-up until the first normal hCG (<5 IU/L) is achieved. Then they will have monthly hCG monitoring for 12 months. If patients do not attain remission and develop persistent GTN as established by FIGO 2000, the tumor will be re-staged and appropriate chemotherapy will be initiated.
16288500|NCT04756700|Experimental|Healthy Participants|Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
16288501|NCT04756700|Experimental|PwMS: Participants with MS|Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
16288503|NCT04756674||Control Group|"Non-Covid -19 associated community acquired pneumonia with oxygen therapy required.
~n=12"
16288504|NCT04756674||Oxygen Therapy|"Confirmed COVID-19 infection via PCR swab, with a new oxygen therapy requirement. NB the researchers will not be involved in the clinical decision of if the participant requires oxygen, this will be the clinical-teams decision.
~n=12"
16288505|NCT04756674||Non-Invasive ventilation therapy|"Confirmed COVID-19 infection via PCR Swab, with a clinical need for non-invasive ventilation.
~NB the researchers will not be involved in the clinical decision if the participant requires non-invasive ventilation, this will be the clinical-teams decision.
~n=12"
16288506|NCT04756661|Experimental|Carbetocin|Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.
16288507|NCT04756661|Active Comparator|Oxytocin plus misoprostol|Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.
16288508|NCT04756648|Experimental|CT0180 cells|CT0180 Cells infusion after lymphocyte-depleting with fludarabine and cyclophosphamide.
16288509|NCT04756635|Experimental|Experimental Group|Measures taken before and after the defined IF periods. Two groups of participants will be included in this project: 1) resistance trained group (tested for neuromuscular function, anaerobic capacity and body composition); 2) endurance trained group (tested for aerobic and anaerobic capacity and body composition). Experimental condition: pre- and post-4 weeks of IF. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48- hour interval) to ensure full recovery.
16342526|NCT04381611||Glaucoma co-morbidity|
16288510|NCT04756635|Other|Control Group|Participants of each group serving as their own controls. Control condition: pre- and post4 weeks of normal diet. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48-hour interval) to ensure full recovery.
16288511|NCT04756622|Experimental|N acetyl cysteine|NAC dissolved in water at a dose of 600 mg three times per day from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
16288512|NCT04756622|No Intervention|Control|No intervention
16288513|NCT04756609|Experimental|Systematic offer of nurse-driven SARS-CoV-2 screening + usual practice|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
16288514|NCT04756609|Active Comparator|Control group: Usual emergency department practice|Usual emergency department practice with physician-directed diagnostic testing
16288515|NCT04756596||Study group|70 patients with normal vision (NVG) 30 patients with low vision (LVG) These patients will be tested on the DDVIT
16288516|NCT04756583|Experimental|Intervention|
16288517|NCT04756583|No Intervention|Control|
16288518|NCT04756570|Active Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose Mini-Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale (SSQOL) assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
16288519|NCT04756570|Active Comparator|Robotic 1|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
16288520|NCT04756570|Active Comparator|Robotic 2|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
16288521|NCT04756557|Experimental|Tooth Brushing HAP Toothpaste|"Experimental: Tooth Brushing HAP HAP-Toothpaste Tooth Brushing HAP Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite two x daily over the duration of the study (18 months).
~Procedure: Tooth Brushing HAP"
16288522|NCT04756557|Active Comparator|Tooth Brushing F Toothpaste|Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (1450 ppm F-), (two x daily over the duration of the study (18 months).
16288523|NCT04756544|Experimental|Depressive Disorders + probiotic|
16288524|NCT04756544|Placebo Comparator|Depressive Disorders + placebo|
16288525|NCT04756544|Experimental|Depressive disorder + metabolic syndrome + probiotic|
16288526|NCT04756544|Placebo Comparator|Depressive disorder + metabolic syndrome + placebo|
16288533|NCT04756518||COVID 19 group|The COVID 19 group will consist of peripheral blood smear slides from patients who are in the hospital who had qPCR results positive for COVID-19.
16288534|NCT04756518||CONTROL group|A control group will consist of i) peripheral blood smear slides from patients with no viral infection and ii) from those with a non-SARS-CoV-2 viral infection. Control group peripheral blood slides will be randomly selected from the laboratory slides archive within the facility. The laboratory slides used will be inclusive of slides archived prior to the emergence of COVID-19 infection in the United Kingdom.
16288536|NCT04756466|Placebo Comparator|Control group|Control group that will receive a daily placebo capsule consisting of maltodextrin during 3 months
16288537|NCT04756466|Experimental|Probiotic group|Experimental group that will receive one capsule with the probiotic strain per day (3x10 9 CFU / day) during 3 months
16288538|NCT04756453|No Intervention|Standard|Standard endoscopic submucosal dissection
16288539|NCT04756453|Active Comparator|Interventional|Mandatory use of the clip-traction device
16288540|NCT04756440|Experimental|Experimental: Intervention Group|Firstly, Pre-tests were applied to the women in the experimental group. The 4-week training program created by taking into account the cultural characteristics of the Roma; It includes the Anatomy of Female Reproductive Organs, Anatomy of the Cervix, Cancer, Cervical Cancer, Early diagnosis and its importance, Pap smear test, HPV-DNA test, Cancer Early Diagnosis, Screening and Education Center. Afterwards, music therapy will be applied to the women in the experimental group with the song written and composed by the researchers who emphasized the importance of early diagnosis. At the end of the program, a focus group discussion will be held with the participants in the experimental group regarding their educational experiences, learning experiences for cervical cancer and screening, and program outcomes. Final tests will be made 3 months after the training ends.
16288541|NCT04756440|No Intervention|No Intervention: Control Group|First, pre-tests will be applied to the women in the control group. Women in this group will not be intervened and post-tests will be made 3 months after the pre-test.
16288542|NCT04756427|Experimental|Sodium citrate 4%|All enrolled participants will received the daily sodium citrate 4% locking solution for CLABSI prophylaxis intervention and be observed prospectively for adverse events
16288543|NCT04756414|Experimental|Treatment group|Patients recieve treatment from standard protocol at a gastroenterology unit. No specific adjustments is made for study purposes. Baseline data is collected before treatment and then again after treatment (POST).
16288544|NCT04756401|Experimental|Treatment (carfilzomib, daratumumab, dexamethasone, selinexor)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16288545|NCT04756388|Active Comparator|Executive Training|The Executive Training (ET) condition will consist of the ET intervention that Dr. Best previously developed and evaluated. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, at home between sessions. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
16288546|NCT04756388|Experimental|Strategy Development only|In Strategy Development only participants will engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life. Between sessions, participants will be encouraged to practice their cognitive strategies in their daily life and track their strategies using the strategy worksheet. There will be no computerized cognitive training in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
16288547|NCT04756388|Experimental|Computerized Cognitive Training only|In Computerized Cognitive Training only participants will spend the entire one-hour session practicing computerized training exercises. Between sessions participants will be encouraged to practice the computerized exercises at home for 40 minutes per day. There will be no strategy development in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
16288550|NCT04756349|Active Comparator|Clearfil SE|
16288551|NCT04756349|Active Comparator|Optibond All-in-One|
16288552|NCT04756349|Active Comparator|Prime & Bond Universal|
16288553|NCT04756336|Experimental|LTX-109 treatment|Patients are treated with LTX-109 gel, 3% w/w twice daily (morning- evening) by application on active hidradenitis lesions during the intervention period of 6 weeks
16288554|NCT04756323|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
16288555|NCT04756323|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
16288556|NCT04756323|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
16288557|NCT04756323|Experimental|medium dosage on day 0, 28(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
16288558|NCT04756323|Experimental|high dosage on day 0, 28(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
16288559|NCT04756323|Placebo Comparator|placebo on day 0, 28(18~59years)|Two doses of placebo on the schedule of day 0,28
16288560|NCT04756323|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288561|NCT04756323|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288562|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
16288563|NCT04756323|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288564|NCT04756323|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
16288565|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
16288566|NCT04756310|Placebo Comparator|Control|"Patients receiving Theavit food supplement considered as a placebo treatment for AMD condition.
~Two capsules/day before breakfast each day for 2 years"
16288567|NCT04756310|Experimental|Retilut|Patients receiving Retilut food supplement. Two capsules/day before breakfast each day for 2 years
16288568|NCT04756284||Bladder Tumor Positive|Patients with previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy or suspected bladder tumor undergoing surveillance cystoscopy.
16288569|NCT04756284||Bladder Tumor Negative|Patients with no suspected bladder tumor.
16288571|NCT04756245|Experimental|Virtual Reality|Participants engage in intervention procedures using virtual reality software.
16288572|NCT04756245|Active Comparator|Video Conference|Participants engage in intervention procedures using video conference software.
16288573|NCT04756232|Experimental|Mecamylamine Challenge|All participants will receive oral mecamylamine for 1 day
16288574|NCT04756232|Placebo Comparator|Placebo Challenge|All participants will receive oral placebo for 1 day
16288575|NCT04756219|Experimental|Contact Video|Participants randomized to this group will watch a video of a person talking about his recovery after attempting suicide.
16288576|NCT04756219|Experimental|Contact Text|Participants randomized to this group will read a personal story of a person who survived a suicide attempt.
16288577|NCT04756219|Experimental|Education Video|Participants randomized to this group will watch a video of a psychiatrist presenting facts about suicide and suicide prevention.
16288578|NCT04756219|Experimental|Education Text|Participants randomized to this group will read a text containing facts about suicide and suicide prevention.
16342527|NCT04381611||Glaucoma untreated|
16288580|NCT04756219|Placebo Comparator|Control Education|Participants randomized to this group will read a text containing facts about heart-attacks and their prevention.
16288581|NCT04756206|Active Comparator|Dutasteride|Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo.
16288582|NCT04756206|Placebo Comparator|Placebo|same form and color of Dutasteride tablet was given at the same regimen to act as a placebo
16288583|NCT04756193||Asymptomatic/Mild COVID-19 Group|50 confirmed COVID-19 patients who showed no or only mild respiratory/GI symptoms (not admitted to the hospital at all)
16288584|NCT04756193||Moderate COVID-19 Group|50 confirmed COVID-19 patients who were able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs (admitted to the hospital, but never to the ICU and no obvious cardiac complications during the stay)
16288585|NCT04756193||Severe COVID-19 Group|50 confirmed COVID-19 patients who had oxygen saturation lower than 92% at rest and PaO2/FiO2 between 200 and 300 (High-flow oxygen group, mostly in the ICU, and may have some cardiac complications)
16288586|NCT04756193||Critical COVID-19 Group|50 confirmed COVID-19 patients who had PaO2/FiO2 less than 200 or required mechanical ventilation (in the ICU, need mechanical ventilation and more likely to have cardiac complications)
16288587|NCT04756193||Control Group|50 age and sex-matched controls from our hospital admission database
16288588|NCT04756180|Experimental|Omacor|Omacor 2gm/day for first 4 week followed by 4gms/day for 8 weeks
16288589|NCT04756180|Placebo Comparator|Placebo|Omacor Placebo 2gm/day for first 4 week followed by 4gms/day for 8 weeks
16288590|NCT04756167|Active Comparator|Conventional Group|The treatment of 21 individuals in the conventional group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes) and exercise(passive and active range of motion) approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week.
16288591|NCT04756167|Active Comparator|Myofascial Release Group|Treatment of 21 individuals in the Myofascial Release group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes),exercise(passive and active range of motion) and myofascial release to subscapularis and serratus anterior muscles approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week. Myofascial release will be done in the first five sessions of treatment programs.
16288592|NCT04756154|Experimental|SP|
16288593|NCT04756154|Active Comparator|SPFF|
16288594|NCT04756154|Placebo Comparator|S|
16288595|NCT04756141|Experimental|CGM Use|Determine CGM accuracy when compared with POC (point of care) glucometers.
16288596|NCT04756128|Experimental|Colchicine-Only Arm|"Patients randomized to a colchicine-containing treatment arm will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00. Patients experiencing gastrointestinal side effects (nausea, vomiting, and diarrhea) on twice daily dosing may have the dose decreased to 0.6 mg daily. Dosing will continue twice daily unless there is a change that requires a dose adjustment or an exclusion criterion is met. Dosing deviations above the study protocol will be allowed if medically necessary for the treatment of an additional indication (e.g. colchicine for viral pericarditis).
~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
16288597|NCT04756128|Experimental|"Colchicine and Naltrexone (Combined) Arm"|"Patients randomized to a colchicine-containing treatment arm (including the combined arm) will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00.
~Patients in the combined arm will also receive naltrexone. Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).
~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
16288598|NCT04756128|Experimental|Naltrexone-Only Arm|"Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).
~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
16288599|NCT04756128|No Intervention|Standard of Care Arm|Patients in this arm will receive the investigating institution's current standard of care for patients with COVID-19. For example, all patients requiring supplemental oxygen (assuming no contraindications) would be candidates for both remdesivir 200 mg x 1 IV dose followed the next day by 100 mg q24h IV x up to 4 doses, as well as dexamethasone 6 mg q24h x 10 up to 10 doses.
16288600|NCT04756115||CASES|Adults (age<18 years) diagnosed with a first episode of critical limb ischemia revascularized at our center from January 2016 to July 2019.
16288601|NCT04756102||FBS lower than 80|Those pregnant patients with FBS less than 80 mg/dl
16288602|NCT04756102||FBS 80-120|Those pregnant patients with FBS between 80-120
16288603|NCT04756089|Experimental|Breast stimulation|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
16288604|NCT04756089|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
16288605|NCT04756076||Control|age and gender matched controls
16288606|NCT04756076||Pulmonary Hypertension Group|Pulmonary Hypertension Patients with Various Degree of Severity
16289728|NCT04747964|Experimental|A single intermediate dose of treatment group|
16288607|NCT04756063|Experimental|Ascorbic Acid (AA)|The first intravenous dosage of 1500mg of AA in 100mL of normal saline (NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
16288608|NCT04756063|Placebo Comparator|Placebo|The first intravenous dosage of placebo (100 mL of NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
16288609|NCT04756050|Experimental|corner pocket|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
16288610|NCT04756050|Experimental|corner+intracluster|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) 10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
16288611|NCT04756050|Experimental|multi|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
16288612|NCT04756037|Experimental|Relugolix/E2/NETA|Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
16288613|NCT04756011||Group A (insulin pump)|30 patients who are on insulin pump.
16288614|NCT04756011||Group B (MDI)|30 patients who are on multiple daily injection.
16288615|NCT04755998|Experimental|Experimental Group|The Experimental Group watched cartoons with virtual reality glasses during vaccination applications.
16288616|NCT04755998|No Intervention|Control Group|Pre-test and post-tests were applied to the non-intervention group
16288617|NCT04755985|Experimental|ARM 1|Period 1 : Reference Drug(AD-2132) Period 2 : Test Drug(AD-213-B)
16288618|NCT04755985|Experimental|ARM 2|Period 1 : Test Drug(AD-213-B) Period 2 : Reference Drug(AD-2132)
16288619|NCT04755972|Active Comparator|N-acetylcysteine|Inhalation of 5 ml-s of N-acetylcysteine every 12 hours.
16288620|NCT04755972|Active Comparator|Hypertonic saline|Inhalation of 5 ml-s of 5% sodium chloride every 12 hours.
16288621|NCT04755972|Active Comparator|Bicarbonate|Inhalation of 5 ml-s 8.4% sodium bicarbonate every 12 hours.
16288622|NCT04755972|No Intervention|Control group|No preventive inhalation.
16288623|NCT04755959||Stroke|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of Ischemic Stroke, between the years 2016-2020 as documented in an institutionally approved data base of stroke, who will consent to provide access to their data from Google Take Out service.
16288624|NCT04755959||Acute myocardial infarction|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of acute myocardial infarction as documented in an institutionally approved data base of myocardial infarction, who will consent to provide access to their data from Google Take Out service.
16288625|NCT04755959||Healthy controls|Unaffected spouses or volunteers who will consent to provide access to their data from Google Take Out service.
16288626|NCT04755946|Experimental|roflumilast arm|
16288627|NCT04755946|Placebo Comparator|placebo arm|
16288628|NCT04755933|Experimental|Intervention|An online learning tool, designed to helps parents develop a calm, consistent behaviour management style, whilst learning skills to discourage children's avoidance.
16288629|NCT04755933|No Intervention|Control|The participants in the control arm will not receive access to the online course, but will complete the same sets of questionnaires at each of the timepoints.
16288630|NCT04755920|Experimental|Patients with colorectal brain metastases|10 mg SGM-101, administration 3 to 5 days prior to surgery.
16288631|NCT04755907||Group A|colorectal cancer patients at resectable stage II/III who will receive adjuvant chemotherapy after surgery
16288632|NCT04755907||Group B|colorectal cancer patients at locally advanced stage who will receive neoadjuvant chemotherapy before surgery and adjuvant chemotherapy after surgery
16288633|NCT04755907||Group C|colorectal cancer patients with liver metastases
16288634|NCT04755894|Experimental|group A|
16288635|NCT04755894|Active Comparator|group B|
16288636|NCT04755881||All anaphylaxis reactions seen during the phase 2 period of the SHARED study.|All patients presenting to the 3 sites emergency departments (Chicoutimi, Alma, Jonquière) diagnosed with an anaphylactic reaction or a severe allergic reaction that is rapidly evolving towards anaphylaxis in the opinion of the treating physician.
16288637|NCT04755868|Experimental|Maintenance therapy with talazoparib|Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
16288638|NCT04755868|Active Comparator|Maintenance therapy with placebo|Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
16288639|NCT04755829||Group 1|Normal screening mammogram (BIRADS 1 or 2)
16288640|NCT04755829||Group 2|Abnormal screening mammogram (BIRADS 3 to 6)
16288641|NCT04755816|Sham Comparator|Control Group|Standard heart failure educational information.
16288642|NCT04755816|Experimental|Dietary Sodium Intervention|The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
16288643|NCT04755816|Experimental|Clinical Worsening Intervention|The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
16288644|NCT04755816|Experimental|Dietary Sodium and Clinical Worsening|Full access to all content in the control, dietary sodium, and clinical worsening interventions.
16288645|NCT04755790|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
16288646|NCT04755790|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
16288647|NCT04755764||Beta blockade|Beta blocker (labetalol or atenolol) will be given for a cardiac output >8 l/min.
16288648|NCT04755764||Nifedipine|Nifedipine will be given for a mean arterial pressure >100.
16288649|NCT04755751||Pediatric Pompe patients|A retrospective - prospective study evaluating pediatric patients with Pompe before and 2 days after ERT on multiple occasions and different dosing. Evaluation included cardiopulmonary exercise testing (CPET), 6 minute-walking test (6MWT), motor function test (GMFM-88) and self-collected blood samples (on a Guthrie card) for enzyme blood levels.
16288650|NCT04755738|Experimental|Almonertinib plus Microwave ablation group|Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.
16288651|NCT04755738|Active Comparator|Almonertinib group|Patients in the group were treated with Almonertinib with the dose of 110mg once daily until disease progression, death or intolerable adverse events.
16288652|NCT04755725|Active Comparator|Epidural Group|epidural catheter inserted pre induction
16288653|NCT04755725|Active Comparator|Rectus sheath catheter Group|rectus sheath catheter inserted by the surgeon at the end of surgery
16288654|NCT04755712|Experimental|ropivacaine in quadratum lumburum block 2|Ropivacaine will be administrated in perineural in quadratum lumburum block 2 after the caesarian.
16288655|NCT04755712|Active Comparator|Intrathecal morphine|Morphine will be administrated in intrathecal
16288656|NCT04755699|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving transcutaneous electrical stimulation to the arms, legs, and/or spinal column to evoke various arm/hand and leg/foot movements.
16288657|NCT04755699|Experimental|Individuals with a Spinal Cord Injury|This arm consists of individuals with a spinal cord injury receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
16288658|NCT04755699|Experimental|Individuals with a Stroke|This arm consists of individuals with a stroke receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
16288659|NCT04755699|Experimental|Individuals with other Brain or Nerve Injuries|This arm consists of individuals with a other brain and nerve injuries receiving transcutaneous electrical stimulation to the arms/hand, legs/foot, and/or spinal column to evoke various arm/hand or leg/foot movements.
16288660|NCT04755686|Experimental|Fast-tracking at geriatric medicine ward|Fast-tracking hip fracture patients at geriatric medicine ward. The goal is to optimize the medical care of older hip fracture patients at a geriatric ward and to shorten the time to operation.
16288661|NCT04755686|No Intervention|Regular admission|Regular admission and care of hip fracture patients at the emergency room prior to surgery.
16288662|NCT04755673|Experimental|Experimental: Atrantil (Medical Food)|All participants in the trial will take two capsules of Atrantil three times a day for 28 days.
16288663|NCT04755660|Experimental|Exercise behavior change group (EBCG)|Behavior Change Theory-based intervention + Resistance Exercise
16288664|NCT04755660|Active Comparator|Elastic band resistance exercise group( EBRG)|Elastic Band Resistance Exercise
16288665|NCT04755660|Sham Comparator|Usual care (UC)|usual care: exercise education
16288666|NCT04755647|Experimental|Nitric Oxide-Releasing Solution (NORS)|Five litre foot bath delivery NORS
16288667|NCT04755647|Placebo Comparator|Saline|Five litre foot bath delivery NORS
16288668|NCT04755634|Experimental|Single Arm|This is a prospective, single-arm, single-center study
16288669|NCT04755621|Experimental|Core stability Group|
16288670|NCT04755621|Active Comparator|Control Group|
16288671|NCT04755608|Experimental|Low Intensity Blood Flow Restriction Group|
16288672|NCT04755608|Active Comparator|High Intensity Resistant Training Group|
16288673|NCT04755595|Experimental|Facial aesthetic treatment|Study participants will receive all three injectables: Botox Cosmetic (onabotulinumtoxinA), Juvéderm Voluma XC (hyaluronic acid gel filler), and Juvéderm Volbella XC (hyaluronic acid gel filler) during a single procedure, with an optional touch-up treatment at 2 weeks.
16288674|NCT04755556|Other|Experimental group|Intensive bimanual training with routine physical therapy
16288675|NCT04755556|Other|control group|routine physical therapy
16288676|NCT04755543|Experimental|I-A|LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.
16288677|NCT04755543|Experimental|I-B|If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.
16288678|NCT04755543|Experimental|I-C|If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.
16288703|NCT04755413|Other|Registry Group|Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.
16288704|NCT04755400|Active Comparator|Potassium Nitrate|4 days treatment with 24 mmol potassium nitrate capsules
16288679|NCT04755543|Experimental|I-D|Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.
16288680|NCT04755543|Experimental|I-E|Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg：If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10^6 or 10^7 or 10^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.
16288681|NCT04755530|Active Comparator|Regular whole milk|Substitution of a part of the habitual diet with 400 g/day of regular whole milk
16288682|NCT04755530|Experimental|Yogurt with live bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with life bacteria
16288683|NCT04755530|Experimental|Yogurt with inactivated bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with inactivated bacteria
16288684|NCT04755530|Experimental|Acidified whole milk|Substitution of a part of the habitual diet with 400 g/day of acidified whole milk
16288685|NCT04755517|Active Comparator|A1|Frequent information of screening results for cytology and/or HPV DNA at the ages of 25 (cytology only) and 28 (cytology only) vs A2
16288686|NCT04755517|No Intervention|A2|infrequent information of cytological screening/ HPV DNA results, only at the age 28 years.
16288687|NCT04755517|Active Comparator|C|The third arm with at 8000 participants devoid of herd effect protection and frequent screening at ages 25 and 28 is enrolled for comparative analyses between A1 vs. C and A2 vs. C.
16288688|NCT04755504|Experimental|EEG evaluation|All patients will be evaluated during 1 night by standard polysomnography and additionally EEG will be evaluated by 2 electrodes behind each ear connected to a recording device (Sensor Dot)
16288689|NCT04755491||Chloride transfer by continuous veno-venous hemofiltration|Chloride transfer over 24h of continuous veno-venous hemofiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
16288690|NCT04755491||Chloride transfer by continuous veno-venous hemodialysis|Chloride transfer over 24h of continuous veno-venous hemodialysis in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
16288691|NCT04755491||Chloride transfer by continuous veno-venous hemodiafiltration|Chloride transfer over 24h of continuous veno-venous hemodiafiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
16288692|NCT04755478||Lung lobectomy via open thoracotomy|participants scheduled for lung lobectomy via open thoracotomy
16288693|NCT04755478||Lung lobectomy via VATS|participants scheduled for lung lobectomy via video-assisted thoracoscopic surgery
16288694|NCT04755465|Experimental|Conventional Exercise Group|The treatment program was designed by reviewing the exercise principles and the literature on physical activity and hematologic cancer patients recommended by the American College of Sports Medicine. Patients will be treated for 3 days / week for 4 weeks. Each session was planned to last 40 minutes. The exercise program will be applied in the patient's own room under the supervision of a physiotherapist. Depending on the health condition of the patient, the exercise will be postponed or canceled for the next day. Conventional exercise program includes active movements of upper and lower extremities, stretching exercises and resistance exercises for lower extremities.
16288695|NCT04755465|Experimental|NMES Training Group|In addition to conventional exercises, NMES will be applied to the quadriceps muscles in both legs of the patients in this group. The application will be made with a portable device using disposable electrodes. One of the electrodes will be placed proximally, that is, at the midpoint of the quadriceps muscle, while the second electrode will be placed on the distal part. Stimulation intensity will be adjusted individually for each limb to achieve the maximum tolerated intensity. In order to ensure that the patients get used to the device, low-intensity current with a frequency range of 2-15 Hz will be used initially. Afterwards, the treatment program will continue with a high frequency current with a frequency range of 20-60 Hz. The duration of treatment will likewise be increased as adaptation is made to the patient.
16288696|NCT04755452|Experimental|Low Intra-abdominal pressure|Intra-abdominal pressure will be set at 7 mm Hg during the procedure.
16288697|NCT04755452|Active Comparator|High (standard) intra-abdominal pressure|Intra-abdominal pressure will be set at 12 mm Hg during the procedure.
16288698|NCT04755439|Other|undergoing deep hypothermic cırculatory arrest patients|Difüsıon magnetic rezonans imaging , neuron spesific enolase enzym level , deep hypotermic cırculatory arrest
16288699|NCT04755426||Patients with severe aortic stenosis|Adults with severe aortic stenosis who either have faced or are facing a decision about valve replacement (depending on the phase of the research)
16288700|NCT04755426||Health care providers|HCPs who guide decisions about managing AS, including interventional cardiologists, cardiac surgeons and advanced practice providers (APPs), including nurse practitioners and physician assistants.
16288701|NCT04755413|Experimental|Optimization Group|Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C<70 mg/dL, hemoglobin A1c <7%, blood pressure <130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index <30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.
16288702|NCT04755413|Active Comparator|Usual Care Group|Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is ≥1 and they have been randomized to the usual care group.
16288707|NCT04755387|Experimental|Ticagrelor 60/45mg|De-escalation strategy group receive ticagrelor 60 mg twice daily or 45mg twice daily if patients with body weight <60kg, or age >75 years old.
16288708|NCT04755374||Group 1|Discharged from palliative care unit in equal or less than 21 days
16288709|NCT04755374||Group 2: Prolonged discharged in longer than 21 days|Discharged from palliative care unit in longer than 21 days
16288710|NCT04755361|Experimental|Housing Outreach Project - Collaboration (HOP-C) + Treatment as Usual|The treatment condition is HOP-C plus treatment as usual (TAU).
16288711|NCT04755361|No Intervention|Treatment As Usual|TAU for this population reflects the standard array of services accessed by transitional youth populations. Most will have some contact with a youth worker with ranging focus and intensity (none likely to receive case management at HOP-C intensity), and very few will have any routine contact with other professionals or peer support. They may have some sporadic access to skills development programs and primary healthcare providers with mental health and addictions needs addressed primarily through emergency services at times of crisis.
16288712|NCT04755348|Experimental|Product usage order ABFCED|Subjects will use each of the 6 products (ABFCED) during an familiarization period, followed by a 4 hour Test Session
16288713|NCT04755348|Experimental|Product usage order BCADFE|Subjects will use each of the 6 products (ABECD) during an familiarization period, followed by a 4 hour Test Session
16288714|NCT04755348|Experimental|Product usage order CDBEAF|Subjects will use each of the 6 products (CDBEAF) during an familiarization period, followed by a 4 hour Test Session
16288715|NCT04755348|Experimental|Product usage order DECFBA|Subjects will use each of the 6 products (DECFBA) during an familiarization period, followed by a 4 hour Test Session
16288716|NCT04755348|Experimental|Product usage order EFDACB|Subjects will use each of the 6 products (EFDACB) during an familiarization period, followed by a 4 hour Test Session
16288717|NCT04755348|Experimental|Product usage order FAEBDC|Subjects will use each of the 6 products (FAEBDC) during an familiarization period, followed by a 4 hour Test Session
16288718|NCT04755335|Other|Early detection of PAD, assessment of the disease progression and treatment response|"The objective of this arm of the study is to evaluate the potentials of Ultrasound Perfusion imaging technique for early detection of peripheral arterial disease in patients and assess the disease progression and monitor the treatment response.
~The investigators anticipate that our new cost-effective and non-invasive ultrasound perfusion technique offers a quantitative imaging of perfusion and microvessels of cuff muscle that would separate PAD from non-PAD and help early detection of PAD and would help monitoring the disease progression and treatment response."
16288719|NCT04755322|Active Comparator|hydroxychloroquine group|hydroxychloroquine 400 mg+ Folic Acid 5 mg+ Low-dose aspirin 75 mg
16288720|NCT04755322|Placebo Comparator|Placebo group|Folic Acid 5 mg+ Low-dose aspirin 75 mg+ Placebo oral tablet
16288721|NCT04755309|Experimental|Typical development infants - experimental|Children without familial risk for language disorders, who participate to the rhythmic intervention.
16288722|NCT04755309|No Intervention|Typical development infants - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
16288723|NCT04755309|Active Comparator|Typical development infants - control|Children without familial risk for language disorders, who are exposed to passive auditory stimulation.
16288724|NCT04755309|Experimental|Infants at familial risk - experimental|Children with familial risk for language disorders, who participate to the rhythmic intervention.
16288725|NCT04755309|No Intervention|Infants at familial risk - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
16288726|NCT04755296|Experimental|Low level laser therapy and aerobic exercises group|They received low level laser therapy and aerobic exercises using a treadmill, 3 sessions per week for 12 weeks.In addition to traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
16288727|NCT04755296|Active Comparator|Control group (aerobic exercises group)|They received aerobic exercises 3 times weekly for 12 weeks.In addition to the same traditional physical therapy program.
16288728|NCT04755283|Experimental|Abelacimab (MAA868)|"Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly
~Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly"
16288729|NCT04755283|Active Comparator|Rivaroxaban|"Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal
~Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily."
16288730|NCT04755270|Experimental|vr-supported hypnofertility|Relaxation, visualization, imagination and affirmation and techniques based on the hypnofertility philosophy were applied to women in the experimental group in four stages
16288731|NCT04755270|No Intervention|Control|Any initiative was not applied to the control group
16288732|NCT04755244|Experimental|evorpacept (ALX148) + venetoclax + azacitidine|"Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine
~Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine"
16288733|NCT04755231|Experimental|PanOptix IOL|AcrySof IQ PanOptix Presbyopia Correcting IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
16288734|NCT04755218|Experimental|Vaginal Misoprostol|Patients will receive vaginal misoprostol 25 micrograms given every 3 hours for a maximum of 5 doses
16288735|NCT04755218|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
16288737|NCT04755179||Complex appendicitis without abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis without clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
16288738|NCT04755179||Complex appendicitis with abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis with clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
16288739|NCT04755166|Experimental|100:0|100 % bone substitute, 0% autogenous bone
16288743|NCT04755127|Active Comparator|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
16288744|NCT04755127|Experimental|arthroscopic synovectomy|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
16288745|NCT04755114|Experimental|Turkish Music Group|After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations, the music group will be played to the music desired by the patient for 30 minutes. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
16288746|NCT04755114|Experimental|Comedy Film Group|fter the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations,the Comedy film group will watch a comedy movie video. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
16288747|NCT04755114|No Intervention|Control group|"After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min).
~Pain level and vital signs will be evaluated and saliva sample will be taken for the final test (30th minute) and follow-up (60th minute) simultaneously with the administration group without any intervention."
16288755|NCT04755062|Experimental|Micronutrient-dense plant-rich Intervention|The intervention will consist of a 2-hour 'immersion' group session, followed by weekly 1-hour group sessions over the following 11 weeks. Groups of no more than 15 individuals will meet weekly for 12 weeks with a trained Lifestyle Coach. Group sessions, held at the Twin Arrows Casino, will provide participants with instructions, assistance with goal setting, support, encouragement, cooking demonstrations, Casino (workplace) dining tours, and will socially engage with other participants. Participants will be requested to follow the mNDPR nutrition protocol for the first 12 weeks. Each week the participants will use a simple tracking method to self-monitor their daily compliance with the nutrition protocol. Lifestyle Coaches will monitor adherence and verify attendance. Instructional materials discussed each week will provide resources and methods to overcome common barriers to dietary change including (i) meal prepping, (ii) social gatherings, and (iii) family resistance.
16288756|NCT04755062|Active Comparator|Wait-list Control|Participants in the wait-list control group will be requested to maintain their typical eating patterns during a 12-week waiting period, until they are scheduled to start the intervention 13-weeks later.
16288757|NCT04755023|Experimental|Treatment Arm|Administration of 6 cycles of chemotherapy
16288758|NCT04754997|No Intervention|Control group|This group will not take any exercise intervention.
16288759|NCT04754997|Active Comparator|Traditional exercise training group|This group will get traditional therapy that is include range of motion exercises and resistance exercise training.
16288760|NCT04754997|Experimental|Specific exercise training group|This group will get a specific programme that combinated with closed kinetic chain exercises and core exercises training
16288763|NCT04754971|Experimental|Table|
16288764|NCT04754958|Experimental|VR|In addition to standard care during MRI scan, patient receives VR intervention.
16288765|NCT04754958|No Intervention|No VR|Standard of care during MRI scan.
16288766|NCT04754945|Experimental|Treatment (isatuximab, chemotherapy)|"All patients will receive Isatuximab plus dexamethasone 4 mg PO/IV days weekly. Based on tolerance, patients will add to their treatment subcutaneous Velcade (earliest time to add Velcade is cycle 1 day 15) and intravenous cyclophosphamide (earliest time to add cyclophosphamide is cycle 4 day 1)
~Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity."
16288767|NCT04754932|Experimental|Community Site 1|CST Implementation community site
16288768|NCT04754932|Experimental|Community Site 2|CST Implementation community site
16288769|NCT04754932|Experimental|Community Site 3|CST Implementation community site
16288770|NCT04754932|Experimental|Community Site 4|CST Implementation community site
16288771|NCT04754932|Experimental|Community Site 5|CST Implementation community site
16288772|NCT04754919|Active Comparator|Transition intervention group|Intervention group -will be working with the specialist diabetes transition nurse. The nurse will follow a specific protocol involving visits, clinic support, community support and appointment rearranging. She will also maintain communication with the Hospital based adult and paediatric diabetes teams and the participants General Practitioner and relevant community health care professionals.
16289236|NCT04751461|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session
16288773|NCT04754919|Placebo Comparator|Post Transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
16288774|NCT04754906||young neurotypical subjects|people from 18 to 40 years old
16288775|NCT04754906||elderly neurotypical subjects|people over 70 years of age
16288776|NCT04754906||Elderly subjects with mild cognitive impairment|people over 70 years of age, with a diagnosis of mild cognitive impairment
16288777|NCT04754893|Experimental|Group A|Healthdot directly after surgery and leave the hospital on the same day (evening) (group A)
16288778|NCT04754893|No Intervention|Group b|Standard of care by staying one night in the hospital before returning home (group B)
16288779|NCT04754880||non-CTO|This group was defined as no chronic obstruction, except for non-critical stenosis, who underwent coronary angiography with the diagnosis of stable angina pectoris.
16288780|NCT04754880||CTO|This group was defined as the presence of complete occlusion in one artery and no critical lesions (> 50%) in the other arteries undergoing coronary angiography with the diagnosis of stable angina pectoris.
16288781|NCT04754867|Experimental|"discontinued-smoker age-progressed"|"Participants in the discontinued smoker age-progressed virtual reality condition will see two rendering of themselves in optimal health twenty years into the future, a frontal and profile view."
16288782|NCT04754867|Experimental|"discontinued-smoker + continued smoking age-progressed"|"Participants in the discontinued smoker + continued smoking age-progressed virtual reality condition will see two frontal renderings of themselves twenty years in the future, one in optimal health and one incorporating appearance-related medical consequences of moderate-heavy smoking over twenty years (e.g., skin that is dry and discolored, increased wrinkles, etc.)."
16288783|NCT04754867|Experimental|Current self virtual reality images|Participants in the current self virtual reality condition will see their present age self in a virtual reality rendering.
16288784|NCT04754841|Experimental|SURVIVAL AND FUNCTIONALITY INVITRO IN CRYOPRESERVED PLATELETS|Platelet concentrates will be administered 3 alternatives of cryopreservative solution: 5% dimethylsulfoxide (solution 1), 5% dimethylsulfoxide plus 160 mg of 5% dextrose (solution 2) and 5% dimethylsulfoxide plus 2% albumine (solution 3 ). They will then be frozen at -80 ° C and their survival and functionality will be subsequently evaluated in vitro.
16288785|NCT04754828|Active Comparator|Bedside|The bedside rounding team will perform patient presentations at the bedside, with a focus on the patient, and will ensure nursing involvement when rounding on each patient,
16288786|NCT04754828|Active Comparator|Hallway|The hallway rounding team will present patients outside of the patient's room, without an emphasis on nurse participation.
16288787|NCT04754815|Experimental|Pembrolizumab + Pemetrexed|Pembrolizumab 200mg intravenous (IV) infusion on Day 1 of each 21 day cycle. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity + pemetrexed 500mg intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21 day cycle up to 35 cycles or until disease progression.
16288788|NCT04754815|Experimental|Pembrolizumab + Paclitaxel OR Paclitaxel|"Pembrolizumab 200mg intravenous (IV) infusion on Day 1 of each 21 day cycle. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity
~+ Paclitaxel 100 mg/m2 intravenous (IV) infusion on days 1 and 8 of each 21 day treatment cycle
~OR Paclitaxel100 mg/m2 intravenous (IV) infusion on days 1 and 8 of each 21 day treatment cycle until disese progression."
16288789|NCT04754802|Experimental|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
16288790|NCT04754802|Experimental|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
16288791|NCT04754789|Active Comparator|group for loading with statin before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.
~Patients will be randomly assigned (1:1) to receive two 80-mg loading doses of atorvastatin, the first loading dose will be administered in the Emergency Room before transfer to Cath Lab, the second dose of 80-mg atorvastatin will be administered 24 hours afterthe first dose."
16288792|NCT04754789|Placebo Comparator|group receive the routine guidelines management before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.
~Patients will be randomly assigned (1:1) to receive only the routine management."
16288793|NCT04754776|Experimental|Low dose|5 x 10^9 vp ChAdOx1 RVF delivered intramuscularly
16288794|NCT04754776|Experimental|Medium dose|2.5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
16288795|NCT04754776|Experimental|High dose|5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
16288796|NCT04754763|Experimental|Propolis|Propolis was applied by disposable micro brush on particular sensitive teeth and left undisturbed for 60 seconds to let it dry. Followup was done at 7th, 15th and 30th day
16288797|NCT04754763|Active Comparator|Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE)|Application of Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE) on sensitive surfaces was applied single coated for 20 seconds, gently applied air for 5 seconds and cured for 10 seconds (as per manufacturer's instructions). Followup was done at 7th, 15th and 30th day
16288798|NCT04754750|Active Comparator|INVEGA Sustenna|INVEGA Sustenna is a one month long-acting injection (PP1M)
16288799|NCT04754750|Active Comparator|INVEGA Trinza|INVEGA Trinza is a three month long-acting injection (PP3M)
16288800|NCT04754737|Other|Prophylactic antibiotic|These patients will receive the current standard of care, which is to receive a single dose of prophylactic antibiotics just prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy. The specific prophylactic antibiotics will vary depending on patient's prior urine culture sensitivities and patient medication allergies/sensitivities and medical comorbidities.
16288801|NCT04754737|Experimental|No antibiotics|These patients will receive no prophylactic antibiotics prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy.
16288802|NCT04754724|Experimental|GIMate|Individuals with suspected lactose intolerance who start with GIMate use first
16288803|NCT04754724|Active Comparator|H2 Check|Individuals with suspected lactose intolerance who start with H2 Check use first
16342528|NCT04381611||Glaucoma Suspect|
16288806|NCT04754698|Other|Patients with rheumatic diseases|CoronaVac 2-dose schedule with 21-28-day interval and a booster dose (third dose of CoronaVac) 6 months after the primary vaccination
16288807|NCT04754698|Other|Patients with PLWHA|CoronaVac 2-dose schedule with 21-28-day interval
16288808|NCT04754698|Other|Healthy controls|CoronaVac 2-dose schedule with 21-28-day interval and a booster dose (third dose of CoronaVac) 6 months after the primary vaccination
16288809|NCT04754685|Active Comparator|Mild knee osteoarthritis|30 patients had mild knee osteoarthritis
16288810|NCT04754685|Active Comparator|Moderate knee osteoarthritis|30 patients had moderate knee osteoarthritis
16288811|NCT04754685|Active Comparator|Severe knee osteoarthritis|30 patients had severe knee osteoarthritis
16288812|NCT04754672|Experimental|Continuous aerobic and resistance exercise (AE+RE)|"Two 60 min moderate-to-high intensity exercise sessions per week supervised by a physiotherapist.
~Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').
~Resistance exercise (25 min): 6 exercises targeting large muscle groups vertical row, squat, bench press, pull over, abdominal crunch, and lunge. 2sets of 10 repetitions at 70-80% of 1 RM. To ensure adequate training load over time, tests are repeated every 3 weeks aligned with the chemotherapy cycle.
~One additional (third) session from home at moderate intensity for at least 30 min.
~A brochure with exercise guidelines is provided."
16288813|NCT04754672|Experimental|Continuous aerobic and aerobic interval exercise (AE+AI)|"Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').
~Aerobic interval (25 min): cycling with high intensity intervals alternated with recovery intervals. Intensity of the interval: between 85% and 95% of estimated maximum heart rate, adjusted to Borg 16-18 'hard - very hard'. In between the intervals, light intensity cycling will be performed for active recovery at 30% of Wmax estimated from Steep ramp test and adjusted to Borg < 12.
~One additional (third) session from home at moderate intensity for at least 30 min.
~A brochure with exercise guidelines is provided."
16288814|NCT04754672|No Intervention|Usual care control group|Patients in the usual care group receive care as usual. In addition, a brochure with exercise guidelines for cancer survivors is provided
16288815|NCT04754659|Experimental|Suprarenal|Individuals that are treated with a suprarenal stentgraft for a previously diagnosed AAA.
16288816|NCT04754659|Active Comparator|Infrarenal|Individuals that are treated with an infrarenal stentgraft for a previously diagnosed AAA.
16288817|NCT04754620|No Intervention|Standard face to face visit|This group will receive a traditional outpatient visit
16288818|NCT04754620|Experimental|Online visit|This group will receive a smartphone-based real-time video conference visit
16288819|NCT04754607|Experimental|Low-level laser therapy group|"Low Level Laser Therapy (LLLT): Low-level laser therapy will be applied to the cases in addition to LT4 hormone replacement therapy.
~LLLT group will be treated using a continuous wave GaAIAs type diode laser (Intelect® Mobile Laser, Model No: 2779, Production Year: 2016; Chattanooga Group) device in the treatment area of 0.07 cm2. Continuous mode at 850 nm wavelength, 100 mW output power,1.43 W/cm2 power density and 28.57 J / cm2 energy density will be used."
16288820|NCT04754607|No Intervention|Control Group|Control Group: The cases in this group will be followed up with LT4 hormone replacement therapy.
16288823|NCT04754581|Other|All Participants|
16288824|NCT04754568|Experimental|Virtual reality instructional design|Completion of virtual reality simulation of an outpatient physical therapy evaluation.
16288825|NCT04754568|Active Comparator|Role-playing instructional design|Completion of traditional role-playing of a scripted outpatient physical therapy evaluation
16288826|NCT04754555||subacute phase|between 7 days and 6 months post-stroke;
16288827|NCT04754555||chronic phase|minimum 6 months post-stroke
16288828|NCT04754542||Discontinuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to discontinue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
16288829|NCT04754542||Continuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to continue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
16288830|NCT04754529|Experimental|Supportive care (yoga)|Patients receive online yoga intervention QW for 12 weeks.
16288831|NCT04754477|Experimental|Active Osseointegrated Steady-State Implant System (OSI)|
16288832|NCT04754464|Active Comparator|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
16288833|NCT04754464|Placebo Comparator|microcrystalline cellulose|microcrystalline cellulose
16288834|NCT04754451|No Intervention|Group P(placebo)|Attach two placebo patches for 12 hours, above and below the incision site.
16288835|NCT04754451|Experimental|Group L(lidocaine patch)|Attach two lidocaine patches for 12 hours, above and below the incision site.
16288836|NCT04754438|Experimental|e-CBT|12 weekly sessions of approximately 30 slides and interactive content, delivered through OPTT. The e-CBT module content mirrors in-person standard CBT content, including different weekly topics, general information, skill overviews, and homework. Participants are instructed to go through the content and complete homework at the end of the session which helps them practice skills they learned through that session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases.
16288837|NCT04754438|Experimental|Mental Health Coaching|"Weekly interactions with the therapist using general questions on the following topics:
~Week 1 (Mood) Week 2 (Sleep) Week 3 (Activity) Week 4 (Hobbies) Week 5 (Friendship) Week 6 (New Events) Week 7 (Job/Study) Week 8 (Diet/Food) Week 9 (Books/Movies/Shows) Week 10 (Phone/Apps/Games) Week 11 (Habits) Week 12 (Accomplishments)"
16288938|NCT04753645|Experimental|No HBCC project and no soap|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
16342529|NCT04381611||Secondary Glaucoma|
16288838|NCT04754425|Experimental|Treatment (erdafitinib, biospecimen collection)|Patients receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may also undergo collection of blood and bone marrow via biopsy and aspirates.
16288839|NCT04754412|Active Comparator|Arm I (control writing)|Patients write about facts regarding their cancer diagnosis and treatment for 3 weekly 30-minute sessions.
16288840|NCT04754412|Experimental|Arm II (self-regulation writing)|Patients write about stress and coping, emotional disclosure, and benefit finding for 3 weekly 30-minute sessions.
16288841|NCT04754412|Experimental|Arm III (self-cultivation writing)|Patients write about positive thoughts and feelings regarding their breast cancer experience for 3 weekly 30-minute sessions.
16288842|NCT04754399|Experimental|Cannabidiol (CBD)|Oral solution given 2x daily.
16288846|NCT04754347|No Intervention|Control|Routine Colonoscopy
16288847|NCT04754347|Experimental|Experimental|Routine Colonoscopy with the use of Skout
16288848|NCT04754334|Placebo Comparator|Placebo|placebo dosed QD
16288849|NCT04754334|Experimental|ORMD-0801|ORMD-0801 8 mg QD
16288850|NCT04754321|Experimental|Arm A (pembrolizumab, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 9. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
16288851|NCT04754321|Experimental|Arm B (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
16288852|NCT04754321|Experimental|Arm C (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
16288853|NCT04754308|Other|Patients referred to social nurse|"After obtaining informed consent, the social nurse reviews the online-questionnaire with the patient and performs a lung function examination requiring the patient to blow into a plastic tube. If a patient is identified as having obstructive reduction of lung function, they are offered a referral to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease.
~In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality)."
16288854|NCT04754295|Experimental|STANDARD|In this arm standard monitoring of vital signs will be used during operation.
16288855|NCT04754295|Experimental|GDT|A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.
16288856|NCT04754282|Active Comparator|Traditional sitting position|Expecting women are positioned in a traditional sitting position for epidural analgesia catheter placement during labour.
16288857|NCT04754282|Experimental|Cross-legged sitting position|Expecting women are positioned in a crosse-legged sitting position for epidural analgesia catheter placement during labour.
16288858|NCT04754269|Experimental|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children. Parents will receive that reinforce and expand on the messages in the video.
16288859|NCT04754269|Experimental|Reading Intervention|Parents will watch a video that promotes reading to children. Parents will receive text messages that reinforce and expand on the messages in the video.
16288860|NCT04754243|Experimental|Study group|Will receive ANTIUI protocol
16288861|NCT04754243|Active Comparator|Control group|Will receive standard protocol in IUI and unexplained infertility
16288862|NCT04754230|Experimental|1,000mg IV Tranexamic acid|Participants in this arm will be given a 1,000mg dose of intravenous tranexamic acid via saline infusion 15 minutes prior to the completion of surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
16288863|NCT04754230|No Intervention|Normal saline|Participants in this arm will not be given any extra intervention over their routine anesthetic care. They will continue to receive their normal saline infusion during surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
16288864|NCT04754217||Group 1|VAVGJ (N=200), including implants of VAVGJ in native or prosthetic valves.
16288865|NCT04754217||Group 2|CAVGJ (N=60), including implants of CAVGJ in native (n=30 subjects) or prosthetic (n=30 subjects) valves
16288866|NCT04754204||Patients indicated for Mobile Cardiac Telemetry Monitoring|Patients indicated for Mobile Cardiac Telemetry Monitoring while meeting inclusion/exclusion criteria and enrolled in sequential manner.
16288868|NCT04754178||Down syndrome|Down syndrome patients and their parents
16288869|NCT04754178||Control group|Healthy children and their parents
16288934|NCT04753697|Experimental|Administration of CC-93538 and Placebo|"CC-93538 360 mg SC once weekly for 24 weeks followed by CC-93538 360 mg SC once every other week for 24 weeks.
~During the Maintenance Phase, matching placebo will be administered once every other week on alternate weeks to maintain the blind."
16288935|NCT04753697|Placebo Comparator|Administration of Placebo|Matching placebo SC once weekly for 24 weeks followed by matching placebo SC once weekly for 24 weeks
16288870|NCT04754165|Experimental|Immersive Virtual Reality plus the enhanced recovery after surgery protocol|"Patients in the immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.
~Patients in the VR group will also be treated according to the existing enhanced recovery after surgery protocol."
16288871|NCT04754165|No Intervention|Enhanced recovery after surgery protocol|Subjects in the control group will only undergo standard enhanced recovery after surgery care.
16288872|NCT04754152|Experimental|TBS Group|On the basis of drug treatment, a course of TBS treatment is performed every three months and 4 courses of treatment a year.
16288873|NCT04754152|Placebo Comparator|Drug Group|Stable doses of cholinesterase inhibitors for the treatment and primary care guidance.Once every 3 months follow-up.
16288874|NCT04754139|Experimental|WeChat mobile mini-application|WeChat mini-application will increase knowledge base about sexual health through interactive health education and counseling support on HIV/STI prevention as well as PrEP initiation and/or adherence management.
16288875|NCT04754126|Experimental|Intervention Group|Educators and students complete a baseline survey. Educators will implement 6 lessons, each 45 minutes, in the classroom. Educators are free to choose the time between lessons, so some can implement all in one week, others can choose to implement once per week. Educators are given a maximum of 6 weeks to implement the curriculum. Educators and students complete a post-program survey. Students complete a 6- and 12-month follow-up survey.
16288876|NCT04754126|No Intervention|Control Group|This group will only complete online surveys that match the time when intervention group is complete the surveys. There is a baseline survey and then a post-survey 6 weeks later for both educators and students. Additionally, students will complete a 6- and 12-month follow-up survey.
16288877|NCT04754113|Experimental|prone position|patients from supine to prone for at least 3 hours than re-supine
16288878|NCT04754100|Experimental|Dosage and Cohorts|"Part 1: Dose escalation without lymphodepletion.
~Dosage Frequency and Mode of Administration: agenT-797 will be administered to subjects as a single IV infusion.
~Part 2: Dose escalation with lymphodepletion (optional)
~Dosage Frequency and Mode of Administration: Subjects will receive lymphodepletion before infusion of agenT-797. Starting dose will be defined based on data from Part 1."
16288879|NCT04754087|Other|G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners|Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.
16288880|NCT04754074|Experimental|Behavioral Education and personalized coaching|
16288881|NCT04754061|Experimental|Psilocybin Microdosing|Participants will receive a 4-week psilocybin microdosing intervention (1-3mg/day, Monday-Friday for up to 4 weeks; start at 1mg with opportunity to increase dose each week)
16288882|NCT04754048|Experimental|Traumatic wounds|Treatment with negative pressure wound therapy.
16288883|NCT04754048|Experimental|Subacute wounds (e.g., dehisced wounds)|Treatment with negative pressure wound therapy.
16288884|NCT04754048|Experimental|Flaps and Grafts|Treatment with negative pressure wound therapy.
16288885|NCT04754035|Experimental|venetoclax + ibrutinib|
16288886|NCT04754022|Active Comparator|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <75 g/L (<7.5 g/dL; <4.7mmol/L) intraoperatively and/or postoperatively.
16288887|NCT04754022|Active Comparator|Liberal Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <95 g/L (<9.5 g/dL; <5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or <85 g/L (< 8.5 g/dL; <5.3mmol/L) on the ward.
16288888|NCT04754009|Active Comparator|Treatment as Usual (TAU)|Participants assigned to treatment as usual group are required to see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
16288889|NCT04754009|Experimental|Trauma-Sensitive Yoga + TAU|Participants assigned to the Trauma-Sensitive Yoga group will attend a 1-hour long session of yoga once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
16288890|NCT04754009|Experimental|Chen Style Tai Chi + TAU|Participants assigned to the Chen Style Tai Chi group will attend a 1-hour long session of tai chi once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
16288891|NCT04753996||Primary Sclerosing Cholangitis (PSC)|Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
16288892|NCT04753996||Control (non-PSC)|Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
16288893|NCT04753983|Experimental|Anterior Nucleus of the Thalamus (ANT) Deep Brain Stimulation (DBS)|"Subjects that have undergone DBS placement for treatment of refractory epilepsy will undergo a fMRI scan. During the fMRI, the subject will undergo alternating short periods of their DBS in the on and off state with high- and low frequency settings to measure the brain activation changes induced by the DBS."
16288894|NCT04753970|Experimental|Cilostazol|Cilostazol 100mg BID
16288895|NCT04753970|No Intervention|No intervention|
16288896|NCT04753957|Active Comparator|Vaginal progesterone|200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
16288897|NCT04753957|No Intervention|Control|No intervention, scheduled cesarean delivery
16288936|NCT04753658||Pediatric Neuroblastoma Patients Treated with Lorlatinib|
16288937|NCT04753645|Experimental|HBCC and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
16288898|NCT04753944|Active Comparator|Probiotic group|Patients will be introduced for 5 weeks with probiotic therapy (in the study group). They will take Ecologic®Barrier (Winclove Probiotics BV, Amsterdam, The Netherlands), consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58. The probiotic dose is going to be 4 capsules daily (one capsule contains 500 million CFUs of living probiotic strains). The treatment will be administered two times a day, during breakfast and supper. The probiotic formula will be Provided by polish distributor of Winclove products, namely Sanprobi sp. z o. o. sp. k
16288899|NCT04753944|Placebo Comparator|Placebo group|Patients will be introduced for 5 weeks with placebo that consist of maize starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily (one capsule). The treatment will be administered two times a day, during breakfast and supper.
16288900|NCT04753931|Experimental|Sensory Training in addition to Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
16288901|NCT04753931|Experimental|Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
16288902|NCT04753918|Experimental|Novel light delivery methods for photodynamic therapy|High refraction-index contrast medium: Lipiodol injected in the bronchial tree can enhance the treatment extension of the photodynamic therapy
16288903|NCT04753892|Experimental|Arm 1|The 3Sm peptide is conjugated to a mutant diphtheria carrier protein (CRM197) and the resulting challenge agent (3SM2-G-CRM197) will be mixed with a squalene adjuvant before intramuscular administration at Months 0, 1, 2 and 4, at a dosage of 32 micrograms of 3SM2-G-CRM197 and 9.7 micrograms of adjuvant.
16288904|NCT04753879|Experimental|Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine|Maintenance of Pembrolizumab and Olaparib
16288905|NCT04753866|Experimental|Rehabilitated|Initial lip support condition of the patient when presents himself/herself at the office with indication for full arch implant rehabilitation. Then, the patient is facially scanned before and after the implant surgery.
16288906|NCT04753853|Experimental|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
16288907|NCT04753840|Experimental|Experimental A: Drug group+lifestyle intervention|Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.
16288908|NCT04753840|Experimental|Experimental B: RIPC group+lifestyle intervention|The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.
16288909|NCT04753840|Other|Experimental c: lifestyle intervention|The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
16288910|NCT04753827|Experimental|Experimental Group 1|Stents were implanted in MV and SB respectively, and DKcrush or Culotte technology was selected according to the lesion characteristics.
16288911|NCT04753827|Experimental|Experimental Group 2|The MV was stented and the SB were treated with just drug-coated balloon(DCB)
16288912|NCT04753827|Experimental|Experimental Group 3|Stents were implanted in the MV and the shaft of side branch SB respectively, then a DCB was applied to the ostium of the SB
16288913|NCT04753814|Other|Identyfication of prognostic factors in HFrEF|Selected prognostic factors will be analyzed in patients with LVEF ≤40%
16288914|NCT04753814|Other|Identyfication of prognostic factors in HFmrEF|Selected prognostic factors will be analyzed in patients with LVEF 41-49%
16288915|NCT04753814|Other|Identyfication of prognostic factors in HFpEF|Selected prognostic factors will be analyzed in patients with LVEF ≥50%
16288916|NCT04753801|Experimental|Best Possible Self (writing only)|Participants are asked to think and write about their best possible future self (15 min).
16288917|NCT04753801|Experimental|Best Possible Self (writing+imagining)|Participants are asked to think and write about their best possible future self (15 min) and, then to imagine their positive future (5 min).
16288918|NCT04753801|Experimental|Best Possible Self (writing+mindfulness)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief mindfulness sequence (5 min).
16288919|NCT04753801|Experimental|Best Possible Self (writing+recall)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief recall imagination task about the past two days (5 min).
16288920|NCT04753801|Active Comparator|Writing about the past|Participants are asked to think and write about activities of the past two days (15 min).
16288921|NCT04753788||Suspected Yaws Cases|Individuals with a lesion clinically suspected to be yaws and with evidence of positive treponemal and non-treponemal serology as assessed by point of care lateral flow tests (DPP Syphilis Screen and Confirm, Chembio)
16288922|NCT04753775|Experimental|22 patients were assigned to Group-A|22 patients were assigned to Group-A
16288923|NCT04753775|Placebo Comparator|22 patients were assigned to Group-B|22 patients were assigned to Group-B
16288924|NCT04753749|Experimental|Shortened DAPT followed by P2Y12 inhibitor monotherapy|
16288925|NCT04753749|Active Comparator|Dual Antiplatelet Therapy|
16288926|NCT04753736|No Intervention|No recurrent implantation failure|
16288927|NCT04753736|Experimental|Recurrent implantation failures|
16288928|NCT04753736|Experimental|Recurrent miscarriage|
16288929|NCT04753723|Experimental|Platform wound device with antibiotic|Antibiotic cream will be applied to study wounds and then dressed with the platform wound device.
16288930|NCT04753723|No Intervention|Standard of Care|Study wounds will be treated per the standard of care.
16288931|NCT04753710|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel
16288932|NCT04753710|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel
16288933|NCT04753697|Experimental|Administration of CC-93538|CC-93538 360 mg Subcutaneously (SC) once weekly for 24 weeks followed by CC-93538 360 mg SC once weekly for 24 weeks
16288939|NCT04753645|Experimental|Soap received but no HBCC|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
16288940|NCT04753645|Experimental|Both HBCC project and Soap received|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
16288941|NCT04753632||Cerebral palsy patients and caregivers|Cerebral palsy patients and caregivers
16288942|NCT04753632||Healthy people and their caregivers|Healthy people and their caregivers
16288943|NCT04753619|Experimental|Niclosamide group: NCS group|NCL + standard therapy
16288944|NCT04753619|No Intervention|Control group|Control group
16288945|NCT04753606|Placebo Comparator|Placebo|once-daily placebo
16288946|NCT04753606|Experimental|obicetrapib 5 mg|once-daily obicetrapib
16288947|NCT04753606|Experimental|obicetrapib 10 mg|once-daily obicetrapib
16288948|NCT04753580|Experimental|group 1|healthy adult 20-35 years old
16288949|NCT04753580|Experimental|group 2|healthy elderly 65+ years old
16288950|NCT04753580|Experimental|group 3|Frail elderly 65+ years old
16288951|NCT04753567|Experimental|Actual pain patch|
16288952|NCT04753567|Placebo Comparator|Sham patch|
16288953|NCT04753554|Active Comparator|Conventional group|The patient group that whose oxygenation will be managed by blood gas analysis.
16288954|NCT04753554|Experimental|ORI group|The patient group that whose oxygenation will be managed by ORI values
16288955|NCT04753528|Experimental|Group A|Personalized stimulation parameters and amplitude
16288956|NCT04753528|Experimental|Group B|Personalized stimulation amplitude
16288957|NCT04753528|Active Comparator|Group C|Non-personalized stimulation
16288958|NCT04753515|Active Comparator|Group DMR|dexmedetomidine combined with midazolam and remifentanil.
16288959|NCT04753515|Active Comparator|Group PMR|propofol combined with midazolam and remifentanil.
16288960|NCT04753489|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
16288961|NCT04753489|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
16288962|NCT04753476|Experimental|Secretome-MSCs (n=24)|This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome
16288963|NCT04753476|Other|Control (n=24)|This group will receive standard Covid-19 therapy with the best supportive care
16288964|NCT04753463||Residents of Ophthalmology working on COVID-19 departments|Residents of ophthalmology working on COVID-19 departments and dealing with SARS-CoV-2 positive patients
16288965|NCT04753463||Residents of Ophthalmology working on general ophthalmic departments|Residents of Ophthalmology working on general ophthalmic departments and not dealing with SARS-CoV-2 positive patients
16288968|NCT04753398|Experimental|Telemonitoring group|Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology
16288969|NCT04753398|No Intervention|Control group|usual care, without telemonitoring
16288970|NCT04753359|Experimental|Med-A|"Med-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of group sessions. For subjects randomized to Med-A the study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized MedDiet exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to maintain weight. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial in-person session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 7.5 months.
~The Med-A group will be asked to maintain their usual physical activity pattern."
16288971|NCT04753359|Experimental|WL-A|"WL-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of group sessions. For subjects randomized to WL-A, the focus will be on daily calorie restriction (-500-750 kcal/day) to achieve a 1-2 lb. per week WL and 5% WL from baseline at 8 months in the context of the subject's typical diet pattern. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial in-person session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 7.5 months.
~The WL-A group will be prescribed an activity program with an initial recommendation of 100 min/week progressing to 150 min/week within 6 weeks. Subjects will also participate in 30 minutes of supervised physical activity during the group sessions"
16289001|NCT04753125|Active Comparator|compliance for blood test|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance, follow-up via a game in a smartphone app through an interactive game with stimuli to pass the phase as the treatment was completed and blood tests were performed in 3,6,9 and 12 months.
16289002|NCT04753125|Placebo Comparator|demographic socio-economic and sexuality questionnaire|Questionnaire applied to all patients with positive VDRL
16288972|NCT04753359|Experimental|WL-Med|"WL-Med will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of group sessions. The study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to lose weight (WL-Med, calorie restriction to achieve a 1-2 lb. per week WL and 5% WL from baseline at 8 months). We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial in-person session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 7.5 months.
~Physical activity. Participants will be prescribed an activity program and will also participate in 30 minutes of supervised physical activity during the group sessions"
16288973|NCT04753359|No Intervention|Control|The study RD will meet individually with the Control group subjects for 1-hour at the start of the 8-month intervention. Control participants will be instructed to maintain current eating and activity patterns and weight over the next 8 months. No dietary recommendations are provided, and they will receive weekly health newsletters that include non-diet related health topics (e.g., flu prevention). Contact will be made again at month-4 and post-intervention (month-8) research visits and during monthly phone calls to collect data pertaining to recent diet intake. At the month-4 assessment, weight will be checked and those with >2.5% WL from baseline will receive additional instruction from the RD to maintain lifestyle patterns. All WL-Med materials are offered to the group in a self-guided format following the 8-month intervention.
16288974|NCT04753346||Mild Disease|Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.
16288975|NCT04753346||Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥ 90% on room air
16288976|NCT04753346||Severe Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea,fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air.
16288977|NCT04753346||Critical Disease|Patients have one of the following: acute respiratory distress syndrome; sepsis; or septic shock.
16288978|NCT04753333|Experimental|Experimental|The participants in the experimental group will receive Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for four weeks.
16288979|NCT04753333|Placebo Comparator|Control|The participants in the experimental group will receive Sham EMG-BF guided isometric quadriceps strengthening without patellar taping five days a week for four weeks.
16288980|NCT04753307||Patients at least 45 years at-risk for cardiovascular complications|
16288981|NCT04753294|Experimental|Avance Solo NPWT System|Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.
16288982|NCT04753294|Experimental|Avance Solo Adapt NPWT System|Treatment with negative pressure wound therapy for Pressure ulcers.
16288983|NCT04753281|Other|Lifestyle counselling|Participants will receive an assessment appointment and up to 8 follow up sessions with a Health Psychologist to help them set goals and monitor changes of their own self management behaviour.
16288984|NCT04753281|No Intervention|Treatment as usual|Treatment as usual
16288985|NCT04753268|Experimental|Treatment group: Noom Healthy Weight Program|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging.
16288986|NCT04753216|Experimental|Treatment (bevacizumab, irinotecan sucrosofate)|Patients receive bevacizumab IV and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16288987|NCT04753203|Experimental|A single arm study with Alpelisib plus Capecitabine|A phase lb/ll, open label, single arm study with Alpelisib plus Capecitabine in patients with PIK3CA mutant metastatic colorectal cancer
16288988|NCT04753190|Placebo Comparator|Dim Room Light Control|Participants in the dim room light control group will not receive any bright light exposure.
16288989|NCT04753190|Experimental|Morning Bright Light Only (MBL)|"Participants in the morning bright light (MBL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive mornings in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
16288990|NCT04753190|Experimental|Afternoon Light Only (ABL)|"Participants in the afternoon bright light (ABL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive afternoons in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
16288991|NCT04753190|Experimental|Morning + Afternoon Light (MBL+ ABL)|"Participants in the morning bright light + afternoon bright light (MBL+ ABL) group will receive bright light from 2 light boxes on 3 consecutive days in the laboratory. The morning exposure will be 1.5 h and the afternoon exposure will be 1.5 h. Bright light exposures will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
16288992|NCT04753177|Experimental|Neoadjuvant combined hormone therapy|Ribocyclib, fulvestrant, triptorelin
16288993|NCT04753177|Active Comparator|Chemotherapy (the control)|doxorubicin, cyclophosphamide, paclitaxel
16288996|NCT04753151|Experimental|Tranexamic acid|Patients scheduled for liver transplantation and allocated for treatment with tranexamic acid (Group 1).
16288997|NCT04753151|Placebo Comparator|Placebo|Patients scheduled for liver transplantation and allocated for treatment with placebo (Group 2).
16288998|NCT04753138|Experimental|SCT with BC sealer|The teeth will be obturated with the single cone technique and BC sealer
16288999|NCT04753138|Active Comparator|WVC with AH+ sealer|The teeth will be obturated with warm vertical compaction and AH+ sealer
16289000|NCT04753125|Active Comparator|compliance treatment|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance for 3, 6. 9 and 12 months
16289126|NCT04752176||Hyperacusis group|At least 20 patients suffering from hyperacusis will be enrolled in the study.
16289003|NCT04753112|Experimental|Treatment|"All the subjects will receive sacubitril/valsartan from weeks 6 to 12. From weeks 1-6 and 12-18 patients will be treated with standard therapy for HFpEF according to PA pressures (diuretics and systemic vasodilators if concomitant hypertension).
~All the subjects will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
~Device: Patients eligible for this study are those with an already implanted CardioMEMS device.
~Drug: Sacubitril/Valsartan Target dose:97/103mg bid"
16289004|NCT04753099|Experimental|Intervention|Receives occupation-based coaching via telehealth
16289005|NCT04753099|No Intervention|Control|No intervention Will receive the occupation-based coaching via telehealth after the 12-weeks
16289007|NCT04753073|Experimental|NIPP|Treatment of the NIPP group with physical low-temperature plasma, subsequently within 8 weeks LEEP-Exzision
16289008|NCT04753073|No Intervention|Controll|LEEP-Exzision
16289009|NCT04753060|Active Comparator|Waxing|Waxing of patients donor site who are undergoing a skingraft procedure, prior to surgery taking place.
16289010|NCT04753060|No Intervention|Standard care|Standard wound preparation
16289011|NCT04753047||Children practicing football|Children in late childhood (age 10-12 years) practicing sport, which is high dynamic (> 75%), and low static (<10&) and in the same time it is open skill exercise sport (football)
16289012|NCT04753047||Children practicing gymnastics|Children in late childhood (age 10-12 years) practicing sport, which is low dynamic (<50%), high static (>30%) and in the same time it is closed skill exercise sport (sport gymnastics)
16289013|NCT04753047||Comparative group|A comparative group of children that do not attend sport classes or sports clubs, but carrying out sports activity and / or in other areas
16289014|NCT04753034|Experimental|TER-101|BID (twice daily) application
16289015|NCT04753034|Placebo Comparator|Vehicle|Vehicle ointment, BID (twice daily) application
16289016|NCT04753021|Experimental|Exercise|Progressive exercise training
16289017|NCT04753008|Experimental|Dopamine group|Cardiac surgery patients receiving dopamine to support their cardiac function (as part of the routine post-operative care).
16289018|NCT04753008|No Intervention|Control group|Cardiac surgery patients receiving no positive inotrope drug.
16289019|NCT04752995|Other|high tibial osteotomy|Under general anesthesia, a one-cm vertical skin incision was done at the medial subcutaneous border of the tibia, one fingerbreadth below the tibial tuberosity. This was confirmed by intra-operative C-arm images. Longitudinal periosteal incision was done with minimal dissection. Incomplete medial transverse osteotomy including both anterior and posterior cortex was performed using drill bit or small thin osteotome.Osteotomy was completed manually by osteoclasis of the lateral cortex to provide postoperative stability by the preserved lateral periosteum. No fibular osteotomy was needed in the present study.
16289020|NCT04752982|Active Comparator|c-SIGHT intervention|Grasp, lift and balance three wooden rods of different lengths.
16289021|NCT04752982|Sham Comparator|c-SIGHT attentional control|Grasp and lift three wooden rods of different lengths from one end only (no attempt to balance rods).
16289022|NCT04752969||Hypothyroidia|20 subjects diagnosed with hypothyroidism
16289023|NCT04752969||Hyperthyroidia|20 subjects diagnosed with hyperthyroidism
16289024|NCT04752969||Healthy|20 age-matched healthy control subjects
16289025|NCT04752956|Active Comparator|Grup1|Nasal steroid spray only (NS) (Each dose contains 27.5 micrograms of fluticasone furoate; administered single dose per day as 1 puff through both nostrils)
16289026|NCT04752956|Active Comparator|Grup 2|NS + administered ambient temperature normal saline (NSS) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (NSS; 0,09% NaCl, pH:4-5)
16289027|NCT04752956|Active Comparator|Grup 3|NS + administered ambient temperature hyaluronic acid (HA) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (Nasorinse plus pediatric® Ingredients: water, sodium chlorine, sodium bicarbonate, and HA; pH balanced)
16289028|NCT04752943|Experimental|Children and caregivers receiving TipsByText messages|
16289029|NCT04752943|No Intervention|Children and caregivers not receiving TipsByText texts|
16289030|NCT04752930|Experimental|ctDNA monitoring|ctDNA monitoring will be performed at protocol-specified intervals and requirement
16289031|NCT04752930|Active Comparator|Imageology (SOC)|Imaging examination will be performed at protocol-specified intervals and requirement
16289032|NCT04752917|Experimental|Intervention|Headphones
16289033|NCT04752917|No Intervention|Control|Standard of care
16289034|NCT04752904|Experimental|ClearSight group|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem, with a finger cuff around the middle finger, and the anesthesiologist manages blood pressure based on this.
16289035|NCT04752904|No Intervention|Control group|The blood pressure is measured at 1-minute intervals by non-invasive blood pressure monitor using the arm cuff, and the anesthesiologist in charge manages the blood pressure based on the measured blood pressure.
16289036|NCT04752891|Experimental|AOM diagnosis with app|
16289037|NCT04752891|Other|AOM diagnosis without app|
16289038|NCT04752852|Experimental|Dexamethasone|Patients with odd numbers were assigned to group A. 8 mg/2 ml dexamethasone was injected intravenously sixty minutes before the induction of anaesthesia
16289039|NCT04752852|Placebo Comparator|Placebo|Patients with even numbers were assigned to group B. Two millilitres (ml) normal saline (0.9%) was given intravenously 60 minutes before the induction of anaesthesia.
16289040|NCT04752839||Exposed Workers|Workers who have been exposed during COVID 19 pandemic.
16289041|NCT04752826|Experimental|Phase I, Part A - Dose escalation and safety of BI-1808 alone|Dose escalation with repeated administrations of BI-1808 infusions as a single agent, in patients with advanced malignacy.
16289042|NCT04752826|Experimental|Phase I, Part B - Dose escalationa and Safety of BI-1808 in combination with pembrolizumab|Dose escalation and safety with repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in patients with advanced malignacy.
16289043|NCT04752826|Experimental|Phase IIa - Part A Expansion cohorts of BI-1808 alone|Repeated administrations of BI-1808 infusions as a singel dose in 3 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer , Cutaneous T-cell lymphoma (Sézary Syndrome and Mycosis Fungoides).
16289044|NCT04752826|Experimental|Phase IIa, Part B - Expansion cohorts of BI-1808 in combination with pembrolizumab|Repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in 2 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer.
16289045|NCT04752813|Experimental|BPM31510, Vitamin K1, RT and TMZ|"Subjects will receive a BPM31510 96hr infusion once weekly for 8 wk. Prophylactic Vitamin K1 at a recommended dose of 10 mg will be given intramuscular (IM) to all subjects prior to the beginning of each week of therapy.
~After 2 wk of treatment with BPM31510, subjects will start concurrent standard RT and TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment."
16289046|NCT04752800|Experimental|active tDCS|"Participants will receive 10 ETCC sessions, for 20 minutes, on alternate days (3 times a week). The electrodes will be positioned on the primary motor cortex (position C3 or C4 according to the international electroencephalogram system - EEG 10/20), with the anode positioned on the affected hemisphere and the cathode on the supraorbital region in the hemisphere contralateral to the injury. The electrodes will be wrapped with sponges of 5 x 7 cm and moistened with saline (NaCl 0.9%).
~The current intensity will be defined based on computational modeling, using the patient's magnetic resonance as a basis, in order to estimate and individualize the dosage to be administered."
16289047|NCT04752800|Sham Comparator|Sham tDCS|The protocol for placebo stimulation will be identical, but the device will stop emitting current 30 seconds after the start of stimulation.
16289048|NCT04752787|Experimental|Experimental|Experimental group 1: Breastfeeding training for successful breastfeeding in twin babies will be given to the online training group. The training will be carried out by the researchers (DM) and (SYC) using visual training tools (power point presentation, simultaneous breastfeeding animations in twin babies and breastfeeding guide). Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. In the first session, about 45 minutes of online slide-assisted training on successful breastfeeding in twin babies and the importance of breast milk will be conducted and questions of pregnant women will be answered. Total training will take approximately one and a half hours.
16289049|NCT04752787|Active Comparator|Active comparator|"Experimental group 2: Breastfeeding training for successful breastfeeding in twin babies will be given to the QR supported online training group. Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. Total training will take approximately one and a half hours.
~In the guideline, there will be 4 vieos ralted to Breastfeeding and Feeding with Breast Milk in Twin Babies, Breastfeeding Techniques and Positions in Twin Babies, Expressing Breastfeeding, Storing and Feeding it to Babies and Problems Encountered in Breastfeeding and its Solutions, and simultaneous breastfeeding used in breastfeeding twin babies and also there will be a total of 7 QR codes, 3 of which are related to the animations (Animation 1-2-3) of the positions (double cradle grip, double football grip, combination of armpit and cradle grip-parallel grip)."
16289050|NCT04752787|No Intervention|Control Groups|Pregnant women in the control group will be followed up in line with the routine health monitoring and information of the hospital.
16289051|NCT04752774|Experimental|Dose escalation|One single administration of study medication (IPN10200, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
16289052|NCT04752774|Experimental|Dose ranging|Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb. Participants will be randomised in the ratio of 3:3:2 (total IPN10200 dose 1: 30 participants; total IPN10200 dose 2: 30 participants; Dysport: 20 participants)
16289053|NCT04752774|Experimental|Total dose|One single injection of study medication will be administered locally into several muscle groups of the upper limb. Participants will be randomised in the ratio of 2:1 (total IPN10200 dose: 30 participants; placebo: 15 participants).
16289054|NCT04752748||Woman with Early Rheumatoid Arthritis|
16289055|NCT04752722|Experimental|Phase 1|Dose escalation phase
16289056|NCT04752722|Experimental|Phase 2|Recommended Phase 2 dose, up to 4 cycles of treatment with EG-70
16289057|NCT04752709|Experimental|Active Group A|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.
16289058|NCT04752709|Active Comparator|Active Group B|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.
16289059|NCT04752696|Experimental|Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU|The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
16289060|NCT04752696|Experimental|Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU|Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
16289061|NCT04752683||Organisation 1|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
16289062|NCT04752683||Organisation 2|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
16289063|NCT04752657|Experimental|Experimental Group|The experimental group will receive the physical function survey at weeks 2, 10, 18, and 26; the physical activity survey at weeks 2, 14, and 26; the events survey at weeks 2, 6, 10, 14, 18, 22, and 26. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
16289064|NCT04752657|Active Comparator|Control Group|The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
16289237|NCT04751461|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session
16289065|NCT04752644|Experimental|Group1: MVA-BN-RSV|"Participants will receive one intramuscular injection of MVA-BN-RSV (nominal titre 5 x 10*8 Inf.U per 0.5 mL) given on day -28 before RSV challenge on day 0.
~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
16289066|NCT04752644|Placebo Comparator|Group 2: Placebo|"Participants will receive one intramuscular injection of Tris-Buffered-Saline (0.5 mL) given on day -28 before RSV challenge on day 0.
~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
16289067|NCT04752631|Experimental|TNK-tPA|TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.
16289068|NCT04752631|No Intervention|Routine Therapy|Patients will be treated with standard of care in compliance with guidelines for acute stroke
16289069|NCT04752618|Experimental|P-STAIR|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. P-STAIR is a combination of STAIR and PCIT. STAIR focuses on reduction of PTSD symptoms through enhancement of emotion regulation skills. PCIT focuses on the reduction of negative parenting skills and the increase of positive parenting skills.
16289070|NCT04752618|Active Comparator|Supportive Counseling|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. Supportive counseling has been modified to permit non-trauma discussion of parenting problems. Each session is client-directed and clinicians take an unconditionally supportive role.
16289071|NCT04752605|Experimental|Intervention|play sessions included as a part of normal early childhood education; parents' evening for all parents; parents' group for the parents of children that have difficulties in self-regulation and that are offered more individualized small group activity
16289072|NCT04752605|No Intervention|Control|normal early childhood education
16289073|NCT04752592|Experimental|SeroSelectTB|The participants in this arm, after providing informed concent, will be tested using the SeroSelectTB rapid assay.
16289074|NCT04752592|No Intervention|Standard of Care|The participants in this arm, after providing informed consent, will receive the established standard of care.
16289075|NCT04752579|Experimental|Pilates exercise program|Participants allocated to this group will receive a 10-week Pilates exercise program with each session having a duration of 45'.
16289076|NCT04752579|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home-based general exercise sheet
16289077|NCT04752566|Experimental|Eculizumab|Participants will receive eculizumab.
16289078|NCT04752566|Placebo Comparator|Placebo|Participants will receive placebo.
16289079|NCT04752540|Experimental|Mild hepatic impairment|120 mg olorofim
16289080|NCT04752540|Experimental|Moderate hepatic impairment|60 to 120 mg olorofim
16289081|NCT04752540|Active Comparator|Normal hepatic function|120 mg olorofim
16289082|NCT04752527|Experimental|Treatment regime|combination of venetoclax plus azacitidine, and Sorafenib for patients with high FLT3-ITD allelic ratio
16289083|NCT04752501|Experimental|Psychologically Informed Video Series|"This 3 part educational video series will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it); Simple methods of cognitive restructuring; and how to respond to activity-related pain."
16289084|NCT04752501|Active Comparator|Biomedical Education Video Series|Participants in the control (biomedical education) group will watch a series videos on the iPad equal in length to the psychologically informed video series. The control video will discuss basic anatomy of the knee and provide no psychosocial education or positive reinforcement about their condition, basic strengthening exercises and proper lower extremity mechanics
16289085|NCT04752488|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
16289086|NCT04752488|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
16289087|NCT04752475|Experimental|Lasix (furosemide)|Furosemide 20 mg, oral, once daily for 5 days
16289088|NCT04752475|Placebo Comparator|Placebo|Identical-appearing placebo, oral, once daily for 5 days
16289089|NCT04752462|No Intervention|Standard of Care with provider|Participant will continue follow up for sleep apnea with provider.
16289090|NCT04752462|Experimental|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
16289091|NCT04752449|Experimental|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
16289092|NCT04752449|No Intervention|Treatment as Usual|Participants continue with their regular standard of care without the addition of virtual Cognitive Behavioural Therapy for Psychosis.
16289093|NCT04752436|Experimental|Supra high intensity interval training|The experimental group will engage in the high intensity interval training.
16289094|NCT04752423||PATIENT group|Adult patients shedule for general anesthesia
16289095|NCT04752423||NURSE group|Nurse anesthesist in charge of the corresponding patient
16289127|NCT04752163|Experimental|Cohort A and B (DS-1594b)|Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16289729|NCT04747964|Experimental|A single high dose of treatment group|
16289096|NCT04752410|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
16289097|NCT04752384|Experimental|Drug Treatment|The main objective of this study is to provide preliminary evidence that FDA approved dose of transdermal buprenorphine in conjunction with oral tramadol can provide adequate analgesia of radiation-induced mucositis pain during treatment and follow up period in head and neck cancer patients.
16289101|NCT04752345|Active Comparator|Control group|Pharmacoinvasive strategy, fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early invasive strategy (in case of successful fibrinolysis)
16289102|NCT04752345|Experimental|Experimental group|Reduced-dose fibrinolysis combined with immediate invasive therapy
16289105|NCT04752319|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
16289106|NCT04752319|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
16289107|NCT04752306||residents|"10 residents
~Minimum 1x > 1week had experience with incontinence material
~MMSE score >23
~good verbal communication"
16289108|NCT04752306||healthcare workers|8 healthcare workers working in setting, no exclusion criteria
16289109|NCT04752306||policymakers|2 policymakers responsible for the purchase of incontinence material
16289110|NCT04752293||Hypertension Cohort|Participants with newly diagnosed primary hypertension
16289111|NCT04752293||Control Cohort|Healthy participants with normal blood pressure
16289112|NCT04752280|Experimental|Arm A: Proton irradiation|Irradiation applied with protons
16289113|NCT04752280|Active Comparator|Arm B: Photon IMRT|Photon irradiation applied as intensity-modulated radiotherapy
16289114|NCT04752267|Experimental|Diagnostic (18F-FMAU, PET/CT, mpMRI)|Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.
16289115|NCT04752241|Experimental|IMAP|Inferior Mesenteric Artery Preservation Performing left hemicolectomy and anterior rectal resection the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
16289116|NCT04752241|Active Comparator|IMAS|Inferior Mesenteric Artery Ligation Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
16289117|NCT04752228|Experimental|ACE Screen|"At the initial visit, the Philadelphia ACE Survey, a validated ACE questionnaire, will be administered by a research coordinator. A Lifestyle Assessment package will also be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire. Patients who test positive for ACE will receive a 3-page printed ACE Resource Pack.
~At 3 months, the Lifestyle Assessment will be administered again.
~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
16289118|NCT04752228|Other|Lifestyle Assessment|"At the initial visit, no Philadelphia ACE Survey will be administered. The Lifestyle Assessment packaged will be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire.
~At 3 months, the Lifestyle Assessment will be administered again.
~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
16289119|NCT04752215|Experimental|BI 765049 single treatment group|BI 765049
16289120|NCT04752215|Experimental|BI 765049 + BI 754091 combination treatment group|BI 765049 + BI 754091
16289121|NCT04752202|Experimental|Test group (group A)|The women were randomly assigned to group A. Test group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
16289122|NCT04752202|Other|Control group (group B)|The women were randomly assigned to group B. Control group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
16289123|NCT04752189|Active Comparator|Standard MMH Curriculum Implementation|Teachers will receive the MMH curriculum manual, standard training and as-needed technical assistance, provided to them by the health coordinators
16289124|NCT04752189|Experimental|Michigan Model for Health: Learning to Enhance and Adapt for Prevention (MI-LEAP)|We will deploy Enhanced REP to include additional tailoring of the MMH curriculum to include trauma-informed approaches, tailored trauma-focused curriculum training, and implementation facilitation, ongoing specialized implementation support.
16289125|NCT04752176||Tinnitus group|At least 20 patients suffering from tinnitus will be enrolled in the study.
16289128|NCT04752163|Experimental|Cohort C (DS-1594b, venetoclax, azacitidine)|Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16289129|NCT04752163|Experimental|Cohort D (DS-1594b, mini-HCVD)|Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.
16289130|NCT04752163|Experimental|Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)|Patients receive DS-1594b PO BID on days 1-8 and 19-28, and posaconazole PO BID on day 9 and QD on days 10-18 or voriconazole PO BID on days 9-18 in the absence of disease progression or unacceptable toxicity.
16289131|NCT04752163|Experimental|Food-Effect (DS-1594b)|Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of disease progression or unacceptable toxicity.
16289132|NCT04752163|Experimental|Phase I (DS-1594b)|Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
16289133|NCT04752150|Active Comparator|Group ESPB = Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
16289134|NCT04752150|Active Comparator|Group RIB = RIB group|In group RIB, RIB block will be performed with patients in the lateral decubitus position while the surgical site up. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 30 ml 0,25% bupivacaine will be injectted into the fascial plane.
16289135|NCT04752137|Other|ICG Dye and use of SPY-PHI Imaging|ICG will be administered in the pre-operative unit via IV injection at the time that they present to the pre-operative unit, which is approximately 4 hours before surgery. ICG Angiography (SPY PHI) will be performed to detect any residual signal
16289136|NCT04752124|Active Comparator|HIIT+CT|HIIT combined with conventional rehabilitation.
16289137|NCT04752124|Placebo Comparator|Conventional therapy|Conventional rehabilitation will be provided to this group of patients.
16289138|NCT04752111|Experimental|Group E (esmolol infusion)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .
16289139|NCT04752111|Placebo Comparator|Group T (TAP block)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.
16289140|NCT04752098|Other|premature infants and full term infants|"The study visits will be at ≥3 time points at ages: within the first 28 days after birth, 2 months, 3 months, and, if still hospitalized, at 4 months and at 6 months.
~The ultrasound machine to the nursery or neonatal intensive care unit at a scheduled time.
~The appropriate ultrasound probe will be placed on the infant's tibia and a miniature hydrophone near the probe. A series of ultrasound measurements will be obtained and the ultrasound data will be saved for offline processing.
~The Investigators will repeat the measurement in 3 locations of the infant's tibia.
~Each ultrasound measurement takes a few seconds. The complete ultrasound study will take about 15 minutes at each visit.
~All procedures will be conducted in the nursery or neonatal intensive care unit to ensure infant safety.
~The ultrasound measurement for full-term infants can be done in ultrasound lab."
16289141|NCT04752072|Experimental|ESTAIR|ESTAIR (Cloitre et al., 2019) will consist of up to 25 sessions, organized in 4 modules of 6 sessions targeting symptoms of PTSD and disturbances in self-organisation (AD: affective dysregulation; NSC: negative self-concept; and DR: disturbances in relationships).
16289142|NCT04752072|Active Comparator|Treatment as usual (TAU)|At present, there are no recommended treatments for CPTSD. TAU will consist of a treatment package that could include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, resembling established protocols for treating PTSD.
16289143|NCT04752059|Experimental|T-DXd 5.4 mg|Single arm phase II trial
16289144|NCT04752046|Active Comparator|obturator group|patients with resected maxillary defects were managed with surgical obturator
16289145|NCT04752046|Active Comparator|scapular flap group|
16289146|NCT04752033|Experimental|Morphine|Subjected to sequential up and down dose titration using biased coin method in parallel with the hydromorphone arm
16289147|NCT04752033|Experimental|Hydromorphone|Subjected to sequential up and down dose titration using biased coin method in parallel with the morphine arm
16289148|NCT04752020|Experimental|Netarsudil use|Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance
16289149|NCT04752007|Active Comparator|RSA group|Conventional RSA to measure the movement in th SI joint.
16289150|NCT04752007|Active Comparator|CT group|Low dose CT to measure the movement in th SI joint.
16289151|NCT04751994|Experimental|Iron supplement/ ferrous sulphate syrup|administration of daily iron drops, 1.5mg/kg/day iron as ferrous sulphate
16289152|NCT04751994|Placebo Comparator|supplement with placebo|administration of daily placebo drops
16289153|NCT04751981|Experimental|Patient Specific Guide|Patients randomized into this group will have pedicle screws placed with the aid of patient specific surgical guides.
16289154|NCT04751981|Other|Navigation|Patients randomized into this group will have pedicle screws placed with conventional navigation.
16289177|NCT04751851|Active Comparator|B.2: Long duration withdrawal programme without ACT|Long duration withdrawal programme without Acceptance and Commitment Therapy
16289730|NCT04747964|Experimental|A single highest dose of treatment group|
16289155|NCT04751968|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
16289156|NCT04751968|Other|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
16289157|NCT04751955|Experimental|Olinvacimab plus Capecitabine|A single arm study with Olinvacimab plus Capecitabine
16289160|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib Monotherapy (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab
~Monotherapy : Participants will receive Abemaciclib orally 2x daily"
16289161|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab
~Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
16289162|NCT04751929|Experimental|CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.
~Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle"
16289163|NCT04751929|Experimental|CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.
~Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
16289164|NCT04751916|Experimental|Proprietary Essential Amino Acid Protein Supplement|Essential amino acid protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
16289165|NCT04751916|Active Comparator|Commercially-available whey protein supplement - Beneprotein®|Beneprotein® whey protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
16289166|NCT04751903|Experimental|Oral motor stimulation|After the infants were assessed by a neonatologist, Oral motor stimulation was administered to the experimental group thrice a day (at 9:00, 12:00, 15:00 hours) for 15 minutes right before feeding, over a 14-day period.
16289167|NCT04751903|No Intervention|Control group|The preterm infant' the control group were only fed by the researcher thrice a day (at 9:00, 12:00, 15:00 hours) over a 14-day period.
16289168|NCT04751890|Experimental|Structured home-based exercise|Program will include two 10-minute sessions/day (6 days/week) of intermittent walking (1-minute work and 1-minute rest while seated) at a prescribed speed converted into a walking cadence and followed at home using a metronome. The walking sessions will be preferably performed indoors at home or on a treadmill. During the study, 2 follow-up visits (at weeks 8 and 16) will be performed to evaluate patient adherence to the program and to update the exercise program with the duration of each session that remained constant. The walking intensity of each exercise regime will be progressively modified to increase the training load. The patients will be asked to fill out a daily training record indicating completion of the exercise and any associated symptoms. Patients will have the ability to contact the rehabilitation team, composed of a physician and a sports science expert, throughout the entire study period via phone.
16289169|NCT04751890|Active Comparator|Walking advice|Patients will receive advice to walk as suggested by the guidelines. In particular, a team member will recommend patients to gather almost 30 minutes of walking at least 3 times per week; when the patient will face claudication pain, he/she will be allowed to rest, and restart walking as soon as possible. A daily log to be compiled will be provided to each patients to record the amount of walk performed.
16289170|NCT04751877|Experimental|Isatuximab/Lenalidomide/Dexamethasone/Bortezomib|
16289171|NCT04751877|Active Comparator|Isatuximab/Lenalidomide/Dexamethasone|
16289172|NCT04751864|Experimental|Active Arm|Participants receive active device for the full 8 week study
16289173|NCT04751864|Sham Comparator|Sham Arm|Participants receive sham device for the first 4 weeks, and then at the week 5 cross over, receive the active device.
16289174|NCT04751851|Experimental|A.1: Medium duration withdrawal programme with ACT|Medium duration withdrawal programme with Acceptance and Commitment Therapy
16289175|NCT04751851|Experimental|A.2: Long duration withdrawal programme with ACT|Long duration withdrawal programme with Acceptance and Commitment Therapy
16289176|NCT04751851|Active Comparator|B.1: Medium duration withdrawal programme without ACT|Medium duration withdrawal programme without Acceptance and Commitment Therapy
16290055|NCT04745598||Control group: Dental model|Patients diagnosed with periodontal disease stage I/II/III
16289178|NCT04751838||Survivor cohort; Non-survivor Cohort|All patients were categorized according to the state of departure from the hospital, named survivor or non-survivor.
16289179|NCT04751838||Training Cohort, Validation Cohort|the eligible patients randomly (7:3) into training cohort and validation cohort. The training cohort were used to build nomogram model, while the validation cohort validated the model.
16289180|NCT04751825|Experimental|I-EAET|Internet administrated Emotional and Awareness and Expression Therapy (I-EAET). 10 weeks. Self-help treatment with therapist contact via text messages at least once a week.
16289181|NCT04751825|No Intervention|WL|Wait-list.
16289182|NCT04751812|Active Comparator|High-pain standard|Patients grading pain associated with venous cannulation >=2.0 allocated to standard treatment.
16289183|NCT04751812|Experimental|High-pain extra|Patients grading pain associated with venous cannulation >2.0 allocated to extra treatment.
16289184|NCT04751812|Active Comparator|Low-pain standard|Patients grading pain associated with venous cannulation to <2.0 allocated to standard treatment.
16289185|NCT04751812|Experimental|Low-pain opioid-free|Patient grading pain associated with venous cannualation to <2.0 allocated to opioid-free anesthesia.
16289186|NCT04751799|No Intervention|Control Group (no VR)|Patients undergoing colposcopy and colposcopically-guided biopsy without further intervention
16289187|NCT04751799|Experimental|VR before and during colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy as well as during colposcopy.
16289188|NCT04751799|Experimental|VR before colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy but not during colposcopy.
16289189|NCT04751786|Experimental|PRECIOUS-01|Eligible subjects will receive three i.v. infusions of PRECIOUS-01 at a 3-weekly interval in three dose-finding cohorts (low: 0.4 mg/kg, intermediate: 0.8 mg/kg, and high: 1.6 mg/kg fixed doses). Subjects will be monitored for safety and the occurrence of Dose-Limiting Toxicities (DLTs). A 3+3 design is used for the dose escalation steps. Three subjects will be enrolled sequentially per cohort. If the maximum tolerated dose (MTD) is not reached in the planned dose escalation cohorts, the RP2D will be based on the observed safety and immune modulatory activity as pharmacodynamic parameter supporting the RP2D. The sample size is based on the determination of the MTD/RP2D. In order to collect sufficient information regarding changes in immune related parameters as readout for pharmacodynamics of the particles, it is planned to extend the two highest dosing cohorts to a total of six subjects or to extend the highest dosing cohort to a total of nine subjects, depending on observed toxicity
16289190|NCT04751773|No Intervention|Standard care alone (CON)|"Participants allocated to CON receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.
~Participants allocated to CON are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program."
16289191|NCT04751773|Experimental|Perioperative exercise training and standard care (EX)|"Participants allocated to EX receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark, and perioperative exercise training.
~The preoperative exercise consists of supervised exercise (high-intensity resistance and aerobic exercise 3 times/week) and unsupervised exercise (continuous moderate-intensity 45 min aerobic exercise 2 times/week). The duration of the preoperative exercise intervention depends on the length of the preoperative period (expectedly 2-6 weeks).
~The postoperative exercise training program consists of 8 weeks of supervised exercise (resistance and aerobic exercise 3 times/week) and unsupervised exercise (aerobic exercise 2 times/week). The intensity and duration are progressively increased during the postoperative period"
16289192|NCT04751760||People with sensitization or allergy|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
16289193|NCT04751747|Experimental|Supportive care (CT simulation, contrast agent)|Patients undergo CT stimulation with or without IV contrast over 1.5 hours on days -15 to -1, then undergo SOC chemoradiation on days 1-40. Patients also undergo additional CT scan simulations without IV contrast over 20 minutes each on days 15 and 29.
16289194|NCT04751734||Vaccinations|SARS-CoV-2 vaccination
16289195|NCT04751721|Experimental|CoronoVac Vaccine Group|
16289196|NCT04751708|Active Comparator|best medical management|Unless contra-indicated patients are treated with a standard full dose of open-label IV rt-PA (0.9mg/kg; 90mg maximum). IVT has to be initiated within 4.5 hours of estimated time of basilar artery occlusion. For the patients in whom the rtPA is contraindicated, the standard medical treatment follows the current guidelines for the early management of patients with acute ischemic stroke from the American Heart Association/American Stroke Association.
16289197|NCT04751708|Experimental|endovascular treatment+ best medical management|Device: endovascular treatment For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
16289198|NCT04751695|Experimental|CoronoVac Vaccine Group|
16289199|NCT04751682|Experimental|BBV154: Single Dose|Group 1 (Single dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on day 0 and with placebo on day 28 via intranasal route.
16289200|NCT04751682|Experimental|BBV154: Two Dose|Group 2 (Two-dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on both day 0 and on day 28 via intranasal route.
16289201|NCT04751682|Placebo Comparator|Placebo|Group 3 (Placebo): In this group, 35 participants will be recruited and administered with placebo on both day 0 and day 28 via intranasal route.
16289202|NCT04751669|Experimental|Micronutrient dietary supplement effervescent tablet|"Tablet containing:
~Retinol (Vitamin A) 700 mcg
~Cholecalciferol (Vitamin D3) 10 mcg
~Alpha-Tocopherol (Vitamin E) 45 mg
~Ascorbic acid (vitamin C) 1000 mg
~Pyridoxine (Vitamin B6) 6.5 mg
~Cyanocobalamin (Vitamin B12) 9.6 mg
~Folic acid 400 mg
~Iron 5 mg
~Zinc 10 mg
~Selenium 110 mg
~Copper 0.9 mg
~Excipients"
16289234|NCT04751474|Experimental|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
16345357|NCT04361708|Experimental|Intermediate Risk UGT1A1 genotype|
16289203|NCT04751669|Placebo Comparator|Placebo dietary supplement effervescent tablet|"Effervescent tablet with only the excipients.
~Sucralose 13 mg
~Sodium Chloride 20 mg
~Potassium Acesulfam 22.5 mg
~Orange P 55 mg
~Sodium Carbonate 70 mg
~Betacarotene 100 mg
~Malic Acid 800 mg
~Citric Acid 960 mg
~Sodium bicarbonate 1,000 mg
~Isomalt 1,459.50 mg"
16289204|NCT04751656|Experimental|Steady Intervention|Participants asked to engage in Steady Intervention for 12 months
16289205|NCT04751643|Experimental|TPE + usual treatments in intensive care unit according to the current state of knowledge.|"TPE + usual treatments in intensive care unit according to the current state of knowledge : 3 TPE sessions i.e. one per day during 3 consecutive days on day 1-3 (day 0 = inclusion Visit date)) + usual treatments in intensive care unit.
~Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)"
16289206|NCT04751643|Active Comparator|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
16289207|NCT04751630|Experimental|Therapeutic Exercise group|The study participants corresponding to the Therapeutic Exercise (ET) intervention group will follow the prescriptions given to them by their primary care physician. In addition, and as the main part of the intervention, they will undergo a six-week ET program with two sessions per week, for a total of 12 sessions. Full participation in 10 sessions will be necessary to be included in the ET group during the statistical analysis. Each session will be one hour long. The sessions will be given and supervised by a physiotherapist expert in therapeutic exercise prescription through the online modality.
16289208|NCT04751630|No Intervention|Control group|Study participants in the control group will follow the prescriptions given to them by their primary care physician and will receive a weekly call to assess their recovery. At the end of the study follow-up, when their participation in the study as a control group ends, participants in this group will be offered to participate in the structured ET program to be carried out by the ET group. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of the research.
16289209|NCT04751617|Experimental|Pulmonary rehabilitation (intervention)|This group will be covered by pulmonary rehabilitation.
16289210|NCT04751604|Experimental|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide [1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)] for 4 weeks
16289211|NCT04751604|Placebo Comparator|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
16289214|NCT04751578|Experimental|Intervention|
16289215|NCT04751565|Experimental|BOP-positive within 30 sec (drop or line) at 1-2 sites/implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients who presented BOP-positive within 30 sec (drop or line) at 1-2 sites/implant.
~Primary outcome
~The primary outcome will be based on probing depth (PD)"
16289216|NCT04751565|Experimental|BOP-positive within 30 sec (drop or line) at 3-4 sites/implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients who presented BOP-positive within 30 sec (drop or line) at 3-4 sites/implant.
~Primary outcome
~The primary outcome will be based on probing depth (PD)"
16289217|NCT04751565|Experimental|BOP-positive within 30 sec (drop or line) at 5-6 sites/implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients who presented BOP-positive within 30 sec (drop or line) at 5-6 sites/implant.
~Primary outcome
~The primary outcome will be based on probing depth (PD)"
16289218|NCT04751552|Active Comparator|Levobupivacaine group|Patients receive an ESPB with the local anaesthetic levobupivacaine
16289219|NCT04751552|Placebo Comparator|Placebo group|Patients receive an ESPB with 0,9% saline
16289220|NCT04751539|Experimental|AND017 single dose escalation|Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.
16289221|NCT04751539|Placebo Comparator|AND017 repeated dose escalation|Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.
16289222|NCT04751539|Placebo Comparator|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
16289223|NCT04751526|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
16289224|NCT04751526|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
16289225|NCT04751513|Experimental|Experimental group|The experimental group will receive acupressure on six auricular points.
16289226|NCT04751513|No Intervention|Control group|The control group will receive no intervention.
16289227|NCT04751500|Experimental|Outpatient Hysteroscopy|Outpatient hysteroscopic morcellation of retained products of conception
16289228|NCT04751500|Active Comparator|Standard Treatment|Standard treatment of retained products of conception in the form of expectant management, medical management, antibiotic therapy and/or surgical management (manual vacuum aspiration/suction curettage/dilatation and curettage)
16289229|NCT04751487|Experimental|Itepekimab Q2W in former smokers|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
16289230|NCT04751487|Experimental|Itepekimab Q4W in former smokers|SC administration of Itepekimab every 4 weeks (Q4W) for 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
16289231|NCT04751487|Placebo Comparator|Placebo in former smokers|SC administration of matching placebo Q2W for 52 weeks
16289232|NCT04751487|Experimental|Itepekimab Q2W in current smokers|SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
16289233|NCT04751487|Placebo Comparator|Placebo in current smokers|SC administration of matching placebo Q2W for 52 weeks
16345358|NCT04361708|Experimental|Low Risk UGT1A1 genotype|
16289238|NCT04751461|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session
16289239|NCT04751461|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session
16289240|NCT04751461|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session
16289241|NCT04751461|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session
16289242|NCT04751461|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session
16289243|NCT04751461|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session
16289244|NCT04751461|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session
16289245|NCT04751461|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session
16289246|NCT04751448||Observational|All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.
16289247|NCT04751435||Breast,Ovarian, Prostate & Pancreatic Cancer|"There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview.
~This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2."
16289248|NCT04751422||Observational (data collection)|Patients' medical data is collected retrospectively.
16289249|NCT04751409|Experimental|Group 1, Arm I (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years consisting of restaging with CT-chest and imaging of the primary site.
16289250|NCT04751409|Experimental|Group 1, Arm II (limited follow-up)|Patients undergo limited follow-up every 6 months for 2 years consisting of restaging with either CT-chest or CXR and imaging of the primary site.
16289251|NCT04751409|Experimental|Group 2 (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years as in Group 1, Arm I.
16289252|NCT04751396||Part A (Interview)|Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
16289253|NCT04751396||Part B Group I (standard information)|Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
16289254|NCT04751396||Part B Group II (educational tool)|Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
16289258|NCT04751344|Experimental|Liposomal Bupivacaine|The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.
16289259|NCT04751344|Active Comparator|Bupivacaine HCl|The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.
16289260|NCT04751331|Experimental|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113) administered as an intravenous bolus.
16289261|NCT04751331|Placebo Comparator|Placebo|Placebo (same volume of 0.9% saline) administered as an intravenous bolus
16289262|NCT04751318|Experimental|Duloxetine Test Produc|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
16289263|NCT04751318|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
16289264|NCT04751305|Experimental|ACE Remote Maintenance Program with Health Coaching|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels. Additionally, the health coaching intervention received weekly zoom calls that were focused on being participant-centered, built on a coach participant relationship, and included participant-determined goals, a self-discovery process to find solutions, patient accountability, and education.
16289510|NCT04749576|Active Comparator|Low dose saffron|healthy, mild-moderate ulcerative colitis for low dose
16289265|NCT04751305|Active Comparator|Only ACE Remote Maintenance Program|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also participants received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels.
16289266|NCT04751292||Lowlanders|People living at low (<1500 m) altitude
16289267|NCT04751292||Highlanders|People living at high (>2500 m) altitude
16289268|NCT04751279||Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)|Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score <2) and recent diagnosis (<5 years)
16289269|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (<5 years)
16289270|NCT04751279||Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis without signs of activity (Benamore score <2), persistent form (>5 years)
16289271|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (>5 years)
16289272|NCT04751266||Patients with MIRPE|first minimally invasive repair of pectus excavatum
16289273|NCT04751266||Patients with Trauma surgery|first osteosynthesis
16289274|NCT04751253|Active Comparator|1500 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 1500 J plus exercises.
16289275|NCT04751253|Active Comparator|3000 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 3000 J plus exercises.
16289276|NCT04751253|Sham Comparator|exercises + sham LASER|consist of 17 patients, they will apply exercises plus sham LASER.
16289277|NCT04751240|Experimental|SIT and Resistance|Participants will complete 10 weeks of a SIT and resistance training paradigm.
16289278|NCT04751227||1|Modafinil 100-200 mg daily for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020
16289279|NCT04751201|Experimental|Receiving mindfulness open and circular program|
16289280|NCT04751188|Experimental|Bezafibrate and Ursodeoxycholic acid|Bezafibrate 200 mg every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
16289281|NCT04751188|Placebo Comparator|Placebo and Ursodeoxycholic acid|Placebo tablet every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
16289282|NCT04751175|Experimental|Ketamina bolus plus Dexamethasone bolus plus infusion ketamine|Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)
16289283|NCT04751175|Experimental|Ketamine bolus plus ketamine infusion|Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.
16289284|NCT04751175|Active Comparator|Dexametasone arm|Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA
16289285|NCT04751175|Placebo Comparator|Saline bolus|Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA
16289288|NCT04751149|Experimental|Early Urinary Catheter Removal|Urinary Catheter will be removed the first postoperative day after rectal resection
16289289|NCT04751149|Experimental|Medium Urinary Catheter Removal|Urinary Catheter will be removed the third postoperative day after rectal resection
16289290|NCT04751149|Experimental|Late Urinary Catheter Removal|Urinary Catheter will be removed the fifth postoperative day after rectal resection
16289291|NCT04751136|Active Comparator|Intervention Arm|infants were given Cerebrolysin®, manufactured by Neuro Pharma Gmbh, in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).
16289292|NCT04751136|No Intervention|Non-intervention Arm|No medication was given
16289293|NCT04751110|Other|block group|ultrasound guided rhomboid intercostal block will performed
16289294|NCT04751097|Experimental|Digital Platform|
16289295|NCT04751097|No Intervention|Routine Care|
16289296|NCT04751084|Active Comparator|treatment group|20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer
16289297|NCT04751084|Placebo Comparator|control group|2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer
16289298|NCT04751071|Active Comparator|Roflumilast|Roflumilast 250 µg tablet plus standard therapy
16289299|NCT04751071|Placebo Comparator|Placebo|placebo tablet plus standard therapy
16289300|NCT04751045|Active Comparator|Percutaneous Liver biopsy|"Technique: The preprocedure time out protocol will be completed prior to initiation of the procedure. The patient will be positioned supine and right hepatic lobe was localized with ultrasound. Conscious sedation with Versed and fentanyl will be initiated and the patient's vital signs were monitored by an independent trained observer during the procedure.
~After placing a mark on the skin overlying the right upper quadrant, the skin was then prepped and draped in the usual sterile fashion. Maximum sterile barrier technique used at the procedure. Under direct sonographic guidance, a 15 gauge percutaneous liver biopsy needle will be used with a 2 cm throw was advanced into the right hepatic lobe. The biopsy samples will be obtained and submitted to pathology."
16289511|NCT04749576|Active Comparator|High dose Saffron|healthy, mild-moderate ulcerative colitis for high dose
16289301|NCT04751045|Active Comparator|Endoscopic ultrasound guided liver biopsy|Procedure details: patients will be screened preoperatively to assess cardiovascular health prior to undergoing procedure as this is standard of care. Patients will follow all standard preoperative instructions prior to anesthesia. Upon undergoing general anesthesia, a videoendoscope will be introduced into the esophagus under direct vision. Once endoscope is in position near the liver, a 19-gauge sharkcore needle will be used to puncture the left lobe with a 3 accentuation and another pass from right lobe with 4 accentuation. Doppler study will be used to interrogate for any significant doppler signals in needle path. Post procedure, patients will be provided instructions to avoid NSAIDs for 4 days and perform lightweight activity for 4 days. Patients will be observed for bleeding and significant abdominal pain postoperatively
16289302|NCT04751006|Experimental|Gaze Group|Participants performed balance training with gaze stabilization exercises
16289303|NCT04751006|Other|Control Group|Participants performed balance training with saccade eye exercises
16289304|NCT04750980||Food allergy|Childen with food allergy
16289305|NCT04750980||Respiratory allergy|Children with respiratory allergy
16289306|NCT04750980||Healthy controls|Healthy subjects
16289307|NCT04750967|Experimental|Active|Greater occipital nerve and supraorbital nerve block with 1% lidocaine once a week for first four weeks then once a month for 5 months
16289308|NCT04750967|Active Comparator|Control|Amitriptyline 25 mg daily for 6 months
16289309|NCT04750954|Experimental|Treatment (peposertib, lutetium Lu 177 dotatate)|Patients receive peposertib PO QD or BID on days 1-21 and lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16289310|NCT04750941|Experimental|Follicular Lymphoma (FL)|"The lymphoma study group will enroll 23 patients with FL.
~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
16289311|NCT04750941|Experimental|Endometrial Cancer (EC)|"The solid tumor group will enroll 19 patients with EC.
~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
16289314|NCT04750915||AARP|Members of AARP, aged 50-71 years and who resided in one of six states or in two metropolitan areas in the United States
16289315|NCT04750902|Active Comparator|0.24% Sodium Fluoride Dentifrice|Toothpaste
16289316|NCT04750902|Experimental|1.5% Arginine Dentifrice|Toothpaste
16289317|NCT04750902|Experimental|4.0% Arginine Dentifrice|Toothpaste
16289318|NCT04750902|Experimental|8.0% Arginine Dentifrice|Toothpaste
16289319|NCT04750889||RFID tags localization|
16289320|NCT04750889||Wire localization|
16289321|NCT04750876|Active Comparator|Conventional support|
16289322|NCT04750876|Experimental|Specific care, including the intervention of a psychologist and a physical therapist.|
16289323|NCT04750850|Experimental|Core stability exercises group|30 minutes of core stability exercises program at a light intensity and take a rest breaks if is necessary. They will be instructed in the use of the 4-5 points of the Borg 10 Rating of Perceived Exertion for self-monitoring of exercise intensity. The exercises will performed twice a day for 5 days a week during 5 weeks. A physiotherapist conducted an initial home visit to ensure correct execution of the exercises. He or she will teach the exercises and then the patient will perform them alone in your home. Once a week the physiotherapist will phone the patient and will ask her/him for doubts.
16289324|NCT04750850|Active Comparator|Control group|The patients to continue as normal and not change their routine in terms of exercise and physical activity during the period of study.
16289325|NCT04750837|Active Comparator|Platelet rich plasma group|chronic diabetic foot ulcer was treated by platelet rich plasma
16289326|NCT04750837|Sham Comparator|conventional dressing group|chronic diabetic foot ulcer was treated by conventional dressing
16289327|NCT04750824||Afatinib cohort|Afatinib cohort
16289328|NCT04750824||other systemic therapy cohort|other systemic therapy cohort
16289329|NCT04750811||Small Bowel obstruction|Patients admitted with a diagnosis of small bowel obstruction at 1 of the 6 participating centres
16289330|NCT04750798||Participants Diagnosed with Cardiac Arrhythmias|Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter will be observed.
16289331|NCT04750785||All Participants|Participants who have been diagnosed with CHM will be enrolled.
16289332|NCT04750772|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
16289333|NCT04750772|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
16289334|NCT04750759|Active Comparator|Niclosamide + Camostat|Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
16289335|NCT04750759|Placebo Comparator|Placebo|Patients will receive placebo orally over a period of 7 days.
16289336|NCT04750746|Active Comparator|Control Group|Control group will get conventional treatment.
16289337|NCT04750746|Experimental|Experimental Group|This group will get base line treatment with exer gaming.
16289338|NCT04750733||Multiple Sclerosis|Ambulatory MS patients
16289380|NCT04750460|No Intervention|Control group (10 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, receiving standard local protocol for hypocalcemia treatment (2 micrograms of alphacalcidol plus 4 grams of oral calcium daily).
16289339|NCT04750720|Experimental|Group with biological samples|Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology). In the vaccine sub-study: additional blood and nasopharyngeal samples before and after vaccination, up to 6 months.
16289340|NCT04750707|Other|single arm|Single arm, open label of hydroxyurea starting at 20mg/kg and increased to 30mg/kg depending on clinical need and according to standard guidelines
16289341|NCT04750694|Experimental|RT + BFRE|High intensity Resistance training combined with Blood Flow
16289342|NCT04750694|Active Comparator|RT|Resistance training alone
16289343|NCT04750681|Placebo Comparator|Control|Each capsule contained 275mg of maltodextrin. Capsules were similar to the saffron investigation product (chlorophyll capsules).
16289344|NCT04750681|Experimental|Saffron|Each capsule contained 259,5mg of maltodextrin and 15,5mg of saffron extract (Saffr'activ® SAF 3C PIM) that corresponds to 1,6mg of dry saffron extract, 0,9mg of crocins (5.82%) and 0,7mg of safranal (4.6%).
16289345|NCT04750668|Experimental|Multisensory Balance Training Group|Multisensory balance training manipulate sensory inputs of vision, vestibular and proprioception.
16289346|NCT04750668|No Intervention|Control Group|Participants in control group maintain their regular activity without any intervention.
16289347|NCT04750655|Placebo Comparator|Intraoperative antibiotics (Abx) only; no postoperative topical antibiotics|intraoperative/ intracameral antibiotic (moxifloxacin) only; no postoperative topical antibiotic drops
16289348|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics four times a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops four times a day for 1 week
16289349|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics once a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops once a day for 1 week
16289350|NCT04750642|Experimental|CI632D Investigational Medical Device (IMD)|
16289351|NCT04750642|Placebo Comparator|CI632 Comparator Device|
16289352|NCT04750629||SARS-Cov-2 RT-PCR AND CoviDx Rapid Antigen Testing|Sequentially enrolled symptomatic patients who present for COVID-19 testing and have a swab collected for high-sensitive, SARS-CoV-2 RT-PCR testing per Standard of Care AND a swab for CoviDx™ Rapid Antigen testing.
16289353|NCT04750616|Experimental|Oral niacinamide|
16289354|NCT04750616|Placebo Comparator|Matched placebo|
16289355|NCT04750603|Placebo Comparator|Salbutamol|Salbutamol (Salbutrim, Trima) inhaler (400 µg) via spacer + Relvar® Ellipta placebo
16289356|NCT04750603|Active Comparator|FF/VI|Placebo Salbutamol inhaler + Relvar® Ellipta (92/22 µg, GSK, UK)
16289357|NCT04750590|Experimental|en bloc resection group|Patients scheduled for laser en bloc tumor resection with subsequent morcellation of exophytic part of the tumor
16289358|NCT04750590|Experimental|piecemeal resection group|Patients scheduled for piecemeal bladder tumor TUR with subsequent removing of tissue using the instrument loop or Janet's syringe.
16289365|NCT04750564|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
16289366|NCT04750564|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
16289367|NCT04750551|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
16289368|NCT04750551|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
16289369|NCT04750538|Experimental|BreEStim 120, then BreEStim 240|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
16289370|NCT04750538|Experimental|BreEStim 240, then BreEStim 120|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
16289371|NCT04750525|Experimental|BreEStim 120, then EStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
16289372|NCT04750525|Experimental|EStim 120, then BreEStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
16289373|NCT04750512|Experimental|real ESP, placebo TAP|US-guided ESP block + sham US-guided TAP block
16289374|NCT04750512|Active Comparator|real TAP, placebo ESP|sham US-guided ESP block + US-guided TAP block before laparoscopic hernia repair
16289375|NCT04750499|Experimental|Treatment|Patients with complex anal fistulas, non related to Crohn's disease.
16289376|NCT04750486|No Intervention|Control|No intervention, the patient will be provided routine care at time of epidural placement without use of sequential compression devices.
16289377|NCT04750486|Experimental|Lower Extremity Compression|Patients will have sequential compression devices prior to epidural placement, and maintained for at least one hour following procedure.
16289378|NCT04750473|Experimental|Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.
16289379|NCT04750460|Experimental|Teriparatide group (10 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, who will receive subcutaneous injections ot recombinant parathyroid hormone (Teriparatide) after surgery in addition to the standard local protocol for hypocalcemia treatment.
16289381|NCT04750447||Open Angle Glaucoma|Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ± cataract surgery
16289382|NCT04750421|Experimental|Transillumination Venolux®|Transillumination using Venolux was used to visualize veins in the hemiface before hyaluronic acid injections
16289383|NCT04750421|No Intervention|Comparator group|No vascular exploration methods were used on the other hemiface
16289384|NCT04750408|Active Comparator|Oxygen use|Patients will use standard oxygen via face mask of nasal prongs as usual care.
16289385|NCT04750408|Experimental|NHF use|Patients will use NHF instead of oxygen. Oxygen will be supplemented via the NHF flow.
16289386|NCT04750395|Experimental|Haloperidol|Every 24 hours, patients will receive two regular doses of OT Haloperidol 2.5mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
16289387|NCT04750395|Experimental|Olanzapine|Every 24 hours, patients will receive two regular doses of OT Olanzapine 5.0mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
16289388|NCT04750382|Experimental|HX008+Cisplatin+Gemcitabine|
16289389|NCT04750356||Cohort A1|Healthcare workers and patients that have previously undertaken a swab or serology test to detect for the presence of SARS-CoV-2. Without the need to seek retrospective consent for the SARS CoV 2 Longitudinal Study, residual samples and derivatives from the Crick COVID -9 Consortium Testing centre and data will be used for the study
16289390|NCT04750356||Cohort A2|3,000 SARS-CoV-2 positive and 3,000 SARS-CoV-2 negative participants (randomly selected) from cohort A1 will be prospectively consented to the study. In addition, vaccine status will also be used to stratify the participants and recruit to the study.
16289391|NCT04750356||Cohort B|Employees at participating centres including but not limited to UCLH and The Francis Crick Institute who have their serology tested and/or are swabbed for viral (SARS-CoV-2 and seasonal viruses) detection as well as participants who are vaccinated will be prospectively consented to the study.
16289392|NCT04750356||Cohort C|Individuals recruited to other REC approved research studies where their samples are processed by the Crick COVID 19 Consortium Testing centre will also be consented in their existing study to allow the use of leftover study samples already collected and to be collected, for use in this longitudinal study.
16289393|NCT04750343|Experimental|Test group 1 - Stage 1 Low dose-level Cohort|2 doses of GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
16289394|NCT04750343|Experimental|Test group 2 - Stage 1 Low dose-level Cohort|2 doses of GBP510 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
16289395|NCT04750343|Placebo Comparator|Placebo group - Stage 1 Low dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16289396|NCT04750343|Experimental|Test group 3 - Stage 1 High dose-level Cohort|2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
16289397|NCT04750343|Experimental|Test group 4 - Stage 1 High dose-level Cohort|2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
16289398|NCT04750343|Placebo Comparator|Placebo group - Stage 1 High dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16289399|NCT04750343|Experimental|Test group 1 - Stage 2|2 doses of GBP510 adjuvanted with AS03 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
16289400|NCT04750343|Experimental|Test group 3 - Stage 2|2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
16289401|NCT04750343|Experimental|Test group 4 - Stage 2|2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
16289402|NCT04750343|Placebo Comparator|Placebo group - Stage 2|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16289403|NCT04750330||Severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the Intensive Care Unit (ICU) during hospitalisation
16289404|NCT04750330||Non-severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the hospital but NOT to the Intensive Care Unit (ICU) during hospitalisation
16289405|NCT04750330||Minor COVID-19|Patients, diagnosed with COVID-19, who were NOT admitted to the hospital and could recover at home
16289406|NCT04750317|Experimental|Patients with reduced oxygen saturation ≤93% treated with tofacitinib|Patients with oxygen saturation ≤93% on admission treated with tofacitinib and standard of care treatment
16289407|NCT04750317|No Intervention|Patients with reduced oxygen saturation treated with SoC|Patients with oxygen saturation ≤93% on admission treated with standard of care only
16289408|NCT04750317|Experimental|Patients with preserved oxygen saturation >93% on admission treated with tofacitinib|Patients with oxygen saturation >93% on admission treated with tofacitinib and standard of care
16289409|NCT04750317|No Intervention|Patients with preserved oxygen saturation >93% on admission treated with SoC|Patients with oxygen saturation >93% on admission treated with standard of care only
16289412|NCT04750278|Experimental|FP-025 100 mg|
16289413|NCT04750278|Experimental|FP-025 300 mg|
16289414|NCT04750278|Placebo Comparator|Placebo|
16289415|NCT04750265|Experimental|Robotic assisted early mobilization|Early mobilization therapy assisted with robotics
16289416|NCT04750265|No Intervention|Standard Care|Mobilization according to standard care by staff
16289417|NCT04750252|Experimental|Subjects with moderate to severe OA of the Knee|
16289418|NCT04750239|Experimental|Nivatrotamab|Subcutaneous administration of nivatrotamab up to 13 cycles
16289421|NCT04750200|No Intervention|Control Arm|Patients randomized to the control arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH.
16289451|NCT04749992||Dreamers|Comparison Group
16289452|NCT04749979|Active Comparator|giving agonist ( eg. decapeptyl )|Giving women agonist
16289453|NCT04749979|Active Comparator|Giving HCG (eg. choriomon )|Giving women HCG
16289422|NCT04750200|Experimental|Interventional Arm|Patients randomized to the interventional arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH as per the standard of care in the institution. These patients will then undergo EMMA within 48 hours after finishing the surgical drainage. The embolic agent and use of general anesthesia vs conscious sedation will be left to operators' preference and the institutional protocol. All patients will be followed as per the institutional standard of the care. Any peri-procedural complications and change in clinical status will be recorded.
16289423|NCT04750187|Experimental|Hypo-pressive abdominal exercise program|
16289424|NCT04750187|No Intervention|No training program|
16289425|NCT04750174|Active Comparator|Kinesiotape Group|In active group, KT was applied with stretching to the suprahyoid muscles with right method.
16289426|NCT04750174|Sham Comparator|Sham Kinesiotape Group|In sham group, KT was applied without stretching to the suprahyoid region and not including the origins of mylohyoid and digastric muscles
16289427|NCT04750161||Psoriasis Vulgaris|
16289428|NCT04750161||Atopic Dermatitis|
16289429|NCT04750161||Ichthyosis Vulgaris|
16289430|NCT04750161||Healthy Controls|
16289431|NCT04750148||Cancer|Individuals with an oncology disease will be included in the study.
16289432|NCT04750135|Placebo Comparator|Control group|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
16289433|NCT04750135|Experimental|Metformin group|participants will receive 500 mg Metformin TID for 8 consecutive weeks in addition to the standard therapy
16289434|NCT04750122|Experimental|Neoadjuvant therapy base on PTC drug screenning|Patients will receive neoadjuvant therapy including trastuzumab, pertuzumab, and chemotherapy based on PTC drug screening.
16289435|NCT04750096||Esophagectomy post enhanced recovery after surgery|Patients undergoing esophagectomy due to oesophageal cancer under Enhanced Recovery After Surgery protocol.
16289436|NCT04750083|Experimental|phase II|Thirty-sixty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
16289437|NCT04750083|Experimental|phase III-experimental|Three hundred and twenty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
16289438|NCT04750083|Experimental|phase III-control|Three hundred and twenty participants will receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
16289439|NCT04750070|Experimental|Dopamine arm|Children in the dopamine arm (Treatment plan A) will receive dopamine, 8 microgram/kg/min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
16289440|NCT04750070|Experimental|Adrenaline arm|Children in the adrenaline arm (Treatment plan B) will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
16289441|NCT04750070|Active Comparator|Blood transfusion arm|Children in the blood transfusion arm (Treatment plan C) will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
16289442|NCT04750044|Experimental|early refeeding group|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.
16289443|NCT04750044|Active Comparator|delayed refeeding group|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.
16289444|NCT04750018||COVID-19 2019|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
16289445|NCT04750018||COVID-19 2020|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
16289446|NCT04750005|Active Comparator|Brush only Group|Participants assigned to this group will brush their teeth using soft bristled toothbrush and colgate cavity protection toothpaste as directed under virtual supervision once daily during the week. Participants will brush second time unsupervised daily in the evening and twice daily over the weekend/holidays at home.
16289447|NCT04750005|Experimental|Brush/Rinse Group|Participants assigned to this group will perform their regimen (brushing [soft bristled toothbrush and colgate cavity protection toothpaste] and rinsing [listerine cool mint antiseptic mouthwash]) as directed under virtual supervision once daily during the week. Participants will brush and rinse a second time unsupervised daily in the evening at home. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over the weekend/holidays. First product use will occur at the site under supervision.
16289448|NCT04750005|Experimental|Brush/Floss Group|Participants assigned to this group will perform their regimen (brushing and flossing) as directed under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening. Over the weekend and holidays, participants will brush and floss once daily. Only brushing will be performed a second time in the evening. First product use will occur at the site under supervision.
16289449|NCT04750005|Experimental|Brush/Floss/Rinse Group|Participants assigned to this group will perform their regimen (brushing [soft bristled toothbrush and colgate cavity protection toothpaste], flossing [reach unflavored waxed dental floss] and rinsing [listerine cool mint antiseptic mouthwash]) as directed under virtual supervision once daily during the week. Participants will brush and rinse a second time unsupervised daily in the evening. Over the weekend and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening at home.
16289450|NCT04749992||Non-Dreamers|Experimental Group
16289455|NCT04749953|Active Comparator|Autogenous bone graft alone|Maxillary sinus floor augmentation with particulated autogenous bone graft alone from the zygomatic buttress area and simultaneously implant placement
16289456|NCT04749953|Experimental|Mixture of 50% autogenous bone graft and 50% Symbios biphasic biomaterial|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios biphasic bone graft material (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placementand
16289457|NCT04749953|Experimental|Mixture of 50% autogenous bone graft and 50% Symbios xenograft granules|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios xenograft granules (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placement
16289458|NCT04749940|Experimental|Hospitalized burn patients|Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
16289459|NCT04749914|Experimental|Lasmiditan + Dabigatran (Part 1)|Participants will receive single doses of dabigatran followed by combination of lasmiditan along with dabigatran etexilate administered orally.
16289460|NCT04749914|Experimental|Lasmiditan + Rosuvastatin (Part 2)|Participants will receive single doses of rosuvastatin followed by combination of lasmiditan along with rosuvastatin administered orally.
16289461|NCT04749901|Other|Patients with epilepsy|
16289462|NCT04749901|Other|Patients with PTSD|
16289463|NCT04749901|Other|Patients with type 1 diabetes|
16289464|NCT04749901|Other|Patients with a heart rhythm disorder|
16289465|NCT04749888|Experimental|Targeted nurse-led home visiting|The intervention group will receive 25-29 home visits during pregnancy and the first 2 years of life conducted by child health nurses. The frequency of home visits will be determined by nurses based on the needs of the families. The content of each home visit is individually tailored to the mother's needs, skills, strengths, and capacity using parenting education materials.
16289466|NCT04749888|No Intervention|Control group|The control group will receive existing maternal and child health services (usual care) except for the targeted nurse-led home visits.
16289467|NCT04749862||Breast Cancer Participants-Before Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
16289468|NCT04749862||Colorectal (bowel) Cancer Participants-Before Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
16289469|NCT04749862||Breast Cancer Participants-After Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
16289470|NCT04749862||Colorectal (bowel) Cancer Participants-After Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
16289471|NCT04749823|Experimental|Blended treatment program|The blended treatment program will consist of a combination of specific active exercises of the neck and general aerobic exercises. This contains a program of 12 weeks, including 9 supervised online sessions supplemented with 1 to 3 individual home exercises sessions without supervision per week, with a total of 3 sessions/week.
16289472|NCT04749823|Active Comparator|Specific strength exercise program|This group will receive an exercise program with specific strength exercises of the neck muscles. Within a 12-week period, patients will receive 9 online treatment sessions under supervision and 1 to 3 additional home exercise sessions without supervision, with a total of 3 sessions/week..
16289473|NCT04749823|Active Comparator|General aerobic exercise program|This control group will perform general aerobic exercises. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
16289474|NCT04749810||Elizaria®|Eculizumab
16289475|NCT04749797|Placebo Comparator|Saline group|The surgeon will administer injectable saline as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
16289476|NCT04749797|Active Comparator|Bupivacaine|The surgeon will administer bupivacaine as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
16289477|NCT04749797|Experimental|Liposomal Bupivacaine|The surgeon will administer Exparel (liposomal bupivacine) as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). 20 mL of Exparel will be diluted with saline to constitute 60 mL total. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
16289478|NCT04749784|Experimental|High dose IP|Two tablets IP daily for 12 weeks
16289479|NCT04749784|Experimental|Low dose IP|One tablet IP + one tablet placebo daily for 12 weeks
16289480|NCT04749784|Placebo Comparator|Placebo|Two tablets placebo daily for 12 weeks
16289512|NCT04749576|Placebo Comparator|Placebo|healthy, mild-moderate ulcerative colitis for placebo
16289513|NCT04749563|Active Comparator|Active|IGC AD1
16289514|NCT04749563|Placebo Comparator|Placebo|IGC AD1 Placebo
16289515|NCT04749537||Ankylosing Spondylitis|100 patients who were diagnosed with AS between the ages of 18-65
16289516|NCT04749537||Healthy Volunteers|100 healthy volunteers compatible with age.
16289481|NCT04749771|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
16289482|NCT04749771|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
16289483|NCT04749758|Experimental|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is approved by Andorra's Government authorities.
16289484|NCT04749745|Active Comparator|L-Theanine|Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
16289485|NCT04749745|Placebo Comparator|Placebo|Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
16289486|NCT04749732|Experimental|WalkingPad plus Psychological Intervention - PsyWPad Group|The participants in Experimental Group 1 will receive a prescription of an HBET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
16289487|NCT04749732|Experimental|WalkingPad plus Virtual Assistant - CyberWPad Group|The participants in Experimental Group 2 will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a virtual assistant that will give motivational support.
16289488|NCT04749732|Active Comparator|Paper WalkingPad group - PaperWPad Group|The participants in the Active Control Group will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
16289489|NCT04749719|Experimental|DLPFC stimulation|F3-SO montage or OLE optimized with 2 mA stimulation for up to 30 min during memory and metamemory task.
16289490|NCT04749719|Sham Comparator|Sham tDCS|F3-SO montage or OLE optimized with sham stimulation for up to 30 min during memory and metamemory task.
16289491|NCT04749706|Active Comparator|Normal weight|the normal weight women will receive the 12-week physical activity intervention and serve as a control group.
16289492|NCT04749706|Experimental|constitutionally lean women - Physical training only|women will receive the 12-week physical activity intervention
16289493|NCT04749706|Experimental|constitutionally lean women - Physical training + proteins|women will receive the 12-week physical activity intervention in addition to a protein supplementation
16289494|NCT04749693||Patient with HbA1c >= 8% despite the use of insulin pump and frequent glycemic control|only group included in the study
16289495|NCT04749680|Experimental|Peritoneal dialysis PD|Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
16289496|NCT04749667|Experimental|Arm A - Crossover with MSCs at baseline and placebo at 6 months|Receives mesenchymal stem cells at baseline and placebo at 6 months
16289497|NCT04749667|Experimental|Arm B - Crossover with placebo at baseline and MSCs at 6 months|Receives placebo at baseline and mesenchymal stem cells at 6 months
16289498|NCT04749654|Experimental|Fixed space maintainers|band-and-loop type fixed space maintainers were applied
16289499|NCT04749654|Experimental|Removable space maintainers|All removable space maintainers were produced of an acrylic base and retention elements that were a vestibule arch, (Adam's and C clasps).
16289500|NCT04749641|Experimental|Open surgical biopsy|A total of 15 subjects with open surgical biopsy indications will receive microsurgical resection, followed by conformal radiotherapy and administration of the researched vaccine.
16289501|NCT04749641|Experimental|Stereotactic biopsy|A total of 15 subjects without open surgical biopsy indications will receive stereotactic biopsy, followed by conformal radiotherapy and administration of the researched vaccine.
16289502|NCT04749628|Placebo Comparator|Sesame Oil|
16289503|NCT04749628|Experimental|400mg cannabidiol|
16289504|NCT04749628|Experimental|800mg cannabidiol|
16289505|NCT04749615|Placebo Comparator|No PAI + ACB & IPACK|Control: saline injection (same injection technique and volumes as described for the active intervention, of normal saline)
16289506|NCT04749615|Active Comparator|PAI + ACB & IPACK|Active intervention: Periarticular injection: one deep injection prior to cementation and then a second more superficial injection prior to closure. The deep injection will consist of bupivacaine 0.25% with 1:200,000 epinephrine, 30 cc; morphine, 8 mg/ml, 1cc; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 in 10 ml; normal saline, 22cc. The superficial injection will be 20 ml 0.25% bupivacaine
16289507|NCT04749602|Experimental|Intrapleural instillation of the nivolumab|Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.
16289508|NCT04749589||iron deficient|ferritin<30 or Transferine saturation<.2
16289518|NCT04749524||Newborns failing initial hearing screening test|Otoacoustic Emissions to be measured with and without suppression noise
16289519|NCT04749524||Adults with normal hearing|Otoacoustic Emissions to be measured with and without suppression noise
16289520|NCT04749524||Adults with hearing loss|Otoacoustic Emissions to be measured with and without suppression noise
16289521|NCT04749498|Active Comparator|White Bread|White bread with a standard test breakfast
16289522|NCT04749498|Active Comparator|Whole Wheat Bread|Whole wheat bread with a standard test breakfast
16289523|NCT04749498|Experimental|Barley Bread|Barley bread with a standard test breakfast
16289524|NCT04749498|Experimental|Oat Bread|Oat bread with a standard test breakfast
16289525|NCT04749485|Experimental|HX008|
16289526|NCT04749472|Experimental|Study Group|Participants received intervention.
16289527|NCT04749459|Experimental|ChapStick Moisturizer, Classic Flavor|This arm will include all the test sites on the participants back where ChapStick Classic Moisturizer (ANZ) will be applied.
16289528|NCT04749459|Experimental|ChapStick Moisturizer, Strawberry Flavor|This arm will include all the test sites on the participants back where ChapStick Strawberry Moisturizer (ANZ) will be applied.
16289529|NCT04749459|Active Comparator|ISO 24444:2010 P2 Standard Sunscreen|This arm will include all the test sites on the participants back where ISO 24444:2010 P2 Standard Sunscreen will be applied.
16289530|NCT04749446||Breast sarcoma|This cohort include patients affected by breast sarcoma, referred to participating Institutions between January 2000 and June 2020.
16289531|NCT04749433|Experimental|Participants with diagnosis of ALS|Participants with a diagnosis of ALS will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
16289532|NCT04749433|Experimental|Healthy Participants without a diagnosis of ALS|Healthy participants (without a diagnosis of ALS) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
16289533|NCT04749420||Patients group|Individuals with cervical radiculopathy
16289534|NCT04749407||chemoradiotherapy|
16289535|NCT04749394|Experimental|Experimental Arm|Camrelizumab plus apatinib as consolidation therapy
16289536|NCT04749381|Experimental|TCM group|Rectal cancer patients randomized to this group will have acupoint application with traditional Chinese medicine.
16289537|NCT04749381|Placebo Comparator|Control group|Rectal cancer patients randomized to this group will have acupoint application with placebo .
16289538|NCT04749368|Experimental|Cohort A|Participants will receive BRII-835 (VIR-2218) for 32 weeks
16289539|NCT04749368|Experimental|Cohort B|Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40
16289540|NCT04749368|Experimental|Cohort C|Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40
16289541|NCT04749355|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m^2/d or 2.3 g/m^2/d, for 6 days
16289542|NCT04749342|Experimental|Complete Decongestive Therapy|Complete decongestive therapy (CDT) is also known as complex decongestive therapy. It involves a two-stage treatment protocol. The first stage consists of skin care, manual lymph drainage, exercises and compression with multi-layered bandages. The second stage aims to optimize and conserve the volume reduction obtained in stage one. This is achieved by using a low-stretch elastic garment in combination with skin care and exercises
16289543|NCT04749342|Experimental|Compression Bandaging|External compression is the mainstay of management for all stages of lymphedema. The efficacy of compression therapy alone, or combined with MLD, has been supported by randomized clinical trials
16289544|NCT04749329|No Intervention|Control Group|no mesh was used for end colostomy fashions
16289545|NCT04749329|Experimental|Mesh Group|Mesh of Bio A was used for end colostomy fashions
16289546|NCT04749316|Experimental|AcuTENS|Patients treated with TENS over Acupuncture points for faecal incontinence
16289547|NCT04749316|Sham Comparator|Sham|Sham treatment arm with no electrical stimulations over acupuncture points
16289548|NCT04749303|Active Comparator|Large screen|This is a high definition screen which gives a 76cm height and 67cm width (area: 5092cm2) endoscopic image.
16289549|NCT04749303|No Intervention|Standard screen|This is a high definition screen which gives a 37.5cm height and 32.5cm width (area: 1218.75cm2) endoscopic image.
16289550|NCT04749290|Experimental|Study Formula|a Cow's Milk Based Infant Formula Containing Both OPO and CPP for term infants (JunLeBao ZhiZhen)
16289551|NCT04749290|Active Comparator|Comparator Formula|Commercially available infant formula without OPO for term infants (JunLeBao LeChun)
16289552|NCT04749290|No Intervention|Human Milk Reference Group|Human milk
16289553|NCT04749277||Endoscopist characterization on WLI and BLI modes|Optical characterization of an identified polyp, first in WLI and then in BLI mode, with CAD EYE® OFF. This evaluation should be systematically performed by two independent endoscopists in the exam room, preferably (but not necessarily) an experienced endoscopist and a trainee. The presence of at least one experienced endoscopist is mandatory. An independent evaluation is guaranteed. First step - The 1st endoscopist (who performing colonoscopy) request the polyp evaluation and record written by the 2nd endoscopist (who not performing the colonoscopy) - blinded evaluation since 1st endoscopist doesn't verbalize his evaluation); 2nd step - when the 2nd endoscopist signals that he completed his record, the 1st endoscopist verbally explicit his classification, which is recorded by the 2nd endoscopist. This evaluation should include polyp histological type (hyperplastic, adenoma, sessile serrated lesion or other type) and the level of confidence of the evaluation performed (high or low).
16289554|NCT04749277||CAD EYE® characterization on BLI mode|Optical characterization mode of CAD EYE® (CAD EYE® ON) in BLI mode should be activated for the evaluation of CAD EYE® optical characterization, in hyperplastic or neoplastic polyps, as well as the level of characterization (graduated from 1 to 3). The evaluation of the CAD EYE® should also be recorded by the endoscopist in the exam room who is not performing the colonoscopy, on its own record sheet. The iconographic record of evaluated polyps in WLI and BLI modes and the evaluation video using CAD EYE® in BLI characterization mode should be done.
16289555|NCT04749264||Mindfulness Meditation Retreat|6 to 7-days mindfulness meditation retreat
16289556|NCT04749264||No intervention, Matched control|Adults participants will be recruited from social media and local community of meditation practitioners, and will be matched to the retreat group by gender, age and level of experience in meditation.
16289557|NCT04749251|Experimental|Individual blood pressure management arm|During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
16289558|NCT04749251|Active Comparator|Standard blood pressure management arm|During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within a fixed range of 70-90 mmHg
16289559|NCT04749238|Experimental|Treatment with NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.
16289560|NCT04749225||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
16289561|NCT04749225||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
16289562|NCT04749225||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
16289563|NCT04749199|Experimental|Enhanced mirror therapy group|Participants in this group will perform complex and randomized finger opposition and reposition movements based on the training protocol, along with enhanced complexity and altered clarity of the displayed image.
16289564|NCT04749199|Sham Comparator|Standard mirror therapy group|Participants in this group will perform simple and sequential finger opposition and reposition movements, along with a clear image showing the exercising hand of the participants.
16289565|NCT04749186|Active Comparator|Structured Didactic Model Group|A standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
16289566|NCT04749186|No Intervention|Standard Training Model|The standard local institutional teaching program
16289570|NCT04749160||Rheumatoid arthritis (RA) with connected device|"RA with DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD.
~the physical activity and sleep quality measured with connected device"
16289571|NCT04749147|Experimental|Black and White Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in black and white and feature black and white graphics.
16289572|NCT04749147|Experimental|Red Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in red text and feature red graphics.
16289573|NCT04749121|Experimental|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes.The protocol was conducted in accordance with the protocol from the OSHA respiratory protection standard , including the number, type, and duration of the exercise, and the seal checks in accordance with the manufacturer's instructions[15] 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol)
16289574|NCT04749108|Experimental|Experimental: Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization."
16289575|NCT04749108|Active Comparator|RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy."
16289576|NCT04749095|Active Comparator|Erector block|
16289577|NCT04749095|Active Comparator|sham block|
16289578|NCT04749069|Experimental|Continuous infusion of remifentanil|In continuous infusion group of patients, remifentanil was infused at a dose of 0.1 µg/kg/min and the additional bolus dose of 0.1 µg/kg was given if required. Before start of the operation, in both groups of patients, intravenous remifentanil at a bolus dose of 0.1 µg/kg was administered slowly in a duration of 60 seconds.
16289579|NCT04749069|Experimental|Patient-controlled sedoanalgesia (PCSA) of remifentanil|In PCSA group of patients, remifentanil was given by bolus PCSA using a pump (Pain Management Provider, Abbott Laboratories and Eczacibasi-Baxter, Ireland). In PCSA group of patients, remifentanil infusion was at a dose of 0.05 µg/kg, a bolus dose of 0.1 μg/kg with a lock-out time of three minutes.
16289580|NCT04749056|Experimental|EPAS screening (intervention)|"Patients undergo EPAS (electronic psycho-oncological adaptive screening), a tablet-based screening application consisting of three adaptive tests and one supportive care checklist. EPAS provides immediate feedback via a printed results page, which presents and interprets the level of distress and contains individualized recommendations for psychosocial services.
~The results pages are printed by research assistants immediately after the screening on a mobile printer and given to the participants together with a brochure containing information about all psychosocial services available at the health care institution.
~The treating physicians also receive a slightly modified results page, but are not expected to discuss these with the patient unless they are highly distressed.
~Before and during the screening, patients are explained how to use the program by the research assistance and supported if needed.
~The whole screening process takes about 30 minutes."
16289581|NCT04749056|No Intervention|Care as usual (control)|"Patients complete the assessment paper pencil. The same instruments as in the intervention condition are used except for the 3 adaptive tests (i.e., the supportive care checklist and the outcomes).
~Neither patients nor physicians receive any feedback of the results. Psychosocial services are recommended by the physicians on their own discretion only, and patients are not handed out the information brochure."
16289582|NCT04749043|Active Comparator|Virtual Reality then Nitrous Oxide|30 minute exposure to virtual reality, 5 minute washout period, then 30 minute exposure to nitrous oxide
16289583|NCT04749043|Active Comparator|Nitrous Oxide then Virtual Reality|30 minute exposure to nitrous oxide, 5 minute washout period, then 30 minute exposure to virtual reality
16289721|NCT04747990||Baseline (Pre-Covid19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2019
16289584|NCT04749030|Other|Faecal microbiota transplantation (FMT)|Donor faeces is obtained from thoroughly screened healthy blood donors and processed in compliance with the European Tissue and Cells Directive.
16289585|NCT04749030|Placebo Comparator|Placebo|Placebo capsules will be identical in terms of visual appearance, weight, and vials and number
16289586|NCT04749017|Experimental|Experimental group|Avena Sativa L. consumption of 900 mg for 60 days.
16289587|NCT04749017|Placebo Comparator|Control group|Identically appearing placebo capsules consumed for 60 days.
16289588|NCT04749004|Experimental|Intervention Group|"Tracking of steps by means of a fitness tracker
~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.
~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)
~Setting-up of a commitment contract on the individual's goal of monthly steps taken
~Provision of financial incentives upon achievement of one's goal of steps taken
~Provision of nudges (reminders)"
16289589|NCT04749004|No Intervention|Control Group|"Tracking of steps by means of a fitness tracker
~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.
~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)
~To keep incentives constant the control group will also receive the flat payment of €10 to disentangle the effects between the contract and financial incentives."
16289590|NCT04748991|Experimental|Intravenous Vernakalant|Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes and an observation period of 15 minutes, if the patient is still in AF, they will receive an additional 2.0mg/kg bolus of Vernakalant.
16289591|NCT04748991|Active Comparator|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive 150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12 hours.
16289592|NCT04748978|Experimental|symptomatic uterine fibroids|patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis
16289593|NCT04748965||Tibial Vessel Involvement in Patients with peripheral artery disease and CLI|The primary goal is to establish a protocol for performing optimal OCT in below-the-knee vessels. OCT images will be analyzed for lesion characteristics, lesion sizing pre- and post-intervention. This will be analyzed against QVA and IVUS (latter if applicable).
16289594|NCT04748952||Adult with horizontal bone defect|"30 implants will be placed in osteotomy sites prepared by osseodensification for patients with horizontal bone deficiency based on radiographic findings (CBCT).
~Alveolar ridge width will be measured intraoperatively before and after osteotomy site preparation to assess the amount of ridge expansion. Implant stability will be measured immediately after implant installation and 16 weeks later."
16289595|NCT04748939|Active Comparator|vaccine|Shingrix vaccine
16289596|NCT04748939|Placebo Comparator|placebo|normal saline injection (0.5mL)
16289597|NCT04748926|Experimental|Group 1|Participants will receive caplets after fast (treatment A) on Day 1 and caplets after meal (treatment B) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.
16289598|NCT04748926|Experimental|Group 2|Participants will receive caplets after meal (treatment B) on Day 1 and caplets after fast (treatment A) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.
16289599|NCT04748913|No Intervention|No intervention|
16289600|NCT04748913|Other|Remineralization|
16289601|NCT04748887||nonsmokers copd cases ,|Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
16289602|NCT04748887||non smokers healthy control|Thirty subjects of non smokers healthy control
16289603|NCT04748874|Experimental|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
16289604|NCT04748874|No Intervention|Postponed mNC-FET|Standard procedure where mNC-FET is performed at least one full menstrual cycle after failed fresh embryo transfer or freeze-all cycle.
16289605|NCT04748861|Experimental|Indoor Cycling (IC)|Participants will engage in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) 3x/week (minimum 90 minutes/week) for 18 months.
16289606|NCT04748861|No Intervention|Usual and Customary Care (UCC)|Participants engage in their habitual level of physical activity.
16289607|NCT04748848|Experimental|CC-90011 in combination with Venetoclax and Azacitidine in Dose Escalation|CC-90011 in combination with venetoclax and azacitidine in dose escalation
16289608|NCT04748848|Experimental|Venetoclax and Azacitidine|Venetoclax and Azacitidine control arm in dose expansion. The participants will be randomized to the treatment arm or control arm at a 2:1 ratio.
16289609|NCT04748848|Experimental|CC-90011 in combination with Venetoclax and Azacitidine in Dose Expansion|CC-90011 in combination with venetoclax and azacitidine in dose expansion
16289610|NCT04748822|Other|Quality of life of patients with AUD.|Patients' demographic data, socioeconomic status, physical diseases, medication use, clinical features of AUD, psychiatric variables, impulsivity, autonomy, sexual functioning, sleep quality, and cognitive functioning will be measured at baseline. The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
16289611|NCT04748809|Active Comparator|Arm_1|Anti-inflammatory diet 1
16289612|NCT04748809|Experimental|Arm_2|Anti-Inflammatory diet 2
16289613|NCT04748796|Experimental|Experimental group|2 days with landiolol IV + usual care
16289614|NCT04748796|Active Comparator|Control group|usual care according to the attending physician and following the guidelines of surviving sepsis campaign.
16289615|NCT04748783|Placebo Comparator|Sterile water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water
16289616|NCT04748783|Active Comparator|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
16289617|NCT04748783|Active Comparator|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
16290056|NCT04745598||Computer-assisted teaching format group|Patients diagnosed with periodontal disease stage I/II/III
16289618|NCT04748783|Active Comparator|Peroxyl & Periogard|Subject participants will complete an on-label sequential rinse starting with Peroxyl (1st) 10ml for 60 seconds and then Periogard (2nd) 15ml for 30 seconds.
16289619|NCT04748783|Active Comparator|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
16289620|NCT04748770||patients with BMI≥30 kg/m2|
16289621|NCT04748770||patients with 25≤BMI≤30 kg/m2|
16289622|NCT04748757|Placebo Comparator|Placebo|Normal saline, 50 ml infusion over 30 minutes every 12 hours for 7 days
16289623|NCT04748757|Experimental|Low dose|50 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
16289624|NCT04748757|Experimental|High dose|100 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
16289625|NCT04748744||Patients undergoing colorectal surgery|
16289626|NCT04748731|Experimental|Experimental Group. Video-feedback intervention.|A weekly online brief intervention using video-feedback and psycho-educational materials on early parenting (detailed description of the intervention on section 5).
16289627|NCT04748731|Other|Control Group. Psycho-educational intervention|They will receive weekly information on parenting in the 1st year of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
16289628|NCT04748718|Experimental|Injury Prevention Arm|
16289629|NCT04748705|Experimental|IMC-1 Oral Tablet|2X IMC-1 Tablet taken orally, each morning and evening.
16289630|NCT04748705|Placebo Comparator|Placebo|2X Placebo Tablet taken orally, each morning and evening.
16289631|NCT04748692|Experimental|Local exercise therapy|The local exercise therapy group focused on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients trained with the support of a physiotherapist. The physiotherapist gradually increased the intensity of the exercises improving muscle endurance. The exercises were supplemented with mobilisations of the patellofemoral joint. Twice a week, patients trained at home following a prescribed exercise program writing down their work-out in an exercise journal.
16289632|NCT04748692|Experimental|Spinal manual therapy|The spinal manual therapy group was treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots were used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment included manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation was conducted if a restriction of range of motion was found in any of the regions. Patients were also asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
16289633|NCT04748679|Experimental|Worry Intervention|The Worry Intervention uses cognitive-behavioral therapy (CBT) techniques to support the patient in reducing the amount of time they worry throughout the week. It is an 8-week manualized treatment with 5 modules. Each session is 45-60 minutes.
16289634|NCT04748679|Active Comparator|Befriending|Befriending therapy controls for the general factors of therapy (warmth, engagement) without any 'active' interventions. Individuals in the befriending arm will spend sessions talking with the therapist about things that interest them. It will also be conducted over 8-weeks with 45-60 minute sessions.
16289635|NCT04748666|Experimental|3 PST sessions and no boosters|
16289636|NCT04748666|Experimental|3 PST sessions with monthly boosters for 6 months|
16289637|NCT04748666|Experimental|6 PST sessions, no boosters|
16289638|NCT04748666|Experimental|6 PST sessions with monthly boosters for 6 months|
16289639|NCT04748653|Experimental|Multi-component reintegration intervention|There is one arm for the feasibility and acceptability study - all intervention participants will receive the intervention: health education, psychosocial counseling, physiotherapy, and economic investment.
16289640|NCT04748640|Experimental|Treatment group|Participants will undergo a thalamotomy contralateral to their previous treatment with Gamma Knife using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
16289641|NCT04748614||Before SARS-Cov2|Before SARS-Cov2
16289642|NCT04748614||After SARS-Cov2|After SARS-Cov2
16289643|NCT04748601|Placebo Comparator|Placebo|
16289644|NCT04748601|Experimental|Qudexy XR|
16289645|NCT04748588|No Intervention|Standard of care|
16289646|NCT04748588|Experimental|Anti SARS-CoV-2 monoclonal antibody|Single IV administration of an anti-SARS-CoV-2 Monoclonal antibody
16289647|NCT04748575|Experimental|Acai smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the acai smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the placebo smoothie.
16289648|NCT04748575|Experimental|Placebo smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the placebo smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the acai smoothie.
16289649|NCT04748562|Active Comparator|400 mg progesterone group|Taking 400 mg vaginal progesterone
16289650|NCT04748562|Active Comparator|200 mg progesterone group|Taking 200 mg vaginal progesterone
16289651|NCT04748549|Experimental|Immersive VR group|"Patients in the Immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.
~To reduce the influence of the anesthesia provider on the determination of sedative requirements, patients will administer their own sedation according to their needs for relaxation and comfort using a patient controlled system."
16289652|NCT04748549|Active Comparator|Music group|Patients randomized to the Music group will be equipped with VR headsets but won't view any content. They will also be equipped with noise cancelling headphones in the same fashion as the immersive VR group. A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient. Patients in the Sham VR group will also use patient controlled sedation.
16289722|NCT04747990||Pandemic (During Covid-19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2020
16289653|NCT04748549|Sham Comparator|Sham VR + Usual Care Control Group|Subjects in the control group will wear VR headsets and headphones but will not view any content or listen to any audible content. They will undergo Monitored Anesthesia Care (MAC) according to a prespecified protocol targeting light or moderate sedation with a propofol infusion.
16289654|NCT04748536|Experimental|Group 1: Dose A IRL201104 or placebo|IRL201104 IV once daily for 5 days OR Placebo IV once daily for 5 days
16289655|NCT04748536|Experimental|Group 2: Dose B IRL201104 or placebo|IRL201104 IV once daily for 7 days OR Placebo IV once daily for 7 days
16289656|NCT04748523|Active Comparator|Intervention group|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
16289657|NCT04748523|Placebo Comparator|Placebo group|arm to receive 15 to 30 mg of placebo for a period of 8 weeks.
16289658|NCT04748510|Active Comparator|Functionally aligned Total Knee Arthroplasty|Knee arthroplasty performed using a functional alignment theory
16289659|NCT04748510|Active Comparator|Mechanical axis aligned Total Knee Arthroplasty|Knee arthroplasty performed using a mechanical alignment theory
16289660|NCT04748497|Other|Parasportives of various disciplines|
16289661|NCT04748484|Other|KCC active or inactive|The medical device KCC will be active, or inactive. Randomization will define when and how long time the medical device will be active, and when and how long time the medical device will be inactive. The patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
16289662|NCT04748471|Experimental|18-45 years old|18 - 45 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
16289663|NCT04748471|Experimental|65-74 years old|65 - 74 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
16289664|NCT04748471|Experimental|At least 75 years old|At least 75 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
16289665|NCT04748458||Congenital hip pathologies|Conical tapered stem for osteoarthritis due to congenital hip pathologies
16289666|NCT04748445||All participants|
16289667|NCT04748432||Multi-drug resistant group (MDR)|Patients with resistant NFGNB isolate as MDR group
16289668|NCT04748432||Non-Multi-drug resistant group (Non-MDR)|Patients with sensitive NFGNB isolate as Non-MDR group
16289669|NCT04748432||Control group (Control)|Patients without suspicion of VAP and other signs of nosocomial infection as the control group
16289670|NCT04748419|Experimental|Hypofractionated radiation therapy (hfRT) with Durvalumab|Combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) of 10Gy x 2 fractions for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy (durvalumab), dose of 10 mg/kg infusion every two weeks concurrently for up to 12 months or disease progression.
16289671|NCT04748406|Active Comparator|Peloid Therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week(16).
16289672|NCT04748406|Active Comparator|ESWT(Extracorporeal Shock Wave Therapy)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied(4).
16289673|NCT04748393||Study cohort|Consecutive female patients between the ages of 18 and 50 with child bearing potential and objectivated, symptomatic VTE, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion.
16289674|NCT04748380|Experimental|CRC DA|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet.
16289675|NCT04748380|Other|Home Safety Pamphlet|Stratifying by sex, 30 will be randomized to receive the home safety information at the visit.
16289676|NCT04748367|Experimental|Intervention group|Children wear VR headset during immunisation
16289677|NCT04748367|No Intervention|Control group|Children did not wear VR headset during immunisation( usual care)
16289678|NCT04748354|Active Comparator|Usual Care|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months.
16289679|NCT04748354|Experimental|Usual Care with Exercise|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months. In addition, they will receive the Otago Exercise Program, an individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist.
16289680|NCT04748341|Active Comparator|Traditional Group|Group A will be taught through the two steps traditional method (2 lectures/week + 1 skill lab/week). First, learn through didactic Lectures and then practice skills on the Mannequins. The educational lecture content will be the same for both groups.
16289681|NCT04748341|Experimental|Pedagogical Group|Group B will learn through the 5-step method [ 2 lectures/week + video + 2skill lab/week (1 session under instructor + 1 session for skill maintenance)], learn skill, see the video on resuscitation, practice on simulator, prove through practice, observe skill on clinical rotation and lastly maintain it through clinical supplemented with simulation.
16289682|NCT04748328||ACL Reconstruction Group|This group received reconstruction treatment in Gatot Subroto Hospital, Jakarta
16289683|NCT04748328||Rehabilitation Group|This group received rehabilitation treatment with optional delayed reconstruction in Arifin Achmad Hospital, Pekanbaru
16289684|NCT04748315|Experimental|SEMT(1:1)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:1.
16289685|NCT04748315|Experimental|SEMPT(1:3)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:3.
16289686|NCT04748315|No Intervention|Control|Participants in this arm will receive no intervention
16289687|NCT04748289|Experimental|NICU patients|All patients admitted to the Neurointensive Care Unit (NICU)
16289688|NCT04748263||Fronto-Temporal Dementia (FTD)|10 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
16289689|NCT04748263||Alzheimer's Dementia (AD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
16289690|NCT04748263||Parkinson's Disease (PD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
16289691|NCT04748263||Healthy volunteers|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
16289723|NCT04747977|Experimental|OTX-DED 0.2mg|Approximately 50 subjects
16289724|NCT04747977|Experimental|OTX-DED 0.3mg|Approximately 50 subjects
16289725|NCT04747977|Placebo Comparator|Hydrogel Vehicle (HV)|Approximately 50 subjects
16289692|NCT04748250|Experimental|Acupuncture Group|This group will receive acupuncture therapy for 30 minutes, three times per week for three months using the internationally recognized standard acupuncture needle which is 3 cm long with diameter o.3 mm, pushing it with twisting movement to the required depth until the De Qi sensation will be obtained.
16289693|NCT04748250|Experimental|Soy Group|This group will receive soy products for three months which including: Soy milk: 100 millilitre of soy milk every day, every bottle of original soy milk contains 300 millilitre or Soy beans: 100 gram of cooked soy beans per day.
16289694|NCT04748250|Experimental|Acupuncture and Soy Group|Every patient in this group will receive acupuncture therapy sessions in abdominal acu-points as in group (A) for 30 minutes, three times per week for three months in addition to administration of soy products in the form of soy milk or soy beans daily in breakfast for three months as in group (B).
16289695|NCT04748237|Experimental|Coronary computed tomopraphic angiography|"Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and referred to a CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days. Local scanning protocols can be used on ≥64-slice multi-detector CT scanners able to perform ECG-gated coronary angiography.
~The coronary angiography will be classified as normal (or near normal) or as having atherosclerosis (CAD). The report will also classify each vessel (left main, prox LAD, mid or distal LAD, LCX and RCA regarding degree of stenosis (no stenosis, 0-49%, ≥50%, or not possible to estimate because of calcification or technical reason).
~The result will be presented to the responsible physician as soon as possible and who will plan further care of the patients."
16289696|NCT04748237|No Intervention|No Coronary computed tomopraphic angiography|"Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always.
~Regardless of diagnostic strategy, the responsible physician is encouraged to initiate secondary prevention measures if the investigations indicate signs of CAD, including medication with aspirin and statins."
16289697|NCT04748224|Active Comparator|group A (bupivacaine only)|Group A will be injected with 20 ml of 0. 25% bupivacaine in each side
16289698|NCT04748224|Active Comparator|group B (bupivacaine plus dexmedetomidine)|Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
16289699|NCT04748211|Experimental|Infraclavicular Block|Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
16289700|NCT04748211|Experimental|Interscalen Block|Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
16289701|NCT04748198|Experimental|Study group|Intracorneal ring segments are implanted for treatment of keratoconus, and posterior corneal surface is assessed preoperatively and postoperatively.
16289702|NCT04748172||Study Group: Women who are planning to be vaccinated|Women that are planning to be vaccinated, before receiving the first shot of the vaccine
16289703|NCT04748172||Control Group: Women who are not planning to be vaccinated|Women visiting other ambulatory clinics that are not planning to be vaccinated
16289704|NCT04748159|Experimental|Infants in prone position|The purpose of this intervention study is to evaluate short-term effects (within one hour) of prone positioning on vital signs in infants under 12 months of age with acute RSV bronchiolitis.
16289705|NCT04748146|Other|Intervention and Control group|Each patient will receive electrical and sham stimulation, meaning that each patient will act as their own control.
16289706|NCT04748133|Active Comparator|acupuncture|"Patients in the acupuncture group will receive a standardised treatment with 12 needles (sharp tip, stainless steel needles, size 0.3 X 40 mm) at 7 acupuncture points Du 26 and Ren 17 (on the middle body line), and bilateral LI 4, HE 7, LV 3, ST 36 and PC 6). Application of the needles is performed by a licensed medical acupuncturist.
~The needles will be inserted after endotracheal intubation and mechanical ventilation and will be removed immediately before patient extubation."
16289707|NCT04748133|Placebo Comparator|placebo|no treatment
16289708|NCT04748120|Active Comparator|Operative management|Treatment with surgery
16289709|NCT04748120|Active Comparator|Non-operative management|Treatment with antibiotics
16289710|NCT04748107|No Intervention|Provider preference: Control group|Provider will prescribe blood pressure medication based on his professional expertise.
16289711|NCT04748107|Experimental|ICG directed therapy group|ICG directed therapy will be used to determine which blood pressure medication is received.
16289712|NCT04748094||Free-breathing versus Compression|This cohort of volunteers and patients will undergo imaging on the MR-Linac investigating free-breathing motion, and comparing it to motion using an abdominal compression device.
16289713|NCT04748094||Free-breathing versus Breath-holding|This cohort of volunteers and patients will undergo imaging on the MRSim investigating free-breathing motion and comparing it to visually-guided breath-hold motion (and reproducibility).
16289714|NCT04748081||Surgery cohort|Patients who underwent hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4) between 2000 and 2012 were identified as the surgery cohort.
16289715|NCT04748081||Control cohort|Patients without any record of hepatectomy between 2000 and 2012 were defined as the control cohort.
16289716|NCT04748068|Experimental|Glidesheath Slender|The transradial procedure will be performed using the 7-Fr glidesheath slender (studied sheath)
16289717|NCT04748068|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 7- French radial sheath (comparator sheath)
16289718|NCT04748042|Experimental|Abiraterone, ADT, Radiation and Olaparib|Abiraterone, ADT, radiation to all metastases and Olaparib.
16289719|NCT04748016|Experimental|3D-printed models plus CT imaging|Fracture repair surgery using sterilized 3DP models, CT-MPR and CT-3DR for planning and intraoperative visualization
16289720|NCT04748016|Active Comparator|CT imaging alone|Fracture repair surgery using CT-MPR and CT-3DR for planning and intraoperative visualization
16289726|NCT04747964|Experimental|A single lowest dose of treatment group|
16289731|NCT04747951|Experimental|total neoadjuvant therapy|Total neoadjuvant therapy consisted chemoradiotherapy with capecitabine and nine weeks of consolidation chemotherapy with XELOX prior to surgery and adjuvant therapy if necessary.
16289732|NCT04747951|Active Comparator|standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
16289733|NCT04747938|Experimental|Energy accumulator|Energy Accumulator was a portable handheld device invented for local heat therapy for healthcare purpose. All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts.
16289734|NCT04747938|Experimental|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
16289735|NCT04747925|Active Comparator|mulligan two leg rotation , core muscle strengthening exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
16289736|NCT04747925|Experimental|Mulligan bent leg raise technique core muscle strengthning exercises.|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
16289737|NCT04747912|Experimental|Treatment Arm - Induction/Consolidation Phase - All Participants|"All participants in this arm will receive the same first round of treatment as part of induction/consolidation therapy. This treatment will use inotuzumab ozogamicin combined with anti-cancer drugs. The additional treatment that participants receive after this first round of treatment will vary based on the participant's response to induction therapy. This phase of treatment will last for 60 days. All participants in this arm will receive the following treatment:
~Treatment Course I (Induction Phase, 28 days):
~Dasatinib 140mg daily continuous
~Dexamethasone 10mg/m^2 PO or IV Days 1-7 and Day 15-Day 22
~InO 0.8mg/m2 Day 8; 0.5mg/m2 D15, 0.5mg/m2 Day 22
~Intrathecal methotrexate 15mg Day 1, Day 28
~Treatment Course II (Consolidation Phase, 28 days):
~Dasatinib 140mg daily continuous
~InO: If in CR/CRi 0.5mg/m2 Day 1, Day 8, Day 15; If not in CR/CRi 0.8mg/m2 on Day 1, 0.5mg/m2 Day 8 and Day 15
~Intrathecal methotrexate 15mg Day 1, Day 28"
16289738|NCT04747912|Experimental|Treatment Arm - Interim/Maintenance Phase - Participants in CMR|"This study arm is for participants who no longer show any detectable signs of BCR-ABL1 (a cancer-causing gene) in response to the previous phase of induction/consolidation treatment (also known as being in complete molecular remission or CMR). Participants in this arm will receive 3 courses of interim/maintenance treatment using dasatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the fourth course of treatment. These treatments will be given in 28-day and 84-day cycles.
~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, then the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.
~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission, they will complete 3 additional courses of maintenance treatment."
16289739|NCT04747912|Experimental|Treatment Arm - Interim/Maintenance Phase - Participants Not in CMR|"This study arm is for participants whose cancer responded to induction/consolidation treatment, but still shows detectable signs of BCR-ABL1 (a cancer-causing gene), so they are not in complete molecular remission. Participants in this arm will receive 3 courses of treatment using ponatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the 4th treatment course. These treatments will be given in 28-day and 84-day cycles.
~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.
~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission (CMR), they will complete 3 additional courses of maintenance treatment.
~If the participant doesn't achieve CMR after 4th treatment course, they will be removed from the study."
16289740|NCT04747899|Active Comparator|Traditional physical therapy|Traditional physical therapy ,Hot Pack, Muscle Stretching and Posture correction
16289741|NCT04747899|Experimental|Positional Release Technique|Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.
16289742|NCT04747886|Active Comparator|WW Only|Participants will receive 3-month access to the WW digital program.
16289743|NCT04747886|Experimental|WW + PolyRules!|Participants will receive 3-month access to the WW digital program and the PolyRules! app.
16289744|NCT04747873|Experimental|e-CBT|12 weekly sessions with approximately 30 slides and interactive content, delivered through OPTT designed to mirror in-person standard CBT. Participants go through the content and complete homework at the end of the session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases. On average, developing this feedback takes a therapist 15-20 minutes per patient. In addition to the weekly feedback, participants have the option to message their therapist through the platform throughout the week regarding any questions or concerns they may have.
16289745|NCT04747873|Experimental|e-CBT + Stepped Care|"1 - Participant will receive message from assigned care provider on OPTT who check-in with them about strategies and techniques they have discussed and remind them of weekly homework due date.
~2.- Participant will receive phone call from therapist who will check-in on them, remind them of therapy strategies, and verbally remind them of weekly homework due date.
~3 - Participant will receive phone call from assigned care provider who will check-in on them, remind them of some therapy strategies and techniques and weekly session due date, and provide CBT summary of previously reviewed CBT concepts.
~4 - articipant will receive video call (Microsoft Teams) from their therapist who will check-in on them, remind them of weekly session due date, and provide CBT content support to participant.
~5 - Participant will receive CBT sessions in live video call (Microsoft Teams) with research psychiatrist involved in care."
16289746|NCT04747847|Experimental|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day
16289747|NCT04747834|Active Comparator|Cohort 1|Subjects with mild to moderate cataracts (Grade 1 to 2) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion.
16289748|NCT04747834|Active Comparator|Cohort 2|Subjects with moderate to dense cataracts (Grade 2+ to 3+) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion..
16289749|NCT04747821|Experimental|First group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the first week of study The vaccine is administrated in two doses with a four-weeks interval
16289750|NCT04747821|Experimental|Second group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the second week of study The vaccine is administrated in two doses with a four-weeks interval
16289751|NCT04747821|Experimental|Third group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the third week of study The vaccine is administrated in two doses with a four-weeks interval
16289752|NCT04747821|Experimental|Fourth group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the fourth week of study The vaccine is administrated in two doses with a four-weeks interval
16289753|NCT04747808|Experimental|LL-BMT1|Group 4 extended-wear contact lens printed with bimatoprost
16289754|NCT04747795|Placebo Comparator|standard care + placebo|The 'standard care' group will receive intermittent infusion of normal saline (3 ampoules of 5 ml 9mg/ml normal saline diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
16289755|NCT04747795|Active Comparator|standard care + Vitamin C|The 'standard care + Vitamin C' group will receive intermittent infusion of Vitamin C (3 ampoules of 500 mg/5ml Vitamin C diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
16289756|NCT04747782||COVID positive|Patients admitted to the ICU with respiratory distress found to be COVID19 positive.
16289757|NCT04747782||COVID negative|Patients admitted to the ICU with respiratory distress found to be COVID19 negative
16289758|NCT04747782||COVID positive delayed|Patients admitted to the ICU for an indication other than respiratory distress, found to be COVID19 positive.
16289759|NCT04747782||never-ICU|Patients admitted to the internal medicine ward with respiratory distress found to be COVID19 positive.
16289760|NCT04747756|Other|Study participants|No participants will be randomized. All participants will have an opportunity to participate in the study procedures.
16289761|NCT04747743||Egyptian dental practitioners|170 dental practitioners in Egypt (professionals both academic and nonacademic).
16289762|NCT04747730|Experimental|Transcendental Meditation training|The intervention of the project is the teaching and learning of Transcendental Meditation technique. The technique involves the use of a sound (mantra) to effortlessly allow the mind to settle down to a state of inner calm. It is a simple, natural and effortless practise, and unlike other meditation strategies, it does not involve concentration or control of the mind. The practice does not require any religion, philosophy, or change in lifestyle. Once learned the technique, participants will practice it twice a day, 20 minutes every morning and 20 minutes in the afternoon.
16289763|NCT04747730|No Intervention|control|no intervention
16289764|NCT04747717|Experimental|Mitomycin C and cisplatin regimen|mitomycin C at 10 mg/m2 and cisplatin at 100 mg/m2
16289765|NCT04747717|Active Comparator|Paclitaxel and carboplatin regimen|paclitaxel at 175 mg/m2 and carboplatin AUC5-6
16289766|NCT04747704|Experimental|Intervention|Participants receiving Three-Principles Counseling
16289767|NCT04747691||Patients assessed with postoperative bedside gastric ultrasound|This patient population will include postoperative patients who received a gastrointestinal surgery and are being assessed with the bedside gastric ultrasound.
16289768|NCT04747665||Patients|Patients who have undergone or refused to undergo colonoscopy
16289769|NCT04747665||Endoscopists|Endoscopists who perform or are training to perform colonoscopy
16289770|NCT04747639|Active Comparator|verum 500|500 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
16289771|NCT04747639|Placebo Comparator|control 500|500 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
16289772|NCT04747639|Active Comparator|verum 250|250 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
16289773|NCT04747639|Placebo Comparator|control 250|250 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
16289774|NCT04747626|Experimental|Treatment|Implantation of a physician-modified endovascular stentgraft(s) to treat the proximal aorta in subjects with aortic disease involving multiple segments.
16289776|NCT04747600||serous cystic neoplasms|
16289777|NCT04747600||mucinous cystic neoplasms|
16289778|NCT04747600||intra-papillary mucinous neoplasms|
16289779|NCT04747600||solid pseudo-papillary neoplasms|
16289780|NCT04747587||Patients with stroke|
16289781|NCT04747587||Controls|
16289782|NCT04747574|Other|EXO-CD24 exosome treatment|"Group 1, 5 patients are treated with 1x10^8 exosome particles per 2 ml saline.
~Group 2: 5 patients are treated with 5x10^8 exosome particles per 2 ml saline.
~Group 3: 20 patients are treated with 1x10^9 exosomes particles per 2 ml saline.
~Group 4: 5 patients are treated with 1x10^10 exosomes particles per 2 ml saline.
~The drug is aerosolized in normal saline for inhalation and administered via a standard hospital-grade inhalation device, QD for 5 days. Study treatment is given as an add-on to the standard of care."
16289783|NCT04747561|Experimental|18F-PEG3-FPN PET|A positron probe for the targeted melanin
16289786|NCT04747535|No Intervention|Control|Regular treatment
16289787|NCT04747535|Experimental|Auto CPAP|Auto CPAP, AirSense 10 AutoSet, ResMed Inc, max pressure 10 cm water, min pressure 5 cm water
16289788|NCT04747535|Other|CPAP since before|Patients with CPAP since before will all continue using CPAP. They will not attend the randomization process. They will be regarded as a separate group.
16289789|NCT04747522||Kidney Transplanted patients|Kidney transplanted patients transplanted at least 6 months prior to SARS-CoV-2 vaccination. Vaccination according to national plan with messenger Ribonucleic acid (mRNA) vaccine
16289790|NCT04747522||Healthy controls|Healthy hospital staff receiving SARS-CoV-2 mRNA vaccine as being front line Healthcare workers.
16289791|NCT04747509|Experimental|Blackburn exercises|Blackburn exercises and hot pack
16289792|NCT04747509|Active Comparator|Conventional physical therapy|Conventional physical therapy and hot pack
16289793|NCT04747496||NVAF patients|NVAF adult patients with one or more risk factors treated with edoxaban.
16289794|NCT04747483|Active Comparator|Extension Oriented Treatment Approach|"The EOTA intervention involves three components. The first component is a series of active extension- oriented exercises: Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension.
~The second component of the EOTA is subject education. Subjects are being educated to maintain the natural lordosis of the lumbar spine while sitting, and are being instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.
~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension.The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
16289795|NCT04747483|Experimental|EOTA+ Mechanical Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.
~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.
~2 sessions being given per week for 3 weeks."
16289796|NCT04747470|Experimental|GS-3583 Dose Escalation|Participants will receive an escalating dose of GS-3583 for up to 52 weeks or until the participant meets study treatment discontinuation criteria.
16289797|NCT04747457|Experimental|Adults and pediatric patients, all etiologies combined|
16289798|NCT04747444|Other|100% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 100% full body weight loading
16289799|NCT04747444|Other|50% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 50% full body weight loading
16289800|NCT04747431|Experimental|Cohort 1|"Drug: PBFT02 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBFT02, via intra cisterna magna
~*GC/g: gene copy per gram of estimated brain weight"
16289801|NCT04747431|Experimental|Cohort 2|"Drug: PBFT02 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna
~*GC/g: gene copy per gram of estimated brain weight"
16289802|NCT04747431|Experimental|Optional Cohort 3|"Drug: PBFT02 Dose 3: 2.2 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna
~*GC/g: gene copy per gram of estimated brain weight"
16289803|NCT04747418||Study Group: Women with low segment uterine scar following cesarean delivery|Women with low segment uterine scar following cesarean delivery, with no other abnormalities observed during diagnostic hysteroscopy
16289804|NCT04747418||Cohort Group: Women with no uterine scar|Women with no uterine scar, with no other abnormalities observed during diagnostic hysteroscopy
16289805|NCT04747405|No Intervention|A standard|standard of care
16289806|NCT04747405|Experimental|B therapy group|standard of care and therapy group
16289807|NCT04747392|Other|Sequence A|The test drug (SAL001) is administrated once by subcutaneous injection in the first period, and the reference drug (FORSTEO) is administrated once by subcutaneous injection in the second period.
16289808|NCT04747392|Other|Sequence B|The reference drug (FORSTEO) is administrated once by subcutaneous injection in the first period, and the test drug (SAL001) is administrated once by subcutaneous injection in the second period.
16289809|NCT04747353|Experimental|Catheter ablation procedure with heart 3D model|Experimental: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
16289810|NCT04747340|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly online sessions, each 90 minutes, 6 participants/group. For participants <18 years at CAP, parents/legal guardians will participate in parts of the sessions. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
16289831|NCT04747262|Experimental|SPACE INTERVENTION|counseling
16289832|NCT04747249|Experimental|Psychological support|Monthly psychological support
16289811|NCT04747340|Active Comparator|Standard Treatment|Standard treatment (ST) as given at each participating study site. ST is based on the health practitioners' knowledge, experience, current guidelines and both the practitioners' and participants' preferences. For young people with depression The Swedish National Board of Health and Welfare recommends social support and psychoeducation (as first priority), Selective Serotonin reuptake inhibitors (as second priority) and cognitive behavioral therapy (as second priority). These recommendations are generally followed and given as stand-alone treatment or in different combinations. In our study we have no control over which of these treatments are given in the ST-arm, nor the combination or timing of them. To obtain data on what treatment has been given in the ST-arm we will go through the individual medical records of all participants at the conclusion of data collection.
16289812|NCT04747327|No Intervention|general health topic|Those in this arm will receive a message about how people have different health preferences.
16289813|NCT04747327|Experimental|specific health incentive information 1|Those in this arm will learn about a financial incentive (with a relatively large sum) or a social incentive
16289814|NCT04747327|Experimental|specific health incentive information 2|Those in this arm will learn about a financial incentive (with a relatively small sum) or a social incentive
16289815|NCT04747327|Experimental|facts only|Those in this arm will receive a statement about vaccine safety.
16289816|NCT04747327|Experimental|mandatory language|Those in this arm will receive a statement about how vaccination may be mandatory.
16289817|NCT04747327|Experimental|freedom language|Those in this arm will receive a statement about how vaccination is currently not required and they have the freedom to choose what they want to do.
16289818|NCT04747314|Experimental|Antidepressant (AD)|Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months.
16289819|NCT04747314|Experimental|Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months.
16289820|NCT04747314|Experimental|Antidepressant (AD) + Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
16289821|NCT04747314|Experimental|AD -> EFAR|"Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks.
~Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months. Those re-randomized to receive EFAR for another 4 months will receive a combination of antidepressant medication and physical therapy, in addition to their current opioid prescription and weaning guidelines, if applicable."
16289822|NCT04747314|Experimental|EFAR -> AD|"Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment.
~Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months. Those re-randomized to receive AD for another 4 months will be under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks."
16289823|NCT04747301|Other|Double-balloon catheter group|Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA).
16289824|NCT04747301|Other|Vaginal insertion Prostaglandin E2 group|Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).
16289825|NCT04747288||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG). Exclusion Criteria: NA.
16289826|NCT04747288||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 and 1997 revised Systemic lupus erythematosus criteria. Exclusion Criteria: NA.
16289827|NCT04747288||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min. Exclusion Criteria: NA.
16289828|NCT04747288||non AIDDES Healthy Controls|Non AIDDES Healthy Controls were enrolled with inclusion criteria: (1) aged between 20 and 75 years; (2) without any Chronic disease. Exclusion Criteria: any Sjögren's syndrome, Systemic lupus erythematosus, or Dry eye syndrome.
16289833|NCT04747236|Experimental|AZA and ROMI|Oral Azacytidine (AZA) (300 mg daily on days 1-14) plus Romidepsin (ROMI) (14 mg/m2 as an intravenous infusion over 4 hours on days 8, 15 and 22 of a 35-day cycle.
16290057|NCT04745598||Plaque-disclosing group|Patients diagnosed with periodontal disease stage I/II/III
16289834|NCT04747236|Active Comparator|Investigator's Choice|Investigator's choice to include: ROMI, 14 mg/m2 IV infusion on days 1, 8, and 15 of a 28 day cycle, belinostat,1000 mg/m2 IV infusion on days 1-5 every 21 days, pralatrexate, 30 mg/m2 IV push once weekly for 6 weeks of a 7-week treatment cycle, or gemcitabine, 1000 mg/m2 IV infusion on days 1, 8, and 15 of a 28-day cycle.
16289835|NCT04747223|Experimental|Retraining (RT) Group|The retraining group will receive a watch accelerometer to use for monitoring their step rate with instructions to increase their preferred step rate by 7.5% over the ten in-field training sessions.
16289836|NCT04747223|No Intervention|Control (CON) Group|The control group will receive the same device to monitor their pace but receive no instruction to change their preferred step rate over the ten in-field training sessions.
16289837|NCT04747210|Active Comparator|Trainig workshop and Coaching one-on-one|Ten-hour training workshop that was divided into three sessions outside working hours. Coaching one-on-one in the daily routines and natural environment.
16289838|NCT04747210|Active Comparator|Trainig workshop|Assistants receive ten-hour training workshop that was divided into three sessions outside working hours.
16289839|NCT04747197|Experimental|EYP-1901 440 ug|EYP-1901 440 ug, single dose
16289840|NCT04747197|Experimental|EYP-1901 2060 ug|EYP-1901 2060 ug, single dose
16289841|NCT04747197|Experimental|EYP-1901 3090 ug|EYP-1901 3090 ug, single dose
16289842|NCT04747184||Asthmatic patients|Asthmatic patients aged 14-year-old, and more were included in the study. Knowing that patient with the age of 14-year is treated as adults at Al Bashir Hospital. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
16289843|NCT04747184||Healthy subjects|Healthy subjects aged 14-year-old, and more were included in the study. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
16289844|NCT04747171|Active Comparator|magnesium intrathecal|
16289845|NCT04747171|Active Comparator|dexamethasone intrathecal|
16289846|NCT04747171|Active Comparator|dexmedetomidine intrathecal|
16289847|NCT04747158|Experimental|Convalescent plasma|COVID-19 convalescent plasma
16289848|NCT04747145|Experimental|Pulsed reduced dose-rate radiotherapy|Chemoradiation, adjuvant chemotherapy.
16289849|NCT04747132|Experimental|Intervention group|Individualized geriatric medical counseling, psychological counseling, nutritional counseling and physical activity counseling through the internet
16289850|NCT04747132|No Intervention|Control group|Health guidance through standardized audiovisual educational material through Intenert
16289851|NCT04747119|Experimental|study group|received the conventional selected exercise program in addition to muscle energy technique
16289852|NCT04747119|Experimental|control group|received the conventional selected exercise program
16289853|NCT04747106|Experimental|plasma exchange|when ADP inhibition >30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
16289854|NCT04747106|No Intervention|standard medical treatment|standard medical treatment
16289855|NCT04747093|Experimental|ITNK group|
16289856|NCT04747080|Experimental|TAC and HD-DXM|"Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
~Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks."
16289857|NCT04747080|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14) .
16289858|NCT04747067||High flux HD|measuring free light chains (Kappa and lambda) reduction ratio , hsCRP reduction ratio and cumulative albumin loss on patients undergoing high flux hemodialysis session.
16289859|NCT04747067||HDF|measuring free light chains (Kappa and lambda) reduction ratio , hsCRP reduction ratio and cumulative albumin loss on patients undergoing hemodiafiltration session.
16289860|NCT04747054|Experimental|Radiotherapy added to pembrolizumab|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.
~Loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) with 54 Gy/18 fractions in the head and neck region."
16289861|NCT04747054|Active Comparator|pembrolizumab alone|Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.
16289862|NCT04747041|Experimental|Alternating each month for 1 year between Phytocyst herbal tea and Cyscontrol|Alternating each month (From Day1 to DAY15) for 1 year between Phytocyst herbal tea and Cyscontrol = Preventive Treatment In case of episode of cystitis : AROMAFEMINA, Capsules for the comfort of the urinary tract Oleocaps 2 : 2 capsules before meals, 3 times a day for 5 consecutive days.
16289863|NCT04747028||Primary dentition|Children from 4 to 6 years old suffering from malnutrition
16289864|NCT04747028||Age 13 to 16|Adolecentsfrom 13 to 16 suffering from malnutrition at present time or during their childhood
16289865|NCT04747015|Active Comparator|Cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus
16289866|NCT04747015|Active Comparator|Active management|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
16289867|NCT04747002|Active Comparator|Administration Group|Patients who are injected with DSP-7888.
16289868|NCT04747002|No Intervention|Non-administration Group|Patients who are only under observation.
16289869|NCT04746989||Probenecid|Reference group
16289870|NCT04746989||Allopurinol|Exposure group
16289871|NCT04746976||Diroximel Fumarate|Participants with RMS who are receiving diroximel fumarate orally in routine clinical practice will be enrolled.
16289872|NCT04746963|Experimental|Low Dose|AXT107 0.1 mg/eye
16289873|NCT04746963|Experimental|Mid Dose|AXT107 0.25 mg/eye
16289874|NCT04746963|Experimental|High Dose|AXT107 0.5 mg/eye
16289875|NCT04746937|Placebo Comparator|Control Group|They will receive standard therapy plus placebo
16289876|NCT04746937|Active Comparator|Nitazoxanide Group|They will receive standard therapy plus nitazoxanide
16289877|NCT04746924|Experimental|Arm A: Tislelizumab plus Ociperlimab|Participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks.
16289878|NCT04746924|Active Comparator|Arm B: Pembrolizumab plus Placebo|Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
16289879|NCT04746924|Placebo Comparator|Arm C: Tislelizumab plus Placebo|Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
16289880|NCT04746911|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
16289881|NCT04746898|Experimental|Virtual Reality Training Group (VR group)|The students in the first group received basic life support practice training with virtual reality applications.
16289882|NCT04746898|Experimental|High Fidelity Simulation Training Group (HFS group)|The students in the second group received basic life support practice training with high fidelity simulators.
16289883|NCT04746898|Experimental|Low Fidelity Simulation Training Group (LFS group)|The students in the third group received basic life support practice training with the classical method, low-reality mannequin.
16289884|NCT04746885|Other|Group A|(interventional group/ DHA): A minimum of 40 preterm infants will be included to receive 100mg DHA daily administered by enteral route for 30 days. This group will be subdivided into breast fed / artificially fed infants.
16289885|NCT04746885|Other|Group B|(control group / Placebo): 40 of preterm infant controls will be included to receive placebo (physically matched solution). This group will be subdivided into breast fed / artificially fed infants.
16289886|NCT04746872|Experimental|Alinity m HR HPV|The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes [(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)].
16289887|NCT04746859|Experimental|Intervention|Patients in the intervention group will be matched to a peer health coach shortly after their BETTER prevention visit and enrollment in the study. They will receive coaching for 6 months.
16289888|NCT04746859|Other|Wait-list Control|After completion of the study, approximately 12 months after their BETTER prevention visit, patients in the wait-list control group will be matched to a peer health coach. They will receive coaching for 6 months.
16289889|NCT04746833|Experimental|SUMMIT|Participants randomized to the experimental intervention will participate in a Motivational Interviewing (MI) session lasting between 30 and 60 minutes with study psychologist. All MI sessions will be audiotaped using a VA-approved digital recorder and transcribed verbatim. Participants will subsequently be shown how to access SUMMIT via a set of unique anonymized login credentials and to navigate the components of SUMMIT on one or more devices, depending on their preference. They will then be trained on how to complete the outcome surveys.
16289890|NCT04746833|Placebo Comparator|control|Participants randomized to the control intervention will use an eHealth comparator: My Pain Diary: Chronic Pain Management (iPhone, Android). This app includes a pain monitoring functioning only, and thus will only minimally overlap, if at all, with SUMMIT's components. Control participants will not participate in a MI session. Participants will download the app and be shown how to use the My Pain Diary app and trained how to complete the outcome surveys
16289891|NCT04746820|Experimental|Experimental (unconscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
16289892|NCT04746820|Sham Comparator|Control group (healthy, conscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
16289893|NCT04746794|Experimental|Point of Care|In the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider. We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
16289894|NCT04746794|Experimental|Direct Patient Engagement|"In the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an active patient list (i.e., those who have had a visit in the past year). We will contact patients by postal mail and email to provide a link to the online risk screening tool. The patient outreach is not tied to a specific visit and the online screening can be completed at any time. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers."
16289895|NCT04746794|No Intervention|Stakeholder Interviews and Surveys|Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and multiple follow-ups. We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews). Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning. The midpoint and final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.
16289896|NCT04746781|Active Comparator|Risk notification/education arm|We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk
16289897|NCT04746781|Experimental|Mobile 360° Video intervention arm|After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
16289898|NCT04746781|Experimental|Motivation and Problem Solving (MAPS) arm|After risk notification and education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals. Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.
16290058|NCT04745598||Intra-oral Camera group|Patients diagnosed with periodontal disease stage I/II/III
16289899|NCT04746768|Experimental|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
16289900|NCT04746755|Experimental|Experimental: Lower back pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced lower back pain; the subjects selection was corroborated by a physiotherapist.
16289901|NCT04746755|Experimental|Experimental: Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the heels of their feet; the subjects selection was corroborated by a physiotherapist.
16289902|NCT04746755|Experimental|Experimental: Knee to Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced Knee to Heel pain; the subjects selection was corroborated by a physiotherapist.
16289903|NCT04746755|Experimental|Experimental: Arch pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the arch of their feet; the subjects selection was corroborated by a physiotherapist.
16289904|NCT04746742|Active Comparator|Tunneled femoral catheter|20 patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
16289905|NCT04746742|Active Comparator|Femoral artery-femoral arteriovenous graft|a straight or loop configuration 28patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
16289906|NCT04746716||Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who had a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
16289907|NCT04746716||No Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who hadn't a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
16289908|NCT04746703|Experimental|MRI before and 6 months after bariatric surgery|"Recruitment of patient with planned bariatric surgery in Louis Mourier Hospital by the nutritionist, during the preoperative day hospitalisation (performed during the multidisciplinary preparation for bariatric surgery) when patients are deemed eligible for bariatric surgery according to HAS (High Authority of Health) criteria.
~Programming of MRI in the month between preoperative visit and surgery. During this exam without injection of contrast agents in the radiology department of Louis Mourier Hospital, additional sequences with specific acquisitions as previously validated in humans will be performed for the study.
~Bariatric surgery will be performed as in usual care in Louis Mourier hospital. The same MRI will be performed in day hospitalization scheduled 6 months after surgery."
16289909|NCT04746690|Active Comparator|Slider neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch on one nerve end and slackness on the other end.
16289910|NCT04746690|Active Comparator|Tensioner neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch of both nerve ends.
16289911|NCT04746690|Active Comparator|Stretching exercises of back extensors, hamstrings and gastrocnemius muscles|Stretching exercises of back extensors, hamstrings and gastrocnemius to relief the pressure on the nerve.
16289912|NCT04746677|Experimental|Complex abdominal aortic aneurysm (AAA)|Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm
16289913|NCT04746677|Experimental|Thoracoabdominal aortic aneurysm (TAAA)|Includes Type I, Type II, and Type III TAAA
16289914|NCT04746677|Experimental|Type B aortic dissection|
16289915|NCT04746664|Other|Nutrition counselling|The intervention will be home-to-home-visit once per week lasting 30 minutes to one hour for one month period. The convenience day and time will be selected in the discussion.
16289916|NCT04746651|Experimental|Guided Self Help|"Four guided self-help booklets were used; Why do I feel so bad? covered formulation/understanding feelings, I can't be bothered doing anything centred on activity scheduling, Why does everything always go wrong? focused on thought-challenging, and How to fix almost everything incorporated problem solving. Linked worksheets were adapted following feedback from Prison Officers."
16289917|NCT04746638|Experimental|Prostate cancer|At least five (5) evaluable subjects with prostate cancer.
16289918|NCT04746638|Experimental|Breast cancer|At least five (5) evaluable subjects breast cancer.
16289919|NCT04746612|Experimental|HH30134|HH30134 administered orally on a continuous once daily(QD), start from 100mg QD.
16289920|NCT04746599|Experimental|Patients with critic limb ischemia|"Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions.
~After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs."
16289921|NCT04746586||Cases|20 patients with adolescent idiopathic scoliosis in a ratio of 5:1 between females and males will be enrolled.
16289922|NCT04746586||Controls|10 healthy controls, of which 5 females and 5 males will be enrolled.
16289923|NCT04746573||Natrox Topical Oxygen Therapy managed by telehealth|Pilot study using topical oxygen managed by telehealth in the home setting.
16289924|NCT04746547|Other|Twice Daily DTG|Twice daily Dolutegravir (50mg) with Rifampicin containing TB treatment
16289925|NCT04746508||Unilateral Flat Foot (UniFF)|Participants with flat foot unilaterally (Only one foot's Calcaneal pitch angle ≤ 20 degree)
16289926|NCT04746508||Bilateral Flat Foot (BiFF)|Participants with flat foot bilaterally (Both feet's Calcaneal pitch angle ≤ 20 degree)
16289927|NCT04746495|Placebo Comparator|Placebo|Participants will be randomized to receive 4 weeks of placebo and then 4 weeks of Eplerenone.
16289928|NCT04746495|Experimental|Eplerenone|Participants will be randomized to receive 4 weeks of Eplerenone and then 4 weeks of Placebo.
16289929|NCT04746482||exposure group|subjects in this group are single visit
16289930|NCT04746469|No Intervention|Control|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
16289931|NCT04746469|Experimental|Intervention|This group will receive standard FIT mailer protocol (as above) PLUS delayed automated phone reminder
16289932|NCT04746456||Menopausal women|Women will complete a series of questionnaires, including the VVAQ
16289933|NCT04746443||STUDENTS|COLLEGE STUDENTS WITH POSITIVE COVID-19 TEST
16289934|NCT04746430|Experimental|Intervention|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
16289935|NCT04746430|No Intervention|Control|Only remote monitoring
16289938|NCT04746391|Experimental|Solacea_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination
~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
16289939|NCT04746391|Experimental|Solacea_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination
~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
16289940|NCT04746391|Experimental|Solacea_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination
~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
16289941|NCT04746391|Experimental|FX800_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination
~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
16289942|NCT04746391|Experimental|FX800_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination
~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
16289943|NCT04746391|Experimental|FX800_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination
~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
16289944|NCT04746378||extracorporeal shockwave lithotripsy|Patients that are included in the study and undergo a shockwave lithotripsy. The pre- and postoperative assessment remains the same across groups
16289945|NCT04746378||uretero(reno)scopy|Patients that are included in the study and undergo a semirigid or flexible uretero(reno)scopy. The pre- and postoperative assessment remains the same across groups
16289946|NCT04746378||percutaneous nephrolithotomy|Patients that are included in the study and undergo a percutaneous nephrolithotomy. The pre- and postoperative assessment remains the same across groups
16289947|NCT04746365|Experimental|ivermectin|ivermectin was given as a total daily dose of 36 mg on days 0, 3, 6. The daily dose was divided into 3 equal doses of 12 mg (2 tablets) every 8 hours
16289948|NCT04746365|Experimental|hydroxychloroquine|hydroxychloroquine was given as 200 mg (one tablet) every 12 hours for 5 days
16289949|NCT04746365|Placebo Comparator|Placebo|Unlabelled standard treatment according to the clinical condition of patients
16289950|NCT04746352|Experimental|BES-SMFR group|Using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. Three standardized programs were used in our study: (1) Tens electricity (first program): 5 min of 50-280 Hz frequency and a pulse duration of 50 µs. (b) Endorphin electricity (second program): 5 min of 1-10 Hz frequency and a pulse duration of 200 µs. (c) Spasmolysis electricity (third program): 5 min of 1-2 Hz frequency and a pulse duration of 300 µs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
16289951|NCT04746352|Active Comparator|BES group|"A standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use.
~Patients were required to participate in intensive training regarding myofascial release techniques. (I) Pressing: press directly on a specific MTrP with gentle, slow pressures (2kg/cm2) using a flat palpation, the pressure was sustained until the participant perceived the pain decreased and taut band released, and then gradually increased to previous level of MTrPs tension and maintained until a reduction of pain again. The process was usually 3 to 5 repetitions for 90 sec. (II) Stretching: stretch in parallel to the direction of the myofascial to facilitate elongation of a contracted muscle. (III) Strumming: stroking and strumming the affected muscles region with the fingertips to aid in MTrPs tension release, the initial pressure was small and increased gradually until the patients adapted."
16289952|NCT04746339|Active Comparator|Apixaban Group|
16289953|NCT04746339|Placebo Comparator|Placebo Group|
16289954|NCT04746326|Other|Conservative treatment|Conservative treatment stopping oral intake, intravenous antibiotic therapy.
16289955|NCT04746326|Other|Operative treatment|Operative procedure Right hemicolectomy Wedge resection of cecum Diverticulectomy + appendectomy Diverticulectomy Appendectomy + drainage
16289956|NCT04746313||Patients with systemic sclerosis|The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization
16289957|NCT04746313||Healthy subjects|Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex
16289958|NCT04746300||Group 1: no sequencing|Participants in this group, for which DNA sequencing could not be reported due to a variety of (quality/technical) reasons, will be treated with standard of care therapy. This group is therefore comparable to patients treated outside the Radboudumc.
16289959|NCT04746300||Group 2: no druggable aberration|Participants in this group received a DNA sequencing report identifying no biomarkers to which a logical treatment option can be connected. These participants will also receive standard of care therapy.
16290027|NCT04745832|Experimental|Rituximab plus chemotherapy|Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles
16289960|NCT04746300||Group 3: allocated to personalized treatment|Participants in this group received a DNA sequencing report which identified presence of a biomarker allowing the participant to be treated with a personalized therapy. This therapy could range from immunotherapy, or PARP inhibitors, to other medication.
16289961|NCT04746287|Experimental|Part A|Single dose administration
16289962|NCT04746287|Experimental|Part B|Multiple dose administration (food Effect)
16289963|NCT04746287|Experimental|Part C|Multiple dose administration
16289964|NCT04746287|Placebo Comparator|Placebo|Matching placebo
16289965|NCT04746274|Experimental|Online large-group one-session multicomponent positive psychological intervention|
16289966|NCT04746274|Active Comparator|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|
16289967|NCT04746274|No Intervention|Waitlist Control Group|
16289968|NCT04746261|Experimental|ASSIP plus treatment as usual|ASSIP according to manual. Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
16289969|NCT04746261|Active Comparator|Treatment as usual|Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
16289970|NCT04746248|No Intervention|Baseline|The baseline arm includes participants from before the implementation of the outpatient regime. All participants are induced according to the standard inpatient protocol.
16289971|NCT04746248|Active Comparator|Women choosing to stay at the hospital|Include women who choose to stay at the hospital after implementing an outpatient alternative.
16289972|NCT04746248|Experimental|Women choosing to go home|Include women who choose the outpatient regime.
16289973|NCT04746235|Experimental|Treatment (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO daily on days 1-5 and venetoclax PO daily on days 1-28 of the first cycle and on days 1-21 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16289974|NCT04746222|Experimental|Treatment|Single dose of 30 oral capsules containing FMT from a stool bank
16289975|NCT04746222|Placebo Comparator|Placebo|Single dose of 30 oral placebo capsules
16289976|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Myeloablative HCT|Patients who are MRD Negative by Flow cytometry but are MRD Positive by High Throughput Sequencing, will receive a myeloablative conditioning regimen which includes total body irradiation (TBI) followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
16289977|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCT|Patients who are MRD Negative by Flow cytometry and are MRD Negative by High Throughput Sequencing, will receive a reduced intensity conditioning regimen followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
16289978|NCT04746196||45 ankylosing spondylitis patients.|Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
16289979|NCT04746196||35 controls|Healthy controls
16289980|NCT04746183|Experimental|CST-2 EIDD-2801|"EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.
~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
16289981|NCT04746183|No Intervention|CST-2 Control|Phase 1b only (standard of care)
16289982|NCT04746183|Placebo Comparator|CST-2 Placebo|Phase II placebo blinded controlled
16289983|NCT04746183|Experimental|CST-3A Nitazoxanide|Phase Ia Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur
16289984|NCT04746183|Experimental|CST-5 VIR-7832|Single doses of VIR-7832 will be administered by intravenous (IV) infusion. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated.
16289985|NCT04746183|Active Comparator|CST-5 VIR-7831|Phase II: 500 mg dose of VIR-7831 will be given by IV infusion.
16289986|NCT04746183|Placebo Comparator|CST-5 Placebo|Phase I and II placebo blinded controlled
16289987|NCT04746183|Experimental|CST3B Nitazoxanide|
16289988|NCT04746183|No Intervention|CST3B Control|Standard of care
16289989|NCT04746170|Experimental|Multiparous|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
16289990|NCT04746170|No Intervention|Multiparous Control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
16289991|NCT04746170|Experimental|Primipar|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
16289992|NCT04746170|No Intervention|Primiparous control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
16289993|NCT04746157|Experimental|Intervention group|Patients will have a directly contact with the lead nurse by telephone during the study. The referent nurse will provide support and will promote engagement of patient to adequate secondary prevention measures. In addition, she will provide education based on stroke risk and identified vascular risk factors by Stroke Riskometer.
16289994|NCT04746157|No Intervention|Usual care|Usual care
16289995|NCT04746131|Experimental|IMM0306|IMM0306 Dose escalation: 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, 0.8mg/kg,1.2mg/kg and 1.6mg/kg through intravenous administration weekly up to 52 weeks.
16289996|NCT04746118|No Intervention|CONTROL|During routine clinical visits the patients will receive a written standard general guidelines for diet and physical activity.
16290028|NCT04745806|Experimental|ActiGraft|Whole blood clot (WBC) gel
16289997|NCT04746118|Experimental|DIET CHANGE|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive a written general guidelines for exercising without supervision.
16289998|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision.
16289999|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY + INTEGRATIVE PRACTICES|"In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision and submitted to orientated mind-fullness, auriculotherapy and laying on of hands approaches that belong to health integrative practices."
16290000|NCT04746105|Experimental|TS-142|Period in which subjects received TS-142 10 mg or The night when subjects received TS-142
16290001|NCT04746105|Experimental|Placebo|Period in which subjects received placebo or The night when subjects received matched placebo
16290002|NCT04746079|Experimental|Positive Imagery Therapy|"Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy below:
~Relax and close your eyes. Take deep breaths in through your nose and out through your mouth as you listen to the sound of my voice. (Three second pause.) I want you to picture yourself lying on a towel on a soft sandy beach. (Three second pause.) You can see a palm trees swaying in the wind beneath a bright blue sky with a few white puffy clouds. (Three second pause.) You can feel the sand between your toes, the warm sunlight on your skin and a cool breeze. (Three second pause) You can smell coconut lotion in the breeze. (Three second pause.) You can hear the sound of waves gently crashing on the beach and seagulls crying in the distance. **End of vignette**"
16290003|NCT04746079|No Intervention|Control|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds with no positive imagery therapy.
16290004|NCT04746053|Other|patient with a mutation in the HNF1B gene|Patient with a mutation in the HNF1B gene and which are followed in the reference centers
16290005|NCT04746040|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16290006|NCT04746040|Active Comparator|Reference Product|ADVAIR DISKUS 250/50
16290007|NCT04746001||Infection|
16290008|NCT04746001||Tumours|
16290009|NCT04745988|Experimental|Lenvatinib Plus Pembrolizumab|One cycle is 21 days, with Lenvatinib plus Pembrolizumab repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
16290010|NCT04745975|Experimental|Personalized treatment guided by Mini-PDX|The tumor tissue is used for drug sensitivity test by Mini-PDX, and acquiring the genetic information by RNA-sequence. Patients with mTNBC will receive personalized treatment guided by the experimental results of mini-PDX and RNA sequencing.
16290011|NCT04745975|Active Comparator|Treatment of Physician's Choice (TPC)|TPC will be administered per standard of care. Patients randomized to TPC will receive chemotherapy, including but not limited to the following agents: nab-paclitaxel, eribulin, vinorelbine, gemcitabine, capecitabine.
16290012|NCT04745962||Procedural group|
16290013|NCT04745949|Experimental|Treatment (brentuximab vedotin, nivolumab, R-CHP)|Patient will receive an immune lead-in of 2 cycles of Brentuximab vedotin and Nivolumab (A-O) (cycles 1 and 2), which has an appropriate futility rules in place to close early if efficacy targets are not met. At cycle 3 and 4, patients will receive A-O with R-CHP. Patients who will have achieved complete response (CR) at PET/CT before cycle 5 will receive 2 more cycles of A-O-R-CHP (cycle 5 and 6) and A-O only for cycle 7 and 8. If these patients still present CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. In case of stable disease or progressive disease at PET/CT after cycle 4, the patient will be taken off the trial. Patients who present further response but no CR, at PET/CT before cycle 5 will receive 4 more cycles A-O-R-CHP (cycles 5-8). If they reach CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. All patients will receive a total of 8 cycles of A-O. The cycle duration is 21 days.
16290014|NCT04745936|Experimental|C-curve group (group C)|In group C, stylet curvature is made similar to the natural curvature of endotracheal tube.
16290015|NCT04745936|Active Comparator|Hockey stick curve group (group H)|In group H, stylet curvature is made similar to hockey stick shape.
16290016|NCT04745923||Patients with chronic kidney disease|Having been diagnosed with chronic kidney disease
16290017|NCT04745923||Healthy individuals|Healthy individuals without chronic disease
16290018|NCT04745910|Experimental|Treatment (pegloticase)|Patients receive pegloticase IV over 120 minutes. Patients whose serum uric acid does not drop below 6 mg/dL within 24 hours receive a second dose of pegloticase IV over 120 minutes on day 2. Patients whose serum uric acid does not drop below 6 mg/dL after two doses of pegloticase receive standard of care rasburicase IV QD for 5 days.
16290021|NCT04745884|Experimental|Monitoring|Imaging guided by monitoring results
16290022|NCT04745871|Experimental|Intervention|All patients with prostate cancer undergo PSMA PET/CT as part of the trial in addition to standard methods (abdo-pelvic MRI and a bone scan).
16290023|NCT04745858|Experimental|Bowen's Technique|Sequence of short gentle moves are applied over Hamstrings.Skin slack is taken to lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are be given for 4 weeks. The treatment time for each session is 20 minutes.
16290024|NCT04745858|Active Comparator|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
16290025|NCT04745845|Experimental|Noradrenalin|treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
16290026|NCT04745832|Experimental|Rituximab plus Zandelisib|Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
16290029|NCT04745793||Thyroids|The aim is to identify and preserve the parathyroid glands during the total or partial removal of the thyroid. Repeating of the procedure for each lobe
16290030|NCT04745793||Parathyroids|The aim is to selectively remove the pathological parathyroid gland(s). Repeating of the procedure for each removed gland
16290031|NCT04745780|Experimental|Study Arm|Treated with a formulation containing Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months.
16290032|NCT04745780|Placebo Comparator|Placebo Arm|Treated with Placebo - Two-times daily on an empty stomach, for 6 months.
16290033|NCT04745767|Experimental|Group 1: A1(T1), B(T2), C(T2 Fed)|Participants will be randomly placed into 6 sequences within Group 1. All participants in Group 1 will receive TAK-994 as Treatment A1 (T1 Formulation) and Treatment B (T2 Formulation) under fasted conditions and Treatment C (T2 Formulation) under fed conditions at different times within three periods.
16290034|NCT04745767|Experimental|Group 2: A2(T1), D(T3), E(T3 Fed)|Participants will be randomly placed into 6 sequences within Group 2. All participants in Group 2 will receive TAK-994 as Treatment A2 (T1 Formulation) and Treatment D (T3 Formulation) under fasted conditions and Treatment E (T3 Formulation) under fed conditions at different times within three periods.
16290035|NCT04745767|Experimental|Group 3: A3(T1), F(T4), G(T4 Fed), H(T5)|Participants will be randomly placed into 6 sequences within Group 3. Participants in Group 3 will receive TAK-994 as Treatment A3 (T1 Formulation), Treatment F (T4 Formulation), and Treatment F (T5 Formulation) under fasted conditions and Treatment G (T4 Formulation) under fed conditions at different times within 4 periods.
16290036|NCT04745754|Experimental|Intervention Condition|The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are trained in survivorship and then embedded within an oncology practice to care for low-risk, early stage breast and colorectal cancer survivors who will be transitioned at 6-12 months post-treatment for comprehensive survivorship care.
16290037|NCT04745754|No Intervention|Control Condition|Usual care for breast and colorectal cancer survivors (oncology-led model).
16290038|NCT04745741||IB-positive group|Patients with level IB metastasis and histologically confirmed positive by biopsy.
16290039|NCT04745728|Active Comparator|cyclophosphamide and prednisone|"Prednisone will be given at 1mg/kg/d p.o. and will be tapered after 2 months and discontinued over a 6-12 month period.
~Cyclophosphamide will be given at 1-2mg/kg/d p.o. with a target accumulated dose of 12g.
~Azathioprine or mycophenolate mofetil are optional which could be given for a short period of time (<6 months）after discontinuation of cyclophosphamide if patients do not remit at 6 month."
16290040|NCT04745728|Active Comparator|Rituximab|"Rituximab 1000mg I.V. on Day1 and at 6 month. After 6 months, in patients with response but without complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be given on the 15th day after each Rituximab infusion if CD19+ B cell count>5/ul on the 15th day.
~Calcineurin inhibitors (CNI) are optional but should be tapered after 6 months and discontinued after 9 months."
16290041|NCT04745702|Other|Low-Calorie Control Group|The control group will receive for 2 calorie-restricted balanced meals per day, consisting of a portion of meat, a portion of vegetables, a portion of medium to high GI carbohydrates and prepared with refined corn oil. The control meals will be devoid of any whole legumes and will contain minimal amounts of spices. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
16290042|NCT04745702|Active Comparator|Low-Calorie Treatment Group|The treatment group will receive for 2 calorie-restricted (isocaloric with control group) meals per day containing 100 g cooked whole legumes (amounting to a total of 200 g cooked legumes, approximately 1 cup of cooked legumes)and/or certain meat analogues (textured vegetable [soy] proteins), and/or a portion of vegetables, low GI, wholegrain carbohydrates for their starch sources (rice/noodles/pasta), added spices (dried spice powder) at dietary and culinary acceptable doses and blended vegetable oil. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
16290043|NCT04745689|Experimental|AZD2811 + Durvalumab|"Induction:
~Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin & Etoposide)
~Maintenance:
~AZD2811 + Durvalumab"
16290044|NCT04745676|Experimental|Experimental|The SICG program consists of the Serious Illness Conversation Guide as well as training and system-level support for physicians to conduct ACP conversations.
16290045|NCT04745663|Experimental|Povidone-Iodine 0.3 %|A tampon is soaked in diluted PI 0.3% and placed on the inside of the lower eyelid of one eye, where it will release iodine molecules for 20 minutes before being removed.
16290046|NCT04745663|Active Comparator|Povidone-Iodine 5 %|Eye drops of 5% PI is the standard disinfection before eye surgery. The drops will be dripped in one eye and allowed to work for 2 minutes.
16290047|NCT04745650||Proton RT|
16290048|NCT04745650||Intensity Modulated Radiation Therapy (IMRT)|
16290049|NCT04745624||manual compression cohort|Manual compression cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via manual compression
16290050|NCT04745624||VASCADE cohort|VASCADE cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via VASCADE device closure
16290051|NCT04745611||COVID-19 non-ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
16290052|NCT04745611||COVID-19 ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
16290053|NCT04745611||COVID-19 non-ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
16290054|NCT04745611||COVID-19 ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
16290059|NCT04745572|Experimental|High Carbohydrate Diet|Enrollment in State of Slim (SOS) weight loss program with high carbohydrate diet plan.
16290060|NCT04745572|Experimental|Reduced Carbohydrate Diet|Enrollment in State of Slim (SOS) weight loss program with reduced carbohydrate diet plan.
16290061|NCT04745559|Experimental|Treatment|Pneumococcal conjugate vaccine (PCV13) .5 ml will be administered intramuscularly three times: 7 days (range 4 to 21 days) before apheresis collection and on day +30 (range +21 to +37) and day +90 (range +75 to +115) after CAR T cell infusion.
16290062|NCT04745546|Experimental|WeFlow-JAAA Stent Graft System|Participants will be treated with WeFlow-JAAA Stent Graft System
16290063|NCT04745533||SARS-CoV2 contacts|Subjects considered close contacts of COVID-19 patients according to the definition of the Ministry of Health in the health area of Cáceres.
16290064|NCT04745520|Experimental|Rib fixation (medical devices)|Surgery and pain medication. The pain of patients will be treated with rib fixation and pain medication.
16290065|NCT04745520|Active Comparator|Pain medication (comparator treatment)|Pain medication only.
16290066|NCT04745507||Arm 1 / C1|This cohort (C1) consists of 180 patients who receive IEHT in the recruiting sites, fulfil inclusion criteria and gave informed consent regarding their study participation.
16290067|NCT04745507||Arm 2 / C2|"This cohort (C2) consist of 180 patients receiving standard inpatient care (TAU) from the IEHT delivering hospital who fulfil inclusion criteria, are identified through a propensity score (PS) function as optimal control user or rather a PS match and gave informed consent regarding their study participation"
16290068|NCT04745507||Arm 3|360 close relatives or informal caregivers living in the same household of the participating patients who gave informed consent regarding their study participation. Thereby, one relative of each patients who is participating in the trial will be assessed (C1 = 180, C2 = 180).
16290069|NCT04745507||Arm 4:|Staff members of participating study cites as well as local and political stakeholders engaged with IEHT who gave informed consent (approximately n = 100 participants overall).
16290070|NCT04745494|Active Comparator|OT administration|All participants will receive a single dose of 24IU OT (40.32µg, Syntocinon) delivered via a nasal spray.
16290071|NCT04745494|Placebo Comparator|Placebo administration|All participants will receive a single dose of a placebo delivered via a nasal spray.
16290072|NCT04745481|Experimental|Trunk stabilization training device|Participants will receive conventional rehabilitation and use trunk stabilization training device 30min each daily, 20 times for 4weeks.
16290073|NCT04745481|Active Comparator|Conventional rehabilitation|Participants will receive conventional rehabilitation 60min daily, 20times for 4weeks.
16290074|NCT04745468|Experimental|Apheresis Group|"20 patients receive 2 apheresis treatments at intervals of 24 ± 12 h (additionally to the standard therapy after bypass surgery). The first treatment starts within 24 h postoperatively. If the CRP concentration increases to at least 30 mg/L 6-18 h after the end of the second treatment, a third treatment is performed.
~For each treatment the 1 - 2.5-fold plasma void is processed. The duration of each treatment is 4-6 h."
16290075|NCT04745468|No Intervention|Control group|17 patients of the control group receive the standard therapy after bypass surgery.
16290076|NCT04745455|Other|Cow's milk based infant formula containing prebiotics, probiotics and postbiotics|
16290077|NCT04745442|Experimental|Best available treatment + Antithrombin|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
16290078|NCT04745442|Active Comparator|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
16290079|NCT04745429|Experimental|Intervention|19 people suffering from psoriasis were performing excersises for 10 weeks
16290080|NCT04745429|No Intervention|Control|19 people suffeing from psoriasis that didn't train the exercises
16290081|NCT04745416||Leukemia and COVID-19|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization and confirmed diagnosis of COVID-19 by RT-PCR test
16290082|NCT04745416||Leukemia|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization without suspicion of COVID-19
16290083|NCT04745403|Experimental|mRNA HBV/TCR T-cells|Escalating regime from 1x10e5 to 5-10x10e6 cells/kg bodyweight (BW) every 2 weeks.
16290084|NCT04745390|Active Comparator|Standard Dose Radiation|Patients in the standard arm will receive a standard dose of 2000cGy in 5 fractions using simple CT planning. IMRT is allowed. Treatment will be every second day excluding weekends and holidays.
16290085|NCT04745390|Experimental|Personalized Dose Selection Radiation|Patients in the experimental arm will receive individually selected prescription dose guided by radiobiological parameters described below, preferably delivered in 5 fractions every other day, excluding weekends and holidays. Volumetric-modulated arc therapy (VMAT) is the preferred planning technique. Typical planning uses 2 arcs, <=10MV and FFF mode where possible as almost all liver treatments are gated). In the event of multiple lesions, multiple isocentres are allowed. Often lateral isocentre shifts are significant and therefore arc ranges should be chosen to minimize collision risk. Treatment will be every second day excluding weekends and holidays.
16290086|NCT04745377||Control Group|Healthy volunteers from hospital personnel vaccinated for covid-19, who sign informed consent for recording of outcomes and monitor of antibody titers in 3 timepoints
16290087|NCT04745377||Cancer patients|Cancer patients with solid tumours, with active disease and/or undergoing active systemic treatment, who will be vaccinated for covid-19
16290088|NCT04745364|Experimental|Session One|Session One participants undergo the 4-week course from 2/21/2021 to 3/15/2021
16290089|NCT04745364|Experimental|Session Two|Session Two participants undergo the 4-week course from 3/22/2021 to 4/12/2021
16290092|NCT04745338|Placebo Comparator|low caloric diet|low caloric diet (1200cal/day)
16290093|NCT04745338|Active Comparator|cryolipolysis|cryolipolysis 3 sessions one session every 6 weeks by 3max cool shaping device
16290167|NCT04744792||Patients|All the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
16290094|NCT04745325|Experimental|Smartphone app - full access|"A smartphone app containing 5 modules: 1) personalized feedback on alcohol use (containing normative feedback by age and sex for those located in the Canada), 2) self-monitoring and goal setting tool, 3) tool to choose a designated driver, 4) blood alcohol content (BAC) calculator, and 5) educational information on alcohol use and its consequences (i.e. fact sheets)."
16290095|NCT04745325|Active Comparator|Smartphone App - education only|"A version of the Smartphone app containing only the module with the educational information on alcohol use and its consequences (i.e. fact sheets)."
16290096|NCT04745312|Active Comparator|Ambient light|Fluorescent ambient lighting
16290097|NCT04745312|Experimental|Ambient light plus task lamp|Fluorescent ambient lighting plus task lamp
16290098|NCT04745299|Experimental|Single cycle administration group|Study drug injections twice in a 26-day interval followed by three times comparator injections every three months.
16290099|NCT04745299|Experimental|Multiple administation group|Study drug injections twice in a 26-day interval followed by repeated three times study drug injections every three months.
16290100|NCT04745299|Placebo Comparator|Control group|Comparator injections twice in a 26-day interval followed by three times comparator injections every three months.
16290101|NCT04745286|Experimental|S-ketamine group|
16290102|NCT04745286|Placebo Comparator|saline group|
16290103|NCT04745273|Active Comparator|Ondansetron|Participants will receive Kemoset 4 mg iv intraoperatively
16290104|NCT04745273|Placebo Comparator|Salin solution|Participants will receive Salin solution 2ml (iv) intraoperatively
16290105|NCT04745260|Experimental|Intranasal Midazolam and Intranasal Fentanyl|Study participants assigned to the combination (experimental) group will receive a weight-based dose of intranasal Fentanyl (50mcg/mL concentration at 2mcg/kg up to 100mcg) followed by intranasal Midazolam (5mg/mL concentration at 0.2mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
16290106|NCT04745260|Active Comparator|Intranasal Midazolam|Study participants assigned to the control (active comparator) group will receive only intranasal Midazolam (5mg/mL concentration at 0.3mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
16290107|NCT04745247|Experimental|RSS|Repetitive somatosensory stimulation (RSS)
16290108|NCT04745247|Placebo Comparator|Sham RSS|Sham Repetitive somatosensory stimulation (RSS)
16290109|NCT04745234|Experimental|Mogamulizumab|
16290110|NCT04745208|No Intervention|standard discharge education|The control group will receive only the standard discharge education.
16290111|NCT04745208|Experimental|standard discharge education+Simulation based education|The intervention group will receive standard discharge education and then simulation based education will be performed
16290112|NCT04745195||Complement-mediated thrombotic microangiopathy|
16290113|NCT04745195||Thrombotic microangiopathty with normal complement regulation|
16290114|NCT04745182|Experimental|MASTERY|For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and will contain space to write a specific physical activity goal and to track physical activity (e.g., through step counter data) over the subsequent week. At the in-person visit #2, interventionists will explain PP exercise 1 and MI session 1 to the participants. Calls will last ~30 minutes. Participants will then independently complete PP exercises and MI-based goals and review them at phone sessions over 12 weeks. PP and MI components will be delivered stepwise within sessions (rather than intertwined) based on our experience, participant feedback, and pilot work.
16290116|NCT04745156|Experimental|RNS System Implantation|This is a device feasibility study, therefore participants will only be enrolled into the investigational arm and will receive the RNS System Implantation.
16290117|NCT04745143|Experimental|NMDAE|An NMDA enhancer
16290118|NCT04745143|Placebo Comparator|Placebo|Placebo
16290119|NCT04745130|Experimental|Intervention arm 1|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
16290120|NCT04745130|Experimental|Intervention arm 2|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with or without cetuximab 500mg/m2 q2w
16290121|NCT04745117||Women with suspected breast cancer|"All women referred under the diagnosis suspected breast cancer will be asked to fill out the questionnaire READHY."
16290122|NCT04745104|Experimental|SHR-1707 Dose level 1|SHR-1707 or placebo is administered intravenous to young healthy subjects
16290123|NCT04745104|Experimental|SHR-1707 Dose level 2|SHR-1707 or placebo is administered intravenous to young healthy subjects
16290124|NCT04745104|Experimental|SHR-1707 Dose level 3|SHR-1707 or placebo is administered intravenous to young healthy subjects
16290125|NCT04745104|Experimental|SHR-1707 Dose level 4|SHR-1707 or placebo is administered intravenous to young healthy subjects
16290126|NCT04745104|Experimental|SHR-1707 Dose level 5|SHR-1707 or placebo is administered intravenous to young healthy subjects
16290127|NCT04745104|Experimental|SHR-1707 Dose level 3 (Elderly subjects)|SHR-1707 or placebo is administered intravenous to Elderly subjects
16290128|NCT04745078|Active Comparator|Carboxy30|carboxy30
16290129|NCT04745078|Active Comparator|Carboxy60|carboxy60
16290130|NCT04745065|Experimental|Connect2BWell Condition|The Connect2BWell program delivers feedback on SUD risk, 3 brief online intervention sessions over 3 months, and text messages for 6 months. Sessions and text messages are tailored to the patient's most problematic drug based on the ASSIST; stage of change for quitting or reducing use of that drug; and stage of change for seeking treatment, if indicated. Online sessions are followed by a dashboard-guided telehealth session with a nurse care manager. The dashboard summarizes the patient's ASSIST risk scores and stage of change data; presents patients' responses to key questions in the online session; and provides tools for collaborating with the patient to select action steps matched to risk level and stage and stage of change for seeking treatment, if indicated. The program provides a patient portal with activities, resources, and tools for tracking progress on action steps.
16290168|NCT04744792||Spouses|Spouses of the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
16290169|NCT04744779|No Intervention|Observation|Observation only.
16350352|NCT04325997|Experimental|Video laryngoscope with mouth opener|
16290131|NCT04745065|No Intervention|Comparison Condition|Patients assigned to the Comparison Condition will receive a brief SBIRT session delivered via telehealth by a member of their clinic care team. The session will include the clinic's standard scripted feedback matched to level of risk for alcohol use and for other drug use; encouragement to quit; and referral to specialty treatment, if indicated.
16290132|NCT04745052||Patients with acute ischemic stroke|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
16290133|NCT04745039|Experimental|Endopatch System|Participants will be treated with Endopatch System
16290136|NCT04745013|Experimental|PRIORITY|Patients randomized to the hybrid exercise intervention (PRIORITY) will receive a personalized exercise prescription generated by the EXPERT tool which will then be person-tailored by the physiotherapist during one-on-one physical activity consultation. Over a period of one year, patients will participate in 18 supervised center-based exercise sessions in adjunct to a remotely monitored and guided home-based exercise intervention.
16290137|NCT04745013|Placebo Comparator|Usual care|The usual care group will receive from the physiotherapist a personalized written exercise prescription that includes an individually tailored recommendation on frequency, intensity, type, time and volume of exercise. This exercise prescription will be generated by means of the EXPERT tool. No counselling or guidance on objective measures of physical activity by means of wearables or platform will be provided.
16290138|NCT04745000||Pulmonary Hypertension Participants|Children with Primary Pediatric Pulmonary Arterial Hypertension
16290139|NCT04745000||Control Participants|Children with a healthy heart and lungs
16290140|NCT04744987||Hypovolemic hyponatremia|Patients with any cause of hypovolemic hyponatremia were included.
16290141|NCT04744987||Euvolemic hyponatremia|Only patients with euvolemic hyponatremia secondary to Syndrome of inappropriate antidiuresis were included.
16290142|NCT04744974|Experimental|Mediterranean diet|Participants will be given dietician counseling on a Mediterranean diet
16290143|NCT04744974|Experimental|DASH diet|Participants will be given dietician counseling on a DASH diet
16290144|NCT04744961||Surgical site infections|
16290145|NCT04744961||Normal would healing|
16290146|NCT04744948|Placebo Comparator|low caloric diet|low caloric diet 1200cal/day
16290147|NCT04744948|Experimental|treadmill|treadmill aerobic exercise training
16290148|NCT04744935|Active Comparator|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
16290149|NCT04744935|Active Comparator|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
16290150|NCT04744922|Experimental|Auraptene and Naringenin Arm|One capsule a day for 9 months
16290151|NCT04744922|Placebo Comparator|Control Arm|One capsule a day for 9 months
16290152|NCT04744909|Experimental|Percutaneous tracheotomy using a new device|
16290153|NCT04744896|Experimental|cryolipolysis|3max cool shaping device is administered 3 times for each patient, one session every 6 weeks, each session is 40 minutes.
16290154|NCT04744896|Experimental|treadmill|aerobic training in form of high intensity interval training, three times per week for 3 weeks by treadmill(jkexer focus 8020A) each session is for 20 minutes.
16290155|NCT04744896|Active Comparator|treadmill+cryolipolysis|aerobic training 3 times per week and cryolipolysis once every 6 weeks
16290156|NCT04744883|Experimental|SMT plus placebo/naloxone|Participants are randomly assigned to an 8 week SMT treatment group conducted by certified physical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
16290157|NCT04744883|Experimental|MT plus placebo/naloxone|Participants are randomly assigned to an 8 week MT treatment group conducted by certified clinical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
16290158|NCT04744857|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
16290159|NCT04744844|Experimental|DNA-amplification selection|In the experimental arm, all blastocysts will undergo routine morphological assessment, with the 3 top-scoring blastocysts undergoing blastocoel fluid biopsy (BF-biopsy) and whole-genomic amplification. A single blastocyst with no DNA amplification will be selected for transfer in a frozen embryo transfer cycle.
16290160|NCT04744844|Active Comparator|Morfological-score selection|In the active comparator arm, all blastocysts will undergo routine morphological assessment. The (single) top-scoring blastocyst will be selected for transfer in a frozen embryo transfer cycle.
16290161|NCT04744831|Experimental|T-DXd 5.4 mg/kg Q3W|Participants will be randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).
16290162|NCT04744831|Experimental|T-DXd 6.4 mg/kg Q3W|Participants will be randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
16290163|NCT04744818|Active Comparator|Immediate iron treatment|Iron and multivitamin syrup
16290164|NCT04744818|Placebo Comparator|Delayed iron treatment|Multivitamin syrup
16290165|NCT04744805||mask wear|
16290166|NCT04744805||dry eye|
16290170|NCT04744779|Experimental|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
16290171|NCT04744766|Active Comparator|Hadfield technique group|central/mammary duct excision is done by the ordinary method described by Hadfield
16290172|NCT04744766|Active Comparator|Al Masad technique group|same procedure with de-epithelization of the upper pararaeolar area
16290173|NCT04744753|Active Comparator|study group|. This group involved 75 patients with history of fertilization failure in which oocytes were activated by calcium ionophores
16290174|NCT04744753|No Intervention|control group|This group involved 75 patients with history of fertilization failure in which oocytes were not activated by calcium ionophores
16290175|NCT04744740||PTSD+Suicidal Ideation|US Military Veterans diagnosed with PTSD and identified via the REACH VET or local high-risk list as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
16290176|NCT04744740||PTSD-Suicidal Ideation|US Military Veterans diagnosed with PTSD not identified as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
16290177|NCT04744727|Active Comparator|paracetamol group|Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
16290178|NCT04744727|Active Comparator|pethidine group|Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
16290179|NCT04744714||GDM group|questionnaire survey and clinical follow-up
16290180|NCT04744714||non-GDM group|questionnaire survey and clinical follow-up
16290181|NCT04744688||48 cytoreductive surgery with HIPEC patients|48 patients with peritoneal metastases from colorectal cancer undergoing cytoreductive surgery with HIPEC (cytoreductive surgery with HIPEC patients)
16290182|NCT04744688||48 minimally invasive patients|48 rectal cancer patients undergoing minimally invasive rectal cancer resection
16290183|NCT04744675|Experimental|Treatment|"The intervention group will receive:
~Suprascapular nerve block - 3 mL of 0.5% Bupivacaine and 1 mL of 40 mg/mL Kenalog
~Median nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog
~Ulnar nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog"
16290184|NCT04744675|Placebo Comparator|Placebo|"Placebo
~The placebo group will receive:
~Suprascapular nerve injection - 4 mL of normal saline
~Median nerve injection - 4 mL of normal saline
~Ulnar nerve injection - 4 mL of normal saline"
16290185|NCT04744662|Experimental|Treatment Group A|ONL1204 Ophthalmic solution (dose A) administered by intravitreal injection
16290186|NCT04744662|Experimental|Treatment Group B|ONL1204 Ophthalmic solution (dose B) administered by intravitreal injection
16290187|NCT04744662|Sham Comparator|Treatment Group C|sham injection without penetrating the eye
16290188|NCT04744649|Active Comparator|XELOX or SOX|XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.
16290189|NCT04744649|Experimental|JS001+XELOX or SOX|XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.
16290190|NCT04744636|Other|Healthy volunteers aged of 18-30 years|
16290191|NCT04744636|Other|Healthy volunteers aged of 50-59 years|
16290192|NCT04744636|Other|Healthy volunteers aged of 60-70 years|
16290193|NCT04744636|Other|Type 2 diabetic patients aged of 50-70 years|
16290194|NCT04744623|Experimental|effect of large dose corticosteroids with intra-lestional injection in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I)
16290195|NCT04744623|Experimental|effect of of (MMF), dapsone and cortisone in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
16290196|NCT04744610|Other|4-hour delayed radiographs|The follow-up radiographs was taken 4 h after the HSG operation.
16290197|NCT04744597|Experimental|Real execution group|The real execution group will perform the acute intervention by the actual performance of the Fitt's law task.
16290198|NCT04744597|Experimental|Motor imagery group|The motor imagery group will perform the acute intervention by simulating (mental process) the Fitt's law task.
16290199|NCT04744597|Active Comparator|Control group|The control group will perform skip counting.
16290200|NCT04744584||Patients with medication reconciliation|Patient with medication reconciliation during 1st hospitalization
16290201|NCT04744584||Patients without medication reconciliation|Patient without medication reconciliation (MR) at 1st hospitalization but with retrospective MR at the next one (3 to 6 months after)
16290202|NCT04744571|Experimental|DCB group|Patients treated with Drug-Coated Balloon Angioplasty after revascularization of Chronic Total Occlusions
16290203|NCT04744571|Active Comparator|DES group|Patients treated with Drug eluting stents Angioplasty after revascularization of Chronic Total Occlusions
16290204|NCT04744558|Experimental|Ketogenic|Low carb high fat ketogenic diet
16290205|NCT04744558|Active Comparator|Non-ketogenic|Low carb high fat non-ketogenic diet
16290206|NCT04744545|Experimental|Meru Health Program plus adjunctive curcumin (MHP-CUR)|Meru Health Program (12 week program) with participants taking 2 turmeric supplements (1500mg/day) curcumin.
16290207|NCT04744545|Active Comparator|Meru Health Program (MHP-ONLY)|Meru Health Program (12 week program)
16290410|NCT04743076|Active Comparator|Control group|Standard medical treatment alone
16290208|NCT04744532|Experimental|Drug: Bosutinib|"3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose lelvels [100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. The dose will be escalated by 1 dose level at a time; no skipping will be allowed.
~Dose escalation and MTD will be determined by the safety assessment committee comprising oncologist, hematologist, ALS Expert based on the incidence of DLT in 4 weeks of treatment among 3 subjects enrolled (6 subjects if additionaly enrolled) in each dose level."
16290209|NCT04744506|Experimental|TAD ARM|
16290210|NCT04744493|Experimental|treatment arm of Exablate 4000 as a single arm|Only one arm of treatment by Exablate 4000 was established.
16290211|NCT04744480|Experimental|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
16290212|NCT04744480|No Intervention|The routine induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group，all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.
16290213|NCT04744467|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
16290214|NCT04744428|Experimental|Autism Parent Navigators Intervention|Autism Parent Navigators Intervention is a manualized, in-home, peer support model for parents with a young child recently diagnosed with ASD.
16290215|NCT04744428|Active Comparator|Peer mentoring|Peer mentors will offer an equivalent number of in-home or telephone visits for families, providing non-manualized peer support.
16290216|NCT04744402|Experimental|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
16290217|NCT04744402|Active Comparator|Microfracture surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.
16290218|NCT04744389|Experimental|Hypothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
16290219|NCT04744389|Experimental|Normothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
16290220|NCT04744376||Major GIS Surgery|"The cohort includes all the patients who undergone major gastrointestinal (GIS) surgery.
~Major GIS surgery includes:
~Gastric surgery
~Duodenal surgery
~Pancreatic surgery
~Hepatobiliary surgery
~Colonic surgery
~Rectal surgery"
16290221|NCT04744363|Experimental|AVT04 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
16290222|NCT04744363|Active Comparator|US Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
16290223|NCT04744363|Active Comparator|EU Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
16290224|NCT04744350|Active Comparator|Surgical|Surgical treatment using a minimal invasive surgical method. At our hospital we perform a percutaneous sacroiliac osteosynthesis using cannulated, perforated and fenestrated screws. This procedure is preferably performed in our hybrid operation theatre, which allows for correct placement using an intraoperative CT-scan.
16290225|NCT04744350|Active Comparator|Conservative|Patients will receive individually tailored physiotherapy and analgesics if necessary.
16290226|NCT04744337|Other|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliance for skeletal class II, Angle's class II division 2 malocclusion.
16290227|NCT04744324|Experimental|Self-supporting Care Group|Self-supporting Care in home
16290228|NCT04744324|Active Comparator|Control group|Home Health Education
16290229|NCT04744298|Experimental|TheraPPP Pathway|"The investigators will perform an effectiveness-implementation hybrid study design (type 1) to evaluate the effectiveness and implementation of the TheraPPP pathway.
~All mechanically ventilated patients admitted to the ICU will enter the pathway. To evaluate effectiveness the investigators will collect patient data for approximately 27 months. To assess acceptability of the pathway the investigators will conduct a survey and focus groups to clinicians who used the Pathway."
16290230|NCT04744285|Active Comparator|Condition 1 (normal cigarettes)|Participants receive regular package cigarettes for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection.
16290231|NCT04744285|Experimental|Condition II (cigarettes with neutral message)|"Participants receive cigarettes with neutral message Nothing about this product's color or name means that it will protect a smoker from the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection."
16290232|NCT04744285|Experimental|Condition III (cigarettes with compensation message)|"Participants receive cigarettes with compensation message This product has a ventilated filter. Filter vents increase how deeply a smoker inhales without them knowing, which can increase the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
16290233|NCT04744285|Experimental|Condition IV cigarettes with blocking message|"Participants receive cigarettes with blocking message This product has a ventilated filter. Be sure not to block the vent holes with your fingers or lips, which can increase the health risks of smoking for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
16290234|NCT04744272|Active Comparator|Intervention|Participants randomised to the intervention arm will be provided with access to the digital web-based application (app) myAsthma.
16290235|NCT04744272|No Intervention|Control|Participants randomised to the control arm will continue with standard care processes
16290236|NCT04744259|Experimental|Behavioural activation|The treatment is designed to be delivered to individuals alongside a carer who provides regular support to them. It is a structured, time limited, manualised psychological therapy, developed to treat those with an intellectual disability and depressive symptoms.
16290237|NCT04744259|No Intervention|Treatment as usual|This will include the existing treatments available in NHS and social care for adults with intellectual disability with depression, including anti-depressants, mood stabilizers, and any available psychological interventions. Additionally, for all those in the study, we will provide their General Practitioner with a summary of the NICE guidelines on treatment of depression for adults with intellectual disabilities.
16290238|NCT04744246|Active Comparator|Without Load|5 kilometer walk with no load carried
16290239|NCT04744246|Experimental|With Load|5 kilometer walk with load
16290240|NCT04744233|Active Comparator|Freshly squeezed orange juice (FS)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juice assayed was freshly squeezed (FS). Six subjects consumed FS-orange juice.
16290241|NCT04744233|Active Comparator|Commercially available low pasteurized orange juice (LP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was commercially available low pasteurized juice (LP). All participants consumed the LP orange juices.
16290242|NCT04744233|Active Comparator|High-pressure processed orange juice(HPP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was high-pressure processed (HPP). All participants consumed the HPP orange juices.
16290243|NCT04744233|Active Comparator|Pulsed electric fields treated orange juice (PEF)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was those treated with pulsed electric fields (PEF). Six participants consumed the PEF-orange juice.
16290244|NCT04744220|Experimental|Yoga Training Group|"Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session.
~During the program, the perceived fatigue intensity of the patients will be questioned with the Modified Borg Scale.
~Yoga Session
~1-4 weeks and duration
~Breathing Exercises 5 min
~Instant Relaxation Technique 2 min
~Warm-up Exercises 10 min
~Quick Relaxation Technique 3 min
~Asanas (Posture Exercises) 15 min
~Deep Relaxation Technique 3 min
~4-8 weeks and duration
~Breathing Exercises 5 min
~Instant Relaxation Technique 2 min
~Warm-up Exercises 10 min
~Quick Relaxation Technique 3 min
~Asanas (Posture Exercises) 15 min
~Alternative Breathing Exercises 10 min
~Deep Relaxation Technique 3 min"
16290245|NCT04744220|No Intervention|Control group|"Training: The exercise program will include respiration exercises that they can do at home.
~Before the exercise program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters and tests used in the evaluation. Respiratory control, breathing exercises, relaxation techniques and the reasons, importance and effects of exercise training in the treatment program will be explained.
~Breathing Exercises (10 min) Pursed-lip breathing training, Chest breathing exercise (10 repetitions), Diaphragmatic breathing exercise (10 repetitions), Bilateral basal expansion breathing exercises (10 repetitions) Warm-up Period Stretching and flexibility exercises (5 minutes) Strengthening exercises with theraband (15-20 minutes) Exercises to strengthen lower extremity and upper extremity muscles Cooling Period Stretching and flexibility exercises (5 minutes)"
16290246|NCT04744207|Experimental|GS-248|GS-248, capsule, 120 mg, once daily for 4 weeks
16290247|NCT04744207|Placebo Comparator|Placebo|placebo, capsule, once daily for 4 weeks
16290248|NCT04744194|Active Comparator|Nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
16290249|NCT04744194|Experimental|Single leg bridge exercise program|The single leg bridge is performed with the participant lying on the ground in supine with one heel on a box that is approximately 60cm in height and the knee in approximately 20 degrees of flexion. The participant then crosses their arms across their chest and pushes down through the heel to lift their hips off the ground so that their hips extend into a position of zero degrees flexion. The participant then allows their hips/buttocks to slowly lower to the ground.
16290250|NCT04744181||cases|patients who fulfill the inclusion criteria
16290251|NCT04744181||controls|Patients who underwent cardiac surgery in 2019 and 2018
16290252|NCT04744168|Experimental|Acupuncture|In the experimental arm, pregnant women at term will benefit one or two acupuncture sessions with five points : 4GI, 6RP, 34VB,36E,3F. The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both.
16290253|NCT04744168|Placebo Comparator|Placebo acupuncture|"In the placebo arm, pregnant women will benefit one or two acupuncture sessions with one point which is located outside the acupuncture meridian.
~The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both."
16290254|NCT04744155|Experimental|Multi-Level Intervention|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral.Those randomized to MLI will be offered immediate, ED-based contraception (i.e., oral pill, transdermal patch, vaginal ring, injection, subdermal implant) in addition to receive a warm referral (provider helping to schedule follow-up appointment) to follow-up on selected method (or to initiate in clinic, if preferred)
16290255|NCT04744155|Active Comparator|Enhanced Standard of Care|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral. eSOC participants may obtain contraception only at the referral.
16290256|NCT04744142|No Intervention|Placebo|Received 10% protein in nutrition + placebo supplement
16290257|NCT04744142|Experimental|Ketone|Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day
16290258|NCT04744142|Experimental|High protein|Received 30% protein in nutrition + placebo supplement
16290259|NCT04744142|Experimental|High protein + ketone|Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day
16290260|NCT04744129|Active Comparator|NN414|To investigate the role of NN414 compared with placebo in migraine patients.
16290261|NCT04744129|Placebo Comparator|Saline|To investigate the role of NN414 compared with placebo in migraine patients.
16290262|NCT04744116|Active Comparator|Arm 1 (ruxolitinib)|Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
16290263|NCT04744116|Experimental|Arm 2 (ruxolitinib, lower dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
16290264|NCT04744116|Experimental|Arm 3 (ruxolitinib, higher dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
16290265|NCT04744103|Experimental|TCA peal|Patients will have their actinic cheilitis treated with a TCA peal.
16290266|NCT04744090|Experimental|Roflumilast add-on|Eligible patients will take 500 Mcg of roflumilast once daily (up to 28 days) plus standard of care.
16290267|NCT04744090|Placebo Comparator|Placebo control|Eligible patients will take placebo plus standard of care.
16290268|NCT04744077|Sham Comparator|Control|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
16290269|NCT04744077|Experimental|Student|Student Co-PI will manage this Instagram account created for the study. Although the student is a Kinesiology student and works within the health field, she will not disclose this information on the account. Instead, she will present herself as a general college student. By withholding her major and career aspirations, we hope to get unbiased feedback on what participants think about the content being presented. The content presented will be identical to study arm #3.
16290270|NCT04744077|Experimental|Scientist|"The PI will manage this Instagram account created for the study. The PI is a certified exercise physiologist and holds a PhD in Rehabilitation Sciences. She will disclose this information on the account. This group is the study's gold standard because it will provide evidence-based content delivered by an exercise scientist."
16290271|NCT04744064|Experimental|Soccer and protein supplementation|Soccer training and post exercise supplementation of protein enriched beverage
16290272|NCT04744064|Experimental|Soccer and carbohydrate supplementation|Soccer training and post exercise supplementation of carbohydrate enriched beverage
16290273|NCT04744064|No Intervention|Control group|A preliminary control group continueing normal lifestyle
16290274|NCT04744051|Active Comparator|50 million cell infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
16290275|NCT04744051|Active Comparator|150 million cell infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
16290276|NCT04744051|Active Comparator|300 million cell infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
16290277|NCT04744051|Placebo Comparator|Placebo|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
16290278|NCT04744038|Experimental|Investigational Device|Participants will then be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device. Participants will use their own mask with the investigational device for the duration of this study.
16290279|NCT04744025|Experimental|Microfluidics|Half of participants eggs will be injected with sperm processed using a microfluidics chamber.
16290280|NCT04744025|Active Comparator|Density gradient centrifugation|Half of participants eggs will be injected with sperm processed using a density gradient centrifugation (the standard method).
16290281|NCT04744012||unique group|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.
~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
16290282|NCT04743999|Experimental|Quality of life evaluation|This prospective arm will consist of evaluating quality of life outcomes in women in women with advanced endometrial cancer undergoing adjuvant concurrent chemotherapy with carbo/Taxol and radiation therapy. Assessments will occur following surgery (baseline), 3, 6, 12, and 24 months.
16290283|NCT04743986|Experimental|Platelet Rich Plasma (PRP)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. Injection was 3-5ml at the site of tendon pathology with the remainder of the PRP preparation infiltrated into the subacromial space. A leukocyte-poor preparation was used from a pre-packaged kit (RegenLab, Lausanne, Switzerland). The samples were centrifuged at 1500g for 5 mins to yield approx 5.5ml of 80% platelets at 1.6x concentration. The supernatant was then resuspended by inverting the tube several times and was drawn into a separate 5-ml syringe for subacromial injection.
16290340|NCT04743531|Experimental|Intervention|Families living in rural Colorado will participate in the HEROs intervention in Fall 2019.
16290284|NCT04743986|Active Comparator|Corticosteroid (CS)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. The blood sample was kept for a similar time delay for centrifugation prior to injection, and was then discarded. 1ml of 40-mg/ml triamcinolone was suspended in 2ml of 0.5% bupivicaine. Injection was performed through a lateral subacromial approach after needle fenestration of the supraspinatus tendon under ultrasound visualization. CS was infiltrated into the subacromial bursa and not the tendon itself.
16290285|NCT04743973|Experimental|Practicing Physicians|Practicing physicians at Mayo Clinic caring for patients during the COVID 19 pandemic will receive the Muse S™ Headband system, and will be asked to utilize it at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
16290286|NCT04743960|Experimental|Nighttime cycled parenteral feeds followed by daytime cycled parenteral feeds|Patients will follow nighttime feeding regimen for one week, and then advance their feeds (approximately 12 hours earlier) to daytime feeding regimen for one week.
16290287|NCT04743947||Patients with kidney failure receiving dialysis|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in dialysis patients (hemodialysis or peritoneal dialysis).
16290288|NCT04743947||Kidney transplant patients|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in kidney transplant patients.
16290289|NCT04743947||age-matched controls in non-dialysis, non-kidney transplant patients|Historical cohort of aged matched non-dialysis and non-kidney transplanted patients who received a SARS-CoV-2 vaccination.
16290290|NCT04743934|Experimental|Flibanserin + ADT|Flibanserin at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
16290291|NCT04743934|Placebo Comparator|Placebo + ADT|Placebo at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
16290293|NCT04743908|No Intervention|Social Network Strategy (SNS Condition)|"This will occur towards the end of the study visit when CEC staff describe the SNS, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. CECs will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared."
16290294|NCT04743908|Experimental|Social Network Strategy + Messaging|"This will occur towards the end of the study visit when CEC staff describe the SNS, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. CECs will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared. Finally, community developed COVID-19 public health messages will be shared in the participant's preferred language."
16290295|NCT04743895|Active Comparator|Stainless Steel Wire Cerclage|Sternotomy closure using Stainless Steel Wire Cerclage
16290296|NCT04743895|Active Comparator|FiberTape Cerclage|Sternotomy closure using FiberTape
16290297|NCT04743882||A|
16290298|NCT04743882||B|
16290299|NCT04743882||C|
16290300|NCT04743869|Active Comparator|KYPHON® ActivOs™10 Bone Cement with hydroxyapatite|As a reference device KYPHON® ActivOs™10 Bone Cement with hydroxyapatite (Medtronic) for treatment of vertebral compression fractures will be used. It is a polymethylmethacrylate (PMMA) bone cement containing hydroxyapatite (HA) for use in the treatment of patients with vertebral compression fractures (VCFs) who are undergoing minimally invasive surgery with KYPHON® Balloon Kyphoplasty. This bone substitute has already been approved and is in use in the patients at the age of 50 or older.
16290301|NCT04743869|Experimental|KyphOs FS™|The test device KyphOs FS™ will be used in patients at the age of 50 and older in order to prove its superiority over the currently used PMMA bone cement.
16290302|NCT04743856|Active Comparator|PAT (Physical activity monitor)|Participants will receive a physical activity tracker and encouragement to increase physical activity.
16290303|NCT04743856|Experimental|ActiveGOALSv2|Participants will receive the ActiveGOALS online program with an integrated activity tracker.
16290304|NCT04743830|Experimental|Treatment Group|Neurodevelopmental Treatment (Bobath) + Scapular Training Group
16290305|NCT04743830|Active Comparator|Control Group|Neurodevelopmental Treatment (Bobath) Group
16290306|NCT04743817|Experimental|OtoSet - Ear Cleaning Sytem|
16290307|NCT04743804|Experimental|Ravulizumab|
16290308|NCT04743804|Placebo Comparator|Placebo|
16290309|NCT04743791|Active Comparator|Dupilumab|Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
16290310|NCT04743791|Placebo Comparator|Placebo|Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
16290311|NCT04743778|Experimental|Virtual Diabetes Self-Management Education and Support|Participants randomized into the virtual empowerment-based DSME/S group will receive one hour of DSME/S delivered by a Certified Diabetes Care and Education Specialist (CDCES) per week for 10 weeks delivered via the Zoom for Health at U-M service may be used for Protected Health Information (PHI, regulated by HIPAA). To ensure treatment fidelity, three DSME/S sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
16290341|NCT04743531|Experimental|Staggered Intervention|Families in the staggered intervention arm will serve as controls for the first intervention arm during Fall 2019. Families the staggered intervention arm will then participate in the HEROs intervention in Spring 2020.
16290342|NCT04743518|Active Comparator|anti-TNF|
16290312|NCT04743778|Active Comparator|Control Group|Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
16290313|NCT04743765|Experimental|Accelerated medical clearance and surgery|Accelerated medical clearance and targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
16290314|NCT04743765|No Intervention|Standard surgical care|Hip fracture repair and surgical care according to treating institution guidelines.
16290315|NCT04743752||Group OSA+NSCLC|According to the baseline sleep monitor results, participants will be divided into Group OSA+NSCLC if apnea hypopnea index(AHI) no less than 15.
16290316|NCT04743752||Group NSCLC|According to the baseline sleep monitor results, participants will be divided into Group NSCLC if apnea hypopnea index(AHI) less than 15.
16290317|NCT04743739|Active Comparator|Rituximab monotherapy|Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.
16290318|NCT04743739|Experimental|Rituximab combined with cyclosporine|"Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count.
~cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period."
16290319|NCT04743726||Endoscopy|Chinese volunteers who are scheduling for gastro-colonoscopy
16290320|NCT04743700|Experimental|Piezocision on Experimental Side A|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome to accelerate maxillary canine retraction
16290321|NCT04743700|Experimental|Micro-osteoperforations on Experimental side B|Three MOPs with the help of mini-implant screw driver,mesial and distal to canine(in a vertical line) with the help of minisrew implant driver to accelrate maxillary canine retraction
16290322|NCT04743687|Experimental|Zanuburutinib|Oral Zanuburutinib 160mg twice a day
16290323|NCT04743661|Experimental|Recurrent Medulloblastoma|This arm aims to estimate event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 131I-omburtamab in patients with recurrent medulloblastoma. Patients with recurrent medulloblastoma will undergo surgery if feasible prior to study entry, followed by Induction Chemotherapy with irinotecan, temozolomide, and bevacizumab on study as per the Children's Oncology Group (COG) trial ACNS0821. Following 2 or 4 courses of chemotherapy and if radiographic disease status is stable or improved, patients will receive 2 therapeutic doses of 50 mCi cRIT 131I-omburtamab during Radioimmunotherapy. Following Radioimmunotherapy, patients may resume to Maintenance Chemotherapy with irinotecan, temozolomide, and bevacizumab for up to 12 total courses of chemotherapy or until disease progression, whichever occurs sooner.
16290324|NCT04743661|Experimental|Recurrent Ependymoma|This is a feasibility cohort. The primary objective is to assess feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma and to assess dosimetry. Patients must have progressed after initial surgery, radiation therapy, or other therapies. Patients will undergo surgery (if feasible) prior to study entry with the goal of achieving stable or better disease. Tumor tissue (archived or new) will be tested for B7H3 prior to enrollment. If positive, patients will enroll on Stratum 2 and receive one dosimetry dose (2 mCi) of cRIT 131I-omburtamab with nuclear medicine scintigraphy using SPECT during the Dosimetry Course (14 days in length). Following the Dosimetry Course and within 2 weeks of the dosimetry dose, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi) of cRIT 131I-omburtamab.
16290325|NCT04743648|Experimental|Intervention Group|After determining the experimental and control groups, pre-tests were performed.The program was applied to students in the experimental group.The program was implemented for six weeks based on the theme of innovative thinking.The program developed a training program based on the Tyler Taba model. This model, which is often used in developing educational programs, includes all the necessary steps to teach and accept a new concept. In the ITDP training program, an interactive educational content has been created in which knowledge will be transformed into behavior.In the training, subjects were taught in units, workshops were held, seminars were given. Post-tests were applied at the end of the training.
16290326|NCT04743648|No Intervention|Control Group I|Pre-test and post-tests were applied to the non-intervention group
16290327|NCT04743648|No Intervention|Control Group II|Pre-test and post-tests were applied to the non-intervention group
16290328|NCT04743635|Experimental|NC8 treatment|Cellulite can be treated across thighs and buttocks
16290329|NCT04743622|Experimental|Monoprost (preservative-free latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
16290330|NCT04743622|Active Comparator|Xalatan (preserved latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
16290331|NCT04743609||Bronchiolitis|- children under 24 months of age (≤) with First episode of bronchiolitis
16290332|NCT04743609||Acute otitis media|define with Paradise Criteria) or otorrhea
16290333|NCT04743609||Pneumonia|defined by the presence of opacity of parenchymal condensation and/or pleural effusion on chest X-ray associated with fever
16290334|NCT04743596||Sarcoidosis group|Consecutive patients with clinical and radiological (CT scan) suspect of sarcoidosis as assessed by a respiratory physician.
16290335|NCT04743583||Endosonography group|Patients with known or suspected lung cancer with indication to endosonography for diagnosis or staging of intrathoracic lymph nodes according to currently accepted international guidelines
16290336|NCT04743570|Placebo Comparator|Placebo treatment|Placebo consisting of Ringer's lactate in matched volume to active drug is added to 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
16290337|NCT04743570|Active Comparator|Methylnaltrexone treatment|0.15 mg/kg methylnaltrexone will be dissolved in 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
16290338|NCT04743557|Experimental|Cohort 1|Weekly infusions of DYN101 at the starting dose level
16290339|NCT04743544||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
16290343|NCT04743518|Active Comparator|vedolizumab|
16290348|NCT04743492|Experimental|CBT group|cognitive behavioral therapy (CBT)+routine medical care
16290349|NCT04743492|Experimental|exercise therapy group|physiotherapy-exercise therapy+routine medical care
16290350|NCT04743492|Experimental|breathe training group|using biofeedback devices to train breathing speed+routine medical care
16290351|NCT04743492|No Intervention|usual care|accepting only routine medical care
16290352|NCT04743479||New Onset Diabetes|"New Onset Diabetes must meet one of the following criteria:
~Documented diabetes diagnosed within the past 3 years.
~Definite new-onset diabetes based on recent fasting blood glucose (FBG) values ≥126 mg/dl (7.0 mmol/L) or Hemoglobin A1c (HbA1c) ≥ 6.5%. All glycemic parameters must be measured in an outpatient setting."
16290353|NCT04743479||Familial pancreatic cancer|"Familial pancreatic cancer must meet one of the following criteria:
~≥ 2 blood relatives with pancreatic cancer (includes 1st-3rd degree relatives)
~One 1st degree relative with PDAC diagnosed before age 60"
16290354|NCT04743479||Inherited syndromes associated with pancreatic cancer|"Family history includes with inherited syndromes associated with pancreatic cancer ( ≥ 2 blood relative, includes 1st-3rd degree relatives).
~Inherited syndromes must meet one of the following criteria:
~Hereditary pancreatitis
~Familial atypical multiple mole and melanoma syndrome
~Hereditary nonpolyposis colon cancer
~Peutz-Jeghers syndrome
~Hereditary breast and ovarian cancer syndromes"
16290355|NCT04743479||Pancreatic Cystic Neoplasm|Pancreatic Cystic Neoplasm, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), which are defined by endoscopic ultrasound or serial imaging.
16290356|NCT04743479||Chronic pancreatitis|Chronic pancreatitis, defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist.
16290357|NCT04743466||Observational (biobank review)|Patients' records from institutional or national biobanks are reviewed.
16290358|NCT04743453|Experimental|Dapagliflozin|
16290359|NCT04743453|Placebo Comparator|Placebo|
16290360|NCT04743440||Physicians|We will include specialists in anaesthesiology who work at the Anaesthesiology Department, Hillerød hospital, during the trial period. It is an inclusion criterion that they take part in the Anaesthesiology Department's specialist in-house on-call rotation (i.e., attending physician). Each of the included physician participants will be responsible for conducting the airway management in four patient participants; two who have been randomised to the i-gelTM LMA, and two to the Ambu® AuraGainTM LMA, respectively.
16290361|NCT04743427|Experimental|physical therapy inervention|"hot pack
~Three active exercises"
16290362|NCT04743427|Experimental|Body-blade exercises in addition to physical therapy intervention|"Three Body-blade exercises will be performed in random order (Two sets of, 3-minute exercise and 5-minute break, for each exercise )
~hot pack
~Three active exercises"
16290363|NCT04743414|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of itraconazole on Day 4 through Day 8, with a single oral dose of CTP-543 being co-administered on Day 7.
16290364|NCT04743401|Experimental|Tele-exergame arm|COVID-19 patients or PUI (persons under investigation) admitted to the MEDVAMC (n=60), with an anticipated length of stay of at least 3 days will be recruited. Participants will be randomized (n=1:1) to either intervention (IG) or control (CG) groups. Both groups will receive standard of care. IG will additionally receive Tele-Exergame MP therapy. Tele-Exergame sessions will range from 3-10 minutes based on patient ability and completed twice daily. They will complete assessments at baseline and at one-month post-hospital discharge.
16290365|NCT04743401|No Intervention|Convention care or control group|Standard of care only
16290366|NCT04743388||Cohort 1|Approximately 300 volunteers, healthy or with chronic diseases (diabetes mellitus, hypertension, heart disease, CRF, etc.) with no autoimmune disorders.
16290367|NCT04743388||Cohort 2|People with hematological malignancies or solid tumors in various phases of their treatment (under treatment or in remission/ follow-up). This cohort may include patients with smoldering multiple myeloma (n=50), multiple myeloma (n=140), chronic lymphocytic leukemia (with or without hypoglobulinemia) (n=50), lymphoma (n=80), AL amyloidosis (n=30), patients who receive PARP (n=30), CDK4/6 (n=30), or immune checkpoint inhibitors (n=40), and patients under therapy with Androgen Receptor Targeted Agents (n=50).
16290368|NCT04743375|Experimental|Sericin dressing with collagen|Sericin dressing with collagen
16290369|NCT04743375|Active Comparator|Bactigras|Commercial dressing
16290370|NCT04743362||Participants with muco-cutaneous lesions|Participants will have muco-cutaneous lesions for non-invasive evaluation (including normal skin or mucosa and benign lesions) and will be identified by their physicians or fellows during routine clinical care.
16290371|NCT04743349|Experimental|Experimental arm|Steam inhalations
16290372|NCT04743349|No Intervention|Control arm|No intervention
16290373|NCT04743336||Normal weight (<25 kg/m2)|
16290374|NCT04743336||overweight (25-29.9 kg/m2)|
16290375|NCT04743336||obese (≥30 kg/m2)|
16290411|NCT04743063||New users of angiotensin receptor neprilysin inhibitor|
16290412|NCT04743063||New users of angiotensin II receptor blockers|
16290413|NCT04743050|Active Comparator|Control Group|The control group will be a group without EFA supplementation.
16290502|NCT04742517|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort) will receive matching Placebo for 7 consecutive days.
16290376|NCT04743323||Study Participants|"Participants will be recruited whilst hospitalized for an acute episode of pancreatitis. They will be interviewed about their health behaviors including alcohol consumption during the two weeks immediately preceding the onset of pancreatitis. Blood and urine bio-specimens will be collected at this time.
~Following discharge from hospital (5-26 weeks) the same participant will be interviewed again during an asymptomatic control period and blood and urine bio-specimens will be collected. This study will compare the participant's exposure immediately preceding the onset of pancreatitis to that of an asymptomatic control period from the same participant.
~Participants will be followed for 24 months via review of their medical records every 6 months to assess any recurrent disease or progression of disease."
16290377|NCT04743310|Experimental|Tozuleristide with Canvas imaging system|
16290378|NCT04743297|Active Comparator|Propess Vaginal Delivery System|Propess - Prostaglandin E2 Vaginal Delivery System. Slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
16290379|NCT04743297|Active Comparator|Prostin Tablet|Prostaglandin E2 Vaginal Tablet 3 mg dinoprostone
16290380|NCT04743284||tele-assessment|The balance evaluations will be applied by the tele-assessment method.
16290381|NCT04743284||face-to-face assessment|The balance evaluations will be applied by the face-to-face assessment method in a clinical setting
16290382|NCT04743271|Experimental|High-Fat Diet|50% fat, 35% carbohydrate and 15% protein; 33% of each mono, poly and saturated fat
16290383|NCT04743271|Active Comparator|Low-Fat Diet|30% fat, 55% carbohydrate and 15% protein
16290384|NCT04743258|Experimental|EXTRACTION|treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
16290385|NCT04743258|Experimental|DISTALIZATION|treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
16290386|NCT04743245|Experimental|PCI with SSO2 therapy|
16290387|NCT04743245|Active Comparator|anterior AMI patients treated with PCI and stenting within 6 hours|
16290388|NCT04743232|No Intervention|Standard practice|Standard practice concerning advanced care directives; care as usual
16290389|NCT04743232|Experimental|Decision aid implementation|Stepped-wedge implementation of the intervention
16290390|NCT04743219|Active Comparator|Biodentine Group|Biodentine group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin with Biodentine as indirect pulp capping material before placement of a definitive direct composite resin restoration.
16290391|NCT04743219|Experimental|No base Group|The experimental group or No Base group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin without the placement of a bioactive material as a base and restored directly with a definitive direct composite resin restoration.
16290392|NCT04743206|Experimental|PIAPD-Portable Internal Airway Percussion device|There will be an Inpatient Arm and Outpatient Arm using the Smart One® portable home spirometer
16290393|NCT04743206|Active Comparator|SACD-Standard Airway Clearance device|"There will be an Inpatient Arm and Outpatient Arm using the SACD.
~A large majority of patients will be using VEST therapy as their standard of care airway clearance. A few might be using an Intrapulmonary Percussion Device that uses a mechanism different from the device the study will be testing."
16290394|NCT04743193||sevoflurane 8 %|In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
16290395|NCT04743193||sevoflurane 2.5 %|In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
16290396|NCT04743180||LUMINOR© drug eluting balloon|
16290397|NCT04743167|Active Comparator|Surgery|Patients undergoing surgery for endometriosis, after surgery, will receive indications for seeking for a natural pregnancy up to 12 months from the time of randomization
16290398|NCT04743167|Active Comparator|In Vitro Fertilization|Patients included in the IVF arm will undergo three complete cycles of IVF (i.e. three oocytes retrievals regardless of the number of embryo transfers)
16290399|NCT04743154||In-hospital complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions at least 24 hours after STEMI and before hospital discharge.
16290400|NCT04743154||After-discharge complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions after hospital discharge within 4-6 weeks after STEMI.
16290402|NCT04743128|No Intervention|Control group|The control group received written recommendations to exercise three times per week, for a period of 12 weeks but they did not attend the training sessions.
16290403|NCT04743128|Experimental|Exercise group|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
16290404|NCT04743115|Experimental|the Dose Escalation Level|"In the first 3-patient cohort, the dose of BS HH 002.SA will be 0.2 mg/m2/day. Enrollment to the next higher dose cohort will be initiated only if none of the 3 patients exhibits a DLT in the first 28-day cycle. Dose escalation will proceed according to a modified Fibonacci scheme, eg, increments of 100%, 100%, 66%, and 33% and the dose of BS-HH-002.SA will be 0.4, 0.8, 1.3, 1.7 mg/m2/day.
~The dose will be administered subcutaneously once daily on Days 1 through 6 and on Days 10 through 15 of a 28 day cycle."
16290405|NCT04743102|Experimental|Biopsy cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, we add multi-points and full-thickness Biopsy to further improve the accuracy of cCR after neoadjuvant therapy for rectal cancer.
16290406|NCT04743102|Active Comparator|Conventional cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, to study accuracy of cCR after neoadjuvant therapy for rectal cancer.
16290407|NCT04743089|Experimental|Spyglass arm|Patients who underwent IHD/EHD stone removal by ERCP with SpyGlass™ DS Direct Visualization System.
16290408|NCT04743089|Other|PTCS arm (historical cohort)|Patients who underwent IHD/EHD stone removal by PTCS
16290409|NCT04743076|Experimental|Intervention group|Standard medical treatment plus endovascular treatment
16290414|NCT04743050|Experimental|1st Experimental Group|The first experimental group will receive supplementation with pure ALA fraction of EFA esters. 5 ml a day of OmegaRegen Original containing 2.9 g of ALA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
16290415|NCT04743050|Experimental|2nd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen EPA+DHA containing 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
16290416|NCT04743050|Experimental|3rd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen MAMA containing 2.9 g of ALA, 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
16290417|NCT04743037|No Intervention|Standard of Care (SOC)|The 15 attentional control group stroke survivors will receive phone calls over the 12-week intervention checking in with them on how they are doing in their everyday life. They will also receive stroke education materials, but they will not receive the same iSMART intervention as the intervention group.
16290418|NCT04743037|Experimental|iSMART|"The 15 iSMART participants will engage in video conference sessions between the pre and post visits. A health coach will collaboratively work with the participant to practice treatment strategies and set goals in weekly individual sections. In addition, all participants will engage in weekly group sessions with a health coach in order to learn and practice specific self-management skills and strategies in a group context. In addition, iSMART entails using an interactive SMS to provide ongoing support and self-monitoring of behavior change goals. The SMS is programmed to touch participants daily; the SMS system prompts participants to report their daily activities and progress in achieving goals via check-in messages and sends immediate, tailored feedback about their progress. If a participant is making progress toward their goal, the SMS system will suggest a change to the participant's goal between visits."
16290419|NCT04743024||Household|Household carer-child pairs will be included according to age and consent criteria
16290420|NCT04743011|Placebo Comparator|Placebo|Participants will receive inhalation with 5mL 0.9% saline solution (placebo), 4/4h, during the day period (5 doses).
16290421|NCT04743011|Active Comparator|Heparin sodium|Participants will receive inhalation with 5mL 0.9% saline solution + 2,5mg of high molecular weight heparin - enriched heparin, 4/4h, during the day period (5 doses).
16290422|NCT04742998||Patients treated for an oral or oropharyngeal tumor for at least 6 months|Patients treated for an oral or oropharyngeal tumor for at least 6 months
16290423|NCT04742985|Experimental|Green tea combined extracts group A|This group takes Green tea combined extracts (62.5 mg) for 8 weeks.
16290424|NCT04742985|Experimental|Green tea combined extracts group B|This group takes Green tea combined extracts (125 mg) for 8 weeks.
16290425|NCT04742985|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
16290426|NCT04742972|Experimental|SABR|
16290427|NCT04742972|Placebo Comparator|SOC|
16290430|NCT04742946|Experimental|TR Group|Personalized Telerehabilitation program during 8 weeks. One session per day. Web and mobile application
16290431|NCT04742946|Active Comparator|Control Group|Standard of care. Rehabilitation program in their hospital or primary care or a health education program to be carried out at home.
16290432|NCT04742920|Other|MMA embolization group|MMA embolization procedure with Onyx™ in addition to standard (surgical/conservative) management
16290433|NCT04742920|Other|Control group|Standard (surgical/conservative) Management alone
16290434|NCT04742907|Experimental|TU-100 15 g/day|Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
16290435|NCT04742907|Experimental|TU-100 7.5 g/day|Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
16290436|NCT04742907|Placebo Comparator|Placebo|Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).
16290437|NCT04742894|Experimental|Aphasia Group|
16290438|NCT04742894|Experimental|Control Group|
16290439|NCT04742881|Experimental|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
16290440|NCT04742881|Active Comparator|Low pressure + standard instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of standard instruments (5mm and 10mm instruments)
16290441|NCT04742868|Experimental|Arm 1 QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with bone will be used as graft for the surgery.
16290442|NCT04742868|Experimental|Arm 2 HAMSTRING TENDON GRAFT|Hamstring tendon with bone will be used as graft for the surgery
16290443|NCT04742868|Experimental|Arm 3. QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without bone will be used as graft for the surgery.
16290444|NCT04742855||Group A|It will consist of 10 adults and 5 children. They will get the yogurt strains
16290445|NCT04742855||Group B|It will consist of 10 adults and 5 children. They will get the Bifidobacterium strains.
16290446|NCT04742855||Group C|It will consist of 10 adults and 5 children. They will get the placebo.
16290447|NCT04742842|Experimental|Arm1 (COVIGEN 0.8 mg ID or Placebo ID)|Participants will be randomized to receive either COVIGEN (0.8 mg) given by ID (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
16290448|NCT04742842|Experimental|Arm2 (COVIGEN 2.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN (2 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
16290449|NCT04742842|Experimental|Arm3 (COVIGEN 4.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN (4 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart
16290450|NCT04742829|Experimental|GROUP 1|Patients treated with INTRAVIT® tablets
16290451|NCT04742829|No Intervention|GROUP 2|patients who will not take any medical therapy to overlap with the activity described for INTRAVIT® tablets.
16290575|NCT04742010|Placebo Comparator|Placebo|Placebo
16290452|NCT04742816|Other|Iohexol injection|The research pharmacist will prepare the iohexol injection in a 1cc tuberculin syringe, consisting of 0.5cc sterile water for injection (SWFI) and 0.5cc iohexol (Omnipaque 300). The study coordinator/personnel (licensed RN) will inject the iohexol dose into the subcutaneous tissue on the opposite arm used for blood sampling; the time will be recorded. The participant will be monitored for adverse events 30 minutes post iohexol administration at the AVRC. If the participant has not had any adverse event within 30 minutes, they will be asked to leave the AVRC and return within 2 hours and 55 minutes post Iohexol injection for lab collection.
16290453|NCT04742803|Other|Epistamp Needling Treatment Without RF|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Epistamp needling without RF (Radio Frequency)
16290454|NCT04742803|Other|Epistamp Needling Treatment With RF|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Epistamp needling with RF (Radio Frequency)
16290455|NCT04742790|Experimental|Patients|The study will recruit volunteers (1) suffering from disabling post-operative pain for more than two weeks following surgery (thoracotomy, sternotomy and breast cancer surgery), (2) currently being treated for their post-operative pain with an opioid analgesic - along with possible other treatments - and (3) for which the treating physician is about to introduce an additional non-opioid drug for the treatment of their pain (e.g. an antiepileptic or an anti-depressant).
16290456|NCT04742777|Experimental|Rapamycin|Rapamycin 1mg for 8 weeks
16290457|NCT04742764|Active Comparator|Group A|Patients randomized to standard medical therapy.
16290458|NCT04742764|Active Comparator|Group B|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 12 hours.
16290459|NCT04742764|Active Comparator|Group C|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 24 hours.
16290460|NCT04742751|Experimental|Treatment|Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With Metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
16290461|NCT04742738|Experimental|Test group 1 - Stage 1 Low dose-level Cohort|2 doses of GBP510 adjuvanted with Alum (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
16290462|NCT04742738|Placebo Comparator|Placebo group - Stage 1 Low dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16290463|NCT04742738|Experimental|Test group 2 - Stage 1 High dose-level Cohort|2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.
16290464|NCT04742738|Placebo Comparator|Placebo group - Stage 1 High dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16290465|NCT04742738|Experimental|Test group 1 - Stage 2|2 doses of GBP510 adjuvanted with Alum (RBD 10μg/dose), 1 dose each on Days 0 and 28.
16290466|NCT04742738|Experimental|Test group 2 - Stage 2|2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.
16290467|NCT04742738|Placebo Comparator|Placebo group - Stage 2|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
16290468|NCT04742725|Placebo Comparator|Placebo|
16290469|NCT04742725|Experimental|Prothione ™|
16290470|NCT04742699|Experimental|Z-Drug-mono cohort|Patients being treated with Z-drug monotherapy at registration
16290471|NCT04742699|Experimental|SUV-mono cohort|Patients being treated with SUV monotherapy at registration
16290472|NCT04742699|Experimental|SUV-combination cohort|Patients being treated with SUV and BZRA combination therapy at registration
16290473|NCT04742699|Experimental|RMT-combination cohort|Patients being treated with RMT and BZRA combination therapy at registration
16290474|NCT04742686|No Intervention|Usual care|
16290475|NCT04742686|Experimental|Intervention|
16290476|NCT04742673|Placebo Comparator|Placebo|"Participants will flow through the trial in the following manner:
~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent
~Pre-randomization phase: twice daily assessments of mental status
~Randomize delirious patients: IV guanfacine or placebo
~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring
~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2
~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
16290477|NCT04742673|Experimental|IV Guanfacine|"Participants will flow through the trial in the following manner:
~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent
~Pre-randomization phase: twice daily assessments of mental status
~Randomize delirious patients: IV guanfacine or placebo
~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring
~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2
~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
16290478|NCT04742660|Placebo Comparator|group R|Participants are administered a dose of 0.3mg of ramosetron (conventional antiemetics) intravenously followed by continuous infusion of 120mL normal saline at a rate of 10mL/min.
16290479|NCT04742660|Active Comparator|group G|participants are administered a dose of 0.3mg of ramosetron followed by continuous infusion of mixture of 20mL glycyrrhizin and 100mL normal saline (total 120mL) at a rate of 10mL/min.
16290480|NCT04742647|Experimental|Single Cerclage|Standard single cervical cerclage will be placed
16290481|NCT04742647|Experimental|Double Cerclage|Double cerclage placement
16290498|NCT04742530|Active Comparator|Fed Morning Exercise|Exercise will take place in the morning, after having consumed a carbohydrate-containing meal 2 hours prior.
16290499|NCT04742517|Experimental|Single ascending dose of ASP1128|Participants (6 for each cohort) will receive a single dose of ASP1128.
16290500|NCT04742517|Placebo Comparator|Single ascending dose of Placebo|Participants (2 for each cohort) will receive a single dose of matching Placebo.
16290501|NCT04742517|Experimental|Multiple ascending dose of ASP1128|Participants (9 for each cohort) will receive daily doses of ASP1128 for 7 consecutive days.
16290776|NCT04740450|Placebo Comparator|Control side|tapped with wound tape following the same technique
16290482|NCT04742634|Experimental|Phase I Dose Level 1: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.
~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1, 2, 3 of a 28 day cycle."
16290483|NCT04742634|Experimental|Phase I Dose Level 2: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.
~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1-4 of a 28 day cycle."
16290484|NCT04742634|Experimental|Phase II MRD Positive: DEC-C|"35 mg decitabine/100 mg cedazuridine taken by mouth once daily per the schedule determined in the Phase I portion of the study. Cycle 1 Day 1 may take place between Day 42 and Day 100 post-transplant. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation.
~Bone marrow biopsy with MyeloSeq-HD will be obtained on Day 180 post-transplant. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C."
16290485|NCT04742634|Active Comparator|Phase II MRD Negative: Observation Arm|"In phase II, up to 77 patients who do not have MRD positivity on Day 30 post-transplant (i.e., the absence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%) will be placed on the observation arm and treated with standard of care.
~Patients on the observation arm will be followed every 3 months for 2 years and every 6 months for 3 years for progression and survival"
16290486|NCT04742608||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples on the day of surgery following anesthesia but prior to incision and at the first routine blood test following surgery. Patients who undergo remnant ablation after total thyroidectomy with radioactive iodine have an additional blood sample collected. Patients also undergo collection of tissue samples following surgical resection of thyroid nodule or thyroid cancer. Patients' medical records are also reviewed.
16290487|NCT04742595|Experimental|Treatment (SARS-COV-2 specific cytotoxic T cells)|Patients receive SARS-COV-2 specific cytotoxic T lymphocytes IV over 30 minutes on day 1. Treatment may repeat every 14 days at investigators' discretion if patient fails to respond, the infection reoccurs, until the viral load becomes negative or until complete resolution of clinical and radiological signs.
16290488|NCT04742582|Active Comparator|Preterm Infants - fed fermented formula|Feeding infants with fermented formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
16290489|NCT04742582|Placebo Comparator|Preterm Infants - fed standard formula|Feeding infants with standard formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
16290490|NCT04742582|Other|Reference Group: Pre-term Infants - breastfed|The breastfeeding infants were the reference group
16290491|NCT04742569||Cohort 1- Exposed/Early Symptomatic|"The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.
~For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day."
16290492|NCT04742569||CoHort 2- Pfizer or Moderna Vaccine|Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing
16290493|NCT04742556|Experimental|BI 3011441|
16290494|NCT04742543|Experimental|Virtual reality glasses|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure with Virtual reality glasses on
16290495|NCT04742543|No Intervention|No intervention. standard treatment|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure without virtual reality glasses (no intervention)
16290496|NCT04742530|Experimental|Fasted Evening Exercise|Exercise will take place in the evening, following a 7 hour period of fasting.
16290497|NCT04742530|Active Comparator|Fed Evening Exercise|Exercise will take place in the evening, after having consumed a carbohydrate-containing meal 2 hours prior.
16290808|NCT04740151|Active Comparator|STANDARD PEEP|During OLV a PEEP of 5 cmH2O will be applied
16290503|NCT04742504||BENRA Treated Patients|Patients with severe eosinophilic asthma who will be treated with benralizumab (Fasenra®, Astra Zeneca) will be able to participate in a volunteer manner in the study after sing informed consent.
16290504|NCT04742504||Non BENRA TREATED PATIENTSP|patients with controlled severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without oral corticosteroids) but without request of benralizumab (Fasenra®, Astra Zeneca) treatment will be recruited
16290505|NCT04742491|Experimental|Immediate Intervention Arm Descovy in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
16290506|NCT04742491|Experimental|Deferred Intervention Arm Descovy in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
16290507|NCT04742491|Experimental|Immediate Intervention Arm Truvada in Brazil|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
16290508|NCT04742491|Experimental|Deferred Intervention Arm Truvada in Brazil|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
16290509|NCT04742491|Experimental|Immediate Intervention Arm Truvada in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
16290510|NCT04742491|Experimental|Deferred Intervention Arm Truvada in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
16290511|NCT04742478||Eligible subjects who underwent RA prior to PCI (with informed consent taken to join the study)|Informed consent to be obtained either prior to PCI with rotational atherectomy planned or within 48 hours after rotational atherectomy. There will be data collection of history/demographics, laboratory results, symptoms, any serious adverse events recording for this cohort as well as a telephone follow up at 12months post rotational atherectomy.
16290512|NCT04742478||Eligible subjects who underwent RA prior to PCI (without informed consent taken to join the study)|Subjects that were demised or refused to give consent will fall under this cohort. The data collection of this cohort will be done through screening of in-hospital data via available local PCI database/registry.
16290513|NCT04742465|Experimental|Augmented reality|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.
~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.
~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
16290514|NCT04742452|Active Comparator|Superior Capsular Reconstruction|
16290515|NCT04742452|Placebo Comparator|Partial Rotator Cuff Repair|
16290516|NCT04742439|Sham Comparator|Sham stimulation|
16290517|NCT04742439|Experimental|Individualized stimulation|
16290518|NCT04742439|Experimental|2mA stimulation|
16290519|NCT04742439|Experimental|4mA stimulation|
16290520|NCT04742426|Active Comparator|WHO group|minimal setting of personal protective equipment (COVID 19) recommended by WHO
16290521|NCT04742426|Experimental|Super-safe setup|maximal super-safe setup of personal protective equipment
16290522|NCT04742413||A|Patients who are prescribed to switch to lurasidone (lurasidone cohort)
16290523|NCT04742413||B|Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)
16290525|NCT04742387||1|Medical records of subjects enrolled on various studies conducted by HAMB/CCR from 1/1/2005 to 12/1/2020
16290526|NCT04742374|Experimental|Group A|Patients alternating single plasma exchange followed by double filtration plasmapheresis etc.
16290527|NCT04742374|Experimental|Group B|Patients alternating double filtration plasmapheresis followed by single plasma exchange etc.
16290529|NCT04742348|Placebo Comparator|Control, Placebo|Similar looking tablet(s) to active drug will be administered in a single dose to those who are randomly assigned to this group.
16290530|NCT04742348|Experimental|Active Drug, Carbidopa + Levodopa|Single dose of immediate release carbidopa-levodopa (50mg/500mg).
16290531|NCT04742322|Placebo Comparator|Placebo|1x capsule/day - maltodextrin, period of 10 to 14 days
16290532|NCT04742322|Experimental|B Lactis|1x capsule/day - 9x10x10 UFC, period of 10 to 14 days
16290533|NCT04742309|Experimental|Pecs-2|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
16290534|NCT04742309|Active Comparator|Paravertebral|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
16290535|NCT04742296|Active Comparator|Treatment group of low level laser therapy|
16290536|NCT04742296|Placebo Comparator|Sham group of low level laser therapy|
16290809|NCT04740138|Experimental|DBT Skills + Parent Training|
16290537|NCT04742283|Experimental|DE-126 Opthalmic Solution 0.002% QD and Vehicle QD|DE-126 Ophthalmic Solution 0.002% is administered once daily (QD)
16290538|NCT04742283|Active Comparator|Timolol Maleate Opthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution 0.5% is administered twice daily (BID)
16290539|NCT04742270|Experimental|SIMEOX+ respiratory physiotherapy telecare|Use the device for 3 months in addition to usual care
16290540|NCT04742257|Experimental|Active Stimulation|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
16290541|NCT04742257|Sham Comparator|Sham Stimulation|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
16290542|NCT04742244|Placebo Comparator|Placebo|0 mg LVE/capsule, 2capsule/day, 14days
16290543|NCT04742244|Experimental|Lemon Verbena extract|200 mg LVE/capsule, 2capsule/day, 14days
16290544|NCT04742231|Experimental|Cohort 1. Patients with brain lesions in non-motor areas undergoing an awake craniotomy (AC)|5 patient minimum
16290545|NCT04742231|Experimental|Cohort 2. Patients with brain lesions within or proximal to motor areas undergoing an AC|5 patient minimum
16290546|NCT04742218|Experimental|Fasted-Fed|Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)
16290547|NCT04742218|Experimental|Fed-Fasted|Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)
16290548|NCT04742205|Active Comparator|tranexamic acid|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
16290549|NCT04742205|Placebo Comparator|Sodium Chloride|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
16290550|NCT04742179|Experimental|Experimental group|The children belonging to the classes of the school complex undergoing the maintenance intervention.
16290551|NCT04742179|No Intervention|Control group|The children belonging to the classes of the school complex that will not undergo the maintenance intervention.
16290552|NCT04742166|Experimental|Side to side gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively
~At Day 90:
~a blood test for albumin and prealbumin
~a GIQLI questionnaire (quality of life score) to be completed by the patient"
16290553|NCT04742166|Active Comparator|Terminolateral gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively
~At Day 90:
~a blood test for albumin and prealbumin
~a GIQLI questionnaire (quality of life score) to be completed by the patient"
16290554|NCT04742153|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
16290555|NCT04742140|Active Comparator|group I|each patient injected 0.5ml in each TrPs of saline by the same operator
16290556|NCT04742140|Experimental|group II|each patient injected 0.5ml in each TrPs of magnesium sulphate by the same operator
16290557|NCT04742127||Patients with septic arthritis of the native hip|
16290558|NCT04742114|Sham Comparator|the face mask without EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The face mask without the application of EPAP will be used.
16290559|NCT04742114|Experimental|the face mask with EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The application of EPAP (15cmH2O) via face mask will be used.
16290560|NCT04742101|Experimental|S65487 with azacitidine|
16290561|NCT04742088|Experimental|Orthosis group|
16290562|NCT04742075|Active Comparator|Olaparib|Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.
16290563|NCT04742075|Experimental|Olaparib + durvalumab|"Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.
~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity."
16290564|NCT04742075|Experimental|Olaparib + durvalumab + UV1|"Olaparib 300 mg tablets twice daily until disease progression or unacceptable toxicity.
~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity.
~Eight UV1 vaccinations during the first 5 month: Four UV1 vaccinations 300 μg (+ 75 μg of sargramostim) during the first 10 days with a minimum of 2 days apart. From cycle 2-5 subjects will receive one UV1 (+ sargramostim) vaccination every 4th week."
16290565|NCT04742062|Active Comparator|ApTOLL single dose|ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).
16290566|NCT04742062|Placebo Comparator|Placebo single dose|Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).
16290567|NCT04742062|Active Comparator|ApTOLL multiple dose|ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).
16290568|NCT04742062|Placebo Comparator|Placebo multiple dose|Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).
16290569|NCT04742049|Experimental|Telerehabilitation|Telerehabilitation based exercise training will be given to the study group.
16290570|NCT04742049|Experimental|Exercise brochure|Exercise training will be provided by sending a document to the control group
16290571|NCT04742036|Experimental|capivasertib|single-dose and multiple-dose capivasertib as monotherapy (Part A) and then in combination with paclitaxel (Part B)
16290572|NCT04742023|Experimental|Intervention Arm|
16290573|NCT04742023|Placebo Comparator|Control Arm|
16290574|NCT04742010|Experimental|Zoledronic Acid|Active treatment
16290576|NCT04741997|Active Comparator|Surveillance|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will receive adjuvant treatment for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
16290577|NCT04741997|Experimental|Encorafenib and Binimetinib after Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
16290578|NCT04741997|Experimental|Encorafenib and Binimetinib after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
16290579|NCT04741997|Experimental|Nivolumab after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will receive nivolumab for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
16290580|NCT04741984|Experimental|MT-201-GBM monocyte vaccine|pp65 monocyte vaccines (MT-201-GBM) - cohorts of patients will receive increasing doses (dose escalation) of MT-201-GBM followed by a dose expansion cohort at the maximum tolerated dose. Patients will receive a total of 3 intravenous vaccines every 4 weeks after completing standard radiation therapy (XRT) and temozolomide (TMZ) and a single course of dose-intensified TMZ.
16290581|NCT04741971|Experimental|Probiotics group|Will give Probiotics with Vit.D 3
16290582|NCT04741971|Placebo Comparator|Non-probiotics group|Will give Vit. D3 as placebo
16290583|NCT04741958|Experimental|ultra sound guided percutaneous core needle biopsy|60 patients that had radiographic evidence of thoracic mass suspected of malignancy .Twenty masses were in the lung, seventeen lesions were in the pleura, ten masses were in the mediastinum, eleven enlarged palpable lymph nodes, and two masses were in chest wall. The sensitivity, PPV and accuracy for detection of chest tumors in chest wall, mediastinum, lung, and pleura were (100 %) for all, and in LN (88.9, 100 and 90.9 %) respectively. The overall diagnostic performance of sonar guided true cut needle biopsy in diagnosis was 97.78 % sensitivity, 98.18% accuracy, and 100 % PPV
16290584|NCT04741945|Experimental|Metformin|2000 mg/daily metformin for 12 months.
16290585|NCT04741932|No Intervention|Care as usual|
16290586|NCT04741932|Experimental|Intervention|
16290587|NCT04741919|Active Comparator|Superior LPI placement|Each participant will be randomized to receive an LPI placement superiorly in one eye.
16290588|NCT04741919|Active Comparator|Temporal LPI placement|Each participant will be randomized to receive an LPI placement temporally in one eye.
16290589|NCT04741906||Previous tooth extraction|Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high dose antiresorptive treatment who have had previous tooth extraction
16290590|NCT04741906||Previous resection|Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
16290591|NCT04741906||Simultaneously with resection|Cancer patients (breast, prostate or multiple myeloma) with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
16290592|NCT04741893|Experimental|faecally incontinent patients|faecally incontinent patients are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
16290593|NCT04741893|Experimental|Asymptomatic individuals|asymptomatic individuals are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
16290594|NCT04741880|Experimental|Group L (Lidocaine)|Lidocaine bolus 1.5 mg.kg-1 intravenous before the onset of lidocaine infusion Lidocaine 2mg.kg-1.h-1
16290595|NCT04741880|Placebo Comparator|Group S (saline solution)|Lidocaine bolus 0.75 mg.kg-1 intravenous before the onset of saline infusion Saline solution infusion
16290596|NCT04741867|Experimental|receiving health education|
16290597|NCT04741867|Experimental|Level of compliance|
16290598|NCT04741867|Experimental|Coping with stress|
16290599|NCT04741854|Experimental|Investigational Device|Participants will be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device.
16290600|NCT04741841|Placebo Comparator|Placebo|The placebo product is identical to active product in taste and appearance but without probiotic
16290601|NCT04741841|Active Comparator|Treatment high dose|High dose GutMagnific™
16290602|NCT04741841|Active Comparator|Treatment low dose|Low dose GutMagnific™
16290603|NCT04741828|Experimental|Vi-DT Typhoid Conjugate Vaccine|Participants receive 1 dose (0.5ml) Vi-DT Typhoid Conjugate Vaccine, intramuscularly.
16290604|NCT04741815|Experimental|Forced Air Warming Group|There is no intervention in patients before the operation. When he comes out of the operation and comes to the post-anesthesia care unit (PACU), he is warmed by forced air. When the body temperature of the patients reaches 36 ° C, they are transferred to the clinic with a cover and blanket.
16290633|NCT04741620|Active Comparator|Citric acid 457,5microM (pH=3,5)|10mL Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
16290634|NCT04741620|Active Comparator|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5)|10mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
16290635|NCT04741620|Placebo Comparator|Placebo|10mL placebo solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
16290636|NCT04741607|Active Comparator|Control group|Delayed implant placement
16290605|NCT04741815|Experimental|Peripheral Carbon Fiber Warming Group|Gloves and socks developed by the researcher are applied half an hour before the operation. These materials, called environmental warming, have three layers. The first layer in contact with the patient is a thermal inner sheath made of 90% Polyester and 10% Polyamide and is used to maintain body temperature. The second layer consists of carbon fiber warmer and foil. The end of the carbon fiber warmer is USB connected. When the connection is plugged in, the warmer works. The third layer is again made of thermal fabric. A rubber bandage is made to separate the last layer from the external environment and to maintain the patient's body temperature. The USB connection is removed while patients are sent for surgery. After the operation, rewarming is started in the post-anesthesia care unit. When the patient's body temperature reaches 36 ° C, he is transferred to the clinic with a cover and blanket.
16290606|NCT04741815|No Intervention|Control Group|A routine hospital procedure is applied. The patient is not warmed before going to surgery. A cover and blanket are used passively after being taken to the PACU from the operation.
16290608|NCT04741776|Experimental|Resilience Enhancement Skills Training|video-based family therapy
16290609|NCT04741776|Active Comparator|Standard of care|video-based individual therapy
16290610|NCT04741763|Placebo Comparator|Placebo|Maltodextrin Placebo: Experimental is 1:2
16290611|NCT04741763|Experimental|Active|Eye Promise Visual Edge containing 8 mg zeaxanthin & 4 mg lutein Placebo: Experimental is 1:2
16290612|NCT04741750|No Intervention|Usual Care within Community Clinics|Complete blood count, comprehensive metabolic panel, international normalized ratio, HCV RNA, hepatitis B virus (HBV) serologies, point of care HIV test, and point of care liver fibrosis measurement. HCV genotype if required by patient's insurance for prior authorization. Care for opioid use disorder and skin infection is offered. Completion of the initial visit workup is sufficient to initiate a prior authorization request for DAAs from payers and an appointment for MAT follow-up in a community clinic if indicated. Patient coordination; authorization with insurance companies; scheduling appointments, follow-up, and ancillary support services will be conducted by a Patient Navigator. Patients are seen every 2-4 weeks for monitoring and adherence support. HCV treatment regimens are at the discretion of the treating provider in accordance with AASLD/IDSA guidelines and insurance requirements. Twelve weeks after HCV therapy completion, SVR12 HCV RNA and SVR12 CMP tests will be obtained.
16290613|NCT04741750|Experimental|Simplified Care within a Mobile Medical Unit|Simplified Care treatment is the same as for Usual Care with the exception that it is taking place within a mobile medical clinic that is scheduled to deliver treatment in alignment with regular syringe exchange services.
16290614|NCT04741737|Experimental|reSLNB arm|repeat SLNB procedure is performed in when the patient is diagnosed with ipsilateral breast tumor recurrence, who had undergone partial mastectomy and sentinel lymph node biopsy for primary operation.
16290615|NCT04741724|Experimental|transcutaneous electrical diaphragmatic stimulation (TEDS)|"Subjects received daily TEDS (30min/day, 5days/week ) until the end of the weaning trial.
~During TEDS, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was performed by applying biphasic waves at a stimulation frequency of 30 Hz, pulse width of 400 μs. TEDS intensity was gradually increased until visible muscle contraction was observed. Each session lasts for 30 min day."
16290616|NCT04741724|No Intervention|Control group|Subjects in the control group did not received TEDS program. Subjects in the control group received the same pre- and post-measurement as those in TEDS group. The control group received medical treatment as those in TEDS group. The pulmonary function was measured at the beginning and end of the intervention.
16290617|NCT04741711|Experimental|Interventional group|The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava
16290618|NCT04741711|Other|Control group|Usual care (i.e. without ultrasound guidance) will be provided.
16290619|NCT04741698|Active Comparator|Propranolol 2mg IV|"At the time of labor dystocia, patients randomized to the treatment arm of propranolol will receive a one-time administration of IV 2mg propranolol in pre-mixed syringes prepared by the pharmacy.
~The propranolol IV administration recommended in clinical practice guidelines is 1 mg IV over 1 minute. Therefore, total administration time will be 2 minutes."
16290620|NCT04741698|No Intervention|No intervention|At the time of labor dystocia, patients randomized to the placebo arm will not receive any intervention
16290621|NCT04741685||SAP with LGS|Type 1 diabetes adults patients treated with sensor-augmented insulin pump with low glucose predictive suspension function
16290622|NCT04741672|Experimental|Intervention group|Providing guidance and calling after discharge routine procedure.
16290623|NCT04741672|Experimental|Control group|Discharge routine procedure.
16290624|NCT04741659|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their actual low oxygen flow
16290625|NCT04741659|Active Comparator|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe with HFNC of 40 L/min
16290626|NCT04741659|Active Comparator|Helmet CPAP|the patients will be asked to breathe with the Helmet CPAP
16290627|NCT04741659|Active Comparator|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
16290628|NCT04741646|Experimental|Treatment Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
16290629|NCT04741646|Placebo Comparator|Control Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
16290630|NCT04741620|Active Comparator|Capsaicin 10microM|10mL capsaicin 10microM solution 3 times/day during 14 consecutive days (2 weeks).
16290631|NCT04741620|Active Comparator|Piperine 150microM|10mL Piperine 150microM solution 3 times/day during 14 consecutive days (2 weeks).
16290632|NCT04741620|Active Comparator|Cinnamaldehyde 756,6microM + zinc 70microM|10mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
16290639|NCT04741581|Other|Thicken up|Assess the effect of ThickenUp® Gel Express at increasing viscosities (slightly thick, nectar, honey, and pudding) on swallowing function compared to water using VFS (N=100), in patients affected by Oropharyngeal dysphagia (OD).
16290640|NCT04741568|Experimental|Parental Psychoeducational Intervention|A brief (one-day or two half days) psychoeducation workshop will be provided alongside a website with downloadable content will be made available to review and refresh any skills and techniques. The psychoeducational intervention will be delivered by a research fellow and research assistant with a background in psychology and delivered in line with a protocol.
16290641|NCT04741568|No Intervention|Wait List Control|Parents randomised to the control arm will be put on the waiting list (wait-list controls) to receive the group intervention after the active treatment group have completed their final follow-up at 3 months.
16290642|NCT04741542|Experimental|Group A|Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week
16290643|NCT04741542|Experimental|Group B|Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week
16290644|NCT04741542|Experimental|Group C|Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week
16290645|NCT04741542|Experimental|Group D|Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week
16290646|NCT04741529|Experimental|Massed condition|Participant will be asked to use the HMP app for 20 minutes per day in one 20-minute meditation session.
16290647|NCT04741529|Experimental|Spaced condition|Participant will be asked to use the HMP app for 20 minutes per day in two 10-minute meditation sessions.
16290648|NCT04741516|Experimental|Medication arm|
16290649|NCT04741503|Experimental|Breast Cancer Screening Decision Support Tool|-After randomization, participants will complete pre-questionnaires, review the Breast Cancer Screening Decision support tool, and then complete the post-questionnaire.
16290650|NCT04741503|Active Comparator|Standard Breast Cancer Screening Education|-After randomization, participants will complete pre-questionnaires, review the standard breast cancer screening education from the NCI, and then complete the post-questionnaire.
16290651|NCT04741490|Experimental|treatment group|The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles
16290652|NCT04741477|Experimental|Topical CBD Product with low level of THC|Participants will topically apply a high CBD-product that also contains low levels of THC.
16290653|NCT04741477|Placebo Comparator|Placebo topical product|Participants will topically apply a placebo product that does not contain cannabinoids.
16290654|NCT04741438|Experimental|Arm A|"Arm A (Experimental arm).
~Nivolumab 3 mg/kg
~Ipilimumab 1 mg/kg"
16290655|NCT04741438|Active Comparator|Arm B|Arm B (Control arm). Pazopanib 800 mg/day
16290656|NCT04741425|Experimental|REST intervention|There will be one session of online antenatal breastfeeding talk, 5 sessions of daily online postnatal individualized breastfeeding coaching, and 7 weekly postnatal telephone follow-ups.
16290657|NCT04741425|No Intervention|Usual care|"Standard antenatal and postnatal care provided by midwives and lactation consultants in the hospitals through by Zoom or by online self-learning through watching videos and reading pamphlets. Participants can also attend other breastfeeding talks or breastfeeding support groups provided by the non-governmental organizations for maternal care.
~After delivery, mothers will be taught about baby care at bedside. Breastfeeding skills will also be taught and assessed by the midwives and lactation consultants individually or in group-based breastfeeding talk in the postnatal ward.
~Upon discharge, a breastfeeding and postnatal hotline will be provided to all women for advices, and a telephone follow-up will be arranged for all the mothers within 3 to 4 days after delivery by midwives or lactation consultants. The mother-baby dyads will be suggested to follow up in MCHCs for baby growth and breastfeeding support."
16290658|NCT04741412||Hypohidrotic Ectodermal Dysplasia|all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
16290659|NCT04741412||Control|individuals of the same age group, but without HED, including pregnant women
16290660|NCT04741386||Cohort A|Patients with CKD stages 4 and 5
16290661|NCT04741386||Cohort B|Patients on hemodialysis and peritoneal dialysis
16290662|NCT04741386||Cohort C|Kidney Transplant Recipients
16290663|NCT04741386||Cohort D|Controls
16290664|NCT04741373|Placebo Comparator|Group of health education|
16290665|NCT04741373|Active Comparator|Group of health education and rehabilitation exercise|
16290666|NCT04741373|Experimental|Group of health education,exercise and ONS|
16290667|NCT04741360|Experimental|Modified Story Memory Technique|
16290668|NCT04741360|Other|Control|
16290669|NCT04741334||patients not in therapy with anticoagulants or antiplatelets drugs|Patients presenting in ED with mild head trauma and not in therapy with antiplatelets and/or anticoagulants drugs
16290670|NCT04741334||patients in therapy with direct anticoagulant|Patients presenting in ED with mild head trauma and in therapy with direct anticoagulants drugs
16290671|NCT04741334||patients in therapy with oral anticoagulant (dicumarolics)|Patients presenting in ED with mild head trauma and in therapy with oral anticoagulants drugs (dicumarolics)
16290672|NCT04741334||patients in therapy with antiplatelet drugs|Patients presenting in ED with mild head trauma and in therapy with antiplatelet drugs
16290673|NCT04741321||Pre-test group|After translation to Spanish, VQ-6 questionnaire is given to 20 patients to assess understanding by the patient.
16290674|NCT04741321||Test and re-test group|80 patients will be recruited to answer VQ-6 questionnaire and SF-12 questionnaire. After 3-4 weeks, these patients will be re-asked with the same questionnaires.
16290675|NCT04741308|Experimental|CBT group|Patients and primary caregivers randomly assigned to CBT group will receive 10 times of CBT treatment before and after surgery.
16290676|NCT04741308|No Intervention|non-CBT group|"Patients and primary caregivers randomly assigned to non-CBT group will receive four sessions of health education in a month after surgery.
~Each session will last 1 hour, including lectures and Q&A . The content of each session is different, including: diagnosis and treatment of colorectal cancer, postoperative adverse reactions and management of colorectal cancer, nutritional support after colorectal cancer surgery and physical exercise after colorectal cancer surgery."
16290677|NCT04741295|No Intervention|Control Group|Adenomyosis patients in control group have normal luteal progesterone support.
16290715|NCT04740970|Placebo Comparator|Placebo|Participants will receive matching placebo SC injection at Week 0 and then every 2 weeks from Week 2 through Week 22.
16290678|NCT04741295|Experimental|Low molecular weight heparin Group|Adenomyosis patients in Low molecular weight heparin group have Low molecular weight heparin in addition to normal luteal progesterone support.
16290679|NCT04741282|Experimental|pulmonary telerehabilitation plus progressive muscle relaxation training|This group will perform six week pulmonary rehabilitation program and progressive muscle relaxation exercise at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
16290680|NCT04741282|Active Comparator|pulmonary telerehabilitation|This group will perform six week pulmonary rehabilitation program at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
16290681|NCT04741269||Lack of knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion.
~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
16290682|NCT04741269||Full knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. Patients in group 2 don't have any asymmetric full knee flexion.
~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
16290683|NCT04741256|Experimental|Tracheostomy discharge protocol|"All head and neck cancer patients regardless of participation in the study will receive the standard of care: A copy of a tracheostomy education booklet and standardized discharge training for patients and their caregivers by nursing staff during their inpatient stay.
~Research personnel will provide protocol training to the inpatient nurses who are to provide training to caregivers.
~Pre-implementation phase: Eligible patient participants identified & healthcare utilization recorded. Nursing staff participants complete nursing survey to capture volume of tracheostomy-related questions received.
~Protocol-phase: Caregiver participants will complete a survey prior to patient tracheostomy, on day of patient discharge, and one week following discharge
~Post-implementation phase: Nursing staff participants will complete an additional survey similar to the one in the pre-implementation phase. EMR will be reviewed for implementation fidelity."
16290684|NCT04741243|Experimental|Extracorporeal shock wave therapy|was used for 15 minutes in a prone position for both groups (A&B) before the treatment. shock wave were used to heat small areas, and allow for decrease pain, muscle spasm, and provide vasodilatation of the blood vessels supplying the area
16290685|NCT04741243|Experimental|dietary modification|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level.
16290686|NCT04741230|Experimental|Gebauer Lenticule|Gebauer Lenticule implant device
16290687|NCT04741204|Experimental|White women|White women on metformin Extended release 750 mg BID
16290688|NCT04741204|Experimental|Black women|Black women on metformin Extended release 750 mg BID
16290689|NCT04741191|Experimental|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown)
16290690|NCT04741191|Active Comparator|Conventional therapy|Patient education and counseling, In bed activities, Ambulation
16290691|NCT04741178||Patient with Covid-pneumonia|Patient with CT scan of pulmonary infiltrates suggestive of Covid pneumonia
16290692|NCT04741165|Experimental|Experimental: HX008+Bevacizumab|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.
16290693|NCT04741165|Experimental|Experimental: HX008+Lenvatinib|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD).
16290694|NCT04741152||Revealed insulinoma|Cases when the tumor was revealed by the preoperative diagnostics and confirmed after the tumor elimination
16290695|NCT04741152||Hidden Insulioma|Group when the insulinoma haven't been revealed preoperative and intraoperatively and the blind resection was performed.
16290697|NCT04741126|Experimental|Intervention Protocol|Hospital-based manually assisted cough technique for 4 weeks.
16290698|NCT04741113|Experimental|Intervention group -educational module|"The study intervention will include an online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.
~The module will be based on relevant literature and expert opinion. The module will be sent to participants via secured link."
16290699|NCT04741113|No Intervention|Control group|No intervention
16290700|NCT04741087|Active Comparator|AMT-101 (Dose A)|Dose A: AMT-101 Tablet
16290701|NCT04741087|Active Comparator|AMT-101 (Dose B)|Dose B: AMT-101 Tablet
16290702|NCT04741074|Active Comparator|Semaglutide|This arm will receive semaglutide.
16290703|NCT04741074|Placebo Comparator|Placebo|This arm will receive placebo.
16290704|NCT04741061|Active Comparator|Sputnik Light Vaccine|study group (4500 receiving the Sputnik-Light vector vaccine) against the SARS-СoV-2-induced coronavirus infection.
16290705|NCT04741061|Placebo Comparator|Placebo Group|control group (1500 subjects receiving placebo)
16290706|NCT04741048|Experimental|CI624 Slim 20 Electrode|
16290707|NCT04741035|Experimental|Modified sternal precautions|Interventional group (Modified sternal precautions)
16290708|NCT04741035|Active Comparator|Conventional sternal precautions|Control group (Conventional sternal precautions)
16290709|NCT04741022||CAD with OSA|coronary artery disease with Obstructive sleep apnea
16290710|NCT04741022||CAD without OSA|coronary artery disease without Obstructive sleep apnea
16290711|NCT04741009|Experimental|CI632 Slim Modiolar Electrode|
16290712|NCT04740983|Experimental|Heliotherapy|will receive 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values along with olive oil (in-house formulation)
16290713|NCT04740983|No Intervention|Control|only will receive olive oil (in-house formulation)
16290714|NCT04740970|Experimental|JNJ-64304500|Participants will receive JNJ-64304500 dose 1 subcutaneous (SC) injection at Week 0 and then dose 2 SC injection every 2 weeks from Week 2 through Week 22.
16290716|NCT04740957|No Intervention|Observational cohort|"100 patients undergoing elective left colonic or rectal resection with a primary anastomosis will be recruited pre-operatively throughout the study period. This study will not affect or delay the intended treatment for study participants.
~Patients will undergo serial endoscopic examination of the anastomosis post-operatively. Blood, urine, stool, and mucosal biopsies will be serially collected."
16290717|NCT04740957|Experimental|Distal limb feeding cohort|"This interventional arm will demonstrate the safety of re-introducing ileostomy effluent into the downstream (distal) limb of an ileostomy. The preliminary data will enable exploration of the association between microbiome and post-operative function and enable adequate powering of future interventional studies.
~A subgroup of 20 patients undergoing a resection with a covering ileostomy will be recruited to the intervention arm. Complete healing of the colorectal anastomosis will first be confirmed by water-soluble contrast enema 8 weeks post-operatively (this is standard practice). Patients will be taught how to inject the output from the proximal ileostomy limb into the distal limb (this connects to the colon and thus the colorectal anastomosis) daily until the ileostomy closure date."
16290718|NCT04740944|Experimental|Intervention group|the intervention group was subjected to salutogenic approach-based interview consisting of 16 sessions twice a week.
16290719|NCT04740944|No Intervention|Control group|The control group continued their routine activities and was interviewed face-to-face 5 times.
16290720|NCT04740931|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
16290721|NCT04740931|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
16290722|NCT04740918|Active Comparator|Arm A: Trastuzumab Emtansine and Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.
16290723|NCT04740918|Experimental|Arm B: Trastuzumab Emtansine and Atezolizumab|Atezolizumab 1200 mg IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.
16290724|NCT04740905|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
16290725|NCT04740905|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
16290726|NCT04740892|Experimental|Wash and Cream Investigational Product (IP)|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks. Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
16290727|NCT04740879|Experimental|Intervention|"The Intervention condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful immediately after randomization to group."
16290728|NCT04740879|Other|Waitlist Control|"The Waitlist Control condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful approximately 4 months after randomization to group."
16290729|NCT04740866|Active Comparator|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy [IMRT] technique.
16290730|NCT04740866|No Intervention|Observation after radical Cystectomy|observation following radical cystectomy
16290731|NCT04740853|Experimental|Sensory Integration Therapy+Special Education|"The therapy program was prepared and applied according to the Ayres theory and based on the basic principles of sensory integration therapy prepared by Parham depending on the evaluation results. Therapy was applied to the intervention group, with a 45-minute session+15 minutes of family information once a week for eight weeks, in addition to the special education sessions they received twice a week in special education institutions. The sensory integration therapy included sensory diet practices and activities consisting of vestibular, tactile, proprioceptive, auditory and visual stimuli.
~The intervention group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. In the special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied."
16290732|NCT04740853|Active Comparator|Special Education|The control group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. Within the scope of special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied.
16290733|NCT04740840|Experimental|Levamlodipine group|Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
16290734|NCT04740840|Sham Comparator|Amlodipine group|To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
16290737|NCT04740814|Experimental|Certolizumab pegol|Subjects in this arm will receive doses of certolizumab pegol for the treatment of Rheumatoid Arthritis, in accordance with the US label.
16290738|NCT04740801|Other|PVI procedure|Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.
16290739|NCT04740788||Monofocal IOL|Patients already implanted with a monofocal IOL
16290741|NCT04740762|Experimental|Intervention group|The study group were provided with individual counseling program and followed in this study, in addition to the usual care provided by healthcare professionals.
16290742|NCT04740762|No Intervention|Control group|The control group continued to receive the routine care
16290743|NCT04740749|Other|Prospective group|Patients who have to undergone the implant surgery
16290744|NCT04740749|Other|Retrospective group|Patients that have already undergone the implant surgery
16290747|NCT04740723|Experimental|Renal denervation|Renal denervation with the iRF system
16290748|NCT04740710|Active Comparator|Standard Breathing and Attention Training|The standard breathing and attention training (BAT) includes guided instructions on deep breathing and relaxation. Participants will practice standard BAT once a day for 15 minutes for 5 days in a row.
16290749|NCT04740710|Experimental|Focused Breathing and Attention Training|The focused BAT is similar to the standard BAT in most ways but includes extra instructions to help focus and alter breathing patterns. Participants will practice focused BAT once a day for 15 minutes for 5 days in a row.
16290750|NCT04740697|Other|Patient with localized breast cancer.|
16290751|NCT04740671|Experimental|A|HLX04-O
16290752|NCT04740671|Active Comparator|B|ranibizumab
16290753|NCT04740645||NOCDURNA cohort|
16290754|NCT04740645||Lower urinary tract symptoms (LUTS) Cohort|
16290755|NCT04740632||Mothers of children with IgE-mediated food allergy diagnosed by a multidisciplinary team|Mothers of children with IgE-mediated FA diagnosed for at least 6 months who plan to visit a specialized level III center for the management of pediatric FA for the first time
16290756|NCT04740632||Mothers of children with IgE-mediated food allergy diagnosed by a non-multidisciplinary team|Mothers of children with IgE-mediated AA diagnosed for at least 6 months who plan to undergo a follow-up visit at a specialized level III center for the management of FA in pediatric age which they have already been followed for at least 6 months
16290757|NCT04740606||Treatment Group|The patients whose chest CT images show that the pulmonary nodules are highly suspected of malignant and scheduled to be diagnosed by bronchoscopy under the guidance of the Augmented Reality Navigation System.
16290758|NCT04740593|Experimental|Group 1 - High refractive error: Intervention|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the intervention group
16290759|NCT04740593|Other|Group 2 - High refractive error: Control|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the control group
16290760|NCT04740593|Other|Group 3 - Mild or no refractive error|Children with mild or no refractive error (i.e. not exceeding the AAPOS 2003 criteria) at age one
16290761|NCT04740580|Experimental|Glycine plus N-acetylcysteine|Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine
16290762|NCT04740580|Placebo Comparator|Alanine|Alanine is an amino-acid (protein), and not a precursor of glutathione synthesis
16290763|NCT04740567|Experimental|Cognitive Intervention|During hospitalization, enrolled patients assigned to the intervention arm will undergo two 20-minute cognitive training sessions daily, 7 days a week. After the patient is discharged from the hospital, cognitive rehabilitation will be administered once a week for 12-weeks at their place of residence. Goal Management Training will be the foundation for cognitive rehabilitation.
16290764|NCT04740567|No Intervention|Usual Care|Enrolled patients will undergo usual care during hospitalization and post-hospital discharge.
16290765|NCT04740554||Duchenne Muscular Dystrophy group with Deflazacort|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of deflazacort.
16290766|NCT04740554||Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of Prednisone/Predinisolone.
16290767|NCT04740554||Duchenne Muscular Dystrophy group without Corticosteroids therapy|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which don't use of corticosteroids.
16290768|NCT04740554||Control Group Typically Developing|Individuals with typical development age 11 to 18 years which don't use of corticosteroids.
16290769|NCT04740541|Experimental|Threonine Requirement in CD Patients|Males aged 18 - 49 with stable Crohn's disease will be seen for pre-study They will be studied up to 5 times for different levels of threonine intakes.
16290770|NCT04740515|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
16290771|NCT04740515|No Intervention|usual care only|Patients were provided with usual care.
16290772|NCT04740502|Other|Concordant preoperative studies|Patients with concordant neck ultrasound and MIBI scan
16290773|NCT04740502|Other|Unclear preoperative studies|Patients with discordant or negative neck ultrasound and MIBI scan
16290774|NCT04740476|Experimental|STK-001 multiple dose levels|Enrollment of patients after completion of study STK-001-DS-101 if eligible for additional dosing in this extension study. Patients will be administered the same dose level they received in study STK-001-DS-101 and will receive a maximum of 3 doses. One dose will be administered every 4 months.
16290775|NCT04740450|Experimental|study side|receive KT technique described by Gozluklu et al in 2020
16290777|NCT04740424|Experimental|FS222 Q4W|The initial cohorts will enroll sequentially as single participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design. Additional participants will be recruited into the PK/PD expansion cohorts at dose levels deemed safe during dose escalation. Once a tolerated dose has been established participants will be recruited into tumour-specific expansion cohorts.
16290778|NCT04740411|Experimental|Common Elements Toolbox (COMET)|
16290779|NCT04740411|No Intervention|Wait-list control condition|
16290780|NCT04740398|Experimental|Ia stage - CBP-1008 Dose escalation/ Ib stage - CBP-1008 monotherapy|"Ia:Patients will receive CBP-1008 IV infusion every 2 weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
~Ib:Patients will receive CBP-1008 RP2D IV infusion every two weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue."
16290781|NCT04740385||Lung cancer patients|Correct position of double lumen endotracheal tube will be assessed using lung sonography, routine chest auscultation and fiberoptic brochoscopy
16290782|NCT04740359|Active Comparator|Control|Routine training; mat exercises and perturbation training
16290783|NCT04740359|Experimental|Study|Trunk training; Functional training, mat exercises and perturbation training
16290786|NCT04740333||Group A- Normal ICU admission blood glucose level|Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
16290787|NCT04740333||Group B- High ICU admission blood glucose level|Patients with admission blood glucose level higher than 180 mg / dL.
16290788|NCT04740320||Healthy Volunteers|Volunteers asked to register details on a SARS-CoV-2 specific web page UKcovidchallenge.com. They will be contacted with a short webform questionnaire to be performed prior to a follow-up telephone questionnaire or will be asked to complete a telephone questionnaire. If inclusion/exclusion criteria are met, appointment for a screening visit will be scheduled. Screening appointments will be conducted at hVIVO. Written consent for screening will be obtained prior to any history-taking, examination or tests are carried out. Medical history will be requested from GP to assess suitability. Once the SARS-CoV-2 characterization study is approved, potential participants will be given the study specific PIS detailing the full study and experimental procedures. The opportunity to discuss further and ask questions will be available prior to booking a study visit.
16290790|NCT04740294|Experimental|Magnesium Sulfate|The patient will receive a bolus of 50mg/kg MgSO4 over twenty minutes.
16290791|NCT04740294|Placebo Comparator|Placebo|The patient will receive a bolus of Normal Saline over twenty minutes.
16290792|NCT04740281||Medical Doctors at Aarhus University Hospital, Denmark|Medical Doctors from different subspecialties at Aarhus University Hospital, Denmark. Blinded for the purpose of the trial, their footwear will be evaluated by trial responsible personal.
16290793|NCT04740268|Other|Epistamp Needling Treatment Without RF|Non-Randomized treatment for patients without atrophic acne skin conditions using the Epistamp Needling without RF (Radio Frequency)
16290794|NCT04740268|Other|Epistamp Needling Treatment With RF|Non-Randomized treatment for patients with atrophic acne skin conditions using the Epistamp needling without RF (Radio Frequency)
16290795|NCT04740255|Other|Epistamp Needling Treatment Without RF|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Epistamp needling without RF (Radio Frequency)
16290796|NCT04740255|Other|Epistamp Microneedling Treatment With RF|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Epistamp needling with RF (Radio Frequency)
16290797|NCT04740242||Cohort of exposed patients (Group 1)|All patients admitted for decompensated HF and presenting MA at the time of admission
16290798|NCT04740242||Cohort of unexposed patients (Group 2)|All patients admitted for decompensated HF and who do NOT present MA at the time of admission
16290799|NCT04740229|Experimental|Moderate-intensity flow-based Yoga|The intervention will consist of participants engaging in a progressive series of moderate-intensity, flow-based yoga poses, along with breathing and relaxation, for eight weeks. The intervention will be titrated in terms of supervision, with first two weeks being completely supervised, followed by partial supervision for three weeks, and three weeks of unsupervised sessions. The sessions will be ~50 minutes long, 3 times/week. All supervised sessions will be conducted online through Google Meet (GM), which is a live video interaction platform. Videos will be provided to guide unsupervised sessions. Sessions will be led by a certified yoga instructor. An orientation will be provided in the first week, given that the participants will have no or minimal experience with yoga. The intervention will consist of basic sun salutations of hatha yoga sun salutation A, sun salutation B and flow sequences, and breathing exercises, and relaxation.
16290800|NCT04740229|No Intervention|Waitlist control|Participants in this group will not receive the 8-week intervention during the course of the study, and will be asked to engage in their regular activities. They will be asked to not start any new activities during the study period. After they complete the study, they will be provided with the same intervention (live instruction, feedback and supportive videos).
16290801|NCT04740216|Experimental|exercise therapy plus jaw device|exercise therapy plus jaw device
16290802|NCT04740216|Placebo Comparator|exercise therapy|exercise therapy
16290803|NCT04740203|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
16290804|NCT04740190|Experimental|interventional arm|Single fraction, low dose (2Gy) whole brain radiation therapy, followed by combination talazoparib and carboplatin
16290805|NCT04740164|Experimental|Arm I (ERCP with LMA Gastro)|Patients undergo ERCP with LMA Gastro.
16290806|NCT04740164|Active Comparator|Arm II (ERCP with standard nasal cannula)|Patients undergo ERCP with standard nasal cannula.
16290807|NCT04740151|Experimental|BEST PEEP|During OLV an individualized PEEP will be applied i.e. the one corresponding to the lower driving pressure, + 2 cmH2O
16290810|NCT04740112|Placebo Comparator|Control breakfast bar with low dietary fiber without product claims|
16290811|NCT04740112|Experimental|Test breakfast bar with high dietary fiber without product claims|
16290812|NCT04740112|Experimental|Test breakfast bar with high dietary fiber with product claims|
16290813|NCT04740099|Experimental|SOONER Training (Intervention)|Arm receives video training and kit designed by SOONER team.
16290814|NCT04740099|Other|Standard of care training (control)|Participant referred to standard of care (community based Naloxone training)
16290815|NCT04740073||Patients|Persons undergoing total knee arthroplasty
16290816|NCT04740073||Controls|Persons not undergoing total knee arthroplasty who are age and sex-matched to the patient group.
16290817|NCT04740060|Experimental|Augmented Feedback without Virtual Reality(VR)|
16290818|NCT04740060|Experimental|Augmented Feedback with Non-Game based VR|
16290819|NCT04740060|Experimental|Augmented Feedback with Game based VR|
16290820|NCT04740047||Pulmonary Nodule|Pulmonary nodule is suitable for elective bronchoscopy with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease.
16290821|NCT04740034|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
16290822|NCT04740034|Experimental|Dose Expansion|An expansion cohort in subjects with mCRPC will be enrolled after RP2D is established.
16290823|NCT04740021|Experimental|Experimental: LP002+EP|Participants recieve LP002 10 mg/kg intravenous (IV) on day 1 PLUS carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on day 1 PLUS etoposide 100 mg/m^2 IV on days 1, 2 and 3 of each 21-day cycle
16290824|NCT04740008|Experimental|Control message on low nicotine cigarettes|
16290825|NCT04740008|Experimental|Test message on low nicotine cigarettes|
16290826|NCT04739995|Experimental|Low-Dose-Naltrexone (LDN)|The LDN treatment will consist of one 4.5 mg naltrexone tablet (lactose-free) taken daily for 12 months before going to sleep.
16290827|NCT04739995|Placebo Comparator|Placebo|The control group will take the placebo daily (a film-coated tablet, identical to the LDN, filled with a lactose-free excipient), for 12 months, following the same guidelines.
16290828|NCT04739982|Experimental|Treatment|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
16290829|NCT04739982|No Intervention|Treatment as Usual|Participants in control group will continue their treatment as usual.
16290830|NCT04739969|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
16290831|NCT04739969|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
16290832|NCT04739956||Patient: point of care (POC) result not shared|Patients in this phase of the study will not be provided with the POC BhCG result. They will await the laboratory result. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
16290833|NCT04739956||Partner: point of care (POC) result not shared|Partners in this phase of the study will not be informed of the POC BhCG result. They will await the laboratory result to be provided to the patient. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
16290834|NCT04739956||Patient: point of care (POC) result shared|Patients in this phase will be informed of the POC test result, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
16290835|NCT04739956||Partner: point of care (POC) result shared|Partners in this phase will be informed of the POC test result with the patient, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
16290836|NCT04739943|Experimental|Mobile Monitoring|Participants will be asked to use a smartphone or tablet application for remote monitoring or respiratory health. They will be followed over time with surveys as well as chart review to assess effects of adding these mobile monitoring elements to their standard care.
16290837|NCT04739930|Experimental|Bone Marrow Aspiration Group|A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.
16290838|NCT04739930|Sham Comparator|Control|The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation.
16290839|NCT04739917|Experimental|Arm N Vaccine|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
16290840|NCT04739917|Placebo Comparator|Arm N Placebo|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
16290841|NCT04739917|Experimental|Arm S Vaccine|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
16290842|NCT04739917|Placebo Comparator|Arm S Placebo|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
16290843|NCT04739904||Preterm born|Premature born but otherwise healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
16290844|NCT04739904||Full-term control|Full-term born healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
16290845|NCT04739878|Experimental|Ultrasound Airway|Ultrasound Airway for subglottic secretion
16290846|NCT04739865|Experimental|Psilocybin|25mg Psilocybin
16290847|NCT04739852|Active Comparator|Healthy Participants|
16290848|NCT04739852|Active Comparator|Metabolic Syndrome|
16290849|NCT04739852|Active Comparator|Rheumatoid Arthritis|
16290850|NCT04739839||Inception cohort, former pupils in different schools in Western Zealand|1327 former Western Zealand pupils (originally 1389). Aged 14-15 in 1997. This is the first follow up on this cohort.
16290853|NCT04739813|Experimental|Arm 1: Dose Escalation|Venetoclax (PO) 600mg on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine MTD of polatuzumab
16290854|NCT04739813|Experimental|Arm 2: Dose Expansion|Venetoclax (PO) 600mg on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)
16290859|NCT04739774|Experimental|Treatment R|Single dose of CHF6001
16290860|NCT04739774|Experimental|Treatment T|Single dose of CHF6001 administered after repeated doses of oral Itraconazole
16290861|NCT04739761|Experimental|Trastuzumab Deruxtecan|Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
16290862|NCT04739748||Respiratory ICU patient|patient in RICU that developed ventilator-associated pneumonia
16290863|NCT04739735|Experimental|Computer Controlled -Intraligamentary Aaanesthesia (CC-ILA)|"CC-ILA will be administered using the Wand-STA system according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted mandibular teeth.
~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle."
16290864|NCT04739735|Active Comparator|Conventional Injection of Inferior Alveolar Nerve Block|"In the control group, a standard technique for the Inferior Alveolar Nerve Block (IANB) will be used supplemented with long buccal infiltration for the buccal gingiva.
~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed between the two primary molars on the opposite side of the arch, entering the tissues at the level of the occlusal plane or slightly lower until bony resistance is met.
~Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. Two-thirds the needle length should be inserted. The needle is withdrawn, then 0.5 ml as a long buccal infiltration distal to the second primary molar is administered."
16290865|NCT04739722|Experimental|ColonoSight Test|All participants will be evaluated with the Colonosight Test system and a colonoscopy.
16290868|NCT04739696|No Intervention|Caregiver Control|biomarker analysis; questionnaire administration; survey administration; treatment as usual
16290869|NCT04739696|Experimental|Caregiver Intervention|biomarker analysis; questionnaire administration; survey administration; PsychoEducation Paced Respiration and Relaxation (PEPRR), which includes virtual one-on-one psychoeducation and stress management intervention.
16290870|NCT04739696|Experimental|Caregiver Self-Directed|biomarker analysis; questionnaire administration; survey administration; Pep-Pal web-accessible video modules of the psychoeducation and stress management intervention.
16290871|NCT04739683|Active Comparator|Foley bulb|16F latex or silicone Foley catheter inflated with 30-40 cc of sterile water. The catheter will be taped to the inner thigh with gentle traction.
16290872|NCT04739683|Active Comparator|DILAPAN-S®|Synthetic hydrogel cervical dilator consists of the dilating part, the polypropylene handle, and the marker string. The dilating part is manufactured from an anisotropic xerogel of AQUACRYL.
16290873|NCT04739670|Experimental|Atezolizumab, Bevacizumab, Gemcitabine and Carboplatin|Atezolizumab 1200 mg Day 1 of each 21 day cycle IV, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV, Carboplatin AUC 5 Day 1 of each 21 day cycle IV
16290874|NCT04739657||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo IVUS measurement with the TrueVisionTM intravascular ultrasound diagnostic catheter and the OptiCrossTM coronary ultrasonic imaging catheter.
16290875|NCT04739644|Experimental|Experimental: WRISTBOT Group|"The patients in the WRISTBOT Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation by WRISTBOT device"
16290876|NCT04739644|Active Comparator|Control group|The patients in the Control Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation performed by physiotherapist.
16290912|NCT04739358|Experimental|Combination Therapy|"Dose Escalation Phase for participants with evidence of MET-driven acquired -resistance.
~Dose Expansion Phase for participants with evidence of MET-driven acquired -resistance with or without measurable CNS disease."
16290913|NCT04739345||Group 1|Non-severe patients should meet all following conditions: (1) Epidemiology history, (2) Fever or other respiratory symptoms, (3) Typical CT image abnormities of viral pneumonia, and (4) Positive result of RT-PCR for SARS-CoV-2 RNA.
16290914|NCT04739345||Group 2|Severe patients should meet at least one of the following conditions: (1) Shortness of breath, RR ≥ 30 times/min, (2) Oxygen saturation (Resting state) ≤ 93%, (3) PaO2/FiO2 ≤ 300 mmHg.
16290877|NCT04739631|Experimental|acupuncture group|The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
16290878|NCT04739631|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
16290879|NCT04739631|No Intervention|waitlist-control group|As an waitlist-control group, no acupuncture will be performed.
16290880|NCT04739618|Experimental|Single arm. Subjects receiving treatment.|Efficacy of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria
16290881|NCT04739592|Experimental|alendronate sodium vitamin D3 tablets|participants will receive alendronate sodium vitamin D3 tablets once per week for one year.
16290882|NCT04739592|Placebo Comparator|placebo|participants will receive a placebo tablet once per week for one year.
16290883|NCT04739579||Anastomotic Leak|
16290884|NCT04739579||Non-Anatomotic Leak|
16290885|NCT04739566|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib 150 mg orally (PO) twice daily, trametinib 2mg PO once daily for 3 months
16290886|NCT04739553|Experimental|His Pacing|Implant of a supplementary His pacing lead in addition to a traditional RV pacing lead.
16290887|NCT04739527|Experimental|Treatment arm|Patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
16290888|NCT04739514|Active Comparator|Mild dysphagia|
16290889|NCT04739514|Active Comparator|Moderate dysphagia|
16290890|NCT04739514|Active Comparator|Severe dysphagia|
16290891|NCT04739501||TACE in HCC group 1|the patient did undergo tace
16290892|NCT04739488|Experimental|Breathing exercise and inhaler training|This group were given pursed lip breathing exercise and inhaler training.
16290893|NCT04739488|Experimental|inhaler training|This group were given only inhaler training
16290894|NCT04739475|Other|Non surgical Periodontal Therapy NPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.
~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
16290895|NCT04739462|Experimental|Intervention|Participants in this arm will receive the study intervention.
16290896|NCT04739462|No Intervention|Routine Antenatal Care|Participants in this arm will receive no intervention.
16290897|NCT04739449|No Intervention|Control|Two facilities will follow their local protocols for infection prevention, including COVID-19 precautions. We will swab environmental surfaces at these sites to compare outcomes.
16290898|NCT04739449|Experimental|Intervention|"Using a cluster-randomized design, we will test a multimodal aging-friendly intervention including four components (4Cs):
~Coaching staff
~Cleaning protocols, standardized
~Communication with staff and leadership
~Collaboration with local expertise
~We hypothesize that the implementation of this organizational QI educational program will be associated with lower odds of SARS-CoV-2 transmission to the environment."
16290899|NCT04739436|Other|Bilateral hearing aid fitting group|
16290900|NCT04739436|Active Comparator|Unilateral hearing aid fitting group|
16290903|NCT04739410|Experimental|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12mg stat per oral and then 12 mg per oral after 12 hours and 12mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. and any side effects of the drugs were noted as well.
16290904|NCT04739410|Placebo Comparator|SOC standard of care|These participants were given standard of care without Ivermectin standard of care only symptomatic treatment
16290905|NCT04739397||Cataract|Patients with bilateral cataracts with Lens grade 2+ or greater, cataract classification nuclear, cortical or posterior subcapsular
16290906|NCT04739397||Non-Cataract|patients with bilateral clear lenses (no cataracts)
16290907|NCT04739384|Experimental|Standard dose of ticagrelor (90 mg twice daily).|Standard dose of ticagrelor (90 mg twice daily) followed by lower dose of ticagrelor (60 mg twice daily).
16290908|NCT04739384|Experimental|Low dose of ticagrelor (60 mg twice daily).|Low dose of ticagrelor (60 mg twice daily) followed by standard dose of ticagrelor (90 mg twice daily).
16290909|NCT04739371|Experimental|Insulin|40 participants will receive 40 IUs of intranasal insulin about 30 minutes before consuming an ad libitum lunch.
16290910|NCT04739371|Placebo Comparator|Placebo|40 participants will receive 40 IUs of intranasal saline about 30 minutes before consuming an ad libitum lunch.
16290911|NCT04739358|Experimental|Monotherapy|"Dose Escalation Phase for participants with MET-driven NSCLC.
~Dose Expansion Phase: CNS Efficacy Dose Expansion Cohort for participants with MET-driven NSCLC and measurable CNS disease."
16290949|NCT04738994|Experimental|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
16290915|NCT04739332|Experimental|NBO intervention for at-risk mothers|NBO intervention for at- risk mothers. 3 NBO sessions added to the routine follow-up delivered once per week during the first month postpartum. The intervention is delivered by a nurse certified in the NBO system.
16290916|NCT04739332|No Intervention|Treatment as usual|Participants receive 3 routine follow-up by the local health visitor/midwife during the first month
16290917|NCT04739319||Age-Related Macular Degeneration|Participants with Age-Related Macular Degeneration
16290918|NCT04739306|Experimental|CT-P42|
16290919|NCT04739306|Active Comparator|Eylea|
16290920|NCT04739293|Experimental|ON 123300|ON 123300 capsules at increasing doses per cohort, starting at 40 mg
16290921|NCT04739280||Single center registry for WACE|We propose a single center registry for patients requiring diagnostic, screening, or surveillance for potential or existing cardiac illness. All eligible patients will undergo an MCG with periodic follow-ups. No treatment decisions will be based on the MCG findings, until CardioFlux has appropriate FDA labelling for clinical use.
16290922|NCT04739241|Experimental|Group A (experimental arm)|Premixed insulin therapy
16290923|NCT04739241|Active Comparator|Group B (active comparator)|Basal bolus insulin therapy
16290924|NCT04739228|Experimental|Guided Written Disclosure Protocol Group|Guided Written Disclosure Protocol is a short-term psychological intervention that stimulates emotional expression, promotes a cognitive reworking of stressful illness events and facilitates the integration between emotional and cognitive processing of traumatic experiences. Intervention aimed at enhancing patients' quality of life, psychological well-being, and emotional regulation, and reducing psychosocial distress.
16290925|NCT04739228|Active Comparator|Active Control Group|
16290926|NCT04739215|Experimental|Clinical Trial: Experimental Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.
16290927|NCT04739215|Placebo Comparator|Clinical Trial: Placebo Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Placebo in a similar pattern.
16290928|NCT04739215|No Intervention|Descriptive Study|Patients with heart failure with preserved ejection fraction but with no type 2 diabetes mellitus (n=10).
16290929|NCT04739202|Experimental|Patients with tumors positive for EBV or microsatellite instable tumors (group 1)|Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).
16290930|NCT04739202|Experimental|Patients with genomically stable tumors (group 2)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
16290931|NCT04739202|Experimental|Patients with tumors with chromosomal instability (group 3)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
16290932|NCT04739189|Experimental|Obese adolescent|
16290933|NCT04739176|Experimental|One-on-one rehabilitation program|
16290934|NCT04739137||Study group|100 patients with diagnosed macular edema will be enrolled
16290935|NCT04739124||Diabetic patients|Patients presenting type 1 or type 2 diabetes, eligible for the prescription of Freestyle Libre
16290936|NCT04739124||Caregivers|Caregiver caring for diabetic patients and practicing therapeutic education on a regular basis
16290937|NCT04739111|Experimental|Experimental Arms|All participants will receive treatment with LDP combined with CDP1. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase.
16290938|NCT04739085||Defocus curve group|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to the distances of 30 cm, 40 cm, 60 cm, and 80 cm, respectively.
16290939|NCT04739085||wDDART group|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
16290940|NCT04739072||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.
16290942|NCT04739046|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and radiation therapy
16290943|NCT04739033|Experimental|Experimental group|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
16290944|NCT04739033|Active Comparator|Control Group|The control group will receive the same webbased lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
16290945|NCT04739020|Active Comparator|PCR SARS-CoV-2 Negative Adults|Healthy adults with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of parents of participating children and other healthy volunteers.
16290946|NCT04739020|Active Comparator|PCR SARS-CoV-2 Positive Adults|Adults with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic parents that are in the hospital with their children and symptomatic adults that are admitted to the infectious disease ward.
16290947|NCT04739020|Active Comparator|PCR SARS-CoV-2 Negative Children|Children with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of children admitted to the Children's Hospital or presenting for planned diagnostic testing or follow up.
16290948|NCT04739020|Active Comparator|PCR SARS-CoV-2 Positive Children|Children with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic children that are admitted to the Children's Hospital for reasons other than COVID-19 and symptomatic children.
16290950|NCT04738994|Active Comparator|Control group|Standard hospital diet
16290951|NCT04738981|Experimental|UC-MSC and anti-CD25 mAb|UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.
16290952|NCT04738981|Active Comparator|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.
16290953|NCT04738968|Experimental|Cochlear implant for single-sided deafness|Children with single-sided deafness, cochlear implant in the deaf ear
16290954|NCT04738968|No Intervention|Control single-sided deafness|Children with single-sided deafness, no intervention
16290955|NCT04738968|No Intervention|Control normal hearing|Children with normal hearing, no intervention
16290956|NCT04738955|Experimental|High dose group|micafungin sodium ≥ 200, ≤ 300 mg/time, once a day, intravenous drip
16290957|NCT04738942|Experimental|Vedolizumab 300 mg in UC cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
16290958|NCT04738942|Experimental|Vedolizumab 300 mg in CD cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
16290959|NCT04738929|Experimental|Normal weight|Normal weight subjects (BMI=18.5-25)
16290960|NCT04738929|Experimental|Obese|Obese subjects (BMI=30-34.99)
16290961|NCT04738916|Experimental|Vibration Group|The vibration group was included in the low frequency (25 Hz), low amplitude (2mm), fixed six-week training on two non-consecutive days of the week.
16290962|NCT04738916|No Intervention|Control Group|No training was given to the control group.
16290963|NCT04738903|Active Comparator|Custom Q treatment group|For every patient, the eye with the greater myopic spherical equivalent (SE) will be assigned for the Custom-Q treatment group.
16290964|NCT04738903|Active Comparator|Wave-front optimized (WFO) group|For every patient, the other eye with the lesser myopic SE will be assigned for the WFO treatment group
16290965|NCT04738890|Experimental|MBCT-PCCFA plus TAU|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing, plus treatment as usual.
16290966|NCT04738890|Other|TAU control|Treatment as usual control group
16290967|NCT04738864|Experimental|behcet's disease patient|patient who presented with manifestation of behcet disease
16290968|NCT04738864|Experimental|Healthy people|healthy control people
16290969|NCT04738851|Experimental|healthy volunteers|Virtual mirror therapy task : TMV Classic mirror therapy task : TMC Control task :TC
16290970|NCT04738838|Experimental|Oxytocin Nasal Spray|Single dose of intranasal oxytocin (48 IU) prior to testing protocol.
16290971|NCT04738838|Placebo Comparator|Placebo Nasal Spray|Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
16290974|NCT04738812|Experimental|Intensified TB treatment|"Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks (initial phase of TB treatment).
~Prednisone 40 to 80 mg once a day (OD) according to weight bands for 2 weeks, followed by 20 to 40 mg OD according to weight bands for 2 weeks, then 10 to 20 mg OD according to weight bands for the last 2 weeks (total duration: 6 weeks). Because of the corticosteroid treatment, albendazole 400 mg OD will be given to participants for 3 days.
~Continuation phase: 16 weeks of RH."
16290975|NCT04738812|Active Comparator|WHO standard TB treatment|"Standard-dose of R 8-12 mg/kg daily + H 4-6 mg/kg daily + Z 20-30 mg/kg daily + E 15-20 mg/kg daily for 8 weeks.
~Continuation phase: 16 weeks of RH."
16290976|NCT04738799|Experimental|Carbohydrate-Last Meal Sequence, Then Carbohydrate-First Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals last during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals first during mealtimes for the following 6 days.
16290977|NCT04738799|Experimental|Carbohydrate-First Meal Sequence, Then Carbohydrate-Last Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals first during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals last during mealtimes for the following 6 days.
16290978|NCT04738786|Active Comparator|Wide surgical safety margin|1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
16290979|NCT04738786|Active Comparator|Narrow surgical safety margin|1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
16290980|NCT04738773|Active Comparator|Patients receiving Naltrexone|
16290981|NCT04738773|Placebo Comparator|Patients receiving Placebo|
16290982|NCT04738760||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with standard dose vitamin D in addition to standard COVID-19 management.
16290983|NCT04738760||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with high dose vitamin Din addition to standard COVID-19 management.
16290984|NCT04738747|Experimental|Study arm (receive a WHOOP device)|Participants randomized to the WHOOP group will be given WHOOP wrist and arm bands to wear 24/7 after an orientation on their use
16290985|NCT04738747|No Intervention|Control arm (no intervention)|The control group will not have any intervention
16290986|NCT04738734|Experimental|CellFX Procedure|CellFX device using pre-defined energy protocols
16290987|NCT04738734|Active Comparator|Cryosurgical Procedure|Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.
16290988|NCT04738708|Experimental|Telemedicine|
16290989|NCT04738708|Active Comparator|Control|
16290990|NCT04738695||Nursing home residents/staff members|Follow-up of seroprevalence
16290991|NCT04738682|Active Comparator|Group 1 (Digital -> Conventional)|Patients allocated to Group 1 (Digital -> Conventional) will undergo three days of digital dietary registration, using mobile devices, followed by three days of conventional dietary registration, using pen and paper.
16290992|NCT04738682|Active Comparator|Group 2 - (Conventional -> Digital)|Patients allocated to Group 2 - (Conventional -> Digital) will undergo the exact opposite sequence, commencing with three days of conventional dietary registration, using pen and paper, followed by three days of digital dietary registration, using mobile devices.
16290993|NCT04738669|No Intervention|Control Arm|No intervention is being conducted in this arm. Routine care is being given to these patients. The patients will be followed up for any readmissions during the intervention period.
16290994|NCT04738669|Experimental|mHealth Arm|"This arm will receive first receive weekly telephone call followed by the SMS in Urdu regarding medication adherence according to the discharge instructions.
~The calls and SMS will be sent on 7, 14, 21 and 30th day post-index discharge. The patients will be followed up for any readmissions during the intervention period."
16290995|NCT04738669|Experimental|Teach back arm|"The trained doctors thoroughly explained the discharge instructions, medication schedule and any other self-care instructions to these participants and asked them to repeat what they have understood from the doctor verbal counselling.
~If the instructions were not clearly comprehended by the patients, then the same would be repeated by the consultant doctor.
~The patients will be followed up for any readmissions during the intervention period."
16290996|NCT04738656||Mediterranean-style diet plan|"Mediterranean-style diet plan (6 months): 22% proteins, 53% carbohydrates, and 25% of lipids.
~52 participants."
16290997|NCT04738656||Open protein diet plan|"Open protein presents (6 months) 40% of proteins, 29% carbohydrate and 31% of lipids.
~26 participants."
16290998|NCT04738643|No Intervention|Usual Care|TUT Service Only
16290999|NCT04738643|Experimental|Tobacco Use Treatment Service + Varenicline Management|TUTS + Varenicline Management
16291000|NCT04738630|Experimental|Experimental: HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
16291001|NCT04738617|Experimental|Warm-up based on small-sided games|Intervention A is based on football-specific small-sided games (SSGs), consisting of 4 versus 4 matches (with mini-goals), performed in a 30 m by 24 m court (Giménez et al., 2018), using five sets of 90 seconds of work interspersed with 30 seconds of pause, in a total duration of 10 minutes.
16291002|NCT04738617|Experimental|Warm-up based on potentiation principles (e.g., speed, change of direction, plyometrics)|"Intervention B is based on speed, COD and plyometrics (i.e., a potentiation protocol), inspired by ideas presented by Howe, Coward, and Price (2017). Participants will perform five repetitions of the following exercises, in this order: unilateral hurdle hops and lateral hurdle hops with each lower limb; CMJ; broad jump; forward in and out; slalom jumps; lateral scissor jumps; single leg linear hops. Each intervention will last ~10 minutes and will be applied in the football field."
16291003|NCT04738604|Active Comparator|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) is the ideal choice for single-tooth restorations, both in the anterior and the posterior region. It has an ultrafine, radiopaque porcelain filler for use in adhesive filling treatment. It can be polished to a high lustrer due to the ultra- fine particle filler, extremely homogeneous restorations can be placed which are easily polished to a high luster. The mechanical properties of a light-cured dental composite material are particularly dependent on its filler content, the type of incorporated fillers and the efficiency of the filler-resin coupling, so high Vickers hardness, compressive strength and flexural strength are recorded refereed to Zenit filler content 83% by weight (70% by volume) and size 0.7 microns
16291004|NCT04738604|Experimental|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany)|contains organically modified ceramic nanoparticles (2 to 3 nm) and nano-fillers (10 nm) that are combined with conventional glass fillers (mean particle size: 1.1 to 1.5 μm). Nanoparticles and nano-fillers comprise a polysiloxane backbone and have methacrylate groups available for polymerization. According to the manufacturer's data, filler concentration is 76% by weight and 57% by volume. Furthermore, most of the conventional resin matrix is replaced by a matrix full of highly dispersed methacrylate modified polysiloxane particles (2- 3 nm).These nano-ceramic particles are inorganic-organic hybrid particles. Both, nano-ceramic particles and nano- fillers have methacrylate groups available for polymerization. CeramX does not contain triethylene glycol dimethacrylate (TEGDMA) as it was found mutagenic and cytotoxic in vitro
16291005|NCT04738591|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
16291006|NCT04738591|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
16291007|NCT04738565|Experimental|Probiotic|The mixture of 3 probiotic strains in the following proportions: 50% Lactobacillus casei ŁOCK 0919, 25% Lactobacillus rhamnosus ŁOCK 0908, 25% Lactobacillus rhamnosus ŁOCK 0900 (Latopic® preparation, Biomed S.A., Cracow, Poland).
16291008|NCT04738565|Placebo Comparator|Maltodextrin|Maltodextrin - a substance in which probiotic strains have been suspended.
16291009|NCT04738539||Patients with or being evaluated for neurogenic bladder|Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics testing.
16291010|NCT04738526|Active Comparator|natural tooth|
16291011|NCT04738526|Experimental|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate (IPS e-max) ceramic crown for crowns in esthetic zone
16291012|NCT04738526|Experimental|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|
16291013|NCT04738513|Active Comparator|Conventional preparation technique|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
16291014|NCT04738513|Experimental|Vertical preprartion|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using Vertical preparation technique.
16291015|NCT04738500|Active Comparator|PENG Block|PENG Block combinate with PCA
16291016|NCT04738500|Sham Comparator|CONTROL|PCA
16291019|NCT04738474|Experimental|PRISM Intervention|Subjects in this group will receive the PRISM intervention
16291020|NCT04738474|Placebo Comparator|Usual Care|Subjects in this arm will receive usual care
16291021|NCT04738461|Experimental|Telerehabilitation|Telerehabilitation program will be applied 5 days a week for 3 weeks to patients in the telerehabilitation group. A physiatrist will meet with patients via videoconferencing over the internet and guide the program.
16291022|NCT04738461|Active Comparator|Standard Physiotherapy|Patients in the standard physiotherapy group will receive one-to-one physiotherapy sessions in the hospital 5 days a week for 3 weeks. In these sessions, active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
16291023|NCT04738461|Active Comparator|Home exercise group|The home exercise program was explained to the patients in the control group by the physiotherapist and the relevant brochures were delivered to the patients. Home exercise program will consist of telerehabilitation group exercises. However, patients will be not under any supervision and exercise themselves at home.
16291024|NCT04738448|Experimental|Art Therapy Group|
16291025|NCT04738422|Experimental|Alkaline glycine Inhalation|Subjects inhale alkaline glycine
16291026|NCT04738409||Ov/Ob group|PCOS subjects (Overweight/Obesity)
16291027|NCT04738409||N group|PCOS subjects (Normal weight)
16291028|NCT04738409||H group|Healthy control subjects
16291029|NCT04738383|Experimental|Version 1: Paramedic|Physician is replaced by a paramedic, but the physician still acts as a supervisor.
16291030|NCT04738383|Experimental|Version 2: Physician-on-call|Physician is not present, but is on call.
16291031|NCT04738383|Experimental|Version 3: Trained instructor|Physician acts as a supervisor, but is not constantly present. The instructor received a special training preparing for emergency cases.
16291032|NCT04738383|No Intervention|Control group|The sessions take place in the usual way, meaning that a physician is present in every session.
16291033|NCT04738370||Pregnancy of unknown location|Patients will be approached for recruitment following PUL classification. Sample collection at time of classification +/- 48 hours later, timed for when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
16291034|NCT04738370||Ectopic Pregnancy|Patients will be approached for recruitment following Ectopic Pregnancy diagnosis. Ectopic pregnancies that are recruited as PUL do not need to be re-approached as they are already part of the study. Sample collection at time of diagnosis when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
16291035|NCT04738357|Experimental|HSK21542|
16291036|NCT04738357|Placebo Comparator|placebo|
16291037|NCT04738344|Experimental|Percutaneous coronary intervention and stent implantation using one long stent|Long coronary lesions will be treated percutaneously with a single long stent (more than 40 mm in length) and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
16291038|NCT04738344|Experimental|Percutaneous coronary intervention and stent implantation using more than one overlapping stents|Long coronary lesions will be treated with more than one overlapping stents and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
16291039|NCT04738318|Experimental|Treatment Arm (Glucocorticoid)|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone. Following surgery, the participant will be provided with a 1) six-day oral methylprednisolone taper course.
16291040|NCT04738318|Placebo Comparator|Control Arm (Placebo)|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
16291041|NCT04738305|Other|Dignity Therapy Intervention|All the patients that accepted to participate in the study were provided with Dignity Therapy Intervention. A short-term intervention aimed at reducing existential distress of patients facing with advanced illness.
16291043|NCT04738279|Experimental|Soft Launch|The study will conduct a soft launch on the first five HF patients enrolled to finetune process and protocol.
16291044|NCT04738279|Experimental|Pilot|After learning from the soft launch and updating the protocol, the study will continue to enroll 45 HF patients.
16291045|NCT04738253||Study group|Stroke patients with limitation of range of motion on the affected shoulder.
16291046|NCT04738240|Experimental|Intra-operative endoscopy|The intervention arm will have an intra-operative endoscopy performed per rectum once the anastomosis has been performed. The anastomosis will be graded from 1 to 3 in the endoscopic group. Grade 1 is defined as circumferentially normal appearing peri-anastomotic mucosa. Grade 2 is defined as ischemia or congestion involving <30% of either the colon or rectal mucosa. Grade 3 is defined as ischemia or congestion involving >30% of the colon or rectal mucosa or ischemia/congestion involving both sides of the staple line. If appearances are grade 2 a suture re-inforcement or re-anastomosis will be performed; if appearances are grade 3 a re-anastomosis will be performed. Images will be obtained via the endoscopy stack during the assessment.
16291047|NCT04738240|No Intervention|Standard air leak test|The control arm will receive an intra-operative leak test. This involves insufflation of air per rectum via bladder syringe while the anastomosis is bathed in sterile water. The presence of air bubbles from the anastomosis denotes a positive test.
16291120|NCT04737694|Active Comparator|Carbohydrate|Isocaloric amount of glucose to match ketone + carbohydrate
16291121|NCT04737681||Normal BMI|BMI 18.5-24.9 kg/m2
16291122|NCT04737681||Obese BMI|BMI ≥ 30 kg/m2
16291048|NCT04738227|Experimental|Low level Laser Therapy Group|"Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.
~6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).
~Following are the parameters which will be employed for the laser:
~Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.
~A sum total of 22 points will receive LLLT per session involving all three major salivary glands."
16291049|NCT04738201|Active Comparator|Control group|Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle.
16291050|NCT04738201|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
16291051|NCT04738188|Experimental|Drug-eluting bead transarterial chemoembolization(DEB-TACE)|
16291052|NCT04738188|Active Comparator|conventional transarterial chemoembolization(cTACE)|
16291053|NCT04738175|Experimental|COVI-AMG|40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
16291054|NCT04738175|Placebo Comparator|Placebo|Placebo will be administered
16291055|NCT04738162|Experimental|5-Aminolevulinic Acid (5-ALA)|Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection
16291058|NCT04738136|No Intervention|Standard of Care (SOC)|Subjects will only receive standard of care treatment for moderate severity COVID19 bronchiolitis/pneumonia.
16291059|NCT04738136|Experimental|Standard of Care(SOC) + S-1226 at either 4% 8% or 12% CO2|Subjects will receive SOC plus the highest tolerated dose of S-1226 at either 4% 8% or 12% CO2 twice daily for up to 5 consecutive days.
16291060|NCT04738123|Experimental|KarXT|
16291061|NCT04738123|Placebo Comparator|Placebo|
16291062|NCT04738110||KCH patients|75 high grade glioma patients from KCH
16291063|NCT04738110||NHNN patients|75 high grade glioma patients from NHNN
16291064|NCT04738097|Experimental|intervention|Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.
16291065|NCT04738097|Active Comparator|control|control gruop will be treat with ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.
16291066|NCT04738084|Experimental|Meru Health Program|The Meru Health Program (MHP) is a 12-week online mobile digital mental health clinic delivered via Smartphone app that includes components of several evidence-based treatments (Cognitive Behavioral Therapy, Behavioral Activation Therapy, Mindfulness Meditation) and also several promising therapies (heart rate variability-biofeedback [HRVB], nutritional psychiatry, sleep training) and a group support component that is overseen by a licensed clinical therapist.
16291067|NCT04738084|No Intervention|Waitlist|12 week waitlist
16291068|NCT04738071||Sex|Female and male patients
16291069|NCT04738071||Age >60 years of age|Patients younger or oder than 6o years of age
16291070|NCT04738071||World region|Patients from different world regions: North America, Europe, Asia, Latin America
16291071|NCT04738071||Stroke vs. TIA|Index event: stroke vs. TIA
16291072|NCT04738071||Neurocardiology Teams|Patients assessed by a neurocardiology team
16291073|NCT04738058|Experimental|Preterm infants diagnosed as feeding intolerance will receive bovine lactoferrin|they will receive bovine lactoferrin 100mg/day with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
16291074|NCT04738058|Placebo Comparator|Preterm infants diagnosed with feeding intolerance will receive placebo|they will receive the placebo with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
16291075|NCT04738045|Placebo Comparator|control|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily for 5 days.
16291076|NCT04738045|Experimental|interventional|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
16291077|NCT04737993|Active Comparator|prf shoulder joint|pulsed rf stimulation of joint capsel and prf stimlation of subscapular nerve
16291078|NCT04737993|Active Comparator|prf subscapular nerve|pulsed RF stimulation of subscapular nerve
16291079|NCT04737993|Active Comparator|subscapular nerve block|lidocain injection of subscapular nerve
16291080|NCT04737980|Experimental|Experimental Group: Interscalene block with liposomal bupivacaine combined with bupivacaine|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 10 ml of liposomal bupivacaine 1.3% (133 mg) combined with 10 ml of 0.5% bupivacaine hydrochloride.
16291081|NCT04737980|Active Comparator|Control Group: Interscalene block with ropivacaine combined with dexamethasone|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 30ml of 0.5% ropivacaine combined with a 2 ml volume of 8mg of dexamethasone.
16291082|NCT04737967|Experimental|Venlafaxine Treated Arm|
16291083|NCT04737967|Experimental|Memantine Treated Arm|
16291084|NCT04737954|Experimental|Suspected VTE patients|Venous blood draw of up to 20ML and up to 6 fingerstick capillary draws
16291085|NCT04737941|Experimental|Immediate foam sclerotherapy|Immediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
16291086|NCT04737941|Active Comparator|Scheduled treatment|Scheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
16291087|NCT04737928|Experimental|latanoprost switch to tafluprost|POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
16291088|NCT04737915|Experimental|Virtual Reality Exposure|Participants completed a single session of exposure administered via a virtual reality headset. The exposure exercise involved looking over virtual railings into an atrium at various floor levels (the virtual environment was designed to look like the atrium in the in vivo exposure condition). Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
16291089|NCT04737915|Experimental|In Vivo Exposure|Participants completed a single session of exposure administered in vivo. The exposure exercise involved looking over actual railings into an atrium at various floor levels. Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
16291090|NCT04737915|No Intervention|Waitlist Control|Participants watched a neutral video during the time participants in other conditions were completing the exposure exercise. Participants received no exposure-based intervention.
16291091|NCT04737902||VATS with ESPB|Study subjects underwent anaesthesia and VATS without a change in their routine care. At the end of the surgery, an erector spinae plane block was performed for acute pain control following our institutional protocol for perioperative care.
16291092|NCT04737889|Experimental|RL-MT|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen: Methotrexate, 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle, Temozolomide, 150mg/m2/d oral administration on day 1 to 10.
~Consolidation Treatment: Autologous hematopoietic stem cell transplantation or reduced whole brain radiotherapy after high-dose chemotherapy.
~Maintenance Treatment: Lenalidomide, 10mg oral administration on day 1 to 21 of each 4-week cycle for 12 months."
16291093|NCT04737876|Experimental|BX002-A|BX002-A: 1 mL liquid for multiple dose oral administration
16291094|NCT04737876|Placebo Comparator|Placebo|Placebo: 1 mL liquid for multiple dose oral administration
16291095|NCT04737863|Experimental|selective root canal retreatment|retreatment process is performed to the affected root only
16291096|NCT04737863|Active Comparator|traditional root canal retreatment|retreatment process is performed to all roots
16291097|NCT04737850|Experimental|PartA, open-label|Hetrombopag plus standard of care
16291098|NCT04737850|Experimental|PartB, double-blind treatment group|Hetrombopag plus standard of care
16291099|NCT04737850|Placebo Comparator|Placebo Comparator|Placebo plus standard of care Part B, double-blind treatment group
16291100|NCT04737837||children|Children aged 4~16 years with focal onset seizures
16291101|NCT04737837||Adult|Adults aged >16 years with focal onset seizures
16291102|NCT04737824|Experimental|Experimental group A|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise."
16291103|NCT04737824|No Intervention|Control group A|No intervention was applied.
16291104|NCT04737824|Experimental|Experimental group B|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home."
16291105|NCT04737824|No Intervention|Control group B|No intervention was applied.
16291106|NCT04737811||Study group|The group consists of Parkinson's disease patients with dysphagia complaints. The participants will be given the Turkish version of the Swallow Disturbance Questionnaire (SDQ-T), which consisted of 15 questions and two scales evaluated with the fiberoptic endoscopic evaluation of swallowing. After two weeks, all participants will be given the SDQ-T for sampling.
16291107|NCT04737798|Experimental|oil pulling with coconut oil|patients used oil pulling therapy with coconut oil for 4 days
16291108|NCT04737798|Active Comparator|oil pulling with sesame oil|patients used oil pulling therapy with sesame oil for 4 days
16291109|NCT04737785||Case group|HSCT recipients who developed a CNS disorder after HSCT
16291110|NCT04737785||Control group|HSCT recipients whom did not develop a CNS disorder
16291111|NCT04737772|Active Comparator|Standard Quitline Treatment As Usual (TAU)|State quitline treatment as usual
16291112|NCT04737772|Experimental|QL Marijuana Check-Up intervention (QL-MJCU).|Newly developed intervention for co-users of marijuana and tobacco.
16291113|NCT04737759|Experimental|Taking Care of Us|Taking Care of Us involves seven sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. The program is a communication-based, relationship-focused intervention that is strengths-based and fosters new skills to support couples managing heart failure. The goals of the program are to 1) target the couple with heart failure as a team; 2) increase shared appraisal within the couple; 3) improve communication skills within the couple; 4) improve collaboration within the couple and dyadic management of heart failure; 5) improve confidence within the couple; and 6) improve both individual and dyadic health and well-being.
16291114|NCT04737759|Active Comparator|SUPPORT|The SUPPORT program involves three sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. This arm is an educational intervention to support management of heart failure.
16291115|NCT04737733|Other|The dementia friendly hospital program|The dementia-friendly hospital program comprised three parts; 1) Educational program for health practitioners to increase the staff's knowledge and awareness of patients with cognitive impairment and/or delirium; 2) Screening, for early identification of cognitive impairment and delirium, using the Four Assessment Test (4AT); 3) Delirium risk factor modification and management for patients defined with potential cognitive impairment and risk of delirium, implying that risk factor modifications should be implemented in the patient's care plan. For patients with suspected delirium, the program promoted an additional delirium management plan.
16291116|NCT04737720||1|This is an expanded use protocol for a named subject.
16291117|NCT04737707|Experimental|Dialectical Behavior Therapy (DBT)|Psychotherapy (duration 5 months) will begin within a maximum of 1 month (the time to set up the group) and will be accompanied by individual follow-up. Evaluations will be carried out within 6 months of the end of the psychotherapy in order to measure its effects.
16291118|NCT04737707|Other|Therapy|waiting list for 5 months before starting psychotherapy (duration 5 months). During this time, the patient can continue your usual therapeutic follow-ups. Likewise, assessments will be carried out within 6 months after the end of the psychotherapy in order to measure its effects. the patient will thus benefit from DBT regardless of the group.
16291119|NCT04737694|Experimental|Ketone + Carbohydrate|573 mg/ kg body weight ketone ester + 110 g glucose
16351275|NCT04319679|Sham Comparator|Control group|Sham therapy
16291123|NCT04737668|Other|Usual care|Pump refill will be performed as usual.
16291124|NCT04737668|Other|Virtual Reality|Children will play a commercially available VR game during pump refill
16291125|NCT04737668|Other|Distraction|Children will watch a commercial 360° music video on YouTube during pump refill
16291126|NCT04737655|Active Comparator|TRIMBOW + Standard of care|"Inclusion
~Maintenance therapy (LAMA or LABA) for COPD
~Age >18
~Admission for AE of COPD
~Signed Inform consent (see protocol attached)
~Admitted in ICU >24h and less than 72h
~Exclusion
~No CI for studied medication
~Not treated with studied medication for at least 3 months
~Admitted in ICU for AE of COPD within the past 3 months
~Intolerance to studied medication
~Hospitalized since >6 days
~ARDS condition (PAFI <200)
~Admitted in ICU >72H
~Patient with severe asthma
~The use of high dose of ICS as baseline therapy
~Right/left heart failure
~Immunocompromized
~Acute myocardial infaction
~Left heart insufficiency (LVEF<35%)
~Stroke <6 months prior to hospital admission
~Patients will be separated in 2 randomized groups (Trimbow + SOC versus SOC) 1:1."
16291127|NCT04737655|No Intervention|standard of care|
16291128|NCT04737642|Experimental|Papillary ballon dilatation|
16291129|NCT04737629|Experimental|Expectancy and Water Condition|
16291130|NCT04737629|Experimental|No Expectancy and Water Condition|
16291131|NCT04737629|Experimental|No Water Condition|
16291132|NCT04737616|Experimental|CO2 Laser +OCT|Postmenopausal women with genitourinary syndrome of menopause who will receive CO2 vaginal laser treatment
16291133|NCT04737616|Experimental|OCT only|Premenopausal, peri-menopausal and postmenopausal women who will only get one time OCT scan
16291134|NCT04737603|Experimental|ED-initiated treatment with buprenorphine/naloxone.|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores >=8. Participants who weigh > 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh <= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
16291135|NCT04737590|Active Comparator|Bioactive glass|20 bone cysts (in 20 patients) are filled with bioactive glass
16291136|NCT04737590|Active Comparator|Allogenic bone|20 bone cysts (in 20 patients) are filled with allogenic bone
16291137|NCT04737577|Experimental|Supramarginal resection (intervention arm)|Planned resection beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
16291138|NCT04737577|Other|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
16291139|NCT04737564|Experimental|ABC10 + SEEK|Participants assigned to this arm will receive the standard Attachment and Biobehavioral Catch-up intervention (ABC 10) as well as SEEK (Safe Environment for Every Kid).
16291140|NCT04737564|Experimental|ABC3 + SEEK|Participants assigned to this arm will receive an abbreviated version of the Attachment and Biobehavioral Catch-up intervention (ABC 3) as well as SEEK (Safe Environment for Every Kid).
16291141|NCT04737564|Active Comparator|SEEK Only|Participants assigned to this arm will receive SEEK (Safe Environment for Every Kid) only.
16291142|NCT04737551||No adjuvant treatment|Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
16291143|NCT04737551||Adjuvant chemotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
16291144|NCT04737551||Adjuvant chemoradiotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
16291145|NCT04737551||Adjuvant chemoradiotherapy + adjuvant chemotherapy|Pancreatic cancer patients who received surgery and both adjuvant chemoradiotherapy and chemotherapy.
16291146|NCT04737538|Experimental|Experimental Dentifrice|Participants assigned to this arm will apply full ribbon of toothpaste (containing sodium bicarbonate, sodium hyaluronate and sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
16291147|NCT04737538|Active Comparator|Positive control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
16291148|NCT04737538|Active Comparator|Negative control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 1100ppm fluoride as sodium fluoride [Crest Cavity Protection]) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
16291149|NCT04737525|Experimental|Test group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and porcine-derived membrane.
16291150|NCT04737525|Experimental|Control group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and connective tissue grafting (CTG).
16291151|NCT04737512|Experimental|Mindfulness-Based ADHD Treatment for Children|
16291152|NCT04737512|Active Comparator|Medication|
16291153|NCT04737512|Active Comparator|Combined (MBAT-C + medication)|
16291154|NCT04737499|Experimental|CASCADe Intervention|Intervention consisted of eight weekly sessions of health education and diabetes management. Topics covered include recognition of diabetes and its complications, risk factors, nutrition knowledge, dietary practices, exercise, behavioral self-monitoring, medication adherence, and stress management. Intervention also included a home visit for training of monitoring devices use, WeChat app and acquiring family support, and weekly WeChat follow-up on education tips, monitoring data summary, and group discussion. The monitoring system used a smartphone to coordinate cloud data transmission from a set of wireless devices to capture daily monitoring data on physical activity, body weight, blood pressure and blood glucose levels.
16291264|NCT04736784|Experimental|Beetroot juice|115 ml of beetroot juice per day for seven days
16291155|NCT04737486|Experimental|Single Ascending Dose Cohort 1-4|Intervention: AV-001, 6 subjects per cohort will receive single doses of 1.4 µg/kg up to 56 µg/kg of AV-001 by intravenous bolus injection.
16291156|NCT04737486|Placebo Comparator|Single Ascending Dose Cohort 1-4, Placebo|Intervention: Placebo, 2 subjects per cohort will receive single doses of D-PBS placebo by intravenous bolus injection.
16291157|NCT04737486|Experimental|Multiple Ascending Dose Cohort 1-2|Intervention: AV-001, 6 subjects per cohort will receive multiple doses of 1.4 µg/kg/day up to 56 µg/kg/day of AV-001 daily for 7 consecutive days by intravenous bolus injection.
16291158|NCT04737486|Placebo Comparator|Multiple Ascending Dose Cohort 1-2, Placebo|Intervention: Placebo, 2 subjects per cohort will receive multiple doses of D-PBS placebo daily for 7 consecutive days by intravenous bolus injection.
16291159|NCT04737473|Experimental|Opiod Free Anesthesia (OFA) group|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium 0.6mg/kg. Anesthesia will be maintained using isofluorane through volume controlled ventilation, and a mixture of magnesium sulfate 40mg/kg (without exceeding 2.5g/24h), lidocaine 1.5mg/kg, ketamine 25mg, and clonidine 1ug/kg in an electric pump syringe at 10 - 15 ml/h.
16291160|NCT04737473|Active Comparator|General anesthesia (GA) group|The GA protocol described in the intervention arm
16291161|NCT04737460|Experimental|AAV9/CLN7|"AAV9/CLN7 is an intrathecally administered AAV9-based gene therapy vector that expresses the fully functional form of MFSD8 under the control of a synthetic promoter. AAV9/CLN7 is designed to achieve stable, potentially life-long expression of MFSD8 in non-dividing cells.
~The first participant will receive a low dose of 5X1014 vg, subsequent participants will receive a higher dose of 1x1015 vg of the AAV9/CLN7 agent."
16291162|NCT04737447|Active Comparator|Group A (Control Group)|20 participants treated with standardized urophysiotherapy twice a week, once for 45 Minutes and then for 15 Minutes. Urophysiotherapy is a well manifested and standardized therapy in the treatment für children's incontinence after the age of five years.
16291163|NCT04737447|Active Comparator|Group B (Study Group)|20 participants treated with standardized urophysiotherapy and Whole Body Vibration training (WBVT). These patients are treated with the standardized urophysiotherapy once a week and furthermore they train with WBVT twice a week for each time 15 minutes. Criteria for modifying the device utilization are based on participant's age and therapy progress. The utilized frequency of the device is individually adapted to the participant. Older patients (> ten years old) are allowed to higher frequency standards than younger participants (< 10 years old). The amplitude (0.5 mm - 2 mm) is alternated to the participant's age and height. If side effects occur (e.g. dizziness), frequency can be alternated. The intended frequency level is between 10 an 20 Hz.
16291164|NCT04737434|Experimental|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave
16291165|NCT04737434|Placebo Comparator|electromagnetic field with no wave|electromagnetic field with no wave
16291166|NCT04737421||Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)|Subjects will be enrolled into Group 1 and treated with NobelActive TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
16291167|NCT04737421||Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)|Subjects will be enrolled into Group 1 and treated with NobelParallel CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
16291168|NCT04737421||Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with NobelReplace CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
16291169|NCT04737421||Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with Nobel Biocare N1 TiUltra TCC implants , only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
16291170|NCT04737408|Active Comparator|"Usual care"|"Usual care prevention: atorvastatin 40 mg per day for 18 months"
16291171|NCT04737408|Experimental|"Intensive care"|"Intensive care prevention: rosuvastatin 40 mg + ezetimib 10 mg per day for 18 months"
16291172|NCT04737395|Experimental|"Device-assisted therapy (Meditouch,MSQUARE)"|40 hours of therapy with the the Hand Tutor (MediTouch) device and a wearable vest (MSQUARE) for arm rehabilitation
16291173|NCT04737382|Other|Biopsy and blood|A histological core biopsy of a tumor lesion and a blood sample for ctDNA analysis will be collected
16291174|NCT04737356|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
16291175|NCT04737356|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
16291176|NCT04737343|Active Comparator|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg QD for 18 months combined with rednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period.All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intoleran.t
16291177|NCT04737343|Experimental|Leflunomide treatment arm|Patient will be treated with Leflunomide 30mg QD for 18 months combined with prednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period. All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intolerant.
16291180|NCT04737304|Experimental|Dose Regimen Low Dose|Low Dose Strength
16291181|NCT04737304|Experimental|Dose Regimen High Dose|High Dose Strength
16291182|NCT04737304|Placebo Comparator|Placebo|Placebo
16291183|NCT04737291|Experimental|Angioplasty by DCB|angioplasty of stenotic , ocluded or recoil segment using drug coated ballon
16291265|NCT04736784|Experimental|Leafy green vegetable juice|250 ml of green leafy vegetable juice per day for seven days
16291266|NCT04736758|Experimental|GP681 tablet 40mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 40mg orally once with 240mL water.
16291184|NCT04737278|Experimental|Cunermuspir|Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.
16291185|NCT04737278|Placebo Comparator|Placebo|Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm
16291188|NCT04737252|Experimental|COMPASS|Immediately receives 8-12 sessions of couple intervention aimed to improve self-injury thoughts and behaviours, emotion dysregulation, borderline personality disorder symptoms, and intimate relationship dysfunction.
16291189|NCT04737239||Patient with CTS/Mild EMG|
16291190|NCT04737239||Patient with CTS/Negative EMG|
16291191|NCT04737226|Experimental|Basketballers|
16291192|NCT04737226|Experimental|Volleyballers|
16291193|NCT04737226|Experimental|Runners|
16291194|NCT04737213|Experimental|SGM-101|Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery
16291195|NCT04737200|Experimental|Nighttime cycled enteral feeds first|Patients will start nighttime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start daytime cycled enteral feeds for 12 hours.
16291196|NCT04737200|Experimental|Daytime cycled enteral feeds first|Patients will start daytime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start nighttime cycled enteral feeds for 12 hours.
16291197|NCT04737187|Experimental|trifluridine/tipiracil in combination with bevacizumab|
16291198|NCT04737187|Active Comparator|trifluridine/tipiracil monotherapy|
16291199|NCT04737174|Experimental|ES-481|Administered as 25 mg oral gelatin capsules
16291200|NCT04737161|Experimental|T regulatory cell infusion|Infusion will be administered to the patient within 72 hours of collection from donor.
16291201|NCT04737135||Patients|Patients with Tetralogy of Fallot
16291202|NCT04737122|Experimental|LM061 Dose Escalation Level 1, 2.5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~first dose: 2.5mg QD, n=1;"
16291203|NCT04737122|Experimental|LM061 Dose Escalation Level 2, 5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~second dose: 5mg QD, n=3;"
16291204|NCT04737122|Experimental|LM061 Dose Escalation Level 3, 10mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~third dose: 10mg QD, n=3;"
16291205|NCT04737122|Experimental|LM061 Dose Escalation Level 4, 20mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~fourth dose: 20mg, n=3;"
16291206|NCT04737122|Experimental|LM061 Dose Escalation Level 5, 30mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~fifth dose: 30mg, n=3;"
16291207|NCT04737122|Experimental|LM061 Dose Escalation Level 6, 40mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~sixth dose: 40mg, n=9;"
16291208|NCT04737122|Experimental|LM061 Dose Escalation Level 7, 60mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.
~seventh dose: 60mg, n=15;"
16291211|NCT04737096|Experimental|tDCS+DAOIB|
16291212|NCT04737096|Placebo Comparator|tDCS+placebo|
16291213|NCT04737083||clubfoot fetuses|
16291214|NCT04737057|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding injections and drilling. It is one of a number of biologically orientated strategies for managing dental decay
16291215|NCT04737057|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a promising therapeutic agent for managing caries lesions in young children and those with special care needs
16291216|NCT04737044|No Intervention|Study 1: Normal sugar|Control group will be required to continue consuming normal sugar intake for 8 weeks.
16291217|NCT04737044|Experimental|Study 1:Minimally refined brown sugar (MRBS)|Intervention group will be required to consume MRBS as added sugar based on their habitual diet for 8 weeks intervention.
16291218|NCT04737044|No Intervention|Study 2: Normal sugar intake|- The control group will have no intervention and will continue with their normal daily intake for six months.
16291219|NCT04737044|Experimental|Study 2: White sugar|"Intervention group I will be advised to reduce sugar intake to no more than 10% from total energy intake.
~Intervention group I will be given white sugar for daily usage.
~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.
~For the first three months, one-to-one diet counseling will be conducted.
~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
16291267|NCT04736758|Experimental|GP681 tablet 20mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 20mg orally once with 240mL water.
16291268|NCT04736758|Placebo Comparator|Placebo group|Patients in the Placebo group is treated with GP681 Simulant orally once with 240mL water.
16291220|NCT04737044|Experimental|Study 2: MRBS|"Intervention group II will be advised to reduce sugar intake to no more than 10% from total energy intake.
~Intervention group II will be given MRBS for daily usage.
~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.
~For the first three months, one-to-one diet counseling will be conducted.
~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
16291221|NCT04737031|No Intervention|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice.
16291222|NCT04737031|Experimental|Clinician Nudge|Clinicians will receive a nudge via Best Practice Alert within the EMR
16291223|NCT04737031|Experimental|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status.
16291224|NCT04737031|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
16291225|NCT04737018|Experimental|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
16291226|NCT04737018|Sham Comparator|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
16291227|NCT04737005|Other|Nano-ceramic hybrid (Grandio Blocs) Endo-crown.|Nano-ceramic hybrid ( intervention)
16291228|NCT04737005|Active Comparator|Lithium di-silicate Ceramic (E.max CAD blocks) Endo-crown|Lithium di-silicate Ceramic ( Control)
16291229|NCT04736966|Experimental|Guselkumab 30mg|
16291230|NCT04736966|Experimental|Guselkumab 70 mg|
16291231|NCT04736966|Experimental|Guselkumab 100mg|
16291232|NCT04736953|Active Comparator|Sirolimus|Sirolimus 1 to 2 mg bid
16291233|NCT04736953|Placebo Comparator|Placebo|Placebo 1 to 2 mg bid
16291234|NCT04736940||Patients|Patients followed or currently treated for a solid or haematological neoplasia
16291235|NCT04736940||Doctors|Medical oncologist or haematologist
16291236|NCT04736940||Paramedical staff|Nurses or assistant nurses
16291237|NCT04736940||Oncopsychologist|Psychologist specialised in the care of patients with cancer
16291238|NCT04736927|Experimental|GLPG3667 + Midazolam|
16291239|NCT04736914|Experimental|Zanubrutinib+R-CHOP/R-DHAOx|"Induction:
~Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:
~ASCT conditioning
~Maintenance:
~Zanubrutinib, 160mg PO BID, continuously for 2 year
~Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT
~Requirements for start of maintenance:
~ANC ≥ 1,000 cells/mm³ (1.0 X 109/L);
~Platelets ≥ 50,000 cells/mm³ (50 X 109/L);"
16291240|NCT04736901||Group 1|Enoxaparin therapeutic dose
16291241|NCT04736901||Group 2|Enoxaparin prophylactic dose
16291242|NCT04736901||Group 3|Rivaroxaban therapeutic dose
16291243|NCT04736901||Group 4|Rivaroxaban prophylactic dose
16291244|NCT04736901||Group 5|Apixaban therapeutic dose
16291245|NCT04736901||Group 6|Apixaban prophylactic dose
16291246|NCT04736888|Sham Comparator|Conventional group|Conventional CPR training consists of a BLS video and a manikin equipped with a feedback device.
16291247|NCT04736888|Active Comparator|XR group|The XR group participants will be provided training via the XR BLS module and are allotted an additional 2 minutes that is needed to adapt to the XR equipment.
16291248|NCT04736875||Dialysis|Patients with hemodialysis-dependent end-stage renal disease and a newly created native arteriovenous fistula
16291249|NCT04736862|Experimental|Continuous monitoring group|
16291250|NCT04736862|Active Comparator|Intermittent monitoring group|
16291252|NCT04736836|Active Comparator|interventional|50 patient take rifaximin plus lactulose for 6 months
16291253|NCT04736836|Placebo Comparator|control|50 patient take lactulose for 6 months
16291254|NCT04736823|Experimental|Part1 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
16291255|NCT04736823|Experimental|Part1 Cohort2(AK112 + Pemetrexed +Carboplatin)|Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
16291256|NCT04736823|Experimental|Part1 Cohort3(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
16291257|NCT04736823|Experimental|Part2 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
16291258|NCT04736823|Experimental|Part2 Cohort2(Penpulimab(AK105) + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive Penpulimab(AK105) plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by Penpulimab(AK105) plus Pemetrexed until progression.
~Squamous NSCLC:Subjects receive Penpulimab(AK105) plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by Penpulimab(AK105) until progression."
16291259|NCT04736810|Experimental|AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride|
16291260|NCT04736810|Experimental|AK105 plus Cisplatin and Gemcitabine|
16291261|NCT04736810|Experimental|AK105 plus Gemcitabine and Anlotinib Hydrochloride|
16291262|NCT04736797||Patient|Transgender people who seek hormone treatment
16291263|NCT04736797||Control participants|volunteers without gender dysphoria
16291269|NCT04736745|Experimental|Dose escalation|"One single injection of study medication (IPN59011 or Placebo) will be injected locally. IPN59011 is injected in a dose-escalation manner.
~In total for this stage at least 40 subjects."
16291270|NCT04736745|Experimental|Dose ranging|"Up to two IPN59011dose(s) groups will be included in parallel groups versus Azzalure group and placebo group. One single injection of study medication will be injected locally into several sites.
~In total for this stage at least 70 subjects."
16291271|NCT04736745|Experimental|Additional dose ranging|"Dose-ranging for three additional placebo-controlled parallel groups. One single injection of study medication will be injected locally into several sites, concomitantly and non-concomitantly.
~In total for this stage at least 110 subjects."
16291272|NCT04736745|Experimental|Total dose for Upper Facial Lines|"One single injection of study medication will be injected locally into Upper Facial Lines.
~In total for this stage approximately 60 subjects."
16291273|NCT04736732||COVID-19 positive patients|"Patients who had previous asymptomatic or mild COVID-19 (mild=never required supplemental oxygen during the acute phase of the infection)
~Patients who had previous moderate or severe COVID-19 (moderate=required supplemental oxygen by nasal cannula during the acute phase of the infection; severe=required supplemental oxygen by either high-flow nasal cannula, non-invasive positive pressure ventilation or intubation
~Patients who had COVID-19 but did not have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis"
16291274|NCT04736732||COVID-19 negative patients|COVID-19 negative control group
16291275|NCT04736719||Warfarin|Reference group
16291276|NCT04736719||Apixaban|Exposure group
16291280|NCT04736693||Raloxifene|Reference Group
16291281|NCT04736693||Zoledronic Acid|Exposure Group
16291282|NCT04736680||Lost Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and missed.
16291283|NCT04736680||Attended Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and attended.
16291284|NCT04736667||Subjects fail screening for TMVI|Subjects with symptomatic mitral valve disease who after referral for TMVI, are deemed not to be candidates for TMVI.
16291285|NCT04736654||Patients group|Individuals with headache
16291286|NCT04736641||Patients group|Individuals with hip disease and chronic pain on hip
16291294|NCT04736602|Experimental|Triptorelin Pamoate 15mg for injection|Triptorelin will be injected at day 1 and month 3.
16291295|NCT04736589|Experimental|Inetetamab plus Rapamycin plus Chemotherapy|"Drug: Inetetamab Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks, until disease progression (PD) or other termination criteria are met;
~Drug: Rapamycin Oral 2mg, once a day;
~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
16291296|NCT04736589|Active Comparator|Pyrotinib plus chemotherapy|"Drug:Pyrotinib Oral 400mg, once a day;
~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
16291297|NCT04736576|Other|Group 1|Palbociclib plus endocrine therapy
16291298|NCT04736576|Other|Group 2|Endocrine monotherapy
16291299|NCT04736563|Experimental|patients with painful arthritis of the knee|Administration of joints and muscle gel Puressentiel containing of 14 essential oils
16291300|NCT04736550|Experimental|Assisted Exercise and I-STOP|Participant will receive Assisted Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
16291301|NCT04736550|Experimental|Voluntary Exercise and I-STOP|Participant will receive Voluntary Rate Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
16291302|NCT04736550|Experimental|No Exercise (TAU) and I-STOP|Participant will receive psychotherapy for pain (I-STOP). I-STOP will be offered 1 day/week.
16291303|NCT04736550|Experimental|Assisted Exercise and No I-STOP (TAU)|Participant will receive Assisted Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
16291304|NCT04736550|Experimental|Voluntary Exercise and No I-STOP (TAU)|Participant will receive Voluntary Rate Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
16291305|NCT04736550|No Intervention|No Exercise (TAU) and No I-STOP (TAU)|Participant will receive their usual behavioral treatment offered at the residential drug treatment center and their medicated assisted treatment (MAT) as applicable.
16291306|NCT04736537|Experimental|Healthy Controls|
16291307|NCT04736511|Other|Healthy volunteers|Handball players
16291308|NCT04736498|No Intervention|Control arm|Control group will follow the standard procedure in our centre and will not undergo USG assessment before spinal anaesthesia. The spinal anaesthesia procedure will be standardized. Under strict aseptic precautions spinal anesthesia will be performed at L3-L4 inter-space using a 25 Gauge Quincke spinal needle (B. Braun Medical SA, Melsungen, Germany) in sitting position. 3 ml of hyperbaric bupivacaine 0.5% (15 mg) will be injected with the needle orifice oriented cranially. After injection, patients will be immediately positioned supine. Meanwhile, the non-invasive blood pressure will be measured and recorded every 3 minute for 30 min and then every 5 min throughout surgery and anesthesia.
16291309|NCT04736498|Experimental|USG arm|In the IVC USG group, USG assessment and volume optimisation using collapsibility index will be done prior to spinal anaesthesia. all patients will be lying supine, for at least 5 min before IVC examination. Ultrasound measurements will be performed using a Sonosite M-Turbo (Sonosite Inc., USA) machine and phased array 5-1 Megahertz transducer (Sonosite Inc.) set to abdominal mode by an M-mode modality through the subcostal view. All IVC measurements will be performed by principal investigator before spinal anaesthesia. Principal investigator should have performed more than 25 scans before the commencement of the study.
16291310|NCT04736485|Experimental|FLOT regimen plus Spartalizumab|"Standard FLOT regimen
~Docetaxel 50 mg/m² IV infusion on D1
~Oxaliplatine 85 mg/m² IV infusion on D1
~Leucovorin 200 mg/m² IV infusion on D1
~Fluorouracile 2600 mg/m² 24 h IV infusion on D1
~with Spartalizumab PDR001 Patients will received the fixed dose of 400 mg per IV infusion on D1 every four weeks (q4w) for 2 pre-operative cycles (8 weeks) and 2 post-operative cycles (8 weeks)"
16291311|NCT04736472|Experimental|DPYD/UGT1A1 pharmacogenetic testing|"All patients will be screened for twelve single nucleotide polymorphisms (SNPs) in DPYD: DPYD*2A, *5, *6, *8, *9A, *10, *12, *13, rs2297595, rs115232898, rs67376798, HapB3.
~All patients will be screened for two SNPs in UGT1A1: UGT1A1*6, *28."
16291312|NCT04736459|Experimental|Washed Catheter|Washed catheter arm: will be washed with culture medium before insemination
16291313|NCT04736459|Sham Comparator|Unwashed Catheter|Unwashed catheter arm: will not be washed with culture medium.
16291314|NCT04736446|Experimental|I-gel® group|Continuous chest compressions from the start of the CPR with early i-gel® device insertion and asynchronous ventilations
16291315|NCT04736446|Other|Standard group|Basic (standard) management by using a ratio of 30 compressions and 2 face mask ventilations
16291316|NCT04736433||ACE Inhibitors|Reference group
16291317|NCT04736433||Sacubitril/Valsartan|Exposure group
16291318|NCT04736420||Warfarin|Reference group
16291319|NCT04736420||Rivaroxaban|Exposure group
16291320|NCT04736407||Repositioned|Allocated to sampling performed around a standard clinical repositioning (lateral side to side), or a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling.
16291321|NCT04736407||Non-repositioned|Allocated to sampling performed with a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling
16291322|NCT04736394|Active Comparator|Epirubicin hydrochloride group|intravesical instillation of Epirubicin hydrochloride
16291323|NCT04736394|Experimental|APL-1202 group|receive APL-1202 single-agent oral treatment
16291324|NCT04736381||Kidney transplanted patients treated with Nulojix|Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.
16291325|NCT04736368|Experimental|EDIP Group|CD participants will receive EDIP diet information
16291326|NCT04736368|Placebo Comparator|Control Group|CD participants will be given diet suggestions according to routine experience.
16291327|NCT04736355|Experimental|DAOIB|oral, for 24 weeks
16291328|NCT04736355|Placebo Comparator|Placebo|oral, for 24 weeks
16291329|NCT04736329|Active Comparator|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
16291330|NCT04736329|No Intervention|Enalapril|Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.
16291331|NCT04736316|Experimental|Early CCLAD|Early community client-led ART delivery groups
16291332|NCT04736303|No Intervention|POD without BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery, with CAM and Nu-DESC tools.
16291333|NCT04736303|Active Comparator|POD with BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery with the implementation of BIS monitoring, with CAM and Nu-DESC tools.
16291334|NCT04736290||Noncardiac surgery|Calculation of the NLR and PLR in patients undergoing noncardiac surgery under general anesthesia
16291335|NCT04736277||Noncardiac surgery|Documentation of HbA1c in patients undergoing noncardiac surgery under general anesthesia
16291336|NCT04736264|Active Comparator|Rehabilitation group|"This is the phase 3 of the entire research protocol. Phase 3 will be initiated once the phase 2 (development of rehabilitation module) is completed. A user friendly and inexpensive device and program with minimal usage of low vision aid will be designed and piloted. There are 3 different rehabilitation modules.
~A total of 300 primary glaucoma patients will be recruited and randomized using SNOSE: 150 intervention group and 150 non-intervention group. The intervention group will comprised of 150 primary glaucoma patients who will be assigned to different rehabilitation program:
~navigation and mobility (50 patients)
~physical activities including special exercise (50 patients)
~reading (50 patients) There will be no patient who will be involved in more than one rehabilitation program at anytime."
16291337|NCT04736264|No Intervention|Non-rehabilititation group|Group of primary glaucoma patients who are not taught and practiced the new rehabilitation module for navigation, physical activity (exercise) and reading. They will be asked to continue their regular activities and provided with the similar reading material (book) to read daily.
16291338|NCT04736238|Experimental|Trial group|The patients who receive arthroscopic surgery.
16291339|NCT04736238|Other|Control group|The patients who receive BrostrÖm surgery.
16291340|NCT04736225|Experimental|ISTE Group|This program includes a 60-min small-group lesson, a 20-min individual instruction. The education program's goal is to teach patients to self-titrate their insulin doses every six days to maintain their six-day average blood glucose levels < 120 mg/dl
16291382|NCT04735952||AIM 2|No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.
16291341|NCT04736225|Placebo Comparator|Non-ISTE Group|The usual care (a 15-min individual education) was giving at the Diabetes Health Education Center. They were taught how to self-inject insulin and test and record their before-breakfast and before-dinner blood glucose levels daily at home.
16291344|NCT04736186|Experimental|Loperamide|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21)
16291345|NCT04736186|Experimental|Loperamide and gold bifid|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + gold bifid2g T.I.D.
16291346|NCT04736186|Experimental|Loperamide and Montmorillonite SAN|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + Montmorillonite SAN 3 g, T.I.D.
16291347|NCT04736186|No Intervention|Non-intervention|Do not intervene and stop diarrhea as needed
16291351|NCT04736147|Experimental|JNJ-64300535|Participants will receive an electroporation-mediated intramuscular (IM) injection of JNJ-64300535 vaccine.
16291352|NCT04736134|Experimental|Active Treatment (BMS 986326) IV|Intravenous (IV)
16291353|NCT04736134|Experimental|Active Treatment (BMS 986326) SC|Subcutaneous (SC)
16291354|NCT04736134|Placebo Comparator|Placebo IV|
16291355|NCT04736134|Placebo Comparator|Placebo SC|
16291357|NCT04736108|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before radical prostatectomy
16291358|NCT04736095||3D ultrasound for diagnosis of submucous myomas|
16291359|NCT04736095||Hysteroscopy for diagnosis of submucous myoma|
16291360|NCT04736082|Experimental|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive the following infant formula: Infant formula manufactured from extensively hydrolyzed proteins and containing pre- and probiotics.
16291361|NCT04736082|Active Comparator|Control Group: Infant Formula with intact protein|Infants will receive the following infant formula: Infant formula manufactured from intact proteins and containing pre- and probiotics.
16291362|NCT04736082|No Intervention|Breast Fed Group|Exclusively breast milk
16291363|NCT04736069|Active Comparator|Inpatient physical therapy program|The group received 21 sessions of physical therapy program including electrotherapy, superficial- deep heat applications and basic knee exercise program at inpatient clinic.
16291364|NCT04736069|Active Comparator|Outpatient physical therapy program|The group received the same physical therapy program including electrotherapy, superficial-deep heat applications and basic knee exercise program at outpatient clinic.
16291365|NCT04736056|Experimental|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|"Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills (MBTI+)
~The MBTI+ intervention will train participants in mindfulness-based sleep strategies and behavioral symptom management techniques. The MBTI+ intervention will consist of 6 weekly sessions that will last between 60 and 75 minutes."
16291366|NCT04736043||Patients with resected pancreatic cancer who require adjuvant chemotherapy|
16291367|NCT04736030|Experimental|Conmigo PA Intervention|12-week program (90 minutes/week)
16291368|NCT04736030|No Intervention|Delayed Abbreviated Intervention|No intervention during experimental phase; participants in control group receive abridged program after the final measurement point (wait list control).
16291369|NCT04736017|Experimental|Verum|The device records EEG and other biosignals throughout the night and scans these signals for slow waves associated with deep Non-Rapid Eye Movement (NREM) sleep. Upon recognition of such slow waves and fulfilment of other criteria, a tone is played via the headphones to stimulate and enhance slow waves without waking up the patient.
16291370|NCT04736017|Sham Comparator|Sham|Playing no tones during NREM sleep but wearing the device and recording the biosignals over a period of 2 weeks, every night.
16291371|NCT04736004||Athletes with COVID-19|
16291372|NCT04736004||Athletes without COVID-19 (control)|
16291373|NCT04735991|No Intervention|Control group|The patient's family members need to fill in the family member quality of life questionnaire during the screening and follow-up period. They are able to contact the doctor for questions in terms of medical treatment.
16291374|NCT04735991|Experimental|Study group|The family members of the patients need to fill in the family member quality of life questionnaire during the screening period and follow-up period, and are involved in an interactive management program on the mobile terminal, full participation required.
16291375|NCT04735978|Experimental|Dose escalation of RP3 - superficial and/or deep/visceral tumors|Dose escalation of RP3 alone in 2 cohorts with intratumoral (IT) injections including use of imaging guided injection for deep tumors.
16291376|NCT04735978|Experimental|Dose combination of RP3 and anti-PD1 therapy - superficial and/or deep/visceral tumors|Dose combination of RP3 and anti-PD1 therapy. IT injections of RP3 including use of imaging guided injection for deep tumors.
16291377|NCT04735978|Experimental|Seronegative cohort|Doses of RP3 (IT) in HSV seronegative participants.
16291378|NCT04735965|Experimental|Dexmedetomidine group|
16291379|NCT04735965|Active Comparator|Meperidine group|
16291380|NCT04735965|Placebo Comparator|Control group|
16291381|NCT04735952||AIM 1|No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.
16291383|NCT04735939||morning dosing radiotherapy|
16291384|NCT04735939||evening dosing radiotherapy|
16291385|NCT04735926|Placebo Comparator|Group 1A|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
16291386|NCT04735926|Experimental|Group 1B|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
16291387|NCT04735926|Experimental|Group 1C|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
16291388|NCT04735926|Placebo Comparator|Group 2A|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
16291389|NCT04735926|Experimental|Group 2B|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
16291390|NCT04735926|Experimental|Group 2C|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
16291391|NCT04735913|Other|Fasting group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
16291392|NCT04735913|Experimental|Postprandial group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)orally after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
16291393|NCT04735900|Experimental|First-line FOLFOX/FOLFIRI and panitumumab.|Chemotherapeutic agents will be given as an intravenous infusion at a dose and interval consistent with standard institutional practice.
16291394|NCT04735887|Experimental|SADL-eM & conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive a copy of the SADL-eM in addition to conventional therapy.
16291395|NCT04735887|No Intervention|Conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive conventional therapy.
16291396|NCT04735874||Children ages 10.0 to 18.0|
16291397|NCT04735861|Experimental|Combination Arm|Sintilimab 200mg iv., q3w, up to 2 years; Bevacizumab 15mg/kg iv., q3w, up to 22 cycles. Treatment is given until confirmed progression, death, unacceptable toxicity, or any other protocol-specified criterion for withdrawal, whichever occurs first.
16291398|NCT04735848|Experimental|6mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
16291399|NCT04735848|Experimental|30mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
16291400|NCT04735848|Experimental|60mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
16291401|NCT04735848|No Intervention|Baseline|Baseline measurement
16291402|NCT04735835|Experimental|Dietary Intervention|Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
16291403|NCT04735822|Experimental|Part 1: Belumosudil Sequence ABFCED|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen A (delivered by Vehicle 1); Regimen B (delivered by Vehicle 2); Regimen F (delivered by Vehicle 6); Regimen C (delivered by Vehicle 3); Regimen E (delivered by Vehicle 5); Regimen D (delivered by Vehicle 4);
16291404|NCT04735822|Experimental|Part 1: Belumosudil Sequence BCADFE|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen B (delivered by Vehicle 2); Regimen C (delivered by Vehicle 3); Regimen A (delivered by Vehicle 1); Regimen D (delivered by Vehicle 4); Regimen F (delivered by Vehicle 6); Regimen E (delivered by Vehicle 5)
16291405|NCT04735822|Experimental|Part 1: Belumosudil Sequence CDBEAF|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen C (delivered by Vehicle 3); Regimen D (delivered by Vehicle 4); Regimen B (delivered by Vehicle 2); Regimen E (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen F (delivered by Vehicle 6)
16291406|NCT04735822|Experimental|Part 1: Belumosudil Sequence DECFBA|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen D (delivered by Vehicle 4); Regimen E (delivered by Vehicle 5); Regimen C (delivered by Vehicle 3); Regimen F (delivered by Vehicle 6); Regimen B (delivered by Vehicle 2); Regimen A (delivered by Vehicle 1)
16291407|NCT04735822|Experimental|Part 1: Belumosudil Sequence EFDACB|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen E (delivered by Vehicle 5); Regimen F (delivered by Vehicle 6); Regimen D (delivered by Vehicle 4); Regimen A (delivered by Vehicle 1); Regimen C (delivered by Vehicle 3); Regimen B (delivered by Vehicle 2)
16291408|NCT04735822|Experimental|Part 1: Belumosudil Sequence FAEBDC|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen F (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen E (delivered by Vehicle 5); Regimen B (delivered by Vehicle 2); Regimen D (delivered by Vehicle 4); Regimen C (delivered by Vehicle 3).
16291409|NCT04735822|Experimental|Part 2: Belumosudil Sequence GHI|Subjects receive 1 dose in the following sequence; Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed)
16291410|NCT04735822|Experimental|Part 2: Belumosudil Sequence HIG|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed)
16291411|NCT04735822|Experimental|Part 2: Belumosudil Sequence IGH|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
16291412|NCT04735822|Experimental|Part 2: Belumosudil Sequence IHG|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet fed)
16291413|NCT04735822|Experimental|Part 2: Belumosudil Sequence GIH|Subjects receive 1 dose in the following sequence: Regimen G (belumosudil 200 mg tablet fed); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
16291414|NCT04735822|Experimental|Part 2: Belumosudil Sequence HGI|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed);
16291415|NCT04735809|Placebo Comparator|Placebo|Microcystalline Cellulose
16291422|NCT04735783|Experimental|Very low-energy, viscous placebo breakfast|Participants will consumed a viscous breakfast meal from a standard bowl with a standard spoon. The volume of the meal will be 5 mL/kg body mass, consisting of 15% (0.75 mL/kg body mass) low-energy flavoured squash, with the remainder made up of tap water. To thicken the solution and increase the perception of energy intake, 0.1 g/kg xanthan gum (a soluble fibre often used as a low-energy thickening agent) will be added and the mixture will be blended thoroughly. An additional 3 mL/kg tap water will be consumed as a drink alongside the meal in this trial.
16291423|NCT04735783|Active Comparator|Typical, whole-food breakfast|Participants will consume a standardised meal consisting of puffed rice cereal, semi-skimmed milk, white bread, seedless strawberry jam, and apple juice. This meal will provide 20% of estimated energy requirements, determined by multiplying estimated resting metabolic rate by a physical activity level of 1.6. A measured volume of tap water will be consumed alongside this meal, in order to match total water content of the typical whole-food breakfast to the very low-energy, viscous placebo breakfast.
16291424|NCT04735783|Active Comparator|Water-only control|Participants will consume 8 mL/kg body mass of plain tap water to match the total water content of the typical whole-food breakfast and the very low-energy, viscous placebo breakfast.
16291425|NCT04735770|Experimental|LTAP|Patients receive laparoscopically inserted TAP block with levobupivacain and local wound anesthesia injections with saline.
16291426|NCT04735770|Active Comparator|Local wound analgesia|Patients receive laparoscopically inserted TAP block with saline and local wound anesthesia injections with levobupivacaine.
16291427|NCT04735757||Healthy volunteers|Healthy volunteers, matched by age and gender to patient groups.
16291428|NCT04735757||COVID-19 patients|Patients discharged from the ICU after invasive ventilation for COVID-19.
16291429|NCT04735757||ICU patients|Patients discharged from the ICU after invasive ventilation for ARDS.
16291430|NCT04735744||Prospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
16291431|NCT04735744||Retrospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
16291432|NCT04735731||EBV-patients|Patients who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves
16291434|NCT04735705|Experimental|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.
16291435|NCT04735692||Control|Evaluation of serum and salivary MMP-9
16291436|NCT04735692||Periodontitis|Evaluation of serum and salivary MMP-9
16291437|NCT04735692||Cardiovascular disease|Evaluation of serum and salivary MMP-9
16291438|NCT04735692||Periodontitis + cardiovascular disease|Evaluation of serum and salivary MMP-9
16291439|NCT04735653|Experimental|Personalized Glaucoma Coaching|
16291440|NCT04735653|Active Comparator|Enhanced standard care|
16291441|NCT04735640|Experimental|Nurse-led teleconsultation group|9-month nurse-led telephone-based personalized behavioural intervention.
16291442|NCT04735640|Active Comparator|SMS group|Behavioural intervention by means of short text messages.
16291443|NCT04735627|Experimental|Levodopameter|During the single study visit, participants will receive either: 1) two separate doses of oral levodopa in a dose equivalent to their home regimen with one dose of carbidopa in a 1:10 ratio and one dose of carbidopa in a 1:4 ratio (carbidopa:levodopa) ratio; or will receive 2) one dose of oral carbidopa 100mg followed by intravenous levodopa in 1.2mg/kg dose. levodopa The Levodopameter microneedle sensor device will serially measure interstitial fluid levodopa levels and blood will be simultaneously collected from an intravenous line for high-performance liquid chromotography analysis of plasma levodopa levels.
16291444|NCT04735614|Experimental|ThoraxBelt|Received ThoraxBelt after the surgery. Standard care for pain management will be the same as the Standard Care Arm.
16291445|NCT04735614|No Intervention|Standard care|Standard care with IV PCA and on-request oral painkiller.
16291446|NCT04735601|Experimental|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome
16291447|NCT04735601|Active Comparator|Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve will be implanted alone with no PLGA
16291448|NCT04735575|Experimental|EMB-06|"In Phase I part: participants enrolled at different time will receive EMB-06 once weekly (IV) at different ascending dose levels.
~In Phase II part: participants will receive EMB-06 once weekly (IV) at previously defined RP2D."
16291449|NCT04735549|Experimental|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks.
~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
16291450|NCT04735549|Active Comparator|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms.
16351276|NCT04319666|Experimental|PCI to left main with IVL|
16291451|NCT04735549|Experimental|Laser Treatment + Topical hormone|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks. During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.
~At the same time local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms."
16291452|NCT04735536|Experimental|Active Treatment- CT1812|Active Treatment- CT1812 at a dose of 300mg
16291453|NCT04735536|Placebo Comparator|Control - Placebo|Drug: Placebo Non-active study drug
16291454|NCT04735523||Warfarin|Reference group
16291455|NCT04735523||Dabigatran|Exposure group
16291456|NCT04735510|Other|Single arm|This is a single arm study in which all subjects will receive study medication.
16291457|NCT04735497||Failed Weaning|Patients who failed to be liberated from mechanical ventillation
16291458|NCT04735497||Successful Weaning|Patients who were liberated from mechanical ventillation and needed no respiratory support
16291459|NCT04735484||Case|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
16291460|NCT04735484||Control|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
16291461|NCT04735471|Experimental|ADI-001 Dose Escalation|ADI-001 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal ADI-001 dose (Part 1).
16291462|NCT04735471|Experimental|ADI-001 Dose Expansion|ADI-001 is administered via infusion to 3 NHL subtypes to confirm dose (Part 2).
16291463|NCT04735471|Experimental|ADI-001 in combination with Interleukin-2|ADI-001 is administered via infusion in combination with subcutaneously administered IL-2 (Part 3).
16291464|NCT04735458|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
16291465|NCT04735458|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
16291466|NCT04735445|Active Comparator|Conventional screening|Standard screening in the participating centers, adjusted to the recommendations of the European AIDS Society (EACS).
16291467|NCT04735445|Experimental|Enhanced screening|Expanded screening for early detection of lung, liver, anal, cervical, breast, prostate, colorectal and skin cancer.
16291468|NCT04735432|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
16291469|NCT04735432|Experimental|efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
16291470|NCT04735419||Cases|Cases are defined as infants who develop invasive GBS disease (iGBS disease= isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life.
16291471|NCT04735419||Controls|Controls are defined as infants who are exposed to the same serotype of GBS at birth as the case - but who do not develop iGBS disease in the first 90 days of life.
16291472|NCT04735406||Multiple Sclerosis (MS)|Data from the participants with diagnosed MS treated and untreated will be part of this study. Medical records of participants will be used to collect demographics and data pertaining to Multiple Sclerosis (MS) management.
16291473|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.|
16291474|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.|
16291475|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.|
16291476|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.|
16291478|NCT04735341||Subjects with planned Ion Endoluminal Procedure with pulmonary nodule|
16291479|NCT04735328|Other|Intervention|"When clinics join the intervention, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.
~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR and CT-PTSD)."
16291480|NCT04735315||Born preterm|"Inclusion :
~Born preterm ≤29 weeks Aged 18-40 years Participants with type-2 diabetes
~Exclusion :
~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
16291481|NCT04735315||Born term|"Inclusion :
~Born full-term at 37-41 weeks Birthweight ˃2500g Aged 18-40 years Participants with type-2 diabetes
~Exclusion :
~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
16291482|NCT04735302||Sarcoidosis, Nonsarcoidosis|
16291483|NCT04735302||Malign, benign|
16291484|NCT04735289||GROUP 1 - 215 Patients and 430 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included
~Localized and metastatic
~Male and female
~Control cases matched by age, sex and italian geographic area"
16291485|NCT04735289||GROUP 2 - Pilot Phase :55 Patients and 110 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included Localized and metastatic Male and female
~Control cases matched by age, sex, and geographic area"
16291486|NCT04735263|Other|Intermediate Age-Related macular degeneration patients|"Subjects can have either:
~Bilateral high-risk iAMD
~High-risk iAMD in one eye with GA and/or CNV in the fellow eye No control arm"
16291487|NCT04735250||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
16291488|NCT04735250||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
16291489|NCT04735250||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
16291490|NCT04735237|Experimental|Autogenous fat injection|Fat will first be harvested from the abdomen, then injected into the lip
16291491|NCT04735237|Active Comparator|Surgical revision with orbicularis oris muscle reconstruction|
16291492|NCT04735211||Children whom develop chronic postsurgical pain|Children whom had chronic pain at 3 moths after surgery
16291493|NCT04735211||Children whom not develop chronic postsurgical pain|Children whom not develop chronic pain at 3 moths after surgery
16291494|NCT04735198|Active Comparator|Experimental group|Patients with midgut neuroendocrine tumor who will undergo only primary tumor surgery.
16291495|NCT04735198|Experimental|Control group|Patients with midgut neuroendocrine tumor that will undergo through primary tumor surgery combined with prophylactic cholecystectomy.
16291496|NCT04735185|Active Comparator|Intradiscal autologous stem cells|Participants in this arm will have autologous stem cells harvested through bone marrow aspiration. The stem cells that were harvested will be processed and injected into affected intradiscal spaces in the lumber spine.
16291497|NCT04735185|Active Comparator|Intradiscal corticosteroid and local anesthetic|Participants in this arm will receive an intradiscal injection of the steroid methylprednisolone and the local anesthetic bupivacaine into affected intradiscal spaces in the lumber spine.
16291498|NCT04735172|Experimental|de novo PD patients|"Patients will be included:
~suffering from idiopathic Parkinson's disease according to UKPDSBB criteria (Gibb & Lees, 1988; Hughes et al., 1992),
~the stage of the disease is I-II according to the Hoehn and Yahr scale,
~which do not receive dopaminergic treatment,
~duration of disease development: 5 years,
~without major cognitive impairment (Moca > 24)
~men or women aged 18 to 75,
~having understood and signed the informed consent form,
~members of a social security scheme."
16291499|NCT04735172|Experimental|control subjects|"subjects male or female aged 18 -75 years
~subjects affiliated to a social security scheme.
~volunteers who have given their written consent. They will be matched to de novo PD patients according to age, sex and level of education."
16291500|NCT04735159|Active Comparator|Study group-SCS Impanted|30 patients with chronic pain (at least 6 months) with pre- and post-surgery evaluation (imaging and clinical evaluation) implanted with Precision SpectraTM for the validation study and for the construction of the predictive model.
16291501|NCT04735159|No Intervention|Comparator-chronic pain|20 patients with chronic pain (at least 6 months) with degenerative spine pain. Non-specific low-back pain, nociceptive pain / mixed neuropathic. This will be the comparator group
16291502|NCT04735159|No Intervention|Control-healthy volunteers|10 volunteers without pain or related disease, age less than 25 years, to establish a control group whose pattern is used as a comparator with chronic pain groups. This is the control group
16291503|NCT04735146|Experimental|Experimental Group|The Experimental Group will be involved in 1 weekly session of adapted physical activity lasting 1 hour for 6 weeks within the normal cycle of accompanying birth meetings provided by the University Hospital of Bologna.
16291504|NCT04735146|No Intervention|Control Group|The control group is expected to participate in 6 birth accompaniment meetings held online, 1 hour of which will be dedicated to the topic of exercise and physical activity recommendations in pregnancy.
16291505|NCT04735133|Experimental|intervention grpup|pNPWT device was placed in the pNPWT group for seven days. The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
16291506|NCT04735133|No Intervention|control group|"The wound of the control group was covered with a sterile gauze dressing. After the wound was left closed for 48 hours in the clinical routine, the surgical site was left open, supporting healing. Therefore, the dressing of the control group was removed after 48 hours, and the wound was left open.
~The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI."
16291507|NCT04735120|Experimental|Laser to reduce pain intraoperatively and post operatively|Diode lasers are used to assess its efficacy in reducing intraoperative and postoperative pain following root canal treatment in mandibular molar teeth with acute irreversible pulpitis
16291508|NCT04735107|Experimental|Reinforcement|Low anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage
16291509|NCT04735094|Experimental|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|
16291510|NCT04735094|No Intervention|Endobronchial biopsy without the use of a balloon attached to the echo-bronchoscope|
16291511|NCT04735081||First group before practice change|Infectious spondylodiscitis when prolonged immoblization in bed was recommanded in our hospital
16291512|NCT04735081||Second group after practice change|Infectious spondylodiscitis when early verticalization was recommanded in our hospital
16291513|NCT04735068|Experimental|Binimetinib and Hydroxychloroquine|"Hydroxychloroquine (HCQ)in combination with Binimetinib (B). The starting dose for HCQ will be 400mg. Tablets of HCQ are available in 200 mg strength. HCQ will be administered in divided doses (every 12 hours) with or without food.
~The starting dose of B is 45mg. B will be administered in divided doses (every 12 hours) with or without food"
16291585|NCT04734535|Active Comparator|control|absorbable gelatin sponge with thrombin
16291514|NCT04735055||Artificial intelligence (AI) machine learning group|"90% machine learning part has also been divided into 2 parts as 70% for AI learning and 30% for testing the learning.
~70% of the acute pancreatitis patients (approximately 840 pts) will form the model training group of the study. 30% of the acute pancreatitis patients (approximately 360 pts) will form the testing group of the study.
~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
16291515|NCT04735055||Validation group|"10% of the acute pancreatitis patients (approximately 134) will form the validation group of the study.
~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
16291516|NCT04735042||SGLT2 and DPP-4 inhibitors|Patients undergoing SGLT2i and DPP4i.
16291517|NCT04735042||SGLT2 inhibitors only|Patients undergoing SGLT2i alone.
16291518|NCT04735029|Experimental|Thermal Gun group|"The thermal gun applied on acupressure points in TCM. The thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
16291519|NCT04735029|Active Comparator|Heat Pack group|A hydrocollator heat pack used to simulate traditional thermal therapy. The application of the heat pack was wrapped with six layers of terry towels to bring the temperature down to around 43°C.
16291520|NCT04735016||Treatment Arm|Patients enrolled and treated with the DiamondTemp™ Ablation System
16291521|NCT04734990|Experimental|Treatment (azacitidine, seclidemstat)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7. Patients also receive seclidemstat PO QD on day 1 of cycle 1 and PO BID on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 planned dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16291522|NCT04734977|Experimental|HILT+exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
16291523|NCT04734977|Sham Comparator|Sham HILT+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
16291524|NCT04734977|Active Comparator|Exercise only|Exercise program was applied in five sessions a week for four weeks, with a total of 20 sessions a day.
16291525|NCT04734964|No Intervention|Control group|Participants underwent only common physical education classes twice per week for 45 minutes each and no additional after-school exercises.
16291526|NCT04734964|Experimental|Coordinative exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
16291527|NCT04734964|Experimental|Cardiovascular exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
16291528|NCT04734951|Active Comparator|Power/resistance exercise|Participants on a power/resistance exercise program
16291529|NCT04734951|Active Comparator|HMB oral supplementation|Participants on HMB oral supplementation
16291530|NCT04734951|Experimental|Power/resistance exercise + HMB|Participants on combined power/resistance exercise program + HMB oral supplementation
16291531|NCT04734938|No Intervention|Habitual Diet|All volunteers will participate in this arm, continuing this habitual diet for 1 week
16291532|NCT04734938|Experimental|100% Huel|All volunteers will participate in this arm of the study and consumer 100% Huel as their food for 4 weeks
16291533|NCT04734912|Other|Gastroscopy in transnasal technique|All patients with indication for gastroscopy in transnasal techqiue are included.
16291534|NCT04734899|Active Comparator|Control grup|"All individuals participating in the study will be taught the exercises given to strengthen weakened muscles, stretch shortened structures and increase proprioception by the physiotherapist and will be asked to do these exercises at least twice a day for 8 weeks.
~The home program will be followed by the exercise daily form."
16291535|NCT04734899|Experimental|Foot core grup|In addition to the exercise program given to the control group, foot core training will be added and taught by the physiotherapist and they will be asked to do these exercises at least twice a day for 8 weeks.
16291536|NCT04734886|Active Comparator|L. reuteri DSM 17938|Probiotic compound
16291537|NCT04734886|Placebo Comparator|Placebo|Placebo compound
16291538|NCT04734873|Experimental|CPI-006 (2 mg/kg) Plus Standard of Care|Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.
16291539|NCT04734873|Experimental|CPI-006 (1 mg/kg) Plus Standard of Care|Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.
16291540|NCT04734873|Placebo Comparator|Placebo Plus Standard of Care|Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.
16291541|NCT04734860|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
16291542|NCT04734860|Placebo Comparator|Placebo|A single injection of placebo will be administered
16291543|NCT04734847|Active Comparator|High-frequency rTMS|"Intensity: rTMS treatment intensity determined using resting motor threshold (RMT). Treatment will be delivered at 80% of the RMT.
~Site of Stimulation: Region of supplementary motor area (SMA) that regulates pelvic floor muscle activity. This target is defined in Montreal Neurological Institute (MNI) Coordinates of X=-2, Y=-16, and Z=68 mm.
~Frequency: 10 Hz.
~Duration: 20 Trains, 10 second duration, 50 second inter-train interval.
~Total number of pulses per session: 2000.
~Total number of session: 5 (one session per day for 5 consecutive days)."
16291544|NCT04734847|Sham Comparator|Sham rTMS|"Identical to the High-frequency rTMS arm except delivered with an inert sham stimulation coil."
16291545|NCT04734834|Placebo Comparator|Placebo|"Placebo will be provided orally to the Placebo Group. Placebo will be blinded and labeled either as A or B."
16291583|NCT04734548|Placebo Comparator|Phase IIa Placebo|Placebo is administered intravenously in one arm which includes 49 patients.
16291546|NCT04734834|Active Comparator|"Prodovite® VMP35"|"Prodovite® VMP35 will be provided orally to the Treatment Group. Prodovite® VMP35 will be blinded and labeled either as A or B."
16291547|NCT04734821|Experimental|NIR Fluorescence guided lymphadenectomy and anastomosis|
16291548|NCT04734782||Protective Mothers (high IGG titers)|Protected group Newborns with congenital heart disease + high titers of anti-RSV IGG in the mother's serum before birth
16291549|NCT04734782||Non-protective mothers (low IGG titers)|Unprotected group Newborn with congenital heart disease + negative anti-RSV IGG titers in the mother's serum before birth.
16291550|NCT04734769||Cycles of embryo transfer from patients with at least one euploid embryo (no rebiopsy group)|Collect retrospectively clinical data on reproductive outcomes
16291551|NCT04734769||Rebiopsy group:|Collect retrospectively clinical data on reproductive outcomes
16291552|NCT04734756|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
16291553|NCT04734743|Other|Cystic fibrosis|
16291554|NCT04734730|Experimental|Treatment (talazoparib, androgen deprivation therapy)|Patients receive talazoparib PO QD, abiraterone acetate PO QD, and prednisone PO QD on days 1-28. Patients also receive androgen deprivation therapy consisting of degarelix SC on day 1; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of subsequent cycles; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of cycles 2, 5, 8, and 11; or goserelin acetate SC monthly or every 3 months. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16291555|NCT04734717|Experimental|COVID19|
16291556|NCT04734717|Experimental|Controll|
16291557|NCT04734704|Experimental|vitiligo patients|Adult patients diagnosed with Vitiligo according to usual criteria
16291558|NCT04734704|Experimental|metastatic melanoma patients under anti-PD-1 who did not develop cutaneous irAEs|metastatic melanoma patients under anti-PD-1 who did not develop Cutaneous Immune-Related Adverse Events (cutaneous irAEs).
16291559|NCT04734704|Experimental|Metastatic melanoma patients under anti-PD-1 who developed vitiligo lesions|patients with metastatic melanoma, under anti-PD-1 who developed vitiligo lesions
16291560|NCT04734704|Experimental|metastatic melanoma patients with vitiligo lesions under anti-PD-1 who discontinued|Metastatic melanoma who developed vitiligo lesions under anti-PD-1 who discontinued the treatment
16291561|NCT04734691|Experimental|Experimental Arm|
16291562|NCT04734691|Active Comparator|Control Arm|
16291563|NCT04734678||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
16291564|NCT04734678||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.
16291565|NCT04734665|Experimental|experimental|Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous
16291566|NCT04734652|Experimental|BIC arm|The Intervention Arm ART regimen is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.
16291567|NCT04734652|Active Comparator|DTG Arm|Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)
16291568|NCT04734639|Experimental|Obese adolescents|20 adolescents with obesity are involved and will perform the three conditions.
16291569|NCT04734626||Mitochondrial Disease|Individuals with suspected (based on clinical presentation) or definite genetic mitochondrial disease
16291570|NCT04734613|Experimental|Tai Chi intervention|Tai Chi exercise intervention provided twice a week for one hour for 12 weeks
16291571|NCT04734613|Active Comparator|self management|self management program provided 6 sessions (one hour per session) for 12 weeks
16291572|NCT04734600|Experimental|aerobic training program|group a:twenty patients who will receive aerobic training program combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
16291573|NCT04734600|Active Comparator|myofascial release technique|group B: twenty patients who will receive myofascial release technique combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
16291574|NCT04734587||Chronic Total Occlusion|Chronic total occlusion patients undergoing percutaneous coronary intervention.
16291575|NCT04734587||Non-Chronic Total Occlusion|Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.
16291576|NCT04734561|Experimental|Inspiratory muscle training group|Participants will perform an inspiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
16291577|NCT04734561|Sham Comparator|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
16291578|NCT04734561|Experimental|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
16291579|NCT04734561|Sham Comparator|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
16291580|NCT04734548|Active Comparator|Phase Ib ApTOLL|ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.
16291581|NCT04734548|Placebo Comparator|Phase Ib Placebo|Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
16291582|NCT04734548|Active Comparator|Phase IIa ApTOLL|ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.
16291586|NCT04734522|Experimental|The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
16291587|NCT04734522|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
16291588|NCT04734509|Experimental|Porter Brown Breathing system|"The Porter Brown has a double mask system that is characterized by a mask-within-a-mask scavenging system. The system includes easy to remove inner masks which vent into the outer mask. This helps in cleaning and sterilization. The soft inner part of the mask system provides a comfortable fit and an excellent seal around the patient's nose.
~This mask is routinely used in inhalation sedation for children's dental treatment.
~This is a sterilisable system."
16291589|NCT04734509|Experimental|Silhouette Breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
16291590|NCT04734496||Chronic Liver Disease|Patients with end-stage liver disease. Standard of care treatment will be nutrition and exercise as per European Association Study of Liver nutrition guidelines.
16291591|NCT04734496||Rheumatoid Arthritis/Psoriatic arthropathy|Patients requiring biological therapy due to ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
16291592|NCT04734496||Inflammatory Bowel Disease|Patients with Crohns or Ulcerative Colitis with ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
16291593|NCT04734496||Healthy volunteers (n=20)|Healthy volunteers
16291594|NCT04734483|Active Comparator|functional findings|Participants with laryngeal stenosis
16291595|NCT04734483|Active Comparator|to find anatomic feathers of larynx|Participants with laryngeal stenosis
16291596|NCT04734483|Active Comparator|to determine the type of stenosis of larynx and method of surgical treatment|Participants with laryngeal stenosis
16291597|NCT04734483|Active Comparator|determining the motor abilities of the muscles of the larynx|Participants with laryngeal stenosis
16291598|NCT04734444|Experimental|SonoClear acoustic coupling fluid (ACF) mimicking brain tissue|SonoClear
16291599|NCT04734431||Survivors|Patients admitted in geriatrics that survived of a bacterial infection after 30 days (still admitted or discharged), and treated by antibiotics.
16291600|NCT04734431||Death|Deceased individuals admitted for a bacterial infection in geriatrics, despite receiving an antimicrobial therapy.
16291601|NCT04734418|Experimental|Remifentanil group|
16291602|NCT04734418|Active Comparator|Dexmedetomidine|
16291603|NCT04734405|Experimental|ProF-001 Group|"ProF-001 Group:
~• During induction period: app. 5 g of ProF-001 for 6 days (twice daily app. 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of app. 2.5 g of ProF-001 at bedtime and 1 placebo capsule on days 1, 4, and 7 and
~• During maintenance period: 2 doses of app. 2.5 g of ProF-001 per week for 22 weeks (total of 44 single doses) and 1 placebo capsule per week for 24 weeks"
16291604|NCT04734405|Active Comparator|Fluconazole Group|"Fluconazole Group:
~During induction period:
~1 Fluconazole 150 mg capsule on days 1, 4, and 7 and a daily dose of app. 5 g of placebo cream for 6 days (twice daily 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of 2.5 g of placebo cream at bedtime and
~During maintenance period:
~capsule of fluconazole 150 mg per week for 24 weeks and two doses of 2.5 g of placebo cream per week for 22 weeks (total of 44 single doses)"
16291605|NCT04734392||Cohort A|Historical cohort 2019 + 2020
16291606|NCT04734392||Cohort B|Prospective study cohort 2020 + 2021 (TAVR implantation according new IFU)
16291607|NCT04734379|Experimental|Treatment|Oral fasudil 180 mg/day
16291608|NCT04734366|Experimental|"Uterine closure with Baseball suture technique"|"Participants will undergo Baseball suture closure of the hysterotomy site at the time of cesarean section."
16291609|NCT04734366|Active Comparator|Single Layer Continuous Locked|Participants will undergo Single Layer Continuous Locked suture closure of the hysterotomy site at the time of cesarean section.
16291610|NCT04734353|Experimental|E5 group|Escalation in CHIP
16291611|NCT04734353|Active Comparator|T60 group|Escalation in CHIP
16291612|NCT04734340|Experimental|EIT-guided group|Treatment based on EIT
16291613|NCT04734340|Placebo Comparator|Control group|Treatment based on ARDS-net Peep setting
16291614|NCT04734327|Experimental|Orthokine periradicular injection|Ultrasound guided injections
16291615|NCT04734327|Active Comparator|Orthokine epidural injection|Ultrasound guided injections
16291616|NCT04734314|Experimental|conventional treatment of back pain|Group A: received conventional treatment of back pain which included; TENS 20 min and hot packs 10 min .The total treatment session is 30 min three session per week for four weeks
16291617|NCT04734314|Experimental|vojta therapy|received conventional treatment of back pain in addition to Vojta therapy . The total treatment session is 40 min.
16291618|NCT04734301|Active Comparator|Group 1: IVES (2 times in a week)|This group included the IVES in addition to all components of the BT. IVES was performed in lithotomy position via electrical stimulation device with a vaginal probe.
16291619|NCT04734301|Experimental|Group 2: IVES (5 times in a week)|This group also included the IVES in addition to all components of the BT as in Group 1. IVES performed in the same way as Group 1, except for frequency of treatment.
16291620|NCT04734288|Experimental|Immune response|This is a single-arm study. All subjects will be treated equally and will receive the same type and amount of nutritional supplements.
16291621|NCT04734275|Experimental|Treatment A (Test Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A), in fasted condition.
16291622|NCT04734275|Experimental|Treatment B (Test Formulation): AZD5718 Dose A, fed|Subjects will receive single dose of AZD5718 (Dose A) in fed condition
16291623|NCT04734275|Active Comparator|Treatment C (Reference Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A) in fasted condition
16291624|NCT04734262|Experimental|Cohort A|Subjects will receive 70mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16291625|NCT04734262|Experimental|Cohort B|Subjects will receive 100mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16351277|NCT04319653|Experimental|Dynamic pelvic MRI|
16291626|NCT04734249|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combined With Chemotherapy
16291627|NCT04734236|Active Comparator|New technique group|
16291628|NCT04734236|Sham Comparator|Xpert group|
16291629|NCT04734223||Group 1|The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
16291630|NCT04734223||Group 2|The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.
16291631|NCT04734223||Group 3|The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
16291632|NCT04734223||Group 4|The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
16291633|NCT04734210|Experimental|SURF-200 (0.02% betamethasone sodium phosphate in vehicle)|One drop twice daily (BID) in the study eye for 14 days.
16291634|NCT04734210|Experimental|SURF-200 (0.04% betamethasone sodium phosphate in vehicle)|One drop BID in the study eye for 14 days.
16291635|NCT04734210|Placebo Comparator|Vehicle|One drop BID in the study eye for 14 days.
16291636|NCT04734197|Experimental|SURF-100 (a combination of 0.3% MPA and 0.01% BSP)|One drop in the study eye twice daily (BID) for 84 days
16291637|NCT04734197|Experimental|0.1% MPA|One drop in the study eye BID for 84 days.
16291638|NCT04734197|Experimental|0.3% MPA|One drop in the study eye BID for 84 days.
16291639|NCT04734197|Experimental|0.01% BSP|One drop in the study eye BID for 84 days.
16291640|NCT04734197|Placebo Comparator|Vehicle|One drop in the study eye BID for 84 days.
16291641|NCT04734197|Active Comparator|Restasis|One drop in the study eye BID for 84 days
16291642|NCT04734197|Active Comparator|Xiidra|One drop in the study eye BID for 84 days
16291643|NCT04734171|Placebo Comparator|Informational sheet (IS)|participant receives an informational sheet about COVID-19
16291644|NCT04734171|Active Comparator|IS + Video Solo|participants an informational sheet about COVID-19 and a 90 seconds video aimed at sensitizing participants to COVID-19 related stigma
16291645|NCT04734171|Active Comparator|IS + Video Friends|participants an informational sheet about COVID-19 and a 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends.
16291646|NCT04734171|No Intervention|Control|No intervention
16291647|NCT04734158||Healthy control|
16291648|NCT04734158||Diabetics with macular edema|
16291649|NCT04734158||Diabetics without macular edema|
16291650|NCT04734145||Participants with an Undiagnosed Pulmonary Nodule|One hundred evaluable individuals aged 21 to 85 years with a single undiagnosed pulmonary nodule measuring <3 cm, clinically staged as cT1N0M0 (eighth edition of the TNM staging manual) by CT and PET scans, will be enrolled in this diagnostic study and will undergo e-nose testing. These patients must have a risk assessment profile that, according to institutional guidelines, identifies them as candidates for subsequent surgical resection of the pulmonary nodule, which will confirm the results of the breathprinting analysis.
16291651|NCT04734132|Experimental|Moringa|Six Moringa oleifera capsules (400 mg dry leaf powder /capsule) consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
16291652|NCT04734132|Placebo Comparator|Placebo|Six placebo capsules containing microcrystalline cellulose consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
16291653|NCT04734119||Group A- same anesthesiologist|In Group A patients were evaluated preoperatively and anesthetized by the same anesthesiologist.
16291654|NCT04734119||Group B- different anesthesiologist|In Group B the preoperative assessment and actual anesthesia was performed by two different anesthesiologists
16291655|NCT04734106|Experimental|Desert Harvest Super-Concentrated, Freeze-Dried Aloe Vera Capsules|Participants will self-administer Desert Harvest super-concentrated, freeze-dried aloe vera capsules orally over a sixteen week period. The dosing regimen includes administering 3 capsules twice daily for the first month, 3 capsules three times daily for the second month, and 4 capsules three times daily for the third month. During the fourth month, participants will administer 10 capsules per day the first week (4 in the morning, 2 in the afternoon, and 4 in the evening), 8 capsules per day the second week (4 in the morning, 4 in the evening), 6 capsules per day the third week (3 in the morning, 3 in the evening), and 4 capsules per day the fourth week (2 in the morning, 2 in the evening). A participant must stay on a minimum of 6 capsules per day for the first three months in order to remain in the study.
16291656|NCT04734106|Placebo Comparator|Placebo|Participants will self-administer placebo capsules orally, matching the dosing regimen of the experimental treatment, over a sixteen week period. Placebo capsules will be identical in appearance and packaging to the experimental capsules.
16291657|NCT04734093||Sohag university recruited patients|
16291658|NCT04734093||Minia university recruited patients|
16291659|NCT04734093||Assuit university recruited patients|
16291660|NCT04734093||Kasr Elini recruited patients|
16291661|NCT04734093||Tanta university recruited patients|
16291662|NCT04734093||Monofia university recruited patients|
16291663|NCT04734093||Aswan university recruited patients|
16291664|NCT04734093||Ain shams university recruited patients|
16291665|NCT04734080|Experimental|Dronabinol|55 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of 5 mg of Dronabinol beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
16291666|NCT04734080|Placebo Comparator|Placebo|55 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of a non-active placebo pill beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
16291667|NCT04734067||observational group|Patients receiving ICIs for the first time
16291668|NCT04734054|Experimental|Rapid maxillary expansion|The rapid maxillary expansion will be conducted using bonded modified Hyrax palatal expander. The expander will be activated twice daily (0.4 mm) until an overcorrection of 2-3 mm will be gained.
16291669|NCT04734054|Active Comparator|Slow maxillary expansion|The slow maxillary expansion using a removable plate with a midline screw will be accomplished. The expander will be activated twice weekly until an overcorrection of 2-3 mm will be gained.
16291670|NCT04734041|Other|Integrative Medicine|Anti-inflammatory (Mediterranean) diet, as well as general behavioral and psychosocial support.
16291671|NCT04734028||PTRG-DES registry|After DES implantation, CAD patients were treated with DAPT with clopidogrel and aspirin. During hospitalization, their platelet function, genotype and inflammation biomarker were evaluated.
16291672|NCT04734015|Experimental|Together Overcoming Diabetes (TOD) curriculum|"A randomized waitlist control trial (RCT) design will be employed with 140 family dyads (adult caregiver and youth) randomly assigned to the Intervention group (Group A): Together Overcoming Diabetes (TOD).
~Group A participant dyads will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months."
16291673|NCT04734015|No Intervention|Waitlist Control|"A randomized waitlist control trial (RCT) design will be employed with 140 family dyads (adult caregiver and youth) randomly assigned to the Waitlist Control group (Group B). Waitlist family dyads will not initially receive the intervention. They will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months.
~Waitlist participant dyads will begin to receive the intervention program (TOD) approximately 24 months (2 years) after enrollment in the RCT."
16291674|NCT04733963|Experimental|Arm A|Maintenance therapy with Fruquintinib Plus Capecitabine
16291675|NCT04733963|Active Comparator|Arm B|Maintenance therapy with Bevacizumab Plus Capecitabine
16291676|NCT04733950|Experimental|Patients with cochlear implant|Patients with cochlear implant for 6 months and more
16291677|NCT04733950|Active Comparator|Healthy volunteers (normal hearing)|Healthy volunteers with a normal tonal audiometry for age
16291678|NCT04733937|Active Comparator|a2 Group|The infant group consuming a2 Platinum® stage 1 infant formula
16291679|NCT04733937|Active Comparator|Control Group|The infant group consuming conventional, A1 and A2 β-casein containing stage 1 infant formula
16291680|NCT04733937|No Intervention|breast feeding|
16291684|NCT04733911|Experimental|Eccentric 75|Participants in this arm will perform an eccentric exercise protocol consisted of 75 eccentric repetetions on an isokinetic dynamometer.
16291685|NCT04733911|Experimental|Eccentric 150|Participants in this arm will perform an eccentric exercise protocol consisted of 150 eccentric repetetions on an isokinetic dynamometer.
16291686|NCT04733911|Experimental|Eccentric 300|Participants in this arm will perform an eccentric exercise protocol consisted of 300 eccentric repetetions on an isokinetic dynamometer.
16291687|NCT04733911|No Intervention|Control|Participants in this arm will receive no intervention.
16291688|NCT04733898|Experimental|Social games|Participants in the social games group will be given access to an app with games that are either adaptations of well-known games or newly developed games, all designed to be played with just text messages and photos. A game is essentially a chat group with the people you invited to play that specific game with. Participants can play with their own network of family and friends, as well as other people in the same condition.
16291689|NCT04733898|Active Comparator|Non-personal games|Participants in the active control group will be given access to an app that offers 'non-personal games'. The portal will contain a subset of the social games, which have been adapted for non-personal play. This means that all aspects that make the games personal are removed and discouraged. The games that remain can still be played with others (family/friends and others in the same condition), but are designed not to elicit personal interaction. Participants are asked to play the games at least twice a week, but may play as often as they like.
16291690|NCT04733898|No Intervention|Passive control|The passive control group will be given access to an app that contains no games. Similar to the other groups, the portal is used to complete the questionnaires. Use of other games, (gaming) apps or social media platforms is allowed in this group, as in the other groups. The only restriction they will not have access to the games offered in the social games and active control groups.
16291691|NCT04733885|Experimental|Electrical Stimulation group|ES and lifestyle advice have been applied ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
16291692|NCT04733885|Sham Comparator|Sham Electric Stimulation group|Sham ES and lifestyle advice have been applied Sham ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
16291693|NCT04733872|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
16291694|NCT04733872|Experimental|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
16291695|NCT04733859|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
16291696|NCT04733859|Experimental|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
16291697|NCT04733846||corneal trauma sutured with Vicryl 10-0 monofilament|corneal trauma sutured with Vicryl 10-0 monofilament will be included. They will have data collection of medical records.
16291698|NCT04733833|Experimental|Arm 1|VB-201 + standard of care
16291699|NCT04733833|Active Comparator|Arm 2|Standard of care
16291700|NCT04733820|Experimental|Adjuvant chemotherapy group|"Participant will receive at least 2 cycles of adjuvant chemotherapy. If having any of the following factors, participant will receive additional 2 cycles of adjuvant chemotherapy per risk factor. All patients received maximum 6 cycles of postoperative chemotherapy.
~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 4cm before surgery."
16291701|NCT04733820|No Intervention|Control group|The participants receive no intervention.
16291702|NCT04733794|Experimental|Surgery for Stoma Reversal|All study participants will receive stoma reversal, complete baseline questionnaire, pelvic floor training and follow up questionnaires
16291703|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and self-injection of 125ml by a volunteer (Arm I):|A volunteer layperson (research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. Then the subject will self-inject a second 125ml of TLE into his/her right anterior thigh.
16291704|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and 125ml by another volunteer (Arm II):|A volunteer layperson (primary research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. The primary research subject will then receive a second 125ml of TLE injected into his/her right anterior thigh by a second adult volunteer who is at least 16 years old and not a medical professional.
16291705|NCT04733781|Active Comparator|Subcutaneous injection of 250ml by a physician into a volunteer (Arm III)|A volunteer layperson (research subject), at least 16 years old, will receive 250ml of TLE injected subcutaneously into the one anterior thigh by a physician.
16291706|NCT04733768|Experimental|18F-PSMA-1007 PET/CT scan|Single Arm study - all enrolled patients will undergo an experimental 18F-PSMA-1007 PET/CT scan
16291707|NCT04733755|Experimental|Beauty Image|
16291708|NCT04733755|Placebo Comparator|Placebo Control|
16291709|NCT04733742|Experimental|Conbined treatment group|intravenous tenecteplase bridging with endovascular treatment
16291710|NCT04733742|Active Comparator|Endovascular treatment alone group|endovascular treatment alone
16291711|NCT04733716|Active Comparator|Total Knee Arthroplasty with using Tourniquet|A pneumatic tourniquet was used before surgery at the proximal thigh and inflated before the skin incision until skin closure in this group. The tourniquet was inflated to either 275 or 325 mmHg, depending on the patient's systolic blood pressure.
16291712|NCT04733716|Active Comparator|Total Knee Arthroplasty without using Tourniquet|A pneumatic tourniquet was not used in this group during the total knee arthroplasty.
16291713|NCT04733690||Healthy Volunteers (Glycemic Index)|The glycemic index (GI) of the common bean product will be assessed in this cohort among 10 study participants. The GI of the product will be assessed on 3 test days over a 120 min period on each study day.
16291714|NCT04733690||Healthy Volunteers(Food Insulin Index)|The food insulin index (FII) of the common bean product will be assessed in this cohort among 10 study participants. This study will recruit 10 participants. The FII of the product will be assessed on 3 test days over a 120 min period on each study day.
16291715|NCT04733690||Type-2 diabetes (T2DM) patients|Glycemic, insulinemic and satiety responses associated with the consumption of the common bean product will be assessed in this cohort among 10 T2DM patients. Participants will attend one study visit lasting approximately 120 min.
16291716|NCT04733677||OSR M-1 N95|All subjects will be fitted with an OSR M1 N95 mask
16291717|NCT04733664|Experimental|Cohort 1|Patients will receive one dose of visible fluorescent injectate (VFI)™ and one dose of iohexol approximately 4 hours prior to undergoing dialysis followed by a second dose of VFI and iohexol approximately 1 hour after completing dialysis.
16291718|NCT04733651|Active Comparator|Control arm|In this arm subjects will receive the hospital COVID-19 standard care
16291719|NCT04733651|Experimental|Isoquercetin arm|In this arm subjects will receive the hospital COVID-19 standard care + Isoquercetin
16291720|NCT04733638||Pre-Viz ICH VOLUME|Patient data collected prior to Viz ICH VOLUME implementation, utilized as a control data set
16291721|NCT04733638||Post-Viz ICH VOLUME|Patient data collected post-Viz ICH VOLUME implementation
16291722|NCT04733625|Active Comparator|Intervention(Vitamin D therapy|40 patients with diabetes and vitamin D deficinecy that are Covid-19 positive. a single dose of Cholecaciferol will be administered
16291723|NCT04733625|Placebo Comparator|Placebo|16 diabetic patients with vitamin D deficiancy and COVID-19 POSITIVE
16291724|NCT04733612|Experimental|SMS Group|In addition to traditional treatment received three to four informative SMS messages per week during the 6-month period
16291725|NCT04733612|No Intervention|Control Group|Followed in accordance with the traditional treatment schedule
16291726|NCT04733599||Adults with pain due to brachial plexus avulsion injury|Adult patients with history of brachial plexus avulsion injury referred for consideration of neuromodulation using high frequency neurostimulation will be considered.
16291727|NCT04733586|Active Comparator|fascia iliaca group|
16291728|NCT04733586|Active Comparator|quadratus lumborum|
16291729|NCT04733573|Active Comparator|Occlusal appliance by Okeson with canone guidance|Occlusal appliance will be used while sleeping for 30 days.
16291730|NCT04733573|Active Comparator|Bimaxillary splint without canine guidance|Bimaxillary splint will be used while sleeping for 30 days.
16291731|NCT04733560|Experimental|Pudendal nerve block|25 women will receive pudendal nerve blocks of 0.25% Bupivicaine 10ml administered vaginally prior to making any surgical incisions.
16291732|NCT04733560|Sham Comparator|Placebo|25 women will receive sham pudendal nerve blocks using normal saline. These will also be administed vaginally prior to making any surgical incisions.
16291733|NCT04733547||Donor hepatectomy|Live donors undergoing hepatectomy
16291734|NCT04733534|Active Comparator|Dasatinib plus Quercetin|"Day 0 (30 per arm, randomization stratified by sex and age)
~At the visit on day 7, blood CD3+ T lymphocyte p16^INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.
~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 will assess the permanence of change after completion of the trial."
16291735|NCT04733534|Active Comparator|Fisetin|"Day 0 (30 per arm, randomization stratified by sex and age)
~At the visit on day 7, blood CD3+ T lymphocyte p16INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.
~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 to will assess the permanence of change after completion of the trial."
16291736|NCT04733521|Experimental|NSCLC|
16291737|NCT04733521|Experimental|BTC|
16291738|NCT04733508|Experimental|111In-exendin-DTPA|Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography
16291739|NCT04733508|Experimental|exendin-IRDye800CW|Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy
16291740|NCT04733495|Experimental|Supportive care (resistance exercise, counseling)|Patients undergo personalized resistance exercises over 1 hour daily. Patients receive dietary counseling over 60 minutes at week 1 and then over 15-30 minutes weekly for up to 6 weeks. Patients also receive group-based behavioral counseling BIW in weeks 1-8, QW in weeks 9-12, and then twice a month in weeks 13-24.
16291741|NCT04733482|No Intervention|Control group|Participants in the control group received usual care during adjuvant chemotherapy. The usual care consisted of written information and verbal guidance on the adverse effects of chemotherapy and related psychological reactions.
16291742|NCT04733482|Experimental|Cosmetic care group|Participants in the intervention group received cosmetic care in combination with usual care. The cosmetic care was a 3-hour, free-of-charge beauty activity, including face moisturizing steps, make-up, wigs, and breast prostheses wearing. It was provided by professional cosmeticians at a cosmetic training base before the patients finished half of their chemotherapy cycle.
16291743|NCT04733469|Experimental|Multimedia Psychoeducational Intervention + Enhanced Usual Care|Intervention participants receive the Multimedia Psychoeducational Intervention in addition to Enhanced Usual Care
16291744|NCT04733469|Other|Enhanced Usual Care|Control participants receive Enhanced Usual Care
16291745|NCT04733456||IBD Patients (UC and CD)|"Participants will complete a Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, *EQ5D-5L, *GAD-774, *PHQ-975, *PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, *Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy (*questionnaires available through the CIHR IMAGINE grant).
~Stool will be collected at baseline and after 16 weeks for assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome (through the International Microbiome Center [IMC], U of C). Blood will be drawn and urine collected at baseline and after 16 weeks for inflammatory markers and metabolomic [IMC] analysis"
16291746|NCT04733443|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 /45mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
16291747|NCT04733443|Active Comparator|SeQuent® Please Neo|paclitaxel released coronary balloon catheters Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
16291748|NCT04733417|Experimental|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
16291749|NCT04733404|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
16291750|NCT04733378|Experimental|Peri-operative neurological monitoring|
16291751|NCT04733365|Experimental|Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
16291752|NCT04733365|No Intervention|Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
16291753|NCT04733352|Experimental|proximal acupoints of knees|GB34, SP9, and EX-LE2
16291754|NCT04733352|Experimental|distal acupoints of knees|LI11, HT3, and TE10
16291755|NCT04733339||'Traditional' group|10 stroke patients
16291756|NCT04733339||'Technology-supported' group|10 stroke patients
16291757|NCT04733326|Experimental|Cryothrapy|5 ml Saline at low temperature (2.5°C) will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
16291758|NCT04733326|Experimental|Ketroloc tromethamine|2ml 30 mg Ketroloc tromethamine will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
16291759|NCT04733326|Placebo Comparator|Saline at room temperature|30 ml Saline at room temperature will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
16291760|NCT04733313|Active Comparator|quadratus lumborum-2|
16291761|NCT04733313|Active Comparator|quadratus lumborum-3|
16291762|NCT04733300|Experimental|Mindfulness-Based College - Standard Dose|MBC standard dose is a 9-week, 9 session program providing systematic and intensive training in mindfulness meditation practices. The curriculum is grounded in the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum. MBSR was adapted to the young adult life stage by: (1) Training mindfulness skills such as attention control, self-awareness and emotion regulation, using the MBSR curriculum, and (2) applying these skills to the health behaviors and priorities most relevant to young adults. Specific behaviors and priorities targeted are social relationships, sleep, stress, diet, physical activity, obesity, alcohol consumption, substance use, digital media use, and performance (e.g. athletic, artistic and academic). The intervention is administered live, online via a video conferencing platform. The standard dose class meets once a week for 2.5 hours for 9 weeks. There is also an all-day retreat that takes place around week 6 of the program.
16291763|NCT04733300|Experimental|Mindfulness-Based College - Low Dose|The MBC low-dose program is mirrored after the standard MBC program (described previously); however, instead of meeting for 2.5 hours each week, the low-dose MBC program is abbreviated to meet for 1.5 hours each week for the 9 weeks. MBC low-dose will be administered live, online via the free video conferencing platform, Zoom.
16291764|NCT04733300|Active Comparator|Health education control group|Those randomized to the health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
16291765|NCT04733287|Experimental|Effect of High Intensity Interval Training|"Young and older subjects will participate in single-leg, high-intensity interval training of the right knee extensors (4 intervals of 4 minutes at 80% of max aerobic power with 4 minute rest intervals between, 3x per week for 6 weeks).
~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
16291766|NCT04733287|Experimental|Effect of Muscle Heat Therapy|"Young and older subjects will participate in single-leg,heat therapy training of a single leg ( quadriceps femoris, 120 minutes of shortwave diathermy to raise the muscle temperature to ~39C) 3 times a week for 6 weeks.
~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
16291767|NCT04733287|Sham Comparator|Effect of Sham Muscle Heat Therapy|"Young and older subjects will participate in a sham treatment of single-leg,heat therapy training of the right knee extensors (120 minutes with shortwave diathermy unit positioned on leg, but not turned on) 3 times a week for 6 weeks.
~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
16351378|NCT04318847|Experimental|Ondransetron|Administration of ondansetron
16291768|NCT04733287|Sham Comparator|Effect of Immobilization with Daily Sham Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of a sham heat therapy treatment each day. For the sham treatment, the heating device will be applied to the limb, but, unbeknownst to the participant, it will not be turned on.
~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
16291769|NCT04733287|Experimental|Effect of Immobilization with Daily Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of heat therapy treatment each day. Heat therapy will consist of 120 minutes of shortwave diathermy to raise the quadriceps femoris muscle temperature to ~39C.
~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
16291770|NCT04733261|Active Comparator|Diaphragmatic mobility|The patient will be in supine, supported on one/two pillows under her head, and a bolster under her knees.
16291771|NCT04733261|Experimental|Chest Physiotherapy|Give passive ROM exercise to all joints of the upper and lower extremities.
16291772|NCT04733248|Active Comparator|Kinesiotaping group|Hot pack, Tens, stretching exercises, Kinesiotaping (I-O) and Home plan
16291773|NCT04733248|Experimental|stretching group|Hot pack, Tens, stretching exercises and Home plan
16291774|NCT04733235||with endometrial compaction|Participants who have endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
16291775|NCT04733235||without endometrial compaction|Participants who have not endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
16291778|NCT04733209|Experimental|Mobilization with movement|"Mobilization with movement technique and traditional physiotherapy were applied to the intervention group. For mobilization with movement technique, the patient was asked to actively flex and extend the wrist with the forearm in neutral in a sitting position on a treatment table, and the pain was asked. The painful side was determined according to the patient's statement.
~In a patient whose painful side was flexion, the wrist joint was shifted manually (with the help of the web space of both hands of the therapist) to the lateral and medial at the same time while the patient actively flexed the wrist. The treatment was done 3 times a week for 4 weeks."
16291779|NCT04733209|Active Comparator|Conventional|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the transverse carpal ligament in the wrist with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; tendon-nerve gliding exercises, night splint, stretching and strengthening exercises applied. The treatment was done 3 times a week for 4 weeks.
16291780|NCT04733196|Experimental|Essential oils|Mouthwash based on essential oils - menthol, eucalypts oil, thymol, alcohol
16291781|NCT04733196|Experimental|Essential oils in combination with clorhexidine 0,12%|Mouthwash based on essential oils - mentol, eucalypt oil, thymol, alcohol, and 0,12% chlorhexidine
16291782|NCT04733196|Placebo Comparator|Placebo mouthwash|Water, colorant, sweetener
16291783|NCT04733196|Experimental|Clorhexidine 0,20% in combination with aroma oils|Mouthwash based on 0,20% chorhexidine without alcohol in combination with aroma oils of rose and lavender
16291784|NCT04733196|Experimental|Prebiotic|Mouthwash based on prebiotic
16291785|NCT04733196|Experimental|Hydrogen peroxide|Mouthwash based on 0,8% hydrogen peroxide in combination with menthol and eucalypts oil
16291786|NCT04733183|Experimental|Arm1: DTIC + L19TNF|Patients will receive Dacarbazine (DTIC) on Day 1 and L19TNF on Days 1, 3 and 5 every 21 days.
16291787|NCT04733183|Active Comparator|Arm 2: DTIC|Patients will receive Dacarbazine (DTIC) on Day 1 every 21-day cycle .
16291788|NCT04733157|Experimental|Study group/Group A|The study group will receive TXA 1g intravenously at the onset of skin incision.
16291789|NCT04733157|Placebo Comparator|Control group/Group B|There is an equivalent volume of normal saline for the control group.
16291790|NCT04733144|Active Comparator|Prednisolone-Dexamethasone|Participants will receive 1 week of low dose (7,5 mg) prednisolone directly followed by 1 week of high dose prednisolone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose dexamethasone (1,125 mg) directly followed by 1 week of high dose dexamethasone (4,5 mg).
16291791|NCT04733144|Active Comparator|Dexamethasone-Prednisolone|Participants will receive 1 week of low dose (1,125 mg) dexamethasone directly followed by 1 week of high dose dexamethasone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose prednisolone (7,5 mg) directly followed by 1 week of high dose prednisolone (30 mg).
16291792|NCT04733131||converted to a belatacept based immunosuppression|Belatacept: infusion on Days 1, 15, 29, 43, 57 then every 28 days. All patients received a background maintenance immunosuppressive regimen of mycophenolate mofetil or mycophenolic acid, with adjunctive corticosteroids, according to their immunosuppressive regimen at the time of enrollment.
16291793|NCT04733118|Experimental|Patient HER 2+ IHC 3+|Patients ≥18 years of age with previously untreated HER2-positive (HER2[+]) (Immunohistochemistry [IHC] 3+) invasive carcinoma according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and tumor size between >5 to 25 mm by breast magnetic resonance imaging (MRI) and node-negative status by clinical exam, MRI, and ultrasound. Patients must have not been previously treated with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy (ET) for invasive breast cancer. Patients with metastatic disease are not eligible. In patients with suspected axillary node involvement, a negative fine needle aspiration biopsy (FNAB) will be mandatory
16291794|NCT04733092|Experimental|Embolization|Embolization of the inflammatory hypervascularization with a lipiodol emulsion
16291795|NCT04733079|Experimental|E-mail follow-up group|Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging
16291796|NCT04733079|Active Comparator|Usual follow-up group|Adaptation and follow-up of ULT according to referring physician's habits
16291797|NCT04733066||Non-treatment Group|"Quality of life assessment (SBS-QoL, SF- 36)
~Nutrition status assessment (BIA, BMI)
~Assessment of functional absorptive small bowel length (citrulline)
~Clinical data (nutritional program, stool characteristics)"
16291798|NCT04733066||Teduglutide-treated Group|"Quality of life assessment (SBS-QoL, SF- 36)
~Nutrition status assessment (BIA, BMI)
~Assessment of functional absorptive small bowel length (citrulline)
~Clinical data (nutritional program, stool characteristics)"
16291799|NCT04733053|Experimental|Diet plus exercise|The initial physiotherapy consultation for participants in this group will last 75 minutes, with 30 minutes for the exercise component and 45 minutes for the diet component. Thereafter, consultations will last 50 minutes, with 20 minutes for the exercise component and 30 minutes for the diet component. The exercise component will be the same as that described for the exercise alone group.
16291800|NCT04733053|Active Comparator|Exercise|Physiotherapy consultations for participants in this group will last 30 minutes initially and then 20 minutes thereafter, consistent with clinical practice. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate and a personalised physical activity plan.
16291803|NCT04733027|Experimental|Arm A: PEP010 as single agent|In arm A, the dose escalation phase will use accelerated titration design (ATD) for the first 4 dose levels (0.15, 0.3, 0.6, 1.2 mg/kg), followed by 3+3 design
16291804|NCT04733027|Experimental|Arm B: PEP010 in combination with paclitaxel.|In arm B, the dose escalation phase will begin with DL4 (1.2 mg/kg) and will follow a 3+3 design
16291805|NCT04733001|Experimental|HSG4112 Treatment Arm: Fasted|Single oral dosing of HSG4112 480 mg under fasted conditions
16291806|NCT04733001|Experimental|HSG4112 Treatment Arm: Low-Calorie Diet|Single oral dosing of HSG4112 480 mg under low-calorie (400-500 kcal with 100-125 kcal fat) diet conditions
16291807|NCT04733001|Experimental|HSG4112 Treatment Arm: High-Calorie Diet|Single oral dosing of HSG4112 480 mg under high-calorie (800-1000 kcal with 500-600 kcal fat) diet conditions
16291808|NCT04732988|Experimental|HSG4112 30 mg Single Dose|Single oral dosing of HSG4112 30 mg
16291809|NCT04732988|Placebo Comparator|Placebo 30 mg Single Dose|Single oral dosing of Placebo 30 mg
16291810|NCT04732988|Experimental|HSG4112 60 mg Single Dose|Single oral dosing of HSG4112 60 mg
16291811|NCT04732988|Placebo Comparator|Placebo 60 mg Single Dose|Single oral dosing of Placebo 60 mg
16291812|NCT04732988|Experimental|HSG4112 120 mg Single Dose|Single oral dosing of HSG4112 120 mg
16291813|NCT04732988|Placebo Comparator|Placebo 120 mg Single Dose|Single oral dosing of Placebo 120 mg
16291814|NCT04732988|Experimental|HSG4112 240 mg Single Dose (Fasted)|Single oral dosing of HSG4112 240 mg under fasted conditions
16291815|NCT04732988|Experimental|HSG4112 240 mg Single Dose (Fed)|Single oral dosing of HSG4112 240 mg under fed conditions
16291816|NCT04732988|Placebo Comparator|Placebo 240 mg Single Dose|Single oral dosing of Placebo 240 mg
16291817|NCT04732988|Experimental|HSG4112 480 mg Single Dose|Single oral dosing of HSG4112 480 mg
16291818|NCT04732988|Placebo Comparator|Placebo 480 mg Single Dose|Single oral dosing of Placebo 480 mg
16291819|NCT04732988|Experimental|HSG4112 720 mg Single Dose|Single oral dosing of HSG4112 720 mg
16291820|NCT04732988|Placebo Comparator|Placebo 720 mg Single Dose|Single oral dosing of Placebo 720 mg
16291821|NCT04732988|Experimental|HSG4112 240 mg Multiple Dose|Once-daily multiple oral dosing of HSG4112 240 mg for 14 days
16291822|NCT04732988|Placebo Comparator|Placebo 240 mg Multiple Dose|Once-daily multiple oral dosing of Placebo 240 mg for 14 days
16291823|NCT04732988|Experimental|HSG4112 480 mg Multiple Dose|Once-daily multiple oral dosing of HSG4112 480 mg for 14 days
16291824|NCT04732988|Placebo Comparator|Placebo 480 mg Multiple Dose|Once-daily multiple oral dosing of Placebo 480 mg for 14 days
16291825|NCT04732962|Experimental|AposHealth|"Following the initial consultation and calibration of the Apos device in the clinic, the patients will receive from his therapist a home-based treatment plan. This usually includes wearing the device for about 20 minutes with about 20% of weight-bearing (patient is instructed to wear the Apos and just be with the device and go about his/her daily routine). A gradual increase in usage time is prescribed reaching up to 60 min wear time with about 40% weight-bearing.
~Patients are requested to return to follow-up (FU) appointments after 1, 3, 6, 9 and 12 months. In addition, patients will have a remote FU after 1-week to confirm they use AposHealth as advised. During the follow-up appointment, re-assessment of clinical outcomes and gait patterns are performed and the calibration of the Apos device is adjusted as needed. The treatment plan is adjusted, and patients are encouraged to continue to wear the device regularly at home."
16291826|NCT04732962|Active Comparator|Total Knee Replacement (TKR)|"Patients will undergo TKR according to Geisinger's policy, guidelines and care protocol.
~The study baseline visit will occur 6 weeks postoperative for TKR groups."
16291827|NCT04732962|Experimental|Post TKR traditional physical therapy (PT) and AposHealth|"Patients who have had a knee replacement and were assigned to the traditional PT+ AposHealth group will follow Geisinger post-operative rehab protocol and will also receive AposHealth and follow the rehabilitation protocol.
~AposHealth will start six weeks post-op and will continue for 12 months. Patients will receive AposHealth similar to the non-invasive group, i.e., will have an initial evaluation (IE) and calibration of the Apos device, have a remote FU after one week from IE and in-clinic FUs at 1, 3 6, 9 and 12 months."
16291828|NCT04732949|Active Comparator|SNG001|SNG001 via inhalation using Ultra device, once a day for 14 days
16291829|NCT04732949|Placebo Comparator|Placebo|Placebo via inhalation using Ultra device, once a day for 14 days
16291830|NCT04732936|Experimental|Device Usability|Device usability and safety will be evaluated.
16291831|NCT04732936|Experimental|Preliminary Efficacy|Preliminary treatment efficacy will be evaluated.
16291832|NCT04732923|Experimental|Experimental arm|"This study is defined in 3 stages :
~STEP 1 : during the cardiac rehabilitation program over 4 weeks
~STEP 2 : monitoring at 6 months after cardiac rehabilitation program
~STEP 3 : monitoring at one year after cardiac rehabilitation program"
16291833|NCT04732897|No Intervention|Control arm|wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
16291834|NCT04732897|Experimental|Interventional arm|wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint
16291835|NCT04732884|Experimental|Weight sensor with biofeedback|Activation of the feedback function of the weight-bearing sensor as mean to possibly enhance compliance to weight-bearing instructions postoperative.
16291836|NCT04732884|Experimental|Weight sensor without biofeedback|Standard patient education considering postoperative weight-bearing parameters and measurement of actual weight-bearing with the sensor.
16291840|NCT04732845|Experimental|Group A - NHL/CLL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.
~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.
~Participants with CD19+ lymphomas and chronic lymphocytic leukemia will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at dose level 1 (DL1) on day 0.
~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
16291841|NCT04732845|Experimental|Group B - ALL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.
~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.
~Participants with Acute Lymphoblastic Leukemia (and lymphoblastic lymphoma as a solid tumor equivalent) will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at DL1 on day 0 and 7.
~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
16291842|NCT04732819|No Intervention|Usual care|Facilities in the 'usual care' arm will be offered electronic messaging and education regarding the COVID-19 vaccine. This material stems from the Centers for Disease Control and Prevention (CDC) and AMDA - The Society for Post-Acute and Long-Term Care Medicine (AMDA) resources and represents a suggested approach to reduce vaccine hesitancy in staff and residents/proxies (e.g., legally authorized representatives, powers of attorney). This electronic quality improvement (QI) material will be developed as part of a QI initiative and disseminated by the American Health Care Association (AHCA) to the SNF chains and using social media.
16291843|NCT04732819|Experimental|High touch|Facilities in the 'high touch' arm will receive the same electronic messaging and educational material as in the 'usual care' arm but will receive an additional high touch multi-pronged behavioral intervention.
16291844|NCT04732806|No Intervention|Treatment as usual|
16291845|NCT04732806|Experimental|Intervention|Six months of ad lib Mightier play in home
16291846|NCT04732793|Experimental|Hyruan ONE®|
16291847|NCT04732793|Active Comparator|Durolane®|
16291848|NCT04732780||Questionnaire group|Individuals who attend the type 1 diabetes clinic will complete a number of self-report questionnaires and a survey.
16291849|NCT04732780||Questionnaire and interview group|"Individuals who attend the type 1 diabetes clinic will complete a number of self-report questionnaires and a survey.
~Approximately 16 individuals who experience avoidance of hyperglycaemia will then take part in a semi-structured interview."
16291850|NCT04732754|Placebo Comparator|Control Group (CG)|This group will receive placebo capsules to be consumed for 8 weeks daily and will not exercise;
16291851|NCT04732754|Active Comparator|Aerobic Exercise (AE)|This group will receive placebo capsules and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
16291852|NCT04732754|Experimental|Aerobic exercise + Theobroma cocoa (AETC)|This group will receive 500mg cocoa capsules to be consumed daily and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% VO2peak) for 8 weeks
16291853|NCT04732754|Experimental|Theobroma cocoa (TC)|This group will receive 500mg cocoa capsules to be consumed daily for 8 weeks.
16291854|NCT04732741||Oral Cancer|patients diagnosed clinically and histopathologically with oral cancer who have yet to receive any treatment.
16291855|NCT04732741||Premalignant lesions|patients diagnosed clinically and histopathologically with oral potentially malignant lesions who have not yet to receive treatment or had a month wash-out period from any previous treatment.
16291856|NCT04732741||Control Group|healthy individuals who will be examined clinically through conventional visual and tactile examination to ensure no oral lesions are present and through thorough medical history
16291857|NCT04732728||Safety Cohort|No intervention will be administered to subjects that comprise the safety cohort.
16291858|NCT04732728||Holter Cohort|No intervention will be administered to subjects that comprise the safety cohort.
16291859|NCT04732715|Experimental|CaRE Course|Black American caregivers of PLWD will participate in the CaRE Course.
16291860|NCT04732689||Groups/Cohorts|The investigators propose to conduct a prospective observational cohort which will include all consecutive adult liver transplant recipients in each center during a one-year period but will exclude same patients who undergo a retransplantation during the same period of observation.
16291861|NCT04732676|Experimental|Experimental group|participants will receive and use during 4 weeks the full interventional version of the smartphone application (combining EMA + EMI) targeting craving and personal situations at risk for use
16291862|NCT04732676|Placebo Comparator|control group|: participants will receive and use a restricted version of the smartphone application (only EMA: 4 electronic questionnaires per day to assess main problematic substance use / addictive behavior) during 4 weeks
16291923|NCT04732286|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16291924|NCT04732260|Experimental|letermovir|Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP
16291863|NCT04732663||Persistently Symptomatic Covid-19 (PS-CoV)|PS-CoV will be defined as individuals with a history of molecular testing confirmed COVID-19 infection, recovered from acute infection but with ongoing symptoms (self-reported, pulmonary, cardiac, musculoskeletal or other symptoms) of at least 4 weeks' duration. Recovery from acute infection will be defined according to provincial health guidelines: at least 10 days' (14 in those hospitalized; 21 in those with immunocompromise) from onset of symptoms with at least 24 hours without a fever, without taking anti-pyretic medications and improvement of other symptoms.
16291864|NCT04732663||Recovered Covid-19|Recovered Covid-19 Survivors will be defined as individuals without complaint of a persisting covid-19 symptom. Recovered Covid-19 survivors will be matched to PS-CoV for age, sex, body mass index and time post corona virus infection.
16291865|NCT04732663||Control|Covid Naïve Controls will be defined as individuals who have no known history of covid-19. Control participants will be matched to PS-CoV for age, sex and body mass index.
16291866|NCT04732637||COVID Positive|Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.
16291867|NCT04732637||COVID Negative|Individuals who have recently tested negative for COVID19 by RTPCR.
16291868|NCT04732624|Experimental|Enteral-based Protocolized Resuscitation|Administration of Enteral-based Resuscitation using Oral Rehydration Solution (ORS) either by mouth of via naso-enteric access for moderate sized burn injuries (20-40% TBSA) per resuscitation protocol for burn-injured patients. Resuscitation will be administered in the acute resuscitation phase of burn injury (24-72 hours post injury). Patients will receive supplemental Intravenous Fluid (IV Fluid) resuscitation using Lactated Ringer's solution as needed per protocol.
16291869|NCT04732624|Active Comparator|Intravenous Fluid Protocolized Resuscitation|Administration of Intravenous Fluid using Lactated Ringer's solution per standard of care resuscitation protocol for patients with moderate sized burn injuries (20-40% TBSA).
16291870|NCT04732611|Experimental|Pilates|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
16291871|NCT04732611|Active Comparator|Walking|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks
16291872|NCT04732598|Active Comparator|Arm A|
16291873|NCT04732598|Experimental|Arm B|
16291874|NCT04732585|Experimental|Patient with PFPS or ACL injury|Physiotherapy intervention Surgical intervention
16291875|NCT04732585|No Intervention|Healthy control group|The healthy control group will not do any intervention
16291876|NCT04732572|Experimental|Adenotonsillectomy|Within 1 to 4 weeks (30 days) of randomization, participants randomized to the adenotonsillectomy arm will undergo surgery under general anesthesia, as occurs as part of routine standard of care.
16291877|NCT04732572|Active Comparator|Watchful waiting with supportive care|Within 1 to 4 weeks after the 7-month visit, participants in the Arm 2 group will be referred for re-evaluation of surgical candidacy. Symptoms and polysomnographic findings (baseline and month 7) will be reviewed by the ENT and a decision whether to proceed with adenotonsillectomy as part of routine clinical care will be made.
16291879|NCT04732533|Experimental|tDCS|Active transcranial direct current stimulation (tDCS) will be administered with the goal of facilitating the excitability of the left dorsolateral prefrontal cortex (dlPFC). Electrode placement and current parameters for each electrode have been optimized using a standard brain with the goal of generating an average electric field of 0.25 V/m67 within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
16291880|NCT04732520|Experimental|Treatment|Patients participating in the treatment group will undergo pulsed electric field (PEF) treatment of a single NSCLC nodule measuring 1 to 4 cm by CT, using the Aliya System. The treatment may be performed endoluminally in conjunction with a diagnostic bronchoscopy, or percutaneously.
16291881|NCT04732520|No Intervention|Control|Patients declining to participate in the treatment arm may self-select to participate in an observational control arm.
16291882|NCT04732507|Active Comparator|One to two needle passes|Receive 1-2 needle passes for needling at each trigger point
16291883|NCT04732507|Active Comparator|Ten needle passes|Receive 10 needle passes for needling at each trigger point
16291884|NCT04732507|Active Comparator|Twenty needle passes|Receive 20 needle passes for needling at each trigger point
16291887|NCT04732481||interventional group|passive leg lift test
16291888|NCT04732481||control group|no intervention (SOC)
16291889|NCT04732468|Experimental|Cohort 1- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 1, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Suspension for injection) again on day 22 (boost).
16291890|NCT04732468|Experimental|Cohort 2- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 2, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Oral capsule) on day 22 (boost).
16291891|NCT04732468|Experimental|Cohort 3 - hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 3, hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on days 1 (prime) and on day 22 (boost).
16291892|NCT04732468|Experimental|Cohort 4 - hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 4, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on days 15 (boost) and 22 (boost).
16291893|NCT04732455|Placebo Comparator|Group Control (C)|20 adult breast cancer patients on Taxane chemo protocol will receive 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
16291925|NCT04732247|Experimental|Oxytocin nasal spray|4x per day (QID) intranasal treatment with oxytocin (48 IU per dose)
16292735|NCT04726631|Other|Basal insulin analogue and premeal rapid acting insulin|
16291894|NCT04732455|Experimental|Group lidocaine infusion (L)|20 adult breast cancer patients on Taxane chemo protocol will receive lidocaine i.v infusion (2 mg/kg) in 200ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy lidocaine (2 mg/kg) re-infused after each session. If lidocaine side effects such as circumoral numbness, twitches, metal test, tachy or bradycardia recorded at any time, lidocaine infusion will be reduced to 1mg/kg, if side effects persist, the patients will be managed accordingly as well as lidocaine infusion will be stopped and patient will be excluded from the study.
16291895|NCT04732455|Experimental|Group duloxetine (D)|20 adult breast cancer patients on chemotherapy will take oral duloxetine tablet 30 mg once per day starting from the night pre chemotherapy session until the end of cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy the duloxetine dose will be adjusted to 60 mg daily till the end of the cycle. They also will receive 200 ml normal saline over forty minutes before each chemotherapy session until end of the cycle.
16291896|NCT04732442|Experimental|Immuno-group|The immuno-group will consist of patients who, as part of preoperative nutritional support, used immunonutrition ONS (2x Impact Oral® Nestle, Switzerland per day) for 2 weeks before surgery.
16291897|NCT04732442|Sham Comparator|Control-group|The control group will consist of patients who, as part of preoperative nutritional support, used standard ONS (3x Fortimel Compact Protein® Nutricia, United Kingdom per day) for 2 weeks before surgery.
16291898|NCT04732429|Experimental|Active Drug|Part B is the 6-month, randomized, double-blind (Subject/Investigator/Sponsor), placebo-controlled, 2-period crossover study consisting of 2 intervention periods of 12 weeks each to evaluate the safety and efficacy of the optimal dose of HST5040 in PA and MMA subjects ≥ 2 years old (N = minimum 12) in addition to SoC determined in Part A (within-subject dose escalation).
16291899|NCT04732429|Experimental|Placebo|Placebo in addition to standard of care.
16291900|NCT04732416|Experimental|HM15136 active|Cohort A / Cohort C
16291901|NCT04732403|No Intervention|0 degree supine position|Surgical bed will be set to a 0 degree supine position
16291902|NCT04732403|Experimental|10-20 degree angle in reverse Trendelenburg|Surgical bed will be set to a 10-20 degree angle in reverse Trendelenburg
16291903|NCT04732390|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
16291904|NCT04732390|Active Comparator|Group (M)|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5. .
16291905|NCT04732377|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
16291906|NCT04732377|Active Comparator|Group (D)|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
16291907|NCT04732364|Placebo Comparator|Group (C) (control group):|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
16291908|NCT04732364|Active Comparator|Group (D) (Dexmetonidine group):|Patient will receive 20ml 0.25% levobupivacaine + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5..
16291909|NCT04732364|Active Comparator|Group (M) (magnesium slphate group):|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5..
16291910|NCT04732351||Active sentry|Cataract procedures conducted with the active Sentry handpiece
16291911|NCT04732351||Non-active sentry|Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece
16291912|NCT04732338|Experimental|Study arm - Osteopathic Manipulative Therapy|"Standard of care including physical therapy, occupational therapy and over the counter medication AND OMT as described below:
~Musculoskeletal examination of the cervical spine. Testing will be comprised of :
~Range of motion testing involving cervical rotation, lateral side bending, flexion and extension.
~Muscular palpation of the cervical paraspinals for hypertonicity of the muscles and/or tenderness.
~Patient placed supine on the examination table.
~Treatment sessions lasting 5-10 minutes each. OMT techniques: cervical muscle energy, myofascial release of the cervical paraspinals and a suboccipital release.
~Assessment with Headache Impact Test (HIT-6) at baseline and follow-up visit and change in pain scores between baseline and post treatment."
16291913|NCT04732338|No Intervention|Control - Standard of care|Standard of care including physical therapy, occupational therapy and over the counter medication.
16291914|NCT04732325|Experimental|Burst / kHz / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
16291915|NCT04732325|Experimental|Burst / Sham / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
16291916|NCT04732325|Experimental|kHz / Sham / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
16291917|NCT04732325|Experimental|kHz / Burst / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
16291918|NCT04732325|Experimental|Sham / Burst / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
16291919|NCT04732325|Experimental|Sham / kHz / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
16291920|NCT04732299||Acute thrombus group|Within 14 days after onset
16291921|NCT04732299||Subacute thrombus group|During 15-30 days after onset
16291922|NCT04732299||Chronic thrombosis group|More than 15-30 days after onset
16291926|NCT04732247|Placebo Comparator|Placebo nasal spray|4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
16291927|NCT04732234|Active Comparator|( Group A)|ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.
16291928|NCT04732234|Placebo Comparator|(Group B)|ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.
16291935|NCT04732208||Diabetic patients|
16291936|NCT04732195|Experimental|Pilocarpine microneedle patch|Participants will receive in their left forearm the microneedle patch. Upon application to skin, the MNs penetrate into the skin's upper layers and dissolve in the interstitial fluid to release the loaded drugs. MN patches are painless and can be administered with little or no training.
16291937|NCT04732195|Active Comparator|Pilocarpine Iontophoresis|Participants will receive in their right forearm the pilocarpine iontophoresis. Uses a gel disc containing Pilocarpine that drives the medication into the skin with a small electric current (iontophoresis) followed a 30-minute period of sweat collection.
16291938|NCT04732182|Experimental|Standard of care medication for early Alzheimer's disease and BrightGo device cognitive training|Participants randomized to the experimental group will have standard of care and 12 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 6 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
16291939|NCT04732182|Other|Standard of care medication for early Alzheimer's disease|Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 6 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
16291940|NCT04732169|Active Comparator|Epidiolex (cannabidiol) (CBD)|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
16291941|NCT04732169|Placebo Comparator|Placebo|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
16291942|NCT04732156|Other|Prospective multicenter cohort|"Constitution of a prospective multicenter cohort of 420 patients with suspected prostate cancer that will undergo prostate multiparametric MRI followed by systematic and targeted biopsy.
~When available (i.e., at the end of the RHU PERFUSE program, November 2022), the final version of the CAD will be used retrospectively to assess the risk that the prostate/targeted lesions harbor ISUP ≥2 cancer.
~In addition, a blood sample will be taken in all patients before the biopsy to assess the performance of the PHI index in predicting the presence of ISUP ≥2 cancer at systematic and targeted biopsy (ancillary study, secondary objective)."
16291943|NCT04732143|Experimental|Incentive Spirometry|Participants will undergo inspiratory muscle training using an incentive spirometer daily for 14 days prior to surgery.
16291944|NCT04732143|No Intervention|Standard Care|Participants will not undergo any inspiratory muscle training prior to surgery.
16291945|NCT04732130|Active Comparator|Time-Restricted Feeding|Participants in the time-restricted feeding are instructed to eat ad libitum from 12:00 to 20:00 daily, and fast from 20:00 to 12:00 daily for 4 weeks.
16291946|NCT04732130|Active Comparator|Alternate Day Fasting|Participants in the alternate day fasting group are instructed to eat every second day ad libitum, but to abstain from calorie intake on fast days (100 % restriction) for 4 weeks.
16291947|NCT04732130|No Intervention|Control|Participants in the control group are instructed to maintain their habitual diet regimen.
16291950|NCT04732104|Experimental|intranasal spray anesthesia|intranasal lidocaine lidocaine 4% topical
16291951|NCT04732104|Active Comparator|injectable local anesthesia|gold standard infiltration local anesthesia (2% lidocaine with 1:100,000 epinephrine)
16291952|NCT04732091||Subproject 1 - acute STEMI|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure until complete a total of 50 minutes.
16291972|NCT04731987|Experimental|Control beverage supplemented with hesperidin formulation (B+HESP)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (identical to drink B but supplemented with hesperidin to reach level of drink A) during 6 weeks
16291953|NCT04732091||Subproject 2 - acute STEMI initially treated with fibrinolytic|Participants with acute STEMI initially treated with fibrinolytic therapy within 12 hours will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI; High MI will continue after PCI procedure until complete a total of 50 minutes.
16291954|NCT04732091||Subproject 3 - NSTEMI|Participants with NSTEMI or with high-risk unstable angina will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
16291955|NCT04732091||Subproject 4 - No reflow|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2 MI) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
16291956|NCT04732091||Subproject 6 - Pre-hospital care (ambulance)|Participants with acute STEMI routing from the ambulance to the emergency department will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
16291957|NCT04732065|Experimental|Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16291958|NCT04732065|Experimental|Arm B: ONC206 + radiation therapy for newly diagnosed participants|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16291959|NCT04732065|Experimental|Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16291960|NCT04732065|Experimental|Arm D: ONC206 Therapy, Primary malignant brain tumors with progression|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16291961|NCT04732052|Active Comparator|Active tDCS|Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the stimulation using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The active stimulation condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration a single tDCS session will be 20 minutes.
16291962|NCT04732052|Sham Comparator|Sham tDCS|Sham Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the sham stimulation using two sponge electrodes soaked in a saline solution. The sham stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation for 10s only. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The sham tDCS is identical to the active tDCS except that the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each sham tDCS session will be 20 minutes.
16291963|NCT04732039|Experimental|LVAD recipients|Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients
16291964|NCT04732039|Experimental|Healthy controls|Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.
16291965|NCT04732026||Cases|150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
16291966|NCT04732026||Controls|450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
16291967|NCT04732013||Study cohort|Single observational cohort of patients who meet study criteria
16291968|NCT04732000|Active Comparator|N-acetyl cysteine|N-acetyl cysteine will be administered as follows: A loading dose of 50 mg/kg will be started as a 1-hour infusion before surgical incision, and will be followed by a maintenance dose of 50 mg/kg administered over 4 hours.
16291969|NCT04732000|Placebo Comparator|Normal Saline|Normal will be administered as follows: A normal saline infusion will administered at a rate and duration to mimic the N-acetyl cysteine administration.
16291970|NCT04731987|Experimental|Orange juice (A)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of orange juice naturally rich in hesperidin (drink A) during 6 weeks
16291971|NCT04731987|Placebo Comparator|Control beverage (B)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (drink B)- a soft drink with sugar concentration identical to drink A - during 6 weeks
16291975|NCT04731961|Active Comparator|Controls|Subjects in this arm will be administered the standard injection site protocol (15 sites).
16291976|NCT04731961|Experimental|Experimental|Subjects in this arm will be administered the same amount of Botox in 5 injection sites.
16291977|NCT04731948|Placebo Comparator|Folic Acid + Placebo|400µg Folic Acid per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
16291978|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 1|400µg Folic Acid + 2 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
16291979|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 2|400µg Folic Acid + 10 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
16291980|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 3|400µg Folic Acid + 50 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
16291981|NCT04731935|Experimental|tAN Therapy|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 120 hours (5 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness.
16291982|NCT04731922|Experimental|TAK-510: Part 1|TAK-510 at starting dose of 5 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part A (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12) will be used based on emerging safety, tolerability, and PK data from Cohort 1 as determined by dose escalation committee.
16291983|NCT04731922|Experimental|TAK-510: Part 2|TAK-510 to be decided (TBD) or placebo-matching solution, subcutaneously, once daily from Day 1 through Day 5. Dose of multiple rising dose (MRD) Cohorts (Cohorts 13-17) of Part 2 will be determined based on emerging safety, tolerability, and available PK data from Part 1 (SRD) determined by dose escalation committee.
16291984|NCT04731922|Experimental|TAK-510: Part 3|TAK-510 TBD or placebo-matching solution, subcutaneously, once daily from Day 1 through Day 14. Dose of dose titration and redosing Cohorts (Cohorts 18-20) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 single rising dose (SRD) and Part 2 (MRD) as determined by dose escalation committee. Single redosing will be performed on Day 14 after 7 days of washout period following the 7 days treatment period.
16291985|NCT04731909|Experimental|Toripalimab Combined With Anlotinib, Etoposide and Platinum|Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d,d1-14,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 or Carboplatin AUC=5, d1, q3w,4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d, was taken orally for 2 weeks and stopped for 1 week until the disease progressed.
16291986|NCT04731896|No Intervention|Late Amniotomy|Initiating induction of labor with oxytocin infusion followed by amniotomy 4-6 hours later
16291987|NCT04731896|Active Comparator|Early Amniotomy|Early amniotomy initiating induction of labor followed by oxytocin infusion 30 minutes later
16291988|NCT04731870||Nurses/Doctors|Covid-19 vaccine confidence and recommendation practices of nurses/doctors
16291989|NCT04731870||Minority populations living in rural south|Covid-19 vaccine confidence and uptake of key at-risk subgroups and tailored Covid-10 vaccine messaging for at-risk subgroups.
16291990|NCT04731857||Genetic diseases|For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.
16291991|NCT04731844|Experimental|Prostate Cancer|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
16291992|NCT04731844|Experimental|Smoldering Multiple Myeloma (SMM)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
16291993|NCT04731844|Experimental|Monoclonal Gammopathy of Unknown Significance (MGUS)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
16291994|NCT04731831||Patient with arthritis starting infliximab or adalimumab|Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab
16291995|NCT04731818|Experimental|ZB-06|All participants will receive a single ZB-06 film for intravaginal administration prior to intercourse.
16291996|NCT04731805|Experimental|Moving On After Breast Cancer - Intervention Arm|Participants are randomized to the intervention arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Participants are given the patient education materials (booklet, therapeutic exercise DVD, small ball, range of motion wand). The research assistant orients the participant to the education materials and summarizes each section of the booklet. The research assistant also teaches the participant how to do the therapeutic exercises in the booklet. All participants in the intervention also receive usual care.
16291997|NCT04731805|No Intervention|Usual Care|Participants are randomized to the usual care arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Usual care consists of pre-operative testing, pre-operative nursing education on care of the surgical incision and pain management followed by breast cancer surgery.
16291998|NCT04731792|Experimental|Virtual Reality group|
16291999|NCT04731792|No Intervention|control group|
16292000|NCT04731779|Placebo Comparator|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
16292001|NCT04731779|Experimental|25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
16292002|NCT04731779|Experimental|50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
16292003|NCT04731779|Experimental|200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
16292004|NCT04731766|Active Comparator|Citrine 5% Sodium Fluoride|It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
16292005|NCT04731766|Experimental|concocuted Nano-silver fluoride|Nano-silver fluoride (NSF) is a laboratory synthesized solution
16292736|NCT04726631|Other|Neutral Protamine Hagedorn with regular insulin|
16292006|NCT04731753||Group treated with study product|Subjects will undergo one mechanical debridement procedure with Cutimed DebriClean
16292007|NCT04731740|Experimental|Pembrolizumab + Lenvatinib|"Experimental treatment:
~Lenvatinib p.o. once a day, pembrolizumab 200 mg i.v. every 21 days started 21 days after start of Lenvatinib
~Duration of treatment per patient:
~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
16292008|NCT04731740|Experimental|Pembrolizumab + Chemotherapy|"Experimental treatment:
~Investigators' choice of the Сhemotherapy, pembrolizumab 200 mg i.v. every 21 days started 21 days after the start of chemotherapy
~Duration of treatment per patient:
~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
16292009|NCT04731727|Experimental|Cross linking treatment for corneal thinning|Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.
16292010|NCT04731714|Other|Experimental: rhythmic MNS, then arrhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS.
16292011|NCT04731714|Other|Experimental: arrhythmic MNS, then rhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS.
16292012|NCT04731688|Experimental|Weight Maintenance Group|Individuals in this group will receive all aspects of the Provider Directed Group plus a comprehensive behavioral fat mass loss intervention with food provision. Individuals in this group will be provided foods to eat to support weight maintenance and loss of body fat throughout pregnancy. They will be asked to attend two behavioral counseling sessions at the beginning of the study to help learn the program and set goals. They will return for brief visits with a lifestyle counselor every two weeks until 20 weeks gestation and at least once a month until delivery. Individuals will be provided a scale to help keep track of weight during pregnancy.
16292013|NCT04731688|No Intervention|Provider Directed Group|Individuals in this group will receive what is standard practice by their prenatal care providers during pregnancy. In addition, individuals in this group will be asked to attend a brief session at the time of randomization to familiarize with the study and what is expected. They will also be provided with materials describing healthy behaviors in pregnancy.
16292014|NCT04731675|Experimental|AMB-05X|"Subjects will receive an injection of AMB-05X once every 2 weeks for 12 weeks (for 6 treatments total).
~Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose."
16292015|NCT04731662|No Intervention|Control Group (8888888)|The Control group will have 8-hours time-in-bed, both weeknights and weekends.
16292016|NCT04731662|Experimental|Stable Short Sleep (8866666)|The short sleep group will have 6-hours time-in-bed on weeknights and 8-hours time-in-bed on weekends.
16292017|NCT04731662|Experimental|Variable short sleep group (8884846)|The short sleep group time in-bed will vary across weeknights but will maintain the same amount of total time-in bed as the stable short sleep (8866666).
16292018|NCT04731649|Experimental|Sex Education + Standard Care|The experimental arm will receive the FTT + intervention
16292019|NCT04731649|No Intervention|No Education + Standard Care|The control arm will not receive the FTT + intervention
16292020|NCT04731636|Experimental|Intervention arm|Patients with Crawford type I-V thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
16292021|NCT04731623|Experimental|ION904|Single ascending dose of ION904 will be administered by SC injection on Day 1.
16292022|NCT04731623|Placebo Comparator|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.
16292023|NCT04731610|Other|Post-operative radiotherapy|Tumour resection followed by radiotherapy.
16292024|NCT04731610|Other|Surveillance after tumour resection|Tumour resection
16292025|NCT04731597||Cases with hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano who presented hip fracture between 2014 and 2019
16292026|NCT04731597||controls without hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano without hip fracture between 2014 and 2019
16292027|NCT04731584||AVC|Patients hospitalized for TM after a proximal ischemic stroke of the middle cerebral artery and whose reperfusion is satisfactory (TICI 2b, 2c and 3). Additional blood sample will be taken during usual treatment the day of the stroke.
16292028|NCT04731584||Control|Population of control patients, consisting of patients admitted on an outpatient basis for a diagnostic cerebral arteriography.
16292029|NCT04731571||Adaptive Radiotherapy|Patients treated using adaptive radiotherapy on the Varian Ethos linear accelerator
16292030|NCT04731571||Conventional Radiotherapy|Patients treated using conventional, non-adaptive radiotherapy on the Varian Truebeam linear accelerator
16292031|NCT04731558|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
16292032|NCT04731558|Other|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
16292033|NCT04731545|Active Comparator|thin buccal bone|
16292034|NCT04731545|Active Comparator|thick buccal bone|
16292035|NCT04731532|Active Comparator|Classical respiratory physiotherapy application|Patient positions, postural drainage application tapping and trifled
16292036|NCT04731532|Active Comparator|classical respiratory physiotherapy with thoracic vibration|Thoracic Vibration: The physiotherapist places his hands open with his / her fingers on the front and side walls of the patient's chest when the elbow is at 5-10 degrees of flexion. The elbow expands the patient's chest with vibrations. Exercise can be repeated 5-10 times a day+Patient positions, postural drainage application tapping and trifled
16292037|NCT04731519|Active Comparator|General Health Education Active Control Group|The control condition will receive General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
16292776|NCT04726293|Experimental|Mango beverage|Mango composite served as a frozen drink
16292038|NCT04731519|Experimental|CI-CT Group|The experimental group will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
16292039|NCT04731519|Other|CI-CT Treatment Development Group|The 3 treatment development groups will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
16292040|NCT04731506|Experimental|Family Connection|2 in-person sessions spaced one week apart & 10 IVR calls/6 months; delivers intervention to parents only
16292041|NCT04731506|No Intervention|Waitlist Standard-Care|6-month delayed start (waitlist) in the FC program; receive post-randomization standard health promotion materials available at the local health department; delivers intervention to parents only
16292042|NCT04731493||therapeutic Education Program|"individual and group sessions will be set up with educational workshops specialized by age group (child / adolescent / transition / adult / entourage / parents), socio-administrative workshops, etc.
~The objectives will be adapted to each age group and to each patient individually."
16292043|NCT04731480|Active Comparator|CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia.
16292044|NCT04731480|Active Comparator|Marsh model group|The target-controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
16292045|NCT04731480|Active Comparator|Schnider model group|The TCI-pump will be programmed to will be programmed to Schnider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia.
16292046|NCT04731480|Active Comparator|Manual group|Propofol administration will be controlled manually using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
16292050|NCT04731454|Experimental|Healthy Nordic Diet (ND)|A healthy diet meeting and exceeding the Nordic Nutrition Recommendations and with more than 80% foods from the Nordic region.
16292051|NCT04731454|Experimental|Control Diet (CD)|A control diet approximating the average depressed person's diet, i.e. of somewhat lower quality than the average Swedish diet.
16292052|NCT04731441|Experimental|Exercise Group|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
16292053|NCT04731441|Active Comparator|Education Group|Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC. Results and outcomes will not be recorded.
16292054|NCT04731428|Experimental|Progressive Relaxation Exercise|In individuals with normal daily circadian rhythms, cortisol levels peak at 8:00 AM, followed by a constantly declining daily cycle throughout the day. Therefore, it is important to collect blood samples taken for the measurement of serum cortisol levels approximately at the same time. Venous blood samples (3 ml) were obtained from the upper arm at 06:45 AM to evaluate the baseline and 45 minutes after Progressive Relaxation Exercise at 08:00. Vital signs and oxygen saturation were assessed at 6:30 AM before Progressive Relaxation Exercise and at 07:20 AM 5 minutes after Progressive Relaxation Exercise. Measurements were performed in the morning on the day of surgery and on postoperative days 1, 2, and 3.
16292055|NCT04731428|No Intervention|Standard Care|In the control group, no application made during and after the surgical intervention, and routine treatment and care applied.
16292056|NCT04731415|Other|Healthy pregnant women|Optical coherence tomography and Optical coherence tomography angiography using Optovue® were performed in each trimester and at 6 weeks after childbirth.
16292057|NCT04731402|Experimental|Acupressure|Acupressure group Acupressure application will be applied twice a week, 24 times in total in 12 weeks. Each acupressure point will be massaged for 30 seconds to provide circulation before compression. After the massage, pressures will be applied consecutively for 90 seconds. The session duration for each woman will be 8 minutes in total, with 2 minutes for each point in each attempt.
16292058|NCT04731402|Experimental|Laughter Yoga|Laughter Yoga group Laughter yoga sessions begin with gentle warm-up techniques that include stretching and stretching movements, songs, applause, and body movements. Therapy sessions are between 30-45 minutes.8 sessions of laughter yoga will be done once a week.
16292059|NCT04731402|Experimental|mindfulness stress reduction program|mindfulness stress reduction program mindfulness stress reduction program consists of 8 weeks. each week is 2.5 hours. each week has a different theme. There is a 6-hour silence day in the 6th week of the program.
16292060|NCT04731402|No Intervention|Control Group|INTERVENTION NOT IMPLEMENTED
16292061|NCT04731389|Experimental|internet CBT|Intervention with remote and self-applicable cognitive behavioral therapy, during 4 weeks.
16292062|NCT04731389|Active Comparator|Quality of life promotion|Control intervention, during 4 weeks.
16292063|NCT04731376|Experimental|Arm I (testosterone cypionate)|Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.
16292064|NCT04731376|Active Comparator|Arm II (best practice)|Patients with normal testosterone levels receive standard peri-operative care.
16292065|NCT04731363|Experimental|Xylitol|oral xylitol, a potent artificial sweetener
16292066|NCT04731363|Experimental|Erythritol|oral erythritol, a potent artificial sweetener
16292067|NCT04731350|Experimental|Shock wave(A)|subjects will recive radial extracorporeal shock wave (2000 shock/session, 10Hz and EFD 0.178 mJ/mm²) on knee joints once per week for four weeks in addition to strengthening exercise
16292068|NCT04731350|Experimental|Iontophoresis (B)|subjects will recive dexamethasone iontophoresis on knee joints once per week for four weeks in addition to strengthening exercise
16292069|NCT04731350|Other|Control (C)|stregnthening exercise;straight leg raising exercisein which the patients were positioned in the crook lying position with the unexercised limb was the flexed one then the patients were asked to contract the quadriceps muscle and elevate the limb to 45º and hold for 6 seconds, slowly lower the limb and then relax for 6 seconds, three sets of 10 repetitions were don ,Isometric quadriceps contraction (quadriceps drill) in full knee extension maintained for 5 seconds, followed by a 5-second rest; the exercise was performed for 20 repetitions per session .treatment once per week for four weeks
16292070|NCT04731337|Active Comparator|Patient's normal canine occlusal relationship|The vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital calliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
16292071|NCT04731337|Sham Comparator|Canine occlusal relationship after full mouth rehabilitation|The vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital calliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
16292072|NCT04731324|Experimental|ZYIL1 Capsule|six subjects will be recruited in each cohort. safety data up to day 3 will be evaluated to determine whether progression to the subsequent dose Cohort is indicated. Single dose will be administered in ascending manner starting from 25 mg.
16292073|NCT04731311|Other|Usability Evaluation of the BrightGo system|Participants with rate the device in each of 4 usability evaluation sessions.
16292074|NCT04731298|Experimental|Emapalumab|"The first cohort of patients will receive a first infusion of 6 mg/kg at TD0, followed by a second infusion at 3 mg/kg after 3 days (treatment day 3 - TD3). Subsequent infusions of 3 mg/kg will be every 3 or 4 days from previous dose until dose 15 or until engraftment.
~A maximum of 2 additional cohorts may be added to allow dosing regimen adaptation based on the PK/PD data observed from the previous cohort(s). Efficacy and safety data will also be considered before adding additional cohorts."
16292075|NCT04731285||Pressure wire based FFR|Pressure wire based FFR was reference group
16292076|NCT04731285||CT-FFR|CFD-based RuiXin-FFR was test group
16292077|NCT04731272|Experimental|Dulaglutide|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of dulaglutide therapy in the intervention period.
16292078|NCT04731272|No Intervention|Observation|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of no intervention in the observation period.
16292079|NCT04731259|Experimental|ATR-04|The intervention is an ointment that will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
16292080|NCT04731259|Placebo Comparator|Placebo|Placebo ointment will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
16292081|NCT04731246|Experimental|Parkinson's disease (mild to moderate stage)|
16292082|NCT04731233|Experimental|PRGF Arm|The PRGF experimental group will have two cc of PRGF infused into the upper joint space after the TMJ arthrocentesis procedure.
16292083|NCT04731233|Active Comparator|Steroid Arm|Two cc containing 40 mg of triamcinolone acetonide with 5 mg bupivacaine will be infused into the upper joint space after the TMJ arthrocentesis procedure.
16292084|NCT04731220||Study group|Newly diagnosed as bile duct cancer
16292085|NCT04731220||Control group|No history of cancer in previous 5 years
16292086|NCT04731207|Other|Healthy pregnant women|All participants will be investigated by Optovue® in follicular phase, ovulatory phase, luteal phase of menstrual cycle. The investigation will be done between 12 PM and 1 PM at each phase. Urine pregnancy testing was done at first and last visits. LH ovulation test was performed by the participants own. if the ovulation was detected by urine strip test, the participant have to underwent the Optovue® within 48 hours.
16292087|NCT04731194|Experimental|performance-based financial incentive program|Village doctors in villages of the intervention group will promote policy awareness, support registration, follow-up patients, and receive financial incentives based on their performance.
16292671|NCT04727086|Placebo Comparator|Placebo pills|Participants will receive matching placebo pills for 14 days.
16292088|NCT04731194|No Intervention|current situation|Village doctors in villages of the control group will not be contacted. The control group would serve as a natural baseline and do not receive any intervention.
16292089|NCT04731181|Experimental|mobile application (little lovely dentist).|intervention mobile application simulating the dental procedure that will be done to the child
16292090|NCT04731181|No Intervention|Tell-Show-Do technique.|control behavior technique where ''tell'' is to tell the child about the procedure in non-threatening words, ''show'' is to demonstrate the procedure to the child, and ''do'' is the execution of the procedure
16292091|NCT04731168|No Intervention|Control|
16292092|NCT04731168|Experimental|MAD|Patients will have a mandibular advancement device during the first postoperative night
16292093|NCT04731155|Active Comparator|standard group|
16292094|NCT04731155|Experimental|experiment group|
16292095|NCT04731142|Experimental|T2DEx remote care service|
16292096|NCT04731142|Other|Matched control group|This study will create a matched control group using propensity score matching (PSM), a quasi-experimental method used to mimic the characteristics of a randomised control trial that has been shown to reduce biases. PSM uses statistical techniques to construct an artificial control group by matching each study participant with a non-treated participant of similar characteristics. PSM computes the probability that a person would enrol in a program based on pre-defined characteristics, giving a 'propensity score'.
16292097|NCT04731116|Experimental|CANNABIDIOL|CANNABIDIOL 5% 3 ml twice daily for 14 days.
16292098|NCT04731103|Active Comparator|Abacavir (ABC)|Participants receive Abacavir (ABC) for 6 weeks and 4 weeks of washout.
16292099|NCT04731103|Active Comparator|Lamivudine (3TC)|Participants receive Lamivudine (3TC) for 6 weeks and 4 weeks of washout.
16292100|NCT04731103|Active Comparator|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Participants receive Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) for 6 weeks and 4 weeks of washout.
16292101|NCT04731090|Active Comparator|Standard antibiotic prophylaxis|IV fluoroquinolone 1 hour preoperatively and oral antibiotics were used for 24h postoperatively.
16292102|NCT04731090|Experimental|enhanced prophylaxis|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
16292104|NCT04731051|Experimental|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
16292105|NCT04731051|Active Comparator|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
16292106|NCT04731038|Experimental|Experimental|Anlotinib 12mg qd. po. d1-d14 q3w Toripalimab 240mg ivgtt. d1 q3w Paclitaxel 135mg/m2 ivgtt. d1 q3w Cisplatin 50mg/m2 ivgtt. d1 q3w Carboplatin AUC=5 ivgtt. d1 q3w
16292109|NCT04731012||healthy oocyte-donation pregnancy|healthy pregnancy
16292110|NCT04731012||preeclamptic oocyte-donation pregnancy|preeclampsia
16292111|NCT04731012||healthy IVF or ICSI pregnancy|healthy pregnancy
16292112|NCT04731012||preeclamptic IVF or ICSI pregnancy|preeclampsia
16292113|NCT04731012||healthy spontaneous conception pregnancy|healthy pregnancy
16292114|NCT04731012||preeclamptic spontaneous conception pregnancy|preeclampsia
16292115|NCT04730999|Experimental|Single Arm|"Induction phase (6 cycles, 21 days duration): carboplatin, etoposide, bevacizumab and atezolizumab.
~Maintenance phase (12 cycles, 21 days duration): bevacizumab and atezolizumab"
16292116|NCT04730986|Experimental|Intervention Arm|This is a single-arm study with all enrolled patients receiving the same ED GOAL Nursing intervention
16292117|NCT04730973|Active Comparator|Evolocumab|Subcutaneous evolocumab 140 mg will be administered every 2 weeks on top of optimal lipid-lowering therapy
16292118|NCT04730973|Placebo Comparator|Standard|No further treatment besides optimal lipid-lowering therapy will be administered
16292119|NCT04730960||Study Group|Healthy patients between the ages of 18 and 30 without neck problems will be included in the study.
16292120|NCT04730947|Experimental|Dapagliflozin Group|Subjects with HFpEF will take the study drug dapagliflozin daily
16292121|NCT04730947|Placebo Comparator|Placebo Group|Subjects with HFpEF will take a placebo daily
16292122|NCT04730934||Healthy population|Healthy individuals aged between 18-65
16292123|NCT04730934||Chronic Low Back Pain Group|Patients aged between 18 and 65 and has at least 3 months of low back pain which started before pandemic.
16292124|NCT04730934||Fibromyalgia Group|Patients aged between 18 and 65 and has a diagnosis of fibromyalgia for at least 6 months
16292125|NCT04730921|Experimental|LBBAP group|AV block patients randomized to left bundle branch area pacing
16292126|NCT04730921|Active Comparator|RVP group|AV block patients randomized to right ventricular pacing group
16292127|NCT04730908|Placebo Comparator|G0 - placebo|Dental gel without fluoride in the composition
16292128|NCT04730908|Sham Comparator|G1: Daily Regenerator Dentalclean Neutro (RDCN)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). NEUTRAL pH
16292129|NCT04730908|Active Comparator|G2: Sensodyne Repair & Protect (SRP)|1426 ppm of sodium fluoride and calcium sodium phosphosilicate 5% (NOVAMIN technology).
16292130|NCT04730908|Experimental|G3: Daily Regenerator Dentalclean Acid (RDCA)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). ACIDIC FORMULA
16292131|NCT04730908|Active Comparator|G4: Colgate Total Daily Repair (CTDR)|1450 ppm F- of as sodium fluoride, 0.30% triclosan, arginine, tetrasodium pyrophosphate.
16292132|NCT04730895|Experimental|Oral 13 cis retinoic acid|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
16292777|NCT04726293|Placebo Comparator|Control beverage|Energy matched Control frozen drink
16292133|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days. All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
16292134|NCT04730895|Experimental|13 cis retinoic acid doses orally in combination with spike protein based vaccine|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
16292135|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days and also, participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
16292136|NCT04730895|Sham Comparator|spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|The participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
16292137|NCT04730882||Healthy Control|Healthy subjects 18-35 years of age
16292138|NCT04730882||DM1|DM1 subjects (18-35 yrs) have DM1 based on WHO diagnostic criteria for > 1 year
16292139|NCT04730869|Experimental|Standard treatment in conjunction with MTP|"Standard:
~Concurrent chemoradiation - Radiation (60-Gy in 30 fractions over 6 weeks or, in adults unfit for this [eg >65 years and/or poor performance status] 40-Gy in 15 fractions over 3 weeks) with daily oral temozolomide.
~Adjuvant chemotherapy - Daily oral temozolomide (5 days per 4-week cycle, starting 4 weeks after completion of chemoradiation, with at least 6 cycles intended).
~MTP:
~If 6 weeks of chemoradiation - Two 5-day fasts (allowing water, salt, tea, coffee, and a magnesium supplement) during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet (one or two 1-hour eating windows per day, allowing oils, meats, vegetables, nuts, seeds, limited berries, and a multivitamin) between fasts.
~If 3 weeks of chemoradiation - One 5-day fast during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet between fasts."
16292140|NCT04730856|Active Comparator|Tinzaparin 4500 UI/day|Procedure: Tinzaparin 4500 UI/day SC until hospital discharge.
16292141|NCT04730856|Active Comparator|Tinzaparin 100 UI/Kg/day|Procedure: Tinzaparin 100 UI/Kg/day SC until hospital discharge.
16292142|NCT04730856|Active Comparator|Tinzaparin 175 UI/Kg/day|Procedure: Tinzaparin 175 UI/Kg/day SC until hospital discharge.
16292143|NCT04730843|Experimental|Part A dose escalation|ES102 will be escalated in patients with advanced solid tumors.
16292144|NCT04730843|Experimental|Part B expansion|Subjects with advanced non-small cell lung cancer, advanced esophageal squamous cell carcinoma, other advanced solid tumors (such as nasopharyngeal carcinoma, cervical cancer, gastrointestinal tumors, other reproductive system tumors, etc.) will be treated with ES102 at the RP2D.
16292145|NCT04730830|Experimental|Only experimental arm|Only experimental arm. Patients filling out questionnaires.
16292146|NCT04730817|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks.
16292147|NCT04730817|No Intervention|Control group|This arm will not be given any kind of treatment and will act as a passive control group.
16292148|NCT04730804|Experimental|Cohort 1: ALXN1830 Single Dose 1/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
16292149|NCT04730804|Experimental|Cohort 2: ALXN1830 Single Dose 2/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
16292150|NCT04730804|Experimental|Cohort 3: ALXN1830 Multiple Dose 1/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
16292151|NCT04730804|Experimental|Cohort 4: ALXN1830 Multiple Dose 2/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
16292152|NCT04730804|Experimental|Cohort 5: ALXN1830 Multiple Dose 3/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
16292153|NCT04730804|Experimental|Cohort 6: ALXN1830 /Placebo in Japanese Population|Japanese participants will receive multiple SC doses of ALXN1830 (HTD) or placebo.
16292154|NCT04730791||Chronic Pain Patients|Adult patients 18-65 years, with chronic pain lasting for 3 or more months, with a pain intensity of at least 3 on a 0-10 numerical pain rating scale on most days.
16292155|NCT04730791||Patients with Fibromyalgia|"Adult patients 18-65 years. The diagnosis of patients with fibromyalgia will be according to the criteria for classification of fibromyalgia by the American college of rheumatology (Wolfe et al 1990)."
16292156|NCT04730791||Control Group|Free pain participants
16292157|NCT04730778||CIN|"STEMI patients who develop CIN contrast induced nephropathy within 1 week from primary PCI."
16292158|NCT04730778||Control|STEMI patients who do not meet criteria of CIN through 1 week post primary PCI
16292159|NCT04730765||Surgical Experimental Group|Patient operated between 01/02/2021 and 30/07/2021, in elective situation of sigmoid diverticulitis
16292160|NCT04730765||Medical Control Group|Patient not operated and medically treated
16292161|NCT04730752||Right Low Quadrant Pain|AIR and AAS scores will be calculated for the patients with right low quadrant pain in emergency service.
16292162|NCT04730726|Experimental|Patients with thyroid nodules|Patients with thyroid nodules that underwent or will undergo an ultrasound with FNA if indicated and if indicated will be scheduled for a (hemi)thyroidectomy
16292186|NCT04730570|Experimental|Essential Coaching for Every Mother Intervention|Women in the intervention arm will receive the Essential Coaching for Every Mother messages up to six-weeks postpartum. No changes in standard care.
16293577|NCT04720378|Experimental|Cohort 4|1.0 ml/kg IV ST266 once a day for 5 days
16292163|NCT04730713||Admitted to the center ICU due to neurosurgery, brain dysfunction and other neurological reasons|Aneurysmal subarachnoid hemorrhage (aSAH), traumatic brain injury (TBI), acute deficiency Blood stroke (AIS), acute cerebral hemorrhage (ICH), hypoxic ischemic encephalopathy (HIE), Sepsis-associated encephalopathy (SAE), intracranial tumor surgery; older than 18 years old, <85 Years old; patients who need lumbar puncture.
16292164|NCT04730700|Active Comparator|Radiofrequency ablation (RFA) with MEE|Radiofrequency ablation involves a minimally invasive procedural technique. It uses radiofrequency waves to burn the nerve causing pain. This nerve will no longer be able to send pain signals to your brain. For this study, the multi-tined expandable electrode needle will be used. This needle will result in a larger treatment area. This may result in better pain relief and longer lasting pain relief. If you undergo the radiofrequency ablation procedure you will have pain medication injected where the ablation will be done. The procedure will take about 20 mins to complete. You will be allowed to go home afterward.
16292165|NCT04730700|Active Comparator|Conventional Medical Management (CMM) Treatment Only|Your current standard of care treatment may already consist of some CMM therapies. Standard of care includes a variety of intervention types such as medication, physical therapy, home exercise programs, back brace, walking aid, and chiropractic care.
16292166|NCT04730687|Placebo Comparator|Traditional non-surgical mechanical therapy|Mechanical instrumentation in all groups continued with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH & Co, Ltd, Stockach, Germany) until the clinician gently felt that the surface was sufficiently debrided.There is no laser application. The laser tip is placed in the peri-implant sulcus but not activated.
16292167|NCT04730687|Active Comparator|Diode laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) has been applied with the aid of a 300 µm diameter optical fiber tip (E3-9 mm) placed approximately 1 mm above the most apical part of the peri implant pocket, parallel to the implant surface. Pocket irrigation was performed with 3% hydrogen peroxide solution for 10 seconds before and after diode laser application.The fiber was moved in apico-coronal and mesial-distal directions for a total of 30 seconds during laser light emission.The laser tip was checked every 7-8 seconds and wiped with sterile saline in order to prevent a possible coagulation or temperature increase.The laser was used in continuous pulse mode, at a power of 0.8 Watt (W), an energy density of 3J / cm2 and a spot diameter of 1 mm. Pulse width and pulse interval were applied as 20 milliseconds.
16292168|NCT04730687|Active Comparator|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) was applied in short pulse '' H '' mode, water cooled with a non-contact sweeping motion for 30 seconds parallel to the implant surface.The settings used are: 1.5 W power, 30 Hz frequency, 50% water, 40% air, 140 s pulse duration and 1 cm spot size.
16292169|NCT04730674|Experimental|post-mastectomty seroma group|female patients with established diagnosis of post-mastectomy seroma following modified radical mastectomy, were treated by local injection of tetracycline after the seroma fluid was aspirated, then a crepe bandage was applied over the mastectomy area. Then after 5 days the patient were examined again for seroma re-collection or the presence of complications. The amount of seroma aspirated in each session.
16292170|NCT04730661|No Intervention|Conventional arm|For the patients enrolled in this conventional arm, the decision of hospitalisation or discharge will be taken with usual criteria (pulsed oxygen saturation (SpO2) in room air <92% and respiratory rate> 22/min, respiratory rate> 30/min, Blood gas hypoxemia, decompensation of comorbidity, home monitoring not possible, other intercurrent pathology requiring hospitalization, several risk factors for COVID infection requiring hospitalization in intensive care (age> 65y, hypertension complicated by a cardiovascular event, chronic cardiovascular disease, unbalanced diabetes with complications, chronic respiratory disease (excluding well-controlled asthma), chronic renal failure dialysis, obesity, progressive cancer under treatment, congenital or acquired immunosuppression)
16292171|NCT04730661|Experimental|Interventional arm|For the patients enrolled in this interventional arm, the decision of hospitalisation or discharge will be taken with usual criteria and the result of Sit to Stand Test.
16292172|NCT04730648|Experimental|pcsk9 inhibitor group|patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
16292173|NCT04730648|No Intervention|control group|Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.
16292176|NCT04730622||Fragility fracture|Patients undergoing a hip replacement for a fragility fracture of the femoral neck (n= 10).
16292177|NCT04730622||Osteoarthritis|Patients undergoing a hip replacement for severe osteoarthritis (n= 10).
16292178|NCT04730609|Experimental|Dexmedetomidine|IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.
16292179|NCT04730596|Placebo Comparator|Group I (Control group)|- The patients in this group will receive normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
16292180|NCT04730596|Experimental|Group II (Ketamine group)|- The patients in this group will receive ketamine at a dose of 0.3 mg/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
16292181|NCT04730596|Experimental|Group III (Dexmedetomidine group)|- The patients in this group will receive Dexmedetomidine in a dose of 0.5 ug/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
16292182|NCT04730583|Active Comparator|Kybella Injection|
16292183|NCT04730583|Active Comparator|980nm laser|
16292184|NCT04730583|Active Comparator|755nm laser|
16292185|NCT04730583|Active Comparator|Radiofrequency|
16292187|NCT04730570|No Intervention|Standard care|Women in the control group will receive no content messages. No changes in standard care.
16292188|NCT04730557|Experimental|Weight-Loss|Participants in the weight-loss intervention arm of the study will be enrolled in an individualized 6-month intervention designed to achieve a 10% reduction of body weight relative to baseline. Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Intervention activities include individual diet counseling, group support, goal setting, self-monitoring, stress management, and problem solving. Weekly group support and education sessions, along with daily food journaling and weekly weigh-ins, are recognized approaches for successful weight loss [30-32]. Once the weight loss goal is achieved, diets will be liberalized for weight maintenance.
16292189|NCT04730557|No Intervention|Wellness Education|Control participants will be counseled to maintain their baseline body weight and level of physical activity. They will report weights weekly and if their weight deviates from baseline they will be asked to keep daily food logs and counseled to return calorie intakes to weight maintenance level. To document diet intakes/adherence, 3-day food records will be collected at months 0, 3, and 6 and analyzed for calorie and nutrient composition. Participants will be encouraged not to change their physical activity levels from baseline and their activity will be monitored by Actigraph activity monitors worn in 7-day periods at months 0, 3, and 6. In addition, each participant will be invited to enter the weight loss intervention after completion of the health education control course.
16292190|NCT04730544|Experimental|Experimental Arm A|"Treatment for 108 weeks (one cycle = 12 weeks; 9 cycles):
~Nivolumab 480 mg every 4 weeks (27 infusions) and ipilimumab 1 mg/kg every 6 weeks (18 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
16292191|NCT04730544|Active Comparator|Control Arm B|"Induction of 12 weeks (one cycle = 3 weeks; 4 cycles):
~Nivolumab 240 mg and ipilimumab 1 mg/kg every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab), Maintenance of 96 weeks (one cycle = 4 weeks; 24 cycles): Nivolumab 480 mg every 4 weeks for 24 dosing cycles (24 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
16292192|NCT04730531|Experimental|Treatment Arm|Local infiltration with 0.25% bupivacaine and epinephrine
16292193|NCT04730531|Placebo Comparator|Control Arm|Placebo of equal volume injectable saline
16292194|NCT04730518|Experimental|Yoga-based Group Therapy|"The yoga-based group therapy (YBGT) involves a four-week intervention with weekly group therapy sessions in addition to TAU. The fifty-minute session takes place with a group size of max. 10 participants and was held once a week by a psychologist who is experienced in yoga-based therapy.
~A yoga session starts with breathing exercises (pranayama), followed by various exercises in standing, sitting and lying down (asanas), which are accompanied by mindful instructions from the psychologist. Every yoga session ends with a final relaxation (shavasana), which can take the form of a body scan, for example."
16292195|NCT04730518|Active Comparator|Treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
16292196|NCT04730505|Experimental|Patient App + HCP Portal (Cohort 1)|Cohort 1 is to assess how patients will use the Patient App if connected in real time with the Healthcare professional (HCP) Portal
16292197|NCT04730505|Experimental|Patient App Alone (Cohort 2)|Cohort 2 is to assess how patients will use the Patient App where there is no connectivity to the Healthcare professional (HCP) Portal and thus no real-time data sharing with the HCP Portal
16292198|NCT04730492||Renal Transplantation|Renal Transplantation
16292199|NCT04730492||Hernias reparation post renal transplantation|Hernias reparation post renal transplantation
16292200|NCT04730466|Experimental|Neuropsychological rehabilitation|In the experimental group, patients will receive a 12-session neuropsychological rehabilitation protocol that will be carried out over four weeks (3 weekly sessions). The protocol and the number of sessions has been designed by neuropsychologists following the Díez-Cirarda et al. recommendations
16292201|NCT04730466|No Intervention|Control|The control group will not receive any therapy. The participants will be simply evaluated at the same time as the experimental group
16292202|NCT04730440||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
16292203|NCT04730440||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
16292204|NCT04730427|Experimental|GX-I7|GX-I7
16292205|NCT04730427|Placebo Comparator|GX-I7 vehicle|GX-I7 vehicle
16292206|NCT04730414||Age, Male, Female, ethnicity,|"The aim of the study is to be inclusive of all groups as to avoid bias. Furthermore, the study aims to determine if its formulation will encompass all skin types, genders and age groups.
~Full-spectrum hemp dosage is determined to begin with 40mg - 2-3X/day = topical application; for a period of 2-3 months.
~Drug: Full Spectrum hemp (0.018% THC), Topical Application Placebo = cream without hemp (Double blinded) One cream will be placed on one side of the face (R/L) and the other cream on the other side of the face."
16292207|NCT04730401|Experimental|High-titre CP|200mL high-titre CP on admittance
16292208|NCT04730401|Active Comparator|low-titre CP|200ml low-titre CP on admittance
16292209|NCT04730401|Placebo Comparator|Placebo|200mL saline as placebo on admittance
16292210|NCT04730375|Active Comparator|( Group A)|: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery
16292211|NCT04730375|Active Comparator|(Group B)|Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
16292212|NCT04730362|Active Comparator|Control group|20 patients in which a Guedel oral airway will be inserted for airway management and to conduct inhalational anesthetic through face mask fixed with harness to the head and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
16292213|NCT04730362|Active Comparator|supraglottic group|20 patients in which supraglottic airway laryngeal mask airway (LMA) will be used and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
16292214|NCT04730349|Experimental|A1W Dosing schema|
16292215|NCT04730349|Experimental|A1F Dosing schema|
16292216|NCT04730349|Experimental|A2W Dosing schema|
16292217|NCT04730349|Experimental|A2F Dosing schema|
16292218|NCT04730349|Experimental|Part B: Cohort B1 Neuroblastoma|
16292219|NCT04730349|Experimental|Part B: Cohort B2 Ewing sarcoma|
16292220|NCT04730349|Experimental|Part B: Cohort B3 Rhabdomyosarcoma|
16292221|NCT04730349|Experimental|Part B: Cohort B4 Miscellaneous solid tumors|
16292222|NCT04730349|Experimental|Part B: Cohort B5 NHL/leukemia|
16292223|NCT04730349|Experimental|Part B: Cohort B6 High-grade glioma|
16292224|NCT04730349|Experimental|Part B: Cohort B7 Medulloblastoma and Embryonal Tumors|
16292225|NCT04730349|Experimental|Part B: Cohort B8 Ependymoma|
16292226|NCT04730349|Experimental|Part B: Cohort B9 Miscellaneous brain tumors|
16292227|NCT04730336|Experimental|Tixel Treatment|Tixel Treatment 3 Tixel treatment sessions, 2 weeks apart follow by 2 Follow up sessions
16292228|NCT04730323|Experimental|Tocilizumab Group|Tocilizumab administration protocol: Patients received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion.
16292229|NCT04730323|Active Comparator|Methylprednisolone (corticosteroid) group|Corticosteroid administration protocol: Patients received methylprednisolone 80mg/day in two divided doses as per national/local guidelines and predefined parameters of disease severity were assessed on each day.
16292230|NCT04730310||Regional Anesthesia (RA)|"RA
~Includes spinal, epidural, peripheral nerve block, excludes local infiltration (unlikely that any major open revascularization can be done under local)
~Defined as: NSQIP Principal (ANESTHES) or additional (ANESTHES_OTHER) anesthesia technique = regional, spinal, epidural, or MAC (in NSQIP RA/Spinal/Local + MAC are coded as MAC; while this includes local + MAC, it would be unlikely that local anesthesia would be sufficient for open revascularization)"
16292231|NCT04730310||General Anesthesia (GA)|"GA
~Defined as: NSQIP Principal or additional anesthesia technique = general
~Since GA is selected as the principal anesthetic technique by default when multiple techniques are present, GA + RA could potentially have been coded as GA if the optional variable of additional anesthesia technique is not filled in, leading to differential misclassification of patients with GA + RA (most likely epidural and peripheral nerve block) in the GA group."
16292232|NCT04730297|Active Comparator|Paracetamol/codeine Group A|analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg
16292233|NCT04730297|Active Comparator|Ibuprofen Group B|analgesic group preoperative oral dose of ibuprofen 400 mg
16292234|NCT04730297|Placebo Comparator|Placebo Group C|Placebo group preoperative placebo
16292235|NCT04730284|Experimental|Health supplements|One arm only
16292236|NCT04730271|Active Comparator|Manual Arm|Subjects enrolled into this arm of the study will receive an ATTUNE primary total knee replacement that has been implanted using manual instrumentation which is the current standard of care at the participating sites.
16292237|NCT04730271|Experimental|Robotic-Assisted Arm|Subjects enrolled into this arm will receive an ATTUNE primary total knee replacement that has been implanted with the use of the VELYS Robotic-Assisted Solution device.
16292238|NCT04730258|Experimental|1A: Monotherapy escalation and expansion|Dose escalation and expansion arm with CFI-400945
16292239|NCT04730258|Experimental|1B: Food Effect|Food effect at the recommended phase 2 dose
16292240|NCT04730258|Experimental|2A: Combination escalation and expansion|Dose escalation and expansion arm with CFI-400945 and azacitidine
16292241|NCT04730258|Experimental|2B: Combination escalation and expansion|Dose escalation and expansion arm with CFI-400945 and decitabine
16292242|NCT04730245|Experimental|Microbiota modification|
16292244|NCT04730219|Experimental|Tislelizumab and Nab Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
16292245|NCT04730206|Experimental|Camostat|4 x 200 milligram per day for 7 days
16292246|NCT04730206|Placebo Comparator|Placebo|4 x per day for 7 days
16292247|NCT04730193|Placebo Comparator|Control|Participants randomized to placebo group will receive placebo capsule
16292248|NCT04730193|Experimental|Caffeine|Participants randomized to caffeine group will receive 100mg caffeine capsule
16292249|NCT04730180|Active Comparator|No neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.
16292250|NCT04730180|Active Comparator|Mixed reality neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.
16292251|NCT04730167||Retired Motorsport Pilots|Concussion assessment
16292252|NCT04730154|Experimental|Pain Neuroscience Education (PNE) + Motivational Interviewing (MI)|Breast cancer survivors assigned to the experimental intervention will participate in 1 online PNE session followed by 3 PNE + MI sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format, allowing to individually tailor content to the patient's maladaptive beliefs and perceived injustice. After the first live session, breast cancer survivors will receive a perceived injustice-targeted PNE information leaflet that they need to read carefully at home.
16292342|NCT04729491|Placebo Comparator|Placebo|Placebo q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
16292253|NCT04730154|Active Comparator|Biomedically-focused Education|Breast cancer survivors assigned to the experimental intervention will participate in 1 online biomedically-focused education session followed by 3 biomedically-focused education sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format in order to balance nonspecific treatment effects between treatment arms, the duration, format and number of sessions as well as the didactical approach will be identical in both treatment groups. After the first live session, breast cancer survivors will receive an information leaflet from 'Kom op tegen Kanker' regarding 'Pain in and after treatment' that they need to read carefully at home.
16292254|NCT04730141|Experimental|mobilization protocol|The early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group.
16292255|NCT04730141|No Intervention|routine care|The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group .
16292256|NCT04730115||Group 1. The treatment group (T)|The treatment group comprised of 30 cases treated with functional appliance for one year in puberty.
16292257|NCT04730115||Group 2. The control group (C)|The control group consists of 12 patients who had insufficient oral hygiene; didn't take any orthodontic treatment for one year.
16292258|NCT04730102||Patients undergoing rectal washout in transanal mesorectal excision|Patients undergoing rectal washout in transanal mesorectal excision for rectal cancer.
16292261|NCT04730050|Experimental|Drug: TT-01025-CL|TT-01025-CL
16292262|NCT04730050|Placebo Comparator|Drug: Placebo|Placebo of TT-01025-CL
16292263|NCT04730037|Active Comparator|Edoxaban group|
16292264|NCT04730037|Active Comparator|Warfarin group|
16292265|NCT04730011|Experimental|Treatment Group|Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week.
16292266|NCT04729998|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
16292267|NCT04729998|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
16292268|NCT04729985|No Intervention|Standard Care|A blinded CGM will be placed to review glucoses after discharge in the Standard Care arm.
16292269|NCT04729985|Active Comparator|Diabetic education and CGM monitoring|Treatment arm will get diabetic education, active CGM use with patient feedback for 14 days, active access to the PI for concerns relating to hospitalization. They will also receive a brief, 15 minute phone call from the PI on day 3-4, 6-7, 9-10 and day 14-15.
16292270|NCT04729972|Experimental|NT-501 CNTF Implant|Participants from the NTMT-01 or NTMT-02 Studies with a CNFT implant in one eye will receive an implant in the fellow eye
16292274|NCT04729946|Experimental|Pure-Vu Treatment|Participants in this arm will undergo colonoscopy using the Pure-Vu cleansing device.
16292275|NCT04729933|Experimental|Treatment|V-Wave Shunt Placement
16292276|NCT04729920||subjects with neuromuscular disease|Adult subjects with neuromuscular disease, with an active prescription of MI-E for more than 3 months
16292277|NCT04729907|Experimental|BIIB058 28 mg (Prior Maintenance Dose 28 mg)|Participants who received maintenance dose of 28 milligram (mg) nusinersen in study 232SM203 (NCT04089566), will receive maintenance dose of 28 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
16292278|NCT04729907|Experimental|BIIB058 50/28 mg (Prior Maintenance Dose 12 mg)|Participants who received maintenance dose of 12 mg nusinersen in study 232SM203 (NCT04089566), will receive loading dose of 50 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
16292279|NCT04729894|Experimental|Safe Medication Storage Device + Education|
16292280|NCT04729894|Active Comparator|Education|
16292730|NCT04726670||A Comparison of Pain Levels|A Comparison of Pain Levels at different time intervals according to the Irrigation Activation Protocols
16292281|NCT04729881|Experimental|Conventional Rehabiliation Group|"Participants 5 days a week for 4 weeks; TENS, US and neck specific exercise program will be applied.
~Conventional TENS will be applied to the participants with the CefarCompex rehab400 (New Chattanooga Compex Rehab, USA) muscle rehabilitation device. It will be applied with electrodes coated with a special adhesive material for each participant for 20 minutes at a frequency of 60-120 Hz. In the study; 4 channels and 8 electrodes will be used. Electrodes will be placed paravertebrally in the cervicothoracic space, covering the painful area. The dose of the current will be increased as the patients become accustomed to the current intensity.
~Continuous Ultrasound will be applied to the participants due to chronic neck pain. It will be applied at a frequency of 1MHz and a dose of 1.5 W / cm2 for 5 minutes."
16292282|NCT04729881|Active Comparator|Spesific Exercise Group|Participants will be given a home exercise program consisting of exercises specifically applied to the neck. Participants will be asked to practice the exercises 5 days a week. The application status of the participants' home exercise program will be followed by the researcher over the phone. Participants who do not practice the home exercise program will be excluded from the study. The exercise program to be applied to the participants in the exercise group is listed below.Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise.
16292283|NCT04729881|Other|Control Group|
16292284|NCT04729868|Other|group Levo-bupivacaine|Group A (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 1ml normal saline under the guidance of ultrasound for infraclavicular brachial plexus block.
16292285|NCT04729868|Other|group levo-bupivacaine plus 50µg dexmedetomidine|Group B (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 50µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
16292286|NCT04729868|Other|group levo-bupivacaine plus 100µg dexmedetomidine|Group C (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 100µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
16292287|NCT04729855||colorectal cancer patients|"Colorectal cancer patients( n = 74 ) from stage I-III with the following criteria:-
~a. Inclusion criteria:
~No sex predilection.
~Age (25-65 yr).
~Colorectal carcinoma confirmed by histopathological examination"
16292288|NCT04729855||Healthy controls ( n = 74)|matched as regarding age and sex as much as possible with cases.
16292289|NCT04729842|Active Comparator|Group - B , Patients who recieved Bupivacaine|30 ml of 0.5% bupivacaine was injected equally divided and injected in four nerves (musculocutaneous, median, radial and ulnar nerves)
16292290|NCT04729842|Active Comparator|Group - R , Patients who received Ropivacaine|30 ml of a solution containing 0.5% ropivacaine was equally divided and injected in the four nerves (musculocutaneous, median, radial and ulnar nerves)
16292295|NCT04729816|Experimental|Dietary Intervention|All participants will stay weight stable while undergoing 5 phases of a dietary intervention that lasts 62 days.
16292296|NCT04729803|Experimental|Attention Guidance + Exposure|Participants will complete teleconferencing-based exposure trials with an attention guidance component.
16292297|NCT04729803|Active Comparator|Exposure Alone|Participants will complete teleconferencing-based exposure trials.
16292298|NCT04729803|Experimental|Attention Control + Exposure|Participants will complete teleconferencing-based exposure trials with an attention control component.
16292299|NCT04729790|Active Comparator|Patients with RCDI will receive FMT capsules from single donor|"Capsules made with intestinal bacteria from single healthy donor
~st treatment day, lyophilized product generated from single donor (90g of stool)
~nd treatment day, lyophilized product generated from single donor (90g of stool)"
16292300|NCT04729790|Experimental|Patient will receive FMT capsules from three donors|"Capsules made of intestinal bacteria from three healthy donors
~st treatment day, lyophilized product generated from three donors (90g of stool)
~nd treatment day, lyophilized product generated from three donors (90g of stool)"
16292301|NCT04729764|Experimental|GP681 Tablet 20mg|Two sentinel subjects were first enrolled in the trial (test drug: placebo=1:1). After the two sentinel subjects completed the 72h safety follow-up after the administration, it was judged that if there was no dose-limiting toxicity , Then start the trial of the remaining 6 subjects in the dose group (experimental drug: placebo = 5:1).
16292302|NCT04729764|Experimental|GP681 Tablet 40mg|10 subjects in 40mg group (including 2 placebo)
16292303|NCT04729764|Experimental|GP681 Tablet 60mg|10 subjects in 60mg group (including 2 placebo)
16292304|NCT04729764|Experimental|GP681 Tablet 80mg|10 subjects in 80mg group (including 2 placebo)
16292305|NCT04729764|Experimental|GP681 Tablet 120mg|10 subjects in 120mg group (including 2 placebo)
16292307|NCT04729725|Experimental|Treatment (SAR439459, cemiplimab)|Patients receive SAR439459 IV over 30 minutes on day 1 and cemiplimab IV over 30 minutes on day 1 starting cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16292308|NCT04729712|Active Comparator|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive an erector spinae block with catheter insertion under ultrasound guidance under general anaesthesia. This regional anaesthesia procedure will be performed by an Anaesthesiologist with experience in performing this block.
16292341|NCT04729491|Active Comparator|Dutasteride|Dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
16293085|NCT04723836|Placebo Comparator|TT genotype placebo group|Placebo supplement from 16th gestational week
16292309|NCT04729712|Experimental|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive a paravertebral block with catheter insertion under under thoracoscopic guidance. This regional anaesthesia procedure will be performed at the start of the operation by a surgeon with experience in performing this block.
16292310|NCT04729699|Experimental|Intervention group|Intervention group (n=10) received 12 physiotherapy sessions and exercises for TMJ 30-45 minutes 2 days per week.
16292311|NCT04729699|Active Comparator|Control group|Control group (n=9) was introduced with physiotherapy program in order to perform it independently at home.
16292312|NCT04729686|Active Comparator|Pericapsular Nerve Block Group|Pericapsular Nerve Block targets the anterior hip capsule by blocking the articular branches of the femoral nerve and accessory obturator nerve.
16292313|NCT04729686|Active Comparator|Fascia Iliaca Nerve Block Group|Fascia Iliaca Nerve Block targets the space between the iliacus muscle and the fascia that overlies it (fascia iliaca), within which the femoral nerve and lateral femoral cutaneous nerve (LFCN) course.
16292314|NCT04729673|Active Comparator|Patient's normal canine occlusal relationship.|Before full mouth rehabilitation with 8 stainless steel crowns for primary molars , the vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
16292315|NCT04729673|Sham Comparator|Canine occlusal relation after full mouth rehabilitation|After full mouth rehabilitation with 8 stainless steel crowns for primary molars , the vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
16292316|NCT04729660|Active Comparator|Study group|Evaluate of the Kinesio tex gold tape that applied to anterior neck localised.
16292317|NCT04729660|Sham Comparator|Sham group|Evaluate of the Kinesio tex gold tape that applied to different neck localised as no-stretched.
16292318|NCT04729647|Other|Axillary Lymph Node Metastasis|
16292319|NCT04729634|Other|Mobilization and breathing training|Usual clinical care
16292320|NCT04729621|Experimental|TVB-009 main treatment period|TVB-009 (denosumab) pre-filled syringe, administered at weeks 1 and 26
16292321|NCT04729621|Active Comparator|PROLIA main treatment period|Prolia® (denosumab) pre-filled syringe, administered at weeks 1 and 26
16292322|NCT04729621|Experimental|TVB-009 main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to TVB-009 in the main treatment period
16292323|NCT04729621|Active Comparator|PROLIA main / PROLIA transition period|Prolia® (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
16292324|NCT04729621|Experimental|PROLIA main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
16292325|NCT04729608|Experimental|AVB-S6-500+Pac|Combination of AVB-S6-500 and Pac
16292326|NCT04729608|Placebo Comparator|Placebo+Pac|Placebo-controlled arm with Pac
16292327|NCT04729595|Active Comparator|Active Treatment|Tempol (MMB-02) 800 mg per Day (n=124)
16292328|NCT04729595|Placebo Comparator|Placebo|Placebo (n=124)
16292329|NCT04729582|Experimental|Verum Group|Participants receive primary human muscle stem cells as one-time injection into the urethral sphincter region under visual control using cystoscopy.
16292330|NCT04729582|Placebo Comparator|Placebo group|Participants receive placebo solution as one-time injection into the external urethral sphincter region under visual control using cystoscopy.
16292331|NCT04729569|Other|Tested finish line preparation|Feather edge finish line preparation (Intervention)
16292332|NCT04729569|Active Comparator|Comparator finish line preparation|Deep chamfer finish line preparation (Comparator)
16292333|NCT04729556|Experimental|Sericin and chitosan cream|A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).
16292334|NCT04729556|Active Comparator|Cavilon|"Active control is a commercial cream containing dimethicone as the substance forms a durable, thin, and transparent film. The cream is used as a moisturizer to prevent the skin against irritation, dryness, and pressure ulcers.
~Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours)."
16292335|NCT04729543|Experimental|Adoptive therapy with autologous MC2 TCR T cells|"Accelerated titration phase I design and a subsequent single arm phase II study
~Prior to T cell transfer (day 0), patients will be treated with valproic acid (dose 50 mg/kg/d, 7d; days -9 to day -3) and 5' azacytidine (dose 75mg/m2/d, 7d; days -9 to day -3)
~Phase I: patients will be treated with one single intravenous administration of MC2 TCR T cells at 5 different escalated doses of 5x10E7, 5x10E8, 5x10E9,1.0x10E10, and the total number of cultured TCR T cells (i.e., usually 1.0-5.0 x10E10 TCR T cells). MC2 TCR T cell infusions will be supported by low dose of IL-2 administrations (s.c. 5x10E5 IU/m2 2qd for 5 days)
~T cells will be processed using IL-15 and IL-21 to generate young T cells"
16292336|NCT04729530|Active Comparator|Active|Air purifier device with standard filter cartridges installed.
16292337|NCT04729530|Placebo Comparator|Placebo|Air purifier device with placebo (non working) filter cartridges installed.
16292338|NCT04729517|Active Comparator|Azelastine Hydrochloride|Patients that will receive azelastine hydrochloride are defined as the active control arm.
16292339|NCT04729517|Experimental|AI201901|Patients that will receive AI201901 are defined as the test arm.
16292340|NCT04729504|Other|Adapted Project BRAVE Group|Participants in this group will receive a single session intervention of a culturally and linguistically adapted Project BRAVE.
16292343|NCT04729478|Other|Natural sleep|"Natural sleep endoscopy (NSE)
~OSA patients will be endoscopically evaluated during natural sleep.
~During NSE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
16292344|NCT04729478|Other|Drug-induced sleep|"Drug-induced sleep endoscopy (DISE)
~OSA patients will be endoscopically evaluated during drug-induced sleep.
~During DISE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
16292345|NCT04729465|Active Comparator|Active Comparator|"Active Comparator: Control Patients with cardiac disaese receive general anesthesia with Propofol
~Interventions:
~Drug: Propofol"
16292346|NCT04729465|Experimental|Experimental|"Experimental: Bispectral Index Monitor Patients with cardiac disease receive a general anesthesia with Propofol where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.
~Interventions:
~Drug: Propofol Device: Bispectral Index Monitor"
16292349|NCT04729426|Experimental|Position Group|Position group
16292350|NCT04729426|No Intervention|Control group|No Position group
16292351|NCT04729413|Experimental|Couples Counseling Intervention|Couples in the intervention group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health, as well as three couple counseling visits (one during pregnancy and two postpartum). The couples counseling sessions will provide (1) information on key relationship topics (communication, trust and respect, love and support); (2) relationship skills exercises (role playing); and (3) the opportunity to discuss health and relationship priorities/goals of the couple.
16292352|NCT04729413|Sham Comparator|Control|Couples assigned to the control group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health. Couples will also have the opportunity after the trial is complete to opt-in to receive a condensed one-session couples counseling visit (data not to be used for study purposes but offered for ethical reasons).
16292353|NCT04729400|Experimental|Experimental group|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
16292354|NCT04729400|Experimental|CONTROL GROUP|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
16292355|NCT04729387|Experimental|Alpelisib+olaparib|Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule.
16292356|NCT04729387|Active Comparator|Paclitaxel or PLD|Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days.
16292357|NCT04729348|Experimental|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment, including evaluations and follow up visits.
~PEMBROLIZUMAB daily, every 3 weeks
~LENVATINIB daily every 3 weeks"
16292358|NCT04729322|Experimental|Arm I (FMT, pembrolizumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.
~POST-COLONOSCOPIC FMT: Patients receive standard of care pembrolizumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients receive fecal microbiota transplantation capsule PO on day 1. Cycles repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
16292359|NCT04729322|Experimental|Arm II (FMT, nivolumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.
~POST-COLONOSCOPIC FMT: Patients receive standard of care nivolumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1 and 8 of cycles 1-2. Beginning in cycle 4, patients receive fecal microbiota transplantation capsule PO on day 1 of every other cycle. Cycles repeat every 14 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
16292360|NCT04729309|Experimental|Mass Balance (MB) Cohort|Participants will receive oral [14C] RO7049389 under fasted conditions, followed by intravenous IV [13C] after a two-hour period.
16292361|NCT04729309|Experimental|Absolute Bioavailability (BA) Cohort|In Periods 1 and 2, participants will receive oral [12C] RO7049389 under fasted conditions, followed by IV [13C] RO7049389. There is a minimum 7-day washout between periods.
16292362|NCT04729296|Experimental|Golimumab|Golimumab for subcutaneous use
16292363|NCT04729296|Placebo Comparator|Placebo|Placebo syringes and vials matching active drug
16292364|NCT04729283||Sigmoidectomy for sigmoid cancer|Sigmoid resection surgery for patients who suffer from sigmoid cancer
16292365|NCT04729283||Sigmoidectomy for diverticulitis|Sigmoid resection surgery for patients who suffer from symptomatic diverticulitis
16292366|NCT04729270|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
16292367|NCT04729270|Experimental|CONTROL GROUP|The intervention for this group consisted of 10 sessions with Transcutaneous Electrical Nerve Stimulation (TENS) for a month.
16292368|NCT04729257|Other|Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
16292369|NCT04729257|Other|Group B (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using digital tests.
16292370|NCT04729257|Other|Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using digital tests.
16292371|NCT04729257|Other|Group D (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
16292372|NCT04729257|Other|Group E (Norms, 18-49 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
16292373|NCT04729257|Other|Group F (Norms, 80-95 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
16292374|NCT04729244|Active Comparator|CBD(hemp oil) cream|cream 2000mg/1oz (50mg/dose) once daily dosing for a total of 4 weeks to area of most pain.Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
16292375|NCT04729244|Active Comparator|CBD (Hemp oil) Tincture|1500mg CBD/30ml (50mg/dose) once daily dosing for total of 4 weeks. Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
16292376|NCT04729231|Active Comparator|Nasalis Sling Flap|
16292377|NCT04729231|Active Comparator|Lobed transposition flap|
16292378|NCT04729218||Familial Mediterranean Fever group|30 participants
16292379|NCT04729218||Healthy group|30 participants
16292380|NCT04729205|Experimental|Promitil 1.6 mg/kg|PROMITIL (1.6 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
16292381|NCT04729205|Experimental|Promitil 2.0 mg/kg|PROMITIL (2.0 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
16292382|NCT04729192||Intervention|The patients will complete the ObsQoR-10T questionnaire on day 1 following delivery
16292383|NCT04729179|Experimental|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
16292384|NCT04729179|Placebo Comparator|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
16292385|NCT04729166|Experimental|Study group|The study group were provided with education with structured educational material and followed in this study, in addition to the usual care provided by healthcare professionals.
16292386|NCT04729166|No Intervention|Control group|Control group was int the usual care.
16292387|NCT04729153||Chronic HCV patients previously treated by DAADs.|
16292388|NCT04729153||Chronic HCV patients not treated by DAADs yet.|
16292389|NCT04729140|Active Comparator|Ivermectin plus Doxycycline|"Ivermectin 200 mcg/kg on day 1 and day 2-plus doxycycline 100 mg tablets twice a day for seven days
~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin
~15-24 kg 1 tablet
~25-35 kg 2 tablets
~36-50 kg 3 tablets
~51-65 kg 4 tablets
~66-79 kg 5 tablets
~80-109 kg 6 tablets
~>110 kg 7 tablets"
16292390|NCT04729140|Active Comparator|Ivermectin plus Placebo|"Ivermectin 200 mcg/kg on day 1 and day 2-plus placebo tablet twice a day for seven days
~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin and Placebo
~15-24 kg 1 tablet
~25-35 kg 2 tablets
~36-50 kg 3 tablets
~51-65 kg 4 tablets
~66-79 kg 5 tablets
~80-109 kg 6 tablets
~>110 kg 7 tablets"
16292391|NCT04729140|Placebo Comparator|Placebo plus Placebo|"Placebo (number of tablets according to weight) plus placebo twice a day for seven days
~Body Weight (kg) Single oral Dose number of 3 mg tablets of Placebo
~15-24 kg 1 tablet
~25-35 kg 2 tablets
~36-50 kg 3 tablets
~51-65 kg 4 tablets
~66-79 kg 5 tablets
~80-109 kg 6 tablets
~>110 kg 7 tablets"
16292392|NCT04729127|No Intervention|Treatment as usual|The families keep receiving their treatment as usual
16292393|NCT04729127|Active Comparator|ImPACT at a dose of 1 hour/week|ImPACT at a dose of 1 hour/week over 6 months
16292394|NCT04729127|Active Comparator|ImPACT at 4 hours/week|ImPACT at 4 hours/week over 6 months.
16292395|NCT04729114|Experimental|Cohort 1|The starting dose will be 180 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
16292396|NCT04729114|Experimental|Cohort 2|Cohort 2 dose will be 360 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
16292397|NCT04729114|Experimental|Cohort 3|Cohort 3 dose will be 720 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
16292398|NCT04729114|Experimental|Cohort 4|Cohort 4 dose will be 1260 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
16292399|NCT04729114|Experimental|Dose Expansion|The recommended Phase 2a dose will be a dose from the cohort dose escalation phase that does not exceed the maximum tolerated dose and adequately suppresses serum testosterone (i.e., to less than or equal to 1 ng/dL) over the course of treatment. More than one dose may be selected for investigation in Phase 2a of the study.
16292400|NCT04729101|Experimental|Treatment A (vonoprazan)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.
~Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
16292401|NCT04729101|Active Comparator|Treatment B (lansoprazole)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.
~Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
16292402|NCT04729088|Experimental|Test Drug|Isosorbide 0.5% gel
16292403|NCT04729049|Experimental|Erector spinae plane block + patient controlled analgesia (PCA) with intravenous morphine|
16292404|NCT04729049|Active Comparator|Patient controlled analgesia (PCA) with intravenous morphine|
16292405|NCT04729036||mandibular fracture group|
16292406|NCT04729023|Experimental|Combined surgery group|In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.
16293840|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome multi dose|
16292407|NCT04729023|Active Comparator|Subsequent surgery group|In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.
16292408|NCT04729010|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
16292409|NCT04729010|Active Comparator|Randomized Subjects receive a real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
16292410|NCT04728984|Experimental|Nalfurafine Hydrochloride 5μg|Oral administration after dinner, once daily for 14 consecutive days
16292411|NCT04728984|Experimental|Nalfurafine Hydrochloride 2.5μg|Oral administration after dinner, once daily for 14 consecutive days
16292412|NCT04728984|Placebo Comparator|Placebo|Oral administration after dinner, once daily for 14 consecutive days
16292413|NCT04728971|Experimental|Micafungin Preventing Group|
16292414|NCT04728971|Active Comparator|Others Preventing Group|
16292415|NCT04728958|Experimental|Gratitude Journal|Participants will be given instructions and asked to write a gratitude journal about their week, focusing upon what they are grateful for. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
16292416|NCT04728958|Experimental|Gratitude Letter|Participants will be given instructions and asked to write a gratitude letter to a person in their life, for whom they are grateful for either in that week or another time in their life. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times, creating 4 different letters).
16292417|NCT04728958|Placebo Comparator|Weekly Diary|Participants will be given instructions and asked to write a diary about their week, focusing upon both the good and the bad they have experienced that week. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
16292418|NCT04728945|Experimental|lung recruitment|Standard ventilatory management with lung recruitment every 30 minutes
16292419|NCT04728945|Active Comparator|control|Standard ventilatory management
16292420|NCT04728932|Experimental|Levosimendan|A continuous infusion of Levosimendan will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
16292421|NCT04728932|Placebo Comparator|Placebo|A continuous infusion of Placebo will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
16292424|NCT04728906|Experimental|Heart patch + cardiomyocytes - hAESC|Patients who undergo bypass (CABG) surgery are given heart patch in areas where grafting (bypass) is not feasible
16292425|NCT04728893|Experimental|Nemtabrutinib|Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.
16292426|NCT04728867|Active Comparator|Surgical textbook|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be a textbook chapter explaining the details for laparoscopic rectal surgery.
16292427|NCT04728867|Active Comparator|3D animation|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational animation video showing laparoscopic rectal surgery.
16292428|NCT04728867|Active Comparator|Cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational cadaveric dissection video showing laparoscopic rectal surgery.
16292429|NCT04728867|Active Comparator|Both 3D animation + cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be both animation and educational cadaveric dissection video showing laparoscopic rectal surgery.
16292430|NCT04728854||Adult bullous pemphigoid patients|Patients with diagnosis of bullous pemphigoid will participate in monitoring with face to face assessment and remote telehealth visits with store and forward images captured.
16292431|NCT04728841|Experimental|Treatment group|Arm of GS001
16292432|NCT04728828||In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination|
16292433|NCT04728815|Experimental|CAMS to Maintenance|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
16292434|NCT04728815|Experimental|CAMS to CAMS|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
16292435|NCT04728815|Experimental|CAMS to DBT|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
16292436|NCT04728815|Experimental|TAU to Maintenance|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
16292437|NCT04728815|Experimental|TAU to CAMS|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
16292438|NCT04728815|Experimental|TAU to DBT|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
16292439|NCT04728815|Experimental|DBT Only|Subject Assigned to DBT for Phase 1, continuing up to 16 weeks.
16292440|NCT04728802|Active Comparator|Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
16292441|NCT04728802|Placebo Comparator|Placebo + Usual Care|Placebo + usual care as determined by care provider
16292442|NCT04728789|Experimental|Avatrombopag treatment group|Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day.
16292443|NCT04728763||Cases|"Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of invasive pulmonary aspergillosis (IPA) or Chronic pulmonary aspergillosis (CPA) in current care :
~Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019) or
~Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)"
16292444|NCT04728763||Control Group|Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care
16292445|NCT04728737|Experimental|combined swallowing and IOPI group|the patients will receive swallowing therapy and IOPI biofeedback exercise program
16292446|NCT04728737|Active Comparator|combined swallowing and NMES group|the patients will receive swallowing therapy and neuromuscular electrical stimulation
16292447|NCT04728737|No Intervention|Normal group|20 normal people will receive sonography evaluations to verify the inter-rater and intra-rater reliability of sonography, and use IOPI to assess maximal muscle strength and endurance of oropharyngeal muscles.
16292448|NCT04728724|Experimental|Group A|Anti-PD-1 monotherapy
16292449|NCT04728724|Experimental|Group B|Anti-PD-1 plus chemotherapy
16292450|NCT04728711|Experimental|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week|
16292451|NCT04728711|Placebo Comparator|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week|
16292452|NCT04728698|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
16292453|NCT04728698|Placebo Comparator|Placebo|Excipient
16292454|NCT04728685|Active Comparator|Group A|One-fifth of body weight traction force will be given
16292455|NCT04728685|Active Comparator|Group B|One-third of body weight traction force will be given
16292456|NCT04728685|Active Comparator|Group C|One-half of body weight traction force will be given
16292457|NCT04728672|Experimental|Experimental Group|Kinesio tape was applied and then outcome measures were noted.
16292458|NCT04728672|Placebo Comparator|Control Group|Placebo Micropore Tape was applied and then outcome measures were noted.
16292459|NCT04728659|Experimental|Desogestrel Group|Ovulation inhibition will be performed using Desogestrel (75 mcg) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first
16292460|NCT04728659|Active Comparator|GnRH antagonist|Ovulation inhibition will be performed using ganirelix (Orgalutran, 0.25 mg/die) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first.
16292461|NCT04728646|Experimental|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
16292462|NCT04728646|Other|Dissolvable intracanalicular plug|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
16292464|NCT04728620|Experimental|Intervention|Participants will have access to a new feature within an established patient portal native app on mobile devices. The new feature aims to address diabetes care gaps.
16292465|NCT04728607|Experimental|Participants|Individuals requiring ring removal.
16292466|NCT04728594|No Intervention|Delayed Contact|This group will not receive an email for at least two days.
16292467|NCT04728594|Experimental|Social Proof|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
16292468|NCT04728594|Experimental|Reframing Side Effects and Adverse Reactions|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.
16292469|NCT04728581|Placebo Comparator|Placebo|use of placebo during first 2 weeks after TKA surgery
16292470|NCT04728581|Experimental|Low dose Mirtazapine|Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg
16292471|NCT04728581|Experimental|Low dose Quetiapine|use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg
16292472|NCT04728568|Experimental|Sintilimab|Sintilimab will be administered every 3 weeks Sintilimab will be administered through IV infusion
16292473|NCT04728555|Experimental|Game before RT start|Intervention of a digital game five days before start of RadioTherapy
16292474|NCT04728555|Experimental|Game after RT start|Intervention of a digital game three days after start of RadioTherapy
16292475|NCT04728542||Origine|Group of 70 subjects who will undergo a surgery with the ORIGIN PS System
16292476|NCT04728542||Vanguard|Group of 70 subjects who will undergo a surgery with the VANGUARD System
16292477|NCT04728529|Experimental|USSM protocol|patient in the intervention group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to USSM protocol of fluid resuscitation.
16292478|NCT04728529|Experimental|ACCM protocol|patient in the control group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to ACCM protocol of fluid resuscitation.
16292479|NCT04728516|Experimental|Vonoprazan-based dual eradication therapy|H. pylori eradication using a dual eradication regimen, a course of 14 days, followed up to 6 months after randomization; the treatment regimen is as follows: routine use of Vonoprazan 20mg bid + amoxicillin 1g tid, a course of 14 days .
16292480|NCT04728516|Active Comparator|Pantoprazole|To take pantoprazole 40 mg daily, followed up to 6 months after randomization.
16292481|NCT04728503|Experimental|5-Minute Mindful Movement Video|5 minute mindful movement video watched in the exam room on an iPad
16292482|NCT04728503|Placebo Comparator|Written Educative Materials|1 page printed written educative material about mindfulness benefits read for 5 minutes in the exam room
16292516|NCT04728191|Experimental|+ asthma + intervention|35 participants with asthma aged 10-17 years, randomized to physiotherapy. The intervention consists of 4 instruction lessons spread over 6 weeks. The participants are instructed in a daily ten-minute-program of breathing exercizes.
16292483|NCT04728490|Experimental|Allogenic transplantation using treosulfan in conditioning regimen|"Haplo-identical transplantation using treosulfan in conditioning regimen Treosuflan, in the conditioning regimen will be administrated as followed 10 gr/m2 per day -4, -3 and -2 IV route
~In combination with:
~Thiotepa 5 mg/kg on day -6 Fludarabine 30 mg/m2 per day from day -5 to day -1"
16292484|NCT04728464||Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Patients will be treated by Periodontally Accelerated Osteogenic Orthodontics using fixed appliances.
16292485|NCT04728451|Active Comparator|Full-Time Spectacle Wear|Parents are asked to encourage their child to wear the spectacles full-time (all waking hours). A study staff member works closely with families throughout the child's participation to provide support and encouragement and to make suggestions on methods parents can use to maximize spectacle wear.
16292486|NCT04728451|Active Comparator|Ad-Lib Spectacle Wear|Parents are asked to encourage their child to wear the spectacles as much as possible for the initial 30 days after dispensing, and thereafter to continue to offer the spectacles to the child but not force the child to wear them if they resist or refuse. Limited support for parents is provided with regard to maximizing spectacle wear.
16292487|NCT04728425|Active Comparator|IVIG + SCIG|This group of MG patients will start with 2g/kg of IVIG on month 1, 1 g/kg of IVIG 4 and then 8 weeks later, and within 2 weeks switch to SCIG treatment
16292488|NCT04728425|Active Comparator|SCIG alone|This group of MG patients will start with SCIG alone
16292489|NCT04728412|Experimental|patients undergoing bronchoscopy under sedation with or at risk of respiratory failure|
16292490|NCT04728399|Experimental|Experimental group|2g Soybean peptide, 3g CLA and ng protein.
16292491|NCT04728399|Placebo Comparator|Control group|2g+N protein and 3g Soybean oil.
16292492|NCT04728386|Experimental|curcumin irrigant|final flush root canal irrigation with 5 ml curcumin solution
16292493|NCT04728386|Experimental|sodium hypochlorite|final flush root canal irrigation with 5 ml sodium hypochlorite
16292494|NCT04728360|Experimental|BAT2206|"Patients who weigh ≤ 100 kg: BAT2206 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.
~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
16292495|NCT04728360|Active Comparator|Stelara (EU-sourced)|"Patients who weigh ≤ 100 kg: EU-sourced Stelara 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.
~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
16292496|NCT04728347|Experimental|ARCT-021|Participants will receive a single dose of ARCT-021 on Day 1
16292497|NCT04728347|No Intervention|Long-term follow up from ARCT-021-01|Participants will not receive intervention but will be followed for safety.
16292498|NCT04728334|Experimental|AK117 monotherapy|AK117 monotherapy intravenous (IV) infusion - Weekly doses
16292499|NCT04728321|Experimental|AK104|AK104 15mg/kg IV every 3weeks (Q3W)
16292500|NCT04728321|Experimental|AK104 and Lenvatinib|AK104 15 mg/kg IV every 3 weeks (Q3W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
16292501|NCT04728308|Active Comparator|Experimental group|20ml of 0.5% bupivacaine is infiltrated in the subcutaneous tissue around the incision site
16292502|NCT04728308|Placebo Comparator|Placebo group|20 ml of distill water is infiltrated in the subcutaneous tissue around the incision site
16292504|NCT04728282|Experimental|RTSA with subscapularis repair|
16292505|NCT04728282|Active Comparator|RTSA without subscapularis repair|
16292506|NCT04728269|Experimental|Lactibiane topic AD|Cosmetical product Lactibiane Topic AD
16292507|NCT04728269|Placebo Comparator|Placebo|Placebo made with the same base as the cosmetical product
16292508|NCT04728256|Experimental|İntervention group|A six-session antenatal care program included both music listening and laughter therapy, and was designed for those in the study group as a session every week. The program was carried out by arranging a session of music listening for one week and a laughter therapy session over the following week. Also, the notes uttered by pregnants women were discussed at the week laughter listening sessions were performed. Data from the intervention group was collected four times as pretest (after providing informed contest), first-interval measurement (fourth week of the intervention), second-interval measurement (the first month following the birth) and post-test (the third month following the birth).The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
16292509|NCT04728256|No Intervention|Control group|Mothers receiving standard antenatal care in the prenatal period, giving birth, and having a three-month-old baby constituted the control group. The Control group was created after the procedures were completed for those in the intervention group. Only the post test was applied to the control group.The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
16292510|NCT04728243|Experimental|WHO QualityRights|Mental health professionals assigned to the experimental arm will be enrolled in the WHO QualityRights online training.
16292511|NCT04728243|Placebo Comparator|WHO Coronavirus Disease of 2019 (COVID19)|Mental health professionals assigned to the control arm will be enrolled in the WHO novel coronavirus 2019 online training series.
16292512|NCT04728230|Experimental|Treatment (chemo-immunotherapy, radiation therapy)|See detailed description.
16292513|NCT04728217|Experimental|Patients receiving Efmoroctocog alfa|For long term prophylaxis, the recommended starting dose is 50 IU of factor VIII per kg body weight at intervals of 3 to 5 days. The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
16292514|NCT04728204|Experimental|Intervention group|8 module, 8 week long internet-based intervention for reducing burden of depression
16292515|NCT04728204|No Intervention|Control group|Participants randomized to the control group will be instructed to wait until the intervention group finishes the treatment and that they will be able to use the same intervention afterwards.
16293086|NCT04723836|Active Comparator|CT genotype active comparator group|5mg riboflavin per day from 16th gestational week
16292517|NCT04728191|Active Comparator|+ asthma - intervention|35 participants with asthma aged 10-17 years, randomized to standard care. Participants are getting advice about dysfunctional breathing by a physician or nurse in the outpatient clinic.
16292518|NCT04728191|Experimental|- asthma + intervention|35 participants without asthma aged 10-17 years, randomized to physiotherapy. The intervention consists of 4 instruction lessons spread over 6 weeks. The participants are instructed in a daily ten-minute-program of breathing exercizes.
16292519|NCT04728191|Active Comparator|- asthma - intervention|35 participants without asthma, which are randomized to standard care. Participants are getting advise about dysfunctional breathing by a physician or nurse in the outpatient clinic.
16292520|NCT04728178|Active Comparator|study group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. When SVV value increased to 13% and over in the study group, 250 ml of crystalloid was given in the first stage, and if it continued to be 13% and over, 250 ml of colloid bolus was given. Vasoconstrictor agent was used when SVV was below 13% and MAP was below 65 mmHg.
16292521|NCT04728178|Placebo Comparator|control group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. They were given 250 ml of crystalloid in the first stage if the MAP was below 65 mmHg, and 250 ml of colloid bolus if the hypotensive episode continued. If hypotension persisted despite these fluid boluses, a vasoconstrictor agent was used. In addition, when the diuresis of the patients was detected at 0.5mg/kg/hr or less, 250 ml of colloid bolus was administered.
16292522|NCT04728165||control group|Age (+/-5 yrs) and BMI (+/- 5 kg/m2) matched control male subjects for inclusion in the control group
16292523|NCT04728165||psoriasis group|Males between the ages of 18 and 70 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group
16292524|NCT04728139|Active Comparator|patients with colorecta cancer|
16292525|NCT04728139|No Intervention|healthy individuals|
16292526|NCT04728126||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
16292527|NCT04728113|Experimental|Early together group|Oncological standard of care at M0, M3, M6, M9 and M12 with early introduction of supportive care every 6 weeks.
16292528|NCT04728113|Active Comparator|Control group|Oncological standard of care at M0, M3, M6, M9 and M12.
16292529|NCT04728087|Experimental|ACCEL|Participant will be treated with up to 2 bellows (10 grams nominal) of ACCEL®.
16292530|NCT04728087|Active Comparator|Gelfoam|Participant will be treated with up to 12.5 cm x 8.0 cm of Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01).
16292531|NCT04728074|Experimental|Intervention|"The ENtering Employment and SUstaining Work (ENESUW) program consists of 6 main topics which are; self-awareness, occupational self-awareness, taking responsibility, teamwork and labor division, problem identification and problem solving. The entire program adopts a very plain and easy to understand method of information transmission in order to facilitate lossless comprehension and strengthen the trust relationship between the therapists and the participants.
~The ENESUW program took 8 weeks in total with twice weekly sessions, making up a total of 16 structured group sessions. The group format enabled the participants to learn through meaningful peer interactions and group activities which were supportive of the main learning goals (i.e. group work, labor division and taking responsibility) of the program. The twice weekly sessions were 45 minutes long in order to keep the participants attentive and active throughout the program."
16292532|NCT04728074|Active Comparator|control|The control group also consisted of individuals with ID. They received face to face, individual vocational based occupational therapy approaches, which were twice a week for 8 weeks (approximately 40-45 minutes)
16292533|NCT04728061|Experimental|Single Ascending Dose|
16292534|NCT04728061|Experimental|Multiple Ascending Dose|
16292535|NCT04728061|Experimental|Multiple Ascending Dose+ Lipopolysaccharide|
16292536|NCT04728048|Experimental|Dural puncture epidural (group DPE)|"The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA). In group DPE, a single dural puncture with confirmation of free-flow CSF will be performed. If there is no free-flow CSF return through the spinal needle, the epidural catheter will be threaded 4-5cm in the epidural space and the patient will still be assigned to the DPE group, as per intent-to-treat protocol."
16292537|NCT04728048|Active Comparator|Standard epidural (group EPL)|The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA).In Group EPL, no dural puncture will be performed and the catheter will be threaded 4-5cm in the epidural space.
16292538|NCT04728035|Experimental|Dose escalation (part 1)|Patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity.
16292539|NCT04728035|Experimental|Dose expansion (part 2)|Once the appropriate dose has been established in Part 1, patients will be enrolled into two expansion cohorts according to the sub-type of breast cancer.
16292540|NCT04728022|Experimental|Students|Education program
16292541|NCT04728009|Experimental|longan and lingzhi mushroom syrup|All participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
16292542|NCT04727996|Experimental|Sitravatinib/Tislelizumab|All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
16292543|NCT04727983|No Intervention|Pelvic Floor Muscle Function|Pelvic floor muscle function will be evulated with the Modified Oxford Scale
16292544|NCT04727983|No Intervention|Bladder function|Bladder function will be evulated with the urinary diary for 3 days
16293628|NCT04719949|Active Comparator|Problem Solving Therapy (PST)|Participants complete four sessions of PST, 60-90 minutes per session.
16292545|NCT04727983|No Intervention|Incontinence Symptoms|Incontinence Symptoms will be evulated with The International Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) and the Coital Incontinence Score (CIS)
16292546|NCT04727983|No Intervention|Quality of Life|Quality of life will be evulated with the King Health Questionnaire (KHQ)
16292547|NCT04727983|No Intervention|Sexual Function|Sexual Function will be evaluated with Pelvic Organ Prolapse / Urinary Incontinence Sexual Questionnaire (PISQ-12).
16292548|NCT04727983|Experimental|NMES group|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS)
16292549|NCT04727983|Sham Comparator|SHAM ES group|The second group will be given sham NMES in addition to LSS
16292550|NCT04727983|No Intervention|End of Treatment Special Evaluations|Subjective perception of improvement and treatment satisfaction of the patients will be questioned
16292551|NCT04727970|Experimental|Tricaprilin|Tricaprilin will be administered for 5-21 days. The total daily dose (individual per subject up to a maximum of 10g/kg/day) will be split into 4 doses administered orally, approximately every 6 hours.
16292552|NCT04727957||Dataset for development and testing|
16292553|NCT04727957||Dataset for external validation|
16292554|NCT04727944|Experimental|MEG and EEG recordings on Healthy volunteers|"All subjects can participate in experiment 1 and/or 2. All analyses are intra-subject (no analyses are between-subject).
~Experiment 1 will test the functional role of beta bursts in naturalistic action preparation, using a combined anatomical MEG-MRI approach which will be conducted in 2 sessions.
~Experiment 2 will study the relationship between beta bursts and naturalistic action preparation using EEG."
16292555|NCT04727931||Newly diagnosed epileptic patients|Newly diagnosed epileptic patients who have never be treated by antiepileptic drugs and who have no psychiatric (mental illness) and/or evolutive neurological history and for minor patients the non-opposition of the parental authority holders.
16292556|NCT04727931||Normal controls|Matched (on age, gender, socio-educationnal level and manual laterality) healthy controls who have no psychiatric (depression, mental illness) and/or neurological (stroke, traumatic brain injury, etc.) history and for minor patients the non-opposition of the parental authority holders.
16292557|NCT04727918|Active Comparator|Cold biopsy forceps (CBF)|Patients will be allocated to the CBF arm after randomization (1:1)
16292558|NCT04727918|Active Comparator|Cold snare polypectomy (CSP)|Patients will be allocated to the CSP arm after randomization (1:1)
16292559|NCT04727905|Experimental|energy drink|Intake after exercise
16292560|NCT04727905|Placebo Comparator|Seasoned water|Intake after exercise
16292561|NCT04727892||complications after epilepsy surgery|Group A with no complication; Group B with complications
16292562|NCT04727879|Other|PMR|"Patients with PMR will be offered biopsy of the synovial membrane with puncture of synovial fluid during cortisone infiltration for analgesic purposes. In case of associated peripheric arthritis, the patient will also be offered a joint fluid sample during a cortisonic infiltration for analgesic purposes, performed as part of routine care
~The study-specific examination that is not part of current practice is the synovial biopsy performed during the cortisonic infiltration procedure."
16292563|NCT04727879|Other|Control|Witnesses recruited into the orthopedic surgery department will be offered a synovial membrane biopsy during a shoulder surgery in the context of mechanical pathology.
16292564|NCT04727866|Experimental|Rostral tsDCS|DCS cathode over ~C3-C5 posteriorly, anode over ~C5-T1 anteriorly
16292565|NCT04727866|Experimental|Caudal tsDCS|DCS cathode over ~T1-T4 posteriorly, anode over ~C5-T1 anteriorly
16292566|NCT04727866|Experimental|Coronal tsDCS|DCS cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
16292567|NCT04727853|Experimental|irinotecan liposome injection|Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle.
16292568|NCT04727840|Other|Intervention|All 20 CKD patients will be receiving a potassium binder while consuming a tailored diet of non-potassium restricted foods
16292569|NCT04727827|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
16292570|NCT04727814||Water exchange with computer-aided detection system|Computer-aided detection system overlaid videos with water exchange colonoscopy method
16292571|NCT04727814||Air insufflation with computer-aided detection system|Computer-aided detection system overlaid videos with air insufflation colonoscopy method
16292572|NCT04727801||Febrile (n=50)|Febrile is defined as having sublingual temperatures of 37.5 °C or above. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
16292573|NCT04727801||Afebrile (n=50)|Afebrile is defined as having sublingual temperatures of less than 37.5 °C. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
16292574|NCT04727775||Complications|Evaluathion
16292575|NCT04727775||Oxygen status|Evaluathion
16292576|NCT04727775||Oxugen support|Evaluathion
16292577|NCT04727749|Experimental|Therapy Dog Team Visit|Patient interacts with the therapy dog and handler.
16292578|NCT04727749|No Intervention|No Therapy Dog Team Visit|No patient interaction with the therapy dog or handler.
16292579|NCT04727736|Experimental|18F-DCFPyL + PET imaging|"Participants will receive a single dose of 18F-DCFPyL and undergo a PET imaging study.
~(The PET imaging may be repeated at a later date if the biopsy of the lesion is negative and if the lesion is present on follow-up imaging.)"
16292580|NCT04727723||Lutathera®|Lutathera® will be administered according to the local label and according to the recommended treatment regimen in adults consisting of four equally divided doses of Lutathera® for a total of 29.6 GBq (800 mCi).
16292581|NCT04727710|Experimental|Part 2: Couples-based mindfulness intervention|Mindfulness-based intervention + Usual care
16292582|NCT04727710|Active Comparator|Part 2: Usual care|Usual care
16292583|NCT04727697|Active Comparator|Standard of Care, preoperative teaching group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care.
16292731|NCT04726670||The evaluation of postoperative pain (Mean Rank) within the group according to time periods|The evaluation of postoperative pain (Mean Rank) within the group according to time periods
16292584|NCT04727697|Experimental|Augmented Reality perioperative experiences group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care in addition to receiving the augmented reality (AR) perioperative experience.
16292585|NCT04727684|Active Comparator|Agonist Group (long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16292586|NCT04727684|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16292587|NCT04727671|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16292588|NCT04727671|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16292589|NCT04727658|Experimental|Radiosurgical thalamotomy on GammaKnife|
16292590|NCT04727632|Experimental|Treatment: all patients|One session of [18F]FES PET/CT Imaging
16292591|NCT04727619|Experimental|Experimental|Participants who participated in the SLEEP program.
16292592|NCT04727619|No Intervention|Control|Participants who did not participate in the SLEEP program.
16292593|NCT04727606|Experimental|Open label|The study provides for a single group, which will be its own control (pre/post intervention study). Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day) for 1 month
16292594|NCT04727593|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|Group intervention on Mindfulness-Based Cognitive Therapy classic program plus 4 monthly consolidation sessions of 90 minutes each.
16292595|NCT04727593|Other|Treatment as Usual (TAU)|TAU will be the control condition.
16292596|NCT04727580|Experimental|HSK7653 10 mg|
16292597|NCT04727580|Experimental|HSK7653 25 mg|
16292598|NCT04727580|Placebo Comparator|Placebo|
16292599|NCT04727567||Multiple Visit Patient (MVP) Program|"The MVP program aims to manage health and lower hospital utilization among patients with a history of high inpatient hospital stays at Atrium Health. Patients eligible for the program have four or more inpatient visits over the 12-month period prior to enrollment. Once enrolled, each MVP program participant receives on-going support from an assigned MVP care manager and larger care management team, including the following core program components:
~customized care plan developed for each patient at the time of enrollment routine, virtual health monitoring and collaborative care management team-based review personalized navigation and coordination across multidisciplinary Atrium Health services, as needed.
~Education, health coaching, and support via telephonic and in-person interactions, as needed."
16292600|NCT04727567||Usual Care|Atrium Health standard of care. Patient's post-discharge usual care depends on the inpatient care management assessment at last hospital admission. Patients can be discharged to home and receive no further care, or home with home health, or to a skilled nursing facility (SNF) or another type of Continuing Care facility. Patients can be referred to advanced illness management, hospice, and Community Care Partners by the inpatient care manager. Patient can be referred to Ambulatory Care Management for care management also via telehealth, by a primary care physician or the Transitions Clinic.
16292601|NCT04727554|Experimental|Part 1a: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
16292602|NCT04727554|Experimental|Part 1b: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
16292603|NCT04727554|Experimental|Part 1c: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
16292604|NCT04727554|Experimental|Part 2: Dose Expansion|Participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404.
16292605|NCT04727541|Experimental|Neoadjuvant therapy with Bintrafusp alfa|1200 mg of Bintrafusp alfa will be administered by intravenous infusion every 2 weeks for a total of 2 dosages (Q2W). Subsequently, the surgery will be performed.
16292606|NCT04727528|Experimental|Open-label correction phase (up to 48 hours)|"All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization.
~Patients with POCT K+ <3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol."
16292607|NCT04727528|Experimental|Randomized, placebo controlled phase (Day 2 or 3 to Day 29)|Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.
16292608|NCT04727515|Experimental|General anesthesia|Patients will receive general anesthesia
16292609|NCT04727515|Experimental|Axillary Block|Patients will receive axillary nerve block
16292610|NCT04727502|Active Comparator|( Group Duloxetine )|• Dosing and administration (Group A) Duloxetine 30 mg /day oral intake at bed time
16292611|NCT04727502|Active Comparator|(Group Pregablin )|control group Pregablin 150mg /day( 75 mg /12 hours ) oral intake.
16292612|NCT04727489||Autism Spectrum Disorder|Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
16292613|NCT04727489||Control without Autism Spectrum Disorder|Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
16292614|NCT04727489||Relatives of probands with Autism Spectrum Disorder|"Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives)
~Without Autism Spectrum Disorder diagnosis according to DSM-V,
~With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders"
16292615|NCT04727489||Relatives of controls|Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives
16292616|NCT04727476||Children with attention deficit disorders|children aged 7-13 years who have attended a specialised outpatient clinic treating children with attention deficit disorders i in the period from 1 April 2013 to 5 November 2019.
16292617|NCT04727450|Active Comparator|1. Integrated format|Integrated or Combination of ABC of A: cognitive training. B: physical training and C: Combined Cognitive and Physical Training (CCPT).
16292618|NCT04727450|Active Comparator|2. Cognitive training + Physical Training (A+B)|Intervention of A & B treatments.
16292619|NCT04727450|Active Comparator|3. Physical training + CCPT (B+C)|Intervention of B & C treatments.
16292620|NCT04727450|Active Comparator|4. CCPT + Cognitive training (C+A)|Intervention of C & A treatments.
16292621|NCT04727450|No Intervention|5. Control group|No intervention
16292622|NCT04727437|Active Comparator|Control|Full dose anticoagulation treatment as standard care for at least 3 months.
16292623|NCT04727437|Experimental|Intervention|Withholding anticoagulation for Isolated Sub-Segmental Pulmonary Embolism (ISSPE) for at least 3 months.
16292624|NCT04727424|Active Comparator|Fluvoxamine Maleate|"Fluvoxamine 100 mg oral tablets:
~One tablet right after randomization (Day 0) followed by 100 mg BID for the following 09 days"
16292625|NCT04727424|Active Comparator|Doxasoxin|"Dosaxozin oral tablets (1 or 2 mg):
~One tablet right after randomization (Day 0) until Day 3, when uptritation of tablets will happen as per protocol, up to 4 pills daily (08 mg/ day) ending on Day 13."
16292626|NCT04727424|Active Comparator|Ivermectin|"Ivermectin 06 mg oral tablets:
~Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 03 consecutive days."
16292627|NCT04727424|Placebo Comparator|Placebo|"Placebo SC normal saline syringe (single day dosing schedule):
~Matching syringes containing 0,5 ml normal saline will be administered by SC route just after randomization Day 0 (single dose SC administration).
~OR
~Placebo oral tablets (3-day dosing schedule):
~Matching tablets started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day, which is designed as Day 0).
~OR
~Placebo oral tablets (10-day dosing schedule):
~Matching tablets started right after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)
~OR
~Placebo oral tablets (14-day dosing schedule):
~Matching tablets started right after randomization (Day 0) until Day 3, when uptritation of tablets will happen as per protocol, up to 4 pills daily (08 mg/ day) ending on Day 13."
16292628|NCT04727424|Active Comparator|Peginterferon Lambda|"Peginterferon Lambda 180 mcg syringe:
~One syringe of Peginterferon Lambda will be administered by SC route just after randomization (Day 0 - single dose SC administration)."
16292629|NCT04727424|Active Comparator|Peginterferon Beta|"Peginterferon Beta 125 mcg syringe:
~One syringe of Peginterferon Beta 1A will be administered by SC route just after randomization (Day 0 - single dose SC administration)."
16292630|NCT04727411|Experimental|Gel Stent implantation|XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
16292670|NCT04727086|Experimental|Medication (BP1.3656)|Participants will receive BP1.3656 in tablet form once daily at a dose of 30 µg/day for the first 4 days, followed by 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
16292631|NCT04727411|Experimental|Trabeculectomy|Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
16292632|NCT04727398|Other|Cataract patients who was scheduled for phacoemulsification|Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.
16292633|NCT04727385|Experimental|single-arm of 3 cohorts|"These patients will be sequentially recruited in 3 cohorts :
~One disc level cohort: 5 patients with only one disc to be treated; First enrolled cohort with 48 weeks of follow-up (9 visits V1-V9)
~Two disc level cohort: 5 patients with 2 discs to be treated; Second enrolled cohort with 36 weeks of follow-up (8 visits, same visits except for V9)
~One or two disc level cohort: 10 patients with 1 or 2 discs to be treated; Third enrolled cohort with 24 weeks of follow-up (6 visits, V1 to 7 except for V4)"
16292634|NCT04727372||Islamabad Group|Individuals residing and surveyed in Islamabad
16292635|NCT04727372||Lahore Group|Individuals residing and surveyed in Lahore
16292636|NCT04727372||Faisalabad Group|Individuals residing and surveyed in Faisalabad
16292637|NCT04727372||Bahawalpur Group|Individuals residing and surveyed in Bahawalpur
16292638|NCT04727359||FIT64b model project|Patients being treated in FIT64b model project at UKT
16292639|NCT04727359||Standard care|Patients being treated in standard care (control hospitals)
16292640|NCT04727346||Study Group|CBCT and DISE
16292641|NCT04727346||Control Group|DISE only
16292642|NCT04727320|Experimental|patient+TUDCA|
16292643|NCT04727320|Placebo Comparator|patient+placebo|
16292644|NCT04727307|Experimental|Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab|Neoadjuvant atezolizumab and adjuvant atezolizumab + bevacizumab in combination with percutaneous radiofrequency ablation
16292645|NCT04727307|Active Comparator|Percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation, standard treatment
16292646|NCT04727294||MGUS, SMM, MM Patients or their Caregivers|"Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile.
~The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility.
~Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete."
16292647|NCT04727281|Experimental|dialysis patients|Patients included in the study will be recruited from the dialysis units in Alexandria University Hospitals.
16292648|NCT04727268||Group 1|"Retrospective data regarding genetic information will be collected from participants' medical records.
~Deep phenotyping of participants will also be completed."
16292649|NCT04727255|Experimental|Intervention|The intervention will be implemented through a group-based delivery format involving internal educated resilience trainers. The Engaged and Resilient training program consists of twenty weekly, short-term sessions to build resilience skills in leaders.
16292650|NCT04727255|No Intervention|Control|Participants in the (waitlist) control group will be exposed to their usual activities in the organization and will not perceive any interventions from the resilience curriculum. After the final data is collected, the control participant will be offered the opportunity to be trained by the internal trainers, educated in the research study.
16292651|NCT04727242|Experimental|Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine|"Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine followed by postoperative systemic chemotherapy with dacarbazine. Conceptually, HIPEC will be administered as a 60 minute heated intraperitoneal infusion (ie, intraperitoneal wash or lavage).
~HIPEC: Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
~Systemic adjuvant chemotherapy starting 30 days ± 14 days post surgery. Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles"
16292652|NCT04727229|Experimental|Bupivacaine Hydrochloride|Injection of Bupivacaine Hydrochloride 0.5% near the stellate ganglion.
16292653|NCT04727229|Placebo Comparator|Normal Saline Solution|Injection of Normal Saline near the stellate ganglion
16292654|NCT04727216|Active Comparator|Continuous DRG-S Dosing|2 week stimulation program using continuous DRG-S dosing at standard stimulation parameters
16292655|NCT04727216|Experimental|1 minute on: 1 minute off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 1 minute off intermittent DRG-S dosing at standard stimulation parameters
16292656|NCT04727216|Experimental|1 minute on: 2 minutes off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 2 minutes off intermittent DRG-S dosing at standard stimulation parameters
16292657|NCT04727203|Experimental|Intervention|Partcipants in this group will receive the 8 week healthy lifestyle program
16292658|NCT04727203|No Intervention|Control|Participants in this group will not receive any intervention
16292659|NCT04727190|Experimental|TBCB group|Specimens were obtained using 1.1 mm ultrathin cryoprobe with or without guide sheath by bronchoscope.
16292660|NCT04727190|Active Comparator|TBFB group|Specimens were obtained using 1.5 mm or 1.9 mm biopsy forceps with or without guide sheath by bronchoscope.
16292661|NCT04727164|Experimental|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors
16292662|NCT04727151|Experimental|TAC01-HER2|Lymphodepletion followed by TAC01-HER2 as a single IV infusion.
16292666|NCT04727112||asthma and rhinitis|Screening of patients with upper and lower airway symptoms
16292667|NCT04727112||asthma and rhintis follow-up|same Group as screened in 2000, was followed up three years later
16292668|NCT04727099|Experimental|Benign Pigmented Lesions|Up to six (6) treatments with PicoWay laser for treatment of benign pigmented lesions
16292669|NCT04727099|Experimental|Wrinkles|Up to six (6) treatments with PicoWay laser for treatment of wrinkles
16292672|NCT04727073|Experimental|Arm A|Experimental: Spironolactone Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium < 4.5 mmol/L.
16292673|NCT04727073|Placebo Comparator|Arm B|Placebo Comparator: Placebo Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
16292674|NCT04727047|Active Comparator|Neuromuscular Electrical Stimulation|"Neuromuscular electrical stimulation will be applied to the calf muscles. The level of stimulation will be increased weekly from 10 to 30 mA during the first 6 weeks after surgery.
~In addition, patients will follow standard therapy for Achilles tendon repair."
16292675|NCT04727047|No Intervention|Control|Patients will follow standard therapy for Achilles tendon repair.
16292676|NCT04727034|Active Comparator|Control group|Propofol（1.5mg/kg）
16292677|NCT04727034|Experimental|Test group 1（Remimazolam tosylate 0.15mg/kg）|Remimazolam tosylate 0.15mg/kg
16292678|NCT04727034|Experimental|Test group 2（Remimazolam tosylate 0.2mg/kg）|Remimazolam tosylate 0.2mg/kg
16292679|NCT04727021|Experimental|Treatment A: Single oral dose of a 20 mg tablet rivaroxaban|"2-way crossover: The subjects will receive the following treatments in a randomized order:
~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
16292680|NCT04727021|Experimental|Treatment B: Single oral dose of 20 mg rivaroxaban, granules|"2-way crossover: The subjects will receive the following treatments in a randomized order:
~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
16292681|NCT04727008|Experimental|CXCR4 modified anti-BCMA CAR T cell therapy|CAR T cell therapy
16292682|NCT04726982|Experimental|Low dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
16292683|NCT04726982|Experimental|High dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
16292684|NCT04726982|Placebo Comparator|Placebo|Matching placebo tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
16292685|NCT04726969|Experimental|Arm A: moxidectin and albendazole|Combination therapy of moxidectin (8 mg, i.e. 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
16292686|NCT04726969|Placebo Comparator|Arm B: albendazole|Placebo (for moxidectin, 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
16292687|NCT04726969|Experimental|Arm C: ivermectin and albendazole|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
16292688|NCT04726956||case cohort|Pancreatic ductal adenocarcinoma patient
16292689|NCT04726956||control cohort|healthy control person
16292690|NCT04726943|Experimental|RF Energy|RF delivery targeting the atrial side of a significant residual leak in patients with acute and chronic evidence of incomplete percutaneous LAA occlusion
16292691|NCT04726930||Intercostal nerve block with surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.
~Code name: ICNB-INUS-check"
16292692|NCT04726930||Paravertebral block with surface ultrasound|Number of participants: 10 Paravertebral blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.
16292693|NCT04726930||Intercostal nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.
~Code name: ICNB-INUS-guide"
16292694|NCT04726930||Paravertebral nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Paravertebral blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.
~Code name: PVB-INUS-guide"
16292695|NCT04726917||Patients with COPD|Patients qualified for 3-week in-hospital pulmonary rehabilitation
16292696|NCT04726904|Other|Conventional lead placement|The cadaver is placed in the prone position. The exact location for insertion of the needle is defined with the conventional technique.
16292697|NCT04726891|Active Comparator|Continued M2M + SNS for 8 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 8 weeks of the study.
16292698|NCT04726891|Active Comparator|Augmented M2M + SNS + IBC for 8 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
16292732|NCT04726657|Active Comparator|Premixed Insulin|Premixed Human Insulin
16292733|NCT04726657|Active Comparator|Premixed insulin|Premixed Insulin Analog
16292734|NCT04726644||patients|cirrhotic patients with ventral hernia
16292699|NCT04726891|Active Comparator|Switched M2M Live for 8 weeks|The remaining half of participants with sub-optimal adherence in the first treatment stage will switch to another M2M-based home exercise intervention, M2M Live. M2M Live involves one-on-one tele-exercise training with an M2M instructor, which provides accountability and immediate, tailored feedback along with custom movements and music. During the first week of M2M Live, the participant will set a schedule to meet with the M2M instructor 3 times a week for an exercise session. The M2M Live instructors are also trained in motivational interviewing in order to coach participants through any barriers to changing their exercise behavior.
16292700|NCT04726891|Active Comparator|Continued M2M + IBC for 4 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 4 weeks of the study.
16292701|NCT04726891|Active Comparator|Augmented M2M + SNS + IBC for 4 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
16292702|NCT04726891|Active Comparator|Switched M2M Live for 4 weeks|The remaining half of participants with sub-optimal adherence in the first treatment stage will switch to another M2M-based home exercise intervention, M2M Live. M2M Live involves one-on-one tele-exercise training with an M2M instructor, which provides accountability and immediate, tailored feedback along with custom movements and music. During the first week of M2M Live, the participant will set a schedule to meet with the M2M instructor 3 times a week for an exercise session. The M2M Live instructors are also trained in motivational interviewing in order to coach participants through any barriers to changing their exercise behavior.
16292703|NCT04726878|Placebo Comparator|Controlled|Standard care without regional block. General anesthesia. After the end of the surgery, the patient-controlled analgesia with oxycodone.
16292704|NCT04726878|Experimental|ESP block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.375% ropivacaine will be performed. Then, the patient will be treated as in the controlled group.
16292705|NCT04726878|Sham Comparator|Sham block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.9% saline will be performed. Then, the patient will be treated as in the controlled group.
16292706|NCT04726852||Patients|Patients having elective cardiac surgery
16292707|NCT04726839||Stroke suspicion|Patients with stroke suspicion within 24 hours of stroke's symptoms
16292708|NCT04726813|Experimental|a self-guided Internet delivered intervention|MinADHD: 7 self-help modules.
16292709|NCT04726813|Placebo Comparator|Psycho-education|One self-guided psychoeducation module
16292710|NCT04726787|Experimental|Bridging Radiotherapy|Disease areas requiring effective long-term control will receive full-dose radiotherapy (20-30Gy/5-15#); other areas will receive low dose (4Gy/2#)
16292711|NCT04726774|Experimental|Hypnosis group|The intervention consisted of two hypnosis sessions by a physician trained in medical hypnosis. The hypnosis group received also the usual rehabilitation program.
16292712|NCT04726774|Active Comparator|Control group|The control group follow the usual rehabilitation program which includes intensive physiotherapy for 2 weeks (i.e., focused on walking and enhancing balance exercises in group or individual and group) and patient education on the risk of falling and on prevention of falls.
16292713|NCT04726761||Frequent/Non-frequent|Patients randomized to this order will first have an ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night) and then a few days later have another ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours)
16292714|NCT04726761||Non-frequent/frequent|Patients randomized to this order will first have an ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours) and then a few days later have another ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night)
16292715|NCT04726748||Urolift cohort|80 patients with prostatic urethral lift surgery will be included
16292716|NCT04726748||Transurethral Resection of the Prostate/laser cohort|80 patients with a transurethral resection of the prostate or laser surgery (enucleation or vaporisation) will be included.
16292717|NCT04726748||National healthcare insurance system database (SNDS) cohort|1200 patients with any transurethral surgery (TURP/laser) will be included and randomly matched to patients of the Urolift cohort with ratio 5:1.
16292718|NCT04726735||Patients with histologically documented normal bladder|
16292719|NCT04726735||Patients with histologically documented Non Muscle Invasive Bladder Cancer|
16292720|NCT04726735||Patients with histologically documented Muscle Invasive Bladder Cancer|
16292721|NCT04726722|Experimental|Design of the CBT treatment content|Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content
16292722|NCT04726722|Experimental|Control of support and feedback|Patient-controlled support and feedback (person-centred) vs. therapist -controlled.
16292723|NCT04726709|Experimental|Poised for Parkinson's|Alexander-technique-based online course to increase embodied agency in people with Parkinson's disease and their care partners.
16292724|NCT04726696|No Intervention|Control group|None intervention to be administered, they continue their normal routine.
16292725|NCT04726696|Experimental|Intervention group|ROLE-AP is a multifaceted program offered over a month period to participating primary care nurses and includes three interactive workshops. Each workshop will be 4 hours long.
16292726|NCT04726683|Experimental|Dry needling|Trigger point dry needling on an active myofascial trigger point of the masseter muscle.
16292727|NCT04726683|Experimental|Injection|Trigger point injection of lidocaine on an active myofascial trigger point of the masseter muscle.
16292728|NCT04726683|Placebo Comparator|Placebo|Combines sham dry needling + sham injection.
16292729|NCT04726683|Active Comparator|Dry needling + Injection|Combines experimental dry needling and injection
16292737|NCT04726592|Placebo Comparator|Control arm|"placebo and standard care :
~Placebo IV
~Ketoprofen 100 mg IV (if nausea-vomiting)
~Metoclopramide 10 mg IV(if nausea-vomiting)"
16292738|NCT04726592|Experimental|Experimental arm|"clorazepate and standard care :
~Clorazepate 20 mg IV
~Ketoprofen 100 mg IV (if nausea-vomiting)
~Metoclopramide 10 mg IV(if nausea-vomiting)"
16292739|NCT04726566||Arthroscopic stabilization|Patient will have an anatomical surgery of chronic lateral ankle instability under arthroscopy
16292740|NCT04726553|Experimental|Anifrolumab plus Standard of Care|Anifrolumab will be added to Standard of Care Treatments for SLE
16292741|NCT04726553|Placebo Comparator|Standard of Care|Standard of Care Treatments for SLE
16292742|NCT04726540||Group I|
16292743|NCT04726540||Group II|
16292744|NCT04726527||Florbetapir F 18 Recipients|Participants in this arm of the study will receive a 10 mCi (370 MBq) bolus injection of florbetapir F 18 and then be scanned in a PET scanner for brain imaging.
16292745|NCT04726514|Experimental|SleepFlex Treatment|
16292746|NCT04726501|Experimental|Low risk group|Ann Arbor stage IA or IIA without bulky disease.
16292747|NCT04726501|Experimental|Intermediate risk group|Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulk disease, and IA or IIA with bulk disease
16292748|NCT04726501|Experimental|High risk group|Ann Arbor stages III or IV with B symptoms
16292749|NCT04726488|Experimental|Periareolar Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
16292750|NCT04726488|Active Comparator|Inframammary Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
16292751|NCT04726475|Experimental|Memory Reactivation + CBD Oil|Immediately after the brief memory reactivation procedure (see interventions), participants will be asked to take a single 300mg oral dose of CBD oil.
16292752|NCT04726475|Placebo Comparator|Memory Reactivation + Placebo Oil|Immediately after the brief memory reactivation procedure (see interventions), participants will be asked to take a single 300mg oral dose of placebo oil.
16292753|NCT04726475|Active Comparator|CBD Oil alone|Participants will be asked to take a single 300mg oral dose of CBD oil.
16292754|NCT04726462|Experimental|Functional exercise group|
16292755|NCT04726462|Experimental|Posture exercises group|
16292756|NCT04726449||psychiatric diagnosis|psychiatric diagnosis : patients who were given a psychiatric diagnosis at the end of the follow up
16292757|NCT04726449||somatic diagnosis|somatic diagnosis: patients who were given a somatic diagnosis at the end of the follow up
16292758|NCT04726436|Experimental|Dextrose 5%|100 mL/ hour of dextrose 5% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon to assess the timing and dosing of dextrose solution effect on PONV.
16292759|NCT04726436|Experimental|Dextrose 10%|100 mL/ hour of dextrose 10% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
16292760|NCT04726436|Placebo Comparator|Saline placebo|100 mL/ hour of normal saline were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
16292761|NCT04726410|Experimental|Cold-stored Platelet (CSP)|early infusion of up to 2 units of urgent release cold stored platelets (CSP)
16292762|NCT04726410|Active Comparator|Standard care|standard care therapy
16292763|NCT04726384||Observed group|The group was monitored for physical activity levels using the SenseWear Armband device. The group was informed of the purpose of the study and asked to wear the device 24 hours a day for the next 4 days (Friday-Monday) excluding bath time, no more than 30 minutes. Patients received the device on Thursday afternoon and returned it on Tuesday. However, the days Friday-Monday were analyzed to have a record of the entire days
16292764|NCT04726371|Active Comparator|Generic Best Practices (GBP)|The ~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.
16292765|NCT04726371|Experimental|Tailored Best Practices (TBP)|The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
16292766|NCT04726345|Experimental|Fexofenadine|Participants in this arm will receive fexofenadine 180mg once daily, in addition to standard of care pain medications (NSAIDs).
16292767|NCT04726345|Placebo Comparator|Placebo|Participants in this arm will receive placebo once daily, in addition to standard of care pain medications (NSAIDs).
16292768|NCT04726332|Experimental|XL102 Single-Agent Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
16292769|NCT04726332|Experimental|XL102 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with triple-negative breast cancer (TNBC) (Cohort D), epithelial ovarian cancer (EOC) (Cohort E), hormone receptor-positive breast cancer (HR+ BC) (Cohort F), and metastatic castration-resistant prostate cancer (mCRPC) (Cohort G).
16292770|NCT04726332|Experimental|XL102 + Fulvestrant Dose-Escalation Cohorts|Subjects with HR+ BC (Cohort B) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
16292771|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts|Subjects with mCRPC (Cohort C) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
16292772|NCT04726332|Experimental|XL102 + Fulvestrant Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with HR+ BC (Cohort H).
16292773|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with mCRPC (Cohort I).
16292774|NCT04726319|Experimental|Intervention|In addition to usual care, patients will be asked to answer questions about any family history through the use of a questionnaire.
16292775|NCT04726319|No Intervention|Usual Care|Patients receive usual care, which consists of health care providers inquiring about and dealing with family history as they would in usual practice.
16292778|NCT04726280|Experimental|10 ml single-shot injection|"In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.
~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
16292779|NCT04726280|Active Comparator|20 ml single-shot injection group|"In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.
~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
16292780|NCT04726267|Other|Glaucoma patients who was scheduled for trabeculectomy|Wide-field OCT was performed 1-2 weeks before the trabeculectomy. The OCT was done postoperatively at 1 month, 3 months, 6 months and 12 months after surgery.
16292781|NCT04726241||Observational (biospecimen collection)|Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).
16292782|NCT04726202||Control arm|standard procedure of coding at hospital
16292783|NCT04726202||Precoding arm|Coding of the standard procedure will be reviewed and corrected
16292784|NCT04726189|Active Comparator|Standard care exercises|This is the currently used treatment in the nine weeks of immobilisation with an orthosis.
16292785|NCT04726189|Experimental|Early progressive strength exercise|This exercise program initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration.
16292789|NCT04726163|No Intervention|Tele-expertise|Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
16292790|NCT04726163|Experimental|Standard|Standard treatment and adaptation of insulin doses according to the usual management of the unit
16292791|NCT04726150||Mildly of Asymptomatic COVID|Athletes with prior COVID-19 that had a mildly or asymptomatic course
16292792|NCT04726150||Moderate to Severe Symptoms, Cardiac Symptoms|Athletes with prior COVID-19 that had a moderate to severely symptomatic course, or who experience(d) cardiac symptoms
16292793|NCT04726150||Hospitalized for|Athletes that were hospitalized for COVID-19
16292794|NCT04726124|Experimental|treatment group|Microwave Ablation Therapeutic Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous microwave therapy using Microwave Ablation Therapy Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, and 6 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
16292795|NCT04726124|Experimental|control group|Semiconductor Laser Treatment Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous laser treatment using Semiconductor Laser Treatment Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, and 6 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
16292796|NCT04726111|Other|Control patients|Control patients (negative serology and PCR)
16292797|NCT04726111|Other|asymptomatic patients|asymptomatic patients (PCR positive)
16292798|NCT04726111|Other|symptomatic patients|symptomatic patients (PCR positive)
16292799|NCT04726111|Other|Cured patients|cured patients who contracted the disease during pregnancy (positive serology in the 15 days preceding childbirth or history of positive PCR during pregnancy and negative PCR within 72 hours)
16292802|NCT04726085|Active Comparator|Ibuprofen|Ibuprofen 600 mg q6 hours for 24 hours- total dose of 2400mg- after emergent cerclage placement
16292803|NCT04726085|Active Comparator|Indomethacin|Indomethacin 50 mg q8 hours for 24 hours- total dose of 150mg- after emergent cerclage placement
16292804|NCT04726072|Experimental|Kundalini Yoga|The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises and meditation. Participants were also asked to do at-home practice for half an hour daily.
16292805|NCT04726072|Active Comparator|Psychoeducation|The psychoeducation group consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily
16292806|NCT04726059|Sham Comparator|ABT+SHAM|The SHAM is low-intensity, ineffective stimulation verified by the absence of lower extremity skeletal muscle activation and delivered at the same anatomical location as TCSCS.
16292807|NCT04726059|Experimental|ABT+TCSCS|Therapeutic TCSCS will be delivered during ABT using an isolated bipolar constant current stimulator. Continuous TCSCS applied over the T11-T12 spinous processes at 5-40 Hz has been shown to induce stepping movements in participants with their legs in a gravity-independent position.
16292808|NCT04726046|Experimental|Antibiotic treatment group|They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
16292809|NCT04726046|No Intervention|Non-antibiotic treatment group|They were Non-antibiotics treatment such as cefotetan 1g before surgery.
16292810|NCT04726033|Experimental|Dose level 1 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu
16292811|NCT04726033|Experimental|Dose level 2 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 8mg of unlabelled TLX592 (mass dose of 10mg).
16292812|NCT04726033|Experimental|Dose level 3 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 18mg of unlabelled TLX592 (mass dose of 20mg).
16292877|NCT04725474|Experimental|Part B: CTL-002 Monotherapy + Checkpoint Inhibitor combination|Up to 2 dose levels with CTL-002 in Part B (expansion)
16351445|NCT04318327|Experimental|PHE885|Patients will receive PHE885
16292813|NCT04726033|Experimental|Confirmation of optimal 64Cu-TLX592 dose|"Based on the result of Groups 1-3, the optimal dose and imaging timepoints will be selected to treat 3 patients with higher tumour burden (≥10 metastatic sites and/or visceral disease as detected on a 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scan).
~Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 0, 8 or 18mg of unlabelled TLX592."
16292814|NCT04726020|Experimental|Intensive monitoring|Intensive phone monitoring of drug adverse events
16292815|NCT04726020|Placebo Comparator|Standard monitoring|Standard monitoring of drug adverse events
16292816|NCT04725994|Other|Group 1|
16292817|NCT04725994|Other|Group 2|
16292818|NCT04725981|Experimental|Arm A (test surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0 and 1 continuous suture with V-Loc 2-0
16292819|NCT04725981|Active Comparator|Arm B (control surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0
16292820|NCT04725955|Placebo Comparator|Glucose Solution|
16292821|NCT04725955|Active Comparator|Wheat bread enriched with a-cyclodextrin|
16292822|NCT04725955|Experimental|Wheat bread enriched with hydroxytyrosol encapsulated in a-cyclodextrin|
16292823|NCT04725916|Active Comparator|Study Arm 1|Subjects assigned to Arm 1 will be instructed to shower daily beginning on post-operative Day 2 and maintain this daily schedule until the subject's 3-month standard of care clinic follow-up visit. They will receive specific instructions on caring for the incision site and drains until they are removed.
16292824|NCT04725916|Active Comparator|Study Arm 2|Subjects assigned to Arm 2 will be instructed not to shower post-operatively until their surgical drains are removed. They will receive specific instructions on bathing and caring for the incision sites and drains.
16292825|NCT04725903|Experimental|Treatment (proton beam therapy)|Patients undergo pelvic proton beam therapy daily on Monday-Friday for 5-7 weeks. Patients may receive a high-dose rate brachytherapy boost.
16292826|NCT04725890|Experimental|Intervention|All eligible participants will receive the DyaMX procedure.
16292827|NCT04725877|Experimental|VIR-1111|
16292828|NCT04725877|Placebo Comparator|Placebo|
16292832|NCT04725851|Experimental|High concentration Oxygen Therapy|12-15 Litre/min O2 delivery via Non-Rebreather Mask (NRM) consecutively for 24 hours.
16292833|NCT04725851|Placebo Comparator|Room air or low concentration oxygen|Room air or low concentration oxygen (0-2 Litre/min O2 ) consecutively for 24 hours.
16292834|NCT04725825|Experimental|Dry needling|"A single dry needling session will be performed on the dominant painful trapezius muscle, with the patient lying in prone position. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down (fast-in, fast-out technique) in three different directions.
~In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct."
16292835|NCT04725825|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
16292836|NCT04725812|Experimental|Eculizumab|Twelve subjects in the interventional arm will receive eculizumab at an induction dose of 900mg IV weekly (q7 days) for 4 weeks followed by a dose of 1200mg IV at week 5. Thereafter, patients will receive a maintenance dose of 1200mg IV every two weeks (q14 days). The last dose of eculizumab will be given up to 48 hours post-partum, with a dose that is dependent on the dosing schedule (i.e. whether the last dose is given within the 4-week induction period or is during the maintenance phase).
16292837|NCT04725799||MESS with and without stressful stimuli|The subjects participate in meal, exercise, sleep activities alone or in combination with stressful stimuli.
16292838|NCT04725786|Experimental|Case group|The intervention of the research corresponds to the realization of a thoracic echography.
16292839|NCT04725773||PD DBS|Patients with Parkinson's disease and deep brain stimulation
16292840|NCT04725760|Experimental|Single Group Assisgnment|
16292841|NCT04725747|Experimental|Midazolam/Ketamine Melt|One Midazolam/Ketamine 3mg/50mg melt administered sublingually
16292842|NCT04725747|Active Comparator|Midazolam Melt|Midazolam 3mg melt administered sublingually
16292843|NCT04725747|Active Comparator|Ketamine Melt|Ketamine 50mg melt administered sublingually
16292874|NCT04725487|Experimental|Standard integration program with social and health promoting intervention|Participants follow the standard integration program offered by Naestved Municipality and participate in various social and health promoting activities in addition
16292875|NCT04725487|Active Comparator|Standard integration program|Participants follow the standard integration program offered by Naestved Municipality
16292876|NCT04725474|Experimental|Part A: CTL-002 Monotherapy + Checkpoint Inhibitor Combination Dose Escalation|Up to five dose levels with CTL-002 administered as IV monotherapy and in combination with an checkpoint inhibitor
16351488|NCT04318093|Placebo Comparator|Placebo|
16292846|NCT04725708|Experimental|normoxy|"Group 1(n=50) FiO2%40, PaO2<180 ve PaO2≥80mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored.
~An rSO2 less than 45% triggered an alarm, the anesthesiologist timed the event, and after 60 seconds initiated an intervention protocol means; PaO2 levels were checked, PaO2> 100 mmHg was achieved, if not improved, pump blood flow, mean arterial pressure were increased, if there is still no response and hematocrit <20%, patients were scheduled for erythrocyte transfusion until the rSO2 was restored to at least 60% at both probes.In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months."
16292847|NCT04725708|Experimental|hyperoxia|Group 2(n=50) FiO2%100, PaO2≥180mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored..In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months.
16292848|NCT04725695|Experimental|Viscous lidocaine|Oral viscous lidocaine 20 mg/ml, 10 ml
16292849|NCT04725695|Placebo Comparator|Placebo|Oral viscous solution without active drug, 10 ml
16292850|NCT04725682|Active Comparator|Sequence 1 (TRTR)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of TRTR.
~Treatment T (Test): 1 × 1mg Test tacrolimus capsules Treatment R (Reference): 1 × 1mg RLD tacrolimus capsules"
16292851|NCT04725682|Active Comparator|Sequence 2 (RTRT)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of RTRT.
~Treatment T (Test): 1 × 1mg Test tacrolimus capsules Treatment R (Reference): 1 × 1mg RLD capsules"
16292852|NCT04725669|Other|Seroprevalence of pertussis among children and adolescents in Croatia|For all patients participating in the study one serum sample will be collected for serological analysis.
16292853|NCT04725656|Active Comparator|Active arm, low concentration (18 mg/mL) nicotine salt e-liquids|
16292854|NCT04725656|Active Comparator|Active arm, high concentration (59 mg/mL) nicotine salt e-liquids|
16292855|NCT04725656|Other|Control group|Receive only smoking cessation counseling
16292856|NCT04725643||Implant Group|Adults who are choosing to get a replacement Nexplanon and agree to track and report their bleeding patterns for one month before replacement and 3 months after.
16292857|NCT04725630|Experimental|Subsidized Healthy Food Prescription Intervention|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider and a healthy food subsidy of $1.50/day/household member for 6 months. The subsidy can be used to purchase whole, minimally processed foods with little to no added fat, sugar or salt in participating supermarkets.
16292858|NCT04725630|Active Comparator|Healthy Food Prescription Comparison|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider. The pamphlet closely mimics current standard of care for patients with diabetes in Alberta (i.e., nutrition counselling).
16292859|NCT04725617|Active Comparator|Health Intervention Approach 1|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
16292860|NCT04725617|Active Comparator|Health Intervention Approach 2|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
16292861|NCT04725591|Active Comparator|Diabeloop closed-loop glucose control session with the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.
~Subjects are asked to declare their meals for 4 weeks.
~A remote monitoring system is provided in closed-loop session."
16292862|NCT04725591|Experimental|Diabeloop closed-loop glucose control session without the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.
~Subjects are asked to not declare their meals for 4 weeks.
~A remote monitoring system is provided in closed-loop session."
16292863|NCT04725578|Experimental|Telehealth Single Session Consultation|
16292864|NCT04725565|Experimental|Genetics ADviSER Decision Aid Plus Standard Genetic Counselling|Participants in the intervention arm will use the Genetics ADviSER to learn about genomic sequencing and to select which results they would like to receive from genomics sequencing results. After using the Genetics ADviSER decision aid they will speak with genetic counselor to discuss their choices and to finalized their selection.
16292865|NCT04725565|Active Comparator|Standard Genetic Counselling Only|Participants will speak with a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
16292866|NCT04725539|Experimental|Intermittent hypoxia (IH) pre-conditioning|"The IH pre-conditioning program will be performed in a sitting position by inhaling a gas mixture with reduced O2 content via face masks.The program will include five sessions per week for 3 weeks. Each session consists of three to five hypoxic (14-10% inspired fraction of oxygen) periods, each lasting 3-5 min with 3-min normoxic intervals.
~The control setting includes breathing room air via face mask."
16292867|NCT04725539|Experimental|Hypoxia pre-adaptation|The hypoxia pre-adaptation program consists of sleeping 1 night at 1900m. The control setting includes sleeping 1 night close to sea level.
16292868|NCT04725526|No Intervention|usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care on site
16292869|NCT04725526|Experimental|mHealth intervention plus usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care plus mHealth intervention on site
16292870|NCT04725513|Active Comparator|Physical Therapy Only|
16292871|NCT04725513|Experimental|Shockwave Therapy and Physical Therapy|
16292872|NCT04725513|Experimental|Photobiomodulation, Shockwave Therapy and Physical Therapy|
16292873|NCT04725500|Experimental|Auto-titrating EPAP|ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.
16351796|NCT04316130|Active Comparator|Exercise using brochure|brochure
16292878|NCT04725461|Experimental|Low cost lower limb socket testing|Fabrication and testing of a low cost lower limb prosthetic socket and ensure this socket has appropriate suspension, comfort and f unction for a transtibial amputee.
16292879|NCT04725448|Experimental|Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin|"Drugs: Toripalimab, 240mg (6ml)/bottle, ivgtt, d1, q3w, administration until PD or death, the longest use time is two years.
~Drugs: Bevacizumab, 7.5mg/kg, ivgtt, d1, q3w,the longest use time is two years.
~Drugs: Nab-paclitaxel, 260mg/m2,ivgtt,d1 or 130mg/m2,ivgtt,d1,8, q3w, up to six cycles.
~Drugs: Carboplatin, AUC=4～5, ivgtt, d1, q3w, up to six cycles."
16292880|NCT04725435|Experimental|Kangaroo care|"No Intervention: Standard care The control group will be followed by infants using nesting in the incubator. It will be followed for 60 minutes without any action or application.
~Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes."
16292881|NCT04725435|Experimental|Facilitated tucking position|"No Intervention: Standard care In the Control Group, the heel stick procedure will be performed in the infants own bed as in the clinical routine.
~Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.
~Experimental 2: Facilitated Tucking Position, with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
16292882|NCT04725422||disease modifying anti-rheumatic drug, DMARD|
16292883|NCT04725422||tumor necrosis factor inhibitor, TNFi|
16292884|NCT04725422||bisphosphonate|
16292885|NCT04725409||Epilepsy patients|All participants will be patients with medically refractory epilepsy undergoing depth electrode placement for seizure localization. For this study participants will complete psychiatric questionnaires measuring depression, anxiety, obsessive compulsive disorder, and impulsivity, and EEG recordings will be collected from the depth electrodes while subjects rest quietly. Some subjects will also participate in neuro cognitive tasks while neural recordings/stimulation are performed.
16292886|NCT04725396|Experimental|Patients undergoing PVP-assisted MR|PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized).
16292887|NCT04725396|Active Comparator|Patients undergoing conventional (i.e. without PVP) MR|Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR.
16292888|NCT04725383|Active Comparator|amitriptyline|Subjects will receive active amitriptyline compounded into look-alike capsules to resemble placebo capsules. Dosing will be as tolerated, up to tid and maximum of 100mg/day or 1.5mg/kg/day, for 12 weeks.
16292889|NCT04725383|Placebo Comparator|placebo|Subjects in this arm will receive placebo compounded into capsules that resemble the compounded amitriptyline capsules, up to 4 capsules a day (1 qam, 1 q4pm and 2 capsules qhs), for 12 weeks.
16292890|NCT04725370||CHOP (US)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2012 to 2019 at the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
16292891|NCT04725370||SFG (Guatemala)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2017 and 2020 with Smiles for Guatemala, Guatemala City, Guatemala.
16292892|NCT04725357|Experimental|Arthroscopic Labral Repair + postoperative Meloxicam|After surgery participants will receive a prescription of 20 pills of 15 mg Meloxicam
16292893|NCT04725357|Active Comparator|Arthroscopic Labral Repair without Meloxicam|After surgery participants will receive a prescription of 20 pills of 5/300 mg vicodin (hydrocodone/acetaminophen)
16292894|NCT04725344|Experimental|ACTIV'DOS group|ACTIV'DOS is a smartphone application of self rehabilitation. There are 7 muscular exercices. Patients going to exercices during 15 minutes per day, during 6 weeks.
16292895|NCT04725344|Experimental|Control group|This group uses a sheet of paper for self-rehabilitation exercise. The self-rehabilitation program is the same as the ACTIV'DOS group. Patients have to exercise during 15 minutes per day, during 6 weeks.
16292899|NCT04725305|Experimental|BiZact|A bipolar electrosurgical device that employs radiofrequency(RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger
16292900|NCT04725305|Active Comparator|Standard of care|In electrocautery tonsillectomy (or diathermy) electric current from a radiofrequency generator is passed through the tissue between two electrodes. The resulting high temperature (400º-600ºC) cuts the tissue and simultaneously seals the blood vessels
16292901|NCT04725279|Experimental|Type of rehabilitation treatment|Depending on whether the cervical pain associated with vertigo in the patients associated pain radiating to the arms or not, treatment with conventional physiotherapy or electrotherapy was prescribed. In addition, both groups had a control group that performed exercises at home prescribed by a physician.
16353274|NCT04305522|Experimental|Probiotic 2 group|A multi-strain probiotic
16292902|NCT04725266|Experimental|family-based intervention plus routine care|This group of participants including drug abusers and their families will be receiving family-based intervention which is a well-designed intervention with group sessions and routine care provided by professional social workers in local social service center.
16292903|NCT04725266|Active Comparator|routine care|The group of participants will receive routine care which is widely used in social service providers and mainly includes individual counselling service for drug abusers.
16292904|NCT04725253|Experimental|Nicotinamide|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously. Study medication will be managed by nurses and administered daily at 7 a.m. This regimen will be continued up to 7 days after admission. The dosage of nicotinamide will be 1,5 gr per day.
16292905|NCT04725253|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization, resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner. Study medication will be managed by nurses and administered daily at 7 a.m. (in these case placebo tablets). This regimen will be continued up to 7 days after admission.
16292906|NCT04725240|Experimental|Setmelanotide|"Investigational product: Setmelanotide, 10 mg/mL in a sterile solution for Subcutaneous (SC) injection .
~Dosage: 1.0, 2.0, 3.0 mg QD for subjects 6 to <16 years of age, and 2.0 to 3.0 mg QD for subjects ≥16 years of age. All subjects will receive study treatment for 16 weeks."
16292907|NCT04725214|Experimental|Experimental|For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)
16292908|NCT04725201|Experimental|Intravenous unfractionated heparin|Administration of intravenous unfractionated heparin according to the Centre hospitalier de l'Université de Montréal (CHUM) deep vein thrombosis (DVT) protocol for 5 days after vascular anastomosis. A bolus will be administered intraoperatively based on the patient's weight. Dosages will be adjusted according to the activated partial thromboplastin time (aim for an APTT of 50-70), which will be measured 6 hours after the start of the protocol and after every dosage adjustment or every morning at 6 a.m. if no adjustments were made in the last 6 hours.
16292909|NCT04725201|Sham Comparator|Control|"No administration of intravenous unfractionated heparin. These patients receive 5000 IU BID of heparin subcutaneously, as a standard post-operative protocol for all in-patients.
~The control group receives sham bolus intraoperatively of normal saline and a post-operative normal saline infusion at a fixed dose through an infusion pump to mimic IV heparin infusion."
16292913|NCT04725175|Experimental|PIPE-307|
16292914|NCT04725175|Placebo Comparator|Placebo|
16292915|NCT04725162||Epilepsy patients|Pediatric patients with focal epilepsy.
16292916|NCT04725162||Control|Age-matched controls who underwent 18F-FDG PET/CT examination for diseases outside brains.
16292917|NCT04725162||Validation|Children who underwent 18F-FDG PET/MRI to examine extracranial tumors.
16292918|NCT04725149|Placebo Comparator|0 ml tart cherry concentrate|Still cherry-flavored beverage, similar in appearance, taste, aroma and calories to the 30 ml and 60 ml tart cherry concentrate beverages
16292919|NCT04725149|Experimental|30 ml tart cherry concentrate|"Low dose tart cherry concentrate beverage"
16292920|NCT04725149|Experimental|60 ml tart cherry concentrate|"High dose tart cherry concentrate beverage"
16292921|NCT04725136|Experimental|High-dose repeat administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 3 repeated subcutaneous injection at 4 week intervals
16292922|NCT04725136|Experimental|High-dose single administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
16292923|NCT04725136|Experimental|Low-dose repeat administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 3 repeated subcutaneous injection at 4 week intervals
16292924|NCT04725136|Experimental|Low-dose single administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
16292925|NCT04725136|Placebo Comparator|Placebo|Normal saline(0.9% NaCl) 3 repeated subcutaneous injection at 4 week intervals
16292926|NCT04725123|Experimental|Clostridioides difficile infection|Stool of patients with Clostridioides difficile infection that will be subject to microbiome analysis. Comparisons will be done between patients with favorable and unfavorable outcome
16292927|NCT04725110|Experimental|T3 Intervention|Participants in this arm will receive the experimental intervention.
16292928|NCT04725110|Placebo Comparator|Placebo Therapy|Participants in this arm will receive placebo therapy.
16292929|NCT04725084||High Flow Nasal Cannula oxygen therapy treatment|Patients treated only by high flow nasal cannula oxygen therapy
16292930|NCT04725084||Non-Invasive Ventilation treatment|Patients treated by non-invasive ventilation (combined or not with HFNC)
16292931|NCT04725084||Continuous Positive Airway Pressure treatment|Patients treated by continuous positive airway pressure (combined or not with HFNC)
16293841|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome multi dose|
16292934|NCT04725058|Experimental|Medical Group Visit|Participants receive obesity management in a group setting let by endocrinologist and nutritionist.
16292935|NCT04725058|Experimental|Dietitian-Led Visit|Participant receives obesity management in an individual setting lead by registered dietitian.
16292936|NCT04725045|Active Comparator|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
16292937|NCT04725045|Experimental|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse)
16292938|NCT04725032|Experimental|sevoflurane-propofol balanced anesthesia|
16292939|NCT04725032|Active Comparator|propofol-based total intravenous anesthesia|
16292940|NCT04725019|Experimental|Active tDCS + motor training|In this arm, participants will receive 20 minutes of active tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games.
16292941|NCT04725019|Experimental|Sham tDCS + motor training|In this arm, participants will receive 20 minutes of sham tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games. Children receiving sham tDCS will wear the tDCS device but not receive active stimulation.
16292942|NCT04725006|Experimental|Stimulation in individuals with implanted stimulation systems|During psychophysical stimulation trials, an external stimulator will be connected to the SCS lead, a volley of stimulation will be performed, and the subject will be asked to respond to standard psychophysical questions, as well as to provide any additional comments.
16292943|NCT04724993|Experimental|Online Aerobic Dance Exercises|In this group, aerobic dance exercises will be applied online under the supervision of a physiotherapist. And participants will record their physical activities on the Physical Activity Tracking Chart.
16292944|NCT04724993|Experimental|Physical Activity Counseling|In this group, participants will be informed online about physical activity and exercise. And they will record their physical activities on the Physical Activity Tracking Chart too.
16292945|NCT04724980|Experimental|Dose Levels|Adjuvant PRGN-2012 at escalating doses
16292946|NCT04724967|Experimental|CeraVe Group|Participants in this group will receive the CeraVe Hydrating Cleanser and Moisturizing Cream for 28 days.
16292947|NCT04724954|Experimental|Rehabilitation Therapy on Experimental Robotic Table and standard of care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited for experimental group.
~The investigators will also recruit the 10 caregivers of the experimental subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
16292948|NCT04724954|Sham Comparator|Rehabilitation Therapy as part of Standard of Care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited as a control group.
~The investigators will also recruit the 10 caregivers of the control subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
16292949|NCT04724941||REM behavior disorder +|"Individuals with REM Sleep Behavior Disorder:
~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
16292950|NCT04724941||REM behavior disorder -|"Individuals without REM Sleep Behavior Disorder with increased risk for PD:
~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
16292951|NCT04724928|No Intervention|non-metastatic MIBC on PET-CT|patients receive classical treatment with neo-adjuvant chemotherapy followed by radical cystectomy (RC) or trimodality therapy (TMT) and regular follow up
16292952|NCT04724928|Experimental|oligo-metastatic MIBC on PET-CT|patients receive classical treatment with neo-adjuvant chemotherapy followed by RC or trimodality therapy TMT and metastasis-directed therapy followed by regular follow up
16292953|NCT04724928|Experimental|poly-metastatic MIBC on PET-CT|patients receive classical treatment with neo-adjuvant chemotherapy followed by RC or trimodality therapy TMT and start of immunotherapy followed by regular follow up
16292954|NCT04724915|Experimental|Robot-assisted TKA|Patients undergoing TKA with the assistance of robot technology.
16292955|NCT04724915|Active Comparator|Conventional TKA|Patients undergoing TKA with manual instrumentarium
16292956|NCT04724902|Experimental|Compression Group|The volunteer must remain supine on a stretcher, with both legs extended and relaxed. The intervention will be performed with elastic bandages (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity). The bandage will involve the knee from the distal to the proximal, respecting the blood flow of the venous return. The level of compression was defined according to recommendations in the literature on compression interventions in lymphedema and venous changes, and should be kept between 30 mmHg and 60 mmHg. Variations on stipulated values may be interfered according to the volunteer's self-report, which should indicate a level of moderate, comfortable and pain-free compression. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days.
16292990|NCT04724694|Experimental|Brief CBT for Chronic Pain and treatment as usual|Participants will receive Brief CBT-CP in addition to usual primary care treatment. Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
16292957|NCT04724902|Sham Comparator|Sham Group|For Sham application, the volunteer must remain supine on a stretcher, with both lower limbs extended and relaxed. Elastic bandages will be used (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity) . The bandage will involve the knee from the distal (tibial tuberosity) to the proximal (femoral condyles), respecting the blood flow of the venous return. However, in this group, no compression force will be performed, maintaining the pressure at 00 mmHg according to a previous reliability study. The procedure will be carried out for 20 minutes, once a day, for 4 consecutive days.
16292958|NCT04724902|No Intervention|Control Group|The Control group will be composed of individuals with knee osteoarthritis, who make up the study's waiting list and will carry out evaluations at the same time intervals as the other groups, but will not receive any type of intervention and will be instructed not to start another treatment during their participation.
16292959|NCT04724889||Patients with underlying AF|Patients that will have AF detected by ILR will be compared with patients without AF.
16292960|NCT04724889||Patients without AF|Patients that will have AF detected by ILR will be compared with patients without AF.
16292961|NCT04724863|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
16292962|NCT04724850||COVID-19 patients|All patients diagnosed with COVID-19 in the community of Extremadura from the beginning of the epidemic to its ending in Spain.
16292963|NCT04724837|Experimental|Part A and Part B: Zibotentan Dose A + Dapagliflozin|Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
16292964|NCT04724837|Experimental|Part A and Part B: Zibotentan Dose A|Participants will receive once daily oral dose A of zibotentan alone for 12 weeks.
16292965|NCT04724837|Experimental|Part A and Part B: Dapagliflozin|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
16292966|NCT04724837|Placebo Comparator|Part A and Part B: Placebo|Participants will receive once daily oral dose of placebo matched to zibotentan or dapagliflozin for 12 weeks.
16292967|NCT04724837|Experimental|Part B Only: Zibotentan Dose B + Dapagliflozin|Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
16292968|NCT04724837|Experimental|Part B Only: Zibotentan Dose C + Dapagliflozin|Participants will receive once daily oral dose C of zibotentan and 10 mg dapagliflozin for 12 weeks.
16292969|NCT04724824|Experimental|Brain-Computer Interface controlled robotic feedback|
16292970|NCT04724824|Sham Comparator|Sham Brain-Computer Interface controlled robotic feedback|
16292971|NCT04724811|Experimental|Weight-bearing as tolerated|Patients are instructed to mobilise the hip and weight-bear as tolerated
16292972|NCT04724811|Active Comparator|Touch-down weight-bearing|Patients are instructed to mobilise the hip. Touch-down weight-bearing for 6-8 weeks
16292973|NCT04724785||patients with persistant low level HBV DNA (<10 IU/ml)|No further intervention(s) to be administered except for monitoring of HBV DNA viraemia
16292974|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) but refuse to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen. If those patients refuse to change the regimen which they are using , No further intervention(s) to be administered except for monitoring of HBV DNA viraemia until those patients change their idea
16292975|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) and agree to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen.They will change their regimen according one which they are using.
16292976|NCT04724772|Experimental|Blepharoplasty patient|Patient receives LA in one eye and LA with TXA in the other eye. They are blinded. They compare eyes without knowing which one received the TXA.
16292977|NCT04724759|Experimental|Opioid-free Anesthesia|Patients in this arm will not receiving opioids but the total intravenous anesthetic during surgery. Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics.
16292978|NCT04724759|No Intervention|Standard Anesthesia|Patients in this arm will undergo the standard of care and receive opioids as part of their anesthetic regimen.
16292979|NCT04724746|Experimental|Written Exposure and Cognitive Behavioral Therapy|Participants receive 5 to 6, 60 minute, sessions of written exposure therapy for posttraumatic stress disorder combined with cognitive behavioral therapy for substance use disorder.
16292980|NCT04724733|No Intervention|Control|The control group will receive incentives for study participation but will not be introduced to the Smoke Sense app.
16292981|NCT04724733|Experimental|Smoke Sense|
16292982|NCT04724733|Active Comparator|Smoke Sense Plus|
16292983|NCT04724720|Active Comparator|Famotidine|Participants in this study arm will receive standard of care and prescribed famotidine at 80mg TID for a maximum of 14 days, or until hospital admission.
16292984|NCT04724720|Placebo Comparator|Placebo|Participants in this study arm will receive standard of care and placebo for a maximum of 14 days.
16292985|NCT04724707||Myocarditis|Proven or suspected myocarditis
16292986|NCT04724707||Heart failure|Heart failure (NYHA functional class II-IV) before or during hospitalization with COVID-19
16292987|NCT04724707||ACS|Combination of COVID-19 with ACS or development of ACS during hospitalization with COVID-19 or performed percutaneous coronary intervention
16292988|NCT04724707||Pulmonary embolism|Proven pulmonary embolism
16292989|NCT04724707||Arrhythmias|Hemodynamically significant arrhythmias (atrial fibrillation, high-grade ventricular premature beats, paroxysmal ventricular arrhythmias), including those associated with the QT interval prolongation
16293842|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome multi dose|
16292991|NCT04724694|Other|Treatment as usual only|Participants assigned to treatment as usual will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
16292992|NCT04724681|Active Comparator|Monitoring arm|Patients in this arm will have their vital signs monitored with continuous wireless devices and patients in this arm will be monitored with standard Early Warning Score
16292993|NCT04724681|No Intervention|standard Early Warning Score arm|Patients in this arm will be monitored with standard Early Warning Score
16292994|NCT04724668|Other|Morning light version+ Melatonin|Morning light version and melatonin 3mg capsule (3hrs before DLMO)
16292995|NCT04724668|Other|Morning light version+ Placebo|Morning light version and placebo capsule (3hrs before DLMO)
16292996|NCT04724655|Other|control group|gastric lavage with saline and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
16292997|NCT04724655|Active Comparator|paraffin group|gastric lavage with paraffin oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
16292998|NCT04724655|Active Comparator|coconut group|gastric lavage with coconut oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
16292999|NCT04724629|Experimental|IL-17 inhibitor (Ixekizumab)|Patients will receive study medication Ixekizumab 80 mg per week, (SC) once a week for 4 weeks or until discharge.
16293000|NCT04724629|Experimental|IL-2 (Aldesleukin)|1.5 million IU per day (SC) for 7 days or until discharge. Patients will receive study medication Aldesleukin 1.5 million IU per day (SC), for 7 days or until discharge.
16293001|NCT04724629|Experimental|Indirect IL-6 inhibitor (Colchicine)|Patients will receive study medication colchicine 0.5 mg every 8 hours for 3 days (PO), followed by 4 weeks (+/-7 days) 0.5 mg twice daily. If a dose is missed, it should not be replaced.
16293002|NCT04724629|Active Comparator|Standard of care|Standard treatment, supplementation of O2 ventilation + standard treatment of the institution, which may include Dexamethasone according to the institutional protocol.
16293003|NCT04724616|No Intervention|Control Group|Participants received no specific educational program
16293004|NCT04724616|Experimental|Intervention Group|Participants received our educational program for five days, with one teaching session per day. Every teaching session will be conducted for 60 minutes in a group of up to 6 children by a trained member of our staff.
16293005|NCT04724603||patients having had avderse event after phagotherapy for bone or joint infection|
16293006|NCT04724577|Experimental|Carbon ion treatment|dose escalation study with five dose levels [54GGyE(Gray equivalent)/12Fx,55.2GyE/12Fx,56.4GyE/12Fx,57.6GyE/12Fx and 58.8GyE/12Fx ].
16293007|NCT04724538|Experimental|Healthy volunteers|CT-scans for exclusion of pneumonia. Accumulated absorbed dose calculation of volunteers' lungs after inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 833 MBq of 99mTc-pertechnetate.
16293008|NCT04724538|Experimental|Patient with COVID-19 pneumonia|Inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 4165 MBq of 99mTc-pertechnetate. CT scans a day before, 7 and 14 days after inhalation procedure. Blood tests a day before, 1, 3 and 7 days after inhalation procedure.
16293009|NCT04724538|No Intervention|Patient with COVID-19 pneumonia without intervention|Blood tests at 1, 3 and 7 days.
16293010|NCT04724512|Active Comparator|polypropylene|patients randomised to receive polypropylene sutures.
16293011|NCT04724512|Active Comparator|polyglactin|patients randomised to receive polyglactin sutures.
16293012|NCT04724499|Experimental|High-Intensity Intervals Training|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control
~Participants assigned to the exercise group (HIIT), will receive an exercise bike and have 3 weekly supervised exercise training sessions for four (4) months/16weeks.
~Participants can choose to participate in the exercise sessions at home via zoom or in clinic.
~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post High-Intensity Intervals Training (HIIT) tests and four (4) month follow up test and receive 3 MRIs over the span of 9 months."
16293013|NCT04724499|Active Comparator|Attention Control|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control
~Participants assigned to the Attention Control group, will receive instruction on a 16 week home-based stretching program.
~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post home-based stretching program tests and receive 3 MRIs over the span of 9 months.
~At the end of the 16-week home-based stretching program, participants will be provided the option to participate in the High-Intensity Intervals Training (HIIT) program."
16293014|NCT04724486|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16293015|NCT04724486|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16293016|NCT04724473|Experimental|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16293017|NCT04724473|Active Comparator|RETIN-A® (Tretinoin) Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16293018|NCT04724473|Placebo Comparator|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
16293019|NCT04724460|Active Comparator|Long DOAC|Administration of Rivaroxaban for 18 months
16293020|NCT04724460|Active Comparator|Short DOAC|Administration of Rivaroxaban for 6 months
16293021|NCT04724447|Experimental|Valganciclovir|900 milligrams (mg) valganciclovir (VGCV) to be taken orally once per day for 8 weeks.
16293022|NCT04724447|Placebo Comparator|Placebo|Placebo equivalent of 900 milligrams (mg) VGCV to be taken orally once per day for 8 weeks.
16293023|NCT04724434||Study group|Patients with positive test for SARS-CoV-2 by PCR
16293024|NCT04724434||Control group|Patients with negative SARS-CoV-2 antibody test
16293025|NCT04724408|Experimental|VieScope|intubation with the VieScope laryngoscope
16293026|NCT04724408|Active Comparator|Conventional|intubation with MacIntosh-type laryngoscope
16293027|NCT04724382|Experimental|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
16293028|NCT04724382|Active Comparator|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
16293029|NCT04724369|Experimental|Study Cohort: Subjects with known or presumed neuroblastoma|"Drug: 18F-mFBG Positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for identification of neuroblastoma.
~Other Names:
~meta-fluorobenzylguanidine
~IRP101"
16293030|NCT04724356|Experimental|Virtual Reality Group|The Kinect based rehabilitation group received virtual reality therapy using Xbox Kinect-based games, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
16293031|NCT04724356|Experimental|Resistance exercise Group|The resistance exercise group received resistance training, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
16293032|NCT04724343|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16293033|NCT04724343|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
16293034|NCT04724330|Experimental|Healthy for Two/Healthy for You (H42/H4U)|Those assigned to the intervention group will receive the H42/H4U health coaching intervention during pregnancy and 12 weeks postpartum.
16293035|NCT04724330|No Intervention|Usual Care Comparison Group: Maintain Health in Pregnancy (mHIP)|Those assigned to the Usual Care comparison group, mHIP, will receive typical, evidence- and guideline-based experience in the prenatal care clinics.
16293036|NCT04724317|Sham Comparator|Steroid Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% added to triamcinolone 40 mg under the ultrasound guidance
16293037|NCT04724317|Active Comparator|Ozone Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by injection of 10 ml of Oxygen-Ozone mixture (15 µg/ml) under the ultrasound guidance
16293038|NCT04724317|Active Comparator|PRF Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by pulsed radiofrequency application under the ultrasound guidance
16293039|NCT04724304|Experimental|Healthy adults|Heathy adults will have blood flow to the heart evaluated using s Real-Time Myocardial Echocardiography (RTMPE) and magnetic resonance image (MRI) to the heart.
16293041|NCT04724265|Experimental|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation
16293042|NCT04724252|Active Comparator|Gabapentin Treatment|Given at a dose of 10mg/kg (max 600mg) perioperatively (immediately prior to surgery) followed by 3mg/kg/dose TID with first dose to be given starting at 8 hours post perioperative dose.
16293043|NCT04724252|Placebo Comparator|Control Group|Given placebo which coincides with the active treatment group
16293044|NCT04724239|Experimental|sintilimab + chidamide + IBI305|
16293045|NCT04724239|Experimental|sintilimab + chidamide|
16293046|NCT04724226|Experimental|C-couple|Camrelizumab and Apatinib after Cryoablation
16293047|NCT04724213|Other|Testing of reliability / validity of new questionnaire|
16293843|NCT04718844|Placebo Comparator|Placebo - Thalassaemia multi dose|
16293048|NCT04724200||Referred from primary care for investigation of suspected heart failure|All patients recruited to the OPERA trial will have been referred from their primary care clinician for investigation of a suspected diagnosis of heart failure.
16293049|NCT04724187|Experimental|intrauterine misoprostol and oxytocin|there will be added effect of misoprostol to stimulate uterine contraction along with oxytocin
16293050|NCT04724187|Active Comparator|oxytocin|only oxytocin will stimulate uterine contraction
16293051|NCT04724174||Pancreaticogastrostomy (PG) group|Patients underwent pancreatoduodenectomy with the PG technique
16293052|NCT04724174||Pancreaticojejunostomy (PJ) group|Patients underwent pancreatoduodenectomy with the PJ technique
16293053|NCT04724161||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Changara, Guro, and Chemba districts.
16293054|NCT04724148|Experimental|Injecting 1~2mg/kg fentanyl intravenously.|"Measuring HVPG after the preparation of TIPS in patients with portal hypertension;
~Measuring HVPG again 5 minutes later after injecting 1~2mg/kg fentanyl intravenously."
16293055|NCT04724135||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
16293056|NCT04724109||Equfina|Participants with parkinson's disease will be administered Equfina 50 milligram (mg) tablets, orally, once daily in combination with levodopa-containing products. On the basis of symptoms, Equfina 100 mg tablet, orally, once daily may be selected for participants. All the participants will be observed for up to 24 weeks prospectively.
16293057|NCT04724096||Non-patient volunteers|5 non-patient volunteers for testing of protocol to allow for the ascertaining of good quality data prior to the scanning of patients.
16293058|NCT04724096||Patients|50 patients to be scanned with the oxygen enhanced MRI scan protocol prior to definitive curative intent therapy.
16293059|NCT04724083||Fabry Disease subjects with cardiomyopathy|Patients (males and females) with confirmed Fabry disease, with clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
16293060|NCT04724083||Fabry Disease subjects without cardiomyopathy|Patients (males and females) with confirmed Fabry disease, without clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
16293061|NCT04724083||Healthy control|The control group will consist of age-and gender-matched healthy individuals.
16293062|NCT04724070||NGS and PDO/PDX establishment|
16293063|NCT04724044|Placebo Comparator|Placebo|These patients will be treated with 1 placebo tablet every 12 hours and intravenously with ceftriaxone 2g once daily as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.
16293064|NCT04724044|Active Comparator|Clarithromycin|These patients will be treated with 1 tablet of 500 mg of clarithromycin every 12 hours intravenously and with ceftriaxone 2g once daily as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.
16293065|NCT04724031||One cohort|women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
16293066|NCT04724018|Experimental|Dose Escalation Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV),|Participants will be given the study drugs Enfortumab Vedotin and then Sacituzumab Govitecan on Days 1 and 8 of a 21-day study cycle. Dose escalation and de-escalation for the Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) combination will be guided using the Bayesian optimal interval (BOIN) design with up to 4 dose level escalations.
16293067|NCT04723979||Exposed to recombinant FVIIa (NovoSeven®)|all women exposed to NovoSeven® during sPPH
16293068|NCT04723979||Standard of Care|Women with postpartum hemorrhage not exposed to NovoSeven®.
16293069|NCT04723953|Experimental|Acute myocardial infarction patient group|
16293070|NCT04723940|Active Comparator|Oral Antibiotics|Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
16293071|NCT04723940|Active Comparator|Intravenous Antibiotics|Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
16293072|NCT04723927||Older adults|The data for motor function and gait pattern analysis was obtained.
16293073|NCT04723914|Experimental|Treatment group|Dual target CAR-T cell therapy
16293074|NCT04723901|Experimental|Treatment group|Dual target CAR-T cell therapy
16293075|NCT04723888|Experimental|alpha-ketoglutarate Group|Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years
16293076|NCT04723888|No Intervention|Normal Control Group|Don't take alpha-ketoglutarate supplements
16293077|NCT04723875|Experimental|Adjuvant chemotherapy group|"Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors；participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors.
~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 2cm"
16293078|NCT04723875|No Intervention|Control group|The participants receive no intervention.
16293079|NCT04723862|Experimental|Spironolactone|Prior to the first or second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
16293080|NCT04723862|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
16293081|NCT04723849|Experimental|Tretment group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
16293082|NCT04723849|Placebo Comparator|Placebo group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
16293083|NCT04723836|Active Comparator|TT genotype active comparator group|5mg riboflavin per day from 16th gestational week
16293084|NCT04723836|Experimental|TT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
16293844|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome|
16293087|NCT04723836|Experimental|CT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
16293088|NCT04723836|Placebo Comparator|CT genotype placebo group|Placebo supplement from 16th gestational week
16293089|NCT04723823|Experimental|fMRI w/ motor or sensory imagery|Individuals will be asked to imagine movements or sensations while fMRI is used to measure brain activity.
16293090|NCT04723810|Experimental|Cohort 1|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has not been fully studied will be enrolled: glioma, breast cancer, colon cancer, rectal cancer, head and neck cancer, pulmonary metastasectomy (colorectal mets), thymoma, ovarian cancer, prostate cancer, renal cell carcinoma, thyroid cancer, parathyroid adenoma, mesothelioma, esophageal cancer, pancreas cancer, stomach cancer.
16293091|NCT04723810|Experimental|Cohort 2|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has been fully studied will be enrolled: non-small cell lung cancer, metastatic sarcoma to the lung, brain meningioma.
16293092|NCT04723797|No Intervention|Control group|The participants in the control group will be asked to maintain their lifestyle as before the study.
16293093|NCT04723797|Experimental|Moderate-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 150min/week. This at a moderate intensity, which means a slightly increased heart rate and breathing also talking is possible.
16293094|NCT04723797|Experimental|Vigorous-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 75min/week. This at a vigorous intensity, which means increased heart rate and breathing also talking is possible.
16293095|NCT04723784|Experimental|Person with disability|"Initial assessment.
~Implementation of AT in the daily life of participants
~Application of outcome measures and analysis of the data"
16293096|NCT04723758|Experimental|GI Genius-assisted colonoscopy (GGC)|In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.
16293097|NCT04723758|Active Comparator|Standard Colonoscopy (SC)|In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.
16293098|NCT04723745||VTRACTS|We will target post-9/11 Veterans with TBI or blast exposure who self-report ongoing post-concussive neurobehavioral symptoms, but V-TRACTS will be open to all post-9/11 Veterans irrespective of any diagnoses.
16293099|NCT04723732|Experimental|Myrrh mouthwash|1% mouthwash of Commiphora myrrha made from resin extract. Participants will use 10 ml of the mouthwash twice daily for 14 days.
16293100|NCT04723732|Active Comparator|Chlorhexidine Mouthwash|Commercial 0.2% Chlorhexidine gluconate mouthwash (Avalon Pharma, Riyadh). Participants will use 10 ml of the mouthwash twice daily for 14 days.
16293101|NCT04723732|Placebo Comparator|Normal saline|Commercial 0.9% sodium chloride solution (Pharmaceutical solutions industry, Jeddah). Participants will use 10 ml of the mouthwash twice daily for 14 days.
16293102|NCT04723719|Experimental|SIESTA training + treatment as usual for ADHD|We developed a cognitive behavioral therapy for sleep problems in adolescents with ADHD. This includes seven individual sessions with the adolescent and two individual sessions with the parent(s)/guardian(s). Participants receive this CBT training called SIESTA next to their treatment as usual for ADHD symptomatology (mostly ADHD-medication).
16293103|NCT04723719|Active Comparator|Treatment as usual for ADHD only|Participants continue their treatment as usual for ADHD (mostly ADHD-medication).
16293104|NCT04723693||individuals With Haemophilia A and with inhibitors on emicizumab|Qualitative interviews
16293105|NCT04723680||Early dose finding cohort|People with Haemophilia who took part in the early dose finding studies
16293106|NCT04723680||Subsequent studies group cohort|People with haemophilia who took part in subsequent gene therapy studies
16293107|NCT04723680||Withdrawn/ineligible Cohort|People with haemophilia who were withdrawn or proved ineligible
16293108|NCT04723680||Not interested cohort|People with haemophilia who are definitely not interested in gene therapy
16293109|NCT04723680||Not offered cohort|People with haemophilia who are interested in gene therapy but have not been the opportunity to take part
16293112|NCT04723654||ICU Population|Patients admitted to one of 3 ICUs at Lurie Childrens
16293113|NCT04723654||Non-ICU Population|Healthy volunteers who are under 18 years of age, whose parents consent to their participation, and who are willing to visit CAMP for a one time study visit can participate in this study.
16293114|NCT04723641|Experimental|STUDY GROUP|they received progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
16293115|NCT04723641|No Intervention|control group|received a designed physical therapy program
16293116|NCT04723628|Experimental|Experimental group|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
16293117|NCT04723628|No Intervention|Control group|All data forms were then completed, and the HbA1c value was taken from the medical data. No additional procedure was performed to the control group. The research data were collected again at the end of 12 weeks.
16293118|NCT04723602|Active Comparator|cAd3-Marburg at 1 x 10^11 Particle Units (PU)|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
16293119|NCT04723602|Active Comparator|cAd3-EBO-S at 1 x 10^11 PU vaccine|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
16293120|NCT04723589|No Intervention|Standard Arm|Participants randomized to standard care will not receive an intervention but will participate in other study procedures, which are blood collection and data collection.
16293121|NCT04723589|Experimental|Intervention Arm|Participants randomized to the intervention arm will receive standard care plus an infusion of thawed plasma, starting rate 30 ml/hour for 24 hours, increased to 50 ml/hour if deemed to be hypovolemic (low fluid volume). Only non-convalescent (COVID-antibody-free) plasma will be used.
16293122|NCT04723576|Experimental|Stress First Aid|"The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. SFA sites will implement SFA through a train-the-trainer model."
16293123|NCT04723576|No Intervention|Usual Care|The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. UC sites will not implement SFA during the study period but will be given full access to all implementation materials following the conclusion of their participation.
16293124|NCT04723563|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: Four times per day Duration: until hospital discharge
16293125|NCT04723563|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: Four times per day Duration: until hospital discharge
16293126|NCT04723550|Experimental|Telemedicine|Diabetes education and support by telemedicine
16293127|NCT04723550|Active Comparator|Usual care|Diabetes education and support in person
16293128|NCT04723537|Experimental|Part A: Upamostat 200 mg|Each day participants will receive a single 200 mg dose of upamostat along with a single matching placebo, for a total of 14 days.
16293129|NCT04723537|Experimental|Part A: Upamostat 400 mg|Each day participants will receive two 200 mg doses of upamostat, for a total of 14 days.
16293130|NCT04723537|Placebo Comparator|Part A: Placebo|Each day participants will receive two matching placebos, for a total of 14 days.
16293131|NCT04723537|Experimental|Part B: Upamostat|Based on dose selected from Part A, each day participants will receive EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
16293132|NCT04723537|Placebo Comparator|Part B: Placebo|Based on dose selected from Part A, each day participants will receive EITHER a single matching placebo OR two matching placebos, for a total of 14 days.
16293133|NCT04723524|Experimental|Treatment group|150 Cases, treated with Jinhua Qinggan (JHQG) Granules
16293134|NCT04723524|Placebo Comparator|Control group|150 Cases, Placebo treated
16293135|NCT04723511|Experimental|GPR|participants in this group receive global postural reeducation technique+ Kendall exercises
16293136|NCT04723511|Active Comparator|Kendall|Kendall exercises
16293137|NCT04723498|Other|Patients|male and female patients, handled on an ambulatory basis in Psychiatric University Clinics, Department of Child and Adolescent Psychiatrythe ages from 8 - 18 years during the study
16293138|NCT04723472|Active Comparator|Classic bismuth quadruple treatment group|
16293139|NCT04723472|Experimental|Cefuroxime containing bismuth quadruple treatment group|
16293140|NCT04723459|Active Comparator|Ivermectin mask group|Contacts who will use ivermectin masks
16293141|NCT04723459|No Intervention|ordinary mask group|Contacts who will use regular masks
16293142|NCT04723446|Experimental|Group 1 (test group; n= up to 10 patients) - 0.2 % Chlorhexidine digluconate|Participants will be instructed to rinse their mouth with 10 ml of Corsodyl® Alcohol free mouthwash for 1 minute.
16293143|NCT04723446|Experimental|Group 2 (test group; n= up to 10 patients) - 1.5% Hydrogen peroxide|Participants will be instructed to rinse their mouth with 10 ml of Colgate® Peroxyl mouthwash for 1 minute.
16293144|NCT04723446|Experimental|Group 3 (test group; n= up to 10 patients) - Cetylpyridinium chloride|Participants will be instructed to rinse their mouth with 10 ml of Oral-B® Gum & Enamel Care mouthwashes for 1 minute.
16293145|NCT04723446|Experimental|Group 4 (control group; n= up to 10 patients) - No rinsing|Patients will be instructed to not rinse their mouth with any solution, not even water.
16293146|NCT04723433|Experimental|"Conservative O2 Supplementation"|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
16293147|NCT04723433|Active Comparator|"Liberal O2 Supplementation"|Oxygen administration will titrated to an SpO2 > 96%.
16293148|NCT04723420|Active Comparator|Steamroller Technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
16293149|NCT04723420|Active Comparator|Direct Technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
16293150|NCT04723407||Exposed patients|Those who had the management strategy implemented by the service during confinement
16293151|NCT04723407||Unexposed patients|Those who could not benefit from this strategy
16293152|NCT04723394|Experimental|AZD7442|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 850) will receive a single dose (× 2 IM injections) of 600 mg of AZD7442.
16293153|NCT04723394|Placebo Comparator|Placebo|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 850) will receive saline placebo.
16293154|NCT04723381|Experimental|Experimental|Partivipants recieved web based genital hygiene education for seven week
16293155|NCT04723381|No Intervention|Control|No intervention was applied to the women in the control group
16293156|NCT04723368|Experimental|Automated flying Drone carrying an Automated external defibrillator (AED)|Five drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating time benefit of drone delivery of AEDs in suspected OHCA.
16293158|NCT04723342|Experimental|Blinatumomab|Consolidation therapy with Blinatumomab administration
16293159|NCT04723329|Experimental|web-based education group|Patients will be given a username and password to access the website. The change stage of the patients will be determined by the researcher with the Exercise Change Phase Short Question Form, and it will be ensured that they reach the educational content prepared according to the transtheoretic model. Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
16293160|NCT04723329|No Intervention|Control Group|In the first interview, the patients in the control group will be collected data and contact information will be obtained using the Patient Information Form, Exercise Change Phase Short Question Form, Change Processes Scale, Decision Making Balance Scale and Self-Efficacy Scale. Later, patients will be given their username and password so that they can log into the website where the scales are located in order to apply the final test. No intervention will be applied to the patients in the control group. At the end of the 6th month, the same scales will be applied on the website as a final test. At the end of the study, it is aimed to gain exercise behavior to the patients in the control group.
16293161|NCT04723303|Experimental|Treatment Arm|A single IV infusion of ULSC's in patients with DM or PM
16293162|NCT04723290|Experimental|Serological tests|All staff at GHdC who want to know their level of antibodies against SARS CoV-2
16293163|NCT04723277|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|"Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
~Baseline pre-intervention data will be collected and endline post-intervention data will be collected"
16293164|NCT04723277|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|"Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
~Baseline pre-intervention data will be collected and endline post-intervention data will be collected"
16293165|NCT04723277|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|"Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
~Baseline pre-intervention data will be collected and endline post-intervention data will be collected"
16293166|NCT04723277|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|"EUC (control arm)
~Baseline pre-intervention data will be collected and endline post-intervention data will be collected"
16293167|NCT04723277|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|"Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
~Baseline pre-intervention data will be collected and endline post-intervention data will be collected"
16293168|NCT04723277|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|"Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
~Baseline pre-intervention data will be collected and endline post-intervention data will be collected"
16293169|NCT04723264|Experimental|Eating behavior activities|
16293170|NCT04723251|Experimental|Taking Photographs|Participants will be asked to take photos with their cell phone.
16293171|NCT04723238|Experimental|Duloxetine Test Product|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
16293172|NCT04723238|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
16293173|NCT04723225|Experimental|Experimental|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided.
16293174|NCT04723225|No Intervention|Control|In control intervention group usual care will be provided.
16293175|NCT04723212||Younger healthy adults|Healthy subjects in the age group of 18-30 years old, and without history of any neurological condition
16293176|NCT04723212||Older healthy adults|Healthy subjects aged 55 years and older, and without history of any neurological condition
16293177|NCT04723186|Experimental|MT1002|MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) via IV access prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure.
16293178|NCT04723173|Experimental|Noise reduction on|The noise reduction is activated. The feature shall support the hearing aid user in noisy situations and shall reduce the listening effort in these special situations.
16293179|NCT04723173|Active Comparator|Noise reduction off|To compare the advantage of the special noise reduction feature the tests will be done additionally with the deactivated feature.
16293180|NCT04723160||Test Group|ophthalmologists read images applying the assistant software
16293181|NCT04723160||Control Group|ophthalmologists read images independently
16293182|NCT04723147|Experimental|Carbidopa Levodopa followed by Placebo|Participants will receive first Carbidopa Levodopa at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day; and then placebo.
16293183|NCT04723147|Experimental|Placebo followed by Carbidopa Levodopa|Participants will receive first placebo, and then Carbidopa Levodopa (L-DOPA) at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day.
16293186|NCT04723121|Other|High risk NMIBC|Patients with primary or recurrent NMIBC for whom primary TURBT was done and intravesical BCG was administered
16293187|NCT04723108|Experimental|Virtual reality arm|Participants will be asked to use virtual reality during their infusion for a duration of at least 10 minutes.
16293188|NCT04723095||Observational (medical chart review)|Patients' medical records are reviewed retrospectively and prospectively. Patients are followed up by email, telephone, or U.S. mail every 4 months for up to 10 years from date of initial study enrollment. Patients, who are beyond 5 years from their initial diagnosis, are followed up by email, telephone, or U.S. mail annually.
16293189|NCT04723069|Experimental|Fuke Qianjin capsule|"Metronidazole tablets Simulant + Doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
~Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
16293190|NCT04723069|Active Comparator|Metronidazole tablets + Doxycycline hyclate tablets|"Metronidazole tablets + Doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
~Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
16293191|NCT04723056|No Intervention|Control Group (TAU only)|Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy.
16293192|NCT04723056|Experimental|Experimental (TAU plus CBT)|Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).
16293193|NCT04723043|Active Comparator|v group|patients will ventilate with volume controlled mode
16293194|NCT04723043|Active Comparator|p group|patients will ventilate with pressure controlled mode
16293195|NCT04723030|Experimental|carleilizumab in combination with apathy mesylate and chemoradiotherapy (paclitaxel (albumin-bound)|Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped.
16293196|NCT04723004|Active Comparator|Experimental group|Toripalimab combined with Bevacizumab
16293197|NCT04723004|Active Comparator|Control group|Sorafenib
16293198|NCT04722991|Experimental|Runcaciguat (BAY1101042), High dose, Part A and B|
16293199|NCT04722991|Experimental|Runcaciguat (BAY1101042), Medium-high dose, Part B|
16293200|NCT04722991|Experimental|Runcaciguat (BAY1101042), Medium-low dose, Part B|
16293201|NCT04722991|Experimental|Runcaciguat (BAY1101042), Low dose, Part B|
16293202|NCT04722991|Placebo Comparator|Placebo, Part A and B|
16293203|NCT04722978|Active Comparator|Experimental group|Gemcitabine combined with carboplatin plus moxifloxacin
16293204|NCT04722978|Placebo Comparator|Control group|Gemcitabine combined with carboplatin plus placebo
16293205|NCT04722965|Active Comparator|Fistulotomy with marsupialization|40 patients with a simple low transsphincteric anal fistula. A fistulotomy with marsupialization is performed.
16293206|NCT04722965|Active Comparator|Fistulotomy with open wound|40 patients with a simple low transsphincteric anal fistula. A fistulotomy leaving the wound open is performed.
16293207|NCT04722952|Experimental|Anti-PD-1 mAb Combined With Azacytidine and HAG regimen|Anti-PD-1 mAb combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen
16293208|NCT04722939||Critical illness with acute kidney injury|See below for detailed inclusion/exclusion criteria
16293209|NCT04722926||PJI|Patients having had a PJI
16293210|NCT04722900||non-GDM|
16293211|NCT04722900||GDM|
16293212|NCT04722887|Experimental|Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)|Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.
16293213|NCT04722887|Experimental|Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)|Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
16353275|NCT04305522|Placebo Comparator|Placebo group|Identical placebo
16293214|NCT04722887|Experimental|Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)|Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.
16293215|NCT04722887|Experimental|Cohort 2: Treatment Period 1 (Alpha-1 15%, 144 mg/kg)|Participants will receive Alpha-1 15% 144 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.
16293216|NCT04722887|Experimental|Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)|Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
16293217|NCT04722887|Experimental|Cohort 2: Treatment Period 2 (Alpha-1 15%, 144 mg/kg)|Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 144 mg/kg, for 8 weekly SC infusions.
16293218|NCT04722874|Active Comparator|Ortho-k|Participants will continue to use ortho-k lenses alone.
16293219|NCT04722874|Experimental|RLRL+Ortho-k|Participants will be treated with RLRL twice a day in addition to ortho-k lenses.
16293220|NCT04722861||Primary Glaucoma|Patients with primary glaucoma diagnosed by glaucoma professionals
16293221|NCT04722861||Glaucoma Suspect Controls|Glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
16293222|NCT04722848|Experimental|Ponatinib+Blinatumomab|patients will receive induction with ponatinib followed by at least 2 cycles of blinatumomab
16293223|NCT04722848|Active Comparator|Chemotherapy+Imatinib|patients will receive a combination of imatinib and chemotherapy.
16293224|NCT04722835||Normal RV/TLC Group:|Plethysmographic RV/TLC equal or less than lower limit of normal.
16293225|NCT04722835||Abnormal RV/TLC Group:|Plethysmographic RV/TLC higher than lower limit of normal.
16293226|NCT04722822|Experimental|Providers recommending HPV vaccine at age 9-10 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 9-10 years of age.
16293227|NCT04722822|Active Comparator|Providers recommending HPV vaccine at age 11-12 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 11-12 years of age.
16293228|NCT04722809|Experimental|Symptomatic patients in the context of bruxism|
16293229|NCT04722796|Experimental|TAVR with Supra-annular sizing strategy|"Experimental: Supra-annular sizing strategy (Hangzhou Solution).
~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.
~Waist sign with less than mild contrast regurgitation: Venus A plus Valve down size and Target implant depth 0-2mm.
~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: annular sizing Venus A plus Valve with implant depth 4-6mm."
16293230|NCT04722796|Other|TAVR with Annulus based sizing strategy|"Control: Traditional sizing strategy (Annulus based sizing strategy).
~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.
~Annular sizing Venus A plus Valve with implant depth 4-6mm."
16293231|NCT04722783|Experimental|ESDM and PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months PCIT-A for 8 months (see Study Protocol, Figure 2).
16293232|NCT04722783|Experimental|ESDM and active control for PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months 1h-ESDM as active control instead of 1h-PCIT-A for 8 months
16293233|NCT04722783|Experimental|PCIT-A and active control for ESDM|Participants receive after 4 month PCIT-A for 8 months and early special needs education as an active control for ESDM.
16293234|NCT04722783|Active Comparator|Active control for ESDM and PCIT-A|Participants receive early special needs education as an active control for ESDM and PCIT-A.
16293235|NCT04722770||Pediatric patients with possible ear infections|Pediatric patients presenting with otitis media (acute otitis media or otitis media with effusion) will be imaged with the PhotoniCare OtoSight.
16293236|NCT04722757|Experimental|transanal IPAA|In the experimental arm, patients will undergo transanal dissection of the distal part of the rectum. After proctectomy, an ileal pouch-anal anastomosis (IPAA) will be created. A Gelpoint Path will be used to create access through the anus. Postoperative care will occur following the hospital specific protocols.
16293237|NCT04722757|Active Comparator|transabdominal IPAA|In the control group, proctectomy will occur through abdominal dissection (laparoscopy, single port laparoscopy, robotic or open). Postoperative care will occur following the hospital specific protocols.
16293238|NCT04722744|Experimental|screwmented metal frameworks based on virtual implant position.|this group will receive a CAD CAM restoration based on virtually planned implant position.
16293239|NCT04722744|Active Comparator|screw-retained metal frameworks based on actual implant position.|this group will receive screw retained CAD CAM restoration based on actual implant position using conventional open tray impression.
16293240|NCT04722731|Experimental|Confident Parents - Brave Children|"The Confident Parents - Brave Children (CPBT) is a group parent training targeted to anxious parents, delivered by a psychologist via video conference (the Zoom software solution).
~The CPBT will comprise six 120-minutes digital sessions. One month after the last group session, all parents will be offered to have an individual booster session with a psychologist over Zoom."
16293241|NCT04722731|Active Comparator|Self-help book|"In the control group, participants will receive a parenting book, titled What all parents ought to know. This is a self-help book for parents, partly based on the scientifically evaluated parent program All Children in Focus."
16293242|NCT04722718|Experimental|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Drug:Sintilimab;Drug:Apatinib;Drug:Albumin-Bound Paclitaxel(Nab-Paclitaxel);Drug:Carboplatin
16293243|NCT04722705|Experimental|combined IPL/fractional Er:YAG laser treatment site|"At baseline, three lesions were randomized to IPL / fractional Er:YAG laser combination therapy site.
~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed all laser treatments including IPL and 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.
~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
16293244|NCT04722705|Active Comparator|fractional Er:YAG laser treatment alone site|"At baseline, three lesions were randomized to fractional Er:YAG laser combination therapy site.
~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.
~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
16293245|NCT04722705|No Intervention|untreated control site|At baseline, three lesions were randomized to untreated control site. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The evaluation of scar site was conducted 3 months later after last treatment.
16293246|NCT04722692|Experimental|Delayed SLND (SPIO-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.
~At reoperation, SPIO is the primary detection tracer."
16293247|NCT04722692|Active Comparator|Late SLND (RI-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.
~At reoperation, Tc is the primary detection tracer."
16293250|NCT04722666|Experimental|MIJ821 (mg/kg) - very low dose|MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
16293251|NCT04722666|Experimental|MIJ821 (mg/kg) - low dose|MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
16293252|NCT04722666|Experimental|MIJ821(mg/kg) - high dose|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
16293253|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
16293254|NCT04722666|Placebo Comparator|Placebo|40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
16293255|NCT04722666|Experimental|MIJ821 (mg/kg) - high dose/Placebo|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
16293256|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose/Placebo|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
16293257|NCT04722653|Experimental|NN0194-0499|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo, Asian participants will only receive NNC0194-0499. There will be 3 cohorts with escalating dose levels. There should be at least 4 days between dose administration of the last participant in a dose level cohort and dose administration of the first participant in the following dose level cohort.
16293258|NCT04722653|Placebo Comparator|Placebo|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo.
16293259|NCT04722640|Experimental|RISAKIZUMAB|SKYRIZI
16293260|NCT04722627|Experimental|AT-752 250 mg single dose|AT-752 administered orally, 250 mg on Day 1
16293261|NCT04722627|Placebo Comparator|Placebo -single dose|Matching placebo administered orally on Day 1
16293262|NCT04722627|Experimental|AT-752 500 mg single dose|AT-752 administered orally, 500 mg single doses on Day 1 and Day 7
16293263|NCT04722627|Placebo Comparator|Placebo- single dose|Matching placebo administered orally on Day 1 and Day 7
16293264|NCT04722627|Experimental|AT-752 1000 mg single dose|AT-752 administered orally, 1000 mg single dose on Day 1
16293265|NCT04722627|Placebo Comparator|Placebo - single dose|Matching placebo administered orally on Day 1
16293266|NCT04722627|Experimental|AT-752 1500 mg single dose|AT-752 administered orally, 1500 mg single dose on Day 1
16293267|NCT04722627|Placebo Comparator|Placebo: single dose|Matching placebo administered orally on Day 1
16293268|NCT04722627|Experimental|AT-752 - 1000 mg QD multiple doses|AT-752 - administered orally, 1000 mg once daily (QD) for 7 days
16293269|NCT04722627|Placebo Comparator|Placebo - Administered once daily (QD)|Matching placebo administered orally once daily (QD) for 7 days
16293270|NCT04722627|Experimental|AT-752 - 500 mg twice daily (BID)|AT-752 administered orally, 500 mg twice daily (BID) for 7 days.
16293271|NCT04722627|Placebo Comparator|Placebo - Administered twice daily (BID)|Matching placebo administered orally twice daily (BID) for 7 days.
16293272|NCT04722614|Active Comparator|Control group|Mechanically ventilated patients who will be subjected to the routine unit intervention for agitation
16293273|NCT04722614|Experimental|Music group|Mechanically ventilated patients who will listen to classic music
16293274|NCT04722614|Experimental|Essential oil group|Mechanically ventilated patients who will inhale bergamot oil
16293275|NCT04722601|Experimental|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 / Starting Dose|"Phase 1/the dose-finding arm of this study will use three dose levels (a starting dose, second dose and highest dose) of the venetoclax, CC-486 and obinutuzumab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to groups 2 and 3 to take higher doses until the safest/ most tolerable dose is found.
~Group 1/ Dose Level 1:
~Participants in group 1 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at a starting dose used in previous human studies. Participants in this group will receive:
~Venetoclax:
~400 mg on days 1-28
~CC-486:
~200 mg on days 1-14
~Obinutuzumab:
~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.
~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
16293276|NCT04722601|Experimental|Phase 2 (Efficacy Arm/ Expansion Cohort)|Participants in this arm will help test the efficacy of the three-drug regimen and dose established in the phase 1 of the study. Participants will take two drugs (venetoclax and CC-48) used in the same three-drug regimen during the first phase of this study. These two drugs will be paired together by themselves and given to participants in the expansion cohort before obinutuzumab (a third drug) is added during cycle 4 of treatment.
16355833|NCT04287205|Experimental|women with endometriosis|
16293277|NCT04722601|Experimental|Phase 1(Dose-Finding Arm): Group 2 - Dose Level 2 /Second Dose|"Participants in group 2 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the second highest dose (dose level 2) set by doctors leading the study. Participants in this group will receive:
~Venetoclax:
~600 mg on days 1-28
~CC-486:
~200 mg on days 1-14
~Obinutuzumab:
~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.
~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
16293278|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 3 - Dose Level 3/ Highest Dose|"Participants in group 3 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the highest dose (dose level 3) set by doctors leading the study. Participants in this group will receive:
~Venetoclax:
~800 mg on days 1-28
~CC-486:
~200 mg on days 1-14
~Obinutuzumab:
~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.
~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
16293279|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 4 - Lower Dose Level 1|"Participants in this group will received a lower dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:
~Venetoclax:
~400 mg on days 1-28
~CC-486:
~150 mg on days 1-14
~Obinutuzumab:
~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
16293280|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 5 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:
~Venetoclax:
~400 mg on days 1-10 only
~CC-486:
~150 mg on days 1-14
~Obinutuzumab:
~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
16293281|NCT04722588|No Intervention|Control period|The control period is represented by standard care procedures, which are similar in all three EDs: Patients cared for in the EDs receive treatment from ED physicians and nurses, and no pharmacists are involved in any of the EDs.
16293282|NCT04722588|Experimental|Intervention period|"During the intervention period, clinical pharmacists will be present in the EDs from 08.00 - 19.00 Monday to Friday.
~The ED pharmacists will collaborate with the interdisciplinary team and perform the following tasks as appropriately as possible and by prioritized need; medication history taking, medication reconciliation, medication review, drug therapy recommendations, guidance on drug administration, medication information and counseling to patients/next of kin and health care personnel and communication about medications and changes in medication regimes. Standardized procedures, like the integrated medicines management (IMM) methodology, will be applied where possible. How, when and which task will be performed for each patient cannot be predetermined, but must be performed according to patient's needs and eventual time constraints."
16293283|NCT04722575|Experimental|ARM A|"Arm A BRAF mutated patients. Over a period of 6 weeks (1) + (2):
~Vemurafenib 960 mg bid p.o. from week 1 to week 6.
~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
16293284|NCT04722575|Experimental|ARM B|"Arm B BRAF mutated patients. Over a period of 6 weeks (1) + (2) + (3):
~Vemurafenib 720 mg bid p.o. from week 1 to week 6.
~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6. Week 4 off.
~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 4 and day 1 of week 7).
~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
16293285|NCT04722575|Experimental|ARM C|"Arm C BRAF WT patients. Over a period of six weeks (1) + (2):
~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6,
~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 1 and day 1 of week 4).
~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
16293286|NCT04722562|Experimental|Child Pugh A|Participants with mild hepatic impairment
16293287|NCT04722562|Experimental|Child Pugh B|Participants with moderate hepatic impairment
16293288|NCT04722562|Experimental|Healthy participants|Participants with normal hepatic function
16293289|NCT04722549|Placebo Comparator|Placebo|Placebo (cellulose)
16293290|NCT04722549|Active Comparator|Butyrate|Sodium butyrate
16293291|NCT04722536||Cervico-isthmic cerclage|Are included in this group the women who underwent cervico-isthmic cerclage between January 1, 2010 and April 1, 2019, in 3 hospitals of the Hospices Civils de Lyon, respecting the inclusion and exclusion criteria, to assess the primary and secondary outcomes before and after performing the cerclage.
16293292|NCT04722523|Experimental|Head and Neck Squamous Cell Cancer/HNSCC|Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
16293293|NCT04722510|Experimental|Effect of repeated TMS on aggressive impulse behavior in patients with BPD.|A protocol of 15 sessions of repeated Transcranial Magnetic Stimulation at 1 Hz on right dorsolateral prefrontal cortex.
16293294|NCT04722497||Physicians and nurses|All physicians, nurses, involved in a cesarean births are included in the cohort.
16293295|NCT04722497||Patients undergoing cesarean births|All patients undergoing cesarean births
16293296|NCT04722484|Experimental|Patients with normal creatine clearance (CLCR)|Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day)
16293297|NCT04722484|Experimental|Normal renal function (Healthy subjects)|Subjects with creatinine clearance at pre-profile day >80 ml/min
16293298|NCT04722484|Experimental|Mildly impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min
16293299|NCT04722484|Experimental|Moderately impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 30-<50 ml/min
16293300|NCT04722484|Experimental|Severely impaired renal function|Subjects with creatinine clearance at pre-profile day <30 ml/min
16293301|NCT04722471||400 mg|Treatments where 400 mg tablet presentation of micronized vaginal progesterone was used, the protocol being one vaginal tablet twice a day.
16293302|NCT04722471||200 mg|Treatments where 200 mg tablet presentation of micronized vaginal progesterone was used, the protocol being two vaginal tablets twice a day.
16293303|NCT04722458||Patients with Lower urinary tract sypmtoms|Patients with Lower urinary tract sypmtoms over 18 years old will be included to this study
16293304|NCT04722432|Experimental|Système de cathéter détachable dehors du scope (DDS)|
16293305|NCT04722419|Experimental|Functional dyspepsia|
16293306|NCT04722419|Active Comparator|Healthy subjects|
16293307|NCT04722406||Low TGR group|Patients with low level of TGR determined by X-tile program
16293308|NCT04722406||High TGR group|Patients with high level of TGR determined by X-tile program
16293309|NCT04722393|Experimental|Pulmonary Rehabilitation Group|An 8-week comprehensive outpatient PR program including respiratory exercises, aerobic and strengthening training
16293310|NCT04722393|Other|Control Group|Respiratory exercises
16293311|NCT04722380|Experimental|test group|10 infrabony defects treated surgically with Nigella Sativa oil extract Mixed with xenograft
16293312|NCT04722380|Placebo Comparator|control group|10 infrabony defects treated surgically with xenograft alone
16293313|NCT04722367|Experimental|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
16293314|NCT04722354|Active Comparator|ABA group|95 ug 2x/day for 14 days
16293315|NCT04722354|Placebo Comparator|Placebo group|Corn Starch 300 mg for 14 days
16293316|NCT04722341|Experimental|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
16293317|NCT04722341|Active Comparator|Control|More than equal to a 12-hour daily eating period
16293318|NCT04722328||CNS infection|
16293319|NCT04722328||Non-CNS infection|
16293320|NCT04722315|Experimental|MAD diet group|15 adult participants with confirmed KMT2D pathogenic mutations. Baseline labs and education about Modified Atkins Diet. Then 12 weeks on a Modified Atkins Diet. Weekly urine dips for ketones and diet logs. Blood draw every 3 weeks.
16293321|NCT04722289|Experimental|Together on Diabetes|The intervention consists of five components: Recruitment of peers and peer supporters; training of peer supporters; matching peers and peer supporters; individual face-to-face meetings between peers and peer supporters; and ongoing supervision and network meetings for peer supporters.
16293322|NCT04722276|Active Comparator|fraction of inspired oxygen 80%|
16293323|NCT04722276|Experimental|Fraction of inspired oxygen 100% with positive end expiratory pressure|
16293327|NCT04722237|Experimental|Immediate Acceptance and Commitment Therapy|Receiving 6-to-12 weekly sessions of Acceptance and Commitment Therapy immediately after allocation. Each session will be up to one hour in length.
16293328|NCT04722237|No Intervention|Waitlist Control|Receiving no intervention during a 12-week wait, though no restrictions will be placed on the use of other services. After the wait participants will receive 6-to-12 weekly sessions of Acceptance and Commitment Therapy. Each session will be up to one hour in length.
16293329|NCT04722224|Experimental|Intervention: Home-based pulmonary rehabilitation|Patients will be treated for 12 weeks. The intervention consists in a strategic mixture of home visits and phone calls. The program includes exercise training and the self-management educational program Living Well with COPD.
16293330|NCT04722211|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
16293331|NCT04722211|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
16293332|NCT04722198|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
16293333|NCT04722185|Experimental|Evaluation of the Veriton SPECT/CT system|To determine if the Veriton system can achieve equal or better image quality than a standard SPECT/CT system.
16293334|NCT04722172|Experimental|Acalabrutinib Combined With Obinutuzumab|Patients will receive acalabrutinib for a minimum of 13 cycles and maximum 26 cycles and Obinutuzumab will be administered during Cycles 2-7. This will be followed by treatment-free observation through the 65th cycle. Patients who progress during the observation period, per iwCLL criteria, will receive 13 cycles of acalabrutinib in combination with obinutuzumab in the retreatment phase of this study.
16293335|NCT04722159||Treatment resistent hypertensives, treated with renal denervation|Patients having undergone renal denervation and fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
16293336|NCT04722159||Treatment resistent hypertensives, conservatively treated|Patients fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
16293337|NCT04722146|Experimental|Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide|Participants will receive teclistamab plus daratumumab plus pomalidomide.
16293338|NCT04722146|Experimental|Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib.
16293339|NCT04722146|Experimental|Treatment Regimen C: Teclistamab + Nirogacestat|Participants will receive teclistamab plus nirogacestat.
16293340|NCT04722146|Experimental|Treatment Regimen D: Teclistamab + Lenalidomide|Participants will receive teclistamab plus lenalidomide.
16293341|NCT04722146|Experimental|Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide|Participants will receive teclistamab plus daratumumab plus lenalidomide.
16293342|NCT04722133|Experimental|HERZUMA+mFOLFOX|
16293343|NCT04722120|Active Comparator|Conventional liver CT|Underwent conventional liver CT on HCC high-risk patient
16293344|NCT04722120|Experimental|Spectral CT|Underwent spectral liver CT with 30% lower radiation dose and 20% contrast media on HCC high-risk patient
16293345|NCT04722107|Experimental|Single arm|Single arm
16293346|NCT04722094||Patients with Psoriasis|All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study
16293347|NCT04722081|Experimental|Control Group|children received selected physical therapy exercises
16293348|NCT04722081|Experimental|Study Group|children received selected physical therapy exercises plus virtual reality training
16293349|NCT04722068|Experimental|Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial|
16293350|NCT04722055||Study group|Single arm of continuously enrolled participants. All eligible participants will be included in the study according to the inclusion criteria. In addition to giving stool samples for multigene methylation test, eligible participants need to undergo colonoscopy examination and have their biopsies taken when necessary (gold standard).
16293351|NCT04722042|Other|Default|The default frequency filters assigned by the clinical software
16293352|NCT04722042|Experimental|Place-based|Frequency filters adjusted to align with the cochlear place frequency
16293353|NCT04722029|No Intervention|Donor|"Donors will be evaluated to determine suitability to undergo apheresis collection and their infectious disease status. Donor evaluation will include history and physical examination, laboratory tests, FDA- approved donor testing of communicable diseases (HIV, HVB, HCV, HTLV-I, II, WNV, T. pallidum, T. cruzi, and Zika virus), ABO and Rh typing, pregnancy tests, and donor serology for ADV.
~Qualified donors will undergo leukapheresis. Collection will proceed for 2 hours or 2 blood volumes, whichever occurs first."
16293354|NCT04722029|Experimental|Recipient|"Recipient will undergo a screening period that will include history and physical examination, laboratory tests, performance status, HLA typing and pregnancy test (if needed).
~Qualified patients will receive ADV-VSTS infusion from haploidentical donors up to a maximum of 5.0 x 104 interferon gamma-negative cells/kg. All patients will be followed for laboratory and clinical response, safety, efficacy and tolerance."
16293355|NCT04722003|Experimental|4CMenB|Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40
16293356|NCT04722003|Placebo Comparator|Placebo|Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10
16293357|NCT04721990|Experimental|Automatic Sound Management 3.0|Current SONNETEAS listeners, who meet the eligibility criteria, will be tested with their current listening configuration and also fit with a SONNET2EAS, programmed with Automatic Sound Management 3.0 (under the Investigational Device Exemption).
16293359|NCT04721964|Experimental|Intervention|All 24 participants will daily consume 6 mg iron/kg body weight for 13 weeks to correct their anaemia and increase their iron stores.
16293360|NCT04721938|Other|Intervention|Systematic weight loss intervention
16293361|NCT04721925|No Intervention|Control group|Link to an educational website about alcohol; link to resources.
16293362|NCT04721925|Experimental|Social media messaging|Health coaching via social media for 8 weeks
16293363|NCT04721912|No Intervention|Standard of Care|Subjects in the control group will not receive any Probiotic capsules and will be advised to continue their routine prenatal self-care.
16293364|NCT04721912|Experimental|Probiotic Dietary Supplement|Participants in the intervention group will begin taking oral study Probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth. The research staff member will sequentially distribute the pre-labeled bottles of study capsules to the intervention group, one bottle of 30 Florajen Digestion probiotic capsules to women in the intervention group at the time of randomization.
16293365|NCT04721899||Vitamin D- recurrent implantation failure (RIF)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
16293366|NCT04721899||Vitamin D- recurrent pregnancy loss (RPL)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
16293367|NCT04721899||Vitamin D- infertility|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
16293368|NCT04721886|Experimental|Diagnostic (CEUS)|Patients undergo ultrasound without contrast. Patients then receive Definity IV over 15 minutes and undergo CEUS.
16293369|NCT04721873|Experimental|Intervention|
16293370|NCT04721873|Placebo Comparator|Placebo|
16293371|NCT04721860|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 4 weeks.
16293372|NCT04721860|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 4 weeks.
16293477|NCT04721119|Experimental|Local Infiltration Anesthetic + Adductor Canal Block|This group of patients will receive the local infiltration anesthetic and adductor canal block combination.
16293373|NCT04721847|Experimental|Pain Neuroscience Education|Pain Neuroscience Education (PNE) sessions. Additionally, treated with Transcutaneous Electrical Nerve Stimulation (TENS), Stretching and Strengthening exercises similar as in control group
16293374|NCT04721847|Active Comparator|Conventional Physical therapy|Control group will be treated by TENS, stretching and strengthening exercises.
16293375|NCT04721834|Active Comparator|Low-intensity ESWT|Patient would be positioned in a supine position. Shockwaves would be delivered to the stretched penis at proximal, mid and distal penile shaft and bilateral crura of penis. (Energy: 0.1-0.25 mJ/mm2; 3000pulses per session; Frequency 3Hz) Treatment consists of 6 sessions over 5 weeks in total. It would be a twice-weekly treatment with one-week interval of resting period. Patient would be discharged home after each treatment session.
16293376|NCT04721834|Sham Comparator|Sham ESWT|Sham therapy would be given with a modified probe which no shockwave would be emitted. A working noise would still be generated which mimicked active treatment.
16293377|NCT04721821||Patients with Rheumatoid Arthritis (RA)|
16293378|NCT04721808||Patients with Rheumatoid Arthritis (RA)|Patients receiving tofacitinib from the Corrona RA Registry from November 2012 onward
16293379|NCT04721795|Experimental|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
16293380|NCT04721795|Active Comparator|Anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs only consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
16293381|NCT04721782||otherwise healthy, smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
16293382|NCT04721782||otherwise healthy, non-smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
16293383|NCT04721769|Active Comparator|Endoscopic strip craniectomy with the use of lateral osteotomies|Patients will have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
16293384|NCT04721769|Experimental|Endoscopic strip craniectomy without the use of lateral osteotomies|Patients will NOT have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
16293385|NCT04721756|Experimental|18F-LY3546117 Scan Cohort 1|18F-LY3546117 PET scan at baseline and between 14-42 days after initiation of immune checkpoint therapy
16293386|NCT04721756|Experimental|18F-LY3546117 Scan Cohort 2|18F-LY3546117 PET scan at time of immune checkpoint therapy response
16293387|NCT04721743||Affected Participants|Participants with Uveitis
16293388|NCT04721730|Experimental|PLH-YC|"The Parents will receive the optimised version of the Parenting for Lifelong Health for Young Children from 2-9 y. (PLH-YC) identified in Phase 2.
~The groups will be conducted with 12 parents per group (with 2 facilitators). If local restrictions due to COVID-19 restrictions do not allow-in person meetings of this size, we will reduce the sample size (6 parents per group, and facilitator) and or conduct the groups online (e.g., using an online video software).
~For each session, parents will receive a snack (or food voucher of same amount), childcare, transportation support (if needed), and a certificate at the end. Also, parents participating in at least four out of five PLH sessions will get a small gift. If the groups need be conducted online because of the COVID-19 pandemic, the parents will receive pre-paid data or another voucher of the same amount."
16293389|NCT04721730|Active Comparator|Lecture|"Parents will receive a lecture called Raising Healthy Children.
~The lecture will be conducted with 12 parents per group (with one facilitator). If local restrictions due to COVID-19 pandemic will not allow in-person meetings, the groups will be online (e.g., using a video meeting software).
~During the lecture, parents will receive a snack (or a food voucher of the same amount), childcare, transportation support (if needed), and a certificate at the end. If the lecture needs be conducted online because of the COVID-19 pandemic and associated restrictions, the parents will receive pre-paid data or another voucher of the same amount (instead of childcare, transport voucher and the snack)."
16293390|NCT04721717||People with SCI|People with paraplegia and quadriplegia
16293391|NCT04721704|Experimental|Group A|Group A will be given Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI based triple regimen
16293392|NCT04721704|Experimental|Group B|Group B will be given Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI based triple regimen
16293393|NCT04721691|Active Comparator|IP|Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Epidiolex at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
16293475|NCT04721132|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery during week 12.
16356190|NCT04284553|Experimental|Open Encounter + Pre-commitment|
16293394|NCT04721691|Placebo Comparator|Placebo|Placebo is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe. The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Placebo at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
16293395|NCT04721678|Experimental|Interpersonal psychotherapy (IPT)|10 weeks of internet-administered interpersonal psychotherapy with therapist support.
16293396|NCT04721678|No Intervention|Wait-list control group|The participants in the control group will receive access to the treatment after the post-treatment assessment has been conducted.
16293397|NCT04721665||NAFLD patients|No intervention
16293398|NCT04721652||Hemodialysis Patients (nondiabetic)|Nondiabetic adult hemodialysis patients
16293399|NCT04721639|Experimental|The experimental intervention (Sphinx Yoga Therapy)|In this group, participants will be intervened with Sphinx Yoga therapy which will take place in a conserved therapy center of Koohi Goth Hospital. This stretching exercise session will take place in the afternoon and for a duration of 10 minutes followed by 30 minutes therapy session five times per week (total 12 weeks).
16293400|NCT04721639|No Intervention|The control intervention (Usual Care)|In this Group, participants won't be receiving any intervention and provided with the usual care.
16293401|NCT04721613||Hypoactive ICU delirium|
16293402|NCT04721613||Hyperactive or mixed ICU delirium|
16293403|NCT04721613||Critically ill patients not suffering form ICU delirium|
16293404|NCT04721600|Experimental|treatment|
16293405|NCT04721587|No Intervention|Standard of care|Office hysteroscopy performed as the standard of care of our Hospital
16293406|NCT04721587|Experimental|Virtual Reality|Office hysteroscopy with the use of VR environment (preprocedure and during procedure)
16293407|NCT04721574|Active Comparator|Bright light therapy|Daily exposure to a high brightness LED light box for 30 minutes as soon as possible after awakening, preferably between 7 and 8 AM in the patient's hospital room The device emits 10,000 lux of cool-white fluorescent light at 50-75 cm from the screen to the cornea with an ultraviolet filter
16293408|NCT04721574|Sham Comparator|Sham Therapy|Light-therapy with filters that reduced lamp output to less than 50 lux. for 30 minutes as soon as possible after awakening.
16293409|NCT04721561||Chronic stroke patients|Patients who are at least 6 months after a first unilateral stroke
16293410|NCT04721561||Healthy controls|Healthy subjects with no history of any neurological condition and who are in the same age group as the chronic stroke patients
16293411|NCT04721548|Placebo Comparator|Minoxidil´s Placebo|The recommended dosage is 1 ml of the solution twice a day.
16293412|NCT04721548|Experimental|Topical Minoxidil 5%|The recommended dosage is 1 ml of the solution twice a day.
16293413|NCT04721535|Experimental|DWJ1248|Camostat mesilate 200mg
16293414|NCT04721535|Placebo Comparator|Placebo|Placebo
16293415|NCT04721509|Experimental|Smartphone-based telemedicine|
16293416|NCT04721509|No Intervention|Conventional management without telemedicine|
16293417|NCT04721496|Experimental|Trained|Athletes who had at least 2 years of continuous strength training experience, and at least 6 months of training with unstable situations and device
16293418|NCT04721496|Experimental|Untrained|Athletes who had at least 2 years of continuous strength training experience, but no training experience with unstable situations and devices
16293419|NCT04721483|Active Comparator|T3-T4 sympathicotomy|In this group, patients underwent a classical T3 and T4 sympathicotomy to treat primary palmar hyperhidrosis
16293420|NCT04721483|Experimental|T3-T4 ramicotomy|In this group, patients underwent a selective T3 and T4 gray ramicotomy
16293421|NCT04721470|Experimental|Combined therapy|Patients undergoing combined therapy
16293422|NCT04721470|Active Comparator|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
16293423|NCT04721470|Active Comparator|Microwave ablation|Patients undergoing Microwave ablation
16293424|NCT04721457|Placebo Comparator|Distilled Water|15-second rinsing with 15 mL of Distilled Water
16293425|NCT04721457|Active Comparator|Povidone Iodine (PVP-I)|15-second rinsing with 15 mL of 1% PVP-I
16293426|NCT04721457|Active Comparator|Hydrogen Peroxide (H2O2)|15-second rinsing with 15 mL of 1.5 % Hydrogen Peroxide
16293427|NCT04721457|Active Comparator|Cetylpyridinium Chloride (CPC)|15-second rinsing with 15 mL of 0.075%CPC
16293428|NCT04721457|Active Comparator|Sodium Hypochlorite|15-second rinsing with 15 mL of 0.1% Sodium Hypochlorite
16293429|NCT04721444||Arm A - Cohort A1|Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)
16293430|NCT04721444||Arms A and B - Cohort B1|Training set B1: IO and RT naive and pneumonia (without COVID-19)
16293431|NCT04721444||Arms A and B - Cohort B2|Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia
16293432|NCT04721444||Arm B - Cohort A2|Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)
16293433|NCT04721444||Arm A - Test Cohort (Cohort C1)|Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis
16293434|NCT04721444||Arm B - Test Cohort (Cohort C2)|Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.
16293435|NCT04721444||Arm C|Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment
16293436|NCT04721431|Experimental|Normal|Body mass index must to be in range limits (18.5-24.9 kg/meter square)
16293437|NCT04721431|Experimental|Overweight|Body mass index must to be in range limits (25-29.9 kg/meter square)
16293438|NCT04721431|Experimental|Obese|Body mass index must to be in range limits (30-34.9 kg/meter square)
16293439|NCT04721418||Cocaine Use Disorder|
16293440|NCT04721418||Healthy Control|
16293445|NCT04721379|Experimental|Heartfulness Meditation Group|Participants will be guided through relaxation and meditation session with a Heartfulness trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
16293446|NCT04721379|Active Comparator|Control Group with Self Meditation|Participants will be self-guided through relaxation and meditation session without a trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
16293447|NCT04721366||Standard of Care (SoC)|Neonatal and pediatric participants who has been on ERT (VPRIV) will be followed up for 36 months from the time of treatment initiation as per SOC.
16293449|NCT04721340||Test Group|people with multiple sclerosis
16293450|NCT04721340||Control Group|healthy volunteers
16293451|NCT04721327|Experimental|Pediatric Arm|Patient ages 1-17 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
16293452|NCT04721327|Experimental|Adult Arm|Patient ages 18-90 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
16293453|NCT04721314|Experimental|Lower rate set to a higher, personalized backup heart rate (myPACE)|Patients randomized to this group will have their pacemaker lower heart rate setting programmed to a personalized lower rate based on a resting heart rate algorithm.
16293454|NCT04721314|Active Comparator|Lower rate left at 60 beats-per-minute|Patients randomized to this group will have their pacemaker lower heart rate setting left at or programmed to the conventional pacemaker lower rate setting of 60bpm.
16293455|NCT04721301|Experimental|Combination immunotherapy|Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment
16293456|NCT04721288|Experimental|Intervention Group|1 year of tailored communication with transplant care team through Reboot application in addition to standard of care communication system.
16293457|NCT04721288|Sham Comparator|Standard of Care Group|1 year of generic communication through Reboot application with communication with transplant care team through standard of care communication system.
16293458|NCT04721275||Sepsis on the elderly population in ED|The elderly population is defined as patients over 65 years old of age.
16293459|NCT04721275||Sepsis on the non-elderly population in ED|The non-elderly population is defined as patients aged of 18 to 64 years old.
16293460|NCT04721262||Patients prescribed Ferumoxytol for iron deficiency anemia|Patients with iron deficiency anemia are commonly prescribed Ferumoxytol periodically as part of their standard clinical care. Multiple studies have characterized the efficacy and safety of Ferumoxytol in the treatment of iron deficiency anemia. Patients prescribed Ferumoxytol for iron-deficiency anemia typically include otherwise healthy women with heavy menstrual periods, patients with inflammatory bowel disease, and patients with chronic kidney disease. Such patients make ideal candidates for characterizing the effects of Ferumoxytol on novel imaging devices by obviating a medically unnecessary injection of the contrast agent.
16293461|NCT04721249|Active Comparator|Verum|
16293462|NCT04721249|Placebo Comparator|Placebo|
16293463|NCT04721236|Experimental|Single|hyperimmune plasma with titre 1:80 or more
16293464|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part1|JAB-3068+JS001 dose escalation
16293465|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part2|JAB-3068+JS001 dose expansion
16293466|NCT04721210|Experimental|Frequency of 1 Hz|continuous stimulation with a frequency of 1 Hz, 2000 pulses, 10 days-daily;
16293467|NCT04721210|Experimental|Frequency of 10 Hz|continuous stimulation with a frequency of 10 Hz-10 seconds with a pause of 50 seconds, 2000 pulses, 10 days-daily;
16293468|NCT04721210|Placebo Comparator|Continuous stimulation placebo|continuous stimulation placebo
16293471|NCT04721171|Active Comparator|Intervention group|The Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
16293472|NCT04721171|Sham Comparator|Placebo Group|The sham is similar in appearance to the Bridge device but does not deliver any electrical stimulation and is a sham that is designed to look identical to the Bridge device. It is placed on the external ear at the beginning of the study and removed by the patient after 5 days.
16293473|NCT04721158|Other|CGM Arm|Children with type 2 diabetes will wear a continuous glucose monitor for 10 days.
16293474|NCT04721145|Experimental|Dexcom G6 Continuous Glucose Monitor|Children with type 1 diabetes will wear a continuous glucose monitor (CGM) for 10 days.
16293476|NCT04721119|Experimental|Local Infiltration Anesthetic|This group of patients will receive the local infiltration anesthetic only.
16293845|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome multi dose|
16293478|NCT04721106||Vizimpro treatment group|This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice
16293479|NCT04721093|Experimental|PBM(Photobiomodulation)|Subjects applied PBM(Color-DNA-WSF U, Color Seven; 610 nm±10nm wavelength; 3.0 mW/㎠±20%) therapy in the locations of the sternocleidomastoid muscle in the ICA area and the trapezius muscle in VA area. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
16293480|NCT04721080||COPD patients with tuberculous sequelae|COPD patients with tuberculous sequelae
16293481|NCT04721080||COPD patients without tuberculosis sequela|COPD patients with tuberculous sequelae
16293482|NCT04721067|Experimental|CBT-I|This arm will receive internet CBT-I using SHUTi, a validated and proven therapy provided via internet in the general population.
16293483|NCT04721067|Active Comparator|Sleep Education/Hygiene|This arm will receive best practices education on sleep hygiene.
16293484|NCT04721054|Active Comparator|group receiving thoracic epidural anesthesia|
16293485|NCT04721054|Active Comparator|group receiving thoracic general anesthesia|
16293486|NCT04721041|Experimental|Washed Microbiota Transplantation (WMT)|Patients undergo once WMT a day for three consecutive days.
16293492|NCT04721002||Participants With Multiple Myeloma|Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.
16293493|NCT04720989|Experimental|Bathing With Baby Cleanser|Skin cleansing products will be used in the first baths of the participants in this group.
16293494|NCT04720989|Experimental|Bathing With only Water|Only water will be used in the first baths of the participants in this group.
16293495|NCT04720976|Experimental|JAB-3312+Pembrolizumab dose escalation|Dose escalation part 1
16293496|NCT04720976|Experimental|JAB-3312+ Binimetinib dose escalation|Dose escalation part2
16293497|NCT04720976|Experimental|JAB-3312+Pembrolizumab dose expansion|Dose expansion part1
16293498|NCT04720976|Experimental|JAB-3312+Binimetinib dose expansion|Dose expansion part2
16293499|NCT04720963|Placebo Comparator|group P (Placebo group)|intranasal placebo 20min before inhalation anesthesia induction
16293500|NCT04720963|Experimental|group R (remimazolam group)|intranasal remimazolam 20min before inhalation anesthesia induction
16293501|NCT04720950|Experimental|Morning exercise|1 hour of exercise completed between 0800-1000
16293502|NCT04720950|Experimental|Evening exercise|1 hour of exercise completed between 1800-2000
16293503|NCT04720924|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through white light EGD examination with assistance of AQCS.
16293504|NCT04720924|No Intervention|Control group|Patients in control group will go through white light EGD examination without AQCS.
16293505|NCT04720911|Experimental|In-person TASCS|This intervention is designed to assess the TASCS app administered via an in-person clinician in the ED, with follow-up telephone calls by a clinician
16293506|NCT04720911|Active Comparator|Telehealth TASCS|This comparison condition is designed to assess the telehealth modality of TASCS in the ED (in contrast to in-person clinician modality), with follow-up telephone calls by a clinician
16293507|NCT04720911|Active Comparator|Self-administered TASCS|This comparison condition is designed to assess the self-administered modality of TASCS (in contrast to clinician modality), with follow-up telephone calls by a clinician
16293508|NCT04720898|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG once a week for 12 weeks.
16293509|NCT04720898|No Intervention|Control|The control group will receive its rehabilitation care.
16293510|NCT04720885||Patients with a placental remnant in medical history|
16293511|NCT04720872|Experimental|Experimental group|"Manual therapy: 4 sessions, 1 session per week (20 minutes approximately).
~Physical therapist-directed vestibular rehabilitation: 4 weeks, 1 session per week with the physical therapist (30 minutes approximately), after manual therapy.
~Home based vestibular rehabilitation: 4 weeks (2 sessions per day)."
16293512|NCT04720872|No Intervention|Control group|Home based vestibular rehabilitation: 4 weeks (2 sessions per day). The participants attended the center once a week to check correct execution of the exercises.
16293513|NCT04720859|Experimental|Patients with PHH following Roux-en-Y-gastric bypass (cases)|Patients diagnosed with PHH following Roux-en-Y-gastric bypass.
16293514|NCT04720859|No Intervention|Healthy individuals (controls)|Healthy normoweight individuals, matched by age and gender with the cases.
16293515|NCT04720846|Active Comparator|Control|Patients will receive standard-of-care physical therapy.
16293516|NCT04720846|Experimental|Matrix-Based PT|Patients will receive matrix-based physical therapy, in addition to standard-of-care physical therapy.
16293517|NCT04720833|Experimental|dried plum (100 g dried plum)|Participants will receive 100 g dried plum daily plus 500 mg calcium and 300 IU vitamin D daily
16293518|NCT04720833|Placebo Comparator|Calcium and vitamin D|Participants will receive 500 mg calcium and 300 IU vitamin D daily
16293519|NCT04720820|Experimental|Early Supported Discharge (ESD) Group|Patients in the ESD group will be discharged to home as soon as the acute medical treatment is finished. The patients will follow a pre-planned ESD program which consists of home-based rehabilitation (at least 30 minutes of physical therapy and 30 minutes of occupational therapy per week) offered by therapists. The ESD team will also provide social/medical services as needed. The ESD program will be provided till 1 months after discharge point.
16293573|NCT04720404|Active Comparator|Daily self-help mindfulness exercises via YouTube-channel|Healthcare workers in the self-help arm will be invited to follow a self-help program with mindfulness/compassion exercises of 30 minutes per day via YouTube channel
16293520|NCT04720820|Active Comparator|Conventional Rehabilitation (CR) Group|The patients in CR group will be provided with inpatient rehabilitation after the acute medical treatment is finished. The length of inpatient rehabilitation may depend on the hospital's current program. Patients will be provided with outpatient based rehabilitation program if needed after discharge.
16293521|NCT04720807|Experimental|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
16293522|NCT04720794|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
16293523|NCT04720781|Active Comparator|Vonoprazan|Vonoprazan (20mg/day) is prescribed for patients with erosive esophagitis
16293524|NCT04720781|Placebo Comparator|Esomeprazole|Esomeprazole (20mg/day) is prescribed for patients with erosive esophagitis
16293525|NCT04720768|Experimental|Dose escalation phase|"Encorafenib (tablet) 450mg PO daily
~Binimetinib (tablet) 45mg PO BD
~Palbociclib (tablet) variable dose PO daily for 21 consecutive days on treatment, followed by 7 consecutive days off treatment in a 28 day cycle"
16293526|NCT04720755|Experimental|Treatment|Participants will receive twice-weekly Li-ESWT treatments of 0.2mJ/mm² over 3 treatment sites along the dorsal penile shaft (distal, mid-shaft, proximal), 1500 shocks per treatment (500 shocks per treatment site) for a total of 3000 shocks per week, for 6 weeks (total of 18,000 shocks)
16293527|NCT04720742|Experimental|Experimental group|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration, and during the first 8 months, a temporary immune intervention including the combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074, which will be infused once per month.
16293529|NCT04720716|Experimental|Sintilimab combined with IBI310|
16293530|NCT04720716|Active Comparator|Sorafenib|
16293531|NCT04720703|Experimental|Intervention Group|The Intervention Group will receive the Family-based Telehealth Intervention for the first three months of the study period. Once they have completed the intervention, there will be a two-week washout period. After the washout period, they will receive monthly newsletters, with similar information learned in the intervention, for three months until the end of the study period.
16293532|NCT04720703|Active Comparator|Wait-list Control Group|The Waitlist Control Group will receive monthly newsletters, with similar information learned in the intervention, for the first three months of the study period while the Intervention Group receives the intervention. Then, there will be a two-week washout period. After the washout period, they will receive the Family-based Telehealth Intervention for 3 months until the end of the study period.
16293533|NCT04720690||Appropriately grown for age infants|40 appropriately grown for gestational age (AGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
16293534|NCT04720690||Small for gestational age infants|40 small for gestational age (SGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
16293535|NCT04720690||Fetal growth restricted infants|40 fetal growth restricted (FGR) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
16293537|NCT04720638|Experimental|Short fiber reinforced flowable resin composite restorations|(everX Flow, GC Europe) + (Gaenial posterior, GC Europe
16293538|NCT04720638|Active Comparator|Conventional resin composite restoration.|(Gaenial posterior, GC Europe)
16293539|NCT04720625|Experimental|Adapt2Quit|These participants will receive Adapt2Quit motivational messaging and quitline facilitation messaging for 6 months.
16293540|NCT04720625|Active Comparator|Control|These participants will receive quitline facilitation-only messaging for 6 months.
16293543|NCT04720586|Experimental|triple procedure|lower eyelid retractors plication , transcutaneous blepharoplasty and wedge resection
16293544|NCT04720586|Active Comparator|combined procedure|lower eyelid retractors plication and transcutaneous blepharoplasty
16293545|NCT04720573|Active Comparator|Group N|Neostigmine was used for the reversal of neuromuscular blockade.
16293546|NCT04720573|Active Comparator|Group S|Sugammadex was used for the reversal of neuromuscular blockade.
16293547|NCT04720547|Experimental|Zolpidem|Participants will be administered zolpidem prior to completing an in-lab night study.
16293548|NCT04720547|No Intervention|Control|Participants complete an in-lab night study without the administration of a drug.
16293549|NCT04720534|Experimental|ARO-APOC3|ARO-APOC3 Injection
16293550|NCT04720534|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl)
16293551|NCT04720521|Experimental|OE+white light|Using white light firstly to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus.
16293552|NCT04720521|No Intervention|White light|Using White light to observe from esophagus to duodenum.
16293553|NCT04720508||Group A (patient group)|"included 25 patients with BC admitted to department of medical Oncology, South Egypt Cancer Institute, Assiut University.
~blood samples will be obtained after getting informed consent."
16293554|NCT04720508||Group B (control group)|included 25 controls age-matched , sex-matched and apparently healthy. blood samples will be obtained after getting informed consent .
16293555|NCT04720495|Active Comparator|One stage ridge splitting|
16293556|NCT04720495|Experimental|Two-stage ridge splitting|
16293557|NCT04720482||Comatose survivors of cardiac arrest|Adult (>18 years) patients remaining comatose during intensive care 48 hours after cardiac arrest. All patients are submitted to both clinical routine measurements: pupillometry and somatosensory evoked potentials.
16293558|NCT04720469|Experimental|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
16293574|NCT04720378|Experimental|Cohort 1|0.1 ml/kg IV ST266 once a day for 5 days
16293562|NCT04720443|Experimental|SAD Part 1 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 10 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
16293563|NCT04720443|Experimental|SAD Part 1 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 30 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
16293564|NCT04720443|Experimental|SAD Part 1 Cohort 3|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 100mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
16293565|NCT04720443|Experimental|SAD Part 1 Cohort 4|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 300 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
16293566|NCT04720443|Experimental|SAD Part 1 Cohort 5|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 600 mg)or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
16293567|NCT04720443|Experimental|SAD Part 1 Cohort 6|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 900 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
16293568|NCT04720443|Experimental|MAD Part 2 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage TBD) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Three dose levels (low dose, medium dose, and high dose) proposed for MAD part will be determined based on the doses evaluated in SAD part (including a dose higher than 900 mg if it is indicated).
16293569|NCT04720443|Experimental|MAD Part 2 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage TBD) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Three dose levels (low dose, medium dose, and high dose) proposed for MAD part will be determined based on the doses evaluated in SAD part (including a dose higher than 900 mg if it is indicated).
16293570|NCT04720443|Experimental|MAD Part 2 Cohort 3|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage TBD) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Three dose levels (low dose, medium dose, and high dose) proposed for MAD part will be determined based on the doses evaluated in SAD part (including a dose higher than 900 mg if it is indicated).
16293571|NCT04720417|Experimental|Treatment (defactinib, VS-6766)|Patients receive defactinib PO BID and VS-6766 PO BIW (Monday and Thursday or Tuesday and Friday) for 3 weeks in every cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16293572|NCT04720404|Experimental|Mindfulness Based Stress Reduction program|Healthcare workers in the MBSR arm will be invited to participate in an adapted online MBSR program added to support as usual
16293575|NCT04720378|Experimental|Cohort 2|0.25 ml/kg IV ST266 once a day for 5 days
16293576|NCT04720378|Experimental|Cohort 3|0.5 ml/kg IV ST266 once a day for 5 days
16293578|NCT04720365|Experimental|play-based rehabilitation|"Patients randomized in the play-based rehabilitation group will perform 2 to 3 gambling rehabilitation sessions at home using the Kinect® system linked to the Curapy.com platform for 12 months."
16293579|NCT04720365|No Intervention|routine care|"Patients randomized in the usual care group will have their usual rehabilitation care provided by their physiotherapist."
16293580|NCT04720352|Sham Comparator|Sham Comparator|Sham delivers non therapeutic levels of radiofrequency and cryogen
16293581|NCT04720352|Experimental|Active Arm|Active arm delivers radiofrequency and cryogen
16293582|NCT04720339|Experimental|Experimental arm|
16293583|NCT04720326|Experimental|Envarsus®|Participants take prolonged-release tacrolimus tablets orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
16293584|NCT04720326|Active Comparator|Advagraf®|Participants take prolonged-release tacrolimus capsules orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
16293585|NCT04720313|Experimental|CART BCMA|The dose escalation phase (Part A) will include the following doses of CAR-positive (CAR+) T cells: 150×10^6, 450×10^6, 800×10^6 or 1200 ×10^6 The expansion phase (Part B) will include a dose between 450×10^6 to 800×10^6 CAR-positive (CAR+) T cells
16293586|NCT04720300|Active Comparator|MaaS app|The Mobility-as-a-Service (MaaS) App will be provided to students in the Intervention Group and is intended to facilitate their use of alternative transportation modes such as public transit, ride-hailing, walking, biking, bike share, and e-scooter share to get to campus. The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app. This means, for instance, that a student can plan a trip that includes driving to a train station, taking the train, and then walking from the alighting train station to their final destination. The app will be white label, i.e. it will have a customized look and feel specific to the participating south Florida colleges, and it will have personalization features so that students can tailor the app to their travel patterns. Students in a cluster assigned to the MaaS group will also receive information concerning housing options. Students complete surveys
16293587|NCT04720300|Placebo Comparator|No app|Students receive no app, no housing information, students complete surveys.
16293588|NCT04720287|Active Comparator|Group 1(QL group)|
16293589|NCT04720287|Active Comparator|Group 2 (CB group)|
16293590|NCT04720274|Experimental|Participants with Hip Pain or Injuries|
16293591|NCT04720274|Active Comparator|Healthy Participants|
16293592|NCT04720261|Other|Caplacizumab|All patients in the study are aTTP and needs to be treated by caplacizumab. The duration of this treatment will be evaluated through the ADAMTS 13 activity.
16293593|NCT04720248||Metamizol postoperatively|Patients submitted to scheduled craniotomy receiving metamizol as analgesic medication postoperatively
16293594|NCT04720248||Paracetamol or other analgesics postoperatively|Patients submitted to scheduled craniotomy receiving paracetamol or other drugs as analgesic medication postoperatively
16293595|NCT04720235|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
16293596|NCT04720222|Experimental|TENA-PROTO1|Investigational device. Early prototype
16293597|NCT04720209|Experimental|Circuit-style aerobic and resistance Exercise(CARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months.
~-16 weeks of circuit-style aerobic and resistance exercise"
16293598|NCT04720209|Experimental|Traditional Aerobic Resistance Exercise (TARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months
~- 16 weeks of traditional aerobic and resistance exercise"
16293599|NCT04720209|Active Comparator|Home-Based Stretching|"Attention Control for 16 weeks home-based stretching
~-structured home-based stretching program, participants will be asked to maintain their current activity level for the 4-month study duration, and will be offered the CARE program upon study completion"
16293600|NCT04720196|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
16293601|NCT04720196|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
16293602|NCT04720183|Experimental|Sulfasalazine + GLPG3970|
16293603|NCT04720170|Other|Single Arm|This is a 26 week, single arm, single-site, Investigator-initiated, exploratory trial evaluating the efficacy of the standard of care revascularization of the lower extremity with the addition of revascularization of the lateral plantar artery and anterior pedal loop of the foot as treatment for participants with PAD, diabetic neuropathy and have a clinical diagnosis of type 1 or type 2 diabetes whose main symptoms are numbness and/or tingling of the feet with or without pain.
16293629|NCT04719936|Experimental|inferior capsulotomy group|inferior capsulotomy will be conducted during posterior approach.
16293630|NCT04719936|Active Comparator|superior capsulotomy group|superior capsulotomy will be conducted during posterior approach.
16293631|NCT04719923||Subjects with autism spectrum disorders|Children affected by autism spectrum disorders
16293632|NCT04719923||Healthy controls|Healthy children
16293846|NCT04718831|Other|Baseline|Did not take nutritious food
16293606|NCT04720144||bIMI cases|"Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:
~i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).
~AND
~iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days."
16293607|NCT04720144||Controls|"For each bIMI case, we will include 2 control cases fulfilling the following criteria:
~i) Receiving continuous posaconazole prophylaxis for at least 7 days
~ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay"
16293608|NCT04720131|Experimental|Camrelizumab combined with Apatinib and Capecitabine|Camrelizumab was administered 200mg iv every 3 weeks. Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle) Apatinib:A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle). The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group. The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
16293609|NCT04720105|Experimental|Participants with plaque type psoriasis|Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion) to be applied thinly once a day on the affected areas of hands and/or feet.
16293610|NCT04720092|Experimental|Treatment A-B|Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
16293611|NCT04720092|Experimental|Treatment B-A|Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
16293612|NCT04720079|Active Comparator|Intercostobrachial nerve Infiltration|Preoperative infiltration of intercostobrachial nerve with 10ml of ropivacaine 0.5%
16293613|NCT04720079|Active Comparator|Ultrasound guided T2 paravertebral block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of ropivacaine 0.5%
16293614|NCT04720053|Experimental|Wearable brain sensing wellness device headband system|Subject diagnosed with fibromyalgia at Mayo Clinic GIM Fibromyalgia Clinic will receive a wearable brain sensing wellness device headband system, and will be given a demonstration of the mindfulness sessions, with detailed instructions on how to begin each session.
16293615|NCT04720040|Experimental|YMS-201B|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 6 weeks (total of 30~42 applications)
16293616|NCT04720027||Closurefast|Patients who were randomised to and underwent radiofrequency ablation using the Closurefast device in the original 3RF Study
16293617|NCT04720027||Radiofrequency Induced Thermal Therapy (RFITT)|Patients who were randomised to and underwent radiofrequency ablation using the RFITT device in the original 3RF Study
16293618|NCT04720027||EndoVenous Radiofrequency (EVRF)|Patients who were randomised to and underwent radiofrequency ablation using the EVRF device in the original 3RF Study
16293619|NCT04720014|Experimental|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training.
16293620|NCT04720001||Experimental: Florbetaben F18 recipients|Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
16293621|NCT04719988|Experimental|Experimental|"Induction treatment
~Modified DCF: every 2 weeks for 8 cycles Docetaxel (40 mg/m², day 1), Cisplatin (40 mg/m², day 1) , 5-FU (1200 mg/m²/day for 2 days)
~Ezabenlimab: 240 mg intravenous, every 3 weeks for 3 cycles
~In case of tumor response:
~Two additional cycles of mDCF and one additional cycle of Ezabenlimab (Q3W).
~Hypofractionated radiotherapy
~Ezabenlimab: 240 mg intravenous, every 3 weeks for 7 cycles
~In absence of tumor response:
~o Chemoradiotherapy (Intensity-Modulated Radiation Therapy [IMRT]) treatment: Chemoradiotherapy using IMRT will begin 3-4 weeks following the last cycle of induction phase, in the absence of toxicities of grade 1 and/or management of toxicities. It will last 7 weeks and will consist of:
~• Standard dose of 45 Gy in 25 fractions over 5 weeks followed by a sequential boost of 14.4 Gy in 8 sessions,
~Concomitantly given with:
~Capecitabine (825 mg/m²/orally twice daily) from Monday to Friday,
~Mitomycin C (10 mg/m² Day 1)"
16293622|NCT04719975|Experimental|Mental Fatigue (Stroop) - Chair task|Participants will be performing the Chair Task (150 submaximal dynamic knee extensions at 50% of their maximal voluntary contraction (MVC)) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
16293623|NCT04719975|Placebo Comparator|Control Task (Documentary) - Chair Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Chair Task, During the whole trial EEG will be measured.
16293624|NCT04719975|Experimental|Mental Fatigue (Stroop) - Bike Task|Participants will be performing the Bike Task (a 9 min cycling task performed at 45 rpm with intensity being constant and will be 10% below VT) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
16293625|NCT04719975|Placebo Comparator|Control task (Documentary) - Bike Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Bike Task, During the whole trial EEG will be measured.
16293626|NCT04719962|Experimental|Disseminated Lyme infection|Only patients presenting with disseminated Lyme borreliosis will be part of the study.
16293627|NCT04719949|Experimental|Behavioral Activation (BA) Therapy|Participants complete four sessions of BA, 60-90 minutes per session.
16293633|NCT04719910|Experimental|Study group|The study group will watch 15 minute long videos of cooking and preparing the food of the patient's preferred type of food prior to be taken to the operating room.
16293634|NCT04719910|Placebo Comparator|Placebo group|The control group will watch 15 minute long non-food related videos.
16293635|NCT04719897|Experimental|FIRST: Repairing Thoughts|
16293636|NCT04719884|No Intervention|Control group|Standard perioperative anesthesia management
16293637|NCT04719884|Active Comparator|Study group|Perioperative extended haemodynamic monitoring of fluid loading, cardiac output and changes of peripheral vascular resistance by analysing the arterial curve was provided by non-invasive haemodynamic monitoring (LIDCO Rapid, Lidco Ltd., United Kingdom).In SG fluid optimisation was performed before pneumoperitoneum and after abdominal desuflation with actions to achieved CI, MAP and SI within 80% of baseline values.
16293638|NCT04719871||with posterior vitreous detachment|patient with stage 3 or more of posterior vitreous detachment on optical coherence tomography
16293639|NCT04719871||without posterior vitreous detachment|patient with stage 2 or less of posterior vitreous detachment on optical coherence tomography
16293640|NCT04719858|Experimental|Intervention|Intervention group that will install the #LIFEGOALS app.
16293641|NCT04719858|No Intervention|Control|Control group that will not receive any intervention.
16293642|NCT04719845|Experimental|Endoscopic laser resection|Using CO2, diode or similar wavelenght laser the stenotic tracheal segment will be vaporized allowing a less than 20% residual stenosis. Dilatation will not be performed after laser resection for residual stenosis.
16293643|NCT04719845|Experimental|Dilatation|Using a ballon or rigid bronchoscope the stenotic tracheal segment will be dilated with or without previous radial incision with electrocautery or laser.
16293644|NCT04719832|Experimental|Participants receiving GSK3511294 (Depemokimab)|Participants will be administered GSK3511294 (Depemokimab) along with SoC.
16293645|NCT04719832|Placebo Comparator|Participants receiving placebo|Participants will be administered matching placebo along with SoC.
16293646|NCT04719819||Usual pratice|Assessment of usual practices
16293647|NCT04719793|Experimental|Wharton's Jelly|Intraarticular injection of Umbilical Cord-derived Wharton's Jelly
16293648|NCT04719780|Active Comparator|Waitlist Control Group (CBT)|Individuals in this arm (n=44) are provided with a transdiagnostic cognitive-behavioural treatment for depression and anxiety (MoodGym) that has been empirically validated after their 15-week wait period is complete.
16293649|NCT04719780|Experimental|EFIT Group|Individuals in the EFIT Group (n=44) will receive 12-15 sessions of EFIT in order to treat their symptoms of depression and anxiety.
16293650|NCT04719767|Experimental|visual|In the visual group, a visual laryngeal mask was placed and endotracheal intubation was guided under visual conditions. The endotracheal tube was removed 10 minutes before the end of the operation, and the laryngeal mask was retained.
16293651|NCT04719767|No Intervention|Non-visual|In the non-visual group, laryngeal mask airway was inserted. After clinical judgment of good counterpoint, endotracheal intubation was inserted blindly through LMA. Endotracheal intubation was removed 10 minutes before the end of the operation, and the laryngeal mask airway was retained.
16293652|NCT04719754||Pregnant women with abnormal vaginal discharge|
16293653|NCT04719754||Pregnant women without abnormal vaginal discharge|
16293654|NCT04719741||O-4PI|4 mg Ondansetron given Pre-Induction
16293655|NCT04719741||O-8PI|8 mg Ondansetron given Pre-Induction
16293656|NCT04719741||O-4PE|4 mg Ondansetron given Pre-Emergence
16293657|NCT04719741||O-8PE|8 mg Ondansetron given Pre-Emergence
16293658|NCT04719741||D-4PI|4 mg Dexamethasone given Pre-Induction
16293659|NCT04719741||D-8PI|8 mg Dexamethasone given Pre-Induction
16293660|NCT04719741||D-4PE|4 mg Dexamethasone given Pre-Emergence
16293661|NCT04719741||D-8PE|8 mg Dexamethasone given Pre-Emergence
16293662|NCT04719741||O-4PI+D-8PI|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-induction
16293663|NCT04719741||O-4PI+D-8PE|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-emergence
16293664|NCT04719741||O-4PE+D-8PI|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-induction
16293665|NCT04719741||O-4PE+D-8PE|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-emergence
16293666|NCT04719741||Placebo Group|2 ml Saline 0.9%
16293667|NCT04719728||pre lingual|aided response, speech perception threshold impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
16293668|NCT04719728||post lingual|aided response, speech perception threshold speech in noise impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
16293669|NCT04719715||Cases with ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
16293670|NCT04719715||Controls with autoimmune diseases other than ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
16293671|NCT04719689|Experimental|Dry needling|Dry needling, hot pack, stretching exercises.
16293672|NCT04719689|Experimental|Dry Cupping|Dry cupping, hot pack, stretching exercises.
16293673|NCT04719676|Experimental|Core strength training using unstable surface|The experimental group will use Core strength training using unstable surface
16293674|NCT04719676|Active Comparator|The stable surface would be gym floor.|The control group will use stable surface.
16293675|NCT04719663|Experimental|1. Congruent Rationale & Treatment: Biological/Pharmacol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
16293676|NCT04719663|Experimental|2. Incongruent Rationale & Treatment: Psychological/Pharmacol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
16293677|NCT04719663|Experimental|3. Congruent Rationale & Treatment: Psychological/Psychol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
16293678|NCT04719663|Experimental|4. Incongruent Rationale & Treatment: Biological/Psychol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
16293679|NCT04719663|No Intervention|5. Natural course control|Participants receive no intervention and remain on the psychotherapy waiting list. Participants who are recruited externally and are not on a waiting list, will be offered the option to join the waiting list.
16293680|NCT04719650|Experimental|zoledronic acid 1mg|Add 20 mL of Zoledronic acid injection (100mL : 5mg) with 80 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
16293681|NCT04719650|Experimental|zoledronic acid 2.5mg|Add 50 mL of Zoledronic acid injection (100mL : 5mg) with 50 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
16293682|NCT04719650|Experimental|zoledronic acid 5mg|Infusion 100 mL of Zoledronic acid injection (100mL : 5mg) with constant speed in 20 minutes. Administration only once.
16293683|NCT04719650|Placebo Comparator|placebo|Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.
16293684|NCT04719637|Experimental|PRDS-001|Renal denervation
16293685|NCT04719624|Experimental|Adaptos-Si [0.5-1 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [0.5-1 mm] (synthetic bone graft material) in combination with a gelatin sponge.
16293686|NCT04719624|Experimental|Adaptos-Si [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
16293687|NCT04719624|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft) in combination with a gelatin sponge.
16293688|NCT04719624|Placebo Comparator|Empty extraction socket|Post-extraction the socket filled only by clot.
16293689|NCT04719624|Experimental|Adaptos [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
16293690|NCT04719611|Experimental|Healthy Women|Healthy women between the ages of 18-40 years will be given a probiotic supplement to evaluate the detection and persistence of the strains in biological samples.
16293691|NCT04719598|Experimental|intervention group is ( internet - based group) who will receive CBT sessions|study group ( group A)
16293692|NCT04719598|No Intervention|control group ( group B)|researchers just answer their questions
16293693|NCT04719585|Experimental|Experimental: Duloxetine group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
16293694|NCT04719585|Active Comparator|Active comparator: Opioid group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
16293695|NCT04719572|Other|Basic treatment group|elemental calcium 600mg/ day + vitamin D 1000IU/day
16293696|NCT04719572|Active Comparator|Basic treatment+ anti-osteoporosis drug group|alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition
16293697|NCT04719572|Other|Basic treatment + non-drug treatment group|diet, exercise, rehabilitation therapy
16293698|NCT04719559|Other|Post-Thyroidectomy Hypertrophic Scar|Patients had all presented a persistent hypertrophic scar at the neck region for more than 1 year after their thyroidectomy.
16293699|NCT04719546||NEC Group|All Premature Neonates born in Nancy and Lyon over 10 years and presenting with Necrotizing Enterocolitis
16293700|NCT04719546||Control Group|All Premature Neonates born in Nancy and Lyon over 10 years without Necrotizing Enterocolitis throughout the neonatal period
16293703|NCT04719520|No Intervention|traditional method|radio and telephone to notify the patient's family to the operating room
16293704|NCT04719520|Experimental|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
16293705|NCT04719507|Experimental|erector spinae arm|ultrasound guided erector spinae block
16293706|NCT04719507|Experimental|thoracic paravertebral arm|ultrasound guided thoracic paravertebral block.
16293707|NCT04719507|Active Comparator|drug arm|pethidine (1 mg/kg ) once
16293708|NCT04719494|Experimental|Training Group|During the 12-training day sessions, subjects will walk on the treadmill for a total of 30 minutes. Participants will walk at a comfortable pace while we perform controlled movements to the treadmill system. Subjects will be fitted with a fall-arrest harness and assisted onto the treadmill system. In the dynamic balance training group, we will move the motion base as participants walk in order to challenge their balance.
16293709|NCT04719494|No Intervention|Control Group|Subjects who are in the control group will also walk on the treadmill, but the motion base will remain stationary. They will complete 12-training day sessions.
16293710|NCT04719481|Experimental|pravastatin 80mg/d|Oral administration of pravastatin at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
16293711|NCT04719481|Placebo Comparator|placebo|Oral administration of placebo at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
16293712|NCT04719468|Experimental|Intervention|
16293713|NCT04719468|No Intervention|Usual Treatment|usual treatment with the addition of joining 'Tea and Biscuit' sessions remotely
16293714|NCT04719455|Experimental|Intervention treatment experienced patients|AIMS
16293715|NCT04719455|Experimental|Intervention starting patients|AIMS
16293716|NCT04719455|Other|Control group treatment experienced patients|Regular care
16293717|NCT04719455|Other|Control group starting patients|Regular care
16293831|NCT04718844|Placebo Comparator|Placebo - Thalassaemia|
16293832|NCT04718844|Experimental|Xmg/kg - Thalassaemia|
16293718|NCT04719442|Experimental|BHF-LC|To test an innovative implementation strategy, four communities will be assigned to pilot test the packaged PWMI and training materials when coupled with a learning collaborative facilitation strategy and sustainability action planning process to support PWMI adoption, implementation, and sustainability (BHF-LC).
16293719|NCT04719442|Active Comparator|BHF-Program Only|Four other communities will be assigned to receive the packaged PWMI and training program only.
16293720|NCT04719429|Experimental|Cricket-derived protein beverage|Ingestion of a cricket-derived protein beverage
16293721|NCT04719429|Experimental|Beef-derived protein beverage|Ingestion of a beef-derived protein beverage
16293722|NCT04719416|Active Comparator|Active Treatment with Relaxation|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
16293723|NCT04719416|Active Comparator|Remission with Relaxation|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
16293724|NCT04719416|No Intervention|Active Treatment without|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
16293725|NCT04719416|No Intervention|Remission without|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
16293726|NCT04719403|Experimental|VIDEO|Participants receive access to video recordings of their clinic visits
16293727|NCT04719403|No Intervention|Usual Care|Participants receive usual care (UC), which is their normal clinic visit and written after-visit summary
16293728|NCT04719390|Experimental|TMI Component On|Randomized at daily time point to ON, text messaging intervention gets sent to participant at that time
16293729|NCT04719390|No Intervention|TMI Component Off|Randomized at daily time point to OFF, text messaging intervention does not get sent to participant at that time
16293730|NCT04719377|Experimental|Powerme midline catheter|Powerme midline catheter
16293731|NCT04719377|Sham Comparator|peripheral intravenous catheter|BD Pegusas peripheral intravenous catheter
16293732|NCT04719364||Focus Groups|10 black, 10 Latinx, and 10 white MSM will be recuited in this focus group 'cohort'
16293733|NCT04719364||Quantitative Survey Group|Cross-sectional group of 100 black, 100 Latinx, and 100 white MSM
16293734|NCT04719351|Experimental|Condition 1: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293735|NCT04719351|Experimental|Condition 2: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293736|NCT04719351|Experimental|Condition 3: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293737|NCT04719351|Experimental|Condition 4: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293738|NCT04719351|Experimental|Condition 5: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293739|NCT04719351|Experimental|Condition 6: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293740|NCT04719351|Experimental|Condition 7: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293741|NCT04719351|Experimental|Condition 8: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: not included;"
16293742|NCT04719351|Experimental|Condition 9: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293743|NCT04719351|Experimental|Condition 10: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293744|NCT04719351|Experimental|Condition 11: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293745|NCT04719351|Experimental|Condition 12: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293833|NCT04718844|Experimental|1.0mg/kg - Myelodysplastic Syndrome|
16293834|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome|
16293746|NCT04719351|Experimental|Condition 13: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293747|NCT04719351|Experimental|Condition 14: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293748|NCT04719351|Experimental|Condition 15: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293749|NCT04719351|Experimental|Condition 16: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: not included;"
16293750|NCT04719351|Experimental|Condition 17: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293751|NCT04719351|Experimental|Condition 18: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293752|NCT04719351|Experimental|Condition 19: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293753|NCT04719351|Experimental|Condition 20: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293754|NCT04719351|Experimental|Condition 21: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293755|NCT04719351|Experimental|Condition 22: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293756|NCT04719351|Experimental|Condition 23: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293757|NCT04719351|Experimental|Condition 24: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: not included;
~Behavioral prompts: included;"
16293758|NCT04719351|Experimental|Condition 25: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293759|NCT04719351|Experimental|Condition 26: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293760|NCT04719351|Experimental|Condition 27: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293761|NCT04719351|Experimental|Condition 28: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: not included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293762|NCT04719351|Experimental|Condition 29: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293763|NCT04719351|Experimental|Condition 30: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: not included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293764|NCT04719351|Experimental|Condition 31: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: not included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293765|NCT04719351|Experimental|Condition 32: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:
~Questions about positive emotions: included;
~Questions about workload/work environment: included;
~Questions about controllability: included;
~Questions with open answers: included;
~Behavioral prompts: included;"
16293835|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome|
16293836|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome|
16293837|NCT04718844|Experimental|3.0mg/kg - Thalassaemia multi dose|
16293766|NCT04719338|Experimental|participants|"Immediately after confirmation of 24 weeks SVR after the end of treatment, we will collect samples of peripheral blood from each patient into EDTA tube and test for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
~All patients included in this study will be subjected to full history taking and thorough clinical examination. The initial pre treatment data of the patients will be revised including body mass index (BMI), pre treatment status (naïve,experienced), pretreatment viral load by sensitive real-time HCV PCR technique, liver function tests, complete blood count, prothrombin time, international normalized ratio , Child-Pugh score, MELD score and FIB-4 score ."
16293767|NCT04719325|Experimental|Herbert screw|
16293768|NCT04719325|Active Comparator|Lag screw|
16293769|NCT04719312|Experimental|transconjunctival Y modification|
16293770|NCT04719299|Experimental|smart phone application|Behavior modification of patients will be done by showing them smartphone application game. The game demonstrates the use of common dental equipment like mirrors, ultrasonic scalers, handpieces and suction tips, etc. in the form of animated pictures with visual and sound effects. The dentist will play the game to show the child the dental procedure that will be performed on him later.
16293771|NCT04719299|Active Comparator|traditional behavior management technique|Using traditional behavior management techniques (Tell-Show-Do) which will be applied prior to local anesthesia administration
16293772|NCT04719286|Experimental|Intervention group|The intervention is the use of the MinSafeStart mobile application. The app utilizes the Pregnancy-Unique-Quantification-of-Emesis-24 (PUQE-24) scale to categorize the women's NVP severity (e.g. mild, moderate, or severe) on a daily basis, and visualizes the fluctuations over time in a graph. Each woman will have their own personal graph based on the information they put in. They will also be able to see how their symptoms are compared to an average graph. The women will get treatment advice based on their PUQE-24 scale, e.g. dietary and lifestyle advice for mild symptoms and referral to see the doctor for moderate and severe symptoms.
16293773|NCT04719286|No Intervention|Control group|Standard care.
16293774|NCT04719273|Experimental|Treatment (onapristone, anastrozole)|Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
16293775|NCT04719260|Experimental|Nutrition Thinking®|Nutrition Thinking® approach to promote weight loss and healthy diet pattern.
16293776|NCT04719260|Active Comparator|Standard Nutritional Approach|The traditional nutritional prescriptive approach.
16293777|NCT04719247|Experimental|Turmeric|Turmeric extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
16293778|NCT04719247|Experimental|Thymus Vulgaris|Thymus Vulgaris extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
16293779|NCT04719247|Experimental|Nigella Sativa|Nigella Sativa extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
16293780|NCT04719247|Experimental|Aloe Vera|Aloe Vera extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
16293781|NCT04719247|Active Comparator|Formocresol|Formocresol will be used as a dental pulp dressing material after pulpotomy to be compared with other materials.
16293782|NCT04719234|Other|lung ultrasound|lung ultrasonography protocol will be applied.
16293783|NCT04719221|Placebo Comparator|Statin+Ezetimibe|Drug: Statin + Ezetimibe (combined cholesterol therapy)
16293784|NCT04719221|Active Comparator|Statin+Ezetimibe+Evolocumab|Drug: Statin + Ezetimibe (combined cholesterol therapy) and Drug: Evolocumab
16293785|NCT04719208|Experimental|Chlorhexidine gluconate (A)|Mouth rinse with 0.2% Chlorhexidine gluconate,
16293786|NCT04719208|Experimental|Hydrogen peroxide (B)|Mouth rinse with 1.5% hydrogen peroxide
16293787|NCT04719208|Experimental|Betadine (C)|Mouth rinse with betadine mouthwash,
16293788|NCT04719208|Experimental|Mouth wash (D)|Mouth rinse with alcohol-based mouthwash
16293789|NCT04719208|Placebo Comparator|Water (E)|Mouth rinse with water
16293790|NCT04719169|Experimental|Post-low pelvic colorectal anastomosis|Single armed study
16293791|NCT04719156|Other|ICG use followed by SPY-PHI imaging.|Participants will be injected with 2.5mg/kg of ICG dye to access tumor margin using Stryker SPY imaging technology.
16293792|NCT04719143|Active Comparator|CBT-I|
16293793|NCT04719143|No Intervention|Waitlist Control|
16293794|NCT04719130|Experimental|Experimental Group|Will received multimodal circuit exercise group.
16293795|NCT04719130|Active Comparator|Control Group|Will received multidisciplinary lectures on pain and usual care provided by the Basic Health Units.
16293796|NCT04719104|Experimental|Participating group of neonates|Participating group: Neonates that have had both a serum bilirubin measurement and transcutaneous measurement post phototherapy. This is a single arm study as we are only targeting one group of individuals with the intervention (transcutaneous bilirubin measurement). However, we will compare the serum bilirubin measurement to the transcutaneous measurement from the same neonate to determine if there is a clinically significant difference between the two measurements.
16293797|NCT04719091|Experimental|HA formulation Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
16293798|NCT04719091|Placebo Comparator|Placebo Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
16293799|NCT04719078|Other|All patients|There are no study arms. All patients obtain all imaging modalities.
16293800|NCT04719065|Experimental|Group A, Mitoxantrone Hydrochloride Liposome Injection, q4w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
16293801|NCT04719065|Experimental|Group B, Mitoxantrone Hydrochloride Liposome Injection, q3w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
16293802|NCT04719052|Experimental|Mediterranean diet group|"1) The MD will be based on high consumption of unsaturated fat from vegetable sources (virgin olive oil and nuts) and minimally processed plant foods (vegetables, fruits, nuts, whole grains and legumes), low consumption of meat (especially red and processed meats) and sweets, and moderate consumption of fish and dairy products (mainly yoghurt and cheese). Accordingly, this diet will provide a high amount of mono and polyunsaturated fatty acids, fibre and phenolic compounds.
~Adolescents in the MD group will replace the intake of conventional breads by sourdough bread consumption (2 servings of 50-60 g daily) and incorporate into their diet chickpeas (2 servings of 150 g/week chickpeas, minimum one of them in hummus format), and they will consume at least another serving of legumes which can be chickpeas or another legume), pomegranate juice (4 servings of 200ml/week) and mixed nuts (4 servings of 30 g/week)."
16293803|NCT04719052|Active Comparator|Low-fat diet group|2) The low-fat diet (control diet) will be based on low consumption of fats. A low-fat diet is the most used diet for obesity treatment in adolescents. This group will not receive any additional specific food by researchers. This diet will be based on the diet proposed as low-fat diet in the PREDIMED study
16293804|NCT04719039|Experimental|Yoga Group|Restorative Yoga intervention
16293805|NCT04719039|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
16293806|NCT04719026||Cases|Patients for the case study group will be recruited from those hospitalized for acute myocardial infarction on the Cardiology Ward and Coronary Care Unit at Aberdeen Royal Infirmary. All patients will be diagnosed using current clinical criteria for type-1 myocardial infarction according to the ESC guidelines10 and recruited within 3 days of admission. Recruitment of this arm is now complete.
16293807|NCT04719026||Controls|A control group of dental patients matched for age (±3 years), gender, and risk factors for CAD (hypertension, obesity, diabetes, smoking, hypercholesterolaemia and family history) but with no history of myocardial infarction will be selected at Aberdeen Dental School or from the SHARE register or via the NHS Research Scotland Primary Care Network on an invitation basis. Thr recruitment of this arm of the study is ongoing.
16293808|NCT04719013|Experimental|treatment|
16293809|NCT04719000|Experimental|rhFSH+rhLH|Ovarian Stimulation with rhFSH+rhLH
16293810|NCT04719000|Active Comparator|rhFSH|Ovarian Stimulation with rhFSH
16293811|NCT04718987|Experimental|Prostate Cancer Patients|Low- or favourable intermediate-risk prostate cancer patients
16293812|NCT04718974|Experimental|"intervention  Call for life- mHealth tool with standard of care for PLHIV"|"The system has options to either use interactive voice response or short message service and the user has to make a choice, get a secret pin code which ensures privacy to end user.
~The mHealth tool/system offers personalised pill reminder calls, health tip messages, clinic appointment reminders and remote symptom reporting"
16293813|NCT04718974|No Intervention|"Standard of care usual care"|"Standard
~• Care and support for people living with HIV, and the first line ART regimen is based on the Apr 2018, consolidated guidelines for prevention and treatment of HIV in Uganda (MoH, 2018), and will also follow the healthcare services package for PLHIV including the Adult Care and Treatment Package."
16293814|NCT04718961|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
16293815|NCT04718961|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
16293816|NCT04718961|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
16293817|NCT04718948||Patients Positive for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention
~The group of cases will consist of patients who meet the inclusion and exclusion criteria in the operative note for:
~Transurethral Resection of Bladder Neoplasia (TURBT)
~Radical Cystectomy for Bladder Neoplasia
~Diagnostic ureterorenoscopy and / or laser treatment of ureteral and / or renal pelvis neoplasia
~Segmental ureterectomy with or without ureteral reimplantation
~Nephroureterectomy with or without bladder cuff excission"
16293818|NCT04718948||Patients Negative for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention
~The control group will consist of patients who meet the inclusion and exclusion criteria in the operative note for:
~Transurethral Resection of Prostate (TURP)
~Other endoscopic treatments of Benign Prostatic Hyperplasia (BPH)
~Open interventions of prostatic adenomectomy
~Endoscopic lithotripsy interventions of bladder stones or cystotomy with removal of bladder stones
~Rigid and / or flexible ureterorenoscopy for the treatment of kidney and / or ureteral stones
~Placement of ureteral catheter for ureteral and / or renal stones
~Bladder Neck Incision (TUIP)
~Endoscopic urethrotomy"
16293819|NCT04718922|Experimental|Experimental Arm|Mouthrinse with 100 ml 0.12% chlorhexidine for 1 min
16293820|NCT04718922|No Intervention|Control Arm|No mouthrinse
16293821|NCT04718909|Experimental|Regorafenib + sintilimab|Regorafenib combined with sintilimab.
16293822|NCT04718909|Active Comparator|Regorafenib|Regorafenib alone.
16293825|NCT04718883|Experimental|JWCAR029 treatment|JWCAR029 be administrated at dose level: 1 x 10^8 CAR+T cells
16293826|NCT04718870|Experimental|Dupilumab|Double dose on day 1 and followed by single dose every 14 or 28 ± 2 or 3 days through week 12 or 14
16293827|NCT04718870|No Intervention|Healthy Volunteer|serve as reference for normal skin
16293828|NCT04718844|Experimental|1.0mg/kg - Thalassaemia|
16293829|NCT04718844|Experimental|3.0mg/kg - Thalassaemia|
16293830|NCT04718844|Experimental|10.0mg/kg - Thalassaemia|
16293849|NCT04718805|Experimental|Treatment A|Participants will receive Treatment A (a single dose of darunavir [DRV]/cobicistat [COBI] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence AB or BA). A washout period of at least 7 days will be maintained between each treatment period.
16293850|NCT04718805|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of DRV/COBI as separate tablets under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence BA or AB). A washout period of at least 7 days will be maintained between each treatment period.
16293851|NCT04718792|Experimental|Psilocybin|10 patients will receive a single administration of psilocybin
16293852|NCT04718779|Experimental|Velaglucerase Alfa (VPRIV)|Participants will receive VPRIV 60 Units per kilogram (U/kg) intravenous infusion every other week for 60 minutes as per physician treatment plan up to 12 months.
16293853|NCT04718753|Experimental|Mindful Breathing Group|Mindful breathing intervention which has been used in mindfulness-based interventions
16293854|NCT04718753|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
16293855|NCT04718740|Experimental|fluzoparib|"Experimental: group A Intervention: Drug: fluzoparib, caffeine, vitamin K, warfarin, omeprazole, and midazolam
~Experimental: group B Intervention: Drug: fluzoparib, repaglinide and bupropion"
16293856|NCT04718727|Placebo Comparator|Group 1|patients will receive oral placebo tablets one hour preoperatively
16293857|NCT04718727|Active Comparator|Group 2|patients will receive oral 5 mg Olanzapine tablets one hour preoperatively
16293858|NCT04718727|Active Comparator|Group 3|patients will receive oral 10 mg Olanzapine tablets one hour preoperatively
16293859|NCT04718714|Active Comparator|midazolam|postoperative ventilation and sedation with continuous intravenous infusion of midazolam only for 24 hours
16293860|NCT04718714|Active Comparator|propofol|postoperative ventilation and sedation with continuous intravenous infusion of propofol only for 24 hours
16293861|NCT04718714|Experimental|dexmedetomidine|postoperative ventilation and sedation with continuous intravenous infusion of dexmedetomidine only for 24 hours
16293862|NCT04718701|Experimental|Experimental Group|Patients who failed first-line therapy with locally advanced or metastatic pancreatic cancer will be assigned to receive anlotinib plus toripalimab and nab-paclitaxel as second-line or maintenance treatment.
16293863|NCT04718688|Experimental|CO-OP intervention|CO-OP intervention
16293864|NCT04718675|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of KB-0742.
16293865|NCT04718675|Experimental|Part 2: Cohort Expansion|"Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) in Part 1, the following expansion cohorts will be enrolled:
~Cohort A: Relapsed or refractory (R/R) solid tumors with evidence of MYC amplication/overexpression.
~Cohort B: Relapsed or refractory (R/R) soft tissue sarcomas with evidence of transcription factor dysregulation."
16293866|NCT04718662|Experimental|Active Treatment with 2'fl|Receiving of the 2'fucosyllactose supplement
16293867|NCT04718662|Placebo Comparator|Placebo|Receiving of the placebo: dextrose
16293868|NCT04718649|Experimental|Celebrex + Joins|"The experimental group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and Joins (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only Joins (taken 3 times a day) at week 12. They will only take Joins for another 24 weeks until the 36th week.
~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
16293869|NCT04718649|Placebo Comparator|Celebrex + Placebo|"The control group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and placebo (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only placebo (taken 3 times a day) at week 12. They will only take Joins placebo for another 24 weeks until the 36th week.
~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
16293871|NCT04718623||Sepsis group (SG)|with source of infection and SOFA Score more than or equal 2
16293872|NCT04718623||Non-Sepsis Group (NSG)|with SOFA score less than 2
16293873|NCT04718610|Active Comparator|Control|Patients will receive only caner treatment. No osteopathic treatment.
16293874|NCT04718610|Experimental|Osteopathic intervention|Patients will receive cancer treatment associated with osteopathic intervention
16293875|NCT04718597||Open hernia repair|Patients who underwent inguinal hernia repair via an open Liechtenstein procedure
16293876|NCT04718597||Robotic assisted hernia repair|Patients who underwent inguinal hernia repair via robotic assisted laparoscopy
16293877|NCT04718584|Experimental|Experimental Arms|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
16293878|NCT04718558||Patients aged between 3-24 month and undergoing cleft palate surgery|
16293879|NCT04718545|Active Comparator|Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a conventionally prepared recipient site and sutured to cover the mucosal recession
16293880|NCT04718545|Experimental|Modified Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a modified recipient site and sutured to cover the mucosal recession
16293881|NCT04718532||patients|patients with retinal diseases
16293882|NCT04718519||Migrant Workers|
16293883|NCT04718506|Experimental|Exercise|Supervised exercise training
16293884|NCT04718506|Active Comparator|Controls|Non-supervised SEPAR exercise guidelines
16293885|NCT04718493|Experimental|Stent|
16293886|NCT04718493|Active Comparator|Dilatation|
16293887|NCT04718480|Placebo Comparator|Placebo|2 x 100 mg placebo daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
16293888|NCT04718480|Experimental|Fluvoxamine|2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
16293951|NCT04718064|Placebo Comparator|Placebo with standard therapy|Patients will be treated with intravascular therapy and placebo.
16293889|NCT04718467|Experimental|adults group (aged 18-59 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
16293890|NCT04718467|Placebo Comparator|adults group (aged 18-59 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
16293891|NCT04718467|Experimental|elderly adults group (aged 60-85 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
16293892|NCT04718467|Placebo Comparator|elderly adults group (aged 60-85 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
16293893|NCT04718454||Equator attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,Equator Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
16293894|NCT04718454||ball attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,ball Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
16293895|NCT04718441|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
16293896|NCT04718428||psoriatic arthritis|Patients with psoriatic arthritis who met the CASPAR criteria and were 18-70 years old were included. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, another rheumatological disease, systemic infection, and pregnancy were excluded.
16293897|NCT04718428||healthy controls|A gender- and age-matched healthy controls were included. They were recruited from the healthy relatives of the hospital staff. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, any rheumatological disease, systemic infection, and pregnancy were excluded.
16293898|NCT04718415|Experimental|sintilimab + carboplatin + nab-paclitaxel|"Treatment with sintilimab, nab-paclitaxel and carboplatin for up to 2 - 4 cycles:
~Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
16293899|NCT04718402|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with advanced gastric carcinoma will receive 20mg/m2Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
16293900|NCT04718389|Experimental|Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment|Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor [anti-IL-5/5R] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
16293901|NCT04718389|Active Comparator|Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)|Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
16293902|NCT04718376|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
16293903|NCT04718363|Experimental|PNF stretching group|
16293904|NCT04718363|Experimental|Non-vibration foam rolling prior to PNF stretching group|
16293905|NCT04718363|Experimental|Vibration foam rolling prior to PNF stretching group|
16293906|NCT04718363|No Intervention|Control Group|
16293907|NCT04718350|Active Comparator|Intravenous administration of Levosimendan at a dosage of 6 mcg/kg after induction of anesthesia|in this group, 6 mcg/kg of levosimendan will be administered intravenously after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
16293908|NCT04718350|Active Comparator|Inhalational administration of Milrinone at a dosage of 50 mcg/kg after induction of anesthesia|in this group, 50 mcg/kg of milrinone will be administered via inhalation after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
16293909|NCT04718324|Experimental|e-PROMS|Patients allocated to the e-PROMS arm will fill an online version of PROMS and then respond to the e-PREMS questionnaire.
16293910|NCT04718324|Active Comparator|p-PROMS|Patients allocated to the p-PROMS arm will fill in PROMS in paper form (p-PROMS) and then respond to the p-PREMS questionnaire.
16293911|NCT04718311|Active Comparator|Tacrolimus treatment|Apply a small amount (about 1 teaspoon) of medication to the lesions, twice a day after brushing the teeth, with a soft bristle toothbrush or with a finger (covered with a well-fitting glove).
16293912|NCT04718311|Placebo Comparator|Anti-inflammatory mouthwash|Anti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
16293913|NCT04718298|Experimental|Inguinal hernia repair laparoscopic|recurrent inguinal hernia after open repair or bilateral hernia patients
16293914|NCT04718285|Experimental|Montelukast|6x10 mg oral montelukast daily for 14 days.
16293915|NCT04718285|Experimental|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 6x10 mg oral montelukast daily for 14 days, concurrently.
16293916|NCT04718285|Active Comparator|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
16293952|NCT04718051|Experimental|Shen Pu Yang Gan Wan|Traditional Chinese Medicine
16293953|NCT04718051|Placebo Comparator|Placebo Comparator|Placebo Comparator
16293917|NCT04718272|Experimental|Puncture tube group|After the operation, the traditional traditional silicone tube which placed through the surgical incision was removed in the operating room, and the small puncture tube was retained for thoracic drainage.
16293918|NCT04718272|No Intervention|Traditional tubes group|Routine thoracic drainage management measures were adopted, that is, both of the small puncture tube and traditional silicone tube were retained after surgery.
16293919|NCT04718259|Experimental|Group A|Will include patients who will receive bupivacaine intrathecal injection without adjuvant.
16293920|NCT04718259|Experimental|Group B|Will include patients who will receive bupivacaine and midazolam.
16293921|NCT04718246|Other|Dental Implants in hyperlipidemia patients|Implants will be placed at T0, then Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks then the impressions (indirect, closed tray echnique) shall be taken to fabricate the final crowns, then the final crowns will be fitted in place.
16293922|NCT04718233|Experimental|sildenafil citrate|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
16293923|NCT04718233|Placebo Comparator|placebo|placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
16293924|NCT04718220|Placebo Comparator|Unexposed (SARS-CoV-2 negative) cohort|Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
16293925|NCT04718220|Active Comparator|Exposed (SARS-CoV-2 positive) cohort|Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
16293926|NCT04718207||Patient with Alzheimer disease|Patients recruited retrospectively with the available nuclear medicine listing of patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
16293927|NCT04718194|Experimental|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
16293928|NCT04718194|Placebo Comparator|Self-monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
16293929|NCT04718181|Experimental|Part 1|"Cohort A+B: participants will receive, in a five-period crossover way, a single oral dose of risdiplam oral solution 5 mg in fasted state and thereafter risdiplam/F21 or F22 dispersible tablet 5 mg as tablet in fasted and fed states; tablet dispersed in water in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations.
~Cohort C+D: participants will receive, in a two-period fixed sequence design, a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state and omeprazole 40 mg once daily for 7 days + a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state, on the 7th day of omeprazole. There will be a 14-day wash-out between the two treatment periods.
~Cohort E: participants will receive, in a two-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations."
16293930|NCT04718181|Experimental|Part 2 (optional)|"Group 1: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as swallowed tablet in fasted state; swallowed tablet in fed state.
~Group 2: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as tablet dispersed in water in fasted state; tablet dispersed in water in fed state."
16293931|NCT04718181|Experimental|Part 3 (optional)|"Group 1: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as swallowed tablet in fasted state; swallowed tablet in fed state.
~Group 2: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as tablet dispersed in water in fasted state; tablet dispersed in water in fed state."
16293932|NCT04718168|Experimental|Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial|
16293933|NCT04718168|Experimental|Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial|
16293934|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial|
16293935|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial|
16293936|NCT04718155|Active Comparator|statin group|will receive atorvastatin for 48 hours
16293937|NCT04718155|Placebo Comparator|control|will receive placebo tablets for 48 hours
16293938|NCT04718142|Experimental|vNEP with various shapes and sizes and overnight PSG|Administer vNEP therapy to study participants on the throat's anterior surface with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O. Assess participants for a reduction in Apnea-Hypopnea Index (AHI) for at least 120 minutes using polysomnography (PSG) and treatment tolerance compared to CPAP.
16293939|NCT04718129|Experimental|Mindfulness|App-based, coached Mindfulness Program. Nne weekly coached sessions with practice exercises between sessions.
16293940|NCT04718129|No Intervention|Control|Participants in this arm are randomly assigned to an assessment-only, no intervention control condition.
16293941|NCT04718116|Active Comparator|tapentadol 50 mg|tapentadol 50mg p.o 3 times daily for two days
16293942|NCT04718116|Active Comparator|tapentadol 75 mg|tapentadol 75 mg p.o 3 times daily for two days
16293943|NCT04718116|Active Comparator|tramadol 100 mg|tramadol 100 mg p.o 3 times daily for two days
16293944|NCT04718103|Experimental|Participants receiving GSK3511294 (Depemokimab)|Participants will receive GSK3511294 (Depemokimab) during the study. All participants will continue their Baseline SoC asthma treatment throughout the study.
16293945|NCT04718103|Placebo Comparator|Participants receiving Placebo|Participants will receive placebo during the study. All participants will continue their Baseline SoC asthma treatment throughout the study.
16293946|NCT04718090|Active Comparator|interscalene block|
16293947|NCT04718090|Active Comparator|PENG block|
16293948|NCT04718077|Experimental|IO dexamethasone injection|
16293949|NCT04718077|Active Comparator|SM dexamethasone injection.|
16293950|NCT04718064|Experimental|fingolimod with standard therapy|Patients will be treated with intravascular therapy and fingomod.
16356191|NCT04284553|Experimental|Order Entry + Different Risks|
16293954|NCT04718025|Experimental|Low-dose ticagrelor with aspirin (LDTA)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, and will receive the following antiplatelet therapy:
~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;
~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until 12 months after ACS."
16293955|NCT04718025|Experimental|Low-dose ticagrelor with placebo (LDTP)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, followed by discontinuation of aspirin after 3 months post-ACS, and will receive the following antiplatelet therapy:
~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;
~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until day 90 after ACS;
~ticagrelor 2x60mg + placebo starting from day 91 until 12 months after ACS."
16293956|NCT04718025|Active Comparator|Standard-dose ticagrelor with aspirin (SDTA)|Patients with ACS in this arm will receive standard dual antiplatelet therapy including ticagrelor 2x90mg + aspirin 1x100mg during the whole 12 months after ACS.
16293957|NCT04717999|Experimental|UWN2D CAR-T|
16293958|NCT04717986|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 12 months
16293959|NCT04717986|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 12 months
16293960|NCT04717960|Active Comparator|study group group (1)|the group which will undergo submucosal injection of platelet rich plasma
16293961|NCT04717960|No Intervention|comparative group group (2)|patients using the usual lines of medical treatment like nasal douching and lubricants
16293962|NCT04717947||Short interval group|≤ 8weeks between the end of neoadjuvant therapy and surgery
16293963|NCT04717947||Intermediate interval group|> 8 and ≤ 12 weeks between the end of neoadjuvant therapy and surgery
16293964|NCT04717947||Long interval group|> 12 weeks between the end of neoadjuvant therapy and surgery
16293965|NCT04717934|Experimental|GAL1906|
16293966|NCT04717934|No Intervention|Control|
16293967|NCT04717921||Patients|Subjects with unipolar depression
16293968|NCT04717921||Healthy|Healthy Control Group
16293969|NCT04717908|Experimental|PZA sensitivity guided all oral regimen|"This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity results, patients will be divided into three sub-groups.
~The regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week).
~PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .
~PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid, cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) ."
16293970|NCT04717895|Experimental|1st Situation|Subjects included will be identified with an even selection number will begin the virtual reality session by viewing a rocking environment followed by a translation environment
16293971|NCT04717895|Active Comparator|2nd Situation|Subjects included will be identified with an odd selection number will start the virtual reality session by viewing a translation environment followed by a rocking environment
16293972|NCT04717882|No Intervention|Control arm|Patients in the control arm will receive the usual treatment
16293973|NCT04717882|Experimental|Intervention arm|After crossing over to the intervention period, attending physicians will receive medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
16293974|NCT04717869||ICU Patients|Adult Surgical, Cardiothoracic, and Neuro- ICU patients will be enrolled within 48 hrs of admission
16293975|NCT04717856|Other|drug users|
16293976|NCT04717843|Experimental|Patients with embolic strokes of undetermined source.|Patients over 18 years old, with embolic strokes of undetermined source, fulfilling the TOAST criteria. The intervention consists of a 4D Flow MRI.
16293977|NCT04717843|Experimental|Patients with non-paroxysmal AF.|Patients over 18 years old, with non-paroxysmal AF. The intervention consists of a 4D Flow MRI.
16293978|NCT04717843|Active Comparator|Heathy volunteers|The control group will include volunteers over 45 years old with no history of cardio-vascular or neuro-vascular disease. The last will be certified by a pre inclusion protocol containing a medical consultation, a Holter ECG and a trans-thoracic echocardiography. The age of 45 was chosen to get comparable age group and set the analyses free of the age-related effect on the cardiac hemodynamic. The intervention consists of an ECG, holter ECG, Trans thoracic echocardiography ETT, Blood sample and 4D Flow MRI.
16293979|NCT04717843|Experimental|ESUS and non-paroxysmal AF patients with cardiac MRI|ESUS and non-paroxysmal AF patients (fulfilling the group 1 et 2 criteria) and who had had cardiac MRI, in a retrospective way. It corresponds to retrospective inclusion of patients which had MRI in the year before the beginning of the study.
16293980|NCT04717830|Experimental|Gamezumab 1/10 therapeutic dose|1/10 therapeutic dose (5 volunteers)
16293981|NCT04717830|Experimental|Gamezumab 1/2 therapeutic dose|1/2 therapeutic dose (5 volunteers)
16293982|NCT04717830|Experimental|Gamezumab full therapeutic dose|therapeutic dose (10 volunteers)
16293983|NCT04717817|Experimental|Group 1: experimental|Daily inspiratory muscle training (IMT) using an IMT Threshold device (Philips) prior to surgery
16293984|NCT04717817|Active Comparator|Group 2: comparator|Standard physiotherapy prior to surgery
16293985|NCT04717804|Active Comparator|AIP (Average Intensity Projection) CT (Computed Tomagraphy)|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
16293986|NCT04717804|Placebo Comparator|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
16293987|NCT04717791|Other|Procedure|Subjects will be followed from the Vivaer® treatment date out to 24 months post index procedure.
16293988|NCT04717778|Experimental|pH milk|Group of children who were given the different types of milk and only the pH was measured
16293989|NCT04717765|Experimental|Preventive in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the first day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.
~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
16293990|NCT04717765|Active Comparator|Preventive in oral mucositis caused by chemo or radiotherapy - Vit E|"Topical Vit. E spray, from the first day to the last day, every day that the chemo or radiotherapy treatment is administered.
~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
16293991|NCT04717765|No Intervention|Preventive in oral mucositis caused by chemo or radiotherapy - mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the first to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
16293992|NCT04717765|Experimental|Curative in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the tenth day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.
~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
16293993|NCT04717765|Active Comparator|Curative in oral mucositis caused by chemo or radiotherapy - mucositis Vit E|"Topical Vit. E spray, application from the tenth day, and until the last day, every day that the chemo or radiotherapy treatment is administered.
~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
16293994|NCT04717765|No Intervention|Curative in oral mucositis caused by chemo or radiotherapy- mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the tenth to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
16293995|NCT04717765|Experimental|Preventive osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + extraction|"For patients who need dental extraction for the adequacy of the oral cavity. Application of LLL phototherapy on the day the dental extraction is performed and every 72hr, totaling 5 applications. It must be done at least 3 months before the beginning of the chemo or radiotherapy treatment.
~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of the root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
16293996|NCT04717765|Active Comparator|Preventive osteonecrosis resulting from chemo or radiotherapy - LPRF+ extraction|"For patients who need dental extraction for the adequacy of the oral cavity. LPRF placement on the day the tooth extraction is performed. The procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.
~After the LPRF has been placed, the suture should be done in a way that facilitates healing for primary intention."
16293997|NCT04717765|No Intervention|Preventive osteonecrosis resulting from chemo or radiotherapy - extraction only|"For patients who need dental extraction for the adequacy of the oral cavity, the procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.
~The suture should be done in a way that facilitates healing for primary intention."
16293998|NCT04717765|Experimental|Curative osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and application of LLL phototherapy on the day of surgery and every 72hr, totaling 5 applications. The suture should be done in a way to facilitate healing for primary intention.
~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of what would be the dental root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
16293999|NCT04717765|Active Comparator|Curative osteonecrosis resulting from chemo or radiotherapy - LPRF + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and placement of the LPRF on the day of surgery will be performed.
~After the LPRF is placed, the suture should be done in a way that facilitates healing for primary intention."
16294000|NCT04717765|No Intervention|Curative osteonecrosis resulting from chemo or radiotherapy - sequestrectomy only|"Patients who were diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy and removal of necrotic tissue will be performed.
~The suture should be done in a way that facilitates healing for primary intention."
16294001|NCT04717752|Experimental|Double trigger unit|HCG: 6000IU (Ovidrel: 250ug) + GnRH-a (Troprilin) 0.2mg
16294002|NCT04717752|Sham Comparator|HCG trigger unit|HCG: 6000IU (Ovidrel: 250ug)
16294003|NCT04717739||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
16294004|NCT04717726|Experimental|MT|Participants in the MT group will be supplemented with Milk Thistle extract for 12 weeks
16294005|NCT04717726|Experimental|LAC|Participants in the LAC group will be supplemented with Lactobacillus Gassri for 12 weeks
16294006|NCT04717726|Experimental|EX|Participants in the EX group will perform aerobic exercise, 5 days per week for 12 weeks
16294007|NCT04717726|Experimental|MT + EX|Participants in the MT + EX group will be supplemented with Milk Thistle extract and exercise for 12 weeks
16294008|NCT04717726|Experimental|LAC + EX|Participants in the LAC + EX group will be supplemented with Lactobacillus Gassri and exercise for 12 weeks
16294009|NCT04717726|Placebo Comparator|CON|Participants in the CON group will be supplemented with maltodextrin pills made to look like the pills received by the MT and LAC groups for 12 weeks
16294010|NCT04717713|Experimental|steroid group|patients receiving steroid injection for preventing postoperative dysphagia
16294011|NCT04717713|Placebo Comparator|placebo group|patients receiving saline injection for comparator
16294012|NCT04717700|Active Comparator|A VRD-light|Bortezomib sc 1.3mg/sqm once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles followed by continuos lenalidomide-dexamethasone
16294013|NCT04717700|Experimental|B -selinexor-lenalidomide/bortezomib-dexamethasone|"Alternating cycles of:
~Selinexor oral 40mg once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 i 28 days cycles and Selinexor oral 80mg once weekly Bortezomib sc 1.3mg/sqm once weekly Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles (8 of each, alternating) followed by continuos selinexor 40mg(once weekly)-lenalidomide-dexamethasone
~for up to 16 cycles followed by continuos lenalidomide-dexamethasone"
16294014|NCT04717687|Experimental|Electrodes|Electrodes
16294015|NCT04717674|Experimental|Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA)|Participants will undergo two PET/CT scans with the tracer [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as [18F]FPIA, on 2 separate visits.
16294016|NCT04717661||76 healthy early pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
16294017|NCT04717661||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
16294018|NCT04717648||Patients with anastomotic leakage|Post operative anastomotic leakage
16294019|NCT04717648||Patients without anastomotic leakage|Post operative without anastomotic leakage
16294020|NCT04717635|Experimental|Canakinumab|All participants receive canakinumab (ACZ885) as open-label study medication. Participants are administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed is 300 mg.
16294021|NCT04717609|Active Comparator|Partial Meniscectomy without Saphenous Nerve Block|Participants scheduled for partial meniscectomy will preoperatively receive 0.5% ropivacaine with epinephrine
16294022|NCT04717609|Experimental|Partial Meniscectomy with Saphenous Nerve Block|Participants scheduled for a partial meniscectomy will preoperatively receive a saphenous nerve block at the medial femoral condyle in addition to an injection of 0.5% ropivacaine with epinephrine
16294023|NCT04717583|Experimental|IPL-treated side|For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits, the IPL-treated side of the face will be treated with IPL, once every 4 weeks for 3 consecutive times.
16294024|NCT04717583|No Intervention|Control side|"For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits (before Week 12), the control side of face will not be treated by IPL.
~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
16294025|NCT04717570|Experimental|TRIA Mitral Valve|Patients receiving the Foldax Mitral Valve
16294026|NCT04717557|Experimental|Hyperbaric Oxygen Plus Regular Care|Hyperbaric oxygen (2 hours at 2 atmospheres absolute) to be administered 1-2 times daily for up to 10 treatments after amputation. Usual care for patients with amputation will be administered in parallel.
16294027|NCT04717557|No Intervention|Regular Care|Usual care for patients with amputation.
16294028|NCT04717544|Active Comparator|Intervention Arm|"Healthcare providers from clinics participating in the intervention refer existing clients to study coordinators for smoking cessation services, wherein the coordinators link clients to the smoking cessation services, which include: 1) a weekly cognitive-behavioral therapy smoking cessation (CBT) counseling group; and 2) smoking cessation medication, which include varenicline (Chantix), bupropion (Zyban) and nicotine patches, gum, and lozenges. Clients interested in these medications will meet with the prescribing clinician to help choose the best prescription option.
~In addition to linking clients to the smoking cessation services, coordinators will invite clients to participate in the outcome study.
~Existing clients can sign-up for these services and/or the outcome study directly with the study coordinators and do not require a healthcare provider referral."
16294029|NCT04717544|No Intervention|Treatment As Usual Arm|Existing clients can be referred to the outcome study by their healthcare providers from clinics designated as TAU or they can sign-up directly with the study coordinators.
16294030|NCT04717531|Experimental|Cohort A|"2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib, epirubicin, and cyclophosphamide (THB*2-ECB*4). The cycles repeated every 21 days.
~Pyrotinib: 400mg, qd, po, day 1-21; Trastuzumab: 6 mg/kg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90 mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
16294031|NCT04717531|Active Comparator|Cohort B|"2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin and cyclophosphamide (THP*2-EC*4). The cycles repeated every 21 days.
~Trastuzumab: 6 mg/kg, day 1; Pertuzumab: 420 mg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
16294032|NCT04717518||Lower Anchor Survey|Patients will likely rate their pain lower.
16294033|NCT04717518||Higher Anchor Survey|Patients will likely rate their pain higher.
16294034|NCT04717505||Healthy Control Group|Demographic information ( age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor).
16294069|NCT04717284|Other|Control condition|Neutral prompt during the initial administration and no intervention during the two-week follow-up.
16294070|NCT04717271|Experimental|Movement Guidance Group (MVG)|In the MVG Group, the physiotherapist will provide kinesthetic stimuli by assisting manually the participant movements.
16294071|NCT04717271|Experimental|No Movement Guidance Group (NO-MVG)|In the NO-MVG, the involvement of the physiotherapist will be restricted to guarantee the safety of the participant.
16294035|NCT04717505||Rheumatological Condition Group|Demographic information (diagnosis, age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor). In addition, in order to evaluate their health status, only the case group will be applied Arthritis Impact Measurement Scales 2 (questionnaire) and Visual Analogue Scale for pain assessment.
16294036|NCT04717479|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
16294037|NCT04717479|Other|Wait-list Control|Participants will wait 8 weeks and then they will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
16294038|NCT04717466|Experimental|Psoriasis Group|Psoriasis participants will be given Secukinumab for a total of 4 months. This is a 300mg subcutaneous injection that will occur at weeks 0, 1, 2, 3, 4, 8, and 12.
16294039|NCT04717466|No Intervention|Healthy Group|Healthy participants will not receive any intervention.
16294041|NCT04717440||Patients accepting palliative care|Patients included in an early phase trial and accepting palliative care
16294042|NCT04717440||Patients refusing palliative car|Patients included in an early phase trial but refusing palliative care
16294045|NCT04717401|Experimental|Strain-counterstrain Group A|Strain Counterstrain (SCS) is a passive positional technique which aims to relieve musculoskeletal pain and dysfunction by indirect manipulation .
16294046|NCT04717401|Experimental|Muscle Energy Technique Group B|MET is a gentle manual therapy for the restricted mobility of the spine and extremities and is an active procedure in which the corrective force is regulated by the patient, not the clinician. This technique requires the patient to perform voluntary muscle contractions of varying intensity, in a specific direction, while the clinician uses a counter-force that does not allow movement to occur The physiological mechanism underlying SCS is unknown though. It has hypothesized that muscle tone inhibition occurs by stimulation of the target muscle's Golgi tendon organ by physical approximation of muscle origin and insertion.
16294047|NCT04717388|Experimental|impact of tinnitus on executive cognitive functioning|
16294048|NCT04717388|Experimental|impact of tinnitus on reorganization of functional/ structural brain connectivity maps|
16294049|NCT04717375|Experimental|BND-22 Dose Escalation (Sub-Part 1A)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 will be administered intravenously (IV), every 2 weeks (Q2W)."
16294050|NCT04717375|Experimental|BND-22 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W)."
16294051|NCT04717375|Experimental|BND-22 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W)."
16294052|NCT04717375|Experimental|BND-22 Dose Expansion (Part 2)|Will include three expansion cohorts enrolling patients with advanced stage squamous cell carcinoma of the head and neck, gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer. Enrollment will start after the RP2D of BND-22 has been established. BND-22 will be administered intravenously (IV), every 2 weeks (Q2W).
16294053|NCT04717362|Experimental|Standard Reboot with Natesto|Standard Reboot Protocol + Natesto
16294054|NCT04717362|No Intervention|Standard Reboot|Standard Reboot Protocol
16294055|NCT04717349||Family Members of PAG patients|Clinical evaluation of family members that would provide clinical information related to the diagnosis of a proband in future research.
16294056|NCT04717349||PAG patient|Pediatric and adolescent patients with gynecologic conditions.
16294057|NCT04717336|Placebo Comparator|PERIOD 1|Participant will be instructed to take 3 pills per day for a total of 3 grams.Participant will take Sodium Chloride or placebo for a two week period
16294058|NCT04717336|Placebo Comparator|PERIOD 2|Participant will be instructed to take 3 pills per day for a total of 3 grams.Participant will take Sodium Chloride or placebo for a two week period
16294059|NCT04717336|No Intervention|WASHOUT OUT PERIOD|Participant will have a wash-out period for three-weeks
16294060|NCT04717323|Experimental|Pelvic Assist (patients)|Pelvic assistance applied for gait retraining
16294061|NCT04717323|Experimental|No Intervention (controls)|Gait with no pelvic assistance
16294062|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#1|Drug: SHR0302 Ointment Twice a day (BID)
16294063|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#2|Drug: SHR0302 Ointment Twice a day (BID)
16294064|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#3|Drug: SHR0302 Ointment Twice a day (BID)
16294065|NCT04717310|Placebo Comparator|Placebo Comparator: Placebo|Drug: Vehicle Twice a day (BID)
16294066|NCT04717297|Experimental|Tailored Medication Management Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart.
16294067|NCT04717297|Sham Comparator|Attention Control Arm|The attention control group will receive two, 75-minute attention visits with a trained research assistant.
16294068|NCT04717284|Experimental|Self-compassion intervention (SCI)|Self-compassion prompt.
16294134|NCT04716868|Experimental|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 gf once a day for 8 week.
16294072|NCT04717258|Experimental|Main FIREFLI trial: Intervention arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) offered by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer) once randomised.
16294073|NCT04717258|No Intervention|Main FIREFLI trial: Control arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer offered 12 months post-randomisation)
16294074|NCT04717258|Experimental|Recruitment SWAT: Self-Determination Theory informed invitation letter|The recruitment pack to take part in the FIREFLI study will include an invitation letter informed by Self-Determination Theory.
16294075|NCT04717258|No Intervention|Recruitment SWAT: Standard invitation letter|The recruitment pack to take part in the FIREFLI study will include the University of York, York Trials Unit's standard invitation letter
16294076|NCT04717258|Experimental|Retention SWAT: Pen arm|A pen (which has the University of York logo on it) will be included with the first four-month reminder questionnaire.
16294077|NCT04717258|No Intervention|Retention SWAT: No pen|No pen will be included with the four-month reminder questionnaire.
16294078|NCT04717245|Active Comparator|Fractional CO2 LASER|Vaginal fractional CO2 LASER 3 sessions applications
16294079|NCT04717245|Active Comparator|Microablative fractional radiofrequency|Vaginal Microablative fractional radiofrequency 3 sessions application
16294080|NCT04717245|Active Comparator|Promestriene Vaginal|Promestriene vaginal use during 3 months
16294081|NCT04717232|Experimental|The blended learning approach to mentoring education for dental health care professionals|The blended learning approach to mentoring education for dental health care professionals will last five weeks, including four face-to-face seminars, interprofessional group work and self-reflection assignments lasting for two days. The educational content will include mentoring as a process, mentoring as a relationship, challenges of mentoring, and personal mentoring.
16294082|NCT04717232|Experimental|The interprofessional online mentoring education|The intervention group will attend mentoring competence education. The Interprofessional online mentoring educations includes videos of specialist lectures, e-learning materials, along with assignments concerning reflection skills and participant-based evaluation. The education content included the processes and interactions of mentoring, goal-oriented mentoring, along with student-based feedback and student-centered evaluation. The mentoring education can be completed in an online learning environment and participants can complete the education at their own pace within six weeks.
16294083|NCT04717232|Active Comparator|The Control group|The control group are dentists´ and dental hygienists´ who are working at health care centers on the Finnish Dental Association site, participate in student mentoring and have not received any education before.
16294084|NCT04717219||Severe CAVD with atherosclerosis|Participants with severe CAVD and significant atherosclerosis
16294085|NCT04717219||Severe CAVS without atherosclerosis|Participants with severe CAVD without significant atherosclerosis
16294086|NCT04717219||Moderate CAVD with atherosclerosis|Participants with moderate CAVD and significant atherosclerosis
16294087|NCT04717219||Moderate CAVD without atherosclerosis|Participants with moderate CAVD without significant atherosclerosis
16294088|NCT04717219||Healthy controls|Healthy controls without CAVD and without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication and overt heart failure (NYHA class III/IV).
16294089|NCT04717219||Controls with bicuspid aortic valve stenosis|Controls with bicuspid aortic valve stenosis, without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication.
16294090|NCT04717206|Experimental|Plyomtric training to male badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to male badminton players.
16294091|NCT04717206|Experimental|Plyomtric training to female badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to female badminton players.
16294092|NCT04717193|Experimental|Rectus Sheath Block|Participants randomized to the experimental arm will receive a bilateral rectus sheath block which is additional to the standard of care (infiltration of 5mg (2mL) 0.25% bupivacaine with epinephrine around port site incisions). For rectus sheath block, use the formula Volume (ml) = 2mg/kg x weight (kg) divided by 2.5mg/ml - 6ml to a maximum of 14ml. Maximum total dose is 2mg/kg. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
16294093|NCT04717193|Active Comparator|Local Anesthetic|Participants in the control arm will receive the standard care which is infiltration of 5mg (2mL) of 0.25% bupivacaine with epinephrine around port site incisions. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
16294094|NCT04717180|Active Comparator|group I|patients who received rehabilitation using the software program for aphasia rehabilitation
16294095|NCT04717180|Active Comparator|group II|patients who received rehabilitation using the conventional therapy
16294096|NCT04717167|Experimental|DN group|All identified MTrPs were inserted with a sterile filiform needle (0,30mm x 40mm or 0,30mm x 75mm, depending on the muscle) that moved up- and downwards until a local twitch response was elicited. When the repeated local twitch response fade away or the subject reported too much pain, the needle was removed. After the treatment, a 15 minutes break(51) was set up and the subjects were not permitted to use a hot pack or to stretch the muscle.
16294097|NCT04717167|Sham Comparator|Sham needling (SN) group|The SN technique was similar to DN, except for penetrating the muscle. In this technique, the needle only penetrated the skin and was therefore impossible to provoke a local twitch response.
16294098|NCT04717154|Experimental|Treatment arm|"Combinatory regimen of nivolumab 3mg/kg and ipilimumab 1mg/kg, followed by nivolumab 480mg flat dose (Q4w) to up to one year.
~This regimen will be given to participants in both cohort 1 and 2."
16294135|NCT04716868|Experimental|Maltodextrin 10 g + Agave Fructans 5 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 week.
16294136|NCT04716868|Active Comparator|Psyllium plantago 15 g|Psyllium plantago 15 g once a day for 8 week.
16294099|NCT04717141|Experimental|Biomecanical evaluation of the selective nerve block effects|"D0 :
~Information, collection of consent, inclusion,
~Clinical and instrumental evaluation,
~Realization of the selective nerve block,
~Post-selective nerve block clinical and instrumental re-evaluation,
~Performance of the botulinum toxin injection if indication selected.
~D28 (+/-5 days) :
~- Clinical and instrumental post-botulinum toxin injection evaluation."
16294100|NCT04717128|Experimental|Baby doll with user remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
16294101|NCT04717128|Active Comparator|Baby doll with hand controlled jaw|In this arm, standardized patients will use a cloth baby doll with a puppet-style mouth to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
16294102|NCT04717115||Genetic diagnosis|
16294103|NCT04717102|Experimental|0.75 MAC desflurane|The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
16294104|NCT04717102|Active Comparator|0.5 MAC desflurane|The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
16294105|NCT04717089||postoperative patients admitted to TMH extended post anaesthetic care in PACU|"Exclusion criteria:
~Patients awaiting ICU admission in the ordinary recovery room
~Patients requiring level 3 intensive care on arrival at the recovery room"
16294106|NCT04717089||Postoperative patient admitted to ICU with case matched|"Inclusion criteria:
~o Based on case matched with the extended post anaesthetic care in PACU"
16294107|NCT04717076|Active Comparator|App-based nutritional concept and fitness tracking|App-based nutritional concept and fitness tracking
16294108|NCT04717076|Experimental|Nutritional concept with individual nutritional counselling|Nutritional concept with individual nutritional counselling
16294109|NCT04717076|Experimental|Nutritional concept without individual nutritional counselling|Nutritional concept without individual nutritional counselling
16294110|NCT04717076|No Intervention|Control group|Control group - no intervention
16294111|NCT04717063|Active Comparator|Peroxyl|"Drug: Peroxyl Mouthwash Mouthwash
~Other Names:
~• 1.5% HP"
16294112|NCT04717063|Placebo Comparator|placebo mouthwash|"Drug: Placebo Mouthwash Mouthwash
~Other Names:
~• 0.0% HP Mouthwash"
16294113|NCT04717050|Experimental|Progressive combine training (PCT)|"Participants will be randomly assigned to Progressive combine training (PCT) group.
~Participants will have two (2) baseline tests, then begin a two phase PCT program.
~Phase 1: Supervised 16-week resistance and cardiovascular exercise at a local YMCA (months 1-4) or remotely at home via Zoom
~Participants will receive midpoint testing, approximately week 8.
~Phase 2: Unsupervised 16-week resistance and cardiovascular exercise at a local YMCA (months 5-8) or remotely at home
~Participants will receive midpoint testing, approximately two months into phase 2.
~After the two (2) 16-week phases, participants will be followed for 4 months."
16294114|NCT04717050|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to Attention Control (AC) group.
~Two (2) baseline tests will be performed prior to starting the program. Participants will perform 12 months of home-based stretching and have a 1x test performed during months 2, 4, 6, 8 and 10. Two (2) tests will be performed in month 12."
16294115|NCT04717037|Experimental|Study|The olive oil massage will be applied initially at 72 hrs of life then twice daily with a dose of 4ml/kg till 28 days .
16294116|NCT04717037|No Intervention|Control|Patients who are assigned to the control group will receive standard care as per unit policies.
16294117|NCT04716998|Experimental|MesenCure treatment|"Clinical interventions:
~Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, x-ray.
~Blood tests: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels."
16294120|NCT04716972||Online Survey|Online survey
16294121|NCT04716972||Interviews|Interviews
16294122|NCT04716959|Experimental|Prepectoral Prosthetic Breast Reconstruction|
16294123|NCT04716959|Active Comparator|Subpectoral Prosthetic Breast Reconstruction|
16294124|NCT04716946|Experimental|Participants with Early-stage Non-Small Cell Lung Cancer|Participants will be diagnosed with Stage I-IIIA NSCLC and will be ineligible for surgery and will have any level of PD-L1
16294125|NCT04716933|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
16294126|NCT04716933|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
16294127|NCT04716920|Experimental|Supportive Care (Tai Chi, Fitbit, Tai4Chijoint group)|Patients attend Tai Chi exercise classes over 1 hour BIW and wear a Fitbit device for up to 12 weeks. Patients are encouraged to complete self-practice over 30 minutes and record practice times daily in a diary log form. Patients also join a Facebook private TaiChi4joint group where they receive instructional videos matching the progress of weekly classes for at-home practices and peer support in Tai Chi engagement.
16294128|NCT04716907||Case : COVID-19 positive patients|patients hospitalized for COVID-19 infection
16294129|NCT04716907||Control : COVID-19 negative patients|patients hospitalized for other reasons
16294130|NCT04716894|Experimental|BI 474121 alone|
16294131|NCT04716894|Experimental|BI 474121 + itraconazole|
16294132|NCT04716881|Experimental|Vivitrol (naltrexone)|Intramuscular injection of Vivitrol (naltrexone), 380 mg. Six doses given 28 days apart.
16294133|NCT04716868|Experimental|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 week.
16294137|NCT04716855||Evaluation tests|RCS cases between the ages of 19-64 (n:40) who agreed to participate were included in the study. Pain severity (Visual Analogue Scale - VAS), range of motion (Universal Goniometer), muscle test (Manual muscle test), upper extremity functional status and disability (Quick-DASH questionnaire), physical activity level (International Physical Activity Questionnaire - UFAA) ) and quality of life (Short Form-36 - SF-36) were evaluated
16294138|NCT04716842||sepsis|In intensive care patients with suspected or proven infection, if the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination, monitoring and treatment will be applied.
16294139|NCT04716842||septic shock|Patients with sepsis who require vasopressor to keep mean arterial pressure above 65 mmHg and lactate> 2 mmol/l will be included in the septic shock group.
16294140|NCT04716842||control|It will be formed from patients who are hospitalized in the intensive care unit for a reason other than sepsis and septic shock, without suspected or proven infection.
16294141|NCT04716829|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG for 12 weeks.
16294142|NCT04716829|No Intervention|Control|The control group will receive its rehabilitation care.
16294143|NCT04716816|No Intervention|traditional treatment|received conventional analgesics.
16294144|NCT04716816|Experimental|Stripping massage|received SM twice daily in the active trigger points of the rhomboid for two weeks.
16294145|NCT04716803|Experimental|Bone marrow aspiration concentrate using the Angel System|"Bone marrow aspirate concentrate (BMAC) will be administered via injection to the knee of interest on day 14 of the study.
~Bone marrow aspiration will be concentrated using the Angel System."
16294146|NCT04716790|Experimental|Ultrasounds once a week|Patients will undergo the application of ultrasound therapy with a frequency of once a week.
16294147|NCT04716790|Experimental|Ultrasounds once every two weeks|Patients will undergo the application of ultrasound therapy with a frequency of once every two weeks.
16294148|NCT04716790|Active Comparator|Standard of care|Patients will be treated using the conventional treatment established by the protocol of the Diabetic Foot Unit of the University Podiatry Clinic of Complutense University of Madrid.
16294149|NCT04716777|Experimental|Brief Transdiagnostic GCBT|Participants receive Brief Transdiagnostic group cognitive-behavioral treatment. Eight weekly sessions.
16294150|NCT04716777|No Intervention|Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the Brief Transiagnostic GCBT for eight weeks.
16294151|NCT04716764||Case Group|The study will include female individuals aged 19-64 years who applied to Necmettin Erbakan University Meram Medical Faculty General Surgery and Medical Oncology Departments and were diagnosed with breast cancer for the first time and volunteering to participate in the study. Patients with breast cancer will be followed up before surgery, before chemotherapy, and in the sixth and twelfth months after starting chemotherapy.
16294152|NCT04716764||Healthy (Control) participants|The control group consists of healthy adult women who applied to the Internal Diseases (Internal Medicine) outpatient clinic of Necmettin Erbakan University Meram Medical Faculty Hospital, who are at the same age as the case group, and who have not been diagnosed with any disease by the doctor, and who are willing to participate in the study. Healthy individuals will be interviewed once. The obtained data will be compared with the preoperative data of breast cancer patients.
16294153|NCT04716751|Experimental|Toripalimab|
16294154|NCT04716738||Irritable Bowel Syndrome with Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
16294155|NCT04716738||Irritable Bowel Syndrome without Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
16294156|NCT04716725|Experimental|Experimental (68Ga-PSMA-11 PET)|Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.
16294157|NCT04716712|Active Comparator|Biannual mass oral azithromycin + child health days|Bi-annual Mass Azithromycin distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
16294158|NCT04716712|Placebo Comparator|Biannual mass placebo + child health days|Bi-annual Mass placebo distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
16294159|NCT04716712|Active Comparator|Resistance Sub Study: Azithromycin + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
16294160|NCT04716712|Placebo Comparator|Resistance Sub Study: Placebo + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
16294161|NCT04716699|Experimental|Health services research (lidocaine, surgery)|Patients receive bolus lidocaine IV per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected.
16294162|NCT04716686|Experimental|Niraparib as maintenance therapy for Endometrial Serous Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
16294163|NCT04716686|Experimental|Niraparib as recurrent therapy for Endometrial Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
16294164|NCT04716673|Experimental|Children (4-11y) with epilepsy|Down-phase-targeted closed-loop auditory stimulation is administered in each arm.
16294165|NCT04716673|Experimental|Teenagers (12-17y) with epilepsy|
16294166|NCT04716673|Experimental|Young adults (18-30y) with epilepsy|
16294171|NCT04716647|Experimental|Ayurveda Intervention|Ashwagandha, Giloy and Tulsi were given in tablet form for oral administration.
16294172|NCT04716634|Experimental|Tislelizumab + Fruquintinib|Participants with one of the tumors will be enrolled: GC,CRC and NSCLC
16294173|NCT04716621|Experimental|Early intervention|Three sites received the Pain Management Support System for Primary Care (PMSS-PC) integrated into the Electronic Health Record.
16294174|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. Three additional sites received the intervention 6 months after the first arm.
16294175|NCT04716608|Active Comparator|Group 1 INT (= intervention)|"physiotherapy program with
~Myofascial Release Massage (quadriceps)
~Foam Rolling lower extremity
~Knee Isometrics in knee extension (sitting position)
~Dynamic and static stretching (quadriceps) in half knee position
~Core Stability (planks)
~Strengthening (calf raises, good morning,squats, squat jump)
~Balance (single leg stance)"
16294176|NCT04716608|Placebo Comparator|Group 2 USC (= usual care)|"usual care treatment with
~Core Stability (prone plank)
~Strengthening: (Hip extension, abduction; Calf raises)
~Stretching (M. rectus femoris (static) in standing position; Hamstring in sitting position)
~Balance (single leg stand)"
16294177|NCT04716595|Experimental|morning administration|K-877 ER 0.2 mg/day morning administration (once daily)
16294178|NCT04716595|Experimental|evening administration|K-877 ER 0.2 mg/day evening administration (once daily)
16294179|NCT04716582|Experimental|SIT group|participants will sitting 4 hours continuously.
16294180|NCT04716582|Experimental|INTERRUPT group|participants will sitting 25 minutes with 5 minutes walking per half hour,40minutes walking in total
16294181|NCT04716582|Experimental|COGN group|participants will perform GED test as cognitive loading task during 4-hour sitting
16294182|NCT04716569|Experimental|intranasal Ivermectin group|Ivermectin group Patients who will receive intranasal ivermectin
16294183|NCT04716569|Other|Control group|patients who will receive regular protocol drugs
16294184|NCT04716556|Experimental|Standard Therapy+Convalescent Plasma|Patients will receive standard therapy + 200-300 ml of convalescent plasma for a maximum of 3 times in 5 days, according to clinical conditions.
16294185|NCT04716556|No Intervention|Standard Therapy|Patients will receive standard therapy for the treatment of SARS-CoV2 infection, according to AIFA indications
16294186|NCT04716543||ILI Investigation|The suspected ILI cases will be first identified using the WHO clinical case definition of ILI and Covid 19 as either with:Acute onset of fever (> 37.5˚C axillary temperature or > 38˚C tympanic temperature) AND cough; OR Acute onset of ANY ONE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anosmia (loss of smell) or ageusia (loss of taste); with symptoms with onset within the last 10 days.
16294187|NCT04716530||born before 2000|No patient treatment is associated with the study.
16294188|NCT04716530||born between 2000-2010|No patient treatment is associated with the study.
16294189|NCT04716530||born after 2010|No patient treatment is associated with the study.
16294190|NCT04716517|Experimental|Cention N|Intervention Alkasite Restoration will be used to restore cervical carious in adult patients.
16294191|NCT04716517|Active Comparator|Resin Modified Glass Ionomer|Comparator Resin-modified glass ionomer material will be used to restore cervical carious in adult patients.
16294193|NCT04716491|Experimental|Intervention group|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
16294194|NCT04716491|No Intervention|Control group|Participants will not use the devices at any time of admission to the intensive care unit
16294195|NCT04716478||Patient in need of endodontic care|
16294196|NCT04716465||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 (symptomatic and asymptomatic) will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
16294197|NCT04716452|Experimental|Open Label Administration of Ceramide NanoLiposome|Ceramide NanoLiposome will be administered by Intravenous Dosing twice per week in accordance with the protocol relative to dose escalation. There is no placebo group or arm of the study.
16294198|NCT04716439||magnesium sulfate effect on IONM reading in spine surgery|one group receives magnesium other do not
16294199|NCT04716426|Experimental|Tetracycline hydrochloride 3%|4 drops of tetracycline hydrochloride 3% (APT™ T3X) applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
16294200|NCT04716426|Placebo Comparator|Placebo|4 drops of placebo applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
16294201|NCT04716413|Experimental|Treatment|Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL. If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.
16294202|NCT04716413|No Intervention|Control|Subjects will be receive routine standard of care.
16294203|NCT04716400|Experimental|Intervention group|"Stop sexual harassment"
16294204|NCT04716400|No Intervention|Control group|No intervention
16294205|NCT04716387||Chlorfenapyr ITN|These study districts will receive Interceptor G2 ITNs during the mass distribution campaign.
16294206|NCT04716387||Piperonyl butoxide ITN|This study district will receive piperonyl butoxide ITN during the mass distribution campaign.
16294207|NCT04716387||Standard LLIN|These study districts will receive standard ITNs during the mass distribution campaign.
16294208|NCT04716387||Pyriproxyfen ITN|This study district will receive Royal Guard ITNs during the mass distribution campaign.
16356192|NCT04284553|Experimental|Open Encounter + Different Risks|
16294209|NCT04716374||Patients with epithelial ovarian cancer|Patients with epithelial ovarian adenocarcinoma with archival tumor tissue available for analysis were identified through the Hellenic Cooperative Oncology Group (HeCOG)'s tumor repository. Patients had received treatment at HeCOG-affiliated institutions following standard international guidelines.
16294210|NCT04716348|Experimental|group A|suboccipital muscle energy technique
16294211|NCT04716348|Sham Comparator|group B|sham muscle energy technique
16294212|NCT04716335|Experimental|Harmine + DMT|
16294213|NCT04716335|Experimental|Harmine + Placebo(DMT)|
16294214|NCT04716335|Placebo Comparator|Placebo(Harmin & Placebo)|
16294215|NCT04716322|Other|Adapted Physical Activity|A 16-week health-adapted physical activity program and 5-year follow-up
16294216|NCT04716309|Active Comparator|VLP|Open reduction and volar locking plate
16294217|NCT04716309|Active Comparator|CRPP|Closed reduction and percutaenous K-wires/pins
16294218|NCT04716296|Experimental|Ketamine arm|Treatment arm consisting of patients randomized to receive a low dose of ketamine for the second stage of DBS surgery.
16294219|NCT04716296|Active Comparator|Control arm|Control arm consisting of patients randomized to receive sham control of saline during the second stage of DBS surgery.
16294220|NCT04716244||Gestational diabetes|Women who were diagnosed with gestational diabetes within the least year
16294221|NCT04716244||Pre-eclampsia|Women who were diagnosed with pre-eclampsia within the past year
16294226|NCT04716218|Placebo Comparator|neutral position|The initial percentage of glottic opening (POGO) by laryngoscopy was recorded in the ramped position. Thereafter, a second POGO (laryngeal view) was scored in the neutral position and then intubation was performed.
16294227|NCT04716218|Experimental|back up head elevated position|The initial POGO was recorded in the neutral position. The second POGO was scored in the ramped position and then the trachea was intubated.
16294228|NCT04716205|Experimental|Mulligan's bent leg raise Technique|Mulligan's bent leg raise Technique and Static Stretching
16294229|NCT04716205|Active Comparator|Static stretching|Static Stretching
16294230|NCT04716192|Experimental|Positional release technique|Positional release technique, Mayofascial release technique and ultrasound
16294231|NCT04716192|Active Comparator|Mayofascial release technique and ultrasound|Mayofascial release technique and ultrasound
16294232|NCT04716179|Experimental|Patients with COVID-19|Patients with confirmed COVID-19 infection
16294233|NCT04716179|Other|Healthy participants|The controlled group with healthy participants without COVID-19 infection.
16294236|NCT04716153|Experimental|Interventional|"Patients in the interventional arm will follow a multifactorial sensory rehabilitation program focused on smell and taste that integrates several non-drug interventions, which are part of the current recommendations: program of workshops at the technical center, hydration of the mucous membranes with daily (3 times a day) liposomal sprays (LipoSaliva® and LipoNasal) between V0 and V1, presentation of visual dishes.
~The workshops will take place at the frequency of one session of 2 hours per week and will last for 3 weeks. Each session will accommodate 6 to 10 participants. The program will include 3 workshops on olfactory rehabilitation and taste rehabilitation.
~Exercises (taking up the themes discussed) will be carried out at home between 2 workshops."
16294237|NCT04716153|Other|Control|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.
~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
16294238|NCT04716140|No Intervention|MTP1 joint with no cartillage laesion or grade I|Patients in whom no treatment of the cartilage lesions is performed: these patients have no cartilage lesion or a grade I cartilage lesion at the MTP I joint that has been found peroperatively. The degree of the cartilage lesions will be determined on the basis of the ICRS scale and an MS Hololens.
16294239|NCT04716140|No Intervention|MTP1 joint with cartillage laesion > grade I - non treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the no treatment group
16294240|NCT04716140|Experimental|MTP1 joint with cartillage laesion > grade I - treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the treatment group. They will be treated through debridement of the lesion and microfracture.
16294241|NCT04716127|Experimental|Women 50 to 65 years with no regular cervical cancer screening|Women aged 50 to 65 years with no cervical smear or no gynecological examination for more than three years, attending the mobile unit for breast cancer screening in the Department of Hérault, or the Medical and Social Care Center in the Department of Aude.
16294242|NCT04716114|Experimental|SKLB1028|Subjects will receive 150 mg orally twice daily (BID) in continuous 28-day cycles
16294243|NCT04716114|Active Comparator|Salvage Chemotherapy|"Chemotherapy will be given in 28-day cycles. Subjects on low-dose cytarabine (LoDAC) will receive 10 to 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injections for 7 to 14 days.
~Subjects on azacitidine will receive 75 mg/m^2 daily by SC or IV, for 5 to 7 days.
~Subjects on homoharringtonine (HHT), cytarabine and aclarubicin (HAA) will receive 2 mg/m^2 of HHT by IV, for 7 days (day 1 to 7) (or HHT 2 mg/m^2, twice daily, day 1 to 3); 100~200 mg/m^2 of cytarabine by IV for 7 days (day 1~7) and 20 mg/d of aclarubicin by IV for 7 days (day 1 to 7).
~Subjects on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1000~2000 mg/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 g/m^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until ANC>0.5 x 10^9 / L."
16294425|NCT04714944|Experimental|whole fiber product|15 g for 2 weeks, followed by 30 g for 10 weeks
16294244|NCT04716101|Experimental|Patients with nonspecific low back pain|Patients will be randomized to receive either a massage technique or a sham massage technique.
16294245|NCT04716101|Active Comparator|Asymptomatic volunteers|Similarly, the volunteers will be randomized to receive either a massage technique or a sham massage technique.
16294246|NCT04716075|Experimental|Acalabrutinib 2x100mg oral capsule +alloSCT|Acalabrutinib administered 2x100mg p.o. daily for 3-6 months before alloSCT +acalabrutinib administered 2x100mg p.o. daily for 9 months after alloSCT
16294247|NCT04716062||subjects who underwent open-air surgery|Fifty-one (37%) out of 138 subjects underwent open-air surgery.
16294248|NCT04716062||subjects underwent laparoscopic-assisted surgery|A total of 87 (63%) out of 138 subjects underwent laparoscopic-assisted surgery.
16294249|NCT04716049|Experimental|Protocol I|Powerade© Carbohydrates+Protein Cherry Juice Foam Roller Cold Water Immersion
16294250|NCT04716049|Experimental|Protocol II|Powerade@ Carbohydrates+Protein Stretching Intermittent Cold-Water Immersion
16294251|NCT04716036|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
16294252|NCT04716036|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
16294253|NCT04716023||Chronic Airflow obstruction / COVID-19|Patients with either chronic airflow obstruction of COVID-19
16294254|NCT04716010|Other|Control|Products that contain red meat will not have warning labels or an increase in price.
16294255|NCT04716010|Experimental|Warning Labels|"The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment."
16294256|NCT04716010|Experimental|Tax|The tax is a 30% increase in the price of products that contain red meat.
16294257|NCT04716010|Experimental|Combined Warning Labels and Tax|"The Combined Warning Labels and Tax arm features both the warning labels and tax. The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment. The tax is a 30% increase in the price of red meat products."
16294258|NCT04715997|Experimental|GX-19: Dose A|Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29.
16294259|NCT04715997|Placebo Comparator|Placebo: Normal saline|Placebo will be intramusculary administered via EP on day 1 and day 29.
16294262|NCT04715971||Patients admitted ≤72 hours to an acute geriatric hospitalisation unit.|All patients aged ≥75 years, admitted to the acute geriatric hospitalisation units of the University Hospitals Leuven in Belgium, were consecutively screened for inclusion within 72 hours of admission in a 2 month period (between October 26 and December 18, 2015).
16294263|NCT04715958|Experimental|Diagnostic (CEUS, Definity)|Patients undergo CEUS and receive perflutren lipid microspheres IV over 10-15 minutes before NAC, after 10% of NAC, and after 30% of NAC
16294264|NCT04715945||Women|12,583 women recruited when non-pregnant
16294265|NCT04715945||Children|3,158 liveborn singleton offspring of women recruited to the study
16294266|NCT04715932|Active Comparator|Hesperidin 1000mg|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
16294267|NCT04715932|Placebo Comparator|Placebo 1000mg|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
16294268|NCT04715919||Patients in ICU|ICU patients with COVID-19
16294269|NCT04715919||Patients in Hospital Ward|Patients with COVID-19 in hospital wards
16294270|NCT04715906|Experimental|UP-Caregiver Group|Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.
16294271|NCT04715893|Experimental|Ostomy belt group|Participants in this group will receive ostomy belts for eight weeks.
16294272|NCT04715880|Active Comparator|Paravertebral Block (PVB) group|"Under complete aseptic precaution, Patient will be in lateral decubitus position a paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity.
~The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour"
16294273|NCT04715880|Active Comparator|Paravertebral block/Intercostal Block (PVB/ICB) group|Under complete aseptic precaution, patient will be in lateral decubitus position a paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
16294274|NCT04715867|Experimental|Test Group for intramuscular route|110 adult participant will get Ravix-VC
16294275|NCT04715867|Active Comparator|Comparator group for intramuscular route|110 adult participant will get Rabipur
16294276|NCT04715867|Experimental|Test Group for Intradermal Route|110 adult participant will get Ravix-VC
16294277|NCT04715867|Active Comparator|Comparator Group for Intradermal Route|110 adult participant will get Rabipur
16294278|NCT04715854|Active Comparator|Nasal canula (flexicare)|Patients will receive oxygen by classical nasal cannula
16294279|NCT04715854|Active Comparator|Intersurgical aerosol mask with one hole closed by tape|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask partially closed (one lateral hole of the face mask closed by tape)
16294280|NCT04715854|Active Comparator|Intersurgical aerosol mask|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask
16294281|NCT04715841||group A|Group A (Study group ) : 25 adolescent females suffering patellofemoral pain syndrome were recruited from the outpatient clinic of the faculty of physical therapy delta university in addition to the medical diagnosis was confirmed by consultant orthopedist using clinical and radiographic investigations .
16294282|NCT04715841||group B|Group B (Control Group):25 adolescent females with healthy knee joints with no clinical and radiographic evidence of patellofemoral pain syndrome , were recruited from the students of the faculty of physical therapy delta university .
16294283|NCT04715828||"control arm fresh"|Fresh semen treated without irradiation before cryopreservation
16294284|NCT04715828||"control arm cryopreserved"|cryopreserved semen without irradiation (n=60)
16294285|NCT04715828||acute irradiation at low dose|Pelvis scanning : acute irradiation (1 or 2 second) using low dose (n=30),
16294286|NCT04715828||long irradiation at low dose|Bone scintigraphy : long irradiation (3h) using low dose (n=30),
16294287|NCT04715828||long irradiation at medium dose|Radioactive Iodine 131 therapy (RAT) applied for thyroid cancer : long irradiation (3h) using medium dose (n=60),
16294288|NCT04715802||PAAG removal + Immediate implant reconstruction|Patients who had a one-stage operation comprising gel removal and immediate breast reconstruction.
16294289|NCT04715802||PAAG removal + Delayed implant reconstruction|Patients who had a two-stage operation comprising gel removal and delayed breast reconstruction at least 3 months later. The first included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
16294290|NCT04715802||PAAG removal + No breast reconstruction|Patients who only underwent surgical PAAG removal without breast reconstruction.
16294291|NCT04715802||PAAG removal + Delayed autologous fat grafting reconstruction|Patients who underwent a two-stage operation comprising surgical PAAG removal and autologous fat injection at least 3months later. Usually, the amount of transplanted fat was 150-200mL/side. A multilayer and multi-tunnel injection method was commonly used.
16294292|NCT04715802||PAAG removal + breast reconstruction with implants|Patients who underwent surgical PAAG removal with immediate or delayed implant breast reconstruction.
16294293|NCT04715802||Primary breast augmentation with implants|Patients who had undergone conventional breast augmentation(BA) with implants during the study period who matched the study cohort by age(±5 years).
16294294|NCT04715789|Experimental|physical therapy intervention|"core stability exercises:
~Multifidus exercises
~Frontal & Side Plank exercise
~Pelvic floor exercises
~abdominal exercises
~Strengthening exercises
~Bridging
~straight leg raise
~gluteus medius strength
~gluteus maximus strengthening for about 20 min to 30 min to strength back and proximal hip control muscles"
16294295|NCT04715789|Experimental|graded exposure and graded activity in addition to phycal therapy intervention|"Graded exposure:This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity
~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities for about 10 min before physical therapy program (strengthening)"
16294296|NCT04715776|Placebo Comparator|Pre-DM patients with placebo|Pre-Diabetes patients uptake placebo as dietary supplement
16294297|NCT04715776|Experimental|Pre-DM patients with supplement|Pre-Diabetes patients uptake Brown seaweed as dietary supplement
16294298|NCT04715776|Placebo Comparator|DM patients with placebo|Diabetes patients uptake placebo as dietary supplement.
16294299|NCT04715776|Experimental|DM patients with supplement|Diabetes patients uptake Brown seaweed as dietary supplement
16294300|NCT04715763|Active Comparator|Telmisartan (80 mg)|Telmisartan 80 mg (given as two 40 mg encapsulated tablets) given orally each day x 21 days
16294301|NCT04715763|Placebo Comparator|Placebo|Two placebo capsules given orally each day x 21 days
16294303|NCT04715737|Experimental|Vasopressin|Vasopressin (20IU) intranasally
16294304|NCT04715737|Experimental|Oxytocin|Oxytocin (24IU) intranasally
16294305|NCT04715737|Placebo Comparator|Placebo|Placebo intranasally
16294306|NCT04715724|Experimental|Baby doll with remote controlled jaw|In this arm, participants will complete a simulation using the Newborn Oral Assessment and Latch Simulator (NORALSim), which is designed to look, feel, and weigh like a healthy human newborn. The NORALSim's jaw can be remotely operated by the user to demonstrate attachment at the breast.
16294307|NCT04715724|Active Comparator|Baby doll with hand controlled jaw|In this arm, participants will complete a simulation using a cloth baby with a puppet-style jaw which can be opened and closed by the user to demonstrate attachment at the breast.
16294308|NCT04715724|Active Comparator|Static baby doll|In this arm, participants will complete a simulation using a rigid, plastic baby with a static, open mouth.
16294309|NCT04715711|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
16294310|NCT04715711|Placebo Comparator|No Intervention|"Participants will participant in passive cooling where they sit in a chair during rest."
16294311|NCT04715698|Experimental|ICG-guided|anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG
16294312|NCT04715698|Active Comparator|Empirical|anti-hypertensive drug selection based on physician's experience only
16294313|NCT04715685|Experimental|40 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294426|NCT04714931|Other|Sentinel Lymph Node|Sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
16356193|NCT04284553|Experimental|Standard Epic Basic Alert|
16294314|NCT04715685|Experimental|40 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294315|NCT04715685|Experimental|40 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294316|NCT04715685|Experimental|40 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294317|NCT04715685|Experimental|20 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294318|NCT04715685|Experimental|20 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294319|NCT04715685|Experimental|20 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294320|NCT04715685|Experimental|20 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
16294321|NCT04715672||copper|
16294322|NCT04715672||no-copper|
16294323|NCT04715672||normal|
16294324|NCT04715659||COPD patients|
16294326|NCT04715633|Experimental|PD-1 inhibitors plus VEGF inhibitors|Patients will be given 4 cycles of Camrelizumab (200mg iv every 3 weeks) plus Apatinib (250mg QD day1-14) before being evaluated for response.
16294327|NCT04715620|Experimental|niraparib|
16294328|NCT04715607|Active Comparator|Nasopharyngeal swab, oropharyngeal swab, and salvia collection|"The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.
~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
16294329|NCT04715607|Active Comparator|Oropharyngeal swab, salvia collection, and nasopharyngeal swab|"The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.
~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
16294330|NCT04715607|Active Comparator|Salvia collection, nasopharyngeal swab, and oropharyngeal swab|"The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.
~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
16294331|NCT04715594||CONNECT DES Registrty|
16294332|NCT04715581|Experimental|Multicomponent prehabilitation group|Patients in the intervention group will receive nutritional optimization and exercise training before the surgery.
16294333|NCT04715581|No Intervention|Control group|Patients in the control group will maintain normal diet and normal activity before surgery.
16294334|NCT04715568|Experimental|Placebo then Losartan|Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.
16294335|NCT04715568|Experimental|Losartan then Placebo|Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.
16294336|NCT04715555||Atrial Fibrillation|Participants with a diagnosis of atrial fibrillation (AF) who exhibited AF in previous AF screening (as part of the SAFER Programme).
16294337|NCT04715555||Non-Atrial Fibrillation|Participants without a diagnosis of atrial fibrillation (AF) who have previously undergone AF screening (as part of the SAFER Programme).
16294338|NCT04715542|Experimental|Stibium metallicum praeparatum 6x|Patients are treated with Stibium metallicum praeparatum 6x (subcutaneus injection), which is authorized in Switzerland and is listed by Swissmedic as an authorized anthroposophic medicinal product.
16294339|NCT04715542|Placebo Comparator|Saline subcutaneous injection|Placebo (a saline subcutaneous injection) is chosen as comparator to the treatment group.
16294340|NCT04715529|Experimental|FZJ-003|
16294341|NCT04715529|Placebo Comparator|Placebo|
16294342|NCT04715516|Experimental|alcohol brief intervention + lifestyle health promotion|"The intervention arm will receive 4 minutes of alcohol brief intervention, and 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight), to increase knowledge of how to improve women's health and reduce breast cancer risk. Alcohol and lifestyle information will be delivered by way of an animation on an iPad. Participant responses to questions about current alcohol use will branch to personalised feedback consistent with level of alcohol consumption (i.e. drinking within or above current Australian Alcohol Guidelines).
~Take-home pamphlets - a pamphlet summarising the alcohol information presented during the animation, and a pamphlet on nutrition to maintain a healthy weight, will be provided."
16294343|NCT04715516|Other|lifestyle health promotion, not inclusive of alcohol information|"The control arm will receive 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight) to increase knowledge of how to improve women's health and reduce breast cancer risk, not inclusive of alcohol information. Lifestyle information will be delivered by way of an animation on an iPad.
~Take-home pamphlet - a pamphlet on nutrition to maintain a healthy weight will be provided."
16294344|NCT04715503|Experimental|PET-IA|68Ga-DOTANOC 18F-FDG
16294345|NCT04715490|Experimental|The Multimedia Symptom Management Program Intervention|The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support.
16294346|NCT04715490|Active Comparator|Control group|Participants in the control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
16294347|NCT04715477||Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
16294348|NCT04715451|No Intervention|Conventional Swaddle|The management of the non-intervention group is with a cotton swaddle that is standard of care. It represents a conventional standard management method using a swaddle made of cotton.
16294349|NCT04715451|Experimental|Novel Swaddle|The Novel Swaddle is made of fabric consisting of 85% nylon and 15% polyurethane. This fabric provides heat retention, is hygroscopic and stretches in both longitudinal and transverse directions, thus more accurately replicating the intrauterine environment. The novel material is sewed into a bag shape.
16294350|NCT04715438|Experimental|Cohort A: Individuals without cancer|A cohort of individuals without a cancer diagnosis is included for comparison. Because age is an important predictor of the ability to mount an effective immune response to vaccination, partners of patients in cohort B, C, and D.
16294351|NCT04715438|Experimental|Cohort B: patients receiving immunotherapy|Cancer patients receiving immunotherapy
16294352|NCT04715438|Experimental|Cohort C: patients receiving chemotherapy|Cancer patients receiving chemotherapy
16294353|NCT04715438|Experimental|Cohort D: patients receiving chemo-immunotherapy|Cancer patients receiving chemo-immunotherapy
16294354|NCT04715425|Active Comparator|Thoracoscopic ablation|Thoracoscopic ablation
16294355|NCT04715425|Active Comparator|Catheter ablation|Catheter ablation
16294356|NCT04715412|Other|Study group|"The standard training sessions were conducted for individual patient by the transplant physician to explain rejections, infections and tumor risks, post-transplant medication. After discharge, all patients had scheduled follow-up visits at the outpatient clinic of the transplant center, where immune suppressant blood levels were measured and their dosing adjusted accordingly. Patients also had the opportunity to discuss any concern of their condition or drug therapy with the transplant physician in charge.
~in addition to this standard transplant training, patients received intensified care by a dedicated clinical pharmacist combining educational and technical interventions aiming at achieving and maintaining adherence to his/her prescribed medication and improving health outcomes."
16294357|NCT04715399||Cross-sectional|
16294358|NCT04715399||Longitudinal|
16294359|NCT04715386||Group 1- StrataXRT|
16294360|NCT04715373|Experimental|DR-LISA|"Experimental:
~Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs. A trained physician will perform LISA using Hobart method. Infants requiring FiO2 >0.8 on CPAP 8 cm H2O to maintain SpO2 88-94% by 20 minutes of life will be intubated prior to transport. After admission to the NICU, CPAP will be titrated 5-8 cm H20."
16294361|NCT04715373|Active Comparator|NICU-LISA|Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs and transported to NICU on CPAP. After admission to NICU, CPAP will be escalated every 30 minutes up to a maximum level of 7 cm H2O at which point infant would qualify for LISA if the FiO2 requirement is ≥0.3. LISA will be performed using Hobart method. Infants requiring FiO2 >0.8 to maintain SpO2 88-94% by 20 minutes of life will be intubated in the DR.
16294362|NCT04715360|Other|Control|Only received standard medication (avigan) for severe COVID-19 management
16294363|NCT04715360|Experimental|PRP Group|received standard medication (avigan) for severe COVID-19 management and autologous activated platelet-rich plasma transfusion
16294364|NCT04715334|Experimental|Single arm study|The intervention is the Mollii suit which is fitted and programmed by the Mollii suit distributor, Inerventions and will be administered by trained physiotherapists from KKH. Participants will be involved in the Intervention phase of the study for 4 weeks with treatment duration of 60 min/ session every day.
16294365|NCT04715321||Training cohort|HCC patients enrolled in our study underwent a perfusion CT examination before surgery . We used CT perfusion parameters to predict the vascular pattern of tumors.
16294366|NCT04715321||Validation cohort|HCC patients who would undergo a perfusion CT examination before surgery will be enrolled in our study from January 15, 2021. We use CT perfusion parameters to predict the vascular pattern of tumors.
16294367|NCT04715295|Experimental|Doxycyclin and Rivaroxaban|Oral Doxycyclin 200 mg daily for 7 days with or without Rivaroxaban
16294368|NCT04715295|Active Comparator|National Standard|Hydroxychloroquine 400 mg daily for 5 days in combination with Azithromycin 500 mg on day 1 and 250 mg daily from day 2 through day 5
16294369|NCT04715282|Other|Epley maneuver|The Epley maneuver was performed for all patients (both EpleyM and EpleyM&Exe groups) included in this study until nystagmus had disappeared in each position. If nystagmus/vertigo was not seen, the Epley maneuver was not performed for patients at the 1st, 3rd, and 6th week assessments.
16294427|NCT04714905||Pregnant Cohort|Pregnant (up to and including 15 weeks), 18+ years of age.
16294428|NCT04714905||Pre-pregnancy Cohort|Anticipating to be pregnant, 18-40 years of age.
16294370|NCT04715282|Other|Cawthorne-Cooksey exercises combined with the Epley maneuver|Additional Cawthorne-Cooksey exercises were prescribed to the EpleyM&Exe group. The physiotherapist explained and demonstrated the exercises to each patient and the patients practiced the exercises until they performed them correctly. Then the exercises were prescribed twice a day and repeated 10 times for 6 weeks as a home exercise program.
16294371|NCT04715269|Experimental|Alprazolam Arm|0.5mg Alprazolam will be given to the patient at the time of presentation
16294372|NCT04715269|Placebo Comparator|Placebo Arm|The empty capsule will be given to the patient at the time of presentation
16294373|NCT04715256|Experimental|KCNQ1 mutated subjects|"This arm includes :
~KCNQ1-mutated subjects with long QT Romano-Ward syndrome
~KCNQ1-mutated subjects without phenotypic expression of the Romano-Ward syndrome
~family relatives of a KCNQ1-mutated enrolled subject, carrying the KCNQ1 family mutation"
16294374|NCT04715256|Sham Comparator|Healthy subjects|Healthy subjects will be matched to KCNQ1 subjects. The matching factors will be age per decade (18-28 years, > 28-38 years, > 38-48 years), gender and body mass index (BMI: ≤ 24.9 kg/m2; 25-29.9 kg/m2; > 30 kg/m2).
16294375|NCT04715243|Other|control|Face-mask NIV is the standard of care
16294376|NCT04715243|Active Comparator|intervention 1|High flow nasal cannula
16294377|NCT04715243|Active Comparator|Intervention 2|Helmet NIV
16294380|NCT04715217|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
16294381|NCT04715217|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of middle dose group will be intravenously infuse with 2.0×10^6 CAR+Tcells/kg.
16294382|NCT04715217|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of high dose group will be intravenously infuse with 5.0×10^6 CAR+Tcells/kg.
16294383|NCT04715217|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
16294384|NCT04715204|Active Comparator|Formula-75/Formula-100|This arm is the control. Formula-75/Formula-100 are the standard formula recommended by WHO to treat severely malnourished children.
16294385|NCT04715204|Experimental|High Energy Oral Nutrition Supplement|High energy oral nutrition supplement (ONS) has energy density of 1.5 kcal/ml, with protein-energy ratio of 8.9% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation. The high energy ONS is beneficial for children who cannot tolerate large volume of feeding.
16294386|NCT04715204|Experimental|Standard Energy Oral Nutrition Supplement|Standard energy oral nutrition supplement (ONS) has energy density of 1 kcal/ml, with protein-energy ratio of 9.6% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation.
16294387|NCT04715191|Experimental|CARE T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 plus IL21 (CARE T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
16294388|NCT04715178||Patients with suspected or confirmed pediatric solid tumors|Patients with suspected or confirmed pediatric solid tumors
16294389|NCT04715165|Active Comparator|Group I|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline.
16294390|NCT04715165|Placebo Comparator|Group II|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
16294391|NCT04715152|Active Comparator|ACB group|Patients will receive ultrasound-guided (USG) ACB with levobupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline.
16294392|NCT04715152|Placebo Comparator|IA group|Patients will receive intra-articular levobupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline.
16294393|NCT04715139||Arthrex ProStop®|The ProStop® arthroereisis subtalar implant is intended to assist in treating the hyperpronated foot by stabilizing the subtalar joint. The main goal is to block forward, downward, medial displacement of the talus, and to help in reducing the talonavicular joint, thereby limiting excessive valgus of the hindfoot.
16294396|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16294397|NCT04715113|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16294398|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16294399|NCT04715113|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16294400|NCT04715100||Experimental group|"The inclusion criteria to participate in the present study are patients: with a diagnosis of hemophilia A and B; adults; and on a prophylactic or on-demand treatment regimen with FVIII / FIX concentrates.
~For their part, patients with: neurological or cognitive alterations that impede understanding of the questionnaires will be excluded from the study; Dependent patients who require help from a third person to get around; patients who have developed a hemarthros in the 4 weeks prior to the study; and those who have not signed the informed consent document.
~For inclusion in the study, patients will continue to be administered the dose of FVIII / FIX concentrates, following the guidelines of the medical criteria established by their reference hematologist. Throughout this study, the medical criteria for drug treatment, the dosage, and the replacement treatment periods will not be changed."
16294401|NCT04715087|Other|Atopic dermatitis patients|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be re-applied (via patchtest) to AD patient. After reading the patch test results, skin biopsies will be performed
16294402|NCT04715087|Other|Healthy controls|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. After reading the patch test results, skin biopsies will be performed.
16294403|NCT04715074|No Intervention|Identify EOCRC Hotspots in Utah|"Linking incidence and mortality data (years 2000-2020) from the Utah Cancer Registry (UCR) and the Utah Population Database (UPDB), we will derive county-level estimates of hotspots for EOCRC incidence and mortality among Utahns aged 18-49; we will obtain county-level estimates using our geospatial methods.39 Counties with high EOCRC incidence and/or mortality rates will be identified as hotspots.
~Using UCR-UPBD linked data, we will determine independent contributions of (1) geographical, (2) personal, and (3) county-level factors on EOCRC incidence/survival. We will perform hierarchical Cox regression models and implement a generalized R-square analysis to determine the variance explained by each factor.
~Central hypotheses: (1) Patients residing in hotspots will have significantly worse EOCRC survival compared with those residing in other Utah areas. (2) Rurality and county-level access to healthcare will contribute to an explanation of EOCRC incidence/survival."
16294404|NCT04715074|Experimental|Ascertain Psychosocial and Lifestyle Challenges|Drawing on factors associated with hotspots identified in Aim 1 and our team's prior research,39-44 we will develop an interview guide with five EOCRC advocate-survivors and conduct one-on-one interviews with 20 individuals first diagnosed with CRC at 18-49 years of age. Interviews will be recorded, transcribed, and analyzed using Hatch's methods previously utilized by our team.45-47
16294405|NCT04715074|Experimental|Develop and Pilot iBeat CRC|"Intervention development will be informed by (1) integrating Aims 1 and 2 findings, (2) Community Action Board [CAB] input, and (3) the Behaviour Change Wheel,48 a step-by-step intervention development approach that identifies and addresses barriers using theory and evidence-based methods.
~The intervention pilot may be based on a multicomponent media campaign, as endorsed by the Community Preventive Services Taskforce for promoting CRC screening among individuals ≥ age 50.49,50 iBeat CRC may entail both outdoor mass media and online social media. iBeat CRC will target Utah hotspots and non-hotspots for comparison, with pre-post-assessment among 17 individuals in each group."
16294406|NCT04715061|Experimental|Cancer patients with MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).
16294407|NCT04715061|Experimental|Cancer patients without MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.
16294408|NCT04715061|Active Comparator|Healthy patients|9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).
16294409|NCT04715048|Experimental|Onabotulinumtoxin A|8-10 units of Botox will be injected in the glabellar lines in one side of the face in 3 different locations. This injection will happen once.
16294410|NCT04715048|Experimental|Prabotulinumtoxin A|8-10 units of Jeuveau will be injected in the glabellar lines in the other side of the face in 3 different locations. This injection will happen once.
16294411|NCT04715035|Active Comparator|Conventional treatment|
16294412|NCT04715035|Experimental|Conventional treatment + eccentric exercises|
16294413|NCT04715022|Placebo Comparator|Placebo infusion|Saline will be administered over 2 hours
16294414|NCT04715022|Active Comparator|Ascorbic acid infusion|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
16294415|NCT04715009||participants use smartphone less than 4 hours per day|participants use smartphone less than 4 hours per day
16294416|NCT04715009||participants use smartphone more than 4 hours per day|participants use smartphone more than 4 hours per day
16294417|NCT04714996|Experimental|ES-481|
16294418|NCT04714996|Placebo Comparator|Placebo|
16294419|NCT04714983|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
16294420|NCT04714983|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
16294421|NCT04714983|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
16294422|NCT04714970|Experimental|iTBS stimulation|The participants randomized into experimental group will receive iTBS stimulation of dlPFC 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
16294423|NCT04714970|Sham Comparator|Sham stimulation|The participants randomized intoSham group will receive Sham stimulation, as the coil vertical to the brain surface, 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
16294424|NCT04714944|Placebo Comparator|Placebo|isocaloric placebo
16294431|NCT04714879|Experimental|Slow oscillating transcranial direct current stimulation (so-tDCS)|7 experimental daytime naps with so-tDCS of different frequencies (fixed frequency of 0.75 Hz versus individually adapted frequency) and durations (5 min, 2 min, 30 sec) (Crossover assignment, applicable for each participant)
16294432|NCT04714879|Sham Comparator|Sham stimulation|sham so-tDCS during a daytime nap (Crossover assignment, applicable for each participant)
16294433|NCT04714866|Experimental|Interventional group|Cognitive behavioral therapy for ADHD
16294434|NCT04714866|No Intervention|waiting list group|No Intervention for the waiting list group
16294435|NCT04714840|Other|Personalized exercise group (INTGroup)|Participants in this group have individually tailored exercise program with supervision, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
16294436|NCT04714840|Other|Generalized exercise group, Attention Control (AC Group)|Study participants in this group receive generalized exercise recommendations, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
16294437|NCT04714827|Experimental|Low Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 1.0×10^6 CAR+T cells/kg.
16294438|NCT04714827|Experimental|Middle Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2.5×10^6 CAR+T cells/kg.
16294439|NCT04714827|Experimental|High Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5.0×10^6 CAR+T cells/kg.
16294440|NCT04714827|Experimental|Amplification Dose Group|CD19-BCMA CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 1.0-5.0×10^6 CAR+Tcells/kg.
16294441|NCT04714801|Active Comparator|Infusion of 100 million ASC|Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors
16294442|NCT04714801|Active Comparator|Infusion of 200 million ASC|Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors
16294443|NCT04714801|Placebo Comparator|Infusion of placebo|Infusion of saline
16294444|NCT04714788|Experimental|Intervention group RECAP_MyLife mobile app|Participants in the intervention group will be instructed to use the mobile app daily for four weeks.
16294445|NCT04714788|Active Comparator|Control group|Comparator will be the usual data collection method applied by the cohorts.
16294446|NCT04714762|Experimental|Intervention (eMOM GDM application)|Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse (measurements) three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum).
16294447|NCT04714762|No Intervention|Control|Participants in the control group will meet a study nurse (measurements) 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals.
16294448|NCT04714749|Experimental|Endovenous treatment|Endovenous treatment with cyanoacrylate glue
16294449|NCT04714736|Active Comparator|DyeVert group|Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be handled by the DyeVert TM system.
16294450|NCT04714736|Sham Comparator|Control group|"Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be carried out by a conventional manual injection syringe. Strategies for limiting CM volume are:
~angiograms will be performed with injection of contrast using a 3-cm 3 syringe; this provides strict control of CM delivery by limiting the volume of contrast that can be administered in a single injection;
~catheters with sideholes will be strictly avoided during percutaneous intervention;
~when exchanging catheters, unused contrast is withdrawn from the catheter lumen (e.g., by back-bleeding through an opened ''Y''-connector or by aspirating residual contrast from the catheter using a syringe)
~''tests'' with ''puffs'' of CM are discouraged."
16294451|NCT04714723|Experimental|Routine education group|350-400 subjects aged 20-65 years with high metabolic risk
16294452|NCT04714723|Experimental|Programmed smartphone intervention group|350-400 subjects aged 20-65 years with high metabolic risk
16294453|NCT04714723|Experimental|Programmed smartphone plus dietitian intervention group|350-400 subjects aged 20-65 years with high metabolic risk
16294454|NCT04714710|Experimental|Potassium canrenoate|Potassium canrenoate 200mg diluted in SODIUM CHLORIDE SOLUTION 0.9%
16294455|NCT04714710|Placebo Comparator|Placebo (SODIUM CHLORIDE SOLUTION 0.9%)|SODIUM CHLORIDE SOLUTION 0.9%
16294456|NCT04714697|Experimental|Cohort 1(post nivolumab and ipilimumab combination)|the subject who failed one prior line by nivolumab and ipilimumab
16294457|NCT04714697|Experimental|Cohort 2 (post pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, or avelumab and axitinib)|the subject who failed one prior line by PD-1/PD-L1 inhibitors in combination with VEGF TKI
16294458|NCT04714697|No Intervention|Cohort 3 (post sequential immunotherapy after VEGFR TKI)|the subject who failed the second line by immunotherapy (PD-1 antibody or PD-L1 antibody) following the first line VEGFR TKI
16294459|NCT04714684|Experimental|fitostimoline proctogel|
16294460|NCT04714684|Experimental|fitostimoline proctogel + muscle relaxants|
16294461|NCT04714684|Experimental|muscle relaxants|
16294462|NCT04714671|Experimental|Euthymics patients with history of suicide attempt (suicide attempters)|Euthymics patients with a lifetime history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
16294463|NCT04714671|Experimental|Euthymics patients without any history of suicide attempt (affective controls)|Euthymics patients without history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
16294464|NCT04714658|Experimental|Immediate PTE|
16294465|NCT04714658|Other|6-month deferred PTE|
16294468|NCT04714632||Children with idiopathic scoliosis|Adolescent between 10-18y with diagnosing idiopathic scoliosis
16294469|NCT04714632||Healthy children|Healthy children between 10-18y without any orthopedics problems
16294471|NCT04714606|Experimental|Sibling support group|8 session, tailored support group for siblings of children who have an ASD
16294472|NCT04714606|Active Comparator|Booklet|Control condition in which siblings of children who have an ASD will receive a tailored booklet to complete at home
16294473|NCT04714593|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
16294474|NCT04714593|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2×10^6 CAR+T cells/kg.
16294475|NCT04714593|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5×10^6 CAR+T cells/kg.
16294476|NCT04714593|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
16294477|NCT04714580|Experimental|Animal Fun Group|Baseline assessment with MABC-2; Animal Fun activity with a certified trainer (physiotherapist) for one month, three times a week, for 30 minutes; one-month follow-up assessment with MABC-2.
16294478|NCT04714580|No Intervention|Control Group|Baseline assessment with MABC-2; normal curricular activity at school with the teachers; one-month follow-up assessment with MABC-2.
16294479|NCT04714567||Patients with severe asthma|Patients of all ages with severe asthma included in the RAG.
16294480|NCT04714554|Experimental|Part 1: Relugolix/E2/NETA Plus Erythromycin|"Treatment Period 1: Healthy premenopausal women will receive a relugolix/E2/NETA (40 mg/1 mg/0.5 mg) alone on Day 1.
~Treatment Period 2: Healthy premenopausal women will receive erythromycin on Day 1 through 12 (500 mg, QID), with co-administration of a single dose of relugolix/E2/NETA (40 mg/1 mg/0.5 mg) with the morning dose of erythromycin on Day 8."
16294481|NCT04714554|Experimental|Part 2: Relugolix Plus Erythromycin|"Treatment Period 1: Male participants will receive a single 120-mg dose of relugolix alone on Day 1.
~Treatment Period 2: Male participants will receive erythromycin on Days 1 through 12 (500 mg, QID), with co-administration of a single 120-mg dose of relugolix with the morning dose of erythromycin on Day 8."
16294482|NCT04714541|Experimental|Ketogenic Diet Adoption Followed by Ketamine Infusion|All 5 Participants Will Be Educated to Adopt a Ketogenic Diet, As Outpatient. After at Least 4 Weeks on the Diet, They Will Have A Series of Titrated Intravenous Ketamine Infusions Over A 2 Week Period
16294483|NCT04714528|Active Comparator|Physical Exercise Group|45 minutes of aerobic, high intensity group training, three times per week during a 12-week period.
16294484|NCT04714528|Other|Relaxation Group|45 minutes of relaxation therapy once per week for 12 weeks.
16294485|NCT04714515||Hydroxychloroquine and Montelukast|Group 1 was given Standard of care (SOC) + HCQ + Montelukast
16294486|NCT04714515||Montelukast|Group 2 was given Standard of care (SOC) + Montelukast
16294487|NCT04714515||Hydroxychloroquine|Group 3 was given Standard of care (SOC) + HCQ
16294488|NCT04714515||Hydroxychloroquine, Montelukast and Invermectin|Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin
16294489|NCT04714502||Infants enrolled in AAMBI1|
16294490|NCT04714489||experimental group|
16294491|NCT04714476|Experimental|Fit test of made-to-measure garments|Healthy subjects will test made-to-measure compression garments
16294492|NCT04714463||Immediate breast reconstruction|Women undergoing immediate breast reconstruction due to breast cancer or a high risk for breast cancer
16294493|NCT04714463||Delayed breast reconstruction|Women undergoing delayed breast reconstruction due to breast cancer or a high risk for breast cancer
16294494|NCT04714450|No Intervention|MMST control|
16294495|NCT04714450|Experimental|MMST+|
16294496|NCT04714437|Active Comparator|F-R/L-A1/A3/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5)
16294497|NCT04714437|Active Comparator|F-R/L-A1/A5/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3)
16294498|NCT04714437|Active Comparator|F-R/L-A3/A1/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5)
16294499|NCT04714437|Active Comparator|F-R/L-A3/A5/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1)
16294500|NCT04714437|Active Comparator|F-R/L-A5/A1/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3)
16294501|NCT04714437|Active Comparator|F-R/L-A5/A3/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1)
16294502|NCT04714424||Participants undergoing vision exams|
16294503|NCT04714411||Retrospective Cohort|A historical matched case cohort
16294541|NCT04714112|Active Comparator|postoperative group|Ultasound guided ISB is performed before operation and intravenous dexamethasone (5mg) is used in postoperative care unit ( PACU)
16294504|NCT04714411||Prospective Cohort|Subjects will be screened daily via review of the EMR reports of inpatient admissions. Those receiving antibiotics with a notated source of skin/soft tissue infection will be further reviewed to determine if the source of infection is a DFI without suspected or confirmed osteomyelitis.
16294505|NCT04714398|Experimental|Opt-In Recruitment|All recruitment messaging will be framed for patients as they must opt-in to participate in the remote monitoring program.
16294506|NCT04714398|Experimental|Opt-Out|All recruitment messaging will be framed as though participation is the default, and patients must opt-out of participating in the remote monitoring program.
16294507|NCT04714398|No Intervention|Usual Care|Patients in the usual care arm will not be contacted by study staff, they will not receive a blood pressure cuff, and they will not be asked to participate in any component of the blood pressure monitoring program.
16294512|NCT04714359|Experimental|MDMA-assisted Psychotherapy|Three open-label sessions of MDMA-assisted psychotherapy with flexible dose of MDMA (80 or 120 mg) and optional supplemental dose of (40 or 60 mg), 1.5 to 2 hours later
16294515|NCT04714307||Symptomatic|Molecularly diagnosed SCA3/MJD Symptomatic subjects.
16294516|NCT04714307||Non-related Controls|Controls matched with symptomatic by age and educational level.
16294517|NCT04714307||At 50% risk for SCA3/MJD group|The offspring of affected individuals with SARA<3. This group will be comprised of two subpopulations: pre-symptomatic individuals and related controls. The determination will be made upon molecular diagnosis to be done in a double-blind manner.
16294518|NCT04714294|Experimental|SAD: Each volunteer will receive 6 mg, 10mg, 20mg, 40mg(or TBD) of IP once daily for 1 day|Drug: HPP737 or placebo One 1 mg capsule and one 5mg capsule taken orally (by mouth) once daily for SAD arm 1/ Two 5mg capsule taken orally (by mouth) once daily for SAD arm 2/ Four 5mg capsule taken orally (by mouth) once daily for SAD arm 3/ Eight 5mg capsule taken orally (by mouth) once daily for SAD arm 4
16294519|NCT04714294|Experimental|MAD: Each volunteer will receive 10mg, 20mg, 40mg(or TBD) of IP once daily for 7 days|Drug: HPP737 or placebo Two 5mg capsule taken orally (by mouth) once daily for MAD arm 1/ Four 5mg capsule taken orally (by mouth) once daily for MAD arm 2/ Eight 5mg capsule taken orally (by mouth) once daily for MAD arm 3
16294520|NCT04714281|Other|Hemodiafiltration HDF|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
16294521|NCT04714268||Procedures with EndoNaut|Endovascular interventions using the EndoNaut workstation. 3D image fusion is used for overlaying arterial information on top of fluoroscopic images
16294522|NCT04714268||Procedures without EndoNaut|Control group, endovascular interventions without 3D image fusion
16294523|NCT04714255|Experimental|TICK-B group as Intervention group|Pediatric patients received TICK-B as a distraction in the TICK-B group Trace Image and Coloring for Kids-Book were conducted on the children undergoing the Cannulation procedure.
16294524|NCT04714255|No Intervention|Standard care provided group as control group|Pediatric patients received standard care (routine care) in the control group.
16294525|NCT04714242||Patients underwent anti-VEGF therapy|intravitreal Anti-VEGF therapy: Three monthly intravitreal injections
16294526|NCT04714242||Control Group|Healthy eyes without actual and previous ocular diseases
16294527|NCT04714229|Experimental|EuMCV4|Healthy adults received 0.5mL single intramuscular dose on Day 0.
16294528|NCT04714229|Active Comparator|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
16294529|NCT04714216|Experimental|Hybrid closed-loop (HCL) automated insulin delivery (AID)|Hybrid closed-loop (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote monitoring and device operation capabilities will be deployed to hospitalized patients admitted to the general medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.
16294530|NCT04714203||cohort|Sarcopenia assessment
16294531|NCT04714190|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
16294532|NCT04714190|Active Comparator|Physician's Choice|Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.
16294533|NCT04714177|Experimental|Edaravone Dexborneol|Edaravone Dexborneol injection
16294534|NCT04714177|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
16294535|NCT04714164|Experimental|Teletherapy Group CBT participants|Patients over the age of 65 with either a Major Depressive Disorder or Generalized Anxiety Disorder who will be participating in a Group CBT delivered by Teletherapy
16294536|NCT04714151|Experimental|Treatment A|K-877 ER 0.2 mg/day (once daily)
16294537|NCT04714151|Experimental|Treatment B|K-877 ER 0.4 mg/day (once daily)
16294538|NCT04714151|Active Comparator|Control A|K-877 IR 0.2 mg/day (twice daily)
16294539|NCT04714125||Patients with COVID-19|Patients hospitalized with COVID-19 from the General Hospital of the University of Sao Paulo, Brazil.
16294540|NCT04714112|Experimental|preoperative group|Intravenous dexamethasone (5mg) is used when ultrasound guided ISB is performed.
16294542|NCT04714099|Experimental|Topical CsA|Group A received topical CsA 0.05% for 3 months
16294544|NCT04714073|Experimental|Reference: BI 706321 alone|First treatment period
16294545|NCT04714073|Experimental|Test: BI 706321 + Itraconazole|Second treatment period
16294546|NCT04714060|Experimental|cohort 1|2.5 mg/kg UB-621 group
16294547|NCT04714060|Experimental|cohort 2|5 mg/kg UB-621 group
16294548|NCT04714047|Experimental|Group 1:|PRT
16294549|NCT04714047|Experimental|Group 2:|PRT + Booster sessions
16294550|NCT04714047|Active Comparator|Group 3:|NEMEX
16294551|NCT04714047|Experimental|Group 4:|NEMEX + Booster sessions
16294552|NCT04714021|Experimental|Single steep arm- CO2 insufflation|PEG will be performed by single step technique and CO2 will be insufflated during the endoscopy
16294553|NCT04714021|Active Comparator|Single steep arm- air insufflation|PEG will be performed by single step technique and air will be insufflated during the endoscopy
16294554|NCT04714021|Experimental|Pull technique arm- CO2 insufflation|PEG will be performed by pull technique and CO2 will be insufflated during the endoscopy
16294555|NCT04714021|Active Comparator|Pull technique arm- air insufflation|PEG will be performed by pull technique and air will be insufflated during the endoscopy
16294556|NCT04714008||Active gamblers in 2019/2020|Three panels of 40 000 gamblers active in 2019 and 2020, either in France or Sweden
16294557|NCT04714008||Newly registered gamblers in 2019 or 2020 (France and Sweden)|Six panels of 10 000 gamblers who newly registered either during the period of March-May 2019 or of March-May 2020, either in France or Sweden
16294559|NCT04713982|Experimental|Deutetrabenazine|The mode of administration is oral. Subjects will be started on deutetrabenazine at a dose of 6mg/day. Dosing will be up-titrated in increments of 6mg/day per week to achieve optimal chorea control.
16294560|NCT04713969|Experimental|Functional dyspepsia patients before and after PPI|Pantoprazole 40mg twice daily in functional dyspepsia patients for 4 weeks
16294561|NCT04713969|No Intervention|Healthy controls before PPI|Baseline investigations
16294562|NCT04713956|Experimental|G-CSF+DAC+BF|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
16294563|NCT04713956|Active Comparator|G-CSF+DAC+BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 to -2.
16294564|NCT04713943|Experimental|>Your< Iron Syrup|
16294565|NCT04713943|Other|Placebo|
16294566|NCT04713930|Experimental|JNJ-61393215|Participants will receive one of 3 single oral doses of JNJ-61393215 on Day 1, escalated sequentially based on the safety review in Cohorts 1, 2, and 3 up to Day 5.
16294567|NCT04713930|Active Comparator|Placebo|Participants will receive a single oral dose of placebo on Day 1 in Cohorts 1, 2, and 3 up to Day 5.
16294568|NCT04713917|Active Comparator|Gel Group|Two applications of HA gel (Mucogyne®) per week during one year.
16294569|NCT04713917|Experimental|Laser Group|Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.
16294570|NCT04713917|Experimental|HA Injection Group|Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).
16294571|NCT04713904|Experimental|Clormadinone Ethinyl estradiol Test Product|
16294572|NCT04713904|Active Comparator|Clormadinone Ethinyl estradiol Reference Product|
16294573|NCT04713891|Experimental|Phase 1a: Cohort 1|KF-0210 tablet will be administered at 120 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
16294574|NCT04713891|Experimental|Phase 1a: Cohort 2|KF-0210 tablet will be administered at 240 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
16294575|NCT04713891|Experimental|Phase 1a: Cohort 3|KF-0210 tablet will be administered at 450 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
16294576|NCT04713891|Experimental|Phase 1a: Cohort 4|KF-0210 tablet will be administered at 600 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
16294577|NCT04713891|Experimental|Phase Ib, Cohort 1|KF-0210 (dose RP2D-2, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
16294578|NCT04713891|Experimental|Phase Ib, Cohort 2|KF-0210 (dose RP2D-1, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
16294579|NCT04713891|Experimental|Phase Ib, Cohort 3|KF-0210 (dose RP2D, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
16294580|NCT04713878|Active Comparator|Group 1|Intubated without comorbidity
16294581|NCT04713878|Active Comparator|Group 2|Intubated with comorbidity
16294582|NCT04713878|Active Comparator|Group 3|No intubated
16294583|NCT04713865||PFA slightly jailed by proximal SFA stent(100 pts)|
16294584|NCT04713865||PFA moderately jailed by proximal SFA stent(100 pts)|
16294585|NCT04713865||PFA totally jailed by proximal SFA stent (100pts)|
16294586|NCT04713839||Participants|The participants were invited to the study, then each participant was asked to complete the self-report questionnaires.
16294589|NCT04713813|Active Comparator|Exercise group 1(Exercise via mechanical horse-riding simulator)|Exercise via mechanical horse-riding simulator; Subjects remained in sitting position for 30 minutes on the simulator during these sessions, with extension of the trunk and stabilization of the pelvis. Feet were placed on the footplates as the simulator produced a rhythmic and repetitive movement similar to a walking horse. The simulator can produce several modes of rhythmic and repetitive motions.
16294590|NCT04713813|Active Comparator|Exercise group 2 (Home exercises)|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
16294591|NCT04713800|Experimental|ZR-TiB|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR)
16294592|NCT04713800|Active Comparator|PFM-GA|Porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM)
16294593|NCT04713787|Experimental|Group A|400 mg (4 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
16294594|NCT04713787|Experimental|Group B|800 mg (8 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
16294595|NCT04713787|Active Comparator|Group C|400 mg (1 tablet of 400 mg) of Albendazole administered orally as a single dose on Day 1. N=83.
16294596|NCT04713761|Experimental|Toripalimab|
16294597|NCT04713748|Other|Tasso- SST blood collection|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
16294598|NCT04713748|Other|Regular Venipuncture|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
16294599|NCT04713735|Placebo Comparator|Control: Placebo|Control: Placebo
16294600|NCT04713735|Experimental|Investigational: 600 mg bovine lactoferrin supplement|Investigational: 600 mg bovine lactoferrin supplement
16294601|NCT04713722||MDD/childhood adversity group|subjects with current MDD who experienced childhood adversity
16294602|NCT04713722||rMDD/ childhood adversity|subjects with a history of MDD who experienced childhood adversity
16294603|NCT04713722||MDD|subjects in a current episode of MDD, with no history of childhood adversity
16294604|NCT04713722||Healthy Control|healthy control subjects, with no history of childhood adversity
16294605|NCT04713709|Experimental|FMXIN001 4 mg Naloxone microspheres powder,|Naloxone powder nasal spray from Nasus Pharma, Israel
16294606|NCT04713709|Active Comparator|Narcan® 4 mg/0.1 mL nasal spray|Naloxone solution nasal spray from Adapt Pharma, Inc., USA
16294607|NCT04713696|Experimental|Functional training|Participants received functional training
16294608|NCT04713696|Active Comparator|Routine training|Participants received routine training
16294609|NCT04713683|Active Comparator|Amplatzer PFO Occluder|Patients randomized in this arm will be implanted with Amplatzer PFO Occluder.
16294610|NCT04713683|Active Comparator|Gore Cardioform Septal|Patients randomized in this arm will be implanted with Gore Cardioform Septal Occluder.
16294611|NCT04713670|Experimental|(A) T-V14|
16294612|NCT04713670|Experimental|(B) T-V7|
16294613|NCT04713670|Experimental|(C) D-V14|
16294614|NCT04713670|Experimental|(D) HD-V14|
16294615|NCT04713670|Experimental|(E) BQ-V14|
16294616|NCT04713670|Experimental|(F) RH-V14|
16294617|NCT04713670|Experimental|(G) BQ-L14|
16294618|NCT04713670|Experimental|(H) T-L14|
16294619|NCT04713657|Active Comparator|Propranolol|The target dose of Propranolol hydrochloride for this study target dose for this study will be 4 mg/kg/day divided in 4 doses. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
16294620|NCT04713657|Placebo Comparator|Placebo|Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age. There is no current standard of care for pharmacologic therapy for infants with ToF. As such, there are no alternative treatments, and the placebo group is standard of care.
16294621|NCT04713644||Burst Suppression|Patients who present burst suppression after standardized propofol administration during anesthetic induction
16294622|NCT04713644||No Burst Suppression|Patients who did not present burst suppression after standardized propofol administration during anesthetic induction
16294623|NCT04713631|Active Comparator|Artesunate and Curcumin|Artesunate 200 mg PO once a day x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
16294624|NCT04713631|Active Comparator|Artesunate and Placebo C|Artesunate 200 mg PO once a day x 2 weeks. Placebo C x 13 weeks.
16294625|NCT04713631|Active Comparator|Curcumin and Placebo A|Placebo A x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
16294626|NCT04713631|Placebo Comparator|Placebo A and Placebo C|Placebo A x 2 weeks. Placebo C x 13 weeks.
16294627|NCT04713618||Supportive Care (pelvic exam, survey)|Patients undergo standard of care pelvic exam at baseline and 1, 3, 6, 12, and 24 month follow ups. Patients also complete patient reported outcome measures at baseline and 1, 3, 6, 12, 18, and 12 month follow ups.
16294628|NCT04713592|Experimental|Risankizumab|Participants will receive risankizumab for 52 weeks
16294629|NCT04713592|Placebo Comparator|Placebo|Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
16294630|NCT04713579||Premature infants|Infants born prematurely requiring a stoma for condition such as necrotizing enterocolitis (NEC) or spontaneous intestinal perforation (SIP).
16294631|NCT04713579||Term Infants|Infants born closer to term requiring a stoma e.g. for congenital causes of bowel obstruction such as intestinal atresia, gastroschisis or meconium ileus
16294632|NCT04713566|Experimental|Group A|will be using Salvadora Persica oral rinse
16294633|NCT04713566|Experimental|Group B|will be using Commercial Phenolic mouthwash.
16294634|NCT04713553|Experimental|Arm 1|30-microgram dose of US manufactured drug substance (Lot 1)
16294635|NCT04713553|Experimental|Arm 2|30-microgram dose of US manufactured drug substance (Lot 2)
16294636|NCT04713553|Experimental|Arm 3|30-microgram dose of US manufactured drug substance (Lot 3)
16294637|NCT04713553|Experimental|Arm 4|30-microgram dose of EU manufactured drug substance (Lot 4)
16294638|NCT04713553|Experimental|Arm 5|20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)
16294639|NCT04713553|Experimental|Booster 1: BNT162b2|30-microgram dose
16294640|NCT04713553|Experimental|Booster 2: BNT162b2.B.1.351|30-microgram dose
16294641|NCT04713514|No Intervention|Arm A : Best Supportive Care|Observational arm (Standard of care)
16294642|NCT04713514|Experimental|Arm B : OSE2101|"OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
~OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion."
16294643|NCT04713514|Experimental|Arm C : OSE2101 + Pembrolizumab|OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
16294644|NCT04713501|Experimental|PARTS|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
16294645|NCT04713488|Experimental|Sputnik Light Vaccine|solution for intramuscular injection Composition for 1 dose (0.5 ml): Active substance: recombinant serotype 26 adenoviral particles containing the SARS-CoV-2 S protein gene, in the amount of (1.0±0.5) x 10*11 particles per dose.
16294646|NCT04713475|Experimental|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Cohort 1: Late Onset Infantile GM1 Gangliosidosis (Type 2a)
~Assigned Intervention:
~Drug: PBGM01 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBGM01, via intra cisterna magna
~Cohort 2: Late Onset Infantile GM1 Gangliosidosis (Type 2a)
~Assigned Intervention:
~Drug: PBGM01 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBGM01, via intra cisterna magna
~Cohort 3: Early Onset Infantile GM1 Gangliosidosis (Type 1)
~Assigned Intervention:
~Drug: PBGM01 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBGM01, via intra cisterna magna
~Cohort 4: Early Onset Infantile GM1 Gangliosidosis (Type 1)
~Assigned Intervention:
~Drug: PBGM01 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBGM01, via intra cisterna magna
~*GC/g: gene copy per gram of estimated brain weight"
16294647|NCT04713475|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBGM01|"Cohort 5: Late Onset Infantile GM1 Gangliosidosis (Type 2a)
~Assigned Intervention:
~Drug: PBGM01 Single dose of PBGM01, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.
~Cohort 6: Early Onset Infantile GM1 Gangliosidosis (Type 1)
~Assigned Intervention:
~Drug: PBGM01 Single dose of PBGM01, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1."
16294650|NCT04713436||Triple antibiotic paste(TAP)|ciprofloxacin, metronidazole and minocycline
16294651|NCT04713436||Doble antibiotic paste(DAP)|ciprofloxacin and metronidazole
16294652|NCT04713436||Modified triple antibiotic paste(mTAP)|ciprofloxacin, metronidazole and cefaclor
16294653|NCT04713410|Experimental|Group A|Steroids will be given for short duration of time i-e 12 weeks
16294654|NCT04713410|Active Comparator|Group B|Steroid will be given for longer duration i-e 20 weeks
16294655|NCT04713397||LLD group|Patients who have functional scoliosis due to structural LLD
16294656|NCT04713397||LLD concurrent with AIS|Patients who have structural LLD concurrent with AIS
16294657|NCT04713384|Experimental|Treatment|Participants will undergo 4 weeks (20 sessions) of experimental rehabilitation in their home. They will play custom therapeutic games that are intensive and adapt to their condition. Before and after the 4-week intervention participants will travel to Kessler Foundation to undergo evaluations. The therapy is designed to improve arm range, strength, endurance, as well as memory, focusing and decision making. Data will be stored on the cloud, protected and monitored by the research team.
16294658|NCT04713371|Other|Single arm. Subjects receiving treatment.|Efficacy of Cryosurgical Freezing and Multiplex Immunochemotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria.
16294659|NCT04713358|Experimental|Nalmefene group|for the nalmefene group, immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
16294660|NCT04713358|Placebo Comparator|Control group|Intravenous injection of normal saline 1ml immediately after surgery
16294661|NCT04713345|Experimental|Experimental group|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
16294662|NCT04713345|Sham Comparator|Control group|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
16294663|NCT04713332|Active Comparator|vitamin E|Oral intake of Vitamin E treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. Patients in the group receiving 500 IU of d-alpha-tocopherol capsules orally (3 times daily).
16294664|NCT04713332|Active Comparator|Hydrogen rich water|Oral intake of HRW (2 ppm) treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The group of patients receiving Hydrogen water took an amount of 250 ml orally 3 times a day.
16294665|NCT04713332|Placebo Comparator|placebo|Oral intake of placebo will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The placebo group received 3 soft gel placebo capsules containing gelatin three times a day.
16294668|NCT04713306||Participants in the Swedish Neuro Register|Participants are patients with parkinsonian symptoms
16294669|NCT04713280|Active Comparator|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary posterior dento-alveolar intrusion
16294670|NCT04713280|Experimental|Bi-maxillary posterior dento-alveolar intrusion|Mini-screw supported bi-maxillary posterior dento-alveolar intrusion
16294671|NCT04713267|Other|ISABel Bed 1 or ISABel Bed 2|The study has a within-subject repeated measures-design. After a baseline measurement, participants will be allocated to either a first experimental night in automated bed 1 (ISABel Bed 1) and a second one in automated bed 2 (ISABel Bed 2) or a first experimental night in bed 2 and a second one in bed 1. Afterwards, the results of each polysomnographic measurement carried out during the intervention will be compared to the off-treatment baseline measurement.
16294672|NCT04713254|Experimental|Lu AG06466|
16294673|NCT04713241|Active Comparator|Group A: SOC|Participants will receive the SOC and will also be asked to complete questionnaires to rate their symptoms
16294674|NCT04713241|Experimental|Group B: Electro-Acupuncture|Participants will receive the SOC + a daily 20-30 minute electro-acupuncture treatment from the time of randomization until the return of bowel function. The first treatment will be provided within 48 hours after the diagnosis of postoperative ileus. Participants will receive acupuncture every day until normal bowel movement function returns.
16294675|NCT04713228|Experimental|Pregnant with Pre-eclampsia|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
16294676|NCT04713228|Experimental|Pregnant with gestational hypertension|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
16294677|NCT04713228|Active Comparator|Pregnant without Hypertension - Control|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.
16294678|NCT04713215||Patients where MCAs are currently being used|Intervention: Patient questionnaire - Part A - patients where MCAs are currently being used
16294679|NCT04713215||Patients where an MCA was discontinued|Intervention: Patient questionnaire - Part B - patients where an MCA was discontinued
16294680|NCT04713215||Patients where an MCA was declined|Intervention: Patient questionnaire - Part C - patients where an MCA was declined
16294681|NCT04713215||Carers where MCAs are currently being used|Intervention: Carer questionnaire - Part A - carers where MCAs are currently being used
16294682|NCT04713215||Carers where an MCA was discontinued|Intervention: Carer questionnaire - Part B - carers where an MCA was discontinued
16294683|NCT04713215||Carers where an MCA was declined|Intervention: Carer questionnaire - Part C - carers where an MCA was declined
16294684|NCT04713202|Experimental|Telotristat Ethyl + PRRT|"Telotristat ethyl, 250 mg, PO, three times daily, continuous.
~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
16294685|NCT04713202|Placebo Comparator|Placebo + PRRT|"Placebo, PO, three times daily, continuous.
~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
16294686|NCT04713189|Experimental|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
16294687|NCT04713189|Experimental|Placebo|Participants in the stage I were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
16294688|NCT04713176|Experimental|DWJ1248 with Remdesivir|Camostat mesylate 200 mg, Remdesivir
16294689|NCT04713176|Placebo Comparator|Placebo with Remdesivir|Placebo, Remdesivir
16294690|NCT04713163||Health care or laboratory-based workers|Healthy individuals about to receive any approved COVID-19 vaccine
16294691|NCT04713163||Outpatients|Outpatients about to receive any approved COVID-19 vaccine
16294692|NCT04713150||COVID-19 Positive During Pregnancy|Fifty women, who have a confirmed positive COVID-19 test during pregnancy, will be recruited and enrolled in this study. All women enrolled must be 18 years of age or older. Her child will go on to participate at 2-5 days of age, and again at 3 months and 6 months of age.
16294693|NCT04713150||COVID-19 Negative During Pregnancy|Twenty-five women, who have a confirmed negative COVID-19 test during pregnancy will be recruited and enrolled in the study. Women without any SARS-CoV-2 positive test during pregnancy or any suspected COVID illness, even if not tested, will be enrolled. All women enrolled must be 18 years of age or older. Her child will go on to participate at 3 months and 6 months of age.
16294694|NCT04713137|Active Comparator|Erythritol|20 volunteers receive 50g erythritol dissolved in 300mL tap water as an oral pre-load.
16294695|NCT04713137|Active Comparator|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
16294696|NCT04713137|Active Comparator|Sucralose|20 volunteers receive 0.0558g sucralose dissolved in 300mL tap water as an oral pre-load.
16294697|NCT04713137|Placebo Comparator|Water|20 volunteers receive 300mL tap water as an oral pre-load.
16294698|NCT04713124|Experimental|R2C-M intervention|"R2C-M telephone intervention - Six approximately weekly sessions of R2C-M telephone-delivered intervention (50 minutes in duration), delivered by the same R2C-M Counsellor each session (a qualified clinical psychologist trained in the R2C protocol by the developer, Dr Kate Hall). Call duration will be recorded. Sessions will be digitally recorded, and an independent researcher will randomly select and rate fidelity of intervention sessions for 20% of participants.
~R2C-M workbooks - Two workbooks to facilitate counsellor-delivered exercises within sessions, and between-session practice, will be mailed/emailed to participants.
~Self-help booklet - (as in control group) R2C-M participants will also receive a booklet of information and self-help strategies for methamphetamine use problems."
16294699|NCT04713124|Active Comparator|Control|"Self-help booklet - Control participants will receive (by mail/email) a booklet of information and self-help strategies for methamphetamine use problems.
~Telephone check-ins + information on further support - (to control for frequency of contact across treatment arms) Participants in this group will receive 6 telephone calls from the research team (lasting maximum 5 minutes, call duration will be recorded). During these calls, participants will be asked about their use of the booklet. Whenever required, the researcher will provide participants with information on further support (e.g. DirectLine or other state/territory AOD helpline for advice or referral)."
16294700|NCT04713111|Other|Lifestyle Intervention Group (Exercisers)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.
~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.
~Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace, 2 or more times a week for a duration of 4 weeks."
16294701|NCT04713111|Other|Lifestyle Intervention Group (Meditators)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.
~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.
~Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks."
16294702|NCT04713111|No Intervention|Garmin wearable arm|Existing stress and recovery participants were invited to participate in a Garmin wearable arm where they were provided a Garmin Vivoactive 4 smartwatch to wear continuously, and in particular, while they were on shift at work for a total of 4 consecutive weeks.
16294703|NCT04713111|No Intervention|Hair cortisol arm|Interested existing stress and recovery participants were invited to participate in a one time hair sample collection for cortisol analysis.
16294704|NCT04713098|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
16294705|NCT04713098|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
16294706|NCT04713085|Active Comparator|Sacral Nerve Stimulation|"Sacral nerve stimulation is surgically implanted within three surgeries:
~Implantation of a test stimulation system for 3 weeks: A trail electrode is implanted to neuronal fibers of S3/4 on both sides as a confirmatory diagnostical step. Stimulation is conducted via an external pulse generator.
~Implantation of the final electrode (tined-lead electrode). The stimulation remains to be generated externally by an external pacemaker.
~Implantation of the internal pacemaker system 4 weeks after the electrode's implantation.
~Stimulation parameters: Single current, frequency 15Hz, duration 210μs. Stimulation intensity is individually determined beyond the pain threshold (adjustable amplitude between 0-10mA, depending on the intraoperative response).
~Start point of clinical evaluation is time of implantation of tined lead electrode.
~Medical and behavioral therapy is to be continued as started before intervention and can be adjusted under neuromodulation."
16294707|NCT04713085|Active Comparator|Non-invasive Sacral Nerve Stimulation|"Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field by single current with a 15 Hz frequency for a duration of 210μs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).
~Start point of clinical evaluation is start of external stimulation.
~Medical and behavioral therapy is to be continued as started before intervention and can be adjusted under neuromodulation."
16294708|NCT04713072|Experimental|ABY-035 40 mg|40 mg ABY-035 SC
16294710|NCT04713072|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 16 weeks
16294711|NCT04713059||patients with CPS ≥ 1 or MSI-H or TMB ≥ 10Mb/MUT|
16294712|NCT04713059||patients with CPS =0 , MSS and TMB < 10Mb/mut|
16294713|NCT04713046|Experimental|Allogeneic bone marrow transplant|non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
16294714|NCT04713046|Experimental|CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme|CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
16294715|NCT04713033|Experimental|Experiment 1|Experiment 1 (Aim 1) will utilize a 16-channel sEMG array to characterize cervical-cranial muscle activity networks in typical speakers at baseline and after a vocal loading task. Flexible laryngoscopy will be performed to exclude any existing pathology and confirm eligibility in the healthy control group. Aim 2 will quantify how cervical muscle networks are perturbed in patients with two different types of dysphonia and examine if standard-of-care treatment restores cervical-cranial muscle networks to more typical states.
16294716|NCT04713033|Experimental|Experiment 2|In Experiment 2 (Aim 2), the study will measure muscle networks in patients with muscle tension dysphonia before and after a course of voice therapy. Patients with muscle tension dysphonia represent an intact but potentially maladaptive network.
16294717|NCT04713033|Experimental|Experiment 3|In Experiment 3 (Aim 2), the study will measure patients with unilateral vocal old paralysis, representing a neurologically impaired network, before and after a vocal fold medialization procedure.
16294718|NCT04713020|Experimental|Effectiveness of Application Education Intervention|This study hopes that through the intervention of mobile device education programs, it can provide patients with easy access and repeated viewing and learning. It can replace traditional leaflet health education and reduce the workload of clinical nurses. It is hoped that it can effectively improve the self-care knowledge of stroke patients, improve self-efficacy, reduce the symptoms of depression, and increase the satisfaction of education and guidance. Eventually, patients can be prevented from recurring from stroke, and they can coexist peacefully with stroke and have a good quality of life.
16294719|NCT04713020|Other|genaral care|Give patients routine care
16294720|NCT04713007|Experimental|Group 1|Supportive Care Materials and Resources
16294721|NCT04713007|Experimental|Group A|Ted Talks/Educational videos
16294722|NCT04712994|Experimental|PrEP Optimization Strategies|Up to 16 facilities will be assigned one of four intervention groups (4 facilities per group). One of the intervention groups is pre-identified (PrEP video counselling, HIV Self-Testing, and optimized delivery and prescription processes), however the other 4 strategies have no yet been identified but will be through other activities in the PrEPARE study.
16294723|NCT04712994|No Intervention|Comparator|Up to 4 facilities will be assigned to the comparator group.
16294724|NCT04712981|Experimental|Intervention|HOPE intervention peer-led online community
16294725|NCT04712981|No Intervention|Control|Online community without HOPE intervention psychological components
16294726|NCT04712968|Experimental|Group 1 (intervention group)|Regular exposure to morning daylight
16294727|NCT04712968|No Intervention|Group 2 (control group)|Treatment as usual.
16294728|NCT04712955|Active Comparator|Bloodflow restricted exercise|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRRE) conducted as 4 sets of bilateral knee extensions at 30% of 1RM until voluntary fatigue. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
16294729|NCT04712955|No Intervention|Non-exercise control|No intervention.
16294730|NCT04712942|Experimental|pevonedistat + azacitidine|pevonedistat in combination with azacitidine
16294731|NCT04712942|Other|azacitidine monotherapy|administration of azacitidine monotherapy
16294732|NCT04712929||Homogenous oral leukoplakia|"uniform, flat, thin, smooth/ wrinkled/corrugated surface throughout the white lesion.
~Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days"
16294733|NCT04712929||Non-Homogenous oral leukoplakia|mixture of red and white lesions with a irregularly speckled/ nodular/ verrucous surface Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days
16294734|NCT04712929||Control group|30 healthy controls ( age and sex matched) would also be recruited from patients who are reporting for other routine dental problems.
16294735|NCT04712916|Experimental|Intervention group|Individualized education on medication use, appropriate diet and physical activity was given to the participants in intervention group.
16294736|NCT04712916|No Intervention|Control group|Participant received usual care in the clinic. No individualized education on medication use, appropriate diet and physical activity was given to the participants.
16294737|NCT04712903|Experimental|Durvalumab in Combination with Platinum-Etoposide|Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
16294738|NCT04712864|Experimental|Experimental LB1901|Drug: anti-CD4 CAR T cells anti-CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells.
16294739|NCT04712851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).
16294746|NCT04712825|Active Comparator|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions
16294747|NCT04712825|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis sessions
16294748|NCT04712812||Proband with AP-4 Associated HSP|Male or female patients of all ages with (1) onset of hereditary spastic paraplegia symptoms before the age of 18 years and/or (2) the presence of variants in HSP related genes and/or a relative of a person with such a diagnosis.
16294749|NCT04712799|Experimental|COPD patients|Wlaking tests before and afrer 1 spray with oxymetazoline
16294750|NCT04712786||Group|27 patients, Group 1 consisted of patients with pseudophakic rhegmatogoneous retinal detachment who underwent pars plana vitrectomy and 12% perflouropropane (C3F8) gas tamponade and 20 patients Group 2 consisted of patients with epiretinal membrane or vitreous hemorrhage who underwent PPV without any tamponade
16294751|NCT04712773|Other|Cardiac surgery patients|Patients scheduled for elective cardiac surgery (CABG or valve surgery).
16294752|NCT04712760||Transient congenital hypothyroidism|- children with congenital hypothyroidism who are no longer treated with Levothyroxine at an age of 3 years and 6 months
16294753|NCT04712760||Permanent congenital hypothyroidism|- children with congenital hypothyroidism who are still treated with Levothyroxine at an age of 3 years and 6 months
16294754|NCT04712747||Cases - patients with stroke|Ophthalmological examinations : At the inclusion visit and 3 months after their stroke Blood pressure measurement at rest : At the inclusion visit
16294755|NCT04712747||Controls - Individuals with no history of stroke|Ophthalmological examinations : At the inclusion visit Blood pressure measurement at rest : At the inclusion visit
16294756|NCT04712734|Experimental|Iloperidone|
16294757|NCT04712721|Experimental|Glioblastoma Multiforme|All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
16294758|NCT04712721|Experimental|Brain Metastasis from HER2+ Breast Cancer|All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
16294759|NCT04712708|Active Comparator|Control Group|Eighteen children with spastic CP will receive especially designed physical therapy program based on Neuro-Developmental treatment (NDT) approach with emphasis on exercise encourage independent standing, stretches exercises, strengthening exercises, approximation, enhancement and facilitation of gait patterning and ankle ROM exercises for one hour for 24 sessions
16294760|NCT04712708|Experimental|Study Group|ighteen children with spastic CP will receive the same program that the control group received in addition to especially designed exercises using rebound therapy (Mini Trampoline) that include push up exercise, standing, squatting, single limb squatting, kneeling position, catching and throwing a ball over head in kneeling position, catching and throwing a ball over head in standing position, kicking the ball, broad jumping with assistance, jumping in place, for 1 hour three times per week for three successive months.
16294761|NCT04712695|Experimental|Graded Motor Imagery Group|
16294762|NCT04712695|Experimental|Mirror Visual Feedback Group|
16294763|NCT04712695|Experimental|Augmented Biofeedback Group|
16294764|NCT04712695|Sham Comparator|Diaphragmatic Breathing Group|
16294765|NCT04712669|Experimental|Rodatristat Ethyl 300 mg BID|Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
16294766|NCT04712669|Experimental|Rodatristat Ethyl 600 mg BID|Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
16294767|NCT04712669|Placebo Comparator|Placebo|Matching placebo tablet + standard of care medication(s) taken for 24 weeks
16294768|NCT04712656||OSA Subjects Treated with CPAP|Patients with moderate to severe OSA (ODI4>15/h) who accept CPAP therapy.
16294769|NCT04712643|Experimental|Arm A: atezolizumab + bevacizumab + TACE|Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.
16294770|NCT04712643|Active Comparator|Arm B: TACE alone|Participants will receive on-demand transarterial chemoembolization.
16294771|NCT04712630|Experimental|NIPSA without grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
16294772|NCT04712630|Active Comparator|NIPSA with grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied and the bone defect will be filled with a composite of xenograft and enamel matrix derivates. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
16294773|NCT04712617||FGIDs|Patient who were diagnosed with NERD/RH, FD, IBS and their overlaps (NERD/RH-FD, NERD/RH-IBS, FD-IBS, NERD/RH-FD-IBS)
16294774|NCT04712617||Healthy controls|Subjects who underwent GI evaluations as part of health check-up or for other problems, such as mild abdominal discomfort or pain for a relatively short period of time, but had no organic problems during GI endoscopy
16294775|NCT04712604|Experimental|MSOS Group|The participants in this group will receive the MSOS Intervention for 4 consecutive weeks.
16294776|NCT04712591||Traumatic Brain Injury Patients|Traumatic brain injury (TBI) patients will be recruited and studied using electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
16294777|NCT04712591||Healthy Volunteers|Healthy volunteers will serve as the control group and will undergo electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
16294778|NCT04712578|Experimental|Caffeinated Pre-workout Supplement|This arm will consist of ingestion of the commercially available, caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
16294779|NCT04712578|Active Comparator|Non-Caffeinated Pre-Workout Supplement|This arm will consist of ingestion of the commercially available, non-caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
16295045|NCT04710914|Active Comparator|sedation with intravenous midazolam|continuation of sedation with intravenous midazolam
16294780|NCT04712578|Placebo Comparator|Placebo|This arm will consist of a flavor-matched placebo beverage without the active components contained in the supplements administered in the other study arms.
16294781|NCT04712565|Experimental|Astra Tech Implant System Profile EV|Implants with sloped marginal configuration without bone augmentation are used.
16294782|NCT04712565|Active Comparator|Astra Tech Implant System EV|Implants with regular neck design and GBR procedure fixed with two membrane pins will be used.
16294783|NCT04712552||Stereotactic robot-guided deep brain stimulation procedure|Patients requiring a stereotactic robot-guided deep brain stimulation procedure (Parkinson's disease, disabling tremor, dystonia)
16294784|NCT04712539|Experimental|Arm I (oseltamivir, baloxavir marboxil)|Patients receive oseltamivir PO BID for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
16294785|NCT04712539|Active Comparator|Arm II (oseltamivir)|Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.
16294786|NCT04712526||AEON Endostapler|Stapling performed with AEON Endostapler
16294787|NCT04712513||Patients with coronary artery disease and hemodynamically stable|
16294788|NCT04712500|Experimental|AND017: Fasted - Fed|Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2
16294789|NCT04712500|Experimental|AND017: Fed - Fasted|Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2
16294790|NCT04712487||Routine discectomy|Patients undergoing routine spine surgery due to degenerative disease of the spine
16294791|NCT04712474|Experimental|In-home decluttering|Study participants receive weekly sessions of in-home decluttering for 10 weeks.
16294792|NCT04712474|No Intervention|Delayed treatment|Study participants receive weekly session of in-home decluttering after a 10 week delay.
16294793|NCT04712461|Experimental|SUPPORTS Implementation Model|The SUPPORTS implementation model will consist of a package of implementation strategies aimed at improving EBP sustainment through reducing provider burnout and turnover and improving organizational climate. The content and structure of SUPPORTS will be informed by the occupational health literature (e.g., psychoeducation about burnout, mindfulness training, or changes involvement of providers in organizational decision-making) and from a needs and context assessment.
16294794|NCT04712461|No Intervention|Implementation as Usual|Agencies in the Implementation as Usual condition will have implementation strategies tied to the implementation of EBPs that these agencies in the community are already using (i.e., the study will measure the implementation strategies being used by the agency but will not provide any additional strategies). There will be no strategies related to reducing provider burnout and turnover and improving organizational climate.
16294795|NCT04712448||Healthy subjects|Donors of the Transfusion Center of Venice Healthy volunteers afferent to BioBIM
16294796|NCT04712448||Patients|Patients with chronic diseases afferent to BioBIM
16294797|NCT04712435|Experimental|Experimental: N-acetylcysteine|Sachets containing N-acetylcysteine 200 mg Powder for Oral Solution administered every 8 hours (Daily dose 600 mg/day). is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
16294798|NCT04712435|Placebo Comparator|Placebo Comparator: Placebo|200mg granulated solution of matching placebo administered every 8 hours (Daily dose 600 mg/day), is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
16294799|NCT04712422||Healthy participants|At least 25 healthy participants aged from 18 to 50 years old. Participants will be excluded if pregnant.
16294800|NCT04712422||Pathologic group|At least 22 participants with diagnosis of Myotonic Dystrophy 1.
16294801|NCT04712409|Active Comparator|SADI-S as a primary surgery|
16294802|NCT04712409|Active Comparator|BPD-DS as a primary surgery|
16294803|NCT04712409|Active Comparator|SADI-S as a revisional procedure|
16294804|NCT04712409|Active Comparator|BPD-DS as a revisional procedure|
16294805|NCT04712396|Experimental|Capivasertib + Itraconazole|Subjects will receive a single oral dose of capivasertib on Day 1 during treatment period 1, itraconazole on Days 3, 4, and 5 during treatment period 2, and single oral dose of capivasertib plus a dose of itraconazole on Day 6, followed by itraconazole alone on Day 7 during treatment period 3.
16294806|NCT04712383|Experimental|Fitbit Care intervention arm|The experimental arm will receive the full Fitbit Care product suite (Fitbit wrist-worn device, Fitbit connected weight scale, and Fitbit Premium + Health Coaching service). Participants in the experimental arm will also be offered support in improving health behaviors that are important to them, including activity, nutrition, sleep, stress management, and medication adherence.
16294807|NCT04712383|No Intervention|Fitbit study control arm|Participants in the control arm will have access to standard healthcare benefits available to all employees, but will not have access to any of the Fitbit Care interventions
16294808|NCT04712370|Active Comparator|Conventional caudal block|Patients of this group will receive the conventional method (blind technique without ultrasound) of caudal block
16294809|NCT04712370|Experimental|Ultrasound-guided caudal block|Patients of this group will receive caudal block using ultrasound.
16294810|NCT04712370|Experimental|Ultrasound guided erector spinae plane Block|Patients of this group will receive ultrasound guided erector spinae plane Block at the level of the transverse process of the second lumbar vertebrae(L2) .
16294811|NCT04712357|Placebo Comparator|Placebo (Vitamin C)|Control placebo (Vitamin C - 500mg / day, for 10 days)
16294812|NCT04712357|Active Comparator|Tenofovir disoproxyl fumarate (TDF)|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
16294813|NCT04712357|Active Comparator|TDF + FTC|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
16294814|NCT04712344|Experimental|COVID-19 convalescent plasma|A total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 and standard treatment.
16294815|NCT04712344|No Intervention|Standard treatment|Standard treatment.
16294816|NCT04712331|Experimental|The Study group A|they received graduated abdominal strengthening exercises for 30 min., 3 times per week for 6 weeks preoperatively.
16294817|NCT04712331|Experimental|The Study group B|they received Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
16294818|NCT04712331|Experimental|The Study group C|they received combination between graduated abdominal strengthening exercises and Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
16294819|NCT04712331|No Intervention|The Control group D|they were instructed to presume in normal activities of daily living preoperatively, without abdominal exercises or Russian stimulation.
16294820|NCT04712318|Other|ReLex Smile surgery|"The aim of this study is to investigate the effect of Relex Smile surgery to correct the residual refractive errors (myopic and hyperopic) 6 months after Trifocal IOL Implantation.
~At myopic residual refraction (min -0.75 D) (100eyes) 6 months after Trifocal IOL Implantation we used Relex-Smile surgery for treatment."
16294821|NCT04712318|Other|ReLex Smile surgery-fresh corneal lenticule implantation|At hyperopic residual refraction 30 eyes 6 months after Trifocal IOL Implantation we used fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
16294822|NCT04712305||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
16294823|NCT04712305||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
16294824|NCT04712292||Study group|Patients undergoing surgery for confirmed colorectal cancer between March and December 2020
16294825|NCT04712292||Control group|Patients undergoing surgery for confirmed colorectal cancer between March and December 2019
16294826|NCT04712279|Active Comparator|Ivermectin 0.6mg/kg/day|
16294827|NCT04712279|Active Comparator|Ivermectin 1.0mg/kg/day|
16294828|NCT04712279|Placebo Comparator|Placebo|
16294829|NCT04712266|Active Comparator|Insulin IV|calculated insulin rate
16294830|NCT04712266|Experimental|Insulin and Glucagon IV|calculated molar ratio insulin:glucagon
16294831|NCT04712240|Other|Respiration rate monitor (concurrently measured with standard of care capnography)|Single group study whereupon participants will be fitted with portable respiration rate monitor around their chest for duration of surgery. Respiration rates acquired by the respiration rate monitor will be compared to capnography, which is standard of care and applied to all surgical cases
16294832|NCT04712227||difficult intubation|patients with a difficult intubation score of 5 or more
16294833|NCT04712227||easy intubation|patients with difficult intubation score less than 5
16294834|NCT04712227||difficult mask ventilation|group 3 and 4 by han mask ventilation grouping
16294835|NCT04712227||easy mask ventilation|group 1 and 2 according to han mask ventilation grouping
16294836|NCT04712214|Experimental|Patients with brain tumours candidate for neurosurgery|Patients will be recruited following the inclusion criteria: any patient with a diagnosis of brain tumour, age ranging from 18 with no upper limit, who will agree to the operation and to take part of the present study, will be enrolled. During surgery, multispectral and/or hyper spectral acquisition of images from the surgical field will be performed. Each patient will have an average acquisition of 6 datasets. As each dataset will correspond to an image, this will be divided into many reading regions (from 10 to 20) for a total of approximatively 60 measurements per patient.
16294837|NCT04712201|Experimental|En bloc|En bloc transurethral resection of the bladder
16294838|NCT04712201|Active Comparator|Conventional|Conventional transurethral resection of the bladder
16294839|NCT04712188||Arcing|"10 patients with traumatic spinal cord injury using the arcing stroke pattern to propel manual wheelchair"
16294840|NCT04712188||Semicirculer|"10 patients with traumatic spinal cord injury using the semicirculer stroke pattern to propel manual wheelchair"
16294841|NCT04712188||Single loop|"10 patients with traumatic spinal cord injury using the single loop stroke pattern to propel manual wheelchair"
16294842|NCT04712188||Double loop|"10 patients with traumatic spinal cord injury using the double loop stroke pattern to propel manual wheelchair"
16294843|NCT04712175||Patients with SARS-CoV-2 infection|
16294844|NCT04712175||Patients without SARS-CoV-2 infection|
16294845|NCT04712162|Other|D: maintain anesthesia with desflurane|D: maintain anesthesia with Suprane® (Desflurane) at 6%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
16294846|NCT04712162|Other|S: maintain anesthesia with sevoflurane.|S: maintain anesthesia with Sevorane® (Sevoflurane) at 2%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
16294847|NCT04712149|Experimental|intervention arm|In the intervention arm, 15 patients will receive a weekly questionnaire. Alerts will be sent to the multidisciplinary care team, who will undertake follow-up actions. In the control arm, 15 patients will receive the standard care pathway without weekly questionnaire and without automatic alerts to the care team. The standard care pathways and the care team are the same in both groups. In this pilot study, the weekly follow-up will be evaluated by a validation questionnaire, semi-structured interviews with patients and the care team, and workload registration of the care team during a six-month period.
16294848|NCT04712149|No Intervention|Control arm|
16294849|NCT04712136|Experimental|Cardiac disease|Children aged of 6 to 18 years old with an inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or those with an inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy).
16294850|NCT04712136|Sham Comparator|Control group|Children aged 6 to 18 years old referred to the paediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography.
16294851|NCT04712123||relapse due to S. aureus|patients having had an initial infection due to S. aureus and who present a relapse with persistence of S. aureus
16294852|NCT04712110|Experimental|TAK-019|TAK-019 0.5 mL, intramuscular injection in the upper arm
16294853|NCT04712110|Placebo Comparator|Placebo|TAK-019 Matching Placebo, intramuscular injection in the upper arm
16295140|NCT04710264||recombinant hFSH|Patient stimulated with recombinant hFSH
16294856|NCT04712084|No Intervention|Control group|Extubation procedure following standard of care
16294857|NCT04712084|Experimental|Pressure support group|Extubation procedure is performed with 100% of O2 but with application of positive pressure before and after extubation
16294858|NCT04712071|Experimental|Ketamine|40 minutes intravenous infusion of 0.5 mg/kg ketamine.
16294859|NCT04712058|Experimental|Same-day initiation with BIC/F/TAF|
16294860|NCT04712045|Experimental|New PPE|Use of Short sleeve gown and single pair of gloves
16294861|NCT04712045|Active Comparator|Old PPE|Use of Long sleeve gown and double pairs of gloves
16294862|NCT04712032|Experimental|Image Guided Bowel Anastomosis group|ICG-guided perfusion assessment
16294863|NCT04712032|No Intervention|Conventional Bowel Anastomosis group|conventional perfusion assessment
16294864|NCT04712019|Experimental|Closed Incision Negative Pressure Therapy (ciNPT) Dressing|Prevena Restor Arthro-Form Dressing with Prevena Plus Therapy Unit
16294865|NCT04712019|Active Comparator|Standard Silver-containing Dressing|
16294866|NCT04712006|Experimental|Cohort 1: JNJ-64304500|Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.
16294867|NCT04712006|Experimental|Cohort 2: JNJ-64304500|Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.
16294868|NCT04711993|No Intervention|Control group|No application will be made to the control group. However, these patients will be included in the exercise program they want after the 8-week treatment period is completed.
16294869|NCT04711993|Experimental|Aerobic exercise group|Patients in the aerobic exercise group will exercise under the supervision of the therapist.
16294870|NCT04711993|Experimental|Stretching exercise group|Patients in the stretching-mobility exercise group will do stretching exercises under the supervision of the therapist
16294871|NCT04711980|Experimental|Mudan granule|"Based on the standard medical care, experimental group were treated with Mudan Granule 7g , 3 times/d.
~Intervention: Drug: Mudan granule"
16294872|NCT04711980|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 7g , 3 times/d Intervention: Drug: Placebo
16294873|NCT04711967|Experimental|Fecal Microbiota Transplantation group|treat with FMT
16294874|NCT04711967|Active Comparator|Control group|treat with traditional medicine
16294875|NCT04711954||ATHENA|Cohort of people living with HIV in the Netherlands
16294876|NCT04711954||LUKCY|Cohort of people living with HIV in the Lviv area, Ukraine
16294877|NCT04711941|Experimental|ToM training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
16294878|NCT04711941|Active Comparator|Non mentalistic training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to provide a historical and descriptive overview of cinema movies, TV news, documentaries, newspapers, and advertising. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
16294879|NCT04711928||Trained athletes|Active individuals with at least 4 training hours per week.
16294880|NCT04711915|Active Comparator|0.1 mg/kg DMT|0.1 mg/kg DMT administered intravenously
16294881|NCT04711915|Active Comparator|0.3 mg/kg DMT|0.3 mg/kg DMT administered intravenously
16294886|NCT04711889|Experimental|Ulinastatin|Ulinastatin 10 0000 Units is taken intravenously three times a day.
16294887|NCT04711889|Placebo Comparator|Saline|Same saline dose as ulinastatin is taken intravenously three times a day.
16294888|NCT04711876||Test group with enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV +
16294889|NCT04711876||Control group with no enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV -
16294890|NCT04711863|Experimental|Fluvoxamine|Start fluvoxamine 50 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
16294891|NCT04711863|Placebo Comparator|Placebo|Start ursodeoxycholate (UDCA) 100 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
16294894|NCT04711837|Experimental|HSK3486|HSK3486 for induction of general anesthesia.
16294895|NCT04711837|Active Comparator|Propofol|Propofol for induction of general anesthesia.
16294957|NCT04711408|Experimental|Virtual reality|women allocated to undergo ultrasound for the diagnosis of endometriosis with Virtual reality System
16294897|NCT04711798||Patients receiving cardiac surgery|Patients receiving cardiac surgery will be included. All patients received a passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system, a lung recruitment maneuver (LRM) and an echographic evaluation of the right cardiac function.
16294898|NCT04711785|Active Comparator|Intervention|Multicomponent exercise program twice a week (2 hours per week) during six months
16294899|NCT04711785|No Intervention|Control Goup|Usual routine.
16294900|NCT04711772||DOR group|Genomic DNA will be extracted from peripheral blood leukocytes to perform whole-genome sequencing in participates with diminished ovarian reserve.
16294901|NCT04711772||Control group|Participants with normal ovarian reserve will be recruited as control group and peripheral blood leukocytes genomic DNA will be extracted to perform whole-genome sequencing.
16294902|NCT04711759|Experimental|Sequence A: High flow nasal cannula - Standard oxygen therapy|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of standard oxygen therapy.
16294903|NCT04711759|Experimental|Sequence B: Standard oxygen therapy - High flow nasal cannula|Once participants are extubated they will receive one hour of standard oxygen therapy followed by one hour of high flow nasal cannula.
16294904|NCT04711746|Experimental|Previous proximal unprovoked pulmonary embolism|
16294905|NCT04711746|Active Comparator|Previous proximal provoked pulmonary embolism|
16294906|NCT04711733||Patients 6-14 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
16294907|NCT04711733||Parents of 6-14 years old patients|Individual interview + Self-report questionnaire
16294908|NCT04711733||Patients 15-25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
16294909|NCT04711733||Parents of 15-25 years old patients|Individual interview + Self-report questionnaire
16294910|NCT04711733||Patients > 25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
16294911|NCT04711733||Parents of > 25 years old patients|Individual interview + Self-report questionnaire
16294912|NCT04711720|Experimental|Navigation|
16294913|NCT04711720|No Intervention|Control|
16294914|NCT04711707|Experimental|Community navigator|This group is guided through the resources and provided bi-monthly support with a community navigator
16294915|NCT04711707|Other|Self-Navigation|This group receives the social needs resources to self-navigation
16294916|NCT04711694|Experimental|Early Mindfulness Intervention|The Early MBI group partake on the mindfulness intervention after first outcome assessment.
16294917|NCT04711694|Placebo Comparator|Late Mindfulness Intervention|"The Late MBI group partake on the mindfulness intervention after the second outcome assessment.
~This groups is the control group for the Early MBI group.
~After the second assessment, this group engage on the same intervention as the early group."
16294918|NCT04711681|Experimental|PBS1|"This group will recieve an enhanced PBS intervention."
16294919|NCT04711681|Active Comparator|PBS 2|"This group will receive standard PBS with fewer training and coaching sessions than PBS 1."
16294920|NCT04711668|Experimental|Group Ketamin|0.5 mg / kg i.v. ketamine bolus at induction and 0.25 mg / kg / hr i.v. ketamine infusion intraoperatively
16294921|NCT04711668|Experimental|Group Lidokain|1.5 mg / kg i.v. lidocaine bolus at induction and 1.5 mg / kg / hr i.v. lidocaine infusion intraoperatively
16294922|NCT04711668|Placebo Comparator|Group Placebo|i.v. saline (in the same volume and duration like group ketamine/lidokain)
16294923|NCT04711655|Experimental|(ARMA) antireflux ablation of the cardiac mucosa|The ARMA (Ablation with electrocoagulation current or by argon gas fulguration) technique will be performed in patients assigned to this treatment arm.
16294924|NCT04711655|Placebo Comparator|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
16294925|NCT04711642|No Intervention|No intervention|Control group.
16294926|NCT04711642|Experimental|Treatment 1|Sodium hyaluronate 0.1% eyedrops (Systane ultra plus), q.i.d from day 7 to day 30 after cataract surgery.
16294927|NCT04711642|Experimental|Treatment 2|Sodium hyaluronate 0.1% eyedrops (Hylo-comod), q.i.d from day 7 to day 30 after cataract surgery.
16294928|NCT04711629|Experimental|Smoker COPD|Patients who continue to smoke
16294929|NCT04711629|Active Comparator|Ex-smoker COPD|Patients who quit smoking.
16294930|NCT04711616|Experimental|physical therapy intervention|
16294931|NCT04711603|Experimental|MR13A9/MR13A9|Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
16294932|NCT04711603|Placebo Comparator|Placebo/MR13A9|Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
16294933|NCT04711590||Successful extubation|The patients pass the spontaneous breathing trial and are successful extubated without reintubation within 72 hours. .
16294934|NCT04711590||Failed extubation|The patients pass the spontaneous breathing trial and are successful extubated with reintubation within 72 hours. .
16294935|NCT04711577|Experimental|Condition 1|Track clinician-determined symptoms
16294936|NCT04711577|Experimental|Condition 2|Track clinician-determined and self-determined symptoms
16294937|NCT04711564||Provision of olive oil emulsions in PN|Olive oil-based (Oliclinomel: 80% OO, 20% LCT provided in a complete all-in-one PN bag by Baxter) parenteral nutrition
16294938|NCT04711564||Provision of soybean emulsions in PN|Soybean-based (Kabiven: 100% LCT provided in a complete all-in-one PN bag)
16294958|NCT04711408|No Intervention|Standart care|women allocated to undergo ultrasound for the diagnosis of endometriosis without VR
16294959|NCT04711395||Cataract Surgery Group|
16294960|NCT04711395||Non-surgical group|
16294961|NCT04711369|Active Comparator|Intervention group (laser therapy)|Participants allocated to the laser-therapy group will receive 2 laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
16294962|NCT04711369|Sham Comparator|Control group (sham laser therapy)|Participants allocated to the control group will receive 2 sham laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
16294939|NCT04711525|Experimental|Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be exposed to interactive classroom instruction, and their parents will be exposed to the Web-based program. In the experimental group, apart from the standard preschool health education curriculum, the preschool children will also be exposed to the interactive activities and quizzes using Web 2.0 tools, educational videos of a healthy lifestyle, sensory-based food education activities, cooking demonstrations, fun, and active games, and exercises. Whereas the parents will be exposed to Web-based healthy lifestyle educational materials, videos, and pictures sharing, quizzes, and communication through the WhatsApp and closed Facebook groups. Besides, a total of 3 messages per week will be delivered to the parents in the experimental group. The messages will be included announcing the release of a new topic, a reminder to log in to the website and read the health information, and a reminder to participate in the online activities.
16294940|NCT04711525|Active Comparator|Standard health education|The children in the control group do not have exposed to the i-MaCHeL interactive classroom instruction, and their parents do not have access to the i-MaCHeL website materials. Thus, the children will be continued with standard health education only in the preschool setting, and their parents will be received Web-based health newsletters. The Web-based newsletters consist of general health information that are relevant to the preschool life stage. In ensuring that the experimental and control groups appear the same, the topics in the Web-based newsletters will have a look and feel similar nature to the experimental group condition. But still, the topics will not be included the interactive components such as videos and pictures sharing activities, quizzes, individualized feedback, and communication through WhatsApp and closed Facebook groups. Only one message (announcement of the release of a new topic) per week will be delivered to parents of the control group.
16294941|NCT04711512||Single Arm (All Participants)|Within this arm, participants are randomized to one of the interventions described below at each of 4 times per day.
16294942|NCT04711499|Experimental|Fatigue Group|The trial will recruit trainee anaesthetists of ST3 grade or higher who take part in a resident night-shift rota at Nottingham University Hospitals NHS Trust. Participants will undergo baseline psychometric testing to measure baseline mood. There will be a series of questions to ascertain levels of fatigue. All participants will then be asked to perform a standardised ultrasound-guided peripheral nerve blockade task using a high fidelity bench-top phantom model. Performance in this task will be independently assessed using a previously-validated scoring tool by two raters blinded to participant group allocation.
16294943|NCT04711499|Active Comparator|Non Fatigued group|The non fatigued group will be asked to perform the same series of questions and tasks after a night at home with no work duties or commitments
16294944|NCT04711486|Experimental|Contraloid acetate|"300 mg Contraloid/participant administered orally (for 28 days) as a single daily dose.
~Other Name: PRI-002"
16294945|NCT04711486|Placebo Comparator|Placebo|300 mg Placebo (Microcrystalline cellulose)/participant administered orally (for 28 days) as a single daily dose.
16294946|NCT04711473|Active Comparator|Colonoscopy Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in colonoscopy, and including a referral for the procedure at a local endoscopy center. Participants will be provided a phone number if interested in navigated colonoscopy scheduling.
16294947|NCT04711473|Experimental|Choice|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in their choice of either colonoscopy or mailed fecal immunochemical testing (FIT). The letter will include both a referral for the colonoscopy at a local endoscopy enter and a FIT kit with a lab requisition and instructions for completion.
16294948|NCT04711473|Experimental|FIT Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in FIT testing. The letter will include a FIT kit with lab requisition and instructions for completion.
16294949|NCT04711460||treatment plus mindfulness comparing young vs old|Eligible participants had a diagnosis from the DSM-V that included psychotic spectrum disorders, were adults from ages 18 to 55 years, and attended a group therapy-based outpatient mental health program for at least five weeks. Scores were matched for younger vs older participants and compared.
16294950|NCT04711460||treatment plus mindfulness practice and no treatment or Treatment As Usual (TAU)|"Participants in the Treatment plus mindfulness practice had Cognitive Behavioral Therapy, mindfulness education and mindfulness technique practice.
~Participants in the Treatment As Usual group had Cognitive Behavioral Therapy and education about the mindfulness process, but no practice of the technique as a group. The scores of each group were compared to determine effect differences."
16294951|NCT04711447|Other|no-tape, experimental KT, sham KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both an experimental-KT (E-KT) and sham-KT (S-KT) condition.
16294952|NCT04711447|Other|no-tape, sham KT, experimental KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both a sham-KT (S-KT) condition and experimental-KT (E-KT).
16294953|NCT04711434|Experimental|Prevention group|Toripalimab: 240mg IV every 3 months for a year
16294954|NCT04711434|No Intervention|Follow-up group|Routine follow-up, no intervention
16294955|NCT04711421|Experimental|Experimental: Feedback|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve feedback regrding the number of steps taken by them at the end of each day
16294956|NCT04711421|No Intervention|No Intervention: Control|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve no feedback regrding the number of steps taken by them.
16295044|NCT04710914|Experimental|sedation by inhaled isoflurane|sedation by midazolam with the MIRUS device
16294963|NCT04711356|Experimental|Study Intervention|All study participants will receive an Ad26.ZEBOV vaccine at a dose of 5x10^10 vp given via IM injection
16294964|NCT04711343|Experimental|BAT2306 injection|150mg /1ml; subcutaneous injection
16294965|NCT04711343|Active Comparator|Cosentyx (US-licensed)|150mg /1ml; subcutaneous injection
16294966|NCT04711343|Active Comparator|Cosentyx (EU-licensed)|150mg /1ml; subcutaneous injection
16294967|NCT04711330||Patients treated with maintenance immunotherapy after concurrent chemo/RT|"Observation of response and response. The microbiome of the patients throat and stool will be analyzed before the standard treatment with IO is initiated after completion of the chemoradiation therapy.
~No intervention is planned."
16294968|NCT04711317|Experimental|Preoxygenation with nasal high flow oxygen|Preoxygenation with nasal high flow oxygen
16294969|NCT04711317|No Intervention|Control group|Standard preoxygenation according to hospital protocol with tight fitting facemask
16294970|NCT04711304|Experimental|Wharton's Jelly|Intraarticular injection of Wharton's Jelly
16294971|NCT04711304|Active Comparator|Hyaluronic Acid|Intraarticular injection of Hyaluronic Acid
16294972|NCT04711304|Placebo Comparator|Saline|Intraarticular injection of Saline
16294973|NCT04711291|No Intervention|Remain on IR-Tac prescribed doses every 12 hours|Patient will remain in Tacrolimus IR-Tac Arm and will complete medication adherence questionnaire monthly. They will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus Trough levels and change in tacrolimus dose levels during their routine follow up.
16294974|NCT04711291|Active Comparator|Convert to Envarsus XR once daily|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR and will complete medication adherence questionnaire. However, patients in this group will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
16294975|NCT04711291|Experimental|Convert to Envarsus XR once daily combined with TransMedAx app use|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR, will receive notification by scanning a QR code through TransMedAx application and will complete medication adherence questionnaire. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
16294976|NCT04711278|Experimental|hypnosis group|Mask-wearing as hypnosis method for patients in this arm.
16294977|NCT04711278|Sham Comparator|comparator group|No hypnosis for patients in this arm.
16294980|NCT04711239||Two types of samples (TE and SCM) will be collected for all blastocysts included in the study|
16294981|NCT04711226|Experimental|AT-1501 Single Arm|
16294982|NCT04711213|Active Comparator|Dexamethasone Dose 1|
16294983|NCT04711213|Active Comparator|Dexamethasone Dose 2|
16294984|NCT04711213|Placebo Comparator|Placebo Dose 1|
16294985|NCT04711213|Placebo Comparator|Placebo Dose 2|
16294986|NCT04711200|Experimental|Adipose derived stromal cells intravenously injected|
16294987|NCT04711187|Experimental|AT-527 Formulation 1 Dose 1|
16294988|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1|
16294989|NCT04711187|Experimental|AT-527 Formulation 2 Dose 2|
16294990|NCT04711187|Experimental|AT-527 Formulation 1 Dose 3|
16294991|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3|
16294992|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1 Fast/Fed|
16294993|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3 Fast/Fed|
16294994|NCT04711174||movement,high Aldrete score group (MH group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 9
16294995|NCT04711174||movement,low Aldrete score group (ML group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 7
16294996|NCT04711174||sedation,high Aldrete score group (SH group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 9
16294997|NCT04711174||sedation,low Aldrete score group (SL group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 7
16294998|NCT04711161|Experimental|Phase 1a: Single Arm, Open Label (GRN-300 monotherapy)|The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 as a single agent will be determined. The overall duration of Phase 1a will be approximately 9-12 months, depending on the rate of enrollment and the number of subjects enrolled.
16294999|NCT04711161|Experimental|Phase 1b: Single Arm, Open Label (GRN-300 plus paclitaxel)|"The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment, in combination with intravenously administered paclitaxel weekly x 3 during each 28-day cycle. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 in combination with paclitaxel will be determined. The overall duration of Phase 1b will be approximately 9-12 months, depending on the rate of enrollment and the number of subjects enrolled. Phase 1b will commence following determination of the MTD and RP2D of GRN-300 monotherapy in Phase 1a.
~Overall duration of the study will be approximately 24 months, depending on the rate of enrollment and number of subjects enrolled."
16295004|NCT04711135|Experimental|GEP-NET and PPGL|All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
16295005|NCT04711122||Role of prophylactic antibiotics in childscore A|Role of prophylaxis against infections in progression of cirrhotic patients with childscore A
16295006|NCT04711109|Experimental|Arm A (denosumab)|Patients receive denosumab SC q6m for up to 5 years in the absence of disease progression or unacceptable toxicity.
16295007|NCT04711109|Placebo Comparator|Arm B (placebo)|Patients receive placebo SC q6m for up to 5 years in the absence of disease progression.
16295008|NCT04711096||Group A|TAB group formed of 65 patients
16295009|NCT04711096||Group B|"Group B : The Infiltration Group formed of 65 patients.
~• This group will B wills provided with single-shot local anesthetic wound infiltration with 20 ml of 0.25% bupivacaine injected subcutaneously above and below skin incision before closure of skin."
16295010|NCT04711096||Group C|"Group C : Narcotics only group formed of 20 patients
~• routine analgesic was taken only without any intervention"
16295011|NCT04711070||Patients with sepsis|Muscle velocity recovery cycles, electromyography, nerve conduction studies, direct musclestimulation, blood test
16295012|NCT04711070||Patients with chronic renal failure|
16295013|NCT04711070||Healthy control|
16295014|NCT04711057|Experimental|Pulmonary Rehabilitation + Community-based PA program|After PR, the experimental group will integrate a community-based PA program.
16295015|NCT04711057|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates PA recommendations.
16295016|NCT04711044|Experimental|Study group|
16295017|NCT04711031||Usual care + FLUS|At index consultation, patients will receive a FLUS examination in addition to the GP's usual care of adults presenting with symptoms of an acute LRTI.
16295018|NCT04711018||Group DL (+)|Grade III or IV laryngeal view according to Cormack-Lehane classification
16295019|NCT04711018||Group DL (-)|Grade I or II laryngeal view according to Cormack-Lehane classification
16295020|NCT04711005|Experimental|SAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.1 mg/kg via slow IV infusion (40 minutes)
16295021|NCT04711005|Experimental|SAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
16295022|NCT04711005|Experimental|SAD Cohort 3|(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes)
16295023|NCT04711005|Experimental|SAD Cohort 4|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes)
16295024|NCT04711005|Experimental|SAD Cohort 5|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes)
16295025|NCT04711005|Experimental|SAD Cohort 6|(2R,6R)-Hydroxynorketamine @ 4.0 mg/kg via slow IV infusion (40 minutes)
16295026|NCT04711005|Experimental|MAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
16295027|NCT04711005|Experimental|MAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
16295028|NCT04711005|Experimental|MAD Cohort 3|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
16295029|NCT04711005|Placebo Comparator|Placebo|Control product (placebo) will be sterile saline also administered via slow IV infusion (40 minutes).
16295030|NCT04710992|Sham Comparator|Needling Group|The needle will be inserted for 90 seconds without galvanic current.
16295031|NCT04710992|Experimental|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
16295032|NCT04710992|Experimental|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
16295033|NCT04710992|No Intervention|Control Group|Non-intervention control group
16295034|NCT04710979|Experimental|Yoga Intervention Group|
16295035|NCT04710979|No Intervention|Control Group|Control participants will receive no guidance from the research staff to change their behavior.
16295036|NCT04710966|Experimental|debridement group|For the debridement group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic debridement will be performed.
16295037|NCT04710966|Experimental|repair group|For the repair group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic repair will be performed.
16295038|NCT04710953|Experimental|CPAP arm|In addition to standard of care, CPAP will be provided at high altitude posts where Gamow bag is not available and all patients of HAPE will be given CPAP when evacuation/descent is either not possible or delayed due to weather conditions.
16295039|NCT04710953|No Intervention|Gamow bag arm/hyperbaric chamber|Posts where Gamow bag would be available, the patients of HAPE will be given standard of care and will be asked to lie inside Gamow bag inflated at 2 Psi for several hours to simulate a descent of 1500 meters when evacuation/descent is either not possible or delayed due to weather conditions.
16295040|NCT04710940|Experimental|Pilot Participants|Patients with type 2 diabetes (n=30) will be recruited to pilot test the DM-BOOST intervention.
16295041|NCT04710927|Active Comparator|Group 1|High Viscosity GIC
16295042|NCT04710927|Experimental|Group 2|SDF and High Viscosity GIC
16295043|NCT04710927|Experimental|Group 3|SDF, Papain-Based Gel and High Viscosity GIC
16295046|NCT04710901|Active Comparator|uTECH|Approximately 165 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months.
16295047|NCT04710901|Active Comparator|Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the YMHP intervention over the course of the first 3 months. Months 3-6 will be inactive, and they will be followed for a total of 12 months.
16295048|NCT04710888|Experimental|basil extract mucoadhesive gel|10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed.
16295049|NCT04710888|Placebo Comparator|mucoadhesive placebo gel|10 patients treated by mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
16295050|NCT04710888|Sham Comparator|healthy patients|10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)
16295051|NCT04710875|Active Comparator|Na-lactate|Iv infusion of sodium D/L lactate
16295052|NCT04710875|Placebo Comparator|Sodium chloride|Iv infusion of Sodium chloride
16295053|NCT04710862|Active Comparator|Breathing training with a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will perform exhalation exercises through a breathing device. Homework activities will be assigned. Post-training testing sessions will also be conducted.
16295054|NCT04710862|Active Comparator|Breathing training without a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will receive training on the use of breathing techniques without a device, but with visual feedback throughout training. Homework activities will be assigned. Post-training testing sessions will also be conducted.
16295055|NCT04710849||Treatment Failure Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. Definition of systemic glucocorticoid treatment failure during hospitalization is (Reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): The following occurs from the 2nd to the 7th day after admission Situation: ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
16295056|NCT04710849||Treatment Success Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. The treatment success group was defined as not meeting any of the following conditions for failure of systemic hormone therapy during hospitalization (reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
16295057|NCT04710823|Experimental|Thoracic paravertebral block|Patients will receive ultrasound-guided continuous thoracic paravertebral blockusing bupivacaine 0.25% for 4 days.
16295058|NCT04710823|Experimental|Serratus anterior plane block|Patients will receive ultrasound-guided continuous SAP block using bupivacaine 0.25% for 4 days.
16295059|NCT04710810|Experimental|Experimental|Patients receive group and rhesus compatible UCB cells through intravenous bolus injections (4 injections at 2-week intervals) after pre-medication with Clemastine (0.025 mg/kg body weight, intravenously). One dose is 250±10 x 10⁶ viable cells per sample.
16295060|NCT04710810|No Intervention|Control|Patients receives standard therapy (applied behavioral analysis, speech therapy).
16295061|NCT04710797|Experimental|No Lymphadenectomy|Comprehensive staging surgery with no Lymphadenectomy
16295062|NCT04710797|Active Comparator|Lymphadenectomy|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
16295063|NCT04710784|Experimental|I-TEST Intervention Package|Each study site will begin in the baseline, pre-implementation phase, and then be randomized to implement the I-TEST intervention package for a duration of three months, followed by the post-implementation phase.
16295064|NCT04710771||Group-A|Patient performed prone lying position for three hours.
16295065|NCT04710771||Group-B|along with Prone lying position, patients also performed alternate nostril breathing for ten minutes.
16295066|NCT04710758|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D2 lymphadenectomy for patients enrolled in this group.
16295067|NCT04710758|Active Comparator|Open total gastrectomy|The surgeon will perform OTG with D2 lymphadenectomy for patients enrolled in this group.
16295068|NCT04710745||Study Group|Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score > 2 (for females > 3) and with more than 3 specific criteria for inclusion.
16295069|NCT04710732|Active Comparator|Control|Peri-operative VTE prophylaxis with a standard once-daily dose of enoxaparin 40 mg and anti-embolic stockings
16295070|NCT04710732|Experimental|Experimental|Peri-operative VTE prophylaxis with an escalated twice-daily dose of enoxaparin 30 mg and anti-embolic stockings
16295071|NCT04710719|Active Comparator|TAC only|Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
16295072|NCT04710719|Active Comparator|TAC + 5FU|Participants will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
16295073|NCT04710706|Active Comparator|Water-alone colonoscopy (water exchange technique)|During water-alone colonoscopy, gas insufflation (air or CO2) is not allowed during the insertion of the colonoscope to the caecum. Instead, water is used to facilitate the passage of the scope to the caecum. On withdrawal, CO2 is permitted.
16295074|NCT04710706|Active Comparator|Water-CO2 hybrid colonoscopy (modified water immersion technique)|During water-CO2 hybrid colonoscopy, the operator has access to both water and CO2. In the left colon, predominately water is used to navigate the sigmoid. Once the splenic flexure is reached, a combination of water and CO2 is used to reach the caecum. On withdrawal, CO2 is permitted.
16295075|NCT04710693|Other|CAD polyp-detection system|In this arm, a CAD polyp detection system will be used during the colonoscopy.
16295076|NCT04710693|No Intervention|Standard (no CAD polyp-detection system)|In this arm, a CAD polyp detection system will not be used during the colonoscopy.
16295077|NCT04710680||group A|
16295078|NCT04710680||group I|
16295079|NCT04710654|Other|Control|"Behavioural therapy
~Exercise program"
16295080|NCT04710654|Active Comparator|connective tissue manipulation|
16295081|NCT04710654|Active Comparator|Interferential current stimulation (100 Hz frequency)|
16295082|NCT04710654|Active Comparator|Interferential current stimulation (0-100 Hz frequency)|
16295083|NCT04710641|Experimental|MTL-CEBPA in combination with sorafenib|Intravenous infusion of MTL-CEBPA 130mg/m2 given once a week for 3 weeks followed by a rest week combined with oral sorafenib 400mg twice day commencing C1D8
16295084|NCT04710628|Experimental|PEMBROLIZUMAB + LENVATINIB|"Pembrolizumab 200 mg will be administered to patients as 30-minute IV infusion every 3 weeks (a window of -5 minutes and +10 minutes is permitted).
~Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab). Lenvatinib cannot be chewed"
16295087|NCT04710602||Minimally invasive|Patients who underwent surgery with a muscle sparing, minimally invasive technique for unstable chest wall after trauma.
16295088|NCT04710602||Historical control|Patients who underwent surgery with large incisions and simultaneous thoracotomy for unstable chest wall after trauma.
16295089|NCT04710589||CTV 3mm|CTV is expanded by 3mm on the basis of GTV.
16295090|NCT04710589||CTV 6mm|CTV is expanded by 6mm on the basis of GTV.
16295094|NCT04710550|Experimental|Safety/Dosimetry Cohort|
16295095|NCT04710550|Experimental|Traumatic Brain Injury|
16295096|NCT04710550|Experimental|AD/MCI|
16295097|NCT04710550|Active Comparator|Healthy Controls|
16295100|NCT04710524|Placebo Comparator|Placebo|orally administer placebo BID for 13 weeks except on Day 91 subject receive a single dose
16295101|NCT04710524|Experimental|FM101 150 mg BID|orally administer FM101 150mg BID for 13 weeks except on Day 91 subject receive a single dose
16295102|NCT04710524|Experimental|FM101 300 mg BID|orally administer FM101 300mg BID for 13 weeks except on Day 91 subject receive a single dose
16295103|NCT04710511||Control group|Medically free children aged from 5 years to 7 years and do not practice oral habits.
16295104|NCT04710511||Oral habit practicing group|Medically free children aged from 5 years to 7 years and practicing oral habits.
16295105|NCT04710498|Experimental|Atezolizumab|Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.
16295106|NCT04710472|Experimental|MH|Arm MH - mobile Mentora app to monitor and track treatment side-effects, vital signs, therapeutics and daily habits;
16295107|NCT04710472|No Intervention|C|SOC
16295108|NCT04710459|Active Comparator|Group 1|it included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy.
16295109|NCT04710459|No Intervention|Group 2|it included include 30 patients, they were subjected to chemoradiotherapy.
16295110|NCT04710446||NSTEMI Patients presenting with normal ECG|NSTEMI Patients presenting with normal ECG
16295111|NCT04710446||NSTEMI Patients presenting with isolated T wave inversion|NSTEMI Patients presenting with isolated T wave inversion
16295112|NCT04710446||NSTEMI Patients presenting with transient ST-segment elevation|NSTEMI Patients presenting with transient ST-segment elevation
16295113|NCT04710446||NSTEMI Patients presenting with resting U wave inversion|NSTEMI Patients presenting with resting U wave inversion
16295114|NCT04710446||NSTEMI Patients presenting with low QRS voltage|NSTEMI Patients presenting with low QRS voltage
16295115|NCT04710433|Active Comparator|Non-invasive Neuromodulation|"Application of non-invasive sacral nerve stimulation for 12 weeks, at least 8 hours per day.
~Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field with a 15 Hz frequency for a duration of 210µs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).
~Medical and behavioral therapy is to be continued as started before intervention."
16295141|NCT04710264||recombinant hFSH : r-hLH|Patient stimulated with recombinant hFSH : r-hLH ratio 2:1
16295116|NCT04710433|Other|Medical/behavioral Therapy|Patients receive an optimized conventional treatment for 12 weeks, including lifestyle changes, toilet training and weight-adjusted medication. Conventional medical options include oral laxative medication with polyethyleneglycol or rectal medication with saline enemas in possible combination with a stimulant laxative (glycerin or bisacodyl).
16295117|NCT04710420||WIfI composite 1-4|Summing the three individual WIfI components together, the WIfI composite score 1-4.
16295118|NCT04710420||WIfI composite 5-9|Summing the three individual WIfI components together, the WIfI composite score 5-9.
16295119|NCT04710407|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.
16295120|NCT04710394|Active Comparator|Unimodal Olfactory Training with Conventional Odors|Participants will undergo smell training without a visual component, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
16295121|NCT04710394|Experimental|Unimodal Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training without a visual component, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
16295122|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Conventional Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
16295123|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
16295124|NCT04710381|Experimental|IMUNOR|Study subjects in this arm will receive IMUNOR preparation as prevention against COVID-19 disease.
16295125|NCT04710368|Experimental|Treatment|Evolocumab subcutaneously administered 140 mg every 2 weeks for 26 weeks
16295126|NCT04710355||Chronic pain|Failed back surgery syndrome
16295127|NCT04710342|Experimental|CTO proximal cap crossing|To demonstrate that CapBuster breaks the proximal cap of CTO's
16295128|NCT04710329||C Vit|The patients who were admitted to the intensive care unit and received a high dose intravenous vitamin C protocol constituted the treatment group
16295129|NCT04710329||non-C Vit|The patients who were admitted to the intensive care unit but did not receive the vitamin C protocol constituted the control group
16295130|NCT04710316|Experimental|Patients|- Hospitalized patients in one of the four centers in Bamako, with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures
16295131|NCT04710316|Experimental|Caregivers|"Caregivers of one of the four centers in Bamako.
~Serological screening: all.
~Molecular screening: with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have seroconverted to SARS-CoV-2 or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures"
16295132|NCT04710303|Experimental|Cohort 1 (n = 10): hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose|hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose on Days 1 and 22
16295133|NCT04710303|Experimental|Cohort 2 (n = 10): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose on Days 1 and 22
16295134|NCT04710303|Experimental|Cohort 3 (n = 15): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose (or 5 × 10e10 VP per dose if safety concerns identified at higher dose) on Days 1 and 22
16295135|NCT04710290|Experimental|Solid beverage powder|Whey portein solid beverage powder use 1 pack for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
16295136|NCT04710290|Experimental|Capsule|Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
16295137|NCT04710290|Placebo Comparator|Placebo|placebo use 1 powder for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
16295138|NCT04710277|Experimental|Novel multimodal protocol group|They will receive scheduled topical ice therapy for 24 hours after surgery. It will be applied over abdominal incisions for 20 minutes every 2-3 hours. Acetaminophen and an NSAID will be scheduled for 96 hours. While inpatient, they will receive acetaminophen 975 mg every 8 hours and IV Toradol 15-30 mg every 6 hours with change to ibuprofen 800 mg every 8 hours when tolerating oral intake. They may take oxycodone 5 mg every 4-6 hours as needed (PRN) for breakthrough pain and pain score >6. They may use ice PRN after 24 hours. They will be prescribed acetaminophen 1000 mg every 8 hours and ibuprofen 800 mg every 8 hours for 96 hours postoperative. They may take them as needed after. If the participant used 0 narcotics in the first 24 hours, they will not be prescribed a narcotic. If up to 5 tablets were used, they will be prescribed 5 tablets of oxycodone 5 mg every 6 hours PRN. If more than 5 tablets were used, they will be prescribed 10 tablets of oxycodone 5 mg every 6 hours PRN.
16295139|NCT04710277|Active Comparator|Usual care protocol group|Participants randomly assigned to the usual care protocol will receive current standard of care: scheduled acetaminophen and an NSAID for 24 hours. They will take acetaminophen 975 mg every 8 hours. They will also receive IV toradol 15 to 30 mg every 6 hours then switch to ibuprofen 800 mg every 8 hours when tolerating oral intake. They can also take oxycodone 5 mg every 4 to 6 hours on an as needed (PRN) basis for breakthrough pain with a pain score >6. Per our current standard of care, usual care participants will be allowed to use either topical heat or ice on an as needed basis during their recovery. On discharge home, they will be prescribed acetaminophen 1000 mg every 8 hours PRN and ibuprofen 800 mg every 8 hours PRN. They will also be prescribed 15 tablets of oxycodone 5 mg every 6 hours PRN.
16295144|NCT04710225|Active Comparator|Group 1 (General anesthesia group)|"Upper limb fracture surgery will be performed with the aid of pneumatic tourniquet. General anesthesia will be induced with intravenous (IV) thiopental sodium and fentanyl.
~Rocuronium will be used as the neuromuscular blocking agent. Endotracheal tube will be placed and anesthesia will be maintained with sevoflurane and IV fentanyl while the lungs were ventilated with O2-N2O (50-50%) to achieve an EtCO2 at 30-35 mm Hg."
16295145|NCT04710225|Active Comparator|Group 2 (Multiple injection axillary block group)|Multiple injection axillary block will be performed with the aid of a nerve stimulator. When the slight twitching of the motor response from the relevant muscles is achieved (at 0.4 mA, 2Hz, 0.1 ms) % 18-20 ml of Bupivacaine 0.5 (90-100 mg) will be injected.
16295146|NCT04710212||Induction Chemotherapy for Acute Leukemia|Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.
16295147|NCT04710212||Hematopoietic stem cell transplantation (HCT)|Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.
16295150|NCT04710186||Male patients with PAD|The cohort was built to collect information about the role of androgen receptor, insulin receptor and Insulin-like Growth Factor 1 Receptor (IGF-IR) expression in patients with peripheral artery disease referred to Vascular Surgeon Specialist.
16295151|NCT04710173||ARDS children|children with severe ARDS
16295152|NCT04710160|Active Comparator|Novel fast setting calcium silicate ( Protooth)|In the form of powder and liquid to be mixed together to form paste.
16295153|NCT04710160|Experimental|MTA|In form of powder to be mixed with saline to form paste.
16295154|NCT04710134|Active Comparator|Reslizumab 3 mg/kg|All patients will initially receive reslizumab 3 mg/kg for at least 16 weeks.
16295155|NCT04710134|Active Comparator|Reslizumab 4 mg/kg|Patients who have uncontrolled sputum eosinophilia at 16 weeks will receive an increased dose of 4 mg/kg for the next 16 weeks. The patients with controlled eosinophilia will continue to receive 3 mg/kg.
16295156|NCT04710134|Active Comparator|Reslizumab 5 mg/kg|Patients who have uncontrolled sputum eosinophilia who were previously receiving reslizumab at 4 mg/kg at 32 weeks will receive an increased dose of 5 mg/kg for the next 16 weeks. The patients remaining patients will continue on the dose they were receiving (i.e., either 3 mg/kg or 4 mg/kg).
16295157|NCT04710121|Experimental|Intervention Arm|"The experimental group will be asked about their anxiety states with the State and Trait Anxiety Inventory, their pain conditions with the Analog Scale (VAS), and their first life findings will be measured, and the first measurement values will be recorded in the Vital Signs Follow-up Form. Virtual reality glasses will be placed on the patient's head during colonoscopy. The duration of the colonoscopy will vary between 3-10 minutes, videos with music background, park, nature and seaside walks, underwater videos, which the patient chooses, will be watched and the Vital Signs Tracking Form Second measurement values will be recorded by making measurements. Immediately after the colonoscopy procedure is completed, Visual Analogue Scale (VAS), Vital Signs Follow-up Form (measurement will be made and 3rd measurement values will be recorded. The State Anxiety Inventory will be read and the answers will be recorded."
16295158|NCT04710121|No Intervention|Control Arm|No application will be made in the control group. during and after colonoscopy and routine treatment and care will be applied.
16295159|NCT04710108|No Intervention|No treatment control|No treatment; no intervention (survey only)
16295160|NCT04710108|Experimental|Video|A Taste of Home video, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
16295161|NCT04710108|Experimental|Print|A Taste of Home comic book, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
16295162|NCT04710095|Active Comparator|Brief Alcohol Intervention|A brief intervention consisting of a 30-45 minute individual face-to-face session based on the principles of motivational interviewing.
16295163|NCT04710095|Sham Comparator|Attention-Matched Control Condition|Brief attention-matched control condition.
16295164|NCT04710082|Active Comparator|Patients planned to undergo conventional 2 step trans-epithelial PTK-PRK|"Patients planned to undergo:
~Epithelial removal using Phototherapeutic Keratectomy PTK as a separate step.
~Laser Vision Correction using Excimer laser wavefront optimized technology."
16295165|NCT04710082|Active Comparator|Patients planned to undergo the new single step trans-epithelial (StreamLight) PRK.|"Patients planned to undergo:
~Epithelial removal and Excimer wavefront optimized Laser Vision Correction in a single step using the new StreamLight Technology."
16295166|NCT04710069|No Intervention|Control/Usual Care|standard treatment of postoperative pain, which involves automatic prescription of a narcotic pain medication regimen after surgery,
16295167|NCT04710069|Experimental|Opt-in/POINT|An opt-in program (POINT), which requires the patient to consent to receiving a prescription for narcotics
16295168|NCT04710043|Experimental|Part 1 group A BNT153|Monotherapy dose escalation.
16295169|NCT04710043|Experimental|Part 1 group B BNT152|Monotherapy dose escalation.
16295170|NCT04710030|Active Comparator|Valacyclovir|Oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day (total dose: 4 grams per day) for 52 weeks.
16295171|NCT04710030|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day for 52 weeks.
16295172|NCT04710017|Other|Tranexamic acid group|will tranexamic acid 500 mg 4 times daily in one group,
16295173|NCT04710017|Other|Medroxyprogesterone acetate|will receive 150mg of medroxyprogesterone acetate once intramuscular.
16295174|NCT04710004|Experimental|Brain stimulation via clinically implanted electrodes|Brain will be stimulated in different patterns including synchronized or asynchronous current.
16295175|NCT04709991||Procedures with EndoNaut|
16295176|NCT04709991||Procedures without Endonaut|
16295177|NCT04709978||Pneumonia|Participants will be over the age of 65 and diagnosed with pneumonia in the UW Emergency Department.
16295178|NCT04709965|Other|Main Study|Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
16295179|NCT04709965|Other|Faces Sub Study|Patients eligible to be recruited to the Faces Sub Study will have biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder.
16295180|NCT04709952|Active Comparator|High real stimulation group|2mA tDCS stimulation daily (42 times) for 6 weeks
16295181|NCT04709952|Active Comparator|Low real stimulation group|1mA tDCS stimulation daily (42 times) for 6 weeks
16295182|NCT04709952|Sham Comparator|Sham stimulation group|sham stimulation daily (42 times) for 6 weeks
16295183|NCT04709939||Patient Participants|Adults patients who are discharged from the hospital on outpatient parenteral antibiotic therapy.
16295184|NCT04709939||Physician Participants|Infectious disease physicians who prescribe OPAT to their patients but were not involved in the study.
16295185|NCT04709926||Paramedics that were eligible to take part in the PRESTO study|Paramedics that are employed by one of the four Ambulance Services involved in the PRESTO study and were eligible to complete the training provided by Manchester University NHS Foundation Trust to take part in the PRESTO study.
16295186|NCT04709913|Active Comparator|Active Treatment: HU6 Planned doses of HU6; N = 32|Drug = HU6 HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
16295187|NCT04709913|Placebo Comparator|Placebo Comparator Non-active study drug N = 8|Placebo Comparator, non-active study drug.
16295188|NCT04709900|Active Comparator|Intervention group|CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy
16295189|NCT04709900|No Intervention|Standard care group|Evaluation and treatment strategy according to contemporary clinical practice
16295190|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, W.|If the rate of popliteal artery stenosis of patients < 50%, the patients only receive the wound treatment.
16295191|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, WT.|If the rate of popliteal artery stenosis of patients < 50%, the patients receive the wound treatment and tibial transverse transport surgery.
16295192|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WV.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and vascular intervention surgery.
16295193|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and tibial transverse transport surgery.
16295194|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WVT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment, vascular intervention and tibial transverse transport surgery.
16295195|NCT04709874|Experimental|Paravertebral block|Patients will receive paravertebral block guided by a nerve stimulator.
16295196|NCT04709874|Active Comparator|Suprascapular block|Patients will receive suprascapular block
16295197|NCT04709861||Retrospective 6 week Weight-Bearing|Delayed weight-bearing 6 weeks after total ankle replacement
16295198|NCT04709861||Prospective 2 week Weight-Bearing|Early weight-bearing 2 weeks after total ankle replacement
16295199|NCT04709848||Pre-screening group|Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
16295200|NCT04709848||Screened group|Individuals undergoing bone marrow transplantation July 2020 - July 2021
16295201|NCT04709835|Experimental|AT-527|Participants will receive 550 mg AT-527 twice a day (BID) in Cohort A. Cohorts B-E doses are to be determined.
16295202|NCT04709835|Placebo Comparator|Placebo|
16295203|NCT04709822|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):
~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week (number of intrusive memories of trauma). Individual baseline phases will be used as control periods for the primary outcome.
~Experimental: Intervention phase ('B'):
~Measurements collected in a daily diary four times a day during the fifth week after the second intervention session for the primary outcome (number of intrusive memories of trauma)."
16295204|NCT04709809|Experimental|Experimental arm|Measurement RVA / IOP / with ECG gating
16295205|NCT04709796|Experimental|Intervention group: EmbryoGlue|Embryo transfer with EmbryoGlue®
16295206|NCT04709796|Active Comparator|Control group|Conventional embryo transfer
16295207|NCT04709783|Experimental|Implementation Arm|Participants will receive the 3-Step Workout for Life program and other rehabilitation services based on the plan of care.
16295208|NCT04709770|Experimental|Low-volume preparation|"Low-volume preparation of 2-liters polyethylene glycol with citrate and simethicone. This formulation includes 4 large (A) and 4 small (B) sachets; the components of 2 sachets A and 2 sachets B are mixed in 1 liter of water.
~Each sachet A contains:
~polyethylene glycol (4000) 52.50 g;
~simethicone 0.08 g;
~sodium sulphate anhydrous 3.75 g.
~Each sachet B contains:
~sodium citrate 1.863 g;
~anhydrous citric acid 0.813 g;
~sodium chloride 0.73 g;
~potassium chloride: 0.37 g;
~acesulfame potassium 0.13 g. Participants will drink the first liter of preparation at 19.00 p.m. on the day before the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids. The second liter of preparation will be administered at 7.00 a.m. on the day of the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids."
16295209|NCT04709770|Active Comparator|High-volume preparation|"High-volume preparation with 4-liters polyethyleneglycol with simethicone. This formulation includes 4 sachets, each dissolved in 1 liter of water.
~Each sachet contains:
~polyethylene glycol (4000) 58.30 g;
~simethicone 0.08 g;
~sodium sulphate anhydrous 5.68 g;
~sodium bicarbonate 1.68 g;
~sodium chloride 1.46 g;
~potassium chloride 0.74 g. Participants will drink the first 2 liters of preparation at 19.00 p.m. on the day before colonoscopy, at a rate of 250 ml every 15 minutes. The remaining 2 liters of preparation will be administered at 6.00 a.m. on the day of the endoscopic procedure, at a rate of 250 ml every 15 minutes."
16295210|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/90|Stimulation delivered at 30 seconds ON and 120 seconds OFF through patient's existing spinal cord stimulator.
16295211|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/360|Stimulation delivered at 30 seconds ON and 360 seconds OFF through patient's existing spinal cord stimulator.
16295212|NCT04709744||SLE patients|SLE patients were presented to chest outpatient clinic and emergency hospital, Mansoura University with manifestation suggesting COVID-19 infection. Vit D was measured in serum by ELISA. Vit D was added to anti COVID-19.
16295310|NCT04709003||unvaccinated|participants who didn't received the Covid-19 vaccine
16295213|NCT04709731|Experimental|Total Patients|Intolerant Group Ponatinib 15 mg tablet, taken orally once daily (QD) Resistant Group Ponatinib 30 mg tablet, taken orally once daily (QD) The dose will be reduced to 15mg once daily (QD) as soon as a Complete Cytogenetic Response will be obtained. In those patients showing Major Molecular Response or better, the dose could be further reduced to 15MG every other day (EOD), due to the prolonged half-life of the drug.
16295214|NCT04709718||churgery of geant liver hemangioma|
16295215|NCT04709705|Experimental|Cryopreserved platelets|Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
16295216|NCT04709705|Active Comparator|Liquid stored platelets|Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
16295217|NCT04709692|Other|Arm 1 A (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
16295218|NCT04709692|Other|Arm 1 B (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
16295219|NCT04709692|Other|Arm 2 A (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax
16295220|NCT04709692|Other|Arm 2 B (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum
16295221|NCT04709692|Other|Arm 3 A (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
16295222|NCT04709692|Other|Arm 3 B (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
16295223|NCT04709679|Experimental|Constant dwell time but varying power and duration|The laser dwell time will be constant but the laser power and duration will be varied for patients
16295224|NCT04709679|Experimental|Constant power but varying dwell time and duration|The laser power will be constant but the laser dwell time and duration will be varied for patients
16295225|NCT04709679|Experimental|Constant duration but varying dwell time and power|The laser duration will be constant but the laser dwell time and power will be varied for patients
16295226|NCT04709666||Endsocopic Retrograde ColangioPancreatography (ERCP)|Endsocopic Retrograde ColangioPancreatography (ERCP)
16295227|NCT04709653|Experimental|Intervention Group|Occupational-based nursing program
16295228|NCT04709653|Experimental|Control Group|Routine nursing care
16295229|NCT04709640|Experimental|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
16295230|NCT04709627||60 minute surgery|Patients completing at least 60 minutes of surgery
16295231|NCT04709601|Experimental|Group 1 - Patients with negative and positive urine culture|
16295232|NCT04709588|Placebo Comparator|placebo group|subjects drank 50 ml every night for 14, 28 days
16295233|NCT04709588|Experimental|collagen drinks|subjects drank 50 ml every night for 14, 28 days
16295234|NCT04709575|Experimental|REGN5713-5714-5715|REGN5713-5714-5715 administered subcutaneously
16295235|NCT04709575|Placebo Comparator|Placebo Only|Placebo matching REGN5713-5714-5715 administered subcutaneously
16295236|NCT04709562|Experimental|High Velocity Nasal Insufflation (HVNI)|Patients randomly assigned to this arm will be placed on HVNI therapy with an appropriately fitted Vapotherm Prosoft HVNI nasal cannula. Physiologic and ventilation parameters will be recorded.
16295237|NCT04709562|Active Comparator|Noninvasive Positive Pressure Ventilation (NIPPV)|Patients randomly assigned to this arm will be placed on NIPPV therapy with an appropriately fitted full face mask using a pressure support mechanical ventilator system. Physiologic and ventilation parameters will be recorded.
16295238|NCT04709549|Active Comparator|Diabetes Prevention Program|The DPP is a behavioral obesity and diabetes prevention program run by the YMCA, over a 12-month period.
16295239|NCT04709549|Experimental|Diabetes Prevention Program + Job and Legal Services|Participants meet with service connectors to receive an individual assessment of your needs and create an individual service plan for job services and be referred to legal support services if also needed.
16295240|NCT04709536|Experimental|IBI306|IBI306 administered subcutaneously (SC)
16295241|NCT04709536|Placebo Comparator|Placebo|administered subcutaneously (SC)
16295242|NCT04709523|Experimental|i-PRF enriched bovine-derived xenograft|Patients treated with i-PRF-enriched bovine-derived xenograft + resorbable membrane
16295243|NCT04709523|Experimental|bovine-derived xenograft|Patients treated with bovine-derived xenograft + resorbable membrane
16295244|NCT04709510|Other|AllPatients|There is only one cohort in this study. They all received the same follow up and ultrasound protocol.
16295245|NCT04709497|Active Comparator|viscotrabeculotomy (VT)).|
16295246|NCT04709497|Active Comparator|visco-circumferential-suture-trabeculotomy (VCST)|
16295247|NCT04709497|Active Comparator|Combined VT-Trabeculectomy with MMC (VT-Trab).|
16295250|NCT04709471|Experimental|Switch to low nicotine e-cigarettes|Switch to e-cigarettes containing 60% of baseline e-cigarette nicotine content.
16295251|NCT04709471|Experimental|Reduce number of e-cigarette pods|Reduce e-cigarette use to 60% of baseline number of pods per week.
16295252|NCT04709471|No Intervention|Use e-cigarettes as usual|Continue using usual nicotine e-cigarettes as usual.
16295253|NCT04709458|Experimental|TBX-2400 treatment|Single intravenous infusion of TBX-2400
16295254|NCT04709445|Experimental|ICG-NIRF Imaging and objective perfusion rate|Intraoperatively, ICG-NIRF imaging is used to visualize the blood supply and the rate of tissue perfusion in the area of the anastomotic site. Postoperatively, an additional ingress and egress analysis at specific regions of interest is performed.
16295255|NCT04709432||ECMO group|children supported by ECMO in the past 10 years
16295256|NCT04709419|Experimental|Celliant Sock|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction. Celliant® fibers are comprised of a proprietary blend of infrared (IR) emitting ceramic materials mixed with polyethylene terephthalate (PET). The proprietary blend consists of the following components: alumina oxide; silicon dioxide; and titanium dioxide. The Celliant fibers are woven or knitted into yarn and used to manufacture the Celliant Sock. The Celliant Sock content will be 82% Celliant polyester, 13% Nylon and 5% Spandex. Celliant fibers absorb energy (heat) generated by the wearer's body by radiation, convection and conduction, and also from the environment, and re emit the energy as infrared radiation back into the wearer's body."
16295257|NCT04709419|Sham Comparator|Control Sock|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
16295258|NCT04709406||obese patients|obese patients underwent bariatric surgery
16295259|NCT04709393|Experimental|Pre-screening|Receiving FRAX+SARC-F questionnaire pre-screening results on estimated fracture risk
16295260|NCT04709393|No Intervention|Control|Not receiving FRAX+SARC-F questionnaire pre-screening preliminary results on estimated fracture risk
16295261|NCT04709380|Experimental|Radiotherapy plus Toripalimab|Patients in the experimental group will be given local vein tumor thrombus/hepatic vein tumor thrombus +/- intrahepatic large lesions with hypofractionated intensity modulated radiotherapy (tumor area dose 40-60Gy/10-20f), concurrent with and followed by 240mg Q3W of teriprizumab within 1 week of radiotherapy.
16295262|NCT04709380|Active Comparator|Sorafenib|Patients in the control group will be treated with sorafenib (400mg, twice a day).
16295263|NCT04709354||rheumatoid arthritis patient|Skin and fingernail examination of newly diagnosed (diagnosed before 1 year) rheumatoid arthritis patients will be done. A detailed dermoscopic examination will be performed on the nails of these patients.
16295264|NCT04709354||patients with spondylopathy|Skin and fingernail examination of newly diagnosed (diagnosed before 1 year) patient with spondylopathy will be done. A detailed dermoscopic examination will be performed on the nails of these patients.
16295265|NCT04709354||psoriatic arthritis|Skin and fingernail examination of patient with psoriatic arthritis will be done. A detailed dermoscopic examination will be performed on the nails of these patients. PASI and NAPSI scores of all patients will be calculated.
16295266|NCT04709354||psoriasis patients without joint involvement|Skin and fingernail examination of patient with psoriasis patients without joint involvement will be done. A detailed dermoscopic examination will be performed on the nails of these patients. PASI and NAPSI scores of all patients will be calculated.
16295267|NCT04709341|Experimental|Group A|
16295268|NCT04709341|Active Comparator|Group B|
16295269|NCT04709328|Experimental|SCTA01 low dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
16295270|NCT04709328|Experimental|SCTA01 middle dose+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
16295271|NCT04709328|Experimental|SCTA01 High dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
16295272|NCT04709328|Placebo Comparator|Placebo+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
16295273|NCT04709315|Active Comparator|saline pretreatment/succinyl group (SS group).|patients receive pretreatment with 10 ml 0.9% saline over 10 minutes, and succinyl choline 1mg/ kg is the intubating muscle relaxant.
16295274|NCT04709315|Experimental|Dex pretreatment/ rocuronium group (DR group),|patients receive pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg is the intubating muscle relaxant.
16295275|NCT04709302||COVID-19 positive, HIV-positive with ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV who are on ART
16295276|NCT04709302||COVID-19 positive, HIV-positive without ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
16295277|NCT04709302||COVID-19 positive, HIV-negative|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
16295278|NCT04709289|Experimental|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
16295279|NCT04709276|Experimental|Neuroendocrine Prostate Cancer (NEPC) or Aggressive Variant Prostate Cancer (AVPC)|"Subjects with neuroendocrine prostate cancer (NEPC) or aggressive variant prostate cancer (AVPC) will receive a combination of nivolumab, ipilimumab, carboplatin and cabazitaxel for up to 10 cycles of 21 days each. After carboplatin and cabazitaxel are discontinued, a combination of nivolumab and ipilimumab will be administered.
~Nivolumab will be administered intravenously at a dose of 360 mg every 3 weeks.
~Ipilimumab will be administered intravenously at a dose of 1 mg/kg every 6 weeks.
~Carboplatin will be administered intravenously at a dose of AUC 4 mg/ml per minute.
~Cabazitaxel will be administered intravenously at a dose of 20 or 25 mg/m2."
16295280|NCT04709250|Active Comparator|group A: receive ultrasound-guided interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine consistent with the overall local anaesthetic dosing of less than 2.5 mg/kg. will be injected with low pressures to avoid intraneural injection.
16295311|NCT04708990|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
16295312|NCT04708990|No Intervention|control group|
16295313|NCT04708977|Active Comparator|Group 1: Indirect Decompression|Lateral lumbar interbody fusion (LLIF), with indirect decompression
16295314|NCT04708977|Active Comparator|Group 2: Direct Decompression|Lateral lumbar interbody fusion (LLIF), with direct decompression
16295281|NCT04709250|Active Comparator|group B: receive ultrasound-guided selective nerve block|The patient will be put in the sitting position, a linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to obtain a view of the suprascapular nerve a 22 G, 8 cm needle will be advanced in-plane and a total of 5-8 mL of 0.25% bupivacaine is injected then the arm adducted the linear probe will be placed at the junction of the pectoralis major muscle and the biceps muscle such that the axillary artery will be visualized in cross-section The probe will be moved towards the biceps muscle (laterally) until the musculocutaneous nerve is visualized and8 ml of 0.25% bupivacaine will be injected
16295282|NCT04709224|Experimental|Cohort 1: LAI Lumateperone 50 mg|
16295283|NCT04709224|Experimental|Cohort 2: LAI Lumateperone 100 mg|
16295284|NCT04709224|Experimental|Cohort 3: LAI Lumateperone 200 mg|
16295285|NCT04709211|Active Comparator|Group I: Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca Block using bupivacaine 0.25%
16295286|NCT04709211|Active Comparator|Group Q: Anterior Quadratus lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using bupivacaine 0.25%
16295287|NCT04709185|Experimental|AVS after 1mg DST|Patients divided into AVS after 1mg DST group need to oral 1mg dexamethasone the night before AVS
16295288|NCT04709185|Placebo Comparator|AVS after placebo|Patients divided into AVS after placebo group need to oral placebo the night before AVS
16295289|NCT04709172|Experimental|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
16295290|NCT04709159|Active Comparator|Intervention|"Participants on this arm will use Interactive Voice Response (IVR) daily pill reminders, thrice-weekly health messages, clinic appointment reminders, remote symptom reporting service and a 24 hour toll-free number to access services. These participants will also have the option to co-register a caregiver who will also receive daily pill reminders, clinic appointment reminder, weekly health tips and remote symptom reporting service.
~In addition, these participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines."
16295291|NCT04709159|No Intervention|Standard|These participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines.
16295292|NCT04709146|Other|Recovered Covid-19 patients|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
16295293|NCT04709146|Other|Healthy Control|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
16295294|NCT04709133|Experimental|multi-ligament knee injures|A chart review will be performed to identify patients who underwent surgical treatment for multiligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
16295295|NCT04709107||Elective|Patients undergoing elective revascularisation (endovascular or surgical) for PAD.
16295296|NCT04709107||Emergent|Patients undergoing emergent revascularisation (endovascular or surgical) for PAD.
16295297|NCT04709094|Experimental|Part 1: Danicopan and Warfarin|"Period 1: Participants received a single dose of warfarin.
~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin.
~Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2."
16295298|NCT04709094|Experimental|Part 2: Danicopan and Bupropion|"Period 1: Participants received a single dose of bupropion.
~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion.
~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2."
16295299|NCT04709094|Experimental|Part 3: Danicopan and EE/NET|"Period 1: Participants received a single dose of EE/NET.
~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET.
~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2."
16295300|NCT04709081|Experimental|Part 1: ACH-0145228, Midazolam, and Digoxin|"Period 1: Participants received single doses of midazolam and digoxin.
~Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin.
~Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2."
16295301|NCT04709081|Experimental|Part 2: ACH-0145228 and Itraconazole|"Period 1: Participants received a single dose of ACH-0145228.
~Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228.
~Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2."
16295302|NCT04709068||COVID19+|
16295303|NCT04709055|Experimental|Co-management arm (geriatric and surgical)|
16295304|NCT04709055|Active Comparator|Usual care|
16295305|NCT04709042|Experimental|Chordal tension measurement and cardiac Magnetic Resonance Imaging|All patient candidates for NeoChord implantation according to the standard of care will be considered for inclusion in this clinical study. Chordal tension measurement will be performed during Neochord implantation. Moreover, all patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
16295306|NCT04709029|Active Comparator|intravenous dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10 ml saline,to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
16295307|NCT04709029|Active Comparator|intrathecal dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0.5% + 4 mg (1 ml) dexamethazone + intravenous 10 ml normal saline to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
16295308|NCT04709016||male or transgender patients|of sexual orientation MSM (men having sex with men) or bi-sexual, consultant in sexual health centers
16295309|NCT04709003||vaccinated|participants who received the Covid-19 vaccine
16295315|NCT04708964|Active Comparator|Flurbiprofen|5 ml of flurbiprofen solution 0.25% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
16295316|NCT04708964|Placebo Comparator|Placebo|5 ml of saline solution 0.9% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
16295319|NCT04708938|Experimental|Treatment group|High voltage electrical stimulation + exercise therapy
16295320|NCT04708938|Active Comparator|Control group|Exercise therapy
16295321|NCT04708925||group A- conservative therpay|hypertriglyceridemia-induced acute pancreatitis patients who recieved conservative therapy
16295322|NCT04708925||group B- plasmapharesis therapy|hypertriglyceridemia-induced acute pancreatitis patients who recieved plasmapharesis therapy
16295323|NCT04708912||1|Mild-Moderate COVID-19
16295324|NCT04708912||2|Severe COVID-19
16295325|NCT04708912||3|Convalsent (COVID-19)
16295326|NCT04708912||4|Healthy persons
16295327|NCT04708899|Active Comparator|Cases|cases will receive the proposed program(the arabic version of differential processing training program)
16295328|NCT04708899|Active Comparator|control|controls will receive the computer based auditory training program (CBAT)
16295329|NCT04708886|Experimental|Females with Chronic SCI|12-month treatment with monthly subcutaneous romosozumab injections (210 mg), followed by 12-month treatment with weekly oral alendronate tablets (70 mg)
16295330|NCT04708873|Experimental|High Intensity Interval Training Group|Participants in this group will initially undergo continuous aerobic training to achieve a baseline fitness level, after which HIIT and resistance training will be employed. Warm-up period will be followed by 4 bouts of 4-minute interval treadmill running and stationary bike cycling at 80-95% of the measured HR reserve, interspersed with active recovery phase at 55-70% HRR. After this resistance exercises will be performed in a circuit fashion for strengthening the upper limbs, lower limbs and trunk. The session will be ended with a 5-7 minute cool-down period
16295331|NCT04708873|Active Comparator|Moderate Intensity Continuous Training Group|Participants in this group will also initially undergo continuous aerobic training to achieve a baseline fitness level, after which the intensity will be increased to moderate continuous training achieving 55-70% of HRR. Every session will be preceded by appropriate warm-up and end with cool down.
16295332|NCT04708860|Experimental|Prolonged Nightly Fasting Plus Exercise|"Participants will be grouped into two cohorts determined by whether they receive palbociclib or alpelisib as part of their breast cancer treatment and then receive a 12 week prolonged nightly fasting plus exercise program consisting of:
~Prolonged overnight fasting: Not consume any calorie-containing food/drinks after 8pm, waiting a minimum of 13 hours after their last meal of the day before eating the next day, target goal of fasting at least 6 days a week, daily record of first and last meals
~Exercise Program: Coach provided at-home, personalized exercise regimen with target goal of 120 minutes of moderate-intensity aerobic activity each week as well as two 30-45-minute virtual strength training classes per week, receive fitbit for exercise and heart rate monitoring, weekly telephone-based support sessions with coach."
16295333|NCT04708847|Experimental|Pre-immobilization active drug group|Subjects will receive a single subcutaneous dose of GYM329 on Day 1 and a single subcutaneous dose of placebo on Day 15.
16295334|NCT04708847|Experimental|Post-immobilization active drug group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of GYM329 on Day 15.
16295335|NCT04708847|Placebo Comparator|Placebo group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of placebo on Day 15.
16295336|NCT04708834|Experimental|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
16295337|NCT04708821|Experimental|DEXTENZA|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
16295338|NCT04708821|Active Comparator|Antihistamine|PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.
16295339|NCT04708821|Active Comparator|Topical Steroid|ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.
16295340|NCT04708808|Experimental|MVA case undergone music therapy|case undergone manual vacuum aspiration are randomised to receive music therapy during the procedure.
16295341|NCT04708808|No Intervention|Control|Routine Care
16295342|NCT04708795|Experimental|Verum|AP701 single dose oromucosal application
16295343|NCT04708782|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
16295344|NCT04708782|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
16295345|NCT04708769|Experimental|Smartphone App Participants (APP)|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist
16295346|NCT04708769|Experimental|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist
16295347|NCT04708756|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
16295348|NCT04708756|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
16295349|NCT04708756|No Intervention|Control Group|Patients will not receive the Collabree application and will continue to receive standard care.
16295350|NCT04708743||CKD group|patients with CKD stage 3-5 including dialysis, followed tongue images by Automatic Tongue Diagnosis System
16295351|NCT04708743||Health group|patients who had no past history or systemic disease, CKD followed tongue images by Automatic Tongue Diagnosis System
16295352|NCT04708730|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
16295353|NCT04708730|No Intervention|control group|
16295354|NCT04708717|Experimental|Stimulation Rate|
16295355|NCT04708717|Active Comparator|Electrode Location|
16295357|NCT04708691|Experimental|Aerobic exercise|aerobic exercise for 30 mins
16295358|NCT04708691|No Intervention|Control|sitting for 30 mins
16295359|NCT04708652||preterm children|Our previous intervention study enrolled 178 VLBW (birth body weight less than 1,500 gm) preterm children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
16295360|NCT04708652||term children|Our previous intervention study enrolled 62 term children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
16295361|NCT04708626||Extended Cohort: Patients tested for any neuronal antibody in the Swedish population|All patients tested for any neuronal antibody in serum or CSF between 2015 and 2019 in Sweden.
16295362|NCT04708626||Core Cohort: Patients with a positive neuronal antibody test belonging to the Uppsala-Örebro region|All patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or cerebrospinal fluid between 2015-2019.
16295363|NCT04708613||Former Professional Football Players|Former professional football players who played in at least 3 professional seasons, with at least 3 games each season.
16295364|NCT04708613||Control Groups|Friends and brothers of the Former Professional Football Player group.
16295365|NCT04708600|Experimental|Group 1|Sham therapy Intervention 1: PET Intervention 2: ART
16295366|NCT04708600|Experimental|Group 2|Sham therapy Intervention 1: ART Intervention 2: PET
16295367|NCT04708587|Active Comparator|dual anti-platelet therapy at least 6 months|
16295368|NCT04708587|Experimental|dual anti-platelet therapy 3months or less|
16295369|NCT04708574|Experimental|Intervention|The intervention group attended a supervised exercise program for women only that presented Arabic music and traditional dance steps (the Lebanese Dabka) three times a week in the London Muslim Mosque Gym. The intervention lasted 12 weeks. There was also a nutrition education component that occurred once per week for the duration of the intervention. The lifestyle intervention group was instructed to walk 10,000 steps per day for the 12 weeks of the program. They were given instructions to take a 30-min walk on days when no formal exercise sessions were offered.
16295370|NCT04708574|Placebo Comparator|Control|The control group participants followed their typical work and leisure routines during the weeks of investigation. The women in the control group were offered the same intervention at the end of the 12 weeks.
16295371|NCT04708561|Experimental|Brain-injured participants|
16295372|NCT04708548||Oligodendroglioma (Grade II and III) Patients|Patients diagnosed with a WHO Grade II or III Oligodendroglioma
16295373|NCT04708535||Bariatric Cohort|For consenting subjects who are undergoing bariatric surgery, a visceral fat sample will be taken during surgery. In addition to the fat sample, insulin resistance will be measured and determined by a modification of the insulin suppression test.
16295374|NCT04708522|Experimental|Breath Control|Participants in the breath control study arm will be given a breathing exercise that is to be completed in a comfortable upright seated posture. This intervention exercise will be completed daily for a period of 8 weeks.
16295375|NCT04708522|Experimental|Guided Mindfulness|Participants in the guided mindfulness study arm will be lead through a seated mindfulness exercise. This intervention exercise will be completed daily for a period of 8 weeks.
16295376|NCT04708522|Sham Comparator|Control|Participants in the control group will receive a sham intervention. The sham intervention will involve minimal instructed meditation exercise. This intervention exercise will be completed daily for a period of 8 weeks.
16295377|NCT04708509|Experimental|Intervention Arm|Wave form data from participants' spontaneous breathing trials (SBT) will be analyzed using Extubation Advisor (EA) to generate an EA report that provides clinical decision support regarding extubation.
16295378|NCT04708496|Experimental|Standard dose of Artemether lumefantrine|Dose comparison-concurrent control In this arm, Participants receiving Efavirenz400mg based ART will be randomized to standard dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
16295379|NCT04708496|Experimental|Double dose Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to double dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
16295380|NCT04708496|Experimental|5 day course of Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to 5 day course of Artemether Lumefantrine as opposed to the standard 3day course when treating uncomplicated malaria in HIV-malaria co-infected participants
16295381|NCT04708483|Experimental|Malignant thoracic tumoral pathology.|Patients suffering from primary malignant thoracic tumoral pathology or second line patients having had a therapy pause of at least 6 weeks.
16295384|NCT04708457|Active Comparator|Early ECMO|Early ECMO therapy for patients who have SARI and have been mechanically ventilated for 5-7 days.
16295385|NCT04708457|No Intervention|Standard Care|Patients with SARI who are already mechanically ventilated will continue to receive the standard intensive care therapies, including ECMO if required.
16295428|NCT04708158|Placebo Comparator|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
16295392|NCT04708405||Inflammatory bowel disease patients|Inflammatory bowel disease patients screened for Helicobacter Pylori Infection
16295393|NCT04708392|Experimental|Tonic spinal cord stimulation|Patients are programmed with tonic (continuous) spinal cord stimulation for a period of four weeks.
16295394|NCT04708392|Experimental|Burst spinal cord stimulation|Patients are programmed with burst (intermittent) spinal cord stimulation for a period of four weeks.
16295395|NCT04708379|Experimental|Intervention group|Nutrition education and physical activity education.
16295396|NCT04708379|No Intervention|Control group|No specific intervention.
16295397|NCT04708366|Experimental|1L PEG|Patients will be prepared with 1L-PEG-based bowel preparation.
16295398|NCT04708366|Active Comparator|2L PEG|Patients will be prepared with 2L-PEG-based bowel preparation.
16295399|NCT04708366|Active Comparator|4L PEG|Patients will be prepared with 4L-PEG-based bowel preparation.
16295400|NCT04708353|Placebo Comparator|control group|the patient will receive one placebo capsule (vitamin c) once one hour before the operation.
16295401|NCT04708353|Active Comparator|Group Pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
16295402|NCT04708353|Active Comparator|Group Pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
16295403|NCT04708340|Active Comparator|Arm A: RJX|"RJX 20 mL (10 mL of Vial A plus 10 mL of Vial B) mixed in normal saline, total volume 120 mL, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.
~Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).
~Patients in Part 1 are allowed to receive only one 7-day cycle of RJX while patients in Part 2 may be treated daily for up to 14 days."
16295404|NCT04708340|Placebo Comparator|Arm B: Placebo|"Placebo (total of 20 mL normal saline) mixed in normal saline IV, total volume 120 mL of normal saline IV, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.
~Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).
~Patients in Part 1 will not receive placebo.
~Patients in Part 2 may be treated daily for up to 14 days."
16295405|NCT04708327|Placebo Comparator|Placebo|
16295406|NCT04708327|Experimental|CYTO-205 22.5 mg|
16295407|NCT04708327|Experimental|CYTO-205 45 mg|
16295408|NCT04708314|Other|30 mg/kg|Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study.
16295409|NCT04708275|Experimental|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
16295410|NCT04708275|Active Comparator|Waitlist|PaCT after a waiting period (3 months)
16295411|NCT04708262|Experimental|Cognitive Analytic Therapy for Containing Self-Harm in Young People|Brief one-to-one psychological therapy using Cognitive Analytic Therapy principles, designed for young people who self-harm
16295412|NCT04708249|Experimental|D-chiroinositol treatment|
16295413|NCT04708236|Experimental|ORTD-1 Low dose|Arm 1: ORTD-1
16295414|NCT04708236|Experimental|ORTD-1 Mid Dose|Arm 2: ORTD-1
16295415|NCT04708236|Experimental|ORTD-1 High Dose|Arm 3 : ORTD-1
16295416|NCT04708236|Placebo Comparator|Vehicle Control|Arm 4: Vehicle control
16295417|NCT04708223|Experimental|Fast-curing composites|
16295418|NCT04708223|Other|Conventionally applied composites|
16295419|NCT04708210|Experimental|Phase Ia Dose-Escalation Stage: IBI319|
16295420|NCT04708197|Other|aphasic patients|post stroke aphasic patients will receive 10 sessions of high frequency rTMS 3 times per week over the damaged hemisphere without language therapy
16295421|NCT04708184|Experimental|GLPG3970 solution|Single oral dose of GLPG3970 in fasted conditions
16295422|NCT04708184|Experimental|GLPG3970 tablet fasted|Single oral dose of GLPG3970 in fasted conditions
16295423|NCT04708184|Experimental|GLPG3970 tablet fed|Single oral dose of GLPG3970 in fed conditions
16295424|NCT04708171||Awake mapping under local anesthesia|
16295425|NCT04708171||Asleep mapping under general anesthesia|
16295426|NCT04708171||Resection under general anesthesia without mapping|
16295427|NCT04708158|Experimental|Active|Inhaled Novaferon, given 20 ug BID, daily for 7 days
16356194|NCT04284553|No Intervention|No Alert (Usual Care)|
16295429|NCT04708145|Experimental|Group 1|"Study eyes without PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if DRSS level is 47 or worse as determined by the treating investigator.
~Subjects may be evaluated every 8 weeks if a 2-step DRSS level worsening compared to the last protocol-scheduled 16-week visit occurs, the DRSS level is 53 or worse, or if a subject has active PDR. Visits can continue every 8 weeks until there is no active PDR, and the DRSS improves to the level observed at the visit before the subject began being seen at 8-week intervals. Thereafter, visits will continue at 16 week intervals."
16295430|NCT04708145|Experimental|Group 2|"Study eyes with PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if the neovascular disease process is active and stable (not new or worse) as determined by the treating investigator. If the neovascular disease is inactive, no treatment will be given.
~If new or worsening neovascularization develops, subjects may be seen and treated every 8 weeks until the neovascular disease is stable or inactive, at which time the interval between visits will increase to 16 weeks."
16295431|NCT04708132|Active Comparator|screw retained restorations|
16295432|NCT04708132|Other|implant-retained ball overdentures|
16295433|NCT04708119|Other|histopathological evaluation|angulation of impacted lower mandibular third molar and histopathological evaluation
16295434|NCT04708106|Experimental|RELX ENDS Tobacco Flavor|Switch from combustible cigarettes to RELX ENDS Tobacco Flavor for 56 days
16295435|NCT04708106|Experimental|RELX ENDS Menthol Flavor|Switch from combustible cigarettes to RELX ENDS Menthol Flavor for 56 days
16295436|NCT04708106|Experimental|RELX ENDS Tobacco and Menthol Flavors|Switch from combustible cigarettes to RELX ENDS Tobacco and Menthol Flavor for 56 days
16295437|NCT04708106|No Intervention|Continue-smoking|Continue smoking combustible cigarettes for 56 days
16295438|NCT04708093|Experimental|whole body vibration training (WBVT)|whole body vibration group
16295439|NCT04708093|No Intervention|Controlled|advised about healthy dieting
16295440|NCT04708080||Group E|patients who underwent thoracic epidural catheter for postoperative analgesia
16295441|NCT04708080||Group I|Patients who cannot be applied thoracic epidural catheter for postoperative analgesia
16295443|NCT04708054|Experimental|Treatment (venetoclax, busulfan, fludarabine, cladribine)|Patients receive venetoclax PO QD on days -22 to -3, busulfan IV over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine phosphate IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the absence of disease progression or unacceptable toxicity. Patients then undergo stem cell transplantation over 1-2 hours on day 0.
16295450|NCT04708028||Control|No exposure to the therapy dog.
16295451|NCT04708028||Dog Therapy|Introduced to a therapy dog and allowed to pet the dog for up to 2 minutes (timed) prior to the dental procedure.
16295452|NCT04708002|Other|First EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
16295453|NCT04708002|Other|Early intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
16295454|NCT04708002|Other|Late intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
16295455|NCT04708002|Other|Last EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
16295456|NCT04707989|Experimental|Ketone-Promoting Food Ingredient 1|Novel ketone-promoting food ingredient (#1) administered in a beverage once daily for 28 days.
16295457|NCT04707989|Placebo Comparator|Ketone Free Placebo|Beverage matched for appearance, volume, taste and texture to experimental arm (ketone promoting food ingredient #1) that does NOT contain a ketone ingredient. Consumed once daily for 28 days.
16295458|NCT04707989|Active Comparator|Ketone-Promoting Food Ingredient 2|Previously characterized ketone-promoting food ingredient (#2) administered in a beverage once daily for 28 days.
16295459|NCT04707976|Experimental|Navina Smart|An electronic medical device to perform transanal irrigation. Treatment period 8 weeks.
16295460|NCT04707976|Active Comparator|Standard Bowel Care|Supportive bowel care without using irrigation.
16295461|NCT04707963|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
16295462|NCT04707963|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
16295482|NCT04707820|No Intervention|control group|- Rouen University Hospital staff free of any symptomatology compatible with an SARS-CoV-2 infection (fever, cough, fatigue, loss of taste, loss of smell) since February 1, 2020
16295483|NCT04707807||Nightshift workers|
16295484|NCT04707807||Non-nightshift workers|
16295514|NCT04707599|No Intervention|OFF intervention|No reminder plus (telephone reminder from therapist) but standard test message reminder (SMS) from second admission
16295463|NCT04707950|Active Comparator|study group will be given tranexamic acid|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).
~The second dose of TXA 1 g Intravenous can be given if:
~Bleeding continues after 30 minutes
~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
16295464|NCT04707950|Placebo Comparator|Control group|The control group will not be given Tranexamic acid but only the standard management ( Oxytocin )
16295465|NCT04707937|Experimental|Online education|Participants will gain access to the online education modules in addition to receiving current standard of care education (pamphlets and one on one teaching with health care provider)
16295466|NCT04707937|Active Comparator|Regular standard of care education|Participants only receive current standard of care education (pamphlets and one on one teaching with health care provider)
16295467|NCT04707924|Experimental|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
16295468|NCT04707924|No Intervention|Control area|No treatment performed on control areas.
16295469|NCT04707911|Experimental|Vaping Intervention|The vaping intervention will be implemented on Instagram. Participants in the treatment condition will be assigned to groups on Instagram, where they will receive up to 3 posts per day for 30 days. Groups are facilitated by a trained Guide, working with the Principal Investigator, Co-Investigators and a Pediatrician on demand if additional expertise or clinical advice is needed. Participants will be educated about signs of nicotine dependence and if they express interest in pharmacotherapy will be encouraged to access this through their personal healthcare providers. The Instagram groups will provide educational and social support, troubleshooting and advice about nicotine replacement therapy (NRT) or other forms of treatment.
16295470|NCT04707911|No Intervention|Control Condition|Participants in the control condition will be directed to the Truth Initiative e-cigarette texting quit program. This innovative and free text message program was created with input from teens, college students and young adults who have attempted to, or successfully, quit e-cigarettes using text coaching methods
16295471|NCT04707898|Experimental|Group Single Bond Universal|Single Bond Universal adhesive system with selective-etch approach following the manufacturer's instruction
16295472|NCT04707898|Experimental|Group G-Premio Bond|G-Premio Bond Adhesive System with selective-etch approach following the manufacturer's instruction
16295476|NCT04707859||Cohort|"Participants consenting to the study will undergo:
~a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years
~Patients with suspicion of coronary stenosis detected by CCTA will after undergo:
~b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)"
16295477|NCT04707846|Experimental|Bright Light Therapy|Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.
16295478|NCT04707846|Active Comparator|Dim Light Therapy|Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).
16295479|NCT04707846|No Intervention|Usual Care|During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).
16295480|NCT04707833|Experimental|Patient infected or cured from covid19|"Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations,
~Nurses at the Rouen University Hospital infected with COVID 19, and cured,
~Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR"
16295481|NCT04707820|Experimental|Patient group|- Patient with an acute SARS-CoV-2 infection, confirmed by PCR or typical CT images, requiring hospitalization in a COVID unit at Rouen University Hospital.
16295485|NCT04707794||Elderly|Patients > 65 years age undergoing non-cardiac surgery will be administered general anesthesia maintained with sevoflurane or desflurane titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
16295486|NCT04707781||prospective patient cohort|patients who will undergo the prospective ILD Screening algorithm
16295487|NCT04707781||retrospective patient cohort|patients with diagnosed ILD
16295488|NCT04707768|Experimental|Vadadustat low dose|Participants previously receiving Mircera® will receive a low dose of vadadustat for up to 52 weeks.
16295489|NCT04707768|Experimental|Vadadustat high dose|Participants previously receiving Mircera® will receive a high dose of vadadustat for up to 52 weeks.
16295490|NCT04707768|Active Comparator|Mircera®|Participants will continue to receive Mircera® for up to 52 weeks.
16295491|NCT04707755|Experimental|Motor imagery technique|Motor Imagery technique Plus Conventional Physical therapy
16295492|NCT04707755|Active Comparator|Conventional Physical therapy|passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
16295493|NCT04707742|Experimental|Povidone-iodine 2% (Betadine© bucal 100 mg/ml)|"Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).
~The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (3 mL of povidone-iodine 10% for oral use - Betadine© with 12 mL of distilled water)."
16295494|NCT04707742|Experimental|Hydrogen peroxide 1% (Oximen® 3%)|Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (5 mL of hydrogen peroxide 3% - Oximen© with 10 mL of distilled water).
16295495|NCT04707742|Experimental|Clorhexidine 0,12% (Clorhexidine Dental PHB©)|"Clorhexidine 0,12% (Clorhexidine Dental PHB©) contains clorhexidine (C22H30N10Cl2).
~Rinses were ready to use in their commercial formulas."
16295496|NCT04707742|Experimental|Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©)|"Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN).
~Rinses were ready to use in their commercial formulas."
16295497|NCT04707742|Placebo Comparator|Control (Distilled Water)|Distilled water.
16295498|NCT04707729|No Intervention|Standard of care|Patients will be intubated according to both the standard of care
16295499|NCT04707729|Experimental|Standard of care + ROX algorithm|In the intervention arm, patients will be intubated according to both the standard of care and the ROX index, whichever are met first. If the patient has a ROX index below different thresholds after different time-point within the first 12 hours since randomization, the NHF support will be increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. Then, the ROX index will be recalculated in 30 minutes. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done, the ROX index will be recalculated after 30 minutes of full NHF support. Then: 1) if the ΔROX is <0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 30 minutes; and 3) if the ΔROX is >0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
16295500|NCT04707716|Experimental|conometric concept (Acuris system)|single implant crown retention using friction only
16295501|NCT04707716|Active Comparator|screw retention|screw retained implant Crown fixation
16295502|NCT04707716|Active Comparator|cementation|cement retained implant Crown fixation
16295503|NCT04707703|Experimental|SOC plus Isavuconazonium sulfate|SOC plus intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by 372mg once daily for up to 28 days
16295504|NCT04707703|Placebo Comparator|SOC plus Placebo|SOC plus intravenous placebo every 8 hours for 6 doses followed by once daily for up to 28 days
16295505|NCT04707690|Active Comparator|Intraurethral laser therapy|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic fluid (Cathejell ®) will be applied to the urethral meatus. Before laser therapy, an intraurethral swab will be taken before treatment in order to determine the intraurethral microbiome.
~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Incontinence mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2."
16295506|NCT04707690|Placebo Comparator|Intraurethral SHAM laser therapy|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
16295507|NCT04707677|Active Comparator|CONTROL GROUP|Implant surgery placement. Tissue Level SLA Titanium implant (Straumann Standard Plus Narrow Neck CrossFit®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
16295508|NCT04707677|Experimental|TEST GROUP|Implant surgery placement. Tissue Level Ceramic monotype implant was placed (Straumann PURE Ceramic implants®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
16295511|NCT04707651|Experimental|Lifestyle intervention|Nutrition advices and formula diet
16295512|NCT04707638||Parkinson's disease or dystonia patients|Patients with Parkinson's disease or dystonia and underwent STN DBS under general anesthesia in neurosurgery department
16295513|NCT04707625|Other|Aflibercept|All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.
16295667|NCT04706611|Experimental|Food Allergic|Fecal Microbiota Transplantation will be performed.
16295515|NCT04707599|Experimental|ON intervention|Reminder plus (telephone reminder from therapist) AND standard test message reminder (SMS) from second admission
16295516|NCT04707586|No Intervention|Control|No application will be made to patients in this group. Routine patient care will be provided. After the patients who develop pain are recorded, the application will be made with a cold application bandage.
16295517|NCT04707586|Experimental|experimental group|Patients in this group will be applied cold application with cold application bandage for 20 minutes as soon as the infusion begins.
16295518|NCT04707573|Experimental|CKD, Stage 3|Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate [eGFR] 30 - 59 milliliters [mL]/minute) received a single 500 milligram (mg) oral dose of vadadustat after fasting for at least 4 hours.
16295519|NCT04707573|Experimental|CKD, Stage 4|Participants with Stage 4 CKD (eGFR <30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of vadadustat after fasting for at least 4 hours.
16295520|NCT04707560|Experimental|Heparin Wet first group|Heparin based wet suction method of EUS FNB will go first for 2 passes and then shift to dry suction method for another 2 passes.
16295521|NCT04707560|Experimental|Dry suction first group|Dry suction method of EUS FNB will go first for 2 passes and then shift to heparin base wet suction method for another 2 passes.
16295522|NCT04707547|Experimental|Radiofrequency Ablation|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
16295523|NCT04707547|Placebo Comparator|Radiofrequency Ablation combine with Nivolumab|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy, and improving immune systems by Nivolumab
16295524|NCT04707534|Experimental|Dexamethasone 20 mg|Dexamethasone 20 mg daily for 5 days, followed by dexamethasone 10 mg daily for 5 days
16295525|NCT04707534|Active Comparator|Dexamethasone 6 mg|Dexamethasone 6 mg daily for 10 days
16295526|NCT04707521|Experimental|3M tape ship-shaped combined with strap fixing method|"Cutting method of 3M adhesive tape of ship shape: cut a piece of 20cm×3cm elastic adhesive tape, fold it in half to form a rectangle of 10cm×3cm, cut 5cm straight line from the middle point of the crease, cut it at an Angle of 45°, fold and open the 3M elastic adhesive tape in half, which is the adhesive tape required for fixing. The final shape is similar to that of a ship, and it is named as 3M adhesive tape of ship shape.
~Fixation method: The ship shape with 3M adhesive tape was pasted upward on the opposite cheek (near zygomatic), and the endotracheal intubation was wound around for two rounds and then glued to the near cheek (near zygomatic).Put the tooth pad next to the endotracheal intubation and wrap the tooth pad and catheter together for two turns with a short 3M adhesive tape of 12cm×1.5cm.Finally, fasten it with a lacing."
16295527|NCT04707521|No Intervention|traditional X-shaped tape and string fixing|traditional X-shaped tape and string fixing
16295528|NCT04707508|Experimental|Valsartan and metformin|
16295529|NCT04707508|Active Comparator|Metformin only|
16295530|NCT04707495|Experimental|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.
~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
16295531|NCT04707495|Active Comparator|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
16295535|NCT04707456|No Intervention|MFM staff-level operator|
16295536|NCT04707456|Other|MFM fellowship trainee-level operator|
16295537|NCT04707443|Experimental|donor human milk|For patients who can be fed orally or through tubes after surgery, donor milk will be used to feeding for 4 weeks.
16295538|NCT04707443|Active Comparator|extensively hydrolyzed formula|For patients who can be fed orally or through tubes after surgery, extensively hydrolyzed formula will be used to feeding for 4 weeks.
16295539|NCT04707404||PEEK|Cranioplasty patients with PEEK.
16295540|NCT04707404||Titanium|Cranioplasty patients with titanium mesh.
16295543|NCT04707378|Active Comparator|active left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC.
16295544|NCT04707378|Sham Comparator|sham left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of sham stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (sham) over the left DLPFC.
16295545|NCT04707365|Experimental|digestive cancers|Colorectal and pancreatobiliary cancers
16295585|NCT04707092|Experimental|Antibiotic one week|Patients will receive one single dose of Antibiotic at induction, plus a 7 day treatment with oral Antibiotic
16295546|NCT04707352|Experimental|Dapagliflozin|The baseline procedures will be performed on the same day of screening or within the next five working days. All the baseline procedures will be performed on the same day. The baseline procedures include biobank, clinical assessment and echocardiogram, on the same day. In the following 24 hours, the patient will initiate Dapagliflozin at the recommended dose of 10 mg daily during 6 months. Temporary discontinuation may be considered at investigator criteria as in cases of symptomatic hypotension or acute declines in renal function and after discarding other potential causes.
16295547|NCT04707339||Acute Appendicitis pre-COVID management|Audit of Acute appendicitis management in 2017-18
16295548|NCT04707339||Acute Appendicitis during COVID management|Audit of Acute appendicitis management in 2020
16295549|NCT04707326||DTG/3TC|HIVRNA suppressed HIV patients who switched to DTG/3TC
16295550|NCT04707326||Triple drug cART|Matched HIVRNA suppressed patients who remained on triple drug cART
16295551|NCT04707313|Placebo Comparator|Placebo|
16295552|NCT04707313|Experimental|PF-06882961 40 milligrams (mg) twice daily (BID), standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID. Titration steps include: 10 mg BID, 20 mg BID, and 40 mg BID.
16295553|NCT04707313|Experimental|PF-06882961 80 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID.
16295554|NCT04707313|Experimental|PF-06882961 120 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID.
16295555|NCT04707313|Experimental|PF-06882961 160 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID, 120 mg BID, 140 mg BID and 160 mg BID.
16295556|NCT04707313|Experimental|PF-06882961 200 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID, 120 mg BID, 140 mg BID, 160 mg BID, 180 mg BID and 200 mg BID.
16295557|NCT04707313|Experimental|PF-06882961 120 mg BID, slow titration|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID.
16295558|NCT04707313|Experimental|PF-06882961 160 mg BID, slow titration|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg, 100 mg BID, 120 mg BID, 140 mg BID and 160 mg BID.
16295559|NCT04707313|Experimental|PF-06882961 200 mg BID, slow titration|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID, 120 mg BID, 140 mg BID, 160 mg BID, 180 mg BID and 200 mg BID.
16295561|NCT04707287||Breast Cancer Patients|All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
16295562|NCT04707274||Patients group|Individuals with greater trochanteric pain syndrome and gluteal tendinopathy
16295568|NCT04707235||Sickle cell disease patients treated with Siklos|
16295569|NCT04707222|Experimental|Antibiotics+FMT|"7 days of antibiotics- Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day.
~Fecal Microbiota Transplant"
16295570|NCT04707222|Placebo Comparator|Placebo|7 days of cellulose placebo pills.
16295571|NCT04707209|Experimental|Intravitreal Sirolimus|
16295572|NCT04707196|Experimental|Abemaciclib + NSAI or Fulvestrant|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally or Fulvestrant administered intramuscularly.
16295573|NCT04707183|Placebo Comparator|Control Arm|1.0mg/kg/hr IV lidocaine infusion
16295574|NCT04707183|Experimental|Treatment Arm|10 mL of 2% lidocaine via ESPB
16295577|NCT04707131|Experimental|LEM-S401|
16295578|NCT04707131|Placebo Comparator|Placebo|
16295579|NCT04707118|Experimental|Thermal perfusion cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
16295580|NCT04707118|Active Comparator|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
16295581|NCT04707105||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
16295582|NCT04707105||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
16295583|NCT04707105||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
16295584|NCT04707092|Experimental|Antibiotic at induction|Patients will receive one single dose of Antibiotic at induction
16295586|NCT04707079|Experimental|Duvelisib|Eligible subjects will be given duvelisib (15mg, 25mg), orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
16295587|NCT04707066|Experimental|1|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
16295588|NCT04707066|Experimental|2|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
16295589|NCT04707066|Experimental|3|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
16295590|NCT04707066|Experimental|4|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
16295591|NCT04707066|Experimental|5|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
16295592|NCT04707066|Experimental|6|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
16295593|NCT04707053||Intraaxial lesion group|Patients with intraaxial brainstem lesions (lesions located in the brainstem) + experienced brainstem surgery in our department during the study period
16295594|NCT04707053||Extraaxial lesion group|Patients with extraaxial brainstem lesions (lesions close to the brainstem) + experienced brainstem surgery in our department during the study period
16295595|NCT04707040|Experimental|Neurocognitive Exercise Program Group|The group received NEP for 10 weeks, one hour per week conducted by the same physiotherapist with 6 years of experience in this field. Children with ADHD were given home exercises for the other six days of the week without a NEP session. Home exercises were followed with an exercise diary under the control of children's parents. The home exercise program consisted of visual-motor and auditory-motor coordination tasks (daily 15 min).
16295596|NCT04707027|Sham Comparator|complete polypoidal regression arm|follow up monthly with color fundus photography and OCT at each visit
16295597|NCT04707027|Active Comparator|incomplete polypoidal regression arm|continue treatment with aflibercept injection (treat and extend regimen)
16295598|NCT04707014|Placebo Comparator|Attention-Distraction techniques|A high-tech distraction technique (Apple®), passive and chosen by the child, either an animated video or his or her favourite music. After standard intravenous sedation, the child is taken to the operating theatre to watch his or her favourite video or music and this is maintained throughout the procedure.
16295599|NCT04707014|Experimental|HIPNOSIS GROUP|A technique of rapid conversational hypnosis, with focus on therapeutic suggestion (guiding the patient into a hypnotic trance), adapted to the child's cognitive development. Induction with hypnotic suggestion focuses and accompanies the child's body sensations and allows their active participation. After standard sedation, therapeutic suggestion is maintained throughout the surgery and in the post-hypnotic period before awakening.
16295600|NCT04707001|Active Comparator|Ultrasound monitoring group|In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.
16295601|NCT04707001|Active Comparator|Symptoms alone group|Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.
16295602|NCT04706975|Active Comparator|Difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg tablet administered twice daily
16295603|NCT04706975|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
16295604|NCT04706962|Experimental|TH1902|TH1902 peptide-drug conjugate
16295605|NCT04706949|Experimental|Pyrotinib combined with pemetrexed plus carboplatin|
16295606|NCT04706936|Experimental|Anti-BCMA CAR-T (CBG-002)|All subjects were intravenous administrated with CBG-002.
16295607|NCT04706923|Experimental|BCV 0.2mg/kg BIW|BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
16295608|NCT04706923|Experimental|BCV 0.3mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
16295609|NCT04706923|Experimental|BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
16295610|NCT04706923|Experimental|BCV 0.4 mg/kg QW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 for a minimum of 4 weeks.
16295611|NCT04706910|Experimental|18F-DOPA injection|All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
16295612|NCT04706897|Sham Comparator|Normal saline (Control) group|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1 mic/kg of IBW).
16295613|NCT04706897|Experimental|Dexmedetomidine, ketamine and lidocaine (Study) group|A loading infusion of syringe (B) containing the mixture was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
16295614|NCT04706871|Experimental|taVNS group|
16295615|NCT04706871|Placebo Comparator|tnVNS group|
16295616|NCT04706845||1|No evident disease
16295617|NCT04706845||2|Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation
16295618|NCT04706845||3|Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type
16295619|NCT04706845||4|Progressive Disease: Tumors bearing NOTCH Mutation
16295620|NCT04706845||5|Progressive Disease: Tumors bearing Notch Wild Type
16295621|NCT04706832|Other|ThorS-MagNT Treatment|Low-frequency, low-intensity repetitive magnetic stimulation bilaterally at T7-8 intravertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
16295622|NCT04706806|Experimental|liquid vinegar|2 tablespoons (diluted in water) taken twice daily with meals
16295623|NCT04706806|Placebo Comparator|vinegar pill|1 vinegar pill taken daily
16295624|NCT04706793|Experimental|Etrasimod 2 mg|
16295625|NCT04706793|Placebo Comparator|Placebo|
16295666|NCT04706611|Experimental|Atopic Dermatitis|Fecal Microbiota Transplantation will be performed.
16295626|NCT04706780||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
16295627|NCT04706767|Experimental|Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery|
16295628|NCT04706767|Experimental|Effect of Dexmedetomidine infusion on Quality of Recovery|
16295629|NCT04706767|Experimental|Effect of Lidocaine infusion on Quality of Recovery|
16295630|NCT04706767|Experimental|Effect of saline infusion on Quality of Recovery|
16295631|NCT04706754||Prospective|Confirmed ALK, EGFR, ROS1, ERBB2 (HER2), exon 20 EGFR mutation, MET and BRAF cancer patients from across participating sites/cancer centers across Canada.
16295632|NCT04706741|Experimental|ABY-035 and maintenance corticosteroid dose|ABY-035 + Prednisolon/Prednisone
16295633|NCT04706741|Experimental|ABY-035 and corticosteroid burst|ABY-035 + Prednisolon/Prednisone
16295634|NCT04706741|Placebo Comparator|Placebo and corticosteroid burst|Placebo + Prednisolon/Prednisone
16295635|NCT04706728|Experimental|Playlists with Expert-Curated Music - four weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
16295636|NCT04706728|Active Comparator|Playlists with Expert-Curated Music - two weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for two weeks (the first four ECT procedures).
16295637|NCT04706728|Placebo Comparator|Playlists with Nature Sounds|Patients can choose from two expert-curated playlists with recorded sounds from nature (Rain, Waves) during ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
16295638|NCT04706715|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval. After completion of imaging, patients will start treatment with cemiplimab with or without platinum-based chemotherapy.
16295639|NCT04706715|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of 89Zr-DFO-REGN3767 in patients before and during treatment with cemiplimab with or without platinum-based chemotherapy.
16295640|NCT04706702|Experimental|Tele-EF|Tele-EnhanceFitness
16295641|NCT04706689||Unresponsive wakefulness syndrome patients (UWS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
16295642|NCT04706689||Minimally conscious patients MINUS (MCS-)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
16295643|NCT04706689||Minimally conscious patients PLUS|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
16295644|NCT04706689||Patients emerging from the minimally conscious state (EMCS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
16295645|NCT04706676|Experimental|Integrative neuromuscular training + motivational counseling + usual care|General and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility.
16295646|NCT04706676|Active Comparator|Active control group + motivational counseling + usual care|home-based training program
16295647|NCT04706663||Cohort 1|Subjects with histologically confirmed prostate cancer and genomic testing results
16295648|NCT04706663||Cohort 2|Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results
16295649|NCT04706637|Experimental|evogliptin|evogliptin 5 mg + metformin, oral administration once a day for 48 weeks
16295650|NCT04706637|Active Comparator|dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
16295651|NCT04706624|Active Comparator|A - High intensity Contingency management + SMS reminders|Participants who respond to the high intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
16295652|NCT04706624|Active Comparator|B - High intensity Contingency management + Matrix only|Participants who do not respond to the high intensity contingency management are randomized into the Matrix only group.
16295653|NCT04706624|Active Comparator|C - High intensity Contingency management + (Matrix + CM)|Participants who do not respond to the high intensity contingency management are randomized into the Matrix plus contingency management group.
16295654|NCT04706624|Active Comparator|D - Low intensity Contingency management + SMS reminders|Participants who respond to the low intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
16295655|NCT04706624|Active Comparator|E - Low intensity Contingency management + Matrix only|Participants who do not respond to the who intensity contingency management are randomized into the Matrix only group.
16295656|NCT04706624|Active Comparator|F - Low intensity Contingency management + (Matrix+CM)|Participants who do not respond to the who intensity contingency management are randomized into the Matrix plus contingency management group.
16295657|NCT04706611|Experimental|Irritable Bowel Syndrome|Fecal Microbiota Transplantation will be performed.
16295658|NCT04706611|Experimental|Constipation|Fecal Microbiota Transplantation will be performed.
16295659|NCT04706611|Experimental|Clostridium Difficile Infection|Fecal Microbiota Transplantation will be performed.
16295660|NCT04706611|Experimental|Functional Dyspepsia|Fecal Microbiota Transplantation will be performed.
16295661|NCT04706611|Experimental|Parkinson's Disease|Fecal Microbiota Transplantation will be performed.
16295662|NCT04706611|Experimental|Metabolic Syndrome|Fecal Microbiota Transplantation will be performed.
16295663|NCT04706611|Experimental|Non-Alcoholic Fatty Liver Disease|Fecal Microbiota Transplantation will be performed.
16295664|NCT04706611|Experimental|Autism Spectrum Disorder|Fecal Microbiota Transplantation will be performed.
16295665|NCT04706611|Experimental|Radiation Enteritis|Fecal Microbiota Transplantation will be performed.
16295668|NCT04706611|Experimental|Graft-versus-Host Disease|Fecal Microbiota Transplantation will be performed.
16295669|NCT04706611|Experimental|Obesity|Fecal Microbiota Transplantation will be performed.
16295670|NCT04706611|Experimental|Diabetes mellitus|Fecal Microbiota Transplantation will be performed.
16295671|NCT04706611|Experimental|Multi-Drug Resistant Infection|Fecal Microbiota Transplantation will be performed.
16295672|NCT04706611|Experimental|Hepatic Encephalopathy|Fecal Microbiota Transplantation will be performed.
16295673|NCT04706611|Experimental|Enteric Dysbacteriosis|Fecal Microbiota Transplantation will be performed.
16295674|NCT04706611|Experimental|Multiple Sclerosis|Fecal Microbiota Transplantation will be performed.
16295675|NCT04706611|Experimental|Pseudomembranous Enteritis|Fecal Microbiota Transplantation will be performed.
16295676|NCT04706611|Experimental|Acute Pancreatitis|Fecal Microbiota Transplantation will be performed.
16295677|NCT04706611|Experimental|Chronic Fatigue Syndrome|Fecal Microbiota Transplantation will be performed.
16295678|NCT04706611|Experimental|Acute-on-chronic Liver Failure with HBV Infection|Fecal Microbiota Transplantation will be performed.
16295679|NCT04706611|Experimental|Alcoholic Liver Disease|Fecal Microbiota Transplantation will be performed.
16295680|NCT04706611|Experimental|Anorexia|Fecal Microbiota Transplantation will be performed.
16295681|NCT04706611|Experimental|Decompensated Cirrhosis|Fecal Microbiota Transplantation will be performed.
16295682|NCT04706611|Experimental|Henoch-Schonlein Purpura|Fecal Microbiota Transplantation will be performed.
16295683|NCT04706611|Experimental|Autoimmune Liver Disease|Fecal Microbiota Transplantation will be performed.
16295684|NCT04706611|Experimental|Systemic Lupus Erythematosus|Fecal Microbiota Transplantation will be performed.
16295685|NCT04706611|Experimental|IgG4-Related Disease|Fecal Microbiota Transplantation will be performed.
16295686|NCT04706611|Experimental|Celiac Disease|Fecal Microbiota Transplantation will be performed.
16295687|NCT04706611|Experimental|Protein-losing Enteropathy|Fecal Microbiota Transplantation will be performed.
16295688|NCT04706611|Experimental|Asperger Syndrome|Fecal Microbiota Transplantation will be performed.
16295689|NCT04706611|Experimental|Rheumatoid arthritis|Fecal Microbiota Transplantation will be performed.
16295690|NCT04706611|Experimental|Ulcerative colitis|Fecal Microbiota Transplantation will be performed.
16295691|NCT04706611|Experimental|Crohn's disease|Fecal Microbiota Transplantation will be performed.
16295692|NCT04706611|Experimental|Psoriasis|Fecal Microbiota Transplantation will be performed.
16295693|NCT04706611|Experimental|Ankylosing spondylitis|Fecal Microbiota Transplantation will be performed.
16295694|NCT04706611|Experimental|Immune checkpoint inhibition-related colitis|Fecal Microbiota Transplantation will be performed.
16295695|NCT04706611|Experimental|Autoimmune enteropathy|Fecal Microbiota Transplantation will be performed.
16295696|NCT04706611|Experimental|Drug-induced diarrhea|Fecal Microbiota Transplantation will be performed.
16295697|NCT04706598|Experimental|Intravesical therapy group|"Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.
~The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years."
16295698|NCT04706598|Active Comparator|Intravenous therapy group|Camrelizumab(SHR-1210) is administered on the first day (D1) of each treatment cycle (21 days) at a dose of 200 mg by 30-min intravenous infusion(the allowable error in infusion time is -5 min, +10 min). The maximum duration of dosing is 2 years.
16295699|NCT04706585||Youth|Young people in Indonesia between the age of 15-24 who are currently attending high school or university-level education to fill in our online survey.
16295700|NCT04706572|Experimental|Patients with Golden Rhythm|Administration of an external auditory cue based on Golden Rhythm
16295701|NCT04706572|Placebo Comparator|Patients with Metronome|Administration of an external auditory cue based on metronome binary rhythm
16295702|NCT04706559|Experimental|Group A (Interventional group)|Along with below mentioned conventional treatment, the participants in group A (i.e. Interventional group) will receive conventional treatment of AD for a short duration along with probiotics for 8 weeks. One probiotic sachet twice a day will be prescribed. A sachet of 2 grams containing 1.25 billion cells per gram of 4 strains (Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii) will be used. The child will receive a total of 5 billion cells of probiotics per day.
16295703|NCT04706559|Active Comparator|Group B (Conventional group)|All patients (i.e. in both arms) with atopic dermatitis will be prescribed emollients and cleanser as a part of routine skin care. Topical corticosteroid (i.e. Fluticasone 0.05% cream) and topical calcineurin inhibitor (tacrolimus 0.1% ointment) for sensitive areas like periorbital regions, flexures and face, will be given once daily. All patients will be given an oral antihistamine (syrup/ tablet cetirizine 0.3mg/kg) at night. It is referred to as conventional treatment.
16295704|NCT04706546|Experimental|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
16295705|NCT04706546|Other|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16295706|NCT04706533||Covid-19|Patients with confirmed SARS-CoV-2 infection presenting specifically for Covid-19
16295707|NCT04706520|Experimental|Group 1: Vinegar|Participants will consume 400 mL/day vinegar beverage providing 1,500 mg/day acetic acid [200 mL vinegar beverage, twice per day (prior to breakfast and dinner)] for 12 weeks.
16295708|NCT04706520|Experimental|Group 2: Vinegar/Placebo Combination|Participants will consume 200 mL/day vinegar beverage and 200 mL/day placebo beverage providing 1,200 mg/day lactate [200 mL placebo beverage 1x/day] and 750 mg/day acetic acid [200 mL vinegar beverage 1x/day] (prior to breakfast and dinner) for 12 weeks.
16295709|NCT04706520|Placebo Comparator|Group 3: Placebo|Participants will consume 400 mL/day placebo beverage containing 1,250 mg/day lactate [200 mL placebo beverage, and 200 mL placebo beverage (prior to breakfast and dinner) for 12 weeks.
16295710|NCT04706507|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge
16295711|NCT04706507|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge
16295712|NCT04706494|Experimental|AlphaWave® LTheanine|
16295713|NCT04706494|Placebo Comparator|Placebo|
16295714|NCT04706481||Healthy Control|Healthy subjects who have provided consent for specimen collection
16295715|NCT04706481||Cancer or Other Diseases|Diseased subjects who have provided consent for specimen collection
16295716|NCT04706468|Experimental|40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
16295717|NCT04706468|Experimental|80 mg TG-1000|Participants received 80 mg of TG-1000 orally on Day 1 and 40 mg of placebo on Day 3.
16295718|NCT04706468|Experimental|40 mg TG-1000+40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of TG-1000 on Day 3.
16295719|NCT04706468|Placebo Comparator|Placebo|Participants received 80 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
16295720|NCT04706455|Active Comparator|sodium hyaluronate 0.1%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then, corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.1% will be installed and biometry and corneal topography will be repeated after 5 minutes.
16295721|NCT04706455|Active Comparator|sodium hyaluronate 0.3%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then,corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.3% will be installed and biometry and corneal topography will be repeated after 5 minutes.
16295722|NCT04706442|Experimental|Standard hospital care with follow up + Supportive Parenting App|Receive standard hospital care and follow up, and access to the Supportive Parenting App from pregnancy to 6 months postpartum
16295723|NCT04706442|No Intervention|Standard hospital care with follow up|Receive standard hospital care with follow up
16295724|NCT04706429|Active Comparator|Trientine|Trientine dihydrochloride 1200 mg per day. This shall be taken orally as two Cufence 200mg hard capsules two times per day. The IMP will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
16295725|NCT04706429|Placebo Comparator|Placebo|The placebo shall be taken orally as two capsules two times per day. This will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
16295726|NCT04706416|Experimental|N-Acetyl Glucosamine|All patients in the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
16295727|NCT04706403|Experimental|Message 1|Participants will be randomized to receive version #1 of 5 different versions of a message from a healthcare provider regarding vaccination.
16295728|NCT04706403|Experimental|Message 2|Participants will be randomized to receive version #2 of 5 different versions of a message from a healthcare provider regarding vaccination.
16295729|NCT04706403|Experimental|Message 3|Participants will be randomized to receive version #3 of 5 different versions of a message from a healthcare provider regarding vaccination.
16295730|NCT04706403|Experimental|Message 4|Participants will be randomized to receive version #4 of 5 different versions of a message from a healthcare provider regarding vaccination.
16295731|NCT04706403|Experimental|Message 5|Participants will be randomized to receive version #5 of 5 different versions of a message from a healthcare provider regarding vaccination.
16295732|NCT04706403|No Intervention|Control|Participants receive a control version of a message from a healthcare provider regarding vaccination.
16295733|NCT04706390||Health care workers|500-1000 health care workers prioritized for early vaccination
16295734|NCT04706390||prioritized patient populations|2000 individuals in patient populations prioritized for vaccinations
16295735|NCT04706377|Active Comparator|Active treatment group|Patients were given oral dispersible tablet with 1000μg of vitamin B12 daily for 12 months.
16295736|NCT04706377|Placebo Comparator|Placebo group|Patients were given placebo tablet similar to the tablet given to the active group once a day for 12 months.
16295737|NCT04706364||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder
16295738|NCT04706364||Healthy Control|Typically developing individuals without a history of autism
16295739|NCT04706338|Experimental|TMS treatment|Patients with TMS treatment
16295740|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
16295741|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
16295742|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.|COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
16295743|NCT04706312|Experimental|hAMSCs injection|hAMSCs were injected via venous in the dorsum of hand.
16295744|NCT04706299|Active Comparator|No Mask|Will not wear a mask
16295745|NCT04706299|Experimental|Surgical mask|Will wear a surgical nose and face covering
16295746|NCT04706286|Experimental|Group 1|"Period 1: Treatment A
~Period 2: Treatment B"
16295747|NCT04706286|Experimental|Group 2|"Period 1: Treatment B
~Period 2: Treatment A"
16295748|NCT04706273||GORE® VIABAHN® Endoprosthesis|Participants with symptomatic peripheral arterial disease in superficial femoral artery lesions.
16295749|NCT04706234||Multiple System Atrophy|Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
16295750|NCT04706234||progressive supranuclear palsy|Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
16295751|NCT04706234||Parkinson Disease|Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
16295752|NCT04706221|Experimental|Blood Volume Monitoring|
16356340|NCT04283695|Experimental|Part 2|IV: [14C]-GX-I7 40 µg
16295753|NCT04706208|Other|One time testing - able-bodied healthy adults|"Participants in this arm will be able-bodied healthy adults who will not receive an intervention.
~This is just a one time testing of clinical assessments (over zoom), one MRI scan, and an optional blood draw test."
16295754|NCT04706208|Experimental|Usual Care, then Cognitive Multisensory Therapy - adults with spinal cord injury + neuropathic pain.|This is a cross-over study for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive usual care and then switch over to the experimental cognitive multisensory therapy training.
16295755|NCT04706208|Experimental|Cognitive Multisensory Therapy, then Usual Care - adults with spinal cord injury + neuropathic pain.|This is a cross-over study for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive the experimental cognitive multisensory therapy training and then switch over to usual care.
16295756|NCT04706195|Experimental|Person-centred care|PCC in the form of a combined eHealth and structured telephone support combined with an eHealth support on top of usual care
16295757|NCT04706195|No Intervention|Usual care|Regular evidence-based treatment and care as outlined in treatment guidelines and followed as usual at their local primary care center
16295758|NCT04706182|Experimental|Combined PRF and PSG|
16295759|NCT04706182|Experimental|Only PRF|
16295760|NCT04706182|Experimental|Only PSG|
16295761|NCT04706182|No Intervention|Control (no treatment)|
16295762|NCT04706169||Older adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Older adult group: over 65 years.
16295763|NCT04706169||Adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Adult groups: 20 to 64 years.
16295764|NCT04706156||Vaccinated Healthcare Workers (CZ)|Czech healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
16295765|NCT04706156||Vaccinated Healthcare Workers (DE)|German healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
16295766|NCT04706156||Vaccinated Healthcare Workers (SK)|Slovak healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
16295767|NCT04706156||Vaccinated Healthcare Workers (TR)|Turkish healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
16295768|NCT04706143||Vaccined group by live attenuated or viral vector or mRNA vaccine|Adults between 25-65 years old
16295769|NCT04706130|Other|Arm1: No primaquine|Enrolled patients will only received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days)
16295770|NCT04706130|Other|Arm2: Primaquine low dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.25 mg/kg/day for 14 days (starting at day 7)
16295771|NCT04706130|Other|Arm3: Primaquine high dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.50 mg/kg/day for 14 days (starting at day 7)
16295772|NCT04706117|Other|Canalicular obstruction|
16295773|NCT04706104||Propofol-Ketamine|2-3 mg/kg propofol and 1-2 mg/kg ketamine will be used for anesthesia induction
16295774|NCT04706104||Midazolam-Fentanyl|0.15 mg/kg midazolam and 10-15 mcg/kg fentanyl will be used for anesthesia induction
16295775|NCT04706091|Experimental|Treatment --> Placebo|This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.
16295776|NCT04706091|Experimental|Placebo --> Treatment|This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.
16295777|NCT04706078||thick-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thick-gingiva (outline if the probe cannot be seen through the gingival)
16295778|NCT04706078||thin-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thin-gingiva (outline of the probe can be seen through the gingival)
16295779|NCT04706065||GROUP 1|Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.
16295780|NCT04706065||Group 2|Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.
16295781|NCT04706052||Superficial Parotidectomy Patient|All the patients with pleomorphic adenoma irrespective of age and gender who underwent Superficial parotidectomy
16295782|NCT04706039|Experimental|Outpatients without hospitalisation criteria|Symptomatic and asymptomatic outpatient without hospitalisation criteria presenting in a COVID-19 screening centre of the Hospices Civils de Lyon
16295783|NCT04706026|Experimental|Local anesthesia|This arm will receive local anesthesia for their inguinal hernia repair.
16295784|NCT04706026|Active Comparator|General anesthesia|This arm will receive general anesthesia for their inguinal hernia repair.
16295785|NCT04706013|Experimental|Single Arm Active|Pyridoxal 5'-Phosphate
16295786|NCT04706000||Study group|endometrial polyp
16295787|NCT04706000||Control group|normal endometrium
16295788|NCT04705987|Experimental|Experimental|Colchicine 0.5 mg
16295789|NCT04705987|Placebo Comparator|Placebo|Placebo
16295790|NCT04705974|Experimental|Fascia iliaca block|ultrasound-guided fascia iliaca block with predetermined dose of 0.4% ropivacaine will be performed.
16295791|NCT04705974|Experimental|Femoral nerve block|ultrasound-guided ultrasound-guided femoral nerve block with predetermined dose of 0.4% ropivacaine will be performed.
16295792|NCT04705974|Experimental|Pericapsular nerve group block (PENG block)|ultrasound-guided ultrasound-guided pericapsular nerve group block with predetermined dose of 0.4% ropivacaine will be performed.
16295793|NCT04705948|Experimental|ketamine group|ketamine gargle (0.5 mg/kg up to 30 ml dextrose water) 15 minutes before the operation
16295794|NCT04705948|Experimental|magnesium sulfate group|magnesium sulfate gargle (20 mg/kg up to 30 mL G5%) 15 minutes before the operation.
16295795|NCT04705935||Term pregnant women without labor contractions or rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample before a scheduled caesarean section.
16295796|NCT04705935||Term pregnant women with labor contractions|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample when labor contractions, but before spontaneous rupture of membranes.
16295797|NCT04705935||Term pregnant women with spontaneous rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.
16295798|NCT04705935||Preterm labor contractions (PLC)|One blood sample when labor contractions before 34 weeks gestation without rupture of membranes.
16295799|NCT04705935||Preterm Prelabor Rupture of the Fetal Membranes (PPROM)|One blood sample when rupture of the fetal membranes before 34 weeks gestation without labor contractions.
16295800|NCT04705935||Control group|Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.
16295801|NCT04705935||Longitudinal cohort during pregnancy|Women with normal pregnancies, where blood samples will be collected at week 12, 20, 28, 34 and 36, as well as at labor.
16295802|NCT04705935||Longitudinal cohort post partum|Women with normal pregnancies, where blood samples will be collected at labor, as well as 2 days, and 4, 8 and 12 weeks after birth.
16295803|NCT04705922|Experimental|Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]|Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
16295804|NCT04705922|Experimental|Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]|Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
16295805|NCT04705922|Experimental|Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]|Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
16295806|NCT04705909|Experimental|Pitavastatin group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Pitavastatin tablets 2 mg once daily.
16295807|NCT04705909|Placebo Comparator|Placebo group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Placebo tablets matching pitavastatin orally once daily.
16295808|NCT04705896|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of slow low efficiency dialysis (SLED) or intermittent hemodialysis (IHD) and another 100 mL 25% Albumin fluid after 4 hours of treatment.
16295809|NCT04705896|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED or IHD and another 100 mL 0.9% Normal Saline after 4 hours of treatment.
16295810|NCT04705883|Other|Prasterone|10 patients will be treated using prasterone during 6 months.
16295811|NCT04705857||test group|"bone reconstructive surgery with the use of Histograft bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone (in a ratio of 50/50) harvested during the surgery"
16295812|NCT04705857||control group|bone reconstructive surgery with the use of shredded bone autograft harvested from iliac crest
16295813|NCT04705844|Experimental|Adalimumab|single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen
16295814|NCT04705844|Placebo Comparator|Placebo|single dose of placebo (administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen
16295815|NCT04705831|Active Comparator|RUCONEST|IV Ruconest
16295816|NCT04705831|Placebo Comparator|Placebo|Placebo
16295817|NCT04705818|Experimental|Cohort A: pancreatic cancer|Patients with pancreatic cancer will be treated by durvalumab prescribed in association with tazemetostat
16295818|NCT04705818|Experimental|Cohort B: not MSI-H or MMR-deficient colorectal cancer|Patients with colorectal cancer will be treated bydurvalumab prescribed in association with tazemetostat
16295819|NCT04705818|Experimental|Cohort C: metastatic solid tumor|Patients with metastatic solid with positive interferon gamma signature and/or presence of tertiary lymphoid structurestumor will be treated bydurvalumab prescribed in association with tazemetostat
16295820|NCT04705818|Experimental|Cohort D: soft-tissue sarcoma|Patients with soft-tissue sarcoma will be treated by durvalumab prescribed in association with tazemetostat
16295821|NCT04705805||Case|Patient presenting an olfactory dysfunction of any acquired aetiology that has been evolving for at least 3 months without total recovery.
16295822|NCT04705805||Control|Patient with no sense of smell problems followed up in ENT for another pathology that does not affect the sense of smell
16295823|NCT04705792|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 12 consecutive weeks.
16295824|NCT04705779|Experimental|HARMONY|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
16295825|NCT04705779|Active Comparator|Nutrition and Exercise Education Workgroup (NEEW)|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
16295826|NCT04705766||COVID-19 Negative|Control group to measure progression of AKI/kidney injury overtime
16295827|NCT04705766||COVID-19 Positive|Study group to assess AKI trajectory/progression and associated risk factors of kidney injury with SARS-CoV-2 infection
16295828|NCT04705753|Experimental|Cretan IAMA (CAPeo)|All patients are to receive Cretan IAMA (CAPeo) from Day 1.
16295829|NCT04705740||September 2013 to August 2015|5 endoscopists
16295830|NCT04705740||September 2015 to December 2017|4 endoscopists
16295831|NCT04705740||January 2018 to June 2020|3 endoscopists
16295832|NCT04705727|Experimental|budesonide/formoterol Turbuhaler®|After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).
16295833|NCT04705727|Active Comparator|nebulisation of terbutaline|0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.
16295834|NCT04705714|Experimental|Frankincense Extract|the anti-bacterial and antibiofilm activity of frankincense extract against Porphyromonas gingivalis clinical isolates were studied
16295835|NCT04705701|Experimental|Arm A group participants receive same day post-op dialysis|Arm A group participants receive same day post-op dialysis
16295836|NCT04705701|No Intervention|Arm B group participants receive dialysis per standard care|Arm B group participants receive dialysis per standard care
16295837|NCT04705688||Left Atrial Appendage Occlusion|Patients undergoing left atrial appendage occlusion.
16295838|NCT04705675|Experimental|Experimental Group|The mothers in the experimental group (152) were administered.
16295839|NCT04705675|No Intervention|Control Group|The mothers in the control group (152) were administered.
16295841|NCT04705636|Experimental|Connected device|Connected device for three months period to support children care
16295842|NCT04705623|Experimental|Intervention|The intervention group receives weekly 90 minute yoga classes over a course of 12 weeks. They are also asked to do two 45-minute yoga classes at home each week and document these in a Diary.
16295843|NCT04705623|No Intervention|Control|The control group receives an assessment of their biofunctional status at the beginning and the end of the study (same as the intervention group).
16295844|NCT04705610|Experimental|Radiologically Isolated Syndrome (RIS)|
16295845|NCT04705610|Experimental|Clinically Isolated Syndrome (CIS)|
16295846|NCT04705610|Experimental|Relapsing-Remitting MS (RRMS)|
16295847|NCT04705610|Experimental|Secondary Progressive MS (SPMS)|
16295848|NCT04705610|Experimental|Primary Progressive MS (PPMS)|
16295849|NCT04705610|Experimental|Healthy volunteer|
16295850|NCT04705597|Experimental|BGE-175|BGE-175 tablet to be taken by mouth once a day for 14 days
16295851|NCT04705597|Placebo Comparator|Placebo|Placebo tablet to be taken by mouth once a day for 14 days
16295852|NCT04705584|Active Comparator|Topical steroids|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.
16295853|NCT04705584|Experimental|Topical Cyclosporine A|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.
16295854|NCT04705584|Experimental|Topical Tacrolimus|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.
16295855|NCT04705571|Experimental|MorpheusV Applicator (active)|
16295856|NCT04705558|Experimental|group I|Continuous aerobic exercise with ketogenic diet for three month
16295857|NCT04705558|Experimental|group II|Ketogenic diet alone for three month
16295858|NCT04705545|No Intervention|molar block|No additional anchorage reinforcements besides the banding first and second molar with and tying them together at the buccal tubes (also known as molar block)
16295859|NCT04705545|Experimental|TPA group|Bands are selected and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a transpalatal archwire.
16295860|NCT04705545|Experimental|Nance button group|Bands are selected and an alginate impression taken over the bands. Bands are replaced on the tooth and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a Nance button
16295865|NCT04705519|Experimental|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel, Bevacizumab
16295866|NCT04705506|Experimental|Gemigliptin group|The participants will receive gemigliptin 50 mg daily
16295867|NCT04705506|Placebo Comparator|Control|The control received standard care of diabetes
16295868|NCT04705493||CASE GROUP|Lidco rapid examination and echo examination were done to septic shock patients then the passive leg raising test was done and fluid responder cases were given mini fluid challenge and fluid challenge
16295869|NCT04705480|Experimental|Pregabalin|
16295870|NCT04705480|Experimental|Gabapentin|
16295871|NCT04705480|Active Comparator|Neither Pregabalin nor Gabapentin|
16295872|NCT04705467|Other|Patients|Device: Gynecological brachytherapy requiring an Interstitial or ring and tandem insert involves insertion of the needle and applicators with no standard real-time image guidance. Occasionally 2-dimensional ultrasound is used, but it greatly limited by its flat nature, preventing a volumetric view of the needle pathways. Interstitial brachytherapy is done under general anesthesia. The trans-abdominal and trans-rectal standard 2D ultrasound that are used in some cases, will be expanded to 3D dimensional imaging through the use of an investigational device. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning.
16295873|NCT04705441|Experimental|SMART intervention|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions over 10-12 weeks. The intervention sessions are held over Zoom.
16295874|NCT04705441|No Intervention|Waitlist|Individuals randomized to WL will continue in their usual care. After they complete their 13-week and 6-month assessments, they will begin participating in the SMART program.
16295875|NCT04705428|Experimental|Group I: intervention group 1|Professional hygiene will be carried out with the application of fluoride varnish (Duraphat) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
16295876|NCT04705428|Experimental|Group II: intervention group 2|Professional hygiene will be carried out with the application of fluorine varnish (Tiefenfluoride) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
16295877|NCT04705428|Experimental|Group III: intervention group 3|Professional hygiene will be carried out with the application of fluorine varnish (Fluor Protector S) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
16295878|NCT04705415|Experimental|ANA001|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned treatment as a single oral dose (1000 mg, 2000 mg, or 3000 mg of ANA001) with a standardized light meal. Each capsule is 250 mg.
~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned treatment twice daily (BID) or thrice daily (TID) (total daily dose is to be determined following the completion of the SAD portion of the study and will not exceed 2000 mg ANA001) with a standardized light meal for 7 consecutive days. Each capsule is 250 mg."
16295879|NCT04705415|Placebo Comparator|Matching Placebo|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) as a single dose (4, 8, or 12 capsules) with a standardized light meal.
~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) dose twice daily (BID) or thrice daily (TID) with a standardized light meal."
16295880|NCT04705402|Experimental|Patients randomized to receive the treatment arm of mannitol.|The mannitol solution used in the hospital contain 18% mannitol in 500ml solution. An equivocal volume of 2.8 cc / kg body weight, which will be given intravenously with the use of an Ivac pump, infused for a duration of 15 minutes through an existing peripheral intravenous access catheter within 15-30 minutes prior to renal artery reperfusion
16295881|NCT04705402|Placebo Comparator|(Control arm) Study participants will receive a 0.9% saline solution|(Control arm) Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
16295882|NCT04705389|Other|Case group|Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).
16295883|NCT04705376|Active Comparator|Breg Polarcare|Patients within the Breg Polarcare treatment arm will use the Breg Polarcare device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Thermazone device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
16295884|NCT04705376|Experimental|Thermazone|Patients within the Thermazone treatment arm will use the Thermazone device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Breg Polarcare device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
16295885|NCT04705363|Experimental|Interaction with a VHA with voice|A virtual health assistant computer-generated doctor who will have a conversation with you.
16295886|NCT04705363|Active Comparator|Interaction with a VHA without voice|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
16295887|NCT04705350|Experimental|Zampilimab Cohorts|Participants will be randomized to receive predefined single doses of zampilimab.
16295888|NCT04705350|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo to maintain the blinding.
16295889|NCT04705337|Experimental|Levosimendan|administration of levosimendan
16295890|NCT04705337|Placebo Comparator|Placebo|administration of placebo
16295891|NCT04705324|Experimental|Operative Hysteroscopy|Hysteroscopic separation
16295892|NCT04705324|Active Comparator|Dilation and Curettage|Curettage separation
16295893|NCT04705311|Experimental|pain neuroscience education plus rotator cuff repair rehabilitation|
16295894|NCT04705311|Active Comparator|rotator cuff repair rehabilitation|
16295895|NCT04705298|Placebo Comparator|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
16295896|NCT04705298|Experimental|Prebiotic|Oligofructose-enriched inulin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
16295897|NCT04705285|Experimental|Erbium:Yag Laser|Patients allocated to the erbium:yag laser are going to undergo 2 sessions of vaginal laser, separated by one month each other.
16295898|NCT04705285|Active Comparator|Pelvic floor training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist.
16295899|NCT04705259|Active Comparator|ENGAGEMENT bundle|A multimodal bundle of interventions to optimise antibiotic prescribing in residential aged care facilities. The bundle includes education for nurses and general practitioners caring for residents, telehealth support and implementation of state-wide guidelines.
16295900|NCT04705259|Placebo Comparator|Usual care|Usual facility practices with regards to antibiotic prescribing and review
16295901|NCT04705246|Experimental|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
16295902|NCT04705233|Experimental|Sputum chart|Use of the 5 point sputum colour chart, adapted from Bronkotest® a self-management (SM) plan and rescue pack (RP) containing 5 days supply of antibiotic and steroid treatment
16295903|NCT04705233|No Intervention|Control|Use of the plan and rescue pack alone (best usual care)
16295935|NCT04704947|Experimental|nonselective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.
16295904|NCT04705220|Experimental|Nutritional Supplementation with Test Product|Subjects will receive 1 tablet of MERIVA® in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months. This treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
16295905|NCT04705220|Placebo Comparator|Control Group without Nutritional Supplementation|Subjects will receive 1 tablet of placebo in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months.
16295906|NCT04705207|Experimental|reflexology massage|foot reflexology massage
16295907|NCT04705207|Placebo Comparator|sham massage|traditional foot massage
16295908|NCT04705194||One stage resection|Patients that are selected for a single hepatectomy of 2 segments or more.
16295909|NCT04705194||Two stage resection|Patients that are selected for a two-stage resection, where the first stage consists of either PVE or ALPPS and the second stage is a hepatectomy of 2 or more segments.
16295910|NCT04705168||Participants displaying nevi|"Participants displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) > 5 mm in diameter. These patients have atypical mole syndrome, which is a high-risk nevus phenotype and the target patient population in this study."
16295911|NCT04705142|Experimental|MgSO4|"MgSO4
~1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.
~Monitoring and Protective measures:
~Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour."
16295912|NCT04705129|Experimental|zanubrutinib+Tislelizumab|Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
16295913|NCT04705116||Vaccinated pregnant women|Pregnant women exposed from 30 days prior to the first day of the LMP to end of pregnancy to at least one dose of a COVID-19 vaccine
16295914|NCT04705116||Non-vaccinated pregnant women|Pregnant women unexposed to a COVID-19 vaccine before enrollment and had a negative screening test for the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) during pregnancy.
16295915|NCT04705103||initial|
16295916|NCT04705103||relapse|
16295917|NCT04705103||inactive|
16295918|NCT04705090|Experimental|YY-20394 treatment|YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.
16295919|NCT04705077|Experimental|Single Dose Treatment|"Each subject will be assigned to the fixed period sequence.
~Period 1: SR419 suspension in the fasted state;
~Period 2: SR419 capsule in the fasted state;
~Period 3: SR419 capsule in the fed state (high-fat meal)."
16295920|NCT04705077|Experimental|Repeated Dose Treatment|Each subject will receive 30 mg of SR419 capsule, once every 8 hours (Q8h), for 5 days.
16295921|NCT04705064||AI_AKI|Adults patients undergoing non-cardiac surgery
16295922|NCT04705051|Experimental|Venglustat|Patients will receive venglustat once daily for 24 months
16295923|NCT04705038|Experimental|Educational Intervention|Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
16295924|NCT04705038|No Intervention|No Intervention|"Participants that decline the education session will continue with routine care of their cancer.
~They will also be asked to complete questionnaires."
16295925|NCT04705025|Experimental|Supportive care (BNT001 app, CBSM, interview)|Prior to participating in the study patients complete an online baseline questionnaire to assess anxiety and depression and general quality of life, as well as some specific questions related to their coping. They are also interviewed by a clinician who rates their level of anxiety and depression. After this, patients use the BNT001 app and undergo 10 sessions of CBSM over 45-60 minutes each consisting of cancer-specific educational videos, guided relaxation training, interactive exercises, and discussion modules. Following completion of the 5th session, patients undergo a telephone check-in assessment to see how things are going, update their treatments and medications, and schedule a phone call to assess for adverse events. At the end of the 10th session, patients complete a post-treatment online questionnaire and a phone debriefing interview to discuss their experience with the intervention.
16295926|NCT04705012|Experimental|Test - increased frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
16295927|NCT04705012|Active Comparator|Control - conventional frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
16295928|NCT04704999|Active Comparator|Low dose tafenoquine (5mg/kg) with a fixed weight dependent dose|"The doses are as follows;
~Weight range Low dose
~>21-25 kg 200 mg
~26-40 kg 200 mg
~41-50 kg 300 mg
~51-60 kg 400 mg
~61-80 kg 400 mg
~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
16295929|NCT04704999|Active Comparator|Medium dose tafenoquine (9mg/kg) with a fixed weight dependent dose|"The doses are as follows;
~Weight range Medium dose
~>21-25 kg 200 mg
~26-40 kg 300 mg
~41-50 kg 400 mg
~51-60 kg 500 mg
~61-80 kg 600 mg
~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
16295930|NCT04704999|Active Comparator|High dose tafenoquine (12.5mg/kg) with a fixed weight dependent dose|"The doses are as follows;
~Weight range High dose
~>21-25 kg 300 mg
~26-40 kg 400 mg
~41-50 kg 600 mg
~51-60 kg 600 mg
~61-80 kg 600 mg
~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
16295931|NCT04704986|Active Comparator|PVI using the Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
16295932|NCT04704986|Active Comparator|PVI using the PolarX Cryoballoon (Boston Scientific)|Pulmonary vein isolation using the PolarX Cryoballoon (Boston Scientific)
16295933|NCT04704973|Experimental|Transdiagnostic short-term psychotherapy|
16295934|NCT04704960||Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)|patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis
16295936|NCT04704947|Experimental|cardio-selective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.
16295937|NCT04704947|Placebo Comparator|Control group|Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.
16295938|NCT04704934|Experimental|Trastuzumab deruxtecan|Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.
16295939|NCT04704934|Active Comparator|Ramucirumab + paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
16295940|NCT04704921|Experimental|RGX-314 Dose 1|RGX-314 Dose 1 administered via subretinal delivery one time.
16295941|NCT04704921|Experimental|RGX-314 Dose 2|RGX-314 Dose 2 administered via subretinal delivery one time.
16295942|NCT04704921|Active Comparator|Control Arm|Ranibizumab administered via intravitreal injection approximately every 28 days
16295943|NCT04704908||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
16295944|NCT04704908||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
16295945|NCT04704908||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
16295946|NCT04704895|Active Comparator|Arm A: Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
16295947|NCT04704895|Experimental|Arm B: Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
16295948|NCT04704882|Experimental|omental patchwork group|
16295949|NCT04704882|No Intervention|non-omental patchwork group|
16295950|NCT04704869|Experimental|Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
16295951|NCT04704869|Active Comparator|Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
16295952|NCT04704856|Active Comparator|Interventiongroup|Interventiongroup, undergo supervised exercise for the first 6 weeks.
16295953|NCT04704856|No Intervention|Controlgroup|Controlgroup, do not undergo supervised exercise for the first 6 weeks (possibility to undergo supervised exercise after 6 weeks).
16295956|NCT04704830|Experimental|Standard Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 months olds
16295957|NCT04704830|Placebo Comparator|Standard Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 months olds
16295958|NCT04704830|Experimental|Seasonal Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 month olds
16295959|NCT04704830|Placebo Comparator|Seasonal Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 month olds
16295960|NCT04704804||Prostate cancer|Man with cancer and localized (non-metastatic) prostate cancer
16295961|NCT04704804||Brain cancer|Male or Female with a brain tumor (primitive)
16295962|NCT04704791|Experimental|Procedure arm|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
16295963|NCT04704778|Active Comparator|Transcutaneous|Transcutaneous electrostimulation and uso of oclusal splint
16295964|NCT04704778|Active Comparator|Percutaneous|Percutaneous electrostimulation and splint
16295965|NCT04704778|Placebo Comparator|Control|Oclusal splint
16295966|NCT04704765|Experimental|The effectiveness of receiving abdominal breathing training|The patients receiving the intervention of abdominal breathing training were in the experimental group. The experimental group received the abdominal breathing training for a total of 8 weeks. During this period, they received the abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time). The control group without training.
16295967|NCT04704765|No Intervention|The effectiveness of not receiving abdominal breathing training|The control group who did not receive abdominal breathing training. The effectiveness assessment used the Beck anxiety inventory and physiological index (heart beats, breath and blood pressure), required to be completed by the control group.
16295968|NCT04704739|Experimental|GLPG1205 oral and [14C]-GLPG1205 IV|Single oral dose of GLPG1205 followed by [14C]-GLPG1205 solution for infusion
16295969|NCT04704739|Experimental|[14C]-GLPG1205 capsule|Single oral dose of GLPG1205 as solid formulation
16295970|NCT04704713|Experimental|Afamelanotide|Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
16295971|NCT04704713|Placebo Comparator|Placebo|Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
16295972|NCT04704700|Active Comparator|patient with inspace device|
16295973|NCT04704700|Placebo Comparator|patient without inspace device|
16295974|NCT04704687|Experimental|tDCS|
16295975|NCT04704687|Active Comparator|Sham|
16295981|NCT04704648|Other|Surgical Excision|Treatment involves EXCISION ONLY (surgery) for the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP). Standard of care topical antibiotics are given for infection prevention following surgery. No drugs or device treatments are administered for treatment of OSSN in this protocol.
16295982|NCT04704635||Ischemic stroke/TIA|Patients with ischemic stroke or transient ischemic attack
16295983|NCT04704622|Active Comparator|dexmedetomidine group|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
16295984|NCT04704622|Active Comparator|ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
16295985|NCT04704622|Active Comparator|midazolam|midazolam intranasal injection,0.2 mg/kg, once, 30 min preoperative
16295986|NCT04704609||Imaging Analysis of patients with uveitis|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
16295987|NCT04704596|Active Comparator|dynamic lung compliance for detection of optimum PEEP|detection of optimum PEEP by measurement of the dynamic lung compliance (by the ventilator machine) after lung recruitment
16295988|NCT04704596|Active Comparator|Lung ultrasound for detection of the optimum PEEP|Lung ultrasound will be used to detect the optimum PEEP after lung recruitment
16295989|NCT04704583|Experimental|Treatment group (active)|Individuals in this group will start treatment after the initial assessment, without a delay.
16295990|NCT04704583|Active Comparator|Wait-list control group|Individuals in this group will start treatment after the initial assessment, with a delay of thirteen weeks.
16295991|NCT04704570|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
16295992|NCT04704570|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
16295993|NCT04704570|Other|Remotely assessment Group-Face to Face Assessment Group|First, a remote evaluation and then a face to face evaluation will be made.
16295994|NCT04704570|Other|Face to Face Assessment Group-Remotely assessment Group|First, a facet o face evaluation and then a remote evaluation will be made.
16295997|NCT04704531|Experimental|Group 1|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) BID in OU during 30 days.
16295998|NCT04704531|Experimental|Group 2|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
16295999|NCT04704531|Experimental|Group 3|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.
16296000|NCT04704518|Experimental|Group 1; Lagricel® Ofteno PF|Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
16296001|NCT04704518|Active Comparator|Group 2; Thealoz® Duo|Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
16296003|NCT04704492|Experimental|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0 , 2.
16296004|NCT04704479|Experimental|combined Russian and EMT|
16296005|NCT04704479|Experimental|EMT only|
16296006|NCT04704453|Experimental|Experimental arm (A): capsaicin patch|
16296007|NCT04704453|Other|Standard arm (B): amitriptyline|
16296008|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16296009|NCT04704440|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16296010|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16296011|NCT04704440|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16296012|NCT04704427|Experimental|Rehabilitative BCI training|The experimental group will receive brain computer interface-based lower limb function training (BCI-LLT), 30 minutes/time, 5 times/week, with a 4-week training period.. The training using the lower limb orthosis targeted the patient's ability to walk.
16296013|NCT04704427|Active Comparator|Traditional physical therapy protocol|The control group will only receive traditional physical therapy protocol. The traditional physical therapy protocol of lower limb conducted with the same treatment frequency, intensity and duration of treatment, including muscle strength training, balance training and walking training, etc.
16296014|NCT04704414|Experimental|Validation of smartphone face scanner|Validation of smartphone face scanner in comparison to Hertel Exophthalmometer and high-definition face scanner.
16296015|NCT04704401||Patients PWV follow-up|"Patients included in the meta-analysis sleep apnea syndrome and arterial stiffness and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire."
16296016|NCT04704388||patients hospitalized in intensive care units for SARS-CoV-2|patients hospitalized in intensive care units for SARS-CoV-2
16296017|NCT04704388||patients hospitalized outside intensive care units|patients hospitalized outside intensive care units
16296018|NCT04704375|Experimental|BEMER|Subjects in the BEMER group received treatment 5 times per week for a period of 3 weeks.
16296019|NCT04704375|Active Comparator|OMT|Each subject in the OMT group received treatment 3 times per week for a period of 3 weeks.
16296020|NCT04704375|Experimental|BEMER + OMT|Each subject in the BEMER + OMT group received treatment 3 times per week for a period of 3 weeks.
16296021|NCT04704375|Sham Comparator|Control|Finally, subjects in the Placebo group will receive the light touch and BEMER sham treatments at same intervals as the corresponding experimental groups.
16296022|NCT04704362|Active Comparator|Training and Supervision as Usual|Non-specialists are trained in a psychological intervention under standard conditions. No feedback from competency-based evaluations is provided to modify the training or supervision curriculum.
16296023|NCT04704362|Experimental|Competency-based Training and Supervision|Non-specialists are trained and supervised in a competency-based approach in which trainers and/or supervisors are provided with the competency scores of trainees in order to modify the training and supervision content and approach as needed.
16296024|NCT04704349|Experimental|Scintigraphy acquisitions|All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.
16296025|NCT04704336|No Intervention|Self-directed without Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and provided standard of care.
16296026|NCT04704336|Experimental|With Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.
16296027|NCT04704323||Experimental: Phase Ia - Dose escalation|Cohorts of 3 subjects will receive intravenous [IV] administrations of escalating doses of CAP-100.
16296028|NCT04704323||Experimental: Phase Ib - Dose expansion|Six subjects will receive intravenous [IV] administrations of CAP-100 at the Recommended Phase 2 Dose determined in Phase Ia - Dose Escalation of this trial.
16296029|NCT04704310|Experimental|Intervention Group|Individuals acting as own control. Looking at changes pre and post intervention
16296030|NCT04704297|Active Comparator|Standard Therapy (ST)|ST will consist of 975mg of Acetaminophen PO and either 30mg of Ketorolac IM or 15 mg IV. Upon discharge ST will consist of prescriptions for acetaminophen 650mg every 4 hours by mouth, Ibuprofen 400mg every 4 hours by mouth, and 10 mg of cyclobenzaprine nightly by mouth. Additionally, participants will be provided a handout going over these medications and the use of heat for low back pain and instructions on the performance of McKenzie stretching exercises for low back pain.4
16296031|NCT04704297|Active Comparator|ST plus Trigger Point Injections (TPI) with 8 mL of 0.5 percent Bupivacaine|ST plus TPI with 8 mL of 0.5 percent Bupivacaine
16296032|NCT04704297|Active Comparator|ST plus TPI with 8 mL of Normal Saline (NS)|ST plus TPI with 8 mL of Normal Saline
16296033|NCT04704284|Experimental|ZTE MRI Imaging|Pediatric patients that have gotten a clinically indicated CT within a 6 week time period will receive a Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)
16296034|NCT04704271|Active Comparator|Delta-9-Tetrahydrocannabinol (THC)|4 mg vaporized THC will be administered.
16296035|NCT04704271|Placebo Comparator|Placebo|Inhaled placebo (no active cannabinoids)
16296036|NCT04704258|Experimental|TAVI + Embolic protection|Subjects with severe native aortic valve stenosis who meet the clinically approved indications for aortic valve interventions such as TAVI
16296037|NCT04704245|Experimental|epidermal growth factor (EGF) containing ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment.
~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.
~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
16296038|NCT04704245|Placebo Comparator|Vehicle ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.
~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.
~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
16296039|NCT04704232|Active Comparator|ACD440|
16296040|NCT04704232|Placebo Comparator|Placebo|
16296041|NCT04704219|Experimental|Pembrolizumab + Lenvatinib|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
16296042|NCT04704206|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
16296043|NCT04704206|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
16296044|NCT04704193|Experimental|Electronic Decision Aid|Participants in this arm will complete an electronic decision aid for genetic testing.
16296045|NCT04704180|Experimental|Experimental Group: Facilitation Tuchking Group|The experimental group neonates received facilitated tucking under the radiant heater after birth of the NICU as well as the routine interventions.
16296046|NCT04704180|No Intervention|Control Group|The control group underwent the routine interventions of the observation unit of the NICU. The group did not receive any other intervention
16296047|NCT04704167|Active Comparator|3D titanium mesh tray|3D titanium mesh tray as a method of fixation for double-barrel vascularized fibula
16296048|NCT04704167|Experimental|3D titanium miniplate|3D titanium miniplate as a method of fixation for double-barrel vascularized fibula
16296050|NCT04704141||Infertile men with leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
16296051|NCT04704141||Infertile men without leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
16296052|NCT04704141||Infertile men with hypogonadism|Standard fertility evaluation and treatments, including hormone replacement therapy such as with clomiphene citrate
16296053|NCT04704128||Case group|women with primary stomatodynia
16296054|NCT04704128||Control group|women without oral disease
16296055|NCT04704102|Experimental|Muscle energy technique group|Use one of the muscle energy technique methods -- postisometric relaxation technique(PIR) as the intervention method.
16296056|NCT04704102|Experimental|Strain-counterstrain group|Use the Strain-counterstrain technique as the intervention method.
16296057|NCT04704102|Sham Comparator|Control group|Use the modified Strain-counterstrain technique as the intervention method.
16296058|NCT04704089||spectrophotometer, and numerical values of tooth color in the populations studied|at the first visit Shooting with Spectrophotometer and at the second visit for all patients except control population: Tooth extraction or restorative treatment Collection of teeth or enamel debris for analysis
16296059|NCT04704076|Experimental|Early, Small-Volume Supplementation (ESVS)|Breastfeeding with up to 59 mL formula daily until 30 days of age, followed by recommendation to breastfeed exclusively through 6 months of age
16296060|NCT04704076|Active Comparator|Exclusive Breastfeeding|Recommendation to breastfeed exclusively for 6 months without any other food or fluid except vitamins, minerals and medications
16296061|NCT04704063|Active Comparator|Active|Tocovid Suprabio 200mg
16296062|NCT04704063|Placebo Comparator|Placebo|Placebo
16296063|NCT04704050|Active Comparator|Treatment Group|Dronedarone 400 mg orally, twice per day (BID)
16296064|NCT04704050|Placebo Comparator|Control Group|Placebo tablet orally, twice per day (BID)
16296065|NCT04704037|Active Comparator|Arm 1: Minimally enhanced usual care|See intervention/treatment description
16296066|NCT04704037|Experimental|Arm 2: Guideline implementation tool|See intervention/treatment description
16296067|NCT04704024|Experimental|Pregnant Women - Tenofovir|Women will be randomized to early initiation (enrollment at 14-28 weeks pregnant) vs standard initiation (at 28 weeks pregnant) of tenofovir disoproxil fumarate (TDF) 300 mg daily oral medication until delivery.
16296068|NCT04704024|Placebo Comparator|Newborn Infants - Lamivudine|Infants exposed to HBV at birth will be randomized to receive oral lamivudine post-exposure prophylaxis or matching placebo. Medication will be administered twice daily for 6 months.
16296069|NCT04704011|Experimental|Arm 1: Basic Needs Assessment|-Patients will receive a phone call from a research team member 2-4 weeks before their colposcopy appointment. The team member will remind the patient of the date and time of their appointment and conduct a basic needs assessment. Those who have at least one unmet basic need or are unsure of their current needs will be referred to the 24-hr assistance hotline, 2-1-1 United Healthy Way Missouri. After the date of their appointment, patients will be contacted to ask whether they contacted 2-1-1 and used any recommended services.
16296070|NCT04704011|Active Comparator|Arm 2: Usual Care Cohort|-Patients will receive an automated phone call two weeks before their colposcopy appointment to remind them of the date and time of their visit.
16296071|NCT04703998|Experimental|Arthroscopic rotator cuff repair and platelet rich plasma|A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.
16296072|NCT04703998|Active Comparator|Arthroscopic rotator cuff repair|A standard double-row arthroscopic rotator cuff repair will be performed.
16296073|NCT04703985||Patients under the protocol of Enteral Nutrition|Patients put under the protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
16296074|NCT04703972|Experimental|Bipolar Patients with connected devices|Patients with bipolar disorder provided with connected devices (wristwatch and wristband)
16296075|NCT04703959||glaucomatous subjects (50)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:
~increase in intraocular pressure (IOP before treatment greater than 21 mmHg) with characteristic alterations of the optic nerve (pathological papillary excavation, papillary pallor, papillary atrophy) with corresponding alterations and characteristics of the visual field. The visual field should be considered reliable (European criteria (European Glaucoma Society, 1999).
~Patients whose age is greater than or equal to 18 years
~Male or female patients
~Patients not objecting to the study
~Affiliation to a social security scheme or beneficiary of such a scheme"
16296076|NCT04703959||non glaucomatous subjects (100)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:
~no known ophthalmological pathologies, with an ophthalmological examination on telephone examination - in the 2 years preceding the polysomnographic examination - normal apart from minor refractive disorders (myopia with spherical equivalent less than -6 diopters or hyperopia with spherical equivalent less than 3 diopters).
~Patients whose age is greater than or equal to 18 years
~Male or female patients
~Patients not objecting to the study
~Affiliation to a social security scheme or beneficiary of such a scheme"
16296077|NCT04703920|Experimental|Talozoparib in combination with Belinostat|Patients will receive Talozoparib in combination with Belinostat
16296078|NCT04703907|Experimental|Intervention group|This group is constituted from patients who will receive the intervention first within 15 weeks
16296079|NCT04703907|No Intervention|Waiting list|This group is constituted from patients who will receive the intervention after 15 weeks
16296080|NCT04703894|Experimental|AYMES 'CARDIFF'|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'CARDIFF' for a period of 30 days.
16296140|NCT04703374|Experimental|B|Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)
16296081|NCT04703881|Experimental|AYMES ActaGain|Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.
16296082|NCT04703868|Experimental|YPI-011 10/500mg|Part A: 1 tablet administered before the breakfast during 7 days
16296083|NCT04703868|Experimental|YPI-011 20/500mg|Part B: 1 tablet administered before the breakfast during 7 days
16296084|NCT04703855|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
16296085|NCT04703842|Experimental|SRD-001|3E13 vg; one-time intracoronary infusion
16296086|NCT04703842|Placebo Comparator|Placebo|One-time intracoronary infusion
16296087|NCT04703816|Experimental|Intervention arm|Physicians in the intervention arm will receive the training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations.
16296088|NCT04703816|No Intervention|Control arm|Physicians in the control group will not receive any specific intervention at this stage.
16296089|NCT04703803|Experimental|1% lidocaine injection|The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
16296090|NCT04703803|No Intervention|Control Group|The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.
16296091|NCT04703790||Adults from the United States|Adult participants 18 years of age or older who are panelists recruited and maintained by Ipsos (KnoweledgePanel). All participants live within the United States.
16296092|NCT04703764|Experimental|480mg Test group|
16296093|NCT04703764|Placebo Comparator|480mg Placebo group|
16296094|NCT04703764|Experimental|720mg Test group|
16296095|NCT04703764|Placebo Comparator|720mg Placebo group|
16296096|NCT04703751|Experimental|CIRCULATE Catheter|CIRCULATE Catheter will be used to deliver nitroglycerin and CardioCell to evaluate safety and efficacy of the device
16296097|NCT04703738|Active Comparator|Control|Soft tissue flap + Connective Tissue Graft
16296098|NCT04703738|Experimental|Test|Soft tissue flap + Geistlich Fibro-Gide®
16296099|NCT04703725|Experimental|Experimental Group|Infertile women recruited to the experimental group by randomization will be given a counseling program including psychosocial care in addition to routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care). IVF treatment
16296100|NCT04703725|No Intervention|Control Group|Routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care) IVF treatment will be applied to infertile women who are randomized to the control group.
16296101|NCT04703712|Active Comparator|Lens extraction combined with goniosynechialysis group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent phacoemulsification combined with goniosynechialysis.
16296102|NCT04703712|Active Comparator|Trabeculectomy Group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent trabeculectomy.
16296103|NCT04703686|Experimental|Obinutuzumab + RO7082859|
16296104|NCT04703673||Sinolpan® group|Sinolpan® group: patients suffering from rhinosinusitis and, where appropriate, from bronchitis; intake of Sinolpan® 100 mg or Sinolpan® forte 200 mg (cineol) according to the instructions for use; before and after treatment for rhinosinusitis and, where appropriate, from bronchitis, patients complete a questionnaire that contains the Rhinosinusitis Quality of Life questionnaire and Questions about the severity of bronchitis symptoms. The latter should only be answered by patients who suffer from bronchitis in addition to rhinosinusitis.
16296105|NCT04703673||Nasal spray group|Control group: patients with rhinosinusitis; Use of nasal decongestants according to the instructions for use. Before and after treatment for rhinosinusitis, patients complete a questionnaire that includes the Rhinosinusitis Quality of Life questionnaire.
16296106|NCT04703660|Active Comparator|group A|This group will receive antero-posterior cervical mobilization at c5-6 grade III oscillation
16296107|NCT04703660|Active Comparator|group B|This group will receive lateral glide cervical mobilization at c5-6 grade III oscillation
16296108|NCT04703660|Active Comparator|group C|This group will receive postero-anterior cervical mobilization at c5-6 grade III oscillation
16296109|NCT04703647||Patients with CRPS type 1: prospective group|"Ambulatory patients of the Clinique romande de réadaptation (CRR) which have a CRPS type 1 of a limb.
~Five measurement times (first visit (T0) and then after 3 (T1), 6 (T2), 12 (T3) and 24 (T4) months). At every time point, following data will be collected: physical examination, monitoring of the health and professional status with the physician, and self-administrated questionnaires. Blood sampling will be performed at T0, T1,T2 and T3.
~Eight different self-administrated questionnaires will be used, in their French or Portuguese version. Each participants will answer seven questionnaires each time, depending if he/she suffers of arm or leg injury.
~We will assess, in blood samples, the expression levels of specific molecules (miRNAs and a selection of cytokines) in patients diagnosed with acute CRPS. In a second time, miRNAs and cytokines profiles will be compared between acute and chronic (CRPS still diagnosed 6 months after the first diagnosis) CRPS patients."
16296110|NCT04703647||control group for blood analysis|"For the blood analysis, we will recruit 30 healthy controls who did not report any kind of pain. They will be recruited via posters that will be posted on the billboards of the Hôpital de Sion (employees and visitors) and on the visitor's billboards of the CRR. If this is not enough, we will expand the recruitment perimeter with other locations. The healthy control will be adjusted for age, sex and BMI with the CRPS groups. They will be informed about the study and procedure. The procedure for the blood samples will be the same as for patients.The screening for miRNAs of interest will be performed using a decision tree-based ensemble method (Random Forest). For this step, miRNAs profile of 30 control patients will be compared to the same number of CRPS patients.
~The control group will have just one blood analysis."
16296141|NCT04703374|Experimental|C|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)
16296142|NCT04703374|Experimental|D|Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)
16296143|NCT04703374|Experimental|E|Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)
16296111|NCT04703634|Experimental|erector spinae group|All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.
16296112|NCT04703634|Placebo Comparator|placebo group|No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.
16296113|NCT04703621|Experimental|Intervention ( safety run-in, cohort 1, cohort 2)|"Safety run-in( 3 patients): daratumumab once a week x 4 doses. If no worsening of thrombocytopenia can be attributed to study treatment or any other life-threatening events, the study will proceed to the main part.
~Cohort 1 ( 9 patients): daratumumab once a week x 8 doses
~If response is <100%:
~Cohort 2 ( 9 patients): daratumumab once a week x 8 doses followed by daratumumab every 2 weeks x 2 doses"
16296114|NCT04703608|Experimental|Arm 1 of Cohort 1|Index Case / Household members Ivermectin / Ivermectin (with preventative package)
16296115|NCT04703608|Experimental|Arm 2 of Cohort 1|Index Case / Household members Ivermectin / Placebo (with preventative package)
16296116|NCT04703608|Placebo Comparator|Arm 3 of Cohort 1|Index Case / Household members Placebo / Placebo (with preventative package)
16296117|NCT04703608|Experimental|Arm 1 of Cohort 2|Aspirin 150mg daily for 28 days or until hospital discharge or death (whichever is sooner)
16296118|NCT04703608|Placebo Comparator|Arm 2 of Cohort 2|Non identical placebo; doses as per above
16296119|NCT04703595||50 non-smoking patients with chronic cough|50 non-smoking patients aged between 30 and 99 years with chronic and / or refractory cough as the only manifestation or associated with gastroesophageal reflux
16296120|NCT04703569|Experimental|Monolayer high compression elastic bandage|An elastic bandage of cotton, viscose, nylon and elastane
16296121|NCT04703569|Active Comparator|Unna boot|A wet bandage with zinc oxide
16296122|NCT04703530|Experimental|Hot footbath effect on schizophrenia patient' sleep quality|Participants were randomly allocated to the experimental group. The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep, and this was repeated five times a week for four weeks. The CPSQI was used to collect the pre- and post-test data.
16296123|NCT04703530|No Intervention|Routine care on schizophrenia patient' sleep quality|Participants were randomly allocated to the control group. They were given routine care for four weeks. The CPSQI was used to collect the pre- and post-test data.
16296124|NCT04703517|Other|Self Controlled|Patients will active as their own comparator
16296125|NCT04703504|Experimental|multi-intervention|"Automatic creation of discharge prescription (personalized checklist of possible therapeutic optimizations generated from clinical data entered into the platform. This checklist will comply with the recommendations on altered left ventricular ejection fraction from European Society of Cardiology 2016.
~Automatic creation of documents for patient:
~Reminder letter to make an appointment with his general practitioner (at 7 days) and cardiologist (1 month) and to report the prescribed blood test.
~Drug prescription.
~Prescription for blood tests (5 days and 25 days before seeing the general practitioner and cardiologist).
~Therapeutic education documents
~Patients will receive numerous messages (SMS / e-mail) in order to 1 / not forget their medical appointments, 2 / not to forget to make and bring back their blood test for the consultation, 3 / to perfect the therapeutic education advice provided previously"
16296126|NCT04703504|No Intervention|Control|Discharge prescription according to the investigator's habits.
16296127|NCT04703491|Experimental|Full intervention|This group receives the full-featured intervention, including CCBT, CBM, Mindfulness, chatbot with many interactive elements.
16296128|NCT04703491|Active Comparator|Limited CCBT control group|This group receives feature-limited intervention (text-based computerized CBT)
16296129|NCT04703491|Other|Waitlist control group|This group receives waitlist control.
16296130|NCT04703478|Experimental|Single group|Implementation of a mobile application for the rehabilitation of patients with respiratory sequelae of COVID-19
16296131|NCT04703465|Experimental|tenofovir alafenamide|tenofovir alafenamide 25mg daily for 48 weeks
16296132|NCT04703452||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test at least 6 months before inclusion in the study.
16296133|NCT04703439|Experimental|Experimental group|This group consisted of 116 participants who received a medication-taking reminder every morning at a random time between 7-8 am on WeChat app. Also, participants received a piece of educational material every five days at a random time between 8 am and 9 am regarding improving medication adherence and preventing coronary heart disease.
16296134|NCT04703439|Placebo Comparator|Control group|This group consisted of 114 participants who only received a piece of educational material every five days at a random time between 8 am and 9 am. The educational materials sent to this group were general medical information, which were not specifically about improving medication adherence or preventing coronary heart disease.
16296135|NCT04703426|Experimental|Sargramostim (GM-CSF) + Pembrolizumab (anti-PD-1)|"Participants will receive 12 weeks of sargramostim (GM-CSF) and pembrolizumab (anti-PD-1). Participants may be pre-medicated with drugs to reduce the chance of having a sensitivity reaction to the study treatment of pembrolizumab (anti-PD-1) and sargramostim (GM-CSF).
~Study cycles are 21 days in length:
~Pembrolizumab (anti-PD-1) will be given by intravenous infusion once on day 1 of every 21 day cycle
~Sargramostim (GM-CSF) will be self-administered by participants via a subcutaneous (below the skin) injection daily for days 1 - 14 of each 21- day cycle.
~Participants will be assessed at 12 weeks for disease response/progression and further study treatment."
16296136|NCT04703413|Experimental|LoFric® OrigoTM or LoFric® SenseTM|Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).
16296137|NCT04703387||Postextubation Success|
16296138|NCT04703387||Postextubation Distress|
16296139|NCT04703374|Experimental|A|Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)
16296206|NCT04702841|Experimental|CAR-γδT|Infusion,iv,0.2-5 ×10^6/ kg,once.
16296144|NCT04703374|Experimental|F|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)
16296145|NCT04703361|Experimental|Niacin|12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.
16296146|NCT04703361|Experimental|Na-3-OHB|"12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.
~All patients will receive Aspirin before intervention and randomization."
16296147|NCT04703348|Other|Healthy patients|Healthy patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
16296148|NCT04703348|Other|Complex regional pain syndrome patients|Complex regional pain syndrome patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
16296149|NCT04703348|Other|Musculoskelettal disorders patients|Musculoskelettal disorders patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
16296150|NCT04703335|Experimental|Non-inferiority and Persistence|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution).
16296151|NCT04703322|Experimental|Pexidartinib|Participants with TGCT who will receive oral pexidartinib 800 mg (400 mg twice daily [BID]).
16296152|NCT04703296|Experimental|MBAT group|Participants in the Mindfulness-Based Attention Training (MBAT) group will receive 4 weeks of the MBAT course.
16296153|NCT04703296|No Intervention|NTC group|Participants in the no-training control (NTC) group will not receive any intervention.
16296154|NCT04703283|Experimental|Lifestyle Medicine Group|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
16296155|NCT04703283|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
16296156|NCT04703270||Exposed|Expectant mothers with a positive nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation regardless of antibody status.
16296157|NCT04703270||Seropositive|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation but positive IgM/IgG antibodies against SARS-CoV-2.
16296158|NCT04703270||Unexposed|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation and negative IgM/IgG antibodies against SARS-CoV-2.
16296159|NCT04703257|Placebo Comparator|Control group|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
16296160|NCT04703257|Active Comparator|Intervention group|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
16296161|NCT04703231||Natural menopause(Control group)|Female patients between 45-60 years of age diagnosed with menopause without any intervention
16296162|NCT04703231||Surgical Menopause (Case group)|Female patients aged 45-60 years included in the study 3 months after bilateral oophorectomy and hysterectomy
16296163|NCT04703218|Experimental|Patients with stroke and olfaction disorder benefiting from specific olfaction training.|
16296164|NCT04703218|No Intervention|Patients with stroke and olfactory disorder benefiting from standard post-stroke rehabilitation|
16296170|NCT04703140|Experimental|nasopharyngeal swabs|One patient will have 2 nasopharyngeal for PCR and COVIDISC
16296171|NCT04703127|Active Comparator|Patients with lifelong premature ejaculation and non-responding to dapoxetine alone|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
16296172|NCT04703127|Active Comparator|Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
16296173|NCT04703114|Experimental|Symptomatic|40 symptomatic patients to COVID-19 infection
16296174|NCT04703114|Experimental|Asymptomatic|40 asymptomatic patients to COVID-19 infection
16296207|NCT04702828||Fallers group|1.60 years to 99 years old 2. have a recent fall within two months 3.can understand and answer the questions 4.can give their informed consent
16296208|NCT04702828||Non-fallers group|1.60 years to 99 years old 2. have any fall experiences in past year 3.can understand and answer the question 4.can give their informed consent
16296233|NCT04702685|Placebo Comparator|Placebo|No injection. Bandage will be placed over the presumed site of injection
16356438|NCT04283201|Experimental|Physical activity|
16296175|NCT04703101|Experimental|Treatment (IMRT, mFOLFOX6, CapeOX, TME)|Patients undergo SCRT in the form of IMRT over 5 fractions daily for 5 consecutive days. Beginning 11-18 days after the last day of radiation therapy, patients receive either oxaliplatin IV and leucovorin IV on day 1 and fluorouracil IV on days 1-3 (mFOLFOX6) or oxaliplatin IV on day 1 and capecitabine PO BID on days 1-14 (CapeOX). Treatment with mFOLFOX6 repeats every 2 weeks for up to 8 cycles, and treatment with CapeOX repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. At 8-12 weeks after completion of all therapy, patients with residual tumor undergo TME. Patients with cCR undergo NOM.
16296176|NCT04703088|Experimental|INTERVENTION GROUP - ONDANSETRON|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
16296177|NCT04703088|Placebo Comparator|CONTROL GROUP - NORMAL SALINE|2 mL of 0.9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
16296178|NCT04703075|Experimental|Rifapentine 600 mg and Isoniazid 300 mg|Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.
16296179|NCT04703075|Active Comparator|Rifapentine 900 mg and Isoniazid 900 mg|Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.
16296180|NCT04703062|Experimental|Experimental group 1|physical activity counseling group + exercise group
16296181|NCT04703062|Experimental|Experimental group 2|physical activity counseling group
16296182|NCT04703036|Experimental|Active arm|The active supplements are glycine and N-acetylcysteine
16296183|NCT04703036|Placebo Comparator|Placebo arm|The placebo arm is alanine
16296184|NCT04703023||COPD|Secretions are collected from Bronchoscopy in clinical routine in COPD patients
16296185|NCT04703023||lung healthy|Secretions are collected from Removal of endotracheal tubes after elective surgery in lung healthy patients
16296186|NCT04703010|Experimental|All participants|All participants undergo the same measurements (longitudinal design)
16296187|NCT04702997|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline urine albumin to creatinine ratio (UACR) less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.
~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.
~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
16296188|NCT04702997|Experimental|Maximum bardoxolone methyl dose of 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline urine albumin to creatinine ratio (UACR) greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4, and 30 mg at Week 6.
~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.
~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
16296189|NCT04702997|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.
~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.
~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
16296190|NCT04702971|Experimental|patients with migraine|patient with migraine will be prescribed with flunarizine or routine clinical care per clinician's decision based on the condition of each individual patient
16296191|NCT04702971|Other|healthy control|healthy control
16296192|NCT04702958||Torsemide|Patients enrolled in the TRANSFORM-HF study randomized to Torsemide
16296193|NCT04702958||Furosemide|Patients enrolled in the TRANSFORM-HF study randomized to Furosemide
16296194|NCT04702945||Registry participants|Patients presenting to participating emergency departments with suspected and or confirmed COVID-19.
16296195|NCT04702932||Patient with Monoclonal gammopathies of inflammatory significance|This group of patient will present a monoclonal gammopathy associated with inflammatory symptoms without known origin.
16296196|NCT04702932||Control group|The Control group will be healthy subject and patients with monoclonal gammopathies without inflammatory symptoms.
16296197|NCT04702919||Healthy volunteers|
16296198|NCT04702906|Active Comparator|control group|All patients will continue to receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation, and antiarrhythmic agents if indicated.
16296199|NCT04702906|Active Comparator|trimetazidine group|"The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride metacardia ® (20 mg three times daily produced by Pharco-Egypt) will be administered twice every 24 hours until at least treatment is no longer needed."
16296201|NCT04702880|Experimental|Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012|
16296202|NCT04702880|Experimental|Arm B: Carboplatin + Etoposide + Nivolumab|
16296203|NCT04702867||Periodontal bone loss group|The cases with level of alveolar crest more than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
16296204|NCT04702867||Healthy group|The cases with level of alveolar crest equal to or less than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
16296205|NCT04702854|Experimental|Experimental|Measure of cutaneous melanomas by ultrasound biomicroscopy
16296209|NCT04702802|Experimental|Arm 1; PRO-149|Viscoelastic substance PRO-149 (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
16296210|NCT04702802|Active Comparator|Arm 2; Healon® EndoCoat|Viscoelastic substance Healon® EndoCoat (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
16296211|NCT04702789|Experimental|Arm 1; Dorzolamide-timolol-brimonidine and latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
16296212|NCT04702789|Experimental|Arm 2; Dorzolamide-timolol and latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
16296213|NCT04702776|Experimental|Arm 1; Humylub Ofteno® PF|Humylub Ofteno® PF (sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) ophthalmic solution applied QID for 30 days.
16296214|NCT04702776|Active Comparator|Arm 2; Hyabak®|Hyabak® PF (sodium hyaluronate 0.15%) ophthalmic solution applied QID for 30 days.
16296215|NCT04702776|Active Comparator|Arm 3; Lagricel Ofteno® PF|Lagricel Ofteno® PF (sodium hyaluronate 0.4%) ophthalmic solution applied QID for 30 days.
16296216|NCT04702763||Multiple Sclerosis (Eye-Tracker®T2 + e-VOG)|Multiple Sclerosis subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
16296217|NCT04702763||Multiple Sclerosis (e-VOG + Eye-Tracker®T2)|Multiple Sclerosis subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
16296219|NCT04702737|Experimental|Part 1: Dose Exploration|The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
16296220|NCT04702737|Experimental|Part 2: Dose Expansion|Participants will received the recommended phase 2 dose (RP2D) identified in Part 1 (dose exploration) of the study.
16296222|NCT04702711||Patients with symptoms of generalized anxiety in primary health care|Patients (18 years or older) with symptoms of generalized anxiety at a primary health care center.
16296223|NCT04702711||Health care professionals|Health care professionals working with patients with symptoms of generalized anxiety in a primary health care center.
16296224|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence A-B-C|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
16296225|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence A-C-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
16296226|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-A-C|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
16296227|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-C-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
16296228|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence C-A-B|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
16296229|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence C-B-A|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
16296230|NCT04702698|Experimental|Part 2: Peposertib Treatment Sequence A-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2. There will be washout period of 7 days between each treatment period.
16296231|NCT04702698|Experimental|Part 2: Peposertib: Treatment Sequence B-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2. There will be washout period of 7 days between each treatment period.
16296232|NCT04702685|Experimental|Ropivacaine|Ropivacaine 0.5% - 20 ml will be administered as erector spinae plane block under ultrasound guidance
16356594|NCT04282096|Experimental|Caseine micellar|
16296234|NCT04702672|Experimental|Type 2 diabetes|Adults with T2D. Hemoglobin A1C between 48-78 mmol/l. No use of insulin or once-weekly glucagon-like peptide-1 (GLP-1) or acarbose. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
16296235|NCT04702672|Experimental|Non-diabetics|Adults without T2D. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
16296236|NCT04702646||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
16296237|NCT04702633||Confirmed diagnosis group|Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
16296238|NCT04702633||Pre-diagnosis group|Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
16296239|NCT04702620||healthy children without symptoms|healthy children without symptoms
16296240|NCT04702620||sick children without wheezing|sick children without respiratory wheezing
16296241|NCT04702620||sick children with respiratory wheezing|
16296242|NCT04702607||contrast enhanced 4DCT|
16296243|NCT04702594|Experimental|UHR and SRH|All patients over the age of 60 present in the UHR and hospitalized in SRH with behavioral disorders in the context of a neurocognitive disorder
16296244|NCT04702581|Experimental|PCV alone|Administration of 6 cycles of PCV chemotherapy alone.
16296245|NCT04702581|Active Comparator|RT + PCV|Radiotherapy followed by administration of PCV chemotherapy.
16296246|NCT04702568|Experimental|BCX9930|Intervention: Drug: BCX9930
16296247|NCT04702555||Vitalis Pharmaceuticals (VTS)-Aspirin and Ketamine|An oral combination drug of VTS-Aspirin and ketamine (VTS-K) would facilitate the shift from IV opioids to a non-IV therapy for patients presenting to the ED with acute MSK pain. This formulation has a potential to provide effective analgesia in the ED with reduced side effects. VTS-K's proprietary oral formulation of established, safe, and well-understood APIs, makes it uniquely appropriate for use in the ED. VTS-K is administered orally, which is suitable for resource-poor environments in which the healthcare setting may be inadequate as well as suitable to improve the throughput of ED Patients by reducing their length of stay. This is especially pertinent given the alternative of IV opioids for pain management of acute MSK pain, which requires both clinical monitoring and equipment, whereas VTS-K promotes weaning off opioids, alleviating the resource consumption.
16296248|NCT04702542|Experimental|Enteral oxygen therapy for the improvement of children with chronic gastroduodenal pathology.|Enteral oxygen therapy is prescribed for children with chronic gastroduodenal pathology during the recovery period, after inpatient treatment, for 14 days, every day, in the form of an oxygen cocktail. An oxygen cocktail is prepared on the basis of a pharmaceutical product using herbal ingredients. The patient takes a 200 ml oxygen cocktail. using a small spoon, during the daytime.
16296249|NCT04702529|Experimental|Three treatments to hypertrophic scar with RAP device|RAP treatments will be administered to the scar every +/- 2 weeks for a total of 3 treatments
16296250|NCT04702516|Experimental|Semaglutide|Ozempic 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
16296251|NCT04702516|Placebo Comparator|Placebo|Placebo (saline) 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
16296252|NCT04702503|Experimental|10% WP1220 ointment|10% WP1220 ointment topically applied 2x day for 84 days
16296253|NCT04702490|Experimental|MET409 A|MET409 Active (50mg)
16296254|NCT04702490|Placebo Comparator|MET409 P|MET409 Placebo (50mg)
16296255|NCT04702490|Experimental|MET409A +Open-Label Empagliflozin|MET409 Active (50mg) + Empagliflozin (10mg)
16296256|NCT04702490|Placebo Comparator|MET409P +Open-Label Empagliflozin|MET409 Placebo (50mg) + Empagliflozin (10mg)
16296257|NCT04702477|Experimental|Only Arm|This is a single-arm, paired-sample pilot intervention study among participants with pre-diabetes or diabetes. Goal to integrate a MBSR intervention into a group-based, lifestyle intervention among patients with prediabetes or diabetes in the primary care setting
16296258|NCT04702464|Experimental|Treatment Administration|"Day 1: Single dose of 100 mg fedratinib
~Days 10 to 23, inclusive: Single dose of 400 mg fluconazole on Day 10 and once daily (QD) doses of 200 mg fluconazole on Days 11 to 23, inclusive
~Day 18: Single dose of 100 mg fedratinib coadministered with the 200-mg fluconazole dose."
16296259|NCT04702451|Experimental|Tailored|Tailored ablation strategy
16296260|NCT04702451|Active Comparator|Anatomical|Anatomical ablation strategy
16296267|NCT04702412|Experimental|Opal patient portal|Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.
16297147|NCT04696419|Other|ANIMAL CONTACT 1|Only one arm - within-subject design
16296268|NCT04702399|Experimental|GEL GROUP|Intracavitary application of an anti-adhesion hyaluronic acid gel (HYALOBARRIER® GEL ENDO)
16296269|NCT04702399|No Intervention|CONTROL GROUP|No Intervention
16296270|NCT04702386||Focus groups|Children aged 8 years or more participating in a focus group with the study psychologist
16296271|NCT04702386||Individual interviews|All children who have an individual interview with the study psychologist
16296272|NCT04702373|Experimental|Passive range-of-motion|daily assisted exercise sessions lasting 15-20 minutes, conducted by trained physical therapists, for up to 21 days prior to hospital discharge, plus standard of care
16296273|NCT04702373|No Intervention|Standard of care|standard of care at study site
16296274|NCT04702334|Experimental|Hyaluronic acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel . This adjunctive treatment was performed at baseline and at the 3 months control.
16296275|NCT04702334|Placebo Comparator|Lidocaine|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic. This adjunctive treatment was performed at baseline and at the 3 months control.
16296276|NCT04702321||Patient cohort|Patients with clinical data and biospecimens
16296277|NCT04702308|Experimental|Intervention Group|The intervention will contain two components: 1) a non-interruptive best practice advisory (BPA) in the Epic Storyboard and 2) a default suggested calculator tab in the MDCalc Connect app. Six clinical decision rules will be included: Canadian CT Head Rule, Canadian C-spine Rule, HEART Score, PERC Rule, Wells' PE Criteria and Wells' DVT Criteria. Predefined criteria based on chief complaint, patient age and vital signs will be used to determine when a decision rule may be relevant in a patient encounter. When a patient meets all of the predefined criteria, the intervention will be triggered.
16296278|NCT04702308|No Intervention|Control Group|The control group will be usual care. Specifically, providers in the control group will not receive the clinical decision rule alert or the default suggested calculator tab in the MDCalc Connect app. The control group providers will have access to the MDCalc Connect app in its standard form and functionality.
16296279|NCT04702282||unilateral Total knee arthroplasty|Patients receiving unilateral Total knee arthroplasty
16296280|NCT04702282||simultaneous bilateral Total knee arthroplasty|Patients receiving simultaneous bilateral Total knee arthroplasty y
16296281|NCT04702256|Experimental|Obinutuzumab arm|Obinutuzumab administration plus oral mycophenolate mofetil (MMF)
16296282|NCT04702256|Active Comparator|Corticosteroids arm|Oral corticosteroids plus MMF
16296283|NCT04702243||Affected Participants|Subjects who have suppurative lung disease without a known genetic diagnosis
16296284|NCT04702243||Unaffected Family Members|Unaffected family members may be enrolled in the study for collection of DNA only
16296285|NCT04702230||post-TAE|
16296286|NCT04702230||post-TARE|
16296287|NCT04702217|Experimental|POTS patients|All POTS patients in the study will perform a 16 week-training program. The present study will be using longitudinal comparisons, meaning that the 100 POTS patients are their own controls. The questionnaires and exercise capacity will be compared before and after the 16-weeks training program.
16296288|NCT04702191|Experimental|Triple P (Positive Parenting Program)|Triple P - level 4 group: All 600 participants will undergo screening and a baseline assessment before randomization. Once randomized, the Triple P group (n=200) will be provided with 8-week group/individual sessions.
16296289|NCT04702191|Experimental|Circle of Security Parenting|Circle of Security - Parenting (COS-P): Once randomized to the COSP group (n=200), caregivers will be provided with an 8-week group session.
16296290|NCT04702191|No Intervention|Treatment As Usual|Treatment as usual: Caregivers randomized to this arm (n=200) will receive either a different program, or brief services depending on the organization.
16296291|NCT04702178|Experimental|Group A-2|COVAC-2 25 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
16296292|NCT04702178|Placebo Comparator|Group B-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
16296293|NCT04702178|Experimental|Group C-2|COVAC-2 50 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
16296294|NCT04702178|Placebo Comparator|Group D-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
16296295|NCT04702178|Experimental|Group E-2|COVAC-2 100 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
16296296|NCT04702178|Placebo Comparator|Group F-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
16296297|NCT04702178|Experimental|Group G-2|COVAC-2 25 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
16296298|NCT04702178|Placebo Comparator|Group H-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
16296299|NCT04702178|Experimental|Group I-2|COVAC-2 50 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
16296300|NCT04702178|Placebo Comparator|Group J-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
16296301|NCT04702178|Experimental|Group K-2|COVAC-2 100 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
16296302|NCT04702178|Placebo Comparator|Group L-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
16296303|NCT04702165|Experimental|VATS resection with J-bar|Each patient with a lung nodule meeting criteria will undergo a lung resection which could be one of three approaches: iVATS with Dyna-CT, VATS, or open. Each approach will use a the experimental device the Lung Resection Marker Locator Kit
16296304|NCT04702152|Experimental|Experimental group|This is a within-subject study with a single group of participants
16296466|NCT04701034|Active Comparator|Active treatment group|Intravenous immunoglobulin and prednisolone. See study description
16296305|NCT04702139|Active Comparator|patient with game-ready splint|Installation of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
16296306|NCT04702139|Placebo Comparator|patient with standard splint|Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
16296307|NCT04702113|No Intervention|Conventional Therapy (Controls)|Treatment with clopidogrel and no pre-emptive genotyping
16296308|NCT04702113|Experimental|Genotype-guided therapy (experimental)|"Treatment with clopidogrel 75 mg daily for non-carriers
~Treatment with ticagrelor 90 mg twice daily for carriers"
16296309|NCT04702100|Experimental|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization+conventional therapy three times per week for four week
16296310|NCT04702100|Experimental|integrated neuromuscular inhibition technique|the patients will receive integrated neuromuscular inhibition technique+ conventional therapy. three times a week for four week
16296311|NCT04702100|Active Comparator|conventional therapy|the patients will receive conventional therapy three times a week for four week
16296312|NCT04702087|Experimental|OLEP|Omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
16296313|NCT04702087|Placebo Comparator|Placebo|isocaloric formula
16296314|NCT04702074|Experimental|Traditional Chinese medicine granules|The experimental group will be given Bu Fei Jian Pi Hua Tan granule or Yi Qi Yang Yin Qing Fei granule based on TCM syndrome differentiation.
16296315|NCT04702074|Placebo Comparator|Traditional Chinese medicine granules placebo|The control group will be given Bu Fei Jian Pi Hua Tan granule placebo or Yi Qi Yang Yin Qing Fei granule placebo based on TCM syndrome differentiation.
16296316|NCT04702061|Active Comparator|Group E|Patients who receive general anesthesia after erector spina plane block
16296317|NCT04702061|Active Comparator|Group T|Patients who receive general anesthesia after thoracic epidural block
16296318|NCT04702048|Experimental|Aflibercept injection|Intravitreal injection of Aflibercept
16296319|NCT04702048|Placebo Comparator|Sham injection|Empty syringe with no needle
16296320|NCT04702035|Experimental|iNPH patients|20 patients with completed diagnostics concerning NPH, in which the indication for implantation of a VP shunt for NPH treatment was found by the responsible surgeon independently from the study.
16296321|NCT04702035|Active Comparator|Healthy volunteers|20 volunteers, matched with group 1 concerning sex and age.
16296322|NCT04702035|Active Comparator|Young healthy volunteers|20 volunteers, matched with group 1 concerning sex only and between 18 and 40 years old.
16296323|NCT04702022|Other|Humoral Arm|"The renal biopsy shows signs of humoral rejection: the patient is excluded from the study and is treated as usual on the basis of the histological results."
16296324|NCT04702022|Other|"Highly Metabolic patients"|"The renal biopsy does not show signs of humoral rejection but the 18FDG PET / CT shows a high metabolic activity of the graft (> 2.4): the patient is treated as usual on the basis of histological findings."
16296325|NCT04702022|Other|" Low metabolic patients"|The renal biopsy does not show signs of humoral rejection and the 18FDG PET / CT shows a weak metabolic activity of the graft (<2.4): the immunosuppressive treatment is gradually weaned off corticosteroids.
16296326|NCT04702009|Active Comparator|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy
16296327|NCT04702009|Experimental|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy
16296328|NCT04701996||cohort|sero-surveillance will start in a cohort of 800 adults (18-50y). In case of an established outbreak, this sample will be extended to 400 children (0-17y) and 400 elderly (50+y).
16296329|NCT04701983|Experimental|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
16296330|NCT04701983|Experimental|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
16296331|NCT04701983|Placebo Comparator|Placebo|SC administration of matching placebo Q2W for 52 weeks
16296332|NCT04701970|Other|changes in the occlusal load distribution|A crossover clinical study was carried out with previously constructed and used conventional complete dentures before relining with soft denture liners and then with the same dentures after relining with soft denture liners. patients were comfortably using their relined mandibular complete dentures for at least three months and the retention and stability of the conventional dentures were assessed before second recording of occlusal parameter. The evaluation of occlusal force distribution was carried out with the aid of T-Scan device
16296333|NCT04701957|Experimental|Modified Atkins 2 :1 Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
16296334|NCT04701957|No Intervention|Control diet|
16296336|NCT04701892||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
16296337|NCT04701879|Active Comparator|Spine decompression with core stability exercises|Interventions in experimental group includes Hot pack, Spinal decompression therapy and core stability exercises
16296338|NCT04701879|Experimental|Spine decompression|Intervention includesHot pack and spinal decompression therapy ..
16296339|NCT04701866|Experimental|Music|Music will be provided for participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks).
16296340|NCT04701866|No Intervention|Usual Care|Participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks) will be administered as per usual care. That is, without music provided or permitted. Contact time with clinicians before, during, and after ketamine treatments will be matched.
16296341|NCT04701853|Experimental|Specific abdominal muscle training|Specific abdominal muscle training which is introduced preoperatively and performed the first year after surgery
16296342|NCT04701853|Active Comparator|Usual care treatment|No specific abdominal muscle training
16296343|NCT04701827|Experimental|Intervention group|AWARE intervention
16296344|NCT04701827|No Intervention|Control group|Treatment as usual (consisting of the standard out-patient mental health service routines in The Capital Region of Denmark)
16296345|NCT04701814|Active Comparator|group A (controlled group)|received passive range of motion (PROM)/ active assisted range of motion (AAROM)/ active range of motion (AROM) exercises, strengthen of rotator cuff, biceps, shoulder and scapular muscles, ultrasound (5 min. - 1.5 W/c.m2 - 1 MHZ), electrical stimulation ( interferential bipolar technique for 20 min. on shoulder joint). This treatment was repeated three times per weeks with 24 hours rest for 3 weeks.
16296346|NCT04701814|Active Comparator|group B(Study group)|All patients in group B received biomechanical scapular mobilization with movement and motor learning and traditional methods.
16296347|NCT04701788|Experimental|Study group|The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.
16296348|NCT04701788|Placebo Comparator|Control group|The control group had never been vaccinated with any pneumococcal vaccine.
16296349|NCT04701775|Experimental|Lactobacillus rhamnosus GG Group|Participants received only 1x106 cfu Lactobacillus rhamnosus GG once a day for 8 weeks.
16296350|NCT04701775|Experimental|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group|Participants recevied a combined Lactobacillus acidophilus 1x109 cfu and Bifidobacterium animalis subsp.lactis 1x109 cfu once a day for 8 weeks.
16296351|NCT04701775|Placebo Comparator|Placebo|Those participants received placebo capsule once a day for 8 weeks.
16296352|NCT04701762|Experimental|videolaryngoscopy|Initial intubation performed using GlideScope videolaryngoscope.
16296353|NCT04701762|Active Comparator|conventional direct laryngoscopy|Initial intubation performed using direct laryngoscopy.
16296354|NCT04701749||with atrial closure|
16296355|NCT04701749||without atrial occlusion|
16296356|NCT04701736|No Intervention|Routine Care|Routine care consists of an oncology pharmacist counselling the patient on supportive care medications prior to the patient getting his or her prescription dispensed.
16296357|NCT04701736|Active Comparator|Intervention|The intervention group will encompass the oncology pharmacist using the computer system to print a Picture Medication Calendar for the patient and use the calendar to explain supportive medications, in addition to routine care.
16296358|NCT04701723|Experimental|Cardiac Coherence Training|"The cardiac coherence training will consist in the realization during 3 months by the patient, at home :
~of 6 respiratory cycles by minute (inspiration : 4,5 seconds/expiration : 5,5 seconds),
~during 5 minutes,
~3 times a day (morning, late morning and late afternoon)"
16296359|NCT04701710|Experimental|Experimental Group|"The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
~Standard biosecurity care"
16296360|NCT04701710|No Intervention|Control Group|Standard biosecurity care
16296361|NCT04701697|Active Comparator|active comparator：HumanAlbumin|Participants received HumanAlbumin 10g/d
16296362|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 10g|Participants received Recombinant Human Albumin Injection 10g/d
16296363|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 20g|Participants received Recombinant Human Albumin Injection 20g/d
16296364|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 30g|Participants received Recombinant Human Albumin Injection 30g/d
16296365|NCT04701684|Experimental|Direct tot Angiography Suite (DTAS) triage workflow|
16296366|NCT04701684|Active Comparator|Conventional CT/MR triage workflow|
16296367|NCT04701671||Normal Weight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are not randomly assigned to undergo MRI scans at baseline and 18-months.
16296368|NCT04701671||Normal Weight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are randomly assigned to undergo MRI scans at baseline and 18-months.
16296369|NCT04701671||Overweight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are not randomly assigned to undergo MRI scans at baseline and 18-months.
16296370|NCT04701671||Overweight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are randomly assigned to undergo MRI scans at baseline and 18-months.
16296371|NCT04701671||Overweight/Obese Experimental, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are not randomly assigned to undergo MRI scans at baseline and 18-months.
16296372|NCT04701671||Overweight/Obese Experimental with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are randomly assigned to undergo MRI scans at baseline and 18-months.
16296373|NCT04701658|Experimental|Bamlanivimab|Participants received 700 milligram single intravenous infusion of Bamlanivimab.
16296374|NCT04701658|No Intervention|Controls|"Matched controls who received standard of care.
~[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.]"
16296375|NCT04701645|Experimental|Cohort 1: Primary cytoreduction|"Patients with a new or suspected diagnosis of ovarian cancer who are deemed surgical candidates for primary cytoreductive surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.
~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.
~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
16297618|NCT04693039|Placebo Comparator|Placebo-150mg|Drug：Placebo；Dosage：150mg；
16296376|NCT04701645|Experimental|Cohort 2: Surgical assessment for primary surgery|"Patients with newly diagnosed ovarian cancers who are being considered for either primary surgery or neoadjuvant chemotherapy by their surgical gynecologic oncologist, and who require a laparoscopic procedure to determine their candidacy for surgery.
~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.
~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
16296377|NCT04701645|Experimental|Cohort 3: Secondary cytoreduction|"Patients with recurrent ovarian cancer who are candidates for secondary cytoreduction, e.g.to confirm diagnosis of recurrent ovarian cancer and/or remove oligometastatic lesions.
~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.
~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
16296378|NCT04701619|Other|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
16296379|NCT04701606|Experimental|Artecom® (pyronaridine-artesunate)|Artecom® is treated orally once a day for 3 consecutive days.
16296380|NCT04701606|Placebo Comparator|Placebo|Placebo is treated orally once a day for 3 consecutive days.
16296381|NCT04701593|No Intervention|Control|No additional drug given
16296382|NCT04701593|Experimental|Experimental (Triamcinolone Acetonide)|receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation
16296383|NCT04701580|Experimental|HD patients|At baseline and 2-year follow-up
16296384|NCT04701580|Active Comparator|Healthy controls|At baseline and 2-year follow-up
16296385|NCT04701567||Liver disease|
16296386|NCT04701567||Pancreatic disease|
16296387|NCT04701554|Experimental|Qigong program|The experimental group participated in the Qigong program during 2 months, 16 sessions with a total of 16 hours.
16296388|NCT04701554|Active Comparator|Active comparator group|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
16296389|NCT04701541|Other|Obese Patients undergoing Bariatric Surgery|"Obesity is a progressively growing morbid condition in the world, and given the direct relationship between body mass index (BMI) and costs, this has a major impact on economic and health policy. Obese patients undergoing bariatric surgery are at high risk for postoperative respiratory complications. In these patients, postoperative respiratory complications are related to various pathophysiological mechanisms that include: decreased lung volumes, respiratory muscle dysfunction and atelectasis. Demographic (age, gender, BMI) and clinical features of the population included: ASA, comorbidity and pre and postoperative respiratory function [PaO2/FiO2, haemogasanalysis (EGA)]. Ultrasound evaluation of DIA was performed.
~T0: preoperative within 24h before surgery: DIA, haemogasanalysis; T1: Post operation: 60 min after extubation: Aldrete Score, DIA, EGA; T2: Post operation: 240 min after extubation: Aldrete, EGA."
16296390|NCT04701528|Experimental|Voclosporin (VCS)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.
~In the experimental arm tacrolimus is switched to voclosporin 6 capsules (of 7.9 mg each) BID for a treatment period of minimal 56 days with a possible extension up to 1 year.
~Safety drug monitoring will take place during the study to ensure that VCS trough levels are maintained between 30-60 ng/mL. If trough levels are not within these levels, dose adjustments will take place."
16296391|NCT04701528|Active Comparator|Tacrolimus (TAC)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.
~In the Active comparator arm tacrolimus dosage is maintained.
~Safety drug monitoring will take place during the study to ensure that TAC trough levels are maintained between 3-7 ng/ml. If trough levels are not within these levels, dose adjustments will take place."
16296392|NCT04701515||Retrospective Cohort|Review electronic medical records of de-identified patients that tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until December 2022
16296395|NCT04701489|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.
16296396|NCT04701489|No Intervention|Control Group|Standard clinical care with no ultrasound stimulation.
16296397|NCT04701476|Experimental|colorectal cancer|metastatic colorectal cancer progressed on at least two lines of chemotherapy
16296398|NCT04701476|Experimental|NSCLC|Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
16296399|NCT04701463|Experimental|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement|
16296400|NCT04701463|Placebo Comparator|Placebo|
16296401|NCT04701450||conventional|consent for anaesthesia is obtained as part of a conversation with physical attendance
16296402|NCT04701450||telephonic|consent for anaesthesia is obtained telephonically
16296403|NCT04701450||digital|a digital survey and video information is used to inform the patient about the anaesthetic procedure
16296404|NCT04701437|Experimental|Peer-enhanced intervention|Those randomized to the peer-enhanced intervention group will be contacted by a peer mentor within 72 hours of enrollment to discuss the early release period, readiness for HCV treatment, and identify ancillary needs. Individuals randomized to this arm will be provided a study cell phone.
16296405|NCT04701437|Placebo Comparator|Standard of care|If randomized to the standard of care intervention, the participant will only receive passive referral to HCV-care.
16296406|NCT04701424|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks
~The CamAPS HX closed-loop system comprises:
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data"
16296407|NCT04701424|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period
16296409|NCT04701398|Experimental|Multimodal intervention|supervised physical training (1-hour sessions, 24 sessions, 8 weeks) + nutritional supplementation + psychological advice
16296410|NCT04701398|No Intervention|Standard Care|Healthy living recommendations
16296411|NCT04701385||NSTEMI|Patients presenting with a myocardial infarction will have blood samples taken for analysis. At the time of their angiography/angioplasty procedure they will have an OCT assessment of the culprit coronary artery to distinguish if the heart attack was caused by a plaque rupture or plaque erosion event
16296412|NCT04701385||Control|Patients undergoing planned angioplasty will have blood samples taken pre and post angioplasty to help as a control for the flow cytometry and for biomarker analysis
16296413|NCT04701372||Obsessive-Compulsive Disorder|adults, adolescents, and children with obsessive-compulsive disorder
16296414|NCT04701359|Experimental|Group A (TiN-coating)|Patients with knee osteoarthritis receive total knee arthroplasty with Titanium-Nitride (TiN)-coated implant.
16296415|NCT04701359|Active Comparator|Group B (CoCr-alloy)|Patients with knee osteoarthritis receive total knee arthroplasty with Cobalt-Chromium (CoCr)-alloy implant.
16296416|NCT04701346|Experimental|Low SAA diet|Dietary intervention
16296417|NCT04701346|Active Comparator|High SAA diet|Dietary intervention
16296418|NCT04701333|Experimental|Cabergoline|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
16296419|NCT04701333|Placebo Comparator|Placebo|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
16296420|NCT04701320|Experimental|Glass carbomer|Nano hydroxyapatite Reinforced Glass Ionomer that results in chemical bond formation with tooth structure mimic that of enamel tissue
16296421|NCT04701320|Active Comparator|Fuji ix|Conventional Glass Ionomer cement fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics, a wear resistant, self-adhesive
16296422|NCT04701307|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21 of cycles 1-4, and on days 1-42 of subsequent cycles. Patients also receive dostarlimab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-4 and every 42 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
16296423|NCT04701294|Experimental|Giomer Beautifil flow plusF03 Shofu-Japan|Giomer beautifil flow plusF03 shofu-Japan an application of flowable resin with sprg as a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the experiment.
16296424|NCT04701294|Active Comparator|Tetric N flow ivoclar vivadent-Germany|Tetric N flow ivoclar vivadent-Germany an application of flowable resin a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the comparator.
16296426|NCT04701268|Experimental|Intervention/treatment|Implantation of the Hemiverse Shoulder Prothesis
16296427|NCT04701255|Experimental|aberration-free IOL|20 human eyes with aberration-free intraocular lens Implantation after phacoemulsification cataract surgery
16296428|NCT04701255|Active Comparator|negative spherical aberration IOL|20 human eyes with negative spherical aberration intraocular lens Implantation after phacoemulsification cataract surgery
16296429|NCT04701242|Active Comparator|Atorvastatin-Ezetimibe combination|Eligible patients randomized to this arm will receive combination of Atorvastatin 80mg plus Ezetimibe 10mg
16296430|NCT04701242|No Intervention|Atorvastatin monotherapy|Eligible patients randomized to this arm will receive Atorvastatin 80mg as monotherapy for LDL-C reduction. They can be upgraded to combination (adding Ezetimibe 10mg) if found in follow-up that they had not achieve recommended LDL-C targets.
16296431|NCT04701229||normal karyotype|control group
16296432|NCT04701229||del5q-RBM22neg-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22, a loss of SLU7.
16296433|NCT04701229||del5q-RBM22neg-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22 but no loss of SLU7
16296434|NCT04701229||del5q-RBM22pos-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22, but a loss in SLU7
16296435|NCT04701229||del5q-RBM22pos-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22 nor SLU7
16296436|NCT04701216|Experimental|Experimental: SHR8735 cohort 1|The subjects will receive a multiple dose of SHR8735 (low dose).
16296437|NCT04701216|Experimental|Experimental: SHR8735 cohort 2|The subjects will receive a single dose of SHR8735 (medium dose).
16296438|NCT04701216|Experimental|Experimental: SHR8735 cohort 3|The subjects will receive a single dose of SHR8735 (high dose).
16296439|NCT04701203|Experimental|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
16296440|NCT04701203|Placebo Comparator|Placebo|Placebo for TransCon PTH delivered once daily by subcutaneous injection
16296467|NCT04701034|Placebo Comparator|Passive treatment group|Human albumin infusion and placebotablet. See study description
16296468|NCT04701021|Experimental|TENDU|Three different doses of the TENDU vaccine are to be investigated: 40, 400 and 960μg.
16297619|NCT04693039|Placebo Comparator|Placebo-300mg|Drug：Placebo；Dosage：300mg；
16296441|NCT04701190|Active Comparator|Noradrenaline 0.05/10|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.
~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.
~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.
~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.
~The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.
~Noradrenaline will be continued until 5 minutes after delivery of fetus."
16296442|NCT04701190|Active Comparator|Noradrenaline 0.075/5|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.
~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.
~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.
~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.
~The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.
~Noradrenaline will be continued until 5 minutes after delivery of fetus."
16296443|NCT04701190|Active Comparator|Noradrenaline 0.1/0|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.
~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.
~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.
~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.
~After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute without bolus dosage will be started.
~Noradrenaline will be continued until 5 minutes after delivery of fetus."
16296444|NCT04701177||Subjective cognitive decline (SCD)|subjective perception of cognitive decline in the absence of cognitive impairment in formal neuropsychological assessment.
16296445|NCT04701177||Mild cognitive impairment (MCI)|Single or multidomain cognitive deficits with preservation of activities of daily living.
16296446|NCT04701177||Prodromal Parkinson's Disease|Parkinson's disease (PD) has a prodromal phase during which nonmotor clinical features as well as physiological abnormalities may be present.
16296447|NCT04701164|Experimental|ANX005 Treatment Group - Dose 1|Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.
16296448|NCT04701164|Experimental|ANX005 Treatment Group - Dose 2|Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.
16296449|NCT04701164|Placebo Comparator|Placebo Group|Participants will receive a single IV infusion of placebo on Day 1.
16296450|NCT04701151|Experimental|Intervention|"Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.
~If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm."
16296451|NCT04701151|Active Comparator|Control|The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.
16296452|NCT04701138|Experimental|Dietary Supplement|All subjects will receive the intervention (SPM Active Supplement)
16296453|NCT04701125|Experimental|Study group|Players receive selective head-neck cooling after concussion
16296454|NCT04701125|No Intervention|control group|Players receive the standard sport-related concussion management
16296455|NCT04701112|Experimental|His-bundle pacing first|"AV sequential His-bundle pacing (or VVI pacing if in atrial fibrillation) via temporary right atrial and His-bundle electrodes.
~Then AV sequential Biventricular pacing via the patient's already implanted CRT device.
~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
16296456|NCT04701112|Active Comparator|Biventricular pacing first|"AV sequential biventricular pacing (or VVI pacing if in atrial fibrillation) via the patient's already implanted CRT device. Then AV sequential or VVI His-bundle pacing via temporary right atrial and His-bundle electrodes.
~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
16296457|NCT04701099||On ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl during ECMO support.
16296458|NCT04701099||Off ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl after weaning off ECMO.
16296459|NCT04701086|Experimental|Cationorm Pro|Cationorm Pro is an ophthalmic sterile unpreserved eye drops emulsion (N=40) Posology: One Drop in each eye 4 times daily for 84 days
16296460|NCT04701086|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
16296461|NCT04701073|No Intervention|"Control group usual care"|Promotion of physical activity and taking usual medicines for pain relief
16296462|NCT04701073|Experimental|Intervention group : lumbar belt|wearing the LombaStab belt during 3 months in addition to usual care (promotion of physical activity and taking usual medicines for pain relief).
16296463|NCT04701060|Experimental|Camrelizumab combined with apatinib|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
16296464|NCT04701047||pessary|Vaginal prolapse being treated by pessary
16296465|NCT04701047||surgery|Vaginal prolapse being treated by surgical repair
16296469|NCT04701008||Patients with significative post-operative pain despite|Patients with significant pain despite receiving narcotics in PACU will receive a bolus dose of IV ketamine to assess its efficacy for pain score reduction. Bolus doses are given by 10mg IV increments, to reach approximate dose of 0,25mg/kg.
16296470|NCT04700995|Experimental|ProTaper rotary NiTi instruments|The ProTaper Universal Retreatment rotary system and ProTaper Gold rotary system were used.
16296471|NCT04700995|Experimental|Hyflex EDM rotary NiTi instruments|Hyflex EDM rotary system was used.
16296472|NCT04700995|Experimental|Reciproc Blue reciprocating NiTi instruments|Reciproc Blue reciprocating system was used.
16296473|NCT04700995|Experimental|Waveone Gold reciprocating NiTi instruments|WaveOne Gold reciprocating system was used.
16296474|NCT04700982||Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).
16296475|NCT04700969|Experimental|A support program to facilitate implementation of EBP for postoperative urinary retention|12- month support program. Multi-professional facilitator-teams will be supported by a 12-month support program including seminars and monthly supervision (e-discussion forum and group teleconferences) to develop an awareness of, and skills in facilitating implementation of evidence/EBP in clinical everyday care.
16296476|NCT04700969|No Intervention|Control-No support program|No support program
16296477|NCT04700956|Active Comparator|the primary suture group|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
16296478|NCT04700956|Experimental|mesh group|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
16296479|NCT04700943||Regional awake anesthesia|"In non-intubated patients, an epidural catheter was placed at T5-T6. An anesthetic load of 0,5 mg/kg of ropivacaine was administered to reach anesthesia of the thoracic wall. Adjunctive local anesthetic infiltration of the incision site was performed by the surgeon with 2% lidocaine and 7,5% Ropivacaine. The cumulative dose of anesthetics drugs was computed as not to exceed the recommended dosage.
~To improve patient comfort through the procedure, sedation with Target Controlled Infusion of propofol (using Schnider algorithm) and low dose remifentanil (0,05 mcg/kg/min) was also administered."
16296480|NCT04700943||General anesthesia|"Either epidural block or an interfascial plane block of the thoracic wall, such as serratus anterior plane block or erector spinae plane block, were performed.
~Patients were then anesthetized with Propofol plus opiates (usually remifentanil) and muscle paralysis was achieved with Rocuronium."
16296481|NCT04700930|Experimental|CBD|Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication
16296482|NCT04700930|No Intervention|Non-CBD|Patients recieve standard psychiatric care including neuroleptic medication
16296483|NCT04700917|Experimental|Intervention Group|This group will receive the iCBT for IBD online intervention once enrolled.
16296484|NCT04700917|No Intervention|Treatment as Usual|This group will be offered the iCBT for IBD intervention 24 weeks after enrollment.
16296485|NCT04700891|Experimental|Patients scheduled for elective surgery aged 65 and +|
16296489|NCT04700865|Other|Examination|Continuous ECG monitoring for minimum 3 days
16296490|NCT04700852|Experimental|allergic rhinitis|Puressentiel protective nasal spray
16296491|NCT04700839|Experimental|SGLT2 inhibitors group|Intervention with SGLT2 inhibitors for 3 months
16296492|NCT04700839|Active Comparator|metformin group|Intervention with metformin for 3 months
16296493|NCT04700826|Experimental|Direct Oral anticoagulants (DOAC)|Commence DOAC even with low or intermediate risk of stroke or thromboembolism, which could include currently licensed drugs apixaban, dabigatran, edoxaban or rivaroxaban; choice of drug and dose according to local practice guidelines
16296494|NCT04700826|No Intervention|No anticoagulant therapy (usual care)|Continuation of usual anticoagulant prescribing practice in patients with AF; e.g. according to National Institute for Health and Care Excellence (NICE), patients with AF should commence oral anticoagulation with a CHA2DS2-VASc score of 2 or above.
16296495|NCT04700800|Experimental|Exercise, Infusion of Amino Acids|Exercise followed by infusion of amino acids, or infusion of amino acids alone.
16296496|NCT04700800|Active Comparator|Exercise|Exercise with no infusion of amino acids
16296497|NCT04700787|Experimental|Sulopenem|Sulopenem intravenous 1000 mg (single dose) on Day 1 followed by oral sulopenem etzadroxil/probenecid 500 mg/500 mg (single dose) on Day 2.
16296498|NCT04700774|Experimental|mBA|Motor enhanced behavioral activation. 10 sessions.
16296499|NCT04700774|Experimental|BA|Standard behavioral activation. 10 sessions.
16296500|NCT04700774|No Intervention|Waitlist|10 week waitlist.
16296501|NCT04700761|Experimental|Group OFA (Opioid-free anesthesia)|Not using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (except a single dose of alfentanil for endotracheal intubation)
16296502|NCT04700761|Active Comparator|Group OUA (Opioid-using anesthesia)|Using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (continuous infusion of remifentanil)
16296503|NCT04700748|Other|Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.|Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.
16296504|NCT04700722||Parkinson's disease|Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
16296505|NCT04700722||Multiple System Atrophy|Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
16296506|NCT04700722||Dementia with Lewy bodies|Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
16296507|NCT04700722||Pure Autonomic Failure|Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
16296508|NCT04700722||Healthy Controls|No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
16296509|NCT04700709|Experimental|RaparoBell® Tablet|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
16296510|NCT04700709|Active Comparator|Mycophenolate Mofetil Tablet/Capsule|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
16296511|NCT04700696|Experimental|EPIC Participants|EPIC participants are 1) matched with trained peer recovery supporters with lived experience related to child welfare and substance EPIC participants are also incentivized to participate in 2) family treatment drug court (FTDC), with medications for opioid use disorders (MOUD); and 3) home-based parenting supports based on the Nurturing Parenting Program.
16296512|NCT04700696|Active Comparator|Ohio Sobriety Treatment And Reducing Trauma (START) participants|Adapted from the evidence-based national START model (Sobriety Treatment and Recovery Teams) this intervention matches child welfare parents in need of addiction services to caseworker and family peer mentor (FPM) dyads for intensive case management services.
16296513|NCT04700696|No Intervention|Treatment as usual (TAU)|Treatment as usual includes home visits by the assigned caseworker, referrals to SUD assessment/treatment, family group decision making, and (non-incentivized) referral to FTDC.
16296514|NCT04700683|Active Comparator|Noninvasive Peripheral Nerve Stimulation|NPNS device programmed to deliver active stimulation.
16296515|NCT04700683|Sham Comparator|Sham control|NPNS device programmed to deliver sham stimulation.
16296516|NCT04700670||Group 1|patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine
16296517|NCT04700670||Group 2|patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
16296518|NCT04700670||Group 3|hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).
16296519|NCT04700670||Group 4|patients hospitalized in a medical non-intensive care ward.
16296520|NCT04700657||15 patients affected by ocular GVHD|
16296521|NCT04700657||15 age-matched normal volunteers.|
16296522|NCT04700631|Active Comparator|healthy subject|healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal BMI
16296523|NCT04700631|Experimental|CRF patients|CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²
16296524|NCT04700618|Experimental|Study group|The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.
16296525|NCT04700618|Placebo Comparator|Control group|The control group had never been vaccinated with any pneumococcal vaccine.
16296526|NCT04700592|Experimental|Gabapentin group|group which receives 600 mg of Gabapentin (two tablets) one hour prior to surgery
16296527|NCT04700592|Experimental|ketamine group|group which receives an injection of ketamine at a dosage of 0.15 mg/Kg before surgery incision
16296528|NCT04700579||TB Cases|"n= 50 (25 HIV positive and 25 HIV negative)
~Xpert MTB/RIF Ultra-confirmed TB"
16296529|NCT04700579||Healthy Household Contacts|"n= (25 HIV positive and 25 HIV negative)
~Culture negative TB result"
16296530|NCT04700579||Sick controls|"n=50
~Diseases: Asthma, Chronic obstructive pulmonary disease (COPD), Cancer, Bronchiectasis (including post-TB) and Pneumonia"
16296531|NCT04700566|Experimental|Injection of Renuva Allograft adipose matrix in vocal fold|Injection of Renuva Allograft Adipose matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
16296532|NCT04700553|Experimental|Conventional physical therapy intervention plus localized muscle vibration|physical therapy intervention plus localized muscle vibration
16296533|NCT04700553|Sham Comparator|Conventional physical therapy intervention|physical therapy intervention
16296534|NCT04700540|Experimental|Intervention Group|The PWMC and Care partner in this group will receive the SR. The project will provide a smartwatch and smartphone for the dyads in the study. All others (family, friends, etc.) will be able to download a smartphone app from an online store. Instructional material will be created to show the suggested information that can be entered into the app. Care partners and PWMC are administered surveys at baseline, 3 months and 6 months following enrollment.
16296535|NCT04700540|No Intervention|Attention Control Group|Care partners are administered surveys at baseline, 3 months and 6 months following enrollment. The attention control group will receive a contact call from one of the researchers 3-months and 6-months after enrollment. Based on our prior experience, PWMC and care partners in an attention control group will often seek information and psychosocial support during these calls. We will provide free information resources (e.g., brochures or websites of the Alzheimer's Association) at that time.
16296538|NCT04700514|No Intervention|Control group|"Children diagnosed with retinoblastoma and received exam under anesthesia (EUA) before the age of 2, and is not yet 4 years old
~Children who are undergoing exams and treatment such as EUA, chemoport insertion, or intra-arterial chemotherapy under general anesthesia
~Sevoflurane is used only for anesthesia"
16296539|NCT04700514|Experimental|Dexmedetomidine group|"Children who are diagnosed with retinoblastoma and are scheduled for the first EUA before their age of 2.
~No history of anesthesia"
16296540|NCT04700501|Other|EYB Implementation study|All participants will have the opportunity to access an online CBT life skills learning programme.
16296541|NCT04700488|Experimental|6D-MRI|Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.
16296654|NCT04699760|Active Comparator|Fish oil|Nutritional supplement with fish oil
16296542|NCT04700475|Experimental|Laser group|Laser group composes of thirty patients who will receive low level laser three times a week, on alternate day (48h interval) Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions
16296543|NCT04700475|Other|Control group|control group composes of thirty patients will be treated with 15mL of a 2% citric acid solution applied as a mouth rinse for 30 sec
16296544|NCT04700462|Experimental|Sm-EMA|Participants will receive the Self-monitoring ecological momentary assessment behavior change tool.
16296545|NCT04700449|Experimental|CBP-307 capsules|CBP-307 capsules oral administration.
16296546|NCT04700449|Placebo Comparator|Placebo capsules|Placebo capsules oral administration.
16296547|NCT04700436|Experimental|Test group|Subject administered with Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
16296548|NCT04700436|Active Comparator|Control group|Subject administered with Suvast tablet 10 mg (Rosuvastatin 10 mg)
16296549|NCT04700423|Experimental|A: moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
16296550|NCT04700423|Active Comparator|B: ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using 3 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
16296551|NCT04700423|Active Comparator|C: albendazole (400 mg)|Monotherapy of albendazole (400 mg) administered orally at day 0 Other names: Zentel®
16296552|NCT04700423|Active Comparator|D: ivermectin (200 µg/kg)|Monotherapy of ivermectin ( 200 µg/kg using 3 mg tablets) administered orally at day 0 Other names: Stromectol®
16296553|NCT04700423|Active Comparator|E: moxidectin (8 mg)|Monotherapy of moxidectin (8 mg using 2 mg tablets) administered orally at day 0
16296554|NCT04700410|Experimental|Pure-Vu|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)
16296555|NCT04700397||Repeatability group 1|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 100 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
16296556|NCT04700397||Repeatability group 2|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 200 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
16296557|NCT04700397||Repeatability group 3|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 300 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
16296558|NCT04700397||pressure-recommended doses of NTG|The patient with systolic blood pressure above 100 mmHg, who will receive the nitroglycerine injection with the dose of recommendation, adjusted according to the blood pressure.
16296559|NCT04700384|No Intervention|Control Group|"Control Group - Baseline Training
~25 Participants allocated. Individuals receive introductory information on using the simulator and the scenario. They perform 5 simple subpial tumour resections for practice and have 5 minutes per trial. After each attempt, the student takes a 5-minute break with no assessment or feedback on their performance. On their 6th attempt they have 13 minutes to perform a different realistic scenario."
16296560|NCT04700384|Experimental|Experimental Group - Virtual Operative Assistance Training|"Experimental Group - Virtual Operative Assistance Training
~25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistance Training assessment of their performance and audiovisual feedback."
16296561|NCT04700384|Experimental|Experimental Group - remote-based expert Instructor Training|25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
16296562|NCT04700371|Active Comparator|Interwoven stent|Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
16296563|NCT04700371|Active Comparator|Laser-cut stent|Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
16296564|NCT04700358||Patients with Cystic Fibrosis|Patients with pulmonary Cystic Fibrosis with or without bacterial colonization
16296565|NCT04700358||Control group|Healthy age- and sex-matched controls including healthy individuals and patients with acute or chronic bacterial infections
16296566|NCT04700345|Experimental|Embolization|Middle meningeal artery(MMA) embolization
16296567|NCT04700345|Active Comparator|No embolization|Traditional treatment group
16296568|NCT04700332|Experimental|High risk prostate cancer|DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy
16296569|NCT04700332|Experimental|Biochemically recurrent prostate cancer|DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.
16296570|NCT04700319|Experimental|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T cell infusion on relapsed or refractory hematological malignancies of CD19 / CD20+ B cell line
16296571|NCT04700306|Experimental|Sophrology|the patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology
16296572|NCT04700306|No Intervention|Control|the patient must make 7 visits with interviews and questionnaires
16296573|NCT04700293|Experimental|AYMES AMSTERDAM|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'AMSTERDAM' for a period of > 7 days.
16296574|NCT04700280|Experimental|GLPG3970|Participants will receive GLPG3970 tablet, orally, once daily for 12 weeks.
16296575|NCT04700280|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
16296578|NCT04700254||working condition|In order to further explore the differences among working status the data will be categorized into three different groups: suspension of work, employment and unemployment.
16296579|NCT04700254||Family status|In order to xplore the differences among the family status, the data will be categorized into the married and the singles DM patients.
16296580|NCT04700254||BMI status|In order to further explore BMI scale results, we divided the data obtained from the participants into normal (18.50 - 24.99 kg/m2), overweight (25-29.99 kg/m2) and obese (≥30 kg/m2), according to the international classification of the World Health Organisation (WHO).
16296581|NCT04700241|Active Comparator|Potassium nitrate|During this experimental day, men will receive 10 mmol of potassium nitrate
16296582|NCT04700241|Placebo Comparator|Placebo|During this experimental day, men will receive an isomolar dose of potassium chloride
16296583|NCT04700228|Placebo Comparator|Group C|0.25% bupivacaine at a total volume of 0.5ml/kg.
16296584|NCT04700228|Active Comparator|Group BD1|0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
16296585|NCT04700228|Active Comparator|Group BD2|0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
16296586|NCT04700215|Active Comparator|Group 01 Effectiveness of BiPAP in reducing post CABG pulmonary complications|Bilevel positive airway pressure device after every 6 hours
16296587|NCT04700215|Active Comparator|Group 02 Effectiveness of IS in reducing post CABG pulmonary complications|Incentive spirometry for 15 minutes after every 4 hours
16296588|NCT04700202||Retrospective Cohort|Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
16296589|NCT04700176|Experimental|Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
16296590|NCT04700176|Experimental|Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
16296591|NCT04700163|Experimental|S1 - low dose|100 mg of C144-LS and 100 mg of C135-LS, subcutaneously
16296592|NCT04700163|Experimental|S2 - mid dose|200 mg of C144-LS and 200 mg of C135-LS, subcutaneously
16296593|NCT04700163|Experimental|V1 - low dose|1.5 mg/kg of C144-LS and 1.5 mg/kg of C135-LS, intravenously
16296594|NCT04700163|Experimental|V2 - mid dose|5 mg/kg of C144-LS and 5 mg/kg of C135-LS, intravenously
16296595|NCT04700163|Experimental|V3 - high dose|15 mg/kg of C144-LS and 15 mg/kg of C135-LS, intravenously
16296596|NCT04700150|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
16296597|NCT04700150|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
16296598|NCT04700137|Active Comparator|Caring Contacts + Introductory Phone Call (CC+)|"Healthcare provider and staff participants who are randomized to both caring text messages and an introductory phone call.
~Adult and adolescent participants who are randomized to both caring text messages and an introductory phone call."
16296599|NCT04700137|Active Comparator|Caring Contacts (without phone call) (CC)|"Healthcare provider and staff participants who are randomized to only caring text messages.
~Adult and adolescent patient participants who are randomized to only caring text messages."
16296602|NCT04700111|Experimental|Pattern 1 spectacle lens|Pattern 1 spectacle lens or treatment 1
16296603|NCT04700111|Experimental|Pattern 2 spectacle lens|Pattern 1 spectacle lens or treatment 2
16296604|NCT04700111|Active Comparator|Control lens|Comparator lens or control arm
16296607|NCT04700085|Experimental|ReMotion Knee|The ReMotion Knee (mechanical prosthetic knee type) was used during measurements
16296608|NCT04700085|No Intervention|Current prosthetic knee|The participant's current prosthetic knee was used during measurements
16296611|NCT04700059|Experimental|Intervention|10 perinatal home visits
16296612|NCT04700059|No Intervention|Usual care|Routine medical care for mother and infant. Access to online resources.
16296613|NCT04700046|Active Comparator|Mexiletine|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg)
16296614|NCT04700046|Placebo Comparator|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
16296615|NCT04700033|Experimental|Somatic IVR|Participants with participate in Somatic IVR protocol three times per week for four weeks.
16296616|NCT04700033|Active Comparator|Distractive IVR|Participants with participate in Distractive IVR protocol three times per week for four weeks.
16296617|NCT04700033|Placebo Comparator|Control IVR|Participants with participate in Control IVR protocol three times per week for four weeks.
16296655|NCT04699747|Experimental|Multiple sclerosis|F-18 3F4AP PET Scan
16296656|NCT04699747|Active Comparator|Healthy controls|F-18 3F4AP PET Scan
16296618|NCT04700020|Other|Patients above the age of 18 years|"In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal.
~MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland."
16296619|NCT04700007|Experimental|Study group|
16296620|NCT04699994|Experimental|FLOT therapy|
16296621|NCT04699981|Experimental|Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure
16296622|NCT04699981|Experimental|Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.
16296623|NCT04699968|Experimental|Treatment group A|
16296624|NCT04699968|Experimental|Treatment group B|
16296625|NCT04699955|No Intervention|Assessment only Control|Participants received no intervention content. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments were delivered via an online survey.
16296626|NCT04699955|Experimental|Positive Message Condition|Participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
16296627|NCT04699955|Experimental|Negative Message Condition|Participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
16296628|NCT04699942|Active Comparator|Conventional low-flow Oxygen Delivery|
16296629|NCT04699942|Experimental|Oxygen Delivery via Revoxa Oxygen Rebreather Device|
16296630|NCT04699929|Experimental|Intervention/treatment|All subject will receive YH001 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
16296631|NCT04699916|No Intervention|Control (Usual care)|Sedation will be guided with a standard protocol based on Sedation Agitation Scale already implemented in the Intensive Care Unit
16296632|NCT04699916|Experimental|EEG-based sedation protocol|Sedation will be guided using a protocol based on 2 parameters from the EEG: Suppression Rate and Spectral Edge Frequency
16296633|NCT04699903||Positive SARS-Cov-2 cohort|Positive diagnosis of COVID-19 confirmed by a positive EUA SARS-CoV-2 PCR will be stratified in three subgroups 0 - 7 days since onset of symptoms 8 - 14 days since onset of symptoms 15 -90 days since onset of symptoms
16296634|NCT04699903||Negative SARS-Cov-2 cohort|Negative diagnosis of COVID-19 confirmed by a negative, EUA SARS-CoV-2 PCR test within 0-7 days of PCR sample collection will be included in the negative cohort.
16296635|NCT04699890||preserved ejection fraction|Patients with a preserved ejection fraction (HF / FEp)
16296636|NCT04699890||reduced ejection fraction|Patients with a reduced ejection fraction (HF / FEr)
16296637|NCT04699890||without heart failure|Patient without heart failure
16296643|NCT04699864|Experimental|Diabetic Retinopathy (DR)|Screening of DR with artificial intelligence (NeoRetina algorithm) and diagnostic evaluation with a standard of care ophthalmological examination.
16296644|NCT04699851|Experimental|Intervention|The intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey.
16296645|NCT04699851|Active Comparator|Control|The control group will receive general recommendations about health prevention in a pandemic.
16296647|NCT04699825|Active Comparator|study group|new-born infants born from preeclampsia mother
16296648|NCT04699825|Other|control group|new-born infants born from mothers with normal pregnancy matched with the same gestational age, sex and race
16296649|NCT04699799|Experimental|record brain activity while smelling odors|Record brain activity while smelling odors
16296650|NCT04699786|Active Comparator|Arm A|Participants randomized to Arm A will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document.
16296651|NCT04699786|Active Comparator|Arm B|Participants randomized to Arm B will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document.
16296652|NCT04699773|Experimental|LITT with Hypofractionated RT|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 25Gy/10 fractions.
16296653|NCT04699760|Placebo Comparator|Placebo|Nutritional supplement without fish oil
16356595|NCT04282096|Other|Sodium Casein|
16296659|NCT04699708||Preterm infants ≤ 32 weeks|All preterm infants ≤ 32 weeks born in two study centers receiving resuscitative measures at the time of birth either in the form of face mask ventilation or intubation.
16296660|NCT04699695||Biologic Treatment|Subjects prescribed a biologic agent per standard of care
16296661|NCT04699695||Other Treatments|Subjects prescribed other treatment modalities exclusive of biologic therapy per standard of care
16296662|NCT04699682|Experimental|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
16296663|NCT04699682|Experimental|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:
~- stool samples taken at different times:
~every 7 days during the first month (M1)
~every 14 days for the following months until the end of the patient's participation (M2 to M12)."
16296664|NCT04699669|Other|Cohort 1: CBL-514 2 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
16296665|NCT04699669|Other|Cohort 2: CBL-514 10 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
16296666|NCT04699669|Other|Cohort 3: CBL-514 20 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
16296667|NCT04699669|Other|Cohort 4: CBL-514 40 mg, 1.0 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
16296668|NCT04699669|Other|Cohort 5: CBL-514 40 mg, 2 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 2 cm^2
16296669|NCT04699669|Experimental|Cohort 6: CBL-514 80 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
16296670|NCT04699669|Experimental|Cohort 7: CBL-514 160 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
16296671|NCT04699669|Experimental|Cohort 8: CBL-514 240 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
16296672|NCT04699669|Experimental|Cohort 9: CBL-514 320 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
16296673|NCT04699656|Experimental|Plazomicin Injection|plazomicin (30-minute IV infusion at 2.5 mg/kg) single dose given before IHD and single dose given after IHD
16296674|NCT04699643|Experimental|EVER4010001 combination with Pembrolizumab|EVER4010001 combination with Pembrolizumab, EVER4010001 started dose escalation from 40mg bid, and then to 60mg bid, 80mg bid, 100mg bid and 120 mg bid if applicable, dose escalation decision will be made by safety monitoring committee which is composed of the study team members. After phase II dose was recommended by safety monitoring committee, this dose will be applied to phase II patients. Pembrolizumab will be administered at 200mg every 3 weeks through the study.
16296677|NCT04699617|Experimental|Active arm|The active arm will include 3 days a week of training with the Dolphin 2.0 for 12 consecutive weeks. Each session will have the duration of 60 minutes.
16296678|NCT04699617|Active Comparator|Delayed-start control arm|The delayed-start control arm will have six-weeks of physiotherapy specialized for PD (3 times/week, 60 minutes/session) and six-weeks of 3 days a week of training with the Dolphin 2.0, with sessions of 60 minutes.
16296679|NCT04699604|Active Comparator|Levocetirizine (LTZ)|Participants will take Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) in addition to their current asthma regimen.
16296680|NCT04699604|Placebo Comparator|Placebo|Participants will take a placebo solution previously developed by the Children's Mercy Investigational Pharmacy to match the color, flavor, and consistency of the active drug in addition to their current asthma regimen.
16296681|NCT04699591|Other|Overall Study|Receive domperidone 4 times a day, weight-dependent dose
16296682|NCT04699552|Experimental|2J 20 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 20Hz
16296683|NCT04699552|Experimental|2J 40 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 40Hz
16296684|NCT04699552|Experimental|2J 60 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 60Hz
16296685|NCT04699539|Experimental|Arm A|GTV uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel.
16296686|NCT04699539|Experimental|Arm B|GTV non-uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel.
16296687|NCT04699526|Experimental|Intervention|Received UPC training, school policy and climate interventions, and Unplugged prevention program
16296688|NCT04699526|No Intervention|Control|Only implemented Unplugged prevention program
16296689|NCT04699513|Experimental|P-SIMV+PS group|The reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV.
16296690|NCT04699513|Experimental|APRV group|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
16296691|NCT04699487|Experimental|Patient receiving Photobiomodulation|
16296692|NCT04699474|Experimental|Early in-bed leg cycling|
16296693|NCT04699461|Experimental|Loncastuximab Tesirine|Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
16296694|NCT04699461|Active Comparator|Idelalisib|Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.
16356596|NCT04282096|Other|Calcium casein|
16296695|NCT04699448|Active Comparator|High-protein hypocaloric diet|Composition of hypocaloric diet: protein:40%,carbohydrates:30% and fat:30%.
16296696|NCT04699448|Active Comparator|High-carbohydrate hypocaloric diet|Composition of hypocaloric diet: carbohydrate 60%, protein:18% and fat:22%
16296697|NCT04699435|Experimental|Control|Patients with a BMI <25 kg / m² requiring general anesthesia with a pre-oxygenation for 3 minutes
16296698|NCT04699435|Experimental|PreOx_3min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 3 minutes
16296699|NCT04699435|Experimental|PreOx_6min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 6 minutes
16296700|NCT04699422|Active Comparator|Experimental group|Patients in the experimental group will receive the serratus anterior plane block combined with postoperative PCIA with Piritramide.
16296701|NCT04699422|Sham Comparator|Control group|Patients in the control group will receive postoperative PCIA with Piritramide.
16296702|NCT04699409|Experimental|FAST|stroke education: FAST
16296703|NCT04699409|Experimental|STROKE 112|stroke education: STROKE 112
16296704|NCT04699396|Experimental|Mobilisation with Movement 1 (MWM1)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at fibula and talus. Three sets of 10 repetitions of each techniques, were administrated.
16296705|NCT04699396|Experimental|Mobilisation with Movement 2 (MWM2)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at talus and fibula (order of application inverted). Three sets of 10 repetitions of each techniques, were administrated.
16296706|NCT04699396|Placebo Comparator|Placebo|The Placebo group participants performed the same number of sets and repetitions of lean/lunge forward into dorsiflexion, without any glide application, in the same position
16296707|NCT04699396|Experimental|Intervention|The experimental groups (MWM1 and MWM2), were later merged into a single Intervention group.
16296708|NCT04699370|Experimental|cognition-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to cognition-targeted exercise .
~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.
~For Cognition- targeted exercise , all standardized physical therapy exercises will be performed in a time-contingent rather than in a symptom-contingent way ."
16296709|NCT04699370|Active Comparator|symptom-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to symptom-targeted exercise .
~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.
~For symptom- targeted exercise, All Standardized physical therapy exercises will be performed in a symptom-contingent way (Stop or adjust the exercise when it hurts)."
16296710|NCT04699357|Active Comparator|Group 1|0.01% atropine
16296711|NCT04699357|Experimental|Group 2|0.04% atropine
16296712|NCT04699357|Experimental|Group 3|0.1% atropine
16296713|NCT04699344||Pre-tissue biopsy patients|Pre-tissue biopsy patients with suspected prostate carcinoma will be the experimental group to determine the sensitivity and specificity of PROUD analysis, the result will be compared with histological results and PCA3 test.
16296714|NCT04699344||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of PROUD analysis.
16296715|NCT04699331|Experimental|Individualized stimulation group|Patients receive five sessions of individualized stimulation obtained from brain image-based transcranial direct stimulation simulation. The simulator generates the electrode's location on the scalp.
16296716|NCT04699331|Active Comparator|Conventional stimulation group|Patients receive five sessions of conventional stimulation with electrodes over C3 and C4 based on the 10-20 system.
16296717|NCT04699331|Sham Comparator|Sham stimulation group|Patients receive five sessions of sham stimulation with electrodes over C3 and C4 based on the 10-20 system.
16296718|NCT04699318|Experimental|Single Dartos TIP|Single dartos tubularized incised plate urethroplasty
16296719|NCT04699318|Experimental|Double Dartos TIP|Double dartos tubularized incised plate urethroplasty
16296720|NCT04699305||ActiGraft|Whole blood clot (WBC) gel
16296721|NCT04699292||Cohort A|MLS patients managed by surgery only
16296722|NCT04699292||Cohort B|MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery
16296723|NCT04699292||Cohort C|MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery
16296724|NCT04699292||Cohort D|MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)
16296725|NCT04699292||Cohort E|MLS patients with oligometastatic and/or oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)
16296726|NCT04699279|Experimental|Statin|
16296727|NCT04699279|No Intervention|Blank|
16296728|NCT04699266|Experimental|Experimental: POD F GF IOL Implantation|Experimental: POD F GF IOL Implantation experimental Multi-center, single-arm, non-masked study Mono- or bilateral implantation of trifocal intraocular lenses POD F GF
16296729|NCT04699253||Consenting participants|Patients meeting the eligibility criteria and are using the SanaCoach heart failure during the study period.
16296730|NCT04699253||Consenting non-participants|Patients meeting the eligibility criteria but do not wish to use the SanaCoach heart failure and only fill-in an anonymized questionnaire once, without any follow-up.
16296731|NCT04699240|Active Comparator|Clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
16296732|NCT04699240|Active Comparator|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
16296952|NCT04697771|Other|Kontrol Group|First Evaluation - 8 week waiting period - Second Evaluation - 8 week Fine Motor Skills Training
16296733|NCT04699227|Sham Comparator|Control group not receiving RIC|Those randomised to the control group will have the blood pressure cuff placed on the arm, but it will not be inflated.
16296734|NCT04699227|Experimental|Interventional group receiving RIC|RIC will consist of 3-4 cycles of cuff inflations to 200 mmHg for 5 min with deflation to 0 mmHg for another 5 min, which is automatically administered by the pre-programmed cuff.
16296735|NCT04699214|Experimental|Endostar combined with chemotherapy AI|"Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar uses 15 medicines per cycle, 15 Endostar medicines and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles.
~AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W."
16296736|NCT04699214|Active Comparator|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
16296737|NCT04699214|Placebo Comparator|Observation group|"The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.
~Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. In the course of medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end."
16296738|NCT04699201|Experimental|Prosthesis|Firstly, a laparoscopic cholecystectomy is performed. After suturing the aponeurosis with a J needle and 0 Polydioxanone, a lightweight, large-pore mesh made of PVDF monofilament (polyvinylidene fluoride - DynaMesh-CICAT, FEC Textiltechnik, Germany) will be placed onlay, overlapping 2cm in all directions from the edge of the aponeurosis incision at the umbilical trocar site. The mesh will be fixed to the aponeurosis with cyanoacrylate glue (Glubran®, GEM, Viareggio, Italy).
16296739|NCT04699201|Active Comparator|Control|Firstly, a laparoscopic cholecystectomy is performed. Closure of the aponeurosis will be performed by standard procedure: under direct vision, suturing the aponeurosis with a J needle and 0 Polydioxanone, with a stitch interval of ≤ 5mm.
16296740|NCT04699188|Experimental|Arm A|JDQ443
16296741|NCT04699188|Experimental|Arm B|JDQ443 in combination with TNO155
16296742|NCT04699188|Experimental|Arm C|JDQ443 in combination with spartalizumab
16296743|NCT04699188|Experimental|Arm D|JDQ443 in combination with TNO155 and spartalizumab
16296744|NCT04699175|Experimental|Treatment group A|
16296745|NCT04699175|Experimental|Treatment group B|
16296746|NCT04699175|Placebo Comparator|Treatment group C|
16296747|NCT04699149|Active Comparator|real stimulation|The PD patients randomized in the experimental group will receive VBT each time preceded by a real rTMS stimulation.
16296748|NCT04699149|Sham Comparator|sham stimulation|The PD patients randomized in the control group will receive VBT each time preceded by a sham TMS.
16296750|NCT04699123|Experimental|Arm 1a - NC318 only|At the discretion of the treating physician, advanced NSCLC patients on arm 1a will receive NC318 alone.
16296751|NCT04699123|Experimental|Arm 1b - NC318 and Pembrolizumab|At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
16296752|NCT04699123|Experimental|Arm 2 (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab|Arm 2 will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive combination therapy with NC318 and pembrolizumab.
16296753|NCT04699110|Experimental|Treatment group|Patients receiving intracoronary adrenaline
16296754|NCT04699110|Active Comparator|Control group|Patients receiving intracoronary adenosine
16296755|NCT04699097||azytromycin|children who recieved azithromycin due to COVID 19 infection
16296756|NCT04699084|Experimental|Music Group|Patients received music intervention and usual postoperative care.
16296757|NCT04699084|No Intervention|Control Group|Patients received only postoperative usual care.
16296759|NCT04699058||Health care workers|questionnaire and COVID antibody test
16296760|NCT04699058||Household members|questionnaire and COVID antibody test
16296765|NCT04699019||Active Runners|All participants will be required to run unshod for a combination of four prescribed speeds (walking and up to 9 mph) and three different foot strike patterns (rearfoot, midfoot, and forefoot) on level ground.
16296766|NCT04698993|Other|Symptomatic|Collection of specimens from symptomatic COVID-19 positive participants
16296767|NCT04698993|Other|Asymptomatic|Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2
16296768|NCT04698980|Other|participants selected according to their G6PD activity|"50 subjects with severe deficit G6PD activity (<30% of the median in the general population, ie 3.6U / g Hb), adults or children two years and over.
~50 subjects with intermediate G6PD activity (30-80%), adults.
~50 subjects with normal G6PD activity (> 80% ie> 9.6U / g Hb), adults."
16296769|NCT04698967|Experimental|CCD-V Group|Veterans in this arm will receive treatment as usual, which is transitional work experience intervention, as well as the CCD-V intervention
16296770|NCT04698967|Active Comparator|Treatment as Usual|Veterans in this arm will receive treatment as usual, which is transitional work experience intervention.
16296771|NCT04698954|Experimental|AIMS intervention group|A nurse-delivered behavioural intervention focussing on medication adherence, physical activity, and symptom management integrated in routine clinical care. AIMS-CHF incorporates nurse-counselling and feedback from electronic monitoring of medication use (using MEMS-buttons) and physical activity (using pedometers).
16296772|NCT04698954|Active Comparator|Treatment-as-usual group|Participants in the control group will receive treatment as usual. They will visit the out patient clinic each 3 or 6 months for 30 minutes.
16296773|NCT04698941|Experimental|Simvastatin + Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
16296774|NCT04698941|Active Comparator|Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles)
16296775|NCT04698928|Experimental|Theta burst stimulation group|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
16296776|NCT04698915|Experimental|Arm A Active GC4711|
16296777|NCT04698915|Placebo Comparator|Arm B Placebo|
16296778|NCT04698902||Circumferential calcification|Patients with circumferential pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium >180 degrees)
16296779|NCT04698902||Eccentric calcification|Patients with an eccentric pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium <180 degrees)
16296780|NCT04698902||Nodular calcification|Patients with calcium nodules identified by OCT (Optical coherence tomography) assessment
16296781|NCT04698889|Active Comparator|Cow milk|Administration of natural cow whole milk
16296782|NCT04698889|Active Comparator|Human milk|Administration of natural human milk
16296783|NCT04698889|Active Comparator|Modified cow milk - low protein|Administration of modified cow milk at low protein content
16296784|NCT04698889|Active Comparator|Modified cow milk - high protein|Administration of modified cow milk at high protein content
16296785|NCT04698876|Experimental|Outpatient measurement of intraocular pressure|The intervention group measures its intraocular pressure itself in their home environment for 7 days at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m. with a self-tonometer (iCareHOME).
16296786|NCT04698876|Active Comparator|Stationary measurements of intraocular pressure|The intraocular pressure of the control group is measured by means of rebound tonometry or Goldmann applanation tonometry in a clinic for minimum 24 hours at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m.
16296787|NCT04698863||high flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 4 L/min for Group High flow rate.
16296788|NCT04698863||low flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 1 L/min for Group Low flow rate.
16296789|NCT04698850|Active Comparator|aflibercept|Patients with RAP who will be receiving aflibercept.
16296790|NCT04698850|Experimental|brolucizumab|Patients with RAP who will be receiving brolucizumab.
16296791|NCT04698811|Other|VIRTUAL ENEAGRAM: QUALITY OF LIFE, STRESS AND ANXIETY.|Training and testing battery.
16296792|NCT04698798|Experimental|Skeletal muscle wasting|investigating acute skeletal muscle wasting in patients infected with SARS-CoV-2 and admitted to the ICU
16296793|NCT04698785|Experimental|Regorafenib and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib and best supportive care followed by a 7-day period of rest.
~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).
~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
16296794|NCT04698785|Placebo Comparator|Placebo and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo and best supportive care followed by a 7-day period of rest.
~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).
~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
16296795|NCT04698772||Survey Packet 1 Group|"Patients who receive Packet 1 will be in group 1, or the treatment group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2. The physician will be asked to administer a sub-dissociative dose of ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)."
16296796|NCT04698772||Survey Packet 2 Group|"Patients who receive Packet 2 will be in group 2, or the control group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2.The physician will be asked to administer morphine 4 mg IV push over 3-5 minutes for pain control."
16296797|NCT04698759||Stunted subject|Children with stunted status condition based on Z score criteria
16296798|NCT04698759||Normal subject|Children with normal status condition based on Z score criteria
16296799|NCT04698746|Active Comparator|Ultrasound guided pericapsular nerve group block|Injection of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline mixture between iliopubic eminentia and psoas tendon under ultrasound guidance
16296800|NCT04698746|Active Comparator|Intra-articular local anesthetic injection|At the end of the surgical case, a total of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline injection intra-articularly.
16296801|NCT04698733|Experimental|Experimental: BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive 2 treatments a week on nonconsecutive days for 6 weeks in the clinic with an active electrical stimulation device.
16296802|NCT04698720|Experimental|Muscle Relaxation with Guided Imagery|The participants in Experimental Group will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
16296953|NCT04697758|Experimental|Low Dose|AXT107 0.1 mg/eye
16296803|NCT04698720|Experimental|Hypnosis with Guided imagery|The participants in Experimental Group will receive a four individual 45-minute sessions, every two weeks, of hypnotic intervention with guided imagery focused on ulcer healing, carried out by the Hypnotherapist on the day of the Diabetic Foot appointments.
16296804|NCT04698720|Placebo Comparator|Active Control Group|Participants in the Active Control Group will receive four individual 45-minute sessions of neutral guided imagery placebo, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
16296805|NCT04698720|No Intervention|Passive Control Group|The participants in the Passive Control Group will not receive any intervention nor placebo session.
16296806|NCT04698707||lower limb lymphedema patients|This retrospective cohort study enrolled 131 lower limb lymphedema patients including 10 patients who have received VLNT as their primary lymphedema surgery showing minimal post-VLNT improvement (Group I) and 121 patients without previous lymphatic surgery (Group II).
16296807|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 40 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 40 V.
16296808|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 60 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 60 V.
16296809|NCT04698681|Other|Biomarker Screening|Patients with stage IV nonsquamous NSCLC not previously treated with systemic therapy for metastatic disease and who meet all of study inclusion criteria and none of the exclusion criteria.
16296810|NCT04698668||1|Patients with pancreatic fluid collection treated with traditional EUS-drainage
16296811|NCT04698668||2|Patients with pancreatic fluid collection treated with fusion imaging
16296812|NCT04698655|Active Comparator|Control group|"Asked to read a single-A4 page of brief osteoarthritis information (what is osteoarthritis)"
16296813|NCT04698655|Experimental|Treatment options group|"Asked to read brief osteoarthritis information + two A4 pages of information on treatment options (osteoarthritis treatment options)"
16296814|NCT04698655|Experimental|Treatment options + recommendation group|Asked to read brief osteoarthritis information + information on treatment options + receive hypothetical general practitioner recommendation for exercise
16296815|NCT04698642|Experimental|CBL-514 180 mg, 1.2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
16296816|NCT04698642|Experimental|CBL-514 240 mg, 1.6 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
16296817|NCT04698642|Experimental|CBL-514 300 mg, 2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
16296818|NCT04698616||Malignant lymphoma patients|Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.
16296819|NCT04698603|Experimental|Phase 1 (Part A): GH001 dose A|
16296820|NCT04698603|Experimental|Phase 1 (Part A): GH001 dose B|
16296821|NCT04698603|Experimental|Phase 2 (Part B): GH001 Individualized Dosing Regimen|
16296822|NCT04698590|Active Comparator|WFG Scleral Lenses|Scleral lenses with customized wavefront guided optics
16296823|NCT04698590|Placebo Comparator|Traditional Scleral Lenses|Scleral lenses with traditional optics
16296824|NCT04698577|Experimental|Attention Training|"Engaged in sustained updating by mentally keeping score during an interactive game without written or verbal aids.
~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
16296825|NCT04698577|Active Comparator|Active Control|"Played the same interactive game as the attention training group without the requirement of mentally keeping score.
~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
16296826|NCT04698564|Experimental|Single-arm study in patients who are suspected or known to have prostate cancer|Perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
16296827|NCT04698551||16 pregnant women and their spouses|16 pregnant women and their spouses
16296828|NCT04698538|No Intervention|Educational Materials|Caregivers in this arm will receive intervention material, but no coaching. The material consists of a self-guided module introducing caregivers to the developmental concepts of joint engagement, social communication, and play.
16296829|NCT04698538|Experimental|JASPER intervention|The caregivers randomized to intervention, will meet twice a week with UCLA staff to do session planning one day and JASPER remote, live coaching another day. The caregivers are expected to meet with the UCLA team twice a week.
16296830|NCT04698525|Active Comparator|Valproate group|This is a well know antiepileptic drug with efficacy as a preventive tic treatment in episodic migraine
16296831|NCT04698525|Active Comparator|Memantine|This is a possible preventive treatment in episodic migraine
16296832|NCT04698512||Arteriovenous Fistuloplasty with MagicTouch™ Balloon|Patients above the age of 21 that have undergone AVF / AVG fistuloplasty with MagicTouch™ at Singapore General Hospital will be included in the study and followed up post-op for 12 months. Patients will be treated and followed-up following standard clinical care pathways.
16296833|NCT04698499|Active Comparator|Pen and Paper|Participants will complete swallowing exercises using printed materials and diary for tracking.
16296834|NCT04698499|Experimental|Mobile health system|Participants will complete swallowing exercises using a mobile health system with surface electromyography (sEMG) biofeedback.
16296835|NCT04698486|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD
~MR spectroscopy verified no steatosis"
16296836|NCT04698486|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD
~MR spectroscopy verified steatosis"
16296837|NCT04698473|Active Comparator|NCPAP|"Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94.
~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
16296911|NCT04698070|Active Comparator|Standard|RUTF 130-200 kcal/kg/day for children with nutritional edema or MUAC < 115 mm or WHZ <-3 and RUSF 500 kcal/d for children 6-23 months with WHZ between -2 and -3 Z and MUAC 115-124 mm.
16296838|NCT04698473|Active Comparator|NIPPV|"Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94.
~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
16296839|NCT04698460|Experimental|Hybrid coronary revascularization (HCR)|Patients with multi-vessel CAD randomized to hybrid coronary revascularization
16296840|NCT04698460|Active Comparator|Conventional coronary artery bypass grafting (CABG)|Patients with multi-vessel CAD randomized to conventional CABG
16296841|NCT04698447|Experimental|Dietary Supplement blinded|20 subjects with the metabolic syndrome receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
16296842|NCT04698447|Placebo Comparator|Placebo blinded|20 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
16296843|NCT04698447|Active Comparator|Dietary Supplement open-label|20 healthy volunteers receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
16296844|NCT04698434|Active Comparator|0.5mg/kg esketamine group|0.5mg/kg esketamine group will be given a single intravenous 0.5mg/kg esketamine
16296845|NCT04698434|Active Comparator|.75mg/kg esketamine group|0.75mg/kg esketamine groupwill be given a single intravenous 0.75mg/kg esketamine
16296846|NCT04698434|Active Comparator|1.0mg/kg esketamine group|1.0mg/kg esketamine group will be given a single intravenous 1.5mg/kg esketamine
16296847|NCT04698421||patients with rare autoimmune neurological diseases|
16296848|NCT04698408|Experimental|high-protein, carbohydrate-reduced diet|
16296849|NCT04698408|Active Comparator|Dutch Nutritional Guidelines|
16296850|NCT04698395|Experimental|HABIT-ILE|Baby HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks
16296851|NCT04698395|Active Comparator|Regular care|Usual customary care intervention during two weeks
16296852|NCT04698382||Non-COVID-19-related sepsis|"Non-COVID-19 sepsis patients will be identified with sepsis or septic shock without a COVID-19 diagnosis code or a positive COVID-19 laboratory test.
~Sepsis patients will be defined as patients with concurrent infection and organ dysfunction. Presumed concurrent infection will be defined as a blood culture order and ≥ 3 days of antibiotics administration, including at least 24h of intravenous antibiotics, or death while on antibiotics within 3 days of admission. Organ dysfunction will be defined by ICD-10-modified acute organ failure score. Sensitivity analyses will use ICD-10 explicit sepsis codes to define non-COVID-19 sepsis instead.
~COVID-19 will be identified based on receiving a diagnosis code for COVID-19 (U07.1) or legacy coding (prior to the implementation of a specific COVID-19 code) present-on-admission and/or a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test on admission"
16296853|NCT04698382||Non-COVID-19, Non-Sepsis Control Population|"This will be defined as patients identified with emergency conditions of interest without a diagnosis code of sepsis, COVID19 or a positive COVID-19 laboratory test.
~These include
~Acute Gastrointestinal Bleeding (GIB): Patients with at least one GIB ICD-10 code and one relevant CPT intervention codes.
~Myocardial Infarction (MI): Patients with at least one MI ICD-10 code and one relevant CPT intervention codes"
16296854|NCT04698369|Experimental|low frequency low amplitude|The vibration frequency is 60 Hz and amplitude is 0.2 mm
16296855|NCT04698369|Experimental|low frequency high amplitude|The vibration frequency is 60 Hz and amplitude is 2 mm
16296856|NCT04698369|Experimental|high frequency low amplitude|The vibration frequency is 120 Hz and amplitude is 0.2 mm
16296857|NCT04698369|Experimental|high frequency high amplitude|The vibration frequency is 120 Hz and amplitude is 2 mm
16296858|NCT04698356|Experimental|Validation of auditory-cognitive training paradigm|In order to provide maximal speech-in-noise training benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate the translated and adjusted sentences (based on the Nottingham UK PLUS training paradigm), the adaptive procedure, and the short-term memory component, in young, normal-hearing adults (18-30 years). Based on the results of this pilot study, the investigators can further optimize the sentences and procedures to be used during the training paradigm for older adults.
16296859|NCT04698343|Experimental|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
16296860|NCT04698330|Experimental|Group A|LADA patients are assigned to receive berberine and inulin for 3-month.
16296861|NCT04698330|Experimental|Group B|LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.
16296862|NCT04698330|Experimental|Group C|LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.
16296863|NCT04698330|Placebo Comparator|Group D|LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.
16296864|NCT04698317|Experimental|beta-tricalcium phosphate plus concentrated growth factors|surgery plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).
16296865|NCT04698317|Placebo Comparator|beta tricalcium phosphate alone(control group)|surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group),
16296866|NCT04698304||Group A：TASC C lesion group|Multiple stenoses or occlusions totaling >15cm or recurrent stenoses or occlusions that need treatment after endovascular interventions (300 cases)
16296867|NCT04698304||Group B：TASC D lesion with common femoral artery involved|Chronic total occlusions >20cm with common femoral artery involved (100 cases)
16296868|NCT04698304||Group C：TASC D lesion with proximal popliteal artery involved|Chronic total occlusions >20cm with proximal popliteal artery involved (300 cases)
16296869|NCT04698304||Group D：TASC D lesion with distal popliteal artery involved|Chronic total occlusions >20cm with distal popliteal artery involved (200 cases)
16296870|NCT04698304||Group E：TASC D lesion with popliteal artery and proximal trifurcation vessels involved|Chronic total occlusion of popliteal artery (P1-3 segment) with proximal trifurcation vessels involved (100 cases)
16296910|NCT04698083||Group2:Rightward axis shift(Rws) and Leftward axis shift (Lws)|Both groups were divided into two main subgroups:patients with Rws and patients with leftward shift(Lws) of the QRS axis.The patient numbers were as follows: NS Rws (n=37),NS Lws(n=43),LS Rws (n=40),andLS Lws (n=40)
16296954|NCT04697758|Experimental|Mid Dose|AXT107 0.25 mg/eye
16296871|NCT04698291||Controls|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
16296872|NCT04698291||Cases|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
16296873|NCT04698278||Surgical Treatment Group|This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.
16296874|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 40 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
16296875|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 20 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 2 uses 20 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
16296876|NCT04698265|Experimental|CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)|CellularMatrix (RegenLab SA, Switzerland) is composed of sterile and non-pyrogenic tubes allowing the mix of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) in the same proportion (2mL of PRP for 2mL of HA).
16296877|NCT04698265|Placebo Comparator|Normal saline|4ml of normal saline
16296878|NCT04698252|No Intervention|Systemic therapy|Patients will receive standard of care with systemic therapy alone.
16296879|NCT04698252|Experimental|Local therapy + systemic therapy|In addition to systemic therapy, patients will receive local therapy for all oligometastatic sites. Options of local therapy will be radiotherapy, radiofrequency ablation, and/ or surgery.
16296880|NCT04698239|Experimental|Laser application ( BEFORE/AFTER)|"All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself.
~The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study."
16296881|NCT04698226|Active Comparator|ILM peel|Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade.
16296882|NCT04698226|Experimental|Inverted flap|Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
16296883|NCT04698213|Experimental|intermittent axitinib plus Avelumab|"All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.
~Treatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner."
16296884|NCT04698200|Experimental|Blood pressure|Measurement of brachial, central and beat-to-beat blood pressure.
16296886|NCT04698174|Experimental|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|
16296887|NCT04698174|Experimental|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|
16296888|NCT04698174|Active Comparator|Standard Photorefractive keratectomy (PRK)|
16296889|NCT04698161||NSCLC|Patients with non-small-cell lung cancer (NSCLC)
16296890|NCT04698161||metastatic melanoma|patients with metastatic melanoma
16296891|NCT04698148||CDI patients|Patients with Clostridium Difficile Infection
16296892|NCT04698148||MDRO patients|Patients with Multi Drug Resistant Organisms infection
16296893|NCT04698148||IBD patients|Patients with Chronic Inflammatory Bowel Disease
16296894|NCT04698148||IBS patients|Patients with Irritable Bowel Syndrome
16296895|NCT04698148||Hepatic Encephalopathy patients|Patients with Hepatic Encephalopathy
16296896|NCT04698148||healthy volunteers|healthy volunteers
16296897|NCT04698135||morbid obesity|Patients with morbid obesity
16296898|NCT04698135||Metabolically healthy obesity|Patients with metabolically healthy obesity
16296899|NCT04698135||Healthy volunteers|Healthy volunteers
16296900|NCT04698122||type 1 diabetes|Patients with type 1 diabetes
16296901|NCT04698122||type 2 diabetes|Patients with type 2 diabetes
16296902|NCT04698122||Healthy volunteers|Healthy volunteers
16296903|NCT04698109||recurrent cervicovaginitis|patients with recurrent cervicovaginitis
16296904|NCT04698109||endometriosis|patients with endometriosis
16296905|NCT04698109||repeated implantation failures|patients with repeated implantation failures
16296906|NCT04698109||healthy volunteers|healthy volunteers
16296907|NCT04698096||metabolic syndrome|Patients with metabolic syndrome
16296908|NCT04698096||Healthy volunteers|Healthy volunteers
16296909|NCT04698083||Group1:normal SpO2(NS,n = 80) and low SpO2(LS, n = 80).|Patients with normal oxygen saturation (SpO2; ≥ 90%) who did not receive oxygen therapy and patients with low SpO2(<90%) who received nasal oxygen therapy were included in this study
16296955|NCT04697758|Experimental|High Dose|AXT107 0.5 mg/eye
16296912|NCT04698070|Experimental|OptiMA|RUTF 170 kcal/kg/d for children with nutritional edema or MUAC < 115 mm; 125 kcal/kg/d for MUAC 115-119 mm and 75 kcal/kg/d for MUAC 120-124 mm.
16296913|NCT04698070|Experimental|ComPAS|RUTF 1000 kcal/d for children with nutritional edema or MUAC < 115 mm and 500 kcal/day for MUAC 115-124 mm.
16296914|NCT04698057|Active Comparator|Amoxicillin clavulanate + ciprofloxacin|Treatment with amoxicillin-clavulanate 1g tib and ciprofloxacine 750mg bid for 5 days
16296915|NCT04698057|Experimental|Amoxicillin clavulanate + Placebo|Treatment with amoxicillin-clavulanate 1g tib for 5 days
16296916|NCT04698044||Healthy|Have not chronic disease
16296917|NCT04698044||Cancer|Have cancer
16296918|NCT04698044||Non-Cancer Crhronic Disease|Have non-cancer chronic disease
16296919|NCT04698031|Experimental|Clopidogrel|"After randomization, patients will receive clopidogrel mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
16296920|NCT04698031|Experimental|Aspirin|"After randomization, patients will receive aspirin daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 1 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
16296921|NCT04698018|Experimental|Faster aspart|Subjects will receive 2 injections of a single dose of faster aspart at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
16296922|NCT04698018|Active Comparator|NovoRapid®|Subjects will receive 2 injections of a single dose of NovoRapid® at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
16296923|NCT04698005|Experimental|Supplementation of exogenous ketones|Exogeneous ketones will be administered orally using monoester 3-OHB concentrate without added salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be administered over 10 mins every 3 hours, 3 times in a row.
16296924|NCT04698005|Placebo Comparator|Control group|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
16296925|NCT04697992|Experimental|group A|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
16296926|NCT04697992|Experimental|group B|one eye was treated with tranexamic acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
16296927|NCT04697966|Experimental|Mindfulness (Headspace app)|
16296928|NCT04697966|Active Comparator|Active Control Condition|
16296929|NCT04697953|Experimental|brolucizumab 6mg|Open label, brolucizumab 6mg, daily dosing, Treat & Extend regimen by up to 2 week intervals. Dosing intervals as per previous therapy and treatment extension intervals
16296930|NCT04697940|Experimental|Refractory or Relapsed Non-Hodgkin's Lymphoma|Decitabine-primed Tandem CAR19/20 engineered T cells
16296931|NCT04697927||MSK Patients|Patients include those undergoing cancer screening and treatment as well as cancer survivors that received COVID-related care. Both adult and pediatric patients will be included.
16296932|NCT04697927||Household Members (identified by MSK Patient)|Individuals over the age of 18 (i.e., individuals currently living in the same household as the MSK enrollee).
16296933|NCT04697914|Placebo Comparator|Control Sock|Control comercial Socks (Lurbel Tierra). These socks are designed to perform trekking.
16296934|NCT04697914|Experimental|Experimental Relief Pressure sock|Experimental Socks (Lurbel Tierra based), with a discharge element (in the own fabric and fibres of the sock).
16296935|NCT04697901|Experimental|Active Stimulation|Active tDCS stimulation will be applied.
16296936|NCT04697901|Sham Comparator|Sham Stimulation|Sham tDCS stimulation will be applied.
16296937|NCT04697888|Experimental|Overall Study|Use of Omegaven for patients with parenteral nutrition associated liver disease.
16296938|NCT04697875|Experimental|Normobaric hypoxia (FiO2 15%)|
16296939|NCT04697875|Sham Comparator|Placebo-ambient air (FiO2 21%)|
16296940|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
16296941|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
16296942|NCT04697849|Experimental|CREST|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
16296943|NCT04697849|Active Comparator|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
16296944|NCT04697836|Experimental|ST (superficial cervical plexus block combined with Translareyngeal block)|Superficial cervical plexus block combined with Translareyngeal block Group.
16296945|NCT04697836|Active Comparator|S (superficial cervical plexus block)|Superficial cervical plexus block Group
16296946|NCT04697823|Active Comparator|study group|Patients receiving an embryo transfer in hyaluronan-enriched transfer medium
16296947|NCT04697823|No Intervention|control group|Patients receiving an embryo transfer in conventional culture medium
16296948|NCT04697810|Experimental|Namodenoson|Namodenoson capsules orally 25 mg every 12 hours for 36 weeks
16296949|NCT04697810|Placebo Comparator|Placebo|Matching placebo capsules orally 25 mg every 12 hours for 36 weeks
16296950|NCT04697784|Experimental|Subjects who receive the TREO Abdominal Stent-Graft System|Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.
16296951|NCT04697771|Experimental|Study Group|First Evaluation - Fine Motor Skills Training - 8 week - 3 session per week - 40 minute per session - Second Evaluation
16296958|NCT04697732||Adult patients age above 18 years|ASA I-IV adult patients over 18 years of age who will receive general anesthesia and are scheduled to be extubated postoperatively, who can give informed consent, have no known psychological or psychiatric problems, and who are suitable for postoperative follow-up.
16296959|NCT04697719|Experimental|Aspirin 81mg, Then Aspirin 325mg|After a 3 week placebo run-in period, participants first receive Aspirin 81mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 325mg capsule daily for another 3 weeks.
16296960|NCT04697719|Experimental|Aspirin 325mg, Then Aspirin 81mg|After a 3 week placebo run-in period, participants first receive Aspirin 325mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 81mg capsule daily for another 3 weeks.
16296961|NCT04697706|Active Comparator|"Study period Water"|Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.
16296962|NCT04697706|Experimental|"Study period Moonstone"|Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.
16296963|NCT04697693|Experimental|Treatment with escitalopram or duloxetine|Participant will be begun on either escitalopram 10mg or duloxetine 30mg. The default medication will be escitalopram. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the Hamilton Rating Score for Depression (HRSD) >7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study. Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 4 weeks, then be increased to 60mg for the remaining 4 weeks of the study.
16296964|NCT04697680|Active Comparator|Group 1|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 1) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
16296965|NCT04697680|Active Comparator|Group 2|Subjects randomized into Group 2 will be provided with a sleep schedule each week based on an algorithm (Algorithm 2) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
16296966|NCT04697680|Active Comparator|Group 3|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 3) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
16296967|NCT04697667|Experimental|Group I|Each subject in this group will receive a combined treatment protocol consisting of three PRP injections to knee joint and supervised exercise program.
16296968|NCT04697667|Active Comparator|Group II|Each subject in this group will receive a treatment of supervised exercise program.
16296969|NCT04697667|Active Comparator|Group III|Each subject in this group will receive a treatment of three PRP injections to knee joint.
16296970|NCT04697654|Experimental|TLC19 (low dose)|TLC19 2ml single dose
16296971|NCT04697654|Experimental|TLC19 (medium dose)|TLC19 4ml single dose
16296972|NCT04697654|Experimental|TLC19 (high dose)|TLC19 6ml single dose
16296973|NCT04697654|Sham Comparator|TLC19 Vehicle (low dose)|TLC19 Vehicle 2ml single dose
16296974|NCT04697654|Sham Comparator|TLC19 Vehicle (medium dose)|TLC19 Vehicle 4ml single dose
16296975|NCT04697654|Sham Comparator|TLC19 Vehicle (high dose)|TLC19 Vehicle 6ml single dose
16296976|NCT04697641|Experimental|Helicobacter pylori eradication therapy Group|Patients with Functional Dyspepsia receiving two week course of triple drug regimen for H pylori eradication followed by six weeks of proton pump inhibitors
16296977|NCT04697641|Active Comparator|Symptomatic treatment group|Patients with Functional Dyspepsia receiving symptomatic therapy with proton pump inhibitors or gastric prokinetics
16296980|NCT04697615||Algometry|In the test stage, pain threshold evaluations were started through the algometer in a randomized manner by two different examiners trained and experienced in the application of the test, following the same order of evaluation of the muscles (middle deltoid, upper trapezius, pectoralis major, biceps brachii , triceps, lumbar multifidus, rectus femoris, biceps femoris, tibialis anterior and soleus, bilaterally), with an interval between each assessment of five minutes in which the participants remained at rest. After the interval described, the retest stage was initiated, which had the same procedures as the test stage.
16296981|NCT04697602|Experimental|Dose titration group|Stepwise dose titration of febuxostat and low-dose colchicine
16296982|NCT04697602|Active Comparator|Standard treatment group|Fixed dose febuxostat and low-dose colchicine
16296983|NCT04697589|Experimental|SBRP 300 mg|300 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
16296984|NCT04697589|Experimental|SBRP 600 mg|600 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
16296985|NCT04697589|Placebo Comparator|Placebo|Colored maltodextrin
16296986|NCT04697576|Experimental|Cohort I (quadrivalent inactivated influenza vaccine)|Patients receive influenza vaccine IM on day 0 and intratumorally on days 2 and 14 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on day 28.
16296987|NCT04697576|Experimental|Cohort II (quadrivalent inactivated influenza vaccine)|Patients receive influenza vaccine IM on day 0 and intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care ipilimumab, nivolumab, or pembrolizumab.
16297055|NCT04697082|Placebo Comparator|Group A|The open surgical method and a moist gauze (with saline) were applied to patients in group A
16296988|NCT04697563|Active Comparator|Laser|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia.
~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions."
16296989|NCT04697563|Placebo Comparator|Placebo Laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
16296990|NCT04697550|Experimental|Fecal moicrobiome transplant|intervention arm
16296991|NCT04697550|Placebo Comparator|Placebo|placebo capsules administration
16296992|NCT04697537|Active Comparator|Ultrasound guided regional anesthesia|Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic block of each 15 ml ropivacaine 0,5% and 0,5 ml dexmedetomidine (100µg/ml).
16296993|NCT04697537|Active Comparator|Local infiltration analgesia|Patient will be given a local infiltration analgesia from their treating surgeon during the operation (in the OR) with 60 ml ropivacaine 0,5% and 1 ml dexmedetomidine (100µg/ml).
16296994|NCT04697524|Experimental|Phase 1: Supportive care (GMV)|Participants will take a baseline assessment to collect socio-demographic information and complete a series of patient-reported outcome assessments (PROs) prior to their first group medical visit (GMV). The GMV intervention will take place over four weekly sessions conducted virtually. At the completion of all four weekly GMV sessions, participants will be asked to complete an exit survey. Participants in phase one will not be contacted or followed after the exit survey.
16296995|NCT04697524|Experimental|Phase 2: Refined GMV|Up to three new cohorts of participants are recruited to assess the acceptability and feasibility of the refined intervention based on the results from the Phase 1 group
16296996|NCT04697511|Experimental|Midazolam and/or M2951|
16296997|NCT04697498|Active Comparator|The Control Group|The control group will include patients who will undergo surgery under general anesthesia.
16296998|NCT04697498|Experimental|The Study Group|The study group will include patients who will undergo surgery under general anesthesia using a bilateral bi-level Erector spine plane block.
16296999|NCT04697485|Experimental|Low-Dose, Triple Polydiuretic Therapy (LDTPT)|Polydiuretic therapy will consist of bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg once daily for 4 weeks.
16297001|NCT04697459|Experimental|HD-EX (patient with intradialytic exercise)|will be enrolled in a 16 week intradilatytic exercise program.
16297002|NCT04697459|No Intervention|HD (patients with standard HD)|patients with standard hemodialysis (e.g. without exercise).
16297003|NCT04697446||Patients from the BLU-667-1101 (ARROW) study|Patients with Non-Small Cell Lung Cancer (NSCLC) who received treatment with pralsetinib as part of the BLU-667-1101 (ARROW) study
16297004|NCT04697446||External Control Group|Patients with Non-Small Cell Lung Cancer (NSCLC) that received best available therapy
16297005|NCT04697433||Myotonometry|The evaluation of myotonometry will be carried out by two independent evaluators. The first evaluator will perform the test bilaterally on the middle deltoid, upper trapezius, pectoralis major, biceps brachii, rectus femoris, anterior tibialis, triceps brachii, lumbar multifidus, biceps femoris and soleus previously marked. Immediately after, the second appraiser will perform the same measurements in the same order (Inter-rater reliability). After a 15-minute interval, the retest (intra-rater reliability) will be performed following the same procedure and order as the test step.
16297006|NCT04697420|Experimental|Group (P)|the patients were received paravertebral block to control pain postoperatively.
16297007|NCT04697420|Experimental|Group (T)|the patients were received transversus abdomins plane (TAP) block to control pain postoperatively.
16297008|NCT04697407|Experimental|MS Patients|Patients with MS at any stage and for any type of MS : MS at the onset of the disease, Clinically isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)
16297009|NCT04697407|Active Comparator|non MS Patients|Patients with a neurological and immunological disease except MS.
16297010|NCT04697407|Active Comparator|Healthy volunteers|
16297011|NCT04697381|Experimental|somatropin - GH naïve pediatric cohort|All participants will receive somatropin.
16297012|NCT04697381|Experimental|somatropin - GH treated pediatric cohort|All participants will receive somatropin
16297013|NCT04697381|Experimental|somatropin - adult cohort|All participants will receive somatropin
16297014|NCT04697368|Experimental|Experimental Group (EG)|The experimental group (EG), in addition to the standard treatment, will perform one session per day, each lasting 40 minutes, with the Armeo Power robotic system for upper limb rehabilitation. Each subject will perform a total of 25 ± 3 treatment sessions with a frequency of 5 times a week for 5 weeks.
16297015|NCT04697368|Active Comparator|Control Group (CG)|The control group (CG), in addition to the standard routine rehabilitation treatment, will follow 40 minutes of conventional upper limb rehabilitation. Each subject will perform a total of 25 ± 3 conventional upper limb treatment sessions with a frequency of 5 times a week for 5 weeks.
16297016|NCT04697355|Experimental|Naringenin + Beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day
16297017|NCT04697342|Active Comparator|NIS with pressure injury(PI) education|Clinical nurses use Nursing information system(NIS) to log in nursing records every day, and pressure injury (PI) education pops out of the NIS window for teaching
16297125|NCT04696562|No Intervention|Control group|The control group is the group that receives standard clinical care.
16297018|NCT04697342|Active Comparator|NIS with PI education, and microvideo|In addition to the built-in PI education in the NIS that nurses use every day, it also provides a flipped digital learning plan course unit, which can be self-study courses anytime, anywhere, without being restricted by time and space. And hold a 4-hour physical course for participants.
16297019|NCT04697342|Experimental|NIS with PI education, and workshop|In addition to the built-in PI education in the NIS that nurses use every day, an 8-hour physical course is also provided.
16297020|NCT04697329|Experimental|Local infiltration|
16297021|NCT04697329|No Intervention|No local infiltration|
16297022|NCT04697316|Experimental|ADHD tDCS|
16297023|NCT04697316|Sham Comparator|ADHD Sham|
16297024|NCT04697316|Experimental|Healthy control tDCS|
16297025|NCT04697316|Sham Comparator|Healthy control Sham|
16297026|NCT04697303||Middle and low rectal cancer|
16297027|NCT04697290|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
16297028|NCT04697277|Active Comparator|Group 1|Group 1 (Prophylactic antibiotic 30 minutes before skin incision): Antibiotic diluted in 10 ml syringe 30 minutes before skin incision and after cord clamping, 0.9% NaCl in 10 ml syringe will be administered intravenously within 15 seconds.
16297029|NCT04697277|Active Comparator|Group 2|Group 2 (prophylactic antibiotic after cord clamping): 30 minutes before the skin incision, 0.9% NaCl in a 10 ml injector and after the cord is clamped, the antibiotic diluted in a 10 ml syringe will be administered intravenously within 15 seconds.
16297030|NCT04697264|Experimental|Patients with endometrial cancer|"Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.
~Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.
~Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.
~For the women undergoing chemotherapy, blood sample will be procured prior to commencing chemotherapy and after 3rd (with the blood test before the fourth cycle of chemotherapy) and 6th cycles of chemotherapy."
16297031|NCT04697251|Other|FOT measurements|FOT measurements in newborns and small infants
16297032|NCT04697238|Experimental|High load (11 % of body weight vests)|Subjects in this arm will carry heavy weight (11 percent of body weight) vests for 5 weeks.
16297033|NCT04697238|Placebo Comparator|Low load (1 % of body weight vests)|Subjects in this arm will carry heavy weight (1 percent of body weight) vests for 5 weeks.
16297034|NCT04697225|Experimental|weight loss program|
16297037|NCT04697199|Placebo Comparator|Placebo group|patients received scaling and root planing using hand and ultrasonic instruments.
16297038|NCT04697199|Active Comparator|Probiotic group|"patients received SRP and by using blunt syringe, subgingival delivery of 1ml of probiotic suspension was applied to these sites at baseline (immediately after SRP), one, two and four weeks. Periodontal dressing was applied after placement of the drug.
~After placement of the drug, patients were instructed to keep away from chewing hard or sticky food, brushing near the treated areas, or using any interdental aids for 24 hours."
16297039|NCT04697186|Experimental|berberine , amoxicillin and rabeprazole triple therapy|Berberine 300mg three time daily for 14days, amoxicillin 1000 mg and rabeprazole 10 mg by mouth, twice daily for 14 days.
16297040|NCT04697186|Active Comparator|Bismuth-containing Quadruple Therapy|amoxicillin 1000 mg，clarithromy 500mg，rabeprazole 10 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
16297041|NCT04697173|No Intervention|Standard consent|This group will be consented for invasive procedures using standard Hospital policy. Informed consent will be obtained either in person or via telephone with a witness from the patient or his/her legal guardian for any/all procedures medically indicated at that time, at the discretion of the Attending Physician.
16297042|NCT04697173|Experimental|Bundled consent|"Upon admission, this group will received the document titled Common PICU Procedures Explained and encourage to read the document. They will then, within 24 hours of admission be consented using the Bundle Consent Document for the group of invasive procedures listed and explained in that document."
16297044|NCT04697147|Experimental|Intervention Group|Immediately randomized to receive the intervention for 12 weeks.
16297045|NCT04697147|No Intervention|Waitlist Control|Randomized to receive the intervention post-study.
16297046|NCT04697134|Experimental|Conscious Discipline Intervention Group|Participants in this group received one-on-one Conscious Discipline classes with a Roving Caregiver. These classes consisted of the dissemination of Conscious Discipline Skills and fun songs, games, and activities to foster connections between the infant and caregiver. Both the infant and caregiver received the intervention simultaneously.
16297047|NCT04697134|No Intervention|Control|Participants in this group did not receive the intervention.
16297048|NCT04697121|Placebo Comparator|Placebo|
16297049|NCT04697121|Active Comparator|Combined Bergamot Phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
16297050|NCT04697108|Other|Proprioception Test (TRMOPL)|In the Familiarization stage (1), the TRMOPL was applied by means of a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability.
16297051|NCT04697095|Experimental|early / intermediate AMD without neovessels and without macular atrophy|
16297052|NCT04697095|Experimental|Late exsudative AMD with neovessels|
16297053|NCT04697095|Experimental|Late AMD with macular atrophy without neovessels|
16297056|NCT04697082|Experimental|Group B|Open surgery and then PRP application were performed on patients in group B. After the cavity was filled with PRP, the wound was covered with a dry gauze.
16297057|NCT04697082|Experimental|Group C|PRP was applied to the patients in group C after curettage of the sinus cavity. And again the wound was covered with a dry gauze.
16297058|NCT04697069|Experimental|ANB019|Biological humanized monoclonal antibody
16297059|NCT04697069|Placebo Comparator|Placebo|Solution
16297060|NCT04697056|Experimental|ANB019 Biological|humanized monoclonal antibody
16297061|NCT04697056|Placebo Comparator|placebo|solution
16297062|NCT04697043|Experimental|systemic therapy followed by surgery|"ُThe main intervention is surgery. After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria
~The eligibility criteria for the study are:
~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
16297063|NCT04697043|No Intervention|Systemic therapy|"After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria
~The eligibility criteria for the study are:
~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
16297064|NCT04697017|Other|Multiple births (twins and triplets)|Twins and triplets who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study
16297065|NCT04697017|Other|Singletons|Singletons who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study.
16297066|NCT04697004|Experimental|SMR Stemless Reverse|
16297067|NCT04697004|Active Comparator|SMR Reverse Shoulder System|
16297068|NCT04696991|Experimental|Experimental Group|The mothers in the experimental group (70) were given the postpartum discharge education with PechaKucha Method.
16297069|NCT04696991|No Intervention|Control Group|The mothers in the control group (70) were given the routine postpartum discharge education.
16297070|NCT04696978||PND group|patients occur neurocognitive disorders according to scores in this group
16297071|NCT04696978||NO PND group|patients do not occur neurocognitive disorders according to scores in this group
16297072|NCT04696965|Experimental|Correct/recheck strategy|Patients of study arm will be asked to show how they use their two inhalers and identify errors using a device-specific checklist by research assistant. Research assistant then show the patient how to use these devices correctly and give the checklist including the steps patients did wrong. After teaching by the research assistant, patients were asked to demonstrate the correct way of wrong step(s) they made at beginning.
16297073|NCT04696965|Active Comparator|Usual verbal instruction|Patients of control arm will be asked to show how thy use their two inhalers and identify errors using specific check list by research assistant. The educational nurse will give verbal instruction.
16297074|NCT04696952|Experimental|TS-142 10 mg|Period in which subjects received TS-142 10 mg
16297075|NCT04696952|Experimental|TS-142 20 mg|Period in which subjects received TS-142 20 mg
16297076|NCT04696952|Experimental|Zopiclone 7.5 mg|Period in which subjects received Zopiclone 7.5 mg
16297077|NCT04696952|Experimental|Placebo|Period in which subjects received placebo
16297078|NCT04696939|Experimental|Atezolizumab + Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Atezolizumab, 1200 milligrams(mg) on Day 1 of every 21-day cycle, 2 cycles; Carboplatin, 75 mg per square meter(mg/m^2) on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.
~Surgery: patients will receive surgery."
16297079|NCT04696939|Active Comparator|Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Carboplatin, 75 mg/m^2 on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.
~Surgery: patients will receive surgery."
16297080|NCT04696926||patients who underwent an aortic valve replacement|
16297081|NCT04696913||Pulmonary Embolism Positive|As determined by CT Pulmonary Angiogram
16297082|NCT04696913||Pulmonary Embolism Negative|As determined by CT Pulmonary Angiogram
16297083|NCT04696900|Other|Exercise training|Two groups of 7 participants each will absolve a prescribed exercise training for 12 months.
16297084|NCT04696887|Experimental|Tele Tai Chi|8-week Tele Tai Chi intervention
16297085|NCT04696861|Experimental|IDEAS for Hope Intervention|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
16297086|NCT04696861|Active Comparator|Enhanced Standard of Care with Safety Planning|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
16297087|NCT04696848|Experimental|CKD-516 plus Durvalumab|Stage 1 : dose escalation durvalumab (1500 mg Q4W) plus CKD-516 at dose levels (9, 11, or 13 mg/m2) Stage 2 : durvalumab (1500 mg Q4W) plus CKD-516 at recommended phase 2 dose
16297088|NCT04696835|Experimental|children with hearing aids|
16297089|NCT04696835|Sham Comparator|control group|
16297090|NCT04696822|Experimental|Adults with seasonal allergic rhinitis|Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge.
16297145|NCT04696458|Placebo Comparator|Placebo|1 Identical Placebo Capsule
16297146|NCT04696432|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
16356631|NCT04281849|Experimental|BAMS-HF Program|
16297091|NCT04696809|Experimental|Japanese Participants with Relapsed or Refractory Multiple Myeloma (MM)|Japanese participants with relapsed or refractory MM will receive Teclistamab subcutaneously (SC) at three dose levels. Cohort 1 will receive Teclistamab at Dose 1 and Dose 2 (step-up doses) up to 10 days prior to the first treatment dose on Day 1 followed by Dose 3 on Days 1,8, and 15 of a 21-day cycle. Cohort 2 will receive Teclistamab at Dose 1 and Dose 4 (step up doses) up to 10 days prior to the first treatment dose on Day 1 followed by Dose 5 on Days 1,8, and 15 of a 21-day cycle. Cohort 3 will receive Teclistamab at Dose 1, Dose 4, and Dose 5 (step up doses) up to 10 days prior to the first treatment dose on Day 1 followed by Dose 6 on Days 1,8, and 15 of a 21-day cycle.
16297092|NCT04696796|Experimental|BasIQ-4 Surgical Knife|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with BasIQ-4 Surgical Knife according to computer generated randomization.
16297093|NCT04696796|Active Comparator|Episiotomy Scissors|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with episiotomy scissors according to computer generated randomization.
16297094|NCT04696783|Experimental|Drug Group|Esomeprazole Magnesium Enteric-coated Tablets and lifestyle adjustment
16297095|NCT04696783|Placebo Comparator|non-Drug Group|Only lifestyle adjustment
16297096|NCT04696770|Experimental|Mindfulness Intervention|"Four face-to-face direct coachings on Mindfulness technique at weekly intervals. The following will be the broad theme of each coaching session
~Week 1 - On the first encounter, the mothers will learn how to practice an introductory mindfulness technique to develop the awareness of any sensations felt in the body while holding their baby.
~Week 2 - On the second encounter, the mothers will learn how to practice a second mindfulness technique to create positive feelings in the body while holding their baby.
~During the third and fourth weekly encounters, the mothers will have a chance to ask their questions and explore further both mindfulness techniques as needed."
16297097|NCT04696770|No Intervention|Control|Standard of care will be offered to all mothers in the control group which includes kangaroo care but does not involve any mindfulness practices.
16297098|NCT04696757|Experimental|Cape|Capecitabine without surgery
16297099|NCT04696744||CTCO|adults with advanced squamous cell carcinoma of the oropharynx with a curative aim
16297100|NCT04696731|Experimental|ALLO-647, ALLO-316|
16297101|NCT04696718|Experimental|Traitement 1|Lactobacillus salivarius
16297102|NCT04696718|Experimental|Traitement 2|Lactobacillus Rhamnosus GG
16297103|NCT04696718|Experimental|Traitement 3|Bifidobacterium lactis
16297104|NCT04696705|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
16297105|NCT04696692|Other|Patient with histologically confirmed diffuse large B-cell lymphoma|
16297106|NCT04696679||Very preterm children group|
16297107|NCT04696679||Control group|
16297108|NCT04696666|Experimental|Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks|Single Group Assignment
16297109|NCT04696653|Other|Comprehensive unit based safety (CUSP) intervention arm|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
16297110|NCT04696640|Experimental|Remote Patient Monitoring|All participants who have successfully established remote data-sharing from their glucose monitors to the research team's Glooko account by conclusion of the one-month baseline period will advance to the six-month intervention period.
16297111|NCT04696627||Dural puncture|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
16297112|NCT04696627||Dural puncture with blood patch|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019 that were treated with an epidural blood patch.
16297113|NCT04696627||No dural puncture|Patients who did not have recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
16297114|NCT04696614|Experimental|aerobic exercise to aerobic exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise
16297115|NCT04696614|Experimental|aerobic exercise to interval training|first 8-week: aerobic exercise second 8-week: interval training
16297116|NCT04696614|Experimental|aerobic exercise to aerobic exercise +resistance exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise +resistance exercise
16297117|NCT04696614|Experimental|interval training to interval training|first 8-week: interval training second 8-week: interval training
16297118|NCT04696614|Experimental|interval training to aerobic exercise|first 8-week: interval training second 8-week: aerobic exercise
16297119|NCT04696614|Experimental|interval training to aerobic exercise+resistance exercise|first 8-week: interval training second 8-week: aerobic exercise +resistance exercise
16297120|NCT04696601|Experimental|Olfactory test|The result of the olfactory test will be compared to the result of the RT-PCR test.
16297121|NCT04696588|Experimental|Kinesiotherapy group|This is the group (n=59) receives treatment i.e complex set of neck exercises and massage
16297122|NCT04696588|No Intervention|Waiting List group|Individuals registered in the waiting list for receiving the treatment specified for kinesiotherapy group (n=59).These patients receive no treatment for tinnitus.
16297123|NCT04696575|Experimental|Treatment (lamivudine, chemoimmunotherapy)|"INDUCTION: Patients receive lamivudine PO QD on days 1-28. Patients also receive carboplatin IV over 30-60 minutes and atezolizumab IV on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lamivudine PO QD on days 1-28 and atezolizumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: Patients who are not eligible for atezolizumab as outlined in exclusion criteria or who refuse to receive atezolizumab may still be treated in this study with carboplatin and etoposide as the IV drug component, in addition to lamivudine orally administered."
16297124|NCT04696562|Experimental|Intervention group|The intervention group is the group in which the investigors applied deep breathing exercises with triflo.
16297126|NCT04696549|Experimental|virtual visual art experience for individuals with dementia and their family care-partners|Individuals with dementia and their family care-partners will participate in three monthly one-hour virtual art sessions in which the facilitator uses Visual Thinking Strategies technique to facilitate participants' viewing and discussion about virtual art images.
16297127|NCT04696536|Experimental|Group 1: Listerine Cool Mint Mouth Rinse (Marketed product)|Participants will receive Alcohol-containing Essential Oil (AEO) containing mouth rinse (Listerine Cool Mint, marketed) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
16297128|NCT04696536|Experimental|Group 2: Negative Control (5 Percent (%) Hydroalcohol Mouth Rinse)|Participants will receive negative control mouth rinse (5% Hydroalcohol mouth rinse) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
16297129|NCT04696536|Experimental|Group 3: Flossing Performed by Dental Hygienist|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Dental hygienist will floss participant's teeth at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
16297130|NCT04696536|Experimental|Group 4: Flossing under Supervision|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Participants floss their teeth under supervision at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
16297131|NCT04696523|Active Comparator|Air/Oxygen|Control arm: air/oxygen with standard of care
16297132|NCT04696523|Experimental|xenon|Xenon arm: xenon inhalation in air/oxygen with standard of care
16297133|NCT04696510||Chronic migraineurs|This group includes patients with chronic migraine.
16297134|NCT04696510||Control group|This group includes healthy subjects.
16297135|NCT04696510||Episodic migraineurs|This group includes patients with episodic migraine
16297136|NCT04696497|Other|Muscular Assessment|All the patients will received the muscular assessments
16297137|NCT04696484|Experimental|Intervention|coopeRATE Prompt
16297144|NCT04696458|Experimental|EXPERIMENTAL PROBIOTIC|1 Multistrain Probiotic Capsule
16297148|NCT04696406||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours
16297149|NCT04696406||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation.
16297150|NCT04696393|Experimental|Treatment Sequence 1: AB|Participants will receive Treatment A (mitapivat 100 milligram [mg] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
16297151|NCT04696393|Experimental|Treatment Sequence 1: BA|Participants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
16297152|NCT04696380|Experimental|High nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 5% nicotine strength.
16297153|NCT04696380|Experimental|High nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 5% nicotine strength.
16297154|NCT04696380|Experimental|Low nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 3% nicotine strength.
16297155|NCT04696380|Experimental|Low nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 3% nicotine strength.
16297156|NCT04696367||Patients with acute intra-abdominal pathology|Patients admitted to hospital with acute intra-abdominal pathology
16297157|NCT04696354|Other|Interrogation Arm|patients will first be evaluated with MPV (limited to 3 views). The prescribed course of treatment based on the MPV results will be documented and patients will then be evaluated using IVUS. A treatment plan based on IVUS results will be compared with the MPV guided treatment plan and any differences will be documented. Any patients determined to still require venous stenting based on IVUS results will be stented accordingly using IVUS to guide stent placement.
16297158|NCT04696354|Other|Deferred Interrogation Arm|"Deferred Interrogation Guidelines for this study are as follows:
~Mandate:
~• Continued compression therapy/stockings as prescribed.
~Allow:
~Periodic leg elevation.
~Sclerotherapy under ulcer bed.
~Recommend mechanical debridement as needed.
~Wound biopsy if evidence of infection.
~Systemic antibiotics if patient is diagnosed with an infection, avoid prophylactic prescription.
~Pain management medication (Pentoxifylline/Trental) allowed but not recommended
~Topical antimicrobial as needed.
~Prohibit:
~Negative pressure systems.
~Artificial and/or autologous skin grafting within first 3 months after randomization and within the first 3 months for subjects that crossover from deferred interrogation to the interrogation arm."
16297159|NCT04696341|Experimental|Matrix Rhythm Therapy|Group I (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound, conventional massage and Matrix Rhythm Therapy were applied. Home-based exercise program and recommendations were also given to patients.
16297160|NCT04696341|Experimental|Control|Group II (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound and conventional massage were applied. Home-based exercise program and recommendations were also given to patients.
16297161|NCT04696328|Experimental|Group of subjects undergoing cell transplantation|Human (allogeneic) iPS cell derived-cardiomyocyte sheet transplantation (only once)
16297162|NCT04696315||SCD subjects with positive amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with positive amyloid show the evidence of amyloid deposition in brain. They have higher risk of conversion to mild cognitive impairment and dementia compared with SCD with negative amyloid. They are also considered as preclinical AD.
16297163|NCT04696315||SCD subjects with negative amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with negative amyloid do not show the evidence of amyloid deposition in brain. They have lower risk of conversion to mild cognitive impairment and dementia compared with SCD with positive amyloid.
16297164|NCT04696302|Experimental|Focus of attention in individuals post chronic stroke during seated lateral weight shifting|Feasibility study
16297165|NCT04696302|Experimental|Focus of attention in individuals post acute stroke during seated lateral weight shifting|Feasibility study
16297166|NCT04696289|Experimental|Standardized catheterization assessment|Assessment of pulmonary veins including angiography, intravascular ultrasound, pressure assessment and compliance testing.
16297167|NCT04696276|Experimental|A-ERAS|will receive ERAS pathways care
16297168|NCT04696276|No Intervention|B-nonERAS|will receive traditional non ERAS care
16297169|NCT04696263|Active Comparator|Extraperitoneal SinglePort (SP) Robotic Radical Prostatectomy (Da Vinci ® SP system)|"All participants will undergo SOC robotic radical prostatectomy.
~The procedure for this arm uses the Da Vinci ® SP system. Access point consists of one 3.5 cm single infraumbilical incision for the SP-RARP"
16297170|NCT04696263|Active Comparator|Extraperitoneal MultiPort (MP) Robotic Radical Prostatectomy (Da Vinci ® Xi system)|"All participants will undergo SOC robotic radical prostatectomy.
~The procedure for this arm uses the Da Vinci ® Xi system, where four 8mm trocars will be used along with a 12 mm assistant trocar (a surgical instrument) to create six small incisions during the surgery"
16297171|NCT04696250||Adverse Events associated with Antineoplastic and Immunomodulating Agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by anticancer drugs, with a chronology compatible with the drug toxicity
16297172|NCT04696237||orthodontists|
16297173|NCT04696237||general dentists|
16297174|NCT04696237||oral and maxillofacial surgeons|
16297175|NCT04696237||plastic surgeons|
16297176|NCT04696237||cleft nurses|
16297177|NCT04696237||cleft lip and palate patients|
16297178|NCT04696237||speech therapists|
16297179|NCT04696237||ENT specialists|
16297180|NCT04696237||psychiatrists|
16297620|NCT04693039|Placebo Comparator|Placebo-600mg|Drug：Placebo；Dosage：600mg；
16297181|NCT04696224|Active Comparator|INTRAVENOUS|30 patients who will receive 15mg / kg of TXA intravenous in 100ml salina solution (0,9%), after anesthetic induction and before incising the skin (administered in 10 minutes). For masking purposes, these patients will also receive at the end of the surgery, and before performing the plan closure, a compress soaked in 80ml of saline solution (0.9%), which will fill all the plans of the incision, and will be kept for 5 minutes.
16297182|NCT04696224|Active Comparator|LOCAL|30 patients who, at the end of the surgery, and before the suture in layers, will receive a compress soaked in a solution of 1.5 g of tranexamic acid (six ampoules of Transamin®, Zydus Nikkho) diluted in 50 ml of saline solution (0.9 %) (total volume of 80ml), which will fill all the plans of the incision and will be maintained for 5 minutes. For masking purposes, these patients will also receive 100ml of saline solution (0.9%) after anesthetic induction and before incising the skin.
16297183|NCT04696224|Placebo Comparator|PLACEBO|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2.
16297184|NCT04696211|Experimental|Experimental group|The music-with-movement exercise program (MMEP) is an 8-week program. In the first 4 weeks a center-based program will be offered in the District Elderly Centers, and from week 1 to week 8 home-based and digital-based activities will be delivered via a WhatsApp group.
16297185|NCT04696211|No Intervention|Control group|The participants in the control group will continue to receive their usual care and receive a one-page pain management pamphlet.
16297186|NCT04696198|Experimental|Range of motion|Treatment is based on a set diagnostic and therapeutic protocol and carried out by registered health care professionals that are additionally trained in manual therapy intervention. 30 minutes of treatment will be given once a week over a period of two months
16297187|NCT04696198|Other|Standard care|Standard care
16297188|NCT04696185|Active Comparator|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg
16297189|NCT04696185|No Intervention|Standard care|No SGLT-2 inhibitor therapy with dapagliflozin
16297190|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) with postoperative ARDS|
16297191|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) without postoperative ARDS|
16297192|NCT04696159|Experimental|Endoscopic Per-Oral Pyloromyotomy (POP)|The study cohort will include 40 patients with a HbA1c >7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).
16297193|NCT04696146|Experimental|Berinert|Berinert 500 units
16297194|NCT04696146|Placebo Comparator|Placebo|Normal Saline in identical volume to Berinert
16297195|NCT04696133|Experimental|conventional training|children in this group will receive conventional program including stretching and strengthening exercise in addition to exercises to enhance fine motor skills for one hour for each child, three times per week along a period of three months
16297196|NCT04696133|Experimental|sensory integration training|Children in this group will receive designed sensory integration program, one hour for each child, three times per week along a period of three months. The program includes tactile, vestibular and proprioceptive stimulation and heavy work activities in addition to fine motor skills.
16297197|NCT04696120|Experimental|Study group: apixaban|apixaban 2.5mg or 5mg bid
16297198|NCT04696120|Placebo Comparator|Control group: placebo|placebo bid
16297199|NCT04696107|Experimental|Intervention Group|Standard pharmacological treatment aimed at controlling mCNCP with four-week face to face psychoeducational intervention.
16297200|NCT04696107|No Intervention|Control Group|Standard pharmacological treatment aimed at controlling mCNCP without psychoeducational intervention.
16297201|NCT04696094||Healthy volunteers|"Health volunteers' inclusion criteria:
~Age between 4-60; Male or female;
~Exclusion criteria:
~Exclude the volunteers with history of cerebrovascular disease."
16297202|NCT04696094||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:
~1.written informed consent had been obtained; 2. more than 4 years old and less than 60 years old; 3. cerebral digital subtraction contrast angiography (DSA) revealed severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'; 4. received surgical revascularization;
~Exclusion Criteria:
~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
16297203|NCT04696068||Control|The patients included in this group will receive meals with the usual presentation (plastic trays) during six days. Their data will be collected at day 1 and day 6.
16297204|NCT04696068||Experimental|The patients included in this group will receive the main course in porcelain plates during six days. Their data will be collected at day 1 and day 6.
16297206|NCT04696042||Lanreotide|Patients treated with lanreotide
16297207|NCT04696029|Experimental|Difluoromethylornithine (DFMO)|study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.
16297208|NCT04696016|Experimental|Skin conductance guided|Sufentanil is titrated by the intensive care team to maintain skin conductance in target
16297209|NCT04696016|Active Comparator|Standard care|Sufentanil is titrated at the discretion of the intensivist
16297210|NCT04696003|No Intervention|control|The patients with classic PPROM between 22/0-26/0 weeks' gestation with oligo/anhydramnion with standard conservative treatment (7 days Amoxicillin/Clarithromycin therapy or 7 days Amoxicillin and once Azithromycin 1 g per os, and corticosteroids like Celestan®, Essex Pharma, Munich, Germany) as RDS prophylaxis will represent the control group (DGGG Guideline AWMF 015-025, February 2019, Version 1.0). The diagnosis of the PPROM must be not early than 20/0 weeks' gestation.
16297390|NCT04694573||POST-TX Covid-19 Serum Study Case|Kidney or liver-transplanted patients being hospitalized due to an infection with SARS-CoV-2
16297211|NCT04696003|Active Comparator|Amnion Flush group (continuous amnioinfusion)|"In the Amnion Flush group additionally to the standard treatment the amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intra-amniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. Amnion Flush Solution (CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h (2400 ml/d) under periodic ultrasound using the standard i.v. pump. The deepest pool of amniotic ﬂuid should be stabilized by about 4 cm. The ultrasound control will be performed daily. Induction of the labour or c-section at 34/0 week of gestation or earlier if indicated."
16297212|NCT04695990|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given Wenyang Huoxue Decoction, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
16297213|NCT04695990|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
16297214|NCT04695977|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
16297215|NCT04695977|Experimental|Nivolumab Monotherapy|All enrolled subjects will receive nivolumab monotherapy IV according to the treatment schedule until a reason for treatment discontinuation is reached.
16297216|NCT04695964|Other|ICG-NIRF Imaging and objective perfusion rate|ICG-NIRF imaging is used to visualise the blood supply and the bowel perfusion rate in the area of the pouch anastomoses. An additional ingress and egress analysis at specific regions of interest is performed. This is to get an objective method of visualisation of the blood inflow and outflow over time and thus bowel perfusion at the anastomotic site.
16297217|NCT04695951|Experimental|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
16297218|NCT04695951|Placebo Comparator|Control|A total of 35 patients treated with the study product Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
16297219|NCT04695938|Other|MRI|MRI examination
16297220|NCT04695925|Active Comparator|osimertinib monotherapy|osimertinib 80 mg po qd.
16297221|NCT04695925|Experimental|combination of osimertinib and chemotherapy|osimertinib 80 mg po qd plus pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance osimertinib and pemetrexed until disease progression
16297222|NCT04695912|Other|Initial activity tracker with feedback followed by control period|Initial activity tracker with feedback followed by control period
16297223|NCT04695912|Other|Initial control period followed by activity tracker with feedback|Initial control period followed by activity tracker with feedback
16297224|NCT04695886|Experimental|CIME intervention|Community-delivered Integrated Malaria Elimination (CIME). The CIME intervention model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and RDT-negative fever.
16297225|NCT04695886|No Intervention|ICMV standard of care|Integrated Community Malaria Volunteer (ICMV) model - this is the current standard of care. This model involves malaria volunteers undertaking additional screening and referral services for a range of other diseases including: dengue, lymphatic filariasis, tuberculosis, HIV/AIDS and leprosy.
16297226|NCT04695873|Experimental|Treatment Group|Foam Cushion, applied daily on Days 1, 2 and 3 of the investigation.
16297227|NCT04695873|No Intervention|No Treatment Group|No treatment
16297228|NCT04695860|Experimental|Open label Burosumab|Burosumab Q4W, 1mg/kg body weight s.c.
16297229|NCT04695847|Experimental|Part 1: M1231|Participants with solid tumors for whom no effective standard therapy exists will be included in this Part. Dose escalation of M1231 will be administered as single agent.
16297230|NCT04695847|Experimental|Part 2: Cohort A M1231: Metastatic NSCLC|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) expressing Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1) on archival tumor tissue will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
16297231|NCT04695847|Experimental|Part 2: Cohort B M1231: Metastatic Esophageal Squamous Cell Carcinoma|Participants with metastatic esophageal squamous cell carcinoma will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
16297232|NCT04695834|Active Comparator|Conservative treatment|"Patients that are randomized to the conservative arm of the trial. These patients will not be operated until primary endpoint is reached.
~If necessary, cross-over can occur after primary endpoint is reached.
~Conservative treatment is considered standard of care."
16297233|NCT04695834|Active Comparator|Surgical treatment|"Patients randomized to the surgical arm will be operated within 1 week after randomization (if possible within 2 days).
~Neurolysis is considered standard of care."
16297264|NCT04695561|Experimental|Self Myofascial Relaxation|In addition to the exercises applied to the participants in the control group, the participants in this group used Foam Roller, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
16297265|NCT04695561|Experimental|Instrument Assisted Soft Tissue Mobilization|In addition to the exercises applied to the participants in the control group, the participants in this group used Instrument Assisted Soft Tissue Mobilization, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
16297425|NCT04694300|Experimental|Naproxen sodium|Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
16297234|NCT04695821|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.
~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
16297235|NCT04695808|Experimental|intervention group|Yoga practice will be done two days a week for 10 weeks.
16297236|NCT04695808|No Intervention|control group|no intervention
16297237|NCT04695782|Experimental|Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily|
16297238|NCT04695782|Experimental|Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily|
16297239|NCT04695769|Experimental|Group A: SOF/VEL/VOX with RBV|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: < or > 60 kg).
~Another name: Vosevi, RBV"
16297240|NCT04695769|Active Comparator|Group B: SOF/VEL/VOX|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).
~Another name: Vosevi"
16297241|NCT04695756||People who require liver transplant|We will compare the year before the beginning of the COVID-19 Pandemia with the period during the COVID-19 Pandemia.
16297242|NCT04695743|Experimental|Intervention|Attendance at online CST groups
16297243|NCT04695743|No Intervention|Control|Treatment as usual
16297244|NCT04695730|Active Comparator|Active physical therapy|Active intervention (including both pain education and home exercises). A 60-minutes education session will be provided, concerning pain mechanisms and management and a demonstration of the exercises to perform individually at home. Home exercises will be performed daily. To support patients during the treatment, a booklet will be created. One 30-minutes booster session will be planned after 4 weeks. Patients will follow this active intervention for 8 weeks.
16297245|NCT04695730|Experimental|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
16297246|NCT04695717|Placebo Comparator|Vaccine|Received two doses of IVACFLU-S vaccine intramuscularly in children aged 6 months to under 9 years old and one dose of IVACFLU-S vaccine in children from 9 years old to under 18 years old adult over 60 years old
16297247|NCT04695717|Other|Placebo|Received two doses of placebo intramuscularly in children aged 6 months to under 9 years old and one dose placebo in children from 9 years old to under 18 years old adult over 60 years old
16297248|NCT04695704|Experimental|Montelukast|10mg oral montelukast once daily for 28 days.
16297249|NCT04695704|Placebo Comparator|Placebo|oral placebo once daily for 28 days.
16297250|NCT04695678||residents and staff of all nursing homes in Solingen|each study participant receives a single nasal/pharyngeal swab
16297251|NCT04695678||staff of one single nursing home in Solingen|each study participant receives a weekly nasal/pharyngeal swab for six months
16297252|NCT04695665|Active Comparator|Cervical pain|Only patients with positive Cervical pain syndrome.
16297253|NCT04695665|Active Comparator|Thoracic pain|Only patients with positive Thoracic pain syndrome.
16297254|NCT04695665|Active Comparator|Lumbar pain|Only patients with positive Lumbar pain syndrome.
16297255|NCT04695652|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
16297256|NCT04695652|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
16297257|NCT04695639||cohort group|A convenient sample of children with spastic hemiparetic CP of both genders will participate in this study. To avoid type II error, sample size calculation was performed prior to the study, based on data of pilot study, using G*POWER statistical software (version 3.1.9.2; Franz Faul, Universitat Kiel, Germany) [Exact tests- correlational study, α=0.05, β=0.2, and effect size = 0.4] and revealed that the appropriate sample size for this study is N=46.
16297258|NCT04695613|Active Comparator|aminoacid group|patients received an IV amino acid infusion 150 ml/kg/hr starting just before and during anesthesia
16297259|NCT04695613|Active Comparator|magnesium sulfate group|patients received an IV magnesium sulphate bolus and infusion 40 mg/kg starting just before and during anesthesia
16297260|NCT04695600|Experimental|Botulinum toxin arm|100 units of botulinum toxin (Botox, Allergan, CA) diluted in 2.5 mL of normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Botulinum toxin will be injected into the muscle in four aliquots into each quadrant using 23 G needle (160cm). Post procedure patient will be observed for an hour for any untoward adverse event
16297261|NCT04695600|Placebo Comparator|Placebo arm|2.5 mL of Normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Post procedure patient will be observed for an hour for any untoward adverse event
16297262|NCT04695587||TakoTsubo|Patients hospitalized with TakoTsubo syndrome according to the INTERTAK criteria
16297263|NCT04695574|Experimental|Volunteer young adults|Healthy young adults
16361199|NCT04250103||patient|patients who receive home health care
16297266|NCT04695561|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the hip flexors, hip extensors and iliotibial band were shown to the participants in the control group for 6 weeks every day of the week.
16297267|NCT04695548|Experimental|Concentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
16297268|NCT04695548|Experimental|Isometric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
16297269|NCT04695548|Experimental|Eccentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
16297270|NCT04695548|Experimental|Analytic passive stretching.|After applying the dry needling technique to the upper trapezius muscle, the patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
16297271|NCT04695535||Chemotherapy with Anlotinib|Patients received chemotherapy with Anlotinib.
16297272|NCT04695522|Experimental|Group of subjects undergoing cell transplantation|
16297273|NCT04695522|Sham Comparator|Group of subjects undergoing sham operation|
16297274|NCT04695509|Experimental|moderate sedation|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with moderate propofol sedation
16297275|NCT04695509|Experimental|deep sedation|Arm Description: patients with American Society of Anesthesiologists (ASA I-II), Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with deep propofol sedation
16297276|NCT04695496|Experimental|Theta bust stimulating group|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
16297277|NCT04695483|Experimental|Corifollitropin alpha group|Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
16297278|NCT04695483|Active Comparator|FSH group|Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
16297279|NCT04695470|Experimental|Fruquintinib with Sintilimab|Patients who met the eligibility criteria took fruquintinib 5mg qd for 2 weeks on and 1 week off Q3w plus Sintilimab 200mg iv, Q3w.
16297280|NCT04695444|Active Comparator|conventional PVC tube|When performing nasotracheal intubation, clinicians use the conventional PVC tube.
16297281|NCT04695444|Experimental|PVC tube with rubber suction catheter|When performing nasotracheal intubation, clinicians use the conventional PVC tube + rubber suction catheter.
16297282|NCT04695444|Experimental|velvet soft PVC tube|When performing nasotracheal intubation, clinicians use the velvet soft PVC tube.
16297283|NCT04695431||Patients from the BLU-285-2101 and BLU-285-2202 studies|Patients with advanced systemic mastocytosis who received treatment with avapritinib as part of the BLU-285-2101 and BLU-285-2202 studies
16297284|NCT04695431||External Control Group|Patients with advanced systemic mastocytosis that received best available therapy
16297285|NCT04695418|Placebo Comparator|Placebo|an isocaloric wheat germ-based supplement
16297286|NCT04695418|Active Comparator|Rice Germ|
16297287|NCT04695405||Treatment-Resistant Depression|Patients, who previously received intravenous ketamine, will be asked to provide genetic samples in order to assess relationships between response and genetic markers.
16297288|NCT04695392|Experimental|Intervention|R2 Bundle
16297289|NCT04695366||Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up|Patients (Diffuse Large B-cell Lymphoma) in complete remission after primary treatment and entering the regular follow-up program at the clinic. Baseline is defined as date of end-of-treatment visit.
16297290|NCT04695353|Experimental|Study group|These patients will receive telemedicine by using Telecommunication Platform videoconferences/messages.
16297291|NCT04695353|No Intervention|Control group|The patients will receive in-office clinical care
16297292|NCT04695340|Experimental|Familial amyloidosis patients|Familial amyloidosis patients with gastro-intestinal pain receiving Psyllium
16297293|NCT04695327|Experimental|Monotherapy|"Patients will receive mulriple administrations of TILT-123.
~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
16297294|NCT04695314|Experimental|Glaucoma Group|Patients with glaucoma come in and get an intraocular pressure check at baseline. They get a 5 minute foot massage and then have their intraocular pressure checked every 30 minutes over 2 hour span.
16297295|NCT04695314|Experimental|Ocular Hypertension Group A|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.
~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again.
~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again."
16297351|NCT04694872|Experimental|a) TELEREHABILITATION BASED LSVT BIG TREATMENT GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
16297621|NCT04693039|Placebo Comparator|Placebo-900mg|Drug：Placebo；Dosage：900mg；
16297296|NCT04695314|Active Comparator|Ocular Hypertension Group B|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.
~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again.
~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again."
16297297|NCT04695301|Experimental|digital platform rehabilitation|Rehabilitation program through a digital platform for 3 months
16297298|NCT04695301|Experimental|control group|Patients without access to technology will do the exercises using booklets and will compose the control group
16297299|NCT04695288||Fibromyalgia Syndrome|100 participants with a diagnosis of Fibromyalgia Syndrome according to the 2016 revised American College of Rheumatology diagnostic criteria.
16297300|NCT04695288||Control subjects|60 healthy participants do not meet the exclusion criteria of the study.
16297301|NCT04695249|Experimental|Exposure intervention|Eleven individual sessions.
16297302|NCT04695236|Experimental|Study group|Study Group: intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group
16297303|NCT04695236|Placebo Comparator|Control group|"Control group: Without intravascular hypothermia therapy group
~ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group"
16297304|NCT04695223|Experimental|Arsenic Trioxide|Arsenic Trioxide (0.16mg/kg,d1-5,ivgtt,28days as a duration) for injection
16297305|NCT04695210|Experimental|Virtual Peer-to-Peer Support|"Those participants randomised to the intervention arm will have access to a 12-week virtual peer-to-peer support programme which entails:
~weekly audio, video, or text private messaging with a peer supporter;
~synchronous weekly discussion forum attended by peer supporters and family caregiver participants moderated by the research team. These forums will discuss specific topics (e.g. caregiver self-care, the emotional impact of caregiving). Ask the expert forums will be moderated by clinical experts every 6 weeks (meaning all participants will have access to 2 ask the expert sessions);
~asynchronous discussion forums in which participants can post questions; and
~access to informational resources."
16297306|NCT04695210|No Intervention|Control|Those participants randomised to the control arm will receive usual care which comprises self-directed access to the MND Association Visitors programme and MND Association educational resources via their website.
16297307|NCT04695197|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine, standard 3-day antimalarial treatment regimen.
16297308|NCT04695197|Experimental|Pyronaridine-artesunate|Pyronaridine-artesunate, standard 3-day antimalarial treatment regimen.
16297309|NCT04695184|Other|ICG-NIRF Imaging|ICG-NIRF imaging is used intraoperatively to visualise precisely the blood supply and bowel perfusion rate in the area of ileal pouch formation and the ileal pouch-anal anastomosis.
16297310|NCT04695171||Prior Primary Large Hiatal Hernia with LINX Placement MSA|Patients who were previously implanted with the LINX device during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at 3 and 5 years to determine recurrence of hiatal hernia.
16297311|NCT04695171||Prior Primary Large Hiatal Hernia with Fundoplication|Patients who previously underwent lower esophageal sphincter reconstruction by fundoplication during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at about 3 and 5 years to determine recurrence of hiatal hernia.
16297312|NCT04695158||COVID-19 group (Group I)|Patients diagnosed with COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatment according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020.
16297313|NCT04695158||Type II Diabetes Mellitus and COVID-19 group (Group II)|Patients diagnosed with both Type II Diabetes Mellitus and COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatments according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020 and routine treatment for Type II Diabetes Mellitus.
16297314|NCT04695158||Control group (Group III)|Healthy volunteers will be in this group. No intervention will be applied in this group.
16297315|NCT04695145|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer with special training in medical issues. The exercise will be monitored with continuous heart rate registration.
~The group training session will begin with a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied."
16297316|NCT04695145|Active Comparator|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
16297317|NCT04695132|Experimental|Illness Management and Recovery treatment programme (intervention group)|These patients receive the Illness Management and Recovery treatment. Treatment takes place during 2 Group sessions and 1 individual session per week.
16297318|NCT04695132|No Intervention|Treatment as usual (control group)|These patients receive treatment as usual consisting of the standard treatment given at the respective inpatient forensic mental health facility where they are admitted.
16297703|NCT04692428|Experimental|FNB group|ultrasound femoral nerve block
16297319|NCT04695106|Experimental|Study population|"In the study group (both STEMI and NSTE-ACS), aspirin will be discontinued, and ticagrelor will be started at a loading dose of 180 mg, irrespective of timing and dosing of clopidogrel, and continued at a maintenance dose of 90 mg twice daily for 1 month, followed by 60 mg twice daily up to 12 months.
~Dabigatran will be used as a standard-of-care. Lower dose dabigatran (110 mg twice daily) will be used in patients ≥80 years of age and will be considered in patients (i) 75-80 years of age, (ii) with creatinine clearance 30-50 ml/min, (iii) at high risk of bleeding (HAS-BLED ≥ 3), (iv) at high-risk of gastrointestinal bleeding (with esophagitis, gastritis, gastroesophageal reflux disease), and (v) treated with verapamil, in accordance with the guidelines."
16297320|NCT04695106|Active Comparator|Control group|"In the control group, aspirin and clopidogrel will be continued depending on the diagnosis (STEMI or NSTE-ACS) and bleeding risk. In patients with STEMI, aspirin will be discontinued after 1-6 months, according to a balance between the estimated risk of recurrent coronary events and bleeding. In patients at high bleeding risk aspirin will be discontinued after 1 month. Subsequently, all patients will be treated with clopidogrel and dabigatran up to 12 months. In the NSTE-ACS group, aspirin will be used up to 1 week (in-hospital period), extendable up to one month in patients at high ischaemic risk. Dual therapy will be continued up to 12 months with the possibility of shortening for patients at high bleeding risk.
~Dabigatran will be used as a standard-of-care (as above)."
16297321|NCT04695093||London (intervention)|1606 children aged 6-9 yrs old, recruited in 44 London primary schools (years 2-4) within the Central London ULEZ area
16297322|NCT04695093||Luton (comparison)|1706 children aged 6-9 yrs old, recruited in 41 Luton and Dunstable primary schools (years 2-4)
16297323|NCT04695080|Active Comparator|Cladribine (MAVENCLAD®)|
16297324|NCT04695080|Placebo Comparator|Placebo|
16297325|NCT04695054|Experimental|Buzzy and EMLA Cream|In the experimental group children will receive the application of EMLA cream 60 minutes before the needle procedure and the use of Buzzy device during the procedure.
16297326|NCT04695054|Active Comparator|EMLA Cream|In the control group children will receive the application of EMLA cream 60 minutes before the needle procedure
16297327|NCT04695041|Experimental|Cohort A: 1200 mg PBI-4050|
16297328|NCT04695041|Experimental|Cohort B: 1600 mg PBI-4050|
16297329|NCT04695041|Experimental|Cohort C: 2000 mg PBI-4050|
16297330|NCT04695041|Experimental|Cohort D: 2400 mg PBI-4050|
16297331|NCT04695041|Experimental|Cohort E: 2400 mg PBI-4050|
16297332|NCT04695041|Experimental|Cohort F (Supplemental): 2400 mg PBI-4050|
16297333|NCT04695028||Persons with crystal related arthropathies|
16297334|NCT04695015||Melanoma and Nevus|Patients diagnosed with melanoma or/and nevus on the skin around the eye before surgery.
16297335|NCT04695015||Basal cell carcinoma;Squamous cell carcinoma;Sebaceous gland carcinoma|Patients diagnosed with basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma before surgery.
16297336|NCT04695002||Control group|Citizens in the control group participate in the existing course of vocational rehabilitation offered in the municipal employment department, without the use of MIRA app.
16297337|NCT04695002||MIRA group|Citizens in the MIRA group will participate in the existing course of vocational rehabilitation offered in the municipal department. In addition they will be introduced to MIRA at the beginning of the rehabilitation course, and use MIRA throughout the course of rehabilitation.
16297338|NCT04694989|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition
~Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
16297339|NCT04694989|Experimental|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition
~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition
~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
16297340|NCT04694976||Sickle cell disease children from Lyon, France|Sickle cell disease children, followed in IHOPe (Institut d'Hématologie et d'Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.
16297341|NCT04694963||Subaute Cough|N=500
16297342|NCT04694950||Group feasibility|Adults undergoing elective urologic laparoscopic robotic surgery.
16297343|NCT04694937||metabolic healthy obese|Demographic, clinical laboratory and heart rate variability assesment
16297344|NCT04694937||metabolic unhealthy obese|Demographic, clinical laboratory and heart rate variability assesment
16297345|NCT04694924||Localized and locally advanced prostate cancer|Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
16297346|NCT04694911||Health Services Research (focus group, interview, OOCAT)|"FOCUS GROUP: Patients participate in focus group session over 60-90 minutes.
~COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT.
~FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference."
16297347|NCT04694898|Other|Control|Households in the control arm receive standard/national nutrition specific interventions, i.e. growth monitoring, vaccination, vitamin A supplementation and deworming
16297348|NCT04694898|Experimental|SURE Intervention|"Households in the intervention group with children younger than 2 years benefit from:
~Interpersonal contacts to provide counselling on infant and young child feeding practices (IYCF) and nutrition-sensitive agriculture advice to mothers and fathers of children under 24 months, inclusive of pregnant women and fathers-to-be, jointly delivered by the local health and agriculture extension workers during routine household visits
~Men's and women's group dialogues targeting all men and women in a given community network, facilitated also by the local health and agriculture extension workers
~Media campaign to reinforce IYCF and dietary diversity messages"
16362010|NCT04244253|Experimental|OPC-64005 10 mg|
16297352|NCT04694872|Active Comparator|b) TELEREHABILITATION BASED FUNCTIONAL BALANCE AND MOBILITY EXERCISES GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.
16297353|NCT04694859||Symptomatic Severe Aortic Valve Stenosis|Patients >18 years old with symptomatic severe aortic valve stenosis.
16297354|NCT04694846|Experimental|Arm I (ETIP)|Patients receive nicotine replacement therapy via trans-dermal patch, gum, nasal spray, inhaler or lozenges for 12 weeks in the absence of unacceptable toxicity. Patients also receive bupropion PO QD BID or varenicline PO QD and BID for 24 weeks in the absence of unacceptable toxicity. Patients undergo 3 cessation counseling sessions in person, via telehealth or phone within 7 days of enrollment into study, 1 week after established quit date and 3 weeks after establishing quit date.
16297355|NCT04694846|Active Comparator|Arm II SOC|Participants randomly assigned to the standard treatment (ST) group will receive an in-office smoking cessation recommendation by the physician and referral to a quit line.
16297356|NCT04694833|Experimental|Stroke patients|Stroke patients with hemiparesis and/or cognitive impairments (such as apraxia, aphasia and hemineglect)
16297357|NCT04694833|Experimental|Healthy subjects|Subjects who do not suffer from any pathology that could affect upper-limb motor function or cognition
16297358|NCT04694807|Experimental|Group-based Cognitive Behavioural Therapy|A group delivered treatment format of CBTgrief (12 sessions).
16297359|NCT04694807|Active Comparator|Individually delivered Cognitive Behavioural Therapy|An individual delivered treatment format of CBTgrief (12 sessions).
16297360|NCT04694794|Experimental|Interventional|Single arm, interventional. All participants will be administered Educational Brochure to educate them regarding management of side effects experienced during chemotherapy treatment
16297361|NCT04694781|Experimental|Monotherapy Dose Escalation|LVGN6051 monotherapy dose escalation
16297362|NCT04694781|Experimental|Monotherapy Dose Expansion|LVGN6051 dose expansion cohorts
16297363|NCT04694781|Experimental|Combination therapy dose escalation|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose escalation
16297364|NCT04694781|Experimental|Combination therapy dose expansion|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose expansion cohorts
16297365|NCT04694755|Placebo Comparator|Heart lung qi deficiency syndrome placebo group|Buyixinfei placebo was given.Tianjiang brand formula granules were used. One dose a day, two times orally, five days a week.
16297366|NCT04694755|Placebo Comparator|Deficiency of lung and Kidney Qi placebo group|Tonifying kidney and protecting lung prescription placebo was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
16297367|NCT04694755|Experimental|Heart lung qi deficiency syndrome drugs group|Buyixinfei formula was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
16297368|NCT04694755|Experimental|Deficiency of lung and Kidney Qi drugs group|The prescription of invigorating the kidney and protecting the lung was given. The drug was Tianjiang brand granule, one dose a day, two times orally, five days a week
16297369|NCT04694742||ARDS COVID-19|Patients who meet Berlin's ARDS diagnostic criteria, with confirmed SARS-CoV-2 infection, requiring invasive mechanical ventilation.
16297370|NCT04694729|Experimental|study group|Videoconference-based
16297371|NCT04694729|Experimental|control group|Video-based
16297372|NCT04694716||Covid-19 group (Group I)|Patients diagnosed with Covid-19 will be enrolled in this group.
16297373|NCT04694716||Control group (Group II)|Healthy individuals will be enrolled in this group.
16297374|NCT04694703||Covid-19 group|Patients diagnosed with COVID-19 will be enrolled in this group.
16297375|NCT04694690|Experimental|RelyX U200 Automix Self Adhesive Resin Cement|Self Adhesive Resin Cement
16297376|NCT04694690|Active Comparator|G-Cem LinkForce Resin Cement|Resin Cement system used after surface treatment
16297377|NCT04694677|Active Comparator|women receiving tranexamic acid|
16297378|NCT04694677|Active Comparator|women receiving misoprostol|
16297379|NCT04694664||Pregnant Women|Pregnant women who are 18 years of age or older.
16297380|NCT04694664||Post-partum women|Women who have at least one child younger than 18 years of age.
16297381|NCT04694638|Experimental|HFNC and NIPPV|Combined use of prone positioning and non-invasive positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC)
16297382|NCT04694625|Experimental|Structured rehabilitation program|Structured rehabilitation program & conventional physical therapy
16297383|NCT04694625|Active Comparator|conventional physical therapy|conventional physical therapy
16297384|NCT04694612|Placebo Comparator|Mild condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive the same quantity of Placebo.
~Duration of treatment : 5 days in each group"
16297385|NCT04694612|Active Comparator|Moderate condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive Inj Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily.
~Duration of treatment : 10 days in Favipiravir group & 5 days in Remdesivir group"
16297386|NCT04694599|Experimental|Early intervention|The experimental group will receive oxygen supplementation when oxygen saturation decreases according to the monitoring of wearable devices.
16297387|NCT04694599|Active Comparator|Typical|The control group will receive oxygen supplementation when oxygen saturation decreases according to typical periodical monitoring.
16297388|NCT04694586|Experimental|High-dose rifampicin and pyrazinamide|"rifampicin 35 mg/kg for 4 months provided as a combination of fixed drug combination tablets (HRZE for 8 weeks and HR Week 9-16) and single drug tablets of rifampicin (R)
~AND
~pyrazinamide 40 mg/kg the first 2 months provided as a combination of fixed drug combination tablets (HRZE) and single drug tablets of pyrazinamide (Z)
~fixed drug combination tablets are: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 16 (total treatment duration 4 months)"
16297389|NCT04694586|No Intervention|Standardized TB treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9-26 (total treatment duration 6 months)
16362011|NCT04244253|Placebo Comparator|Placebo|
16297391|NCT04694573||POST-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection after TX; matching according to
~age (18-34, 35-59, 60-75 years)
~sex
~type of transplantation
~time after transplantation (0-180, 181-365, 366-1095, 1096-2555, >2555 days after TX)"
16297392|NCT04694573||PRE-TX Covid-19 Serum Study Case|Patients being kidney or liver-transplanted after having had an infection with SARS-CoV-2
16297393|NCT04694573||PRE-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection prior to TX; matching according to
~age(18-34, 35-59, 60-75 years)
~sex
~type of transplantation"
16297394|NCT04694560||CLL/SLL|Diagnosis of CLL or SLL confirmed by the enrolling institution
16297395|NCT04694534|Experimental|"Remediation program via a serious game"|"Classic care (recommended by the French Haute Autorité de Santé) accompanied by cognitive remediation by serious game"
16297396|NCT04694534|Placebo Comparator|Classic care (French Haute Autorité de Santé)|Classic care (recommended by French Haute Autorité de Santé)
16297397|NCT04694521|Experimental|antegrade colorectal single stapler anastomosis|open Side to end antegrade colorectal anastomosis colo rectal cancers.
16297398|NCT04694521|Experimental|open end to end colorectal stapler anastomosis|open end to end colorectal single anastomosis in non-emergent colo rectal cancers.
16297399|NCT04694508|Experimental|Group A|Headphones (Disok, Alicante, España)
16297400|NCT04694508|No Intervention|Group B|Without music therapy
16297401|NCT04694495||volunteers from health examination center|volunteers(n = 50/center) doing gynecologial examination recruited from health examination center, who shows no symptoms and signs in reproductive tract and are potentially regarded as the healthy controls
16297402|NCT04694495||volunteers from gynecology outpatient|volunteers(n = 150/center) recruited from gynecology outpatient, who show abnormal symptoms and signs in reproductive tract and are potentially regarded as the cases with conditions in reproductive tract
16297403|NCT04694482||psychiatric patients|Psychometric scales
16297404|NCT04694482||healthy controls|Psychometric scales
16297405|NCT04694469||Group Day|operated at 07:30 AM - 06:30 PM
16297406|NCT04694469||Group Night|operated at 06:30 PM - 07:30 AM
16297407|NCT04694456|Experimental|Facioscapulohumeral muscular dystrophy|Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)
16297408|NCT04694443|Active Comparator|Study group|The study group will receive the multidisciplinary tele-health intervention plus standard medical care
16297409|NCT04694443|Placebo Comparator|Control group|The control group will receive the best standard medical care
16297410|NCT04694430||Severe exacerbation of COPD|N = 250
16297411|NCT04694430||Mild and moderate exacerbations of COPD|N = 250
16297412|NCT04694417|Experimental|Compression stocking|Compression stockings are mainly used for the prevention and reduction of lower limb oedema or venous thrombosis. There are three compression classes used in health care. The compression stocking group of the study will receive CE-marked stockings within the compression class of 1 (25-40 mmHg compression). The correct size for the compression stockings will be defined by the reported circumference of the participant's ankle and calf. The participants will be given instructions to put the stockings on immediately after getting out of bed in the morning and to take them off before going to bed in the evening for the last four weeks of the study. Stockings within the mild compression class have no harmful effects on individuals when the exclusion criteria are considered. The participants will be instructed to communicate with a dedicated research assistant via e-mail or phone in case of any problems or questions.
16297413|NCT04694417|Active Comparator|Magnesium|"Magnesium is a mineral substance which regulates many biochemical reactions in the body, for example protein synthesis and the function of the muscles and nerves. It has a significant role in controlling blood sugar, blood pressure, energy generation and the formation of the bones. The recommended dietary allowance for magnesium is 420 mg for males and 320 mg for females over 50 years old. Dark green vegetables, leguminous plants, nuts, seeds and wholegrains are good sources of magnesium (11,12).
~In the average Finnish diet, the recommendation is usually exceeded, and excessive amounts of magnesium in the body are extremely rare. The magnesium arm of the study will take oral tablets containing 620 mg of magnesium hydrochloride daily for the last four weeks of the study, which is equivalent to 250 mg of pure magnesium per day. The magnesium tablets for this study were manufactured and analysed by the Pharmia pharmaceutical company in Finland."
16297414|NCT04694417|Placebo Comparator|Placebo|The placebo tablets will consist of microcrystalline cellulose, magnesium stearate (anti-caking agent) and silicon dioxide. The placebo tablets were manufactured and analysed by the Pharmia pharmaceutical company in Finland. The placebo arm will receive placebo tablets to be taken daily for the last four weeks of the study. The participants will not know whether they are randomised into the magnesium arm or the placebo arm. The packaging and the appearance of the placebo and magnesium tablets are identical.
16297415|NCT04694404|Experimental|S-1 Plus Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-10, q2w)
16297416|NCT04694391||Recurrence|The period of recurrence was within 2 years after radiotherapy. Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
16297417|NCT04694391||No recurrence|The period was more than 3 years after radiotherapy and no recurrence signs were observed.
16297418|NCT04694365|Experimental|Normal Hepatic Function|
16297419|NCT04694365|Experimental|Mild Hepatic Impairment|
16297420|NCT04694365|Experimental|Moderate Hepatic Impairment|
16297421|NCT04694352|Experimental|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side
16297422|NCT04694352|Active Comparator|Conventional|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.
~Skipping."
16297423|NCT04694326||Inpatients|Patients who were inpatients of units other than internal medicine services and internal medicine side-branch services
16297424|NCT04694313|Experimental|OPM|Two types of measurement will be compared (SQUID and OPM) with the reference that constitutes the in-depth recordings (Stereotactic-EEG or SEEG) used to precisely define the region of the brain to be resected in order to cure epileptic patients of their seizures.
16297426|NCT04694300|Active Comparator|Acetaminophen|Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)
16297427|NCT04694287||Volume flow group|The study will include consecutive patients undergoing standard fluoroscopically-guided percutaneous balloon angioplasty due to dysfunctional AVF. Intraprocedural volume flow measurements will be obtained just prior to the procedure and after final balloon dilation.
16297428|NCT04694274||group 1|patients with temporomandibular disorders
16297429|NCT04694274||group 2|healthy control
16297430|NCT04694261|Experimental|SM-ART Intervention|Intervention group will receive SM-ART module training along with the flyers on resilience building tips.
16297431|NCT04694261|No Intervention|Control Group|Control group will only receive flyer on resilience building tips
16297432|NCT04694248|Experimental|Anticoagulant plus antiplatelet therapy|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
16297433|NCT04694235|No Intervention|Observational cohort (control group)|In the observational cohort, pregnant mothers in the 2nd trimester (n=500) will be recruited and they will be followed up until their children are 24 months old. The control group women will receive standard intervention in the form of Ante Natal Care from village midwives (Polindes) or Puskesmas (IFA tablet, calcium tablet, nutrition counselling).
16297434|NCT04694235|Experimental|Intervention group|The intervention group women (n=153) will be provided one egg three times per week from recruitment (2nd trimester) until term along with the standard Ante Natal Care.
16297435|NCT04694222|Other|Control Group|scaling and root planning (SRP) was applied.
16297436|NCT04694222|Active Comparator|LANAP Group|After scaling and polishing, three LANAP stages were performed : In the first stage, Nd:YAG laser was applied. In the second stage, full mouth SRP procedure was performed. In the third stage, Nd:YAG laser was applied again.
16297437|NCT04694222|Active Comparator|LLLT Group|after SRP Low Level Laser Therapy was performed using Nd:YAG laser.
16297438|NCT04694222|Active Comparator|LANAP+LLLT Group|after scaling both LANAP and LLLT were applied.
16297439|NCT04694209|Experimental|Fixed implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a hybrid prosthesis. a metal framework, acrylic resin denture base and acrylic resin teeth
16297440|NCT04694209|Active Comparator|Removable implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a telescopic retained overdenture, both primary and secondary copings are custom made. the secondary copings are conncetd via a metal framework
16297441|NCT04694196|Experimental|Locate occlusal plane|Use anatomical landmark to locate OP in edentulous patients.
16297442|NCT04694183|Experimental|Camrelizumab combined with chemotherapy|The enrolled patients will be administered in two ways according to the difference between peritoneal metastasis and liver metastasis
16297443|NCT04694170|Experimental|Experimental group|Patients with musculoskeletal pain in the lumbar region. Patients with typical symptoms of functional dysfunction of kidney undergo conventional physiotherapy and an alternative approach by yoga set exercising and regimen restriction according to traditional Chinese medicine.
16297444|NCT04694170|Active Comparator|control group|Patients with musculoskeletal pain in the lumbar region. Patients with kidney dysfunction symptoms treated by conventional physiotherapy only.
16297445|NCT04694157||Treatment group|The treatment group will receive cardiac shock wave therapy. The CSWT entire treatment will period last 3 months with 9 sessions. CSWT will administered in the first week, followed by a 3-week non-treatment interval.
16297446|NCT04694131|Other|MS|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects. There will be two experiment days, during which TMS will be delivered during the behavioral tasks (spatial task trials and encoding phase of the memory task). Participants will receive TMS delivered to parietal cortex on one day and vertex stimulation on the other day. Each experiment day will include one block of TMS delivered prior to task trial onsets and one block delivered simultaneously with trial onsets.
16297447|NCT04694118|Experimental|15 hemiparetic cerebral palsy,walking back group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
16297448|NCT04694118|Experimental|15 hemiparetic cerebral palsy,rebound therapy group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
16297449|NCT04694105|Active Comparator|dexmedetomidine|Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
16297450|NCT04694105|Active Comparator|dexamethasone|Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml)
16297451|NCT04694105|Placebo Comparator|control group|Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline
16297452|NCT04694092|Experimental|Intensive rate control with landiolol|Intensive heart rate control using landiolol with the goal to achieve HR<115 during the first 2 hours.
16297453|NCT04694092|Active Comparator|Standard therapy|Standard heart rate control with therapy other than landiolol
16297454|NCT04694079|Experimental|Group 1, CMR-guided VT ablation|"Patients randomized to Group 1, will undergo CMR-guided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).
~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
16297455|NCT04694079|Experimental|Group 2, CMR-aided VT ablation|"Patients randomized to Group 2, will undergo CMR-aided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).
~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
16297498|NCT04693793|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the Janssen test results.
16297810|NCT04691544|Active Comparator|Fecal microbiota transplant from donor C|One FMT delivered by enema
16297456|NCT04694079|Active Comparator|Group 3, Electroanatomical guided ablation|Patients assigned to Group 3, will not undergo LGE-CMR. Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.
16297457|NCT04694066|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (followup; 8 hours). The sessions will be supervised by an experienced qigong master.
16297458|NCT04694066|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise only, with the same duration and frequency of supervised sessions identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
16297459|NCT04694040||healthy adult volunteers showing no signs of temporomandibular disorders|
16297460|NCT04694027|Active Comparator|group a|will receive omega 3 plus vitamin E
16297461|NCT04694027|Active Comparator|Group b|will receive vitamin E
16297462|NCT04694027|No Intervention|Group c|no intervention just reassurance and analgesics on need
16297463|NCT04694014||Emotional Intelligence Skills study among frontline HCW managing Covid19 in Busia Kenya|Researchers from Alupe University College will select study participants as follows 6 Clinical officers, 2 nurses, 1 nutritionist, 1 lab technician, 2 lab technologists, 7 members on the sub county surveillance Matayos, Teso north and Bunyala 2 from UHC office
16297464|NCT04694001|Other|Hemiplegia due to Cerebrovascular Accident (CVA)|
16297465|NCT04693988|Experimental|Case management|Patient receives case management while in hospital.
16297466|NCT04693988|No Intervention|Usual Care|This control condition does not receive intervention of case management
16297467|NCT04693962||Partial Nephrectomy (PN)|Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
16297468|NCT04693962||Hemicolectomy (HC)|Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
16297469|NCT04693962||Nephrolithotomy (NL)|Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
16297470|NCT04693949|Active Comparator|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
16297471|NCT04693949|Experimental|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
16297472|NCT04693936|Active Comparator|Nutraceuticals|Participants will receive a combination of nutraceuticals and will be instructed to follow a Mediterranean diet
16297473|NCT04693936|No Intervention|Control|Participants will follow usual diet
16297474|NCT04693923|Experimental|Group A (rapid fluid challenge)|Patients will receive a rapid fluid challenge (4ml/kg of crystalloids in 5 minutes using a syringe of 60 mL and a timer in the multiparameter monitor).
16297475|NCT04693923|Active Comparator|Group B (standard fluid challenge)|Patients will receive a standard fluid challenge (500 ml of crystalloids in 30 minutes).
16297476|NCT04693910|Experimental|Multimedia information group|The experimental group received a weekly multimedia hormone therapy information program for 6 weeks.
16297477|NCT04693910|No Intervention|Routine care group|The control group will receive routine care.
16297478|NCT04693897||Overactive bladder with Mirabegron|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Mirabegron 50mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
16297479|NCT04693897||Overactive bladder with Solifenacin|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Solifenacin 5mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
16297480|NCT04693897||Urinary tract infection|Urinary samples for beta-3 adrenoceptor concentration of 100 patients with urinary tract infection.
16297481|NCT04693897||Control|Urinary samples for beta-3 adrenoceptor concentration of 100 patients without lower urinary tract symptoms.
16297482|NCT04693884|Experimental|High THC, Smoked|
16297483|NCT04693884|Experimental|High THC, Vaporized|
16297484|NCT04693884|Experimental|High CBD, Smoked|
16297485|NCT04693884|Experimental|High CBD, Vaporized|
16297486|NCT04693871||high-flow rate group|
16297487|NCT04693871||low-flow rate group|
16297488|NCT04693858|Experimental|Child Anxiety Learning Modules (CALM)|Children randomly assigned to this condition will receive the CALM intervention.
16297489|NCT04693858|Active Comparator|Child Anxiety Learning Modules--Relaxation (CALM-R)|Children randomly assigned to this condition will receive the CALM-R intervention.
16297490|NCT04693858|No Intervention|Waitlist control|Within each nurse, 20% (1 in 5) children will be randomly assigned to wait a period of eight weeks prior to starting the intervention with their school nurse. During this period, the child is not prevented from seeing the school nurse, nor are they prevented from continuing to utilize stable doses of community treatment (i.e., therapy outside of school or medication); nurses are simply asked to provide normal support and avoid using techniques specific to CALM or CALM-R. After the 8 weeks, youth are re-evaluated and nurses begin delivering the intervention to the student.
16297491|NCT04693845|Active Comparator|Treatment as Usual|Community Mental Health Center Next Day Appointment clinic
16297492|NCT04693845|Experimental|Experimental|Collaborative Assessment and Management of Suicidality (CAMS)
16297493|NCT04693832|Experimental|5inD|All children receive routine antiemetic therapy before chemotherapy. Children in the experimental group will use the interactive mobile application (5inD) for seven days from the first day of chemotherapy. The games in this application will help distract their attention and manage their nausea and vomiting.
16297494|NCT04693832|No Intervention|Control group|All children receive routine antiemetic therapy before chemotherapy.
16297495|NCT04693819||Hyperacusis|Abnormally reduced tolerance to sound
16297496|NCT04693806|Experimental|Continuous CO2 Level|embryos will remain in a single incubator set at a continuousCO2 level
16297497|NCT04693806|No Intervention|Sequential CO2 Level|Current standard of care
16297612|NCT04693065||Ponseti|Patients treated by ponseti method
16363474|NCT04233905||healthy adults|healthy adults control group
16297499|NCT04693793|Experimental|Educational Materials and Janssen Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
16297500|NCT04693793|Experimental|Educational Materials and Janssen Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
16297501|NCT04693780|Experimental|Structured guide with pre-appraisal content|Once logged into the website, participants in the intervention group will navigate health information through an annotated structured guide to health evidence which is designed to inform participants where to find specific health information but it will also provide information to understand why such content is more valuable than other content. This structured annotated guide to evidence will also outline the value of pre-appraisal and will help them navigate to products produced for them. These products have been produced by the research team and include a collection of web resource ratings, evidence summaries and blog posts modelled after those developed and presented on the McMaster Optimal Aging Portal. The topics of this citizen content match the scope of the IMAGINE Network.
16297502|NCT04693780|Placebo Comparator|Listing without pre-appraisal content|Once logged into the website, participants in the control group will navigate health information through a structured one-page guide (see Appendix 1) that does not include pre-appraisal information. Instead it will list the main organizations in the field that produce citizen content with descriptions of the type of content they produce with links to their individual websites. This will be presented to participants when they login to the platform. None of the citizen content produced specifically for the study will be provided to them prior to crossing-over.
16297505|NCT04693741|Other|"Autogenous iliac bone graft group A"|The autogenous iliac bone graft will be used to fill the alveolar defect.
16297506|NCT04693741|Other|"Xenograft with PRF group B"|Xenograft with PRF will be used to fill the alveolar defect.
16297507|NCT04693728|Active Comparator|Behavioral Intervention|The study intervention arm was a behavioral treatment that consisted of training resilient intrinsic self-regulation strategies to help alleviate chronic pain.
16297508|NCT04693728|No Intervention|Wait-list with no treatment|The control comparison arm consisted of a wait-list condition in which participants received no treatment during a time interval comparable to the intervention arm.
16297509|NCT04693715|Experimental|RNS60 0.5 mL/kg/h|RNS60 0.5 mL/kg/h infusion for 48h (up to a maximum of 60 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
16297510|NCT04693715|Experimental|RNS60 1 mL/kg/h|RNS60 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
16297511|NCT04693715|Placebo Comparator|Placebo 1 mL/kg/h|Placebo (normal saline) 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
16297512|NCT04693702||Age-related Macular Degeneration|
16297513|NCT04693702||Diabetic Macular Edema|
16297514|NCT04693689|Experimental|Conventional vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 0%."
16297515|NCT04693689|Experimental|Conventional vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 20%."
16297516|NCT04693689|Experimental|Conventional vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 40%."
16297517|NCT04693689|Experimental|Conventional vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 60%."
16297518|NCT04693689|Experimental|Conventional vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 80%."
16297519|NCT04693689|Experimental|RNA vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 0%."
16297613|NCT04693052||Patients receiving mental health care prior to and during the COVID-19 pandemic|
16297614|NCT04693039|Experimental|FLZ-150mg|Drug：Phenlarmide；Dosage：150mg；
16297520|NCT04693689|Experimental|RNA vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 20%."
16297521|NCT04693689|Experimental|RNA vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 40%."
16297522|NCT04693689|Experimental|RNA vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 60%."
16297523|NCT04693689|Experimental|RNA vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 80%."
16297524|NCT04693676|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
16297525|NCT04693663|Other|ReLex Smile surgery|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster).
16297526|NCT04693650|Experimental|Treatment group- UHF(+RF) stimulation|Patients implanted with leads and be administered with UHF stimulation
16297527|NCT04693650|No Intervention|Control group|Patients implanted with lead receiving fake stimulation (no stimulation but same device procedure with test group)
16297528|NCT04693637|Experimental|Viralym-M (OL)|Open Label Cohort
16297529|NCT04693637|Placebo Comparator|Placebo|No Viremia Cohort & Viremia Cohort, Arm 2
16297530|NCT04693637|Experimental|Viralym-M|No Viremia Cohort & Viremia Cohort, Arm 1
16297531|NCT04693624||Hormonal levels|Blood samples are collected for analysis of progesterone, hCG, inhibin-A, and 17-OH-Progesterone levels.
16297532|NCT04693611|Experimental|Intervention Group|"Participants who meet the inclusion criteria will be randomised to the CS intervention group or to the control group that will maintain their usual treatment.
~Participants in the intervention group will participate in two CS sessions per 12 weeks besides their treatment as usual."
16297533|NCT04693611|No Intervention|Control Group|Participants in the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed dementia-specific medication.
16297534|NCT04693598|Experimental|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the lower dose (N=3 participants)
16297535|NCT04693598|Experimental|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the higher dose (N=3 participants)
16297536|NCT04693585|Experimental|Arm 1: live support|Real-time live voice call plus standard of postnatal care.
16297537|NCT04693585|Experimental|Arm 2: asynchronous support|Text-based, asynchronous, on-demand social support plus standard of postnatal care
16297538|NCT04693585|Experimental|Arm 3: both live and asynchronous support|Real-time live voice call plus standard of postnatal care; text-based, asynchronous, on-demand social support plus standard of postnatal care
16297539|NCT04693585|No Intervention|Arm 4: control|Standard of postnatal care.
16297540|NCT04693572||Parturients undergoing repeated caesarean sectiona|
16297541|NCT04693559|Other|autogenous iliac bone graft (group A)|autogenous iliac bone graft will be used to fill the alveolar defect
16297542|NCT04693559|Other|Nano crystalline Hydroxyapatite (group B)|Nano crystalline Hydroxyapatite will be used to fill the alveolar defect
16297543|NCT04693533|Other|treatment effect|No 2 arms and only 1 intervention
16297544|NCT04693520|Experimental|Active treatment|ALZ-801 265 mg tablets once daily for two weeks and twice daily thereafter
16297545|NCT04693507|Experimental|Teverelix TFA 120 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (120 mg SC + 120 mg IM) and teverelix TFA maintenance doses of 120 mg SC at week 6 and 6-weekly thereafter up to week 24
16297546|NCT04693507|Experimental|Teverelix TFA 90 mg 4-weekly|Participants receive teverelix TFA loading dose on Day 0 (90 mg SC + 90 mg IM) and teverelix TFA maintenance doses of 90 mg SC at week 4 and 4-weekly thereafter up to week 24
16297547|NCT04693494|Experimental|Intervention group|"Four training sessions (before the baby is 1 month old, at 3 months, at 6 and at 9 months old) teaching the main motor milestones to get in the next 3 months and how to help infants with the correct stimuli, positions or plays; triptychs containing the main points explained at the session and links to short videos about the given advices.
~Two evaluations of motor milestones at the age of 9 and 12 months old"
16297548|NCT04693494|No Intervention|Control group|Two evaluations of motor milestones at the age of 9 and 12 months old
16297549|NCT04693481|Experimental|experimental group: 5 seconds for each photo|receive the intervention, which is viewing each nature photo for 5 seconds
16297550|NCT04693481|Experimental|experimental group: 15 seconds for each photo|receive the intervention, which is viewing each nature photo for 15 seconds
16297551|NCT04693481|Experimental|experimental group: 30 seconds for each photo|receive the intervention, which is viewing each nature photo for 30 seconds
16297552|NCT04693481|No Intervention|control group|not receive the intervention, which is viewing each nature photo for 0 seconds.
16297553|NCT04693468|Experimental|Arm I (talazoparib, palbociclib)|Patients receive talazoparib PO QD on days 1-21 or 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
16297554|NCT04693468|Experimental|Arm II (talazoparib, axitinib)|Patients receive talazoparib PO QD on days 1-28 and axitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
16297555|NCT04693468|Experimental|Arm III (talazoparib, crizotinib)|Patients receive talazoparib PO QD on days 1-28 and crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
16297556|NCT04693455|Experimental|Experimental: Cohort 1, Dose 1 of ZD03 or Placebo|Dose 1 of ZD03 or matching Placebo capsules by mouth
16297557|NCT04693455|Experimental|Experimental: Cohort 2, Dose 2 of ZD03 or Placebo|Dose 2 of ZD03 or matching Placebo capsules by mouth
16297558|NCT04693455|Experimental|Experimental: Cohort 3, Dose 3 of ZD03 or Placebo|Dose 3 of ZD03 or matching Placebo capsules by mouth
16297559|NCT04693455|Experimental|Experimental: Cohort 4, Dose 4 of ZD03 or Placebo|Dose 4 of ZD03 or matching Placebo capsules by mouth
16297560|NCT04693455|Experimental|Experimental: Cohort 5, Dose 5 of ZD03 or Placebo|Dose 5 of ZD03 or matching Placebo capsules by mouth
16297561|NCT04693455|Experimental|Experimental: Cohort 6, Dose 6 of ZD03 or Placebo|Dose 6 of ZD03 or matching Placebo capsules by mouth
16297562|NCT04693455|Experimental|Experimental: Cohort 7, Dose 7 of ZD03 or Placebo|Dose 7 of ZD03 or matching Placebo capsules by mouth
16297563|NCT04693442||Burn patients|with the condition
16297564|NCT04693442||Control group|without the condition (blood sampling only for adults) and children undergoing general anaesthetic procedures that involve skin resections (blood sampling and excised skin)
16297565|NCT04693429|Experimental|Arm 1|PRO-172 Ophthalmic Solution QID (four times per day)
16297566|NCT04693416|Experimental|Intrapersonal Stigma Reduction|The intervention will include education about substance use disorders (diagnosis, prognosis, and treatment), goal setting to assist the individual in preparing for change, and decisional balance to assist the individual in measuring the costs and benefits about disclosure of mental health problems and exercises to practice how to disclose. Facilitation of an intake assessment for treatment will be offered (with assistance in making the appointment, getting transportation and childcare, and securing a pro-bono status at a outpatient treatment facility).
16297567|NCT04693416|Experimental|Interpersonal Stigma Reduction|The intervention for family members and support persons of enrolled intrapersonal participants will include education about substance use disorders (diagnosis, prognosis, and treatment), stigma reduction, and how to provide support for someone with substance use disorder.
16297568|NCT04693403|Experimental|High-flow oxygen nasal cannula (HFNC)|In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.
16297569|NCT04693403|Experimental|Continuous positive airway pressure (CPAP)|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.
16297570|NCT04693403|Active Comparator|Standard Low flow Oxygen Arm|Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).
16297571|NCT04693390|Experimental|Acupuncture|The acupuncture will be applied at points LI4, ST36, HT7, in association with auriculotherapy point Master Cerebral, immediately after induction of anesthesia for 20 minutes
16297572|NCT04693390|No Intervention|Standard care group|The patients will follow the standard procedure
16297573|NCT04693377|Active Comparator|Arm A (SBRT)|Patients undergo stereotactic body radiation therapy for 1 fraction.
16297574|NCT04693377|Experimental|Arm B (cryoablation, SBRT)|Patients undergo cryoablation. Within 10 days after cryoablation, patients undergo stereotactic body radiation therapy for 1 fraction.
16297575|NCT04693364||Observational (questionnaire, 3D breast model, discussion)|Patients complete questionnaire over 5 minutes about difficulties in making decision about breast cancer treatment, then participate in a consultation with regular care doctor and study doctor/study staff using the 3D breast model. Patients then complete questionnaires over 5-10 minutes about their opinions on the breast model and different breast surgical treatment options available.
16297578|NCT04693338|Experimental|Supportive care (ICP)|Patients completion surveys of 4 common symptoms: fatigue, hot flashes, insomnia, and sexual dysfunction and receive educational material via mobile app to help with bothersome symptoms. Patients also complete questionnaires.
16297579|NCT04693325|Experimental|Prolonged normothermic machina perfusion|Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
16297580|NCT04693312|Experimental|Group I|scalene muscle level injection of depomedrol
16297581|NCT04693312|Experimental|Group II|Rheumboid muscle level injection of depomedrol
16297615|NCT04693039|Experimental|FLZ-300mg|Drug：Phenlarmide；Dosage：300mg；
16297616|NCT04693039|Experimental|FLZ-600mg|Drug：Phenlarmide；Dosage：600mg；
16297617|NCT04693039|Experimental|FLZ-900mg|Drug：Phenlarmide；Dosage：900mg；
16297582|NCT04693299||Study cohort|"Inclusion criteria:
~Outpatient and hospitalized patients, adults, candidates for colonoscopy for any pathology, as part of the normal care process, with the need to repeat bowel preparation due to inadequate cleansing.
~Exclusion criteria:
~Emergency regime
~Inability to obtain consent
~Refusal of the patient"
16297583|NCT04693286|Active Comparator|Vaccine candidate arm|In this arm, participants will get nOPV2 vaccine candidate 1
16297584|NCT04693286|Placebo Comparator|Placebo arm|In this arm, participants will get inactive substance like sucrose in BME media and buffer.
16297585|NCT04693273||Carpal Tunnel Release surgical patients|This is the group the investigators survey who are candidates for carpal tunnel release (CTR) surgery: patients should be 18 years or older, comprehend and read English, and patients who consent to do the survey.
16297586|NCT04693260|Other|Hand-held Device Supported by Mobile Application|Insight device ETDRS measurement compared to a standard ETDRS chart
16297587|NCT04693247|Active Comparator|Refraction with a Hand-held Refraction Device|This is the device that will be compared to a standard device.
16297588|NCT04693247|Other|Autorefractor|Standard Device
16297589|NCT04693234|Other|Tislelizumab and Ociperlimab (BGB-A1217) Combination (Cohort 1)|Participants will receive tislelizumab 200 milligrams (mg) on Day 1 followed by the administration of ociperlimab (BGB-A1217) 900 mg of each 21-day cycle.
16297590|NCT04693234|Other|Tislelizumab Monotherapy (Cohort 2)|Tislelizumab 200 mg will be administered on Day 1 of each 21-day cycle
16297591|NCT04693221|Sham Comparator|Control|VNS therapy with randomly-set combination of parameters (similar to current practice)
16297592|NCT04693221|Experimental|Experimental|VNS therapy with set combination of parameters chosen based on the lowest phase lag index
16297593|NCT04693208|Experimental|Laser|Laser light will be applied to the surgery site after tonsils excision.
16297594|NCT04693208|No Intervention|Standard care|
16297595|NCT04693195|Experimental|BLU-5937 oral tablet|Eligible participants will receive BLU-5937 BID orally for 4 weeks.
16297596|NCT04693195|Placebo Comparator|Placebo oral tablet|Eligible participants will receive matching Placebo BID orally for 4 weeks.
16297597|NCT04693182|No Intervention|With quick returns|The control condition in this trial implies that employees maintain the same number of quick returns as in previous years for the six-month intervention period. Hospital units in the control group are not expected to experience any increase in the number of quick returns.
16297598|NCT04693182|Experimental|Without quick returns|The intervention entails implementing a shift schedule which abolishes quick returns for a six-month intervention period. The number of quick returns in the various hospital units in this trial varies from 329-2356 per year. The intervention means that this number is abolished or reduced as much as possible. For practical reasons it is reasonable to expect that for many of the units it may be a matter of reducing rather than completely abolishing quick returns, as ensuring adequate staffing (e.g., due to sickness absence), often on short-notice make it impossible to comply with the rule of avoiding quick returns. The human resources department at the hospital assisted shift planners in scheduling shift schedules without quick returns.
16297599|NCT04693169|Experimental|[Al18F]PSMA137 PET/CT imaging|All study participants will be allocated to this arm (single-arm study).Study participants will undergo [Al18F]PSMA137 PET/CT scans.
16297600|NCT04693156|Active Comparator|oblique subcostal tap block|ultrasound-guided right oblique subcostal TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl (sodium chloride) 10ml and ultrasound-guided posterior TAP block with %0.9 NaCl 30ml
16297601|NCT04693156|Active Comparator|posterior tap block|ultrasound-guided right oblique subcostal TAP block with %0.9 NaCl 30ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
16297602|NCT04693156|Active Comparator|dual tap block|ultrasound-guided right oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
16297603|NCT04693143|Other|Parenteral Nutrition for Critically Ill Children|Total Parenteral Nutrition for critically ill children
16297604|NCT04693130|Experimental|Mindfulness-based prenatal education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
16297605|NCT04693130|Experimental|Application for prenatal education|The intervention includes
16297606|NCT04693130|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
16297607|NCT04693117|Experimental|Study Group|Participants were voluntarily participated by non-probability consecutive sampling. It was a one group study with a limitation of non-randomization. The interventional group had performed interval training for 12 weeks, 3 days/week (figure 1). They sedentary conferring to activity level (≥ 30-minute, 3 days/weeks, moderate-intensity physical activity). They were not participated in any interval training program before participating in the study from six months. Written consent was taken after demonstration of the purpose, procedure, and related pros and cons. They were instructed to participate regularly in interval training.
16297608|NCT04693104|Experimental|PVA Hydrogel|PVA Hydrogel (Rottapharm Biotech, Monza): 2 mL prefilled syringe for intra-articular injection
16297609|NCT04693104|Active Comparator|Synvisc-One®|Synvisc-One® (Genzyme Corporation, Ridegield, New Jersey, USA): 6 mL prefilled syringe for intra-articular injection
16297610|NCT04693091|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.
~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
16297611|NCT04693078|Experimental|Intervention Arm|Consecutive patients undergoing screening or surveillance colonoscopy in whom a new polyp detection system based on deep learning will be used during the procedure.
16297622|NCT04693026|Experimental|Group A: Remdesivir + Baricitinib treatment group|"Remdesivir (Injectable solution):
~A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.
~+
~Baricitinib (oral tablet form):
~Baricitinib tablets 4 mg/day for 2 to 4weeks"
16297623|NCT04693026|Active Comparator|Group B: Remdesivir + Tocilizumab treatment group|"Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.
~+
~Tocilizumab (Injectable solution):
~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
16297624|NCT04693013|Experimental|Interventional|use of virtual reality (VR)
16297625|NCT04693013|No Intervention|Control|no use of VR
16297626|NCT04693000|Experimental|Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|"An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.
~Keratotic nodular size observation after 12 weeks"
16297627|NCT04692987|Experimental|Intervention|Participants will receive decision-aid video
16297628|NCT04692987|No Intervention|Usual care|Participants will receive usual care
16297629|NCT04692974|Experimental|Intervention Group|Participants in the intervention group will be given the wearables which they will use together with the accompanying mobile application for the period of the study (6 months). During the period of intervention, the wearable will track the physical activity of the older adults via the number of steps taken and number of hours of moderate physical work (based on heart rate). Heart rate and steps will be tracked whenever participants are wearing the watch, which is when they are awake. The watch is to be charged every night when they are sleeping. Participants will have to log down their physical activity by activating the physical activity tracker either on the watch or on the mobile application. If they did not hit the required level of physical activity, they will be sent a notification prompt through the mobile application with details of nearby workout locations as recommendation.
16297630|NCT04692974|No Intervention|Control Group|For the control group, they will wear the wearables as a tracking device for the period of the study (6 months). No prompts will be given and the mobile application will only be installed but not used for this group.
16297631|NCT04692961|Experimental|Patients after free flap harvested|Patients receiving peroneal artery-based free flap harvest
16297632|NCT04692948|Experimental|TAA6 cell injection|"Drug: TAA6 cell injection（Targeting CD276 autologous chimeric antigen receptor T cells）
~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells.Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
16297633|NCT04692935||Asian lung adenocarcinoma|Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital
16297634|NCT04692935||Caucasian lung adenocarcinoma|Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the AACR GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations
16297635|NCT04692922||Patients with disorders of consciousness|patients with a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
16297636|NCT04692909|Active Comparator|Active|Active dTMS
16297637|NCT04692909|Placebo Comparator|Placebo|Placebo dTMS
16297638|NCT04692896|Experimental|0.1% lidocaine|
16297639|NCT04692896|Experimental|0.2% lidocaine|
16297640|NCT04692896|Experimental|0.3% lidocaine|
16297641|NCT04692857|Experimental|group 30|participants received a supra inguinal fascia iliaca compartment block with 30 ml of 0.2% ropivacaine
16297642|NCT04692857|Experimental|group 40|participants received a supra inguinal fascia iliaca compartment block with 40 ml of 0.2% ropivacaine
16297643|NCT04692857|Experimental|group 50|participants received a supra inguinal fascia iliaca compartment block with 50 ml of 0.2% ropivacaine
16297644|NCT04692844||Patients with essential tremor treated with Propranolol|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Propranolol in the course of routine medical practice, will be included.
16297645|NCT04692844||Patients with essential tremor treated with Primidone|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Primidone in the course of routine medical practice, will be included.
16297646|NCT04692831|Experimental|Arm A|Patients in Arm A will receive 89Zr-ss-pertuzumab first, followed by 89Zr-pertuzumab. 89Zr-pertuzumab will be administered followed by 1 PET/CT scan 5-8 days post administration. For standard first in-human dosimetry, the first 6-8 patients who receive 89Zr-ss-pertuzumab will be followed by PET/CT imaging at 3 timepoints: 24 hours post administration (scan 1), 3-4 days post administration (scan 2) and 5-8 days post administration (scan 3). Once the optimal imaging timepoint for 89Zr-ss-pertuzumab is determined from these 6-8 patients, the remaining 12-14 participants will be scanned only at this optimal imaging timepoint
16297647|NCT04692831|Experimental|Arm B|Patients in Arm B will receive 89Zr-pertuzumab first, followed by 89Zr-ss-pertuzumab. 89Zr-pertuzumab will be administered followed by 1 PET/CT scan 5-8 days post administration. For standard first in-human dosimetry, the first 6-8 patients who receive 89Zr-ss-pertuzumab will be followed by PET/CT imaging at 3 timepoints: 24 hours post administration (scan 1), 3-4 days post administration (scan 2) and 5-8 days post administration (scan 3). Once the optimal imaging timepoint for 89Zr-ss-pertuzumab is determined from these 6-8 patients, the remaining 12-14 participants will be scanned only at this optimal imaging timepoint
16297648|NCT04692818|Experimental|Clinically indicated breast tumor biopsy|Subjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed
16297649|NCT04692805|Experimental|EUS-guided treatment of varices|"Procedure: EUS-guided injection of coils with cyanoacrylate glue (CYA) and sclerosing agent.
~First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.
~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.
~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with Coils plus CYA and sclerosing agent (Group A)."
16297650|NCT04692805|Experimental|EUS-guided partial splenic embolization + EUS-guided treatment of varices|"Procedure: EUS-guided partial splenic embolization + EUS-guided treatment of varices First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.
~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.
~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with coils plus CYA and sclerosing agent.
~At the same procedure, a branch of splenic artery will be identified by EUS and implanted with coils plus CYA (Group B)."
16297651|NCT04692792|Placebo Comparator|Placebo drink|
16297652|NCT04692792|Experimental|Dai Dai flower drink|
16297653|NCT04692779||Intubated ARDS patients undergoing prone positioning|
16297654|NCT04692766|Experimental|RPH-104 80 mg|subjects will receive RPH-104 at a dose of 80 mg subcutaneously once every 2 weeks
16297655|NCT04692766|Placebo Comparator|Placebo|subjects will receive placebo subcutaneously once every 2 weeks
16297656|NCT04692753||Pre-intervention|baseline data prior to training and education of health care workers. Intervention: intensive training and education of workers for maintenance of venous access devices.
16297657|NCT04692753||Post intervention|observation after training and education of health care workers
16297658|NCT04692740|Experimental|Chlorambucil|
16297659|NCT04692727|Active Comparator|Exercise grup|An exercise program that includes stretching, strengthening and balance exercises accompanied by physiotherapist in the clinic will be applied to all individuals participating in the study for 6 weeks, 2 times a week (12 sessions). Each session will take approximately 40 minutes and patients will be asked to repeat the exercises at least 2 sets a day at home when they are not in the clinic (other 5 days a week). The home program will be followed by the exercise daily form.
16297660|NCT04692727|Experimental|McConnell patellar taping grup|McConnell patellar taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group. The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
16297661|NCT04692727|Experimental|Femoral rotational taping grup|Femoral lateral rotation taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group.The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
16297662|NCT04692714|Experimental|Experimental knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented without additional cement using the MAKO robot
16297663|NCT04692714|Active Comparator|Conventional knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented with additional cement using the MAKO robot
16297664|NCT04692701|Experimental|Pulvinar stimulation|Medial pulvinar deep brain stimulation
16297665|NCT04692688|Experimental|APX3330|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
16297666|NCT04692688|Placebo Comparator|Placebo|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
16297668|NCT04692649|Experimental|PPCS|Novel intervention
16297669|NCT04692649|Active Comparator|CBS|Cross arm stretch gave to individuals
16297670|NCT04692636||Total study cohort|Patients with dysfunctional hemodialysis vascular access referred for PTA or patients who received maintenance hemodialysis will be prospectively enrolled.
16297671|NCT04692623|Experimental|Moxfloxacin Group|In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.
16297672|NCT04692623|Experimental|Gemifloxacin Group|In this arm 30 healthy volunteers were selected and they were given Gemifloxacin
16297673|NCT04692610|Placebo Comparator|Group A|Postoperative Education Group received stoma education and stoma care after surgery beginning from the postoperative day-1. In the preoperative period they were informed about stoma and stoma sites were marked.
16297674|NCT04692610|Active Comparator|Group B|Pre- and Postoperative Education Group received stoma education both before surgery and on the postoperative day-1. They received stoma care postoperatively as usual. In the preoperative period they were also informed about stoma and stoma sites were marked.
16297675|NCT04692610|Experimental|Group C|Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery. These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.
16297676|NCT04692597|Experimental|Group 1 (LLLT)|"Group 1: Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes affected per hand.
~The protocol for each group will involve one minute of LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
16297811|NCT04691544|Placebo Comparator|Fecal microbiota transplant from autologous feces|One FMT delivered by enema
16363475|NCT04233892|Experimental|CBD-bFGF|
16297677|NCT04692597|Sham Comparator|Group 2 (LLLT Sham)|"Group 2: Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes affected per hand.
~The protocol for each group will involve one minute of sham LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
16297678|NCT04692584|Experimental|The Lullaby Group|In this group, their mothers sang a lullaby during the vaccination process.
16297679|NCT04692584|No Intervention|Control Group|"In this group, their mothers did not sing a lullaby during the vaccination process.
~Mothers were allowed to touch and talk to their babies during the vaccination. However, the mothers did not take any action to divert the infant's attention."
16297680|NCT04692571|Experimental|Study B: Limb-Absent Subject|"Ten unilateral transradial limb-absent subjects will each participate in one, half-day experimental session. Subjects will be seated and prepared in test apparatus seat (16 electrodes on the affected side, hand-wrist on the able side secured to load cells). Subjects will complete the 1-DoF and 2-DoF dynamic (force-varying) contractions (40-s duration, 0.75 Hz bandlimited, uniform random target). With 2 DoF contraction trials, hand Opn-Cls will always be one of the dimensions. The subject will then be released from the cuff and their able side not further involved in the experiment. The force feedback triangle cursor on the computer screen will be deleted such that only the target remains. Subjects will then repeat 1-DoF and 2-DoF trials in which the affected side attempts to produce hand-wrist effort that mimic movement of the target (with no feedback provided)."
16297681|NCT04692571|Experimental|Study B: Able-bodied Subjects|Ten able-bodied subjects, the electrodes will be mounted on the dominant arm for the EMG-force and EMG-target tracking trials. In addition, the non-dominant arm will also be constrained and measured in a second load cell. This load cell will not be used for feedback during the experiment, but will compare (RMS error, off-line) the dominant vs. non-dominant forces. For EMG-target tracking, the dominant hand will remain in the wrist cuff (to prevent flailing during contractions), with the screen feedback disabled. These subjects will repeat the trials with the electrodes moved to the non-dominant side. EMG-force tracking will be repeated using mirrored contractions. The three training methods (EMG-force ipsilateral, EMG-force contralateral mirrored, EMG-target on the dominant side) will be contrasted to help understand the source of errors when training with limb-absent subjects.
16297682|NCT04692558|Experimental|HYALURONIC ACID|CAF+CTG+HA
16297683|NCT04692558|Active Comparator|WITHOUT HYALURONIC ACID|CAF+CTG
16297684|NCT04692545||A|patients receiving immunonutrition supply
16297685|NCT04692545||B|patients receiving standard dietary advice
16297686|NCT04692532|Experimental|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
16297687|NCT04692532|Experimental|Calorie restriction|25% energy restriction every day
16297688|NCT04692532|No Intervention|Control|Usual diet
16297689|NCT04692519|Experimental|Intervention|The Duet 2.0 intervention is comprised of six training modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. Modules were translated into Spanish. Participants will watch one Duet intervention module a week and have up to 3 months to complete all 6 modules. As intervention families review the modules on their own time at home, they will receive remote coaching from an assigned interventionist and weekly module-specific fidelity/comprehension questions. Interventionists will check-in weekly via phone or video (~30-60 minutes), whichever is more convenient for the family. During the check-in, interventionists will do teach-back about the module, guide the family on how to incorporate the strategies into their daily lives, and provide feedback. Intervention participants will be scheduled for follow-up data collection at 3 months, 6 months, and pending funding, 1-year after baseline.
16297690|NCT04692519|No Intervention|Delayed Access|Participants who are in the delayed access control group will not have to complete the modules and will be scheduled for a 3-month, 6-month, and pending funding, a 1-year follow-up calls. They will have delayed access to the modules, which means that they will receive access to the module videos at their 6-month study session and will be offered the opportunity to contact the research team with any questions.
16297691|NCT04692506|Active Comparator|Low dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.
~The sachet should be emptied in, and mixed with, a bottle of milk."
16297692|NCT04692506|Active Comparator|High dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.
~The sachet should be emptied in, and mixed with, a bottle of milk."
16297693|NCT04692506|Placebo Comparator|Placebo Sachet|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.
~The sachet should be emptied in, and mixed with, a bottle of milk."
16297696|NCT04692480|Experimental|Breastfeeding Video Education|"Participants will view a breastfeeding educational video entitled Breastfeeding in the First Hour, It's in Your Hands."
16297697|NCT04692480|Other|Control|Participants will view a PDF of breastfeeding education materials available for inclusion in standard discharge paper work.
16297698|NCT04692467|Experimental|Intervention (Early hypertension)|Participants randomized to the early HTN treatment arm will initiate 5mg daily of amlodipine immediately, increasing to 10 mg if SBP >130 mmHg after 1 month.
16297699|NCT04692467|No Intervention|Standard of Care|Participants randomized to the SOC arm will not be initiated on any medications initially. They may be initiated on amlodipine only if they develop HTN (SBP ≥140 or DBP ≥90 mm Hg).
16297700|NCT04692454|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
16297701|NCT04692441|Other|Intervention|All participants undergo the same intervention: Drinking heavy cream and undergoing MRI.
16297702|NCT04692428|Experimental|FIBSI group|ultrasound supra inguinal Fascia iliaca block
16297704|NCT04692415|Active Comparator|degludec arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IDeg-100 In phase one they received IDeg-100 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IDeg-100 to IGlar-300 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
16297705|NCT04692415|Active Comparator|glargine arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IGlar-300 In phase one they received IGlar-300 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IGlar-300 to IDeg-100 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
16297706|NCT04692402|Other|open label|open label prospective feasibility trial.
16297707|NCT04692389|Experimental|Jalosome® Soothing gel|"The medical device will be applied by the patient himself, after appropriate training carried out by the nurse, twice a day, in the quantity necessary to cover the lesion (0.2g of gel /16 cm2 of skin (one spray), repeated as many times as necessary to cover the entire lesion). The treatment will last 8 weeks.
~The medical device will be delivered in the quantity strictly necessary to carry out the therapies between visits, in order to monitor its use. Patients will be seen weekly by the nurse, in order to ensure the best continuity of care and promote adherence to the study. Patients will be asked to keep a weekly diary, in which they will report their level of pain, analgesic therapy and medication. Nurses will be available for telephone counselling, if necessary."
16297708|NCT04692376|Experimental|MSCs group|MSCs group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.
16297709|NCT04692376|Active Comparator|Control group|Glucocorticoids and CsA will be used for treatment.
16297710|NCT04692337|Experimental|Ommaya Reservoir placement|Subjects undergoing surgery for a confirmed or suspected brain tumor will have an Ommaya Reservoir placed at the time of surgery.
16297711|NCT04692324|Experimental|Cerebrospinal Fluid Collection Arm|All subjects enrolled will have CSF collected at two time points (can opt-in for additional collections).
16297712|NCT04692311|Experimental|Persons with central nervous system diseases|Persons with central nervous system diseases received additional training with i-ACT during 6 weeks. After final training, a semi-structured interview was performed. And at six weeks follow-up, a final assessment took place.
16297713|NCT04692311|Other|Occupational therapists|Occupational therapists were invited to a semi-structured interview to gather information about their professional opinion regarding i-ACT.
16297714|NCT04692298|Other|Pulse|Participants will consume kidney beans, lentil, pinto beans, black-eyed pea, chickpea
16297715|NCT04692285|Active Comparator|Patients with focal dystonia treatment first placebo second|Zolpidem 5 mg single dose
16297716|NCT04692285|Placebo Comparator|Patients with focal dystonia placebo first treatment second|Placebo 5 mg single dose
16297717|NCT04692272|No Intervention|CONTROL group|The CONTROL group did not exercise.
16297718|NCT04692272|Experimental|XBOX group|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
16297719|NCT04692259|Experimental|experimental arm|Single arm study. All patient who had an MRI performed before liver resection is included
16297720|NCT04692246|Experimental|Test Group|Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
16297721|NCT04692246|Placebo Comparator|Control Group|Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
16297722|NCT04692233|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (follow-up; 8 hours). The sessions will be supervised by an experienced qigong master. Throughout the intervention period, participants will be asked to self-practice BQ for 30 minutes twice a week from weeks 1 to 8, and then three times a week from weeks 9 to 16 (20 hours).
16297723|NCT04692233|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise without any abdominal breathing and meditation techniques. The duration and frequency of supervised sessions and self-practice will be identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
16297726|NCT04692181|Placebo Comparator|Placebo + IV Meropenem|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
16297727|NCT04692181|Active Comparator|SYN-004 + IV Meropenem|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
16297728|NCT04692181|Placebo Comparator|Placebo + IV Piperacillin/Tazobactam|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
16297729|NCT04692181|Active Comparator|SYN-004 + IV Piperacillin/Tazobactam|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
16297874|NCT04691115|Experimental|Active AM1476|AM1476 will be administered as capsules in an escalating manner
16297730|NCT04692181|Placebo Comparator|Placebo + IV Cefepime|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
16297731|NCT04692181|Active Comparator|SYN-004 + Cefepime|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
16297732|NCT04692168||Entire group|The group will be test prior and three months after a neurotoxic chemotherapy for gynecological cancer.
16297733|NCT04692155|Experimental|phase 1b and phase 2|"for phase 1 B portion, Ublitixumab will be given IV at dosage 900mg from Cycle 1 Day1 till cycle 6. If investigator decides to continue the treatment as maintenance, Ublitixumab will be given IV every 8 weeks for 24 months Umbralisib (800mg) will be given orally once a day within 30 minutes of a meal from Cycle 1 Day1 till cycle 6.If investigator decides to continue the treatment as maintenance,• Umbralisib will be given at orally daily for 24 months.
~Chemotherapy combination of CHOP-cyclophosphamide IV 750mg/m2 for Age <70 years, 500 mg/m2 for Age>70 years doxorubicin IV 50mg/m2for Age <70 years, 25 mg/m2 for Age>70 years , and vincristine IV 1mg/m2 (max 2mg)) are administered on Cycle 1 day 1 till Cycle 6. Prednisone 50-100mg will be given orally on days 1 through 5 of every cycle.
~For Phase II portion- Once Umbralisib dose is defined in phase Ib, the study will expand to phase II portion after SMC/DSMB (Safety monitoring committee/Data Safety Monitoring Committee) agrees."
16297734|NCT04692142|Active Comparator|Passive online|Before L1, all students will be asked to complete a set of multiple-choice questions (MCQs), formative exam (i.e. pre-test). Following the test , the lecture will be delivered to the participants of PG using a passive online teaching format for 60 minutes (i.e., live-video streaming). After the lecture is completed, students will be asked to re-take the same pre-test exam and complete questionnaire regarding their experience with the teaching methods.
16297735|NCT04692142|Experimental|Flipped classroom|"Participants of FG will have an access to a recorded lecture. and they will be taught using an active teaching model known as flipped classroom model. In this model, participants will have 7 -day monitored remote access to the recorded L1. Similar to PG, completing the online pre-test formative exam will be preliminary requirement to access the published recorded L1.
~At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately. After the lecture is completed, students will be asked to re-take the same pre-test of L1 and complete questionnaire regarding their experience with the teaching methods."
16297736|NCT04692116|Experimental|ExAblate Arm|ExAblate Model 4000 System for the treatment of Parkinson's disease
16297738|NCT04692090|Experimental|Yoga Group|Hatha yoga will be practiced twice a week for 10 weeks
16297739|NCT04692090|No Intervention|Control group|This group will not have any intervention.
16297740|NCT04692077|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or may be offered the opportunity to join an open label CAB study instead, if such a study is being implemented in their area at the time.
16297741|NCT04692051|Experimental|Nab-paclitaxel + Cisplatin|Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
16297742|NCT04692051|Active Comparator|Gemcitabine + Cisplatin|Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
16297743|NCT04692038||Treatment Group|The subjects would receive forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
16297744|NCT04692025|Experimental|Group 1|ASC41 one tablet, on Day 1 before meal；ASC41 one tablet, on Day 15 after meal.
16297745|NCT04692025|Experimental|Group 2|ASC41 one tablet, on Day 1 after meal；ASC41 one tablet, on Day 15 before meal.
16297746|NCT04692012|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
16297747|NCT04691999|Experimental|Intermittent Fasting|All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week.
16297750|NCT04691973||Access to tool|Access to the digital tool. Participants use the tool at their own in addition to usual care and do the different themes that are available. They are recommended to use it at least every other week.
16297751|NCT04691973||No access to tool|Participants are followed by their ordinary healthcare provider and are not exposed to the tool.
16297752|NCT04691960|Experimental|Ketogenic Diet|
16297753|NCT04691947|Experimental|Low dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 3 µg/0.5 ml Vaccine Intervention Description:Two applications on Days 0 and 21
16297754|NCT04691947|Experimental|Medium dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 6 µg/0.5 ml Vaccine Intervention Description: Two applications on Days 0 and 21
16297755|NCT04691947|Placebo Comparator|Placebo|Placebo Vaccine, containing 0.9 % saline Intervention Description: Two applications on Days 0 and 21
16297756|NCT04691908|Active Comparator|Phase III Adult-vaccine (A Sample, blind study)|Group 1 (phase III): 2400 volunteers from 18 years old and elder who will be the QazCovid-in® twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16297875|NCT04691115|Experimental|Placebo|Comparator will be administered as capsules
16297757|NCT04691908|Placebo Comparator|Phase III Adult-Placebo (A Sample, blind study)|Group 1 (phase III): 600 volunteers from 18 years old and elder who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16297758|NCT04691895||Patients admitted to hospital for COVID19 disease (case group)|"The study cohort will be composed by consecutively enrolled COVID19 confirmed inpatients (case group)
~Inclusion criteria:
~Signed informed consent
~Age ≥18 years and ≤85 years
~Consecutive COVID19 confirmed patients (COVID +ve)
~Ability to conform to study protocol
~Exclusion criteria:
~Patients under mechanical ventilation
~Patients unable to report required data
~Current diagnosis of cancer"
16297759|NCT04691895||Patients admitted to hospital in absence of COVID19 disease (control group)|"The study cohort will be composed by consecutively enrolled COVID19 negative patients hospitalized for other reasons (controls group)
~Inclusion criteria:
~Signed informed consent
~Age ≥18 years and ≤85 years
~Consecutive hospitalized COVID19 negative patients (COVID -ve)
~Ability to conform to study protocol
~Exclusion criteria:
~Patients under mechanical ventilation
~Patients unable to report required data
~Current diagnosis of cancer"
16297760|NCT04691882|Experimental|Diaphragmatic contraction|
16297761|NCT04691882|Active Comparator|Diaphragmatic relaxation|
16297762|NCT04691869|No Intervention|Control|Patients will be randomized into a control group and study group. The control group will receive an informational discussion with the nurse-practitioner regarding steps to reduce the risk for osteoporosis, as well as an informational handout in their discharge papers.
16297763|NCT04691869|Experimental|Interventional|The study group will undergo the QUS (performed by a member of the study team) and receive the same informational discussion and handouts, with the addition of a QUS screening to take to their follow-up appointment. The QUS screening will come with a half-page description, describing the screening and what their results mean. A discussion lead by the nurse-practitioner, who is a member of the study staff, regarding the results will happen prior to discharge.
16297764|NCT04691856|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
16297765|NCT04691856|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
16297766|NCT04691856|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
16297767|NCT04691843|Active Comparator|Standard iron dose|Iron supplementation of 4mg/kg/day will start when infant is on full enteral feedings of 120-150mL/kg/day and at least two weeks old. Iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day.
16297768|NCT04691843|Experimental|Early, high-dose iron|Iron supplementation will start at 3mg/kg/day when infant is on enteral feeds of 60mL/kg/day and at least one week old, then increased to 6mg/kg/day when enteral feeds are at 100mL/kg/day. Iron dosing will be adjusted to maintain ferritin level of 70-400ng/mL. At 36 weeks corrected age, iron supplementation will be adjusted to the dose routinely used for preterm infants.
16297769|NCT04691830|Experimental|group IA|"Preschool cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
16297770|NCT04691830|Active Comparator|group IB|preschool control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the preschool age control group.
16297771|NCT04691830|Experimental|group IIA|"School age cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
16297772|NCT04691830|Active Comparator|group IIB|School age control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the school age control group.
16297773|NCT04691817|Experimental|Atezolizumab and Tocilizumab|Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
16297774|NCT04691804|Experimental|Treatment group A|Fuzuloparib plus AA-P
16297775|NCT04691804|Placebo Comparator|Treatment group B|Fuzuloparib Placebo plus AA-P
16297776|NCT04691778|Active Comparator|CTO PCI using antegrade wiring strategy starting with the Gladius guidewire|Study subjects will undergo CTO PCI with primary antegrade wiring strategy starting with the Gladius guidewire. In case of failed CTO crossing with the Gladius wire, the decision on continuing antegrade wire escalation with a different wire or switching to a different CTO PCI strategy will be left to the discretion of the operator.
16297777|NCT04691778|Other|CTO PCI using standard antegrade wire escalation strategy|Control subjects will undergo CTO PCI using standard antegrade wiring strategy starting with the lower/intermediate penetration force guidewires and, if necessary, escalating up to high gram-force guidewires, but without the use of first-choice Gladius guidewire.
16297778|NCT04691765|Experimental|100 mg SC|100 mg of Kineret (anakinra) will be administered sub-subcutaneously once a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
16297779|NCT04691765|Experimental|100 mg SC BID|100 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
16297780|NCT04691765|Experimental|200 mg SC BID|200 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
16297812|NCT04691531|Experimental|group C|After induction of general anesthesia, patients will undergo caudal block by classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
16297781|NCT04691752||COPD patients|"Adults (men or women) aged more than 40 years old
~Diagnostic code in Andalusian clinical records (Diraya) in accordance with ICD-9 (Diagnostic codes 496, 492.8, 494.0, 491.20, 493.2)
~Current of former smokers of at least 10 pack- years
~Patient with a minimum follow up of 1 year, who have been assisted in a scheduled primary care appointment at inclusion date."
16297782|NCT04691739|Active Comparator|In-person occupational therapy|occupational therapy delivered in-person
16297783|NCT04691739|Active Comparator|Teletherapy|Video-conferencing occupational therapy
16297784|NCT04691726|Active Comparator|Lidocaine infusion|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 2 mg/kg IBW i.v., continuous infusion of 1% lidocaine postoperatively rate 1 mg/kg IBW i.v. for 24 hours
16297785|NCT04691726|Placebo Comparator|Saline infusion|equal volumes of placebo - 0,9% saline i.v.
16297786|NCT04691713|Experimental|Targeting CD276 autologous chimeric antigen receptor T cells|
16297787|NCT04691700|Active Comparator|Goreisan|Goreisan (TJ-17) will be added at a dose of 7.5g per day to standard treatment
16297788|NCT04691700|Active Comparator|No Goreisan|Standard treatment without Goreisan (TJ-17)
16297789|NCT04691687|No Intervention|Standard of Care (Group 1)|Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.
16297790|NCT04691687|Placebo Comparator|IV Placebo Infusion|Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.The infusions were continuous over 3 hours, biweekly over a one-month period.
16297791|NCT04691687|Experimental|IV Furosemide Infusion|The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions). The infusions were continuous over 3 hours, biweekly over a one-month period.Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP <80 mmHg or symptoms of presyncope).
16297792|NCT04691674|Experimental|Study group|Endoscopic removal of pancreatic duct stent at 4 weeks following ERCP, unless spontaneously dislodged.
16297793|NCT04691674|Placebo Comparator|Control group|Endoscopic removal of pancreatic duct stent at 2 weeks following ERCP, unless spontaneously dislodged.
16297794|NCT04691661|Placebo Comparator|Placebo: Dose escalation|Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
16297795|NCT04691661|Experimental|Radotinib HCl: Dose escalation|"Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
~The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC)."
16297797|NCT04691635||Group 1|Patients with Progressive Supranuclear Palsy
16297798|NCT04691635||Group 2|Patients with Parkinson's disease
16297799|NCT04691635||Group 3|Healthy controls
16297800|NCT04691622|Experimental|Norovirus -specific T-cell (NST) therapy for chronic norovirus infection|"This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. There are two arms in this study:
~Arm A: Participants who receive donor-derived NST therapy after HSCT
~Arm B: Participants who receive partially HLA matched NSTs. The following participants apply:
~Participants with PID who have not undergone HSCT
~Participants who undergo HSCT but do not have available donor derived NSTs
~Participants who have donors from whom NSTs cannot be generated due to norovirus seronegativity"
16297801|NCT04691596|Active Comparator|Control Group|One fourth of participants were assigned to the Control Group, and received a basic training with the StepUp app and were asked to contact the study team with any problems or questions they encountered during the eight-week study period. No other intervention tools or app reminders were provided to the Control Group.
16297802|NCT04691596|Experimental|Treatment Group 1|Additionally eligible to receive weekly $5 Amazon gift cards over the first four weeks of the study for performing a ≥10-minute walk (i.e. non-cue-contingent incentives)
16297803|NCT04691596|Experimental|Treatment Group 2|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were similarly eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any time of day (i.e. non-cue-contingent incentives)
16297804|NCT04691596|Experimental|Treatment Group 3|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any the pre-specified time of their chosen contextual cue (i.e. cue-contingent incentives)
16297805|NCT04691570|Experimental|ANX005|Participants will receive two once-weekly doses of ANX005 at specific time points
16297806|NCT04691557|Experimental|Intervention Group|"The intervention group receives the mobile health application delivered for the smartphone additionally to usual care. The application named AST-M is a web-based mobile health app has been developing user-focused for adolescents with asthma by the research team."
16297807|NCT04691557|Active Comparator|Control Group|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by education nurses for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this training with adolescents, video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
16297808|NCT04691544|Active Comparator|Fecal microbiota transplant from donor A|One FMT delivered by enema
16297809|NCT04691544|Active Comparator|Fecal microbiota transplant from donor B|One FMT delivered by enema
16297813|NCT04691531|Experimental|Group S|After induction of general anesthesia, patients will undergo caudal block by Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
16297814|NCT04691518|Active Comparator|Acute Intermittent Hypoxia (AIH)|Undergoing Acute Intermittent Hypoxia sessions
16297815|NCT04691518|Placebo Comparator|Sham AIH|Undergoing Sham AIH sessions
16297816|NCT04691505||Methotrexate|Reference group
16297817|NCT04691505||Hydroxychloroquine|Exposure group
16297818|NCT04691492|Experimental|Friends-Based Motivational Interview (FMI) Group|Will participate in the Friends-Based Motivational Interview (FMI) program.
16297819|NCT04691492|No Intervention|Wait List Control|The Wait List Control group will also be offered to participate in the Friends-Based Motivational Interview Program but at a deferred date (12 weeks later).
16297820|NCT04691479|Experimental|PIMAGroup|"Educational and training program using motivational interview technical.
~Stratification labels: to determine the personalized intervention plan are obtained from two types of variables: personal and modulation variables. For psychological variables the Perceived Competence Evaluation Questionnaire validated in Adherence to CPAP in OSA (CEPCA) is used. Drowsiness is obtained through the administration of the Epworth Somnolence Test, and the apnoea-hypopnea index is taken from the patient's clinical history.
~Segmentation: With the psychological and clinical variables, in this first visit, predictive information is obtained on how the patient's adherence will be: high adherence, moderate adherence or low adherence.
~Taking this information into account, the care plan will start considering how the patient is and their situation with respect to adherence. Depending on their evolution, the care plan is adapted. For patients with low adherence, telemonitoring is used."
16297821|NCT04691479|Experimental|Control|The patients followed the standard of care, which consists of starting therapy in the hospital, where the nurse performed training in the use of CPAP equipment, mask adjustment, and safety and maintenance instructions. For follow-up, the patient was always referred to the Hospital, with a frequency established by the Spanish Society of Pulmonology and Thoracic Surgery (Day 30, Day 90 and Day 180). The follow-up procedure consisted of reviewing the CPAP hour meter and resolving any incidents that may have arisen, with the necessary corrective actions (change of mask, positive reinforcement, and explanation of specific aspects).
16297822|NCT04691466||HIP_R|Patients undergoing hip replacement surgery
16297823|NCT04691466||KNEE_R|Patients undergoing knee replacement surgery
16297824|NCT04691453|Active Comparator|QM-C Hysterectomy|QM-C Hysterectomy
16297825|NCT04691453|Experimental|QM-B Hysterectomy|QM-B Hysterectomy
16297826|NCT04691440|Experimental|HBOT|Hyperbaric oxygen breathing at 2.4 atm.abs for 90 minutes. The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
16297828|NCT04691401|No Intervention|Standard WL (white light) colonoscopy|all patients receive standard colonoscopy (with high definition- HD- endoscopes) with white light (WL) in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
16297829|NCT04691401|Experimental|Standard colonoscopy with assistance of Artificial Intelligence (CAD-EYE (Fujifilm Co, Tokyo, Japan)|all patients receive colonoscopy examinations (with HD endoscopes) equipped with an Ai system (CAD-EYE, Fujifilm Co, Tokyo, Japan) in both insertion and withdrawal phase). This system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.All polyps identified are removed and sent for histopathology examination.
16297830|NCT04691388|Experimental|Amlotinib+Sindili|Patients will be treated with amlotinib hydrochloride combined with Sindili monoclonal antibody
16297831|NCT04691375|Experimental|Part A: PY314 Single agent dose level 1|PY314 single agent dose level will depend on any safety signal observed in this cohorts only. Following the determination of the safety and tolerability of at least two PY314 dose levels by the safety review committee.
16297832|NCT04691375|Experimental|Part A: PY314 Single agent dose level 2|PY314 single agent dose level 2 dose escalation of PY314 as a single agent will continue in the absence of unacceptable dose limiting toxicity to the maximum administered dose as defined in the predefined dose escalation schema.
16297833|NCT04691375|Experimental|Part A: PY314 Single agent dose level 3|PY314 single agent dose level 3 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314
16297834|NCT04691375|Experimental|Part A: PY314 Single agent dose level 4|PY314 single agent dose level 4 to characterize the pharmacokinetic profile of PY314 as a single agent.
16297835|NCT04691375|Experimental|Part A: Combination dose level 1|Combination dose level 1 to characterize the safety and tolerability of PY314 as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including refractory to check point inhibitor.
16297836|NCT04691375|Experimental|Part A: Combination dose level 2|PY314 combination dose level 2 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314 administered alone and in combination with pembrolizumab.
16297837|NCT04691375|Experimental|Part A: Combination dose level 3|PY314 combination dose level 3 to characterize the pharmacokinetic profile of PY314 as a single agent and in combination with pembrolizumab.
16297838|NCT04691375|Experimental|Part A: Combination dose level 4|PY314 combination dose level 4 to describe, in subjects selected by pre-specified tumor histology, anti-tumor activity of PY314 administered alone and in combination with pembrolizumab.
16297839|NCT04691375|Experimental|Part B: Single agent dose expansion dose level 1|PY314 single agent dose expansion dose level 1 to define further the safety and tolerability of PY314 alone.
16297840|NCT04691375|Experimental|Part B: Single agent dose expansion dose level 2|PY314 single agent dose expansion dose level 2 to further characterize the PK profile of PY314 as a single agent.
16297870|NCT04691154|Experimental|L606|
16297871|NCT04691141|Experimental|ATG-016|5 mg QD×Days 1-5/week will be the initial dose of this study.
16297841|NCT04691375|Experimental|Part B: Combination dose expansion cohort 1|PY314 in combination with pembrolizumab dose expansion cohort 1 to define the safety and tolerability of PY314 alone and in combination with pembrolizumab over multiple treatment cycles in subjects with pre-defined tumor histologies and confirmed TREM2 expression.
16297842|NCT04691375|Experimental|Part B: Combination dose expansion cohort 2|PY314 in combination with pembrolizumab dose expansion cohort 2 to further characterize the PK profile of PY314 as a single agent and in combination with pembrolizumab.
16297843|NCT04691375|Experimental|Part B: Combination dose expansion cohort 3|PY314 in combination with pembrolizumab dose expansion cohort 3 to characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
16297844|NCT04691375|Experimental|Part B: Combination dose expansion cohort 4|PY314 in combination with pembrolizumab dose expansion cohort 4 to evaluate the incidence of ADA formation and TREM2 expression.
16297845|NCT04691362|Active Comparator|Oral Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
16297846|NCT04691362|Active Comparator|Intravenous Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
16297847|NCT04691349|Experimental|Chimeric antigen receptor T cell|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells
16297848|NCT04691336|Experimental|PIMAGroup|All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
16297849|NCT04691323|Other|HU-Go app intervention arm|Participants will use the HU-Go app intervention arm for 12 months.
16297850|NCT04691310|Active Comparator|Kinesio taping study|Kinesio tex gold tape was applied to neck localised lymphedema as stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
16297851|NCT04691310|Sham Comparator|Kinesio taping sham|Kinesio tex gold tape was applied to neck localised lymphedema as no-stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
16297852|NCT04691297|Experimental|Escape|The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening
16297853|NCT04691297|Experimental|Standard Care|The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
16297854|NCT04691284|Experimental|Observational arm|Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including miR and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S rRNA gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used. Moreover, we might be able to characterized potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.
16297855|NCT04691271|Experimental|Intervention group|In addition to routine anesthesia management and surgical operations, a stellate ganglion block was performed before induction of anesthesia, and related statistical indicators were collected prospectively.
16297856|NCT04691271|No Intervention|Blank control group|In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions. Only relevant statistical indicators were collected prospectively.
16297857|NCT04691258|Active Comparator|Restricted Group (RG)|Intervention with the movement technique traditional of squat exercise.
16297858|NCT04691258|Experimental|Complete Group (CG)|Intervention with the squat exercise technique prioritizing the full range of motion.
16297859|NCT04691245|Experimental|Intervention|Femoral access using 3D US
16297860|NCT04691245|Active Comparator|Control|Femoral access using 2D US
16297861|NCT04691232|Experimental|Regulatory T cells|Intravenous infusion of a single dose of 0.5x10e6, 1x10e6, 2x10e6, 5x10e6 or 10x10e6 Treg/kg body weight
16297862|NCT04691219|Experimental|Mulberry leaves powder plus diet control|
16297863|NCT04691219|Other|Diet control alone|
16297864|NCT04691206|Other|standardized step-wise operative curriculum|"General surgery residents at Mayo Clinic will complete surveys measuring resident autonomy, performance, confidence and case complexity at baseline and postoperatively following laparoscopic cholecystectomy to serve as a pre-intervention baseline.
~A standardized step-wise operative curriculum will then be implemented Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID). The effectiveness of the intervention will then be measured by comparing survey results pre and post intervention."
16297865|NCT04691193||study and control group|The study group included patients with low back pain for less than 3 months. The control group consists of healthy volunteers.
16297866|NCT04691180|Experimental|Cohort 1|BRII-196 and BRII-198 dose level 1 or placebo
16297867|NCT04691180|Experimental|Cohort 2|BRII-196 and BRII-198 dose level 2 or placebo
16297868|NCT04691167|Active Comparator|group 1, Active intervention group|
16297869|NCT04691167|Sham Comparator|group 2, sham controlled group|
16297876|NCT04691102||Stroke group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.
~The whole assessment procedure will last approximately 40 minutes."
16297877|NCT04691102||Traumatic Brain Injury group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.
~The whole assessment procedure will last approximately 40 minutes."
16297878|NCT04691102||Mild Cognitive Impairment group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.
~The whole assessment procedure will last approximately 40 minutes."
16297879|NCT04691102||Parkinson Disease group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.
~The whole assessment procedure will last approximately 40 minutes."
16297880|NCT04691102||Multiple Sclerosis group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.
~The whole assessment procedure will last approximately 40 minutes."
16297881|NCT04691102||Healthy subjects groups|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.
~The whole assessment procedure will last approximately 40 minutes."
16297882|NCT04691076|Experimental|Propofol/Esketamine sedation|Propofol target-controlled infusion is performed first,when the infusion concentration reaches 1.5μg/ml,esketamine 0.15mg/kg is injected intravenously;then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration, the corresponding increase of esketamine is 0.05mg/kg; the total dose of esketamine used in surgery shall not exceed 0.5mg/kg.
16297883|NCT04691076|Active Comparator|Propofol/Fentanyl sedation|Propofol target-controlled infusion is performed first.When the infusion concentration reaches 1.5μg/ml, fentanyl 0.6μg/kg is injected intravenously; then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration,the corresponding increase of fentanyl is 0.2ug/kg; the total dose of fentanyl used in surgery shall not exceed 1.2ug/kg.
16297884|NCT04691063|Experimental|Treatment group A|
16297885|NCT04691063|Placebo Comparator|Treatment group B|
16297886|NCT04691050|Other|OrthoMta (BioMTA)|OrthoMTA was applied in primary molars without successors
16297887|NCT04691037||CCTA|
16297888|NCT04691024|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
16297889|NCT04691024|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
16297890|NCT04691011|Other|Muscle|
16297891|NCT04691011|Other|Spinal cord|
16297892|NCT04691011|Other|Brain|
16297893|NCT04690998|Other|Without treatment for SMA|Patient that will not take treatment for SMA during the two years of the study.
16297894|NCT04690998|Other|Under treatment for SMA|Patient that will take treatment for SMA during the two years of the study
16297895|NCT04690985|Sham Comparator|Control group|The control group will be asked to continue their own daily routes. One research assistant, who will not be involved in other procedures of the study, will contact with the participants to talk about different issues except the SO related topic. The frequency of face-to-face meetings and telephone calls will be similar to the experimental group. The issues talked in the control group could be as follows but not limited: a) normal social communication topics such as greetings, recent living conditions, news in the past week; b) health consultations asked by the participants; c) avoid to mention dietary or exercise related information. An appointment of post-test will be made in the last time telephone call.
16297896|NCT04690985|Experimental|Experimental group|The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive 6 times face-to-face meetings (on week 1, 2, 3, 4, 8 and 12) and weekly telephone call. Each face-to-face meetings will last for around 1 hour, during which the reseacher will help to establish the participants' intention for dietary behavior change, then help transform the intention into detailed plan, and help monitor the execution of the plan continuously.
16297897|NCT04690972||Hepato-bilio-pancreatic surgery|Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care
16297898|NCT04690972||biopsy of the hepatic parenchyma|Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care
16297899|NCT04690972||Viral chronic infection|Patients with a viral chronic liver disease
16297900|NCT04690959|Experimental|Neural gliding mobilization|Initial participant positioning for gliding will be : lying in supine, shoulder at approximately 90 of abduction, wrist in neutral, elbow at 90 flexion and head/neck neutral. From this starting position, participants actively and simultaneously will perform extension of the elbow (to 45) and ipsilateral neck flexion (to approximately 45) and then returned to 90 of elbow flexion and 45 of contralateral neck flexion while maintaining the shoulder at 90 abduction. According to Silva et al., (2014) this combination of movements was the one that promoted the greatest excursion of the median nerve (10.2 mm) . For gliding, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series was performed.
16297901|NCT04690959|Experimental|Neural tensioning mobilization|Tensioning will be performed with the subject lying supine. The investigator will perform the upper limb neurodynamic test as reported by Butler (2000): shoulder depression; 110 of shoulder abduction; external shoulder rotation; wrist and fingers extension; forearm supination and then elbow extension. The final test position will be defined as either i) end of joint amplitude or ii) the joint amplitude that provokes pain, paresthesia or numbness. In this case, a decrease of 5 to 10 of range of motion (elbow extension) will be allowed for symptoms to disappear and from this end position the investigator will perform repetitive movements of approximately 10 of elbow flexion/extension while maintaining the test end position for all the other joints. For tensioning, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series will be performed. After each cycle of 10 repetitions, the position will be held for 10 seconds.
16297902|NCT04690959|Sham Comparator|Control|Participants in the sham group will receive a treatment consisting of maneuvers that mimic the neural mobilization treatment but not to stress the neural tissues in the upper extremity. The sham mobilization consists of passively positioning the participants in the following consecutive positions: (1) a neutral cervical spine (0° of lateral flexion), (2) 45°of shoulder abduction without scapula depression, and (3) 45° of shoulder external rotation combined with 45° of elbow flexion with forearm pronation. This will be immediately followed by 10 cycles of passive wrist flexion/extension at a rate of approximately 6 seconds per cycle (3 seconds into extension and 3 seconds into flexion) . Upon moving from wrist flexion to extension, an initial sense of resistance will be used as a sign to alternate directions. Following the 10th cycle, a static hold will be maintained while in wrist flexion for 10 seconds.
16297903|NCT04690946|Active Comparator|Cognitive Behavioral Therapy|14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
16297904|NCT04690946|Active Comparator|Emotion-Focused Therapy|14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
16297905|NCT04690933||Multicentric NAViRe cohort with biocollection|"The National Reference Center (CNR) for cytomegalovirus with the French Society for Medullary Transplantation and Cell Therapy (SFGM-TC) has set up a surveillance cohort of allografted patients (NAViRe cohort) receiving, as prevention or treatment, Anti-Cytomegalovirus (Anti-CMV) molecules, new or less recent, thus allowing the development of a new observatory evaluating in real life the potentials of these drugs in terms of efficacy, emergence of resistance, tolerance and morbidity and mortality associated with CMV infection.This work is useful to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients and allows the emergence of an real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients."
16297906|NCT04690920|No Intervention|Control|
16297907|NCT04690920|Experimental|Tocilizumab|
16297908|NCT04690920|Experimental|Remdesivir|
16297909|NCT04690920|Active Comparator|Standard Treatment|
16297910|NCT04690907|Experimental|Intervention group|Dietary intervention: Written material on healthy diet during pregnancy, 2 virtual dietary counseling sessions given by a dietician. Otherwise basic care and counseling at maternity care clinics.
16297911|NCT04690907|No Intervention|Control group|Written material on healthy diet during pregnancy, otherwise basic care and counseling at maternity care clinics.
16297912|NCT04690894|Active Comparator|Erector spinae group|the child received ultrasound-guided erector spinae muscle block in a dose of 0.4mg/kg of 0.25%bupivacaine between the 10th transverse process and erector spinae muscle
16297913|NCT04690894|Active Comparator|caudal group|child received ultrasound-guided caudal block in a dose of 2.5mg/kg of bupivacaine 0.25%
16297914|NCT04690894|No Intervention|control|child didn't received any regional block
16297915|NCT04690881|Experimental|Psychodrama group psychoteraphy|Psychodrama is not just a training but also a treatment technique where an individual is offered a potential cure, as well as improvement and awareness for his or her ongoing relationships within the group. In psychodrama, the participant is given an opportunity to re-experience of earlier incidents for a second time so that the person could be free from the impacts of that earlier experience. All of this happens simultaneously with joy, tears, laughter, and depth of feeling.Prenatal psychodrama is held by psychodrama psychotherapists in individual and group therapy sessions. In these sessions the pregnant mother encounters herself, her baby, her partner, her mother, her fear of childbirth and the moment of birth; she may act as protagonist in some scenes and in this way she closes any unfinished business from the past and rehearses the future in a safe therapeutic environment. In this study, 90-minute psychodrama practice was conducted in addition to pregnancy training for 6 weeks.
16297939|NCT04690673|Experimental|Study group|All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.
16298214|NCT04688632|Active Comparator|Group 1a|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin <Dose A>
16297916|NCT04690881|No Intervention|Childbirth-antenatal education|Childbirth is one of the most significant events in a parent's life and has the potential to be an exhilarating and fulfilling experience for some or a frightening anxiety provoking experience for others. Structured antenatal classes have developed worldwide as traditional methods of information sharing have declined and expectant parents look for strategies to prepare for childbirth. In this study, routine pregnancy training was conducted for 6 weeks.
16297917|NCT04690868|Experimental|ARM 1|Period 1 : Reference Drug(AD-2131) Period 2 : Test Drug(AD-213-A)
16297918|NCT04690868|Experimental|ARM 2|Period 1 : Test Drug(AD-213-A) Period 2 : Reference Drug(AD-2131)
16297919|NCT04690855|Experimental|Study Treatment Arm|"All patients will be treated with induction talazoparib of 1mg PO daily starting Day 1. Patients will then receive 8 Gy x 3 fractions to 2-4 metastatic lesions beginning Day 12,13, or 14 and given QOD. 840 mg of atezolizumab will be given intravenously (IV) on Day 15 of the 1st cycle and then on Day 1 and Day 15 of the remaining cycles. The sequence of administration is not specified on the days in which talazoparib and atezolizumab are given on the same day. Each cycle equals 28 days. Treatment will continue until progression or severe toxicity.
~A safety lead in of up to 6 patients will be performed. Immune-related and non-immune related adverse events will be tracked up to 12 weeks post initiation of atezolizumab, as the majority of treatment-related toxicities from talazoparib, radiation, and atezolizumab occur within this time period."
16297925|NCT04690803|Active Comparator|treatment with forced-air cooling|comparing treatment with and without forced-air cooling in a comparative lower extremity model
16297926|NCT04690803|No Intervention|treatment without forced-air cooling|comparing treatment without forced-air cooling in a comparative lower extremity model
16297927|NCT04690777|Experimental|VESTIBULAR EXERCISE|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:
~Head and eye movements while sitting.
~Head and body movements while sitting.
~Paused exercises.
~Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
16297928|NCT04690777|Active Comparator|MULTICOMPONENT EXERCISE|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
16297929|NCT04690751|Experimental|Types of Cenobamate|"Treatment A: Oral Dose of cenobamate administered as a single 200 mg tablet under fasted conditions
~Treatment B: Oral Dose of cenobamate administered as a single 200 mg/20 mL suspension under fasted conditions
~Treatment C: Oral Dose of cenobamate administered at a single 200 mg/20 mL suspension under fed conditions"
16297930|NCT04690738||Post Pancreas Transplant Patients|Patients that have received a pancreas transplant (Pancreas After Kidney or Simultaneous Pancreas Kidney) from 2012 through present will have a fecal elastase stool sample collected.
16297931|NCT04690725|Experimental|TQB3525 arm|3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
16297932|NCT04690712|No Intervention|Socio-Demographic Characteristics of Students|When the socio-demographic characteristics of the students are examined according to the pre-test findings; It was seen that 27% were in the first grade, 20.9% in the second grade, and 25.7% in the third grade. When the age groups were evaluated, it was determined that 47.8% were in the 7-8 age group, 51.5% were in the 9-10 age group and 50% of them were female students and 50% were male students. It was observed that 27.6% of the students had a bad income and 59.3% had a medium level of income. When the father's education status was questioned, it was determined that 17.6% of them did not finish primary school, 55.4% of them were primary school graduates, 2.6% of them were high school graduates. On the other hand, 55% of their mothers did not complete primary school, 43.5% were primary school graduates and 1.5% were secondary school graduates
16297933|NCT04690712|Experimental|Comparison of Students' Pretest and Posttest Development Screening Average|According to the results of height and weight screening at the pre-test stage; the average height of the students is 127.0 ± 9.11; It was determined that the average weight was 26.1 ± 6.19, the average height was 130.61 ± 8.83 and the average weight was 29.92 ± 6.39 in the final test stage. A significant difference was found between pre-test and post-test screening results
16297934|NCT04690712|Experimental|Comparison of Pre-Test and Post-Test Screening Results of Students|In the statistical evaluation, it was found that there was no significant difference between pre-test and post-test screening results
16297935|NCT04690699|Experimental|Arm 1: PVSRIPO and Anti-PD-1/L1 Therapy|Subjects will be treated with a combination of PVSRIPO and an FDA-approved anti-PD-1/L1 therapy, the choice of which will be determined based on the solid tumor cancer of interest and specified in the associated tumor specific appendix.
16297936|NCT04690686|Experimental|LW-02 device immunopheresis combined with atezolizumab|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus atezolizumab 1200 milligrams (mg) q3w until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first [N=8]
16297937|NCT04690686|Experimental|LW-02 device immunopheresis combined with weekly paclitaxel|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus paclitaxel 80 mg/m2 /week × 6 followed by 2 weeks rest until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
16297938|NCT04690686|Experimental|LW-02 device immunopheresis|LW-02 column immunopheresis treatments ~3x/week for 16 weeks alone until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
16298415|NCT04687072|Placebo Comparator|Placebo PH20 SC|Patients receiving placebo PH20 SC treatment
16297940|NCT04690647|Placebo Comparator|Opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia without preoperative regional anaesthesia and dexamethasone.
16297941|NCT04690647|Experimental|Regional anaesthesia, opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and without preoperative dexamethasone.
16297942|NCT04690647|Experimental|Regional anaesthesia, dexamethasone, opioid and non opioid postoperative analgesia|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and dexamethasone.
16297943|NCT04690634|Experimental|PCOS group|obese female patients with Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
16297944|NCT04690634|Active Comparator|control group|obese female patients without Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
16297945|NCT04690608|Experimental|resistant diabetic macular edema and central retinal vein occlusion|"Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included.
~The study will be conducted from January 2021 to June 2021.
~For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required.
~Cases with recent onset central retinal vein occlusion less than 2 months duration will be included"
16297947|NCT04690582|Active Comparator|Treatment As Usual|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a self-guided safety plan. As a recommended standard care practice with suicidal patients, the combination of CPT and safety plan represents treatment as usual. The safety plan will be assigned during the first therapy session.
16297948|NCT04690582|Experimental|Crisis Response Plan (CPT+CRP)|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a collaborative crisis response plan (CRP). The CRP includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be collaboratively created during the first therapy session.
16297949|NCT04690569||Infectious|Eligible pediatric and adult patients from ED\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.
16297950|NCT04690569||Healthy|For the purpose of establishing a normal reference range.
16297951|NCT04690556|Active Comparator|Lucentis (ranibizumab)|Intravitreal injection
16297952|NCT04690556|Experimental|LUBT010 (proposed ranibizumab biosimilar)|Intravitreal injection
16297953|NCT04690543|Active Comparator|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
16297954|NCT04690543|Experimental|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
16297955|NCT04690530||patients admitted in medical intensive care unit who require mechanical ventilation and sedation|The main goals of the study are to characterize cerebral hemodynamics and oxygenation as well as to study the effects of therapeutics on it in critically-ill patients. For this purpose, we plan to include all consecutive patients admitted in our medical intensive care unit who require mechanical ventilation and sedation and in whom the attending physician decides to perform one of the studied therapeutics (fluids, vasopressors or inotropes administration, blood transfusion, prone positioning, passive leg raising test, end-expiratory occlusion test) within the first 72h of ventilation onset. Cerebral hemodynamics (cerebral blood flow and cerebral autoregulation) as well as cerebral oxygenation will be non-invasively studied before and after therapeutics.
16297956|NCT04690517|Other|Tracheal ultrasound|The patients in cardiopulmonary arrest should be performed tracheal ultrasound when tube is passed through the trachea or esophagus.
16297957|NCT04690478|Experimental|Remote blood pressure management group|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
16297958|NCT04690478|Other|Non-remote blood pressure management group|Non-remote blood pressure management group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
16297959|NCT04690478|Other|Routine blood pressure management group|Routine blood pressure management group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
16297960|NCT04690465|Experimental|Resistance training|In the 16 week resistance training, there will be 3 sessions per week, the duration of each session will be 60 minutes, which include 10min of warm-up, 40min of main exercise, and 10min of cool-down. The intensity will be light to somewhat hard (Rating of Perceived Exertion (RPE) 11 to 13; using the Cantonese version of RPE). In resistance training, the weights (resistance) will be from participants' own bodies, dumbbells, and adjustable ankle weights.
16297961|NCT04690465|Active Comparator|Eight-form Yang-style Tai Chi program|In Tai Chi, the 16-week program will be divided into cognitive, associated, and automatic stages. The coach will apply a group teaching with individual instruction on specific movements based on participant's needs in skills learning and acquisition. The same training principles of individuality and progression as well as training log-book used in resistance training will also be applied to Tai Chi training program.
16297962|NCT04690465|No Intervention|Non-treatment Concurrent Control|Participants in this group will not participate in any specific intervention during the whole study (the 16-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, medicine used, illness, diet, sleep quality and other health and physical activity related information (e.g., attending healthy eating workshops).
16298047|NCT04689841|Placebo Comparator|Control Group|In the control group, a placebo intervention is administered, similar to an experimental intervention
16297963|NCT04690452|Experimental|Intervention condition|Intervention group that receive a standardized 8 weeks Compassion Cultivation Training from a faculty member certified CCT© instructor (https://www.compassioninstitute.com/about-us/teacher-directory/)
16297964|NCT04690452|Other|Waitlist control condition|"The participants assigned to the waitlist control will fill in the same questionnaires as the intervention group at the different time points (i.e., pre, post, 2-month and 6-month follow-ups).
~Two months after finishing the intervention, will become participants of a CCT© program themselves given by the same faculty member certified CCT© teacher as for the experimental group."
16297965|NCT04690439|Experimental|Treatment group|The treatment group receives 18 sessions of photobiomodulation therapy (2x/week for 9 weeks) in combination with 18 sessions of manual lymphatic drainage .
16297966|NCT04690439|Sham Comparator|Control group|The control group receives 18 sessions of the sham photobiomodulation therapy (2x/week for 9 weeks) in combination with 18 sessions manual lymphatic drainage.
16297967|NCT04690426|Placebo Comparator|Cohort 1, Low Dose, Placebo|Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
16297968|NCT04690426|Experimental|Cohort 1, Low Dose, PRV-101|Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
16297969|NCT04690426|Placebo Comparator|Cohort 2, High Dose, Placebo|High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
16297970|NCT04690426|Experimental|Cohort 2, High Dose, PRV-101|High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
16297971|NCT04690413|Experimental|Persons tested with investigational device|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
16297972|NCT04690400|Experimental|Active care group|Participants will practice stretching exercises twice a week, at a distance and under the supervision of a professional, for 12 weeks. In addition, the experimental group will receive the same written guide and video of the comparator group.
16297973|NCT04690400|Active Comparator|Self-care group|Participants will receive stretching advice by written guide and video with stretching exercises, to be performed individually, without distance supervision, for 12 weeks. Participants will be able to resolve questions about the protocol at any time, via telephone.
16297974|NCT04690387|Experimental|0.1 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen
16297975|NCT04690387|Experimental|0.33 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen
16297976|NCT04690387|Experimental|1.0 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen
16297977|NCT04690387|Experimental|0.1 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
16297978|NCT04690387|Experimental|0.33 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
16297979|NCT04690387|Experimental|1.0 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
16297980|NCT04690387|Experimental|0.1 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
16297981|NCT04690387|Experimental|0.33 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
16297982|NCT04690387|Experimental|1.0 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF
16297983|NCT04690374||Desmoplastic small round cell tumor (DSRCT)|Collect historical/longitudinal clinical, radiographic and molecular features of DSRCT patients as documented in medical records to improve knowledge about DSRCT
16297984|NCT04690348|Active Comparator|Resection without brachytherapy|Patients will undergo craniotomy.
16297985|NCT04690348|Experimental|Resection plus brachytherapy|Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
16297986|NCT04690335|Experimental|MV-012-968|Dose: 1 x10^6 Plaque Forming Unit (PFU), given intranasally, followed approximately 28 days later by inoculation with RSV-A (Memphis 37b).
16297987|NCT04690335|Placebo Comparator|Placebo|Sodium Chloride 0.9% w/v intravenous infusion B.P (Normal Saline) matched to reference article product, given intranasally.
16297988|NCT04690322|Active Comparator|Extended half-life factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.
~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
16297989|NCT04690322|Active Comparator|Non-Factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.
~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
16297990|NCT04690309|Active Comparator|Patients treated with human insulin preparations|Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper and with Neutral Protamine Hagedorn insulin (isofane insulin) administered subcutaneously before sleep.
16297991|NCT04690309|Active Comparator|Patients treated with insulin analogues|Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper and with glargine administered subcutaneously before sleep.
16297992|NCT04690296|Experimental|US group|a group underwent real time USG-SCV catheterization
16297993|NCT04690296|Experimental|LM group|a group in whom anatomical LM method was used
16297994|NCT04690283|Placebo Comparator|Placebo-control group|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and placebo treatment twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
16297995|NCT04690283|Experimental|Treatment group I|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Huangqi Guizhi Wuwu granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
16298416|NCT04687059|Experimental|PQ Grass Standard Dosing Regimen|Cumulative dose 27600 SU
16297996|NCT04690283|Experimental|Treatment group II|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Danggui Sini granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
16297997|NCT04690270|Experimental|Sumatriptan 100 mg|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
16297998|NCT04690270|Placebo Comparator|Placebo|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
16297999|NCT04690257|Experimental|TICK-B group as Intervention group|"Experimental: TICK-B group
~-Pediatric patients received TICK-B as a distraction in the TICK-B group"
16298000|NCT04690257|No Intervention|Standard care provided group as control group|-Pediatric patients received standard care (routine care) in the control group.
16298001|NCT04690244|Experimental|Tai Chi Chuan group|"Fifteen healthy elderly subjects participated in 10 weeks of Tai Chi Chuan practice. Inclusion criteria were:
~aged 60 years and older;
~sedentary behavior for at least 6 months;
~no previous experience of Tai Chi Chuan practice;
~good physical health determined by Physical Activity Readiness Questionnaire as - confirmed by medical history;
~no cognitive impairments determined by baseline Mini-Mental State Examination score of ≥ 45.
~All participants were asked to not perform any sports activities while the research was ongoing."
16298002|NCT04690244|No Intervention|Control group|In the control group, fifteen subjects also had to meet the same criteria and did not perform any exercises or make changes in their daily living life.
16298003|NCT04690231|Experimental|Apatinib+IE|
16298004|NCT04690231|Active Comparator|IE|
16298005|NCT04690218||Mastalgia|"Mastalgia group will consist of women with confirmed mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
16298006|NCT04690218||Controls|"Controls group will consist of women attending to general surgery clinic for reasons other than mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
16298007|NCT04690205|Experimental|End of Life (EOL) Care at at Home|End of Life (EOL) Care at at Home intervention entails the following: patient-reported symptoms and home monitored vital signs and body weight with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
16298008|NCT04690192|Experimental|CNCT19 following ASCT|Participants will receive high-dose chemotherapy followed by stem-cell reinfusion, and a fixed dose of CNCT19 (2×10^6/kg) will be infused in a single-dose on day +2, +3 or +4.
16298009|NCT04690166||Cancer Patients|"In outpatients clinic, the first group consists of 60 head and neck cancer patients who were treated by ours. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
16298010|NCT04690166||Healty Control|"In outpatients clinic, the control group consists of 60 patients who have not speech and hear impairments. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
16298011|NCT04690140|Active Comparator|modified coronally advanced tunnel technique|Initial sulcular incisions and flap separation were then carried out with tunnel knives. Dissection was extended at least 8 mm apically to the mucogingival junction and the muscle attachments were removed with curettes so that the flap could be moved in a coronal direction without tension. Interdental papillae were undermined to prepare the bed for connective tissue graft placement. Connective tissue graft was then inserted under the tunnel at the sites of recession and retracted laterally by sutures towards each end of the tunnel. After connective tissue graft positioning, the flap was gently stretched coronally to obtain passive flap closure. The exposed connective tissue was covered by connecting the adjacent flap margins with additional sutures.
16298012|NCT04690140|Active Comparator|epithelialized free gingival graft|A partial-thickness flap was elevated (blade #15c) with horizontal incisions at the cemento-enamel junction level of the adjacent teeth. Then, two vertical incisions extending to the apical were made from two ends of the horizontal incision. The epithelium in the framed region was removed with a scalpel and the underlying connective tissue was exposed. To achieve the best vascularization from the recipient site, bed preparation was completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region.
16298013|NCT04690127|Experimental|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). Except for one session that will be applied every two weeks, all other trainings will be given on the basis of telerehabilitation via distance education tools.
16298014|NCT04690127|No Intervention|Control Group|Volunteers in this group will not participate in any training.
16298015|NCT04690088||Manual infusion (control) group|
16298016|NCT04690088||TCI (case) group|
16298017|NCT04690075|Experimental|Intervention|To receive routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
16298018|NCT04690075|Placebo Comparator|Control|To receive routine nutrition management for 12 weeks.
16298019|NCT04690062|Experimental|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
16298020|NCT04690049|Experimental|Neuromuscular resistance exercise group|Subjects will develop an innovator program consisting in the performance of exercises of increasing difficulty, with movements based on functional tests to analyze the subjects' neuromuscular capacities. Participants will attend to 80 individual, face-to-face physiotherapy sessions, including both supervised and semi-supervised monitoring. From the total, a minimum of 15 sessions will be supervised, including 6 sessions to teach and monitor the exercises, and 9 sessions to perform the tests in order to quantify the load; 37 sessions will be semi-supervised, where subjects will perform the exercises independently, but with the presence of an instructor; additionally, the remaining 28 sessions will consist in non-supervised aerobic work at a 70-80% from maximum heart rate, obtained according to the methodology of Tanaka et al.
16298021|NCT04690049|Active Comparator|Control exercise group|This program will be based on a home exercise protocol considering painful sensation and self-perceived stability as progression criteria: regarding pain management, exercises will be planned in a way that increased pain after their performance reverts to before-exercise levels prior to the next session; regarding self-perceived stability, participants will be asked to maintain a constant sensation of joint stability and control during the execution of the exercises. Participants will perform shoulder rotations (external and internal) and abduction up to 30º by using elastic bands. The resistance of the band will be adjusted by the physiotherapist so that participants perceive the exercises as demanding enough but not too unpleasant, being able to complete the 10 repetitions before taking the rest. Likewise, exercises will progress until a maximum of 90º of shoulder abduction.
16298022|NCT04690036|Experimental|one group|All patients encountered EBV reactivation after allo-HCT could be enrolled in this study, there was only one group of treatment.
16298023|NCT04690023|Active Comparator|PENG block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block. Patients in PENG group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
16298024|NCT04690023|Active Comparator|SFICB block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block. Patients in SFICB group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
16298025|NCT04690010|Active Comparator|Ambulatory tubeless PCNL|Patients will be discharged home on the same day as surgery. No nephrostomy tube will be placed (tubeless).
16298026|NCT04690010|Active Comparator|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days with a nephrostomy tube placed at the time of surgery that will then be removed prior to discharge.
16298027|NCT04689997|Experimental|computerized Substance Brief Intervention cSBI|Enhanced care PCPs will address the serious morbidity of teen substance use during routine check-up visits using cSBI and follow up care using a new Module of CHADIS that facilitates guideline-based care. The CHADIS c-SBI Module will include pre-visit screening tools and embedded education that cover substance use and strengths and goals. It will also include reminders to the patient about their goals and commitments for change and teleprompted interview hints for the PCP. These hints will be aimed at enhancing a patient focused discussion of individual strengths and barriers related to the teens' goals in a motivational interviewing style.
16298028|NCT04689997|No Intervention|Standard care|Standard care PCPs will screen using a standard SU tool and carry out their usual health supervision visits without additional decision support.
16298029|NCT04689984|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and astaxanthin 6 mg tablet once daily (experimental group).
16298030|NCT04689984|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
16298031|NCT04689971|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily (experimental group).
16298032|NCT04689971|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
16298033|NCT04689958|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin D 5000 IU once daily (experimental group).
16298034|NCT04689958|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline
16298038|NCT04689932|Experimental|Pre- Dialyzer Infusion and Post- Dialyzer Infusion|On study day 1, day 3 and day 5, patients will receive 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the pre-dialyzer blood line. On study day 2, day 4 and day 6, patients will receive the 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the post dialysis blood line.
16298039|NCT04689919|Active Comparator|Reference Group [Xarelto 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
16298040|NCT04689919|Experimental|Test Group [Xaroban 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
16298041|NCT04689893|Experimental|68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT scan|Patients of Tumor-induced osteomalacia PET/CT imaging: The patients were subcutaneously injected with 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and underwent PET/CT scan 20~40min after the injection in two consecutive days.
16298042|NCT04689880||XLIF Decade Plate|
16298043|NCT04689867|Experimental|CBSPp|Cognitive Behavioral Suicide Prevention for psychosis is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions.
16298044|NCT04689854||Cohere Cervical|
16298045|NCT04689854||Modulus Cervical|
16298046|NCT04689841|Experimental|Vojta Therapy|In Vojta therapy, the therapist selectively presses certain areas of the body, with the patient lying prone, - supine or - lateral. These types of stimuli, in humans of any age, provoke automatically and without their own initiative, that is, without the active voluntary collaboration of the person
16298050|NCT04689815|Experimental|Oral arsenic trioxide-Azacitidine|12 monthly cycles of oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle).
16298051|NCT04689789||Patients with RAP|Patients with previous diagnosis of retinal angiomatous proliferation
16298052|NCT04689789||Patients with reticular pseudodrusen|Patients with previous diagnosis of reticular pseudodrusen
16298053|NCT04689789||Control group|Healthy eyes without actual and previous ocular diseases
16298054|NCT04689776|Experimental|High Frequency Dual-Task Training (HF)|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-120 minutes of training.
16298055|NCT04689776|Experimental|Low Frequency Dual-Task Training (LF)|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-120 minutes of training.
16298056|NCT04689763|Experimental|Lifestyle Redesign Training|The participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training.
16298057|NCT04689750||Allogeneic HSCT recipients and donors|
16298058|NCT04689737|Experimental|Experimental group|Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days
16298059|NCT04689698|Experimental|experimental group|
16298060|NCT04689659|Experimental|chimeric antigen receptor T cell treatment|
16298061|NCT04689646|Experimental|Mind-Body Intervention 1|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 1.
16298062|NCT04689646|Active Comparator|Mind-Body Intervention 2|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 2.
16298063|NCT04689646|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
16298064|NCT04689633|Active Comparator|Quadratus lumborum block|received bilateral ultrasound-guided Quadratus lumborum block using 20 ml bupivacaine 0.25% on each side
16298065|NCT04689633|Active Comparator|Erector spinae block|received bilateral ultrasound-guided erector spinae block using 20 ml bupivacaine 0.25% on each side
16298066|NCT04689633|No Intervention|Control|didn't received any block
16298067|NCT04689620|Experimental|HELIUM NEON LASER plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
16298068|NCT04689620|Experimental|GALLIUM ARSENIDE plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
16298069|NCT04689620|Active Comparator|regular ulcer care|dressing for the ulcer
16298070|NCT04689607|Experimental|Mulligan Traction Straight Leg Raise (TSLR)|This technique involves sustained traction applied to the limb. Patient actively does the SLR and both the therapist and the patient note the range. Therapist now grasp patient lower leg proximal to the ankle joint and raise it off the bed to a position just short of the painful range. Therapist flexes his knees and holds the clasped leg to his (therapist's) chest. When the therapist extends his knees this will effectively apply a longitudinal traction to the leg provided the bed is low enough and the therapist is tall enough. Sustain this traction and undertake a straight leg raise as far as it will go provided there is no pain.When pain free SLR with traction is given for three times.
16298071|NCT04689607|Active Comparator|Post Isometric Relaxation technique (PIR):|The patient is placed in the supine position with the non-affected leg lying flat on the table. The knee of the affected leg is gently placed in extension, and the affected hip is then flexed. The calf of the patient is then placed on the shoulder of the practitioner The practitioner stands on the side of the affected leg. The hands of the practitioner are then placed over the upper leg, just proximal to the knee. The hip of the affected leg is then passively flexed until resistance is felt. The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance. The practitioner resists hip extension to create an isometric contraction and then, after appropriate time and breathing instructions. The patient is instructed to relax and the practitioner gently flexes the hip until the next barrier is reached. After a period of relaxation, the technique will be repeated three to four times.
16298072|NCT04689594|Experimental|CLS2702C/CLS2702D|
16298073|NCT04689581|Experimental|Bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
16298074|NCT04689581|Experimental|Modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
16298075|NCT04689568|Active Comparator|Moodkit|MoodKit is a cognitive behavioral therapy (CBT)-based app designed to provide tools for managing depressed mood, anxiety and stress.
16298076|NCT04689568|Active Comparator|Moodgym|Moodgym is an online cognitive behavioral therapy (CBT)-based program designed to prevent or reduce symptoms of depression and anxiety by helping users identify and overcome problem emotions and to develop good coping skills.
16298077|NCT04689568|Active Comparator|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey. The Toolkit offers help to people who are experiencing problems with a mood disorder as well as with stress and anxiety.
16298078|NCT04689555|Experimental|Novel method without manual compression|
16298079|NCT04689555|Active Comparator|Standard method with manual compression|
16298080|NCT04689542|Experimental|Surgical Facemask|The surgical facemask will be worn during the sit-to-stand test
16298081|NCT04689542|No Intervention|Control|No facemask will be worn during the sit-to-stand test
16298215|NCT04688632|Active Comparator|Group 1b|Day 1: Single dose of Moxifloxacin <Dose A>; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin Placebo
16298084|NCT04689516|Experimental|Control Group|will receive a hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively and will stop after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
16298085|NCT04689516|Experimental|The TFC Group|will receive hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively . The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
16298088|NCT04689477||COVID-19|Hospitalized patients diagnosed with COVID-19, presenting with arterial hypoxemia.
16298089|NCT04689477||Control|Healthy subjects
16298090|NCT04689477||Non-COVID critically ill patients|Non-COVID critically ill patients admitted to the ICU.
16298091|NCT04689464||mild covid|
16298092|NCT04689464||moderate covid|
16298093|NCT04689464||severe covid|
16298094|NCT04689451||Perclose ProGlide|Perclose ProGlide group: use Perclose ProGlide to suture the artery
16298095|NCT04689451||Surgical Arterial Repair|Surgical Arterial Repair group : suture the artery by surgery
16298096|NCT04689438||Healthy control groups|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
16298097|NCT04689438||Gingivitis groups|Consisted of individuals with a BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.
16298098|NCT04689438||Stage III -Grade C periodontitis groups|Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4. Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.
16298099|NCT04689425|Experimental|MNC+PRP|The combination of PRP and MNC
16298100|NCT04689425|Active Comparator|PRP|PRP alone.
16298101|NCT04689412||Cases|Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection
16298102|NCT04689412||Controls|Children spontaneously treated with nasal lavage at the beginning of each upper airways infection
16298103|NCT04689386|Experimental|"Group I Stimulation of reflex rolling from the Vojta method"|
16298104|NCT04689386|Experimental|Group II Expiratory flow increase technique|
16298105|NCT04689386|No Intervention|Control Group|Routine intervention in the NICU with mechanical ventilation.
16298106|NCT04689347|Experimental|FLIRT-bevacizumab|"Bevacizumab intravenous infusion (IV), irinotecan IV, leucovorin (LV) IV, 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU), given every 14 days, in combination with oral (PO) temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days.
~The treatment will consist of an induction period of four 28-day cycles of FLIRT- bevacizumab followed by maintenance regimen of 5-FU/LV-bevacizumab administered every 14 days in combination with PO temozolomide according to dose level over days 1-5 every 28 days in patients without progressive disease at the end of the induction period."
16298107|NCT04689321||Phase 1|Patients recruited for phase 1 will undergo a semi-structured interview to identify issues that may be relevant to include in the revised EORTC QLQ-BN20 questionnaire.
16298108|NCT04689321||Phase 3|Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
16298109|NCT04689308|Experimental|Part A: Dose Escalation and Determination of RP2D|Part A: Dose Escalation and determination of RP2D, multiple dose levels of MH048 to be evaluated
16298110|NCT04689308|Experimental|Part B: Dose Expansion in Selected Relapsed/Refractory B-cell Malignancies|Part B: Selected relapsed/refractory B-NHL subjects with at least 1 prior systemic OR standard-of-care therapy.
16298111|NCT04689295|Other|experiment group|Three dimensional scoliosis therapy method (Schroth) will be applied to the participants for 6 weeks. It consist of 15 different exercises combined with rotational breathing exercise.
16298112|NCT04689295|Other|control group|Traditional scoliosis exercises will be applied to the participants for 6 weeks. It consist of 6 different exercises
16298113|NCT04689282|Experimental|Intranasal M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.
~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
16298114|NCT04689269|Active Comparator|McGrath-King Vision|The participants will attempt double-lumen tube intubation using the McGrath (X-blade) laryngoscope then they will use the King Vision (channelled blade size 3) in the same order.
16298115|NCT04689269|Active Comparator|King Vision-McGrath|The participants will attempt double-lumen tube intubation using the King Vision (channelled blade size 3) then they will use the McGrath (X-blade) laryngoscope in the same order.
16298116|NCT04689256|Experimental|MR-010 walking therapy|Subjects will use the MR-010 three times a week for 30 minutes per session for 90 days. Subjects will undergo a 10-meter walk test bi-weekly and at 45 and 90 days.
16298117|NCT04689256|No Intervention|Standard of Care|Subjects will undergo a 10-meter walk test bi-weekly for 90 days and at 45 and 90 days
16298118|NCT04689243|Experimental|ALA-PDT|
16298119|NCT04689243|Other|red light|
16298120|NCT04689230|Active Comparator|upper eyelid blepharoplasty|"traditional upper eyelid blepharoplasty : upper eyelid entire length incision followed by proper dissection medially to medial pad fat.
~medial pad fat identification and excision. closure of the wound with subcuticular 6/0 vicryl suture"
16298417|NCT04687059|Experimental|PQ Grass Alternative Dosing Regimen|Cumulative dose 27600 SU
16298121|NCT04689230|Experimental|small incision technique|"medial upper eyelid 4 mm length incision followed by proper dissection medially to medial pad fat.
~medial pad fat identification and excision. closure of the wound with interrupted 6/0 vicryl sutures"
16298122|NCT04689217|Experimental|Group F|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml fentanyl (25 μg)
16298123|NCT04689217|Experimental|Group N|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.8 mg nalbuphine hydrochloride
16298124|NCT04689217|Placebo Comparator|Group C|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml normal saline
16298125|NCT04689204|Experimental|Administration of CTA30X|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16298126|NCT04689191|Experimental|Experimental Vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
16298127|NCT04689191|Active Comparator|Active Comparator Vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
16298128|NCT04689178|Experimental|Invitation letter + GP reminder (Arm 1)|
16298129|NCT04689178|Active Comparator|Invitation letter (Arm 2)|
16298130|NCT04689178|No Intervention|Usual care (Arm 3)|
16298131|NCT04689165|Experimental|Experimental Vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
16298132|NCT04689165|Active Comparator|Active Comparator Vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
16298133|NCT04689152|No Intervention|Control group|Best Supportive care
16298134|NCT04689152|Experimental|Injection group: Cellgram-LC|Within 1 month after extracting bone marrow, directly inject 7X10^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
16298135|NCT04689139|Experimental|Thoracic aorta surgery patients|Blood samples on proadrenomedullin, presepsin, NT-proBNP, Troponin I, procalcitonin are acquired
16298136|NCT04689126|Experimental|intervention|diagnosis and treatment plan before and after cone beam computed tomography scan
16298137|NCT04689113|Experimental|Intervention Group|ıntervention group After determining the women according to the research criteria, they were randomized into intervention and control groups.Firstly, Pre-tests were applied to the women in the experimental group. The Incontinence Health Belief Development Program was applied to the women in the experimental group as 5 sessions.This program includes the following topics; urinary system anatomy and physiology, urinary incontinence and risk factors, definition of kegel exercise and its place in urinary incontinence treatment, kegel exercise applied expression, health motivation. A WhatsApp group was established to remind women in the intervention group about the kegel exercise 3 times a day for 3 months to increase their self-efficacy. In addition, a facebook group was opened and posts about urinary incontinence and kegel exercises were made. Posttests were made 3 months after the training ended
16298138|NCT04689113|No Intervention|Control Group|Firstly, Pre-tests were applied to the women in the control group. No intervention was applied to this group.Posttests were made 3 months after pre-test.
16298139|NCT04689100|Experimental|Dose Escalation Cohort|"Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
~Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design.
~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
16298140|NCT04689100|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
16298141|NCT04689087|Experimental|Second line conventional treatment|
16298142|NCT04689074||ADPKD|Patients with ADPKD
16298143|NCT04689074||advanced CKD|Patients with advanced CKD
16298144|NCT04689074||DKD|Patients with DKD
16298145|NCT04689074||IgAN|Patients with IgAN
16298146|NCT04689074||Healthy volunteers|Healthy volunteers
16298147|NCT04689061||Biocomposite FastThread Interference Screw|The absorbable Biocomposite Interference Screws combine the inherent degradation characteristics of a biocompatible polymer with the bioactivity of a ceramic. They are made of a combination of 70% poly (L-lactide-co-D, L-lactide) (PLDLA) and 30% biphasic calcium phosphate (BCP). The material has withstood the test of time with over a decade of clinical use and millions of implantations. It has been shown that the Biocomposite Interference Screw integrates well into the surrounding bone, produces little to no inflammatory response, and partially degrades 2 years after implantation
16298148|NCT04689048|Other|PET/CT, MRI|In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted 18F-fluciclovine is 5 mL. After administration, flush with normal saline to ensure full delivery of the dose.
16298149|NCT04689035|Experimental|Cohort 1|AVLX-144_dose1
16298150|NCT04689035|Experimental|Cohort 2|AVLX-144_dose2
16298151|NCT04689035|Experimental|Cohort 3|AVLX-144_dose3
16298152|NCT04689035|Experimental|Cohort 4|AVLX-144_dose4
16298153|NCT04689035|Experimental|Cohort 5|AVLX-144_dose5
16298154|NCT04689035|Experimental|Cohort 6|AVLX-144_elderly
16298155|NCT04689022|Other|Group І received general anesthesia (n=53)|"The sedation with constant rate infusion of 1% propofol, 1-4mg/kg/h, guided by Bispectral analysis (60-70 - for regional anesthesia and 40-60 - for the general one). 0.005% fentanyl analgesia was injected, 3-10 mkg/kg or 0.05-0.2 mkg/kg/min during induction; and 2-10 mkg/kg/h for maintaining analgesia, by periodic bolus injection 25-100 mkg or by permanent infusion.
~The postoperative pain management of the I group patients was provided according to the local clinical protocol: paracetamol+/-non-steroid anti-inflammatory drugs +/-opioids.
~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
16298181|NCT04688853|Experimental|Single Arm, Open label|"This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.
~For the Dose escalation segment, 3-9 patients per dose cohort will receive:
~Dose level 1: Low
~Dose level 2: Medium
~Dose level 3: High
~For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose"
16298156|NCT04689022|Other|Group II received regional anesthesia: peripheral block was performed (n=73)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.
~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.
~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
16298157|NCT04689022|Other|Group III received regional anesthesia with sedation (n=92)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.
~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.
~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
16298158|NCT04689009|Active Comparator|SOC Group|SOC Group (or control group) will follow the standard therapy with visits twice a week. More specifically, the treatment consists of: dressing change, cleansing and eventual debridement of the lesion, the topic treatment and compression bandage.
16298159|NCT04689009|Experimental|EmoLED Group|EmoLED Group will be visited once a week. Therapy in this case includes, in addition to the standard therapy, a treatment with EmoLED device; it consists in irradiating each 5 cm diameter area of the lesion for 60 seconds, with the blue light emitted by the device. For lesions larger than 5 cm, several applications will be applied on adjacent areas, until the whole lesion is covered.
16298160|NCT04688996||Malagasy Participants|Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
16298161|NCT04688996||USN Health Research Center|USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
16298162|NCT04688983|Active Comparator|Arm 1|Ponatinib plus standard induction and consolidation
16298163|NCT04688983|Active Comparator|Arm 2|Imatinib plus standard induction and consolidation (comparator arm)
16298164|NCT04688983|Experimental|Arm 3|Ponatinib plus Blinatumomab
16298165|NCT04688970||Acute stroke with affection of the upper extremity|"Subject is 18 years or above.
~Subject has an acute stroke affecting one UE (FMA less than 50).
~Subject or caregiver understands the study and its procedures and gives informed consent.
~If the subject is not able to give informed consent:
~The assumed will of the patient is to be determined by the patient's provision (if existing), the health care proxy (if existing) and/or the moral concepts expressed by the patient to close relatives.
~The legal representative gives informed consent because participation is the assumed will of the patient as assessed by the aforementioned points."
16298166|NCT04688957|Active Comparator|osteotome sinus lifting|
16298167|NCT04688957|Experimental|oseodensification sinus lifting|
16298168|NCT04688944||patients|patients with lumbar spinal stenosis;age>18 years old; without other spinal disease.
16298169|NCT04688944||healthy people|healthy people without lumbar diseases
16298170|NCT04688931|Experimental|UGN-102 ± TURBT|6 once-weekly intravesical instillations of 75 mg UGN-102 starting at Day 1 + TURBT for patients who have a NCR at the 3-month disease assessment (7 weeks ± 1 week after the last weekly instillation of UGN-102).
16298171|NCT04688931|Active Comparator|TURBT Alone|TURBT on Day 1 + repeat TURBT for patients who have a NCR at the 3-month disease assessment (12 weeks ± 1 week after the initial TURBT).
16298172|NCT04688918|Active Comparator|Group A (Retrolamianar block(RLB))|Ultrasound-guided RLB with injection of 0.4ml/kglocal anesthestic (bupivacaine) 0.25%will be performed under strict aseptic precautions with ultrasound guidance with patient in the prone position.
16298173|NCT04688918|Active Comparator|Paravertebral group|Ultrasound-guided paravertebral injection of 0.4ml/kg saline 0.9% will be performed under strict aseptic precautions under ultrasound guidance with patient in the prone position.
16298174|NCT04688905||Dyspnea explained by heart failure with preserved ejection fraction|All patients fulfilling invasive criteria for heart failure with preserved ejection fraction
16298175|NCT04688905||Dyspnea not explained by heart failure with preserved ejection fraction|All patients not fulfilling invasive criteria for heart failure with preserved ejection fraction
16298176|NCT04688892|Active Comparator|Intervention Group|The type of cupping therapy will be dry-cupping with moving-cupping (dynamic cupping therapy). The participants will remain in the supine position on a massage table (Posturarte® Olympic), without inclination. Cupping therapy will be performed with a plastic suction cup (5.08 cm in diameter) (K.S. Choi Corp®) and with a pistol for dosing pumps (K.S. Choi Corp®). Prior to the cupping therapy, a small amount of massage cream (ATL®) will be applied throughout the median nerve pathway in order to facilitate the sliding of the suction cup. The cupping therapy will performed with the suction cup sliding with a slow rhythm, insufflation of the suction cup with two pumps for 5 minutes along the median nerve path.
16298177|NCT04688892|No Intervention|Control Group|The participants will remain at rest in a supine position on a massage table (Posturarte® Olympic) without inclination for 5 minutes.
16298178|NCT04688879||According to the degree of occlusion, 13 patients were divided into complete and incomplete groups.|Seven patients were complete occlusion and 6 patients were incomplete occlusion and all underwent thrombolysis with intra-arterial urokinase and the outcome was analysed..
16298179|NCT04688866||Pregnant women with cervical insufficiency (Cases)|Pregnant women with a shortened (<25 mm) or dilated cervix in the second trimester (or late first trimester)
16298180|NCT04688866||Pregnant women without cervical insufficiency (Controls)|Pregnant women with a normal-length (>= 25 mm) and closed cervix in the second trimester (or late first trimester)
16298213|NCT04688645|Active Comparator|Normal saline|0.9% sodium chloride solution.
16298182|NCT04688840||study results and satisfaction with telemedicine|the investigators designed a group on WhatsApp for all patients included in the study. The questionnaires were sent on the group to be filled by the patients in addition to a request for routine x ray follow up. Also, the investigators used the group to send any announcement, schedule of routine visits and some instructions about how to answer the questionnaires. To keep the privacy of patients' informations, every patient was asked to resend the file and x- ray pictures to the surgeon private account. the investigators collected data received by all patients and reviewed all x-rays. If there was any serious complain or major radiological finding the investigators asked the patient for immediate clinical visit.
16298183|NCT04688840||study results and satisfaction with routine follow up|the investigators asked the patients to come for routine follow up visit (RV) and reevaluate them clinically and radiologically. the investigators asked patients to calculate total time needed for completion of the questionnaires, time needed for x-ray and the investigators added time needed for reviewing these files. The same was done at the RV including time of transportation
16298184|NCT04688827|Experimental|training group 1: low-intensity resistance training|
16298185|NCT04688827|Experimental|training group 2: moderate-intensity resistance training|
16298186|NCT04688814|Active Comparator|Morphine Group|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine. Intravenous morphine in a dose of 0.05 mg/kg will be given as a rescue analgesic when the VAS ≥4 postoperatively for 24 hours
16298187|NCT04688814|Experimental|SEQ group|Patients will receive ultrasound guided SEQ block preoperatively before the induction of general anaesthesia. Twenty five ml of 0.25 % bupivacaine will be given in the QL plane and 25 ml of the same concentration will be given in the erector spine plane
16298188|NCT04688801|Active Comparator|Chemotherapy± Radiotherapy Group|Chemotherapy± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
16298189|NCT04688801|Experimental|Chemotherapy + Immunotherapy ± Radiotherapy Group|Chemotherapy + Immunotherapy ± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
16298190|NCT04688788|Experimental|Rituximab|Intravenous biosimilar rituximab (Ruxience®) 1000 mg given every 6th month (first 2 infusions 1000mg/1000 mg given 2 weeks apart).
16298191|NCT04688788|Active Comparator|Ocrelizumab|Intravenous ocrelizumab (Ocrevus®) 600 mg every 6th month (first 2 infusions 300 mg/300 mg given 2 weeks apart).
16298194|NCT04688762||Group without the e-consult tool|standard consultation
16298195|NCT04688762||Group with the e-consult tool|The e-consult tool is a digital application developed and designed by the Center François Baclesse, This tool is a consultation support to explain the surgical management of the patient.
16298196|NCT04688749||Healthy Control|Individuals without skin damage (melanoma, BCC, SCC, etc)
16298197|NCT04688749||Skin lesion|Individuals diagnosed with confirmed skin damage by Dermatologists
16298198|NCT04688736|Experimental|Placebo|Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.
16298199|NCT04688736|Active Comparator|Chlorpheniramine|Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.
16298200|NCT04688723|Active Comparator|Dabigatran/Clopidogrel|Patiënt receive standard care, with dabigatran + clopidogrel 75mg once daily up to 12 months.
16298201|NCT04688723|Experimental|Dabigatran/Ticagrelor|Patiënt receive standard care, with dabigatran + ticagrelor 90mg twice daily up to 12 months.
16298202|NCT04688710|Active Comparator|Self-Hypnosis (HYP)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Self-Hypnosis. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
16298203|NCT04688710|Active Comparator|Mindfulness Meditation (MM)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Mindfulness Meditation. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
16298204|NCT04688710|No Intervention|Treatment as Usual (TAU)|Participants will not receive treatment from the study during the treatment phase. Participants will continue to receive their normal care outside of the study for MS and fatigue. Participants will have the option to access either the Self-Hypnosis or Mindfulness Meditation treatment after all study assessments have been completed.
16298205|NCT04688697|Experimental|Prepectoral Group|Prepectoral implant-based reconstruction applied for patients in this group
16298206|NCT04688697|Active Comparator|Subpectoral Group|Subpectoral implant-based reconstruction applied for patients in this group
16298207|NCT04688684|Experimental|Family-based intervention|These participants will undergo the health coach based intervention with fitness tracker and diet changes, which will be delivered to all family members who meet the inclusion criteria and are enrolled in the study.
16298208|NCT04688684|Active Comparator|Usual care|These will be age and gender matched patients who present to Kanad Hospital's outpatient clinic and undergo the usual care of dietician appointments and support.
16298209|NCT04688671|Experimental|ETX-018810|
16298210|NCT04688671|Placebo Comparator|Placebo|
16298211|NCT04688658|Experimental|Duvelisib plus Nivolumab|"Phase 1: Duvelisib will be taken orally in doses from 15mg once a day, 25mg once a day or 25mg twice a day, 12 hours a part, to determine the recommended dose for the Phase II study when combined with nivolumab.
~Nivolumab, 240mg, IV, every 2 weeks for the first four cycles; thereafter it may be switched to 480mg, IV, once every 4 weeks if deemed appropriate by the study doctor.
~Phase II: The Recommended Phase II dosage of duvelisib administered will not be determined until Phase I is completed.
~Nivolumab, 480mg, IV, every 4 weeks, for up to 1 year."
16298212|NCT04688645|Experimental|Balanced crystalloid solution|Balanced crystalloid solution - Plasmalyte.
16298216|NCT04688632|Experimental|Group 2 - Treatment|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 7: Single daily dose of Ampreloxetine <Dose A>; Day 8 - Day 14: Single daily dose of Ampreloxetine <Dose B>; Day 15: Single dose of Moxifloxacin Placebo; Day 15: Single dose of Ampreloxetine Placebo;
16298217|NCT04688619|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by receiving activities to do with their children, given to the adolescents during the scool program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
16298218|NCT04688619|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
16298219|NCT04688606||Two groups|"Initial diagnosis of suspected hepatocellular carcinoma;
~patients undergoing liver transplantation, radical resection or ablation of liver cancer"
16298220|NCT04688580|Experimental|XW10172|
16298221|NCT04688567|Experimental|Patient-driven iCBT|Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment program
16298222|NCT04688567|Active Comparator|Standardized iCBT (TAU)|Patients who are randomized to the control condition undergo the usual iCBT program available for anxiety disorders for a standardized time period of 8 weeks
16298223|NCT04688554||Refractory Obsessive Compulsive Disorder|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical capsulotomy
16298224|NCT04688554||Refractory Pain|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
16298225|NCT04688554||Refractory Tremor|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical thalamotomy
16298226|NCT04688554||Refractory Depression|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
16298227|NCT04688541|Active Comparator|First standard Foley catheter than Optitip catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:
~Study period 1 = Standard Foley catheter Study period 2 = Optitip catheter"
16298228|NCT04688541|Active Comparator|First Optitip catheter than standard Foley catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:
~Study period 1 = Optitip catheter Study period 2 = Standard Foley catheter"
16298229|NCT04688528|Experimental|Arm A: Unilateral RT|If SPECT/CT shows ipsilateral drainage and the tumor does not cross the midline, the subject will automatically be assigned to Arm A, and will receive ipsilateral Radiotherapy with reduced prophylactic dose outside of the macroscopically involved nodes. The contralateral side of the neck will be spared according to the absence of sentinel lymph node drainage.
16298230|NCT04688528|Experimental|Arm B: Whole level|"If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.
~Arm B 'Whole Level': on the contralateral side of the neck, the whole level(s) containing the draining sentinel lymph node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A."
16298231|NCT04688528|Experimental|Arm C: SLN alone|"If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.
~Arm C 'SLN alone': on the contralateral side of the neck, only the sentinel node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A."
16298232|NCT04688515|Experimental|Intervention group|Intervention group refers to mother-child dyads who will be participating in a nutrition program consisting of nutrition education and cooking sessions for 3 months.
16298233|NCT04688515|No Intervention|Comparison group|The comparison group will not receive any intervention but will be provided with the developed educational materials used in the program after the program has been completed.
16298238|NCT04688489|Active Comparator|Intervention|The intervention consists of a supplement of maltodextrin at training episodes combined with added dietary carbohydrates at all meals
16298239|NCT04688489|No Intervention|Control|The control receives no intervention. Standard treatment will be administered.
16298240|NCT04688450|Experimental|Intervention group|The investigational system will be evaluated for safety and user acceptance in 20 patient-subjects and associated nurse-subjects
16298241|NCT04688437||Patients with degenerative scoliosis|
16298242|NCT04688424|Experimental|FES + Cycling|Functional electrical stimulation cycling group
16298243|NCT04688424|Active Comparator|Cycling only|Volitional cycling group (no electrical stimulation)
16298244|NCT04688424|No Intervention|Control|control group
16298245|NCT04688411|Other|MED-Go app Intervention|Participants will use MED-Go app intervention for a total of 12 weeks
16298246|NCT04688411|No Intervention|Control Arm|Standard of care
16298247|NCT04688398|Experimental|Seal oil|Daily intake of 15 ml of seal oil containing 534 mg of EPA + 1129 mg of DHA + 530 mg of DPA during 12 weeks
16298248|NCT04688398|Active Comparator|Control|Daily intake of vegetable oil during 12 weeks
16298249|NCT04688385|Experimental|Multipeptide Vaccine + XS 15|a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes
16298250|NCT04688372||Inpatient encounters with COVID-19 present-on-admission|See Study description above
16298251|NCT04688359|Experimental|Intervention group|Those receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
16298252|NCT04688359|No Intervention|Control group|Those not receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
16298253|NCT04688346|Placebo Comparator|Control|Saline Pellet
16298254|NCT04688346|Experimental|Intervention|Racemic Epinephrine Pellet
16298255|NCT04688333|Experimental|Supportive care (iConquerFear program, questionnaires)|Patients complete 5 sessions of iConquerFear program online over 5 weeks. Patients also complete questionnaires at baseline, after the intervention, and 2 months later.
16298256|NCT04688320|Experimental|Recombinant nonimmunogenic staphylokinase|lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
16298257|NCT04688320|Experimental|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
16298260|NCT04688294|Experimental|Sacubitril/valsartan|Group 30 patients will undergo treatment with sacubitril/valsartan combination according to guideline-directed medical therapy.
16298261|NCT04688294|Active Comparator|Valsartan|Group 30 patients will undergo treatment with valsartan according to guideline-directed medical therapy.
16298262|NCT04688281|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
16298263|NCT04688281|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
16298264|NCT04688268||deep neuromuscular blockade|patients who underwent surgery with deep neuromuscular blockade
16298265|NCT04688255|Experimental|Intervention group (MSTEP)|REHABILITATIVE EXERCISE: Participants will be asked to exercise at home daily for 6 weeks, meeting with an RA weekly via video conference to gradually increase the intensity and duration of exercise based on symptom tolerance. The eventual goal will be to achieve 60 minutes of MVPA daily (US Federal recommendations). They will wear a personal fitness device (Fitbit) to track whether they are achieving their HR goals.
16298266|NCT04688255|Active Comparator|Control group (Stretching)|STRETCHING: Participants will be asked to complete stretches daily. They will initially be given two stretches, primarily focused on the neck and upper back. Additional stretches will be added through weekly discussions with the study RA.
16298267|NCT04688242|Experimental|Treatment Arm|Anal dilatation plus probiotics per anus Q3D, starting from 2 weeks after proctectomy until reduction of ileostomy.
16298268|NCT04688242|No Intervention|Control Arm|No anal dilatation or probiotics per anus was allowed, from 2 weeks after proctectomy until reduction of ileostomy.
16298269|NCT04688229|Experimental|Hummingbird intervention group|10 one-hour sessions of focused hand training (affected or dominant hand) using the Hummingbird device in addition to standard of care inpatient rehabilitation
16298270|NCT04688229|Active Comparator|Comparison (sham) group|10 one-hour sessions of activity focused on playing games or puzzles gaged to the ability of the subject in addition to Standard of care inpatient rehabilitation
16298271|NCT04688216||MDRO|
16298272|NCT04688216||Non-MDRO|
16298273|NCT04688203|Active Comparator|Magnesium sulfate infudsion|patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
16298274|NCT04688203|Active Comparator|Labetalol infusion|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
16298275|NCT04688190||Transcatheter Mitral Valve Implantation (TMVI)|Patients with successful TMVI screening, who underwent Transcatheter Mitral Valve Implantation subsequently. All devices may be included.
16298276|NCT04688190||Interventional mitral valve edge-to-edge repair (E2E)|Patients with TMVI screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair.
16298277|NCT04688190||Mitral valve surgery (Surgery)|Patients with TMVI screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement).
16298278|NCT04688190||Medical therapy (OMT)|Patients with TMVI screening failure, who subsequently underwent conservative or optimal medical therapy (OMT).
16298279|NCT04688177||smokers|cigarette smokers male 20 ≤ age ≤ 45 years old female 20 ≤ age ≤ 55 years old
16298280|NCT04688177||never smokers|age and gender-matched non-smokers
16298281|NCT04688164|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).
16298282|NCT04688164|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
16298283|NCT04688138||ischemic stroke|Patients with ischemic stroke within 7 days of onset
16298284|NCT04688086||Women with no personal history of breast cancer|Women who came in for a breast mammography between ages 30 and 80 years were invited to take part in the study. All the women included in the study underwent breast cancer screening first by Thermalytix, the AI-based thermal imaging test, followed by mammography.
16298285|NCT04688073|Experimental|Downhill running|Running at 60% VO2max on -15% slope for 30 min on a treadmill
16298286|NCT04688073|Experimental|Level running|Running at 60% VO2max on level surface for 30 min on a treadmill
16298287|NCT04688073|Placebo Comparator|Control|Rest 30 min
16298418|NCT04687059|Placebo Comparator|Placebo Option 1|Suspension for injection
16298288|NCT04688060||fallers|stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure Patients who have fallen 1 or more times since stroke
16298289|NCT04688060||non-fallers|"stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure.
~Patients who have not fallen 1 or more times since stroke"
16298290|NCT04688047|Experimental|Experimental|Women aged 18 and over with urinary incontinence will be taken. A total of seven online interviews will be conducted with the women in the experimental group, one of which is pre-test, one is the last interview where the post-tests are applied, and five of which are motivational. Women in the experimental group were interviewed every 2 weeks and the women will be followed up by phone / mail every 2 weeks.
16298291|NCT04688047|No Intervention|Control|Women aged 18 and over with urinary incontinence will be taken. A total of two online interviews will be conducted with women in the control group, one of which is a pre-test interview and one is a final interview where post-tests are applied.
16298292|NCT04688034|Experimental|OP-724 400 mg / 20 mL / vial (20 mg / mL)|"Dose: [Cohort 1] 140 mg/m2/4 hours (starting dose) , [Cohort 2] 280 mg/m2/4 hours
~Administration method: In the single administration, the safety of concomitant use with the investigational drug and antiretroviral drug will be confirmed and then the cycle administration will be started. For the single administration, at 14 days before the first cycle of administration, the dose planned for the first cycle with continuous intravenous administration for 4 hours will be administrated once. When an integrase inhibitor is used in combination as a key drug for antiretroviral drugs, it should be administered at the same time as the start of investigational drug administration only after the single administration. For the cycle administration, the continuous intravenous administration for 4 hours twice a week is defined as one cycle, and 12 cycles (12 weeks in total) will be performed."
16298293|NCT04688021|Experimental|Tocilizumab cohort|Each patient receives Tocilizumab (8 mg/kg, i.v.) on day -1 added to conventional acute GVHD prophylaxis regimen (CsA+MTX+low-dose MMF+ATG) of haploidentical HSCT.
16298294|NCT04688008|Other|Treatment sequence #1|29 of 58 subjects were given single oral dose of early phase hetrombopag olamine formulation in period 1 and late phase formulation in period 2
16298295|NCT04688008|Other|Treatment sequence #2|29 of 58 subjects were given single oral dose of late phase hetrombopag olamine formulation in period 1 and early phase formulation in period 2
16298296|NCT04687995|Active Comparator|Tragal preichondrium graft|Tragal perichodrium graft for endoscopic myringoplasty as a reference graft
16298297|NCT04687995|Active Comparator|pretragal ( SMAS) fascia graft|pretragal ( SMAS) fascia graft for endoscopic myringoplasty as a new graft
16298298|NCT04687982|Experimental|mDLI infusion|"The planned number of mDLI is 3.
~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.
~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.
~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
16298299|NCT04687969||COHORT A: PROSTATE CANCER PATIENTS|"Primary prostate cancer patients scheduled to undergo radical prostatectomy.
~Twenty five (25) prostate cancer patients will undergo two [18F]DCFPyL PET/MRI scans and
~Sixty (60) additional prostate cancer patients will undergo one [18F]DCFPyL PET/MRI scan."
16298300|NCT04687969||COHORT B: SOLID TUMOR PATIENTS|"Patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma).
~Up to fifty (50) patients will undergo up to three [18F]DCFPyL PET/MRI scans"
16298301|NCT04687956|Experimental|LYMPHA|LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.
16298302|NCT04687956|Active Comparator|Control|No LYMPHA procedure is performed
16298303|NCT04687943||PELOID therapy|A total of 15 sessions of peloid therapy for 3 weeks, 5 days a week for 42 patients in the first group
16298304|NCT04687943||Kinesio tape|42 patients in group 2 will be given 2 sessions of muscle and fascia correction techniques per week, with kinesio tape application and cold application
16298305|NCT04687943||Exercise|42 patients in the third group will be given 3 sets of 10 repetitions home exercise programs for 3 weeks
16298306|NCT04687930|Active Comparator|Active genicular nerve block group|group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
16298307|NCT04687930|Other|intra-articular steroid injection group|while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.
16298308|NCT04687917|Active Comparator|Training, Feedback, Consultation, and Facilitation|A multilevel implementation strategy
16298309|NCT04687917|Experimental|Training, Feedback, Consultation, Facilitation, and P4P|An enhanced version of the multilevel implementation strategy
16298310|NCT04687904|Active Comparator|Therapeutic education group|"The psychologist associated with the project takes care of the patient to receive a 1.5 hour therapeutic education interview (control group)."
16298311|NCT04687904|Experimental|Mindfulness meditation group|"The psychologist associated with the project takes care of the patient to receive training in mindfulness meditation twice (1.5 hours) (active group)"
16298312|NCT04687878|Experimental|Insulin|Regular Insulin, 20 IU twice a day, intranasally, every day for 12 weeks
16298313|NCT04687878|Placebo Comparator|Placebo|Normal saline, twice a day, intranasally, every day for 12 weeks
16298314|NCT04687852|Experimental|Focused Pelvic Floor Exercise with Motor ImageryTechnique Group|5 minute-Meditation Therapy 10 minute-Progressive Relaxation training ( Bernstein-Borkovec Method) 5 min - Breathing Exercises (Diaphragmatic Breathing Exercise, Pursed lip breathing Exercise) 35 min -Motor Imagery Technique Focused Pelvic Floor Exercises-MOPEXE 5 min - Meditation Therapy Twice a week for 60 minutes 12 weeks Participants will be evaluated online at the beginning of the research and at the end of the 12-week program.
16298315|NCT04687852|Active Comparator|Nonsteroidal Anti-Inflammatory Drug(NSAID) Group|Naproxen Sodium 550 mg film-coated tablet prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the pain of the patient. Treatment time; 12 weeks.
16298316|NCT04687852|Other|Diosmin Group|Diosmin (90%) 500 mg film-coated tablets prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the patient's pain. Treatment time; 12 weeks.
16298317|NCT04687852|Experimental|Acupressure Group|"4 acupuncture points will be applied twice a day for 12 weeks. These points are; LI4, CV4, CV6, SP6
~."
16298318|NCT04687852|No Intervention|Control Group|Participants will not be treated.
16298319|NCT04687839|Experimental|Healthy adult subjects|"It's a randomized intra-individual comparative study with two injured study areas (treated and untreated) for each subject.
~The randomization will determine the application side on which the tested product will be applied (RIGHT or LEFT forearm).
~Twice daily application on the treated area."
16298320|NCT04687826||Pancreaticoduodenectomy in 2015|Patients who underwent pancreaticoduodenectomy in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique. Most of the patients spent the first postoperative night in ICU where the monitoring of urine output and fluid balance are more specific than in a normal ward.
16298321|NCT04687826||Pancreaticoduodenectomy in 2017|Patients who underwent pancreaticoduodenectomy in 2017 got liberal intraoperative fluid therapy and most of the patients spent the first postoperative night in a regular ward.
16298322|NCT04687813|Experimental|Single Ascending Doses 100mg|Drug: FTP-198, single dose 100mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
16298323|NCT04687813|Experimental|Single Ascending Doses 300mg(food-impact)|Drug: FTP-198, single dose 300mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet 2-X: fasting (Period 1) ; 2-Y:Postprandial (Period 1) 2-X:Postprandial (Period 2); 2-Y:fasting (Period 2)
16298324|NCT04687813|Experimental|Single Ascending Doses 600mg|Drug: FTP-198, single dose 600mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
16298325|NCT04687800|Experimental|Dextenza 0.4mg|Intracanalicular insert
16298326|NCT04687800|Active Comparator|Durezol 0.05%|difluprednate ophthalmic emulsion
16298327|NCT04687787|Experimental|Group I|This group will receive Core Stability Exercises with Application of TENS
16298328|NCT04687787|Active Comparator|Group II|This group will receive Routinely prescribed Exercises with application of TENS
16298329|NCT04687761|Experimental|AZA-Based|"Azacitidine 75 mg/m2/daily SC on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle plus Venetoclax (ramp-up) 400 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.
~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the AZA-based schedule.
~AZA and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:
~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.
~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of AZA + Venetoclax + Quizartinib regimen (30 patients)."
16298330|NCT04687761|Experimental|LDAC-Based|"Low-dose subcutaneous cytarabine 20 mg/m2/daily SC, days 1 to 10 plus Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.
~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the LDAC-based schedule.
~LDAC and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:
~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily-Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.
~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of LDAC + Venetoclax + Quizartinib regimen (30 patients)."
16298331|NCT04687748|Experimental|EMG BF Group|Pelvic floor muscle contraction will be performed via an S-EMGBF device; patients in the s-EMGBF group will receive visual and auditory feedback.
16298332|NCT04687748|Active Comparator|Control Group|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds.
16298333|NCT04687735|Experimental|Intervention arm|Patients with frozen shoulders at any stage
16298334|NCT04687722|Experimental|High Intensity Aerobic Training Group.|The experimental group will receive High Intensity Aerobic Training at 80-90% of Heart Rate Maximum calculated using karvonen rule.
16298335|NCT04687722|Active Comparator|Control Group|The control group will receive routine low Intensity aerobic Training at 40-60% of Heart Rate Maximum calculated using karvonen rule.
16298336|NCT04687696|Experimental|Post Isometric Relaxation Group|The participants in this group will perform post isometric relaxation stretching in modified cross body position for 6 weeks.
16298337|NCT04687696|Experimental|Isolytic Stretching Group|The participants in this group will perform isolytic stretching in modified cross body position for 6 weeks..
16298338|NCT04687696|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position for 6 weeks.
16298339|NCT04687683|Experimental|Post Isometric Relaxation Group|The participants in this group will receive post isometric relaxation stretching in modified cross body position.
16298340|NCT04687683|Experimental|Isolytic Stretching Group|The participants in this group will receive isolytic stretching in modified cross body position.
16298341|NCT04687683|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position.
16298342|NCT04687670|Experimental|Intervention group(pET)|Personalized embryo transfer of a single vitrified blastocyst in a HRT cycle according to the ERA test results.
16298343|NCT04687670|Active Comparator|Control group(FET)|Frozen embryo transfer of a single vitrified blastocyst in a HRT cycle according to the clinical standard practice.
16298344|NCT04687657|Experimental|cord blood transfusion|The arm that will receive the target treatment.
16298370|NCT04687449|Active Comparator|Active Comparator: Curcumin therapy added to standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
16298345|NCT04687644|Experimental|Online Education|The education program developed within the scope of the research consists of five modules. In order to use the question and answer method in education, to make the education interactive and to receive feedback, 4 separate training groups of 7 people will be formed. The training will take place on the online platform, not face to face. Midwives will be contacted by phone and / or e-mail and the researcher will give a brief information about the research after introducing himself. A social media group will be created for each training group in order to communicate, announce trainings and inform changes.
16298346|NCT04687644|Active Comparator|Control|Midwives who attend the online forms of study will complete the survey. In the survey there are demographic and their view about woman centred care question forms. There are also Patient Centred Care Competency Scale and Minnesota Job Satisfaction Questionnaire. They will complete the survey.
16298347|NCT04687631|Experimental|mFOLFOXIRI plus Cetuximab|
16298348|NCT04687631|Experimental|mFOLFOXIRI plus Bevacizumab|
16298349|NCT04687618|Experimental|Automatic control of FiO2|Infants randomized to this arm will be monitored using automatic oxygen control system on the High Flow Nasal Cannula. When infants oxygen saturation are out of the target range the OAM module on HFNC will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation in the target range.
16298350|NCT04687618|Active Comparator|Manual Control of FiO2|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
16298351|NCT04687605|Experimental|Optimum duration of hypercapnia|Daily serial measurement of 2 hours under target hypercapnia of pCO2 50 - 55 mmHg by changes of respirator settings once per day
16298352|NCT04687579|Experimental|Umbilical hernia repair|Patients with cirrhosis undergoing umbilical hernia repair with or without preoperative optimization. See the section about interventions.
16298353|NCT04687579|Other|Watchful waiting|Patients who do not agree for operation but consent for follow-up. Patients will be followed in the whole inclusion period and can at any time change their preference if they wish to undergo surgery.
16298354|NCT04687566|Experimental|dextromethorphan|Dextromethorphan, 60 mg per day, once daily, for 12 weeks
16298355|NCT04687566|Experimental|memantine|Memantine, 5 mg per day, once daily, for 12 weeks
16298356|NCT04687566|Experimental|dextromethorphan and memantine|Dextromethorphan (60mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks
16298357|NCT04687566|Placebo Comparator|placebo|placebo, once daily, for 12 weeks
16298358|NCT04687553|Experimental|Patients with vegetative state|Patients with vegetative state were assessed by the SECONDs and CRS-R for two days.
16298359|NCT04687553|Experimental|Patients with minimally conscious state|Patients with minimally conscious state were assessed by the SECONDs and CRS-R for two days.
16298360|NCT04687540|Placebo Comparator|Study day 1 (study visit 1)|Baseline measurements (pre-intervention) are obtained on study visit 1.
16298361|NCT04687540|Active Comparator|Study day 21 (study visit 2)|Post-intervention measurements: Participants will be under the influence of tocilizumab, which was injected at the end of study visit 1.
16298362|NCT04687514|Experimental|Phase a (V1a-Ev2a): Dulaglutide first- Phase b (V1b-Ev2b) Placebo second|Dulaglutide is injected via pen s.c. once a week. The titration scale will be 1x 1.5mg in 0.5 ml in the first week and 2x 1.5 mg in 2x 0.5 ml once weekly for 3 further weeks. Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
16298363|NCT04687514|Experimental|Phase a (V1a-Ev2a): Placebo first- Phase b (V1b-Ev2b) Dulaglutide second|The Placebo will be injected via syringe and contains 0.5ml (only first injection) or 2x0.5ml (second to fourth injection) of 0.9% sodium chloride (0.9% NaCl). Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
16298364|NCT04687501|Experimental|VR-group|"The participants randomised into this group can choose for an immersive guided relaxation VR experience or an interactive VR experience. The VR intervention is additional to the standard postoperative care management, the standard pain protocol is explained below.
~The VR-intervention will be given using the Oculus Go Virtual Reality glasses with touchpad."
16298365|NCT04687501|No Intervention|Standard care-group|"The participants randomized into the standard care- group will receive the usual standard pre-and postoperative management.
~Standard pain protocol:
~Preoperative (arrival day-care unit) start with 1000mg paracetamol orally administered.
~Postoperative Meloxicam 15mg orally administered, or when oral medication is not possible (due to nausea e.g.) than diclofenac supp 100mg or diclofenac i.v. 75mg.
~On recovery ward, when necessary depending on pain score (NRS>4): dipidolor 2.5-5mg i.v. and 10-15mg i.m. after consulting the anesthesiologist.
~Postoperative at home 4dd1000mg paracetamol will be continued, in combination with meloxicam 1dd15mg during 3 days. Also tramadol 50mg with a maximum of 4dd will be prescribed."
16298366|NCT04687488|Other|Fluorescein|"Fluorescein dye and ultraviolet (UV) light are used to assess the aerosol contamination during endonasal investigations. We will dilute medical fluorescein vials (FLUORESCEINE 10% Faure; SERB, 40 Avenue George V, 75008 Paris, France) to a concentration of 1% fluorescein in 10ml of normal saline solution. Next, we swab the nasal cavity with a compress soaked (15 droplets with a pipette) in fluorescein and we apply 5 droplets into the nasal cavity and nasopharynx at the beginning of the investigation.
~After coating the nose with fluorescein, the patient will wear a surgical nose-mouth mask and will be positioned in the bed used for HRiM or MII-pH probe insertion. As the MII-pH probe is removed 24h after placement of the probe, prior to this activity the same fluorescein application method (fluorescein drops and a cotton swab) will be used."
16298367|NCT04687475|Experimental|Clinical Tool (Mobile Spirometry and Survey)|All subjects enrolled will be placed into the clinical tool arm. The clinical tool is comprised of a mobile application based assessment of home spirometry and a survey measuring patient reported outcomes.
16298368|NCT04687462|Experimental|Experimental|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
16298369|NCT04687462|Active Comparator|Control|TKRA operation undergoing 2-mm thickness variance polyethylene insert total knee arthroplasty system (Lospa, Corentec)
16298413|NCT04687085|Experimental|Mindful Meditation|Participants will listen to a 10 minute mindful meditation recording just prior to epidural catheter placement.
16298414|NCT04687072|Experimental|Efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
16298371|NCT04687449|Active Comparator|Active Comparator: Placebo with Standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
16298372|NCT04687436||Foley catheter group|
16298373|NCT04687436||Double-balloon group|
16298374|NCT04687423|Experimental|Experimental: phase I dose exploration|FCN-011 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
16298375|NCT04687410|Active Comparator|FNA|
16298376|NCT04687410|Experimental|FNB|
16298377|NCT04687397||Disorders of consciousness|Patients diagnosed as either in a Vegetative State or in a Minimally Conscious State
16298378|NCT04687384|Experimental|Robotic-assisted surgery|Patients undergoing robotic-assisted colectomy for colonic neoplasm
16298379|NCT04687384|Active Comparator|Laparoscopy|Patients undergoing conventional laparoscopic colectomy for colonic neoplasm
16298380|NCT04687371|Experimental|Grup I|Proprioceptive vestibular rehabilitation exercises, Cawthorne Cooksey Exercises and Gaze Stabilization exercises,
16298381|NCT04687371|Experimental|Grup II|Cawthorne Cooksey Exercises and Gaze Stabilization exercises
16298382|NCT04687371|Other|Grup III|No intervention will be made, patients will be asked to continue their daily life
16298383|NCT04687358||Active RP|Patients who are currently under the care of a physician for treatment of RP, currently on treatment for RP, and have had an episode (recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis) in the last 3 years prior to enrollment. Once included in the registry, these patients will have both retrospective and prospective follow-up and data collection (hybrid design).
16298384|NCT04687358||Inactive RP|Patients who have had a diagnosis of RP, have not had an episode for 3 years and have not been prescribed any treatment for RP in the last 3 years, prior to enrolling in the registry. Once included in the registry, data collected from these patients will be retrospective only.
16298385|NCT04687345||Propeller Flap|The propeller flap is based on a perforator that serves as a pivot joint, allowing the flap to rotate up to 180°. It provides the advantages of greater freedom of movement and versatility in flap design.
16298386|NCT04687345||Rotation Flap|The rotation flap is primarily supplied by the perforator artery accompanied by the random supply from the skin base. It is also associated with a lower venous congestion risk.
16298387|NCT04687332|Experimental|plasma exchange|patients were treated with plasma exchange
16298388|NCT04687332|Experimental|immunadsorption|patients were treated with immunadsorption
16298389|NCT04687306||Females|15 females
16298390|NCT04687306||Males|15 Males
16298391|NCT04687293|Experimental|HUBER|"HUBER is an isometric strengthening device. It consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed.
~Intervention will consist of 2 sessions of HUBER per week. Each session lasts approximatively 30 minutes. The intervention is 8 weeks long."
16298392|NCT04687293|No Intervention|Control|The control group will not received any intervention except usual care.
16298393|NCT04687241|Experimental|Almonertinib|
16298394|NCT04687241|Placebo Comparator|Placebo Almonertinib|
16298395|NCT04687228|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
16298396|NCT04687228|Experimental|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
16298398|NCT04687202||Patients developing CA|Including patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019
16298399|NCT04687189|Experimental|Women with a known history of submucosal fibroids|
16298400|NCT04687189|Experimental|Women recruited from a general population subject to I/E criteria|
16298401|NCT04687176|Experimental|Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)|"Induction: Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and Ascorbic acid 1g daily for 42 days Consolidation: ral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles.
~Maintenance: Oral Arsenic trioxide 10mg daily, ATRA (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total)."
16298402|NCT04687163|Experimental|OXA 130|Patients received sorafenib or lenvatinib Plus HAIC of 130 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
16298403|NCT04687163|Active Comparator|OXA 85|Patients received sorafenib or lenvatinib Plus HAIC of 85 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
16298404|NCT04687150|Active Comparator|The study group|The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit
16298405|NCT04687150|Placebo Comparator|The control group|The control group will be given colored water at same timepoints
16298406|NCT04687137|Experimental|TAK-743|
16298407|NCT04687124|Active Comparator|Fish oil|dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
16298408|NCT04687124|Placebo Comparator|standard care|The departmental usual procedure with the possibility of requiring of a dietician when needed
16298409|NCT04687111|Active Comparator|Control|Valsartan 40mg bid titrated to maximum dose of 160mg bid
16298410|NCT04687111|Experimental|Intervention|Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid
16298411|NCT04687098|Other|Risk-adapted postremission treatment.|Induction (idarubicin, cytarabine), first consolidation (high dose cytarabine), risk- stratification: allogeneic matched related or unrelated donor transplant vs. consolidation courses.
16298412|NCT04687085|Placebo Comparator|Neutral Content|Participants will listen to a 10 minute neutral content recording just prior to epidural catheter placement.
16298419|NCT04687059|Placebo Comparator|Placebo option 2|Solution for injection
16298420|NCT04687046||Cohort 1 JUVÉDERM VOLUX® with 3D Imaging|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.
16298421|NCT04687046||Cohort 2 JUVÉDERM VOLUX®|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 2 will have follow-up on-site visits at Months 1 and 3 and follow-up telephone calls at Months 6 and 12.
16298422|NCT04687033|Experimental|Dual-tDCS & PT|"Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about
~1 hour). The current intensity is fixed at 2 mA and the current will flow continuously. Physical therapist will give an intervention program for lower limb performance."
16298423|NCT04687033|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, the current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performance.
16298424|NCT04687020|Other|Non-interventional (United States) / Low-interventional (Canada) : Viltolarsen|Patients will receive viltolarsen (recommended dose 80mg/kg/week) during a treatment period up to 120 months.
16298425|NCT04687007|Experimental|SMART-ALD - Experimental group (EG)|Participants will receive 12 months of SMART-ALD intervention
16298426|NCT04687007|Other|Waiting List - Control group (CG)|Participants will receive 6 months of SMART-ALD after a 6-months waiting period
16298427|NCT04686994|Experimental|ASC41|ASC41 two tablets, once daily, from Day 1 to Day 28.
16298428|NCT04686994|Placebo Comparator|ASC41 placebo|ASC41 placebo two tablets, once daily, from Day 1 to Day 28.
16298429|NCT04686981||mesenteric artery thromboembolism patients without intestinal necrosis|After laparoscopic exploration, If there is no intestinal necrosis, minimally invasive intravascular thrombus aspiration treatment will be performed,
16298430|NCT04686981||mesenteric artery thromboembolism patients with intestinal necrosis|After laparoscopic exploration, If intestinal necrosis occurs, open surgery, mesenteric artery embolectomy and necrotic bowel resection, intestine fistula will be performed.
16298431|NCT04686968|Experimental|Greenhouse group|Patients underwent greenhouse technique：The high-strength suture was passed through the tendon using Mason-Allen method, and then Crimson duvet procedure was performed on the foot print area from the articular surface of the humeral head to the apex of the greater tubercle. Immediately after this procedure, a lateral row anchor was used.
16298432|NCT04686968|Active Comparator|Vent group|The three-line anchor suture method is the same as before, the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
16298433|NCT04686955|Experimental|Group A|Group A will receive Xiao-Xian-Gui-Fu-Tang three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks. Post-follow-up will be 4 weeks later.
16298434|NCT04686955|Placebo Comparator|Group B|Group B will receive a placebo three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang for another 6 weeks. Post-follow-up will be 4 weeks later.
16298435|NCT04686942||Before sonazoid|US detection liver metastases before sonazoid
16298436|NCT04686942||After sonazoid|US detection liver metastases after sonazoid
16298437|NCT04686929|Experimental|Cohort 1|The participants in Cohort 1 will receive a lower dose of abatacept s.c as maintenance
16298438|NCT04686929|Experimental|Cohort 2|The participants in Cohort 2 will receive a higher dose of abatacept s.c as maintenance
16298439|NCT04686916|Experimental|IP2018_dose 1|IP2018_dose1
16298440|NCT04686916|Experimental|IP2018_dose 2|IP2018_dose2
16298441|NCT04686916|Placebo Comparator|Placebo|Placebo
16298442|NCT04686903|Experimental|Epiduroscopy|Epiduroscopy in patients with FBSS
16298443|NCT04686903|Experimental|Racz catheter epidural procedure|Racz catheter epidural procedure in patients with FBSS
16298444|NCT04686903|Experimental|Caudal epidural block|Caudal epidural block treatment of FBSS
16298445|NCT04686890|Active Comparator|postoperative opiod (morphine) consumption|patient-controlled analgesia (15 minutes. lock time, 2 ml bolus= total 1 mg morphine intravenously, limited to maximum 4 bolus / per hour )
16298446|NCT04686890|Active Comparator|peroperative continuous opioid (remifentanil) consumption|continuous remifentanil infusion was given during the whole procedure
16298447|NCT04686890|Active Comparator|postoperative numerated rating scale|at the 1, 3, 6, 12 and 24 th hour postoperatively - numerated rating scale score was evaluated and recoded as 0= no pain (better), 10: unbearable pain (worse)
16298448|NCT04686877|Experimental|STAPLE group|For patients in STAPLE group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided aspiration followed by urokinase clot irrigation (every 12 h for up to 5 days or until reduction of ICH to ≤10 mL). CT will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset. On the 1st, 3rd, 5th, and 7th day of post-operation, patients will be re-examined using CT. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
16298449|NCT04686877|No Intervention|Conservative treatment group|We used the 2015 ASA/AHA and 2020 Chinese multidisciplinary expert consensus recommendations for treatment of spontaneous intracerebral hemorrhage, including a standard approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacological treatment of intracranial mass effect. Patients allocated to the standard medical care group had follow-up CT scans and other monitoring assessments on the same schedule as those in the STAPLE group. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
16298450|NCT04686864|Experimental|Parent Support Group|Support and psychoeducation in a group setting for parents who have a child or adolescent with an eating disorder.
16298451|NCT04686851|Experimental|Intervention|Comprehensive Geriatric Assessment and follow-up as add on to standard oncologic care
16298452|NCT04686851|No Intervention|Control|standard oncologic care according to national guidelines
16298453|NCT04686838|Experimental|READyR II A|Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.
16298454|NCT04686838|Active Comparator|READyR II B (comparison)|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.
16298455|NCT04686825|Experimental|T1|DA-8010 2.5 mg (Fasting)
16298456|NCT04686825|Experimental|T2|DA-8010 2.5 mg (Fed)
16298457|NCT04686825|Experimental|T3|DA-8010 5 mg (Fasting)
16298458|NCT04686825|Experimental|T4|DA-8010 5 mg (Fed)
16298459|NCT04686812|Experimental|Worksite health promotion program|Participants had a baseline health risk assessment (HRA) after which they were invited to participate in a workplace health promotion program. The intervention lasted six months and included the following components: nutrition counseling, physical activity, and stress management. HRAs were performed 6 and 12 months after intervention onset.
16298460|NCT04686812|No Intervention|Control|Participants only had a baseline and follow-up health risk assessments at 6 and 12 months.
16298461|NCT04686799|Experimental|SD-doxycycline group|12 weeks SD-doxycycline: doxycycline hyclate 20 mg tablet by mouth twice daily
16298462|NCT04686786|Experimental|CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Week 57 during the treatment period.
16298463|NCT04686773|Experimental|AZD1222 5×10^10 vp + rAd26-S (1.0±0.5) х 10^11vp|Subjects will receive 1 intramuscular (IM) injection of 5×10^10 viral particles (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×10^11 viral particles (nominal) on Day 29 of the study.
16298464|NCT04686760|Experimental|Nitroglycerin solution|
16298465|NCT04686760|No Intervention|standard solution|
16298466|NCT04686747||Esophageal Cancer|
16298467|NCT04686747||Gastric Cancer|
16298468|NCT04686747||Pancreatic Cancer|
16298469|NCT04686747||Colorectal Cancer|
16298470|NCT04686734||SARS-CoV-2 positive|
16298471|NCT04686734||SARS-CoV-2 negative|
16298472|NCT04686721||Patients at risk of developing tracheal stenosis after prolonged intubation or tracheostomy|Patients older than 18 years of age who underwent either prolonged intubation or tracheostomy will be enrolled. A minimum of 2 months follow-up from hospital discharge is required. Patients tested negative for SARS-CoV-2 will be used as a control group
16298473|NCT04686708||Pre-pandemic period|Patients managed in the pre-pandemic period
16298474|NCT04686708||Pandemic period|Patients managed in the pandemic period
16298475|NCT04686695|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation|
16298476|NCT04686682|Experimental|JAB-8263 Part1|Monotherapy, dose escalation
16298477|NCT04686682|Experimental|JAB-8263 Part 2|Monotherapy, dose expansion
16298478|NCT04686669|Experimental|Subjects receiving treatment sequence ABC|Subjects will receive treatment sequence ABC on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
16298479|NCT04686669|Experimental|Subjects receiving treatment sequence BCA|Subjects will receive treatment sequence BCA on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
16298480|NCT04686669|Experimental|Subjects receiving treatment sequence CAB|Subjects will receive treatment sequence CAB on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
16298481|NCT04686669|Experimental|Subjects receiving treatment sequence ACB|Subjects will receive treatment sequence ACB on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
16298482|NCT04686669|Experimental|Subjects receiving treatment sequence BAC|Subjects will receive treatment sequence BAC on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
16298483|NCT04686669|Experimental|Subjects receiving treatment sequence CBA|Subjects will receive treatment sequence CBA on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
16298484|NCT04686656|Active Comparator|nasal oxygen supplementation group|supplemental oxygen will be administered with nasal cannula
16298485|NCT04686656|Active Comparator|buccal oxygen supplementation group|supplemental oxygen will be administered with Ring-Adair-Elwyn (RAE) tube
16298486|NCT04686643|Experimental|Treatment|AGSAVI
16298487|NCT04686643|Active Comparator|Reference|AGLS
16298488|NCT04686630||Single group|Only observational study
16298489|NCT04686617|No Intervention|No-force group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction on one side and the other side was used as the premolar tooth control group. Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks. At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
16298523|NCT04686344|Active Comparator|Hypertonic saline intermittent boluses Group|will receive Hypertonic saline intermittent boluses for 48 hours
16298524|NCT04686331||Suspected CAP|All patients admitted to the emergency department with suspected community-acquired pneumonia (CAP) assessed by the receiving physician
16298525|NCT04686318||suspected acute pyelonephritis|All patients admitted to the emergency department with suspected acute pyelonephritis assessed by the receiving physician
16298526|NCT04686305|Experimental|Arm 1A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
16298490|NCT04686617|Active Comparator|Force Group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction to one side and the other side was used as the premolar tooth control group. As in no-force group, same device procedure was used for the application of vibration. Self-ligating Speed (Strite Industries, Cambridge, Ontario, Canada) tubes and brackets with 0.022×0.026 inch slots were bonded to the buccal surfaces of the right and left first molar teeth and first premolar teeth.150g of buccally directed forces, producing by a 0.017×0.025-in beta-titanium-molybdenum alloy (3M Unitek, Monrovia, Calif) cantilever spring, were applied to premolar teeth on both side.The force magnitude was measured with a strain gauge (Dentaurum). At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
16298491|NCT04686604|Experimental|Electron Health Record-based Provider Alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
16298492|NCT04686604|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
16298493|NCT04686591|Experimental|AZD9977|"In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL).
~In Period 2, one 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)."
16298494|NCT04686578||Fibromyalgia group|Diagnosed as Fibromyalgia according to American College of Rheumatology Fibromyalgia 2018 classification criteria over 1 year, and disease activity was stabil with the same drug at least 3 months.
16298495|NCT04686578||Control Group|The participants who have no physicological or severe musculoskeletal, rheumatologic diseases.
16298496|NCT04686552|Experimental|cinnamon|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served with 6 g of ground cinnamon.
16298497|NCT04686552|No Intervention|control|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served without 6 g of ground cinnamon
16298498|NCT04686539|Experimental|Recipients of CBD oil|Patients receiving Cannabidiol oil drops, administered sublingual, 3 times a day, while hospitalized. Dosing and administration frequency would be assessed bi-daily by the medical staff.
16298499|NCT04686539|Placebo Comparator|Recipients of Placebo|Patients receiving placebo oil, administered sublingual, 3 times a day, while hospitalized.
16298500|NCT04686513||Obese young adult|
16298501|NCT04686513||Non Obese young adult|
16298502|NCT04686500|Other|Deep Inspiration Breath-hold (DIBH) Respiratory Motion|DIBH qualified patient will experience one high-resolution CT scan as SOC and additional 3 low resolution/lower dose CT scans to further investigate inter-DIBH patient surface and tumor position stability and repeatability
16298504|NCT04686474|Experimental|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment will be used twice daily for 12 weeks
16298505|NCT04686461|Experimental|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment dose- twice daily for 12 weeks
16298506|NCT04686448|Active Comparator|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
16298507|NCT04686448|Active Comparator|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
16298508|NCT04686435||Non-surgical treatment|Shoulder patients referred for non-surgical treatment after being diagnosed at the medical examination.
16298509|NCT04686435||Surgical treatment|Shoulder patients referred for surgical treatment after being diagnosed at the medical examination.
16298510|NCT04686422|Experimental|Tetric PowerFill Class I and II restorations|
16298511|NCT04686396|Experimental|Interpositional Group|Demineralized bone matrix
16298512|NCT04686396|No Intervention|Control|Without demineralized bone matrix
16298513|NCT04686383|Experimental|Cohort 1: 20 mg CAL056 mesylate|Patients will receive oral dose of 20 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
16298514|NCT04686383|Experimental|Cohort 2: 40 mg CAL056 mesylate|Patients will receive oral dose of 40 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
16298515|NCT04686383|Experimental|Cohort 3: 80 mg CAL056 mesylate|Patients will receive oral dose of 80 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
16298516|NCT04686383|Experimental|Cohort 4: 120 mg CAL056 mesylate|Patients will receive oral dose of 120 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
16298517|NCT04686383|Experimental|Cohort 5: 160 mg CAL056 mesylate|Patients will receive oral dose of 160 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
16298518|NCT04686370|Active Comparator|sandblasted acid-etched implants|implant will be installed intraforaminal
16298519|NCT04686370|Experimental|laser treated implants|implant will be installed intraforaminal
16298520|NCT04686357|Experimental|Intervention group (mET)|Microbiome-driven embryo transfer of a single vitrified blastocyst in an HRT cycle according to the EMMA/ALICE test results.
16298521|NCT04686357|Active Comparator|Control group (FET)|Frozen embryo transfer of a single vitrified blastocyst in an HRT cycle according to the clinical standard practice.
16298522|NCT04686344|Active Comparator|Hypertonic saline continuous infusion Group|will receive Hypertonic saline continuous infusion
16298527|NCT04686305|Experimental|Arm 1B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
16298528|NCT04686305|Experimental|Arm 1C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
16298529|NCT04686305|Experimental|Arm 1D: T-DXd|T-DXd
16298530|NCT04686305|Experimental|Arm 2A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
16298531|NCT04686305|Experimental|Arm 2B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
16298532|NCT04686305|Experimental|Arm 2C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
16298533|NCT04686305|Experimental|Arm 2D: T-DXd, Durvalumab|T-DXd, Durvalumab
16298534|NCT04686292||Suspected infection|All patients admitted to the emergency department with suspected infections assessed by the receiving physician
16298535|NCT04686279|Experimental|TFV Medicated Douche|Once enrolled, participants will complete a baseline sampling session and then a single dose of study product administration. Post-dose observations and data collection will follow at 1, 6, 24, and 72 hours, using a sparse PK sampling design in which plasma and peripheral blood mononuclear cells (PBMC) are collected at each designated time. Between sampling windows, YMSM will complete a web-survey examining their perceived reactions and comfort using the study douche, factors influencing product use in the future, and comfort with the trial procedures. The survey will be administered after dosing but scheduled not to interfere with other study assessments. Sampling for safety, PK, PD, and acceptability assessments will be collected according to the schedule of events. Phase I Trial participants will complete an in-depth interview as part of their Termination visit.
16298536|NCT04686266|Experimental|ViCCY: Health Information + Health Coaching|This group will receive 10 front-loaded sessions of virtual health coaching by trained Health Coaches over 6 months with content based on the theoretical framework our prior research. Sessions are provided using tablets. Initially, sessions are weekly to build the relationship, but the frequency of sessions decreases over time
16298537|NCT04686266|No Intervention|Health Information|Caregivers in the Health Information group are asked to spend at least 30 minutes weekly using the computer tablet provided to you by the study team to access recommended websites
16298538|NCT04686253||PFO patients with CS or/and TIA|PFO patients with CS or/and TIA (transcatheter closure of PFO was performed).
16298539|NCT04686253||PFO patients with migraine|PFO patients with migraine (transcatheter closure of PFO was performed).
16298540|NCT04686253||PFO patients without symptom|PFO patients without symptom (5-year follow-up).
16298541|NCT04686227||Group-1, women with normal uterus|
16298542|NCT04686227||Group-2, women with any uterine malformations|Group-2 is going to be sub-grouped according to ASRM and ESHRE classifications
16298543|NCT04686214|Experimental|study group|
16298544|NCT04686214|No Intervention|control group|
16298545|NCT04686201|Experimental|intervention group|
16298546|NCT04686201|No Intervention|control group|
16298547|NCT04686175|Experimental|INZ-701|The study design is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.
16298548|NCT04686162|Experimental|Group using the smartphone application bae|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months.
16298549|NCT04686149||Neo CCRT+Neo CTx +/- cystectomy|Patients receive neoadjuvant CCRT and neoadjuvant CTx. Radical cystectomy is performed depending on pathologic response. The patients showing clinical complete response after neoadjuvant CCRT and initially stage T2N0M0 are not treated with neoadjuvant chemotherapy.
16298551|NCT04686123|Experimental|Group A|Group A performed active Stretching of Pectoralis Minor (PMi) muscle along with the strengthening of Lower Trapezius muscle under the supervision of a physiotherapist
16298552|NCT04686123|Active Comparator|Group B|Group B performed active Stretching of the Pectoralis Minor (PMi) muscle only under the supervision of a physiotherapist.
16298553|NCT04686110|Other|Patients Amyotrophic Lateral Sclerosis|
16298554|NCT04686110|Other|Control subjects|
16298555|NCT04686097|Experimental|experimental group (electrocoagulation)|Participants in the experimental group will receive ultrasound-guided puncture of coagulation incompetent perforator veins.
16298556|NCT04686097|Active Comparator|control group (sclerotherapy)|Participants in the control group will receive an ultrasound-guided sclerosing agent injected.
16298557|NCT04686084|Experimental|CT scan|CT scan (MDCT, standard of care) and DE-CBCT (Investigational)
16298558|NCT04686071|Experimental|PNF method|
16298559|NCT04686071|Other|standard rehabilitation|
16298560|NCT04686058|Active Comparator|TCI propofol|Target controlled infusion propofol titrated by the investigator intra-procedure, based on the Modified Observer's Assessment of Alertness and Sedation Scale
16298561|NCT04686058|Active Comparator|PCS propofol|Patient-controlled sedation titrated by the patient to comfort level
16298562|NCT04686058|Active Comparator|midazolam and pethidine|Midazolam and pethidine bolus doses administered by the investigator based on clinical parameters and observation
16298563|NCT04686032|Experimental|Advanced Rehab Group|The experimental group will receive early physical therapy interventions including patient education, ambulation, in-bed exercises, deep breathing exercises, connective tissue manipulation and TENS during the first 3 post-operative days following abdominal hysterectomy
16298564|NCT04686032|Active Comparator|Early ambulation Group|Participants of this group will receive patient education and early ambulation during the first 3 post-operative days following abdominal hysterectomy
16298565|NCT04686019|Experimental|Intervention group|"2 x IMT (5-10 min) 2 times a day 7 days a week for 3 weeks with or without supervision
~Log-book
~Conventional neurorehabilitation"
16298566|NCT04686019|Active Comparator|Control group|Conventional neurorehabilitation
16298567|NCT04686006||Graves disease|
16298568|NCT04685993|Experimental|Treatment A|LPCN 1144
16298569|NCT04685980||Failed spinal anaesthesia group|Failed spinal anaesthesia: failure of anaesthetic level of blockade both sensory and motor blockage, and consequently receive general anaesthesia
16298570|NCT04685980||Control Group|Patient receiving spinal anaesthesia and successfully finish the cesarean section
16298571|NCT04685967|Experimental|Glass-ionomer|Equia Forte HT, GC, Tokyo, Japan (EHT)
16298572|NCT04685967|Experimental|Bulk-Fill|SonicFill2, Orange, CA, USA (SBF)
16298573|NCT04685954|Experimental|Bulk-Fill|Filtek™ Bulk Fill Posterior, 3M ESPE, St. Paul MN, USA (FB)
16298574|NCT04685954|Experimental|Incremental|Filtek Ultimate Universal, 3M ESPE, St. Paul MN, USA (FU)
16298577|NCT04685928|Experimental|MRI arm|MRI prostate with contrast, followed by MRI-guided biopsy under local anaesthesia only if MRI show suspicious lesion. Men with non-suspicious MRI will not receive a biopsy.
16298578|NCT04685928|Active Comparator|TP-arm Systematic biopsy|24-core Systematic transperineal prostate biopsy under local anaesthesia
16298579|NCT04685915|Experimental|Ibrutinib + Copanlisib|"During 28 day study treatment cycle, participants will:
~Take Ibrutinib daily at predetermined dose for as long as there are no serious side effects and disease progression
~Receive intravenous infusion of Copanlisib at a predetermined dose days 1, 8 and 15 for cycles 1-6."
16298580|NCT04685902||Adult patients with tracheostomy|Adult patients who currently have a tracheostomy and receive an order for one-way speaking valve trial
16298581|NCT04685889|Active Comparator|Icon Group|Icon® resin infiltration treatment was performed on 58 permanent central teeth with MIH and evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
16298582|NCT04685889|No Intervention|Control Group|No treatment was performed on healthy teeth. However, similar to the treated teeth, 58 healthy permanent central teeth of the same individuals were evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
16298583|NCT04685876|Active Comparator|liposomal bupivacaine|40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.
16298584|NCT04685876|Active Comparator|plain bupivacaine|50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.
16298585|NCT04685876|Placebo Comparator|Normal Saline|patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.
16298586|NCT04685837|Experimental|Tele-rehabilitation group|The participants randomly assigned to the tele-rehabilitation group will use a computer application to know and execute the exercise protocol. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the application works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
16298587|NCT04685837|Experimental|Face to face group|Participants randomly assigned to the face-to-face group will use the physical therapy clinic to do the exercises controlled by the principal investigator. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the protocol works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
16298588|NCT04685824|Active Comparator|Biofeedback Training|"Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).
~30 min daily reading at home for 4 weeks."
16298589|NCT04685824|Experimental|Biofeedback Training + Immersive VR|"Biofeedback training (BFT) [1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks], 1 session per week for 4 weeks (4 sessions total).
~30 min daily reading at home for 4 weeks
~Immersive virtual-reality stimulation (IVR) [1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks], 1 session every 2 days for 4 weeks (14 sessions total)."
16298590|NCT04685811|Experimental|68Ga-PSMA-cyclotron Vesus 68Ga-PSMA-generator|Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
16298591|NCT04685798|Experimental|DWI MRI|-The patients will undergo an optimized research neck DWI MRI, up to 3 weeks post-treatment and then a standard-of-care 3-month post-treatment FDG PET/CT examination.
16298594|NCT04685746||Typically developing school-aged children|Study group to achieve objective 1 and 2; control group to achieve objective 3 and 4 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
16298595|NCT04685746||Vestibular-impaired school-aged children|Study group to achieve objective 3 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
16298596|NCT04685746||Neurodevelopmental group (ADHD, ASD and/or DCD)|Study group to achieve objective 4 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
16298597|NCT04685733||Group 1|Comparison of blood pressure, LVET and CO/SV measures with respective Gold Standards
16298598|NCT04685733||Group 2|Comparison of blood pressure and HRV measures with respective Gold Standards
16298599|NCT04685733||Group 3|Comparison of blood pressure and CO/SV measures with respective Gold Standards
16298600|NCT04685720|Experimental|Inhaled NO delivered using LungFit|Inhaled Nitric Oxide in doses up to 250 ppm
16298601|NCT04685707|Active Comparator|Active-Sedentary Control|
16298602|NCT04685707|Experimental|Active-Sedentary Experimental|
16298603|NCT04685694|No Intervention|Expectant|No medication is assigned.
16298604|NCT04685694|Experimental|Medical|SL 800 mcg Misoprostol
16298605|NCT04685681|Experimental|Hiking Challenge|This group receives access to the local hiking challenge after completion of baseline measure
16298606|NCT04685681|Active Comparator|Activity list|This group receives access to a resource sheet with activity ideas after completion of baseline measure and does not receive the main resource of interest (hiking challenge) until after the post-test (delayed intervention)
16298608|NCT04685655|No Intervention|COVID-19 therapy according to center standard alone|
16298609|NCT04685655|Active Comparator|Therapeutic plasma exchange and COVID-19 therapy according to center standard|
16298610|NCT04685642|No Intervention|non-drug|
16298611|NCT04685642|Active Comparator|Aspirin|
16298612|NCT04685642|Active Comparator|Statin|
16298613|NCT04685616|Active Comparator|ABVD +/- ISRT|"2 x 28 day cycles of ABVD: Doxorubicin 25mg/m^2 IV days 1 & 15 Bleomycin 10000 IU/m^2 days 1 & 15 Vinblastine 6mg/m^2 days 1 & 15 Dacarbazine 375mg/m^2 days 1 & 15
~PET-CT after 2 cycles will determine subsequent treatment:
~Deauville score 1-3 (PET CMR): 1 further cycle of ABVD then follow up Deauville score 4 (PET positive): 2 further cycles of ABVD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
16298614|NCT04685616|Experimental|A2VD +/- ISRT|"2 x 28 day cycles of A2VD: Doxorubicin 25mg/m^2 IV days 1 & 15 Brentuximab vedotin 1.2mg/kg (max 120mg) days 1 & 15 Vinblastine 6mg/m^2 days 1 & 15 Dacarbazine 375mg/m^2 days 1 & 15 Filgrastim (or equivalent haematopoietic growth factor) for 5-7 days from day 2 and day 16 (or single dose of peg-filgrastim on days 2 & 16)
~PET-CT after 2 cycles will determine subsequent treatment:
~Deauville score 1-3 (PET CMR): 1 further cycle of A2VD then follow up Deauville score 4 (PET positive): 2 further cycles of A2VD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
16298615|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
16298616|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 0 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
16298617|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
16298618|NCT04685603|Experimental|Experimental: AV-COVID-19 (0.1 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
16298619|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
16298620|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
16298621|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
16298622|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
16298623|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
16298624|NCT04685590|Experimental|Treatment|Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb). Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research). Both are administered orally.
16298625|NCT04685590|Placebo Comparator|Placebo|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
16298626|NCT04685577|Experimental|Nefopam|NEFOPAM 3% cream will be applied topically to healing deep dermal scratches in the lateral hip of burn patients daily (twice) for 3 weeks during the proliferative phase of wound healing.
16298627|NCT04685577|Placebo Comparator|Placebo|This will work as a placebo for the experimental drug.
16298628|NCT04685564|Experimental|RBD1016 experiment group|Subjects in experiment groups will receive a single subcutaneous injection of RBD1016.
16298629|NCT04685564|Placebo Comparator|placebo gruop|Subjects in placebo groups will receive a single subcutaneous injection of placebo.
16298630|NCT04685551|Experimental|Survivorship Management among African American and Latinx Cancer Dyads|"This arm will implement a one group pre-test and posttest design to improve health outcomes of African American and Latinx cancer survivors and caregivers in collaboration with health professional students trained as Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs)."
16298631|NCT04685538|Experimental|Chloroprocaine 3%|All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
16298632|NCT04685538|Active Comparator|Tetracaine 0.5%|All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.
16298633|NCT04685525|Experimental|Mycobiome Supporting Diet|Participants will be able to abide by the allowed and disallowed foods in MSD diet for at least four consecutive weeks prior to conditioning and up to 10 days after transplant. Participants will maintain a diary of foods they consume and any adverse effects they are experiencing and will self- collect fecal samples 28 days before transplant, 2 days before transplant and 10 days after transplant
16298634|NCT04685512|Experimental|TDF / FTC|2 tablets on Day-1 then 1 tablet/day for 6 days
16298635|NCT04685512|No Intervention|usual care|Standard of Care
16298636|NCT04685499|Experimental|Telomelysin (OBP-301)|All patients will receive intratumoral injection(s) with OBP-301. If tolerated and no progression is observed, up to twelve injections may be given in each patient.
16298637|NCT04685486|Experimental|Virtual Reality|Virtual reality-enhanced distraction using a portable head mounted display during panful events (such as wound dressing changes or physical therapy sessions) in addition to standard of care.
16298638|NCT04685486|No Intervention|Treatment as Usual|Standard of care during painful event (such as wound dressing changes or physical therapy sessions).
16298639|NCT04685473|Experimental|T-1101 (Tosylate)|
16298640|NCT04685460|Experimental|3D-printed bolus|
16298641|NCT04685460|No Intervention|Conventional bolus|
16298642|NCT04685447|Experimental|Expanded Hemodialysis|Hemodialysis modality performed by using a medium cut-off membrane
16298643|NCT04685447|Experimental|Protein-leaking hemodialysis|Hemodialysis modality performed by using a membrane with accentuated absorption capacities.
16298644|NCT04685434||pediatric patients diagnosed with rheumatic diseases.|The Shriners Hospital for Children Upper Extremity Evaluation, the Jebsen-Taylor Hand Function Test, and the Childhood Health Assessment Questionnaire will be administered in children with rheumatic diseases. The Shriners Hospital for Children Upper Extremity Evaluation will be administered two weeks after the first examination and the results will be compared.
16298645|NCT04685421|Experimental|Liposomal Bupivacaine PK|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
16298646|NCT04685408|Experimental|TargEted MAnageMent Intervention (TEAM)|This arm will receive the experimental intervention, TargEted MAnageMent Intervention (TEAM)
16298647|NCT04685408|Active Comparator|Enhanced treatment as usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
16298648|NCT04685395|Active Comparator|Benzydamine hydrochloride|"group I ( benzdymine HCL ); subject will be instructed to use Benzydamine hydrochloride gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).
~dose :5 ml every time dosage form ; mouth wash"
16298649|NCT04685395|Active Comparator|Rebamipide|"group II ( rebamipide) :subject will be instructed to use Rebamipide gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).
~dosage form ; mouth wash"
16298650|NCT04685369||Active smokers with wet AMD|
16298651|NCT04685356|Experimental|IBAIP Group|Children benefiting from assessment and intervention providing by a healthcare professional (physiotherapist or psychomotor therapist) trained and certified for IBAIP. This care will take place upon discharge from the hospital at the rate of one session per month for 6 months. The sessions will take place in the presence of at least one of the parents and at home. These children will also benefit from standard follow-up (medical follow-up, paramedical or specialized medical support depending on the development and needs).
16298652|NCT04685356|Active Comparator|Control group|Children benefiting from standard care upon discharge from hospital with 1 medical consultation per month and, medical sepcialist and / or paramedical(physiotherapy, speech therapy, psychomotricity, etc.). consultations if indicated by the physician providing follow-up
16298653|NCT04685343|Experimental|fMRI and laboratory pain induction|
16298654|NCT04685330||Adult patients undergoing an ultrasound-guided procedure|Adult patients undergoing an ultrasound-guided procedure, such as paracentesis, thoracentesis, or biopsy
16298655|NCT04685317|Experimental|Sentinel® Cerebral Protection System Group|Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation
16298656|NCT04685317|No Intervention|Standard of Care Group|Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation
16298657|NCT04685304|Experimental|PGx-guided care|Pharmacogenetic results (e.g., CYP2D6, CYP2C9) and a pharmacist consultation will be provided to their primary care provider. This consultation note (PharmD consult) will aid primary care providers in the interpretation and application of PGx results in prescribing decisions. The ultimate prescribing decision is at the discretion of the primary care provider and patient.
16298658|NCT04685304|Active Comparator|Standard care|"Care for study subjects will occur without PGx results at the discretion of the study subject, their primary care provider.
~After the active participation ends (i.e. after the three month follow up is complete), PGx results and a PharmD consult will be provided similar to the PGx-guided arm."
16298659|NCT04685291|Active Comparator|Group 1: Control|Systemic conventional pain management. Adult patients with acute fractures of the clavicle, who are scheduled to have internal fixation of the fracture within the next 24 hours receive oral and intravenous pain management.
16298660|NCT04685291|Active Comparator|Group 2: Nerve Block|Adult patients with acute fractures of the clavicle, who are scheduled for an internal fixation of the fracture within the next 24 hours will receive an ultrasound-guided block of the supraclavicular nerves using a maximum of 3 ml of a long-acting local anesthetic. The injection is carried out directly in the emergency department following a sonographic or radiological diagnosis.
16298663|NCT04685252|Experimental|Pre-Partum and Post-Partum (BL) NCC3001|One stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
16298664|NCT04685252|Placebo Comparator|Placebo Control|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
16298665|NCT04685252|Experimental|Post-Partum (BL) NCC3001 (Crossover Arm)|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily for 3 months during pre-partum, followed with switch to one stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily for 3 months post-partum.
16298666|NCT04685239|Active Comparator|Unipolar cup|Patients randomized to receive a conventional unipolar acetabular cup
16298667|NCT04685239|Active Comparator|dual mobility cup|Patients randomized to receive a double mobility acetabular cup
16298669|NCT04685213|Active Comparator|Active E-Stim|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for up to 4 weeks.
16298670|NCT04685213|Sham Comparator|sham E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for up to 4 weeks.
16298673|NCT04685161|Experimental|Surgical extrusion|Novel and alternative treatment option for horizontal crown root fractured maxillary incisors
16298674|NCT04685161|Active Comparator|Fibre post|Treatment modality normally used for crown-root fractured tooth
16298675|NCT04685148|Experimental|Intervention|Estradiol patches (200 μg per day) 0-3 weeks postpartum.
16298676|NCT04685148|Placebo Comparator|Placebo|Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum
16298679|NCT04685109|Experimental|Alocross|Cross-linked HA 0.2% + Aloe Vera 0.1% solution (N=40) Posology: One Drop in each eye 4 times daily for 84 days
16298680|NCT04685109|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
16298681|NCT04685096||Asian skin|Twice-daily application for 55 Days
16298682|NCT04685096||African-American skin|Twice-daily application for 55 Days
16298683|NCT04685083||Patients with Depression in consolidation phase|
16298684|NCT04685083||Patients with Depression in acute onset|
16298685|NCT04685083||Healthy subjects|
16298686|NCT04685070|Experimental|HS-10296 (Almonertinib)|
16298687|NCT04685057|Placebo Comparator|Placebo|This arm will receive placebo for 6 months then probiotic for 6 more months.
16298688|NCT04685057|Experimental|Probiotic|This arm will receive probiotic for 6 months then will keep receiving probiotic for 6 more months.
16298689|NCT04685044|Other|Healthy Volunteers|BrainPET insert
16298690|NCT04685031|Experimental|nitroglycerin|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
16298691|NCT04685031|Experimental|clobetasol|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
16298692|NCT04685031|No Intervention|routine|routine nursing care
16298693|NCT04685018||HC|Mentally and medically healthy adults between 18 and 60 years, free from any current or previous medical or psychiatric condition.
16298694|NCT04685018||OCD|Adults between 18 and 60 years, with a diagnosis of Obsessive-Compulsive Disorder and medication-free or with stable medication regimen for at least 3 weeks prior to the study.
16298695|NCT04685005|Experimental|Wake up|Drinking regular formula of Wake Up
16298696|NCT04685005|Active Comparator|Caffeine|Drinking 100mg of Caffeine
16298697|NCT04685005|Placebo Comparator|Placebo|Drinking Placebo (only water with sugar)
16298698|NCT04685005|Experimental|Wake up Double Dose|Drinking formula of Wake Up with double doses of guarana, green tea, elderberry and Fruit-up
16298699|NCT04685005|Experimental|Wake up tripple dose|Drinking formula of Wake Up with tripple doses of guarana, green tea, elderberry and Fruit-up
16298700|NCT04684992|Experimental|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
16298701|NCT04684979|Experimental|HLA-compatible Related Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
16298702|NCT04684979|Experimental|Unrelated Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
16298703|NCT04684966|Experimental|Experimental group (EG)|"Randomized intervention in the NMES (GE) group:
~Patients in the NMES group will receive, in addition to conventional rehabilitation, combined quadriceps femoris and triceps surae NMES.
~Detail of the NMES :
~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (possibility of 16 electrodes).
~One device per lower limb of each patient is necessary: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.
~Stimulation frequency: 50hz.
~Pulse duration: 400 μs.
~Contraction time: 6 seconds.
~Rest time: 6 seconds.
~The intensity must generate a visible muscular contraction and must be well supported. by the patient.
~The voluntary contraction accompanies the electrical stimulation.
~Surface electrode 50 × 50 mm."
16298704|NCT04684966|Sham Comparator|Control group (CG)|"Patients in the control group (GC) will receive, in addition to the classical rehabilitation, the combined sham NMES of the quadriceps femoris and triceps surae.
~Detail of the NMES :
~It is carried out 5 times a week for 4 weeks, supervised by a physiotherapist.
~The device used will be the same as in the EG group.
~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (16 electrodes can be used).
~One device per lower limb of each patient is required: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.
~Stimulation frequency: 5hz.
~Pulse duration: 100 μs.
~Contraction time: 6 seconds.
~Rest time: 6 seconds.
~The intensity must generate a visible muscle contraction and must be well supported by the patient.
~The voluntary contraction accompanies the electrical stimulation.
~Surface electrode 50 × 50 mm."
16298705|NCT04684953|Active Comparator|Thyroid autotransplantation|Implantation of 5-10 gm thyroid gland after mincing it in saline in quadriceps femoris muscle.
16298706|NCT04684953|Other|control group|the patients in this group won't undergo thyroid autotransplantation. instead, hormonal replacement therapy shall be prescribed for them.
16298707|NCT04684940|Experimental|Valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg in Active Inhibitor Population (Part A) and Prior Inhibitor Population (Part B).
16298708|NCT04684927|Experimental|MID-C treatment|Follow-up measurements during 5 years post MIC-C system implantationin order to evaluate safety and efficacy parameters.
16298709|NCT04684914|Experimental|HepTcell|Dose administered at intervals of 4 weeks for 6 doses
16298710|NCT04684914|Placebo Comparator|Placebo|Dose administered at intervals of 4 weeks for 6 doses
16298711|NCT04684901|No Intervention|Standard of Care Group|Standard of Care - No AlloWrap used during surgery
16298712|NCT04684901|Experimental|AlloWrap Group|AlloWrap used in surgery
16298776|NCT04684524|Placebo Comparator|Matching placebo|Placebo administered every 2 or 4 weeks based on weights
16298810|NCT04684277|Experimental|antidepressant treatment|recieve antidepressant treatment
16298713|NCT04684888|Active Comparator|Visumax Femto-flap|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. Refractive surgery was planned for both eyes and they chose the Visumax Femto-LASIK after a complete explanation of all the possible complications, costs, and differences. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
16298714|NCT04684888|Active Comparator|Sub Bowman's keratomileusis (SBK )-Flap group|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. They chose LASIK with mechanical SBK microkeratome surgical approach to be their refractive surgery for both eyes after all the possible complications, costs and differences had been explained clearly. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
16298715|NCT04684875||Long-Term Study Subjects|All subjects who were treated with the Aerin Medical InSeca/RhinAer Stylus in the 50-subject TP668 interventional study, who consent to continue to provide quality of life data.
16298716|NCT04684862|Experimental|Hepatic Artery Infusion (HAI) Therapy|Eligible patients will be implanted with a device that combines components of two commercially available drug delivery pumps to administer regional chemotherapy (FUDR) to the liver. Specifically, a Medtronic pump is being used with an Intera tapered catheter, instead of the Medtronic catheter.
16298717|NCT04684836||Synchronous telemedicine alone|
16298718|NCT04684836||Telemedicine-supplemented in-person care|
16298719|NCT04684836||In-person care alone|
16298720|NCT04684823|Experimental|Use of Patch Cap and Patch App|Subjects will use Patch Technologies to track their medication regimen compliance
16298721|NCT04684810||Treatment Group|Participants seeking treatment completed longitudinal data
16298722|NCT04684797|Experimental|Intervention group|Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.
16298723|NCT04684784|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
16298724|NCT04684784|Placebo Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
16298725|NCT04684771|Active Comparator|MYOSTIM®|MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
16298726|NCT04684771|Placebo Comparator|PLACEBO|PLACEBO 2 bars/day during 12 weeks
16298727|NCT04684745|Experimental|BION-1301 Q2W|BION-1301 will be administered once every 2 weeks (Q2W) as an intravenous infusion.
16298728|NCT04684745|Experimental|BION-1301 Q4W|BION-1301 will be administered once every 4 weeks (Q4W) as an intravenous infusion.
16298729|NCT04684732||Apixaban dose concordant to leaflet|Patients who were prescribed apixaban dose concordant to apixaban leaflet approved by Thai FDA
16298730|NCT04684732||Apixaban dose discordant to leaflet|Patients who were prescribed apixaban dose discordant to apixaban leaflet approved by Thai FDA
16298731|NCT04684719|Experimental|Whole Blood|Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care.
16298732|NCT04684719|Active Comparator|Standard Care|Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service.
16298733|NCT04684706|Other|Compressed iTBS schedule|Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.
16298734|NCT04684693|Experimental|Laser Group|
16298735|NCT04684693|Active Comparator|Control Group|
16298736|NCT04684680|Experimental|zamzam water|patient will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
16298737|NCT04684680|Active Comparator|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
16298738|NCT04684667|Other|Propranolol Therapy|This arm will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.
16298739|NCT04684654|Experimental|Part A (SAD)|Single Ascending Dose (SAD)
16298740|NCT04684654|Placebo Comparator|Part A (SAD) Placebo|
16298741|NCT04684654|Experimental|Part B (MAD)|Multiple Ascending Dose (MAD)
16298742|NCT04684654|Placebo Comparator|Part B (MAD) Placebo|
16298743|NCT04684654|Experimental|Part C (pSS)|Primary Sjögren's Syndrome (pSS)
16298744|NCT04684654|Placebo Comparator|Part C (pSS) Placebo|
16298745|NCT04684641|Experimental|Phage therapy|Participants will be randomized to receive 3mL phage therapy, nebulized daily for 7 days.
16298746|NCT04684641|Active Comparator|Placebo|Participants will be randomized to receive the 3mL placebo, nebulized daily for 7 days.
16298747|NCT04684628|Experimental|Biochemical Reoccurrence|"Patients with biochemical reoccurrence (post-prostatectomy or post radical radiotherapy) or patients with biochemical relapse with rising PSA in spite of taking hormone treatment (this situation is characterized as non-metastatic castration resistant prostate cancer M0CRPC) and compare it to bone scan and CT in 2 groups:
~PSA >= 0.2 ng/mL and <= 0.5 ng/mL or PSA > 0.5 ng/ml"
16298777|NCT04684511|Experimental|TRM-201 (Rofecoxib)|1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
16299201|NCT04681521|Placebo Comparator|PLACEBO: GROUP C|Inoperative compress Group
16298748|NCT04684628|Experimental|High Risk Prostate Cancer|Patients with high risk prostate cancer who have not received any definitive treatment. These high-risk patients are defined using the D'Amico Classification System: Those with a PSA of more than 20, or a Gleason score equal to or greater than 8, or have a clinical stage greater than T2c.
16298750|NCT04684602|Experimental|Arm 1: Autoimmune Diseases|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298751|NCT04684602|Experimental|Arm 2: Cardiovascular Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiovascular disorders and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298752|NCT04684602|Experimental|Arm 3: Diabetes Complications|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for diabetes complications. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298753|NCT04684602|Experimental|Arm 4: Integumentary Disease|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for integumentary diseases and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298754|NCT04684602|Experimental|Arm 5: Musculoskeletal Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic and musculoskeletal conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298755|NCT04684602|Experimental|Arm 6: Neurodegenerative Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic and neurodegenerative disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298756|NCT04684602|Experimental|Arm 7: Pulmonary Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298757|NCT04684602|Experimental|Arm 8: Sexual Dysfunction|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for sexual dysfunction conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298758|NCT04684602|Experimental|Arm 9: Urologic Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298759|NCT04684602|Experimental|Arm 10: Viral Illnesses|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for viral illnesses. Outcomes will be compared to results in peer-reviewed literature for several conditions.
16298760|NCT04684589|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.
16298761|NCT04684589|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.
16298762|NCT04684576|Experimental|Explorer Mini First (AB Arm)|Children randomized into this arm will first trial a Permobil Explorer Mini powered mobility device over an 8-week intervention period, then trial a modified ride-on car over a second 8-week intervention period in their home and community environments.
16298763|NCT04684576|Active Comparator|Modified Ride On Car First (BA Arm)|Children randomized into this arm will first trial a modified ride-on car over an 8-week intervention period, then trial a Permobil Explorer Mini powered mobility device over a second 8-week intervention period in their home and community environments.
16298771|NCT04684550|Placebo Comparator|Placebo|Health personnel who work in places of greater risk (hospitals and primary level consultation) with conventional protection elements added to the application of 2 nasal puff every 8 hours of a nasal spray containing 0.9% SSN (placebo) and gargles (SSN 0.9%).
16298772|NCT04684550|Experimental|Experimental|Health personnel who work in higher risk places (hospitals and primary level consultation) with conventional protection elements added to the application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
16298773|NCT04684537|Active Comparator|Shockwave group|each subject will receive extracorporeal shockwave therapy
16298774|NCT04684537|Active Comparator|Injection group|each subject will receive ultrasound-guided piriformis corticosteroid injection
16298775|NCT04684524|Experimental|Dupilumab|Dupilumab administered every 2 or 4 weeks based on weights
16298809|NCT04684290|Active Comparator|Surgical Septal Myectomy|
16298778|NCT04684511|Placebo Comparator|Placebo|1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II
16298779|NCT04684498|Experimental|Tamiflu (Oseltamivir Phosphate Capsules)|Standardized STEMI treatment + oseltamivir phosphate capsule (75mg, 2 times/day, 7days, oral)
16298780|NCT04684498|Other|no intervention|Standardized STEMI treatment + no intervention
16298781|NCT04684485|Placebo Comparator|Placebo of SCD-044 product|Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
16298782|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
16298783|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
16298784|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
16298785|NCT04684472|Experimental|Modified anti-CD19 CAR T cell therapy|CAR T cell therapy
16298786|NCT04684459|Experimental|CAR-T cell therapy|Dual-targeting HER2 and PD-L1 CAR-T cell therapy
16298787|NCT04684446|Experimental|Arm 1|AZD1222 on Day 1 followed by rAd26-S on Day 29
16298788|NCT04684446|Experimental|Arm 2|rAd26-S on Day 1 followed by AZD1222 on Day 29
16298789|NCT04684433||Surgical intervention|Patients who had a surgical procedure since the start of the lockdown in Belgium due to the COVID19 pandemic (16 of March 2020 to the 12 of April 2020.
16298794|NCT04684407|Active Comparator|calcium hydroxide|calcium hydroxide powder is mixed with normal saline and placed as intra-canal medication
16298795|NCT04684407|Experimental|Triple antibiotic paste|"Triple antibiotic paste (TAP)- combination of metronidazole,ciprofloxacin and minocycline mixed in a ratio of 1:1:1 .
~TAP paste is combined with propylene glycol and placed as intra canal medication."
16298796|NCT04684394|Experimental|GEM103 + SoC|
16298797|NCT04684394|Sham Comparator|Sham+SoC|
16298798|NCT04684381|Experimental|L-glutamine|Pharmacokinetic characteristics of L-glutamine
16298801|NCT04684355|No Intervention|Standard-of-care group|Participants in this group received their colonoscopic and pathological diagnosis simultaneously at next clinical visit, which arranged in 1 to 2 weeks later.
16298802|NCT04684355|Experimental|Intervention group|Participants in this group received their colonoscopic diagnosis right after they awake from general anesthesia, and then received pathological diagnosis at next clinical visit, which arranged in 1 to 2 weeks later.
16298803|NCT04684342|Experimental|cirrhotic ICU Patients|about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
16298804|NCT04684316|No Intervention|Care-as-usual: all consult physician|All employees at risk are invited to attend screening. Upon arrival, several biometrics are measured (weight, length, Body Mass Index, blood pressure), along with spirometries, a vision test, and a blood and urine test. The OP then investigates the general health status and systems of the employee, which includes an anamnesis with questions about new health burdens or changes in occupational risks, follow-up questions on previous complaints, medical advice, referral to a healthcare provider, or booking another appointment with an occupational health specialist. After the PHS, a (employee-unique) link to an online questionnaire is sent by email to gather information on final (health, health care use, absenteeism and presenteeism) and intermediary (health literacy, help-seeking behaviour) outcomes.
16298805|NCT04684316|Experimental|Intervention: Electronic survey with selective consultations|In the intervention group, all employees at risk receive a (employee-unique) link to an online health screening questionnaire by email. Dependent upon their answers, 20% of the employees (i.e. the 20% of the employees that mostly need contact with the OP) are referred to the occupational physician for a discussion of the results. The OP then gives medical advice, refers to a healthcare provider (e.g. general practitioner or specialist), or books a (follow-up) appointment with an occupational health specialist (OP, occupational nurse, etc.).
16298806|NCT04684303|Experimental|Lumbar medial branch RF neurotomy|Procedure lumbar medial branch RF neurotomy By raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be > 4 )
16298807|NCT04684303|Experimental|Lumbar medial branch cryoablation|"Procedure lumbar medial branch cryoablation Decreasing the temperature of the electrode to - 85 C for 120 seconds in two cycles.
~Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be =/> 4 )"
16298808|NCT04684290|Active Comparator|Alcohol Septal Ablation|
16298811|NCT04684277|Experimental|antidepressant treatment combined with Internet-based interventions|recieve antidepressant treatment combined with Internet-based interventions
16298812|NCT04684264|Experimental|Pharmacist-directed collaborative practice|Participants will be referred to a pharmacist-directed collaborative practice for heart failure prevention.
16298813|NCT04684264|No Intervention|Usual care|Participants will receive usual care with their primary care physician.
16298814|NCT04684251|Experimental|Treatment arm|The treatment arm will undergo the intervention with embolisation of their hemorrhoidal arteries. The embolisation will be performed using a standard right femoral puncture and after inserting a 5 Fr introducer sheath. The inferior mesenteric artery will be catheterised using a Simmons catheter (radiofocus-Terumo). The superior rectal arteries will be then catheterized with a rapid transit microcatheter Progreat microcatheter (Radiofocus-Terumo) and embolised with coils. The treatment will include the use of fluoroscopy for which the radiation protection department of Oxford University Hospitals NHS Foundation Trust has been consulted. The technical success of the procedure will be assessed fluoroscopically by achieving stasis of blood flow distally to the site of the embolization. CE marked coils will be used for the embolisation of the arteries feeding the haemorrhoids.
16298815|NCT04684238|Active Comparator|Drug: Midazolam|Midazolam for sedation in the ICU
16298816|NCT04684238|Experimental|Drug: Isoflurane|Volatile for sedation in the ICU
16298817|NCT04684225|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
16298818|NCT04684225|Experimental|Home-exercises|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied by their own at home for 3 sessions per week.
16298819|NCT04684225|No Intervention|Control|They will have no intervention for 8 weeks. After the period, they will do home exercises.
16298820|NCT04684212|Other|LAmbreTM Left Atrial Appendage Closure System|single center, pilot study will enroll a total of 15 patients
16298821|NCT04684199|Active Comparator|Melatonin|"Melatonin
~All participants will receive a 5 mg. dose of melatonin before bed for a period of two weeks during study period."
16298822|NCT04684199|Placebo Comparator|Placebo|"Placebo
~All participants will receive a placebo comparative in substance, color, and flavor, before bed for two weeks during the study."
16298823|NCT04684186||Endovascular fiducial marker insertion|Fiducial markers are inserted and released near the tumor through femoral puncture. A catheter is led through the venous system to the right heart and from there through the heart into the pulmonary arteries.
16298824|NCT04684186||Bronchoscopic fiducial marker insertion|Fiducial markers are inserted and released near the tumor into the bronchi using an endoscopic route
16298825|NCT04684173||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight >2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
16298826|NCT04684173||Preterm infants|The inclusion criteria for preterm infants are: gestational age <37 weeks, birth weight <2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
16298827|NCT04684160|Active Comparator|Fixed-bearing group|
16298828|NCT04684160|Experimental|Mobile-bearing group|
16298829|NCT04684147|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
16298830|NCT04684134||experimental group|patients with colorectal polyps
16298831|NCT04684134||control group|patients without intestinal diseases
16298834|NCT04684108|Experimental|SG301|Study treatment: SG301 administered every week via intravenous infusion
16298835|NCT04684095|No Intervention|routine follow-up group|only according to the routine follow-up frequency to the center visit.
16298836|NCT04684095|Experimental|ePRO group|ePRO group : self-evaluation in ePRO mode was accepted, and the patients were visited in the center according to the routine follow-up frequency.
16298837|NCT04684082||Single Group Assignment|Patients will receive colonic irrigation as bowel preparation prior to colonoscopy.
16298838|NCT04684069|Active Comparator|syringe free long axis in-plane|
16298839|NCT04684069|Sham Comparator|Short axis out-of-plane|
16298840|NCT04684056||Riva-control group|Routine concentration of Rivaroxaban (Peak)
16298841|NCT04684056||Riva-High group|High concentration of Rivaroxaban (Peak)
16298842|NCT04684056||Riva-Low group|low concentration of Rivaroxaban (Peak)
16298843|NCT04684056||Dabi-control group|Routine concentration of Dabigatran(Peak)
16298844|NCT04684056||Dabi-High group|High concentration of Dabigatran(Peak)
16298845|NCT04684056||Dabi-low group|low concentration of Dabigatran(Peak)
16298846|NCT04684056||Edo-control group|Routine concentration of Edoxaban(Peak)
16298847|NCT04684056||Edo-high group|High concentration of Edoxaban(Peak)
16298848|NCT04684056||Edo-low group|low concentration of Edoxaban(Peak)
16298849|NCT04684043||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
16298850|NCT04684030|Experimental|CGMS group|Using continuous glucose monitoring system(CGMS) group
16298851|NCT04684030|Active Comparator|SMBG group|Self-monitoring of blood glucose group (conventional fingerpricking method)
16298852|NCT04684017|Experimental|Anlotinib plus etoposide and carboplatin|Etoposide and carboplatin plus anlotinib for 4 cycles and anlotinib as maintenance therapy
16298853|NCT04684004||TTC patients with hyperglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.
16298854|NCT04684004||TTC patients with normoglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.
16298855|NCT04683991|Experimental|treatment group 1|At the same time of implant implantation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
16298856|NCT04683991|Experimental|treatment group 2|During the second stage operation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
16298857|NCT04683965|Experimental|Pemetrexed + TAS-102 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ TAS-102, capsule, 35mg/m2, bid,po, d1~5, d8~12 + Bevacizumab 5 mg/kg d1, d14; Repeated every 4 weeks
16298858|NCT04683952|Experimental|Rehabilitation with HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC).
~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
16298859|NCT04683952|Active Comparator|Control Group rehabilitation without HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC).
~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
16298860|NCT04683939|Experimental|Part 1A - BNT141 monotherapy escalation|Administration once every three weeks (Q3W)
16298861|NCT04683926|Experimental|Desmetramadol 10 mg, fasted|While fasting a single oral dose of 10 mg desmetramadol under.
16298862|NCT04683926|Experimental|Desmetramadol 20 mg, fasted|While fasting a single oral dose of 20 mg desmetramadol.
16298863|NCT04683926|Experimental|Desmetramadol 30 mg , fasted|While fasting a single oral dose of 30 mg desmetramadol.
16298864|NCT04683926|Experimental|Desmetramadol 30 mg , fed|After feeding a single oral dose of 30 mg desmetramadol.
16298865|NCT04683913|Experimental|Immediate Intervention: Telerehabilitation|Immediate entry into the gait modification intervention delivered using teleconferencing methods
16298866|NCT04683913|Experimental|Delayed Intervention: Telerehabilitation|Delayed (6 weeks) entry into the gait modification intervention delivered using teleconferencing methods
16298867|NCT04683900|Experimental|Standard of Care + Mediterranean Diet|Participants will be given standard of care for constipation (handout) plus individualized diet education on the Mediterranean diet and instructed to follow the diet during the 8-week intervention period. Diet education will be administered by a study dietitian and followed with weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
16298868|NCT04683900|Active Comparator|Standard of Care|Participants will be given standard of care for constipation (handout) to utilize during the 8-week intervention period. A study dietitian will follow up with weekly phone calls to support adherence and monitor for adverse events.
16298869|NCT04683887|Experimental|Tape application|
16298870|NCT04683887|No Intervention|No tape application|
16298871|NCT04683874|Experimental|3D printed tray|3D printed tray
16298872|NCT04683861|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
16298873|NCT04683848|Experimental|MT-3921|Intravenous (IV)
16298874|NCT04683848|Placebo Comparator|Placebo|Intravenous (IV)
16298875|NCT04683835||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
16298876|NCT04683822|Experimental|Exercise group|Patients who receive telerehabilitaton
16298877|NCT04683822|No Intervention|Control|Patients with routine care
16298878|NCT04683809|Experimental|Exercise group|Patients in this group will attend telerehabilitation sessions.
16298879|NCT04683809|No Intervention|Control group|Patients in this arm will be subject to routine follow up.
16298880|NCT04683796|Experimental|100% APRP|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
16298881|NCT04683796|Active Comparator|100% AS|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
16298882|NCT04683770||HR + / HER2 - advanced breast cancer|
16298883|NCT04683744||Healthcare system leadership, providers, and staff|Leadership, providers, and staff at the study team's affiliated health systems.
16298884|NCT04683744||Patients receiving primary care at the study team's affiliated health systems|Patients who had a least one primary care visit during the past 24 months at the study team's affiliated health care systems.
16298885|NCT04683731|Active Comparator|Group 1|Patients view decision aid without personalized message and whose providers do not receive the personalized message.
16298886|NCT04683731|Experimental|Group 2|Patients view decision aid with personalized message and whose providers do not receive the personalized message.
16298887|NCT04683731|Experimental|Group 3|Patient view decision aid without the personalized message and whose providers receive the personalized message.
16298888|NCT04683731|Experimental|Group 4|Patients view decision aid with the personalized message and whose providers receive the personalized message.
16298889|NCT04683718|Experimental|BIOTRONIK Prospera™ SCS (Spinal Cord Stimulation) System|Eligible participants will be permanently implanted with a BIOTRONIK Prospera™ SCS (Spinal Cord Stimulation) System with HomeStream™ Remote Management.
16298890|NCT04683705||patients without shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the asymptomatic shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
16298891|NCT04683705||patients with shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the painful shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
16299196|NCT04681547|Active Comparator|Local infiltration Analgesia|Administration of ropivacaine 0.2% 150 ml will be performed.
16298894|NCT04683679|Experimental|Arm A|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT + olaparib
16298895|NCT04683679|Experimental|Arm B|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT only
16298896|NCT04683653|Experimental|Hypofractionated Radiation Treatment (Dose-Finding Arm)|All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).
16298897|NCT04683653|Experimental|Expansion Cohort (Efficacy Arm)|"Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is (efficacy) at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment."
16298898|NCT04683640|Experimental|Daily Oral GABA|You will take, by mouth, 2 pills of GABA (500 mg) (Capsule 250mg) daily at home for 4 weeks
16298899|NCT04683640|Placebo Comparator|Daily Placebo|You will take, by mouth, 2 pills of Placebo daily at home for 4 weeks
16298900|NCT04683627|Experimental|HP-5000 Treatment|HP-5000 Topical Patch will be evaluated against placebo topical patches.
16298901|NCT04683627|Placebo Comparator|Placebo Treatment|Placebo patches without diclofenac sodium will be used.
16298902|NCT04683614|Experimental|Fresh frozen plasma|early administration of fresh frozen plasma
16298903|NCT04683614|Experimental|Low dose norepinephrine|low dose epinephrine 5 mic/kg/hr
16298904|NCT04683588|Experimental|intervention arm|"Polyclinic: Pre-tests (pain, anxiety, self-care and daily living activities), General coaching, 60 minutes
~Before Surgery: Nursing coaching, 30-45 minutes
~Surgery Day: Nursing coaching, 30-45 minutes
~Postoperative 1st Day: Nursing coaching, 30-45 minutes
~Postoperative 2nd Day: Nursing coaching practice, 30-45 minutes
~Day of discharge: Nursing coaching, 30-45 minutes.
~15 days after discharge: Nursing coaching, 60 minutes
~45 days after the operation: Nursing coaching, 60 minutes.
~90 days after surgery: Nursing coaching, 60 minutes."
16298905|NCT04683588|No Intervention|Control arm|Patients in the control group will receive routine postoperative nursing care.
16298906|NCT04683575|Experimental|experimental group|Patients with differentiated thyroid carcinoma with low blood selenium are treated with selenium yeast（dosage form：capsule dosage：200μg bid duration: 5 years）.
16298907|NCT04683575|Placebo Comparator|Placebo control group|Patients with differentiated thyroid cancer with low blood selenium are given placebo treatment（dosage form：capsule dosage：200μg bid duration: 5 years）
16298908|NCT04683575|No Intervention|No intervention group|Patients with differentiated thyroid cancer with low blood selenium are not treated.
16298909|NCT04683562|Other|Normal pregnancy group|
16298910|NCT04683562|Other|Placenta accreta group|
16298911|NCT04683536||control group|Patients underwent TUR-BT under spinal anesthesia
16298912|NCT04683536||Study group|Patients underwent TUR-BT under spinal anesthesia combined with ultrasound guided obturator nerve blockade
16298913|NCT04683523|Experimental|Anaerobic exercise training|
16298914|NCT04683523|Active Comparator|Aerobic exercise training|
16298918|NCT04683497|Experimental|CE-IOUS|Patients with pancreatic cancer undergoing surgery with the performance of CE-IOUS
16298919|NCT04683484|Experimental|Low dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
16298920|NCT04683484|Experimental|Middle dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
16298921|NCT04683484|Experimental|High dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
16298922|NCT04683484|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
16298923|NCT04683471|Experimental|Neuromodulation|Neuromodulation
16298924|NCT04683471|Sham Comparator|Sham|Sham
16298925|NCT04683458||Paclitaxel-coated devices|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any drug-coated medical device (e.g., drug-eluting stent, drug-coated balloon).
16298926|NCT04683458||Controlls|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any medical device except drug-coated techniques (e.g., drug-eluting stent, drug-coated balloon).
16298927|NCT04683445||HR+/HER2- advanced breast cancer|Efficacy and Safety of Eribulin in the Treatment of HR+/HER2- Advanced Breast Cancer
16298928|NCT04683445||HER2+ advanced breast cancer|Efficacy and Safety of Eribulin and anti-HER2 Targeted therapy in the Treatment of HER2+ advanced breast cancer
16298929|NCT04683445||triple negative advanced breast cancer|Efficacy and Safety of Eribulin and Immunotherapy in the Treatment of triple negative advanced breast cancer
16298963|NCT04683237|Experimental|MA+liraglutide|enrolled patients will receive megestrol acetate 160mg po qd plus liraglutide (1.8mg/d or the max tolerable dosage)
16298930|NCT04683419|Experimental|Patients with pleural effusion of Undetermined etiology|Patients with undiagnosed exudative pleural effusion will undergo modified pleural cryobiopsies and conventional pleural forceps biopsies in the same settings
16298931|NCT04683406|Experimental|ZSP1273 600 mg + Oseltamivir Placebo BID|Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
16298932|NCT04683406|Active Comparator|Oseltamivir 75mg + ZSP1273 Placebo|Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
16298933|NCT04683406|Placebo Comparator|Placebo Comparator|Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
16298934|NCT04683393||Healthy Subjects|To compare the markers of frailty (MoF) in patients with multiple myeloma (MM) with the healthy subjects.
16298935|NCT04683393||MM Patients|Patients with multiple myeloma (MM), the aim is to assess if any of the proposed parameters and markers of frailty (e.g. biomarkers of cellular senescence and organ damage, inflammatory markers, physical tests such as gait speed and hand grip test) are associated with frailty status, defined according to the GA, at baseline.
16298936|NCT04683367|Experimental|clinical hernia|developing clinical hernia
16298937|NCT04683354|Experimental|Dose Escalation|There are 3 cohorts for the dose escalation study. Six subjects each cohort will receive oral administration of HL-085 capsules at three daily dose levels (12 mg, 18 mg and 24 mg). Three subjects of each cohort will receive TID and 3 subjects will receive BID dose regimen. Dose escalation can occur after 6 patients have completed 28 days of treatment and no or 1 DLT is identified.
16298938|NCT04683341|Experimental|Arm A - initial TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and HBV NUC treatment naïve or experienced (except prior TAF) will receive initial treatment (Arm A) with TAF 25 mg/day.
16298939|NCT04683341|Experimental|Arm B - switch to TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and currently under HBV NUC treatment (except TAF) with HBV DNA < 20 IU/mL within 6 months prior screening will switch (Arm B) to TAF 25 mg/day
16298940|NCT04683328|Experimental|SCTA01 Group|SCTA01+Best Supportive Care
16298941|NCT04683328|Placebo Comparator|Placebo Group|Placebo+Best Supportive Care
16298942|NCT04683315|Experimental|Subtype diagnosis and classification: Basal|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Upon diagnosis, patients categorized as basal will receive two months of the Gemcitabine/Nab-paclitaxel Treatment Regimen.
16298943|NCT04683315|Experimental|Subtype diagnosis and classification: Classical|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Patients in the classical group will receive two months of the mFOLFIRINOX Treatment Regimen.
16298944|NCT04683315|Experimental|Basal Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
16298945|NCT04683315|Experimental|Classical Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
16298946|NCT04683315|Experimental|Basal Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
16298947|NCT04683315|Experimental|Classical Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
16298948|NCT04683315|Experimental|Basal Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
16298949|NCT04683315|Experimental|Classical Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
16298950|NCT04683302|Active Comparator|control|conventional 2D guided internal jugular vein catheterization
16298951|NCT04683302|Experimental|intervention|3D biplanar guided internal jugular vein catheterization
16298952|NCT04683289|Experimental|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy
16298953|NCT04683289|Active Comparator|viscotrabeculotomy|Viscotrabeculotomy
16298954|NCT04683276|Active Comparator|small flap medium-sized macular hole (SFMM)|small flap (1-2 disc-diameter) was performed in medium sized macular hole (250-400 um)
16298955|NCT04683276|Active Comparator|large flap medium-sized macular hole (LFMM)|large flap (3-4 disc-diameter) was performed in medium sized macular hole (250-400 um)
16298956|NCT04683276|Active Comparator|small flap large-sized macular hole (SFLM)|small flap (1-2 disc-diameter) was performed in Large sized macular hole (>400 um)
16298957|NCT04683276|Active Comparator|large flap Large-sized macular hole (LFLM)|large flap (3-4 disc-diameter) was performed in large sized macular hole (>400 um)
16298958|NCT04683263|Active Comparator|Intervention|Fisiocrem®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
16298959|NCT04683263|Placebo Comparator|Placebo|topical cream with similar characteristics and aspect, without active ingredients.
16298960|NCT04683250|Experimental|TAS0953/HM06 Phase 1|Dose escalation and dose expansion until recommended Phase 2 dose determined
16298961|NCT04683250|Experimental|TAS0953/HM06 Phase 2|Treatment phase at recommended Phase 2 dose in three different populations
16298962|NCT04683237|Other|MA alone|enrolled patients will receive megestrol acetate 160mg po qd
16299197|NCT04681534|Active Comparator|conventional DBS|
16298964|NCT04683224|Placebo Comparator|Placebo Stratum 1: 18 to 59 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
16298965|NCT04683224|Experimental|UB-612 Stratum 1: 18 to 59 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
16298966|NCT04683224|Placebo Comparator|Placebo Stratum 2: ≥60 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
16298967|NCT04683224|Experimental|UB-612 Stratum 2: ≥60 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
16298968|NCT04683224|Placebo Comparator|Placebo Stratum 3: 18 to 59 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
16298969|NCT04683224|Experimental|UB-612 Stratum 3: 18 to 59 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
16298970|NCT04683224|Placebo Comparator|Placebo Stratum 4: ≥60 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
16298971|NCT04683224|Experimental|UB-612 Stratum 4: ≥60 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
16298972|NCT04683198|Experimental|Experimental: camrelizumab +apatinib+ Carboplatin + Etoposide|Induced stage：camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1 ; maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
16298973|NCT04683185|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
16298974|NCT04683185|Experimental|Cohort 3: E6742 400 mg or Placebo|Participants will receive E6742 400 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
16298975|NCT04683185|Experimental|Cohort 1: E6742 100 milligram (mg) or Placebo|Participants will receive E6742 100 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
16298976|NCT04683172|Experimental|Active tDCS|Active tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
16298977|NCT04683172|Sham Comparator|Sham tDCS|Sham tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
16298978|NCT04683159|No Intervention|Control|No intervention, only routine pre-operative drops
16298979|NCT04683159|Experimental|Brimonidine 0.15%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.15% in the operating eye
16298980|NCT04683159|Experimental|Brimonidine 0.025%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.025% in the operating eye
16298981|NCT04683146|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propranolol- 1 60% as control.
16298982|NCT04683146|Active Comparator|Hand antisepsis with solution of alcohol, chlorhexidine digluconate and potassium sorbate|Effectiveness of pre-surgical hand washing in reducing bacterial load using a solution of alcohol, chlorhexidine digluconate and potassium sorbate
16298983|NCT04683133|Other|Single arm|Optical coherence tomography evaluation of coronary arteries with intermediate to severe stenosis.
16298984|NCT04683120|Experimental|Single Arm Study|This is a single arm study, which will involve all patients qualifying for Breast Conservation Therapy as a part of their breast cancer management excluding patients undergoing neoadjuvant therapy for inoperable disease.
16298985|NCT04683107|Experimental|Eccentric protocol|
16298986|NCT04683107|Experimental|Isometric protocol|
16298987|NCT04683081||Foley catheter group|pregnant women who were applied Foley catheter for cervical ripening
16298988|NCT04683081||Cook balloon catheter group|pregnant women who were applied Cook balloon catheter for cervical ripening
16298989|NCT04683081||Modified double-balloon Foley catheter group|pregnant women who were applied modified double-balloon Foley catheter for cervical ripening
16298994|NCT04683042|Active Comparator|TENS with PT|TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.
16298995|NCT04683042|Other|No TENS with PT|The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.
16298996|NCT04683029|Experimental|Group A: Guselkumab|Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase).
16298997|NCT04683029|Placebo Comparator|Group B: Placebo|Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase).
16298998|NCT04683016||Periodontitis patients|Patients with a diagnosis of periodontitis, irrespective of its stage and grade.
16298999|NCT04683003|Experimental|Prophylactic Cohort: TAK-755|Participants who are TAK-755 non-naïve will receive prophylactic treatment, a single dose of TAK-755 intravenous (IV) infusions at a dose of 40 international units per kilogram (IU/kg) once every 1 week (Q1W) or once every 2 weeks (Q2W) for approximately 3 years, or participants enrolling from an expanded access program will continue same dose of TAK-755 but not exceeding 40 IU/kg Q1W and not less than 40 IU/kg Q2W or participants who participated in study 281102 (NCT03393975) and had an allergic response to standard-of-care treatment will receive TAK-755 at a starting dose of 40 IU/kg Q2W. Participants who are TAK-755 naïve will receive initial prophylactic PK dose of 40 IU/kg followed by prophylactic treatment Q1W or once Q2W for approximately 3 years, or until commercial availability of investigational product (IP) in the country, or decision not to launch in the country whichever occurs first.
16299000|NCT04683003|Experimental|On-Demand Cohort: TAK-755|All the participants will receive an initial single dose of 40 IU/kg TAK-755 on Day 1 followed by subsequent tapering dose of 20 IU/kg on Day 2 then an additional daily dose of 15 IU/kg TAK-755 starting at Day 3 until 2 days after the acute event is resolved with an approximate treatment duration of one month. Upon resolution of the acute event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study.
16299001|NCT04682990|Experimental|Pulmonary TB|"This arm will enroll 80-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with pulmonary TB proved by TB LAMP test.
~Interventions:
~They will be asked to perform a breath exhalation with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam,and HIV status.
~Other interventions:
~Sputum samples for Ziehl Neelsen smear or Culture in L-J or GeneXpert MTB/RIF;
~Chest X-ray Follow Up 5 days after beginning of Tx Follow Up 15 days after beginning of Tx Follow Up 30 days after beginning of Tx"
16299002|NCT04682990|Active Comparator|Non Pulmonary TB|"This arm will enroll 50-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with Negative pulmonary TB status proved by TB LAMP test. These Negative TB patients can be healthy controls or TB suspects.
~Interventions:
~They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, and HIV status.
~Other interventions:
~Sputum samples for Ziehl Neelsen smear or Culture in L-J GeneXpert MTB/RIF;
~Chest X-ray."
16299003|NCT04682977|Experimental|IPROACTIF|12 weekly sessions. First two sessions focus on comprehensive assessment of physical and executive functioning, assessment of home safety and accessibility, assessment of ADL/IADL competence and performance in context; information in these areas is used by the interventionist to collaboratively identify three patient-centered goals. Goal planning is followed by 10 treatment sessions. Treatment sessions focus on chronic disease education, problem solving issues related to disease management by modifying daily routines, recommendations for embedding physical activity in everyday tasks, and environmental modifications or activity adaptations to increase ADL/IADL independence.
16299004|NCT04682977|Other|Usual care|Participants in the control group will receive usual services which might include primary care and prescription medications for chronic disease management.
16299005|NCT04682964|Experimental|Nebulizer inhalation bacteriophage therapy|To study the effects of bacteriophage therapy on acute tonsillitis in children and adolescents in an outpatient setting.
16299006|NCT04682938||adrenal incidentalomas in Chinese community adults|Patients aged over 18 years with adrenal incidentaloma (the maximum diameter of tumor ≥ 10 mm) were found by low-dose chest CT in physical examination center.
16299007|NCT04682925|Experimental|skin care arm of where evidence-based practices in the implementation guide|Participants in this arm will be given evidence-based skin care interventions, which are included in the guidelines to prevent medical device-related pressure injuries, and are implemented by the researcher nurse. After the nasogastric tube is inserted by the patient's physician.
16299008|NCT04682925|Experimental|hydrocolloid (Convatec Granuflex-extra thin) dressing|Patients in this arm will be applied a translucent hydrocolloid cover, which is compatible with the sensitive skin structure, can be applied to all body surfaces and nasal mucosa, and allows the underlying mucosa and skin to be observed after the nasogastric tube is inserted by the patient's physician. This cover will be applied to the nasal mucosa and nasal wing under the nasogastric tube.
16299009|NCT04682925|Other|control|Participants in the control group will be given no intervention , these patients will receive the routine clinical care(dressing change and nasal skin cleaning once a day) applied in the intensive care unit.
16299010|NCT04682899|Experimental|PCT-guided antibiotic therapy (PCT group)|Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT<0.1ng/ml，strongly discouraged；if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT>0.25 ng/ml, Strongly recommended.
16299011|NCT04682899|Active Comparator|Guideline-guided antibiotic therapy (guideline group)|Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).
16299012|NCT04682873|Experimental|Enisamium iodide|Hospitalized patients who were randomized in to this treatment group will receive enisamium iodide containing capsules (Amizon® Max).
16299013|NCT04682873|Placebo Comparator|Placebo|Hospitalized patients who were randomized in to this treatment group will receive placebo containing capsules.
16299198|NCT04681534|Experimental|adaptive DBS|
16299014|NCT04682860|Placebo Comparator|Placebo|In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds
16299015|NCT04682860|Active Comparator|Hyoscine N butylbromide|In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.
16299016|NCT04682847||Primary and metastatic liver tumors and hepatic cirrhosis|This study is a single arm prospective study that will enroll 25 patients with primary and metastatic liver tumors and hepatic cirrhosis eligible for liver SBRT who will be receiving treatment at a single center - Allegheny General Hospital.
16299019|NCT04682808|Experimental|Dose Escalation and Expansion|FCN-338 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL , until the maximum tolerated dose or recommended dose is reached. Followed by up to 43 patients enrolled in the expansion cohort at the recommended dose.
16299020|NCT04682795|Experimental|Needle-free injector group|To evaluate the efficacy and safety of the needle-free injector in T2DM
16299021|NCT04682795|Active Comparator|Insulin pen group|To evaluate the efficacy and safety of the insulin pen in T2DM
16299022|NCT04682782|Experimental|Esketamine|Participants randomized to this arm will receive Esketamine (1 mg/ml) infused at 0.1 mg/kg/hour (0.1 ml/kg/h) throughout the operation
16299023|NCT04682782|Placebo Comparator|Saline|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the operation
16299024|NCT04682769||Patients with medically stable coronary heart disease and Depressive Disorder|
16299025|NCT04682756||CNN model|Electronic health information of NSTEMI and UA patients in two chest pain centers from 2017 to 2019 was collected，After manual labeling, the characteristics of patient admission records were selected, and through the construction of one-dimensional convolution (CNN) model. Taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
16299026|NCT04682756||XG boost|Through the construction of XG boost model,taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
16299027|NCT04682743|Sham Comparator|saline group|
16299028|NCT04682743|Active Comparator|ondansetron group|
16299029|NCT04682743|Active Comparator|paracetamol group|
16299030|NCT04682730|Experimental|Deliberative Loop|28-page Context-Setting Document; 2-page addendum to Context-Setting Document; 90 minute Deliberative session; 8-page post-session survey
16299031|NCT04682717||PI group|A cut-off value of baseline PI below which hypotension at 5 min post induction could be predicted will be the primary outcome, while positive and negative predictive values at 15 minutes will be secondary outcomes.
16299032|NCT04682704|Experimental|Frequency 20Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
16299033|NCT04682704|Active Comparator|Frequency 5Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
16299034|NCT04682704|Active Comparator|Frequency 20Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
16299035|NCT04682704|Active Comparator|Frequency 5Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
16299036|NCT04682691|Sham Comparator|Group (C)|who will receive flavored water in total volume 15 ml at two hours preoperative.
16299037|NCT04682691|Active Comparator|Group (M)|will be receive 10 ml of oral metoclopramide (10mg)
16299038|NCT04682691|Active Comparator|Group (E)|will receive 10 ml of oral Erythromycin (400mg)
16299039|NCT04682678|Sham Comparator|OFF STIM|without stimulation
16299040|NCT04682678|Active Comparator|ON STIM|stimulation with the most effective parameters
16299041|NCT04682665||Experimental|Patients randomized to the experimental arm of the EMT2 trial, receiving Icosapent Ethyl (EPA-EE) according to the EMT2 protocol.
16299042|NCT04682665||Placebo comparator|Patients randomized to the placebo comparator arm of the EMT2 trial, receiving placebo capsules according to the EMT2 protocol.
16299043|NCT04682652|Experimental|GAE Treatment|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
16299044|NCT04682652|No Intervention|Observational|"Subjects randomized to the observational group will not undergo the experimental GAE Treatment.
~PI will offer subjects enrolled into the observational group to crossover to the experimental GAE Treatment group after they have completed their 6-month follow-up assessments."
16299045|NCT04682639|Experimental|Etrasimod Dose 1|
16299046|NCT04682639|Experimental|Etrasimod Dose 2|
16299047|NCT04682639|Placebo Comparator|Placebo|Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
16299048|NCT04682626|Experimental|VD3 group|"Dietary Supplement: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg once weekly for 8 weeks.
~."
16299049|NCT04682626|No Intervention|Control group|
16299112|NCT04682184|Experimental|Wearable Biosensor Patch Device + Propranolol|Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.
16299050|NCT04682613|Experimental|"Prevention Program young In Favor of Myself, active teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers will also participate by delivering planned activities to do with their pupils in addition to each week's topic, parallel to the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
16299051|NCT04682613|Active Comparator|"Prevention Program young In Favor of Myself, passive teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers won't participate in the program, they will only be present in the classroom during the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
16299052|NCT04682600|Experimental|Open-label|Volunteers who have agreed to participate in the study will have their liver scanned using the FibroScan, VE (Liver Incytes System) and MRE techniques.
16299053|NCT04682574|Active Comparator|vitamin C|The dose would be 30 grams a day (10 grams TDS) for 2 days with standard treatment
16299054|NCT04682574|No Intervention|Placebo|Distill water in the same dose with same standard treatment
16299055|NCT04682561|Experimental|Supportive Trauma Exposure Preparation (STEP) Program|Nurses or personal support workers at Unity Health Toronto - Providence Healthcare will undergo the STEP Program Psychotherapy
16299056|NCT04682535||Cohort 1|Spousal/partner family caregivers to persons living with dementia. Participants will complete 14-days of surveys about their relationships, social interactions, as well as health and health behaviors. A subsample of n=15 may volunteer to provide diurnal saliva samples.
16299059|NCT04682509|Experimental|Study group|All study subjects will receive glecaprevir/pibrentasvir (Mavyret®) 300/120 mg orally x 14 days, starting on POD 0 prior to transplantation of the HCV positive kidney. If HCV RNA is detectable after 2 weeks of therapy, Mavyret® will be continued to complete a full course of 8 weeks per standard of care. Safety monitoring and frequent surveillance for HCV viremia will occur for all subjects throughout the duration of the study. The kidney transplantation procedure and routine post-transplant management will be performed per standard of care.
16299060|NCT04682496|Experimental|intratendon vascularization|Intratendon vascularization will be quantified using a proprietary methodology using ImageJ 1.47v image analysis software, determining the different variables related to the Doppler signal within an intratendon region of interest.
16299061|NCT04682483||Cardiogenic Shock Patients|"Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below.
~Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP < 60mmHg or a >30mmHg drop in MAP from baseline, SBP < 90mmHg or a >30mmHg drop in SBP from baseline, Pulse > 100, Cardiac Index < 2.2, Cardiac Power Output ≤ 0.6 or PAPI < 1.0.
~Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets."
16299062|NCT04682470||All patients|
16299063|NCT04682457||Late Onset|Participants diagnosed with Type 1 diabetes at over 30 years of age.
16299064|NCT04682457||18 to 30|Participants diagnosed with Type 1 diabetes between 18 and 30 years of age
16299065|NCT04682444|Experimental|Group 1 - Active Treatment|Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
16299066|NCT04682444|Placebo Comparator|Group 2 - Placebo|Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
16299067|NCT04682431|Experimental|Part A: PY159 Single agent dose level 1|PY159 dose level 1 IV administration, Q3 weekly until consent withdrawal, intolerable toxicity or investigator decision.
16299068|NCT04682431|Experimental|Part A: PY159 Single agent dose level 2|PY159 dose level 2
16299069|NCT04682431|Experimental|Part A: PY159 single agent dose level 3|PY159 dose level 3
16299070|NCT04682431|Experimental|Part A: PY159 single agent dose level 4|PY159 dose level 4
16299071|NCT04682431|Experimental|Part A: PY159 single agent dose level 5|PY159 dose level 5
16299072|NCT04682431|Experimental|Part A: PY159 single agent dose level 6|PY159 dose level 6
16299073|NCT04682431|Experimental|Part A: PY159 single agent dose level 7|PY159 dose level 7
16299074|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 1|PY159 dose level 1 in combination with pembrolizumab
16299075|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 2|PY159 dose level 2 in combination with pembrolizumab
16299076|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 3|PY159 dose level 3 in combination with pembrolizumab
16299077|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 4|PY159 dose level 4 in combination with pembrolizumab
16299078|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 5|PY159 dose level 5 in combination with pembrolizumab
16299079|NCT04682431|Experimental|PY159 Part B: Single agent dose expansion cohort(s)|PY159 Single agent dose expansion cohort(s)
16299080|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort(s)|PY159 in combination with pembrolizumab dose expansion cohort(s)
16299081|NCT04682418|Experimental|xvision Spine|
16299113|NCT04682184|Experimental|Wearable Biosensor Patch Device + Pseudoephedrine|Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.
16299114|NCT04682184|Experimental|Wearable Biosensor Patch Device (Alone)|Participants will wear biosensor patch device (alone) during one of three study periods.
16299115|NCT04682171|Experimental|Low level Laser Therapy|Low Level Laser Therapy and Conventional Exercise therapy
16299116|NCT04682171|Active Comparator|Conventional ExerciseTherapy|Conventional ExerciseTherapy
16299199|NCT04681521|Experimental|HOT THERAPY:GROUP A|Hot Compress Group
16299200|NCT04681521|Experimental|COLD THERAPY:GROUP B|Cold Compress Group
16299082|NCT04682405|Experimental|Uproleselan + Standard of Care Melphalan|"On the evening of Day -3, patients will receive dose #1 of uproleselan
~On the following morning of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #2 of uproleselan
~On the evening of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #3 of uproleselan
~On Day -2 following completion of dose #3 of uproleselan, the patient will be administered the conditioning dose of melphalan (200mg/m^2) as per institutional practice.
~On the following morning of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #4 of uproleselan
~On the evening of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #5 of uproleselan
~On the following morning of Day 0 (12 +/- 2 hours from prior dose) patients will receive dose #6 (final dose) of uproleselan
~On Day 0, 4 hours (+/- 2 hours) after the final dose of uproleselan, the patient will be infused with the HSC product. The patient will remain inpatient until engraftment"
16299083|NCT04682405|Placebo Comparator|Placebo + Standard of Care Melphalan|"On the evening of Day -3, patients will receive dose #1 of placebo
~On the following morning of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #2 of placebo On the evening of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #3 of placebo.
~On Day -2 following completion of dose #3 of placebo, the patient will be administered the conditioning dose of melphalan (200mg/m^2) as per institutional practice.
~On the following morning of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #4 of placebo.
~On the evening of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #5 of placebo.
~On the following morning of Day 0 (12 +/- 2 hours from prior dose) patients will receive dose #6 (final dose) of placebo.
~On Day 0, 4 hours (+/- 2 hours) after the final dose of placebo, the patient will be infused with the HSC product. The patient will remain inpatient until engraftment"
16299084|NCT04682392|Active Comparator|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|This group will use Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction for rehab.
16299085|NCT04682392|Active Comparator|Non Delfi PTS Personalized Tourniquet System for Blood Flow Restriction Group|Standard post operative ACL rehab without Blood flow restriction
16299086|NCT04682379||AIS with Proprioceptive Defect|AIS subjects possessing statistically significant difference on testing outcomes compared with healthy controls.
16299087|NCT04682379||AIS without Proprioceptive Defect|AIS subjects with similar testing results compared with healthy controls.
16299088|NCT04682366|Experimental|Tamsulosin|Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
16299089|NCT04682366|Placebo Comparator|Placebo|Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.
16299090|NCT04682353|Experimental|Group 1 - 120 mg/0.4 mL|
16299091|NCT04682353|Experimental|Group 2 - 180 mg/0.6 mL|
16299092|NCT04682353|Experimental|Group 3 - 240 mg/0.8 mL|
16299093|NCT04682353|Active Comparator|Group 4 - 104 mg/0.65 mL|
16299094|NCT04682340||Hashimoto's Group|Thyroid antibody positive and hypothyroidism
16299095|NCT04682340||Graves' Group|Thyroid antibody positive and hyperthyroidism
16299096|NCT04682340||Control Group|Thyroid antibody negative and euthyroidism
16299097|NCT04682327||Responder group|"After the 4 cycles of anti-PD-1/PD-L1 mAbs treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .
~Responders are defined as complete remission, partial remission, or stable disease."
16299098|NCT04682327||Nonresponder group|"After the 4 cycles of anti-PD-1/PD-L1 treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .
~Nonresponders are defined as disease progression."
16299099|NCT04682301||Observational (focus group, interview)|"AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining potential methods of SDM.
~AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback. Participants may attend a telephone interview over 45 minutes 1 month later."
16299100|NCT04682288|Experimental|Levofloxacin Ocular Implant|Biphasic levofloxacin antibiotic implant
16299101|NCT04682275|Other|Female Group|Females with periodontal disease (71 subjects with gingivitis, 100 subjects with periodontitis)
16299102|NCT04682275|No Intervention|Male Group|males with periodontal disease (72 subjects with gingivitis, 96 subjects with periodontitis)
16299103|NCT04682262|Experimental|Cervical dilatation|Patients receive cervical dilatation up to 10 millimeter Hegar dilator under general anaesthesia. Patient undergo standard hysteroscopy operation.
16299104|NCT04682262|No Intervention|Expectant|Patients are scheduled for follow-up.
16299105|NCT04682249|Experimental|Systemic Chemotheray, Apatinib plus Sintilimab|
16299106|NCT04682223|Experimental|Aphasia Remote Therapy (ART)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.
~All treatment will be done remotely with a speech-language pathologist through an online platform using therapy applications. Participants will be provided with teletherapy kits (including an Internet hotspot if needed) to complete the therapy tasks."
16299107|NCT04682223|Active Comparator|In-Clinic Therapy (I-CT)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.
~All treatment will be done in person with a speech-language pathologist at the UofSC Aphasia Lab."
16299108|NCT04682210|Experimental|Arm A|sintilimab 200mg + bevacizumab 7.5mg/kg IV Q3W
16299109|NCT04682210|No Intervention|Arm B|Active surveillance
16299194|NCT04681573|Other|Single ARM|Only one arm
16299117|NCT04682158|Active Comparator|Chemoradiation Therapy - Group I|Patients receiving beta-blockers undergo radiation therapy in the form of IMRT or 3D CRT over 23-28 fractions for 5 days per week (Monday-Friday) for 5 weeks, and receive paclitaxel IV QW and carboplatin IV QW for 5 weeks in the absence of disease progression or unacceptable toxicity.
16299118|NCT04682158|Active Comparator|Chemoradiation Therapy - Group II|Patients undergo CRT as in Group I in the absence of disease progression or unacceptable toxicity.
16299119|NCT04682158|Experimental|Chemoradiation Therapy plus Propanolol|Patients undergo radiation therapy as in Group I. Patients receive propranolol PO BID for 4-6 weeks while receiving CRT in the absence of disease progression or unacceptable toxicity.
16299120|NCT04682145||Haemophilia A patients|All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS
16299121|NCT04682119|Experimental|LY3526318 (Part A)|LY3526318 administered orally as single ascending doses.
16299122|NCT04682119|Experimental|LY3526318 (Part B)|LY3526318 administered orally as multiple doses.
16299123|NCT04682119|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
16299124|NCT04682119|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
16299125|NCT04682106|Experimental|LY3493269|Multiple doses of LY3493269 administered orally.
16299126|NCT04682106|Placebo Comparator|Placebo|Placebo administered orally.
16299127|NCT04682080|Active Comparator|Needle-free injection group|In needle-free injection techniques, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using the Comfort-In system. Pain intensity and anxiety levels of patients were measured.
16299128|NCT04682080|Active Comparator|Dental injection group|In the conventional dental-injection method, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using a 27G, 50-mm, disposable syringe with a needle. Pain intensity and anxiety levels of patients were measured.
16299129|NCT04682067|Experimental|Contingency Management|Participants in the contingency management (CM) treatment arm will receive the usual care (UC) treatment program offered at the Tobacco Treatment Research Program (TTRP) and will be eligible to earn gift cards at each weekly visit on their quit date up until four weeks post-quit for proof of abstinence. They will earn $20 in gift cards for quitting on the specified quit day (i.e., one week after the orientation visit), and this amount will increase by $5 with each successive weekly abstinent visit (i.e., up to $40 in gift cards at 4 weeks post-quit; up to $150 total).
16299130|NCT04682067|Placebo Comparator|Usual Care|Participants in the usual care (UC) group will receive the standard smoking cessation treatment offered at the Health Promotion Research Center's Tobacco Treatment Research Program (TTRP) at the University of Oklahoma. This includes at least 4 treatment sessions of counseling and the opportunity to use nicotine replacement therapy or medications.
16299131|NCT04682054|Experimental|surgically-removed eye tissue|
16299132|NCT04682041|Experimental|EnteraGam + standard of care|Subjects will receive EnteraGam® (oral nutritional therapy) + standard of care for COVID-19 for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
16299133|NCT04682041|Other|Control (standard of care)|Subjects will receive standard of care for COVID-19 alone for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
16299134|NCT04682028|Other|experiment group|Nurses provide web-based continuous care to patients.
16299135|NCT04682028|Other|contral group|Nurses provide the routine care to patients.
16299136|NCT04682015|Experimental|Intervention|The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
16299137|NCT04682015|No Intervention|Control|Control group will receive usual care and follow up in hospitals and community health centers.
16299138|NCT04682002|Experimental|OMT + multidisciplinary path|Patients in the experimental group will follow the obstetrician's and multidisciplinary path which provides osteopathic treatments, mindfulness, yoga, clinical nutrition, coaching and usual obstetric care.
16299139|NCT04682002|Other|Usual care|Patients in control group will continue the routine obstetrical care as established by international guidelines
16299140|NCT04681989|Experimental|MOVE-ABC intervention arm|"MOVE-ABC interventional group participants receive usual care plus the MOVE-ABC education instruction and materials. After the participant completes the baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:
~instructions on the education materials by a research staff member
~a range of motion wand
~a small ball
~MOVE-ABC education booklet and video
~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment. The follow-up phone calls are expected to take 20 - 30 minutes each time. During these follow-ups research staff will review material, and answer any questions the participant may have. All documentation of phone calls and questions asked by participants during these reviews will be captured in REDCap."
16299141|NCT04681989|No Intervention|Control/Usual Care arm|Control group participants will be measured at baseline and at 1 month follow-up. They receive usual care. Usual care does not include specialized, physical therapy-based education on recovery from breast cancer.
16299142|NCT04681976|Experimental|Intervention group|Intervention Group participants will perform a 3-month telematic dance program based on choreographic work, 2 times per week
16299143|NCT04681976|No Intervention|Control group|Control group will follow their daily routine without added exercise
16299144|NCT04681963||Suspected pneumonia diagnosis|Acutely admitted patients suspected having pneumonia.
16299145|NCT04681937|Experimental|Hyaluronic Acid + Physical Therapy|4 ml hyaluronic acid (subacromial)
16299146|NCT04681937|Experimental|Platelet-Rich-Plasma (PRP) + Physical Therapy|4 ml platelet-rich-plasma (subacromial)
16299147|NCT04681937|Experimental|Steroid + Physical Therapy|methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) (subacromial)
16299148|NCT04681937|Experimental|Placebo (serum saline) + Physical Therapy|4 ml serum saline (subacromial)
16299149|NCT04681924|Experimental|Low carb diet|Low carb diet (n=54)
16299150|NCT04681924|Experimental|Low fat diet|Low fat diet (n=40)
16299195|NCT04681547|Experimental|Genicular nerve block|An ultrasound-assisted genicular nerve block will be performed. 4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.
16299151|NCT04681911|Experimental|Inetetamab Combined With Pyrotinib and Chemotherapy|"Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
~Pyrotinib: 400mg, oral, every day.
~Chemotherapy: the choice of physicians，as the following regimens:
~Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle Carboplatin, AUC = 6, 3-week cycle Albumin paclitaxel, 100 mg/m2, weekly Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle"
16299152|NCT04681885|Experimental|Tapered bristles A|
16299153|NCT04681885|Active Comparator|Tapered bristles B|
16299154|NCT04681885|Active Comparator|End rounded bristles|
16299155|NCT04681872|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
16299156|NCT04681872|Active Comparator|Pulmonary vein isolation arm|
16299157|NCT04681859|Active Comparator|High Flow Nasal Oxygen (HFNO) treatment|
16299158|NCT04681859|Experimental|Continuous positive airway pressure (CPAP) therapy using OxyJet|
16299159|NCT04681833|Experimental|Cohort 1: BARS13 low repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.
16299160|NCT04681833|Placebo Comparator|Cohort 1: BARS13 placebo low repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
16299161|NCT04681833|Experimental|Cohort 2: BARS13 high repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.
16299162|NCT04681833|Placebo Comparator|Cohort 2: BARS13 placebo high repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
16299163|NCT04681833|Experimental|Cohort 3: BARS13 high repeat multiple dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.
16299164|NCT04681833|Placebo Comparator|Cohort 3: BARS13 placebo high repeat multiple dose|Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
16299165|NCT04681820||flumatinib|flumatinib 600mg QD, fasting administration
16299166|NCT04681820||nilotinib|nilotinib 400mg BID, fasting administration
16299167|NCT04681807|Experimental|Emotion Recognition Training|
16299168|NCT04681807|Active Comparator|Active Control Training|
16299169|NCT04681794|Experimental|MayoP4 Group|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, hopping/jumping, and movement-based mindfulness.
16299170|NCT04681794|No Intervention|Control Group|No intervention
16299171|NCT04681742|Experimental|CO-OP Group|10, 45-60 minute Cognitive Orientation to daily Occupational Performance intervention sessions
16299172|NCT04681729|Experimental|Dupilumab|Dose regimens, on top of regular or as needed non-sedating H1-antihistamine
16299173|NCT04681729|Placebo Comparator|Matched Placebo|Placebo,on top of regular/as needed non-sedating H1-antihistamine
16299174|NCT04681716|Active Comparator|ELDOA GROUP|ELDOA position was instructed to this group
16299175|NCT04681716|Experimental|CONVENTIONAL PHYSIOTHERAPY|Hot pack,TENS and mobalization was given in this group
16299176|NCT04681703|Experimental|Intervention group|In addition to usual care: a 1-h educational and training program conducted by the family nurse (FN) in a dedicated room of the ambulatory care centers. During the program, the nurse instructed patients on how to self-measure blood pressure (BP) using the BP self-measurement device and on the importance of adequate device maintenance. The intervention was carried out by the FN on a daily basis during outpatient visits of the participants to the general practitioner (GP).
16299177|NCT04681703|No Intervention|Conrol group|Management of hypertensive patients, usual care: verbal and written instructions during which the family nurse (FN) or general practitioner (GP) advised the patient to follow the recommendations regarding correct HBPM. A written summary of the recommendations was given to all participants by the GP or FN at the end of the training program.
16299178|NCT04681677|Experimental|Experimental: Intra-operative Radiation Therapy - IORT|Radiation: Intra-operative Radiation Therapy - IORT
16299179|NCT04681664|Experimental|50 % fat diet|In the high fat group the subjects were assigned to the diet containing in average 50 % fat, 25 % proteins and 25 % carbohydrates for four weeks.
16299180|NCT04681651|Experimental|NBO group|Normobaric Hyperoxia combined with endovascular mechanical thrombectomy
16299181|NCT04681651|Placebo Comparator|Control group|Inhale air placebo plus endovascular mechanical thrombectomy
16299182|NCT04681638|Experimental|Plasma|Pathogen-Reduced Plasma resuscitation
16299183|NCT04681638|Active Comparator|Crystalloid|Standardized crystalloid resuscitation
16299184|NCT04681625|Active Comparator|Standard silodosin treatment|Peroral treatment with silodosin at a dose of 8 mg daily
16299185|NCT04681625|Experimental|Standard silodosin treatment with PFMT|Peroral treatment with silodosin at a dose of 8 mg daily Intervention: Behavioural: Pelvic floor muscle training (PFMT) with suppressive urgency technique
16299186|NCT04681612||MINOCA|Patients hospitalised with MINOCA according to the recently published consensus document of ESC after cardiac MRI confirmation.
16299187|NCT04681599|No Intervention|Nebulization without filter or scavenger|Subject will use a standard nebulizer
16299188|NCT04681599|Experimental|Nebulization with a filter or scavenger|Subject will use a nebulizer with a filter placed at the other end of nebulizer mouthpice or a scavenger outside the nebulizer mask
16299189|NCT04681599|No Intervention|High-flow nasal cannula|Subject will use high-flow nasal cannula at 40 L/min
16299190|NCT04681599|Experimental|High-flow nasal cannula with a scavenger face tent|Subject will use high-flow nasal cannula at 40 L/min, with a scavenger face tent
16299191|NCT04681599|Active Comparator|High-flow nasal cannula with a surgical mask|Subject will use high-flow nasal cannula at 40 L/min, with a surgical mask over nasal cannula
16299192|NCT04681586|Experimental|Bright white light|
16299193|NCT04681586|Placebo Comparator|Dim red light|
16299202|NCT04681508|Experimental|All patients|All patients undergo chest CT without contrast enhancement and chest X-ray. Blood and urine sampling from patients subsequently undergoing emergency laparoscopy or laparotomy. Otherwise standard care
16299203|NCT04681495|Other|Usability of Bullying Prevention Online Application|This intervention has a single arm. It consists of conducting focus groups and usability testing of a bullying prevention online application for middle-school-aged students.
16299204|NCT04681482||Apixaban Group|The cohort prescribed apixaban and diagnosed with Atrial Fibrillation
16299205|NCT04681482||Warfarin Group|patients prescribed warfarin only diagnosed with Atrial Fibrillation.
16299206|NCT04681469|Experimental|Single Arm Treatment|"For all patient's population:
~Niraparib 200 mg/day: day -49 to day -21;
~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.
~If no clinical evidence of disease progression:
~Niraparib 200 mg/day: day -21 to day -7
~Dostarlimab 500 mg iv: day -7
~Radiological assessment (day -1, ± 3 days),
~Surgery (original margin) at day 0 (±3 days)
~Standard postoperative (chemo)radiotherapy according to pathologic report;
~Maintenance Niraparib, 200 mg/day for 6 months
~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
16299207|NCT04681443|Active Comparator|Successful treatment|Patients with successfully treated pilonidal sinus disease
16299208|NCT04681443|Active Comparator|Treatment failure|Pilonidal sinus disease patients with treatment failure
16299209|NCT04681430|Experimental|convalescent plasma (CP)|Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1
16299210|NCT04681430|Other|Standard of Care|Standard of care allowed
16299211|NCT04681430|Experimental|Camostat Mesilate|Tablets 600 mg per day in 3 doses over 7 days
16299212|NCT04681430|Placebo Comparator|Placebo camostat|Placebo Tablets in 3 doses over 7 days (blinded)
16299213|NCT04681417|Experimental|Study 1: Melphalan or Melphalan + Topotecan|Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
16299214|NCT04681417|Other|Study 2: Etoposide, carboplatin and vincristine|Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.
16299215|NCT04681404|Active Comparator|Total Knee Arthroplasty (TKA)|Patients intended to undergo surgery for total knee arthroplasty
16299216|NCT04681404|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patients intended to undergo surgery for unicompartmental knee arthroplasty
16299217|NCT04681404|No Intervention|Healthy Control|
16299218|NCT04681391||anodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During anodal tDCS, the anode was placed over right temporoparietal junction, and the cathode was placed over left supraorbital area.
16299219|NCT04681391||cathodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During cathodal tDCS, the cathode was placed over right temporoparietal junction, and the anode was placed over left supraorbital area.
16299220|NCT04681391||sham (as a control condition)|same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds.
16299221|NCT04681378|Active Comparator|Classical double layer closure|a holding Vicryl 1-0 was placed in the in the left corner to stabilize and define the demarcation of the suture line. A continuous unlocked stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, including the decidual layer. The second unlocked stitch was performed by Vicryl 1-0 in a lateral -lateral (horizontal) position, adapting the first layer. Up to three additional single sutures were added for hemostasis if required.
16299222|NCT04681378|Active Comparator|Turan technique|beginning in one corner, the incision is closed using Vicryl 1-0 stitch. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously in the form of a purse string closure. With this technique, the original string is returned to the starting point and tied with a knot. Following the double layered purse-string closure, the aperture left in the middle of the uterine incision is closed with one separate figure of eight suture
16299223|NCT04681378|Active Comparator|Double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
16299224|NCT04681365||Simulation Suite|Participating staff will use BubblePAPR and evaluate its function in the non-clinical simulation suite, ensuring that simulated tasks appropriate to role can be undertaken safely whilst wearing the Bubble
16299225|NCT04681365||Low-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered low risk (ie non-COVID-19).
16299226|NCT04681365||High-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered high risk (ie suspected or confirmed COVID-19).
16299227|NCT04681339||Pneumonia with antibiotics|Children with non-severe community acquired pneumonia and fever: managed with antibiotics
16299228|NCT04681339||Pneumonia without antibiotics|Children with non-severe community acquired pneumonia and fever: managed without antibiotics
16299320|NCT04680663||Non-severe complications group|where the non-complicated patients is the patients running the normal postoperative course of surgery and without any need for intervention
16299321|NCT04680663||severe complications group|any deviation from the normal post-operative course
16299325|NCT04680637|Experimental|Efavaleukin Alfa Dose Level One + Standard of Care|
16299229|NCT04681326|Experimental|Biological prosthesis|The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia to allow the positioning of the transfix stitches necessary to the mesh fixation. Successively the retro-muscular rectum muscles plane will be prepared by the separation of the rectum muscles from the posterior rectum-muscles fascia. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched placed at the cardinal and inter-cardinal points. The prosthesis will be placed with a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt (JP) 10 suction drain will be placed under the prosthesis. A JP 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate- reabsorbable-time suture. Another JP 10 suction drain will be placed over the anterior fascia. No subcutaneous suture. Skin stapler or interrupted stitches will be used to close.
16299230|NCT04681326|No Intervention|Standard of care|Normal abdominal wall closure
16299231|NCT04681300||Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis|
16299232|NCT04681300||Patients with plastic surgery interventions|
16299233|NCT04681287|Experimental|inetetamab and PD-1 inhibitor combined with chemotherapy.|
16299234|NCT04681274||patient with hepatocellular carcinoma|Phenotype signature database building Image features extraction and clustering
16299235|NCT04681235|Experimental|Training Group|Training Group recieved 10 sessions on VR (Grail Motekforce, Netherlands) during two weeks. One session lasted 40 minuties.
16299236|NCT04681222||LFCN|Patients received LFCN + PENG blocks
16299237|NCT04681222||Wound Infiltration|Patients received wound infiltration + PENG blocks
16299238|NCT04681209|Experimental|DRT-Condition|This is the experimental group that engaged in the DRT-based intervention activity.
16299239|NCT04681209|Active Comparator|Empathy-Condition|This is the experimental group that engaged in the empathy-based intervention activity.
16299240|NCT04681196||patients affected by OSA treated with CPAP / paradox effect group|patients with obstructive sleep apnea, exhibiting persistent obstructive events and paradoxical obstruction when wearing oronasal masks during CPAP, that were fully recovered with the shift to nasal one with the same or also lower pressure
16299241|NCT04681196||patients affected by OSA treated with CPAP / control group (no paradox effect)|patients with obstructive sleep apnea, with no obstructive events when wearing oronasal masks during CPAP
16299242|NCT04681170|Other|Age 5-10 years|Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
16299243|NCT04681170|Other|Age11-15years|Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
16299244|NCT04681170|Other|16 to ≤17 years|Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
16299246|NCT04681131|Experimental|CAB-AXL-ADC (BA3011)|CAB-AXL-ADC (BA3011) alone
16299247|NCT04681131|Experimental|CAB-AXL-ADC (BA3011)+PD-1 inhibitor|CAB-AXL-ADC (BA3011) with PD-1 inhibitor
16299248|NCT04681105|Experimental|Treatment (flotetuzumab)|"INDUCTION THERAPY: Patients receive flotetuzumab via continuous IV infusion on days 1-28. Patients who achieve SD/PR (Cohort A) or PR/CI (Cohort B), receive an additional induction cycle. Patients who achieve PR (Cohort A) or PR/CI/MMR (Cohort B) after cycle 2 re-induction, may continue induction therapy for up to 4 more cycles.
~CONSOLIDATION THERAPY: Patients who achieve CR/CRi/CRh/MLFS (Cohort A) or CR/MR (Cohort B) after cycle 1 or cycle 2 of induction therapy, receive flotetuzumab via continuous IV infusion on days 1-28 for up to 5 and 6 cycles, respectively, in the absence of disease progression or unacceptable toxicity. Patients with PR (Cohort A) or PR/CI/MMR (Cohort B) who have received up to 6 cycles of induction therapy may receive up to 2 cycles of consolidation therapy in the absence of disease progression or unacceptable toxicity."
16299249|NCT04681092|Experimental|AKS-452 s.c.(A)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL) single-dose
16299250|NCT04681092|Experimental|AKS-452 s.c. (B)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL), two-dose
16299251|NCT04681092|Experimental|AKS-452 s.c. (C)|Subcutaneous injection of pre-defined dose (45 ug, 205 uL), single-dose
16299252|NCT04681092|Experimental|AKS-452 s.c. (D)|Subcutaneous injection of pre-defined dose (45 ug, 250 uL), two-dose
16299253|NCT04681092|Experimental|AKS-452 s.c. (E)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), single-dose
16299254|NCT04681092|Experimental|AKS-452 s.c. (F)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), two-dose
16299255|NCT04681092|Experimental|Phase 2, single-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (90 ug, 500 uL)
16299256|NCT04681092|Experimental|Phase 2, two-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (45 ug, 500 uL) twice.
16299257|NCT04681079||Crossover Sequence 1|Subjects randomized to receive commercially available albuterol sulfate via MDI with spacer first, followed by albuterol sulfate via nebulizer with filtered mouthpiece.
16299258|NCT04681079||Crossover Sequence 2|Subjects randomized to receive commercially available albuterol sulfate via nebulizer with filtered mouthpiece first, followed by albuterol sulfate via MDI with spacer.
16363476|NCT04233892|Experimental|Collagen/BMMNCs|
16299263|NCT04681053|Active Comparator|Group (A) received both oral and inhaled ivermectin in addition to the standard of care.|use oral and inhaled ivermectin
16299264|NCT04681053|Active Comparator|B) received oral ivermectin in addition to the standard of care|receive oral ivermectin
16299265|NCT04681053|Active Comparator|c) received inhaled ivermectin in addition to the standard of care|received inhaled ivermectin
16299266|NCT04681053|No Intervention|Group (d) received the current standard of care only|received standard of care only
16299267|NCT04681040||UrBMC19 Group (International Cooperative Group)|The examination of urine for mild pre-diagnosed COVID-19 cases are conducted to evaluate the risk classification and detect the effectiveness of early intervention by COVID-19 treatment such as dexamethasone, chloroquine, remdesivir, ivermectin, actemra, and so forth within the period of 14 days after starting the intervention.
16299268|NCT04681027|Active Comparator|Pediatric Age Groups: 7 to ≤12 years|Participants expected to require ATC opioids for an extended period of time
16299269|NCT04681027|Active Comparator|Pediatric Age Groups: 13 to ≤17 years|Participants expected to require ATC opioids for an extended period of time
16299270|NCT04681001|Experimental|Coldamaris pro|One puff per nostril three puffs into mouth
16299271|NCT04681001|Placebo Comparator|Coldamaris sine|One puff per nostril three puffs into mouth
16299272|NCT04680988|Experimental|Doublet Arm|SHR-1210+SHR-1020
16299273|NCT04680988|Experimental|Single Arm|SHR-1210
16299274|NCT04680988|Active Comparator|Physician's choice chemotherapy|Albumin-bound paclitaxel injection or Pemetrexed disodium for injection or Gemcitabine for injection
16299275|NCT04680975|Experimental|Belumosudil 200 mg PO BID|Subjects will receive open-label belumosudil 200 mg orally twice daily
16299276|NCT04680962|Experimental|MabionCD20 / MabionCD20|Patients receive one or two treatment courses of MabionCD20, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
16299277|NCT04680962|Active Comparator|EU-Rituximab / EU-Rituximab|Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
16299278|NCT04680962|Active Comparator|US-Rituximab / MabionCD20|Patients receive a single treatment course of Rituxan®, consisting of two 1000 mg i.v. infusions at Day 1 and Day 15. After 24 weeks of follow-up, all patients eligible for re-treatment, are switched to receive a single treatment course of MabionCD20, consisting of two 1000 mg i.v. infusions at Week 24 and Week 26.
16299279|NCT04680949|Placebo Comparator|Placebo|Patients receiving standard-of-care (SOC) and placebo. Placebo is injected subcutaneously once daily for 10 days
16299280|NCT04680949|Experimental|Anakinra|Patients receiving SOC and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
16299281|NCT04680936|Active Comparator|low dose dextrose arm (5% dextrose)|Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
16299282|NCT04680936|Active Comparator|high dose dextrose arm (15% dextrose)|Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
16299283|NCT04680936|Active Comparator|Isotonic saline arm (0.9% NaCl)|Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
16299284|NCT04680923|Experimental|CPPLAI|Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.
16299285|NCT04680923|Placebo Comparator|Placebo|Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.
16299287|NCT04680897|Other|Standard Group|Participants may resume vaginal penetration at 6 weeks.
16299288|NCT04680897|Other|Early Group|Participants may resume intercourse at 2 weeks
16299289|NCT04680884|Experimental|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
16299290|NCT04680884|Experimental|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
16299291|NCT04680884|Experimental|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
16299292|NCT04680884|Other|Best standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
16299293|NCT04680871||Normal Temperature Subjects|"Subjects will sit for 20 to 30 minutes. The subject may be covered with a blanket. At the end of the wait period, a homogeneous temperature will be taken from both thermometers. The subjects will be disconnected from the devices and excused.
~The study is expected to take 30 minutes to an hour for each normal temperature subject."
16299322|NCT04680650|Experimental|Group DS|Anesthesia was maintained with sevoflurane and target-controlled infusion of remifentanil in the group DS
16299323|NCT04680650|Active Comparator|Group DP|Anesthesia was maintained with propofol and target-controlled infusion of remifentanil in the group DP
16299294|NCT04680871||Induced Febrile Subjects|"Heating of the body will be created using multiple heating devices. A vapor barrier will cover the entire body of the subject from the base of the neck down, including the feet. The purpose of the vapor barrier is to prevent evaporative cooling during the heating period. Subjects will then sit in an infrared sauna. Electric heating pads will be placed on the back, torso, and/or feet. Finally, a nylon cape will be placed over the body from the base of the neck to the floor and a head covering will be placed on the head. (See Figure 2 for reference)
~During the Warming period (approximately 90 minutes) the sublingual temperature will be raised to a minimum of 99.5°F (as determined by the Reference Clinical Thermometer). A febrile temperature will be recorded from both thermometers."
16299295|NCT04680858|No Intervention|Standard Communication|Endoscopic procedures performed by skilled endoscopic team with standard communication (no headset)
16299296|NCT04680858|Experimental|DECT enhanced Communication|Endoscopic procedures performed by skilled endoscopic team with enhanced communication tools ( DECT headset)
16299297|NCT04680845|Experimental|Self-affirmation|"Participants will be asked to complete a standard questionnaire including:
~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.
~If I feel threatened or anxious, then I will… …think about the things I value about myself
~remember things that I have succeeded in
~think about what I stand for
~think about things that are important to me
~If…______________________________________________________________________"
16299298|NCT04680845|No Intervention|Control|Participants will be asked to complete a standard questionnaire.
16299299|NCT04680832|Experimental|ILD patients|Patients diagnosed with one of the most prevalent fibrotic ILDs: IPF, CHP, CTD-ILD, iNSIP, IPAF, and unclassifiable ILD (defined as unclassifiable disease at the time of the first MDT).
16299300|NCT04680819||Compared with given anatolian propolis group and do not use anatolian propolis group|According to the spectrophotometic analysis report of this anatolian group, there should be a minimum phenolic 106.0 mg gae per ml and 73.1 mg ke flavonoid content in each ml and a total content of 253.9 mg te / ml.
16299301|NCT04680806|Experimental|Er,Cr:YSGG laser 2780 nm|Group A was treated by an Er,Cr:YSGG laser 2780 nm cylindrical tip (tip 600 μm, 45 millijoule /pulse, average power 2.25 W, frequency 50 Hz, pulse duration 60 µs, energy density 43 J/cm2, water 50%, and air 40%). The procedure was performed completely without anesthesia with the laser tip at angulation ~30° and distance of ~1 mm from the gingival tissue. The laser tip was advancing in scanning movement from in the cervical-apical direction in all pigmented areas. The following settings was used to achieve hemostasis in case of the bleeding was present (tip 600 μm, 30 millijoule /pulse, average power 1.5 W, frequency 50 Hz, pulse duration 700 µs, energy density 28.7 J/cm2, water 10%, and air 20%).
16299302|NCT04680806|Experimental|Diode laser 940 nm|Group B was treated with diode 940 nm Laser. The procedure was performed with a pencil-sized handpiece containing a 400 µm lasing fiber (400 μm initiated tip, average power 0.8 watts, Pulsed mode, Duty cycle 20%, Pulse duration 10 μs, energy density 636.9 J/cm2 per second, no water or air). Infiltration anesthesia was injected for B group . The laser tip was placed in angle ~30° with the gingival surface. Short light paint brush strokes were used in the cervical-apical direction in all pigmented areas.
16299303|NCT04680793|Other|EDS Patients|No intervention during the control period (9 weeks) and then experimental during the rehabilitation stage (9 weeks).
16299304|NCT04680780|Experimental|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 month
16299305|NCT04680780|Experimental|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months.
16299306|NCT04680780|Placebo Comparator|Control|Patients are allowed to eat ad libitum
16299307|NCT04680767|Experimental|[¹⁴C]-LY3502970|A single dose of LY3502970 and [¹⁴C]-LY3502970 administered orally.
16299308|NCT04680754|Experimental|Experimental Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to patients in experimental group after thyroidectomy. A brochure was developed in line with the literature on head-neck stretching exercises. Since the patients came to the clinic on surgery day, the exercises were examined by the patient on the first postoperative day. The patient was asked to perform the exercises 3 times a day, in the morning, noon and evening for a month, provided that each movement was 5 times. Then, the Patient and Observer Scar Rating Scale (POSAS)  was applied.
~The pain level of the patient on postoperative day 1 was evaluated using VAS. For further evaluations, the patient was called by phone at the 1st week and 1st month. Neck pain and discomfort status was evaluated with the Neck Pain and Disability Scale (NPAD), and then the scar appearances with the Patient and Observer Scar Assessment Scale by requesting neck photographs at the 1st week and 1st month."
16299309|NCT04680754|No Intervention|Control Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to the control group after thyroidectomy. Follow-up of the patients with the scales applied in the experimental group were also performed to the control group at the same intervals. After thyroidectomy, patients were called by phone in the 1st week and 1st month. Neck pain and discomfort scale and Patient and Observer Scar Rating Scale were applied again in both phone calls. Photographs of the scar appearance at the 1st week and the 1st month were requested from the patients."
16299310|NCT04680741|Experimental|Addiction Pilot App|"Patients in this arm will be asked to use an application that works by allowing patients to check in to meetings and tracks patients' location for a period of 90 days.
~Patients will be asked to download the application to their smart phone. At each of patients' usual meetings we will ask patients to check in and check out of the meeting via the App. At the conclusion of this study patients may be invited to participate in a focus group."
16299311|NCT04680728||patient|Patient admitted to intensive care for less than 24 hours.
16299312|NCT04680715|Experimental|Per-Operative Radiotherapy technique by Papillon +TM|Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM
16299313|NCT04680702|Experimental|Metabolic Syndrome and Sims Score|
16299314|NCT04680689||Fuse-Heart -SG 01|Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.
16299315|NCT04680689||Fuse-Heart -SG 02|Study subjects surviving an acute myocardial infarction, revascularized or not.
16299316|NCT04680676|Experimental|BI 730357 - low dose|
16299317|NCT04680676|Experimental|BI 730357 - medium dose|
16299318|NCT04680676|Experimental|BI 730357 - high dose|
16299319|NCT04680676|Placebo Comparator|Placebo|
16299326|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Two + Standard of Care|
16299327|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Three + Standard of Care|
16299328|NCT04680624|Other|Single Group|
16299329|NCT04680611||Patients with severe eosinophilic asthma Phase 1|Patients with severe eosinophilic asthma on Nucala(R) treatment
16299330|NCT04680611||Patients with severe eosinophilic asthma Phase 2|Patients with severe eosinophilic asthma to start Nucala(R) treatment
16299331|NCT04680611||Partners of patients with severe eosinophilic asthma Phase 2|Partners of patients with severe eosinophilic asthma to start Nucala(R) treatment
16299332|NCT04680611||Phase 3: Patients with severe eosinophilic asthma from Phase 2|A sub-group of patients who participate in Phase 2
16299333|NCT04680611||Phase 3: Partners of patients in Phase 3|Partners of the sub-group of patients who participate in Phase 3
16299334|NCT04680598||high HBV-DNA group|patients with HBV-DNA >500 IU/ml
16299335|NCT04680598||low HBV-DNA group|patients with HBV-DNA≤500 IU/ml
16299336|NCT04680585|Other|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
16299337|NCT04680585|Experimental|MOVIN|Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
16299338|NCT04680572|Active Comparator|Bipolar hemiarthroplasty group|
16299339|NCT04680572|Active Comparator|Dual mobility cups total hip replacement group|
16299340|NCT04680559|Experimental|MCBI Group|Training in mindfulness and compassion (MCBI) is facilitated in eight weekly sessions of 2 hours. With a didactic format, through theory, class discussions, and guided meditation practices.
16299341|NCT04680559|Active Comparator|Active-Wait List Group|Completion of a record during these 8 weeks. Active work of introspection about one's own sensations, thoughts, distractions, judgments, etc. in therapy sessions. Registered after each session.
16299342|NCT04680533|Experimental|TENS device - Type 1|The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
16299343|NCT04680533|Experimental|TENS device - Type 2|The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs. It has different timing settings for the treatment and rest periods than the Type 1 device.
16299344|NCT04680520|Experimental|Best practice skin care advice booklet plus emollient (Doublebase Gel® or Diprobase Cream®)|Use of emollient (Doublebase Gel® or Diprobase Cream®) plus best practice skin care advice. The advice is given in the form of a booklet containing advice on skin care. This will contain information on avoiding soap etc. It will also explain how to apply the emollient i.e. in the direction of the hair, all over the child's skin daily for the first year of life. Intervention group will receive both emollients and parents are asked to choose their preferred.
16299345|NCT04680520|Active Comparator|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
16299346|NCT04680494|Experimental|Rest|Participants rest quietly for 30 minutes, sitting on a chair. They may read magazines not involving motion-related elements
16299347|NCT04680494|Experimental|Moderate intensity exercise|Participants cycle on a cycle ergometer during 30 minutes at 65% of their maximal cardiac frequency
16299348|NCT04680494|Experimental|High intensity exercise|Participants cycle on a cycle ergometer during 15 minutes at 75% of their maximal cardiac frequency. This session also includes 3 minutes of warm-up and three minutes of cool down at 50% of their maximal cardiac frequency
16299349|NCT04680481|Experimental|Stimulation Theta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 4 Hz (theta condition).
16299350|NCT04680481|Experimental|Stimulation Beta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 23 Hz (beta condition).
16299351|NCT04680468|Experimental|Belantamab mafodotin|Patients receive Belantamab mafodotin 2.5 mg/kg by intravenous infusion on day -42 relative to autologous stem cell infusion (day 0), on day +60, and every 90 days thereafter, for up to 2 years following ASCT.
16299352|NCT04680455|Experimental|Resistance Training + (RT+)|"Participants in RT+ group will be asked to exercise three times per week and perform four basic RT exercises in a circuit manner for 12 weeks while supervised via an online platform such as Skype or TEAM.
~The first four weeks of sessions will be fully supervised. Participants will be eased into the program using a three-week progressive start, completing 120 minutes of exercise in week one, 150 minutes in week two, 180 minutes in week three and week four. Participants will be supervised 3X/week for the first four weeks, then 2X/week for the next four weeks and 1X/week for the remaining four weeks.
~At each session, a participant will perform the four prescribed exercises (i.e., squats, tricep dips, lunges, and push-ups) for 45 seconds each, then switch immediately (15 seconds) to the next exercise followed by one-minute of rest at the end of each circuit. The circuit will repeat until the session is complete."
16299353|NCT04680455|No Intervention|Standard care|Participants allocated to the control standard care group will receive free access to an exercise platform (V-Shred-Ripped-in-90-days) for the same period of time (12 weeks) to become more active. It will be recommended that they do a minimum of 150 minutes of moderate to vigorous aerobic activities and two resistance training sessions using the platform.
16299354|NCT04680442|Active Comparator|Control Group|Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations.
16299385|NCT04680182|Active Comparator|Control group|When the drain produces less than 100 mL over 24 hours, the self-suction bulb is removed and the drain is shortened and drained into a colostomy bag placed around the site of drain insertion. A request is filed with the community nursing system to have a visiting nurse to pull out the drain 1-2 cm per day.
16299475|NCT04679558|Experimental|Intervention|Adding chlorhexidine to the preventive protocol
16299355|NCT04680442|Experimental|Intervention Group|The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the criteria listed in Table 3. For reasons of practicality, in the intervention group, the first dose of trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) after randomization can be administered up to 3 weeks late. This will allow time for the participant to be reviewed by a cardiologist and to receive ACE-I/angiotensin receptor blocker and/or beta-blocker, and for dose titration.
16299356|NCT04680429|Experimental|RP7214, Single and multiple doses|"In Part 1 up to 3 cohorts with single ascending doses of RP7214 at 100 mg QD, 200 mg QD and 400 mg QD.
~In Part 2 up to 2 cohorts with multiple ascending doses of RP7214 at 200 mg BID, 400 mg BID."
16299357|NCT04680429|Placebo Comparator|Placebo, Single and multiple doses|In Part 1 up to 3 cohorts and in Part 2 up to 2 cohorts with matching placebo to RP7214 tablet
16299358|NCT04680403|Experimental|supervised exercise plan|patients will receive a tailored exercise regimen and behavior change techniques focused on adherence to the exercise program. These will be delivered by using a video platform, much liker telehealth clinic appointments. These telehealth visits will be over a 12-week period, occur 3 times a week, and last for 1 hour each.
16299361|NCT04680377||Participants receiving standard of care durvalumab|Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment
16299362|NCT04680364|Experimental|participants|to analyze the effects of 6-month ballroom dance (3 times/wk) on physical fitness and reaction time in twenty-four experienced older adults
16299363|NCT04680351|Experimental|phrenic stimulation|
16299364|NCT04680338|Active Comparator|Cardiac magnetic resonance imaging|Cardiac magnetic resonance (CMR) stress perfusion imaging with feedback of clinically actionable findings
16299365|NCT04680338|No Intervention|Control|No intervention, following the natural course of coronary atherosclerosis
16299366|NCT04680325|Placebo Comparator|Placebo juice|
16299367|NCT04680325|Active Comparator|Cranberry juice|
16299368|NCT04680286|Placebo Comparator|Placebo|A 5 ml syringe with saline will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
16299369|NCT04680286|Experimental|Methadone|A 5 ml syringe with 1 mg/ml of methadone will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
16299370|NCT04680273|Experimental|Part 1: [14C]-GDC-9545|Participants will be enrolled to receive a single dose of Carbon-14 labelled [14C]-GDC-9545.
16299371|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BCD|Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
16299372|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BDC|Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
16299373|NCT04680260|Active Comparator|A: Standard of care|Standard decision making regarding adjuvant chemotherapy with fluoropyrimidine and oxaliplatin as per institutional standards.
16299374|NCT04680260|Experimental|B: ctDNA guided therapy approach|Post ablation ctDNA results will be used for treatment decision.
16299375|NCT04680247|Active Comparator|VA-LCP|Osteosynthesis with a VA-LCP system
16299376|NCT04680247|Active Comparator|NCB-PT|Osteosynthesis with a NCB-PT system
16299377|NCT04680234|Active Comparator|Cryotherapy group|Patients underwent superficial cryotherapy using dimethyl ether and propane (DMEP) at -57C very 2 weeks for maximum six sessions
16299378|NCT04680234|Active Comparator|Microneedling group|Patients underwent microneedling 2 weeks for maximum six sessions
16299379|NCT04680221|Active Comparator|Treatment|The transversus abdominis plane block is a procedure involving injection of a local anesthetic solution into the abdominal plane between the internal oblique muscle and the transversus abdominis muscle. In our institution, this is done under ultrasound guidance which is the current standard to improve efficacy and limit complications. Liposomal bupivacaine uses an innovative technology consisting of lipid-based particles containing active pharmaceutical agent (bupivacaine) which extends the duration of the medication through a process of gradual release for metabolism.This drug delivery technology extends the duration of action to up to 96 hours when given at a dose of 266 mg liposomal bupivacaine admixed with 30 ml of bupivacaine 0.25% and 30 ml of saline. Forty ml of solution is deposited on the left side of the abdomen and 40 ml on the right.
16299380|NCT04680221|Placebo Comparator|Control|The transversus abdominis plane block will be performed under ultrasound guidance with deposition of 80 ml of saline (40 ml on either side).
16299381|NCT04680208||Planned ICU admission|Cases who were planned for postoperative ICU admission at the time of preanesthetic check up
16299382|NCT04680208||Unplanned ICU admission|Cases who got admitted to ICU postoperatively without anticipation
16299383|NCT04680195|Experimental|Thalidomide treatment Group|"Induction period:
~Thalidomide tablets: 50-100 mg/d, qn, po.
~Maintenance period:
~Thalidomide tablets: 50-75 mg/d qn, po."
16299384|NCT04680182|Experimental|Study group|Wound drain is kept until until a scheduled visit three weeks after the surgery unless the drain produced less than 30 ml/day for two consecutive days, in which case it could be removed earlier.
16299386|NCT04680169|Active Comparator|Group A: Bronchoscopic intubation using AuraGain LMA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using AuraGain
16299387|NCT04680169|Active Comparator|Group B: Bronchoscopic intubation with I-gel SGA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using I-gel
16299388|NCT04680156||EN3835|Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies
16299389|NCT04680156||Placebo|Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies
16299390|NCT04680143|Experimental|Systemic erythropoietin injections|The study included 10 patients diagnosed as post papilledemic optic atrophy
16299391|NCT04680130||Neurodegenerative symptoms|
16299392|NCT04680117|Other|Cases with SA, classified by age group|Patient hospitalized for assessment of severe asthma
16299393|NCT04680117|Other|Controls among children w/ SA: frequent&infrequent exacerbators|Frequent exacerbators have 2 or more asthma severe exacerbations in the past years
16299394|NCT04680104||Cohort A|Infusion of Na-Lev plus 5-FU (unique administration by one 48h-infusional pump)
16299395|NCT04680104||Cohort B|Infusion of Ca-Lev followed by infusion of 5-FU (two separated administrations by using one plastic bag followed by one 48h-infusional pump)
16299396|NCT04680091|Experimental|Efavirenz 600 mg + Pyrotinib 400 mg|
16299397|NCT04680091|Active Comparator|Pyrotinib 400 mg|
16299398|NCT04680078|Active Comparator|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop. The sutures are removed 1 week after the surgery.
16299399|NCT04680078|Active Comparator|Conventional Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop.
16299400|NCT04680065|Experimental|Active Treatment|
16299401|NCT04680065|Sham Comparator|Placebo Surgery|
16299402|NCT04680052|Experimental|Arm A : tafasitamab + rituximab + lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
16299403|NCT04680052|Placebo Comparator|Arm B : placebo+rituximab+lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
16299404|NCT04680026|Experimental|Drug: HBI-3000, Stage A Dose Level 1|Stage A Open Label HBI-3000 Dose Level 1: 200 mg
16299405|NCT04680026|Experimental|Drug: HBI-3000, Stage A Dose Level 2|Stage A Open Label HBI-3000 Dose Level 2: 350 mg planned
16299406|NCT04680026|Experimental|Drug: HBI-3000, Stage A Dose Level 3|Stage A Open Label HBI-3000 Dose Level 2: 500 mg planned
16299407|NCT04680026|Experimental|Drug: HBI-3000, Stage B Dose Level 1|Stage B Double-blind placebo controlled, Cohort 1 HBI-3000 Dose Level 1: Selected based on Stage A results
16299408|NCT04680026|Experimental|Drug: HBI-3000, Stage B Dose Level 2|Stage B Double-blind placebo controlled, Cohort 2 HBI-3000 Dose Level 2: Selected based on Stage A, and Stage B Cohort 1 results
16299409|NCT04680013||Cognitive Control|Participants in this group are cognitively intact.
16299410|NCT04680013||Mild Cognitive Impairment|Participants in this group have mild cognitive impairment.
16299411|NCT04680013||Dementia Group|Participants in this group have dementia.
16299412|NCT04680000|Active Comparator|Standard BCBT-CP|Brief Cognitive Behavior Therapy for Chronic Pain (BCBT-CP) is a seven-module intervention for chronic pain based on the efficacious specialty-care, ten-session version of this treatment called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP).
16299413|NCT04680000|Experimental|Standard BCBT-CP with Telephone Booster|"Participants will receive standard BCBT-CP as described in the Standard BCBT-CP arm. They will also receive telephone or video teleconference booster contacts as follows:
~BCBT-CP Booster Contacts are intended to refresh BCBT-CP content without introducing new skills. To accomplish this, Booster Contacts are manualized (see appended Booster Protocol form) to cover assessment of pain since last contact, review of most recent BCBT-CP module(s) and reminder about the next BCBT-CP appointment (if one is scheduled)."
16299414|NCT04679987||paroxysmal Af|
16299415|NCT04679987||no paroxysmal Af|
16299416|NCT04679974|Experimental|MBCT treatment|Melodic-based communication treatment
16299417|NCT04679961||Experimental|"Epidermal inflammations, including eczematous diseases and psoriasis
~Epidermal tumors, including benign tumors and malignant tumors
~Pigmented diseases, including hypopigmentation and hyperpigmentation"
16299418|NCT04679961||Control|Healthy skin
16299419|NCT04679948|Experimental|Period 1 with reference treatment alone|
16299420|NCT04679948|Experimental|Period 2 with reference and test treatment|
16299421|NCT04679935|Experimental|Brolucizumab 6 mg non-loading|One initial injection followed by treatment every 12 weeks.
16299422|NCT04679935|Experimental|Brolucizumab 6 mg loading|3 x 4-weekly injections followed by treatment every 12 weeks.
16299423|NCT04679922|Active Comparator|Peri Implant mucosal thickness connective tissue graft|
16299424|NCT04679922|Experimental|Peri Implant mucosal thickness fascia lata graft|
16299425|NCT04679909|Experimental|Single Low Dose AdCOVID|
16299426|NCT04679909|Experimental|Single Medium Dose AdCOVID|
16299427|NCT04679909|Experimental|Single High Dose AdCOVID|
16299428|NCT04679909|Experimental|Two Low Doses AdCOVID|
16299429|NCT04679909|Experimental|Two Medium Doses AdCOVID|
16299430|NCT04679909|Experimental|Two High Doses AdCOVID|
16299433|NCT04679896|Experimental|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
16299434|NCT04679896|Other|Local autograft|
16299435|NCT04679883|Experimental|GLH8NDE 5% and GLH8NDE Placebo|Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo
16299436|NCT04679883|Experimental|GLH8NDE 5%|Total 6 times 1 drop of GLH8NDE 5%
16299437|NCT04679883|Placebo Comparator|GLH8NDE Placebo|Total 6 times 1 drop of GLH8NDE Placebo
16299439|NCT04679857|Experimental|UC|TKA with an ultracongruent insert
16299440|NCT04679857|Active Comparator|PS|TKA with posterior stabilized design
16299441|NCT04679844|Experimental|MagnetOs Putty|"Interventions
~Procedure: Instrumented posterolateral spine fusion
~Device; MagnetOs Putty"
16299442|NCT04679844|Active Comparator|Autograft Bone|"Interventions
~Procedure: Instrumented posterolateral spine fusion
~Device: Autologous bone graft"
16299443|NCT04679831|Experimental|Ujiplus® porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
16299444|NCT04679831|Active Comparator|Praziquantel 400mg|Arm receiving the approved Praziquantel treatment of 400mg once with plain porridge daily (without papaya seeds)
16299445|NCT04679818|Active Comparator|Control Group|Clinicians will be blinded to PMD-200 NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when.
16299446|NCT04679818|Active Comparator|PMD-200 NOL group|Clinicians will titrate fentanyl to keep PMD-200 NOL under 25 - always using good clinical judgement for individual patients
16299447|NCT04679792||operated|Patients Under 18 years of age who are operated for Chiari Malformation on the basis of routine neurosurgical assessment.
16299448|NCT04679792||non operated|Patients Under 18 years of age who are not operated for Chiari Malformation on the basis of routine neurosurgical assessment.
16299449|NCT04679779|Experimental|control group|receive occupational therapy program
16299450|NCT04679779|Experimental|study group|receive wii virtual reality
16299451|NCT04679766|Experimental|Patients with non-restorable tooth in maxillary bi-cuspid region with labial/buccal plate dehiscence|
16299452|NCT04679753|Active Comparator|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
16299453|NCT04679753|Active Comparator|Brainsway DTMS with High Frequency Stimulation (HF)|Brainsway DTMS with High Frequency Stimulation (HF)
16299454|NCT04679714|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
16299455|NCT04679701||Recruited Amputees|The amputee participants will be recruited over the course of 6 months. Once a patient is recruited and has given consent, they will be fitted with a prosthesis using the Confidence Socket technology and be administered an initial survey. A follow-up meeting for one month after the fitting is scheduled. At the follow-up appointment adjustments to the prosthesis are made as needed and the patient is administered another survey.
16299456|NCT04679675|Active Comparator|Usual Care|
16299457|NCT04679675|Active Comparator|Education|
16299458|NCT04679675|Active Comparator|Direct Mail|
16299459|NCT04679675|Active Comparator|Opt-in|
16299460|NCT04679662|Experimental|Single-arm study of PLAR Implant and Delivery System to treat severe mitral regurgitation|All enrolled patients will receive the study device
16299461|NCT04679649|Experimental|Trial A - Intervention Group (manual mobilisation)|Participants will continue to receive routine care and 13 sessions of manual spinal mobilisation will be administered over a 6 months period to compare routine care vs routine care plus manual spine mobilisation physiotherapy.
16299462|NCT04679649|No Intervention|Trial A - Control Group (routine care)|Participants in control group will continue to receive routine care, and routine care measurements for axial spondyloarthritis will be taken at baseline, 3 months and 6 months plus follow up.
16299463|NCT04679636|Experimental|Experimental group|receive biofeedback training for heart rate variability for eight weeks
16299464|NCT04679636|No Intervention|Control group|receive conventional treatment
16299465|NCT04679623|Experimental|Midazolam Injection|Midazolam injection, 10 mg
16299466|NCT04679623|Active Comparator|Seizalam™|Seizalam, 10 mg
16299467|NCT04679597||total neoadjuvant therapy|Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.
16299468|NCT04679597||standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
16299469|NCT04679584||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).
16299470|NCT04679584||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).
16299471|NCT04679584||Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).
16299472|NCT04679571|Experimental|Targeted Albumin with Standard Medical Treatment|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks
16299473|NCT04679571|Active Comparator|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.
~Follow up: 2 week, 4 weeks then every 3 months for 1 year"
16363477|NCT04233892|Experimental|Estrogen|
16299476|NCT04679545|Experimental|CBD|Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
16299477|NCT04679545|Placebo Comparator|Placebo Control|A placebo sublingual tablet to be taken three times a day for 28 days.
16299478|NCT04679532|Other|Validation. Gx sweat collection patch|Left ventral forearm placement using Epicore Biosystems Gx patch
16299479|NCT04679532|Other|Validation. Reference sweat collection patch|Right ventral forearm placement using a well-established methodology as published in peer-reviewed journals
16299480|NCT04679519|Active Comparator|Control|Control group that was not given a supplement.
16299481|NCT04679519|Experimental|BCAA|Supplement group that was given Branched Chain Amino Acids (BCAA).
16299482|NCT04679519|Experimental|Leucine|Supplement group that was given Leucine.
16299483|NCT04679519|Experimental|HMB|Supplement group that was given β-Hydroxy β-methylbutyric acid (HMB)
16299484|NCT04679493|Experimental|XC7 100 mg single|Cohort 1 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 100 mg (3 subjects) or placebo (1 subject, see placebo single arm)
16299485|NCT04679493|Experimental|XC7 200 mg single|Cohort 2 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 200 mg (3 subjects) or placebo (1 subject, see placebo single arm)
16299486|NCT04679493|Placebo Comparator|Placebo single|Placebo comparator arm will consist of 2 subjects (1 subject from Сohorts 1 and 2)
16299487|NCT04679493|Experimental|XC7 200 mg multiple|Cohort 3 - 6 subjects will be randomized in a 6:2 ratio to be treated either XC7 200 mg (6 subjects) or placebo (1 subject, see placebo multiple arm)
16299488|NCT04679493|Placebo Comparator|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 3
16299489|NCT04679480|Experimental|Intervention|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).
~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion at the trial site and administered as a flat 350mg dose in 100ml sodium chloride 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.
~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
16299491|NCT04679454|Experimental|Preoperative Radiation Treatment|
16299492|NCT04679441|Active Comparator|Healthy individuals Skills training only|These participants will receive CFSAT training only (n = 60). They will train for 24 hours over 12 weeks.
16299493|NCT04679441|Experimental|MCI, Skills training only|These participants will receive 24 hours of CFSAT training over 12 weeks following the same training protocol as the NC sample.
16299494|NCT04679441|Experimental|MCI, Combined treatment|Participants assigned to this condition will initially train for 3 weeks @ 60 minutes twice per week on CT (Posit Science). Participants will train 90 minutes on Double Decision and 30 minutes on Hawkeye. They can train on Hawkeye in 15- minute increments and intersperse it within the Double Decision training. They will then train CFSAT for 9 weeks at the recommended dosage. Each task will be trained twice before advancing to the next task
16299495|NCT04679415|Experimental|Standard of care + hzVSF-v13 200 mg at D1, hzVSF-v13 100mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
16299496|NCT04679415|Experimental|Standard of care + hzVSF-v13 400 mg at D1, hzVSF-v13 200mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
16299497|NCT04679415|Placebo Comparator|Standard of care + 3 doses of the placebo (normal saline) IV|Drug: Placebo (Normal saline solution) Dosage form: 0.9% NaCl Solution Frequency Frequency: Dose at Day 1, 3, 7 Other names: 0.9% Normal saline
16299498|NCT04679402|Experimental|Respiratory Muscle Training Breathing Low Dose Carbon Monoxide|Carbon monoxide 200 ppm in air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe the experimental gas through a mouthpiece with nose-clip in place.
16299499|NCT04679402|Sham Comparator|Respiratory Muscle Training Breathing Air|Air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe air through a mouthpiece with nose-clip in place.
16299500|NCT04679389|Experimental|Acetazolamide|Acetazolamide administered via capsule or liquid suspension. Capsule would be 250 mg oral capsules encapsulated by gelatin capsule and filled with lactose to match placebo. Liquid suspension would be 25 mg/mL oral suspension but adding 125 mg Acetazolamide tablets to suspending agent Ora-blend
16299501|NCT04679389|Placebo Comparator|Placebo|Placebo administered via capsule or liquid suspension. Capsule would be a gelatin capsule filled with lactose powder to match Acetazolamide. Liquid suspension would be Ora-blend.
16299502|NCT04679376|Experimental|Group 1|Atorvastatin (40 mg daily)
16299503|NCT04679376|Placebo Comparator|Group 2|
16299504|NCT04679363|Experimental|Active release technique group|Active release technique group (ART group) will receive Oscillatory mobilization with active release technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
16299505|NCT04679363|Experimental|Post isometric relaxation group|Post isometric relaxation group (PIR group) will receive Oscillatory mobilization with post isometric relaxation technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
16299506|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
16299507|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
16299508|NCT04679350|Experimental|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
16299509|NCT04679350|Placebo Comparator|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
16299510|NCT04679311|Experimental|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with 2 units of fresh frozen plasma that have been preselected to contain ACE activity ≥50 U/L
16299511|NCT04679311|Placebo Comparator|Normal Saline|Subjects will be treated with normal saline 500 cc.
16299512|NCT04679298||Apixaban|N=20
16299513|NCT04679298||Edoxaban|N=20
16299514|NCT04679298||Dabigatran|N=20
16299515|NCT04679298||Rivaroxaban|N=20
16299516|NCT04679259|Experimental|Cardiac surgical patients|
16299517|NCT04679246|Experimental|General Intervention|The strategies will be implemented in the three intervention elementary schools. The schools were conveniently chosen for the size of the student population. In addition to having a sufficient population, it was important that the authorities of each school site agreed to participate.
16299518|NCT04679246|Experimental|Subsample intervention|A group will be randomly selected from each school grade from the intervention schools, and within each chosen group 12 children will be randomly selected per group (48 children in total per school).
16299519|NCT04679246|No Intervention|Control|Three primary schools were selected from a close locality (Villa Corona, Jalisco). This was chosen because it is similar in relation to the social, economic, and geographical context to the locality of intervention. The schools were selected for the similarity in the size of the student population of the intervention schools.
16299520|NCT04679233|Experimental|Arm 1: Intervention Arm|Arm 1 will receive the aerobic prescription exercise intervention. As this is a feasibility and safety study, there will not be a second arm.
16299521|NCT04679220|Active Comparator|Non-heated Resin Composite group|Patients received Non-heated nanofilled resin composite on one side of the mouth
16299522|NCT04679220|Placebo Comparator|Preheated Resin Composite group|Patients received preheated nanofilled resin composite on the other side of the mouth
16299523|NCT04679194|Experimental|Mana 312|"Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days.
~Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses"
16299524|NCT04679181|Experimental|Active arm|use of telemedicine
16299525|NCT04679155|Experimental|eTRE|participants allocated to this group will be required to eat only between 0800h and 1600h.
16299526|NCT04679155|Active Comparator|lTRE|participants allocated to this group will be required to eat only between 1200h and 2000h
16299527|NCT04679142||Adult patients starting a treatment with Baclocur®|Baclofen(Baclocur®) 10mg, 20mg, 30mg, 40mg.
16299528|NCT04679129|Experimental|Single Ascending Dose-ASC42|ASC42 tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
16299529|NCT04679129|Experimental|Multiple Ascending Dose-ASC42|ASC42 tablet, Dose 1，Dose 2，Dose 3，q.d.×14 days
16299530|NCT04679129|Placebo Comparator|Single Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
16299531|NCT04679129|Placebo Comparator|Multiple Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，q.d.×14 days
16299532|NCT04679116|Other|Laparoscopic|laparoscopic inguinal hernia repair, TAPP
16299533|NCT04679116|Other|Open|open inguinal hernia repair
16299534|NCT04679103|Experimental|Eculisumab (JSC GENERIUM, Russia)|Eculizumab
16299535|NCT04679090|Experimental|Participant|Participants will answer a series of questionnaires, wear a physical activity tracker (pedometer) and do functional tests (six minute walk test, chair stand test, balance, back scratch, sit and reach, leg strength and hand strength) pre and post.
16299536|NCT04679077|Other|Cytocam-IDF Imaging|All patients will undergo the same interventional test.
16299537|NCT04679064|Active Comparator|Phisician's choice of standard chemotherapy|"Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21
~+/- Bevacizumab at defined scehedule"
16299538|NCT04679064|Experimental|Niraparib+Dostarlimab|Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count <150,000 /μL and/or body weight <77kg QD po q 28
16299539|NCT04679051|Experimental|8 hours time in bed|Participants will be asked to spend 8 hours time in bed with the aim of achieving one week of normal sleep duration (7 to 8 hours).
16299540|NCT04679051|Experimental|11 hours time in bed|Participants will be asked to spend 11 hours time in bed with the aim of achieving one week of long duration sleep as defined as 9+ hours of sleep.
16299541|NCT04679038|Experimental|combinational therapy part|SHR-1701 + famitinib
16299542|NCT04679038|Experimental|monotherapy part|famitinib
16299543|NCT04679025||Diabetes with postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
16299544|NCT04679025||Diabetes without postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
16299545|NCT04679025||No diabetes with postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
16299546|NCT04679025||No diabetes and no postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
16299547|NCT04679012|Experimental|Polatuzumab vedotin plus R-EPCH|Polatuzumab vedotin will be given in conjunction with 6 cycles of R-EPCH (rituximab, etoposide, prednisone, cyclophosphamide, hydroxydaunorubicin). The dosing schedule and regimen for R-EPCH will follow established protocols. Polatuzumab vedotin will be administered on Day 1 of each 21-day cycle.
16299548|NCT04678999|Experimental|Tai Chi|The intervention will delivered via a secure Zoom video platform. One of two Tai Chi instructors will teach each of the classes. Tai Chi instructors will be selected prior to study start on the basis of familiarity with our previous Tai Chi protocols and experience working with OA patients.
16299604|NCT04678596|Active Comparator|Clearfix|In the Clearfix group, the patients were given three different thickness and hardness aligner and they were asked to use each aligner for one week from soft to hard.
16299549|NCT04678999|Experimental|Wellness Education|At each session, a variety of health professionals will provide a didactic lesson on a topic relating to knee OA. An informational brochure on knee OA education is presented to all participants during the first session. Each session will last 60 minutes including a 10-minute instructor-led program of stretching or flexibility exercises via a zoom platform.
16299550|NCT04678986||ER2 participants|all participants of ER2 database will be included in the analysis
16299551|NCT04678973|Experimental|Intervention|Participants in the intervention group will receive a 4 week program delivered via text message. Week 1 will include psychoeducation delivered via brief readings and video. Weeks 2-4 will include daily guided mindfulness practice focusing on self-compassion and weight and body image concerns.
16299552|NCT04678973|No Intervention|Wait-list control|Participants in the control group will receive no study content during the 4 week intervention period. They will receive access to intervention content (text messages, audio files) after completing end-of-treatment surveys 4 weeks after randomization.
16299553|NCT04678960|No Intervention|Standard Reentry Practice|Youth/safe adult participants only receive assessments (baseline assessment while youth are at the facility; 3, 6, 12, 18 months follow-up assessments after youth are released from the facility).
16299554|NCT04678960|Experimental|TBRI Group Training only|"Youth/safe adult dyads participate in 8 TBRI caregiver modules (caregivers only), 8 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.
~After the youth's release, they would receive phone support (only when requested by the caregiver or youth)."
16299555|NCT04678960|Experimental|TBRI Group Training + TBRI In-Home Structured Coaching|"Youth/safe adult dyads participate in 8 TBRI caregiver modules (caregivers only), 8 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.
~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads in which they meet 4 times (once monthly) over the first 4 months following release."
16299556|NCT04678960|Experimental|TBRI Group Training + TBRI In-Home Responsive Coaching|"Youth/safe adult dyads participate in 8 TBRI caregiver modules (caregivers only), 8 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.
~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads. They meet a minimum of 2 times during the first 2 months after release. Starting from Month 3, TBRI Practitioners would provide additional coaching when requested or when a research assistant (RA) identifies a need for additional coaching sessions."
16299559|NCT04678934||Bicuspid aortic valve subgroup|For analysis in Bicuspid aortic valve population.
16299560|NCT04678921|Experimental|Dose Level 1|1mg/kg Q1W
16299561|NCT04678921|Experimental|Dose Level 2|3 mg/kg Q1W
16299562|NCT04678921|Experimental|Dose Level 3|10mg/kg Q1W
16299563|NCT04678921|Experimental|Dose Level 4|15 mg/kg Q1W
16299564|NCT04678908|Experimental|HB0025|HB0025 IV every 2 weeks (q2w)
16299565|NCT04678895|Experimental|Group A, Low-Dose Naltrexone, Then Placebo|Group A will receive active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the first 8 weeks. Capsules of different dosages will be indistinguishable. Then followed by 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily).
16299566|NCT04678895|Experimental|Group B, Placebo, Then Low-Dose Naltrexone|Group B will receive 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily). Then followed by active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the last 8 weeks. Capsules of different dosages will be indistinguishable.
16299567|NCT04678882|Experimental|Dupilumab|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
16299568|NCT04678882|Placebo Comparator|Placebo|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
16299569|NCT04678869|Experimental|Cirprofloxacin prophylaxis|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
16299570|NCT04678869|Active Comparator|Standard of care|standard of care
16299571|NCT04678856|Experimental|Part A and B: Dupilumab|Dupilumab administered every 2 weeks.
16299572|NCT04678856|Placebo Comparator|Part A and B: Matching placebo|Placebo administered every 2 weeks
16299573|NCT04678843|Experimental|Virtual Family-Based Treatment|Family-based treatment is the gold standard treatment for youth and adolescents with anorexia nervosa. A therapist works with the family to help parents take charge of the process of re-feeding their child, and with progress this control is gradually given back to the youth/adolescent. Other developmental issues are discussed in order to help the youth/adolescent get back to normal development.
16299574|NCT04678830|Placebo Comparator|Placebo|
16299575|NCT04678830|Experimental|700mg Leronlimab|
16299576|NCT04678804|Experimental|Matrix Graft Group|patients treated with Porcine Derived Volume Stable Matrix
16299577|NCT04678804|Other|Autogenous ctg group|patients treated with autologous tissue
16299578|NCT04678791|Experimental|Nimotuzumab+ chemoradiotherapy|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy.
16299579|NCT04678791|Active Comparator|Chemoradiotherapy|Patients receive cisplatin and undergo external-beam radiation and brachytherapy
16299602|NCT04678609|No Intervention|Control|The untreated control group will receive patient's usual care of local government hospital which includes information about clinical manifestations, risk factors, diagnosis, treatment and nursing care for knee OA. Control group did not receive any home exercises guidance.
16299603|NCT04678596|Active Comparator|EonAligner|Patients in the EonAligner group were given a single thickness and hardness aligner and were asked to use the same it for 3 weeks.
16299580|NCT04678778|Experimental|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR arm will participate in our customized spatial navigation program that increases difficulty and length per trial over time. As described in the Game Design section, each session will consist of 5 trials. The first trial will be a long-delay free recall condition from the previous day's path. The next 4 trials will consist of learning, cued recall, and free recall. This VR-based spatial navigation program has been tested in our feasibility trial for safety and tolerability in older adults.
16299581|NCT04678765|Active Comparator|Ultrasound-guided distal peripheral nerve block|Patients will receive the ultrasound-guided distal peripheral nerve block (locoregional anesthesia)
16299582|NCT04678765|Experimental|Ultrasound-guided quadruple-injection axillary nerve block|Patients will receive the ultrasound-guided quadruple-injection axillary nerve block (locoregional anesthesia)
16299583|NCT04678752|Active Comparator|Standard of Care|Each primary care provider will administer weight loss care per their standard practice.
16299584|NCT04678752|Experimental|PATHWEIGH|A weight management care path that support primary care both through the EHR and training for the clinicians.
16299585|NCT04678739|Experimental|Group A: Remdesivir + Tocilizumab treatment group|"Drug: Remdesivir Injectable solution Tocilizumab Injectable solution A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.
~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
16299586|NCT04678739|No Intervention|Group B: Control group|Treatment as given without Remdesivir and Tocilizumab.
16299587|NCT04678713|Experimental|Fat rich diet|Participants consuming 3 days of fat rich diet
16299588|NCT04678713|Experimental|Carbohydrate rich diet|Participants consuming 3 days of carbohydrate rich diet
16299589|NCT04678700|Experimental|Experimental groupe|"Intervention; 10 sessions telematics. Before starting and at the end of the respiratory physiotherapy program, the patient complete an online form which includes a quality of life questionnaire, an effort dyspnea questionnaire and an anxiety questionnaire.
~The intervention of the following study follow the recommendations of chest physiotherapy in the management of the patient post covid-19 (1)(17).
~Pre-session; respiratory frequency, dyspnea, oxigenation level are taken. Breathing techniques;
~Abdominal-diaphragmatic breathing(1)(16). (10 times).
~Costal expansion exercises with flexion and abduction of the upper limbs. (10 times)(1).
~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration(25)(26).
~Jacobson's progressive relaxation(27). Post-session, respiratory frequency and the Borg's dyspnea index/ oxigenation level."
16299590|NCT04678700|Other|control groupe|The control group will complete the same questionnaires before and after the intervention, which will give us an idea of whether our intervention has had any improvement. In order for all patients to be able to receive the therapy if they want to. The control group will be on the waiting list to perform the sessions.
16299591|NCT04678687|Other|COVID-19 group|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
16299592|NCT04678674|Experimental|bone defect surgery|augmentation on insufficient alveolar ridges with autologous teeth will be performed (wisdom tooth or periodontally compromised tooth)
16299593|NCT04678661|Experimental|My Dose Coach (Insulin Dosing Support App)|"Phase 1 Titration: Patients receive insulin therapy education from diabetes educator (DE). Plus, DE trains patients to use My Dose Coach (MDC) for titration guidance according to an algorithm prepared by endocrinology provider (EP). Patients are asked to return for a 3-month (mo) follow-up clinic visit. Patients who successfully reach glycemic target are invited to Phase 2.
~Phase 2 Maintenance: At 3-mo clinic visit, an EP or DE trains patients the MDC Maintenance Module to support proper insulin dosing. Patients are asked to return for follow-up clinic visits at mo 6. Patients are surveyed (0, 3, 6 mo) to assess changes in behavioral and psychosocial factors that influence diabetes self-management and MDC acceptability."
16299594|NCT04678661|Active Comparator|Usual Care Group|A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants.
16299595|NCT04678648|Experimental|RSC-1255 Treatment|Single Arm Study. All study participants receive RSC-1255.
16299596|NCT04678635|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. The stimulation will happen simultaneously to aerobic exercises for 20 minutes. Total number of stimulation associated with aerobic exercise sessions: 16
16299597|NCT04678635|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session. However, the patients will do aerobic exercises for 20 minutes. Total number of sham-stimulation associated with aerobic exercise sessions: 16
16299598|NCT04678622||Classic Orthrosis|Group of patients who they will wear the usual splint indicated by the servicio physicians
16299599|NCT04678622||3D Orthrosis|Group of patients who they will wear the personalized splint designed by the company OPTIMUS 3D.
16299600|NCT04678609|Experimental|Open kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
16299601|NCT04678609|Experimental|Closed kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
16299605|NCT04678583|Experimental|A - Anatomical resection|removal of the entire, tumor-bearing liver segment(s)
16299606|NCT04678583|Active Comparator|B - Non-anatomical resection|metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
16299607|NCT04678570|Experimental|Intervention Group-1|White Noise intervention and standard care, procedures will be applied.
16299608|NCT04678570|Experimental|Intervention Group- 2|The swaddling method and standard care, procedures will be applied.
16299609|NCT04678570|Experimental|Intervention Group- 3|White Noise, swaddling method, and standard care, procedures will be applied.
16299610|NCT04678570|No Intervention|No Intervention Group|Standard care and procedures to be applied.
16299611|NCT04678557|Experimental|Sentinel units (aka Cohort 1)|VC-01 Combination Product; Up to ten (10) VC-01 sentinels
16299612|NCT04678557|Experimental|Dose-finding units (aka Cohort 2)|VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels
16299613|NCT04678544|Experimental|Intervention Group|Before the chemotherapy, patients in intervention group will use cooling cap 30 minutes before chemotherapy. Once chemotherapy drug be ready, patients will receive chemotherapy. After the chemotherapy, patients go to the cooling cap area (room) and wear the cooling cap additional 20 minute for Taxane and 90 minute for other drugs, respectively.
16299614|NCT04678544|No Intervention|Controlled Group|chemotherapy with usual care
16299615|NCT04678531|Experimental|Swabs containing tea tree oil and chamomile oil|The swabs will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
16299616|NCT04678531|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks
16299617|NCT04678518|Active Comparator|SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group I (SIRS)
16299618|NCT04678518|Placebo Comparator|NON-SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group II (Non-SIRS)
16299619|NCT04678505|Experimental|Panel A: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of 100 mg MK-3402 via intravenous (IV) infusion on Day 1
16299620|NCT04678505|Experimental|Panel B: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1
16299621|NCT04678505|Experimental|Panel C: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1
16299622|NCT04678505|Experimental|Panel D: Healthy Participants|Healthy Matched Control will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1
16299623|NCT04678505|Experimental|Panel E: End-Stage Renal Disease (ESRD) Undergoing Hemodialysis|Participants with ESRD undergoing HD will receive a single dose of 100 mg MK-3402 via IV infusion before HD on Day 1 of Period 1 and after HD on Day 1 of Period 2. There will be at least a 6-day washout period before dosing in Period 2.
16299624|NCT04678492|Experimental|High-dose esomeprazole and amoxicillin dual therapy|Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days
16299625|NCT04678492|Active Comparator|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
16299626|NCT04678453|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once every three weeks (Q3W) for four cycles.
16299627|NCT04678453|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered Q3W for four cycles.
16299628|NCT04678453|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered Q3W for four cycles.
16299629|NCT04678453|Experimental|Cohort 4 - SNK01 at Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)|SNK01 (at MTD/RP2D) administered Q3W for four cycles.
16299630|NCT04678440|Experimental|Healthy Volunteers|Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.
16299631|NCT04678440|Experimental|Non-Small Cell Lung Cancer Patients (NSCLC)|Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
16299632|NCT04678427|Experimental|Supportive Care (TEAM Me)|Patients complete a 6-minute walk test and a timed get up and go test on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients also complete surveys over 10 minutes about quality of life and fatigue levels on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients who are able and allowed to, may also walk and participate in other intense physical activities to earn stickers. Patients who are unable to walk have tailored goals created by a physical/occupational therapist to earn stickers and participate in physical activity as prescribed by their therapist.
16299633|NCT04678414||Observational (focus group, survey)|"FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development.
~SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later.
~TELEPHONE SURVEY: Patients complete a telephone survey."
16299634|NCT04678401|Experimental|IS-FREE TREG CRAFT_ENGINEERED HaploHCT|"After meeting eligibility criteria and being enrolled, patients will receive:
~Day -15 to -6 prior to hematopoietic stem cell transplant (HSCT), preparatory regimen of radiation and chemotherapy: Total Myeloid and Lymphoid Irradiation (TMLI): Days -15 to -11 prior to HSCT; - Chemotherapy (infusion): Day -10 to day -6 prior to HSCT: Fludarabine (all days), Thiotepa (days -10 and -9) and Cyclophosphamide and Mesna (days -8 and -7)
~Day -4 prior to (HSCT), a Treg-enriched donor cell infusion and graft vs host disease (GVHD) assessment
~Day -1 prior to (HSCT), a unmodified donor T Cell infusion and (GVHD) assessment
~Day of (day 0) (HSCT), CD34+ Haplo Peripheral Blood Stem Cell Infusion/Transplant and (GVHD) assessment
~Days 30, 60,100, 180, 365 post hematopoietic stem cell transplant (HSCT), participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD)"
16299635|NCT04678388|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug 1
~Period 3: Test drug 2"
16299636|NCT04678388|Experimental|Group 2|"Period 1: Test drug 2
~Period 2: Reference drug
~Period 3: Test drug 1"
16299637|NCT04678388|Experimental|Group 3|"Period 1: Test drug 1
~Period 2: Test drug 2
~Period 3: Reference drug"
16299638|NCT04678388|Experimental|Group 4|"Period 1: Test drug 2
~Period 2: Test drug 1
~Period 3: Reference drug"
16299639|NCT04678388|Experimental|Group 5|"Period 1: Test drug 1
~Period 2: Reference drug
~Period 3: Test drug 2"
16299640|NCT04678388|Experimental|Group 6|"Period 1: Reference drug
~Period 2: Test drug 2
~Period 3: Test drug 1"
16299641|NCT04678375||Retinal diseases diagnosed by artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
16299642|NCT04678362|Experimental|Talazoparib+avelumab|"Talazoparib will be administered at the daily dose of 1 mg given orally in a 28-day cycle, except for patients with mild renal impairment (Creatinine clearance 30-59 mL/min) who will receive 0.75 mg per day.
~Avelumab will be administered by intravenous (I.V.) route over 60 minutes at the dose of 800 mg on D1 and D15, in a 28-day cycle."
16299643|NCT04678349|Experimental|PHGG|Patient who met inclusion criteria and consented during intervention period will be assigned as PHGG group. Surgical medical officer will obtain consent from eligible subject. After consented, subjects will be assessed weight and PG-SGA during admission. They will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar once allowed orally. Staff nurse in charged will monitor compliance of subject on the PHGG. Daily stoma output & consistency will be recorded and daily energy protein intake will be assessed by dietitian in charged. Renal profile will be taken daily as routine procedure for patients with ileostomy.
16299644|NCT04678349|Other|CG|Historical records of patients with ileostomy under conventional care from January 2016 to June 2019 (before started on PHGG) will be assessed and traced retrospectively from the medical system. Data will be recorded in data collection sheet.
16299645|NCT04678336|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
16299646|NCT04678323|Active Comparator|Phentermine Plus Lifestyle Therapy|Participants in this arm will receive 15 mg p.o.q.day of phentermine plus lifestyle therapy for 52 weeks.
16299647|NCT04678323|Placebo Comparator|Placebo Plus Lifestyle Therapy|Participants in this arm will receive a matching placebo plus lifestyle therapy for 52 weeks.
16299648|NCT04678310||Intervention Group|A patient will be assessed as 'eligible' for participation in the iLIVE Volunteer Study if they have an advanced, incurable illness that is unlikely to be cured, and they have been assessed by their clinical team as being in the last month of life. If patients meet this criteria, they will be offered support from the hospital palliative and end of life care volunteer service (developed for this study). Patients who agree to support will be recruited to the 'Intervention Group'.
16299649|NCT04678310||Case Control Comparison Group|If a patient is 'eligible' to receive support from the hospital palliative and end of life care volunteer service (see 'Intervention Group'), but declines involvement, they will be approached for inclusion in the study, as part of the 'Case Control Comparison' group for comparative analysis to assess the 'impact' of the volunteer service.
16299650|NCT04678297|Experimental|Physical activity + emotion regulation group|
16299651|NCT04678297|Active Comparator|Physical activity control group|
16299652|NCT04678284|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
16299653|NCT04678271|Experimental|AFIX-OB Intervention Arm|Practices randomized to this arm will choose from a suite of quality improvement interventions that address patient, provider, and practice-level factors relating to maternal vaccination.
16299654|NCT04678271|No Intervention|Control Arm|Practices randomized to this arm will continue to provide their normal standard of care to pregnant patients at their practice.
16299655|NCT04678258|Active Comparator|Group 1: MVG ablation|Group 1 - MVG: high-resolution mapping and maximum voltage guided stepwise CTI ablation (stepwise voltage guided approach (SVG)).
16299656|NCT04678258|Active Comparator|Group 2 - control: linear ablation|Group 2 - control: conventional bipolar mapping and conventional linear CTI ablation.
16299657|NCT04678245|Experimental|Immediate Above the Influence-Vaping Intervention|School receives Above the Influence-Vaping (ATI-V) prevention program training after baseline assessment. Training and intervention continue over two school years (approximately 18 months). Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade).
16299658|NCT04678245|Active Comparator|Delayed Above the Influence-Vaping Intervention|Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade). ATI-V prevention program training after 4th assessment - after 28 months.
16299659|NCT04678232|Experimental|receive PATH therapy|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
16299660|NCT04678219|Experimental|Low-Protein/Vegan/Low-Sulfur Diet|This is a specific diet that is both vegan and low in protein. The vegan diet eliminates all animal products, (including meats, eggs, dairy products) and animal by-products such as honey.
16299661|NCT04678219|Experimental|Specific Carbohydrate Diet|"The Specific Carbohydrate Diet emphasizes consumption of specific carbohydrates that require minimal digestion. Therefore, it eliminates most carbohydrates, including grains, starches, dairy and sugars.
~The idea behind this diet is that it reshapes the microbiome of the intestines. The diet restricts the intake of certain carbohydrates that may increase the growth of bad bacteria possibly contributing to inflammation. By restricting the amount of these carbohydrates in the microbiome, the diet aims to reduce their activity in the gut and reduce inflammation."
16299662|NCT04678206|Experimental|BLU-5937 Dose A|BLU-5937 oral dose A twice a day.
16299663|NCT04678206|Experimental|BLU-5937 Dose B|BLU-5937 oral dose B twice a day.
16299664|NCT04678206|Experimental|BLU-5937 Dose C|BLU-5937 oral dose C twice a day.
16299665|NCT04678206|Placebo Comparator|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
16299666|NCT04678206|Experimental|BLU-5937 Dose A (Population with baseline cough < 25 coughs/hour)|BLU-5937 oral dose A twice a day.
16299667|NCT04678206|Placebo Comparator|Placebo (Population with baseline cough < 25 coughs/hour)|Matching Placebo for BLU-5937 oral dose twice a day.
16299668|NCT04678193||COVID19 PCR positive test and negative or high risk asymptomatic|Patient population COVID-19 infection risk assessment real time epidemiology with 27000 subjects
16299669|NCT04678193||COVID19 PCR positive test Stage 1 infection|Patient population of PCR positive COVID-19 Stage 1 infection in registry targeted for ECL-19 treatment for reduced hospitalization with 2700 subjects (10% ECL-19 and 20% Placebo)
16299670|NCT04678180|Experimental|Virtual tic training|A combination of treatment using virtual tic training and training at the hospital. In total nine sessions using a combined training of HRT and ERP. In four of the nine sessions (session 3, 5, 6, 7) training is performed as a virtual training. All sessions last 60 minutes
16299671|NCT04678180|Experimental|Video tic training|A combination of treatment using self-instructive videos and training at the hospital. In total nine sessions using a combined training of HRT and ERP. Four of the nine sessions are completed at the hospital (session 1 and 2 are combined 120 minutes, session 4: 60 minutes, session 8: 60 minutes and session 9: 60 minutes). For all sessions, self-instructive videos have been recorded instructing the child and their families how they should perform the training
16299672|NCT04678167|Experimental|Boarding ring glasses|"Realization of the following examinations WITH Boarding ring glasses :
~caloric tests,
~measurement of the speed of Nystagmus,
~angle of deviation in Fukuda,
~Alexander's degree of nystagmus,
~EHTEV and EEV questionnaires,
~anxiety VAS"
16299673|NCT04678167|Placebo Comparator|Placebo glasses|"Realization of the following examinations WITH Placebo glasses :
~caloric tests,
~measurement of the speed of Nystagmus,
~angle of deviation in Fukuda,
~Alexander's degree of nystagmus,
~EHTEV and EEV questionnaires,
~anxiety VAS"
16299674|NCT04678167|Other|No glasses|"Realization of the following examinations WITHOUT glasses :
~caloric tests,
~measurement of the speed of Nystagmus,
~angle of deviation in Fukuda,
~Alexander's degree of nystagmus,
~EHTEV and EEV questionnaires,
~anxiety VAS"
16299675|NCT04678154|Active Comparator|Control|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
16299676|NCT04678154|Experimental|Treatment|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
16299677|NCT04678141|Other|Composite and compomer materials|Children aged 5-6 years with at least two carious proximal surface primary molars
16299678|NCT04678128|Active Comparator|Dance4Healing control group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will not have a dance buddy.
16299679|NCT04678128|Experimental|Dance4Healing Buddy Group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will have a dance buddy.
16299680|NCT04678115|Experimental|MLP first, KTFS second|Participants in this arm will receive the MLP in the first period of the crossover and the KTFS in the second period.
16299681|NCT04678115|Experimental|KTFS first, MLP second|Participants in this arm will receive the KTFS in the first period of the crossover and the MLP in the second period.
16299682|NCT04678102|Experimental|Cohort 1 (PHI-101 40mg/day)|In the starting dose cohort 1 subject will be administered 40mg/day PHI-101 and will be assessed for DLT ('single subject cohort'), and until an ADR ≥ [CTCAE version 5.0] grade 2 occurs, higher doses will be explored in single subject cohorts in a stepwise fashion. If an ADR ≥ [CTCAE version 5.0] grade 2 occurs, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme.
16299683|NCT04678102|Experimental|Cohort 2 (PHI-101 80mg/day)|In cohort 2, the subject will be administered 80mg/day PHI-101.
16299684|NCT04678102|Experimental|Cohort 3 (PHI-101 120mg/day)|In cohort 3, the subject will be administered 120mg/day PHI-101.
16299685|NCT04678102|Experimental|Cohort 4 (PHI-101 160mg/day)|In cohort 4, the subject will be administered 160mg/day PHI-101.
16299686|NCT04678102|Experimental|Cohort 5 (PHI-101 200mg/day)|In cohort 5, the subject will be administered 200mg/day PHI-101.
16299687|NCT04678102|Experimental|Cohort 6 (PHI-101 240mg/day)|In cohort 6, the subject will be administered 240mg/day PHI-101.
16299688|NCT04678089||Health group|The healthy control group mainly collected patients with other chronic diseases or blood tumors who did not meet the exclusion criteria and were not diagnosed with multiple myeloma. Also，we need some healthy volunteers. Healthy volunteers refer to people without serious physical disease, immune disease and family history of mental illness.There is no distinction between age, gender and nationality.
16299689|NCT04678089||Multiple Myeloma group|In the exposure group, all patients with multiple myeloma met the inclusion and did not meet exclusion criteria, including planning for autologous stem cell transplantation or not. There is no distinction between age, gender and nationality.
16299690|NCT04678076|Experimental|ketoprofen 25mg/5ml oral gel stick pack|Single dose of ketoprofen 25mg/5ml oral gel stick pack will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
16299691|NCT04678076|Active Comparator|OKi 80 mg granules for oral solution (bipartite sachet)|Single dose of half sachet containing 40 mg of ketoprofen lysine salt (corresponding to 25 mg as ketoprofen) will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
16299765|NCT04677530|Experimental|Part 2: JNJ-40411813|Participants will receive a single oral dose of JNJ-40411813 in Cohort 4.
16299766|NCT04677530|Experimental|Part 3: JNJ-40411813 or Matching Placebo|Participants will receive a multiple oral dose of JNJ-40411813 or a matching placebo in Cohort 5 and optional Cohort 6.
16299692|NCT04678063|Experimental|Asthmatic subjects allergic to cat|Group A will be randomized into 2 subgroups of 10 subjects: group A1 and A2. Both subgroupes will be exposed to placebo on exposure 1 then Subgroup A1 will be exposed to dose A on exposure 2 and dose B on exposure 3. Subgroup A2 will be exposed to dose B on exposure 2 and dose A on exposure 3. Dose A and B correspond to different Allergen concentration in the EEC.
16299693|NCT04678063|Active Comparator|Asthmatic allergic subjects not sensitized to cat|Group B will be exposed to placebo at exposure 1, and then at exposure 2, the concentration of cat allergens corresponding to the dose that achieved the main objective (Dose A or B).
16299694|NCT04678050|Active Comparator|group I received ketamine/propofol (ketofol) solution|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
16299695|NCT04678050|Active Comparator|group II received the Dex solution (4 µg/mL|A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h.
16299696|NCT04678037|Active Comparator|Group A (PROs assessment every 2 weeks)|
16299697|NCT04678037|Active Comparator|Group A (PROs assessment every 4 weeks)|
16299698|NCT04678011||Personalized surveillance and intervention protocol|
16299699|NCT04677998||Personalized surveillance and intervention protocol|
16299700|NCT04677985|Experimental|Menthol based topical analgesic|Menthol based topical analgesic was applied to a variety of upper and lower body muscles and tendons.
16299701|NCT04677985|Placebo Comparator|Placebo|Placebo (cream that smelled like menthol) was applied to a variety of upper and lower body muscles and tendons.
16299702|NCT04677972|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 28 days, with 84-day followup
16299703|NCT04677972|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 28 days, with 84-day followup
16299704|NCT04677959|Experimental|Digital System (DS)|DS group participants utilizing the eMDPI DS, including inhaler, smart device application (App), DHP (Cloud solution), and dashboard
16299705|NCT04677959|Active Comparator|Standard of Care (SoC) Group|SoC group participants will be treated with their standard of care medications
16299706|NCT04677946|Experimental|Healthy Cookie Group|All participants in the study
16299707|NCT04677933|Experimental|Arm A|Patients will receive 5 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
16299708|NCT04677933|Experimental|Arm B|Patients will receive 10 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
16299709|NCT04677933|Experimental|Arm C|Patients will receive Diluent placebo BIW for 15 days (Day 1, 4, 8, 11 and 15) Mode of Administration: Subcutaneous injection
16299710|NCT04677920|Experimental|Healthy Cookie Group|All participants in the study
16299711|NCT04677907|Active Comparator|Cemented knee replacement|total knee replacement with cemented modular knee replacement as per current standard for total knee replacements.
16299712|NCT04677907|Experimental|Uncemented knee replacement|total knee replacement with uncemented modular knee replacement, which is CE certified and accepted in the field.
16299713|NCT04677894||Group Direct Laringoscopy|Group DL: Group of patients intubated using a Macintoch blade laryngoscope.
16299714|NCT04677894||Group Videolaringoscopy|Group VL: Group of patients intubated using a McGrath video laryngoscope.
16299715|NCT04677881|Placebo Comparator|Wholegrain bread with yeast|The control group will be given min. 5 slices of bread baked with yeast per day.
16299716|NCT04677881|Experimental|Wholegrain bread with sourdough|The experimental group will be given min. 5 slices of bread baked with sourdough per day.
16299717|NCT04677868|Experimental|MTX and corticosteroid|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
16299718|NCT04677855|Experimental|PCUR-101 Dose Escalation|PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
16299719|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 1|PCUR-101 dosed orally once per day in 28 day cycles
16299720|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 2|PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
16299721|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 3|PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles
16299722|NCT04677829|Experimental|PNT001 1000mg|PNT001 diluted in 5% dextrose for infusion
16299723|NCT04677829|Experimental|PNT001 4000mg|PNT001 diluted in 5% dextrose for infusion
16299724|NCT04677829|Placebo Comparator|Placebo|5% dextrose for infusion
16299725|NCT04677816|Experimental|Vitamin D Supplementation Group - Deficient Levels|Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week.
16299726|NCT04677816|Active Comparator|Observational Arm - Vitamin D at Normal Levels|Standard of care neoadjuvant chemotherapy
16299727|NCT04677803|Experimental|Treatment|"Subcutaneous (SC) injection:
~BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21."
16299728|NCT04677790|Active Comparator|"Very short arm (12 months)"|Very short arm (12 months): 3 months between every step. Step by step gradual introduction of egg containing food products during 12 months, unless next step can not be taken.
16299729|NCT04677790|Active Comparator|"Short arm (20 months)"|Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.
16299730|NCT04677777|Other|Standard of Care|Patients randomized to receive this treatment will receive standard of care appropriate for the condition.
16299731|NCT04677777|Experimental|PP-007|Patients randomized to receive this treatment will receive a single infusion of PP-007
16299767|NCT04677517|Experimental|Implanted patients|All the participants are patients with post-lingual deafness and fitted with cochlear implants
16363558|NCT04233411|Experimental|60g|Acute ingestion of 60 g mycoprotein
16299732|NCT04677764|Experimental|Wii Fit Group|Received Standard of care and Wii Fit protocol consisted of strength, balance, and aerobic programs that were performed on the Wii Fit balance board (Nintendo Inc., Kyoto, Japan). For muscle strengthening exercise, lunges, single-leg extensions, sideways leg lifts, single leg twists, and rowing squats were performed. For exercise that enhances balancing sense, the soccer heading, ski slalom, penguin, table tilt, and balance bubble games were used. Aerobic games as hula hoop, super hula hoop and basic step.
16299733|NCT04677764|Other|Standard of care group|On discharge from the hospital, patients in the SOC group were given instructions on how to perform physical therapy and occupational therapy exercises after discharge. After education, patients could perform the physical therapy and occupational therapy exercises either at their own home or a gym.
16299737|NCT04677712|Sham Comparator|Cohort 1|
16299738|NCT04677712|Active Comparator|Cohort 2: Compression Garments|
16299739|NCT04677712|Active Comparator|Cohort 3: Instant Cold Packs|
16299740|NCT04677712|Active Comparator|Cohort 4: Arnica Gel Patches (OcuMend)|
16299741|NCT04677712|Active Comparator|Cohort 5: INhance Post-Injection Serum with TriHex Technology®|
16299742|NCT04677712|Active Comparator|Cohort 6: Pulse Dye Laser Treatment (PDL)|
16299743|NCT04677699||Birth Cohort|Newborns less than 8 months old and born in the state of Washington.
16299744|NCT04677699||Kids Cohort|Children ages 4-7 years and born in the state of Washington.
16299745|NCT04677686||Pre-implementation phase (October 2018 - September 2019)|"During this time period, 137 patients underwent colorectal surgery. Only basic measures for preventing SSI were performed:
~Hair was removed in the operating field with a clipper instead of shaving hair.
~Blood glucose was monitored only during the operation.
~Antibiotic prophylaxis was applied 60 minutes before the operation.
~The application of an antibiotic prophylaxis was repeated if the operation lasted longer than 4 hours.
~Measures of warming were only applied during the operation and in the recovery room.
~Instruments and gloves were changed after finishing the anastomosis."
16299746|NCT04677686||Implementation phase (October 2019 - September 2020)|"During this phase, additional measures have been introduced:
~Implementation of wound protectors during colorectal surgery.
~Colorectal operations were only performed with the support of an experienced consultant surgeon."
16299747|NCT04677686||Post-implementation phase (October 2020 - September 2021)|"During this phase, additional measures are implemented.
~Close monitoring of blood glucose. During the stay in the recovery room and for 48 hours post-operative, blood glucose is monitored closely. Moreover, if blood glucose is higher than 9 mmol/l, the patient will be treated with insulin. This measure is applied to diabetic as well as to non-diabetic-patients.
~The measures of warming will be intensified. First of all, during the operation and during the stay in the recovery room patients will be placed on warming mattresses. Moreover, a warming towel will be placed on the operating field directly after the operation.
~The patients will be asked to take a shower the night before surgery. In case of an emergency operation, patients will be asked to wash the axilla, trunk, genitalia, groins and umbilicus"
16299748|NCT04677673|Experimental|NAC PLUS SURGERY|Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.
16299749|NCT04677673|Active Comparator|SURGERY FIRST|Patients undergo curative gastrectomy without any prior chemotherapy.
16299750|NCT04677660|Experimental|TAK-919|TAK-919 0.5 mL, intramuscular injection in the upper arm
16299751|NCT04677660|Placebo Comparator|Placebo|TAK-919 Matching Placebo, intramuscular injection in the upper arm
16299752|NCT04677647|Experimental|OurChild|
16299753|NCT04677634|Other|Tolerability Arm|This is a single arm study. All subjects will receive the test material. The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily for 30 days.
16299754|NCT04677621|Experimental|Nurse Telehealth Intervention|Allocated to tele-intervention
16299755|NCT04677621|Active Comparator|Standard Deep Brain Stimulation (DBS)|Allocated to conventional approach
16299756|NCT04677595|Experimental|Cohort 1|Treatment Naive participants
16299757|NCT04677595|Experimental|Cohort 2|Participants received one or two prior lines of treatment
16299758|NCT04677582|Experimental|Intervention Group|The intervention group will receive weekly education sessions about nutrition, exercise, and behavioral health.
16299761|NCT04677556|Other|Severe acute bronchiolitis|Infants under 6 months admitted in Pediatric Intensive Care Unit for a severe acute bronchiolitis needing NIV (modified Woof clinical asthma score (WCAS) >4 and/or hypercapnic acidosis (pH<7,3 and/or pCO2>50mmHg)
16299762|NCT04677543|Active Comparator|ALIS + Azithromycin + Ethambutol|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
16299763|NCT04677543|Placebo Comparator|ELC + Azithromycin + Ethambutol|Participants will be administered ELC (empty liposome control), a matching placebo to ALIS, once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
16299764|NCT04677530|Experimental|Part 1: JNJ-40411813 or Matching Placebo|Participants will receive a single oral dose of JNJ-40411813 or a matching placebo in Cohorts 1, 2, and 3.
16299770|NCT04677491|Active Comparator|VVA-FSIAD ospemifene group|Women treated with ospemifene 60 mg/day
16299771|NCT04677491|Placebo Comparator|VVA-FSIAD placebo group|Women treated with placebo
16299772|NCT04677465|Experimental|RheOx Treatment|
16299773|NCT04677465|Sham Comparator|Sham Procedure|
16299774|NCT04677452|Experimental|JWCAR129|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
16299775|NCT04677439|Experimental|Flumatinib|
16299776|NCT04677426|Experimental|Subjects with Progressive Interstitial Lung Disease|Assess the intra-visit reliability and sensitivity to progression of 129Xe MR imaging measurements using a standardized imaging protocol in subjects with IPF and cHP.
16299777|NCT04677413|Experimental|Phase I Dose Cohorts|"DOSE LEVEL 1 : 30 Gy (tumor)/ 25 Gy (pelvis)
~DOSE LEVEL 2 : 35 Gy (tumor)/ 25 Gy (pelvis)
~DOSE LEVEL 3 : 40 Gy (tumor)/ 25 Gy (pelvis)"
16299778|NCT04677400|Experimental|Experimental Group|Participants in the Experimental group start the MBA intervention immediately (Time 0; T0).
16299779|NCT04677400|Active Comparator|Waiting-list group|Participants in the waiting-list group start the MBA intervention at Time 1 (T1; 15 days after the Experimental group).
16299780|NCT04677387|Placebo Comparator|Prescribe to Prevent Naloxone Training Module|This a 55-minute online module that covers basic information about naloxone that is relevant to community pharmacists.
16299781|NCT04677387|Experimental|Nalox-Comm|This is a newly developed 30-60 minute online module focused on teaching pharmacists how to overcome naloxone communication barriers.
16299782|NCT04677374|Placebo Comparator|Standard of care|Participants in this arm will be offered Standard of Care (SOC) referral process for voluntary medical male circumcision (VMMC) services
16299783|NCT04677374|Experimental|Block 1|Participants in this arm will be offered intensified health education
16299784|NCT04677374|Experimental|Block 2|Participants in this arm will be offered intensified health education and SMS/telephonic tracing
16299785|NCT04677374|Experimental|Block 3|Participants in this arm will be offered intensified health education, SMS/telephonic tracing and transport reimbursement
16299786|NCT04677361|Experimental|MILs™ in Combination with Pembrolizumab|"Each patient will have their bone marrow collected, MILs produced, and the patient will be dosed with all of the MILs produced for that individual patient. The minimum requirement for treatment is 2 x 108 cells. The MILs™ must be administered via a central catheter which could either be a PICC line, port or central line.
~Subjects will be treated with MILs™ and pembrolizumab (200 mg Q3W) combination. MILs™ will be administered on Day 0 and pembrolizumab administered on Day 1. Pembrolizumab will be administered as a 30 minute IV infusion with a window of -5 minutes and +10 minutes is permitted."
16299787|NCT04677348|Experimental|PENG group|pericapsular nerve group (PENG) block before surgery
16299788|NCT04677348|Active Comparator|FICB group|suprainguinal fascia iliaca compartment block (FICB) before surgery
16299789|NCT04677335|Experimental|Nutraceutical|Nutraceutical capsules taken once daily for 12 weeks
16299790|NCT04677335|Placebo Comparator|Control|Placebo capsules taken once daily for 12 weeks
16299791|NCT04677309||Lung resection less than lobectomy|participants scheduled for lung resection that is less than lobectomy
16299792|NCT04677309||Lung resection equal to or greater than lobectomy|participants scheduled for lung resection that is equal to or greater than lobectomy
16299793|NCT04677296|Experimental|VS002A|Amino acid based ORS/medical food (VS002A). Initial treatment dosing with VS002A will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
16299794|NCT04677296|Active Comparator|Standard WHO-ORS|Standard WHO-ORS. Initial treatment dosing with WHO-ORS will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
16299795|NCT04677270|Experimental|Traditional interface|Digital problem solving tool with a simple textbased graphical interface
16299796|NCT04677270|Experimental|Advanced interface|Digital problem solving tool with an advanced graphical interface and automatic functions
16299797|NCT04677257|Experimental|STEMI acute myocardial infarction treated with effective primary PCI|STEMI patients treated with effective primary PCI to assess the ability of coronary physiology parameters (CFR and IMR) measured soon after recanalization to predict myocardial tissue characterization assessed with cardiac magnetic resonance (CMR) within a week of the acute event.
16299798|NCT04677244|Experimental|Portal vein blood sample|
16299799|NCT04677218|No Intervention|First Group|First group of fixation will be knottless and without retensioning the hamstring autograft after tibial fixation
16299800|NCT04677218|Experimental|Second Group|In the second group, the hamstring autograft will be retensioned after tibial fixation.
16299801|NCT04677218|Active Comparator|Third Group|In the third group, the hamstring autograft will be knotted and retensioned after tibial fixation.
16299802|NCT04677192|Experimental|Microwave Ablation Combined with Chemotherapy|All patients will receive microwave ablation of oligohepatic metastasis and chemotherapy according to NCCN guidelines,and the efficacy was evaluated every 8 weeks until the disease progressed or the patient could not tolerate it.
16299806|NCT04677166|Experimental|NPWT with Instillation|"NPWT coupled with instillation will be employed via use of V.A.C. VeraFlo device. The protocol to be used is as follows:
~Instillation Solution: normal saline Dwell/Soak Time: 30 seconds Cycle Time: 4 hours Pressure: 125mmHg"
16299807|NCT04677166|Active Comparator|Standard NPWT|Standard NPWT with use of V.A.C. Ulta device employed at 125mmHg continuous suction.
16299808|NCT04677153|Experimental|Test and Treat plus Peer Mentors Intervention Arm|Participants offered 8 weeks of glecaprevir/pibrentasvir (GLE/PIB) at OTP plus peer support.
16299809|NCT04677153|Active Comparator|Standard of Care Referral Arm|Participants referred to offsite (non-OTP) location for HCV treatment.
16299810|NCT04677140||experiment group|By a specialist physician with existing anteroposterior and lateral radiographs have been diagnosed with adolescent idiopathic scoliosis
16299811|NCT04677127|Experimental|Intervention|The intervention group was given training based on the health belief model with groups of 10-12-13 people every week for 6 weeks in the Family Health Center, followed by telephone counseling in the following 6 weeks and follow-up for 12 weeks.
16299812|NCT04677127|No Intervention|Control|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
16299813|NCT04677114|Experimental|Outpatient Parenteral Antibiotic Therapy (OPAT)|Patients with opioid use disorder (OUD) and severe, injection-related infections (SIRI) will be treated with buprenorphine and be discharged with outpatient parenteral antibiotic therapy (OPAT).
16299814|NCT04677114|Active Comparator|Treatment as Usual (TAU)|Patients with OUD and severe, injection-related infections (SIRI) will receive usual care.
16299815|NCT04677101||Subjects with NASH documented by liver biopsy|One hundred subjects with NASH documented by liver biopsy and no evidence of another form of liver disease with a BMI ≥30 and ≤55 kg/m2.
16299816|NCT04677101||Healhy Donor|Fifty subjects with normal liver who underwent laparoscopic elective cholecystectomy, but otherwise in healthy conditions, will be used as controls.
16299817|NCT04677088|Experimental|HBV/ TCR T cell infusion|Autologous T cells with HBV antigen-specific TCR
16299818|NCT04677075||mastectomy group|patients with breast cancer and eligible for mastectomy
16299819|NCT04677062|Experimental|GV-328|"The treatment should be carried out for 4 days. Children between 3 and 6 years old had to consume 4 pills a day, children between 7 and 10 years old 5 pills, and children between 11 and 13 years old up to 6 pills. The patient had to slowly thin the tablet in the mouth, maintaining direct contact with the area to be treated.
~The study consisted of 2 visits, one initial and one final. In the initial visit , the documentation (informed consent) and the treatment were delivered. During this visit, baseline assessments of pain level, functional limitation, marginal mucosal edema, and lesion size were recorded. In addition, a photograph of the area to be treated was taken. Parents were also given a chart, in which they had to record the intensity of pain daily using the Wong-Baker face scale."
16299820|NCT04677049|Experimental|Niacin|"Niacin controlled release technology (CRT):
~Niacin CRT™ is to be started 7 days before concurrent Radiation Therapy (RT)- Temozolomide (TMZ) treatment.
~Chemo/Radiation Therapy:
~For all patients, regardless of the phase of the study, concurrent RT and TMZ for 6 weeks followed by 6-12 cycles of monthly TMZ will be given.
~Concurrent Temozolomide:
~TMZ will be administered from the first to the last day of RT at 75 mg/m2 orally (PO) for a maximum of 49 days.
~Monthly Temozolomide:
~Cycles of chemotherapy Day 1 to Day 5 every 28 days will start 28 days (+/- 2 days) after the end of RT-TMZ. First cycle of TMZ is administered at 150 mg/m2 Day 1-Day 5 by mouth (PO) and increased to 200 mg/m2 Day 1-Day 5 PO from cycle 2 onwards if well tolerated. While 6 cycles are standard of care, the Neuro-Oncologist may continue up to 12 cycles if clinically appropriate."
16299821|NCT04677036||TUH Staff|Staff within Tallaght University Hospital - anonymised
16299822|NCT04677036||ASIT Members|Members of the Association of Surgeons in Training - anonymised
16299823|NCT04677023|Other|Admira fusion X--tra® bulk|The special ORMOCER® compound molecules in Admira Fusion x-tra reduce the volume shrinkage to an extremely low level (1.25 % by volume) in conjunction with very low shrinkage stress (3.87 MPa). Admira Fusion x-tra is the bulk fill version of Admira Fusion. This means that this restorative material can be applied in layers of up to 4 mm and then reliably cured. This makes placing posterior restorations particularly quick and economical. The universal shade U further simplifies handling, as it provides aesthetic results by adapting, chameleon-like, to the surrounding dental substance
16299824|NCT04677023|Other|GrandioSO x-tra® bulk|a nano-hybrid composite which is in a class of its own. It is distinguished by outstanding handling and excellent physical properties, modelled on the natural tooth.its the packable bulk fill material for the highest standards in durability and aesthetics.GrandioSO x-tra has outstanding surface hardness, at 223 MHV, which is closer to natural tooth enamel, compared with other bulk fill composites. Because of this, GrandioSO x-tra ensures restorations which are abrasionresistant and dimensionally stable over the long term. In addition to the surface hardness, reliable curing is very important when larger increments are used. Here as well, GrandioSO x-tra achieves an outstanding result and, at the 219 MHV measured at a depth of 4 mm, it even significantly exceeds the values measured for other bulk fill composites at the surface.
16299825|NCT04677010|No Intervention|Run-in period, patients with cerebral palsy or muscular dystrophy|10 weeks of no exercise
16299826|NCT04677010|Active Comparator|Exercise period, patients with cerebral palsy or muscular dystrophy|10 weeks of exercise
16299827|NCT04676997|Experimental|Camrelizumab+Chemotherapy|Participants receive Camrelizumab d1,15 (Q2W) + nab-paclitaxel d1,8,15(QW 3/4) x 4 cycles, followed by Camrelizumab Q2W + epirubicin + cyclophosphamide Q2W x 4 cycles as neoadjuvant therapy prior to surgery
16299828|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
16299829|NCT04676971|Experimental|100 mg hzVSF-v13 IV + SOC|100 mg hzVSF-v13 IV + SOC
16299830|NCT04676971|Experimental|200 mg hzVSF-v13 IV + SOC|200 mg hzVSF-v13 IV + SOC
16299831|NCT04676971|Placebo Comparator|Placebo (saline) IV + SOC|Placebo (saline) IV + SOC
16299832|NCT04676958|Placebo Comparator|Placebo|380 mg capsule/day micro-crystalline cellulose
16299833|NCT04676958|Active Comparator|Vitamin K2|380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2
16299834|NCT04676945||untreated control group|NO MDS disease modifying therapy
16299836|NCT04676932|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory will be applied to the intervention groups.
~Care will given when women after receiving the HSG attendance appointment. Care will terminated on the 15 minutes after the end of HSG undergoing.
~The time of the study 1-3 days for each women. Intervention Nursing Care Based on Kolcaba's Comfort Theory"
16299837|NCT04676932|No Intervention|Routine hospital schedule|The researcher sincerely answered all questions asked by the control group during the HSG period.
16299838|NCT04676919|Experimental|pulsed mode phonophoresis group|Phonophoresis therapy with pulsed mode ultrasound.
16299839|NCT04676919|Experimental|continuous mode phonophoresis group|Phonophoresis therapy with continuous mode ultrasound.
16299840|NCT04676919|Sham Comparator|sham group|Sham ultrasound
16299841|NCT04676906|Experimental|Study compound 1|Up to 6 volunteers will receive one dose of study compound 1
16299842|NCT04676906|Experimental|Study compound 2|Up to 6 volunteers will receive one dose of study compound 2
16299843|NCT04676906|Experimental|Study compound 3|Up to 6 volunteers will receive one dose of study compound 3
16299844|NCT04676893|Experimental|Reference-Test|
16299845|NCT04676893|Experimental|Test-Reference|
16299846|NCT04676880|Experimental|Intervention arm - Left atrial appendage occlusion (with Watchman FLX or Amplatzer Amulet device)|Patients randomized to the intervention arm will receive left atrial appendage occlusion. In order to prevent device-related thrombus, they will use dual antiplatelet therapy (acetylsalicylzuur + clopidogrel) for three months and single antiplatelet therapy (acetylsalicylzuur) until at least 12 months after the procedure.
16299847|NCT04676880|No Intervention|Control arm - no or usual care|The patients in the control arm will stay on optimal treatment as decided by the referring physician (antiplatelet therapy or nothing).
16299848|NCT04676867|Active Comparator|900 mg dose|Patients will receive Dalcetrapib 900 mg for 10 days
16299849|NCT04676867|Active Comparator|1800 mg dose|Patients will receive Dalcetrapib 1800 mg for 10 days
16299850|NCT04676867|Active Comparator|3600 mg dose|Patients will receive Dalcetrapib 3600 mg for 10 days
16299851|NCT04676867|Placebo Comparator|Placebo tablets|Patients will receive Placebo for 10 days
16299853|NCT04676841||Hemiarthroplasty|Hip fracture patients operated with hemiarthroplasty
16299854|NCT04676828|Experimental|SPECT functional avoidance treatment|SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.
16299855|NCT04676828|No Intervention|Standard treatment|CT-based radiation therapy given over 5- 6.5 weeks.
16299856|NCT04676815||NBI PATIENT|Diagnostic Test: NBI in combination with electronic bronchoscope
16299857|NCT04676815||Non-NBI PATIENT|Diagnostic Test: Electronic bronchoscope without NBI
16299858|NCT04676802|Experimental|NSAIDS|Following surgery will receive NSAID capsules following surgery. Will take online and phone surveys.
16299859|NCT04676802|Experimental|Opioids|Following surgery will receive opioid capsules following surgery. Will take online and phone surveys.
16299860|NCT04676789|Experimental|Intervention/treatment|Patients will receive sintilimab,200mg,ivdrip,day1; pegaspargase,2,500 unit/m2 deep intramuscular injection at three different sites,day 1, every 3 weeks for 4 cycles before radiation.Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent sintilimab of 200mg and pegaspargase,2,500 unit/m2 will be administered every 3 weeks for 2 cycles during IMRT for patients who do not achieve complete remission to previous induction therapy. After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.
16299861|NCT04676776|Experimental|Missed period pill regimen|1.5 mg levonorgestrel given on day 1 200 mg mifepristone given on day 3
16299862|NCT04676763|Experimental|Substance P challenge in Part 1|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 1 will include a single challenge visit.
16299863|NCT04676763|Experimental|Substance P challenge in Part 2|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 2 will include two challenge visits.
16299864|NCT04676750|Experimental|MBSR|receives 8-week MBSR course
16299865|NCT04676750|No Intervention|control|receives intervention after experiment finishes
16299866|NCT04676737|No Intervention|Group 1 DWEK/DSO|Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114
16299867|NCT04676737|Experimental|Group 2 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO
16299868|NCT04676737|Experimental|Group 3 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO
16299869|NCT04676737|Experimental|Group 1a|Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections)
16299870|NCT04676737|Experimental|Group 3a|Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections)
16299871|NCT04676724|Experimental|GSK3228836 for 24 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 24 weeks, followed by up to 24 weeks of PegIFN.
16299872|NCT04676724|Experimental|GSK3228836 for 12 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 12 weeks, followed by up to 24 weeks of PegIFN.
16299873|NCT04676711|Experimental|GFH312|
16299874|NCT04676711|Placebo Comparator|Placebo|
16299875|NCT04676698|Experimental|Three Good Things|"Three times weekly for three weeks, participants will receive a text-based survey asking them to type or dictate three good things."
16299876|NCT04676698|Active Comparator|Waitlist Control Arm then Three Good Things|Participants will have surveys in the waiting period for 3 months and then be crossed over to the treatment arm Three Good Things.
16299877|NCT04676685|Experimental|Part A, Cohort 1: E2730 20 Milligram (mg) or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 20 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
16299878|NCT04676685|Experimental|Part A, Cohort 2: E2730 40 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 40 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
16299879|NCT04676685|Experimental|Part A, Cohort 3: E2730 60 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 60 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
16299880|NCT04676685|Experimental|Part A, Cohort 4: E2730 80 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 80 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
16299881|NCT04676685|Experimental|Part B, E2730 80 mg: Fasted + Fed|Participants will receive a single treatment of E2730 (80 mg capsule) in fasted condition on Day 1 treatment period 1 followed by E2730 80 mg capsule in fed condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
16299882|NCT04676685|Experimental|Part B, E2730 80 mg: Fed + Fasted|Participants will receive a single treatment of E2730 80 mg capsule in fed condition on Day 1 of treatment period 1 followed by E2730 80 mg capsule in fasted condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
16299883|NCT04676659|Experimental|Group 1 (rhTNK-tPA 0.10 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.10 mg/kg IV bolus over 5-10 seconds.
16299884|NCT04676659|Experimental|Group 2 (rhTNK-tPA 0.25 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.25 mg/kg IV bolus over 5-10 seconds.
16299885|NCT04676659|Experimental|Group 3 (rhTNK-tPA 0.32 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.32 mg/kg IV bolus over 5-10 seconds.
16299886|NCT04676659|Active Comparator|Group 4 (rt-PA 0.9 mg/kg)|10% of rt-PA 0.9 mg/kg administered as an initial IV bolus followed by the remaining 90% as an IV infusion over the next 1 hour.
16299894|NCT04676620||CK surgery|Conductive keratoplasty (CK) had shown to be a safe and effective procedure for the treatment of low to moderate hypeopia. It had been approved by the U.S. Food and Drug Administration (FDA) to treat presbyope in early 2004. CK appeals to both surgeons and patients as it avoids the need for flap creation, the use of high intraocular pressure (IOP), or tissue ablation.
16299895|NCT04676620||LASIK surgery|LASIK surgery is femtosecond laser assisted conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
16299896|NCT04676607|Experimental|treatment group|SHR7390
16299897|NCT04676594||Diagnosis of Pulmonary Fibrosis on Chest CT|Retrospective chart review of patients with a diagnosis of pulmonary fibrosis on chest CT.
16299898|NCT04676581||Aeromonas infection|
16299899|NCT04676581||No infected|
16299900|NCT04676581||bacterial infection|
16299901|NCT04676568|Active Comparator|extravesical VVF repair|
16299902|NCT04676568|Active Comparator|Transvesical VVF repair|
16299903|NCT04676555||Ocrelizumab|Ocrelizumab is administered intravenously (IV) under the guidance of a specialized physician and followed by one-hour observation after the infusion. It requires a corticosteroid pre-medication and some antipyretics may also be administered.
16299904|NCT04676555||Ofatumumab|Ofatumumab is administered through a subcutaneous injection and allows self-administration after training.
16299905|NCT04676542|Experimental|One group taking part in 2 separate conditions|The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).
16299906|NCT04676529|Experimental|PXS-5505, Dose Level 1, Escalation Phase (Cohort A)|Patients will receive PXS-5505 dose level 1, twice daily for a period of 4 weeks.
16363559|NCT04233411|Experimental|80g|Acute ingestion of 60 g mycoprotein
16299907|NCT04676529|Experimental|PXS-5505, Dose Level 2, Escalation Phase (Cohort B)|Patients will receive PXS-5505 dose level 2, twice daily for a period of 4 weeks.
16299908|NCT04676529|Experimental|PXS-5505, Dose Level 3, Escalation Phase (Cohort C)|Patients will receive PXS-5505 dose level 3, twice daily for a period of 4 weeks.
16299909|NCT04676529|Experimental|PXS-5505, Expansion Phase|All patients will receive PXS-5505 at the selected twice daily dose for a period of 24 weeks, or until progressive disease, unacceptable toxicity, dose-limiting toxicity or withdrawal of consent.
16299910|NCT04676516|Experimental|Experimental Arm|Participants randomized to treatment with GSK3326595 will be requested to take 15 +/- 3 days of the medication at the dose of 200 mg orally daily (2 capsules of 100 mg) prior to their breast cancer surgery or repeat biopsy. GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
16299911|NCT04676516|No Intervention|No Intervention Arm|Participants will receive no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.
16299912|NCT04676503|Experimental|Test Arm - Biovaginil 480 mg capsules|All patients will be treated with 1 capsule/day of BIOVAGINIL for two treatment cycles of 14 days each.
16299916|NCT04676477|Experimental|Dose Escalation: Patritumab deruxtecan + osimertinib|Participants in the Dose Escalation phase will receive patritumab deruxtecan IV Q3W + osimertinib PO once daily. The dose of patritumab deruxtecan in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.
16299917|NCT04676477|Experimental|Second-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)|Participants in the Second-line Dose Expansion phase will be randomized to receive patritumab deruxtecan + osimertinib at the RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
16299918|NCT04676477|Experimental|Second-line Dose Expansion: Patritumab deruxtecan|Participants in the Second-line Dose Expansion phase will be randomized to receive patritumab deruxtecan 5.6 mg/kg IV Q3W
16299919|NCT04676477|Experimental|First-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)|If the RCD includes an osimertinib dose of 80 mg PO once daily, then participants will receive treatment with patritumab deruxtecan and osimertinib at the RCD or, if relevant, at one of the provisional RCDs once established in dose escalation
16299920|NCT04676464||ultra- sound|ultra- sound assessment of their quadriceps muscle layer thickness (QMLT)
16299921|NCT04676451|Experimental|Femto-AK Patients|Femtosecond laser assisted cataract surgery with creation of astigmatic keratotomies for the correction of corneal astigmatism.
16299922|NCT04676438||Patients receiving surgery breast surgery for cancer at National Institute of Oncology|No intervention will be administered
16299923|NCT04676425|Experimental|Hepatic Impairment|Participants with hepatic impairment will receive a single dose of MK-8189 4 mg orally on Day 1.
16299924|NCT04676425|Experimental|Healthy|Healthy participants will receive a single dose of MK-8189 4 mg orally on Day 1.
16299927|NCT04676399|Experimental|Participants receiving Hydrochlorothiazide Pill (12.5 mg twice a day)|"Planned use in this study
~Condition/disease indication(s): Hypertension
~Subject population: Chronic pain
~Dose(s): 12.5 mg twice per day for 28-35 days until the end of the study.
~Administration: Oral
~Dosing regimen: 12.5 mg twice per day"
16299928|NCT04676399|Placebo Comparator|Participants receiving Placebo Pills|"Has no active ingredients but is made to look like the study drug.
~2 pills/day for 28-35 days until the end of the study."
16299929|NCT04676386||PD1/PD-L1|Standard of Care: PD1/PD-L1 monotherapy
16299930|NCT04676386||PD1/PD-L1 + chemo|Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
16299931|NCT04676373|Experimental|Alglucosidase Alfa|A dose of 20 mg/kg body weight once every 2 weeks for a minimum of 52 weeks
16299932|NCT04676360|Experimental|(BELANTAMAB MAFODOTIN|"Belantamab mafodotin will be administered intravenously on day 1 of a 21-day cycle.
~Treatment is intended to be administered on an outpatient basis."
16299933|NCT04676347||Eligible population|All patients admitted in the semi-intensive care units attending the study. Be basing on the average number of patients yearly treated in those units, we expect to have at least 39000 patients during the 5 years of the study.
16299934|NCT04676334|Experimental|Rucaparib|Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision
16299935|NCT04676308||AI arm|Standard colonoscopy with Artificial Intelligence-GI GeniusTM
16299936|NCT04676308||Cuff arm|Endo-cuff Vision aided colonoscopy with Artificial Intelligence -GI GeniusTM
16299937|NCT04676295|Experimental|PE intervention|A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile.
16299938|NCT04676295|No Intervention|PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
16299939|NCT04676295|No Intervention|Non-PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
16299940|NCT04676282||Survey 1 Statin - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm.
16300033|NCT04675645|Other|HU-Go app intervention arm|Participants will use HU-Go app intervention arm for a total of 12 weeks.
16299941|NCT04676282||Survey 1 Stain - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may lack benefit.
16299942|NCT04676282||Survey 1 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
16299943|NCT04676282||Survey 1 PPI - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm.
16299944|NCT04676282||Survey 1 PPI - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may lack benefit.
16299945|NCT04676282||Survey 1 PPI - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm and lack benefit.
16299946|NCT04676282||Survey 2 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
16299947|NCT04676282||Survey 2 Statin - Cardiologist|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin previously started by a cardiologist.
16299948|NCT04676282||Survey 2 Statin - Daughter Preference|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's adult daughter prefers for her to continue the medication.
16299949|NCT04676282||Survey 2 Statin - Husband Stroke|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's husband previously had a stroke after he stopped his statin.
16299950|NCT04676282||Survey 2 Statin - Flier|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient saw an educational flier about strokes in the waiting room.
16299951|NCT04676282||Survey 2 Statin - Difficulty Maintaining Lifestyle Changes|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient recognizes that they have had difficulty exercising and eating healthier foods.
16299952|NCT04676269|Sham Comparator|Amnion only|Amnion bilayer as a scaffold to overlay the endometrium, with minor curettage prior to stick the scaffold.
16299953|NCT04676269|Experimental|Amnion- self endometrium stem cells (EnSC)|Amnion bilayer as a scaffold, seeded with endometrium stem cells to regenerate the thin endometrium.
16299954|NCT04676269|Experimental|Amnion- amnion epithelial stem cells (AESC)|Amnion bilayer as a scaffold, seeded with amnion epithelial stem cells to regenerate the thin endometrium.
16299955|NCT04676269|Experimental|Amnion- co culture self EnSC - AESC|Amnion bilayer as a scaffold, seeded with co-culture of endometrium stem cells and amnion epithelial stem cells to regenerate the thin endometrium.
16299956|NCT04676256|Experimental|Early Vitrectomy|Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis
16299957|NCT04676256|Active Comparator|Comparator|"Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.
~Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up"
16299958|NCT04676243|Experimental|Quizartinib plus standard of care (SOC)|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Quizartinib
16299959|NCT04676243|Active Comparator|Physician's choice|Physician's choice (usually Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Midostaurin)
16299960|NCT04676230|Experimental|Experimental group|caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
16299961|NCT04676230|Active Comparator|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
16299962|NCT04676217|Active Comparator|FDP|Face down positioning
16299963|NCT04676217|Experimental|NSP|"No positioning named non-supine positioning. Participants are to avoid recumbent positioning."
16299964|NCT04676204||Cladribine|Participants with MS commencing cladribine disease modifying treatment as clinically prescribed.
16299965|NCT04676204||Dimethyl Fumarate|Participants with MS commencing dimethyl fumarate disease modifying treatment as clinically prescribed.
16299966|NCT04676204||Fingolimod|Participants with MS commencing fingolimod disease modifying treatment as clinically prescribed.
16299967|NCT04676204||Teriflunomide|Participants with MS commencing teriflunomide disease modifying treatment as clinically prescribed.
16299968|NCT04676191|Experimental|Patients with sleep disorders, cardiorespiratory or neuromuscular disorders|
16299969|NCT04676178|Experimental|SAD Cohorts 1-6 Experimental Arm|Subjects will receive single intravenous doses of PRA023 in a dose escalation format
16299970|NCT04676178|Placebo Comparator|SAD Cohorts 1-6 Placebo Arm|Subjects will receive intravenous doses of placebo
16299971|NCT04676178|Experimental|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three intravenous doses of PRA023, one dose every 2 weeks, in a dose escalation format
16299972|NCT04676178|Placebo Comparator|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three intravenous doses of placebo, one dose every 2 weeks,
16299973|NCT04676165|Experimental|SAM Group|At discharge from hospital, patients (and/or caregivers) will receive access to Smart About Meds (SAM), a medication management mobile application that has been developed by the McGill Clinical and Health Informatics (MCHI) Research Group.
16300177|NCT04674566|Experimental|Cohort 1|COR-101 low dose
16299974|NCT04676165|No Intervention|Usual Care Group|At discharge from hospital, patients will be provided with a written discharge prescription to be filled at their community pharmacy, and may or may not receive written or verbal instructions about changes made to therapy.
16299975|NCT04676139|Experimental|Fluoxetine|patients will undergo maintenance therapy selective serotonin reuptake inhibitors, fluoxetine, 10 mg capsules once daily for 12 weeks
16299976|NCT04676139|Placebo Comparator|Placebo|patients will undergo maintenance therapy Placebo for 12 weeks
16299977|NCT04676126|Experimental|Experimental|Subjects in the experimental arm will consume 1.5 Tbsp (22.2 mL) of a commercial macular pigment-containing medical food (liquid) once per day and use a carbonic anhydrase inhibitor topical eye drop (2% dorzolamide ophthalmic solution) three times per day in both eyes for 3 months.
16299978|NCT04676126|Placebo Comparator|Placebo|Subjects in the placebo arm will consume 1.5 Tbsp (22.2 mL) of a placebo liquid which resembles the commercial macular pigment-containing medical food (liquid) in taste once per day and use a lubricating eye drop (0.5% sodium + 0.9% glycerin ophthalmic solution) three times per day in both eyes for 3 months.
16299979|NCT04676113||Pediatric Patients with Sickle Disease who are overweight/obese|Pediatric Patients age 10-19 years diagnosed with Sickle cell disease who have a BMI of >85%ile.
16299980|NCT04676113||Pediatric Patients with Sickle Cell Disease who are underweight/normal weight|Pediatric Patients age 10-19 years diagnosed with Sickle Cell disease who have a BMI<85%ile.
16299981|NCT04676087|Experimental|Treatment (mogamulizumab, ECP)|"INDUCTION (WEEKS 1-7): Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, and 36 in the absence of disease progression progression and unacceptable toxicity. Patients also undergo extracorporeal photopheresis on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression and unacceptable toxicity.
~TREATMENT (CYCLES 1-12): Patients receive mogamulizumab IV over 60 minutes on days 1 and 15, and undergo extracorporeal photopheresis on days 1 and 15 of cycles 1-6, then day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression and unacceptable toxicity.
~MAINTENANCE (CYCLES 13+): Patients with clinical benefit may continue extracorporeal photopheresis on day 1. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity."
16299982|NCT04676074|No Intervention|control group|the participant will not do any exercise program but just they will take the routine medication.
16299983|NCT04676074|Experimental|study group|will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.
16299984|NCT04676061|Placebo Comparator|Control Group|Placebo to Norethindrone acetate (NTA)
16299985|NCT04676061|Active Comparator|Treatment Group|Norethindrone acetate (NTA)
16299986|NCT04676048|Experimental|ASC618|Experimental Arm
16299987|NCT04676035|Experimental|SHR3680+ Midazolam, Warfarin, Omeprazole, VitaminK1|administrate Midazolam, Warfarin, Omeprazole, VitaminK1 on Day1 and Day22, SHR3680 on day 6-27.
16299988|NCT04676022|Experimental|Spinal Cord Stimulation|To receive Spinal Cord Stimulation programming
16299989|NCT04676022|Other|Conventional Medical Management|To receive conventional medical management
16299990|NCT04676009|Experimental|Exercise arm :|"Patient randomized to the Exercise arm will receive physical activity recommendations at inclusion and nutritional assessment will be carried out during the first and last treatment cure. Patients will receive an acute physical exercise just before immunotherapy and chemotherapy infusion.They will have a home walking program and will have to wear an activity tracker during the 3 months of intervention.
~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3)."
16299991|NCT04676009|No Intervention|Control arm|"Patients will receive physical activity recommendations at inclusion and a nutritional assessment will be carried out during the first and last treatment cure. They will receive the usual care and standard treatment protocol (immunotherapy and chemotherapy).
~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place 40 min before the administration of treatments (1), just before the administration of treatments (2) and 12 hours after the start of treatment (3)."
16299992|NCT04675996|Experimental|Phase 1/1b|"Phase 1: dose escalation phase with a 'hybrid' 3+3 design in all-comers cancer patients. Approximately 30 patients will be included.
~Phase 1b: dose expansion phase in selected tumor types at the recommended phase 2 dose. Approximately 50 patients will be included."
16299993|NCT04675983|Experimental|Sintilimab + Ramucirumab|Ramucirumab on days 1 and 8 in combination with Sintilimab on day 1 of each 21-day cycle until disease progression, intolerable toxicity or other criteria for treatment discontinuation
16299994|NCT04675983|Active Comparator|Cisplatin+ 5-fluorouracil/Oxaliplatin+capecitabine|Cisplatin on day 1 in combination with 5-fluorouracil, continuous pumping for 24 hours a day on days 1 to 5 of each 21-day cycle. (FP regimen) or Oxaliplatin on day 1 in combination with capecitabine on days 1 to 14 of each 21-day cycle. (XELOX regimen)
16299995|NCT04675944|Experimental|BIA 5-1058 / treprostinil|Three treatment periods separated by a washout period of at least 10 days
16299996|NCT04675931|Experimental|IV KAE609 Dose regimen 1|Intravenous KAE609 (cipargamin) 20 mg
16299997|NCT04675931|Experimental|IV KAE609 Dose regimen 2|Intravenous KAE609 (cipargamin) 40 mg
16299998|NCT04675931|Experimental|IV KAE609 Dose regimen 3|Intravenous KAE609 (cipargamin) Dose regimen 3 (dose will be evaluated post Interim analysis from Cohort 1 and Cohort 2.
16299999|NCT04675931|Active Comparator|IV Artesunate|IV Artesunate 2.4 mg/kg (for participants weighing at least 20 kg) IV Artesunate 3 mg/kg (for participants weighing less than 20 kg)
16300000|NCT04675931|Other|Coartem|Standard of care (Coartem) will be given to all participants for 3 days as part of treatment.
16300001|NCT04675905||PACORUS-D Main cohort|Eligibility, Endpoints as described above
16300002|NCT04675905||PACORUS-D Delirium-Subcohort|Eligibility: patients aged >= 65 years undergoing noncardiac nonneurosurgical procedures (definition see above); Endpoints as described above; additional explanatory variable: postoperative Delirium detected by CAM on postoperative day 1 and 2
16300003|NCT04675892|Active Comparator|A1 pulley group|A1 pulley division only
16300004|NCT04675892|Experimental|A1 pulley + FDS group|Combination of A1 pulley division and excision of one or both slips of the flexor digitorum superficialis tendon
16300005|NCT04675879|Experimental|Velpau bandage (Group 1)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with velpau bandage.
16300006|NCT04675879|Experimental|Shoulder arm sling (Group 2)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with shoulder arm sling.
16300007|NCT04675879|Experimental|Padded shoulder arm sling (Group 3)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with padded shoulder arm sling with 30 degree abduction.
16300008|NCT04675866|Experimental|camrelizumab+albumin-bound paclitaxel+S-1|camrelizumab+albumin-bound paclitaxel+S-1
16300009|NCT04675853||Participants with PD|
16300010|NCT04675853||Care Partners of PD participants|
16300011|NCT04675840|Active Comparator|intrathecal morphine|Spinal injection of 15mg Bupivakain and 0,25mg morphine before surgery.
16300012|NCT04675840|Active Comparator|opiate po/iv|Patient given 10mg Oxycodone orally before surgery.
16300013|NCT04675827|Experimental|RCB = 0|"Treatment administration: adjuvant pertuzumab + trastuzumab (P+T) fixed dose combination (FDC) SC for 14 cycles.
~Sub-study: 121 of the subjects who achieved a pCR (thus assigned to continue treatment with P+T FDC SC) will be randomised at a 1:1 ratio to receive 3 cycles of P+T FDC SC in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period."
16300014|NCT04675827|Experimental|RCB > 0|Treatment administration:adjuvant T-DM1 for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
16300015|NCT04675801||Bridging therapy with LMWH (n=475)|Bridging therapy with LMWH was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
16300016|NCT04675801||Bridging therapy with tirofiban (n=475)|Bridging therapy with tirofiban was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
16300021|NCT04675775|Experimental|Medically-tailored meals|Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than 2000 grams a day).
16300022|NCT04675762|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
16300023|NCT04675762|Placebo Comparator|Placebo with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with placebo.
16300024|NCT04675736|Experimental|brushing force|
16300025|NCT04675710|Experimental|Treatment (dabrafenib, trametinib, pembrolizumab)|Patients receive 21-day cycles of dabrafenib 150 mg orally (PO) twice daily from Days 1-21, trametinib 2mg PO once daily from Days 1-21, and pembrolizumab 200mg intravenously (IV) on Day 1 of each cycle.
16300026|NCT04675697|Experimental|Anlotinib+EP|
16300027|NCT04675684|Experimental|Recovery-group|"The recovery group consists of:
~Physical, mental and social health education, advice and feedback from a health investigator.
~Daily self-monitoring about their mood and health in an app, Monsenso.
~Intersectoral collaboration between 1) Mental Health Centre Copenhagen Rigshospitalet, IAOC 2) Centre for Research and Education in General Practice, University of Copenhagen 2) Centre for Social Medicine at Frederiksberg Hospital, 3) Competence Centre for Rehabilitation and Recovery, Mental Health Centre Ballerup, and 5) Private Practicing Psychiatrists."
16300028|NCT04675684|No Intervention|Control-group|The control group consists of usual treatment at their General Practitioner and / or Private Practicing Psychiatrist.
16300029|NCT04675671||Pregabalin group (Group P)|Group pregabalin patients will be received 75 mg of pregabalin twice daily for 2 days before surgery
16300030|NCT04675671||Control group (Group C)|The Control group will be received plasebo capsule mg at the same point in time
16300031|NCT04675658|Active Comparator|Classroom Intervention|"Physical activity support is provided by integrating daily structured activities in the classroom delivered by physical activity leaders through a video conferencing platform in partnership with the classroom teacher. Activities last about 10 minutes or less and have the flexibility of being integrated with academic lessons or serving as a break from academics.
~The activities are simple and get kids moving in place. The activities will be delivered by a research staff member via video conferencing (using the schools preferred platform). A combination of live activities led by the research team and pre-recorded videos will be used (see example below). If live videos do not work for the teacher, they will have the option to only use the pre-recorded videos or receive a list of resources to promote CBPA in their classrooms."
16300032|NCT04675658|Experimental|Classroom Intervention plus family support|"Same components as the Classroom Intervention Arm plus the following:
~Family Component: A newsletter will be sent to parents or guardians once every two weeks over the semester and posted on the study website. The newsletters include physical activity information related to safety/protection, skills building, motivation, overcoming barriers, and goal setting and monitoring (all newsletters are included as an appendix). As part of the program, children also receive a Garmin wearable physical activity monitor. Parents or guardians will receive text messages with behavior change messages based on the Garmin data (text message content is included as an appendix). Text messages also contain links to website materials.
~Texts will be sent out using the Twilio platform."
16300034|NCT04675632||The intervention group|the tibial run off would be treated through endovascular therapy
16300035|NCT04675632||the non-intervention group|the tibial run off would not be treated through endovascular therapy
16300036|NCT04675619|Experimental|Oral pirfenidone|Pirfenidone will be administered orally in 267 mg capsules taken with food. The dose will be titrated over 2 weeks from one capsule three times a day during Week 1 to two capsules three times a day during Week 2 then maintenance dose (three capsules three times a day Week 3.
16300037|NCT04675619|Experimental|Standard care|Standard care
16300038|NCT04675606|Active Comparator|Low fiber diet|Patients in this arm will receive low fiber diet starting postoperative day 1. This is currently the standard protocol at our institution.
16300039|NCT04675606|Experimental|Regular diet|Patients in this arm will receive regular diet starting postoperative day 1. This will be the experimental arm.
16300040|NCT04675593|Experimental|iTAB-CV + Self Monitoring|Receives iTAB-CV intervention plus self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
16300041|NCT04675593|Active Comparator|Self Monitoring|Receives self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
16300042|NCT04675593|Experimental|iTAB-CV + Self Monitoring - High Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the high intensity booster group will start off receiving 1 reminder per day and taper down to 1 reminder per week over 2 months, in addition to self monitoring.
16300043|NCT04675593|Experimental|iTAB-CV + Self Monitoring - Low Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the low intensity booster group will receive 1 reminder per week for 2 months, in addition to self monitoring.
16300044|NCT04675580|Experimental|Tele Toy Talk|Caregivers of child participants receive 1-hour of telemedicine featuring parent-mediated naturalistic developmental behavioral intervention weekly for 10 weeks.
16300045|NCT04675580|No Intervention|Multiple Baseline|Prior to receiving the intervention, participants will be randomized into one of three baseline conditions: a three-, four-, or five-week baseline period. At each weekly baseline session, caregivers will record the Tele-BOSCC (see Outcomes Measures section).
16300046|NCT04675567|Active Comparator|Safety-Net Intervention|
16300047|NCT04675567|No Intervention|Treatment as Usual|
16300048|NCT04675528|Experimental|Fasting treatment|
16300049|NCT04675528|Experimental|Fed treatment|
16300050|NCT04675515|No Intervention|Usual Tobacco Treatment|All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals
16300051|NCT04675515|Experimental|Intensive Tobacco Treatment|"Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ).
~These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months."
16300052|NCT04675502|Experimental|Supervised Exercise Group|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.
16300053|NCT04675502|Experimental|Home Exercise Group|For patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.
16300054|NCT04675489|Other|Vivity Toric IOL|Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.
16300055|NCT04675476|Experimental|Multilevel Intervention|
16300056|NCT04675476|No Intervention|Nonequivalent Control Group|
16300057|NCT04675463|Other|Budesonide/Glycopyrronium/Formoterol arm|52 weeks treatment
16300058|NCT04675463|Other|Glycopyrronium/Formoterol arm|52 weeks treatment
16300059|NCT04675450|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
16300060|NCT04675450|Active Comparator|NBP|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
16300061|NCT04675437|Experimental|Frail patients (CABG, HF or mini-AVR)|12-weeks cardiac exercise program (3 sessions per week) consisting of aerobic exercises (ergometer, treadmill and arm ergometer).
16300062|NCT04675411|Other|usual care|After a fall leading to hip fracture, patients are cared for by orthopedists and receive internal fixation or arthroplasty. Consultations for internal medicine care are occasionally made depending on the patient's condition. During the first 1 to 2 days after surgery, nurses teach patients how to exercise while still in bed, using caution while changing their position. Pain-relief medications and antibiotics are also administered (for 2-3 days). The first day after surgery, physical therapy usually starts with rehabilitation training only on patients receiving arthroplasty. The average hospital stay is 5 to 7 days. After hospital discharge, very few patients use in-home or community rehabilitation or are admitted to a 2-week subacute rehabilitation unit. Patients usually come back to the clinic around 1, 3, 6, and 12 months after hospital discharge. However, adherence to this follow-up schedule is poor. Telephone follow-ups are seldom used.
16300063|NCT04675411|Experimental|Smart Care Model|"The smart care model (SCM) will contain the components of geriatric assessment, continuous rehabilitation, and discharge planning.
~Sensors will be installed in bedrooms and living areas of the patient's home to receive signals from the smart clothing. Instant alerts and feedbacks from research nurses to family caregivers about the patient's condition and activity level will be provided."
16300064|NCT04675398|Active Comparator|Open-loop deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation.
16300065|NCT04675398|Active Comparator|Randomized deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation at random time points.
16300066|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb movement|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of contralateral limb movement.
16300067|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb rest|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of no movement for contralateral limb.
16300068|NCT04675372|Experimental|Group 1|Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
16300069|NCT04675372|Active Comparator|Group 2|Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam
16300070|NCT04675359|Active Comparator|Enzymatic digestion group|A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue
16300071|NCT04675359|Active Comparator|Mechanical fragmentation group|A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint
16300072|NCT04675346||Questionnaire|The EUNASS Study Questionnaire is an electronic questionnaire (using the Qualtrics programme) designed to assess management after diagnosis of melanoma and during follow-up, health status, fear of melanoma recurrence, melanoma-specific supportive care needs, sun protection behaviour, views and habits about SSE and standard socio-demographic details.
16300073|NCT04675346||Interviews|A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.
16300074|NCT04675333|Experimental|Evorpacept (ALX148) + Pembrolizumab + Chemotherapy|Evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.
16300075|NCT04675333|Active Comparator|Pembrolizumab + Chemotherapy|Pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.
16300076|NCT04675320||Mutated BRCA epithelial ovarian cancer|
16300077|NCT04675320||Recurrent epithelial ovarian cancer|
16300078|NCT04675294|Experimental|Evorpacept (ALX148) + Pembrolizumab|Evorpacept (ALX148) 45 mg/kg IV and pembrolizumab 200mg IV given every 3 weeks.
16300079|NCT04675294|Active Comparator|Pembrolizumab|Pembrolizumab 200mg IV given every 3 weeks.
16300080|NCT04675281||Critically-ill adult patients who died in the Intensive Care Unit from a documented COVID-19|
16300081|NCT04675268|Experimental|7 night home oximetry|Patients will undergo 7 nights home monitoring with oximetry.
16300082|NCT04675255|Active Comparator|Immediate switch|Immediate switch
16300083|NCT04675255|Active Comparator|Delayed switch|Delayed switch
16300084|NCT04675242|Experimental|NCX 4251|NCX 4251 Ophthalmic Suspension
16300085|NCT04675242|Placebo Comparator|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension
16300086|NCT04675216||Posterior fossa lesion|This group will be integrated by patients with posterior fossa lesion that likely to rise the posterior fossa intracranial pressure
16300087|NCT04675216||Post-operative posterior fosa surgical patients|This group will be integrated by patients operated for posterior fossa lesions in which we will try to find out what range of posterior fossa pressure is to be expected in this situation
16300088|NCT04675203||Normal tooth eruption|
16300089|NCT04675190||Case|Cases will be patients in the department of surgery above 18 years with ultrasound findings of gall stone disease.
16300090|NCT04675190||Control|Controls will be patients in the department of surgery above 18 years with ultrasound findings showing evidence of no gallstones
16300091|NCT04675177|Active Comparator|Polidocanol foam sclerotherapy|Patients submitted to polidocanol foam sclerotherapy
16300092|NCT04675177|Active Comparator|Doppler-guided hemorrhoidal artery ligation|Patients submitted to doppler-guided hemorrhoidal artery ligation
16300093|NCT04675164|Active Comparator|LAISS group|Viable immotile testicular sperms will be selected before ICSI using laser assisted immotile sperm selection (study group).
16300094|NCT04675164|Active Comparator|HOST group|Viable immotile testicular sperms will be selected before ICSI using hypo-osmotic swelling test (control group).
16300095|NCT04675151|Experimental|Nyxol + Pilocarpine|1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)
16300096|NCT04675151|Active Comparator|Nyxol|1 drop of Nyxol (Treatment 1)
16300097|NCT04675151|Active Comparator|Pilocarpine|1 drop of Pilocarpine (Treatment 2)
16300098|NCT04675151|Placebo Comparator|Placebo|1 drop of Placebo (Treatment 1)
16300099|NCT04675112|Experimental|group A genetically informed intervention|Group A patients are offered a genetically based approach to tinnitus management that includes a genetic test and at least three office based treatment sessions. A rationally-designed personalized management plan based on the genetic results is based on four single nucleotide polymorphisms (SNPs) of the dopamine and serotonin pathways, namely COMT rs4680, HTR2A rs7997012, HTR2A rs6311, and TPH2 rs4570625, that have been associated with behavioral or cognitive responses
16300100|NCT04675112|Other|group B control|In Group B, treatments are offered randomly taking care to offer CBT to equal number of patients as in Group A. In both groups, during the first visit, patients are offered a simple, few-minute tinnitus update and advice, relevant to their educational level and are being suggested that an average of 4 sessions are required over a period of approx. 4 months for making tinnitus noise less or not bothersome
16300101|NCT04675099|Active Comparator|Control|Standard Early Intervention services
16300102|NCT04675099|Experimental|Intervention|pCARE
16300103|NCT04675086|Experimental|Aralast NP + Antiviral Treatment + Standard of Care|"The investigational product is alpha1-proteinase inhibitor, administered as a loading dose of 120mg/kg/body weight intravenous infusion on the first day, and then 60mg/kg/BW intravenous infusion on Days 3, 5, 7 and 9. Booster infusion of 120 mg/kg/BWon Day 17.
~The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes
~Standard of Care treatments are at the investigator's discretion based on best practices."
16300104|NCT04675086|Active Comparator|Antiviral Treatment + Standard of Care|"The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes
~Standard of Care treatments are at the investigator's discretion based on best practices."
16300105|NCT04675073|Experimental|ABLATE arm|Ventricular tachycardia substrate ablation intending to: i) eliminate all the potential arrhythmogenic substrate, aiming for complete electrical isolation/elimination of all the electrograms with delayed components or showing hidden slow conduction properties, and ii) non-inducibility or ventricular tachycardias at the end of the procedure. Standard medical treatment will also be given for these patients.
16300106|NCT04675073|No Intervention|NO-TREAT arm|Only standard medical treatment will be offered for these patients.
16300107|NCT04675060|Experimental|Cohort 1|TQ-B3139 capsules administered single dose of 600 mg under fasted conditions in day 1 followed by single dose of 600 mg with a high-fat meal in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
16300108|NCT04675060|Experimental|Cohort 2|TQ-B3139 capsules administered single dose of 600 mg with a high-fat meal in day 1 followed by single dose of 600 mg under fasted conditions in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
16300109|NCT04675047||healthy control|healthy control
16300110|NCT04675034|Experimental|Cohort 1|Dose A: MEDI7352 Q2W
16300111|NCT04675034|Experimental|Cohort 2|Dose B: MEDI7352 Q2W
16300112|NCT04675034|Experimental|Cohort 3|Dose C: MEDI7352 Q2W
16300113|NCT04675034|Experimental|Cohort 4|Dose D: MEDI7352 Q2W
16300114|NCT04675034|Placebo Comparator|Cohort 5:|Placebo to match MEDI7352 Q2W
16300115|NCT04675021|Experimental|AZD6094 (Savolitinib) D5084C00010|All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010
16300116|NCT04675008|Experimental|Study arm|Dacomitinib
16300117|NCT04674995||Stent|Patients with tracheal stenosis treated with stent placement via rigid bronchoscopy.
16300118|NCT04674995||Balloon dilatation|Patients with tracheal stenosis treated with balloon dilatation via laryngoscope.
16300119|NCT04674982|Experimental|Vibration Group|In the vibration group, a vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz) was applied to the middle/side area through which the sural nerve passes immediately below the knee of the extremity from which heel blood was to be collected approximately 30 seconds prior to commencement of the heel lance procedure. The vibration was continued throughout the heel lance procedure unless there was redness, swelling, bruising or a change in the skin integrity in the area to which the vibration was applied, and the vibration was stopped once the procedure was over.
16300120|NCT04674982|No Intervention|Control Group|No interventions were made on the newborns in the control group during the heel lance procedure.
16300121|NCT04674969||Clinical Cohort|All enrolled patients are included in the Clinical Cohort and will complete assessments per standard of care through 5-year follow-up.
16300122|NCT04674969||Outcomes Cohort|Patients at select sites will complete the Clinical Cohort standard of care assessments and additional assessments as part of the Outcomes Cohort, including Quality of Life questionnaires, six-minute walk test (6MWT), and Healthcare Utilization data collection.
16300123|NCT04674956|Experimental|Treatment arm|Regimens：anti-PD1 antibody and AG regimens.
16300124|NCT04674956|Placebo Comparator|Control arm|Regimens：Placebo and AG regimens.
16300125|NCT04674943|No Intervention|Control group|No physical therapy intervention was given. Only pharmacological treatment was provided.
16300126|NCT04674943|Experimental|Breathing exercise group|1. Pursed lip breathing 15 reps x 3 sets) 2: Diaphragmatic breathing (15 reps x 3 sets) 3:Lateral costal breathing 15 reps x 3 sets)
16300127|NCT04674930|No Intervention|Control group|Pharmacological management
16300128|NCT04674930|Experimental|Exercise group|"Aerobic training: The target training zone was set at 40-60% of the peak heart rate, as determined in the baseline 6min walk test (6MWT), with a rating of 11-13 on the Borg rating of perceived Exertion scale.
~Resistance Training: This training was prescribed at 70% of one repetition maximum (RM). Patients were instructed to train a variety of upper and lower body muscle groups (e.g., latissimus, deltoid, biceps, quadriceps, and gastrocnemius muscles), using Thera-band"
16300129|NCT04674917|Experimental|Group A|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
16300130|NCT04674917|Experimental|Group B|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
16300131|NCT04674917|Other|Group C|Hot pack , TENS, Mobilization, Exercise therapy
16300132|NCT04674904|Experimental|Group A|Dry Needling
16300133|NCT04674904|Active Comparator|Group B|Hot pack , TENS , Stretching
16300134|NCT04674891|Active Comparator|baseline physical therapy treatment|baseline physical therapy treatment ,Control group- Group A
16300135|NCT04674891|Experimental|Cervical Stabilization exercises|baseline physical therapy treatment along with Cervical Stabilization exercises- Experimental Group- Group B
16300136|NCT04674878|Experimental|MET group|METs for accessory muscles of respiration including sternocleidomastoid, scalenes and trapezius given thrice a week for 8 weeks.
16300137|NCT04674878|Active Comparator|Breathing exercise group|Diaphragmatic breathing, pursed lip breathing and diaphragmatic breathing with resistance given thrice a week for 8 weeks.
16300138|NCT04674865|Active Comparator|Conventional treatment protocol group|Standardized treatment protocol including chest physical therapy as well as limb physical therapy and functional mobility was addressed.
16300139|NCT04674865|Experimental|ANB group|2 sessions per day was added to the standardized treatment protocol
16300140|NCT04674852|Other|Marking cN+ nodes|These patients have already undergone neoadjuvant chemotherapy for locally advanced breast cancer with metastasis to the axillary lymph nodes. During standard of care needle-directed I-125 seed localization, the research marker will also be deployed through the same needle. Ultrasound detection of the marker will be compared to conventional biopsy markers and the I-25 seed.
16300141|NCT04674839|Experimental|MS-20|8 ml/day for 8 weeks
16300142|NCT04674839|Other|Placebo|8 ml/day for 8 weeks
16300143|NCT04674826|Experimental|TR (Test-Reference)|Treatment period 1: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T) Treatment period 2: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R)
16300144|NCT04674826|Experimental|RT (Reference-Test)|Treatment period 1: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R) Treatment period 2: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T)
16300145|NCT04674813|Experimental|Administration of CC-95266|Subjects will receive CC-95266 after completion of lymphodepleting (LD) chemotherapy (fludarabine and cyclophosphamide)
16300146|NCT04674800|Experimental|Single, test arm|MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval
16300147|NCT04674774|Experimental|tegoprazan based bismuth quadruple therapy group|tegoprazan based bismuth quadruple therapy group
16300148|NCT04674774|Active Comparator|PPI based bismuth quadruple therapy group|PPI based bismuth quadruple therapy group
16300149|NCT04674761|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 24 weeks.
16300150|NCT04674761|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks.
16300151|NCT04674748|Experimental|Dose Escalation of INCB086550|In this study 3 dose levels will be evaluated to determine the MTD or RP2D (Decided by SMC according to the safety and PK data)
16300152|NCT04674735|Experimental|APSLXR|
16300153|NCT04674722|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99mTc-NM-02 (99mTc labeled anti-HER2 sdAb) in a single dose injection.
16300154|NCT04674722|Experimental|Injection of 188Re-NM-02|Ten breast cancer patients recruited to the study will be administered 66 MBq/kg of 188Re-NM-02 (188Re labeled anti-HER2 sdAb) in a single dose injection.
16300155|NCT04674709|Placebo Comparator|Safety of Oleander 4X HPUS|: To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).
16300156|NCT04674709|Experimental|Pharmacokinetics evaluation of Oleander 4X HPUS|To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.
16300157|NCT04674696|Experimental|Experimental|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
16300158|NCT04674683|Experimental|Test Arm|HBI-8000 30 mg oral BIW + nivolumab 480 mg IV Q4W
16300159|NCT04674683|Placebo Comparator|Control Arm|Placebo oral BIW + nivolumab 480 mg IV Q4W
16300160|NCT04674670|Active Comparator|Substudy 1: Fibromyalgia patients, active comparator|Substudy 1 incorporates a 12-weeks a pharmacological intervention (drug or placebo) in patients with fibromyalgia and two MRI testing sessions pre- and post-treatment. Low-dose naltrexone (LDN) will be administered as the active comparator in substudy 1 to down-regulate microglial activation.
16300161|NCT04674670|Placebo Comparator|Substudy 1: Placebo comparator for Fibromyalgia patients|Substudy 1 incorporates a 12-weeks a pharmacological intervention (drug or placebo) in patients with fibromyalgia and two MRI testing sessions pre- and post-treatment. In this arm, a placebo will be administered for comparison with the low dose naltrexone as the active comparator.
16300162|NCT04674670|Experimental|Substudy 2: Healthy controls|In this arm of substudy 2, healthy controls will be administered placebo or a dopamine receptor agonist or a dopamine receptor antagonist on separate days to investigate the role of dopamine and fronto-striatal functional connectivity in relation to emotional-motivational pain processing.
16300163|NCT04674670|Experimental|Substudy 2: Fibromyalgia patients|In this arm of substudy 2, fibromyalgia patients will receive placebo or a dopamine receptor agonist to investigate the effects of normalizing dopamine transiently on fronto-striatal connectivity and emotional-motivational pain processing.
16300164|NCT04674657||caspofungin|Adult critically ill patients on ECMO receiving caspofungin therapy
16300165|NCT04674657||posaconazole|Adult critically ill patients on ECMO receiving posaconazole therapy
16300166|NCT04674644|Other|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals|Dental professionals
16300167|NCT04674631||Case group 1|60 patients with score of 12 or more on Leeds assessment of neuropathic symptoms and signs (LANSS) questionnaire will be included in the neuropathic pain group.
16300168|NCT04674631||Case group 2|60 patients with scores less than 12 on LANSS will be included in the group without neuropathic pain.
16300169|NCT04674631||Control group|60 age and BMI-matched healthy controls
16300170|NCT04674618|Experimental|US-assisted nusinersen administration|A paramedian sagittal oblique view will be used to identify with ultrasound specific lumbar interspaces. After local anesthesia the spinal needle will be used to identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
16300171|NCT04674618|No Intervention|landmark based nusinersen administration|The desired intervertebral space will be first identified by manual palpation of surface landmarks and marked on the skin. After local anesthesia the spinal needle will be usedto identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
16300172|NCT04674605||ocular myasthenia gravis|
16300173|NCT04674605||generalized myasthenia gravis|
16300174|NCT04674592||Tibial fracture|Patients with a traumatic tibial fracture and without acute compartment syndrome.
16300175|NCT04674592||Tibial fracture complicated by acute compartment syndrome|Patients with a tibial fracture and acute compartment syndrome of fractured leg.
16300176|NCT04674592||Acute compartment syndrome without fracture|Patients with acute compartment syndrome but without a fracture.
16300181|NCT04674540||Sedation and Analgesia Implementation Status Group|To investigate the implementation status of sedation and analgesia in ICU critical patients.
16300182|NCT04674527|Experimental|experimental group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.And elemene injectable emulsion will be given for 80 -120 ml/day in each 14-day cycle or 21-day cycle.
16300183|NCT04674527|Experimental|contral group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
16300184|NCT04674514|Experimental|Arm A (Single agent)|Dose escalation APG-2575 at 3 dose levels 3+3 design.
16300185|NCT04674514|Experimental|Arm B (combo)|Dose escalation APG-2575 at 3 dose levels in combination with Rd, 3+3 design.
16300186|NCT04674501||Thoracic irradiation|A cohort of cancer patients who receive thoracic irradiation. Patients with any type of malignancy, such as lung cancer, breast cancer, esophageal cancer, or thymoma, are eligible as long as the patients undergo thoracic irradiation.
16300187|NCT04674488|Experimental|TILs intervention|
16300188|NCT04674462|Experimental|CpG-adjuvanted HBV Vaccine|
16300189|NCT04674462|Active Comparator|Traditional HBV Vaccine|
16300190|NCT04674449|Active Comparator|Intervention Group - Stratified Medicine|All randomised participants will receive stratified medicine. The subjects will undergo functional coronary angiography involving guidewire-based coronary function tests (interventional diagnostic procedure, IDP) as an adjunct to invasive coronary angiography. The IDP results will be disclosed to the catheter laboratory clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and IDP findings.
16300191|NCT04674449|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also receive the IDP at time of the angiogram. The results of the IDP will be concealed from the catheter laboratory clinician who will be blinded. The cardiac physiologist / clinical scientist will remain unblinded for the purpose of data recording and quality assurance. The sham procedure is intended to be the same as in the Intervention Group. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and IDP findings.
16300192|NCT04674436|Experimental|6 minute walking break|Participants will walk casually for 6 minutes following one hour of game play, then continue play for one more hour.
16300193|NCT04674436|Experimental|6 minute rest break|Participants will rest supine for 6 minutes following one hour of game play, then continue play for one more hour.
16300194|NCT04674436|No Intervention|Continuous play|Participants will play continuous for 2 hours.
16300195|NCT04674423|Experimental|TAF Treatment|TAF treatment for 144 weeks and followed for 48 weeks after 144-week TAF treatment
16300196|NCT04674423|No Intervention|Observation arm|Observation for 144 weeks
16300197|NCT04674410||Empiric Antibiotic|All patients with COVID19 diagnosed on admission who received empiric antibiotics within 48 hours of admission without another site of infection identified or suspected septic shock.
16300198|NCT04674410||Control group|All patients admitted with COVID19 who did not receive empiric antibiotics in the first 48 hours of admission
16300199|NCT04674397||Test group|Living kidney donors
16300200|NCT04674384|Active Comparator|Intermittent Low Energy Diet (ILED)|
16300201|NCT04674384|Active Comparator|Continuous Low Energy Diet (CLED)|
16300202|NCT04674358|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.|
16300203|NCT04674358|Placebo Comparator|Vehicle Ophthalmic Solution administered over two consecutive days.|
16300204|NCT04674345|Experimental|Sorafenib group|Sorafenib will be administered at 45-60 days post-transplantation and continued until one year post-transplantation.
16300205|NCT04674345|No Intervention|Non-maintenance group|Neither sorafenib nor other FLT3 inhibitors will be used, unless the patient experiences relapse.
16300206|NCT04674332|Experimental|long acting insulin|
16300207|NCT04674332|Active Comparator|multiple dose regimen|
16300208|NCT04674319|Experimental|Brain engagement while using compesatory modes for walking|Brain engagemnent (recruitment of attention) is measured during four walking conditions
16300209|NCT04674306|Experimental|α-lactalbumin and zymosan|"Participants will be treated with successively higher doses of α-lactalbumin and zymosan in a traditional 3 + 3 phase I trial design. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants will be enrolled sequentially into 1 of 3 different dose levels each comprised of cohorts of 1-6 participants until the MTD has been identified (intra-patient dose escalation not permitted), after which the MTD will be expanded to 6 participants. Successively lower doses will be expanded to 6 participants until the lowest DL associated with immune response has been expanded. A dose level intermediate between 100 and 1000 mcg will be studied if the 1000 mcg dose is above the MTD and the 100 mcg dose does not produce the desired immunologic effect
~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan
~DL2: 100 mcg a-lactalbumin + 100 mcg Zymosan
~DL3: 1000 mcg a-lactalbumin + 1000 mcg Zymosan"
16300210|NCT04674267|Other|Pre-Implementation Phase|"To evaluate the perceived needs of Older Adults A diagnosed with gastrointestinal malignancies, their identified caregivers, staff, and faculty to characterize the implementation setting at DF/BWCC for a geriatric consultation.
~To refine the proposed REACH program implementation plan based on qualitative feedback provided by OA patients, their identified caregivers, staff, and faculty."
16300211|NCT04674254|Active Comparator|Anti-vascular endothelial growth factor agent|Intravitreal injections of 1.25 mg/0.05 ml of Bevacizumab every 4 weeks through 12- week visit then pro re nata to complete 12 months according to Protocol S.
16300237|NCT04674072|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions
16300587|NCT04671589|Placebo Comparator|Placebo|Placebo intravenous every 8 hours
16300212|NCT04674254|Active Comparator|Targeted retinal photocoagulation|Targeted retinal photocoagulation guided by fundus fluorescein angiography will be administered after topical anesthesia, directed to areas of nonperfused peripheral retina plus a 1-disc area margin using the Mainster lens. Subsequent treatments if needed will be delivered at 3 monthly intervals for a minimum follow-up of 12 months. The extent of the laser applied will be determined based on areas of nonperfusion identified by fundus fluorescein angiography.
16300213|NCT04674254|Active Comparator|Standard pan-retinal photocoagulation|"Standard pan-retinal photocoagulation will be performed at baseline and then every 3 months thereafter if needed, for a minimum follow-up period of 12 months.
~PRP will be performed at two consecutive sessions with adherence to the guidelines of the Early Treatment Diabetic Retinopathy Study Group. Following topical anesthesia, 1000 to 1200 laser spots will be applied to the retina at each session with a 532 nm frequency doubled Nd-YAG laser (VISULAS, Carl Zeiss, Germany) using a spot size of 300-500 μm. PRP will be applied in all 4 retina quadrants.
~The Mainster lens will be used. Retreatment will be done according to the Diabetic Retinopathy Clinical Research network protocol S classification for patients with stable, worsening, or with failure of regression of neovascularization."
16300214|NCT04674241|Active Comparator|DEX group|The DEX group will receives dexmedetomidine intraoperative.
16300215|NCT04674241|Placebo Comparator|Placebo group|The placebo group will receives 0.9% saline intraoperative.
16300216|NCT04674228||Observational (medical record review)|Patients who participated in MAY2016-07-01 undergo review of medical records.
16300217|NCT04674215|Experimental|intervention group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.
~The patients in the intervention group were given a planned in-bed turning and mobilization training in the patient's room by the researcher one day before the surgery. This training included explaining the importance of postoperative mobility, demonstrating the correct in-bed turning and mobilization steps through pictures with the Illustrated In-Bed Turning and Mobilization Training Material, answering questions (if any), and finally, simulating postoperative in-bed turning and the first mobilization using the role-playing technique in collaboration with the patient."
16300218|NCT04674215|Other|control group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.
~Patients in the control group received routine clinical care. This care included the provision of verbal information to the patient at different times by the primary physician and/or nurse about postoperative in-bed turning and mobilization and answering questions if any."
16300219|NCT04674202||Pharmaceutical interview|This group will benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
16300220|NCT04674202||No pharmaceutical interview|This group will not benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
16300221|NCT04674189|Experimental|CVnCoV: Group 1, Lot 1|Participants in Group 1 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16300222|NCT04674189|Experimental|CVnCoV: Group 2, Lot 2|Participants in Group 2 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16300223|NCT04674189|Placebo Comparator|Placebo|Participants will receive a placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16300224|NCT04674176|Experimental|Rifaxamin (R)|Patients in the experimental group will receive additional instructions to take 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet. The experimental group will be provided the required doses of Rifaximin at the initial weigh-in and office visit.
16300225|NCT04674176|No Intervention|Control|Participants in the control group will undergo no intervention and will only be asked to follow an Intermittent fasting diet.
16300226|NCT04674163|Experimental|Patients with clinical signs that suggest Multiple Sclerosis (MS) or Guillain Barré Syndrome (GBS)|
16300227|NCT04674150|Sham Comparator|Non-AR Group|Patients allocated to the control group will be able to interact with the iPad and visualize objects and decals in the walls but not able to initiate the AR technology. In other terms, patients in this group will be provided with the same iPad to the AR group patients with the only exception that the AR technology will be off and will only see objects through the device camera in normal reality.
16300228|NCT04674150|Active Comparator|AR Group|Patients randomized to the AR group will be able to use the iPad and SpellBound app to initiate the AR experiences in the game.
16300229|NCT04674137|Experimental|XC8 100 mg|XC8 100 mg orally
16300230|NCT04674137|Placebo Comparator|Placebo|Placebo orally
16300233|NCT04674111|Experimental|Vortex Feasibility Study (Vortex FIH)|Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)
16300234|NCT04674098||Usual Care|Every patient who is admitted or transferred to the target unit during both the baseline and intervention phases of the study will be approached by a member of the research staff to be a subject in the study. The patient will be informed of the overall study objectives and be requested to provide informed consent to participate. The patient's involvement in the study will include having the research staff access and extract relevant outcome variables collected from their electronic health record (EHR) (AEs, admissions to the ICU, hospital length of stay and activation of the rapid response team) as a result of their hospital stay.
16300235|NCT04674098||Intervention|If the patient provides consent during the intervention phase, the BAS technology will passively monitor their vital signs generated by the Philips vital sign monitor by relaying their deidentified vital signs data to the CLU, proprietary Cloud server, and subsequently Lumori® on a study-issued cell phone of the RN who is primarily responsible for the patient's care. Patient's admitted or transferred to the targeted unit will NOT be excluded from being approached to participate in the study.
16300236|NCT04674072|Experimental|Intervention group|The intervention group will be instructed to include the reverse Nordic curl exercise into their warm up 15 to 20 mins before training session (3 times per week) during one season (6 months).
16300238|NCT04674046|Experimental|Nonoperative treatment if deltoid ligament is intact|AirCast Air-stirrup (DJO Global) functional orthosis for 6 weeks.
16300239|NCT04674046|Experimental|Operative treatment if deltoid ligament is ruptured|Open reduction, internal fixation of the fibular fracture using plate and screws.
16300240|NCT04674033||Consumer|Participants who self-report regular consumption of non-nutritive sweeteners (>/=5 servings/week) based on a pre-screening dietary survey.
16300241|NCT04674033||Non-Consumer|Participants who self-report no consumption of non-nutritive sweeteners (0 servings/week) based on a pre-screening dietary survey.
16300242|NCT04674020|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI).
16300243|NCT04674007||Healthy basketball, volleyball and handball players|Healthy basketball, volleyball and handball players
16300244|NCT04673994||Chronic Stroke|Individuals 40-80 years old who have had a stroke 6 months to 5 years ago.
16300245|NCT04673994||CON|Control group (CON) comprised of age- and sex-matched healthy adults.
16300246|NCT04673994||CONyoung|Healthy, young adult control group (CONyoung) who are age 18-30 years old.
16300247|NCT04673981|Experimental|patient treated for a oral cavity and oropharynx cancer|questionnaire and tests to evaluate neuropathic pain
16300248|NCT04673968|Active Comparator|prehabilitation (P)|inhospital exercise training 5 times/week, 5~6 weeks during nCRT (neoadjuvant chemoraiotherapy); home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
16300249|NCT04673968|No Intervention|control group (C)|no prehabilitation
16300250|NCT04673942|Experimental|Part 1: Dose Escalation Safety Run-In|Subjects will be treated with AdAPT-001 as a single injection, one time.
16300251|NCT04673942|Experimental|Part 2: Dose Expansion Single-Agent|6 subjects will be enrolled in the Lead In Cohort. A Safety Analysis will be performed after 6 subjects have received at least 4 doses. Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled. All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
16300252|NCT04673929||patients with HNC recurrence treated with TORS|Report of disease-free survival at 2 years for patients with HNC recurrence treated with TORS
16300253|NCT04673916|Active Comparator|Clobetasol treatment|The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied [11]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
16300254|NCT04673916|Active Comparator|Anti-inflammatory mouthwash|In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
16300255|NCT04673903|Experimental|Intervention group|"The intervention group will be instructed to include the Copenhagen adduction exercise into their warm up before training session (3 times per week) during one season (6 months).
~The Copenhagen adduction exercise is a body-weight exercise which mainly works the groin and hip adductor. It has a large eccentric component, meaning the muscles are working whilst lengthening."
16300256|NCT04673903|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
16300257|NCT04673877|Experimental|Bier Block Group|Subjects will receive antibiotic Vancomycin from a Bier Block (injected into an arm vein with a tourniquet up to keep antibiotics in the arm). Samples will be collected from bone and tissue that is normally removed during surgery.
16300258|NCT04673877|Active Comparator|Systemic Intravenous IV Group|Subjects will receive antibiotic Vancomycin through intravenous administration. Samples will be collected from bone and tissue that is normally removed during during surgery.
16300259|NCT04673864|Experimental|Sequence 1|"Period 1: D012, D326, D337- A single oral dose of 3 tablets under fasting condition
~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition
~Period 3: D012, D326, D337- A single oral dose of 3 tablets under fasting condition
~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
16300260|NCT04673864|Experimental|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition
~Period 2: D012, D326, D337- A single oral dose of 3 tablets under fasting condition
~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition
~Period 4: D012, D326, D337- A single oral dose of 3 tablets under fasting condition"
16300261|NCT04673851|Experimental|FEP Clients|Approximately 30 first episode psychosis (FEP) clients recruited from First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in the online platform Horyzons for 3 months as a part of their care plan. Participants will be encouraged to use both the therapeutic content and the moderated online community throughout their time in the study.
16300262|NCT04673851|Other|FEP Clinicians|Approximately 20 providers (clinicians and peer support specialists) affiliated with First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in a focus group discussing the implementation and integration of Horyzons into their care routine with clients who participated in the study.
16300263|NCT04673838|Experimental|Lower Extremity Sensory Training + Bobath Therapy|Intervention Group will have Lower extremity sensory training and Bobath Therapy.
16300264|NCT04673838|Active Comparator|Bobath Therapy|Control Group will have only Bobath Therapy. Bobath approach will be applied for 4 weeks, 3 days a week and 12 sessions in total.
16300265|NCT04673825|Experimental|Intervention: patient initiated care + telemonitoring|Patients in the intervention group will only have a scheduled outpatient visit at baseline and after 1 year. Patients will answer questionnaires and have routine blood tests done before every visit. At 6 months, there will be a remote monitoring check-up and results will be checked by the physician. If indicated, a telephone or video call can take place or a physical visit can be planned. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
16300266|NCT04673825|No Intervention|Control group|The standard care group will have a scheduled outpatient visit at baseline and after 1 year, and in between as usual, scheduled at the discretion of the treating rheumatologist. Prior to each visit, patients complete questionnaires in SpA-Net and have routine blood tests done. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
16300267|NCT04673812|Active Comparator|Bupivacaine-Fentanyl Spinal Anaesthesia|
16300268|NCT04673812|Active Comparator|Bupivacaine-Fentanyl-Naloxone Spinal Anaesthesia|
16300269|NCT04673799|Experimental|MV088|MV088 injection (60mg) by subcutaneous injection once on the first day
16300270|NCT04673799|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day
16300271|NCT04673786|Experimental|CT-P43|All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.
16300272|NCT04673786|Active Comparator|Stelara|Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.
16300273|NCT04673773|Experimental|Feasibility / A massive open course|"The online MOOC contains eight units which cover the following topics (Understanding low back pain (LBP), Physical activity and exercise in relation to LBP, Psychological factors, Sleep / nutrition, Management of LBP at the workplace, Communication with health care, Other issues related to LBP). Each unit will include short factual texts, short videos (2-5mins) with older workers (aged 55+ years) with low back pain and professional experts, as well as knowledge tests. The complete MOOC will take 2-3 hours to complete. It would be possible to complete the MOOC at one time however users will be recommended to complete two units per week over a month period.
~The mobile game is designed to encourage participation with the MOOC by providing feedback on engagement with the MOOC, presentation of quizzes to test knowledge gained on the MOOC, as well as feedback on clinical markers of their condition e.g. Mood, pain, physical activity levels."
16300274|NCT04673760|Experimental|Arm 1:Highly structured specialized palliative home care|"Specialized palliative home care teams provide ambulant palliative care following the PROAKTIV approach. This approach, including additional to usual care:
~Creating and systematically updating of a palliative care plan (including advance directives).
~Regular palliative assessment of the care situation. Updating general practitioner and home care nurses about the care situation. Specialized palliative care educational material and support."
16300275|NCT04673760|Other|Arm 2: Normally structured specialized palliative home care|Specialized palliative home care teams provide ambulant palliative care as usual
16300276|NCT04673760|No Intervention|Arm 3: No care of specialized palliative home care teams at study inclusion|No care of specialized palliative home care teams at study inclusion
16300277|NCT04673747|Experimental|Group 1 (Total Hip Arthroplasty with intraoperative manual correction)|Patients will undergo total hip arthroplasty with intraoperative manual correction of Iliosacral displacement of the sacroiliac joint
16300278|NCT04673747|Active Comparator|Group 2 (Total hip Arthroplasty: standard method)|Patients will undergo total hip arthroplasty according to the standard method
16300279|NCT04673721|Active Comparator|Fortified eggs + Intermittent fasting|Consume at least 12 fortified eggs per week with 16-hour fast and then an 8-hour nutritional window.
16300280|NCT04673721|Active Comparator|Non-egg supplemented diet + Intermittent fasting|Maintain consumption of 2 or less eggs per week with 16-hour fast and then an 8-hour nutritional window.
16300281|NCT04673721|Active Comparator|Fortified eggs + Usual care diet|Consume at least 12 fortified eggs per week with consistency with current diet.
16300282|NCT04673721|Placebo Comparator|Non-egg supplemented diet + Usual care diet|Maintain consumption of 2 or less eggs per week with consistency with current diet.
16300283|NCT04673708|Other|Hashim Talib Hashim|It is a video with +18 different contents to know the effect of much video than the others.
16300284|NCT04673708|Experimental|Mustafa Ahmed Ramadhan|Is is an assessment of the vital signs among the participants and the change with the showing of videos.
16300285|NCT04673695|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)
~Period 2: Test drug(CKD-344 60 mg)"
16300286|NCT04673695|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)
~Period 2: Reference drug(Lixiana 60 mg)"
16300287|NCT04673682|Experimental|Group 1|"Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)
~Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)"
16300288|NCT04673682|Experimental|Group 2|"Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)
~Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)"
16300289|NCT04673669|Experimental|Single group|measuring the strength of the tendon of the posterior tibial muscle in healthy subjects with a hand-held dynamometer by two examiners and with an isometric dynamometer
16300290|NCT04673656|Placebo Comparator|Test Group 1|Group 1 will receive 84 days of placebo BID
16300291|NCT04673656|Active Comparator|Test Group 2|Group 2 will receive 84 days of 0.5 g of BKR-017 BID
16300292|NCT04673656|Active Comparator|Test Group 3|Group 3 will receive 84 days of 1.0 g of BKR-017 BID
16300293|NCT04673656|Active Comparator|Test Group 4|Group 4 will receive 84 days of 1.5 g of BKR-017 BID
16300294|NCT04673643|Experimental|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
16300296|NCT04673617|Experimental|Dose confirmation of AB-101 as monotherapy and in combination with rituximab (Phase 1)|
16300297|NCT04673617|Experimental|Indolent NHL arm--AB-101 given with rituximab to patients with indolent B-cell NHL (Phase 2)|
16300298|NCT04673617|Experimental|Aggressive NHL arm--AB-101 given with rituximab to patients with aggressive B-cell NHL (Phase 2)|
16300299|NCT04673604|Placebo Comparator|Triple preservative-free therapy with placebo in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use placebo (artificial tears) in the evening (21:00) for 6 months. At the end of this period patients will be crossed over to the other therapy (cyclosporine 0.1% in the evening)
16364340|NCT04227977|Experimental|Treatment|JuxtaFlow
16300300|NCT04673604|Active Comparator|Triple preservative-free therapy with cyclosporine 0.1% in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use cyclosporine 0.1% drops in the evening (21:00) for 6 months. At the end of this period all patients will be crossed over to the other therapy (placebo in the evening)
16300301|NCT04673591|Experimental|Tregalizumab|
16300302|NCT04673591|Placebo Comparator|Matched placebo|
16300303|NCT04673578|Experimental|Celecoxib|Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight > 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.
16300304|NCT04673578|Placebo Comparator|Placebo (microcrystalline cellulose)|Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.
16300305|NCT04673565|No Intervention|Control|Control groups that undergo standard audiological care
16300306|NCT04673565|Experimental|Treatment|Treatment groups that undergo motivational interviewing with audiological care
16300307|NCT04673539||Single group|Instrument validation in stroke patients
16300308|NCT04673526|Experimental|Intersphincteric resection|After a laparoscopic TME (total mesorectal excision) is carried out down to the elevator ani plane and the anorectal junction, the intersphincteric plane is dissected, opening the space between puborectalis muscle and interior sphincter. Margin of resection is at least 1 cm below the lower margin of the tumor. Rectal excision is completed with transanal circumferential dissection and after specimen extraction through the anus, a colo-anal hand sewn anastomosis is fashioned.
16300309|NCT04673526|Active Comparator|Abdomen-perineal procedures|After identification of the elevator ani plane, the descendent colon is transected with a linear stapler and a terminal stoma is fashioned. Then, a circumferential incision is made around anal orifice and perineal dissection is performed circumferentially to the pelvic cavity. Perineal defect is repaired performing mono-lateral or bilateral inferior gluteal flap.
16300310|NCT04673513|Active Comparator|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy will be provided as described in Beck et al. (1979) and Beck (2011), with adaptations for the treatment of comorbid personality disorders as described in Beck et al. (2015).
16300311|NCT04673513|Active Comparator|Cognitive Behavioral Therapy - Skill enhanced (CBT-SE)|This condition includes a variation of CBT (as provided in the other condition) with special emphasis on helping clients to develop the skills of CBT.
16300312|NCT04673500|Experimental|Propofol-lidocaine through large vein|Eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the antecubital fossa and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
16300313|NCT04673500|Placebo Comparator|Propofol-lidocaine through small vein|Another eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the dorsum of hand and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
16300314|NCT04673474|Experimental|Arm A|Hemay022 Period 1, Fasted control → Period 2, Fed control
16300315|NCT04673474|Experimental|Arm B|Hemay022 Period 1, Fed control → Period 2, Fasted control
16300316|NCT04673461|Experimental|STA363 containing 90 mg (60 mg/mL) lactic acid|"STA363 containing 90 mg (60 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.
~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
16300317|NCT04673461|Experimental|STA363 containing 180 mg (120 mg/mL) lactic acid|"STA363 containing 180 mg (120 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.
~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
16300318|NCT04673461|Placebo Comparator|Placebo|"Placebo will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.
~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
16300320|NCT04673435|Experimental|Permeaderm as temporary coverage|A: temporary coverage with PermeaDerm until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
16300321|NCT04673435|Active Comparator|FHCA as temporary coverage|B: temporary coverage with FHCA until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
16300322|NCT04673435|Experimental|Permeaderm over widely meshed autograft|C: temporary coverage of widely meshed autograft with PermeaDerm until healing occurs and PermeaDerm can remove
16300323|NCT04673435|Active Comparator|FHCA over widely meshed autograft|D: temporary coverage of widely meshed autograft with FHCA until healing occurs
16300324|NCT04673422|Experimental|Montelukast|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
16300325|NCT04673422|Placebo Comparator|Placebo|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
16300326|NCT04673409||Suspected myocarditis of undefined aetiology|Patients with signs and symptoms of acute myocarditis (as defined by the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases).
16300327|NCT04673409||Suspected myocarditis with autoimmune rheumatic disease|Patients with suspected myocarditis due to an underlying AIRD.
16300328|NCT04673396|Experimental|Tolerance test|The design is based on 3+3 dose escalation: three subjects were enrolled in each dose group, administered once a day for 2 weeks, and were observed for 7 days after withdrawal. If dose-limiting toxicity (DLT) was not observed, the dose was incresed to the next dose group. If dose-limiting toxicity (DLT) was found in 2 or more patients in a given dose group, the climbing test was terminated and the dose was reduced by 1 dose. If there were only three subjects, three more subjects were observed, so that the MTD dose group had at least six evaluable subjects.If DLT occurs in 1 patient in a given dose group, 3 more subjects should be added to that dose group. If DLT occurs in 1 or more of these 3 subjects, the climb will be stopped and the dose group will be reduced by 1 dose group. If there are only 3 subjects, 3 more subjects will be observed, so that at least 6 patients in the MTD dose group can be evaluated.
16300329|NCT04673396|Experimental|Pharmacokinetic studies|At the same time of tolerance test, blood PK sampling was performed. At the end of the tolerance test in each group, on the premise of good safety, and after evaluation by the researchers, additional cases were selected from the three dose groups (low, medium and high) for pharmacokinetic study, so as to ensure that at least 8 patients could be evaluated for PK in each group.
16300330|NCT04673396|Active Comparator|Comparative Study|It is planned to select the 20mg dose of norcantharidin sodium for injection to carry out pharmacokinetic study of 8 cases. The specific research design will be formulated after the tolerance and pharmacokinetic test of norcantharidin lipid microsphere injection is completed.
16300331|NCT04673383|Experimental|Healthy volunteers (active)|SPL026 to be administered by IV injection
16300332|NCT04673383|Experimental|Healthy volunteers (placebo)|SPL026-matched placebo to be administered by IV injection
16300333|NCT04673383|Experimental|Patients (active)|SPL026 to be administered by IV injection
16300334|NCT04673383|Experimental|Patients (placebo)|SPL026-matched placebo to be administered by IV injection
16300335|NCT04673370|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
16300336|NCT04673370|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
16300340|NCT04673344|No Intervention|Partial Rotator Cuff Repair|Routine partial rotator cuff repair
16300341|NCT04673344|Active Comparator|Partial Rotator Cuff Repair with Regeneten Scaffold|Routine partial rotator cuff repair with the addition of the Regeneten scaffolding patch
16300342|NCT04673331||Cystic fibrosis|"Inclusion Criteria:
~Having been diagnosed with cystic fibrosis Being over 18 years old The clinical condition is stable Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis
~Exclusion Criteria:
~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
16300343|NCT04673331||Healthy individuals|"Inclusion Criteria:
~Being over 18 years old Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis
~Exclusion Criteria:
~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
16300344|NCT04673318|No Intervention|Control|Course of recovery with standard of care.
16300345|NCT04673318|Active Comparator|Exercise training|low resistance velocity based exercise training ~40 min, 3 times a week at home for 8 weeks
16300346|NCT04673318|Experimental|heat therapy|heat therapy (~40C skin temperature) with a leg garment 5 times a week for 40-55 min for 8 weeks
16300347|NCT04673305|Experimental|Arm 1|patients ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months
16300348|NCT04673292|Experimental|Fixed site SOC testing|Fixed site Standard of Care (SOC) testing
16300349|NCT04673292|Experimental|Community-based testing|Community-based, mobile van testing
16300350|NCT04673292|Experimental|Self-collected testing|Self-collected, home-based testing
16300351|NCT04673266|Experimental|romiplostim|Romiplostim will be administered from the beginning of the next chemotherapy cycle with a starting dose of 3 mcg/kg subcutaneously. Dose will be adjusted once weekly, from week 2, based on PLT response to the individualized target dose (ITD). The maximum dose of romiplostim will be 6 mcg/kg.
16300352|NCT04673253|Active Comparator|Passive leg raise|group for passive leg raise
16300353|NCT04673253|Placebo Comparator|Control|
16300354|NCT04673227||Contact with active TB/ LTBI|After a close contact with bacteriologically confirmed TB suspicion for LTBI with an evidence of previous BCG vaccination status TB confirmed with TST (TST ≥ 5 mm or BCG unvaccinated or TST ≥ 15 mm for BCG vaccinated) 20 children and adolescents 20 adults
16300355|NCT04673227||Active TB group|Active TB group with positive microbial culture and pathological chest radiography or chest CT 20 children and adolescents 20 adults
16300356|NCT04673227||Contact with active TB/ negative|After a close contact with bacteriologically confirmed TB no evidence of TB in TST or IGRA test for 3 months 20 children and adolescents 20 adults
16300388|NCT04673006||anesthesiologists who will perform endotracheal intubation and extubation for general anesthesia|All anesthesiologists in this study will use face shield for facial protection. Face shield swab will be done before and after the procedures (intubation and extubation)
16367351|NCT04206982|Active Comparator|Pulmonary vein isolation arm|
16300357|NCT04673214|Experimental|Triple therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban tablets of 10 mg will take 1 every 24 hours for 10 days
16300358|NCT04673214|Active Comparator|Double therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half a tablet orally every 24 for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.
16300359|NCT04673201|Active Comparator|Viscotrabeculotomy group|Management of medically uncontrolled steroid induced glaucoma by viscotrabeculomy technique
16300360|NCT04673201|Active Comparator|"Trabeculectomy with MMC group"|Management of medically uncontrolled steroid induced glaucoma by trabeculotomy with MMC
16300361|NCT04673175|Experimental|Ceftolozane-Tazobactam|Participants receive ceftolozane-tazobactam by injection directly into the vein (intravenously, IV) every 8 hours for 10-14 days.
16300362|NCT04673162|Experimental|A SOC plus MP|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Methylprednisolone 1gr daily iv on days 1,2,3
16300363|NCT04673162|Active Comparator|B SOC plus Pb|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Placebo
16300364|NCT04673149|Experimental|GLS-5310 0.6mg [Group 1a]|0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
16300365|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
16300366|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1c]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12.
16300367|NCT04673149|Placebo Comparator|Placebo [Group 2a]|Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12).
16300368|NCT04673149|Experimental|GLS-5310 1.2mg [Group 2b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12).
16300369|NCT04673136|Experimental|Colonoscopy assisted by GI-GENIUS|
16300370|NCT04673136|Placebo Comparator|Standard colonoscopy|
16300371|NCT04673123|Experimental|Core stabilization+Traditional physical therapy Informing about fall prevention|Core stabilization + Traditional physical therapy (patient-specific upper and lower extremity stretching, relaxation and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
16300372|NCT04673123|Active Comparator|Traditional physical therapy + Informing about fall prevention|Traditional physical therapy (patient-specific upper and lower extremity stretching, relaxation and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
16300373|NCT04673110||Anastomotic leakage group|9 patients developed anastomotic leakage (8%) in a median of 8 days (range: 5-9) median CRP level postoperative day 4:164mg/dL
16300374|NCT04673110||no Anastomotic leakage group|117 patients (92%) median CRP level postoperative day 4: 64mg/dL
16300375|NCT04673097|Experimental|Group 1|
16300376|NCT04673097|Active Comparator|Group 2|
16300377|NCT04673097|Active Comparator|Group 3|
16300378|NCT04673071|Active Comparator|Thread Embedding Acupuncture (TEA)|TEA once a month for 4 months + AEDs
16300379|NCT04673071|Sham Comparator|Sham-TEA (STEA)|STEA once a month for 4 months + AEDs
16300383|NCT04673045|Active Comparator|Active neuromuscular electrical stimulation|This group will receive active NMES delivered the electrical current through electrodes inserted in saline-soaked sponges.
16300384|NCT04673045|Sham Comparator|Sham neuromuscular electrical stimulation|This group will receive sham NMES
16300386|NCT04673019|Experimental|Immediate Intervention|"The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months:
~Months 1- 3 (Approximately Day 1-Day 90)
~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).
~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator. We are interested in learning whether the phone calls are necessary or if the Nurse AMIE platform can stand alone and see the same effect.
~Months 4-6 (Approximately Day 91-180) o Participant will continue to use Nurse AMIE, but without phone calls from study facilitator"
16300387|NCT04673019|Other|Delayed Intervention|"The delayed intervention group will receive the intervention 3 months after consent (3 months of no intervention followed by with 3 months of intervention, for a total of 6 months); the participant will follow the pattern listed below:
~Months 1- 3 Approximately (Day 1-Day 90)
~o No use of Nurse AMIE
~Months 4-6 (Approximately Day 91-180)
~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).
~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator"
16300389|NCT04672993|Experimental|Urine Collection Device for Men|Test of Urine Collection Device for Men for 7 (+/- 3/0 days).
16300390|NCT04672980|Experimental|RTX-321 Dose Escalation|Phase 1: RTX-321 administered intravenously on Day 1 of each cycle monotherapy dose escalation
16300391|NCT04672980|Experimental|RTX-321 Dose Expansion|Phase 1: RTX-321 administered intravenously on Day 1 of each cycle.
16300394|NCT04672954|Active Comparator|BI 474121|
16300395|NCT04672954|Placebo Comparator|Placebo|
16300396|NCT04672941||COPD patients|COPD patients switching from Tiotropium monotherapy to dual therapy with Tiotropium bromide plus Olodaterol
16300397|NCT04672928|Experimental|IBI318 in combination with paclitaxel|
16300400|NCT04672876|Experimental|Telotristat Ethyl (Xermelo®)|After the surgery is performed, study participants will stop taking telotristat ethyl (Xermelo®) as part of this study and there will be no follow-up visits or calls required outside of the usual postoperative care. The research team will collect clinical data on the participants' outcomes up to 30 days after surgery by accessing medical records.
16300401|NCT04672863|No Intervention|Standard of Care Group|Subjects will participate in a standardized Transplant Nutrition class between day 21-40 as per institutional protocol and will be counseled as per the Mayo Clinic standard of care vis a vis dietary intervention, standard aerobic and resistance exercise recommendations (consistent with AASLD guidelines) and other lifestyle interventions.
16300402|NCT04672863|Experimental|Behavioral: Structured Modified Mediterranean Diet|Subjects will participate in a one-on-one counselling session with a dietician, as opposed to attending the standardized Transplant Nutrition class. Counselling will be provided on the elements of the modified Mediterranean diet which emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt, moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats.
16300403|NCT04672850|Placebo Comparator|Placebo|Rice flour
16300404|NCT04672850|Active Comparator|Probiotic|Probiotic bacteria, yeast, zinc and rice brand
16300405|NCT04672837|Experimental|Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
16300406|NCT04672837|Active Comparator|Stretching Group|"A protocol of Stretching at home. 3-5 sessions twice a day. Each stretch will be maintain10 to 30 seconds. Each session 15 will take no less than 15 minutes. 7 days a week.
~Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
16300407|NCT04672824|Experimental|ChAdOx1 RVF group 1|Participants will receive ChAdOx1 RVF 5 x 10^9 vp, delivered intramuscularly
16300408|NCT04672824|Active Comparator|Control group|Placebo (Normal Saline), 0.5ml delivered intramuscularly
16300409|NCT04672824|Experimental|ChAdOx1 RVF group 2|Participants will receive ChAdOx1 RVF 2.5 x 10^10 vp, delivered intramuscularly
16300410|NCT04672824|Experimental|ChAdOx1 RVF group 3|Participants will receive ChAdOx1 RVF 5 x 10^10 vp, delivered intramuscularly
16300411|NCT04672811|Experimental|App/Sensor Intervention|All subjects will be enrolled into the same experimental group for the duration of the study
16300412|NCT04672798|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinical trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.
~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
16300413|NCT04672798|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive treatment from their mental health clinician which may include safety planning.
16300414|NCT04672785||Patients who underwent a posterior fossa craniectomy for a cerebellar hematoma|
16300415|NCT04672772||Recurrent and/or metastatic SCCHN|Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
16300416|NCT04672759||Cohort 1|Cohort 1 will include patients with unresectable stage III non-small cell lung cancer. Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16300417|NCT04672759||Cohort 2|Cohort 2 will enroll patients with histologically or cytologically confirmed NSCLC or SCLC who will or have received chemotherapy/radiotherapy at the physician's discretion.
16300418|NCT04672746|Experimental|Brief MI interaction via instant communication|The interaction communication using brief motivational interviewing will be applied via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
16300419|NCT04672746|Placebo Comparator|General health information|"The subjects will receive general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
16300420|NCT04672720|Experimental|Adding l-carnitine to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. In the experimental group, the women will receive 3 tablet of L-carnitine daily (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) from day 2 of the previous menstrual cycle until pregnancy test day.
16300480|NCT04672408|Active Comparator|His bundle pacing|Pacing programmed from the His bundle lead
16300481|NCT04672408|Placebo Comparator|Right ventricular pacing|Pacing programmed from the right ventricular lead
16300421|NCT04672720|Placebo Comparator|Adding placebo to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. The patients in the control group will receive 3 placebo tablets in similar way for 8 weeks.
16300422|NCT04672707|Experimental|Group A|Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days
16300423|NCT04672707|Experimental|Group B|Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days
16300424|NCT04672707|Experimental|Group C|Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)
16300425|NCT04672707|Experimental|Group D|Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day
16300426|NCT04672694|Active Comparator|VNB (vagus nerve block)|Vagus nerve block
16300427|NCT04672694|Placebo Comparator|Control|No vagus nerve block
16300430|NCT04672655|Experimental|ONBOARD Intervention Group|Those randomized to the ONBOARD condition will receive the intervention which consists of four 60-minute sessions with study interventionist. Each session will be scheduled two weeks apart from each other.
16300431|NCT04672655|No Intervention|CGM Only Group|Those randomized to the CGM Only group will not receive the ONBOARD intervention during their 12-month participation in the study. There will only receive 12 weeks of CGM supplies and provide A1Cs, data downloads, and survey responses during various time points in the study.
16300432|NCT04672642|Experimental|SpyGlass DS after endoscopic treatment|
16300433|NCT04672616|Experimental|Group psychotherapy|Weekly group meeting w/psychotherapist: All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or problems the group members have
16300434|NCT04672603|Experimental|Complete Preservation of Denonvilliers Fascia|Complete preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
16300435|NCT04672603|No Intervention|Partial Preservation of Denonvilliers Fascia|Partial preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
16300436|NCT04672590||Cases|Patients admitted to a study hospital meeting criteria for confirmed or probable acute new-onset neurological disease and confirmed or probable COVID-19.
16300437|NCT04672590||Controls|Patients admitted to a study hospital meeting criteria for confirmed or probable COVID-19, without confirmed or probable acute new-onset neurological disease.
16300438|NCT04672577||Arboviral infection or malaria positive cohort|
16300439|NCT04672564|Experimental|Carrimycin|Patients will receive oral dose of 400 mg carrimycin once-daily and SOC for 14 days.
16300440|NCT04672564|Placebo Comparator|Placebo|Patients will receive oral dose of Placebo once-daily and SOC for 14 days.
16300441|NCT04672551|No Intervention|Waitlist control group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. No intervention or any other procedure will be conducted during the study period of 36 weeks. Afterwards these subjects will be offered an EMDR therapy as provided in the intervention.
16300442|NCT04672551|Experimental|Intervention group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
16300443|NCT04672538|Experimental|Low transition to High Vt protocol|This arm of the study will begin with lower tidal volumes at higher respiratory rates for initial hemodynamic measurements. They will then be transitioned to the higher tidal volume at lower respiratory rate condition for repeat hemodynamic measurement.
16300444|NCT04672538|Experimental|High transition to Low Vt protocol|This arm of the study will begin with higher tidal volumes at lower respiratory rates for initial hemodynamic measurements. They will then be transitioned to the lower tidal volume at higher respiratory rate condition for repeat hemodynamic measurement.
16300445|NCT04672525|Active Comparator|RIFAMPICIN|Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.
16300446|NCT04672525|Experimental|RIFABUTIN|Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.
16300447|NCT04672512|Experimental|SAD Cohort A CORT125329|Participants will receive a single dose of CORT125329 30 mg lipid capsule formulation 1 in the fasted state on Day 1
16300448|NCT04672512|Experimental|SAD Cohort B CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 in the fasted state on Day 1. The dose will be determined after review of safety, tolerability, and PK data from SAD Cohort A.
16300449|NCT04672512|Experimental|SAD Cohorts C through H CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
16300450|NCT04672512|Placebo Comparator|SAD Cohorts A through H Placebo|Participants will receive a single dose of placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each placebo cohort will match that used in the corresponding CORT125329 cohort.
16300482|NCT04672395|Experimental|Group 1|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
16300483|NCT04672395|Placebo Comparator|Group 2|0.9% sodium chloride
16300451|NCT04672512|Experimental|MAD Cohorts A through D CORT125329|Participants will receive CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency (once- or twice-daily), formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
16300452|NCT04672512|Placebo Comparator|MAD Cohorts A through D Placebo|Participants will receive placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency, formulation, and prandial state for each cohort will match that used in the corresponding CORT125329 cohort.
16300453|NCT04672512|Experimental|Pharmacodynamic (PD) Effect Cohort|Participants will receive a single dose of prednisone 25 mg in the fasted or fed state on Day 1 of Period 1. The prandial state for the Period 1 treatment will be determined after review of safety and tolerability data from the SAD Cohorts. After a 7-day washout period, participants will receive a single dose of prednisone 25 mg and a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 of Period 2. The formulation and dose level of CORT125329 treatment in Period 2 will be determined after review of safety, tolerability, and PK data from the SAD cohorts. The prandial state for treatment in Period 2 will be the same used in Period 1.
16300454|NCT04672499|Experimental|Cohort 1: Miricorilant 900 mg (Regimen A1)|Participants will receive a single oral dose of miricorilant 900 mg (3 X 300 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
16300455|NCT04672499|Experimental|Cohort 1: Miricorilant 300 mg (Regimen A2)|Participants will receive a single oral dose of miricorilant 300 mg (2 X 150 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
16300456|NCT04672499|Experimental|Cohort 2: Miricorilant (Regimen B1 and B2)|Participants will receive a single oral dose of miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
16300457|NCT04672499|Placebo Comparator|Cohort 2: Placebo (Regimen B1 and B2)|Participants will receive a single oral dose of placebo matching miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
16300458|NCT04672499|Experimental|Cohort 3: Miricorilant (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
16300459|NCT04672499|Placebo Comparator|Cohort 3: Placebo (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
16300460|NCT04672486|Experimental|Intervention Arm|Participants will be offered an online problem-solving intervention that is delivered through a smartphone app (called POD Adventures) with telephone-based guidance from a lay counsellor. The app teaches problem-solving skills through interactive animated vignettes and personalized action plans, with encouraging prompts and feedback offered through an in-app guide character. In addition, methods of gamification are used to model and practice complementary coping strategies (e.g., relaxation) and enhance engagement. Participants will use the app remotely (i.e., from their home) in their own time.
16300461|NCT04672486|No Intervention|Usual Care|Participants randomized to the control arm will be provided with usual care. This will consist of information and contact details about local mental health service providers and two recently established government provided/affiliated helplines: (i) Manodarpan, a student mental health helpline supported by the Ministry of Human Resource Development; and (ii) a 24/7 mental health helpline (KIRAN) supported by the Social Justice and Empowerment Ministry. The same information will be provided to participants in the intervention arm.
16300462|NCT04672473|Experimental|Treatment|DAC combined with Ag-CTL
16300465|NCT04672447|Experimental|L-Citrulline + Glutathione|Citrulline: 2 grams/day, Glutathione: 200mg/day for 4 weeks
16300466|NCT04672447|Experimental|L-Citrulline|Citrulline: 6 grams/day
16300467|NCT04672447|Placebo Comparator|Placebo|Maltodextrin: 6 grams/day
16300468|NCT04672434|Experimental|Sym024 Dose Level 1|Part I, Sym024 monotherapy dose level 1
16300469|NCT04672434|Experimental|Sym024 Dose Level 2|Part I, Sym024 monotherapy dose level 2
16300470|NCT04672434|Experimental|Sym024 Dose Level 3|Part I, Sym024 monotherapy dose level 3
16300471|NCT04672434|Experimental|Sym024 Dose Level 4|Part I, Sym024 monotherapy dose level 4
16300472|NCT04672434|Experimental|Sym024 Dose Level -1|Part I, Sym024 monotherapy dose level -1. Evaluate only if needed based on tolerability
16300473|NCT04672434|Experimental|Sym021+Sym024 Dose Level 2|Part II, Sym021 in combination with dose level 2 of Sym024
16300474|NCT04672434|Experimental|Sym021+Sym024 Dose Level 3|Part II, Sym021 in combination with dose level 3 of Sym024
16300475|NCT04672434|Experimental|Sym021+Sym024 Dose Level 4|Part II, Sym021 in combination with dose level 4 of Sym024
16300476|NCT04672434|Experimental|Sym021+Sym024 Dose Level 1|Part II, Sym021 in combination with dose level 1 of Sym024. Evaluate only if needed based on tolerability
16300477|NCT04672434|Experimental|Dose Expansion Sym021 (+Sym024)|Part III, dose expansion Sym024 and/or Sym021+Sym024
16300478|NCT04672421|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after laparoscopic surgery
16300479|NCT04672421|Sham Comparator|Placebo|laparoscopic surgery
16367387|NCT04206657|Experimental|Single dose administration of 6mg KHK7580|
16300484|NCT04672382|Experimental|Morphine|"During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), while two areas will be treated with injections of isotonic saline (0.05 ml, 0.9%) as vehicle. Fifteen minutes after the injections, the measurement of FLPI and wheal size will be conducted in one morphine and one saline treated area.
~This measurement will be followed by application of histamine and cowhage in the four areas (two pre-treated with morphine and two pre-treated with vehicle)"
16300485|NCT04672369|Experimental|IBI939 in combination with Sintilimab|
16300486|NCT04672369|Active Comparator|sintilimab|
16300487|NCT04672356|Experimental|Phase Ia: IBI939 in combination with Sintilimab|IBI939 10mg/kg combination with Sintilimab
16300488|NCT04672356|Experimental|Phase Ia:IBI939 in combination with Sintilimab|IBI939 20mg/kg combination with Sintilimab
16300489|NCT04672330|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to radical nephroureterectomy and lymphadenectomy.
~Drug: Tislelizumab 200 mg per cycle, IV on day 1 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
16300490|NCT04672317|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.
~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.
~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
16300491|NCT04672291|Experimental|Safety Cohort|A randomized (4:1) initial safety cohort of 13 patients will receive 2 cycles of drug (N=10) or placebo (N=3)
16300492|NCT04672291|Experimental|Expansion Cohort|A randomized (4:1) expansion cohort will receive 3 cycles of drug (N=24) or placebo (N=6). A total of 30 patients will be accrued.
16300493|NCT04672278|Experimental|Group A|
16300494|NCT04672278|Experimental|Group B|
16300495|NCT04672265|Experimental|Mother tongue and Norwegian|Written material related to screening sent to the invitee in two languages.
16300496|NCT04672265|No Intervention|Norwegian|Written material related to screening sent to the invitee in Norwegian only.
16300497|NCT04672252|Experimental|Cohort 1|
16300498|NCT04672252|Placebo Comparator|Cohort 2|
16300499|NCT04672239|Experimental|SiS|"Participants will be onboarded (remotely) to the smartphone app Smiling instead of Smoking (SiS), and will be asked to use it for 7 weeks while they quit smoking."
16300500|NCT04672239|Active Comparator|QG|"Participants will be onboarded (remotely) to the smartphone app QuitGuide (QG), and will be asked to use it for 7 weeks while they quit smoking."
16300501|NCT04672239|Other|CTA|"Participants will be onboarded (remotely) to the NCI brochure Clearing the Air (CTA), and will be asked to use it for 7 weeks while they quit smoking."
16300502|NCT04672226|Experimental|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
16300503|NCT04672213|No Intervention|No TXA|No preoperative, intraoperative, or postoperative tranexamic acid will be given
16300504|NCT04672213|Experimental|IV TXA|1g IV TXA bolus will be given at the time of incision intraoperatively
16300505|NCT04672213|Experimental|Pre-Oral TXA|Three 650 mg tablets of oral TXA 2 hours prior to incision
16300506|NCT04672213|Experimental|Full Oral TXA|Three 650 mg tablets of oral TXA 2 hours prior to incision and three 650 mg tablets of oral TXA given each day for three days postoperatively (while in the hospital as an inpatient).
16300507|NCT04672200|Experimental|Intervention arm|This group will receive the weekly group exercise which will be delivered online initially, and in the community clubs once they are allowed to reconvene according to government guidance. The duration of the intervention is 12 weeks.
16300508|NCT04672174|Other|Effect of hearing loss on dementia|Effect of hearing loss on dementia, collected with a standardized questionnaire
16300509|NCT04672161|Experimental|Vaccine Education|Patients randomized to the Experimental arm will receive a baseline educational intervention on vaccination following a vaccination history survey. Patients will be followed 6-months after the intervention to record prospective clinical data. Evidence of vaccination-status will be documented. Besides standard of care visits and testing, no additional procedures will be carried out for the purpose of this study.
16300510|NCT04672161|No Intervention|No Vaccine Education|Patients randomized to the No Intervention arm will not receive the Vaccine Education. They will only complete the survey on their vaccination history.
16300511|NCT04672148||A|Patient who died in the 30 days after receiving mechanical thrombectomy, no matter the mortality cause
16300512|NCT04672148||B|Non-30-day-mortality group after receiving mechanical thrombectomy
16300513|NCT04672135|Active Comparator|Study Drug|Each subject receives either a single dose (SAD) or a multiple dose (MAD) of REM0046127 as oral solution with a concentration of 100 mg/mL REM0046127. The starting dose for the first cohort in the SAD is 35mg up to a maximum of 2000mg at cohort 5. The starting dose for the MAD study is 0,75 of the Maximum Tolerated Dose (MTD) from the SAD.
16300514|NCT04672135|Placebo Comparator|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of REM0046127 as oral solution with a concentration of 0 mg/mL REM0046127. The dose for each cohort is corresponding the amount of solution needed in the verum group.
16300545|NCT04671966|Experimental|Placebo add back with GnRHant|Subjects are given placebo patch.
16300546|NCT04671953|Experimental|Arm 1: BMS-986165 Dose 1 + Metformin|
16300547|NCT04671953|Experimental|Arm 2: BMS-986165 Dose 2 + Metformin|
16300519|NCT04672109|Experimental|Anodal-tDCS|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the supraorbital area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
16300520|NCT04672109|Experimental|Cathodal-tDCS|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) of non-dominant hemisphere and Anode on the supraorbital area of dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
16300521|NCT04672109|Experimental|Dual-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the primary motor area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
16300522|NCT04672109|Sham Comparator|Sham-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins. Anode on dominant hemisphere, Cathode on non-dominant hemisphere. The scope of intervention is to investigate effect of tDCS on muscle strength.
16300523|NCT04672096|Experimental|Neuronoff BASMATI Injectrode|Subjects will be provided with the placement of an Injectrode insert. The maximal placement duration will be 28 days.
16300524|NCT04672083|Experimental|Cohort 1|6 subjects receiving a single subcutaneous injection of CPT31 (0.01 mg/kg) and 2 subjects receiving matching placebo SC injection
16300525|NCT04672083|Experimental|Cohort 2|6 subjects receiving a single subcutaneous injection of CPT31 (0.04 mg/kg) and 2 subjects receiving matching placebo SC injection
16300526|NCT04672083|Experimental|Cohort 3|6 subjects receiving a single subcutaneous injection of CPT31 (0.12 mg/kg) and 2 subjects receiving matching placebo SC injection
16300527|NCT04672083|Experimental|Cohort 4|6 subjects receiving a single subcutaneous injection of CPT31 (0.24 mg/kg) and 2 subjects receiving matching placebo SC injection
16300528|NCT04672070|Active Comparator|Selective Caries Removal|The patient will be treated with Selective Caries Removal (SCR)
16300529|NCT04672070|Active Comparator|Pulpotomy|The patient will be treated with full coronal Pulpotomy.
16300530|NCT04672057|Active Comparator|Right hemiparetics|right-sided affected hemiparetic individuals
16300531|NCT04672057|Active Comparator|Left hemiparetics|left-sided affected hemiparetic individuals
16300532|NCT04672057|Active Comparator|Control|healthy individuals
16300535|NCT04672031|No Intervention|Control Arm|Patients in the control arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the control arm will be defined as follows: fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL (i.e. conventional targets). Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
16300536|NCT04672031|Experimental|Interventional Arm|Patients in the experimental arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the intervention arm will be defined as follows: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL. Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
16300537|NCT04672018|Experimental|Treatment group|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
16300538|NCT04672018|Active Comparator|Control group|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
16300539|NCT04672005|Experimental|Treatment Regimen: mFOLFIRINOX + mGnabP|"All study participants will receive the following treatment:
~mFOLFIRINOX (28-day cycle)
~Day 1 and Day 15:
~Oxaliplatin 85 mg/m2 2-hour intravenous infusion followed by leucovorin 400 mg/m2 2-hour infusions with the addition of irinotecan 150 mg/m2 as a 90 minute infusion. 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours will follow irinotecan.
~Day 3 and Day 17:
~Pegylated-Granulocyte Colony Stimulating Facotr (peg-GCSF) 6 mg subcutaneous injection following disconnection of 5-FU infusion, first cycle and then per investigator discretion.
~Biweekly mGnabP (28-day cycle)
~Day 1 and Day 15:
~Nab-paclitaxel 125 mg/m2 infused over 30 minutes, immediately followed by Gemcitabine 1200 mg/m2 intravenously infused at the rate of 10mg/m2/min (over 120 minutes).
~Patients will receive one month of each regimen, alternately monthly until progression of disease."
16300540|NCT04671992|Active Comparator|Ultrasound Guided Out of-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding horizontal)
16300541|NCT04671992|Active Comparator|Ultrasound Guided In-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding vbertical)
16300542|NCT04671966|Experimental|Fasting only|To acutely elevate myocardial triglyceride content, subjects will be asked to abstain from eating for 2 days (reproducibly causes a significant and physiological increase in myocardial fat deposition, transiently). Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
16300543|NCT04671966|Experimental|LBNP Only|Subjects undergo lower body negative pressure at 40 mmHg.
16300544|NCT04671966|Experimental|Estrogen add back with GnRHant|Subjects are given estradiol patch.
16300548|NCT04671940||Retrospective Cohort|"Patients who have previously had radiotherapy and then have had their local residual/recurrent disease managed with salvage TORS at the Royal Marsden Hospital will be eligible for inclusion. They will be informed of the RECUT+ study by a member of their usual care team at RMH during their routine outpatient appointments for follow up of their H&N cancer.
~Potential participants will be asked to consent to provide blood/saliva sample for germline DNA and for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis. Where patients have returned to their referring institution and are no longer under active regular follow up at RMH, a research pack will be sent to the patient via post and email. This pack will contain the Cover Letter, the Participant Information Sheet and the Informed Consent Form. It will also contain a saliva collection tube, buccal swab, blood tubes and instructions for how to provide blood/saliva samples."
16300549|NCT04671940||Prospective Cohort|Patients who have previously had radiotherapy and then are due to have their local residual/recurrent disease managed with salvage transoral robotic surgery at the Royal Marsden Hospital (RMH) will be approached prior to their salvage surgery at a routine outpatient appointment. They will be asked to consent to provide blood/saliva sample for germline DNA pre and post operatively. They will also be asked for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis
16300550|NCT04671914|Active Comparator|Hyaluronic acid gel after D&C|After abortion in the II trimester, we provide D&C and after the procedure, we apply in uterine cavity Hyaluronic acid gel.
16300551|NCT04671914|Active Comparator|Only D&C|After abortion, in the II trimester, we provide only D&C.
16300552|NCT04671901|Experimental|Pediatric Participants|Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of N8 or EFT.
16300553|NCT04671888|Experimental|COPD patients|
16300554|NCT04671875|Experimental|MIL93|
16300555|NCT04671862|Experimental|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW
~1 Treatment pre radiotherapy
~3 treatments weekly during radiotherapy"
16300556|NCT04671849|Experimental|adult patients_Dose 1|
16300557|NCT04671849|Experimental|adult patients_Dose 2|
16300558|NCT04671849|Experimental|adult patients_Dose 3|
16300559|NCT04671849|Experimental|adult patients_Dose 4|
16300560|NCT04671849|Experimental|adult patients_Dose 5|
16300561|NCT04671849|Experimental|adult patients_Dose 6|
16300562|NCT04671849|Experimental|adult patients_Dose 7|
16300563|NCT04671849|Experimental|adult patients_Dose 8|
16300564|NCT04671836|Experimental|Lorazepam first|This arm comprises of participants who were randomized to receive lorazepam 1 mg prior to the first MRI scan and then placebo on the second MRI scan a week later.
16300565|NCT04671836|Placebo Comparator|Placebo first|This arm comprises of participants who were randomized to receive placebo prior to the first MRI scan and then lorazepam 1 mg orally prior to the second MRI scan a week later.
16300566|NCT04671797|Experimental|Early Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at an early dinner time (DLMO-3h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
16300567|NCT04671797|Experimental|Late Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
16300568|NCT04671797|Experimental|Late Dinner + Late Sleep first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by delayed bedtime (DLMO+6h). This arm will cross-over to the other 2 arms in random order.
16300569|NCT04671784||Enlarged mediastinal or abdominal|Consecutive patients with enlarged mediastinal or abdominal detected by cross-sectional imaging and confirmed at EUS will be enrolled.
16300570|NCT04671771|Experimental|Experimental: InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
16300571|NCT04671758||AR TAVI|The population consists in patients with severe symptomatic AR on native aortic valve who are candidates for surgical aortic valve replacement but who are deemed inoperable by the heart team due to technical issues (i.e., porcelain aorta, previous coronary artery bypass grafting,…), extreme left ventricular dysfunction or comorbidities (liver cirrhosis, severe chronic obstructive pulmonary disease…).
16300572|NCT04671745||Expérimental|patient receiving care with interactive music
16300573|NCT04671745||Control|patient receiving care without interactive music
16300574|NCT04671732||Fenestrated endovascular aortic aneurysm repair (FEVAR)|
16300575|NCT04671732||Open repair (OR)|
16300576|NCT04671693|Experimental|PASCA intervention|
16300577|NCT04671680||Pregnant women with suspected placenta accreta|Pregnant women undergoing cesarean delivery with suspected placenta accreta spectrum.
16300581|NCT04671641|Experimental|Endovenous Radiofrequency Ablation Closure System|
16300582|NCT04671641|Active Comparator|ClosureFast™ Radiofrequency Ablation System|
16300583|NCT04671628|Experimental|Relaxing music|
16300584|NCT04671628|No Intervention|Control|
16300585|NCT04671615||Patients with metastatic, HR+/HER2- breast cancer.|Patients who initiated first or subsequent lines of treatment with palbociclib
16300586|NCT04671589|Experimental|Meropenem|Meropenem 1 gram intravenous every 8 hours
16300588|NCT04671576|Active Comparator|Control Formula|A standard, milk-based, infant formula.
16300589|NCT04671576|Experimental|Investigational Formula|An organic milk-based infant formula.
16300590|NCT04671563|Experimental|Viproof Film Coated Tablets 300mg|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
16300591|NCT04671563|Active Comparator|Viread Tablets|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
16300592|NCT04671537|Experimental|Study group (preloading with crystalloid fluid - isotonic solution)|Preloading with crystalloid fluid (isotonic solution) at 10 ml/kg of ideal body weight
16300593|NCT04671537|No Intervention|Control group (not preloading)|no preloading
16300594|NCT04671524|Experimental|pediatric patients diagnosed with rheumatic diseases.|"Exercise group; a combination of stretching, range of motion, and strengthening exercise.
~The exercise program will take 8 weeks, 3 days per week, and 45 minutes."
16300595|NCT04671524|No Intervention|healthy controls|The healthy control group will be examined and the outcomes will be compared with the experimental group.
16300596|NCT04671511|Experimental|Targeted Axillary Dissection|Ultrasound of the axilla preoperative. Clipped biopsy proven positive node. I125 radioactive seed before surgery. Sentinel node biopsy using Tc99 +/- blue dye. Targeted Axillary Node Dissection performed at surgery
16300597|NCT04671498||Ancillary-correlative (biospecimen collection) (Breast Cancer patients)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
16300598|NCT04671498||Ancillary-correlative (biospecimen collection) (Volunteer)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
16300599|NCT04671485|Active Comparator|ARM A : standard care|standard care : Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
16300600|NCT04671485|Active Comparator|ARM B : standard care + Autohypnosis|"In addition to the standard care, the patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.
~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
16300601|NCT04671485|Active Comparator|ARM C : standard care + Musicotherapy|"In addition to the standard care, the patient will choose the music he want to listen from a music database (3 specific moods).
~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
16300602|NCT04671472|Experimental|Aceneuramic acid tablets|Aceneuramic acid tablets 6 g/day, divided 3 times a day for 48 weeks
16300603|NCT04671472|Placebo Comparator|Aceneuramic acid placebo tablets|Matching placebo 3 times a day for 48 weeks
16300604|NCT04671459|Experimental|TTFields and SRS based on MRI or FET-PET|All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.
16300605|NCT04671446||Severe eosinophilic asthma and/or EGPA|
16300606|NCT04671446||Other respiratory conditions|Milder asthma, other vasculitides, eosinophilic COPD, and/or eosinophilic oesophagitis
16300607|NCT04671446||Healthy controls|
16300608|NCT04671433|Experimental|Experimental - Immediate Treatment|RPGR4e11
16300609|NCT04671433|Other|Deferred Treatment|Deferred Treatment
16300610|NCT04671433|Active Comparator|Experimental Immediate Treatment|RPGR2e11
16300611|NCT04671420|Experimental|HLX01|
16300612|NCT04671420|Active Comparator|EU-sourced rituximab (Mabthera®)|
16300613|NCT04671407|Active Comparator|CONTROL|40ml of hypersal saline (3% NaCl) will be administered to bladder the after the surgery
16300614|NCT04671407|Placebo Comparator|PLACEBO|40ml of normal saline (0.9% NaCl) will be administered to bladder the after the surgery
16300615|NCT04671394|Experimental|Test (FMUD + DLIG)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by irrigation with indocyanine green solution and diode laser irradiation.
16300616|NCT04671394|Sham Comparator|Control (FMUD + ST)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by sham therapy.
16300620|NCT04671368|Experimental|Artificial Intelligence|A deep learning based artificial intelligence diagnostic system(DOI:10.1093/neuonc/noaa163)
16300621|NCT04671368|Active Comparator|Practicing Pathologists|One pathologist who has at least 5 years of experience
16300622|NCT04671368|Other|Gold Standard|A committee composed of two expert pathologists who has at least 10 years of experience and one expert pathologist who has at least 15 years of experience
16300623|NCT04671355|Experimental|Trimbow|Pressurized metered dose inhaler
16300624|NCT04671355|Active Comparator|Relvar|Dry powder inhaler
16300626|NCT04671329|Other|Affirm Contrast Biopsy|Women 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
16300627|NCT04671316|Experimental|T1T2R|"Period I: T1, DA-5209 60mg without water Period II: T2, DA-5209 60mg with 150mL water Period III: R, Lixiana 60mg with 150mL water"
16300628|NCT04671316|Experimental|T1RT2|"Period I: T1, DA-5209 60mg without water Period II: R, Lixiana 60mg with 150mL water Period III: T2, DA-5209 60mg with 150mL water"
16300629|NCT04671316|Experimental|RT1T2|"Period I: R, Lixiana 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: T2, DA-5209 60mg with 150mL water"
16300630|NCT04671316|Experimental|RT2T1|"Period I: R, Lixiana 60mg with 150mL water Period II: T2, DA-5209 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
16300631|NCT04671316|Experimental|T2RT1|"Period I: T2, DA-5209 60mg with 150mL water Period II: R, Lixiana 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
16300632|NCT04671316|Experimental|T2T1R|"Period I: T2, DA-5209 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: R, Lixiana 60mg with 150mL water"
16300633|NCT04671303|Experimental|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.
~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
16300634|NCT04671290||Control|Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides).
16300635|NCT04671290||Cases|Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides).
16300636|NCT04671277|Experimental|Chewing of breads|"6 samples (2x3 full factorial design with 2 white sandwich bread types (a regular gluten-containing (GC) and a gluten-free version (GF)) and 3 spread conditions (no spread, butter and mayonnaise)) were evaluated in two sessions of 30 min each. The first session was designed for video recording and the second session for the evaluation of texture attributes and collection of food bolus.
~Bread samples were served as two stacked cylinders resembling the consumption of a sandwich (diameter: 3.5 cm, approximate total height: 2.4 cm) (Figure 1). Due to differences in bread density, the average weight of two stacked cylinders was 5.1 ± 0.2 and 5.7 ± 0.4 for GC and GF breads, respectively. Butter and mayonnaise were added to breads at approximately 12% w/w."
16300637|NCT04671264|Experimental|VC group|"Vibrating capsule (VC) was proposed and applied for the patent by professor Liao Zhuan from Changhai Hospital, developed and manufactured by the Ankon Medical Technology Co., Ltd. The system consisted of a vibrating capsule and an external configuration device (ECD). It's 26.7 mm in length, 11.8 mm in diameter and 4.5 + 0.5 g in weight.
~Each VC has its own semiconductor chip with serial number in order to be recognized and controlled by ECD. VC can be stopped by ECD or mobile-phone application. There was a bidirectional radio frequency communication signal between VC and ECD. In addition, an application (APP) named VCP can be connected to ECD through smart phone to select mode and debug specific parameters for VC. The capsule can be activated by ECD, and then the vibration mode can be controlled by a configurator or an smartphone application."
16300638|NCT04671264|Placebo Comparator|Control group|The Intervention of control group were similar to VC group except the capsule function. Sham capsule we used in control group which had no function of vibrating.
16300639|NCT04671251|Experimental|AEVI-007|
16300640|NCT04671238||Patient for SPECT/CT scan|Patients referred for SPECT/CT scan of the spine as part of a vertebroplasty workup and selected retrospectively.
16300641|NCT04671225|Experimental|Intervention - Psychoeducation at the referral hospital|Intervention: Manual-structured group psychoeducation.
16300642|NCT04671225|Other|Waiting list - at the referral hospital|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
16300644|NCT04671186|Experimental|Probiotic group|Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) throughout the study
16300645|NCT04671186|Placebo Comparator|Placebo Group|Placebo group is to receive placebo oral capsule daily throughout the study.
16300646|NCT04671173|Experimental|Experimental arm (only one arm)|Only one arm, the participants will all received the device to measure Intra-compartmental pressure after consenting to study participation.
16300647|NCT04671160||1|Group treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
16300648|NCT04671160||2|Group treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
16300649|NCT04671160||3|Group not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
16300650|NCT04671160||4|Group not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
16300651|NCT04671147||Skull tong femoral traction|
16300652|NCT04671147||Cotrell longitudinal traction|
16300653|NCT04671134|Experimental|Biomimetic remineralizing agent|
16300654|NCT04671134|Active Comparator|Resin modified glass ionomer varnish|
16300655|NCT04671121|Active Comparator|Grup LP (n = 31)|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
16300656|NCT04671121|Active Comparator|Grup SP (n = 31)|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
16300657|NCT04671108|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
16300658|NCT04671108|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
16300663|NCT04671069|Experimental|MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet|
16300664|NCT04671056|Experimental|MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet|MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
16300665|NCT04671043|Experimental|CAF+lowCHO|A drink containing caffeine and 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
16300666|NCT04671043|Active Comparator|10g CHO|A drink containing 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
16300667|NCT04671043|Placebo Comparator|placebo|A drink containing an artificial sweetener (aspartame) dissolved in 200 mL of tap water
16300668|NCT04671030|Experimental|Treatment group|Subjects are screened by criteria, intravenous and transdermal iontophoresis then undergo the study during which they will be administered the placebo alternating with real drug without being aware of which is being given.
16300669|NCT04671030|Placebo Comparator|Placebo group|Placebo will be given without the subject being aware of the time in advance.
16300673|NCT04670991|Other|EXATRAC imaging|For each radiotherapy session, patient will first have an Exatrac imaging and then a CBCT imaging. Patient's repositionning will be performed accoding to CBCT data
16300674|NCT04670978|Experimental|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxel, 260mg/m2，ivdrip，D1，once every three weeks bevacizumab biosimilar, 10mg/kg，ivdrip，D1, once every three weeks
16300675|NCT04670965||E-PRF/rhBMP-2 (similar ratios)|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
16300676|NCT04670965||E-PRF/ACS/rhBMP-2|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
16300677|NCT04670965||rhBMP-2/E-PRF|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
16300678|NCT04670965||E-PRF only|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
16300679|NCT04670952|Experimental|Low Pressure Laparoscopic Cholecystectomy|"LPLC refers to Low Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 10mmHg."
16300680|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|"This is taken as the control group. SPLC refers to Standard Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 14 mmHg."
16300681|NCT04670939|Experimental|SPT|
16300682|NCT04670926|Experimental|TruGraf - Group 1:|Patients randomized to Group 1 will receive serial TruGraf testing at months 3, 4, 5, 6, 7, 8, 9, and 12. Results will be available in real-time and used by the physician to guide management of immunosuppression.
16300683|NCT04670926|Active Comparator|CPMC Standard of Care - Group 2:|Patients randomized to Group 2 or CPMC Standard of Care Group patients will have current standard of care laboratory assessments.
16300684|NCT04670913|Experimental|Camrelizumab plus Apatinib|Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po
16300685|NCT04670900|Active Comparator|Operative|Patients will be operated according to Orthopedic Trauma Association (OTA) principles with either tension band wiring or plate fixation with an anatomical precontoured plate.
16300686|NCT04670900|Experimental|Non-operative|Patients will be offered a plaster cast for 1-2 weeks
16300687|NCT04670887|Active Comparator|Immediate surgery|Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
16300688|NCT04670887|Active Comparator|Active surveillance|Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
16300689|NCT04670874||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-20 minutes about symptoms, emotions, and functioning related to diagnosis of cutaneous lymphoma.
16300690|NCT04670861|Experimental|experimental group|Upper extremity Biodex balance training program three times/week for eight weeks in addition to regular weightlifting training exercises
16300691|NCT04670861|Active Comparator|control group|regular weightlifting training exercises
16300692|NCT04670848|Experimental|Patients suspected of suffering from sleep apnea|
16300693|NCT04670848|Experimental|Healthy volunteers|
16300694|NCT04670835||Case Group (unic)|"Group/Cohort Label :
~Users of Emergency Call Centers Users of French territory 'Region Pays de la Loire'
~Group/Cohort Description:
~All Users calling through the five Emergency Medical Centers of the French Pays de la Loire region (5 areas of the region are : Loire-Atlantique, Maine-et-Loire, Mayenne, Sarthe, Vendée).
~In each Emergency Medical Center, an advanced telephone system automatically keeps track of all inbound calls.
~Average annual number of incoming calls for the 5 Emergency Medical Center of Pays de la Loire region is 1,6 million."
16300697|NCT04670809|Experimental|Clevidipine Butyrate Injection|
16300698|NCT04670809|Active Comparator|Ncardipine Hydrochloride Injection|
16300699|NCT04670796|Experimental|HLX02|patient receive one dose of HLX02
16300700|NCT04670796|Active Comparator|EU-sourced Trastuzumab (Herceptin®)|patient receive one dose of EU-sourced Trastuzumab (Herceptin®)
16300701|NCT04670796|Active Comparator|US-licensed Trastuzumab (Herceptin®)|patient receive one dose of US-licensed Trastuzumab (Herceptin®)
16300703|NCT04670757|Experimental|CPL409116|"PART A. IMP is to be administered orally in single ascending dose in the groups consisting of 3 volunteers according to '3+3' design'. Dose escalation scheme is to be determined based on preclinical results and due to dose limiting observation (DLT).
~PART A additional. Assessing the effect of food on bioavailability of CPL409116. IMP is to be administered orally in single dose in fasted and fed state in the group of 12 volunteers.There is to be one week wash-out between two treatment periods for this cohort."
16300704|NCT04670757|Experimental|PLACEBO|PART B. Two participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
16367388|NCT04206657|Experimental|Single dose administration of 12mg KHK7580|
16300705|NCT04670718|Experimental|OCT probe|The examination of gastrointestinal tract resected specimen with the use of the OCT probe
16300706|NCT04670692|Experimental|5G-MCE examination|There will be 20 volunteers assigned to the 5G-MCE system group. These patients will accept the magnetically controlled capsule examination in Yinchuan. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the assistant in Yinchuan. Then, the assistant activated the capsule with the capsule locator. The patient is instructed to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. After the capsule entering into the stomach, the examination will be performed through the 5G-MCE system by the endoscopist (W.Z.), with experience of more than 1000 cases of MCE operation, in Shanghai.
16300707|NCT04670692|Active Comparator|MCE examination|There will be 20 volunteers assigned to the MCE system group as comparator group. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient is instructed to assume the left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist (W.Z.) face to face, subject continue the examination of stomach and duodenum.
16300708|NCT04670679|Experimental|Dose Escalation (Part A): ERAS-601 monotherapy|ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
16300709|NCT04670679|Experimental|Dose Escalation (Part B): ERAS-601 in combination with cetuximab|ERAS-601 will be administered in sequential ascending doses in combination with cetuximab to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
16300710|NCT04670679|Experimental|Dose Expansion (Part C): ERAS-601 monotherapy|ERAS-601 will be administered at the monotherapy recommended dose (as determined from Part A) to study participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
16300711|NCT04670679|Experimental|Dose Expansion (Part D): ERAS-601 in combination with cetuximab|ERAS-601 will be administered with cetuximab at the combination therapy recommended dose (as determined from Part B) to study participants with advanced or metastatic head and neck squamous cell carcinomas (HNSCC) or colorectal cancer (CRC).
16300712|NCT04670666|Experimental|MADALENA|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:
~1 tablet Madalena association, oral;
~1 tablet empagliflozin + linagliptin association placebo, oral;
~1 tablet metformin placebo, oral."
16300713|NCT04670666|Active Comparator|Metformin + empagliflozin + linagliptin|"The patient must take 3 tablets once a day, as follows:
~1 tablet Madalena association placebo, oral;
~1 tablet empagliflozin + linagliptin association, oral;
~1 tablet metformin, oral."
16300714|NCT04670653|Experimental|MAGNÓLIA|Two applications in each nostril, once a day.
16300715|NCT04670653|Active Comparator|MOMETASONE FUROATE|Two applications in each nostril, once a day.
16300716|NCT04670640|Experimental|Breath Focus|Participants receiving the breath focus study intervention.
16300717|NCT04670640|Experimental|Vibration|Participants receiving the vibration study intervention.
16300718|NCT04670640|Experimental|Vibration With Breath Focus|Participants receiving the vibration with breath focus study intervention.
16300719|NCT04670640|Experimental|Screens Free|Participants receiving the screens free study intervention.
16300720|NCT04670627||Seasonal Allergic Rhinitics|"Non-smoking males and females aged 18-70 years, inclusive with history of Seasonal Allergic Rhinitis defined by:
~Sensitization to at least one seasonal aeroallergen via skin prick testing (wheal =3 mm than negative control), AND History of physician-diagnosed seasonal allergic rhinitis, OR Symptoms consistent with seasonal allergic rhinitis, such as runny nose, nasal congestion, sneezing, or nasal pruritis."
16300721|NCT04670627||Control|Non-smoking males and females aged 18-70 years, inclusive with no history of physician-diagnosed allergic rhinitis and no history of seasonal runny nose, nasal congestion, sneezing or nasal pruritis. Negative results to a panel of aeroallergens via skin prick testing.
16300722|NCT04670614|Other|Nerve Block Procedure|Supra-orbital and Infra-orbital peripheral nerve blocks with 0.5% ropivicaine
16300723|NCT04670614|Sham Comparator|Placebo sham control|sham control 0.9% Normal Saline
16300724|NCT04670601|Experimental|Flurbiprofen 8.75 mg|Flurbiprofen 8.75 mg lemon and honey flavour lozenge
16300725|NCT04670601|Active Comparator|Strepfen 8.75 mg|Strepfen 8.75 mg lemon and honey lozenge
16300726|NCT04670588||Locally advanced rectal cancer patients|Patients with LARC undergoing TNT.
16300727|NCT04670575||Vivity|Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
16300728|NCT04670549|Other|Pre and post implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.
~Post-implementation phase: during the post-implementation phase patients with hip and knee OA will receive OA care more in line with the treatment recommendations."
16300729|NCT04670536||PASS LP implants|Patient suffering from a spinal degenerative disease and who is operated with PASS LP
16300730|NCT04670536||PASS Degen implants|Patient suffering from a spinal degenerative disease and who is operated with PASS DEGEN
16300731|NCT04670536||PASS Tulip PRIME implants|Patient suffering from a spinal degenerative disease and who is operated with PASS TULIP PRIME
16300732|NCT04670536||PASS Tulip GENESIS implants|Patient suffering from a deformity and who is operated with PASS TULIP GENESIS implant(s)
16300733|NCT04670523|Other|Test group|Test group: The patients of the study group are getting their chest tube removed according to the investigators' current airleak protocol (Flow <20 mL/ min on digital suction device) but already in the operating room immediately following wound closure (Postoperative day 0 (POD0)). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
16300734|NCT04670523|Other|Control group|In the control group, the chest tube gets removed according to the investigators' traditional standard protocol not earlier than on postoperative day 1 (POD1).
16300735|NCT04670510|Experimental|Aerobic Exercise|The Aerobic Exercise (AE) condition will involve 150-minutes of moderate-intensity AE per week for 6-months and will involve a graded decline in supervision. Supervised AE will occur in groups, though each participant's AE prescription will be personalized based on baseline exercise capacity, as assessed by a maximal cardiopulmonary fitness test. Supervised AE sessions will involve the treadmill, elliptical, and/or bike, and routines will be varied to promote adherence. Supervised AE sessions will gradually increase to 50-minutes per session; however, participants will be encouraged to engage in home-based AE sessions according to their own preference of length and frequency in order to achieve 150 minutes of AE per week.
16300736|NCT04670510|Active Comparator|Social Engagement|The Social Engagement (SE) condition will be designed to control for the social component of the AE intervention (i.e., supervised on-site sessions with professional staff, frequent phone contact from study staff). A variety of enjoyable group-based activities will be scheduled throughout the 6-month period (e.g., movie club, cooking, cultural perspectives on aging), with a gradual decline in frequency of meetings. This condition will involve twice weekly, 1-hour-long on-site meetings for the first 6-weeks of the intervention, weekly group meetings during weeks 7-12, and bi-weekly meetings during weeks 13-26 (grand total of 25 sessions).
16300737|NCT04670497|Active Comparator|ultrasound guided lumbar plexus block|patients were recieved lumbar plexus block ultrasound guided by shamrock technique using 0.5% bupavacaine in a dose 0.3ml/kg
16300738|NCT04670497|Active Comparator|ultrasound guided Fascia iliaca block|patients were received fascia iliaca block ultrasound guided using 0.5% bupoavacaine in a dose 0.3ml\kg
16300739|NCT04670484|Other|Healthy subjects wearing masks|Subjects wearing masks to prevent coronavirus infection spread in COVID19 pandemic
16300740|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 2.0 ng/mL|
16300741|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 4.0 ng/mL|
16300742|NCT04670458||CA group|Patients with In-Hospital Cardiac Arrest
16300743|NCT04670458||CONTROL group|Patients without In-Hospital Cardiac Arrest
16300744|NCT04670445|Experimental|Refine Intervention and Study Procedure|"Small open pilot (n=10) to refine the intervention and study procedures.
~The study will involve three surveys (one before first infusion, one after, and one six weeks later).
~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video
~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team."
16300745|NCT04670445|Experimental|Educational Video and QPL List|"Randomized into Intervention Arm
~The study will involve three surveys (one before first infusion, one after, and one six weeks later).
~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video
~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team.
~Audio Recorded Conversation with oncologist"
16300746|NCT04670445|Active Comparator|Usual Care|"Randomized into Usual Care Arm
~The control group will have three surveys (one before first infusion, one after, and one six weeks later)
~Audio Recorded Conversation with oncologist"
16300747|NCT04670432|Experimental|Treatment group|Hydroxyethylrutoside oral tablet twice daily for 8 weeks starting at the time of randomization, in addition to usual care.
16300748|NCT04670432|No Intervention|Control group|Usual care, consisting of anticoagulant treatment and elastic compression therapy for full study duration.
16300749|NCT04670419||HEV gt 3 clade abchijklm|patients infected with HEV gt 3 clade abchijklm
16300750|NCT04670419||HEV gt 3 clade efg|patients infected with HEV gt 3 clade efg
16300751|NCT04670406|Experimental|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
16300752|NCT04670393|Experimental|FertyBiotic Woman Plus|Participants received FertyBiotic Woman Plus one sachet a day
16300753|NCT04670393|Placebo Comparator|Placebo|Participants received 400 mcg of folic acid once a day
16300754|NCT04670367|Placebo Comparator|Arm A: usual care|routine usual care
16300755|NCT04670367|Experimental|Arm B: walk|walk 30mins per day, 5 days per week.
16300756|NCT04670367|Experimental|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
16300757|NCT04670367|Experimental|Arm D: Baduanjin plus walk|walk 30mins then Baduanjin 12 mins per day, 5 days per week.
16300758|NCT04670341|Experimental|chewing tapioca pearls in the bubble tea drinks|In the first week, the subjects drink as much as 100 ml of bubble tea over a span of 5 minutes once a day for 3 days
16300759|NCT04670341|Placebo Comparator|drink tea without chewing tapioca pearls|In the second week, the subjects drink tea without tapioca pearls as much as 100 ml for 5 minutes per day for 3 days.
16300760|NCT04670328||Covid-19 disease severity|Mild, moderate, severe and critical disease
16300761|NCT04670315||Single Group|Scale validation in stroke patients
16300762|NCT04670302|Active Comparator|Control group (Tendon repair)|The control group will undergo tendon repair procedure only (without augmentation)
16300763|NCT04670302|Experimental|Experimental group (Tendon repair augmented with AAdMSC-HAM composite)|The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite
16300764|NCT04670289|Experimental|Treatment|TenoMiR intralesional injection
16300765|NCT04670289|Placebo Comparator|Placebo|0.9% saline intralesional injection
16300766|NCT04670276|Experimental|Experimental arm|Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
16300767|NCT04670263|Experimental|Dry Eye Disease|Subjects who will be diagnosed at baseline with Dry Eye Disease according to standard diagnosis
16300768|NCT04670263|Active Comparator|Healthy|Subjects who will be diagnosed at baseline with no Dry Eye Disease according to standard diagnosis
16300769|NCT04670250||newly diagnosed patients with ulcerative colitis|patients who are newly diagnosed to have ulcerative colitis who are above 18 years old,not pregnant and not known to have cancer colon
16300770|NCT04670224|Experimental|QLB technique|
16300771|NCT04670224|Active Comparator|Intravenous anesthesia without QLB|
16300772|NCT04670211||Tooth-borne distractor|Maxillary distraction with the use of a tooth-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
16300773|NCT04670211||Bone-borne distractor|Maxillary distraction with the use of a bone-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
16300774|NCT04670211||Hybrid distractor|Maxillary distraction with the use of a hybrid distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
16300775|NCT04670198|Experimental|Intervention|The intervention arm will receive the Youth Empowerment Skills (YES) programme.
16300776|NCT04670198|Other|Waiting-list control|The waiting-list control arm will receive usual care for six months before receiving the Youth Empowerment Skills (YES) programme.
16300777|NCT04670185|Experimental|Internet-based parent training|Five weeks of therapist-guided online delivered parents training
16300778|NCT04670185|No Intervention|Waitlist|Five weeks of waitlist
16300779|NCT04670172||Chronic rhinosinusitis patients|Adult chronic rhinosinusitis patients capable of using a mobile application.
16300780|NCT04670159|Experimental|Online Education Group|
16300781|NCT04670159|Experimental|Brochure Group|
16300782|NCT04670133|Experimental|Inulin|Supplementation with inulin for 4 weeks prior to and 10 weeks after sanative therapy. 10 g daily, divided into two equal doses.
16300783|NCT04670133|Placebo Comparator|Placebo|Supplementation with maltodextrin (as placebo) for 4 weeks prior to and 10 weeks after sanative therapy. 10 g daily, divided into two equal doses.
16300784|NCT04670120|Experimental|First group|Pyfazimine 100mg group, 12 cases.
16300785|NCT04670120|Experimental|Second group|Pyfazimine 200mg group, 12 cases.
16300786|NCT04670120|Experimental|Third group|Pyfazimine 300mg group, 12 cases.
16300787|NCT04670120|Active Comparator|Forth group|Pyrazinamide 1500mg group, 10 cases.
16300788|NCT04670120|Active Comparator|Fifth group|Pyfazimine 200mg + Pyrazinamide 1500mg group, 10 cases.
16300789|NCT04670107|Experimental|combination group|
16300790|NCT04670094||Covid19 infection related patients|"Patients over the age of 18 hospitalized for SARS-CoV-2 up to end of June 2020 in the San Gerardo Hospital and other centers will be included.
~Patients are followed until discharge from hospital or death."
16300791|NCT04670081|Placebo Comparator|Nicotinamide|1st dose: 100 mg Nicotinamide (Vitamin B3) - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
16300792|NCT04670081|Experimental|Psilocybin (low-dose)|1st dose: 5 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
16300793|NCT04670081|Experimental|Psilocybin (high-dose)|"1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 5 mg Psilocybin
~1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin"
16300794|NCT04670068|Experimental|CAR.B7-H3 T cell product|Up to 12 patients will receive three weekly CAR.B7-H3 T cell product infusions at the same dose. To determine the recommended phase 2 dose (RP2D), a modified 3+3 dose escalation design will be used to evaluate two dose levels: Dose Level 1 (7.5x10^7 cells/infusion), Dose Level 2 (2x10^8 cells/infusion). If this dose is not tolerated, then a lower dose of 3.75 × 10^6 cells/infusion will be explored. Up to 3 dose levels of CAR.B7-H3 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 9 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
16300795|NCT04670055|Experimental|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16300796|NCT04670042|Experimental|SPRINT® Peripheral Nerve Stimulation (PNS) System|SPRINT PNS System will be offered to patients with postoperative knee pain following primary unilateral total knee arthroplasty (TKA) who meet eligibility criteria and consistent with established coverage policy. SPRINT PNS System will be implanted for 60 days. At the discretion of the physician, the first lead may be placed to stimulate the nerve innervating the region of greatest pain. If pain is not adequately addressed by the first lead when assessed at 10 days, a second lead may be placed approximately 2 weeks following the initial lead placement.
16300797|NCT04670029|No Intervention|Standard|
16300798|NCT04670029|Experimental|APA|"During the first 3 cures, 3 APA sessions will be offered per week:
~2 sessions of anaerobic type of 1 hour with muscle strengthening, stretching, flexibility and balance, supervised in the room,
~1 aerobic type exercise session of 1.5 hours (Nordic walking: outdoors) or a 3rd indoor session if not possible,
~+ home exercise book if the patient so wishes with record the time in minutes per session and the intensity felt and the modalities of the exercises carried out.
~During the 5 remaining cycles, 3 APA sessions will be offered per week:
~1 session of 1 hour in an anaerobic exercise room (muscle strengthening, stretching, flexibility, balance) supervised,
~1 session of anaerobic exercise per week in autonomy at home (with exercise book),
~1 or more session per week of one hour of walking or cycling independently at home (aerobic effort) with declaration in the logbook of the intensity of exertion felt and the time in minutes per session."
16300799|NCT04670016||Patient/Caregiver dyad diagnosed with DIPG|"All of these criteria must be met for a patient to be eligible for this study:
~Patient aged >2 and <21 years treated with a repeat course of radiation for DIPG
~Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).
~Enrollment within 14 days of starting re-irradiation (RT2).
~Patients with malignant transformation of the first tumour are eligible.
~There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.
~The patient is treated at a site where the study is approved by the local ethics board
~Consent, and, if applicable, assent, has been obtained according to institutional standards"
16300800|NCT04670016||Patient/Caregiver dyad with re-RT for a recurrent brain tumour|"All of these criteria must be met for a patient to be eligible for this study:
~Patient aged >2 and <21 years treated with a repeat course of radiation for a recurrent or progressive brain tumour (stratum 2).
~Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).
~Enrollment within 14 days of starting re-irradiation (RT2).
~Patients with malignant transformation of the first tumour are eligible.
~There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.
~The patient is treated at a site where the study is approved by the local ethics board
~Consent, and, if applicable, assent, has been obtained according to institutional standards"
16300801|NCT04670003||users|users of web-application
16367605|NCT04205201|Experimental|Group A|Latanoprost
16300802|NCT04669977|Experimental|Auxiliary|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. They are expected to finish the mulberry juice in 10 to 11 days. Measurements of clinical symptoms and blood sampling are conducted on day 1 of every other week for 5 weeks. If clinical measurements or blood extractions fail or miss, a substitute assessment or blood sample will be obtained on day 2 or day 3. The research period for these participants is 29 days (4 weeks). The checkpoints are arranged because patients with oxaliplatin treatment visit the clinic every two weeks, and patients with paclitaxel treatment visit the clinic every week. For patients having docetaxel therapy, the research period is 43 days (6 weeks) because docetaxel is administered every three weeks.
16300803|NCT04669977|No Intervention|Non-auxiliary|For the non-auxiliary group (control group), patients are informed of their allocation results and they will not consume mulberry juice during the research period but will receive the mulberry juice after the research period.
16300804|NCT04669964||High-Risk For Dehydration|Patients with an Ileostomy output of >1L at discharge.
16300805|NCT04669951|Experimental|uPAR expression|Immunohistochemistry
16300806|NCT04669938||Patients hospitalized for COVID-19|
16300807|NCT04669925||Users of Lombardy Emergency System 2018-2020|Adults (affected or not affected by Covid-19) who asked for assistance to the Lombardy region's emergency system during the pandemic period and the previous two years
16300808|NCT04669899|Experimental|Stage 1, Dose Escalation: JTX-8064 monotherapy dose escalation|Dose Escalation, Stage 1 JTX-8064 Monotherapy. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies
16300809|NCT04669899|Experimental|Stage 2, Dose Escalation: JTX-8064 in combination with pimivalimab|Dose Escalation, Stage 2: JTX-8064 in combination with pimivalimab. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies
16300810|NCT04669899|Experimental|Stage 3 Expansion: JTX-8064 monotherapy (Ovarian)|Cohort will enroll subjects with advanced/metastatic PD-1/PD-L1 (PD-(L)1)-naïve, platinum-resistant ovarian cancer
16300811|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (ccRCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced clear cell renal cell carcinoma (ccRCC)
16300812|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (TNBC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced triple negative breast cancer (TNBC)
16300813|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (HNSCC)|Experimental: Expansion, Stage 4: JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, PD-L1+ head and neck squamous cell carcinoma (HNSCC)
16300814|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (Ovarian)|TX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, platinum resistant ovarian cancer
16300815|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (NSCLC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced non-small cell lung cancer (NSCLC)
16300816|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (cSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced cutaneous squamous cell carcinoma (cSCC)
16300817|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (UPS & LPS)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS)
16300819|NCT04669873|Active Comparator|Active Comparator: Standard|Whole breast Radiotherapy, 40 Gray (40Gy) fractions
16300820|NCT04669873|Experimental|Experimental 1: Hypofractionated radiotherapy|Whole breast Radiotherapy, 26 Gray (26Gy) in 5 fractions
16300821|NCT04669873|Experimental|Experimental 2: Accelerated Partial Breast Irradiation|Partial Breast Irradiation 26 Gray (26Gy) to the tumor bed in 5 fractions.
16300822|NCT04669860||calcium oxalate urolithiasis group|Participants with CO urolithiasis scheduled for definitive endoscopic stone removal will be evaluated to identify bacterial and fungal microbiome in mid-stream voided urine sample, urine sample collected from the bladder, kidney stone fragment, and a renal papillae biopsy specimen.
16300823|NCT04669860||renal cell carcinoma group|Participants with RCC scheduled for definitive kidney removal surgery will be evaluated to identify bacterial and fungal microbiome in a catheterized urine specimen from the bladder, a biopsy of the tumor, and a biopsy of normal-appearing renal papillae specimen.
16300824|NCT04669860||healthy control group|The participants will provide a clean-catch voided midstream urine sample to identify bacterial and fungal microbiome.
16300825|NCT04669847|Experimental|Study Group|Patients who performed Trunk-oriented exercise program and conventional exercise program
16300826|NCT04669847|Experimental|Control Group|Patients who performed a conventional exercise program
16300827|NCT04669834|Other|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program based on a recent systematic review in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators using clamshell exercise . No emphasis will be placed on stabilizing the core musculature before initiating any of those exercises.
16300828|NCT04669834|Experimental|group B|Patients in this group will receive the same program as group (A) plus core stability exercise , but the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
16300829|NCT04669821|Experimental|HSK3486|
16300830|NCT04669821|Active Comparator|Propofol|
16300834|NCT04669795|Placebo Comparator|Group 1|Placebo was given to ten patients during consolidation period ( 2 capsule daily for 6 months during consolidation period)
16300835|NCT04669795|Experimental|Group 2|Cissus quadrangularis in form of capsules given to ten patients ( 2 capsule daily for 6 months during consolidation period)
16300836|NCT04669782|Experimental|Patients with osteoporosis treated with teriparatide + Vitamin K|Patients will have to take teriparatide (standard of care) + Vitamin K (MK7) at the dosage of 375 microg / day
16300837|NCT04669782|Active Comparator|Patients with osteoporosis treated with teriparatide|Patients will have to take teriparatide (standard of care)
16300838|NCT04669782|No Intervention|Controls|Subject without osteoporosis, no treatment will be administered.
16300839|NCT04669769||shaving|patients with DIE and shaving
16300840|NCT04669769||disc resection|patients with DIE and Disc resection
16300841|NCT04669769||segmental resection|patients with DIE and segmental resection
16300842|NCT04669769||multifocal|patients with multifocal DIE having more than one bowel procedure
16300843|NCT04669756|Experimental|A|ovariopexy for 2 days
16300844|NCT04669756|Experimental|B|ovariopexy for 4 days
16300845|NCT04669756|Experimental|C|ovariopexy for 6 days
16300846|NCT04669756|Placebo Comparator|D|Placebo Operation for 2 days
16300847|NCT04669743|Experimental|Study Population|Subjects will be recruited and consented following screening. Subjects will be characterized into cohorts based on presence of COPD and smoking status. All subjects enrolled will be undergoing the same interventions: 1st Bronchoscopy (3 wks pre-exposure), Ozone Exposure, 2nd Bronchoscopy (1 day post-exposure), 3rd Bronchoscopy (5 days post-exposure). Ozone exposure will take place in an exposure chamber.
16300848|NCT04669730|Placebo Comparator|Arm A: usual care|Routine usual care
16300849|NCT04669730|Active Comparator|Arm B: walk|Walk 30mins per day, 5 days per week.
16300850|NCT04669730|Active Comparator|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
16300851|NCT04669730|Experimental|Arm D: Baduanjin plus walk|Walk 30mins then Baduanjin 12 mins per day, 5 days per week.
16300852|NCT04669717|Active Comparator|Amoxicilline and Metronidazole for 7 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 7 days
~Systemic antibiotics after sub gingival mechanical debridement"
16300853|NCT04669717|Active Comparator|Amoxicilline and Metronidazole for 3 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 3 days
~Systemic antibiotics after sub gingival mechanical debridement"
16300854|NCT04669717|Active Comparator|Azithromycine for 3 days|"Drug: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH
~1/d 500mg for 3 days
~Systemic antibiotics after sub gingival mechanical debridement"
16300855|NCT04669704|Experimental|Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.
~The exercise program will be individualized according to each pathology."
16300856|NCT04669704|Active Comparator|Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
16300863|NCT04669678||Group 1 DOR + ETG|100mg DOR-containing ART [oral tablet taken daily] + 68mg ETG implant (follow up for 30 weeks)
16300864|NCT04669678||Group 2 DOR + DMPA|100mg DOR-containing ART [oral tablet taken daily] + 150mg IM DMPA (follow up for 18 weeks)
16300865|NCT04669678||Group 3 DOR + MPA|100mg DOR-containing ART + 104mg SC MPA (follow up for 18 weeks)
16300866|NCT04669678||Group 4 DOR + IUD|100mg DOR-containing ART + 1 non-hormonal IUD device (follow up for 30 weeks)
16300867|NCT04669678||Group 5 DTG + DMPA|50mg DTG-containing ART + 150mg IM DMPA (follow up for 18 weeks)
16300868|NCT04669665|Experimental|SLS-002 + Standard of care|Participants will receive SLS-002 (intranasal racemic ketamine) 90 milligram (mg) two times per week for 2 weeks with standard of care treatment
16300869|NCT04669665|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 2 weeks with standard of care treatment
16300870|NCT04669652|No Intervention|ICSI|Traditional microinjection (ICSI) is performed on oocytes.
16300871|NCT04669652|Experimental|Piezo-ICSI|Microinjection (ICSI) is performed using the Piezo-ICSI technique.
16300872|NCT04669639|Experimental|The block group (a)|Patients were randomized in a 1:1 :1ratio, group (a) will receive SSN. The nerve blocks The procedure will be performed after induction of anaesthesia and endotracheal intubation.
16300873|NCT04669639|Experimental|The block group (b)|Patients were randomized in a 1:1:1 ratio. group (b) will receive the Erector spinae plane block. The procedure will be performed after induction of anesthesia and endotracheal intubation.
16300874|NCT04669639|Placebo Comparator|control group|Patients were randomized in a 1:1:1 ratio. this group will receive general anesthesia (GA) only
16300875|NCT04669626|Other|Group 2|Wound cleansing with NaCl (natrium chlorid) solution 0.9%
16300876|NCT04669626|Experimental|Group 1|Wound cleansing with Octenilin®
16300877|NCT04669613|Experimental|Patients|
16367606|NCT04205201|Other|Group B|Brimonidine
16300878|NCT04669600|Experimental|BIVV0020|All eligible participants will receive BIVV020 for at least 52 weeks.
16300879|NCT04669587|Experimental|Part A: Dose Escalation of ZB716 monotherapy (with Food Effect Cohort)|Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy will be 4 weeks following the initial dose of study drug on Cycle 1 Day 1. There will be 2 ~ 6 days between dose escalations to allow sufficient time for an adequate safety review. The max. dose may be lower than 400 mg. In the first dosing group of Part A (Cohort A1), subject dosing will be staggered such that administration of the first dose is separated by at least 7 days between the first 2 subjects. In each of Cohorts A1 to A5, 3 to 6 subjects will receive ZB716 doses according to the assigned dose level in the fasted state. For Cohort A6, Period 1, doses will be administered in the fasted state in Treatment Period 1 and 2, doses will be given 30 min. after starting a standard high fat breakfast.
16300880|NCT04669587|Experimental|Part B: Dose Expansion of ZB716 monotherapy|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.
~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part B. For Part B, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined monotherapy RD of ZB716 (based on Part A) QD in a 28-day cycle. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
16300881|NCT04669587|Experimental|Part C: Dose Escalation of ZB716 in combination with palbociclib|Cohorts will follow a 3+3 study design. Approx. 6 to 12 subjects will be enrolled in the dose escalation phase of ZB716 in combination with Palbociclib. For Part C, doses will be administered at escalating doses starting with 1 dose level below the monotherapy RD (determined in Part A) and Palbociclib will be dosed at the fixed standard dose of 125 mg QD. ZB716 will be administered on a 28 day cycle and Palbociclib will be administered for 21 days in the cycle with 7 days off treatment. Administration of the higher dose level (at monotherapy RD) of ZB716 (with the standard dose of Palbociclib) to subsequent subjects will be based on the occurrence of DLTs during the DLT observation period (Cycle 1), until MAD of ZB716 with combination of Palbociclib is reached. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison.
16300882|NCT04669587|Experimental|Part D: Dose Expansion of ZB716 in combination with palbociclib|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.
~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part D. For Part D, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined RD of ZB716 QD for 28 days from Part C in combination with the standard dose of Palbociclib (125 mg QD for 21 days with 7 days off treatment). Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
16300883|NCT04669574||Group 1|Participants who are newly diagnosed and have initiated front-line treatment.
16300884|NCT04669574||Group 2|Participants who have previously had one progression.
16300885|NCT04669574||Group 3|Participants who have previously had a second recurrence.
16300886|NCT04669574||Group 4|Participants who are on imaging surveillance and not receiving anti-neoplastic treatment
16300887|NCT04669561|Experimental|Single /arm|All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
16300888|NCT04669548||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay
16300889|NCT04669535|Experimental|AXO-AAV-GM2|AXO-AAV-GM2 infusion
16300890|NCT04669509||Group 1|Patients with normal ALT, AST and total bilirubin values
16300891|NCT04669509||Group 2|Patients whose ALT, AST or total bilirubin levels are up to 3 times upper limit of normal
16300892|NCT04669509||Group 3|Patients whose ALT, AST or total bilirubin levels are increased more than 3 times upper limit of normal
16300893|NCT04669496|Experimental|Neoadjuvant treatment|"Gemox chemotherapy D1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.
~Lenvatinib (8mg/d) for 9 weeks of continuous use.
~Toripalimab (240 mg, once every 3 weeks), used 3 times in a row. All patients undergoing resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses."
16300894|NCT04669496|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, a total of 8 courses.
16300895|NCT04669483||Intervention group (post-interruption)|Patients receive evidence-based informed consent forms for total knee arthroplasty and related anaesthesia procedures
16300896|NCT04669483||Control group (pre-interruption)|Patients receive standard consent forms (of the study centre) for total knee arthroplasty and related anaesthesia procedures
16300897|NCT04669470|Active Comparator|Group with adjustable IGB|
16300898|NCT04669470|Active Comparator|Group with nin-adjustable IGB|
16300899|NCT04669457|Experimental|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
16300900|NCT04669457|Active Comparator|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
16300901|NCT04669444|Experimental|Low Driving Pressure Protocol|The patients ventilator driving pressure will be decreased (as tolerated by the patient) for 2 hours while on extracorporeal membrane oxygenation (ECMO) support.
16300902|NCT04669431|Experimental|Xbox kinect Training|X Box Games include Tennis Playing, Joy riding, Rally ball.
16300903|NCT04669431|Active Comparator|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living
16300904|NCT04669418||Group 1|70 children with cancer and a positive blood culture.
16300905|NCT04669418||Group 2|50 children with cancer and no positive blood culture.
16300906|NCT04669405|Active Comparator|HILT group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving high intensity laser therapy.
16300907|NCT04669405|Other|Control group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving exercise.
16300908|NCT04669392|Experimental|70% Ethanol|Using 70% Ethanol Alcohol as a root canal irrigating solution before obturating the lower primary second molar with Metapex
16300909|NCT04669392|No Intervention|Normal Saline|Irrigating the canals with Normal Saline before obturating the lower primary second molar with Metapex
16300910|NCT04669379|Experimental|Intervention group (IG/EXPECT)|
16300911|NCT04669379|No Intervention|Standard of Care (SOC)|
16300912|NCT04669366||Patients in Sweden with metastatic renal cell carcinoma|The cohort of patients with metastatic renal cell carcinoma in Sweden
16300913|NCT04669353|Active Comparator|Platelet Rich Plasma|In the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe.
16300914|NCT04669353|No Intervention|control group|In the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure
16300915|NCT04669340|Experimental|Intervention group|"Participants in the intervention group will receive patient education through an e-learning program at home. A study nurse will introduce patients to the program and they will be asked to accomplish the program within four weeks. Furthermore, they will be encouraged to go through the program as many times as necessary and involve family and relatives if they like.
~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
16300916|NCT04669340|Active Comparator|Control group|"Participants in the control group will receive conventional patient education from a nurse in the out-patient clinic within four weeks after inclusion. Relatives can take part in the conversation.
~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
16300917|NCT04669327||Normal|normal subjects
16300918|NCT04669327||Scoliosis|subjects with moderate idiopathic scoliosis
16300919|NCT04669301|Active Comparator|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
16300920|NCT04669301|Experimental|MAAT-G intervention|The MAAT-G intervention will be delivered by a trained psychology fellow at the University of Rochester Medical Center. The intervention will be delivered through televideoconferencing and participants will be provided a tablet equipped with a HIPPA compliant televideoconferencing application to use for the MAAT-G workshop sessions. We will use the University of Rochester Zoom application which is HIPPA compliant. A tablet instruction manual will be given to patients to help guide them through how to use a tablet and how to navigate the Zoom application. A unique meeting ID number will be given to each patient to log in to the Zoom application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study
16300921|NCT04669288|Active Comparator|Treatment - Active|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered the active drug per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
16300922|NCT04669288|Placebo Comparator|Treatment - Placebo|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered placebo per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
16300923|NCT04669275|Experimental|telephone counseling|People receiving telephone counselling.
16300924|NCT04669275|Experimental|telephone counselin|People receiving telephone counselling.
16300925|NCT04669262|Experimental|Part 1: BGB-DXP604|Part 1A: Single low dose of BGB-DXP604 or placebo Part 1B: Single high dose of BGB-DXP604 or placebo
16300926|NCT04669262|Experimental|Part 2 : BGB-DXP604 + BGB-DXP593|Single dose of BGB-DXP593 followed by a single dose of BGB-DXP604 or placebo
16300927|NCT04669249|Experimental|PROCare|Technology-enabled, reward-based recovery platform
16300928|NCT04669249|No Intervention|Control|Treatment-as-Usual
16300929|NCT04669236|Experimental|Intervention group|Intervention promoting healthy sleep behaviour in adolescents based on a participatory health research approach. Based on participatory session, the pupils of the action group will develop the intervention. They will participate in every step of the development to maximize their input.
16300930|NCT04669236|No Intervention|Control group|Participants in the control group will receive no intervention.
16300931|NCT04669223|Other|Seldinger chest drain 14F|Patients with seldinger chest drain 14F inserted
16300932|NCT04669223|Active Comparator|Seldinger chest drain 8F|Patients with seldinger chest drain 8F inserted
16300933|NCT04669210|Active Comparator|PTCY tacrolimus MMF|"Conditioning:
~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os
~GVHD prophylaxis:
~cyclophosphamide 50 mg/kg day+3, +4 tacrolimus 0.03 mg/kg from day+5 to 100 mycophenolate mofetil 30 mg/kg from day+5 to 35"
16301442|NCT04665713||Normal|children whose BMI are in the normal range(From P5 to P85)
16300934|NCT04669210|Experimental|PTCY ruxolitinib|"Conditioning:
~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os ruxolitinib 5 mg tid days -7 to -2
~GVHD prophylaxis:
~cyclophosphamide 50 mg/kg day+3, +4 ruxolitinib 5 mg tid days +5 to +21 ruxolitinib 5 mg bid days +22 to +150"
16300935|NCT04669197|Other|Treatment|Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine
16300936|NCT04669171|Experimental|Cohort 1|Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 for 6 weeks followed by addition of lenalidomide week 7 and rituximab week 19 (depending on response). Four to 18 evaluable (previously treated) patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) will be Included based on safety findings
16300937|NCT04669171|Experimental|Cohort 2|15 Previously untreated patients with FL Or MZL. Evaluation of EO2463 monotherapy at the established dose in Cohort 1
16300938|NCT04669171|Experimental|Cohort 3|15 Previously untreated patients with FL or MZL. Evaluation of EO2463 at the established dose in cohort 1 as monotherapy for 6 weeks and in combination with rituximab from week 7
16300939|NCT04669171|Experimental|Cohort 4|15 Previously treated patients with FL Or MZL. Evaluation of EO2463 at the established dose in Cohort 1 in combination with lenalidomide and with addition of rituximab from week 19 onwards (depending on response)
16300940|NCT04669158|Experimental|Idebenone|Participants will take Idebenone 200 mg for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
16300941|NCT04669158|Placebo Comparator|Placebo|Participants will take Placebo for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
16300942|NCT04669145|Experimental|Continuous Regional Anesthesia Lower Limb Surgery|Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks A catheter will be placed for the given block for 48 hours. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
16300943|NCT04669145|Experimental|Single Shot Regional Anesthesia Lower Limb Surgery|"Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks. These blocks will be given via a single dose or single shot. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia."
16300944|NCT04669145|Experimental|Continuous Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
16300945|NCT04669145|Experimental|Single Shot Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
16300946|NCT04669132|Experimental|Olanzapine + Netupitanto + Palonosetron|Olanzapine 5 mg/day d 0-4 + Netupitanto 300 mg/day d 1 + Palonosetron 0.56 mg/day d 1;
16300947|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins
16300948|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and placebo|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and placebo
16300949|NCT04669119|Placebo Comparator|Placebo|Patients treated post-operatively for 30 days with placebo
16300950|NCT04669106||Healthy group|90 research subjects coming from mothers who had healthy children
16300951|NCT04669106||Stunting group|90 research subjects came from mothers who had stunted children or other nutritional disorders
16300952|NCT04669093|Experimental|Placebo|All participants will participate in two sessions, one with a placebo suggestion that matches the participant's motivational style, and one with placebo suggestion that does not match their motivational style, in a pseudo-random order.
16300953|NCT04669093|Experimental|Control|Each session will also include a control phase, in which the same cream will be applied, and participants will be instructed that the cream has no analgesic effects.
16300954|NCT04669080|Other|Cost navigation training intervention|
16300955|NCT04669067|Experimental|TL-895 combined with KRT-232|"TL-895 will be administered orally, twice a day (BID) continuously starting on Day 1 in a 28-day cycle.
~KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle."
16300956|NCT04669041|Experimental|Single pill combination (SPC)|Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks
16300957|NCT04669041|Active Comparator|Rosuvastatin|Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks
16300958|NCT04669028|Experimental|NE3107|Hard gelatin capsule containing 20 mg micronized NE3107 drug substance blended with common excipients for oral formulations
16300959|NCT04669028|Placebo Comparator|placebo|Hard gelatin capsule containing only common excipients for oral formulations
16300960|NCT04669015|Experimental|Active plus SOC|Inhaled Novaferon, given 20 ug BID, daily for 10 days, plus Standard of Care
16300961|NCT04669015|Placebo Comparator|Placebo plus SOC|Inhaled vehicle formulation (placebo), given BID, daily for 10 days, plus Standard of Care
16300962|NCT04669002|Experimental|Phase 2A Cohort 1|Patients with advanced platinum resistant ovarian cancer who are PARP inhibitor naive and who have received no more than 1 prior line of therapy which must be platinum-based chemotherapy
16300963|NCT04669002|Experimental|Phase 2A Cohort 2|Patients with advanced ovarian cancer who have received at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by a PARP inhibitor as maintenance treatment as their last treatment regimen
16300964|NCT04668989|Experimental|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week then cross-over to the control lenses for one week.
16301179|NCT04667468|Experimental|Cold-stored Platelet (CSP)|early infusion of one apheresis unit urgent release cold stored platelets (CSP)
16300965|NCT04668989|Active Comparator|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week then cross-over to the test lenses for one week.
16300966|NCT04668976|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
16300967|NCT04668963|Experimental|INTENSIVE MIRROR THERAPY|The intensive therapy group participants received 5 Mirror Therapy (+physiotherapy) sessions /week for 6 weeks, which makes a total of 30 sessions.
16300968|NCT04668963|Active Comparator|SPACED OVER TIME MIRROR THERAPY|The conventional therapy group received the same number of sessions but more spaced in time, consisting in 3 Mirror Therapy (+physiotherapy) sessions/week for 10 weeks.
16300969|NCT04668950|Experimental|Fluvoxamine|Start fluvoxamine 50mg capsule once, then 100mg twice daily. May reduce dose for tolerability reasons. Will be followed in the RCT for approximately 15 days.
16300970|NCT04668950|Placebo Comparator|Placebo|Start placebo one capsule, twice daily. May reduce dose for tolerability reasons. Will be followed in RCT for approximately 15 days.
16300971|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2019|
16300972|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2020|
16300973|NCT04668924|Experimental|Epi-on PiXL in high oxygen|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
16300974|NCT04668911||Controls tested PCR (-) for COVID-19|
16300975|NCT04668911||Tested PCR (+) for COVID-19, Mild - not admitted to the hospital|
16300976|NCT04668911||Tested PCR (+) for COVID-19, Severe - admitted to ICU (Intensive Care Unit)|
16300977|NCT04668898||LRRK2 Parkinson Disease|Individuals with LRRK2-related Parkinson Disease
16300978|NCT04668898||GBA Parkinson Disease|Individuals with GBA-related Parkinson Disease
16300979|NCT04668898||Idiopathic Parkinson Disease|Individuals with Idiopathic (without any known genetic cause) Parkinson Disease
16300980|NCT04668898||LRRK2 non-manifesting carriers|Individuals without Parkinson Disease who have a LRRK2 mutation
16300981|NCT04668898||GBA non-manifesting carriers|Individuals without Parkinson Disease who have a GBA mutation
16300982|NCT04668898||Healthy control|Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease
16300983|NCT04668885|Experimental|Primary refractory/relapsed AML|Lower dose CPX-351 in participants with primary refractory/relapsed AML. Participants will receive an induction and maintenance phase of CPX-351
16300984|NCT04668885|Experimental|MDS after HMA failure|Lower dose CPX-351 in participants with MDS after HMA failure. Participants will receive an induction and maintenance phase of CPX-351
16300985|NCT04668872||Participants with colorectal cancer liver metastases|The study population is represented by patients with colorectal cancer liver metastases that have been deemed clinically appropriate/eligible to receive Y90 TARE for the management of their liver metastases.
16300986|NCT04668859|Active Comparator|Midodrine Arm|Patients will receive the drug Midodrine
16300987|NCT04668859|Placebo Comparator|Placebo Arm|Patients will receive placebo.
16300988|NCT04668833|Experimental|Treatment (Autologous Lymphocyte Infusions)|The purpose of this study is to determine the safety and preliminary efficacy of un-manipulated autologous lymphocyte infusion (ALI) using the patient's own lymphocytes collected using apheresis, and infused after the completion of radiation/chemoradiation.
16300989|NCT04668820|Experimental|Children who admit to Pediatric Rehabilitation outpatient clinic|Children who admit to Pediatric Rehabilitation outpatient clinic of the Department of Physical Medicine and Rehabilitation will be evaluated by face to face and virtually by using zoom application via video Pediatric Gait, Arms, Legs and Spine (V-pGALS)
16300990|NCT04668807|Experimental|Connected Medical Device|"SMART ANGEL Intra-hospital System 's Connected Medical Device (DMC) measuring physiological parameters in the operating room"
16300991|NCT04668807|Active Comparator|Traditional system|Traditional wired transmission system between the sensor and the data processing device in the operating room
16300992|NCT04668781|Active Comparator|Epidural analgesia|
16300993|NCT04668781|Experimental|Wound catheter analgesia|
16300994|NCT04668768|Experimental|Glucarpidase|Prophylactic glucarpidase treatment
16300995|NCT04668755|Active Comparator|Charcot Restraint Orthotic Walker 3d printed sole|the group fit with Charcot Restraint Orthotic Walker 3d printed sole for 12 week. the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
16300996|NCT04668755|Active Comparator|Generic Charcot Restraint orthotic walker|the group fit with Generic Charcot Restraint Orthotic Walker for 12 week.the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
16300997|NCT04668742|Experimental|Arm 1: DYNAtraq - tracheostomy fixation device|Use of DYNatraq installed in chest with skin adhesive and fixed to tracheostomy tube
16300998|NCT04668742|No Intervention|Arm 2: Usual management of tracheostomy|No interventions will be used additional to usual management
16300999|NCT04668729|No Intervention|Control group|20 people will be included in the control group. 3 measurements will be taken one week apart in total. Measurements will consist of maximum isometric muscle strength, lumbar range of motion, balance performance, and pain intensity. And it will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD) and Modified Schober test, flamingo balance test, and visual analog scale.
16301000|NCT04668729|Experimental|Chiropractic group|20 people will be included in the experimental group. Lumbal chiropractic HVLA (High Velocity, Low amplitude: HVLA) spinal manipulation and sacroiliac joint chiropractic HVLA manipulation will be applied 3 times in total with a weekly interval. The maximum isometric muscle strength before and immediately after the application, lumbar joint range of motion, balance performance, and pain intensity will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD), and Modified Schober test, flamingo balance test, and visual analog scale.
16301001|NCT04668703|Experimental|combined cataract surgery and intravitreal Conbercept injection|Subjects will receive conbercept injections at a dose of 0.5 mg/eye at the conclusion of cataract surgery.
16301002|NCT04668703|No Intervention|cataract surgery alone|Subjects will undergo cataract surgery by phacoemulsification and intraocular lens implantation.
16301003|NCT04668690|Experimental|Experimental: Mitoxantrone Hydrochloride Liposome Injection|Patients with relapsed/refractory PTCL will receive Mitoxantrone Hydrochloride Liposome Injection every 28 days (a cycle) for a maximum of 8 cycles. The dose of Mitoxantrone Hydrochloride Liposome Injection is 20 mg/m2.
16301004|NCT04668690|Active Comparator|Active Comparator: Chidamide|Patients with relapsed/refractory PTCL will receive Chidamide 30 mg p.o., twice per week until disease progression.
16301005|NCT04668651||diabetic|diabetic patients
16301006|NCT04668651||non diabetic|non-diabetic patients
16301007|NCT04668638|Other|Control group|Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.
16301008|NCT04668638|Other|Intervention group|Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.
16301009|NCT04668625|Experimental|Experimental group|Participate in a massive musical event
16301010|NCT04668625|No Intervention|Control Group|Not participate in a massive musical event
16301011|NCT04668612|Active Comparator|Standard-bolus|Standard boluses for all meal
16301012|NCT04668612|Experimental|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m
16301013|NCT04668599||Patient with chronic lung or cardiac diseases|"This study will focus on patients with obstructive or restrictive lung diseases eligible for pulmonary rehabilitation.
~Patient with cardiac disease such as heart failure, coronary artery disease or cardiomyopathies who are eligible for cardiac rehabilitation will also be included."
16301014|NCT04668586|Experimental|Holmium:YAG laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
16301015|NCT04668586|Experimental|Thulium Fiber laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.
16301016|NCT04668573|Experimental|Trunk exercise group|Participants received trunk exercise for 30 minutes per session, twice a week for 12 weeks.
16301017|NCT04668573|No Intervention|Control group|Participants remained their regular activities.
16301018|NCT04668560|Experimental|Intervention|Course intervention, six weeks wellbeing course
16301019|NCT04668560|No Intervention|Control|Follow-up as usual
16301020|NCT04668547|Experimental|Interventional arm|Single arm, no comparison
16301021|NCT04668534|Experimental|Treatment group 1|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
16301022|NCT04668534|Experimental|Treatment group 2|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
16301023|NCT04668534|Active Comparator|Control group|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left earlobe. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
16301024|NCT04668521||COHORT A|Women with a pelvic mass, symptomatic or asymptomatic.
16301025|NCT04668521||COHORT B|Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
16301026|NCT04668521||COHORT C|Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
16301027|NCT04668508|Experimental|anlotinib combined with radiation|
16301028|NCT04668495||Cangrelor Group|This is the study cohort that the blood sample will be obtained from. There are no interventions
16301029|NCT04668482|Experimental|SCS off|SCS is switched off
16301030|NCT04668482|Experimental|SCS on|SCS is switched on
16301031|NCT04668469|Experimental|Ivermectin plus standard care in Mild/Moderate COVID-19 (Group I)|100 patients with Mild/Moderate COVID-19 (Coronavirus disease) infection received a 4-days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard of care as issued by Egyptian protocol of COVID-19 treatment.
16301032|NCT04668469|Active Comparator|hydroxychlorquine plus standard care in Mild/Moderate COVID-19 (Group II)|100 patients with mild/moderate COVID-19 infection received hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care.
16301033|NCT04668469|Experimental|Ivermectin plus standard care and steroids in Sever COIVD-19 (Group III)|100 patients with severe COVID-19 infection received a 4 days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard care and steroids
16301034|NCT04668469|Active Comparator|hydroxychlorquine plus standard care and steroids in Sever COVID-19 (Group IV)|100 patients with Severe COVID-19 infection received hydroxychlorquine (400 mg every 12 hours for one day followed by 200 mg every 12 hours for 9days) plus standard care and steroids
16301035|NCT04668469|Experimental|Ivermectin plus personal protective measures in COVID-19 prophylaxis (Group V)|100 health care and or household contacts received a prophylactic dose of ivermectin 400 micrograms/kg single oral dose before breakfast to be repeated after one week in addition to Personal Protective Measures ( (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
16301036|NCT04668469|Active Comparator|Personal protective measures in COVID-19 prophylaxis (Group VI)|100 health care and or household contacts received only Personal Protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
16301037|NCT04668456|Placebo Comparator|Group C (control group)|Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
16301038|NCT04668456|Active Comparator|Group SD (subtenon dexmedetomiine)|Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
16301039|NCT04668456|Active Comparator|Group ID (iv dexmedetomidine)|Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.
16301040|NCT04668443||Prospective participants in D²EFT study|HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)
16301041|NCT04668443||Researchers obtaining informed consent for D²EFT study|Healthcare givers involved in the participant informed consent process of D²EFT
16301042|NCT04668430|Other|patients|"Patients for whom orthopedic surgery is indicated and planned among :
~Tibial valgus osteotomy
~Supra-malleolar osteotomy
~Hallux osteotomy for hallux valgus
~Total knee arthroplasty
~Total ankle arthroplasty
~Ankle arthrodesis
~Hallux arthrodesis
~Rear foot torque arthrodesis
~Inverted shoulder prosthesis
~Anterior lumbar interbody arthrodesis"
16301043|NCT04668417|Active Comparator|Reminders with direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with a link enabling direct scheduling
16301044|NCT04668417|Active Comparator|Reminders with no direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with no direct scheduling link
16301045|NCT04668404||COVID-19 positive patient with ARDS|All patients with COVID-19 diagnosed with RT-PCR.
16301048|NCT04668378|Experimental|Time restricted eating (TRE) - two month|partecipants underwent 2 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
16301049|NCT04668378|Active Comparator|Normal Diet (ND) - two month|partecipants underwent 2 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
16301050|NCT04668378|Experimental|Time restricted eating (TRE) - twelve month|partecipants underwent 12 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
16301051|NCT04668378|Active Comparator|Normal Diet (ND) - twelve month|partecipants underwent 12 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
16301052|NCT04668365|Experimental|Zanubrutinib Combined With Standard Chemotherapy|"A: For the first-line treatment:
~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.
~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 6 cycles for patients with CD79A/CD79B genetic abnormality.
~Zanubrutinib combined with Rituximab for the 7 cycle.
~B: For R/R DBCLC:
~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen: GemOx(Gemcitabine, Oxaliplatin)/ DHAP(Cisplatin, Cytarabine, Dexamethasone)/ ICE(Ifosfamide, Etoposide, Carboplatin)/ GDP(Gemcitabine, Cisplatin, Dexamethasone): repeated every 3 weeks, up to 5 cycles.
~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 5 cycles for patients with CD79A/CD79B genetic abnormality.
~Maintenance treatment: Zanubrutinib, 160mg twice daily continuous oral administration for 12 months."
16301053|NCT04668352|Experimental|Dactolisib 10mg once daily|
16301054|NCT04668352|Placebo Comparator|Placebo|
16301055|NCT04668339|Experimental|Study Group 1, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
16301056|NCT04668339|Experimental|Study Group 2, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
16301057|NCT04668339|Experimental|Study Group 3, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
16301058|NCT04668339|Placebo Comparator|Study Group 4, Younger Adult Participants|Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208
16301059|NCT04668339|Experimental|Study Group 1, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
16301060|NCT04668339|Experimental|Study Group 2, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
16301061|NCT04668339|Experimental|Study Group 3, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
16301062|NCT04668339|Placebo Comparator|Study Group 4, Older Adult Participants|Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208
16301063|NCT04668326|Active Comparator|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
16301064|NCT04668326|Experimental|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
16301103|NCT04668066|Experimental|Multiple ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive multiple subcutaneous doses PF-07242813 or placebo
16301443|NCT04665713||Overweight|children whose BMI are above the normal range(over P85)
16301065|NCT04668300|Experimental|Treatment (oleclumab, durvalumab)|Patients receive oleclumab IV over 1 hour every 2 weeks for 5 doses, then every 4 weeks thereafter. Patients also receive durvalumab IV over 1 hour every 4 weeks. Cycle repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16301066|NCT04668287|Other|Increasing Self-Esteem|All participants will be included in working groups.
16301067|NCT04668274|Experimental|Initial Dose|First Low dose, initially 200 mg resveratrol as JOTROL
16301068|NCT04668274|Experimental|Second (ascending) dose|Second (presumed) intermediate dose estimated at 500 mg resveratrol as JOTROL
16301069|NCT04668274|Experimental|Third (ascending) dose|Third (presumed) and highest dose estimated at 1000 mg resveratrol as JOTROL
16301070|NCT04668274|Experimental|Highest dose level (above) with a concomitant food evaluation|Third (presumed) and highest dose estimated at 1000 mg resveratrol as JOTROL administered in conjunction with a food effect evaluation
16301071|NCT04668261||Neurosurgical patients|"• Neurosurgical diseases with the potential to alter blood flow to the brain:
~Cerebrovascular disease
~Brain tumors
~Normal Pressure Hydrocephalus"
16301072|NCT04668261||Healthy subjects|"Male and Female subjects >18 years of age
~Written Informed Consent by the participant after information about the project. Foreign speaking healthy subjects should be accompanied by a person with sufficient German language proficiency to act as a translator"
16301075|NCT04668235|Experimental|Arm AZVUDINE|"Experimental:
~AZVUDINE 1mg tablet,
~Interventions:
~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days"
16301076|NCT04668235|Placebo Comparator|Arm Placebo|"Control:
~AZVUDINE placebo,
~Interventions:
~AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days"
16301077|NCT04668222|Experimental|Deficiency of Qi and Yang (QYang-group)|Participants will receive Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
16301078|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yang (PQYang-group)|The placebo is made of 5% Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
16301079|NCT04668222|Experimental|Deficiency of Qi and Yin (QYin-group)|Participants will receive Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
16301080|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yin (PQYin-group)|The placebo is made of 5% Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
16301081|NCT04668209|Active Comparator|Silmitasertib|Standard of care / supportive care in combination with Silmitasertib (CX-4945)
16301082|NCT04668209|No Intervention|Standard of Care|Standard of care / supportive care
16301083|NCT04668196||High-flow nasal cannula treatment|
16301084|NCT04668196||Continuous positive airway pressure (CPAP) treatment|
16301085|NCT04668196||Noninvasive ventilation treatment|
16301086|NCT04668183||Pudendal Nerve Block|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
16301087|NCT04668183||Dorsal Penile Nerve Block|Ultrasound (US) guided dorsal penile nerve block with in plane technique was done. Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
16301088|NCT04668170||hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:
~Patients with severe disease requiring on admission ICU management for SARS, Non-severe hospitalized patients with secondary clinical worsening requiring ICU management, Non-severe hospitalized patients without clinical worsening requiring ICU management."
16301089|NCT04668170||healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
16301090|NCT04668157|Experimental|TAK-536|TAK-536 granule formulation, orally once daily before or after breakfast. The initial dose of TAK-536 will be 0.1 mg/kg (not exceeding 2.5 mg/day). After the initial dose, TAK-536 will be titrated to 0.2 mg/kg (not exceeding 5 mg/day), 0.4 mg/kg (not exceeding 10 mg/day), and 0.8 mg/kg (not exceeding 20 mg/day) if the subjects do not achieve the target blood pressure and no concerns are found in safety and tolerability.
16301091|NCT04668144|Active Comparator|Prasugrel|Prasugrel only administered at the start of PCI
16301092|NCT04668144|Experimental|Prasugrel + Cangrelor|Cangrelor plus prasugrel concomitantly administered at the start of PCI
16301093|NCT04668144|Active Comparator|Cangrelor followed by Prasugrel|Cangrelor administered at the start of PCI plus prasugrel administered at the end of the cangrelor infusion
16301094|NCT04668131|Experimental|Artificial tears|
16301095|NCT04668131|Active Comparator|Acupuncture|
16301096|NCT04668118|Experimental|Diquafosol group|The treatment period is 12 weeks. The day after subjects who meet the inclusion criteria undergo baseline examination is the day starting the medication. Dosing frequency was six times daily for 3% Diquafosol Ophthalmic Solution. The follow-up time points are 2, 4, 8, 12 weeks, and no other medication is required on the follow-up day.
16301097|NCT04668105|Experimental|High volume nordic hamstring exercise|High volume Nordic hamstring exercise
16301098|NCT04668105|Experimental|Low volume Nordic Hamstring exercise|Low volume Nordic Hamstring exercise
16301099|NCT04668092|Experimental|Functional dry needling|Functional dry needling for shortened hamstring muscle
16301100|NCT04668079|Experimental|Modified cross body stretch|modified cross body stretch
16301101|NCT04668079|Experimental|Modified sleeper stretch|modified sleeper stretch
16301102|NCT04668066|Experimental|Single ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive a single intravenous dose of either PF-07242813 or placebo
16301444|NCT04665700|Experimental|BI 764198 Single dose part|
16301104|NCT04668066|Experimental|Single dose of PF-07242813 or placebo in participants with moderate to severe atopic dermatitis|Participants will receive a single intravenous dose of either PF-07242813 or placebo
16301105|NCT04668053|Active Comparator|Traditional training protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills
16301106|NCT04668053|Experimental|Hip flexor resistance protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills and hip flexors resistance protocol
16301107|NCT04668040|Experimental|Muscle energy technique|Muscle energy technique applied in the lower cross syndrome muscle pattern.
16301108|NCT04668040|Active Comparator|Stretching|Stretching technique applied in the lower cross syndrome muscle pattern.
16301109|NCT04668027|Experimental|chronic airway disease group|Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC <0.7 are divided into the dilation test group.
16301110|NCT04668001|Experimental|Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
16301111|NCT04668001|Placebo Comparator|Sham Transcranial Photobiomodulation (tPBM-Sham)|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
16301112|NCT04667988|Experimental|RA patients|newly diagnosed RA will started therapy with conventional synthetic DMARDs (including methotrexate)
16301113|NCT04667988|Experimental|control|JAK2 mutation assesment by PCR
16301114|NCT04667975|Experimental|Part 1(Dose escalation)|"Part 1: 3 or 6 subjects are enrolled, per each dose group in a traditional 3+3 design.
~Begin with the starting dose determined by the non-clinical study and increase the dose according to the dose levels. If DLT does not occur in the 3 subjects when they have completed the 1st cycle at each dose level, increase the dose to the next level. Dose escalation proceeds until the maximum tolerated dose (MTD) is reached.
~Dose-limiting toxicity (DLT) is evaluated following the completion of dosing for the 1st cycle of all subjects enrolled in each dose group in order to determine whether to proceed to the next level. Following completion of the DLT evaluation of the planned dose level in this study, the SRC reviews the outcome of the evaluation and determines whether to set additional dosing or proceed to PART 2 (Dose expansion)."
16301115|NCT04667975|Experimental|Part 2(Dose expansion)|"Part 2: The primary objective of Part 2 is to evaluate the efficacy of CKD-702 by identifying the ORR after administering the RP2D of CKD-702 determined in Part 1. Along with this, to determine the CKD-702 effective patient group, the patient groups were classified into several cohorts based on non-clinical study results.
~Therefore, in Part 2, the RP2D determined in Part 1 is administered until the occurrence of an adverse event causing PD occurrence, death or treatment discontinuation, and tumor response is evaluated based on RECIST version 1.1."
16301116|NCT04667962||Hospital service change|This group is composed of caregivers who changed hospital service during COVID-19 health crisis.
16301117|NCT04667962||No hospital service change|This group is composed of caregivers who have not changed hospital service during COVID-19 health crisis.
16301118|NCT04667949|Experimental|Fingolimod|Fingolimod 0.5 mg capsule taken orally once daily
16301119|NCT04667936||moderate to severe COVID-19 ARDS|patients with an oxygenation index <200 under intubation anesthesia and mechanical ventilation.
16301120|NCT04667910|Experimental|601 1.25mg|
16301121|NCT04667910|Experimental|Ranibizuman 0.5 mg|
16301122|NCT04667897|Experimental|601 1.25mg|
16301123|NCT04667897|Experimental|Ranibizuman 0.5 mg|
16301124|NCT04667884|Experimental|Group A|a mixture of Xylooligosaccharides, Stachyose, Fructooligosaccharides, and Water-soluble Dietary Fiber, 12 g/d, 4 weeks
16301125|NCT04667884|Experimental|Group B|a mixture of Fructooligosaccharide, water-soluble dietary fiber, polydextrose, and isomalt oligosaccharide, 12 g/d, 4 weeks
16301126|NCT04667884|Experimental|Group C|a mixture of Polydextrose, wheat fiber, and Seed shell of Plantago rotundifolia, 12 g/d, 4 weeks
16301127|NCT04667884|Experimental|Group D|a mixture of Fructooligosaccharides, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001, 3 g/d, 4 weeks
16301128|NCT04667884|Placebo Comparator|Group E|Maltodextrin， 3 g/d, 4 weeks
16301129|NCT04667871||Eyes for cataract surgery|Eyes for cataract surgery
16301130|NCT04667871||Eyes without cataract surgery|Eyes without cataract surgery
16301131|NCT04667832||abnormal ABI|those patients with ankle brachial index ( ABI) less than 0.9
16301132|NCT04667832||normal ABI|Those patients with ankle brachial index more than 0.9
16301133|NCT04667819|Experimental|sodium hyaluronate|Sodium hyaluronate has become a novel and effective eye drop for the treatment of the dry eye. However, we design a special method of usage of sodium hyaluronate in dry eye patients.
16301134|NCT04667793|Experimental|Thymoma|"Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Carboplatin AUC 5, Amycin 50mg/m2, Cyclophosphamide 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.
~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.
~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines."
16301135|NCT04667793|Experimental|Thymic carcinoma|"Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Cisplatin 50mg/m2, Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.
~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.
~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines."
16301136|NCT04667780|Experimental|Colchicine|"This arm will receive Standard COVID-19 care + Colchicine
~The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half."
16301137|NCT04667780|Other|Control - Standard COVID-19 care|This arm will receive standard COVID-19 care as per the hospital guidelines.
16301138|NCT04667767|Experimental|Intervention|"In addition to the national standard outpatient treatment for uncomplicated severe acute malnutrition, caregivers of participants will receive a WASH kit containing a plastic container, a supply of Aquatabs® (effervescent chlorine tablets), and training in their use and associated hygiene practices."
16301139|NCT04667767|Active Comparator|Control|National standard outpatient treatment for uncomplicated severe acute malnutrition
16301140|NCT04667754|Experimental|10 week ICBT|CBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
16301141|NCT04667728|Experimental|intervention group (IGr)|The IGr participants wore a professional continuous glucose monitoring (CGM) sensor (iPro™2) during the first six days of the study. Following this period, IGr participants had a medical consultation for the CGM results and treatment adjustments. Additionally, they received a personalized diet plan from a dietitian. After three months, the IGr participants again wore the CGM sensor for one week. These participants also followed the regular institutional Comprehensive Diabetes Care program care plan.
16301142|NCT04667728|No Intervention|control group (CGr)|The control group followed the regular institutional Comprehensive Diabetes Care program care plan.
16301143|NCT04667715|Active Comparator|Exablate Test Arm|Subjects will undergo ExAblate BBBD prior to their standard of care tumor removal
16301144|NCT04667715|No Intervention|Control Test Arm|Subjects will undergo their standard of care tumor removal
16301145|NCT04667702||Patient Focused Interviews|
16301146|NCT04667702||Caregiver Focused Interviews|
16301147|NCT04667702||Healthcare Provider Focused Interviews|
16301148|NCT04667689|Other|CAMPFIRE Assessment|NIH Toolbox Cognitive Assessment and PROMIS Surveys
16301149|NCT04667676|Experimental|TENS Therapy Group|patients received acupoint TENS
16301150|NCT04667676|Sham Comparator|Control group|patients received shame acupoint TENS
16301151|NCT04667663|Experimental|CPD-DARA|"Drug: Daratumumab Other Name: Darzalex
~Drug: Cyclophosphamide
~Drug: Pomalidomide Other Name: Pomalyst/ Imnovid
~Drug: Dexamethasone"
16301152|NCT04667637|Placebo Comparator|0.9% NaCl|Intravenous injections of 0.9% NaCl BID for 12 ±2days.
16301153|NCT04667637|Experimental|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.
16301154|NCT04667624|Active Comparator|Reference|TWYNSTA Tablet 80/5mg(Telmisartan/Amlodipine)
16301155|NCT04667624|Experimental|Test|LodienT Tablet 80/2.5mg(Telmisartan/S-amlodipine)
16301156|NCT04667611||Mild|
16301157|NCT04667611||Moderate|
16301158|NCT04667611||Severe|
16301159|NCT04667598|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
16301160|NCT04667598|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
16301161|NCT04667585|Experimental|Interim PET-CT with dose de-escalation|Participants will receive an interim PET-CT approximately 2 weeks into radiation therapy.
16301162|NCT04667585|Active Comparator|Interim PET-CT with standard radiation|
16301163|NCT04667572|Experimental|Pulsed 5mW/cm2|5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time
16301164|NCT04667572|Experimental|Pulsed 8mW/cm2|8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time
16301165|NCT04667546|Other|Patient having urinary tract infection|Patients with a confirmed urinary tract infection in accordance with the GPIP (french Pediatric Infectious Disease Group) definition and inclusion criteria.
16301166|NCT04667533|Experimental|Desidustat tablet|
16301167|NCT04667520|Experimental|LPA+Fitbit|Participants in this group receive a Lifestyle Physical Activity intervention and are provided with a Fitbit to collect activity data
16301168|NCT04667520|Active Comparator|Fitbit Only|Participants in this group are provided with a Fitbit to collect activity data
16301169|NCT04667507|Experimental|Dextenza (Group A)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery
16301170|NCT04667507|Experimental|Dextenza (Group B)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 6-8 days prior to surgery
16301171|NCT04667507|Experimental|Dextenza (Group C)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 13-15 days prior to surgery
16301172|NCT04667507|Experimental|Dextenza (Group D)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 19-23days prior to surgery
16301173|NCT04667507|Experimental|Dextenza (Group E)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 26-31 days prior to surgery
16301174|NCT04667507|No Intervention|Control|Will not receive Dextenza (dexamethasone ophthalmic insert 0.4mg)
16301175|NCT04667494|Experimental|Sonotherapy|All participants will undergo sonotherapy
16301180|NCT04667468|Active Comparator|Standard Care|resuscitation, blood and blood component transfusion per site standard care
16301181|NCT04667455|No Intervention|Control subjects|Infants and Children with no evidence of congenital heart disease based on echocardiography and standard ECG assessment
16301182|NCT04667455|Active Comparator|Congenital heart disease subjects|Infants and Children with evidence of predefined congenital heart disease lesions based on echocardiography and standard ECG assessment
16301183|NCT04667442||EUA RT-PCR positive|
16301184|NCT04667442||EUA RT-PCR negative|
16301185|NCT04667429|Experimental|Food effect|HEC83518 40mg will be administered fasted, or with high-fat meal for once.
16301186|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 20mg|HEC83518 20mg will be administered before sleep for 15 days .
16301187|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 40mg|HEC83518 40mg will be administered before sleep for 15 days .
16301188|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 80mg|HEC83518 80mg will be administered before sleep for 15 days .
16301189|NCT04667429|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo will be administered before sleep for 15 days .
16301190|NCT04667416|No Intervention|Standard of Care (SOC)|Participants will receive SOC for chronic ulcers of the lower extremities.
16301191|NCT04667416|Experimental|PalinGen Flow Treatment plus SOC|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
16301192|NCT04667403|Experimental|Telemedicine|"Pain is monitored, from the patient's home, using a computer application accessible from a smartphone or a computer with internet access.
~This application will allow the patient to describe his or her pain by means of a self-questionnaire. Healthcare professionals (nurse coordinator, pain specialist and oncologist) will thus be able to remotely interpret the data collected, enabling them to provide patients with a rapid response to adapt their pain treatment without the patient having to travel to the establishment."
16301193|NCT04667390|Active Comparator|total knee arthroplasty using the active robotic system|total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
16301194|NCT04667390|Active Comparator|total knee arthroplasty using computer navigation|Primary total knee arthroplasty using computer navigation and intraoperation control system
16301195|NCT04667390|Active Comparator|total knee arthroplasty using the standard manual tekhnik|Primary total knee arthroplasty using the standard recommended set of instruments
16301196|NCT04667377|Experimental|Very low dose group|
16301197|NCT04667377|Placebo Comparator|Placebo group|
16301198|NCT04667377|Experimental|Low dose group|
16301199|NCT04667377|Experimental|Medium dose group|
16301200|NCT04667377|Experimental|High dose group|
16301201|NCT04667364|No Intervention|Group MED|A group of participants that receives treatment as usual that consists of medicinal treatment, prescribed by a specialist doctor (Carsten Kock-Jensen, MD) from the CRPS clinic and will be monitored using patients' medicinal records.
16301202|NCT04667364|Experimental|Group TENS|A group of participants that receives transcutaneous electrical nerve stimulation (TENS) which is an inexpensive, noninvasive and safe treatment for pain.
16301203|NCT04667351|Active Comparator|5-fu 2400|
16301204|NCT04667351|Experimental|5-fu 1200|
16301205|NCT04667338||Cohort A: NT1 Participants|Participants with confirmed diagnosis of narcolepsy type 1 (NT1) between 2014 to 2019, as defined by defined by the International Classification of Sleep Disorders, Third Edition (ICDS-3) will be observed for up to 24 months.
16301206|NCT04667338||Cohort B: NT2 Participants|Participants with confirmed diagnosis of narcolepsy type 2 (NT2) between 2014 to 2019, as defined by defined by the ICDS-3 will be observed for up to 24 months.
16301207|NCT04667299|Experimental|BMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid and metronidazole 0.4 g qid for 14 days
16301208|NCT04667299|Active Comparator|BMQ group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and amoxicillin 1 g bid for 14 days
16301209|NCT04667286|Experimental|Oxygen and Prone Position (PP)|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96% plus PP for a minimum of 10 hrs a day
16301210|NCT04667286|Active Comparator|Oxygen|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96%
16301211|NCT04667273|Experimental|Exercise Training (ET) + Neuromuscular Electrical Stimulation (NMES) group|volunteer patients with Subacromial Impingement Syndrome
16301212|NCT04667273|Other|Exercise Training (ET) group|volunteer patients with Subacromial Impingement Syndrome
16301213|NCT04667260|Placebo Comparator|Bone substitue|Bone augmentation with bone substitute
16301214|NCT04667260|Experimental|Coagulum|Bone augmentation with coagulum
16301215|NCT04667247|Experimental|Mushrooms|Fomitopsis officinalis and Trametes versicolor
16301216|NCT04667247|Placebo Comparator|Placebo|Organic brown rice
16301217|NCT04667221|Experimental|Anodal transcranial direct current stimulation|Patients will be bilaterally stimulated with anodal tDCS at the parietal cortex (Broadman Area 7).
16301218|NCT04667221|Experimental|Cathodal transcranial direct current stimulation|Patients will be bilaterally stimulated with cathodal tDCS at the parietal cortex (Broadman Area 7).
16301219|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for anodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Broadman Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
16301220|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for cathodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Broadman Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
16301221|NCT04667195||Suspected acute pyelonephritis|Diagnosis of APN suspected at the initial clinical assessment by the receiving emergency department physician
16301222|NCT04667182||Combined Diabetes Management Data|Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.
16301445|NCT04665700|Experimental|BI 764198 Multiple dose low|
16301446|NCT04665700|Placebo Comparator|Placebo|
16301223|NCT04667169|Experimental|Laser Haemorrhoidoplasty|A stab incision was made at the ano-cutaneous junction and the anodermis was tunneled with artery forceps to the pedicle of the haemorrhoids. The laser catheter was introduced submucosally towards the pedicle guided by a visible beam to ascertain the exact location of the laser fibre. This was then followed by about six pulsed laser energy delivered at five mm interval, while gradually withdrawing the laser catheter.
16301224|NCT04667169|Experimental|Haemorrhoidal Artery Ligation|In addition to the delivery of laser energy as per the procedure described above, each identified pedicle was ligated with a suture, without Doppler guidance.
16301225|NCT04667156|Experimental|Sequence 1|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 traditional formulation (R) in the last period
16301226|NCT04667156|Experimental|Sequence 2|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 new formulation 2 (T2) in the last period
16301227|NCT04667156|Experimental|Sequence 3|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 1 (T1) in the last period
16301228|NCT04667156|Experimental|Sequence 4|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 2 (T2) in the last period
16301229|NCT04667156|Experimental|Sequence 5|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 traditional formulation (R) in the last period
16301230|NCT04667156|Experimental|Sequence 6|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 new formulation 1 (T1) in the last period
16301231|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR|
16301232|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR|
16301233|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR|
16301234|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR|
16301235|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR|
16301236|NCT04667130|Experimental|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
16301237|NCT04667117|Experimental|Cohort 1|RMS patients receiving a 2020-2021 inactivated influenza vaccine at least two weeks prior to ofatumumab start
16301238|NCT04667117|Experimental|Cohort 2|RMS patients receiving a 2020-2021 inactived influenza vaccine at least 4 weeks after ofatumumab start.
16301239|NCT04667117|Experimental|Cohort 3|RMS patients currently on iDMT receiving a 2020-2021 an inactivated influenza vaccine
16301240|NCT04667104|Experimental|Treatment Period (TP) 1 (JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)|Participants will receive combination treatment with JNJ-73763989 + 56136379 + nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + 56136379 + NA plus PegIFN-α2a for 12 weeks during Treatment Period 2.
16301241|NCT04667091|Experimental|Experimental|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:
~1. Positional Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
16301242|NCT04667091|Active Comparator|Comparator|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:
~1. Myofascial Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
16301243|NCT04667078|Experimental|Cangrelor group|treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms/kg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms/kg/min IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.
16301244|NCT04667078|Active Comparator|Best medical management group|treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.
16301245|NCT04667065|Other|Physical activity with smartwatch before bronchial cancer surgery|
16301246|NCT04667052|Experimental|JNJ 64304500: Reference|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 reference formulation.
16301247|NCT04667052|Experimental|JNJ 64304500: Test|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 test formulation.
16301250|NCT04667013|Experimental|Cohort 1|2 x 300 mg TBN tablets for a total dose of 600 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
16301251|NCT04667013|Experimental|Cohort 2|4 x 300 mg TBN tablets for a total dose of 1200 mg or 4 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
16301252|NCT04667000|Experimental|lower extremities|the women's lower extremities will be heated with Forced Air Warming
16301253|NCT04667000|Experimental|upper extremities|the women's upper extremities will be heated with Forced Air Warming
16301254|NCT04667000|Experimental|whole body|the women's whole body will be heated with Forced Air Warming
16301255|NCT04667000|No Intervention|control group|there is no intervention for this group
16301256|NCT04666987||Xultophy®|Participants are patients with Type 2 Diabetes (T2D) treated with Xultophy® (IDegLira) in a real-world setting in Italy
16301287|NCT04666766|Active Comparator|Healthy age-matched volunteers|Healthy age-matched volunteers with no previous trauma to the head within the past two weeks.
16301257|NCT04666974|Experimental|Phase 3: iCBT + Treatment As Usual|CWs in the iCBT group, will be assigned to one the six therapy modules, based on their gender and diagnosis (i.e. Female/Male * GAD, MDD or PTSD). Each CW will be assigned a specific clinician (a trained psychiatrist/psychologist/ social worker) who would be their care liaison through the study. Each week, the clinician would send one session of the 12-session curriculum to the CW on a pre-determined day of the week. Each weekly session consists of 20-30 slides followed by a homework assignment. It usually takes 40-60 minutes for a participant to complete one weekly session which they have to complete by a specific day of the week. The clinician will review the CW's assignments and provide feedback on their performance. The clinician feedback is structured and takes approximately 15 minutes to complete. The clinician will then send the content for the next session along with the feedback.
16301258|NCT04666974|No Intervention|Phase 3: Treatment as Usual|Participants will complete clincally validated questionnaires to measure symptoms while continuing with their regular daily activities and treatments (if any) (i.e., exercise, diet, medications, etc.)
16301259|NCT04666974|Experimental|Phase 4: iCBT + Treatment as Usual|Participants will be randomly assigned to this group and take part in the iCBT module program from phase 3.
16301260|NCT04666974|Active Comparator|Phase 4: In-Person CBT + Treatment as Usual|Participants will be randomly assigned to this group and complete in-person CBT with similar content, homework, and feedback as in the iCBT + TAU group. All in-person CBT will be delivered by a trained professional and each session will take approximately 60-75 minutes.
16301261|NCT04666961|Experimental|Extended ductal carcinoma in situ with mastectomy indication|"Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation.
~Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 :
~Tamoxifen: box of tablets dosed at 20 mg
~Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months.
~Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months."
16301262|NCT04666948|Active Comparator|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring, according to institutional guidelines during 30 day study period
16301263|NCT04666948|Experimental|vancomycin model-informed precision dosing|Area Under the Concentration (AUC)-time curve/MIC-based model-informed precision dosing of vancomycin using a CE labelled dosing calculator during 30 day study period
16301264|NCT04666935|Experimental|Intervention group|The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).
16301265|NCT04666935|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
16301266|NCT04666922|Experimental|BI 765080 treatment group|BI 765080
16301267|NCT04666922|Placebo Comparator|Placebo group|Placebo
16301268|NCT04666909||Hypertension Group|Participants will receive a free blood pressure screening and receive educational counseling about the importance of maintaining a healthy blood pressure. In addition, educational counseling will be administered in months 3 and 6.
16301269|NCT04666896|Experimental|Evidence-based tailored care (group A)|Patients who were randomized to group A received a tailored exercise program, with exercises developed based on recent hEDS/HSD research data.
16301270|NCT04666896|Active Comparator|Evidence-based standard care (group B)|This exercise program was composed in order to reflect evidence-based standard care, in a telerehabilitation format.
16301271|NCT04666883||Splenic flexure cancer patients|Splenic flexure cancer patients
16301272|NCT04666870||axis length|1007 healthy students with moderate to high myopia (SE ≤ -4.00D) and 894 without myopia (-0.50D ≤ spherical power ≤ +2.00D) were enrolled.
16301273|NCT04666870||gender|male were 54.29% (N=1032), and female were 45.71% (N=869)
16301274|NCT04666857|No Intervention|standard care|Control subject will receive standard care of treatment
16301275|NCT04666857|Experimental|intervention group|intervention group will receive early intervention
16301276|NCT04666844||Survey|Clinicians will be asked to provide responses to the two surprise questions for each of their PD patients.
16301277|NCT04666831|Experimental|AMI and CBT Intervention|Participants will receive four weekly sessions of individual therapy (60 minutes) with a graduate student therapist over videoconferencing technology or telephone. The intervention combines Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT) techniques for food addiction. Participants will complete questionnaires at baseline, postintervention or 1-month postbaseline, and 2- and 4-months postbaseline.
16301278|NCT04666831|No Intervention|Waitlist Control|Participants will complete questionnaires at baseline, 1-month postbaseline, and 2- and 4-months postbaseline (at timepoints comparable to the intervention arm). They will not receive any intervention during this time. Following the 3-month waitlist, they will cross over into the same procedure as the intervention arm.
16301279|NCT04666818||Self Monitoring Blood Glucose (SMBG)|Women used self-monitoring of blood glucose= Control group (CG)
16301280|NCT04666818||Flash Glucose Monitoring (FGM)|Women used flash glucose monitoring= FGM group (FG)
16301281|NCT04666805||Drug Group|Endocrine therapy drugs include selective estrogen receptor modulators (Tamoxifen, Toremifene) and aromatase inhibitors (Anastrozole, Letrozole, Exemestane), which have been widely used in the adjuvant treatment of hormone receptor positive breast cancer.
16301282|NCT04666792|Other|PrEP for HIV-1 uninfected for women accessing family planning|Women accessing family planning will be assessed for HIV risk and PrEP eligibility. If eligible and willing to initiate PrEP, they will be provided PrEP in accordance with national guidelines as part of their standard of care at the family planning clinic.
16301283|NCT04666779||No access|Group not accessing chiropractic care
16301284|NCT04666779||Access to care|Group with access to care in a 6 months period. Differences in the degree of access, measured in ranges of numbers of visits, will be used as independent variable within this group.
16301285|NCT04666766|Active Comparator|Traumatic intracranial hemorrhage|Patients with traumatic intracranial hemorrhage diagnosed by Computerized Tomography of the head
16301286|NCT04666766|Active Comparator|Trauma without traumatic intracranial hemorrhage|Patients with trauma to the head but traumatic intracranial hemorrhage ruled out by Computerized tomography of the head
16301288|NCT04666753||ImmunoFormulation cohort|"Patients treated* with IMUNO TF® with a combination of nutraceuticals.
~*Without restrictions on the adjuvant treatment received."
16301289|NCT04666753||Control cohort|"Control cohort: patients not treated* with IMUNO TF® with a combination of nutraceuticals.
~*Without restrictions on the adjuvant treatment received."
16301290|NCT04666740|Experimental|Cohort A: Core HRD|Patients with either pathogenic germline or somatic alterations of 3 core homologous recombination-genes (HR-genes) - (BRCA1/2, or PALB2) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort A.
16301291|NCT04666740|Experimental|Cohort B: Non core HRD|Patients with either pathogenic somatic or germline non-core 14 HR-gene alterations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort B.
16301292|NCT04666740|Experimental|Cohort C: Platinum sensitive|Patients without any of the above HR-gene alterations included in Cohort A and B who have platinum-sensitivity, which is defined as a partial response (PR) or complete response (CR) for the best overall response (BOR) during at least 4 months on platinumbased therapy. Variants of unknown significance of candidate HR-genes from Cohort A or B will be eligible for Cohort C if they meet the partial response to platinum criterion.
16301293|NCT04666714|Experimental|Praga formulation|"The study is double-dummy. The participant must take pills twice a day, as follows:
~Morning:Placebo pregabalin tablet, oral Night: Placebo pregabalin tablet, oral plus Praga formulation,oral"
16301294|NCT04666714|Active Comparator|Pregabalin|"The study is double-dummy. The participant must take pills twice a day, as follows:
~Morning:Pregabalin tablet, oral Night: Pregabalin tablet plus, oral placebo Praga formulation, oral"
16301295|NCT04666701|Experimental|Escócia association|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:
~1 tablet Escócia association, oral
~1 dragee Placebo Scopolamine, oral
~1 tablet Placebo Ketorolac, sublingual"
16301296|NCT04666701|Active Comparator|Ketorolac|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:
~1 tablet Ketorolac, sublingual
~1 tablet Placebo Escócia association, oral
~1 dragee Placebo Scopolamine, oral"
16301297|NCT04666701|Active Comparator|Scopolamine|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:
~1 dragee Scopolamine, oral
~1 tablet Placebo Ketorolac, sublingual
~1 tablet Placebo Escócia association, oral"
16301298|NCT04666688|Experimental|Part 1 dose escalation|LYT-200 in metastatic solid tumors
16301299|NCT04666688|Experimental|Part 2 dose expansion|LYT-200 in select metastatic solid tumors, eg., pancreatic cancer, cholangiocarcinoma
16301300|NCT04666675|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A once daily (QD).
16301301|NCT04666675|Experimental|Upadacitinib Dose B|Participants will receive Upadacitinib Dose B QD.
16301302|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose A|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose A QD.
16301303|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose B|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose B QD.
16301304|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 500 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 500 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
16301305|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 750 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 750 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
16301306|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 1000 IU/m² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m² of Pegcrisantaspase in an IV every 14 days ( per cycle)
16301307|NCT04666649|Experimental|Cohort 600mg Venetoclax, 1000 IU/m ² of Pegcrisantaspase|The subject will take 600mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m ² of Pegcrisantaspase in an IV every 14 days ( Per cycle)
16301308|NCT04666636|Placebo Comparator|Placebo|Participants in the group will receive placebo.
16301309|NCT04666636|Experimental|Mirabegron|Participants in this group will receive Mirabegron for 16 weeks.
16301310|NCT04666623|Active Comparator|intranasal esketamine (56mg)|
16301311|NCT04666623|Placebo Comparator|placebo|
16301312|NCT04666610|Experimental|Brivaracetam 200 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:
~Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
16301313|NCT04666610|Experimental|Placebo to 200 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:
~Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period."
16301314|NCT04666610|Experimental|Brivaracetam 100 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:
~Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
16301315|NCT04666610|Experimental|Placebo to 100 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:
~Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period."
16301316|NCT04666610|Experimental|Optimal dose of BRV (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment Period (AT):
~Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period."
16301317|NCT04666610|Experimental|Placebo to BRV optimal dose (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment (AT) Period:
~Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period."
16301318|NCT04666610|Experimental|Brivaracetam received during RDW|"Randomized Withdrawal (RDW) Period:
~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period."
16301319|NCT04666610|Experimental|Placebo received during RDW|"Randomized Withdrawal (RDW) Period:
~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks."
16301320|NCT04666597||Modified CariesCare International management intervention group|
16301321|NCT04666584|Active Comparator|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon before implantation with a Magmaris bioresorbable scaffold
16301322|NCT04666584|Active Comparator|Standard non-compliant balloon|Pre-dilatation with a non-compliant balloon before implantation with a Magmaris bioresorbable scaffold
16301323|NCT04666571|Experimental|Personalised (TOKA)|"During HTO surgery, the personalised plate will be inserted below the knee.
~The investigational device and comparator are two types of metal plate used to fix the bone in place during a high tibial osteotomy (HTO)."
16301324|NCT04666571|Active Comparator|Standard (Tomofix)|During HTO surgery, the standard plate will be inserted below the knee.
16301325|NCT04666558|No Intervention|Standard Care|The standard of care response to COVID. Educational materials will be provided to patients via email. The package will include a combination of personalized exercises, and nutrition information for healthy eating. Participants will also receive a Garmin watch to track their activity over the intervention.
16301326|NCT04666558|Experimental|App-Based, Personnel-Light Care|"An app-based, personnel-light approach to virtual care with a focus on support through group-based interactions with the Trainers, Dietitians and other participants. The patient's personalized 12-week home based exercise program will be enabled in the app after a baseline exercise specialist appointment. The 10-week nutrition program will be enabled at week 3 after a virtual dietitian assessment in week 2 (~1 hour). The home programs will auto-progress. Participants will also receive a Garmin watch to track their activity over the intervention."
16301327|NCT04666558|Experimental|App-Based, Personnel-Intensive Care|"An app-based, personnel-intensive approach to virtual care with support through a combination of group-based interactions with Trainers, Dietitians and other participants, as well as one-on-one support with Exercise Trainers and Dietitians. In addition to Group 2 features, patient interaction with Trainers will be via live group classes AND 1-to-1 sessions: up to seven 1-to-1 consultations with an exercise specialist and three 1-to-1 consultations with a dietitian to review progress and goals and make any necessary modifications to programming. Participants will also receive a Garmin watch to track their activity over the intervention."
16301328|NCT04666545|Experimental|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
16301329|NCT04666545|No Intervention|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
16301330|NCT04666506||VR as distraction during a medical procedure|Paediatric outpatients undergoing a medical procedure, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a distraction method during a potentially painful or scary procedure (e.g., vaccination, wound care, venipuncture,...).
16301331|NCT04666506||VR as relaxation method during a hospital stay|Paediatric inpatients, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a relaxation method during a potentially stressful hospital stay (e.g., patients with psychosomatic complaints, patients with eating disorders,...).
16301332|NCT04666493|Experimental|Facing Your Fears - Open label|All participants in the study will receive 12 weekly sessions of Facing Your Fears intervention, each lasting approximately 1 to 1.5 hour. Each session involves a component with all the parents and children (30-45 minutes) and a separate time with all the parents only (30-45 minutes). Additionally, there will be two check-in calls (30 minutes each) with the families after weeks 7 and 9 of the program.
16301333|NCT04666480|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
16301334|NCT04666467|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
16301335|NCT04666454|Active Comparator|Randomisation 1: Adenosine and Dipyridamole|Adenosine infusion 70 µg/kg/min for 3 hours, followed (first dose 60 minutes apart from the end of the adenosine infusion) by daily oral treatment with the adenosine reuptake inhibitor dipyridamole (200 mg b.i.d.) until normalization of Left Ventricular (LV) function (EF≥50%) is documented on the study-specific echocardiographic assessment at 72 hours or at any subsequent echocardiographic examination, or for 30 Days.
16301336|NCT04666454|Other|Randomisation 1: Control|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology.
16301337|NCT04666454|Active Comparator|Randomisation 2: Apixaban|Apixaban 5mg b.i.d. per oral until normalization of LV function (EF≥50%) is documented on the study-specific echocardiographic assessment at 72 hours or any subsequent echocardiographic examination, or for 30 Days.
16301338|NCT04666454|No Intervention|Randomisation 2: No anticoagulant therapy|
16301339|NCT04666441|Experimental|IV Dose 1|Combination therapy intravenous (IV) single dose
16301340|NCT04666441|Experimental|IV Dose 2|Combination therapy IV single dose
16301341|NCT04666441|Experimental|IV Dose 3|Combination therapy IV single dose
16301342|NCT04666441|Experimental|IV Dose 4|Combination therapy IV single dose
16301343|NCT04666441|Experimental|Placebo IV Dose|Matching placebo IV single dose
16301344|NCT04666441|Experimental|SC Dose 1|Combination therapy subcutaneous (SC) single dose
16301345|NCT04666441|Experimental|SC Dose 2|Combination therapy SC single dose
16301346|NCT04666441|Experimental|Placebo SC Dose|Matching placebo SC single dose
16301383|NCT04666142|Active Comparator|Comparison of the Individuals in the experimental and control groups after 24 hours of sleep|The effect of light after 24 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
16301447|NCT04665700|Experimental|BI 764198 Multiple dose medium|
16301347|NCT04666415|Experimental|Osteopathic treatment + as-usual treatment|"Osteopathic treatment: a protocol of 5 sessions of osteopathic treatment that have a 25 minutes duration and are spaced of around one week between two sessions.
~As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers."
16301348|NCT04666415|No Intervention|As-usual treatment|As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers.
16301349|NCT04666389|Placebo Comparator|Control group|No statins being used for prevention
16301350|NCT04666389|Active Comparator|Low-dose statin therapy|Atorvastatin 40 mg
16301351|NCT04666389|Active Comparator|High-dose statin therapy|Atorvastatin 80 mg
16301352|NCT04666376|Other|Vitrified ovarian tissue|Ovarian tissue will be vitrified and warmed by Ova kit type M protocol.
16301353|NCT04666363|Experimental|Lavender oil|On the first day (before intervention), the intensity of needle insertion-related pain was measured. The experimental group inhaled lavender essence (12 consecutive hemodialysis seasons).
16301354|NCT04666363|No Intervention|Control group|The patients will not smell lavender oil.
16301355|NCT04666337|Active Comparator|Group B (bupivacaine group)|patients received 20 ml bupivacaine 0.5% plus normal saline (2ml)
16301356|NCT04666337|Active Comparator|Group F (fentanyl group)|patients received 20 ml bupivacaine 0.5% plus fentanyl (100µg-2 ml)
16301357|NCT04666337|Active Comparator|Group T (tramadol group)|patients received 20 ml bupivacaine 0.5% plus tramadol (100mg-2 ml)
16301358|NCT04666324|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
16301359|NCT04666324|Experimental|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
16301360|NCT04666311||Adult presumptive TB cases|Adult presumptive TB cases (age ≥18years) with one or more TB symptoms (WHO recommended four-symptom screening; cough, weight loss, night sweats, fever) of any duration.
16301361|NCT04666298|Experimental|300 mg inclisiran sodium|Subcutaneous injection
16301362|NCT04666298|Experimental|200 mg inclisiran sodium|Subcutaneous injection
16301363|NCT04666298|Experimental|100 mg inclisiran sodium|Subcutaneous injection
16301364|NCT04666298|Placebo Comparator|Placebo|Subcutaneous injection
16301365|NCT04666272||dabrafenib in combination with trametinib as adjuvant treatment|Patients will be treated according to the China package insert for dabrafenib and trametinib. The approved starting doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) will be used.
16301369|NCT04666233|Experimental|Resuscitation with PPE for prevention of SARS-Cov-2 infection|
16301370|NCT04666233|Active Comparator|Resuscitation without PPE for prevention of SARS-Cov-2 infection|
16301371|NCT04666220||Renal cell carcinoma (RCC)|"For all series, clinical and epidemiological features will be recorded, all available histological slides will be reviewed and, on the primary tumor slides, histological characteristics will be re-assessed.
~Whenever multiple samples of tumors would be present, those having the tumor-surrounding tissue interface will be selected and stained with CD34 antibody.
~VETC will be evaluated independently by, at least, two pathologists, blinded to clinical data. VETC will be recorded as positive or negative, being VETC defined as CD34 unequivocal immunoreactivity of a continuous lining of endothelial cells around tumor clusters. VETC will be considered alternative to the common capillary pattern, consisting in small circular or linear blood vessels."
16301372|NCT04666220||Adrenal carcinoma|see (RCC)
16301373|NCT04666194|Active Comparator|Cold forceps|4-6mm polyps were removed with cold forceps
16301374|NCT04666194|Active Comparator|Cold snare|4-6mm polyps were removed with cold snare
16301375|NCT04666194|Active Comparator|Hot snare|4-6mm polyps were removed with hot snare
16301376|NCT04666181|Experimental|Dual-task training|Dual-task training will consist of balancing on the dynamic stability platform and responding to auditory stimuli. Participants will perform 18 trials total in 3 blocks of 6 trials. Each trial will be 30 seconds (s) in duration followed by 30 s of rest (i.e. quiet standing on the platform while holding onto the rails.) Between each training block, the participant will step off the platform and rest for 2 minutes. Dual-task training will occur on consecutive visits 2-6.
16301377|NCT04666168|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
16301378|NCT04666155|Experimental|Intermittent Colon Exoperistalsis|ICE Treatment with Mowoot device. 20min dayly for 12 weeks
16301379|NCT04666155|Active Comparator|Standard-of-Care|Standard-of-care for chronic constipation for 12 weeks.
16301380|NCT04666142|Active Comparator|Individual Characteristics of the Individuals in the Experimental and Control Groups|The personal characteristics of the individuals included in the study were examined.
16301381|NCT04666142|Active Comparator|Disease Characteristics of the Individuals in Experimental and Control Groups|The intensive care experience of the individuals included in the study, their status of receiving respiratory support, and the reason for staying in the intensive care unit were explained.
16301382|NCT04666142|Active Comparator|Distribution of Findings Regarding Sleep Activity of the Individuals in Both Groups|The personal characteristics of the individuals in the experimental and control groups regarding sleep were examined.
16301448|NCT04665700|Experimental|BI 764198 Multiple dose high|
16301384|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 24 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 24 hours after their admission to the ICU.
16301385|NCT04666142|Active Comparator|Comparison of the Sleep Times of the Individuals in Both Groups 48 Hours After Intensive Care|The effect of light after 48 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
16301386|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 48 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 48 hours after their admission to the ICU.
16301387|NCT04666142|Active Comparator|Distribution of Total Sleep Times of the Individuals in the Experimental and Control Groups|The sleep times of the individuals in both groups were compared
16301388|NCT04666129|Experimental|Part 1: Relugolix plus Abiraterone plus a Corticosteroid|Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.
16301389|NCT04666129|Experimental|Part 2: Relugolix plus Apalutamide|Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.
16301390|NCT04666129|Experimental|Part 3: Relugolix plus Docetaxel with or without Prednisone|Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.
16301391|NCT04666116|No Intervention|COVID-19 patients no dietary administration|Only medication agreed by the hospital committee
16301392|NCT04666116|Experimental|COVID-19 patients with dietary administration|Medication agreed by the hospital committee and nutritional supplement.
16301393|NCT04666103|Experimental|Thyroid lobectomy with intraoperative thermal ablation|"Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection. After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
16301394|NCT04666103|No Intervention|Thyroid lobectomy|Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection.
16301395|NCT04666090|Experimental|Carillizumab|"Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.
~Carillizumab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
16301396|NCT04666077|Experimental|Home-based MT through Supervised, Supported Singing (H3S)|Treatment arm 1
16301397|NCT04666077|Experimental|H3S and IMT|Treatment arm 2 received both Home-based Supervised, Supported Singing (H3S) and Individualized Music Therapy (IMT)
16301398|NCT04666077|Placebo Comparator|Attention Control (AtCon)|Comparison condition with comparable attention
16301399|NCT04666051|Experimental|Fibrin glue|A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
16301400|NCT04666051|No Intervention|Control|Lymphadenctomy wound was closed after insertion of a drain,
16301401|NCT04666038|Experimental|Arm A (LOXO-305)|Orally
16301402|NCT04666038|Active Comparator|Arm B (Idelalisib plus rituximab [IdelaR] or bendamustine plus rituximab [BR])|Investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).
16301403|NCT04666025||Observational (biospecimen collection, medical chart review)|"DONORS: Prior to HCT, sibling donors (MRD and haplo) undergo a nasopharyngeal swab per standard of care for SARS-Cov-2 testing. For MUD donors, initial testing may consist of a questionnaire. All donors undergo collection of blood and saliva at the time of granulocyte-colony stimulating factor (G-CSF). Donors' medical charts are also reviewed.
~RECIPIENTS: Patients undergo a nasopharyngeal swab for SARS-Cov-2 testing at 30, 60, 90, 120 days post-HCT, and afterwards as deemed necessary by the treating physician. Patients also undergo the collection of blood and saliva specimens at days 30, 60, 90, 120, 150, and 180 post-HCT. Recipients' medical charts are also reviewed."
16301404|NCT04666012|Experimental|Group 1: low dose|Subject will receive single dose of AdCLD-CoV19(2.5x10^10VP) as intramuscular injection.
16301405|NCT04666012|Experimental|Group 2: middle dose|Subject will receive single dose of AdCLD-CoV19(5.0x10^10VP) as intramuscular injection.
16301406|NCT04666012|Experimental|Group 3: high dose|Subject will receive single dose of AdCLD-CoV19(1.0x10^11VP) as intramuscular injection.
16301407|NCT04666012|Experimental|Group 4: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
16301408|NCT04666012|Experimental|Group 5: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
16301409|NCT04665999||Free-cycling females|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
16301410|NCT04665999||Females taking Monophasic contraception|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
16301411|NCT04665986|Experimental|NHP|Navelbine, Herceptin, Pertuzumab
16301412|NCT04665986|Active Comparator|THP|Docetaxel, Herceptin, Pertuzumab
16301413|NCT04665973|Experimental|Oral semi-structured interview|The oral semi-structured interview uses the principles of motivational interviewing (partnership with the patient, no judgment, altruism, evocation) and follow the content of the booklet used in the control group.
16301414|NCT04665973|Active Comparator|Booklet|The information booklet was designed by the physiotherapists at Cliniques universitaires Saint-Luc and is specifically dedicated to raise patient's awareness about the benefits of physical activity (PA) in the context of cancer.
16301415|NCT04665947|Experimental|[177Lu]Lu DOTA-ABM-5G dose escalation therapy study|Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of [68Ga]Ga DOTA-5G PET/CT will be offered therapy. Escalating doses of 25-200 mCi of [177Lu]Lu DOTA-ABM-5G will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
16301416|NCT04665947|Experimental|Recommended Phase 2 dose [177Lu]Lu DOTA-ABM-5G therapy study|Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy.10 patients will be enrolled in the dose expansion cohort and recieve the highest dose achieved in the [177Lu]Lu DOTA-ABM-5G dose escalation therapy study
16301417|NCT04665921|Experimental|SGN-STNV|SGN-STNV monotherapy
16301418|NCT04665908|Other|PT-led triage|Patients are assessed by PT
16301419|NCT04665908|Other|Standard care|The patiens are assessed by a orthopedic surgeon
16301420|NCT04665895|Experimental|Test Product|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
16301421|NCT04665895|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
16301422|NCT04665895|Placebo Comparator|Placebo|Placebo
16301423|NCT04665882|Experimental|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
16301424|NCT04665882|No Intervention|Standard axillary lymph node dissection|Standard axillary lymph node dissection was performed with complete resection of Berg's levels I and II.
16301425|NCT04665869|Experimental|Combined balance and brisk walking training|Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)
16301426|NCT04665869|Active Comparator|Flexibility and strengthening exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session
~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session
~Participants practice own flexibility and strengthening exercise 2-3 times/week (to aim at 150 min of exercise per week)"
16301427|NCT04665856|Experimental|Tiragolumab + Atezolizumab + Carboplatin and Etoposide|Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
16301428|NCT04665856|Placebo Comparator|Placebo + Atezolizumab + Carboplatin and Etoposide|Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
16301429|NCT04665843|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab followed by tiragolumab every three weeks (Q3W) on Day 1 of each 21-day cycle.
16301430|NCT04665843|Placebo Comparator|Atezolizumab + Placebo|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle.
16301431|NCT04665830|Active Comparator|Group 1|Evolocumab group, patients who are receiving this therapy for 12 months.
16301432|NCT04665830|Placebo Comparator|Group 2|The Statin group includes patients who are maintained on statin therapy.
16301433|NCT04665804|Experimental|Experimental Group A (Creatine Supplementation)|
16301434|NCT04665804|Experimental|Experimental Group B (Glucosamine and Chondroitin sulfate Supplementation)|
16301435|NCT04665791|Experimental|Challenge|Challenge participants will be inoculated intranasally with reconstituted, previously lyophilised Neisseria lactamica (LyoNlac). The initial dose will be 10^5 colony forming units and will be escalated to a maximum of 10^7 colony forming units to find the dose which successfully colonises at least 70% of volunteers.
16301436|NCT04665778||high risk of hospitalization|
16301437|NCT04665778||not high risk of hospitalization|
16301438|NCT04665765|Experimental|Treatment (PolaR-ICE)|"SALVAGE THERAPY: Patients receive polatuzumab vedotin IV on day 1, rituximab IV on day 1, etoposide IV on days 1-3, carboplatin IV on day 2, and ifosfamide IV on day 2 or days 1-3. Treatment repeats every 21 days for up to 2-3 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response or stable disease by C2D15 may receive 1 additional cycle of PolaR-ICE IV.
~CONSOLIDATION THERAPY: Within 30-60 days after ASCT, patients receive polatuzumab vedotin IV on day 1. Treatment repeats every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity."
16301439|NCT04665752||Affected Participants|Participants previously diagnosed with COVID-19.
16369676|NCT04190420||Patients|250 patients with primary hypertension
16301449|NCT04665674||Pulmonary Langerhans cell histiocytosis (PLCH)|All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses
16301450|NCT04665661|Experimental|High-intensity aerobic training (HIAT)|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
16301451|NCT04665661|Active Comparator|Wait-list control (WLC)|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
16301452|NCT04665648|Experimental|Treatment arm|Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
16301453|NCT04665648|Placebo Comparator|Placebo arm|Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention
16301454|NCT04665635|Active Comparator|Rectosigmoid resection|
16301455|NCT04665635|Active Comparator|Rectosigmoid seromuscular tumor shaving|
16301456|NCT04665622|Other|Fronto-temporal Dementia|10 subjects
16301457|NCT04665622|Other|Alzheimer's Dementia|20 subjects
16301458|NCT04665622|Other|Parkinson's Disease|20 subjects
16301459|NCT04665622|Other|Healthy volunteers|20 subjects
16301460|NCT04665609|Experimental|Anlotinib and TQB2450 solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Oral anlotinib (12 mg/d) will be administered and its cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks. The treatment continues until disease progression or treatment intolerance. Anlotinib and TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
16301461|NCT04665609|Active Comparator|TQB2450 Solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks.TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
16301462|NCT04665596|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
16301463|NCT04665583||Prehabilitation|All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.
16301464|NCT04665570||Treatment|The decision to prescribe Acarbose/Metformin fixed dose combination (FDC) will be solely at the discretion of the Investigator and in accordance with his/her experience. Patients can only be enrolled in the study if the decision to treat with Acarbose/Metformin fixed dose combination has been made by the treating physician in advance and independent of study inclusion.
16301467|NCT04665544|Experimental|Early-stage endometrial cancer patients|"Histologically proven endometrial cancer (any tumour type).
~Apparent early-stage endometrial cancer with intermediate or high risk prognostic factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant metastases on preoperative conventional imaging studies; minimum requirement for clinical staging includes expert US or pelvic MRI for local staging and abdominal US or abdominal CT scan or PET CT for distant staging.
~Performance status ECOG: 0-1.
~Age ≥18, ≤85.
~History of second primary cancer only if more than 5 years with no evidence of disease.
~Approved and signed informed consent"
16301468|NCT04665531|Experimental|Group A - Erector Spinae Catheter group|"Patients in the experimental group will receive the erector spinae catheter prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
~Anesthetic regimen: initial bolus of 20ml 0.5% levobupivacaine before the end of surgery. Then continually ropivacaine 0,2% 5ml/h with intermittent boluses 15ml ropivacaine 0,2% every 4h.
~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
16301469|NCT04665531|Active Comparator|Group B - Intercostal block|"Patients will receive standard treatment, i.e. the multi-level intercostal block administered at the end of the surgery by the surgeon. They will receive 20ml 0,5% levobupivacaine on 6 levels of the thoracic wall according to the operative wound level.
~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
16301470|NCT04665518|Experimental|Acupressure group|The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before acupressure is applied, the patient is allowed to sit in a comfortable position on the sofa in the single blood collection room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point [LI 4], Large Intestine Meridian 11th Point [LI 11], and Heart Meridian 7th Point [HT 7]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is given to each patient, and each acupressure session lasts 10 minutes. Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
16301471|NCT04665518|No Intervention|Control group|Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
16301581|NCT04664738|Experimental|10% PEP and TISSEEL|Cohort 3: Subjects will receive 10% PEP and TISSEEL to the skin graft donor wound.
16369810|NCT04189419|Placebo Comparator|Placebo|IV infusion.
16301472|NCT04665505|Experimental|ICU Staff|The study group is composed of ICU care providers at the Ottawa Hospital Civic campus and the Montfort Hospital, including intensivists, fellows, nurses and allied health professionals. The study site participant breakdown is approximately 58 TOH staff respondents and 15 Montfort respondents.
16301473|NCT04665492||SCI with CNP|People with subacute spinal cord injury and no chronic pain
16301474|NCT04665492||SCI no CNP|People with subacute spinal cord injury with central neuropathic pain
16301475|NCT04665492||Able bodied|Able bodied people with no chronic pain
16301476|NCT04665479|Experimental|Intervention group|A total of 30 children with any progressively declining (acute or chronic) life-threatening diagnosis per parent report (aged 8 to 17) and their primary parent caregivers will be recruited as a dyad. Dyads will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
16301477|NCT04665466||Group A|QFR≤0.80 vessels with PCI strategy and low PPG index
16301478|NCT04665466||Group B|QFR≤0.80 vessels with PCI strategy and high PPG index
16301479|NCT04665466||Group C|QFR≤0.80 vessels with conservative strategy
16301480|NCT04665453|Experimental|Melatonin peroral|0,1mg/kg melatonin will be given in the form of a syrup to the participant before EEG and vital functions monitoring
16301481|NCT04665453|Experimental|Dexmedetomidine intranasally|3 mcg/kg of dexmedetomidine in the form of a nasal spray will be given to the participant before EEG and vital functions monitoring
16301482|NCT04665453|Experimental|Dexmedetomidine sublingually|3 mcg/kg of dexmedetomidine will be given to the participant sublingually before EEG and vital functions monitoring
16301483|NCT04665440|Other|Voice only then distraction|First intervention: mother's voice without tactile stimuli Second intervention: mother's voice with tactile stimuli
16301484|NCT04665440|Other|Distraction then voice only|First intervention: mother's voice with tactile stimuli Second intervention: mother's voice without tactile stimuli
16301485|NCT04665427|Other|Patient in whom a bilioenteric anastomosis is performed for any etiology.|Patient in whom a bilioenteric anastomosis is performed for any etiology..
16301486|NCT04665401|Active Comparator|Standard MERIT|24 sessions of Metacognition Reflection and Insight Therapy
16301487|NCT04665401|Experimental|Tailored MERIT|24 sessions of personalized Metacognition Reflection and Insight Therapy (sessions personalized using real-world interactions)
16301488|NCT04665388||EBV-related cancer cohort|up to N=30
16301489|NCT04665388||HPV-related cancer cohort|up to N=45
16301490|NCT04665388||HCC cohort|up to N=30
16301491|NCT04665375|Experimental|DOR/3TC/TDF|100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)
16301492|NCT04665362|Experimental|M1-c6v1 combined with SHR-1210 and Apatinib|Single-arm
16301493|NCT04665349|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
16301494|NCT04665349|No Intervention|Control|No intervention
16301495|NCT04665336|Experimental|Intervention Group Lifestyle counseling|"Obese individuals with evening chronotype will be trained on sleep hygiene in order to create behavioral changes in line with circadian rhythms and an intervention program called Circadian Timing Program which was created by the researcher in line with the relevant literature will be implemented for 12 weeks. This program includes sleep hygiene recommendations and regulation of daylight exposure, sleep, meal, caffeine intake and exercise times. To determine participants' sleep times they will be asked to keep a sleep diary and sleep records will be taken with the smart bracelet. Participants will be given a password to access the research website. The website of the study will be used for the training, control, motivation and communication of the Participants."
16301496|NCT04665336|No Intervention|Control group|Participants will be asked to follow their normal daily lifestyle, maintain normal sleep and eating habits and no further instructions or suggestions will be provided during the study.
16301497|NCT04665323||People living with FOP|
16301498|NCT04665323||Parent or legal guardian primary caregivers|
16301499|NCT04665323||Parent or legal guardian|
16301500|NCT04665323||Siblings|
16301501|NCT04665310|Active Comparator|Group 1 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.
~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.
~Target Tacrolimus Trough Concentrations:
~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
16301502|NCT04665310|Active Comparator|Group 1 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.
~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.
~Target Tacrolimus Trough Concentrations:
~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
16301503|NCT04665310|Active Comparator|Group 1 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.
~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.
~Target Tacrolimus Trough Concentrations:
~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
16301504|NCT04665310|Active Comparator|Group 2 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.
~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.
~Target Tacrolimus Trough Concentrations:
~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
16301505|NCT04665310|Active Comparator|Group 2 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.
~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.
~Target Tacrolimus Trough Concentrations:
~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
16301506|NCT04665310|Active Comparator|Group 2 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.
~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.
~Target Tacrolimus Trough Concentrations:
~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
16301507|NCT04665297|Experimental|Intervention arm|Subjects from intervention clusters will receive the GMCD intervention, delivered in monthly visits to the home by frontline health workers, for 24 months. 0-12 months represents the primary effectiveness study, and 12-24 months a secondary maintenance study.
16301508|NCT04665297|No Intervention|Control Arm|Subjects in control clusters will continue to receive usual care from their frontline health workers. After 12 months (primary effectiveness study) control will cross into the intervention for months 12-24.
16301509|NCT04665284|Experimental|Empagliflozin|
16301510|NCT04665284|Active Comparator|Usual Care Group|
16301511|NCT04665271|Experimental|Immediate Treatment - Zemedy App|Participants will be given immediate access to the Zemedy app for IBS.
16301512|NCT04665271|Active Comparator|Active Control - Education and Relaxation Training App|Participants will be given access to a education and relaxation training app. After 8 weeks they will then be crossed over to the Zemedy app.
16301513|NCT04665258||COVID-19 vaccine group|Participants scheduled to receive the COVID-19 vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
16301514|NCT04665245||COVID-19 Positive Patients|The study only includes one cohort: COVID-19 positive patients. Enrollees will not receive any therapeutic intervention; participants will simply report their temperature and any symptoms experienced twice per day for 10 days.
16301515|NCT04665232||Patients affected by autoimmune diseases|Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone
16301516|NCT04665219|Active Comparator|Control group|Only receive a standard message.
16301517|NCT04665219|Experimental|Test group|Receive HBM-based messages.
16301518|NCT04665206|Experimental|VT3989 Dose Escalation|VT3989 dosed orally in 21 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase
16301519|NCT04665206|Experimental|Dose Expansion|VT3989 dosed in 21 day cycles in patients with refractory metastatic solid tumors, or advanced pleural malignant mesothelioma, with NF2 mutant tumors.
16301520|NCT04665193|Experimental|Abbott Panbio test device|WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device
16301521|NCT04665180|Experimental|Primary knee arthroplasty|Questionnaires
16301522|NCT04665167|Active Comparator|Body image exposure|Guided non-judgmental exposure, 40 minutes total
16301523|NCT04665167|Active Comparator|Self-compassion|8 Short self-compassion meditations, 40 minutes total
16301524|NCT04665154|Experimental|MAS825 dose A|single i.v. dose
16301525|NCT04665154|Experimental|MAS825 dose B|single s.c. dose
16301526|NCT04665154|Placebo Comparator|Placebo dose A|single i.v. dose
16301527|NCT04665154|Placebo Comparator|Placebo dose B|single s.c. dose
16301528|NCT04665141||Standard of care|Patients with severe asthma being treated with non-biological standard therapies, mainly systemic corticosteroids.
16301529|NCT04665141||Biological therapies|Patients with severe asthma being treated with omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab.
16301530|NCT04665115|Experimental|Cohort I (ibrutinib)|Patients may continue to receive ibrutinib PO daily or stop ibrutinib per provider's discretion.
16301531|NCT04665115|Experimental|Cohort II Arm 2A (ibrutinib)|Patients continue to receive ibrutinib PO daily in the absence of disease progression or unacceptable toxicity.
16301532|NCT04665115|Experimental|Cohort II Arm 2B (temporary interruption)|Patients undergo temporary interruption of ibrutinib for up to 28 days unless they are discharged home and are thought to be medically fit by the primary caregiver to resume therapy according to their primary treating oncologist.
16301533|NCT04665102||No pathology|
16301534|NCT04665102||Pathology|
16301535|NCT04665089|Active Comparator|Erythromycin arm|The erythromycin arm (n=40) receives, in addition to the standard antimicrobial therapy, erythromycin 1 g three times per day intravenously: each gram is diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
16301536|NCT04665089|Placebo Comparator|Placebo arm|The placebo arm (n=40) receives, in addition to the standard antimicrobial therapy, isotonic saline, intravenously, 20 ml diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
16301537|NCT04665076|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
16301538|NCT04665063|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
16301539|NCT04665050|Experimental|pPCV|Participants receive a single dose of pPCV on Day 1.
16301540|NCT04665050|Active Comparator|PNEUMOVAX™23|Participants receive a single dose of PNEUMOVAX™23 on Day 1.
16301543|NCT04665024|Active Comparator|Group 1|"G1 included patients undergoing planned surgery who performed chest physiotherapy at home in two weeks period before the surgical operation pre and postoperative chest physiotherapy was performed in G1.
~The chest physiotherapy included the following steps
~Snipping through the nose several times, then breathe out through the mouth
~Taking a deep breath through the nose, hold the air in, push it down in the stomach, than back to the chest, and in the end breath out through the mouth
~Put both hands on the shoulders. Lift the elbows to the sides and take a deep breath through the nose, then lower them, breathe out through the mouth. This procedure was done for the other side as well.
~Put both hands on your hips. Lift your right arm to the side, turn backwards with it and take a deep breath through the nose, then turn back, put your hand back to the hip and breathe out through the mouth.This procedure was done for the other side as well"
16301582|NCT04664738|Experimental|20% PEP and TISSEEL|Cohort 4: Subjects will receive 20% PEP and TISSEEL to the skin graft donor wound.
16301583|NCT04664725|Experimental|SHR3680+ Repaglinide, Bupropion|"Experimental: Repaglinide, Bupropion and SHR3680
~Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26"
16301584|NCT04664712|Active Comparator|shock wave|
16301585|NCT04664712|Active Comparator|shock wave and tendon supplement|
16301544|NCT04665024|Active Comparator|Group 2|"G2 included patients who patients undergoing planned surgery but did not perform preoperative chest physiotherapy at home.only postoperative chest physiotherapy made in G2.
~The patient was seen on the first day after surgery in the intensive care unit and was asked if he had performed breathing exercises at home before surgery and then re-evaluation of both groups with respect to respiratory functions and oxygen saturation values from the first day until the seventh after surgery. Also, a daily chest physical therapy program was introduced in accordance with the hospital's policy until the patient's discharge.
~Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy mentioned above but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.
~The exercises were repeated 10 times and performed 3-4 times per day."
16301545|NCT04665011||Clinically stable adults, including heart failure patients visiting an outpatient clinic|Observational to compare simultaneous pulse tracings from PPG and non-invasive blood pressure monitors in capturing the pulse responses to a Valsalva maneuver.
16301546|NCT04664998|Active Comparator|Male participants|200 male participants whose partners are enrolled in the parent study (Kampala Women's Bone study). All male participants will undergo the same study procedures at each visit, such as HIV and STI testing, and urine tenofovir testing if on PrEP.
16301547|NCT04664998|Active Comparator|Female participants|300 female participants from the parent study (Kampala Women's Bone study) will be enrolled to recruit their male sexual partner(s). All female participants will receive HIV testing, STI testing, and urine tenofovir testing (if on PrEP) at quarterly visits.
16301548|NCT04664985|Active Comparator|Mucogyne®|The dosage during the study will be 1 Mucogyne® ovule per day at bedtime for 10 days and then 1 ovule every 2 days until the end of the 3-month follow-up.
16301549|NCT04664985|No Intervention|Control|No treatment for this arm.
16301550|NCT04664972|Placebo Comparator|TAC|The control group was treated with TAC (docetaxel 75mg/m2 + adriamycin 50mg /m2 + cyclophosphamide 500mg/m2) for 6 cycles, 21 days as a cycle.
16301551|NCT04664972|Experimental|TP|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
16301552|NCT04664959|Experimental|SB16 (Proposed Denosumab Biosimilar)|Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.
16301553|NCT04664959|Active Comparator|Prolia® (Denosumab)|"Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
~At Month 12, subjects in Prolia® treatment group will be re-randomised in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. After re-randomisation, subjects transited to SB16 group will receive SB16, and subjects remaining in Prolia® group will continue to receive Prolia® at Month 12."
16301554|NCT04664946|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
16301555|NCT04664933|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
16301556|NCT04664920||Intervention|Exergame intervention arm.
16301557|NCT04664907|Experimental|Patients suffering from post traumatic stress disorder|
16301558|NCT04664881|No Intervention|Control (standard treatment) Group|Participants will receive routine cardiac treatment
16301559|NCT04664881|Experimental|SmartHeart Device Group|In addition to routine cardiac treatment, participants will wear the SmartHeart device
16301560|NCT04664855|Experimental|Experimental Yoga Group|35 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
16301561|NCT04664855|No Intervention|Control Group (No Yoga Intervention)|20 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
16301562|NCT04664842|Experimental|Manual Therapy Group|
16301563|NCT04664842|Sham Comparator|Manual Control Group|
16301564|NCT04664842|Experimental|Breathing Training Group|
16301565|NCT04664842|Sham Comparator|General Exercise Control Group|
16301566|NCT04664842|Experimental|Manual Therapy Combined Breathing Training Group|
16301567|NCT04664829|Experimental|Bexarotene and Capecitabine|
16301568|NCT04664816|Experimental|n-3PUFAs group|These patients will receive omega-3 plus (1200 mg) orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
16301569|NCT04664816|Placebo Comparator|Control group|These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
16301570|NCT04664803|Experimental|Cefecin Tab.|Cefecin Tab./Placebo to Omnicef Cap.
16301571|NCT04664803|Active Comparator|Omnicef Cap.|Omnicef Cap./Placebo to Cefecin Tab.
16301572|NCT04664790|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week.
16301573|NCT04664790|Active Comparator|Cognitive training|Neuropsychologist guided cognitive training.
16301574|NCT04664777||Group1|"Living liver donors who operated between 1 August and 15 november:
~After anesthesia induction and surgical field sterilization, before surgical incision; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded.
~After the surgical procedure is over and before the patient is awakened from anesthesia; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded."
16301575|NCT04664764|Active Comparator|degludec arm|Group A received insulin degludec,
16301576|NCT04664764|Active Comparator|glargine arm|group B received insulin glargine
16301577|NCT04664764|Active Comparator|NPH group|Group C received NPH insulin
16301578|NCT04664751||Patients scheduled for general surgery with anesthesia|Patients scheduled for general surgery with anesthesia, receiving Nil-per-Oral order.
16301579|NCT04664738|Experimental|10 % PEP only|Cohort 1: Subjects will receive 10% PEP to the skin graft donor wound.
16301580|NCT04664738|Experimental|20% PEP only|Cohort 2: Subjects will receive 20% PEP to the skin graft donor wound
16301586|NCT04664699|Other|Plethysmographic Variability Index group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the PVI group
16301587|NCT04664699|Other|Standard monitoring group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the standard monitoring group
16301588|NCT04664686|Active Comparator|AF catheter ablation|
16301589|NCT04664686|Active Comparator|AV node ablation|
16301590|NCT04664673|Experimental|HABIT-ILE|HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks adapted for adults stroke survivors
16301591|NCT04664673|Active Comparator|Regular care|Usual customary treatment for adults stroke survivors during two weeks
16301592|NCT04664660||Patients with previous histologic diagnosis of endometriosis|
16301593|NCT04664660||Patient without endometriosis|
16301594|NCT04664647||Patients with CCPD|"Inclusion criteria：
~Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.
~Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination.
~Exclusion criterion:
~Secondary demyelinating diseases or changes."
16301595|NCT04664621|Experimental|HepQuant Testing|
16301596|NCT04664595|Sham Comparator|Group SP|The Supreme™ group
16301597|NCT04664595|Active Comparator|Group PS|The ProSeal™ group
16301598|NCT04664595|Active Comparator|Group IG|The I-gel™ group
16301599|NCT04664595|Active Comparator|Group LT|The Laryngeal Tube Suction IITM group
16301600|NCT04664582|Experimental|Sentinel Lymph Node Biopsy|Lymphoscintigraphy will be ordered alongside usual pre-operative investigations. Intra-operatively, the excision of the primary tumor will be done with the aim of histologically clear margins and appropriate closure as per routine practice at the operating surgeon's discretion. The patients are injected with technicium 99 pre-operatively and a sentinel lymph node biopsy will be performed with a handheld gamma probe.
16301601|NCT04664582|No Intervention|Standard of Care|These patients will be treated with standard of care, which is wide local excision of the primary tumor without performance of sentinel lymph node biopsy, if not indicated.
16301602|NCT04664569||Cohort of bacterial meningitis in children|
16301603|NCT04664556||Cohort of invasive pneumococcal disease in children|
16301604|NCT04664543|Active Comparator|3 days of low residue diet|Currently participants in the colorectal cancer screening program follow a 3 days low residue diet before colonoscopy. This is the active comparator arm of this study.
16301605|NCT04664543|Experimental|Free diet|Participants assigned to this arm are NOT instructed to follow any kind of restriction in the diet before colonoscopy.
16301606|NCT04664530|Placebo Comparator|Control group|
16301607|NCT04664530|Experimental|Treatment group|
16301608|NCT04664517|Active Comparator|FIN (Flexible intramedullary nail)|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
16301609|NCT04664517|Active Comparator|Long arm cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
16301610|NCT04664517|Other|Patient Choice FIN|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
16301611|NCT04664517|Other|Patient Choice cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
16301612|NCT04664504|Active Comparator|Group CRT|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
16301613|NCT04664504|Experimental|Group SCRT|Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
16301614|NCT04664504|Experimental|Group es-SCRT|Local dose increase of Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
16301615|NCT04664491|Experimental|Standardized management|Patients will be managed according to recommendations in GOLD guideline and China's guidelines for COPD care.
16301616|NCT04664491|Other|Usual care|Patients will undergo usual care according to current clinical practice in study sites.
16301618|NCT04664439|Experimental|CT-FFR|The CCTA images of the patients in this group will be analyzed and the FFR values of the lesions will be measured using the indicated software. ICA will be determined according to the value of CTFFR.
16301619|NCT04664439|No Intervention|direct ICA|The patients will be submitted to undergoing ICA procedure according to the decision of the investigators.
16301620|NCT04664426||Renal transplant recipients|Renal transplant recipients will undergo examination according to the amTCNS, QST (thermal threshold testing), and NCS (amplitude, velocity and distal latency of measurements at the sural sensory nerve, ulnar sensory nerve, peroneal motor nerve, tibial motor nerve and ulnar motor nerve, soleus H reflex will be measured).
16301621|NCT04664400|Experimental|Main arm|
16301622|NCT04664387||patients with myocardial bridge|patients who underwent coronary angiography and was diagnosed as myocardial bridge
16301623|NCT04664387||patients without myocardial bridge|patients who underwent coronary angiography and was diagnosed as without myocardial bridge
16301624|NCT04664374||Mood Disorder|Based on screening questions administered on-line as part of the enrollment process, participants will be divided into two groups: (i) those who screen positive for a history of mood disorders and (ii) all other participants. All outcome measures apply only to the mood disorder group.
16301625|NCT04664374||Other|see above
16301626|NCT04664361|Experimental|NMN 250|NMN tablet (250 mg)
16301627|NCT04664361|Experimental|NMN 500|NMN tablet (500 mg)
16301628|NCT04664361|Placebo Comparator|Placebo|NMN-free placebo tablet.
16301629|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (extension of the lumbar spine)|
16301630|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (lumbar spine in neutral positioning)|
16301631|NCT04664335||endometriosis cases|endometriosis laparoscopically removed / child wish
16301632|NCT04664335||controls|endometriosis laparoscopically excluded / child wish
16301633|NCT04664322||NIV/HFNC|patients receiving non-invasive ventilation than high flow nasal canulae oxygen therapy
16301634|NCT04664322||HFNC/NIV|patients receiving high flow nasal canulae oxygen therapy than non-invasive ventilation
16301636|NCT04664296||Children|Hospitalized children, 0 to 17 years of age, 25 subjects, consecutive sample survey
16301637|NCT04664296||Adults|Hospitalized adults, 18 years and above, 50 matched subjects
16301638|NCT04664283|Experimental|DCB group by OCT guided|
16301639|NCT04664283|Active Comparator|DES group by OCT guided|
16301640|NCT04664270|Experimental|e-Psychotherapy|Group will receive 8-week online program including CBT in combination with mindfulness and problem-based therapy in addition to treatment as usual. The content will reflect challenges cancer and palliative patients face through the course of treatment and developed into interactive and engaging therapy modules. All online sessions and interactions will occur through a secure online platform. Pre-designed therapy modules are assigned to the patients, accessible to them at any time throughout the week. Each module consists of approximately 30 slides, which take 45-50 minutes to complete. Each module highlights a different topic and includes general information, an overview of skills, and homework that is to be completed within that week. This homework can be directly submitted through the platform to the clinician who will then provide personalized feed-back to the patient. The average time spent per week by a clinician with a particular patient is about 15 minutes.
16301641|NCT04664270|No Intervention|Treatment as Usual|The control group will receive treatment as usual in the first 8 weeks; if still significantly symptomatic (less than 50% response to treatment from baseline), they will then be offered the 8-week e-psychotherapy program. They will be instructed to continue with any lifestyle activities (i.e., diet, exercise, medication, etc.)
16301642|NCT04664257|Experimental|e-CBT|All e-CBT sessions will be administered through OPTT and will consist of approximately 30 slides per week. The content and format of each weekly online session will be designed to mirror in-person CBT for the treatment of BAD-II. Participants will complete the module and submit the assigned homework to their clinician through OPTT where the clinician will be able to provide personalized feedback. These pre-designed engaging and multimedia modules will be able to streamline the therapy process, helping care providers save time on repeating similar materials to all patients and focusing on delivering personalized feedback to each patient. The slides will highlight a different topic each week and include general information, an overview of skills, and homework that is to be completed within that week. All weekly sessions have an estimated completion time of 50 minutes. During the 12 weeks, both groups will continue with their TAU.
16301643|NCT04664257|No Intervention|Treatment as Usual|Participants will continue with treatment as usual and any lifestyle activities (diet, exercise, medication, etc.)
16301644|NCT04664244|Experimental|All eligible patients|All eligible patients enrolled
16301645|NCT04664231||Children with JIA|Children with JIA coming to clinic
16301646|NCT04664231||Healthy Children|Healthy Children in the school
16301647|NCT04664218|Experimental|patients with Peritoneal carcinomatosis|Peritoneal carcinomatosis (PC) is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin. On occurrence, PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy.
16301648|NCT04664205|Experimental|High intensity interval training, then Moderate Intensity Continuous Training|Participants randomly assigned to this arm will first receive high intensity interval training followed by moderate intensity continuous training.
16301649|NCT04664205|Experimental|Moderate Intensity Continous Training, then High Intensity Training|Participants randomly assigned to this arm will first receive moderate intensity continuous training followed by high intensity interval training.
16301650|NCT04664205|No Intervention|Control: No exercise|Participants will complete the same pre- post measurements, with no exercise in between.
16301651|NCT04664192||Lung transplant Recipients|Biobank registry for Lung transplant recipients
16301652|NCT04664179|Experimental|Arm A: Treatment with lymphodepletion chemotherapy|C7R-EBVSTs with lymphodepletion chemotherapy
16301653|NCT04664179|Experimental|Arm B: Treatment without lymphodepletion chemotherapy|C7R-EBVSTs
16301654|NCT04664153|Experimental|atopic dermatitis - PF-07038124 ointment|
16301655|NCT04664153|Placebo Comparator|atopic dermatitis - vehicle ointment|
16301656|NCT04664153|Experimental|plaque psoriasis - PF-07038124 ointment|
16301657|NCT04664153|Experimental|plaque psoriasis - vehicle ointment|
16301658|NCT04664140|Experimental|QFR-based virtual PCI|"Before starting PCI, the operator must acquire QFR angiographic projections after nitroglycerin administration at 15 frames/second. Angiographic projections should be at least 25 apart, aiming for minimal vessel foreshortening and minimal vessel overlap. In agreement with previous studies, operators follow a table of recommended projection angles. Afterwards, online QFR analysis must be performed. The tool residual vessel QFR should be used to anticipate the result of stenting (virtual PCI) by placing the proximal (p) and distal (d) marker in order to obtain a post-PCI QFR ≥0.90. then, the operator has to implant one or more stents following the pre-PCI plan and utilizing the QFR and angio to place the stent(s) according to the virtual PCI plan. Post-dilation with non-compliant (NC) balloon is strongly suggested. Blinded QFR projections must be obtained after PCI."
16301659|NCT04664140|Active Comparator|Angiography-based PCI|Invasive coronary angiography and PCI are performed following best local practices. Post-dilation with a noncompliant balloon is strongly suggested. Blinded QFR projections must be obtained before and after PCI.
16301660|NCT04664127||Combination therapy (Kagocel + Valacyclovir: n=25)|Therapy according to routine practice (including Kagocel). Groups will be splitted during the final data analysis.
16301661|NCT04664127||Monotherapy by Valacyclovir (n=20)|Therapy according to routine practice. Groups will be splitted during the final data analysis.
16301682|NCT04664010|Experimental|moderate COVID-19 with traditional Chinese medicine group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
16301662|NCT04664114|Experimental|Experimental group|Both the evaluation of the fetus and the ultrasound for visual purposes took 15-20 minutes in total. These pregnant women were asked to bring their mobile phones with them during delivery. When the birth of the pregnant woman started, she was hospitalized by the third researcher. The follow-up and deliveries during the labor were carried out by the 3rd and 4th researchers. With an application installed on the pregnant woman's phone, these two-dimensional images were transformed into three-dimensional images and the pregnant women were watched consecutively with the VR Box 3D virtual reality glasses. In cases where the program was not compatible with the phone of the pregnant woman, the researcher was watched by the midwife. The total image viewing time was recorded.
16301663|NCT04664114|No Intervention|Control Group|Only one pregnant woman was included in the study at the same time in order to avoid any interruption in the follow-up of the pregnant women. VAS was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale and the Perinatal Anxiety Screening Scale were applied.
16301664|NCT04664101|Experimental|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
16301665|NCT04664101|Other|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
16301666|NCT04664088|Experimental|Acupuncture group|Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions).
16301667|NCT04664088|Active Comparator|Medication group|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks.
16301668|NCT04664062|Active Comparator|Home|This induction arm is asynchronous and unobserved. The home induction is done primarily by the participant in their home or current residence. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. Home induction is initiated by the participant at a time and place (other than the practice) determined by the participant. The participant determines when to stop taking opioids, begins withdrawal, monitors symptoms, administers the SOWS, and determines when to take first dose of medication, per the instructions and protocol provided. The clinic team does not observe or have contact with the participant while the participant undergoes these steps or takes the first dose. The participant continues this process for additional doses. Follow-up contact with clinic team may occur after the first or second day, typically within a week.
16301669|NCT04664062|Active Comparator|Office|This induction arm is synchronous and observed by the clinical team. The participant receives instruction from clinic team at an in-person or telehealth visit. On a pre-determined day, the participant stops taking opioids and comes to office with mild to moderate withdrawal. The clinic team monitors the participant, assesses symptoms, administers COWS to determine time of first dose of medication, and administers first dose with the participant. The clinic team observes and has in-person contact with the participant. Office induction includes the observed administration of the first dose, followed by observation and evaluation 30-60 minutes after the first dose. After 30-60 minutes of observation, the clinic team and participant decide whether to administer the second dose in the office or for the participant to leave the clinic to administer subsequent doses. On rare occasions, a second dose may not be needed (if the participant has a low COWS score after just one dose).
16301670|NCT04664062|Active Comparator|Telehealth|This induction arm is synchronous via phone or video contact and observed. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. The participant undergoes the same process as an office induction but from a location other than the clinic. Like an office induction, the participant has regular contact with someone from the practice team on Day 1 of induction. Prior to initiating the first dose, the participant has contact by phone or video with the clinic team to assess symptoms and determine level of withdrawal (using COWS or SOWS). The administration of the first dose of medication is determine by the clinic team during phone or video contact, and the clinic team is in contact with the participant by phone or video when the first dose is taken. This process continues through the second and possible third dose. The participant is re-assessed via video or phone regularly by clinic staff and prescriber throughout this process.
16301671|NCT04664049||NRICM101|Subjects who confirmed, suspected or prevented infected of COVID 19 disease and received dietary supplement NRICM101
16301672|NCT04664036||NAFLD + type 1 diabetes|type 1 diabetes patient with NAFLD on screening
16301673|NCT04664036||noNAFLD + type 1 diabetes|type 1 diabetes patient without NAFLD on screening
16301674|NCT04664023||Patients with severe SARS-CoV-2 infection|Patients with severe SARS-CoV-2 infection hospitalised in intensive care unit
16301675|NCT04664023||Patients with intermediate SARS-CoV-2 infection|Patients with intermediate SARS-CoV-2 infection hospitalised in infectious and tropical diseases department
16301676|NCT04664023||Little symptomatic patients with SARS-CoV-2 infection|Little symptomatic ambulatory patients with SARS-CoV-2 infection
16301677|NCT04664023||Patients with SARS-CoV-2 infection hospitalised in geriatry department|Patients with SARS-CoV-2 infection hospitalised in geriatry department to study influence of age on the studied mechanisms
16301678|NCT04664023||Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
16301679|NCT04664023||Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
16301680|NCT04664010|Experimental|moderate COVID-19 group|patients with moderate COVID-19 receiving western medicine treatment
16301681|NCT04664010|Experimental|severe COVID-19 group|patients with severe COVID-19 receiving western medicine treatment
16301683|NCT04664010|Experimental|moderate COVID-19 with combination therapy group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
16301684|NCT04664010|Experimental|severe COVID-19 with traditional Chinese medicine group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
16301685|NCT04664010|Experimental|severe COVID-19 with combination therapy group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
16301686|NCT04663997|Experimental|177 Lu-PSMA-617|
16301687|NCT04663997|Active Comparator|Docetaxel|
16301688|NCT04663971||Crohn's disease|Patients with Crohn's disease.
16301689|NCT04663971||Ulcerative colitis|Patients with Ulcerative colitis
16301690|NCT04663945|Experimental|Intervention|"This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions.
~Other: remote controlled exercise plus home exercise
~Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise"
16301691|NCT04663945|No Intervention|Control|"This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training.
~Other: basic education"
16301692|NCT04663932|Placebo Comparator|immediate stenting group|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
16301693|NCT04663932|Experimental|deferred stenting group|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
16301694|NCT04663919|Active Comparator|Anorexia Nervosa|Patients diagnosed with Anorexia Nervosa, having a BMI of <18, being followed up and treated in the Psychiatry Eating Disorders Polyclinic and endocrinology outpatient clinics, and who have approximately 10% weight gain during the treatment process
16301695|NCT04663919|Active Comparator|Morbidly Obese|Patients with a BMI> 40 diagnosed with Morbid Obesity and who lost approximately 10% of their weight by performing obesity surgery (gastric bypass or sleeve gastrectomy)
16301696|NCT04663919|No Intervention|Healthy Volunteer|Volunteers with normal BMI and without any additional chronic disease
16301697|NCT04663906||Isotretinoin|Test population, prescribed oral isotretinoin between March and October 2020.
16301698|NCT04663906||Control|Background age-matched population, not prescribed oral isotretinoin during March to October 2020
16301699|NCT04663880|Experimental|Asthmatic subjects allergic to house dust mite|24 subjects were randomized in a doubleblinded manner into six subgroups. All were exposed first to placebo then in cross over to three different Der p1 concentrations, respectively 15, 25, and 46 ng/m3.
16301700|NCT04663880|Active Comparator|Asthmatic subjects not allergic to house dust mite|13 subjects were exposed first to placebo then to Der p1 concentration of 25 ng/m3.
16301702|NCT04663854|Experimental|Trehalose|Trehalose Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks.
16301703|NCT04663854|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks.
16301704|NCT04663828|Other|Structured counseling|Patients will receive a structured counseling therapy
16301705|NCT04663828|Other|Hearing Aids|Patients will receive hearing aids support
16301706|NCT04663828|Other|Cognitive behavioral therapy|Patients will receive cognitive behavioral therapy
16301707|NCT04663828|Other|Sound therapy|Patients will follow a sound therapy program
16301708|NCT04663828|Other|Combination of sound therapy and cognitive behavioral therapy|Patients will receive a combination of sound therapy and cognitive behavioral therapy
16301709|NCT04663828|Other|Combination of hearing aids and cognitive behavioral therapy|Patients will receive a combination of hearing aids and cognitive behavioral therapy
16301710|NCT04663828|Other|Combination of hearing aids and structured counseling|Patients will receive a combination of hearing aids and structured counseling
16301711|NCT04663828|Other|Combination of structured counseling and sound therapy|Patients will receive a combination of structured counseling and sound therapy
16301712|NCT04663828|Other|Combination of hearing aids and sound therapy|Patients will receive a combination of hearing and sound therapy
16301713|NCT04663828|Other|Combination of cognitive behavioral therapy and sound therapy|Patients will receive a combination of cognitive behavioral therapy and sound therapy
16301714|NCT04663815|Other|AB arm|Animal-assisted activity intervention on 2nd day of hospitalization, control intervention on the 4th day of hospitalization.
16301715|NCT04663815|Other|BA arm|Control intervention on 2nd day of hospitalization, animal-assisted activity intervention on the 4th day of hospitalization.
16301716|NCT04663802|Active Comparator|Default order set|This arm will have the default order set implementation strategy
16301717|NCT04663802|Active Comparator|Physician-targeted accountable justification|This arm will have the physician-targeted accountable justification implementation strategy
16301718|NCT04663802|Active Comparator|Default order set + physician-targeted accountable justification|This arm will have the default order set and physician-targeted accountable justification
16301719|NCT04663802|Placebo Comparator|Standard of Care|This arm will have no interventions and standard of care practices will be in place.
16301720|NCT04663802|Active Comparator|Physician-targeted accountable justification + RT-targeted accountable justification|This arm will have the default order set and respiratory therapist-targeted accountable justification
16301721|NCT04663789|Experimental|Staple line plus reinforcement|In this experimental group, a lock stitch will be placed after transecting the pancreas with stapler.
16301722|NCT04663789|Other|staple line with no reinforcement|In this control group, no additional reinforcement is used after transecting the pancreas with stapler.
16301763|NCT04663516|Experimental|experimental|exercise through video game (Wii)
16371959|NCT04175002||Healthy fertile women with a BMI greater than 27|
16301723|NCT04663763|Experimental|Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy|"A total of 40 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 4 cycles of CAPOX chemotherapy.
~Interventions:
~Shor-course radiotherapy: 25Gy/5Fx;
~Induction immunotherapy: Sintilimab 200mg ivgtt d1 q3w x 4 cycles;
~Concurrent Chemotherapy: Oxaliplatin: 130mg/m2 d1 q3w + Capecitabine: 1000mg/m2 d1-14 q3w x 4 cycles;"
16301724|NCT04663750|Experimental|Arm A - Surgery with aflibercept|Surgery with aflibercept at the end of surgery, with post-operative review day 1 and week 1 (day 7)
16301725|NCT04663750|Active Comparator|Arm B - Aflibercept monotherapy|Aflibercept monotherapy commencing at baseline.
16301726|NCT04663737|Experimental|Group A|Group A will receive the best supportive care and/or recommended standard of care (at this point no standard of care drugs are recommended by CDC for patients with moderate COVID-19) in combination with the study drug Silmitasertib
16301727|NCT04663737|Active Comparator|Group B|Group B (control) that will receive the same care as the Group A but without Silmitasertib
16301728|NCT04663724|Experimental|Experimental Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
16301729|NCT04663724|Active Comparator|Comparator Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
16301730|NCT04663698|Experimental|Healthy|Lung-healthy subjects, randomized lung function testing
16301731|NCT04663698|Experimental|Patient 1|COPD patients, randomized lung function testing
16301732|NCT04663698|Experimental|Patient 2|COPD patients, randomized lung function testing
16301733|NCT04663698|Experimental|Patient 3|COPD patients, randomized lung function testing
16301734|NCT04663698|Experimental|Patient 4|COPD patients, randomized lung function testing
16301735|NCT04663685|Experimental|Single Arm|This is the only arm in the study. All participants will be allocated to this arm, where they will receive an 8-week remotely-delivered exercise and nutrition program.
16301736|NCT04663672|Experimental|Exposure Therapy + Exposure Scent Cue During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of the exposure scent.
16301737|NCT04663672|Placebo Comparator|Exposure Therapy + Novel Scent During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of a novel scent.
16301738|NCT04663672|Sham Comparator|Exposure Therapy + No-Scent Control During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of an odorless control vehicle.
16301739|NCT04663659||diabetic group|Patients over the age of 18 with diabetes mellitus in intensive care unit
16301740|NCT04663659||non-diabetic group|Patients over the age of 18 without diabetes mellitus in intensive care unit
16301741|NCT04663646|Experimental|Intervention Group|
16301742|NCT04663646|Placebo Comparator|Control Group|
16301743|NCT04663633|Experimental|Core stability training|"The EG performed an 8-week core stability training, consisting in 30 min of core stability and plyometric exercises 3 days per week, 24 sessions in total.
~The CST sessions were conducted in a gym suitable for RG practise and the safety of the participants will be maintained. The equipment necessary for the training was provided to the participants.
~The coaches are RG professionals with national coach level in RG and volunteered to lead the specific CST designed by a RG national coach and an expert core stability physiotherapist.
~Before each session EG and CG performed a 15 min warm up. The load of the session was calculated by the RPE (rate of perceived exertion). And was modulated in order to maintain 7-8 intensity."
16301744|NCT04663633|No Intervention|Traditional RG training|The CG performed the traditional training while the EG carried out the CST. The training load was calculated to be 7-8 RPE in order that both groups (EG and CG) undergo an equivalent intensity and training load.
16301745|NCT04663620|Active Comparator|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
16301746|NCT04663620|Placebo Comparator|No Saving Babies Lives Programme|Control arm
16301747|NCT04663607|No Intervention|Control|Participants will receive paper-based health education as part of standard of care
16301748|NCT04663607|Experimental|App|Participants will receive health education via a mobile app, PretermConnect
16301749|NCT04663594|Experimental|Ways of Being online Experience|Ways of Being (WoB) every day for three days
16301750|NCT04663594|Other|Ashmolean Website|The Ashmolean Website every day for three days
16301751|NCT04663581|Experimental|Left Sided Colonoscopy|Left Sided starting position in colonoscopy
16301752|NCT04663581|Active Comparator|Right sided Colonoscopy|Right Sided starting position in colonoscopy
16301753|NCT04663568|Other|Levonorgestrel-releasing intrauterine system|
16301754|NCT04663555|Experimental|DEX 20 mg|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10.
16301755|NCT04663555|Active Comparator|DEX 6 mg|Patients in the control group after randomization will receive dexamethasone 6 mg day 1-10.
16301756|NCT04663542|Experimental|0-week immobilization|0-week brace immobilization after the surgery will be conducted.
16301757|NCT04663542|Experimental|2-week immobilization|2-week brace immobilization after the surgery will be conducted.
16301758|NCT04663542|Other|4-week immobilization|4-week brace immobilization after the surgery will be conducted.
16301759|NCT04663542|Other|6-week immobilization|6-week brace immobilization after the surgery will be conducted.
16301760|NCT04663529||CLADE|contact lens wearers with DED
16301761|NCT04663529||non-CLADE|DED without contact lens wear
16301762|NCT04663529||NC|normal control
16301764|NCT04663516|No Intervention|control|children in this group will be given advice about the importance of exercising
16301765|NCT04663503|Experimental|Intervention arm -Exercise Program|This structured exercise program will incorporate a specially designed, low intensity, resistance based exercise regime created by our physical therapist. It consists of strengthening, endurance, stretching and relaxation exercises tailored according to age and their ability to perform activities throughout their hospitalization (Appendix 3). This exercise program will be done three times a week for 30-45 mins supervised by the same physiotherapist throughout hospitalization and will be self-administered every weekend. A home exercise program printout with the appropriate resistance exercises will be provided to the family upon discharge, with instructions on how often to complete throughout the week. Discharged children will attend one supervised exercise session per week with the physiotherapist for six weeks. The family and patient will also be provided a weekly sheet to check off the days they completed strengthening and endurance exercises.
16301766|NCT04663503|No Intervention|Control arm- No intervention|The second arm of the study involves patients following standard of care during the HSCT period in the hospital with PT evaluation and management prescribed as needed by their transplant medical team including any additional PT interventions as a result of clinical indications. No additional intervention is incorporated in this group
16301767|NCT04663490||simple acute diverticulitis|Ninety-one percent (n=295) were categorized as simple acute diverticulitis
16301768|NCT04663490||complicated acute diverticulitis|9% (n=30) presented were categorized as complicated acute diverticulitis
16301769|NCT04663477||Trained nurse-completed CRS|
16301770|NCT04663477||Patient-completed CRS|
16301771|NCT04663464|Experimental|abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)|Abaloparatide-SC injection (Period 1) followed by abaloparatide-sMTS application (Period 2). Abaloparatide-SC is a drug-device combination product consisting of abaloparatide, an active synthetic peptide analog of parathyroid hormone related peptide (PTHrP), administered to the periumbilical region via an injection pen. Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide.
16301772|NCT04663464|Experimental|Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)|Abaloparatide-sMTS (Period 1) application followed by Abaloparatide-SC injection (Period 2).
16301773|NCT04663451||Toxic Nodule|Hyperthyroid patients with underlying toxic nodule
16301774|NCT04663451||Toxic multinodular goiter|Hyperthyroid patients with underlying toxic multinodular goiter
16301775|NCT04663438||Arm A|200/Atezolizumab combined with EC regimen Atezolizumab:1200 mg Q3w
16301776|NCT04663438||Arm B|100/Atezolizumab combined with chemotherapy Atezolizumab:1200mg Q3w
16301777|NCT04663425||Sleeve gastrectomy operation|Outcome of patients that underwent sleeve gastrectomy with BMI greater than 60.
16301778|NCT04663425||Gastric bypass operation|Outcome of patients that underwent gastric bypass with BMI greater than 60.
16301779|NCT04663425||Gastric Band operation|Outcome of patients that underwent gastric banding with BMI greater than 60.
16301780|NCT04663412|Experimental|Patients FIGO IB stage|Vulvar Cancer IB stage
16301781|NCT04663360|Experimental|Intervention|Intervention to be administered: Adverse Drug Reactions (ADRe) Profile. asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
16301782|NCT04663360|No Intervention|Control|Usual clinical care.
16301783|NCT04663347|Experimental|Arm 1 - Epcoritamab + R-CHOP|Epcoritamab + R-CHOP in subjects with previously untreated DLBCL
16301784|NCT04663347|Experimental|Arm 2 - Epcoritamab + R- Lenalidomide|Epcoritamab + R- Lenalidomide in subjects with R/R FL
16301785|NCT04663347|Experimental|Arm 3 - Epcoritamab + BR|Epcoritamab + BR in subjects with previously untreated FL
16301786|NCT04663347|Experimental|Arm 4 - Epcoritamab + R-DHAX/C|Epcoritamab + R-DHAX/C in subjects with R/R DLBCL Eligible ASCT
16301787|NCT04663347|Experimental|Arm 5 - Epcoritamab + GemOx|Epcoritamab + GemOx in subjects with R/R DLBCL Ineligible ASCT
16301788|NCT04663347|Experimental|Arm 6 - Epcoritamab + R- Lenalidomide|Epcoritamab + R- Lenalidomide in subjects with previously untreated FL
16301789|NCT04663347|Experimental|Arm 7 - Epcoritamab maintenance|Epcoritamab alone in subjects with FL who achieved a CR or PR after receiving SOC treatment
16301790|NCT04663321|Experimental|MK-1942 Daily Dose Group|Participants receive a total daily dose titrated from 5 mg to 20 mg of MK-1942 twice daily (BID), orally, over 4 weeks of treatment duration: 5 mg in Week 1, 10 mg in Week 2, and 20 mg in Weeks 3 and 4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
16301791|NCT04663321|Experimental|MK-1942 Intermittent Dose Group|Participants receive a total daily dose of 10 mg of MK-1942 twice weekly (BIW), orally, for Weeks 1-4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
16301792|NCT04663321|Placebo Comparator|Placebo|Participants receive a dose-matched placebo BID, orally, for 4 weeks. Participants receive matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
16301793|NCT04663308|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
16301794|NCT04663308|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
16301795|NCT04663308|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
16301796|NCT04663295|Experimental|Subjects with Type 1 diabetes wearing HCL pump system|Subjects 14-75 years of age who have been diagnosed with Type 1 diabetes.
16301799|NCT04663269|Other|Control|Standard Care Protocol - peritubal block standard local analgesic administration in the form of a peritubal block
16303698|NCT04649710|Experimental|Cohort 4: Dose 2 or placebo|Korean participants
16301800|NCT04663269|Experimental|ANES Block|Patients randomized to the erector spinae block (Group 2) will have the block placed in the preoperative area by the anesthesia team. 0-4 mg midazolam and/or 0-100 mcg of fentanyl may be provided prior to and in order to place the block itself. The local anesthetic will diffuse to involve the dorsal and ventral rami of the spinal nerves, achieving a sensory block of the affected area. The erector spinae block analgesic will be administered by the anesthesia team. The analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone.
16301801|NCT04663256|Experimental|Cognitive Stimulation Group|This group receives physical training based on exercises for cognitive stimulation.
16301802|NCT04663256|No Intervention|Control Group|This group does not receive any treatment.
16301803|NCT04663243|Experimental|Quasi experimental study|Before intervention and after intervention comparison
16301804|NCT04663230||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
16301805|NCT04663230||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
16301806|NCT04663230||Control|Patients with invasive exclusion of pulmonary hypertension (mean pulmonary arterial pressure below 25 mmHg) undergoing diagnostic CMRI due to the evaluation of dyspnoea.
16301807|NCT04663217||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
16301808|NCT04663217||Pulmonary hypertension due to left heart disease|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.
16301809|NCT04663217||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
16301810|NCT04663217||Control|Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.
16301811|NCT04663204|Experimental|Sparsentan|Sparsentan will be administered once daily, starting at a dose of 200 mg (two 100 mg oral capsules) for the first 2 weeks of the study. Patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg (one 400 mg tablet). Patients who do not tolerate the target dose will have their dose reduced back to 200 or 100 mg/day; throughout the study, patients will be maintained on the maximum allowed dose of sparsentan they can tolerate. All patients will be treated with sparsentan for a total of 110 weeks.
16301812|NCT04663191||Full VATS|
16301813|NCT04663191||VATS with conversion|
16301814|NCT04663191||Thoracotomy upfront|
16301815|NCT04663178|Experimental|Warm Salt Water Foot Bath Group|"In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale (PFS) were applied to the patients. A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to patients.
~Each patient received iodine salt and a liquid thermometer to measure the temperature of the water. The patients were asked 1 day after the treatment to apply warm salt water bath of 41-42ºC once a day for 20 minutes for 7 days.
~Subsequently, the fatigue level of the patients was evaluated 30 minutes after having a warm saltwater foot bath and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. In the last interview PFS was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
16301816|NCT04663178|No Intervention|Control Group|"A training booklet about chemotherapy-induced fatigue
~In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale were applied to the patients.
~A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to experimental group.
~Subsequently, the fatigue level of the patients was evaluated and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. The patients were evaluated in the evening. In the last interview conducted with the patient on the 7th day, Piper's Fatigue Scale was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
16301817|NCT04663165|Other|Flap surgery alone|Access flap
16301818|NCT04663165|Other|Flap surgery with adjunctive EMD|Access flap and adjunctive enamel matrix derivative
16301819|NCT04663152|Experimental|INSTACARE arm|Participants in this arm will receive the INSTACARE intervention for three months.
16301820|NCT04663139|Experimental|normal weight healthy adult volunteers receiving Xla1|one capsule Xla1 given once daily
16301821|NCT04663139|Experimental|overweight and class 1 obese adult patients receiving Xla1|one capsule Xla1 given once daily
16301822|NCT04663139|Placebo Comparator|overweight and class 1 obese adult patients receiving placebo|one capsule placebo given once daily
16301823|NCT04663126|Experimental|Treatment group|Patients diagnosed with advanced melanoma (stage III-IV) will receive IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m before the first cycle of clinically scheduled anti-PD-1 immunotherapy.
16301824|NCT04663113|Other|Control group|Standard physiotherapy (1st Group): It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
16301825|NCT04663113|Experimental|Aerobic Exercises group|Aerobic exercise will be given with bicycle ergometer in addition to Standard physiotherapy (It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises)
16301826|NCT04663113|Experimental|the group in which the exercise protocol to be developed was applied|Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.
16301853|NCT04662866|Active Comparator|Metformin|Metformin 500 mg x 1, morning, for 2 weeks, then Metformin 500 mg x 2, morning and evening for 10 weeks.
16371960|NCT04175002||Healthy fertile women with a BMI lower than 25|
16301827|NCT04663100|Experimental|Pharmacist Coordinated care Oncology Model|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.
16301828|NCT04663087|Experimental|Treatment with XSTAT|Participants randomized to the treatment arm will be treated using the study device - XSTAT.
16301829|NCT04663087|Other|Standard Care|Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.
16301830|NCT04663074||IVUS Group|Patients treated by BEVAR/CHEVAR/FEVAR due to a thoracoabdominal aneurysm.
16301831|NCT04663061|Experimental|High intensity medical weight loss (HIWL)|Participants randomized to the HIWL treatment group will be placed on a meal replacement-based weight loss protocol. Participants will consume a minimum of 80 grams of protein daily in 4-5 servings of meal replacement. Participants will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-24, caloric prescriptions will be between 1100 to 1600 calories a day, using a combination of meal replacements and food, for continued weight loss. Beyond week 25, caloric intake will be individually tailored to achieve continued gradual weight loss or maintenance of body weight based on individual weight loss goals. We will recommend continued use of at least 1 serving of meal replacement per day for maintenance of weight loss.
16301832|NCT04663061|Active Comparator|Diabetes self-management education (DSME)|"The DSME intervention will be administered and delivered at the Wake Forest Baptist Health Diabetes Center, located next to the Weight Management Center, by a team of certified diabetes educators, nurses, and nutritionists in group and individual settings.
~The diabetes education program is accredited by the American Diabetes Association in recognition of meeting national standards for diabetes self-management education. The goal of the program is to provide participants with information to make informed decisions about how to best integrate diabetes management strategies into their daily lives. Assessment, planning, implementation, and evaluation are the basic components of the diabetes education process."
16301833|NCT04663061|Experimental|High intensity medical weight loss (HIWL) plus continuous glucose monitoring (CGM)|Participants randomized to the HIWL + CGM treatment group will be placed on a meal replacement-based weight loss protocol as described in the HIWL arm. In addition, the participants in this arm will receive a supply of continuous glucose monitors to use throughout the trial. The CGM we provide will give the patient instant feedback on blood glucose levels and be readable using a mobile phone device or an associated CGM reader. The data from the CGM will be integrated into the Carium app and used to help guide the patient's actions based on defined care pathways.
16301834|NCT04663048|Experimental|Protocol A|PiXL treatment with pulsed UV illumination (1.0 sec on /0.8 sec off) in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 10 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
16301835|NCT04663048|Active Comparator|Protocol B|PiXL treatment with pulsed (0.5 sec on / 1 sec off) UV illumination in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 16:40 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
16301836|NCT04663035|Experimental|Ablation Plus Tislelizumab|Patients in this arm will receive ablation followed by tislelizumab, which will be started within 3-7 days after ablation until disease progression or intolerable toxicity, for 12 months.
16301837|NCT04663035|Active Comparator|Ablation Alone|Patients in this group will receive ablation therapy and then enter the follow-up phase.
16301838|NCT04663022||Child with cochlear implant|15 childs with coclear implant but without autism spectrum disorder
16301839|NCT04663022||Child with cochlear implant and autism spectrum disorder|15 childs with coclear implant and with autism spectrum disorder
16301840|NCT04663009||Mechanical chest compression|Patients recieving LDB CPR
16301841|NCT04663009||Manual chest compressions|Patients recieving manual CPR
16301842|NCT04662996|Experimental|1- Chemotherapy|Intervention : one blood sample is done before beginning chemotherapy as a first treatment line for a metastatic castration resistant prostate cancer
16301843|NCT04662996|Experimental|2- Novel Hormonal Agent|Intervention : one blood sample is done before beginning a novel hormonal agent (abiraterone, enzalutamide) as a first treatment line for a metastatic castration resistant prostate cancer
16301844|NCT04662983|Experimental|Experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions.
16301845|NCT04662970|Experimental|Device programming|
16301846|NCT04662957|Experimental|Probiotic preparation|Multi-strain probiotic mixture. The daily dose was five billion (2 capsules/day).
16301847|NCT04662957|Placebo Comparator|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture (2 capsules/day).
16301848|NCT04662944||Licensed anti-VEGFs|Patients being treated for nAMD with licensed anti-VEGFs
16301850|NCT04662905|Experimental|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
16301851|NCT04662879|Experimental|Intervention Arm|"Two interventions are performed:
~Have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated, and if Score is >0,
~Have abdominal imaging performed."
16301852|NCT04662879|No Intervention|Observation Arm|Passive follow-up by electronic medical record for study endpoints of pancreatic cancer diagnosis.
16301854|NCT04662866|Active Comparator|Empagliflozin|Empagliflozin 10 mg x 1, morning, for 2 weeks, then Empagliflozin 10 mg morning + Placebo evening for 10 weeks.
16301855|NCT04662866|Active Comparator|Linagliptin|Linagliptin 5 mg x 1, morning, for 2 weeks, then Linagliptin 5 mg morning + Placebo evening for 10 weeks.
16301856|NCT04662866|Active Comparator|Pioglitazone|Pioglitazone 30 mg x 1, morning, for 2 weeks, then Pioglitazone 30 mg morning + Placebo evening for 10 weeks.
16301857|NCT04662853||Patients with positive results in the fecal occult blood test.|Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain), were invited to participate in the CCR-microbiome study. This program is screening Andalusian population aged between 50 and 69 years old for colo-rectal cancer presence by fecal occult blood test, and further colonoscopy when positive for this test. Patients included in CCR-microbiome study were recruited between January 2017 and March 2020, at the Reina Sofia University Hospital (Cordoba, Spain) with the consumption of antibiotic within the previous month as exclusion criteria.
16301858|NCT04662840|Sham Comparator|Sham procedure|"The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. A script detailing the procedure verbally will be followed by the interventionalists to waste time, but the only actual medical act that will be done is freezing of the skin around the knee (as for nerve ablation procedure) and at the groin (as for embolization procedure). Dressings will be applied at the knee and groin area."
16301859|NCT04662840|Active Comparator|Geniculate artery embolization|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee (as for the ablation procedure) and at the groin and in this group a geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint. Dressings will be applied at the knee and groin area.
16301860|NCT04662840|Active Comparator|Geniculate nerve ablation|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee and at the groin (as for the embolization procedure) and in this group a geniculate nerve ablation will be performed by advancing a radiofrequency ablation (RFA) needle at three locations alongside the tibia and femur where the nerves course and ablation performed. Dressings will be applied at the knee and groin area.
16301861|NCT04662827|Experimental|Palmithylethanolamid|Probands receive PEA 3xday for 28 days, 8 weeks wash out will follow, then they receive placebo for 28 days
16301862|NCT04662827|Placebo Comparator|placebo|Probands receive placebo 3xday for 28 days, 8 weeks washout will follow, then they receive PEA for 28 days
16301863|NCT04662814|Experimental|shock wave|shock wave for primary dysmenorrhea for study group along side to dietary modification
16301864|NCT04662814|Active Comparator|dietary modification|dietary modification for primary dysmenorrhea for control group
16301865|NCT04662801|Experimental|Behavioral Weight Loss|
16301866|NCT04662801|Experimental|Behavioral Weight Loss + Medication|
16301867|NCT04662788|Experimental|Administration of NK cells/Combined Monoclonal Antibodies|
16301868|NCT04662775|Experimental|Intervention group|This group received the multi-component physical activity intervention (physical activity programme, weekly behaviour change support calls, non-reply text messages)
16301869|NCT04662775|No Intervention|Waitlist control|Participants in the wait-list control group were asked to continue their usual PA habits and received no additional contact from the research team outside of data collection points. Following post-intervention data collection, control group participants were invited to participate in the same intervention as described above.
16301870|NCT04662762|Experimental|nursing intervention group|An educational interview by trained nurses was performed at three months in patients allocated to the intervention group. The visit was carried out at the hospital. Family and caregivers were also asked to attend this visit for instruction. For patients unable to move, the nursing team went to their home to perform the intervention, or it was conducted by phone. The duration of this interview was approximately 40 minutes and was focused on some measures and recommendations to improve or maintain adherence. Then, there is a reminder call at 6 months.
16301871|NCT04662762|No Intervention|Usual care group|The patient is followed up and regular visits
16301872|NCT04662749||concave group|the group whose level of sinus floor is lower than both of the adjacent teeth
16301873|NCT04662749||angle group|the group whose level of sinus floor is lower than one of the adjacent teeth and higher than the other one of the adjacent teeth
16301874|NCT04662749||flat group|the group whose level of sinus floor is similar to both of the adjacent teeth
16301875|NCT04662736||patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|
16301876|NCT04662723|Experimental|Corticosteroids combined with RASBs|Patients assigned to the corticosteroid group will receive (pulse) methylprednisolone succinate 500-1000 mg/day for 3 consecutive days followed by oral prednisolone (0.5 mg/kg/bw) on alternate days until the end of month. This treatment will be repeated for three consecutive months. In addition, patients will receive RASBs that will be titrated to their maximum anti-proteinuric effect. The dose of methylprednisolone succinate will be individualized (15 mg/kg) based on the ideal body weight. In overweight and obese IgAN patients the ideal body weight will be considered. The drug will be administered in a single daily dose intravenously for 30-60 min. To avoid obesity and diabetes corticosteroids will be administered only in the morning.
16301877|NCT04662723|Active Comparator|RASBs|Patients will receive RASBs alone that will be titrated to their maximum anti-proteinuric effect.
16301878|NCT04662723|Experimental|SGLT2i combined with Ramipril|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria> 0.5 g/day and GFR >30ml/min/1.73 m2) will receive SGLT2i combined with RASBs.
16301879|NCT04662723|Active Comparator|Ramipril|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria> 0.5 g/day and GFR >30ml/min/1.73 m2) will receive RASBs alone.
16301906|NCT04662515||DOAC|Information about which type of DOAC and the dose that is prescribed to the patient will be collected.
16301907|NCT04662515||Warfarin|A PK-INR ≤3.0 retained whitin the last 24 hours have to be present for inclusion.
16301908|NCT04662515||No blood thinners|
16301882|NCT04662684|Experimental|Rivaroxaban|Rivaroxaban 10mg OD for 35+/- 4 days post-hospital discharge
16301883|NCT04662684|No Intervention|No intervention|control
16301884|NCT04662671|Experimental|RD-X19 Device|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
16301885|NCT04662671|Sham Comparator|Sham|
16301886|NCT04662658|Other|Visit 1 UVA|"Visit 1 will last approximately 4 hours, and will include consenting, collection of data, questionnaires, and procedures as follows:
~Informed consent
~Demographic data
~Smoking history
~Medical history review
~Medication review
~Limited physical exam
~6-minute walk test
~St. George's Respiratory Questionnaire (SGRQ)
~Baseline dyspnea index (BDI)
~Chronic respiratory questionnaire (CRQ)
~PFTs including:
~Pre-bronchodilator spirometry/ post bronchodilator spirometry.
~Body plethysmography (static lung volumes)
~Carbon monoxide diffusion capacity (DLCO)
~Collection of peripheral blood (20mL), exhaled breath condensate (EBC), and urine
~Hyperpolarized xenon-129 MRI (HXeMRI) if all eligibility criteria are met"
16301887|NCT04662658|Other|Visit 2 Duke University|"Visit 2 will last about 3 hours, and will occur within 2-12 weeks of Visit 1. The purpose of this study visit is to obtain a measure of basic test-retest variability on 6 e-cigarette users and 6 control subjects. Participants will be selected based on age and sex matching needs at the time of enrollment.
~During Visit 2, changes in health since Visit 1 will be assessed. In addition, the following will be done in accordance with the parent protocol:
~The standard MR compatibility screening form will be completed.
~Spirometry will be performed before and after MR imaging.
~A limited physical exam
~Female subjects who could be pregnant will take a urine pregnancy test prior to imaging.
~Xenon MRI will be performed
~In addition to the above, the following will be completed:
~Carbon monoxide diffusion capacity (DLCO)
~Peripheral blood (20mL) and urine"
16301888|NCT04662645|Experimental|Supportive care (embedded palliative care)|Participants and caregivers undergo embedded palliative care comprising symptom management (physical and psychological), advanced directives and goals of care discussion, caregiver support, and referral for adjunctive supportive services as needed at each clinic visit.
16301891|NCT04662619|Experimental|B. infantis|A once-daily feeding of activated B. infantis EVC001 (8.0 *10^9 colony forming units [CFU]) will be provided to infants for 12 weeks.
16301892|NCT04662619|Placebo Comparator|Placebo|A once-daily oral feeding of lactose placebo will be provided to infants for 12 weeks.
16301893|NCT04662606|No Intervention|Fasting-group|
16301894|NCT04662606|Experimental|Fed-group|
16301895|NCT04662593|Experimental|Intervention Group|"The intervention group participates in a 17-week whole health program including:
~Weekly, small group online meetings with a health coach;
~Supportive social media including a private Facebook group and selective text messaging;
~Exposure to community tree planting and stewardship (through live streaming or in-person if COVID-19 public health guidance at the time, permits."
16301896|NCT04662593|No Intervention|Control Group|The control group participates only in questionnaire data collection at baseline, 4 months, and 6 months as well as daily weighing. Control group participants will be offered 3 web-based seminars (webinars) highlighting the effective lifestyle approaches demonstrated in the study and intervention group health education materials. The webinars and materials will be provided after the 6-month data collection which concludes the study.
16301897|NCT04662580|Experimental|ARX517 Part 1 (Dose Escalation)|Subjects will be administered ascending dose levels of ARX517 via intravenous (IV) infusion every 3 weeks. Subjects will be enrolled into escalating dose levels during the Dose Escalation period of the study.
16301898|NCT04662580|Experimental|ARX517 Part 2 (Dose Expansion)|Subjects will be administered maximum dose levels of ARX517 via intravenous (IV) infusion every 3 weeks. Subjects will receive the maximum tolerated dose during the Dose Expansion period of the study.
16301899|NCT04662567|Active Comparator|Oral acetaminophen group|the subjects in this group will receive 1000 mg oral acetaminophen 30-45min prior to oocyte retrieval
16301900|NCT04662567|Active Comparator|IV acetaminophen group|the subjects in this group will receive 1000 mg IV acetaminophen formulation intraoperatively
16301901|NCT04662554|Experimental|Novel PET Camera|Patients already undergoing a PET/CT scan for HNC will afterwards undergo a PET scan with the proposed device, thus no additional radioactivity is needed as part of this study.
16301902|NCT04662541|Experimental|Mobile Integrated Health (MIH)|Patients with urgent medical needs are seen and treated in the home by trained community paramedics. The community paramedics perform a standardized assessment, including a physical examination, vital signs, home safety evaluation, and medication reconciliation. During the MIH encounter, the emergency medicine physician at each site is contacted via telemedicine. Physicians can access clinical notes, discharge summaries, and medication lists via the institutional EHR. Adjustments to outpatient medications can be e-prescribed and follow-up appointments can be scheduled with primary care clinicians.
16301903|NCT04662541|Active Comparator|Transitions of care coordinator (TOCC)|Patients receive a follow-up phone calls for a nurse coordinator within 48-72 hours of hospital discharge. Phone calls include clinical/social needs assessment with escalation to primary care team, emergency care, or social work as needed; patient education; and reminder about follow-up appointments.
16301904|NCT04662528|Placebo Comparator|Placebo|
16301905|NCT04662528|Experimental|MAT9001 (omega-3-pentaenoic acid)|
16304203|NCT04646317|Placebo Comparator|normaL SALINE 0.9%|Four 50 ml syringes of .9 % Normal SALINE
16301909|NCT04662489|Active Comparator|Control arm. Pulmonary vein isolation|Pulmonary vein isolation with ablation.
16301910|NCT04662489|Experimental|Treatment arm. Radial ablation|Pulmonary vein isolation plus radial ablation of rotational activity sites.
16301911|NCT04662476|Active Comparator|Vitamin D supplement|331 children will each received 60,000IU of vitamin D once a month for 3 months.
16301912|NCT04662476|Active Comparator|Intervention|The intervention arm will receive vitamin D3.
16301913|NCT04662463|Experimental|CBM-I assignment|Patients will receive CBM-I assignments
16301914|NCT04662463|Placebo Comparator|Placebo assignment|Patients will receive placebo assignments
16301915|NCT04662450|Experimental|Affective pain stimuli group|affective/neutral word pairs
16301916|NCT04662450|Experimental|Sensory pain stimuli group|sensory/neutral word pairs
16301917|NCT04662450|Placebo Comparator|Control group|affective/neutral and sensory/neutral word pairs
16301918|NCT04662437||Covid-19 Patient Group|10 ml of venous blood was taken from the forearm venous vein from people in the Covid-19 Patient Group, and the level of parathyroid hormone, calcium, phosphorus, alkaline phosphatase was measured from this blood.
16301919|NCT04662437||Healthy Control Group|10 ml of venous blood will be taken from the forearm venous vein from the healthy control group and the parathyroid hormone, calcium, phosphorus, alkaline phosphatase level will be measured from this blood.
16301920|NCT04662424|Experimental|MUSIC|music in labor
16301921|NCT04662424|No Intervention|control|no music during labor
16301922|NCT04662411|Placebo Comparator|Placebo|
16301923|NCT04662411|Experimental|butyrate and hexanoate amount 1|1325 mg of butyrate and hexanoate
16301924|NCT04662411|Experimental|butyrate and hexanoate amount 2|
16301925|NCT04662411|Experimental|butyrate and hexanoate amount 3|
16301926|NCT04662398|Active Comparator|Case (Testes shocker device)|The shocker will be used in delivering the current gradually on the testes and penis to improve the blood flow and stimulates the sexual activity among males.
16301927|NCT04662398|Sham Comparator|Control (non testes shocker device)|These groups will not given the shocks, shame device will be used instead and then compare the two results.
16301928|NCT04662385|Experimental|aloe vera toothpaste group|a recently available aloe vera toothpaste for gingival care, offers a completely improved approach for treatment of gingivitis. aloe vera toothpaste was certified as an antibacterial .This innovative toothgel is made using stabilized aloe vera gel from Forever's own plantations and can help you fight plaque as part of a regular brushing routine.
16301929|NCT04662385|Active Comparator|colegate total toothpaste group|Active Ingredient: Stannous fluoride 0.454% (0.15% w/v fluoride ion) Purposes: Anticavity, Antigingivitis, Antisensitivity. Inactive ingredients: Zinc phosphate, Water, Sorbitol, Hydrated silica, Glycerin, PEG-12, Tetras
16301930|NCT04662372||Patients|Patients
16301931|NCT04662359|Other|Ultrasound Assessment of Rheumatoid Arthritis Severity|All patients will receive an ultrasound scan to assess the severity of their arthritis. This scan will then be placed in their medical record to allow their rheumatologist to utilize the scan when making treatment recommendations.
16301932|NCT04662346|Other|patients undergoing robotic pancreatoduodenectomy|patients have pancreatic neoplasm and undergoing robotic pancreatoduodenectomy
16301933|NCT04662333|Active Comparator|Crestal sinus lift|Implant site preparation with detachment of Schneiderian membrane and subsequent implant placement. The corresponding healing abutment is made up of PEEK (poly-ether-ether-ketone)
16301934|NCT04662333|Experimental|Crestal sinus lift with adjunctive xenograft|Implant site preparation with detachment of Schneiderian membrane. After that, collagen membrane plus xenogenic bone substitute will be placed into the site before implant placement. The corresponding healing abutment is made up of titanium.
16301935|NCT04662320|Experimental|Brief Electrical Stimulation|Single, 10 minute dose of electrical stimulation delivered to the ulnar nerve during surgical intervention for cubital tunnel decompression.
16301936|NCT04662320|No Intervention|Standard of Care|Surgical intervention for cubital tunnel decompression.
16301937|NCT04662307|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The intelligent cardiopulmonary rehabilitation system is designed to improve the user's adherence to pre-determined training intensity. The training intensity is pre-determined using the 60%-80% heart rate reserve which is obtained from the cardiopulmonary exercise test at prestest. The system allows dynamically auto-adjust the paddling resistance in accordance to the patient's current hear rate and paddling rate, with the goal to maintain the patient's heart rate at the pre-determined heart rate zone through the training period.
16301938|NCT04662294|Experimental|Administration of CD70 CAR T-cells|
16301939|NCT04662281|Experimental|LX9211|LX9211, once daily
16301940|NCT04662281|Placebo Comparator|Placebo|Placebo, once daily
16301941|NCT04662255|Experimental|Arm A (LOXO-305)|Orally
16301942|NCT04662255|Active Comparator|Arm B (ibrutinib, acalabrutinib, or zanubrutinib)|Orally
16301943|NCT04662242|Experimental|low serum selenium with selenium supplement|Patients having low serum selenium with selenium supplement given
16301944|NCT04662242|Placebo Comparator|low serum selenium with placebo supplement|Patients having low serum selenium with placebo given
16301945|NCT04662242|Active Comparator|non-low serum selenium with selenium supplement|Patients having normal serum selenium with selenium supplement given
16301946|NCT04662242|Placebo Comparator|non-low serum selenium with placebo supplement|Patients having normal serum selenium with placebo given
16301947|NCT04662229|Experimental|Experimental: 10 hz stimulatión|Eco-guided percutaneous electrical stimulation application of low frequency electrical current at 10 hz, 240 microsecond, over the median and ulnar nerve in the arm, for 1 minute on each nerve. The intensity of the current will reach the excitomotor threshold, causing visible but comfortable contractions.
16301948|NCT04662229|Sham Comparator|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and a sound will be applied.
16301949|NCT04662216|Active Comparator|control group|Scaling and root planing
16301950|NCT04662216|Experimental|test group|"scaling and root planing + Perisolv +Hyadent BG gels."
16301951|NCT04662190|Active Comparator|Control grup|Conventional surgery.
16301952|NCT04662190|Experimental|Intervention group|Surgery planned, simulated and guided by 3D printing.
16301953|NCT04662177|Experimental|Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies|The group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression.
16301954|NCT04662177|No Intervention|Group 2: Standard anaesthesia with propofol and electrophysiological studies|The group 2 receive standard anaesthesia management.
16301955|NCT04662164|Placebo Comparator|placebo|control
16301956|NCT04662164|Active Comparator|4.2mg hepalatide|low dose
16301957|NCT04662164|Active Comparator|6.3mg hepalatide|middle dose
16301958|NCT04662164|Active Comparator|8.4mg hepalatide|high dose
16301959|NCT04662151|Experimental|Phase 1b open-label AT-100|Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
16301960|NCT04662151|Sham Comparator|Phase 1b open-label air-sham|Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
16301961|NCT04662125|Active Comparator|group A|Group A (conservative treatment): Patients will receive good hydration, recumbent positioning, three tablets per day (combined paracetamol and caffeine tablet) for three days and stool softener.
16301962|NCT04662125|Active Comparator|group B|Group B (oral prednisolone): Patients will receive three tablets per day (one oral tablet prednisolone 20 mg plus two tablets of vitamins to maintain blinding) for three days.
16301963|NCT04662125|Active Comparator|group C|Group C (oral pregabalin): Patients will receive three tablets per day (oral tablet pregabalin 100 mg) for three days.
16301964|NCT04662112|Experimental|NASOX|Liposomal irinotecan+S-1+oxaliplatin
16301965|NCT04662099|Experimental|Conditioning chemotherapy plus CAR T cells infusion|
16301966|NCT04662086|Experimental|Acebilustat|Participants are randomized to receive either active acebilustat or matching placebo for 28 days.
16301967|NCT04662086|Experimental|Camostat|Participants are randomized to receive either active camostat or matching placebo for 10 days.
16301968|NCT04662073|Experimental|Camostat|Participants are randomized to receive camostat for 10 days.
16301969|NCT04662073|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match camostat for 10 days.
16301970|NCT04662060|Experimental|Acebilustat|Participants are randomized to receive acebilustat for 28 days.
16301971|NCT04662060|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match acebilustat for 28 days.
16301972|NCT04662047||Adults and children living in the 11 principal cities of Cataluña, Spain.|Adults and children living in the 11 principal cities of Cataluña, Spain: Barcelona, Hospitalet de Llobregat, Tarrasa, Badalona, Sabadell, Lérida, Tarragona, Mataró, Santa Coloma de Gramanet, Reus, Girona.
16301973|NCT04662034|Experimental|Device plus Standard of Care|Device plus Standard of Care
16301974|NCT04662034|Other|Standard of Care|Standard of care drug treatment
16301975|NCT04662021|Experimental|Exercise group|
16301976|NCT04662021|Experimental|Cognitive therapy group|
16301977|NCT04662008|Active Comparator|High resource tailored intervention|Tele-coaching arm
16301978|NCT04662008|Active Comparator|Low-resource web-only intervention|Website arm
16301979|NCT04661995|Experimental|Amplification + Notched Noise Therapy|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. This treatment group will include a Notched Noise Therapy, a 1-10 kHz noise notched within a 1-octave range centered around the psychoacoustic tinnitus pitch match measured. Randomized participants will wear their hearing aids with this loaded software for 8 weeks. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
16301980|NCT04661995|Active Comparator|Amplification + Broadband Noise|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. A popular and commonly used sound therapy treatment, this treatment group will listen to a broadband noise, or white noise, that is housed on the manufacturer's hearing aid tinnitus program. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
16301981|NCT04661995|Placebo Comparator|Amplification Only|Following the baseline assessment, participants will be randomly assigned to one of the study groups. Hearing aids are ear-level, self-contained, FDA-approved hearing device. Hearing aids help individuals with hearing loss and provide safe amplification/gain to frequencies that have loss.
16301982|NCT04661982||Observational (long term follow-up)|Patients undergo long term follow-up and complete questionnaires.
16301983|NCT04661969||1|Foreign Substance disseminated to both lower extremities and buttocks
16301984|NCT04661969||2|Foreign Substance isolated to buttocks with moderate to severe skin changes
16301985|NCT04661969||3|Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations
16301986|NCT04661969||4|Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration
16301987|NCT04661956|Experimental|Transbronchial cryobiopsy|Transbronchial cryobiopsy was performed in the patiens of pulmonary peripheral nodule
16301988|NCT04661956|Other|Transbronchial lung biopsy|Transbronchial lung biopsy was performed in the patiens of pulmonary peripheral nodule
16301989|NCT04661943|Experimental|Arm A|Chidamide Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
16301990|NCT04661930|Experimental|Fenofibrate + Usual Care|Participants in this arm will receive the study drug, Fenofibrate, in combination with usual care.
16301991|NCT04661930|Placebo Comparator|Placebo + Usual Care|Participants in this arm will receive a placebo treatment, in combination with usual care.
16301992|NCT04661917|Experimental|BAY2327949|Participants will receive 60 mg of BAY2327949 (2 tablets of 30 mg) once daily for 28 days.
16301993|NCT04661917|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 28 days.
16301994|NCT04661904|Experimental|cTBS group|Patients randomly assigned to cTBS group will receive 12 sessions cTBS for total four days after surgery.
16301995|NCT04661904|Sham Comparator|sham group|Patients randomly assigned to sham group will receive 12 sessions sham stimulation for total four days after surgery.
16301996|NCT04661891|Experimental|Healthy Participants|The investigators will look at muscle activity of healthy participants from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
16301997|NCT04661891|Experimental|Clinical Participants|The investigators will look at muscle activity of participants post-stroke from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
16301998|NCT04661878|Experimental|Smartphone App to Improve Treatment Adherence|Participants randomized to the intervention condition will receive access to the smartphone app customized for this study. This study will customize HealthMpowerment, a theory-based smartphone app with features including an anonymous interactive discussion forum, a medication and adherence tracker, a platform to ask questions to an Expert, a section with engaging activities (including quizzes, self-assessments, and goal-setting activities), and a multi-media resource center.
16301999|NCT04661878|No Intervention|Standard of Care|Participants randomized to the control condition will receive standard adherence counseling through routine clinical care.
16302000|NCT04661865|Other|Control group|Routine care only They will receive routine antenatal care that included iron supplementation with follow up of hemoglobin level
16302001|NCT04661865|Experimental|Intervention group|They will receive the Heath Information Package Program (HIP program)
16302002|NCT04661852|Experimental|CABOZANTINIB WITH TOPOTECAN-CYCLOPHOSPHAMIDE|"Participants will be accrued to dose levels in cohorts of 3 using the 3 + 3 design with a combination of cabozantinib, topotecan and cyclophosphamide.
~Each study treatment cycle lasts 21 days.
~Participants may receive up to 17 cycles.
~Participants will be assigned a specific dose and schedule of the study drugs determined when enrolled in the study."
16302003|NCT04661839|Experimental|COVID-HIGIV Dose Level 1|Eligible subjects will be randomized to receive a single IV infusion of COVID-HIGIV dose level 1.
16302004|NCT04661839|Experimental|COVID-HIGIV Dose Level 2|Eligible subjects will be randomized to receive a single IV infusion of COVID-HIGIV dose level 2.
16302005|NCT04661839|Experimental|COVID-HIGIV Dose Level 3|Eligible subjects will be randomized to receive a single IV infusion of COVID-HIGIV dose level 3.
16302006|NCT04661839|Placebo Comparator|Dose Placebo (saline)|Eligible subjects will be randomized to receive a single IV infusion of saline placebo.
16302007|NCT04661826|Experimental|Oncofid-P-B|Oncofid-P-B will be administered once a week for 6 weeks in the first treatment phase and once a month for 6 months followed by other 6 months in the second maintenance phase
16302008|NCT04661813|Experimental|EXTRA-CVD Virtual Care|"An adapted version of a Nurse-led intervention to EXtend the HIV TReatment CascAde for CardioVascular Disease prevention (EXTRA-CVD)."
16302009|NCT04661800|Other|Test de bâton de Sniff|Cohorte
16302010|NCT04661774|Other|Sham massage before reflexology massage (RP)|Sham massage (MS) comparator will be realised before RP.
16302011|NCT04661774|Other|Reflexology massage (RP) before Sham massage|RP will be realized before Sham massage.
16302012|NCT04661761|Experimental|stimulated salivary flow rate|stimulated salivary flow rate determined in a crossover design: first using Paraffin Pellets from Aurosan GmbH; thereafter using Chewing wax from the Saliva-Check Buffer from GC Europe
16302013|NCT04661748|Active Comparator|Intervention arm|Active alarms
16302014|NCT04661748|No Intervention|no intervention|No alarms
16302015|NCT04661709|Experimental|Wen Xin granule|Patients are given Wen Xin granule by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
16302016|NCT04661709|Placebo Comparator|WXG placebo|Patients are given Wen Xin granule placebo by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
16302017|NCT04661696|Experimental|single-arm|Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.
16302018|NCT04661683|Experimental|Peripheral Endothelial Function|Brachial artery flow-mediated dilation will be used to measure endothelial function
16302019|NCT04661683|Experimental|Central Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness.
16302020|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by articulating paper|In this group the final occlusal correction will be performed with the patient in supine position using 20 um thick articulating paper and articulating foil 8 um thick. The patient will be asked to tap 3 times on the articulating paper and occlusal correction will be done using carbide laboratory bur and rubber cone till uniform contact on all teeth is achieved in centric relation which is illustrated on the splint by a series of uniformly appearing articulating paper dots. Then the patient will be asked to make protrusive and right and left excursions to ensure smooth anterior guidance and posterior disocclusion.
16302021|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by T-scan|"In this group the same adjustment sequence will be done using T Scan III (software version 8.0) computerized occlusal analysis, a new patient file will be opened, the patient's biological data will be entered, and the T Scan dental arch size is customized to fit the patients arch anatomy. The patient will be asked to clench to record occlusal force and areas that needs adjustment will be grinded using the paper marks as the guideline and carbide laboratory bur till bilateral force balance achieved and the center of force (COF) icon sits close to the midline.
~Mandibular excursions are then adjusted in a similar fashion. Contacts rather than anterior and canine guidance will be eliminated till achieving anterior guidance and posterior disocclusion in time less than 0.5 seconds."
16302022|NCT04661657||COVID-19|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have tested positive or have been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
16302043|NCT04661566|Experimental|Education+Narratives+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Scenarios, and Future"
16302074|NCT04661501|Active Comparator|DermACELL group|Device for immediate implant based breast reconstruction.
16302023|NCT04661657||Control|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have never tested positive and/or has never been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
16302024|NCT04661644|Experimental|Test Group 1 (Low Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.
16302025|NCT04661644|Experimental|Test Group 2 (High Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia.
16302026|NCT04661618|Active Comparator|GT|12 weeks of progressive training in the first phase and 12 weeks of maintenance training in the second phase.
16302027|NCT04661618|Other|Control|"No intervention for the first phase and will be active comparator in the second phase.
~No intervention for the first 12 weeks (first phase) and 12 weeks of progressive training in the second phase."
16302028|NCT04661592|Experimental|Control|Neurologically healthy individuals will be recruited for the longitudinal study
16302029|NCT04661579|Experimental|Group 1: Positive baseline parasitemia, antimalarial treatment, RTS,S/AS01E vaccine|Group 1 subjects have detectable P. falciparum parasitemia at baseline measured by PCR. Anti-malarial treatment with Dihydroartemisinin-piperaquine (DHA/Pip) to clear asexual stage and young gametocyte parasites plus low dose primaquine (LD PQ) to clear mature gametocytes will be given 4 weeks prior to immunization with RTS,S/AS01E. A 2nd course of DHA/Pip plus Primaquine will be given 2 weeks before second RTS,S/AS01E immunization. One week before 3rd RTS,S/AS01E immunization, a three-day course of Artemether/lumefantrine (A/L) plus Primaquine will be administered to clear infection. Rationale for administration of A/L is its preferred shortened half-life allowing for evaluation of vaccine efficacy thereby excluding any confounder effect due to prolonged anti-malarial effect of drug.
16302030|NCT04661579|Experimental|Group 2: Negative baseline parasitemia, antimalarial prophylaxis, RTS,S/AS01E vaccine|Group 2 subjects have no detectable P. falciparum parasitemia as measured by PCR at enrolment. It is proposed to initiate anti-malarial chemoprevention to subjects (prophylaxis effect) with DHA/Pip plus LD PQ 4 weeks prior to immunization with RTS,S/AS01E. A 2nd course of DHA/Pip plus Primaquine will be given 2 weeks before second RTS,S/AS01E immunization. One week before 3rd RTS,S/AS01E immunization, a three-day course of A/L plus Primaquine will be administered to clear infection.
16302031|NCT04661579|Experimental|Group 3: Positive baseline parasitemia, RTS,S/AS01E vaccine|Group 3 subjects have detectable P. falciparum parasitemia at baseline measured by PCR but will not receive any anti-malarial medications to clear PCR-positive parasites. This group includes 35 subjects and is included only for immunological assessment and not for vaccine efficacy. Subjects in Group 3 will be administered RTS,S/AS01E three times on a 0, 1, 7 month schedule.
16302032|NCT04661579|Placebo Comparator|Group 4: Positive baseline parasitemia, antimalarial treatment, rabies vaccine|Group 4 subjects have detectable P. falciparum parasitemia at baseline measured by PCR (note any positive result from PCR will be considered positive for purposes of group selection and study endpoints as with Group 1) and will receive DHA/Pip , Primaquine, and A/L on the same schedule as subjects in group 1. Subjects in Group 4 will be administered Abhayrab rabies vaccine on a 0, 1, 7 month schedule.
16302033|NCT04661579|Placebo Comparator|Group 5: Negative baseline parasitemia, antimalarial prophylaxis, rabies vaccine|Group 5 subjects have no detectable P. falciparum parasitemia as measured by PCR at enrolment and will receive DHA/Pip, Primaquine, and A/L on the same schedule as subjects in group 2. Subjects in Group 5 will be administered Abhayrab rabies vaccine on a 0, 1, 7 month schedule.
16302034|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, Scenarios, Future, and Risk"
16302035|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, Scenarios, and Future"
16302036|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, Scenarios, and Risk"
16302037|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, and Scenarios"
16302038|NCT04661566|Experimental|Education+Narratives+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, Future, and Risk"
16302039|NCT04661566|Experimental|Education+Narratives+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, and Future"
16302040|NCT04661566|Experimental|Education+Narratives+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Skills, and Risk"
16302041|NCT04661566|Experimental|Education+Narratives+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives and Skills"
16302042|NCT04661566|Experimental|Education+Narratives+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives. Scenarios, Future, and Risk"
16302044|NCT04661566|Experimental|Education+Narratives+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Scenarios, and Risk"
16302045|NCT04661566|Experimental|Education+Narratives+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives and Scenarios"
16302046|NCT04661566|Experimental|Education+Narratives+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives, Future, and Risk"
16302047|NCT04661566|Experimental|Education+Narratives+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives and Future"
16302048|NCT04661566|Experimental|Education+Narratives+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives and Risk"
16302049|NCT04661566|Experimental|Education+Narratives|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Narratives"
16302050|NCT04661566|Experimental|Education+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills, Scenarios, Future, and Risk"
16302051|NCT04661566|Experimental|Education+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills, Scenarios, and Future"
16302052|NCT04661566|Experimental|Education+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills, Scenarios, and Risk"
16302053|NCT04661566|Experimental|Education+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills and Scenarios"
16302054|NCT04661566|Experimental|Education+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills, Future, and Risk"
16302055|NCT04661566|Experimental|Education+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills Future"
16302056|NCT04661566|Experimental|Education+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills and Risk"
16302057|NCT04661566|Experimental|Education+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Skills"
16302058|NCT04661566|Experimental|Education+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Scenarios, Future, and Risk"
16302059|NCT04661566|Experimental|Education+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Scenarios and Future"
16302060|NCT04661566|Experimental|Education+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Scenarios and Risk"
16302061|NCT04661566|Experimental|Education+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Scenarios"
16302062|NCT04661566|Experimental|Education+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Future and Risk"
16302063|NCT04661566|Experimental|Education+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Future"
16302064|NCT04661566|Experimental|Education+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:
~Risk"
16302065|NCT04661566|Experimental|Education|Participants will receive a version of the Mission Wellness app (intervention) that only includes the static educational component.
16302066|NCT04661553|Experimental|Group1: patients with a low risk of premature birth|Asymptomatic patient receiving usual follow-up in the maternity ward.
16302067|NCT04661553|Experimental|Group2: patients with a high risk of premature birth|Symptomatic patients with cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm. Asymptomatic patients with a history of premature delivery or late miscarriage and cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm.
16302068|NCT04661540|Experimental|Auxora|"Auxora will be given as a continuous infusion:
~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours; After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
16302069|NCT04661540|Placebo Comparator|Placebo|"Placebo will be given as a continuous infusion:
~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours. After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
16302070|NCT04661527|Experimental|Sarilumab arm|
16302071|NCT04661514|Experimental|Safety, Tolerability, and Treatment|On dosing day, each participant will receive 1 x 25 mg treatment bottle containing 5 x 5 mg oral capsules of psilocybin. The administration session will last approximately 4-6 hours and will be supported by a lead therapist and an assisting therapist.
16302072|NCT04661501|Active Comparator|AlloDerm group|Device for immediate implant based breast reconstruction.
16302073|NCT04661501|Active Comparator|AlloMax group|Device for immediate implant based breast reconstruction.
16302075|NCT04661501|Active Comparator|Flex HD group|Device for immediate implant based breast reconstruction.
16302076|NCT04661488||Children and adolescence|
16302077|NCT04661475|Experimental|Dexmedetomidine adjunctive to ECT arm|
16302078|NCT04661475|Placebo Comparator|Normal Saline adjunctive to ECT arm|
16302079|NCT04661449|Experimental|Lifestyle Intervention|every 3 months within 1 year.
16302080|NCT04661449|No Intervention|control group|Regular follow-up every 6 months within 1 year.
16302081|NCT04661423|Experimental|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last between 5 and 7 days during the post-ICU hospitalization, at rest and during rehabilitation exercises.
16302082|NCT04661410|Experimental|Reward Re-Training|10 weekly sessions of Reward Re-Training Group Therapy.
16302083|NCT04661410|Active Comparator|Supportive Therapy|10 weekly sessions of Supportive Group Therapy.
16302084|NCT04661397|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
16302085|NCT04661397|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COBI] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
16302086|NCT04661384|Experimental|Treatment (IL13Ralpha2-CAR T cells)|Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16302087|NCT04661371|Experimental|The experimental group in acute cholecystitis|"inclusion criteria
~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
~Gallbladder with surrounding organs due to gallbladder inflammation
~Patients over 19 years of age
~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
16302088|NCT04661371|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
~Gallbladder with surrounding organs due to gallbladder inflammation
~Patients over 19 years of age
~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
16302091|NCT04661345||Septic group|The septic group is composed of patients with prosthetic joint infection mediated by coagulase-negative Staphylococci (CoNS)
16302092|NCT04661345||Aseptic group|The aseptic group is composed of patients with implant failure unrelated to infection.
16302093|NCT04661332||Endoscopic retrograde cholangio-pancreatography|Endoscopic retrograde cholangio-pancreatography procedure
16302094|NCT04661319|Experimental|video editing training group|"- inclusion criteria
~trainees in general surgery
~No experience of laparoscopic cholecystectomy
~Less than 5 experiences of laparoscopic surgery
~Uncomplicated symptomatic gallstone disease
~The experimental group received video editing training"
16302095|NCT04661319|Experimental|traditional training group|"- inclusion criteria
~trainees in general surgery
~No experience of laparoscopic cholecystectomy
~Less than 5 experiences of laparoscopic surgery
~Uncomplicated symptomatic gallstone disease
~The control group received tradtional training"
16302096|NCT04661306|Experimental|SHUTi|
16302097|NCT04661280|No Intervention|Cognitive remediation|Non-drug treatment, cognitive remediation, cognitive stimulation
16302098|NCT04661280|Experimental|Cognitive remediation + Donepezil|Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
16302099|NCT04661267|Experimental|Supplement formula|Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
16302100|NCT04661267|Placebo Comparator|Placebo formula|Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
16302101|NCT04661254|Other|Lymphapheresis|Blood is drawn from one of the patient's two arms and passes through a separation circuit. After removing the white blood cells, it is reinjected into the other arm.
16302102|NCT04661241|Experimental|Investigational Scan|The proposed sequence (<15 minutes) will be added as a supplementary sequence only for the preoperative imaging if subjects agree to participate.
16302103|NCT04661241|Active Comparator|Current Clinical Practice|All patients will undergo a routine clinical preoperative MRI of the brain under general anesthesia to reduce movement artifacts.
16302104|NCT04661215||Symptoms of gastroparesis|Participants with symptoms of gastroparesis with minimum GCSI score of 2.0 (18/45 x 5)
16302105|NCT04661215||Control participants|Non-diabetic participant undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of PAGI-SYM questionnaire
16302106|NCT04661202|Experimental|Exercise training group|"Aerobic exercise
~Resistance exercise (including pelvic floor muscle training with biofeedback)
~Stretching exercise
~Home exercise"
16302107|NCT04661202|No Intervention|Control group|"．Usual care
~After baseline assessment, the participants will receive health and lifestyle advices related to bowel symptoms, which include maintaining moderate physical activity, healthy diet, and ideal defecation posture, and establishing a personal bowel schedule and other behavioral changes that promote regular bowel movements.
~Upon request, the participants will be provided with the same intervention program as the exercise training group after 8 weeks participation."
16302108|NCT04661189|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
16302109|NCT04661189|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
16302110|NCT04661163|Experimental|Virtual reality avatar therapy|Patients will be offered seven individual sessions of avatar therapy and two booster sessions conducted by a skilled therapist. In the initial phase of treatment, the participants create a virtual avatar that corresponds to their visual perception of the source of their voice. The therapist initiates, encourages and supports a dialogue between the participant and the avatar by alternating between talking as the avatar and as a supportive therapist. The therapy sessions last 45 minutes of which around 15 minutes is spent in dialogue with the avatar. The remaining 30 minutes will be used on preparing the patient for the confrontation with the avatar, evaluating on the interaction with the avatar, and use general cognitive behavioral techniques to reduce the auditory hallucination. The treatment is conducted with the use of virtual reality, so the participant will wear VR headset during treatment and watch and talk with the avatar shown in front of him or her.
16302111|NCT04661163|No Intervention|Treatment as usual (TAU) (comparison group)|TAU consists of seven session with health professionals providing supportive counselling and simple cognitive behavioral techniques. TAU does not involve psychotherapy specifically targeting auditory hallucinations.
16302114|NCT04661137|Experimental|Carfilzomib-containing Regimen|"Carfilzomib 56 mg/m2 on days 1, 8 and 15. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.
~Selinexor 80 mg on days 1, 8 and 15."
16302115|NCT04661137|Experimental|Pomalidomide-containing Regimen|"Pomalidomide 4 mg po daily for 21 days. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.
~Selinexor 60 mg on days 1, 8 and 15."
16302116|NCT04661137|Experimental|Exploratory/Daratumumab-containing Regimen|"Daratumumab on current schedule (16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on).
~Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.
~Selinexor 100 mg on days 1, 8, 15 and 22."
16302117|NCT04661124|Other|Adult Normal Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
16302118|NCT04661124|Other|Adult Pathology Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
16302119|NCT04661111|Experimental|Hymovis ONE Arm|Hymovis® ONE (32 mg/4 ml) intra-articular mono injection. Patients will be followed during 12 months including 6 visits.
16302120|NCT04661098|Experimental|Postpubertal patients with imperforate hymen|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
16302121|NCT04661085||Patients with a suspected infection|Acutely admitted patients from the emergency department across 3 sites who have a suspected infection.
16302122|NCT04661072||Patients with Congenital Uterine Anomalies (CUA)|The rates of renal, breast, uterine, ovarian and vaginal cancers in women who have been diagnosed with a CUA will be studies
16302123|NCT04661046|Experimental|TCM Syndrome Types|Traditional Chinese Medicine
16302125|NCT04661020|Experimental|Administration of CD19 CAR T-cells|
16302126|NCT04661007|Experimental|Part 1 : tafasitimab monotherapy|Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 2 groups: Group 1 will evaluate weight-based doses of tafasitamab, and Group 2 will evaluate fixed doses of tafasitamab.
16302127|NCT04661007|Experimental|Part 2 : tafasitamab combination therapy|tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.
16302128|NCT04661007|Experimental|Part 3 : Dose Expansion of tafasitamab +parsaclisib|tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2
16302129|NCT04660994||Therapeutic education|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
16302130|NCT04660994||Therapeutic education and Yapouni educational game|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
16302131|NCT04660981|Experimental|İntervention Group|"The women in the intervention group were individually provided with Training Program on Fear of Childbirth Based on Motivational Interview Method once a week, four sessions in total."
16302132|NCT04660981|No Intervention|Control Group|No interventions were made for those in the control group other than routine hospital practices.
16302133|NCT04660968|Experimental|Dyadic Health Behaviour Change Intervention|The dyadic health behaviour change intervention is a 10 sessions program provided over 16 weeks. It includes nutritional, physical activity and sedentary related information, as well as couples-based adaptation of motivational interviewing, self-monitoring, goals setting, stimulus control, problem-solving, and relapse prevention as well as specific strategies to support their partner's autonomy and intrinsic motivation.
16302134|NCT04660968|Active Comparator|Dyadic nutrition counselling intervention|The couples-based nutrition counselling intervention is a 10 sessions program provided over 16 weeks. Topics are based on Dietitians of Canada's Practice-based Evidence in Nutrition discussions. Participants are also encouraged to meet the current physical activity recommendations. Both members of the couples are seen at the same, but no intervention target specifically the behaviour change process or the romantic relationship.
16302135|NCT04660955||Patients|Patients who had ACL reconstruction
16302136|NCT04660955||Controls|Controls who have no previous knee injury or surgery, no diagnosis of osteoarthritis
16302137|NCT04660942||Control|Healthy child
16302138|NCT04660942||Experimental|Patients with developmental delay
16302139|NCT04660929|Experimental|Group 1 and Group 2|Both groups will receive the full dose manufactured per patient. Group 1 will undergo intra subject dose escalation of IV administrations of up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5. Group 2 will receive the full dose IV on Day 1 of up to 5 billion cells.
16302140|NCT04660916||isotretinoin|The patients aged 18-45 that were planned to begin treatment with isotretinoin for acne
16302141|NCT04660916||control|Healthy volunteers aged 18-45 without any diseases/drugs affecting the nail
16302142|NCT04660903|Experimental|Intervention|One arm study - the intervention arm is the only actual
16302143|NCT04660890|Experimental|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants will receive all 3 doses of ALXN2050 in a multiple-ascending fashion over 3 periods:
~Treatment A (Period 1): ALXN2050 Dose 120 milligrams (mg) and moxifloxacin-matching placebo.
~Treatment B (Period 2): ALXN2050 Dose 240 mg and moxifloxacin-matching placebo.
~Treatment C (Period 3): ALXN2050 Dose 360 mg and moxifloxacin-matching placebo."
16302144|NCT04660890|Placebo Comparator|Control Arm (DEF)|"Treatment Sequence DEF - Participants will receive ALXN2050-matching placebo over 3 periods:
~Treatment D (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.
~Treatment E (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin.
~Treatment F (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin-matching placebo."
16302145|NCT04660890|Placebo Comparator|Control Arm (GHI)|"Treatment Sequence GHI - Participants will receive ALXN2050-matching placebo over 3 periods:
~Treatment G (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin.
~Treatment H (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.
~Treatment I (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin."
16302146|NCT04660877|Experimental|Cheddar chese|Once enrolled, participants will either ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
16302147|NCT04660877|Active Comparator|Milk|Once enrolled, participants will ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
16302148|NCT04660864|Experimental|Rhinochill|Treatment with nasal cavity cooling 10 minutes during three consecutive migraine attacks.
16302149|NCT04660851|Experimental|Coached|10 weeks of diet coaching
16302150|NCT04660851|No Intervention|Not-coached|No coaching provided
16302151|NCT04660825|Experimental|High intensity resistance band exercise|Randomly assigned as exercise group, exercise intervention. This will be a progressive exercise programme with the aim being to participate three times per week, one in a group session and two in-home sessions.
16302152|NCT04660825|Experimental|Non resistance band exercise|Randomly assigned non-exercise group
16302153|NCT04660812|Experimental|etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab|Patients will receive oral etrumadenant in combination with zimberelimab +mFOLFOX-6 +/-bevacizumab by IV infusion.
16302154|NCT04660812|Active Comparator|mFOLFOX-6 +/-bevacizumab|Patients will receive mFOLFOX-6 +/- bevacizumab by IV infusion.
16302155|NCT04660812|Active Comparator|regorafenib|Patients will receive oral regorafenib
16302156|NCT04660812|Experimental|etrumadent+ zimberelimab + AB680|Patients will receive oral etrmadenant in combination with zimberelimab +AB680 by IV infusion.
16302157|NCT04660799|Active Comparator|Rituximab IV+CHOP|Participants will receive 8 cycles of IV rituximab in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
16302158|NCT04660799|Experimental|Rituximab SC+CHOP|Participants will receive 1 cycle of IV plus 7 cycles of SC in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
16302159|NCT04660786|Active Comparator|intralesional injection of triamcinolone acetonide|5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions
16302160|NCT04660786|Active Comparator|intralesional injection of vitamin D|(2.5 mg/mL) every 4 weeks for 3 sessions
16302161|NCT04660773|Active Comparator|NB UVB phototherapy|(20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.
16302162|NCT04660773|Active Comparator|pregabalin|20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
16302163|NCT04660760|Experimental|Arm A (TAS-102, ramucirumab)|Patients receive TAS-102 PO BID on days 1-5 and 8-12, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16302164|NCT04660760|Active Comparator|Arm B (paclitaxel, ramucirumab)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16302165|NCT04660734|Experimental|3D printing group|"Group 1 (G1) consisted of 20 patients who underwent preoperative molding of the osteosynthesis plate on a 3D printed model of the pelvis. A preoperative scan of the healthy hemi-pelvis was used to create the 3D-printed model for patients in G1 according to the following three-step methodology: 1) A scanographic acquisition of images was performed using a multi-strip scanner in thin sections. These images were recorded as digital images in the standard medical format of digital imaging and communications ; 2) A digital, 3D model of the pelvis in the stereolithography format was created to digitally treat the 2D images. The individualization of the healthy hemi-pelvis, to which a mirror effect was applied allowed for the creation of a symmetrical 3D image, as hemi-pelvises are globally symmetrical. 3) A 3D printer was used to create a physical, 3D-printed model of the affected hemi-pelvis using polylactic acid."
16302166|NCT04660734|Experimental|conventional technique group|Group 2 (G2 or control group) included 23 patients who underwent surgery using the conventional technique.The patients in the control group (G2) underwent surgery following the conventional procedure based on radiographic and CT images with 3D reconstructions.
16302167|NCT04660721|Experimental|sFilm-FS|
16302168|NCT04660721|Active Comparator|TACHOSIL®|
16302198|NCT04660474||Late reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT>7days were assigned to Late reperfusion group.
16302199|NCT04660461|Experimental|1. Randomized placebo-controlled, parallel-group study, crossover-design|
16302200|NCT04660461|Experimental|2. Randomized placebo-controlled, parallel-group study, crossover-design|
16302169|NCT04660708|Experimental|Pregnant women|"Physical assessment for women 20-34 weeks gestation including evaluating pain, back and hip range of motion, strength of hip and abdominal muscles, diastasis recti, and strength, amount of scar tissue from previous pregnancies / deliveries, level of muscle overactivity, and the extent of any prolapse of pelvic floor muscles.
~Treatment: internal and external myofascial release of the pelvic floor muscles, pelvic floor stretching, and instruction diaphragmatic breathing and exercises for postpartum recovery to perform at home. Exercises include: Pelvic floor stretching: happy baby stretch, deep squat, butterfly stretch; Belly breathing; transverse abdominis contraction, transverse abdominis march, bridge, shoulder blade; Instruction and education on perineal massage and posture."
16302170|NCT04660695||Group 1|Patients included will undergo an EUS-guided gastroenterostomy with a 15x10mm or a 20x10mm lumen apposing metal Stent (Axios, Boston Scientific, Mass).
16302171|NCT04660682|Experimental|Modified static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the modified cross-body stretching position. Additionally, they will receive standard physiotherapy program.
16302172|NCT04660682|Experimental|Traditional static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the traditional standing cross-body stretching position. Additionally, they will receive standard physiotherapy program.
16302173|NCT04660682|Active Comparator|Control Group|The participants in this group will receive sham stretching and standard physiotherapy.
16302174|NCT04660669|Other|ESDM 15h|This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.
16302175|NCT04660669|Other|ESDM 8h + MOOC|This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.
16302176|NCT04660643|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
16302177|NCT04660643|Placebo Comparator|Placebo|Placebo administered SC
16302178|NCT04660630|Experimental|Precision group|The subjects were tested for gene, and the corresponding therapeutic drugs were selected according to the results of gene detection. Regular follow-up was conducted according to the study design to evaluate the efficacy and adverse reactions.
16302179|NCT04660630|Active Comparator|Experience group|The subjects were treated with drugs selected by doctors according to their experience. Follow up was performed at the same frequency as the precision group to evaluate the efficacy and adverse reactions.
16302180|NCT04660630|No Intervention|Observation group|The subjects did not accept any intervention, including follow-up, especially regular evaluation of efficacy and adverse reactions.
16302181|NCT04660604|Experimental|Graston Technique® Group|Participants were asked to warm up at a speed that they felt comfortable for 5 minutes at a gentle tempo with an ergometer. Time was followed by a stopwatch. Participants who completed warm-up were taken to GT® application. Application was implemented by a GT® certified therapist with 13 years of experience in orthopedic rehabilitation. Intervention dosage was determined as 2 times a week, 12 sessions over 6 weeks. GMed muscle was scanned between crista iliaca and trochanter major, and a fascial release was applied. Each session lasted 5 minutes. At the end of sessions, iliotibial band stretching exercises (30 seconds, 3 repetitions) was given to the treated side. Application protocol has been determined with reference to GT® manual
16302182|NCT04660604|No Intervention|Control Group|Control group is followed up for 6 weeks without intervention.
16302183|NCT04660591|Active Comparator|standard femoral stem|standard length femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
16302184|NCT04660591|Active Comparator|long femoral stem|long femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
16302185|NCT04660578|Experimental|Single Group|A.Chohan continuous squeezing suture (ACCSS); An Obstetrical procedure using half circle 40mm round body polyglactin 910 suture #1 (Vicryl plus by Ethicon®), for controlling hemorrhage from the lower uterine segment, in patients with placenta previa / accreta for the prevention of hysterectomy at cesarean section.
16302186|NCT04660565|Experimental|Glucocorticoid monotherapy Group|Patients treated with single glucocorticoid
16302187|NCT04660565|Experimental|Combination therapy Group|Patients treated with Belimumab and glucocorticoid
16302188|NCT04660552|Experimental|CognilumTM|During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
16302189|NCT04660552|Placebo Comparator|Placebo condition|During the study participants will be wearing the photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
16302191|NCT04660526|Experimental|Intervention (Enhanced Standard of Care)|Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
16302192|NCT04660526|No Intervention|Control (Standard of Care)|Usual care, continuing standard quality improvement effort
16302193|NCT04660513||Morbid obesity|BMI 32.5 kg/m2 and above
16302194|NCT04660513||Non-obese healthy controls|BMI below 25 kg/m2
16302195|NCT04660500|Experimental|PD Drivers Using AV Technologies On-road|Each driver will drive on-road, everybody will be exposed to two drives (Drive 1, Drive 2) one drive with and the other without in-vehicle technology. The order of technology (with vs. without IVIS or ADAS) and the order of the routes (Drive 1 vs. Drive 2) will be randomly allocated to control for order effects.
16302196|NCT04660474||Early reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT<24 hours were assigned to Early reperfusion group.
16302197|NCT04660474||Intermediate reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT ranging from 24 hours to 7days were assigned to Intermediate reperfusion group.
16302510|NCT04658199|Experimental|UCB0107 (bepranemab)|Subjects in this study arm will receive Intravenous UCB0107.
16302201|NCT04660435||Women with ER+/Her2 negative metastatic breast cancer|Patients with ER+/HER2-negative metastatic breast cancer candidate to first-line treatment with a CDK4/6 inhibitor and an aromatase inhibitor as per standard clinical practice
16302205|NCT04660409|Other|Child Pugh A|
16302206|NCT04660409|Other|Child Pugh B|
16302207|NCT04660409|Other|Child Pugh C|
16302208|NCT04660409|Other|HCC|
16302209|NCT04660409|Other|Healthy|
16302210|NCT04660396||Outpatients following discharge for treatment of heart failure|Daxor Corporation's commercially available Blood Volume Analyzer, BVA-100, will be performed at 5 timepoints for each patient.
16302211|NCT04660383|Experimental|IMT 50|"IMT intervention: IMT50 - 50% of the maximum inspiratory pressure (MIP), using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
16302212|NCT04660383|Experimental|IMT 30|"IMT intervention: IMT30 - 30% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
16302213|NCT04660383|Sham Comparator|IMT 10|"IMT intervention: IMT10 - 10% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
16302214|NCT04660370|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
16302215|NCT04660370|Experimental|Sequence 2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
16302218|NCT04660331|Experimental|Aim I (interview, environmental scan)|Participants participate in a semi-structured interview in-person or via phone over 90 minutes about barriers/facilitators of HPV vaccination in pharmacies. Pharmacies of which the pharmacy staff participants work undergo an environmental scan to characterize the pharmacy's environment, vaccination workflow, and team dynamics.
16302219|NCT04660331|Experimental|Aim 2 (survey, training, communication intervention)|Participants provide feedback on survey questions via cognitive testing. Pharmacy staff complete an online survey over 10-15 minutes to assess the acceptability, appropriateness, and feasibility of providing HPV vaccination to children aged 9-17 in their pharmacies. Pharmacy staff then attend communication training sessions, and then undergo a communication strategy intervention over no more than 120 minutes consisting of identifying vaccine-eligible children and recommending HPV and other vaccines. Pharmacy staff employ the new communication strategy in their pharmacy over 6 months, and then complete an online survey over 10-15 minutes.
16302220|NCT04660318|Experimental|Experimental: remote photoplethysmography for physiological parameters Monitor Readings|
16302221|NCT04660318|Other|Control: rstandard acquisition system for physiological parameters Monitor Readings|
16302222|NCT04660305|Experimental|AT278|Single subcutaneous injection 0.3U/kg
16302223|NCT04660305|Active Comparator|NovoRapid|Single subcutaneous injection 0.3U/kg
16302224|NCT04660292|Experimental|Study Group|The study group was treated with Maitland mobilization and manipulation techniques including postero-anterior Maitland mobilization for C1-C2, Maitland lateral PA glide for C3-C6 and Maitland thrust manipulation for cervico-thoracic junction. Frequency of mobilization was 2 days a week for 4 weeks. While intensity of mobilization was grade 3 and 4 based on the Maitland concept.13 Time of oscillations was 2 or 3 oscillations in a second for 1 to 2 minutes.
16302225|NCT04660292|Active Comparator|Control Group|While placebo treatment with conventional physiotherapy (active exercises-10 repetitions in all direction in pain free range, isometrics 5-10 seconds brief but maximum contraction each held for 5-16 seconds for flexors, extensors, side flexors and rotators)14 without gliding, oscillations and thrust were recommended for the control group.The placebo group was treated with baseline treatment including TENS 10 minutes and moist hot packs in sitting position for 15 minutes on cervical region in with head resting on table with a pillow.
16302226|NCT04660279|Other|Validate|D-WB PET/CT scans + arterial blood sampling.
16302227|NCT04660266|Other|all cohort|
16302228|NCT04660253|Experimental|LTP Plus Dads|Participants in this group will receive 10 sessions of LTP plus dads
16302229|NCT04660240|Active Comparator|Abluminus Sirolimus Eluting Stent System (ASES)|The Abluminus sirolimus eluting stent manufactured by Envision and distributed by Concept Medical.
16302230|NCT04660240|Experimental|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|The Orsiro sirolimus eluting stent manufactured by Biotronik.
16302231|NCT04660227|Experimental|Exercise Group|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour.
16302232|NCT04660227|Other|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks.
16302233|NCT04660214|Active Comparator|Vessel sealing device|Endoscopic diverticulectomy is performed with the LigaSure (TM) device
16302234|NCT04660214|Active Comparator|Dissecting Knife device|Endoscopic diverticulectomy is performed with the SB-Knife(TM) device
16302237|NCT04660188|Experimental|Multidisciplinary collaborative care arm|Post-treatment clinical follow-up visits will be staggered between the oncologist and a dedicated PCP. A patient navigator will be assigned to each study participant to conduct follow-up sessions over the phone regularly at an approximate interval of 3 months.
16302238|NCT04660188|No Intervention|Attentional control arm|BCS will receive follow-up care by their oncologists and any other healthcare providers under existing usual care practices at NCCS.
16302239|NCT04660175|Experimental|Non-resistance therapy|From the 2nd to 5th day of hospitalization, once a day, 4 times of non-resistance therapy is administered. And non-resistance therapy group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
16302240|NCT04660175|Active Comparator|Oriental medicine integrated treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
16302241|NCT04660162|Experimental|Arm-1: Laser speckle contrast imaging|(Perimed AB, Järfälla, Sweden)
16302242|NCT04660162|Experimental|Arm-2: Laser Doppler perfusion imaging|(Moor Instruments, Devon, UK)
16302243|NCT04660136|Experimental|CEUS|
16302244|NCT04660123|Experimental|Quadruple therapy with colloidal bismuth pectin granules|colloidal bismuth pectin granules 150 mg, Selection of 2 antibiotics and 1 proton pump inhibitor based on China's fifth national consensus report on the management of H. pylori infection.All medication is taken orally, twice a day.
16302245|NCT04660110|Active Comparator|Intervention arm|A single dose/round of IPT with DP (40mg/320mg tabs, Fosun Pharmaceuticals)
16302246|NCT04660110|No Intervention|Standard of care|Health information, no study drugs
16302247|NCT04660097|Other|Outcome of Durvalumab-Etoposide-platinum in untreated ES-SCLC(CASPIAN trial)|The outcome of CASPIAN
16302248|NCT04660084|Other|Ultra-rapid molecular point-of-care testing|Extended and more rapid diagnostics on microbiological specimens and an active feedback to treating staff with results.
16302249|NCT04660084|No Intervention|Standard of care|Standard collection of microbiological specimens and standard reply to treating staff.
16302250|NCT04660058||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
16302251|NCT04660058||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
16302252|NCT04660058||gastric cancer|patients with gastric cancer according to histopathological results
16302253|NCT04660045|Experimental|Acalabrutinib|Acalabrutinib 100 mg will be administered orally twice daily continuously in 28-day cycles until treatment is discontinued for any reason.
16302254|NCT04660032|Experimental|Nudge|Obstetric care providers will receive electronic prompts (nudge) for participants in this arm
16302255|NCT04660032|No Intervention|Usual care|Usual postpartum follow-up with visit at 4-12 weeks postpartum
16302256|NCT04660019|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
16302257|NCT04660019|Placebo Comparator|sham acupuncture|Auricular points sticker
16302258|NCT04660006||Control|Patients undergoing uneventful cataract surgery with no retinal vascular disease.
16302259|NCT04660006||Diabetic Retinopathy (DR)|Patients with non-proliferative diabetic retinopathy with no diabetic macular edema treatment in the 6 months prior to uneventful cataract surgery.
16302260|NCT04660006||Diabetic Macular Edema (DME)|Patients with diabetic macular edema undergoing active Anti-VEGF treatment (within the last 3 months) undergoing uneventful cataract surgery.
16302261|NCT04659993||Telemental Group|The virtual group will be conducted within a secure platform such as Microsoft WebEx. Assessments (pre-, post-, mid-way) will be distributed through REDCap, a secure virtual platform, as will session handouts and forms.
16302262|NCT04659980|Active Comparator|hilotherapy|
16302263|NCT04659980|Active Comparator|frozen gloves|
16302264|NCT04659967|Experimental|Pre/Post Training (Within subject)|Participants will complete a baseline questionnaire followed by immediate virtual training, and complete a post-training questionnaire. Participants will also be asked to complete a questionnaire 1-month, 3-months, and 6-months post-training.
16302265|NCT04659954|Experimental|Application O'DIDE|The subjects will use the application O'DIDE during 8 weeks
16302266|NCT04659941|Experimental|BCG vaccine|0.1 ml of the reconstituted vaccine to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
16302267|NCT04659941|Placebo Comparator|0.9% sodium chloride (NaCl) saline solution|0.1 ml of 0.9% NaCl saline solution to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
16302268|NCT04659928|Experimental|High volume evacuation (HVE) suction only and hydrogen peroxide|
16302269|NCT04659928|Experimental|HVE suction and extraoral vacuum aspirator (EVA) and hydrogen peroxide|
16302270|NCT04659928|Experimental|HVE suction and external evacuation device (EED) and hydrogen peroxide|
16302271|NCT04659915|Experimental|Metformin + Prednison|"During one of the study periods, subjects receive Metformin 500 mg tablets p.o. for seven days (starting with a dose of 500 mg /d, then the dose will be increased by 500 mg the next days until 2000 mg /d is achieved).
~Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days."
16302272|NCT04659915|Placebo Comparator|Placebo + Prednison|During the other study period, subjects receive the same dose of placebo tablets p.o instead of metformin. Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days.
16302273|NCT04659902|Placebo Comparator|CON|Participants will ingest a drink containing a control protein only
16302274|NCT04659902|Active Comparator|CON-C|Participants will ingest a drink containing a control protein plus Capolac® (9547 mg to provide 2500mg of calcium)
16302275|NCT04659902|Active Comparator|PRO|Participants will ingest a drink containing an aggregate protein only
16302276|NCT04659902|Active Comparator|PRO-C|Participants will ingest a drink containing an aggregate protein plus Capolac® (9547 mg to provide 2500mg of calcium)
16302277|NCT04659889||Patients with clinical features of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are currently displaying symptoms of long Covid
16302278|NCT04659889||Patients with no symptoms of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are not displaying symptoms of long Covid
16302279|NCT04659876||Grup S (Survivors)|Survivors in ICU follow-up
16302280|NCT04659876||Grup NS (Nonsurvivors)|Patients who died in ICU follow-up
16302283|NCT04659850|Other|Group 1|Group 1 participants in the young 18 - 30 age group
16302284|NCT04659850|Other|Group 2|Group 2 participants in the older 55 - 75 age group
16302285|NCT04659837|Active Comparator|Inhibitory Control Training|Active Inhibitory Control Training vs. Sham Inhibitory Control Training
16302286|NCT04659837|Other|Gameification|Gameified elements added vs. No gameified elements added
16302287|NCT04659824||Healthy|
16302288|NCT04659811|Experimental|Stratum A: Treatment for recurrent meningioma (pembrolizumab, stereotactic radiosurgery)|Participants with recurrent grade II or III meningioma will receive stereotactic radiosurgery. in conjunction with pembrolizumab 200mg IV infusion on day 1 (to -1) of radiation and then every 3 weeks
16302289|NCT04659811|Experimental|Stratum B: Treatment for multiple recurrence meningioma (pembrolizumab, stereotactic radiosurgery)|Participants with multiple recurrent (>=2) grade I meningioma will receive stereotactic radiosurgery. in conjunction with pembrolizumab 200mg IV infusion on day 1 (to -1) of radiation and then every 3 weeks
16302290|NCT04659798||Participants with MM|Participants diagnosed with MM who have received treatment within 12 months preceding the enrollment will be observed prospectively. Data will be collected from the participants medical charts and via electronic case report forms (eCRFs).
16302291|NCT04659798||Participants with AL Amyloidosis|Participants diagnosed with AL Amyloidosis who have received treatment within 12 months preceding the enrollment will be observed prospectively. Data will be collected from the participants medical charts and via eCRFs.
16302292|NCT04659785|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
16302293|NCT04659772|Experimental|Clazakizumabl Group|
16302294|NCT04659772|Placebo Comparator|Placebo Group|
16302295|NCT04659759||COVID-19 Positive|Patients diagnosed with COVID-19 during pregnancy or while breastfeeding
16302296|NCT04659759||COVID-19 vaccine|Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding
16302297|NCT04659759||Controls|Reproductive age women exposed to COVID-19 vaccine
16302298|NCT04659759||Pregnant Control|Pregnant women who delivered at TJUH, COVID negative
16302299|NCT04659746|No Intervention|Control|Participants allocated to the control group will receive the routine care and follow-up for chronic patients in Pandemic situation at Hospital Regional de Encarnación (Encarnación, Paraguay), according to epidemiological surveillance and preventive isolation management protocol released by the Ministry of Health of Paraguay (URL: https://www.mspbs.gov.py/dependencias/portal/adjunto/c1c79a-ProtocoloVigilanciaEpidemiolgica.pdf)
16302300|NCT04659746|Experimental|Intervention|"Participants allocated to the intervention group will follow the same routine care as the control group. Additionally, they will receive access to the MejoraCare app.
~The MejoraCare app delivers the following functionalities:
~Remote symptoms monitoring through an electronic Patient Reported Outcome (ePRO)
~Patient empowerment through personalized educational resources promoting healthy lifestyles"
16302301|NCT04659733|Experimental|Anlotinib hydrochloride|
16302302|NCT04659720|Active Comparator|summers' osteotome technique for closed sinus lift|Implant stability will be evaluated after closed sinus lift using summer's osteotome technique in posterior edentulous maxilla
16302303|NCT04659720|Active Comparator|Patient satisfaction evaluation after closed sinus lifting using summers' osteotome technique|"Will be assessed numerically using a patient satisfaction chart .
~Time of assessment: immediately after surgery"
16302304|NCT04659707|Experimental|COVID-19 Survivors|Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.
16302305|NCT04659694|Other|Single arm study|This study only contains one arm
16302306|NCT04659681|Active Comparator|PVI Guided Fluid Therapy|Patients will receive PVI guided fluids during surgery PVI to be maintained below 12% if PVI >12 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 Lung zones in both lungs to measure total number of B-lines.
16302307|NCT04659681|Active Comparator|CVP Guided Fluid Therapy|Patients will receive Standard CVP Guided Fluids , CVP maintained between 10-16 cms H20 , if CVP< 10 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 zones in both lungs to measure total number of B-lines.
16302308|NCT04659668|Experimental|MMG-23-04-2019|MMG-23-04-2019 is composed by sodium hyaluronate at concentration of 2% (20 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.
16302309|NCT04659655|Other|surgical aortic valve replacement|n=20 patients with aortic valve pathology and indication for surgical aortic valve replacement
16302310|NCT04659655|Other|surgical mitral valve replacement|n=10 patients with mitral valve pathology and indication for surgical mitral valve replacement
16302311|NCT04659642|Active Comparator|dexmedetomidine group (group A)|will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
16302312|NCT04659642|Active Comparator|Fentanyl group (group B)|will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
16302313|NCT04659642|Active Comparator|Both Dexmedetomidine and fentanyl group (group C)|will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
16302314|NCT04659629|Experimental|Part 1: NL-201 Dose Escalation|NL-201 given by intravenous administration testing ascending doses and two different schedules.
16302315|NCT04659629|Experimental|Part 2: NL201 Expansion Cohorts|NL-201 given by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1.
16302316|NCT04659616|Experimental|Treatment (cytarabine, daunorubicin, pemigatinib)|"INDUCTION: Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, and pemigatinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients with hematologic count recovery (assessed between days 25-42) after induction proceed to consolidation therapy.
~CONSOLIDATION: Patients receive high dose cytarabine IV BID on days 1, 3, and 5, and pemigatinib PO QD on days 8-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression of unacceptable toxicity."
16302317|NCT04659603|Experimental|Cohort A metastatic breast cancer (mBC)|SAR408701
16302318|NCT04659603|Experimental|Cohort B metastatic pancreatic adenocarcinoma (mPAC)|SAR408701
16302319|NCT04659577|Experimental|internet based CBT|all patients will be offered active treatment via internet based CBT
16302320|NCT04659564|Other|Breast-cancer related lymphedema (BCRL)|
16302321|NCT04659551|Experimental|Arm 1|Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.
16302322|NCT04659538|Experimental|CAPTIS Embolic Protection|TAVR will be performed according to standard institutional practice under local or general anesthesia by the transfemoral approach. The investigational device will be advanced and deployed across the aortic arch covering the ostia of the 3 great vessels (innominate, left carotid, and left-subclavian arteries) at the initiation of the procedure and withdrawn at the completion of the TAVR procedure.
16302323|NCT04659525|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
16302324|NCT04659525|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
16302325|NCT04659499|Experimental|Nab-paclitaxel in combination with pyrotinib treatment group|Nab-paclitaxel 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib 240mg daily for one year
16302326|NCT04659486|Experimental|Exercise training|A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises
16302327|NCT04659486|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
16302328|NCT04659460|Experimental|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
16302329|NCT04659460|Sham Comparator|Sham Remote Ischemic Conditioning|RIC sham interventions will be applied to the upper extremity for a total of 20 cumulative minutes. For sham, inflation will occur.
16302330|NCT04659447|Experimental|Platelet-Rich Plasma|Four semitendinosus tendons and gracilis tendons are prepared. 4 ml platelet-rich plasma is completely absorbed by a gelatin sponge and fixed in the center of the four tendons. 4-0 absorbable line is used for fixation.Then we use conventional surgical techniques to reconstruct the ACL.
16302331|NCT04659447|No Intervention|control group|We performed conventional surgical techniques to reconstruction without using platelet-rich plasma.
16302332|NCT04659434|Experimental|treatment group|Sintilimab 200mg ivdrip Q3W; Rituximab 375mg/m2 ivdrip; Gemcitabine 1000mg ivdrip; Oxaliplatin 100mg/m2 ivdrip
16302333|NCT04659421|Experimental|Low-grade gliomas|Treated with Recombinant human endostatin, Carboplatin, and Vincristine
16302336|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained in an one-day course
16302337|NCT04659382|Experimental|Single arm|XELOX + bevacizumab + atezolizumab + SIRT (Therasphere)
16302338|NCT04659369|Experimental|CMAB819|CMAB819 480 mg intravenous (IV) solution for Injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
16302339|NCT04659369|Active Comparator|Nivolumab|Nivolumab 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent, or the study ends or up to 4 doses in subjects without disease progression, whichever occurs earlier. After completing 4 doses of Nivolumab therapy, administer of CMAB819 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
16302340|NCT04659356||Patients admitted in Intensive Care Units|All patients admitted in our ICU since august were enrolled in our study, after they have been informed and given their consent for their participation in this observational study.
16302341|NCT04659343||Cohort 1|Patients treated for metastatic renal cell carcinoma in Denmark over a 2-year period.
16302342|NCT04659330|Other|Intervention group|All patients underwent intervention
16302343|NCT04659317|Active Comparator|Opioid Group|"Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
16302344|NCT04659317|Experimental|Placebo Group|"Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
16302345|NCT04659304|Active Comparator|Cohort 1|Single Intravenous (IV) dose of Allocetra-OTS with 5x10^9 cells
16302346|NCT04659304|Active Comparator|Cohort 2|Single Intravenous (IV) dose of Allocetra-OTS with 10x10^9 cells
16302347|NCT04659304|Active Comparator|Cohort 3|Two IV doses of Allocetra-OTS with 10x10^9 cells in each dose
16302348|NCT04659278|Placebo Comparator|Group 1 Placebo|Placebo Isolate Placebo (Hemp seed oil and peppermint flavoring)
16302349|NCT04659278|Active Comparator|Group 2 Isolate Comparator|Isolate Placebo Isolate (CBD no terpenes Hemp seed oil [slightly lower concentration of CBD ratio])
16302350|NCT04659278|Placebo Comparator|Group 3 Placebo Comparator|Placebo OMD Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
16302351|NCT04659278|Experimental|Group 4 Experimental Placebo|OMD Placebo Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
16302352|NCT04659265|Active Comparator|No suspected diagnosis (control group)|Participants receive the information that the pre-treating physician thought that the patient is suffering from a medical emergency (no diagnosis).
16302353|NCT04659265|Active Comparator|Correct suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from an acute myocardial infarction (correct diagnosis).
16302354|NCT04659265|Active Comparator|Wrong suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from a pulmonary embolism (wrong diagnosis).
16302355|NCT04659239|Experimental|Investigational Vaccine|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) according to the immunization schedule of D0, D14.
16302356|NCT04659239|Placebo Comparator|Placebo|Participants will receive 2 doses of the placebo according to the immunization schedule of D0, D14.
16302357|NCT04659226|Experimental|Episodic or chronic migraine|Women starting treatment with erenumab according to clinical indication
16302358|NCT04659213|Experimental|Interventional Group|Placement of a luminal esophageal temperature probe (LET) and insertion of esolution esophageal retractor. In the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation
16302359|NCT04659213|No Intervention|Control Group|Placement of a luminal esophageal temperature probe (LET) during RF ablation
16302360|NCT04659200||Covid Disease Patient Group|Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
16302361|NCT04659200||Covid-Free Control Group|Researchers evaluated the results of serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in the non-patient control group.
16302362|NCT04659187||All hospitalized COVID-19 patients|All consecutive hospitalized patients, tested positive for SARS-CoV-2 at 45 Asklepios hospitals in Germany
16302363|NCT04659187||Subgroup: Detailed cohort of 7 hospitals|Cohort of 7 hospitals with detailed data set
16302364|NCT04659187||Subgroup with cardiovascular events|Definition: Patients hospitalized to COVID-19, who developed a cardiovascular event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke
16302365|NCT04659187||Subgroup with oncological patients|Definition: Patients hospitalized to COVID-19 with prior or preexisting oncological disease
16302366|NCT04659187||Subgroup with critical ill COVID-19 patients|Definition: Patients hospitalized to COVID-19 with intensive care treatment
16302368|NCT04659161|Experimental|KarXT|
16302369|NCT04659161|Placebo Comparator|Placebo|
16302370|NCT04659122|Experimental|AT-100 75 mg|Once daily AT-100 via intratracheal administration for up to 7 doses.
16302371|NCT04659122|Experimental|AT-100 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe & tolerated.
16302372|NCT04659122|Experimental|AT-100 75 mg or 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe & tolerated dose as determined by the prior 2 dosing levels.
16302373|NCT04659109|Experimental|glenzocimab 1000 mg|
16302374|NCT04659109|Placebo Comparator|Placebo|
16302375|NCT04659096|Experimental|ION537|Multiple ascending doses of ION537 will be administered by intravenous (IV) injection on Days 1, 4, 8, 11, 15, and 22 in Cycle 1 and weekly dosing in each subsequent cycle until disease progression.
16302376|NCT04659070|Experimental|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
16302377|NCT04659070|Active Comparator|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
16302378|NCT04659070|Active Comparator|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
16302379|NCT04659057|Active Comparator|Group L|Lidocaine group; 45 randomly assigned patients.
16302380|NCT04659057|Active Comparator|Group D|Demedetomidine group; 45 randomly assigned patients.
16302381|NCT04659057|Active Comparator|Group DL|Combined lidocaine and dexmedetomidine group. 45 randomly assigned patients.
16302382|NCT04659057|Placebo Comparator|Group C|Control group; 45 randomly assigned patients.
16302411|NCT04658875|Experimental|Exercise group|Systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
16302383|NCT04659044|Experimental|Treatment (rituximab, polatuzumab vedotin, venetoclax)|"INDUCTION: Patients receive rituximab IV on day 1 of cycle 1 and rituximab and hyaluronidase human SC over 5 minutes on day 1 of cycles 2-6. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 and venetoclax PO daily on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive venetoclax PO daily and rituximab and hyaluronidase human SC over 5 minutes every 60 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
16302384|NCT04659031|Experimental|Cohort D1|X.X mg / kg ABC008
16302385|NCT04659031|Experimental|Cohort D2|X.X mg / kg ABC008
16302386|NCT04659031|Experimental|Cohort D3|X.X mg / kg ABC008
16302387|NCT04659031|Experimental|Cohort D4|X.X mg / kg ABC008
16302388|NCT04659031|Experimental|Cohort D5|tbd (if an alternative dose cohort is needed)
16302389|NCT04659018||patient|individual performing a screening colonoscopy
16302390|NCT04659005|Experimental|Nurse-led decision counseling group|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
16302391|NCT04659005|Other|Control group|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.
16302392|NCT04658979|Experimental|Intervention group|
16302393|NCT04658966||cases|Women with a history of pre-eclampsia
16302394|NCT04658966||controls|Women with no history of hypertensive disorder during pregnancy
16302395|NCT04658953|Experimental|Ultrasound-guided infiltration|The patient is positioned in the prone position with a block under his stomach. After disinfection of the lumbosacral region with alcoholic chlorhexidine 0.5%, the investigators position the convex probe of the ultrasound machine in the transverse plane. Once the spine has been located, the investigators look for the spinous processes of the lower lumbar vertebrae L4 and L5 with the mark on the cranial side and the side opposite the mark on the side of the sacrum. The latter is visualized as a continuous hyperechoic line. Then, the probe is tilted 90 ° to be in a transverse plane. A 22G needle is introduced in a transverse axis starting from the laterality by inserting it in the direction of the median bone contacts of the lower lumbar vertebrae L3, L4 and L5. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels).
16302396|NCT04658953|Experimental|Fluoroscopy-guided infiltration|"The patient is positioned in the prone position with a block under his stomach. The lumbosacral region is disinfected with alcoholic chlorhexidine 0.5%.
~The C-shaped arm of a X-ray fluoroscopy is positioned around the patient in an antero-posterior view tilted ¾ in order to free the classic view called scotty dogs . The puncture point is determined by the positioning of the needle in so-called tunnel vision. The needle is thus brought to the bone contact corresponding to the eye of the scotty dog in tunnel vision, an area corresponding to the passage of the lumbar median branch. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels)."
16302397|NCT04658940|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
16302398|NCT04658927|Experimental|Dexamethosone intracanalicular insert|All 30 eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye).
16302399|NCT04658927|Active Comparator|Group 1: Prednisolone actetate 1%|15 fellow eye will undergo iLux and receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days.
16302400|NCT04658927|Sham Comparator|Group 2: Sham dilation|"15 fellow eye will undergo ILux and receive punctal sham dilation (control eye)."
16302401|NCT04658914|No Intervention|rotarix only|Rotarix will be administered at 6 and 10 weeks of age following the national Expanded Program for Immunization (EPI) schedule. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
16302402|NCT04658914|Experimental|P2 VP8 only|Parenteral P2-VP8 subunit vaccine will be administered at 6, 10 and 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
16302403|NCT04658914|Experimental|Rotarix + 1 dose P2-VP8|Rotarix will be administered at 6 and 10 weeks of age, followed by parenteral P2-VP8 subunit vaccine at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
16302404|NCT04658914|Experimental|Rotarix + 3 doses P2-VP8|Rotarix and parenteral P2-VP8 subunit vaccine will be coadministered at 6 and 10 weeks of age, with an additional dose of P2-VP8 subunit vaccine administered at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
16302405|NCT04658901|Experimental|test group|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) made by Acotec Scientific Co.,Ltd.
16302406|NCT04658901|Active Comparator|control group|use the ClosureRFG™ and ClosureFast™ made by Medtronic Inc.
16302407|NCT04658888|Experimental|Modified letter with self-sampling request card|This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening. They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house. The kit will include a pre-paid mailer so that it can be sent back to the lab for testing. The result will then be shared with the participant.
16302408|NCT04658888|No Intervention|Standard letter|Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
16302409|NCT04658875|Experimental|Spirulina maxima supplementation and exercise group|Supplementation with Spirulina maxima (4.5 g/d) with a systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
16302410|NCT04658875|Experimental|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) without exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
16302412|NCT04658875|Active Comparator|Control group|No systematic physical exercise program and No supplementation during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
16302413|NCT04658862|Experimental|TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with Cetrelimab.
16302414|NCT04658862|Active Comparator|Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy|Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 6 treatment weeks or gemcitabine intravenously twice weekly for 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray [Gy], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.
16302415|NCT04658849|Experimental|Pioglitazone Arm|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.
~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
16302416|NCT04658849|Placebo Comparator|Placebo Arm|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
16302417|NCT04658836|Experimental|Triamcinolone application|Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery
16302418|NCT04658823|Experimental|HOV-12020|Palm tocotrienols complex Oral softgel capsule (containing 285mg mixed tocotrienols and tocopherol)
16302419|NCT04658823|Placebo Comparator|PLACEBO|Placebo Oral Softgel capsule (each capsule containing vitamin E stripped soybean oil)
16302422|NCT04658784|Experimental|Intervention|Receives posterior colporrhaphy closure using standardized technique with 2-0 V-Loc 90TM, Medtronic
16302423|NCT04658784|Active Comparator|Control|Receives posterior colporrhaphy closure using standardized technique with conventional 2-0 PDS® Ethicon
16302424|NCT04658771|Experimental|All patients|"Patients will undergo MR-HIFU ablation procedure of OO under general anesthesia. Patients will be monitored for disease status and adverse events for 12 months following procedure. Patients with incomplete or partial response at 28 days after MR-HIFU will be permitted a second MR-HIFU procedure.
~If there is still incomplete pain relief without medication use by 28 days following the second MR-HIFU treatment, patients will be offered standard of care treatment with RFA and followed for one year."
16302425|NCT04658745|Experimental|iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
16302426|NCT04658745|Sham Comparator|Sham iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere, but with a sham coil (i.e., sham iTBS). After the sham stimulation, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
16302427|NCT04658745|Sham Comparator|iTBS to the ipsilesional primary motor cortex plus sham mirror therapy|"iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time, but with a covered mirror (e.g., sham mirror therapy).
~In the sham mirror therapy condition, the mirror is covered by a cloth and the participant is instructed to move both arms while looking at a cross mark on the covered mirror and imaging the analogous movements of the affected arm. The movement practice will involve 5 table-top tasks (same as mirror therapy) and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes."
16302428|NCT04658732|Experimental|Alprazolam (A group)|patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer.
16302429|NCT04658732|Experimental|Gabapentin (G group)|patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer.
16302430|NCT04658732|Experimental|Dexmedetomidine (D group)|Dexmedetomidine 0.25 µg/kg loading dose will be infused intravenously over 10 minutes through syringe pump before surgery in the control group (Prepared using Precedex vial 200mcg/2ml manufactured by Hospira Inc, Highway 301,Rocky Mount,NC 278001 USA)
16302431|NCT04658719|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
16302432|NCT04658719|Active Comparator|Standard Care|Foley catheter, uncoated
16302433|NCT04658706|Sham Comparator|Control|a physical activity prescription to be performed autonomously
16302434|NCT04658706|Experimental|Prehabilitation|They will receive a supervised exercise programat least 2 weeks before starting the conventional chemoradiotherapy treatment and concomitant
16302435|NCT04658706|Experimental|Rehabilitation|They will receive a supervised exercise programat 12 weeks after the first radiotherapy session, once standard treatment has finished
16302436|NCT04658693|Experimental|Multi contact electrode implant|"Ten subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.
~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
16302437|NCT04658680|Experimental|BCG available at first health facility contact|Infants living in catchment areas of HFs randomized to opening of BCG vial if just 1 eligible child is present.
16302438|NCT04658680|No Intervention|Usual availability of BCG at health facilities|Infants living in catchment areas of HFs randomized to BCG availability according to the per usual restricted vial opening policy aiming at reducing vaccine wastage. This entails that BCG vaccination is commonly only available on specific predefined days where a BCG vial will only be opened if several children are present.
16302439|NCT04658667|Experimental|Full dose IHV01 and A244|Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg). All injections, whether vaccine or placebo, will be given by IM administration into the quadriceps muscle at study Day 0.
16302440|NCT04658667|Experimental|Fractional dose IHV01 and A244|Participants will receive a fractional dose of IHV01 (approximately 60μg) and A244 (approximately 60μg). All injections will be given by IM administration into the quadriceps muscle at study Day 0.
16302441|NCT04658667|Experimental|Full dose IHV01 and A244 + ALFQ|Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg) plus ALFQ. All injections will be given by IM administration into the quadriceps muscle at study Day 0.
16302442|NCT04658667|Experimental|Fractional dose IHV01 and A244 + ALFQ|Participants will receive a fractional dose of IHV01 (approximately 60μg) and A244 (approximately 60μg) plus ALFQ. All injections will be given by IM administration into the quadriceps muscle at study Day 0.
16302443|NCT04658667|Placebo Comparator|Placebo|Saline will serve as a placebo for the trial. All placebo injection volumes will match the study injection volumes for the group in which a participant has been randomized. All injections will be given by IM administration into the quadriceps muscle at study Day 0.
16302444|NCT04658654|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 24 weeks
16302445|NCT04658654|Experimental|Roflumilast 50ug|Roflumilast (50 microgram) oral capsule, once daily for 24 weeks
16302446|NCT04658654|Experimental|Roflumilast 100ug|Roflumilast (100 microgram) oral capsule, once daily for 24 weeks
16302447|NCT04658641|Active Comparator|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
16302448|NCT04658641|Experimental|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse).
16302449|NCT04658615|Other|group with rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
16302450|NCT04658615|Other|group without rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
16302451|NCT04658602|Active Comparator|Direct composite restoration|Bulk-fill composite (Filtek bulk flow, 3M Espe ) will be used and covered using a nanohybrid copmosite (filtek XT, 3M Espe )
16302452|NCT04658602|Active Comparator|Preformed metal crowns|Preformed stainless-steal crowns cemented by glass ionomer lutting cement (ketac cem. 3M Espe )
16302453|NCT04658589|Experimental|Laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
16302454|NCT04658589|Active Comparator|Open distal gastrectomy|Open distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
16302455|NCT04658563|Experimental|Group 1: Yoga|High-density HY training; average 90-110 minutes, 2 sessions per week under the supervision of the physiotherapist, once a week as a home program, will be applied for a total of 8 weeks to the first group.
16302456|NCT04658563|No Intervention|Group 2: Control|Individuals in the second group will not included in any exercise training program
16302457|NCT04658550||Remote Weight Loss Behaviour Modification Program with Meal Replacements|This is the prospective study group who will receive 26-weeks of weight loss and maintenance counselling in a remote setting and a low-calorie meal replacement as part of their usual care.
16302458|NCT04658550||In Person Weight Bahaviour Modification Program with Meal Replacements|This is the retrospective study group who received 26-weeks of weight loss and maintenance counselling in person and a low-calorie meal replacement as part of their usual care.
16302459|NCT04658537|Active Comparator|Standard Arm|8 Gy / 1 Fraction
16302460|NCT04658537|Experimental|Single Fraction Dose Escalation|8Gy Planning Target Volume / 12Gy Clinical Target Volume +/- 14Gy Gross Tumour Volume / 1 fraction
16302461|NCT04658524||Chonic kidney disease stages 3, 4 and 5|Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2
16302462|NCT04658511|Experimental|Participants|Patients diagnosed with cubital tunnel syndrome who are being scheduled for a primary endoscopic cubital tunnel release by the principle investigator will be recruited
16302463|NCT04658498|Experimental|Usual Care (UC)|Intermittent spontaneous breathing periods
16302464|NCT04658498|Experimental|UC + High-intensity inspiratory muscle training (HI-IMT)|
16302465|NCT04658498|Experimental|UC + Low-intensity inspiratory muscle training (LI-IMT) (sham IMT)|
16302466|NCT04658485|Active Comparator|Active tDCS|
16302467|NCT04658485|Placebo Comparator|Sham tDCS|
16302468|NCT04658472|Experimental|SOC-Treated|"Part A: Eligible participants will receive BIVV020 for 24 weeks. Weeks 1-12 (overlap period): Participants will be administered BIVV020 with superimposing effects of standard of care (SOC) therapy; Weeks 13-24: BIVV020 administration.
~Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).
~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving BIVV020 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last BIVV020 dose (at approximately week 98)."
16302508|NCT04658212|Experimental|3D LCBDE group|
16302509|NCT04658212|Active Comparator|ERCP group|
16302469|NCT04658472|Experimental|SOC-Refractory|"Part A: Eligible participants will receive BIVV020 for 24 weeks.
~Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).
~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving BIVV020 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last BIVV020 dose (approximately week 98)."
16302470|NCT04658472|Experimental|SOC-Naive|"Part A: Eligible participants will receive BIVV020 for 24 weeks.
~Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).
~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving BIVV020 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last BIVV020 dose (approximately week 98)."
16302471|NCT04658459||Results at short term follow up|Functional and Radiological results at short-term follow up (one year at least)
16302472|NCT04658459||Results at middle term follow up|Functional and Radiological results at the last follow up of the patient (2 years at least)
16302473|NCT04658446|Experimental|Augmented Reality-Assisted Bonding|The quadrant of the upper arch that shall use the AR-assisted bonding method. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
16302474|NCT04658446|Active Comparator|Digitally-Asssited Indirect Bonding|The quadrant of the upper arch that shall use the digitally-assisted bonding method utilizing a 3D printed tray. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
16302475|NCT04658433|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 8 weeks.
16302476|NCT04658433|No Intervention|Control group|
16302477|NCT04658420|Experimental|Ketamine|One group will receive IV ketamine 0.5mg/kg infused over forty minutes
16302478|NCT04658420|Experimental|Ketamine + Music|One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music
16302479|NCT04658420|Experimental|Music|One hour of pre-planned music without ketamine
16302480|NCT04658420|No Intervention|Treatment as usual|No music nor ketamine given
16302481|NCT04658407||all patients diagnosed with a severe hepatic failure|Retrospective cohort using only data already entered in the Health data warehouse of the APHP (Public Paris Hospital)
16302482|NCT04658394|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.
16302483|NCT04658394|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
16302484|NCT04658381|Experimental|Genetic analysis|
16302485|NCT04658368||Control|Participants with a history of major limb amputation at the University of Wisconsin (UW) that did not undergo TMR
16302486|NCT04658368||Retrospective TMR|Participants with a history of major limb amputation that underwent primary or secondary TMR with attending plastic surgeon at UW
16302487|NCT04658368||Prospective Secondary TMR|Participants who are scheduled to undergo secondary TMR at the UW
16302488|NCT04658368||Prospective Primary TMR|Participants who are scheduled to undergo primary TMR at the UW
16302489|NCT04658355|Active Comparator|Povidone-Iodine|Povidone-iodine to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
16302490|NCT04658355|Experimental|Chlorhexidine Gluconate|Chlorhexidine gluconate to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
16302491|NCT04658342||Oral Cancer Patients|
16302492|NCT04658316||20-39Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
16302493|NCT04658316||40-59Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
16302494|NCT04658316||60-79Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
16302495|NCT04658316||20-39Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
16302496|NCT04658316||40-59Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
16302497|NCT04658316||60-79Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
16302498|NCT04658303||Pimonidazole|Single dose of 0.5 gm/m^2 of pimonidazole (approximately 13 mg/kg)
16302501|NCT04658264|Experimental|Treatment Arm|The Treatment group shall receive 2 Kg of the composite flour every week, sufficient for 21 chapattis, and shall eat chapattis made from this flour instead of their usual wheat flour chapattis. The participants shall continue to receive the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study.
16302502|NCT04658264|No Intervention|Control Group|This group shall receive only the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study. They will continue to eat their usual diet as before their enrollment. They shall however receive usual counseling on lifestyle modifications including diet
16302503|NCT04658251||Patients with an intronic variant unknown in a gene implicated in cone disorders.|
16302504|NCT04658238||Dry eye disease|Patients with dry eye disease
16302505|NCT04658238||Healthy controls|Healthy controls without dry eye disease
16302506|NCT04658225|Active Comparator|Solution 1|0.12% chlorhexidine
16302507|NCT04658225|Placebo Comparator|Solution 2|Saline solution
16302513|NCT04658173|Experimental|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
16302514|NCT04658173|Active Comparator|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1.5 to 2mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
16302515|NCT04658160|No Intervention|Control|None- normal care
16302516|NCT04658160|Experimental|Intervention/Tracking|This group will have access to the longitudinal tracking and intervention platform for Medicare Advantage patients. Members of this group's care team will have access to the longitudinal data on the platform and will be able to intervene if any red flags emerge (i.e. if a patient displays signs of depression on a patient reported outcome measure/survey)
16302517|NCT04658147|Experimental|Arm A - Nivolumab|Participants receive Nivolumab only.
16302518|NCT04658147|Experimental|Arm B - Nivolumab and Relatlimab|Participants receive Nivolumab and Relatlimab.
16302519|NCT04658134|Experimental|Glycine supplementation|Glycine supplementation
16302520|NCT04658121||Senior Living Facilities|Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
16302521|NCT04658121||Outpatient Healthcare Facilities|Adults attending outpatient healthcare in neighborhoods of selected research sites
16302522|NCT04658121||General Communities|Adults and children (>2 months of age) in neighborhoods of selected research sites
16302523|NCT04658095|Active Comparator|Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System|
16302524|NCT04658095|Active Comparator|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System|
16302525|NCT04658095|Active Comparator|Ab-interno implantation of iStent inject (2 microstents)|
16302526|NCT04658082|Other|Non invasive glucose monitor|Single arm. All subjects will have glucose levels measured both by non invasive glucometer and by core lab
16302527|NCT04658069||One Cohort receiving routine hemodialysis therapy without any specific interventions|all HD patients enrolled in this study
16302528|NCT04658056||WATER AQUABEAM Robotic System cohort|WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.
16302529|NCT04658056||WATER TURPS cohort|WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.
16302530|NCT04658043|Experimental|ASD Intervention Group|Participants in the ASD intervention group will receive training to help children improve socioemotional functioning.
16302531|NCT04658043|No Intervention|Wait List Control Group|Participants in this group will be placed on the wait list and receive the ASD intervention training 2 months after the other groups
16302532|NCT04658030|Experimental|VR 360 video surgery preparation|Preparing pediatric patients for surgery with a newly developed VR 360 degree video. Maximum 30 minutes, one time.
16302533|NCT04658030|Active Comparator|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
16302534|NCT04658017|Experimental|GARNET device|All enrolled subjects will receive treatment with the GARNET device.
16302535|NCT04658004|Experimental|Administration of NKG2D CAR T-cells|
16302538|NCT04657978||Substrate guided intervention arm|Participants recruited to the study will undergo High Density Wave Solution™ guided substrate mapping of the left atrium. Ablation will thereafter be performed to comprise wide area circumferential ablation of the pulmonary veins in pairs, followed by ablation of low voltage zones in the left atrium.
16302539|NCT04657965|Experimental|Administration of LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
16302540|NCT04657952|Active Comparator|Standard medical Treatment (paracetamol)|Patients will receive paracetamol 1 gm every 6 hours daily intravenously for a day.
16302541|NCT04657952|Experimental|Sphenopalatine block|Patients will receive sphenopalatine block
16302542|NCT04657939|Active Comparator|Liraglutide-Pioglitazone|Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
16302543|NCT04657939|Active Comparator|Pioglitazone-Liraglutide|Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.
16302544|NCT04657926|Experimental|APPA|"APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) & 2-hydroxy-4-methoxyacetophenone (2H4MA) administered to 75 participants as 2 x 400mg capsules b.d. for 28 days
~."
16302545|NCT04657926|Placebo Comparator|Placebo|2 capsules b.d. for 28 days
16302546|NCT04657913|Experimental|cold water spray group|application of cold water in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
16302547|NCT04657913|Experimental|cold saline spray group|application of cold 0.9% SF (saline) in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
16302548|NCT04657913|No Intervention|control group|no intervention
16302549|NCT04657900||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
16302550|NCT04657874|Active Comparator|Bromelain and Escin|
16302551|NCT04657874|Placebo Comparator|Placebo|
16302552|NCT04657861|Experimental|Administration of APRIL CAR T-cells|Each subject receive APRIL CAR T-cells by intravenous infusion
16302553|NCT04657848|Experimental|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
16302554|NCT04657835|Experimental|Coronary Artery Bypass Grafting|"Patient with indication of Coronary Artery Bypass Grafting will be included. They will have:
~before surgery : cardiac Magnetic Resonance Imaging (MRI), Blood sample
~during surgery : Cardiac muscle biopsy
~after surgery : Holter-electrocardiogram (ECG), medical examination"
16302555|NCT04657822|Experimental|Crizanlizumab|All participants will receive crizanlizumab (SEG101) at the same dose/schedule as in the parent study.
16302558|NCT04657770|Experimental|Telerehabilitation|Patients will receive 36 treatment sessions over 6 weeks, consisting of 3 sessions/week that are supervised rehab therapy sessions (which begin with a 30-minute videoconference with the licensed OT or PT), alternating with 3 sessions/week of unsupervised rehab therapy sessions whereby the patient follows the instructions on the screen to engage in rehab therapy. Because patients sometimes miss a session, e.g., due to a conflict, we allow up to 8 weeks for patients to complete their 36 rehab therapy sessions.
16302559|NCT04657757|Experimental|Intraoral apparatus|intraoral apparatus in which two platelets of each of the 8 materials (Esteticor Lumina PF; Esteticor Lumina PF - after Lactic acid storage; Pagalinor 2; Esteticor Economic; Pekkton ivory - untreated; Pekkton ivory - rough; Oralloy; Machined Titan Zirconia (TiZr) alloy) are to be examined. Examination is a crystal violet OD595 staining (10 minutes). The color absorbed by the bacteria is then dissolved with a 30% acetic acid and measured spectrophotometrically at 595 nm. The plaque formed on the material surface is removed immediately after removal from the oral cavity and analyzed by determination of Colony Forming Unit (CFU) number.
16302560|NCT04657744|Experimental|A test|Test drug (Sphingomod ) 1 capsule contains 0.5 mg Fingolimod
16302561|NCT04657744|Active Comparator|B reference|Reference drug (Gilenya) 1 capsule contains 0.5 mg Fingolimod
16302562|NCT04657718|Other|All subjects|The KODEX-EPD system will be used in combination with leads to image during all procedures.
16302563|NCT04657705|Experimental|High power ablation|High power ablation parameters (50-55 W)
16302564|NCT04657705|Active Comparator|Standard ablation power|Standard ablation power parameters (40-45 W)
16302565|NCT04657679||African American/Black|Subject who self identify as African American or Black with metastatic HR+/HER2- advanced breast cancer (3 participants who are CYP3A5 poor metabolizers and 15 participants who are CYP3A5 intermediate or normal metabolizers)
16302566|NCT04657679||Non-Hispanic White|Subjects who self-identify as non-Hispanic White with metastatic HR+/HER2- advanced breast cancer (3 participants who are CYP3A5 poor metabolizers and 15 participants who are CYP3A5 intermediate or normal metabolizers)
16302567|NCT04657666|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Each spray delivers 100 microliters (μL) of nabiximols. Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
16302568|NCT04657666|Placebo Comparator|Placebo|"Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients.
~Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
16302569|NCT04657640|Experimental|weekly iron and folic acid supplementation (IFA)|
16302570|NCT04657640|Experimental|daily multiple micronutrient supplement (MMS)|
16302571|NCT04657640|No Intervention|control|
16302572|NCT04657627|Experimental|PACE plus calorie information intervention group|PACE plus calorie information intervention group will receive PACE plus calorie information of discretionary foods via social media posts.
16302573|NCT04657627|Active Comparator|Calorie-only information comparator group|Calorie-only information comparator group will receive calorie-only information of discretionary foods via social media posts.
16302574|NCT04657614|Experimental|Neutral Alignment Group|A straight pylon with the ankle at neutral.
16302575|NCT04657614|Experimental|Anterior Alignment Group|An anteriorly displaced pylon with ankle dorsiflexion at 5 degrees.
16302576|NCT04657614|Experimental|Posterior Alignment Group|A posteriorly displaced pylon with 5 degrees of plantarflexion at the ankle.
16302577|NCT04657601||Treatment Group|Patients undergo polypectomy facilitated by the study device.
16302578|NCT04657588|Experimental|Anal insert|This group will be asked to use anal inserts to help manage their faecal incontinence during the treatment period
16302579|NCT04657588|Sham Comparator|Care as usual|This group will be asked to continue with their care as usual (e.g. incontinence pads)
16302580|NCT04657575|No Intervention|ASTI|
16302581|NCT04657575|Active Comparator|Narcotrend|
16302582|NCT04657562||Kidney/Liver transplant recipients|"The group will consist of 110 adult (age > 18 years) male and female recipients of deceased kidney or liver transplant from the Regional Qualification Center (Warsaw, Poland).
~Additional 10% of patients will be included to the study to compensate for follow-up loss or blood samples destabilization (total N=121)."
16302583|NCT04657549|Active Comparator|Tonsillectomy|Patients will undergo tonsillectomy under general anesthesia within three weeks after enrollment.
16302584|NCT04657549|Active Comparator|Tonsillotomy|Patients will undergo tonsillotomy under general anesthesia within three weeks after enrollment.
16302585|NCT04657549|No Intervention|Watchful waiting|Patients will be closely monitored for the 5-6 months monitoring period.
16302586|NCT04657536|Experimental|TRF group|the group who treated with temperature controlled radiofrequency
16302587|NCT04657536|Active Comparator|Estriol group|the group who treated with promestriene vaginal soft capsules
16302588|NCT04657523|Experimental|Investigational Ultrasound Imaging for Liver Fat Quantification|
16302589|NCT04657510||Proximal femur fracture AND COVID-19|Surgical treatment of femur fracture
16302590|NCT04657510||Proximal femur fracture NO COVID|Surgical treatment of femur fracture
16302614|NCT04657367||Diabetes|Patients with diagnosed diabetes
16302591|NCT04657497|Experimental|FOY-305 group|Camostat Mesilate tablets 600 mg will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
16302592|NCT04657497|Placebo Comparator|Placebo group|Placebo tablets will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
16302593|NCT04657484|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 2 weeks, 10 mg/day for 2 weeks
16302594|NCT04657484|Active Comparator|Low dose prednisolone|A dose of 10 mg/day of prednisolone will be administered for 6 weeks
16302595|NCT04657471|Experimental|revised HOMe-CoV|Revised HOME-CoV
16302596|NCT04657445||home-quarantined patients|home-quarantined patients
16302597|NCT04657445||inhospitalized patients|inhospitalized patients
16302598|NCT04657432|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302599|NCT04657432|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302600|NCT04657432|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302601|NCT04657432|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302602|NCT04657432|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302603|NCT04657432|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302604|NCT04657432|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302605|NCT04657432|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302606|NCT04657432|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302607|NCT04657432|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302608|NCT04657432|Experimental|Study 2: 10 Active Doses|All participants will be assigned to 10 sessions (per treatment day) of accelerated rTMS for 5 treatment days. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 active sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16302609|NCT04657419||Participant|Patient or health professional coming to the Bordeaux University Hospital screening center for COVID-19 screening
16302610|NCT04657393|Active Comparator|Alternative Ventilation Rate|ventilation is performed at 20 breaths/min
16302611|NCT04657393|Active Comparator|Conventional Ventilation Rate|ventilation is performed at 10 breaths/min
16302612|NCT04657380|Active Comparator|Usual case management practices|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network of caring and non-caregiving professionals, working together with a view to the successful recovery of the patient. The patient and his or her family are at the center of care and receive proposals for psychoeducation and support throughout the different phases of the illness. This is concomitant with a regular evaluation of patients in order to update the care offer according to their clinical needs.
16302613|NCT04657380|Experimental|Mobile case-management application|"The intervention tested will be a mobile application used during consultations involving the patient and the case manager to define care objectives. The mobile application to be evaluated will result from the process of a co-design phase based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers. These stakeholders will define the content and form of the smartphone application during co-building workshops.
~The main purpose of the final application will be to assist in the definition of patients' goals using an approach rooted in recovery theory, with the monitoring of goal achievement in three phases : 1) defining priorities for the patients, through a recovery oriented discussion with the patient and the case manager 2) Setting the concrete objectives and list concrete actions tho achieve them 3) evaluating the achievements."
16302615|NCT04657367||Prediabetes|Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance
16302616|NCT04657367||Normoglycemia|Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance
16302617|NCT04657354|Active Comparator|Fast track|Study subjects in Fast Track arm will get an MRI done on the same day. If the MRI shows concordant findings of herniated disc, the subject will be referred to a spine surgeon to be seen within one week. If the surgeon and subject decide on discectomy, the surgery is scheduled within the same week. Total timespan from first interview to surgery will be no longer than 2 weeks.
16302618|NCT04657354|No Intervention|Usual care|"Study subjects in Usual Care will be treated following the Danish National Guidelines in which a conservative approach for the first 4-6 weeks with focus on pain relief by pain-relief medication, exercises and encouragement to resume normal activities as much as possible. Patients in this arm will be scheduled 2 and 4 week follow-up appointments as per national guidelines.
~If the symptoms have not resolved after this period, then a referral to a multidisciplinary spine care department is made. However, if symptoms are still present at 8-12 weeks first then a referral for a spine surgeon assesment can be done."
16302619|NCT04657315|Other|The investigational drug into the Intratumoral administration|The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery
16302620|NCT04657302|Experimental|R/R DLBCL|Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
16302621|NCT04657289|Experimental|Arm A [Q36W] 36-weeks between refill-exchange procedures|Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.
16302622|NCT04657289|Active Comparator|Arm B [Q24W] 24-weeks between refill-exchange procedures|Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.
16302623|NCT04657276||Down Syndome|Infants with Down Syndrome
16302625|NCT04657250|Experimental|Smoking cessation + quitline linkage text messages|Text messaging for smoking cessation + text messages with proactive linkage to quitline
16302626|NCT04657250|Placebo Comparator|Passive quitline referral|Single text message with contact information for the Quitline
16302627|NCT04657237|No Intervention|control group|all patients will receive general anesthesia and will receive intravenous paracetamol (1 g) before skin closure and then given every 6 hrs in the 1st postoperative day
16302628|NCT04657237|Active Comparator|TPVB group|Patients will receive total volume (20 ml) 0.25% bubivicaine divided equally at each level of T4 and T6 at thoracic paravertebral space then they will recive general anesthesia.
16302629|NCT04657224|Experimental|Part A: Dose escalation: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.
16302630|NCT04657224|Experimental|Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
16302631|NCT04657211||Group A|Participants will receive treatment from settled general practitioners (GPs) (GPs, primary care, practitioner/registered doctor).
16302632|NCT04657211||Group B|Participants will receive treatment from settled pulmonologists (specialists, primary or secondary care).
16302633|NCT04657211||Group C|Participants will receive treatment at outpatient lung centers (clinics, ambulances, acute care centers).
16302637|NCT04657185||Before OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place but without OR PathTrac feedback optimization.
16302638|NCT04657185||After OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place AND OR PathTrac feedback optimization.
16302639|NCT04657172|Experimental|Pilocarpine 1% Solution|1% pilocarpine ophthalmic solution administered with the Optejet dispenser
16302640|NCT04657172|Experimental|Pilocarpine 2% Solution|2% pilocarpine ophthalmic solution administered with the Optejet dispenser
16302641|NCT04657172|Placebo Comparator|Placebo Solution|Placebo ophthalmic solution administered with the Optejet dispenser
16302642|NCT04657159||2010-2016|Patients treated 2010-2016
16302643|NCT04657159||2017-2019|Patients treated 2017-2019
16302644|NCT04657146||Patients with suspected newly-diagnosed Glioblastoma (GBM)|Patients, ≥18 years of age, with newly diagnosed GBM, World Health Organization (WHO) Grade IV, undergoing gross total resection (defined as >90% of contrast enhancing volume removed on post-operative MRI) and collection of blood, bone marrow, and tumor.
16302645|NCT04657133|Experimental|Intervention group|Subjects in the intervention group will receive remote ischemic conditioning and standard background medical treatment.
16302646|NCT04657133|Placebo Comparator|Sham group|Subjects in the placebo group will receive sham remote ischemic conditioning and standard background medical treatment alone.
16302647|NCT04657120|Experimental|YEARS algorithm|Patients randomized to this arm will be evaluated according to the YEARS algorithm.
16302648|NCT04657120|Active Comparator|CTPA as single test|Patients randomized to this arm will undergo a contrast enhanced CTPA.
16304460|NCT04644536||Wedges in long bone & extremities|Osteotomies with fixation
16302649|NCT04657107|Placebo Comparator|Saline group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous normal saline before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
16302650|NCT04657107|Experimental|K1 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.2mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
16302651|NCT04657107|Experimental|K2 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.3mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
16302652|NCT04657094|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with acalabrutinib may be continued beyond 12 cycles for a maximum of 36 cycles if, in the opinion of the treating physician, the patient might benefit from ongoing therapy.
16302653|NCT04657081|Experimental|Oral administration of ASTX727 and venetoclax combination|"Cycle 1: ASTX727 according to a prescribed dosing regimen and venetoclax on day 1 (100 mg daily), day 2 (200 mg daily), and days 3-28 (400 mg daily) of a 28-day cycle.
~Cycle 2 and beyond: ASTX727 according to a prescribed dosing regimen and venetoclax on days 1-28 (400 mg daily) of a 28-day cycle."
16302654|NCT04657068|Experimental|Part A1|Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21 day cycles. Up to 68 participants will participate in this dose escalation arm.
16302655|NCT04657068|Experimental|Part A2|Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 12 participants will participate in this dose escalation arm.
16302656|NCT04657068|Experimental|Part B1|Part B1 will evaluate ART0380 monotherapy in up to 40 participants with solid cancers that fail to express ATM (ataxia-telangiectasia mutated) protein.
16302657|NCT04657068|Experimental|Part B2|In Part B2, up to 60 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open-label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.
16302658|NCT04657055|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
16302659|NCT04657042||Healthy|Healthy volunteers from the local community
16302660|NCT04657042||Liver cancer|Patients undergoing radiotherapy for liver cancer
16302661|NCT04657042||Lung cancer|Patients undergoing radiotherapy for lung cancer
16302662|NCT04657029|Experimental|Treadmill condition|The intervention condition consisted of a single session of moderate-high intensity aerobic exercise (65% of heart rate reserve) for 30 minutes walking on a standard treadmill. The single treadmill session included a progressive increase in intensity to reach the target heart rate (approx. 5 mins) as well as a cooling down period (approx. 5 mins). The warm-up and cool-down were included as part of the total 30 minutes of walking exercise. Target heart rates were calculated using the Karvonen method [25] with levels adjusted for those taking heart rate lowering medications (i.e. beta blockers), following methods previously published in post stroke populations [26, 27]. Participants were asked to self-rate their intensity of exercise every 10 minutes verbally using BORG's 6-20 scale rating of perceived exertion [28]. Participants were instructed to walk at a pace that resulted in a rating between 11 (fairly light) and 14 (somewhat hard) on the scale.
16302663|NCT04657029|Other|Control condition|The control condition involved an equivalent time period (30 minutes) of seated resting where participants were provided with an education session about the impact and effects of stroke by the same research assistant.
16302664|NCT04657016|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
16302665|NCT04657016|Placebo Comparator|Placebo|Administered SC
16302669|NCT04656990|Experimental|Gross motor and social-emotional integrated intervention group|Participants will receive a nine-month intervention which focuses on gross motor skills, physical activity, and social-emotional skills.
16302670|NCT04656990|No Intervention|Control|Participants will receive the center's everyday business as usual curriculum.
16302729|NCT04656535|Experimental|AB122 + AB154 Safety Cohort (Cohort A)|Eligible patients will be sequentially enrolled to receive intravenous AB154 combined with AB122 (N=6). AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat).
16302671|NCT04656977|Active Comparator|VR+TAU|Participants will participate first to a VR-based intervention and then to the TAU condition. The TAU condition is a homogenous standard program proposed by the Centre d'études et de recherché en intervention familiale (CERIF) at Université du Québec en Outaouais (UQO) based on group counseling offered to women and men who experienced a perinatal loss.
16302672|NCT04656977|Active Comparator|TAU+VR|Participants will be invited first to participate to the TAU condition and then to the VR-based intervention.
16302673|NCT04656964|Experimental|Remimazolam Tosilate group|Patients received remimazolam tosilate to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.4 ug/kg of remifentanil for 1 min during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
16302674|NCT04656964|Active Comparator|Midazolam group|Patients received midazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.4 ug/kg of remifentanil for 1 min during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
16302675|NCT04656951|Experimental|Daratumumab added to VCd in induction, Vd in maintenance and Rd at relapse|"Daratumumab at standard dose of 1800 mg will be administered subcutaneously at weekly intervals in cycles 1-2 and every 2 weeks in cycles 3-6 and every 4 weeks in cycles 7-8 together with VCD using bortezomib weekly s.c. for 8 cycles of 28 days each, cyclophosphamide i.v. at 500 mg/m2 on d1 of every cycle and dexamethasone p.o. at 20 mg per week.
~Maintenance will be daratumumab subcutaneously every 4 weeks with bortezomib s.c. and dexamethasone 20 mg every 2 weeks until progression or intolerance.
~At relapse/progression treatment will be daratumumab 1800 mg subcutaneously weekly during cycle 1-2, every 2 weeks in cycle 3-6 and every 4 weeks thereafter together with lenalidomide 25 mg p.o. day 1-21 and dexamethasone 20-40 mg weekly."
16302676|NCT04656925|Experimental|Contingency management A-B-A|All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods.
16302677|NCT04656912||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
16302678|NCT04656899|Active Comparator|Pillsy arm|Participants in the Pillsy arm will receive a prescription for buprenorphine-naloxone with an ''active'' Pillsy smart cap that will continuously collect data on pill bottle openings, missed doses, text messages sent, automated phone calls made. A participant who misses an entire day of buprenorphine-naloxone will automatically receive a survey about cravings and risk of relapse.
16302679|NCT04656899|No Intervention|Service as usual arm|Participants in the Service As Usual arm will receive a prescription for buprenorphine-naloxone with an ''inactive'' Pillsy smart cap that will track openings but will not provide reminders or any other messaging. They will receive a basic application that can deploy patient satisfaction surveys.
16302680|NCT04656886|Experimental|Ketalar|0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.
16302681|NCT04656886|Placebo Comparator|Saline|Single, intravenous, steady state infusion over 40min.
16302682|NCT04656873||ICI treatment|Adult cancer patients starting ICI monotherapy or combination therapy at UNC Chapel Hill per clinical standard of care and willing to allow specimens from surplus tissue to be banked for research purposes (in the case of resections) AND willing to have additional specimens taken for research purposes (in the case of biopsies). Patients will be followed for samples and clinical data from medical records from before starting ICI therapy until 2 years after the end of ICI treatment.
16302683|NCT04656860|Experimental|Juice Plus+|Participants will consume 6 capsules daily consisting of a combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend and Juice Plus+ Berry Blend. Participants will consume supplements for 24-months.
16302684|NCT04656860|Placebo Comparator|Placebo|Participants will consume 6 capsules daily consisting of microcrystalline cellulose, rice starch, vegetarian capsule (cellulose), and magnesium stearate. Participants in this condition will receive 1-year of supplements after the study is completed.
16302685|NCT04656834||Hand incision closure type 1|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: buried monocryl sutures and skin glue
16302686|NCT04656834||Hand incision closure type 2|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: simple nylon sutures
16302687|NCT04656821|Active Comparator|Control Group|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
16302688|NCT04656821|Experimental|Erector Spinae Block (ESB) group|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
16302689|NCT04656821|Experimental|Thoracic Paravertebral Block group|Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography
16302690|NCT04656808|Experimental|Guilt focused intervention|Following literature on factors associated with guilt experiences in caregivers (Gonyea et al., 2008; Gallego-Alberto et al., 2019; Losada et al., 2014; Prunty & Foli, 2019; Romero-Moreno et al., 2014; Spillers et al., 2008) and previous intervention studies testing an Acceptance and Commitment Therapy intervention for dementia family caregivers (Losada et al., 2015; Márquez-González et al., 2020), a guilt focused intervention was specifically designed for caregivers who experienced high levels of guilt and emotional distress. The program is based on CBT (Márquez-González et al., 2007) and Acceptance and Commitment Therapy (ACT) approaches (Losada et al., 2005; Márquez-González et al., 2010), combined with techniques of Compassion-Focused Therapy (CFT; Gilbert, 2009), which were adapted to work with guilt experienced by family dementia caregivers.
16302780|NCT04656210||Group 2: MD type 1 Diabetes|"patients with type 1 myotonic dystrophy with diabetes. Patients with carbohydrate intolerance (pre-diabetes) who became diabetic at 3 years of age will be divided into Group 2."
16302691|NCT04656808|Active Comparator|Cognitive behavioral therapy|Following the cognitive behavioral model adapted to caregiving (Losada et al., 2006) and considering other previous CBT intervention studies with dementia caregivers (Gallagher-Thompson et al., 2003), a CBT intervention developed and tested for dementia family caregivers (Márquez-González et al., 2007) was used for this study. Specifically, this intervention consists of different components that are described in more detail in Losada et al. (2011) and Márquez-González et al. (2007): a) a cognitive restructuring module aimed at modifying caregivers' dysfunctional thoughts about caregiving into other, more appropriate thoughts which promote the use of more adaptive coping strategies for caregivers; b) increasing pleasant activities or behavioral activation; c) asking for help skills; and d) relaxation techniques for reducing physiological activation.
16302692|NCT04656795|Experimental|Subjects with severe renal impairment|
16302693|NCT04656795|Experimental|Subjects with normal renal function|
16302694|NCT04656795|Experimental|Subjects with moderate renal impairment|
16302695|NCT04656795|Experimental|Subjects with mild renal impairment|
16302696|NCT04656782||Expert panelists|Expert panelists will be recruited from EORTC Imaging Group, EORTC GI Group, ESOI and ESGAR and will actively participate in the imaging survey rounds.
16302697|NCT04656782||Facilitators|The two central facilitators will moderate and guide the survey rounds. Blinded results will be forwarded to the expert panelists by the facilitators. Further Survey rounds will be adapted by the facilitators according to the previous answers given by the panelists.
16302698|NCT04656769||PERI group|
16302699|NCT04656769||EV group|
16302700|NCT04656756|Experimental|Experimental Group|The mothers in the experimental group (60) were administered.
16302701|NCT04656756|No Intervention|Control Group|The mothers in the control group (60) were given the routine care.
16302702|NCT04656743|Experimental|intra-articular injection group|will receive ultrasound guided intraarticular injection consisting of 20 mL of 0.25% bupivacaine before surgical procedure. The surgical procedure will be started 30 min after intraarticular injection.
16302703|NCT04656743|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% before surgical procedure. The surgical procedure will be started 30 min after genicular nerve block.
16302704|NCT04656730|Experimental|Study 1: Experimental: Study 2: Experimental|Iberogast® (STW5) or Iberogast® N (STW5-II) 20 drops TID per 14 days
16302705|NCT04656730|Placebo Comparator|Study 1: Comparator Study 2: Comparator|Placebo 20 drops TID per 14 days
16302706|NCT04656704|Experimental|Hyaluronidase 200mg monthly|Hyaluronidase 200mg monthly (Weeks 0, 4, 8, 12, 16, 20); for six doses; a 6-month treatment course with follow-up 1 month after
16302707|NCT04656691|Experimental|Participants with COVID-19|Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.
16302708|NCT04656678|Experimental|DynaCAD / UroNAV|This is a single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. UroNav is a stereotaxic accessory for image-guided interventional and diagnostic procedures of the prostate gland. It provides 2D and 3D visualization of Ultrasound (US) images and the ability to fuse and register these images with those from other imaging modalities such as Magnetic Resonance (MR), Computed Tomography, etc. It also provides the ability to display a simulated image of a tracked insertion tool on a computer monitor screen that shows images of the target organ and the current and the projected future path of the interventional instrument. DynaCAD 5.0 is an image analysis and planning system that will provide off station, pre planning and review of interventional study data. It interfaces with the Uronav 4.0 fusion guidance system.
16302709|NCT04656665|Experimental|75mg|Take 75mg of aspirin daily in tihis group
16302710|NCT04656665|Active Comparator|100mg|Take 100mg of aspirin daily in this group
16302711|NCT04656665|No Intervention|blank|Not taking aspirin in this group
16302712|NCT04656652|Experimental|DS-1062a 6.0 mg/kg|Participants will be randomized to receive 6.0 mg/kg of DS-1062a.
16302713|NCT04656652|Active Comparator|Docetaxel 75 mg/m^2|Participants will be randomized to receive 75 mg/m^2 docetaxel.
16302714|NCT04656626|Experimental|COVID19 Frontline Health Care Providers recieving mindfulness intervention|This arm will receive mindfulness audios (randomized and double blinded)
16302715|NCT04656626|Placebo Comparator|COVID19 Frontline Health Care Providers receiving progressive muscle relaxation|This arm will receive progressive muscle relaxation audios (randomized and double blinded)
16302716|NCT04656613|Experimental|Vaccine|a study group of 750 subjects receiving the Gam-COVID-Vac combined vector vaccine against the SARS-СoV-2-induced coronavirus infection
16302717|NCT04656613|Placebo Comparator|Placebo|a reference group of 250 subjects receiving placebo
16302718|NCT04656600|Experimental|Cerezyme® / Imiglucerase|Cerezyme® (imiglucerase for injection) is administered by intravenous infusion, 60 U/kg once every 2 weeks.
16302719|NCT04656587|Other|Standard Therapy (Control)|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
16302720|NCT04656587|Experimental|Standard Therapy plus BPAP|Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
16302721|NCT04656574|Experimental|Experimental Group|Experimental group received the course explaining vaginal delivery for the first timethat used simulation-based training.
16302722|NCT04656574|No Intervention|Control Group|Control group received the course explaining vaginal delivery for the first time
16302723|NCT04656561|Experimental|ANX007 Group 1|ANX007 administered every month
16302724|NCT04656561|Experimental|ANX007 Group 2|ANX007 administered every other month
16302725|NCT04656561|Sham Comparator|Sham Group 3|Sham injection administered every month
16302726|NCT04656561|Sham Comparator|Sham Group 4|Sham injection administered every other month
16302727|NCT04656548||HydroPICC|Cohort who received the HydroPICC
16302728|NCT04656548||Standard of Care|Cohort who received something different than HydroPICC
16302781|NCT04656197||Patients with dry eye disease|
16302782|NCT04656197||Healthy controls|
16302730|NCT04656535|Experimental|AB154 Surgical Cohort (Cohort B1)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.
~B1 (N=10): AB154 single agent (10 mg/kg) + placebo
~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
16302731|NCT04656535|Experimental|AB122 Surgical Cohort (Cohort B2)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.
~B2 (N=10): AB122 single agent (240 mg) + placebo
~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
16302732|NCT04656535|Experimental|AB154 + AB122 Surgical Cohort (Cohort B3)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.
~B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg)
~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
16302733|NCT04656535|Experimental|Placebo Surgical Cohort (Cohort B4)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.
~B4 (N=10): Two placebo infusions
~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
16302734|NCT04656522|Experimental|Participatory Comic Intervention|This is a pre-test/post-test trial, therefore all participants will participate in the participatory comic intervention.
16302735|NCT04656509|Experimental|4-s sprint inertial load training|Participants trained three times a week for eight weeks following the training program consisting of 30 bouts of 4s all-out cycling on an inertial-load ergometer with progressively decreasing recovery time (30 to 24 to 15s).
16302736|NCT04656496|Experimental|NOURISH-T+|NOURISH-T+ targets parents as agents of change by providing intensive parent skills training emphasizing role modeling of positive health behaviors to foster the development of healthy eating and physical activity in pediatric cancer survivors. The NOURISH-T+ group will have 6 weekly, 1-1.5 hour, manualized sessions delivered using video-conferencing. There will be 2 additional brief sessions where the child will participate along with their parent to promote child engagement. Additionally, there will be one session with a pediatric oncology dietician based out of Nicklaus Children's Hospital who will discuss personalized nutritional strategies. Brief booster sessions at 2-, 4-, 8-, and 10- months will maximize retention and follow-up participation. NOURISH-T+ content is theory-based, manualized, and builds upon strengths of our prior work with NOURISH-T (our pilot) and NOURISH (our work with otherwise healthy overweight and obese children).
16302737|NCT04656496|Active Comparator|EUC - Brief NOURISH-T+|The EUC condition (Brief NOURISH-T+) engages parents in one information session moderated by a USF-based interventionist using videoconferencing. Session content is taken from the publicly available We Can! Manual. Parents in this group will receive nationally available web-based brochures on pediatric overweight/obesity on two occasions during the 6 weeks that NOURISH-T+ families participate in the study. Check-ins will take place at 2-, 4-, 8-, and 10- months post-intervention.
16302738|NCT04656483|Experimental|Telemedicine Video Feedback Arm|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
16302739|NCT04656483|Active Comparator|Psychoeducational booklet arm|Mothers assigned to condition B will receive an informative booklet addressing the same themes discussed in the experimental intervention (i.e., responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant or specific parenting challenges.
16302740|NCT04656470|Experimental|Dexmedetomidine, Then Ketamine|On the first study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.7mcg/kg/hr will be maintained for an additional 20-30 minutes. On the second study visit, patients will be delivered ketamine anesthesia. 0.5mg/kg of ketamine solution will be infused gradually over 10 minutes and then up to 0.5mg/kg/hr will be maintained for an additional 20-30 minutes.
16302741|NCT04656470|Experimental|Ketamine, Then Dexmedetomidine|On the first study visit, patients will be delivered ketamine anesthesia. 0.5mg/kg of ketamine solution will be infused gradually over 10 minutes and then up to 0.5mg/kg/hr will be maintained for an additional 20-30 minutes. On the second study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.7mcg/kg/hr will be maintained for an additional 20-30 minutes.
16302742|NCT04656457|Active Comparator|resistance exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting) three times daily and five times per week. The 1 repetition maximum (1RM) is measured at baseline and following the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last 6 weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. Time of exercise equal time of rest
16302813|NCT04655963|Experimental|Dose 1|All participants would receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within a seven-day span. A single session=600 pulses at 120% rMT, iTBS triplets at 50 Hz for 2 s and repeated every 10 s for a total of 190 s to left dlPFC. Total pulses=14,400.
16302743|NCT04656457|Active Comparator|aerobic exercise|Aerobic training (AT) program of submaximal intensity will include a 45-minute session five times per week under the supervision of the researcher. Aerobic exercise will consist of three phases: warm-up, training and cool down. At the beginning of exercise session, subjects will have a ten-minute warm-up. The warm up protocol will be slowly running on treadmill. Then, the warm-up phase will be followed by the training phase. At baseline, the training phase will be commenced with two 30- minute running on treadmill at 50% of their maximal heart rate (MHR) in the first week and increased to 70% MHR by the final week of training. By the end of exercise session, subjects will have a five-minute cool down. The cool down protocol will be slowly running on treadmill. The vital measures such as HR and blood pressure was monitored before patient left the department (Dimeo et al.,2016), maximum heart rate will be calculated using the formula: (HR Max =220- age)
16302744|NCT04656444||phone call to emergency department|
16302745|NCT04656431|Experimental|Hyperpolarized pyruvate (13C) Single Image (Cohort 1)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline
16302746|NCT04656431|Experimental|Hyperpolarized pyruvate (13C) Multiple Images (Cohort 2)|"Newly diagnosed PCNSL participants with planned treatment of standard high-dose methotrexate,temozolomide plus rituximab (MT-R) regimen
~Images using 13C will be performed both at baseline and after three cycles of standard induction chemotherapy. Participants in Cohort 2 will also have option to undergo an additional imaging at a later time if their cancer progresses."
16302747|NCT04656418|Experimental|CSL312|Subjects with C1-INH HAE receiving CSL312
16302748|NCT04656418|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
16302749|NCT04656405|Experimental|Online real-time CPR training program|Online real-time quality measurement and feedback video-based CPR training will be provided to participants
16302750|NCT04656405|Active Comparator|Online real-time CPR training without quality measurement program|Online real-time feedback video-based CPR training without quality measurement will be provided to participants
16302751|NCT04656405|Placebo Comparator|Conventional CPR training program|Conventional CPR training will be provided to participants
16302752|NCT04656392|Other|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
16302753|NCT04656366||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
16302754|NCT04656366||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
16302755|NCT04656353|Experimental|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online psychosocial program and the questionnaire and distress survey. They will be asked to use the website within two weeks and then to complete the questionnaire and distress survey after using it and mail them back in a self-addressed stamped envelope. The participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted.
16302756|NCT04656353|Experimental|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
16302757|NCT04656340|Active Comparator|Standard rehabilitative care (SC)|Twice weekly physical therapy, occupational therapy and pain psychoeducation
16302758|NCT04656340|Experimental|Complementary and Integrative Health (CIH) therapies in addition to Standard rehabilitate care (SC)|Twice weekly chiropractic, acupuncture, yoga and foam roller instruction, in addition to SC
16302759|NCT04656327||Non interventional group|Community-dwelling elders dependent for care
16302760|NCT04656314||Healthy participants aged 18 to 40|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
16302761|NCT04656314||Healthy participants aged 60 and above|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
16302762|NCT04656301|Experimental|Psilocybin|A single dose of Psilocybin 25mg p.o.
16302763|NCT04656288|Experimental|Formula A under fasted conditions - Part 1|
16302764|NCT04656288|Experimental|Formula B under fasted conditions - Part 1|
16302765|NCT04656288|Experimental|Formula B under fasted conditions - Part 2|
16302766|NCT04656288|Experimental|Formula C under fasted conditions - Part 2|
16302767|NCT04656288|Experimental|Formula D under fasted conditions - Part 2|
16302768|NCT04656288|Experimental|Formula B under fed conditions - Part 2|
16302772|NCT04656262|Experimental|Metronomic cyclophosphamide|Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
16302773|NCT04656262|Active Comparator|Doxorubicin|Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.
16302774|NCT04656249|Experimental|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
16302775|NCT04656236|Experimental|Intervention|3 hours of continuously intravenous infusion of 3-hydroxybutyrate.
16302776|NCT04656236|Placebo Comparator|Control|3 hours of continuously intravenous infusion of saline (NaCl).
16302777|NCT04656223||MF/IND/GLY Breezhaler® plus Propeller Health|patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label
16302778|NCT04656223||Other FDC therapy|patients receiving ICS+LABA+LAMA FDC therapy according to label
16302779|NCT04656210||Group 1: MD type 1 normal|patients with type 1 myotonic dystrophy with normal carbohydrate tolerance
16302783|NCT04656184|Experimental|KINERET|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature <38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
16302784|NCT04656184|Active Comparator|Intravenous Immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
16302785|NCT04656171|Experimental|Minor patients with Fanconi anemia|MRI of hands and forearm, neuropsychological and neuromotor tests
16302786|NCT04656171|Active Comparator|Minor controls|MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
16302787|NCT04656158|Experimental|Therapeutic horticulture|handling (gardening equipment) and gardening task (outdoor and greenhouse tasks)
16302788|NCT04656158|Active Comparator|Handiwork|Handling tasks (materials) and handiwork (manufacturing of piece of wooden furniture)
16302789|NCT04656145|Experimental|Chlorhexidine Gluconate Gel Dressing|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
16302790|NCT04656145|No Intervention|Standard of Care|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
16302791|NCT04656132|Experimental|Participants with cardiovascular disease or cardiovascular disease risk factors|Population We will recruit 59 males and females age > 18 being seen in the NYU Langone Center for Prevention of Cardiovascular Disease (4F). Participants have cardiovascular disease or cardiovascular disease risk factors.
16302792|NCT04656119||patients without irAEs or patients with good efficacy|
16302793|NCT04656119||patients with irAEs or patients with poor efficacy|
16302794|NCT04656106||Ryzodeg|Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.
16302795|NCT04656093|Experimental|Intervention|"Intervention group - Cognitive Restructuring, Motivational Interviewing, and Multi-Medication Adherence.
~The pilot intervention is comprised of three educational sessions for individual study patients, conducted by interventionist with a master's degree in psychology with cognitive behavioral therapy training. The topics addressed in the sessions are as follows:
~Review of COPD medication inhaler technique, psychoeducation on maladaptive beliefs and emotional response."
16302796|NCT04656093|Active Comparator|Control|Control group - Supportive counseling for comorbidity management
16302797|NCT04656080||transplant recipients <1year without AMR|20 recent transplant recipients (<1 year) without antibody-mediated rejection (AMR);
16302798|NCT04656080||3 months post-heart transplant with AMR|• 7 transplant recipients, at least 3 months post-transplant, with antibody-mediated rejection
16302799|NCT04656067|Active Comparator|Oxytocin(only)|oxytocin is given IV infusion 5-10 minutes before the start of skin incision in the Elective Cesarean Section
16302800|NCT04656067|Active Comparator|Tranexamic acid and Ethamsylate|Tranexamic acid and Ethamsylate are given IV slowly 5-10 minutes before the start of skin incision in the Elective Cesarean Section
16302801|NCT04656041|Experimental|FOLFOX/ nal-IRI|"Treatment will be administered on an outpatient basis.
~FOLFOX with nal-IRI for eight two-week cycles (16 weeks total)
~Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
~Surgery"
16302806|NCT04656002|Experimental|Paclitaxel, Ramucirumab + TEW-7197|"Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
~-Paclitaxel, Ramucirumab Intravenous (IV) Ramucirumab injection, provided as a single-use 500-mg/50-mL vial containing 10 mg/mL of product in histidine buffer, with disease progression, toxicity requiring discontinuation, or without interruption for any reason. After diluting to 8 mg/kg every 2 weeks, IV It is administered by infusion.
~Paclitaxel is administered at a dose of 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle, with disease progression, toxicity requiring discontinuation, or without interruption for any reason."
16302807|NCT04655989|Experimental|Routine first|Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).
16302808|NCT04655989|Experimental|Investigational first|Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).
16302809|NCT04655989|Other|VARRM sub-study|Following completion of the initial 8-week treatment, subject's were eligible to participate in the sub-study, VARRM. The total participation time for the VARRM sub-study was approximately 1.5 weeks.
16302810|NCT04655976|Experimental|Participants receiving cobolimab+dostarlimab+docetaxel|
16302811|NCT04655976|Experimental|Participants receiving dostarlimab+docetaxel|
16302812|NCT04655976|Active Comparator|Participants receiving docetaxel|
16304022|NCT04647513|Experimental|Art Filler Lips (very deep nasolabial folds)|Injection of Art Filler Lips in very deep nasolabial folds
16302814|NCT04655937|No Intervention|non-randomised no treatment arm|Participants who do not opt in to group support will only provide self-report data on their wellbeing and quality of life every 3 months for up to 12 months. Data collected through online survey platforms using validated questionnaires
16302815|NCT04655937|Experimental|randomised invite Acceptance and Commitment Therapy (ACT) Group|Only those who opt in to invites for group support will be randomised. Randomisation will occur once sufficient numbers have been recruited and in a 2:1 ratio (intervention: attention control). Participants in this arm will be invited to 8 weekly ACT-informed therapy sessions involving core values identification, mindfulness practices and committed action plans. There will be homework in between sessions.
16302816|NCT04655937|Active Comparator|randomised invite Social Support Group|Only those who opt in to invites for group support will be randomised. Randomisation will occur once sufficient numbers have been recruited and in a 2:1 ratio (intervention: attention control). Participants in this arm will be invited to 8 weekly group sessions involving social support activities. There will be homework in between sessions.
16302817|NCT04655924|Experimental|Active Intervention|Intervention delivered to patients by digital health platform.
16302818|NCT04655924|Active Comparator|Active Control|Intervention delivered to patients by digital health platform.
16302819|NCT04655911||ABO-101|Participants from prior interventional trials involving the administration of ABO-101.
16302820|NCT04655898|Experimental|Administration of [14C]CC-90001|A single oral dose of [14C]CC-90001, containing approximately 100 μCi of radioactivity, will be administered on Day1 under fasted conditions.
16302821|NCT04655885|Experimental|Optimization of cardiac flow by base water-electrolyte supply|Optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
16302822|NCT04655885|Other|Control arm|Increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
16302823|NCT04655872|Experimental|[14C]TPN171H|
16302824|NCT04655859||severe early childhood caries|
16302825|NCT04655859||healthy children|
16302826|NCT04655846|Active Comparator|Control group|Usual manage during prenatal control program
16302827|NCT04655846|Experimental|Intervention group|Educational intervention towards the maintenance of exclusive breastfeeding in the first six months in first pregnant adolescents enrolled in the prenatal control program
16302828|NCT04655807|Experimental|Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo subcutaneous (SC) injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to adalimumab or its biosimilar as SOC therapy.
16302829|NCT04655807|Experimental|Group 2: SOC Biological Therapy: Ustekinumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo SC injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to ustekinumab as SOC therapy.
16302830|NCT04655794||had >= grade 2 adverse reactions|
16302831|NCT04655794||had <2 frade 2 adverse reactions|
16302832|NCT04655781|Experimental|N-T group|ILM was peeled off from nasal retina to temporal retina.
16302833|NCT04655781|Experimental|T-N group|ILM was peeled off from temporal retina to nasal retina
16302834|NCT04655768|Active Comparator|Operative Arm|Radius fractures C1/C2 treated by palmar plate fixation
16302835|NCT04655768|No Intervention|Conservative Arm|Radius Fractures C1/C2 treated by cast fixation
16302837|NCT04655742|Experimental|single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
16302838|NCT04655716|Experimental|Sodium bicarbonate|Intravenous sodium bicarbonate infusion
16302839|NCT04655716|No Intervention|Standard care|Standard of care by the clinical team
16302840|NCT04655703|Experimental|Cohort 1|Cohort 1- Study group-Home discharge. Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
16302841|NCT04655703|No Intervention|Cohort 2|Cohort 2- Control group-Home discharge. Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
16302842|NCT04655703|Experimental|Cohort 3|Cohort 3- Study group-Transfer to an inpatient rehabilitation center. Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
16302843|NCT04655703|No Intervention|Cohort 4|Cohort 4- Control group-Transfer to an inpatient rehabilitation center. Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
16302844|NCT04655690|Experimental|NNC0471-0119|Participants randomised to NNC0471-0119
16302845|NCT04655690|Active Comparator|Faster aspart|Participants randomised to faster aspart.
16302846|NCT04655677|Experimental|Autologous EXP039 administered by intravenous (IV) infusion|Autologous EXP039 administered by intravenous (IV) infusion
16302847|NCT04655664|Experimental|Treatment Group|Men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders
16302848|NCT04655664|Active Comparator|Regularly Group|Subjects who consumed vitamin D supplements regularly, were pregnant, or were breastfeeding.
16302849|NCT04655651||Frailty|patients with a FRAIL Scale of 3 to 5
16302850|NCT04655651||Non-frailty|patients with a FRAIL Scale of 0 to 2
16302853|NCT04655625|Experimental|Group A (AG-0302-COVID19)|
16302854|NCT04655625|Placebo Comparator|Group A (Placebo)|
16302855|NCT04655625|Experimental|Group B (AG-0302-COVID19)|
16302856|NCT04655625|Placebo Comparator|Group B (Placebo)|
16302857|NCT04655599|Experimental|Olorinab, Then Placebo|Participants will first receive olorinab, followed by a washout period, and they then will receive placebo.
16302858|NCT04655599|Placebo Comparator|Placebo, Then Olorinab|Participants will first receive placebo, followed by a washout period, and they then will receive olorinab.
16302859|NCT04655586|Experimental|rNAPc2 Higher Dose|loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5
16302860|NCT04655586|Experimental|rNAPc2 Lower Dose|loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5
16302861|NCT04655586|Active Comparator|Heparin|heparin at either prophylactic or therapeutic doses per Standard of Care at Institution
16302862|NCT04655573||Patient Derived Micro-Organospheres (PDMO)|Subjects will undergo image-guided biopsy as a standard of care clinical biopsy from which extra tissue is taken for research purposes. Following the biopsy, a PDMO will be generated and they will receive a chemotherapy regimen as determined by their treating physician. PDMO are successfully generated, and the patient begins treatment with a hemotherapy backbone. A patient will be considered evaluable if pathology results are available from the biopsy.
16302863|NCT04655560||Women living with HIV|
16302864|NCT04655547|No Intervention|Control|The participants will follow the usual offered course on the outpatient clinic of Hammel Neurocenter. They wil anticipate in data collection three times in line with the intervention group.
16302865|NCT04655547|Experimental|Intervention|The participants will receive dietary guidance from an dietician, with focus on energy intake and food texture. This guidance will include two sessions on site and three phone meetings. The last on site meeting, will be concluding.
16302866|NCT04655534|Experimental|IMW Group|Patients who performed inspiratory muscle warm-up (IMW) before inspiratory muscle training (IMT)
16302867|NCT04655534|Experimental|Standart IMT Group|Patients who performed standard inspiratory muscle training (IMT) without inspiratory muscle warm-up (IMW) protocol
16302868|NCT04655521||COVID-19 patients|
16302869|NCT04655521||Healthy controls|
16302870|NCT04655521||Non-COVID-19 patients with respiratory tract infection|
16302871|NCT04655508|Experimental|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber
~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
16302872|NCT04655508|Placebo Comparator|placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
16302873|NCT04655495|Experimental|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
16302874|NCT04655495|Active Comparator|Balanced gluten free diet|Balanced gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients.
16302875|NCT04655482|Experimental|Treatment arm|"Patients treated with aflibercept (2.0ml/0.05cc) using treat-and-extend regimen.
~Three monthly loading injections followed by proactive treatment using treat-and-extend regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
16302876|NCT04655443||Control Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that maintained sinus rhythm will be assigned to Control."
16302877|NCT04655443||Afib Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that developed persistent atrial fibrillation will be assigned to Afib."
16302878|NCT04655430|Experimental|3-second SDF application|3-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302879|NCT04655430|Experimental|5-second SDF application|5-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302880|NCT04655430|Experimental|10-second SDF application|10-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302881|NCT04655430|Experimental|15-second SDF application|15-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302882|NCT04655430|Experimental|30-second SDF application|30-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302883|NCT04655430|Experimental|45-second SDF application|45-second application time of silver diamine fluoride (38% SDF) in arresting tooth decay (dental caries) in the primary teeth of preschool children.
16302884|NCT04655430|Experimental|60-second SDF application|60-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302885|NCT04655430|Experimental|120-second SDF application|120-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302886|NCT04655430|Experimental|180-second application time|180-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
16302887|NCT04655417|Experimental|INTERVENTION GROUP|SINGLE ARM OF PATIENTS WHO WILL RECEIVE SAME TREATMENT
16302888|NCT04655404|Experimental|Larotrectinib|Larotrectinib will be administered orally, twice daily, at 100 mg/m2 continuously on a 28-day cycle schedule.
16302889|NCT04655391|Experimental|Chapter 1 (glasdegib, decitabine, venetoclax)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.
~TREATMENT SEGMENT: Patients receive glasdegib PO QD on days 1-28,decitabine IV over 1 hour on days 1-5, and venetoclax PO QD on days 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16303238|NCT04652999|No Intervention|Passive Control Group|The participants in the Passive Control Group will not receive any intervention nor placebo session.
16302890|NCT04655391|Experimental|Chapter 2 (glasdegib, gilteritinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.
~TREATMENT SEGMENT: Patients receive glasdegib PO QD and gilteritinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16302891|NCT04655391|Experimental|Chapter 3 (glasdegib, bosutinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.
~TREATMENT SEGMENT: Patients receive glasdegib PO QD and bosutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16302892|NCT04655391|Experimental|Chapter 4 (glasdegib, ivosidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.
~TREATMENT SEGMENT: Patients receive glasdegib PO QD and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16302893|NCT04655391|Experimental|Chapter 5 (glasdegib, enasidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.
~TREATMENT SEGMENT: Patients receive glasdegib PO QD and enasidenib PO QD on days 1-28 .Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16302894|NCT04655378||Acute Rheumatoid Purpura|
16302895|NCT04655378||Rheumatoid Purpura in Remission|
16302896|NCT04655378||Controls|Without infection, inflammatory or auto-immune pathology
16302897|NCT04655365|Experimental|Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging Subjects|Enrolled subjects will receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL Injection followed by a single PET/CT scan acquired at 1-2 hours post-dosing. After initial 18F-DCFPyL PET/CT, the patients with positive 18F-DCFPyL PET/CT imaging will be treated with enzalutamide (160 mg po id) for M0CRPC disease within less than two weeks. 18F-DCFPyL PET/CT scan will then be repeated 90 days after the start of enzalutamide treatment.
16302898|NCT04655352||Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by MB40 intervention
16302899|NCT04655339|Experimental|Group-1|Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally. Remaining residual is injected into port incision sites.
16302900|NCT04655339|Experimental|Group-2|Bilateral abdominal Lap-TAP liposomal Bupivacaine (Exparel®) injection with 133mg (20ml) Exparel® plus bupivacaine 0.25% (30ml), plus 10ml of normal saline for a total volume of 60ml, injecting 30ml each side.
16302901|NCT04655339|No Intervention|Group-3|
16302902|NCT04655326|Experimental|Treatment Group|Each participant receives a customized probiotic based on the results of the test of their microbiota
16302903|NCT04655313|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
16302904|NCT04655300||Group 1|
16302905|NCT04655300||Group 2|
16302906|NCT04655300||Group 3|
16302907|NCT04655300||Group 4|
16302908|NCT04655300||Group 5|
16302909|NCT04655300||Group 6|
16302910|NCT04655274||RayOne Trifocal intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of RayOne Trifocal (Rayner IOL, Ltd.) intraocular lenses
16302911|NCT04655274||AcrySof IQ PanOptix intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Inc.) intraocular lenses
16302912|NCT04655261||Participants Treated With Venetoclax + Obinutuzumab|Participants will receive venetoclax (Venclexta) in combination with Obinutuzumab according to local label.
16302913|NCT04655235||patients with schizophrenia|200 patients with a DSM 5- diagnosis of schizophrenia
16302914|NCT04655235||healthy relatives of patients with schizophrenia|200 healthy relatives of the patients with schizophrenia
16302915|NCT04655235||healthy control subjects|healthy control subjects without relatives with mental disorders
16302916|NCT04655222||All Participants|Pregnant Multiple Sclerosis (MS) participants treated with SC interferon beta therapy or an IM interferon beta therapy in the German PSP of the MSSC.
16302917|NCT04655209|Experimental|M1-Seq group|
16302918|NCT04655209|Experimental|PMC-Seq group|
16302919|NCT04655209|Sham Comparator|MT with sham tDCS|
16302920|NCT04655196|Experimental|Internet-based self-help + weekly feedback by a coach|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text, audio and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly feedback by a coach.
16302921|NCT04655196|Experimental|Internet-based self-help + weekly automated messages|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text-, audio- and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly automated messages in order to increase motivation.
16302922|NCT04655196|No Intervention|Waiting control group|
16302923|NCT04655183|Experimental|Part 1A (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight < 77 kilograms (kg) or baseline platelet count < 150, 000 per cubic millimeter will be included in this Part. Dose escalation of M4344 administered along with niraparib.
16302924|NCT04655183|Experimental|Part 1B (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight > =77 kilograms (kg) and baseline platelet count >=150, 000 per cubic millimeter will be included in this Part. M4344 will be administered at a dose and schedule that was determined as the recommended dose for expansion (RDE) in Part 1A. Dose of niraparib will be escalated to the next higher dose level.
16302925|NCT04655183|Experimental|Part 2 (Dose expansion): PARPi resistant, Niraparib plus M4344|Participants with Poly(ADP-ribose) polymerase inhibitor (PARPi) resistant, germline breast cancer 1/2 mutated (gBRCA1/2m) human epidermal growth factor receptor 2 (HER2) negative advanced Breast Cancer (aBC) will receive the combination of niraparib and M4344 at the RDE which was determined in Part 1.
16302926|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive niraparib as a single agent.
16302927|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib plus M4344|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive the combination of niraparib and M4344 at the RDE as determined in Part 1 of this study.
16302928|NCT04655170|Experimental|Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin 175 μg once per day and Formoterol 20 μg twice per day via jet nebulizer for 7 days or until discharge if prior to day 7.
16302929|NCT04655170|Active Comparator|Group 2: Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care|Albuterol and Ipratropium every 6 hours nebulized over the 7-day treatment period or until discharge if prior to day 7.
16302930|NCT04655157|Experimental|Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab|Patients will be treated with 300mg encorafenib and 3mg/kg nivolumab and 1 mg/kg ipilimumab (triple therapy).
16302931|NCT04655157|Experimental|Phase 1 (cohort 2): 450mg encorafenib + 45mg binimetinib + 3mg/kg nivolumab + 1mg/kg ipilimumab|Patients will be treated with 450mg encorafenib, 45mg binimetinib, 3mg/kg nivolumab and 1mg/kg ipilimumab (quadruple therapy).
16302932|NCT04655144|Experimental|Dexamethasone Arm|A total of 5mg dexamethasone will be administered into each uterine artery (10mg total) prior to uterine artery embolization.
16302933|NCT04655144|Placebo Comparator|Saline Arm|A volume of normal saline, equal to the total volume delivered in the Dexamethasone Arm, will be administered into each uterine artery prior to uterine artery embolization.
16302934|NCT04655131|Active Comparator|Protein consumption : 0 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate
16302935|NCT04655131|Experimental|Protein consumption : 12.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate
16302936|NCT04655131|Experimental|Protein consumption : 25 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate
16302937|NCT04655131|Experimental|Protein consumption :37.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate
16302938|NCT04655131|Experimental|Protein consumption : 50 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate
16302939|NCT04655131|Experimental|Protein consumption : 62.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate
16302940|NCT04655118|Experimental|Arm 1a, Relapsed/Refractory Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
16302941|NCT04655118|Experimental|Arm 1b, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
16302942|NCT04655118|Experimental|Arm 2a, JAKi Intolerant Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
16302943|NCT04655118|Experimental|Arm 2b, JAKi Intolerant Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
16302944|NCT04655118|Experimental|Arm 3a, JAKi Ineligible Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
16302945|NCT04655118|Experimental|Arm 3b, JAKi Ineligible Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
16302946|NCT04655118|Experimental|Arm 1 Expansion, Relapsed/Refractory Myelofibrosis|TL-895 administered orally at RP2D and schedule
16302947|NCT04655118|Experimental|Arm 2 Expansion, JAKi Intolerant Myelofibrosis|TL-895 administered orally at RP2D and schedule
16302948|NCT04655118|Experimental|Arm 3 Expansion, JAKi Ineligible Myelofibrosis|TL-895 administered orally at RP2D and schedule
16302949|NCT04655105|Experimental|Truanatomy rotary file|use of tru anatomy rotary files root canal instrumentation followed by post operative pain evaluation
16302950|NCT04655105|Experimental|hyflex EDM rotary file|use of hyflex EDM rotary files root canal instrumentation followed by post operative pain evaluation
16302951|NCT04655105|Experimental|edge endo reciprocating rotary file|use of edge endo reciprocating rotary files root canal instrumentation followed by post operative pain evaluation
16302952|NCT04655105|Active Comparator|protaper gold rotary file|use of protaper gold rotary files root canal instrumentation followed by post operative pain evaluation
16302953|NCT04655092|Experimental|P1101 (Ropeginterferon alfa-2b)|Conventional treatment based on phlebotomies, lowdose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated prolineinterferon alpha-2b (P1101, Ropeginterferon alfa-2b) once every 2 weeks.
16302954|NCT04655079|Experimental|Real tDCS group|Participants receive anodal tDCS on the left dlPFC for 5 days/week for 2 weeks
16302955|NCT04655079|Sham Comparator|Sham group|Participants receive sham stimulation on the left dlPFC for 5 days/week for 2 weeks
16302956|NCT04655053|Active Comparator|Goal intention condition|"Participants in this condition are asked to form the goal condition: I will walk as fast as I can for as long as I can"
16302957|NCT04655053|Experimental|Implementation intention (behavior initiation) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if I do the task, then I will walk as much as I can!)"
16302958|NCT04655053|Experimental|Implementation intention (goal preference management) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if at this moment I prefer not to walk because of my pain (or fatigue; depending on person), then I will accept that I have this difficulty and I will walk as much as I can!)"
16302995|NCT04654754|Experimental|high-flow high humidity oxygen device with tracheostomy adapter|This device provides high-flow gas to tracheostomy patients with heat and humidification. A special adapter is used to connect the tracheostomy tube and circuit.
16303564|NCT04650711|Experimental|Study group|All eligible participants as one group accept P16INK4A testing, with cytology and/or hrHPV assay.
16302959|NCT04655040|Experimental|Caffeine and Ritlecitinib|"In Period 1 Day 1, participants will be dosed with a single oral administration of caffeine 100 milligram (mg) tablet.
~In Period 2 Day 1 to Day 7, participants will be dosed with a single oral administration of ritlecitinib 200 milligram (mg) tablet. On Day 8, participants will be dosed with caffeine 100 milligram (mg) tablet within 5 minutes after administration of a 200 milligram (mg) dose of ritlecitinib on the morning of Day 8. Dosing with oral 200 milligram (mg) ritlecitinib QD will continue until Day 9."
16302962|NCT04655014|Experimental|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
16302963|NCT04655001|Experimental|MORPH|Participants engage in 12 weeks of group and 1-on-1 coaching meant to promote physical activity throughout the day and caloric restriction. Participants engage with a custom smartphone application, use a smart scale and physical activity monitor, and meet using video conference software. At the end of 12 weeks, participants are provided with tools to continue meeting virtually on their own if desired, and will be followed for an additional 12-week maintenance phase.
16302964|NCT04655001|No Intervention|Control|This condition receives the wearable activity monitor and simply asked to use it and continue in their daily lives for 24 weeks.
16302965|NCT04654988|Experimental|Immunsuppression|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and Azathioprine: 2 mg/kg daily for 12 months
16302966|NCT04654988|Placebo Comparator|Placebo|placebo matching prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and placebo matching azathioprine: 2 mg/kg daily for 12 months
16302967|NCT04654962||patients receiving preoperative analgesic management with anesthetic block|This cohort includes all patients that received preoperative anesthetic block for hip fracture surgery as main analgesic management during the study period.
16302968|NCT04654962||patients receiving conventional preoperative analgesic management|This cohort includes all patients that received conventional preoperative analgesic management (oral, intravenous or intramuscular medication) for hip fracture surgery as main analgesic management during the study period.
16302969|NCT04654949|Experimental|Horticultural Therapy|The Horticultural Therapy group receives 30 minutes of horticultural therapy activities using mobile horticulture kits conducted by therapists or therapy assistants to engage participants at their bedside.
16302970|NCT04654949|No Intervention|Existing Care|The existing Care group receives 30 minutes of routine ward-based engagement leisure activities (e.g. watching television, reading newspapers, etc).
16302971|NCT04654936|Experimental|MIND diet with support|This intervention group are to follow the MIND diet guidelines for 12 weeks with the support of a 12 week online theory driven website and resources
16302972|NCT04654936|Experimental|MIND diet no support|This group are to follow the MIND diet guidelines with no website support
16302973|NCT04654936|No Intervention|Control|The group follow usual diet
16302974|NCT04654910|Placebo Comparator|Control|enrolled subjects that do NOT receive explanation of PROMIS measures during visit.
16302975|NCT04654910|Active Comparator|Intervention|enrolled subjects that DO receive explanation of PROMIS measures during visit.
16302977|NCT04654884|Active Comparator|Group 1|The participants in group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy) during 8 weeks.
16302978|NCT04654884|No Intervention|Group 2|Group 2, the control group, will receive TaU and will, just like goup 1, have a follow-up after 8 weeks.
16302979|NCT04654871|Experimental|Experimental Group|
16302980|NCT04654871|Experimental|Active Comparator Group|
16302981|NCT04654858|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used after infiltration or block anaesthesia for affected molar, following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
16302982|NCT04654858|Active Comparator|Performed metal crowns|PMCs (3M Espe, Seefeld, Germany) will be placed after infiltration or block anaesthesia for affected molar, followed by removal of carious dentin and enamel, Tooth preparation for fitting the crown, The correct size of crown will be chosen, and then Cemented with glass ionomer luting cement (KetacCem, 3M Espe).
16302983|NCT04654845|Experimental|Pulpotomy|Only the tissue in the pulp chamber will be removed.
16302984|NCT04654845|Active Comparator|Pulpectomy|Both the chamber´s and root´s pulp tissue will be removed up to a 25 gauge.
16302985|NCT04654819|No Intervention|Control group|This group made anesthesia application on patients without training on simulators.
16302986|NCT04654819|Experimental|Study group|This group made anesthesia application on patients after training on simulators.
16302987|NCT04654793|Experimental|Intervention group|Robot assisted inclined bed treatment and FES
16302988|NCT04654793|Active Comparator|Control group|conventional inclined bed treatment
16302989|NCT04654780|Experimental|tax on purchases|"exposed to high-price purchases of high in foods, including sugary drinks."
16302990|NCT04654780|Experimental|subsidies on purchases|exposed to purchases with prices that consider subsidies in fruits and vegetables.
16302991|NCT04654780|Placebo Comparator|Control|It will not be subjected to any intervention and therefore will buy with current or market prices.
16302992|NCT04654767||COPD-PH group|Patients with confirmed COPD and pulmonary hypertension
16302993|NCT04654767||IPF-PH|Patients with confirmed pulmonary fibrosis and pulmonary hypertension
16302994|NCT04654767||Control group|Control group without diagnosed COPD, IPF, or pulmonary hypertension
16303063|NCT04654221||Male, BMI >29|Male subjects with a BMI of greater than 29
16303064|NCT04654221||Female, BMI >29|Female subjects with a BMI of greater than 29
16302996|NCT04654754|Active Comparator|large-volume nebulizer (cool aerosol) with trach collar|This device is the conventional device that is commonly utilized to provide humidification for spontaneous breathing patients with tracheostomy.
16302997|NCT04654754|Placebo Comparator|Venturi-adapter with trach collar|This device did not provide any humidification but only oxygen
16302998|NCT04654754|Experimental|large-volume nebulizer (cool aerosol) with T-piece and a filter|this device is added with a filter, in order to reduce aerosol particle concentrations in the surrounding environment
16302999|NCT04654754|Experimental|high-flow high humidity device with a scavenger or a surgical mask|this device is added with a scavenger or a surgical mask over the adapter, in order to reduce aerosol particle concentrations in the surrounding environment
16303000|NCT04654741|Experimental|Progestin Primed ovarian stimulation Group|progestin 10 mg daily during ovarian stimulation
16303001|NCT04654741|Active Comparator|GnRH antagonist|GnRH antagonist 0.25 mg daily during ovarian stimulation
16303002|NCT04654728|Active Comparator|ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
16303003|NCT04654728|Other|Dacron graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
16303004|NCT04654715||Localized prostate cancer treatment induced rectourethral fistula|Every patient over 18 years old operated for closure of a rectourethral fistula with gracilis flap interposition after localized prostatic cancer treatment (Radiotherapy, surgery, cryotherapy and HIFU).
16303005|NCT04654689|Experimental|Intervention group|50 patients will be given the combination of resveratrol and curcumin liposomed with G04CB02, in a single daily dose for 6 months.
16303006|NCT04654689|Placebo Comparator|Control group|50 patients, who will receive a placebo with the same dosage pattern and for the same period of time. The placebo will consist of water with sucrose replacing the liposomal polyphenols, and a soft capsule of microcrystalline methylcellulose instead of G04CB02. Both the packaging and the capsule format will be identical to those of the treatment administered in the intervention group
16303007|NCT04654637|Experimental|Arm A|fix model of cycle exercise(online supervise) and routine nutrition consult
16303008|NCT04654637|Experimental|Arm B|fix model of cycle exercise(online supervise) and online nutrition consult
16303009|NCT04654637|Experimental|Arm C|individualize cycle exercise(online supervise) and routine nutrition consult
16303010|NCT04654637|Experimental|Arm D|individualize cycle exercise(online supervise) and online nutrition consult
16303011|NCT04654624|Experimental|Silver Diamine Fluoride|
16303012|NCT04654624|Active Comparator|Atraumatic Restorative Treatment|
16303013|NCT04654611|Other|Treatment group|The intervention will be preservative free tafluprost 0.0015% topical ophthalmic solution given once daily for the study duration.
16303014|NCT04654598|Other|BPA level|BPA (bisphenol A) in urine, blood and follicle fluid samples
16303015|NCT04654585|Experimental|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
16303016|NCT04654585|Active Comparator|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.
~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
16303017|NCT04654572|Experimental|burned group|burned patients
16303018|NCT04654572|Experimental|control group|sedentary people
16303019|NCT04654559|Other|Unobtrusive data collection|
16303020|NCT04654546|Experimental|Abdominal scans|Participants who performed an abdominal CT exam up to one month prior to the experimental ultrasound exam.
16303021|NCT04654533|Experimental|COSC|"Eight weekly manualized sessions of Circle of Security Classroom (COSC), delivered in groups, two hours per session, 5-10 childcare providers per group.
~COSC is facilitated by a psychologist who is a registered COSP facilitator and who has completed the an additional COSC online training."
16303022|NCT04654533|No Intervention|Control|"Usual care control condition, i.e., standard practice in the participating childcare centers.
~Teams of childcare providers are allocated to either COSC or waitlist in clusters, and baseline and follow-up measures are collected parallel in both groups. Childcare providers allocated to the waitlist will receive COSC after the follow-up data have been collected."
16303023|NCT04654520|Experimental|Drug therapy combined with radiotherapy for primary tumor omitted CTV|"IMRT (omitted CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.
~IMRT (omitted CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
16303024|NCT04654520|No Intervention|Drug therapy combined with radiotherapy for primary tumor with CTV|"IMRT (with CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.
~IMRT ((with CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
16303025|NCT04654507|Active Comparator|Adjuvant dexamethasone|Drug: Dexamethasone
16303026|NCT04654507|Placebo Comparator|Placebo|Drug: Placebo
16303027|NCT04654494||Chron's disease patients with colorectal cancer|This group of patients with Chron's disease have been diagnosed with colorectal cancer and treated surgically
16303028|NCT04654481|Active Comparator|Standard Care Plus Monitoring|All subjects will be monitored via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
16303029|NCT04654481|Experimental|Standard Care Plus Monitoring and HCFWO|In addition to home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments, subject will receive an Afflovest device for home use.
16303133|NCT04653714|Sham Comparator|Supragingival plaque/calculus removal|
16303565|NCT04650698|Experimental|Tranexamic acid (TXA)|IV TXA
16303030|NCT04654468|Experimental|Crovalimab|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
16303031|NCT04654442||Cases|30 cases will be recruited : Patient diagnosed by RT-PCR for a COVID19 at Grenoble University Hospital
16303032|NCT04654442||Controls|30 controls will be recruited : Patient suspected for a COVID-19 but negative by RT-PCR for a COVID19 at Grenoble University Hospital
16303033|NCT04654429|Placebo Comparator|Lower OT temperature with placebo (LP)|Lower OT temperature with placebo This group function as a main control arm. Incidence of PSS will be documented usual / standard OT temperature which is 17-19 degree celsius, and without giving any pharmacological intervention to prevent PSS.
16303034|NCT04654429|Active Comparator|Higher OT temperature with placebo (HP)|Higher OT temperature with placebo This group will receive one non-pharmacological intervention, which is higher OT temperature 19-22 degree celsius. The aim of this intervention is to reduce heat loss therefore incidence of PSS for obstetric population coming for lower segment cesarean section (LSCS) by reducing the temperature gradient between the body and environment.
16303035|NCT04654429|Active Comparator|Lower OT temperature with IV Ondansetron 4mg (LO)|Lower OT temperature with Ondansetron 4mg intravenous. This group also will receive one pharmacological intervention, which is IV ondansetron 4mg to prevent incidence of PSS under standard OT temperature 17-19 degrees.
16303036|NCT04654429|Active Comparator|higher OT temperature 19-22 and IV ondansetron 4mg (HO)|This group will receive 2 interventions - higher OT temperature 19-22 and IV ondansetron 4mg. This group is designed to see if when both intervention combined, will further reduce the incidence of PSS among obstetrics population.
16303037|NCT04654416||Steroids|Dexamethasone 6mg intravenous OD for seven to ten days
16303038|NCT04654416||Colchicine|Patients treated with colchicine at a dose of 0.5 mg every 12 hours for 7 to 14 days.
16303039|NCT04654403|Experimental|Camrelizumab|Camrelizumab (200 mg every 2 weeks),Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years)
16303040|NCT04654403|Active Comparator|Camrelizumab plus chemotherapy|Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
16303041|NCT04654390|Experimental|DWP16001 Amg, Dapagiflozin Bmg placebo|Tablets, Orally, Once daily
16303042|NCT04654390|Active Comparator|DWP16001 Amg placebo, Dapagliflozin Bmg|Tablets, Orally, Once daily
16303043|NCT04654377|Experimental|Personalised education|"Greetings
~Recording clinical/imaging data.
~Questionnaires administration.
~Explaining the disease and possible outcome in the context of clinical/lab/imaging data.
~Answering specific queries from patients and care givers."
16303044|NCT04654377|No Intervention|Standard communication|"Greetings
~Recording clinical/imaging data.
~Administration of questionnaire.
~Addressing general queries from patients and care givers."
16303045|NCT04654351|Experimental|TAK-667|TAK-667, single SC administration on the abdomen on Day 1. The dose of TAK-667 will be dependent on the participant's body weight (Up to 30 mg; 10 mg for 12 kg to 25 kg, 15 mg for 26 kg to 40 kg, 20 mg for 41 kg to 50kg, 25 mg for 51 kg to 65 kg, 30 mg for >65 kg).
16303046|NCT04654338|Experimental|Intervention Arm|
16303047|NCT04654325|Other|Patients attending to the COVID19 screening facility|Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan
16303048|NCT04654312|Experimental|Intervention|Intake of HCT 25 mg, 1 tablet/d for 15 days
16303049|NCT04654312|Placebo Comparator|Placebo|Intake of Placebo, 1 tablet/d for 15 days
16303050|NCT04654299||standard PD (ST-PD)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and standard hepaticojejunostomy
16303051|NCT04654299||PD with external biliary stent(PD-BS)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and hepaticojejunostomy with external biliary stent for externalization of bile fluid
16303052|NCT04654286|Active Comparator|Control group (Nerve transfer procedure)|Patient will receive nerve transfer procedure without augmentation
16303053|NCT04654286|Experimental|Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)|Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation
16303054|NCT04654260|Experimental|Behavioral Therapy for Irritability in Autism (BTIA)|BTIA consists of 15 ninety-minute weekly sessions that will be conducted with the teens and their parents by experienced therapists using a structured, detailed manual.
16303055|NCT04654260|Active Comparator|Psychoeducation and Supportive Therapy (PST)|PST consist of 15 weekly, ninety-minute sessions focused on learning about and discussing issues of diagnosis, treatment and educational services with an experienced therapist could be helpful to children on the autism spectrum and their families.
16303056|NCT04654247|Sham Comparator|Control group|Endoscopists in control group were informed standard quality indicators requirements and the corresponding references during informed consent.
16303057|NCT04654247|Experimental|Feedback group|Endoscopists in feedback group were informed standard quality indicators requirements and the corresponding references during informed consent. In addition to the quality requirements, endoscopists randomized to feedback group received customized quality reports feedback from Endo.Adm weekly.
16303058|NCT04654234||Total-body PET/CT (uExplorer)|Patients with locally advanced NSCLC will receive total-body PET/CT (uExplorer) scans before, during and after the treatment
16303059|NCT04654221||Male, BMI <= 24.9|Male subjects with a BMI of less than or equal to 24.9
16303060|NCT04654221||Female, BMI <= 24.9|Female subjects with a BMI of less than or equal to 24.9
16303061|NCT04654221||Male, BMI 25-29|Male subjects with a BMI of 25 to 29
16303062|NCT04654221||Female, BMI 25-29|Female subjects with a BMI of 25 to 29
16303065|NCT04654208||HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)|Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
16303066|NCT04654208||HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant|Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
16303067|NCT04654182|Experimental|Log reduction in bacterial count|Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
16303068|NCT04654169|Experimental|The IAI and SSNB group|Ultrasound-guided IAI and SSNB are planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
16303069|NCT04654169|Active Comparator|The only-IAI group|Ultrasound-guided IAI is planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
16303070|NCT04654156||Pathological group|Patients with pulmonary embolism on thoracic CT angiography
16303071|NCT04654156||Healthy group|Patients without pulmonary embolism on thoracic CT angiography
16303075|NCT04654130|Experimental|Neurofeedback (NFB)|Participants in the NFB condition will complete 19 weekly sessions of NFB from home with research staff supervision (via videoconferencing), and pre-, post- and 3-month follow-up assessments.
16303076|NCT04654130|No Intervention|Wait List|Participants in the Wait List condition will receive no NFB for approximately 31 weeks, and will be asked to complete pre-, post- and 3-month follow-up assessments. After study completion, they will be offered the same 19 weeks of NFB.
16303077|NCT04654117|No Intervention|Baseline|Following completing the online tutorial, each agency will have a baseline lasting 3-6 weeks (this will be staggered by agency).
16303078|NCT04654117|Experimental|Treatment (Consultation)|Consultation will be conducted in 4-week phases that correspond to the three consultation components. The phases will occur in a randomized order. During a given phase, no components of any other phases will be provided. Feedback phase. Consultees will submit 5-minute clips of session recordings of their Project ImPACT session with their enrolled family for feedback. Oral feedback will be provided by the consultant and peers. Case support phase. The consultant will lead the group in problem-solving common barriers that providers experience with their cases. Skill rehearsal phase. The consultant will lead skill rehearsal practices in which providers role play elements of a Project ImPACT session.
16303079|NCT04654117|No Intervention|Follow Up|During the follow-up period, consultation will not occur, and providers will continue implementing Project ImPACT with their cases. Eight weeks post-consultation, providers will submit a recorded Project ImPACT session with their enrolled family. Providers and caregivers will complete a final online questionnaire.
16303080|NCT04654104||Healthy never smokers|Clinical evaluation of immune check points expression. A prospective study
16303081|NCT04654104||Smokers with normal lung function|evaluation of immune check points expression
16303082|NCT04654104||Lung cancer|evaluation of immune check points expression
16303083|NCT04654104||COPD|evaluation of immune check points expression
16303084|NCT04654091|Experimental|Cryoteraphy with liquid nitrogen|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
16303085|NCT04654091|Experimental|Nitric-zinc complex|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
16303086|NCT04654078|Experimental|Group 1|Group 1
16303087|NCT04654078|Experimental|Group 2|Group 2
16303088|NCT04654078|Experimental|Group 3|Group 3
16303089|NCT04654078|Experimental|Group 4|Group 4
16303090|NCT04654078|Experimental|Group 5|Group 5
16303091|NCT04654078|Experimental|Group 6|Group 6
16303092|NCT04654065|Experimental|IN-C004|IN-C004
16303093|NCT04654052|Other|VerifyNow® PRUTest ≤30 (De-escalated Prasugrel Ticagrelor )|Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will be de-escalated to Clopidogrel 75 mg q.d during 11 months.
16303094|NCT04654052|Other|VerifyNow® PRUTest ≤30 (Prasugrel or Ticagrelor )|Active comparator: Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will continue with these previous treatment during 11 months.
16303096|NCT04654026||CAA Group|Patients with cardiovascular and cerebrovascular disease with cerebral amyloidosis
16303097|NCT04654026||None CAA Group|Patients with cardio-cerebrovascular disease without cerebral amyloid vascular disease
16303098|NCT04654013|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
16303099|NCT04654013|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (18 months).
16303100|NCT04654000|Experimental|Rheopheresis group|"In addition to the standards of care, the experimental group will carry out the rheopheresis in two stages:
~Stage 1: induction treatment: 3 apheresis sessions during the first week (w0; i.e. between D1 and D7) and then 2 apheresis sessions each week for 3 weeks (from w1 to w3; i.e. between D8 and D28) ;
~Step 2: maintenance treatment with 1 apheresis session per week until the 11th week (i.e. between D29 and D84)."
16303101|NCT04654000|Sham Comparator|Sham-apheresis group|In addition to the standards of care, the comparator group will carry out Sham-apheresis sessions according to the same scheme as the rheopheresis sessions of the experimental group.
16303102|NCT04653987||Puncture angle : ≤30 (group I) >30 (group II)|The patients will be divided into two groups based on the puncture angle: ≤30° group and >30° group. The two groups will be retrospectively analyzed for technical success, fluoroscopy time and complications.
16303103|NCT04653987||Technical Parameters of all Interventions|Peripheral bile duct diameter, central bile duct diameter, number of punctures, type of drainage and total fluoroscopy time will be noted.
16303104|NCT04653974|Active Comparator|Needle-free injection group|In needle-free injection techniques, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using the Comfort-In system.
16303105|NCT04653974|Active Comparator|Dental injection group|In the conventional dental-injection method, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using a 27G, 40-mm, disposable syringe with a needle.
16303106|NCT04653961|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro Decision Support System-MDI algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 2.5 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
16303107|NCT04653948||Cohort Study|Women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age seeking antenatal care at Kawempe National Referral Hospital in their first and second trimesters of pregnancy will be invited to participate in the study until a sample size of at least 4000 women is achieved. They will be followed-up along with their liveborn infants until a minimum of 14 weeks post-delivery.
16303108|NCT04653948||EMR Cohort|Anonymised data from the entire maternal and infant population that attend Kawempe Hospital for antenatal and/or delivery +/- post-partum care during the two-year study period will be analysed to describe maternal, obstetric and neonatal outcomes.
16303109|NCT04653935|Experimental|Full app with all app components|Users receive app that contains all intervention components including: Symptom and Lifestyle information, Energy management, Goal Setting, Managing Difficult Times, Assertiveness and Communication Skills.
16303110|NCT04653935|Active Comparator|Control minimal app with information component only|Users receive app that contains only Symptom and Lifestyle information, and cannot see other intervention components.
16303111|NCT04653922|Experimental|Bioengineered corneal substitute|A cell-free, sterilized bioengineered corneal substitute made from medical grade collagen
16303112|NCT04653909|Experimental|Case|A patient who was diagnosed with the calfan syndrome
16303113|NCT04653896|Experimental|Knee OA group|Individuals who are over 18 years and have medical diagnosis of Grade 3 or 4 knee OA
16303114|NCT04653870|Experimental|cyriax manipulation|cyriax manipulation have three types of classes, rotation, extension and anti-deviation, which is further divided into subclasses. On the inferior level of lumber spine L4-L5 and L5-S1rotation intervention of manipulation are capable of having striking effects of decreasing herniation. First of all we have to perform the simple 'stretch' on lumber spine, which is being the little rotation pressure applied on the body. The patient position of the body is in side lying with the effected side upward so that the outside part of the joint are separated easily on the involved side. After that, whenever it is essential by making use of femur as a rigid bar or support, this maneuver is go along with powerful rotation technique.
16303115|NCT04653870|Experimental|lumber decompresion|Spinal decompression therapy has been developed a treatment without surgery for the prolapsed disc and deteriorative spinal disc disease one of the considerable reason for low back pain. This noninvasive interventional treatment for herniated disc and deteriorative disc diseases operated on the principle of remarkably decreasing the pressure on the disc between vertebras.
16303116|NCT04653857||High-level athlete who had a recent COVID 19 infection, symptomatic or not|High-level athlete who had a recent COVID 19 infection, symptomatic or not
16303117|NCT04653831|Other|Standard of Care - Control|Standard of care (Soc) according to current guidelines and the discretion of treating physician.
16303118|NCT04653831|Experimental|Pirfenidone Treatment|"In addition to SoC, Pirfenidone 2,403 mg administered orally or per nasogastric tube as 801mg TID, for 4 weeks.
~Pirfenidone dose will be 2,403mg daily, from day one of admission to the ICU, titrated over 3 days:
~Day 1 - 801mg x 1/d (801mg) Day 2 - 801mg x 2/d (1,602 mg) Day 3 - 801mg x 3/d (2,403 mg) Feeding and medication delivery will be upon the discretion of the treating physician according to tolerability. Powdered 801mg tablets will be administered through the nasogastric tube: Each tablet will be crushed and dissolved in 20cc of water. The nasogastric tube will be flushed afterwards to avoid obstruction..
~If the patient is able to swallow and the nasogastric tube is removed, pirfenidone will continue to be delivered orally."
16303119|NCT04653818|Active Comparator|DAAs group|Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.
16303120|NCT04653818|Active Comparator|Postponed DAAs group|Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.
16303121|NCT04653792|Experimental|Pregabalin|Participants received Pregabalin 75mg capsule twice daily from preoperative day to 1 week postoperative
16303122|NCT04653792|Placebo Comparator|Pregabalin Placebo|Participants received Pregabalin placebo capsule matching Pregabalin twice daily from preoperative day to 1 week postoperative
16303123|NCT04653779|Experimental|Group A|Patients receive Evogliptin 5mg/Metformin 1000mg once a day
16303124|NCT04653766|Experimental|Ir-CPI - Dose 1|Participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
16303125|NCT04653766|Experimental|Ir-CPI - Dose 2|Participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
16303126|NCT04653766|Experimental|Ir-CPI - Dose 3|Participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
16303127|NCT04653766|Experimental|Ir-CPI - Dose 4|Participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
16303128|NCT04653766|Placebo Comparator|Placebo|Participants received a single intravenous dose of placebo during 6 hours
16303129|NCT04653753|Experimental|Orthosis Group|Use of kneeSOFT500 device
16303130|NCT04653753|No Intervention|Control Group|No use of the device
16303131|NCT04653727||Online survey with 3.000 participants using mobile website technology|
16303132|NCT04653714|Experimental|Full mouth debridement|
16303134|NCT04653701||Patients with hepatocellular carcinoma treated with TAMDEM® 100 micron and SEQURE® microcatheter|Patients included in this study and with chemoembolization indications will be superselective embolized using TAMDEM® 100 micron preloaded particles (Doxorubicin) and SEQURE® microcatheter combination (SYNERGIC EFFECT). Objective tumoral response and 30 days-complications (Safety) are primary outcomes.
16303135|NCT04653688|Experimental|Parkinsonian syndromes patients|
16303136|NCT04653688|Sham Comparator|healthy subjects|
16303137|NCT04653662|Experimental|Treatment group|Treatment group arm. Open label. Only 1 arm study
16303138|NCT04653649|Experimental|HSP-CAR30 (anti-CD30 CAR T cells)|"Phase I:
~Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.
~Phase IIa:
~Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy."
16303139|NCT04653636||Adhesive capsulitis|Patients presenting to the physical medicine and rehabilitation department [tertiary care] of Cochin Hospital with a clinically diagnosis of severe adhesive capsulitis for whom first-line medical treatment is not effective.
16303140|NCT04653623|Experimental|Tranexamic acid before high tibial osteotomy|"Interventions
~Procedure/Surgery: High tibial osteotomy
~Drugs: Tranexamic acid"
16303141|NCT04653623|Active Comparator|High tibial osteotomy only|"Interventions
~- Procedure/Surgery: High tibial osteotomy"
16303142|NCT04653610||HIV-infected individuals|
16303143|NCT04653610||HIV-seronegative healthy volunteers|
16303144|NCT04653597|Experimental|Conservative airway management|decision to intubate will be withheld as long as the patient's state allows it. The patient will be closely monitored and decision of intubation will be made upon presence of regurgitation, seizure, shock, or sign of respiratory distress.
16303145|NCT04653597|Other|Routine practice|decision of intubation left at the discretion of the emergency physician
16303146|NCT04653584||1|Parkinson Disease patients treated by domperidone according the recommendation
16303147|NCT04653584||2|Parkinson Disease patients treated by domperidone in misuse conditions regarding the recommendation
16303148|NCT04653584||3|Parkinson Disease patients without treathment by domperidone
16303149|NCT04653571||CASPR2 encephalitis|Cohort of patients with a CASPR2 antibody-associated auto-immune encephalitis.
16303150|NCT04653558||definite LNB|patients with definite early Lyme neuroborreliosis
16303151|NCT04653558||possible LNB|patients with possible early Lyme neuroborreliosis
16303152|NCT04653532|Experimental|mHealth Technology|Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
16303153|NCT04653532|Active Comparator|Exercise Counselling|Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
16303154|NCT04653519|Experimental|Virtually guided minimally invasive preparation|
16303155|NCT04653506|Experimental|Paracetamol group|Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)
16303156|NCT04653506|Experimental|Ibuprofen group|Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)
16303157|NCT04653493|Experimental|CD19 CAR-T cells|Pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukemia (R/R B-ALL)
16303158|NCT04653480|Experimental|Surufatinib, Toripalimab and Chemotherapy|Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity
16303159|NCT04653467|Experimental|GLPG4399 SAD|Single doses of GLPG4399 at up to 6 dose levels in ascending order
16303160|NCT04653467|Placebo Comparator|Placebo SAD|Single doses of placebo
16303161|NCT04653467|Experimental|GLPG4399 MAD|Multiple ascending doses of GLPG4399
16303162|NCT04653467|Placebo Comparator|Placebo MAD|Multiple doses of placebo
16303163|NCT04653467|Experimental|GLPG4399 FE-rBA|Single dose of GLPG4399 in fed and fasted state
16303164|NCT04653467|Experimental|GLPG4399 FE|Single dose of GLPG4399 in fed and fasted state
16303165|NCT04653454|Experimental|CGM Patients|Patients with diabetes mellitus admitted to the hospital and using a CGM will be encouraged to continue to use these devices in inpatient setting. The device alarms of high or low glucose levels will be communicated to the nursing staff.
16303166|NCT04653441|Experimental|Child-only Intervention|The children in this arm will receive only child intervention curriculum (peer group activities). The child intervention includes 20 hours of facilitator-guided programming delivered in 10 sessions in a peer-group setting and aims to increase resilience by developing a number of skills including positive thinking, emotional regulation, coping, and problem solving.
16303167|NCT04653441|Experimental|Child+Caregiver Intervention|The children in this arm will receive child intervention and their caregivers will receive the caregiver intervention, At the caregiver level, caregivers receive 10 hours of facilitator-guided programming delivered in five sessions that aims to increase positive parenting skills and build the capacity of the caregiver to engage in self-care and seek support.
16303168|NCT04653441|Experimental|Child+Caregiver+Community Intervention|The children in this arm will received child intervention; their family will receive caregiver intervention and community-based intervention. At the community level, trained community advocates (e.g., teachers, village nurses) conduct monthly home visits and organize a series of community-based activities over a period of two years to promote cohesion and strength within local communities and to increase community support for affected families.
16303169|NCT04653441|No Intervention|Attention Control|Children and caregivers who do not receive any intervention activities
16303170|NCT04653415|Active Comparator|Study Group|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
16303171|NCT04653415|Placebo Comparator|Controls group|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - saline solution.
16303172|NCT04653402|Experimental|Study arm 1|Placing a closed suction drain after hydrocelectomy for primary vaginal hydrocele
16303173|NCT04653402|Active Comparator|Study arm 2|Not placing a drain after hydrocelectomy in primary vaginal hydrocele
16303174|NCT04653389|Experimental|Preoperative TACE+Sintilimab+/-Radiotherapy of vein tumor thrombus+postoperative Sintilimab|The first TACE and immunotherapy will be performed at the same time on the first day of treatment. Anti-PD-1 Injection will be administered every three weeks ,until the disease progresses according to mRECIST criteria or intolerable toxicity or the patients' request, or surgery.Hypofractionated radiation therapy will be adopted for Type Vp2, Vp3 PVTT or Type Vv2 HVTT about 2 weeks after the first TACE.If the imaging examination 4 weeks after the surgery confirm that there is no recurrence and no contraindications to receive immunotherapy, anti-PD-1 antibody adjuvant therapy can be started.Every 21 days is a course of treatment, and the longest medication duration lasts for 6 months.
16303175|NCT04653376||Chronic tonsillitis|Patients with tonsil sizes grade 1 and 2, and tonsillectomy indications included frequently recurrent tonsillary infection, sore throat, and malodorous mouth problems were accepted as the chronic tonsillitis group.
16303176|NCT04653376||Tonsillar hypertrophy|Patients with tonsil size grades 3 and 4 and tonsillectomy indications included obstructive symptoms such as snoring, open mouth breathing, difficulty in breathing, and swallowing problems were accepted as the tonsillar hypertrophy group.
16303177|NCT04653363||1|study1 is the patients who will be assessed by first rater.
16303178|NCT04653363||2|study2 is the patients who will be assessed by second rater.
16303179|NCT04653363||3|Theh are healty peers control patients who will be assessed by first rater.
16303182|NCT04653337|Active Comparator|Robot-assisted rTMS and Antidepressants|Patients with suicidal ideation and depression will receive antidepressants combined with robot-assisted rTMS.
16303183|NCT04653337|Active Comparator|Conventional rTMS and Antidepressants|Patients with suicidal ideation and depression will receive antidepressants combined with conventional rTMS.
16303184|NCT04653337|Sham Comparator|Sham rTMS and Antidepressants|Patients with suicidal ideation and depression will receive antidepressants combined with sham rTMS.
16303185|NCT04653311|Experimental|Endomina procedure + lifestyle intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. This group will also receive the medical standard treatment defined as lifestyle intervention.
16303186|NCT04653311|No Intervention|Lifestyle intervention|The group will receive the medical standard treatment defined as lifestyle therapy combining diet (mediterranean diet) with increased physical activity
16303189|NCT04653272||Experimental|"Patients aged 16 to 40 years with ACL anterior cruciate ligament rupture, meniscal injury, patella instability or dislocation (Young Adult group),
~Patients over 55 years of age with gonarthrosis (Senior adults group)."
16303190|NCT04653272||Control|"a group of young (16 to 40 years old)
~senior (over 55 years old) adult controls
~Everybody free of knee pathology."
16303191|NCT04653259|Experimental|Intervention Group|The INT group will meet with their health coach over the phone or video chat. The health coach will orient them to the LyfeMD, app and ensure the participant has received a nutrition plan in the app. They will be asked to complete the app assessment tools to design a personalized nutrition, physical activity and yoga and meditation program. They will set goals in each area they are interested in implementing. The health coach will then follow-up by phone, video or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach will use the following schedule to discuss app related content: First visit nutrition content; second visit behaviour change tools; third visit Yoga, meditation and breathing plans, and; the fourth visit the physical activity plans. The health coach will also be available to answer questions when required using email. Goal attainment will be collected weekly within the app.
16303192|NCT04653259|No Intervention|Conventional Management Group|The CM group (n=22) will receive conventional care as well as a similar health coaching schedule as the intervention group. The health coach will meet the patient over the phone or video chat to outline their role over the next 3 months and to provide general nutrition guidelines using Canada's Food Guide and Alberta Health Services online resources. The health coach will then follow-up by phone, video chat or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach session topics will be the same as the intervention group. For example, the second visit will provide online resources from Alberta Health Services focused on promoting behaviour change, the third visit will orient the patient to Alberta Health Services focused online stress management tools and the final visit will share online versions of the Canadian guidelines for physical activity and sedentary time.
16303193|NCT04653246|Experimental|Isa-RVD|"The main study consists of 4 phases a) 28-day screening phase; b) an induction phase inclusive of two 42-day induction treatment cycles: Isatuximab (IV), Bortezomib (SQ). Lenalidomide (PO), Dexamethasone; c) Followed by stem cell mobilization (at the discretion of the Principal Investigator [PI]);d) Participants will proceed with either autologous stem cell transplant or two additional induction cycles.
~- Induction will be followed by a maintenance phase that continues until disease progression."
16303194|NCT04653233|Experimental|Intervention|After the theoretical lesson, the students in the experimental group were taken to the laboratory room where the 3D Systems Touch Haptic Simulator is located. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option. Since the preparation of the material in the full teaching method in the simulator takes a long time, these steps were removed to show similarity with the control group. The skill practice option for an average of 5-10 minutes where all steps of the Checklist for Teaching Urinary Catheterization Skill can be applied was used. Urinary catheterization with 3D Systems Touch Haptic Simulator was explained by 1 researcher who was responsible for the Fundamentals of Nursing course.
16303566|NCT04650698|No Intervention|Control|No TXA
16303195|NCT04653233|No Intervention|Control|"After the theoretical lesson, the control group was taken to Fundamentals of Nursing Skill Laboratory. 1 researcher, who is responsible for the Fundamentals of Nursing, was explained on the Simple Urinary Catheterization Model by applying the steps of Checklist for Teaching Urinary Catheterization Skills. The students were allowed to ask questions and the questions asked were answered. Then all the students in the control group were taken to an empty class. The two researchers prepared the necessary materials for the urinary catheterization skill practice in the same way in separate rooms. The doors were closed to keep the environment calm during the application. One student was taken to each laboratory rooms in order not to be affected by each other. While the student was practicing, both researchers filled in the Checklist for Teaching Urinary Catheterization Skills. Satisfaction Questionnaire was given to the student who completed the application and asked to fill it."
16303196|NCT04653220|Other|Control 1|Glucose 25g
16303197|NCT04653220|Other|Control 2|Glucose 25g
16303198|NCT04653220|Experimental|Standard Crokao|Commercially available snack bar
16303199|NCT04653220|Experimental|Low sugar variant 1|Low sugar snack bar with sticky rice
16303200|NCT04653220|Experimental|Low sugar variant 2|Low sugar snack bar with promitor
16303201|NCT04653220|Experimental|Low sugar variant 3|Low sugar snack bar with inulin
16303202|NCT04653220|Experimental|Low sugar variant 4|Low sugar snack bar with yellow soy
16303203|NCT04653220|Experimental|Low sugar variant 5|Low sugar snack bar with rice syrup
16303204|NCT04653207|Other|Control 1|Glucose 50g
16303205|NCT04653207|Other|Control 2|Glucose 50g
16303206|NCT04653207|Other|Control 3|Glucose 50g
16303207|NCT04653207|Experimental|Sucrose/Isomaltulose 100:0|A drink with 50g sucrose/isomaltulose 100:0
16303208|NCT04653207|Experimental|Sucrose/Isomaltulose 0:100|A drink with 50g sucrose/isomaltulose 0:100
16303209|NCT04653207|Experimental|Sucrose/Isomaltulose 50:50|A drink with 50g sucrose/isomaltulose 50:50
16303210|NCT04653207|Experimental|Sucrose/Isomaltulose 60:40|A drink with 50g sucrose/isomaltulose 60:40
16303211|NCT04653207|Experimental|Sucrose/Isomaltulose 70:30|A drink with 50g sucrose/isomaltulose 70:30
16303212|NCT04653207|Experimental|Sucrose/Isomaltulose 80:20|A drink with 50g sucrose/isomaltulose 80:20
16303213|NCT04653194|Experimental|Biktarvy treatment|First-line HIV treatment of Biktarvy OD for 48 weeks
16303214|NCT04653194|Active Comparator|Symtuza treatment|First-line HIV treatment of Symtuza OD for 48 weeks
16303215|NCT04653181|Experimental|Iron arm|Half of patients get i.v. iron preoperatively
16303216|NCT04653181|No Intervention|non-iron arm|Half of patients are treated without i.v. iron substitution
16303217|NCT04653168|Experimental|LY3041658 Low Dose|LY3041658 administered by subcutaneous (SC) injection.
16303218|NCT04653168|Experimental|LY3041658 High Dose|LY3041658 administered by SC injection.
16303219|NCT04653155|Experimental|Treatment arm|Participants in the treatment group will show significant improvement on insomnia symptoms after intervention compared to those in the waitlist control group.
16303220|NCT04653155|No Intervention|Waitlist control|Participants in the waitlist control group will show little improvement on insomnia symptoms after the treatment period of the treatment group.
16303221|NCT04653142|Experimental|BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)|
16303222|NCT04653129|Experimental|Group (A): Primary nerve repair with autologous fat graft|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope with autologous fat grafting around site of repair
16303223|NCT04653129|Active Comparator|Group (B): Standard primary nerve repair|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope without fat grafting.
16303224|NCT04653103||Patients with obesity|Subjects with different classes of obesity
16303225|NCT04653090||Varus group|Radiographic stem axis was assessed on standard anteroposterior hip radiographs performed at the 3-month follow-up visit. Alignment was evaluated as described by Reina et al., by the angular deviation of the anatomic femoral axis and the stem axis. The 3 degrees minimal-value was considered to be the threshold defining a varus stem.
16303226|NCT04653090||Neutral group|Alignment between anatomic femoral axis ans stem axis was less than 3°.
16303227|NCT04653077|Experimental|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
16303228|NCT04653064|Experimental|Placebo Cream first|"Each participant will undergo thermal pain tasks after being administered a treatment cream to one of eight body sites."
16303229|NCT04653064|Experimental|Control Cream first|"Each participant will undergo thermal pain tasks after being administered a control cream to one of eight body sites."
16303230|NCT04653051||Patients who received DVR Plating System|
16303231|NCT04653038|Experimental|Unresectable, recurrent or metastatic melanoma|Cohort1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy
16303232|NCT04653038|Experimental|Untreated mucosal or acral lentiginous melanoma|Cohort2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma
16303233|NCT04653025|Experimental|Test group|Test group patients received an immediate implant with provisional restoration, bone augmentation and soft tissue grafting
16303234|NCT04653025|Experimental|Control group|Patients in the control group received soft tissue grafting after tooth extraction and an implant with bone augmentation after 6 weeks of healing.
16303235|NCT04653012|Experimental|Macro-microelectrode implantation|Implantation of macro-micro electrodes of the Adtech Benkhe-Fried type in epileptic patients who are undergoing evaluation with intracranial EEG electrodes
16303236|NCT04652999|Experimental|Muscle Relaxation with Guided Imagery|The participants in Experimental Group will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
16303237|NCT04652999|Placebo Comparator|Active Control Group|Participants in the Active Control Group will receive four individual 45-minute sessions of neutral guided imagery placebo, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
16303239|NCT04652973||1/Prostate cancer dataset|Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.
16303240|NCT04652973||2/Multiphase CT dataset|Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.
16303241|NCT04652960|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO QD or BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16303242|NCT04652934|Experimental|Intervention group|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
16303243|NCT04652934|Sham Comparator|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
16303244|NCT04652921|Experimental|Creatine-guanidinoacetic acid|2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening
16303245|NCT04652921|Placebo Comparator|Inulin|4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening
16303246|NCT04652908|Experimental|Treatment with PMSC-ECM|One-time administration of PMSC-ECM during the course of in utero fetal myelomeningocele surgery will be administered
16303247|NCT04652908|Other|non-PMSC untreated contemporaneous cohort|Contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort).
16303248|NCT04652895||Moderate-to-severe traumatic brain injury inpatients|Moderate-to-severe traumatic brain injury inpatients
16303251|NCT04652869|Experimental|Mindfulness Training|Mindfulness training
16303252|NCT04652869|Experimental|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
16303253|NCT04652869|Experimental|Mindfulness + tDCS|Mindfulness training with transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
16303254|NCT04652856|Experimental|Electrical and Sham Electrical Brain Stimulation|Electrical brain stimulation and sham electrical brain stimulation will be administered to all participants.
16303255|NCT04652843|Other|Idiopathic REM sleep behavior disorders|Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
16303256|NCT04652843|Other|Beginning Parkinson's disease|Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy
16303257|NCT04652843|Other|Parkinson's disease state Phase|Group of 20 patients with Parkinson's Disease for more than 5 years
16303258|NCT04652843|Other|Control|Group of 20 patients undergoing coloscopy for family screening for digestive polyps
16303259|NCT04652830|Active Comparator|Naprapathy training|Training program for three months
16303260|NCT04652830|Placebo Comparator|Control group|No change of daily routines
16303261|NCT04652817|Experimental|MMI-22-04-2019|Sodium hyaluronate at a concentration of 2.5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent administered once or twice depending on the individual necessity.
16303262|NCT04652804|Active Comparator|Arm 1: Low Intensity Intervention|4 weeks dispensation + standard adherence counseling
16303263|NCT04652804|Active Comparator|Arm 2: Medium Intensity Intervention|4 weeks dispensation + support from patient navigator
16303264|NCT04652804|Active Comparator|Arm 3: High Intensity Intervention|Directly Observed Therapy with flexible dispensing and support from patient navigator
16303265|NCT04652791||Wangbi Capsule|Patients who are taking Wangbi Capsule for the treatment.
16303266|NCT04652791||Other drugs|Patients who are not taking Wangbi Capsule for the treatment.
16303267|NCT04652765|No Intervention|Standard of care (SOC)|SARS-CoV-2 positive participants will receive SOC therapy alone.
16303268|NCT04652765|Active Comparator|SOC plus camostat and bicalutamide|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat and bicalutamide for 7 days.
16303269|NCT04652752|Experimental|CONNETTIVINA HI TECH patch|CONNETTIVINA HI TECH patch will be applied to eligible patients. CONNETTIVINA HI TECH will be renewed every two day, according with general principles of wound management
16303270|NCT04652739|Experimental|Lycopene|
16303271|NCT04652739|Active Comparator|Corticosteroids|
16303274|NCT04652713|Experimental|High protein breakfast|Participants will be served a dairy-based protein-rich breakfast meal.
16303275|NCT04652713|Experimental|High carbohydrate breakfast|Participants will be served a carbohydrate-rich breakfast meal
16303276|NCT04652713|Experimental|No breakfast|Participants will be served no breakfast
16303314|NCT04652440|Experimental|Radiofrequency ablation combined with PD-1 monoclonal antibody|Patients who meet the inclusion criteria will receive PD-1 treatment after primary radiofrequency ablation.
16303279|NCT04652687||VIA Disc NP|Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment for discogenic low back pain.
16303280|NCT04652687||Non Surgical Management|Patients receiving non surgical management (i.e., physical therapy, transforaminal epidural steroid injection, lifestyle modification, or surgical intervention)
16303281|NCT04652674|Experimental|Group I|Patients who will undergo telemedicine visit approximately 1 week postoperatively, then an in-person clinic visit approximately 4 weeks postoperatively
16303282|NCT04652674|Active Comparator|Group II|Patients who will undergo in-person clinic visit approximately 1 week postoperatively, then a telemedicine visit approximately 4 weeks postoperatively
16303283|NCT04652661|Experimental|Dexmedetomidine Group|30 children will be sedated with 2 μg/kg intranasal dexmedetomidine
16303284|NCT04652661|Active Comparator|Midazolam Group|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
16303285|NCT04652648|Active Comparator|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID for 10 days
16303286|NCT04652648|No Intervention|Control|No Intervention
16303287|NCT04652635|Active Comparator|Nail plate removal, nail bed repair|Participants will undergo nail plate removal and nail bed repair, and follow up at clinic visits at 1 week, 3 months, and 6 months
16303288|NCT04652635|No Intervention|Observation|Participants will follow up at clinic visits at 1 week, 3 months, and 6 months
16303289|NCT04652622|Experimental|Intervention arm|Participants will receive 4 hours of exposure to the Mindful Garden digital therapeutic platform in addition to standard care
16303290|NCT04652622|No Intervention|Control Arm|Participants will be monitored over a 4 hour period of standard care interventions
16303291|NCT04652609|Experimental|PRESIONA|An adapted therapeutic exercise program using blood flow restriction cuff perfomed during chemotherapy treatment. 24-36 sessions of 1 hour multimodal components: aerobic, strength and fascial release exercises. Frequency will be adapted to the recovery status of each patient.
16303292|NCT04652609|No Intervention|Control group|Patients undergoing usual medical treatment
16303293|NCT04652596|Active Comparator|Fresh Connect Produce Prescription Program|Investigators will partner with a community organization, About Fresh, that administers a produce prescription program (PPR) and operates mobile fresh foods markets. Participants randomized to this comparator will receive a stipend to Fresh Connect PPR to purchase fresh food items available at mobile markets and at independent farmers markets throughout Boston.
16303294|NCT04652596|Active Comparator|Grocery store gift cards|Participants randomized to this comparator will receive grocery gift cards redeemable at conventional grocery stores.
16303295|NCT04652583|Active Comparator|Active Stimulation 20 minutes|Intramuscular stimulation
16303296|NCT04652583|Active Comparator|Active Stimulation 60 minutes|Intramuscular stimulation
16303297|NCT04652583|Sham Comparator|Sham Stimulation 20 minutes|Muscle-free-zone stimulation
16303298|NCT04652570|Experimental|VB119 dose escalation|Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.
16303299|NCT04652557|Experimental|Fampridine SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 26 days depending on the individual scheduling of each subject."
16303300|NCT04652557|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
16303301|NCT04652544|Experimental|"Low dose"|One vial with 600 µg cholecalciferol (corresponding to a total of 24'000 IU vitamin D) and one vial with placebo every month.
16303302|NCT04652544|Experimental|"High dose"|Two vials with 600 µg cholecalciferol each (corresponding to a total of 48'000 IU vitamin D) every month.
16303303|NCT04652544|Placebo Comparator|Placebo|Two vials with a placebo every month.
16303304|NCT04652531|Experimental|Treatment|In the treatment arm, the lesion will be treated with EV for 3 weeks once a week
16303305|NCT04652531|Sham Comparator|Internal control|The contralateral ulcer will be treated with a standard dressing and an elastic-compression bandage for 3 weeks.
16303306|NCT04652518|Experimental|LYT-100|LYT-100 taken orally BID for 91 days
16303307|NCT04652518|Placebo Comparator|Placebo|Placebo matching LYT-100 taken orally BID for 91 days
16303308|NCT04652505||Observational (questionnaires)|Patients complete 3 questionnaires online over 15 minutes regarding coping strategies that may have been used, mental health and physical well-being in the past month, and if they have been following certain behaviors which the WHO has recommended during the coronavirus pandemic, such as regular hand washing and social distancing.
16303309|NCT04652492|Experimental|Tislelizumab in combination with cTACE|Tislelizumab in combination with on-demanded cTACE
16303310|NCT04652479|Experimental|Treatment Group 1|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
16303311|NCT04652479|Experimental|Treatment Group 2|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days (in the opposite sequence from Treatment Group 1)
16303312|NCT04652453|Experimental|Post-Intervention Group (Geriatrics Bundle)|Enrolled participants in the intervention arm will receive all 3 components of the geriatrics bundle: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
16303313|NCT04652453|No Intervention|Pre-Intervention Group (Control)|Participants in the control arm will be enrolled prior to implementation of the geriatrics bundle to gather preliminary data about the secondary outcomes.
16303315|NCT04652427|Experimental|Use Dexmedetomidine Hydrochloride to maintain a sedative|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
16303316|NCT04652427|Placebo Comparator|Sedative were maintained with a 0.9% sodium chloride injection|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
16303317|NCT04652414|Experimental|Prednisone|Patients randomized to the intervention arm will receive prednisone 50mg PO daily for 7 days.
16303318|NCT04652414|Placebo Comparator|Placebo|Patients will receive matching placebo PO daily for 7 days.
16303319|NCT04652388|Experimental|Nutritional counseling|Children with autism spectrum disorders to whom administer nutritional counseling
16303320|NCT04652388|No Intervention|Controls|No intervention
16303321|NCT04652375|Experimental|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
16303322|NCT04652375|Experimental|Lactated Ringer's Solution|Participants will receive lactated Ringer's for fluid resuscitation post-surgery
16303323|NCT04652362|Experimental|Growth Mindset Intervention|
16303324|NCT04652362|Active Comparator|Supportive Therapy Intervention|
16303325|NCT04652349|Experimental|HGP1910|
16303326|NCT04652349|Experimental|HCP1903|
16303327|NCT04652349|Active Comparator|HGP1909|
16303328|NCT04652349|Active Comparator|HGP1911|
16303329|NCT04652336|Active Comparator|LSG|This group will receive standard laparoscopic sleeve gastrectomy
16303330|NCT04652336|Experimental|LSG with LTC|This group will receive LSG along with the novel LTC procedure
16303331|NCT04652323||Control|Twenty-one empty polyethylene tubes remained empty to bewere used as in the control group.
16303332|NCT04652323||ProRoot MTA|ProRoot White MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
16303333|NCT04652323||Medcem MTA|Medcem MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
16303334|NCT04652323||Medcem Pure Portland Cement|Medcem Pure Portland Cement mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
16303335|NCT04652310|Active Comparator|Extended-Short Nail|Implantation of TFNA extended-short nail (235 mm)
16303336|NCT04652310|Active Comparator|Long nail|Implantation of TFNA long nail (260-480 mm)
16303337|NCT04652297|Experimental|HS-10356 single dose|Single oral dose of HS-10356 ascending dose
16303338|NCT04652297|Placebo Comparator|placebo single dose|Single oral dose of placebo ascending doses
16303339|NCT04652297|Experimental|HS-10356 multiple doses|Multiple oral doses of HS-10356 ascending doses
16303340|NCT04652297|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo ascending doses
16303341|NCT04652284|Active Comparator|Rifabutin full dose|oral amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd 14 days
16303342|NCT04652284|Active Comparator|Rifabutin low dose|oral amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd 14 days
16303343|NCT04652284|Active Comparator|Standard of Care|Standard of care in previously untreated patients will consist of concomitant treatment (oral amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole 40 mg all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available
16303344|NCT04652271||Patients undergoing pancreatic surgery|Patients undergoing any type of pancreatic surgery.
16303345|NCT04652258|Other|Treatment arm|"The patients will be administered Tocilizmab (Actemra) at the following dosage :
~First dose: 8mg/kg, max. 800mg iv. during 60min
~If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose"
16303346|NCT04652245|Experimental|Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period|Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray and Placebo nasal spray
16303347|NCT04652245|Experimental|Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period|Placebo nasal spray and Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray
16303348|NCT04652232|Active Comparator|Treated group|This group will receive the RV3466F lotion and a neutral shampoo
16303349|NCT04652232|Other|Control group|This group will receive a neutral shampoo
16303350|NCT04652219|Experimental|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
16303420|NCT04651699|Experimental|Active Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes at 2 milli amps.
16303695|NCT04649710|Experimental|Cohort 1: Dose 1 or placebo|Chinese participants
16303351|NCT04652206|Experimental|SCO-101 in combination with gemcitabine and nab-paclitaxel|"Patients receive escalating doses of SCO-101 in combination with the standard recommended dose of gemcitabine and nab-paclitaxel according to local clinical practice. Gemcintabine and nab-paclitaxel is the recommended treatment for the patient group.
~Starting dose of SCO-101 is 150 mg. Maximum dose tested is 350 mg. The dose is increased with 50 mg increments between each cohort."
16303352|NCT04652180|Experimental|Robot-assisted thoracic approach in Ivor Lewis esophagectomy|Robot-assisted thoracic approach in Ivor Lewis esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
16303353|NCT04652180|Active Comparator|Open transthoracic approach in Ivor Lewis esophagectomy|Traditional open transthoracic esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
16303354|NCT04652167||Patients suspected of community-acquired pneumonia|All patients admitted to the emergency department with suspected community- acquired pneumonia by the attending physician
16303355|NCT04652154|Other|Control|Control group is recieving treatment as ususal
16303356|NCT04652154|Experimental|Intervention group|The intervention group getting the new assessment by a complementary professional team
16303357|NCT04652141|Active Comparator|AsthmaTuner field tests|Trail treatment with AsthmaTuner up to 3 months. Objective asthma criteria: Positive reversibility test, FEV1 >12% and 200 ml or positive periodic variability PEF/FEV1 >20%. Treatment recommendation is prescribed individually by treating physician.
16303358|NCT04652141|No Intervention|Traditional trial treatment|Treatment recommendation is prescribed individually to patient by treating physician. The treatment plan is transferred to patient on printed paper and/or oral communication.
16303359|NCT04652128|Experimental|zoledronate|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
16303360|NCT04652128|Placebo Comparator|saline|Subject will receive a single infusion of physiological saline 100mL intravenously.
16303361|NCT04652115|Experimental|Defibrotide|Defibrotide IV
16303362|NCT04652102|Experimental|Phase 2b: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16303363|NCT04652102|Placebo Comparator|Phase 2b: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16303364|NCT04652102|Experimental|Phase 3: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16303365|NCT04652102|Placebo Comparator|Phase 3: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
16303366|NCT04652089|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg capsule once a day for 7 days
16303367|NCT04652089|Placebo Comparator|Control arm: Placebo|Placebo capsule once a day for 7 days
16303368|NCT04652076|Other|Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)|Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
16303369|NCT04652076|Other|Arm B: Experimental double combination [Standard Chemotherapy +NP137]|Experimental double combination [Standard Chemotherapy +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
16303370|NCT04652076|Other|Arm C: Experimental double combination [Pembrolizumab +NP137]|Experimental double combination [Pembrolizumab +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
16303371|NCT04652076|Other|Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]|Experimental triple combination [Pembrolizumab+ Standard Chemotherapy + NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
16303372|NCT04652063|Experimental|OMM|Neonates randomized to receive osteopathic manipulation
16303373|NCT04652063|No Intervention|Control|Neonates randomized to receive standard care only
16303374|NCT04652050||lung transplants|Lung transplants on Tolsura for infection
16303375|NCT04652037|Experimental|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|
16303376|NCT04652024|No Intervention|CONTROL GROUP|Girls in the control group received pelvic floor muscle exercise (kegel exercise) daily in the outpatient clinic 12 weeks.
16303377|NCT04652024|Experimental|STUDY GROUP|Girls in the study group received the same physical therapy program given to the control group in addition to anorectal biofeedback for six sessions per week. in addition to kegel exercise
16303378|NCT04652011||Patients with chronic pelvic pain|Patients with chronic pelvic pain and a benign gynecologic disease associated, referring to our Unit, medically or surgically treated from 2010 to 2019
16303379|NCT04651985||Injured Achilles tendon participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
16303380|NCT04651985||Healthy Achilles tendon (contralateral) of participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
16303381|NCT04651959|Experimental|AVICOD then AVIGAN|Participants first received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state. After a washout period of 24 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
16303382|NCT04651959|Experimental|AVIGAN then AVICOD|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 24 hours, they then received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state.
16303383|NCT04651933||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
16303384|NCT04651933||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
16303385|NCT04651920||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
16303386|NCT04651920||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
16303421|NCT04651699|Sham Comparator|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.
16303524|NCT04650984|Experimental|Arm 2|Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in combination with 60 mg/m2 doxorubicin (once every 3 weeks).
16303696|NCT04649710|Experimental|Cohort 2: Dose 2 or placebo|Chinese participants
16303387|NCT04651907|Experimental|acupuncture group|The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3mm×30mm. The needle placed for the real acupuncture group will be the same needle size as 0.3mm×30mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
16303388|NCT04651907|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
16303389|NCT04651907|No Intervention|waitlist-controlled group|As an waitlist control group, no acupuncture will be performed.
16303390|NCT04651881|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug 1
~Period 3: Test drug 2"
16303391|NCT04651881|Experimental|Group 2|"Period 1: Test drug 2
~Period 2: Reference drug
~Period 3: Test drug 1"
16303392|NCT04651881|Experimental|Group 3|"Period 1: Test drug 1
~Period 2: Test drug 2
~Period 3: Reference drug"
16303393|NCT04651881|Experimental|Group 4|"Period 1: Test drug 2
~Period 2: Test drug 1
~Period 3: Reference drug"
16303394|NCT04651881|Experimental|Group 5|"Period 1: Test drug 1
~Period 2: Reference drug
~Period 3: Test drug 2"
16303395|NCT04651881|Experimental|Group 6|"Period 1: Reference drug
~Period 2: Test drug 2
~Period 3: Test drug 1"
16303396|NCT04651868|Experimental|CCK + GLP-2|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
16303397|NCT04651868|Experimental|CCK + placebo|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with isotonic NaCl
16303398|NCT04651868|Experimental|Placebo + GLP-2|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
16303399|NCT04651868|Experimental|Placebo + placebo|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with isotonic NaCl
16303400|NCT04651855|Experimental|Treatment arm|It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture.
16303401|NCT04651842||HOMA IR high|classified based on equal tertile of HOMA IR level into 3 equal groups ( high>6.6)
16303402|NCT04651842||HOMA IR intermediate|classified based on equal tertile of HOMA IR level into 3 equal groups ( intermediate 4.6-6.6, )
16303403|NCT04651842||HOMA IR low|classified based on equal tertile of HOMA IR level into 3 equal groups (low ≤ 4.6, )
16303404|NCT04651816|Active Comparator|Control PSH DPP only|This group will be enrolled the PSH DPP program. There will be two cohorts for this arm.
16303405|NCT04651816|Experimental|Treatment 1 Financial Incentives A|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
16303406|NCT04651816|Experimental|Treatment 2 Financial Incentives B|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
16303407|NCT04651816|Experimental|Treatment 3 Motivational Text Messaging|This group will receive text messages with motivational messages while participating in the PSH DPP program. There will be two cohorts for this arm.
16303408|NCT04651803||Traumatic brain injury patients|Traumatic brain injury patients admitted in intensive care unit.
16303409|NCT04651790|Active Comparator|Vaccine 0-14|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
16303410|NCT04651790|Experimental|Vaccine 0-28|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
16303411|NCT04651777|Experimental|Participants with poorly controlled moderate to severe asthma|Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements.
16303412|NCT04651764|Experimental|Robotically assisted transanal endoluminal resection of rectal lesion|
16303413|NCT04651751|No Intervention|Control|No Intervention: Control Participants exercised on their own without receiving any instructions.
16303414|NCT04651751|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
16303415|NCT04651738|Experimental|Study group|All eligible participants consenting to participate the study.
16303416|NCT04651725|Active Comparator|Exercise group 1: Exercise via mechanical horse-riding simulator|All patients in both groups were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
16303417|NCT04651725|Active Comparator|Exercise group 2: Home exercises|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
16303418|NCT04651712|No Intervention|Standard care|A treating physician must perform a clinical assessment within half an hour of patient arrival. This assessment includes the decision whether the patient is suspected of having pneumonia and if this is the case, a sputum specimen and chest x-ray will be ordered. Patients with suspected pneumonia who can deliver a sputum specimen will be randomly allocated with a 1:1 computer-generated randomization schedule with permuting blocks in relation to optimal therapeutical intervention strategy. All standard care sputum samples will be cultured and analysed according to the sites' standard procedures. Under standard care, the treating physician alone decides on the optimal therapeutical intervention.
16303419|NCT04651712|Active Comparator|POC-PCR analysis supplied with a recommended action list developed by a microbiologist|Along with standard analyses, the specimens will be analysed with POC-PCR and the treating physician will receive an action-list with the results from POC-PCR.
16303422|NCT04651686|Experimental|Bronchial artery protection|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
16303423|NCT04651660|Experimental|Manual Insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole MANUAL insertion (by the surgeon).
16303424|NCT04651660|Experimental|Robotic insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole ROBOTIC insertion.
16303425|NCT04651647||Bone graft group|The bone graft group (n=19) who underwent open nailing with open bone graft for aseptic subtrochanteric nonunion
16303426|NCT04651647||Non bone graft group|The non-BG group (n=18) who underwent closed reamed nailing without bone graft for aseptic subtrochanteric nonunion
16303427|NCT04651634|Experimental|20 mg|MIT-001 20 mg
16303428|NCT04651634|Experimental|40 mg|MIT-001 40 mg
16303429|NCT04651634|Experimental|60 mg|MIT-001 60 mg
16303430|NCT04651634|Placebo Comparator|Placebo|Matching placebo
16303431|NCT04651621|Experimental|Open label active cTBS|Four consecutive days with 40s cTBS, 100% MT over the SMA, five times a day with 50 minutes between stimulations
16303432|NCT04651621|Experimental|active cTBS|One test session with 40s active cTBS, 100% MT, over the SMA in the initial double blind cross-over phase
16303433|NCT04651621|Sham Comparator|Sham cTBS|One test session with 40s sham cTBS, 100% MT, over the SMA in the initial double blind cross-over phase with a special sham coil that diverts the magnetic field to be only superficial
16303434|NCT04651608|Experimental|manuel acupressure|In this group, manual acupress was applied to children receiving chemotherapy with moderate and high emetogenic effects.
16303435|NCT04651608|Experimental|sea-band acupressure|In this group, sea-band acupressure was applied to children receiving chemotherapy with moderate and high emetogenic effects.
16303436|NCT04651595|Experimental|Caudal|
16303437|NCT04651595|Active Comparator|Control|
16303438|NCT04651582|Experimental|Cognitive Training|20 hours of computerized brain exercises
16303439|NCT04651582|Active Comparator|Cognitively Stimulating Activities|20 hours of computerized brain exercises
16303440|NCT04651556|Active Comparator|Parenteral Analgesia|receive ordinary analgesics via intravenous route as paracetamol (7.5- 10 mg/kg) and ketorolac (0.5 mg/kg).
16303441|NCT04651556|Active Comparator|Intraperitoneal instillation|receive (Magnesium sulphate 40 mg/kg and bupivacaine 4mg/kg) in 30 ml of isotonic 0.9%N.S intra peritoneal at the end of surgery.
16303442|NCT04651543|Experimental|no control X-Ray|patients with a proximal humeral fracture without one-week X-Ray control
16303443|NCT04651543|Active Comparator|one-week X-Ray control|patients with a proximal humeral fracture with one-week X-Ray control
16303444|NCT04651530|Active Comparator|Phaco|Cataract surgery only
16303445|NCT04651530|Experimental|Phaco+ECP|Cataract surgery combined with endoscopic cyclophotocoagulation
16303446|NCT04651517|Experimental|Study arm|Subjects undergoing procedures with the XACT ACE Robotic system.
16303447|NCT04651504|Experimental|Primary Care Clinics|"Southern Illinois Healthcare System will contact the site management and ask for participation in the study
~Eligible providers and staff will be identified by clinic management. The research coordinator will work with the clinic to schedule a virtual site visit(s). The study team will interview providers and staff at the beginning and/or end of each active intervention period to assess knowledge and attitudes about CRC screening and follow-up processes, the Consolidated Framework for Implementation Research (CFIR) constructs such as role clarity within the clinical team, and satisfaction with the intervention and implementation. Post-implementation surveys will also ask about work-arounds and adaptations of the intervention tools and perceived efficacy."
16303448|NCT04651491||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel)
16303449|NCT04651478|Experimental|Action Observation+Motor Imagery through BCI|"Action Observation+Motor Imagery through a Brain-Computer Interface training paradigm in Virtual Reality using the NeuRow platform during 10 sessions of 20 minutes, divided in 4 series of 5 minutes."
16303450|NCT04651478|Placebo Comparator|Action Observation through non-related with movement illustrations|Control Action Observation protocol of non-related with movement illustrations during 10 sessions of 20 minutes, divided in 4 series of 5 minutes.
16303451|NCT04651465|Experimental|Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
16303452|NCT04651465|No Intervention|Business as usual|"control groups have business as usual, and then get offered the intervention program after one year follow-up assessment."
16303453|NCT04651452|Active Comparator|Value Affirmation|Participants in the value affirmation condition will complete six writing prompts regarding their personal values over the course of six months. For example, participants will be given a list of values and will be asked to rate them in order of importance within their own lives and write about a time when their top value was particularly important. Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
16303454|NCT04651452|Active Comparator|Reflective Journaling|Participants in the reflective journaling condition will complete six writing prompts over the course of six months. However, the reflective journaling condition will be writing about values that are not important to them and discuss why they could be important to others. In other tasks, they will write about aspects of daily life (e.g. morning routine). Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
16303455|NCT04651439|Experimental|FILGRASTIM|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + ZARZIO@ (30 MU/0,5mL and/or 48 MU/0,5mL - solution of 20 ml diluted in GLUCOSE 5%) administrated by IV or subcutaneous route over a period of 5 consecutive days (1 injection per day during 30 minutes)
16303456|NCT04651439|Placebo Comparator|PLACEBO|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + 20 ml GLUCOSE 5% administrated by IV route over a period of 5 consecutive days (1 injection per day during 30 minutes)
16303457|NCT04651426|Placebo Comparator|Placebo|The Placebo is a Patch identical to the F3 and F4 patches in aesthetics but without any biomineral, therefore with no reflectance ability.
16303458|NCT04651426|Active Comparator|F3 Patch|The F3 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum 2 m x kg
16303459|NCT04651426|Active Comparator|F4 Patch|The F4 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum of 4 m x kg
16303460|NCT04651413||Covid-19 Ct Value|All patients enrolled onto the ISARIC COVID-19 trial at The University Hospitals of North Midlands NHS Trust between the period 1st February 2020 to 1st July 2020 will be included in this study, provided that a laboratory cycle threshold (Ct) value is available.
16303461|NCT04651400||COVID-19 patients who had received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
16303462|NCT04651400||COVID-19 patients who had not received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
16303463|NCT04651400||Non-COVID-19 patients who had received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.
~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
16303464|NCT04651400||Non-COVID-19 patients who had not received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.
~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
16303465|NCT04651387|Experimental|Intervention group|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered"
16303466|NCT04651387|No Intervention|Control group|For the control group, the placebo will be not considered and they will follow the routine standard treatments for COVID-19.
16303467|NCT04651374|Experimental|Geko Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
16303468|NCT04651374|No Intervention|No Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
16303469|NCT04651361|Active Comparator|Naldebain group|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
16303470|NCT04651361|Placebo Comparator|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
16303471|NCT04651348|Experimental|MIL95|
16303472|NCT04651335|Active Comparator|Concentric|uses an afferent virtual reality program
16303473|NCT04651335|Active Comparator|Eccentric|uses an efferent virtual reality program
16303474|NCT04651322|Experimental|Training group|
16303475|NCT04651322|Other|Control group|
16303476|NCT04651309|Other|Ultrasound group|Labor progress assessed by US, avoiding digital exams as much as possible;
16303477|NCT04651309|No Intervention|Control group|Labor progress assessed according to the regular protocol
16303478|NCT04651296|Experimental|compassion meditation|10 week, group-based manualized compassion meditation training
16303479|NCT04651296|Active Comparator|health education|10 week, group-based manualized health education protocol
16303480|NCT04651283|Experimental|Adaptive seating equipment group|Study group who received the same selected program for hand function on adaptive swiss ball seating
16303481|NCT04651283|Active Comparator|Traditional seat group|Control group who received a specially selected physical therapy program for hand function on a standard chair seating.
16303482|NCT04651270|Experimental|SurroundScope|For laparoscopic camera system, the SurroundScope. 270-degree angle videoscope (270Surgical, Israel) was used
16303483|NCT04651244||Patients with suspected acute pyelonephritis|Patients admitted in the ED with suspected infection, where the initial medical assessment raises suspicion of APN.
16303522|NCT04650997|Sham Comparator|Exercise|12 weeks eccentric exercise combined with 6 sessions of sham extracorporeal shockwave therapy in the initial 6 weeks
16303523|NCT04650984|Active Comparator|Arm 1|Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference treatment).
16303484|NCT04651231|Active Comparator|tight flap technique group (forty patients-group A)|in this arm forty patients did tight flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to close the apex of triangular scleral flap tightly and two releasable stitches were used at the sides of triangular scleral flap.
16303485|NCT04651231|Experimental|loose flap technique (securing sutures) group (forty patients-group B).|in this arm forty patients did loose flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to secure the edges of the flap at the apex of and two-four releasable stitches were used at the sides of triangular scleral flap in group B.
16303486|NCT04651218|No Intervention|control|sedentary control group watches TV between being assessed for outcome measures
16303487|NCT04651218|Experimental|exercise|exercise treatment performs exercise between being assessed for outcome measures
16303488|NCT04651205|No Intervention|Untreated|This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).
16303489|NCT04651205|Experimental|Mg-B1 early start|Participants in the Mg-B1 are the 'early start' group where they will receive 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a total duration of 8 weeks (MgB1).
16303490|NCT04651205|Experimental|B1-Mg early start|Participants in the B1-Mg are the 'early start' group where they will receive 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a total duration of 8 weeks (B1Mg).
16303491|NCT04651192||Soldiers|50 Israeli Defense Forces (IDF) infantry soldiers, all male, aged 18 years, with Hebrew as the dominant language and no condition excluding an MRI scan.
16303492|NCT04651192||Students|50 Reserve Officer Training Corps (ROTC) undergraduate students at Tel-Aviv University, all male, aged 18-19, with Hebrew as the dominant language and no condition excluding an MRI scan.
16303493|NCT04651166|Placebo Comparator|Placebo|100mL saline or lactated ringer without tranexamic acid added given intravenously over 10 minutes at start of procedure
16303494|NCT04651166|Active Comparator|Active Comparator|1g tranexamic acid mixed in 100mL saline or lactated ringer given intravenously over 10 minutes at start of procedure
16303495|NCT04651153|Experimental|UCB7853|Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
16303496|NCT04651153|Placebo Comparator|Placebo|Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
16303497|NCT04651140|Active Comparator|Tremor group|Participants in the tremor group have tremor as the main clinical manifestation
16303498|NCT04651140|Active Comparator|Stiff group|Participants in the tremor group have stiff as the main clinical manifestation
16303499|NCT04651127|Experimental|Toripalimab + Chidamide Arm|
16303500|NCT04651114|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
16303501|NCT04651101||vitamin D deficient|those patient with vitamin D level below 30 ng/dl
16303502|NCT04651101||non vitamin D deficient|those patient with vitamin D above 30 ng/dl
16303503|NCT04651088|Placebo Comparator|Metabolic diet|Controlled metabolic diet arm.
16303504|NCT04651088|Active Comparator|Potassium citrate|
16303505|NCT04651088|Active Comparator|Sodium Bicarbonate|
16303506|NCT04651088|Active Comparator|Litholyte arm|
16303507|NCT04651088|Active Comparator|Crystal Lite|
16303508|NCT04651088|Active Comparator|Potassium Bicarbonate|
16303509|NCT04651075|Experimental|music theraphy|One of the 4 music genres (Turkish Folk, Classical, Turkish Art and Sufi Music), which was determined by the researcher by scanning the literature 30 minutes before the CAG procedure, and the expert opinion was taken to the participants in this group was played with a 5-minute headset. The musical genres were arranged in instrumental, nonverbal, 70 decibels in terms of rhythm and duration and played according to the individual's choice.
16303510|NCT04651075|Experimental|information education|Participants in this group were trained to inform them about CAG in visual, audio and written form. Information training was provided by the researcher 30 minutes before the CAG procedure after the outpatient clinic controls of the patient. Information education prepared by the researcher by scanning the literature and getting expert opinion; It includes 7 minutes of video explanation about the CAG process, discussion after video watching, question and answer, and the delivery of a training book prepared in written form.
16303511|NCT04651075|No Intervention|nursing care|Individuals in this group received routine nursing care and no intervention was made by the researcher. In routine nursing care for individuals who will receive CAG procedure in the clinic; Preparation for the CAG procedure, which involves opening the vascular access and dressing the surgical gown, is included in the pre-and post-procedure routine once and more frequently when there are deviations from normal, and if the patient asks questions about the procedure, measurement of blood pressure, heart rate and oxygen saturation.
16303512|NCT04651062|Experimental|endocuff|all patients having performed a screeningscolonoscopy and being randomized to colonoscopy with the use of endocuff
16303513|NCT04651062|Active Comparator|no cuff|all patients participating in a screeningscolonoscopy being randomized to colonoscopy without the use of endocuff
16303514|NCT04651049||Propranolol treatment group|
16303515|NCT04651036|Experimental|Pegfilgrastim biosimilar product|QL0605 subcutaneously at a dose of 6 mg/0.6 mL.
16303516|NCT04651036|Active Comparator|US Neulasta|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
16303517|NCT04651023|Placebo Comparator|control group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (0g NnEx) per day with or after meals.
16303518|NCT04651023|Experimental|low concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (1g NnEx) per day with or after meals.
16303519|NCT04651023|Experimental|high concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (2g NnEx) per day with or after meals.
16303520|NCT04651010|Experimental|Multimodal MRI|
16303521|NCT04650997|Experimental|Combined|12 weeks eccentric exercise combined with 6 sessions of extracorporeal shockwave therapy in the initial 6 weeks
16303563|NCT04650724|Experimental|T cell infusion agent targeting BCMA chimeric antigen receptor|
16303525|NCT04650971|Experimental|"Vaccine UniFluVec 6.7 log EID50/dose"|"Cohort 1 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 6.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
16303526|NCT04650971|Experimental|"Vaccine UniFluVec 7.7 log EID50/dose"|"Cohort 2 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 7.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
16303527|NCT04650971|Placebo Comparator|Placebo|Placebo comparator arm consists of 20 subjects (10 subject in each Сohort).
16303528|NCT04650958|Active Comparator|STN DBS stimulation group|In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
16303529|NCT04650958|Sham Comparator|Sham stimulation group|In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
16303532|NCT04650932|Experimental|Sustained Dual Frequency, Dual Region, Stimulation|
16303533|NCT04650919|Experimental|Experimental arm|
16303534|NCT04650906|Experimental|Intervention group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
16303535|NCT04650906|No Intervention|Control group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
16303536|NCT04650893|Placebo Comparator|Control|no steroid or non steroidal anti-inflammatory
16303537|NCT04650893|Active Comparator|Ketorolac|one time dose of 30mg of IV Ketorolac at time of closure
16303538|NCT04650893|Active Comparator|dexamethasone|one time dose of 10mg of IV dexamethasone at the time of closure
16303539|NCT04650880|Active Comparator|Vitamin D|Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
16303540|NCT04650880|Placebo Comparator|Placebo|Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
16303541|NCT04650867||Patients with Crohn's disease|Patients diagnosed or with suspected Crohn's disease.
16303542|NCT04650867||Patients with Ulcerative colitis|Patients diagnosed or with suspected Ulcerative colitis
16303543|NCT04650867||Patients with unclassified inflammatory bowel disease (U-IBD)|Patients diagnosed or with suspected unclassified inflammatory bowel disease (U-IBD)
16303546|NCT04650841|Experimental|Naloxone Group|Participants will receive 4mg naloxone nasal spray.
16303547|NCT04650841|Experimental|Saline Group|Participants will receive saline in the nasal spray.
16303548|NCT04650828||Experimental:person with TDF+LDT|TDF combined with LDT for 12 months
16303549|NCT04650828||Active comparator:person with TDF|TDF monotherapy was continued for 12 months
16303550|NCT04650815||1 - 5 Years|Infants and Children up to age 5 years in the Sabou Health District
16303551|NCT04650815||10 - 18 Years|Children ranging in age 10 to 18 years in the Sabou Health District
16303552|NCT04650815||19 + Years|Adults ranging in ages 19 years to 65 years in the Sabou Health District
16303553|NCT04650815||5 - 10 Years|Children ranging in age 5 years through 10 years in the Sabou Health District
16303554|NCT04650802|Experimental|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
16303555|NCT04650776|Experimental|High heat strain|participants exercised at 75% of their heart rate maximum (HR max) and wore light athletic clothing (t-shirt and shorts)
16303556|NCT04650776|Experimental|Low heat strain|participants exercised at 50% HR max, wearing protective firefighter clothing (jacket and trousers)
16303557|NCT04650763|No Intervention|Control Group|Dental implant was placed in these patients following full protocol of immediate implant placement.
16303558|NCT04650763|Experimental|PRP Group|In this group Platelet Rich Plasma (PRP) was injected in soft tissue over surgical site.
16303559|NCT04650750|Experimental|Xiao-Feng-San; Shian-Fang-Hwa-Ming-Yiin|Xiao-Feng-San 2g+ Shian Fang Hwa Ming Yiin 2g; twice a day for two months
16303560|NCT04650750|Placebo Comparator|Placebo|Similar placebo 4g twice a day for two months
16303561|NCT04650737|Active Comparator|Group A (single shot,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine ;ultrasound guided ESPB
16303562|NCT04650737|Active Comparator|Group B (continous infusion,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs;ESPB
16303567|NCT04650685|Experimental|The novel Salvadora persica toothbrush|The novel toothbrush is under Al-Abyad Miswak brand that will be supplied by Insight Prestige Sdn Bhd. Participants are expected to use this oral hygiene tool for 3 weeks.
16303568|NCT04650685|Experimental|The Salvadora persica (miswak) chewing sticks|The chewing sticks are under the brand of Al-Khair. They will be prepared into equal length of 15 cm with uniform diameter of 1.0-1.5 cm and are sealed in airtight plastic bags. Participants are expected to use this oral hygiene tool for 3 weeks.
16303569|NCT04650685|Other|Standard toothbrush and toothpaste (control)|Participants will be given straight-handle soft-bristle Oral-B™ standard toothbrush and Colgate® fluoride tooth. Participants are expected to use this oral hygiene tool for 3 weeks.
16303570|NCT04650659||Part one of the project|83 patients with Systemic Sclerosis will perform three functional exercise tests on the same day. All 83 patients will be examined with NVC.
16303571|NCT04650659||Part two of the project|Half of the patients from part one of the project will be invited to repeat the three functional exercise tests approximately one week later in reverse order to determine test-retest reliability.
16303572|NCT04650646|Experimental|Hypoglycaemic clamp i combination with exercise|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with an exercise session. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
16303573|NCT04650646|Experimental|Hypoglycaemic clamp in combination with bed rest|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with bed rest. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
16303575|NCT04650620|Experimental|Plenhyage® thin|Plenhyage® thin for the treatment of mild wrinkles;
16303576|NCT04650620|Experimental|Plenhyage® medium|Plenhyage® medium for the treatment of moderate wrinkles;
16303577|NCT04650620|Experimental|Plenhyage® strong|Plenhyage® strong for improving the skin tones and irregularities (atrophies) of the skin surface in neck, abdomen, thighs and buttocks
16303578|NCT04650607||Adverse event after injection of phages|patients having a BJI/PJI treated by injection of phages, with or without surgery
16303579|NCT04650594|Experimental|case group|Patients with knee bone malignancy
16303580|NCT04650581|Experimental|Ipatasertib + Fulvestrant|
16303581|NCT04650581|Placebo Comparator|Placebo|
16303582|NCT04650568|Experimental|Mesenchymal Stem Cell Recipient|Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.
16303583|NCT04650568|Placebo Comparator|Control Sham Incision|Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care.
16303584|NCT04650555|Experimental|Single Ascending Dose Cohort 1|500 mg BIO 300 Oral Powder administered as a single dose
16303585|NCT04650555|Experimental|Single Ascending Dose Cohort 2|1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
16303586|NCT04650555|Experimental|Single Ascending Dose Cohort 3|2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
16303587|NCT04650555|Experimental|Single Ascending Dose Cohort 4|Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3
16303588|NCT04650555|Experimental|Multiple Single Dose Cohort 5|Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days
16303589|NCT04650542|Experimental|HBI-3000 alone (Period 1) followed by HBI-3000 with Paroxetine (Period 2)|"HBI-3000: 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2
~Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2"
16303590|NCT04650516|Experimental|Endocare treatment|Patients will receive the treatment on a dedicated virtual reality headset to display the Endocare® application, with high quality headphones
16303591|NCT04650516|Active Comparator|Digital control treatment|Patients will receive the digital control on a dedicated tablet to display the digital control, with high quality headphones
16303592|NCT04650503||Patients with eosinophilic asthma at baseline|Patients showing ≥3% sputum eosinophils at baseline
16303593|NCT04650503||Patients with non eosinophilic asthma at baseline|Patients showing <3% sputum eosinophils at baseline
16303594|NCT04650490|Experimental|Immediate SRS followed by IO|Participants will receive SRS followed by physician's choice of standard of care immunotherapy, given at the FDA-approved dose within 14 days of SRS.
16303595|NCT04650490|Experimental|Immediate IO followed by SRS|Participants will receive physician's choice of immunotherapy, given at the FDA-approved dose followed by SRS, if deemed appropriate, at the time of intracranial progression.
16303596|NCT04650477|Active Comparator|Fixated in the EP position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the extension-pronation (EP) position
16303597|NCT04650477|No Intervention|Fixated in the neutral position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the neutral position (elbow 90 degrees flexed and hands positioned with the thump pointing up
16303598|NCT04650451|Experimental|HER2-targeted dual-switch CAR-T cells|Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.
16303599|NCT04650438|Experimental|High-creativity|Here participants are allocated to the high-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
16303600|NCT04650438|Experimental|Low-creativity|Here participants are allocated to the low-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
16303601|NCT04650425|Experimental|Intervention group|Each participant will undergo one or two sessions, consisting of cognitive tasks, video-EEG recording and administering of questionnaires.
16303602|NCT04650412|Experimental|Intervention|Bundle of comorbidities care
16303603|NCT04650412|No Intervention|Control|Standard care
16303604|NCT04650399|Experimental|Vaccine arm|Live-attenuated CHIKV in a lyophilized formulation (1x10E4 TCID50 per 0.5 mL) in a IM single dose
16303605|NCT04650399|Placebo Comparator|Placebo arm|Placebo (0.5 mL) in a IM single dose
16303606|NCT04650386|No Intervention|Treatment As Usual (TAU)|Participants assigned to the TAU condition will be scheduled for buprenorphine medication management appointments and will receive OBOT at the FQHC and adjunctive psychosocial treatment as typically provided at the FQHC. The team will continue to meet with the patient during subsequent MAT visits on a decreasing frequency, with some slight site-specific variation. The schedule of MAT visits generally includes 3 clinic visits during the week of induction, 1-2 visits per week until the patient is stabilized, and monthly thereafter. Behavioral health clinicians provide support to the patient, discuss UDS results, assist with strategic problem-solving around recovery and adjustment to sobriety, and monitor the patient's engagement in MAT.
16303607|NCT04650386|Experimental|Adaptive Intervention|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
16303608|NCT04650373||Surgical management|Underwent bariatric surgery
16303609|NCT04650373||Non-surgical management|Patients treated medically
16303610|NCT04650360|Experimental|Postoperative Intervention Educational Program|The intervention group will receive an educational program during admission. The health educational program will consist of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics will be addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls
16303611|NCT04650360|No Intervention|Control|The patients in the control group will not receive any educational program. These patients will be treated according to routine protocols
16303612|NCT04650347|Experimental|internal urethrotomy using Holmium laser representing group|In group 1, a three hundred micron laser fiber was used to conduct the laser energy. holmium laser pulse energy of approximately 1 joule was used that was generated from a Holmium laser Quanta device and total power of 15 watts. the laser fiber was aimed directly to the midline at 12 o'clock position to start the procedure and cut the fibrous tissue till access to a wide lumen.
16303613|NCT04650347|Active Comparator|internal urethrotomy with Sachs cold knife|In group B, Sache cold knife internal urethrotomy was used with the same technique as Holmium laser internal urethrotomy at the same site to mechanically cut instead of the laser fiber.
16303614|NCT04650334|Other|Perinatal Collaborative Care|Experimental: Perinatal Collaborative Care in Can Tho, Vietnam This is an active treatment arm consisting of 3 health centers receiving training in collaborative care and enrollment of a total of 100 perinatal patients into collaborative care.
16303615|NCT04650321|Experimental|Home infusion of ocrelizumab|Patients will receive infusion of ocrelizumab at home, instead of at clinic.
16303616|NCT04650308|Active Comparator|Healthy group|healthy men and women aged 20-60 years old.
16303617|NCT04650308|Active Comparator|Non-healthy group|pregnant women, nursing mothers, impaired kidney and liver function, chronic disease, or other metabolic disorders.
16303618|NCT04650295|Experimental|Household Remedy|
16303619|NCT04650295|Placebo Comparator|Tap Water|
16303620|NCT04650282|Experimental|Lidocaine in SphenoCath device|One treatment will be given.
16303621|NCT04650282|Placebo Comparator|Saline Solution in SphenoCath device|One treatment will be given.
16303622|NCT04650269|Experimental|Rapid ART group|Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.
16303623|NCT04650256|Experimental|CAM arm|Participants will be given the CAM intervention during scheduled, standard of care radiotherapy (up to 6 weeks) and 8-12 weeks (weeks 14-18) after radiotherapy.
16303624|NCT04650243|Experimental|ursodeoxycholic acid 250mg bid|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally twice a day.
16303625|NCT04650243|Experimental|ursodeoxycholic acid 250mg qd|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally once a day.
16303626|NCT04650243|Active Comparator|ursodeoxycholic acid standard dosage|Patients will receive standard dosage of ursodeoxycholic acid 250mg orally three times a day.
16303627|NCT04650230|Active Comparator|high flow nasal cannula (HFNC)|Participants in the HFNC group received heated and humidified gas flow with the Fisher & Paykel Healthcare HFNC system. The flow rate was usually started at the maximum flow rate for the size of cannula and a constant flow temperature of 37 °C.The flow rate will be progressively decreased when inspired fraction of oxygen (FiO2) was inferior to 30 percent (%).
16303628|NCT04650230|Active Comparator|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)|Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.
16303629|NCT04650217|Active Comparator|L-DOPA + Exercise|N=20 subjects assigned to L-DOPA + Exercise will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive exercise training 4 times a week (exercise)
16303697|NCT04649710|Experimental|Cohort 3: Dose 1 or placebo|Korean participants
16303630|NCT04650217|Active Comparator|LDOPA + Control|N=20 subjects assigned to L-DOPA + Control will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive a stretching and toning regime (Control).
16303631|NCT04650217|Placebo Comparator|Placebo + Exercise|N=20 subjects assigned to Placebo + Exercise will receive placebo three times daily and also will receive exercise training 4 times a week (exercise).
16303632|NCT04650217|Placebo Comparator|Placebo + Control|N=20 subjects assigned to Placebo + Control will receive placebo three times daily and also will receive a stretching and toning regime (Control).
16303633|NCT04650204|Experimental|Arm A (perampanel)|Patients receive perampanel PO daily 40 weeks in the absence of disease progression or unacceptable toxicity.
16303634|NCT04650204|Active Comparator|Arm B (ASD)|Patients receive ASD per standard of care for 40 weeks in the absence of disease progression or unacceptable toxicity.
16303635|NCT04650191||Mild COVID-19 infection|Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
16303636|NCT04650191||Moderate COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
16303637|NCT04650191||Severe COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
16303638|NCT04650178||Observational (questionnaire, quality of life)|Patients complete an online questionnaire over 15 minutes about their experiences regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
16303639|NCT04650152||Fenofibrate|Adult patients with triglycerides > 2,3 mmol/l who are on statins and who are primary prescribed fenofibrate (or fenofibrate treatment break is at least 6 months) in accordance with ordinary physician practice in Russia.
16303640|NCT04650139||successful CTO|
16303641|NCT04650139||non- successful CTO|
16303642|NCT04650126|Experimental|ATM001|Escalating dose levels of ATM001 administered as single dose in healthy subjects
16303643|NCT04650126|Placebo Comparator|ATM001 Placebo|Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects
16303644|NCT04650113|Experimental|group A|placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude ) 9.The pellet will be remove, and the pulp chamber filled with MTA. 10.The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement
16303645|NCT04650113|Active Comparator|group B|"Pre-operative radiograph showing all roots and their apices.
~Local anesthesia will be administered and a rubber dam will take place ,that ensure good isolation of the treated teeth.
~Removal of caries
~Pulp chambers will access using a no.330 bur in a high-speed hand piece with water coolant.
~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece
~Pulp amputation will perform using a spoon excavator.
~Hemorrhage control will obtain within 5 minutes using sterile cotton pellets placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude )
~The pellet will be remove, and the pulp chamber will be filled with MTA.
~The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement.
~The periapical radiographic will be taken at this baseline visit ."
16303646|NCT04650100|Experimental|PENG group|For the PENG group, the ultrasound-guided PENG block (20 ml of Ropivacaine 4.75 mg/ml) is performed before the surgery.
16303647|NCT04650100|No Intervention|Control group|No additional intervention, only standard care
16303648|NCT04650087|Active Comparator|Apixaban|Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
16303649|NCT04650087|Placebo Comparator|Placebo|Drug: Placebo Participants will be given study medication at the time of discharge from the hospital. Participants will take the Placebo twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
16303650|NCT04650074|Active Comparator|LIDOCAINE 20 mg|4 injections (on day 1, day 7, day 14, day 30) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).
16303651|NCT04650074|Experimental|LIDOCAINE 20 mg + KETAMINE 20 mg|4 injections (on day 1, day 7, day 14, day 30) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).
16303652|NCT04650074|Experimental|LIDOCAINE 20 mg + KETAMINE 40 mg|4 injections (on day 1, day 7, day 14, day 30) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).
16303653|NCT04650061|Experimental|PIMA Group|"MEntA: Educational & Training Program
~Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)
~Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support
~Identification of Care plan and Schedule next visits
~Follow-up D21-D90-D120-D180 depending of the care plan, through the channel that belong for each care plan"
16303654|NCT04650061|Active Comparator|Control|"Training program
~Schedule next visits
~Follow-up D21-D90-D120-D180 using the same process: visit at home or phone."
16303655|NCT04650048|Active Comparator|Active tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
16303656|NCT04650048|Placebo Comparator|Sham tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
16303657|NCT04650022||TPCIV-ABAO|TPCIV-ABAO
16303658|NCT04649996||Pandemic period|patients admitted in hospital for acute appendicitis
16303659|NCT04649996||control period|patients admitted in hospital for acute appendicitis
16303660|NCT04649983|Experimental|Arm 1|Patients will be be treated with CD19 and CD22 CAR-T cells
16303661|NCT04649970||malignant uropathy|Antegrade double-J stent
16303662|NCT04649957||Cohort Observation|"Study investigators will identify eligible participants within 72 hours of expected discharge from hospital. Eligibility will be determined using the criteria outlined in section 5.1 which incorporates the Post-COVID-19 Functional Status (PCFS) Scale, a tool which has been developed and endorsed by the European Respiratory Society to measure functional status over time following COVID-19 infection. Patients graded 2, 3 or 4 on the PCFS will be eligible for participation. Eligible patients will be provided with a detailed explanation of the study including the provision of written information (PIS). Patients will be given time to consider participation in the research study before being approached again by the research team.
~If the patient expresses an interest in study participation the research team will invite participants to a baseline data collection session that will be held at the University of Derby (Kedleston Road campus) in the days following discharge."
16303663|NCT04649918||mild to moderate COVID 19|patients post-acute mild to moderate COVID 19
16303664|NCT04649918||severe to critical COVID 19|patients post-acute severe to critical COVID 19
16303665|NCT04649905||Surgical Treatment|
16303666|NCT04649905||Nonoperative Treatment|
16303667|NCT04649892|Experimental|Naltrexone|A 12 week Naltrexone flexible dose administration plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
16303668|NCT04649892|Placebo Comparator|Placebo|A 12 week placebo matching tablets plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
16303669|NCT04649879|Experimental|Convalescent plasma treatment|"Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions.
~If steroid therapy has not already been initiated, betamethasone 3 mg daily will be given concomitantly with steroid therapy or longer if clinically indicated but for a maximum of 10 days."
16303670|NCT04649879|Active Comparator|Control|Standard of care for COVID-19 patients.
16303671|NCT04649866|Experimental|Test group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
16303672|NCT04649866|Active Comparator|Control group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
16303673|NCT04649853||Acute Wounds|Patient with either traumatic or surgical wounds
16303674|NCT04649853||Chronic Wounds|Patient with chronic wounds either peripheral vascular disease related or surgical/traumatic wound
16303675|NCT04649853||Pressure Injuries Present on Admission|Patient admitted with one or more pressure injury of any stage on admission
16303676|NCT04649853||At Risk for Pressure Injury|Patient admitted with risk for pressure injury and has no pressure injuries at time of admission. Identified as at risk for based on mobility.
16303677|NCT04649840||COVID-19 moderate|moderate COVID-19 associated pneumonia
16303678|NCT04649840||COVID-19 severe|severe COVID-19 associated pneumonia
16303679|NCT04649827||COVID-19|Patients with confirmed COVID-19 by RT-PCR or serological test
16303680|NCT04649801|No Intervention|conventional|
16303681|NCT04649801|Active Comparator|interventional|
16303682|NCT04649788|Active Comparator|Ultrasound-guided axillary vein access|This group of patients will receive the cardiac implantable electronic device with ultrasound-guided axillary venous access.
16303683|NCT04649788|Active Comparator|Cephalic vein access|This group of patients will receive the cardiac implantable electronic device with cephalic venous access.
16303684|NCT04649775|Active Comparator|Device intervention|Intervention participants will receive the AirFLO2 device and training via video with reinforcement from the coordinator how to use and to self-apply it. Clinical data will be recorded before and after intervention. Questionnaires will be completed at baseline and at serial time points after intervention starts.
16303685|NCT04649775|No Intervention|Standard of Care- Control|Participants will receive standard of care, clinical data will be recorded. Baseline and end of study questionnaires will be performed.
16303686|NCT04649762||Control|Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis
16303687|NCT04649762||TAC|Group 2 includes patients with anxiety consulting a doctor practicing hypnosis
16303688|NCT04649749||Patients - bionic hand acquired|3 adult patients who acquired a bionic hand at the Medical University of Vienna after a traumatic brachial plexus lesion.
16303689|NCT04649749||Patients - bionic hand not yet acquired|3 patients eligible for the bionic hand prior to a possible amputation.
16303690|NCT04649749||Control subjects|Ten control subjects will be included for comparison.
16303691|NCT04649736|Experimental|Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support|"Participants in the intervention arm will receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.
~Additionally, these participants will receive the intervention program that involves home-based respiratory physiotherapy and telephone-based psychological support for 6 weeks."
16303692|NCT04649736|No Intervention|Control|Participants in the control arm will only receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.
16303693|NCT04649723|Experimental|Rifampicin 600 mg + SHR1459 Tablets 200 mg|
16303694|NCT04649723|Active Comparator|SHR1459 tablets 200 mg|
16303699|NCT04649697|Experimental|Rebamipide|The enrolled subjects will be treated with Rebamipide in orabase for 2 weeks or until complete healing.
16303700|NCT04649697|Experimental|Nanoparticulated Rebamipide|The enrolled subjects will be treated with nanoparticulated Rebamipide in orabase for 2 weeks or until complete healing.
16303701|NCT04649697|Active Comparator|Clobetasol|The enrolled subjects will be treated with Clobetasol in orabase for 2 weeks or until complete healing.
16303702|NCT04649684|Experimental|Conventional robot-assisted gait training group|they got conventional robot-assisted gait training, guidance force given equally to both limbs
16303703|NCT04649684|Experimental|Lower CIMT robot-assisted gait training group|they got robot-assisted gait training based on CIMT concept
16303706|NCT04649658||Prone position|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to prone position
16303707|NCT04649658||Standard care|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to standard care
16303708|NCT04649645|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
16303709|NCT04649645|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS.
16303710|NCT04649645|Active Comparator|Control Arm (Arm C)|Participant continues to not smoking or using of any nicotine/tobacco products.
16303711|NCT04649619|Other|Single-arm-study|Prospective clinical trial with intentional sample selection that aims to describe the results of the gastric Bypass surgery modified by De Melo, for the purpose of endoscopic access to the excluded remaining stomach, as well as to monitor the clinical conditions of comorbidities and the quality of life of the patient.
16303712|NCT04649606||Experimental|Eligible subjects will undergo repeated observations to evaluate the Meibomian gland appearance
16303713|NCT04649593|No Intervention|according to clinical guidlines|Dystocic progress and an observed low AFL value (< 12.0 mmol/l).
16303714|NCT04649593|Experimental|intevention|"At dystocic labor and an observed high AFL value, the woman is randomized to one of the intended two study groups.
~Group 1) Delivery according to the clinic's guidelines in case labor dystocia, i.e., oxytocin stimulation Group 2) Two bags of Samarin mixed in a glass of water. After an hour, In case of lack of progress, oxytocin stimulation is started."
16303715|NCT04649580||Online Survey|
16303716|NCT04649580||One-to-one interviews|
16303717|NCT04649554|Experimental|Experimental: ExAblate 4000 System|Exablate treatment on Neuropathic Pain
16303718|NCT04649541|Active Comparator|Single intravenous doses of MRX-8|Single escalating doses of MRX-8
16303719|NCT04649541|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-8
16303720|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 7 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 7 days.
16303721|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 7 days|Multiple intravenous doses of placebo every 12 hours for 7 days to match MRX-8.
16303722|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 14 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 14 days.
16303723|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 14 days|Multiple intravenous doses of placebo every 12 hours for 14 days to match MRX-8.
16303724|NCT04649528|Experimental|Supervised HIIT|Exercise intervention, 20 supervised by healthcare professional
16303725|NCT04649528|Experimental|APP HIIT|Exercise intervention, 20 self-monitored assisted by a mobilephone application
16303726|NCT04649515|Experimental|TY027 1,500 mg|1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
16303727|NCT04649515|Experimental|TY027 2,000 mg|2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
16303728|NCT04649515|Placebo Comparator|Placebo|Placebo will be administered via IV infusion over a period of 30 minutes.
16303729|NCT04649502|Experimental|Metformin combined with doxycycline|
16303730|NCT04649502|Placebo Comparator|Doxycyline combined with placebo|
16303731|NCT04649489||Arm A (experimental arm)|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
16303732|NCT04649489||Arm B (control arm)|atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
16303733|NCT04649476|Experimental|Neoadjuvant PD-1 blockade alone|The participants will receive 3 doses of neoadjuvant PD-1 blockade. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
16303734|NCT04649476|Experimental|Neoadjuvant PD-1 blockade plus TPF induction chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TPF induction chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
16303735|NCT04649463|Active Comparator|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
16303736|NCT04649463|Sham Comparator|Concealed ABPM results|ABPM results were not used in the decision making for adjustments in antihypertensive medication at follow up visit.
16303766|NCT04649229|Experimental|aprepitant, placebo, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
16303767|NCT04649216|Experimental|Mass Balance|Subjects will receive a single oral dose of [14C]PCO371 Oral Solution.
16303737|NCT04649450|Experimental|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days (post-operative day 1, 2 and 3) at the neurosurgical ward they will receive music twice a day for 30 minutes. All participants will further receive standard of clinical care.
16303738|NCT04649450|No Intervention|Standard of clinical care|Standard of clinical care.
16303739|NCT04649437|Other|Symptomatic patients|Subjects with symptoms of atrial fibrillation i.e. AF-6 sum score 30 points or more.
16303740|NCT04649437|Other|Asymptomatic patients|Subjects with no symptoms of atrial fibrillation i.e. AF-6 sum score = 0.
16303741|NCT04649424|Experimental|CanSwab - 1st|CanSwab will be swabbed first
16303742|NCT04649424|Experimental|CanSwab - 2nd|CanSwab will be swabbed second.
16303743|NCT04649411|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 24 weeks at a starting dose based on body weight categories.
16303744|NCT04649411|Active Comparator|Standard of care|Participants aged 12 to <18 years and 6 to <12 years will receive standard of care treatment for 24 weeks.
16303745|NCT04649398||oral nimodipine|60mg of nimodipine is orally administered every 4 h,
16303746|NCT04649398||intra-venous nimodipine|nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4
16303747|NCT04649398||intra-arterial nimodipine|during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes
16303748|NCT04649385|Experimental|Phase 1a: Dose Escalation|"Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 5 increasing doses for up to 6 months
~Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy ) for up to 12 months"
16303749|NCT04649385|Experimental|Phase 1b: Dose Expansion|Phase 1b dose expansion will begin based upon the recommended Phase 2 dose (RP2D) for BGB-15025 alone or in combination with tislelizumab as determined from Phase 1a
16303750|NCT04649372|Other|EndoVE endosCopic Treatment for Oesophageal and Gastric canceR|The patient will be placed under General Anaesthetic or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged. There will be a telephone follow up after 2 days, 7 days, 4 weeks and 8 weeks. The patient will be requested to attend the clinic for a 12-week follow up for clinical review.
16303753|NCT04649346||SGA type 1|Observe the function of SGA type 1
16303754|NCT04649346||SGA type 2|Observe the function of SGA type 2
16303755|NCT04649320||cancer patients|adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
16303756|NCT04649307|Other|MI-CBT|The treatment will be based on the AF treatment developed by the research group and further be developed and adapted during the course the study, based on the clinical presentation of the MI patients and their response to the CBT interventions detailed below. The MI-specific CBT will consist of 8 weekly face-to face digital video sessions with home assignments that can be reviewed and reported in the research groups secure platform. CBT for MI primarily targets two processes of disability; cardiac anxiety, and depressive inactivity
16303757|NCT04649281|Other|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
16303758|NCT04649268|Active Comparator|Optokinetic stimulation treatment with visual motion DVDs|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with visual motion DVDs
16303759|NCT04649268|Experimental|Optokinetic stimulation treatment with Virtual Reality|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with Virtual Reality environments delivered with headset (e.g. Oculus Quest headset)
16303760|NCT04649255|Experimental|Lava LES|
16303761|NCT04649242|Active Comparator|BHV3000 (active drug)|BHV3000 (rimegepant) 75 mg or 50 mg ODT
16303762|NCT04649242|Placebo Comparator|Placebo|Matching 75 mg or 50 mg ODT placebo
16303763|NCT04649229|Experimental|placebo, aprepitant, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
16303764|NCT04649229|Experimental|placebo, aprepitant, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
16303765|NCT04649229|Experimental|aprepitant, placebo, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
16303768|NCT04649216|Experimental|Absolute Bioavailability and Mass Balance|Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of [14C]PCO371 over 10 min, starting 2 h post-oral dose.
16304023|NCT04647500|Other|22q11DS naive|22q11DS participants naive to methylphenidate
16303769|NCT04649203|Experimental|Group 1|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 10 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 75 days
16303770|NCT04649203|Placebo Comparator|Group 2|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 10 days + Placebo, 2 tablets 2 times a day, for 75 days
16303771|NCT04649190||TAVI|
16303772|NCT04649177|Other|study group|There is only one study group in this study. All subjects will receive the OCT scanning and PROSE lens fitting.
16303773|NCT04649164|Other|Focus group participants|"Subjects participating in focus groups will be either:
~caregiver mentees in our previous peer mentoring study
~peer mentors and completed 16 weeks of mentoring in our previous peer mentoring study
~current family caregivers of community-dwelling LBD patients in the Chicago area.
~The investigators will conduct virtual focus groups using a password-protected videoconference platform. The informed consent process will take place online prior to the focus group. Focus groups will be led by a qualified neuropsychologist using open-ended questions. The aim of these groups is to revise and improve upon our previous peer mentor program's curriculum. Participants will be presented with the previous program's curriculum and a variety of proposed educational resources for inclusion in the revised curriculum. The investigators will obtain participants' feedback. Focus groups will be recorded and transcribed."
16303774|NCT04649164|Other|Peer mentors|Mentors will attend one 6-7 hour virtual training session. Study expectations and logistics will be reviewed with each potential mentor prior to the training session via phone. Informed consent process will take place online via REDCap prior to the training session. Baseline data will be collected via online surveys. Next, mentors will receive training regarding topics including active listening, mentoring, goal-and boundary-setting, an overview of LBD, risk factors for hospitalization, impact on caregiver, practical approaches to symptom management, and caregiving issues. The study team will present the PERSEVERE curriculum and accompanying handbook. The team will solicit questions and lead roleplay conversations. Finally mentors will complete post-training assessments. Once all caregiver mentees (Arm 3) are recruited, the mentors will contact their mentees once weekly by phone for 16 weeks to deliver the PERSEVERE curriculum.
16303775|NCT04649164|Experimental|Caregiver mentees|Once Aim 2 is complete and mentors have been trained, caregiver mentees will be matched with mentors by relationship to LBD patient, then by sex and age, as much as possible. The study team will contact mentees once a match is available for them. The mentee will complete baseline primary and secondary outcome assessments online via REDCap, including: mastery and loneliness scales, Short Zarit Burden Interview, Hospital Anxiety and Depression Scale. The team will provide the mentor's contact information and send the PERSEVERE handbook. Mentoring pairs will begin the 16-week peer mentor program. Pairs will be expected to speak for >15-30 minutes weekly, and to review that week's PERSEVERE topics in the handbook before or during each call to facilitate meaningful conversations. Mentors and mentees will complete online study diaries every 2 weeks. Upon completion of the 16-week mentor program, mentors and mentees will be sent a link to complete postmentoring assessments online.
16303776|NCT04649151|Experimental|mRNA-1273|"Part A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram [ug] each), 28 days apart, on Day 1 and Day 29.
~Part B (Open-Label Phase): Participants who continue in Part B, will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29."
16303777|NCT04649151|Placebo Comparator|Placebo|Part A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
16303778|NCT04649125|Active Comparator|standard|standard radiotherapy 5 fractions
16303779|NCT04649125|Experimental|single fraction dose escalation|8Gy to Planned Target Volume, 12Gy to Clinical Target Volume +/- 14Gy to Gross Target Volume
16303780|NCT04649112|Experimental|Dose Level 1|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).
~Route of Administration: Intravenous injection/infusion."
16303781|NCT04649112|Experimental|Dose Level 2|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).
~Route of Administration: Intravenous injection/infusion."
16303782|NCT04649112|Experimental|Dose Level 3|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).
~Route of Administration: Intravenous injection/infusion."
16303783|NCT04649099|Experimental|Leaflex™ Performer|
16303784|NCT04649086|Experimental|Eccentric group|The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session.
16303785|NCT04649086|Active Comparator|Concentric group|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
16303786|NCT04649073|Experimental|OPC-415 (up to 1×10^7cells/kg)|
16303787|NCT04649060|Experimental|Study Treatment Arm A (melflufen+dexamethasone+daratumumab)|"Treatment will be given in cycles and may be given in an outpatient treatment setting. Each cycle is 28 days.
~Melflufen 30 mg i.v. infusion at Day 1 of each cycle
~Dexamethasone 40 mg p.o. weekly (if ≥75 years 20 mg weekly).
~Daratumumab 1800 mg s.c. Cycle 1 and 2: Day 1, 8, 15 and 22. Cycle 3 to 6: Day 1 and 15. Cycle 7+: Day 1."
16303788|NCT04649060|Active Comparator|Study Treatment Arm B (daratumumab)|"Treatment will be given in cycles and may be given in an outpatient treatment setting. Each cycle is 28 days.
~• Daratumumab 1800 mg s.c. Cycle 1 and 2: Day 1, 8, 15 and 22. Cycle 3 to 6: Day 1 and 15. Cycle 7+: Day 1."
16303789|NCT04649047|Experimental|Intervention|All participants will be assigned to the experimental group and receive a 3-weekly intervention via web and individual health coaching. The educational topics cover stress management, healthy eating, and physical activity
16303790|NCT04649034||86 patients ischemic DCM|A cohort of 86 patients with ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
16304811|NCT04642352||SLN intervention group|Participants will undergo a superior laryngeal nerve (SLN) block
16303791|NCT04649034||86 patients non ischemic DCM|A cohort of 86 patients with non-ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
16303792|NCT04649034||86 patients hypertrophic cardiomyopathy|A cohort of 86 patients with hypertrophic cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 55% or with an apical aneurism diagnosed in an image test
16303793|NCT04649021|Experimental|BNT162b2 18-85 years of age|
16303794|NCT04649021|Placebo Comparator|Placebo 18-85 years of age|
16303795|NCT04649008|Experimental|Epilepsy patient volunteers|Patients recruited for the study with intractable epilepsy who are anticipated to undergo epilepsy surgery
16303796|NCT04648995|Other|High energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
16303797|NCT04648995|Other|Low energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
16303798|NCT04648969|Experimental|Experimental: kisspeptin, GnRH|• Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.
16303799|NCT04648956||Knee/Hip osteoarthritis|Patients referred for physical therapy rehabilitation
16303800|NCT04648943|Active Comparator|Patients undergoing Ex-Press mini shunt insertion|Patients in this arm had the Ex-Press mini shunt inserted in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
16303801|NCT04648943|Active Comparator|Patients undergoing trabeculectomy|Patients in this arm had standard trabeculectomy in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
16303802|NCT04648930||Xolair|S.C. Injection
16303803|NCT04648917|Experimental|Arm A|In Arm A: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval (weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
16303804|NCT04648917|Placebo Comparator|Arm B|In Arm B: 40 patients will receive the placebo tablets: 100-200mg, tid, po, 2 weeks treated then 1 week black interval.
16303805|NCT04648904|Experimental|Post-Mastectomy Radiotherapy|Treatment will consist of PMRT delivered using external beam RT techniques to a dose of 26 Gy in 5 fractions of 5.2 Gy delivered on consecutive weekdays with an optional chest wall boost of 5.2 Gy for 1-2 fractions or an alternate boost schedule of 2.5 Gy for 1-4 fractions at the discretion of the treating physician.
16303806|NCT04648891|Other|Control|Patients will receive laryngeal injection of Botox via a transcricothyroid approach without additional anesthesia
16303807|NCT04648891|Experimental|Lidocaine|Patients will receive laryngeal injection of Botox via a transcricothyroid approach following subcutaneous injection of 0.5cc 2% lidocaine in 1:100,000 epinephrine (done approximately 2 minutes before Botox injection)
16303808|NCT04648891|Experimental|Vibrating Wand|Patients will receive laryngeal injection of Botox via a transcricothyroid approach while a vibrating instrument is held adjacent to cricothyroid space
16303809|NCT04648878|Experimental|Group A - Hybrid combination|Group A (n=12) will receive 18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks.
16303810|NCT04648878|Experimental|Group B - Powered Exoskeleton only|Group B (n=12) will receive 18 visits of powered exoskeleton only, three times a week for approximately 6 weeks.
16303811|NCT04648878|Experimental|Group C - Physical Therapy only|Group C (n=12) will receive 18 visits of physical therapy, three times a week for approximately 6 weeks. Upon completion of the data collection portion of the study, group C will receive 9 sessions, three times a week for approximately three weeks of powered exoskeleton therapy. Data will not be collected or reported during this phase, but but may be retained for future approved use.
16303812|NCT04648865|Experimental|LY3537031|LY3537031 administered subcutaneously (SC).
16303813|NCT04648865|Placebo Comparator|Placebo|Placebo administered SC.
16303814|NCT04648852||Participants in the third wave of the HUNT study|General population participating in the third wave of the HUNT study
16303815|NCT04648852||Participants in the second wave of the HUNT study|General population participating in the second wave of the HUNT study
16303816|NCT04648839||Benralizumab|Patients that received at least one dose of benralizumab according to routine clinical practice
16303819|NCT04648813|Experimental|tiotropium bromide monohydrate (Spiriva Respimat)|
16303820|NCT04648813|Placebo Comparator|matching placebo|
16303821|NCT04648800|No Intervention|Group I|with positive RT23 test reading, not randomised and not vaccinated against tuberculosis
16303822|NCT04648800|Active Comparator|Group II|with negative RT23 test reading, receiving BCG-10 Vaccine
16303823|NCT04648800|Placebo Comparator|Group III|with negative RT23 test reading, receiving placebo
16303824|NCT04648787|Experimental|Intervention group: traditional nursing with family-integrated care|traditional nursing with family-integrated care
16303825|NCT04648787|Experimental|Control group: traditional nursing|traditional nursing
16303826|NCT04648774|Active Comparator|Active serratus anterior plane (SAP) block with Ropivacaine 0.2%|
16303827|NCT04648774|Placebo Comparator|Placebo serratus anterior plane (SAP) block with normal saline|
16303828|NCT04648761|Experimental|OPTIMAL group|This group will have their anti IL 5 biologics titrated by OPTIMAL algorithm
16303829|NCT04648761|No Intervention|Control group|This group will continue their treatment with anti IL 5 biologics unchanged
16303864|NCT04648514|Active Comparator|Patient satisfaction evaluation after using bone osteotomes|Evaluation of patient satisfaction numerically will be done after using summers' osteotome technique by bone osteotomes for closed sinus lifting in posterior edentulous maxilla
16303830|NCT04648735|Experimental|Drivers with cognitive impairments|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
16303831|NCT04648735|Active Comparator|drivers with normal cognition|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
16303832|NCT04648722||Left-side hemithyroidectomy|Patients who received a hemithyroidectomy of the left thyroid lobe since 1994
16303833|NCT04648722||Right-side hemithyroidectomy|Patients who received a hemithyroidectomy of the right thyroid lobe since 1994
16303834|NCT04648709||asymptomatic patients|asymptomatic patients with PCR-positive PCR
16303835|NCT04648709||mild symptoms patients|patients with mild symptoms and PCR positive
16303836|NCT04648709||seriously symptomatic patients|seriously symptomatic patients with PCR positive
16303837|NCT04648709||patients in resuscitation|patients in resuscitation with positive PCR
16303838|NCT04648709||heathly volunteer|heathly volunteer as control
16303841|NCT04648683|Experimental|Postsurgical Telehealth Mindfulness Program|Telehealth mindfulness sessions
16303842|NCT04648670|Experimental|Group intervention|"The experimental group consists of 101 participants have been subdivided into two groups of 25/26 that perform the same intervention but on a different day of the week.
~The two subgroups have received 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.
~."
16303843|NCT04648670|No Intervention|Group Control|The control group consists of 100 participants. The no intervention group did not receive any type of intervention
16303844|NCT04648657||acute hypoxemic respiratory failure patients|Mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) with P/F ratio < 300 with at least PEEP 5 cmH2O)
16303845|NCT04648644||Study population|All patients undergoing emergency abdominal surgery for infection or occlusion and treated with bowel resection with or without anastomosis; intestinal bypass or adhesiolysis
16303846|NCT04648631|Experimental|ABWG|The participants in this group will be receiving the ABWG daily for 4 consecutive weeks.
16303847|NCT04648618||OSA + DME +|Patients with OSA and DME
16303848|NCT04648618||OSA - DME +|Patients with DME, but no evidence of OSA
16303849|NCT04648605|Experimental|Questionary|Questionary for all parents
16303850|NCT04648592|Experimental|Intervention|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.
16303851|NCT04648592|Placebo Comparator|Control|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.
16303852|NCT04648579|Experimental|Hillrom|The intervention involves an automated vital signs document system consisting of a mobile medical device for measuring vital signs (CSM / Hillrom) that collects and analyzes data acquired at the bedside to be sent to a remote data processing point (Digital Control Station), using Hillrom Connecta software.
16303853|NCT04648579|Active Comparator|Control|Hospital usual care.
16303854|NCT04648566|Placebo Comparator|IIU control group|
16303855|NCT04648566|Active Comparator|IIU PBMC group|
16303856|NCT04648566|Placebo Comparator|FIV control group|
16303857|NCT04648566|Active Comparator|FIV PBMC group|
16303858|NCT04648566|Active Comparator|RIF group|
16303859|NCT04648553|Experimental|Task-Based Grounding|Participating parents will be provided with three 50-minute Task Based Grounding sessions using a standardized manual over 6 weeks.
16303860|NCT04648553|Sham Comparator|Connected Care (Enhanced treatment as usual)|"Participating parents will be provided with two sessions and one phone check-in call over 6 weeks. They will work with a care navigator to assess their child's needs, find them an appropriate referral for care, and help problem solve barriers to finding a therapist."
16303861|NCT04648540|Experimental|Opioid-Free Anesthesia (OFA)|"The following drugs will be administered 10 minutes before induction of anesthesia in group I (OFA):
~Pregabalin 150 mg orally with a small sip of water
~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes
~Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes
~Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes
~For simplicity, the weight-based doses of dexmedetomidine and lidocaine will be prepared in a 20 mL syringe
~the following drugs will be administered as a continuous infusion:
~Dexmedetomidine 0.5 mic/kg/h
~Lidocaine 0.5 mg/kg/h
~Patients in both groups will be extubated when they meet our institutional criteria for extubation. Postoperative analgesia will be started as follows:
~Group I (OFA):
~Acetaminophen 1 gm/6h
~ketorolac 30 mg/8h
~Pregabalin 150 mg once at night
~Celecoxib 200 mg/24 hours"
16303862|NCT04648540|Active Comparator|Opioid Anesthesia (OA)|"Before induction In Group II (OA) patients will receive placebo pills and normal saline in equivalent volumes .
~Maintenance
~In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h)
~Patients in both groups will be extubated when they meet our institutional criteria for extubation. Postoperative analgesia will be started as follows:
~• Morphine 0.1 mg /kg PRN every 8 hours"
16303863|NCT04648514|Active Comparator|Using of bone osteotomes for closed sinus lifting|Using of summers' osteotome technique by bone osteotomes for closed sinus lifting then evaluation the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement in posterior edentulous maxilla .
16303867|NCT04648488|Experimental|Early mobilisation|Patients will start unloaded exercise treatment 3 days after surgery. They will remove the plaster 5 times every day to perform range of motion exercises.
16303868|NCT04648488|Active Comparator|Standard treatment|Patients will have a plaster 3 weeks after surgery and after that start with exercise treatment.
16303869|NCT04648475|Experimental|Arm 1|CD19 and CD22 targeted CAR-T cells treat
16303870|NCT04648436|Other|Early surgery|
16303871|NCT04648436|Other|Initial conservative treatment|
16303872|NCT04648423|Experimental|sodium oxybate|Sodium oxybate solution for oral administration (175 mg/mL). Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
16303873|NCT04648423|Placebo Comparator|placebo|Placebo solution for oral administration. Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
16303874|NCT04648410||Members of European Society of Intensive Care|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
16303875|NCT04648397|Experimental|Short chewing|Subjects consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a short chewing protocol.
16303876|NCT04648397|Experimental|Long chewing|Subjects will consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a long chewing protocol.
16303877|NCT04648384|Experimental|Protein Supplementation and Resistance exercise|Protein supplementation composed of 20 gram of whey protein or casein in different proportions (80:20) and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
16303878|NCT04648384|Placebo Comparator|Placebo Supplementation|Placebo supplementation composed of 20 gram of Maltodextrin and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
16303879|NCT04648384|Experimental|Resistance Training|Resistance Exercise will be performed before supplementation and is composed by 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise.
16303880|NCT04648371|Active Comparator|Cognitive Remediation and Active Transcranial Direct Current Stimulation|Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the begining of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 6-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
16303881|NCT04648371|Sham Comparator|Cognitive Remediation and Sham Transcranial Direct Current Stimulation|CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
16303882|NCT04648358|Active Comparator|Control group|The control group will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000
16303883|NCT04648358|Experimental|DEX4mg group|DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000.
16303884|NCT04648345|Experimental|Erector spinal plane block group (ESPB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block will be performed in the ESPB group.
16303885|NCT04648345|Active Comparator|Vertebral side block group (VSB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral vertebral side block will be performed in the VSB group.
16303886|NCT04648345|Placebo Comparator|Local block group （LB group）|Local block will be performed at the surgical incisions after the surgery under general anesthesia.
16303887|NCT04648332|Experimental|Group 1|Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
16303888|NCT04648332|No Intervention|Group 2|Patients in group 2 underwent intraoperative spinal anaesthesia at the level of L3-L4 with hyperbaric bupivacaine at a dose of 10-15 mg.
16303889|NCT04648332|No Intervention|Group 3|Group 3 patients underwent general inhalation anaesthesia with sevoflurane with a constant infusion of fentanyl for analgesia.
16303890|NCT04648319|Experimental|locally advanced, metastatic or recurrent cholangiocarcinoma|D1: Compound: BMS-936558 treatment d8: radiotherapy D 20: CT guided Biopsy D 28: BMS-936558 treatment monthly: BMS-936558 treatment CT CAP: after 4doses
16303891|NCT04648306||Impella cohort|Single arm study of patients who underwent non-emergent percutaneous coronary intervention with prophylactic Impella support
16304815|NCT04642326|No Intervention|Control Group|Control: Antiviral + Antimalarial + Antibiotic Treatment
16303892|NCT04648293||Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. Improvement in hemodynamics is exhibited by an increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
16303893|NCT04648293||No Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. No Improvement in hemodynamics is exhibited by no increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
16303894|NCT04648280|Experimental|Fostemsavir|Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
16303895|NCT04648267|Active Comparator|Control group|Patients who have the cast and bolster on for standard 5 days after their radial forearm free flap and 7 days after their fibula free falp
16303896|NCT04648267|Experimental|Experimental group|Patients who have the cast and bolster on for 10-14 days
16303897|NCT04648254|Experimental|Dose escalation (Q702)|Participants will receive escalating doses of Q702
16303898|NCT04648241|Experimental|≥16 Years Old|TBE vaccine 0.5 mL (intramuscular injection).
16303899|NCT04648241|Experimental|1 to <16 Years Old|TBE vaccine 0.25ｍL (intramuscular injection).
16303900|NCT04648228|Experimental|ACT + MBRP|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) group will follow a manualized clinical protocol. Treatment will include 12 weekly group-based sessions, each lasting 90 minutes. Group sizes will range from 3 to 8.
16303901|NCT04648228|Active Comparator|Education Control (EC)|The EC group will follow a protocol that combines opioid education sessions and psychology-led pain education sessions that are offered as part of the interdisciplinary pain program. Specifically, education will include 12 group-based sessions, each lasting 60 minutes. Group sizes will range from 3 to 8.
16303902|NCT04648215|Experimental|lavender oil|lavender oil as aromatherapy two drops dispensed on a 2x2 gauze and pinned to subject's gown
16303903|NCT04648215|Placebo Comparator|grapeseed oil|grapeseed oil as aromatherapy two drops dispensed on a 2x2 gauze and pinned to subject's gown
16303904|NCT04648215|No Intervention|Standard of Care|
16303905|NCT04648202|Experimental|FS120 Q4W|The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design.
16303907|NCT04648176|Active Comparator|HoLEP|Conventional laser
16303908|NCT04648176|Experimental|m-HoLEP|Moses technology
16303909|NCT04648150|Experimental|VERUM|An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months
16303910|NCT04648150|Sham Comparator|SHAM|An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.
16303911|NCT04648137|Experimental|Patients with central diabetes insipidus|
16303912|NCT04648137|Experimental|Healthy volunteers|
16303913|NCT04648124||Patients for whom there is no planned implant surgery|
16303914|NCT04648124||Patients for whom implantation surgery is planned|
16303915|NCT04648124||case|
16303916|NCT04648098|Experimental|Experimental: Intervention group|Discharge training and telephone counseling
16303917|NCT04648098|No Intervention|No Intervention: Control Group|Routine care
16303919|NCT04648072|Experimental|Periarticular Injection + Adductor Canal Block (Local Anesthestic)|"The experimental arm with receive both the periarticular injection and the adductor canal block.
~The periarticular injection will be performed by the surgeon and will consist of 100 mL of injectate being distributed in the following manner: 30 mL to the posterior capsule, 10 mL to the medial collateral ligament, 10mL to the lateral collateral ligament (ensuring not to infiltrate common peroneal nerve), 20mL to the quadriceps and anterior capsule, and 30 mL to the subcutaneous tissue. The periarticular injection will consist of 250 mg of ropivacaine, 30 mg of ketorolac, and 0.5 mg of epinephrine.
~The adductor canal block will be completed by the anesthesiologist after spinal anesthesia has been initiated, but before the surgery commences. The block will be completed using an aseptic technique under dynamic, in-plane US guidance. 20 mL of injectate consisting of 100mg of ropivicaine and 50 mcg of epinephrine will be injected around the hyperechoic saphenous nerve."
16303920|NCT04648072|Placebo Comparator|Periarticular Injection + Adductor Canal Block (Normal Saline)|"The control arm with receive a periarticular injection and a sham adductor canal block.
~The periarticular injection will be carried out in the same manner as described for the experimental group. The technical aspects of the sham adductor canal block will be the same as for the experimental arm; however, the injectate will consist of 20 mL of normal saline."
16303921|NCT04648059||Lupus nephritis +ve|This group consists of patients with Lupus nephritis
16303922|NCT04648059||Lupus nephritis -ve|This group consist of patients with SLE without Lupus nephritis
16303923|NCT04648046|Experimental|Low Dose CAR-T Cells Only|Participants will NOT undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
16303924|NCT04648046|Experimental|Conditioning + Low Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
16303925|NCT04648046|Experimental|Conditioning + High Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused into the participant. ART will be interrupted immediately after infusion.
16304018|NCT04647513|Experimental|Art Filler Fine Lines (crow's feet)|Injection of Art Filler Fine Lines in crow's feet
16303926|NCT04648033|Other|Atovaquone in Combination with concurrent CRT|"Atovaquone is taken during an initial run in period (2 weeks +/- 7 days), then continued during standard of care CRT. Atovaquone dose level is allocated to each patient by a TiTE-CRM statistical model which takes into account all toxicity data to date: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
~Two 21-day cycles of cisplatin and vinorelbine chemotherapy will be given concurrently during radiotherapy treatment. Patients will receive 80 mg/m2 cisplatin on days 1 & 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 & 29. Thoracic radiotherapy will be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday).
~The last dose of atovaquone will be on the morning of the last fraction of radiotherapy. Total duration of atovaquone treatment will be 59 days (+/- 7 days), unless stopped earlier for toxicity or any other reason.
~Patients will be followed up at 1, 3 and 6 months post-CRT."
16303927|NCT04648020|Placebo Comparator|Placebo|Placebo Mucoadhesive Buccal Tablet given daily during chemoradiotherapy
16303928|NCT04648020|Experimental|Clonidine HCl Mucoadhesive Buccal Tablet (MBT)|Clonidine HCl MBT given daily during chemoradiotherapy
16303929|NCT04648007||Control|10 patients with no personal or family problems with gambling as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
16303930|NCT04648007||Moderate Gamblers|10 patients with moderate gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
16303931|NCT04648007||Severe Gamblers|10 patients with severe gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
16303932|NCT04647994||Covid-19 HC patients|Pregnant women hospitalized with symptoms and diagnosis of SARS-CoV-2 at HC-FMUSP.
16303933|NCT04647994||Delivery patients|Asymptomatic pregnant women that tested SARS-CoV-2 serology (positive or negative serology) at the delivery time at Universitarian Hospital HU-USP and HC-FMUSP.
16303934|NCT04647994||Prenatal patients|Pregnant women that performs prenatal care in Universitarian Hospital HU-USP or HC-FMUSP with diagnosis of SARS-CoV-2.
16303935|NCT04647994||Negative serology patients|Pregnant women that performs prenatal care with symptoms and tested serology/swab negative for SARS-CoV-2.
16303936|NCT04647981||Xpert® Bladder Test|A urine sample is collected before cystoscopy.
16303937|NCT04647968|Other|Primary closure of tracheo-cutaneous fistula|This group will undergo a protocoled primary closure of their tracheotomy.
16303938|NCT04647968|Other|Secondary closure of tracheo-cutaneous fistula|This group will undergo a protocoled secondary closure of their tracheotomy.
16303939|NCT04647955|Experimental|Itopride|Oral dose of itopride 100 mg three times daily before the meal for 8 weeks
16303940|NCT04647955|Placebo Comparator|Placebo|Oral dose of placebo three times daily before the meal for 8 weeks
16303941|NCT04647942||Meniscectomy|Patients who underwent a meniscectomy
16303942|NCT04647929|Experimental|PRESERFLO MicroShunt|Patients will undergo Santen PRESERFLO MicroShunt implantation with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
16303943|NCT04647929|Active Comparator|Trabeculectomy|Patients will undergo trabeculectomy with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
16303944|NCT04647916|Experimental|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16303949|NCT04647890|Experimental|FT011 200mg|200mg once daily for 12 weeks
16303950|NCT04647890|Experimental|FT011 400mg|400mg once daily for 12 weeks
16303951|NCT04647890|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
16303952|NCT04647877|Experimental|Phenytoin 10 percent cream|Phenytoin 10 percent cream, 2 to 4 times daily application, 2 weeks long
16303953|NCT04647877|Experimental|Phenytoin 20 percent cream|Phenytoin 20 percent cream, 2 to 4 times daily application, 2 weeks long
16303954|NCT04647877|Placebo Comparator|Placebo cream|Placebo cream, 2 to 4 times daily application, 2 weeks long
16303955|NCT04647864||Group 1|Edwards Sapien 3 and Edwards Sapien 3 Ultra
16303956|NCT04647864||Group 2|Medtronic Corevalve Evolut R and Medtronic Corevalve Evolut PRO
16303957|NCT04647864||Group 3|Boston Scientific Acurate neo and Boston Scientific Acurate neo2
16303958|NCT04647864||Group 4|St. Jude Medical Portico
16303959|NCT04647851|Experimental|Remote exercise intervention Down syndrome|Intervention: The program we will be using is specifically developed for individuals with Down syndrome based on the Mann Method PT Principles. The MMPT Principles TM focus on a progressive program of therapeutic activity (cardiovascular activity), therapeutic exercise (foundational strengthening and hip strengthening activities), and neuromuscular rehabilitation (visual/vestibular and balance activities) to address the unique needs of individuals with Down syndrome. This program has been developed and successfully implemented in Down syndrome activity centers across the country. This program will be offered through Zoom. Intensity will be submaximal for both data collection and during the exercise sessions, and recorded with Polar heart rate monitors.
16303960|NCT04647838|Experimental|NSCLC|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
16303961|NCT04647838|Experimental|Other cancers|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
16303962|NCT04647812|Experimental|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology
16303963|NCT04647812|Experimental|Conventional rehabilitation|Traditional multidisciplinary rehabilitation
16304019|NCT04647513|Experimental|Art Filler Universal (lips volume)|Injection of Art Filler Universal in lips
16304020|NCT04647513|Experimental|Art Filler Universal (nasolabial folds)|Injection of Art Filler Universal in nasolabial folds
16304021|NCT04647513|Experimental|Art Filler Lips (lips volume)|Injection of Art Filler Lips in lips
16304816|NCT04642313|Placebo Comparator|PLACEBO group|Placebo treatment: starch tablets (250 mg)
16303964|NCT04647799||forward head position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes in forward head position while Children will sit on chair with their feet on the ground without any tension, the upper limbs are rested in a table then, the angle between the line passing horizontally from the spinous process of C7 and the line passing between the tragus and spinous process of C7 will be measured by goniometer and goniometer pro application to evaluate the craniovertebral angle recording, we will fix the craniovertebral angle between 40.7° and 43.2°(severe FHP )
16303965|NCT04647799||neutral position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes while Children will sit on chair with their feet on the ground with head in anatomical position, the upper are rested in a table and used both hand on touch screen of mobile phone
16303966|NCT04647786|Experimental|Humidified and Augmented gas flows|
16303967|NCT04647786|Experimental|Humidified but not Augmented gas flows|
16303968|NCT04647786|Experimental|Not Humidified but Augmented gas flows|
16303969|NCT04647786|No Intervention|Neither humidified nor augmented gas flows|
16303970|NCT04647786|Experimental|Use of finalised device (SEA CtV) in final phase|
16303971|NCT04647786|No Intervention|Standard care (no SEA CtV)|
16303972|NCT04647773|Experimental|HSK16149 20mg BID|
16303973|NCT04647773|Experimental|HSK16149 40mg BID|
16303974|NCT04647773|Experimental|HSK16149 60mg BID|
16303975|NCT04647773|Experimental|HSK16149 80mg BID|
16303976|NCT04647773|Active Comparator|Pregabalin 150mg BID|
16303977|NCT04647773|Placebo Comparator|Placebo BID|
16303980|NCT04647747|Other|Self measurement of peripheral saturation|Participant will be equipped with a pulse oximeter and perform saturation measurements.
16303981|NCT04647734|Experimental|High intensity interval training|The experimental group will on top of standard care undergo a 12 weeks supervised exercise high intensity interval exercise training on an ergometer bike three times a week for 38 minutes. The specific intervals will be determined from our ongoing pilot study (NCT04549337)
16303982|NCT04647734|Active Comparator|Control group|This group will be allocated to standard care and therefore no supervised exercise regimen.
16303985|NCT04647708|Experimental|Part A (Cohort 1): M5049 Dose A|
16303986|NCT04647708|Experimental|Part A (Cohort 2): M5049 Dose B|
16303987|NCT04647708|Experimental|Part A (Cohort 3): M5049 Dose C|
16303988|NCT04647708|Experimental|Part A (Cohort 4): M5049 Dose D|
16303989|NCT04647708|Placebo Comparator|Part A: Placebo|
16303990|NCT04647708|Experimental|Part B (Cohort 5): M5049 Dose E|
16303991|NCT04647708|Placebo Comparator|Part B: Placebo|
16303992|NCT04647695|Experimental|IFN-beta 1b and remdesivir|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
16303993|NCT04647695|Active Comparator|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
16303994|NCT04647682||One single group study|Patients aged 75 years and over Hospitalized in a French covid-19 geriatric unit Positive Covid-19 infection made by Real-time Polymerase Chain Reaction Covid-19 or suspected on thoracic lesions on computerized tomography.
16303995|NCT04647669|Placebo Comparator|Local Standard of Care|Local Standard of Care
16303996|NCT04647669|Active Comparator|Remdesivir|Remdesivir (daily infusion for 10 days)
16303997|NCT04647669|Active Comparator|Acalabrutinib|Acalabrutinib (orally twice daily for 10 days)
16303998|NCT04647669|Active Comparator|Interferon|Interferon β1a(daily injection for 6 days).
16303999|NCT04647656|Active Comparator|HBOT treatment group|40 daily hyperbaric oxygen treatment sessions will be administered 5 days per week
16304000|NCT04647656|Sham Comparator|HBOT sham group|40 daily Sham non-hyperbaric oxygen treatment will be administered 5 days per week
16304001|NCT04647643||Paclitaxel Drug Coated Balloon|Patients treated with paclitaxel drug-coated balloon
16304002|NCT04647643||Paclitaxel Drug Coated Stent|Patients treated with paclitaxel drug-coated stent
16304003|NCT04647630||CAP|community acquired pneumonia
16304004|NCT04647617|Experimental|Quantitative Weight-bearing|Experimental wearing 0.5 kg quantitative sandbag 12~15 Repetitions/set X 5 set X 3day. Weight adjustment: After the first month of intervention, if the experimental can perform for more than 20 repetitions/set , we will asked to increase the weight of the sandbag to 1 kg until the end of the experiment
16304005|NCT04647617|Placebo Comparator|Control group|They are keep their normal live style
16304006|NCT04647604|Active Comparator|Omega|Omegaven® (2 mL/kg/day, equivalent to 6 g Docosahexaenoic Acid (DHA)+Eicosapentaenoic Acid (EPA) in a 70 kg individual) once daily for 5 days
16304007|NCT04647604|Placebo Comparator|Sodium chloride (NaCl)|2 mL/kg/day) once daily for 5 days
16304008|NCT04647591|Experimental|ENT Barotrauma incidence and link with risk factors|
16304009|NCT04647578||Child with IBD|
16304010|NCT04647578||Healthy child witnesses|
16304011|NCT04647552||hydrocortisone|The patients with septic shock who required a noradrenaline infusion rate above 0.5µg/kg
16304012|NCT04647552||control|The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP>65 mmHg
16304013|NCT04647526|Experimental|[Lu-177]-PNT2002 (Arm A)|[Lu-177]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)
16304014|NCT04647526|Active Comparator|Control Arm (Arm B)|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).
16304015|NCT04647513|Experimental|Art Filler Fine Lines (forehead)|Injection of Art Filler Fine Lines in Forehead wrinkles
16304016|NCT04647513|Experimental|Art Filler Fine Lines (upper lip)|Injection of Art Filler Fine Lines in upper lip wrinkles
16304017|NCT04647513|Experimental|Art Filler Fine Lines (cheek folds)|Injection of Art Filler Fine Lines in cheek folds
16304024|NCT04647500|Other|22q11DS consumer|22q11DS participants with a prolonged treatment of methylphenidate
16304027|NCT04647474||Radical Prostatectomy|Participants undergoing any curative surgical treatment option for prostate cancer irregardless of approach (open, laparoscopic or robotic)
16304028|NCT04647474||Active Surveillance|Participants undergoing active surveillance as the management option for prostate cancer as defined by regular surveillance attendance at the primary treating site.
16304029|NCT04647474||Androgen Deprivation Therapy|Participants undergoing medical (Gonadotropin-releasing hormone (GnRH) agonists or antagonists) or surgical castration (e.g. orchidectomy) options as the primary treatment for prostate cancer.
16304030|NCT04647474||Radical Radiotherapy|Participants undergoing primary radiotherapy treatment for prostate cancer irregardless of delivery methods (e.g. External beam radiation therapy or brachytherapy).
16304031|NCT04647461|Experimental|BRIDIN-T Eye drops 0.15%(Non preservative)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
16304032|NCT04647461|Active Comparator|ALPHAGAN-P Eye drops 0.15%(Preservatives)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
16304033|NCT04647448||Healthy volunteers|Participants with no known cardiovascular disease
16304034|NCT04647448||Chest pain|Patients with symptoms of chest pain, undergoing elective coronary artery CT
16304035|NCT04647435|Experimental|APSCTC|Oral tablets every 6h for 3 days
16304036|NCT04647435|Active Comparator|Toragesic®|Oral tablets every 6h for 3 days
16304037|NCT04647435|Active Comparator|Tramal®|Oral tablets every 6h for 3 days
16304038|NCT04647422|Experimental|AUD patients|Alcohol Use Disorder patients
16304039|NCT04647422|Experimental|AUD controls|Healthy control participants matched to group 1
16304040|NCT04647422|Experimental|First-degree relatives|Healthy first-degree relatives of AUD patients
16304041|NCT04647422|Experimental|First-degree controls|Healthy control participants matched to group 3
16304042|NCT04647409|Other|participants|
16304043|NCT04647396|Experimental|Intervention group|
16304044|NCT04647396|No Intervention|Control group|
16304045|NCT04647383|Experimental|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
16304046|NCT04647383|Experimental|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
16304047|NCT04647383|Experimental|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
16304048|NCT04647383|Experimental|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
16304049|NCT04647370|Active Comparator|Remote ischemic preconditioning|
16304050|NCT04647370|Sham Comparator|Sham remote ischemic preconditioning|
16304051|NCT04647357|Experimental|SHR-1316|
16304052|NCT04647344|Experimental|Nonsquamous NSCLC|
16304053|NCT04647344|Experimental|Squamous NSCLC|
16304054|NCT04647318|Experimental|Compassion focused imagery, relaxation imagery and control task|Participants engage in three tasks (compassion focused imagery, relaxation imagery and control task), three or four times every three days.
16304055|NCT04647305|Experimental|Closed face shield + Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
16304056|NCT04647305|Active Comparator|Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial. Additionally, each participant will receive an educational intervention (video).
16304057|NCT04647292|Experimental|Target systolic blood pressure 115-125 mmHg|Recommended target SBP 115-125 millimetres of mercury (mmHg).
16304058|NCT04647292|Active Comparator|Target systolic blood pressure 130-139 mmHg|Target SBP 130-139 mmHg (per American Stroke Association, European Stroke Organisation guidelines).
16304059|NCT04647279||Normal control group|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
16304060|NCT04647279||Osteopenia|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
16304061|NCT04647279||Osteoporosis|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
16304062|NCT04647253|Experimental|AGENT DCB|Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
16304063|NCT04647253|Active Comparator|Commercially available, PTCA Dilation Catheter|
16304064|NCT04647240|Active Comparator|Dermacyte® Liquid (human amniotic fluid)|Dermacyte® Liquid (human amniotic fluid) solution 1.0mL to 2.0mL weekly
16304065|NCT04647240|Placebo Comparator|Placebo (0.9% saline)|Matching placebo solution 1.0mL to 2.0mL weekly
16304113|NCT04646980|Placebo Comparator|Placebo|This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
16304177|NCT04646473|Experimental|App plus Coaching plus Incentives|Sweetgoals app + incentives=yes + coaching=yes
16304066|NCT04647227|Other|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
16304067|NCT04647214||Bimatoprost intracameral implant (DURYSTA) 10μg|Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
16304068|NCT04647201||Control|Non-sepsis and non-GI adults
16304069|NCT04647201||Sepsis patients without GI|Patients who meet the criteria of sepsis3.0 with AGI grade I or less
16304070|NCT04647201||Sepsis patients with GI|Patients who meet the criteria of sepsis3.0 with AGI grade II or above
16304071|NCT04647188||Urology group|Includes patients undergoing prostatectomy (n=100)
16304072|NCT04647188||Colorectal group|Includes patients undergoing anterior rectal resection (n=100)
16304073|NCT04647188||Thoracic group|Includes patients undergoing lobectomy (n=100)
16304074|NCT04647188||Gynaecological group|Includes patients undergoing hysterectomy (n=100)
16304075|NCT04647188||HpB group|Includes pancreatic tumour resection patients (n=50)
16304076|NCT04647188||Ear, Nose & Throat group|Includes patients undergoing tongue base mucosectomy (n=50)
16304077|NCT04647175|Other|Fermented aronia - aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
16304078|NCT04647175|Other|Fermented aronia - placebo - aronia|The participants receive each intervention for 8 weeks in the stated order.
16304079|NCT04647175|Other|Placebo - aronia - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
16304080|NCT04647175|Other|Placebo - fermented aronia - aronia|The participants receive each intervention for 8 weeks in the stated order.
16304081|NCT04647175|Other|Aronia - placebo - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
16304082|NCT04647175|Other|Aronia - fermented aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
16304083|NCT04647162|Active Comparator|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
16304084|NCT04647162|Experimental|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
16304085|NCT04647149|Experimental|Early Time-Restricted Eating|8-hour eating window between 08:00 and 16:00
16304086|NCT04647149|Experimental|Delayed Time-Restricted Eating|8-hour eating window between 12:00 and 20:00
16304087|NCT04647149|Experimental|Control|12-hour eating window between 08:00 and 20:00
16304088|NCT04647136|Active Comparator|Fertility Health Screening|Clinic-based fertility health screening and counselling
16304089|NCT04647136|Active Comparator|Fertility Awareness Tools|Online intervention to provide fertility education and behavioural nudge for optimal reproductive timing.
16304090|NCT04647136|No Intervention|Control|No intervention but exposed to usual information from the media on fertility and family benefits (no different from general population).
16304091|NCT04647123||Hopeless teeth|The teeth that can not be treated periodontally and who are desperate for extraction will be included in this group.
16304092|NCT04647123||Periodontitis|Teeth diagnosed with periodontitis will be included in this group.
16304093|NCT04647123||Gingivitis|Teeth diagnosed with gingivitis will be included in this group.
16304094|NCT04647123||Healthy|Teeth diagnosed with helthy will be included in this group.
16304095|NCT04647110||Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients|
16304096|NCT04647097|Active Comparator|Standard intervention plus repeated intervention|Patients randomized to the standard intervention plus repeated intervention arm
16304097|NCT04647097|Active Comparator|Standard intervention only|Patients randomized to the standard intervention only arm
16304098|NCT04647084|Experimental|Intradermal Lidocaine 2%|
16304099|NCT04647084|Experimental|Buzzy|
16304100|NCT04647071|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
16304101|NCT04647071|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
16304102|NCT04647058|Active Comparator|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
16304103|NCT04647058|Experimental|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
16304104|NCT04647045|Active Comparator|IBS-C group|77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days
16304105|NCT04647045|Other|Non-IBS group|88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
16304106|NCT04647032|Experimental|Theta Stimulation Group|This group will receive 6 Hz (theta) stimulation
16304107|NCT04647032|Active Comparator|Delta Stimulation Group|This group will receive 1 Hz (delta) stimulation
16304108|NCT04647019|Experimental|Blueberry|
16304109|NCT04647019|Placebo Comparator|Placebo|
16304110|NCT04647006|Other|Conventional Thyroidectomy|Conventional Thyroidectomy
16304111|NCT04647006|Active Comparator|Transoral endoscopic thyroidectomy vestibular approach|Transoral endoscopic thyroidectomy vestibular approach
16304112|NCT04646980|Experimental|Biobran/MGN-3|This arm consisted from 20 males and 20 females. Biobran/MGN-3 was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
16304114|NCT04646967|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen postoperatively as needed.
16304115|NCT04646967|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
16304116|NCT04646954|Experimental|Study group|All eligible participants are included in the study group
16304117|NCT04646941||T2DM with OSA|Type 2 diabetes patients with obstructive sleep apnea
16304118|NCT04646941||T2DM without OSA|Type 2 diabetes patients without obstructive sleep apnea
16304119|NCT04646915||Patients with CuRC undergoing day surgery|Patients with CuRC undergoing laparoscopic colectomy or anterior resection in day surgery center.
16304120|NCT04646902||HTN_OSA|"Patients with hypertension* with obstructive sleep apnea**
~* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values >= 140 mmHg and/ or diastolic blood pressure values >= 90 mmHg.
~** OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:
~an apnea-hypopnea index > 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR
~an apnea-hypopnea index > 15 events per hour, AND
~no significant changes in health, medications, or lifestyle since the polysomnography."
16304121|NCT04646902||HTN_NoOSA|Patients with hypertension without obstructive sleep apnea
16304122|NCT04646902||NoHTN_OSA|Patients without hypertension with obstructive sleep apnea
16304123|NCT04646902||NoHTN_NoOSA|Patients without hypertension without obstructive sleep apnea (healthy controls)
16304124|NCT04646889|Experimental|Renal Impairment|Subjects with various degrees of renal impairment
16304125|NCT04646889|Experimental|Normal Renal Function|Subjects with normal renal function
16304126|NCT04646876|Active Comparator|intervention arm ( Group A )|"including 30 patients Group A was given magnesium Sulphate
~Administration regimen of Mgso4 was as following:
~Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs."
16304127|NCT04646876|Placebo Comparator|Placebo arm (Group B )|including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate
16304128|NCT04646863|Experimental|group A|consists of 20 patients received a multiwave locked system laser
16304129|NCT04646863|Experimental|group B|consists of 20 patients received Pilates exercises
16304130|NCT04646863|Experimental|group C|consists of 20 patients received a multiwave locked system laser and Pilates exercises
16304131|NCT04646837|Experimental|Experimental Arm|Durvalumab 1000 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IB-IIIA NSCLC adult patients followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 15000mg Q4W for 8 months
16304132|NCT04646824|Experimental|ahead|A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
16304133|NCT04646811|Experimental|Tricuspid valve|tricuspid valve percutaneous repair strategy with clip for the tricuspid valve
16304134|NCT04646811|Other|Best medical treatment|
16304135|NCT04646798|Active Comparator|Hemi Arthroplasty (HA) of the elbow.|Hemi Arthroplasty (HA) of the elbow, where the surgeon replaces the bottom of the humerus bone at the elbow.
16304136|NCT04646798|Active Comparator|Total Elbow Arthroplasty (TEA).|Total Elbow Arthroplasty (TEA), where the surgeon fits a new elbow joint replacing damaged parts of the humerus bone and forearm bone that it joins onto.
16304137|NCT04646785|Experimental|Mindfulness-based cognitive therapy (MBCT) added to treatment as usual|Patients in the MBCT arm will in addition to their treatment as usual be invited to participate in MBCT.
16304138|NCT04646785|Active Comparator|Treatment as usual (TAU)|Patients in this arm will receive treatment as usual.
16304139|NCT04646759|Experimental|Fulvestrant Combined With Pyrotinib|Fulvestrant, 500 mg, was injected intramuscularly on D1, D15, D28, D28, once every 28 days； Pyrotinib, 400mg, orally administered daily.
16304140|NCT04646759|Active Comparator|Capecitabine Combined With Pyrotinib|Capecitabine, 1000mg / m^2, twice daily; Pyrotinib, 400mg, orally administered daily.
16304141|NCT04646746|Experimental|100 g of 100% wheat bread|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
16304142|NCT04646746|Experimental|Nude barley 50%|"Intake of 250 ml of tap water and 100 g of bread baked with 50% nude barley flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
16304143|NCT04646746|Experimental|Nude barley 75%|"Intake of 250 ml of tapwater and 100 g of bread baked with 75% nude barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
16304175|NCT04646473|Experimental|App plus Incentives|SweetGoals app + incentives=yes + coaching=no
16304176|NCT04646473|Experimental|App plus Coaching|Sweetgoals app + incentives=no + coaching=yes
16304144|NCT04646746|Experimental|Gen-modified high-amylose barley|"Intake of 250 ml of tap water and 100 g of bread baked with 50% gene-modified high-amylose barley and 50% wheat. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
~The gene-modified barley is produced by researchers at Aarhus and Copenhagen Universities as published in 'Carciofi M, et al., Concerted suppression of all starch branching enzyme genes in barley produces amylose-only starch granules. BMC Plant Biol. 2012 Nov 21;12:223. doi: 10.1186/1471-2229-12-223' The wheat flour is standard commercial available flour."
16304145|NCT04646733|Experimental|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet.
16304146|NCT04646733|Active Comparator|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water.
16304147|NCT04646720||Neck pain patients|Patients with neck pain evaluated with new technologies and face-to-face
16304148|NCT04646707|Experimental|Study group|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
16304149|NCT04646707|Placebo Comparator|Placebo Group|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
16304150|NCT04646694|Experimental|Study Group 1|Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
16304151|NCT04646694|Placebo Comparator|Study group 2|Patient will receive Placebo at a matching dose every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Placebo for three days or nine doses total.
16304152|NCT04646681|Experimental|Group 1|
16304153|NCT04646681|No Intervention|Group 2|
16304154|NCT04646668|Active Comparator|E-Cigarette then Heat not burn.|We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
16304155|NCT04646668|Active Comparator|Heat not burn then E-Cigarette|We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.
16304156|NCT04646655|Active Comparator|Enoxaparin at prophylactic dose|Enoxaparin at prophylactic dose: standard 4.000 IU QD via subcutaneous injection (6000 IU if body weight>100 kg)
16304157|NCT04646655|Experimental|Enoxaparin at therapeutic dose|"Enoxaparin at therapeutic dose : 70 U/Kg b.i.d. (every 12 h)
~In order to easily calculate the correct therapeutic dose of enoxaparin for each patient, a simplified categorization will be applied, as follows:
~weight < 65 Kg: 4.000 IU b.i.d. (every 12 h)
~weight ≥ 65 Kg: 6.000 IU b.i.d. (every 12 h)
~weight ≥ 100 Kg: 8.000 IU b.i.d. (every 12 h) The most appropriate dose will be evaluated in patients with creatinine clearance between 30 and 50 ml/min"
16304158|NCT04646629|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment"
16304159|NCT04646629|Sham Comparator|sham electroacupuncture treatment|"sham electroacupuncture treatment participants in the control group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
16304160|NCT04646616|Experimental|Community popular opinion leader (POL)|After successful completion of the new COVID-19 training module, POLs will reach out to members of their social networks to model and diffuse social norms to reduce the risk of COVID-19 infection and transmission, screen for symptoms and counsel regarding COVID-19, SAVAME syndemic factors, and refer at-risk or affected individuals to appropriate community services (e.g. free COVID-19 testing and treatment, mental health services, substance use services, violence prevention, support groups, etc.). As in other POL based interventions and pragmatic trials, POLs be asked to follow up with their community contacts to monitor their situation and provide additional support, but there will be flexibility with the frequency and number of follow up contacts depending on their needs identified and the preferences of the community contact. POLs will be continually supported by the research team via face-to-face biweekly booster sessions (if COVID-19 situation requires it) or by zoom.
16304161|NCT04646603|Experimental|MRG-001|"Single SC dose of 0.005 mL/kg MRG-001 (n=4) will be administered every other day for the duration of 5 days totaling 3 injections.
~Single SC dose of 0.01 mL/kg MRG-001 (n=4) will be administered every other day for the duration of 5 days totaling 3 injections.
~Single SC dose of 0.02 mL/kg MRG-001 (n=4) will be administered every other day for the duration of 5 days totaling 3 injections."
16304162|NCT04646603|Placebo Comparator|Placebo|"Single SC dose of 0.005 mL/kg Sterile Injectable Saline (n=2) will be administered every other day for the duration of 5 days totaling 3 injections.
~Single SC dose of 0.01 mL/kg Sterile Injectable Saline (n=2) will be administered every other day for the duration of 5 days totaling 3 injections.
~Single SC dose of 0.02 mL/kg Sterile Injectable Saline (n=2) will be administered every other day for the duration of 5 days totaling 3 injections."
16304163|NCT04646590|Experimental|Investigational Vaccine|Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
16304164|NCT04646590|Placebo Comparator|Placebo comparator|Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
16304165|NCT04646577|Active Comparator|Active|
16304166|NCT04646577|Sham Comparator|Sham|
16304167|NCT04646564|Active Comparator|control arm|standard of care
16304168|NCT04646564|Experimental|study arm|radiotherapy + standard of care
16304169|NCT04646538|Experimental|X3 group|
16304170|NCT04646512|Active Comparator|Taurine group and exercise|Intervention with taurine supplementation and physical training.
16304171|NCT04646512|Placebo Comparator|Placebo group and exercise|Intervention with placebo supplementation and physical training.
16304172|NCT04646499|Experimental|Gamma Stimulation Group|This group will receive gamma stimulation
16304173|NCT04646486|Experimental|Intervention - Video debriefing|Baseline period (year 1): Standard practice. Intervention period (year 2-3): All teams will be assigned to video debriefing.
16304174|NCT04646473|Experimental|App only|Sweetgoals app only
16304178|NCT04646460|Experimental|Observed Success - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
16304179|NCT04646460|Experimental|Observed Failure - Experienced Failure|"This participant group (N=30) will witness a failed placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
16304180|NCT04646460|Experimental|Observed Success - Experienced Failure|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
16304181|NCT04646460|Experimental|Observed Failure - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
16304182|NCT04646447|Experimental|L-serine treatment|All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.
16304183|NCT04646434|Experimental|Supportive Care (brain and muscle monitoring, questionnaire)|Patients perform standard of care Kegel exercises while undergoing brain and muscle activity monitoring by EEG and EMG, respectively, before surgery, 6 weeks after surgery, and at 3, 6, and 12 months after surgery. Patients complete questionnaires over 5-10 minutes about urinary function
16304184|NCT04646421||Motivational intervention - clients reached|Gamblers successfully reached with the motivational telephone intervention.
16304185|NCT04646421||Control group: clients not reached for the motivational intervention|Clients aimed to be reached for the same intervention, but who were not reached and therefore were not exposed to the intervention.
16304186|NCT04646421||Prospective intervention group|Clients subject to the prospective study part (target N 200), who are successfully reached by the intervention from November, 2020, and who provide informed consent to the web survey study. Studied as a cohort without control group, but with the pre-intervention situation as their own control condition.
16304187|NCT04646408||Participants with CKD|Recruitment is from a cohort of HIV positive individuals of African ancestry with Chronic Kidney Disease CKD defined as eGFR <60 mL/min/1.73m2, and/or albumin/creatinine ratio >30 mg/mmol or protein/creatinine ratio >50 mg/mmol Anticipated n=75
16304188|NCT04646408||Participants with diabetes|"Recruitment is from a cohort of HIV positive individuals of African ancestry with diabetes. Diabetes is defined as being on diabetic medications or HbA1c >48 mmol/mol.
~Anticipated n=75"
16304189|NCT04646408||Participants with ischaemic heart disease/stroke|Recruitment is from a cohort of HIV positive individuals of African ancestry with previous ischaemic heart disease or stroke Anticipated n=50
16304190|NCT04646408||No CKD/DM/CVD cohort|"Recruitment is from a cohort of HIV positive individuals of African ancestry who do not have CKD, diabetes or prior ischaemic heart disease/stroke.
~Anticipated n=200"
16304192|NCT04646382|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
16304193|NCT04646382|Experimental|Intervention|Garlic concentrated extract. Onion concentrated extract. Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
16304194|NCT04646369|Active Comparator|"screening as usual"|"Participants in the screening as usual' group will have a symptoms scores report of results sent to their provider based on their Screening Wizard responses."
16304195|NCT04646369|Experimental|Screening Wizard 2.0|Participants in the Screening Wizard 2.0 Report group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses.
16304196|NCT04646369|Experimental|Screening Wizard 2.0 + SOVA|Participants in the Screening Wizard 2.0 + SOVA group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses. This group will also receive access to the SOVA website aimed at addressing perceptions about mental health providing support to teens through peer interaction.
16304197|NCT04646356|Experimental|Tacrolimus immediate-release capsules|subjects will be treated with a 6 months course of oral low-dose tacrolimus capsules to be taken twice daily starting dose of 0.025 mg/kg/day, adjusted to maintain drug blood levels of 2-5ng/ml
16304198|NCT04646343||group for cross cultural adaptation of questionnaire|Pre final French version of the CISS and PWES will be administered to French native speaking patients suffering from various hand injuries. 30 patients are sufficient. They will be asked to write commentaries on difficulties of questionnaire's items, especially comprehension of the different items (clear or unclear).If the item is considered unclear, the patient is asked to provide suggestions for making the item clearer .The distribution of the responses will be examined for searching missing responses. An item considered unclear by 20 % or more of the patients must be re-evaluated . The definitive version of French-CISS and French PWES (F-CISS and F- PWES) and the verification of the different stages of the cross-cultural adaptation will be validated during a new consensus meeting.
16304199|NCT04646343||group for validation of questionnaire|For the second part (validation study) we will administered F-CISS, F-PWES, F-DASH, F-HFS, F-SF 36 questionnaires and a pain VAS to a population of in and outpatients with hand injuries. We aim to include patients during one year for a total expected of 100 patients.
16304200|NCT04646330|Experimental|1|AK104+anlotinib
16304201|NCT04646330|Experimental|2|AK104+anlotinib
16304202|NCT04646317|Experimental|Dexmedetomidine|Dexmedetomidine infusion four 50 ml syringes containing 1 microgram per ml dexmedetomidine
16304204|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants in the objective feedback group will receive a report that compares their performance in Set 1 to that of the staff surgeons' using the target interval as a reference. Participants receiving objective feedback will then complete Sets 2 and 3 knowing what factors to improve upon.
16304205|NCT04646304|No Intervention|No Feedback|Participants receiving no feedback will complete all sets with no intervention.
16304206|NCT04646291||Heterosexual Females with a Male partner|This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
16304207|NCT04646291||Females in LGBTQ Relationships|This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
16304208|NCT04646291||Solo parent|This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle. However, it might also be a male who is using a surrogate female.
16304209|NCT04646278|Experimental|Hyperemic stimuli|Hyperemic stimuli of coronary flow by adenosine or nicorandil injection
16304210|NCT04646265|Experimental|periodontal treatment|non-surgical root debridement
16304211|NCT04646239||Participants in the CROWN CORONATION trial|The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline). All participants in this sub-study receive SARS-CoV-2 specific vaccine subsequent to the MMR or Placebo injection.
16304214|NCT04646213|Experimental|Therapy|psychotherapeutic intervention
16304215|NCT04646200|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
16304216|NCT04646200|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
16304217|NCT04646187|Experimental|Intervention group|In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
16304218|NCT04646187|No Intervention|Control group|Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.
16304219|NCT04646174|Experimental|Multi-component Behavioral Treatment|This treatment consists of nine weekly phone-based individual treatment sessions, 45-60 minutes each, delivered by a trained study therapist.
16304220|NCT04646174|Experimental|Self-guided Treatment|This treatment consists of self-help materials from the American Lung Association that address evidence-based smoking cessation and self-management strategies.
16304221|NCT04646161||prostaglandins before iud insertion group|this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion
16304222|NCT04646161||placebo group|this group will receive placebo tablet before mirena iud insertion
16304223|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
16304224|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
16304225|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES recieve prompting Text messages,
16304226|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages, and financial Incentives to attend yoga classes
16304227|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
16304228|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes and One-on-One individual sessions with a Yoga Instructor
16304229|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages and One-on-One individual sessions with a Yoga Instructor
16304230|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive financial Incentives to attend yoga classes, prompting Text messages and One-on-One individual sessions with a Yoga Instructor
16304461|NCT04644536||HA paste in long bone & extremities|Filling of post-traumatic or surgically created bone defects
16304231|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos
16304232|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive financial Incentives to attend yoga classes and Personal Practice Videos
16304233|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos and prompting Text messages
16304234|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages and financial Incentives to attend yoga classes
16304235|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
16304236|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages but DOES receive financial Incentives to attend yoga classes, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
16304237|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive prompting Text messages, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
16304238|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
16304239|NCT04646135|Experimental|Sequence 1|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:
~Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hours
~Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hours
~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
16304240|NCT04646135|Experimental|Sequence 2|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:
~Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hours
~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours
~Day 3: Continuous Infusion at 0.03 mg/kg/hour LZ"
16304241|NCT04646135|Experimental|Sequence 3|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:
~Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hours
~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours
~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
16304242|NCT04646109|No Intervention|Control Group|"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with PCR positivity in respiratory tract samples were included into the study. They were randomized to the control and study group, respectively. Hydroxychloroquine, favipiravir and azithromycin (HFA) standard treatment protocol were given to the control group as recommended in the COVID-19 (SARS-CoV-2 Infection) Guide prepared by the Republic of Turkey Ministry of Health."
16304243|NCT04646109|Experimental|Study Group|In addition to HFA treatment, ivermectin 200 micrograms/kg/day (9mg between 36-50 kg, 12mg between 51-65 kg, 15mg between 66-79 kg and 200 micrograms/kg in > 80 kg) in the form of a solution prepared for enteral use was added (HFA+I) to the treatment protocol of the study group's for five days. Blood sample was taken with the first dose of ivermectin and haplotype analysis was performed in ABCB1 and CYP3A4 genes in the whole study group.
16304244|NCT04646096|Experimental|Mako THA 4.0 group|Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
16304245|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using Inferior pedicle|Wise pattern reduction mammaplasty using Inferior pedicle
16304246|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using superomedial pedicle|
16304247|NCT04646057|Experimental|Treatment Arm|
16304248|NCT04646057|No Intervention|Historical Control Arm|
16304251|NCT04646018|Experimental|Lumbar Manipulation Group|Group that receives experimental lumbar non-thrust manipulation
16304252|NCT04646018|Sham Comparator|Sham Manipulation Group|Group that receives sham lumbar non-thrust manipulation
16304253|NCT04646005|Experimental|Cemiplimab+ISA101b|
16304254|NCT04645992|Active Comparator|study group|study group will receive only one session of yoga eye exercise for 20 minutes followed by transcutaneous electrical nerve stimulation by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
16304255|NCT04645992|Sham Comparator|control group|control group will be treated with the same protocol as the study group but with the unit of transcutaneous electrical nerve stimulation is off .
16304256|NCT04645979||Participants|Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.
16304257|NCT04645966|Experimental|MenABCWY with PLP - 6 months of age|Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.
16304258|NCT04645966|Experimental|MenABCWY - 6 months of age|Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule
16304259|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP during primary vaccinations
16304260|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule
16304261|NCT04645966|Experimental|Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.
16304262|NCT04645966|Experimental|Bivalent rLP2086 (120-µg Dose) and Nimenrix - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule
16304263|NCT04645966|Experimental|MenABCWY with PLP - 2 months of age|Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given PLP during primary vaccinations.
16304264|NCT04645966|Experimental|MenABCWY - 2 months of age|Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule
16304265|NCT04645966|Experimental|Bexsero and Nimenrix with PLP - 2 months of age|Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations
16304266|NCT04645966|Experimental|Bexsero and Nimenrix - 2 months of age|Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule
16304267|NCT04645966|Experimental|MenABCWY with / without PLP - 2 months of age|Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with a determined ratio of participants given or not given PLP during primary vaccinations.
16304268|NCT04645966|Experimental|Bexsero and Nimenrix with / without PLP - 2 months of age|Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, with a determined ratio of participants given or not given PLP during primary vaccinations
16304272|NCT04645940|Experimental|Fed/Fasted|fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
16304273|NCT04645940|Experimental|Fasted/Fed|fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
16304274|NCT04645927|Placebo Comparator|Placebo control beverage group|The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
16304275|NCT04645927|Experimental|Experimental flax beverage group|Flax beverage (30 gr daily, oral) is presented in liquid form in plain unmarked packages. For 180 days (6 months) participants will consume 2 servings of 330 ml of flax beverage (treatment group; 30 gms flax/day beverage) per day.
16304276|NCT04645914|No Intervention|No smokers|Healthy subjects who do not consume any nicotine products
16304277|NCT04645914|Experimental|Smokers/Vapers|Healthy subjects who consume nicotine products
16304278|NCT04645901|Experimental|SYHA1805|Part 1: Subjects will receive a single dose of oral SYHA1805 tablets. Part 2: Subjects will receive single ascending doses of SYHA1805 tablets. Part 3: Subjects will receive a single dose SYHA1805 tablets in a fasted state and a single dose of SYHA1805 tablets after a high-fat, high-calorie meal, with sequence determined by randomization.
16304279|NCT04645901|Placebo Comparator|Placebo|Subjects will receive the matching placebo tablets.
16304280|NCT04645888|Active Comparator|Articaine|"All surgeries were performed by the same surgeon and monitored by the same person. 4 % articaine with 1:200.000 epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.
~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
16304281|NCT04645888|Active Comparator|Bupivacaine|"All surgeries were performed by the same surgeon and monitored by the same person. % 0.5 bupivacaine without epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.
~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
16304282|NCT04645875|Experimental|Sit regimen|Participants will be instructed to restrict walking and standing to ≤1 h/day each (total ≤2 h/day ) and the remainder of the waking day will be seated apart from visiting the toilet.
16304283|NCT04645875|Experimental|SitLess regimen|Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
16304284|NCT04645849||"Cohort A or End of treatment"|16 patients recruited at the end of breast cancer treatment and followed during 9 months
16304285|NCT04645849||"Cohort B or Diagnosis"|Patients recruited at breast cancer before any treatment: one blood sample to provide comparative values.
16304286|NCT04645836|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.
~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
16304287|NCT04645836|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
16304288|NCT04645823|Active Comparator|Spinal fentanyl|Using a combined spinal epidural technique a single dose of 20 µg of fentanyl diluted into 2 ml with NaCl 0.9 % will be injected into the CSF at lower lumbar interspace. An epidural catheter is left in place for subsequent analgesic doses.
16304289|NCT04645823|Experimental|Epidural lidocaine and fentanyl|Using a catheter in the epidural space in the lower lumbar interspace a single dose of lidocaine (80 mg) and fentanyl (100 µg) is given. The epidural catheter is left in place for subsequent analgesic doses.
16304290|NCT04645810|Experimental|Experimental: High-Dose-Rate prostate brachytherapy|High-Dose-Rate brachytherapy, 2 fractions
16304291|NCT04645797|Experimental|APR003 Dose Escalation|This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.
16304292|NCT04645784|Experimental|Intervention|Receives the supporting student-athlete mental wellness module
16304293|NCT04645784|No Intervention|Waitlist|Receives no intervention
16304294|NCT04645771|Experimental|Microwave ablations|A total of 50 patients with varicose veins of lower extremities treated with microwave ablation catheter were selected to observe their annual venous closure rate and postoperative adverse reactions.
16304295|NCT04645758|Active Comparator|Dry Needling Group or (DN)|Dry needling for 5 mins on the flexor group of muscles of dominant forearm.
16304296|NCT04645758|Active Comparator|Extra corporeal Shockwave therapy Group or (ESWT)|Delivering of Shock wave pulses of 1250 at the energy intensity of 0.58 mj/mm2 on the flexor group of muscles of dominant forearm
16304297|NCT04645745|Experimental|myo-inositol plus alpha-lactalbumin|Patients were treated with 2 g myo-inositol, 50 mg alpha-LA and 200 mcg of Folic Acid twice a day for 6 months. Controls were the same patients at baseline (t0)
16304298|NCT04645732|Experimental|Personalized exercise therapy and self-management program in addition to usual care|"Participants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour).
~Furthermore, this group will receive the treatment described under usual care below."
16304299|NCT04645732|Active Comparator|Usual care alone|Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
16304300|NCT04645719|Placebo Comparator|Lactate ringer group|Patients will receive only general anesthesia
16304301|NCT04645719|Active Comparator|Real weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the actual body weight
16304302|NCT04645719|Active Comparator|Corrected ideal weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the corrected ideal weight
16304303|NCT04645693||HIV Subjects with Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with no diagnosis of non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
16304304|NCT04645693||HIV Subjects without Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with a diagnosis of one or more systemic non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
16304305|NCT04645680|Experimental|Arm I (isocaloric high-fiber diet)|Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
16304306|NCT04645680|Active Comparator|Arm II (isocaloric diet)|Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
16304307|NCT04645667||Adult patients of allogeneic hematopoietic HCT|Patients who receive their first allogeneic HCT transplant and who receive tacrolimus for aGVHD prophylaxis per standard of care.
16304308|NCT04645654|Experimental|Hypnosis|3 sessions of script-based hypnosis (analgesic suggestions) + recordings provided for self-hypnosis
16304309|NCT04645654|No Intervention|Standard of care|Standard of care ERAS based optimized multimodal analgesia, without any complementary medicine
16304310|NCT04645641|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
16304311|NCT04645628|Experimental|All subjects will have an MRI examination|
16304312|NCT04645615|Experimental|CURE AF|
16304313|NCT04645602|Experimental|Lenvatinib + Pembrolizumab|"Participants will take:
~Lenvatinib - At a pre-determined dose, 1x daily during each 3 week study cycle up to 35 cycles/2 years
~Pembrolizumab - At a pre-determined dose, 1x on Day 1 of each 3 week study cycle up to 35 cycles/2 years
~Participants will be given a drug diary and asked to document information in the drug diary about the study treatment.
~Participants will be asked to check their blood pressure 3x every week and document in a supplied diary.
~Participants will be followed up to one (1) year after study treatment."
16304314|NCT04645589||Myfortic|Oral administration
16304315|NCT04645576|Other|Midface zone|Injection in the mid-facial areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
16304316|NCT04645576|Other|Temple|Injection in the temples (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
16304317|NCT04645576|Other|Jaw-line|Injection in the jaw-line areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
16304318|NCT04645576|Experimental|Chin|The chin will only receive one injection of Art Filler Volume.
16304319|NCT04645563||Whatsapp Group|"This group includes 54 patients who have consulted via whatsapp. The ID physician will be consulted for all the subjects once laboratory results and CT reports were complete. All the consultations were performed with the same smartphone, and every Whatsapp consultation held since the very beginning of the pandemic was evaluated.
~In this type of consultation, Thorax CT images of the patient were turned into a video of approximately 30-35 seconds, and during this video recording, the patient's clinical condition and laboratory results were also transferred to the ID physician. The ID physician, on the other hand, will state his/her admission-discharge decision via Whatsapp as hospitalization or discharge. Eventually the consultation result will be recorded in the patient's folder. The moment the video was sent will be recorded as the beginning of the patient's consultation period and response time to whatsapp video will be saved as consultation response time."
16304320|NCT04645563||Bedside Consultation Group|"This group includes 90 patients who have consulted bedside. The patients that has problems which are concerning multiple consultation will be excluded.
~The ED physician wrote a consultation note over the hospital information system by specifying the patient's clinical status, history and laboratory parameters. A physician will be consulted for all the eligible subjects after their laboratory results and CT reports were complete. The ID physician examined the subjects at the bedside within 30 minutes (the legal response time in Turkey) of seeing the consultation request. Consultation response time will be saved as time between entering consultation information through the system to completion of the consultation note Although the consultant ID physicians will be informed via Whatsapp, they held the consultation at the bedside for the subjects they deemed appropriate."
16304321|NCT04645550|Experimental|Apixaban with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Apixaban 2.5mg bid for six months.
16304322|NCT04645550|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for six months irrespective of the occurrence of portal vein thrombus.
16304323|NCT04645550|Experimental|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for six months.
16304324|NCT04645537||FinACAF cohort|The study cohort consists of all patients with AF diagnosis (ICD-10 I48) living in Finland during 1.1.2004-31.12.2018. The study cohort is obtained from data of Finnish national registries. Patients with permanent residence in Finland less than 12 months prior to index date and patients with age below 18 years at index date are excluded from the study.
16304325|NCT04645524|Experimental|AD182|Oral capsule administered before bed
16304326|NCT04645524|Experimental|AD504|Oral capsule administered before bed
16304327|NCT04645524|Placebo Comparator|Placebo|Oral capsule administered before bed
16304328|NCT04645511|Experimental|Chronic sinusitis: Balloon sinuplasty|30 patients with chronic maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
16304329|NCT04645511|Sham Comparator|Chronic sinusitis: Placebo|30 patients with chronic maxillary sinusitis that are randomized to be treated with sham surgery.
16304330|NCT04645511|Experimental|Recurrent sinusitis: Balloon sinuplasty|30 patients with recurrent maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
16304331|NCT04645511|Sham Comparator|Recurrent sinusitis: Placebo|30 patients with recurrent maxillary sinusitis that are randomized to be treated with sham surgery.
16304332|NCT04645498||Metabolism, Inborn Errors|Patient affected by an inherited metabolic disease
16304333|NCT04645485|Experimental|Experimental arm|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
16304334|NCT04645472||CT-Ultrasound group|
16304335|NCT04645459|Experimental|low phosphorus meal group (LP group)|The proteins of the low phosphorus meal had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process.
16304336|NCT04645459|Placebo Comparator|control group|The boiling method did not process for the control meals.
16304337|NCT04645446|Experimental|Pro-ocular™ 1% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.7 mg of progesterone
16304338|NCT04645446|Experimental|Pro-ocular™ 0.5% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.35 mg of progesterone
16304339|NCT04645446|Placebo Comparator|Placebo topical gel|Multidose formulation identical in appearance to Experimental Products despensing unit doses of 0.07 g of topical gel containing 0 mg of progesterone
16304340|NCT04645433||Favipiravir therapy|Favipiravir was advised to all patients with severe pneumonia and progressing pneumonia findings or worsening clinical manifestations except pregnant, breast feeding, postpartum woman. PCR results were not waited to start favipiravir in this group of patients and continued if it would be negative but tomography findings were consistent with COVID-19. Loading dose was 1600 mg twice a day. Maintenance dose was 600 mg per 12 hours for four days.
16304341|NCT04645433||Lopinavir-ritonavir therapy|Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
16304342|NCT04645420|Experimental|Apremilast|"15 PsA patients with active disease and naïve to conventional synthetic and biologic disease modifying anti-rheumatic drugs.
~Treatment with apremilast orally in the whole group (n = 15). Escalating dose the first Week (10 mg once day1, 10 mg bid day2, 10 mg-20 mg day3, 20 mg bid day4, 20 mg-30 mg day5, 30 mg bid on day6), and 30 mg bid from day7 until week24."
16304343|NCT04645407|Experimental|FZHY Group|conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
16304344|NCT04645407|No Intervention|Control Group|conventional therapy
16304345|NCT04645394|Placebo Comparator|Placebo|The participants are receiving 1 dose of each in the stated order.
16304346|NCT04645394|Active Comparator|Fermented aronia high dose|The participants are receiving 1 dose of each in the stated order.
16304347|NCT04645394|Active Comparator|Fermented aronia low dose|The participants are receiving 1 dose of each in the stated order.
16304348|NCT04645394|Active Comparator|Aronia|The participants are receiving 1 dose of each in the stated order.
16304349|NCT04645381||Participants with RA|
16304350|NCT04645368||Longidaze|80 subjects Longidaze® (bovhyaluronidase azoxymer), lyophilisate for solution for injection
16304351|NCT04645368||Dynamic control|80 subjects Patients not receiving active therapy
16304352|NCT04645355|Experimental|New-onset guttate psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
16304353|NCT04645355|Experimental|Chronic plaque psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
16304354|NCT04645342|Experimental|Baylis Versacross RF wire|Device: Baylis Versacross radiofrequency wire
16304355|NCT04645342|Active Comparator|Baylis RF Needle|Device: conventional Baylis radiofrequency needle
16304356|NCT04645329|Experimental|group I (no immobilization)|patients will be allowed to freely use their arm without any immobilization after surgery
16304357|NCT04645329|Active Comparator|group II (3-week immobilization)|patients will be kept in an immobilization device for three weeks after surgery
16304358|NCT04645316|Active Comparator|Sevoflurane|Sevoflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
16304359|NCT04645316|Active Comparator|Desflurane|Desflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
16304360|NCT04645316|Placebo Comparator|Total intravenous anesthesia|Total intravenous anesthesia (propofol/remifentanyl) will use for anesthesia maintenance for liver donor hepatectomy surgery
16304361|NCT04645303|Experimental|Hyaluronic acid|1mL of hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1-pulley.
16304362|NCT04645303|Active Comparator|Triamcinolone acetonide|1 mL of Triamcinolone acetonide 10mg/ml infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1 pulley.
16304363|NCT04645290|Experimental|"Intervention group: Educational Intervention KARER"|General objective of the intervention: Implement self-care strategies and care actions aimed at people facing chronic diseases with disabilities, applying knowledge, ability and attitudes that allow them to act in a timely manner, reducing the risk of complications, improving well-being and the quality of life of the person cared for and of himself. Through face-to-face, virtual interdisciplinary educational actions (B-learning) and with simulation support.
16304364|NCT04645290|No Intervention|Usual Care|The people assigned to this group will receive their own responses from the institution providing care services to which they belong. These instructions consist of: information on the disease process and treatment received from the medical group, information on assistance by the nursing group and finally, the administrative procedures carried out by social work.
16304365|NCT04645277||Patients with MRI using two dimensional reconstruction|
16304366|NCT04645277||Patients with MRI using three dimensional reconstruction|
16304370|NCT04645238|Active Comparator|Static Hamstring Stretching|Static Hamstring Stretching
16304371|NCT04645238|Active Comparator|PNF Stretching|PNF Hamstring Stretching (Hold-Relax)
16304372|NCT04645212||1|Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
16304373|NCT04645186||Calcium Phosphate Cement (CPC)|Evaluation of CPC in long bone & extremities
16304374|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
16304375|NCT04645173||Tyrx Envelope|Participants who received a Tyrx envelope during CIED implantation
16304376|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
16304380|NCT04645134||Inactive|Older adults who have a sedentary or under-active lifestyle.
16304381|NCT04645134||Highly Active|Older adults who have a highly active lifestyle.
16304382|NCT04645121||Hemodialysis group|Subjects receiving maintenance hemodialysis for at least three months
16304383|NCT04645121||Case group|Healthy subjects with eGFR above 60 ml/min/1.73m2
16304384|NCT04645108|Experimental|Coached|
16304385|NCT04645108|Active Comparator|No Coach|
16304386|NCT04645095|Active Comparator|Conventional TENS|Frequency:80 Hz, duration:100 μs
16304387|NCT04645095|Active Comparator|Burst TENS|Frequency:100 Hz, fr mod: 0, 200 µs, 2 Bps Hz
16304388|NCT04645095|Active Comparator|Modulated TENS|Frequency:80 Hz, fr mod: 50%, Amplitude mode: 40%, duration: 200 µs
16304389|NCT04645069|Experimental|ADG126 Dose Escalation Level 1|
16304390|NCT04645069|Experimental|ADG126 Dose Escalation Level 2|
16304391|NCT04645069|Experimental|ADG126 Dose Escalation Level 3|
16304392|NCT04645069|Experimental|ADG126 Dose Escalation Level 4|
16304393|NCT04645069|Experimental|ADG126 Dose Escalation Level 5|
16304429|NCT04644770|Experimental|Part 2: Dose Expansion|Participants will receive intravenous (IV) injection of JNJ-69086420 at one of the RP2D(s) determined in Part 1.
16304430|NCT04644757|Experimental|Treatment|
16304431|NCT04644744|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of end-ischemic Hypothermic machine perfusion (HOPE) for a minimum of 2 hours (until hepatectomy)
16304394|NCT04645056|Experimental|Intervention group|"a. Intervention Group: Neck stretching and movement
~The patient starts the stretching exercises the morning after surgery with instructions from a trained professional at the department. The patient is informed that the stretching exercises will not affect the surgical wound. The patient is instructed in performing five repetitions of each of the following nine exercises three times each day in four weeks:
~Relax shoulders and neck sufficiently
~Look down - Stretching and movement
~Look to each side - movement
~Lower the head to each side - stretching
~Lower the head diagonally to each side - stretching
~Small nod movements
~Lift the shoulders - movement
~Roll the shoulders - movement
~Lift the arms - movement
~The first stretching session is observed by the instructor who gives feedback and correct the exercises, if necessary. Furthermore, the patient is given a training brochure."
16304395|NCT04645056|No Intervention|Control group|b. Control group The patients in the control group are not instructed in any intervention but are answering completely similar questionnaires as the intervention group.
16304396|NCT04645043|Experimental|US_Eso|US application on the participant
16304397|NCT04645030||Patients suspected of pneumonia|Patients suspected for pneumonia after initial evaluation by the treating physician.
16304398|NCT04645017|Experimental|Intergenerational Music Program|An intergenerational music program will be administered by adolescent musicians for older adults with early-stage cognitive decline.
16304399|NCT04645004|Other|Aspirin|81mg aspirin daily
16304400|NCT04644991|Active Comparator|Group 1|Experimental group consisting of transfemoral amputees who kinesiology tape will be applied
16304401|NCT04644991|Sham Comparator|Group 2|The placebo group of transfemoral amputees who shame kinesiology tape will be applied
16304402|NCT04644978||Trainees and specialists in child and adult psychiatry|"The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing I agree on the website, after reading the information leaflet and the informed consent form."
16304403|NCT04644965||Abdominal Wall Defect|patients born with an abdominal wall defect
16304404|NCT04644965||Control Group|age and sex matched Control Group
16304405|NCT04644952||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
16304406|NCT04644939|Experimental|Interventional group|Patients will receive bowel preparation instructions in a conventional way in addition to a telephone call for education purposes one day prior to procedure
16304407|NCT04644939|Placebo Comparator|Conventional group|Patients will receive bowel preparation instructions in a conventional way
16304408|NCT04644926|Experimental|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is performed at inclusion and repeated 12 h and 24 h later.
16304409|NCT04644900|Active Comparator|the Mouthwash group|Patients in the mouthwash group received 15 ml of honeysuckle antibacterial mouthwash and vomited it out after 2 minutes
16304410|NCT04644900|Active Comparator|the gum group|patients in group gum chewed one piece of herbal sugar-free gum for 2 minutes and then spat it out.
16304411|NCT04644887|Experimental|Healthy diet CC genotype|The participants will follow the intervention diet during the 12-week intervention period.
16304412|NCT04644887|Active Comparator|Control diet CC genotype|The participants will follow the control diet during the 12-week intervention period.
16304413|NCT04644887|Experimental|Healthy diet GG genotype|The participants will follow the intervention diet during the 12-week intervention period.
16304414|NCT04644887|Active Comparator|Control diet GG genotype|The participants will follow the control diet during the 12-week intervention period.
16304415|NCT04644874||Older cancer patients|All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,
16304416|NCT04644861|Other|Elders aged 70|Program of adapted physical activity
16304417|NCT04644848|Experimental|Pre-sentinel node biopsy ultrasonographical tattooing|Preoperative ultrasonographical tattooing of the suspicious lymph nodes. Sentinel Lymph Node Biopsy (SLNB),
16304418|NCT04644835|Experimental|LESW group|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
16304419|NCT04644835|Sham Comparator|Control group|This group of patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
16304420|NCT04644822|Experimental|[18F]PSMA-1007 Injection|A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)
16304421|NCT04644809|Experimental|LY3561774 (Part A)|Single ascending doses of LY3561774 administered subcutaneously (SC).
16304422|NCT04644809|Experimental|LY3561774 (Part B)|Repeat doses of LY3561774 administered SC.
16304423|NCT04644809|Experimental|LY3561774 (Part C)|Single doses of LY3561774 administered SC in Japanese Participants.
16304424|NCT04644809|Placebo Comparator|Placebo (Part A, B & C)|Placebo administered SC.
16304427|NCT04644783|Experimental|Blood test with assays|Ten patients with FPIES exhibiting reactions to 2-3 foods, and up to 10 exhibiting FPIES reactions to 4 or more foods will be recruited.
16304428|NCT04644770|Experimental|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
16304459|NCT04644536||Granules in long bone & extremities|Filling of post-traumatic or surgically created bone defects
16304432|NCT04644744|Experimental|Normothermic machine perfusion (NMP)|Application of end-ischemic normothermic machine perfusion (NMP) for a minimum of 4 hours (up to 24 hours)
16304433|NCT04644744|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
16304434|NCT04644731||Pediatric patients who require fluid removal|Pediatric patients who require fluid removal with the Aquadex™ System per local standard of care
16304435|NCT04644718|Experimental|Anodal-tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with real tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
16304436|NCT04644718|Sham Comparator|sham tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with sham tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
16304437|NCT04644705|Active Comparator|Part A: verum niclosamide|"The SAD cohorts are planned as follows:
~Cohort A1: 200 mg (fasted conditions) Cohort A2: 600 mg (fasted conditions) Cohort A3: 1600 mg (fasted and fed conditions)"
16304438|NCT04644705|Placebo Comparator|Part A: placebo to niclosamide|"The SAD cohorts are planned as follows:
~Cohort A1: placebo to niclosamide 200 mg (fasted conditions) Cohort A2: placebo to niclosamide 600 mg (fasted conditions) Cohort A3: placebo to niclosamide 1600 mg (fasted and fed conditions)"
16304439|NCT04644705|Active Comparator|Part B: verum as solution (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
16304440|NCT04644705|Active Comparator|Part B: verum as chewing tablet (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
16304441|NCT04644705|Active Comparator|Part C: verum (niclosamide and camostat)|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
16304442|NCT04644705|Placebo Comparator|Part C: placebo to niclosamide and camostat|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
16304443|NCT04644692||Case group: patients with heart failure with preserved ejection fraction|
16304444|NCT04644692||Control Group:Never diagnosed with either preserved or altered ejection fraction heart failure.|Non dyspnoeic patients with no history of Heart failure.
16304445|NCT04644679|Active Comparator|48-hr|48-hr electrocardiographic monitoring
16304446|NCT04644679|Experimental|7-day|7-day electrocardiographic monitoring
16304447|NCT04644640|Active Comparator|Telerehabilitation|
16304448|NCT04644640|Active Comparator|In-Person Rehabilitation|
16304449|NCT04644627|Experimental|Single arm|Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.
16304450|NCT04644614|Active Comparator|Group 1: Magnetic Stimulation|Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.
16304451|NCT04644614|Sham Comparator|Group 2: Sham Magnetic Stimulation|"The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient.
~During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device."
16304452|NCT04644588||Children being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and hand function using postural zone software to assess scapular alignment and pediatric arm function test toassess upper limb function .
16304453|NCT04644575|Experimental|Arm A: Previously treated in BIVV001 study|This arm includes all participants who have completed the previous phase 3 studies on BIVV001, as well as participants who have completed Arm B or Arm C of this study rolling over in Arm A, and participants who will have completed any future BIVV001 study who will be proposed to continue BIVV001 treatment. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once-weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
16304454|NCT04644575|Experimental|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll into arm A.
16304455|NCT04644575|Experimental|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
16304456|NCT04644562|Experimental|patients undergoing Lower Limb vascular Surgery|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
16304457|NCT04644549||Subjects with CLN6 Batten disease|
16304458|NCT04644549||Subjects with juvenile CLN3 Batten disease|
16304462|NCT04644536||Granules in Spine|Spinal cage filling
16304464|NCT04644510||Lung ultrasonography group|Patient which benefited from a Lung ultrasonography during the medical consultation
16304465|NCT04644497||Transphyseal drilling technique|
16304466|NCT04644497||Physeal sparing drilling technique|
16304467|NCT04644484|Experimental|Experimental Group: SYN023+Rabies Vaccine|"SYN023:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.
~Dosage form: 6mg/2mL, liquid, Dosage: 0.3 mg/kg of SYN023 Frequency/duration: at Day 1
~Rabies vaccine :
~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
16304468|NCT04644484|Active Comparator|Control Group: HRIG+Rabie Vaccine|"HRIG:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible Dosage form: 100 IU/mL, liquid, Dosage: 20 IU/kg Frequency/duration: at Day 1
~Rabies vaccine :
~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
16304469|NCT04644445|No Intervention|Control|Standard bariatric clear liquid diet to be started 4 hours after surgery
16304470|NCT04644445|Experimental|Intervention|Bariatric full liquid diet (clear liquid diet + protein shakes) to be started 4 hours after surgery
16304471|NCT04644432|Experimental|A - for patients with a DNA mutation that match a targeted treatment|"Listed below are the possible study drugs and dosages:
~Erlotinib 150 mg once a day for 4 weeks.
~Osimertinib 80 mg once a day for 4 weeks.
~Alectinib 600 mg twice a day for 4 weeks
~Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks
~Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week
~Olaparib 400 mg twice a day for 4 weeks
~Pembrolizumab iv infusion 2 mg/kg every 3rd week
~Cabozantinib 60 mg once a day for 4 weeks
~Crizotinib 250 mg twice a day for 4 weeks
~Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week
~Imatinib 400 mg once a day for 4 weeks
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
16304472|NCT04644432|Experimental|B - for patients with an angiogen profile|"Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
16304473|NCT04644432|Experimental|C - for patients with an immune profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
16304474|NCT04644432|Experimental|D - for patients that have neither mutations nor an immune- or angiogen profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
16304475|NCT04644419|No Intervention|Control|Patients in the control arm will receive standard of care.
16304476|NCT04644419|Experimental|Palliative And supportive Care inTervention (ACT)|This ancillary study does not include intervention development component. The detail intervention can be found in the parent study protocol (NCT04570709).
16304477|NCT04644380|Experimental|Treatment Group|During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
16304478|NCT04644367|Experimental|Tai Chi group|The Tai Chi (TC) group will receive or be taught TC in a class size consisting of about 5-12 students. Classes will be taught by a TC master with more than 4 years of experience practicing either Yang or Wu style TC. The participants will be allowed to practice TC at home and during their leisure time so long as they keep an activity log of their daily TC practice. This monitoring form (i.e. activity log or journal) will be distributed to all members of this group and collected weekly.
16304479|NCT04644367|Active Comparator|Regular Physical Activity (control) group|The regular physical activity (control) group will be asked to maintain or engage in at least 60 minutes of regular physical activity. The participants will be instructed as to the type of regular PA that they may engage in. These types of PA include: walking, cleaning or performing chores inside the home, and/or climbing the stairs. No restriction will be made to limit others forms of physical activity; individuals in the control group will be permitted to engage in organized sports, instructor-led class such as boxing, dance, etc. to ensure the participant recruitment process is feasible. Similar to the TC group, participants in this group will be asked to complete an activity log (or journal) that will be collected weekly to monitor their regular PA levels.
16304480|NCT04644354||Group A - Advanced Preterm Labor (aPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions 4 or more in 20 minutes and cervical dilatation at 2 cm and above
16304481|NCT04644354||Group B - Threatened Preterm Labor (tPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions less then 4 in 20 minutes and cervical dilatation less then 2 cm
16304482|NCT04644341||COVID survivors|Individuals who were infected by CPVID-19 and recovered.
16304483|NCT04644328|Experimental|Intervention|Treatment: individuals receive up to 10 Facebook ads over a 2 week period. The ad contains a short video recorded by a physician using a script that discusses the importance of staying safe during Thanskgiving by considering not traveling and using a mask when appropriate.
16304484|NCT04644328|No Intervention|Control|There are no procedures
16304486|NCT04644302||non-COVID sepsis|Patients admitted to ICU with sepsis of non-COVID origin
16304487|NCT04644302||COVID sepsis|Patients admitted to ICU with sepsis of COVID origin
16304488|NCT04644289|Other|cohort A - olaparib monotherapy|Olaparib tablets 2 × 300 mg per day for 3 weeks prior to surgery until one day prior to surgery or withdrawal of informed consent and as maintenance for 24 months after completion of primary therapy (chemotherapy).
16304489|NCT04644289|Other|cohort B - olaparib + durvalumab combination|Olaparib tablets 2 × 300mg per day for 4 weeks plus durvalumab 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle).
16304517|NCT04644120|Placebo Comparator|Part A: Group 1: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
16304490|NCT04644276|Active Comparator|Mask with Mask Adhesive/Arm 1|Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
16304491|NCT04644276|Placebo Comparator|Mask without Mask Adhesive/Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.
16304492|NCT04644263||Validity and reliability|
16304493|NCT04644250|Experimental|Arm1|Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
16304494|NCT04644237|Experimental|Trastuzumab deruxtecan 6.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 6.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
16304495|NCT04644237|Experimental|Trastuzumab deruxtecan 5.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 5.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
16304496|NCT04644224|Experimental|Group I (coaching session, navigation session, support group)|Parents/caregivers whose churches are randomized to Group I, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
16304497|NCT04644224|Experimental|Group II (coaching session, navigation session, support group)|Families whose churches are randomized to Group II, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
16304498|NCT04644224|Active Comparator|Group III (educational handbook)|Families whose churches are randomized to Group III, receive an educational handbook on cancer prevention.
16304499|NCT04644211|Experimental|Ruxolitinib Stage 1|"In stage 1, participants will be divided into two cohorts:
~Very low, Low, and Intermediate-risk ETpatients with significant symptom burden and Low-risk PV patients with significant symptom burden
~Study cycles are 28 days long, participants in both cohorts will receive:
~Ruxolitinib 2x daily for 6 study cycles."
16304500|NCT04644211|Experimental|Ruxolitinib Stage 2|"Stage 2 will commence based on 3 or more participants in Stage 1 showing a predetermined positive response to Ruxolitinib.
~In stage 2, participants will be divided into two cohorts:
~Very low, Low, and Intermediate-risk ET patients with significant symptom burden and Low-risk PV patients with significant symptom burden
~Study cycles are 28 days long, participants in both cohorts will receive:
~Ruxolitinib 2x daily for 6 study cycles."
16304501|NCT04644198|Active Comparator|Convalescent Plasma Treatment|Convalescent Plasma
16304502|NCT04644198|No Intervention|Control|Standard of care
16304503|NCT04644185|Experimental|SCTA01 Low Dose+BSC|SCTA01in a lower dose+best supportive care
16304504|NCT04644185|Experimental|SCTA01 High Dose+BSC|SCTA01in a higher dose+best supportive care
16304505|NCT04644185|Active Comparator|Placebo+BSC|SCTA01 excipients+best supportive care
16304506|NCT04644172|Experimental|Immediate Treatment|The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
16304507|NCT04644172|Other|Delayed Treatment|Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.
16304508|NCT04644159||Housolds|Pupils, teachers and non-teaching staff who attended schools of the city during the 2019-2020 school year and members of their households
16304509|NCT04644159||Subjects hospitalized or residing in health care facilities|Residents and patients from retirement homes and long-term care units
16304510|NCT04644159||Staff of health care institutions|Staff of health care institutions
16304511|NCT04644146||SEVERE|Patients affected by SARS-CoV2 infection with severe lung dysfunction needing oxygen complementation and critical care supports - criteria 18-70yr old and without any comorbidities
16304512|NCT04644146||CONTROL|Patients affected by SARS-CoV2, as shown by PCR and/or antigen testing diagnosis and without any or minor clinical expression
16304513|NCT04644133||Healthy|Subjects without bowel issues will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
16304514|NCT04644133||Constipation|Subjects diagnosed with constipation will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
16304515|NCT04644133||Fecal Incontinence|Subjects diagnosed with fecal incontinence will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
16304516|NCT04644120|Experimental|Part A: Group 1: ABBV-47D11 Dose A|Participants will receive ABBV-47D11 Dose A on Day 1.
16304518|NCT04644120|Experimental|Part A: Group 2: ABBV-47D11 Dose B|Participants will receive ABBV-47D11 Dose B on Day 1.
16304519|NCT04644120|Placebo Comparator|Part A: Group 2: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
16304520|NCT04644120|Experimental|Part A: Group 3: ABBV-47D11 Dose C|Participants will receive ABBV-47D11 Dose C on Day 1.
16304521|NCT04644120|Placebo Comparator|Part A: Group 3: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
16304522|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A|Participants will receive ABBV-2B04 Dose A on Day 1.
16304523|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A + ABBV-47D11|Participants will receive ABBV-2B04 Dose A in combination with ABBV-47D11 on Day 1.
16304524|NCT04644120|Placebo Comparator|Part B: Group 1: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
16304525|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B|Participants will receive ABBV-2B04 Dose B on Day 1.
16304526|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B + ABBV-47D11|Participants will receive ABBV-2B04 Dose B in combination with ABBV-47D11 on Day 1.
16304527|NCT04644120|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
16304528|NCT04644081|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of a total of 12 (social distancing) group training sessions (60-90 minutes) and will deliver two sessions on a weekly basis for six weeks.
16304529|NCT04644081|Active Comparator|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of counselling services).
16304530|NCT04644068|Experimental|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
16304531|NCT04644068|Experimental|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
16304532|NCT04644068|Experimental|Module 3: AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel
16304533|NCT04644055||Chronic liver disease with liver cirrhosis|Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.
16304534|NCT04644055||Control patients|Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.
16304535|NCT04644042|Experimental|Glenohumeral arthroscopy and arthroscopic subacromial decompression|
16304536|NCT04644042|Active Comparator|Glenohumeral arthroscopy and skin incision|
16304539|NCT04644016|Experimental|Participants with non-malignant and malignant hematologic disorders|Participants with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
16304540|NCT04644003|Experimental|STP1 Low Dose|1 capsule and 1 tablet per intake
16304541|NCT04644003|Experimental|STP1 High Dose|1 capsule and 1 tablet per intake
16304542|NCT04644003|Placebo Comparator|Placebo|1 placebo capsule and 1 placebo tablet per intake
16304543|NCT04643990||LDT Combined with TDF for Treatment|The patients take one tablet of LDTand one tablet of TDF every night and continue to 12 months.
16304544|NCT04643990||Only TAF treatment.|The patients take one tablet of TAF every night and continue to 12 months.
16304545|NCT04643977|Experimental|mesohyal ARGIBENONE|Name of the investigation medical device: mesohyal ARGIBENONE Code of the MD for the purpose of the clinical investigation: mARG-01-17 GMDN code: 59131 mARG-01-17 is a dermal filler recommended for cutaneous filling, facial wrinkle improvement and general condition of the skin, which is administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging.
16304546|NCT04643964|Experimental|Entrée: Cognitive Skills|
16304547|NCT04643964|Experimental|Entrée: Behavioral Skills|
16304548|NCT04643964|Experimental|Entrée: Interpersonal Skills|
16304549|NCT04643964|Experimental|Sampler Skills|
16304550|NCT04643964|No Intervention|Control|Participants are not given videos to watch until their involvement in the study ends.
16304551|NCT04643938||Two spontaneous abortions|No intervention
16304552|NCT04643938||three spontaneous abortions|No intervention
16304553|NCT04643938||Four or more spontaneous abortions|No intervention
16304554|NCT04643925|Experimental|hCG priming|"Control cycle: A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy.
~Study cycle: hCG priming by Ovitrelle 260 IE once daily for 8 weeks followed by a standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by a single blastocyst transfer at day 5."
16304555|NCT04643912|Experimental|Injured wrist or ankle|"Child with trauma needing wrist or ankle x-ray:
~Will receive vibration analysis blinded to x-ray findings."
16304556|NCT04643899|No Intervention|Control group|Patients benefiting only from the usual nutritional rehabilitation program G1a: diabetic patients G1b: non-diabetic patients
16304557|NCT04643899|Experimental|Electrostimulation group|Patients benefiting from the usual program AND muscle electrostimulation sessions G2a: diabetic patients G2b: non-diabetic patients
16304558|NCT04643886|Experimental|Cohort with Genetic Profile A|"Subjects will have Genetic Profile A.
~Intervention: Biological: GEM103."
16304559|NCT04643886|Experimental|Cohort with Genetic Profile B|"Subjects will have Genetic Profile B.
~Intervention: Biological: GEM103"
16304560|NCT04643873|Experimental|Experimental group 1|physical activity counseiling +pilates exercise group
16304561|NCT04643873|Experimental|Experimental group 2|only physical activity counseiling group
16304562|NCT04643873|No Intervention|Control Group|only followed by family physician
16304563|NCT04643860||General population|Subjects, at low and high risk of SARS-Cov-2, who undergo the nasopharyngeal swab procedure for the diagnosis of SARS-CoV-2 infection will be consecutively recruited at the Clinic Laboratory of IRCCS Neuromed in Pozzilli and Diagnostica Medica Spa in Avellino, Italy.
16304564|NCT04643847|Experimental|Stereotactic radiosurgery with Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
16304565|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.05mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.05mcg/kg iv q 12h, for 10 days, starting within 6h of birth
16304566|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
16304567|NCT04643821|Experimental|NAC 40mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 40mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
16304568|NCT04643808|Experimental|taVNS once daily|taVNS paired with bottle feeding once daily for 2-3 weeks
16304569|NCT04643808|Experimental|taVNS twice daily|taVNS paired with bottle feeding twice daily for 2-3 weeks
16304570|NCT04643795|Experimental|40 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
16304571|NCT04643795|Experimental|60 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
16304572|NCT04643795|Experimental|80 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
16304573|NCT04643795|Experimental|100 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
16304574|NCT04643782|Active Comparator|ANNE + HST|"Subjects will wear the ANNE One and HST for 1 night.
~This will serve to determine the diagnosis of moderate or severe OSA by determining a patient's Apnea-Hypopnea Index (AHI) using the ANNE One system against the Home Sleep Apnea Test (HST) over 1 night worn concomitantly"
16304575|NCT04643782|Active Comparator|ANNE + PSG|"Subjects will wear the ANNE One during an attended PSG study for 1 night.
~This will server to determine the diagnosis of moderate or severe OSA by determining a patient's Apnea-Hypopnea Index (AHI) using the ANNE One system against the Polysomnography (PSG) over 1 night worn concomitantly"
16304576|NCT04643782|Experimental|ANNE Only|"Subjects will wear the ANNE One only at home for 3 nights.
~This will serve for evaluation of AHI over multiple nights with the ANNETM One alone"
16304583|NCT04643756|Active Comparator|Conventional Physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound. Procedure/Device: Conventional Physiotherapy Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm2 and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
16304584|NCT04643756|Active Comparator|Conventional Physiotherapy + Kinesiotaping|Kinesiotaping application in addition to classical electrotherapy method consisting of tens, hotpack and ultrasound.It will be applied to reduce pain, increase proprioception and awareness. Kinesiotaping will be re-applicated every day. Space taping will be applied to the waist area. Space taping creates a vacuum effect on the skin, loosening the adhesions in the tissue layers. With this lifting effect, it creates a space under the skin, causing an increase in circulation and a decrease in pain. Four pieces of I-tape will be used for taping. The middle point of the first tape will be attached with maximum tension. The ends of the tape will be tensionless. The second tape will also be applied at a 90 degree angle. The third and fourth tapes will be taped at an angle of 45 degrees.
16304585|NCT04643743||Subjects who did receive POLYPATCH® for vascular angioplasty|Subjects who did receive POLYPATCH® at least one year ago for vascular angioplasty. 2 main sub-populations will be studied depending on location of surgery (carotid and femoral) but data will be collected for all subjects who did receive POLYPATCH.
16304586|NCT04643730|Experimental|Reflexology Group|Foot Reflexology was applied to the babies before heel lancing
16304587|NCT04643730|Experimental|Acupressure Group|Acupressure was applied to the babies before heel lancing
16304588|NCT04643730|Active Comparator|Control Group|No pre-application was made to the babies in the control group as a routine procedure
16304589|NCT04643717||intensive care patients|
16304590|NCT04643704||FPIES|100 patients
16304591|NCT04643704||IgE mediated food allergy|100 patients
16304592|NCT04643704||Celiac disease|100 patients
16304593|NCT04643704||Control group|100 patients
16304594|NCT04643691|Experimental|losartan / spironolactone|Losartan 50 mg and Spironolactone 25 mg pillules oral use
16304595|NCT04643691|No Intervention|usual care|Usual care of COVID-19 infection in intensive care
16304596|NCT04643678|Active Comparator|Anakinra Group|Anakinra + Standard of Care
16304597|NCT04643678|Other|Standard of Care Group|Standard of Care Alone
16304598|NCT04643665||No grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
16304599|NCT04643665||Grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
16304600|NCT04643652|No Intervention|Control|Usual Care
16304601|NCT04643652|Experimental|Intervention|Implementation of a Noise Reduction Bundle
16304602|NCT04643639|Experimental|Active|
16304603|NCT04643639|No Intervention|Control|
16304633|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 4|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
16304604|NCT04643626|Experimental|IG|artificial intelligence dietary application, iDSA, will be introduced and installed. Explanation on the function and application of iDSA will be given. Daily energy and macro-nutrients requirement target will bed set. The daily energy and macronutrients requirement target is secured by password. Subjects will record their daily dietary intake (food with cooking method and portion size) and nutrition impact symptoms via smartphone application at least 3 times a week. Subjects able to keep track their intake at home. During follow up session, subjects show the iDSA diet intake summary records to Researcher for further assessment.
16304605|NCT04643626|No Intervention|CG|CG will receive conventional dietitian care includes nutrition care process using conventional 24 hours diet recall method for dietary assessment
16304606|NCT04643613|Experimental|PCNF|Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks (84 days).
16304607|NCT04643600|Active Comparator|Smokers|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients who are smokers will have recorded : the age of onset of smoking, the year of smoking experience and the average number of cigarettes smoked per day. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
16304608|NCT04643600|Active Comparator|Non - smokers|All patients will be maesured: body weight, height, BMI (body mass index), waist circumference, pulse (cp), saturation (SpO2), blood pressure, respiratory index and thoracic spine mobility index measured. All patients will do a 6-minute walk test and test on a bicycle erogometer. The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
16304609|NCT04643587|Experimental|CSL787 (SAD dose 1)|Inhalation by mouth of a nebulized aerosol in healthy subjects
16304610|NCT04643587|Experimental|CSL787 (SAD dose 2)|Inhalation by mouth of a nebulized aerosol in healthy subjects
16304611|NCT04643587|Experimental|CSL787 (SAD dose 3)|Inhalation by mouth of a nebulized aerosol in healthy subjects
16304612|NCT04643587|Experimental|CSL787 (SAD dose 4)|Inhalation by mouth of a nebulized aerosol in healthy subjects
16304613|NCT04643587|Experimental|CSL787 (MAD dose 1)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
16304614|NCT04643587|Experimental|CSL787 (MAD dose 2)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
16304615|NCT04643587|Experimental|CSL787 (MAD dose 3)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
16304616|NCT04643587|Placebo Comparator|Placebo|Inhalation by mouth of a nebulized aerosol
16304617|NCT04643574|Experimental|NeoTIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (fludarabine and cyclophosphamide), Low Dose Irradiation (LDI), ex vivo expanded Tumor Infiltrating Lymphocyte (TIL), enriched for tumor antigen specificity (NeoTIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
16304618|NCT04643561|Experimental|intervention|5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention
16304619|NCT04643522||Before COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed before the diagnosis of COVID-19.
16304620|NCT04643522||After COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed after the diagnosis of COVID-19.
16304621|NCT04643509||cardiac surgery|patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery
16304622|NCT04643496||Patients requiring ileocolic resection for Crohn disease.|All consecutive patients requiring an ileocolic resection for Crohn disease, between January 2010 and March 2020 at the Digestive Surgery Units of CHU Montpellier.
16304623|NCT04643483|Experimental|Certolizumab pegol low dose arm|"Participants randomized to certolizumab pegol (CZP) who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 100 mg CZP subcutaneously (sc) every 2 weeks (Q2W).
~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by placebo and a maintenance dose of 200 mg CZP sc Q2W."
16304624|NCT04643483|Experimental|Certolizumab pegol high dose arm|"Participants randomized to CZP who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 200 mg CZP sc Q2W.
~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 300 mg CZP sc Q2W."
16304625|NCT04643483|Active Comparator|Adalimumab reference arm|"Participants randomized to adalimumab who weigh ≥17 kg to <40 kg will receive a loading dose of 80 mg at Week 0 and 40 mg at Week 2, followed by a maintenance dose of 20 mg sc Q2W.
~Participants randomized to Adalimumab who weigh ≥40 kg will receive a loading dose of 160 mg at Week 0 and 80 mg at Week 2, 40 mg and placebo at week 4 followed by a maintenance dose of 40 mg sc and placebo Q2W."
16304626|NCT04643470|Experimental|Zanubrutinib Low Dose|Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks
16304627|NCT04643470|Experimental|Zanubrutinib High Dose|Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks
16304628|NCT04643470|Experimental|Zanubrutinib Medium Dose|Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks
16304629|NCT04643470|Experimental|Placebo|Participants will receive placebo to match zanubrutinib for 72 weeks
16304630|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
16304631|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
16304632|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 3|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
16304689|NCT04643093|Active Comparator|Pitavastatin|Pitavastatin
16304634|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 5|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
16304635|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
16304636|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
16304637|NCT04643457|Placebo Comparator|Part A: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
16304638|NCT04643457|Placebo Comparator|Part A: Subcutaneous Placebo arm|Subjects randomized to this arm will receive subcutaneous Placebo to maintain the blinding.
16304639|NCT04643457|Experimental|Part B: Intravenous UCB9741 arm|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
16304640|NCT04643457|Placebo Comparator|Part B: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
16304643|NCT04643405|Experimental|APG1387 in combination with Gemcitabine and Nab-Paclitaxel|
16304644|NCT04643392||Patients with Lipedema|Participants who were diagnosed with upper extremity lipedema by a lymphologist.
16304645|NCT04643379|Experimental|Olaparib + Pembrolizumab + Carboplatin AUC|"-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows:
~Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles.
~Pembrolizumab 200 mg intravenous (IV) Day 1.
~Carboplatin AUC 5 IV on Day 1 for up to six cycles."
16304646|NCT04643366|Experimental|Concurrent Chemotherapy/ Radiation Therapy|5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.
16304647|NCT04643353|Experimental|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.
~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia)with SMOOTH mode setting, which enables non-ablative, thermal-only operation). The parameters are selected based on extensive preclinical and clinical studies.
~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
16304648|NCT04643353|Active Comparator|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
16304649|NCT04643340||active group 1|This group will train the insular cortex by real-time fMRI
16304650|NCT04643340||active group 2|This group will train the visual cortex by real-time fMRI
16304651|NCT04643340||sham|This group will only train the insula by a particular strategy
16304652|NCT04643327|Experimental|Active arm|125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days
16304653|NCT04643327|Placebo Comparator|Placebo arm|125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days
16304654|NCT04643314|Experimental|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:
~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
16304655|NCT04643314|No Intervention|Traditional intraoperative teaching|"Subjects randomized to this group will undergo their usual residency training.
~The recordings of the 5 submitted consecutive laparoscopic cholecystectomy procedures performed by the participant as the primary operator will be stored. However participants in this arm of the study will not have access to the uploaded videos until the end of the study."
16304656|NCT04643301|Experimental|Adding Liraglutide to current treatment program|Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
16304657|NCT04643288|Experimental|OFD control group|open flap debridement for periodontal intrabony defects
16304658|NCT04643288|Experimental|n-HA bone graft intervention group|Nanocrystalline Hydroxyapatite (n-HA) bone graft substitute was added to periodontal intrabony defects
16304659|NCT04643275|Experimental|Non-invasive lipolysis of the upper arms|The treatment administration phase consists of four (4) treatment visits, delivered 5- 10 - days apart. Each therapy session will last 30 minutes. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
16304660|NCT04643262||Intraoperative morbidity and mortality|Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
16304661|NCT04643262||peri-operative morbidity and mortality (<30 days)|Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
16304662|NCT04643262||Post-operative morbidity and mortality (>30 days)|Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
16304664|NCT04643236|Experimental|periodontal health educational group (test)|25 subjects diagnosed with gingivitis received periodontal health education session
16304665|NCT04643236|Active Comparator|oral hygiene motivation group (control)|25 subjects diagnosed with gingivitis received standard oral hygiene motivation session
16304666|NCT04643223|Active Comparator|Kinesio tape with tension|The intervention group will receive the elastic bandage - kinesio tape with tension between seventy to ninety percent on the selected hypertrophic scar. The application of kinesio tape follows a protocol, which involves the cleaning of the selected scar with liquid soap, drying, alcohol application for sebum removal, scar measurement and marking of the therapeutic zone and anchors. Following the application of the kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the Vancouver assessments and collections of scarring material for the histopathology will be carried out, in the time intervals corresponding to the beginning of the study intervention / entry (time 0), 45 days and 90 days after being eligible, to agree to participate in the study study and intervention.
16304667|NCT04643223|Sham Comparator|Kinesio tape without tension|The controlled sham group will receive the application of kinesio tape without tension will follow the same protocol above, including the three moments of evaluation, beginning of the intervention (time 0), 45 days and 90 days, after the beginning of the intervention.
16304668|NCT04643210|Experimental|F2F MoB EI and access to MoB Digital Platform (MoB DP) group|"The design of the face-to-face Management of my Bipolarity educational intervention (F2F MoB EI) will rely on the Colom & Vieta model, Cognitive- Behavioural techniques and the results of the relevant literature review and data acquired in the qualitative research of bipolar disease patients' educational needs. A textbook will be devised explaining in detail the step-by-step process and the techniques of the experimental educational method of the MoB F2F EI.
~This group will also receive the technology-based intervetion, which regards access to the MoB DP. This is an ecosystem where the participants will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile."
16304669|NCT04643210|Active Comparator|The MoB DP group|This group will receive the technology-based intervention, which regards access to the MoB DP. The structure of the MoB DP has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
16304670|NCT04643197|Experimental|Experimental arm|Abdominal fascia will be closed with barbed suture.
16304671|NCT04643197|Active Comparator|Control|Abdominal fascia will be closed with non-barbed suture.
16304674|NCT04643171|Experimental|Exercised group|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
16304675|NCT04643171|Active Comparator|group of electroacupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6, 5 times per week, for 12 week
16304676|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 1|Randomised participants will receive oral inhalation of AZD1402 Dose 1 via DPI.
16304677|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 2|Randomised participants will receive oral inhalation of AZD1402 Dose 2 via DPI.
16304678|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 3|Randomised participants will receive oral inhalation of AZD1402 Dose 3 via DPI.
16304679|NCT04643158|Placebo Comparator|Part 1 and Part 2: Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
16304680|NCT04643145|Active Comparator|Ureteral catheter|This group will receive ureteral catheter for 2 days after the procedure
16304681|NCT04643145|Active Comparator|Indwelling double J stent|This group will receive indwelling double J stent for 2-4 weeks after the procedure
16304682|NCT04643132|Placebo Comparator|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
16304683|NCT04643132|Active Comparator|S-ketamine at low dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
16304684|NCT04643132|Active Comparator|S-ketamine at high dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
16304685|NCT04643119|Active Comparator|Cruciate-Retaining Insert|
16304686|NCT04643119|Experimental|Medial-Congruent Insert|
16304687|NCT04643106|Experimental|Hemostatic agent group|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.
16304688|NCT04643106|Active Comparator|Suturing group|During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.
16304692|NCT04643080|No Intervention|Control|Subjects were asked to avoid consuming fermented foods for 12 weeks.
16304693|NCT04643080|Experimental|Yogurt|Subjects were asked to consume 6 oz. of yogurt daily for 12 weeks.
16304694|NCT04643067|Active Comparator|0.15mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
16304695|NCT04643067|Active Comparator|0.6mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
16304696|NCT04643067|Active Comparator|2mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
16304697|NCT04643067|Placebo Comparator|Placebo arm|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
16304698|NCT04643054|Experimental|Ovotransferrin|Dietary Supplement: Ovotransferrin
16304699|NCT04643054|No Intervention|Standard of care|Standard of care
16304700|NCT04643041|Experimental|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3W) therapy and start watch and wait.
16304701|NCT04643028|Other|Home exercise|The exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
16304702|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
16304703|NCT04643028|Other|Cervical stabilization|In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
16304704|NCT04643015||Study Participants|Patients of any age, including males and females, who are being treated in the Department of Pediatrics and are already scheduled to undergo MRI
16304705|NCT04643002|Active Comparator|Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 1)|"Isatuximab dose, intravenous (IV) weekly (QW) × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
~Pomalidomide dose os (PO) daily Day 1 to Day 21.
~Dexamethasone dose PO QW."
16304706|NCT04643002|Experimental|isatuximab + SAR439459 + dexamethasone) (Substudy 2)|"Part 1 SAR439459 in combination with isatuximab+dexamethasone 3 dose levels (DLs) of IV SAR439459
~DL1 SAR439459 dose Q2W
~DL2 SAR439459 dose Q2W
~DL3 SAR439459 dose Q2W
~Isatuximab dose IV every week (QW)x5 weeks (Cycle 1) followed by Q2W (subsequent cycles)
~Dexamethasone fixed dose/schedule: QW per os (PO) In Cycle 1, first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab at Cycle 1 Day 8). When isatuximab+SAR439459 are administered same day, SAR439459 is administered first, at least 60 min before isatuximab.
~Part 2
~SAR439459 dose, IV Q2W
~Isatuximab dose, IV QWx5 weeks (Cycle 1) followed by Q2W (subsequent cycles)
~Dexamethasone fixed dose/schedule:QW PO In Cycle 1, first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab at Cycle 1 Day 8). When isatuximab+SAR439459 are administered same day, SAR439459 is administered first, at least 60 min before isatuximab."
16304707|NCT04643002|Experimental|isatuximab + dexamethasone + belantamab mafodotin (Substudy 3)|"Isatuximab dose, intravenous (IV)
~Dexamethasone fixed dose and schedule: QW PO.
~belantamab mafodotin dose IV Q4W"
16304708|NCT04642989|Sham Comparator|Healthy Control + Sham Treatment|Healthy participants who received the sham treatment
16304709|NCT04642989|Active Comparator|Healthy Control + Facial Effleurage|Healthy participants who received the Facial Effleurage treatment
16304710|NCT04642989|Active Comparator|Acute Rhinosinusitis + Antibiotics|Sick participants who received the recommended antibiotics
16304711|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment|Sick participants who received the sham treatment
16304712|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage|Sick participants who received the Facial Effleurage treatment
16304713|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment + Antibiotics|Sick participants who received the recommended antibiotics and the sham treatment
16304714|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage + Antibiotics|Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
16304715|NCT04642976||Atrial fibrillation ablation|All patients undergoing ablation with undergo pre-procedural CT as well as HFS mapping and ablation of GPs.
16304716|NCT04642963|Experimental|Cardiac Radiosurgery|Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
16304812|NCT04642339|Experimental|Vaccine Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
16304717|NCT04642950|Experimental|NPC-26|Sargramostim (125 μg) will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
16304718|NCT04642950|Placebo Comparator|NP-26 Placebo|Physiological saline will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
16304719|NCT04642937|Experimental|hP1A8|Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
16304720|NCT04642924|Experimental|Locally Advanced Rectal Cancer|Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery
16304721|NCT04642924|Experimental|Recurrent rectal cancer|Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery
16304722|NCT04642898|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
16304723|NCT04642898|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
16304724|NCT04642898|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
16304725|NCT04642898|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
16304726|NCT04642898|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
16304727|NCT04642898|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
16304728|NCT04642885||dyad|parent with dementia and an adult child who is a caregiver
16304729|NCT04642872|Experimental|infant cimt|
16304730|NCT04642872|Active Comparator|Infant BIT|
16304731|NCT04642872|Active Comparator|Infant CIMT/BIT|
16304732|NCT04642872|Active Comparator|Conventional Therapy|
16304733|NCT04642859|Experimental|Dyslexia|Students with dyslexia before and after the intervention
16304734|NCT04642846|Experimental|one application of SDF|
16304735|NCT04642846|Experimental|two application of SDF one month apart|
16304736|NCT04642820|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
16304737|NCT04642820|Experimental|MethamphetamineThen Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
16304738|NCT04642807|Active Comparator|"Group 1 Long-arm full cast and routine follow-up"|Patients assigned to Group 1 will be placed in a long arm cast, at 90-100 degrees in neutral rotation. A referral will then be made to the orthopedic department and the patient reviewed at week 3 with cast removal, clinical assessment and radiographic assessment as determined by the normal practice at the local center.
16304739|NCT04642807|Experimental|"Group 2 Long-arm soft cast and no clinical or radiographic follow-up"|"Patients assigned to group 2 will be placed in a long arm cast at 90-100 degrees in neutral rotation. They will be given verbal and written information on the injury, when and how to remove the cast and contact details if there are any concerns.
~Since they will not be attending clinical follow-up, an email or telephone survey will be undertaken at 3 weeks and after 6 months. The survey will inquire initially about pain, unplanned returns to the Family Physician and hospital, complications, parent/patient satisfaction and a standardized patient reported outcome score will be taken. Please see attached documentation for the itemized survey questions. The 6 month follow-up will include photographs and an illustrated guide will be given to the families on how to obtain pictures of maximal flexion, extension and the child's carrying angle (attached). Measurements of range of motion from photographs are considered comparable to clinical assessment of range of motion"
16304740|NCT04642781||healthy children aged 8-13years (schoolgrade 2-5)|Primary school children are asked to read a German text presented on a laptop screen
16304741|NCT04642768|Experimental|3-Hydroxybutyrate treatment|KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
16304742|NCT04642768|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
16304743|NCT04642755||Group 1|LTBI+ and severe to moderate malnutrition
16304744|NCT04642755||Group 2|LTBI+ and uncontrolled DM
16304745|NCT04642755||Group 3|LTBI+ and helminth infection
16304746|NCT04642755||Group 4|LTBI+ with more than one of the above conditions (severe to moderate malnutrition, DM, helminth infection)
16304747|NCT04642755||Group 5|"Healthy LTBI+ controls who are negative for all of the above conditions (severe to moderate malnutrition, DM, helminth infection)"
16304748|NCT04642755||Group 6|Healthy LTBI negative controls with none of the above conditions (severe to moderate malnutrition, DM, helminth infection).
16304749|NCT04642742||Plant sterol chewable|
16304750|NCT04642729|Other|ReLex Smile surgery|The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
16304751|NCT04642729|Other|fresh corneal lenticule implantation|Using VisuMax Femtosecond Laser we make intrastromal pocket incision 2-3 mm in periphery of cornea (Because the macular dystrophy is in the center more progressive) and 150 µm deep to put fresh corneal lenticule. After one month using VisuMax we create a flap using autologous serum with purpose to remove more dead keratocytes and adding live keratocytes with aim to regenerate the metabolism of cornea.
16304752|NCT04642716|Other|Salivary free amino acids profile observation|Saliva samples of periodontitis patients and healthy controls were collected. The AA analysis of the saliva was performed by LC-MS/MS by using the Thermo Scientific TSQ Quantum Access MAX (Thermo Scientific, Schaumburg, IL, USA) .
16304753|NCT04642703||COVID-19 ventilated patients subjected to tracheostomy|Patients who receive percutaneous or surgical tracheostomy due to prolonged mechanical ventilation. The indication is made by an experts team and based on national guidelines
16304813|NCT04642339|Placebo Comparator|Placebo|Placebo
16304754|NCT04642703||COVID-19 ventilated patients without tracheostomy|Patients supported with mechanical ventilation by 10 days or more in who an experts team of physicians decided do not perform a tracheostomy
16304755|NCT04642690||Group 1-NSE|Patients found to have grossly normal squamous epithelium during endoscopy
16304756|NCT04642690||Group 2-EEG|Patients found to have grossly apparent erosive esophagitis >1cm with Los Angeles Classification A-D
16304757|NCT04642690||Group 3-NDBE Short|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Short Segment)
16304758|NCT04642690||Group 4-NDBE Long|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Long Segment)
16304759|NCT04642690||Group 5|Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
16304760|NCT04642690||Group 6-Esophagectomy|Patients undergoing resection of esophageal cancer
16304761|NCT04642690||Group -7 Pilot and Feasibility|Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
16304762|NCT04642677|Experimental|Group A|"Patients and caregivers were received palliative sedation with healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock)."
16304763|NCT04642677|No Intervention|Group B|Patients and caregivers were received palliative sedation without intervention.
16304764|NCT04642664|Experimental|Apatinib plus Camrelizumab|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.
~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
16304765|NCT04642651|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
16304766|NCT04642651|Placebo Comparator|Control group|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
16304773|NCT04642625||wound infiltration analgesia|25 patients who underwent wound infiltration analgesia
16304774|NCT04642625||ultrasound-guided bilateral erector spina plan block analgesia|25 patients who underwent ultrasound-guided bilateral erector spina plan block analgesia
16304775|NCT04642625||wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia both together|25 patients who underwent wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia
16304776|NCT04642612||Treatment Arm|Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.
16304777|NCT04642599|Experimental|Chronic Cerebellar Stroke|Participants with a chronic cerebellar stroke
16304778|NCT04642599|Active Comparator|Healthy Individuals (Controls)|healthy participants
16304779|NCT04642586|Experimental|Hypertensive participants|diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;
16304780|NCT04642586|Experimental|Normotensive participants|absence of HTA confirmed by Ambulatory Blood Pressure Measure
16304781|NCT04642560||Usual practice|Any child hospitalized in Pediatric or Neonatal ICU and receiving systemic (intravascular, intramuscular or oral) antibiotic treatment for an episode of suspected or proven community-acquired or nosocomial bacterial infection
16304782|NCT04642547|Experimental|Combination therapy with Lenvatinib and Gefitinib|First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight > 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight > 60Kg). Route of administration: Oral.
16304783|NCT04642534||Postpartum women who had gestational diabetes mellitus|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
16304784|NCT04642534||Postpartum women after an uneventful pregnancy|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
16304785|NCT04642521||Iron deficiency anaemia|Preoperatively, participants who are iron deficient with or without anaemia will receive intravenous iron (Monofer) as per ProPBM protocol.
16304786|NCT04642521||No iron deficiency anaemia|Patient in this group will not be given intravenous iron.
16304787|NCT04642508|Other|Prepectoral Reconstruction|Women with breast cancer or with high risk for breast cancer in whom a sparing mastectomy and prepectoral reconstruction was performed
16304788|NCT04642495||Human subjects aged 4 and above|Human volunteers aged 4 and above.
16304814|NCT04642326|Experimental|Test Group: experimental - UVC Therapy applied|Test: Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy
16304789|NCT04642482|Experimental|Synbiotic|"A fine powder to be taken orally consists of
~Viable cell 1,0 x 10^9 Colony Forming Unit of :
~Lactobacillus plantarum 8,55 mg
~Streptococcus thermophilus 8,55 mg
~Bifidobacterium bifidum 2,55 mg
~Fructooligosaccharide 480 mg
~Additional components : isomalt, xylitol"
16304790|NCT04642482|Active Comparator|Placebo|A powder of 5 gram maltodextrin is given as active comparator, taken orally.
16304793|NCT04642456|Other|Control group|"Healthy subjects or volunteers
~Intervention:
~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis EOS stereoradiographic full body exam"
16304794|NCT04642456|Other|ASD group|"Patient group with ASD
~Intervention:
~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis 2 EOS stereoradiographic full body exam Balance Assesment Scale 2 Trunk strength measurement with EMG 2"
16304795|NCT04642443|Active Comparator|Intracranial Hemorrhage|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:
~A molded plastic headpiece containing the antenna array
~An intermediate control unit that contains:
~a. The driving electronics for the array of antennae
~A processing control unit that contains:
~A spectrum analyzer
~The operating software that controls the device function and data acquisition, processing and archiving.
~The user interface for inputting patient information and displaying the output of the data"
16304796|NCT04642443|Active Comparator|Traumatic Brain Injury|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:
~A molded plastic headpiece containing the antenna array
~An intermediate control unit that contains:
~a. The driving electronics for the array of antennae
~A processing control unit that contains:
~A spectrum analyzer
~The operating software that controls the device function and data acquisition, processing and archiving.
~The user interface for inputting patient information and displaying the output of the data"
16304797|NCT04642430|Active Comparator|Apixaban group|"5 mg PO, twice daily for 12 months of treatment. A dose reduction* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age > 80 years; weight < 60 kg; creatinine >133 micromol/L.
~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
16304798|NCT04642430|Active Comparator|Rivaroxaban Group|"20 mg PO, once daily for 12 months of treatment. A dose reduction* to 15 mg daily will apply to patients with creatinine clearance <50 ml/min.
~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
16304799|NCT04642417|Experimental|Experimental|intervention give experience dietary fiber literacy
16304800|NCT04642417|No Intervention|No Intervention|give standard education
16304801|NCT04642404|Experimental|Epidiolex 10mg/kg single dose|After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
16304802|NCT04642404|Experimental|Epidiolex 20mg/kg single dose|The 20mg/kg dose is the maximum recommended daily dose from the manufacturer. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
16304803|NCT04642404|Placebo Comparator|Placebo group|Placebo drug will be a solution with the same taste, texture and color as the drug. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
16304804|NCT04642391||RAI|Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol <9mcg/dL.
16304805|NCT04642391||Non-RAI|Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol >= 9mcg/dL.
16304806|NCT04642378|Experimental|iNCDSS group|Artificial intelligence assisted insulin titration system group
16304807|NCT04642378|Active Comparator|Routine treatment group|Physician decided insulin titration group
16304808|NCT04642365|Experimental|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
16304809|NCT04642365|Experimental|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
16304810|NCT04642365|Experimental|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
16304817|NCT04642313|Experimental|Magnesium group|Magnesium group: Magnesium gluconate (250 mg)
16304818|NCT04642313|Experimental|Potassium group|Potassium group: Potassium chloride (250 mg)
16304819|NCT04642313|Experimental|Magnesium + Potassium group|Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
16304820|NCT04642300|Active Comparator|Holmich Protocol|Treatment will be administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions
16304821|NCT04642300|Active Comparator|Myofascial Release Technique|Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.
16304822|NCT04642287|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
16304823|NCT04642287|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
16304824|NCT04642274|Experimental|ERAS|
16304825|NCT04642274|No Intervention|Control|
16304826|NCT04642261|Experimental|Empagliflozin group|Empagliflozin 10mg daily for 52 weeks
16304827|NCT04642261|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks
16304828|NCT04642248|Active Comparator|Non-intervention|This group will have the analysis and their data will be used to determine risk factors for developing running injuries.
16304829|NCT04642248|Experimental|Intervention|This group will get a personalized program based off of 3D and movement analysis results to judge the ability to reduce musculoskeletal injuries.
16304830|NCT04642235|Experimental|Nature Nook|Nature Nook builds on our prior work with a standard vacant lot greening intervention involving: removing trash, grading the land, planting new grass and trees, installing a low wooden perimeter fence, and regular maintenance. This greening intervention was designed as a blight removal strategy. People in this arm receive no intervention.
16304831|NCT04642235|Experimental|Nature Coach|The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
16304832|NCT04642235|Experimental|Nature Nook + Nature Coach|This is a combined arm: a place-based intervention (Nature Nook) and a person-based intervention (Nature Coach).
16304833|NCT04642235|No Intervention|Control|The study lots randomly selected for this arm, as well as the participants living near them, receive no intervention.
16304834|NCT04642222|Experimental|APOLO-Teens Intervention Group (APOLO-Teens group)|In addition to the Treatment As Usual for pediatric obesity offered in Portuguese public hospitals, participants in this group receive the APOLO-Teens web-based intervention. It comprises three key components: 1) a manualized psychoeducational intervention implemented via Facebook® private groups, including cognitive-behavioral therapy strategies; 2) A weekly self-monitoring system (the APOLO-Teens web application) with automatic feedback messages assessing hours of physical activity, sedentary time, and consumption of fruits and vegetables; and 3) Monthly chat sessions.
16304835|NCT04642222|Active Comparator|Treatment As Usual (TAU) Control Group (TAU control group)|Treatment As Usual control group receives the standard intervention for pediatric obesity offered in Portuguese public hospitals. It comprises pediatric or/and nutritional appointments, usually a 30-minute appointment every 3 months. These appointments usually include a physical examination (weight, height) and personalized dietary/lifestyle recommendations. The Treatment As Usual intervention is common to the APOLO-Teens group and TAU control groups.
16304836|NCT04642209||Aggregometry|surgical timing will be guided by the results obtained by aggregometry
16304837|NCT04642157|Experimental|ELIOS group|In addition to receiving the same generic mental health resources as in the control group, the participants of the ELIOS arm will benefit from the intervention of the ELIOS team.
16304838|NCT04642157|Other|control group|Participants of the control arm will receive generic professional help contacts.
16304839|NCT04642144|Experimental|Yerba mate and carbohydrate|Consumption of yerba mate infusion and carbohydrate-based meal.
16304840|NCT04642144|Active Comparator|Yerba mate and fasting|Consumption of yerba mate infusion and stay in a fasting state.
16304841|NCT04642144|Active Comparator|Carbohydrate and water|Carbohydrate meal consumption and water intake.
16304842|NCT04642131|Experimental|Personalized insoles|Personalized insoles without supplementation
16304843|NCT04642131|Experimental|Caffeine supplementation|Standard insoles with caffeine supplementation (3mg/kg)
16304844|NCT04642131|Placebo Comparator|Control condition|Standard insoles without supplementation
16304845|NCT04642118|Experimental|Pulmonary recruitment maneuver 30 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.
~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 30 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
16304846|NCT04642118|Active Comparator|Pulmonary recruitment maneuver 40 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.
~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 40 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
16304847|NCT04642118|No Intervention|Control|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.
~The patients in this group will not be received any positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist."
16304848|NCT04642105|Experimental|Hospital-based study|The investigators will select 15 patients with refractory focal epilepsy who are admitted to the videoEEG room for longterm videoEEG recording as part of a presurgical evaluation. The Sensor-Dot and Plug 'n Patch recordings will be compared with the gold-standard videoEEG recordings.
16304849|NCT04642105|Experimental|Home-based study|The investigators will select 30 patients with refractory focal epilepsy, 15 patients with refractory idiopathic generalized epilepsy and 15 patients with frequent tonic-clonic seizures, i.e. a group at increased risk for sudden unexpected death in epilepsy (SUDEP).
16304850|NCT04642092|Experimental|PsicAP protocol|The treatment of the experimental group will be according to the PsicAP protocol: seven sessions of a psychological treatment based on transdiagnostic approaches, collaborative interventions, group-sessions, and evidence-based psychological techniques derived from cognitive behavioral therapy.
16304851|NCT04642092|Active Comparator|Conventional treatment|The control group will have seven sessions based on the typical psychological services that currently are offered in the Dominican Primary Care Units.
16304856|NCT04642066|Experimental|Active Group|Healthy volunteers were followed during the 5-month CWI exposition under standard conditions (three times per week 7-10 min). Neoprene equipment was not allowed; volunteers with followed weight or muscle mass changes over 5% were excluded
16304857|NCT04642066|Sham Comparator|Sham control|Control without CWI exposition
16304858|NCT04642053|Experimental|Immediate Treatment|Participants in the Immediate Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin between 1-3 weeks following the diagnostic evaluation.
16304859|NCT04642053|Experimental|Delayed Treatment|The Delayed Treatment Group serves as a control during the period in which participants are waiting to begin treatment. A delayed treatment onset is employed to control for maturation effects. Participants in the Delayed Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin after an 8-week delay following the diagnostic evaluation.
16304860|NCT04642040|Experimental|Pulmonary Rehabilitation|Patients are included in a personalized pulmonary telerehabilitation program consisting of patient education, respiratory and peripheral muscle training, and breathing strategies for 4 weeks. In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive instructional exercise videos for these 3 days.
16304861|NCT04642027|Active Comparator|Conventional|Conventional sEBRT
16304862|NCT04642027|Experimental|Hypofractionation|Hypofractionated sEBRT
16304863|NCT04642014|Experimental|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
16304864|NCT04642001|Other|Group G1|Photon Laser III-DMC (without radiation emission) + My First- Colgate
16304865|NCT04642001|Experimental|Group G2|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rápido Alívio/GSK
16304866|NCT04642001|Experimental|Group G3|Photon Laser III-DMC (with irradiation emission) + My First- Colgate
16304867|NCT04642001|Experimental|Group G4|Photon Laser III-DMC (with irradiation emission) + Sensodyne® Rápido Alívio/GSK
16304868|NCT04641975|Experimental|Mirabegron Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily pediatric equivalent dose (PED) low dose of IP (Investigational Product) orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
16304869|NCT04641975|Placebo Comparator|Placebo Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
16304870|NCT04641975|Experimental|Mirabegron Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
16304871|NCT04641975|Placebo Comparator|Placebo Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
16304878|NCT04641949|Active Comparator|Methoxyflurane|Inhalation methoxyflurane 99,9%, 3 ml, single dose. Intravenous NaCl 9 mg/ml, XX ml, single dose.
16304879|NCT04641949|Active Comparator|Fentanyl|Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.
16304880|NCT04641949|Placebo Comparator|Placebo|Intravenous NaCl 9 mg/ml, XX ml, single dose. Inhalation NaCl 9 mg/ml, 3 ml, single dose.
16304881|NCT04641936||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
16304882|NCT04641936||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
16304883|NCT04641923|Experimental|Seprafilm|Antiadhesion barrier applied
16304884|NCT04641923|No Intervention|No seprafilm|No barrier applied
16304885|NCT04641897|Other|Sequence A|Sequence A: Low RR for 12 hours - High RR for 12 hours
16304886|NCT04641897|Other|Sequence B|Sequence B: High RR for 12 hours - Low RR for 12 hours.
16304887|NCT04641871|Experimental|Sym021+Sym022 [ARM A]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
16304888|NCT04641871|Experimental|Sym021+Sym023 [ARM B]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
16304889|NCT04641871|Experimental|Sym021+Sym023+irrinotecan|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
16304890|NCT04641858|Active Comparator|BCG-Denmark|Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
16304891|NCT04641858|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color and appearance as the resuspended BCG vaccine.
16304892|NCT04641845|Experimental|Heel height increases|All participants consecutively walked with four heel height conditions (0 millimeter, 3 millimeter, 5 millimeter and 8 millimeter). The order of the heel height conditions was randomized.
16304893|NCT04641832|Experimental|Chronic cannabis use and subconcussive head impacts|"Group: Chronic cannabis users Criteria: self-reported chronic THC use (average use once per week but not dependent). Urine cannabis test must show positive.
~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
16304894|NCT04641832|Active Comparator|Non-cannabis use and subconcussive head impacts|"Group: Non cannabis users Criteria: self-reported none THC use. Urine cannabis test must show negative.
~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
16304895|NCT04641819|Experimental|Yangzheng Compound Mixture plus conventional treatment|"Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least.
~Conventional treatment:
~Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.
~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
16304896|NCT04641819|Other|conventional treatment only|"Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.
~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
16304897|NCT04641806||Lymphoma cases|Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. Past history of B-cell NHL in remission, active surveillance or during first-line or second-line treatment Affiliated with a social security, consenting to the study
16304898|NCT04641806||Controls|"Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. No past history of lymphoma .
~Affiliated with a social security, consenting to the study"
16304899|NCT04641793|Experimental|SCI|
16304900|NCT04641793|Experimental|STROKE|
16304901|NCT04641793|Experimental|UNIMPAIRED|
16304902|NCT04641780||Rexulti Tablets|Target is 300 patients in the Philippines diagnosed with Schizophrenia and Major Depressive Disorder
16304903|NCT04641767||BIOTRABIS>18 - Pathologic patients|Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
16304904|NCT04641767||BIOTRABIS>18 - Control patients|Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
16304905|NCT04641767||BIOTRABIS<18 - Pathologic patients|Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).
16304906|NCT04641767||BIOTRABIS<18 - Control patients|Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
16304907|NCT04641754|Experimental|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
16304908|NCT04641741||Control|Healthy adults
16304909|NCT04641741||Severe eosinophilic asthma|Severe uncontrolled asthma according to ERS/ATS criteria and persistent eosinophilia in blood (>300 cells/μL)
16304910|NCT04641728|Experimental|pembrolizumab plus olaparib|Until RECIST-based confirmation of progressive disease (PD), death, manifestation of intolerable toxicity, or participant withdrawal from the study, study participants will continue intravenous infusion of pembrolizumab 200 mg every three weeks (Q3W) in combination with oral olaparib 300 mg twice daily (BID) (combination therapy)
16304911|NCT04641702|Experimental|Pharmacologic challenge|Measurement of esophageal response toatropine using functional lumen imaging probe (FLIP)
16304912|NCT04641689|Active Comparator|Desk Only|Participants will receive a height-adjustable desk to use in their home work environment.
16304913|NCT04641689|Active Comparator|Program Only|Participants will receive 12 weeks of online content to support reductions in sedentary behavior while working from home. Content will be based on social cognitive theory.
16304914|NCT04641689|Experimental|Desk + Program|Participants will receive a height-adjustable desk to use in their home work environment AND 12 weeks of online content to support reductions in sedentary behavior while working from home.
16304915|NCT04641689|No Intervention|Waitlist Control|Participants will receive the intervention (desk + program) after all follow-up data have been collected.
16304916|NCT04641676|Other|Foundation medicine NGS in parallel with local NGS|The patient will have in parallel FMI NGS test and Local reimbursed NGS test.
16304917|NCT04641676|Other|Foundation Medicine NGS|The patient will have only FMI NGS test.
16304918|NCT04641676|Experimental|LB Foundation Medicine NGS test|The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.
16304919|NCT04641663|Experimental|100 RDD|100% of recommended daily dose (RDD) of the MORNING tablet dose (5 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
16304920|NCT04641663|Experimental|80 RDD|80% of recommended daily dose of the MORNING tablet dose (4 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
16304921|NCT04641663|Experimental|60 RDD|60% of recommended daily dose of the MORNING tablet dose (3 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
16304922|NCT04641637|Other|Selective catheterization of segmental or more peripheral arteries in TACE|From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders.
16304923|NCT04641624||Premature ovarian insufficiency (POI)|"POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotrophins and low estradiol.
~The study population will be consisted of 45 women with POI as study group."
16304924|NCT04641624||Control group|45 patients with normal healthy women as control group.
16304925|NCT04641611|Active Comparator|Cavoatrial cannulation|Cannulation of the atrium with 2-stage venous cannula.
16304926|NCT04641611|Experimental|Bicaval cannulation|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures.
~This technique is not routinely used in CABG operations."
16304927|NCT04641598|Experimental|Endometrial scratch|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
16304928|NCT04641598|Sham Comparator|Sham procedure|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.
16304929|NCT04641585|Experimental|Patients affected by Brugada Syndrome 1|Patients with spontaneous or drug-induced Brugada Syndrome 1
16304930|NCT04641585|Active Comparator|Controls|Patients with no condition associated with spontaneous or drug-induced Brugada Syndrome 1
16304931|NCT04641572|No Intervention|Supine position|group A ( control ) will follow the hospital routine positions either supine or lateral during labor
16304932|NCT04641572|Experimental|Upright position|Group B (intervention) will follow the Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions. Then the researcher will register the time ( minutes/hours) that will be taken and which will be more preferable by the participant.
16304933|NCT04641559|Experimental|Personalized nutrition group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue during four months.
16304934|NCT04641559|Experimental|Personalized Plan group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue and behavioural change program during four months.
16304935|NCT04641559|Placebo Comparator|Control group|General recommendations but not personalization nor behavioural change advice will be implemented during four months.
16304936|NCT04641546|Experimental|Occupation-Based Intervention + Therapeutic Exercise Intervention Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of 30 minutes therapeutic exercise followed by 30 minutes of occupation-based intervention.
16304937|NCT04641546|Experimental|Therapeutic Exercise Control Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of therapeutic exercise only.
16304938|NCT04641533|Experimental|L-PRF + DPSC|Mandibular third molars were extracted and DPSC with L-PRF placed into the socket.
16304939|NCT04641533|Active Comparator|L-PRF|Mandibular third molars were extracted and L-PRF placed into the socket
16305032|NCT04641052|No Intervention|No Intervention Group|The control group patients will receive standard care only
16304940|NCT04641507|Active Comparator|Tamsulosin treated group|83 patient with lower ureteric stone will take tamsulosin 0.4 mg once daily .Therapy will be given for a maximum of 4 weeks.
16304941|NCT04641507|Active Comparator|Tadalafil treated group|83 patients with lower ureteric stone will take tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
16304942|NCT04641494|Placebo Comparator|Placebo|28 subject received 2 capsules 3times a day for 12 weeks Each capsule contain 1gm (High Oleic Acid Safflower oils)
16304943|NCT04641494|Active Comparator|CLA group|Participants received 2 capsules3 times a day for 12 weeks Each capsule is 1 gm and it provided 0.75 gm CLA in a 50:50 mixture
16304944|NCT04641481|Experimental|Study vaccine|BBV152B (6µg-Algel-IMDG)
16304945|NCT04641481|Placebo Comparator|Placebo|Phosphate buffered saline with Alum (without antigen)
16304946|NCT04641468|Other|Mediana 010 or 001 left main bifurcation lesion|DCB alone combined with retracted DES implantation if necessary (d-p-d strategy)
16304947|NCT04641455|Experimental|A mucolytic solution|mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy
16304948|NCT04641455|Active Comparator|B mucolytic solution|mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy
16304949|NCT04641455|Placebo Comparator|C Water|100 ml of water 20-30 minutes prior to upper endoscopy
16304950|NCT04641455|No Intervention|D No intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
16304951|NCT04641442|Experimental|MAS825|Experimental drug
16304952|NCT04641442|Placebo Comparator|Placebo|matching placebo
16304953|NCT04641429|Experimental|Qigong|Participants in the experimental group receive Qigong exercise training.
16304954|NCT04641429|Active Comparator|stretching|Participants in the control group receive stretching exercise training.
16304955|NCT04641416||Noninvasive pump monitoring|All patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.
16304956|NCT04641403|No Intervention|Group 1 (Standard IV analgesia group (SA), n=40):|In this group, the block will be administered with normal saline (NS) and all port sites will be infiltrated with NS.
16304957|NCT04641403|Active Comparator|Group 2 (Local analgesia group (LA), n=40):|In this group, the block wiil be administered with NS and local anesthetic will be administered to the port sites.
16304958|NCT04641403|Experimental|Group 3 (two qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, right sided two-quadrant block will be performed using bupivacaine.
16304959|NCT04641403|Experimental|roup 4 (Four qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, bilateral four-quadrant block will be performed using bupivacaine.
16304960|NCT04641390||Casos|altered vaginal microbiome resistant to drug treatment
16304961|NCT04641390||Controles|Altered vaginal microbiome not resistant to drug treatment
16304962|NCT04641390||semen donors|The semen donors included in the present work will be men between 18 and 35 years old who are included in the donation program of Instituto Bernabeu after having passed a series of physical, psychological, analytical, genetic and serological evaluations and are considered suitable for donation as established by Royal Decree-Law 9/2014. Likewise, donors are subjected to a series of seminal quality evaluations and seminal freeze-thaw tests in order to guarantee their fertile potential. In this way, the donors who are part of the Instituto Bernabeu donation program also comply with current legal regulations with a strict evaluation to be considered the gold standard of potentially fertile semen. In addition, it will be necessary for them to provide a signed informed consent accepting their participation in the study.
16304963|NCT04641377|Experimental|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
16304964|NCT04641377|Active Comparator|Health education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
16304965|NCT04641364|Placebo Comparator|Control: placebo|Subjects received 0.9% sodium chloride injection.
16304966|NCT04641364|Active Comparator|Control: Human Serum Albumin(HSA)|Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
16304967|NCT04641364|Experimental|Experimental:recombinant human albumin|Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
16304968|NCT04641351|Experimental|corticosteroid|"Triamcinolone extended release (32 mg) administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.
~Knee injury and Osteoarthritis Outcome Score (KOOS) pain at 6 and 12 months
~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months
~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months
~3D bone shape from MRI Osteoarthritis Knee Score (MOAKS) using statistical shape modeling at 3 and 12 months
~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
16305001|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
16304969|NCT04641351|Placebo Comparator|Placebo|"Normal saline of 5 mL administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.
~KOOS pain at 6 and 12 months
~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months
~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months
~3D bone shape from MRI using statistical shape modeling at 3 and 12 months
~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
16304970|NCT04641338|Experimental|Intervention group|
16304971|NCT04641338|Active Comparator|Control group|
16304972|NCT04641325|Experimental|Exercise Intervention Group|Group of 10 randomized patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
16304973|NCT04641325|Other|Current Care Group|Group of 10 randomized patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening), however will not receive the exercise intervention until the second phase of the study. CCG will serve as the control for the first phase.
16304978|NCT04641299|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection.
16304979|NCT04641299|Experimental|AZD8233 high dose|AZD8233 high dose for subcutaneous injection.
16304980|NCT04641299|Experimental|AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
16304981|NCT04641299|Experimental|AZD8233 low dose|AZD8233 low does for subcutaneous injection.
16304982|NCT04641286||Stroke|Individuals admitted to the Hyper Acute Stroke Unit.
16304983|NCT04641273|Experimental|Part A: BAY1817080 150 mg BID|In Part A, Participants will be randomized to this arm with BAY1817080 150 mg BID.
16304984|NCT04641273|Placebo Comparator|Part A: Placebo BID|In Part A, Participants will be randomized to this arm with placebo for BAY1817080.
16304985|NCT04641273|Experimental|Part B: BAY1817080 25 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 25 mg BID and placebo for pregabalin.
16304986|NCT04641273|Experimental|Part B: BAY1817080 75 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 75 mg BID and placebo for pregabalin.
16304987|NCT04641273|Experimental|Part B: BAY1817080 150 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 150 mg BID and placebo for pregabalin.
16304988|NCT04641273|Placebo Comparator|Part B: Placebo BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and placebo for pregabalin.
16304989|NCT04641273|Active Comparator|Part B: Pregabalin|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and pregabalin.
16304990|NCT04641260|Experimental|Fezolinetant: Fed State then Fasted State|Participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 2.
16304991|NCT04641260|Experimental|Fezolinetant: Fasted State then Fed State|Participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 2.
16304992|NCT04641247|Experimental|Participants receiving niraparib|Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
16304993|NCT04641234||Cohort 1|Adult Belgian patients diagnosed with neovascular age-related macular degeneration (nAMD) with treatment-naïve study eye.
16304994|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
16304995|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
16304996|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
16304997|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
16304998|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
16304999|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
16305000|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
16305002|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
16305003|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
16305004|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
16305005|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
16305006|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
16305007|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
16305008|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
16305009|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
16305010|NCT04641195|Placebo Comparator|Placebo- Placebo|Participants in the PLACEBO-PLACEBO group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
16305011|NCT04641195|Experimental|Vitamin D- Placebo|Participants in the VITAMIN D-PLACEBO group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and daily placebo zinc supplements.
16305012|NCT04641195|Experimental|Placebo-Zinc|Participants in the PLACEBO-ZINC group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and actual daily zinc supplements.
16305013|NCT04641195|Experimental|Vitamin D- Zinc|Participants in the VITAMIN D-ZINC group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and actual daily zinc supplements.
16305014|NCT04641182||Prone position|Prone position per institutional protocol and as indicated by the treating physician
16305015|NCT04641182||No prone position|The control group will not be in prone position
16305016|NCT04641169|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations
~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
16305017|NCT04641156|Experimental|Low level LASER Therapy|Subjects in this group received low-level laser therapy
16305018|NCT04641156|Experimental|Exercise group|Subjects in this group received additional planned exercise therapy program
16305019|NCT04641143|Active Comparator|Troriluzole|Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.
16305020|NCT04641143|Placebo Comparator|Placebo|Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.
16305021|NCT04641130|Experimental|Exposure to birch pollen|"Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.
~The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.
~If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).
~Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.
~A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures."
16305022|NCT04641117|Experimental|Exercise|Six months of power training
16305023|NCT04641104|Experimental|Thiamine|Patients in this arm will receive a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9%.
16305024|NCT04641104|Placebo Comparator|Placebo|Patients in this arm will receive a solution of 100 ml of NaCl 0.9% alone.
16305025|NCT04641091||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)
~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
16305026|NCT04641091||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)
~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
16305027|NCT04641078|Experimental|Arm A|SBRT + 6 months of darolutamide (600 mg b.i.d.)
16305028|NCT04641078|Other|Arm B|SBRT only
16305029|NCT04641065|Experimental|Music Intervention Group|The music intervention group will be listened to Traditional Turkish Military music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
16305030|NCT04641065|No Intervention|No Intervention Group|The control group patients will receive standard care only
16305031|NCT04641052|Experimental|Music Intervention Group|The music intervention group will be listened to the music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
16305033|NCT04641039|Active Comparator|Anterior annulus removal|In these patients the anterior portion of the annulus fibrosus will be removed when inserting a complete lumbar disc prosthesis
16305034|NCT04641039|Active Comparator|Anterior annulus replacement|In these group of patients the anterior portion of the annulus fibrosus will be opened up in to flaps hinged lateraly and replaced once the complete lumbar disc prosthesis is inserted
16305035|NCT04641026|Active Comparator|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
16305036|NCT04641026|Active Comparator|Deuterium oxide-labeled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
16305037|NCT04641026|Placebo Comparator|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
16305038|NCT04641026|Placebo Comparator|Deuterium oxide-labeled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
16305039|NCT04641013||People with HIV over the age of 55 years|
16305040|NCT04641013||People without HIV over the age of 55 years|
16305041|NCT04640987|Experimental|Experimental: Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. The participant's cells will then be manipulated via a T-allo10 cell addback. Participants will be followed for outcomes for two years.
16305042|NCT04640974|Experimental|Cingal|
16305043|NCT04640961|Experimental|Cingal|
16305044|NCT04640948|Experimental|High flow nasal therapy (HFNT)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
16305045|NCT04640948|Active Comparator|Low flow oxygen (LFO)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
16305046|NCT04640922|Active Comparator|Gedea Pessary|pHyph, vaginal tablet, daily in Part 1 and once weekly in Part 2
16305047|NCT04640922|Placebo Comparator|Placebo|placebo, vaginal tablet, daily in Part 1 and once weekly in Part 2
16305048|NCT04640909|Other|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
16305049|NCT04640896|Sham Comparator|Lidocaine skin wheal|They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
16305050|NCT04640896|Active Comparator|Trigger point injection with normal saline|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
16305051|NCT04640896|Experimental|Trigger point injection with bupivacaine|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine HCl + intra- and postoperative standardized analgesia regimen
16305052|NCT04640883|Experimental|Sprints during low-intensity cycling|
16305053|NCT04640883|Active Comparator|Low-intensity cycling|
16305054|NCT04640857|Experimental|Test group: Silk'n Toothwave with an electromagnetic field|Silk'n Toothwave with an electromagnetic field use twice a day for 3 months.
16305055|NCT04640857|Sham Comparator|Control group: Silk'n Toothwave with-out an electromagnetic field|Silk'n Toothwave without an electromagnetic field use twice a day for 3 months.
16305056|NCT04640844|Experimental|patients hospitalized|for surgery of the aorta and / or arteries of the lower limbs.
16305057|NCT04640831|Experimental|GH001 dose A|
16305058|NCT04640831|Experimental|GH001 dose B|
16305059|NCT04640831|Experimental|GH001 dose C|
16305060|NCT04640831|Experimental|GH001 dose D|
16305061|NCT04640831|Experimental|GH001 Individualized Dosing|
16305062|NCT04640818||CLAD-GROUP|Patients with cladribine therapy
16305063|NCT04640818||CD20-GROUP|Patients with anti CD20 therapy (ocrelizumab or rituximab)
16305064|NCT04640805|No Intervention|Control group (standard fortification)|Pasteurized Donor Human Milk (PDHM) will be fortified as per unit protocols, at 1 packet of Human Milk Fortifier (Similac) to every 25ml PDHM at a feed volume of 80ml/kg/day
16305065|NCT04640805|Experimental|Intervention group (modified targeted fortification)|Pasteurized Donor Human Milk (PDHM) will be analyzed using the Miris Human Milk Analyzer, and PDHM with a fat content of 3.8g/dL or higher will be selected. Additional protein will be added using liquid protein fortifier (Similac) at 1ml to every 25ml PDHM to give an additional 0.67g/dL protein.
16305066|NCT04640792|No Intervention|Common Colonoscopy (Group A)|Patients will be examined with Conventional Colonoscopy (CC)
16305067|NCT04640792|Experimental|Magentiq Eye Assisted Colonoscopy (Group B)|Patients will be examined with Magentiq Eye Assisted Colonoscopy (MEAC)
16305068|NCT04640779|Experimental|Treatment (selinexor, choline salicylate)|Patients receive selinexor PO BIW on days 1, 3, 8, 10, 15, 17, 22, and 24, and choline salicylate PO TID on days 1-28. Patients undergoing pharmacokinetic analysis receive choline salicylate beginning on D3C1 and beginning on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patents who achieve >= stable disease continue treatment for an additional 6 cycles (maximum of 12 cycles) at the discretion of the treating physician and patient.
16305069|NCT04640766|Experimental|Participants with ADHD|
16305070|NCT04640740|Experimental|anterolateral approach (ALA)|anterolateral surgical approach of total hip arthroplasty
16305071|NCT04640740|Experimental|posterior approach (PA)|posterior surgical approach of total hip arthroplasty.
16305072|NCT04640727|Experimental|open reduction and internal fixation|open reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
16305073|NCT04640727|Experimental|closed reduction and internal fixation|closed reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
16305112|NCT04640415|Active Comparator|Active alarms|Patients will be connected to monitoring equipment, registering data, and data will be available to clinical staff, including alarms for vital sign deterioration.
16305074|NCT04640714|Experimental|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|"Participants with advanced cancer will receive a video visit conducted by an oncology Nurse Practitioner (NP) within three (3) business days of hospital discharge.
~The visit will involve: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
~Participant and clinician may also be interviewed for their feedback on the video visit.
~The ultimate goal of the intervention is to improve patients' confidence in managing their health condition and reduce burdensome health care utilization after discharge, particularly reducing 30-day hospital readmissions."
16305075|NCT04640662|Experimental|Platelet-Rich plasma|2 ml PRP using commercial kit- YCell Biokit
16305076|NCT04640662|Active Comparator|Prolotherapy|2 ml 16.5% Dextrose solution
16305077|NCT04640649|Experimental|Prediction Algorithm|Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
16305078|NCT04640649|No Intervention|Control|Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
16305079|NCT04640636|Experimental|Ketamine|Ketamine hydrochloride 0.5 mg/kg IM single injection
16305080|NCT04640636|Active Comparator|midazolam|Midazolam 0.06 mg/kg IM single injection
16305081|NCT04640623|Experimental|Cohort 1: TAR-200 and Cetrelimab|TAR-200 is placed into the bladder through a urinary placement catheter on Day 0 and will be dosed every 21 days for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Study Year 2). In addition, Cetrelimab will be dosed every 3 weeks (Q3W) through Week 78 (18 months).
16305082|NCT04640623|Experimental|Cohort 2: TAR-200|TAR-200 is placed into the bladder through a urinary placement catheter on Day 0 and will be dosed every 21 days for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Study Year 2).
16305083|NCT04640623|Experimental|Cohort 3: Cetrelimab|Participants will receive Cetrelimab which will be dosed Q3W through Week 78 (18 months).
16305084|NCT04640610||Adenoidectomy / tonsillectomy|Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.
16305085|NCT04640571|Experimental|placebo, then metformin, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
16305086|NCT04640571|Experimental|metformin, then polysorbate 80, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
16305087|NCT04640571|Experimental|polysorbate 80, then placebo, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
16305088|NCT04640571|Experimental|polysorbate 80, then metformin, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
16305089|NCT04640571|Experimental|placebo, then polysorbate 80, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
16305090|NCT04640571|Experimental|metformin, then placebo, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
16305091|NCT04640558||Group 1. Latent Myofascial Trigger Point Group|24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.
16305092|NCT04640558||Group 2. Non-Latent Myofascial Trigger Point Group|24 participants who don't have latent myofascial trigger point.
16305093|NCT04640545|Experimental|LBL-007+Toripalimab|LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv
16305094|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 1|"TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
16305095|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 2|"TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
16305096|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 1|"TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
16305097|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 2|"TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
16305098|NCT04640532|Experimental|Cohort 3 (JAKi Intolerant MF)|KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
16305099|NCT04640519|Experimental|TASC Intervention|TASC patients will receive a BP monitoring kit and electronic tablet and tailored infographics, and attend 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
16305100|NCT04640519|Active Comparator|TASC Control|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
16305101|NCT04640493|Experimental|SLGT2-SDB|Patients with newly diagnosed SDB will be given dapagliflozin (standard dosage, 10mg)
16305102|NCT04640480|Experimental|Cohort 1|Dosage 1
16305103|NCT04640480|Experimental|Cohort 2|Dosage 2
16305104|NCT04640480|Experimental|Cohort 3|Dosage 3
16305105|NCT04640480|Experimental|Cohort 4|Dosage 4
16305106|NCT04640480|Experimental|Cohort 5|Dosage 5
16305107|NCT04640480|Experimental|Cohort 6|Dosage 6
16305108|NCT04640467||Pregnant women|Women with uncomplicated singleton pregnancy who are planning a vaginal delivery, gestational age from 36 ± 0/7 weeks until onset of active labor (cervical dilatation ≤ 4cm) and cephalic presentation
16305109|NCT04640441|No Intervention|Control group|Participants in the control group received usual care.
16305110|NCT04640441|Experimental|Sit-to-stand care group|Intervention was provided once daily by trained nurses for a maximum of 14 days or until hospital discharge or death.
16305111|NCT04640415|No Intervention|No alarms|Patients will be connected to monitoring equipment, registering vital sign data, but data will be blinded to clinical staff.
16305234|NCT04639765|Experimental|ADM with Personalization|Video provides information about antidepressant medications and describes how treatment can be personalized.
16305113|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
16305114|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
16305115|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
16305116|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
16305117|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
16305118|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
16305119|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
16305120|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
16305121|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
16305122|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
16305123|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
16305124|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
16305125|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
16305126|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
16305127|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
16305128|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
16305129|NCT04640389||Urban|Urban adolescents living in Moshi District, Tanzania, who are between 10-14 years of age.
16305130|NCT04640389||Rural|Rural adolescents living in Kilosa District, Tanzania, who are between 10-14 years of age.
16305131|NCT04640376|Experimental|Paracetamol UNIFLASH 125mg|1 sachet Paracetamol UNIFLASH 125mg + 2 placebo capsule
16305132|NCT04640376|Placebo Comparator|Placebo|1 Placebo sachet + 2 placebo capsule
16305133|NCT04640376|Active Comparator|Paracetamol 500mg|1 Placebo sachet + 1 placebo capsule + 1 capsule Panadol 500mg
16305134|NCT04640376|Active Comparator|Paracetamol 1000mg|1 Placebo sachet + 2 capsules Panadol 500mg
16305135|NCT04640337|Experimental|Group E1: IPE applied, participants believe they are receiving IPE.|IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
16305136|NCT04640337|Placebo Comparator|Group E2: IPE applied, participants believe they are receiving placebo.|IPE will be applied following the standard protocol for PT. Subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
16305137|NCT04640337|Placebo Comparator|Group P1: IPE not applied, participants believe they are receiving IPE.|The needle will be inserted under the skin but the current will not be passing through. The subjects will see a shame video on the ultrasound screen so they will believe that the IPE is being performed.
16305138|NCT04640337|Placebo Comparator|Group P2: IPE not applied, participants believe they are receiving placebo.|The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
16305139|NCT04640324|No Intervention|NAFLD wild type control group|Consisted of not treated NAFLD wild type patients
16305140|NCT04640324|Active Comparator|NAFLD wild type treated group|Consisted of NAFLD wild type patients treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
16305141|NCT04640324|Experimental|NAFLD mutated treated group|Consisted of NAFLD patients carrying at least one mutation among PNPLA3, TM6SF2, MBOAT7 genes, treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
16305142|NCT04640311|Experimental|Part A: Daprodustat Dissolution 1/Dissolution 2/Reference|
16305143|NCT04640311|Experimental|Part A: Daprodustat Dissolution 2/Reference/Dissolution 1|
16305144|NCT04640311|Experimental|Part A: Daprodustat Reference/Dissolution 1/Dissolution 2|
16305145|NCT04640311|Experimental|Part B: Daprodustat Process 1/ Process 2|
16305146|NCT04640311|Experimental|Part B: Daprodustat Process 2/ Process 1|
16305147|NCT04640298|Experimental|Cingal|
16305148|NCT04640285|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS Tobacco Flavor Period 2 - RELX ENDS Menthol Flavor Period 3 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 4 - Usual Brand Cigarette
16305149|NCT04640285|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS Menthol Flavor Period 2 - Usual Brand Cigarette Period 3 - RELX ENDS Tobacco Flavor Period 4 - Nicorette White Ice Mint Nicotine Polacrilex Gum
16305150|NCT04640285|Experimental|Product Use Sequence 3|Period 1 - Usual Brand Cigarette Period 2 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 3 - RELX ENDS Menthol Flavor Period 4 - RELX ENDS Tobacco Flavor
16305151|NCT04640285|Experimental|Product Use Sequence 4|Period 1 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 2 - RELX ENDS Tobacco Flavor Period 3 - Usual Brand Cigarette Period 4 - RELX ENDS Menthol Flavor
16305153|NCT04640259||EGFR|
16305154|NCT04640259||ROS1|
16305155|NCT04640259||ALK|
16305156|NCT04640259||KRAS|
16305157|NCT04640259||NSCLC Other|
16305158|NCT04640246|Experimental|TBX-3400|TBX-3400 by intravenous infusion
16305324|NCT04639063||Cesarean sectioned|All females who treated in our hospital by Cesarean section operation during two-years-period
16305159|NCT04640233|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
16305160|NCT04640233|Placebo Comparator|Control Group|Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21
16305161|NCT04640220|Experimental|Adhesive capsulitis in breast cancer survivors|Intra-articular steroid injection
16305162|NCT04640207|Experimental|Facial skin treatment|Facial skin treatment using the Alma Hybrid system.
16305166|NCT04640181|Active Comparator|Adaptive Dosing: Enoxaparin|"Low 40mg subcutaneous (SQ) daily, or
~Intermediate 40mg SQ q12 hours, or
~Therapeutic 1mg/kg SQ q12 hours"
16305167|NCT04640181|Active Comparator|Adaptive Dosing: Rivaroxaban|"Low 10mg po daily
~Intermediate 10mg po daily
~Therapeutic 20mg po daily"
16305168|NCT04640168|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
16305169|NCT04640168|Experimental|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
16305170|NCT04640155|Other|Regular Diet|
16305171|NCT04640155|Experimental|Low FODMAP|
16305173|NCT04640129|Active Comparator|TDF group|tenofovir 300mg taken orally per day.
16305174|NCT04640129|Experimental|peg-IFN-α plus TDF group|peg-IFN-α 180ug given subcutaneous injection per week combined with tenofovir 300mg taken orally per day .
16305175|NCT04640116|Experimental|TIPS combined with microwave ablation|
16305176|NCT04640103||adjuvant therapy|Patients who received immunotherapy in adjuvant treatment stage only
16305177|NCT04640103||neoadjuvant therapy|Patients who received immunotherapy in neoadjuvant treatment stage and achieved R0 resection
16305178|NCT04640090|Experimental|Smartphone app|All participants in this single-arm study will receive two months of subsidized, full access to the smartphone wellness application.
16305181|NCT04640064||Patient with type 1 diabetes|Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included.
16305182|NCT04640051||LAAO group|Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation
16305183|NCT04640038|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
16305184|NCT04640025|Experimental|itacitinib|Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.
16305185|NCT04640012|Experimental|DC371739 100mg|Single dose of 100 mg tablet orally administered
16305186|NCT04640012|Placebo Comparator|Placebo|Placebo orally administered
16305187|NCT04639999||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
16305188|NCT04639986|Experimental|Arm A|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle.
16305189|NCT04639986|Active Comparator|Arm B|"Recommended doses and schedules as per package insert depending on region.
~Eribulin (1.4 mg/m2 of eribulin mesylate or 1.23 mg/m2 of eribulin IV on Days 1 and 8 of a 21-day cycle)
~Capecitabine (1000 to 1250 mg/m2 PO twice daily on Days 1 to 14 of a 21-day cycle)
~Gemcitabine (800 to 1200 mg/m2 IV on Days 1, 8, and 15 of a 28-day cycle)
~Vinorelbine (25 mg/m2 IV on Day 1 weekly)"
16305190|NCT04639973|Experimental|Group 1 (First trimester ultrasound)|
16305191|NCT04639973|Active Comparator|Group 2 (Second trimester anatomy ultrasound)|
16305192|NCT04639960|Experimental|Risperidone|
16305193|NCT04639960|Placebo Comparator|Placebo|
16305194|NCT04639947|Experimental|EyeCheck|EyeCheck pressures will be measured with contact lens in place
16305195|NCT04639947|Active Comparator|Traditional Tonometer (Goldmann and Tonopen)|Pressures will be measured with both Goldmann and Tonopen (both traditional tonometers to take the intraocular pressure (IOP) measurements of the eye).
16305196|NCT04639934||Breast cancer patients|Breast cancer patients being seen at SingHealth
16305197|NCT04639921|Experimental|active - placebo|intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days
16305198|NCT04639921|Placebo Comparator|placebo - active|intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days.
16305199|NCT04639908||barriers|find out what are the barriers
16305200|NCT04639908||facilitators|find out what are the facilitators
16305201|NCT04639895|Experimental|Virtual Reality|Standard treatment protocol and 12 sessions (30 minutes each) of personalized cognitive activities in a virtual city environment (Reh@City).
16305202|NCT04639895|Experimental|Paper and Pencil|Standard treatment protocol and 12 sessions (30 minutes each) of personalized paper-and-pencil cognitive activities,using the Task Generator tool.
16305203|NCT04639895|Active Comparator|Control Group|The standard treatment protocol.
16305204|NCT04639882|Experimental|Control-Remote-$0|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure remotely
~are compensated $0 for completing the baseline and intervention procedure"
16305205|NCT04639882|Experimental|Control-Remote-$30|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure remotely
~are compensated $30 for completing the baseline and intervention procedure"
16305206|NCT04639882|Experimental|Control-InPerson-$0|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $0 for completing the baseline and intervention procedure"
16305207|NCT04639882|Experimental|Control-InPerson-$30|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $30 for completing the baseline and intervention procedure"
16305208|NCT04639882|Experimental|PNF-Remote-$0|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure remotely
~are compensated $0 for completing the baseline and intervention procedure"
16305209|NCT04639882|Experimental|PNF-Remote-$30|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure remotely
~are compensated $30 for completing the baseline and intervention procedure"
16305210|NCT04639882|Experimental|PNF-Inperson-$0|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $0 for completing the baseline and intervention procedure"
16305211|NCT04639882|Experimental|PNF-Inperson-$30|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $30 for completing the baseline and intervention procedure"
16305212|NCT04639869|Experimental|Phenyramydol then Cabral|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
16305213|NCT04639869|Active Comparator|Cabral then Phenyramydol|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
16305214|NCT04639869|Experimental|Phenyramydol then Cabral Replicate|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
16305215|NCT04639869|Active Comparator|Cabral then Phenyramydol Replicate|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
16305216|NCT04639856|Active Comparator|on-pump CABG|CABG using Cardiopulmonary Bypass Machine
16305217|NCT04639856|Active Comparator|off-pump CABG|CABG without Cardiopulmonary Bypass Machine
16305222|NCT04639817||Levofloxacin targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
16305223|NCT04639817||TMP/SMX targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
16305224|NCT04639804|Active Comparator|Tegoprazan 50 mg|Multiple doses of tegoprazan alone once daily (QD) for 7 days
16305225|NCT04639804|Active Comparator|NSAIDs|Multiple doses of NSAIDs alone twice daily (BID) for 7 days
16305226|NCT04639804|Active Comparator|Tegoprazan 50 mg + NSAIDs|Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days
16305227|NCT04639791||Severe asthma patients|on step 4& 5 of GINA treatment
16305228|NCT04639778|Active Comparator|Control Group|In the control group, patients will follow a care pathway respecting the current recommendations : a systematic clinical visit scheduled each year with the multidisciplinary team.
16305229|NCT04639778|Experimental|Experimental Group|In the intervention group, patients will follow a new care pathway with visits triggered by weight evolution
16305230|NCT04639765|No Intervention|No video|This condition involves no video presentation.
16305231|NCT04639765|Experimental|CBT without Personalization|Video provides information about cognitive behavioral therapy.
16305232|NCT04639765|Experimental|CBT with Personalization|Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
16305233|NCT04639765|Experimental|ADM without Personalization|Video provides information about antidepressant medications.
16305235|NCT04639765|Experimental|Combined Treatment without Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
16305236|NCT04639765|Experimental|Combined Treatment with Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.
16305237|NCT04639752|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
16305238|NCT04639752|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
16305239|NCT04639739|Experimental|anti-CD19 CAR NK cells|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
16305240|NCT04639726|Active Comparator|Whey Protein|
16305241|NCT04639726|Placebo Comparator|Placebo|
16305243|NCT04639700|Experimental|Psycho-educational intervention|All participants will receive receive 4 individual sessions with an interventionist in addition to the standard post-hospital HSCT information for patient follow-up care as provided by the patient's oncologist
16305244|NCT04639687|Experimental|Immediate intervention|If randomized to this group, household of child and participating caregiver receives 12 weekly deliveries of vegetables plus added whole grains, along with text messages containing links to cooking instruction videos
16305245|NCT04639687|Other|Wait list control (delayed intervention)|If randomized to this group, participants do not get any intervention activities for the first 12 weeks, and their outcome data at V2 contribute as controls. For ethical reasons, this low-income population ultimately gets the intervention (food)later, and data after they receive the intervention contributes to follow-up data only.
16305246|NCT04639674|Experimental|AST-120|"sachet Three times a day. (2g/pack*3pack/box)
~1 month"
16305247|NCT04639674|No Intervention|Control|No intervention
16305248|NCT04639622|Other|asymptomatic at-risk individual|First-degree relative of a family member affected with the frontotemporal dementia.
16305249|NCT04639622|Other|symptomatic individual|Patient who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum
16305250|NCT04639609|Experimental|Group 1 : Patients|
16305251|NCT04639609|Other|Group 2 : healthy volunteers|
16305252|NCT04639596|Experimental|MBTS|It will consist of four hours of sailing and mindfulness training at the Jordanelle Reservoir. Boats and skippers will be provided by Park City Sailing Association, a non-profit community organization.
16305253|NCT04639596|Experimental|SRT|SRT will occur on four separate occasions during the summer of 2019. SRT will consist of 4 hours of bowling at a community bowling alley.
16305254|NCT04639583|Experimental|Observational Arm|Any infant consented to participate in the study will have the NIRS applied for the first 96 hours of life. It will be the goal to apply the NIRS sensors in the first 12 hours of life. All infants will have the same treatment if in the study, but clinicians will not be able to see the data obtained so that there is no clinical interpretation during this time.
16305255|NCT04639570|Experimental|KneuroKnits group|Participants in the KneuroKnits group
16305256|NCT04639557|Experimental|Virtual Intervention|Mothers in this group will participate in 16, once per week, scheduled 2-hour virtual group therapy sessions through Zoom for Healthcare. These sessions will include both visual media (e.g., presentations, recorded examples of skills), and discussions. A technician will be present in the virtual group therapy session to manage the technical component. These sessions will be supplemented with a 1-hour drop-in session moderated by a facilitator each week in which participants will be able to clarify topics for that week, discuss the material in more depth, and/or connect with other participants to share about the skill practice.
16305257|NCT04639557|Experimental|Therapy Intervention Pre-recorded|Mothers in this group will have access to short pre-recorded videos of the presentations with facilitator commentary (i.e., 10-12 minutes) with additional video material as warranted each week (e.g., recorded examples of skill practice) for a maximum of 30-minutes of material per week. This arm will also have a 1-hour drop-in session each week with a group facilitator to moderate homework check-ins and discussion of the material.
16305258|NCT04639544|Placebo Comparator|Control group|Volunteers will take 1 capsule per day with maltodextrin for 6 months
16305259|NCT04639544|Experimental|Probiotic group|Volunteers will take 1 capsule per day with the Lactobacillus strain for 6 months
16305260|NCT04639531|Experimental|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from Virtual Reality-base Intelligent O&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O&M skill training programs in virtual streets.
16305261|NCT04639531|Active Comparator|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from human Certified O&M Specialists (COMS) in real streets
16305262|NCT04639531|Placebo Comparator|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O&M) difficulties watching low vision education videos and discuss low vision issues not related to O&M with COMSs.
16305263|NCT04639518|Experimental|Sub-study 1|Pre-term formulas with HMO
16305264|NCT04639518|Experimental|Sub-study 2|Pre-term formulas without HMO
16305265|NCT04639505||ELISA|ELISA kit detecting the serum AMH level
16305266|NCT04639505||Chemiluminescence|CLIA method detecting the serum AMH level
16305267|NCT04639492|Experimental|MBS oral solution|fermented soybean extract-MBS
16305268|NCT04639466|Experimental|Arm I (COH04S1)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
16305269|NCT04639466|Active Comparator|Arm II (COH04S1, placebo)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.
16305325|NCT04639063||Complicated with Abdominal wall endometriosis|All the surgically excised endometrioma cases during the same time period
16305270|NCT04639466|Placebo Comparator|Arm III (placebo)|Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
16305271|NCT04639453||Stroke|Individuals with post-stroke hemiparesis in subacute phase will be included in the study.
16305272|NCT04639440||Obese or overweight patients|
16305273|NCT04639440||Patients without overweight|
16305274|NCT04639414|Experimental|Combined treatment with Empagliflozin and Semaglutide|Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly
16305275|NCT04639414|Experimental|Empagliflozin monotherapy|Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
16305276|NCT04639414|Placebo Comparator|Placebo|Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
16305277|NCT04639401|Experimental|persons with Multiple Sclerosis|
16305278|NCT04639401|Placebo Comparator|Healthy controls|
16305279|NCT04639388|Experimental|22q11.2DS|Children aged from 4 to 13 years old with 22q11.2 deletion syndrome
16305280|NCT04639388|Active Comparator|Control Group (Non22q11.2DS)|Children aged from 4 to 13 years old without developmental disease
16305281|NCT04639375|Experimental|Vaccinated with polio vaccine (IPV)|All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
16305282|NCT04639362|Experimental|Intensification|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
16305283|NCT04639362|Experimental|Observation|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
16305284|NCT04639349|Experimental|Exercised group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
16305285|NCT04639349|Other|control group|The control group will not be trained
16305286|NCT04639336||Patients with Pompe disease|
16305287|NCT04639323||Overall eligible participants|Eligible participants whose varix size will be measured by endoscopists and endoscopic ruler will receive standard esophagogastroduodenoscopy
16305290|NCT04639297|Experimental|NeuroVision® IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
16305291|NCT04639297|Active Comparator|Conventional hospital based IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
16305292|NCT04639284||Combinational therapy|Participants who receive systemic treatment with an anti-angiogenic agent, including sorafenib, lenvatinib, apatinib, and bevacizumab, in combination with an anti-PD-1/PD-L1 antibody, including pembrolizumab, nivolumab, sintilimab, toripalimab, camrelizumab, tislelizumab, and atezolizumab.
16305293|NCT04639271|Experimental|Pyrotinib Plus Trastuzumab And Abraxane|Pyrotinib Plus Trastuzumab And Abraxane
16305295|NCT04639245|Experimental|Treatment (FH-MagIC TCR-T cells, atezolizumab)|"LYMPHODEPLETION: Patients receive cyclophosphamide IV and fludarabine IV on days -4, -3, and -2 before each T-cell infusion.
~T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion.
~In the Phase II portion of the study, patients will receive atezolizumab IV every 3 weeks beginning 24-72 hours after T cell infusion. Atezolizumab will be given for at least 1 year in the absence of disease progression or unacceptable toxicity. If an alternative PD1 inhibitor is instead available for a patient, it may be substituted instead."
16305296|NCT04639232|Placebo Comparator|Control group|Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.
16305297|NCT04639232|Experimental|Prob-milk|Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.
16305298|NCT04639232|Experimental|Voluntas-Prob|Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain
16305300|NCT04639206|Experimental|HOBSCOTCH group|Participants in this study arm will receive the HOBSCOTCH intervention immediately.
16305301|NCT04639206|No Intervention|Wait-listed control|Participants in this study arm will be wait-listed for 6 months and will then receive the HOBSCOTCH intervention.
16305326|NCT04639050|Experimental|Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
16305327|NCT04639050|Placebo Comparator|Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
16305302|NCT04639193|Experimental|Placebo, then Dual-Therapy, then Single/Triple-Therapy|"Subjects will start with a 3-day PLACEBO regimen:
~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.
~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.
~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
16305303|NCT04639193|Experimental|Dual-Therapy, then Placebo, then Single/Triple-Therapy|"Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:
~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.
~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.
~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
16305304|NCT04639180|Experimental|Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))|Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)
16305305|NCT04639180|No Intervention|Control group (Active surveillance)|
16305306|NCT04639167|Experimental|Paths to everyday life (PEER)|The Paths to everyday life (PEER) intervention added to service as usual (SAU) consists of a 10-week group course and an opportunity of individual companionship to persons with mental vulnerability and mental health difficulties. The 10 week group sessions is facilitated by two volunteer peers with their own lived experiences with mental vulnerability.
16305307|NCT04639167|No Intervention|Service as usual (SAU)|Participants who will be allocated to the control group of the trial will receive service as usual (SAU) by their social security officer, or no specific service if the participant has been referred to the trial by self-referral. Participants who are referred to the trial via §82 in the municipality, can receive other §82 offers depending on the individual municipality.
16305308|NCT04639154|Placebo Comparator|control group|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
16305309|NCT04639154|Active Comparator|tramadol 50|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
16305310|NCT04639154|Active Comparator|tramadol 100|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
16305311|NCT04639141|Active Comparator|Synbiotic|"Dosing: one sachet/dose per day for 12 weeks. The combination includes: Lactobacillus rhamnosus (1x10^10 CFU/dose), Lactobacillus plantarum (4 x 10^9 CFU/dose), Bifidobacterium animalis subsp. lactis (5 x 10^9 CFU/dose), Bifidobacterium longum (1 x 10^9 CFU/dose) + 4g/dose of partially hydrolysed guar gum (PHGG).
~Mode of administration: oral."
16305312|NCT04639141|Experimental|Synbiotic + gut-directed hypnotherapy|"Includes the daily oral synbiotic (as pervious described) + a home-based therapy program.
~Home-based therapy program: based on the Manchester model of gut-directed hypnotherapy (GDH) adapted for use in children with ASD. The GDH core therapy focus areas will be relaxation, control of gut function and ego-strengthening.
~Schedule: daily use of a home-based audio recordings. The program will consist of six (6) therapy sessions/recordings over 12 weeks. Each recording (sessions 1 through 6) is to be used daily for a fortnight. Each session is approximately 15-20 minutes in duration."
16305313|NCT04639128|No Intervention|No-Device|No placement of an adductor canal catheter
16305314|NCT04639128|Experimental|Device|Placement of an adductor canal catheter
16305315|NCT04639115|Experimental|Ozanimod in subjects with mild hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with mild hepatic impairment
16305316|NCT04639115|Experimental|Ozanimod in subjects with moderate hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with moderate hepatic impairment
16305317|NCT04639115|Experimental|Ozanimod in healthy subjects|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in healthy subjects
16305318|NCT04639102|Experimental|PATH Intervention|Patients in the treatment arm will receive a personalized plan of care upon discharge from the emergency department.
16305319|NCT04639102|No Intervention|Routine Care|Patients in the control arm will receive standard-of-care services (the care plan that the emergency physician would normally offer if PATH were not available) without PATH enrollment.
16305320|NCT04639089|Experimental|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure
16305321|NCT04639089|Placebo Comparator|We will apply 10cm saline on the sternal edge before sternal closure|We will apply 10cm saline on the sternal edge before sternal closure
16305322|NCT04639076|Active Comparator|Behavioral Weight Loss Group|Participants in this arm will receive a standard behavioral weight loss approach that recommends a calorie deficit based on starting weight, a standard activity minute goal progression based on baseline activity and standard behavioral weekly counseling.
16305323|NCT04639076|Experimental|Personalized Behavioral Weight Loss Group|Participants in this arm will receive a personalized weight loss approach that recommends either a low carbohydrate or low fat calorie reduced diet; personalized activity plan with either daily or weekly bout-related goals; and eating frequency of either 3 times per day or 5-6 times per day.
16305328|NCT04639050|Experimental|Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
16305329|NCT04639050|Placebo Comparator|Cohort 2: Placebo|Participants will receive matching placebo to dose level 2 Q4W for 28 weeks followed by a 28-week safety follow-up period.
16305330|NCT04639050|Experimental|Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
16305331|NCT04639050|Placebo Comparator|Cohort 3: Placebo|Participants will receive matching placebo to dose level 3 Q4W for 28 weeks followed by a 28-week safety follow-up period.
16305332|NCT04639050|Experimental|Cohort : Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
16305333|NCT04639050|Placebo Comparator|Cohort 4: Placebo|Participants will receive matching placebo to dose level 4 Q4W for 28 weeks followed by a 28-week safety follow-up period.
16305334|NCT04639037|Active Comparator|Manual adjustment of vasopressor|Fluid and vasopressor will be managed as standard practice guided by the EV1000 monitoring device (manually infusion of both fluid and vasopressors) Objective being to maintain MAP within a target MAP range of 80-90 mmHg (fluid will be optimized and stroke volume index will be maintained within normal values)
16305335|NCT04639037|Experimental|Automated adjustment of vasopressor|Fluid will be managed using the EV1000 monitoring in order to optimize stroke volume index and vasopressor will be automatically deliver by a closed-loop system to maintain the MAP within the target range of 80-90 mmHg
16305336|NCT04639024|Experimental|ADCT-301 Infusion|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
16305337|NCT04639011|Active Comparator|Group A Placebo|Participants randomized to Group A will receive placebo (sugar pill) and Boston Medical Center (BMC) standard of care.
16305338|NCT04639011|Experimental|Groups B Intervention|Participants randomized to Group B will receive duloxetine and Boston Medical Center (BMC) standard of care.
16305339|NCT04638998||Healthy Control|The healthy control group are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. This cohort do not experience any Gulf War Illness symptoms.
16305340|NCT04638998||Gulf War Illness|The GWI cohort are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. The men in this cohort will also meet the Kansas Inclusion Criteria for GWI.
16305341|NCT04638985|Experimental|group 1 (sIPV+DTaP+MMR)|150 subjects; simultaneously administration of sIPV+DTaP+MMR as booster immunization at the age of 18 months old, 0.5 ml each, respectively
16305342|NCT04638985|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
16305343|NCT04638985|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
16305344|NCT04638985|Active Comparator|group 4 (MMR)|150 subjects; vaccination of 0.5 ml MMR as booster immunization at the age of 18 months old
16305345|NCT04638972||Tactile Sense Method|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
16305346|NCT04638972||Radiographic Method (digital periapical radiography)|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
16305347|NCT04638972||Ipex® EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
16305348|NCT04638972||Propex® pixi EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
16305349|NCT04638959||GC|patients diagnosed with GC
16305350|NCT04638959||HC|patients diagnosed with chronic gastritis by histopathology
16305351|NCT04638946|Experimental|Titration to high intensity exercise|
16305352|NCT04638946|Active Comparator|Low intensity exercise|
16305353|NCT04638933||OSA patients|Patients with proven OSA (apnea-hypopnea index ≥20/h, ESS >10, age ≥18 years) and initiation of CPAP treatment
16305354|NCT04638920||Exacerbators|Patients with COPD exacerbation
16305355|NCT04638907||Observational study group|Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.
16305356|NCT04638881|Experimental|Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
16305357|NCT04638881|Placebo Comparator|Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
16305358|NCT04638868|Experimental|Isolation of circulating tumor cells|Both portal venous and peripheral blood will be obtained from the patient and subjected to analysis for pancreatic cancer circulating tumor cells
16305359|NCT04638855|Experimental|Medicurtain®|Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery
16305360|NCT04638855|Sham Comparator|Placebo|No device after hysteroscopy surgery
16305361|NCT04638842|Experimental|Grief COVID intervention|Participants in this group will receive 12 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, hopelessness, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life.
16305431|NCT04638413|Experimental|Walking regimen (W)|
16305362|NCT04638842|No Intervention|Waiting List group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 12 sessions will receive the intervention.
16305363|NCT04638829|Other|Avatrombopag|Avatrombopag 20 mg oral tablet formulation for 90 days
16305364|NCT04638816|Experimental|Restylane Volyme|Hyaluronic Acid
16305365|NCT04638816|Experimental|Restylane Lyft Lidocaine|Hyaluronic Acid
16305366|NCT04638803|Experimental|Crossover (fasted)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
16305367|NCT04638803|Experimental|Single Group (fed)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
16305368|NCT04638790|Experimental|Early favorable HL|HL without adverse prognostic factors
16305369|NCT04638790|Experimental|Early unfavorable HL|Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)
16305370|NCT04638790|Experimental|Advanced stages HL|(age less than 50 years)
16305371|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and PFC|
16305372|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and sham rTMS over PFC|
16305373|NCT04638777|Sham Comparator|Sham rTMS over M1 and PFC|
16305374|NCT04638764|Active Comparator|Aerobic interval training with high loads resistance training|"Patient to be randomised into combined aerobic training with high loads resistance training group."
16305375|NCT04638764|Active Comparator|Aerobic interval training with low loads resistance training|"Patient to be randomised into combined aerobic training with low loads resistance training group."
16305376|NCT04638764|Active Comparator|Aerobic interval training|"Patient to be randomised into aerobic training training group."
16305377|NCT04638751||NSCLC|Stage 3 or stage 4 non-small cell lung cancer patients, being administered checkpoint inhibitor therapy for the first time. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16305378|NCT04638751||Triple-negative breast cancer|Stage 3 or stage 4 metastatic triple-negative breast cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16305379|NCT04638751||Colorectal cancer|Stage 3 or stage 4 colorectal cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16305380|NCT04638751||Pancreatic cancer|Stage 3 or stage 4 pancreatic cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16305381|NCT04638738||Pre-implementation|Pre-implementation of digital alerting sensor systems
16305382|NCT04638738||Post-implementation|Implementation of digital alerting sensor systems
16305383|NCT04638725||HER2 positive breast cancer treated only with trastuzumab|
16305384|NCT04638725||HER2 positive breast cancer treated with pertuzumab|
16305385|NCT04638725||HER2 positive breast cancer treated with neratinib|
16305386|NCT04638725||HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)|
16305387|NCT04638725||HER2 positive breast cancer treated with TDM1 and neratinib|
16305388|NCT04638712|Other|Group 1 without trastuzumab|
16305389|NCT04638712|Other|Group 2 with trastuzumab|
16305390|NCT04638699|No Intervention|Phase 1 Survey of the actual state|
16305391|NCT04638699|Other|Phase 2 Survey after the OptiScreen training|
16305392|NCT04638673|Experimental|Active-Active Stimulation Group|This group will be randomized into the active stimulation group for weeks 1&2 of stimulation and active stimulation during weeks 3&4 of stimulation of study participation.
16305393|NCT04638673|Sham Comparator|Sham-Active Stimulation Group|This group will be randomized into the sham stimulation group for weeks 1&2 of stimulation and active stimulation for weeks 3&4 of stimulation of study participation.
16305394|NCT04638660|Experimental|Phentolamine Ophthalmic Solution 0.75%|One drop in both eyes at or near bedtime (8PM to 10PM)
16305395|NCT04638660|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop in both eyes at or near bedtime (8PM to 10PM)
16305396|NCT04638647|Experimental|Secukinumab s.c.|Participants will be started on 75 mg, 150 mg or 300 mg s.c. Q4W depending on what dose the participant was receiving in the parent trial (for trials with i.v. formulation the starting dose will be 300 mg s.c.). The study medication dose may be modified basedu pon clinical need, the judgement of the investigator and health authority guidelines (if applicable). For pediatric participants, the dose should not be increased beyond the maximum dose evaluated in the respective weight category in the parent protocol.
16305397|NCT04638634|Experimental|CSL760 (low dose)|Administered as an intravenous infusion
16305398|NCT04638634|Experimental|CSL760 (high dose)|Administered as an intravenous infusion
16305399|NCT04638608|Other|EMBRACE (Relatives)|Feasibility test of a new palliative rehabilitation blended learning program for relatives of people with ALS/cognitive impairments
16305400|NCT04638608|Other|EMBRACE (Health care providers)|Feasibility test of a new palliative rehabilitation blended learning program health care providers helping people with ALS/cognitive impairments
16305401|NCT04638595||Normative|50 neurotypical pediatric subjects
16305432|NCT04638413|Experimental|Gamified inhibitory control training (PolyRules!)|
16305433|NCT04638413|Experimental|Walking regimen + gamified inhibitory control training (W+PolyRules!)|
16305434|NCT04638400|Active Comparator|Simvastatin|Obese subjects with elevated cholesterol
16305435|NCT04638400|Active Comparator|Ezetimibe|Obese subjects with elevated cholesterol
16305402|NCT04638582|Experimental|Neoadjuvant pembrolizumab + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles.
~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
16305403|NCT04638582|Experimental|Neoadjuvant pembrolizumab and chemotherapy + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles in combination with standard of care histology-specific chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 3 cycles.
~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
16305404|NCT04638569|Active Comparator|Ultrasound-guided obturator nerve block group|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.
16305405|NCT04638569|Active Comparator|obtutaror nerve block with anatomical landmarks|In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.
16305406|NCT04638556||Normal|A healthy, disease-free population.
16305407|NCT04638556||T2DM|T2DM group was simple type 2 diabetes mellitus.
16305408|NCT04638556||DPN|The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal.
16305409|NCT04638543|Experimental|ABP-671|The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.
16305410|NCT04638543|Placebo Comparator|Placebo|
16305411|NCT04638530|Other|Residents|All residents will participate in the activity
16305412|NCT04638517|Active Comparator|Danazol|800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.
16305413|NCT04638517|Placebo Comparator|Placebo|Matching placebo capsules.
16305414|NCT04638504||11-14 weeks of normal pregnancy.|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
16305415|NCT04638504||11-14 week obese pregnant|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
16305416|NCT04638504||24-28 week normal pregnant|24-28. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery, and maternal uterine artery dopes will be examined ultrasonographically.
16305417|NCT04638504||24w-28w obese normal pregnant|24w-28w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
16305418|NCT04638504||37w -40w normal pregant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
16305419|NCT04638504||37-40 w obese normal pregnant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
16305420|NCT04638491|Experimental|single-arm|PM01183-Dose Escalation
16305421|NCT04638465||A - Surgery Only|"Participants with the following diagnosis will receive transoral robotic surgery with neck dissection:
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN0 or N1 (single node)
~Tonsil - Stage: cT1-3, cN0 or N1 (single node)
~Unknown primary - Stage: cT0 N1 (single node)
~Radiation also given if indicated by intermediate or high risk features following surgery."
16305422|NCT04638465||B - Surgery with Adjuvant Therapy|"Participants with the following diagnosis will receive surgery followed by 6 Cycles of Cisplatin 40 mg/m2:
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN1 (2-4 nodes) or N2
~Tonsil - Stage: cT1-3, N1 (2-4 nodes)
~Radiation also given if indicated by intermediate or high risk features following surgery."
16305423|NCT04638465||C - Concurrent Chemo/Radiation Therapy - Dose Level 1|"Participants with the following diagnosis will receive 6 Cycles of Cisplatin 40 mg/m2 + 60 Gy Radiation:
~Tonsil - Stage: cT1-3, N2
~Unknown Primary - Stage: cT0, N2"
16305424|NCT04638465||D - Concurrent Chemo/Radiation Therapy - Dose Level 2|"Participants with the following diagnosis will receive 7 Cycles of Cisplatin 40 mg/m2 + 70 Gy Radiation:
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT3-4, any N
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cAny T, N3
~Tonsil - Stage: cT1-3, N3
~Tonsil - Stage: cT4, any N
~Unknown Primary - Stage: cT0, N3"
16305425|NCT04638452|Other|Epidemiology|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
16305426|NCT04638439|Experimental|P1101 + Nivolumab + Entecavir|
16305427|NCT04638426|Experimental|Treatment A|HL237 tab. 200mg/day
16305428|NCT04638426|Experimental|Treatment B|HL237 tab. 400mg/day
16305429|NCT04638426|Experimental|Treatment C|HL237 tab. 800mg/day
16305430|NCT04638426|Placebo Comparator|Placebo|Placebo of HL237 tab.
16305436|NCT04638387|Experimental|PB125|Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience). Treatment will last 12 weeks.
16305437|NCT04638387|Placebo Comparator|Placebo|Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience). Treatment will last 12 weeks. Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
16305438|NCT04638361||No laryngeal mobility disorder post cardiac surgery|No Follow up, no questionnaires and no nasofibroscopic control.
16305439|NCT04638361||Laryngeal mobility disorder post cardiac surgery|During a follow-up consultation, questionnaires will be offered to assess the child's quality of life.
16305440|NCT04638348|Experimental|New Biofeedback|Women allocated to the new biofeedback group will be instructed to attach the biofeedback device to their underpants and then perform pelvic floor muscle training.
16305441|NCT04638348|Active Comparator|Conventional Biofeedback|Women allocated to the conventional biofeedback group will undergo pelvic floor muscle training with the conventional biofeedback probe inserted in the vagina
16305442|NCT04638348|Active Comparator|Control group|The control group will perform pelvic floor muscle training without any biofeedback device.
16305443|NCT04638335||travelers over the age of 60|blood sample taken to test the presence of Anti-HAV antibodies
16305444|NCT04638335||travelers having lived in a tropical country for more than 5 years|blood sample taken to test the presence of Anti-HAV antibodies
16305445|NCT04638322|Experimental|HIFT Group|This group receives physical training based on exercises of high intensity interval functional training.
16305446|NCT04638322|No Intervention|No intervention group|This group does not receive any treatment.
16305447|NCT04638309|Experimental|Cohort 1|Dose level 1
16305448|NCT04638309|Experimental|Cohort 2|Dose level 2
16305449|NCT04638309|Experimental|Cohort 3|Dose level 3
16305450|NCT04638296||Physicians|surgeons, anesthesiologists, and surgical residents
16305451|NCT04638296||Nurses|OR Nurses
16305452|NCT04638283|Experimental|Interventioh group|"The intervention consists of
~Eight group sessions of two hours duration, focusing on GMT and ADHD. The Group consists of six participants and is directed by one neuropsychologist and one psychologist.
~Four individual sessions with the neuropsychologist/psychologist directing the Group where the participant is guided through the process of formulating GAS-goals.
~Bi-weekly Telephone follow up focusing on GAS-goal attainment the thre first months following the Group session phase."
16305453|NCT04638283|No Intervention|Control Group|Participants in the Control Group receive TAU. Participation in the study does not influence decisions regarding pharmacological interventions in either of the groups.
16305454|NCT04638270|Experimental|anti-CD19 FasT CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.
~3×10^5 /KG 6×10^5 /KG 1×10^6/KG"
16305455|NCT04638257|Experimental|Lactobacilli|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14 Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
16305456|NCT04638257|Placebo Comparator|Placebo|Receives placebo
16305457|NCT04638244|Experimental|BOMI Group (Intervention Group)|Listening to an expert-selected, theory-guided and self-chosen song each day actively in a personalized and focused way (Brief Online Music Intervention: BOMI) for 3 months
16305458|NCT04638244|Active Comparator|POM Group (Control Group)|Receiving psychoeducational online message (POM) (for focused reading for 5 minutes) daily for 3 months
16305459|NCT04638231|Active Comparator|Text Message Group|This group will receive daily supportive messages through Short Messaging Service (SMS) on their mobile phones in addition to standard care
16305460|NCT04638231|Experimental|Email Message Group|This group will receive same supportive message as the Text Message group but through their email addresses, in addition to receiving standard care
16305461|NCT04638218|Experimental|Augmented Reality|The system provides visual and audio feedback which makes the rehabilitation training process more relaxing, interesting and convenient to guide the patients performing appropriate upper-limb, lower-limb exercises and balance training.
16305462|NCT04638205||Suicide attempt cases|Adolescents and young adults who attempted suicide between 7 and 30 days prior the inclusion
16305463|NCT04638205||Non-suicidal controls|Adolescents and young adults without history of suicide attempt or ideation
16305464|NCT04638192|Experimental|subject-specific tACS|Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency
16305465|NCT04638192|Experimental|standard tACS|Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency
16305466|NCT04638192|Sham Comparator|Sham tACS|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect
16305467|NCT04638179||HF-PAC|(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
16305468|NCT04638179||HF-non PAC|(2)The control group received traditional health education in general care and routine health care.
16305469|NCT04638166|Experimental|Mineral water group|The mineral water group were instructed to consume 1.25L of a commercially supplied bicarbonate rich mineral water per day at meal times, supplemented by other fluid intake up to 2.5 - 3L/day.
16305470|NCT04638166|Active Comparator|Plain water group|The plain water group consumed only plain water up to 2.5 - 3L/day.
16305471|NCT04638153|Experimental|Low Dose|Low Dose
16305472|NCT04638153|Experimental|Medium Dose|Medium Dose
16305473|NCT04638153|Experimental|High Dose|High Dose
16305474|NCT04638140||Healthy hip population|
16305475|NCT04638140||Hip defect population|
16305476|NCT04638127|Experimental|PREEMIE PROGRESS|PREEMIE PROGRESS is an innovative, video-based intervention that applies evidence-based family management theories to better equip parents to meet the chronic, complex healthcare needs of their preterm infant.
16305505|NCT04637932|Active Comparator|Use of Pro-seal LMA and Bronchoscopy During Percutaneous Dilatation Tracheostomy|group 2 as pro-seal laryngeal mask group.
16305477|NCT04638127|Active Comparator|Attention Control|"To maintain their attention, control parents will view Welcome Videos that explain hand hygiene, visitor IDs, parking, etc. on their mobile devices."
16305478|NCT04638114|Experimental|CAM lesion|Mini-Open DAA Hip Arthroscopy
16305479|NCT04638114|Other|PINCER impingement|Mini-Open DAA Hip Arthroscopy
16305480|NCT04638101|Experimental|Intervention group (RCT)|Participants from the intervention group participated in the mindfulness-based intervention between Time 1 and Time 2.
16305481|NCT04638101|Experimental|Waiting group (RCT)|Participants from the waiting group took part in the mindfulness-based intervention between Time 2 and Time 3.
16305482|NCT04638088||robot-assisted laparoscopy|radical prostatectomy performed by robot-assisted laparoscopy
16305483|NCT04638088||conventional laparoscopy|radical prostatectomy performed by conventional laparoscopy
16305484|NCT04638088||laparotomy|radical prostatectomy performed by laparotomy
16305485|NCT04638075|No Intervention|Group A Bottle Supplementation|Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
16305486|NCT04638075|Experimental|Group B SNS Supplementation|Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
16305487|NCT04638062|Experimental|Post Isometric Relaxation|"This study ARM will receive following therapies
~Post isometric relaxation (Upper Trapezius and Levator Scapulae muscles)
~Isometric neck strengthening exercises
~Cryotherapy"
16305488|NCT04638062|Experimental|Myofascial Release Therapy|"This study ARM will receive following therapies
~Myofascial release therapy (Upper Trapezius and Levator Scapulae muscles
~Isometric neck strengthening exercises
~Cryotherapy"
16305489|NCT04638049|Active Comparator|Prostate (Bed) only RadioTherapy (PBRT)|Primary, adjuvant or salvage RT of the prostate (bed) without RT of the pelvic nodal regions in the small pelvis, according to local hospital guidelines and protocols.
16305490|NCT04638049|Active Comparator|Whole Pelvis RadioTherapy (WPRT)|Primary, adjuvant or salvage RT of the pelvic nodal regions in the small pelvis with possible additional RT of the prostate (bed), according to local hospital guidelines and protocols.
16305491|NCT04638036|Experimental|NIR endoscopy and surgery with cetuximab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, cetuximab-IRDye800CW will be administered to a total of 15 patients with proven locally advanced rectal cancer
16305492|NCT04638010|Experimental|Cancer control navigation (CNN) plus General referral (usual care)|"Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
~Additionally, Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only."
16305493|NCT04638010|Active Comparator|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
16305494|NCT04637997|Other|Study group 1|Wearing of compression stockings class I between Investigation day 28 to 56. Wearing of compression stockings class II between Investigation day 56 to 84.
16305495|NCT04637997|Other|Study group 2|Wearing of compression stockings class II between Investigation day 28 to 56. Wearing of compression stockings class I between Investigation day 56 to 84.
16305496|NCT04637984|Experimental|Implementation Group|Predictions will be provided to the rehabilitation team and discussed with the patient and their family. Patients will receive a multidisciplinary rehabilitation according to their individual needs.
16305497|NCT04637984|No Intervention|Control Group|This group will not received any information on the PREP2
16305498|NCT04637971|Experimental|Coaching|The present intervention is a structured, group-based coaching program that is facilitating an active process of change through the identification of achievable personal goals, the formulation of action plans, the provision of constructive feedback, and progressive monitoring of goal attainment.
16305499|NCT04637971|Active Comparator|Self-help tips plus telephone support|Self-help tips including stress coping methods. Our project staff will contact the subject to encourage her to make use of the tips we sent her.
16305500|NCT04637958||pain|THA
16305501|NCT04637958||no pain|THA
16305502|NCT04637945|Placebo Comparator|placebo|The placebo will be delivered in softgels consisting of colorant, olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, glycerin and water.
16305503|NCT04637945|Experimental|ACRB|The ACRB product will be delivered in softgels consisting of anthocyanin-rich blend. Each softgel will contain: i) 49 mg bilberry extract; ii) 101 mg black currant extract; and iii) 303 mg black rice extract. The high ACRB will deliver at least 108 mg anthocyanins. The product will also contain olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, and water.
16305504|NCT04637932|Active Comparator|Use of endotracheal tube During Percutaneous Dilatation Tracheostomy|Group 1 was determined as endotracheal tube
16305506|NCT04637919|Experimental|IN-B001 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16305507|NCT04637919|Experimental|IN-B001 CVA16 B dose|Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16305508|NCT04637919|Experimental|IN-B001 Bivalent C dose|Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16305509|NCT04637906|Experimental|L-arginine|Bioarginina®, 2 orally administered vials per day
16305510|NCT04637906|Placebo Comparator|Placebo|2 orally administered vials per day of Bioarginina® without L-arginine
16305511|NCT04637867|Other|RT-PCR confirmed COVID-19 patients|RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.
16305512|NCT04637854|Experimental|Operating Microscope.|"Surgical technique is the same used for extraction of the lower third molar. Patients will be enrolled (baseline) whenever sign their written informed consent to participate to the study, after having read and understand the informative pamphlet.
~The intervention will be performed under local anesthesia (mepivacaine 20 mg/ml with adrenaline 1:100000) and by the use of microscope.
~At the end of the surgical procedure, all patients will receive a 100mg Nimesulide cpr and apply the ice pack on the cheek.
~At the end of each procedure will give post-operative instructions for all patients and prescribe an antiseptic therapy with chlorhexidine coll. 0.2% 3 times/ day for 10 days from the day following the intervention and anti-inflammatory therapy Nimesulide 100 mg cpr to take up to 2 times / day for up to 4 days.
~Each patients will be recalled for follow-up visits at 7 days."
16305513|NCT04637854|Active Comparator|Surgical Loupes with coaxial illumination.|The same as above but the intervention will be performed with the use of surgical loupes
16305514|NCT04637854|Active Comparator|Naked Eye.|The same as above but the intervention will be performed at naked eyes
16305515|NCT04637841|Active Comparator|Diabetes Mellitus Kinesiology Taping Group|Kinesiology tape will be applied to the left foot of the participants in diabetes mellitus group.
16305516|NCT04637841|Active Comparator|Kinesiology Taping Control Group|Kinesiology tape will be applied to the left foot of the healthy participants in the control group.
16305517|NCT04637841|Active Comparator|Diabetes Mellitus Myofascial Release Group|Myofascial Release Technique will be applied to the right foot of the participants in diabetes mellitus group.
16305518|NCT04637841|Active Comparator|Myofascial Release Control Group|Myofascial Release Technique taping will be applied to the right foot of the healthy participants in the control group.
16305519|NCT04637828|Experimental|GNS561 plus standard of care|All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
16305520|NCT04637828|No Intervention|standard of care|All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
16305521|NCT04637815|Experimental|Intervention|The intervention will consist of four sessions spaced two weeks apart that will last approximately 30 minutes each and consist of two parts: a network interview to capture network data about the time period since their last interview and a discussion of a resulting network visualization conducted in a motivational interviewing style. Participants will receive the intervention as part of existing case management.
16305522|NCT04637815|Active Comparator|Usual Care|As part of residency, participants receive regular case management meetings.
16305523|NCT04637802|Active Comparator|Pre-operative and Post-operative Education intervention|This arm receives access to Patient Education intervention in the pre- and post-operative phases.
16305524|NCT04637802|Experimental|Pre-operative CBT intervention (SurgeryPal), Post-operative Education intervention|This arm receives access to CBT intervention in the pre-operative phase and Patient Education in the post-operative phase.
16305525|NCT04637802|Experimental|Pre-operative Education intervention, Post-operative CBT intervention (SurgeryPal)|This arm receives access to Patient Education intervention during the pre-operative period and CBT intervention during the post-operative period.
16305526|NCT04637802|Experimental|Pre-operative and Post-operative CBT intervention (SurgeryPal)|This arm receives access to CBT intervention during the pre-operative and post-operative period.
16305527|NCT04637789|Other|controlled group|
16305528|NCT04637789|Experimental|experimental group|
16305529|NCT04637776||Patients with Heart Failure|Patients with heart failure who were discharged within the past month after hospitalization for any reason.
16305532|NCT04637750|Experimental|Educational intervention|Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
16305533|NCT04637750|No Intervention|Control group|GPs not receiving any informative intervention
16305534|NCT04637737|Experimental|Training group|
16305535|NCT04637737|Other|Control group|
16305536|NCT04637724|Experimental|active tDCS|active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
16305537|NCT04637724|Sham Comparator|Sham tDCS|Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
16305538|NCT04637711|Experimental|Specific surgical Intervention|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery
16305539|NCT04637711|No Intervention|Extensive lesion excision|
16305540|NCT04637698|Experimental|Dose expansion|OH2 injection will be administered at 1E+07 CCID50/mL .
16305541|NCT04637685|Active Comparator|Standard pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg
16305542|NCT04637685|Active Comparator|Low or physiological pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg
16305543|NCT04637659||Healthy non-treated teeth|Healthy teeth being treated for restorative or prosthodontics reasons
16305544|NCT04637659||Healthy treated teeth|Teeth being retreated for restorative or prosthodontics reasons
16305545|NCT04637659||Irreversible pulpitis|Teeth being treated because of a poor pulpal status
16305546|NCT04637659||Post-treatment apical periodontitis|Teeth being retreated due to the presence of an apical lesion
16305547|NCT04637659||Necrosis|Teeth being treated because of pulpal necrosis
16305548|NCT04637646||children with MPS|
16305549|NCT04637633|Experimental|Cyclosporine A|All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
16305550|NCT04637620|Experimental|NMDAE|An NMDA enhancer
16305551|NCT04637620|Active Comparator|SSRI|Sertraline (selective serotonin reuptake inhibitor)
16305552|NCT04637620|Placebo Comparator|Placebo|Placebo
16305553|NCT04637607|Experimental|Ear-Acupressure Group|The subjects will receive true auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive sham auricular acupoints stimulation.
16305554|NCT04637607|Sham Comparator|Sham-Acupressure Group|The subjects will receive sham auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive true auricular acupoints stimulation. (Crossover)
16305555|NCT04637594|Active Comparator|Arm A (immune checkpoint inhibitor)|"CONTINUATION OF ICI TREATMENT:
~Patients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity."
16305556|NCT04637594|Experimental|Arm B (immune checkpoint inhibitor)|"DISCONTINUATION OF ICI TREATMENT:
~Patients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion."
16305557|NCT04637581|Experimental|Wraparound|Wraparound is a 12-month intervention including a family-centered discovery process to identify values, needs, and strengths to help the family be successful in reaching family functioning and parental recovery goals; weekly or twice weekly family meetings with the Wraparound coordinator; intensive care coordination among systems and providers (substance use disorder, mental health, schools, pediatrics, homeless shelters, etc.); and bi-monthly family-centered team meetings (including the family's natural and professional supports) to discuss strategies, progress and continued needs. Wraparound coordinators (2) work with up to 10 families at a time and receive extensive training (including observation) and supervision by expert trainers at University of New Hampshire.
16305558|NCT04637581|No Intervention|treatment-as-usual|"The treatment-as-usual group will receive a packet of local services and referral contacts and treatment as usual as directed by any healthcare providers working with the family. The project team will contact treatment-as-usual families on a monthly basis to confirm any services the family may be receiving, provide reminders of scheduled assessment dates, and give small incentives ($10 gift card) when families report changes in contact information to reduce risk for loss to follow-up."
16305559|NCT04637568||Maxillary Deficiency|59 CT scans of patients with maxillary deficiency requiring Le Fort osteotomy
16305560|NCT04637568||Control|61 CT scans of healthy patients
16305561|NCT04637555|Experimental|LCZ696 (sacubitril/valsartan)|Following start of treatment, patients will receive LCZ696. Possible doses are level 1, 2, and 3 (50, 100 and 200 mg twice daily respectively)
16305562|NCT04637542|Experimental|Control Group (Traditional)|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Anatomy Laboratory. The laboratory consists of three application rooms, one control room and one analysis room. The Anatomy of the Organs Forming the Genital System was explained using an anatomical model of the genital system organs by a researcher responsible for the human anatomy course. Students were given time until the end of the lesson to work on the models. During this time, their questions were answered. At the end, all of the students were given a State Inventory by the researcher and asked to fill it in. Students were then asked to use textbooks and atlases to study for the Knowledge Test (post-test) which took place three days later."
16305563|NCT04637542|Experimental|Experimental Group (Mobile)|"Application in Experimental Group: After the theoretical lesson, students in the experimental group were taken to an empty classroom. The mobile application was installed on the smartphones of the students in the experimental group by the researchers and they were told not to share it with anyone until the end of the study. At the end of the study, the mobile application was also installed on the phones of the students in the control group due to ethical sensitivity. Anatomy of Organs Forming the Genital System was explained on the mobile application containing the genital system organs. The students were allowed to ask questions and the questions were answered. Afterwards, all students in the experimental group were given a State Inventory by the researcher and asked to fill it in. Students were then asked to study using the genitalsystem.apk mobile application until the Knowledge Test (post-test) which took place three days later."
16305564|NCT04637529|Experimental|S (+) - Ibuprofen|S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
16305565|NCT04637529|Active Comparator|Ibuvix® - ibuprofen|Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
16305566|NCT04637516|Active Comparator|Programme Version 60 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 60 sec"
16305567|NCT04637516|Placebo Comparator|Programme Version 300 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 300 sec"
16305568|NCT04637503|Experimental|effectiveness of CAR-T cells targeting GD2, PSMA and CD276|Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB
16305569|NCT04637490|Experimental|patellar resurfacing|patellar resurfacing in TKA
16305570|NCT04637490|No Intervention|non-resurfacing|non-resurfacing TKA
16305571|NCT04637477|Experimental|Virtual ELM|
16305572|NCT04637464|Experimental|Experimental group|"Discontinuation of empirical antibiotics, despite neutrophil count below 0.5x10⁹ cells/L, after 48 hours of apyrexia and clinical stability.
~A child is considered clinically stable when there is resolution of all symptoms and signs of infection, and normalization of vital signs including heart rate, respiratory rate, oxygen saturation, blood pressure, and daily diuresis."
16305573|NCT04637464|No Intervention|Control group|Discontinuation of antibiotics when neutrophil count is equal to or above 0.5x10⁹ cells/L, and the child is afebrile and clinical stable OR the child has received 10 days of antibiotics and have been afebrile and clinically stable for 7 days
16305574|NCT04637451|Experimental|Gingival Unit Graft|For test group, gingival recessions were treated with gingival unit graft.
16305575|NCT04637451|Other|Connective Tissue Graft|For Control group, gingival recessions were treated with connective tissue graft.
16305576|NCT04637438|Active Comparator|Fecal Microbiota Transplantation|
16305577|NCT04637438|Placebo Comparator|Plasebo|
16305578|NCT04637425|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
16305579|NCT04637425|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
16305580|NCT04637412|Experimental|Control label|"Participant will see a QR code and footnote saying, Scan the QR code for more menu information. The label will be applied to all menu items displayed."
16305581|NCT04637412|Experimental|Icon plus text added sugars label|Participant will see a label containing an icon plus text label with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 18 variations of icons and text in this arm.
16305582|NCT04637412|Experimental|Icon only added sugars label|Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
16305583|NCT04637399||Ulcerative Colitis|Participants diagnoses with Ulcerative Colitis.
16305584|NCT04637399||Crohn's Disease|Participants diagnosed with Crohn's Disease.
16305585|NCT04637386||Group A (inevitable/incomplete abortion):|Includes 15 patients with severe vaginal bleeding or part of the product of conception pass through the cervix, cx opened, and -ve fetal pulse.
16305586|NCT04637386||Group B (with vaginal bleeding during cerclage placement):|Includes 15 patients with vaginal bleeding during cerclage
16305587|NCT04637373|Experimental|the group|Women aged 18-40 years who admit to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment, are having Hysteroscopy assisted suction curettage as detailed previously. retained products of conception found at the end of the procedure, and intrauterine adhesions found on follow up are compared to the data in the literature.
16305588|NCT04637360|Experimental|Cinacalcet treatment|hyperparathyroid dialysis patients using cinacalcet and active vitamin D for 6 months
16305589|NCT04637360|Experimental|traditional therapy active vitamin D|hyperparathyroid dialysis patients using traditional therapy active vitamin D without use cinacalcet for 6 months.
16305590|NCT04637347|Other|IP-ISV|In plane infraclavicular subclavian vein catheterization
16305591|NCT04637347|Other|IP-SSV|In plane supraclavicular subclavian vein catetherization
16305592|NCT04637308|Experimental|Succinylated gelatin|The patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day.
16305593|NCT04637308|No Intervention|Control|Observation.
16305594|NCT04637282|Experimental|PLX-200|This is randomized, placebo-controlled comparator study of PLX-200 in patients with CLN3 disease.
16305595|NCT04637282|Placebo Comparator|Placebo|This is randomized comparator study of PLX-200 vs. placebo in a 2:1 ratio in patients with CLN3 disease.
16305596|NCT04637269|Experimental|BCMA CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
16305597|NCT04637230||Sinus Rhythm|Subjects/patients in normal sinus rhythm
16305598|NCT04637230||Atrial Fibrillation|Patients with atrial fibrillation
16305599|NCT04637230||Atrial Premature Complexes|Patients with atrial premature complexes in between sinus beats
16305600|NCT04637230||Ventricular Premature Complexes|Patients with ventricular premature complexes in between sinus beats
16305601|NCT04637230||Ventricular Tachycardia, Nonsustained|Patients with episodes of nonsustained ventricular tachycardia in between sinus beats
16305602|NCT04637217||Control|
16305603|NCT04637217||Diabetes mellitus without Diabetic Retinopathy|
16305604|NCT04637217||Diabetes mellitus with Diabetic Retinopathy|
16305605|NCT04637204||Subgroup 1|Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
16305606|NCT04637204||Subgroup 2|Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
16305607|NCT04637204||Subgroup 3|Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
16305608|NCT04637204||Subgroup 4|Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)
16305609|NCT04637191|Experimental|MentalPlus®|This group performed the task in the digital game for 25 minutes and later will be evaluated with standardized and validated neuropsychological tests for the studied population.
16305610|NCT04637178|Experimental|Resistance training added to endurance training|Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks
16305611|NCT04637178|Other|Endurance training|Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks
16305612|NCT04637152|No Intervention|Group A: Usual recommended therapy|Antihypertensive regimen based on the usual recommended (optimized) therapy.
16305613|NCT04637152|Experimental|Group B: Sacubitril/Valsartan|Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.
16305614|NCT04637139|Experimental|Group 1|VBR 300 mg solution containing 2 µCi [14C]VBR
16305615|NCT04637126||mechanically ventilated and sedated patients with sinus rhythm|all mechanically ventilated and sedated patients with sinus rhythm hospitalized in our ICU and fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure
16305616|NCT04637113||All patients admitted to the PICU meeting eligible criteria|This is a non-interventional study.
16305617|NCT04637100|Experimental|Experimental|The patient will utilize their personal mobile or tablet device to play a pre-selected set of problem-solving games for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
16305618|NCT04637100|Active Comparator|Control|The patient will utilize their personal mobile or tablet device to watch a pre-selected set of stroke-related educational videos for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
16305619|NCT04637087|Experimental|Atrial Fibrillation Risk Estimation Tool|For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.
16305620|NCT04637061||REC4T study patients|Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)
16305621|NCT04637035|Experimental|Supportive Oncology Care at Home|"Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital.
~The Supportive Oncology Care at Home intervention consists of three key components:
~Daily monitoring of patient-reported symptoms, vital signs, and body weight.
~Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight.
~Structured communication with the oncology team regarding care delivered to ensure continuity of care."
16305622|NCT04637022||3D laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 3D laparoscopic camera
16305623|NCT04637022||4k laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 4k laparoscopic camera
16305624|NCT04637009|Experimental|Part 1 (dose escalation)|Oral administration of TAS1553 once daily at specific time points.
16305625|NCT04637009|Experimental|Part 2 (dose expansion)|Oral administration of TAS1553 once daily at specific time points.
16305626|NCT04636996|Experimental|artificial intelligence assisted follow-up group|artificial intelligence assisted follow-up group
16305627|NCT04636996|Placebo Comparator|Control group|Control group
16305628|NCT04636983|Experimental|BV100|BV100 intravenous infusion
16305629|NCT04636983|Placebo Comparator|Placebo|Saline intravenous infusion
16305630|NCT04636970|No Intervention|Control group|Patients randomised to control group will get usual recommendations regarding physical activity after a discharge from inpatient cardiac rehabilitation.
16305631|NCT04636970|Experimental|Intervention group|Patients randomised to intervention group will continue home exercise training that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after. Study participants well receive telephone calls every other week and were asked to answer questions regarding their health and physical activity.
16305632|NCT04636957|Experimental|ciprofloxacin 0.3% plus fluocinolone acetonide 0.025%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h , morning and evening) for 7 consecutive days.
16305633|NCT04636957|Active Comparator|ciprofloxacin 0.3%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h, morning and evening) for 7 consecutive days
16305634|NCT04636918|Other|Single arm|Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
16305635|NCT04636905||Survivorship Wellness Group|Participants will be enrolled in a 15 week program to assess quality of life and general health outcomes
16305636|NCT04636892|Experimental|Severe aortic stenosis|"Patients with echocardiographic evidence of severe aortic stenosis as defined by:
~Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2"
16305637|NCT04636892|Experimental|Severe mitral regurgitation|"Patients with echocardiographic evidence of severe mitral regurgitation as defined by:
~Central jet MR >40% LA or holosystolic eccentric jet MR
~Vena contracta ≥0.7 cm
~Regurgitant volume ≥60 mL
~Regurgitant fraction ≥50%
~ERO ≥0.40 cm2
~Angiographic grade 3 to 4+"
16305638|NCT04636892|Experimental|Heart Failure with Reduced EF <35%|Patients with echocardiographic evidence of left ventricular ejection fraction of < or = to 35%
16305639|NCT04636892|Experimental|Pulmonary Hypertension|Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) >20mmHg
16305640|NCT04636892|Experimental|Suspected coronary artery disease|Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease
16306684|NCT04629781|Experimental|Docetaxel micellar|Trial Treatment with Docetaxel micellar
16305644|NCT04636866||Gastric ulcer|
16305645|NCT04636866||Duodenal ulcer|
16305646|NCT04636853|Experimental|Affected Individual|A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
16305647|NCT04636840|No Intervention|Control Group|Care as usual-referral to nationwide resources for eating disorders (NEDA)
16305648|NCT04636840|Experimental|Experiemental Group A- Mobile App with Social Networking Feature|Access to Space From Body and Eating Concerns program on SilverCloud Health App in addition to access to Private Facebook group for social networking support.
16305649|NCT04636840|Experimental|Experimental Group B- Mobile App Only|Access to Space From Body and Eating Concerns program on SilverCloud Health App.
16305650|NCT04636827|Experimental|group 1 (sIPV+DTaP+HepA)|150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively
16305651|NCT04636827|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
16305652|NCT04636827|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
16305653|NCT04636827|Active Comparator|group 4 (HepA)|150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old
16305654|NCT04636814|Experimental|CHF6001 1600µg|
16305655|NCT04636814|Experimental|CHF6001 3200µg|
16305656|NCT04636814|Placebo Comparator|Placebo|
16305657|NCT04636814|Active Comparator|Roflumilast|
16305658|NCT04636801|Experimental|CHF6001 1600µg|
16305659|NCT04636801|Experimental|CHF6001 3200µg|
16305660|NCT04636801|Placebo Comparator|CHF6001 Placebo|
16305661|NCT04636788|Other|pancreatic cancer group|"pancreatic cancer, anticipated participants: 68
~other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34"
16305662|NCT04636775||Immunotherapy naïve NSCLC patients|Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade
16305663|NCT04636762|Experimental|Treatment (etoposide, cisplatin, carboplatin, radiation, Atezolizumab)|Participants receive EC/EP chemotherapy combined with Atezolizumab for 2 cycles, and the efficacy is evaluated 2 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy with EC/EP(2 cycles) + Atezolizumab will be initiated. After concurrent chemoradiotherapy+ Atezolizumab, Atezolizumab was maintained until PD or intolerance or for at most 2 years. Participants with brain metastases will receiveradiotherapy forbrain metastases during the first 2 cycles of chemotherapy.
16305664|NCT04636749|Active Comparator|Erbium laser|Treatment with Erbium laser
16305665|NCT04636749|Sham Comparator|Sham laser|Treatment with sham laser
16305666|NCT04636736||HIV POLISH (PL)|HIV infected people with polish nationality, who most probably acquired infection in Poland
16305667|NCT04636736||HIV MIGRANTS (M)|HIV infected people, originating from outside of Poland, where they were diagnosed with HIV infection
16305668|NCT04636723||CSS Patients|HNC patients presenting chronic systemic symptoms
16305669|NCT04636723||Healthy Controls|Non-clinical controls
16305670|NCT04636710|Experimental|Sentinal Node Identification|"Within standard of care treatment for inflammatory breast cancer, participants will undergo a series of Lymphoscintigraphies: an imaging procedure to determine where their lymphatic system drains from their breast.
~Prior to neoadjuvant chemotherapy
~Day before surgery
~These two imaging studies will be compared and the information used during participant's surgery to perform the sentinel node biopsy procedure.
~During surgery participants will have a blue dye injected to affected breast to map drainage and identify sentinal nodes. The sentinal nodes will be removed first, followed by standard of care procedure to remove all axillary lymph nodes.
~After surgery, a small amount of tissue from the tumor removed during surgery will be evaluated.
~Participants will complete a Lymphedema Questionnaire after each Lymphoscintigraphy then every 6 months for 2 years post surgery."
16305671|NCT04636697|Placebo Comparator|Placebo|Placebo (0.5 mL)
16305672|NCT04636697|Experimental|3.75 µg of CoVLP Vaccine adjuvanted|3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)
16305673|NCT04636684|Experimental|patients undergoing surgical valve replacement for degenerative aortic stenosis|
16305674|NCT04636671|Experimental|Methylprednisolone|"A. On day 1, loading dose of methylprednisolone (MP) 80 mg IV in 30 minutes, promptly followed by continuous infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.
~B. From day 2 to day 8: infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.
~C. From day 9 and beyond:
~If not intubated patient and PaO2/FiO2 > 200, taper to MP 20 mg IV in 30 minutes three times a day for 3 days, then MP 20 mg IV twice daily for 3 days, then MP 20 mg IV once daily for 2 days, then switch to MP 16 mg/day PO for 2 days, then MP 8mg/day PO for 2 days, then MP 4mg/day PO for 2 days;
~If intubated patient or PaO2/FiO2 <= 200 with at least 5 cmH2O CPAP, continue infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h until PaO2/FiO2 > 200 then taper as in a)"
16305675|NCT04636671|Active Comparator|Dexamethasone|"A. Dexamethasone (DM) 6 mg IV in 30 minutes or PO from day 1 to day 10 or until hospital discharge (if sooner).
~B. After day 10 study treatment is interrupted."
16305676|NCT04636658|Active Comparator|Incentive spirometer training|Incentive spirometer training
16305677|NCT04636658|Experimental|diaphragmatic resistance exercises|Incentive spirometer training with diaphragm breathing with resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient
16305678|NCT04636645|Active Comparator|Normal Treadmill|After completion of the baseline evaluation, Group A participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. For each session, 20% support will be given to participants
16305679|NCT04636645|Experimental|Anti-gravity treadmill with lower limb positive pressure|Group B participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
16305680|NCT04636645|Experimental|Anti-gravity treadmill with without lower limb positive pressure|Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
16305681|NCT04636632|Experimental|Weekly Arm|fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy
16305682|NCT04636632|Active Comparator|Triweekly Arm|fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy
16305683|NCT04636619|Active Comparator|Incomplete polypectomy report|An online course will be offered that will explain the technique for excision of lesions with a cold loop and the importance of complete resection, techniques to determine the edges of the lesion and possible remains at the polypectomy base through images, video clips. and interaction with the speakers
16305684|NCT04636619|Active Comparator|On-line training course|Each participant will receive the global data, the results obtained by all the endoscopists (anonymously except for each interested party, the rest being identified by codes), as well as a detailed analysis of their results, comparing them with the joint data and the 3 tertiles.
16305685|NCT04636606|Active Comparator|Home Exercise|Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
16305686|NCT04636606|Active Comparator|Manual Therapy Combined with Home Exercise|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.
~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
16305687|NCT04636606|Active Comparator|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|"Orofacial Myofunctional therapy includes stretching the tongue muscles, tongue rotation exercises, isometric and isotonic strengthening of the tongue, special maneuver, effortful swallow exercise, strengthening exercise of hyoidal muscles.
~Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.
~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
16305688|NCT04636593|Experimental|Induction group|If the lung V20 of initial radiation plan is equal to or more than 28%, then the patient will receive 2 months almonertinib before concurrent thoracic radiotherapy
16305689|NCT04636593|Experimental|Concurrent group|If the lung V20 of initial radiation plan is less than 28%, then the patient will receive concurrent thoracic radiotherapy with almonertinib.
16305690|NCT04636580|Experimental|anxious parent|Parents were divided into two groups anxious and non-anxious.
16305691|NCT04636580|Experimental|non-anxious parent|Parents were divided into two groups anxious and non-anxious.
16305692|NCT04636567|Experimental|Nerindocianine for injection|One Arm: Nerindocianine for Injection (0.055 mg/kg body weight); solution, intravenous, one time administration during surgery.
16305693|NCT04636541|Experimental|Goal Management Training|GMT modules were adapted for French-speaking patients with PD-MCI. Each session was reduced from nine 90-120-minute sessions (original GMT) to five 60-90-minute sessions, one session per week, in order to avoid fatigue. As for original GMT, participants were given exercises between sessions (mindfulness exercises and metacognitive reflections). In original-GMT, some information is repeated several times, but not in Adapted-GMT. Exercises demanding motor dexterity, such as card distribution, were removed. Adapted-GMT included information on PD-MCI and executive dysfunction (some psychoeducation). In addition, Adapted-GMT modules were administered individually with an iPad, as opposed to a power-point group presentation in original-GMT. A workbook was handed to participants, as in previous studies.
16305694|NCT04636541|Active Comparator|Psychoeducation sessions coupled mindfulness exercises|Five modules were designed as a discussion with patients and caregivers about various PD symptoms: module I-brain and motor symptoms; module II-autonomic symptoms; module III- psychological symptoms; module IV-brain and cognition; and module V-cognitive impairments in PD. Patients were handed the information book about the five modules at the beginning of the study. The objective was to improve their understanding of their condition and to discuss other components that could affect their cognitive abilities. After the 40-60-minute informative part, mindfulness exercises were offered for 20-30 minutes per session. Participants were not invited to practice exercises between sessions, but 3/6 participants reported they did.
16305695|NCT04636528|Experimental|Digital Rehabilitation|Home-based 8-week rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist
16305696|NCT04636528|Active Comparator|Conventional Rehabilitation|Outpatient clinic-based 8 week rehabilitation program with face-to-face PT sessions
16305697|NCT04636515|Experimental|Single Arm|
16305698|NCT04636502||Cohort|Participants who had treated with fSCIG (HyQvia) for not more than 27 months and SCIG 20% (Cuvitru) for not more than 35 months.
16305699|NCT04636489|Experimental|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.
16305700|NCT04636489|Placebo Comparator|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.
16305701|NCT04636476|Other|Modified Nesbit technique followed by dorsal dartos flap|Modified Nesbit technique to correct penile curvature followed by dorsal dartos flap to correct penile torsion
16305702|NCT04636463|Experimental|Hand Surgery with Music|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) while listing to music
16305777|NCT04635956|Experimental|Study group|Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab
16305703|NCT04636463|No Intervention|Hand Surgery without Music (Control Group)|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) without listening to music
16305704|NCT04636450|Active Comparator|Adult manual instrumentation|Primary mandibular molars who are treated with a manual pulpectomy and a K-file system.
16305705|NCT04636450|Experimental|Pediatric manual instrumentation|Primary mandibular molars treated with a manual pulpectomy and a Kedo-SH system.
16305706|NCT04636450|Active Comparator|Adult rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system.
16305707|NCT04636450|Experimental|Pediatric rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a Kedo-S system
16305708|NCT04636437|Experimental|DOR 100 mg + TAF/FTC (or TAF/3TC, depending on location)|By mouth daily with or without food
16305709|NCT04636437|Experimental|DOR 100 mg + TDF/FTC (or TDF/3TC, depending on location)|By mouth daily with or without food
16305710|NCT04636437|Experimental|Continuation of entry INSTI+TAF/FTC (or TAF/3TC)|
16305711|NCT04636424|Experimental|spastic diplegic group|assessment of the speed and weight distribution during gait
16305712|NCT04636424|Experimental|hemiplegic group|assessment of the speed and weight distribution during gait
16305713|NCT04636411|Experimental|Intervention group|This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients
16305714|NCT04636411|Active Comparator|Control group|This group will receive the standard care for diabetic patients
16305715|NCT04636398|Experimental|MESSAGE mHealth group intervention|Participants in the one arm will be exposed to the mHealth group intervention. As this is a pilot developmental study, the participants will be exposed to various strategies for information delivery (live presentation at a scheduled time versus voice recording accessible at any time), discussion facilitation (heavily managed with request to speak vs. natural discussion participation), and text communication management (moderator-facilitated vs. group-led).
16305716|NCT04636372|Experimental|Intense pulsed light therapy group|
16305717|NCT04636372|Experimental|Hot compress massage group|
16305718|NCT04636372|Experimental|Intense pulsed light therapy and hot compress massage group|
16305719|NCT04636359|Experimental|Long term course of migraine patient without aura|Patients in this group have the history of migraine without aura more than 5 years.
16305720|NCT04636359|Experimental|Short term course of migraine patient without aura|Patients in this group have the history of migraine without aura equal or less than 5 years.
16305721|NCT04636346||COMPASS (Psychoeducational / Behavioral Program)|Group Acceptance and Commitment Therapy program as part of clinical service for cancer patients
16305722|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
16305723|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
16305724|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
16305725|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
16305726|NCT04636333|Experimental|Middle-dose vaccine (> 59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
16305727|NCT04636333|Experimental|High-dose vaccine (> 59 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
16305728|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 14.
16305729|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Three dose regimen|Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
16305730|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 14.
16305731|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
16305732|NCT04636333|Placebo Comparator|Middle-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
16305733|NCT04636333|Placebo Comparator|High-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
16305734|NCT04636320|Experimental|Patient group COVID-19|120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization
16305735|NCT04636320|Active Comparator|Healthy volunteer group|120 healthy volunteers. Age- and sex-matched controls
16305736|NCT04636294||COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.|
16305739|NCT04636268|Experimental|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.
~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
16305740|NCT04636255|Experimental|Exercise training group|Patients in the experimental group, under clinic follow up will perform combined exercise training for 16 weeks
16305741|NCT04636255|Sham Comparator|Control Group|Patients will be only clinically followed up. They will not perform exercise training.
16305742|NCT04636242|Experimental|Group 1: Phototherapy Group|patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be applied to the area of the shoulder where the 5-ALA was administered
16305743|NCT04636242|Active Comparator|Group 2: Control Group|patient will undergo standard of care surgery
16305744|NCT04636229|Experimental|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
16305745|NCT04636229|Placebo Comparator|Placebo|Participants receive a single IA injection of 4 mL of normal saline
16305747|NCT04636203||General population|A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate.
16305748|NCT04636203||Healthcare workers (HCWs)|All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects.
16305749|NCT04636190|Other|Triathlon All-Polyethylene Tibia Knee|All subjects enrolled will have received the Triathlon All-Polyethylene Tibia Knee device.
16305750|NCT04636177|Active Comparator|Standard Physiotherapy Rehabilitation (SPR)|Sessions are individually-tailored and based on the Guide to Physical Therapy Practice 3.0 consisting of 1) therapeutic exercise, 2) balance and proprioception, 3) strength training, and 4) use of modalities (e.g., heat/cold pack). Patients will be given a structured Home Exercise Program (HEP) with prescribed exercises for home. SPR participants will be allocated a VR headset for recreational use.
16305751|NCT04636177|Experimental|Pain Rehabilitation Virtual Reality (PRVR)|Sessions will follow the same guidelines as SPR, with half of the physiotherapy (PT) sessions delivered in virtual reality (VR). VR in PT will engage participants in a series of immersive games customized to align with individual PT needs. Patients in the PRVR arm will be given a structured HEP to practice prescribed exercises at home with integrated VR activities. PRVR participants will be allocated a VR headset for use in PT sessions and with HEP.
16305752|NCT04636164|Experimental|DNN group|using deep neural networks for skin lesion diagnosis
16305753|NCT04636164|No Intervention|Control group|conventional diagnosis
16305754|NCT04636151|Experimental|Individual Treatment|Participants will have up to three individual sessions with a study therapist. One or more treatment modules will be presented in each session.
16305755|NCT04636151|Experimental|Group Treatment|Participants will have up to three group sessions with a study therapist. One or more treatment modules will be presented in each session.
16305756|NCT04636151|Experimental|Workshops|Participants will have one workshop with a study therapist. All three treatment modules will be presented in one session.
16305757|NCT04636138|Experimental|Single arm|
16305758|NCT04636125|Other|Revision Total Shoulder Arthroplasty|Routine cultures are taken at the time of surgery. All patients are seen by an Infectious Disease Specialist and placed on 2 weeks oral doxycycline 100 mg (or alternative based on allergy or sensitivity) pending culture results.
16305759|NCT04636112||control group|Patients hospitalized and diagnosed as non-AMI during the same time period were matched. All patients underwent coronary angiography and CAD was defined as at least one main coronary artery with > 50% narrowing of luminal diameter.
16305760|NCT04636112||AMI group|Patients were diagnosed as MI when a cardiac biomarker (preferably cardiac troponin) rose or fell at least one value in its 99th percentile upper reference limit and at least one of the following criteria was met, including ischemic symptoms, electrocardiogram (ECG) changes of new ischemia, pathologic Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy.
16305761|NCT04636099|Experimental|CTA Group|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
16305762|NCT04636099|No Intervention|Non-CTA Group|The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery
16305763|NCT04636086|Experimental|Test treatment|Test Treatment: Ampoule for enteral use containing 25,000 IU/mL of cholecalciferol taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
16305764|NCT04636086|Placebo Comparator|Placebo treatment|Placebo Treatment: Ampoule of placebo for enteral use containing excipient only taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
16305765|NCT04636073|Experimental|Leaflex™ Performer|
16305766|NCT04636060|Experimental|Iron-treatment group|
16305767|NCT04636034|Experimental|Ropivacaine-Lidocaine|
16305768|NCT04636034|Placebo Comparator|Placebo|
16305769|NCT04636034|Sham Comparator|"Sham-block with Placebo"|
16305770|NCT04636008|Experimental|Experimental arm|Sintilimab+Hypofractionated radiotherapy
16305771|NCT04635995|Experimental|Monotherapy dose escalation|The monotherapy dose escalation phase includes 8 dose levels of LVGN7409. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
16305772|NCT04635982|Placebo Comparator|Placebo Group|With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
16305773|NCT04635982|Experimental|Experimental Group|In rectus femoris, origin was under the anterosuperior iliac spines, and taping finished with a Y-shape pattern under the patella. After that, an I-shaped KT was applied over vastus medialis and vastus lateralis muscles in both quadriceps. Finally, subjects were taped with a Y-shaped KT at the gluteus maximus muscles. Tape tension was between 25% and 50%.
16305774|NCT04635982|No Intervention|Control Group|It has not done any intervention in this group.
16305775|NCT04635969|Experimental|Experimental: Children training|All registered participants in intervention group will participate in a series of trainings on sexuality education.
16305776|NCT04635969|No Intervention|Control: No intervention|All registered participants in control group will not participate in a series of trainings on sexuality education.
16307042|NCT04627181|Placebo Comparator|Placebo + placebo|"Placebo: Single dose
~Placebo: Single dose"
16305778|NCT04635943|Active Comparator|Ivermectin|Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.
16305779|NCT04635943|Placebo Comparator|Placebo|Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.
16305780|NCT04635930|Experimental|Taping plus Traditional exercises|"kinesio tape for improving the alignment of the scapula by inhibiting the hyperactive upper trapezius and facilitating the weak serratus anterior muscleStretching of the tight muscles of upper limb.
~Reaching forward sidewise and backward.
~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).
~Prone lying weight bearing on elbows (four point kneeling)
~side sitting with weight bearing on the effected side, for 5 minutes.
~Wall pushups.
~Catching and throwing of ball"
16305781|NCT04635930|Active Comparator|Traditional exercises|"Stretching of the tight muscles of upper limb.
~Reaching forward sidewise and backward.
~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).
~Prone lying weight bearing on elbows (four point kneeling)
~side sitting with weight bearing on the effected side, for 5 minutes.
~Wall pushups.
~Catching and throwing of ball"
16305782|NCT04635917|Experimental|Personalized diet - Black adults|Young Black adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
16305783|NCT04635917|Experimental|Personalized diet - White adults|Young White adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
16305784|NCT04635917|Other|Conventional dietary advice- Black adults|Young Black adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
16305785|NCT04635917|Other|Conventional dietary advice- White adults|Young White adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
16305786|NCT04635904|Experimental|Imaginal exposure|A behavioral intervention in imagery
16305787|NCT04635904|Experimental|Imagery rescripting|A different behavioral intervention in imagery
16305788|NCT04635891||MOVE FSHD Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits will occur per standard of care and are anticipated to occur at least once a year.
16305789|NCT04635878||Sepsis group|patients suffering from sepsis hospitalized in intensive care unit
16305790|NCT04635878||Control group|patients without infection hospitalized in intensive care unit
16305791|NCT04635865|Experimental|3D-printed patient-specific plate group|3D-printed patient-specific plate will be used for reconstruction in this patient group
16305792|NCT04635865|Active Comparator|Conventional plate group|conventional commercial plates will be used for reconstruction in this patient group
16305793|NCT04635852|Experimental|Fentanyl|Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet)
16305794|NCT04635852|Active Comparator|Immediate release morphine|Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)
16305795|NCT04635839|Active Comparator|Standard Dosing|Standard dose of unfractionated heparin
16305796|NCT04635839|Active Comparator|Gestational Age-Based Dosing|Dose of unfractionated heparin based on trimester of pregnancy
16305797|NCT04635826|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
16305798|NCT04635826|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo
16305799|NCT04635826|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
16305800|NCT04635826|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall
16305801|NCT04635813||Group 1 - COVID group|Patients that underwent surgery during COVID-19 pandemic
16305802|NCT04635813||Group 2 - control group|Patients that underwent surgery during 2019
16305803|NCT04635800|Experimental|Cohort 1|Cohort 1; open-label, non-randomized, single administration
16305804|NCT04635800|Experimental|Cohort 2|Cohort 2; open-label, non-randomized, single administration
16305805|NCT04635800|Experimental|Cohort 3|Cohort 3, open-label; non-randomized, single administration
16305806|NCT04635800|Experimental|Cohort 4|Cohort 4, open-label, non-randomized, single administration
16305807|NCT04635787||Healthy Adults|Adults 18 years or older
16305808|NCT04635787||COVID19|Adults 18 years or older diagnosed with COVID 19
16305809|NCT04635774|Active Comparator|Treatment Group|The treatment group will receive 40 IU via four activations of an intranasal spray.
16305810|NCT04635774|Placebo Comparator|Placebo Group|The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).
16305811|NCT04635761|Experimental|Prevention (AIR Program)|Participants complete the Roswell Awareness, Information and Resources for Lung Cancer Screening (AIR) Program over 45 minutes and then receive the High-Risk Lung Cancer Tip Sheet..
16305812|NCT04635735|Experimental|Ipilimumab After Stem Cell Transplantation|The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
16305813|NCT04635722|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
16305814|NCT04635709|Experimental|behavioral therapy|applying biofeedback training on the pelvic floor muscles
16305815|NCT04635709|Experimental|interferential therapy (IF)|Interferential current was applied to the body using four surface electrodes placed on the lower abdomen and lower buttocks.
16305816|NCT04635696|Experimental|Ethyl Chloride|Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
16305817|NCT04635696|Placebo Comparator|Tissue culture grade water|Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
16305818|NCT04635683|Experimental|Treatment (lenalidomide, umbralisib, ublituximab)|Patients receive lenalidomide PO QD on days 1-21 and umbralisib PO QD on days 1-28. Beginning in cycle 2, patients also receive ublituximab IV over 90 minutes to 4 hours on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial or complete response after cycle 6 continue treatment of lenalidomide PO QD and umbralisib PO QD for 12 additional cycles, and ublituximab IV on day 1 of subsequent even cycles (8, 10, 12, 14, 16, and 18). Patients with stable disease after cycle 6 may continue on treatment for an additional 12 cycles at the discretion of the investigator.
16305819|NCT04635670|Placebo Comparator|Placebo|Soluble powder for oral use twice daily
16305820|NCT04635670|Active Comparator|Active|The investigational product is soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
16305821|NCT04635657||Meningioma Group|This group will include all patients in the study, regardless of location (frontal or temporal lobe) or surgical approach (endoscopic endonasal or craniotomy). Fifty patients will be included in the cohort
16305822|NCT04635644|Active Comparator|Erector Spinae Plane Block|Patients will receive Erector spinae plane block.
16305823|NCT04635644|Active Comparator|Intrathecal morphine ITM|Patients will receive Intrathecal morphine.
16305824|NCT04635631|Experimental|talazoparib|1 mg QD
16305825|NCT04635618|Experimental|Intervention I: Cognitive Behavioral Brief-Telepsychotherapy|Four sessions of cognitive-behavioral therapy (CBT) conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content and content related to CBT technique.
16305826|NCT04635618|Experimental|Intervention II: Brief Interpersonal Telepsychotherapy|Four sessions of interpersonal therapy (IPT) conducted by video call by a psychologist, accompanied by the sending of 2 to 3 minute videos with psychoeducational content and content related to the ITP technique.
16305827|NCT04635618|Active Comparator|Active Comparator: Telepsychoeducation group|One single session of psychoeducation conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content for 4 weeks.
16305828|NCT04635605|Experimental|Methylene Blue|Methylene Blue 100 mg capsules. Patients will receive Methylene blue (MB) capsules of 100mg every 12 hours for a total of 5 days.
16305829|NCT04635605|Active Comparator|control group|The control intervention would be the group receiving 100 mg placebo capsules twice a day for five consecutive days
16305830|NCT04635579|Experimental|Anterior cruciate ligament reconstruction group|Single session blood flow restriction of lower limb to individuals who have undergone anterior ligament reconstruction surgery
16305831|NCT04635579|Active Comparator|Control group|Single session blood flow restriction of lower limb to individuals who have no musculoskeletal injuries
16305832|NCT04635566|Active Comparator|Mebeverine|Mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
16305833|NCT04635566|Placebo Comparator|Placebo|Placebo one time/day at the evening.
16305834|NCT04635540|Experimental|Interventional Arm|The Interventional Arm will receive the educational brochure and complete the study tasks and questionnaires.
16305835|NCT04635527|Experimental|IBI318 combined with conventional TACE (cTACE)|
16305836|NCT04635527|Placebo Comparator|Placebo combined with conventional TACE (cTACE)|
16305837|NCT04635514||Study group of 32 subjects|"Thirty-two women who presented with symptomatic lateral vaginal prolapse (deep dyspareunia, sensation of vaginal fulness, and heaviness) composed the study's group.
~The surgical lateral vaginal reconstruction (lateral colporrhaphy) of the lateral vaginal wall was administered."
16305838|NCT04635501|Experimental|ABS 5.6.7|Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
16305839|NCT04635488||Trainning group|70% of the whole participants would be randomly divided into the training group to build the predicition model.
16305840|NCT04635488||validation group|30% of the whole participant would be divided into the validation group to validate the model
16305841|NCT04635475|No Intervention|Control Group|Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
16305842|NCT04635475|Experimental|Intervention Group|Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
16305843|NCT04635462|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
16305844|NCT04635462|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
16305845|NCT04635449|Active Comparator|Intervention|age-specific information, complemented by a follow-up targeted telephone call
16305846|NCT04635449|No Intervention|Treatment as usual|usual information given at PICU discharge
16305847|NCT04635436||Pathologic group|At least 20 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled.
16305848|NCT04635423|Experimental|V503|Participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
16305849|NCT04635423|Placebo Comparator|Placebo|Participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.
16305850|NCT04635358|Experimental|Intervention|Setting up hypnosis sessions, psychological and nutritional assistance.
16305851|NCT04635345|Experimental|Vibrator Therapy + dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel) plus an external vibrator.
16305852|NCT04635345|Active Comparator|Dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel).
16305853|NCT04635332|Experimental|Intervention|In the intervention arm, participants will be exposed to the developed intervention materials and face to face group sessions.
16305854|NCT04635332|Active Comparator|Control arm|In the control arm, participants will only be given the developed intervention materials. Face to face group sessions will not be held for the control arm.
16305855|NCT04635319||18-40 years old of both sexes|patient from 18 to 40 years old seeking orthodontic treatment
16305856|NCT04635306|Experimental|Low Nitrogen GEBT test meal|GEBT test meal containing low %N content (below 7%)
16305857|NCT04635293|Active Comparator|patients who were administered levosimendan at a dose of 0.1µg/Kg/min for 24 hours prior to surgery|
16305858|NCT04635293|Placebo Comparator|patients who were not administered levosimendan prior to surgery|
16305859|NCT04635280|Experimental|Closed-loop automatic insulin delivery system|Adults type 1 diabetic patients equiped with a closed-loop automatic insulin delivery system (or artificial pancreas)
16305860|NCT04635267||patients with ARDS|
16305861|NCT04635254|Active Comparator|Halophites-based cream 24 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
16305862|NCT04635254|Active Comparator|Halophites-based cream 48 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
16305863|NCT04635241|Experimental|Inhaled heparin|Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days
16305864|NCT04635241|No Intervention|Standard care|Standard care
16305865|NCT04635215||Participants|There are not multiple groups in this study
16305866|NCT04635202|Experimental|group A|patients (n=30) in this group will receive 16 weeks of elliptical training on elliptical trainer, 3 times per week. the training will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
16305867|NCT04635202|Other|Group B (control group)|patients (n=30) in this group will receive general advises on maintaining physical activities
16305868|NCT04635189|Active Comparator|Experimental Arm: Cycle 1-4 All subjects|"Subjects will be treated with the following:
~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
16305869|NCT04635189|Experimental|Experimental Arm: Cycle 5+ Partial Response or Better|"Subjects will be treated the following:
~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
~Lenalidomide 25 milligrams/kilograms daily days 1-21 out of a 28 day cycle"
16305870|NCT04635189|Active Comparator|Experimental Arm: Cycle 5+ Less than Partial Response|"Subjects will be treated the following:
~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
16305871|NCT04635176|Placebo Comparator|Sham iPACK block|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
16305872|NCT04635176|Active Comparator|Real IPACK block.|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
16305873|NCT04635150|Experimental|Post-intervention parents and staff|An educational intervention for the multidisciplinary staff of a neonatal intensive care unit.
16305874|NCT04635137|Experimental|Ablation and Cementoplasty|All patients undergoing thermal ablation and cementoplasty procedure for one or more painful bone lesion
16305875|NCT04635124|Active Comparator|1: Dog visit with a dog, no additional activity (D)|The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
16305876|NCT04635124|Experimental|2: Dog visit with an additional activity (DA)|"The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.
~Apart from the visitor, an observer is present."
16305877|NCT04635124|Active Comparator|3: Visit without dog, with an additional activity (A)|"The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.
~Apart from the visitor, an observer is present, but no dog is present.."
16305878|NCT04635111||Symptomatic TGCT Participants|Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
16305879|NCT04635098|Experimental|dexmedetomidine|0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 22:00 pm to 6:00 am
16305880|NCT04635098|Placebo Comparator|saline|the same rate as dexmedetomidine
16305881|NCT04635085|Experimental|Empowerment-based Cognitive behavioral therapy for insomnia for MCI (intervention)|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups.
16305882|NCT04635085|No Intervention|Social Activities provided by the community centers (active control)|The control group will not receive any structured cognitive training or sleep promoting interventions during the study period. The participants in the control group will continue to participate in the social activities offered by the elderly community centers. They have access to the newspapers, board games and computer facility in the centers. Upon completion of collecting all evaluation data for both groups at the three different time points, the empowerment-based CBT-I will be offered to participants in the control group.
16306646|NCT04630054|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
16305883|NCT04635072|Experimental|Stabilised Whole Rice Bran (SWRB)|"Patients with mild AD will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, one time per day.
~Patients with moderate disease will be instructed to use SWRB as a cleanser as above. In addition, they will also use SWRB as an emollient after constituting it into a paste as in instructions, apply at night and leave it overnight."
16305884|NCT04635059|Experimental|Pacritinib|Pacritinib is an oral drug.
16305885|NCT04635046||Patients with tears to their peroneal tendons|Patients with pain over their peroneal tendons clinically, with a verified injury to either of the two tendons on MRI, where we might expect a tendon transfer of the peroneus longus, or extirpation of the peroneus longus, during surgery.
16305886|NCT04635033||Intervention|2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months
16305887|NCT04635020|Experimental|Stable glaucoma iStent|Cataract surgery combined with iStent inject
16305888|NCT04635020|Experimental|Stable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
16305889|NCT04635020|Active Comparator|Stable glaucoma|Cataract surgery
16305890|NCT04635020|Experimental|Unstable glaucoma iStent|Cataract surgery combined with iStent inject
16305891|NCT04635020|Experimental|Unstable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
16305892|NCT04635007|Experimental|Group 1: Tranexamic acid group|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
16305893|NCT04635007|Experimental|Group 2: Misoprostol group|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
16305894|NCT04634994|Experimental|[F-18]SDM-8 tracer|Subjects will be administered standardized questionnaires for cognitive testing/other co-morbidities. They will undergo PET Scan and 3T Brain MRI. For PET Scan, an intra-arterial catheter will be inserted into the radial artery for [F-18]SDM-8 metabolite blood sampling by a trained anesthesiologist. Allen's test will be performed prior to insertion of the intra-arterial catheter. If arterial line can't be established to obtain metabolite samples, a venous line will be placed. In addition, an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer. Radiopharmaceutical will be injected as a bolus (approximately 5mCi for [F-18]SDM-8 followed by 5 mL of saline). The PET session will last up to 120 min. A head support apparatus will be used to minimize head motion. Brain PET data acquisition will begin at the moment of radiotracer injection. For MRI, several pulse sequences will be performed, no IV contrast will be used.
16305895|NCT04634981||Group general anesthesia (G)|patients will positioned with pelvic wedge on operating table and preoxygenated. Then rapid sequence induction with precalculated doses of propofol (2 mg/kg) and rocuronium (0.9 mg/kg) will followed by endotracheal intubation. After delivery of the baby, fentanyl will be administered. Later, anesthesia will be maintained with isoflurane (1%).
16305896|NCT04634981||Group Spinal anesthesia (S)|all parturients will co-loaded with 500 ml of colloid solution. In the left lateral position, the patients' back will be cleaned with povidone iodine. In the meantime, the spinal anesthetic drug and local anesthetic drug will be prepared. After wiping povidone iodine with alcohol, a rapid single shot of 2.5 ml of 0.5% hyperbaric bupivacaine will be administered intrathecally using 22 G spinal needle. Oxygen will be administered using simple face mask till the delivery of the baby.
16305897|NCT04634968|Experimental|intervention group|The interactive Brief MI-based text message communication via instant messaging apps (e.g., WhatsApp, WeChat) will be applied in the intervention group. The chatting function of WhatsApp and WeChat will be used as the intervention platform. The intervention will start on the first day after the participants join the follow-up group. The whole interactive text-communication intervention lasts for 1 month. The frequency of message communication will be at least twice a week. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
16305898|NCT04634968|Placebo Comparator|control group|The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
16305899|NCT04634955|Active Comparator|S1 transforaminal injection with oboique view|S1 transforaminal injection with oblique fluoroscopic view
16305900|NCT04634955|Active Comparator|S1 transforaminal injection with AP view|S1 transforaminal injection with anteroposterior fluoroscopic view
16305901|NCT04634942|Experimental|Cold Spray Group|Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
16305902|NCT04634942|Experimental|ShotBlocker Group|ShotBlocker group injection process step; In addition to the IM injection procedure steps, after cleansing the skin of the patients in this group, the protruding part of the ShotBlocker was placed in contact with the skin. ShotBlocker was pressed firmly against the skin and the injection was made through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
16305903|NCT04634942|No Intervention|Control Group|Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
16305927|NCT04634773|Experimental|Group 1: Early Degeneration ('Disease')|Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
16305904|NCT04634942|Placebo Comparator|Cold Spray Placebo Group|Cold spray placebo group injection procedure step; In addition to the IM injection procedure steps, the patients in this group were treated with tap water in a cold spray bottle after cleansing the skin. After spraying 3 puffs of tap water in a placebo bottle at a distance of 20 cm to the skin, the injection was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
16305905|NCT04634942|Placebo Comparator|ShotBlocker Placebo Group|ShotBlocker placebo group injection procedure step; In addition to the IM injection procedure steps, in patients in this group, the non-protruding part of the ShotBlocker was placed in contact with the skin after skin cleaning. ShotBlocker was pressed firmly against the skin and the injection was applied through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed.
16305906|NCT04634929||bariatric surgery participants|participants with obesity planning to undergo bariatric surgery
16305907|NCT04634929||conservative diet participants|participants with obesity planning to controlled conservative behavioral weight loss program
16305908|NCT04634916|Experimental|EndoAVF|
16305909|NCT04634903|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
16305910|NCT04634903|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
16305911|NCT04634903|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
16305912|NCT04634890|Other|Type 2 Diabetes|Subjects with type 2 diabetes, diagnosed within the last 3-5 years, treated with metformin only as an anti-diabetic drug
16305913|NCT04634890|Other|Prediabetes|Subjects with prediabetes, defined as impaired fasting glucose or/and impaired glucose tolerance
16305914|NCT04634890|Other|Normoglycemia|Subjects with normal fasting glucose and normal glucose tolerance
16305917|NCT04634864|Active Comparator|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation
16305918|NCT04634864|Sham Comparator|sham tDCS|40 minutes of 0mA intensity. the session starts with a ramp up to 2mA, but machine is switched off after 2 minutes of stimulation.
16305919|NCT04634851|Experimental|Intervention|These participants will get virtual home visits with the urologist and dietitian
16305920|NCT04634851|No Intervention|Control|These participants will get standard urologist and dietitian counseling
16305921|NCT04634838|Other|MedCu Antibacterial Wound Dressings with Copper Oxide|Wound dressings impregnated with copper oxide microparticles will be applied in wounds treated with antibacterial wound dressings with silver that their sizes were not reduced by at least 50% during three weeks of treatment.
16305922|NCT04634825|Experimental|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
16305923|NCT04634825|Experimental|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
16305924|NCT04634812|Experimental|[14C]-KBP-5074|
16305925|NCT04634799|Active Comparator|TM5614|TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days
16305926|NCT04634799|Placebo Comparator|Placebo|Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days
16305997|NCT04634201|Sham Comparator|control group|
16305928|NCT04634773|Active Comparator|Group 2: No Degeneration ('Healthy')|Those who have posterior subluxation of the humeral head and show no signs of degeneration.
16305929|NCT04634747|Experimental|PVX-410/pembrolizumab/chemotherapy|
16305930|NCT04634721|Active Comparator|Laparoscopic TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
16305931|NCT04634721|Active Comparator|Ultrasaund TAP block|injecting bupivacaine in transversus abdominis plane to block the somatic nerves
16305932|NCT04634721|No Intervention|no TAP block|no TAP block would be done
16305933|NCT04634708||Pediatric patients on EXCOR VAD support|
16305934|NCT04634682|Experimental|MYODM|MYODM, three times a day, orally
16305935|NCT04634682|No Intervention|No intervention|Patients will follow the same evaluation schedule but will not receive MYODM
16305936|NCT04634669|Experimental|AXS-05 (dextromethorphan-bupropion)|
16305937|NCT04634656|Active Comparator|Group L|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery.
16305938|NCT04634656|Placebo Comparator|Group C|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery.
16305939|NCT04634617||Observational (questionnaires)|Patients complete questionnaires over 45-60 minutes consisting of demographic, treatment, lifestyle, disease, and comorbidity questions, as well as multiple study instruments assessing quality of life as it pertains to common toxicities of uterine cancer treatment.
16305942|NCT04634591||Obesity - undergoing bariatric surgery|Patients with morbid obesity, treated with the bariatric surgery
16305943|NCT04634591||Obesity - without bariatric surgery treatment|Patients with morbid obesity, not treated with the bariatric surgery
16305944|NCT04634591||Non-obese|Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
16305947|NCT04634565|Experimental|PF-06651600|PF-06651600 200 milligrams(mg) once daily for 10 days
16305948|NCT04634552|Experimental|Part 3: Cohort A (Talquetamab)|Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
16305949|NCT04634552|Experimental|Part 3: Cohort B (Talquetamab)|Cohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
16305950|NCT04634552|Experimental|Part 3: Cohort C (Talquetamab)|Cohort C will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
16305951|NCT04634539|Experimental|Gemcitabine + Nab-paclitaxel + L-glutamine|For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.
16305952|NCT04634513|Experimental|Cohort 1: Shigella Vaccine at 10^8 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
16305953|NCT04634513|Experimental|Cohort 2: Shigella Vaccine at 10^9 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
16305954|NCT04634513|Experimental|Cohort 3: Shigella Vaccine at 10^10 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
16305955|NCT04634513|Experimental|Cohort 4: Shigella Vaccine or Placebo|2:2:1 randomization to receive either two doses of vaccine, 1 dose of vaccine and one dose of placebo, or two doses of placebo at Days 1 and 29 (Cohort n=30)
16305956|NCT04634500|Experimental|Study group|DWP16001 A mg, Dapagliflozin placebo
16305957|NCT04634500|Active Comparator|Control group|DWP16001 A mg placebo, Dapagliflozin
16306055|NCT04633850||Before implementation|Perineural bupivacaine without adjuvants.
16306056|NCT04633850||After implementation|Perineural bupivacaine with intravenous dexamethasone.
16305958|NCT04634474|Experimental|Pain on Endotracheal Suction|Before and after endotracheal aspiration, the pain of the patient will be evaluated according to the DAS and VAS scale. VAS scores will be compared with DAÖ scores. Aspiration process will be applied to all patients by the same nurse. According to the DAQ, the pain will be assessed by a volunteer nurse who is not a researcher.
16305959|NCT04634448|Other|Interval appendectomy|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
16305960|NCT04634448|Other|Follow-up MRI|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
16305962|NCT04634422|Experimental|Plasma Exchange and convalescent Plasma|2 plasma exchange procedures within 24 hours and in addition 2 bags of CCP (equalling 600 ml CCP) infused at the end of the 2nd procedure.
16305963|NCT04634422|No Intervention|Control without intervention|Standard care without the use of PLEX or convalescent plasma.
16305964|NCT04634409|Experimental|LY3819253 + LY3832479|LY3819253 + LY3832479 administered IV.
16305965|NCT04634409|Experimental|LY3819253|LY3819253 administered IV.
16305966|NCT04634409|Placebo Comparator|Placebo|Placebo administered IV.
16305967|NCT04634409|Experimental|LY3819253 + VIR-7831|LY3819253 + VIR-7831 administered IV.
16305968|NCT04634409|Experimental|LY3853113|LY3853113 administered IV.
16305969|NCT04634409|Experimental|LY3853113 + LY3819253 + LY3832479|LY3853113 + LY3819253 + LY3832479 administered IV.
16305970|NCT04634396|Other|Experimental TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACICS. Participants will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1 hour sessions by a trained interventionalist
16305971|NCT04634383|Experimental|WFMA Cortical Visual Prosthesis Single-arm Study|The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
16305972|NCT04634370|Experimental|Intervention|"Each patient will receive on dose of intravenous natural killer cell in following levels:
~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
16305973|NCT04634357|Experimental|ET140203 T Cells|ET140203 T Cells
16305975|NCT04634331|Active Comparator|Traditional Multi-Modal Training|A physical therapist will provide 1:1 multi-modal training. Multi-modal training is the simultaneous performance of a motor and a cognitive task (i.e. marching while answering math questions)
16305976|NCT04634331|Experimental|Augmented Reality Multi-Modal Training|Multi-modal training will be administered via the Microsoft HoloLens 2 augmented reality head set. Augmented reality allows user to see the real world, and inserts holograms into the environment. For example, the user could see boxes on the ground that they need to step around when walking. The boxes are not real, but rather a hologram that only the user can see. The augmented reality device will instruct the participant on the motor and cognitive task that should be performed simultaneously in a similar manner to the physical therapist in the traditional multi-modal training group. The intervention will be overseen by a physical therapist.
16305977|NCT04634318|Active Comparator|Respiratory rehabilitation program group (RR).|Post-COVID-19 patients carrying out a respiratory rehabilitation program (RR).
16305978|NCT04634318|Experimental|Respiratory tele-rehabilitation program group (TRR).|Post-COVID-19 patients carrying out a respiratory tele-rehabilitation program (TRR).
16305979|NCT04634305||Total elbow arthroplasty|Total elbow arthroplasty, all indications combined
16305980|NCT04634292||Children with cerebral palsy 7-9 years|21 children
16305981|NCT04634292||Children with cerebral palsy 10-12 years|21 children
16305982|NCT04634292||Healthy children 7-9 years|21 children
16305983|NCT04634292||Healthy children 10-12 years|21 children
16305984|NCT04634279|Experimental|Collaborative Care Plus|Intervention is administered to patients in this arm. Care to be delivered via collaborative care. The supplement intervention adds family involvement in care and Caring Contacts, a suicide prevention method.
16305985|NCT04634279|No Intervention|Control|Patients in this arm will receive enhanced usual care.
16305986|NCT04634266|Experimental|Experimental intervention|Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)
16305987|NCT04634266|No Intervention|Control intervention|OMT for severe tricuspid regurgitation in right-sided heart failure
16305991|NCT04634240|Experimental|Complete Revascularization|Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of >70% in vessels ≥2.5mm in diameter.
16305992|NCT04634240|No Intervention|Medical Therapy Alone|No revascularization of coronary artery lesions.
16305993|NCT04634227|Experimental|Gemcitabine + High-Dose Ascorbate|Ascorabte is administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator. Treatment will be terminated with progression of disease. Disease will be assessed by CT of the chest, abdomen and pelvis or MRI of the lesion every 2 cycles for progression.
16305994|NCT04634214||COVID 19 positive patients without diabetes|COVID 19 positive patients without diabetes
16305995|NCT04634214||COVID 19 positive patients with diabetes|COVID 19 positive patients with diabetes
16305996|NCT04634201|Experimental|Experimental group|
16305998|NCT04634188||Meningioma Group|"This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.
~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
16305999|NCT04634188||Glioma Group|"This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.
~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
16306000|NCT04634188||Brain Metastasis Group|This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
16306001|NCT04634175|Experimental|Mind-body group|The mind-body group will practice mind-body intervention.
16306002|NCT04634175|Active Comparator|Sham group|The sham group will practice sham intervention.
16306003|NCT04634162|Experimental|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
16306004|NCT04634162|Placebo Comparator|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
16306005|NCT04634149|Experimental|Group A: Moderate Hepatic Impairment|
16306006|NCT04634149|Experimental|Group B: Severe Hepatic Impairment|
16306007|NCT04634149|Experimental|Group C: Normal Hepatic Function|
16306008|NCT04634136|Active Comparator|Active Substance: Full-spectrum Medical Canabis Product (HemPhar)|For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
16306009|NCT04634136|Placebo Comparator|Placebo|For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
16306010|NCT04634123|Experimental|Primary anterior teeth pulpotomy by White Portland Cement|
16306011|NCT04634123|Other|Primary anterior teeth pulpotomy by White MTA|
16306012|NCT04634110|Experimental|Patients with ALK+ NSCLC and brain metastases|Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib.
16306013|NCT04634097|Experimental|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:
~A. DECLIC program set up in the centers, open to concerned patients.
~B. 3 training sessions :
~one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.
~one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).
~for healthcare professionals in order to train them as educators in this program.
~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
16306014|NCT04634097|Other|Standard group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
16306015|NCT04634084|Experimental|Experimental group|
16306016|NCT04634084|Active Comparator|Control Group|
16306017|NCT04634071|Experimental|Group 1: Varenicline, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306018|NCT04634071|Experimental|Group : Varenicline, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306019|NCT04634071|Experimental|Group 3: Varenicline, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306020|NCT04634071|Experimental|Group 4: Varenicline, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306021|NCT04634071|Experimental|Group 5: Buproprion, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306022|NCT04634071|Experimental|Group 6: Buproprion, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306023|NCT04634071|Experimental|Group 7: Buproprion, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306024|NCT04634071|Experimental|Group 8: Buproprion, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306025|NCT04634071|Experimental|Group 9: Nicotine, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306026|NCT04634071|Experimental|Group 10: Nicotine, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306057|NCT04633837|No Intervention|Group 1 Control|Group 1 will undergo standard arthroscopic shoulder surgery without the ECM injection.
16306027|NCT04634071|Experimental|Group 11: Nicotine, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306028|NCT04634071|Experimental|Group 12: Nicotine, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
16306029|NCT04634058|Experimental|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 antibody combined with CTLA-4 antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
16306031|NCT04634032||Hernia|Patients planned to undergo routine indirect inguinal hernia repair procedure
16306032|NCT04634032||Control|Patients planned to undergo routine circumcision procedure
16306033|NCT04634019|No Intervention|Control arm|Providers in control facilities will not receive any additional training or knowledge assessments.
16306034|NCT04634019|Experimental|Financial incentive arm|Providers in treatment facilities will be visited once a quarter for a knowledge assessment using vignettes. Facilities performing well in this assessment will receive a quarterly bonus payment, which will be distributed among providers.
16306035|NCT04634006|Active Comparator|active tDCS 1|Anodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the cathode will be placed over the the vertex (Cz), using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
16306036|NCT04634006|Active Comparator|active tDCS 2|Anodal tDCS will be applied over the right IFG (1/3 of the distance between F8 and C6) according to the 10-20 EEG electrode systems and the cathode will be placed posterior to left mastoid, using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
16306037|NCT04634006|Sham Comparator|sham tDCS|Anodal tDCS will be applied over the left DLPFC (N=13) or right IFG (N=12) according to the 10-20 EEG electrode systems and the cathode will be placed over vertex or posterior to left mastoid, respectively, using square saline-soaked sponge pads 25 cm2. Sham stimulation will be maintained for 19 min without current flow by increasing current for 30 s followed by a decrease for 30 s.
16306038|NCT04633993|Experimental|PCSMP|Patient-centered self-management program for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
16306039|NCT04633993|No Intervention|Usual Care|Routine care.
16306040|NCT04633980|Experimental|Experimental group|
16306041|NCT04633954|Experimental|Brimonidine Group|Patients in this arm receive an extra drop of brimonidine in addition to routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
16306042|NCT04633954|No Intervention|Control Group|Patients in this arm only receive routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
16306043|NCT04633941||Post Bariatric Surgery|Post Bariatric Surgery more than 6 month. Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
16306044|NCT04633941||Medical Weight Management|Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
16306045|NCT04633928|Experimental|N-TEC|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for about 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The tissue engineered graft is then implanted in the nasal septum in an interposition graft with a temporoparietal fascia flap.
16306046|NCT04633915||Dialysis|Patients with CKD stage 5, treated with maintenance hemodialysis
16306047|NCT04633915||Healthy|Volunteers who are not dialysis-dependent
16306048|NCT04633902|Experimental|Olaparib + Pembrolizumab|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration including mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCA, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B.
16306049|NCT04633889|Experimental|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
16306050|NCT04633889|Placebo Comparator|Placebo|Normal saline (240mL) intravenous infusion over 12 hours
16306051|NCT04633876|Active Comparator|Control group|The subjects allocated to this group receive some results from baseline measurements (as do subjects in the intervention) but do not receive lifestyle counselling
16306052|NCT04633876|Experimental|Individual coaching|These subjects receive individual counselling during the study.
16306053|NCT04633876|Experimental|Group coaching|These subjects receive individual counselling during the study.
16306054|NCT04633863|Experimental|MDI - 101|Artificial tear containing arabinogalactan, trehalose and hyaluronic acid
16306058|NCT04633837|Active Comparator|Group 2: ECM Injectable graft|Group 2 will undergo arthroscopic shoulder surgery and receive 2cc of the injectable extracellular matrix injection placed into the glenohumeral joint space via a transtendon approach at the end of the surgery
16306059|NCT04633824||Patients with private insurance|
16306060|NCT04633824||Patients with public/self-payer insurance|
16306061|NCT04633811|Experimental|Controlled Diet and Weight Loss Program|Subjects will consume a low oxalate diet with blood and urine collections to establish baseline levels before undergoing a weight loss program with Optifast VLCD products. After completing the weight loss program, subjects will once again consume a low oxalate diet with blood and urine collections to observe any changes that may have occurred due to the weight loss.
16306062|NCT04633798|Experimental|IPL/Lipiflow|the group in which patients treated with IPL combined with lipiflow
16306063|NCT04633798|Active Comparator|IPL/MGX|the group in which patients treated with IPL combined with meibomian gland massage
16306064|NCT04633785||wrist BP|
16306065|NCT04633772|Placebo Comparator|Placebo|
16306066|NCT04633772|Experimental|Angiotensin-(1-7)|
16306067|NCT04633759|Experimental|Blood Flow Restriction Exercise|Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
16306068|NCT04633746||sepsis with AKI|Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
16306069|NCT04633746||Sepsis without AKI|Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
16306070|NCT04633733|Experimental|Single arm|"This single arm is conducted in fixed-sequence(Treatment A ->(washout period) -> Treatment B -> Treatment C -> Maintenance treatment).
~Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days"
16306071|NCT04633720|Experimental|Evaluation of intratidal compliance|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.
~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg
~Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg
~Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg
~Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
16306072|NCT04633707|Experimental|Adjunctive morning BLT group|treat participants with adjunctive BLT in the morning
16306073|NCT04633707|Experimental|Adjunctive afternoon BLT group|treat participants with adjunctive BLT in the afternoon
16306074|NCT04633707|Placebo Comparator|Adjunctive placebo therapy group|treat participants with adjunctive dim red light in the afternoon
16306075|NCT04633694|Experimental|Insect protein|The participants are are given insect protein
16306076|NCT04633694|Experimental|Pea protein|The participants are are given pea protein
16306077|NCT04633694|Experimental|Whey protein|The participants are are given whey protein
16306078|NCT04633681|Experimental|Cake matrix|3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
16306079|NCT04633681|Experimental|Biscuit matrix|3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
16306080|NCT04633681|Experimental|Yoghurt matrix|3 phases of 2-week daily consumption of yoghurt product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
16306081|NCT04633681|Experimental|Chocolate matrix|3 phases of 2-week daily consumption of chocolate product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
16306082|NCT04633681|Experimental|Cereal matrix|3 phases of 2-week daily consumption of cereal product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
16306083|NCT04633681|Experimental|Universal Eating Monitor study|A sub-group of the yoghurt matrix will be selected for assessment of eating rate and microstructure of feeding using Universal Eating Monitors.
16306084|NCT04633681|Experimental|fMRI study|A sub-group of the chocolate matrix will be selected for assessment of neural activation to images of food using fMRI.
16306085|NCT04633668|Experimental|CBT-p|cognitive behavioral therapy, Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
16306086|NCT04633668|Active Comparator|Self-monitoring|Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
16306087|NCT04633655||Patients who are receiving a neurotoxic chemotherapy|"List of neurotoxic drugs eligible for enrolment
~Platinum drugs
~Taxanes
~Vinca alkaloids
~Epothilones
~Proteasome inhibitors
~Thalidomide
~Vedotin-based drugs
~checkpoint inhibitors
~Any combination of the aforementioned drugs"
16306088|NCT04633642|Experimental|Ultrasound Group (UAW group)|UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
16306089|NCT04633642|Active Comparator|Surgical group|"All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.
~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus."
16306090|NCT04633629||Patients with acute heart failure|Patients hospitalized for acute heart failure in medical department.
16306091|NCT04633616|Experimental|Tailored Delivery of Education|Communication will be tailored as the mode of weblink delivery will be customized to patient preference.
16306092|NCT04633616|Placebo Comparator|Non-tailored Delivery of Education|Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
16306154|NCT04633109||normal weight|Normal weight adults with BMI ranging from 18.5-24.9; men and women; age range 18-69years; written informed consent
16306680|NCT04629807|Active Comparator|Demineralized Bone Matrix (DBM)|
16306093|NCT04633603||All patients|There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.
16306094|NCT04633590|Experimental|home-based exergaming|The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment and receive training on how to use the system
16306095|NCT04633590|Active Comparator|gym-based training|As suggested in the American Diabetes Association (ADA) position statement on exercise and diabetes (Colberg et al., 2016) the aim of this session will be to create an individualised exercise programme tailored to the specific needs of each participant. Participants will be given a specific gym induction with a gym instructor at a dedicated gymnasium in the Bern area (Migros Fitnessclub). During this session the training will be adapted to the participants needs. As suggested in the ADA position statement on exercise and diabetes the aim of the program will be for the participants to engage in at least 150 min of moderate to vigorous intensity exercise (defined as a HR of 50-70% HRmax) or 75 min of vigorous intensity (defined as a HR of 70-85% HRmax) or interval training per week by the end of the program. Participants will be encouraged to train 3 times per week. Participants will also be advised of the benefits of resistance training.
16306096|NCT04633577|Experimental|Group Lidocaine|20 eligible patients are received 1.5mg/kg 1%lidocaine intravenously over 30-60s. Then, 4mg/kg/h lidocaine infused intravenously until end of procedure.
16306097|NCT04633577|Placebo Comparator|Group Control|2020 eligible patients are received equal 0.9% normal saline.
16306098|NCT04633564|Experimental|MYL-1402O|"Patients will begin Period 1 receiving bevacizumab combination therapy (MYL-1402O15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as MYL-1402O ).
~In Period 2, eligible patients will continue to receive bevacizumab ( MYL- 1402O) every 3 weeks as monotherapy."
16306099|NCT04633564|Active Comparator|Avastin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin).
~In Period 2, eligible patients will continue to receive bevacizumab (Avastin) every 3 weeks as monotherapy."
16306100|NCT04633551|Experimental|Intervention|Participants in this arm will receive a commercially available anti-inflammatory supplement.
16306101|NCT04633551|No Intervention|Control|Participants in this arm will not receive a commercially available anti-inflammatory supplement.
16306102|NCT04633525|Experimental|Optimum Cup Orientation|
16306103|NCT04633512|Experimental|ActivSight Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=26) Patients undergoing cholecystectomy with ActivSight (n=14)
16306104|NCT04633499|Active Comparator|dmPFC tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the dmPFC while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
16306105|NCT04633499|Experimental|rTPJ tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the rTPJ while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
16306106|NCT04633499|Active Comparator|Social cognition tasks in younger participants|Participants will conduct two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking but without tDCS stimulation.
16306107|NCT04633473|Experimental|SIBTime|50 primary parents will be assessed at enrollment, then provided the SIBTime technology and exposed to the learning routines for 4 weeks, and then re-assessed at 4 weeks (after treatment completion).
16306108|NCT04633460|Experimental|Ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
16306109|NCT04633460|Placebo Comparator|Placebo|KE-free solution
16306112|NCT04633434|Experimental|The Talk Parenting Skill for Alexa|52 parents will be assessed at enrollment, then provided an Amazon Echo Dot and exposed to the prototype Bedtime Routine module of the Talk Parenting program for 6 weeks, and then re-assessed at 6 weeks (at treatment completion)
16306113|NCT04633421|Experimental|PRECISe protocol EN (8g protein/100kcal)|Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
16306114|NCT04633421|Active Comparator|PRECISe protocol EN (5g protein/100kcal)|Enteral (EN) feed with 5 grams protein per 100 kcal (1.2 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
16306115|NCT04633408|Experimental|Intervention|The investigators will recruit 15 Latino caregivers for each study arm (total sample size of 30). The sample size was based on a rule of thumb of 12 to 15 participants per group for pilot studies. This group will have access to the app.
16306116|NCT04633408|No Intervention|Control|12 to 15 participants, will not have access to the app.
16306155|NCT04633109||obese|Subjects with obesity as defined by BMI >= 30; men and women; age range 18-69 years; written informed consent
16306117|NCT04633395|Experimental|Music before bedtime|Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks. Participants will also receive the sleep hygiene guidelines, and be told to follow these.
16306118|NCT04633395|Active Comparator|Sleep hygiene|Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
16306119|NCT04633382|Experimental|Conducting research of enhanced recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.
~Refusal from complete starvation. Carbohydrate drink 2 hours before surgery.
~Refusal of cleansing enemas.
~Refusal of premedication. NSAIDs 30 minutes before surgery
~Prevention of thromboembolic complications
~Multimodal analgesia: epidural catheter, paracetamol.
~Minimally invasive access.
~Prevention of hypothermia
~Targeted infusion therapy.
~Failure or limited time use of drainages: gastric, intra-abdominal, bile duct drainage.
~Early activation of the patient.
~Early enteral nutrition.
~Prevention of nausea and vomiting."
16306120|NCT04633382|Placebo Comparator|Conducting research of traditional recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.
~Fasting for 2 days
~Use of cleansing enemas. Bowel preparation
~Premedication
~Prevention of thromboembolic complications
~Without multimodal analgesia
~Traditional access.
~Prevention of hypothermia
~Targeted infusion therapy.
~Use of drains: gastric, intra-abdominal, bile duct drainage.
~Activation of patients within 2 days.
~Enteral nutrition after 2 days after surgery.
~Without the use of metoclopramide"
16306121|NCT04633369|Experimental|Fructo-oligosaccharide|Fructo-oligosaccharide 20g
16306122|NCT04633369|Experimental|Arabinogalactan|Arabinogalactan 12g
16306123|NCT04633369|Experimental|Glucomannan|Glucomannan 4g
16306124|NCT04633356|Experimental|EUS-portal pressure gradient measurement (PPGM)|All patients would receive measurement of PPGM using the study device
16306125|NCT04633343|Experimental|Small Volume Breath Group|Small volume breath and fast breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation
16306126|NCT04633343|Experimental|Large Volume Breath Group|Large volume breath and slow breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation.
16306127|NCT04633330|Experimental|Study Arm|AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
16306128|NCT04633330|Placebo Comparator|Control Arm|Simulation of AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
16306129|NCT04633317|Experimental|Group A Regimen|Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days
16306130|NCT04633317|No Intervention|Group B Regimen|Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days
16306131|NCT04633304|Other|AVF|Single arm study using primary and secondary end points as comperators between subjects.
16306132|NCT04633278|Experimental|CMP-001 and Pembrolizumab|All subjects will receive CMP-001 IT and pembrolizumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
16306133|NCT04633265|Experimental|ECG-I Mapping and Ablation of drivers|ECG-I Mapping will be performed and drivers will be ablated as directed by ECG-I.
16306134|NCT04633252|Experimental|1/Dose Escalation|Docetaxel plus M9241 dose escalation with optional prednisone and ADT as part of SOC
16306135|NCT04633252|Experimental|2/Safety Run-in|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
16306136|NCT04633252|Experimental|3/mCSPC: Dose Expansion|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
16306137|NCT04633252|Experimental|4/mCRPC: Dose Expansion|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
16306140|NCT04633213|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
16306141|NCT04633213|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
16306142|NCT04633200|Experimental|Intervention|Participants in the intervention arm will receive a mobile app to support their daily PrEP adherence.
16306143|NCT04633200|No Intervention|Control|Participants in the control group will receive a 2-page PrEP patient education document based information about PrEP from on the CDC website.
16306144|NCT04633187|Experimental|EDP-938|
16306145|NCT04633187|Placebo Comparator|Placebo|
16306146|NCT04633174|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38oC, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
16306147|NCT04633148|Experimental|UniCAR02-T-pPSMA|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.
16306148|NCT04633135|No Intervention|Control|Households enrolled in the control arm of the study did not receive either improved cookstove
16306149|NCT04633135|Experimental|Gyapa/Gyapa|Households enrolled in the Gyapa/Gyapa arm of the study received two Gyapa stoves for free
16306150|NCT04633135|Experimental|Gyapa/Philips|Households enrolled in the Gyapa/Philips arm of the study received one Gyapa stove and one Philips stove for free
16306151|NCT04633135|Experimental|Philips/Philips|Households enrolled in the Philips/Philips arm of the study received two Philips stoves for free
16306152|NCT04633122|Experimental|Ripretinib|50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.
16306153|NCT04633122|Active Comparator|Sunitinib|12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.
16306263|NCT04632550|Active Comparator|Circumferential pulmonary vein isolation(CPVI) group|
16306156|NCT04633096|Experimental|tailored feedback|Using a randomized-controlled study design one third of the participants will receive individually tailored feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
16306157|NCT04633096|Experimental|standardized feedback|Using a randomized-controlled study design one third of the participants will receive a standard feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
16306158|NCT04633096|No Intervention|no feedback|Using a randomized-controlled study design one third of the participants will not receive any feedback.
16306159|NCT04633083|Other|Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbosacral level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbosacral level ii. Scapular plane abduction under 150°
~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
16306160|NCT04633083|Other|No Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbar level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbar level ii. Scapular plane abduction under 150°
~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
16306161|NCT04633057|Experimental|TJ101|TJ101 1.2 mg/kg once a week for 52weeks
16306162|NCT04633057|Active Comparator|NordiFlex|NordiFlex Injection 0.034 mg/kg once a day for 52 weeks
16306163|NCT04633044|Placebo Comparator|Placebo|400 mg of lactose daily for 12 weeks
16306164|NCT04633044|Experimental|Supplement|400 mg of betaine daily for 12 weeks
16306165|NCT04633031||Group 1|Cheneau brace
16306166|NCT04633031||Group 2|Boston brace
16306167|NCT04633018|Experimental|Patient-centered asthma intervention feasibility|Investigate the effect of the patient-centered asthma intervention using the AsthmaMD app on school days missed and medication adherence.
16306168|NCT04633018|Experimental|Wait list control|Control group with usual care (not using app).
16306169|NCT04633005|Experimental|Polypill Arm|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include metoprolol succinate (a beta-blocker), empagliflozin (an SGLT2-inhibitor), and spironolactone (a mineralocorticoid antagonist). Three dose formulations of the pill, varied in metoprolol succinate dose, will be available for up-titration of the beta-blocker dose per ACC/AHA/HFSA guidelines.
16306170|NCT04633005|Active Comparator|Control Arm|Patients will receive GDMT as usually prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
16306186|NCT04632979|Experimental|Backward runners|Training protocol patients
16306187|NCT04632966|Experimental|PTP-001 - Low Dose (100 mg)|intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline
16306188|NCT04632966|Experimental|PTP-001 - High Dose (200 mg)|intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline
16306189|NCT04632953||Previously Treated with Triheptanoin|Patients who have been previously treated with triheptanoin in clinical studies: UX007-CL201 (NCT01886378), UX007-CL202 (NCT02214160), Investigator Sponsored Trials (ISTs), or UX007-EAP (NCT03773770).
16306264|NCT04632550|Experimental|Posterior box isolation(POBI) group|
16306190|NCT04632953||Currently Treated with Triheptanoin|New patients enrolling into the DMP currently being treated with triheptanoin (excluding those in the previously treated with triheptanoin cohort).
16306191|NCT04632953||Triheptanoin Naïve|New patients enrolling into the DMP with no exposure to triheptanoin.
16306192|NCT04632953||Triheptanoin Naïve Transitioned toTriheptanoin|Patients already enrolled into the triheptanoin naïve cohort but transition to triheptanoin during the DMP after enrollment.
16306195|NCT04632927|Experimental|Secukinumab|AIN457
16306196|NCT04632927|Experimental|Ustekinumab|
16306197|NCT04632914|Experimental|trunk stabilizing exercise|trunk stabilizing exercises three times/week for four weeks
16306198|NCT04632914|Active Comparator|cardiac rehabilitation programe|cardiac rehabilitation program three times/week for four weeks
16306199|NCT04632901||Testing of Visual Acuity (VA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
16306200|NCT04632901||Testing of Critical Visual Acuity (CVA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
16306201|NCT04632888|Experimental|Study group/Telephone support for breastfeeding follow-up|"Study group: The women in the study group will be provided with a video call every day for the first week after discharge from the hospital, to provide consultancy to the mother on the matters she needs and to be recorded in the Baby Monitoring Form. The general appearance of the baby, observation during sucking, jaundice, drowsiness, reluctance to suck will be observed. The consultancy will be provided to the mother on these issues.
~In the following weeks, the consultancy will continue to be given to the study group by making a video talk one week apart.
~The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded."
16306202|NCT04632888|No Intervention|Control Group|"Control Group: No additional attempt or routine call will be made to mothers in the control group. The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded.
~The control group will be called to fill in the scales for monitoring purposes."
16306203|NCT04632875|Experimental|Loving-Kindness Meditation|4-week guided Loving-Kindness Meditation training (administered online).
16306204|NCT04632875|Experimental|Relaxation Meditation|4-week guided Relaxation Meditation training (administered online).
16306205|NCT04632862|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
16306206|NCT04632862|Placebo Comparator|DWP16001 Amg Placebo|DWP16001 Amg Placebo, Tablets, Orally, Once daily
16306207|NCT04632849|Experimental|GEM + CGM|A self-directed lifestyle intervention for controlling Type 2 Diabetes
16306208|NCT04632836||NIV participant (non invasive-ventilation participant)|"From patient:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~equipment data (type, indication, parameters, observance, usage data),
~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)
~From partner:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
16306209|NCT04632836||CPAP participant (continuous positive airway pressure participant)|"From patient:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~equipment data (type, indication, parameters, observance, usage data),
~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)
~From partner:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
16306210|NCT04632836||LTOT participant (long term oxygen therapy participant)|"From patient:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~equipment data (type, indication, parameters, observance, usage data),
~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)
~From partner:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
16306211|NCT04632823|Experimental|Comprehensive non-pharmacological program intervention|The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.
16306212|NCT04632823|No Intervention|Usual diabetes care|This group is control, the patients receive usual diabetes care routines.
16306213|NCT04632810|Experimental|Ketogenic diet + weight loss|
16306214|NCT04632810|Active Comparator|non-Ketogenic diet + weight loss|
16306215|NCT04632810|Active Comparator|Ketogenic eucaloric diet|
16306216|NCT04632797|Active Comparator|Cryocompression|Patients in this group receive cryocompression for the hands.
16306217|NCT04632797|Active Comparator|Cryotherapy|Patients in this group receive cryotherapy for the hands.
16306218|NCT04632784|Experimental|Artiflex Presbyopic|About 125 - 140 subjects will receive the Artiflex Presbyopic lens bilaterally and will be followed for a period of 3 years.
16306219|NCT04632771||Pilot survey: non-pregnant, non-lactating women|Survey of non-pregnant, non-lactating women 15-49 years of age (n=250)
16306220|NCT04632771||Pilot survey: lactating women|Survey of lactating women 15-49 years of age who are currently breastfeeding a child 4-18 months of age (n=250)
16306221|NCT04632771||Pilot survey: children|Survey of children 2-5 years of age (n=250)
16306222|NCT04632771||RID Pilot 1|Two-week study to assess total body vitamin A stores in a sample of non-pregnant, non-lactating women 15-49 years of age (n=30)
16306223|NCT04632771||RID Pilot 2|"Kinetic study with Super-woman design to develop a prediction equation to assess total body vitamin A stores among non-pregnant, non-lactating women 15-49 years of age (n=123)"
16306224|NCT04632771||Focus group discussions|Focus group discussions conducted among women of reproductive age, older women, and men (n=120 total)
16306225|NCT04632771||Market assessment|Survey of retail outlets selling fortified staple foods and/or bouillon (n=50 shop owners or operators)
16306226|NCT04632771||Recipe observations|Observations of cooking of local dishes by selected participants (n=50) enrolled in the pilot survey.
16306227|NCT04632758|Experimental|WX-0593 Tablets|Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
16306228|NCT04632758|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
16306229|NCT04632745|Other|Cast Group|participant with distal radius fracture will be treated with short arm fiberglass cast
16306230|NCT04632745|Other|Splint Group|participant with distal radius fracture will be treated with short arm velcro wrist splint
16306231|NCT04632732||COVID+, SARS|patients COVID+ SARS mechanically ventilated and/or needing more than 6L/min of O2-40% FiO2 for a SpO2 equal or above 90% for more than 24hours.
16306232|NCT04632732||COVID+, nonSARS|patients COVID+ nonSARS respiratory symptomatic, with or without lung infiltrates, non mechanically ventilated, and needing less than 6L/min O2-40% FiO2 for a SpO2 equal or above 90%. They are hospitalized on floors (pulmonolgy, internal medecine or in intensives cares units).
16306233|NCT04632732||COVID-, ARDS|patients are in ARDS according to the Berlin definition and the lung injury is categorized in the direct form (e.g. pneumonia, aspiration).
16306234|NCT04632732||COVID-, nonARDS|patients are not in ARDS according to the Berlin definition but are respiratory symptomatic, with or without lung infiltrates and needing less than 6L O2/min-40% FiO2 for a SpO2 equal or above 90%.
16306235|NCT04632732||COVID-, control, MV+|patients hospitalized and mechanically ventilated for non-respiratory reasons (post hoc with sex-age matching).
16306236|NCT04632732||COVID-, control, MV-|non mechanically ventilated patients hospitalized for non-respiratory reasons (post hoc with sex-age matching).
16306237|NCT04632719|Experimental|Covid-19 Study Group|The Study Group will be the group that was remiss for COVID-19 and has some of the mentioned comorbidities as asthma, cardiovascular disease, cancer even if controlled by drugs or treatments.
16306238|NCT04632719|Active Comparator|Covid-19 Control Group|The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
16306239|NCT04632706|Experimental|50mcg/kg (oral)|Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 50mcg/kg from D2 to D28
16306240|NCT04632706|Experimental|75mcg/kg (oral)|Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 75mcg/kg from D2 to D28
16306241|NCT04632706|Experimental|100mcg/kg (oral)|Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 100mcg/kg from D2 to D28
16306242|NCT04632706|Placebo Comparator|Matching Placebo (oral)|Placebo using tablets identical to the Active IMP
16306243|NCT04632693|Experimental|CAF with SCTG and vitamin C|Coronally advanced flap with subepithelial connective tissue graft and vitamin C.
16306244|NCT04632693|Active Comparator|CAF with SCTG|Coronally advanced flap with subepithelial connective tissue graft.
16306245|NCT04632680|Experimental|PVI followed by targeting of drivers|Patients will undergo intra-procedural mapping using the ECG-I. The pulmonary veins will be isolated. Drivers will then be targeted as guided by the ECG-I system aiming for termination of AF.
16306246|NCT04632667|Active Comparator|Comparison School Group|
16306247|NCT04632667|Experimental|Intervention School Group|
16306248|NCT04632654|Experimental|PAfitME|For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention.
16306249|NCT04632654|No Intervention|Attention Control|For 6 weeks, the attention control group will receive National Cancer Institute-based survivorship education and exergame equipment (Wii Fit and Xbox Kinect without PAfitME).
16306250|NCT04632641|Experimental|Perclose ProGlide Suture-Mediated Closure System (SMC) - SMALL-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes less than or equal to 13F.
16306251|NCT04632641|Active Comparator|Figure 8 Suture - SMALL-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes less than or equal to 13F.
16306252|NCT04632641|Active Comparator|Manual Compression - SMALL-BORE PROCEDURES|Manual compression will be used as a closure technique for venous access sites using sheath sizes less than or equal to 13F.
16306253|NCT04632641|Experimental|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes greater than 13F.
16306254|NCT04632641|Active Comparator|Figure 8 Suture - LARGE-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes greater than 13F.
16306255|NCT04632628|Experimental|NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia|This is a pilot trial with one treatment condition (CBT-I).
16306256|NCT04632602|Other|patients in prone position followed by dorsal decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
16306257|NCT04632602|Other|dorsal decubitus followed by prone decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
16306258|NCT04632589|Experimental|Losartan|6 weeks of daily (50mg/day) oral losartan potassium tablet
16306259|NCT04632589|Placebo Comparator|Placebo|6 weeks of daily oral placebo tablet
16306260|NCT04632576|Experimental|auricular acupuncture|"auricular acupuncture is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing fine needles in specifically designated puncture points on the external ear."
16306261|NCT04632576|No Intervention|Control|No intervention is given.
16306262|NCT04632563||Member of BioResource|Any BioResource member who consents to take part in the study and completes the study questionnaire.
16306266|NCT04632537|Active Comparator|TICE BCG (for intravesical use, Merck) BCG LIVE|Participants randomized to the BCG arm will receive Tice® BCG (for intravesical use) BCG LIVE is a live freeze-dried vaccine made from an attenuated strain of Mycobacterium bovis. The freeze-dried vaccine will be delivered in vials, each containing 1 to 8 x108 colony forming units (CFU). Tice® BCG (for intravesical use) BCG LIVE will be reconstituted in ~5 mL of preservative-free saline, as needed for yielding 2- x107 CFU/ mL. [34] Administration of 0.1 mL will contain 2x106 CFU, which accounts for approximately 0.1 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally. A sterile tuberculin 1mL syringe and sterile fine short needle (25 or 26 gauge with 3/8-3/4 length), will be used for each injection. The injection should be made slowly after inserting the needle ~2 mm into the superficial layer of the dermis of the upper arm (usually deltoid area), to make a symmetrical superficial bleb.
16306267|NCT04632537|Placebo Comparator|placebo vaccine|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
16306268|NCT04632524|Active Comparator|MgSO4|Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.
16306269|NCT04632524|Placebo Comparator|Placebo|Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse
16306270|NCT04632511|Other|Obese group|Metabolome measurements on feces and urine.
16306271|NCT04632511|Other|Children with overweight, not yet obese|Metabolome measurements on feces and urine.
16306272|NCT04632511|Other|Normal-weight control group|Metabolome measurements on feces and urine.
16306273|NCT04632498|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
16306274|NCT04632498|No Intervention|Wait-list Control (WL)|Patient Control receiving no treatment
16306275|NCT04632498|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
16306276|NCT04632485||Aim 1: Ultrasound Only|Approximately 280 asymptomatic participants will participate in ultrasound (US) studies and blood work.
16306277|NCT04632485||Aim 2: Ultrasound and MRI|A sub-group of 40 at risk volunteers determined from the clinical ultrasound scans and bloodwork from Aim 1 will be asked to participate in a longitudinal US and MRI study. Participants will be selected from a population of individuals that do not have significant atherosclerosis, but present with increased risk due to the presence of soft, lipid rich plaque that are hypoechogenic or echolucent on ultrasound B-mode images. These participants may also satisfy the current clinical guidelines of increased vessel diameter and decreased blood flow velocity with ultrasound that may result in plaque deposition for being in the at risk population. Participants will receive US, strain and shear wave imaging every 2 years after the first scan in Aim 1 and MRI Imaging in Year 1 and Year 5: separated by 4 years
16306278|NCT04632472|Active Comparator|Active fixation bipolar lead|Left ventricular bipolar pacemaker lead, fixated by a side helix
16306279|NCT04632472|Placebo Comparator|Passive fixation quadripolar lead|Left ventricular quadripolar passive fixation pacemaker lead
16306280|NCT04632459|Experimental|pembrolizumab plus ramucirumab|"Ramucirumab 8mg/kg on q2W
~Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)
~If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles"
16306281|NCT04632433|Experimental|single arm|Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
16306282|NCT04632420||Women with child birth|Women attending chronic pain clinic who have previously experienced childbirth
16306283|NCT04632420||Women without childbirth|Women attending chronic pain clinic who have not previously experienced childbirth
16306284|NCT04632407|Experimental|"Flax milk"|"A total of 30 women will receive flax (FLX) milk on a daily basis for a total of 4 months. The FLX milk will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3."
16306285|NCT04632407|Experimental|"Oat fibre milk"|"A total of 30 women will receive the oat fiber milk on a daily basis for a total of 4 months. The oat fibre milk will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water."
16306286|NCT04632394||Cases|Patients with scar-dependent ventricular tachycardia, requiring ablation. These patients will have satisfied the inclusion/exclusion criteria and be put forward for VT ablation. They will undergo the previously described study protocol, including generation of a computational model of the heart from their cardiac MRI and a VT ablation where we will study the points of interest generated from the MRI model in detail.
16306291|NCT04632368|Active Comparator|Transcendental Meditation Intervention Arm|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to a randomized group of eligible HCPs ( N=40)providing care during COVID-19 pandemic.
16306292|NCT04632368|No Intervention|Treatment as usual(TAU) Control Arm|Control group consists of eligible HCPs who are randomized to control group(N=40) and would not receive any intervention. At the end of 3 month study period, control group participants would be eligible for TM training.
16306293|NCT04632342|Experimental|Experimental group 1|HL301 1,200mg/day
16306294|NCT04632342|Experimental|Experimental group 2|HL301 1,800mg/day
16306295|NCT04632342|Placebo Comparator|Control group|Placebo
16306296|NCT04632316|Experimental|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
16306297|NCT04632303|Experimental|Early Palliative Care|Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
16306298|NCT04632303|No Intervention|Standard Care Arm|Palliative care visit only upon request from attending oncologist(s) or patient/family.
16306299|NCT04632290|Experimental|All participants|All participants receive the same intervention.
16306300|NCT04632277|Placebo Comparator|Placebo|"A tap water,"
16306301|NCT04632277|Experimental|Expermental recieve low MG|Low Mg bottle water (50mg/l)
16306302|NCT04632277|Experimental|Expermental recieve high MG|high Mg bottle water (100 mg/l)
16306305|NCT04632251|Other|Familiarisation|The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study.
16306306|NCT04632238|No Intervention|Control|
16306307|NCT04632238|Experimental|Metrics-driven quality improvement (MDQI) intervention|
16306308|NCT04632225|Active Comparator|Engensis|64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
16306309|NCT04632225|Placebo Comparator|Placebo|32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
16306310|NCT04632212|Experimental|1|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (ON)
16306311|NCT04632212|Experimental|2|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (OFF)
16306312|NCT04632212|Experimental|3|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (ON)
16306313|NCT04632212|Experimental|4|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (OFF)
16306314|NCT04632212|Experimental|5|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (ON)
16306315|NCT04632212|Experimental|6|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (OFF)
16306316|NCT04632212|Experimental|7|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (ON)
16306317|NCT04632212|Experimental|8|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
16306318|NCT04632212|Experimental|9|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (ON)
16306319|NCT04632212|Experimental|10|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (OFF)
16306320|NCT04632212|Experimental|11|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (ON)
16306321|NCT04632212|Experimental|12|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (OFF)
16306322|NCT04632212|Experimental|13|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (ON)
16306323|NCT04632212|Experimental|14|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (OFF)
16306324|NCT04632212|Experimental|15|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (ON)
16306325|NCT04632212|No Intervention|16|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
16306326|NCT04632199|Experimental|111In-IPN01087 Low dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a low mass dose of IPN01087
16306327|NCT04632199|Experimental|111In-IPN01087 High dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a high mass dose of IPN01087
16306328|NCT04632186|Experimental|Intervention|"3 sessions with 3 different interventions 1) Transcutaneous electric nerve stimulation (TENS)- at the shoulder according to current best evidence and practice 2) EXOPULSE Mollii suits- local stimulation at the shoulder, 3) EXOPULSE Mollii suit- according to current best experienced practice
~The order in which the participants´ receive the different treatments will be randomized.
~Each session lasts for approximately 2.5 hours (approximately 60 min for assessment, 30 min for settings and adjustments and 60 min for treatment)"
16306329|NCT04632160|Experimental|Treatment|Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
16306330|NCT04632147|Experimental|Pranayama Group|Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 3 day a week for 8 weeks, under the online supervision of a physiotherapist. The training program will last 8 weeks.
16306331|NCT04632147|No Intervention|Control Group|No intervention will be made to this group.
16306332|NCT04632134|Experimental|Transcutaneous vagal nerve stimulation (tVNS)|"After positioning the tVNS electrodes in the right ear but without delivering tVNS (Sham tVNS), above mentioned signals will be recorded for 10 minutes while supine, for 15 minutes during 75° head-up tilt.
~The same protocol will be performed during active tVNS.
~The tVNS will be performed while 15 minutes in supine position and during 75°head-up Tilt.
~Thereafter, every patient will be provided with a Nemos© device and electrodes for home daily stimulation. Daily stimulation will consist of 4 hours of stimulation organized as 4 sessions each lasting 1 hour, to be applied at the patient's convenience."
16306333|NCT04632121||Group A|will receive standard treatment + 20 mg nicorandil prior to PPCI, and then maintained on 20 mg b.i.d for 3 months .
16306334|NCT04632121||Group B|will be given standard treatment, without nicorandil loading or maintainance.
16306335|NCT04632108|Experimental|ASKB589 Injection|Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
16306336|NCT04632095|Active Comparator|Sternotomy AVR|Aortic valve replacement due to sternotomy
16306337|NCT04632095|Active Comparator|Mini AVR|Aortic valve replacement due to parasternal right anterior mini-thoracotomy
16306524|NCT04630834|Active Comparator|Intervention group|Intervention Group: ibuprofen 10 mg/kg (maximum 600mg) plus acetaminophen 15mg/kg (maximum 650mg)
16306338|NCT04632082|Experimental|Intervention: Telepsychoeducation with personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology. The intervention is complemented by the sending of 4 videos of 2 to 3 minutes, with psychoeducational content, sent each week by the therapist.
16306339|NCT04632082|Active Comparator|Comparator: Telepsychoeducation without personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology.
16306340|NCT04632069|Experimental|NAC + taVNS|NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
16306341|NCT04632056||Beovu|Brolucizumab (Genetical Recombination) 6 mg (0.05 mL) is administered by intravitreal injection every 4 weeks for the first three doses(loading phase). In the following maintenance phase, Brolucizumab is basically administered every 12 weeks. The interval between treatments is adjusted as appropriate according to the symptoms. The interval between two doses should not be shorter than 8 weeks
16306342|NCT04632043|Active Comparator|Early intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will undergo intubation.
16306343|NCT04632043|Active Comparator|Delayed intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.
16306344|NCT04632030|Active Comparator|Control|The tobacco power wall and number of products appears in a typical format: large power wall with a large number of products (defined here as three large cabinets)
16306345|NCT04632030|Experimental|Small|The tobacco power wall and number of tobacco products appear in their smallest format: small power wall with a small number of products displayed (defined here as one large cabinet)
16306346|NCT04632030|Experimental|Medium|The tobacco power wall and number of tobacco products appear in a format sized between the control and small conditions: a medium sized power wall with a medium number of products displayed (defined here as two large cabinets).
16306347|NCT04632017||pPROM|Singleton pregnancies admitted for pPROM to the Obstetrics ward
16306348|NCT04632017||Control group|Healthy pregnant women matched for gestational age
16306349|NCT04632004|Other|Questionnaire survey|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
16306350|NCT04631991||Non-pathological high myopia|Comprehensive ophthalmologic examination
16306351|NCT04631991||Control|Comprehensive ophthalmologic examination
16306352|NCT04631978||Underweight|Comprehensive ophthalmologic examination
16306353|NCT04631978||Control|Comprehensive ophthalmologic examination
16306354|NCT04631965||Cohort in Finland|253 young patients who attend clinics in Finland with no hospital-wide transition support service available
16306355|NCT04631965||Cohort in Australia|250 young patients who attend clinics in Victoria, Australia and who have received support from a hospital-wide transition support service
16306356|NCT04631952|Experimental|Online exercise|SMS messages on encouraging active lifestyle plus an online exercise video
16306357|NCT04631952|Active Comparator|SMS message|SMS messages on encouraging active lifestyle
16306358|NCT04631939|Experimental|study intervention|"The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world Macu'ta. The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions."
16306359|NCT04631939|Sham Comparator|control intervention|The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.
16306360|NCT04631926|Other|Hip Muscle Exercises|Hip Muscle Exercises
16306361|NCT04631900|Experimental|Spiritual Intervention Programme|"The intervention is a 6 weeks' programme. The Christianity approach as the framework for spiritual intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group.
~Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose."
16306362|NCT04631900|No Intervention|Wait-list Control group|Participants recruited in the waitlist control will be initially tested to generate pre-test scores and will then tested six weeks later which is equivalent to the timespan between the pre-test and post-test for the experimental spiritual programme. In between these two testing sessions, the waitlist control group will not receive any type of spiritual intervention. For ethical reasons, following the second testing session, the participants in the waitlist group will be given the opportunity to participant in the spiritual intervention programme.
16306363|NCT04631887|Experimental|Intervention Arm: Doing What Matters in Times of Stress: An Illustrated Guide|The intervention arm will receive the assigned intervention for five weeks. They will receive the intervention materials and will be called by psychologists three times (at the beginning, middle and end) during the intervention.
16306364|NCT04631887|No Intervention|Control Arm: Wait List|The control arm has no intervention. The participants in the control arm will receive the intervention after the post-assessments are completed.
16306365|NCT04631874|Experimental|Sequence A(RT)|Reference drug (Champix) -> washout -> test drug (CDFF0318)
16306366|NCT04631874|Experimental|Sequence B(TR)|Test drug (CDFF0318) -> washout -> reference drug (Champix)
16306367|NCT04631848||ULTRASCORE™ Focused Force PTA Balloon|
16306368|NCT04631835|Experimental|HS-10352|There are five escalating dose cohorts
16306525|NCT04630834|Placebo Comparator|Placebo Group|Placebo Group: Ibuprofen 10mg/kg (maximum 600 mg) plus placebo 15mg/kg (maximum 650mg)
16306369|NCT04631822|Active Comparator|Dexamethasone, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.
~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 4 mg dexamethasone."
16306370|NCT04631822|Active Comparator|Dexmedetomedine, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.
~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 0.5 Mg/kg dexmedetomidine."
16306371|NCT04631809|Active Comparator|invasive Coronary Angiography alone|
16306372|NCT04631809|Experimental|CT-Coronary Angiography + invasive Coronary Angiography|
16306373|NCT04631796|Experimental|LID020098 contact lenses|Lehfilcon A contact lenses worn in both eyes for 2 weeks. Lenses will be removed nightly for cleaning and disinfection.
16306374|NCT04631770|Experimental|Mediastinal lymph node dissection group|A
16306375|NCT04631770|Active Comparator|Mediastinal lymph node non-dissection group|B
16306376|NCT04631757|Experimental|Camrelizumab plus Chemoradiotherapy|Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
16306377|NCT04631744|Experimental|Cabozantinib Arm|
16306378|NCT04631731|Experimental|Immune-checkpoint inhibitors (ICIs)|
16306379|NCT04631731|Active Comparator|ICIs + platinum-based chemotherapy|
16306380|NCT04631731|Experimental|ICIs + kinase inhibitors|
16306389|NCT04631692|No Intervention|Usual care|Usual care in participating primary care practices.
16306390|NCT04631692|Active Comparator|Health literacy intervention|Health literacy intervention combining health literacy and colorectal cancer screening training for general practitioners with a short brochure and video targeting eligible patients.
16306391|NCT04631679||Group A: anemic patients with iron treatment|For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
16306392|NCT04631679||Group B: non-anemic patients without iron treatment|For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
16306393|NCT04631666|Experimental|Group 1A (uninfected) - 2.5 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg
16306394|NCT04631666|Experimental|Group 1B (uninfected) - 10 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg
16306395|NCT04631666|Experimental|Group 1C (uninfected) - 40 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
16306396|NCT04631666|Experimental|Group 1D (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg
16306397|NCT04631666|Experimental|Group 2C (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
16306398|NCT04631666|Experimental|Group 2D (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will be randomized 2:1 to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg or placebo
16306399|NCT04631653|Experimental|Verisee|Screening diabetic retinopathy using Verisee software
16306400|NCT04631627|Active Comparator|aspirin group|aspirin,tablet,100/150mg per day,(BMI<30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks<16 to 35 weeks or the day of delivery.
16306401|NCT04631627|Sham Comparator|control group|with no intervention
16306402|NCT04631614|Experimental|Manual therapy plus muscle strengthening exercises|The procedures to be performed with participants in the experimental group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) two ankle manual therapy techniques - [a] passive calf muscle stretching and [b] ankle joint mobilization; (3) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
16306589|NCT04630353|Experimental|HB-201 Intratumorally on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
16306681|NCT04629807|Active Comparator|Cellular Bone Matrix (CBM)|
16306403|NCT04631614|Active Comparator|Muscle strengthening exercises|The procedures to be performed with participants in the control group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
16306415|NCT04631588|Experimental|Open Label BOTOX|Participants will receive BOTOX at Baseline (Day 1)
16306416|NCT04631588|Experimental|Double-Blind Randomized BOTOX|Participants will receive BOTOX at Baseline (Day 1)
16306417|NCT04631588|Placebo Comparator|Double Blind Randomized Placebo|Participants will receive placebo at Baseline (Day 1)
16306418|NCT04631575|Experimental|Healthy participants|Intervention: Drug: SHR6390 single dose
16306419|NCT04631575|Experimental|Mild liver impairment|Intervention: Drug: SHR6390 single dose
16306420|NCT04631575|Experimental|Moderate liver impairment|Intervention: Drug: SHR6390 single dose
16306421|NCT04631562|Experimental|ALXN1820|Participants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
16306422|NCT04631562|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
16306423|NCT04631549|Experimental|Healthy participants|Intervention: Drug: SHR3680 single dose
16306424|NCT04631549|Experimental|Mild liver impairment|Intervention: Drug: SHR3680 single dose
16306425|NCT04631549|Experimental|Moderate liver impairment|Intervention: Drug: SHR3680 single dose
16306426|NCT04631536|Experimental|Endothelial Dysfunction Protocol|"Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin, nicorandil, l-arginine, folic acid and nebivolol) in patients already on optimal medical therapy for the treatment of COVID0-19 virus.
~Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc).
~Atorvastatin or continue home statin Atorvastatin will be provided as a 40 mg tablet to be given PO once daily. This dose was suggested because high intensity statin has been associated with a better endothelial profile (Int J Cardiol 2017 Oct 1;244:112-118.-- Eur J Clin Pharmacol 2014 Oct;70(10):1181-93)
~Nicorandil Nicorandil 10 mg PO BID as the recommended dose for coronary vasodilatation by the manufacturer
~Nebivolol Nebivolol 2.5-5 mg PO ONCE daily while keeping Heart Rate (HR) between 50-90 bpm
~Folic Acid Folic Acid 5 mg po once daily
~L-Arginine L-Arginine 1 g po TID"
16306427|NCT04631536|Placebo Comparator|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
16306428|NCT04631523||IGD Group|The eligibility criteria were for IGD group as follows: being male in age between 10-18 years old; having accepted the research on a voluntary basis and signed the informed consent and being diagnosed with IGD according to DSM-5. Healthy adolescents in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
16306429|NCT04631523||Healthy Group|The eligibility criteria were for healthy group as follows: being male in age between 10-18 years old and having accepted the research on a voluntary basis and signed the informed consent. The adolescents with IGD in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
16306430|NCT04631510|Experimental|Critically ill patients|Administer gabapentin 300 mg PO at 8 PM for sleep
16306431|NCT04631497||Healthcare workers|The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
16306432|NCT04631484|Experimental|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
16306433|NCT04631484|Placebo Comparator|Placebo|Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
16306434|NCT04631471|Active Comparator|Ibudilast|Increasing dose of Ibudilast up to 100mg/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
16306435|NCT04631471|Placebo Comparator|Placebo|Increasing dose of matched placebo containing mannitol instead of ibudilast up to 10 pills/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
16306436|NCT04631445|Experimental|Ketogenic (KD) + Triplet|Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
16306437|NCT04631445|No Intervention|Non-ketogenic + Triplet|Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
16306438|NCT04631432||Study participation|All participants will complete the same protocol
16306439|NCT04631419|Experimental|Maxillary flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 maxillary arches (experimental side) before canine retraction.
16306440|NCT04631419|Active Comparator|Maxillary control group|Canine retraction will be done on the other side without Laser corticotomy .
16306441|NCT04631419|Experimental|Mandibular flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 mandibular arches (experimental side) before canine retraction.
16306442|NCT04631419|Active Comparator|Mandibular control group|Canine retraction will be done on the other side without Laser corticotomy .
16306443|NCT04631406|Experimental|Neural Stem cells injected intracerebrally|Subject cohorts will be treated with increasing doses of Neural Stem Cells injected intracerebrally using a traditional 3+3 trial design
16306444|NCT04631380|No Intervention|CONTROL|THIS GROUP WILL RECEIVE THE PROTCOLL TREATMENT GIVEN TO PATIENTS COVID -POSITIVE TESTED.
16306445|NCT04631380|Experimental|PRAYER|THIS GROUP WILL RECEIVE THE SAME TREATMENT GIVEN TO THE CONTROL GROUP, PLUS PRAYERS BY THEOLOGIANS WHOSE PRAYERS INTERCEDE IN FAVOR OF THEIR PROMPT RECOVERY
16306446|NCT04631367|Experimental|Kukaa Salama: mHealth intervention|This is a pre-test/post-test trial, therefore all participants will receive the Kukaa Salama mHealth intervention and will be offered a COVID-19 prevention parcel.
16306447|NCT04631354|Experimental|Sequence A|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S-770108 inhaler at a target peak inspiratory flow rate (PIFR) of 15 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 30 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
16306448|NCT04631354|Experimental|Sequence B|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S- 770108 inhaler at a target PIFR of 30 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 15 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
16306449|NCT04631341|Experimental|Melatonin Group|Take melatonin supplements
16306450|NCT04631341|No Intervention|Normal Control Group|Don't take melatonin supplements
16306451|NCT04631328|Experimental|Intervention|Growing Together program
16306452|NCT04631328|No Intervention|Control|
16306453|NCT04631315|Experimental|Intervention|Difluprednate Ophthalmic Emulsion 0.05%
16306454|NCT04631315|Active Comparator|Comparator|Prednisolone Acetate 1% - Phenylephrine 0.12% Ophthalmic Suspension
16306455|NCT04631302|Experimental|Mindfulness|
16306456|NCT04631302|Active Comparator|Light Physical Exercise|
16306457|NCT04631289||metformin/non-metformin group|"Preadmission metformin exposure was defined as a record of metformin usage in Medications on admission in MIMIC-III.
~Metformin group included non-AKI type 2 diabetes patients with preadmission metformin exposure.
~Non-metformin group included non-AKI type 2 diabetes patients without preadmission metformin exposure."
16306458|NCT04631276|Experimental|Single evaluation of H3 receptor occupancy|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 2.5, 25 mg TS-091 prior to an evaluation of H3 recepto occupancy
16306459|NCT04631276|Experimental|Multiple evaluations of H3 receptor occupancy|Subjects received single-dose of 5, 12.5, 25 mg TS-091 prior to Multiple evaluations of H3 recepto occupancy
16306460|NCT04631263|Experimental|Treatment Group|
16306461|NCT04631263|No Intervention|Control Group|
16306462|NCT04631250|Experimental|Right: daylight illumination|The right side of the face was treated using daylight PDT
16306463|NCT04631250|Experimental|Left face: conventional illumination with red light|The left side was treated with conventional PDT.
16306464|NCT04631237||Focus Groups|N=52
16306465|NCT04631237||Cognitive Interviews|N=24
16306466|NCT04631237||Survey|N=600
16306467|NCT04631211|Experimental|Thrombosomes Low Dose|
16306468|NCT04631211|Experimental|Thrombosomes Medium Dose|
16306469|NCT04631211|Experimental|Thrombosomes High Dose|
16306470|NCT04631211|Active Comparator|Liquid Stored Platelets (Control)|
16306471|NCT04631198|No Intervention|No Intervention: GROUP CONTROL|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, expiratory flow acceleration, fractional inspiration in times, diaphragmatic breaths and aspiration when required
16306519|NCT04630873|Experimental|HIGH-LOW VOLUME|initially a high volume of the drug (100IU botulinum toxin diluted in 4 ml) after a safe washout period of 6 months the same patients will be injected with a low volume (100IU botulinum toxin in 2 ml) of the drug.
16306472|NCT04631198|Experimental|Active Comparator: INTERVENTION GROUP|The patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
16306473|NCT04631185|Active Comparator|SPD (Arm A)|Single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD): Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
16306474|NCT04631185|Experimental|WPO (Arm B)|The patients assigned to this arm will receive same pre-op and intraoperative antibiotics similar to SPD (Arm A). In addition, patients in this group will receive one week of post-operative antibiotics (WPO). The post-operative antibiotic will be a first generation Cephalosporin of their surgeon's choice.
16306475|NCT04631159|Experimental|Mobile app group|They are required to wear fitness watches to record steps ,patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel.
16306476|NCT04631159|Placebo Comparator|Control group|they are required to wear fitness watches to record steps ,patients will be asked to self-manage and there is no intervention during the tracking process.
16306477|NCT04631146||Camrelizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
16306478|NCT04631133||Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirmann MRI class.)|"Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification) in the following clinical applications:
~Massive herniated disc in young adults
~Recurrent herniated disc or herniated disc accompanying an L5 sacralization transitional anomaly, treated by discectomy
~Degenerative disc disease at a segment adjacent to a fusion
~Degenerative lesions with or without Modic 1
~Lumbar canal stenosis treated by decompression"
16306479|NCT04631120|Active Comparator|Standard of Care|The proposed arm will involve an initial assessment using the Clinical Dementia Rating (CDR) Scale and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score for patients and Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard educational material from the AA and Association for the Advancement of Retired Persons (AARP). Two phone sessions with a study nurse will occur post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment; a summary of these and professional education on national evidence-based guidelines will be mailed to the patient's PCP of record. Education provided in this arm will be both patient- and caregiver-centered.
16306480|NCT04631120|Experimental|Integrated Dementia Practice Unit Arm|"The integrated practice unit design is a coordinated, team-based, comprehensive, technology enabled, family focused care delivery design comprised of:
~Dementia Central: Nurses, physicians, psychologists, social workers, and other relevant healthcare providers that will meet monthly to review participants progress and issues. Telehealth visits would facilitate home care.
~Dementia Mobile: A nurse and lay health educator team will perform monthly visits, conduct assessments of subjects and provide education/coaching.
~Dementia Link: Technologies that facilitate communication between Dementia Central and Dementia Mobile and foster proactive collaboration/coaching for study subjects include an mHealth software that allows for real time intervention/communication between professional teams and dyads, combined with management of dyads for multiple parameters like health metrics, behavioral measures and stress management and a portal tailored to specific clinical needs."
16306481|NCT04631107|Experimental|AD109 dose1|
16306482|NCT04631107|Experimental|AD109 dose2|
16306483|NCT04631107|Placebo Comparator|Placebo|
16306484|NCT04631094|Experimental|Group 1|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
16306485|NCT04631094|Experimental|Group 2|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
16306486|NCT04631094|Experimental|Group 3|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
16306487|NCT04631094|Experimental|Group 4|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
16306488|NCT04631094|No Intervention|Group 5|The group that will undergo standard hospital blood collection procedure.
16306489|NCT04631081|Active Comparator|Occlusive dressing group|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film according. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing
16306490|NCT04631081|Active Comparator|Surgical group|In surgical group, coverage with a bipedicled palmar island flap will be performed ambulatory, either on admission if patients are directly oriented to the Hand Surgery department, or within 48h of initial visit for patients addressed from the Emergency department. The flap group will be evaluated on admission, at 48h, and 6 weeks.
16306491|NCT04631068|Active Comparator|Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)|"The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.
~Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
16306520|NCT04630860|Experimental|56mg dose group|
16306521|NCT04630860|Experimental|84mg dose group|
16306522|NCT04630860|Experimental|112mg dose group|
16306523|NCT04630847|Experimental|Autism Subjects|These subjects will be administered fecal microbiota transplant by colonoscopy
16306682|NCT04629794|Active Comparator|Demineralized Bone Matrix|
16306492|NCT04631068|Placebo Comparator|J&J TECNIS ZCB00 Intraocular Lens (IOL)|"The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.
~Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
16306493|NCT04631055|Experimental|DCB group|use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.
16306494|NCT04631055|Active Comparator|Stent group|use the Intracranial Stent System made by MicroPort.
16306496|NCT04631029|Experimental|Treatment (carboplatin, etoposide, atezolizumab, entinostat)|"INDUCTION THERAPY: Patients receive carboplatin IV over 30-60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, atezolizumab IV over 30-60 minutes on day 1, and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive atezolizumab IV over 30 minutes on day 1 and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity."
16306499|NCT04631003|Other|Dynamic testing|"There are only one arm in this study. All patients get the same diagnostics and therapy. The preoperative assessments consist of an arthroCT of the wrist as well as the collection of demographic data, accident mechanism, medication intake, etc. within the scope of the usual medical history on the emergency ward. With the arthro-CT, in addition to the fracture balance, the proof of a possible rupture of the scapholunary tape apparatus takes place.
~The dynamic determination of the scapholunary instability takes place during the osteosynthesis of the radius fracture.
~With the dynamic functional test, the change of the scapholunary distance is assessed by illumination by movement of the wrist from the radial abduction into the ulnar abduction, before and after the execution of the osteosynthesis of the distal radius fracture.
~Subsequently, the results of the scapholunary dissociation of the arthro-CT are checked with the results of the intraoperative dynamic test for correlation."
16306500|NCT04630990||Participants Treated With Elagolix|Participants will receive Elagolix according to the local label.
16306501|NCT04630977|Experimental|Multi-Ingredient Pre-workout Supplement|"This group of participants will intake a multi-ingredient supplement around ~15 minutes before every workout.
~The nutritional information of the supplement is: ~90 Kcal. for 25g of powder: carbohydrates -isomaltulose, fructose, maltodextrin- 15 g, essential amino-acids -Beta-alanine: 2.5g, L-arginine AKG: 2.5g, L-Leucine: 800mg, Taurine: 500mg, L-citrulline: 500mg- 6.8 g, Creatine monohydrate: 2.0g, Guarana Extract: 800mg, total caffeine: 160mg, and Magnesium: 112.5mg.
~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).
~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.
~The training sessions and the nutritional guideline will be the same for the three groups."
16306502|NCT04630977|Active Comparator|Isocaloric Placebo|"This group of participants will intake an isocaloric (only carbohydrates: Maltodextrin) supplement comparator, around ~15 minutes before every workout.
~The nutritional information of the supplement is: ~90 Kcal. for 23g of powder.
~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).
~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.
~The training sessions and the nutritional guideline will be the same for the three groups."
16306503|NCT04630977|Sham Comparator|Control|"These participants will drink a non-caloric admixture with the same taste, texture and flavour.
~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).
~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.
~The training sessions and the nutritional guideline will be the same for the three groups."
16306504|NCT04630964|Experimental|psilocybin|25 mg Single Oral Dose
16306505|NCT04630964|Active Comparator|placebo|100 mg Single Oral Dose
16306506|NCT04630951|Experimental|Strength training based on low loads with blood flow restriction (Experimental group I)|"Squat
~Single Deadlift
~Back Squat"
16306507|NCT04630951|Experimental|Strenght training based on high loads (Experimental group II)|"Squat
~Single Deadlift
~Back Squat"
16306508|NCT04630938|Active Comparator|G-M|Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.
16306509|NCT04630938|Active Comparator|G-ML|Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.
16306510|NCT04630938|Placebo Comparator|G-0|Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.
16306513|NCT04630912|Experimental|Acceptance and Commitment Therapy|12 weekly, 90 minute ACT sessions with person with dementia (with a review at week 6)
16306514|NCT04630899|Experimental|Active Joint Mobilization|
16306515|NCT04630899|Experimental|Passive Joint Mobilization|
16306516|NCT04630886|Experimental|Tranexamic acid|The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
16306517|NCT04630886|Active Comparator|Control|The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
16306518|NCT04630873|Active Comparator|LOW-HIGH VOLUME|Initially a low volume of the drug (100IU botulinum toxin diluted in 2 ml) after a safe washout period of 6 months the same patients will be injected with a high volume (100IU botulinum toxin in 4 ml) of the drug.
16306526|NCT04630821|Experimental|Treatment with Dilute Sodium Hypochlorite solution|Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.
16306527|NCT04630808|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
16306528|NCT04630808|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
16306529|NCT04630795||3D printed insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest, while the Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
16306530|NCT04630782||Aim 1|"The investigators will compare PET-MRI imaging and stool biomarkers between patients with VEDOSS/early SSc (n=40) and those with late SSc (n=20) not on immunosuppressive treatment.
~Participants will undergo a PET-MRI scan once at baseline."
16306531|NCT04630782||Aim 2|"In early SSc patients (n=35), the investigators will determine change in biomarker levels from pre-treatment baseline to 6 months (primary end-point) and 12-months (secondary end-point) following MMF treatment.
~Participants will undergo PET-MRI scans at baseline, 6-month and 12-month."
16306532|NCT04630782||Exploratory aim|"In patients with VEDOSS/early SSc (n=15) not on immunosuppressive treatment, the investigators will characterize imaging and stool biomarker changes over one year.
~Participants will undergo PET-MRI scans at baseline and 12-month."
16306533|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^7 cells/dose on Day 1, 8, and 15|
16306534|NCT04630769|Experimental|Monotherapy: IP FT516 at 3 x 10^8 cells/dose on Day 1, 8, and 15|
16306535|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^8 cells/dose on Day 1, 8, and 15|
16306536|NCT04630769|Experimental|Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6|
16306537|NCT04630769|Experimental|Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6|
16306538|NCT04630756|Experimental|AZD4573: Cohorts 1, 2, and 3|"Each cohort (1, 2, and 3) has a different target dose level.
~Participants will receive intravenous ascending doses of AZD4573 once weekly with oral acalabrutinib twice daily continuously in Part A. In Part B, participants will receive the RP2D of AZD4573 from Part A."
16306539|NCT04630743|Other|Cognitive and Behavioral Intervention|Non-pharmacological strategies for the Management of episodic breathlessness
16306540|NCT04630730|Experimental|Recombinant intravesical BCG|"The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment.
~4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine.
~After surgery atezolizumab will be administered in the adjuvant setting for 13 cycles."
16306541|NCT04630717|Active Comparator|control group|normal discussion before general anesthesia induction
16306542|NCT04630717|Active Comparator|Hypnosis group|hypnosis session before general anesthesia induction
16306543|NCT04630704||Non vascular repeatibility|This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
16306544|NCT04630704||Non vascular physiology|This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
16306545|NCT04630704||CLTI physiology|This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
16306546|NCT04630691||Control|Patients with HbA1c around 6,0
16306547|NCT04630691||T2DM|Patients with HbA1c above 6,5
16306548|NCT04630678|Experimental|Virtual Reality Group|"The first group was received conventional physiotherapy and virtual reality therapy for 60 minutes.
~The conventional physiotherapy interventions, including joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles and special for the needs of the child, was applied to both groups. The virtual reality group received that simulate daily life and contain individual scenarios by using the USE-IT system for thirty minutes. USE-IT (Most Rehabilitation, Ankara, Turkey) is a 2D non-immersive virtual reality system that plays games on a 50-inches touchscreen. The children played the matching, plumber, plumber, math, and car wash games in accordance with their reaching map results. The treatment were given three times a week for eight weeks."
16306549|NCT04630678|Active Comparator|Activity Training (Control) Group|The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
16306550|NCT04630665|Other|thin buccal bone|immediate implant placement in thin buccal bone wall socket
16306551|NCT04630665|Other|≥1 buccal bone|immediate implant placement in 1 mm or more buccal bone thickness socket
16306552|NCT04630652|Experimental|Psoriasis treatment with risankizumab|Moderate-to-severe psoriasis treatment with risankizumab for 16 weeks
16306553|NCT04630639|Experimental|Validation Arm|Participants will wear the Sparkle device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
16306554|NCT04630626||Simplify Disc|Extended follow-up of IDE Subjects treated with the Simplify Cervical Artificial Disc during IDE G140154
16306555|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
16306556|NCT04630600|Other|Control|Normal waiting room
16306557|NCT04630600|Experimental|Intervention#1|Waiting room with partially-equipped aquarium (without fish)
16306558|NCT04630600|Experimental|Intervention#2|Waiting room with fully-equipped aquarium (with fish)
16306590|NCT04630353|Experimental|HB-201 Intravenously on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
16306559|NCT04630587|Experimental|Indirect restorations|For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.
16306560|NCT04630587|Active Comparator|Direct restorations|The direct composite restorations are performed based on normal treatment practices. For both direct and indirect restorations, commercially available short-fibre reinforced composite material (everX Flow, GC) is used for core material (replacing dentin) and flowable composite material (G-ænial® Universal Injectable, GC) for surface (replacing enamel), according the manufacturer´s instructions. The occlusion and articulation are checked and adjusted, and the restoration is finished with polishing instruments.
16306561|NCT04630574||Patients with Huntington's disease|Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.
16306562|NCT04630561|Experimental|Intervention Group|Subjects will participate in a 15 minute postural intervention program 2-3 times per week
16306563|NCT04630561|No Intervention|Control Group|Subjects will NOT participate in any postural intervention.
16306564|NCT04630548|Active Comparator|post placental IUD insertion|Following placental delivery, uterine cavity will be examined to exclude the presence of malformations or fibroids. Uterus will be stabilized by grasping it at fundus and the copper IUD (CuT 380 IUD) will be placed (within 10 minutes following the placental delivery) through the uterine wall incision high up in the uterine fundus (either by hand or using its applicator).
16306565|NCT04630548|Active Comparator|post puerperal IUD insertion|IUD will be inserted 6 - 8 weeks following caesarean delivery (during the post puerperal visit).
16306566|NCT04630535||Obstructive Sleep Apnea|Pacient with OSA (AHI≥5) undergoing aorto-bifemoral bypass
16306567|NCT04630535||Without Obstructive Sleep Apnea|Patinets without OSA undergoing aorto-bifemoral bypass
16306568|NCT04630522|Experimental|JMT103- 120 mg SC Q4W|Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.
16306569|NCT04630522|Experimental|JMT103- 120 mg SC Q8W|Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.
16306570|NCT04630522|Experimental|JMT103- 180 mg SC Q8W|Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.
16306571|NCT04630496|Experimental|PRE-OPERATIVE EXERCISE TRACKING|"Participant baseline information will be collected from their electronic medical records.
~After enrollment, participants will be provided a mobile device (Fitbit) to wear for tracking steps for 1 week prior to their scheduled surgery.
~Participants will keep a log of daily steps for the 1 week they are wearing the device and receive one progress check-in call during the week.
~The device and log will be turned in either on a pre-surgery clinic visit or on the day of surgery whichever comes first."
16306572|NCT04630483||Group I: INHA|Inhalational anesthesia (INHA)
16306573|NCT04630483||Group II: TIVA|Total intravenous anesthesia (TIVA)
16306574|NCT04630470|Placebo Comparator|The placebo control group|Each patient received the massage therapy with baby oil on both lower leg areas for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
16306575|NCT04630470|Experimental|The study group|Each patient received the massage therapy with lavender oil on both lower legs for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
16306576|NCT04630457|Active Comparator|Meridium-RoFT|order of existing prosthesis-Meridium prosthesis-RoFT prosthesis
16306577|NCT04630457|Active Comparator|RoFT-Meridium|order of existing prosthesis-RoFT prosthesis-Meridium prosthesis
16306578|NCT04630444|Experimental|Intervention Group|30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).
16306579|NCT04630431||Observational (questionnaire, medical record review)|Patients complete a questionnaire about their preferences, understanding, and attitudes regarding clinical trials. Patients also have their medical records reviewed.
16306580|NCT04630418|Experimental|NanoSilk Cosmo|Participants will receive a 30 mL jar of NanoSilk Cosmo
16306581|NCT04630405|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
16306582|NCT04630405|Active Comparator|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
16306583|NCT04630392|Experimental|Intervention Group|There are two intervention groups: treadmill walking only, whole-body vibration plus treadmill walking.
16306584|NCT04630379|Experimental|Group A (visit with neuro-oncologist)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months to address concerns that are identified via the survey and the domain of concern identified by patient and caregiver.
16306585|NCT04630379|Experimental|Group B (visit with neuro-oncologist and palliative care team)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist and palliative care team monthly for 6 months to address concerns that are identified by the survey and domains of concerns. Caregivers also attend support sessions led by a social worker monthly for 6 months.
16306586|NCT04630379|Active Comparator|Group C (visit with neuro-oncologist, palliative care team)|Patients and primary caregiver complete quality of life portion of the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months and address important concerns that come up on the survey. Patients may also receive palliative care consultation as deemed appropriate by the neuro-oncologist.
16306587|NCT04630366|Experimental|NST-1024|NST-1024 capsules given once daily for up to 14 days
16306588|NCT04630366|Placebo Comparator|Placebo|Matching placebo capsules to NST-1024 given once daily for up to 14 days
16306683|NCT04629794|Active Comparator|Bone Morphogenic Protein|
16306591|NCT04630353|Experimental|HB-201 Intratumorally 7 to 14 days before chemoradiation|Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype.
16306592|NCT04630340|Active Comparator|STEADES-2 (Intervention) arm|"Subjects in the intervention arm will fill up the questionnaire embedded in the STEADES app and be inducted to the use of STEADES-2 device by the CRC. The CRC will assist to download the STEADES app into the subject's smartphone; demonstrate the use of the app and the procedure for the serious games; and linkage to the virtual coach. The subject will use the STEADES-2 device to assess their smoking status and play the game according to the stipulations in the protocol. The STEADES-2 app provides a portal for the subject to interact with the assigned virtual coach and for motivation messages to be delivered to them. The primary outcome is total smoking cessation as measured by
~exhaled breath carbon monoxide using the STEADES-2 device and
~urine cotinine level which indicates the nicotine from the cigarette smoking The secondary outcome is the score using the System Usability Scale (SUS) to assess the use and experience in using the STEADES-2 system"
16306593|NCT04630340|No Intervention|Usual Care|"In the control arm, the subjects will be enrolled into the existing smoking cessation program at the respective polyclinic, which covers smoking cessation advice, together with an exhaled breath analyzed using a commercially available eCO measurement device by a trained nurse counsellor. They will complete a questionnaire and their smoking status will be re-assessed at 12 weeks after their enrolment. The primary outcome is total smoking cessation at the end of the study:
~as measured by the exhaled breath carbon monoxide level determined by the STEADES-2 device and
~urine cotinine levels which is a marker of nicotine level from smoking"
16306594|NCT04630327||Breast Cancer Patients|Breast cancer patients with no history of previously diagnosed depression or anxiety and who have been referred to or have been receiving treatment at Almaty Oncology Center
16306595|NCT04630314||Consecutive patients treated with covered stents post PCI CAP|
16306596|NCT04630301||Measurement of pleural pressure|a. Patients admitted to the Johns Hopkins Hospital with spontaneous, iatrogenic, or tension pneumothorax referred to the Division of Interventional Pulmonology for thoracostomy will be recruited. Using standard sterile technique, a 14fr catheter will be inserted into the pleural space. An electronic manometer (Compass, Medline Industries, Inc.) will be connected in-line to the introducer needle and Ppl will be recorded for 3-5 respiratory cycles. After measurement, the manometer will be removed and the catheter will remain in place per routine standards of practice.
16306597|NCT04630288||Clopidogrel|Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover. Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
16306598|NCT04630288||Ticagrelor|Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor. This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
16306599|NCT04630262|Active Comparator|ATTUNE Cementless CR Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Cruciate Retaining Configuration.
16306600|NCT04630262|Active Comparator|ATTUNE Cementless PS Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Posterior Stabilizing Configuration.
16306601|NCT04630249|Experimental|Listening to Women|This group will receive text-message based SBIRT with phone based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, other drugs including prescription medication), and domestic violence.
16306602|NCT04630249|No Intervention|Treatment as Usual|This group will receive in-person screening and referral to treatment assessment. The same screening tools are used to assess substance abuse and mental health problems in LTW and TAU groups.
16306603|NCT04630236|Other|Ultrasound|
16306604|NCT04630223||intrauterine growth retardation|Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
16306605|NCT04630223||healthy fetuses|Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
16306606|NCT04630210|Experimental|A: Letrozole|Letrozole 2.5 mg/day oral until surgery
16306607|NCT04630210|Experimental|B: Letrozole + atezolizumab|Letrozole 2.5 mg/day oral until surgery and Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
16306608|NCT04630210|Experimental|C: Atezolizumab|Atezolizumab 840 mg IV single-dose 14 days (+/- 4 days) before surgery
16306609|NCT04630210|No Intervention|D: Observation|Observation until surgery
16306643|NCT04630067|Experimental|AZD3427: Cohort 6b|Participants with HFpEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
16306644|NCT04630067|Placebo Comparator|Part B: Placebo|Participants with HFrEF or HFpEF will receive SC dose of placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
16306645|NCT04630054|Experimental|Mask Intervention|"Communities and individuals randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use.
~In the community experiment, every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people.
~In the individual experiment, individuals randomized to the intervention arm will not be asked to recommend masks to others, but will also not be discouraged from recommending mask use to others."
16306610|NCT04630197|Experimental|e-CBT|16 weekly sessions will be conducted through OPTT and consist of approximately 30 slides and interactive therapist videos. The content and format will mirror in-person CBT for OCD. The connection between thoughts, behaviours, emotions, physical reactions, and the environment will be a focus. Moreover, mindfulness, body scanning, self-care, goal setting, thinking errors, the 5-part model, thought records, and ERP will be incorporated. Slides will highlight different topics each week and include general information, an overview of skills, and homework on that topic. The homework will be submitted through OPTT and reviewed by therapists with personalized feedback provided within 3 days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. After each completion of the e-CBT program, participants will be interviewed to investigate their experience using OPTT and their perception of how the treatment went.
16306611|NCT04630184|Experimental|Virtual reality and exercice|This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
16306612|NCT04630184|Placebo Comparator|Placebo and exercice|This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
16306613|NCT04630184|No Intervention|waiting list|This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
16306614|NCT04630171|Experimental|Group 1: VerTouch for labor epidural or spinal anesthesia procedure|VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
16306615|NCT04630171|Active Comparator|Group 2: Ultrasound (US) for labor epidural or spinal anesthesia procedure|Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
16306616|NCT04630171|Active Comparator|Group 3: Control group, palpation for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
16306617|NCT04630171|Experimental|Group 4: VerTouch for lumbar puncture procedure|VerTouch utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
16306618|NCT04630171|Active Comparator|Group 5: Ultrasound (US) for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
16306619|NCT04630171|Active Comparator|Group 6: Control group, palpation for lumbar puncture procedure|Control group, palpation utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
16306620|NCT04630158|Placebo Comparator|SAF312 Placebo|Randomized to a 1:1:1 topical eye drops, twice daily
16306621|NCT04630158|Experimental|SAF312 dose 1|Randomized to a 1:1:1 topical eye drops, twice daily
16306622|NCT04630158|Experimental|SAF312 dose 2|Randomized to a 1:1:1 topical eye drops, twice daily
16306623|NCT04630145|Experimental|Group A: Bedaquiline (BDQ) + Clarithromycin (CAM) + Ethambutol (EB)|Participants will receive BDQ 400 milligrams (mg) (4*100 mg tablets) once daily (qd) from Week 1-2 (loading phase), BDQ 200 mg (2*100mg tablets) bi-weekly (biw) from Week 3 to 48 (maintenance phase) and CAM 400 mg twice daily (2*200 mg tablets) along with EB 500-750 mg qd or maximum daily dose of 1.0 gram for up to Week 48.
16306624|NCT04630145|Active Comparator|Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB|Participants will receive maximum of 4 capsules of RFP 450 mg daily (or maximum daily dose of 600 mg), CAM 400 mg (2*200 mg tablets) twice a day along with EB 500-750 mg daily followed by 2 capsules of RBT 150 mg once a day (qd) or maximum daily dose of 1.0 gram for up to Week 48.
16306625|NCT04630132||Frailty Group|"The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:
~Decreased grip strength
~Self-reported exhaustion
~Unintentional weight loss of more than 4.5 kg over the past year
~Slow walking speed
~Low physical activity"
16306626|NCT04630132||Non-Frailty Group|"The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:
~Decreased grip strength
~Self-reported exhaustion
~Unintentional weight loss of more than 4.5 kg over the past year
~Slow walking speed
~Low physical activity"
16306627|NCT04630119||Study group of female homemakers with chronic neck pain|All female patients aged between 18-55 years with chronic neck pain (pain lasting for more than 3months) who were homemakers were included in the study. All participants reported the presence of pain in the preceding one week
16306628|NCT04630093|Experimental|Panel-based pharmacogenetic genotyping|All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
16306629|NCT04630080|Experimental|Scalp Cooling|
16306630|NCT04630067|Experimental|AZD3427: Cohort 1a|Participants will receive single SC dose A of AZD3427 on Day 1.
16306631|NCT04630067|Experimental|AZD3427: Cohort 2a|Participants will receive single SC dose B of AZD3427 on Day 1.
16306632|NCT04630067|Experimental|AZD3427: Cohort 3a|Participants will receive single SC dose C of AZD3427 on Day 1.
16306633|NCT04630067|Experimental|AZD3427: Cohort 4a|Participants will receive single SC dose D of AZD3427 on Day 1.
16306634|NCT04630067|Experimental|AZD3427: Cohort 5a|Participants will receive single IV dose E of AZD3427 on Day 1.
16306635|NCT04630067|Experimental|AZD3427: Cohort 6a|Participants of Japanese descent will receive single SC dose anticipated equal to the highest dose of AZD3427 in the global cohorts on Day 1.
16306636|NCT04630067|Experimental|AZD3427: Cohort 7a|Participants will receive single SC dose F of AZD3427 on Day 1
16306637|NCT04630067|Placebo Comparator|Part A: Placebo|Participants will receive single SC or IV dose of placebo matched to AZD3427 on Day 1.
16306638|NCT04630067|Experimental|AZD3427: Cohort 1b|Participants with HFrEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
16306639|NCT04630067|Experimental|AZD3427: Cohort 2b|Participants with HFpEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
16306640|NCT04630067|Experimental|AZD3427: Cohort 3b|Participants with HFrEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
16306641|NCT04630067|Experimental|AZD3427: Cohort 4b|Participants with HFpEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
16306642|NCT04630067|Experimental|AZD3427: Cohort 5b|Participants with HFrEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
16306647|NCT04630041|Experimental|Social Needs Assessment|Patients in the Emergency Department will complete a social needs assessment screener that may refer them to 211 services
16306651|NCT04630015||Observational (surveys)|Patients complete surveys over 5-10 minutes at baseline (i.e. before participating in the program), and at 9 and 15 weeks follow up on the impact of COVID-19 on survivorship. Patients also complete a survey assessing how patients rate telehealth classes in the Survivorship Wellness program.
16306652|NCT04630002|Experimental|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
16306653|NCT04630002|Experimental|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
16306654|NCT04630002|Experimental|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
16306655|NCT04629989|Active Comparator|Low-flow nasal cannula|The standard oxygen delivery system (low-flow nasal cannula) is worn by the patient, without the DTM or the SM
16306656|NCT04629989|Experimental|Double-Trunk Mask|The Double-Trunk Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
16306657|NCT04629989|Experimental|Surgical Mask|The Surgical Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
16306658|NCT04629976|Experimental|NCO-48 Fumarate 4 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
16306659|NCT04629976|Experimental|NCO-48 Fumarate 20 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
16306660|NCT04629976|Active Comparator|Tenofovir alafenamide 25 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
16306661|NCT04629963|Experimental|Pain Evaluation|Subjects receive the United Nations Istanbul Protocol (UNIP) evaluation. Subjects will complete the validated, self-administered pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Subjects will receive a non-invasive physical exam and pain assessment by a pain specialist.
16306662|NCT04629950|Experimental|Rimegepant|Participants receive a rimegepant 75 mg tablet orally every other day for 16 weeks.
16306663|NCT04629950|Placebo Comparator|Placebo|Participants receive a placebo tablet matching rimegepant orally every other day for 16 weeks.
16306664|NCT04629937|Experimental|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
16306665|NCT04629924|Experimental|sleeper one|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).
~Osteocentral anesthesia performed with the SleeperOne® 5 system (Dental Hi Tec) loaded with Articaine 1/200000 carpule."
16306666|NCT04629924|Active Comparator|conventional technique|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).
~Anaesthesia using a conventional technique, i.e. a metal syringe loaded with Articaine 1/200000 carpule."
16306667|NCT04629911|Experimental|HFNO arm|Patients will receive HFNO therapy during laryngomicrosurgery.
16306668|NCT04629885|Experimental|Oxytocin 400 IU|1mL Oxytocin 400 IU vaginal gel once daily for 12 weeks
16306669|NCT04629885|Placebo Comparator|Placebo|1mL Placebo vaginal gel once daily for 12 weeks
16306670|NCT04629872|Experimental|endovascular treatment with fingolimod|
16306671|NCT04629872|No Intervention|endovascular treatment without fingolimod|
16306672|NCT04629859|Experimental|study arm|dento skeletal class III patients will undergo a mandibular setback surgery and maxillary advancement
16306673|NCT04629859|Experimental|controlled arm|dento skeletal class III patients will undergo a mandibular setback surgery
16306674|NCT04629846|Experimental|Trastuzumab Plus（+） QL1209 + Docetaxel|Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
16306675|NCT04629846|Active Comparator|Trastuzumab Plus（+） Pertuzumab + Docetaxel|Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery
16306676|NCT04629833|Experimental|MC0518|Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
16306677|NCT04629833|Active Comparator|Best Available Therapy (BAT)|Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
16306678|NCT04629820|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
16306679|NCT04629820|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).
16306685|NCT04629768|Other|Duodenal EMR + PuraStat|PuraStat will be applied to the defect after duodenal EMR of the lesion
16306686|NCT04629755|Experimental|Intervention|The intervention was delivered via a series of daily text messages to mobile phones. Participants first were delivered an introductory text message at 6:00 pm on Day 7 of the study. This message alerted the participants to expect their first suggestion via text message at 8:00 am the following morning. For the next 14 days (Days 8 - 22), participants received one of 14 suggestions in random order. The specific daily suggestions varied in length and complexity: The simplest ones included text messages and a brief audiofile delivered via text; the more complex suggestions included text messages and a link to a web-page, which included text or embedded audiofiles describing why a suggestion was being made, how to engage in the suggested practice, and audiotaped exchanges between members of the production team describing what it was like to try the practices themselves. Some suggestions were supplemented with additional reminder and check-in text messages at noon and 4:00 pm.
16306687|NCT04629755|No Intervention|Control|Assessment only.
16306688|NCT04629742|Experimental|Seawater Pizza|Administration of a seawater pizza
16306689|NCT04629742|Active Comparator|Standard Pizza|Administration of a Standard pizza
16306690|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-Cell Lymphoma|FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma
16306691|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
16306692|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma
16306693|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, CLL|FT819 single-dose monotherapy in adult subjects with r/r CLL
16306694|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, CLL|FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL
16306695|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, CLL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL
16306696|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-ALL|FT819 single-dose monotherapy in adult subjects with r/r B-ALL
16306697|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-ALL|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL
16306698|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-ALL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL
16306699|NCT04629716||Intervention|The intervention group will be comprised of adults 50 and older who report severe or chronic pain, are newly registered for the Medical Marijuana Registry in the State of Florida, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
16306700|NCT04629716||Control|The control group will be comprised of adults 50 and older who report severe or chronic pain, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
16306701|NCT04629703|Active Comparator|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care
16306702|NCT04629703|Placebo Comparator|Placebo (twice daily for 14 days) + Standard of Care|Placebo (twice daily for 14 days) + Standard of Care
16306703|NCT04629690|No Intervention|Control Arm|The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit
16306704|NCT04629690|Experimental|SOLAR arm|The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.
16306705|NCT04629677||Cohort A (questionnaire, medical record review)|Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
16306706|NCT04629677||Cohort B (medical record review)|Patients' medical records are reviewed retrospectively.
16306707|NCT04629664|Active Comparator|FX-322|FX-322, 1 dose (N=24)
16306708|NCT04629664|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
16306709|NCT04629651|Experimental|Captopril|"In phase I, Cohorts of 3 patients each will receive doses of captopril with a goal dose of 150mg total by mouth (PO) daily. Initial dose per patient will start at 12.5 mg daily, which will then be increased on weekly intervals as tolerated. To be administered per the intra-patient dose escalation scheme below
~Phase I:
~Day 0: 12.5mg/day Day 7: 12.5mg twice daily Day 14: 12.5mg three times daily Day 21: 25mg three times daily Day 28: 50mg three times daily
~Phase II: The efficacy of captopril will be assessed in the Phase II portion. Captopril given at Maximum Tolerated Dose - bone marrow evaluation to be done at 6 months"
16306710|NCT04629638||covid -19 positive pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth.
16306711|NCT04629638||covid -19 negative pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-negative pregnant women in the 3rd month after birth.
16306712|NCT04629625|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
16306713|NCT04629625|Active Comparator|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
16306714|NCT04629625|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
16306715|NCT04629612|Experimental|Regional anesthesia|Regional block applied according to surgical area
16306716|NCT04629612|No Intervention|No Regional anesthesia|No regional anesthesia applied
16306774|NCT04629170|Experimental|MAD HV: SYNB8802 (3 x 10^11 live cells)|HV subjects receive SYNB8802 (3 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
16306977|NCT04627675|Experimental|2B: Age > 50; CORVax + pIL-12|Healthy volunteers age > 50 will receive CORVax + pIL-12
16306717|NCT04629599|Experimental|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
16306718|NCT04629599|Active Comparator|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
16306719|NCT04629586||Individuals diagnosed with type 1 diabetes|"T1D Exchange Registry is currently looking for participants:
~Of all ages, genders, races, and ethnic groups
~Living in the United States
~Diagnosed with type 1 diabetes
~Currently taking insulin or have had a pancreatic or islet cell transplant"
16306720|NCT04629573|Active Comparator|Group 1|Epidural Anesthesia
16306721|NCT04629573|Active Comparator|Group 2|General Anesthesia
16306722|NCT04629560|Experimental|Miracle Fruit Arm|Patient will be randomly assigned, by a computer generated randomization, to receive one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures.
16306723|NCT04629560|No Intervention|Control Arm (supportive measures only)|standard of care supportive measures
16306724|NCT04629547|Experimental|Poor sleep treatment group|100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
16306725|NCT04629547|Placebo Comparator|Poor sleep control grop|100 participants will be randomized to take placebo daily at h.s. for two years.
16306726|NCT04629534|Experimental|Group A|
16306727|NCT04629534|Placebo Comparator|Group B|
16306728|NCT04629521|Experimental|CyPass Micro-Stent|CyPass Micro-Stent placed in the angle of the eye at the conclusion of cataract surgery (COMPASS trial)
16306729|NCT04629508|Experimental|Part 1 : Dose Escalation of itacitinib|Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
16306730|NCT04629508|Experimental|Part 2 : Dose Expansion of itacitinib|Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
16306731|NCT04629495|Active Comparator|RAPA (rapamycin) treatment group|Subjects will receive active drug
16306732|NCT04629495|Placebo Comparator|Placebo group|Subjects will receive placebo
16306733|NCT04629482||Children with attention deficit hyperactivity disorder with developmental delays|Children with attention deficit hyperactivity disorder with developmental delays
16306734|NCT04629482||Children with typical development|Children with typical development
16306735|NCT04629469|Experimental|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
16306736|NCT04629456|Experimental|group 1|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
16306737|NCT04629456|Experimental|Group 2|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion(24).
16306738|NCT04629443|Experimental|S64315 (also referred as MIK665) with azacitidine|
16306739|NCT04629430|Experimental|Prebiotic diet|2 servings a day of pre-biotics every day from start of conditioning regimen for HSCT through 100 days following HSCT
16306742|NCT04629404|Experimental|LY03003|
16306743|NCT04629404|Placebo Comparator|Placebo|
16306744|NCT04629391|Active Comparator|Anatomic TSA|The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
16306745|NCT04629391|Experimental|RTSA|The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
16306775|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^12 live cells)|HV subjects receive SYNB8802 (1 x 10^12 live cells) TID for 5 days in the MAD study (Part 1).
16306746|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus pyrazinamide|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
16306747|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus bedaquiline|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
16306748|NCT04629378|Active Comparator|Rifafour standard of care treatment|Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
16306749|NCT04629365|Experimental|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
16306750|NCT04629365|Active Comparator|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
16306751|NCT04629352|Experimental|Verum Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
16306752|NCT04629352|Placebo Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Sham-tDCS, no current will be delivered beyond initial ramp-up time.
16306753|NCT04629339|Experimental|INCB086550|INCB086550 will be administered orally twice a day.
16306754|NCT04629326|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
16306755|NCT04629313||periodontal disease group|"Gingivitis: BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.
~SI Periodontitis: interdental AL of 1-2 mm, PD≤4 mm and no tooth loss SII Periodontitis: interdental AL of 3-4 mm, PD≤5 mm and no tooth loss SIII Periodontitis: interdental AL ≥5 mm, PD≥6 mm SIV Periodontitis: interdental AL ≥5 mm teeth, radiographic bone lose extending to middle or apical third of the root,"
16306756|NCT04629313||periodontal healthy group|consisted of individuals with clinically healthy gingiva
16306757|NCT04629300|Experimental|Supportive Care Mobile Application|"Complete study questionnaires at two time points:
~upon enrollment at baseline prior to randomization
~approximately 12 weeks after the baseline assessment time point.
~Participants will be provided with a study-issued tablet computer to access mobile app and receive a comprehensive tutorial and detailed instructions on how to use the app.
~Participants will have approximately 10 weeks to complete the intervention modules at self initiated pace. The app will provide prompts as reminders to complete the modules.
~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
16306758|NCT04629300|Active Comparator|Usual Care|"Complete study questionnaires at two time points:
~upon enrollment at baseline prior to randomization
~approximately 12 weeks after the baseline assessment time point.
~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
16306759|NCT04629287|Experimental|KPCXM18 for injection|KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route
16306760|NCT04629287|Placebo Comparator|Placebo|Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
16306761|NCT04629274|Experimental|Test of Imotopes® candidates on blood cells of patients with stabilized NMO|To test in vitro the binding of different Imotopes® to class II HLA antigens on PBMC isolated from patients presenting a diagnosed and stabilized neuromyelitis optica spectrum disorders, as well as their ability to generate a cytolytic response directed against the immune cells involved in the maintenance and triggering of the disease (i.e. non-cytolytic T cells recognising the same epitopes and antigen presenting cells (APC) presenting the same epitopes).
16306762|NCT04629261|Experimental|Users with no incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will not receive a discount fee for enrollment.
16306763|NCT04629261|Experimental|Users with incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will do receive a discount fee for enrollment.
16306764|NCT04629261|No Intervention|Non-users|Participants with an age range similar to the intervention groups, who work or lives nearby ECOBICI's bicycle station, that are not enrolled in the ECOBICI program or in a health related program (ex. reducing weight).
16306765|NCT04629248|Experimental|Open Label Treatment: Obinutuzumab|Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).
16306766|NCT04629248|Active Comparator|Open Label Treatment: Tacrolimus|Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).
16306767|NCT04629235|Active Comparator|24 hours of bedrest|- 24 hours of bedrest
16306768|NCT04629235|Experimental|Intervention group|- Wonder around after 8 hours of bedrest
16306769|NCT04629209|Experimental|Arm A: ONC201 with Surgical Resection in Glioblastoma|Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
16306770|NCT04629209|Experimental|Arm B: ONC201 in Glioblastoma|Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
16306771|NCT04629196|Experimental|IV Weight-Based Induction Dose|
16306772|NCT04629196|Active Comparator|Standard Subcutaenous Dose|
16306773|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^11 live cells)|HV subjects receive SYNB8802 (1 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
16306897|NCT04628403|Experimental|massage|
16306776|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 1)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
16306777|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 2)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
16306778|NCT04629170|Placebo Comparator|MAD HV: Placebo|HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
16306779|NCT04629170|Other|Crossover Arm 1: SYNB8802 crossover to Placebo|In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
16306780|NCT04629170|Other|Crossover Arm 2: Placebo crossover to SYNB8802|In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
16306781|NCT04629157|Experimental|All patients|All patients entering the study will undergo paired testing of a lateral flow device using an anterior nasal swab and an RT-PCR using a nose and throat swab.
16306782|NCT04629144|Experimental|Belimumab|Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.
16306783|NCT04629144|Placebo Comparator|Placebo|Placebo of Belimumab administered subcutaneously weekly from week 0 to week 24.
16306784|NCT04629131|Experimental|Cohort 1 TNM002 10 μg/kg/Placebo|Sentinel dosing will be conducted for Cohort 1. Two participants will be dosed (1 with TNM002, 1 with placebo) at least 72 hours prior to subsequent dosing. The remaining participants will only be dosed if no significant safety signals are identified in the sentinel participants. In total, eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
16306785|NCT04629131|Experimental|Cohort 2 TNM002 35 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
16306786|NCT04629131|Experimental|Cohort 3 TNM002 100 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
16306787|NCT04629131|Experimental|Cohort 4 TNM002 250 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
16306788|NCT04629118||Selution SLR™ 018 Drug Eluting Balloon|Subjects will undergo fistuloplasty with the study device - Selution SLR™ 018 Drug Eluting Balloon
16306789|NCT04629105|Active Comparator|Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.
16306790|NCT04629105|Placebo Comparator|Cohort (SARS-CoV-2): Arm 2 (Placebo)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.
16306791|NCT04629105|Active Comparator|Cohort 2 (Flu): Arm 3 (LMSCs)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.
16306792|NCT04629105|Placebo Comparator|Cohort 2 (Flu): Arm 4 (Placebo)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.
16306793|NCT04629066|No Intervention|Usual care|Usual care will include regularly scheduled visits with the clinical heart failure care team and medical therapy as prescribed by that team.
16306794|NCT04629066|Experimental|Remote prescription for aerobic exercise|The exercise prescription will be created by an exercise physiologist after incorporating remotely collected data from a patient directed smartphone app assessing HF symptom severity, vital signs, weight, and blood sugar, and cardiac implant measures of physical activity, heart rate, heart failure volume status and heart rhythm, and Fitbit measures of physical activity.
16306795|NCT04629053||Patients with an acute febrile illness|Patients with acute febrile illness, 4,800 children and 2,400 adults, divided equally across three countries (Laos, Myanmar and Bangladesh) and three age groups: >28 days to <5 years; ≥5 years to <15 years, and ≥15 years of age.
16306796|NCT04629040|Experimental|Intervention|
16306797|NCT04629040|Placebo Comparator|Control|
16306798|NCT04629001||with Covid-19 infection|
16306799|NCT04629001||without Covid-19 infection|
16306801|NCT04628975|Experimental|with transillumination|The nurses will use the Transillumination method for a period P1. Then these same nurses will use the control method (without transillumination) for a period P2.
16306802|NCT04628975|No Intervention|without transillumination (control method)|The nurses will use the control method for a period P1. Then these same nurses will use the Transillumination method for a period P2.
16306803|NCT04628962||Asthma-COPD Overlapped (aCOPD)|30 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
16306804|NCT04628962||Non-Exacerbator COPD (neCOPD)|30 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
16306805|NCT04628962||frequent Excacerbator with Emphysema COPD (eeCOPD)|30 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
16306806|NCT04628962||frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)|30 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
16306807|NCT04628962||Asthma patients (AST)|30 subjects affected by asthma comparable by age and sex with the other recruited subjects
16306808|NCT04628962||Healthy subjects (CTRL)|200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
16306898|NCT04628403|Experimental|lasertherapy|
16306810|NCT04628936|Experimental|KZR-616 45 mg + standard therapy (open-label)|All patients will receive a subcutaneous (SC) injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 through Week 48 (EOT Visit).
16306811|NCT04628923|Experimental|QLB|"With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.
~The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively."
16306812|NCT04628910|Active Comparator|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
16306813|NCT04628910|Experimental|Simulated Flotation Therapy|Participants will utilize the Zerobody dry flotation therapy.
16306814|NCT04628884|Active Comparator|Protamine dosing according the total heparin administrated|The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin
16306815|NCT04628884|Experimental|Protamine dosing according the residual heparin determined by a pharmacokinetic model|The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin
16306819|NCT04628858||Primary group|
16306820|NCT04628845|Placebo Comparator|SRP and endontic treatment without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals without using laser 940nm.
16306821|NCT04628845|Active Comparator|SRP and endodontic treatment with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
16306822|NCT04628832|Experimental|PMP Use Mandate|
16306823|NCT04628832|Experimental|Prescribing Information|
16306824|NCT04628832|Experimental|Prescribing Information + PMP Use Mandate|
16306825|NCT04628832|No Intervention|Control / As-Usual|
16306826|NCT04628819|Experimental|Babybiane Imedia|Patients receive Babybiane Imedia once daily during seven days.
16306827|NCT04628819|Placebo Comparator|Placebo|Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.
16306828|NCT04628806||HSP70CTC|Isolation of circulating tumor cells by HSP70
16306829|NCT04628793|Experimental|Cohort 1|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
16306830|NCT04628793|Experimental|Cohort 2|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
16306831|NCT04628793|Experimental|Cohort 3|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
16306832|NCT04628780|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07209960 at escalating dose levels
16306833|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
16306834|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 2 (RCC)|Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
16306835|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 3 (UC)|Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1
16306839|NCT04628754|Experimental|Intervention|Resistance exercise and dietary protein guidance
16306840|NCT04628754|No Intervention|Control|Usual care
16306841|NCT04628741|Active Comparator|Dynamic Coaching Model|The Dynamic Coaching Model is an established treatment approach that entails training college students with executive function impairments (e.g., those with a history of traumatic brain injury) to rely on their own executive functions in order to problem solve and reason in real-life situations requiring them to do so (e.g., taking college classes).
16306842|NCT04628741|Experimental|Apprenticeship Approach for College Students|The Apprenticeship Approach is a novel treatment approach that incorporates explicit education about: (a) traumatic brain injury definition; (b) traumatic brain injury symptomatology; and (c) individuals who may be able to provide assistance to the individual with traumatic brain injury into the existing Dynamic Coaching Model.
16306974|NCT04627675|Experimental|1A: Age 18-50; CORVax|Healthy volunteers age 18-50 will receive CORVax
16306843|NCT04628728||Current referral letters|One letter will be chosen from the selection of current referral letters (of average quality according to the results of the study mentioned above). Any data that would allow identification of the respective patient (i.e. name, date of birth, social insurance number, address) will be anonymised (not blackened in order not to disturb fluent reading).
16306844|NCT04628728||New referral letters|The other one will be a corrected version of the first letter according to the ELGA (Elektronische Gesundheitsakte) requirements and the identified needs of patients and stakeholders (see Previous Work 1).
16306845|NCT04628715|Experimental|Supervised RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The main goal during this intervention is to breath at resonance frequency which is slower than the usual breathing frequency. Participants will be guided towards this lower breathing frequency by using appropriate breathing techniques and the provision of a breathing pacer during the supervised sessions. During home practice, the participants will be provided with an application which will visualise a breathing pacer at their resonance frequency. At the third session, participants will no longer receive a breathing pacer but are instructed to breath in phase with their heart rate which is visualised on the computer screen instead of the breathing pacer.
16306846|NCT04628715|Sham Comparator|Supervised sham RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The sham-control treatment will follow the same steps as outlined in the supervised intervention arm. However, the participants in this control group will not receive any information regarding their own heart rate and they will not practice at their resonance frequency. Instead, a default mode will be shown during the sessions and in their application for home practice.
16306847|NCT04628715|Experimental|Non-supervised RSA biofeedback|1 short guided session (30 minutes) and daily practice (20 minutes; 4 bouts of 5 minutes) for 5 weeks. The biofeedback protocol will be provided by an application, similar to the supervised protocol but without guidance throughout the sessions, except for the first session. During this first session, the information will be provided about the application and the heart rate sensor (Polar band) which will detect changes in heart rate during the training. In addition, the resonance frequency of the participant will be determined so they can practice breathing at this frequency for the next 5 weeks.
16306848|NCT04628715|No Intervention|No intervention|No intervention is given.
16306849|NCT04628702|Experimental|Intervention group|receives tablet-training
16306850|NCT04628702|No Intervention|Control group|no training
16306851|NCT04628689|Active Comparator|Group 0.25% bupivacaine|30 ml 0.25% bupivacaine
16306852|NCT04628689|Active Comparator|Group 0.375% bupivacaine|0.375% bupivacaine
16306853|NCT04628676|Experimental|TXA group|tranexamic acid added to irrigation solution
16306854|NCT04628676|Experimental|EPN group|epinephrine added to irrigation solution
16306855|NCT04628663|Active Comparator|DEX group|Dexmedetomidine given at a bolus dose of 1,0 μg/kg 10min before induction of anesthesia and then after as a continuous infusion 0,4-0,8 μg/kg/h until the end of the surgery.
16306856|NCT04628663|Placebo Comparator|Placebo group|Normal saline given as a bolus dose 10min before induction of anesthesia and then after as a continuous infusion until the end of the surgery.
16306857|NCT04628637||Control Group|"Inclusion Criterias are consisted of; Not to have known acute, subacute or chronic disease history, Not to suffer from any infection in the last fortnight, Not to be on a particular medication, Presenting to the ED with reasons other than infectious complaints, and Giving their written consent to participate in the study.
~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease"
16306858|NCT04628637||Covid-19 (-) Pneumonia Group|Inclusion Criterias are consisted of; Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria To have nasopharyngeal swab samples taken in the ED were negative for PCR, and To give their informed consent to participate in the study. Exclusion Criteria The exclusion criteria consisted of diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative
16306859|NCT04628637||Covid-19 Infection Group|"This cohort included the patients InculUsion Criteria Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria and whose PCR tests were positive To have Covid-19 PCR tests were positive as a result of contact tracing, Presenting to the ED for further examination.
~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative."
16306860|NCT04628624|Placebo Comparator|Placebo group|Placebo - capsulated, colour matched potato starch (~450mg per capsule) - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
16306861|NCT04628624|Experimental|Green tea 1|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
16306862|NCT04628624|Experimental|Green tea 2|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG + 150mg quercitin and 150mg alpha lipoic acid - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
16306975|NCT04627675|Experimental|1B: Age 18-50; CORVax + pIL-12|Healthy volunteers age 18-50 will receive CORVax + pIL-12
16306863|NCT04628611|Active Comparator|Video laryngoscopy Group (V) using Storz c-mac laryngoscope|video laryngoscope without a channel used for endotracheal intubation, the device used to obtain a view of the larynx, and the endotracheal tube is passed through the vocal cords independent of the device. The device is connected to the monitor via connecting cable
16306864|NCT04628611|Active Comparator|The flexible intubating laryngoscopy Group (F) using Storz flexible intubation video endoscope set|The flexible intubating scope is used to locate the vocal cords and acts as a stylet for the endotracheal tube once the scope is placed into the trachea.This device consists of a flexible insertion cord that contains a small camera at the tip, used to transmit images to camera head. The cord includes a channel for a light source, a working channel for suction or administration of oxygen or local anesthetic, and a cable that allows the operator to flex the tip of the scope. The cord attaches to a handle with a light source,camera head control lever for flexion/extension of the tip, and a working channel port. The device is connected to the monitor via connecting table
16306865|NCT04628598|Experimental|Home visiting pregnant women|The pregnant women in the experimental group will be given education and care with home visits.
16306866|NCT04628598|No Intervention|Control Group|Home visits will not be made to the control group, only the primary care antenatal care will be followed.
16306867|NCT04628585||Subjects with sickle-cell disease|Subjects treated with ex vivo gene therapy drug products in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study
16306868|NCT04628572||Cohort 1|Eligible adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice
16306869|NCT04628559|Active Comparator|Dexmedetomine|Patients recieving Dexmedetomidine.
16306870|NCT04628559|Active Comparator|Ketamine|Patients recieving Ketamine.
16306871|NCT04628559|Placebo Comparator|Placebo|Patients recieving Saline.
16306872|NCT04628546|Experimental|Intervention|
16306873|NCT04628546|No Intervention|Assessment Only|
16306874|NCT04628533|Experimental|Four Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 16 weeks in a well-established behavioral weight loss program.
16306875|NCT04628533|Active Comparator|Six Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 24 weeks in a well-established behavioral weight loss program.
16306876|NCT04628520|Sham Comparator|Maintenance|Oral hygiene instruction and periodontal maintenance
16306877|NCT04628520|Active Comparator|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
16306878|NCT04628520|Active Comparator|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
16306879|NCT04628507||Patients undergoing IVF|
16306880|NCT04628494|Experimental|Epcoritamab (GEN3013; DuoBody®CD3xCD20)|Epcoritamab will be administered in Cycles of 28 days until disease progression
16306881|NCT04628494|Active Comparator|Investigator's choice of chemotherapy|R-GemOx will be administrated in Cycles of 28 days. BR will be administrated in Cycles of 21 days.
16306884|NCT04628468|Experimental|Possibility to use the mobile application without a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and no predefined traditional physiotherapy.
16306885|NCT04628468|Experimental|Possibility to use the mobile application with a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and a predefined number of traditional physiotherapy sessions
16306886|NCT04628468|No Intervention|Usual care|Rehabilitation after hip or knee arthroplasty without the use of a mobile application.
16306887|NCT04628455|Other|Inversion and Snaring|needlescopic inversion, snaring, and excision of the hernia sac using two Suture Grasper Sevice of Mediflex Company and a home made snare
16306888|NCT04628442||TIP-OB (Office-Based)|Those in TIP-OB will be undergoing regularly scheduled office-based procedures at the otolaryngology clinic at UCSF Mount Zion campus. The investigators will be collecting nasal mucus and blood samples during each of their visits to the clinic, up to 9 times.
16306889|NCT04628442||TIP-OR (Operating Room)|Those in TIP-OR will be undergoing regularly scheduled surgeries in the operating room at UCSF Parnassus or Mount Zion campus. The investigators will be collected nasal polyp tissue, nasal mucus if possible, and blood samples during each of their surgeries, up to 9 times. The investigators will also collect inferior turbinate tissue if consented to.
16306890|NCT04628429||Episodic Migraine|All patients who have been diagnosed with migraine without aura or migraine with aura according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
16306891|NCT04628429||Chronic Migraine|All patients who have been diagnosed with chronic migraine (≥15 headache days per month 8 of which with migrainous features) according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
16306892|NCT04628429||Healthy Control|Controls must be healthy (free of any diagnosed chronic disease, acute infection requiring medication, family history or personal history of migraine), chosen to be as similar as possible to migraine patients, in terms of age and sex.
16306893|NCT04628416|Experimental|Experimental arm|
16306894|NCT04628416|Other|Control|
16306895|NCT04628403|No Intervention|control|
16306896|NCT04628403|Experimental|shock waves|
16306899|NCT04628390|Experimental|Experimental|The low-power therapeutic diode laser will be applied with a wavelength 810nm ± 15nm, output power 0-2 W CW / 0-4.8 W peak power (pulse mode), for a time of 20 seconds per centimeter at lo along the buccal surface of the root of the upper and lower teeth.
16306900|NCT04628390|Placebo Comparator|Placebo|A simulation of the application of therapeutic laser will be carried out as a placebo effect, for a time of 20 seconds per centimeter along the vestibular surface of the root of the upper and lower teeth.
16306901|NCT04628377||Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
16306902|NCT04628377||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the culprit vessel after successful revascularization. Those patients have follow-up data after 10 years from index procedure. This cohort is STEMI subgroup derived from Institutional registry of Samsung Medical Center, whose results were previously published (JACC Cardiovascular Intervention. 2019 Apr 8;12(7):607-620.) Among 490 STEMI patients from the overall study cohorts, 309 patients with available angiograms and who were suitable for angiographic FFR and IMR measurement will be analyzed. Primary clinical outcome will be cardiac death at 10 years from index procedure. Secondary outcome will be any myocardial infarction, ischemia-driven revascularization, definite or probable stent thrombosis, congestive heart failure admission at 10 years from index procedure.
16306903|NCT04628351|Experimental|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
16306904|NCT04628351|No Intervention|Control Group|Routine patient training was given to the patients in the control group by a nurse working in the clinic.
16306905|NCT04628338|Experimental|IFN-γ|100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)
16306906|NCT04628325|Experimental|high dose furosemide plus HSS|Patients treated high dose furosemide plus HSS
16306907|NCT04628325|Active Comparator|high dose furosemide alone|Patients treated high dose furosemide alone
16306908|NCT04628312|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
16306909|NCT04628299|Placebo Comparator|Sham Laser|A non-emission laser will be applied in plantar fascia
16306910|NCT04628299|Experimental|Experimental group Myofascial Induction|Myofascial Induction in plantar fascia
16306911|NCT04628286|Placebo Comparator|Sham Laser|Placebo laser application in plantar fascia
16306912|NCT04628286|Experimental|Experimental group Myofascial Induction|Myofascial Induction technique application in plantar fascia
16306913|NCT04628273||radiolucent stone group|
16306914|NCT04628273||radiopaque stone group|
16306915|NCT04628247|Experimental|Study group|They will receive the same traditional physical therapy exercise program in addition to gait training on spring gravity bar for one hour
16306916|NCT04628234||Patients with an onco-hematologic solid tumor in palliative care|
16306917|NCT04628208||Negative for COVID-19|Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
16306918|NCT04628208||Positive for COVID-19|Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
16306919|NCT04628169||group A|group A : placental tissue of 30 patients with placenta accreta
16306920|NCT04628169||group B|group B : placental tissue of 20 normal pregnancy as a control group
16306921|NCT04628156||Outpatients in Cerebral Palsy Greece - Open Door|Outpatients with a diagnosis of cerebral palsy
16306922|NCT04628143|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
16306923|NCT04628143|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
16306924|NCT04628117|No Intervention|Control|Nutritional counselling by individualized nutritional plan for 8 weeks.
16306925|NCT04628117|Experimental|Oral nutritional supplementation|Nutritional counselling by individualized nutritional plan plus oral nutritional supplementation for renal disease (237 mls per day) for 8 weeks.
16306926|NCT04628104||COVID-19 patients presented with myocardial infarction|
16306927|NCT04628104||Non-COVID-19 patients presented with myocardial infarction|
16306928|NCT04628091|Experimental|Test group|Test group is composed of 20 women of reproductive age devoid of any pathology coming to the hospital for a salpingectomy for contraceptive purposes or for a total hysterectomy.
16306929|NCT04628065|Experimental|Intervention Arm|Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
16306930|NCT04628052|Experimental|Music|
16306931|NCT04628052|No Intervention|No-Music|
16306932|NCT04628039|Other|Rehabilitation-focused program|Subjects will receive multiple services in a rehabilitation-focused program
16306933|NCT04628026|Experimental|1|standard chemotherapy in combination with venetoclax
16306934|NCT04628026|Placebo Comparator|2|standard chemotherapy in combination with placebo
16306935|NCT04628013|Experimental|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied for a single treatment in Aim 1 and after a washout period, will be applied 3x/week for 2-weeks (6 sessions) for Aim 2.
16306936|NCT04628000||Vitamin D deficiency and COVID19|Vitamin D deficiency and COVID19
16306937|NCT04627987||Main study|Patients with severe, symptomatic aortic stenosis will be recruited and followed up with primary outcome of heart failure death and hospitalisation (n=192). Of these, 170 will have an implantable cardiac monitor placed to detect presence and burden of non-sustained VT.
16306976|NCT04627675|Experimental|2A: Age > 50; CORVax|Healthy volunteers age > 50 will receive CORVax
16306938|NCT04627974||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
16306939|NCT04627961|Experimental|Patient|Patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease
16306940|NCT04627935||COPD patients|Patients with a diagnosis of COPD aged over 60 years
16306941|NCT04627922|Experimental|N-acetyl cysteine (NAC) & cognitive behavioral therapy|N-acetyl cysteine (NAC) & cognitive behavioral therapy experimental arm consists of 30 daily cigarette smokers with current TUD and CUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and CUD.
16306942|NCT04627922|Placebo Comparator|Placebo Comparator: Placebo & cognitive behavioral therapy|Placebo comparator & cognitive behavioral therapy arm consists of 30 daily cigarette smokers with current TUD and CUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and CUD.
16306943|NCT04627909||Group under Robot treatment|Interaction with the Humanoid Robot for 15 minutes
16306944|NCT04627909||Group involved with medical personnel|Interaction with medical personnel for 15 minutes
16306945|NCT04627909||Control group|Exclusive interaction with the caregiver for 15 minutes
16306946|NCT04627896|Experimental|Katty focal therapy|Patients fulfilling inclusion criteria undergo focal treatment with Trinity-guided Katty device
16306947|NCT04627883|Other|Group 1:2|Patients in the control group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2.
16306948|NCT04627883|Other|Group 2:1|Patients in the IRV group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1.
16306949|NCT04627870|Experimental|DCB group|use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis
16306950|NCT04627870|Active Comparator|PTA group|use PTA balloon to treat intracranial in-stent restenosis
16306951|NCT04627857|Active Comparator|Arm 1: Manual toothbrush|
16306952|NCT04627857|Experimental|Arm 2: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
16306953|NCT04627857|Experimental|Arm 3: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
16306954|NCT04627857|Experimental|Arm 4: Sonic toothbrush (Philips Sonicare ProtectiveClean) and water flosser|
16306955|NCT04627844|Placebo Comparator|Delayed Feeds|"Patients will receive tube feeds beginning at 6 hours after PEG tube placement. This is our institutions current practice
~Intervention Type: Dietary"
16306956|NCT04627844|Experimental|Immediate Feeds|"Patients will receive tube feeds beginning immediately after PEG tube placement.
~Intervention Type: Dietary"
16306957|NCT04627831|Experimental|CE-Iohexol|Subject is randomized to receive CE-Iohexol Injection
16306958|NCT04627831|Active Comparator|Omnipaque™ (Iohexol)|Subject is randomized to receive Omnipaque™ Iohexol Injection
16306960|NCT04627805|No Intervention|Phase 2: Usual Care|The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
16306961|NCT04627805|Experimental|Phase 3: MyPath Pilot|Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
16306962|NCT04627792|Other|Waitlist Group|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
16306963|NCT04627779|Experimental|Male Group|
16306964|NCT04627779|Active Comparator|Female Group|
16306965|NCT04627766|Experimental|Monitored children|PICU Children that will be monitored with the device
16306966|NCT04627753|Experimental|Lenalidomide and Rituximab therapy|"The clinical trial drug is administered in one cycle for 28 days and is administered as follows.
~Drug : Rituximab It will be administered 375 mg/m² IV infusion Day 1. (Rituximab: up to 6 cycles)
~Drug : Lenalidomide It will be administred 20 mg PO day 1 -21.
~The medication is taken for up to 2 years, and if there is no recurrence, it is stopped after 2 years
~, Or stop when disease progression is confirmed during the administration period."
16306967|NCT04627740|Experimental|CART treatment|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
16306968|NCT04627727|Experimental|low FODMAP diet|
16306969|NCT04627714|Experimental|Early Fencing|"patients of the Early Fencing arm will start adapted fencing practice (1h30/week) within 4 weeks after the breast surgery and for a duration of 3 months"
16306970|NCT04627714|Experimental|Delayed Fencing|"patients of the Delayed Fencing arm will start adapted fencing practice (1h30/week) 3 months after the breast surgery and for a duration of 3 months"
16306971|NCT04627701|Experimental|ClearRing Device|
16306972|NCT04627688|Active Comparator|Standard dietary advices|
16306973|NCT04627688|Experimental|Time restricted feeding|
16306978|NCT04627662|Other|Care Partners|Based on previous work, we will recruit up to 75 Care Partners and their 75 care recipients with dementia. This allows for 20% attrition. We will recruit participants from three Alzheimer's Disease Research Centers (ADRCs) located at OHSU, University of Kentucky (UK) and Emory University. We anticipate we will recruit equal numbers from each site (e.g. 25 families from each site); however, these are not firm quotas. We may have more from one site than another.
16306979|NCT04627636|Experimental|study group|which treated with MTrPs release combined with shockwave therapy and conventional program
16306980|NCT04627636|Experimental|control group|which treated with conventional physical therapy program
16306981|NCT04627623||Screened arm|"6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).
~From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies."
16306982|NCT04627584|Active Comparator|MW33 injection-1200mg|
16306983|NCT04627584|Active Comparator|MW33 injection-2400mg|
16306984|NCT04627584|Placebo Comparator|Placebo|
16306985|NCT04627571||Patient Population|Patients diagnosed with neurotrophic keratopathy.
16306986|NCT04627558||stroke patients, balance assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
16306987|NCT04627545|Experimental|IVF: 2h exposure|Half of a patients' oocytes will be subjected to 2h exposure to sperm
16306988|NCT04627545|Active Comparator|IVF: overnight exposure|Half of a patients' oocytes will be subjected to overnight incubation with sperm (=usual practice).
16306989|NCT04627532|Experimental|Treatment|PF-07304814 assignment
16306990|NCT04627532|Placebo Comparator|Placebo|Placebo assigned
16306991|NCT04627519|No Intervention|SoC alone|Standard of Care alone (days 1 to 9)
16306992|NCT04627519|Experimental|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after meal (every 12 hours) for 9 days to be provided together with Standard of Care.
16306993|NCT04627506|No Intervention|Control Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.
~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design.
~Standardized anesthesia and surgical management will be conducted according to routine institutional practice."
16306994|NCT04627506|Experimental|Study Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.
~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
16306995|NCT04627493|No Intervention|Waitlist (Control)|Usual care
16306996|NCT04627493|Experimental|Exercise|Online exercise program
16306997|NCT04627480|Experimental|Experiment Arm|Active Fisher Wallace device for full 8 weeks
16306998|NCT04627480|Sham Comparator|Sham Arm|Sham Fisher Wallace device for 4 weeks, then cross over at 4 weeks to active device.
16306999|NCT04627467|Experimental|Chloroquine 150mg base|Volunteers received chloroquine tablets orally at days 0, 15, 30, 45, 60 and 75.
16307000|NCT04627454|Experimental|dynamic cervical implant|dynamic cervical implant in treatment of cervical disc disease
16307001|NCT04627454|Experimental|discectomy|insertion of dynamic cervical implant post cervical discectomy single level
16307002|NCT04627441|Experimental|TESS-EES|Transcutaneous Electrical Spinal Stimulation (TESS), used during the first month of training sessions, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
16307003|NCT04627428|Experimental|50,000 cells|Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.
16307004|NCT04627428|Experimental|150,000 cells|Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.
16307005|NCT04627428|Experimental|250,000 cells|Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.
16307006|NCT04627415|Experimental|Face to Face Treatment|The F2F version of PEAK contains 10 BPE sessions (1.5 hours each). Session content includes: 1) Introduction to ADHD, 2) Attending, Rewards and Ignoring, 3) General Behavior Management Strategies, 4) Problem-Solving Approach, 5) Preventive Intervention, 6) Instructive Interventions, 7) Response Strategies, 8) Extending What Works to Community Settings, 9) Promoting Early Reading and Math Skills, and 10) Effective Communication Strategies. Each session contains didactic instruction and activities designed to enhance engagement. Sessions include video examples and interactive activities. Weekly homework is assigned for strategy practice. At the start of the following session, the leader checks in with families on the use of the chosen strategy. The session leader praises successes and troubleshoots challenges. The intervention also includes optimistic training which aims to identify/improve pessimistic thinking patterns that parents have about their parenting and child's behaviors.
16307007|NCT04627415|Experimental|Online Treatment|For the online version of the program, in addition to content regarding an overview of ADHD, the initial session consists of brief video clips demonstrating how to access PEAK sessions on the Internet, and an orientation to online content (e.g., handouts, interactive chat sessions, research team contact links). Prior to the session, parents are provided with password-protected individual access codes. Similar to the F2F program, check-ins are provided weekly via each parent's preferred mode of communication (i.e., text, internet, phone) to query strategies implemented, praise success, and troubleshoot alternative strategies. Parents in the online condition will also receive supplemental optimistic training to improve pessimistic thinking patterns about their child and parenting.
16307008|NCT04627415|Other|Waitlist Control|The comparison condition is a waitlist control group that will receive no intervention throughout the intervention timeframe. Instead, participants will receive wellness information about typical child development and constructs unrelated to the intervention content. Subsequent to the 12-month follow-up assessment, they will be provided access to the online version of the program. To encourage ongoing participation in the absence of services, parents will be informed that, at the end of the intervention timeframe, they will receive support (i.e., weekly contact to answer questions) while they complete the online program.
16307009|NCT04627402|Experimental|Injection combo agents|Intravitreous injection of triamcinolone acetonide (TA) and conbercept.
16307010|NCT04627402|Active Comparator|Injection single agent|Intravitreous injection of conbercept only.
16307011|NCT04627389|Experimental|study arm|20 patients with a unilateral cleft lip will be repaired with orbicularis oris muscle Z-plasty modification of modified Millard technique
16307012|NCT04627389|Active Comparator|controlled arm|20 patients with a unilateral cleft lip will be repaired with modified Millard technique
16307013|NCT04627376|No Intervention|Control|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.
16307014|NCT04627376|Experimental|Intervention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
16307015|NCT04627363|Experimental|HAIC plus Bevacizumab and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.
16307016|NCT04627350||LDCT|Single arm - all patients undergo low-dose CT (LDCT) examination of lungs
16307017|NCT04627337|Experimental|Saccharomyces boulardii (1 capsule of 250 ug BID) + Dietary advice|Patients received 1 capsule of Saccharomyces boulardii 250 ug BID plus dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
16307018|NCT04627337|Active Comparator|Dietary advice without medication|Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
16307019|NCT04627324|Experimental|The smart toothbrush and smart mirror (STM) system toothbrushing instruction (TBI)|Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
16307020|NCT04627324|Active Comparator|conventional toothbrushing instruction (TBI)|Participants received using conventional TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
16307021|NCT04627298|Active Comparator|Video Game|This arm tests use of video game to help preteens in the decision to pursue HPV vaccination. Participants in the intervention group are asked to play the Land of Secret Gardens game and complete 3 tasks: (1) play a shield game with blue spikey virus balls, (2) find hidden objects in 4 different garden sheds, and (3) create a potion (vaccine). Participants in the intervention arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance, the Physical/Emotional/Narrative Presence Scale (PENS) to gauge preteens' immersion in the game, and game play experience.
16307022|NCT04627298|No Intervention|No Video Game|This arm does not test the video game. Participants in the comparison arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance.
16307023|NCT04627285|Experimental|Lacosamide|Subjects in this arm will receive various single doses of lacosamide
16307024|NCT04627272|Experimental|AutoDX and Gold Standard|A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
16307025|NCT04627259||patient|patients with thumb pain or functional problems
16307026|NCT04627246|Experimental|PEP-DC + Nivolumab + SOC|PEP-DC: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides Nivolumab SOC: Standard of Care Chemotherapy
16307027|NCT04627233|Placebo Comparator|No intervention:control group|
16307028|NCT04627233|Experimental|Experimental:Intervention group|
16307029|NCT04627220||group 1|Group 1: Pressure of arterial oxygen> 200 mmHg during the coronary surgery
16307030|NCT04627220||group 2|Group 2: Pressure of arterial oxygen<200 mmHg and >80 mmHg during the coronary surgery
16307031|NCT04627207|Experimental|Reference-Reference-Test|Sequence 1
16307032|NCT04627207|Experimental|Reference-Test-Reference|Sequence 2
16307033|NCT04627207|Experimental|Test-Reference-Reference|Sequence 3
16307034|NCT04627194||Mild and asymptomatic COVID-19 patients|Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
16307035|NCT04627194||Moderate severity COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia] at the time of hospitalization.
16307036|NCT04627194||Severe-to-critical COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) < 90% on room air] or for critical COVID-19 disease presentation [including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium] at the time of hospitalization.
16307037|NCT04627194||COVID-19 survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
16307038|NCT04627194||COVID-19 non-survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
16307039|NCT04627181|Experimental|FCM + placebo|"Ferric carboxymaltose: Single dose, 500 mg
~Placebo: Single dose"
16307040|NCT04627181|Experimental|B12 + placebo|"Hydroxycobalamine: Single dose, 1000 mcg
~Placebo: Single dose"
16307041|NCT04627181|Experimental|FCM +B12|"Ferric carboxymaltose: Single dose, 500 mg
~Hydroxycobalamine: Single dose, 1000 mcg"
16307043|NCT04627168|Experimental|Spinal cord injured persons|Persons living with spinal cord injury presenting with constipation due to neurogenic bowel dysfunction.
16307044|NCT04627168|Experimental|Persons without neurogenic bowel dysfunction|Abled-bodied persons with chronic constipation.
16307045|NCT04627155|Experimental|7mg dose group|
16307046|NCT04627155|Experimental|14mg dose group|
16307047|NCT04627142|Experimental|Expansion dose 1|Part C: Combination therapy expansion part
16307048|NCT04627142|Experimental|Expansion dose 2|Part C: Combination therapy expansion part
16307049|NCT04627129|Experimental|SHR2554+Itraconazole|SHR2554 50 mg QD on Day 1 and Day 8, Itraconazole 200 mg once daily (QD) from Study Day 4 - 12
16307050|NCT04627116|Experimental|Tecarfarin 10mg|
16307051|NCT04627116|Experimental|Tecarfarin 20mg|
16307052|NCT04627116|Experimental|Tecarfarin 30mg|
16307053|NCT04627116|Experimental|Tecarfarin 40mg|
16307054|NCT04627103|Experimental|Device Placement|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.
16307055|NCT04627090||LCH Patients|Adult patients with LCH, diagnosed starting from January 2001
16307056|NCT04627077||SIC drug therapy patients|Patients with a cancer diagnosis currently being treated at SIC clinic
16307057|NCT04627064|Experimental|Abemaciclib-Arm 1|"Arm 1
~Abemaciclib will be taken at a standard recommended starting dose 2X daily during 28 day study cycles and will be taken until radiographic progression, unacceptable toxicity or withdrawal.
~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both Arm 1 and Arm 2."
16307058|NCT04627064|Experimental|Abemaciclib and MK-6482-Arm 2|"Arm 2
~Arm 2 will start enrolling only after there is experience with Arm 1 to see what abemaciclib effects are when given alone,
~Dose escalation will occur following a 3+3 design.
~Abemaciclib will be taken 2X daily uring 28 day study cycle
~MK-6482 will be taken 1x daily during 28 day study cycle
~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both arms."
16307059|NCT04627051|Experimental|Dysfunction AV graft|Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty
16307062|NCT04627025|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
16307063|NCT04627025|Placebo Comparator|Placebo|Placebo for apraglutide, SC injection once weekly
16307064|NCT04626999|Active Comparator|Synovial fluid COMP|Knee joint fluid is aspirated for ELISA COMP examination
16307065|NCT04626999|Active Comparator|MRI T2 Mapping|Affected knee is subjected to an MRI T2 mapping examination to see the condition of cartilage
16307066|NCT04626999|Active Comparator|Instability Examination|Lachmant Test, Pivot shift test and Rolimeter Measurement
16307069|NCT04626973|Experimental|Intensive-targeting group|
16307070|NCT04626973|Active Comparator|Conventional-targeting group|
16307071|NCT04626960||Patient|OAB patients
16307072|NCT04626960||Control|Healthy
16307073|NCT04626947|Other|Open label|Single arm
16307074|NCT04626934|Active Comparator|control group|Patients in the control group will recieve conventional occupational therapy treatment: 3 weeks of all together 12 sessions, 45 minutes each.
16307075|NCT04626934|Experimental|Intervention group|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
16307076|NCT04626921|Experimental|Active treatment with 30 mg of CNM-Au8|Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.
16307077|NCT04626908|Experimental|Administration of GC022F CAR-T cells|Each subject receive GC022F CAR T-cells by intravenous infusion
16307078|NCT04626895|Other|Scalp Cooling|Patients who be will using the scalp cooling device during chemotherapy will be enrolled in tis arm
16307079|NCT04626895|No Intervention|Non Scalp-Cooling|Patients who do not use scalp cooling device during chemotherapy will be enrolled in this arm.
16307080|NCT04626882|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
16307112|NCT04626739|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) non-Hodgkin lymphoma
16307081|NCT04626882|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after PCI for IRA (during primary PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
16307082|NCT04626869|Active Comparator|Interscalene block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) to detect the brachial plexus. At the cervical level 5-6, the posterior brachial plexus will be approached as in-plane from the posterior with the needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed with stimulation in the upper extremity muscles with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
16307083|NCT04626869|Active Comparator|Anterior suprascapular nerve block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) will be placed in the suprascapular region in a coronal oblique manner. The omohyoid muscle, under it the suprascapular nerve, the brachial plexus and the subclavian artery will be identified. The suprascapular nerve will be approached from the posterior as in-plane with a needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed by stimulation in the supraspinous muscle with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
16307084|NCT04626856|Experimental|Low dosage in adults|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
16307085|NCT04626856|Experimental|Medium dosage in adults|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
16307086|NCT04626856|Experimental|High dosage in adults|High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
16307087|NCT04626856|Experimental|Low dosage in adolescents|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
16307088|NCT04626856|Experimental|Medium dosage in adolescents|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
16307089|NCT04626856|Experimental|High dosage in adolescents|High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
16307090|NCT04626856|Experimental|Low dosage in infants (7-71 months old)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
16307091|NCT04626856|Experimental|Medium dosage in infants (7-71 months old)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
16307092|NCT04626856|Experimental|High dosage in infants (7-71 months old)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
16307093|NCT04626856|Experimental|Low dosage in infants (2-6 months old, two-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
16307094|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, two-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
16307095|NCT04626856|Experimental|High dosage in infants (2-6 months old, two-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
16307096|NCT04626856|Experimental|Low dosage in infants (2-6 months old, three-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
16307097|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, three-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
16307098|NCT04626856|Experimental|High dosage in infants (2-6 months old, three-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
16307099|NCT04626856|Placebo Comparator|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
16307100|NCT04626856|Placebo Comparator|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
16307101|NCT04626843|Experimental|Intermittent fasting|
16307102|NCT04626830|Experimental|Mobile Application Intervention|Participants in the intervention group will receive 6 months the mobile application (OKTED) for improving symptoms and adherence to oral anticancer agents. The mobile application will consist of three modules. The first module will include OAA-specific information, a calendar in which start/end dates can be record, and a medication reminder. The second module will include information about common and urgent symptoms and recommendations for the management of these symptoms. The last module will comprise a question and answer section.
16307103|NCT04626830|No Intervention|Standard Care|Participants in the control group will receive standard oncology care only.
16307104|NCT04626817|Active Comparator|Isotretinoin receiving group|Isotretinoin receiving group for acne vulgaris
16307105|NCT04626817|Placebo Comparator|Local treatment receiving group|Local treatment receiving group for acne vulgaris
16307106|NCT04626804|Experimental|1 Test the usability, perceptions, and acceptability of R/S|Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.
16307107|NCT04626791|Experimental|Treatment (modified VR-CAP, acalabrutinib)|"CYCLES 1, 3, AND 5: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive bortezomib SC on days 1, 8, and 15, rituximab (or rituximab and hyaluronidase human) IV, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1, and prednisone PO on days 1-5.
~CYCLES 2, 4, AND 6: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive rituximab (or rituximab and hyaluronidase human) IV on day 1 and cytarabine IV on days 1-2.
~Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16307108|NCT04626778|Active Comparator|Peroxyl|1.5% Hydrogen Peroxide mouthwash
16307109|NCT04626778|Placebo Comparator|placebo mouthwash|0.0% Hydrogen peroxide mouthwash
16307110|NCT04626765|Experimental|volunteer|The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens
16307111|NCT04626752|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) Multiple Myeloma (MM)
16307113|NCT04626726|Experimental|Volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with acute B lymphocytic leukemia expressing specific target antigens
16307114|NCT04626713|Experimental|Intervention|Participants will undergo a brief interactive psychoeducation session four times a week for two weeks. For each session, participants will wear a commercially available Electroencephalography (EEG) headset and play a downloaded online game for a total of 30 minutes. Participants can feel free to play the game for more than the instructed frequency during their 2-week intervention participation.
16307115|NCT04626713|No Intervention|Waitlist control|Participants in Waitlist Control will receive no intervention in the first four weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
16307116|NCT04626700|Experimental|iNAP|
16307117|NCT04626700|Active Comparator|CPAP|
16307118|NCT04626687|Experimental|test DCB group|use the DCB made by Acotec Scientific
16307119|NCT04626687|Active Comparator|RESTORE DCB group|use the DCB made by CARDIONOVUM GmbH
16307120|NCT04626674|Experimental|SRP-9001|Participants will receive a single intravenous (IV) infusion of SRP-9001 on Day 1.
16307121|NCT04626661||Health volunteers|The study population will consist, initially, of healthy volunteers. This group was chosen to perform measurements on, to eliminate the effect of critical illness and interventions on the critically ill patients and to better explore the effect of time-since-application of the 5-aminolevulinic acid-patches.
16307122|NCT04626661||Patients admitted to the ICU after neurosurgery|This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
16307123|NCT04626648|No Intervention|Surgery without intraoperative pause|Surgical procedure without pause
16307124|NCT04626648|Experimental|Surgery with intraoperative pause|Three-minute long intraoperative pause, including a sugar-containing drink
16307125|NCT04626635|Experimental|Dose Escalation|Variety of mixed advanced solid tumor types
16307126|NCT04626635|Experimental|Dose Expansion A|Microsatellite-Stable Colorectal Cancer (MSS CRC)
16307127|NCT04626635|Experimental|Dose Expansion B|Triple Negative Breast Cancer (TNBC)
16307128|NCT04626635|Experimental|Dose Expansion C|Cutaneous Squamous Cell Carcinoma (CSCC)
16307129|NCT04626635|Experimental|Dose Expansion D|Non-Small Cell Lung Cancer (NSCLC)
16307130|NCT04626622||ARVI and influenza prophylaxis with Kagocel (n=50)|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.
~Group of patients receiving Kagocel for prevention of ARVI and influenza"
16307131|NCT04626622||ARVI and influenza prophylaxis without any antiviral medicines (n=25)|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
16307132|NCT04626609||EoE group|Patients with confirmed eosinophilic esophagitis
16307133|NCT04626609||GERD group|Patients with gastro-esophageal reﬂux disease
16307134|NCT04626609||Control group|Individuals with no esophageal disease
16307135|NCT04626596|Experimental|ENG implant|Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
16307136|NCT04626583|Active Comparator|Low dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 µL at the low dose level.
16307137|NCT04626583|Active Comparator|Medium dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL at the medium dose level.
16307138|NCT04626583|Active Comparator|High dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 µL each at the high dose level.
16307139|NCT04626570|Experimental|Cognitive and Behavioural Therapy plus Management as usual|12 sessions of CBT during 18 weeks AND management of obesity with nutritional and dietary treatment as usual
16307140|NCT04626570|No Intervention|Management as usual|management of obesity with nutritional and dietary treatment as usual
16307141|NCT04626557||Women with astma|At the 7th -14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
16307142|NCT04626557||Women without asthma|At the 7th - 14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
16307143|NCT04626544||Dizziness|Patients with dizziness referred to a secondary referral center
16307144|NCT04626544||Healthy controls|Healthy controls without dizziness or neck pain symptoms for the last 3 months
16307145|NCT04626531|Experimental|Intervention Group|After the pre-tests (Self-Care Activities, Self-Efficacy, Quality of Life) , the patients were given web based education and containing information and recommendations on self-management strategies for three months.
16307146|NCT04626531|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
16307156|NCT04626492||F0|Normal control group
16307157|NCT04626492||F1|Grade 1 of liver fibrosis
16307158|NCT04626492||F2|Grade 2 of liver fibrosis
16307159|NCT04626492||F3|Grade 3 of liver fibrosis
16307160|NCT04626492||F4|Hepatic cirrhosis
16307165|NCT04626466||Non-metastatic prostate, rectum, anal canal, endometrium, or cervix carcinoma Radiotherapy treatment|
16307166|NCT04626453|Experimental|sedentary older adults with Type 2 Diabetes|Sedentary older adults with Type 2 Diabetes as the intervention group will do a 2-month home exercise.
16307167|NCT04626453|No Intervention|Active older adults with Type 2 Diabetes|Active older adults with Type 2 Diabetes will not do exercise.
16307168|NCT04626453|No Intervention|Healthy older adults|Healthy older adults will not do exercise.
16307169|NCT04626440||Group 1|Group 1 [(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available]
16307170|NCT04626440||Group 2|subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
16307171|NCT04626440||Group 3|Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 [(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC].
16307172|NCT04626427|Experimental|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
16307173|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fed condition|Single dose of 30 mg ferric maltol capsule in a fed condition
16307174|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fasted condition|Single dose of 30 mg ferric maltol capsule in a fasted condition
16307175|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fed condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
16307176|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fasted condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
16307177|NCT04626401|Placebo Comparator|Control diet during immobilisation|A 2 day controlled dietary intervention.
16307178|NCT04626401|Experimental|Branched chain amino acid restricted diet during immobilisation|A 2 day branched chain amino acid restricted dietary intervention.
16307179|NCT04626375|Placebo Comparator|Placebo|Placebo (2 vials per os without active substance every 12 hours)
16307180|NCT04626375|Active Comparator|Bioarginine|Bioarginine (2 vials per os of 1.66 g every 12 hours)
16307181|NCT04626362|Experimental|Experimental: Cranberry juice consumption|Participants will be provided cranberry juice to consume for 21 days
16307182|NCT04626362|Experimental|Placebo juice consumption|Participants will be provided placebo juice to consume for 21 days
16307183|NCT04626349|Experimental|FOCUS+|Dyads in the FOCUS+ arm will receive the face-to-face nurse-led FOCUS+ program.
16307184|NCT04626349|Experimental|iFOCUS|Dyads in the iFOCUS arm will receive the web-based iFOCUS program.
16307185|NCT04626349|No Intervention|Standard care|Dyads in the control group will receive standard care as usual, as determined by the healthcare system in the participating countries. The dose and frequency of usual care will be as deemed appropriate by the medical practitioner in charge of their treatment.
16307186|NCT04626336||Patients who undergo a cystectomy|Patients who undergo a cystectomy for cancer or not, since 2010 to 2020
16307187|NCT04626323|Experimental|RYGB (intervention arm)|Thirty (30) obese patients with DKD will undergo gastric bypass. Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA. The surgical procedure will consist of a laparoscopic surgery performed by an experienced surgeon (approximately 6000 bariatric surgeries), who is accredited as surgeon of excellence by the Brazilian Society of Bariatric and Metabolic Surgery and Surgical Review and Surgical Review Corporation program since 2009.
16307188|NCT04626323|Active Comparator|BMT (control arm).|Thirty (30) obese patients with DKD will undergo best medical treatment for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA.
16307189|NCT04626310|Experimental|Dialectical behavior therapy - emotion regulation skills training|Dialectical behavior therapy - emotion regulation skills training
16307190|NCT04626310|Experimental|Dialectical behavior therapy - interpersonal effectiveness skills training|Dialectical behavior therapy - interpersonal effectiveness skills training
16307191|NCT04626310|Active Comparator|Non-skills-oriented interpersonal psychotherapy group|Non-skills-oriented interpersonal psychotherapy group
16307194|NCT04626284|Experimental|Donors After Circulatory Determined death|Recipients receiving an organ from donors after circulatory determined death
16307195|NCT04626258|Active Comparator|Active comparator: Fluconazol|Once a month one capsule Fluconazol 150 mg
16307196|NCT04626258|Experimental|L-Mesitran|The first month every day apply L-mesitran, the next five months apply L-mesitran every week on the vagina
16307197|NCT04626245|Experimental|Mindfulness training|Phone-delivered mindfulness training
16307198|NCT04626245|Other|Treatment as usual|Prenatal care
16307199|NCT04626232|Experimental|N SLEEVE|Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
16307200|NCT04626232|Other|SLEEVE|The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
16307201|NCT04626219|Experimental|1|Period of 12 hours where participants eat regulated meals
16307202|NCT04626219|Experimental|2|Period of 12 hours where participants do not eat anything
16307203|NCT04626206||Imaging to asess treatment response post-SRS|"There will be only one group. All recruited patients will have 3 scans, the multi-parametric MRI, contrast-clearance analysis MRI (TRAMs) and 18F-choline-PET/CT.
~This is a non interventional study. Only the results of the contrast-clearance analysis MRI (TRAMs) will be used to make clinical decisions (as this is the current standard of care at the recruiting site). The multi-parametric MRI and 18F-choline PET/CT will be treated as research scans."
16307204|NCT04626193|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline,Levofloxacien,tinadizole
16307205|NCT04626193|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole,amoxicilline
16307206|NCT04626180|Active Comparator|Regular Extubation|
16307207|NCT04626180|Experimental|Pre Extubation Manual Hyperinflation|
16307208|NCT04626167|Experimental|Intervention group|Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or construction.
16307209|NCT04626154|Active Comparator|Respiratory insufficiency or distress|Patients demonstrating respiratory insufficiency or distress.
16307210|NCT04626154|Sham Comparator|No respiratory insufficiency or distress.|Patients NOT demonstrating respiratory insufficiency or distress.
16307211|NCT04626141|Experimental|Abaloparatide group|Patients in the experimental group will receive abaloparatide after their surgery.
16307212|NCT04626141|Placebo Comparator|Control group|Patients in the control group will receive a placebo after their surgery.
16307213|NCT04626128|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of 0.03 mg CLS-AX
16307214|NCT04626128|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of 0.10 mg CLS-AX
16307215|NCT04626128|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of 0.30 mg CLS-AX
16307216|NCT04626102|No Intervention|Enrollment|"Participants were recruited by using a convenience sampling method. Potential participants were reached through lecturers and professors who are teaching classes at different universities in Istanbul, Turkey.
~Participants were asked to fill out a questionnaire package covering Demographic Information Form, Eating Disorders Examination Questionnaire (EDEQ), Eating Attitudes Test - 40 (EAT-40), Body Image Satisfaction Questionnaire (BISQ), and Sociocultural Attitudes towards Appearance Questionnaire-4-Revised (SATAQ-4R). Filling out the questionnaire package took approximately 25-minutes."
16307217|NCT04626102|Experimental|Intervention Period|"Participants were randomly assigned to one of these conditions:
~Experimental condition: Healthy Eating Attitudes and Behaviours Group Program - 6 weekly sessions, each session was about 45-minutes to 60-minutes
~Active control condition: Eating Disorders and Body Dissatisfaction: A Group Work - single session about 1.5 hours to 2 hours
~Wait-list control condition: Participants in this condition were informed that they will be asked to fill out questionnaires that sent to them, and at the end of 6 months, they will be invited to participate in Healthy Eating Attitudes and Behaviours Group Program."
16307218|NCT04626089|Experimental|Metformin glycinate|620 mg bid (PO) plus standard treatment for 14 days
16307219|NCT04626089|Placebo Comparator|Placebo|Placebo tablets bid (PO) plus standard treatment for 14 days
16307220|NCT04626076||Aga Khan University|Pakistan
16307221|NCT04626076||Wits Reproductive Health Institute|South Africa
16307222|NCT04626076||African Medical and Research Foundation- Uganda|Uganda
16307223|NCT04626076||African Medical and Research Foundation- Kenya|Kenya
16307224|NCT04626076||African Medical and Research Foundation- Zambia|Zambia
16307225|NCT04626076||African Medical and Research Foundation- Senegal|Senegal
16307226|NCT04626076||World Mosquito Program|Indonesia
16307227|NCT04626076||54Gene|Nigeria
16307228|NCT04626076||African Institute of Biomedical Science & Technology|Zimbabwe
16307229|NCT04626063|Active Comparator|Isolated non-steroid anti-inflammatory drug group|A isolated NSAIDs group received 400 mg etodolac twice a day for 10 days in treatment of acute low back pain.
16307230|NCT04626063|Experimental|Non-steroid anti-inflammatory drug plus magnesium group|This group received 400 mg etodolac twice a day and 365 mg magnesium oral supplementation once a day for 10 days in treatment of acute low back pain.
16307231|NCT04626063|Active Comparator|Non-steroid anti-inflammatory drug plus paracetamol group.|This group 400 mg etodolac twice a day and 500 mg paracetamol twice a day for 10 days in treatment of acute low back pain.
16307232|NCT04626050|Experimental|Medical Music (Phase I)|Participants will complete four medical music sessions that are 30 minutes in length each.
16307233|NCT04626050|Experimental|Narrative Writing (Phase I)|Participants will complete four narrative writing sessions that are 30 minutes in length each.
16307234|NCT04626050|Active Comparator|Interpersonal Psychotherapy (Phase II)|IPT is comprised of ten 75-minute sessions scheduled twice weekly.
16307235|NCT04626050|Active Comparator|Prolonged Exposure Therapy (Phase II)|ET is comprised of ten 75-minute sessions scheduled twice weekly.
16307236|NCT04626037|Experimental|All Participants in Group Zoom Sessions|During each session, the mother-child dyads will meet with Nurture Science program staff virtually. The entire procedure will be done on Zoom or in person depending on school opening. All mother-child pairs will then be asked to interact, with the child sitting on the mother's lap face-to-face. The rest of the session may continue with: (1) Reading Cuddle and Calm Book (2) Mutual Mother and Child Emotional Exchange Prompts (3) Mothers Support Circle to identify and engage members of the mother's family in helping the dyad with emotional connection (4) Mommy Baby Book (5) Bottle of Emotions (6) Plans for continuing the work in the family. Returning mothers will be asked how they have progressed using the Cuddle and Calm and mutual narrative over the week and what their experience with their child after the session has been.
16307237|NCT04626024|Experimental|All Subjects Enrolled (stop taking TKI)|Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for > 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
16307238|NCT04626011|Active Comparator|Group One|Participants receiving full mouth disinfection and extractions in one stage.
16307239|NCT04626011|Active Comparator|Group Two|Participants receiving full mouth disinfection at stage one and extractions at stage two after 7 days.
16307240|NCT04625998|Experimental|Intervention|Elementary schools and Head Start centers in the intervention catchment areas implemented (1) an enhanced Coordinated Approach To Child Health (CATCH) program for elementary schools using the CATCH Coordination Guide (Enhanced CATCH Elementary School Program), and (2) CATCH Early Childhood program for Head Start Centers.
16307241|NCT04625998|No Intervention|Comparison|Elementary schools and Head Start centers in the comparison catchment area used their regular school and early care and education (ECE) nutrition and physical activity programs. Elementary schools were required by law to implement a coordinated school health program.
16307242|NCT04625985|Experimental|Metformin glycinate|620 mg bid (PO) for 14 days plus standard treatment
16307243|NCT04625985|Placebo Comparator|Placebo|Placebo tablet bid (PO) for 14 days plus standard treatment
16307244|NCT04625972|Experimental|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
16307245|NCT04625972|Placebo Comparator|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
16307246|NCT04625959|Active Comparator|Base BT|16 weekly sessions of behavioral therapy.
16307247|NCT04625959|Experimental|Base BT + Distress Tolerance|16 weekly sessions of behavioral therapy with distress tolerance components of MABTs.
16307248|NCT04625959|Experimental|Base BT + Emotion Regulation|16 weekly sessions of behavioral therapy with emotion regulation components of MABTs.
16307249|NCT04625959|Experimental|Base BT + Mindful Awareness|16 weekly sessions of behavioral therapy with mindful awareness components of MABTs.
16307250|NCT04625959|Experimental|Base BT + Values|16 weekly sessions of behavioral therapy with values components of MABTs.
16307251|NCT04625959|Experimental|Base BT + Distress Tolerance and Emotion Modulation|16 weekly sessions of behavioral therapy with emotion regulation and distress tolerance components of MABTs.
16307252|NCT04625959|Experimental|Base BT + Distress Tolerance and Mindful Awareness|16 weekly sessions of behavioral therapy with distress tolerance and mindful awareness components of MABTs.
16307253|NCT04625959|Experimental|Base BT + Distress Tolerance and Values|16 weekly sessions of behavioral therapy with distress tolerance and values components of MABTs.
16307254|NCT04625959|Experimental|Base BT + Emotion Modulation and Mindful Awareness|16 weekly sessions of behavioral therapy with emotion regulation and mindful awareness components of MABTs.
16307255|NCT04625959|Experimental|Base BT + Mindful Awareness and Values|16 weekly sessions of behavioral therapy with values and mindful awareness components of MABTs.
16307256|NCT04625959|Experimental|Base BT + Emotion Modulation and Values|16 weekly sessions of behavioral therapy with emotion regulation and values components of MABTs.
16307257|NCT04625959|Experimental|Base BT + EM, DT, MA|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and distress tolerance components of MABTs.
16307258|NCT04625959|Experimental|Base BT + DT, ER, and V|16 weekly sessions of behavioral therapy with emotion regulation, distress tolerance, and values components of MABTs.
16307259|NCT04625959|Experimental|Base BT + DT, MA, and V|16 weekly sessions of behavioral therapy with distress tolerance, mindful awareness, and values components of MABTs.
16307260|NCT04625959|Experimental|Base BT + ER, MA, and V|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and values components of MABTs.
16307403|NCT04625101|Placebo Comparator|Placebo|Placebo administered orally for 13 weeks.
16307261|NCT04625959|Experimental|Base BT + ER, MA, V, DT|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, distress tolerance, and values components of MABTs.
16307262|NCT04625946|Experimental|Metformin|Standard of care ablation with recommendations for lifestyle modification and metformin.
16307263|NCT04625946|Other|Standard of care|Standard of care ablation with recommendations for lifestyle modification.
16307264|NCT04625920|Experimental|Virtual reality|women allocated to undergo hysteroscopy with Vr System
16307265|NCT04625920|Experimental|Standart care|women allocated to undergo hysteroscopy without VR
16307266|NCT04625907|Experimental|Phase 1b Dose finding: VHR induction - IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.
~Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
16307267|NCT04625907|Active Comparator|CT1A: VHR induction - IVADO|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4"
16307268|NCT04625907|Experimental|CT1A: VHR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
16307269|NCT04625907|Active Comparator|CT1B: HR Induction IVA|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
16307270|NCT04625907|Experimental|CT1B: HR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
16307271|NCT04625907|Experimental|RT1A: Preoperative Radiotherapy|To be given either 41.4 Gy or 50.4 Gy prior to surgery
16307272|NCT04625907|Active Comparator|RT1A: Post operative radiotherapy|To be given either 41.4 Gy or 50.4 Gy following surgery
16307273|NCT04625907|Experimental|RT1B: Radiotherapy for resectable disease: dose escalated|To receive 50.4 Gy
16307274|NCT04625907|Active Comparator|RT1B: Radiotherapy for resectable disease: standard dose|To receive 41.4 Gy
16307275|NCT04625907|Experimental|RT1C: Radiotherapy for unresectable disease: dose escalated|To receive 59.4 Gy
16307276|NCT04625907|Active Comparator|RT1C: Radiotherapy for unresectable disease: standard dose|To receive 50.4 Gy
16307277|NCT04625907|Experimental|RT2: Radiotherapy to primary tumour and involved lymph nodes|Radiotherapy to the primary tumour and involved regional lymph nodes only
16307278|NCT04625907|Experimental|RT2: Radiotherapy to all metastatic sites|Radiotherapy given to all metastatic sites
16307279|NCT04625907|Experimental|CT2A: VHR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
16307280|NCT04625907|No Intervention|CT2A: Maintenance -Stop treatment|To stop treatment at the point of randomisation
16307281|NCT04625907|Experimental|CT2B: HR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
16307282|NCT04625907|No Intervention|CT2B: HR Maintenance - Stop Treatment|To stop treatment at the point of randomisation
16307283|NCT04625907|Active Comparator|Relpased Chemotherapy - VIR|Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5
16307284|NCT04625907|Experimental|Relapsed Chemotherapy - VIRT|Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 given orally on days 1-5
16307285|NCT04625894|Experimental|Treatment Arm|Patients with oligometastatic gastrointestinal cancer will receive multisite SABR, followed by Camrelizumab within one week from completion of radiation. Camrelizumab for injection at 200 mg, d1, q2w, 14-day cycle will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
16307286|NCT04625881|Active Comparator|Active product|A powder containing 20 g of apple derived fiber will be consumed daily
16307287|NCT04625881|Placebo Comparator|Placebo|A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided
16307288|NCT04625868|Experimental|Soft tissue surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
16307289|NCT04625868|No Intervention|Soft tissue surgery - no video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
16307290|NCT04625868|Experimental|Bone/joint surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
16307291|NCT04625868|No Intervention|Bone/joint surgery - no video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
16307292|NCT04625855|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr
16307293|NCT04625842|Experimental|Patient focus group|Patients who received radiation treatment
16307294|NCT04625842|Experimental|Family focus group|Family of patients who received radiation treatment
16307295|NCT04625816|Experimental|Arthroscopic shoulder surgery patients|
16307367|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
16307296|NCT04625803|Experimental|chemotherapy, PD-1 inhibitor and Apatinib|Participants received 5 preoperative cycles of PD-1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery. Apatinib,PD-1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.
16307297|NCT04625790|Experimental|Study group|After randomization, this group will take 10 sessions of 1-Hz low frequency rTMS will be applied to the inferior frontal gyrus of the right frontal lobe for 20 minutes during the stroke treatment process before 10 days of speech therapy. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
16307298|NCT04625790|Placebo Comparator|Control group|This group will take 10 sessions of sham rTMS for 20 minutes during the stroke treatment process before 10 days of speech therapy. The sham therapy will consist of positioning the coil on the cranium at the same spot, but without a magnetic stimulation, only with the device open and the sounds will be audible. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
16307299|NCT04625777|No Intervention|Waitlist control|In this waitlist control condition, participants will not receive any programming intervention. They will know that they have access to stress reduction programming after a certain date. They will also provide survey data at 3 time points and heart rate variability data at 2 time points while waiting. The survey questions will include a wide variety of stress items.
16307300|NCT04625777|Experimental|One of three stress reduction interventions|There are three stress reduction interventions: Mindfulness Based Stress Reduction, Daily Examen, and stress inoculation.
16307301|NCT04625764|Experimental|patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB|
16307302|NCT04625751||T2DM +CAN|
16307303|NCT04625751||T2DM -CAN|
16307304|NCT04625751||Healthy control|
16307305|NCT04625738|Experimental|MSC Arm|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.
~day 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg"
16307306|NCT04625738|Placebo Comparator|Placebo Arm|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
16307307|NCT04625725|Experimental|AZD7442|"Approximately 5150 participants will be randomized in a 2:1 ratio
~• Arm 1 (n=approximately 3433) will receive a single dose (× 2IM injections) of 300 mg of AZD7442"
16307308|NCT04625725|Placebo Comparator|Placebo|"Approximately 5150 participants will be randomized in a 2:1 ratio
~• Arm 2 (n=approximately 1717) will receive saline placebo"
16307309|NCT04625712|Experimental|Group A (experimental arm, surgery intervention)|Cholecystectomy within the first week after a mild acute biliary pancreatitis.
16307310|NCT04625712|Active Comparator|Group B (active comparator, surgery intervention)|Cholecystectomy four weeks later a mild acute biliary pancreatitis.
16307311|NCT04625699|Experimental|durvalumab+ tremelimumab|durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
16307312|NCT04625686||Inpatient Treatment|Inpatient psychiatric treatment
16307313|NCT04625686||OCIC Treatment|In-person outpatient crisis intervention
16307314|NCT04625686||Telehealth Therapy Treatment|Virtual outpatient therapy
16307315|NCT04625686||No Show Group|Participant who do not attend recommended treatment
16307316|NCT04625673|Active Comparator|Group A|Group A will wear the OsciPulse device for the first 24 hours then switch to the standard IPC device for the second 24 hours.
16307317|NCT04625673|Active Comparator|Group B|Group B will wear the standard IPC device for the first 24 hours then switch to the OsciPulse device for the second 24 hours.
16307318|NCT04625660|Experimental|Single Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
16307320|NCT04625634|Experimental|Consecutive work|Subjects will complete 2 consecutive days of simulated firefighting tasks in the heat. The simulated work consists of 20 minutes of simulated structural work in a hot environment, followed by 20 minutes of seated rest in a temperate room, mimicking a typical recovery period in structural firefighting. Subjects then re-enter the environmental chamber and complete 23 minutes of simulated overhaul work in a temperate environment.
16307321|NCT04625608|Other|Standard care|Participants in this arm shall receive 3.6 ml/kg of water a minimum of 1 hour prior to the induction of general anaesthesia. This is standard practice in the 2 participating institutions.
16307322|NCT04625608|Experimental|Paracetamol arm|Participants in this arm shall receive 3 ml/kg of water plus 15 mg/kg of oral paracetamol suspension a minimum of 1 hour prior to the induction of general anaesthesia.
16307323|NCT04625595|Experimental|350 mg BID (700 mg total daily dose) of active drug or placebo|Low dose, drug IMT-002
16307324|NCT04625595|Experimental|1050 mg QD (1050 mg total daily dose) of active drug or placebo|Moderate dose, drug IMT-002
16307325|NCT04625595|Experimental|700 mg BID (1400 mg total daily dose) of active drug or placebo|Moderate to high dose, drug IMT-002
16307326|NCT04625595|Experimental|1050 mg BID (2100 mg total daily dose) of active drug or placebo|High dose, drug IMT-002
16307327|NCT04625582|Experimental|Face-to-face intervention|90 trainees at Vigo Family Medicine and Community Nursing Training Unit
16307328|NCT04625582|Experimental|Online intervention|70 trainees at Aragón Family Medicine and Community Nursing Training Unit
16307329|NCT04625582|No Intervention|Usual training|180 trainees at Balearic Islands Family Medicine and Community Nursing Training Unit
16307330|NCT04625556||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
16307331|NCT04625556||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
16307332|NCT04625556||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
16307333|NCT04625556||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
16307402|NCT04625101|Experimental|NBI-827104|NBI-827104 administered orally for 13 weeks.
16307334|NCT04625543|Experimental|intervention group|Neoadjuvant immunotherapy (PD-1) plus concurrent chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
16307335|NCT04625543|Active Comparator|controll group|Neoadjuvant chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
16307336|NCT04625530|Experimental|ferric carboxymaltose|ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
16307337|NCT04625530|Experimental|tranexamic acid|tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
16307338|NCT04625530|Experimental|ferric carboxymaltose and tranexamic acid|"ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day
~-7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered."
16307339|NCT04625530|No Intervention|"no treatment accordingly current standard of care"|"no treatment accordingly current standard of care will be given"
16307340|NCT04625517|Experimental|Breast cancer patients|Patients with ipsilateral intact biopsy-proven breast cancer
16307341|NCT04625504|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
16307342|NCT04625504|No Intervention|Wait-list Control (WL)|Patients Control receiving no treatment
16307343|NCT04625504|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
16307344|NCT04625491||Location on lower limb|Proximal (thigh) Medium (leg) Distal (ankle and foot)
16307345|NCT04625478||Patients having had an osteo-articular infection with Stahylococcus|Patients having had an osteo-articular infection with Stahylococcus managed at the Croix Rousse hospital
16307346|NCT04625465|No Intervention|No Intervention, No Intervention (AA)|Participants do not receive text messages during Interval 2 or Interval 3.
16307347|NCT04625465|Active Comparator|No Intervention, Attention-Control Texts (AB)|Participants do not receive text messages during Interval 2. Participants receive attention control text messages during Interval 3.
16307348|NCT04625465|Experimental|No Intervention, CBT Texts (AC)|Participants do not receive text messages during Interval 2. Participants receive CBT text messages during Interval 3.
16307349|NCT04625465|Active Comparator|Attention-Control Texts, No Intervention (BA)|Participants receive attention control text messages during Interval 2. Participants do not receive text messages during Interval 3.
16307350|NCT04625465|Active Comparator|Attention-Control Texts, Attention-Control Texts (BB)|Participants receive attention control text messages during Interval 2. Participants receive attention control text messages during Interval 3.
16307351|NCT04625465|Experimental|Attention-Control Texts, CBT Texts (BC)|Participants receive attention control text messages during Interval 2. Participants receive CBT text messages during Interval 3.
16307352|NCT04625465|Experimental|CBT Texts, No Intervention (CA)|Participants receive CBT text messages during Interval 2. Participants do not receive text messages during Interval 3.
16307353|NCT04625465|Experimental|CBT Texts, Attention-Control Texts (CB)|Participants receive CBT text messages during Interval 2. Participants receive attention control text messages during Interval 3.
16307354|NCT04625452|Experimental|BBCC+5A's+GS|Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)
16307355|NCT04625452|No Intervention|Normal care|They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)
16307356|NCT04625439|Experimental|Personality Feedback|The intervention arm will read about the Five-Factor model and receive a feedback report with individualized personality results and self-management recommendations.
16307357|NCT04625439|No Intervention|No-feedback Control|The control arm will read about the Five-Factor model but will not receive feedback or their personality results until after the study.
16307358|NCT04625426|Experimental|3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant|"Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).
~The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer."
16307359|NCT04625426|Experimental|Conveen EasiCleanse and Conveen Critic Barrier|Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.
16307360|NCT04625426|Active Comparator|Soap and water / Incontinence wipes and Conveen Critic Barrier|Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.
16307361|NCT04625413|Experimental|Experimental: Experimental Arm: single|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.
16307362|NCT04625400|Experimental|post intubation tracheal stenosis patients|all ICU patients who were mechanically ventilated will be assessed for the possibility of presence of tracheal stenosis using spirometery and dyspnea will be assessed using (mMRC) score, chest X-ray to assess the location of tracheal stenosis and finally flexible bronchoscopy to confirm the presence of stenosis and identify the proper management.
16307363|NCT04625387|Experimental|Dry Needle plus exercise|Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
16307364|NCT04625387|Experimental|Dry Needling alone|Group B received Dry Needling alone having 25 individuals. Treatment lasted four weeks duration, twice a week.
16307365|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（pilot trial arm）|Healthy subjects receive single dose of tablets HEC122505MsOH
16307366|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）|Healthy subjects receive single dose of HEC122505MsOH or matching placebo
16307368|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
16307369|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
16307370|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
16307371|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
16307372|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
16307373|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
16307374|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
16307375|NCT04625348|Experimental|residents|daily care of 40 residents will be provided on the Ultracore Repose® mattress
16307376|NCT04625335|Experimental|Group 1: Intervention First|Adult, healthy volunteers will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test. Following the crossover, these participants will then complete the Cold Pressor Test without prior massage.
16307377|NCT04625335|Experimental|Group 2: Intervention Last|Adult, healthy volunteers will complete the Cold Pressor Test without prior massage. After crossover, they will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test.
16307378|NCT04625322|No Intervention|Referral to outpatient specialty for HCV care|Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
16307379|NCT04625322|Experimental|Receive HCV care during inpatient admission by a hospitalist|CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
16307380|NCT04625309|Experimental|Sport|This group will be made up of subjects with a spinal cord injury that are actively participating in adaptive sports teams.
16307381|NCT04625309|No Intervention|No sport|This group will be made up of subjects with a spinal cord injury that are not actively participating in any sports team.
16307382|NCT04625296||Healthcare professional|Communities Health professionals (doctors, nurses, physiotherapist) Working in the city, In metropolitan France, Having managed patients with COVID-19
16307383|NCT04625283|Experimental|Ketamine|Participants in this arm will receive intraoperative ketamine bolus (0.5mg/kg) followed by continuous infusion 5 mcg/kg/min and also will receive postoperative ketamine infusion (2.5 mg/kg/min, up to 100kg max) for 48 hours.
16307384|NCT04625283|Placebo Comparator|Saline|Participants in this arm will receive an equivalent volume of intraoperative saline bolus followed by continuous saline infusion and also will receive postoperative saline infusion for 48 hours.
16307387|NCT04625244|No Intervention|Group 1: In-person therapy|Standard of care, in-person therapy with a Certified Hand Therapist (CHT)
16307388|NCT04625244|Experimental|Group 2: Home therapy program|Participants will be sent video links to three therapy videos demonstrating postoperative recovery exercises, starting 4 weeks after surgery.
16307389|NCT04625231|Experimental|Shared-Decision Making Tool Group|
16307390|NCT04625231|No Intervention|Standard of Care Group|
16307391|NCT04625205|Experimental|NEO-PTC-01 Part 1 dose finding phase|
16307392|NCT04625205|Experimental|NEO-PTC-01 Part 2 dose expansion phase|
16307393|NCT04625192|Experimental|Sinus lifting with trephine osteotomy|
16307394|NCT04625179|Experimental|Melatonin and hyaluronic acid and sinus membrane elevation|melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement
16307395|NCT04625179|Active Comparator|sinus membrane elevation without any materials|no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.
16307396|NCT04625153|Experimental|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
16307397|NCT04625153|Experimental|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
16307398|NCT04625127|Experimental|Aim 2: Efficacy of the GaitBetter to improve motor-cognitive function of chronic stroke survivors|The investigators propose a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. This design was chosen given the expected stability of functional recovery in this population.
16307399|NCT04625127|Experimental|Aim 3: Efficacy of the GaitBetter to improve rehabilitation outcomes in sub-acute stroke survivors|The investigators propose a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
16307400|NCT04625114|Experimental|Camostat|camostat 100mg 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
16307401|NCT04625114|Placebo Comparator|Placebo|Placebo 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
16307407|NCT04625075||COVID-19 with myocardial injury|Patients hospitalised with severe COVID-19 infection and evidence of myocardial. Involvement: elevation of plasma cardiac troponin concentration (>99th centile of the upper reference limit), abnormalities on electrocardiography or abnormal echocardiography. Some patients will have suspected myocarditis or takotsubo cardiomyopathy. We will identify subgroups of interest who have left/right ventricular systolic dysfunction ± regional wall motion abnormalities, on echocardiography.
16307408|NCT04625075||COVID-19 without myocardial injury|Patients hospitalised with severe COVID-19 infection but without known elevation of plasma cardiac troponin concentration, clinically significant ECG abnormalities or an abnormal echocardiogram.
16307409|NCT04625062|Experimental|Condition 1: Visual-acoustic biofeedback|Visual-acoustic biofeedback treatment (behavioral) administered via telepractice
16307410|NCT04625062|Experimental|Condition 2: Motor-based treatment|Motor-based articulation treatment administered via telepractice
16307411|NCT04625036||Group 1: COVID-19 patients|Patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
16307412|NCT04625023||Cohort of BC patients|Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.
16307413|NCT04625010|Experimental|Group 2 (Swaddling group)|Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
16307414|NCT04625010|Experimental|Group 3 (Maternal Holding group)|Maternal holding group: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
16307415|NCT04625010|No Intervention|Group 1|In the control group, the heel stick procedures were conducted using the standard method and the neonates received no interventions during the procedures.
16307416|NCT04624997||Patient suspected COVID-19|"Follow-up of patients as usual in care for infection. No specific puncture. Blood sample collect at admission and every 72h during hospitalisation for hemostasis evaluation, DNA extraction, Circulating endothelial cells measuring.
~Sampling can be delayed for 24h to match a planned blood collection for care or other research."
16307417|NCT04624984|Experimental|PD-1 Inhibitor or PD-1 Inhibitor with GVD|"All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen.
~Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial."
16307418|NCT04624958|Experimental|zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance|"Part A (Zanubrutinib and Rituximab): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve CR.
~PART B (Consolidation chemotherapy of R-DHAOx): Patients receive R-DHAOx regimen every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Elderly patients (> 65 years old) and patients who achieved CR and minimal residual disease negative after PART B receive zanubrutinb maintenance therapy. Young patients (<65 years old) who achieved CR but minimal residual disease positive after PART B can receive autologous stem cell transplantation and then zanubrutinb maintenance therapy. Patients with PD, SD or PR after PART B quit the trial.
~ZANUBRUTINB MAINTENANCE: Patients receive zanubrutinib every day for up to one year."
16307419|NCT04624945||SICU cohort|150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. Frequency of blood sampling will be stipulated atday 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples.
16307420|NCT04624932|Experimental|Risk Reframing (RR) Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.
~Chapter 1: reflecting on their own childhood play activities; what they got out of these experiences; outdoor play activities of the children at their center; what they do to promote children's outdoor play; what gets in the way in promoting children outdoor play.
~Chapter 2: imagining themselves in six video segments where they must decide how to communicate with parents; and, whether they allow children to engage in rough and tumble play, play at heights, play with tools, play at speed/mud play, and resolve conflicts amongst themselves
~Chapter 3: reflecting on their barriers and things that helped them promote and support the children's outdoor play at their center. Participants to assess whether there is anything they want to change to set a realistic goal, outlining steps for attaining that goal."
16307421|NCT04624932|Sham Comparator|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play.
~It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety."
16307424|NCT04624906|Experimental|Single arm intervention|"100 mg Acalabrutinib (ACP-196) oral capsules twice daily for 1 year
~Bendamustine and rituximab will be given for 6 x 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)."
16307425|NCT04624893||Pola BR/R|Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
16307426|NCT04624880||Participants with HIP previously measured|This cohort of patients will have their genetics analyzed and compared to their HIP scores.
16307427|NCT04624880||Participants without HIP measured|This cohort of patients from the control group of the knee replacement trial (who did not have their HIP measured) will have their genetics, pain, and opioid use analyzed, and compared to the genetics, pain, and opioid use of the hypnosis group from that trial.
16307428|NCT04624867|Experimental|HP-1050 patch|HP-1050 and Xulane will be administered simultaneously.
16307429|NCT04624854|Placebo Comparator|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
16307430|NCT04624854|Experimental|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
16307431|NCT04624841|Experimental|ICG group|"Participants receive an intravenous injection of 0.05 mg/kg of ICG 45 minutes preoperatively.
~A Pinpoint Endoscopic Fluorescence System (Novadac Technologies Inc., Canada) for ICG Fluorescence Observation with the easy switchable white light-fluorescent mode is used.
~Before dividing any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of ICG as initially used.
~After the division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage."
16307432|NCT04624841|No Intervention|No ICG Group|No ICG is administered after randomization of the patient to a control group and hence will not produce any enhancement of the image on A Pinpoint Endoscopic Fluorescence System for ICG Fluorescence Observation. This will continue as a routine Laparoscopic cholecystectomy without fluorescent imaging enhancement.
16307433|NCT04624828|Experimental|Stereotactic body radiation treatment (SBRT)|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).
~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
16307434|NCT04624802|Experimental|maternal exercise training group|Pregnant women in experimental group are invited to participate in 16 exercise weekly classes for 40 min including 15 min aerobic exercise，10 min relaxation exercise, and 15 min aerobic exercise, from week 16 to week 32 of gestation, and receive antenatal care and examination regularly.
16307435|NCT04624802|No Intervention|antenatal care group|Pregnant women in antenatal care group receive antenatal care and examination regularly.
16307436|NCT04624789||GM1-Gangliosidosis - Sialidosis|"Confirmed diagnosis of:
~GM1-Gangliosidosis Morquio B Variant
~Sialidosis
~Galactosialidosis"
16307437|NCT04624789||GM2-Gangliosidoses|"Confirmed diagnosis of:
~Tay-Sachs Disease, incl. B1-Variante
~Sandhoff Disease
~GM2-Activator-Deficiency"
16307438|NCT04624776|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
16307439|NCT04624776|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
16307440|NCT04624763|Experimental|LBBP group|In this arm, a left bundle branch pacing(LBBP) lead is attempted to be placed.
16307441|NCT04624763|Active Comparator|RVP group|In this arm, a right ventricular pacing(RVP) lead are placed.
16307442|NCT04624750|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
16307443|NCT04624711|Experimental|Eribulin Mesylate Combined With Anlotinib|Patients receive eribulin mesylate plus anlotinib.
16307444|NCT04624698|Experimental|Implantation|Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.
16307445|NCT04624672|Placebo Comparator|Control Arm|Once weekly injection of placebo 4-6 months at prescribed dose
16307446|NCT04624672|Active Comparator|Test Arm|Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose
16307447|NCT04624659|Experimental|Double blind FT-4202 Low Dose|
16307448|NCT04624659|Experimental|Double blind FT-4202 High Dose|
16307449|NCT04624659|Experimental|Double Blind Placebo|
16307450|NCT04624659|Experimental|Open label FT-4202|
16307451|NCT04624633|Experimental|Cohort 1-Relapsed Disease|"Participants with relapsed disease
~Treatment with Acalabrutinib & Umbralisib beginning C1D1,
~Ublituximab beginning C7D1
~Assessment of treatment response
~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
16307452|NCT04624633|Experimental|Cohort 2-Treatment Naive|"Participants with previously untreated disease
~Treatment with Acalabrutinib & Umbralisib beginning C1D1,
~Ublituximab beginning C7D1
~Assessment of treatment response
~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
16307454|NCT04624607|Experimental|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive transspinal stimulation over the thoracolumbar region and non-invasive brain stimulation during assisted stepping.
16307455|NCT04624607|Experimental|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive brain stimulation and non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping.
16307456|NCT04624594|Experimental|Artificial Intelligence (AI) Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the AI group then performed 10 more practice repetitions with real-time audiovisual feedback from the app followed by one minute of rest. The AI's design provided one piece of feedback, if necessary, with a vocal statement and on-screen video per repetition (e.g. when a participant performed a squat repetition with their neck flexed downward, AI suggested keeping their head up with on-screen instruction). Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
16307457|NCT04624594|Active Comparator|Physical Therapist Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the PT group (n=15) also performed 10 practice repetitions with one piece of feedback per repetition, if necessary, from the PT followed by one minute of rest. Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
16307458|NCT04624581|Experimental|Patient with fibromyalgia syndrome|250 patients with fibromyalgia syndrome (according to American College of Rheumatology 2016) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate the distribution of gene polymorphism.
16307459|NCT04624581|Sham Comparator|Healthy subjects|50 healthy matched volunteers (age, sex and menopausal status for women) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate distribution of gene polymorphism
16307460|NCT04624568|Experimental|Papilocare group|"Papilocare® for 6 months according to the following schedule:
~1 self-applying single dose per day for 21 days over 28 during the first month, then 1 day over 2 during the following 5 months, with a 7-day break during the menstrual period. (This break must be respected even in menopausal women or women undergoing artificial amenorrhea (amenorrhea induced by certain contraceptives: implant, hormonal IUD, micro-progestogen)."
16307461|NCT04624568|No Intervention|Control group|No treatment for 12 months. Smear and HPV test will be perform by all patients at 6 and 12 months
16307462|NCT04624542||group 1|Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.
16307463|NCT04624542||control group|-30 healthy active individuals ranging from 18-36 yrs as a controlled group
16307464|NCT04624516|Experimental|Intervention group|The group received training in self-structured foot exercise and they were encouraged to do self-structure foot exercise 3 times a week. They received usual care
16307465|NCT04624516|No Intervention|Control Group|the group received usual care
16307466|NCT04624490|Experimental|Hyperpolarized 129Xe|Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.
16307467|NCT04624477||Active Surveillance|Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
16307468|NCT04624477||Immediate Thyroid Surgery (total or partial thyroidectomy)|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
16307469|NCT04624464||Cohort 1: VRE negative at admission|"150 patients meeting the following inclusion criteria:
~≥ 18 years
~Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days
~High risk of exposure to antibiotics during the stay
~Written informed consent of the patient after clarification has been given
~Exclusion criteria:
~Already known current or documented past colonisation or infection by VRE
~Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use)."
16307470|NCT04624464||Cohort 2: VRE positive at admission|"A total 20 known VREf-positive patients meeting the following inclusion criteria:
~Intestinal VREf colonization already known at the time of admission (e.g. based on examinations during previous stays or in external facilities)
~Accommodation in a single room or alternatively multi-bed room with single occupancy on standard wards
~Expected stay of at least 7 days"
16307471|NCT04624438|Experimental|Electromyostimulation - EMS|Experimental group comprised of healthy young adults that undergoes unilateral isometric training using electromyostimulation over quadriceps femoris
16307472|NCT04624438|Experimental|Voluntary activation - VOLUNTARY|Experimental group comprised of healthy young adults that undergoes unilateral isometric training based on voluntary activation of quadriceps femoris
16307473|NCT04624438|Experimental|Combination of EMS and VOLUNTARY - COMBINED|Experimental group comprised of healthy young adults that undergoes unilateral isometric training that combines electromyostimulation and voluntary activation of quadriceps femoris.
16307474|NCT04624438|No Intervention|Control group - CONTROL|Group of healthy young adults who received no intervention.
16307475|NCT04624425|Experimental|Segmental breathing exercises|Segmental breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
16307476|NCT04624425|Active Comparator|Buteyko breathing exercises|Buteyko breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
16307477|NCT04624412|Experimental|Continuous Aerobic Moderate Intensity Exercise|(Treadmill walking exercise) 50% - 70% of max Heart Rate (HR) (3-6 METS)
16307478|NCT04624412|Experimental|Continuous Aerobic (Mild intensity Exercise)|(Treadmill walking exercise) 30% -50 % of max HR (1-3 METS)
16307479|NCT04624399|Experimental|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
16307480|NCT04624386||Postmenopausal/Study|Women older than 45 years of age and who have not had any menstruation for the past 12 months are considered as having entered menopause. These women are included in this group.
16307481|NCT04624386||Premenopausal/Control|Healthy women who are still having regular menstruations are included in this group
16307482|NCT04624373||Identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
16307483|NCT04624373||Non identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
16307484|NCT04624360|Experimental|Study Drug A|Dexamethasone 8mg intravenous administration stat dose post clamping of the umbilical cord
16307485|NCT04624360|Placebo Comparator|Study Drug B|Normal saline 2cc intravenous stat dose administered after clamping of the umbilical cord
16307486|NCT04624347|Experimental|Acess to Videos and Movement curves|with caregivers' access to videos and movement curves (4 days)
16307487|NCT04624347|No Intervention|No Acess to Video and Movement curves|without caregivers' access to videos and movement (4 days)
16307488|NCT04624334||Children with motility disorder|
16307489|NCT04624334||Healthy children|
16307490|NCT04624334||Adults with motility disorder|
16307491|NCT04624334||Healthy adults|
16307492|NCT04624321|Experimental|Access to tool|Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
16307493|NCT04624321|Placebo Comparator|Usual care|They are followed by their ordinary healthcare provider.
16307494|NCT04624308|Experimental|TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab|TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or >75%PR. If not, operation is suggested.
16307495|NCT04624295|Active Comparator|Early Antiplatelet Therapy|
16307496|NCT04624295|Placebo Comparator|Non-Early Antiplatelet Therapy|
16307497|NCT04624282||Patients with chronic superficial gastritis|Patients with chronic superficial gastritis
16307498|NCT04624282||Patients with chronic atrophic gastritis|Patients with chronic atrophic gastritis
16307499|NCT04624282||Patients with gastric carcinoma|Patients with gastric carcinoma
16307500|NCT04624269|Experimental|Hydroxychloroquine sulfate Tablets|drug:Hydroxychloroquine sulfate Tablets,0.1mg bid po
16307501|NCT04624269|Placebo Comparator|placebo|drug:placebo,0.1mg bid po
16307502|NCT04624256|Experimental|Treatment (radiotherapy, genomic DNA testing)|Patients undergo SBRT per standard of care, then undergo collection of cheek swab and blood samples for the analysis of germline biomarkers. Afterwards, patients and their physicians engage in discussion about which form of radiotherapy to proceed with. Based on the decision, patients predicted to be at low risk of toxicity with SBRT continue to receive SBRT over 14 days while patients predicted to be at high risk of toxicity with SBRT will be counseled to undergo either conventionally fractionated radiotherapy over 63-70 days, moderate hypofractionated radiotherapy over 28-35 days, or may opt to still receive SBRT over 14 days per standard of care.
16307509|NCT04624217|Experimental|SHR-1701|SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel
16307513|NCT04624191|Experimental|Intervention Group|Intervention group participants will be asked to measure their oxygen saturation on a daily basis.
16307514|NCT04624191|No Intervention|Control Group|Usual Care
16307515|NCT04624178|Experimental|Rucaparib in combination with Nivolumab|"One treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks.
~Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy."
16307516|NCT04624152|Experimental|Normobaric Hypoxia|"Large weather balloons will be filled with a normobaric hypoxic inspirate (FiO2 = 0.15) produced by a nitrogen generator (CAT 12; Colorado Altitude Training, Boulder, CO) to simulate an altitude of 2600 m (8500 ft). Participants breathed this inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).
~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
16307517|NCT04624152|Placebo Comparator|Normobaric Normoxia|"Large weather balloons will be filled with room air (FiO2 = 0.21). Participants breathed this normobaric normoxic inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).
~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
16307518|NCT04624139|Experimental|Intervention, group 1|Combined intervention of stress reducing I-CBT and physiotherapy.
16307519|NCT04624139|Active Comparator|Active control group, group 2|Physiotherapy only
16307520|NCT04624126|Experimental|3D-Erect arm|Participants will be asked to use the 3D-printed penile device during their intercourse with partners.
16307521|NCT04624113|Experimental|Phase I: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).
~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend on dose level assigned
~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
16307522|NCT04624113|Experimental|Phase 2: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).
~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend of recommended phase 2 determined in Phase I portion of study.
~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
16307523|NCT04624100||All consecutive patients with primary ventral or incisional hernia|
16307524|NCT04624087|Experimental|High Dose|Participants will perform the food-specific computerized go/no-go training four times per week for 4 weeks.
16307525|NCT04624087|Experimental|Low Dose|Participants will perform the food-specific computerized go/no-go training one time per week for 4 weeks.
16307526|NCT04624087|Active Comparator|Active Control|Participants will perform the generalized, nonfood-specific computerized go/no-go training one time per week for 4 weeks.
16307527|NCT04624074|Experimental|Teen Marijuana Checkup - adapted|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
16307528|NCT04624061|Experimental|Intervention|"The integrated HIV/HTN care model with the following components;
~Training and capacity building on the INTEGRATED HIV/HTN model and NCD care
~Integrated HIV/HTN care delivery model by promoting HTN screening and care in HIV clinics.
~HMIS enhancements through mentorship and coaching on the use of NCD registers and NCD patient cards and HTN data capture in the (Electronic Medical Record) EMR system.
~SMS and/or WhatsApp for data coordination and communication among providers, District Health officers (DHOs) and study team (Mentors) to strengthen feedback."
16307529|NCT04624061|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV and Hypertension care visits at the health facilities include;a) Provision of BP machines b)Provision of NCD register and NCD patient card and ; c) Following MOH treatment guidelines
16307530|NCT04624048||University population|Survey to analyze the impact of COVID-19.
16307531|NCT04624035|Active Comparator|Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.|Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
16307532|NCT04624035|Active Comparator|Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults|Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
16307534|NCT04623983|Experimental|resilient bonding tray|Patients receiving resilient orthodontic bonding trays
16307535|NCT04623983|Experimental|rigid bonding tray|Patients receiving rigid orthodontic bonding trays
16307536|NCT04623970|Experimental|Propofol sedation group|Patients in this experimental group received propofol sedation agent.
16307537|NCT04623970|Experimental|Ketofol 1:3 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:3 mixture.
16307538|NCT04623970|Experimental|Ketofol 1:4 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:4 mixture.
16307539|NCT04623957|Experimental|ForgTin|Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
16307540|NCT04623957|No Intervention|No intervention|Patients randomized into group 2 will receive no device for a duration of 3 months.
16307541|NCT04623944|Experimental|NKX101 - CAR NK cell therapy|"All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 or 2 weekly doses of NKX101. Regimen A will dose on Day 0, 7, and 14 of a 28-day cycle. Regimen B will dose on Day 0 and 7 of a 28-day cycle.
~Part 1: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used
~Part 2: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used"
16307542|NCT04623931|Experimental|Treatment (temozolomide, radiation therapy)|Patients receive temozolomide PO daily and radiation therapy over 5 days a week (weekdays only) for 6 weeks. Beginning 28 days after the last dose of radiation therapy, patients receive temozolomide PO for 12 months in the absence of disease progression or unacceptable toxicity.
16307543|NCT04623918|Experimental|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
16307544|NCT04623918|Active Comparator|Control rice|Control rice (C4)
16307545|NCT04623892|Experimental|TQB2618|TQB2618 administered intravenously (IV) on Day 1 of each 21-day.
16307546|NCT04623879||F508del homozygous adult CF patients|F508del homozygous adult CF patients who commenced treatment with LUM-IVA
16307547|NCT04623866|Active Comparator|Huaiqihuang Group|Huaiqihuang granules 60g/1.73m2 bid 24 weeks
16307548|NCT04623866|Active Comparator|Valsartan group|Valsartan granules 80mg/1.73m2 based qd 24 weeks
16307549|NCT04623853|Experimental|Aim 2|Participants will carry out a protocol comprised of treadmill walking in a laboratory setting while wearing the Dynamic AFO device.
16307550|NCT04623853|Experimental|Aim 3|"Participants will be asked to take the Dynamic AFO home and wear the device for up to 4 weeks. The device will be set in either an adjustment-capable mode, or a locked mode that functions similar to their own orthotic--the order in which they are tested will be randomized."
16307551|NCT04623840|Experimental|Exercised group|.(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
16307552|NCT04623840|Active Comparator|non-exercised group|(n=30) will be sedentary obese men with ED. All participants will receive only five milligrams of tadalafil, one time per day, for eight weeks.
16307553|NCT04623814|Experimental|Food effect|HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.
16307554|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 10mg|HEC113995 10mg will be administered fasted for 10 days
16307555|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 20mg|HEC113995 20mg will be administered with food for 10 days
16307556|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 40mg|HEC113995 40mg will be administered with food for 10 days
16307557|NCT04623814|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo arms will be administered fasted or with food for 10 days
16307559|NCT04623788||Myocarditis|Twenty patients with acute myocarditis will be recruited if the diagnosis has been made by a cardiologist based on clinical, biochemical, electrographic and imaging data. This reflects the diagnostic criteria set out by the European Society of Cardiology (ESC) Task force 2013.
16307560|NCT04623788||Takotsubo Cardiomyopathy|Twenty patients with takotsubo cardiomyopathy will be recruited. The diagnosis will be made according to the Mayo clinic and the European Society of Cardiology (ESC) Heart Failure Association criteria, including a normal coronary angiogram, typical appearances on cardiac imaging including ventriculography, and no evidence of fibrosis on cardiac magnetic resonance imaging.
16307561|NCT04623788||Reversible Ischaemia|Forty patients who have undergone stress echocardiography or magnetic resonance imaging; twenty with positive (areas of reversible akinesis/hypokinesis during pharmacological stress), and twenty with a negative stress result (no reversible wall motion abnormalities during pharmacological stress) as per international guidelines. They will be matched for age and sex.
16307562|NCT04623788||Healthy Volunteer|Twenty healthy volunteers of comparable age and sex to the other cohorts.
16307563|NCT04623775|Experimental|Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))|
16307564|NCT04623775|Experimental|Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))|
16307565|NCT04623775|Experimental|Part 2: Arm C (Nivolumab + Relatlimab Dose 1 or Dose 2 + PDCT)|
16307566|NCT04623775|Placebo Comparator|Part 2: Arm D (Nivolumab + Placebo + PDCT)|
16307567|NCT04623762|No Intervention|Control group|yoga was not done
16307568|NCT04623762|Experimental|Experimental group|yoga was done
16307569|NCT04623749|Active Comparator|Percutaneous US guided FNAC in pancreatic masses|
16307570|NCT04623749|Active Comparator|EUS guided FNAC in pancreatic masses|
16307571|NCT04623736|Experimental|quitSTART|
16307572|NCT04623723|Sham Comparator|Perio Slim (PS)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with PS (DS-016A, EMS® Piezon, Switzerland) scaler tip
16307573|NCT04623723|Active Comparator|Conventional scaler tip|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with conventional (FS-407, EMS® Piezon, Switzerland) scaler tip
16307574|NCT04623710|Experimental|Cohort 1: Severe Impaired Renal Function|Participants will receive ALXN2050.
16307575|NCT04623710|Experimental|Cohort 2: Moderate Impaired Renal Function|Participants will receive ALXN2050.
16307576|NCT04623710|Experimental|Cohort 3: Mild Impaired Renal Function|Participants will receive ALXN2050.
16307577|NCT04623710|Experimental|Cohort 4: Healthy Control|Participants will receive ALXN2050.
16307578|NCT04623684|Experimental|Study Group|Mydriasis with microdrops
16307579|NCT04623684|Active Comparator|Control Group|Mydriasis with standard drops
16307657|NCT04623216|Experimental|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
16307658|NCT04623216|Experimental|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
16307580|NCT04623671|Active Comparator|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
16307581|NCT04623671|Placebo Comparator|Placebo|Matching placebo solution
16307582|NCT04623658||Sacrococcygeal teratoma|Fetuses and infants diagnosed with sacrococcygeal teratoma and cared for between 2007 and 2017 in the main Parisian fetal medicine and pediatric surgery units: Necker-Enfants Malades Hospital, Antoine Béclère Hospital, Armand Trousseau Hospital, Robert Debré Hospital and Le Kremlin-Bicêtre Hospital.
16307583|NCT04623645|Experimental|ultrasound group|patient using ultrasound technique.probe will be placed over submandibular area, the thyrohoid muscle and thyrohyoid membrane will be identified between greater horn fo hyoid bone and thyroid cartilage , 3 ml of lignocaine will be placed on space between thim and the procedure will repeated on contra lateral side.
16307584|NCT04623645|Active Comparator|anatomical blind group|patient using anatomical land mark technique, internal branch of superior laryngeal nerve will be blocked slightly anterior to greater horn of hyoid bone . by 3 ml lignocaine . the procdure will be repeated on contra lateral side .
16307585|NCT04623632|Active Comparator|Bupivacaine|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique; syringes contained bupivacaine 0.25% 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
16307586|NCT04623632|Placebo Comparator|Placebo|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique syringes contained either normal saline 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
16307587|NCT04623619|Experimental|Acetyl L-Carnitine|Acetyl L-Carnitine
16307588|NCT04623619|No Intervention|Standard of care|Standard of care
16307589|NCT04623606|No Intervention|Prospective Control (Untreated) and historical controls|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database
16307590|NCT04623606|Experimental|Treatment|Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
16307591|NCT04623593|Active Comparator|ACDF|Anterior cervical discectomy and fusion.
16307592|NCT04623593|Experimental|ACDA|Anterior cervical discectomy with arthroplasty.
16307593|NCT04623580||Inguinal or femoral hernia repair|All consecutive inguinal or femoral hernia repair (primary or mesh)
16307594|NCT04623567|Experimental|Jiangtang Tiaozhi Recipe Group|Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.
16307595|NCT04623567|Active Comparator|Metformin Group|500mg metformin tablet per time, 3 times a day, take it with meals.
16307596|NCT04623554|Active Comparator|Intervention arm|Prehabilitation program
16307597|NCT04623554|No Intervention|Control arm|Usual care
16307598|NCT04623541|Experimental|Experimental|Experimental: Epcoritmab Open label single arm
16307599|NCT04623528||Pericarditis patients with constrictive physiology|Patients with pericarditis and signs of constrictive physiology (increased ventricular coupling)
16307600|NCT04623528||Pericarditis patients without constrictive physiology|Patients with pericarditis but without signs of constrictive physiology (normal ventricular coupling)
16307601|NCT04623528||Dilated cardiomyopathy patients with biventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular and right ventricular ejection fraction less than 35%
16307602|NCT04623528||Dilated cardiomyopathy patients with preserved right ventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular ejection fraction less than 35%, and right ventricular function >45%
16307603|NCT04623528||Patients with pulmonary arterial hypertension|Cohort of patients with pulmonary hypertension, either idiopathic or secondary to pulmonary emboli
16307604|NCT04623528||Control group|Cohort of subjects with no evidence of pericarditis, pulmonary hypertension, dilated cardiomyopathy and normal findings at cardiovascular magnetic resonance imaging
16307605|NCT04623515||Surgery Only Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
16307606|NCT04623515||Surgery and Radiation Therapy Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
16307607|NCT04623502|Experimental|13C-Glucose|
16307608|NCT04623502|Experimental|13C-Acetate|
16307609|NCT04623502|Experimental|13C-Lactate|
16307610|NCT04623502|Experimental|13C-Glutamine|
16307611|NCT04623502|Experimental|13C-Fructose|
16307612|NCT04623476|Experimental|Pathophysiological Excision for Chron's disease|Consecutive patients (>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD
16307659|NCT04623216|Experimental|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
16307699|NCT04622995||Exposed|Patients prescribed opiate replacement therapy plus a benzodiazepine.
16307613|NCT04623463|Other|Exercise intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
16307614|NCT04623450|Experimental|High Carbohydrate Meal|A smoothie including maltodextrin and low-fat strawberry yoghurt - 289 kcal, 61g carbohydrate, 6.7g protein, 1.9g fat.
16307615|NCT04623450|Experimental|High Fat Meal|A smoothie including double cream and low-fat strawberry yoghurt - 312 kcal, 13.3g carbohydrate, 7g protein, 25.5g fat.
16307616|NCT04623450|Experimental|High Protein Meal|A smoothie including whey protein and low-fat strawberry yoghurt - 307 kcal, 13.6g carbohydrate, 57g protein, 2.7g fat.
16307617|NCT04623411|Experimental|Intervention Group|Neonatal resuscitation training with classical method and serious game simulation method
16307618|NCT04623411|Experimental|Control Group|Neonatal resuscitation training with classical method.
16307619|NCT04623398|Experimental|Lithium|"Li+ is an FDA (NDA: 016834) and ANSM (AMM 3400931376339) approved drug. There are two lithium salts that are marketed in France, Teralithe LI (cp 250mg) and Teralithe LP (cp 400mg).
~The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials."
16307620|NCT04623398|Placebo Comparator|Placebo|"Capsules containing lactose monohydrate in all points resembling the capsules of active ingredients.
~Capsules of pla62.5 mg, pla125 mg and pla250 mg (pla=placebo)"
16307621|NCT04623385|Active Comparator|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
16307622|NCT04623385|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
16307623|NCT04623372|Experimental|suture|
16307624|NCT04623372|Experimental|Directed wound healing|
16307625|NCT04623359|Experimental|Patients|Patient with constipation will have a high resolution manometry
16307626|NCT04623359|Other|Healthy volunteers|Healthy volunteers will have a high resolution manometry
16307627|NCT04623346||Weber B-type Ankle fractures in prepandemic period|Patients with AO Weber B-type ankle fracture in prepandemic period
16307628|NCT04623346||Weber B-type Ankle fractures in pandemic period|Patients with AO Weber B-type ankle fracture in pandemic period
16307629|NCT04623346||Wrist fractures in prepandemic period|Patients with extraarticular distal radius fracture in prepandemic period
16307630|NCT04623346||Wrist fractures in pandemic period|Patients with extraarticular distal radius fracture in pandemic period
16307631|NCT04623346||Proximal humerus fractures in prepandemic period|Patients with 2-part,3-part and 4-part fractures in prepandemic period
16307632|NCT04623346||Proximal humerus fractures in pandemic period|Patients with 2-part,3-part and 4-part fractures in pandemic period
16307633|NCT04623333|Experimental|TQB2450 injection|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
16307634|NCT04623320||NAFLD+T1DM+|Subjects with type 1 diabetes and ultrasound-defined NAFLD
16307635|NCT04623320||NAFLD-T1DM+|Subjects with type 1 diabetes without ultrasound-defined NAFLD
16307636|NCT04623307||Brain damage patients|Brain damage patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
16307637|NCT04623307||Brain edema patients|Brain edema patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
16307638|NCT04623307||Healthy subjects|Healthy subjects were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
16307639|NCT04623294||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
16307640|NCT04623294||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
16307641|NCT04623294||Deep coma patients for HLH Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
16307642|NCT04623294||Deep coma patients for LHL Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
16307643|NCT04623294||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
16307644|NCT04623294||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
16307645|NCT04623281||Observational group|Observational group of 10 haemodialysis patients following usual care for 3 weeks.
16307646|NCT04623268||Adult offspring|Adult female and male offspring to AAA patients 45-80 years of age at inclusion Children to detected AAA patients. Found in the Multigeneration registry
16307647|NCT04623268||Control group|Matched women and men, without parents with AAA. Matched in the Swedish Multigeneration registry
16307648|NCT04623255|No Intervention|STANDARD OF CARE|Standard patient care for severe COVID-19
16307649|NCT04623255|Active Comparator|Plasma exchange|Standard patient care for severe COVID-19 with. plasma exchange daily for 5 days x 3 courses as required
16307650|NCT04623242|Experimental|Gantenerumab|
16307651|NCT04623242|Experimental|Solanezumab|
16307660|NCT04623216|Experimental|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
16307661|NCT04623216|Experimental|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to < 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
16307662|NCT04623203||children with migraine|Children that were diagnosed at the neurology clinic with migraine at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
16307663|NCT04623203||children with TTH|children that were diagnosed at the neurology clinic with TTH at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
16307664|NCT04623190|Experimental|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline. The providers will be delivering the PREVENT tool.
16307665|NCT04623190|Active Comparator|Patients - Wait-List Control|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail
~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
16307666|NCT04623190|Experimental|Patients - PREVENT Tool|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail
~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
16307667|NCT04623177||Anticoagulation|Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
16307668|NCT04623177||Thromboprophylaxis|Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
16307669|NCT04623177||No heparin|Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission
16307670|NCT04623164|No Intervention|1 Group (Control)|ten students with healthy periodontium
16307671|NCT04623164|Experimental|2 Group|ten patients receiving standard non-surgical periodontal treatment (NSPT)
16307672|NCT04623164|Experimental|3 Group|ten patients receiving standard non-surgical periodontal treatment NSPT + 28-day chronotherapy with complex phytoadaptogens (CFA)
16307673|NCT04623151|Experimental|Online leaflet in narrative format|
16307674|NCT04623151|Active Comparator|Online leaflet in non-narrative format|
16307675|NCT04623151|No Intervention|No leaflet (control)|
16307676|NCT04623138||Garmin Study Device Group|Individuals who are randomly assigned to receive the Garmin vívosmart® 4
16307677|NCT04623138||Empatica Study Device Group|Individuals who are randomly assigned to receive the Empatica E4
16307678|NCT04623125|Experimental|Spaced Repetition|Two weeks (10 sessions) of online picture-naming training with 60 words.
16307679|NCT04623112|Other|FC Deactivated|Frequency Compression feature on hearing aids is deactivated for 4 weeks
16307680|NCT04623112|Experimental|FC activated & set to default|Frequency compression feature activated on hearing aids and set to default software settings for 4 weeks.
16307681|NCT04623112|Experimental|FC activated and set to hearing loss|Frequency Compression feature activated on hearing aids and set to hearing loss cut-off for 4 weeks
16307682|NCT04623099|Other|Standard dosing|Patients randomized to standard dosing (std) will initiate escitalopram at 5 mg daily and will then increase to 20 mg/day at week 4.
16307683|NCT04623099|Experimental|Pharmacogenetically-guided escitalopram dosing|Patients randomized to PGx-guided treatment, escitalopram titration will be based on CYP2C19 phenotype and predicted escitalopram exposure. In poor metabolizers (PM), escitalopram will be initiated at 5 mg daily and increased to 10 mg daily at week 4.
16307684|NCT04623086|Experimental|Insulin Glargine and Insulin Degludec|Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
16307685|NCT04623086|Placebo Comparator|Insulin Degludec and placebo|Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
16307686|NCT04623073||Patients who underwent DAA THA|Patients who underwent DAA THA by a single surgeon who routinely documents the distance from the should of the stem to the upper end of the EO footprint
16307687|NCT04623060|Experimental|Intervention|3 sessions/week for 6 weeks
16307688|NCT04623047||Adults 18 years of age and up|The study will recruit any adult over the age of 18 years.
16307689|NCT04623034|Experimental|400 mg MSI-195 - SAD|400 mg MSI-195 (within Stage 1, single ascending dose)
16307690|NCT04623034|Experimental|800 mg MSI-195 - SAD|800 mg MSI-195 (within Stage 1, single ascending dose)
16307691|NCT04623034|Experimental|1600 mg MSI-195 -SAD|1600 mg MSI-195 (within Stage 1, single ascending dose)
16307692|NCT04623034|Experimental|800 mg MSI-195 - fasted|800 mg MSI-195 fed (within Stage 2, cross-over comparison)
16307693|NCT04623034|Experimental|1600 mg SAM-e Complete TM - fasted|1600 mg SAM-e Complete (within Stage 2, cross-over comparison)
16307694|NCT04623034|Experimental|800 mg MSI-195 - fed|800 mg MSI-195- fed (within Stage 2, fed arm)
16307695|NCT04623021|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
16307696|NCT04623021|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
16307697|NCT04623008|Experimental|Goal-Oriented Episodic Future Thinking (GOEFT) Intervention|In addition to usual prenatal care, intervention participants will receive a 20-week intervention via web and individual health counseling. The intervention topics focus on stress management, healthy eating, and physical activity.
16307698|NCT04623008|No Intervention|Usual Prenatal Care|The usual prenatal care group will receive usual care from their providers
16307700|NCT04622995||Unexposed|Patients prescribed opiate replacement therapy with no benzodiazepine prescribing.
16307701|NCT04622982|Experimental|All participants|Obese subjects with BMI >= 30 and with one or more of metabolic comorbidities (type 2 diabetes mellitus, dyslipidemia, high blood pressure, hyperuricemia, and others).
16307702|NCT04622969|Experimental|Intervention|Provide the 15-week Healthy Child Development Program intervention
16307703|NCT04622969|No Intervention|Wait list control|
16307704|NCT04622956|Experimental|Experimental|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
16307705|NCT04622956|No Intervention|Control Group|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on day +5). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present.
16307706|NCT04622943|Experimental|firearms safety|Children will spend two 30-minute sessions engaged on ShootSafe, an internet-based training program on firearms safety.
16307707|NCT04622943|Active Comparator|nutrition|Children will spend two 30-minute sessions engaged on nourishinteractive.com, an internet-based training program on nutrition and exercise.
16307708|NCT04622930|Experimental|Experimental: Smartphone-delivered CBT for SAD|12-week Smartphone delivered CBT for SAD.
16307709|NCT04622930|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for SAD following the 12-week waitlist control).
16307710|NCT04622917|Active Comparator|Methylprednisolone|Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage
16307711|NCT04622917|Placebo Comparator|Sodium Chloride (NaCl)|NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage
16307712|NCT04622904|Active Comparator|lidocaine-magnesium group|combination of lidocaine and magnesium infusions
16307713|NCT04622904|Active Comparator|lidocaine-ketamine group|combination of lidocaine and ketamine infusions
16307714|NCT04622904|Active Comparator|lidocaine group|lidocaine infusion alone
16307715|NCT04622891|Experimental|clarithromycin|clarithromycin group
16307716|NCT04622891|Active Comparator|Azithromycin|azithromycin group
16307717|NCT04622891|Placebo Comparator|control|control group
16307718|NCT04622878|Other|acute lower limb ischemia patients|patients with no palpable pulsations or audible signals in the lower limb
16307719|NCT04622865|Experimental|Masitinib plus Isoquercetin plus Best Supportive Care|"Patients will receive oral masitinib dose of 3 mg/kg/day for 4 days then 4.5 mg/kg/day.
~The dose of isoquercetin will be 1 g/day by oral route. Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs."
16307720|NCT04622865|Active Comparator|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.
16307721|NCT04622852||Group A: ALPS-PHP device|Patients operated with angular stable plate for displaced PHF with an ALPS plate
16307722|NCT04622852||Group B: Philos device|Patients operated with angular stable plate for displaced PHF with a Philos plate
16307723|NCT04622839|Experimental|Group 1|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
16307724|NCT04622839|Experimental|Group 2|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
16307725|NCT04622839|Experimental|Group 3|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
16307726|NCT04622826|Experimental|sequential immune plasma infused patients|immune covid 19 plasma infusion
16307727|NCT04622813|Placebo Comparator|Placebo group|
16307728|NCT04622813|Experimental|Multimodal group|
16307729|NCT04622800|Other|Individuals applied with proprioceptive neuromuscular fasilition techniques|No exercise intervention was made.
16307730|NCT04622787||Tuscany, Italy|Infants at risk of Cerebral Palsy in Tuscany, Italy
16307731|NCT04622787||Infants at risk of Cerebral Palsy in Georgia|Infants at risk of Cerebral Palsy in Georgia
16307732|NCT04622787||Sri-Lanka|Infants at risk of Cerebral Palsy in Sri-Lanka
16307733|NCT04622787||Denmark|Infants at risk of Cerebral Palsy in Denmark
16307734|NCT04622787||Infants at risk of Cerebral Palsy in the Netherlands|the Netherlands
16307735|NCT04622787||remote Queensland, Australia|Infants at risk of Cerebral Palsy in remote Queensland, Australia
16307736|NCT04622787||Medical professionals|Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
16307737|NCT04622774|Experimental|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
16307738|NCT04622761|No Intervention|control|Immediate surgery (radical prostatectomy) (standard care)
16307779|NCT04622462||Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia|"No evidence of dysplasia
~Mild dysplasia
~Moderate dysplasia
~Severe dysplasia"
16307780|NCT04622449||Chronic liver disease with anemia|All patients with anemia as diagnosed by WHO criteria in patients with liver disease of any etiology.
16307781|NCT04622423||PDAC liver-MTS|Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.
16307739|NCT04622761|Experimental|treatment|"14 days prior to starting Cabazitaxel patients will take 50mg Bicalutamide once daily for 21 days.
~7 days prior to starting Cabazitaxel patients will be given 3 months LHRH treatment via injection. The entire dose will be administered via one injection 7 days prior to starting Cabazitaxel. This may be either leuprorelin or goserelin acetate and should be given as per local practice.
~At least 30 minutes prior to each administration of Cabazitaxel, patients will be administered IV premedication consisting of:
~50mg Ranitidine 10mg Chlorphenamine 8mg Dexamethasone Daily from Day 1 until end of Cabazitaxel treatment patients will take 10mg Prednisolone once daily from Day 1 until end of Cabazitaxel treatment Day 1 of each cycle - Patients will receive Cabazitaxel 25 mg/m2 intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles."
16307740|NCT04622748||COVID-19|Recovered COVID-19 patients in Wuhan
16307741|NCT04622748||Healthy Control|Uninfected people in Wuhan
16307742|NCT04622735|Experimental|FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
16307743|NCT04622735|Active Comparator|Paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
16307744|NCT04622735|Active Comparator|Nefopam hydrochloride 30 mg (X2)|Each dose: 2 tablets (included in masking capsule)
16307745|NCT04622722|Active Comparator|Group A|Group A: Drinking Nutren Diabetes provides energy at 360 kcal per 360 ml
16307746|NCT04622722|Placebo Comparator|Group B|Group B: Having Isocaloric diet provide 360 kcal.
16307747|NCT04622709|Experimental|Study drug administration: furosemide|Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant.
16307748|NCT04622696||Prospective - Performance Cohort|Subjects will undergo an ultrasound-guided breast biopsy procedure with placement of HydroMARK Breast Biopsy Site Marker per site standard of care and will return to the office at 6-12 weeks post-implant for ultrasound imaging to evaluate device visibility.
16307749|NCT04622696||Retrospective - Safety Cohort|Device-related adverse events will be collected via retrospective medical chart review for a minimum of 90 days post-HydroMARK Breast Biopsy Site Marker implant (unless the subject was exited according to the medical records due to the implant being removed/explanted or subject death).
16307750|NCT04622683|Experimental|Control Group- Healthy, Lean Individuals|Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.
16307751|NCT04622683|Active Comparator|Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance|Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
16307752|NCT04622670|Experimental|Group I (yoga group)|Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over 5-10 minutes and receive a yoga manual and DVD during and after CRT.
16307753|NCT04622670|Active Comparator|Group II (wait list control)|Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
16307754|NCT04622657|Experimental|parkinson disease|Assessment
16307755|NCT04622644|Experimental|Single Arm|All patients perform StrokeWave exam, after NCCT and before CTA acquisition.
16307756|NCT04622631||PRRT positive|patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans
16307757|NCT04622631||PRRT negative|no response to PRRT treatment
16307758|NCT04622618|Active Comparator|G 300|The patients will receive 300 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
16307759|NCT04622618|Active Comparator|G 600|The patients will receive 600 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
16307760|NCT04622618|Active Comparator|G 900|The patients will receive 900 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
16307761|NCT04622605|Experimental|Treatment Group|Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent
16307762|NCT04622592|Experimental|Vaccine (30 µg/strain) adjuvanted with AS03|Treatment group 2: 30 µg/strain QVLP vaccine adjuvanted with AS03
16307763|NCT04622592|Active Comparator|Vaccine (30 µg/strain) unadjuvanted|Treatment group 4: 30 µg/strain QVLP vaccine unadjuvanted
16307764|NCT04622592|Active Comparator|Vaccine (60 µg/strain) Fluzone HD Quad|Treatment group 5: 60 µg/strain Fluzone HD Quad vaccine
16307765|NCT04622579|Experimental|lenalidomide combined with rituximab|Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
16307766|NCT04622566|Experimental|Lenvatinib and Pembrolizumab in Resectable mucosal Melanoma.|
16307767|NCT04622553|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
16307768|NCT04622540|Experimental|Experimental group|Application of external biliary drainage
16307769|NCT04622540|No Intervention|Control group|Conventional duct-to-duct anastomosis (with or without internal stent)
16307770|NCT04622527|Active Comparator|A = Virtual Reality paradigm A|Paradigm A with virtual reality headgear
16307771|NCT04622527|Active Comparator|B = Virtual Reality paradigm B|Paradigm B with virtual reality headgear
16307772|NCT04622527|Sham Comparator|C = Non-Virtual Reality paradigm A|Paradigm A without virtual reality headgear
16307773|NCT04622527|Sham Comparator|D = Non-Virtual Reality paradigm B|Paradigm B without virtual reality headgear
16307774|NCT04622514|Experimental|people-centered integrated care|
16307775|NCT04622514|Active Comparator|usual care|
16307776|NCT04622488|Active Comparator|Diclofenac Potassium|In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.
16307777|NCT04622488|Experimental|Calcium Hydroxide|
16307778|NCT04622475|Experimental|Treatment|Fecal Microbiota Transplant (FMT) Capsule
16307782|NCT04622423||CRC liver-MTS|Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).
16307783|NCT04622423||Primary not-MTS PDAC|Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.
16307784|NCT04622423||Healthy volunteers|Negative control for the clinical study.
16307785|NCT04622397|Active Comparator|Group T (tranexamic acid),n=15|Group T: tranexamic acid 10 mg/kg will be injected locally
16307786|NCT04622397|Placebo Comparator|Group S (saline) (n=15)|Group S saline will be injected
16307787|NCT04622384||ICU patients|Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
16307788|NCT04622371|Experimental|moderate exercises group|Patients received 30 minutes of aerobic exercise at 40-60% of maximum heart rate
16307789|NCT04622371|Experimental|Light exercises group|Patients treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
16307790|NCT04622358|Experimental|AD-214-02/Rabeprazole|Period 1 : Test Drug(AD-214-02) Period 2 : Reference Drug(Rabeprazole)
16307791|NCT04622358|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole) Period 2 : Test Drug(AD-214-02)
16307792|NCT04622345|Experimental|VSJ-110 Solution|
16307793|NCT04622345|Placebo Comparator|Placebo Solution|
16307794|NCT04622332|Experimental|SIR1-365|SIR1-365 dose 1 daily for 14 days
16307795|NCT04622332|Placebo Comparator|Matching placebo|Matching placebo dose 1 daily for 14 days
16307796|NCT04622319|Experimental|Trastuzumab deruxtecan (T-DXd)|Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.
16307797|NCT04622319|Active Comparator|Trastuzumab ematansine (T-DM1)|Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.
16307798|NCT04622306|Active Comparator|Control|Commercial Natural Rubber Latex Male Condom
16307799|NCT04622306|Experimental|Polyurethane Condom A|Polyurethane Condom A (002)
16307800|NCT04622306|Experimental|Polyurethane Condom B|Polyurethane Condom B (001)
16307801|NCT04622293|Experimental|Solriamfetol|Those who are receiving solriamfetol will receive 37.5 mg, 75 mg, or 150 mg. Patients will begin at a 75 mg dose and then after three days titrate up or down as needed, determined by consultation visits with primary investigator. Solriamfetol will be taken orally.
16307802|NCT04622293|Placebo Comparator|Placebo|Those who are not receiving solriamfetol will receive the placebo drug, which will be encapsulated in matching capsules to reduce any bias or speculation with participants.
16307803|NCT04622267|Active Comparator|Standard suture|Standard antimicrobial suture (vicryl) - control arm
16307804|NCT04622267|Experimental|Barbed suture|Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue
16307809|NCT04622241|Experimental|Eave Tubes - Traditional House|Installation of eave tubes in traditional homes.
16307810|NCT04622241|Experimental|Eave Tubes - Modern House|Installation of eave tubes in modern homes.
16307811|NCT04622241|Experimental|Eave Ribbons - Traditional House|Installation of eave ribbons in traditional homes.
16307812|NCT04622241|Experimental|Eave Ribbons - Modern House|Installation of eave ribbons in modern homes.
16307813|NCT04622241|Experimental|Full House Screening - Traditional House|Installation of full house screening, includes screening eaves and windows, in traditional homes.
16307814|NCT04622241|Experimental|Full House Screening - Modern House|Installation of full house screening, includes screening eaves and windows, in modern homes.
16307815|NCT04622241|Experimental|Partial House Screening - Traditional House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
16307816|NCT04622241|Experimental|Partial House Screening - Modern House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
16307817|NCT04622241|No Intervention|Control - Traditional House|Control group with no intervention in traditional homes
16307818|NCT04622241|No Intervention|Control - Modern House|Control group with no intervention in modern homes.
16307820|NCT04622215|Other|ICIQ questionnaire|
16307821|NCT04622202|Active Comparator|pregabalin|oral capsule pregabalin 150 mg.
16307822|NCT04622202|Placebo Comparator|multivitamin|oral multivitamin capsule.
16307823|NCT04622189|Experimental|Action observation training for the upper limb rehabilitation|Neurorehabilitation training for the upper limb using AOT consists of watching videos related to every day actions. The subjects will be asked to reproduce, as accurately as possible, the actions proposed by the system, that will record their execution. In order to keep high motivation and participation in activities, simple games of skill will also be created that will involve the patient on both the motor and cognitive side. The training program includes 250 videos of every day transitive and intransitive actions: 20 consecutive sessions of 1 hour, five times a week over four weeks.
16307824|NCT04622176||Patients with rectal cancer|Patients with rectal cancer will be included and asked to participate in the study where a MMUS will be used after resection to test diagnostic accuracy.
16307825|NCT04622163|Experimental|Secondary Mentor Plus Career Development Resources|Subjects will be assigned a secondary mentor for 6 months. Subjects will also receive career development resources.
16307826|NCT04622163|Other|Career Development Resources Alone|Subjects will not be assigned a secondary mentor. Subjects will receive career development resources only.
16307827|NCT04622150|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the experimental intervention, Customized Adherence Enhancement (CAE).
16307828|NCT04622150|Active Comparator|Enhanced Treatment as Usual (eTAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (eTAU).
16307829|NCT04622137|No Intervention|Arm sling only group (group S)|Participants used only arm sling for clavicula fracture
16307830|NCT04622137|Active Comparator|Arm sling with kinesiotaping therapy group (group K).|Participants used arm sling and the investigators applied kinesiotheraphy for clavicula fracture
16307831|NCT04622124|Placebo Comparator|Part 1 Single Ascending Dose (SAD) study|The single ascending dose trial set up 7 dose groups of 2.5, 5, 10, 20, 40, 60 and 80 mg. The 2.5 mg dose group was the exploratory part with open label, while the other dose groups were double-blind. 8 subjects were randomly enrolled in each dose group, 6 of whom received FCN-207 tablets and 2 of whom received placebo. This part of the study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic studies of single dose FCN-207 tablets in healthy volunteers.
16307832|NCT04622124|Experimental|Part 2 Food-effect study|Twelve subjects were enrolled and randomly divided into two groups. The subjects were given FCN-207 tablets after fasting and high-fat diet with double Cross experiment , and feces samples were collected for metabolism/excretion characteristics study.
16307833|NCT04622124|Placebo Comparator|Part 3 Multiple Ascending Dose (MAD) study|A total of 16 subjects were randomly assigned to each dose group for multiple dose study , including 12 who received FCN-207 tablets and 4 who received placebo for a 10-day administration cycle. The dosage of multiple administration was based on the results of single ascending dose study results , and the method of drug administration refers to the results of the food influence test.
16307834|NCT04622111|Experimental|CPL207280|"PART A: 8 cohorts are to receive single dose of IMP.Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.
~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
16307835|NCT04622111|Placebo Comparator|Placebo|PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
16307836|NCT04622111|Experimental|CPL207280 120 mg + Metformin 750 mg|1 cohort (total of 12 participants) are to receive single dose of IMP in fed and fasted state, IMP with metformin and metformin alone to assess the effect of food and metformin on bioavailability of CPL207280. There is to be one week wash-out between four treatments periods for this cohort.
16307837|NCT04622098||patients with SEL|"Any patient with detected sub-epithelial lesion during upper endoscopy either symptomatized or accidently discovered.
~Patients diagnosed by EUS, CT scan or surgically removed lesions."
16307838|NCT04622085|Experimental|ANIMERS Chiara LA|
16307839|NCT04622085|Active Comparator|JUVÉDERM VOLUMA®|
16307840|NCT04622072|Experimental|Experimental group|For dose escalation phase, subjects are enrolled for different doses of the experimental drug.
16307841|NCT04622059|Experimental|acoustic stimulation|Fetuses in the group A (n=105) received an acoustic stimulation
16307842|NCT04622059|No Intervention|no acoustic stimulation|Fetuses in the group B (n=105) no intervention was performed
16307843|NCT04622046|Experimental|ALXN2060|Participants will receive ALXN2060.
16307844|NCT04622033|Experimental|Brodalumab 210mg|
16307845|NCT04622020||Adult patients with chronic neck pain (> 3 months) following whiplash injury|Cervical plexus block with local anaesthesia followed by Cervical Plexus block with depot steroids
16307850|NCT04621994|Active Comparator|Steri Strips Arm|
16307851|NCT04621994|Experimental|Dermabond Arm|
16307852|NCT04621981|Experimental|Sodium Bicarbonate Ringer's Solution|Intravenous drip, 500~1000ml per time. Infusion speed: 15ml/kg/h or according to guidelines or department routine.
16307853|NCT04621981|Active Comparator|Normal Saline|"Intravenous drip, 500~1000ml per time. Dosage depends on age、weight and symptoms.
~Infusion speed: According to the department process or clinician's decision."
16307854|NCT04621942|Experimental|Training group|12 women after mastectomy. Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Moreover, women from training group participated in rehabilitation gymnastics twice a week.
16307855|NCT04621942|Active Comparator|Control group|12 women after mastectomy. All women participated in rehabilitation gymnastics twice a week.
16307856|NCT04621929|Experimental|Allocated to intervention/treatment|Daily phentermine/topiramate x 18 months
16307857|NCT04621929|Active Comparator|Allocated to pragmatic control|Remain on their current regimen
16307858|NCT04621916|Active Comparator|Emicizumab + FVIII weekly|In addition to emicizumab prophylaxis,participants will receive non-prophylactic exposure to FVIII concentrates through weekly 50 IU/kg ±10% doses - the choice of FVIII concentrate is at the discretion of the PI.
16307859|NCT04621916|Active Comparator|Emicizumab only|Participants will only receive emicizumab prophylaxis.
16307860|NCT04621903|Experimental|Ayurveda|
16307918|NCT04621448|Experimental|Delayed Start|A Delayed Start group will be encouraged to continue with their usual daily activities during the first 12 weeks of the study and will begin the Moving Together program after completing the mid-point assessment.
16307919|NCT04621435|Experimental|Dosimetry population (Cohort 1)|PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection. Contrast may be administered if clinically indicated.
16307861|NCT04621890|Experimental|LOAN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary deductions from a virtual bank of $210 for missed doses of insulin at mealtimes. According to the methodology for calculating BOLUS(1) breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will deduct $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus missed (maximum -$1.50/day). Youth can also lose an additional amount of up to $5.00/week for weeks during which they don't achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will deduct the virtual account up to $2.00 per week for failing to share their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum deduction of $24.00). Maximum total deductions is $210.
16307862|NCT04621890|Experimental|COIN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary incentives for dosing insulin at mealtimes. Mealtimes will be defined based on hour of the day and the presence of a carbohydrate entry associated with the insulin bolus. Breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will reimburse youth up to $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus completed (maximum $1.50/day). We will offer the opportunity for youth to earn a bonus reimbursement of up to $5.00/week for weeks during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth up to $2.00 per week for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum $24.00). Therefore, maximum total incentive available is $210.
16307863|NCT04621890|No Intervention|Control|This group will engage have usual diabetes care without intervention. They will fill out all questionnaires, attend clinic visits and provide A1C samples at the same times as the participants in the other groups.
16307864|NCT04621877|Experimental|"Volunteer-delivered Behavioral Activation - Do More, Feel Better"|"Do More, Feel Better (DMFB) is a streamlined, simplified version of Behavioral Activation (BA) delivered by lay volunteers to depressed senior center clients."
16307865|NCT04621877|Active Comparator|Master's Level Clinician-delivered Behavioral Activation|Traditional Behavioral Activation (BA) delivered by master's level mental health clinicians
16307866|NCT04621851||Retrospective cohort|Patients who discontinued before the opening of this study will contribute to the retrospective cohort.
16307867|NCT04621851||Prospective cohort|Patients who will discontinue after it will contribute to the prospective cohort.
16307868|NCT04621851||Retrospective/Prospective cohort|Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.
16307869|NCT04621838|Experimental|Assigned intervention.|"Silicone Foam Dressing. Silicone Foam Lite.
~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silicone Foam dressing and Silicone Foam Lite Dressing."
16307870|NCT04621825|Experimental|Assigned intervention|"ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam.
~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam."
16307871|NCT04621799|Experimental|Fibrin Group|Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin
16307872|NCT04621786|Experimental|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
16307873|NCT04621773||PGS(Preimplantation Genetic Screening)|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure
16307874|NCT04621773||SP(spontaneous pregnancy )|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.
16307875|NCT04621760|Experimental|HIV Prevention DST Intervention|Participants in this arm will receive the HIV prevention DST intervention and will receive the intervention immediately before their provider visit.
16307876|NCT04621760|Active Comparator|Standard Counseling|Participants in this arm will receive usual care.
16307877|NCT04621747|Experimental|Study group|healthy volunteers aged 18-35, balanced sex ratio, all of them undergoing the same battery of psychophysical explorations.
16307878|NCT04621734|Active Comparator|Nasal bridle to secure feeding tube|The nasal bridle will be used to secure the nasoenteric feeding tube.
16307879|NCT04621734|Placebo Comparator|Adhesive Tape use to secure feeding tube|Adhesive tape will be used as standard of care to secure the nasoenteric feeding tube.
16307880|NCT04621721|Experimental|Intervention Group|The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
16307881|NCT04621721|Active Comparator|Attention Control Group|The Attention Control group will receive an educational intervention via a journal in which to record their clinic appointments, and standardized American Cancer Society pamphlets which have been adjusted to fit within the journal binding for easy reference. At each data collection encounter, the intervention research assistant will discuss the information in each pamphlet, allowing time for questions related to the material. The educational materials consist of 1) Emotions and Breast Cancer; 2) Body Image and Sexuality After Breast Cancer; 3) Follow up Care After Breast Cancer Treatment; 4) Nutrition and Cancer. Sessions last approximately 45-60 minutes and occur at the same intervals as the intervention group and will precede data collection. Attention Control group participants will receive telephone calls every other week which will entail a social visit and reminder of data collection/attention intervention appointments to further equalize contact.
16307882|NCT04621708|Experimental|Left DLPFC iTBS rTMS|
16307883|NCT04621695|Other|Rubber band ligation|Rubber band ligation is performed by a suction device that allows a rubber band to be applied at the base of the haemorrhoid via a proctoscope. Maximal suction force used is 40 mmHg. A maximum of 3-4 bands are used per session. This rubber band constricts the blood supply causing it to become ischaemic before being sloughed approximately 1-2 weeks later. The resultant fibrosis reduces any element of haemorrhoidal prolapse that may have been present. No sedation is required for this day-care procedure. Patients are asked to administer an enema 2 hours prior to the procedure.
16307884|NCT04621695|Other|Hemorrhoidectomy|"There are two main excisional procedures currently carried out: open (Milligan and Morgan) and closed (Ferguson). Both have the intention of excising the haemorrhoidal cushions. The procedure is performed under either general or spinal anaesthesia in a day-care setting.
~Patients were asked to administer an enema 2 hours prior to the procedure."
16307885|NCT04621682|Active Comparator|Non technical skills and check list|10 hours of training in non-technical skills and checklists in high Fidelity simulation
16307886|NCT04621682|Active Comparator|check list|Control: 10 hours of standard training with checklists in high Fidelity simulation
16307887|NCT04621669|Experimental|digoxin, Rosuvastatin calcium,SHR3680|
16307888|NCT04621669|Experimental|metformin hydrochloride ,SHR3680|
16307889|NCT04621656||Type 2 Diabetes|Individuals that have been previously diagnosed with Type 2 Diabetes. Those with Fasting Blood Glucose levels 126 mg/dL in two separate tests and/or HbA1C values greater than 6.5%. Individuals may take Metformin, SGLT2 inhibitors, of GLP-1 therapeutics. Not including those using Insulin therapeutics.
16307890|NCT04621656||Pre-Diabetes|Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
16307891|NCT04621656||Healthy|Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
16307892|NCT04621643|Experimental|digital cognitive behavioral therapy (dCBT-I)|
16307893|NCT04621643|Active Comparator|Patient education about sleep (PE)|
16307894|NCT04621630|Experimental|Single Dose|Single dose administration
16307895|NCT04621630|Experimental|Multiple Dose|Multiple dose administration
16307896|NCT04621630|Experimental|Solid Dose Comparison|Solid dose administartion
16307897|NCT04621617|Active Comparator|Albumin + Midodrine + SMT|Human albumin plus oral midodrine
16307898|NCT04621617|Active Comparator|Albumin + SMT|Human albumin plus placebo of midodrine
16307899|NCT04621617|Placebo Comparator|SMT|standard medical therapy plus placebo of midodrine
16307900|NCT04621604|Experimental|Patients|
16307901|NCT04621591|Experimental|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care EGD procedure performed using the Saneso 360° gastroscope. Immediately thereafter Patients will then have an EGD procedure using a standard Gastroscope (Olympus GIF 180) performed by a second endoscopist.
16307902|NCT04621578|Experimental|Transcutaneous electrical acupoint stimulation arm|Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.
16307903|NCT04621578|Sham Comparator|Sham stimulation arm|Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.
16307904|NCT04621565|Experimental|Hydrocortisone withholding group|Patients receive no hydrocortisone
16307905|NCT04621565|Active Comparator|Hydrocortisone group|Patients receive routine hydrocortisone
16307906|NCT04621539||Infected without an SMO|Defined as an acute infection not associated with admission to the intensive care unit (ICU), mechanical ventilation, or the use of vasopressors.
16307907|NCT04621539||Infected with an SMO|defined as an acute infection associated with intensive care unit (ICU) admission, mechanical ventilation, or vasopressor use.
16307908|NCT04621526|Active Comparator|dexmedetomidine- ketamine|patients will receive combination of ketamine 1.5mg/kg and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
16307909|NCT04621526|Active Comparator|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
16307910|NCT04621513|Experimental|Collaborative Care Model of TCM and WM|Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair
16307911|NCT04621513|Active Comparator|Western medicine|Western Medicine (WM):intra-nasal corticosteroid with singulair
16307912|NCT04621500|Other|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
16307913|NCT04621487|Active Comparator|concomitant|Concomitant therapy consists of 14 days pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg all twice daily.
16307914|NCT04621487|Active Comparator|tailored|Tailored therapy consists of 14 days antibiotic therapy according to H. Pylori strains antibiotic sensitivity test together with pantoprazole 40 mg twice daily.
16307915|NCT04621461|Placebo Comparator|Experimental Arm #1|Placebo
16307916|NCT04621461|Experimental|Experimental Arm #2|Zinc sulfate
16307917|NCT04621448|Experimental|Immediate Start|The Immediate Start group will participate in the 12-week Moving Together program after completing the baseline assessment. Moving Together is a gentle, live-streaming, group movement program designed specifically for people with memory loss (PWML) and caregivers (CG) to do together. It is based on the in-person Preventing Loss of Independence through Exercise (PLIÉ) and Paired PLIÉ programs. The program combines physical movements to help maintain daily function with mindful body awareness exercises and social interactions to provide a comprehensive, multi-domain program.
16308848|NCT04615026||COVID 19 patients|all patients with positive SARS-CoV 2 swap
16307920|NCT04621435|Experimental|Participants with metastatic disease (Cohort 2)|Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.
16307921|NCT04621435|Experimental|Participants without metastatic disease (Cohort 3)|Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if if clinically indicated.
16307922|NCT04621409|Experimental|liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
16307923|NCT04621409|Placebo Comparator|Placebo|IV infusion of saline, approximately 5 hours
16307924|NCT04621396||Next Generation Cohort|We will follow the children from mothers who either have T2D, GDM, or are controls.
16307925|NCT04621383|Experimental|whey protein plus collagen group|Participants received a dose of 30 grams of whey protein plus 20 grams of collagen seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
16307926|NCT04621383|Placebo Comparator|whey protein plus maltodextrin group|Participants received a dose of 30 grams of whey protein plus 20 grams of maltodextrin seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
16307927|NCT04621370|Active Comparator|Arm A|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy
~Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1
~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total
~Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
16307928|NCT04621370|Active Comparator|Arm B|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy
~Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1
~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles
~Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
16307929|NCT04621357|Experimental|Patient with intracerebral haemorrhage|Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
16307930|NCT04621331|Experimental|Roxadustat|Starting doses of 20, 50, 70 or 100 mg based on weight.
16307931|NCT04621318|Experimental|SB16|SB16 (proposed denosumab biosimilar)
16307932|NCT04621318|Active Comparator|EU Prolia|EU sourced Prolia (denosumab)
16307933|NCT04621318|Active Comparator|US Prolia|US sourced Prolia (denosumab)
16307934|NCT04621305|Placebo Comparator|group P (Placebo group)|Patients were assigned to group P (Placebo group) using a computer-generated random number table
16307935|NCT04621305|Experimental|group B (Bolus group)|Patients were assigned to group B (Bolus group) using a computer-generated random number table
16307936|NCT04621305|Experimental|group C (continuous infusion group)|Patients were assigned to group C (continuous infusion group) using a computer-generated random number table
16307937|NCT04621279||Mild Hypoxic Ischemic Encephaolpathy|"Infant ≥ 360/7 weeks with evidence of BOTH 1) perinatal event fetal acidosis and 2) encephalopathy on exam.
~Perinatal depression as defined by NICHD based on at least one of the following; pH <7.00 in a cord gas or Base deficit ≥15 mmol/L in a gas (arterial or venous) obtained at <60 min of age, Apgar score <5 at 10 minutes, or Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP).
~Mild encephalopathy, as defined by PRIME-study 1-6 hours after birth. At least 1 of 6 Sarnat criteria is scored as a mild, moderate, or severe abnormality, and Fewer than 3 of 6 Sarnat criteria are scored as a moderate or severe abnormality"
16307938|NCT04621266|Experimental|Home-based peer support intervention|Participants will receive intervention on top of standard usual care.
16307939|NCT04621266|No Intervention|Standard usual care|Participants will receive standard usual care.
16307940|NCT04621253|Active Comparator|Ciprofloxacin|Day 1: 750 mg ciprofloxacin capsule in the morning and evening Day 2: 750 mg ciprofloxacin capsule in the morning and evening Day 3: 750 mg ciprofloxacin capsule in the morning and evening Day 4: Study day, 750 mg ciprofloxacin 1h prior to 1000 mg metamizole.
16307941|NCT04621253|Active Comparator|Fluconazole|Day 1: 400 mg fluconazole in the morning, placebo capsule in the evening Day 2: 200 mg fluconazole in the morning, placebo capsule in the evening Day 3: 200 mg fluconazole in the morning, placebo capsule in the evening Day 4: Study day, 200 mg fluconazole 1h prior to 1000 mg metamizole.
16307942|NCT04621253|Placebo Comparator|Placebo|Day 1: placebo capsule in the morning and evening Day 2: placebo capsule in the morning and evening Day 3: placebo capsule in the morning and evening Day 4: Study day, placebo capsule 1h prior to 1000 mg metamizole.
16307943|NCT04621240|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
16308045|NCT04620616|Experimental|Product Use Sequence 4|"Products use sequence:
~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor"
16309219|NCT04612426|Experimental|Brain-computer Interface-Pedaling Training System|
16307944|NCT04621227|Other|Period 1|Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.
16307945|NCT04621214||Group-A|Group A were performing their duties on visual triage
16307946|NCT04621214||Group-B|Group A were performing their duties on Audio-visual triage
16307947|NCT04621188|Experimental|Lorlatinib|100 mg once daily
16307948|NCT04621175|Active Comparator|EAA+W & Carbohydrate: Balance (BAL) first, then Deficit (DEF)|Participants will consume an essential amino acid plus whey (EAA+W) beverage with added Carbohydrate during energy balance (BAL) first, then again during energy deficit (DEF).
16307949|NCT04621175|Active Comparator|EAA+W & Carbohydrate: DEF first, then BAL|Participants will consume an essential amino acid plus whey beverage with added Carbohydrate during energy deficit first, then again during energy balance.
16307950|NCT04621175|Active Comparator|EAA+W & EAA: BAL first, then DEF|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy balance first, then again during energy deficit.
16307951|NCT04621175|Active Comparator|EAA+W & EAA: DEF first, then BAL|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy deficit first, then again during energy balance.
16307952|NCT04621162|Experimental|Positive Expectations (initial)|
16307953|NCT04621162|Experimental|Negative Expectations (initial)|
16307954|NCT04621162|Placebo Comparator|Neutral Expectations (initial)|
16307955|NCT04621162|Experimental|Positive Expectations (during intervention)|
16307956|NCT04621162|Experimental|Negative Expectations (during intervention)|
16307957|NCT04621162|Placebo Comparator|Neutral Expectations (during intervention)|
16307958|NCT04621149|Placebo Comparator|placebo|1 liter of filtered water
16307959|NCT04621149|Active Comparator|chlorine dioxide aqueous solution (AS)|1 liter of filtered water with AS
16307960|NCT04621149|Active Comparator|placebo with zinc acetate (ZA)|1 liter of filtered water with ZA
16307961|NCT04621149|Active Comparator|AS with ZA|1 liter of filtered water with AS and ZA
16307962|NCT04621149|Active Comparator|placebo with famotidine, lactoferrin and green tea extract (FLG)|1 liter of filtered water with FLG
16307963|NCT04621149|Active Comparator|AS with FLG|1 liter of filtered water with AS and FLG
16307964|NCT04621149|Active Comparator|placebo with ZA and FLG|1 liter of filtered water with ZA and FLG
16307965|NCT04621149|Active Comparator|AS with ZA and FLG|1 liter of filtered water with AS, ZA, and FLG
16307966|NCT04621136|Experimental|Ripasudil eye drops|Ripasudil eye drops
16307967|NCT04621123|Experimental|Experimental group|Subjects randomized to convalescent anti-SARS-CoV-2 MBT plasma plus SMT will receive one infusion of 200 to 300 ml of ABO-compatible convalescent plasma obtained from a convalescent donor.
16307968|NCT04621123|Placebo Comparator|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300 ml of sterile saline solution 0.9%.
16307969|NCT04621110|Experimental|intranasal dexmedetomidine and fentanyl|Dexmedetomidine (precedex®) and fentanyl will be administered by intranasal routes, seeing if both sedative (dexmedetomidine) and analgesic (fentanyl) can give enough sedation for procedure
16307970|NCT04621110|Active Comparator|intravenous ketamine and midazolam|ketamine (ketalar®) and midazolam intravenous will be using to compare the efficiency of intranasal drugs
16307971|NCT04621097|Experimental|pulsed electro magnetic field|30 patients will receive the physical therapy program in form of low frequency pulsed electro magnetic field application. with frequency 15hz, and low intensity with flux density of 20 Gauss (2mT), in pulse duration 200 usec , pulsed rectangular pulses for 60 min is applied to the dorsal surface of lower leg , ankle and foot in addition to their regular medications prescribed , 3 times per week for 8 week
16307972|NCT04621097|Experimental|Treadmilltraining|"In this group, 30 patient will receive the physical therapy program in form of supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
~At first , a 5 minutes- warm up period will be allowed, it will include stretching exercises for calf muscles , hamstrings and quadriceps (i.e. each for at least 10 -15 seconds) . Patients should start with walking on the treadmill at a comfortable speed, and should not stop at the onset of leg pain but instead , he/she would continue until moderate pain is reached. At this point, he/she has to rest until pain completely subsides, then walking is resumed again . The intensity of exercise will be determined by claudication pain scale, and should not exceed the score of 4 on this scale. The exercise can be progressed if the patient can walk continuously for 10 minutes without the need to stop."
16307973|NCT04621097|Placebo Comparator|medications|It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
16308046|NCT04620616|Experimental|Product Use Sequence 5|"Products use sequence:
~Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor"
16308047|NCT04620616|Experimental|Product Use Sequence 6|"Products use sequence:
~Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS"
16308075|NCT04620421|Experimental|Training group (Rhythm-based multitask training)|Randomized to participate in the rhythm-based multitask training intervention
16309097|NCT04613154|Placebo Comparator|Placebo|Given placebo once daily during the day of surgery and the next 6 Days.
16307976|NCT04621058|Experimental|D VITAMIN GROUP|"The administration of vitamin D will be carried out using the following treatment scheme:
~If vitamin D deficiency (< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (< 40 ng/ml): treatment with 1 capsule of 0.266 mg
~Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study.
~In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges."
16307977|NCT04621058|Placebo Comparator|PLACEBO GROUP|The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.
16307978|NCT04621045|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
16307979|NCT04621045|Active Comparator|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
16307980|NCT04621032||OSA +|Patients with visceral obesity and newly diagnosed Obstructive Sleep Apnea (during the study)
16307981|NCT04621032||OSA -|Patients with visceral obesity in whom Obstructive Sleep Apnea diagnosis have been excluded (during the study)
16307982|NCT04621019|Experimental|Non-invasive lipolysis and circumference reduction of the abdomen|The treatment administration phase consists of four (4) treatment visits, delivered at least 1 week apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
16307983|NCT04621006||UC group|Patients with active ulcerative colitis
16307984|NCT04620993||Group 1: pregnant women with pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy and have pelvic girdle pain.
16307985|NCT04620993||Group 2:pregnant women without pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy but have not pelvic girdle pain.
16307986|NCT04620993||Group 3: healthy women|This group will consist of healthy women who have not been pregnant.
16307987|NCT04620980||Cases|"Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.
~Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.
~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
16307988|NCT04620980||controls|"Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.
~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
16307989|NCT04620967|Experimental|Iasp-Fiasp|First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp
16307990|NCT04620967|Experimental|Fiasp-Iasp|First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp
16307991|NCT04620954|Experimental|Intervention|
16307992|NCT04620928|Experimental|Concept Retrieval|Patients will be given behavioral intervention, and their brain activity recorded.
16307993|NCT04620915|Experimental|High-level construal|"Participants will be sent messages asking them to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014)."
16307994|NCT04620915|Experimental|Effortful down-regulation of craving for cigarettes|"Participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences)."
16307995|NCT04620915|Experimental|Up-regulation of goal energization|Participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking.
16307996|NCT04620915|Placebo Comparator|Treatment-as-usual control|Participants will be sent generic messages through NCI's text messaging cessation program, SmokefreeTXT (National Cancer Institute, 2013).
16307997|NCT04620902||Dementia|Dementia
16307998|NCT04620902||MCI|Mild cognitive impairment
16307999|NCT04620902||SCD|Subjective cognitive decline
16308000|NCT04620902||HC|Cognitively healthy control
16308001|NCT04620889||PVP|Bypass or reconstruction of diseased or occluded blood vessels
16308002|NCT04620889||AV Access|Arteriovenous shunting for blood access.
16308003|NCT04620876|Experimental|Bimodal and coaxial high resolution imaging of the retina|Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT)
16308004|NCT04620863|Experimental|tDCS group|Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
16308005|NCT04620863|Sham Comparator|Sham Group|The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
16308006|NCT04620850|Experimental|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time) Acupressure at below knee the point ai locate about4 finger spcae below patella on the lateral side of tibia bone
16308007|NCT04620850|No Intervention|No acupressure|Standard post-operative care
16308008|NCT04620837|Experimental|Treatment Arm|Tislelizumab：200mg Q3W IV Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.
16308009|NCT04620824||Trial Participants|"Overall Description of Trial Participants: The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.
~Inclusion Criteria: The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of spleen samples from radical surgery are adult age and presence of splenic tissue in the discarded material after hepato-pancreato-biliary surgery.
~Exclusion Criteria: The main exclusion criterion is acute invasive bacterial and viral infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
16308010|NCT04620811|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)
16308011|NCT04620798|Experimental|Intervention|Participants will be given their results of their antibody test immediately (within 24 hours) and will be followed and surveyed to see if having this knowledge changes their engagement with SARS-CoV-2 prevention behaviors.
16308012|NCT04620798|No Intervention|Control (Delayed)|Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
16308013|NCT04620785|Experimental|methylene blue/IPL|"will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.
~This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions."
16308014|NCT04620785|Experimental|IPL|will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.
16308015|NCT04620785|Placebo Comparator|saline|will undergo intralesional saline.
16308016|NCT04620772|Experimental|Cyclophosphamide arm|Participants randomized to the cyclophosphamide arm will be administered 750 mg/m2 body weight (rounded off to the nearest 50 mg above the calculated value) of cyclophosphamide diluted in normal saline every month (Total 6 months) along with equal dose of mesna 50% administered prior to infusion and 50% after the infusion of cyclophosphamide
16308017|NCT04620772|Other|Placebo arm|Participants randomized to the placebo group will be given similar quantity of normal saline and mesna as described above
16308018|NCT04620759|Experimental|Psilocybin Treatment|Participants will be administered 25mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.
16308019|NCT04620759|Placebo Comparator|Placebo|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.
16308020|NCT04620746|Active Comparator|Skin Testing Arm|These subjects with reported PCN allergy and reported low risk responses will receive skin testing followed by oral challenge
16308021|NCT04620746|Active Comparator|Direct Oral Challenge|These subjects with reported PCN allergy and low risk responses will bypass skin testing and have direct oral challenge with amoxicillin
16308025|NCT04620720|No Intervention|control group|routuine analgesics wil be given
16308026|NCT04620720|Experimental|intervention group|patient will receive cap gabapentin 1200 mg 2 hours before surgery
16308027|NCT04620707|Experimental|RGS based therapy|
16308028|NCT04620707|Active Comparator|Treatment as usual|
16308029|NCT04620694||Radial artery cannulation|Patients whom radial artery was cannulated at the beginning of the surgery.
16308030|NCT04620694||Aortic cannulation (brachial or femoral artery)|"Patients whom femoral or brachial artery was cannulated at the beginning of the surgery.
~Active comparator"
16308031|NCT04620681|Experimental|Phase 1 Dose Level 1|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10^6 CD4 T Cells/kg
16308032|NCT04620681|Experimental|Phase 1 Dose Level 2|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10^7 CD4 T Cells/kg
16308033|NCT04620681|Experimental|Phase 1 Dose Level 3|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10^7 CD4 T Cells/kg
16308034|NCT04620681|Experimental|Phase 2 -Treatment at Maximum Tolerated Dose (MTD)|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.
16308035|NCT04620668|Experimental|Treatment Group (Wysa)|
16308036|NCT04620668|No Intervention|Control Group|
16308037|NCT04620655|Experimental|RD13-01 cell infusion|
16308038|NCT04620642||Registry group|Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
16308039|NCT04620629||control group|Late premature and term babies without any disease
16308040|NCT04620629||probiotic group|Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.
16308041|NCT04620629||antibiotic group|Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.
16308042|NCT04620616|Experimental|Product Use Sequence 1|"Products use sequence:
~Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS"
16308043|NCT04620616|Experimental|Product Use Sequence 2|"Products use sequence:
~Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor"
16308044|NCT04620616|Experimental|Product Use Sequence 3|"Products use sequence:
~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor"
16308048|NCT04620603|Experimental|LDR + Nivolumab|Participants will receive one treatment of brachytherapy on treatment day 1 (LDRD1). After a minimum of 7 days but no more than 30 days to allow antigenic release, participants will then begin immunotherapy treatment with Nivolumab at the standard FDA approved dose of 480mg given on the first day of every 28 day cycle. Participants can receive up to 12 doses of Nivolumab.
16308049|NCT04620590|Experimental|Treatment Arm|Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
16308050|NCT04620577||Antibiotic group|Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.
16308051|NCT04620577||No-antibiotic group|Infusion of Normal saline within 1h before and 12h after PTCD.
16308052|NCT04620564||Patients|
16308053|NCT04620564||Relatives|
16308054|NCT04620551|Experimental|PD with DBS|Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
16308055|NCT04620538||Controls|Healthy Controls with or without risk factors for Chronic Liver Disease (i.e. patients referred due to concerns re: liver disease but found to have no evidence of chronic liver disease following assessment)
16308056|NCT04620538||Fibrosis|Patients with evidence of Liver Fibrosis on the basis of current diagnostic techniques / expert opinion.
16308057|NCT04620538||Compensated Cirrhosis|Patients with evidence of Compensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
16308058|NCT04620538||Decompensated Cirrhosis|Patients with evidence of Decompensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
16308059|NCT04620538||Hepatocellular Carcinoma|Patients with evidence of Hepatocellular Carcinoma on the basis of current diagnostic techniques / expert opinion.
16308060|NCT04620525||Participants with the relevant condition|Participants with the relevant condition
16308061|NCT04620525||Healthy controls|Healthy controls
16308062|NCT04620499|Experimental|Experimental|EEG-guided drug prescription
16308063|NCT04620499|No Intervention|Control|Will receive EEG, but drugs will be prescribed as usual
16308064|NCT04620486|Experimental|Active Best Practice Alert|Care providers taking care of these patients will receive a Best Practice Alert (BPA) in the electronic medical record (EMR) one hour before an antibiotic expires with no subsequent doses ordered. The BPA will prompt the care provider to re-order the antibiotic and give information on recommended dosage and frequency based on indication and patient characteristics.
16308065|NCT04620486|No Intervention|Inactive Best Practice Alert|The Best Practice Alert described in the Experimental Arm will not be active for patients in this arm. Care providers will proceed with usual care.
16308066|NCT04620473|Experimental|Anlotinib+Capeox|neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
16308067|NCT04620473|Active Comparator|Capeox|neoadjuvant treatment with Capeox
16308068|NCT04620460|Active Comparator|LIFUS-left DLPFC|20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.
16308069|NCT04620460|Sham Comparator|LIFUS-SHAM|20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.
16308070|NCT04620447|Active Comparator|Mindfulness Meditation|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 7
~Final number of participants: 118
~Mindfulness Meditation intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
16308071|NCT04620447|Active Comparator|Cognitive Behavior Therapy|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 19
~Final number of participants: 102
~Cognitive Behavior Therapy intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
16308072|NCT04620447|Active Comparator|Novel 'Intelligent Virtual Reality Therapy System' (IVRTS)|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 10
~Final number of participants: 115
~Novel 'Intelligent Virtual Reality Therapy System' (IVRTS) was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
16308073|NCT04620447|No Intervention|Control Group|"A 7-week intervention course (In this case, no intervention) was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 0
~Final number of participants: 125
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
16308074|NCT04620434||patient|39 patients who are planning surgeries that require general anesthesia and tracheal intubation
16308076|NCT04620421|No Intervention|Control group (Continuation of regular activity schedule)|Randomized to the control group who is encouraged to continue their regular everyday routines, which may include self-administrated training exercises.
16308077|NCT04620408|Experimental|Group A|The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.
16308078|NCT04620408|Experimental|Group B|Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.
16308079|NCT04620395|No Intervention|Joint tap|Joint tap and aspiration of synovial fluid
16308080|NCT04620395|Experimental|Punch biopsy|Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane
16308081|NCT04620382|Active Comparator|Midodrine|Single oral dose of midodrine (5-10mg) combined with sham abdominal compression
16308082|NCT04620382|Experimental|Abdominal Compression|Abdominal compression (up to 40 mmHg) combined with a placebo pill
16308083|NCT04620369|Experimental|Arm A (rose geranium in sesame oil nasal spray)|Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
16308084|NCT04620369|Placebo Comparator|Arm B (isotonic nasal saline)|Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.
16308085|NCT04620356|Experimental|DryNites arm|"Participants in this arm use DryNites every night for 4 weeks (run-in period), an additional 4 weeks (intervention core trial period), and an optional additional 4 weeks (extension period). All participants in this arm also receive absorbent bad mats to use every night."
16308086|NCT04620356|No Intervention|No Pants arm|"Participants in this arm use DryNites every night for 4 weeks only during the initial run-in period. Thereafter, participants in this arm do not use DryNites during the 4 week intervention core trial period or the optional additional 4 weeks extension period. All participants in this arm also receive absorbent bad mats to use every night."
16308087|NCT04620343|Active Comparator|Phase 1, Group 1|"Patients are provided with basic information and breathing advice with biofeedback (IBA).
~This is the reference treatment against which the other methods will be measured."
16308088|NCT04620343|Experimental|Phase 1, Group 2|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT)
16308089|NCT04620343|Experimental|Phase 1, Group 3|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with speech therapy
16308090|NCT04620343|Experimental|Phase 1, Group 4|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT) and speech therapy
16308091|NCT04620343|No Intervention|Phase 2, Group 1|Groups 2,3,4 in Phase 1 Wait for therapy effect
16308092|NCT04620343|Experimental|Phase 2, Group 2|If patients from Phase 1, Group 1 (reference treatment) have unchanged CLE-scoring, they are treated with inspiratory muscle training (IMT) and speech therapy.
16308093|NCT04620343|Experimental|Phase 3, Group 1|Treated with Surgery, supraglottoplasty - full procedure
16308094|NCT04620343|Experimental|Phase 3, Group 2|Treated with Surgery, supraglottoplasty mini-invasive procedure
16308095|NCT04620343|No Intervention|Phase3, Group 3|Non-surgery control group
16308098|NCT04620317|Active Comparator|Synbiotic|The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.
16308099|NCT04620317|Placebo Comparator|Placebo|Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.
16308100|NCT04620304|Experimental|Cohort A|receive 4 weekly fixed doses of UB-421 SC at 250 mg
16308101|NCT04620304|Experimental|Cohort B|receive 4 weekly fixed doses of UB-421 SC at 500 mg
16308102|NCT04620304|Experimental|Cohort C|receive 4 weekly fixed doses of UB-421 SC at 700 mg
16308103|NCT04620291|Experimental|Cohort A|250 mg UB-421 SC: ART-treated subjects
16308104|NCT04620291|Experimental|Cohort B|500 mg UB-421 SC: ART-treated subjects
16308105|NCT04620291|Experimental|Cohort C|700 mg UB-421 SC: ART-treated subjects
16308106|NCT04620291|Experimental|Cohort D|500 mg UB-421 SC: Treatment naive subjects
16308107|NCT04620291|Experimental|Cohort E|700 mg UB-421 SC: Treatment naive subjects
16308108|NCT04620265|Experimental|Treadmill training 100%|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
16308109|NCT04620265|Experimental|Treadmill training 75%|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
16308110|NCT04620265|Experimental|Treadmill training 50%|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
16308111|NCT04620265|Experimental|Treadmill training 25%|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
16308112|NCT04620265|Sham Comparator|Conventional program|This group received the conventional exercise program only.
16308113|NCT04620252|Experimental|Chewing calcium supplements|"Participants will be given one of 4 different treatments to chew: a negative control group and 3 calcium supplements with different calcium compositions.
~Participants will be randomized to determine the sequence of exposure to the different treatments."
16308114|NCT04620252|Experimental|Fluoride rinse|Participants will rinse with an over the counter sodium fluoride rinse for 1 min, either alone or after having chewed with the calcium supplement providing the maximum calcium release in arm 1.
16308200|NCT04619706|Placebo Comparator|Arm C: Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
16308116|NCT04620226|No Intervention|Conventional Serum Testing|Participants will be screened by conventional HCV antibody (anti-HCV) serology and if screen positive, a second sample will be collected and tested for HCV RNA using a standard commercial assay.
16308117|NCT04620226|Experimental|Rapid Point-of-Care Testing|Participants will be screened using the OraQuick® Rapid Anti-HCV Point-of-Care Test (OraSure) and if screen positive, an additional whole blood sample will be collected and tested for HCV RNA using Xpert® HCV RNA (Cepheid) point-of-care testing and confirmed using a standard commercial assay.
16308118|NCT04620213|Experimental|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
16308119|NCT04620213|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
16308120|NCT04620200|Experimental|ARM A|2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care
16308121|NCT04620200|Experimental|ARM B|2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
16308122|NCT04620187|Experimental|Standard of Care + T-DM1 in HER2-Positive Salivary Gland Cancer|"Participants will undergo standard of care surgery followed by standard of care radiation and chemotherapy with the addition of T-DM1.
~Study cycles are 21 days (3 weeks):
~Participants will be given the study treatment T-DM1 at a predetermined dose (3.6 mg/kg) intravenously once (1x) every 3 weeks for up to 52 weeks (or about 1 year).
~Participants will be given standard of care radiation and chemotherapy
~Radiation will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1
~Chemotherapy (cisplatin 40 mg/m2 intravenously or carboplatin AUC 2 intravenously) will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1
~Participants will be followed for 3 years."
16308123|NCT04620174|Other|Custom-made zirconia crowns Group|Ten decayed primary molars will be restored with custom-made zirconia crowns.
16308124|NCT04620174|Other|Prefabricated zirconia crowns Group|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
16308125|NCT04620174|Other|Control Group|Twenty intact contralateral teeth will be evaluated as the controls (10 molars will be the controls for custom-made ZrCs and 10 molars will be the controls for prefabricated ZrCs).
16308126|NCT04620161|Experimental|Pradigastat Tablets 20mg|The patients in this arm will receive one tablet a day of Pradigastat 20mg and one tablet a day of Pradigastat 40mg matching placebo
16308127|NCT04620161|Experimental|Pradigastat Tablets 40mg|The patients in this arm will receive one tablet a day of Pradigastat 40mg and one tablet a day of Pradigastat 20mg matching placebo
16308128|NCT04620161|Placebo Comparator|Placebo|The patients in this arm will receive one tablet a day of Pradigastat 20mg matching placebo and one tablet a day of Pradigastat 40mg matching placebo
16308129|NCT04620148|Experimental|TAK-242|Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
16308130|NCT04620148|Placebo Comparator|Placebo|Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
16308131|NCT04620135|Experimental|Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle|1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
16308132|NCT04620135|Active Comparator|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|1 drop ripasudil twice dairy in the morning and evening in each eye.
16308133|NCT04620122|Experimental|intervention group|Progressive Muscle Relaxation Training and Music Therapy are applied to the intervention group.
16308134|NCT04620122|No Intervention|control group|No intervention is applied to the control group.
16308135|NCT04620109|Placebo Comparator|SDE Placebo|Subjects will receive placebo (drops without drug).
16308136|NCT04620109|Active Comparator|SDE 0.03 mg/eye|Actual dose is 0.03 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 0.5 mg/mL for 1 time.
16308137|NCT04620109|Active Comparator|SDE 0.06 mg/eye|Actual dose is 0.06 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 1.0 mg/mL for 1 time.
16308138|NCT04620109|Active Comparator|SDE 0.12 mg/eye|Actual dose is 0.12 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 2.0 mg/mL for 1 time.
16308139|NCT04620109|Active Comparator|SDE 0.24 mg/eye|Actual dose is 0.24 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 4 mg/mL for 1 time.
16308140|NCT04620109|Active Comparator|RDE 0.06 mg/eye|The actual dosage is 0.06 mg/eye given 4 times a day for a maximum daily dosage of 0.24mg (60μL KDR2-2 eyedrops concentration of 1.0 mg/mL), which will continues for 6 days plus 1 administration of 0.06 mg/eye in the morning of Day 7. That cohort only started after safety proof from SDE 0.24 mg/eye cohort.
16308141|NCT04620109|Active Comparator|RDE 0.12 mg/eye|The actual dosage is 0.12 mg/eye given 4 times a day for a maximum daily dosage of 0.48mg (60μL KDR2-2 eyedrops concentration of 2.0 mg/mL), which will continues for 6 days plus 1 administration of 0.12 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
16308142|NCT04620109|Active Comparator|RDE 0.24 mg/eye|The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
16308143|NCT04620109|Placebo Comparator|RDE Placebo|Subjects will receive placebo (drops without drug).
16309502|NCT04610450|Experimental|RCI-BE-10|Robot assisted cochlear implant surgery.
16308144|NCT04620083|No Intervention|Control Group|For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week.
16308145|NCT04620083|Experimental|Experimental 3-day Normal Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 3 days per week.
16308146|NCT04620083|Experimental|Experimental 5-day Intensive Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 5 days per week. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.
16308147|NCT04620070|No Intervention|Conventional|In the Netherlands, out-of-hospital cardiac arrest (OHCA) is managed by paramedics. In this study, in the conventional arm, OHCA is managed by a physician of the Helicopter Emergency Medical Services (HEMS), but without the possibility of prehospital ECPR.
16308148|NCT04620070|Experimental|Intervention group|OHCA managed by the physician of the HEMS team, but with the possibility of prehospital ECPR.
16308149|NCT04620057|Experimental|Butyrate + standard care for pediatric obesity|standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)
16308150|NCT04620057|Placebo Comparator|placebo + standard care for pediatric obesity|standard care for pediatric obesity + placebo (cornstarch)
16308151|NCT04620044|Experimental|Kaledo Game|Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
16308152|NCT04620044|Experimental|Education|"The students in the training group were trained for 20 minutes once a week for 12 weeks. Training subjects were prepared in line with health belief model components.
~The following subjects were included in the training content. What is obesity?Risk factors for obesity, Characteristics of obese individuals, What is a healthy diet?Relationship between unhealthy nutrition and obesity, The consequences of unhealthy diet Health problems caused by obesity, What should be done to prevent and control obesity. How should nutrition be to lose weight? Positive results which show up with weight loss, Barriers to a healthy diet, Ways to reduce and eliminate barriers How to take action to lose weight?, Benefits of weight loss, Success stories in the fight against obesity, How are eating habits changed?, How can we achieve self-efficacy to change eating habits?"
16308153|NCT04620044|Experimental|Control|There was no intervention in the control group.
16308154|NCT04620031|Experimental|HSK3486|
16308155|NCT04620031|Active Comparator|Propofol|
16308156|NCT04620018|Active Comparator|Pre and post op Antibiotic|subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
16308157|NCT04620018|Active Comparator|Pre-op antibiotic|subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery)
16308158|NCT04620018|Active Comparator|Post-op antibiotic|subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
16308159|NCT04620005||ECMO|The first group will include practitioners who work in intensive care unit with ECMO services
16308160|NCT04620005||Non-ECMO|The second group will include practitioners who work in non-ECMO inventive care unit
16308161|NCT04619979||preoperative anxiety group|
16308162|NCT04619979||Non-preoperative anxiety group|
16308163|NCT04619953|Active Comparator|Postural Stability group (PSg)|The Postural Stability group (PSg) will perform 30 minutes of conventional neuromotor rehabilitation and 20 minutes of dynamic postural stability training.
16308164|NCT04619953|Active Comparator|Cognitive-Motor group (CMg)|The Cognitive-Motor group (CMg) performed 30 minutes of conventional neuromotor rehabilitation and 20 minutes of cognitive-motor training.
16308165|NCT04619940|Experimental|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
16308166|NCT04619940|Active Comparator|Standard goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
16308167|NCT04619927|Experimental|Intervention group|The intervention includes testing of patients for carriage of the CYP2C19*2 and *3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
16308168|NCT04619927|Active Comparator|Comparison group|The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19*2 and *3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.
16308169|NCT04619914|Experimental|Group A (clomiphene citrate & estradiol group)|included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14
16308170|NCT04619914|Experimental|Group B (Letrozole group)|included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7.
16308171|NCT04619901||Parents only|
16308172|NCT04619901||Children and Parents|
16308173|NCT04619888||HeartLogic cohort|Patients implanted with a defibrillator enabling HeartLogic
16308174|NCT04619875|Other|Lactulose|
16308175|NCT04619875|Other|KB5|
16308176|NCT04619875|Other|SG1|
16308201|NCT04619693||The study population|The study population corresponds to patients hospitalized for proven SARS-COV-2 pneumonia with an indication (hypoxemia) for dexamethasone (see eligibility criteria)
16308177|NCT04619862|Experimental|Medication|"Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.
~The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day."
16308178|NCT04619862|Placebo Comparator|Placebo|Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.
16308179|NCT04619849|Experimental|palmaris longus and carpal tunnel|EMG measurements of median and ulnar nerves will be made in patients with palmaris longus muscle.
16308184|NCT04619823|Other|Patient infected by arboviruses|
16308185|NCT04619810|Other|Intervention arm|quasi-experimental pre-post study
16308186|NCT04619797|Experimental|Tiragolumab+Atezolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with tiragolumab in combination with atezolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab in combination with atezolizumab and pemetrexed on Day 1 of each 21-day cycle.
16308187|NCT04619797|Placebo Comparator|Placebo+Pembrolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with placebo in combination with pembrolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo in combination with pembrolizumab and pemetrexed on Day 1 of each 21-day cycle.
16308188|NCT04619784|Experimental|Treatment Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Patients will receive 12 sessions of pilates. Patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.
16308189|NCT04619784|Other|Control Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Their routine medical treatments were continued
16308190|NCT04619771|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
16308191|NCT04619758|Experimental|Emollient Group|Mothers of the neonates in group A will be advised massage with sunflower oil.
16308192|NCT04619758|No Intervention|Non-Emollient Group|Mothers of the neonates in group B will be advised massage without any emollient.
16308193|NCT04619745|Experimental|Intervention Group|All children enrolled in the study will complete five study visits. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity. The intervention group will complete individualized, parent-led, home and play-based activity plans for 6 months, beginning as soon as the child returns to the inpatient unit. The activities in the plan will be tailored to each phase of treatment (in hospital, discharge to week 7, week 8 to 6 months), follow a standardized format and provide content individualized to each child's age and previous visit assessments.
16308194|NCT04619745|Experimental|Wait List Control Group|All children enrolled in the study will complete five study visits. After the first visit is complete, children will be randomized to either the intervention or wait-list control study group. Control participants will follow the same schedule of assessments at each visit, but the intervention will be provided between the 12-month and 16-month assessments. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity.
16308195|NCT04619732|Experimental|Marginal Kidneys|"Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease.
~Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians.
~The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days."
16308196|NCT04619719|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen Therapy (HBOT) + Standard of Care (SOC) as defined by current best practice treatments for COVID-19
16308197|NCT04619719|No Intervention|Standard of Care|Standard of Care (SOC) as defined by current best practice treatments for COVID-19
16308198|NCT04619706|Experimental|Arm A: FSD201 600 mg|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
16308199|NCT04619706|Experimental|Arm B: FSD201 1200 mg|Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
16309802|NCT04608422|No Intervention|Control|The patients only will be evaluated and reassessed.
16308204|NCT04619667|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
16308205|NCT04619667|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
16308206|NCT04619667|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
16308207|NCT04619654|Experimental|Cataract Surgery with concurrent MIGS|
16308208|NCT04619641|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
16308209|NCT04619641|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
16308210|NCT04619641|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
16308211|NCT04619628|Placebo Comparator|Saline|Normal saline
16308212|NCT04619628|Experimental|Low dose cohort 1|COVI-VAC, single dose
16308213|NCT04619628|Experimental|Medium dose cohort 1|COVI-VAC, single dose
16308214|NCT04619628|Experimental|High dose cohort 1|COVI-VAC, single dose
16308215|NCT04619628|Experimental|Low dose cohort 2|COVI-VAC, two doses 28 days apart
16308216|NCT04619628|Experimental|Medium dose cohort 2|COVI-VAC, two doses 28 days apart
16308217|NCT04619628|Experimental|High dose cohort 2|COVI-VAC, two doses 28 days apart
16308218|NCT04619615|Experimental|Asynchronous self-directed digital training|A digital training program platform that delivers an interactive case-based modular curriculum covering evidence-based psychotherapy principles and IPT-specific principles and strategies with homework will take roughly 13 hours to complete, with 4.5 hours of online learning, and an additional 7.5 hours of reading and homework assignments. The reading and homework includes viewing captioned videotaped role plays and completing self-directed lesson plans. The digital curriculum leverages audio, video, and visual content, and is self-directed - for completion within a 2-week period. Residents can access this content through a smartphone, tablet or computer at their own pace, revisit modules and digital content as needed, and access a curated list of additional resources to supplement their learning.
16308219|NCT04619615|Active Comparator|Synchronous large group online workshop|This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional ~7.5 hours in total).
16308220|NCT04619602|Experimental|GSNO therapy|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
16308221|NCT04619563|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
16308222|NCT04619550|Other|Exercise intensity|Jogging or walking at RPE 9, 11, 13, and 15
16308223|NCT04619537|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
16308224|NCT04619524|Experimental|A: Patients undergo cycle with the transfer of fresh embryos|In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.
16308225|NCT04619524|Experimental|B: Patients undergo cycle with the transfer of frozen embryos|In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.
16308226|NCT04619498|Experimental|PediAppRREST app|The teams assigned to the PediAppRREST arm will manage the simulated scenario of pediatric cardiac arrest using the new PediAppRREST tablet app as a cognitive aid.
16308227|NCT04619498|Active Comparator|CtrlPALS+|The teams assigned to the CtrlPALS+ arm will manage the simulated scenario of pediatric cardiac arrest using the American Heart Association Pediatric Advanced Life Support (AHA-PALS) pocket reference card.
16308228|NCT04619498|No Intervention|CtrlPALS-|The teams assigned to the CtrlPALS- arm will manage the simulated scenario of pediatric cardiac arrest using no PALS-related cognitive aids.
16308229|NCT04619485|Sham Comparator|SHAM LASER|Group A: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to zero potence.
16308230|NCT04619485|Active Comparator|EFFECTIVE LASER|Group B: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to regular potence.
16308232|NCT04619459|Experimental|Newborns receiving Kangaroo Mother Care (KMC)|The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. At Minute 5, the newborns' Apgar scores were assessed and recorded during KMC. The newborn's examination and injections (Hepatitis-B and K vit) were postponed until the first breastfeeding took place. A pediatrician performed a detailed examination of the newborns under the radiant infant warmer after the first breastfeeding. Following the examination, the newborn was positioned on the mother's breast for KMC. During this KMC, the newborn was administered 1 mg K vitamin in the right leg and 0.5 ml Hepatitis-B vaccine in the left leg via intramuscular injections. The KMC session was continued for 3 hours. Care attempt of mothers such as episiotomy repair was taken that the position of KMC.
16308233|NCT04619459|No Intervention|Newborns receiving standard postpartum care (SPC):|He received the standard care of the hospital. KMC not applied.
16308234|NCT04619446||Removable Twin Block appliance group|Patient to be treated with removable twin block appliance that are known Class II skeletal and dental subjects.
16308235|NCT04619446||Fixed Functional Appliance AdvanSync group|Patients to be treated with fixed functional appliance, AdvanSync (Molar-to-Molar) Class II Corrector
16308236|NCT04619433|Experimental|Treatment group A|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
16308237|NCT04619433|Placebo Comparator|Treatment group B|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
16308240|NCT04619407||teacher|"Employed in a school in Mecklenburg-Vorpommern
~Age between 18 to 67 years
~Willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
16308241|NCT04619407||pupils|"Attending school in Mecklenburg-Vorpommern
~Age between 6 to 17 years
~Agreement to participate
~Legal representative willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
16308242|NCT04619407||childcare educators|"Employed in a kindergarten in Mecklenburg-Vorpommern
~Age between 18 to 67 years
~Willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
16308243|NCT04619407||preschoolers|"Attending kindergarten in Mecklenburg-Vorpommern
~Age between 3 to 6 years
~Agreement to participate
~Legal representative willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
16308244|NCT04619394|No Intervention|Control Group (CG)|Control Group (CG): Formed by those pregnant women who do not perform any physical exercise, only the basic and instrumental activities of daily life (ABVD and AIVD respectively) and intensity of the physical labor load of very light to moderate. The period from 10-12 SG to 37-41 SG.
16308245|NCT04619394|Active Comparator|Experimental Group 1 (GE1)|Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
16308246|NCT04619394|Active Comparator|Experimental Group 2 (GE2)|Experimental Group 2 (GE2): In this third and last group, we incorporated the AIPAP program into the exclusive programs of each monitor in the various public and private sports centers and swimming pools in the South of the Autonomous Community of Galicia. The researcher trained in this method, together with the monitors who voluntarily wish to do so, will translate said format and program into their sessions.
16308247|NCT04619381||African Americans with Coronary Artery Disease|African Americans with Coronary Artery Disease and currently taking clopidogrel
16308248|NCT04619355||TVC K-Registry|
16308249|NCT04619342|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.
16308250|NCT04619342|Active Comparator|GSMs-TACE Group|Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.
16308251|NCT04619329|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using Lobaplatin and GSMs (150-350μm, 350-560μm, 560-710μm or 710-1000μm), patients will receive surgical resection 15-30 days later, as specified per protocol.
16308252|NCT04619329|Active Comparator|Surgical Resection Group|Patients will receive surgical resection, as specified per protocol.
16308253|NCT04619316|Other|BRAF wild type|In BRAF wild type patients trametinib 2mg (1-0-0) is applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
16308254|NCT04619316|Other|BRAF V600E Mutation|In BRAF wild type patients trametinib 2mg (1-0-0) and dabrafenib 75mg (2-0-2) are applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
16308255|NCT04619303|Experimental|Dexamethasone Implant|Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.
16308256|NCT04619303|Active Comparator|Bevacizumab|Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
16308405|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose, Lumbar Catheter|GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
16308257|NCT04619290|Experimental|Methylene blue treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
16308258|NCT04619290|Active Comparator|Conventionally treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
16308259|NCT04619277||Ulsan Medical Center|Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea
16308260|NCT04619277||Queen Elizabeth Hospital|Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia
16308261|NCT04619277||Pecking University Shougand Hospital|Department of Cardiology, Peking University Shougang Hospital, Peking, China
16308262|NCT04619277||Ulsan University Hospital|Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
16308263|NCT04619277||Kangwon National University School of Medicine|Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea
16308264|NCT04619277||Korea University Guro Hospital|Cardiovascular Center, Department of Cardiology, Korea University Guro Hospital, Seoul, South Korea
16308265|NCT04619264|Experimental|Papacarie-Duo|
16308266|NCT04619264|Active Comparator|Atraumatic Restorative Treatment|
16308267|NCT04619251|Experimental|SRD part, active drug, poor metabolizers|
16308268|NCT04619251|Experimental|SRD part, active drug, extensive metabolizers|
16308269|NCT04619251|Placebo Comparator|SRD and MD part, placebo|
16308270|NCT04619251|Experimental|DDI part, poor metabolizers|DDI part will be initiated after SRD part
16308271|NCT04619251|Experimental|MD part, active drug, poor metabolizers|
16308272|NCT04619238||no urinary incontinence|patients without UI
16308273|NCT04619238||stress urinary incontinence|patients with SUI
16308274|NCT04619238||overactive bladder|patients with OAB
16308275|NCT04619238||mix urinary incontinence|patients with MUI
16308276|NCT04619238||Urge|patients with urge incontinence
16308279|NCT04619212|Other|Standard of Care|Standard of Care
16308280|NCT04619212|Other|new device|new device
16308282|NCT04619173|Experimental|Thoracic manipulation|additional thoracic manipulation along with hotpack, transcutaneous electrical nerve stimulation ,serratus anterior,pectoralis major,minor, posterior capsular stretches..
16308283|NCT04619173|Active Comparator|Conventional Physical Therapy Program|hot pack transcutaneous electrical nerve stimulation, serratus,anterior,pectoralis major, minor, posterior capsular stretches.
16308284|NCT04619160|Active Comparator|propofol|
16308285|NCT04619160|Active Comparator|sevoflurane|
16308286|NCT04619147||Patients without invasive fungal infections (IFI)|This will be our control cohort. Most of the patients would have been on posaconazole prophylaxis.
16308287|NCT04619147||Patients with invasive fungal infections (IFI)|This will be the group that we will be interested in. IFI would be diagnosed based on EORTC/ MSG definitions, and most of them would have been on posaconazole prophylaxis. Underlying risk factors of acquiring IFI in this cohort of patients will be compared with that of the control cohort.
16308288|NCT04619134|Experimental|NCSR Program|Non Pain Contingent Spinal Rehabilitation
16308289|NCT04619134|Active Comparator|Conventional Physical therapy|Conventional Physical Therapy
16308290|NCT04619121|Experimental|Treatment with real NIR-tPBM on top of standing pharmacotherapy|NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, 20 minutes a day, for 8 consecutive weeks.
16308291|NCT04619121|Sham Comparator|Sham device on top of standing pharmacotherapy|Sham device with neglectable energy to the dorsolateral prefrontal cortex, bilaterally and simultaneously, 20 minutes a day, for 8 consecutive weeks.
16308292|NCT04619095|Experimental|Psyllium|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
16308293|NCT04619095|Placebo Comparator|Placebo|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
16308294|NCT04619082|Experimental|TAF prophylaxis|Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients
16308295|NCT04619069|Active Comparator|Arm 1: Standard of Care|Intermittent Hormone treatment (minimum of 8 months)
16308296|NCT04619069|Experimental|Arm 2: SBRT to mets|"Intermittent Hormone treatment (minimum of 8 months)
~+ SBRT to all sites of metastatic disease"
16308297|NCT04619056|Experimental|Cohort 1|CEB-01 with total SN-38 dose: 9 mg
16308298|NCT04619056|Experimental|Cohort 2|CEB-01 with total SN-38 dose: 18 mg
16308299|NCT04619056|Experimental|Cohort 3|CEB-01 with total SN-38 dose: 36 mg
16308300|NCT04619043|Experimental|Ankle Orthotic|The participant will wear two different ankle orthotics, their currently prescribed orthotic and the experimental orthotic.
16308301|NCT04619030|Experimental|Augmented Reality Leaflet|Patient Leaflet with Augmented reality component
16308302|NCT04619030|Active Comparator|Traditional Leaflet|Traditional leaflet without Augmented Reality component
16308303|NCT04619017|Experimental|Segmental allergen challenge|Allergic individuals with and without asthma will be enrolled.
16308304|NCT04619004|Experimental|Study Group 1: Patritumab deruxtecan 5.6 mg/kg|Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)
16308305|NCT04619004|Experimental|Study Group 2: Patritumab deruxtecan Up-Titration|Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)
16308306|NCT04618991|Experimental|Adult patients with SAHOS for whom maxillary transversal surgery|Adult patients with SAHOS for whom maxillary transversal surgery is recommended.
16308307|NCT04618978|Other|PSG and actigraphy device evaluations|All patients will be evaluated and diagnosed according to the records by Gold standard for PLMs diagnosis and also by the actigraphy devices recording.
16308308|NCT04618965|Placebo Comparator|Control (Placebo) group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
16308309|NCT04618965|Experimental|Intrathecal dexmedetomidine group|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
16308310|NCT04618965|Experimental|Intravenous dexmedetomidine group|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
16308311|NCT04618952|Active Comparator|treatment|patients received calcium D
16308312|NCT04618952|Placebo Comparator|control|patients received placebo
16308313|NCT04618939|Experimental|BR-TD-1001|Randomized subjects were assigned to receive a single dose of BR-TD-1001
16308314|NCT04618939|Active Comparator|Td-pur inj|Randomized subjects were assigned to receive a single dose of Td-pur inj
16308315|NCT04618926||intubating Laryngeal Tube Suction Disposable|intubating Laryngeal Tube Suction Disposable Airway control
16308316|NCT04618926||intubating laryngeal Tube suction Disposable|intubating laryngeal Tube Suction Disposable
16308317|NCT04618913||VTE and history of cancer|VTE and history of cancer
16308318|NCT04618913||VTE and active cancer|VTE and active cancer
16308319|NCT04618900|Experimental|Osteotome-mediated sinus floor elevation with Bio-Oss collagen|Sinus floor elevation with a grafting material (Bio-Oss collagen)
16308320|NCT04618900|Placebo Comparator|Osteotome-mediated sinus floor elevation with no grafting material|Sinus floor elevation with no grafting material
16308321|NCT04618887||Meige sydrome patients|
16308322|NCT04618874|Experimental|ROSE group|Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation
16308323|NCT04618874|No Intervention|US NAB group|Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation
16308324|NCT04618861||Control Group|"This cohort involved the volunteers who had no known acute, subacute or chronic disease history, who did not suffer from any infection in the last fortnight, who were not on a particular medication, who presented to the ED with reasons other than infectious complaints, and who gave their written consent to participate in the study.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
16308325|NCT04618861||CT (+), PCR (-) Covid-19 Suspected Pneumonia Group|"This group consisted of patients who applied to the emergency department with symptoms of Covid-19, whose thorax CT according to RSNAEC criteria showed typical Covid-19 pneumonia findings, but whose RT-PCR test was negative in the swab sample taken in the emergency room.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
16308326|NCT04618861||CT (+), Covid-19 Pneumonia Group|"This cohort consisted of the patients (a) who applied to the emergency department with SARS-CoV-2 symptoms and was diagnosed with SARS-CoV-2 infection according to WHO guideline (13) (b) whose CT imagings were compatible with SARS-CoV-2 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria (14), (c) whose nasopharyngeal swab samples taken in the ED were positive for RT-PCR, and (d) who gave their informed consent to participate in the study.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
16308327|NCT04618861||CT (-), PCR (+) Covid-19 infection group|"This cohort included the patients (a) who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms, (b) whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive, (c) whose SARS-CoV-2 PCR tests were positive as a result of contact tracing, and (d) who presented to the ED for further examination.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
16308328|NCT04618848||Adult Oncology Patients|Adult oncology patients
16308329|NCT04618835||Emergency presentations|Patients discharged after a presentation to practitioners in the community, primary and secondary care.
16308330|NCT04618822|Experimental|Teaching involving whole-body movements|
16308331|NCT04618822|Experimental|Teaching involving hand movements|i.e. arms and hands
16308332|NCT04618822|Active Comparator|teaching involving minimal motor movements|i.e. seated on a chair using paper and pencil
16308333|NCT04618809|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire, which evaluates the approach to older mGC patients at each site.
~Phase 2 - Providers participate in an hour-long didactic session and begin enrolling eligible metastatic gastric cancer (mGC) patients. Enrolled mGC patients complete a comprehensive geriatric assessment (CGA). Providers complete the treatment plan and review of geriatric assessment questionnaires, which also includes an evaluation of their overall view of the utility of the geriatric assessment.
~Phase 3 - Follow-up chart reviews (2-3 months post intervention) are completed to assess for actual implementation of recommended interventions identified by the geriatric assessment."
16308334|NCT04618783|Experimental|Low-dosage experimental group|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
16308335|NCT04618783|Experimental|Medium-dosage experimental group|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
16308336|NCT04618783|Experimental|High-dosage experimental group|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
16308337|NCT04618783|Active Comparator|Control wIPV group|Three doses of control wIPV, vaccinated within one-month interval between doses
16308338|NCT04618783|Active Comparator|Control sIPV group|Three doses of control sIPV, vaccinated within one-month interval between doses
16308340|NCT04618757|Experimental|Hedonic Reward|Participants' reward for meeting monthly step targets is in the form of reimbursements of up to $50 for expenses on hedonic activities of their choice
16308341|NCT04618757|Experimental|Cash Reward|Participants' reward for meeting monthly step targets is in the form of $50 cash disbursements
16308342|NCT04618744|Placebo Comparator|Placebo|Fish oil
16308343|NCT04618744|Experimental|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
16308344|NCT04618718|Experimental|Intervention|ProtEmbo device will be used as distal protection device in subjects undergoing TAVR
16308348|NCT04618692|Active Comparator|Surgical Loupes|In this group , patients will undergo biliary reconstruction using surgical loupe
16308349|NCT04618692|Active Comparator|Microscope|In this group , patients will undergo biliary reconstruction using microscope
16308350|NCT04618679||18F-FDOPA PET|Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
16308351|NCT04618666|Experimental|laparoscopic and open appendectomy|comparative study between laparoscopic and open appendectomy
16308352|NCT04618653||Early AA Attenders with Alcohol Use Disorder|observational study that includes three fixed assessments (Baseline, 3, and 6-month). Subset of participants will also provide daily EMA data.
16308353|NCT04618640|Experimental|DTaP-IPV combination vaccine|DTaP-IPV 0.5ml IM boosting
16308354|NCT04618614|Experimental|HD-tDCS S1 1 mA|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
16308355|NCT04618614|Active Comparator|HD-tDCS M1 1 mA|Single session of 15-min HD-tDCS to the right primary motor cortex with an intensity of 1 mA. The session will last approximately one hour.
16308356|NCT04618614|Sham Comparator|Sham control|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
16308357|NCT04618601|Active Comparator|High-dose spironolactone|Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure
16308358|NCT04618601|No Intervention|Standard of care|Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily
16308359|NCT04618588|Experimental|"Sinus elevation using Low Window Sinus Lift technique"|
16308360|NCT04618575|Experimental|Ursodeoxycholic acid combined with total glucosides of paeony|
16308361|NCT04618575|Other|Ursodeoxycholic acid only|
16308362|NCT04618562|Experimental|Revival Active Program|Revival Program included supervised play group, twice a week followed by home practice.
16308363|NCT04618549|Active Comparator|Direct anterior approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by direct anterior approach, using a regular OR table, without hip hyperextension.
16308364|NCT04618549|Active Comparator|Mini Posterior Approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a mini posterior approach.
16308365|NCT04618549|Active Comparator|Lateral approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a lateral (Hardinge) approach.
16308366|NCT04618536|Experimental|Inorganic sunscreen|
16308367|NCT04618536|Experimental|Organic sunscreen|
16308368|NCT04618523|Experimental|Artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
16308369|NCT04618523|Experimental|Artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
16308370|NCT04618510|Experimental|SEED 1-dayPure EDOF soft contact lens|The participant will be requested to wear the daily disposable lens 8-10 hours per day and replaced daily. All participants will be followed for 12 months (followup visit schedule; 3 months, 6 months, 12 months) post-contact lens wear.
16309316|NCT04611685|Active Comparator|Tramadol|Tramadol (im.) for once & Tramcontin (po.) for routine use during the first 3 postop. days.
16308371|NCT04618510|Sham Comparator|Single vision spectacle lens|The participant will be requested to wear the spectacle lens daily. All participants will be followed for 12 months (follow up visit schedule; 3 months, 6 months, 12 months) post spectacle lens wear.
16308372|NCT04618497|Experimental|Inhalational methoxyflurane (Penthrox)|
16308373|NCT04618497|Active Comparator|Intramuscular ketorolac|
16308374|NCT04618484|Experimental|Biomodulation|6-weeks post-operative cryo-, photo- and electro-biomodulation protocol after repair
16308375|NCT04618484|No Intervention|Control|standard rehabilitation after repair
16308377|NCT04618458|Experimental|Intervention Arm|Eligible overweight/obese children and their overweight/obese parent (N=20 families) will receive the same telehealth diabetes prevention intervention based on Power to Prevent and delivered by a trained lifestyle coach. Families will meet weekly for 11-weeks (60-min sessions), and then monthly (60-min sessions) for 4 pilot behavioral reinforcement maintenance sessions (15 sessions total). Participants will meet in their respective groups (n=5 families per group) via videoconference using Wi-Fi-enabled tablets with cellular connectivity for the entire intervention. Sessions will consist of nutrition and physical activity behavior change strategies (20 min), problem solving and decision-making skills to circumvent barriers to behavioral change (20 min), and family goal setting and action planning (20 min). Assessment measures will be collected from the child and parent participants at baseline, 12-weeks (post-intervention), and 30-weeks (follow-up).
16308378|NCT04618445||Undergraduate students|prevalence of TMD among undergraduate students
16308379|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
16308380|NCT04618406|Experimental|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
16308381|NCT04618406|Active Comparator|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
16308382|NCT04618393|Experimental|EMB-02|"In Phase I part: participants enrolled in the different time will receive EMB-02 once weekly (IV) at different ascending dose levels.
~In Phase II part: participants will receive EMB-02 once weekly (IV) at previously defined RP2D."
16308383|NCT04618380||Bilateral trifocal implantation|Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
16308384|NCT04618380||Myopic monovision|The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
16308385|NCT04618380||Hybrid monovision|Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
16308386|NCT04618380||Premium monovision|Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
16308387|NCT04618367|Experimental|HAIC plus Lenvatinib and Sintilimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.
16308388|NCT04618354||LADA group|The patient was diagnosed with late-onset autoimmune diabetes (LADA).
16308389|NCT04618354||T2DM group|The patient was diagnosed with type 2 diabetes (T2DM).
16308390|NCT04618354||T1DM group|The patient was diagnosed with type 1 diabetes (T1DM).
16308391|NCT04618328|Experimental|ATRA treatment group|ATRA is given at a daily dose of 10 mg twice daily orally for 12 weeks
16308395|NCT04618289|Experimental|Vitamin D Group|The vitamin D3-fortified fruit juice supplement that will be used is vitamin D3 cholecalciferol (4000 IU, 100 mcg, Fiatec Biosystem Sdn Bhd, Selangor, Malaysia).
16308396|NCT04618289|Placebo Comparator|Placebo Group|The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
16308397|NCT04618276|Experimental|Arm A (MAL group)|"Skin swab for culture in the groin for baseline
~PDT with 5% topical methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
~Skin swab for culture
~Skin antisepsis
~Skin swab for culture"
16308398|NCT04618276|Experimental|Arm B (Methylene Blue group)|"Skin swab for culture in the groin for baseline
~PDT with 0.01% methylene blue based photosensitizer (NF-031)
~Skin swab for culture
~Skin antisepsis
~Skin swab for culture"
16308399|NCT04618276|No Intervention|Control group|"Skin swab for culture in the groin for baseline
~NO PDT
~Skin antisepsis
~Skin swab for culture"
16308400|NCT04618263|Experimental|GATE-101, 5 mg IV, Single Dose|GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
16308401|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose|GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
16308402|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose|GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
16308403|NCT04618263|Experimental|GATE-101, 150 mg IV, Single Dose|GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
16308404|NCT04618263|Experimental|GATE-101, 450 mg IV, Single Dose|GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
16308406|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose, Lumbar Catheter|GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
16308407|NCT04618263|Experimental|GATE-101 5 mg IV, Five Daily Doses|GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
16308408|NCT04618263|Experimental|GATE-101 15 mg IV, Five Daily Doses|GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
16308409|NCT04618263|Experimental|GATE-101 150 mg IV, Five Daily Doses|GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
16308410|NCT04618263|Placebo Comparator|Placebo Comparator, Single Dose|Placebo Comparator, Single Dose, with follow up for 28 days
16308411|NCT04618263|Placebo Comparator|Placebo Comparator, Five Daily Doses|Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
16308412|NCT04618250|Experimental|Coordinated, co-produced health care|
16308413|NCT04618250|No Intervention|Care as usual|Care as usual
16308414|NCT04618224||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language
~30 patients with low vision (LVG) with adequate literacy of written Greek language
~These patients are tested on the digital reading test DDART."
16308415|NCT04618224||Study group|The same patients as those in the control group (NVG, LVG) are tested on the online version of the Greek digital reading test DDART (wDDART).
16308416|NCT04618211|Other|Low dose/placebo|Single low dose of PHA-022121 or placebo
16308417|NCT04618211|Other|Medium dose/placebo|Single medium dose of PHA-022121 or placebo
16308418|NCT04618211|Other|High dose/placebo|Single high dose of PHA-022121 or placebo
16308419|NCT04618198|No Intervention|Diagnosis dependent / conventional dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days
~If subsequent TB test positive, then WHO recommended weight-based anti-TB therapy x 28 days"
16308420|NCT04618198|Experimental|Immediate anti-TB therapy/conventional dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric WHO recommended weight-based dose anti-TB therapy x 28 days
16308421|NCT04618198|Experimental|Diagnosis dependent/sepsis specific dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days
~If subsequent TB test positive, then sepsis specific dose anti-TB therapy x 28 days"
16308422|NCT04618198|Experimental|Immediate anti-TB therapy/sepsis specific dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric sepsis specific dose anti-TB therapy x 28 days
16308423|NCT04618185||p.Phe508del homozygous genotype|People with CF with 2 copies of p.Phe508del and previously eligible for Symkevi (Tezacaftor/Ivacaftor)
16308424|NCT04618185||p.Phe508del heterozygous genotype|People with CF with 1 copy of p.Phe508del and not previously eligible for any CFTR modulator
16308425|NCT04618172|Experimental|Exercising group|This group practises 30 minute long aerobic exercises twice a week besides filling out the questionnaires.
16308426|NCT04618172|No Intervention|Control group|This group fills out the questionnaires without practising 30 minute long aerobic exercises twice a week.
16308427|NCT04618159|Other|Helipyl|helipyl wil be given to 10 children with asymptomatical helicobacter pylori infection
16308428|NCT04618146|Placebo Comparator|Group C|given intrathecal bupivacaine 12.5 mg.
16308429|NCT04618146|Active Comparator|Group M25|given intrathecal bupivacaine 12.5mg + morphine 25 microgram.
16308430|NCT04618146|Active Comparator|Group M50|given intrathecal bupivacaine 12.5mg + morphine 50 microgram.
16308431|NCT04618133|Experimental|Early time-restricted eating|Duration: 12 weeks
16308432|NCT04618133|Experimental|Late time-restricted eating|Duration: 12 weeks
16308433|NCT04618133|Active Comparator|Active control|Duration: 12 weeks
16308434|NCT04618120|Experimental|Virtual Reality-based Exercise Group|"Virtual reality-based exercises, breathing exercises and patient education on general considerations.
~Virtual reality-based exercises were done using the Microsoft Xbox 360 Kinect system. Among the 'Kinect Sports' games, especially tennis, table tennis, boxing and bowling games including upper extremity movements were selected. These games require all-directional and repetitive motion of the shoulder and elbow joint. Patients played the games using the operated / affected side arms. Between games, the patient was rested in a chair. In the meantime, deep breathing exercises were done.
~The patients participated in virtual reality-based exercises 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). Each exercise session was set to last 30-40 minutes in total."
16308435|NCT04618120|Experimental|Exercise Group|"Stretching exercises, range of motion exercises, posture exercises, breathing exercises and patient education on general considerations.
~11 different exercises consisting of shoulder range of motion in all directions, stretching exercises, posture exercises and breathing exercises were performed in the presence of a physiotherapist.The patients participated in this exercise program 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). One session of the exercises was completed in an average of 30-40 minutes. The same exercises were repeated in each session."
16308436|NCT04618120|No Intervention|Control Group|Only patient education on general considerations.
16308437|NCT04618107|Experimental|Wide awake surgery|Wide awake local anaesthesia was used as mode of aneasthesia for tendon repair surgery. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
16308438|NCT04618107|Active Comparator|General anaesthesia|Tendon repair surgeries were performed under general anaesthesia. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
16308439|NCT04618094|Experimental|High intensity interval group|
16308440|NCT04618094|Active Comparator|Moderate continous intensity group|
16308441|NCT04618094|No Intervention|non-exercising group|
16308442|NCT04618081||Participants with FL or MZL|Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.
16308443|NCT04618055|Experimental|NiTiDent Tuah Porous NiTi Dental Implants|
16308444|NCT04618055|Active Comparator|Control Implant|
16308445|NCT04618042|Experimental|FX06|
16308446|NCT04618042|Placebo Comparator|Placebo|
16308447|NCT04618029|Experimental|Treatment Group|"Home Assessment and Modification A two-component individualized home hazards management program will be provided for each participant in the intervention group according to the results of the HOME FAST. Basic home safety strategies and basic modifications are developed and will be prescribed for this study according to the HOME FAST assessment (weeks et al. 2010)
~Education Education on optimization of functional performance in the home will be provided via pamphlets on fall prevention, including energy conservation techniques (Chumbler et al., 2010), ergonomics (Edwards et al., 2019) and task simplification techniques (Wesson et al., 2013) will be provided. These techniques will also be provided for participants' caregivers."
16308448|NCT04618029|No Intervention|Controlled Group|1. Standard Care The standard care defined for this study is any care that are provided from the respective hospital. This will include common therapies and interventions for stroke rehabilitation in general.
16308449|NCT04618016||With Vitamin E|
16308450|NCT04618016||Without Vitamin E|
16308451|NCT04618003||Athletes with Spinal Cord Injury|Group of athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
16308452|NCT04618003||Non-athletes with spinal cord injury|Group of non-athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
16308453|NCT04618003||Able-bodied control group|Group of non-athletes able-bodied control subjects that was assessed at rest and during a physical activity in virtual reality.
16308454|NCT04617977|Experimental|Parent-child I-BMS intervention group|Children with eczema and their parent caregivers will attend the six sessions simultaneously in a parallel group format. Parent caregivers will attend the parents group in the first 2.5 hours; while children will attend the children group in the first 2.5 hours. Both parents and children will later reunite in the joint group in the final 0.5 hours.
16308455|NCT04617977|Experimental|Parent only I-BMS intervention group|Only parent caregivers of children with eczema will attend the six sessions. The content of the 2.5-hour parents group will be the same as the one in Arm 1 (Parent-child I-BMS intervention group), with an additional 0.5 hour of reflective discussion among group members. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
16308456|NCT04617977|Active Comparator|Parent only health education active control group|Only parent caregivers of children with eczema will attend the six sessions. Each session consists of teaching in the first 2.5 hours and Q&A in the final 0.5 hour. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
16308457|NCT04617964||IUGR|sample of 40 pregnant women affected by intrauterine growth restriction (IUGR) Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
16308458|NCT04617964||NORMAL|Ssample of 40 healthy pregnant women Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
16308459|NCT04617951|Experimental|Ishige Okamurae extracts group|This group takes Ishige Okamurae extracts for 12 weeks.
16308460|NCT04617951|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
16308461|NCT04617938|Experimental|TACUNA|Randomized participants will attend 3 virtual TACUNA workshops, focused on behavioral, physical, and spiritual domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use. They will also attend a wellness gathering, focused on healthy social networks and engaging in traditional practices.
16308462|NCT04617938|Active Comparator|Opioid education|Randomized participants will attend 1 virtual opioid education workshop, focused on behavioral and physical domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use.
16308463|NCT04617925|Experimental|belantamab mafodotin|Belantamab mafodotin will be administered as an IV infusion at a dose of 2.5 mg/kg every six weeks until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of eight doses (approximately 12 months), according to the response adapted modifications
16308464|NCT04617912|Experimental|PennPET Explorer|"All subjects will be scanned in the CT scanner and then the scanner bed will be moved into position in the PennPET Explorer for initiation of the PET scan. For all PET scans a radioactive imaging drug is used.
~The radiotracer injection may be performed according to one of the following scenarios:
~As part of a clinical standard-of-care (SOC) PET/CT scan (using an FDA-approved radiotracer; the PennPET Explorer cannot yet accommodate a study that requires a commercially available 510(k)-approved instrument for clinical results, subjects in this group will be scanned on both a commercial instrument and the PennPET Explorer),
~As part of another research study (using either an FDA-approved radiotracer or an investigational radiotracer),
~As a research injection designed specifically to utilize the PennPET Explorer (using an FDA-approved radiotracer)."
16308465|NCT04617899|Experimental|Novasight IVUS/OCT|A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
16308466|NCT04617886|Experimental|Sadness condition|
16308467|NCT04617886|Experimental|Happiness condition|
16308468|NCT04617873|Experimental|Deep bain stimulation and Spinal cord stimulation therapy|The patients in this group will receive bilateral STN-DBS and SCS stimulation
16308469|NCT04617860|Experimental|WVE-120102 (Dose A)|
16308470|NCT04617847|Experimental|WVE-120101 (Dose A)|
16308471|NCT04617834||Quality Surveillance Data|For this quality surveillance study, data will be collected retrospectively through electronic health record (EHR) queries for all eligible patients treated for acute cardiovascular symptoms by one of the study sites.
16308472|NCT04617821|Experimental|albumin bound paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine were given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.
16308473|NCT04617821|Active Comparator|mFOFLIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
16308474|NCT04617808||Headache pattern|Telephone call from center 15 for the headache pattern
16308475|NCT04617795|Experimental|Basal-Bolus (Group A)|"2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:
~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:
~4 weeks Omnipod 5 system use in Automated Mode with simplified bolus
~6-month optional extension using Automated Mode"
16308476|NCT04617795|Experimental|Basal (Group B)|"2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:
~2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by:
~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:
~If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR
~If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus
~6-month optional extension using Automated Mode"
16308477|NCT04617782|Experimental|Treatment A|5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
16308478|NCT04617782|Experimental|Treatment B|10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
16308479|NCT04617782|Active Comparator|Treatment C|10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
16308480|NCT04617769|Placebo Comparator|Psychoeducation alone (PSYED)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors.
16308481|NCT04617769|Active Comparator|Psychoeducation followed by exposure (PSYED+EXP)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated.
16308482|NCT04617769|Experimental|Psychoeducation & exposure/Antagonistic Actions (PSYED+EXP+AA)|"The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated. Antagonistic action strategies during exposure to the trauma-videoclips will include (a) adopting an open posture; (b) eating a palatable snack; (c) smiling; and (d) wishing on high levels of emotional distress (e.g., come on distress hit me with your best shot). The participant will engage in all of the four antagonistic actions for the six exposure trials."
16308484|NCT04617743||High residual volume|Bladder tumor patients with high residual volume
16308485|NCT04617743||Low residual volume|Bladder tumor patients with low residual volume
16308486|NCT04617730|Active Comparator|Control arm|
16308487|NCT04617730|Experimental|Interventional arm|
16308488|NCT04617704|Experimental|Experimental:GC012F treatment|BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0
16308489|NCT04617691|Experimental|Group 1: Guselkumab PFS-U|Participants will receive single intravenous (IV) guselkumab formulation using UltraSafe Plus Passive Needle Guards (PFS-U) to create the IV solution.
16308490|NCT04617691|Experimental|Group 2: Guselkumab FVP|Participants will receive single IV guselkumab formulation using Final Vialed Product (FVP) to create the IV solution.
16308491|NCT04617678|Active Comparator|Prospective Prehabilitation|Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
16308492|NCT04617678|No Intervention|Retrospective Control|Retrospectively comparing patients that did not enroll into the prehabilitation program for head and neck cancer.
16308493|NCT04617665|Other|One-handed mask ventilation|For the one-handed mask ventilation, only one hand can be used to achieve the face mask seal. The left thumb and index finger form a ''C,'' providing anterior pressure over the mask, while the third, fourth, and fifth fingers form an ''E'' to lift the jaw.
16308494|NCT04617665|Other|Two-handed mask ventilation|For the two-handed mask ventilation, the provider's thumb and thenar eminence of each hand are held parallel, adjacent to the mask connector, and depress each side of the mask. The second through fifth digits wrap around and elevate the mandible to draw it anteriorly into the mask establishing both a jaw-thrust and chin-lift maneuver when appropriate.
16308495|NCT04617652|Active Comparator|Group M|Magnesium group
16308496|NCT04617652|Placebo Comparator|Group C|Control group
16308497|NCT04617639|Experimental|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
16308498|NCT04617639|Active Comparator|Control group I|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
16308499|NCT04617639|Other|Control group II (observation group)|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel.
16308594|NCT04616911|Active Comparator|Rerouting seton|Placement of seton with rerouting of the fistula tract around the internal anal sphincter
16308595|NCT04616911|Active Comparator|LIFT|Ligation of the intersphincteric fistula tract
16308500|NCT04617626|Other|Azithromycin|All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
16308501|NCT04617613|Active Comparator|Standard triple therapy|Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
16308502|NCT04617613|Experimental|Quadruple therapy group|Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.
16308503|NCT04617600|Active Comparator|Mineral trioxide aggregate (MTA)|Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
16308504|NCT04617600|Experimental|TheraCal PT|Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
16308505|NCT04617587|Experimental|Early Intervention|All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.
16308508|NCT04617561|Active Comparator|Ursodeoxycholic Acid group|Ursodeoxycholic Acid 13-15mg/kg/d
16308509|NCT04617561|Experimental|Ursodeoxycholic Acid+Low Dose Glucocorticoid group|Ursodeoxycholic Acid 13-15mg/kg/d+Methylprednisolone 12mg/d in induction period and 2-4mg/d in maintenance period
16308510|NCT04617548|Experimental|tDCS and CO-OP Group|One-hour session three times per week for 4 weeks. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. Following each tDCS session, the participants will complete a sensations questionnaire.The basis for each session will be task-based practice of client-chosen goals and the use of cognitive strategies using CO-OP.
16308511|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Moderate Liver Impairment|Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
16308512|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Normal Liver function|Participants with advanced or metastatic solid tumor and normal hepatic function will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
16308513|NCT04617509|Experimental|Part I GS-248 Formulation A|Formulation A given in fasting state.
16308514|NCT04617509|Active Comparator|Part I GS-248 Formulation B|Formulation B given in fasting state.
16308515|NCT04617509|Other|Part II GS-248 Formulation A or B|Formulation A or B given in fed condition
16308516|NCT04617496|Experimental|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features that encourage a higher level of speech performance.
16308517|NCT04617496|Active Comparator|Control group|Health education
16308518|NCT04617483|Experimental|Aged 26-45, Commercial Scale|Commercial scale inactivated SARS-CoV-2 vaccine in adults aged 26-45 years.
16308519|NCT04617483|Experimental|Aged 18-59, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in adults aged 18-59 years.
16308520|NCT04617483|Experimental|Aged ≥60, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in elderly aged above 60 years.
16308521|NCT04617457|Experimental|NAPOX chemotherapy|NAPOX chemotherapy in 14-day cycles with the four IMPs given intravenously in the following order: nal-irinotecan, oxaliplatin, folinic acid and 5-fluouracil.
16308522|NCT04617444|Experimental|Intervention group|
16308523|NCT04617444|Active Comparator|Control group|
16308524|NCT04617431|Experimental|Intervention group|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
16308525|NCT04617431|No Intervention|Control group|"The participants of control group had a wearable device and could upload their dietary diary to the health management platform every day. But no LINE group was created, and no reminding."
16308526|NCT04617418||subjects with refractory focal epilepsy with a seizure frequency|The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.
16308527|NCT04617405||Type A|Healthy normal-weight pregnant women
16308528|NCT04617405||Type B|Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)
16308529|NCT04617405||Type C|Pregnant women with type 2 diabetes
16308530|NCT04617405||Type D|Healthy overweight pregnant women
16308531|NCT04617392|Active Comparator|controlled group|25 patients after bariatric-metabolic surgery without controlled postprocedural training
16308532|NCT04617392|Experimental|active group|25 patients after bariatric-metabolic surgery with controlled postprocedural training
16308533|NCT04617379|Experimental|Active Treatment Group|15 minutes daily stretch for 1 year
16308534|NCT04617379|No Intervention|Control Group|No stretches
16310087|NCT04606771|Experimental|Arm A|"Savolitinib 300 mg oral QD
~Osimertinib 80 mg oral QD"
16308535|NCT04617366|Experimental|Individualized rTMS strategy|The individualized strategy will adjust the rTMS parameters promptly based on the results of fNIRS. This arm selects either the high-frequency rTMS to the contralesional dorsal premotor cortex (PMd) or the low-frequency rTMS to the contralesional primary motor cortex (M1) based on the lateralization index of the PMd measured by fNIRS.
16308536|NCT04617366|Active Comparator|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1.
16308537|NCT04617353|Experimental|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
16308538|NCT04617353|Other|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
16308539|NCT04617340|No Intervention|Usual care group|No pharmacist will be actively involved in the medication review, counseling or discharge and post-discharge procedure. In both groups the best possible preadmission drug list will be compiled for inpatients within 72 hours after admission to the geriatric ward. If potentially dangerous or life-threatening drug errors are observed in the usual care group, this will be communicated to the treating physician
16308540|NCT04617340|Experimental|Intervention group|"The clinical pharmacist-collaborative service in the intervention group comprises six steps based on the clinical pharmacy intervention proposal of Van der Linden et al (Drugs Aging 2020).
~The first three steps focus on optimizing the drug therapy of geriatric inpatients. The remaining steps target a safe transition from the hospital to the community."
16308541|NCT04617327|Experimental|Experimental : Short Course Pre-operative RadiothErapy|"As part of the planning process, you need to undergo a CT Simulation.It is special type of CT scan used to measure and design the radiation fields to precisely target the tumor.It is done at the Radiation Oncology Department at the MUHC. Some patients may be asked to also undergo an MRI Simulation, and the CT simulation. You may asked to provide a blood sample to ensure good kidney function prior to the CT and MRI scans. Both CT and MRI simulations are considered standard of care.
~Once the simulation studies are done, there is about a 2 week waiting period for radiation planning prior to starting the radiation treatments.
~The hypofractionation technique will be delivering five fractions (one fraction delivered every 2nd day) of 7 Gy daily of external beam radiotherapy (EBRT) over a period of one and half weeks for a total of 35 Gy. The treatment should last approximately 30 minutes. Once treatments are done, there is a 4 to 6 week wait for surgery."
16308542|NCT04617314|Experimental|RC108|Participants will be allocated to one of the following dose groups: 0.1, 0.3, 0.9, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC108-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
16308543|NCT04617301||Group 1. Internal root resorption (IRR)|Internal root resorption is the progressive destruction of intraradicular dentin and dentinal tubules along the middle and apical thirds of the canal walls as a result of clastic activities. It is seen as a radiolucent area around the pulpal cavity, usually of incisors and mandibular molars. The various etiological factors suggested for internal root resorption include traumatic injury; infection and orthodontic treatment.
16308544|NCT04617301||Group 2. external cervical resorption (ECR)|"Cementum is considered to protect the underlying root dentin from being resorbed. It is broadly accepted that damage to or deficiency of this protective cementum layer below the epithelial attachment exposes the root surface to osteoclasts, which then resorb the dentin.
~Clinical sign; Located in cervical region of tooth Pink spot might be noted by patient/dentist Tooth usually responds positively to vitality tests unless there is pulpal involvement (in very advanced cases) Spontaneous and profuse bleeding on probing Sharp, thinned out edges around the resorptive cavity"
16308545|NCT04617301||Grup 3. external replacement resorption (ERR)|external replacement resorption also known as trauma-induced resorption - and this resorption may occur in teeth that also have external inflammatory resorption. This review will not discuss external replacement resorption in detail but it will be mentioned where relevant as both types of resorption may occur in some cases. This is because replacement resorption is a consequence of the same injuries that typically cause external inflammatory resorption - such as intrusion and avulsion where there is significant damage to the external root surface during the injury, as well as sometimes during the repositioning/ replantation of the tooth.
16308546|NCT04617288|Experimental|Mean and standard deviations of age and height between group A and B|100 subjects with a mean age of 30.82±6.75 (group A, 31.42±6.67; group B, 30.82±6.82) ranging from 20 to 45 years, with a mean height of 165.52±7.85 (group A, 164.92±7.79; group B, 166.12±7.87) centimeters
16308547|NCT04617288|Experimental|Between group comparison of VAS, NDI and ROM|VAS, NDI and Neck ROM between two groups were compared at pretest (0 day) and posttest (end of two weeks)
16308548|NCT04617275|Experimental|Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
16308549|NCT04617275|Experimental|Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
16308550|NCT04617275|Experimental|Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
16308551|NCT04617275|Experimental|Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
16308552|NCT04617275|Placebo Comparator|Arm 5 - Placebo in subjects with T2DM and Obesity|Matching Placebo tablets taken twice a day (BID)
16308553|NCT04617275|Experimental|Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
16308679|NCT04616313||former or current c-cigarette users|Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
16308554|NCT04617275|Experimental|Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
16308555|NCT04617262|Experimental|Remote Problem Management Plus|Five individual sessions of low-intensity psychological intervention
16308556|NCT04617249|Active Comparator|Giving median anesthesia|
16308557|NCT04617249|Active Comparator|Giving paramedian anesthesia|
16308558|NCT04617236|Experimental|Cultivando la Salud Educational Intervention|After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
16308559|NCT04617236|No Intervention|Control|No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
16308560|NCT04617223|Other|Treatment|
16308561|NCT04617210||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
16308562|NCT04617197|Experimental|Variable-frequency combination 1|Non disclosure
16308563|NCT04617197|Active Comparator|Variable-frequency combination 2|Non disclosure
16308564|NCT04617197|Placebo Comparator|Control (Placebo)|Non-disclosure
16308565|NCT04617184||Inflammatory Bowel Disease|any patient with IBD will be included in the registry
16308566|NCT04617171|Experimental|Benralizumab|Benralizumab 30 mg given in the form of subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
16308567|NCT04617171|Placebo Comparator|Placebo|Normal Saline given subcutaneously every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
16308568|NCT04617158|Active Comparator|Early adjustable suture surgery|Suture adjustment after 2 hours of surgery
16308569|NCT04617158|Active Comparator|Late adjustable suture surgery|Suture adjustment after 24 hours of surgery
16308570|NCT04617145|Active Comparator|Aerobic exercise group|Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week.
16308571|NCT04617145|Active Comparator|Resistive exercise group|Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Sessions were conducted three sessions/week for eight weeks.
16308572|NCT04617132||Online Mindfulness Group|Families with PPDA receiving evidence-based MBCT/MBSR intervention
16308573|NCT04617119|Experimental|Conventional physical therapy treatment and IMT|"The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
~In addition, the patient will receive inspiratory muscle training (IMT) by using a threshold IMT device. Patient will ask to use the device twice daily. In each time, patient will perform 3 sets of 10 breaths with 1-minute rest between sets.
~Exercise intensity will start with 10 % of pre-measured maximal inspiratory pressure.
~Once the patient successfully completed 30 breath twice a day, the exercise load will increase 5% more in the subsequent training session.
~This treatment protocol will perform daily for 2 weeks."
16308574|NCT04617119|Active Comparator|Conventional physical therapy|The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
16308575|NCT04617106|Active Comparator|Conventional Palpation group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using the conventional palpation method.
16308576|NCT04617106|Active Comparator|DNTP group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using USG-guided dynamic needle tip positioning method.
16308577|NCT04617093|Experimental|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
16308578|NCT04617080|Active Comparator|SUPRACOR Regular|
16308579|NCT04617080|Experimental|SUPRACOR Strong|
16308580|NCT04617067|Experimental|All Patients|Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.
16308581|NCT04617054|Experimental|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106|
16308582|NCT04617028|Experimental|Jaktinib|Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.
16308583|NCT04617028|Active Comparator|Hydroxycarbamide|Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.
16308584|NCT04617015|Experimental|Ipratropium bromide|All subjects will receive ipratropium bromide HFA and will have spirometry performed before and after ipratropium.
16308585|NCT04616989|Experimental|Psycho-education intervention arm|Participants will receive psycho-education materials
16308586|NCT04616989|Active Comparator|Comparator arm|Participants will receive COVID-19 leaflets
16308587|NCT04616976||convalescent plasma therapy group|the patients received convalescent plasma therapy
16308588|NCT04616976||Control group|the patients with similar situation without convalescent plasma therapy
16308589|NCT04616963|Other|FTC 200 mg / TDF 300 mg and FTC 200 mg / TAF 25 mg|"Phase I: Participants will continue or initiate F/TDF for PrEP for a minimum 12-week lead-in period prior to switching to F/TAF.
~Phase II: Participants will be switched to study-provided F/TAF for PrEP until 48 weeks after initiation. Participants will receive study treatment for the duration of the study unless they meet criteria for discontinuation."
16308590|NCT04616937|Active Comparator|Galacto-oligosaccharides (GOS) Group|Daily dose of GOS over 4 weeks
16308591|NCT04616937|Placebo Comparator|Placebo group|Daily dose of maltodextrin over 4 weeks
16308596|NCT04616898|Active Comparator|Diode Laser Treatment Only|Group 1: Patient 1- Laser Only This patient will present 20+, 14, 7, and 1 days prior to his/her scheduled abdominoplasty. Between 20 and 30 days prior, the patient will receive the first laser treatment on the 20+ day site 1. 14 days prior, the patient will receive laser treatment on the 14 day site 2. 7 days prior, the patient will receive laser treatment on the 7 day site 3. 1 day prior to the scheduled abdominoplasty, the patient will receive laser treatment on the 24 hour site 4.
16308597|NCT04616898|Active Comparator|Diode Laser and RadioFrequency Treatment|This patient will present 14 days and 7 days prior to his/her scheduled abdominoplasty. 14 days prior, the patient will be treated at site 1 with the laser and radiofrequency and site 3 with the laser only. 7 days prior, the patient will be treated at site 2 with the laser and radiofrequency and site 4 with the laser only.
16308598|NCT04616898|Active Comparator|Multiple Diode Treatments|These patients will present for three treatments, each four weeks apart, with the abdominoplasty scheduled four weeks following the last laser treatment. These patients will receive laser treatment every four weeks for twelve weeks on the sites labelled Multiple Tx below (sites 1 and 2) on Days -90, -60, and -30 prior to abdominoplasty. At the final treatment (Day -30), two additional diodes will be placed on the sites labelled Single Tx below (sites 3 and 4). 4 diodes total will be used at this visit. Four weeks following this last treatment, the scheduled abdominoplasty will be performed and the pannus containing the treated tissue will be excised.
16308599|NCT04616872|Experimental|Methotrexate-LDE|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
16308600|NCT04616872|Placebo Comparator|Placebo-LDE|Lipid nanoparticle (LDE)
16308601|NCT04616859|Experimental|Alcohol and Energy Drink (AmED)|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml"
16308602|NCT04616859|Active Comparator|Alcohol and Energy drink Placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)"
16308603|NCT04616859|Active Comparator|Alcohol placebo and Energy drink|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL"
16308604|NCT04616859|Placebo Comparator|Alcohol placebo and Energy drink placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL"
16308605|NCT04616846|No Intervention|Control cohort|
16308606|NCT04616846|Experimental|Infected cohort|
16308607|NCT04616794|Experimental|Cognitive Engagement Group|Participants eligible to enter this group must show low cognitive engagement in cognitively stimulating activities, defined as a score < 22 on the Cognitive Activity Questionnaire (CAQ)
16308608|NCT04616794|Experimental|Physical Activity Group|Participants eligible to enter this group must have a low level of physical activity defined as less than 600 MET-min/week (~150 minutes/week) of moderate to vigorous physical activity (MVPA), measured using the International Physical Activity Questionnaire - short form (IPAQ-SF)
16308609|NCT04616794|Experimental|Diet Group|Participants eligible to enter this group must have a low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale (MDS).
16308610|NCT04616794|Experimental|Multi-modal Group|Participants eligible to enter this group must be eligible for at least two of the three single-arm conditions.
16308611|NCT04616781|Active Comparator|Ketone ester with alcohol consumption|Drink a single dose of ketone ester 1.9 kcal/kg, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
16308612|NCT04616781|Placebo Comparator|Isocaloric dextrose placebo drink with alcohol consumption|Drink a single dose of Isocaloric dextrose placebo drink, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
16308613|NCT04616768|No Intervention|Arm A - Control|An arm of ≤42 patients will not receive PRO surveys, a Fitbit device, or patient feedback texts messages. They will receive shortened utility surveys at 3 and 6 months following enrollment, but their clinicians will not receive dashboards or utility surveys.
16308614|NCT04616768|Experimental|Arm B - Intervention without text feedback|"An arm of ≤42 patients enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months."
16308615|NCT04616768|Experimental|Arm C - Intervention with text feedback|"An arm of ≤42 patients enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months. Patients in this arm will receive an additional text prior to appointments that summarizes their symptoms and incorporates an active nudge question."
16308616|NCT04616755|Active Comparator|Bonded retainer 13-23|This group have bonded retainer behind six front teeth in the maxilla to keep front teeth stable.
16308617|NCT04616755|Active Comparator|Bonded retainer 12-22|This group have bonded retainer behind four front teeth in the maxilla to keep front teeth stable.
16308618|NCT04616755|Active Comparator|Vacuum-formed retainer|This group have Vacuum-formed retainer covering all erupted teeth in maxilla to keep front teeth stable
16308619|NCT04616742|Experimental|[14C]SHR6390|
16310088|NCT04606771|Experimental|Arm B|"Savolitinib 300 mg oral QD
~Placebo to Osimertinib 80mg oral QD"
16308620|NCT04616729|Experimental|GnRH agonist Depot form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix or Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 3.75 mg Depot form will be used for final oocyte maturation. Ganirelix/Cetrorelix 0.25mg daily (in the morning) will resume for 7 days from the evening of the day of oocyte retrieval onwards. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval.
16308621|NCT04616729|Active Comparator|GnRH agonist Daily form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix/Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 0.2 mg Daily form will be used for final oocyte maturation. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval. The first administration of Triptorelin 3.75mg depot will be scheduled on the first day of the menstrual cycle after oocyte retrieval. To prevent the flare-up produced by the GnRH agonist, daily doses of 0.25mg of Ganirelix/Cetrorelix will be given for seven days.
16308622|NCT04616716|Experimental|1|"Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3
~FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3"
16308623|NCT04616716|Experimental|2|"Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3
~FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3"
16308624|NCT04616716|Experimental|3|"Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3
~FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3"
16308625|NCT04616716|Experimental|4|"Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3
~FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3"
16308626|NCT04616716|Experimental|5|"Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3
~FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3"
16308627|NCT04616716|Experimental|6|"Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3
~FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3"
16308628|NCT04616703||BMI < 25 kg/m2|Those with NFAT and BMI < 25 kg/m2.
16308629|NCT04616703||BMI 25-30 kg/m2|Those with NFAT and BMI 25-30 kg/m2.
16308630|NCT04616703||BMI > 30 kg/m2|Those with NFAT and BMI > 30 kg/m2.
16308634|NCT04616651|Active Comparator|Pre-Chatbot survey arm|Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
16308635|NCT04616651|Experimental|Post-Chatbot survey arm|Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)
16308636|NCT04616638|Experimental|RT-POWER Intervention|Six familiarization sessions and 20 RT-POWER sessions.
16308637|NCT04616638|Active Comparator|Control Intervention|Six control familiarization sessions and 20 traditional RT sessions.
16308638|NCT04616625||Methamphetamine exposed|Infants born to mothers with prenatal history of MA use during current pregnancy and/or positive meconium toxicology positive for MA in infant.
16308639|NCT04616625||Methamphetamine non-exposed|Infants born to mothers without prenatal history of MA use during this pregnancy and negative meconium toxicology for MA in infant.
16308640|NCT04616612|Experimental|SystemCHANGE (TM)|"SystemCHANGE™ focuses on using patients' already established and reliable systems to support medication-taking, rather than focusing on personal effort and remembering.When applied to medication adherence, the goal is to reduce medication-taking variability and move towards consistently taking medication with a 6-hour window of time (for daily medications like RAAS) and avoid missing medications. SystemCHANGE™ improvement cycles rely on efficient use of performance feedback in order to make decisions about whether system solutions work or if there is a need to select other solutions."
16308641|NCT04616612|Active Comparator|Attention Control|Participants in the attention control will receive educational materials about chronic kidney disease (CKD). The content will be focused on diet, exercise, and living with CKD.
16308642|NCT04616586|Experimental|Arm A|Drug - Siltuximab
16308643|NCT04616586|Other|Arm B|Comparator - Normal Saline
16308644|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System|
16308645|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery using OMNI surgical System|
16308646|NCT04616573|Active Comparator|iStent Inject implantation|
16308680|NCT04616313||never smokers|Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
16308681|NCT04616287|Experimental|dementia with Lewy bodies|
16308682|NCT04616287|Active Comparator|Alzheimer disease|
16308648|NCT04616547|Experimental|Supportive care (tin Sn 117m DTPA)|Patients receive tin Sn 117m DTPA IV over 5-10 minutes on day 1. Treatment repeats every 8 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive tin Sn 117m DTPA for an additional 2 cycles if pain recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans, or evidence of clinical progression.
16308649|NCT04616534|Experimental|Treatment (gemcitabine, BAY 1895344)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and BAY 1895344 PO BID on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16308650|NCT04616521|Experimental|Asymmetric DBS group|In this arm, a one-staged combined unilateral STN and contralateral GPi DBS will be implanted into PD patients. For postural instability and gait difficulty (PIGD)-dominant patients, the GPi in the side contralateral to the leg with longer step length will be targeted. For tremor-dominant (TD) patients, the STN in the side contralateral to the body side that mostly affected will be targeted. For PD patients of mixed type, the choice of target will depend on the judgement of a multidisciplinary team based on clinical features.
16308651|NCT04616508|Experimental|Behavioral testing|
16308652|NCT04616495||Liver transplanted patients|
16308653|NCT04616482||Digital therapeutic carbohydrate restriction (TCR) program|The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.
16308654|NCT04616469|Active Comparator|Root canal treatment using RaCe rotary system|Canal shaping using RaCe rotary system powered with endodontic motor with real time torque monitoring capacity
16308655|NCT04616469|Experimental|Root canal treatment using TruNatomy rotary system|Canal shaping using TruNatomy rotary system powered with endodontic motor with real time torque monitoring capacity
16308657|NCT04616443|Experimental|Dose escalation|"The HX008 injection is combined with OH2 injections at 10ˆ6 and 10ˆ7 CCID50/mL at a fixed dose of 200 mg, respectively.
~OH2 will be injected individually in the first week, followed by every two weeks while HX008 will be injected every three weeks after the first injection which will be in the second week."
16308658|NCT04616430|Placebo Comparator|Control|Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
16308659|NCT04616430|Active Comparator|Topical Endoxifen 10mg/breast/day|10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
16308660|NCT04616430|Active Comparator|Topical Endoxifen 20mg/breast/day|20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
16308662|NCT04616404|Active Comparator|Intervention Group|
16308663|NCT04616404|Placebo Comparator|Control Group|
16308664|NCT04616391|No Intervention|MDI group:|The patient continues MDI treatment as per routine procedures
16308665|NCT04616391|Experimental|AHCL group|The patient will use MiniMed 780G AHCL system
16308666|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Participants everyday use of prosthesis
16308667|NCT04616378|Experimental|Phase 2 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
16308668|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Participants everyday use of prosthesis
16308669|NCT04616378|Experimental|Phase 3 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
16308670|NCT04616378|Experimental|Phase 3 No Prosthesis|Participant performs tasks with no prosthetic device attached
16308671|NCT04616365|Experimental|Semi-Elective Lung Transplantation|Planned Semi-Elective Lung Transplantation Using 10°C Cold Static Preservation
16308672|NCT04616339|Experimental|Treatment Sequence 1|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D)
16308673|NCT04616339|Experimental|Treatment Sequence 2|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment D); Period 4 (Treatment C).
16308674|NCT04616339|Experimental|Treeatment Sequence 3|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment A); Period 3 (Treatment C); Period 4 (Treatment D).
16308675|NCT04616339|Experimental|Treatment Sequence 4|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment C)
16308678|NCT04616313||c-cigarette never users|Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
16308685|NCT04616261|Experimental|SET-HIGH|High volume speed endurance training
16308686|NCT04616261|Experimental|SET-LOW|Low volume speed endurance training
16308687|NCT04616248|Experimental|Cohort A (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16308688|NCT04616248|Experimental|Cohort B (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16308689|NCT04616235|Placebo Comparator|CON|This group will do intense aerobic exercise without concomitant IL-6R blockade
16308690|NCT04616235|Active Comparator|BLOCK|This group will do intense aerobic exercise with concomitant IL-6R blockade
16308691|NCT04616222||CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery
16308692|NCT04616222||Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery
16308693|NCT04616209|Experimental|PB103 (donor-derived NK cells) infusion|Cohort 1: 0.5×10^9，Cohort 2:1×10^9 or Cohort 3: 1.5×10^9 cells
16308696|NCT04616183|Experimental|Arm A (ERK1/2 inhibitor LY3214996, cetuximab)|Patients receive ERK1/2 inhibitor LY3214996 PO QD on days 1-28 and cetuximab IV over 1-2 hours on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16308697|NCT04616183|Experimental|Arm B (ERK1/2 inhibitor LY3214996, cetuximab, abemaciclib)|Patients receive ERK1/2 inhibitor LY3214996 and cetuximab as in Arm A. Patients also receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16308698|NCT04616170|Active Comparator|Usual care|Patients in this arm will be randomized to the routine positioning instructions given at the time of crowning of the fetal vertex during vaginal delivery.
16308699|NCT04616170|Experimental|Hip extension|Patients in this arm will be randomized to hip extension at the time of crowning of the fetal vertex during vaginal delivery.
16308700|NCT04616157|Experimental|ICBT-I|The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
16308701|NCT04616144|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal lenticule implantation as allogenic implant that will be taken from myopic patients to implant in hyperopic patients with high astigmatism using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity (far, intermediate, near vision) and secondary objective to stabilize(decrease) high astigmatism by reducing K values. Fresh corneal lenticule implantation as allogenic implant that we took from myopic patients (-5.0D) to implant in hyperopic patients (+4.0 D +3.0cyl) according to high K2 values. The stromal pocket diameter was 8 mm, 4mm super incision and 130-µm cap thickness.
16308702|NCT04616118|Experimental|Phone|Participants randomized to this arm will receive usual care via telephone only
16308703|NCT04616118|Experimental|Video|Participants randomized to this arm will receive usual care via video call
16308704|NCT04616105|Experimental|Cohort 1|Single ascending subcutaneous (SC) dose 1 of REGN6490 or matching placebo
16308705|NCT04616105|Experimental|Cohort 2|Single ascending subcutaneous (SC) dose 2 of REGN6490 or matching placebo
16308706|NCT04616105|Experimental|Cohort 3|Single ascending subcutaneous (SC) dose 3 of REGN6490 or matching placebo
16308707|NCT04616105|Experimental|Cohort 4|Single ascending intravenous (IV) dose 4 of REGN6490 or matching placebo
16308708|NCT04616092|Experimental|FERINJECT Group|Patients with FERINJECT injection
16308709|NCT04616092|No Intervention|Observation Group|Patients without FERINJECT injection
16308710|NCT04616079|Experimental|IV Cohort 1|Single intravenous (IV) dose 1 of REGN6490 or matching placebo
16308711|NCT04616079|Experimental|IV Cohort 2|Single IV dose 2 of REGN6490 or matching placebo
16308712|NCT04616079|Experimental|IV Cohort 3|Single IV dose 3 of REGN6490 or matching placebo
16308713|NCT04616079|Experimental|IV Cohort 4|Single IV dose 4 of REGN6490 or matching placebo
16308714|NCT04616079|Experimental|IV Cohort 5|Single IV dose 5 of REGN6490 or matching placebo
16308715|NCT04616079|Experimental|SC Cohort 1|Single subcutaneous (SC) dose 1 of REGN6490 or matching placebo
16308716|NCT04616079|Experimental|SC Cohort 2|Single SC dose 2 of REGN6490 or matching placebo
16308717|NCT04616079|Experimental|SC Cohort 3|Single SC dose 2 of REGN6490 or matching placebo
16308720|NCT04616053|Experimental|Intervention group|IMPACT intervention
16308721|NCT04616053|No Intervention|Control group|Usual care
16308722|NCT04616040||unresectable locally advanced/recurrent or metastatic esophageal cancer|
16308723|NCT04616027|Experimental|Healthy participants with normal renal function|This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
16308724|NCT04616027|Experimental|Participants with T2DM with normal renal function|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
16308725|NCT04616027|Experimental|Participants with T2DM with mild renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
16308726|NCT04616027|Experimental|Participants with T2DM with moderate renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
16308727|NCT04616027|Experimental|Participants with T2DM with severe renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
16308728|NCT04616014|Other|ORMD-0801 QD|8 mg QD, daily, in the morning
16308729|NCT04616014|Other|ORMD-0801 BD|8 mg BD, daily in the morning and in the evening
16308730|NCT04616001|Experimental|IVIG|IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days
16308731|NCT04615988||Participants being treated with immunotherapy|Participants who are to receive standard of care immunotherapy targeting PD-1 or PDL1 as treatment for malignancy
16308732|NCT04615975|Experimental|Intervention|Patients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
16308733|NCT04615962|Experimental|SNG100|Combination of low potency steroid with hydrating and moisturizing agents
16308734|NCT04615962|Active Comparator|Hydrocortisone|This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).
16308735|NCT04615962|Active Comparator|Mometasone furoate|This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
16308738|NCT04615936|Experimental|Methylene Blue-Photodisinfection|The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
16308739|NCT04615923|Experimental|Pridopidine|Pridopidine is administered orally twice daily for 24 weeks.
16308740|NCT04615923|Placebo Comparator|Matching Placebo|Matching placebo is administered orally twice daily for 24 weeks.
16308741|NCT04615910|Experimental|Verapamil|Patients treated with Verapamil within the Ver-A-T1D trial
16308742|NCT04615910|Placebo Comparator|Placebo|Patients treated with placebo within the Ver-A-T1D trial
16308743|NCT04615897|Experimental|Experimental aging|The subjects received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
16308744|NCT04615897|No Intervention|Control Aging|The subjects doesn´t received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
16308745|NCT04615884|Experimental|Chinese herbs formula: Shu Yu Wan|Participants will receive Shu Yu Wan capsules, to take 3 times daily for 6 weeks.
16308746|NCT04615884|Placebo Comparator|Placebo|Participants will receive capsules to take 3 times daily for 6 weeks.
16308747|NCT04615871|Experimental|semaglutide|Eligible subjects randomized to this arm will receive semaglutide 0.25 mg s.c. after randomization (Day 0), then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21 in addition to standard of care.
16308748|NCT04615871|No Intervention|control|Eligible subjects randomized to the control arm will receive no active treatment, only standard of care.
16308749|NCT04615858|Active Comparator|Genepro Generation 3|1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
16308750|NCT04615858|Active Comparator|Whey Protein|1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
16308752|NCT04615832|Active Comparator|Comparator full face mask 1|
16308753|NCT04615832|Active Comparator|Comparator full face mask 2|
16308754|NCT04615832|Active Comparator|Comparator full face mask 3|
16308755|NCT04615832|Experimental|Toffee Full Face Mask|
16308756|NCT04615819|Experimental|Arm 1|KTFT
16308757|NCT04615819|Experimental|Arm 2|PN
16308758|NCT04615806|Experimental|NIR-ICG|After positioning,Indocyanine green（ICG） dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.
16308759|NCT04615806|No Intervention|Control|This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.
16308760|NCT04615793|No Intervention|CONTROL GROUP|The control group will receive flexibility exercises and strength training focusing on the trunk and lower limb muscles, postural control exercise in different positions and different surfaces and general endurance training . Control group will receive intervention in the form of five minutes warm up followed by 12 minutes of walking at their comfortable pace and concluded with a five minutes cool down
16308761|NCT04615793|Experimental|EXPERMINTAL GROUP|The experimental group will obtain Pilate exercises, consist of strengthening,stretching and coordinated exercises on lower and trunk muscle
16308762|NCT04615780|Experimental|mouthwash with green tea group|The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily.
16308763|NCT04615780|Placebo Comparator|mouthwash with tap water group|The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
16308764|NCT04615767|Experimental|D-chiro-inositol|Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days
16308765|NCT04615754|Experimental|3-OHB vs Saline|3-OHB will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
16308766|NCT04615754|Experimental|Saline vs 3-OHB|Saline will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
16310089|NCT04606758|Active Comparator|PCNL under fluoroscopic control|
16308767|NCT04615741|Experimental|Trauma Informed Yoga|Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
16308768|NCT04615741|Experimental|Trauma Informed Psychotherapy|Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
16308769|NCT04615741|No Intervention|Control|These participants will not receive an intervention.
16308770|NCT04615728||pre-COVID cohort|Patients recruited from 1st November 2019 to 9th March 2020
16308771|NCT04615728||COVID cohort|Patients recruited from 10th March 2020 to 5th July 2020
16308772|NCT04615715|Experimental|CMV Risk-Reduction Intervention|One-on-one CMV prevention and education visit followed by 12 weeks of CMV prevention and education text messages
16308773|NCT04615715|Placebo Comparator|Stress Reduction Messaging|One-on-one stress reduction messaging visit followed by 12 weeks of reducing stress text messages
16308774|NCT04615702||application of recent guidelines in the management of acute biliary pancreatitis|all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up
16308775|NCT04615689||Infants with febrile urinary tract infection|The investigators will recruit infants hospitalized for acute febrile urinary tract infection. Before starting antibiotics treatment, The investigators will collect feces with the informed consents from infants' parents.
16308776|NCT04615689||Healthy infants|The investigators will recruit healthy controls from the clinics for routine check up with the informed consents from infants' parents.
16308777|NCT04615663||face-to-face patients|During this visit, the investigator will complete the SMI score.
16308778|NCT04615663||Email patients|this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.
16308779|NCT04615650|Active Comparator|Surgical treatment|Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.
16308780|NCT04615650|Experimental|Non-surgical treatment|Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.
16308781|NCT04615637|Experimental|Sensors|All subjects will follow the same experimental procedure: a recording using classical MEG followed by a recording in the same condition with the OPM He4 prototype.
16308782|NCT04615624|Experimental|Furosemide|When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.
16308783|NCT04615624|Placebo Comparator|Placebo|When patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.
16308784|NCT04615611|Experimental|salbutamol|salbutamol, 800 microgram from metered dose inhaler
16308785|NCT04615611|Placebo Comparator|placebo|placebo
16308786|NCT04615598|Experimental|Action observation group|
16308787|NCT04615598|Placebo Comparator|Placebo group|
16308788|NCT04615585|Experimental|Aloe Vera + Scaling and root planing|
16308789|NCT04615585|Active Comparator|Scaling and root planing|
16308790|NCT04615559|Experimental|contrast enhanced ultrasound|CEUS will be performed at one month post-op, six months post-op and at one year.
16308791|NCT04615546|Experimental|Remote Phase: PBH Patients|Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.
16308792|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. May include participants from the Remote Phase or newly enrolled participants.
16308793|NCT04615546|No Intervention|In-Clinic Phase: Surgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
16308794|NCT04615546|No Intervention|In-Clinic Phase: Nonsurgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
16308795|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients with indwelling gastrostomy tube|Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.
16308796|NCT04615533||Frail older adults, assessment|Frail older adults, assessment Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinetti Blance and Gait Scale
16308797|NCT04615481|Experimental|Elliptical Training Group|Total 30 minutes of elliptical cross training, including warm up, progressive elliptical training and cool down.
16308798|NCT04615481|Experimental|Ergo-metric Training Group|Total 30 minutes of ergometric training
16308799|NCT04615468|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
16308800|NCT04615455|Experimental|Adipose tissue-derived mesenchymal stem cells (ASCs)|One transconjunctival injection of allogeneic ASCs into the LG in one eye.
16308801|NCT04615455|Placebo Comparator|Placebo (vehicle, Cryostor CS10)|One transconjunctival injection of Cryostor CS10 into the LG in one eye.
16308802|NCT04615442|Experimental|All subjects|Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2 periods of 4h during the video EEG.
16308803|NCT04615429|Experimental|Mesenchymal Stromal cells|Approximately 1x10E6 MSC/kg
16308804|NCT04615429|Placebo Comparator|Control group|Solution identical to experimental treatment, without the MSC
16308805|NCT04615416|Experimental|Emotion Regulation Training via Telehealth|All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
16308806|NCT04615403|Experimental|Implantation and Exchange|Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.
16308807|NCT04615377|Experimental|Kaia hip and knee pain app|Kaia software application: Kaia Knee and Hip pain app (version 2.37.0) The Kaia Knee and Hip pain app is an investigational device, which is intended as a digital aid for the self-management of osteoarthritis for use by adults (between 22 to 75 years old) without supervision by healthcare professionals in a home setting.
16308808|NCT04615377|Active Comparator|Treatment as usual|Participants will be encouraged to continue the treatment that they have been on without restriction
16308809|NCT04615351|Active Comparator|Metformin|Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
16308810|NCT04615351|No Intervention|Routine Care|Discharge information about maintaining a healthy diet
16308814|NCT04615325|Experimental|Single ascending dose stage|Patients will receive a single dose of RO7303359, in multiple escalating cohorts (A-D)
16308815|NCT04615325|Experimental|Expansion cohort stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
16308816|NCT04615325|Experimental|Optional cohort E|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
16308817|NCT04615325|Experimental|Optional cohort F|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
16308818|NCT04615312|Experimental|a CDK4 / 6 inhibitor and a MEK inhibitor|Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment
16308819|NCT04615299|Active Comparator|Auricular acupuncture|Auricular (Battlefield) acupuncture needles will be utilized in the test arm, location of needles and stickers will be placed according to 5 VA approved BFA auricular acupuncture points associated with PONV, pain, and anxiety respectively
16308820|NCT04615299|Sham Comparator|Sham acupuncture|The control arm will receive sham or placebo acupuncture via pressing of a blunt needle on the specified BFA locations and then application of adhesive stickers. In the control group simulating acupuncture, the needles will never enter the patients' skin and will give the impression to the patient that the procedure has taken place.
16308821|NCT04615286|Experimental|Short course|Antibiotic course of 2-3 weeks overall duration for treating pleural infection
16308822|NCT04615286|Active Comparator|Long course|Antibiotic course of 4-6 weeks overall duration for treating pleural infection
16308823|NCT04615273|Experimental|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
16308824|NCT04615273|Placebo Comparator|Placebo|Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection
16308825|NCT04615273|Active Comparator|Somatropin|Somatropin administered once-daily by subcutaneous injection
16308826|NCT04615260|Other|Single arm subject is own control|Posterolateral fusion is bilateral, patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.
16308827|NCT04615247|Experimental|Yoga Program|The study yoga intervention is designed to provide instruction and practice in selected yoga postures and techniques chosen by an expert panel for their potential to improve pelvic pain in women.
16308828|NCT04615247|Active Comparator|Physical Conditioning Program|A low-impact, muscle stretching and strengthening program.
16308829|NCT04615234||Experimental: Treated with Genetic Test Guide (TGTG)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder guided with the pharmacogenomic test (PGs)
16308830|NCT04615234||Control: Treated as Usual (TAU)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder.
16308831|NCT04615221|Other|Graft recipient|During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.
16308832|NCT04615221|Other|Living donor|The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.
16308833|NCT04615221|Other|Witness|10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.
16308834|NCT04615195||children between 8 and 15 years old|answer to the CRIES 13 questionnaire
16308835|NCT04615182|Experimental|OCS Preservation|
16308836|NCT04615169|Experimental|multi-component cognitive intervention using simulated everyday tasks (MCI-SET)|the 12-week intervention, 2 hours weekly session of MCI-SET.
16308837|NCT04615156|Experimental|Evaluation for adverse events from 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer|
16308838|NCT04615143|Experimental|Tislelizumab|Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w*2 cycles) and as adjuvant treatment after surgery for 1 year
16308839|NCT04615130|Experimental|Intervention|Patients will undergo 6 weeks of outpatient rehabilitation.
16308840|NCT04615130|No Intervention|Control|Patients will receive no intervention throughout the 6 weeks period.
16308841|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
16308842|NCT04615104||Pelvic Ring Fracture|Patients with pelvic ring fractures.
16308843|NCT04615104||Acetabular Fracture|Patients with acetabular fractures.
16308844|NCT04615078|Experimental|"Telemonitoring group"|Medical Telemonitoring in Non-Invasive Ventilation
16308845|NCT04615078|No Intervention|"Standard of Care group"|Standard medical follow-up: standard home Non-Invasive Ventilation service, with transmission of their ventilator data without analysis leading to alerts
16308846|NCT04615052|Experimental|Exercise group|
16308847|NCT04615052|No Intervention|Control group|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
16308849|NCT04615013|Experimental|Treatment (NBTXR3, IMRT, chemotherapy)|Patients receive NBTXR3 IT or IN on day 1. Beginning day 15, patients undergo IMRT 5 days per week for 6 weeks for a total of 28 fractions, in the absence of disease progression or unacceptable toxicity. Concurrent with IMRT, patients receive a chemotherapy regimen consisting of either fluorouracil and oxaliplatin with or without leucovorin, oxaliplatin and capecitabine, docetaxel and fluorouracil with or without leucovorin, docetaxel and paclitaxel, or carboplatin and paclitaxel per physician discretion.
16308850|NCT04614987||Participants undergoing CAR T transfusion|Participants will undergo baseline examination followed by evaluations between Days 3 and 5 post-transfusion, on Day 30 post-transfusion date (PTD), PTD 90, and PTD 180. At baseline this will include plasma testing, lumbar puncture (voluntary), neuroimaging (voluntary) and neuropsychiatric performance testing (voluntary). Between post-transfusion Day 3 and day 5, participants will undergo repeat exam, plasma testing, lumbar puncture (voluntary), and neuroimaging (voluntary). Day 30 testing will again test all modalities, including serum, CSF/lumbar puncture (voluntary), brain imaging (voluntary), and formal neuropsychiatric performance testing (voluntary). Finally, Day 90 and 180 will repeat serum testing, brain imaging, and formal neuropsychological performance testing.
16308851|NCT04614974|Experimental|Speech Language Therapy Alone|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
16308852|NCT04614974|Active Comparator|Speech Language Therapy and Acid Suppression Therapy|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
16308853|NCT04614961||Patients with overweight, obesity or after bariatric surgery|Patients with overweight, obesity or after bariatric surgery
16308854|NCT04614948|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57.
16308855|NCT04614948|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine.
16308856|NCT04614935|No Intervention|Standard of Care|Pediatric patients with functional constipation who are treated with medications and/or behavioral therapies as they would be if they were not enrolled in the study. In addition to standard of care treatment, these families will fill out a brief quality of life survey.
16308857|NCT04614935|Experimental|Action Plan|Pediatric patients with functional constipation who are treated with standard of care medications and/or behavioral therapies and are also provided with a medication adherence log along with a constipation action plan. These families will also fill out a brief quality of life survey.
16308858|NCT04614922|Experimental|Acceptance and Commitment Therapy|
16308859|NCT04614922|Other|control group|
16308860|NCT04614909|Experimental|Arm A Newly diagnosed glioblastoma treated with pamiparib|Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
16308861|NCT04614909|Experimental|Arm B Recurrent glioblastoma treated with pamiparib|Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
16308862|NCT04614909|Experimental|Arm C Recurrent glioblastoma treated with olaparib|Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
16308863|NCT04614896|Experimental|Ultrasound for measuring DOI in tongue tumors|All patients included with tongue carcinoma
16308864|NCT04614883|Other|Asymptomatic patients or Healthy volunteers|Patient with no symptom of COVID-19 infection but for whom a PCR test needs to be done because he has been in contact with a COVID-19 positive person
16308865|NCT04614883|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
16308866|NCT04614883|Other|Symptomatic patients with negative PCR but with seroconversion within 4 to 8 weeks|Patients with symptoms of COVID-19 and whose PCR result is negative at inclusion but presents a seroconversion within 4 to 8 weeks post inclusion
16308867|NCT04614857|Experimental|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
16308868|NCT04614844|Experimental|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
16308869|NCT04614844|Active Comparator|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
16308870|NCT04614831||Psoriasis and Psoriatic Arthritis|The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis
16308871|NCT04614818||pulmonary lymphoepithelioma-like carcinoma|The primary site of lymphoepithelioma-like carcinoma locates in the lungs.
16308872|NCT04614818||lymphoepithelioma-like carcinoma of thymus|The primary site of lymphoepithelioma-like carcinoma locates in the thymus.
16308873|NCT04614818||lymphoepithelioma-like carcinoma of salivary glands|The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.
16308874|NCT04614818||lymphoepithelioma-like carcinoma of stomach|The primary site of lymphoepithelioma-like carcinoma locates in the stomach.
16308875|NCT04614818||lymphoepithelioma-like carcinoma of esophagus|The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.
16308876|NCT04614818||lymphoepithelioma-like carcinoma of liver|The primary site of lymphoepithelioma-like carcinoma locates in the liver.
16308877|NCT04614818||lymphoepithelioma-like carcinoma of ovaries|The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.
16308878|NCT04614818||lymphoepithelioma-like carcinoma of cervix|The primary site of lymphoepithelioma-like carcinoma locates in the cervix.
16308879|NCT04614818||lymphoepithelioma-like carcinoma of tonsil|The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.
16308880|NCT04614792|Experimental|active treatment|open label experimental treatment
16308881|NCT04614779|Experimental|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) or higher dose (15 mg/kg bw, bid) for 24 or 48 weeks, according to the administration plan.
~The dosage form is tablets."
16308882|NCT04614766|Experimental|Combination Therapy|Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
16308883|NCT04614766|Active Comparator|Lutathera® only|Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
16308884|NCT04614753|Active Comparator|Muscadine Wine First|Participants in this arm will receive Muscadine wine for 28 days. After a 14 day wash-out period, participants will receive Sprite for 28 days.
16308885|NCT04614753|Active Comparator|Sprite First|Participants in this arm will receive Sprite for 28 days. After a 14 day wash-out period, participants will receive Muscadine wine for 28 days.
16308886|NCT04614740|Experimental|VC004|1. Dose escalation stage: subjects in the 50 mg, 100 mg, 200 mg, and 300 mg dose groups took a single oral dose on the first day; starting from the fourth day, each group of subjects took the corresponding dose twice a day. 2. Dose expansion stage: subjects in the 100mg and 200mg dose groups took the corresponding dose twice a day on an empty stomach; 3. Phase II clinical trial stage: oral administration twice a day before meals, and the dosage is to be determined.
16308887|NCT04614727|Experimental|polymeric nano calcium fluoride containing varnish, NANO SEAL.|
16308888|NCT04614727|Other|Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish,MI varnish|CPP-ACP with 5%NaF
16308889|NCT04614714|Experimental|NR First|Mothers will receive NR during the first 7 days of intervention, then placebo for the 7 days following washout.
16308890|NCT04614714|Experimental|Placebo First|Mothers will receive placebo during the first 7 days of intervention, then NR for the 7 days following washout.
16308891|NCT04614688|Experimental|Patient Education Group|Patients in this group will undergo the standard physician-led informed consent process and then be provided with an interactive patient education platform for hysteroscopy on a tablet available in the clinic for up to one hour of time. After the patient has explored the patient education platform, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
16308892|NCT04614688|No Intervention|Standard Consent Group|Patients in this group will undergo the standard physician-led informed consent process only. After they have consented to the surgery, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
16308893|NCT04614675|Active Comparator|Transarticular lateral release (TALR)|TALR The first toe is pulled distally for access into the lateral aspect of first MTPJ. A No.15 beaver blade is advanced from the medial incision laterally to divide the lateral capsule vertically and adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
16308894|NCT04614675|Active Comparator|Percutaneous lateral release (PCLR)|PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
16308895|NCT04614662|Experimental|Intervention|"Participants enrolled at intervention sites will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback and links to symptom management care pathways sent to their healthcare providers.
~Symptom screening using SPARK can be performed at any time and as often as desired, but screening will be prompted three times weekly for eight weeks.
~Each day the participant completes symptom screening and has at least one severely bothersome symptom, the primary healthcare team will receive an email summarizing the symptom report and highlighting symptoms that are a lot or extremely bothersome.
~Upon study activation, we will work with each of the 10 intervention sites to develop site-specific, adapted care pathways that consider relevant work flows, institutional culture and available resources."
16308896|NCT04614662|No Intervention|Control|At control sites, usual care will be provided, which may or may not include symptom screening, access to CPGs or care pathways. Participants will complete SSPedi to obtain the primary outcome at weeks 0, 4 and 8 but the scores will not be revealed to providers and will not be linked to care pathways.
16308897|NCT04614636|Experimental|FT538 Monotherapy|FT538 monotherapy in subjects with r/r AML
16308898|NCT04614636|Experimental|FT538 in Combination with Daratumumab|FT538 in combination with daratumumab in subjects with r/r MM
16308899|NCT04614636|Experimental|FT538 in Combination with Elotuzumab|FT538 in combination with elotuzumab in subjects with r/r MM
16308900|NCT04614623|No Intervention|Current Diabetes Management Continued|Continued Insulin Delivery Method and Current Clinic Care of Diabetes
16308901|NCT04614623|Experimental|Video Conferencing+Current Insulin Delivery|Patients continue current insulin delivery modality but receive enhanced clinical management support via video conferencing link by diabetes coordinator
16308902|NCT04614623|Experimental|AHCL pump without Video Conferencing|Patients switch to use of an Advanced Hybrid Closed Loop pump without Video Conferencing standard support
16309317|NCT04611672||Patients with stroke|Patients with stroke of all subtypes, with and without different Kind of Lysis therapy
16308903|NCT04614623|Experimental|AHCL pump+Video Conferencing|Patients will use Advanced Hybrid Closed Loop pump with enhanced clinical support via video conferencing
16308904|NCT04614610|Active Comparator|Lidocaine|Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
16308905|NCT04614610|Placebo Comparator|Placebo|Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
16308906|NCT04614597||Three-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.
16308907|NCT04614597||Two-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.
16308908|NCT04614584|Experimental|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
16308909|NCT04614584|Placebo Comparator|Placebo|Placebo 30 mg PO Daily x 4 days
16308910|NCT04614571|Other|Gluten Challenge|
16308911|NCT04614558|Experimental|Isatuximab for MGRS|Subjects will receive Isatuximab for 6 months and will be followed for an additional one year post therapy for outcome follow-up.
16308912|NCT04614545|Experimental|Virtual Visits|"All patients will be seen face to face on visit 1. Patient will be evaluated by an obesity-medicine specialist and also by a registered dietitian and exercise physiologist via telemedicine. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated), and will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored remotely and patients will receive a remote scale and a remote blood pressure cuff.
~Subjects will then initiate 3 one to one virtual visits with the obesity specialist. On each of this visit the five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. A personalized nutrition and exercise program will be developed. If felt relevant by the provider, subjects may also be referred to a mental health specialist and/or sleep clinic. All medical care will be provided virtually."
16308913|NCT04614545|Active Comparator|Face to face visits|"All patients independently of the randomization arm will be seen face to face on visit 1. Patients will be evaluated by an obesity-medicine specialist and patient will also be seen face to face by a registered dietitian and exercise physiologist. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated). Patients will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored in each of the visits.
~Subjects will then initiate 3 face to face visits with the obesity specialist provider every 4 weeks. The five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress.
~The patient will be provided a personalized nutrition and exercise program and may be referred to a mental health specialist and/or sleep clinic per provider discretion. All medical care will be provided via a face-to-face manner."
16308914|NCT04614532|Other|patients with alzheimer's disease|
16308915|NCT04614532|Other|control subject|Matching by age (± 5 years), gender, and grade level
16308916|NCT04614519|Active Comparator|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
16308917|NCT04614519|Experimental|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
16308918|NCT04614506||Subject with DS|Participants will complete two visits spaced out by 4 - 8 weeks to undergo neurophysiological assessments (Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]).
16308919|NCT04614493|Experimental|Ultrasound experimental arm|Standard of Care + 15 Ultrasound BBB opening
16308920|NCT04614493|Other|Control arm|Standard of Care
16308921|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells|
16308922|NCT04614467|Placebo Comparator|Placebo|
16308923|NCT04614454|Experimental|Experimental arm|Devices will be programmed by our study coordinator to provide a sham signal or the experimental signal. The location of the TENS electrodes will be determined by the location of the pain with the goal of placing the unit at the top of the dermatological level corresponding to the pain. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
16308924|NCT04614454|Sham Comparator|Sham arm|The sham unit looks identical to the experimental unit. There may be a sensation experienced by subjects with the sham device but it does not deliver an electric current as the experimental units. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
16308925|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
16308926|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
16308927|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
16308928|NCT04614428|No Intervention|Standard Care Group|Participants will receive the standard care provided by their institution.
16308929|NCT04614428|Active Comparator|RESILIENCE Program group|Participants will receive the RESILIENCE Program on top of the standard care provided by their institution.
16308930|NCT04614415|Experimental|Treatment group|group 1 will be treated with autocrosslinked Hyaluronic acid
16308931|NCT04614415|Placebo Comparator|control group|group 2 treated with placebo (isotonic saline solution).
16308932|NCT04614389|Other|CEUS and SWE|CEUS & SWE
16308933|NCT04614376||Control Group|The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
16308934|NCT04614376||Case Group|The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
16308935|NCT04614363|Experimental|68 Ga PSMA|Comparison between the results of 68 Ga-PSMA PET/CT to conventional imaging (bone scan, CT) in men with high risk prostate cancer.
16308936|NCT04614350|Experimental|A-Active|Markman Biologics microsurfaced ADM
16308937|NCT04614350|Active Comparator|B-Control|AlloDerm ADM
16309318|NCT04611672||Controls|Healthy controls of all Ages above 18 years
16308943|NCT04614311|Active Comparator|Intervention|Intra-articular corticosteroid injections into active joints
16308944|NCT04614311|No Intervention|Comparator|No intra-articular injections
16308945|NCT04614298|Experimental|KHK4827 210 mg SC (Subcutaneous)|Single SC administration
16308946|NCT04614298|Placebo Comparator|Placebo SC|Single SC administration
16308947|NCT04614285|Experimental|Partial excavation|The treatment will be performed after applying local anesthetic according to individual needs. The intervention group will receive partial removal of the carious lesion; In the inner part of the lesion, the caries removal will be limited to reach leathery or slightly soft dentin by probing. The restorations will be placed according to evidence based methods and the material used according to the operators material of choice.
16308948|NCT04614285|Active Comparator|Complete excavation|The treatment will be performed after applying local anesthetic according to individual needs. The control group will receive the same treatment procedure as the intervention group, but the excavation procedure will include total removal of the carious tissue. The total caries removal will be ensured with hardness on probing and the visual examination. Photographs will be used as benchmark.
16308949|NCT04614272|Experimental|active prayer group|the active prayer group will mediate over an active type of prayer
16308950|NCT04614272|Experimental|passive prayer group|the passive prayer group will mediate over a passive type of prayer
16308951|NCT04614272|Sham Comparator|control group|the control group will read a poem
16308952|NCT04614259|Experimental|intravenous analgesia|
16308953|NCT04614259|Experimental|infraorbital nerve block|
16308954|NCT04614246|Experimental|BAY1817080 150 mg|Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period
16308955|NCT04614246|Experimental|BAY1817080 75 mg|Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period
16308956|NCT04614246|Experimental|BAY1817080 25 mg|Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period
16308957|NCT04614246|Active Comparator|Elagolix|Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period
16308958|NCT04614246|Placebo Comparator|Placebo|Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period
16308959|NCT04614233|Experimental|RiduZone (90% Oleoylethanolamide (OEA))|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA) daily for 16 months.
16308960|NCT04614233|Placebo Comparator|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months.
16308961|NCT04614194|Experimental|Arm A: Abemaciclib + Letrozole|Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
16308962|NCT04614194|Experimental|Arm B: Letrozole|Patient will take daily letrozole only (Arm B) according to treatment arm for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
16308963|NCT04614181|Experimental|Carbohydrate and protein loading|Nestle Resource drink
16308964|NCT04614181|Active Comparator|Usual care|Usual fracture care as determined by clinical team
16308965|NCT04614168|Active Comparator|Group 1 - Standard Care|This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
16308966|NCT04614168|Experimental|Group 2- Automated insulin delivery and low carbohydrate diet|This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
16308967|NCT04614155|Experimental|Screening (questionnaire, health education, self-collection)|Participants complete questionnaires, take part in a health education session, and receive HPV self-collection kit.
16308968|NCT04614142|Experimental|Experimental: Glecaprevir/pibrentasvir for HCV+ kidney transplant recipient|"Glecaprevir (100mg) / pibrentasvir (40mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor.
~Subject will receive first dose on day 3 (+/- 2 days) post-kideny transplantation and continue daily for 8 weeks."
16308969|NCT04614129|Experimental|Low-Dose CT|Low Dose CT Scan of the Chest
16308970|NCT04614116|Other|Biopsy without cold induction|Participants will undergo a fat biopsy after the first scan, without cooling
16308971|NCT04614116|Other|Biopsy with cold induction|Participants will undergo a fat biopsy after the second scan, with cooling
16308976|NCT04614090||99 warfarin patients|warfarin patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture. All patients on warfarin were reversed if necessary to INR≤1.5 before surgery using vitamin K and/or four-factor prothrombin complex concentrate (PCC)
16308977|NCT04614090||99 patients without anticoagulants|As a 1:1 ratio control group matched for age, gender and surgical implant. All patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture.
16308978|NCT04614077||A( saline)|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
16308979|NCT04614077||B specific solution|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
16308980|NCT04614064|Experimental|COPD patients|As per inclusion and exclusion criteria for COPD patients
16308981|NCT04614064|Experimental|Healthy volunteers|As per inclusion and exclusion criteria for healthy volunteers
16308982|NCT04614051|Experimental|Cellgram-DC|Cellgram-DC is injected Subcutaneous injection near the upper arm lymph nodes
16308983|NCT04614025|Experimental|PLX-PAD Treatment|"PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).
~Single administration in addition to best standard medical care."
16308984|NCT04614025|No Intervention|Control Group|Best standard medical care
16308985|NCT04614012|Experimental|hyperimmune plasma|treated with hyperimmune plasma
16308986|NCT04613999|Other|Single Arm|Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
16308987|NCT04613986|No Intervention|Standard|Standard of care according to our current in house SOP
16308988|NCT04613986|Experimental|Treatment|Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)
16308989|NCT04613973||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
16308990|NCT04613973||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
16308991|NCT04613960|Active Comparator|Magnesium arm|patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.
16308992|NCT04613960|Placebo Comparator|Placebo arm|patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.
16308993|NCT04613947|Active Comparator|Control|The group with standard (written and verbal) information without multiple intelligence test
16308994|NCT04613947|Experimental|Visual/Spatial:|The group with higher visual intelligence according to the multiple intelligence test results and watch video. Also, will given with a written informed consent document
16308995|NCT04613947|Experimental|Verbal/Linguistic|The group with higher verbal/linguistic intelligence according to the multiple intelligence test results and verbally informed in detail about the operation. lso, will given with a written informed consent document
16308996|NCT04613947|Experimental|Bodily/Kinesthetic|The group with higher bodily/kinesthetic intelligence according to the multiple intelligence test results and informed with a dental model. lso, will given with a written informed consent document
16308997|NCT04613921||Group 1|patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
16308998|NCT04613921||Group 2|patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD > 20) at the time of listing (n=500)
16308999|NCT04613921||Group 3|patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)
16309000|NCT04613908|Active Comparator|standard care or usual rehabilitation|It will consist of the usual treatment performed by the intensive care physiotherapist, it will be applied every day that the study lasts.
16309001|NCT04613908|Experimental|neuro muscular electro stimulation|They received 5 sessions per week (except weekends) of neuromuscular electrostimulation of 30 minutes duration. Also, every day that the study is carried out in the morning and in the afternoon, the subjects will receive the usual treatment performed by the intensive care physiotherapist.
16309002|NCT04613908|Experimental|early mobilization protocol|Throughout the duration of the study, an early mobilization protocol will be applied to apply a specific treatment based on different levels of treatment for each subject of the group; It differs from the usual procedure in protocolized progression according to the objectives reached by the patient, unlike the usual treatment, where the progression is in accordance with the clinical criteria of the treatment professional.
16309003|NCT04613895|Experimental|fed state group|just after a meal
16309004|NCT04613895|Experimental|fasted state group|before a meal
16309005|NCT04613882|Experimental|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
16309006|NCT04613882|Active Comparator|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
16309007|NCT04613882|Active Comparator|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
16309008|NCT04613869|Experimental|High-dose esketamine group|After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
16309009|NCT04613869|Experimental|Low-dose esketamine group|After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
16309096|NCT04613154|Active Comparator|Magnesium|Given 1000 mg oral magnesiumcitrate once daily (4*250mg) during the day of surgery and the next 6 Days.
16309010|NCT04613869|Placebo Comparator|Control group|PCIA formula: 6mg of hydromorphone + 10mg of tropisetron into 100ml of 0.9% sodium chloride injection, the first dose is 20ug/kg, the background dose is 2ug/kg/h, and the single dose is 4ug/kg/time.
16309011|NCT04613856|Active Comparator|Current Best Practice - 237 mL water bolus|
16309012|NCT04613856|Experimental|New Intervention - 500 mL water bolus|
16309013|NCT04613843|Active Comparator|Water stirring|
16309014|NCT04613843|Experimental|No water stirring|
16309015|NCT04613830|Active Comparator|Erector spinae group|patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
16309016|NCT04613830|Placebo Comparator|Opioid GROUP|Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
16309017|NCT04613804|Experimental|Toripalimab group|Toripalimab 240mg ivgtt Q21d
16309018|NCT04613778|Experimental|Laser acupuncture|Laser acupuncture with knee-chest position
16309019|NCT04613778|No Intervention|No intervention|usual care with knee-chest position
16309020|NCT04613765||Non-migrants|"53 non-migrant patients will be enrolled. Non-migrants will be defined as the group of native-born persons with a Belgian nationality or with a foreign nationality but with both parents native-born."
16309021|NCT04613765||Migrants|"60 migrant patients will be enrolled. This group will include both First Generation (FG) migrants defined as the group of foreign-born persons and Second Generation (SG) migrants defined as people native-born but with either a foreign nationality or with one or both parents foreign-born."
16309022|NCT04613752|Experimental|experimental group|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
16309023|NCT04613739|Experimental|Insurance navigation|The intervention group will be offered access to AAFA's insurance chat bot and navigation services. Navigation will be provided through AAFA's existing online patient community platform that provides assistance with clinical, educational and financial questions and includes secure, personal messaging capabilities that will be supplemented with telephonic outreach.
16309024|NCT04613739|No Intervention|Wait-list controls|Control subjects will be offered the chat bot after completion of data collection for the intervention group (after completion of the four-month follow-up surveys)
16309025|NCT04613726|Placebo Comparator|IV 10 ml normal saline|Control group consisted of patients receiving IV 10 ml normal saline.
16309026|NCT04613726|Active Comparator|IV 8 mg ondansetron in 10 ml of normal saline|This group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
16309027|NCT04613726|Active Comparator|IV 3 mg granisetron in 10 ml of normal saline|This group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
16309028|NCT04613713|Experimental|Somatocognitive physiotherapy|Somatocognitive therapy is a multi-modal physiotherapy intervention utilized for women with longstanding chronic pelvic pain and provoked vestibulodynia developed at the beginning of the 2000s as a collaboration between the department of psychosomatic medicine, Oslo University Hospital (OUH) and department of physiotherapy (OsloMet)
16309029|NCT04613713|Active Comparator|Treatment as usual|The participants randomized to the treatment as usual group will follow available treatment options based on the current recommendations from Vulva clinic at Oslo University Hospital, a center that is specialized in treatment of vulvar conditions.
16309030|NCT04613700|Active Comparator|Secretin|
16309031|NCT04613700|Placebo Comparator|Placebo|
16309032|NCT04613687|Experimental|URGOBD001|Compression bandage
16309033|NCT04613674|Experimental|Arm A|
16309034|NCT04613674|Experimental|Arm B|
16309035|NCT04613661||Researcher 1|The first researcher assessing elbow, wrist, and ankle spasticity, respectively
16309036|NCT04613661||Researcher 2|The second researcher assessing elbow, wrist, and ankle spasticity, respectively
16309037|NCT04613648||Group A|Painful and stiff hemiplegic side shoulders of stroke patients
16309038|NCT04613648||Group B|Asymptomatic non-hemiplegic side shoulders of stroke patients
16309039|NCT04613648||Group C|Non-dominant side shoulders of healthy volunteers
16309040|NCT04613635|Experimental|Stratafix|
16309041|NCT04613635|Active Comparator|Vicryl|
16309043|NCT04613609|Placebo Comparator|Placebo|E-cigarette containing no nicotine.
16309044|NCT04613609|Active Comparator|Nicotine|E-cigarette containing nicotine
16309046|NCT04613583||SAFeR Fetuses|Different maternal lifestyle factors: smoking, BMI, social deprivation, alcohol use, medicines. Depends on specific subproject analyses.
16309047|NCT04613570|Experimental|Yearly endoscopy|Upper gastrointestinal endoscopy every year (12-16 months)
16309048|NCT04613570|Other|Endoscopy every 3 years|Upper gastrointestinal endoscopy every three years (32-40 months)
16309049|NCT04613557|Experimental|CYAD-211|Infusion post preconditioning non-myeloablative chemotherapy
16309050|NCT04613544||Atrial Fibrillation|Atrial fibrillation diagnosed patients.
16309051|NCT04613531||Participants with PD|patients with clinically diagnosed Parkinson's disease
16309052|NCT04613531||Participants without PD|participants clinically diagnosed without Parkinsons' Disease
16309053|NCT04613518|Experimental|BMS-986165 Dose 1|
16309054|NCT04613518|Experimental|BMS-986165 Dose 2|
16309055|NCT04613518|Placebo Comparator|Placebo|
16309056|NCT04613505||Phase 1: Instrument Development|Parents will be asked to participate in a semi-structured interview with one of the researchers that will explore their attitudes toward day of surgery consent. Particular attention will be given to a) study designs, b) previous research experience, and c) previous medical experiences.
16309057|NCT04613505||Phase 2: Questionnaire Adaptation|Parents will be given approximately 5 minutes to review a questionnaire we developed using participant responses in Phase 1. After reviewing the questionnaire, participants will be asked to participate in a semi-structured interview with one of the investigators.
16309058|NCT04613505||Phase 3: Questionnaire Application & Development of Day of surgery consent Table of Guidelines|Participants will be asked to complete the questionnaire developed in Phase 2.
16309059|NCT04613505||Phase 4: Table of Guidelines Refinement|Participants will be given approximately 5 minutes to review the table of guidelines developed in Phase 3. After reviewing the guidelines, participants will be asked to participate in a semi-structured interview with one of the investigators.
16309060|NCT04613492|Experimental|Single dose MEDI9253, sequential Durvalumab|Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing
16309061|NCT04613492|Experimental|Multiple dose MEDI9253, sequential Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;
16309062|NCT04613492|Experimental|Multiple dose MEDI9253, concurrent Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.
16309063|NCT04613453|Experimental|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
16309064|NCT04613453|Active Comparator|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
16309065|NCT04613440|Other|Standard of care - Proband-mediated cascade testing|Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.
16309066|NCT04613440|Other|Intervention - Facilitated cascade testing|In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.
16309067|NCT04613427||Unruptured intracranial aneurysm|Patients admitted at Haukeland University Hospital in the study period for treatment of UIA.
16309068|NCT04613427||Aneurysmal subarachnoid hemorrhage|Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH.
16309069|NCT04613414|Experimental|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
16309070|NCT04613414|No Intervention|Usual Care|Scheduled for sleep physician appointment approximately 6 months after home sleep apnea test/triage
16309071|NCT04613401||VAD-patients with Telemonitoring|
16309072|NCT04613375|Other|All participants|1 arm study
16309073|NCT04613362|Experimental|TENACITY Telehealth Cognitive Behavioral Therapy|Six sessions of standardized Cognitive Behavioral Therapy for patients with diagnosed chronic migraine headaches will be delivered by a clinical health psychologist via telehealth platform. All patients have access to a set of standardized educational, headache self-management materials.
16309074|NCT04613362|Active Comparator|Usual Care Outpatient Cognitive Behavioral Therapy Face to Face|Usual care Cognitive Behavioral Therapy will be delivered by clinical health psychologists for patients with diagnosed chronic migraines face to face at the VAMC outpatient clinics. All patients have access to a set of standardized educational, headache self-management materials.
16309075|NCT04613310|Other|Saliva and nasopharyngeal swabs|One patient will have 4 swabs taken, 2 saliva for PCR and RDT, 2 nasopharyngeal for PCR and RDT
16309076|NCT04613297|Other|COVID-19 uninfected patients|Patient with negative PCR result
16309077|NCT04613297|Other|non-hospitalized COVID-19 infected patients|Patient with positive PCR result who does not require hospitalization for COVID-19
16309078|NCT04613297|Other|hospitalized COVID-19 infected patients|Patient with positive PCR who require hospitalization for COVID-19
16309079|NCT04613284|Experimental|Endostar combined Radiation|
16309080|NCT04613271|Experimental|Group 1|"Assignment of Administration Group 1:
~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
16309081|NCT04613271|Active Comparator|Group 2|Administration Group 2: Azithromycin 500 mg once a day for 5 days.
16309082|NCT04613258|Active Comparator|SCAR Porridge Group|There were 22 subjects in the intervention group (I) who received 50 g of SCAR porridge once per day, along with dietary counseling.
16309083|NCT04613258|Active Comparator|Counseling Group|21 subjects in the control group (C) who only received dietary counseling
16309084|NCT04613245||Patient with asthma|
16309085|NCT04613232|Experimental|Apple Watch|The research intervention is continuously monitoring of heart rate and physical activity (minimum 12h/day) with a smartwatch which is connected to a smartphone.
16309086|NCT04613206|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.7 mL HD-IIV (60µg of each influenza antigen) 28-42 days apart
16309087|NCT04613206|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.5 mL SD-IIV (15µg of each influenza antigen) 28-42 days apart
16309088|NCT04613206|Experimental|One Dose High Dose Quadrivalent Inactivated Influenza Vaccine|one dose of 0.7 mL HD-IIV (60µg of each influenza antigen) followed by placebo 28-42 days later
16309089|NCT04613193|Active Comparator|Strict BP intervention group|SBP < 120 mmHg and a reduction in SBP of >= 15 mmHg
16309090|NCT04613193|Other|Conventional BP control group|In patients < 75 years: SBP = 135 mmHg In patients >/= 75 years: SBP = 145 mmHg
16309091|NCT04613180|Placebo Comparator|Group I (control group)|40 patients with obstructive bronchitis who received placebo
16309092|NCT04613180|Active Comparator|Group II|40 patients who received oral montelukast sodium oral, at a dosage of 0.2-0.4 mg/kg/day
16309093|NCT04613167|Experimental|Alirocumab|The first group of patients will receive 150 mg of alirocumab every two weeks subcutaneously for 6 months
16309094|NCT04613167|Experimental|Evolocumab|the second group of patients will receive evolocumab 140 mg every two weeks subcutaneously for 6 months
16309095|NCT04613167|Experimental|Control group|Control group will be included in the treatment after 6 months. During this time, the control group will not receive treatment with alirocumab or evolocumab, only standard guidelines-based treatment
16309419|NCT04610892|Placebo Comparator|Placebo Low dose|Monthly Subcutaneous administration.
16309098|NCT04613141|Sham Comparator|Mobility-plus|"Mobility-plus is a pseudo placebo comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease."
16309099|NCT04613141|Experimental|WalkingTall-PD|WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
16309100|NCT04613128||Pediatric|Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.
16309101|NCT04613115||Group A|patients without uremia and variant arteries
16309102|NCT04613115||Group B|patients without uremia, but with variant arteries
16309103|NCT04613115||Group C|patients with uremia ,without variant arteries
16309104|NCT04613115||Group D|patients with uremia and variant arteries
16309105|NCT04613102|Experimental|interventional arm, phase 2|"All participant of phase 2 will receive CBD cream for their chronic wound treatment.
~This is an open-label part of the study."
16309106|NCT04613102|Experimental|Interventional arm, phase 3|"Each participants of the phase 3 will receive the active study medication (AVCN583601) during the entire study treatment period on the one of his body sides, and placebo cream - on the other body side simultaneously (left/right). So, each participant will be his own control.
~The research support pharmacy will randomize, which side of the body participant should apply CBD cream on, and provide two jars with the study medications, labeled accordingly ( Left /Right)."
16309121|NCT04613076|Experimental|"Me cuido y me siento mejor"|Patients in the primary care clinics assigned to the intervention will receive eight sessions of a computer-assisted, psycho-educational intervention delivered by trained therapists; structured telephone calls by social worker to monitor clinical progress and treatment adherence; usual medical care for chronic diseases; and access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles. Study therapists will receive biweekly and monthly supervision by psychologist and psychiatrist, respectively. A monthly meeting will be held between the PCC team and a member of the research team to ensure continuity of care.
16309122|NCT04613076|Active Comparator|Enhanced Usual Treatment|The patients in the primary care clinics assigned to the comparator will receive the usual treatment for depression and their physical conditions -all the guaranteed interventions for people with depression, hypertension, and/or diabetes in primary care, according to the Clinical Guidelines for the Treatment of Depression- and their associated basket of health benefits included in the Regime of Explicit Health Care Guarantees. They will have access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles.
16309123|NCT04613050|Active Comparator|Group A (Respiratory Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive respiratory training for 6 weeks.
16309124|NCT04613050|Active Comparator|Group B : (Aerobic Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive aerobic training for 6 weeks
16309125|NCT04613050|No Intervention|Group C : (control group)|It will include 20 patients of both sexes, recovered from COVID-19 infection on medical drugs only will receive no exercise as control group.
16309126|NCT04613037|Experimental|Treatment arm|Fecal Microbial Transplantation in adults with Atopic Dermatitis
16309127|NCT04613024|Experimental|Experiment|Topamax randomized group
16309128|NCT04613024|Active Comparator|Control|Gabapentin randomized group
16309129|NCT04612998|Sham Comparator|Comparator group|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
16309130|NCT04612998|Active Comparator|Active control group|Active control group consisted of patients performing CSEA in the sitting position.
16309131|NCT04612985|Experimental|Procedures with XACT Robotic System|Device: XACT Robotic System The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous lung procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
16309420|NCT04610892|Placebo Comparator|Placebo Medium dose|Monthly Subcutaneous administration
16309132|NCT04612972|Experimental|Investigational vaccine 1. Wuhan|Inactivated SARS-CoV-2 vaccine (Vero cell); 200WU/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
16309133|NCT04612972|Experimental|Investigational vaccine 2. Beijing|Inactivated SARS-CoV-2 vaccine (Vero cell); 4μg/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
16309134|NCT04612972|Placebo Comparator|Placebo/Aluminum Adjuvant of Inactivated SARS CoV|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine; Active Ingredient: None; Virus Contents: None; Adjuvant: aluminum hydroxide; Specification: 0.5 mL/ dose, 0.5mL for per human use; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
16309135|NCT04612959|Experimental|Psychosexual care|The psychosexual caring program will be conducted online psychoeducation as a group intervention. The program includes four sessions with home assignments and home readings papers.
16309136|NCT04612959|No Intervention|Standard care|Standard care includes the information given by the nurse about the treatment methods to be applied once.
16309137|NCT04612946|Experimental|Intervention Arm|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit and asked for permission to be referred (name and phone number) to the LCS navigator at Penn Medicine to schedule a telemedicine visit. Patients will also be given the option to directly contact the LCS navigator.
16309138|NCT04612946|Active Comparator|Control Arm|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their primary care providers.
16309139|NCT04612933|Experimental|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.
~Patients will follow their usual treatment."
16309140|NCT04612933|No Intervention|No intervention|"All appointments, scheduled and non-scheduled are by face-face communication with the health care professionals.
~Patients will receive their usual treatment."
16309141|NCT04612920|Experimental|Study Group|Participants will receive ibuprofen 800mg every eight hours and acetaminophen 1000mg every eight hours, given at the same time, along with oxycodone five mg every six hours PRN for breakthrough pain.
16309142|NCT04612920|No Intervention|Standard Group|Participants will receive current OU standard of care therapy which includes ibuprofen 800mg every eight hours as needed (PRN), acetaminophen 1000mg every eight hours PRN, and oxycodone five mg every six hours PRN.
16309143|NCT04612907|Active Comparator|Moderate hypo-fractionation|Radiotherapy to the prostate delivered in 3Gy fractions x 19
16309144|NCT04612907|Experimental|Ultra hypo-fractionation|Radiotherapy to the prostate delivered in 6.1Gy fractions x 6
16309145|NCT04612894|Experimental|Neoadjuvant Camrelizumab + Apatinib|Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.
16309146|NCT04612881||fitostimoline vaginal pessaries|
16309147|NCT04612868|Experimental|AEYE Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
16309148|NCT04612855||Painful post-traumatic trigeminal nerve injuries|Patients presenting with painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
16309149|NCT04612855||Non-painful post-traumatic trigeminal nerve injuries|Patients presenting with non-painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
16309150|NCT04612855||Temporary nerve injuries|Patients with a trigeminal nerve injury with symptom resolution within 3 months after data of trauma.
16309151|NCT04612855||Persistent nerve injuries|Patients with a trigeminal nerve injury and complaints persisting longer than 3 months after the trauma.
16309152|NCT04612842|Experimental|Motivational Interviewing (MI) goup|The MI experimental group will receive all the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 12-month period. MI is an evidence-based communication approach for various health behavior change.
16309153|NCT04612842|No Intervention|Control group|The control group participants will only receive study measurements at baseline, 3-, 6-, and 12-months after the benchmark STEADI clinic visit.
16309154|NCT04612829|Experimental|Intervention- Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
16309155|NCT04612803||IBS-D + dermatographism|IBS-D patients with dermatographism. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
16309156|NCT04612790|Experimental|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.
~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
16309157|NCT04612790|Experimental|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
16309158|NCT04612777|Experimental|Opening Doors to Recovery|Participants will receive services from the team of three ODR navigators: one professional social worker, one navigator who is a family member of someone with SMI, and one peer navigator with lived experience.
16309159|NCT04612777|Active Comparator|Intensive Case Management or Case Management|Participants randomized to the control group will either receive standard services of Intensive Case Management or Case Management, depending on the services that are available in their county.
16309184|NCT04612634|Active Comparator|Research Group 2|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
16309161|NCT04612738|Active Comparator|Group 1:Advance care planning conversation game, 'Hello'|"The 'Hello' game is a commercially available serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The game is played with 4 - 5 players, with each receiving a game booklet and chips. A play reads the first question in the book. Then each player writes down their answers individually and takes turns sharing their answers with the group. Players control what they share, how long they share and when to move to the next questions. During the conversation, plays can acknowledge others for a thoughtful, poignant or even funny comments by giving them a chip. A pre-game coin flip determines whether the player with the most chips wins the game (heads) or player with the least chips win (tails) the game.
~Other names; previously name My Gift of Grace"
16309162|NCT04612738|Active Comparator|Group 2: The Conversation Project (CP) Starter Kit|The 'CP Starter Kit' (available for free online) is an 11-page workbook with open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so.
16309163|NCT04612738|Placebo Comparator|Group 3: Control Arm (Placebo control game, 'Table Topics')|A placebo/attention control l conversation game called 'Table Topics' will be used. Table Topics is a general conversation starter game that is unrelated to advance care planning. It involves answering open-ended questions in a group setting about a variety of topics.
16309164|NCT04612725|Experimental|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
16309165|NCT04612725|Experimental|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
16309166|NCT04612725|Experimental|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
16309167|NCT04612725|Experimental|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
16309168|NCT04612725|Experimental|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
16309169|NCT04612712|Experimental|Donafenib+ KN046|Donafenib 50mg BID/100 mg BID/200 mg BID orally + KN046 5mg/kg Q3W iv
16309170|NCT04612699|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid
16309171|NCT04612699|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 50mg*2 Bid
16309172|NCT04612699|Experimental|Jaktinib 100mg Bid|Jaktinib 50mg*2 Bid+ Placebo 75mg Bid
16309173|NCT04612699|Placebo Comparator|Placebo|Placebo 50mg*2 Bid+ Placebo 75mg Bid
16309174|NCT04612686||Frail|"At screening participants will be classed as frail if their Electronic Frailty Index score is >0.24 and if their Clinical Frailty Scale score is 6. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 3 or more frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as frail.
~All participants will receive the same assessment procedures."
16309175|NCT04612686||Pre-frail|"At the point of screening, participants will be classed as pre-frail if their Electronic Frailty Index score is 0.13-0.24 and if their Clinical Frailty Scale score is 4-5. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 1 or 2 frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as pre-frail.
~All participants will receive the same assessment procedures."
16309176|NCT04612686||Non-frail|"At the point of screening, participants will be classed as non-frail if their Electronic Frailty Index score is 0-0.12 and if their Clinical Frailty Scale score is 1-2. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting no frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as non-frail.
~All participants will receive the same assessment procedures."
16309177|NCT04612673|Experimental|Treatment|Participants received Sintilimab, 200mg, iv, d1, Q3W,and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
16309178|NCT04612660|Experimental|Specific Education and Dynamic Group|"Motivational group education specifically focused on cervical cancer prevention;
~Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
~Engaging community bilingual physicians in cervical cancer screening and referral;
~Patient navigation assistance."
16309179|NCT04612660|Active Comparator|General Health Education|Comparison group participants received general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
16309180|NCT04612647|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)-[Parents and Children-Workshop Group]. In addition to the workshops, this group and the home-based group will receive information (activity booklets) and physical education (physical activity)-related equipment.
16309181|NCT04612647|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops, but they will receive the same information (activity booklets) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
16309182|NCT04612647|No Intervention|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks and 3 months after the completion of the 12-week period. Immediately following the follow-up test (3 months after the intervention), participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
16309183|NCT04612634|Experimental|Research Group 1|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
16309185|NCT04612634|Active Comparator|Research Group 3|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
16309186|NCT04612608|No Intervention|Control|Usual Care
16309187|NCT04612608|Active Comparator|Intervention|Intervention arm
16309188|NCT04612595||Group A|Group A are males with CKD stage 1-2.
16309189|NCT04612595||Group B|Group B are males with CKD stage 3-4.
16309190|NCT04612595||Group C|Group C are females with CKD stage 1-2.
16309191|NCT04612595||Group D|Group D are females with CKD stage 3-4.
16309192|NCT04612582|Experimental|Group1|Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
16309193|NCT04612582|Experimental|Group2|Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.
16309194|NCT04612556||late-onset severe eosinophilic asthma and fixed obstruction|Patients with late-onset severe eosinophilic asthma and fixed obstruction will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
16309195|NCT04612543|Active Comparator|Genial Posterior Composite with Polyethylene fiber|The enamel and dentin were conditioned with bonding procedure.After bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus - Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
16309196|NCT04612543|Active Comparator|Genial Posterior Composite|The enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
16309197|NCT04612530|Active Comparator|Arm A: Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will start with the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
16309198|NCT04612530|Experimental|Arm B: IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will first receive (an incomplete) IRE of the primary pancreatic tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
16309199|NCT04612530|Experimental|Arm C: CpG + IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), a toll-like receptor ligand (CpG) will be administered into the primary pancreatic tumor. A week later, the patient will receive (an incomplete) IRE of the primary tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
16309200|NCT04612517|Experimental|ZP7570|Four ascending doses of ZP7570
16309201|NCT04612517|Placebo Comparator|Placebo|Corresponding volume of placebo
16309202|NCT04612504|Experimental|Part 1 Cohort 1: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 1, SynOV1.1 will be administered at 3×10^11 VP by IT injection, Q3W.
16309203|NCT04612504|Experimental|Part 1 Cohort 2: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 2, SynOV1.1 will be administered at 1×10^12 VP by IT injection, Q3W.
16309204|NCT04612504|Experimental|Part 1 Cohort3: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 3, SynOV1.1 will be administered at 3×10^12 VP by IT injection, Q3W.
16309205|NCT04612504|Experimental|Part 2 Cohort 1: SynOV1.1 in combination with Atezolizumab dose escalation|"Recommended dose for combination study (RDCS) of SynOV1.1will be established based on results from Part 1.
~SynOV1.1 will be administered intratumorally at 0.5 × RDCS every 3 weeks up to 6 doses. Atezolizumab will be administered at the dose of 1200 mg in 3-week cycles."
16309206|NCT04612504|Experimental|Part 2 Cohort 2: SynOV1.1 in combination with Atezolizumab dose escalation|"Recommended dose for combination study (RDCS) of SynOV1.1will be established based on results from Part 1.
~SynOV1.1will be administered intratumorally at RDCS every 3 weeks up to 6 doses. Atezolizumab will be administered at the dose of 1200 mg in 3-week cycles."
16309207|NCT04612504|Experimental|Dose expansion|In dose expansion study, Atezolizumab will be administered intravenously at the dose of 1200 mg and SynOV1.1 will be administered by IT injection every 3 weeks for up to 6 cycles.
16309208|NCT04612491||Pre-operative Consultation|
16309209|NCT04612491||No consultation|
16309210|NCT04612478|Other|Clinic-Based Physical Therapy|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
16309211|NCT04612478|Other|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program. The SDEP manual will provide detailed instructions on exercises, such as repetitions, frequency, and required equipment, which can be implemented in the home environment. The basis for the exercise regimen is derived from the American Academy of Orthopaedic Surgeons (AAOS) sample home based exercise program available in handout form. The program provides instructions on exercises, repetitions or duration, frequency, and required equipment which can be implemented in the home environment.
16309212|NCT04612478|No Intervention|Observational|Patients who are unwilling to be randomized will be enrolled in an observational arm of the study. They will be asked to complete all baseline and follow-up assessments, and participation in formal PT or SDEP will be documented.
16309213|NCT04612465|Experimental|ASC (test arm)|(Autologous Adipose-derived Mesenchymal Stem Cells)
16309220|NCT04612426|Sham Comparator|Traditional Pedaling Training System|Patients wear the same EEG equipment that only collect data, but not guide training.
16309221|NCT04612413|Placebo Comparator|Cohort 1|375 ml Ringer's lactate solution
16309222|NCT04612413|Experimental|Cohort 2|Single IV dose of Allocetra-OTS contain 5x10^9 cells
16309223|NCT04612413|Experimental|Cohort 3|Single IV dose of Allocetra-OTS contain 10x10^9 cells
16309224|NCT04612413|Experimental|Cohort 4|Single or two IV doses of Allocetra-OTS contain 10x10^9 cells in each dose
16309227|NCT04612387|Experimental|Mind-body Intervention arm|Online yoga, meditation and nutrition tips.
16309228|NCT04612374|Experimental|Phase 1: Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
16309229|NCT04612374|Experimental|Phase 1: Experimental: Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
16309230|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
16309231|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
16309232|NCT04612361||non impaired sleep group|about 200-250 patients
16309233|NCT04612361||insomnia group|about 200 patients
16309234|NCT04612361||sleep deprived group|about 200-250 patients
16309235|NCT04612348||NJ tube fed|Critically ill children receiving nutrition via a nasojejunal feeding tube.
16309236|NCT04612348||NG tube fed|Critically ill children receiving nutrition via a nasogastric feeding tube.
16309237|NCT04612335|Experimental|Watchful waiting|the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate <110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
16309238|NCT04612335|Other|Routine care|Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
16309239|NCT04612322||Patients undergoing coronary microvascular function assessment|
16309240|NCT04612309||Treated|Patient with colorectal cancer already treated with immunotherapy
16309241|NCT04612283|Active Comparator|NGA-01 gel|A formulation with natural ingredients expected to be used for joint pain in Osteoarthritis
16309242|NCT04612283|Placebo Comparator|Placebo gel|Placebo gel with no active ingredient
16309243|NCT04612270|Experimental|Participants for blood collection|The blood samples of all participants will be treated equally according to the study protocol. No intervention in-vivo.
16309244|NCT04612257|Experimental|Insulin alone closed-loop|Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
16309247|NCT04612231|Active Comparator|T-STEP Intervention|The T-STEP is a comprehensive 12-week transition program that will be delivered in a community college setting. The curriculum includes 36 hours of group-based instruction delivered within a traditional school academic semester (i.e., 24 ninety-minute classes across 12 weeks). Students also participate in a weekly community-based internship to practice the skills learned in the intervention group (2 hours per week for 12 weeks). In addition, students participate in 12 hours of manualized individual counseling services that are traditionally available on a college campus (e.g., job exploration/career counseling, academic counseling, and self-advocacy counseling).
16309248|NCT04612231|Active Comparator|Counseling Only Intervention|Participants in the Counseling Only condition will receive the same manualized counseling sessions that are included in the T-STEP program. Specifically, 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
16309249|NCT04612205|Experimental|group A|females complain from SUI treated by TECAR and pelvic floor exercises
16309250|NCT04612205|Active Comparator|group B|females treated by pelvic floor exercises only
16309251|NCT04612192|Experimental|Active light|active blue-enriched bright light
16309252|NCT04612192|Placebo Comparator|Placebo light|dim red placebo light
16309253|NCT04612179||All Comer Patients|All-comer patients (≥80 years) affected by acute coronary syn-drome (NSTE-ACS), stabile angina, or silent angina, who qualify for percutaneous coronary intervention (PCI) according to ESC-treatment guidelines and physicians' clinical routine estimation.
16309254|NCT04612166|Experimental|Intervention|Patients will receive a medication action plan approved by themselves and their primary care providers to reduce their medications. They will also receive check in calls and follow ups from study health coaches to monitor their progress. During health coaching sessions motivational interviewing techniques and patient empowerment strategies will be used by trained health coaches.
16309255|NCT04612166|No Intervention|Control|Will participate in assessments for the study (baseline and 6 month follow up) and will complete 24 months of falls calendars. No intervention will be given to this group, but standard practices of care delivered by the MercyOneSM Health Network.
16309421|NCT04610892|Placebo Comparator|Placebo High dose|Monthly Subcutaneous administration
16309256|NCT04612140|Experimental|Radiosurgery|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
16309257|NCT04612140|Active Comparator|Repeated catheter ablation|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
16309258|NCT04612127|Experimental|Experimental group - Spinach|"Consumption for 90 days of spinach extract (1000mg)
~Four capsules will be consumed per day, two with breakfast and two with lunch."
16309259|NCT04612127|Placebo Comparator|control group Placebo (sucrose)|Four capsules will be consumed per day, two with breakfast and two with lunch.
16309260|NCT04612114||Possible OSA|Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
16309261|NCT04612088|Experimental|Bariatric Multivitamin|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
16309262|NCT04612088|No Intervention|Waitlist|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
16309263|NCT04612075||All patients referred to fast track clinical pathway for HNC cancer|MRI as part of staging, including a 5-minute additional sequence.
16309264|NCT04612075||Patients with locally advanced HNC|FDG-PET/MRI
16309265|NCT04612062|Experimental|Healthy Subjects (Part A)|
16309266|NCT04612062|Experimental|Atopic Dermatitis (Part B)|
16309267|NCT04612049||Children with hemiplegia|40 children with hemiplegia, 7-16 years-old at Gross Motor Function Classification System (GMFCS) Levels I-III and Manual Ability Classification System (MACS) Levels I-II will be recruited as participants. This age range was chosen based on our preliminary research in which children under the age of 7 had difficulty attending to repetitive task practice. Individuals will be recruited without regard to race or ethnicity. Our goal is to have a study sample that is 50% male and 50% female, and approximates the population of the Greater Boston, MA region.
16309268|NCT04612049||Typically developing children|40 typically developing children, 7-16 years-old.
16309269|NCT04612036||Journey II Bi-Cruciate Stabilized|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
16309270|NCT04612036||Journey II Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
16309271|NCT04612036||Journey II Bi-Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
16309272|NCT04612023|Active Comparator|1 mL NyDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 1 mL NyDYN injection.
16309273|NCT04612023|Active Comparator|2 mL NuDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL NyDYN injection.
16309274|NCT04612023|Placebo Comparator|Placebo of Sterile Saline|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL dose of sterile saline.
16309275|NCT04612010|Active Comparator|Alpha frequency|Wobble oscillation will revolve the individual alpha frequency
16309276|NCT04612010|Active Comparator|Alpha frequency plus|Wobble oscillation will revolve the individual alpha frequency plus 0.5Hz
16309277|NCT04612010|Sham Comparator|Theta frequency|Wobble oscillation will revolve the individual theta frequency
16309278|NCT04611997|Experimental|Group A|Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group)
16309279|NCT04611997|Placebo Comparator|Group B|Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)
16309280|NCT04611984|Experimental|Piezocision|Piezocision was performed on the mesial and distal side of the maxillary right canine tooth which was served as the piezocision group. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
16309281|NCT04611984|Active Comparator|Control|Maxillary left canine served as the control group and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
16309282|NCT04611971|Active Comparator|Active Arm: Benlysta + Candin|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously.
16309283|NCT04611971|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta.
16309284|NCT04611958|Experimental|Bupivacaine arm|Participants undergoing ERCP as part of routine clinical care will be consented for this study.
16309285|NCT04611932|Experimental|Reference-Reference-Test|
16309286|NCT04611932|Experimental|Reference-Test-Reference|
16309287|NCT04611932|Experimental|Test-Reference-Reference|
16309288|NCT04611906||Stroke patient|Patients who have acute cerebral ischemic symptoms attributed by cSVD can be recruited into this study. Eligible patients will be screened by Neurologists based on the inclusion and exclusion criteria. The time window for recruitment of the patient is 4 weeks from the qualifying stroke.
16309422|NCT04610879|Active Comparator|Carbamazepine plus sleep intervention|
16309423|NCT04610879|Active Comparator|Carbamazepine plus standard care|
16309289|NCT04611893||Ischemic stroke patient|Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
16309290|NCT04611880|Other|Single Arm Study|Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion. Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle. On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual. Crizanlizumab will be administered over 30 minutes by IV infusion
16309291|NCT04611867|Experimental|Intervention Arm|"The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:
~Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff
~Daily monitoring of self-reporting by study staff
~Intervention if required based on self-reporting
~Reports to oncologists (at consultation)
~Information module about treatment, side effects and contact information"
16309292|NCT04611867|No Intervention|Standard Arm|"Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. call early and often."
16309293|NCT04611854|Active Comparator|ICBT for alcohol misuse: Guidance|In this arm, participants will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
16309294|NCT04611854|Experimental|ICBT for alcohol misuse: Self-Guidance|Participants who select this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol each week and measures of depression and anxiety administered at the beginning of week 5. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation).
16309295|NCT04611828|Experimental|Philips SmartSleep Device|"Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):
~continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities
~block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation
~in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave
~Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation"
16309296|NCT04611815|Active Comparator|Robotic-assisted total knee arthroplasty|Patients undergoing robotic-assisted total knee arthroplasty with use of Journey II BCS implants
16309297|NCT04611815|Active Comparator|Conventional total knee arthroplasty|Patients undergoing conventional total knee arthroplasty with use of Journey II BCS implants
16309298|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period. One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.
16309299|NCT04611802|Placebo Comparator|Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.
16309300|NCT04611789|Experimental|LY3832479|LY3832479 administered subcutaneously (SC).
16309301|NCT04611789|Placebo Comparator|Placebo|Placebo administered SC.
16309302|NCT04611776|Experimental|Arm A: Atezolizumab + platinum-doublet followed by atezolizumab maintenance|
16309303|NCT04611776|Placebo Comparator|Arm B: Placebo + platinum-doublet followed by placebo maintenance|
16309304|NCT04611763|Experimental|Pre FA Group|
16309305|NCT04611763|Active Comparator|Post FA Group|
16309306|NCT04611750|Experimental|Active Medication (AD036)|Participants will take AD036 QHS for 14 days.
16309307|NCT04611750|Placebo Comparator|Placebo Medication|Participants will take placebo QHS for 14 days.
16309308|NCT04611737|Experimental|Experimental group|The researcher interviews with participants for 3 times.
16309309|NCT04611737|No Intervention|Control group|The participants receive usual care.
16309310|NCT04611724|Experimental|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
16309311|NCT04611711|Other|decitabine＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine (10mg ivgttqd, d1-5) combined with TQB2450 injection (1200mg ivgtt, d5)
16309312|NCT04611711|Other|decitabine + anlotinib ＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine and Anlotinib (decitabine 10mg ivgtt qd, d1-5; Anlotinib 8mg po.qd, d5-18) combined with TQB2450 injection (1200mg ivgtt, d5), using the traditional 3+3 experimental design (First enroll 3 subjects. If 1 case of DLT is observed, 3 more subjects need to be added to the same dose group to further evaluate the toxicity) to observe DLT to evaluate MTD. The trial starts from the 8mg dose of Anlotinib Start.
16309313|NCT04611698|Experimental|Immediate loading group|Visit 1 Implant surgery + Device loading Baseline Visit 2 Followup examination 2 weeks (2/+ 5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
16309314|NCT04611698|Experimental|2-week loading group|Visit 1 Implant surgery Baseline Visit 2 Device loading 2 weeks (2/+5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
16309315|NCT04611685|Experimental|NSAIDs|Parecoxib (iv.) for once & Loxoprofen (po.) for routine use during the first 3 postop. days.
16309319|NCT04611659|Active Comparator|Information Only|Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
16309320|NCT04611659|Experimental|Motivational Interviewing and Educational Training (MIET)|Women randomized to the treatment group will complete the baseline survey and receive the same brochure; however, they also will receive structured education regarding unintended pregnancies among women using opioids, potential complications associated with opioid, alcohol, and other drug use, and education on contraceptive use (with an emphasis on LARC). This structured education will be coupled with a brief, initial MI conversation. The interventionist will receive respective patients' MINI for opioids,37 contraceptive survey, and WHO-QOL-B from the research coordinator, and the answers to the survey forms will expedite the conversation around each woman's contraceptive desires.
16309321|NCT04611646|Experimental|Heat-suit training|Low-intensity endurance training with heat suit
16309322|NCT04611646|Other|Non-heat-suit training|Low-intensity endurance training without heat suit
16309323|NCT04611620||Breast Cancer and Colorectal Cancer Survivors|The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
16309324|NCT04611594|Experimental|Fluid restriction|Prescription to ingest approximately 20 ml / kg of ideal weight.
16309325|NCT04611594|No Intervention|Control|Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.
16309326|NCT04611581||PD patients with apathy|PD patients with apathy according to the diagnostic criteria by Robert et al. 2018
16309327|NCT04611581||PD patients with impulse control disorder|PD patients with a) at least one item >2 or b) at least two items >1 on the hyperdopaminergic subscale of the Ardouin Scale of Behaviour in Parkinson's Disease
16309328|NCT04611581||PD patients without any relevant neuropsychiatric symptoms|PD patients with a score <2 on each item of the Ardouin Scale of Behaviour in Parkinson's Disease
16309329|NCT04611568|Experimental|Prevention (health educational campaign)|"MEDIA CAMPAIGN: Participants view digital media strategies.
~PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.
~MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.
~HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture."
16309330|NCT04611555||CI users|
16309331|NCT04611542|Experimental|FIR Prototype Evaluation|30 fathers in recovery from opioid-use disorder will receive the prototype FIR online intervention.
16309332|NCT04611529|Experimental|Oral ibuprofen + topical diclofenac|Oral ibuprofen 400mg Topical diclofenac 2gm
16309333|NCT04611529|Active Comparator|Oral ibuprofen + topical placebo|Oral ibuprofen 400mg Topical placebo
16309334|NCT04611529|Active Comparator|Oral placebo + topical diclofenac|Oral placebo Topical diclofenac 2gm
16309335|NCT04611503|Experimental|Subretinal injection of rAAV.hPDE6A|Single subretinal injection of rAAV.hPDE6A
16309336|NCT04611477|Placebo Comparator|Placebo|One capsule/day to be taken orally 30 minutes before breakfast
16309337|NCT04611477|Active Comparator|Synbiotic365 Ver 5|One capsule/day to be taken orally 30 minutes before breakfast
16309338|NCT04611477|Active Comparator|Synbiotic365 Ver 7|One capsule/day to be taken orally 30 minutes before breakfast
16309339|NCT04611464||Single-group cross-sectional cohort|"Patients who have previously received off-label prescriptions of misoprostol for lumbar spinal stenosis for any duration and who are willing to provide verbal and informed consent.
~Once enrolled, patients will complete the Swiss Lumbar Spinal Stenosis Questionnaire (SSSQ) as well as the Oswestry Disability Index (ODI). The SSSQ will elicit patients' responses specifically related to their usage of misoprostol for lumbar spinal stenosis.
~Then their walking tolerance will be assessed by having them walk along a measured walkway of up to 500 feet to determine the onset of their neurogenic claudication symptoms at a certain distance, their claudication distance.
~Prescription information on dosage and frequency of misoprostol use, and any reported side effects with use of this medication, and any cessation or stoppage of use of this medication will all be recorded."
16309340|NCT04611451|Experimental|whole body vibration group|Patients in the WBV exercise group; 24 sessions of TVT exercise 3 days a week (with at least 1 day of rest between each session) was performed under the supervision of a physician for a total of 8 weeks. Patients in the WBV exercise group were also shown a classic lumbar home exercise program and they were asked to apply for 8 weeks
16309341|NCT04611451|Active Comparator|exercise|The second group (control) only received classical lumbar home exercise program.
16309342|NCT04611438|Experimental|CBD|The patient would be on cannabidiol for 24 weeks and would go through laboratory, electroencephalography, and neuropsychological tests before, during, and after intervention.
16309343|NCT04611425|Experimental|Remimazolam|"Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours.
~The dose of Remimazolam will be adapted according to our ICU protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale)"
16309344|NCT04611412||1 group|Group I consisted of 17 people (16.83%) with a uniform type of obesity
16309345|NCT04611412||2 group|Group II included 38 children with AO, and 20 of them had normal BLOOD pressure
16309346|NCT04611399|Experimental|VR Group|"The treatment for the participants allocated to the VR Group consists of three home-sessions of approximately 30 minutes each, conducted over two weeks (three per week). In each session, participants will be asked to try for about 15 minutes MIND-VR. Subsequently, they will try the virtual relaxation content The Secret Garden."
16309424|NCT04610879|Active Comparator|Levetiracetam plus sleep intervention|
16309425|NCT04610879|Active Comparator|Levetiracetam plus standard care|
16309426|NCT04610879|Active Comparator|No AED plus sleep intervention|
16309427|NCT04610879|No Intervention|No AED plus standard care|
16309347|NCT04611399|Active Comparator|Non-VR Group|"Participants assigned to this condition will receive the same training protocol of the VR Group without virtual reality. Both psychoeducation and relaxation will be presented on a computer screen. In particular, psychoeducation will be offered through textual material on stress and anxiety, based on content presented within MIND-VR. Relaxation will be induced by watching a non-immersive video of The Secret Garden. In each session, participants will be asked to sit at a desk in front of their PC, in which they will read a presentation on psychoeducational material for 15 minutes, and then they will watch the relaxation video for the next 10 minutes."
16309348|NCT04611399|No Intervention|Waiting List Group|The WL Group will undergo pre- and post-protocol tests without undergoing any treatment.
16309349|NCT04611386||rivaroxaban group|20 rivaroxaban using patients
16309350|NCT04611386||apixaban group|20 apixaban using patients
16309351|NCT04611386||edoxaban group|20 edoxaban using patients
16309352|NCT04611386||control group|5 control group patients
16309353|NCT04611373|Experimental|A|Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
16309354|NCT04611360|Experimental|Anodal Transcranial Direct Current Stimulation Group|Anodal Transcranial Direct Current Stimulation and Conventional training exercises
16309355|NCT04611360|Active Comparator|Conventional Training Exercises Group|Conventional Training Exercises : Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk
16309356|NCT04611347|Active Comparator|Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
16309357|NCT04611347|Active Comparator|Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
16309358|NCT04611334|Experimental|experimental group|HRV biofeedback
16309359|NCT04611334|No Intervention|control group|routine care
16309360|NCT04611321|Experimental|Phase Ib/II|Patients with advanced CSCC. IBI318 administered intravenously every 2 weeks.
16309361|NCT04611308||cases|
16309362|NCT04611308||controls|
16309363|NCT04611295|Experimental|Teleneurological evaluation and support|teleneurological evaluation using a medical device certified as telemedicine system
16309364|NCT04611282|Experimental|Microsurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using microsurgery technique.
16309365|NCT04611282|Active Comparator|Macrosurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using macrosurgery technique.
16309366|NCT04611269||Adult, patients with COVID-19 admitted to the ICU requiring mechanical ventilation|"This is a prospective cohort study including patients >18 years RT-PCR positive for SARS Cov-2 admitted to the ICU that require mechanical ventilation. Epidemiological data, comorbidities, previous signs of symptoms of COVID-19. On admission, severity of disease scores, laboratory management data, blood gases and acid-base chemistry,respiratory and mechanical ventilation management,and complications (Development of ARDS, septic shock, acute kidney injury, thromboembolic events, infections and septic shock, will be recorded. If patients die, causes of death will be recorded.Treatments administered by attending physicians will be registered.
~Dates of hospital and ICU admission, of death and/or discharge will be recorded.
~No intervention will be administered. Follow-up will continue until death or ICU/hospital discharge"
16309367|NCT04611256|Experimental|MSC transfusion|
16309368|NCT04611256|Active Comparator|Control|
16309369|NCT04611243||COVID survivors|
16309370|NCT04611243||Vaccination with CoronaVac vaccine|
16309371|NCT04611243||Vaccination with BionTech vaccine|
16309372|NCT04611243||third dose vaccination with CoronaVac vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
16309373|NCT04611243||third dose vaccination with BionTech vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
16309374|NCT04611230||Adult Volunteers (Low Risk Group)|Volunteers with jobs that do not require close contact with (i.e., within 6 feet of) the general public or co-workers.
16309375|NCT04611230||Adult Volunteers (Medium - Low Risk Group)|Volunteers with jobs that require in-frequent contact with (i.e., within 6 feet of) the general public or co-workers.
16309376|NCT04611230||Adult Volunteers (Medium - High Risk Group)|Volunteers with jobs that require frequent contact with (i.e., within 6 feet of) the general public or co-workers.
16309377|NCT04611230||Adult Volunteers (High Risk Group)|Volunteers with jobs that require frequent and/or close contact with (i.e., within 6 feet of) individuals with high potential for exposure to known or suspected sources of COVID-19.
16309382|NCT04611178||CIV-ABAO|CIV-ABAO
16309428|NCT04610866|Experimental|1|Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
16310090|NCT04606758|Active Comparator|PCNL under ultrasound control|
16309383|NCT04611165|Experimental|single|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.
~Prescription dose to PTVs as according to the following schema:
~PTV1: 30 - 50 Gy /10 fx, 5Gy fraction dose, 5 days/week (The prescribed dose to PTV will be decided by physician depending on the dose-volume histogram (DVH) constraints of the normal tissues, such as liver, bowel, etc. The detail of DVH constraints of normal tissues are summarized in the following table) PTV2: 30 Gy /10 fx, 3Gy fraction dose, 5 days/week"
16309384|NCT04611152|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
16309385|NCT04611152|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
16309386|NCT04611139|Experimental|SP-2577 Plus Pembrolizumab|
16309387|NCT04611126|Other|Without Ipilimumab|"At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.
~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1."
16309388|NCT04611126|Other|With Ipilimumab|"At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.
~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1"
16309389|NCT04611113|Experimental|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
16309390|NCT04611113|Active Comparator|Control nutritional support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
16309391|NCT04611100|No Intervention|Conventional|Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
16309392|NCT04611100|Experimental|Radiofrequency ablation|Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
16309393|NCT04611087||Observational (focus group, interview)|"PHASE I: Participants attend 4 sessions of focus groups.
~PHASE II: Participants attend virtual Zoom interviews or one-on-one interviews."
16309394|NCT04611061||ARVI and influenza prophylaxis with Kagocel|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.
~Group of patients receiving Kagocel for prevention of ARVI and influenza"
16309395|NCT04611061||ARVI and influenza prophylaxis without any antiviral medicines|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
16309396|NCT04611048|Experimental|Main study|Several electrophysiological and behavioural tests will be performed to properly diagnose the patients/check that the healthy controls do not suffer of neuropathy.
16309397|NCT04611035||Patient|Patient with first-line gastrointestinal cancers and patient with advanced and refractory GI cancers (>1 line of treatment), or post-progression biopsy)
16309398|NCT04611022|Experimental|Patients Eligible for HPV Vaccine|
16309399|NCT04611009|Experimental|motor training|intervention: motor training
16309400|NCT04611009|Active Comparator|awareness training|intervention: mindfulness exercises
16309401|NCT04610983|Experimental|Control|Control 2 * Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.
16309402|NCT04610983|Experimental|Treatment 1 - Semi-Solid food matrix|Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.
16309403|NCT04610983|Experimental|Treatment 2 - Solid food matrix|Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.
16309404|NCT04610970|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
16309405|NCT04610957|Experimental|The 1st group|included eighty (80) women receiving Clomiphene citrate (CC) in the form of (Clomid 50 mg tablet, Sanofi Aventis, France) at dose (100 mg/day in two divided doses, starting from day 3 to day 7 of the cycle), plus Phytoestrogens (Isoflavonoids) in the form of (RosaFem 800 mg tablet, DeluxLab, Egypt) at dose (1600 mg/day in two divided doses (each dose one tablet), starting from day 3 to day 12 of the cycle
16309406|NCT04610957|Experimental|The 2nd group|included eighty (80) women receiving Clomiphene citrate only, at dose (100 mg/day, starting from day 3 to day 7 of the cycle).
16309407|NCT04610944|Experimental|Intervention|Intervention nursing homes will receive the training and control nursing homes will complete assessments, but not receive the training.
16309408|NCT04610944|Active Comparator|Waitlist Control|After the intervention nursing homes complete the training, the waitlist control nursing homes will crossover and complete the training.
16309409|NCT04610931|Experimental|Cybertherapy|use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
16309410|NCT04610931|Active Comparator|Treatment as usual|Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
16309411|NCT04610918||Cases - Pediatric Intestinal Failure Patients|DXA BIA Skin fold measurements Strength tests Physical activity monitoring
16309412|NCT04610918||Controls|BIA Skin fold measurements Strength tests Physical activity monitoring
16309413|NCT04610905|No Intervention|Control group|This group will be asked to maintain their daily routine.
16309414|NCT04610905|Experimental|Reducing sedentary behavior|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
16309415|NCT04610905|Experimental|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.
16309416|NCT04610892|Experimental|MEDI6570 Low dose|Monthly Subcutaneous administration.
16309417|NCT04610892|Experimental|MEDI6570 Medium dose|Monthly Subcutaneous administration.
16309418|NCT04610892|Experimental|MEDI6570 High dose|Monthly Subcutaneous administration.
16309429|NCT04610840|Active Comparator|Direct puncture|Direct puncture of the caliceal system performed under ultrasound or Xray control
16309430|NCT04610840|Active Comparator|Non-direct puncture|Puncture of the caliceal system performed under ultrasound or Xray control and retrograde contrast
16309431|NCT04610827|Active Comparator|Ferrous sulfate daily|Subject will take 3 mg/kg oral iron in the morning
16309432|NCT04610827|Active Comparator|Ferrous sulfate twice daily|Subjects will take 1.5 mg/kg oral iron twice daily
16309433|NCT04610827|Active Comparator|Ferrous sulfate every other day|6 mg/kg oral iron every other day in the morning
16309434|NCT04610814||Blood products during transport|Administration of appropriate blood products during transport
16309435|NCT04610814||Standard of Care|Receiving standard prehospital air medical care
16309436|NCT04610801|No Intervention|No treatment|No treatment given
16309437|NCT04610801|Experimental|Treatment|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours
16309438|NCT04610801|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nosetrils, every 6 hours
16309441|NCT04610775|Other|Small Cuff (0, +1, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Small
16309442|NCT04610775|Other|Small Cuff (0, +2, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Small
16309443|NCT04610775|Other|Small Cuff ( +1, 0, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Small
16309444|NCT04610775|Other|Small Cuff ( +1, +2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Small
16309445|NCT04610775|Other|Small Cuff ( +2, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Small
16309446|NCT04610775|Other|Small Cuff ( +2, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Small
16309447|NCT04610775|Other|Regular Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Regular
16309448|NCT04610775|Other|Regular Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Regular
16309449|NCT04610775|Other|Regular Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Regular
16309450|NCT04610775|Other|Regular Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Regular
16309451|NCT04610775|Other|Regular Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Regular
16309452|NCT04610775|Other|Regular Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Regular
16309453|NCT04610775|Other|Large Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Large
16309454|NCT04610775|Other|Large Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Large
16309455|NCT04610775|Other|Large Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Large
16309456|NCT04610775|Other|Large Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Large
16309457|NCT04610775|Other|Large Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Large
16309458|NCT04610775|Other|Large Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Large
16309459|NCT04610775|Other|Extra Large Cuff (0, -2, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Extra Large
16309460|NCT04610775|Other|Extra Large Cuff (0, -1, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Extra Large
16309461|NCT04610775|Other|Extra Large Cuff (-1, 0, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Extra Large
16309462|NCT04610775|Other|Extra Large Cuff (-1, -2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Extra Large
16309463|NCT04610775|Other|Extra Large Cuff (-2, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Extra Large
16309464|NCT04610775|Other|Extra Large Cuff (-2, 0, -1 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Extra Large
16309465|NCT04610762||(Ex) Drug users recognized at-risk population of infection with Hepatitis C virus|
16309466|NCT04610736|Experimental|Single arm|Temozolomide 40 mg/ml, Oral suspension
16309467|NCT04610710|Active Comparator|Operation|Operation for severe endometriosis
16309468|NCT04610710|Active Comparator|Fertility treatment|Fertility treatment for women with severe endometriosis.
16309469|NCT04610697|Experimental|Cognitive Remediation|"Participants in the cognitive remediation condition will complete computerised exercises followed by bridging discussions delivered using tele-heath.
~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
16309470|NCT04610697|Active Comparator|Active control|"Participants in the active control condition will also complete computerised exercises followed by bridging discussions delivered using tele-heath.
~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
16309501|NCT04610463|Other|Standard|Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
16309471|NCT04610684|Experimental|Study Treatment Arm|4 cycles of induction treatment with Atezolizumab (1200 mg on Day 1) combined with carboplatin (5-6 AUC on Day 1) and etoposide (80-100 mg/m2 on Days 1-3). After 4 cycles of induction treatment, subjects will receive atezolizumab maintenance 1200 mg on Day 1 of each 3-week cycle.
16309472|NCT04610671|Experimental|Participants Receiving CG0070 & Nivolumab|Both CG0070 (x 6 instillations) and nivolumab (x 2 doses) will be administered at their single-agent dose and schedule.
16309473|NCT04610658|Experimental|Phase 1 Dose Level 1: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 1: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 1.5 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 1 every 3 weeks.
16309474|NCT04610658|Experimental|Phase 1 Dose Level 2: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 2: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 2.6 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 2 every 3 weeks.
16309475|NCT04610658|Experimental|Phase 1 Dose Level 3: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
16309476|NCT04610658|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Participants will be treated with nivolumab 1mg/kg, ipilimumab 3mg/kg plus maximum tolerated dose of lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at MTD every 3 weeks.
16309477|NCT04610645||Head and Neck Cancer Patients|Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
16309478|NCT04610619||RYR1 related malignant hyperthermia/rhabdomyolysis|
16309479|NCT04610606|Experimental|Multimodal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization (diet + mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids) and relaxation strategies.
16309480|NCT04610606|No Intervention|Standard of care (SOC)|Education on benefits of physical activity and healthy diet, with no specific information.
16309481|NCT04610593|Experimental|Intervention Group|This group will receive a Mindfulness-based intervention for 8 weeks, and after the intervention this participants will continuous their treatment as usual
16309482|NCT04610593|No Intervention|Treatment as Usual|Patients in the control group received treatment as usual in the hemodialysis setting: Carry out hemodialysis sessions three times a week, on alternate days, for approximately 4 hours added to appointments and procedures performed by professionals from different areas (medicine, nursing, nutrition, physical education, social work, pharmacy, psychology).
16309483|NCT04610580|Experimental|Crossover ALXN1840 Sequence 1|Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.
16309484|NCT04610580|Experimental|Crossover ALXN1840 Sequence 2|Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.
16309485|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 1|Participants will receive a single dose of ALXN1840.
16309486|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 2|Participants will receive a single dose of ALXN1840.
16309487|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 3|Participants will receive a single dose of ALXN1840.
16309488|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 4|Participants will receive a single dose of ALXN1840.
16309489|NCT04610567|Experimental|MTX-LDE phase 1|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
16309490|NCT04610567|Experimental|MTX-LDE phase 2|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
16309491|NCT04610567|Placebo Comparator|Placebo-LDE phase 2|Lipid nanoparticle (LDE)
16309492|NCT04610541|Experimental|Remdesivir-HU|"Day 1 - single loading dose of remdesivir-HU 200 mg given by intravenous infusion
~• Day 2 onwards - 100 mg given once daily by intravenous infusion."
16309493|NCT04610528|Experimental|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
16309496|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation S|"Experimental equine Imunoglobulins antiSARSCov Formuation S"
16309497|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation M|"Experimental equine Imunoglobulins antiSARSCov Formuation M"
16309498|NCT04610489|Other|Study Population|All subjects will undergo bilateral mid-turbinate swabs for COVID Antigen (Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA)) as well as bilateral rt-PCR testing (Quest SARS-CoV-2 rRT-PCR).
16309499|NCT04610476|No Intervention|Control group|Individual previous stable glucocorticoid/DMARD therapy is continued
16309500|NCT04610476|Experimental|Reduction group|Individual previous stable dosage of glucocorticoids/DMARDs will be stepwise reduced according to a predefined algorithm
16309503|NCT04610437|Active Comparator|intramedullary reabsorbable fixation system PLLA.|Arthrodesis interphalangeal with intramedullary reabsorbable fixation system PLLA.
16309504|NCT04610437|Placebo Comparator|K-wire|Arthrodesis interphalangeal with kirschner wire
16309505|NCT04610424|Experimental|Cooperative Parent Mediated Therapy|"Cooperative Parent Mediated Therapy (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015). CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016). The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019)."
16309506|NCT04610424|Active Comparator|Control|Control group
16309507|NCT04610411|Experimental|surgical navigation|standard surgical method except for navigated instrumentation of pedicle screws and rod implants
16309508|NCT04610411|Active Comparator|standard surgical method|standard surgical method established at the institution
16309509|NCT04610398|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
16309510|NCT04610398|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
16309511|NCT04610385||ileal conduit|
16309512|NCT04610385||cutaneous ureterostomy|
16309513|NCT04610372|Active Comparator|standard|External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks
16309514|NCT04610372|Experimental|High dose rate brachytherapy|A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.
16309515|NCT04610372|Experimental|Permanent seed implant brachytherapy|A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate
16309516|NCT04610372|Experimental|Stereotactic body radiotherapy|36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.
16309517|NCT04610359|Experimental|Stem cell group|Interstitial cystitis patients who receive submucosal injection of hESC-MSCs
16309520|NCT04610333|Experimental|School teacher training|"Teacher training programme:
~MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
~Four-day residental course
~3 x 2 seminar days
~Modified MBSR programme delivered to the students:
~- 1hour group session once a week in 10 weeks taught by the educated teachers on class"
16309521|NCT04610333|No Intervention|Usual practice|
16309522|NCT04610320|Experimental|Daratumumab-SC Injection|"Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.
~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
16309523|NCT04610307|Placebo Comparator|control group|patients receiving 1 % plain xylocaine
16309524|NCT04610307|Experimental|intervention group|patients receiving buffered 1 % xylocaine
16309525|NCT04610294||Aerus air sterilization|Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
16309526|NCT04610294||Conventional air handling|Only routine room air filtration will be used in an operation room.
16309527|NCT04610281|No Intervention|Control|"Wards without the Inner Garden biofeedback tool"
16309528|NCT04610281|Experimental|Inner Garden|"Wards with the Inner Garden biofeedback tool"
16309529|NCT04610268|Experimental|tDCS group|The anode of tDCS is placed on the occipital lobe and the cathode on the frontal lobe, or the anode of tDCS is placed on the left temporal lobe and the cathode on the right temporal lobe.
16309530|NCT04610255|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
16309531|NCT04610255|Experimental|Dynamic myofascial release|Experimental group was given Dynamic myofascial release along with the cervical isometrics and muscle stretching
16309532|NCT04610242|Experimental|Experimental group|Patients undergo diagnostic tests before the initial infusion of rituximab, including skin prick tests, intradermal tests, and challenge tests successively. If the skin test shows a positive result, the patient will receive desensitization procedure, and if the skin test is negative, the challenge test will be done, meaning normal infusion of rituximab according to manufacturer instructions. All the HSRs in the process of desensitization or normal infusion will be recorded. Peripheral blood will be drawn from all the subjects during their infusion to investigate the mechanism of HSRs to rituximab.
16309533|NCT04610229|Experimental|Treated with hypofractionation|1
16309534|NCT04610216||Bilateral users: two implant systems|For bilateral CI users two Naida CI M sound processors (one per ear) will be used during the study.
16309535|NCT04610216||Bimodal users: hearing aid contralateral|For bimodal subjects there will be one Naida CI M sound processor on the implanted ear as well as one hearing aid on the contralateral ear.
16309536|NCT04610203|Placebo Comparator|Glucose|Glucose - 50 g
16309537|NCT04610203|Experimental|Nutralys S85 Plus 25 g|Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose
16309538|NCT04610203|Experimental|Nutralys S85 Plus 50 g|Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose
16309539|NCT04610190|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
16309540|NCT04610164|Experimental|Group 1: TXA group|Patient will receive 1 gram intravenous TXA prior to surgery
16309541|NCT04610164|No Intervention|Group 2: Control Group|Patient will not receive TXA prior to surgery
16309542|NCT04610151|Experimental|Guided Imagery|Guided Imagery Intervention:The pretest data of the patients with a pain score of 4 or higher according to VAS were collected. Afterwards, the experiment group patients were applied guided imagery.
16309543|NCT04610151|No Intervention|No-Reflexology Application , control group.|No intervention was applied on the control group patients.
16309544|NCT04610138|Experimental|Active treatment with 60 ml low-dose ZnAg|(Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours
16309545|NCT04610138|Experimental|Active treatment with 60 ml high-dose ZnAg|(Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
16309546|NCT04610138|Placebo Comparator|60 ml matching placebo|60 ml matching placebo, po q12 hours
16309547|NCT04610125|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
16309548|NCT04610099|Active Comparator|Standard SG|100 patients undergo a standard sleeve gastrectomy
16309549|NCT04610099|Experimental|Banded SG|100 patients undergo a banded sleeve gastrectomy
16309550|NCT04610086||False positive FIT|Participants in the colorectal cancer screening program, with a positive FIT and with a normal colonoscopy
16309551|NCT04610086||Polyps|Participants in the colorectal cancer screening program, with a positive FIT and diagnosed of colorectal polyps in the colonoscopy
16309552|NCT04610086||Colorectal cancer|Participants in the colorectal cancer screening program, with a positive FIT diagnosed by colorectal cancer
16309553|NCT04610073|Experimental|Interactive multimedia training|the intervention group 1 completed the pretest knowledge, attitude, and behavior questionnaire. Then, interactive multimedia was made available to this group. The questionnaire was completed again by the group, one week after completion of training, and then one month afterward.
16309554|NCT04610073|Experimental|illustrated booklet|First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
16309555|NCT04610073|Experimental|No Intervention|In the control group, no intervention was performed. Only before the intervention, one week and one month after the intervention, they completed the knowledge, attitude and behavior questionnaires.
16309556|NCT04610060|Experimental|Power walking group|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.
~Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018)."
16309557|NCT04610060|Active Comparator|Standardised outpatient cardiac rehabilitation group|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018).
16309558|NCT04610047|Experimental|Norketotifen|Norketotifen oral capsules, twice daily for 7 days
16309559|NCT04610047|Placebo Comparator|Placebo|Placebo oral capsules, twice daily for 7 days
16309560|NCT04610034|Experimental|"Resilient Caregivers"|Intervention program
16309561|NCT04610034|Other|Control group|Care as usual
16309562|NCT04610021|No Intervention|Control|Control group: autologous bone + bench bone
16309563|NCT04610021|Experimental|i-Factor|I-Factor group: autologous bone + bench bone + i-Factor™ bone graft
16309564|NCT04610008||APON|Retrospective review of routine clinical images from patients with an acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
16309565|NCT04610008||No APON control|Retrospective review of routine clinical images from patients with NO acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
16309566|NCT04609995|No Intervention|No financial incentive|No financial incentives will be provided for completing a PrEP evaluation
16309567|NCT04609995|Active Comparator|Fixed incentive|A fixed incentive ($25 Amazon.com gift card) will be provided for completing a PrEP evaluation
16309568|NCT04609995|Active Comparator|Lottery incentive|An entry into a lottery for a 20% chance to win a $100 Amazon.com gift card will be provided for completing a PrEP evaluation
16309569|NCT04609982|Experimental|wearing ear plugs|
16309570|NCT04609982|No Intervention|Not wearing ear drops|
16309571|NCT04609969|Experimental|Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
16309572|NCT04609956|Experimental|virtual reality|Experimental arm is a virtual reality headphones
16309573|NCT04609956|Other|standard|Control arm is a usual practice (hydroxyzine + patient music with headphones)
16309579|NCT04609930||The study population|Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1
16309580|NCT04609917||trainee group|Patients with native papilla who underwent selective biliary cannulation with trainee involvement
16309581|NCT04609917||non-trainee group|Patients with native papilla who underwent selective biliary cannulation without trainee involvement
16309582|NCT04609904|Experimental|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
16309583|NCT04609904|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
16309584|NCT04609904|Active Comparator|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
16309585|NCT04609904|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
16309586|NCT04609891|Experimental|Avatrombopag Tablets Oral|When patient is diagnosed with thrombocytopenia induced by chemotherapy of malignant tumor, avatrombopag will be given to patients as a therapeutic plan.
16309591|NCT04609865|Experimental|Lidocaine 2%|The lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours,and then 0.6mg/kg/h for 14 days or until extubation.
16309592|NCT04609865|Placebo Comparator|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
16309593|NCT04609852|Experimental|Cohort 1: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
16309594|NCT04609852|Experimental|Cohort 2: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
16309595|NCT04609852|Experimental|Cohort 3: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
16309596|NCT04609852|Experimental|Cohort 4: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
16309597|NCT04609839||Patient admitted to intensive care unit for COVID-19|
16309598|NCT04609826|Experimental|Arm A: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until a recommended Phase 2 dose (RP2D) has been identified.
16309599|NCT04609826|Experimental|Arm B: JNJ-74856665 + Azacitidine (AZA)|Participants will receive JNJ-74856665 orally in combination with AZA administered intravenously (IV) or subcutaneously (SC) in a 28-day cycle.
16309600|NCT04609826|Experimental|Arm C: JNJ-74856665 + Venetoclax (VEN)|Participants will receive JNJ-74856665 orally in combination with VEN in a 28-day cycle.
16309601|NCT04609826|Experimental|Arm D: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. Participants with transfusion dependent relapsed/refractory Myelodysplastic Syndrome (MDS) will be included.
16309602|NCT04609813|Experimental|Cytology sample collection|A nurse who has received related operation training uses the Shikang No. 1 collection device to collect cytology samples.
16309603|NCT04609787|Experimental|All participants|Quantitative sensory testing will be completed and current pain levels obtained. 20-minutes of immersive virtual reality will be completed, and then complete quantitative sensory testing again. We will compare pre-IVR quantitative sensory testing with post IVR levels.
16309604|NCT04609761|Experimental|IVIG treatment|Single-arm open-label
16309605|NCT04609748|Active Comparator|The group that received nimesulide|
16309606|NCT04609748|Experimental|The group that received CBD Oil|
16309607|NCT04609735|Experimental|Experimental: Electric DN, Manual therapy, exercise and US|Dry needling, manual therapy, exercise and ultrasound
16309608|NCT04609735|Active Comparator|Active comparator: Manual therapy, exercise and ultrasound|Active comparator: Manual therapy, exercise and ultrasound
16309609|NCT04609722|Experimental|intervention group|Solution-Focused Support Program will apply to the participants.
16309610|NCT04609722|No Intervention|control group|No intervention will be applied to the parents in the control group.
16309611|NCT04609709|Experimental|thrust manipulation, electric dry needling and exercise|thrust manipulation, electric dry needling and exercise
16309612|NCT04609709|Active Comparator|non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|non-thrust mobilization, soft-tissue mobilization, exercise and TENS
16309613|NCT04609696|Experimental|Part 1: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 1 formulation under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
16309614|NCT04609696|Experimental|Part 1: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 1 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
16309663|NCT04609384||Post device installation|Health care workers who perform the surgical rub following installation of the device that should increase the time spend on surgical rub.
16309692|NCT04609124||Control group:|Patients (n=35) fasting for 8 hours and received intravenous 10 mL saline 0.9% as placebo
16309615|NCT04609696|Experimental|Part 1: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fasted conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
16309616|NCT04609696|Experimental|Part 2: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 2 formulation under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
16309617|NCT04609696|Experimental|Part 2: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 2 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
16309618|NCT04609696|Experimental|Part 2: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fasted conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
16309619|NCT04609683|Experimental|Hydrostasis group|"50 study subjects scheduled for an EP procedure will have AleriTM sensors on subject's bicep, forearm, or wrist, to start data collection.
~Measurements will be made from the subject for a period of approximately 1 hours prior to the EP procedure. . Measurements will continue as patient is moved to the operating room. Once the EP procedure is complete, the subject will be transferred from the operating room to a hospital room, where they will stay overnight. Measurements will be made for 3-5hours post-operation.Detailed analysis will investigate how does AleriTM data correlate with known measures such as saline volume/rate, urine production volume, USG, Blood osmolality and body weight;"
16309620|NCT04609670|Experimental|[14C]-ALXN2050|Participants will receive [14C]-ALXN2050.
16309621|NCT04609657|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
16309622|NCT04609657|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
16309623|NCT04609657|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
16309624|NCT04609657|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
16309625|NCT04609657|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
16309626|NCT04609657|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
16309627|NCT04609644|No Intervention|Passive|"Passive arm participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are commercially available and have not been modified for this study. Participants will be asked to use these devices regularly throughout study Year 1. Participants can optionally continue to use devices during Year 2, if they have met requirements during Year 1 to keep study devices. To be eligible to keep devices, participants must meet pre-specified levels of adherence to study procedures.
~Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. However, passive participants will not have access to the Study App features designed to support asthma self-management."
16309628|NCT04609644|Experimental|Active|"Active arm participants will be sent the same devices, also at no cost, and asked to use them in the same manner.
~Only the active arm will have access to Study App features for asthma self-management, including:
~Smart nudges that may promote proactive asthma self-management
~Asthma symptom and trigger tracking
~Evidence-based asthma education
~The ability to photograph and easily reference an asthma action plan from a healthcare provider.
~A 90-day summary of self-reported asthma symptoms/triggers and device-recorded heart rate and respiratory rate. This summary can be shared with providers.
~In-app viewing of active asthma medications, refills available, and phone numbers to call for refills (subject to prescription benefits).
~Active participants can, but are not required to, use the Study App in Year 2. Those who choose to may keep using study devices in Year 2, provided they meet requirements to keep devices. These requirements are the same for both arms."
16309629|NCT04609631|Experimental|Tai Chi (5 times/week)|5 sessions of Tai Chi per week for 12 weeks
16309630|NCT04609631|Experimental|Tai Chi (3 times/week)|3 sessions of Tai Chi per week for 12 weeks
16309631|NCT04609631|Experimental|Tai Chi (1 time/week)|1 session of Tai Chi per week for 12 weeks
16309632|NCT04609631|Active Comparator|cognitive behavior therapy (CBT)|1 session of CBT per week for 12 weeks
16309633|NCT04609631|No Intervention|Waiting-list|Participants will maintain their routine treatment and life style for 12 weeks.
16309634|NCT04609618|Experimental|Obstructive Sleep Apnea patients|Appscent device will discharge odor during the in lab night sleep
16309635|NCT04609605|Experimental|patients with acute pulmonary embolism|speckle tracking echocardiography for patient with acute pulmonary embolism
16309636|NCT04609592|Experimental|Lutathera|2 cycles of 177Lu Dotatate, followed by cytoreductive surgery, followed by additional 177Lu Dotatate (up to 2 cycles) for residual disease as determined by 68Ga DOTA TATE PET/CT
16309690|NCT04609137|Active Comparator|Standard drain removal|Participants will receive the current standard of care at San Raffaele Hospital.
16309691|NCT04609124||Intervention group:|Patients (n=35) fasting for 8 hours and received 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
16309729|NCT04608890||Healthy volunteers|Healthy volunteers
16309637|NCT04609579|Experimental|SNX281 Monotherapy|"SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 66 participants will take part in this arm of the study.
~Subjects enrolled in the dose expansion phase of this arm may be eligible to add pembrolizumab to their SNX281 therapy following identification of the maximum tolerated dose (MTD) or optimal dose of SNX281 in combination with pembrolizumab. Subjects must, in the opinion of the Investigator, have demonstrated tolerance to SNX281 and have experienced sub-optimal response to therapy (i.e., disease stability for 4 cycles or progression on treatment with SNX281 at any time)."
16309638|NCT04609579|Experimental|SNX281 in Combination with Pembrolizumab|SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter. Participants will also receive pembrolizumab once every cycle for up to 6 cycles. The combination of SNX281 and pembrolizumab will be given for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 and pembrolizumab (or SNX281 alone) beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 62 participants will take part in this arm of the study.
16309640|NCT04609553|Active Comparator|Usual care including ROR|Literacy promotion is a pediatric standard of care. Participants in this group will receive usual care that includes ROR, a primary care literacy promotion intervention.
16309641|NCT04609553|Experimental|ROR plus text messages|In addition to ROR, participants will receive three text messages per week, plus one interactive follow-up message per month, for the study period with scheduled breaks.
16309642|NCT04609553|Experimental|ROR plus text messages plus connection to community resources|In addition to ROR and text messages, participants will be referred to a county-based single point of entry system for referrals to community resources. This system simplifies access to poverty-reducing resources by creating a centralized access point, maintaining an updated data base of resources with existing capacity to support families, and providing case management.
16309643|NCT04609540||Pyrotinib and Trastuzumab group|Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
16309644|NCT04609514|Experimental|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
16309645|NCT04609514|Active Comparator|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
16309646|NCT04609488||COVID|
16309647|NCT04609488||non-COVID|
16309648|NCT04609475|Experimental|Osseodensification technique|
16309649|NCT04609475|Active Comparator|Motor driven expanders' technique|
16309650|NCT04609462|Active Comparator|Conventional oxygen therapy (COT) group|Oxygen therapy will be delivered by conventional nasal cannula / prongs, venturi mask, or mask with reservoir, with flows between 3 and 15 liters / minute, to ensure SpO2 ≥ 92%.
16309651|NCT04609462|Experimental|High-flow nasal cannula (HFNC) group|Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
16309652|NCT04609449|Experimental|Long biliopancreatic limb|Patients submitted to long biliopancreatic limb Roux-en-Y gastric bypass.
16309653|NCT04609449|Active Comparator|Standard biliopancreatic limb|Patients submitted to standard Roux-en-Y gastric bypass.
16309654|NCT04609436||Single arm|This is a single arm trial. The patient is his own control.
16309655|NCT04609423|Experimental|Cod liver oil|supplementation for 6 months
16309656|NCT04609423|Placebo Comparator|Corn oil (placebo)|supplementation for 6 months
16309657|NCT04609410|Experimental|Deep neuromuscular blockade|"During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is > 1.
~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided."
16309658|NCT04609410|Active Comparator|Moderate neuromuscular blockade|"During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC > 5.
~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided."
16309659|NCT04609397|Experimental|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
16309660|NCT04609397|Experimental|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
16309661|NCT04609397|Placebo Comparator|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
16309662|NCT04609384||Prior to installation of device|Health care workers who perform the surgical rub prior to installation of the device that should increase the time spend on surgical rub.
16309664|NCT04609371|Experimental|self-care tools|"Arms Assigned Interventions Experimental: self-care tools
~The tools are adapted from those successfully deployed in the DIRECTsc depression self-care project focusing on patients with depressive symptoms, but abbreviated to meet the needs of the proposed short-term intervention for a broader sample of patients to include those with anxiety symptoms and with minimal symptoms. Tools will include individual chapters of the Antidepressant Skills Workbook; the mood monitoring tool; a workbook on managing worry; relaxation audio files and information on exercise and healthy eating. In view of the short duration of the intervention (8 weeks), a maximum of 2 tools will be sent to each participant.
~An algorithm will determine which self-care tools, matched to the specific mental health symptoms reported by participants, will be sent to the participants."
16309665|NCT04609371|Experimental|coaching|Participants will receive the algorithm-determined self-care tools, matched to the specific mental health symptoms reported by participants as in the first arm. They will ALSO be offered up to 3 coach calls. Coaching by a trained lay coach will be structured and guided by a manual. Trained lay coaches will call participants in the week following delivery of the toolkit to guide them through the self-care toolkit over an 8-week period. Coaches will contact participants a maximum of 3 times, with calls expected to average 15-20 minutes. Call content will be guided by a structured coaching manual adapted from those used in the team's previous two RCTs of the self-care materials. The coaches will follow structured agendas, keep records of all contacts.
16309666|NCT04609358|Experimental|Intervention group|The patients' nutrition were supported according the the algorithm of the enteral nutrition.
16309667|NCT04609358|No Intervention|Control group|The patients' nutrition were supported according the prescription of the physicians and dietician in our hospital.
16309668|NCT04609319||Cohort 1|
16309669|NCT04609306|Experimental|Subjects getting 3% H2O2 applied to the incision|For the experimental cohort, a lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes. Following the 3 minutes, the sponge will be removed, the wound will be flushed with 100 mL of normal saline, and the exposed dermis will be swabbed and sent for culture.
16309670|NCT04609306|No Intervention|Subjects not getting 3% H2O2 applied to the incision|In the control cohort, the dermis will be swabbed and sent for culture immediately after the skin incision is made and the knife is removed from the field.
16309671|NCT04609293||Camrelizumab+apatinib+Hypofractionated radiation therapy|"Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
~Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
~Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy."
16309672|NCT04609280|Experimental|Reduced C/L elective nodal volume|All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
16309673|NCT04609267|Experimental|Paper Baseline|Half of the participants will complete the PHQ-9 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa.
16309674|NCT04609267|Experimental|Mirror Baseline|Half of the participants will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa at their first appointment. At their second appointment 1-month later, they will will complete the PHQ-9 in the traditional paper format.
16309675|NCT04609254|Experimental|First Group|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
16309676|NCT04609254|Experimental|Second Group|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
16309677|NCT04609254|Experimental|Third group|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
16309678|NCT04609241|Experimental|Administration of CD79b CAR-T Cell|
16309679|NCT04609228||Blood-transfusion non-acceptors|Blood-transfusion non-acceptors
16309680|NCT04609228||Blood-transfusion acceptors|Blood-transfusion acceptors
16309681|NCT04609215|Experimental|ALECSAT|"This is an exploratory single arm study. 20 patients will be included with the objective to investigate the safety, tolerability and trends of efficacy of ALECSAT for the treatment of recurrent TNBC.
~ALECSAT is a form of adoptive cell therapy medicinal product. ALECSAT is an abbreviation for Autologous Lymphoid Effector Cells Specific Against Tumor. ALECSAT is an autologous product that induces an immune response against a broad repertoire of CTAs expressed on cancer cells (including TNBC) leading to killing of these cells.
~Patients will receive standard treatment with carboplatin and gemcitabine along with ALECSAT."
16309682|NCT04609202|Experimental|Nurse led person centred care|Participants in the nurse led, person centred care arm will receive person centred follow up after hospitalization for atrial fibrillation. The person centred care and usual care routines are provided by nurses.
16309683|NCT04609202|Active Comparator|Usual care|Participants in the usual care arm will receive care as usual, ie follow up by doctors after hospitalization for atrial fibrillation.
16309684|NCT04609189|Experimental|Pearlium®/EffectiCal®|
16309685|NCT04609189|Active Comparator|Calcium Carbonate/Vitamin D3|
16309686|NCT04609176|Experimental|Camrelizumab+Apatinib+SOX|Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
16309687|NCT04609176|Experimental|Camrelizumab+Apatinib|Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
16309688|NCT04609150||Multiple myeloma patients with vertebral fractures|Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events
16309689|NCT04609137|Experimental|Early drain removal|Participants will have an early drain removal (before postoperative day 3 (POD 3)) if specific conditions will be verified
16309693|NCT04609111|Active Comparator|No aspirin|To start prasugrel monotherapy before the index percutaneous coronary intervention (PCI) and to change into clopidogrel monotherapy at 1-month after the PCI.
16309694|NCT04609111|Active Comparator|1-month DAPT|To start dual antiplatelet therapy comprising of aspirin and prasugrel before the index percutaneous coronary intervention (PCI) and to change into aspirin monotherapy at 1-month after the PCI.
16309695|NCT04609098|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
16309696|NCT04609098|Experimental|DP with 0.415mg/kg Tafenoquine (TQ)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
16309697|NCT04609098|Experimental|DP with 0.83 mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
16309698|NCT04609098|Experimental|DP with 1.66mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.
16309701|NCT04609059|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
16309702|NCT04609059|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
16309704|NCT04609033|Active Comparator|bupivacaine group|
16309705|NCT04609033|Active Comparator|bupivacaine + morphine|
16309706|NCT04609033|Active Comparator|bupivacaine + morphine + ketamine|
16309707|NCT04609033|Placebo Comparator|isotonic saline|
16309708|NCT04609020|Experimental|JUVÉDERM, BOTOX|Facial filler injections (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine and/or JUVÉDERM VOLUX with Lidocaine) will be administered into areas that the subject desires and qualified for per the inclusion/exclusion criteria and within the approved clinical indications at Visits 1 and 2. BOTOX administered at Visit 3. BOTOX touch up treatment administered at Visit 4 if needed.
16309709|NCT04609007|Active Comparator|Treatment as usual|The TAU condition consists of a single session of regular help-line telephone counselling
16309710|NCT04609007|Experimental|Cognitive behavioral therapy|The experimental condition consists of a single session of regular help-line telephone counselling plus four therapist guided online CBT sessions.
16309711|NCT04608981|Experimental|Prednisolone premedication|Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
16309712|NCT04608981|Experimental|Diclofenac potassium premedication|Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
16309713|NCT04608981|Placebo Comparator|Placebo|Placebo tablet 1 hour before starting endodontic treatment.
16309714|NCT04608955|Experimental|Arm A: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
16309715|NCT04608955|Experimental|Arm B: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
16309716|NCT04608955|Experimental|Arm C: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
16309717|NCT04608955|Active Comparator|Arm D: Standard treatment|Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
16309718|NCT04608955|Experimental|Arm E: WX-081+MBT|Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
16309719|NCT04608955|Active Comparator|Arm F: Bedaquiline+MBT|Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
16309720|NCT04608942|Experimental|Jett Plasma Medical Lift Application|In the study group, the plasma jet will be applied to the superior and inferior eyelid margin in both eyes.
16309721|NCT04608942|Active Comparator|Mechanical Debridement|In the control group, the mechanical debridement of the superior and inferior eyelid margin with a scalpel blade will be performed.
16309722|NCT04608929|Experimental|Intervention|The arm where the Kegel exercise focused intervention is applied
16309723|NCT04608929|Experimental|Control|The arm where home follow-up and scale evaluations are made
16309724|NCT04608916|Active Comparator|Scalpel incision group|This group of patients will receive skin incision made with use of a scalpel blade.
16309725|NCT04608916|Experimental|Electrocautery incision group|This group of patients will receive skin incision made with use of electrocautery.
16309726|NCT04608903|Experimental|Sulforaphane Group|Administration of 4g L-Sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.
16309727|NCT04608903|Placebo Comparator|Placebo Group|Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.
16309728|NCT04608890||Long-standing T1D patients|Patients with long-standing type 1 diabetes
16309732|NCT04608864|Experimental|varicocelectomy arm|The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele
16309733|NCT04608864|No Intervention|Control (No varicocelectomy) arm|Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI
16309734|NCT04608851|Experimental|Nissle group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
16309735|NCT04608851|Placebo Comparator|Control group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
16309736|NCT04608838|Experimental|JTR-161|
16309737|NCT04608838|Placebo Comparator|Placebo|
16309738|NCT04608812|Experimental|Direct Infusion of OS2966|OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery using the Infuseon Cleveland Multiport Catheter
16309739|NCT04608786|Experimental|Combined the therapy using Capecitabine and PD-L1|PD-L1 antibody ZKAB001 D1 5mg/kg every three weeks,up to 16 cycles or 1 year of treatment or the patient has tumor recurrence or metastasis Capecitabine 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis
16309740|NCT04608773|Other|Biotene Spray, followed by Refresh Spray|The Biotene Spray followed by Refresh Spray Arm will be asked to complete a 2 week trial using Biotene Spray first, then will be asked to complete a 2 week trial using Refresh Spray second. (after the appropriate 1 week washout periods have been completed)
16309741|NCT04608773|Other|Refresh Spray, followed by Biotene Spray|The Refresh Spray, followed by Biotene Spray Arm will be asked to complete a 2 week trial using Refresh Spray first, then will be asked to complete a 2 week trial using Biotene Spray second. (after the appropriate 1 week washout periods have been completed)
16309742|NCT04608760|Active Comparator|Meksibel|Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
16309743|NCT04608760|Active Comparator|Indometacin|Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
16309744|NCT04608760|Active Comparator|Meloksicam|Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
16309745|NCT04608760|Active Comparator|Oktride|Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
16309746|NCT04608747|Experimental|Intervention arm|After an overnight fast, participants subjected to baseline measurements and blood and urine collection and then consumed an amount of 50 g of tahini. Blood and urine collection and other measurements were repeated 4 h postprandially.
16309747|NCT04608734|Experimental|Buccal midazolam|
16309748|NCT04608734|Active Comparator|Intranasal midazolam|
16309749|NCT04608721||Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI).
16309750|NCT04608708||Group 1. Periapical Cemento-Osseous Dysplasia|In Periapical Cemento-Osseous Dysplasia , the lower anterior teeth are usually affected. In these lesions, normal bone is replaced by fibrous tissue that contains amorphous vascularised calcifications. In the early stage, it can mimic a periapical lesion, but it is usually associated with vital teeth, without any clinical complaint, and it requires no intervention. Histopathologically, the lesion is similar to fibrous dysplasia and ossifying fibroma.
16309751|NCT04608708||Group 2. Focal Cemento-Osseous Dysplasia|It occurs in a single area of the posterior teeth. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
16309752|NCT04608708||Grup 3. Florid Cemento-Osseous Dysplasia|When the lesions involve two or more quadrants of the jaw, it is defined as Florid Cemento-Osseous Dysplasia. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
16309753|NCT04608695|No Intervention|Control ovary|
16309754|NCT04608695|Experimental|Punctured ovary|
16309755|NCT04608682|Experimental|Sugammadex group|
16309756|NCT04608682|Sham Comparator|control group|
16309757|NCT04608669|Other|Temperature comparison|
16309758|NCT04608669|Active Comparator|No change|
16309759|NCT04608656|Experimental|Intervention arm 1: Livestock feed only|Households in villages assigned to intervention arm 1 will receive a pre-defined amount of feed to maintain two tropical livestock units for a total of 60 days during the dry season (when animals would be moved away in search of pastures).
16309760|NCT04608656|Experimental|Intervention arm 2: 1. Provision of Livestock feeds, 2. Nutrition counselling|Households recruited into intervention arm two will receive livestock feeds similar to intervention arm 1 and will be enrolled in a nutritional education and counselling program through Infant and Young Child Nutrition (IYCF) feeding program and household food utilization. The IYCF program through the Baby Friendly Community Initiative (BFCI) will include the promotion of exclusive breastfeeding in the first six months, continued breastfeeding up to the age of two years, adequate complementary feeding, hygiene promotion and the uptake of child health services including immunization, treatment of illness, moderate and severe acute malnutrition and micro-nutrient supplementation.
16309797|NCT04608448|Active Comparator|Topical Rapamycin|Ointment is applied to a color coded area on the subject forearm daily.
16309798|NCT04608448|Placebo Comparator|Placebo|Placebo ointment is applied to a color coded area on the subject forearm daily.
16309799|NCT04608435||Male Group|
16309800|NCT04608435||Female Group|
16309801|NCT04608422|Experimental|Electrical stimulation|The patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.
16309761|NCT04608656|No Intervention|Control arm|The households recruited under this arm will receive none of the two study interventions. These households will receive identical assessment and data collection like other study households in the study. Their access to support through other interventions will be monitored. Households within the control arm will receive nutritional counselling and education given outside of the project. This is mainly at health facilities when mothers present for antenatal care or visit health facilities seeking healthcare. On some occasions in places where community health volunteers are present, nutritional counselling and education may be provided at the community level. The study instruments have been designed to collect information at the household level if such nutritional counselling and education has been provided.
16309762|NCT04608630|Active Comparator|Denosumab|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
16309763|NCT04608630|Active Comparator|Zoledronic acid|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride, administered via intravenous infusion over at least 15 minutes on Study Day 1.
16309764|NCT04608630|Placebo Comparator|Placebo|Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
16309765|NCT04608617||Pre-Viz|Pre-Viz LVO implementation patient data utilized as a control data set
16309766|NCT04608617||Post-Viz|Patient data collected post-Viz LVO implementation
16309767|NCT04608604|Active Comparator|Physiotherapy 1|
16309768|NCT04608604|Active Comparator|Physiotherapy 2|
16309769|NCT04608578|Experimental|Intervention group|The intervention group gain access to the game after filling in the baseline online questionnaire. The participants are asked to play at least two characters in the game. They have two weeks to play the game.
16309770|NCT04608578|No Intervention|Control group|Waitlist control group
16309771|NCT04608565|Other|Remote biomonitoring sensor device|250 readings for a power of 80% and to detect a 5% difference in measurements with 95% confidence interval from mothers and newborns was ascertained. Once 3 probes were strapped (radiant warmer, RBM device and multichannel), a waiting period of 10 minutes for temperature stabilization was given. First RBM device & multichannel probe provided readings continuously (every few seconds); Then radiant warmer probe and manual thermometer readings were taken every 15 minutes for 5 timings: 0, 15, 30, 45 and 60 minutes. Participant safety for newborns was ensured following routine appropriate care protocols.
16309772|NCT04608552|Active Comparator|Active Myofunctional Therapy|Active Myofunctional Therapy is comprised of five 30-minute weekly sessions for 4 weeks.
16309773|NCT04608552|Sham Comparator|Inactive Myofunctional Therapy|Sham MT will be comprised of recommendations for five 30-minute nasal breathing exercises each week, use of nasal lavage with application of 10ml of saline in each nostril two times per day.
16309774|NCT04608539|Experimental|Intravenous iron group|Single-dose intravenous infusion of 20 mg/kg body weight ferric derisomaltose/iron isomaltoside 1000 (MonoFer®)
16309775|NCT04608539|Active Comparator|Oral iron group|Oral therapy with 100 mg oral ferrous sulfate twice daily
16309776|NCT04608526||Group 1|Patients without deep dentin caries / apical rarefying osteitis
16309777|NCT04608526||Group 2|Patients with deep dentin caries / apical rarefying osteitis on the right or left sides
16309778|NCT04608526||Group 3|Patients with deep dentin caries / apical rarefying osteitis on either the right and left side
16309779|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 1)|Soft capsule for oral administration
16309780|NCT04608513|Placebo Comparator|Placebo single dose (dose level 1)|Soft capsule for oral administration
16309781|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 2)|Soft capsule for oral administration
16309782|NCT04608513|Placebo Comparator|Placebo single dose (dose level 2)|Soft capsule for oral administration
16309783|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 1)|Soft capsule for oral administration
16309784|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 1)|Soft capsule for oral administration
16309785|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 2)|Soft capsule for oral administration
16309786|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 2)|Soft capsule for oral administration
16309787|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 3)|Soft capsule for oral administration
16309788|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 3)|Soft capsule for oral administration
16309789|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 4)|Soft capsule for oral administration
16309790|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 4)|Soft capsule for oral administration
16309791|NCT04608500|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
16309792|NCT04608500|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
16309793|NCT04608487|Experimental|Fludarabine + Cyclophosphamide + Axicabtagene Ciloleucel|"Two (2) cohorts of particpants: Cohort 1: relapsed/refractory primary CNSL (PCNSL) and secondary CNSL without systemic aggressive B cell non-Hodgkin lymphoma (NHL) including diffuse large B cell lymphoma (DLBCL), high grade B cell lymphoma (HGBL), primary mediastinal large B cell lymphoma (PMBL), and transformed follicular lymphoma (tFL). Cohort 2: relapsed/refractory systemic aggressive B cell non-Hodgkin lymphoma, including DLBCL, HGBL, PMBL, and tFL, with either active CNSL or previously treated CNSL
~Prior to receiving axi-cel, participants will undergo leukapheresis and the need for a Ommaya reservoir placement will be assessed and administered.
~Day -5 to Day -3 of 28 day study cycle Fludarabine and cyclophosphamide; Day -1 admitted to hospital, receive axi-cel on day 0; Till at least cycle day 7 hospital monitoring; post treatment follow up will occur on day 14 and day 28 of cycle 1, monthly in cycles 2, 3, 6, 9,12,15,18,21,24, then yearly after cycle 24."
16309794|NCT04608474|Experimental|Evolocumab only|This arm includes subjects who are treated using Evolocumab.
16309795|NCT04608474|Experimental|Evolocumab plus statin|This arm includes subjects who are treated using a combination of Evolocumab and a statin-based drug.
16309796|NCT04608461|Experimental|pumpkin seeds extract containing cream|Intervention-pumpkin seeds extract containing cream, dose-twice daily for 12 weeks
16309803|NCT04608409|Experimental|Lapatinib - Group 1|Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).
16309804|NCT04608409|Experimental|Lapatinib - Group 2|Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).
16309805|NCT04608409|Experimental|Lapatinib - Group 3|Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).
16309806|NCT04608409|Experimental|Lapatinib - Group 4|Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).
16309807|NCT04608396|Experimental|AXS-05|
16309808|NCT04608396|Placebo Comparator|Placebo|
16309809|NCT04608370|Experimental|Active tPBM session group|Participants in the active tPBM group will take active tPBM session, which include 12 minutes active tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
16309810|NCT04608370|Active Comparator|Sham tPBM session group|Participants in the sham tPBM group will take sham tPBM session, which include 12 minutes sham tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
16309811|NCT04608344|Experimental|Sequence AB|Atorvastatin (ATV) 40 mg (Day 1); Washout period (Day 2); Pravastatin (PRA) 40 mg + Rosuvastatin (ROS) 10 mg (Day 3); Washout period (Days 4-6) in Treatment A Period 1; Filgotinib (FIL) 200 mg (Days 7-11). FIL 200 mg + ATV 40 mg (Day 12 ); FIL 200 mg (Day 13); FIL + PRA 40 mg + ROS 10 mg (Day 14); FIL 200 mg (Days 15-17) in Treatment B Period 2.
16309812|NCT04608344|Experimental|Sequence BA|FIL 200 mg (Days 1-5); FIL 200 mg + ATV 40 mg (Day 6); FIL 200 mg (Day 7); FIL + PRA 40 mg + ROS 10 mg (Day 8); FIL 200 mg (Days 9-11); Washout period (Days 12-17) in Treatment B Period 1. ATV 40 mg (Day 18); Washout period (Day 19); PRA 40 mg + ROS 10 mg (Day 20) in Treatment A Period 2.
16309813|NCT04608331|Experimental|Dexmedetomidine group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
16309814|NCT04608331|Placebo Comparator|Placebo group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
16309815|NCT04608318|Experimental|I (Ibrutinib)|Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.
16309816|NCT04608318|Experimental|VG (Obinutuzumab + Venetoclax)|12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone
16309817|NCT04608318|Experimental|VI (Venetoclax + Ibrutinib)|15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles
16309818|NCT04608305|Experimental|phase I - Group Ia, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0
16309819|NCT04608305|Experimental|phase I - Group Ib, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0
16309820|NCT04608305|Experimental|phase I - Group Ic, Prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0
16309821|NCT04608305|Experimental|phase I - Group Id, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
16309822|NCT04608305|Experimental|phase II - Group IIa, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
16309823|NCT04608305|Experimental|Phase II - Group IIb, Prime, low dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
16309824|NCT04608305|Experimental|phase II - Group IIc, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
16309825|NCT04608305|Experimental|phase II - Group IId, Prime, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
16309826|NCT04608305|Experimental|Phase II - Group IIe, prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
16309827|NCT04608305|Experimental|Phase II - Group IIf, Prime, high dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
16309828|NCT04608305|Experimental|phase II - Group IIg, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
16309829|NCT04608305|Experimental|phase II - Group IIh, prime-boost, low dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
16309830|NCT04608305|Experimental|phase II - Group IIi, prime-boost, medium dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
16309831|NCT04608305|Experimental|phase II - Group IIj, prime-boost, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
16309832|NCT04608305|Experimental|phase II - Group IIk, prime-boost, high dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
16309833|NCT04608305|Experimental|phase II - Group IIl, prime-boost, high dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
16309834|NCT04608305|Experimental|phase II - Group IIm, prime-boost, top dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
16309835|NCT04608305|Experimental|phase II - Group IIn, prime-boost, top dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
16309836|NCT04608292|Active Comparator|Single-voxel MRS|MRS
16309837|NCT04608292|Active Comparator|Multi-voxel MRSI|MRSI
16309838|NCT04608292|Active Comparator|Magnetization Transfer Imaging|MTI
16309839|NCT04608292|Active Comparator|Single-voxel MRS + ClearMate(TM)|MRS+CM
16309840|NCT04608292|Active Comparator|Multi-voxel MRSI + ClearMate(TM)|MRSI+CM
16309841|NCT04608292|Active Comparator|Magnetization Transfer Imaging + ClearMate(TM)|MTI+CM
16309842|NCT04608292|Active Comparator|Single-voxel MRS + CM + Blood Sampling|MRS+CM+B
16309843|NCT04608292|Active Comparator|Multi-voxel MRSI + CM + Blood Sampling|MRSI+CM+B
16309844|NCT04608292|Active Comparator|Magnetization Transfer Imaging + CM + Blood Sampling|MTI+CM+B
16309845|NCT04608266|Experimental|Camostat mesylate|Camostat mesylate, oral administration 600mg/day
16309846|NCT04608266|Placebo Comparator|Placebo|Placebo tablets, oral administration
16309847|NCT04608253||All enrolled subjects received an 11C-choline PET/CT prior to enrollment.|Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
16309848|NCT04608227||Third trimester pregnant women undergoing ceasarean section|
16309849|NCT04608214|Experimental|Alisporivir|Administration of alisporivir and standard of care (SOC)
16309850|NCT04608214|Active Comparator|Standard of care (SOC)|Locally accepted regimen protocols for patient care
16309851|NCT04608201|Experimental|NICOTINE transdermal patch|NICOTINE 7 mg / 24h, transdermal patch
16309852|NCT04608201|Placebo Comparator|Placebo of NICOTINE transdermal patch|Placebo of nicotine patch
16309853|NCT04608188|Experimental|Summer Program|Children in the intervention will attend a summer day camp operated at their school.
16309854|NCT04608188|No Intervention|No Program|The control children will not receive an intervention of any kind and will be asked to go about their summer as they typically would.
16309855|NCT04608175|Experimental|Acupuncture group|"The experimental group will receive the standard treatment administered in these cases (analgesic regimen and nursing care procedures), in addition to the following acupuncture therapy.
~In the first visit (preoperative), the anamnesis and energy diagnosis of each patient will be carried out following the practices of Traditional Chinese Medicine (TCM) to design a personalized treatment based on the patient's medical history. A treatment of approximately 10 to 12 acupuncture points will be designed considering the TCM diagnosis and medical history of each patient. Both TCM diagnosis and the points used will be reassessed in each session. The points belonging to the upper extremity of the affected breast will be treated on the contralateral side, taking care not to insert any needle in the limb on the affected side. No points in the operated region will be used."
16309856|NCT04608175|No Intervention|Control group|The control group will only receive standard care procedures (analgesic regimen and nursing care procedures), although they will have the same follow up visits as the patients in the intervention group to facilitate analysis of the study variables.
16309857|NCT04608162|Active Comparator|Group I|Group one received PEMF and exercise (PEMF+EX)
16309858|NCT04608162|Placebo Comparator|Group II|Group two received placebo PEMF and exercise (PPEMF+EX)
16309859|NCT04608162|Active Comparator|Group III|Group three will be treated by PEMF alone (PEMF)
16309860|NCT04608149||Subjects treated with Carpediem system|All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.
16309861|NCT04608136|Experimental|Yolk ketogenic diet|consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
16309862|NCT04608136|Experimental|White ketogenic diet|consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
16309863|NCT04608136|Active Comparator|Control group|decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
16309864|NCT04608123||DBS Patients with NFS|Patients with PD treated with STN DBS between 2016 and 2019 who underwent NFS testing in pre and post-op conditions
16309865|NCT04608110|Experimental|Azacitidine + Cedazuridine|"Drug: Azacitidine Tablets for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
~Drug: Cedazuridine Tablets for oral administration"
16309866|NCT04608097|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
16309867|NCT04608097|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
16309868|NCT04608084|Experimental|Treatment group|Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
16309869|NCT04608071||M group|In M group, patients underwent modified post-pyloric feeding tube bedside placement
16309870|NCT04608071||C group|In C group, patients underwent conventional Corpak protocol
16309871|NCT04608071||EM group|In EM group, patients received standard electromagnetic guided tube placement.
16309872|NCT04608058|Experimental|Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, asynchronous Diabetes self-management training, using digital storytelling was made available to this group. Post-test data were collected 3 months after the pretest."
16309873|NCT04608058|Experimental|No Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, the control group received the clinics' routine training. Post-test data were collected 3 months after the pretest."
16309946|NCT04607655|Experimental|Oral GB1211, 10 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
16309947|NCT04607655|Placebo Comparator|Oral GB1211, Placebo, twice a day|Placebo is administered as inhalation once a day
16310091|NCT04606719|Other|Blood Clot|It is induced through apical foramen by penetrating the periapical area by stainless steel file size 30 to fill the root canal system by growth factors also to be considered as scaffold
16309875|NCT04608032|Experimental|Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz]|to inform the patient about cognitive impairments and their repercussions ; to train the patient in problem-solving skills through exercices ; to implement strategies in daily life. Duration : two month. Frequency : Two one hour individual sessions and one hour of at-home training per week. Modalities : pen and papers exercices (tools (token, cards, maps and chessboard). Modules : Psychoeducation, Attention, Memory, Executive functions, Social cognition and metacognition, Functional impairments
16309876|NCT04608032|Active Comparator|[THoR] Recovery-Oriented Therapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' and functional impact, social skills, motivation and the regulation of sleep and daily activities
16309877|NCT04608019|Experimental|Immediate Antibiotics|increased airway clearance plus early initiation of oral antibiotics
16309878|NCT04608019|Experimental|Tailored Therapy|increased airway clearance alone, with addition of antibiotics for worsening symptoms or failure to improve
16309879|NCT04608006||Vaginal Delivery|Delivered both twins vaginally
16309880|NCT04608006||C-Section Delivery|Delivered both twins by Cesarean Section
16309881|NCT04608006||Vaginal/C-Section Delivery|Delivery first twin vaginally and second twin By C-Section.
16309882|NCT04607993|Experimental|Prone position ventilation technique|Prone position ventilation for children with congenital heart disease after surgery
16309883|NCT04607993|No Intervention|Control group|conventional postoperative position, no prone position ventilation
16309884|NCT04607980|Experimental|Treatment Group A (ABP 654)|Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to [<=] 100 kg) or 90 mg (baseline BW greater than [>] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.
16309885|NCT04607980|Experimental|Treatment Group B (Ustekinumab - ABP 654)|Participants will receive SC injection of ustekinumab,45 mg (baseline BW <= 100 kg) or 90 mg (baseline BW > 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.
16309886|NCT04607967|No Intervention|"Conventional oxygen-therapy (study group CO)"|"Patients randomized in the Coventional Oxygen group will be treated according to the national and international recommandations with a conventional oxygen-therapy device (nasal cannula or nasal-oral mask).
~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
16309887|NCT04607967|Experimental|"High Flow Nasal Oxygen (study group HNFO)"|"Patients randomized in the HNFO group will be treated according to the CE Certification with the high flow nasal oxygen device.
~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
16309888|NCT04607954|Experimental|Treatment (durvalumab, topotecan hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16309889|NCT04607941||Cases|Subjects diagnosed as positive for SARS-CoV-2 infection
16309890|NCT04607941||Close Subjects|"Subjects living within the same household as cases:
~close cases if tested positive for SARS-CoV-2 following contact tracing recommendations
~close controls if tested negative for SARS-CoV-2 following contact tracing recommendations"
16309891|NCT04607941||Control Subjects|Controls selected within the population to allow for an age, gender and location of residence-matched analysis with cases
16309892|NCT04607928|Placebo Comparator|Placebo|No anti-fibrotic treatment. Patients in placebo and treatment arm may be on corticosteroid treatment
16309893|NCT04607928|Experimental|Treatment|Pirfenidone
16309894|NCT04607915|Experimental|Intervention for TECC Model|
16309895|NCT04607902|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
16309896|NCT04607902|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
16309897|NCT04607902|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
16309901|NCT04607876|Active Comparator|Standard of Care|The FAR Control Arm will involve risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
16309902|NCT04607876|Other|Enhanced Intervention|"This intervention will involve risk factor assessment and web based risk factor management.
~Technological facilitators including a population health care management portal which will be used to facilitate risk factor management to monitor risk factor control, and to facilitate new symptom and complications management;
~Telemedicine to allow FAR Coordinator and providers capability for evaluation and management in home/facility, which facilitates real time communication and collaboration and virtual evaluation of the subject when higher level of intervention is required
~Educational portal provides a common educational platform for professional and subject education around stroke symptoms, complications, recovery and risk factor management, and lifestyle changes.
~FAR EI teams will be coordinated at FAR Central where a centralized group of specialists initiate and monitor risk factor mitigation strategies tailored to the individual participant."
16309903|NCT04607863||Low back pain|Patients with low back pain
16309904|NCT04607863||No low back pain|No low back pain patients
16309914|NCT04607837|Experimental|Etrasimod 2 mg|
16309915|NCT04607837|Placebo Comparator|Placebo|
16309916|NCT04607824||Duchenne Muscular Dystrophy group|Forty-five male subjects were included in the Duchenne Muscular Dystrophy (DMD) group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer.
16309917|NCT04607824||Typical Development group|Forty-five male subjects were included in the healthy Typical Development (TD) control group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer
16309918|NCT04607811|No Intervention|Control arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will complete study surveys at baseline and the end of the 8 week intervention.
16309919|NCT04607811|Experimental|Gamification arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will have a weekly step goal they are encouraged to meet. Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
16309920|NCT04607798|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments.
16309921|NCT04607785|Active Comparator|Miswak mouthwash group|Miswak sticks were bought from local markets, Baghdad, Iraq, washed with cold water and dried then crushed into powder. Later,7 grams of the miswak powder weighted and added to 350 ml of distilled water (D.W.) in a conical flask for 24 hours. Finally, the solution then filtered and stored in tightly closed bottles in a cool place.9
16309922|NCT04607785|Other|Chlorhexidine mouthwash group|0.12% chlorhexidine gluconate mouthwash for seven days
16309923|NCT04607772|Experimental|Arm A: Selinexor with Bendamustine and Rituximab (S-BR))|Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
16309924|NCT04607772|Experimental|Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
16309925|NCT04607772|Experimental|Arm C: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m^2 on Day 1, and IV dose of bendamustine 90 mg/m^2 on Days 1 and 2 during primary treatment for Cycle 1 to 6.
16309926|NCT04607772|Experimental|Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1 and 3 for Cycle 1 to 6 (each cycle consists of 14 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2, IV dose of gemcitabine 1000 mg/m^2, and Oxaliplatin IV dose of 100 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
16310037|NCT04607122|Experimental|Landiolol group|Landiolol infusion (2µg/kg/min) administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
16309927|NCT04607772|Experimental|Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-4) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg once daily on Day 1 to 28 during primary treatment for Cycle 1 to 6. Participants will also receive ibrutinib oral dose of 420 mg once daily at all dose levels during continuous treatment.
16309928|NCT04607772|Experimental|Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment for Cycle 1 to 6. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 at all dose levels during the continuous treatment.
16309929|NCT04607772|Experimental|Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 12 during primary treatment and 40 (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). During the primary treatment, participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, and tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg on Days 1 and 15 for all dose levels during the continuous treatment.
16309930|NCT04607772|Experimental|Arm H: Selinexor with Venetoclax (S-V)|Participants will receive 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8 and 15 for Cycle 1 to 6 of primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-5) during continuous treatment (28 days per cycle). Participants who received 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for Cycle 1; 400 mg daily for Cycle 2 to 6. Participants who received 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6. Participants who received 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6. Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
16309931|NCT04607759|Experimental|Experimental group (cucumber)|"Consumption for 90 days of cucumber extract (20mg/day)
~Two capsules a day orally for 90 days."
16309932|NCT04607759|Placebo Comparator|control group Placebo (sucrose)|Two capsules a day orally for 90 days.
16309933|NCT04607746|Experimental|Capsule|Participants will swallow the capsule for imaging prior to completing colonoscopy. Capsule swallow may be 1 day prior or 3-6 weeks prior to colonoscopy.
16309934|NCT04607733|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS)
16309935|NCT04607733|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by subcutaneous injection (SC) via an autoinjector (AI)
16309936|NCT04607720|Experimental|the artificial-EUS-FNA group|the first two passes were made without the AI-assisted diagnosis system guidance during EUS-FNA, and then two passes were made under guidance from the AI-assisted diagnosis system
16309937|NCT04607720|Experimental|the AI-EUS-FNA group|the first two passes were made with the AI-assisted diagnosis system guidance and then another two manual passes without the AI-assisted diagnosis system guidance.
16309938|NCT04607707||Postmenopausal Women|Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.
16309939|NCT04607694|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
16309940|NCT04607694|Active Comparator|Photon radiotherapy|Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
16309941|NCT04607681|Experimental|1 GROUP|"Patients who agree to participate in the study will be informed about the study and their written and verbal consent will be obtained. At this stage, which will last 6 weeks for each patient;
~On the first day, the patients will be evaluated first by filling the Individual Descriptive Features Form, Information Need Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices,
~In order for the patients in the intervention group to use the web-based asthma education program, a web-based asthma education program will be introduced by giving their username and password.
~After 6 weeks of training, second data will be collected on the web in the intervention group."
16309942|NCT04607681|No Intervention|2 GROUP|"Written and verbal consents will be obtained from patients who agree to participate in the study by providing information about the study.
~At this stage, which will take 6 weeks for each patient; On the first day, the patients will first be evaluated by filling the Individual Descriptive Characteristics Form, Information Requirement Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices, Second data after 6 weeks will be collected in the control group via Google form or phone call"
16309945|NCT04607655|Experimental|Oral GB1211, 100 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
16309948|NCT04607642|Experimental|A BMX-001|Patients will receive standard of care radiation therapy plus Cisplatin. BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
16309949|NCT04607642|Placebo Comparator|B Placebo|Patients will receive standard of care radiation therapy plus Cisplatin. Placebo will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
16309950|NCT04607629|Experimental|Genolar® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
16309951|NCT04607629|Active Comparator|Xolair® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
16309952|NCT04607616|Experimental|3 baselines sessions Treatment As Usual (TAU)|Patients received 3 baseline sessions before interactive guidance therapy
16309953|NCT04607616|Experimental|4 baselines sessions TAU|Patients received 4 baseline sessions before interactive guidance therapy
16309954|NCT04607616|Experimental|5 baselines sessions TAU|Patients received 5 baseline sessions before interactive guidance therapy
16309955|NCT04607616|Experimental|6 baselines sessions TAU|Patients received 6 baseline sessions before interactive guidance therapy
16309956|NCT04607616|Experimental|7 baselines sessions TAU|Patients received 7 baseline sessions before interactive guidance therapy
16309957|NCT04607616|Experimental|8 baselines sessions TAU|Patients received 8 baseline sessions before interactive guidance therapy
16309958|NCT04607603|Experimental|Cannabidiol|In the Cannabidiol (CBD) arm CBD will be titrated up to 600 mg per die (titration 1 week) in capsules (3 daily doses) and maintained at 600mg per die (3 daily doses) for 7 weeks
16309959|NCT04607603|Placebo Comparator|Placebo|In the placebo arm the placebo comparator will be administered in capsules in 3 daily doses
16309960|NCT04607590||Group I (DY)|Patients and their partners attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy.
16309961|NCT04607590||Group II (PY)|Patients attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy. Once data collection is completed, partners will be offered intervention materials, and encouraged to attend yoga classes at the Integrative Medicine Clinic.
16309962|NCT04607590||Group III (WLC)|Patients and their partners receive usual care. Once data collection is completed, couples may participate in the DY or PY program of their choice over 60 minutes each. Partners are also offered intervention materials along with five 60 minute optional yoga sessions.
16309963|NCT04607564|Experimental|No comparison pilot group|Attendance at ten Ntombi Vimbela workshops running for a total 35 hours over six weeks.
16309964|NCT04607551|Experimental|Prone positionning|
16309965|NCT04607551|Active Comparator|Supine position|
16309969|NCT04607525|Experimental|Group D|Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline
16309970|NCT04607525|Placebo Comparator|Group C|Patients received equal volume and rate of normal saline as Group D.
16309971|NCT04607512|Experimental|Telaglenastat|800 mg telaglenastat (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
16309972|NCT04607512|Placebo Comparator|Telaglenastat Placebo|800 mg placebo (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
16309973|NCT04607512|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin (1 x 400 mg tablet) administered on the morning of Day 4
16309974|NCT04607499||Pregnant women|Pregnant women without intervention
16309975|NCT04607486||CVA and spasticity|Adults with first-ever chronic CVA and leg spasticity
16309976|NCT04607486||CVA without spasticity|Control group
16309977|NCT04607486||healthy subjects|Control group
16309978|NCT04607473|Experimental|ABUS|ABUS is performed by experienced technicians using a GE inveniaTM. Each breast is imaged in three views with an automated 15.4-cm 14-6-MHz linear- array transducer, which acquires up to 1000 two-dimensional images in the transverse plane, imaging the breast in three parts: the central (anteroposterior), lateral, and medial portions of the breast. To ensure inclusion of all breast tissue, particularly in participants with very large breasts, additional views are obtained as deemed necessary by the technician to cover the entirety of the breast.
16309979|NCT04607460|Experimental|EMG-Biofeedback|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 8 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
16309980|NCT04607460|No Intervention|Treatment as usual|Participants in this group will receive no active treatment.
16309981|NCT04607447|Active Comparator|Atorvastatin plus Dexamethasone tablets|
16309982|NCT04607447|Experimental|drugs+low intracranial pressure strategy treatment|Drugs means treatment with Atorvastatin plus Dexamethasone tablets
16310038|NCT04607122|Placebo Comparator|Placebo group|Saline solution infusion administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
16310154|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 4|PF-07248144 Monotherapy Escalation
16309988|NCT04607408|Experimental|Part A, Group 1: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 2.5 mcg GLA-SE, to be administered as a 0.25 mL intramuscular (IM) injection into either thigh at Weeks 0, 8, 16, 32, and 54.
16309989|NCT04607408|Placebo Comparator|Part A, Group 2: Placebo|Participants will receive Placebo to be administered as a 0.25 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
16309990|NCT04607408|Experimental|Part B, Group 3: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
16309991|NCT04607408|Placebo Comparator|Part B, Group 4: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
16309992|NCT04607408|Experimental|Part C, Group 5: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
16309993|NCT04607408|Placebo Comparator|Part C, Group 6: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
16309994|NCT04607408|Experimental|Part C, Group 7: CH505TF gp120 + GLA-SE|Participants will receive 5 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
16309995|NCT04607408|Placebo Comparator|Part C, Group 8: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
16309996|NCT04607395||pre-operative radiographs of deep carious lesion|
16309997|NCT04607382||Low-dose estrogen progestin products (LEP)|The patients in the LEP cohort should not have taken LEP in the last 2 months before the enrollment in the study, and will take LEP during the study period.
16309998|NCT04607382||Non-LEP|Those patients in the Non-LEP cohort should not have taken LEP in the last 2 months before the enrollment and will take NSAIDs and/or Chinese medicine (CM) during the study period.
16309999|NCT04607369||Groups in General all were done under the wcgIRB, even those that were Practice groups|"Groups 1-3 were practice groups, gathering smartphone app installation, functional and usability feedback in preparation for later phase groups
~Groups 4a and 4b Cohort 1 and 2 is the FDA application finalized and submitted study groups
~Group 5-6 currently in continuing clinical trial during FDA application process"
16310000|NCT04607369||1,2,3 Developmental team, Technician and Non-Clinical Groups are all PRACTICE groups|Individuals on the developmental team and Technicians, medical students, post doctor research fellows included in this group. Non-clinical groups were individuals that are not in formal medical practice who agreed to try the app
16310001|NCT04607369||4a. Cohort 1. FDA group|Patients in Neuro-Ophthalmology of Texas (NOT) PLLC practice which has referrals from multiple practices including retinal patients.
16310002|NCT04607369||4b. Cohort 2. FDA group|Patients in NOT practice
16310003|NCT04607369||5. Retinal in continuing clinical trial during FDA decision|Patients in Macula, Vitreous, Retina-Physicians and Surgeons-
16310004|NCT04607369||6. At Home in continuing clinical trial during FDA decision|Patients in all practices who wish to work with Neuro-ophthalmology of Texas (NOT) where patients will be educated at home via app video clips and brochure, and as necessary, online training with COA (ophthalmic assistants/technicians or other trained educators) in order to do remote physiologic vision monitoring and screening.
16310005|NCT04607356|Active Comparator|Evidence-informed care|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises.
16310006|NCT04607356|Experimental|Evidence-informed care + Blood Flow Restriction (BFR)|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises with the addition of BFR while performing resistive exercises.
16310039|NCT04607096|Active Comparator|Prediabetic subjects - cluster 3|Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
16310040|NCT04607096|Active Comparator|Prediabetic subjects - cluster 5|Presence of a cluster 5 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
16310204|NCT04606264|Active Comparator|Orthopedic: Neuraxial Analgesia|
16310007|NCT04607343|Experimental|Assigned Interventions|Patients will undergo a conventional flexible nasopharyngeal laryngoscopy in which the degree of obstruction and the laryngopharyngeal sensitivity during wakefulness will be determined. Electrostimulation will be applied at different submandibular points with increasing intensity until the contraction of the dilation muscles of the airway or until the patient cannot tolerate the electrostimulation. The presence of contraction of stimulated muscles will be determined by external and endoscopic inspection.
16310008|NCT04607330|Experimental|High protein liquid|A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
16310009|NCT04607317|Experimental|Exercise Intervention|Participants in this arm will be enrolled in a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day). Participants will meet weekly 1:1 with a trained health coach via a Webex platform. Weekly exercise goals will be tailored to the individual's abilities and specific barriers. Coaching will utilize social cognitive theory and self-determination theory to develop self-efficacy for sustainable behavior change.
16310010|NCT04607317|Active Comparator|Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks. They will continue to wear the Garmin activity tracker and can view their activity but will not be given an exercise program. They will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
16310011|NCT04607304|Experimental|ABCA2 GIRMS|Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized
16310012|NCT04607291|Experimental|Health services research (Witness CARES services) Intervention|Patients who are not prepared for a colonoscopy or stool test receive educational materials, messages, and videos electronically or by mail with information about colorectal screening and are followed up by phone within 2 weeks. Patients desiring colonoscopy, receive navigators assistance with obtaining the screening (e.g.,determining gastrointestinal doctor, scheduling appointment, prep materials and process, transportation, escort). Patients desiring a stool test, receive navigators assistance by facilitating fecal tests.
16310013|NCT04607278|Experimental|Probiotic|Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
16310014|NCT04607278|Active Comparator|Prebiotic|The prebiotic (Inulin) was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
16310015|NCT04607278|Placebo Comparator|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
16310016|NCT04607265||Ventricular tachycardia (VT) group|NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.
16310017|NCT04607265||Control group|NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.
16310018|NCT04607252|Experimental|Metformin plus megestrol acetate|Metformin 1500mg per day plus megestrol acetate 160mg per day.
16310019|NCT04607252|Active Comparator|Megestrol acetate|Megestrol acetate 160mg per day.
16310020|NCT04607239|Experimental|Telemonitoring|"In addition to the usual care, this group benefits from a weekly telephone call by the Clinical Research Associate (CRA) for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.
~This group will also benefit from a monthly call by the attending physician for treatment titration and side effects check."
16310021|NCT04607239|Other|Conventional|"This group will benefit form the usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.
~The usual care includes attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician."
16310022|NCT04607226|Experimental|Active tVNS - 2 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency
16310023|NCT04607226|Experimental|Active tVNS - 8 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency
16310024|NCT04607226|Experimental|Active tVNS - 30 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency
16310025|NCT04607226|Experimental|Active tVNS - 100 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency
16310026|NCT04607226|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
16310027|NCT04607213|Active Comparator|Advancement-rotation approach|
16310028|NCT04607213|Experimental|Straight-line approach|
16310029|NCT04607200|Experimental|Monotherapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks for up to 24 months
16310030|NCT04607200|Experimental|Combination Therapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks + AGEN1884 - dose of 1 mg/kg IV every 6 weeks (following AGEN2034 infusion), for up to 24 months
16310031|NCT04607187||Normals, Dupuytren's subjects with and without treatment|Ultrasound analysis of patient receiving treatment for Dupuytren's
16310032|NCT04607174||Pathologic group|At least 20 participants with various neurologic or orthopaedic conditions (for example, hemiparesis post-stroke, multiple sclerosis, traumatic knee injuries, knee osteoarthritis) will be enrolled.
16310033|NCT04607148|Experimental|RG6147 20 mg Q4W|Participants will receive 20 milligrams (mg) RG6147 via ITV injection every 4 weeks (Q4W).
16310034|NCT04607148|Experimental|RG6147 20 mg Q8W|Participants will receive 20 mg RG6147 via ITV injection every 8 weeks (Q8W).
16310035|NCT04607135|Experimental|Acoustic radiation force impulse (ARFI)|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
16310036|NCT04607135|Active Comparator|MR-ultrasound fusion|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
16310041|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)|Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
16310042|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)|Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
16310043|NCT04607083||Patients with at least one diminutive rectosigmoid polyp|"Consecutive adult (>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
~Exclusion criteria:
~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer
~patients with inadequate bowel preparation
~patients in which caecal intubation was not achieved or scheduled for partial examinations
~polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment
~patients undergoing urgent colonoscopy."
16310044|NCT04607070||Stroke patient|This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018.
16310045|NCT04607057|Experimental|experimental group (Arm A)|"Preparation of parenteral nutrition (PN): Among winuf(1820cc for central vein, 1,450cc for peripheral vein), smofkabaven(986cc for central vein, 1206cc for peripheral vein), and nutriplex(1875cc for central vein, 1,250cc for peripheral vein) Amount of PN: Total energy expenditure (TEE) of the patients will be calculated with Harris-Benedict Equation, activity factor, and stress factor. The amount of calorie from oral intake will be subtracted from TEE then the remainder will be provided through PN.
~Route of PN Injection: PICC (percutaneously-inserted central catheter) will be secured for PN for the central vein. PN for the peripheral vein will be injected directly through peripheral superficial vein.
~Day0 : fasting(NPO) + crystalloid fluid
~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid
~POD#2 : Semifluid diet (SFD) + crystalloid fluid
~POD#3 : Semifluid diet (SFD) + PN
~POD#4-7: Soft blended diet (SBD) + PN"
16310046|NCT04607057|No Intervention|control group (Arm B)|"Day0 : fasting(NPO) + crystalloid fluid
~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid
~POD#2 : Semifluid diet (SFD) + dextrose 5% water
~POD#3 : Semifluid diet (SFD) + dextrose 5% water
~POD#4-7: Soft blended diet (SBD)"
16310047|NCT04607031||ischemic stroke patients|20 patients with ischemic stroke, onset within 24 hours, NIHSS≥8
16310048|NCT04607018|Active Comparator|Chronic intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product already before the study started (since 28 days before or even longer)
16310049|NCT04607018|Active Comparator|Naive intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product only since the first day of the study
16310050|NCT04607005|Experimental|Participants receiving mepolizumab + Standard of care (SoC)|Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
16310051|NCT04607005|Placebo Comparator|Participants receiving placebo + SoC|Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
16310052|NCT04606992|Experimental|CELS resection|All patients included in the study will be in this arm
16310053|NCT04606979|Experimental|Parkinson Disease - Group 1a - Active tDCS first|Half of the subjects with PD will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive sham (placebo) tDCS.
16310054|NCT04606979|Sham Comparator|Parkinson Disease - Group 1b - Sham tDCS first|Half of the subjects with PD will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive active (anodal, real) tDCS.
16310055|NCT04606979|Experimental|Healthy Controls - Group 2a - Active tDCS first|Half of the healthy controls will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive sham (placebo) tDCS.
16310056|NCT04606979|Sham Comparator|Healthy Controls - Group 2b - Sham tDCS first|Half of the healthy controls will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive active (anodal, real) tDCS.
16310057|NCT04606966|Experimental|Therapeutic Horseback Riding|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual. Participants will have an assigned horse and volunteer(s) Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table for five minutes, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for two minutes while watching a 1-minute sand timer, then, participants will then don their riding helmets and enter the riding arena. Each week after conclusion of the THR intervention, participants will again sit with their group at an art table for 20 minutes followed by doing another saliva sample.
16310058|NCT04606966|Active Comparator|Barn Activity|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor. Participants will have one assigned volunteer and will have no contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse in for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table for five minutes, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for two minutes while watching a 1-minute sand timer. Each week after conclusion of the BA intervention, participants will again sit with their group at an art table for 20 minutes followed by doing another saliva sample
16310059|NCT04606966|No Intervention|Waitlist|Those assigned to the waitlist group will not have any horse-related intervention during a 10-week waiting period. Following this waiting period and the completion of post assessments, participants in this condition will begin a Hybrid group (see Hybrid Arm)
16310082|NCT04606810|Other|Arm2, Participants in arm2 received the educational intervention after 3 months|Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.
16310060|NCT04606966|Experimental|Hybrid|Participants who complete the Waitlist Arm and post assessments, will begin a Hybrid group that will consist of a 5- week one hour Barn Activity (BA) group condition that consists of a small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor. Participants will have one assigned volunteer and will have no contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse in for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM. After the first 5 weeks of BA, participants will then complete 5-weeks of Therapeutic Horseback Riding small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual. Participants will have an assigned horse and volunteer(s) Group times will be between 1:00-5:00 PM.
16310061|NCT04606953|Experimental|Attention Process Training (APT-II)|Patients in the experimental group receive the APT-II training program (Attention Process Training) individually with a psychologist for 8 weeks (2 sessions/week). The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to each patient's profile in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains towards the most problematic daily activities in order to reduce the impact of the patients' cognitive problems in their daily lives.
16310062|NCT04606953|No Intervention|Standard care|Patients in the control group receive standard routine care.
16310063|NCT04606940||IO-KIN|Patients with a histological or cytological confirmed recurrent, metastatic or advanced HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or unknown origin (but being treated as HNSCC). Patients who are going to receive at least one dose of anti-PD1 antibody (nivolumab or pembrolizumab).
16310064|NCT04606927|Active Comparator|Natriuresis guided treatment|
16310065|NCT04606927|No Intervention|Standard of care|
16310066|NCT04606914|Experimental|neoadjuvant chemotherapy regimen|"IV Carboplatin AUC 5 (Q21 days) 7 cycles (first cycle is Carbo alone, dosing for C1D1 will be provider's choice)
~IV Mirvetuximab 6 mg/kg (adjusted ideal body weight) day 1 (Q21 days) 6 cycles (starting with cycle #2)"
16310067|NCT04606901|Active Comparator|Sugammadex|Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
16310068|NCT04606901|Active Comparator|Neostigmine/Glycopyrrolate|Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade
16310069|NCT04606888|Experimental|Transcutaneous electrical acupoint stimulation group|Transcutaneous electrical acupoint stimulation group patients received Transcutaneous electrical acupoint stimulation (Neiguan [PC6], Yintang [GV 29], Zusanli [ST36]) for 30 min before the induction of anaesthesia until the end of the surgery and the night before operation, the first, second and third night after operation 30 min once a day with an altered frequency 2/100 Hz, disperse-dense waves, adjusted electricity intensity which was less than 10 mA.
16310070|NCT04606888|No Intervention|Control group|In Control group, except the electronic stimulation was not applied, the treatment was the same as the Transcutaneous electrical acupoint stimulation group.
16310071|NCT04606875||Control Group|Subjects will have no personal or family psychiatric history and no suicide attempts.
16310072|NCT04606875||Patients with Suicidal Ideation and Low Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
16310073|NCT04606875||Patients with Suicidal Ideation and High Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
16310074|NCT04606862|Experimental|Investigational Arm|The patients enrolled into the investigational arm at each participating hospital will be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis.
16310075|NCT04606862|No Intervention|Control Arm|The patients enrolled into the control group of each participating hospital will not be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis. These patients will be monitored according to each institution's standard sepsis screening practices.
16310076|NCT04606849|Other|Physician Survey|A modified version of a previously validated REDCap questionnaire will be administered to Instacare clinicians in the cluster where ePNa-CheXED was deployed via email at 6 months after ePNa-CheXED implementation. Our questionnaire includes questions on respondent demographics and Likert-style questions about respondents' experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components
16310077|NCT04606849|Other|Adapt ePNa-CheXED for InstaCares|"Adapt ePNa-CheXED for Instacares and after in silico testing, pilot it among super user clinicians during Instacare shifts and assess its usability. ePNa needs adaptation for more limited patient data available in Instacare clinics, calibration of severity measures for lower observed mortality, and a chest imaging prompt in patients with pneumonia signs and symptoms. ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion)."
16310078|NCT04606836|Experimental|Prospective Cases|These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
16310079|NCT04606836|No Intervention|Retrospective Controls|Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.
16310081|NCT04606810|Active Comparator|Arm1, Participants received the multidisciplinary educational intervention at baseline|Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
16310083|NCT04606797|Experimental|Nicotine Replacement Therapy|
16310084|NCT04606797|No Intervention|Control|
16310092|NCT04606719|Active Comparator|Standard PRF|Standard Platelet-rich fibrin will be prepared by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 3000 rpm for 10 min. After centrifugation, three layers will formed in the test tube-base layer of RBCs, top layer of a-cellular plasma, and a PRF clot in the middle. This clot will then pressed between two gauze pieces to form a membrane.
16310093|NCT04606719|Experimental|Advanced PRF|A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
16310094|NCT04606706|Experimental|Maternal, lactating mother & young child (Intervention)|mHealth education intervention for 6 months
16310095|NCT04606706|No Intervention|Maternal, lactating mother & young child (Control)|Conventional health education
16310096|NCT04606693|No Intervention|Patients with negative diagnosis of SAHS|Patients with low risk or negative diagnosis of SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit
16310097|NCT04606693|Other|Patients with positive diagnosis of SAHS|Patients with intermediate or high risk of SAHS and positive diagnosis
16310098|NCT04606680|Experimental|Heat application group|Participants will receive heat application at acupoints plus lifestyle modification. Participants will receive heat application treatment once every other day, 3 times per week, for 4 consecutive weeks.
16310099|NCT04606680|Experimental|Medicated plaster group|Participants will receive medicated plaster at acupoints plus lifestyle modification. Participants will receive medicated plaster at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
16310100|NCT04606680|Experimental|Herb-partitioned moxibustion group|Participants will receive herb-partitioned moxibustion at acupoints plus lifestyle modification. Participants will receive herb-partitioned moxibustion at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
16310101|NCT04606667|Experimental|Multi component program|"The intervention lasted 16 weeks, with the evaluations carried out at baseline, after 8 weeks and at the end.
~The multi-component exercise program took place in day centers or collective residences. It was supervised by physiotherapists. The classes took place 3 times a week, at the same hour and on alternate days, for 45-60 minutes, for a total of 48 sessions. The program consisted on a warm-up (5 min) with exercises and walking, a balance and strength training (35-40 min) with exercises repeated 3 times and held for 15 seconds flexibility / relaxation (5 to 10 mins) periods. The strength training is performed with the resistance of the body weight or accessible and low cost equipment, with two series of 10 to 15 repetitions, after maximum resistance was calculated.
~The flexibility and cooling training consists of 3 repetitions maintained for 15 seconds."
16310102|NCT04606654|Experimental|Handgrip strength training with Blood flow restriction|"Three sessions per week will be given to individual subject. and training will be with Blood flow restriction.
~Subjects will be followed for two weeks for;
~Hand grip strength
~Forearm circumference"
16310103|NCT04606654|Active Comparator|Handgrip strength training without Blood flow restriction|"Three sessions per week will be given to individual subject and training will be without Blood flow restriction.
~Subjects will be followed for two weeks for;
~Hand grip strength
~Forearm circumference"
16310104|NCT04606641|Experimental|Goal specific functional tasks with mirror therapy):|"The session will be performed thrice in a week for total of 4 weeks. Each session will last for 20 minutes. Mirror therapy procedure and functional tasks will be explained to the patient before the start of treatment.
~In this group, a mirror will be placed in the sagittal plane of the patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror"
16310105|NCT04606641|Active Comparator|Goal specific functional tasks without mirror therapy|"Session will be performed thrice in a week for total 4 weeks. Each session will last for 20 minutes.
~The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks as mentioned in the table below Functional tasks will be same in both groups"
16310106|NCT04606628|Experimental|Intervention|Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks.
16310107|NCT04606628|Experimental|Placebo|Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks.
16310108|NCT04606615||Adults: AD + FA|Adults: atopic dermatitis and food allergy to peanut
16310109|NCT04606615||Adults: AD - FA|Adults: atopic dermatitis and no food allergy
16310110|NCT04606615||Adults: NC|Adults: Normal Control
16310111|NCT04606615||Children: AD+ Peanut|Children: atopic dermatitis and food allergy to peanut
16310112|NCT04606615||Children: AD + Milk|atopic dermatitis and food allergy to milk
16310113|NCT04606615||Children: AD + Egg|atopic dermatitis and food allergy to egg
16310114|NCT04606615||Children: AD only|atopic dermatitis and no food allergy
16310115|NCT04606615||Children: NC|Normal Control
16310116|NCT04606602|Experimental|30 mg|
16310117|NCT04606602|Placebo Comparator|Placebo|
16310118|NCT04606602|Experimental|100 mg|
16310119|NCT04606602|Experimental|300 mg|
16310120|NCT04606602|Experimental|600 mg|
16310121|NCT04606602|Experimental|900 mg|
16310122|NCT04606602|Experimental|100 mg multi dose|
16310123|NCT04606602|Experimental|200 mg multi dose|
16310124|NCT04606602|Experimental|300 mg multi dose|
16310125|NCT04606602|Experimental|600 mg multi dose|
16310126|NCT04606602|Placebo Comparator|Placebo multi dose|
16310127|NCT04606589|No Intervention|Standard-of-care|The standard-of-care arm will receive intermittent monitoring of pulse rate and blood oxygen saturation with a conventional pulse oximeter. Temperature and respiratory rate will also be monitored intermittently with a digital thermometer and manual counting of breaths respectively.
16310128|NCT04606589|Experimental|neoGuard vital signs monitor|The intervention group will receive continuous vital signs monitoring of pulse rate, blood oxygen saturation, temperature and respiratory rate with the neoGuard device.
16310129|NCT04606576|Placebo Comparator|Placebo|Fish Oil
16310130|NCT04606576|Experimental|ORMD-0801 QD|8 mg ORMD-0801 administered QD at night
16310131|NCT04606576|Experimental|ORMD-0801 BID|8 mg ORMD-0801 administered at night and in the morning 45 minutes before breakfast.
16310132|NCT04606563|Experimental|Losartan|Patients will initially receive 25 mg oral losartan, increased to 50 mg after 24 hours and then increased to a max dose of 100 mg after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at 25 or 50 mg.
16310133|NCT04606563|No Intervention|Usual Care Control|Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
16310134|NCT04606550|Experimental|Vaginal Laser HR+|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
16310135|NCT04606550|Active Comparator|Vaginal Estrogen HR-|The women in the vaginal estrogen group will be prescribed and asked to administer: Conjugated estrogen cream (Premarin®): 0.5 g of cream intravaginally daily (using applicator or fingertip) for two weeks (fourteen days) then 0.5 g twice weekly for 24 ± 2 additional weeks.
16310136|NCT04606550|Active Comparator|Vaginal Laser HR-|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
16310137|NCT04606537|Experimental|Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)|
16310138|NCT04606537|Experimental|Cohort 2 (Effects of CYP3A4 induction on KBP-5074)|
16310139|NCT04606524||study group|25 postmenopausal females will be included in this study
16310140|NCT04606524||control group|25 premenopausal females will be included in this tudy
16310141|NCT04606511|Other|Breast cancer patients with lymphedema|
16310142|NCT04606511|Other|Breast cancer patients without lymphedema|
16310143|NCT04606498||1- Retrospective|Retrospective Seraph® 100 - this group will be composed of subjects that were treated with Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site. A waiver of informed consent will be requested from the Institutional Review Board (IRB) to allow the collection of these retrospective data
16310144|NCT04606498||2 - Prospective|Prospective Seraph® 100 - To identify prospective Seraph® 100 patients, the individual site investigators will review currently admitted ICU patients for inclusion criteria and exclusion criteria. The study team will then ask the physician caring for the patient to contact the study team should the patient require therapy with Seraph® 100. Additionally, the study team will review the medical records of admitted patients to see if they have recently been started on Seraph. Patients found to meet eligibility will be offered the opportunity to consent and participate in the study. Note that patients that were started on Seraph® 100 before the date of approval but are still admitted, will not be eligible to give biospecimens.
16310145|NCT04606498||3 - Historical Control|The historical control group will be a sample of convenience, composed of patients admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site. A waiver of informed consent will be requested from the IRB to allow the collection of these retrospective data
16310146|NCT04606485|Placebo Comparator|Placebo group|"Since acupressure administration was reported to have placebo effects, a placebo group was used to investigate the true effect of acupressure use. The application of placebo may consist of moderate pressure on an incorrect acupuncture point or a light touch on a real acupuncture point. This will allow us to determine the contribution of the placebo effect resulting from direct human contact and interaction in the light touch group.
~At postoperative 0, 4, and 8 hours, a light touch was applied to the ST25 (Stomach Meridian 25th point), CV12 (Conception Vessel Meridian 12th point), TH6 (Triple Heater Meridian 6th point) and HT7 (Shenmen point points) for one second. No patients experienced pain or a feeling of pressure."
16310147|NCT04606485|Experimental|Experimental group|"As invasive acupuncture may cause hematoma and the wristband method of non-invasive acupressure may cause patient discomfort, itching, swelling of the wrist, and skin destruction, manual acupressure was applied in this study to reduce the risk of complications to a minimum.
~The frequency and duration of the application of acupressure was decided from a scan of literature and expert opinion. The first acupressure session was applied in the first postoperative hour immediately after routine treatment and care of the patients who came to the ward from the recovery unit. Acupressure by applying pressure with the thumbs for a total of 12 mins, as 3 mins at each of the ST25, CV12, TH6 and HT7 acupuncture points, was performed at 0, 4 and 8 hours postoperatively. The acupuncture points were determined using the measurements of the patient's own fingers."
16310148|NCT04606472|Experimental|Study treatment|Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
16310149|NCT04606459|Active Comparator|Optimal medical therapy|"Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines.
~Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina."
16310150|NCT04606459|Experimental|Coronary sinus reducer|The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.
16310151|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 1|PF-07248144 Monotherapy Escalation
16310152|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 2|PF-07248144 Monotherapy Escalation
16310153|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 3|PF-07248144 Monotherapy Escalation
16310205|NCT04606264|Active Comparator|Orthopedic: Regional Analgesia|
16310155|NCT04606446|Experimental|1B Combination Dose Finding Arm level 1|PF-07248144 with Fulvestrant Combination Dose Finding
16310156|NCT04606446|Experimental|1B Combination Dose Finding Arm Level 2|PF-07248144 with Fulvestrant Combination Dose Finding
16310157|NCT04606446|Experimental|1C Combination Dose Finding Arm Level 1|PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
16310158|NCT04606446|Experimental|1C Combination Dose FInding Arm Level 2|PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
16310159|NCT04606446|Experimental|2A Monotherapy Dose Expansion Arm|PF-07248144 Monotherapy Dose Expansion
16310160|NCT04606446|Experimental|2B Combination Dose Expansion Arm|PF-07248144 with either Fulvestrant or Letrozole + Palbociclib Dose Expansion
16310161|NCT04606433|Experimental|Study treatment|Patients receive GNC-038 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another four cycles at the same dose level.
16310162|NCT04606420|Experimental|Experimental (Intervention) Group|These patients will receive the comprehensive lifestyle medicine intervention from day 1 through the end of the study. They will be tested at baseline, after 20 weeks, and after 40 weeks. There may be subsequent testing after 2 years.
16310163|NCT04606420|No Intervention|Control (Non-Intervention) Group|"These patients will be asked to continue their current diet and lifestyle without making any changes for 20 weeks. They will be tested at baseline and after 20 weeks. Then, they will cross over and receive the same lifestyle medicine intervention for 20 weeks and will be tested again after 20 weeks of the intervention and also after 40 weeks of the intervention. There may be subsequent testing after 2 years."
16310164|NCT04606407|Experimental|Treatment|Inhaled NO delivered using LungFit™ in addition to standard of care
16310165|NCT04606407|No Intervention|Standard of care|Standard of care
16310166|NCT04606394|Other|Open label treatment|All subjects receive Trelegy and Ventolin for 2 weeks
16310167|NCT04606381|Experimental|Part 1: Ami-LC-MD and Ami-LC|Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
16310168|NCT04606381|Experimental|Part 2: Ami-HC and Ami-HC-CF|Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
16310169|NCT04606368|Experimental|Interventional cohort|Each subject will serve as their own control. Left side of lower jaw and submental area is control side. Right side of subject's lower jaw and submentum area will receive treatment.
16310170|NCT04606355||PDI Check & Conventional|Autostereoscopic, dynamic forced choice game (ie on Nintendo 3DS) and Rosenbaum or HOTV near card, Ishihara color plates, Innova Rabin color test, Titmus Stereo test
16310171|NCT04606329|Experimental|LuminoMark inj.|Injection LuminoMark inj. 0.2mL once in this study.
16310172|NCT04606329|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
16310173|NCT04606316|Experimental|Nivolumab and Ipilimumab Before and After Surgery|"One dose of nivolumab plus ipilimumab will be administered 14(±5) days before surgery.
~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
16310174|NCT04606316|Experimental|Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab After Surgery|"One dose of nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.
~After surgery, participants receive nivolumab alone every 4 weeks."
16310175|NCT04606316|Experimental|Placebo-Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab and Ipilimumab After Surgery|"One dose of placebo-nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.
~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 12 weeks and then nivolumab alone every 4 weeks."
16310176|NCT04606303|Experimental|Toripalimab Combined With Platinum-containing Dual-agent.|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer.
16310177|NCT04606290|Active Comparator|Manual|Fixed dose oxygen
16310178|NCT04606290|Experimental|O2matic|Automated oxygen titration
16310179|NCT04606277||Young Adult|
16310180|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Hydration Gatorade:|
16310181|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Hydration CarbRich Beverage|
16310182|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Analgesia Adjunct|
16310183|NCT04606264|No Intervention|Major Abdominal: No Preoperative Oral Analgesia Adjunct|
16310184|NCT04606264|Active Comparator|Major Abdominal: Neuraxial Analgesia|
16310185|NCT04606264|Active Comparator|Major Abdominal: Regional Analgesia|
16310186|NCT04606264|Active Comparator|Major Abdominal: PONV Prophylaxis Perphenazine|
16310187|NCT04606264|Active Comparator|Major Abdominal: PONV Prophylaxis Aprepitant|
16310188|NCT04606264|Active Comparator|Major Abdominal: Primary Anesthetic Volatile Agent|
16310189|NCT04606264|Active Comparator|Major Abdominal: Primary Anesthetic TIVA|
16310190|NCT04606264|Active Comparator|Major Abdominal: Fluid Therapy Stroke Volume Optimization|
16310191|NCT04606264|Active Comparator|Major Abdominal: Fluid Therapy Maintain Euvolemia|
16310192|NCT04606264|Active Comparator|Major Abdominal: Analgesia Adjuncts Ketamine|
16310193|NCT04606264|Active Comparator|Major Abdominal: Anesthesia Adjuncts Lidocaine|
16310194|NCT04606264|Active Comparator|Major Abdominal: Anesthesia Adjuncts Ketamine and Lidocaine|
16310195|NCT04606264|No Intervention|Major Abdominal: No Anesthesia Adjuncts|
16310196|NCT04606264|Active Comparator|Major Abdominal: Intraoperative Opioid|
16310197|NCT04606264|No Intervention|Major Abdominal: No Intraoperative Opioid|
16310198|NCT04606264|Active Comparator|Major Abdominal: Postoperative Oral Analgesia Adjunct|
16310199|NCT04606264|No Intervention|Major Abdominal: No Postoperative Oral Analgesia Adjunct|
16310200|NCT04606264|Active Comparator|Orthopedic: Preoperative Oral Hydration Gatorade|
16310201|NCT04606264|Active Comparator|Orthopedic: Oral Hydration CarbRich Beverage|
16310202|NCT04606264|Active Comparator|Orthopedic: Preoperative Oral Analgesia Adjunct Gabapentin|
16310203|NCT04606264|No Intervention|Orthopedic: No Preoperative Oral Analgesia Adjunct|
16310206|NCT04606264|Active Comparator|Orthopedic: PONV Prophylaxis Perphenazine|
16310207|NCT04606264|Active Comparator|Orthopedic: PONV Prophylaxis Aprepitant|
16310208|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic Volatile Agent|
16310209|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic Spinal|
16310210|NCT04606264|Active Comparator|Orthopedic: Fluid Therapy Stroke Volume Optimization|
16310211|NCT04606264|Active Comparator|Orthopedic: Fluid Therapy Maintain Euvolemia|
16310212|NCT04606264|Active Comparator|Orthopedic: Analgesia Adjuncts Ketamine|
16310213|NCT04606264|Active Comparator|Orthopedic: Intraoperative Opioid|
16310214|NCT04606264|No Intervention|Orthopedic: No Intraoperative Opioid|
16310215|NCT04606264|Active Comparator|Orthopedic: Postoperative Oral Analgesia Adjunct|
16310216|NCT04606264|No Intervention|Orthopedic: No Postoperative Oral Analgesia Adjunct|
16310217|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic TIVA (Propofol)|
16310218|NCT04606251|Experimental|Arm 1: Exercise Group|This group will consist of the subjects taken for 6 weeks of exercise.
16310219|NCT04606251|No Intervention|Arm 2: Control Group|This group will consist of the subjects who did not receive any intervention for 6 weeks and were evaluated before and after 6 weeks.
16310220|NCT04606238|No Intervention|Group without DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
16310221|NCT04606238|Other|Group with DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
16310222|NCT04606225|Experimental|Losartan group|Drug: Losartan
16310223|NCT04606225|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
16310224|NCT04606212|Experimental|Losartan group|
16310225|NCT04606212|Placebo Comparator|Placebo group|
16310226|NCT04606199|Experimental|Mindfulness-based intervention|Participants will be randomly assigned to an app-based intervention that includes brief (<5 min) audio-guided mindfulness and compassion-based practices.
16310227|NCT04606199|No Intervention|No intervention|Participants will continue their normal activities and not practice any form of mindfulness mediation at the time of app-notification.
16310228|NCT04606186|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
16310229|NCT04606186|Placebo Comparator|Placebo-lozenges (BioGaia)|
16310230|NCT04606173|Experimental|Standard Practice plus TEACH|Primary care teamlets will receive standard organizational education and support regarding suicide prevention and also engage in Team Education for Adopting Changes in Healthcare (TEACH) huddles.
16310231|NCT04606173|No Intervention|Standard Practice|Standard Practice condition will involve the current evidence-based support included in web-based provider-trainings and electronic medical record reminders/templates that are standard within an organization
16310232|NCT04606160|Experimental|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
16310233|NCT04606160|No Intervention|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
16310234|NCT04606147|Experimental|Group 1 ((Serratus Anterior Plane Block SAPB)) N=3o|Patients received Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
16310235|NCT04606147|Experimental|Group 2 ((Erector Spinae Plane Block ESPB)) N=3o|Patients received Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
16310236|NCT04606134|Experimental|Experimental|
16310237|NCT04606134|Placebo Comparator|Control|
16310238|NCT04606108|Experimental|Experimental|camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention
16310239|NCT04606095|Experimental|Aim 1 - Healthy control|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
16310240|NCT04606095|Experimental|Aim 1 - Fibromyalgia participant|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
16310241|NCT04606095|Experimental|Aim 3 - HD-tDCS of M1|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
16310242|NCT04606095|Experimental|Aim 3- HD-tDCS of ES|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
16310243|NCT04606095|Sham Comparator|Aim 3 - Sham|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
16310244|NCT04606082|Experimental|Group 1|Granulocyte Colony Stimulated Factor was intrauterine injected once at ovum pick up day
16310245|NCT04606082|Active Comparator|Group 2|500 IU Human Chorionic Gonadotropins was injected intrauterine once at ovum pick up day
16310246|NCT04606069|Experimental|Active Arm|Regadenoson will be given intravenously as 5 ug/kg loading dose (up to 400 mg/patient) over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
16310247|NCT04606069|Placebo Comparator|Control Arm|The same volume of saline will be given intravenously for 30 mins followed by a continuous infusion for 6 hours.
16310248|NCT04606056||Patients who underwent contrast enhanced CT scans|
16310249|NCT04606043|Experimental|Sandblasting|The enamel surfaces will be subjected to sandblasting prior to acid etching
16310250|NCT04606043|Active Comparator|Acid Etching Alone|Acid etching will be applied alone before the rebounding procedures
16310251|NCT04606030|Experimental|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
16310252|NCT04606030|Active Comparator|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
16310253|NCT04606017||Vitamain D|This group of patients were supplemented with 125IU/d Vitamin D
16310254|NCT04606017||Control|The other group did not receive the supplementation of 125IU/d Vitamin D
16310255|NCT04606004|Experimental|Experimental (standard of care + stool application)|In addition to standard of care, they will apply stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time.
16310256|NCT04606004|Active Comparator|Control group (standard of care)|Will follow standard of care for skin care pre-operatively. They will not be applying ostomy stool output to the skin but can apply an OTC skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.
16310258|NCT04605978|Experimental|S95011 concentrate for solution for infusion|S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
16310259|NCT04605978|Placebo Comparator|S95011 Placebo concentrate for solution for infusion|S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
16310260|NCT04605952||SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020|As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days
16310261|NCT04605939|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated lievr fibrosis for 68Ga-DOTA-FAPI PET/MR imaging.
16310262|NCT04605926|Experimental|EQ001|EQ001 administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
16310263|NCT04605926|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
16310264|NCT04605913|Experimental|Modified GCN+TTF treatment|The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
16310265|NCT04605900|Experimental|Standard Footwear (SF)|Intervention: plantar orthoses, education on foot self-care and appropriate standard footwear.
16310266|NCT04605900|Experimental|Orthopedic Footwear (OF)|Intervention: plantar orthoses, education on foot self-care and orthopedic footwear.
16310267|NCT04605887|Active Comparator|treatment group|Ang 1-7 subcutaneously 500 mcg/kg /day
16310268|NCT04605887|Placebo Comparator|control group|NaCl 0.9% subcutaneously 2.0 cc once a day
16310269|NCT04605874|Experimental|2 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 2 cigarillos per pack.
16310270|NCT04605874|Experimental|4 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 4 cigarillos per pack.
16310271|NCT04605861|Experimental|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on abdomen, thigh or upper arm.
16310272|NCT04605861|Placebo Comparator|Placebo|Placebo (Liraglutide Injection simulator), once a day, injected subcutaneously on abdomen, thigh or upper arm.
16310273|NCT04605848|Experimental|BAT group|"Patients will be divided in two groups for statistical analysis:
~patients with detectable BAT by PET-CT (BAT+)
~patients with no detectable BAT by PET-CT (BAT-)"
16310274|NCT04605835||Main group|484 children with congenital obstructive uropathies
16310275|NCT04605809|Experimental|combined motor and cognitive training|The combined motor and cognitive training group will undertake physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training.
16310276|NCT04605809|Active Comparator|motor training alone|The motor training alone group will train the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group.
16310277|NCT04605809|Active Comparator|cognitive training alone|The cognitive training alone group will train the same set of cognitive training while sitting as the combined motor and cognitive training group.
16310278|NCT04605809|No Intervention|no intervention control group.|No intervention control group will maintain habit and daily activity.
16310279|NCT04605796|Experimental|Single Arm|"Experimental group:
~Toripalimab combined with Bevacizumab"
16310280|NCT04605783|Experimental|Bimuno®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
16310281|NCT04605783|Experimental|Florastor®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
16310282|NCT04605783|Experimental|Travelan®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
16310283|NCT04605783|Placebo Comparator|Placebo|Placebo will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
16310284|NCT04605770|Experimental|pemetrexed+cisplatin|Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.
16310285|NCT04605757||Patients with acute respiratory failure due to SARS-COV-2|Patients admitted to hospital with acute respiratory failure due to SARS-COV-2 infection causing pneumonia
16310286|NCT04605731|Experimental|Treatment (durvalumab, tremelimumab)|Patients undergo standard of care radioembolization with Yttrium-90 SIR-spheres intra-arterially over 60-90 minutes on day -14. Patients then receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on day 1. Cycles with durvalumab repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
16310287|NCT04605718|Experimental|Part 1 (SAD)|Due to mandatory sentinel dosing, participants will be divided into two groups: 2 participants will be dosed on one day (sentinel group with 1 on active treatment and 1 on placebo) and remaining participants of the dose cohort (randomized as 5 on active treatment and 1 on placebo) at the earliest 24 hours after the first dosing occasion.
16310288|NCT04605718|Experimental|Part 2 (MAD)|In each dose cohort, a minimum of 4 participants and a maximum of 12 participants will receive either multiple IV doses of RO72232809 or placebo daily for 10 days (3:1 ratio of active:placebo treatment). Based upon the review of emerging data, there will be the option to adjust the number of participants on active treatment and placebo per dose level.
16310289|NCT04605705||Group 1|NIRS values will be recorded during the surgery and until 24 hours postoperatively. No intervention will be done.
16310290|NCT04605705||Group 2|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
16310291|NCT04605679|Experimental|Recipient of HCV positive kidney graft|A single center, open-label, pilot study examining 20 adult HCV negative kidney transplant patients who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after kidney transplantation, unless extenuating clinical circumstances arise (such as the development of fibrosing cholestatic HCV, which would prompt earlier treatment, or clinical events or comorbidities which would prompt delay in treatment).
16310292|NCT04605666|Experimental|CAR-T group|
16310293|NCT04605653|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
16310294|NCT04605640|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
16310295|NCT04605627||Chronic coronary syndrome|50 patients with chronic coronary disease
16310296|NCT04605627||Non ST segment-elevation myocardial infarction|75 patients with non ST-elevation myocardial infarction
16310297|NCT04605627||ST-elevation myocardial infarction|75 patients with ST segment-elevation myocardial infarction
16310298|NCT04605614|Experimental|Treatment (pembrolizumab, 64Cu-DOTA-pembrolizumab, PET)|Patients receive pembrolizumab IV over 30 minutes, and within 6 hours also receive 64Cu-DOTA-pembrolizumab via slow IV push over > 1 minute on day 0. Patients then undergo PET over 60 minutes on day 1.
16310299|NCT04605601|Experimental|Study Group|
16310300|NCT04605601|Other|Control Group|
16310301|NCT04605588|Active Comparator|Active Study Drug|5 day dosing of Nitazoxanide, Ribavirin & Hydroxychloroquine sulfate
16310302|NCT04605588|Placebo Comparator|Placebo|5 day dosing of placebo
16310303|NCT04605575|Experimental|Pyrotinib plus vinorelbine|
16310304|NCT04605562|Experimental|IC+CCRT with palbociclib|If patients were non-Immune Subtype.
16310305|NCT04605562|Experimental|IC+CCRT with galunisertib and PD-1 blocking antibody|If patients were Evaded Immune Subtype.
16310306|NCT04605562|Experimental|IC+CCRT with PD-1 blocking antibody|If patients were Active Immune Subtype.
16310307|NCT04605549|Experimental|CIN-107 Dose 1|
16310308|NCT04605549|Experimental|CIN-107 Dose 2|
16310309|NCT04605549|Experimental|CIN-107 Dose 3|
16310310|NCT04605549|Placebo Comparator|Placebo for CIN-107|
16310311|NCT04605536|Other|Intervention|Give explanations about conventional capsule endoscopy and watch animation videos
16310312|NCT04605536|Other|Control|Give explanations about conventional capsule endoscopy
16310313|NCT04605523||Patients with Ataxia Telangiectasia|
16310314|NCT04605523||Healthy controls|
16310315|NCT04605510|Experimental|Intervention Group|24 female participants with non-specific neck pain included in the mobilization group will undergo detailed manual cervical examination. In the evaluation, the most painful segment with dysfunction will be selected and mobilization application and algometric measurements will be performed on this segment. Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied in 3 sets, 30 seconds, to the segment with the detected dysfunction.
16310316|NCT04605510|No Intervention|Healthy Control Group|Healthy volunteer participants included in the control group will only be applied an evaluation protocol and blood samples will be taken without any application.
16310317|NCT04605497|Experimental|Intervention Arm|Use of Dexcom G6 real-time CGM to monitor blood glucose levels continually.
16310318|NCT04605497|Other|Referent Arm|Self-capillary blood glucose monitoring (SCBG) testing 4x/day with blinded CGM every 2 weeks.
16310319|NCT04605484|Experimental|Posoleucel|Cohort A, Arm 1: Regimen A
16310320|NCT04605484|Experimental|Posoleucel and Placebo|Cohort A, Arm 2: Regimen B
16310321|NCT04605484|Placebo Comparator|Placebo|Cohort A, Arm 3: Regimen A
16310322|NCT04605484|Experimental|Cohort B, Arm 1|Following interim analysis, optimal posoleucel dosing regimen from Cohort A
16310323|NCT04605484|Placebo Comparator|Cohort B, Arm 2|Same dosing interval as Cohort B, Arm 1
16310350|NCT04605289|Experimental|Group I (study group)|Scaling and root planing + intra-pocket application of 2% Cymbopogon citratus (lemon-grass) gel
16310324|NCT04605471||PMS I study|"'PMS I' was conducted in contrast-enhanced X-ray examination between June 1999 and November 2003 in 27 countries in Europe, Africa and Asia and comprised 74,717 patients of which 2,172 were children and 32,103 were elderly patients.
~Ref. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11."
16310325|NCT04605471||IMAGE study|"'IMAGE' consists of 44,835 patients with contrast-enhanced X-ray examination and was conducted in 21 European and Asian countries from February 2008 to September 2009, 1,451 patients were children, and 15,654 were elderly patients.
~Ref. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang SX, et al. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012;53(2):179-86."
16310326|NCT04605471||TRUST study|"'TRUST' assessed the safety and tolerability of Ultravist in patients undergoing cardiac catheterization. It was conducted from August 2010 to September 2011 in China and included 17,513 patients of which 12 were children and 8,918 were elderly patients.
~Ref. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015;31(7):1281-91."
16310327|NCT04605471||Ultravist in CT study|"'Ultravist in CT' was performed with focus on contrast-enhanced CT examination between November 2006 and December 2008 and included 15,168 patients in Germany, Iran, Romania and Saudi Arabia. A total of 417 patients were children, 7,453 were elderly patients.
~Ref. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014;55(6):707-14."
16310328|NCT04605458|Experimental|Contingency Management|
16310329|NCT04605458|Active Comparator|Standard Care|
16310330|NCT04605445|Experimental|1 visit endodontics|Root canal treatment is performed in one visit.
16310331|NCT04605445|Active Comparator|2 visits endodontics|Root canal treatment is performed in two visits.
16310332|NCT04605432|Experimental|PEG-FFI prep|"On the day before colonoscopy, an experienced researcher would go to the ward to have a face-to-face conversation with the patient to know if patients have the risk factors for bowel preparation failure.
~The bowel preparation regimens for patients with risk factors would be optimized. In addition to drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min, the patient also drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at 20:00- 21:00 hours on the day before the colonoscopy. Patients without risk factors drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
~Patients would received a booklet to explain the details of diet restriction, preparation method and the pictures of bowel preparation of results.The researcher would give a detailed oral explanation of the booklet."
16310333|NCT04605432|Active Comparator|PEG-nonFFI prep|Patients in the PEG-nonFFI group would only receive routine patient education on bowel preparation of colonoscopy, which was completed by ward nurse. all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
16310334|NCT04605419|Experimental|Calcium electroporation|Calcium chloride
16310335|NCT04605393|Experimental|Placebo/THC|Oral placebo followed by inhalation of cannabis containing THC.
16310336|NCT04605393|Experimental|CBD/THC|Oral CBD 1000mg followed by inhalation of cannabis containing THC.
16310340|NCT04605367|Experimental|100% PP, a-TDCS|"After the pre-test:
~repetition of the correct sequence as many times as possible (12 blocks of 30s).
~After the post-test:
~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
16310341|NCT04605367|Experimental|100% PP, sham TDCS|"After the pre-test :
~physical repetition of the correct sequence as many times as possible, during 12 blocks of 30s.
~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
16310342|NCT04605367|Experimental|100% MP, a-TDCS|"After the pre-test :
~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.
~After the post-test:
~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm².)"
16310343|NCT04605367|Experimental|100% MP, sham TDCS|"After the pre-test :
~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.
~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
16310344|NCT04605367|Experimental|50% MP and 50% PP, a-TDCS|"After the pre-test :
~mental repetition of the correct sequence as many times as possible, during 6 blocks of 30s. Then physical repetition of the correct sequence as many times as possible, during 6 blocks of 30s.
~After the post-test : they will receive the real stimulation. Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
16310345|NCT04605367|Experimental|50% MP and 50% PP, sham TDCS|For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
16310346|NCT04605367|No Intervention|No practice, No stimulation|After the pre-test, this group will read an article for 12 minutes. After this training, they will perform the post-test. Immediately after this, they will read another article during 15 minutes.
16310347|NCT04605341|Active Comparator|group one|patient with metacarpal fracture that will use minipate for fixation
16310348|NCT04605341|Active Comparator|gruop two|patient with metacarpal fracture that will use buried k wires for fixation
16310349|NCT04605302|Experimental|Single Arm Tandem Study|Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy
16310351|NCT04605289|Placebo Comparator|Group II (control group)|Scaling and root planing +intra-pocket application of placebo gel
16310352|NCT04605276||Pre-biopsy cohort|"Male patients of age ≥18 suspected for prostate cancer who are scheduled for systematic and/or targeted biopsy after mpMRI examination.
~No intervention study"
16310353|NCT04605276||Pre-radical prostatectomy cohort|Male patients of age ≥18 diagnosed with prostate cancer who are scheduled for radical prostatectomy
16310354|NCT04605263|Active Comparator|STN DBS|Subjects will receive traditional bilateral STN devices and stimulation.
16310355|NCT04605263|Experimental|STN-PPN DBS|Patients will be implanted with both bilateral STN and bilateral PPN devices. These patients will undergo a crossover between 3 and 15 months post-op in which they will double-blindly receive PPN stimulation for six months and have stimulation turned off for six months. All patients will receive stimulation from 0-3 months post-op (mapping visits occur in this window) and from 15-27 months.
16310356|NCT04605250|Other|Adults undergoing abdominal surgery with laparotomy|Respiratory variability before and after abdominal surgery
16310357|NCT04605224||Culinary class (intervention group)|The culinary class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
16310358|NCT04605224||Social studies class (control group)|The social studies class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
16310359|NCT04605211|Experimental|Being Present (Supportive Care)|Patients and caregivers receive Being Present intervention consisting of online audio-based mindfulness meditation exercise over 15 minutes at least 5 times per week, daily meditation reminders, and online webinars over 30-60 minutes every week.
16310360|NCT04605198|Experimental|Modified Mindfulness-based Stress Reduction|
16310361|NCT04605198|Active Comparator|Health Promotion Attention Control|
16310362|NCT04605185|Experimental|Donafenib/JS001/TACE|Donafenib and JS001 Combined With TACE
16310363|NCT04605172||Lockdown Group|newborn born prematurely during confinement (1st March - 1st June 2020)
16310364|NCT04605172||Control group|newborn born prematurely in comparative years over the same period (1st March - 1st June from 2015 to 2019)
16310365|NCT04605159|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group will receive a single dose of RSV MAT vaccine at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm
16310366|NCT04605159|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group will receive a single dose of Placebo at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm
16310367|NCT04605146|Experimental|Tele-monitoring group|"In the experimental group, in addition to routine practice, each patient will benefit of a tele-monitoring of one year, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.
~50 patients are expected in this arm."
16310368|NCT04605146|No Intervention|Control group|"In the control group, patients will have a routine follow-up as per institutional practice, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.
~50 patients are expected in this arm."
16310369|NCT04605133||ARDS|Patients with mild or severe ARDS necessitating of prone position during mechanical ventilation
16310370|NCT04605120|Experimental|Allogeinic Bone Paste|Supercritical CO2 viral-inactivated allogeinic bone paste derived from human living donor femoral heads
16310371|NCT04605107|Experimental|A test|Epifasi 5000 I.U. Ampoules
16310372|NCT04605107|Active Comparator|B reference|Pregnyl 5000 I.U. Ampoules
16310373|NCT04605094|Experimental|Benralizumab|
16310374|NCT04605094|Experimental|Placebo / Benralizumab|
16310377|NCT04605068|Active Comparator|Transverse preputial island flap (Duckett's technique)|72 patients (Group I) with penoscrotal hypospadias with chordee
16310378|NCT04605068|Active Comparator|Double-faced preputial flap (DFPF)|72 patients (Group II) with penoscrotal hypospadias with chordee
16310379|NCT04605055|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
16310380|NCT04605055|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
16310381|NCT04605042|Experimental|WET First group|COOK ECHO-HD 22-C EchoTip Procore needle biopsy in WS-SNP-WS-SNP sequence
16310382|NCT04605042|Experimental|STANDARD first group|COOK ECHO-HD 22-C EchoTip Procore needle in SNP-WS-SNP-WS sequence
16310383|NCT04605029||Critically Ill patients|No Intervention
16310384|NCT04605016|Experimental|Hydrophilic surface implants|
16310385|NCT04605016|Active Comparator|Hydrophobic surface implants|
16310386|NCT04605003|Active Comparator|Conventional Autoclave|The conventional autoclave is the gold standard of sterilising all medical equipments.
16310387|NCT04605003|Active Comparator|Novel rig-S|A novel devise used with the high level disinfectant
16310388|NCT04604977|Other|Mindfulness by Smartphone|an approach that is alternative to current practice, particularly as far as reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness
16310389|NCT04604964||Patients undergoing recto-sigmoid resection plus anastomosis|Patients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
16310390|NCT04604951|Experimental|Moderate|Group 1: Moderate 2 times per week transcutaneous spinal cord stimulation.
16310391|NCT04604951|Experimental|Intensive|Group 2: Intensive 5 times per week transcutaneous spinal cord stimulation.
16310392|NCT04604938|Experimental|Losartan group|Drug: Losartan
16310393|NCT04604938|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
16310394|NCT04604925||Remote patient monitoring for hypertension|RPM Integration: All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
16310395|NCT04604925||Usual care|Matching patients from control practices will be selected from remaining Northwestern Medical Group primary care sites and be chosen to provide as sufficiently large number of eligible patients for comparison. These groups will contribute EHR data through the NM EDW but will not have any new procedures put in place
16310396|NCT04604912||Peanut-allergic patients' group|The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
16310397|NCT04604912||Control group|The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.
16310398|NCT04604899|Experimental|Retreated subjects|Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
16310399|NCT04604886|Experimental|Passive Leg Raising|Passive leg raising (PLR) test is used to predict fluid responsiveness, which is performed by raising the legs of the patient to 45°. Cardiac output will be collected from both PAC and LiDCO before and after PLR.
16310400|NCT04604886|Experimental|Dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
16310401|NCT04604873|No Intervention|No hospital one day care|No hospital one day care
16310402|NCT04604873|Other|Hospital one day care|Hospital one day care
16310403|NCT04604860|Experimental|EL-FIT|Patients using the EL-FIT app
16310404|NCT04604847|Other|Total knee arthroplasty|patient operated for a total knee arthroplasty
16310405|NCT04604834|Experimental|PFAT first|1 eyedrop of PFAT every 2 hours in study eye.
16310406|NCT04604834|Experimental|APRP first|1 eyedrop of APRP every 2 hours in study eye.
16310407|NCT04604834|Experimental|APRP+PFAT first|1 eyedrop of PFAT and APRP every 2 hours in study eye.
16310408|NCT04604821|Experimental|Enhanced Milieu Teaching|Child-caregiver dyads receive up to 24 speech-language therapy sessions (50minutes, 2x per week for 3 months) where parents are taught by the interventionist to use Enhanced Milieu Teaching Strategies. Children and their families may continue to participate community-based educational programs.
16310409|NCT04604821|Other|Community Treatment as Usual|Child-caregiver dyads may continue to participate in community-based educational programs. Researchers provide up to 4 educational sessions to caregivers (50 minutes, every 3 weeks). During educational sessions parents are taught developmental milestones from the CDC Learn the Signs Act Early Public Health Campaign.
16310410|NCT04604808||Non hypocalcemic group|Patients that don't develop post-thyroidectomy hypocalcemia
16310411|NCT04604808||Hypocalcemic group|Patients that develop post-thyroidectomy hypocalcemia
16310412|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,3,4,intravenous (IV) microdose and placebo (Sequence A)|In Part A, participants will receive dose levels (DLs) 1, 3, 4, IV microdose of GSK3915393, and placebo in a pre-determined sequence (Sequence A). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data.
16310413|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,4,IV microdose and placebo (Sequence B)|"In Part A, participants will receive dose levels 1, 2, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence B).
~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
16310414|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,3,IV microdose and placebo (Sequence C)|"In Part A, participants will receive dose levels 1, 2, 3, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence C).
~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
16310415|NCT04604795|Experimental|Part A:GSK3915393 DLs 2,3,4,IV microdose and placebo (Sequence D)|"In Part A, participants will receive dose levels 2, 3, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence D).
~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
16310416|NCT04604795|Experimental|Part B: Cohort 1: Participants receiving GSK3915393 DL X|Participants will receive GSK3915393 dose level X twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A.
16310417|NCT04604795|Placebo Comparator|Part B: Cohort 1: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level X during Part B of the study.
16310418|NCT04604795|Experimental|Part B: Cohort 2: Participants receiving GSK3915393 DL Y|Participants will receive GSK3915393 dose level Y twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
16310419|NCT04604795|Placebo Comparator|Part B: Cohort 2: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Y twice daily during Part B of the study
16310420|NCT04604795|Experimental|Part B: Cohort 3: Participants receiving GSK3915393 DL Z|Participants will receive GSK3915393 dose level Z twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
16310421|NCT04604795|Placebo Comparator|Part B: Cohort 3: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Z twice daily during Part B of the study.
16310422|NCT04604795|Experimental|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+water/GSK3915393+GFJ/GSK3915393+ITZ (Sequence A)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and itraconazole (ITZ) in period 2. Participants will then receive oral GSK3915393 plus water in period 3, oral GSK3915393 plus grape fruit juice (GFJ) in period 4 and oral GSK3915393 plus ITZ in period 5.
16310423|NCT04604795|Experimental|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+GFJ/GSK3915393+water/GSK3915393+ITZ (Sequence B)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and ITZ in period 2. Participants will then receive oral GSK3915393 plus GFJ in period 3, oral GSK3915393 plus water in period 4 and oral GSK3915393 plus ITZ in period 5.
16310424|NCT04604782|Experimental|adolescents aged 12 to <18 years|
16310425|NCT04604782|Experimental|children aged 2 to <12 years|
16310426|NCT04604782|Experimental|infants aged 1 to <24 months and who weigh at least 3 kg|
16310427|NCT04604769||Daily routine, control group|ICU medical staff were asked about their stress and causes of stress during their daily professional life.
16310428|NCT04604769||During Covid-19|ICU medical staff were asked about their stress and causes of stress in their daily professional life during COVID-19 crisis.
16310429|NCT04604756|Experimental|Losartan group|Drug: Losartan
16310430|NCT04604756|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
16310431|NCT04604743|Experimental|Intervention|2 Clinics
16310432|NCT04604743|No Intervention|Control|2 Clinics
16310433|NCT04604730|Experimental|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
16310434|NCT04604730|Active Comparator|Anastomosis with protective stoma|Anastomosis with protective stoma
16310435|NCT04604717|Experimental|Pulmonary rehabilitation|8 weeks of pulmonary rehabilitation (twice weekly training) Exercise and education sessions accompanied by home exercise program
16310436|NCT04604717|No Intervention|Control group|Usual medical treatment for 8 week period
16310437|NCT04604704|Experimental|Treatment with LDN and NAD+|LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of tablets. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.
16310438|NCT04604691|Experimental|Blinatumomab Treatment|
16310439|NCT04604678|Experimental|Treatment with Metformin and LDN|Patients will be treated with 1500 mg/day of metformin and 4.5 mg/day of LDN for a total of 4 weeks.
16310440|NCT04604678|No Intervention|Regular health care comparison group|Patients will receive regular health care and will serve as a control group.
16310441|NCT04604665|Experimental|High frequency postural change|"Repositioning or rotation of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency. It has to be performed on each patient between an interval less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to the right lateral, supine, left lateral, supine, or prone position to supine position. The repositioning will be provided until a patient is discharged from ICU, die or begin ambulation. When providing each repositioning, avoid dragging the patient, the shear, and the friction to increase UPP risk. This must be applied to avoiding massage. Patients in any position should use pressure-reducing items such as pillows."
16310442|NCT04604665|Active Comparator|Conventional care|Repositioning or rotation of patients hospitalized will be the conventional or usual care. Units in this group are not going to receive any intervention. Will be only observed in their current intervention of repositioning.
16310443|NCT04604652|Experimental|Open-label|HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
16310444|NCT04604639||Out-of-hospital cardiac arrest|Patients suffering an out-of-hospital cardiac arrest to who the ambulance service was requested to attend.
16310445|NCT04604626||Population 1|Adults and children with severe obesity ie (BMI> 35 kg / m² for adults and Z BMI score> 3DS for age and sex for children) and / or eating disorders with genetic diagnosis as part of care.
16310446|NCT04604626||Population 2|Adults and children with obesity and / or eating disorders hypothalamic lesion (craniopharyngioma example).
16310447|NCT04604613||Ancillary-Correlative (biospecimen collection, node mapping)|Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.
16310448|NCT04604600|Experimental|amyloid PET、T807 PET|PET/CT
16310449|NCT04604587|Experimental|amyloid PET、T807 PET|PET/CT
16310450|NCT04604574|Other|Pre/Post-Intervention|Patients who receive the novel IHSS intervention will be compared to historical controls who received the abstinence-based treatment model.
16310451|NCT04604561||Participants receiving SmartClip|Participants will undergo a preoperative physical exam and at least one preoperative ultrasound demonstrating the mass for resection. The SmartClip will be placed under ultrasound guidance. Post-placement mammogram will be obtained after placement of the clip. The SmartClip can be placed up to 30 days prior to the planned surgical resection. At the time of definitive surgery, the Envisio system will be used to identify the clip and the targeted lesion for resection. Intraoperatively, a specimen radiograph will be performed to confirm the presence of the SmartClip and the targeted lesion in the surgical specimen. The breast surgical specimen will be sent for gross examination, including measurements of the tumor in 3 axes. Immediately post-procedure, the performing surgeon will fill out a questionnaire to determine the ability of localizing in-breast lesions using the Envisio Navigation and SmartClip system in surgery.
16310452|NCT04604561||Radiologist Placing SmartClip|Radiologist will place SmartClip under ultrasound guidance. A Post-placement mammogram will be obtained after placement of the SmartClip. Immediately post-procedure, the performing radiologist will fill out a questionnaire.
16310453|NCT04604561||Surgeon|The surgeon will use the EnVisio™ Navigation System to identify the SmartClip and the targeted lesion for resection. Immediately post-procedure, the performing surgeon will fill out a questionnaire
16310553|NCT04603833|Active Comparator|SHR3680|
16310455|NCT04604535|Active Comparator|Concentrated beetroot juice|70mL of concentrated beetroot juice with 400mg nitrate
16310456|NCT04604535|Placebo Comparator|Placebo|70mL of concentrated beetroot juice with <0.01mmol/L nitrate
16310457|NCT04604522||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of blood samples and 3 brushings of the airway during SOC bronchoscopy. After the bronchoscopy, patients undergo 2 nasal brushings (swabs). Patients' medical records are also reviewed for data collection.
16310458|NCT04604509|Experimental|Group I (varenicline, counseling)|Participants receive varenicline PO daily or BID for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
16310459|NCT04604509|Experimental|Group II (NRT, counseling)|Participants receive NRT consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
16310460|NCT04604509|Experimental|Group III (varenicline or NRT, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 additional weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
16310461|NCT04604509|Experimental|Group IV (varenicline or NRT, counseling)|Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
16310462|NCT04604509|Experimental|Group V (higher dose varenicline or NRT, counseling)|Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
16310463|NCT04604509|Experimental|Group VI (varenicline or NRT, bupropion, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion PO daily for 6 weeks and behavioral smoking cessation counseling.
16310464|NCT04604509|Experimental|Group VII (varenicline and NRT, counseling)|Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling.
16310465|NCT04604496|Experimental|PF-06882961 participants without Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
16310466|NCT04604496|Experimental|PF-06882961 participants with mild Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
16310467|NCT04604496|Experimental|PF-06882961 participants with moderate Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
16310468|NCT04604496|Experimental|PF-06882961 participants with severe Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
16310469|NCT04604483|Experimental|PTNS|Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.
16310470|NCT04604470||Standard treatment|Chemotherapy Chemoradiotherapy Radiotherapy Immunotherapy Or a combination of above
16310471|NCT04604470||ImmunoSABR treatment|"SABR combined immunotherapy
~Radiotherapy combined immunotherapy"
16310472|NCT04604457|No Intervention|Standard of Care|Palliative care specialists would not reach out to primary care providers. Palliative care needs would be met via existing mechanisms.
16310473|NCT04604457|Experimental|Predictive Model|Palliative care specialists review recommendations from the predictive model and contact a patient's primary care provider (PCP) when appropriate to recommend a palliative care consult.
16310474|NCT04604444|Experimental|Multimodal Intensive Rehabilitation of Aphasia/AOS (MIRAA)|A minimum of 3 hour speech-language training daily during 10 days.
16310475|NCT04604431|Experimental|Intervention (CDS Tool Integrated)|Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.
16310476|NCT04604431|No Intervention|Control (No CDS Tool Integrated)|No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.
16310477|NCT04604405|Experimental|photobiomodulation|Eyes are irradiated with 650nm low energy red light
16310478|NCT04604405|No Intervention|blank|no intervention except for wear glasses
16310479|NCT04604392|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
16310480|NCT04604392|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
16310481|NCT04604392|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
16310482|NCT04604366|Active Comparator|vaginal mesoprostol|Vaginal dose---800 microgram 3 hourly two doses
16310483|NCT04604366|Experimental|sublingual mesoprostol|Sub lingual 600 microgram 3 hourly two doses
16310484|NCT04604353|Experimental|PRS score group|Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation
16310485|NCT04604353|Active Comparator|CCS score group|Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation
16310488|NCT04604327|Active Comparator|Prophylactic bemiparin (3,500 IU/day)|Bemiparin 3,500 IU daily for 10 days
16310489|NCT04604327|Experimental|Full therapeutic bemiparin (weight adjusted)|Bemiparin at full therapeutic dose, adjusted to body weight, for 10 days
16310490|NCT04604314|Experimental|Endocrown Onlay Restoration|Endocrown onlay preparation = Buccal and lingual walls are intact with an occlusal-gingival height at least equal to half the original crown height of the tooth. Remaining buccal and lingual walls maintain a thickness ≥ 2.0 mm.
16310491|NCT04604314|Experimental|Endocrown Shoulder Restorations|Endocrown shoulder preparation = Buccal and/or lingual walls are less than half the original occlusal-gingival height of the tooth or the buccal or lingual surfaces were previously prepared axially due to a prior restoration.
16310492|NCT04604301|Experimental|Crown, 1.0mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.0 mm delivered with a conventional Calcium Aluminate Ionomer cement
16310493|NCT04604301|Experimental|Crown, 1.5mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.5 mm delivered with a conventional Calcium Aluminate Ionomer cement
16310494|NCT04604301|Experimental|Crown, 1.0mm thickness, dual cure resin cement|occlusal thickness of 1.0 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
16310495|NCT04604301|Experimental|Crown, 1.5mm thickness, dual cure resin cement|occlusal thickness of 1.5 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
16310496|NCT04604275|Experimental|Sucrase intervention followed by placebo|Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
16310497|NCT04604275|Experimental|Placebo followed by sucrase intervention|Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.
16310498|NCT04604262|Experimental|Treatment Group|Waterpik® in addition to the manual toothbrush
16310499|NCT04604262|No Intervention|Control|Manual toothbrush
16310500|NCT04604236|Experimental|Mapping Enhanced Counseling (MEC)|MEC will target attitudes and norms. Attitudes include motivation for change, such as problem recognition and a belief that treatment will help. Subjective norms include normative beliefs about SU in adolescence (e.g., belief that it is ok to allow SU with parental supervision; experimentation is normal) and expectations about treatment.
16310501|NCT04604236|Experimental|Active Linkage (AL)|AL will target perceived control. Perceived control includes perceived logistical barriers and the degree to which individuals feel they can overcome them.
16310502|NCT04604223|Experimental|Pioglitazone|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total.
16310503|NCT04604223|Placebo Comparator|Placebo|Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
16310504|NCT04604210|Experimental|Dysphoric target|"The dysphoric target is a region in the dorsolateral prefrontal cortex. TMS targeted to this region has been shown to be more effective for depression than anxiety."
16310505|NCT04604210|Experimental|Anxiosomatic target|"The anxiosomatic target is a region in the dorsomedial prefrontal cortex. TMS targeted to this region has been shown to be more effective for anxiety than depression."
16310508|NCT04604184|Experimental|Treatment group|
16310509|NCT04604184|Placebo Comparator|Placebo group|
16310510|NCT04604171|Experimental|Action Observation Training|Conventional treatment for 60 mins plus Action Observation Training for 30 mins
16310511|NCT04604171|Active Comparator|Task Oriented Training|Conventional treatment for 60 mins plus Task Oriented Training for 30 mins
16310512|NCT04604158|Experimental|Elly Mobile Phone Application|
16310513|NCT04604145|Other|Positive NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a positive NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
16310514|NCT04604145|Other|Negative NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a negative NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
16310515|NCT04604132|Experimental|Derazantinib|In Substudies 1 and 3.1, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib.
16310516|NCT04604132|Experimental|Derazantinib-paclitaxel-ramucirumab|In Substudies 2 and 3.2, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-paclitaxel-ramucirumab in combination.
16310517|NCT04604132|Experimental|Derazantinib-atezolizumab|In Substudy 3.3, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-atezolizumab in combination.
16310518|NCT04604132|Active Comparator|Standard of care|In Substudy 3.4, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive the Standard of Care drugs paclitaxel-ramucirumab in combination.
16310519|NCT04604106||Patient group|Infant aged 12 months (± four weeks) with a history of general anesthesia exposure
16310520|NCT04604106||Healthy subject group|Infant aged 12 months (± four weeks) without a history of general anesthesia
16310521|NCT04604093||SMBG, self-monitoring of blood glucose|Subjects will be randomized to continue use traditional SMBG, self-monitoring of blood glucose, to manage their diabetes.
16310522|NCT04604093||FreeStyle Libre 2|Subjects will be randomized to use the FreeStyle Libre 2 Flash Glucose Monitoring System to manage their diabetes.
16310523|NCT04604080||single group|Respondents will be given survey form, filled and will be collected back
16310554|NCT04603833|Active Comparator|Docetaxel|
16310555|NCT04603807|Experimental|Entrectinib|Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
16310556|NCT04603807|Active Comparator|Crizotinib|Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
16310557|NCT04603794|Active Comparator|1% Hydrogen Peroxide Mouth Rinse|30 second oral rinse with 1% Hydrogen Peroxide
16310524|NCT04604067|Experimental|Arm with 4 cohorts|"Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles.
~Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline:
~Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (>2log10 reduction of ctDNA)) results:
~Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent.
~Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent.
~Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total).
~Follow up: Patients off treatment will be followed for 5 years."
16310525|NCT04604054|Experimental|Group 1|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Granulocyte Colony Stimulating Factor as a treatment.
16310526|NCT04604054|Active Comparator|Group 2|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Human Chorionic Gonadotropin as a treatment.
16310527|NCT04604028|Experimental|Lenalidomide and low-dose cyclophosphamide|Oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide [Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days
16310528|NCT04604015|Experimental|NeuralBot Investigational System|Robotic TCD monitoring during bubble exam
16310529|NCT04604002|Experimental|Subjects with Normal Eyes|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology
16310530|NCT04604002|Experimental|Subjects with Pathology|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology
16310531|NCT04603989|Experimental|HNC042|HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
16310532|NCT04603989|Placebo Comparator|Placebo|Placebo, multiple ascending doses, Intravenous route
16310533|NCT04603976|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
16310534|NCT04603963|No Intervention|group control|alternate exercises: in one day breathing exercises, active or with a load of large muscle groups (according to tolerance) with a maximum limit of 2 kg, sedation out of bed, walking. On another day aerobic exercise with cycle ergometer limited to 30 minutes.
16310535|NCT04603963|Experimental|intervention group|He received the same intervention as the control group, associating respiratory muscle training 1 time a day with power breathe 3 series of 10 repetitions (started with 30% of the Pimax value) with readjusted load every 7 days.
16310536|NCT04603950|Experimental|study group|The first 20 patients received Continue Adductor Canal Block + Infiltration between the Popliteal Artery and Capsule of the Knee
16310537|NCT04603950|Sham Comparator|control group|The second 20 patients received Continue Adductor Canal Block alone
16310538|NCT04603937|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
16310539|NCT04603937|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
16310540|NCT04603924|Experimental|ANA001|Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
16310541|NCT04603924|Placebo Comparator|Matching Placebo|Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
16310542|NCT04603911|Active Comparator|Control|Control arm will receive standard of care solution for the ESPB block
16310543|NCT04603911|Active Comparator|Liposomal Bupivicaine|Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block
16310545|NCT04603885|Experimental|Aerobic exercise group|Aerobic exercise will be measured with a Polar United fitness watch. Heart rate during exercise will be measured using a Polar United fitness watch, which has been validated for monitoring moderate and high intensity physical activity.
16310546|NCT04603885|Placebo Comparator|Attention control group|The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
16310547|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells and dasatinib|Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.
16310548|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells|Dose levels of CAR-T cells are based on clinical trials of similar foreign products.
16310549|NCT04603859|Experimental|Elective induction of labour|Elective induction of labour at 39 gestational weeks and 0 to 3 days.
16310550|NCT04603859|No Intervention|Expectant management|Awaiting spontaneous labor.
16310551|NCT04603846|Experimental|Combined treatment group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
16310552|NCT04603833|Experimental|SHR3680+Docetaxel|
16310558|NCT04603794|Active Comparator|0.12% Chlorhexidine Gluconate Mouth Rinse|30 second oral rinse with 0.12% Chlorhexidine Gluconate
16310559|NCT04603794|Active Comparator|0.5% Povidone Iodine Mouth Rinse|30 second oral rinse with 0.5% Povidone Iodine Mouth wash
16310560|NCT04603794|Placebo Comparator|0.9% Normal Saline Mouth Rinse|30 second oral rinse with 0.9% Normal Saline
16310561|NCT04603781|Active Comparator|CBD-Isolate 300 mg.|Nightly administration of 300 mg. of CBD-Isolate for 28 consecutive days
16310562|NCT04603781|Active Comparator|Full-Spectrum CBD Oil 300 mg.|Nightly administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
16310563|NCT04603781|Active Comparator|Broad-Spectrum CBD oil 300 mg.|Nightly administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
16310564|NCT04603781|Placebo Comparator|Placebo Oil|Nightly administration of 300 mg. of Placebo Oil for 28 consecutive days
16310565|NCT04603768|Experimental|Theraband exercises|Group A: baseline physical therapy treatment along with theraband exercises
16310566|NCT04603768|Experimental|Co-contraction exercises|Group B: baseline physical therapy treatment along with co-contraction exercises
16310567|NCT04603768|Experimental|isometric exercises|Group C: baseline physical therapy treatment along with isometric exercises
16310568|NCT04603742|Experimental|Anakinra IV|Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
16310569|NCT04603742|Placebo Comparator|Normal Saline IV|Patients in the placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
16310570|NCT04603729|Active Comparator|group 1 dexamethasone|participants will receive dexamethasone 8mg/day Intravenous for 5 days
16310571|NCT04603729|Active Comparator|group 2 methylprednisolone|participants will receive methylprednisolone 1mg/kg/day intravenous for 5 days
16310572|NCT04603716|Experimental|Eccentric Muscle Energy Technique|conventional physical therapy Along with eccentric muscle energy technique
16310573|NCT04603716|Experimental|concentric muscle energy technique|Conventional physical therapy along with concentric muscle energy technique
16310574|NCT04603703|Experimental|HVLAT Manipulation|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics, HVLAT
16310575|NCT04603703|Active Comparator|Conventional physical therapy|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics
16310576|NCT04603690|Experimental|Colchicine|"This arm will receive Colchicine + Standard care as per hospital guidelines.
~The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half."
16310577|NCT04603690|No Intervention|Control group|This arm will receive standard care as per the hospital guidelines.
16310578|NCT04603677||Acute phase of SARS-CoV-2 infection|Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
16310579|NCT04603677||Convalescent phase of SARS-CoV-2 infection|Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
16310580|NCT04603664||study group|blood sampling and measduring of serum NGAL and cystatin c on admission and after 48 hours and creatinine every day
16310581|NCT04603638|Active Comparator|magnesium|participations will be given intravenous magnesium.
16310582|NCT04603638|Placebo Comparator|control|participations will be given intravenous isotonic.
16310583|NCT04603625|Experimental|sitting position centering femoral heads|sitting position centering femoral heads according to Lespargot diagram
16310584|NCT04603625|Active Comparator|Usual postural management|sitting with the trunk aligned and hips abducted to facilitate activities of daily living
16310585|NCT04603612|Other|NMIBC patients|Patients with diagnosed bladder tumors seen the urology department (Urology and Nephrology Center, Mansoura University, Egypt) will be assessed for eligibility to the study and inclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study and will be provided with an informed consent form. Study participants will be enrolled, and the appropriate scheduled procedures will be performed.
16310586|NCT04603599||benign endometrial changes|
16310587|NCT04603599||endometrial hyperplasia|
16310588|NCT04603599||endometrial cancer|
16310589|NCT04603586|Experimental|Arm A|SBRT with BED 60-70Gy combined with Gemcitabine + albumin-bound paclitaxel
16310590|NCT04603586|Experimental|Arm B|SBRT with BED >70Gy combined with Gemcitabine + albumin-bound paclitaxel
16310591|NCT04603573|Experimental|(intervention)|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
16310592|NCT04603573|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
16310593|NCT04603560|Experimental|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
16310594|NCT04603560|Experimental|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
16310595|NCT04603560|No Intervention|Control|No intervention will be provided to physicians in the control arm.
16310596|NCT04603534|Experimental|Intervention group|
16310597|NCT04603521||Hypertrophic cardiomyopathy (HCM)|Survival after Myectomy Operation
16310598|NCT04603508|Experimental|Berlim 25/10|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/10 association, oral;
~1 tablet empagliflozin placebo, oral;
~1 tablet rosuvastatin calcium placebo, oral."
16310599|NCT04603508|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/10 association placebo, oral;
~1 tablet empagliflozin , oral;
~1 tablet rosuvastatin calcium, oral."
16310602|NCT04603482|Experimental|Self-Management|
16310603|NCT04603482|Active Comparator|Attention Control Condition|
16310604|NCT04603469||Trisomy 21 patients|Children <18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3
16310605|NCT04603456|Experimental|Probiotic Group|consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.
16310606|NCT04603456|Experimental|SLIT Group|included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)
16310607|NCT04603456|Experimental|Combined treatment Group|included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months
16310608|NCT04603443|Experimental|BCAA 20g/daily|Branched Chain Amino Acids, 10g BID x 12 weeks
16310609|NCT04603443|Experimental|BCAA 40g/daily|Branched Chain Amino Acids, 20g BID x 12 weeks
16310610|NCT04603443|Experimental|BCAA 60 g/daily|Branched Chain Amino Acids, 30g BID x 12 weeks
16310611|NCT04603443|Placebo Comparator|Placebo 60 g/daily|Protein without BCAA, 30g BID x 12 weeks
16310612|NCT04603430||Physical Therapy Students|Students will be participating in a focus group and completing a survey.
16310613|NCT04603430||Senior STEPS Participants|Seniors will be participating in a focus group, completing a survey, and researchers will be conducting a retrospective chart review on relevant documented health outcomes of the STEPS program.
16310614|NCT04603417||Patients|Patients with CRPS diagnosis
16310615|NCT04603417||Controls|Healthy controls with known Neurological Disorders
16310616|NCT04603391|Experimental|Exposure A|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)
16310617|NCT04603391|Active Comparator|Exposure B|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.
16310618|NCT04603378|Other|KB195|
16310619|NCT04603378|Other|Polydextrose|
16310620|NCT04603378|Other|Pullulan|
16310621|NCT04603378|Other|Maltodextrin|
16310623|NCT04603352|Experimental|Intervention group: Hip Helpers home program|Participants in the intervention group will be given a custom pair of Hip Helpers® to use at home. Parents will begin the Hip Helpers® home program upon study entry and stop the program once the child is able to pull to stand independently. The Hip Helpers® home program protocol, which consists of using the orthotic garment twice daily for 30 minutes each time, will be given to the parents and supervised by the physical therapist. The Hip Helpers® should be donned when the child is actively playing, and not used sleep or when child is inactive.
16310624|NCT04603352|No Intervention|Control group: No additional home program|Participants assigned to the control group will continue with their usual care.
16310625|NCT04603339|Experimental|Intervention Arm|Single arm trial, all participants will receive the intervention
16310626|NCT04603326||Non-manifesting LRRK2 mutation carriers|Patients must have confirmed LRRK2 G2019S mutation Age 30 years or older at date of informed consent.
16310627|NCT04603326||LRRK2 Parkinson Disease (PD) Participants:|Patients must have confirmed LRRK2 G2019S mutation Patients must meet the MDS criteria for Parkinson's disease Disease duration: any Age 30 years or older at time of PD diagnosis.
16310628|NCT04603326||Idiopathic PD (iPD) Particpants:|Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
16310629|NCT04603326||Control (C) Participants:|Age 30 years or older at date of informed consent.
16310630|NCT04603313||Experimental group|12 departments in mainland France covered by the tele-advice system open to general practitioners
16310631|NCT04603313||Control group|84 departments in mainland France not covered by the tele-advice system.
16310632|NCT04603300|Active Comparator|Active treatment|INT301 dosing as determined by cohort assignment
16310633|NCT04603300|Placebo Comparator|Placebo|Placebo as determined by cohort assignment
16310634|NCT04603287|Experimental|Study treatment|Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
16310635|NCT04603274|Other|upper extremity diagnosed with carpal tunnel syndrome|8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
16310636|NCT04603261||eGFR <30 mL/min/1.73m2|Patients with eGFR <30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+.
16310637|NCT04603261||eGFR 30-59 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
16310638|NCT04603261||eGFR >=60 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
16310639|NCT04603248|Experimental|Single Arm|
16310640|NCT04603235|Experimental|Intervention|This is a quasi-experimental study
16310641|NCT04603222|Experimental|Treatment Group|Group treating blepharitis with SUMMIT BRUSH and Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
16310642|NCT04603222|Active Comparator|Control Group|Group treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
16310643|NCT04603209||IORT|Participants will undergo partial mastectomy for treatment of early stage breast cancer. IORT will then be delivered following surgical resection of the tumor. After surgery, participants are followed under routine care.
16310644|NCT04603196||Patients with Multiple Sclerosis with obstructive sleep apnea|Patients with Multiple Sclerosis with obstructive sleep apnea
16310645|NCT04603196||Patients with MS without obstructive sleep apnea|Patients with MS without obstructive sleep apnea
16310646|NCT04603183|Experimental|Interventional Arm (Arm A)|Abemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
16310647|NCT04603183|Active Comparator|Control Arm (Arm B)|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
16310650|NCT04603131|Experimental|BBV87 - 10 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
16310651|NCT04603131|Placebo Comparator|Placebo|Placebo administered intramuscularly on Day 0, 29 and 57
16310652|NCT04603131|Experimental|BBV87 -30 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
16310653|NCT04603131|Experimental|BBV87 -20 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
16310654|NCT04603118|Other|The patients with Idiopathic intracranial hypertension (IIH)|33 patients who applied to the neurology clinic with the pre-diagnosis of IIH were performed lumbar puncture. 25 of them diagnosed with IIH. Optic nerve sheath diameter was measured by optic ultrasonography from both eyes before and after the LP.
16310655|NCT04603118|Other|Control group|In the control group, optic nerve sheath diameter was measured from both eyes by optic ultrasonography.
16310656|NCT04603105||Single Study Cohort|Patients will be recruited from the main study after being determined to having COVID-19 and Cancer
16310657|NCT04603092|Experimental|Disadvantaged women in primary setting receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This group will receive the digital health literacy intervention.
16310658|NCT04603092|No Intervention|Disadvantaged women in primary setting not receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This control group will not receive the digital health literacy intervention.
16310659|NCT04603079|Experimental|Currently practicing nurses who will receive intervention|An intervention for COVID-19 preventive protocols will be delivered to the nurses in the experiment group.
16310660|NCT04603079|No Intervention|Currently practicing nurses who will not receive intervention|No intervention for COVID-19 preventive protocols will be delivered to the nurses in the control group.
16310661|NCT04603066|Experimental|Ondansetron + Tariquidar|
16310662|NCT04603066|Placebo Comparator|Ondansetron + Placebo|
16310663|NCT04603053|Experimental|CBot-A Group|Participants randomly assigned to this arm will receive access to CBot-A app.
16310664|NCT04603053|No Intervention|Wait List Group|Participants randomly assigned to this arm will be offered the intervention after the completion of the trial.
16310665|NCT04603040|Experimental|Experimental group|Experimental group:ToripalimabTreatment
16310666|NCT04603027|Experimental|Cohort 1|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 0.8 x 10^11 cells, capsule, once daily, 16 weeks
16310667|NCT04603027|Experimental|Cohort 2|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 3.2 x 10^11 cells, capsule, once daily, 16 weeks
16310668|NCT04603027|Experimental|Cohort 3|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 8.0 x 10^11 cells, capsule, once daily, 16 weeks
16310669|NCT04603014|Experimental|Interdialytic peritoneal ultrafiltration|Will receive incremental interdialytic peritoneal ultrafiltration with a 10% dextrose solution, twice a week for three consecutive weeks
16310670|NCT04603001|Experimental|Dose Escalation Arm A (Monotherapy)|Patients not requiring a strong CYP3A4 inhibitor.
16310671|NCT04603001|Experimental|Dose Escalation Arm B (Monotherapy)|Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
16310672|NCT04603001|Experimental|Cohort 1|Patients with R/R AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
16310673|NCT04603001|Experimental|Cohort 2|Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
16310674|NCT04603001|Experimental|Cohort 3|Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation,
16310675|NCT04603001|Experimental|Cohort 4|Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
16310676|NCT04602988||Patients admitted to an inpatient hospital unit|Patients admitted to an inpatient hospital unit will receive EEG based monitoring of mental status
16311171|NCT04599738|Placebo Comparator|Wheat muffin|Muffin made with 100% wheat flour
16310689|NCT04602962||Fertility preservation performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
16310690|NCT04602962||Fertility preservation not performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
16310691|NCT04602949|Experimental|COVID-19 patients|subjects who were found as COVID-19 positive patients by swab RT-PCR
16310692|NCT04602949|Other|Healthy controls|subjects who were found as COVID-19 Negative, by swab RT-PCR
16310693|NCT04602936|Active Comparator|Solriamfetol|All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.
16310694|NCT04602936|Placebo Comparator|Placebo|Placebo (i.e., inactive compound for comparison)
16310695|NCT04602923|Experimental|XEN Gel Stent implantation|Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation
16310696|NCT04602923|Experimental|Trabeculectomy|Participants suffering from glaucoma who are candidates for trabeculectomy
16310697|NCT04602923|Experimental|GDD implantation|Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)
16310698|NCT04602910|Experimental|the phases of planning and acting|Each part of the website page was assessed for comprehensibility and usability by patients. Health care providers were asked to assess the acceptability of the website. A 5-point Likert scale was used for patient and health care provider ratings for each item. If the score were less than 3, then we would modify the website content based on the user feedback from patients and health care providers
16310699|NCT04602897|Experimental|cough group|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
16310700|NCT04602897|No Intervention|control|the control group received no pain management at all during different steps of IUD insertion
16310701|NCT04602884|Experimental|COVID-19 Positive patients|subjects who were found COVID-19 Positive according to swab test.
16310702|NCT04602884|Other|Healthy subjects|subjects who were found COVID-19 Negative according to swab test.
16310703|NCT04602871|Experimental|COVID 19 Positive patients|Patients with COVID-19, qPCR for SARS-CoV-2 confirmed
16310704|NCT04602871|Other|Healthy subjects|COVID-19 Negative subjects
16310705|NCT04602858|Experimental|Reactive Balance Training|"Participants randomised to the intervention group will initially undertake 3 x 40 min training sessions of reactive balance training over 3 weeks followed by 3-monthly retraining sessions at 3, 6 and 9 months, and final assessment at month 12.
~During the training, participants will be exposed to unpredictable slips and trips whilst they are walking on the Trip and Slip Walkway (Okubo et al. 2019). They will be required to consistently walk at their normal walking pace using our gait regulation protocol (i.e. individually adjusted stepping tiles and metronome). Each training session will involve up to 30 trips and slips which progress in unpredictability.
~Participants will also receive a Staying active and on your feet fall prevention booklet containing guidance regarding fall risk factors including exercise, diet, vision, footwear, medications and home safety."
16310706|NCT04602858|Active Comparator|Control|"After exposing the control group to one trip and one slip at baseline, participants will then be provided with the Staying active and on your feet fall prevention booklet, an educational booklet providing guidance on fall risk factors including exercise, diet, vision, footwear, medications and home safety. The control group will then return for a reassessment after 12 months."
16310755|NCT04602494|Experimental|Varenicline|Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
16310866|NCT04601844|Experimental|Cohort 3|Cemdisiran at dose 2 SC single dose and pozelimab at dose 2 SC single dose, both administered on day 1
16310709|NCT04602832|Experimental|ENHANCE Treatment Group|The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
16310710|NCT04602832|No Intervention|Wait-List Control Group|Over the course of the study, participants will be asked to refrain from accessing the ENHANCE program materials to ensure the integrity of the research design. At the end of the study duration, participants will receive the full ENHANCE program.
16310711|NCT04602819|Experimental|Experimental|
16310712|NCT04602806||Moderate to Severe TBI Subjects|Adult patients (age 18-65y inclusive) presenting to the Emergency Department (ED) with a history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria (i.e., patient has sustained a traumatically-induced physiological disruption of brain function).
16310713|NCT04602780||CI users|
16310714|NCT04602767|Experimental|Vasopressin|Low dose vasopressin as first line vasopressor in cardiac surgery.
16310715|NCT04602767|Experimental|Phenylepherine|Low dose phenylephrine as first line vasopressor in cardiac surgery
16310716|NCT04602754|Experimental|BERLIM 25/20|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/20 association, oral;
~1 tablet empagliflozin placebo, oral;
~1 tablet rosuvastatin calcium placebo, oral."
16310717|NCT04602754|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/20 association placebo, oral;
~1 tablet empagliflozin, oral;
~1 tablet rosuvastatin calcium, oral."
16310718|NCT04602741|Experimental|A4i Intervention|"App4Independence (A4i)
~Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.
~Specific A4i functionality includes:
~Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.
~Fostering illness self-management through evidence-informed content.
~A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).
~Daily wellness and goal attainment check-ins.
~An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.
~Passively collected data on phone use as a proxy for sleep.
~A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU)."
16310719|NCT04602741|No Intervention|Treatment As Usual|Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
16310720|NCT04602728|Experimental|Back2Life Program|Youth with chronic SCD pain and their parents or caregivers receiving an adaptive cognitive behavioral treatment program for pain coping skills.
16310721|NCT04602715|Experimental|MET-2 20 g|Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
16310722|NCT04602715|Placebo Comparator|Placebo|Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
16310723|NCT04602689|Experimental|Fibrin glue group|Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD
16310724|NCT04602689|No Intervention|Control group|No intervention after gastric ESD
16310725|NCT04602676|Experimental|Diarrheal Assessment with DEP, then diarrheal assessment|Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
16310726|NCT04602676|Experimental|Diarrheal Assessment, then Diarrheal assessment with DEP|Participants will go through a 4 week period where clinicians will use a rehydration calculator. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm.
16310727|NCT04602663|Experimental|follow up every week|Variceal Band ligation every week.
16310728|NCT04602663|Experimental|follow up every 2 weeks|Variceal Band ligation every 2 weeks
16310729|NCT04602663|Experimental|follow up every 3 weeks|Variceal Band ligation every 3 weeks
16310730|NCT04602663|Experimental|follow up every 4 weeks|Variceal Band ligation every 4 weeks
16310731|NCT04602650||Type 2 Diabetic|Type 2 diabetic individuals of Mexican descent.
16310732|NCT04602650||Non-diabetic Controls|Non-diabetic individuals of Mexican descent.
16310733|NCT04602637||P1|
16310734|NCT04602637||P2|
16310735|NCT04602637||P3|
16310736|NCT04602624|Experimental|SAGE-718|Participants will receive a single dose of SAGE-718 oral tablets, once daily in the morning for 14 days.
16310739|NCT04602598|Experimental|Zanubrutinib|Zanubrutinib orally at a dose of 80mg BID for 24 weeks
16311090|NCT04600284|Experimental|Sequence 6|Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
16310740|NCT04602585|Experimental|Experimental|After discharge, the program manager will link the participants with a VHT nearest to them. The participants (randomized to the intervention arm) will be informed during the consent procedure that they will undergo 6 psycho-education sessions (1 per month) together with a family member at the participant's residence. The VHTs and participants will meet and schedule appointments for the next engagements. This shall be done on a case by case basis. Some psycho-education sessions could take place in the patient's residence, others in the nearest public space (school or church or mosque compounds). The investigators will document where the majority of these sessions happen. This will help the investigators document feasibility. The PI and RAs will sit in some of the sessions during the pilot phase of data collection to ensure fidelity to the manual.
16310741|NCT04602585|Placebo Comparator|Usual care arm|Participants will receive usual care
16310742|NCT04602572||Non-surgical group.|Patients will be offered a standardized program comprised of individual consultations by a trained nurse every 3 months over 2 years, participation in a lifestyle course with 13 group sessions focusing on healthy diet and physical activity, and pharmacotherapy.
16310743|NCT04602572||Surgical group|After completing the systematic work-up and the lifestyle course, eligible subjects will be offered bariatric surgery. The surgical procedure will be chosen at the surgeon's discretion taking into consideration the target weight, comorbidities, risk of complications, the patient's ability to cope with side effects and complications, and the patient's motivation.
16310744|NCT04602559|Experimental|MOBIDERM Panty group|"MOBIDERM Panty group :
~All patients will wear the Panty MOBIDERM device for 12 weeks, day and night recommended. A removable pad is also recommended to be worn additionnaly to the panty."
16310745|NCT04602546|Active Comparator|Sevoflurane alone|"Sevoflurane will be administered in steps to achieve a loss of consciousness via a tight-face mask by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until MOAA/S scales at values less than 2 is reached.
~The equilibration time for each targeted concentration will be approximately 12 minutes to maintain a constant ETSEVO. The BIS™ value, MOAA/S score and picture recall test will be assessed when the patient is awake and at the different ETSEVO concentrations.
~ETSEVO is decreased by the same steps until consciousness is regained."
16310746|NCT04602546|Active Comparator|Sevoflurane with Remifentanil Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed by the start of an infusion. Approximately within 7 minutes, the infusion rate of remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml.
~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of less than 2 is reached.
~ETSEVO is decreased by the same steps until consciousness is regained."
16310747|NCT04602546|Active Comparator|Sevoflurane with Fentanyl Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of fentanyl of 2 ng/mL, an initial IV bolus of fentanyl will be given followed by the start of an infusion. Approximately within 10 minutes, the infusion rate of fentanyl may be adjusted to maintain the effect-site concentration of fentanyl of 2 ng/ml.
~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of equal to or less than 2 is reached.
~ETSEVO is decreased by the same steps until consciousness is regained."
16310748|NCT04602546|Active Comparator|Desflurane Group|"Due to desflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to desflurane. Once correct LMA placement has been confirmed, there will be an equilibrium time of approximately 15-20 minutes to allow the effect site concentration of propofol to reach a level consistent with a pharmacodynamic effect of consciousness as measured by a MOAA/S score of 2 or 3. Desflurane will then be administered via a tight-face mask at the targeted end-tidal concentration (ETDES) of 2, 5, 7, 8, 9, 10 %, or higher until an MOAA/S score of less than 2 is reached.
~The BIS™ value will be correlated with desflurane ETDES concentration. ETDES is decreased by the same steps until consciousness is regained."
16310749|NCT04602546|Active Comparator|Isoflurane Group|"Due to isoflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to isoflurane.Isoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness (MOAA/S of 0,1) by increasing the end-tidal concentration of Isoflurane (ETISO). Targeted concentration for ETISO are 0.25, 0.5, 0.75, 1, 1.5% or higher until MOAA/S scales at values less than 2 is reached.
~The BIS™ value will be correlated with desflurane ETISO concentration. ETISO is decreased by the same steps until consciousness is regained."
16310750|NCT04602533|Experimental|Durvalumab|"Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy)
~Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities."
16310751|NCT04602533|Other|standard of care|"Induction phase: Radiochemotherapy according to guideline
~Maintenance: Standard of care"
16310752|NCT04602520||Dying patients|"Behavioral: Focused end of life conversations to promote connections among patients, family members and clinicians.
~All eligible dying patients and families in the 3 participating acute care wards are invited to participate in wish elicitation and implementation. For clinician interviews, criterion sampling will be used, based on involvement in the care of enrolled dying patients. We will use qualitative and quantitative methods to collect and analyze data. Quantitative data will include characteristics of patients, families and clinicians. Qualitative data will be based on interviews. Pending the pandemic burden, and the status of their grief, family members of deceased patients may be invited for an interview later months after the death of their loved one."
16310753|NCT04602507|Experimental|Intervention|50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
16310754|NCT04602507|Placebo Comparator|Control|50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
16310862|NCT04601857|Experimental|Futibatinib and Pembrolizumab (Cohort A)|Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.
16310756|NCT04602494|Placebo Comparator|Placebo|Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
16310757|NCT04602468|Other|Standard group|The standard testing group will be available for both age cohorts with sites having a predefined recruitment cap for each testing group. The standard testing will involve the following assessments; sweat chloride, LCI, height/weight/BMI, FEV1, airway sampling (micro), FeNO, liver function testing, liver ultrasound, liver examination, stool collection, blood collection, abdominal symptom score, CFQ-R, pharmacy records medication pick up rate, adherence questionnaires, MEMs caps and antibiotic use.
16310758|NCT04602468|Other|Advanced group|In addition to all elements of the standard testing group, the advanced testing group will undergo: Ultra-low dose spirometry-controlled CT scanning, sputum collection and nasal lavage collection. This will be available for both age cohorts with sites having a predefined recruitment cap for each testing group.
16310759|NCT04602455|Experimental|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a week webinar for 30 minutes during the four weeks. UCLA Loneliness scale was recorded prior to the start of the study and at its end after the duration of 4 weeks. The score was reviewed to see the changes in the loneliness scale.
16310760|NCT04602455|No Intervention|Control Group|The control group had no change in their daily routines.
16310761|NCT04602442|Experimental|EXO-1|Participants (n=30) in this group will receive standard therapy and exosomes of the first type.
16310762|NCT04602442|Experimental|EXO-2|Participants (n=30) in this group will receive standard therapy and exosomes of the second type.
16310763|NCT04602442|Placebo Comparator|Placebo|Participants (n=30) in this group will receive standard therapy and inhalation placebo solution.
16310764|NCT04602416||Control (Health)|The control had two sessions: the Introduction and another on Health. The health sessions were based on topics used by United States Peace Corps medical officers training volunteers about how to stay healthy in Tanzania: nutrition, worms, HIV/AIDS, and first aid.
16310765|NCT04602416||Entrepreneurship|The sessions for this arm were six: the two sessions of the Control arm, plus Sources of Capital, Marketing, Saving and Investing Profit, and Writing a Business Plan. Each session lasted one day.
16310766|NCT04602416||Beekeeping|The Beekeeping arm had six sessions: the two sessions of the Control arm, plus Beginning Beekeeping, Environment-Forests-Bees, Building a Beehive, and Harvesting.
16310767|NCT04602416||All Interventions|This arm was 10 sessions, and included all sessions of the Control, Entrepreneurship, and Beekeeping
16310768|NCT04602403|Placebo Comparator|placebo group|people who given placebo to become agroup of comparison with the other group
16310769|NCT04602403|Active Comparator|tamsulosin group|people who given tamsulosin to know the effect on ureteroscopy and compare with the control group
16310770|NCT04602390|Experimental|ANK-700 SAD Cohort 1, Dose A|All enrolled patients will receive one dose of ANK-700 Dose A
16310771|NCT04602390|Experimental|ANK-700 SAD Cohort 2, Dose B|All enrolled patients will receive one dose of ANK-700 Dose B
16310772|NCT04602390|Experimental|ANK-700 SAD Cohort 3 Dose C|All enrolled patients will receive one dose of ANK-700 Dose C
16310773|NCT04602390|Experimental|MAD Cohort 4 ANK-700 Dose A or Placebo|All enrolled patients will receive three doses of ANK-700 Dose A or placebo
16310774|NCT04602390|Experimental|MAD Cohort 5 ANK-700 Dose B or placebo|All enrolled patients will receive three doses of ANK-700 Dose B or placebo
16310775|NCT04602377|Experimental|Pembrolizumab|Single arm study
16310776|NCT04602364||Miga-Fab patients|Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat
16310777|NCT04602325||Inherited Hyperammonemias|"A clinical diagnosis of 1 of 7 diagnosed urea cycle disorders:
~N-acetylglutamate Synthetase Deficiency (NAGS)
~Carbamyl Phosphate Synthetase Deficiency (CPSD)
~Ornithine Transcarbamylase Deficiency (OTCD)
~Argininosuccinate Synthetase Deficiency (ASD)
~Argininosuccinate Lyase Deficiency (ALD)
~Arginase Deficiency (AD)
~Hyperammonemia-Hyperornithinemia-Homocitrullinuria (HHH)
~A clinical diagnosis of 1 of 2 organic acidemias:
~Propionic Acidemia (PA)
~Methylmalonic Acidemia (MMA)"
16310778|NCT04602325||Acute Metabolic Disorder + Neurological Sequelae|"Acute metabolic disorder without hyperammonemia but with neurological sequelae:
~Maple Syrup Urine Disease (MSUD)
~Glutaric Acidemia (GA1)"
16310779|NCT04602325||Fatty Acid Oxidation Disorders|"Acute metabolic disorder without hyperammonemia and without neurological sequelae:
~Medium Chain-Acyl CoA Dehydrogenase Deficiency
~Very Long Chain-Acyl CoA Dehydrogenase Deficiency
~Trifunctional Protein Deficiency
~Long Chain Hydroxyacyl-CoA Dehydrogenase Deficiency
~Carnitine Palmitoyltransferase I or II Deficiency
~Carnitine/Acylcarnitine Translocase Deficiency
~Primary Carnitine Transport Deficiency"
16310780|NCT04602325||Hypoxic-Ischemic Encephalopathy|Patients with hypoxic-ischemic encephalopathy
16310781|NCT04602312|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce coronavirus-related catastrophizing."
16310782|NCT04602312|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
16310783|NCT04602312|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
16310784|NCT04602312|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
16310785|NCT04602299|Experimental|Set the minimum time of gastroscopy|
16310786|NCT04602299|No Intervention|Observe the procedure time of gastroscopy|
16310787|NCT04602286|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce pain intensity and unpleasantness."
16310863|NCT04601857|Experimental|Futibatinib and Pembrolizumab (Cohort B)|All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors).
16310788|NCT04602286|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
16310789|NCT04602286|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
16310790|NCT04602286|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
16310791|NCT04602273||High Risk MDS|New diagnosed patients treated with Azacitidine 75 mg/sqm SC QD on a 28 days based cycles (both 7-0-0 and 5-0-2 regimens are allowed) until disease progression, unacceptable toxicity, death or investigator decision
16310792|NCT04602260||Prospective Cohort|The prospective cohort will assess patients upon admission to general internal medicine, at hospital discharge, and at 3, 6, 9, and 12-month follow-up.
16310793|NCT04602260||Retrospective Cohort|The retrospective cohort will assess patients at 3, 6, 9, and 12-months after being discharged from the hospital.
16310794|NCT04602247|Experimental|SIC|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.
16310795|NCT04602247|Experimental|SIC + AA combined|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid
16310796|NCT04602247|Active Comparator|FeSO4|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe
16310797|NCT04602247|Active Comparator|FeSO4 + AA combined|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid
16310798|NCT04602247|Experimental|EP + FeSO4 combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe
16310799|NCT04602247|Experimental|EP + FeSO4 + AA combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid
16310800|NCT04602234|Experimental|LUS group|
16310801|NCT04602234|No Intervention|No LUS group|
16310802|NCT04602221|Experimental|Lamotrigine treatment (T1)|
16310803|NCT04602221|Experimental|BI 409306 treatment (T2)|
16310804|NCT04602221|Placebo Comparator|Placebo treatment (R)|
16310805|NCT04602221|Experimental|BI 425809 treatment (T3)|
16310806|NCT04602208||Focal HIFU for primary localized prostate cancer|Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
16310807|NCT04602182|Experimental|music therapy gruop (experimental group)|Experimental group: Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
16310808|NCT04602182|Active Comparator|control group|Control group: Patient will follow the usual clinical practice for the weaning from mecanichal ventilation to the end of the weaning.
16310809|NCT04602169|Active Comparator|PVI only group|Patients allocated to this group will receive PV re-isolation alone
16310810|NCT04602169|Active Comparator|PVI + SVC group|Patients allocated to this group will receive PV re-isolation with SVC isolation.
16310811|NCT04602156|Experimental|Group T|Patients will be randomized to undergo PC catheter placement (8-French) using the trocar method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
16310812|NCT04602156|Active Comparator|Group S|Patients will be randomized to undergo PC catheter placement (8-French) using the Sellinger method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
16310813|NCT04602143|Experimental|Testosterone gel 4 weeks|Patients with low ovarian reserve received 4-week TTG application before controlled ovarian hyperstimulation.
16310814|NCT04602143|Experimental|Testosterone gel 6 weeks|Patients with low ovarian reserve received 6-week TTG application before controlled ovarian hyperstimulation.
16310815|NCT04602143|No Intervention|Control group|Patients with low ovarian reserve received no medication before controlled ovarian hyperstimulation.
16310816|NCT04602130|Experimental|Massage|Massages were performed starting from the face, focused on the newborns forehead, and then around the eyes and cheeks with gentle touches. Then, newborns' chest area and the upper and lower extremities were massaged. Finally, newborns'were placed prone position and the back was massaged. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
16310817|NCT04602130|Experimental|Sponge Bathing|In the sponge bathing group, the newborns' eyes, faces (outward from the midline), around the ear and the back of the ear were wiped from the inside out with cotton wipes and dried. Then, the chest area and arms, abdomen and back, legs and feet, respectively, were wiped and dried. Finally, the genital area was cleaned, before diapering the newborn. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form
16310818|NCT04602130|Experimental|Tub bathing|In the tub bathing group, before being immersed in the tub, the newborns' faces and heads were cleaned outwards from the midline and dried. Then, the neck, chest, arms, back, legs and genital area were soaped, before the full body was rinsed and dried. Finally, umbilical cord care was performed, and the baby was diapered. Nurses recorded the newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
16310819|NCT04602130|No Intervention|Control|The newborns in the control group did not undergo any intervention other than standard clinical practices. All physiological measurements (pulse, respiration, oxygen saturation and body temperature) were performed by nurses and recorded on the Newborn Follow-up Form.
16310864|NCT04601844|Experimental|Cohort 1|Cemdisiran at dose 1 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
16310865|NCT04601844|Experimental|Cohort 2|Cemdisiran at dose 2 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
16310827|NCT04602078|Experimental|AUREA single-arm|"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.
~Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles."
16310828|NCT04602065|Experimental|Previously received anti-PD1/PD-L1 antibodies|Patients previously received anti-PD1/PD-L1 antibodies, except for those were primarily refractory to them.
16310829|NCT04602065|Experimental|Patients previously never received anti-PD1/PD-L1 antibodies|Patients previously never received anti-PD1/PD-L1 antibodies.
16310830|NCT04602052|Active Comparator|Medical arm|Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.
16310831|NCT04602052|Experimental|Surgical arm|Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.
16310832|NCT04602039|Experimental|People without Diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
16310833|NCT04602039|Experimental|Participants with Pre-diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
16310834|NCT04602039|Experimental|Participants with Type 2 diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
16310835|NCT04602026|Active Comparator|Arm I (best practice)|Non-frail patients receive standard of care.
16310836|NCT04602026|Active Comparator|Arm II (best practice)|Frail patients receive standard of care.
16310837|NCT04602026|Experimental|Arm III (physical therapy consultation, exercise intervention)|Frail patients undergo a physical therapy consultation and complete home exercises 3 days per week.
16310838|NCT04602013|Experimental|Immunotherapy combined with chemoradiotherapy|"Immunotherapy combined with chemoradiotherapy
~Sintilimab Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W.
~Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).
~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)
~Radiotherapy The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week)."
16310839|NCT04602000|Experimental|CT-P59 Arm 1|
16310840|NCT04602000|Experimental|CT-P59 Arm 2|
16310841|NCT04602000|Placebo Comparator|Placebo|
16310842|NCT04601987|Active Comparator|Counseling about the Maternal Benefits of Breastfeeding|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the maternal health benefits of breastfeeding.
16310843|NCT04601987|Active Comparator|Counseling about the benefits of Smoke-free Homes|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the health benefits of smoke free homes.
16310844|NCT04601974|Experimental|lentiviral gene therapy treatment (Intervention Arm)|Patients will receive a single dose of lentiviral gene therapy treatment administered once intracranially
16310845|NCT04601961|Active Comparator|SEVO Group|Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.
16310846|NCT04601961|Experimental|TIVA group|The patients in TIVA group will be anaesthetized using total intravenous propofol.
16310847|NCT04601948|Experimental|Intervention|Participants will receive a Fitbit activity monitor and access to the mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
16310848|NCT04601935|Experimental|LCAR-BCX cells product|Each subject will be given a single-dose infusion in each dose levelThe dose-finding phase of this study is designed primarily using the Bayesian optimal interval (BOIN) method, which is combined with accelerated titration at the beginning of the study to assess incidence of DLT (dose-limiting toxicity) and estimate MTD (maximum tolerated dose).
16310849|NCT04601922||Emergency Medicine Consultants|
16310850|NCT04601922||General Practitioners|
16310851|NCT04601922||Acute care nursing staff|
16310852|NCT04601922||Patients presenting with suspected cardiac chest pain|
16310853|NCT04601909|Active Comparator|FX-322|FX-322, 1 dose (N=24)
16310854|NCT04601909|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
16310855|NCT04601896||Live patients admitted for Refractory Cardiac Arrest with ECMO|
16310856|NCT04601896||Live patients quality of life admitted for Refractory Cardiac Arrest without ECMO|
16310857|NCT04601883|Experimental|Colchicine|Tablet colchicine 0.5 mg administered two times daily
16310858|NCT04601883|Placebo Comparator|Placebo|Tablet placebo administered two times daily
16310859|NCT04601870|Experimental|No Financial Incentive|N=180 participants randomized to not be offered monetary incentive to participate in an intervention to quit smoking.
16310860|NCT04601870|Experimental|Financial Incentive (100 dollars)|N=180 randomized participants will be offered a 100 dollar incentive to participate in an intervention to quit smoking.
16310861|NCT04601870|Experimental|Financial Incentive (50 dollars)|N=180 randomized participants will be offered a 50 dollar incentive to participant in an intervention to quit smoking.
16310867|NCT04601831|Experimental|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.
~*If >5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (>=7.5 cm in largest dimension) sites be treated."
16310868|NCT04601818|Experimental|Interventional arm|During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.
16310869|NCT04601818|No Intervention|Retrospective arm|Outcomes will be compared to conventional transplant patients matched by age, medical diagnosis, BMI, lung allocation score and donor type ( DCD vs. NDD) using a 1:2 matching.
16310870|NCT04601805||Group (1) : Patient diagnosed with IBD with no treatment received|
16310871|NCT04601805||Group(2): Patient diagnosed with IBD and received treatment for a long time|
16310872|NCT04601792|Experimental|Individualized Decoction|"It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For subjects with lung and spleen qi deficiency syndrome, the investigators added Radix Codonopsis Pilosulae, Pericarpium Citri Reticulatae, and Atractylodes Macrocephala Koidz. The investigators can adjust the individualized decoction in accordance with the change in the patient's condition throughout the whole study duration.
~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
16310873|NCT04601792|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.
~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
16310874|NCT04601792|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
16310875|NCT04601779|Other|Cluster I|Cluster I is randomized to start the VIPP-PUF intervention phase January 1, 2022
16310876|NCT04601779|Other|Cluster II|Cluster II is randomized to start the VIPP-PUF intervention phase May 1, 2022
16310877|NCT04601779|Other|Cluster III|Cluster IiI is randomized to start the VIPP-PUF intervention phase September 1, 2022
16310878|NCT04601766|Experimental|Group A|
16310879|NCT04601766|Experimental|Group B|
16310880|NCT04601753||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
16310881|NCT04601740||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
16310882|NCT04601727||Rectal cancer patients|
16310883|NCT04601701|Experimental|CRVO: Bevacizumab and intravitreal Dexamethasone.|Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
16310884|NCT04601701|Active Comparator|CRVO: Bevacizumab|Participants with CRVO will receive a combination of Bevacizumab only.
16310885|NCT04601688|Experimental|BRVO: Bevacizumab and intravitreal Dexamethasone|Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
16310886|NCT04601688|Active Comparator|BRVO: Bevacizumab|Participants with BRVO will receive Bevacizumab only.
16310887|NCT04601675|Experimental|Diabetic ME: Ranibizumab and intravitreal Dexamethasone|Participants with diabetic macular edema will receive a combination of Ranibizumab and intravitreal Dexamethasone
16310888|NCT04601675|Active Comparator|Diabetic ME: Ranibizumab|Participants with diabetic macular edema (ME) will receive Ranibizumab only.
16310889|NCT04601662|Experimental|Corticision|Patients in this group will be subjected to corticision to accelerate orthodontic movement
16310890|NCT04601662|Active Comparator|Traditional treatment|Patients in this group will undergo normal traditional treatment without any acceleration method.
16310891|NCT04601649|Experimental|Intervention|Participants will take part in the PrEP Talk intervention sessions.
16310892|NCT04601649|No Intervention|Control|Participants will receive standard care.
16310893|NCT04601636|Active Comparator|Active Prewarming group (PW group)|Group randomized to receive at least 30 minutes of active prewarming before induction of anesthesia, combined to active warming intraoperatively.
16310894|NCT04601636|Placebo Comparator|Control group (C group)|Group randomized to receive the standard care : passive prewarming before induction of anesthesia combined to active warming intraoperatively.
16310895|NCT04601610|Experimental|Cohort 1|Subjects who have not received first-line system treatment previously;
16310896|NCT04601610|Experimental|Cohort 2|Subjects who have received at least first-line system treatment
16310903|NCT04601571|Active Comparator|Feeding Tube Placement using CORTRAK stylet|Subjects will already have a feeding tube placed and are undergoing X-rays for placement confirmation.
16310904|NCT04601571|No Intervention|Feeding Tube Placement using X-Ray|Routine X-ray is used to confirm feeding tube placement
16310905|NCT04601558|No Intervention|Control group|The first group of participants was control group. The number of participant was 70, and the participants in this group after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
16310906|NCT04601558|Sham Comparator|Passive-intervention group|The second group of participant was passive-intervention group. There were 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, they were receiving remainder on their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
16310907|NCT04601558|Active Comparator|Active-intervention group|The third group of participant was active-intervention group. There were also 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, active-intervention group were receiving Cochrane abstracts in the form of blog-shots.
16310908|NCT04601545|Experimental|VR therapy group|Pulmonary rehabilitation supplemented by VR therapy
16310909|NCT04601545|Active Comparator|Active Control Group|Pulmonary rehabilitation supplemented by Schultz Autogenic Training
16310910|NCT04601532|Active Comparator|Silver sulfadiazine|Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
16310911|NCT04601532|Experimental|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
16310912|NCT04601519||Patients-type 1 diabetes|Participants are recruited by e-mail, among the users of the libreview platform (Abbott), who are followed up for type 1 diabetes at the CHU Grenoble Alpes (France), to participate in an anonymous online questionnaire and to allow their glycemic data extracted from the libreview platform to be used for the research.
16310913|NCT04601506|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
16310914|NCT04601506|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
16310915|NCT04601506|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
16310916|NCT04601506|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
16310917|NCT04601493|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
16310918|NCT04601493|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
16310919|NCT04601493|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
16310920|NCT04601493|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
16310921|NCT04601480|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
16310922|NCT04601480|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
16310923|NCT04601480|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
16310924|NCT04601480|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
16310925|NCT04601467|Experimental|AZD5718|Patients will receive once daily oral dose of AZD5718 for 12 months
16310926|NCT04601467|Placebo Comparator|Placebo|Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months
16310927|NCT04601454|Experimental|Spinal Cord Stimulation|Enrolled subjects are implanted with a spinal cord stimulation system that is activated and programmed to on-label parameters.
16310928|NCT04601441|Other|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
16310929|NCT04601428|Experimental|Investigational Arm|
16310930|NCT04601415||GP Referrals|Patients with HF referred by GP to echo department
16310931|NCT04601415||Echo patients|Non-selected patients attending echo department in hospital
16310932|NCT04601402|Experimental|GEN-001 with avelumab|"Dose Escalation Cohort includes patients with advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination) will be enrolled. 3 or 6 patients will be enrolled per escalating or de-escalating dose levels.
~Dose Expansion Cohort includes patients with advanced or metastatic NSCLC, SCCHN, and UC who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)will be enrolled."
16310933|NCT04601389|Experimental|"GNR-044 (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
16310934|NCT04601389|Active Comparator|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
16310935|NCT04601376|Experimental|Mobile monitoring group|
16310936|NCT04601363||Patients with Personalized SpineRods|The patient is being treated with the patient-specific rod with a surgery date planned
16310937|NCT04601363||Patient with other hardware|Patients with other hardware not patient-specific
16310938|NCT04601350|Experimental|Remimazolam 1|
16310939|NCT04601350|Experimental|Remimazolam 2|
16310940|NCT04601350|Experimental|Remimazolam 3|
16310941|NCT04601350|Experimental|Remimazolam 4|
16310942|NCT04601337||Brachial plexus and/or nerve transfer surgery patients|Patients set to undergo brachial plexus reconstruction or nerve transfer surgery that are 18 years or older.
16310943|NCT04601324|Active Comparator|Dymista (Azelastine hydrochloride and fluticasone propionate)|Participants will receive standard of care, which includes twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride and 50 mcg of fluticasone propionate per spray) separated by 12 hours.
16310944|NCT04601324|Experimental|Fluticasone Propionate and Rupatadine|Participants will administer fluticasone propionate nasal spray once daily (2 sprays in each nostril, 50 mcg fluticasone propionate per spray)and 1 tablet of Rupatadine (10mg) once daily in the morning.
16310947|NCT04601298||AUS|
16310948|NCT04601298||FLUS|
16310949|NCT04601285|Experimental|Dose Escalation|
16310950|NCT04601272||Breast Cancer Screening|Women between the ages of 35-55 when they received a decision aid for breast cancer screening with no prior diagnosis of breast cancer. These people will see items only pertaining to breast cancer screening.
16310951|NCT04601272||Colon Cancer Screening|Men and women between the ages of 45-75 when they received a decision aid for colon cancer screening with no prior diagnosis of colon cancer. These people will see items only pertaining to colon cancer screening.
16310952|NCT04601272||Prostate Cancer Screening|Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
16310953|NCT04601272||Lung Cancer Screening|Men and Women between the ages of 50-80 when they received a decision aid for lung cancer screening with no prior diagnosis of lung cancer. These people will see items only pertaining to lung cancer screening.
16310954|NCT04601259|Experimental|Orkla corn plaster with Salicylic acid|
16310955|NCT04601259|Active Comparator|Orkla corn protector without salicylic acid|
16310956|NCT04601233|Experimental|Treatment open label arm|Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.
16310957|NCT04601207|Experimental|Solutech™- TC10|10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic
16310958|NCT04601207|Active Comparator|MCT-diluted Cannabis Product|10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic
16310959|NCT04601194|Experimental|Coaching and Virtual Provider Group|Mental Health Coaching and assigned practice with a Virtual Provider Program
16310960|NCT04601181|Experimental|ThisCART22 cells injection|In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
16310961|NCT04601155||AlloSure Group|Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years. For the quarterly AlloSure tests, approximately 20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) to analyze the presence of donor-derived cell-free DNA.
16310962|NCT04601155||Control Group|The control group was never followed with AlloSure as part of their post-transplant follow-up care. Matched control data will originate from UNOS SRTR data.
16310963|NCT04601142||glucocorticoid sensitive (GS) group|
16310964|NCT04601142||glucocorticoid resistance (GR) group|
16310965|NCT04601129||patients|undergoing a minimally invasive nephrectomy, eligible to an Enhanced Recovery After Surgery Program.
16310966|NCT04601116|Active Comparator|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg tablets per day for 2 years
16310967|NCT04601116|Placebo Comparator|Placebo|Placebo tablets 1 per day for 2 years.
16310968|NCT04601077|Active Comparator|Nitric Oxide|Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
16310969|NCT04601077|Placebo Comparator|Placebo|Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
16310970|NCT04601064|Experimental|Collaborate Care (CC) Model|For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
16310971|NCT04601064|No Intervention|Usual Care (UC)|For patients randomized to the UC referral arm, the patient's HIV provider will receive an electronic alert of the patient's positive screen for a Mental Health and Substance Use Disorder. The patient will not be contacted by the P-CM. The provider, at their discretion, will initiate referral to the psychiatry service available onsite. For patients with Substance Use Disorder, providers refer to the in-clinic Substance Use Disorder treatment program that is managed by a nurse practitioner with Substance Use Disorder care experience. Once referred, the patient is seen by the nurse practitioner (separate from the HIV provider) who manages prescription of and assessment of adherence to buprenorphine, including monitoring of urine toxicology results with support from an addiction counselor. The Bartlett Clinic runs 2 substance use groups weekly and has processes for referral to a higher level of Substance Use Disorder care at offsite Substance Use Disorder treatment programs.
16311091|NCT04600271||Study Group|Patients over the age of 18 and who undergone major elective non-cardiac abdominal surgery.
16310974|NCT04601038|Other|MCI|Individuals with mild cognitive impairment due to Alzheimer's disease
16310975|NCT04601038|Other|Cognitively Normal|Individuals who are cognitively normal but who are at risk for Alzheimer's disease
16310976|NCT04601025|Experimental|Yoghurt|
16310977|NCT04601025|Experimental|Chickpea+Yoghurt|
16310978|NCT04601025|Experimental|Oat+Yoghurt|
16310979|NCT04601012||Patients with COVID19|The patients with previous diagnosis of COVID19
16310980|NCT04601012||Control subjects|Healthy subjects without actual and previous ocular diseases
16310981|NCT04600999|Experimental|Group Avigan|Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.
16310982|NCT04600999|No Intervention|Group Control|Supportive care (symptomatic therapy)
16310983|NCT04600986|Experimental|New oocyte triggering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl) and in addition a repeat dose of 0.1 mg s.c triptorelin (decapeptyl) will prescribed 12 h following the first dose.
16310984|NCT04600986|Other|Routine oocyte trigering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl), 35 h prior to oocyte retrieval.
16310985|NCT04600973|Active Comparator|Surveillance with Technical Assistance|Surveillance will be offered to 3 teams with Technical Assistance (TA) in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported.
16310986|NCT04600973|Active Comparator|Surveillance with EBIP Coaching|Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
16310987|NCT04600973|Active Comparator|Technical Assistance No Surveillance|TA will be offered to 3 teams. TA will have monthly scheduled TA calls (60 minutes each) with each team individually to review and discuss the protocol interventions (as is done in the EBIP group) and allow for a consultation with experts on the peri-operative interventions. Surveillance toolkit will only be used for transmission data collection.
16310988|NCT04600973|Active Comparator|EBIP Coaching No Surveillance|EBIP will be offered to 3 teams. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Surveillance toolkit will only be used for transmission data collection.
16310989|NCT04600960|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take eltrombopag at the indicated dose.
16310990|NCT04600947|Experimental|LP002|Participants will receive LP002 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W) for up to 24 months.
16310991|NCT04600934|Active Comparator|Standard POBA (plain old balloon angioplasty)|The first 50 patients will be pre-treated with standard POBA
16310992|NCT04600934|Experimental|Shockwave|The second 50 patients will be treated primarily with Shockwave
16310993|NCT04600921|Active Comparator|Ertugliflozin|The subject will receive Ertugliflozin 5mg.
16310994|NCT04600921|Placebo Comparator|Placebo|The subject will receive Placebo 5mg.
16310995|NCT04600908||Non-physician staff|All non-physician staff who have had commuting accidents
16310996|NCT04600895|Experimental|Favipiravir|
16310997|NCT04600895|Placebo Comparator|Placebo|
16310998|NCT04600869|Experimental|Nursing Group|Nurses in the control group accepted the other non-fertility (standard) nursing training for the intervention, whereas those in the experimental group accepted the oncofertility training. Based on research ethics and design, a standard education course was held for the control group after completing data collection in the nursing experimental group. We began to recruit patients into the patient experimental group after all nurses completed their educational courses.
16310999|NCT04600843|Experimental|Physical therapy with Patient education|Treated with proper physical therapy treatment protocol according to patient presenting condition and patient education manual
16311000|NCT04600843|Experimental|Physical Therapy without patient Education|Treated with proper physical therapy treatment protocol according to patient presenting condition
16311001|NCT04600830|Experimental|Dry Needling Group|Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
16311002|NCT04600830|Active Comparator|Foam Roller Group|The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
16311003|NCT04600817|Experimental|TJ107|
16311004|NCT04600817|Placebo Comparator|TJ107Placebo|
16311092|NCT04600258|Experimental|Chocolate Group|Administration of 40g dark chocolate per day, for 2 months
16311093|NCT04600258|No Intervention|Control Group|No intervention and analysis will be performed before and after 2 months
16311005|NCT04600804||All patients registered in the MCL0208 trial|"About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.
~In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only."
16311007|NCT04600778|Placebo Comparator|placebo|twice daily
16311008|NCT04600778|Experimental|Cavosonstat 5 mg|twice daily
16311009|NCT04600778|Experimental|Cavosonstat 10 mg|twice daily
16311010|NCT04600778|Experimental|Cavosonstat 25 mg|twice daily
16311011|NCT04600765|Active Comparator|Diet Before|Typical diet contaminated with Bisphenol A. Patient assigned to this arm will consume a typical American diet as defined by USDA.
16311012|NCT04600765|Active Comparator|Diet After|Bisphenol A reduced. Patient assigned to this arm will consume a diet analogous to atypical American diet as defined by USDA, but with known Bisphenol A sources reduced or eliminated.
16311013|NCT04600752|Experimental|Participants receiving Augmentin (ES)-600|Eligible participants will receive Augmentin (ES)-600 at 90/6.4 mg/kg/day administered in two divided doses, every 12 hours with food for 10 days.
16311014|NCT04600739||AVD Patients|Patients suffering from aortic valve stenosis receiving replacement of the diseased valve using a TAVI procedure.
16311015|NCT04600726||older adults with known mild NCD|Older adults with known mild neuro-cognitive disorders
16311016|NCT04600726||older adults with non-communicable diseases|older adults with non-communicable diseases such as diabetics, hypertension and chronic obstructive airway diseases
16311017|NCT04600726||Older adults with healthy condition|Older adults who are free from neuro-cognitive disorders and non-communicable diseases
16311018|NCT04600713|Experimental|PT-X and IMT|Physiotherapist-led exercise-based cardiac rehabilitation (PT-X) and inspiratory muscle training (IMT).
16311019|NCT04600713|No Intervention|Control|The participants in the control group will be offered PT-X at the end of the control period.
16311020|NCT04600700||CDSS weaning group|This group will be exposed to the CDSS to inform inotrope weaning
16311021|NCT04600687|Experimental|Intervention Arm|Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.
16311022|NCT04600674|Experimental|delayed cord clamping|DCC performed at 60 sec after birth
16311023|NCT04600674|Experimental|early cord clamping|ECC performed at 15 sec after birth
16311024|NCT04600661|Experimental|control group (Traditional therapy group)|control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training
16311025|NCT04600661|Experimental|Experimental group I (BFR training group)|Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.
16311026|NCT04600661|Experimental|Experimental group II (Neuromuscular training group)|Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises
16311027|NCT04600648|Active Comparator|Weight loss with bariatric surgery|Patients scheduled to undergo bariatric surgery will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
16311028|NCT04600648|Active Comparator|Weight Loss|Patients to receive lifestyle weight loss treatment will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
16311029|NCT04600635||patients with a medical history of obesity|Patients included are subject who entered a structured program of care for their obesity, with or without bariatric surgery.
16311030|NCT04600622|Experimental|Intervention Arm|Participants will receive Rural Diabetes One-Day Education and Care program (R-D1D). A one time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
16311031|NCT04600622|Active Comparator|Active Comparator|Participants will receive diabetes education materials.
16311032|NCT04600596||Roux-en-Y gastric bypass patients|Severely obese non-diabetic adult female patients scheduled for RYGB.
16311033|NCT04600596||Obese (BMI ≥ 35) controls|Severely obese non-diabetic adult female patients not undergoing surgery.
16311034|NCT04600596||Lean (BMI ≤ 25) controls|Lean healthy non-diabetic adult females.
16311035|NCT04600583|Active Comparator|Alignment according to Functional Alignment philosophy|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System aligned according to Functional Alignment philosophy. This method of implant alignment is defined by a patient's native joint line as well as the soft tissue envelope. Triathlon Total Knee System components will be positioned relative to intra-operative soft tissue laxity assessment. A mobile application (KneeBalancer) will be used to assist surgeon decision making during the dynamic joint balancing surgical step.
16311036|NCT04600583|Active Comparator|Alignment to the patient's natural Mechanical axis|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System neutrally aligned to the Mechanical axis. More specifically, the femoral component and tibial component are aligned 0° to the mechanical axis of each respective limb. Femoral component rotation is fixed to the trans-epicondylar axis. Soft tissue releases are performed at the discretion of the surgeon to achieve balance and full range of motion.
16311037|NCT04600557|Experimental|Self-compassion only|Describing a shameful experience using a self-compassionate prompt and receiving no verbal responses from confederates
16311038|NCT04600557|Experimental|Compassion from others only|Describing a shameful experience using a neutral prompt and receiving compassionate responses from confederates
16311039|NCT04600557|Experimental|Self-compassion plus compassion from others|Both describing a shameful experience using a self-compassionate prompt and receiving compassionate responses from confederates
16311040|NCT04600557|Active Comparator|Sharing-only control|Describing a shameful experience using a neutral prompt and receiving no verbal responses from confederates
16311212|NCT04599374||high TSH and low FT3|patients with high TSH and low FT3
16311041|NCT04600531|Experimental|Group 1a - Conventional tDCS - Anodal first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
16311042|NCT04600531|Sham Comparator|Group 1b - Conventional tDCS - Sham first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
16311043|NCT04600531|Experimental|Group 2a - HD tDCS - Anodal first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
16311044|NCT04600531|Sham Comparator|Group 2b - HD tDCS - Sham first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
16311045|NCT04600518||Low risk|good prognosis with surgery only and adjuvant chemotherapy patients
16311046|NCT04600518||Intermediate risk|moderate prognosis
16311047|NCT04600518||High risk|poor prognosis
16311048|NCT04600505|Experimental|Treatment Sequence ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment B; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
16311049|NCT04600505|Experimental|Treatment Sequence BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment C; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
16311050|NCT04600505|Experimental|Treatment Sequence CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment A; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
16311051|NCT04600505|Experimental|Treatment Sequence ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment C; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
16311052|NCT04600505|Experimental|Treatment Sequence BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment A; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
16311053|NCT04600505|Experimental|Treatment Sequence CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment B; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
16311054|NCT04600492|Active Comparator|Active Comparator: Active drug group Riociguat|Riociguat 0.5mg、1.0mg、2.5mg
16311055|NCT04600492|Placebo Comparator|Placebo group|Placebo 0.5mg、1.0mg、2.5mg
16311056|NCT04600479|Experimental|prevalence and follow-up of HCV positive patients|"Cross-sectional assessment of prevalence : evaluation of the prevalence of HCV, HBV and HIV viral infections
~Cohort follow-up of HCV positive patients : evaluation of care pathway and barriers to care for hepatitis C"
16311057|NCT04600466||Retrospective Non-Hispanics|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
16311058|NCT04600466||Retrospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
16311059|NCT04600466||Prospective Non-Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
16311060|NCT04600466||Prospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
16311061|NCT04600453|Experimental|Training group|"Multicomponent exercise group (intervention): The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day (morning and evening).
~The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RMcombined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital."
16311062|NCT04600453|No Intervention|Usual care group|Usual care
16311063|NCT04600440|Experimental|Plasma treatment|Convalescent plasma 200 ml daily during three days
16311064|NCT04600440|No Intervention|No plasma|Best conventional treatment
16311094|NCT04600245|Experimental|M-FAM|Will undergo the procedure with assistance from the M-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
16311095|NCT04600245|Experimental|CARTOSOUND-FAM|Will undergo the procedure with assistance from the CARTOSOUND-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
16311096|NCT04600232|Experimental|Diagnosis arm|Urine TB-LAM, sputum smear, Gene Xpert, mycobacterial culture
16311097|NCT04600206||Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor or stage III lung or ovarian tumor) from diagnosis to terminal stages
16311065|NCT04600427|Experimental|Epidural anesthesia|The patient will be positioned appropriately and the T11-12 (if not accessible we will accept 1-2 spaces above or below) interspace landmarked using established ultrasound guidance techniques. The patient's back will be prepped and draped in a sterile fashion. An epidural catheter will be inserted into the T11-12 interspace with a midline or paramedian approach using a 17G Tuohy needle. Plain preservative free bupivicaine 0.25% will be the local anesthetic used. After a 2-3 mL test dose to rule out intrathecal catheter positioning, a loading dose of 5-8 mL will be administered over 5-10 minutes to further rule out intravascular positioning of the catheter. Successful epidural placement will be defined by catheter insertion and confirmed by sensory blockade assessed by ice or pin prick testing. When correct positioning is confirmed, a continuous infusion of 3 mL per hour of bupivacaine 0.25% plain solution will begin.
16311066|NCT04600414|Active Comparator|Collaborative Care for Mental Health Disorders|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for mental health disorders.
16311067|NCT04600414|Experimental|Collaborative Care for Opioid Use Disorder|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for opioid use disorder.
16311068|NCT04600401|Experimental|Participants integrate the Mentis Plus+ program|Mentis Plus+ Program was developed based in The Multifactorial Model of Positive Mental Health and its construction resulted from a systematic literature review and validation through focus group. The duration of the Mentis Plus+ program depends on the number of the six factors to be worked on. The Mentis Plus+ lasts at least 7 weeks (1 session per week, lasting 1 hour) and can work individually or in groups (2-12 people). There will be 2 initial sessions of 1 hour each and 3 sessions for each factor to work with duration of 1 hour. Still, a final session and a follow-up session (3-6 months after the program) will be held.
16311069|NCT04600401|No Intervention|Participants on a waiting list (Control Group)|Participants in the control group were told they were on a waiting list for 3-6 months, as a minimum, before they integrate the Mentis Plus+ program. Given the preventive nature of this study, a waiting list control group won't bring risks or damages to participants
16311070|NCT04600375|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP
~Survey A
~Routine clinic visit
~Verbal consultation only
~Survey B
~Verbal consultation AND Written Action Plan
~Survey C"
16311071|NCT04600375|Experimental|Experimental: Written Action Plan|"INTERVENTION GROUP
~Survey A
~Routine clinic visit
~Verbal consultation AND Written Action Plan
~Survey C"
16311072|NCT04600362|Experimental|Dupilumab|Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.
16311073|NCT04600362|Placebo Comparator|Placebo|Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.
16311074|NCT04600349|Experimental|Identity Oriented Psychotrauma Therapy (IOPT)|35 participants will be randomly allocated to the IOPT group. They will attend 10 groups of IOPT every two weeks and they will work 10 Intentions. The groups will be conducted by clinicians or psychotherapists specialized in IOPT. IOPT represents a group treatment developed by Franz Ruppert 20 years ago. It is an effective therapeutic intervention, offering access to less conscious aspects of our psyche, with the help of other persons, named 'representatives.' The method is based on the theory of multigenerational psychotraumatology developed by Ruppert. Although it is very often and widely used all over the world, it has not previously been the subject of randomized controlled trials (RCT), and therefore, its potential efficacy is unknown. In the current study, we want to test this new intervention model on autoimmune thyroiditis.
16311075|NCT04600349|Active Comparator|Treatment as Usual|35 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
16311076|NCT04600336|Experimental|Arm A (low-dose oxybutynin)|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
16311077|NCT04600336|Experimental|Arm B (high-dose oxybutynin chloride)|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
16311078|NCT04600336|Placebo Comparator|Arm C (low-dose placebo)|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm A per physician discretion.
16311079|NCT04600336|Placebo Comparator|Arm D (high-dose placebo)|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm C per physician discretion.
16311080|NCT04600323|Placebo Comparator|Placebo|Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day
16311081|NCT04600323|Experimental|Sodium bicarbonate|Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.
16311082|NCT04600310|Other|Study Arm 1 Conventional Prep/Control|The preoperative preparation for the control group will use ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) that will be applied to the skin using a sponge-on-a-stick method; this solution is widely recognized as optimal. After the alcohol-based solution has evaporated (no less than 3 minutes), the patient extremity is draped for surgery.
16311083|NCT04600310|Other|Study Arm 2 ULTRAPREP Group/Intervention Arm|ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) will be poured into the ULTRAPREP bag which will be placed on the patient's extremity while in the holding area; it will be removed only after scrub time of 3 minutes is complete and the patient has been transferred to the OR, anesthetized, and positioned. The patient is draped only after the solution has evaporated (no less than 3 minutes).
16311084|NCT04600297|Experimental|3D printed resin composite posterior FDP|Three units posterior fixed dental prosthesis made with 3D printed resin composite material
16311085|NCT04600284|Experimental|Sequence 1|Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
16311086|NCT04600284|Experimental|Sequence 2|Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
16311087|NCT04600284|Experimental|Sequence 3|Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
16311088|NCT04600284|Experimental|Sequence 4|Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
16311089|NCT04600284|Experimental|Sequence 5|Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
16311098|NCT04600206||Caregivers|Adult informal caregivers of patients who are diagnosed with stage IV solid tumors or stage III lung or ovarian tumors
16311099|NCT04600193|Experimental|Phosphate modified diet with organic phosphate|
16311100|NCT04600193|Experimental|Phosphate modified diet with inorganic phosphate|
16311101|NCT04600180||Palliative treatment with immunotherapy|
16311102|NCT04600167|Experimental|Isoniazid and Rifapentine (INH-RPT)|Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
16311103|NCT04600167|Placebo Comparator|Control|Participants in the control arm will receive placebo once weekly for 12 weeks.
16311104|NCT04600154|Experimental|MS-20|4ml, twice, daily
16311105|NCT04600154|Placebo Comparator|Placebo|4ml, twice, daily
16311106|NCT04600141|Active Comparator|Group 1 - Therapeutic anticoagulation|"(I) intravenous UFH started at a dose of 18 IU/kg/h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value; OR
~(II) subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours."
16311107|NCT04600141|Active Comparator|Group 2 - Prophylactic anticoagulation|"(I) subcutaneous UFH 5,000 IU every 8 hours; OR
~(II) subcutaneous LMWH - enoxaparin 40 mg daily."
16311108|NCT04600141|Experimental|Group 3 - Therapeutic anticoagulation with tocilizumab|"(I) Intravenous UFH initiated at a dose of 18 IU / kg / h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value associated with 8 mg / kg / tocilizumab infusion / intravenous dose in a single dose; OR
~Subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours associated with an infusion of tocilizumab 8 mg / kg / dose in a single dose."
16311109|NCT04600141|Experimental|Group 4 - Prophylactic anticoagulation with tocilizumab|"(I) subcutaneous UFH 5,000 IU every 8 hours associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose; OR
~(II) subcutaneous LMWH - enoxaparin 40 mg daily associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose."
16311110|NCT04600128|Active Comparator|Dairy-based Greek yogurt|Plain dairy-based Greek yogurt
16311111|NCT04600128|Active Comparator|Dairy-based cheddar cheese|Mild dairy-based cheddar cheese
16311112|NCT04600128|Active Comparator|Plant-based Greek yogurt|Plain plant-based Greek yogurt
16311113|NCT04600128|Active Comparator|Plant-based cheese|Medium cheddar plant-based cheese
16311114|NCT04600115|Experimental|MRI vs.PET with/without Cardiac disease|Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
16311115|NCT04600102||GROUP 1|Healthy able-bodied individuals with no history of lower extremity trauma.
16311116|NCT04600102||GROUP 2|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
16311117|NCT04600089|Placebo Comparator|Standard of Care|Participants in this group will receive standard of care as well as a saline infusion during the study period.
16311118|NCT04600089|Experimental|Sub-Dissociative Ketamine|Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
16311119|NCT04600076|Experimental|BabyCenter site and the community group|
16311120|NCT04600063|Other|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
16311121|NCT04600063|Experimental|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
16311122|NCT04600050|Active Comparator|Control group: stroke patients with education|
16311123|NCT04600050|Experimental|Experimental: stroke patients with exercise|
16311124|NCT04600037|Active Comparator|Group 1|Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
16311125|NCT04600037|No Intervention|Group 2|Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
16311126|NCT04600024||Piriformis syndrome group|Patients who were diagnosed as PS by diagnostic injection with ultrasound guidance
16311127|NCT04600024||Age and sex match control group|Patients who were excluded from the diagnosis of PS and had anteroposterior (AP) direct radiographic imaging
16311128|NCT04600011|Other|TELEREHABILITATION ARM|ARM 1: The TELEREHABILITATION ARM where participants receive the full originally-intended protocol that includes one initial in-person PT/OT evaluation, four virtual PT/OT visits, and one final in-person (or virtual, if in-person is not possible) PT/OT evaluation. The study duration for Arm 1 is about 10 weeks of the primary intervention as described with 3- and 6-month follow-up calls. The mobile virtual platform for Arm 1 is comprised of a tablet on a height-adjustable rotating tablet floor stand with a gooseneck and wheels.
16311167|NCT04599764|Active Comparator|Anodal Stimulation|Participants will receive anodal tDCS daily for two weeks
16311168|NCT04599764|Active Comparator|Anodal tDCS with Cognitive training|Participants will receive anoale tDCS daily and cognitive training for two weeks
16311169|NCT04599764|Sham Comparator|sham stimulation|Participants will receive cathodal tDCS daily for two weeks
16311170|NCT04599751|Experimental|Hair removal treatment|Trio laser module (Alma Lasers)
16311129|NCT04600011|Other|VIRTUAL HOME SAFETY EVALUATIONS (HSE)-ONLY ARM|ARM 2: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
16311130|NCT04599998||COVID-19 inpatients|Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
16311131|NCT04599985|Experimental|Star excursion balance training (SEBT)|Received star excursion balance training (SEBT) program. Performed 3-trials in all 8 directions of the SEBT grid.
16311132|NCT04599985|Active Comparator|Simplified star excursion balance training (SSEBT)|Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
16311133|NCT04599972|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
16311134|NCT04599972|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
16311135|NCT04599959|Experimental|Overall (Swab/Saliva)|
16311136|NCT04599946|Experimental|Experimental formula|Infant and follow-on goat milk formula
16311137|NCT04599946|Active Comparator|Control formula|Infant and follow-on cow milk formula
16311138|NCT04599933|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
16311139|NCT04599933|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
16311140|NCT04599920|Active Comparator|Red meat supplementation providing 25% of protein intake|A diet supplemented with 760 g of cooked and boneless red meat per week, corresponding the average consumption of red meat in Finnish men.
16311141|NCT04599920|Experimental|Red meat mostly replaced with legume-based foods|A diet supplemented with legume-based foods providing 20% of protein intake and with 200 g per week of red meat providing 5% of protein intake.
16311142|NCT04599907|Experimental|Roll-In Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
16311143|NCT04599907|Experimental|Randomized Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
16311144|NCT04599907|Sham Comparator|Randomized Cohort: Sham Patch|Subjects will undergo identical procedure with an inactive sham device
16311145|NCT04599894|Sham Comparator|control group|Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
16311146|NCT04599894|Experimental|study group|Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
16311147|NCT04599881|Experimental|PTR-01 3 mg/kg|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg every other week for a total of 7 doses.
16311148|NCT04599868|Active Comparator|low dose of magnesium sulfat|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 1g / h ( low dose group
16311149|NCT04599868|Active Comparator|High dose of magnesium sulfat|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h ( high dose group )
16311153|NCT04599842|No Intervention|GROUP SA|Group SA was categorized as the group which spinal anaesthesia alone (SA) was performed
16311154|NCT04599842|Active Comparator|GROUP SA+ESP|Group SA+ESP was categorized as group which SA+ESP block was performed.
16311155|NCT04599829||Orthosis Group 1|Use of AnkleSTRONG100 device
16311156|NCT04599829||Control Group 1|Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
16311157|NCT04599829||Orthosis Group 2|Use of AnkleSTRONG500 device
16311158|NCT04599829||Control Group 2|Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
16311159|NCT04599829||Orthosis Group 3|Use of AnkleSTRONG900 device
16311160|NCT04599829||Control Group 3|Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
16311161|NCT04599816|Active Comparator|levosimendan administration at a dose of 3 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction
16311162|NCT04599816|Active Comparator|levosimendan administration at a dose of 6 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction
16311163|NCT04599816|Active Comparator|levosimendan administration at a dose of 12 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction
16311164|NCT04599803|Experimental|Participants diagnosed with Obstructive Sleep Apnea|This will be a single arm study of participants that are diagnosed with Obstructive Sleep Apnea (OSA) during the study. Upon confirmation of OSA and prescription of positive airway pressure (PAP) therapy, the participant will begin using the Verily Sleep Apnea (VSA) app to supplement PAP treatment.
16311165|NCT04599790|Experimental|TACE-Len-Sin|TACE combined with lenvatinib and sintilimab.
16311166|NCT04599777|Experimental|TACE-Sor-Tis|TACE combined with sorafenib and tislelizumab.
16311172|NCT04599738|Experimental|Finger millet grain muffin|Muffin made with 50% wheat flour and 50% finger millet crushed grain
16311173|NCT04599725||Pregnant people|
16311174|NCT04599699|Experimental|1|"Simultaneously integrated boost or sequential integrated boost
~Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.
~Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy."
16311175|NCT04599686|Active Comparator|ADT|Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.
16311176|NCT04599686|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
16311177|NCT04599673|Experimental|AMNIOGEN|Intraoperative1 kit of AMNIOGEN injection into shoulder joint after RCT repair.
16311178|NCT04599673|Placebo Comparator|Normal saline|Intraoperative 10 ml of normal saline injection into shoulder joint after RCT repair.
16311179|NCT04599660||Low Risk GISTs|This cohort include patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020.
16311182|NCT04599621||patients with unstable angina|This group included patients with frequent anginal attacks, with a burdened history and comorbid conditions.
16311183|NCT04599595||Multiple Scerosis (MS) Group|This group will be composed by 150 MS patients who, consecutively, from the start of the study, will refer to the MS clinic of the Neurology Unit of the Ferrara University Hospital, Italy. The first 50 patients with a PACQoL score ≥ 32 will be asked to be willing to enter the next phase of the study that continues at the Coloproctological Outpatient Clinic of Ferrara University Hospital, Italy with an appointment provided by the neurologist with a pre-established schedule (with written consent).
16311184|NCT04599582|Active Comparator|SP-CL|
16311185|NCT04599582|Active Comparator|Corail|
16311189|NCT04599543|Experimental|Administration of IL3 CAR T-cells|
16311190|NCT04599530|Other|Biomechanical|All experimental tasks will be evaluated on biomechanical outcome measures
16311191|NCT04599530|Other|Psychological|All experimental tasks will be evaluated on psychological outcome measures
16311192|NCT04599530|Other|Physiological|All experimental tasks will be evaluated on biomechanical outcome measures
16311193|NCT04599530|Other|Performance|All experimental tasks will be evaluated on biomechanical outcome measures
16311196|NCT04599491|Experimental|INTELLiVENT-ASV with sidestream capnography|Patients randomized into the 'Sidestream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring.
16311197|NCT04599491|Active Comparator|INTELLiVENT-ASV with mainstream capnography|Patients randomized into the 'Mainstream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring.
16311198|NCT04599478|Experimental|Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
16311199|NCT04599478|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.
16311200|NCT04599478|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.
16311201|NCT04599478|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
16311202|NCT04599465|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
16311203|NCT04599452|Experimental|10 patients with recurrent refractory elderly AML were treated|The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
16311204|NCT04599439||High arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass > 5.15 g will be considered at highest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
16311205|NCT04599439||Low arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass < 5.15 g will be considered at lowest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
16311206|NCT04599426|Experimental|Test Group|10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.
16311207|NCT04599387|Active Comparator|Supervised Exercise arm|
16311208|NCT04599387|Placebo Comparator|Usual care arm|
16311209|NCT04599374||high TSH and high FT4|patients with high TSH and high FT4
16311210|NCT04599374||high TSH and low FT4|patients with high TSH and low FT4
16311211|NCT04599374||high TSH and high FT3|patients with high TSH and high FT3
16311213|NCT04599361||Patients with CHD|"outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)
~Patients will receive questionnaires."
16311214|NCT04599348|Experimental|Active Ginseng treatment|People with CFS or Fibromyalgia will receive HRG 80 Red GInseng
16311215|NCT04599335|Experimental|HA + Lidocaine|
16311216|NCT04599335|No Intervention|Negative|
16311217|NCT04599322|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
16311218|NCT04599309||PRE-MERIDIAN|Patients with a histological or cytological diagnosis of LA-HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx (stage III HPV positive or stage III-IV HPV negative). Patients who are candidates for standard definitive treatment such as surgery followed by radiotherapy +/- chemotherapy, or definite radiotherapy, or definite chemoradiotherapy.
16311219|NCT04599296|Active Comparator|Hip Brace|This group will be assigned to wear a hip brace post surgery.
16311220|NCT04599296|No Intervention|No Intervention|This group will not be assigned a hip brace after surgery.
16311221|NCT04599283|Active Comparator|Symptomatic|"You have to be a male patient.
~You must have a smartphone (iPhone or Android).
~You are at least 35 years old and have already been diagnosed with BPH or Overactive Bladder (OAB) condition OR you are presenting at least one of the following BPH / OAB symptoms:
~1. Frequent or urgent need to urinate 2. Increased frequency of urination at night (nocturia) 3. Difficulty starting urination 4. Weak urine stream or a stream that stops and starts 5. Dribbling at the end of urination 6. Inability to completely empty the bladder 7. Experience urge incontinence - the involuntary loss of urine immediately following an urgent need to urinate"
16311222|NCT04599283|Active Comparator|Asymptmatic|"You have to be a male patient.
~You must have a smartphone (iPhone or Android).
~You are at least 18 years old and have not been diagnosed with BPH or OAB, and you are not presenting any of the above symptoms."
16311223|NCT04599270|Experimental|Intervention group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.
~If adolescent have not risk personality traits, the patient will go out of the study.
~If adolescent have risk personality traits, other tests and scales will be performed to study the intensivity of dependance of substance use and the patient will be randomized.
~If he is randomized in intervention group, the patient will follow PREVENTURE program (2 session of 90 min by videoconference), within 3 months after inclusion and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after sessions to answer the same tests and scales."
16311224|NCT04599270|Active Comparator|Control group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.
~If adolescent have not risk personality traits, the patient will go out of the study.
~If adolescent have risk personality traits, other tests and scales will be performed to study the severity of substance use disorders and the patient will be randomized.
~If he is randomized in control group, the patient will follow routine care and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after inclusion to answer the same tests and scales."
16311225|NCT04599257|Experimental|Hip and thigh circumference changes|"The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits. All of the study subjects will receive the treatment with the subject device.
~At the baseline visit, MRI imaging will be performed; the subject's weight and hip and thigh circumference will be recorded. Photos of the treated area will be taken.
~The treatment administration phase will consist of four (4) treatments, delivered once a week. The applicator of the device will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
~At the last therapy visit, the subject's weight and hip and thigh circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire to fill in."
16311226|NCT04599244|Experimental|emergency pulpotomy|intervention arm
16311227|NCT04599244|Active Comparator|complete pulp extirpation|control arm
16311228|NCT04599231|Experimental|Study group|"The investigators would perform the following tests preoperatively on the study subjects.
~Hospital Anxiety and Depression Scale (HADS)
~Amsterdam Preoperative Anxiety and Information Scale (APAIS)
~Coping and Adaptation Processing Scale-Short Form (CAPS-SF)
~Quality of Recovery -15 (QOR-15)"
16311229|NCT04599218|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as an ultrasound guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy.
16311230|NCT04599205|Experimental|Microneedling group A|"Patients will be subjected to the following:
~Combined laser (power=3.6 mJ) and topical tranexamic acid (TXA) (one finger unit) gel on the right half of the face.
~Combined microneedling (by dermapen) and topical TXA gel only on the left half. Self application of topical TXA gel (2 finger units) on both sides on daily base."
16311231|NCT04599205|Experimental|Laser group B|"Patients will be subjected to the following:
~Combined laser(power=3.6 mJ) and topical TXA gel (one finger unit) on the right half.
~Laser (power=3.6 mJ) only on the left one."
16311232|NCT04599205|Experimental|Gel group C|patients will be subjected to: Daily application of topical TXA gel (2 finger units) on both face sides.
16311233|NCT04599192||Women Presenting with Cardiac Ischemia|Women presenting with cardiac ischemia as indicated by standard of care non-invasive stress testing with cardiac magnetic resonance (CMR), SPECT myocardial perfusion, and PET myocardial perfusion imaging. This cohort of women must also meet the clinical criteria to undergo coronary angiography. Women may be approached for consent either before or after their coronary angiography procedure.
16311234|NCT04599179||Group 1|Patients underwent placement of a self-expandable metal stent (SEMS)
16311235|NCT04599179||Group 2|Patients underwent to stomach-partitioning gastrojejunostomy
16311265|NCT04598932||2 Keratoconus|Patients with various stages of keratoconus
16311236|NCT04599166|Experimental|Participant arm|Participants will be recruited to complete the WWYC intervention.
16311237|NCT04599153|Experimental|High initial|At the one month follow-up, the shunt is adjusted into a high opening pressure (2.5), which is crossed over to 1.0 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
16311238|NCT04599153|Experimental|Low initial|At the one month follow-up, the shunt is adjusted into a low opening pressure (1.0), which is crossed over to 2.5 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
16311239|NCT04599140|Experimental|Treatment (SX-682, nivolumab)|"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.
~COMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16311240|NCT04599127|Experimental|Mobilization with movement|Mobilization with movement on the shoulder abduction and external rotation
16311241|NCT04599127|Placebo Comparator|Conventional physical therapy|Postural correction exercise and muscle strengthening of the rotator cuff muscle and surrounding muscle on the subacromial region
16311242|NCT04599114|Experimental|VIRTUES Arm|Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
16311243|NCT04599101|Active Comparator|Nose frida nasal suction device|nose frida nasal suction device to clear nasal secretions
16311244|NCT04599101|Active Comparator|Bulb syringe nasal suction device|bulb syringe nasal suction device to clear nasal secretions
16311245|NCT04599088|Experimental|Brain functional MRI with simplified urodynamics|Females with urgency urinary incontinence
16311246|NCT04599075|Experimental|Intravenous Insulin Infusion|Patients will be randomized to discontinuation of the CSII pump intrapartum and initiation of IV insulin infusion per hospital protocol.
16311247|NCT04599075|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Patients will be randomized to continuation of their CSII pump intrapartum and will be managed in accordance with the CSII hospital protocol.
16311248|NCT04599062|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy
~Talimogene Laherparepvec Dose Levels:
~Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly
~Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks"
16311250|NCT04599036|Experimental|Feasibility|To explore if the feasibility of adding an EMG controlled device to the acute rehabilitation for stroke subjects with severe arm deficit.
16311251|NCT04599023||MS patients including CIS|Patients with a diagnosis of MS, including Clinically Isolated Syndrome (CIS), who have the ability to understand the audio and visual instructions for the MSPT modules and whose visual function that does not preclude an ability to see the screen of the MSPT tool.
16311252|NCT04599010|Active Comparator|Calorie-restricted arm|Permissive feeding volume restriction to 110 ± 10 mL/kg/day without increasing the milk calorie density, for 2-weeks
16311253|NCT04599010|Active Comparator|Standard feeding|The standard feeding approach will include an oral feeding volume goal of 150 ± 10 mL/kg/day during the 2-week study period
16311254|NCT04598997||600 patients involved in the prospective study|These patients will be contacted by telephone follow-up, offered participation in the study and sent the information and non-opposition letter. In case of refusal, data will not be used.
16311255|NCT04598997||1000 patients involved in a non-human study|To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiograms performed in a stable disease context will also be identified.
16311256|NCT04598984||Low levels of serum adipokines|
16311257|NCT04598984||High levels of serum adipokines|
16311258|NCT04598971||Cystitis|Patients with lower UTI will be included in this group
16311259|NCT04598971||Pyelonephritis|Patients with higher UTI will be included in this group
16311260|NCT04598958|Experimental|IMPROVE|A cluster of 6 health facilities are to receive the IMPROVE Intervention. The IMPROVE intervention includes: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees with particular attention to HIV-positive women to minimize loss to follow-up.
16311261|NCT04598958|No Intervention|Standard of care|A cluster of 6 health facilities receive Standard of Care. Routine health facility services offering the national standard of care for pregnant and breastfeeding women in Lesotho
16311262|NCT04598945|Experimental|Adults|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
16311263|NCT04598945|Experimental|Children|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
16311264|NCT04598932||1: Normal Controls|Patients with normal corneas without any prior surgery to serve as the control group
16311266|NCT04598932||3: LASIK|Patients with normal corneas who are undergoing laser in situ keratomileusis (LASIK)
16311267|NCT04598932||Group 4: PRK|Patients with normal corneas who are undergoing photorefractive keratectomy (PRK)
16311268|NCT04598932||5: SMILE|Patients with normal corneas who are undergoing small incision lenticular extraction (SMILE)
16311269|NCT04598932||6: CXL|Patients with keratoconus who are undergoing corneal cross-linking (CXL)
16311270|NCT04598919|Active Comparator|Saracatinab|saracatinib 125 mg once daily by mouth for 24 weeks
16311271|NCT04598919|Placebo Comparator|Placebo|matching placebo once daily by mouth for 24 weeks
16311272|NCT04598906|Experimental|Virtual environment rehabilitation - Paper-pencil rehabilitation|The participants in this arm completes Virtual environment rehabilitation as the first condition and then crossover to Paper-pencil rehabilitation.
16311273|NCT04598906|Experimental|Paper-pencil rehabilitation - Virtual environment rehabilitation|The participants in this arm completes Paper-pencil rehabilitation as the first condition and then crossover to Virtual environment rehabilitation.
16311274|NCT04598893||Teplizumab|Participants who received teplizumab in the PROTECT study
16311275|NCT04598893||Placebo|Participants who received placebo in the PROTECT study
16311276|NCT04598880|Experimental|Pleinvue|Subjects receive polyethylene glycol + ascorbate (PEG1A) as laxative treatment for colonoscopy preparation.
16311277|NCT04598880|Experimental|Citrafleet|Subjects receive sodium picosulfate + magnesium citrate (PSCM) as laxative treatment for colonoscopy preparation.
16311278|NCT04598867|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner for 32 weeks.
16311279|NCT04598867|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, and dinner for 8 weeks.
16311280|NCT04598867|Active Comparator|Afobazol 30 mg/day|Patients assigned to the Afobazol 30 mg/day group will receive 1 tablet of Afobazol (10 mg) before breakfast, before lunch and before dinner for 8 weeks.
16311281|NCT04598854|Experimental|Treatment group|The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
16311282|NCT04598854|Sham Comparator|Control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
16311283|NCT04598828|Experimental|Treatment 1|Participants will receive Experimental treatment 1 stimulation for a duration of 12 weeks, twice daily for 19 minutes
16311284|NCT04598828|Experimental|Treatment 2|Participants will receive Experimental treatment 2 stimulation for a duration of 12 weeks, twice daily for 19 minutes
16311285|NCT04598815|Experimental|Sirolimus and Placebo|Sirolimus for 12 weeks, followed by a 12-week wash-out period, and by a 12-week follow-up period.
16311286|NCT04598815|Experimental|Placebo and Sirolimus|Placebo for 12 weeks, followed by a 12-week wash-out period, and by a 12-week treatment with Sirolimus.
16311287|NCT04598802||Covera Plus|
16311288|NCT04598763|Other|classic group|"the classic group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove)"
16311289|NCT04598763|Other|intensive|"the intensive group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce)."
16311290|NCT04598737|Experimental|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
16311291|NCT04598737|Experimental|Lithium disilicate|Lithium disilicate laminate veneer treatment
16311292|NCT04598724||Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
16311293|NCT04598724||Care Givers for Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
16311294|NCT04598711|Experimental|Remote Limb Ischemic Conditioning (RLIC)|"RLIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 200 mmHg on the more involved thigh. RLIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RLIC is performed on visits 1-14.
~Interventions:
~Behavioral: RLIC
~Behavioral: Muscle power training
~Behavioral: Balance training
~Behavioral: Treadmill training"
16311295|NCT04598711|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved thigh. Sham involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. Sham conditioning is performed on visits 1-14.
~Interventions:
~Behavioral: RLIC
~Behavioral: Muscle power training
~Behavioral: Balance training
~Behavioral: Treadmill training"
16311296|NCT04598672|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
16311297|NCT04598646|Experimental|Cario-Oncology Rehabilitation (CORE)|"CORE consists of exercise therapy, CVD risk factor management for the first 6 months and behavioural support for 2 years.
~Exercise therapy: Staff will prescribe and deliver a standardized, yet individually tailored (based on CPET results), aerobic exercise programs consisting of two days of supervised, facility-based high-intensity interval training (HIIT) and one day of supervised home-based moderate-intensity continuous training (MICT) per week. Exercise HRs and durations will be monitored using an accurate commercially available wrist-worn HR monitor and PA tracker (e.g., Apple watch).
~CVD risk factor management: CVD risk factors will be assessed and treated according to Canadian guidelines.
~Behavioural support: All participants will receive a planned sequence of educational and instructional material via email and ongoing PAYA-CS tailored education and peer support during the follow-up period using a peer support online system."
16311398|NCT04597840|Other|standard of repair group|Patient will undergo incisional hernia repair according to the standard of repair, which is simple suture or mesh reinforcement (using synthetic or biological meshes).
16311399|NCT04597827||Semantic dementia|Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)
16311400|NCT04597827||Alzheimer's disease|NIAAA 2011 criteria
16311401|NCT04597827||Control|MMSE above 27, no neurological or psychiatric disorder
16311298|NCT04598646|Active Comparator|Support|The Support group will receive the behavioural support only. The timing and nature of all education, information, and Young@Heart-based peer support provided to Support participants will be identical to what is provided to CORE participants. The key difference in the long-term behavioural support strategy between CORE and Support participants is how weekly exercise goals are defined. Unlike the CORE participants who will be encouraged to use the PAI Score, Support participants will be given the challenge of meeting and maintaining the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).
16311299|NCT04598646|Active Comparator|Passive Behavioural Support (PBS) Groups|All PBS cohort participants will receive the same wrist-worn HR monitor and PA tracker as the CORE and Support participants. However, PBS participants will be blindly randomized to one of two passive behavioural support interventions (PBS1 and PBS2). PBS1 participants will be asked to download the same PAI Health application as CORE participants and will similarly be given the challenge of meeting and maintaining a weekly PAI Score ≥100 throughout the 18-month follow-up period. PBS2 participants will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week). PBS participants will not receive any additional interventions and will be followed up with and reassessed at 12- and 24-months.
16311300|NCT04598633|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
16311301|NCT04598633|Placebo Comparator|Placebo-lozenges (BioGaia)|
16311302|NCT04598607|Experimental|Hypidone Hydrochloride 60mg|30mg(10mg×3) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
16311303|NCT04598607|Experimental|Hypidone Hydrochloride 80mg|40mg(10mg×4) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
16311304|NCT04598607|Experimental|Hypidone Hydrochloride 100mg|50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
16311305|NCT04598607|Placebo Comparator|Placebo 60mg|3 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
16311306|NCT04598607|Placebo Comparator|Placebo 80mg|4 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
16311307|NCT04598607|Placebo Comparator|Placebo 100mg|5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
16311308|NCT04598594|Experimental|Nicotine patch|
16311309|NCT04598594|Placebo Comparator|Placebo patch|
16311310|NCT04598581|Active Comparator|Low Dose Radiation Therapy (LD-RT)|
16311311|NCT04598581|Sham Comparator|Sham irradiation|
16311312|NCT04598568||balanSys UNI knee prosthesis|Participants treated with a balanSys® UNI knee prosthesis
16311313|NCT04598542|Experimental|TA injection followed by LOR injection|IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.
16311314|NCT04598542|Experimental|LOR injection followed by TA injection|IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.
16311315|NCT04598529|Active Comparator|A2 milk|A2 milk, organic, 200ml, twice daily
16311316|NCT04598529|Placebo Comparator|Conventional milk|Pasteurized semi-skimmed milk, organic, 200ml, twice daily
16311317|NCT04598503||cases|All the babies admitted to the hospital with congenital anomalies during this period were included
16311318|NCT04598503||control|newborns without congenital anomalies
16311319|NCT04598490|Experimental|Healed extraction site|Old Extraction Space
16311320|NCT04598490|Experimental|unhealed extraction site|Recent Extraction space
16311321|NCT04598477|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
16311322|NCT04598464|Experimental|Exercise group|The home-based training program
16311323|NCT04598464|No Intervention|control group|All patients participated in a one-session educational program conducted by the investigators at each clinic.
16311324|NCT04598451|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
16311325|NCT04598451|Experimental|placebo|patients receiving placebo on top of prednisone
16311326|NCT04598438|Experimental|Music intervention treatment group|Participants attending the music behavioral early intervention program
16311327|NCT04598438|Active Comparator|Arts and crafts active control group|Participants attending the arts and crafts developmental enhancement program
16311328|NCT04598425|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
16311329|NCT04598412||Mexican sample|Aged >60 years (n = 187)
16311330|NCT04598412||German sample|Aged >75 years (n = 97)
16311331|NCT04598412||Northamerican sample|Aged >60 years (n = 200)
16311332|NCT04598412||British sample|Aged >70 years (n = 38)
16311333|NCT04598399|Experimental|MBRP program:|
16311334|NCT04598399|Active Comparator|Standard care|
16311335|NCT04598386|Experimental|PR Lotion Topical Solution|Approximately 50 grams of PR Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. This lotion will be applied once during the 4th of session of their PR Lotion Phase and will remain on the skin for approximately 4.5 hours.
16311336|NCT04598386|Placebo Comparator|Placebo Lotion Topical Solution|Approximately 50 grams of the Placebo Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. The only difference in ingredients for this Placebo Lotion will be the exclusion of the sodium bicarbonate ingredient. This lotion will be applied once during the 4th of session of their Placebo Lotion Phase and will remain on the skin for approximately 4.5 hours.
16311337|NCT04598373||IDT patients|Allocated to an IDT program
16311338|NCT04598373||Non-IDT patients|Not allocated to an IDT program
16311339|NCT04598360|Experimental|Experimental: Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS
16311402|NCT04597814||interstitial lung disease patients|interstitial lung disease patients who need lung transplantation
16311403|NCT04597814||non- interstitial lung disease patients|non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
16312189|NCT04592263||Group 2 - Quantitative phase|Pilot study of the tools developed from phase 1.
16311340|NCT04598347||Pregnant women diagnosed with SARS-CoV-2|Pregnant women diagnosed with SARS-CoV-2 infection(by PCR on nasopharyngeal aspirate or serology)that have an indication to perform an invasive technique(chorionic biopsy or amniocentesis) along thegestation.The sample size will depend on the duration of theSARS-CoV-2 pandemic.Initially we propose a study period of 18months in which we would have an approximate total of 225pregnant women with indication of invasive technique.It is planned to conduct a PCR study for SARS-CoV-2 in amniotic fluid or chorionic villi to thosepregnant women diagnosed with SARS-CoV-2 infection(approximately 5% of the total pregnant womenwith indication of invasive technique (11-12 pregnant women)).This determination is made as part of theroutine clinical practice in the context of the study of screening for perinatal infections
16311341|NCT04598334||COVID-19 positive by RT-PCR|specified number of COVID-19 positive patients will be followed up from admission to outcome (discharge/death/referral). Blood samples will be tested at different time points; cytokines and stool microbiota will be tested at the end of the study and we will analyze the study findings.
16311342|NCT04598321|Experimental|Planned Therapy|Talazoparib monotherapy as 1 mg capsule orally on a daily basis for three cycles, defined as a 21-day period, prior to surgery. Volunteers will continue treatment to complete three cycles, unless disease progression or unacceptable toxicity occurs.Volunteers who complete neoadjuvant treatment with talazoparib should undergo surgical cytoreduction within three weeks of their last dose of talazoparib. All volunteers should then undergo standard of care adjuvant therapy using carboplatin and paclitaxel. For volunteers, who agree to continue talazoparib as maintenance therapy, treatment should begin three weeks (+/- 2 weeks) from the end of adjuvant chemotherapy or after cytoreductive surgery alone.
16311343|NCT04598308||patients undergoing invasive assessment of the microcirculation|All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.
16311344|NCT04598295|Experimental|microbial consortia (DS-01)|DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
16311345|NCT04598295|Placebo Comparator|placebo|Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
16311346|NCT04598282|Placebo Comparator|Control Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID (four times daily) for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
16311347|NCT04598282|Active Comparator|Treatment Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion). The treatment arm will also receive the placement of PROKERA SLIM for 5-7 days. A second PROKERA SLIM may be applied based on investigator's discretion. For patients with bilateral involvement only the worse eye will be enrolled for the treatment arm.
16311348|NCT04598269|Experimental|ATI-1777 topical solution 2.0% w/w|ATI-1777 topical solution 2.0% w/w, twice daily
16311349|NCT04598269|Placebo Comparator|Vehicle|Vehicle topical solution, twice daily
16311350|NCT04598256||Children who underwent endoscopic procedures|"Children between the ages of 1-18 who were underwent endoscopic procedures
~Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure
~Patients who volunteered to study"
16311351|NCT04598243|Experimental|Treatment of CFS/FMS with the nutritional combination|
16311352|NCT04598230|Active Comparator|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy and one of three study medications (fluoxetine, sertraline, or escitalopram).
16311353|NCT04598230|Active Comparator|Cognitive behavioral therapy (CBT)|Participants randomized to this arm will receive cognitive behavioral therapy (CBT) only
16311354|NCT04598204|Experimental|Treatment Arm|To treat the enrolled patients with oral rapamycin at an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
16311355|NCT04598191|Placebo Comparator|Control group|Participants in this group are administered inhaled normal saline.
16311356|NCT04598191|Experimental|iloprost group|Participants in this group are administered inhaled iloprost.
16311357|NCT04598178||Taiwan Cohort|For normative Taiwan people, cognitive function will be assessed by the Taiwan version of questionnaire Qmci (Qmci-TW) on Day 0, Day 2, Day 180.
16311358|NCT04598165|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
16311359|NCT04598165|No Intervention|No SMS Control|Control receiving standard of care.
16311360|NCT04598152|Experimental|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
16311362|NCT04598126|Active Comparator|Traditional physical therapy|Traditional physical therapy
16311363|NCT04598126|Experimental|patient education manual +traditional physical therapy|Patient education manual +traditional physical therapy
16311364|NCT04598113|Active Comparator|Effective Traction/Sham Traction|Group of patients treated firstly with Effective Traction then with Sham Traction
16311365|NCT04598113|Sham Comparator|Sham Traction/Effective Traction|Group of patients treated firstly with Sham Traction then with Effective Traction
16311443|NCT04597502|Placebo Comparator|Oral Placebo, Topical Placebo|Oral Placebo, Topical Placebo on both forearms and dorsal hands
16311366|NCT04598100|Active Comparator|FOCUS-EC|"FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment & combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's home activity, primary activity and discussion, selection of a new home activity, and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions."
16311367|NCT04598100|No Intervention|Web-Based Family Education|Families in the WB condition will be provided access to online educational materials covering topics such as typical child development, effects of early childhood separations, common child reactions to family stress, and the importance of self-care. CDM families in this condition will also have access to the standard services that are available to OEF/OIF/OND veterans through the VHA system, TriCare, and California Department of Veterans Affairs.
16311370|NCT04598074|Experimental|Opioid Package Prototype (OPP)|Oxycodone 5mg tablets dispensed in the Opioid Package Prototype (OPP) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
16311371|NCT04598074|Active Comparator|Usual Care (standard amber vial)|Oxycodone 5mg tablets dispensed in the standard amber vial (usual care) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
16311372|NCT04598061||Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery|Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery
16311373|NCT04598048||EMMACE 3|Participants who were recruited to the EMMACE 3 study and have agreed to contact for further research.
16311374|NCT04598035||Primary Group|Patients with chronic low back pain that candidates them for surgical implant of a SCS device, and received a permanent SCS device.
16311375|NCT04598035||Control Group|Patients with chronic low back pain that are candidates for a surgical implant of a SCS device and do not receive a permanent SCS device after trial leads are placed.
16311376|NCT04598022||vegan|subjects having a vegan nutrition pattern for at least the last 3 months
16311377|NCT04598022||vegetarian|subjects having a vegetarian nutrition pattern for at least the last 3 months
16311378|NCT04598022||omnivores|subjects having a omnivore nutrition pattern for at least the last 3 months
16311379|NCT04598009|Experimental|Treatment (binimetinib, imatinib)|Patients receive binimetinib PO BID on days 1-28 and imatinib PO QD on days 1-28. Cycles repeat every 28 days
16311380|NCT04597996|Experimental|Web Based Education|A pre-test will be applied. Web-based education will be conducted. The post-test will be applied 3 months after Web-based education is completed.
16311381|NCT04597996|No Intervention|No Intervention Group|The control group will not have any intervention during the study.
16311382|NCT04597983|Experimental|2S-hesperidin|This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks
16311383|NCT04597983|Placebo Comparator|Placebo|This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks
16311384|NCT04597970|Experimental|cTACE-HAIC(oxaliplatin and raltitrexed)|Patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle
16311385|NCT04597957|Experimental|Fresh Rx Intervention group|The Fresh Rx intervention group will receive up to 8 visits to the community based farmers market with $10 incentive for fruits and vegetables at each visit.
16311386|NCT04597957|Active Comparator|Diabetic Standard of Care Control group|Diabetic standard of care control group will receive no incentive for the community based farmers market.
16311388|NCT04597931|Experimental|SC Romosozumab 210 mg/monthly|SC Romosozumab 210 mg/monthly
16311389|NCT04597931|Active Comparator|IV Zoledronic acid 5 mg|IV Zoledronic acid 5 mg
16311391|NCT04597905||CD Participants|Participants diagnosed with CD from the 7 participating countries will take part in survey to collect data regarding their preferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
16311392|NCT04597905||UC Participants|Participants diagnosed with UC from the 7 participating countries will take part in survey to collect data regarding theirpreferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
16311393|NCT04597879||Severe traumatic brain injury|
16311394|NCT04597879||Severe trauma without brain trauma|
16311395|NCT04597879||Healthy controls|
16311396|NCT04597866||CRPS|
16311397|NCT04597840|Experimental|biosynthetic mesh group|Patient will undergo incisional hernia repair with biosynthetic mesh reinforcement. Based on the discretion of the surgeon, two types of biosynthetic mesh from different brand can be used: the Phasix mesh from BARD or the BioA mesh from GORE. These two biosynthetic meshes are resorbable, which means they are gradually absorbed by the body.
16311444|NCT04597502|Experimental|Oral Placebo, Topical TC|Oral Placebo, Topical TC on both forearms and dorsal hands
16311404|NCT04597801|Experimental|Fluorescein sodium|A single dose of fluorescein sodium is applied before brain tumor resection. 20-40 minutes prior to the planned tumor resection, a bolus of 5 mg per kg body weight is administered intravenously, staining tumor tissue with fluorescent dye to visualize tumor cells.
16311405|NCT04597788|Experimental|Protein supplemented very low calorie diet program|The lifestyle intervention using protein supplemented very low calorie meals will be implemented with individual counseling sessions for 12 months. Initial intensive weight loss stage will be delivered during the first 4 month period with total meal replacement to partial meal replacement using protein supplemented very low calorie meals. During the weight loss maintenance stage, regular intermittent very low calorie meal replacement one week per month will be delivered for the entire period. Mobile counseling will be offered to help patients achieve weight loss as well as weight loss maintenance.
16311406|NCT04597788|Active Comparator|Conventional low calorie diet program|The conventional low calorie diet program will be offered to participants assigned to control group using educational material and individual counseling sessions for 12 months. Mobile counseling will be also offered for weight loss and weight loss maintenance.
16311407|NCT04597775|Experimental|Arm 1 hydroxychloroquine 800mg day 1 and hydroxychloroquine 400mg day 2-5|hydroxychloroquine 800mg (400mg twice daily) given orally on day 1, (loading dose) hydroxychloroquine. Then 400mg (200mg 2 tablets) on day 2,3, 4 and 5.
16311408|NCT04597775|Active Comparator|Arm 2 hydroxychloroquine 400mg day 1 and hydroxychloroquine 200mg day 2-5|hydroxychloroquine 400mg (200mg twice daily) Given orally first day (loading dose), then 200mg once daily on day 2,3, 4 and 5.
16311409|NCT04597775|No Intervention|No Intervention|No Intervention- SARS-CoV-2 surveillance Standard control measures in the country of interest such as self isolation, good personal hygiene and good nutrition.
16311410|NCT04597762|Experimental|right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye
16311411|NCT04597762|Experimental|left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye
16311412|NCT04597749|Experimental|Concurrent PSG, HSAT, and Screener App Test|Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone.
16311413|NCT04597736|Experimental|cohort|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
16311414|NCT04597723|Experimental|80% oxygen|80% oxygen given group
16311415|NCT04597723|Experimental|60% oxygen|60% oxygen given group
16311416|NCT04597723|No Intervention|routine hospital care|The patients in this group received routine hospital care.
16311417|NCT04597697|Experimental|Subjects with normal hepatic function|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
16311418|NCT04597697|Experimental|Subjects with mild hepatic impairment, child-pugh grade A|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
16311419|NCT04597697|Experimental|Subjects with moderate hepatic impairment, child-pugh grade B|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
16311420|NCT04597697|Experimental|Subjects with severe hepatic impairment, child-pugh grade C|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
16311421|NCT04597684|Active Comparator|Treatment/Intervention|Total Knee Arthroplasty (TKA) with cementless knees
16311422|NCT04597684|Active Comparator|Control|Total Knee Arthroplasty (TKA) with cemented knees
16311423|NCT04597671|Experimental|Arm A|Durvalumab with low-dose PCI
16311424|NCT04597671|Active Comparator|Arm B|Durvalumab with observation
16311425|NCT04597658|Active Comparator|Conventional rehabilitation|
16311426|NCT04597658|Experimental|Body weightsupported treadmill training|
16311427|NCT04597645|Experimental|Elastic band (EB)|EB group participants who are attending sheltered employment will received Elastic Thera band training program two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainer) over 16 weeks for a total of 32 sessions.
16311428|NCT04597645|No Intervention|Control group (CG)|Control group participants will receive usual care.
16311429|NCT04597632|Experimental|brolucizumab 6 mg|Participants will receive brolucizumab 6 mg/0.05 mL solution by intravitreal injection in a Treat-to-Control regimen with injection intervals from 4 up to 20 weeks. Intervals may be changed in steps of 4 weeks at a time per investigators' decisions determined by the disease activity.
16311430|NCT04597619|No Intervention|Pre-Implementation Cohort|Cohort undergoing PCNL prior to implementation of the novel nonopioid pathway
16311431|NCT04597619|Experimental|Implementation Cohort|Cohort undergoing PCNL with implementation of the novel nonopioid pathway
16311432|NCT04597606||Cohort|"All patients will be performed a basal test that consist on continuous cyclergometer exercise, under constant load, with spontaneous breathing, after that the same exercise protocol performed will be carried out under non-invasive ventilation (NIV test). Parameters will be titrated previosuly.
~Finally the patient will perform the same exercise at a constant load under high flow oxygen therapy ( HFNC test)."
16311433|NCT04597593||ADR Group|ISTH bleeding scale Major Bleeding
16311434|NCT04597593||Control Group|No ADR, No Treatment Failure
16311435|NCT04597593||Treatment Failure Group|Recurrent MI, Ischemic stroke, Other thromboembolic disorders
16311436|NCT04597567|Active Comparator|Metal removal|
16311437|NCT04597567|No Intervention|Metal retention|
16311438|NCT04597554|Experimental|Cranberry|4 oz. cranberry beverage (breakfast) and 2 chewable cranberry gummies (lunch) per day for 8 weeks.
16311439|NCT04597554|Placebo Comparator|Placebo|4 oz. placebo beverage (breakfast) and 2 chewable placebo gummies (lunch) per day for 8 weeks.
16311440|NCT04597541|Experimental|1|AK112
16311441|NCT04597528||Elective induction group|Nulliparous singleton gestations undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age
16311442|NCT04597515|Experimental|Robot Reduction|The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .
16311445|NCT04597502|Experimental|Oral TC, Topical Placebo|Oral TC, Topical Placebo on both forearms and dorsal hands
16311446|NCT04597502|Experimental|Oral TC, Topical TC|Oral TC, Topical TC on both forearms and dorsal hands
16311447|NCT04597489||Angiography + FFR|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
16311448|NCT04597489||Angiography only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
16311449|NCT04597489||Subgroup ACS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.
~This subgroup consists of patients presenting with ACS."
16311450|NCT04597489||Subgroup CCS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.
~This subgroup consists of patients presenting with CCS."
16311451|NCT04597489||Subgroup revascularization|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.
~This subgroup consists of patients undergoing revascularization after an angiography (with or without FFR) during the index hospital stay."
16311452|NCT04597489||Subgroup optimal medical therapy|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.
~This subgroup consists of patients undergoing optimal medical therapy after an angiography (with or without FFR) during the index hospital stay."
16311453|NCT04597476|Experimental|Fucoidan Group|Fucoidan powder at 4.4 g per sachet (dose) for oral administration. Fucoidan 4.4 g, PO, bid for 24 weeks
16311454|NCT04597476|Placebo Comparator|Potato starch|Potato starch at 4.4 g per sachet (dose) for oral administration. Potato starch 4.4 g, PO, bid for 24 weeks
16311455|NCT04597463|Experimental|Endometrial injury|Endometrial injury before the embryo transfer of a frozen cycle
16311456|NCT04597450|Experimental|Lu AG06466|
16311457|NCT04597450|Placebo Comparator|Placebo|
16311458|NCT04597437|Experimental|Zanamivir|In the treatment group, participants will receive 600 mg for adults and 12 mg/kg in children intravenously every twelve hours for 5 days adjusted for renal function.
16311459|NCT04597437|Placebo Comparator|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
16311460|NCT04597424|Experimental|doxycycline and Bexsero® vaccine|-doxycycline will be taken by participants as PEP (prophylaxy post exposition) and participants will received Meningococcal B vaccine (Bexsero®) at D0 and M2
16311461|NCT04597424|Experimental|doxycycline|-doxycycline will be taken by participants as PEP (prophylaxy post exposition)
16311462|NCT04597424|Experimental|Bexsero® vaccine|-Meningococcal B vaccine (Bexsero®) at D0 and M2
16311463|NCT04597424|No Intervention|No treatment|-no doxycycline and no Bexsero® vaccine
16311464|NCT04597411|Experimental|Group A (Men with castrate levels of testosterone)|Men with castrate levels of testosterone that have received prior cytotoxic chemotherapy and/or novel androgen axis drugs will receive a dose of 225^Ac-PSMA-617 via intravenous injection no more frequently than every 8 weeks (+/- 1 week) for no more than 6 cycles.
16311465|NCT04597411|Experimental|Group B (Men previously treated with lHRH agonists or orchiectomy and primary anti-androgen therapy)|Men previously treated with lHRH agonists or orchiectomy and primary anti-androgen therapy that have not received prior cytotoxic chemotherapy or novel androgen axis drugs will receive a dose of 225^Ac-PSMA-617 via intravenous injection no more frequently than every 8 weeks (+/- 1 week) for no more than 6 cycles.
16311466|NCT04597398||Group A|A total of 39 patients underwent the procedure prior to June 2019
16311467|NCT04597398||Group B|11 patients underwent the procedure as of June 2019
16311468|NCT04597385||Long-term Follow-Up|No intervention.
16311469|NCT04597372|Experimental|Tamsulosin|"10 capsules will be distributed to subjects to be taken daily. Each capsule contains 0.4mg of Tamsulosin. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.
~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
16311470|NCT04597372|Placebo Comparator|Placebo|"10 capsules will be distributed to subjects to be taken daily. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.
~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
16311473|NCT04597333|Active Comparator|2nd Dinoprostone.|Women induced with a second dinoprostone insert.
16311474|NCT04597333|Active Comparator|Cervical ripening balloon.|Women induced with a cervical ripening balloon.
16311475|NCT04597320|Active Comparator|Fentanyl group|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
16311476|NCT04597320|Experimental|Esketamine group|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
16311477|NCT04597307||IN.PACT™ Admiral™ DCB Cohort|De novo patients not previously treated with a DCB who are successfully treated with the IN.PACT™ Admiral™ DCB (ability to cross the target lesion).
16311590|NCT04596540|Experimental|SEL-212A|IV infusion of SEL-212A every 28 days for a total of up to 12 infusions
16311478|NCT04597294|Experimental|Perioperative FLOT + prophylactic HIPEC + surgery|After 4 doses of preoperative FLOT chemotherapy diagnostic laparoscopy will be performed - patients without distant metastases will be randomised, in those randomised to experimental arm HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)
16311479|NCT04597294|Active Comparator|Perioperative FLOT + surgery|Standard treatment regimen for advanced gastric cancer
16311480|NCT04597281|Experimental|Mediterranean lifestyle|Mediterranean lifestyle, including dietary advice and physical activity advice. In addition, families receive extra-virgin olive oil and fish and two sessions of physical activity per week, for free.
16311481|NCT04597281|No Intervention|Usual care|General care by their pediatricians.
16311482|NCT04597268|Experimental|dexmedetomidine|IV dexmedetomidine
16311483|NCT04597268|Experimental|ketamine|IV ketamine
16311484|NCT04597268|Active Comparator|Midazolam|IV midazolam
16311485|NCT04597255|Experimental|Holographic optical coherence tomography|Healthy phakic participants
16311486|NCT04597229|Active Comparator|Instant multigrain|Oral instant multigrain supplement
16311487|NCT04597229|No Intervention|Standard care|Standard care without oral instant multigrain supplement
16311488|NCT04597216|Other|unique arm|there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
16311489|NCT04597203|Experimental|split face - left side|
16311490|NCT04597203|Active Comparator|split face - right side|
16311491|NCT04597190|Active Comparator|SSRI Then Augmentation by WET|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment augmented by Written Exposure Therapy (WET) delivered by an integrated behavioral health consultant.
16311492|NCT04597190|Active Comparator|SSRI Then Switch to SNRI|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment switched to the SNRI (serotonin-norepinephrine reuptake Inhibitor) venlafaxine.
16311493|NCT04597190|Active Comparator|WET Then Switch to SSRI|Integrated behavioral health consultants will deliver WET. Patients who do not respond to treatment by four months will be switched to one of three SSRIs (sertraline, fluoxetine or paroxetine).
16311494|NCT04597177|Active Comparator|ST-IMRT|standard parotid sparing IMRT
16311495|NCT04597177|Experimental|SW-IMRT|swallowing sparing IMRT
16311498|NCT04597151|Experimental|Supportive care (diet education)|Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
16311499|NCT04597125|Experimental|Arm A|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive radium-223 dichloride
16311500|NCT04597125|Active Comparator|Arm B|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive second novel anti-hormonal therapy (NAH)
16311501|NCT04597112|Experimental|Myofascial Release Group|Intervention group, who received conventional therapy and myofascial release therapy.All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. In the intervention group, the myofascial release technique will be applied to the wrist flexors and extensors, elbow flexors and extensors, pectoralis, supraspinatus, infraspinatus, trapezius muscles, starting from the fingers after the conventional treatment, 3 days a week for 4 weeks.
16311502|NCT04597112|Active Comparator|Exercise Group|The control group will consist of patients who received conventional therapy and exercise therapy. All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. After conventional treatment, a program consisting of neck extension, lateral flexion and rotation range of motion, stretching of the trapezius muscles and strengthening of the neck extensor muscles will be applied to the control group in the presence of a physiotherapist 3 days a week for 4 weeks.
16311503|NCT04597099|Experimental|Flutamide|Prior to the first or second admission (randomly determined), subjects will be pretreated for 4 weeks with Flutamide (250 mg twice daily)
16311504|NCT04597099|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
16311507|NCT04597073|No Intervention|Healthy|included individuals with probing depth (PD) ≤3mm, no sites with attachment loss, and no radiographic evidence of alveolar bone resorption. They exhibited no sign of inflammation (GI=0).
16311508|NCT04597073|Experimental|Gingivitis|had varying degrees of gingival inflammation (GI≥1), PD≤3mm with no clinical attachment loss or with no alveolar bone destruction.
16311509|NCT04597073|Experimental|Chronic Periodontitis|was defined as those who were with PD ≥ 4mm, clinical attachment loss (CAL) ≥ 2mm, and who had bone loss affecting >30% of the existing teeth on clinical and radiographic examination.
16311510|NCT04597060|Experimental|Split Keloid - first side|
16311511|NCT04597060|Experimental|Split Keloid - second side|
16311512|NCT04597047|Other|All Patients:|Capillary and Venous Blood Collections
16311551|NCT04596787||Non-Obese Patients (Group NO: body mass index (BMI) <30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
16311552|NCT04596787||Obese Patients (Group O: body mass index (BMI) ≥30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
16311630|NCT04596254|Other|Juice Intake|
16311513|NCT04597034|Experimental|AN69 Oxiris|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.
~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.
~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.
~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
16311514|NCT04597034|Active Comparator|AN69 Standard|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.
~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.
~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.
~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
16311515|NCT04597008|Active Comparator|Control|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
16311516|NCT04597008|Experimental|Treatment|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
16311517|NCT04596995|Experimental|Rozanolixizumab Maintenance Arm|All study participants will begin with the Maintenance Arm. 30% of the study participants are planned to be randomized to enter an 4 months Exploratory Arm, and then return back to the Maintenance Arm. Study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Maintenance Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
16311518|NCT04596995|Experimental|Rozanolixizumab Exploratory Arm|Study participants randomized to the Exploratory Arm will receive a fixed-unit dose of rozanolixizumab across body weight tiers during the Exploratory Treatment Period. Dose frequency will be adjusted based on platelet count values or medical needs.
16311519|NCT04596969|Experimental|SFD Tapioca 20g|20g soluble fiber dextrin derived from tapioca
16311520|NCT04596969|Experimental|SFD Tapioca 40g|40g soluble fiber dextrin derived from tapioca
16311521|NCT04596969|Experimental|SFD corn 20g|40g soluble fiber dextrin derived from corn
16311522|NCT04596969|Experimental|SFD corn 40g|
16311523|NCT04596969|Placebo Comparator|Control|Maltodextrin
16311524|NCT04596956|Experimental|sodium bicarbonate Ringer injection|
16311525|NCT04596956|Active Comparator|Ringer lactate solution|
16311526|NCT04596930|Experimental|LITT arm|Patients will be randomized to receive biopsy and LITT (n=10)
16311527|NCT04596917|Experimental|Preferred music listening|Patients will be randomized to listen to music with iPod that has preferred music selections that patients can choose.
16311528|NCT04596917|Experimental|Hypnotic music with relaxation breathing|Patients will be randomized to listen to hypnotic music with relaxation breathing narrative.
16311529|NCT04596904|Experimental|Lavender oil group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
16311530|NCT04596904|Placebo Comparator|Distilled water group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
16311531|NCT04596891|Experimental|Intervention|Remotely delivered psychotherapy combining exposure therapy with mindfulness
16311532|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV
16311533|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV
16311534|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV
16311535|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV
16311539|NCT04596852|Experimental|Healthy children|
16311540|NCT04596852|Experimental|Children with cerebral palsy|
16311541|NCT04596839|Experimental|Remdesivir with Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
16311542|NCT04596839|Other|Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy.
16311543|NCT04596826|Experimental|healthy subjects|
16311544|NCT04596826|Experimental|glaucoma patients|
16311545|NCT04596826|Placebo Comparator|healthy volunteers|
16311546|NCT04596826|Placebo Comparator|Glaucoma patients|
16311547|NCT04596813|No Intervention|standard of care|
16311548|NCT04596813|Active Comparator|standard of care and treatment with the Cytosorb® device|
16311549|NCT04596800|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
16311550|NCT04596800|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
16311553|NCT04596774||Group 1|Group 1 patients were applied traditional approach. Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
16311554|NCT04596774||Group 2|Group 2 received Enhanced Recovery After Surgery (ERAS) approach. Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
16311555|NCT04596761|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
16311556|NCT04596761|Experimental|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
16311557|NCT04596748|Placebo Comparator|Placebo|Participants will be taking a placebo supplement that they will be taking by mouth once per day.
16311558|NCT04596748|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
16311559|NCT04596735||Patients undergoing general endotracheal anesthesia that will be extubated following the procedure|Patients 60 years of age and older undergoing general anesthesia and non-cardiac surgery will be observed by a member of the research team independent from the team caring for the patient at the time of emergence and extubation
16311560|NCT04596722|Active Comparator|Assigned Interventions|oral active pomella taken by mouth once per day
16311561|NCT04596722|Placebo Comparator|Placebo|oral placebo taken by mouth once per day
16311562|NCT04596709|Active Comparator|Vitalose|dissolved in water
16311563|NCT04596709|Active Comparator|isomaltulose|dissolved in water
16311564|NCT04596709|Placebo Comparator|sucrose|dissolved in water
16311565|NCT04596709|Placebo Comparator|glucose|dissolved in water
16311566|NCT04596696|Other|Single arm Rotavac|Single arm Open Label study without comparator
16311567|NCT04596683|Experimental|Interested in SDS NSM or SSM|Patients interested same day discharge after NSM or SSM that do not have conditions that would exclude them. Based on discharge outcome after surgery, will be split into SDS group and Admit group.
16311568|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy|"Cancer patients who have not undergone radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.
~Interventions:
~Drug: 68Ga-ICAM-1pep Device: PET/CT"
16311569|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy|"Cancer patients post-radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.
~Interventions:
~Drug: 68Ga-ICAM-1pep Device: PET/CT"
16311570|NCT04596657|Experimental|Intervention|
16311571|NCT04596657|No Intervention|Control|
16311572|NCT04596644|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
16311575|NCT04596618|Active Comparator|Forearm Cooling|Participants will be actively cooled during rest breaks.
16311576|NCT04596618|No Intervention|No Forearm Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
16311577|NCT04596605|Experimental|T2309|4 capsules daily for 12 weeks
16311578|NCT04596605|Active Comparator|Nutrof Total|2 capsules daily for 12 weeks
16311579|NCT04596592||Transgender|
16311580|NCT04596592||Cisgender|
16311585|NCT04596566|Other|CD-TDI|Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.
16311586|NCT04596566|No Intervention|Conventional management|Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24HR food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare
16311587|NCT04596553|Active Comparator|Essential Amino Acid|Participants will consume 1 dose of: 15 g crystalline essential amino acid supplement (Pure Encapsulation Essential Aminos 180) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
16311588|NCT04596553|Active Comparator|Collagen Peptide|Participants will consume 1 dose of: 15g collagen peptide (Gelita TENDOFORTE) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
16311589|NCT04596553|Placebo Comparator|Maltodextrin Placebo|Participants will consume 1 dose of:15 g maltodextrin (Canadian Protein Maltodextrin) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
16311591|NCT04596540|Experimental|SEL-212B|IV infusion of SEL-212B every 28 days for a total of up to 12 infusions
16311592|NCT04596540|Placebo Comparator|Placebo|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
16311593|NCT04596527|Experimental|18F-FMPP PET MPI (following off-study 13N-ammonia PET MPI)|"Imaging Procedure: 18F-FMPP PET Day 1: All subjects will receive rest and stress IV boluses of 18F-FMPP injections in a large peripheral vein. The dosages of 18F-FMPP Injection administered at rest and during stress conditions are 2.5 mCi and 6.0 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor.
~Imaging Procedure: 13N-Ammonia PET All subjects will receive 2 IV boluses of 13N-ammonia Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of 13N-ammonia Injection administered at rest and during stress conditions is 20mCi and 20 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor."
16311594|NCT04596514|Experimental|Intervention group - REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
16311595|NCT04596514|Active Comparator|Control group - ACLS|Advanced cardiovascular life support as described in the guidelines
16311598|NCT04596488|Experimental|Efavirenz 400mg+TDF+3TC|Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.
16311599|NCT04596475|Experimental|Treatment Arm|
16311600|NCT04596462|Experimental|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
16311601|NCT04596449|Experimental|healthy volunteers|
16311602|NCT04596423||A|Extended fetal heart examination
16311603|NCT04596423||B|Modified extended heart examination
16311604|NCT04596423||C|Sief_Twist sign only examination
16311605|NCT04596410|Experimental|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
16311606|NCT04596410|Active Comparator|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day
16311607|NCT04596397|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
16311608|NCT04596397|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
16311609|NCT04596384|Experimental|Group I (telemonitoring program, actigraph, TapCloud)|Before surgery, patients complete a functional and nutritional assessment. The home environment of patients will also be assessed. Based on findings, patients undergo personalized prehabilitation. Patients also wear an actigraph throughout the study to measure and record daily steps taken and sedentary time. Patients use the TapCloud app on a smart device (phone, tablet) or home computer to collect, track, and report their symptoms. Based on patient input in the TapCloud app, a real-time alert is sent to an RN when predetermined thresholds are met. RNs then contact the patient via the TapCloud app and further phone calls if necessary. Patients, caregivers and surgeons may also participate in a focus group in-person, via telephone, or videoconferencing.
16311610|NCT04596384|Active Comparator|Group II (surgeon-only perioperative care program)|Patients and their families meet with the surgeon at least once before surgery. After surgery, patients are managed daily during post-operative care. Patients may receive a referral for functional and nutritional prehabilitation at the discretion of the surgeon/surgical team. Patients and their families receive instructions to follow the standard procedures for reporting problems between clinic visits, including contacting their surgical team if symptoms become severe and physical function worsens; and the use of the hospital call line to report problems. Patients, caregivers and surgeons may receive the opportunity to participate in focus group in-person, via telephone, or videoconferencing.
16311611|NCT04596358||Healtcare workers|Women who work as nurses or doctors in public hospitals of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
16311612|NCT04596358||Non-Healthcare workers|Women who perform technical and managerial professions in a public administration body of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
16311613|NCT04596345||University students|"This group will include all those participants who declare to be attending a study program to get a higher education degree.
~No intervention will be applied."
16311614|NCT04596345||Non-university-attending peers|"This group will include all those participants who are not attending a study program to get a higher education degree.
~No intervention will be applied."
16311615|NCT04596332||Group A|Patients with the initial central venous pressure(CVP1) <8 mm Hg
16311616|NCT04596332||Group B|Patients with 8≤CVP1≤12mm Hg
16311617|NCT04596332||Group C|Patients with CVP1>12 mm Hg
16311618|NCT04596319|Experimental|AP-PA02|Anti-pseudomonal bacteriophage
16311619|NCT04596319|Placebo Comparator|Placebo|Inactive isotonic solution
16311620|NCT04596306||UNDER 70 Y-O|
16311621|NCT04596306||OVER 70 Y-O|
16311622|NCT04596293|Experimental|BBT-401-1S (800mg)|
16311623|NCT04596293|Experimental|BBT-401-1S (1,600mg)|
16311624|NCT04596293|Placebo Comparator|Placebo|
16311625|NCT04596280||Hinchey Classification|
16311626|NCT04596280||AAST classification|
16311627|NCT04596280||WSES classfication|
16311628|NCT04596267|Experimental|Pitolisant|Subjects will take an 8.9 mg dose (two 4.45 mg pills) of pitolisant once per day on day 1 through 4. On day 5, 8.9 mg will be taken in front of staff prior to an alcohol self administration trial.
16311629|NCT04596267|Placebo Comparator|Placebo|Subjects will take an placebo once per day on day 1 through 4. On day 5, a placebo will be taken in front of staff prior to an alcohol self administration trial.
16311631|NCT04596241|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.
16311632|NCT04596228|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device
16311636|NCT04596189|Experimental|Dupilumab|Sterile Dupilumab 150 mg/mL will be provided in pre-filled syringes (2.25 total volume) to deliver 300 mg in 2 mL.
16311637|NCT04596189|Placebo Comparator|Placebo|Sterile placebo for Dupilumab will be provided in identically matching pre-filled syringes to deliver 2 mL.
16311638|NCT04596176|No Intervention|Business As Usual|Families who were involved in the child welfare services
16311639|NCT04596176|Active Comparator|Intensive Supportive Housing for Families|Families who were randomly assigned in this group
16311640|NCT04596176|Active Comparator|Program Supportive Housing for Families|Families who were randomly assigned in this group
16311641|NCT04596163|Active Comparator|Intervention|Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
16311642|NCT04596163|Placebo Comparator|Control|Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
16311646|NCT04596137|Experimental|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
16311647|NCT04596124|Experimental|fitostimoline plus cream|
16311648|NCT04596124|Experimental|fitostimoline plus gauze|
16311649|NCT04596124|Active Comparator|connettivina bio plus cream|
16311650|NCT04596124|Active Comparator|connettivina bio plus gauze|
16311651|NCT04596098||Group A|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient not previously followed in Grenoble University Hospital for a chronic disease.
16311652|NCT04596098||Group B|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient followed in Grenoble University Hospital for a chronic disease.
16311653|NCT04596085|Active Comparator|Investigational product|Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy
16311654|NCT04596085|Placebo Comparator|Placebo|Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy
16311655|NCT04596072|No Intervention|control|basic treatment+ Cognitive rehabilitation training
16311656|NCT04596072|Experimental|treatment|basic treatment+ Cognitive rehabilitation training+Chinese traditional rehabilitation
16311657|NCT04596046|Active Comparator|Group S (systemic-peroral steroid)|Medication of oral methylprednisolonewas administered to the patients following the adjustment based on the severity of the lesion and regarding the clinic. The prednisolone dose was 0.5 mg/kg/day in patients with painful, small (<5.0 cm) unilateral lesions whereas in multiple, bilateral lesions with the diameter of ≥5 cm or for those who had significant cutaneous ulceration, the prednisolone dose was specified as 1 mg/kg/day
16311658|NCT04596046|Experimental|Group L (local-intralesional steroid)|Triamcinolone acetonidewas administered to the patients through injecting inside the lesion. The practice was based on the dose of TCA administered in acute and chronic inflammatory skin lesions. If the lesion is single-focused and small (<5.0 cm), 20mg / mL TCA was injected and if the lesion is multifocal or large (>5.0 cm) then 40mg / mL TCA was injected into the lesion with the guidance of ultrasonography
16311661|NCT04596020|Experimental|Blood Flow Restriction Group|This group will perform 2 lower extremity exercises (sitting unilateral knee extension, standing unilateral knee curl) under occlusion (i.e., BFR) for 4 sets (30/15/15/15 reps) each followed by 2 shoulder exercises (scaption and sidelying external rotation) 3 sets x 15 reps each. Exercises will be performed at 30% of 1RM.
16311662|NCT04596020|Active Comparator|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
16311663|NCT04596007|Experimental|HEC83518 tablets|There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
16311664|NCT04596007|Placebo Comparator|placebo tablets|There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
16311786|NCT04595045|Experimental|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
16311665|NCT04595994|Experimental|Selinexor + Gemcitabine|"Dose escalation levels (Phase I):
~All included patients will take both drugs:
~Selinexor weekly (given on days 1,8 and 15 of each cycle) will be dispensed at different dose levels: dose level 1:60 mg, dose level 2: 60 mg, dose level 3: 60 mg, and dose level 4: 80 mg).
~Gemcitabine weekly (given on days 1, 8 of each cycle) will be administered at different dose levels: (dose level 1:1000 mg/m2 (30 min), dose level 2:1000 mg/m2 (10 mg/m2/min), dose level 3:1200 mg/m2 (10 mg/m2/min) and dose level 4: 1200 mg/m2 (10 mg/m2/min)).
~Selinexor: tablet (20 mg tablets) Oral use.
~Gemcitabine: Concentrate for solution for infusion. Intravenous use."
16311666|NCT04595981|Experimental|Chemo-embolization|Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)
16311667|NCT04595968|Experimental|Vestal DM active device|100 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
16311668|NCT04595968|Sham Comparator|Vestal DM sham device|100 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
16311669|NCT04595955|Experimental|Intervention group|This arm uses the CMyLife platform for at least 6 months
16311670|NCT04595955|No Intervention|Control group|This arm does not use the CMyLife platform
16311671|NCT04595942|Active Comparator|Midodrine|10 mg midodrine three times a day
16311672|NCT04595942|Active Comparator|Fludrocortisone|0.1 mg fludrocortisone two times a day
16311673|NCT04595942|Other|Lifestyle modification|Education, salt and water intake, counter-pressure maneuvers
16311674|NCT04595929|Experimental|PIPAC group|"Staging laparoscopy + peritoneal lavage.
~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.
~Radical gastrectomy with D2 - lymph node dissection.
~Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
~Adjuvant chemotherapy according to indications."
16311675|NCT04595929|Active Comparator|Control group|"Staging laparoscopy + peritoneal lavage.
~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.
~Radical gastrectomy with D2 - lymph node dissection.
~Adjuvant chemotherapy according to indications."
16311676|NCT04595916|Experimental|Polyene Phosphatidylcholine|
16311677|NCT04595916|Active Comparator|Magnesium Isoglycyrrhizinate|
16311678|NCT04595903|Experimental|Hemopurifier®|The Hemopurifier® will be placed within the extracorporeal circuit, all connections secured, treatment will utilize a blood pump at an initial flow rate of 100mL/min. The blood flow rate is to be increased gradually in a stepwise fashion over the first minutes of treatment to a maximum blood flow rate of 200mL/min. The circuit must be continually monitored for blood leaks and blood clotting within the filter. If the treatment is halted before 4 hours, another filter may be connected, and the treatment may be restarted with a goal of achieving a minimum of 4 hours of therapy. If the filter shows signs of clotting or blood leaks, the treatment must be paused, the blood will be returned to the patient and a new filter will be placed into the extracorporeal circuit. The therapy will be resumed with consideration of altering the level of anticoagulation.
16311679|NCT04595890|Experimental|Intervention Group|Injection of Autologous Nucleated Cells
16311680|NCT04595877|Experimental|Dipyrone group|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
16311681|NCT04595877|Placebo Comparator|Placebo group|The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
16311682|NCT04595864|Experimental|treatment group|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
16311683|NCT04595864|No Intervention|control group|no neo-adjuvant treatment before operation
16311684|NCT04595851|Other|Pharmacist Coordinated care Oncology Model (PCOM)|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and primary care pharmacists.
16311685|NCT04595838|Experimental|Arm A:Best supportive oral care and Chemo Mouthpiece|Patients will receive best supportive oral care along with using the Chemo Mouthpiece device
16311686|NCT04595838|Other|Arm B Best supportive oral care only|Patients will receive best supportive oral care only.
16311687|NCT04595825|Experimental|CM-101|
16311688|NCT04595825|Placebo Comparator|Placebo|
16311689|NCT04595812|Active Comparator|Misoprostol group|receive two tablets of 200µg misoprostol (Pfizer Limited, United Kingdom) administered into the posterior fornix of the vagina 1 hour before the onset of surgery
16311690|NCT04595812|Active Comparator|Oxytocin group|After induction of general anaesthesia and immediately prior to the operation, an infusion of 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h will be started during myomectomy.
16311691|NCT04595812|Experimental|Carbetocin group|receive 100 μg IV Carbetocin (1ml) [Pabal, Ferring (UK)] in 5 ml saline over 1 minute just before skin incision
16311692|NCT04595812|Active Comparator|pericervical tourniquet group|pericervical tourniquet using a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision.
16311697|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
16311699|NCT04595721|No Intervention|Standard of care|Participants will receive standard injection procedures
16311700|NCT04595721|Active Comparator|Visual distraction|Participants engage in visual distraction during the injection procedures
16311701|NCT04595721|Active Comparator|Physical distraction|Participants engage in physical distraction during the injection procedures
16311702|NCT04595708|Experimental|Intervention - Calls|Participants randomized to the intervention will receive a call of between 5 - 10 minutes in length each by a consistent caller, five times a week, Monday through Friday for 4 consecutive weeks to check in on them. After the first week of calls, subjects in the intervention arm will be asked if the frequency of calls is acceptable or if they would like to reduce the call frequency, potentially to a minimum of twice per week.
16311703|NCT04595708|No Intervention|Control - No calls|Participants randomized to a control group will not receive the intervention calls. The control group will receive calls from a member of the research team at the beginning of the study to collect baseline survey data and at the post-4-week period to collect post-study survey data.
16311704|NCT04595695|Experimental|Transparent Mask|Surgeons will be provided a transparent mask for use during in-person clinic visits with a new patient. Otherwise, visits will be conducted as per usual and the patient will be surveyed immediately after the visit.
16311705|NCT04595695|Active Comparator|Covered Mask|Surgeons will be instructed to wear a typical, covered mask for the in-person clinic visit with a new patient. The visit will be conducted as it typically would, and the patient will be surveyed immediately after the visit.
16311706|NCT04595682|Experimental|Study Participants|Participants in this group will track their menstrual cycle, provide daily saliva samples, and undergo two rounds of alcohol sensitivity testing (with both placebo and alcohol).
16311707|NCT04595669|Experimental|Personalised advice|
16311708|NCT04595643|Experimental|Specialized dysphagia treatment|Dysphagia treatment is provided by occupational therapists specialized in dysphagia.
16311709|NCT04595617|Experimental|Patients with diagnosis of Glanzmann Thrombastenia (GT)|Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months
16311710|NCT04595604|Experimental|Trimodal prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:
~Physical status (walking, respiratory training) Nutrition (nutritional supplements) Mental status (weekly groups led by clinical psychologist on anxiety and depression management).
~Each patient will be treated in an ERAS program preoperatively."
16311711|NCT04595604|Active Comparator|ERAS + nutritional prehabilitation|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
16311712|NCT04595591|Active Comparator|Group Ⅰ|titration dosing speeds of propofol at 2mg/kg/min
16311713|NCT04595591|Active Comparator|Group Ⅱ|titration dosing speeds of propofol at 1mg/kg/min
16311714|NCT04595591|Active Comparator|Group III|titration dosing speeds of propofol at 0.5mg/kg/min
16311715|NCT04595578|Active Comparator|Cerebellar rTMS + Physical therapy|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
16311716|NCT04595578|Sham Comparator|Sham stimulation + Physical therapy|Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
16311717|NCT04595565|Experimental|Sacituzumab govitecan|Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.
16311718|NCT04595565|Other|Treatment of physician´s choice|TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.
16311719|NCT04595552|Experimental|Study group|Children with cochlear implant were given Auditory training and language therapy
16311720|NCT04595539|Experimental|Simultaneous interventions|In this condition, both interventions are proposed simultaneously. Condition 1 is spread over 5 weeks with 5 weekly laboratory sessions of 2-hours (one hour of BATD and one hour of ATT separated by a break). A 30-minutes ATT sessions at home were prescribed between sessions for a total of 5 laboratory ATT sessions and 5 at home ATT sessions.
16311721|NCT04595539|Experimental|Sequential interventions|In this condition, the interventions are introduced sequentially. Condition 2 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 4 with of one hour of ATT followed by one hour of BATD separated by a break). A six 30-minutes ATT sessions were prescribed between the first 4 sessions of ATT for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
16311722|NCT04595539|Experimental|Sequential interventions in reverse order|In this condition, the interventions are introduced sequentially in the reverse order than the condition 2. Condition 3 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 5 with of one hour of BATD followed by one hour of ATT separated by a break). A six 30-minutes ATT sessions were prescribed between the 4 last sessions for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
16311723|NCT04595526|Active Comparator|Tracheal suction|Uses the local standard procedure of tracheal suction to obtain secretions from the lower respiratory tract
16311724|NCT04595526|Experimental|Forced expiratory technique and induced sputum|This procedure is without suction. The patient's attempts to deliver a sputum sample after forced exhalation and coughing technique. Regardless of the result the patient then receives hypertonic saline by an inhalation mask to induce the sputum. If the patient cannot deliver a sample, tracheal suction will be performed in order to obtain a specimen for the analyses.
16311787|NCT04595019|Active Comparator|5 fraction|MRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
16311725|NCT04595513|Experimental|Stage 1 Open Label|Phase I, open-label PK and initial safety analysis. TAVT-18 administered orally twice/daily to achieve precision dosing target of 10 ng/ml. Whole blood sirolimus levels will be assessed at defined intervals on days 1, 7, and 14. After day 14, participants in Stage 1 can elect to continue open-label treatment with TAVT-18 until 12 months of age.
16311726|NCT04595513|Placebo Comparator|Stage 2 Randomized|Phase II, randomized, double- blind, placebo-controlled safety and efficacy of TAVT-18 to prevent or delay seizure onset in TSC infants. TAVT-18, or matching placebo, administered orally twice/daily and steady state sirolimus levels in whole blood will be assessed at defined intervals to achieve precision dosing target of 10 ng/ml.
16311727|NCT04595500||GERD|
16311728|NCT04595500||Control|
16311729|NCT04595487|Experimental|left ventricular septal pacing|Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
16311730|NCT04595487|Active Comparator|right ventricular pacing|Implantation of a pacemaker with the ventricular lead placed in the RV.
16311731|NCT04595474||Study Cohort|533 adult subjects with type 1 diabetes with no secondary causes of fatty liver
16311732|NCT04595461|Placebo Comparator|Control|Standard of care patient education with verbal and written education
16311733|NCT04595461|Experimental|Video Group|Patient education supplemented with four short youtube videos regarding chronic rhinosinusitis and endoscopic sinus surgery
16311734|NCT04595448||Patients|Patients suffering from moderate tricuspid valve regurgitation
16311735|NCT04595448||Controls|Cardiovascular healthy, age, gender and weight matched controls.
16311736|NCT04595435||Cohort A- Preoperative Prospective|Subjects are eligible to receive IORT and have agreed to participate in the study prior to any intervention.
16311737|NCT04595435||Cohort B- Postoperative Prospective|Subjects who have had IORT performed within the previous 6 month who agree to participate.
16311738|NCT04595422|Experimental|Call center staff (educational intervention)|Participants undergo training consisting of a 60-minute educational session.
16311739|NCT04595422|Experimental|Callers substudy (LCS educational materials, questionnaire)|Participants are referred to lung cancer screening educational materials. Participants also complete questionnaires at 1 week and 6 months after referral to educational materials.
16311740|NCT04595409|Experimental|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive subcutaneous injections of FYB202 as detailed in the protocol.
16311741|NCT04595409|Active Comparator|Stelara® (Ustekinumab)|Patients will receive subcutaneous injections of Stelara® as detailed in the protocol.
16311742|NCT04595383|No Intervention|Control|Usual care and usual communication with health professional
16311743|NCT04595383|Experimental|Intervention|They will be trained to use the ti.care platform and will be able to use it as a communication channel for any questions or clarification they require during the time elapsed between routine control visits. This platform will be a complement to the visits, but in no case will it replace them or be used as a diagnostic or therapeutic method. The platform does not have any treatment algorithm and only aims to facilitate communication between the patient at home and the health professional, both the doctor and the nurse educator. It will be used in a preventive and advisory manner for the patient for follow-up. In no case it will be used for emergencies. Daily during working hours from Monday to Friday, health professionals will review patient requests and respond to them.
16311744|NCT04595370|Experimental|AZD9977 Dose A + dapagliflozin 10 mg|Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
16311745|NCT04595370|Experimental|AZD9977 Dose B + dapagliflozin 10 mg|Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
16311746|NCT04595370|Experimental|AZD9977 Dose C + dapagliflozin 10 mg|Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
16311747|NCT04595370|Experimental|AZD9977 Dose C|Participants will receive once daily oral dose C of AZD9977 alone for 12 weeks.
16311748|NCT04595370|Experimental|Dapagliflozin 10 mg|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
16311749|NCT04595370|Placebo Comparator|Placebo|Participants will receive once daily oral dose of placebo matched to AZD9977 or dapagliflozin for 12 weeks.
16311750|NCT04595344|Active Comparator|Diagnostic cystoscopy , Binaural beat group|patients listened to binaural beats
16311751|NCT04595344|Active Comparator|Diagnostic cystoscopy, Classical music group|patients listened to classical music
16311752|NCT04595344|Placebo Comparator|Diagnostic cystoscopy , Placebo group|patients no audio only headphones
16311753|NCT04595344|Active Comparator|Ureteral stent removal, Binaural beat group|patients listened to binaural beats
16311754|NCT04595344|Active Comparator|Ureteral stent removal ,Classical music group|patients listened to classical music
16311755|NCT04595344|Placebo Comparator|Ureteral stent removal, Placebo group|patients no audio only headphones
16311756|NCT04595331|No Intervention|Treatment Group in pivotal study|followed for long-term safety and effectiveness with no additional treatment
16311757|NCT04595331|Experimental|Control Group in the pivotal study|receiving treatment in the extension study
16311758|NCT04595318|Active Comparator|Standard clinical care|Four weeks of medication-assisted treatment (MAT) with standard clinical care (SCC). MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
16311759|NCT04595318|Active Comparator|Standard clinical care and varenicline|Four weeks of MAT with standard clinical care plus varenicline therapy (SCC and VT). Varenicline therapy included a one-month supply of standard doses: 0.5mg for the first three days, 0.5mg twice a day for the following four days, and 1 mg twice a day for the remaining 21 days. MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
16311760|NCT04595305|Other|Treatment Arm - Standard of Care|Implantation of CRT-P or CRT-D for a clinical indication as per standard of care.
16311761|NCT04595292||older adults, assessment|
16311762|NCT04595279|Experimental|Smoking sessions|This is the single arm that will go through cigarette smoking sessions
16311763|NCT04595266|Active Comparator|Control|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
16311764|NCT04595266|Experimental|Experimental|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
16311765|NCT04595253|Experimental|acupressure|After recruitment, participants will be randomized to receive acupressure or control group. In the acupressure group, participants will receive acupressure treatment.
16311766|NCT04595253|No Intervention|routine care|After recruitment, participants will be randomized to receive acupressure or control group. In the control group, participants will receive routine care, including routine pain control.
16311767|NCT04595227||Normal Subjects|Healthy eyes had intraocular pressure of less than 22 mmHg with no history of increased intraocular pressure and normal standard automated perimetry (SAP) results.
16311768|NCT04595227||Suspect Glaucoma|Eyes with suspect glaucoma were defined as those with suspicious neuroretinal rim thinning or retinal nerve fiber layer (RNFL) defects on masked stereophotographic assessment, without repeatable abnormal SAP results. Eyes with suspect glaucoma also included those with intraocular pressure (IOP) > 21 mm Hg but with healthy-appearing optic discs and without repeatable abnormal SAP results
16311769|NCT04595227||Primary Open Angle Glaucoma, early stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -0.01dB≤MD≤-6.00dB)
16311770|NCT04595227||Primary Open Angle Glaucoma, moderate stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -6.01≤MD≤-12.00dB)
16311771|NCT04595227||Primary Open Angle Glaucoma, advanced stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -12.00≤MD≤-20.00dB)
16311772|NCT04595188|Experimental|Sulphur amino acids in Adults > 60|"Total sulphur amino acid, as methionine only: all subjects will receive up to 7 methionine test levels, without dietary cysteine, assigned in random order.
~Minimum methionine, with excess dietary cysteine: all subjects will receive up to 7 methionine test levels, in the presence of excess and constant dietary cysteine, assigned in random order."
16311773|NCT04595162|Experimental|CAR-T treatment group|The patients will receive one dose of GC019F.
16311774|NCT04595149|Other|Immunotherapy|Adding bintrafusp alfa (a combined TGF-β en PDL-1 inhibitor) to definitive chemoradiation with Paclitaxel and Carboplatin
16311775|NCT04595136|Experimental|COVID19-0001-USR|Group 1 Patients with SARS-COV-2 (COVID19) positive test will receive Investigational Drug administer by nebulization ( COVID-19-0001-USR) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
16311776|NCT04595136|Placebo Comparator|Normal Saline|Group 2 of patients with positive tests intervention SARS-COV-2 (COVID19) with placebo (i.e., normal saline 0.9% NS) plus standard baseline treatment for covid provided by Primary care provider ( Azithromycin, dexamethasone, and/or anticoagulants) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
16311777|NCT04595097|Experimental|Intervention Group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. IMT in both groups will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the intervention group will be set initially at a load of 50% of patients' maximal inspiratory mouth pressure (MIP). This initial load will be continuously and gradually increased to the highest tolerable intensity during each of the supervised sessions.
16311778|NCT04595097|Active Comparator|Control group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. Sham IMT will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the control group will be set at 10% baseline PImax and will be not modified throughout the intervention period.
16311779|NCT04595084|Experimental|MBCT-R + CHA-MW|Mindfulness-Based Cognitive Therapy (MBCT) is an effective group intervention for depression and anxiety that combines mindfulness training with elements of cognitive therapy. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
16311780|NCT04595084|Active Comparator|iCBT (MoodGym) + CHA-MW|MoodGym is a form of iCBT, which an evidence-based online program for depression, anxiety, stress and general psychological well-being. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
16311781|NCT04595084|Active Comparator|CHA-MW|Participants randomized to the CHA-MW arm will only receive CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
16311782|NCT04595071|No Intervention|Standard Control|Use of standard two-site myoelectric control of multi-articulating hand.
16311783|NCT04595071|Experimental|Voice Recognition Control|Use of voice recognition control in addition to standard two-site myoelectric control of a multi-articulating hand.
16311784|NCT04595058|Active Comparator|EUSDB-LAMS|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent . Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.
~EUSDB-LAMS (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent)"
16311785|NCT04595058|Experimental|EUSDB-LAMS-Pigtail|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents without coaxial plastic stent. Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.
~In this arm, a double pigtail through the lumen apposing metal stent will be inserted as an axis-orienting stent.
~EUSDB-LAMS-Pigtial (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent through LAMS)"
16311788|NCT04595019|Experimental|2 fraction|MRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.
16311789|NCT04595006|Experimental|Cold Stimulation (CS)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.
16311790|NCT04595006|Experimental|Browning Nutraceutical (BN)|Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
16311791|NCT04595006|Experimental|Cold Stimulation and Browning Nutraceutical (CSBN)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
16311792|NCT04594980|Other|Minimally invasive TLIF|Patients will undergo a single level decompression and fusion using a minimally invasive technique. Followed posterior screw fixation is mandatory.
16311793|NCT04594980|Other|Open TLIF|Patients will undergo a single level decompression and fusion using an open traditional technique. Followed posterior screw fixation is mandatory.
16311794|NCT04594954|Experimental|Diet + Exercise + FMT|
16311795|NCT04594954|Active Comparator|Diet+Exercise|
16311796|NCT04594941|Experimental|Group 1|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the HPLC method
16311797|NCT04594941|Experimental|Group 2|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the SPE method
16311798|NCT04594941|Experimental|Group 3|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method
16311799|NCT04594941|Experimental|Group 4|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method
16311800|NCT04594928|Experimental|GLPG3667 Dose A|Daily doses of GLPG3667 for 4 weeks.
16311801|NCT04594928|Experimental|GLPG3667 Dose B|Daily doses of GLPG3667 for 4 weeks.
16311802|NCT04594928|Placebo Comparator|Placebo|Placebo to match will be administered as capsules for daily oral use.
16311803|NCT04594915||Study Group|Patients diagnosed with AF who are currently using Edoxaban for stroke prevention in Turkey.
16311804|NCT04594902|Experimental|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
16311805|NCT04594902|Active Comparator|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
16311806|NCT04594889|Experimental|Sirolimus|Sirolimus eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
16311807|NCT04594889|Active Comparator|Paclitaxel|Paclkitaxel eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
16311808|NCT04594876|Other|Flouroscopic guidance Cervical Epidural injection|Group (P) flouroscopic guidance cervical epidural injection
16311809|NCT04594876|Other|Flouroscopic guidance cervical facet injection|Group (F) Flouroscopic guidance cervical facet injection
16311810|NCT04594863||cachexia|patients suffering from cachexia recently
16311811|NCT04594863||no cachexia|patients are not suffering from cachexia recently
16311812|NCT04594850|No Intervention|Placebo-Control group|Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.
16311813|NCT04594850|Experimental|Injection group: Cellgram-ED|Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.
16311814|NCT04594837|Experimental|Unpowered Physical Therapy Robot (Phase I)|2 weeks (3 sessions per week, total 6 sessions, ~30-45 minutes duration each session) of over-ground gait training while wearing the unpowered robot (mass only, no robotic active assistance) on foot drop in chronic hemiparetic stroke patients. f training with the unpowered robot does not significantly improve key foot drop outcomes as hypothesized, then Phase II will consist of a two group design comparing PTR (Physical Therapy while wearing Robot group) vs. PT (Physical Therapy only). If Phase I shows that wearing the unpowered robot improves the foot drop outcomes, then Phase II will use a three group randomized study design comparing PTR, PT and UPTR (Unpowered Physical Therapy Robot) groups
16311815|NCT04594837|Experimental|PTR (Physical Therapy while wearing Robot group) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
16311816|NCT04594837|Experimental|PT (Physical Therapy Only) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
16311817|NCT04594824||Term neonates|
16311818|NCT04594824||Preterm neonates|
16311819|NCT04594811|Experimental|Dose escalation|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.
~Nivolumab will be administered on Day 1 of every 4 week cycles (Q4W)."
16311820|NCT04594811|Experimental|Phase 2: NT-I7 and Nivolumab|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W) at the recommended phase 2 dose (RP2D) identified during Dose escalation phase.
~Nivolumab will be administered on Day 1 of every 4 week cycles (Q4W)."
16311821|NCT04594811|Active Comparator|Phase 2: Nivolumab Alone|Nivolumab will be administered on Day 1 of every 4 week cycles (Q4W).
16311894|NCT04594226|Active Comparator|Medication group|Participants in this group will only receive gabapentin.
16311822|NCT04594798|Experimental|Experimental: Polatuzumab Vedotin and R-CHOP|The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
16311823|NCT04594772|Experimental|Neoadjuvant therapy|All patients will receive Neoadjuvant therapy.
16311824|NCT04594759|Experimental|Treatment Group|
16311825|NCT04594746|Experimental|Oral Amiodarone|Amiodarone hydrochloride 2000 mg
16311826|NCT04594746|Placebo Comparator|Placebo|Oral placebo
16311827|NCT04594733|Active Comparator|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Participants will be randomized to 8 weeks of placebo, minimum 2 week washout period, and then 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily) followed by a final 2 week washout
16311828|NCT04594733|Active Comparator|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|Participants will be randomized to 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily), minimum 2 week washout period, and then 8 weeks of placebo followed by a final 2 week washout
16311829|NCT04594720||Thyroid cancers|Enrolled study population have papillary thyroid cancers and benign thyroid tumors
16311830|NCT04594707|Experimental|PRM-151|"Corhort A: Participants entering, following participation in study PRM-151-202.
~Cohort B: Participants entering, following participation in study WA42293."
16311831|NCT04594694|Active Comparator|Treatment A: BZF 200 mg IR|Bezafibrate (BZF): 200 mg IR Ocaliva (OCA) Placebo Bezafibrate (BZF) 400 mg Placebo
16311832|NCT04594694|Active Comparator|Treatment B: BZF 400 mg SR|Bezafibrate (BZF): 400 mg SR Ocaliva (OCA) Placebo Bezafibrate (BZF) 200 mg Placebo
16311833|NCT04594694|Experimental|Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 200 mg IR Bezafibrate (BZF) 400 mg Placebo
16311834|NCT04594694|Experimental|Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 400 mg SR Bezafibrate (BZF) 200 mg Placebo
16311835|NCT04594681|Placebo Comparator|Placebo|
16311836|NCT04594681|Experimental|KHK4951|
16311837|NCT04594668|No Intervention|Standard treatment|Standard intensive care
16311838|NCT04594668|Active Comparator|Senicapoc|Senicapoc
16311839|NCT04594642|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
16311840|NCT04594642|Experimental|Dose Expansion in Subjects with DLBCL or HGBL|An expansion cohort in subjects with DLBCL or HGBL will be enrolled after RP2D is established.
16311841|NCT04594642|Experimental|Dose Expansion in Subjects with FL|An expansion cohort in subjects with FL will be enrolled after RP2D is established.
16311842|NCT04594629|Sham Comparator|nitroglycerine group|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
16311843|NCT04594629|Active Comparator|PGI2 group|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres.
16311844|NCT04594616|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
16311845|NCT04594616|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
16311846|NCT04594603||Group(1): Cataract with no diabetic retinopathy|
16311847|NCT04594603||Group (2): Cataract associated with diabetic retinopathy|
16311848|NCT04594590||Patients with SLC25A46 deficiency|Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
16311849|NCT04594577|Experimental|Fluispotter|Fluispotter automated blood sampling system
16311850|NCT04594551|Experimental|Group 1: VRVg-2 + HRIG|"VRVg-2 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21
~+ HRIG at D0"
16311851|NCT04594551|Active Comparator|Group 2: Verorab + HRIG|"Verorab 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21
~+ HRIG at D0"
16311852|NCT04594525|Experimental|Perinatal women receiving Low intensity psychosocial interventions|One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low intensity psychological interventions through Telemental health.
16311853|NCT04594525|No Intervention|Participants-Perinatal women (pregnant women and post-partum) not receiving intervention|One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention through Telemental health.
16311854|NCT04594512|Other|LENTICULE IMPLANTATION|The present study may suggest that this procedure safely, reliably, and effectively increases corneal thickness and improves visual acuity with no adverse effects. It may even provide new avenues in the treatment of corneal ectasia. Stem cells and live keratocytes are well organized based on cornea transparency and in anterior segment OCT.
16311855|NCT04594473|No Intervention|Standard of Care (SOC)|Participants randomized to SOC will be instructed to continue their typical lifestyle activity.
16311856|NCT04594473|Experimental|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|Participants randomized to CORE will be instructed to follow the clinical algorithm for this study. An in-clinic assessment consisting of two questionnaires will be used to identify the appropriate pathway for triage. Participants will be triaged into one of three pathways: Physical Medicine & Rehabilitation, Personal Optimism With Exercise Recovery, or Exercise Self-Management.
16311857|NCT04594460|Experimental|experimental Group|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
16311858|NCT04594460|Active Comparator|Control Group|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
16311859|NCT04594447|Other|Physica KR|Subject that receive Physica Kinematic Retaining total Knee replacement system
16311860|NCT04594447|Other|Physica CR|Subject that receive Physica Cruciate Retaining total Knee replacement system
16311861|NCT04594434|Experimental|protocol EMDR + SB / SMP protocol (adjusted)|"Association of a positive memory with the recommended therapy based on EMDR."
16311862|NCT04594434|Active Comparator|protocol EMDR (standard).|"recommended therapy based on EMDR."
16311867|NCT04594395||Healthy volunteers|Any adult aged 18 to 65 years of age living in Phnom Penh that is sufficiently healthy and willing to undergo fingerstick by the mobile unit for SARS-CoV-2 ELISA assays.
16311868|NCT04594395||Household contacts|Adult relatives of the healthy volunteers.
16311869|NCT04594382|Active Comparator|T30/60|Before extubation, opioid administration will be given by a single dose of opioids in case of measured PDR values of ≥12.
16311870|NCT04594382|Active Comparator|Non-T30/60|A standardized single dose of opioid will be given intravenously before extubation, regardless of the measured pupillometry PDR values.
16311871|NCT04594382|No Intervention|Standard Care group|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
16311875|NCT04594356||Patients with COVID-19 infection|"As part of this research, existing clinical data of patients infected with COVID-19 is collected from the patients' computerized medical records.
~During the hospitalization of the patients, in addition to the clinical and laboratory data collected, the dosage of IL-6, apparently playing a central role in the worsening of the symptoms of COVID-19, was performed. The remainder of the contents of the tube used to perform this assay will allow further research by assaying the DNA-myeloperoxidase (DNA-MPO) complexes. These complexes reflect a phenomenon called netosis, most likely involved in the widespread inflammation that patients have suffered from."
16311876|NCT04594343|Experimental|Disulfiram|
16311877|NCT04594343|Placebo Comparator|Placebo|
16311878|NCT04594330|Active Comparator|Group 1 - 30 COVID-19 patients aged ≥ 18 years old receiving the investigational drug|Group 1 - 30 COVID-19 patients receiving standard therapy and the investigational drug (Virgin Coconut Oil)
16311879|NCT04594330|Placebo Comparator|Group 2 - 30 COVID-19 patients aged ≥ 18 years old receiving placebo|Group 2 - 30 COVID-19 patients receiving standard therapy and placebo
16311880|NCT04594317|Experimental|low level laser therapy|970 ± 15-nm diode laser (Biolase Epic X, Biolase, Irvine, California, USA)will be activated at 0.5 W and 10 Hz at a distance of approximately 10 mm to the tissue around the apex of the root. A circular movement will be performed during application. Pulse duration will be 0.5 s, and pulse pause will be 50%. Total application time will be30 s for the tooth. For this application, a 200-μm optical tip will be used.
16311881|NCT04594317|Active Comparator|Calcium hydroxide intracanal medication|calcium hydroxide paste (Metapaste, Meta Biomed Co., Ltd, Korea) will be inserted in the canal using disposable plastic tip and placed at a distance 1 or 2 mm less than the working length.
16311882|NCT04594304|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports upon survey completion, and their PCP will receive automatic supports in the EMR to assess and treat the patient's alcohol and/or tobacco use. In cases where a patient does not have risky alcohol and tobacco use, a personalized eToolkit based on their physical activity levels will be administered, and their PCP will receive automatic supports in the EMR to facilitate physical activity discussions. Intervention arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and a 3 months follow-up e-survey following their appointment. Resources will be automatically produced for the patient and PCP following completion of the baseline e-survey.
16311883|NCT04594304|No Intervention|Usual care|The control arm will not receive intervention materials. Control arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and 3 months follow-up e-survey following their appointment.
16311884|NCT04594278|Experimental|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
16311885|NCT04594265|Experimental|Ketone Monoester|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
16311886|NCT04594265|Placebo Comparator|Placebo Treatment|Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
16311887|NCT04594265|Active Comparator|Ketone Monoester in presence of low-dose insulin clamp|Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
16311888|NCT04594252|Experimental|ALXN1840|Participants will be administered repeat doses of ALXN1840 30 milligrams (mg) for 15 days.
16311893|NCT04594226|Experimental|EA combined with medication group|Patients in this group will receive electroacupuncture combined with gabapentin.
16311899|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator, we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
16311900|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
16311901|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
16311902|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
16311903|NCT04594200|No Intervention|Control Group|Participants in this group will not receive a personalized antibiotic prescribing feedback letter and they will not receive a viral prescription pad.
16311904|NCT04594187|Experimental|Group I (immunotherapy, radiation therapy)|Within 12 weeks of SLNB, patients start nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). Immunotherapy planned to begin at any time after SLNB.
16311905|NCT04594187|Active Comparator|Group II (immunotherapy)|Patients planned to undergo immunotherapy.
16311906|NCT04594174||Responders|
16311907|NCT04594174||Non responders|
16311908|NCT04594161|Active Comparator|Percutaneous Nephrostomy|drainage of the kidney by means of a percutaneous Nephrostomy
16311909|NCT04594161|Active Comparator|Double J catheter|drainage of the kidney by means of a double J catheter
16311910|NCT04594148|Experimental|Weight-shift training|The experimental group will receive a single session of 10x 2.5min of weight-shift training with the VR Wasp Game
16311911|NCT04594148|No Intervention|Passive control|The passive control group will not receive any form of training. Instead, they will relax for 25min (i.e. talking with the researcher and/or reading a magazine)
16311912|NCT04594135|Experimental|anti-CD5 CAR T cells|Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg
16311913|NCT04594122|No Intervention|Control|No intervention in this group
16311914|NCT04594122|Experimental|Intervention|Hygiene package, training, branding, and certification
16311915|NCT04594109|Active Comparator|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
16311916|NCT04594109|Experimental|Tailored Counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
16311917|NCT04594096|Experimental|Immediate Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.
~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.
~Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual."
16311950|NCT04593849|Placebo Comparator|placebo group( topical agent without therapeutic effects)|topical agent without therapeutic effects will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
16311918|NCT04594096|Experimental|Delayed Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.
~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.
~Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits)."
16311919|NCT04594083|Experimental|Palm Stimulator|The Palm Stimulator was placed in the palm of the child's active hand 20 seconds before the injection. It ensured by researcher that the apparatus was held tightly in the child's palm throughout the procedure. The apparatus was taken back from the child after completing the injection process.
16311920|NCT04594083|Experimental|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
16311921|NCT04594083|No Intervention|Control|The routine IM injection was applied to the children in the control group.
16311922|NCT04594070|Active Comparator|Daily iron supplementation|Oral ferrous sulfate, 325 mg, take once daily
16311923|NCT04594070|Experimental|Alternate day iron supplementation|Oral ferrous sulfated, 650mg, taken once daily every other day
16311924|NCT04594057|Active Comparator|Early Start|Begin 6 weeks of gaze and postural stability training 10-14 days following surgery.
16311925|NCT04594057|Experimental|Delayed Start|Begin 6 weeks of gaze and postural stability training 6 weeks following surgery.
16311926|NCT04594044|Experimental|Individual HRT and ERP|Individual treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
16311927|NCT04594044|Experimental|Group HRT and ERP|Group treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
16311928|NCT04594031|Experimental|ECT-001-CB|"An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.
~Patients will receive standard supportive care and GVHD prophylaxis"
16311929|NCT04594018|Experimental|FINLÂNDIA|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:
~1 tablet finasteride placebo, oral, once a day.
~1 mL Finlândia hair lotion, topical, twice a day."
16311930|NCT04594018|Active Comparator|Minoxidil + finasteride|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:
~1 tablet finasteride, oral, once a day.
~1 mL minoxidil hair lotion, topical, twice a day."
16311931|NCT04594005|Experimental|abemaciclib+paclitaxel|
16311932|NCT04593992|Experimental|HTEMS|High-tone external muscle stimulation 5 times within a week for 12 weeks
16311933|NCT04593992|Placebo Comparator|Placebo|Placebo stimulation 5 times within a week for 12 weeks
16311934|NCT04593966||Pediatric AVM|"AVM patients' age under 18-years-old who underwent intervention in investigators' institution.
~Patients' lesions were located in eloquent and confirmed by image."
16311935|NCT04593966||Adult AVM|"AVM patients' age over 18-years-old who underwent intervention in investigators' institution.
~Patients' lesions were located in eloquent and confirmed by image."
16311936|NCT04593953|No Intervention|CONTROL|Standard general anesthesia
16311937|NCT04593953|Experimental|TLIP|Standard general anesthesia + TLIP block
16311942|NCT04593914|Experimental|Cavilon Advanced Skin Protectant|"Cavilon Advanced Skin Protectant forms a film barrier intended to protect intact or damaged skin. It is effective in conditions where skin is frequently or continuously exposed to moisture and caustic irritants such as feces, digestive fluids, wound drainage and urine. Cavilon Advanced Skin Protectant also can be used in areas exposed to friction and shear from bedding, clothing, shoes or any other material that would rub against the skin.
~The skin barrier protectant will be applied on the irradiated skin from the third week of radiotherapy until 1 week after the final radiotherapy session."
16311943|NCT04593901|Other|Video and App Review|Single arm study in which home healthcare workers review and provide feedback on scripts and/or videos and on the usefulness, usability, and desirability of an interactive app in an iterative, participatory manner.
16311944|NCT04593888|No Intervention|No intervention|The group will be followed without any intervention, with regular visits at the research clinic.
16311945|NCT04593888|Experimental|Gluten reduced diet|"Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten.
~The group will be followed with regular visits at the research clinic."
16311946|NCT04593862|Experimental|Exercise Group|The exercise intervention will consist of 36 high-volume high-intensity interval sessions over a 12-week period. The exercise frequency will be three times per week during the 6 weeks of intravesical therapy and the 6 weeks of recovery (total 12 weeks) prior to a surveillance cystoscopy.
16311947|NCT04593862|No Intervention|Usual Care:|Patients randomized to the control group will be asked not to initiate any exercise program or to increase their exercise level from baseline during the 12-week study. After the post-intervention assessments and 3-month cystoscopy, patients in the control group will be offered a 4-week supervised exercise program at the Behavioural Medicine Fitness Centre, University of Alberta.
16311948|NCT04593849|Active Comparator|group A (Ru-Yih-Jin- Huang-Saan group)|Herbal medicine(Ru-Yih-Jin- Huang-Saan) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
16311949|NCT04593849|Experimental|group B (Wan-Yin-Gao-Jia-Jean-Wey group)|Herbal medicine (Wan-Yin-Gao-Jia-Jean-Wey) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
16311951|NCT04593849|No Intervention|control group|only oral analgesics will be applied to patients
16314126|NCT04578938|Active Comparator|No-infusion (TAU) + Cognitive Training|
16311952|NCT04593836|Experimental|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
16311953|NCT04593836|Placebo Comparator|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
16311954|NCT04593823|Experimental|Furoscix Infusor|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).
16311955|NCT04593823|No Intervention|Continued Medical Therapy|The subjects enrolled in this arm will receive treatment as usual
16311956|NCT04593810|Experimental|INTELLiVENT-ASV|Use of INTELLIVENT-ASV after intubation and during all mechanical ventilation in the ICU.
16311957|NCT04593810|Active Comparator|Conventional ventilation|Use of conventional ventilation after intubation and during all mechanical ventilation in the ICU.
16311958|NCT04593797||Patients undergoing major upper abdominal surgery|major open upper abdominal surgery eg pancreatic, liver surgery
16311959|NCT04593784|Experimental|Cohort 1|Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
16311960|NCT04593784|Experimental|Cohort 2|Subjects receive 20 mg rivaroxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 4 hours after administering rivaroxaban, study drug (ciraparantag or placebo) will be intravenously administered.
16311961|NCT04593771|Experimental|Experimental group|80 healthy people were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD once.
16311962|NCT04593771|Other|control group|80 healthy people were randomly assigned to the experimental group and the control group. The control group was injected with BCG-PPD was marketed once.
16311963|NCT04593758|Experimental|CPI-613 + Hydroxychloroquine|dosing regimen was 2.5 mg/kg hydroxychloroquine PO followed 2 hours later by 1,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 2.5 mg/kg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.
16311965|NCT04593719|Experimental|Experiment|Lactation management model is applied to the experimental group.
16311966|NCT04593719|No Intervention|Control|Lactation management model is not applied to the control group.
16311967|NCT04593706|Active Comparator|keloids|each patient will be injection by all 4 steroids for comparison patients with 4 or more keloids will be injection with each steroid for different keloid
16311968|NCT04593706|Active Comparator|hypertrophic scars|each patient will be injection by all 4 steroids for comparison patients with a 11 cm hypertrophic scar will be injected by all 4 steroids along the scar with a 1 cm distance between each steroid
16311969|NCT04593693|Other|Invia Motion Endure NPWT system|Use of Negative Pressure Wound Thearpy
16311972|NCT04593667|Other|Full Inflation|100% TR Band inflation relative to recommended inflation with 15-18 cc air injected in TR band bladder
16311973|NCT04593667|Other|Mid Inflation|75% TR Band inflation relative to recommended inflation with 11-14 cc air injected in TR band bladder
16311974|NCT04593667|Other|Low Inflation|50% TR Band inflation relative to recommended inflation with 8-9 cc air injected in TR band bladder
16311975|NCT04593654||low dose thromboprophylaxis|Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin
16311976|NCT04593654||medium dose thromboprophylaxis|Daily dose of >4500 IU but <175 IU/kg of body weight tinzaparin or >5000 IU but <200 IU/kg of body weight dalteparin
16311977|NCT04593654||high dose thromboprophylaxis|Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin
16311978|NCT04593641|Experimental|Cohort 1 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59
~CT-P59 will be administered
~Drug: Placebo
~Placebo-matching CT-P59"
16311979|NCT04593641|Experimental|Cohort 2 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59
~CT-P59 will be administered
~Drug: Placebo
~Placebo-matching CT-P59"
16311980|NCT04593641|Experimental|Cohort 3 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59
~CT-P59 will be administered
~Drug: Placebo
~Placebo-matching CT-P59"
16311981|NCT04593628|Experimental|All Participants|
16311982|NCT04593615|Experimental|Group A|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
16311983|NCT04593615|Placebo Comparator|Group B|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
16312044|NCT04593199|Sham Comparator|Physical Activity Tracking App Only|Over a 4-week period, participants were asked to use the Fitbit app to track their daily physical activity.
16314127|NCT04578938|Sham Comparator|No-infusion (TAU) + Sham Training|
16311984|NCT04593602|Experimental|Early Mobilization Intervention|The bedside nurse determines the prehospital Level of Function based on patient and family report and current Level of Function based on nursing mobility assessment. Each Level of Function has 3 primary activities designed to promote the patient to the next level. The nurse leads mobility activities based on the patient's current Level of Function once per shift, twice daily (AM+PM). If a patient is able to complete each of the 3 activities, the nurse on the subsequent shift will assess whether the Level of Function can be advanced. Physiotherapy consultation is available if required, although not obligatory. Patients are encouraged to spend as much time in the chair and ambulatory as possible.
16311985|NCT04593602|Active Comparator|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
16311986|NCT04593589|Experimental|Transplantation|Submandibular Gland Stem Cell Transplantation
16311987|NCT04593576|Experimental|Structured physical activity/outdoor sports.|Out door sports and structured physical activity protocol will be administered on children with Autism.
16311988|NCT04593576|Active Comparator|Intensive table teaching control group|Control group will only be exposed to intensive table teaching instead of physical activity protocol.
16311989|NCT04593563|Experimental|Psilocybin 25mg|Psilocybin 25mg Single does with supportive conditions.
16311990|NCT04593550||Observational (BrainCheck, 3D-CAM, EEG)|Patients undergo cognitive function assessment BrainCheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3D-confusion assessment over 10 minutes BID on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). Patients also undergo EEG during surgery and collection of blood samples 30-60 minutes after surgery.
16311991|NCT04593537||MDD group|Participants with current major depressive disorder (MDD)
16311992|NCT04593537||Control group|Participants without a family and personal history of a mood disorder, schizophrenia or substance/alcohol abuse but other disorders often co-morbid with MDD are allowed such as anxiety disorders
16311993|NCT04593524|Active Comparator|Treatment Group|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
16311994|NCT04593524|Active Comparator|Counseling Group|24 participants which only receives nutritional counseling for 28 days
16311995|NCT04593511|Experimental|Formulation 1|a single dose of LY03009 F1
16311996|NCT04593511|Experimental|Formulation 2|a single dose of LY03009 F2
16311997|NCT04593511|Experimental|Formulation 3|a single dose of LY03009 F3
16311998|NCT04593511|Experimental|Formulation 4|a single dose of LY03009 F4
16311999|NCT04593498||ESVEA|ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
16312000|NCT04593498||Non-ESVEA|Participants not meeting inclusion criteria
16312001|NCT04593485|Experimental|Cohort 1|patients with postoperative recurrence of malignant melanoma of the female genital tract requiring adjuvant therapy, Camrelizumab for injection
16312002|NCT04593485|Experimental|Cohort 2|patients with metastatic or unresectable malignant melanoma of the female genital tract, Camrelizumab for injection
16312003|NCT04593472|Experimental|SHARE|"SHARE components include: 1) a letter from the practice introducing the initiative, 2) access to a designated person (medical assistant, social worker, nurse, or lay person) trained to lead advance care planning discussions, 3) person-family agenda-setting to align perspectives about the role of the caregiver and stimulate discussion about goals of care, and 4) education about communication and available resources, including a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor, a blank easy to complete advance directive, and facilitated registration to the patient portal (for patient and caregiver participants) to extend electronic interactions and information access to family."
16312004|NCT04593472|Placebo Comparator|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
16312005|NCT04593459|Experimental|Probiotic|"Probiotic product consisting of these 7 bacterial strains:
~Lactobacillus salivarius W57
~Lactobacillus casei W56
~Lactobacillus rhamnosus W71
~Lactococcus lactis W58
~Enterococcus faecium W54
~Lactobacillus plantarum W62
~Lactobacillus acidophilus W22
~Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D
~Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months"
16312006|NCT04593459|Placebo Comparator|Placebo|"Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D
~Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate"
16312007|NCT04593459|Active Comparator|Metformin|"Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.
~Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention."
16312008|NCT04593446|Experimental|Oral Sulfate Tablet(ORA·FANGⓇ)|Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery
16312009|NCT04593446|Active Comparator|Sodium Picosulfate Solution(PicosolutionⓇ)|Subjects who are randomized into experimental arm will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery
16312010|NCT04593433|Experimental|Intervention|Group with the virtual museum guided tours
16312045|NCT04593199|Active Comparator|Physical Activity Tracking + Gamified Smartphone App|Over a 4-week period participants were asked to use the Fitbit app to track their daily physical activity. Additionally, they were asked to use the gamified smartphone app, Draco, during the intervention period.
16312046|NCT04593186|Experimental|Trans-oral magnifying endoscopy with NBI|Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
16314259|NCT04578041|Active Comparator|Arm 2: TRPMS + Adaptive Cognitive Training|
16312011|NCT04593407|Active Comparator|Endoscopic Mucosal Resection (EMR):|Piecemeal EMR is a conventional endoscopic resection technique. A submucosal injection of a large volume of a solution (normal saline or other) with or without dilute epinephrine (1/10,000) with or without indigo carmine is performed. Then, sequential piecemeal resection is performed with use of a combination of stiff-type snares. At the end of the procedure when macroscopically visible adenoma has been totally resected, a snare tip soft coagulation (STSC) of the margin of the scar is performed to eliminate non visible residual neoplastic tissue. This procedure is quicker and safer than ESD but led to more recurrent disease (around 20% with the standard technique but recently reduced to 5% after the introduction of STSC)
16312012|NCT04593407|Experimental|: Endoscopic Submucosal Dissection (ESD):|ESD is a newer resection technique that allows en bloc resection for large LSLs. A submucosal injection is also needed but, in this case, different endo-knives are used to achieve the resection instead of diathermic snares. The en bloc resection allows a more precise pathological analysis and the risk of recurrence is lower (<2%) when margins are tumor-free.
16312013|NCT04593394||Severe asthma|Gina-guidlines treatment-step 4 or 5
16312014|NCT04593394||Mild-moderate asthma|Gina-guidlines treatment-step 1-3 and good asthma-controll (Score om asthma controll test over 20)
16312015|NCT04593394||Subjects without asthma|Matches control-group without asthma
16312016|NCT04593381|Experimental|SBRT treatment|Intervention: Radiation: SBRT
16312017|NCT04593368|Experimental|FMT|
16312018|NCT04593355||HCV|
16312019|NCT04593342|Active Comparator|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
16312020|NCT04593342|Sham Comparator|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
16312021|NCT04593329|Experimental|TIRADENTES|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:
~1 tablet Tiradentes association, oral;
~1 capsule tramadol placebo, oral;
~1 tablet dipyrone placebo, oral."
16312022|NCT04593329|Active Comparator|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:
~1 tablet dipyrone, oral;
~1 tablet Tiradentes association placebo, oral;
~1 capsule tramadol placebo, oral."
16312023|NCT04593329|Active Comparator|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:
~1 capsule tramadol, oral;
~1 tablet dipyrone placebo, oral;
~1 tablet Tiradentes association placebo, oral."
16312024|NCT04593316||Exertional heatstroke group|Patients presenting or having presented exertional heatstroke.
16312025|NCT04593316||Control group|Healthy people who never experienced exertional heatstroke.
16312026|NCT04593303|Active Comparator|Internal iliac artery group|Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
16312027|NCT04593303|Other|No internal iliac artery group|Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
16312028|NCT04593290|Experimental|Mild Cognitive Impairment (MCI)|MCI is defined as an early stage of cognitive decline that lies between normal age-matched cognitive function and the onset of very mild forms of dementia, and is associated with a slight but noticeable decline in abilities such as memory and thinking skills. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
16312029|NCT04593290|Active Comparator|Cognitively Healthy|This group is 40-85 years old and has no significant neurological or psychiatric disease. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
16312030|NCT04593277|Experimental|Arm I (INSPIRE, telehealth care)|Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.
16312031|NCT04593277|Active Comparator|Arm II (control website)|Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
16312032|NCT04593277|Active Comparator|Group 0 (INSPIRE, printed material)|Patients have access to the digital INSPIRE program and receive printed SCP materials without telehealth.
16312035|NCT04593251|Experimental|CALY-002|
16312036|NCT04593251|Placebo Comparator|Placebo|
16312037|NCT04593238|Experimental|Double antibiotic paste intra-canal medication group (n=25)|500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
16312038|NCT04593238|Active Comparator|Calcium hydroxide intra-canal medication group (n=25)|Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
16312039|NCT04593225|Experimental|TAU + multicomponent treatment VIRTUAL SFCAMINA|VIRTUAL SFCAMINA is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
16312040|NCT04593225|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
16312041|NCT04593225|Active Comparator|Physiotherapy part of VIRTUA SFCAMINA|The physiotherapy part of the VIRTUAL SFCAMINA is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
16312042|NCT04593212||Septic Shock Survivors|
16312043|NCT04593212||Septic Shock Non-Survivors|
16312251|NCT04591769|Active Comparator|Group C(Cylindrical-shaped)|Tracheal intubation using Hi-Contour Tracheal Tube
16312047|NCT04593160|Experimental|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
16312048|NCT04593160|Experimental|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
16312049|NCT04593160|Placebo Comparator|Placebo|Preoperative single dose of placebo
16312050|NCT04593147|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with Sn-2 Palmitate, Alpha Lactalbumin and Lactoferrin to better mimic human milk.
16312051|NCT04593147|Active Comparator|Brand|A commercially available Infant Formula, for healthy term infants 0 to 2 months of age (Enfamil TM, Milk-Based Powder with Iron).
16312052|NCT04593134|Experimental|exercise group|A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a Week.
16312053|NCT04593134|No Intervention|usual-care group|These participants follows the standard post-surgery follow-up consisting of counseling by dietitians, nurses and doctors.
16312054|NCT04593121|Experimental|Cohort 1A|Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
16312055|NCT04593121|Experimental|Cohort 2A|Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
16312056|NCT04593121|Experimental|Cohort 3A|Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
16312057|NCT04593121|Experimental|Cohort 4A|Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
16312058|NCT04593121|Experimental|Cohort 5A|Participants will receive Dose 2 of BIIB107 or placebo intravenous (IV) on Day 1.
16312059|NCT04593121|Experimental|Cohort 6A|Participants will receive Dose 5 of BIIB107 or placebo IV on Day 1.
16312060|NCT04593121|Experimental|Cohort 1B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
16312061|NCT04593121|Experimental|Cohort 2B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
16312062|NCT04593121|Experimental|Cohort 3B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
16312063|NCT04593108||Letrozole misoprostol|"Group (A):
~A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
16312064|NCT04593108||Misoprostol,placebo|"Group (B):
~A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
16312065|NCT04593095|Experimental|Experimental|Each SSC session will last 2-hr during the day including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise. The 2-hr SSC will be followed by a 1-hr quiet period where infants will rest in their incubator/crib with a pad immersed with their mother breast milk for olfactory stimulation and where the control of light and noise levels will be continued. The NeuroN-QI will be done 4 times/wk for each dyad.
16312066|NCT04593095|No Intervention|Control|Mothers-infant dyads will do 4 SSC/wk. During these sessions, no attempt will be made by the RA to control the light and noise levels nor to encourage auditory stimulation. The SSC periods will not be followed by a quiet period nor olfactory stimulation.
16312067|NCT04593082||Pediatric MS Subjects|Subjects with pediatric MS will undergo fasting lab work, non-contrasted MRI, DEXA scan, and surveys.
16312068|NCT04593082||Healthy controls|Non-MS pediatric control subjects who will undergo fasting lab work, DEXA scan, and surveys for comparison to control group.
16312069|NCT04593069|Other|COVID-19 patients|Neurocognitive impairment in COVID-19 patients
16312070|NCT04593056||Warfarin|Reference group
16312071|NCT04593056||Rivaroxaban|Exposure group
16312072|NCT04593043||Warfarin|Reference group
16312073|NCT04593043||Dabigatran|Exposure group
16312074|NCT04593030||Warfarin|Reference group
16312075|NCT04593030||Apixaban|Exposure group
16312076|NCT04593017|Experimental|Active Probiotic|Probiotic contain active microorganism
16312077|NCT04593017|Placebo Comparator|Placebo Probiotic|Probiotic with no active microorganism
16312078|NCT04593004|Experimental|Teledermatology|
16312079|NCT04593004|Active Comparator|Face-to-face consultation|
16312080|NCT04592991|Active Comparator|AAA Group|"Participants with AAA will undergo routine clinical evaluation of AAA including ultrasound and CT and scheduling of open surgical repair as directed by the treating physician. We will record age and tobacco use of participant. If participant has not had a renal function blood test performed within the past 90 days, we will draw approximately 2 teaspoons of blood for a creatinine test. We will also ask the participant's permission to use a contrast dye for the CT portion of the PET-CT scan. If the participant agrees we will additional questions to gauge eligibility to receive the contrast dye.
~If available, we would like to collect any discarded AAA tissue from the surgical procedure. This discarded tissue will be kept as part of a Washington University vascular research repository. If the participant agrees to this there will be a separate consent form to sign allowing the collection of the leftover tissue along with some information about medical history."
16312081|NCT04592991|Active Comparator|Aortoiliac Occlusive Disease Group|Participants with non-aneurysmal aortoiliac occlusive disease, will be eligible for the study based on lifestyle limiting claudication (lack of blood flow to muscles causing cramping), pain in the feet or toes at rest, and/or tissue loss (leg or foot ulcers that don't heal or gangrene) that requires aortofemoral bypass. The aortofemoral bypass is not part of this research study.
16312082|NCT04592978|Experimental|Pain-Alcohol Personalized Feedback Intervention|
16312083|NCT04592978|Active Comparator|Control Personalized Feedback Intervention|
16312084|NCT04592965|Experimental|Clinical and neuropsychological examinations|Participants will be assessed by means of validated and lab-tailored clinical scales, alongside with semi-structured interviews, to assess the status of the disease (PD), amongst others, such as cognitive capabilities.
16312085|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation|Participants will manipulate a patented robotic system designed to induce the PH and other accompanying bodily illusions. At the end, participants will report on various subjective experiences, by answering a structured questionnaire.
16312086|NCT04592965|Experimental|Resting-state fMRI acquistion|We will acquire resting-state data in the MRI scanner for all the participants. Respiration and heart beat rate data will also be acquired.
16312087|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation (MRI)|All healthy participants, and all patients who are deemed capable of performing the robotic manipulation task in the MRI scanner, will take part on this arm. Participants will perform a robotic manipulation task, with a patented robotic system, capable of inducing the PH and other accompanying bodily illusions in the MRI scanner. At the end participants will report on the various subjective experiences, by answering a structured questionnaire.
16312088|NCT04592952|Experimental|Single-Arm|"Provocation Phase: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
~Open-Label Treatment Phase: Erenumab packed in a SureClick® Autoinjector Pen (AI)"
16312089|NCT04592939|Other|Group 1: immediate weight bearing|
16312090|NCT04592939|Other|Group 2: 6 week toe touch weight bearing|
16312091|NCT04592926|Experimental|Accuro ultrasound|
16312092|NCT04592926|Sham Comparator|Control|
16312093|NCT04592913|Placebo Comparator|Arm B|placebo product and FLOT chemotherapy
16312094|NCT04592913|Experimental|Arm A|Durvalumab and FLOT chemotherapy
16312095|NCT04592900|Experimental|the control group|the control group Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and balance training exercises and gait training in open environment.
16312096|NCT04592900|Experimental|the virtual reality group|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
16312097|NCT04592900|Experimental|the Biodex Balance Training group|Group 3 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
16312098|NCT04592887|Experimental|FLASH radiotherapy for painful bone metastasis(-es)|
16312099|NCT04592874|Experimental|AL002 Dose 1|AL002 every 4 weeks
16312100|NCT04592874|Experimental|AL002 Dose 2|AL002 every 4 weeks
16312101|NCT04592874|Experimental|AL002 Dose 3|AL002 every 4 weeks
16312102|NCT04592874|Placebo Comparator|Placebo|Placebo every 4 weeks
16312103|NCT04592861|Experimental|Carbon ion radiotherapy|Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday). The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
16312104|NCT04592861|Active Comparator|Routine standard of care|Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
16312105|NCT04592848||Population study|"Female patients who undergone a cystectomy and/or urinary diversion for a non-malignant disease at Lyon Sud Hospital between January 2007 and December 2019."
16312106|NCT04592835|Experimental|Cohort 1 (288mg)|72 mg/0.3 mL x 4 injection sites
16312107|NCT04592835|Experimental|Cohort 2 (576 mg)|144 mg/0.6 mL x 4 injection sites
16312108|NCT04592835|Experimental|Cohort 3 (960 mg)|216 mg/1.0 mL x 4 injection sites
16312109|NCT04592822|Experimental|Treatment T|30 minutes after the start of a standard breakfast, subjects will take one straw of WD-1602 Dabigatran Etexilate Mesylate Granules (150 mg) in 100 mL water as oral administration.
16312110|NCT04592822|Active Comparator|Treatment R|30 minutes after the start of a standard breakfast, subjects will receive a single Pradaxa® 150 mg capsule swallowed with 240 mL water as oral administration.
16312111|NCT04592809|Active Comparator|Ketamine|0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
16312112|NCT04592809|Active Comparator|Midazolam|0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
16312113|NCT04592796||Nursing-home residents|Older adults in a nursing-home who report a self-perception of poor sleep quality
16312114|NCT04592783|Experimental|Tight Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 140/90 mmHg
16312115|NCT04592783|Experimental|Liberal Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 150/95 mmHg
16312116|NCT04592770|Experimental|The experimental intervention (walk):|In this group, the nature walk will take place in a conserved and by far the largest recreational area of Karachi city. The safari park covering an area of 148 acres (0.60 km2), It has a zoo, geared with woodland, mountain viewing, safari tracks, as well as two natural lakes. The experiment will take place in the afternoon on a 5 km marked area. The duration of the stretching exercise sessions will be of 10 minutes followed by 50 minutes' walk session five times per week (total 12 weeks). participants will be asked to walk at moderate pace.
16312117|NCT04592770|Placebo Comparator|The control intervention (sit & relax):|Subjects will undergo 12 weeks of nature therapy that includes exposure to natural landscapes. The duration of the sessions will be 60 minutes five times per week. The subjects will be asked to sit and relax in the evening, in the same recreational area which is used for the experimental group.
16312118|NCT04592757|Experimental|Subacute stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
16312119|NCT04592757|Experimental|Chronic stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
16312160|NCT04592458|Experimental|Experimental|10 transfusion dependent β-thalassemia major subjects who are 8-16 years older will be transplanted with β-globin restored autologous hematopoietic stem cells that are modified with lentiviral vector LentiHBBT87Q encoding the human β-globin gene.
16312161|NCT04592445|Active Comparator|Axon Treatment Arm|Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
16314860|NCT04574063|Experimental|Lifestyle website PLUS group coaching PLUS SNPs|
16312120|NCT04592744|Experimental|Intervention|Patients assigned to the study group will receive Ang 2 infusion in addition to standard vasopressor regimen. Ang 2 is currently approved at UCLA as a second line vasopressor and will be used as such for the purposes of our study. Hemodynamic goals will be established at the beginning of the case by the anesthesiology and surgical teams. Ang 2 will be started as a second vasopressor once the norepinephrine dose has reached 0.05mcg/kg/min. Ang 2 will be initiated at a starting dose of 5ng/kg/min. That dose will be up titrated one time to 10ng/kg/min as vasopressor requirements escalate. Once a patient is on the 10ng/kg/min dose of ang 2, no additional up titration will be performed. Hemodynamic management will continue throughout the case with titration of other vasopressors as needed. Ang 2 will be continued throughout the intraoperative period but will be weaned off prior to leaving the operating room.
16312121|NCT04592744|Active Comparator|Control|Patients assigned to the control group will undergo intraoperative management with a standard vasopressor regimen composed of norepinephrine, vasopressin and epinephrine based on hemodynamic goals established by the surgical and anesthesia teams prior to surgery.
16312122|NCT04592731|Experimental|Gel containing Acetylated Natural Nucleotides|
16312123|NCT04592731|Placebo Comparator|Vehicle Gel|
16312124|NCT04592718|Experimental|Slow deep breathing plus breath counting|Participants in this group will do a daily 5-min slow deep breathing exercise (6 breaths/minute) and will also count their breaths
16312125|NCT04592718|Active Comparator|Normal-paced breathing plus breath counting|Participants in this group will do a daily 5-min normal-paced breathing (15 breaths/minute) and will also count their breaths
16312126|NCT04592718|No Intervention|Control|Participants in this group will serve as a control and will not do any breathing exercises or breath counting.
16312127|NCT04592705|Experimental|Therapeutic plasma exchange|
16312130|NCT04592679|Experimental|FES-C|
16312131|NCT04592679|Active Comparator|Standard|
16312132|NCT04592666|Experimental|Combinational therapy|
16312133|NCT04592666|Active Comparator|Single TKI|
16312134|NCT04592653|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of ALKS 4230.
16312135|NCT04592640|Experimental|Uremic Calciphylaxis Patients|Human amniotic mesenchymal stem cells (hAMSCs)
16312136|NCT04592627||Simulated home environment visit with the dyad participants|The cohort consists of six stroke survivor-informal caregiver (e.g., spouse or family member) dyads. Individual dyads will participate in the simulated home environment visit while the investigative team collects the data.
16312137|NCT04592614|Experimental|High dose|CTM-NS participants receiving monthly virtual group meetings for 2 years (24 meetings total)
16312138|NCT04592614|Experimental|Low dose|CTM-NS participants receiving quarterly virtual group meetings for 2 years (8 meetings total)
16312139|NCT04592601|Experimental|S.L.I.M.M.S. Procedure|Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure
16312140|NCT04592588|Experimental|Common Elements Toolbox (COMET)|The Common Elements Toolbox is an online intervention consisting of modules from empirically supported treatments for common mental health problems.
16312141|NCT04592588|Sham Comparator|Wait-list control condition|
16312142|NCT04592575||TBI that are positive on screening tool|Patients that are identified on the AbilityLab Vestibular screening tool as possibly having vestibular dysfunction
16312143|NCT04592575||TBI patients not positive on screening tool|Patients that are not identified on the Ability Lab Vestibular screening tool as possibly having vestibular dysfunction
16312144|NCT04592562|Experimental|GAE Arm|Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.
16312145|NCT04592549|Experimental|Cohort 1: Low dose IM injection of active drug or placebo|"Subjects in cohort 1 will receive a low dose IM injection of either active drug or placebo.
~Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo"
16312146|NCT04592549|Experimental|Cohort 2: High dose IM injection of active drug or placebo|"Subjects in cohort 2 will receive a high dose IM injection of either active drug or placebo.
~Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo."
16312147|NCT04592549|Experimental|Cohort 3: High Dose IM injection of active drug or placebo|"Subjects in cohort 3 will receive a high dose IM injection of either active drug or placebo.
~Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo"
16312148|NCT04592549|Experimental|Cohort 4: High Dose IM injection of active drug or placebo|"Subjects in cohort 4 will receive a high dose IM injection of either active drug or placebo.
~Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo"
16312152|NCT04592523||All Participants|Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.
16312153|NCT04592497|Experimental|QDOT|will undergo the AF ablation procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system
16312154|NCT04592497|Active Comparator|standard|will undergo the AF ablation procedure with assistance standard Thermocool Smartouch SF system
16312155|NCT04592484|Experimental|CDK-002|
16312156|NCT04592471||Orthosis Group 1|Use of kneeMID500 device
16312157|NCT04592471||Control Group 1|Control Group of the kneeMID500 Orthosis Group - No use of the device
16312158|NCT04592471||Orthosis Group 2|Use of kneeSTRONG700 device
16312159|NCT04592471||Control Group 2|Control Group of the kneeSTRONG700 Orthosis Group - No use of the device
16312162|NCT04592445|Sham Comparator|Sham Control Arm|Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
16312163|NCT04592432|Experimental|SIGN@L-A followed by SIGN@L-B|"Participants in this arm will have access to the prototype SIGN@L-A of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-B."
16312164|NCT04592432|Experimental|SIGN@L-B followed by SIGN@L-A|"Participants in this arm will have access to the prototype SIGN@L-B of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-A."
16312165|NCT04592419|Experimental|KSI-301 (Arm A)|"Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.
~In the Extension Phase, participants randomized to KSI-301 (5 mg) in the Primary Study will continue to receive KSI-301 (5 mg) based on protocol-defined disease activity criteria."
16312166|NCT04592419|Active Comparator|Aflibercept (Arm B)|"Intravitreal injection of aflibercept (2 mg) once every 4 through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 weeks from Week 24 to Week 44.
~In the Extension Phase, participants randomized to aflibercept in the Primary Study will cross over to treatment with KSI-301 (5 mg). They will receive their first dose of KSI-301 (5 mg) at Week 48 and will receive additional treatment with KSI-301 (5 mg) based on protocol-defined disease activity criteria."
16312167|NCT04592393|Experimental|Abbreviated PB MRI|Short and Focused non-contrast MRI for surveillance
16312168|NCT04592380|Experimental|Stage 1: Clevidipine (double-blinded)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Clevidipine will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter per the Food and Drug Administration (FDA) approved clevidipine label, to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
16312169|NCT04592380|Placebo Comparator|Stage 1: Placebo (double-blinded)|Placebo will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Placebo will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter according to the same dosing instructions as for clevidipine to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
16312170|NCT04592380|Experimental|Stage 2: Clevidipine (open-label)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
16312171|NCT04592380|Active Comparator|Stage 2: Standard of Care (open-label)|For patients randomized to SOC, the infusion must be continuous, administered per the institution's treatment practice, and dose titration must be performed to a maximum allowed or maximum tolerated dose to achieve target SBP. If treatment with an alternative IV anti-hypertensive agent is required, the patient will be transitioned to an alternative IV antihypertensive agent according to the institutional standard of care.
16312172|NCT04592354|Active Comparator|Oxaloacetate Therapeutic Arm|"Anhydrous Enol-Oxaloacetate
~A 500 mg oxaloacetate capsule taken by mouth twice a day
~Planned study duration is 6 weeks with an interim assessment at the end of 2 weeks and final assessment at 6 weeks"
16312173|NCT04592354|Placebo Comparator|Placebo Arm|"Rice Flour
~A 500 mg rice flour capsule taken by mouth twice a day"
16312174|NCT04592341|Experimental|Gantenerumab|Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103.
16312175|NCT04592328||Patients planned for elective open cardiac surgery|
16312176|NCT04592315|Experimental|1|Dose 5 mg
16312177|NCT04592315|Experimental|2|Dose 10 mg
16312178|NCT04592315|Experimental|3|Dose 20 mg
16312179|NCT04592315|Experimental|4|Dose 40 mg
16312180|NCT04592315|Experimental|5|Dose 60 mg
16312181|NCT04592315|Experimental|6|Dose 80 mg
16312182|NCT04592302||Smoking Cessation Group|participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)
16312183|NCT04592302||Smoker Group 2|participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period
16312184|NCT04592289|Experimental|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery
~Day prior to surgery:
~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml
~18.00 - 19.00 Clear fluids 500 ml
~19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml
~20.00 - 21.00 Clear fluids 500 ml"
16312185|NCT04592289|Active Comparator|Mechanical bowel preparation only|"Day prior to surgery:
~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml
~18.00 - 19.00 Clear fluids 500 ml
~19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml
~20.00 - 21.00 Clear fluids 500 ml"
16312186|NCT04592276|Experimental|PS128|Each PS128 capsule contained 3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg .
16312187|NCT04592276|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
16312188|NCT04592263||Group 1 - Qualitative phase|4 focus groups and 6 semi-structured interviews.
16312190|NCT04592250||Observational (survey)|Participants will complete a survey packet that is estimated to take about 30 minutes. The survey packet will be collected at baseline and at 6 months.
16312191|NCT04592237|Experimental|Group I (niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16312192|NCT04592237|Experimental|Group II (cetrelimab, niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16312193|NCT04592211|Experimental|olaparib+pembrolizumab+paclitaxel|
16312194|NCT04592198|Experimental|A (Buccal 0.25 Mg)|Palonosetron HCl Buccal Film 0.25 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
16312195|NCT04592198|Experimental|B (Buccal 0.5 Mg)|Palonosetron HCl Buccal Film 0.5 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
16312196|NCT04592198|Active Comparator|C (IV Injection 0.25 Mg)|IV palonosetron 0.25 Mg (ALOXI®) and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
16312197|NCT04592172|Experimental|Bedtime Routine Education|50 families will be randomly assigned to receive the bedtime routine intervention, 3 Cs for Bedtime ZZZs delivered by research assistants at the 12-month and 15-month well-child visits, in additional to receiving usual clinical care. The intervention will take approximately 30-45 minutes to implement at each study visit. Research assistants will be trained and supervised by board-certified Behavioral Sleep Medicine providers. This intervention focuses on developing an individualized bedtime routine, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling, based on parent's preferences. Families will receive appropriate materials for their bedtime routine, including a CuddleBright kit, bedtime books, toothbrush/toothpaste, and the created bedtime chart to take home.
16312198|NCT04592172|No Intervention|Control group|50 families will be randomly assigned to control group (usual care).
16312199|NCT04592159|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
16312200|NCT04592159|Placebo Comparator|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
16312201|NCT04592146|Active Comparator|Control group|Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
16312202|NCT04592146|Experimental|Intervention group|"Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person.
~As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected."
16312203|NCT04592133||Scoliosis Patients|
16312204|NCT04592133||Control Group|
16312205|NCT04592120|Experimental|Coalition Check-Up|The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
16312206|NCT04592120|No Intervention|Technical assistance as usual|Coalitions in the comparison condition will receive a feedback report but no additional support from technical assistance providers beyond what is already available to them.
16312207|NCT04592094|Experimental|Blueback® Physio|Classic protocole with the use of Blueback® Physio during physiotherapy sessions, , and using the Blueback® Physio in the active mode (patient and physiotherapists see the biofeedback in real time)during the tests required by the protocol of the study.
16312208|NCT04592094|No Intervention|Standard Care|Classic protocole without the use of Blueback® Physio during physiotherapy sessions, and using the Blueback® Physio in the blind mode during the tests required by the protocol of the study
16312209|NCT04592081|Experimental|DEXTENZA placed within the upper canaliculus|Dextenza placed within the upper canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
16312210|NCT04592081|Active Comparator|DEXTENZA placed within the lower canaliculus|Dextenza placed within the lower canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
16312211|NCT04592068||Retinal multi-diseases diagnosed by DL algorithm|
16312212|NCT04592068||Retinal multi-diseases diagnosed by expert panel|
16312213|NCT04592042|Experimental|Feel-Good-Group|Pre-post assessment of feasibility and putative efficacy of an emotion-oriented cognitive-behavioral group intervention over 8 sessions and four weeks.
16312214|NCT04592029|Experimental|TACE-Sin-Bev|TACE combined with sintilimab and bevacizumab.
16312215|NCT04592016|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
16312216|NCT04592016|Experimental|Pivotal Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
16312217|NCT04591990|Experimental|AVP + placebo hydrocortisone|REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.
16312218|NCT04591990|Experimental|placebo AVP + hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
16312219|NCT04591990|Experimental|AVP + hydrocortisone|REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
16312220|NCT04591990|Experimental|placebo AVP + placebo hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone
16312221|NCT04591977|Experimental|Self-Sampling Kit|Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
16312222|NCT04591964|Active Comparator|baseline|standard medical therapy + using of mobile application + improving therapy
16312223|NCT04591964|No Intervention|Control|standard medical therapy
16312224|NCT04591951|Active Comparator|I2-ART Group|I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
16312225|NCT04591951|Placebo Comparator|Control Group|"The caregivers in the control group will receive usual care."
16312226|NCT04591938|Other|Single arm|Fantom Encore Bioresorbable scaffold implantation
16312227|NCT04591925|Experimental|"Investigative Device - SteadiSet™ device with coil-reinforced soft polymer indwelling cannula"|Participants are randomized into the investigational device (SteadiSet™) insulin infusion set group and then switched to a Commercially available infusion set (using a soft Teflon indwelling cannula) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the investigational infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Control device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
16312228|NCT04591925|Active Comparator|Commercially available Insulin Infusion device using a soft Teflon indwelling cannula|Participants are randomized into the Commercially available insulin infusion set (using a soft Teflon indwelling cannula) group and then switched to Investigative Device infusion set (SteadiSet™) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the Control infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Investigational Device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
16312229|NCT04591912|Experimental|mind. body. voice.|The 10-week mind. body. voice. program.
16312230|NCT04591912|No Intervention|Control|Assessment-only control
16312231|NCT04591899|Experimental|CAD/CAM SS|
16312232|NCT04591899|Active Comparator|Conventionally manufactured SS|
16312233|NCT04591886|Experimental|mind. body. voice.|The 10-week mind. body. voice. program
16312234|NCT04591886|No Intervention|Control|Assessment-only control
16312235|NCT04591873||Critical patients in the emergency department|
16312236|NCT04591860|Active Comparator|Sutures only|"Patients with a large hiatal hernia undergo the cruroplasty with sutures only.
~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
16312237|NCT04591860|Active Comparator|Absorbable Mesh|"Patients with a large hiatal hernia undergo the cruroplasty with mesh implantation.
~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
16312238|NCT04591860|Active Comparator|Pledgeted sutures|"Patients with a large hiatal hernia undergo the cruroplasty with pledgeted sutures.
~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
16312239|NCT04591847|Experimental|Vitamin D supplemented group|Vitamin D2 20000 IU 1 tab oral weekly start at GA 18 -22 weeks until delivery
16312240|NCT04591847|Experimental|Placebo group|Placebo drug (Appearance same as Vitamin D2) 1 tab oral weekly start at GA 18 -22 weeks until delivery
16312241|NCT04591834||Observational|No Intervention
16312242|NCT04591808|Experimental|S05167|
16312243|NCT04591808|Active Comparator|Lipitor®|
16312244|NCT04591808|Active Comparator|Coversyl®|
16312245|NCT04591795|Experimental|100 mg SHT extract|Drug: Sahastara remedy alcoholic extract comparison with diclofenac
16312246|NCT04591795|Experimental|25 mg dicolfenac|Drug: diclofenac comparison with diclofenac
16312247|NCT04591782|Experimental|PomJuice (PJ)|8 oz of PJ
16312248|NCT04591782|Active Comparator|Sugar Water|8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
16312249|NCT04591782|Other|Water|8 oz of water
16312250|NCT04591769|Experimental|Group T(Tapered- shaped)|Tracheal intubation using TaperedGuard Tracheal Tube
16312252|NCT04591756|Active Comparator|N95 Filtering Facepiece Respirator|Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear
16312253|NCT04591756|Active Comparator|Elastomeric Half-Mask Respirator with P100 filters|Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear.
16312254|NCT04591743|Experimental|Experimental group|
16312255|NCT04591743|Placebo Comparator|Placebo group|
16312256|NCT04591730||Type I maternity|Fathers who experienced a first childbirth in a type I maternity in Lorraine.
16312257|NCT04591730||Type II maternity|Fathers who experienced a first childbirth in a type II maternity in Lorraine.
16312258|NCT04591730||Type III maternity|Fathers who experienced a first childbirth in a type III maternity in Lorraine.
16312259|NCT04591717|Experimental|Cohort 1: 0.5 mL of hAd5-S-Fusion+N-ETSD SC|0.5 mL of hAd5-S-Fusion+N-ETSD SC (5 × 10e10 VP/dose) on days 1 and 22
16312260|NCT04591717|Experimental|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) on days 1 and 22
16312261|NCT04591717|Experimental|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
16312262|NCT04591717|Experimental|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; no vaccine on day 22
16312263|NCT04591717|Experimental|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
16312264|NCT04591717|Experimental|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on days 15 and 29
16312265|NCT04591704||Diabetic groups|COVID-19 patients with diabetes mellitus
16312266|NCT04591704||Control groups|COVID-19 patients without diabetes mellitus
16312267|NCT04591678||SMA nusinersen adult cohort|"The nusinersen treatment will be given as standard of care. The treatment (which is NOT research, but the standard care) will be given by an injection into the cerebrospinal fluid (fluid in your spine) through a needle inserted into your lower back. Participants will receive a 12 mg (5 mL) dose during each administration/injection, which will occur on the following days: 1 (baseline), 15, 29, and 60. Following the 60 day treatment, participants will receive treatment every 4 months (6, 10, 14 etc.).
~After the 60 day, 6 month, 10 month, 14 month, 18 month and 22 month treatments the study team will see each participant afterwards to collect information to evaluate your general health, function and response to the treatment for the study."
16312268|NCT04591652|Experimental|99mTc-MIRC208 SPECT/CT scan|The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.
16312269|NCT04591639|Other|Patients with heart failure without type 2 diabetes|60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
16312270|NCT04591639|Other|Patients with heart failure with type 2 diabetes|60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
16312273|NCT04591613|Other|Standardized clinical and paraclinical follow-up|"Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format.
~All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
~Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
~Total serum, plasma and naso-paaryngeal samples will be collected."
16312274|NCT04591600|Experimental|Ivermectin-Doxycycline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
16312275|NCT04591600|Active Comparator|Control|Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.
16312276|NCT04591587|Active Comparator|Smile Group|Twenty patients (20) underwent SMILE surgery (first group)
16312277|NCT04591587|Active Comparator|Lenticule Group|Twenty patients (20) underwent lenticule implantation (second group)
16312278|NCT04591574|Other|Intervention Group|All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.
16312279|NCT04591574|Active Comparator|Usual care group|Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital
16312405|NCT04590703||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
16312280|NCT04591548||Endometriosis|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
16312281|NCT04591548||Primary infertility|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
16312282|NCT04591535|Experimental|WD-1603 (tablet strength 1) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
16312283|NCT04591535|Experimental|WD-1603 (tablet strength 2) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
16312284|NCT04591535|Experimental|WD-1603 (tablet strength 3) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
16312285|NCT04591535|Experimental|WD-1603 (tablet strength 4) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
16312286|NCT04591522|Experimental|FMT group|Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.
16312287|NCT04591522|No Intervention|control group|
16312288|NCT04591496|Experimental|SmartFeeding4Kids|SmartFeeding4Kids: information about children's healthy diet and effective parental feeding practices, with a behavioral intervention (5 sessions plus 2 brief booster sessions online intervention)
16312289|NCT04591496|Active Comparator|SmartFeeding4Kids Health|Psychoeducational condition: information about children's healthy diet and effective parental feeding practices (5 sessions plus 2 brief booster sessions online intervention)
16312291|NCT04591470||General population|
16312292|NCT04591470||Pazients undergone inguinal hernia correction|
16312293|NCT04591457|Experimental|Insulin Glargine Sansulin|Drug product Insulin Glargine, Sansulin Log-G 100 IU/mL (PT. Sanbe Farma)
16312294|NCT04591457|Active Comparator|Insulin Glargine Lantus|Drug product Insulin Glargine, Pen Injector [Lantus] 100 IU/mL (PT. Sanofi-Aventis)
16312295|NCT04591444|Active Comparator|ClinproTM White Varnish|"Application of ClinproTM White Varnish containing sodium fluoride (5%) and Tricalcium phosphate (TCP).
~A technology that allows calcium and phosphate ions to coexist with fluoride ions separately, forming a more resistant mineral on the tooth surface (3M ESPE Clinpro White Varnish; 3M ESPE Clinpro 5000)."
16312296|NCT04591444|Active Comparator|ClinproTM XT Varnish|"Application of ClinproTM XT Varnish, a resin-modified glass ionomer sealant.
~Creates a protective layer on exposed dentin, which is durable and has the ability to release fluoride, calcium and phosphate into the surroundings. (3M ESPE Clinpro XT Varnish)."
16312297|NCT04591444|Placebo Comparator|Placebo Group|Participants who were part of the placebo group continuously used only the conventional toothpaste provided in the oral hygiene kit during the initial four weeks of the research and received a simulated treatment.
16312298|NCT04591431|Experimental|Tailored Therapy|"Patients will be treated with target therapy and/or immunotherapy according to their genomic profile evidenced by the FO (Foundation One) profiling. Patients will be treated with one or more drugs of the following list according to their genomic profile and independently from their type of cancer:
~TARGETED THERAPY (MOLECULAR TARGET) ERLOTINIB (EGFR mutation) TRASTUZUMAB, PERTUZUMAB, TDM1, LAPATINIB (ERBB2 amplifications/mut) EVEROLIMUS (mTOR mutations, AKT mut) VEMURAFENIB, COBIMETINIB (BRAFV600E mutations) ALECTINIB, BRIGATINIB (ALK, RET) PALBOCICLIB (CDK4/6, CDKN2A/p16) PONATINIB (Bcr-abl) VISMODEGIB (SMO/PTCH1) ITACITINIB (JAK mutation) INCB054828 (FGFR1/2/3) IPATASERTIB (PI3K, AKT, PTEN) ENTRECTINIB (NTRK1/2/3 -TRK fusion proteins-, ROS1)
~IMMUNOTHERAPY (BIOMARKERS) ATEZOLIZUMAB, NIVOLUMAB, IPILIMUMAB (MSI, HIGH TUMOR MUTATIONAL BURDEN, OTHER ) Drugs will be administered according to their respective SmPCs (or IBs in case of drugs under development)."
16312299|NCT04591431|Active Comparator|Standard of Care|Patients will be treated according the current version of the AIOM (Italian Association of Medical Oncology) guidelines for their type of cancer. As an example, patients could be treated with standard chemotherapy and/or targeted therapy according to the histological results.
16312300|NCT04591418|Active Comparator|Rotary handpieces|
16312301|NCT04591418|Experimental|Er:YAG laser|
16312302|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
16312303|NCT04591405|Placebo Comparator|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
16312304|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
16312305|NCT04591405|Placebo Comparator|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
16312306|NCT04591392|Experimental|Device|ASD closure with the reSept ASD Occluder
16312307|NCT04591379|Experimental|Intervention arm|
16312308|NCT04591366|Active Comparator|Control|Standard skin prep prior to procedure will be performed and an adhesive iodine-infused barrier dressing will be applied post procedure but prior to taking the culture swab and closing the incision.
16312309|NCT04591366|Experimental|Intervention|Standard skin prep prior to procedure plus an adhesive iodine-infused barrier dressing prior to incision, post procedure a culture swab will be taken and the incision closed.
16312310|NCT04591353|Experimental|"Investigational group (PENG Block group)"|Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
16312311|NCT04591353|Active Comparator|Control group|"Control group participants will be transferred to the block area preoperatively, and care will proceed as if they were receiving injection.
~Patients will be placed in the supine position resting comfortably. Standard noninvasive monitors will be applied, and oxygen will be administered via nasal cannula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area. The ultrasound probe will be used to identify the iliopubic eminence (IPE). Only skin will be numbed using 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected."
16312312|NCT04591340||test group|all the patients treated with HSCT are with nutrition risk, so they will be all included to accept nutrition therapy.
16312313|NCT04591327||general anesthesia|
16312314|NCT04591327||spinal anesthesia|
16312315|NCT04591314|Experimental|Neurofeedback participants|All the participants studied.
16312316|NCT04591301|Experimental|HEC113995 PA•H2O 2.5mg|Healthy subjects are given HEC113995 PA•H2O 2.5 mg in a single dose.
16312317|NCT04591301|Active Comparator|HEC113995 PA•H2O 5mg|Healthy subjects are given HEC113995 PA•H2O 5 mg in a single dose.
16312318|NCT04591301|Active Comparator|HEC113995 PA•H2O 10mg|Healthy subjects are given HEC113995 PA•H2O 10 mg in a single dose.
16312319|NCT04591301|Active Comparator|HEC113995 PA•H2O 20mg|Healthy subjects are given HEC113995 PA•H2O 20 mg in a single dose.
16312320|NCT04591301|Active Comparator|HEC113995 PA•H2O 40mg|Healthy subjects are given HEC113995 PA•H2O 40 mg in a single dose.
16312321|NCT04591301|Active Comparator|HEC113995 PA•H2O 60mg|Healthy subjects are given HEC113995 PA•H2O 60 mg in a single dose.
16312322|NCT04591301|Active Comparator|HEC113995 PA•H2O 80mg|Healthy subjects are given HEC113995 PA•H2O 80 mg in a single dose.
16312323|NCT04591301|Placebo Comparator|placebo|Healthy subjects are given placebo in a single dose.
16312324|NCT04591288|Experimental|FES + Treadmill|Functional Electrical stimulation walking group.
16312325|NCT04591288|Active Comparator|Treadmill only|Treadmill walking group (no electrical stimulation).
16312326|NCT04591288|No Intervention|Control|"Control group.
~After control period of 12 weeks, they are randomized into FES + Treadmill or Treadmill group."
16312327|NCT04591275|Experimental|CMAB807|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
16312328|NCT04591275|Active Comparator|Prolia®|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
16312329|NCT04591262|Experimental|PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV|PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
16312330|NCT04591249|Other|Usual postoperative care|Participants randomized to usual care group will receive postoperative care as determined by their treating surgeon.
16312331|NCT04591249|Experimental|Usual postoperative care + Physical activity intervention|Participants randomized to the physical activity intervention group will receive usual postoperative care as determined by their treating surgeon and novel physical activity intervention.
16312332|NCT04591236|Experimental|Gait training with brain stimulation|Treadmill gait training and transcranial direct current stimulation (tDCS) on the leg motor areas
16312333|NCT04591236|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
16312334|NCT04591223|Experimental|TAU + six weekly sessions of competency-based module (CbM)|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider as well as a well-designed, one on one structural physical workout module to be offered by a licensed senior physical trainer in public sports ground or gymnasium.
16312335|NCT04591223|No Intervention|TAU|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider.
16312336|NCT04591210|No Intervention|No Treatment (Standard of Care)|Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
16312337|NCT04591210|Experimental|ACEi treatment|The physician will initiate any ACE inhibitor and dose at their discretion.
16312338|NCT04591210|Experimental|ARB treatment|The physician will initiate any ARB and dose at their discretion.
16312339|NCT04591184|Experimental|Active Covigenix VAX-001|Dose-ranging, 2 dose levels. 24 subjects receiving active i.m. vaccine
16312340|NCT04591184|Placebo Comparator|Placebo|Placebo injection. 12 subjects receiving placebo
16312341|NCT04591171|Experimental|n-of-1 trial guided clinical decision making|
16312342|NCT04591158|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
16312343|NCT04591145||Observational group|Patients received bowel preparation and colonoscopy. The withdrawal phase video was saved and their lesions detection was record.
16312344|NCT04591132|Experimental|kinematic analysis|each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.
16312345|NCT04591119|Active Comparator|Transversus Thoracic Muscle Plane Block (TTMPB) Group|At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
16312346|NCT04591119|Active Comparator|Parasternal Intercostal Block (PSIB) Group|At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
16312347|NCT04591119|No Intervention|Control Group|At the control group, no intervention for pain management will be done.
16312348|NCT04591106||Group 1|50 healthy subjects and 50 subjects with NAFLD between ages of 6-17 years old. Will receive 1 MRI/MRE exam. the MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
16312349|NCT04591106||Group 2|60 subjects with Liver Disease and Fibrosis between ages of 6-17 years old. Will receive 1 MRI/MRE exam. the MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
16312350|NCT04591106||Group 3|15 healthy subjects and 15 at-risk subjects (mother had gestational diabetes) between ages of 1-6 months old. Will receive 1 MRI scan.
16312351|NCT04591093|Active Comparator|CI with FineHearing with 10 more apical electrodes activated then 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated first during 1 month then FineHearing Strategy with 10 more basal electrodes activated during 1 month
16312352|NCT04591093|Active Comparator|CI with FineHearing with 10 more basal electrodes activated then 10 more apical electrodes activated|Cochlear implant with FineHearing Strategy with 10 more basal electrodes activated first during 1 month then FineHearing Strategy with 10 more apical electrodes activated during 1 month
16312353|NCT04591080|Experimental|GUMMETAL TiNbTaZr|"TiNbTaZr (Beta-Titanium) Alloy used to manufacture orthodontic archwires. We will be using an archwire with the size of 0.016 x 0.022"
16312354|NCT04591080|Active Comparator|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
16312355|NCT04591067||Hip Dysplasia group|Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
16312356|NCT04591054|Active Comparator|Extended Vision IOL|Vivity
16312357|NCT04591054|Active Comparator|Neutral Aspheric Monofocal IOL|enVista [MX60E]
16312358|NCT04591041|Experimental|Training by Mixed Reality Simulation|
16312359|NCT04591041|Active Comparator|Training by Mannequin Based Simulation|
16312360|NCT04591028|Other|Intervention|Injection of Indocyamine Green.
16312361|NCT04591015|Experimental|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
16312362|NCT04591015|Active Comparator|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
16312363|NCT04591002|Active Comparator|Osemertinib|
16312364|NCT04591002|No Intervention|Observation|
16312365|NCT04590989|Experimental|Personalized Plan (PP)|"Each subject in the PP group will be allocated to one of five clusters based on their metabolic and genetic health biomarkers from samples of urine, plasma, serum, and saliva. 58 biomarkers will be included to characterize the 5 metabolic clusters/processes in the PREVENTOMICS platform: 1) oxidative stress; 2) inflammation; 3) carbohydrate metabolism; 4) lipid metabolism; 5) microbiota-generated metabolites. Eurecat Nutrition Team has prepared a list of recommended food items to increase and food to exclude/limit from the diet for each cluster. The list will be adopted by Simple Feast in creating five different menus that will encompass the 12 meals/week of breakfasts and dinners for the five different metabolic clusters. Additionally, subjects will receive personalized actionable Do's push notifications by ONMI. The messages are personalized based on user reports from the behavioral questionnaire at V2 in addition to inputs from the nutritional recommendations of food to increase."
16312366|NCT04590989|Placebo Comparator|Control Group|"Dietary intervention:
~The second group of 50 subjects will receive meals from Simple Feast, after integrating their metabolic profile and other blood biomarkers by PREVENTOMICS, which are based on the national dietary guidelines.
~Behavioral intervention:
~Subjects will also receive nudges, after filling out ONMI's behavioral questionnaire at V2, but that will not be personalized (i.e. basic information that is available online from NHS and WHO)."
16312367|NCT04590976||Healthcare Professionals (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
16312368|NCT04590976||Stage 1 (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
16312369|NCT04590976||Stage 2 (n = 10)|"Intervention: Single, Think Aloud Interview Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed."
16312370|NCT04590976||Stage 3 (n = 300)|Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit
16312373|NCT04590950||Single-group study|Severe haemophilia B patients substituted with eftrenonacog-alfa
16312374|NCT04590937|Experimental|Reference|
16312375|NCT04590937|Experimental|BI 730357|
16312406|NCT04590677||Group 1|Pregnant women at 36 weeks gestational age, who are not expected to have risk factors for preterm birth, n=150.
16312376|NCT04590911|Experimental|CEP intervention|Cognitive Enrichment Program (CEP) : tailored for individuals who sustain a TBI in later adulthood. The CEP is a 12-week multimodal intervention structured into three modules designed to simultaneously address cognitive problems resulting from TBI, as well as age-related cognitive issues in the following domains: self-awareness, attention and memory, and executive functions.
16312377|NCT04590911|No Intervention|Usual care|Usual care : interventions within a holistic interdisciplinary rehabilitation program focused on resuming daily activities and social roles, if needed, as determined by treating physician; does not include any form of cognitive rehabilitation.
16312378|NCT04590898||significant peri-device leakage after LAA occlusion|Peri-device leakage closure after left atrial appendage occlusion
16312379|NCT04590885|Other|Couple Communication and Support|CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support. It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving. Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
16312380|NCT04590885|Other|Healthy Lifestyle Informaion|Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment. Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care. Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
16312382|NCT04590859||Penile block|Patients undergoing procedure with penile block
16312383|NCT04590859||caudal block|Patients undergoing procedure with caudal block
16312384|NCT04590846|Experimental|Constipation Health Education|"Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of seeing leaflets, accumulating points, and redeeming prizes is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw."
16312385|NCT04590846|Active Comparator|General Health Course|"In order to correctly evaluate the effectiveness of health education intervention, only the parents of the experimental group will receive the health education leaflet during the intervention period. However, after the end of the trial, an electronic file of parental health education in the control group will be provided. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. After the children's points are counted, a lottery will be drawn based on the total number of points. Since the experimental group and the control group have different benchmarks for points, the lottery will be drawn separately from each school. During the lottery process, the time will be announced in advance, and the number will be randomly selected by the computer in a live broadcast method."
16312386|NCT04590833|Experimental|Aerobic exercise group|
16312387|NCT04590833|Placebo Comparator|Attention control group|
16312388|NCT04590820|Experimental|Tazemetostat + Rituxan|"Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1.
~Rituximab will be administered by either Subcutaneous injection or IV infusion on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles."
16312389|NCT04590807|Active Comparator|Posterior spinal fusion with pedicle screws|
16312390|NCT04590807|Active Comparator|Anterior vertebral body tethering|
16312392|NCT04590781|Experimental|Part A: XmAb18087 Monotherapy|Part A, will enroll subjects with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
16312393|NCT04590781|Experimental|Part B: XmAb18087 + pembrolizumab|Part B, will enroll subjects with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
16312394|NCT04590781|Experimental|Part C: XmAb18087 monotherapy|Part C will enroll subjects with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
16312395|NCT04590768|Experimental|Fermotein™|daily lunch with 11 grams of Fermotein™ dry powder, mixed in bread, soup or a burger
16312396|NCT04590768|Active Comparator|Matched control products|daily lunch with a control bread matched in macronutrient content. Control meat alternative burgers and soup from the local supermarket.
16312397|NCT04590755|Experimental|Interactive father-child sessions and use of website|Intervention group will receive the Run Daddy Run intervention.
16312398|NCT04590755|No Intervention|No intervention (no interactive father-child sessions and use of website)|Intervention group will not receive the Run Daddy Run intervention.
16312399|NCT04590742|Placebo Comparator|Group 1|Placebo Tablet
16312400|NCT04590742|Active Comparator|Group 2|Melatonin (6mg)
16312401|NCT04590729|Experimental|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
16312402|NCT04590729|Experimental|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 15 minutes for 3 hours to match the total exercise duration in the first protocol.
16312403|NCT04590729|No Intervention|Sitting|Sitting control.
16312404|NCT04590703||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
16312407|NCT04590677||Group 2|Pregnant women who have presented with signs and symptoms of threatened preterm labour (e.g. ruptured membranes, contractions, bleeding), at or after 24 weeks gestation, n=50.
16312408|NCT04590664|Experimental|Treatment (verteporfin)|Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16312409|NCT04590651|Experimental|Standard PHACO cataract surgery|In this group normal phacoemulsification cataract surgery will be preformed.
16312410|NCT04590651|Experimental|PHACO + extra aspiration|In this group an extra one minute anterior chamber angle aspiration will be preformed at the end of a standard cataract operation.
16312411|NCT04590638|Active Comparator|Tumescent with adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution containing adrenaline.
16312412|NCT04590638|Active Comparator|Tumescent without adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution not containing adrenaline.
16312413|NCT04590625|Experimental|Group1|"Neoadjuvant therapy:
~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.
~Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.
~Adjuvant therapy:
~After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.
~Adjuvant therapy is 3 cycles
~maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
16312414|NCT04590625|Experimental|Group2|"1.Adjuvant therapy:
~After primary cytoreductive surgery,patients will received adjuvant therapy:
~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.
~Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
16312415|NCT04590612|Active Comparator|Carbidopa-Levodopa|Patients will be randomized to any of the 2 arms. In Levodopa/carbidopa arm, patients will be taking Carbidopa-Levodopa (25-100mg) three times a day for the duration of the study.
16312416|NCT04590612|Experimental|Citalopram|Patients will be randomized to any of the 2 arms. In Citalopram arm, patients will be taking Citalopram (20mg) daily for the duration of the study.
16312417|NCT04590599|Experimental|Placebo+Sintilimab|
16312418|NCT04590599|Experimental|IBI310+Sintilimab|
16312419|NCT04590586|Experimental|Apremilast and standard of care (SoC)|
16312420|NCT04590586|Placebo Comparator|Apremilast placebo and standard of care (SoC)|
16312421|NCT04590586|Experimental|Lanadelumab and standard of care (SoC)|
16312422|NCT04590586|Placebo Comparator|Lanadelumab placebo and standard of care (SoC)|
16312423|NCT04590586|Experimental|Zilucoplan and standard of care (SoC)|
16312424|NCT04590586|Placebo Comparator|Zilucoplan placebo and standard of care (SoC)|
16312425|NCT04590573|Experimental|CBCT|Cognitive behavioural couple therapy (CBCT), 5-session
16312426|NCT04590573|Experimental|EFCT|Emotion focused couple therapy (EFCT), 5-session
16312427|NCT04590573|Active Comparator|Control|Social activity wait-list groups (Control), 5-session
16312428|NCT04590560|No Intervention|1-year screening interval|Women will follow the normal screening program (they will be invited to screen every year)
16312429|NCT04590560|Experimental|2-year screening interval|Women will be invited to screen every two years
16312430|NCT04590560|Experimental|3-tailored screening interval|the screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)
16312434|NCT04590534|Experimental|study Group A|patients will receive one capsule of [garcinia 500 mg and chromium 281 mg] 3 times daily for 12 weeks.
16312435|NCT04590534|Active Comparator|Active control Group B|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
16312436|NCT04590534|Placebo Comparator|Placebo Group C|patients will receive placebo 3 times daily for 12 weeks
16312437|NCT04590521|Experimental|Intervention|A standard 3-dose schedule (0, 2 and 6 months) of licensed HPV vaccine (Gardasil®, Merck) will be administered to all participants intramuscularly.
16312438|NCT04590508|Experimental|Xanthohumol|Participants will take capsules containing 24 mg of xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
16312439|NCT04590508|Placebo Comparator|Placebo|Participants will receive capsules filled with a rice protein vehicle by mouth once daily with the first daily meal.
16312440|NCT04590495|Active Comparator|300 mg Cannabidiol (CBD) oil|
16312441|NCT04590495|Placebo Comparator|Placebo|
16312442|NCT04590482|Experimental|letrozole then misoprostol|description:letrozole 2.5 mg each 12hours for 2 days at home followed by misoprostol 800mcg vaginally at hospital repeated after 4 hours if needed
16312443|NCT04590482|Placebo Comparator|placebo then misoprostol|Description:placebo each 12 hours for 2days at home followed by 800mcg misoprostol vaginally at hospital and repeat dose after 4 hours if needed
16312444|NCT04590469|Experimental|WHELD training/virtual coaching programme supported with digital resources|WHELD training/virtual coaching programme supported with digital resources
16312445|NCT04590469|No Intervention|Treatment as Usual|Usual Best practice
16312446|NCT04590456|Experimental|Placebo group|
16312447|NCT04590456|Experimental|PEMF group|
16315054|NCT04572828|Active Comparator|Group 4: Waiting 60 Minute After Taking Oral NSAIDs|
16312451|NCT04590430|Experimental|HFB30132A|Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
16312452|NCT04590430|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
16312454|NCT04590404|Experimental|MIST (Metabolism-Informed Smoking Treatment)|At hospital discharge, participants randomized to the MIST precision care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescriptions will be informed by nicotine metabolism (i.e., NMR result) such that faster metabolizers are prescribed varenicline and slower metabolizers are prescribed NRT.
16312455|NCT04590404|Active Comparator|Usual Care|At hospital discharge, participants randomized to the Usual Care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescription will not be informed by nicotine metabolism.
16312456|NCT04590391|Other|Visual and Auditory Breathing-swallowing Coordinated Training device|
16312457|NCT04590378||Covid-19 Patients with Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
16312458|NCT04590378||Covid-19 Patients without Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
16312459|NCT04590365|Experimental|Coldamaris plus|verum Coldamaris plus i.e. 0.12% Iota-Carrageenan plus 0.04% Kappa-Carrageenan in 0.5% saline
16312460|NCT04590365|Placebo Comparator|Coldamaris sine|Coldamaris sine i.e. 0.5% saline
16312461|NCT04590352||Index case and household contacts|"nasophryngeal and throat swab at day 0.
~collection of mucosal lining fluid: day 0, 7, 14, 28 for index case and day 0, 3, 6, 28 for household contacts.
~fingerprick at day 28 (optional).
~daily record of symptoms from day 0-28."
16312462|NCT04590339|Active Comparator|Repositioning the bone window|Computer guided inferior alveolar nerve lateralization and implant placement with subsequent repositioning of the osteotomized bone window.
16312463|NCT04590339|Active Comparator|Augmentation using sticky bone|Computer guided inferior alveolar nerve lateralization and implant placement with grafting around the implant using sticky bone
16312464|NCT04590326|Experimental|Module 1|REGN5668 and cemiplimab
16312465|NCT04590326|Experimental|Module 2|REGN5668 and REGN4018
16312466|NCT04590313|Active Comparator|Arthrodesis|MTPJ I Arthrodesis
16312467|NCT04590313|No Intervention|Watchful waiting|No intervention, patient information leaflet
16312468|NCT04590300|Other|Schizophrenia|"1 questionnaire at the beginning of the study, before FTE program
~1 questionnaire at the end of FTE"
16312469|NCT04590300|Other|Bipolar disorder|"1 questionnaire at the beginning of the study, before FTE program
~1 questionnaire at the end of FTE"
16312470|NCT04590287||Patients after ischemic stroke|The analysis included the presence of CVD risk factors in patients after ischemic stroke durning in the early rehabilitation.
16312471|NCT04590287||Patients after hemorrhagic stroke|The analysis included the presence of CVD risk factors in patients after hemorrhagic stroke durning in the early rehabilitation.
16312472|NCT04590274|Experimental|Regimen|0-400 mg Hydroxychloroquine 0-500 mg Azithromycin 0-50 mg elemental Zinc 0-3,000 mg Vitamin C 0-5,000 IU Vitamin D3 0-1200 mg N-acetylcysteine 0-600 mg Elderberry 0-600 mg Quercetin
16312473|NCT04590261|Other|group 1|Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
16312474|NCT04590261|Other|Group 2|Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, > 5 L/mn Oxygen treatment
16312475|NCT04590261|Other|Group 3|Physician examination in the Pneumology ward, Cochin Hospital
16312476|NCT04590261|Other|Group 4|Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
16312477|NCT04590248|Experimental|Adavosertib|Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
16312478|NCT04590235|Experimental|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. Then, selumetinib 25 mg/m^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
16312479|NCT04590222||Female, BMI≥30, mild|"Females:
~Obese BMI≥30 With Mild infection n = 10"
16312480|NCT04590222||Female, BMI≥30, severe|"Females:
~Obese BMI≥30 With severe infection n = 10"
16312481|NCT04590222||Female, BMI<30, mild|"Females:
~Non-Obese BMI<30 With Mild infection n = 10"
16312482|NCT04590222||Female, BMI<30, severe|"Females:
~Non-Obese BMI<30 With severe infection n = 10"
16312483|NCT04590222||male, BMI≥30, mild|males: Obese BMI≥30 With Mild infection n = 10
16312484|NCT04590222||male, BMI≥30, severe|males: Obese BMI≥30 With severe infection n = 10
16312485|NCT04590222||male, BMI<30, mild|males: Non-Obese BMI<30 With Mild infection n = 10
16312486|NCT04590222||male, BMI<30, severe|males: Non-Obese BMI<30 With severe infection n = 10
16312487|NCT04590222||Healthy donors from the EFS (Etablissement Français du Sang, St Louis)|Healthy donors from the EFS (Etablissement Français du Sang, St Louis) including 5 men and 5 women
16312488|NCT04590209|Experimental|Acrosyndrome|"The blood sample, skin biopsy and other biological samples will be taken from patients
~The precise description of the semiology of skin lesions, their topography, as well as the analysis of the entire skin integument and mucous, cardiac and pulmonary auscultation and neurological examination will be done as required."
16312489|NCT04590196|Experimental|treatment|
16312490|NCT04590196|Placebo Comparator|control|
16312491|NCT04590183|Experimental|The experimental group|
16312492|NCT04590183|Sham Comparator|The control group|
16312493|NCT04590157|Experimental|study group|received pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints
16312494|NCT04590157|Experimental|control group|received pelvic floor muscle training
16312495|NCT04590144|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead
16312496|NCT04590131|Experimental|Hubrid revaskularization|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
16312497|NCT04590131|Active Comparator|Endovascular treatment|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
16312498|NCT04590118|Experimental|Experimental: it-hMSC|Single intravenous infusion of 0.5×10^6, 1×10^6, 2×10^6 it-hMSC/kg
16312499|NCT04590118|Placebo Comparator|Placebo-controlled: Placebo|Single intravenous infusion of 1 ml/kg placebo
16312500|NCT04590105|Experimental|App Subject|"Users who were assigned to use a smartphone app downloaded a free app from the iOS App or Google Play stores titled SB Colonoscopy Prep. The app informed subjects about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite."
16312501|NCT04590105|Active Comparator|Written Instruction Subjects|Subjects in the control group were given a three-page document that described the procedure and instructed users on how to take the preparation medications. The written instructions had a list of frequently asked questions about colonoscopies and the URL of a website where users could view the animated video that was included in the app. The written instructions also contained the time and date of the procedure. All subjects were instructed to arrive one hour before their scheduled procedure.
16312502|NCT04590092|No Intervention|Control|Study Participants who do not receive a pessary. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and will continue to have standard antenatal care with their maternity provider.
16312503|NCT04590092|Experimental|Pessary|Study Participants who are fitted with a pessary for urinary incontinence. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and pessary use in pregnancy. They will continue to have standard antenatal care with their maternity provider.
16312504|NCT04590079|Experimental|First intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment and daily sessions with the medical device - 1 month of wash-out - 3 months of conventional pain treatment.
16312505|NCT04590079|Experimental|Second intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment - 1 month of wash-out - 3 months of conventional pain treatment and daily sessions with the medical device.
16312506|NCT04590066|No Intervention|Holdout control|Participants will only receive the standard pharmacy messaging.
16312507|NCT04590066|Experimental|Unpacking Risks Treatment|Participants will be asked to think about the risks of catching the flu this flu season and to respond with the location they are most likely to catch the flu out of a list of given options (e.g. at work, at home).
16312508|NCT04590066|Experimental|Unpacking Risks Control|Participants will be asked to think about the risks of catching the flu this flu season and to respond to confirm that they have received the message.
16312509|NCT04590066|Experimental|Active Commitment Treatment|"Participants receive a gain framed notification that they are eligible for a flu shot. In addition, participants are told Many people find it helpful to make a plan to get their shot and are asked to commit by texting back I will get a flu shot. Depending on their response, participants receive a general reminder or a commitment reminder 3 days later."
16312510|NCT04590066|Experimental|Active Commitment Control|Participants receive a gain framed notification that they are eligible for a flu shot. Participants receive a general reminder 3 days later.
16312511|NCT04590066|Experimental|Self-Generated Social Norms Treatment|Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
16312512|NCT04590066|Experimental|Self-Generated Social Norms Control|articipants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
16312513|NCT04590066|Experimental|Foot-in-the-Door Treatment|Participants will first receive a message enjoining them to encourage someone else to receive a flu vaccine this year. They will then be given a message that they might copy-paste to forward to friends, thereby lowering the effort costs of messaging others. They will receive a reminder 3 days later.
16312514|NCT04590066|Experimental|Foot-in-the-Door Control|Participants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
16312515|NCT04590066|Experimental|Prosocial Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (i.e., protecting loved ones; preserving scarce resources).
16312516|NCT04590066|Experimental|Self-Oriented Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot.
16312517|NCT04590066|Experimental|Prosocial + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (e.g., protecting loved ones; preserving scarce resources). The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
16312518|NCT04590066|Experimental|Self-Oriented + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
16312519|NCT04590066|Experimental|Dynamic + Static Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before and how many Americans got their flu shot last year.
16312520|NCT04590066|Experimental|Dynamic Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before.
16312521|NCT04590066|Experimental|Dynamic Norms Control|Participants will only receive a text message encouraging them to get a flu shot. They will not receive any norm information.
16312557|NCT04589858|Experimental|Group B|Received manual therapies including both myofascial mobilization and manipulation technique in addition to a supervised exercise protocol.
16312522|NCT04590066|Experimental|Sharing Humor|Participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
16312523|NCT04590066|Experimental|Humor Placebo|Participants will receive a text message encouraging them to get the flu shot. This message will include the same joke but participants will not be encouraged to share it.
16312524|NCT04590066|Experimental|No Humor Condition|Participants will receive a text message encouraging them to get the flu shot.
16312525|NCT04590066|Experimental|Connecting the Past Self to the Future Self Treatment|"Participants will receive a text message prompt to recall the negative experience of getting sick. When asked, Do you wish you could have avoided getting sick by getting a simple shot?, participants will have the chance to respond Y for yes or N for no. Regardless of their response, they will be prompted with a second text message to connect their past experience with present-day opportunities for preventative care (getting a flu shot) to protect the future self from the flu."
16312526|NCT04590066|Experimental|Connecting the Past Self to the Future Self Control|In the first text message, participants will receive a simple text message encouragement to receive a flu shot. In the second text message, they will receive a reminder of the appointment time and provider name.
16312527|NCT04590066|Experimental|Reverse Inference Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are healthier, wealthier, and more educated.
16312528|NCT04590066|Experimental|Reverse Inference Control Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are less likely to get the flu.
16312529|NCT04590053|Experimental|COVID-19|Up to 24 subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
16312530|NCT04590040|Placebo Comparator|Toothpaste 1|Toothpaste 1 containing 0% nano-hydroxyapatite (HAP) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
16312531|NCT04590040|Active Comparator|Toothpaste 2|Toothpaste 2 containing 15% nano-HAP will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
16312532|NCT04590040|Active Comparator|Toothpaste 3|Toothpaste 3 containing 5% potassium nitrate (KNO3) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
16312533|NCT04590014|Active Comparator|Conventional HVNI Device Design (Control)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea.
16312534|NCT04590014|Experimental|New HVNI Device Design (Randomized)|The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
16312535|NCT04590001|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD device.
16312536|NCT04589988|Experimental|REBIL- Intervention arm|Participants in this arm will receive the Removing Environmental Barriers to Independent Living (REBIL) intervention.
16312537|NCT04589988|Sham Comparator|Waitlist Attentional control|Participants in this arm will receive a sham intervention until the 6 month follow-up visit. At that point participants in this arm will receive the full REBIL intervention.
16312538|NCT04589962||Percutaneous Group|
16312539|NCT04589962||Surgical Group|
16312540|NCT04589949|Experimental|ConvP|300 mL convalescent plasma with a minimum of neutralizing antibodies
16312541|NCT04589949|Active Comparator|FFP|300 mL Fresh Frozen plasma
16312542|NCT04589936|Experimental|COVID-19|Non-ventilated patients with COVID-19
16312543|NCT04589936|Active Comparator|Pneumonia control|Patients with pneumonia unrelated to COVID-19 requiring supplemental O2.
16312544|NCT04589923||Group 1 - participants expected to have abnormal oxygen saturation|Within each study session, participants will have their oxygen saturation, heart rate and respiratory rate measured three times using standard of care equipment and methods. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's primary and secondary objectives only. The app does not return any measurements to the user or participant.
16312545|NCT04589923||Group 2 - participants expected to have abnormal blood pressure|Within each study session, participants will have their blood pressure and respiratory rate measured three times using standard of care equipment. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's secondary objectives only. The app does not return any measurements to the user or participant.
16312546|NCT04589910|Other|Ultra-sound arm|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
16312547|NCT04589897|Experimental|Experimental|Manuka honey sinus rinse
16312548|NCT04589897|Active Comparator|Standard|Standard sinus rinse
16312549|NCT04589884||Parathyroid disease|
16312550|NCT04589884||Thyroid disease|
16312551|NCT04589884||Liver tumors and metastases|
16312552|NCT04589884||Digestive tumors|
16312553|NCT04589884||Digestive perfusion|
16312554|NCT04589871|Experimental|Group A|Group A received a taping technique in addition to the supervised exercises protocol
16312555|NCT04589871|Active Comparator|Group B|Group B received supervised exercises protocol only
16312556|NCT04589858|Active Comparator|Group A|Received a supervised exercise protocol including both strengthening and stretching exercises for specific muscle groups.
16312606|NCT04589572|Experimental|XLIF - group|
16312569|NCT04589832|Experimental|Study Treatment Arm|Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIST 1.1 criteria), unacceptable toxicity, subject withdrawal of informed consent, or subject death either from progression of disease, the therapy itself, or from other causes.
16312570|NCT04589819|Active Comparator|Teriparatide|Study participants will be randomized into either the study medication arm or a placebo arm. The study medication Forteo (teriparatide [rDNA origin] injection) (El-Lilly, Indiana, USA), will be administered via an blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection.
16312571|NCT04589819|Placebo Comparator|Placebo|The placebo will be administered in a replica, blinded, injection pen in the same fashion. The study participant will self-administer the medication after being given a teaching session on medication administration by the study nurse.
16312572|NCT04589806|Experimental|2-stage ridge splitting with simultaneous implant placement|
16312573|NCT04589793|No Intervention|Control|Conventional treatment
16312574|NCT04589793|Active Comparator|Intervention|Motivational interview
16312575|NCT04589780||Posture Assessment|Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958
16312576|NCT04589780||Sagittal spinal alignment and mobility|Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device.
16312577|NCT04589780||Injury risk assessment|Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS
16312578|NCT04589767||children admitted in PICU|children enrolled will be evaluated by two nurses using CAPD Italian version. One nurse will repeat the evaluation two minutes later.
16312579|NCT04589754|Experimental|Sintilimab plus chemotherapy|Adriamycin and ifosfamide combined with sintilimab in the treatment of advanced or unresectable soft tissue sarcoma
16312580|NCT04589741|Experimental|toripalimab combined with CAV / IE regimen|toripalimab combined with CAV / IE regimen in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
16312581|NCT04589728||Study group|All patients being observed during the study duration.
16312607|NCT04589572|Active Comparator|PLIF - Group|
16312608|NCT04589559|Experimental|Intervention: Heart Rate Variability Biofeedback|Participants in this intervention group complete at-home heart rate variability biofeedback (HRVB) training using a wrist-worn heart rate monitor and a smartphone app. They complete at least 10 minutes per day of HRVB training on at least 5 days per week for 3 weeks.
16312609|NCT04589546|Experimental|Vitamin B3|
16312610|NCT04589546|Placebo Comparator|Placebo|
16312582|NCT04589715|Experimental|electroacupuncture group|patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
16312583|NCT04589715|Sham Comparator|sham electroacupuncture group|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
16312584|NCT04589702||females with isolated patellofemoral arthritis|those with anterior knee pain
16312585|NCT04589702||healthy females|those without anterior knee pain
16312586|NCT04589689|Experimental|Intervention Group|The intervention group will participated in the The Insul-In This Together intervention, which consists of 6 weekly 30-minute online family sessions to discuss topics related to diabetes distress and parent-teen communication. Sessions include structured education, discussions, and skill-building activities related to parental involvement, parental monitoring, and parent-adolescent conflict. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week follow-ups (after every 2 sessions for the intervention group and later the control group). Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
16312587|NCT04589689|Experimental|Waitlisted Control Group|The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
16312588|NCT04589676|Active Comparator|Face-to-face training|Participants in the face-to-face training condition will receive training in groups of 20. Standardized content will teach them to use the PulsePoint app, respond safely to calls, and administer Naloxone.
16312589|NCT04589676|Experimental|Online training|Participants in the online training condition will receive training in groups on Smartphones and other devices at their own pace. Standardized content will teach them to use the PulsePoint app, respond safely to calls, and administer Naloxone.
16312590|NCT04589663|Experimental|Mometasone furoate followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 followed by a single inhaled dose of QMF149 on Day 6
16312596|NCT04589624|Active Comparator|Arm I ( Health Volunteer MRI)|Healthy volunteers undergo MRI over 30 minutes.
16312597|NCT04589624|Experimental|Arm II (Thyroid Cancer Patient hpMRI)|Patients with thyroid cancer undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
16312598|NCT04589611|Experimental|Phase I single amobarbital/Gel-One dose|Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
16312599|NCT04589611|Active Comparator|Phase IIa Part 1 amobarbital/Gel-One dose|20 subjects will be randomized to amobarbital/Gel-One single dose.
16312600|NCT04589611|Placebo Comparator|Phase IIa Part 1 Placebo|10 subjects will be randomized to amobarbital/Gel-One single dose.
16312601|NCT04589611|Active Comparator|Phase IIa Part 2 amobarbital/Gel-One dose|20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
16312602|NCT04589611|Placebo Comparator|Phase IIa Part 2 placebo|20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
16312603|NCT04589598|Experimental|FNS|those who are treated with femoral neck system (FNS)
16312604|NCT04589598|Active Comparator|MCS|those who are treated with multiple cannulated screw (MCS)
16312605|NCT04589585|Experimental|DiVeRt treatment|DiVeRt device to be used in the single arm
16312611|NCT04589533||EDUCATIONAL PROGRAM GROUP|This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
16312612|NCT04589533||CONTROL GROUP|Control group will not receive educational program. This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
16312613|NCT04589520|Experimental|HeartBot Group|The HeartBot group downloaded the app and used it daily for 21 days based on a calendar that provided them with step by step outlines of the tools for each day.
16312614|NCT04589520|No Intervention|Control Group|The control group did not download the app and experienced no change to their daily routines.
16312615|NCT04589494|Active Comparator|tramadol group|tramadol hydrochloride 100 mg three times daily
16312616|NCT04589494|Active Comparator|morphine group|morphine 30 mg twise times daily
16312617|NCT04589481|Experimental|candy intake|
16312618|NCT04589468|Experimental|Dose-Finding/Escalation|Fifty (n=50) post-treatment patients with colorectal cancer and detectable ctDNA. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
16312619|NCT04589468|Experimental|Dose Expansion|An independent cohort of 20 post-treatment patients with colorectal cancer and detectable ctDNA. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
16312620|NCT04589455|Experimental|hennep extract|A hennep extract administered in soft gel capsules in a fasted state
16312621|NCT04589455|Experimental|hennep extract + high fat meal|A hennep extract administered in soft gel capsules in a fed state
16312622|NCT04589442|Active Comparator|Standard of Care Dermal Graft|Standard of care cryopreserved cadaveric split thickness skin grafts
16312623|NCT04589442|Experimental|Standard of Care Dermal Graft - Microsurfaced|Microsurfaced cryopreserved cadaveric split thickness skin grafts
16312624|NCT04589429|Active Comparator|MN group|intrathecal morphine 300 micrograms+2mg nalbuphine
16312625|NCT04589429|Placebo Comparator|M group|intrathecal morphine 300 micrograms
16312626|NCT04589416|Active Comparator|Single Bond 2|Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
16312627|NCT04589416|Active Comparator|Clearfil SE Bond|Clearfil SE bond is traditional two step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
16312628|NCT04589416|Active Comparator|Tri-S Bond|Tri-S bond is traditional one step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
16312629|NCT04589403|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.
16312630|NCT04589403|Experimental|OPT101|The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.
16312631|NCT04589390|Other|Selexipag|Selexipag will be up titrated for a period that will last 12 weeks (Phase 2). The initial dose will be 200 mcg of selexipag every 12 hours, with weekly dose increases of 200 mcg, up to the maximum dose of 1600 mcg every 12 hours or until the classic side effects of the prostacyclin pathway drugs (headache, mandibular pain), among others) arise. The dose will then be reduced by 200 mcg per dose, and this will be the maximum dose considered for that particular patient, maintained in Phase 3 (16 weeks).
16312632|NCT04589377|Experimental|Mindfulness Training|Participants receive 20 minutes of mindfulness training per day for five continuous days (Monday through Friday). Training is delivered remotely to participants' computers and smartphones.
16312633|NCT04589377|No Intervention|No-Training|Participants do not receive training. On Monday and Friday, they listen to a 20 minute audiobook to match for time.
16312634|NCT04589364|Experimental|abobotulinum toxin A|"Abobotulinum Toxin Type A (Dysport) dose was investigated:
~dose: 100 units ( various units each site depend on clinical )"
16312635|NCT04589364|Experimental|neubotulinum toxin A|"Neubotulinum Toxin Type A (Neuronox) dose was investigated:
~dose: 33.33 units ( various units each site depend on clinical )"
16312636|NCT04589351|Active Comparator|Ezetimibe|One treatment period of 16 weeks with1 capsule of ezetimibe 10mg per day, as add-on to standard care.
16312637|NCT04589351|Placebo Comparator|Placebo|One treatment period of 16 weeks with 1 capsule of matching placebo per day, as add-on to standard care.
16312638|NCT04589338|Experimental|Endurance training group|
16312639|NCT04589338|Experimental|Resistance training group|
16312640|NCT04589338|No Intervention|Control group|
16312641|NCT04589325|Experimental|Ixekizumab|
16312642|NCT04589325|Placebo Comparator|Placebo|
16312643|NCT04589312|Active Comparator|Pregnant women not living with HIV, Td vaccine|
16312644|NCT04589312|Experimental|Pregnant women not living with HIV, Tdap vaccine|
16312645|NCT04589312|Active Comparator|Pregnant women living with HIV, Td vaccine|
16312646|NCT04589312|Experimental|Pregnant women living with HIV, Tdap vaccine|
16312647|NCT04589299|Active Comparator|Patients treated with immunoglobulin intravenously (IVIG)|Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
16312648|NCT04589299|Active Comparator|Patients treated with immunoglobulin subcutaneously (SCIG)|Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
16312649|NCT04589286|Experimental|Pack Health's Digital Life Coaching (DLC)|Participants will receive 16 weeks of access to a trained human life coach employed by Pack Health. Coaches will communicate via phone calls, text messages, emails, and links to web-based Pack Health resources plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
16312650|NCT04589286|Active Comparator|Quasi-usual care control arm|Participants will receive usual supportive care for stem cell transplantation plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
16312651|NCT04589273|Experimental|Alginate capsule|The participants of this arm will be give the alginate capsules
16312652|NCT04589273|Placebo Comparator|Placebo|The participants of this arm will be give the placebo capsules
16312653|NCT04589260|Experimental|TD-1058|"Part A (SAD): 6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of TD-1058
~Part B (MAD): 6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of TD-1058
~Part C (IPF subjects): 8 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of TD-1058"
16312654|NCT04589260|Placebo Comparator|Placebo|"Part A (SAD): 2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of placebo
~Part B (MAD): 2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of placebo
~Part C (IPF subjects): 4 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of placebo"
16312655|NCT04589247||Patients with cancer treated with definitive-intent radiotherapy|Histologically confirmed loco-regional to advanced primary cancer, including but not limited to lung cancer, esophageal, or gastro-intestinal cancers at risk of developing radiotherapy-related toxicity.
16312656|NCT04589234|Experimental|Saltikva with FOLFIRINOX|30 patients will be enrolled to receive standard of care FOLFIRINOX with oral Salmonella-IL2 (Dose 10-9) every 2 weeks for 2 years
16312657|NCT04589234|Experimental|Saltikva with Gemcitabine/Abraxane|30 patients will be enrolled to receive standard of care Gemcitabine/Abraxane with oral Salmonella-IL2 (Dose: 10-9) every 3 weeks for 2 years
16312658|NCT04589221||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification
~Soft and hard foods manipulated by cooking method"
16312659|NCT04589208|Experimental|Ketamine|ketamine
16312662|NCT04589182|Experimental|Verum|Patients will receive all-night auditory stimulation during sleep over 3 nights using a portable, safe, in-home device (MSHL-SleepBand). This device records biosignals (EEG) and precisely plays tones (between 45-65 dB, maximum 80 dB) targetted to the up-phase of sleep slow waves.
16312663|NCT04589182|Sham Comparator|Sham|Patients will receive all-night sham stimulation over 3 nights, i.e. the wearable stimulation device will be applied (EEG will be recorded), but no tones will be played.
16312664|NCT04589169||Positive cohort|Patients who develop delirium
16312665|NCT04589169||Experimental control group|Patients who do not develop delirium
16312666|NCT04589143|Experimental|Experience group|In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.
16312667|NCT04589143|Placebo Comparator|Contral group|In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.
16312668|NCT04589130|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets.
16312669|NCT04589130|Placebo Comparator|Placebo|Group given placebo
16312670|NCT04589117|Experimental|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.
~The progression of writing exercises flows as follows:
~Week 1: Writing to expressive difficult emotions
~Week 2: Writing to cultivate compassion & forgiveness
~Week 3: Writing to nurture positive emotions
~Week 4: Writing to invite insight, perspective, & growth"
16312671|NCT04589104|Experimental|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:
~Week 1: Writing to expressive difficult emotions
~Week 2: Writing to release & integrate difficult emotions
~Week 3: Writing to nurture gratitude
~Week 4: Writing to enhance strengths & resources
~Week 5: Writing to cultivate positive meaning & savor goodness
~Week 6: Writing to invite insight, perspective, & growth"
16312672|NCT04589091||Group(1): Patient who underwent PRK|
16312673|NCT04589091||Group(2): Patient underwent LASIK|
16312674|NCT04589078||Interficial Intelligence|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
16312675|NCT04589065|Experimental|Selective Cytopheretic Device|
16312677|NCT04589026|Active Comparator|Active Arm: Candin + Consentyx|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously.
16312678|NCT04589026|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% NaCl, and no Cosentyx.
16315293|NCT04571125||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
16312679|NCT04589000|Experimental|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.
~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
16312680|NCT04589000|No Intervention|control|No accupressure will be applied. Milk will be expressed for a total of 15 minutes, 1 time on the post-op 0th day, 2 times on the post-op 1st day and once on the post-op 2nd day for a total of 15 minutes and will be recorded in the milk measurement table.
16312681|NCT04588987|Experimental|Neoadjuvant group|Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
16312682|NCT04588987|Experimental|Adjuvant group|Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
16312683|NCT04588974||Screening|Sixty-five cirrhotic patients with portal hypertensive symptoms (such as platelets count less than 100,000) will be enrolled to evaluate for the presence and stage of esophageal varices by using a magnetic-assisted capsule endoscope system with or without 3D image processing.
16312684|NCT04588974||Follow-up|Thirty-five cirrhotic patients with a history of endoscopy-confirmed esophageal varices will be included for the follow-up examination by using the magnetic-assisted capsule endoscope system with or without 3D images.
16312685|NCT04588974||Control|Another 40 volunteers with GI symptoms but no known gastrointestinal disease will be enrolled as the control group.
16312686|NCT04588961|Active Comparator|Control group|Patients undergoing trapeziectomy with suspensionplasty for primary basal thumb osteoarthritis
16312687|NCT04588961|Active Comparator|Study group|Patients undergoing joint alloplasty using prothesis for primary basal thumb osteoarthritis
16312688|NCT04588948|Experimental|Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
16312689|NCT04588948|Experimental|Non-Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
16312690|NCT04588935|No Intervention|Group 1|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
16312691|NCT04588935|Active Comparator|Group 2|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril
16312692|NCT04588922|Experimental|GFH009|
16312693|NCT04588896|Experimental|CGM+LMP|Continuous glucose monitoring (CGM) for 8 weeks in conjunction with lifestyle modification
16312694|NCT04588896|Other|LMP only|Lifestyle modification only
16312695|NCT04588883|Experimental|Intervention Arm|Patients, adults and adolescents, will be recruited from patient registries at 7 government operated HIV clinics in Meru County, Kenya. Patients will complete validated questionnaires at baseline, 1.5 year and 3 years into a novel adaptation of a community empowerment program. The program utilizes savings- and internal-lending/group-based microfinance process to facilitate exchange of savings amongst patients and adolescent guardians. A byproduct of this process is the development of social capital, which will be used to facilitate education, peer learning, and collective problem solving to improve determinants of well-being and clinical adherence among participants. Expected outcomes include improved viral suppression, ART adherence, clinical attendance, and mental health.
16312696|NCT04588870|Experimental|Preoperative Cochlear Implant|The intervention will be the use of a surgical simulation system preoperatively by the surgeon to develop the surgical plan to optimize electrode array placement with respect to scalar location and modiolar distance.
16312697|NCT04588857|Experimental|Active drug|dexamethasone 24 mg i.v., single dose
16312698|NCT04588857|Placebo Comparator|Placebo|saline i.v., single dose
16312699|NCT04588844|Experimental|Growth Hormone group|Growth Hormone pretreatment for 6 weeks before ovarian stimulation
16312700|NCT04588844|No Intervention|Control group|No pretreatment before ovarian stimulation
16312701|NCT04588831|Experimental|Pre-fabricated|
16312702|NCT04588831|Experimental|Mouth-formed|
16312703|NCT04588831|Experimental|Custom-fitted|
16312704|NCT04588818|Experimental|Adalimumab plus Methotrexate|
16312705|NCT04588805||Colorectal Cancer Patients|
16312706|NCT04588792|Experimental|Inhaled Furosemide|40 mg furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline solution) over 30 mins four times daily (Q6H) for up to 28 days
16312707|NCT04588792|Placebo Comparator|Nebulized Saline|Placebo, given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily (Q.I.D.) for up to 28 days
16312708|NCT04588779|Experimental|Graston|Ultrasound, Graston technique, piriformis stretching, home plan (hip abductor and extensor strengthening)
16312709|NCT04588779|Active Comparator|Manual myofascial release|Ultrasound, Manual myofascial release, piriformis stretching, home plan (hip abductor and extensor strengthening)
16312710|NCT04588766||constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
16312711|NCT04588766||control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
16312712|NCT04588753|Active Comparator|Active Isolated Stretch|active isolated stretching, strengthening exercises
16312713|NCT04588753|Active Comparator|Post Facilitation Stretch|Post Facilitation Stretching, strengthening exercises
16312714|NCT04588740|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
16312715|NCT04588740|Placebo Comparator|Placebo|The placebo beet root juice is made by the same company (BEET IT, James White Drinks, Ipswich, UK) and contains no inorganic nitrate.
16315294|NCT04571125||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
16312716|NCT04588727|Experimental|AZD3366 Dose 1 Part A|Randomized healthy subjects will receive Dose 1 of AZD3366.
16312717|NCT04588727|Experimental|AZD3366 Dose 2 Part A|Randomized healthy subjects will receive Dose 2 of AZD3366.
16312718|NCT04588727|Experimental|AZD3366 Dose 3 Part A|Randomized healthy subjects will receive Dose 3 of AZD3366.
16312719|NCT04588727|Experimental|AZD3366 Dose 4 Part A|Randomized healthy subjects will receive Dose 4 of AZD3366.
16312720|NCT04588727|Experimental|AZD3366 Dose 5 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
16312721|NCT04588727|Experimental|AZD3366 Dose 6 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
16312722|NCT04588727|Experimental|AZD3366 Dose 7 Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
16312723|NCT04588727|Placebo Comparator|Placebo Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
16312724|NCT04588727|Experimental|AZD3366 Dose X Part B|Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
16312725|NCT04588727|Placebo Comparator|Placebo Dose X Part B|Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
16312726|NCT04588714|Experimental|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|"RENEW is a 12-week program in which participants are paired with a peer mentor who serves as their health coach throughout the intervention period. The website serves as the program workbook to help promote skill practice and attainment in areas like goal setting, pacing, relaxation, etc."
16312727|NCT04588701||persons with anal fistulas|all persons with anal fistulas treated by a single surgeon over 22 years
16312728|NCT04588688|Experimental|Mifepristone|Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.
16312729|NCT04588662||Uveal Melanoma|Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent
16312730|NCT04588649|Other|THK-5351|Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical
16312731|NCT04588649|Other|AV-45|Name: [18F]AV-45, (E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical
16312732|NCT04588636|Active Comparator|Behavioral and self-care therapy control group|Subjects received verbal and written information on the etiology and prognosis of TMDs. In addition, advice on habits and behavior changes, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
16312733|NCT04588636|Active Comparator|Rigid occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a rigid occlusal splint
16312734|NCT04588636|Active Comparator|Soft occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a soft occlusal splint
16312735|NCT04588636|Placebo Comparator|Non-occlusive splint group|Subjects in this group received behavioral and self-care therapy, in combination with a non-occlusive splint
16312736|NCT04588623|Active Comparator|Omnibiotic Stress Repair (OBSR)|After randomisation, patients will receive a box with one sachet containing 3g of OBSR for each day.
16312737|NCT04588623|Placebo Comparator|Placebo|After randomisation, patients will receive an identical box with one sachet containing 3g of Placebo for each day.
16312738|NCT04588571|Experimental|Endovascular treatment|Patients (n=55) with recanalization of the femoral-popliteal arterial segment (TASC II, type D) above the knee with a biomimetic braided nitinol stent.
16312739|NCT04588571|Active Comparator|Open surgery|Patients (n=55) with femoropopliteal proximal bypass with a prolonged atherosclerotic lesion of the femoropopliteal arterial segment (TASC II, type D).
16312740|NCT04588558|Experimental|Flywheel exercise|The term isoinertial is derived from the words iso (same) and inertial (resistance), which define the primary concept of the isoinertial system in a terminology or that expresses both the concentric and eccentric phases of the same muscle contraction. Isoinertial refers to resistance used in exercise training, maintaining a constant inertia throughout the range of motion, a constant resistance in all respects, and facilitating maximum muscle strength. All participants received home exercise for 8 weeks.
16312741|NCT04588558|Active Comparator|Electrotherapy modality|"Electrotherapy modalities especially transcutaneous electrical nerve stimulation (TENS) and ultrasound is used to treat OA.
~All participants received home exercise for 8 weeks."
16312742|NCT04588558|Active Comparator|Home exercise|All participants received home exercise three times a week for 8 weeks. Home exercises are structured with squats. The exercise program includes stretching exercises and strengthening (isometric and isotonic) exercises.
16312743|NCT04588545|Experimental|Radiation Therapy followed by 10 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 1 of 4 with 10 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
16312744|NCT04588545|Experimental|Radiation Therapy followed by 20 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 2 of 4 with 20 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
16315300|NCT04571047||Colorectal cancer patients|Patients diagnosed with colonrectal cancer between 2008-2016
16312745|NCT04588545|Experimental|Radiation Therapy followed by 40 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 3 of 4 with 40 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
16312746|NCT04588545|Experimental|Radiation Therapy followed by 80 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 4 of 4 with 80 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
16312747|NCT04588532|Experimental|doxepin|"Drug: Doxepin + BAM8-22 Doxepin will be applied for 1.5 hrs followed by the application of BAM8-22. 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Doxepin + Histamine Doxepin will be applied for 1.5 hrs followed by the application of Histamine. 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Doxepin + Cowhage Doxepin will be applied for 1.5 hrs followed by the application of cowhage. 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Doxepin + Placebo Doxepin will be applied for 1.5 hrs followed by the application of placebo. 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
16312748|NCT04588532|Experimental|itch|"Drug: BAM8-22 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Histamine 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Cowhage 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Placebo 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
16312749|NCT04588519|Experimental|Active Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA
16312750|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Lower Trapezius group|Rotator cuff tears excluding the subscapularis muscle repaired using Lower Trapezius tendon
16312751|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Latissimus Dorsi group|Rotator cuff tears excluding the subscapularis muscle repaired using Latissimus Dorsi tendon
16312752|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Pectoralis group|Rotator cuff tears involving the subscapularis muscle repaired using Pectoralis tendon
16312753|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Latissimus Dorsi group|Rotator cuff tears involving the subscapularis muscle repaired using Latissimus Dorsi tendon
16312754|NCT04588480|Experimental|BNT162b2|BNT162b2 (intramuscular injection)
16312755|NCT04588480|Placebo Comparator|Placebo|Placebo (intramuscular injection)
16312756|NCT04588467|Active Comparator|Conservative group|Conservative treatment included dietary modification (intake of at lest 3 liters of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application (Lidocaine 2.5%+Prilocaine 2.5%, 2g twice a day) for 10 days
16312757|NCT04588467|Experimental|Surgical group|Thrombectomy and local excision of external hemorrhoids were performed with the patient in the lithotomy position under local infiltrative anesthesia with UltracainDS 1:200000 1.7ml
16312758|NCT04588454|Experimental|18F-PSMA-1007 PET/CT|
16312759|NCT04588441|Experimental|Adenosine|Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
16313107|NCT04586374||Control Group|Transported patients with full monitoring (including an arterial line), without inotropic/vasoactive support.
16312770|NCT04588415|Experimental|Virtual Support Group Arm|Those with severe symptoms (indicated by an ICG-r score >25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the virtual support groups. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were >6 months post-loss, and those with higher baseline symptom levels. However, no participant in our study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the family members.
16312771|NCT04588415|No Intervention|Non-Virtual Support Group Arm|Family members that choose not to participate in the Virtual Support Group will be part of this non-intervention arm
16312772|NCT04588389|Active Comparator|Group 1 Standard of Care|Group I will receive the standard of care multimodal pharmacological management.
16312773|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block II|Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.
16312774|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block III|Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.
16312775|NCT04588376|Experimental|Clinician-level and clinic-level monthly feedback|Group of 22 clinics to receive clinician-level and clinic-level monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
16312776|NCT04588376|Active Comparator|Clinic-level only monthly feedback|Group of 17 clinics to receive clinic-level only monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
16312777|NCT04588363||SARS-CoV-2 positive children|"Individuals less than 21 years of age who fulfill one or more of the following criteria:
~SARS-CoV-2 detection from a respiratory specimen, and/or
~Meets criteria for MIS-C, and/or
~Meets criteria for MIS-C, except has involvement of only 1 organ system"
16312778|NCT04588350|Experimental|i-SEP autotransfusion system|Use of i-SEP autotransfusion system during the surgery
16312779|NCT04588324|Experimental|Phase 1 Dose-Escalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
16312780|NCT04588324|Experimental|Phase 2 Dose-Expansion|SHR2150 RP2D will be combined with chemotherapy plus PD-1 or CD47 antibody in 3-week treatment cycles.
16312781|NCT04588311|Active Comparator|Erythropoietin (EPO)|Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
16312782|NCT04588311|Placebo Comparator|Placebo|Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
16312790|NCT04588285|Experimental|Ambroxol|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
16312791|NCT04588285|Experimental|Placebo|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
16312792|NCT04588272||2 liters|40 patients will receive O2 supply at rate of 2 liters per minute and then an arterial blood gas (ABG) sample is taken and compared with capnographic measures from DualGuard.
16312793|NCT04588272||4 liters|40 patients will receive receive O2 supply at rate 4 liters per minute and then an arterial blood gas (ABG) sample is taken and compared with capnographic measures from DualGuard.
16312794|NCT04588272||6 liters|: 40 patients will receive O2 supply at rate 6 liters per minute and then an arterial blood gas (ABG) sample is taken and compared with capnographic measures from DualGuard.
16312795|NCT04588259|Experimental|Faster aspart|4 daily injections of faster aspart given with insulin degludec and with or without metformin
16312796|NCT04588259|Active Comparator|Insulin aspart|4 daily injections of insulin aspart given with insulin degludec and with or without metformin
16312797|NCT04588246|Experimental|Arm I (salvage SRS, memantine, HA-WBRT)|Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
16312798|NCT04588246|Active Comparator|Arm II (salvage SRS)|Patients undergo salvage SRS.
16312799|NCT04588233|Experimental|Administration of Melatonin|
16312800|NCT04588233|Placebo Comparator|Administration of Placebo|
16312801|NCT04588220||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
16312802|NCT04588220||Control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
16312803|NCT04588207|Experimental|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
16313139|NCT04586153|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
16312804|NCT04588207|Experimental|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
16312805|NCT04588194|Experimental|Romiplostim, Rituximab, Dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.
16312806|NCT04588181|Experimental|CBT 6 sessions|
16312807|NCT04588181|Active Comparator|CBT 12 sessions|
16312808|NCT04588168|Experimental|Experimental: Chemotherapy + mpMRI + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology
~Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy"
16312809|NCT04588168|Experimental|Experimental: Chemotherapy + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology
~Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy"
16312810|NCT04588155||Chronic Low-Back Pain|Subjects diagnosed with Chronic Low-Back Pain in rehabilitation program: functional assessment (with temporal and kinematic analysis) and clinical assessment.
16312811|NCT04588155||Healthy|Healthy subjects: functional assessment (with temporal and kinematic analysis)
16312812|NCT04588142|Experimental|Experimental group|Participants are randomized to receive probiotics for 6 weeks
16312813|NCT04588142|Placebo Comparator|Placebo group|Participants are randomized to receive placebo for 6 weeks
16312814|NCT04588129|Experimental|LB-102 50 mg, single dose Cohort 1|LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.
16312815|NCT04588129|Experimental|LB-102 xx mg, single dose Cohort 2|LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.
16312816|NCT04588129|Experimental|LB-102 xx mg, single dose Cohort 3|LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.
16312817|NCT04588129|Experimental|LB-102 xx mg, multiple dose Cohort 4|LB-102 formulated capsule will be administered orally twice daily for one day in up to 4 subjects.
16312818|NCT04588116|Experimental|The web- based occupational therapy intervention SEE|The web-based intervention starts with eight educational modules focusing on engagement in activities and strategies to support an active life. The modules, that is delivered on a secure national health platform, include short education videos followed by self-reflections and digital assignments supporting the change process. The occupational therapist provides feedback after each assignment and, also, meet the patients for face- to- face online guiding sessions at three times during these first two- three weeks of the intervention. Thereafter, an individually tailored activity plan with goals and activity-based strategies are established. During the change process, the patients receive continued support from the occupational therapist until the goals are achieved.
16312819|NCT04588103|No Intervention|Control|Participants will be asked to maintain their regular physical activity habits for the duration of the 8-week intervention period.
16312820|NCT04588103|Experimental|Heat therapy|Participants will be asked to undergo 45 minutes of lower limb hot water immersion (42 degrees C) 3 times per week for 8 weeks.
16312821|NCT04588103|Experimental|Exercise training|Participants will be asked to undergo 45 minutes of moderate-intensity cycling exercise (~40-59% VO2 reserve) 3 times per week for 8 weeks.
16312822|NCT04588103|Experimental|Combined training|Participants will be asked to undergo 90 minutes of moderate-intensity cycling exercise and lower limb hot water immersion sequentially 3 times per week for 8 weeks.
16312823|NCT04588090|Experimental|Experimental group|The concurrent 3 weeks treatment group（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing 3 weeks chemotherapy）
16312824|NCT04588090|Placebo Comparator|Standard chemoradiation group|Standard chemoradiation（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing weekly chemotherapy）
16312825|NCT04588077|Experimental|Cirrhosis, 3-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
16312826|NCT04588077|Active Comparator|Cirrhosis, 2-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
16312827|NCT04588077|Experimental|Non cirrhosis, 3-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
16312828|NCT04588077|Active Comparator|Non cirrhosis, 2-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
16312829|NCT04588064|Experimental|18F-FDG PET/CT scan|Each subject receives a single intravenous injection of 18F-FDG, and undergo PET/CT imaging within the specified time.
16312830|NCT04588051|Experimental|Cabozantinib|
16312831|NCT04588038|Experimental|Treatment (efineptakin alfa)|Patients receive one dose of efineptakin alfa IM.
16312832|NCT04588025|Active Comparator|Healthy Volunteers|
16312833|NCT04588025|Active Comparator|Pancreatic Cancer Participants|
16312834|NCT04588012|Experimental|Online self-help the OurRelationship.dk program|Couples in the intervention condition will receive the full OurRelationship program including the three modules, the Observe, the Understand, and the Respond module. The program takes 6-8 hours to complete the program after the randomization. The second coach call will take place after the Observe phase. The third coach call will take place after the Understand phase. The fourth coach call will take place after the Respond phase.
16312835|NCT04588012|Active Comparator|"Off line self-help the book Pas på Parforholdet"|"Couples in the active control group receive two copies of the book Pas på parforholdet, når kærligheden er kommet for at blive [Take care of your relationship when love is here to stay] by Mattias Stølen Due (2016). This book includes general research based knowledge on maintaining a healthy relationship as well as questions and exercises for couples to do on their own. To support couples in an activate self-help approach, a sheet with guidelines on using the book will help couples plan their reading and couple conversations. Regular questionnaires will be sent to couples in the control group (matched timely to the questionnaires received by the intervention group). As such, the active control condition will mirror the benefit that couples are likely to get from using well-chosen, solid literature with the addition of any benefit that the research participation (filling in questionnaire) will generate."
16312836|NCT04587999|Experimental|bladder stimulation|
16312837|NCT04587999|Active Comparator|Quick wee|
16312838|NCT04587986|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of BTL-703 will be applied over the umbilicus. The active group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
16312839|NCT04587986|Sham Comparator|Sham control|The treatment administration phase will also consist of three (3) treatments, delivered once a week. The sham group will receive a treatment with the intensities of the magnetic field and radiofrequency energy set to 5% of the maximum device output.
16312840|NCT04587973|Active Comparator|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml) plus dexmedetomidine 1 mcg/kg
16312841|NCT04587973|Active Comparator|Group Ropivacaine|Plain ropivacaine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml)
16312842|NCT04587973|Placebo Comparator|Group Control|Control group - Preoperative bilateral erector spinae plane block with N/S 0,9% (40 ml)
16312843|NCT04587960|Active Comparator|Primary closure of Cesarean wound|Immediate closure of skin incision where healing occurs by primary intention
16312844|NCT04587960|Experimental|Delayed primary closure of Cesarean wound|Delayed closure of skin incision following regular wound dressing for 2 to 3 days.
16312845|NCT04587934|Experimental|iRes Warmer with ResusView|iRes Warmer with ResusView program with experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
16312846|NCT04587934|Active Comparator|iRes Warmer without ResusView|An external non-experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
16312847|NCT04587921|Experimental|Patients monitored with oximeter|The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
16312848|NCT04587908|Experimental|TAS-205|
16312849|NCT04587908|Placebo Comparator|Placebo|
16312850|NCT04587895|Experimental|MI Intervention|The VITAAL exergame intervention for MI includes 36 training sessions with three sessions per week, each lasting around 45 minutes (30 minutes real training time) resulting in 12 weeks of training (two weeks of break/holiday allowed). A training session includes an individually calculated amount of strength, cognitive-motor and balance training, which remains the same over the 12 week intervention period.
16312851|NCT04587895|Active Comparator|MI Control|"Participants of the MI control group are instructed to do a non-individualized conventional training including 15 minutes walking exercise (in nature or on treadmill) and additional 15 minutes of strength, balance, and cognitive-motor exercises (at the therapy centre or at home). The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu). The participants will receive a training booklet with the exercises. In total there are three different training programs which are divided according to their level of difficulty. Participants are instructed to start with the first level for four weeks and then go on to the next level for another 4 weeks. The control group training in this study includes 36 training session with three sessions per week, each lasting around 45 minutes resulting in 12 weeks of training (two weeks of break/holiday allowed)."
16312852|NCT04587895|Experimental|UI Intervention|For the incontinent women in this study, the VITAAL exergame intervention will last over 12 weeks and consists of three parts 1) VITAAL exergame (2 sessions/week) lasting 45 minutes each (30 minutes real training time) at the physio centre, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home.
16312853|NCT04587895|Active Comparator|UI Control|The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
16312854|NCT04587882|Experimental|Telehealth|Participants will be provided with a smartwatch, have access to activity tracking and goal setting through the VALENTINE app, receive micro-randomized, contextually tailored notifications, and receive weekly activity summaries via email, which will be provided to participants and to their exercise physiologist while enrolled in cardiac rehabilitation.
16312855|NCT04587882|Active Comparator|Control|Participants will continue to receive usual care and a smartwatch but without access to the micro-randomized notifications or weekly activity summaries.
16312856|NCT04587869|Experimental|Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
16312857|NCT04587869|No Intervention|No-treatment control|Participants who are assigned to the control group will not receive the intervention.
16312858|NCT04587856|Other|Biological evaluation|evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
16312859|NCT04587843|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets
16312860|NCT04587843|Placebo Comparator|Placebo|Group given placebo
16312861|NCT04587830|Experimental|ADI-PEG 20 plus Radiotherapy and Temozolomide|"ADI-PEG 20 Dose: 18 and 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 5 weeks of surgery (diagnostic and/or resection)
~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
16312901|NCT04587609|No Intervention|Control - Standard UBI|Participants will continue to be monitored as a part of their standard UBI and receive educational material about distracted driving in the enrollment period
16312902|NCT04587609|Other|Free Phone mount|Participants in this arm will be monitored through standard UBI, receive educational material about distracted driving in the enrollment period, and free phone mounts
16312862|NCT04587817||Camrelizumab+Hypofractionated radiation therapy|"Camrelizumab: 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
~Hypofractionated Radiotherapy(SABR): tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed when one week following completion of the first immunotherapy. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy."
16312863|NCT04587804|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|simultaneous treatment by repetitive pulse magnetic stimulation and radiofrequency energy for toning of abdomen and reduction of subcutaneous fat
16312864|NCT04587791|Active Comparator|CBD 400mg|CBD 400 mg
16312865|NCT04587791|Active Comparator|CBD 800mg|CBD 800mg
16312866|NCT04587791|Active Comparator|CBD 1200mg|CBD 1200mg
16312867|NCT04587791|Placebo Comparator|Saline|saline
16312868|NCT04587778|Experimental|Esketamine ((S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.
~In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan."
16312869|NCT04587778|Experimental|Racemic ketamine ((R,S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.
~In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan."
16312870|NCT04587765|Experimental|Extra sports group|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
16312871|NCT04587765|No Intervention|Conventional group|The group follows the schedule of school teaching programme. Students arrange their own after-school time after school.
16312872|NCT04587752|Experimental|CBT for Weight Bullying|Cognitive-Behavioral Therapy (CBT) for children who have experienced weight-related bullying
16312873|NCT04587739|Experimental|Experimental group|
16312874|NCT04587726|Experimental|Edutainment Body Image Video 100%|Behavioural: Girl's room video - watching 100% of the video
16312875|NCT04587726|Experimental|Edutainment Body Image Video 50%|Behavioural: Girl's room video - watching 50% of the video
16312876|NCT04587726|Experimental|Edutainment Body Image Video 25%|Behavioural: Girl's room video - watching 25% of the video
16312877|NCT04587726|Active Comparator|Control Video 100%|"Chicken Girl's Episode - 100%
~Appearance neutral episode matched for target audience and video length"
16312878|NCT04587726|Active Comparator|Control Video 50%|"Chicken Girl's Episode - 50%
~Appearance neutral episode matched for target audience and video length"
16312879|NCT04587726|Active Comparator|Control Video 25%|"Chicken Girl's Episode - 25%
~Appearance neutral episode matched for target audience and video length"
16312880|NCT04587713|Experimental|Part A, Sequence 1|"Part A, Sequence 1 = Treatment (Tx) C, Tx A, Tx C, Tx A
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout between treatments"
16312881|NCT04587713|Experimental|Part A, Sequence 2|"Part A, Sequence 2: Tx D, Tx B, Tx D, Tx B
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312882|NCT04587713|Experimental|Part A, Sequence 3|"Part A, Sequence 3: Tx C, Tx A, Tx D, Tx B
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312883|NCT04587713|Experimental|Part A, Sequence 4|"Part A, Sequence 4: Tx D, Tx B, Tx C, Tx A
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312884|NCT04587713|Experimental|Part A, Sequence 5|"Part A, Sequence 5: Tx A, Tx C, Tx A, Tx C
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312885|NCT04587713|Experimental|Part A, Sequence 6|"Part A, Sequence 6: Tx B, Tx D, Tx B, Tx D
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312886|NCT04587713|Experimental|Part A, Sequence 7|"Part A, Sequence 7: Tx A, Tx C, Tx B, Tx D
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312887|NCT04587713|Experimental|Part A, Sequence 8|"Part A, Sequence 8: Tx B, Tx D, Tx A, Tx C
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
16312888|NCT04587713|Experimental|Part B,Treatment A|Single oral dose of Treatment A on Day 1
16312889|NCT04587700||Non-marijuana user|Has never consumed marijuana or has abstained for at least the past 12 months
16312890|NCT04587700||Chronic Marijuana User|Has used marijuana in any form at least once a week for the past 3 months
16312891|NCT04587687|Experimental|Treatment (brentuximab vedotin, bendamustine)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and bendamustine IV over 60 minutes on days 1 and 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who respond to combination treatment and do not experience excessive toxicity may continue to receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
16312892|NCT04587674|Other|Spinal Cord Stimulation|
16312893|NCT04587661|Active Comparator|off-the-shelf digital CBT|standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
16312894|NCT04587661|Experimental|adapted digital CBT|has content or references to SCD, chronic pain, and the unique challenges facing minority groups
16312895|NCT04587635|Active Comparator|PHGG fiber|PHGG Fiber
16312896|NCT04587635|Placebo Comparator|Placebo Maltodextrin|Maltodextrin
16312897|NCT04587622|Experimental|Group 1 - Healthy subjects with normal hepatic function|Healthy subjects with normal hepatic function - Control
16312898|NCT04587622|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment: Child-Pugh A (Score 5-6)
16312899|NCT04587622|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment: Child-Pugh B (Score 7-9)
16312900|NCT04587622|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment: Child-Pugh C (Score 10-15)
16312903|NCT04587609|Other|Commitment + Habit tips|Participants in this arm will receive educational material about distracted driving during the enrollment period, be sent a free phone mount with installation instructions, sign a personalized commitment contract to reduce their phone use, set personal phone use reduction goals, and be sent personalized habit tips framed to help them reduce their handheld phone use while driving;
16312904|NCT04587609|Other|Habit Formation + Social Gamification|Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
16312905|NCT04587609|Other|All + Contest Financial Incentive|Participants in this arm will receive all of the treatments of arm 4 plus be entered into a financial incentive contest where they can either finish in the highest level and split the prize money amongst all participants that reached that level, and the safest driver (driver ranked #1 on the leader board of their group) will receive a small weekly financial prize.
16312906|NCT04587596||Clinical staff|All clinical staff employed at one surgery in Middlesbrough, UK who wish to participate
16312907|NCT04587583|Active Comparator|WeCareAdvisor|immediate use of the WeCareAdvisor tool for a 1 month period
16312908|NCT04587583|Active Comparator|WeCareAdvisor after 1 month|after a wait period of 1 month, use of the WeCareAdvisor tool for a 1 month period
16312909|NCT04587570|Experimental|Group 1: Infiltration of PRP|The proband gets Platelet Rich Plasma injected in the thumb saddle joint.
16312910|NCT04587570|Experimental|Group 2: Infiltration of Fat|The proband gets fat injected in the thumb saddle joint.
16312911|NCT04587570|Experimental|Group 3: Infiltration of PRP and Fat|The proband gets a mixture of Platelet Rich Plasma (PRP) and Fat injected in the thumb saddle joint.
16312912|NCT04587570|Placebo Comparator|Group 4: Infiltration of NaCl|The proband gets NaCl injected in the thumb saddle joint.
16312913|NCT04587557|Experimental|ASD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for children with Autism Spectrum Disorder
16312914|NCT04587557|Active Comparator|ASD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for children with Autism Spectrum Disorder
16312915|NCT04587557|Experimental|TD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for typically developed children
16312916|NCT04587557|Active Comparator|TD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for typically developed children
16312917|NCT04587544|Experimental|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
16312918|NCT04587544|No Intervention|No Intervention|The participants would not receive Cold Water Intervention. However, they are allowed to received the usual care
16312919|NCT04587531|Active Comparator|Active CES Therapy|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
16312920|NCT04587531|Sham Comparator|Sham CES Therapy|Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
16312923|NCT04587505|Active Comparator|Epidural anesthesia and analgesia|Epidural catheter insertion: Th 12- L 1 or Th 11 - Th 12 using the midline approach. Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml). Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml).
16312924|NCT04587505|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
16312925|NCT04587492||Children with SMA|All children with SMA are eligible for the study
16312926|NCT04587479|Experimental|JAB-8263|Monotherapy, dose escalation
16312927|NCT04587453|Experimental|Tralokinumab+TCS|Week 0 to Week 16: Tralokinumab will be given as subcutaneous injections. Participants will receive tralokinumab loading dose on Day 0 followed by multiple tralokinumab injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
16312928|NCT04587453|Placebo Comparator|Placebo+TCS|Week 0 to Week 16: Placebo will be given as subcutaneous injections. Participants will receive placebo loading dose on Day 0 followed by multiple placebo injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
16312929|NCT04587440|Experimental|Patient|"All patients will have a clinical examination before surgery and another 3 months after surgery, each including :
~A medical examination
~3 pelvic inclination measurements (1 sitting, 1 lying and 1 standing). These measurements will be done by ultrasound devices.
~2 EOS X-rays (1 standing and 1 sitting) of the lower limbs and spine
~Harris hip score
~Pain quantification thanks to an EVA scale
~hand-ground distance"
16312930|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
16312931|NCT04587414|Experimental|eHealth + counselling contacts|6-month eHealth physical activity intervention complemented by face-to-face and telephone counselling contacts on physical activity..
16312932|NCT04587414|Experimental|eHealth|6-month eHealth physical activity intervention
16312933|NCT04587414|Other|Usual care|Usual care of type 2 diabetics within the primary health care setting.
16312934|NCT04587401|Experimental|normotensive patients|Cerebral perfusion of normotensive patients who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
16315301|NCT04571034|Sham Comparator|Control Group|Healthy adults receiving sham comparator.
16312935|NCT04587401|Experimental|patients with high blood pressure diagnosis|Cerebral perfusion of patients with high blood pressure diagnosis who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
16312936|NCT04587401|Experimental|patients who do not know they are hypertensive but actual blood pressure is high|cerebral perfusion of patients who do not have high blood pressure diagnosis but actual preoperative blood pressure is higher than normal levels will be measured by transcranial doppler ultrasonography during lumbar surgery
16312937|NCT04587362||Psoriatic Arthritis|Subjects newly diagnosed with psoriatic arthritis (< 5 years), confirmed by a rheumatologist and fulfilling the CASPAR criteria.
16312938|NCT04587362||Psoriasis without musculoskeletal symptoms|Patients with dermatologist confirmed psoriasis, without any history of Psoriatic Arthritis, and musculoskeletal symptoms.
16312939|NCT04587362||Non-Inflammatory Rheumatic conditions|Patients with non-inflammatory rheumatic conditions such as osteoarthritis, non-specific back pain, soft tissue rheumatism, degenerative tendinopathy and fibromyalgia. Patients with present or past history of psoriasis, psoriatic arthritis, known or suspected rheumatic inflammatory conditions (e.g. rheumatoid arthritis, spondyloarthritis and gout), and/or inflammatory bowel disease will be excluded.
16312940|NCT04587349|Active Comparator|Exercise+FU 2/week|Post stroke group that received 2 years of intensive therapy. (2/week)
16312941|NCT04587349|Active Comparator|Exercise+FU 3/week|Post stroke group that received 2 years of intensive therapy. (3/week)
16312942|NCT04587349|Active Comparator|physiotherapy|Post stroke group that received 2 years of traditional physiotherapy. (3/week)
16312943|NCT04587349|No Intervention|Exercise+FU - controll|He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
16312944|NCT04587336||Aim 0 - Cognitive Interview|Cognitive Interviews: Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
16312945|NCT04587336||Aim 1 - Baseline Survey|Conduct Baseline Survey: Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
16312946|NCT04587336||Aim 3 - TARDIS Pilot|TARDIS Intervention: Design & pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors
16312947|NCT04587323||Group 1:|Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);
16312948|NCT04587323||Group 2:|Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).
16312949|NCT04587323||Group 3:|Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)
16312950|NCT04587323||Group 4:|Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).
16312951|NCT04587284||Patients with robot-assisted laparoscopic radical prostatectomy|
16312952|NCT04587284||Patients with open retropubic radical prostatectomy|
16312953|NCT04587284||Patients with laparoscopic radical prostatectomy|
16312954|NCT04587271|Experimental|Lactating Mothers (Moringa)|Lactating mothers.
16312955|NCT04587271|Experimental|Breastfeeding Infants (Moringa)|Breastfeeding infants from lactating mothers
16312956|NCT04587271|Experimental|Children (Moringa)|Children from 6-59 months of age.
16312957|NCT04587271|Placebo Comparator|Lactating Mothers (placebo)|Lactating mothers.
16312958|NCT04587271|Placebo Comparator|Breastfeeding Infants (placebo)|Breastfeeding infants from lactating mothers
16312959|NCT04587271|Placebo Comparator|Children (placebo)|Children from 6-59 months of age.
16312960|NCT04587258||Breast Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.
16312961|NCT04587258||Colorectal Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies
16312963|NCT04587219|Experimental|Gam COVID Vac Vaccine|the test drug will be administered according to the prime-boost scheme: the introduction of component 1 (Ad26) will be carried out on the 1st day, and component 2(Ad5)- on the 21st day of the study.
16312964|NCT04587206|Experimental|Experimental: Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
16312965|NCT04587206|Experimental|Experimental: Sequence2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
16312966|NCT04587193|Experimental|PD participants|Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
16312967|NCT04587180||Patients with cutting-through|Patients who had cutting-through during the lateral knotless anchor fixation.
16312968|NCT04587180||Patients without cutting-through|Patients who didn't have cutting-through during the lateral knotless anchor fixation.
16312969|NCT04587167|Experimental|HPV ECHO|Clinics randomly assigned to this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. The intervention has a curriculum of 10 sessions focused on the evidence-based Announcement Approach. Sessions will be 60 minutes in duration and held every other weekly for 4 months at regularly scheduled times.
16312970|NCT04587167|Experimental|HPV ECHO+|Clinics randomly assigned to this arm will receive the HPV ECHO intervention plus a systems communication strategy to deliver recall notices to parents who initially decline HPV vaccination. This arm includes 12 primary care clinics in Pennsylvania.
16312971|NCT04587167|No Intervention|Control|Clinics randomly assigned to this arm will receive no ECHO interventions. This arm includes 12 primary care clinics in Pennsylvania.
16315406|NCT04570397|Experimental|Interventional arm|ravulizumab
16312972|NCT04587154|Experimental|Intervention Group|This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
16312973|NCT04587154|No Intervention|Control Group|This arm will not change their diet for the duration of the study. They will also weigh themselves each week and report weight and hot flash frequency/severity weekly.
16312974|NCT04587141|Experimental|Sucrosomial iron|One or two capsules/die of sucrosomial iron will be assumed by the participant, depending on hemoglobin (Hb) concentration and participant body weight, for 8 weeks. Each capsule contains 30 mg of iron.
16312975|NCT04587141|Active Comparator|Ferric gluconate|Ferric gluconate will be administered by iv infusion, 125 mg of elemental iron once or twice weekly for 4 or 8 weeks depending on Hb concentration and patient body weight.
16312976|NCT04587141|Active Comparator|Ferric carboxymaltose|Two or three iv infusions of 500-1000 mg of elemental iron will be given as ferric carboxymaltose, over a 4 week period. Dosage and number of infusions will be established depending on Hb concentration and patient body weight.
16312977|NCT04587128|Experimental|Cohort A: No Previous EGFR|"Participant who have not be previously exposed to anti-EGFR therapies and are in the first or second-line metastatic treatment setting.
~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle"
16312978|NCT04587128|Experimental|Cohort B: Retreatment|"Participants with treatment refractory disease who have previously benefitted (greater than or equal to 4 months ago) from anti-EGFR therapy.
~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle, +/- Irinotecan (180mg/m^2) every 2 two weeks per standard of care"
16312979|NCT04587115|Placebo Comparator|Oxycodone|This arm will be considered the control arm, containing oxycodone as the placebo.
16312980|NCT04587115|Experimental|Oxycodone and Risperidone|Administration of oxycodone plus risperidone in a single capsule
16312981|NCT04587115|Experimental|Oxycodone and Ziprasidone|Administration of oxycodone and risperidone in a single capsule
16312982|NCT04587102|Active Comparator|whole body viberation :group A|will receive low vibrational training in the form of whole body vibration for 8 weeks
16312983|NCT04587102|Active Comparator|control group (B)|control
16312984|NCT04587089|Experimental|Conventional Treatment + Guedes-Pinto Paste Group|In this group, the conventional endodontic treatment will be made, the canals will be irrigated and filled with Guedes-Pinto paste.
16312985|NCT04587089|Experimental|Irrigation + Guedes-Pinto Paste Group|In this group,the canals will be irrigated and filled with Guedes-Pinto paste.
16312986|NCT04587089|Experimental|Irrigation + aPDT + Guedes-Pinto Paste Group|In this group, the canals will be irrigated, antimicrobial photodynamic therapy will be performed and the canals will be filled with Guedes-Pinto paste.
16312987|NCT04587063|Active Comparator|Standard Email|"The standard of care email is the same as one used in prior outreach efforts at the health system, emphasizing reduced cost for medications and convenience."
16312988|NCT04587063|Experimental|Email with Healthcare Cost Savings|The email emphasizes future reductions in healthcare costs due to increased adherence with mail-order pharmacy, in addition to mentioning reduced prices for medications. It also uses fear appeals by stating the risk of hospital stays and how mail-order pharmacy could be an easily-achievable way to avoid this negative consequence.
16312989|NCT04587063|Experimental|Email with Endorsement|The email is a letter from a doctor at the health system's health plan--who may been seen as a trusted source of information--encouraging the benefits of using a mail-order pharmacy.
16312990|NCT04587063|Experimental|Email with Comparison Table|The email includes a table comparing the benefits and drawbacks of mail-order and chain pharmacies, which appeals to their sense of agency and allows them to make the choice that best suits them.
16312991|NCT04587063|No Intervention|No Contact|Members do not receive an email.
16312992|NCT04587050||Cohort 1|Women with perinatally acquired HIV aged 18 or over who are sexually active
16312993|NCT04587050||Cohort 2|Women with perinatally acquired HIV aged 18 or over who are not sexually active
16312994|NCT04587037|Experimental|Fascia lata group|
16312995|NCT04587037|Experimental|Dermal allograft group|
16312998|NCT04587011|Experimental|T1|Tegoprazan A mg or placebo
16312999|NCT04587011|Experimental|T2|Tegoprazan B mg or placebo
16313000|NCT04587011|Experimental|T3|Tegoprazan C mg or placebo
16313001|NCT04587011|Experimental|T4|Tegoprazan D mg or placebo
16313002|NCT04586998|Experimental|"Exhaled drug monitor Edmon"|Comparison between propofol in exhaled breath and blood plasma
16313003|NCT04586985|Experimental|Single ascending dose (SAD) cohorts in healthy subjects (Part A)|Subjects will be randomized to receive a single dose FTX-6058 or placebo. Cohorts 1 and 2 will enroll 5 subjects per cohort randomized 3:2. Cohorts 3-8 will enroll up to 7 subjects per cohort randomized 5:2. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), 40 mg (Cohort 6), 60 mg (Cohort 7), and 90 mg (Cohort 8).
16313004|NCT04586985|Experimental|Multiple ascending dose (MAD) cohorts in healthy subjects (Part B)|Subjects will be randomized 6:2 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 6 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), and 40 mg (Cohort 6).
16313005|NCT04586985|Experimental|Pilot Food Effect Cohort in healthy subjects (Part C)|"Ten subjects will be randomized to receive two single 20 mg doses of FTX-6058 with and without a high fat meal.
~Dosing Period 1: Single dose within 30 minutes of high-fat meal.
~Washout Period: Interval of 7 ± 2 days
~Dosing Period 2: Single dose without high fat meal."
16313006|NCT04586985|Experimental|Potential for CYP3A Induction Cohort (Part D)|Sixteen subjects will receive 3 mg midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 once daily. On Day 12, 3 mg midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
16313007|NCT04586959|Experimental|Surgery With UM (Arm MAN UA)|Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)
16313008|NCT04586959|Active Comparator|Surgery Without UM (Arm Control)|Subjects that undergo a MIS approach without a uterine manipulator (control arm)
16313009|NCT04586933|Active Comparator|Omega-3|"0,9 gram omega-3/capsule x 4 = 3,6 gram omega-3 daily
~It will be investigated whether diet optimization followed with supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used"
16313010|NCT04586933|Placebo Comparator|Placebo capsules|Soya oil
16313011|NCT04586920|Experimental|LY3509754 - Part A|Escalating doses of LY3509754 administered orally
16313012|NCT04586920|Placebo Comparator|Placebo - Part A|Placebo administered orally
16313013|NCT04586920|Experimental|LY3509754 plus Itraconazole - Part B|LY3509754 and Itraconazole administered orally
16313014|NCT04586920|Placebo Comparator|Placebo plus Itraconazole - Part B|Placebo and Itraconazole administered orally
16313015|NCT04586920|Experimental|LY3509754 plus Midazolam - Part C|Multiple doses of LY3509754 administered orally. Some participants will also receive midazolam orally.
16313016|NCT04586920|Placebo Comparator|Placebo plus Midazolam - Part C|Multiple doses of placebo administered orally. Some participants will also receive midazolam orally.
16313017|NCT04586920|Experimental|LY3509754 (Japanese) - Part D|Multiple doses of LY3509754 administered orally to Japanese participants
16313018|NCT04586920|Placebo Comparator|Placebo (Japanese) - Part D|Placebo administered orally to Japanese participants
16313019|NCT04586907|Experimental|LY3537021 (Part A/Healthy)|LY3537021 administered subcutaneously (SC) to healthy participants.
16313020|NCT04586907|Experimental|LY3537021 (Part A/Type 2 Diabetes)|LY3537021 administered SC to participants with type 2 diabetes mellitus (T2DM).
16313021|NCT04586907|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
16313022|NCT04586907|Experimental|LY3537021 (Part B/Healthy)|LY3537021 administered SC to healthy participants.
16313023|NCT04586907|Experimental|LY3537021 (Part B/Type 2 Diabetes)|LY3537021 administered SC to participants with T2DM.
16313024|NCT04586907|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
16313025|NCT04586894||Patients|
16313026|NCT04586868|Experimental|A psychotic disorder|Patients, age 13-18 years old, diagnosed with a psychotic disorder (WHO ICD-10 )
16313027|NCT04586855||Healthy persons|Noninvasive ventilation and Cough Assist
16313028|NCT04586842|Experimental|Community-based Occupational Therapy|Experimental study group that will receive a domiciliary and community-based occupational therapy on mental health, developed on the basis of the Model Of Human Occupation.
16313029|NCT04586842|Active Comparator|Standard community-based intervention|Control group of the study that will receive community-based interventions, public or private level (e.g. community nursing, social education and/or psychology).
16313030|NCT04586829|Active Comparator|Conventional diet|Conventional diet. (50% carbohydrate, 30% lipids, 20% protein). Current dietary recommendations from official guidelines will be reinforced.
16313031|NCT04586829|Experimental|Ketogenic diet|Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.
16313032|NCT04586816|Placebo Comparator|vehicle only-placebo|Vehicle cream base containing no maple leaf extract to be applied twice daily to the face
16313033|NCT04586816|Experimental|1% red maple leaf extract|lotion preparation with 1% red maple leaf extract to be applied twice daily to the face
16313034|NCT04586816|Experimental|5% red maple leaf extract|lotion preparation with 5% red maple leaf extract to be applied twice daily to the face
16313035|NCT04586803|Experimental|A|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
16313036|NCT04586803|Experimental|B|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
16313037|NCT04586803|Experimental|C|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
16313038|NCT04586803|Experimental|D|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
16313039|NCT04586803|Experimental|E|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
16313040|NCT04586803|Experimental|F|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
16313041|NCT04586790|Experimental|midodrine group|midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine
16313042|NCT04586790|Experimental|minirin group|the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin
16313043|NCT04586790|Experimental|control group|the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
16313044|NCT04586777|Experimental|Anodal tvDCS|20 minutes of anodal tvDCS will be applied over the spine at 2.5mA.
16313045|NCT04586777|Experimental|Cathodal tvDCS|20 minutes of cathodal tvDCS will be applied over the spine at 2.5mA.
16313046|NCT04586777|Sham Comparator|Sham tvDCS|20 minutes of sham tvDCS will be applied over the spine.
16313049|NCT04586738|Other|Non-resorbable uveoscleral implant associated with absorbable collagen matrix|non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix
16313050|NCT04586738|Other|Isolated absorbable collagen matrix implant|non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant
16313051|NCT04586725|Active Comparator|Encouragement every minute|Patients will be randomised to six tests at one week apart
16313052|NCT04586725|Active Comparator|Encouragement every two minutes|Patients will be randomised to six tests at one week apart
16313053|NCT04586712|Experimental|Active CBD-extract high dose|High Dose (1000mg/30mL hemp extract = 62.5mg/day)
16313054|NCT04586712|Experimental|Active CBD low dose|Low Dose (500mg/30mL hemp-extract = 25mg/day)
16313055|NCT04586712|Placebo Comparator|Vehicle-Control (Placebo)|(0mg/30mL hemp extract = no hemp extract)
16313056|NCT04586699|Experimental|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
16313057|NCT04586699|Active Comparator|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
16313058|NCT04586686|Other|Group 1: right ovarian biopsy|Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
16313059|NCT04586686|Other|Group 2: left ovarian biopsy|Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
16313060|NCT04586673|Experimental|ChAdOx1.tHIVconsv1 low dose|3 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^9 vp
16313061|NCT04586673|Experimental|ChADOx1.tHIVconsv1 higher dose|10 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10^8 pfu and MVA.tHIVconsv4 at 0.9 x 10^8 pfu.
16313062|NCT04586660|Experimental|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone [GCTB], or multiple lesions including pulmonary metastases).
16313063|NCT04586660|Experimental|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
16313064|NCT04586647|Experimental|Noom Health Weight Program|
16313065|NCT04586647|No Intervention|Wait List Control|
16313066|NCT04586634|Active Comparator|Peristeen|Subjects to use newly developed Peristeen cone catherter device
16313067|NCT04586634|No Intervention|Standard of care|subjects continue with their standard of care treatment
16313068|NCT04586621|Experimental|Atoldys/ Lexilens - SHAM|
16313069|NCT04586621|Experimental|SHAM- Atoldys/ Lexilens|
16313070|NCT04586608|Active Comparator|active comparator|
16313071|NCT04586608|Other|soybean oil-based IVFE|soybean oil-based IVFE
16313072|NCT04586595|Experimental|Intervention arm|GP trainees in this arm will receive the REVISiT intervention which will involve having their prescribing reviewed and feedback provided, at two time points (approximately 100 prescriptions at each time point) separated by approximately a 3-month time period.
16313073|NCT04586595|No Intervention|Control arm|GP trainees in this arm will continue with training as usual and will have their prescribing (approximately 200 prescriptions) reviewed once but representing two time points - separated by an approximate 3-month time period. Feedback will occur at one time point, to cover the review for the 200 prescriptions.
16313074|NCT04586582||ST-segment resolution <40.15%|ST-segment resolution <40.15%
16313075|NCT04586582||ST-segment resolution >40.15%|ST-segment resolution >40.15%
16313076|NCT04586569|No Intervention|Standard Education|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham.
16313077|NCT04586569|Experimental|Pediatric Interactive Relational Agent (PIRA)|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham and will be given access to an interactive, online educational tool for use prior to surgery. This Pediatric Interactive Relational Agent (PIRA) will be able to be accessed as many times as the family would like prior to surgery.
16313078|NCT04586556|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps, follow-up and prediction of pathology. The full-length colonoscopy videos will be annotated for the exact time of the identification of the anatomical landmarks, polyps, also for polyp- and procedural-related characteristics.
16313079|NCT04586543|Experimental|Selegiline+ Docetaxel|Selegiline and plus Docetaxel
16313080|NCT04586543|Active Comparator|Docetaxel|Docetaxel
16313104|NCT04586413||Intensive care post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised in an Intensive Care Unit
16313105|NCT04586387|Experimental|Active brain stimulation|
16313106|NCT04586387|Sham Comparator|Inactive brain stimulation|inactive TMS
16313527|NCT04583319||SARS-CoV-2 Positive|patients tested positive for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
16313081|NCT04586530|Experimental|Memory and Attention Adaptation Training (MAAT)|"A videoconference-delivered cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8 weekly 45-minute visits with a survivor workbook, that targets: 1) enhancement of survivor self-awareness of at risk situations where memory failures occur; 2) emotion regulation through modification of survivor causal attributions and negative cognitive appraisals of memory failures; and 3) training in compensatory strategies to improve performance on daily tasks for which memory."
16313082|NCT04586530|Active Comparator|Supportive Therapy (ST)|"Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8, 45-minutes visits. ST, emphasizes non-specific psychotherapeutic factors of clinician-participant alliance: empathy, support and warmth. ST will be directed at concerns with cancer survivorship and CRCD. Clinicians will set expectations with ST participants that they will be provided validation of experience, support, and encouragement of building their own coping resources if asked directly about what to do about cognitive problems. ST emphasizes reflective listening to help deepen knowledge of the emotional experience of the participant."
16313083|NCT04586517|Experimental|Intervention group|Participants will receive supervised heavy-load resistance training twice a week during treatment with chemotherapy (approximately 16-weeks). After end of chemotherapy, participants will be encouraged to continue the training program and are provided with 12-month membership at a local gym.
16313084|NCT04586517|Active Comparator|Control group|Participants will be encouraged to continue with their usual activities during chemotherapy and not start resistance training (approximately 16-weeks). After end of chemotherapy participants will be offered to attend a 2-week introduction to the strength-training program and provided with a 12-month membership at a local gym.
16313085|NCT04586504|Experimental|0.2 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.2 mg/kg.
16313086|NCT04586504|Experimental|0.3 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.3 mg/kg.
16313087|NCT04586504|Experimental|0.4 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.4 mg/kg.
16313088|NCT04586504|Experimental|0.5 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.5 mg/kg.
16313089|NCT04586491|Experimental|Study group/ Oral care protocol with saline solution|All patients took oral care protocol in the unit with saline solution
16313090|NCT04586491|Experimental|Control group/ Oral care protocol with sodium bicarbonate solution|All patients took oral care protocol in the unit with sodium bicarbonate solution
16313091|NCT04586478|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
16313092|NCT04586465|Experimental|Neoadjuvant ICI combination with chemotherapy for stage Ⅱ-Ⅲ NSCLC|Eligible patients with clinical stage Ⅱ-Ⅲ NSCLC will receive dynamic PET-CT before and after 3 cycles neoadjuvant pembrolizumab plus chemotherapy, then patients receive surgical resection. Changes in tumor size were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Net uptake rate constant of FDG-Ki value based on dynamic PET will be calculated to evaluate Ki changes before and after treatment. Pathological tumor response were evaluated according to IASLC recommendations. Dynamic PET will be compared with RECIST whether it can better predict the pathological tumor response and disease free survival.
16313093|NCT04586452|Experimental|AAA Group (Aim 3A)|40 (20 men; 20 women) participants with a diagnosis of AAA (40-80 years) will undergo a PET/CT scan prior to their scheduled surgical repair of their condition. The radiotracer, 64Cu-DOTA-ECL1i, will be injected to detect CCR2+ inflammatory cells. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
16313094|NCT04586452|Experimental|Non-AAA Group|10 (5 men; 5 women) participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard of care. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
16313095|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens.
16313096|NCT04586452|Other|Radiotracer and CCR2 (Aim 2B)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair.
16313097|NCT04586452|Experimental|AAA Group (Aim 3B-Reproducibility)|20 (10 men; 10 women) will receive a second PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
16313098|NCT04586439|Experimental|Panel A: JNJ-73763989|Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
16313099|NCT04586439|Experimental|Panel B: J NJ-73763989|Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.
16313100|NCT04586426|Experimental|Part 1: Dose Escalation|Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
16313101|NCT04586426|Experimental|Part 2: Dose Expansion|Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the RP2R(s) of the study treatment identified in Part 1.
16313102|NCT04586413||Non-hospitalised post-COVID-19 patients|This cohort will have had a confirmed positive test for COVID-19 or antibody test confirming they had COVID-19 but they were not hospitalised for this
16313103|NCT04586413||Hospitalised post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised but were not in an Intensive Care Unit
16313108|NCT04586374||Study Group|Transported patients with full monitoring and vasoactive/inotropic support being delivered by a syringe driver.
16313109|NCT04586361|Experimental|Experimental group 1|Intraoperative1 kit of Platelet-rich plasma(PRP) injection into knee joint after anterior cruciate ligament (ACL) reconstruction.
16313110|NCT04586361|Experimental|Experimental group 2|Intraoperative1 kit of PRP+Hyaluronic acid(HA) injection into knee joint after ACL reconstruction.
16313111|NCT04586361|Placebo Comparator|Experimental group 3|Intraoperative 20 ml normal saline injection into knee joint after ACL reconstruction.
16313112|NCT04586348|Experimental|Low Iodine Supplement|Iodine (potassium iodide) 20 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
16313113|NCT04586348|Active Comparator|Standard Iodine Supplement|Iodine (potassium iodide) 200 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
16313114|NCT04586335|Experimental|CYH33 in Combination with Olaparib|CYH33 in Combination with Olaparib; 20 mg CYH33 QD in combination with olaparib 300 mg BID. Two additional dose levels of CYH33 at 30 mg QD and CYH33 at 40 mg QD in combination with olaparib 300 mg BID will be evaluated.
16313115|NCT04586309|Experimental|Early TM Training|This group will receive training in Transcendental Meditation and will complete assessments at baseline, 1 month and 3 months.(3 assessments in total).
16313116|NCT04586309|Active Comparator|Delayed TM training|This arm will complete the baseline, 1 month and 3 month assessments and then will receive the TM training, followed by additional 1 month and 3 month post-training assessments (5 in total)
16313117|NCT04586296|Experimental|Telemedicine Group|Group that will be receiving the telemedicine intervention in addition to the standard of care post-op.
16313118|NCT04586296|No Intervention|Standard Treatment|Patients will be receiving the standard of care, post op visits at 2, 6, and 12 weeks.
16313119|NCT04586283|Experimental|Maternal Prone Position|Participants will initially be assessed in left-lateral position for 20 minutes. Participants will then be asked to lie in a prone position for 30 minutes supported by a specially designed pillow. Participants will then return to a left-lateral position for 20 minutes.
16313120|NCT04586270|Experimental|TAS0612 Escalation|TAS0612 administered orally
16313121|NCT04586270|Experimental|TAS0612 Expansion|TAS0612 administered orally
16313122|NCT04586257|Experimental|Group I|patients in this group will receive Erector spinae plane block after induction of general anesthesia.
16313123|NCT04586257|Experimental|Group II|patients in this group will receive thoracolumbar interfascial plane block after induction of general anesthesia
16313124|NCT04586244|Experimental|Treatment Group A|epacadostat will be administered in combination with retifanlimab.
16313125|NCT04586244|Experimental|Treatment Group B|retifanlimab will be administered as monotherapy.
16313126|NCT04586244|Experimental|Treatment Group C|epacadostat will be administered as monotherapy.
16313129|NCT04586218|Active Comparator|Manual control of vasopressor infusion|"Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure > 65 mmHg.
~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
16313130|NCT04586218|Experimental|Computer guided vasopressor infusion|"Vasopressor will be titrated automatically by the closed-loop system to maintain mean arterial pressure > 65 mmHg.
~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
16313131|NCT04586192|Experimental|COMET|Participants receive modules focused on cognitive restructuring, gratitude, behavioral activation and self-compassion. Participants were randomized to receive 3 of the 4 possible modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.Participants in the intervention condition were randomized to receive descriptions of the four modules at the beginning of the intervention that were phrased to focus on building and improving strengths (positive) or reducing negative emotions and behaviors (negative).
16313132|NCT04586192|Sham Comparator|Self-Awareness Control|Participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
16313133|NCT04586192|No Intervention|Waitlist|Participants filled out all pre-test and post-test measures without having access to COMET of the active control exercises. Participants in this condition will receive access to COMET at the end of the study.
16313134|NCT04586179|Active Comparator|Aerobic (treadmill) Exercise|Participants will wear a heart rate monitor and complete the Buffalo Concussion Treadmill Test
16313135|NCT04586179|Experimental|Dynamic Exercise|Participants will wear a heart rate monitor and complete a dynamic exertion assessment that incorporates directional changes that incrementally increases in exercise intensity
16313136|NCT04586166|Experimental|RP Sling Group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
16313137|NCT04586166|Experimental|SIS Group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
16313138|NCT04586153|Experimental|Meplzaumb|This arm is combined with 3 groups, low dose, middle dose, and high dose. Low dose group: First dose: 0.12 mg/kg - Day 1; second dose: control - Day 8 Middle dose group: First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8 High dose group: First dose: 0.3 mg/kg - Day 1; second dose: 0.3 mg/kg - Day 8
16313140|NCT04586140||Patients with COVID-19 infection|This study will be carried out on patient data usually collected as part of their care. The patients were infected with COVID-19 and hospitalized between 03/25/2020 and 05/07/2020, and who benefited from GAREC's intervention.
16313141|NCT04586140||Nursing staff AND GAREC Members|This study also concerns data collected in the context of semi-structured interviews with health professionals, in a prospective manner. These are caregivers who are members of GARED or who called on GAREC between 25/03/2020 and 07/05/2020.
16313142|NCT04586127|Experimental|Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)|Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
16313143|NCT04586114||Early corticosteroid|Corticosteroid treatment within first seven days after ICU admission
16313144|NCT04586114||Late corticosteroid|Corticosteroid treatment later than seventh day's after ICU admission
16313145|NCT04586114||No corticosteroid|No corticosteroid treatment during ICU stay
16313146|NCT04586101|Experimental|Training intervention|
16313147|NCT04586101|No Intervention|Control interverntion|
16313148|NCT04586088|Experimental|Apatinib plus Camrelizumab arm|Subjects receive apatinib plus camrelizumab
16313149|NCT04586075||Undiagnosed Disease Group|Blood or other relevant biological samples obtained from consenting research subjects will be banked and extracted for DNA and RNA.
16313152|NCT04586036|Experimental|young healthy adults|Gait measured by Vicon Nexus System
16313153|NCT04586036|Experimental|young adults with chronic ankle joint instability|Gait measured by Vicon Nexus System
16313154|NCT04586023|Experimental|fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
16313155|NCT04586023|Active Comparator|teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
16313156|NCT04586010|Experimental|fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
16313157|NCT04586010|Active Comparator|teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
16313158|NCT04585997|Active Comparator|Mepolizumab|Mepolizumab
16313159|NCT04585997|Active Comparator|Omalizumab|Omalizumab
16313160|NCT04585984|Placebo Comparator|Control|140 men will be taking a placebo once a day during 21 days prior to the start of the IVF/ICSI cycle.
16313161|NCT04585984|Experimental|Experimental|140 men will be taking the probiotic compound (50% of each probiotic: Lactobacillus rhamnosus and Bifidobacterium longum at a dose of 10^9 cfu/day) once a day for 21 days prior to the start of the IVF/ICSI cycle.
16313162|NCT04585971||Subjects|Cerebral blood flow of a subject is measured using three methods in both common carotid and vertebral arteries. 1) Phase-contrast MR 2) Doppler sonography 3) Signal Intensity Gradient (SIG) To determine whether there is a correlation between the measured values, the correlation coefficient is calculated and analyzed.
16313163|NCT04585958|Experimental|Treatment (trastuzumab deruxtecan, olaparib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16313164|NCT04585945||Group 1 (Cases)|Patients that test positive for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
16313165|NCT04585945||Group 2 (Control)|Historic group of patients delivering prior to the COVID-19 pandemic.
16313166|NCT04585932|Active Comparator|Group I (apalutamide, leuprolide, degarelix)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
16313167|NCT04585932|Experimental|Group II (apalutamide, leuprolide, degarelix, RT)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo RT between cycles 4-7 in the absence of disease progression or unacceptable toxicity.
16313168|NCT04585919|Experimental|Paired Screening Intervention|
16313169|NCT04585919|No Intervention|Usual Care Control|In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.
16313170|NCT04585906|Experimental|Sessions with a community mental health specialist|Those randomized into the intervention group will receive 5-15 hour-long sessions with a community mental health specialist, taking place over 12 weeks. The common elements treatment approach intervention includes psychoeducation and addresses safety (when identified as a problem area). It can also include teaching relaxation, cognitive coping, exposure-trauma memories, exposure-live, cognitive restructuring, behavioral activation, and problem solving.The exact number of sessions will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues).
16313171|NCT04585906|Active Comparator|Wait-list|This study employs a wait-list control design. Participants in the control group will be asked to wait until the intervention group has all begun the intervention sessions before they begin.
16313172|NCT04585893|Experimental|Single Arm Rituximab|"The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually.
~High-risk patients (defined as patients with ECOG performance status >2 or hemoglobin <8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2).
~Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone."
16313173|NCT04585880|Experimental|Virtual Collaborative Care Clinic|The Virtual Collaborative Care Clinic arm participants use a home blood pressure monitor and routine blood pressure measurements will be uploaded to a dashboard monitored by clinical pharmacists. Blood pressure will be managed aggressively by the clinical pharmacists in coordination with Primary Care Physicians.
16313497|NCT04583566||COVID-19 Mild Symptoms|Patients with moderate symptoms, like normal flu symptoms. They do not need oxygen or ventilation
16313174|NCT04585880|No Intervention|Control Intervention|The control intervention will consist of providing the participant with educational material and a home blood pressure monitor. The patients in the control group will not have support from Virtual Collaborative Care Clinic pharmacists. Routine blood pressure measures using their device will not be collected via the dashboard and will not be available for pharmacist review. Participants will continue to see their physicians for their usual care for blood pressure management.
16313175|NCT04585867|Active Comparator|Liposomal bupivacaine|Exparel (266mg) given by surgeon just prior to sternal closure
16313176|NCT04585867|Active Comparator|Bupivacaine|40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure
16313178|NCT04585841|Experimental|Intervention group|Cancer patients receiving cannabidiol
16313179|NCT04585841|No Intervention|Control group|Cancer patients not receiving cannabidiol
16313180|NCT04585828|Experimental|Bili Cocoon|The infants will be treated with phototherapy using a double sided fiber optic pad called Bili Cocoon with an irradiance of 30 uW/cm2/nm from both sides.
16313181|NCT04585828|Active Comparator|Conventional blue light|The infants will be treated with blue light from above at 30 Uw/cm2/nm which is the standard treatment.
16313182|NCT04585815|Experimental|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
16313183|NCT04585815|Experimental|Sub-Study B|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
16313184|NCT04585802||Suicide Attempters (1)|patients with a suicide attempt
16313185|NCT04585802||Suicide Ideators (2)|patients with suicidal ideation
16313186|NCT04585802||Control Group (3)|patients without suicide attempt and without suicide ideation
16313187|NCT04585789|Experimental|Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) along with JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets) once daily up to 48 weeks. Participants may receive optional treatment with pegylated interferon alpha-2a (PegIFN-alpha-2a) after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.
16313188|NCT04585789|Experimental|Panel 1: Arm 2: JNJ-73763989 + NA|Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with NA treatment (either ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.
16313189|NCT04585789|Experimental|Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA|Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.
16313190|NCT04585789|Experimental|Panel 2: Arm 2: JNJ-73763989 + NA|Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with NA treatment (either ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.
16313191|NCT04585776|Experimental|LY900014 + Insulin Degludec|LY9000014 and insulin degludec given subcutaneously (SC).
16313192|NCT04585763|Experimental|Single Arm|
16313193|NCT04585750|Experimental|Phase 1 Dose Escalation|Multiple dose levels of PC14586 will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D).
16313194|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort A|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort A participants will have advanced solid tumors harboring a p53 Y220C mutation who meet all eligibility criteria and have measureable disease per RECIST 1.1.
16313195|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort B|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort B participants will have advanced solid tumors harboring a p53 Y220C mutation who do not meet all eligibility criteria (e.g. have a primary central nervous system (CNS) tumor) and do not have measurable disease per RECIST 1.1.
16313196|NCT04585737|Experimental|Treatment group 1|Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.
16313197|NCT04585737|Active Comparator|Treatment group 2|Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food.
16313201|NCT04585711|Other|Optimal dosing|Obese children (≥ 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.
16313202|NCT04585698||headache patients|
16313203|NCT04585698||healthy subjects|
16313228|NCT04585516||Patients < 50 years that were admitted for gastroscopy|All patients younger than 50 years that were admitted to the endoscopy department for a gastroscopy between jan 2018 and April 2019 (n= 1915)
16313498|NCT04583566||Control Healthy|Healthy group with out any infection or symptoms.
16313208|NCT04585672|Other|Healthy and Cirrhosis|Ammonia infusion with and without ammonia targeting
16313209|NCT04585659|Experimental|Qigong Intervention|60-90 minute community qigong classes, once per week plus at least 10 minutes of home practice
16313210|NCT04585659|No Intervention|Wait-List Control|Participants asked not to do any qigong, yoga or taichi for 10 weeks. Participants have the option to cross-over to the experimental arm after 10 weeks of no intervention.
16313211|NCT04585633||Low Risk|no complication develop within 30 days after the operation and high GOS value
16313212|NCT04585633||High Risk|"complication or complications develop within 30 days after the operation and low GOS value
~Complications:
~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),
~İntracranial hypertension requiring post op surgical drainage,
~Status epilepticus or seizures,
~The need for tracheal intubation or use of mechanical ventilation after surgery,
~Decrease in GKS,
~Unmanageable agitation that requires restriction or sedation,
~Need for respiratory failure and oxygen therapy,
~Unexpected serious motor deficit
~Died"
16313213|NCT04585620|Active Comparator|BTX-A|"Onabotulinum toxin A is reconstructed with 4 ml of normal saline in a vial containing 100 U (Allergen Units).
~At a single treatment session, test subjects receive a series of subcutaneous injections with 2,5 U Onabotulinum toxin A equivalent to 0,1 ml of solution after reconstruction. One injection is given per 1 square centimeter in the painful area in relation to the scar on the chest wall. The maximum number of subcutaneous injections is 40, equivalent to a maximum dose of 100 U of Onabotulinum toxin in a total volume of 4 ml solution. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes."
16313214|NCT04585620|Placebo Comparator|Placebo|At a single treatment session, test subjects receive a series of subcutaneous injections with one injection per 1 square centimeter in the painful area in relation to the scar on the chest wall with an inert solution, i.e. 0.1 ml injections of normal saline up to a total volume of 4 ml, depending on the area of the painful area. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.
16313215|NCT04585607|Experimental|Expanded hemodialysis (HDx)|HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
16313216|NCT04585607|Active Comparator|Conventional hemodialysis|Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
16313217|NCT04585594|Experimental|Mi Propio Camino (MPC; My Own Way)|Participants will complete the MPC intervention alongside usual care for hypertension
16313218|NCT04585594|Active Comparator|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|Participants will complete the HCP intervention alongside usual care for hypertension.
16313219|NCT04585581|Experimental|diet + training|
16313220|NCT04585581|Active Comparator|controls|
16313221|NCT04585555||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay.
16313222|NCT04585542|Experimental|Polyethylene glycol 3350 (MiraLax)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut."
16313223|NCT04585542|Experimental|Sodium polystyrene sulfonate (Kayexalate)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
16313224|NCT04585542|Experimental|Patiromer (Veltassa)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
16313225|NCT04585542|Experimental|Sodium zirconium cyclosilicate (Lokelma)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
16313226|NCT04585516||Patient with suspected colorectal cancer|All patients that were admitted to the department of surgery with suspected colorectal cancer between January 2016 and December 2018 (n=459).
16313227|NCT04585516||Patients admitted according to the standardized course of care for colorectal cancer|All patients that were admitted to the endoscopy department according to the standardized course of care for colorectal cancer between September 2016 and December 2018 (n=1271).
16315407|NCT04570397|No Intervention|Control arm|patients in this arm will recieve standard care
16313229|NCT04585516||Patients >80 years that were admitted for colonoscopy|All patients older than 80 years that were admitted to the endoscopy department for a colonoscopy between Sept 2016 and Jan 2019 (n= 981)
16313230|NCT04585503|Experimental|Central nervous system monitoring|Each 20 patients will be implanted with subdural or intra cortical electrodes
16313231|NCT04585490|Experimental|Cohort 1 minimal residual disease positive (MRD+)|Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy [carboplatin/pemetrexed] and durvalumab (1500 mg IV every 21 days, for 1 year), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks.Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.
16313232|NCT04585490|Experimental|Cohort 2 minimal residual disease negative (MRD )|Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab(10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.
16313233|NCT04585477|Experimental|Cohort 1 minimal residue disease positive(MRD+)|"Subjects with detectable ctDNA (MRD+) will receive up to 12 cycles of durvalumab (1500mg dose by intravenous (by vein) injection every 28 days). ctDNA will be re checked following 2 cycles (8 weeks) of durvalumab and compared to baseline levels. In the absence of progression or toxicity after 2 cycles, subject will continue with durvalumab to complete 1 year of treatment about 10 additional cycles).
~Subjects will be monitored for secondary endpoints of progression free survival (PFS) and overall survival (OS)."
16313234|NCT04585477|Active Comparator|Cohort 2 minimal residue disease negative (MRD-)|Subjects with undetectable ctDNA (MRD) will receive Standard of care and no treatment
16313235|NCT04585464|Experimental|Healthy Volunteer: Single Ascending Dose|"Single oral ascending dose in healthy volunteers
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
16313236|NCT04585464|Experimental|Healthy Volunteer: Multiple Ascending Dose|"Multiple oral ascending doses in healthy volunteers
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
16313237|NCT04585464|Experimental|Becker Muscular Dystrophy: Multiple Ascending Dose|"Multiple oral ascending doses in adults with Becker muscular dystrophy
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
16313238|NCT04585451||Chronic Pain Patients|
16313239|NCT04585451||Healthy Controls|
16313240|NCT04585438|Experimental|Single trans-mucosal bio-adhesive disc containing Diclofenac Potassium|Premedication 1 hour before starting endodontic treatment.
16313241|NCT04585438|Placebo Comparator|Placebo Control|Premedication 1 hour before starting endodontic treatment. Identically-appearing trans-mucosal bio-adhesive disc (Does not contain medication)
16313242|NCT04585425|Other|Control|Treatment as usual including sleep hygiene advice
16313243|NCT04585425|Experimental|Intervention|Treatment as usual (sleep hygiene advice) and bedtime music listening
16313244|NCT04585412|Experimental|Palonosetron (Stothu®)|Stothu® Solution for Injection 0.25 mg/5 mL
16313245|NCT04585412|Active Comparator|Palonosetron (Aloxi®)|Aloxi® Solution for Injection 0.25 mg/5mL
16313246|NCT04585399|Experimental|Contingency Management|Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
16313247|NCT04585399|No Intervention|Standard Care|Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
16313248|NCT04585386|Experimental|ATLAS|"Medical device named ATLAS which is an active corset (rigid lumbar restraint) and connected."
16313249|NCT04585386|Active Comparator|Standard lumbar support belt|Standard lumbar support belt : LombaSkin® or Lombogib®
16313250|NCT04585373|Experimental|(24 hours)|kinesio-tapping along with conventional therapy
16313251|NCT04585373|Experimental|(48hours)|kinesio-tapping along with conventional therapy
16313252|NCT04585373|Experimental|(72 hours)|kinesio-tapping along with conventional therapy
16313253|NCT04585360||Patient with Behcet disease|adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre
16313254|NCT04585347|Experimental|Regimen A|ALZ-801 171 mg tablet, fasting, once
16313255|NCT04585347|Experimental|Regimen B|ALZ-801 205 mg tablet, fasting, once
16313256|NCT04585347|Experimental|Regimen C|ALZ-801 205 mg tablet, after food once
16313257|NCT04585347|Experimental|Regimen D|ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once
16313258|NCT04585334|Experimental|Arm A Tricortin|Tricortin 1000 by intramuscular route
16313259|NCT04585334|Active Comparator|Arm B Itami|Itami Diclofenac sodium medicated plaster by topical application
16313260|NCT04585334|Placebo Comparator|Arm C Placebo|Placebo
16313261|NCT04585321|Other|T-R|"Part 1 (QD) and part 2 (BID):
~Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.
~Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac."
16313262|NCT04585321|Other|R-T|"Part 1 (QD) and part 2 (BID):
~Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.
~Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster."
16313263|NCT04585308|Experimental|Single arm|Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.
16313264|NCT04585295|Experimental|Betaine|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.
~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.
~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
16313265|NCT04585295|Experimental|Placebo|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.
~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.
~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
16313266|NCT04585295|Experimental|NOW Foods Big 6|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.
~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.
~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
16313267|NCT04585282|Experimental|intervention group|The study group was treated with intensive cognitive behavioral therapy for insomnia.
16313268|NCT04585282|Active Comparator|control group|The control group was treated with traditional cognitive behavioral therapy for insomnia.
16313269|NCT04585269|Experimental|Bright IDEAS-YA|Intervention consists of six 45-minute one-on-one sessions between a patient and a trainer, who teaches the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach and worksheets. In addition, participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer Network (NCCN) adolescent and young adult patient guidelines.
16313270|NCT04585269|No Intervention|Enhanced Usual Care|Participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer network (NCCN) adolescent and young adult patient guidelines.
16313271|NCT04585256|Active Comparator|Trendelenburg|Women positioned in the trendelenburg position during external cephalic version.
16313272|NCT04585256|No Intervention|Control|Women positioned on their back during external cephalic version.
16313273|NCT04585243|Experimental|Self-Sampling Kit|Participants will be mailed a Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
16313274|NCT04585230|Active Comparator|Group 1: (CBD + MO cohort)|Roll on stick containing CBD and mineral oils (CBD + MO cohort)
16313275|NCT04585230|Active Comparator|Group 2: (MO cohort)|Roll on stick containing mineral oils only (MO cohort)
16313276|NCT04585230|Active Comparator|Group 3: (CBD Cohort)|Roll on stick containing CBD only (CBD cohort)
16313277|NCT04585230|Placebo Comparator|Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)|Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
16313278|NCT04585217|Active Comparator|Plain gut suture|Plain gut suture closure of blepharoplasty incision
16313279|NCT04585217|Active Comparator|Polypropylene suture|Polypropylene suture closure of blepharoplasty incision
16313280|NCT04585204|Active Comparator|50 gr-100 gr OGTT|patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT
16313281|NCT04585204|Active Comparator|75 gr OGTT|patients are tested by 75 gr OGTT
16313282|NCT04585191|Experimental|Pre-Visit Conversation Aid|"Patients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
16313283|NCT04585191|Active Comparator|General Health Education Handout|"Patients in the attention control arm will receive an existing 1-page health education handout entitled Embracing Life as You Age which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well."
16313284|NCT04585165||Risk of HIV acquisition|Individuals reporting behavioral risk of HIV acquisition.
16313285|NCT04585152|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells) How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
~Where: in Hospital When and how much: once; diluted in 1000 ml of normal saline."
16313286|NCT04585152|Active Comparator|Mycophenolate mofetil|"Drug Name: Mycophenolate Mofetil (MMF)
~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis Procedures: MMF 1,200 mg/m2 orally divided in 2 daily doses"
16313287|NCT04585139|Other|Phase 1 -- Introduction to Dexcom G6 CGM|A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM
16313288|NCT04585139|Active Comparator|Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM|1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.
16313289|NCT04585126|No Intervention|General anesthesia without intermediate cervical block|General anesthesia performed by the anesthesiologist
16313290|NCT04585126|Active Comparator|General anesthesia with intermediate cervical block|General anesthesia performed by the anesthesiologist associated with an echoguided intermediate cervical block (bilateral in total thyroidectomy, unilateral in partial thyroidectomy) : 10 to 30cc of ropivacaine (2 to 3,75 %)
16313291|NCT04585113||People with hand OA awaiting surgery|Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.
16313292|NCT04585100|Experimental|Bioequivalent test of FM101 oral solution and FM101 tablet|
16313293|NCT04585100|Experimental|Phase 2a|
16313295|NCT04585061|Active Comparator|sweet test group|Local anesthesia with conventional syringe Procedure: Local anesthesia with conventional syringe + xylitol sublingual tablet Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.
16313296|NCT04585061|Active Comparator|Virtual reality group|"Local anesthesia with conventional syringe + VR device Device: Local anesthesia with conventional syringe + VR device Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.
~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized."
16313297|NCT04585048|No Intervention|waiting list|waiting list
16313298|NCT04585048|Experimental|treatment|treatment with the Integrated Behavioral Therapy fo Selective Mutism
16313302|NCT04585022|Active Comparator|Magnum|A metal-on-metal large diameter head total hip arthroplasty
16313303|NCT04585022|Active Comparator|Recap|A metal-on-metal hip resurfacing arthroplasty
16313304|NCT04585009|Experimental|Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
16313305|NCT04585009|Experimental|Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
16313306|NCT04585009|Experimental|Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
16313307|NCT04585009|Experimental|Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
16313308|NCT04585009|Experimental|Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
16313309|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
16313310|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo. There will be at least 10 days of wash-out period between doses for each participant.
16313311|NCT04585009|Experimental|Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
16313312|NCT04585009|Experimental|Cohort 3: Participants receivings repeated doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
16313313|NCT04585009|Experimental|Cohort 4: Participants receiving repeat doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
16313314|NCT04585009|Experimental|Cohort 5: Participants receiving repeat doses of GSK3923868|Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
16313315|NCT04584996||Pancreatic cancer|Patients being evaluated at MDT for suspected Pancreatic Ductal Adenocarcinoma (PDAC), via radiological test (e.g. endoscopic ultrasound (EUS), endoscopic retrograde cholangiography (ERCP), cross-sectional imaging), serum tumour marker (i.e. CA 19-9), or other diagnostic procedure
16313316|NCT04584996||Control|Patients diagnosed and/or due to undergo surgery for benign pathology (e.g. gallstones, chronic pancreatitis, etc); or patients with a diagnosis of a pre-malignant lesion (e.g. pancreatic intraductal papillary mucinous neoplasm); Pancreatic Neuroendocrine Tumour, or a Biliary Tract Cancer (i.e. cholangiocarcinoma; gallbladder cancer; ampullary cancer)
16313317|NCT04584983|Active Comparator|usual prescribed intralipid (UL) regimen|
16313318|NCT04584983|Experimental|restricted prescribed intralipid (RL) regimen|
16313319|NCT04584970|Experimental|Virtual reality device|Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
16313320|NCT04584970|Active Comparator|iPad device|Participants will be offered an iPad device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
16313321|NCT04584957|Active Comparator|VAC therapy|Prophylactic ciNPWT therapy positioning YES. Patients enrolled for placement of the device over a closed incision immediately post-operatively.
16315540|NCT04569370||Difficult criteria|Intervention: Procedure: Laparoscopic cholecystectomy
16313322|NCT04584957|No Intervention|Standard Closure|Prophylactic ciNPWT therapy positioning NO. Patients enrolled for standard laparotomic closure without ciNPWT positioning
16313323|NCT04584944||Healthy adult men|Healthy young men, 20- 44 years old
16313324|NCT04584944||Healthy adult women|Healthy young women, 20- 44 years old
16313325|NCT04584931|Experimental|Treatment of gingival recession with colored composite|Composite restoration will be applied to the gingival recession defect
16313326|NCT04584931|Active Comparator|Treatment of gingival recession with coronally advanced flap|coronally advanced flap at the gingival defect
16313328|NCT04584879|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
16313329|NCT04584879|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
16313330|NCT04584879|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
16313331|NCT04584879|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
16313332|NCT04584879|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
16313333|NCT04584879|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
16313334|NCT04584866|Active Comparator|Study Intervention|Endonasal endoscopic pituitary surgery in semi-sitting position
16313335|NCT04584866|Active Comparator|Control Intervention|Endonasal endoscopic pituitary surgery in supine position
16313336|NCT04584853|Active Comparator|Endocrine Therapy only|
16313337|NCT04584853|Experimental|Endocrine Therapy with abemaciclib|
16313338|NCT04584840|No Intervention|Group 1 (non-surgical treatment)|"Soft diet.
~Suspension of the use of prostheses or intraoral devices.
~Oral hygiene guidelines.
~Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.
~Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotic treatment can be prolonged indefinitely until infection and symptoms are controlled."
16313339|NCT04584840|Experimental|Group 2 (surgical treatment)|"Same guidelines of conservative treatment plus surgical treatment according to the following protocol:
~Specific protocol for surgical treatment:
~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.
~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.
~Secure a two layered waterproof closure without tension (simple or with local flaps).
~Samples will be sent for Pathological and microbiological analysis.
~Stitches removal after two weeks
~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
16313340|NCT04584827||complication positive (up to 30 days after surgery)|"Complications:
~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),
~İntracranial hypertension requiring post op surgical drainage,
~Status epilepticus or seizures,
~The need for tracheal intubation or use of mechanical ventilation after surgery,
~Decrease in GKS,
~Unmanageable agitation that requires restriction or sedation,
~Need for respiratory failure and oxygen therapy,
~Unexpected serious motor deficit
~Died"
16313341|NCT04584827||complication negative (up to 30 days after surgery)|No complications are seen within 30 days and the patient is healthy
16313342|NCT04584814|Active Comparator|Babies born Preterm|Preterm babies, healthy at the time of the study , free of neonatal diseases and/or sequelae or malformations or genetic diseases
16313343|NCT04584814|Active Comparator|Newborn born at term|Term healthy babies, without respiratory and/or cardiovascular malformations or genetic diseases
16313344|NCT04584801||Part A|"Development Phase Any adult (between 18 to 80 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator <0.70)
~Cohort A (N=50): COPD stage 1
~Cohort B (N=50): COPD stage 2
~Cohort C (N=50): COPD stage 3
~Cohort D (N=50): COPD stage 4
~Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)"
16313345|NCT04584801||Part B|"Validation Phase
~Cohort A (N=50): COPD stage 1
~Cohort B (N=50): COPD stage 2
~Cohort C (N=50): COPD stage 3
~Cohort D (N=50): COPD stage 4
~Cohort E (N=50): Suspected COPD"
16313346|NCT04584775|Experimental|Traditional Chinese Medicine plus Standard Care|Participants in this group will receive standard Palliative Care and will additionally see a practitioner of Traditional Chinese Medicine. No strict protocol for the actual intervention exists (pragmatic approach). The participants will at least receive acupuncture and/or chinese herbal medicine. The standard care will include any established medical intervention according to currently available guidelines in palliative care.
16313347|NCT04584775|Other|Standard Care|The standard care will include any established medical intervention according to currently available guidelines in palliative care.
16313348|NCT04584762|Sham Comparator|Sham treatment|"The AVPI device software is set in sham mode which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
16313349|NCT04584762|Experimental|Active Treatment|"The AVPI device software is set in active mode which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
16313350|NCT04584749|Experimental|LIDOCAINE|"2% lidocaine will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.
~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
16313351|NCT04584749|Placebo Comparator|PLACEBO|"0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction . After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine/placebo.
~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing Physiological Serum as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
16313352|NCT04584736|Experimental|Livalo 2mg, Ezetrol 10mg|Pitavastatin 2mg, Ezetimibe 10mg
16313353|NCT04584736|Active Comparator|Livalo 2mg|Pitavastatin 2mg
16313354|NCT04584736|Experimental|Livalo 4mg, Ezetrol 10mg|Pitavastatin 4mg, Ezetimibe 10mg
16313355|NCT04584736|Active Comparator|Livalo 4mg|Pitavastatin 4mg
16313356|NCT04584710|Experimental|10 mg daily RTB101|"RTB101
~TORC1 inhibitor"
16313357|NCT04584710|Placebo Comparator|Placebo|Placebo
16313358|NCT04584697|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
16313359|NCT04584697|Placebo Comparator|Placebo|A single injection of placebo will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
16313360|NCT04584684|Placebo Comparator|Saline|Subject participants will rinse mouth one time for 60 seconds with 10 mL of Isotonic Saline.
16313361|NCT04584684|Active Comparator|1.5% w/v Hydrogen Peroxide|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 1.5% w/v hydrogen peroxide rinse.
16313362|NCT04584684|Active Comparator|0.12% Chlorhexidine Gluconate|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 0.12% Chlorhexidine Gluconate.
16313363|NCT04584684|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 10 mL 27% ethanol plus essential oils.
16313364|NCT04584684|Active Comparator|0.5% w/v Povidone-iodide|Subject participants will rinse mouth one time for 60 seconds with 10 mL .5% w/v povidone-iodide.
16313365|NCT04584684|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 10 mL 0.075% Cetylpyridinium Chloride.
16313366|NCT04584671||Mild COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of mild COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
16313367|NCT04584671||Severe COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of severe COVID-19 infection, including at least 50 participants who were hospitalized with COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
16313368|NCT04584645|Experimental|cardiovascular disorders digital intervention arm (CVD-I)|Individuals with cardiovascular disease who receive a targeted digital intervention aimed at increasing influenza vaccination
16313369|NCT04584645|No Intervention|cardiovascular disorders without digital intervention arm|Individuals with cardiovascular disease who receive no intervention
16313370|NCT04584632|Experimental|EVSS|Efemoral Vascular Scaffold System (EVSS)
16313371|NCT04584593|Other|SARV-Cov|Men will give semen, saliva, urine and blood specimens
16313372|NCT04584580|Active Comparator|Therapeutic dose low-molecular-weight heparin (LMWH)|Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours
16313373|NCT04584580|Experimental|D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy|"from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH
~D-Dimer level Body Weight LMWH dose
~<1 mg/dl <100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD >150kg Enoxaparin 60mg BD
~1-3 mg/ dl <100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD >150kg Enoxaparin 120mg BD
~>3 mg/ dl Enoxaparin 80mg BD"
16313374|NCT04584567|Experimental|DOXY ZINC|Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)
16313375|NCT04584567|Placebo Comparator|DOXY PLACEBO|Doxycycline daily dosing (100mg) placebo of Zinc
16313376|NCT04584567|Placebo Comparator|PLACEBO|placebo of Doxycycline daily dosing placebo of Zinc
16313377|NCT04584554|Experimental|Intervention|
16313378|NCT04584541|Other|case|Index cases (RA and SpA patients under immunosuppressive treatments)
16313379|NCT04584541|Other|controls|Members of index cases family cluster infected with the same viral strain
16313380|NCT04584528|Other|EHR-embedded Individualized Pain Plan (IPP)|The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
16313381|NCT04584515|Experimental|IMP4297 40 mg|Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.
16313382|NCT04584515|Experimental|IMP4297 100 mg|Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.
16313383|NCT04584502|Experimental|Intervention as adjunct to Treatment as Usual|Participants will attend an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
16313384|NCT04584502|No Intervention|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
16313385|NCT04584476|Experimental|SCR group|underwent superior capsular reconstruction
16313386|NCT04584476|Other|Partial group|underwent partial rotator cuff repair
16313387|NCT04584450||1|COVID-19 survivors.
16313388|NCT04584437|Other|Vitality Therapy|"i. 500 to 1000 cubic centimeters of micro-clustered, hydrogen rich alkaline Vital Water.
~ii. Irradiation in infrared sauna for 60 minutes at high fever temperature. iii. Supplementation - Multivitamins and Minerals."
16313389|NCT04584398|Experimental|Intervention|The intervention group (A) will perform respiratory muscle training and steam inhalation with WellO2 device for 30 days.
16313390|NCT04584398|No Intervention|Control|The control group (B) will continue on their conventional treatment without respiratory muscle training or steam inhalation with WellO2. After 30 days, the group B performs the same 30-day intervention with the WellO2 device (test) as the group A.
16313391|NCT04584385||Childhood epilepsy|Children with refractory tonic, myoclonic or atonic seizures
16313392|NCT04584372|Active Comparator|High-nitrate (HI-NI) intervention|The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
16313393|NCT04584372|Placebo Comparator|Low-nitrate (LO-NI) intervention|The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
16313394|NCT04584359|Experimental|HVLA techiniques (G1)|Performed with thrust (also known as HVLA) in the sacroiliac joint and T10-L2 level
16313395|NCT04584359|Experimental|Global osteopathic protocol (G2)|Several elements were emphasized - myofascial, bone, and visceral.
16313396|NCT04584359|Experimental|Pelvic floor muscle training (G3)|Muscle Training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes.
16313397|NCT04584359|No Intervention|Control group (G4)|No intervention and was simply evaluated and re-evaluated.
16313398|NCT04584346|Experimental|Arm A|Ketogenic Diet
16313399|NCT04584346|Active Comparator|Arm B|Standard American Diet &amp; ketogenic diet
16313400|NCT04584333|Experimental|INTERVENTION|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established.
16313401|NCT04584333|No Intervention|NO INTERVENTION|Group 2 (non-intervention group): you will receive the usual information regarding the characteristics of your injuries and the role of tobacco and alcohol in their evolution and the importance of abandoning these habits.
16313402|NCT04584320||Premature neonates with necrotizing enterocolitis|
16313403|NCT04584320||Premature neonates without necrotizing enterocolitis|
16313404|NCT04584307|Experimental|Elotuzumab + Pomalidomide|Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
16313405|NCT04584294|Experimental|Intervention (MyPath)|Patients scheduled to see providers randomized to this arm will receive a weblink to the decision tool via text message after study enrollment and prior to their scheduled visit.
16313406|NCT04584294|No Intervention|Uusal Care|Patients scheduled to see providers randomized to the usual care arm will receive no intervention and will receive usual primary care.
16313407|NCT04584268|Experimental|mindfulness|3 30 minute in person interventions as well as promotion and involvement of self-guided meditations on the Insight Timer smart phone application
16313408|NCT04584268|Active Comparator|control|standard medical resident education
16313409|NCT04584255|Experimental|Arm A Triple Negative Breast Cancer (TNBC)|"Participants will be randomized 1:1 to treatment with the combination (Arm A)
~Niraparib-Daily beginning with week 1, day 1
~Dostarlimab-Once every three weeks beginning with week 1, day 1"
16313410|NCT04584255|Experimental|Arm B TNBC|"Participants will be randomized 1:1 to treatment with the combination (Arm B)
~3-week lead-in of niraparib monotherapy followed by treatment with the combination
~Niraparib Daily beginning with week 1, day 1
~Dostarlimab Once every three weeks beginning with week 4, day 1"
16313411|NCT04584255|Experimental|Arm C ER+/HER2-|"exploratory cohort of estrogen receptor (ER) positive HER2-negative participants will be enrolled to Arm C.
~Niraparib Daily beginning with week 1, day 1
~Dostarlimab Once every three weeks beginning with week 1, day 1"
16313412|NCT04584242|Experimental|Pioglitazone|
16313413|NCT04584242|Experimental|Evogliptin|
16313414|NCT04584229||question not suitable for study|question not suitable for study
16313415|NCT04584216|Experimental|Steam Eye Mask With Acupoints Stimulation|"The Steam Eye Mask with acupoints stimulation (SEM with acupoints stimulation), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.
~Also, on the eyebrow have the acupoints made by nonwoven fabric can use hands to massage.
~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes and use hands to massage the acupoints on the eyebrows for the first 3 minutes."
16313416|NCT04584216|Active Comparator|Steam Eye Mask|"The Steam Eye Mask (SEM), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.
~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes."
16313417|NCT04584177|Experimental|Arm-hand BOOST + Control|First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
16313418|NCT04584177|Experimental|Control + Arm-hand BOOST|First 4 weeks control program, afterwards 4 weeks arm-hand boost program
16313419|NCT04584164|No Intervention|Control arm|This arm involves patients applying the basic hygiene rules (with mouthwashes) without the sialendoscopy method.
16313420|NCT04584164|Experimental|Sialendoscopy arm|This arm involves patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
16313421|NCT04584151|No Intervention|standard of care|Peri operative analgesia by opioid
16313422|NCT04584151|Experimental|Continuous regiona analgesia|Peri operative algesia by continuous bilateral ESP catheters
16313423|NCT04584125|Experimental|Ex vivo cross linking of donor corneal tissue|The donor corneal tissue used in the penetrating keratoplasty procedures will previously undergo ex vivo crosslinking.
16313424|NCT04584112|Experimental|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
16313425|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.
16313426|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.
16313427|NCT04584086|Experimental|MRI 3 Tesla|Patients will be followed by 3 Tesla MRIs during the study
16313428|NCT04584073|Active Comparator|Adenoidectomy|Adenoidectomy
16313429|NCT04584073|Active Comparator|Adenoidectomy and Myringotomy|Adenoidectomy and Myringotomy
16313430|NCT04584073|Active Comparator|Adenoidectomy,Myringotomy and Tympanostomy tube application|Adenoidectomy and Myringotomy and Tympanostomy tube application
16313431|NCT04584060||Conventional|Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
16313432|NCT04584060||ERAS|Preoperative information, education and counselling, If possible, Clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, Short acting anesthetic agents,avoid opioid agents, Post operative nausea and vomiting prophylaxis, Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off, Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward, Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, Removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
16313433|NCT04584047|Experimental|Intervention group|This arm had blood collected at the time of CVS.
16313434|NCT04584034|Active Comparator|Salbutamol|Salbutamol inhalation 4x200ug daily for 7 days, delivered using a Babyhaler
16313435|NCT04584034|Placebo Comparator|Placebo|Placebo 4 x 2 inhalations daily for 7 days, delivered using a Babyhaler
16313436|NCT04584021||Stress study participants|Adults who reported stress problems derived from work
16313437|NCT04584008|Experimental|Matched Targeted Agent|Matched Targeted Agent
16313438|NCT04584008|Active Comparator|Unmatched Therapy|Unmatched Therapy
16313439|NCT04583995|Experimental|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
16313440|NCT04583995|Placebo Comparator|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
16313441|NCT04583995|Experimental|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
16313442|NCT04583995|Placebo Comparator|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
16313443|NCT04583982||Prospective Study Arm SARS-CoV-2 negative and positive samples|
16313448|NCT04583930||Patients with Haemophilia A|"Patients suffering from moderate to severe haemophilia A
~Age ≥ 18-years
~Treatment with FVIII prophylaxis
~Submitted written informed consent"
16313449|NCT04583904||Adults - inpatient|
16313450|NCT04583904||Adults- ambulatory|
16313451|NCT04583904||Children|
16313456|NCT04583865||teleconsultation|Patient with teleconsultation of pre-anesthesia
16313457|NCT04583852|Experimental|brightening micro-needle patch|apply brightening micro-needle patch to one of the two assigned spots on the face according to the instructions on the package
16313458|NCT04583852|Placebo Comparator|Placebo|apply placebo micro-needle patch to another one of the two assigned spots on the face according to the instructions on the package
16313496|NCT04583566||COVID-19 Severe Symptoms|Patients with severe symptoms need oxygen and ventilation.
16313459|NCT04583839|Experimental|Navigation Group|Women who are randomized into SWEET will be assigned to a patient navigator. The navigator will meet women during hospitalization, at postpartum appointments, during primary care appointments, and as needed. At these face-to-face meetings, the navigator will perform education about the postpartum OGTT, post-GDM management plan, diabetes mellitus risks, lifestyle modification, and primary care transition. The navigator will facilitate the development of an individualized GDM Care Plan in conjunction with the patient and the medical team. The navigator will assess individual barriers to T2DM screening and prevention. At appointments, the navigator will also ensure a woman understands her diabetes-related care plan and will perform health education and barrier-reducing tasks as needed.
16313460|NCT04583839|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
16313461|NCT04583826|Experimental|CAVA|20 participants will wear the CAVA device, and a consumer-grade sleep monitoring device, and undergo polysomnography, for one night. 40 participants will wear the CAVA device and undergo polysomnography for two nights
16313462|NCT04583813|Active Comparator|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
16313463|NCT04583813|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 24 months
16313465|NCT04583774|Other|Anorexia Nervosa Group|Participants with anorexia nervosa
16313466|NCT04583774|Other|Healthy Control Group|Participants who are considered to be healthy controls
16313467|NCT04583761||cases|Healthcare workers with mild symptoms of COVID-19 and a positive RT-PCR test for SARS-CoV-2
16313468|NCT04583761||controls|Healthcare workers with mild symptoms of COVID-19 and a negative RT-PCR test for SARS-CoV-2
16313469|NCT04583748|Experimental|Sahaj Samadhi Meditation|Participants randomized to the Sahaj Samadhi Meditation (SSM) arm will undergo SSM training in groups of 10. SSM will be delivered virtually using the Cisco WebEx platform by trained, certified non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
16313470|NCT04583748|Active Comparator|Health Enhancement Program|Participants randomized to the Health Enhancement Program (HEP) arm will undergo HEP training in groups of 10. HEP will be delivered virtually using the Cisco WebEx platform by trained non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
16313471|NCT04583748|No Intervention|Treatment as Usual|Participants randomized to the Treatment as Usual (TAU) arm will continue to receive their treatment as usual. The usual standard of care for irreversible age-related vision patients includes no active treatment since eye surgeons have done all that could possibly be done to restore vision.
16313474|NCT04583722|Other|AX oleoresin|Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)
16313475|NCT04583722|Experimental|AX-olive oil-PP emulsion|Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)
16313476|NCT04583709|Experimental|ECG Belt|ECG belt will be used to record ECG during baseline rhythm, LBBP in unipolar and bipolar configurations and / or during HOT-CRT using HBP or LBBP. These ECG belt characteristics would then be compared with baseline and existing data on RV pacing and traditional Biventricular pacing.
16313477|NCT04583696|Experimental|Walnut Consumption of Healthy Volunteers|
16313478|NCT04583683|Active Comparator|Intensive lifestyle modification: Very low calorie diet|Patients will undergo a very low calorie diet
16313479|NCT04583683|Active Comparator|Metabolic Surgery|Patients will undergo metabolic surgery
16313480|NCT04583670||30 general practitioners, who will use ultrasound during their consultations|
16313481|NCT04583657|Placebo Comparator|Control|"Consumption of two classical eggs per day during three months. The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%."
16313482|NCT04583657|Experimental|Test|Consumption of two test eggs per day during three months. These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%, total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
16313483|NCT04583644|Experimental|Device - FETO|Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of balloon using the BALT GOLDBAL2 balloon and BALTACCIBDPE100 catheter.
16313484|NCT04583631||Chronic adenoiditis|Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis.
16313485|NCT04583631||Adenoid hypertrophy|Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group.
16313491|NCT04583605||PREVENA|A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
16313492|NCT04583605||NON PREVENA|A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
16313493|NCT04583592|Experimental|Camostat Mesilate|Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.
16313494|NCT04583592|Placebo Comparator|Placebo|Participants will receive placebo for 14 days in addition to standard of care treatment.
16313499|NCT04583514|Experimental|Control|The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
16313500|NCT04583514|Experimental|Overfeeding|The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
16313501|NCT04583501|Experimental|Omalizumab|Ex vivo exposure of excised human surgical polyp tissue to omalizumab.
16313502|NCT04583488|Experimental|Intraperitoneal docetaxel|Participants will receive intraperitoneal docetaxel combined with the standard of care. A standard 3 + 3 dose escalation design will be used according to the dose escalation plan.
16313503|NCT04583462|Experimental|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
16313504|NCT04583462|Placebo Comparator|Placebo|Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm), started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
16313505|NCT04583449|Experimental|Outcome imagery|Outcome imagery condition participants will be asked to visualize themselves successfully wearing a face covering in all required public places/situations over coming week, and to imagine how they would feel. The importance of imagining distinctive relevant visual imagery linked to having successfully routinely worn face covering will be underscored in this passage. Outcome imagery participants will then be asked to write in a free-text box how they would feel having successfully worn a face covering in required public places/situations over the week ahead.
16313506|NCT04583449|Experimental|Process imagery|Process imagery condition participants will be asked to visualize the kinds of strategies involved in successfully wearing a face covering in all required public places/situations over the coming week. The importance of imagining distinctive relevant visual imagery linked to having effective strategies involved in successfully wearing a face covering in required public places/situations over the week ahead will be underscored in this passage. Process imagery participants will then be asked to write in a free-text box about the kinds of strategies that would be involved in successfully wearing a face covering in all required public places/situations over the coming week.
16313507|NCT04583449|Experimental|Combined imagery (outcome imagery and process imagery)|A third experimental condition will receive both outcome and process imagery exercises to read and complete in sequential order.
16313508|NCT04583449|No Intervention|Public health message|A fourth condition will involve viewing a UK Government public health message (HM Government, 2020) circulated on social media as an image concerning the importance of wearing face covering while in public places.
16313509|NCT04583436|Experimental|Endovascular recanalization|"Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
~n=45"
16313510|NCT04583436|Active Comparator|Open surgery|"Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
~n=45"
16313515|NCT04583410|Experimental|Nicotine patch|
16313516|NCT04583410|Placebo Comparator|Placebo patch|
16313517|NCT04583397|Experimental|Experimental: WiFi - Sham|first intervention WiFi, second intervention sham
16313518|NCT04583397|Experimental|Experimental: Sham - WiFi|first Intervention sham, second Intervention WiFi
16313519|NCT04583384|Other|Assigned Intervention|"Addition to the cervical angio-MRI, of a sequence of 1H-SRM 3T (SUCCESS) centered on the lesion studied, performed according to the following parameters: PRESS asymmetric monovoxel PROBE, TE 144 ms, TR 2500 ms, 768 or 1024 medium."
16313520|NCT04583371|No Intervention|GROUP CONTROL|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.
~In the control group, patients will be ventilated for 1 minute with 100% inspired oxygen (FiO2), followed by three aspirations for 15 seconds and with an interval of 30 seconds."
16313521|NCT04583371|Active Comparator|INTERVENTION GROUP|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.
~In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the supine position, the headboard elevated to 30º in assisted pressure-controlled ventilatory mode, increasing 10 cmH2O in inspiratory pressure and in assisted ventilation mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, with Ppeak not exceeding 40 cmH2O and drive pressure not exceeding 15 cmH2O in both ventilation modes, and then a new aspiration in the same way as the control group."
16313524|NCT04583345||Hypertensive|Diagnosis of hypertension
16313525|NCT04583345||Healthy|Healthy blood pressure level and absence of any chronic disease
16313526|NCT04583332|Other|Rhymes, Individual Items in Rhymes, Objects|Existing method Post intervention
16313528|NCT04583319||SARS-CoV-2 Negative|participants tested negative for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
16313529|NCT04583306||Healthy Subjects|40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
16313530|NCT04583306||COVID-19 Positive|40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
16313531|NCT04583306||COVID-19 Negative|40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
16313532|NCT04583293||COVID AKI|Participants who were admitted to the hospital with COVID-19 and developed AKI during their hospital stay.
16313533|NCT04583293||COVID non-AKI|Participants who were admitted to the hospital with COVID-19 and did not develop AKI during their hospital stay.
16313536|NCT04583267|Experimental|PrEP|
16313537|NCT04583254|Experimental|Arm 1 EBRT+High-dose (HDR) Brachytherapy Experimental|
16313538|NCT04583254|Active Comparator|Arm 2 EBRT+High-dose (HDR) Brachytherapy Standard of Care|
16313539|NCT04583241||BJI group|"Patients with an BJI on material (prosthesis or other implant) infected by Streptococcus aureus* Patients are follow-up during two years after surgery.
~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
16313540|NCT04583241||Control Group With material|"Patients with mechanical problems on implanted equipment (control cohort), without infection* Patient of this group are follow-up until surgery.
~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
16313541|NCT04583241||Group osteomyelitis|"Patients with chronic hematogenous osteomyelitis* Patient of this group are follow-up until surgery.
~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
16313542|NCT04583241||Control Group with cruciate ligament surgery|Patients having cruciate ligament surgery Patient of this group are follow-up until surgery.
16313543|NCT04583228|Experimental|Sequence 1|Random allocation to HLX71 2.5 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
16313544|NCT04583228|Experimental|Sequence 2|Random allocation to HLX71 5 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
16313545|NCT04583228|Experimental|Sequence 3|Random allocation to HLX71 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
16313546|NCT04583228|Experimental|Sequence 4|Random allocation to HLX71 15 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
16313547|NCT04583215|Active Comparator|Active PAS|After completing the N-back and PAS-EEG at Visit 3, MCI participants randomized to the active condition will receive a 10-session course of PAS (Visits 4-13), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
16313548|NCT04583215|Sham Comparator|PAS-Control (PAS-C)|After completing the N-back and PAS-EEG at Visit 3, MCI participants randomized to the sham condition will receive a 10-session course of PAS-C (Visits 4-13), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
16313549|NCT04583215|No Intervention|Healthy Control|Healthy Controls will complete screening and baseline N-Back and PAS-EEG. They will not complete the 10-session course of PAS or follow-up assessments.
16313550|NCT04583202|Placebo Comparator|Placebo exposure|All patients undergo 2 placebo exposures
16313551|NCT04583202|Experimental|Birch Pollen Exposure|All patients undergo 4 allergen exposures
16313552|NCT04583189|Other|Test rapid antigenic and Test RT-PCR|
16313553|NCT04583163||Neuro-critical Care Patients|"Up to 12 subjects will be recruited over a 1 year period. Patients enrolled in the study are recruited from the pool of neuro-critical care patients admitted to the surgical intensive care unit (SICU).
~To meet study inclusion, transcranial Doppler (TCD) testing will be ordered as part of the standard of care for these patients. The test will not be ordered solely for research purposes. There are no known side effects from the non-invasive measurement of cerebral blood flow using ultrasound.
~Three different TCD technicians will perform triplicate readings on 3 consecutive days on up to 12 patients already undergoing TCD as ordered by their treating team. Standard of care on specific neuro critical care patients (such as cerebral aneurysms) is to undergo daily TCD monitoring to assess for possible vasospasm. Patients will be in the supine position while measurements are obtained. The probe will be placed in the preauricular region of the temporal window."
16313554|NCT04583150||Obese women with planned surgery (BS group)|Obese women with planned BS procedure in standard care
16313555|NCT04583150||Obese women with no planned surgery (control group)|Obese women matched for age and BMI who did not undergo surgery
16313556|NCT04583137|Experimental|Buffered lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution combined with bicarbonate 8.4% in a 1:10 ratio.
16313557|NCT04583137|Experimental|Plain lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution.
16313558|NCT04583124|Experimental|ATENTO-B|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed before the begining of medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).
~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
16313590|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
16313559|NCT04583124|Active Comparator|ATENTO-T|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed throughout medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).
~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
16313560|NCT04583111|Experimental|Domperidone group|Patients in Domperidone group took 10mg of domperidone 30min before PEG.
16313561|NCT04583111|Experimental|Sulpiride group|Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.
16313562|NCT04583111|No Intervention|Control group|Patients in Control group followed the regular routine of 3L split-dose of PEG.
16313563|NCT04583098||carbapenem-resistant Enterobacteriaceae|
16313564|NCT04583098||vancomycin-resistant Enterococci|
16313565|NCT04583085||CP + CHD group|This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
16313566|NCT04583085||CP group|25 patients with chronic periodontitis who were systemically healthy were selected
16313567|NCT04583085||HP group|25 patients who were systemically and periodontally healthy, were considered as HP group.
16313572|NCT04583059|Experimental|Taping Group|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lower end of the shank. Second step involved application of the stirrup. During this step, the foot was held in neutral, and the tape applied to pass from the medial side of the ankle, under the foot just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. The second step was repeated to apply the second stirrup. Both ends of the stirrups were firmly attached to the anchor tape applied during the first step and this attachment was reinforced with a locking tape during the third and final step by once again applying the tape circumferentially just above the malleolar level at the lower end of the shank. Taping was applied by a physical therapist according to the health association requirements
16313573|NCT04583059|Experimental|Bandaging Group|Standard 10 cm width elastic bandage was used. The elastic bandage was wrapped around the ankle joint to form an 8-figure shape starting from the forefoot. Then, the bandage was taken diagonally upwards, steeply enough to go well above the heel. Then, the bandage was taken around the lower calf area to form an anchor. Then its diagonally taken down across the midfoot. Again the bandage was wrapped around the forefoot and going diagonally up to finish off around the lower calf, leaving the heel open. During the bandage application process, the therapiest didn't stretch the bandage, because bandage does note need to be stretched during the application, as the bandage becomes naturally tight when its layers wraped over each others. the participant was asked to wear his/her sport shoes over the bandage during the measurement procedures.
16313574|NCT04583046|Placebo Comparator|placebo|normal saline inhalation group
16313575|NCT04583046|Experimental|iloprost group|iloprost inhalation group
16313576|NCT04583033|Experimental|Cognitive Behavioral Therapy (CBT) Group|Participants will receive CBT intervention bi-weekly for total of six (6) sessions.
16313577|NCT04583033|No Intervention|Control Group|Participants will not receive any intervention as part of the study.
16313578|NCT04583020|Experimental|Neoadjuvant PD-1 inhibitor|Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
16313579|NCT04582994||Young participants|"30 young participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:
~Day 1. Beta tACS (22Hz)
~Day 2. Alpha tACS (10 Hz)
~Day 3. Sham tACS"
16313580|NCT04582994||Old participants|"30 old participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:
~Day 1. Beta tACS (22Hz)
~Day 2. Alpha tACS (10 Hz)
~Day 3. Sham tACS"
16313583|NCT04582968|Experimental|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Fractionated stereotactic radiotherapy(FSRT) or whole brain radiation therapy (WBRT) Drug: Pyrotinib combined with capecitabine pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
16313584|NCT04582955|Experimental|Arm A|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
16313585|NCT04582942|Placebo Comparator|PEG (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will only be PEG.
16313586|NCT04582942|Experimental|PEG+lactulose (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will be PEG combined with lactulose.
16313587|NCT04582929|Experimental|50 unit of Neubotulinum Toxin Type A (Neuronox)|50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
16313588|NCT04582929|Experimental|100 unit of Neubotulinum Toxin Type A (Neuronox)|100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
16313589|NCT04582916|Other|One Arm|All subject receive the same tests
16313591|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current),typically but not always supported by a positive PCR test for viral RNA
16313592|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavyor extensive COVID-19 exposure in the workplace or home environment
16313593|NCT04582877|Other|FFR Measurement in Intermediate-Grade Coronary Stenosis|Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).
16313595|NCT04582851||Postgraduate students|prevalence of TMD among postgraduate students.
16313596|NCT04582838||Spontaneous breathing ICU non-COVID|"Spontaneously breathing non-COVID-19 critically ill patients with sinus rhythm.
~Inclusion and exclusion criterion are listed elsewhere."
16313597|NCT04582838||Spontaneous breathing ICU COVID|"Spontaneously breathing COVID-19 critically ill patients with sinus rhythm.
~Inclusion and exclusion criterion are listed elsewhere."
16313598|NCT04582812|Experimental|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training|
16313599|NCT04582812|Active Comparator|Isolated high-intensity inspiratory muscle training|
16313600|NCT04582799|Active Comparator|Standard of Care (NIV)|Patients in the control group will be treated with non-invasive ventilation only.
16313601|NCT04582799|Experimental|Extracorporeal CO2 Removal (NIV+ECCO2R)|Patients in the treatment group will be treated with non-invasive ventilation combined with Extracorporeal CO2 Removal.
16313602|NCT04582786|Active Comparator|Standard group|Standard treatment (morphine) administered according to usual practice
16313603|NCT04582786|Experimental|Test group: Infusion with bolus|STR-324 or morphine HCl infusion started with a initial bolus
16313604|NCT04582786|Experimental|Test group: Infusion without bolus|STR-324 or morphine HCl infusion started without a initial bolus
16313605|NCT04582760|Experimental|early mobilization Arm|In addition to conventional bedside physical therapy, the mobilization program will be administered for 30 mins per session, two sessions per day, 7 days per week, until the patients are discharged from the ICU.
16313606|NCT04582760|No Intervention|non-early mobilization Arm|Conventional bedside physical therapy will be administered for 30 mins per session, one session per day, 5 days per week (only on working days), until the patients are discharged from the ICU.
16313607|NCT04582747||Major abdominal Surgery patients|Major Abdominal Surgery Patients
16313608|NCT04582734|Experimental|Intervention group - cognitive behavioral therapy|The intervention consists of three parts: 1) screening of hospitalised and outpatient cardiac patients at four university hospitals using the Hospital Anxiety and Depression Scale (HADS), scores ≥8 are invited to participate. (2) Assessment of type of anxiety by Structured Clinical Interview for DSM Disorders (SCID). (3) Investigator-initiated randomised clinical superiority trial with blinded outcome assessment, with 1:1 randomisation to cognitive-behavioural therapy (CBT) performed by a cardiac nurse with CBT training, plus usual care or usual care alone.The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
16313609|NCT04582734|No Intervention|Usual Care group|The usual care group (control group) will receive usual care which consists cardiac disease control and treatment.
16313610|NCT04582721|Active Comparator|CON-SCS with subcutaneous stimulation|7 days Conventional Spinal Cord Stimulation with subcutaneous stimulation
16313611|NCT04582721|Active Comparator|HF-SCS|7 days High Frequency Spinal Cord Stimulation
16313612|NCT04582721|Active Comparator|Combination Therapy|7 days a combination of CON-SCS with subcutaneous stimulation and HF-SCS
16313613|NCT04582708|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after abdominal surgery.
16313614|NCT04582695|Active Comparator|Written Exposure Therapy|
16313615|NCT04582695|Experimental|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|
16313616|NCT04582669|Placebo Comparator|Sodium Chloride 0.9%|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
16313617|NCT04582669|Active Comparator|Intralesional Triamcinolone 10 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
16313618|NCT04582669|Experimental|Intralesional Triamcinolone 20 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
16313619|NCT04582669|Experimental|Intralesional Triamcinolone 40 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
16313620|NCT04582656|Experimental|Targeted microwave ablation|Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
16313621|NCT04582643|Experimental|6P intervention|6P assessment along with education provided based on the 6P components.
16313622|NCT04582630||Omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
16313623|NCT04582630||Control (standart)|Standart medical nutrition therapy
16313628|NCT04582604|Experimental|Ruxolitinib combined with Decitabine|Ruxolitinib and Decitabine conditioning regimen All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Decitabine. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), decitabine (20 mg/m2/day, days -15 to -10), cytarabine (4 g/m2/day, days -10 to -9 (for unrelated donors or haploidentical donors; and 4 g/m2/day, days -9 for sibling donors)), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4);carmustine(BCNU)(250mg/m2/day, day -3),
16313629|NCT04582591|Experimental|Cannabidiol|Patients will receive cannabidiol in conjunction with their standard chemotherapy treatment
16313630|NCT04582578|No Intervention|Control Group|The control group will be treated with practice guideline optimal medical therapy for HF.
16313631|NCT04582578|Experimental|BiV-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
16313632|NCT04582578|Experimental|CS-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
16313633|NCT04582565|Active Comparator|Control group|Control group will have standard of care, consisting of verbal and written information on lymphoedema prevention and standard access to breast care nurse.
16313634|NCT04582565|Experimental|Combination product|Decongestive lymphatic therapy (DLT). DLT group will involve manual lymphatic drainage with a trained manual lymphatic drainage therapist.
16313635|NCT04582552||Ovarian cancer patients treated with PARP inhibitors|PARP inhibitors therapy until disease progression
16313636|NCT04582539|Experimental|INCB000928|INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
16313637|NCT04582526|Experimental|Intervention arm|BMS program
16313638|NCT04582513||Pre-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed according to current hospital standard without a standardized checklist.
16313639|NCT04582513||Post-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed after implementation of the AnCHor-CHecklist, a standardized checklist based on the SBAR concept.
16313640|NCT04582500||patients undergoing CTC receiving iohexol|Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for clinical purposes. They will be given 50 ml of Iohexol as a oral contrast
16313641|NCT04582487|Other|Biological evaluation|A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.
16313642|NCT04582474|Experimental|Dengue module and rapid diagnostic tests|
16313643|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region abdomen|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
16313644|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region upper arm|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
16313645|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region thigh|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
16313646|NCT04582435|Experimental|Insulin icodec|Participants will receive individualised weekly doses of insulin icodec
16313647|NCT04582422|Experimental|Touch Therapy|"The main purpose is to provide Touch Therapy intervention measures, the degree of fear of dental treatment for preschool children.
~Use the chip chip tool (PCT) to ask the children's degree of fear of dental treatment. The control group uses questionnaires to ask the caregiver's age, social and economic status, education, past dental experience, etc. In the intervention group, the questionnaire was used to ask the caregiver's age, socioeconomic status, education, past dental experience, etc. During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation , Ask the children how scared they are after seeing a doctor,"
16313648|NCT04582422|No Intervention|dental education|The Chip Chip Tool (PCT) asked the children how scared they were about dental visits. The control group used questionnaires to ask the caregiver 's age, socioeconomic status, education, past dental experience, etc. before the visit to provide routine dental care, provide dental health education, how to use toothbrush Dental floss education,
16313651|NCT04582396|Experimental|Stellate Ganglion Block + Psychoeducation|For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
16313652|NCT04582396|Placebo Comparator|Normal saline injection + Psychoeducation|For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
16313653|NCT04582383|Experimental|Spironolactone|In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
16313654|NCT04582383|Active Comparator|Doxycycline hyclate|This arm is an active-comparator arm in which participants will receive doxycycline hyclate 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
16313655|NCT04582370|Experimental|Theater program|"The design of the 10-week theater program is based on the principles of acting as written and practiced by Constantin Stanislavski in his revolutionary text on acting: An Actor Prepares [Stanislavsky C, 1989]. The exercises target concentration, voice, physical skills, emotion memory, observation, and dramatic analysis and include 3 components: 1. Preparation for the Actor (which involves relaxation , collaboration, movement, posture, and vocality; 2. Learning the Components of the Repeatable Acting Process (which involves physicality, attention, and concentration); and 3. Synthesizing Components into Characterization (which involves creativity and emotional expression).
~Each of these components will be addressed during each of 20 sessions through the use of group warm ups, group ensemble exercises, and group recitations. Participants will perform physical, mental, and emotional exercises similar to those given to beginning acting students in traditional theater schools."
16313656|NCT04582370|No Intervention|Wait-list control|During the study period, the control group will not receive any type of intervention. However, they will be offered the same theater program experience after the primary data collection period ends.
16313657|NCT04582357|Experimental|Exercise arm|This arm is the only arm of the study, every patient is included in this arm, the patients will follow the physical activity program
16313658|NCT04582344|Experimental|SARS-COV-2 Vaccine|600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
16313659|NCT04582344|Placebo Comparator|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
16313660|NCT04582331||COVID-19 positive|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 positive status is confirmed by diagnostic testing and clinical diagnosis.
16313661|NCT04582331||COVID-19 negative, symptomatic|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 negative status is confirmed by diagnostic testing and clinical diagnosis.
16313662|NCT04582331||Normal Healthy Volunteers|Asymptomatic healthy participants recruited from hospital staff or co-living family members, or co-living family member of a COVID-19 positive study participant.
16313663|NCT04582318|Experimental|Part 1 Dose Level 1 - Active|
16313664|NCT04582318|Placebo Comparator|Part 1 Dose Level 1 - Placebo|
16313665|NCT04582318|Experimental|Part 1 Dose Level 2 - Active|
16313666|NCT04582318|Placebo Comparator|Part 1 Dose Level 2 - Placebo|
16313667|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 1 - Active|
16313668|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 1 - Placebo|
16313669|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 2 - Active|
16313670|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 2 - Placebo|
16313671|NCT04582305|Active Comparator|Bleomycin jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
16313672|NCT04582305|Placebo Comparator|Placebo jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
16313673|NCT04582279|Experimental|Receiving Ultrasound|Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
16313676|NCT04582253||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:
~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
16313677|NCT04582253||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
16313678|NCT04582253||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
16313679|NCT04582227||The ETT group|Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.
16313680|NCT04582227||The LMA group|The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.
16313681|NCT04582214|Experimental|OLE Therapy with The MetaNeb® System|Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.
16313721|NCT04581915|Experimental|Interventional|Participants to receive Triazavirin 250mg po 8 hourly for 5 days
16313722|NCT04581915|Placebo Comparator|Control|Participants to receive placebo po 8 hourly for 5 days
16313682|NCT04582214|No Intervention|Control Group|The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.
16313683|NCT04582201|Experimental|Dosage and Cohorts|"Cohort 1 100 × 10^6 iNKT Cohort 2 300 × 10^6 iNKT Cohort 3 1000 × 10^6 iNKT
~Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized patients as a single IV infusion."
16313684|NCT04582175||group A|patients who received complete revascularization by angioplasty during the PPCI
16313685|NCT04582175||Group B|patients who underwent complete revascularization by angioplasty in a staged procedure
16313686|NCT04582162|Experimental|Unsplinted implants|
16313687|NCT04582162|Active Comparator|Splinted implants|
16313688|NCT04582149|Experimental|EyeControl Eye-tracking Device|Ventilated ICU patients using the EyeControl wearable, eye-tracking device.
16313689|NCT04582136|Experimental|Sirolimus plus SOC|Sirolimus plus standard therapy (SOC) for SLE; Generic name: sirolimus (0.5mg capsule); Dosage: 1.5mg/day; Administration route: Oral
16313690|NCT04582136|Placebo Comparator|Placebo plus SOC|Placebo plus standard therapy (SOC) for SLE; Drug: Placebo comparator plus SOC; Administration route: Oral
16313691|NCT04582123|Other|comparison of two cross pin fixation methods|Fixation of supracondylar humerus fractures with 2 crossed pins and 3 crossed pins are compared in terms of Flynn's criteria
16313692|NCT04582110||Patients with Beta Thalassemia|Patients with previous diagnosis of Beta Thalassemia
16313693|NCT04582110||Control Group|Healthy fellow eyes without actual and previous ocular trauma
16313694|NCT04582097|Experimental|Ramipril|Ramipril, 2.5 mg daily, administered orally for 16 weeks
16313695|NCT04582097|Placebo Comparator|Placebo|Placebo, matched for the interventional drug, administered orally, daily for 16 weeks
16313696|NCT04582084||Autoimmune Arthritis|Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings
16313697|NCT04582071|Experimental|Arm 1 (Psychotherapy, Intervention arm)|Subjects undergoing a 3 step IPAA will receive the four sessions of psychotherapy preceding and following their first surgery only, and receive an additional set of questionnaires again after their third surgery.
16313698|NCT04582071|No Intervention|Arm 2 (Non-Therapy, Control Arm)|Subjects will receive questionnaires which will be administered remotely via telemedicine if patient and psychologist/ research team member are unable to meet in person.
16313699|NCT04582058|No Intervention|Control Group (CG)|Control Group (CG): Standard of care, normally follow up, without mobile health
16313700|NCT04582058|Experimental|Interventional Group (IG)|Interventional Group (IG): Mobile Health to patients with an orientation about daily activities and protocol of physical exercise
16313701|NCT04582045||low risk, silver impregnated|low risk, silver impregnated
16313702|NCT04582045||low risk, border bandage|low risk, border bandage
16313703|NCT04582045||high-risk, silver impregnated|high-risk, silver impregnated
16313704|NCT04582045||high-risk, wound vacuum|high-risk, wound vacuum
16313705|NCT04582032|Active Comparator|Dexketoprofen group,|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in dexketoprofen group were administered intravenous dexketoprofen (50 mg/2ml) and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
16313706|NCT04582032|Other|Saline group|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in control group were administered intravenous 2 ml of saline and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
16313707|NCT04582019|Active Comparator|Patients with polyurethane DJ stent|Polyurethane DJ stent, 6Fr. The stent will be removed using flexible cystoscopy.
16313708|NCT04582019|Active Comparator|Patients with polyurethane DJ stent with magnet|Polyurethane DJ stent with magnet (Blackstar, Urotech), 7Fr. The stent will be removed under ultrasound control using a magnetic retriever
16313709|NCT04582006||LSG|Patients undergoing laparoscopic sleeve gastrectomy.
16313710|NCT04582006||LRYGB|Patients undergoing laparoscopic Roux-en-Y gastric bypass.
16313711|NCT04581993|Experimental|Intervention|Pregnant and lactating women (PLW) will receive Super Cereal - wheat soya blend with sugar and children aged 6-23 months will receive lipid-based nutrient supplement-medium quantity (LNS-MQ). Social and behavior change communication (SBCC), community mobilization, referrals, identification of model families, food demonstrations, local recipe) ration/beneficiary entitlement cards will be provided for easy verification and tracking during delivery of intervention.
16313712|NCT04581993|No Intervention|Control|Control districts will receive routine health care services available in the study area.
16313716|NCT04581954|Active Comparator|Standard of care|
16313717|NCT04581954|Active Comparator|Fostamatinib|
16313718|NCT04581954|Active Comparator|Ruxolitinib|
16313719|NCT04581941||Patients with essential tremor|Patients with essential tremor who have clinically been deemed candidates for DBS (Deep Brain Stimulation) surgery. Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses. This intervention is not part of the study. The investigators are going to recruit patients who receive the Medtronic Percept device, which allows for brain signal recordings (this feature is FDA approved). The investigators will be conducting an observational study using this device to collect data that the subjects receive as standard of care.
16313720|NCT04581928||COVID-19|Highly educated people Low educated people
16313723|NCT04581902|Experimental|Morning rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
16313724|NCT04581902|Experimental|Afternoon rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
16313725|NCT04581889||Children|Children from1 to 18 years, enrolled in kindergartens, primary, or secondary school located in city of Tübingen, Germany.
16313726|NCT04581889||Adult comparator|Adults of unknown status of previous SARSCoV-2 infection.
16313727|NCT04581889||Adult validation|Adults who report a history of SARS-CoV-2 infections between 1. February 2020 and the time point of sampling.
16313728|NCT04581876|Experimental|raltitrexed for injection + nab-paclitaxel|Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
16313729|NCT04581863|Active Comparator|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
16313730|NCT04581863|Experimental|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
16313733|NCT04581811|Experimental|Prolonged Proning Arm|Patients will receive 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study
16313734|NCT04581811|Active Comparator|Traditional Proning Arm|Patients will receive standard 16 hour prone positioning followed by 8 hours in the supine position for the duration of the study
16313735|NCT04581798||OSA|Patients with OSA confirmed by polysomnography, aged 35-65
16313736|NCT04581798||Non-OSA|Patients without OSA aged 35-65
16313737|NCT04581785|Experimental|Dose Level 1 Part A|3 year-olds to12 year-olds
16313738|NCT04581785|Experimental|Dose Level 1 Part B|6 month to 2 year-olds
16313739|NCT04581785|Experimental|Dose Level 2 Part A|3 year-olds to12 year-olds
16313740|NCT04581785|Experimental|Dose Level 2 Part B|6 month to 2 year-olds
16313741|NCT04581772|Experimental|Cohort A|
16313742|NCT04581772|Experimental|Cohort B|
16313743|NCT04581772|Experimental|Cohort C|
16313744|NCT04581759|Experimental|RIPC|Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after endovascular treatment while in-hospital.
16313745|NCT04581759|Sham Comparator|foundational treatment group (FT)|Patients in the FT group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs, during the study period without remote ischemic postconditioning after endovascular treatment.
16313746|NCT04581746|Other|experimental arm|questionnaire and follow-up visit
16313747|NCT04581733|Experimental|Single Arm|Male and female Participants <18 years
16313748|NCT04581720|Experimental|Participants|The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
16313749|NCT04581707||Kyphoplasty Single Balloon Catheter Allevo|
16313750|NCT04581707||Quattroplasty Double Balloon Catheter Stop'n GO|
16313751|NCT04581694|Experimental|TAVI without contrast|
16313752|NCT04581681|Experimental|Group CBT for Perinatal Anxiety|Using cognitive-behavioural therapy principles, this group therapy is intended to treat perinatal anxiety.
16313753|NCT04581681|Active Comparator|Waitlist Control|This is a control condition in which patients are randomly assigned to the waitlist control condition before receiving the treatment.
16313754|NCT04581668|Other|Neurally adjusted ventilatory assist first|Ventilation in NAVA mode then ventilation in conventional mode
16313755|NCT04581668|Other|Conventional ventilation first|Ventilation in conventional mode then ventilation in NAVA mode
16313756|NCT04581629|Experimental|CLTX-305|CLTX-305 (encaleret) dose finding study to determine safety, tolerability and dose response during three (3) periods and a long term extension of this study with dose levels at QD and BID; up to 41 months of active treatment per participant
16313757|NCT04581616|Active Comparator|ICNB group|After patient was turned to lateral decubitus position, local anesthetics is injected around incision site and ICNB is performed once after surgeon geys into chest cavity.
16313758|NCT04581616|Experimental|ESPB group|After patient was turned to lateral decubitus position, ESPB is performed via ultrasound guided technique before sound incision.
16313759|NCT04581603|Active Comparator|TOP + CBT-I|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Cognitive Behavioral Therapy for Insomnia (CBT-I) and TOP for the next 8 weeks.
16313760|NCT04581603|Placebo Comparator|TOP + SHE|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Sleep Hygiene Education (SHE) and TOP for the next 8 weeks.
16313761|NCT04581590|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training + cognitive training.
16313762|NCT04581590|Sham Comparator|Sham group|In the group G2 will be administered: tDCS active + dual-task motor training
16313763|NCT04581577||Adult patients with neuromuscular or neurological disorders|Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders
16313764|NCT04581577||Parents of paediatric patients with neuromuscular or neurological disorders|Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders
16313765|NCT04581564|Experimental|Rhythm intervention|
16313766|NCT04581564|Active Comparator|Non-rhythm intervention|
16313767|NCT04581551|Experimental|Stroke group|"SWE for 6 shoulder muscles will be performed by 2 assessors in randomised order.
~m. supraspinatus
~m. infraspinatus
~m. rhomboideus major
~m. deltoideus
~m. pectoralis major
~m. pectoralis minor"
16313768|NCT04581551|Active Comparator|Healthy controls|"SWE for 6 shoulder muscles will be performed by 1 assessors.
~m. supraspinatus
~m. infraspinatus
~m. rhomboideus major
~m. deltoideus
~m. pectoralis major
~m. pectoralis minor"
16313769|NCT04581538|No Intervention|Control group|This arm is being provided with continued home care as it was before
16313770|NCT04581538|Experimental|E-learning platform & networking platform|This arm is being provided with the e-learning platform and networking platform as components of the 24-h-quAALity package
16313771|NCT04581538|Experimental|Entire intervention|This arm is being provided with the entire intervention (e-learning platform, networking platform and digital care documentation)
16313772|NCT04581525|Experimental|tDCS of DLPFC|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left dorsolateral prefrontal cortex (DLPFC). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
16313773|NCT04581525|Experimental|tDCS of M1|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
16313774|NCT04581525|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Subjects will undergo stimulation once a day for 10 consecutive weekdays.
16313776|NCT04581499|Experimental|DynamiCare Motivation Support Program|Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.
16313777|NCT04581499|Other|Untreated or Routine Care Control Group|Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.
16313778|NCT04581486|Experimental|OMI intervention|Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
16313779|NCT04581486|Other|Control intervention (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
16313780|NCT04581473|Experimental|CT041 autologous CAR T-cell injection|This study will be divided into three phases, phase Ib dose exploration phase and dose extension phase and phase II effectiveness and safety confirmation phase.
16313781|NCT04581460||Patients|Patients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy
16313782|NCT04581447|Experimental|Metformin + Standard care|"The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).
~All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups."
16313948|NCT04580199|Active Comparator|total thyroidectomy|excision of thyroid gland
16313783|NCT04581447|Other|Standard Care|All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.
16313784|NCT04581434|Experimental|Trauma-Focused Therapy|Patients randomized to Trauma Focused Therapy will receive either Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT). According to standard VA practice, assignment will be determined according to which trauma-focused therapy the assigned provider is verified to provide; if the assigned therapist is verified in both PE and CPT, the provider will decide which treatment to deliver. PE and CPT are both recommended as frontline treatments by all published PTSD guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted.
16313785|NCT04581434|Experimental|Non-Trauma-Focused Therapy|"Those randomized to non-trauma-focused therapy will receive present centered therapy (PCT). Originally designed as a strong comparator for psychotherapy research that included the components of good therapy, PCT is now a bona-fide PTSD treatment suggested at the second tier in multiple clinical practice guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted."
16313786|NCT04581421|Experimental|High Carb first|
16313787|NCT04581421|Experimental|Low Carb first|
16313788|NCT04581408|Experimental|Orkambi|"Generic name: Lumacaftor/Ivacaftor
~Dosage form: tablet
~Dosage: each tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor
~Frequency: two tablets twice a day."
16313789|NCT04581395|Other|Not pretreated|Succinylcholine administration with no Rocuronium pre-treatment
16313790|NCT04581395|Active Comparator|Pre-treated 1 minute before succinylcholine administration|Succinylcholine administration 1 minute following Rocuronium pre-treatment
16313791|NCT04581395|Active Comparator|Pre-treated 2 minutes before succinylcholine administratjion|Succinylcholine administratjion 2 minutes following Rocuronium pre-treatment
16313792|NCT04581382|Experimental|Treatment (radiation therapy, plasma exchange, immunotherapy)|Patients undergo radiation therapy daily on days 1-5 (weekdays). Patients then undergo therapeutic plasma exchange over 1-2 hours on days 4-6 or 5-7. Beginning on day 7, patients receive pembrolizumab IV or nivolumab IV. Treatment with pembrolizumab continues every 3 weeks or treatment with nivolumab continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
16313796|NCT04581356|Experimental|voxelotor|Voxelotor 1500mg daily orally
16313797|NCT04581343|Experimental|Canakinumab, spartalizumab, nab-paclitaxel and gemcitabine|Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.
16313798|NCT04581330|Experimental|DEKA SmartXide C02 laser|One half of the subject's neck will be treated with ablative fractional CO2 laser.
16313799|NCT04581330|No Intervention|Control|The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.
16313800|NCT04581317|Experimental|Phase 1 (meals only)|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.MOW will once a week deliver in-person enough frozen meals to cover lunch for 5 days and breakfast for 7 days. Study staff will call the participants twice a week to ask 5 questions about their health, mood, and meal consumption.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure Fried Frailty Phenotype(FFP), MHS, CES-D, MOCA, Activities of Daily Living (ADL)/Instrumental activities of daily living(IADL)s, NSI, and ZCBI. Caregivers will not receive meals during this first phase as the focus is on the nutritional status of the cognitively impaired older adult.
16313801|NCT04581317|Experimental|Phase 2 (Meals + Amazon Echo Show 8 (AES 8) basic usage)|Participants will have meals delivered and the AES device installed for basic usage
16313802|NCT04581317|Experimental|Phase 3 (meals + AES 8 advanced )|Participants will have meals delivered and the AES device installed for advanced usage
16313803|NCT04581304|Experimental|Bio-Oss Collagen|Transcrestal approach sinus augmentation using Geistlich Bio-Oss Collagen®.
16313804|NCT04581304|Active Comparator|Bio-Oss Granules|Transcrestal approach sinus augmentation using Geistlich Bio-Oss®.
16313805|NCT04581291|Experimental|Intervention group|
16313806|NCT04581291|Experimental|Control group|
16313807|NCT04581265|Experimental|nab-PTX, ifosfamide and cisplatin|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.
16313808|NCT04581239|Active Comparator|Active neural mobilization|Therapist supervised active neural mobilization of sciatic nerve in lumber radiculopathy patients
16313809|NCT04581239|Experimental|passive neural mobilization|Therapist done passicive neural mobilization of sciatic nerve in lumber radiculopathy patients
16313810|NCT04581226|Experimental|Lung ultrasound|Sonographic assessments including the lung consolidation score, B-line score and Lung aeration score will be recorded 1min. after intubation, at end of surgery and 2h postoperatively.
16313813|NCT04581174|Experimental|1st degree of hypertrophy according to Camacho|Patients with 1st degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
16313814|NCT04581174|Experimental|2nd degree of hypertrophy according to Camacho|Patients with 2nd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
16313815|NCT04581174|Experimental|3rd degree of hypertrophy according to Camacho|Patients with 3rd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
16313816|NCT04581174|Experimental|4th degree of hypertrophy according to Camacho|Patients with 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
16313817|NCT04581161|Experimental|Life2000® Ventilator|Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.
16313818|NCT04581161|No Intervention|Control Group|Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record.
16313823|NCT04581135||COVID-19 Lung|COVID-19 survivors in Switzerland
16313824|NCT04581122|Experimental|Selective lymphadenectomy|
16313825|NCT04581122|No Intervention|Systematic lymph node dissection|
16313826|NCT04581109|Experimental|Patients with metastatic prostate cancer|
16313827|NCT04581083||Volunteer participants|Samples of volunteer participants will be collected after informed consent and classified as symptomatic, asymptomatic and negative.
16313828|NCT04581057|Experimental|First CVE|
16313829|NCT04581031|Other|Wearable monitors - Isansys Patient Status Engine|All patients will wear the continuous vital sign monitoring sensors.
16313830|NCT04581018|Active Comparator|Health supplements + standard care|28 days of health supplements (Synbiotic) daily plus standard care
16313831|NCT04581018|No Intervention|Standard care|No intervention
16313832|NCT04581005|Experimental|Supervised Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.
~This group will receive a supervised, in-hospital training."
16313833|NCT04581005|Experimental|Home-based Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.
~This group will receive a home-based training."
16313834|NCT04580992||Ajmaline group|
16313835|NCT04580979||Patients with ferredoxin reductase deficiency|Male and female patients from age 2 to age 65 with clinically confirmed FDXR mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
16313836|NCT04580966|Experimental|Inquiry Based Stress Reduction (IBSR) workshop|Participants of this group received an IBSR intervention workshop.
16313837|NCT04580966|No Intervention|Control group|Participants of this group did not take a part in the workshop.
16313838|NCT04580953|Experimental|Treatment with CardiaCareTM RR2|
16313839|NCT04580940||Subjects with complex pancreaticobiliary disease|All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.
16313840|NCT04580927|Experimental|Randomized to breastfeeding self-efficacy enhancing intervention with nurse|Participants receiving breastfeeding self-efficacy enhancing nurse-led intervention plus postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
16313841|NCT04580927|No Intervention|Randomized to usual postpartum care|Participants receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
16313842|NCT04580927|No Intervention|Non-randomized observational arm|Participants who are not planning to breastfeed receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
16313843|NCT04580914|Experimental|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
16313844|NCT04580901|Experimental|Group interpersonal psychotherapy|Group IPT consists of 12 weeks of virtually-delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions, with the first 12 sessions taking place twice weekly (acute phase) for 6 weeks and the last 3 sessions occurring every other week (maintenance phase) for 6 weeks.
16313845|NCT04580901|No Intervention|Usual care|Usual care refers to any care that the women wish to access, and there are no limits on the women in either group. It may include, but is not limited to, the family physician, obstetrician, and/or midwife, participation in regional standard perinatal depression programming, private therapy, online therapies, medication, etc.
16313846|NCT04580888|Experimental|Intervention arm|Assessment using an early transthoracic echocardiography (after 500 mL of fluids) to identify the hemodynamic profile responsible for the acute circulatory failure associated with sepsis / septic shock and to guide ongoing treatment (therapeutic algorithm) and monitor its efficacy and tolerance.
16313847|NCT04580888|Other|Control arm|Conventional management according to current standards of care based on SSC recommendations, including a standardized fluid resuscitation of 30 mL/kg.
16313848|NCT04580875|Active Comparator|Minimally invasive surgery (laparoscopy, laparoscopic-assisted procedures)|This study will be conducted out at 3 pediatric surgery tertiary centers (Al-Azhar University hospitals in Cairo, Prince Mohammed bin Abdulaziz Hospital in Riyadh and Maternity & Children's Hospital in Bisha) on patients aged from 1-14 years presenting to the ER by stable penetrating abdominal trauma with significant clinical/radiologic findings, in the period from April 2017 to March 2022. Responders to initial resuscitation will be managed by minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures). All patients enrolled in the study will give a written informed consent even for possible conversion to laparotomy if necessary.
16313849|NCT04580875|Active Comparator|Conservative management|patients aged from 1-14 years presenting to the ER by penetrating abdominal trauma with imsignificant findings will be managed conservatively.
16313850|NCT04580862|Experimental|group 1 Non-surgical endodontic retreatment in single visit|Single visit treatments have gained more popularity. Completing the treatment in a single appointment has many advantages including reduction in treatment time and cost, lower risk of micro leakage and recontamination of root canals between appointments
16313851|NCT04580862|Active Comparator|group 2 Non-surgical endodontic retreatment in Two-visit|Two-visit endodontic treatment with intra-canal medication was traditionally found to be effective in decreasing the number of flare-up in all retreatment cases and in reducing postoperative pain of previously symptomatic teeth
16313852|NCT04580849|Experimental|telerehabilitation with dance (Parkinson's)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
16313853|NCT04580849|Active Comparator|telerehabilitation with dance (Healthy controls)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
16313854|NCT04580836|Experimental|Treatment (MRI-guided SBRT)|Patients undergo an MRI scan to check the status and location of the disease, including the motion of the tumor during breathing. Two weeks after MRI, patients undergo SBRT over 1-2 hours on 3 non-consecutive weekdays in the absence of disease progression or unacceptable toxicity.
16313855|NCT04580823|No Intervention|Control|Fasting without exogenous ketone salt supplement
16313856|NCT04580823|Experimental|Fasting with exogenous ketone salt supplement|Fasting with exogenous ketone salt supplement
16313857|NCT04580823|Experimental|Post-Prandial with exogenous ketone salt supplement|Post-Prandial with exogenous ketone salt supplement
16313858|NCT04580810|Experimental|CBT4CBT in the Black Church|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:
~Understanding and changing patterns of alcohol use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
16313859|NCT04580810|No Intervention|Community Based Treatment as Usual|Treatment as usual, typically groups, offered by a specialty community based treatment center (MCCA)
16313860|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR1_fed|Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4
16313861|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR1_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4
16313862|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR1_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4
16313863|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR2_fed|Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
16313864|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR2_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4
16313865|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR2_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
16313866|NCT04580797|Experimental|PF-06700841 MR3 (Dose A) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition
16313867|NCT04580797|Experimental|PF-06700841 MR3 (Dose B) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition
16313868|NCT04580797|Experimental|PF-06700841 MR3 (Dose C) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition
16313869|NCT04580784|Experimental|Hypofractionation|Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.
16313870|NCT04580771|Experimental|Treatment (radiation therapy, cisplatin, PDS0101)|Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
16313871|NCT04580758|Active Comparator|Fractional laser with PRP fluid|Fractional CO2 laser then the PRP is injected afterwards
16313872|NCT04580758|Active Comparator|Fractional laser with PRP gel|Fractional CO2 laser then the PRP gel is injected afterwards
16313873|NCT04580745|Experimental|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.
~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.
~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
16313874|NCT04580745|Experimental|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.
~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
16313875|NCT04580732|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
16313876|NCT04580732|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
16313877|NCT04580719||Patiente|Patients aged 18 to 50, presenting menstrual cycles, consulting in the obstetrics and gynecology department of the University Hospital of Reims whatever the reason for consultation can participate in the study after signing the consent of no opposition. Participation in the study will not change the patient's medical management.
16313878|NCT04580693||Healthy Volunteers/Control|Age and body surface area (BSA) matched volunteers who are sedentary or normally active. Normally active is defined as less than 5 hours of exercise per week. Healthy volunteer subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
16313879|NCT04580693||Hypertrophic Cardiomyopathy/HCM|HCM subjects are patients that are age and BSA-matched with the athletes who then have an established clinical diagnosis of HCM without left ventricular (LV) outflow tract obstruction. There can be no anticipated changes to baseline exercise program (if any) over the study period. HCM subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
16313880|NCT04580693||Endurance Athletes|Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
16313881|NCT04580667||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from normal tissues shortly after the start of radiotherapy provides an early indication of patients at high risk of radiation-related toxicity. Blood specimens for RadTox test will be collected: (a) prior to radiotherapy (T0); (b) after the 2nd but before the 4th radiotherapy dose during week 1 (T1); (c) on Week 2 during radiotherapy (T2); and (d) 3 months after completion of radiotherapy (T3).
16313882|NCT04580654|Experimental|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
16313883|NCT04580654|Experimental|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
16313884|NCT04580654|Experimental|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
16313885|NCT04580654|Experimental|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
16313886|NCT04580654|Experimental|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
16313887|NCT04580641||Subjects with migraine|No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.
16313888|NCT04580615|Experimental|Inpatients subjects|Inpatients subjects diagnosed with a Respiratory disease/impairment or subjects with no known Respiratory disease/impairment
16313889|NCT04580602||ADR Group|Major Bleeding BARC Bleeding Criteria Type 2,3,5
16313890|NCT04580602||Control Group|No ADR or treatment failure, case-control matched to experimental groups
16313891|NCT04580602||Treatment Failure Group|Major Adverse Cardiovascular Events (MACE)
16313892|NCT04580589||Adverse Drug Reaction on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience major bleeding or clinically relevant non-major bleeding per International Society of Thrombosis and Haemostasis criteria. This is an observational study, so there will be no intervention.
16313893|NCT04580589||Treatment Failure on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience treatment failure (e.g., recurrent MI, systemic embolism, ischemic stroke, etc.). This is an observational study, so there will be no intervention.
16313894|NCT04580589||Case Control|Participants on Direct Oral Anti-coagulants (DOACs) who experience neither major bleeding or treatment failure.
16313895|NCT04580576||Female group|Pediatric female patients undergoing hematopoietic stem cell transplantation
16313896|NCT04580576||Male group|Pediatric male patients undergoing hematopoietic stem cell transplantation
16313897|NCT04580563|Experimental|Experimental group|"The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.
~OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
16313898|NCT04580563|Placebo Comparator|Control group|The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.
16313899|NCT04580550|Other|Axial length variability|Aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of AL.
16313900|NCT04580537|Experimental|Laser-assisted Enstilar delivery|Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
16313901|NCT04580537|Active Comparator|Enstilar|Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
16313902|NCT04580524|Active Comparator|Phasix Mesh|Phasix mesh will be used in the repair of the hernia
16313903|NCT04580524|Active Comparator|Current Care|The hernia will be repaired with either synthetic mesh or suture repair, as determined by the operating surgeon.
16313904|NCT04580498|Experimental|Treatment group A|SHR-1701+Paclitaxel+carboplatin
16313905|NCT04580498|Experimental|Treatment group B|SHR-1701
16313949|NCT04580199|Active Comparator|hemi thyroidectomy|excision half of thyroid gland
16313950|NCT04580199|Active Comparator|ethanol ingection|ingection of ethanol into thyroid nodule under guidance of ultrasound
16313906|NCT04580485|Experimental|Treatment Group A (TGA) - INCB106385|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.
~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
16313907|NCT04580485|Experimental|Treatment Group B (TGB) - INCB106385+INCMGA00012|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.
~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
16313908|NCT04580472|Placebo Comparator|Placebo - leg|If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.
16313909|NCT04580472|Experimental|Antibiotic- leg|The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered
16313910|NCT04580472|Placebo Comparator|Placebo- nose|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.
16313911|NCT04580472|Experimental|Antibiotic- nose|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
16313912|NCT04580472|Placebo Comparator|Placebo- ear|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.
16313913|NCT04580472|Experimental|Antibiotic- ear|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
16313914|NCT04580459|Experimental|CARE Parenting Group Treatment|Participants receive the CARE mentalizing-focused group parenting intervention.
16313915|NCT04580459|Other|Treatment as Usual (TAU)|Participants continue to receive treatment as usual in the outpatient child mental health clinic.
16313916|NCT04580446|Experimental|Hypofractionated radiotherapy with concurrent chemotherapy (weekly cisplatin 40 mg/m2)|"Level 1: 44.4 Gy in 12 fractions, 4 fractions/week
~Level 0: 46.5 Gy in 15 fractions, 5 fractions/week
~Level -1: 52 Gy in 20 fractions, 5 fractions/week"
16313917|NCT04580433|Experimental|Time-Restricted Feeding|Participants will receive 16:8 TRF.
16313918|NCT04580420|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
16313919|NCT04580407|Experimental|TAK-672|TAK-672 will be administered at an initial dose of 200 U/kg with intravenous infusion at a rate of 1-2 mL/min. Subsequent doses will be determined based on the post-infusion factor VIII activity (FVIII:C) achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer (when available)
16313920|NCT04580394|Experimental|AD109|Oral capsule administered before sleep
16313921|NCT04580394|Active Comparator|Atomoxetine|Oral capsule administered before sleep
16313922|NCT04580394|Active Comparator|R-oxybutynin|Oral capsule administered before sleep
16313923|NCT04580394|Placebo Comparator|Placebo|Oral capsule administered before sleep
16313924|NCT04580381||Standard Interval Dosing (SID)|Patients continuing Natalizumab treatment with standard interval dosing defined as > 11 infusions per year
16313925|NCT04580381||Extended Interval Dosing (EID)|Patients switching to extended interval dosing defined as ≤ 10 infusions per year
16313926|NCT04580368|Experimental|CFTR modulator or other therapies|CFTR modulator or active therapy
16313927|NCT04580355|Experimental|FMUD + Placebos|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
16313928|NCT04580355|Active Comparator|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
16313929|NCT04580342|Experimental|Ivabradine group|
16313930|NCT04580342|Experimental|propranolol group|
16313931|NCT04580329|Experimental|NMES group|
16313932|NCT04580329|Experimental|control group|
16313933|NCT04580316|Experimental|Experimental group|75 children were managed during intervention using Parental Active Presence.
16313934|NCT04580316|Placebo Comparator|control group|75 children were managed with passive parent presence.
16313935|NCT04580303|Active Comparator|Uniform 0.1-mL 1-Aliqout GRID Injection Technique|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
16313936|NCT04580303|Active Comparator|Uniform 0.3-mL 2-Aliquot GRID Injection Technique|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
16313937|NCT04580277|Experimental|Chronic pouchitis|This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks
16313938|NCT04580264|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
16313939|NCT04580251||Magnetic marker Magseed|Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.
16313940|NCT04580251||Iodine seed 125I marker|Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
16313941|NCT04580251||Carbon suspension|Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
16313942|NCT04580238|Experimental|Treatment Arm|The treatment group will consist of 40 patients randomly allocated to receiving Botox according to the treatment regime.
16313943|NCT04580238|Active Comparator|Control|The control group will consist of 40 patients randomly allocated to Non-Botox, standard of care treatments, to a total study population of 80 patients.
16313944|NCT04580225|Active Comparator|Group A: Partial Wrist Arthrodesis without Triquetral Excision|Four-Corner Arthrodesis
16313945|NCT04580225|Active Comparator|Group B: Partial Wrist Arthrodesis with Triquetral Excision|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
16313946|NCT04580212|Experimental|Intervention arm|
16313947|NCT04580212|No Intervention|Control arm|
16313951|NCT04580199|Active Comparator|monopolar radiofrequency|using radiofrequency for ablation of thyroid nodule
16313952|NCT04580199|Active Comparator|laser photocaugulation|using laser for ablation of thyroid nodule
16313953|NCT04580173||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
16313954|NCT04580173||0 < SYNTAX score <=22|Low SYNTAX group
16313955|NCT04580173||23<=SYNTAX score<=32|Intermediate SYNTAX group
16313956|NCT04580173||SYNTAX score>=33|High SYNTAX group
16313957|NCT04580160|Experimental|Duo Venous Stent System Implantation|
16313958|NCT04580147|Experimental|Intervention (serial IAI)|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
16313959|NCT04580147|Sham Comparator|Control|Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
16313960|NCT04580134|Experimental|Biotype 1 - Clozapine (B1C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
16313961|NCT04580134|Placebo Comparator|Biotype 1 - Risperidone (B1R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
16313962|NCT04580134|Active Comparator|Biotype 2 - Clozapine (B2C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
16313963|NCT04580134|Placebo Comparator|Biotype 2 - Risperidone (B2R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day
16313964|NCT04580121|Experimental|RO7283420 Part A|Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.
16313965|NCT04580121|Experimental|RO7283420 Part B|Multiple-participant cohorts of >= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A of RO7283420 once Q3W starting on C1D1 up to Cycle 6 to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). If needed, a step-up dosing regimen with more frequent administrations of RO7283420 during cycle 1 will be evaluated.
16313966|NCT04580121|Experimental|RO7283420 Part C|Participants will receive the respective RP2D for Group I and Group II.
16313967|NCT04580108||Patients with systemic lupus erythematosus|Patients with systemic lupus erythematosus enrolled in the PLUS cohort between 2007 and 2010
16313968|NCT04580095|Experimental|With AI algorithm|"In the With AI algorithm arm, the sonographer will perform the echocardiographic exam using the AI algorithm."
16313969|NCT04580095|No Intervention|Without AI algorithm|"In the Without AI algorithm, the echocardiographic exam will be performed without the use of the AI algorithm."
16313970|NCT04580082|Experimental|Mindfulness lessons|"There are 14 lessons in total, each lasting approximately 20 minutes. Participants will be asked to listen to one lesson per day for 14 consecutive days, but to allow for possible missed days, they will have up to 25 days to complete as many of these 14 lessons as they can. The lessons will be delivered via the internet, and participants can use a variety of devices (e.g. smartphone, desktop computer, laptop computer, tablet) to access them. While the lessons cannot be downloaded, they are available for streaming anytime and anywhere there is an internet connection. Participants are welcome to revisit any lesson they have listened to previously, but are not allowed to skip ahead to other lessons until they have completed all preceding lessons. This is done because the lessons build on one another, which means that skipping lessons makes continued participation difficult. We will be able to track each participant's usage pattern and will analyze differences across users."
16313971|NCT04580082|Other|Delayed-start Mindfulness Lessons|"The control group will not receive the intervention until the intervention group has completed lesson listening. During this waiting period, they will receive periodic emails letting them know that their turn to listen to lessons is coming soon.
~Once available, the control group will have 25 days to listen to the 14 lessons."
16313972|NCT04580069|Experimental|Lymphatic drainage|Patients subjected to manual lymphatic drainage
16313973|NCT04580069|Experimental|Connective tissue|Patients subjected to connective tissue massage
16313974|NCT04580069|Active Comparator|control group|Subjects hat followed standard rehabilitative treatment
16313975|NCT04580056||Incision Group|Women following IVF treatment with donor oocytes who underwent during hysteroscopy fundus endometrial scratching by incision, before embryo transfer.
16313976|NCT04580056||No incision Group|Women following IVF treatment with donor oocytes who underwent office hysteroscopy without fundus endometrial scratching by incision, before embryo transfer.
16313977|NCT04580043|Experimental|cTBS + Habit Override Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Habit Override Training.
16313978|NCT04580043|Active Comparator|Sham TBS + Habit Override Training|Sham Transcranial Magnetic Stimulation, paired with Habit Override Training.
16313979|NCT04580043|Active Comparator|cTBS + Sham Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Sham Training.
16313980|NCT04580043|Sham Comparator|Sham TBS + Sham Training|Sham Transcranial Magnetic Stimulation, paired with Sham Training.
16313981|NCT04580030||hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
16313982|NCT04580030||no hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
16313983|NCT04580004|Experimental|Medication Optimization Group|Patients randomized to the medication optimization group will receive an evidence-based medication recommendation intervention.
16313984|NCT04580004|No Intervention|Control Group|Patients in the control group will receive the same intervention, delayed 2 weeks after the intervention group. During those initial 2 weeks they will act as a control.
16313985|NCT04579991|Active Comparator|Active Group|Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
16313986|NCT04579991|Placebo Comparator|Placebo Group|Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
16313987|NCT04579978||Subjects with advanced solid tumors starting immunotherapy|Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors
16313988|NCT04579978||Subjects with advanced solid tumors receiving ICIs|Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors
16313989|NCT04579965|Other|combined contraceptive pills|treat patients with isthmocele with oral contraceptive pills
16313990|NCT04579965|Other|Misotac|treat patients with isthmocele with misotac.
16313991|NCT04579952|Experimental|Intervention Group|The IG will receive a 20 minute program of active tDCS (2mA intensity, anode placed on primary motor cortex controlateral to the TKA, cathode placed on controlateral supraorbital region) followed by a 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
16313992|NCT04579952|Placebo Comparator|Control Group|The CG will receive a 20 minute program of sham tDCS (15 seconds of activation and then no stimulation, same position of IG) followed by the same 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
16313993|NCT04579939|Experimental|Experimental|All 10 participants will go through the experimental arm receiving the dextrose candy oral glucose tolerance test.
16313994|NCT04579926|Experimental|Pinpoint App|Tablet and smartphone application.
16313995|NCT04579913||iTind subjects|Patient who participated previously in the MT-03 study in the iTind arm
16313996|NCT04579900|Experimental|Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
16313997|NCT04579900|Active Comparator|Non Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
16313998|NCT04579887|Experimental|Brain changes triggered by PH induction in Parkinson's disease|Clinical and neuropsychological evaluations + Sensorimotor task for PH-induction
16313999|NCT04579874|Experimental|LIVERFASt validation|blood draw for LIVERFASt
16314000|NCT04579861||High human development|Countries classified as very high and high human development as per the United Nations development programme.
16314001|NCT04579861||Low and medium human development|Countries classified as low and medium human development as per the United Nations development programme.
16314002|NCT04579848|Active Comparator|Methotrexate|"Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.
~Additional Folic acid 1mg prescribed daily."
16314003|NCT04579848|Placebo Comparator|Placebo|"3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.
~Additional Folic acid 1mg prescribed daily."
16314004|NCT04579822||Pregnant women vaccinated with a QIV|Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
16314005|NCT04579822||Pregnant women unvaccinated with a QIV|Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
16314006|NCT04579809|Active Comparator|children below six years|children below sex years both genders
16314007|NCT04579809|Active Comparator|cooperative children|repair of the tendos by modified kessler
16314008|NCT04579796|Experimental|women with first trimester missed abortion|
16314009|NCT04579783|Active Comparator|Ultrasound intracarpal corticosteroid injection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.
~1st injection (0 week): 40mg triamcinolone acetonide (40mg/mL ) with 4mL normal saline, 2nd injection (6 week): 5 mL normal saline"
16314010|NCT04579783|Active Comparator|Ultrasound guided intracarpal dextrose hydro-dissection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.
~Group B: 1st injection (0 week): 5 mL 5% dextrose, 2nd injection (6 week): 5 mL 5% dextrose"
16314011|NCT04579770|Placebo Comparator|Placebo|Only carbohydrates will be provided
16314012|NCT04579770|Experimental|Ketone ester|Ketone ester with carbohydrates will be provided
16314013|NCT04579770|Experimental|Ketone ester + bicarbonate|Ketone ester with bicarbonate and carbohydrates will be provided
16314014|NCT04579770|Experimental|Bicarbonate|Bicarbonate and carbohydrates will be provided
16314055|NCT04579497|Experimental|42° C footbath|Footbath with warm water at a constant temperature of 42° C
16314056|NCT04579497|Experimental|Rising temperature footbath|Footbath with warm water rising from 38° C to 42° C
16314017|NCT04579731||Fecal Impaction (LUTD-FI)|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
16314018|NCT04579731||Lower Urinary Tract Dysfunction Not Related to Fecal Impaction|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI). They serve as a control group.
16314019|NCT04579718||Eclipse|
16314020|NCT04579718||Zeus Cloud TPS V1.0|
16314021|NCT04579705|Experimental|Group I (Brushed-1 minute)|Surgical hand scrubbing will be performed in 1 minute using a brush.
16314022|NCT04579705|No Intervention|Group II (Brushless-1 minute)|Surgical hand scrubbing will be performed in 1 minute without using a brush.
16314023|NCT04579705|Experimental|Group III (Brushed-2 minutes)|Surgical hand scrubbing will be performed in 2 minute using a brush.
16314024|NCT04579705|No Intervention|Group IV (Brushless-2 minutes)|Surgical hand scrubbing will be performed in 2 minute without using a brush.
16314025|NCT04579692|Experimental|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called central lateral thalamic nucleus. Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
16314026|NCT04579679|Experimental|Surufatinib|"Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
~Cohort D:
~Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1"
16314029|NCT04579653|Experimental|Group A: Experimental|Within-subjects design with a randomization of the order of tVNS administered parameters
16314030|NCT04579653|Active Comparator|Group B: Active Comparator|Within-subjects design with a randomization of the order of tVNS administered parameters
16314031|NCT04579640|No Intervention|Control|Standard of care (national recommendation of 400 IU/day vitamin D)
16314032|NCT04579640|Experimental|Intervention: Lower-dose vitamin D|Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
16314033|NCT04579640|Experimental|Intervention: Higher-dose vitamin D|Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
16314034|NCT04579627||Hospital Doctors|Hospital doctors working at Royal Cornwall Hospital during the COVID-19 pandemic
16314035|NCT04579614|Active Comparator|Organizational Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own, and with the organizational target. These updates and targets are sent bi-weekly."
16314036|NCT04579614|Experimental|Achievable Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a static and achievable target based on their previous year's flu vaccination success rate."
16314037|NCT04579614|Experimental|Variable|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a variable target that will fluctuate bi-weekly, based on their previous bi-weekly flu vaccination success rate."
16314038|NCT04579601||ERAS group|We recruited 50 patients throughout 2018 and 2019, patients undergoing thoracic surgery within an ERAS program
16314039|NCT04579601||Standard group|A group of 50 patients selected randomly prior the implementation of the ERAS program, in 2016.
16314040|NCT04579588||COVID-19 participants|
16314041|NCT04579588||Control participants|
16314042|NCT04579562||COVID-19 positive AKI|
16314043|NCT04579562||COVID-19 positive no AKI|
16314044|NCT04579562||COVID negative AKI|
16314045|NCT04579549|Experimental|Repeat Testing for SARS-CoV-2|Anyone over the age of 5yrs old with consent to provide a saliva sample for SARS-CoV-2 assay will be eligible to participate. Assay takes 20 minutes.
16314046|NCT04579536|Experimental|Study group|This is the study group; it will consist of 84 first permanent molars. These molars will be sealed using light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA). reapplication will be done after 3,6, 12, and 18 months.
16314047|NCT04579536|Other|Control group|This group will consist of 84 first permanent molars. These molars will receive 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA). These molars will serve as a control group. reapplication will be done after 3,6, 12, and 18 months.
16314048|NCT04579523|Experimental|Arm A (²¹¹At-OKT10-B10, fludarabine, TBI, HCT)|Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 IV on day -7 (day -10 to -5) and fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo TBI and allogeneic HCT on day 0.
16314049|NCT04579523|Experimental|Arm B (²¹¹At-OKT10-B10, chemotherapy, TBI, HCT)|Patients with HLA-matched haploidentical donors receive ²¹¹At-OKT10-B10 IV on day -8 (day -14 to -7), fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on day -6 and -5. Patients then undergo TBI on day -1 and allogeneic HCT on day 0.
16314050|NCT04579510|Active Comparator|nOPV2 only|Participants in this arm will receive nOPV2 at 6, 10, and 14 weeks of age
16314051|NCT04579510|Active Comparator|nOPV2 and bOPV|Participants in this arm will receive both nOPV2 and bOPV at 6, 10, and 14 weeks of age
16314052|NCT04579510|Active Comparator|bOPV only|Participants in this arm will receive bOPV at 6, 10, and 14 weeks of age
16314053|NCT04579497|Experimental|38° C footbath|Footbath with warm water at a constant temperature of 38° C
16314054|NCT04579497|Experimental|40° C footbath|Footbath with warm water at a constant temperature of 40° C
16315944|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 tablets at Dose 3
16314057|NCT04579471||Transplanted patients|All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven
16314058|NCT04579471||Transplanted patients with past SARS-CoV-2 infection|Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity
16314059|NCT04579471||Transplanted patients without past SARS-CoV-2 infection|100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection
16314060|NCT04579458||COVID-19 Positive|COVID-19 positive in nasopharyngeal swabs and tears or saliva.
16314061|NCT04579445||TAVI patients|Consecutive, severe aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) (there will be a retrospective part: documentation of 30 patients who underwent TAVI; and a prospective part enrolling 50 patients undergoing TAVI)
16314062|NCT04579432|Experimental|Training Group|
16314063|NCT04579432|No Intervention|Control Group|
16314064|NCT04579419|Experimental|Sodium Bicarbonate|
16314065|NCT04579419|Placebo Comparator|Normal Saline|
16314066|NCT04579406||non-diabetic group|The non-diabetic patients undergoing non-cardiac surgery.
16314067|NCT04579406||Diabetic group|The diabetic patients without peripheral neuropathy undergoing non-cardiac surgery.
16314068|NCT04579406||Diabetic neuropathic group|The diabetic patients with peripheral neuropathy undergoing non-cardiac surgery.
16314069|NCT04579393|Active Comparator|Intervention|fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
16314070|NCT04579393|Placebo Comparator|Intervention - Placebo|Placebo in combination with standard of care (SOC) for the treatment of COVID-19
16314073|NCT04579354|No Intervention|Standardized Anaesthesia briefing|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia. This corresponds to the current procedure before an operation.
16314074|NCT04579354|Experimental|Virtual reality (VR) tour|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia.Subsequently, the patients are shown a virtual tour of the operation using VR glasses. This includes the way through the clinic to the operating theatre: Admission -> inpatient preparation for the operation -> administration of premedication -> way to the operating theater -> OP preparation (holding) -> safe surgery
16314075|NCT04579341|Active Comparator|probiotics arm|probiotics administered in addition to insulin regimen
16314076|NCT04579341|No Intervention|control|regular insulin regimen
16314077|NCT04579328|Experimental|Lessons with Growth Mats|Participants, clustered by neighbor groups, will be given lessons on stunting. During the lessons the trainers will use the growth mats to demonstrate their points. In these villages, village-wide events will expose the full community to the messages in combination to the mats.
16314078|NCT04579328|No Intervention|Lessons without Mats|Participants, clustered by neighbor groups, will be given lessons on stunting without the aid of the growth mats. In these villages, village-wide events will expose the full community to the messages without the aid of the mats.
16314079|NCT04579315|Active Comparator|Intervention group, NNRD group|"Main principles of the interventional whole food approach are:
~Maximum of 850 mg phosphorous/day
~Protein: 0.8 g/kg/day
~80% vegetable products; 20% animal products
~Maximum of 5-7 g NaCl/day (table salt)
~Fresh raw products
~Seasonal oriented
~Fish: At least once a week
~Vegetarian: At least once a week
~Wide range of fruit and vegetables
~Easy to follow in daily practice
~Rich in flavors
~Sufficient content of micro- and macronutrients"
16314080|NCT04579315|No Intervention|Control group|There is no intervention, patients are following their habitual diet
16314081|NCT04579302|Experimental|serratus anterior block|serratus anterior block with 20 ml bupivacaine
16314082|NCT04579302|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
16314083|NCT04579302|Sham Comparator|control group|sham block with 20 ml saline
16314084|NCT04579276|Experimental|"surgical method"|
16314085|NCT04579276|Active Comparator|"anesthetic method"|
16314086|NCT04579263|Experimental|Patient with diabetes mellitus type 1 (T1DM)|Treatment by transplantation of fecal microbiota
16314087|NCT04579263|Experimental|Patient with diabetes mellitus type 2 (T2DM)|Treatment by transplantation of fecal microbiota
16314091|NCT04579237||1/All Subjects|Data will be derived from primary studies on all subjects.
16314122|NCT04578990|No Intervention|Control group|It will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level.
16314123|NCT04578951||Patients receiving a prosthesis from the FHK® range|
16314095|NCT04579211||Adults with a diagnosis of CF with history of negative NTM sputum cultures|Male or female participants age 18 or greater at time of enrollment with diagnosis of CF consistent with the 2017 CFF Guidelines and NTM culture status of negative, as defined by a review of at least 3 year or more years of culture data and at least 3 NTM negative cultures with one of those negative cultures being within the last 3 years and no known history of previous positive cultures for pathogenic NTM by chart review.
16314096|NCT04579198|Experimental|Families receiving intervention|
16314097|NCT04579185|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
16314098|NCT04579172|Experimental|Group A|Circular isthmic-cervical sutures
16314099|NCT04579172|Experimental|Group B|Resection of the infiltrated part of anterior uterine wall
16314100|NCT04579159|Other|only control group|To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
16314101|NCT04579146||HIV-1 patients and treated effectively for more than 12 months|X-ray examination with contrast by a 64-slice CT coronary angiography.
16314102|NCT04579133|Experimental|durvalumab plus olaparib|Durvalumab 1500 mg IV week 0, 3, 6 plus Olaparib tablets will be given orally on a continuous dosing schedule 300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min) to complete 9 weeks of treatment.
16314103|NCT04579133|Experimental|durvalumab alone|Durvalumab 1500 mg IV week 0, 3, 6 to complete 9 weeks of treatment
16314104|NCT04579120||African American|African American participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
16314105|NCT04579120||Non-Hispanic White|Non-Hispanic White participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
16314106|NCT04579107|Other|Contrast Enhanced Mammography|All included women go through a Contrast Enhanced Mammography added to the standard of care examinations.
16314107|NCT04579094||1/elderly dependent persons|
16314108|NCT04579094||2/healthcare workers (HCW)|
16314109|NCT04579068|Experimental|Screening and Brief Intervention of Problematic Alcohol Use|We plan to test the feasibility and effectiveness of the delivery of the peer-based SBIRT using the RAPS4-QF screening tool with CDU students. Furthermore, we will compare delivery by AAPLs' race/ethnicity, drinking status (abstainer vs. non-abstainer), and adverse life experiences. Following the screening by AAPLs, we expect a 30% detection of problematic alcohol use (i.e. high episodic drinking [HED] or AUD) and at-risk alcohol use. Participants that screen positive will receive brief motivational interviewing and referral to treatment and will be contacted 6 months following the SBIRT to assess their drinking behaviors. We expect that participants will decrease their alcohol consumption or drinking risk at the 6-month follow up.
16314110|NCT04579055|Experimental|1-min STS test: chair seat height adjusted to 90° knee flexion|In this experimental condition, the patient performs the 1-minute sit to stand test on an individually adjusted seat height of 90° knee joint flexion.
16314111|NCT04579055|Active Comparator|1-min STS test: chair seat height standardized of 46cm|In this experimental condition, the patient performs the 1-minute sit to stand test on a standard height chair of 46cm.
16314113|NCT04579029|Experimental|Surgical Cohort|"Patients randomised to the surgical group will undergo near infrared spectroscopy imaging to assess suitability and plan the surgical procedure.
~Limb measurements with perometry and bio-impedance spectroscopy will be performed at baseline. Under general anaesthetic multiple LVA bypass procedures will be performed on the affected arm. Near infrared spectroscopy imaging will be used throughout. One week after discharge the patient will return for the bandages to be removed and the wounds inspected for any evidence of infection before renewing the bandage. Again, two weeks after surgery, the patient will return for inspection of wound and removal of sutures. It is at this point that the surgical patients will be returned into a standard lymphoedema compression garment, fitted by the research nurse. Thereafter, standard follow up (Bilateral) measurements and checks will be done at 1 month, 3 months, 6 months and 1 year."
16314114|NCT04579029|No Intervention|Non-surgical cohort|"The main intervention for the non-surgical group largely encompasses limb measurements with perometry and bio-impedance spectroscopy at baseline before a compression garment is applied. The compression garments will be measured and fitted by a trained lymphoedema specialist and will be given the standard advice as is best practice for such patients currently. This cohort will likewise be followed up at 1 month, 3 months, 6 months and 1 year and undergo perometry readings and measurements with comparable collection of data.
~For patients in both surgical and non-surgical groups, the compression garments will be measured and fitted by a trained lymphoedema specialist and they will be given the standard advice as is best practice for such patients currently. For each patient key details of the surgical technique, garment specification, imaging results and perometry/BIS measurements will be recorded on a study specific form for subsequent entry onto the database."
16314115|NCT04579016|Active Comparator|Standard care|Standard care
16314116|NCT04579016|Experimental|PAIGE2 intervention|One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
16314117|NCT04579003|Experimental|Mobilization|Mobilization, heat application, ultrasound, TENS
16314118|NCT04579003|Active Comparator|Mobilization with movement|Mobilization with movement, heat application, ultrasound, TENS
16314119|NCT04578990|Experimental|Walking intervention group|It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.
16314120|NCT04578990|Experimental|Strength intervention group|The training program consists of performing a training program with resistance exercises for 36-72 weeks.
16314121|NCT04578990|Experimental|Concurrent intervention group|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.
16314124|NCT04578938|Experimental|Ketamine + Cognitive Training|
16314128|NCT04578925|Experimental|Happy, Healthy, Loved|"Both parents will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. For the next 6 weeks participants' will receive 4 personalized text messages per week based on their tablet survey responses. Participants will be asked one yes/no question each week (still breastfeeding? Text Y for yes, N for no). Once a no response has been received from a participant, all remaining text messages will emphasize coping and partner support rather than breastfeeding."
16314129|NCT04578925|No Intervention|Control|Control group participants will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. The control group participants will be sent 4 text messages per week for the first 6 weeks, but the content of the texts will be non-breastfeeding related. The content will instead summarize infant development facts.
16314130|NCT04578912|Active Comparator|CBIT + rTMS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with 1 Hz repetitive Transcranial Magnetic Stimulation (rTMS).
16314131|NCT04578912|Active Comparator|CBIT + cTBS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with continuous Theta Burst Stimulation (cTBS).
16314132|NCT04578912|Sham Comparator|CBIT + Sham|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with either a cTBS or rTMS sham treatment.
16314133|NCT04578899|Active Comparator|Transvertebral magnetic stimulation (Experimental group)|Experimental intervention will receive non-invasive transvertebral magnetic stimulation of the sacral spine roots (level S2-S3).
16314134|NCT04578899|Placebo Comparator|Transvertebral magnetic stimulation (Control group)|"Control group will receive an equivalent number of stimulation sessions using the placebo option."
16314135|NCT04578886|Placebo Comparator|Placebo|Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
16314136|NCT04578886|Experimental|Guanfacine|Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
16314137|NCT04578873|Experimental|QPX7831 SAD Cohorts|oral, single ascending dose (or placebo)
16314138|NCT04578873|Experimental|QPX7831 MAD Cohorts|oral, multiple ascending dose (or placebo)
16314139|NCT04578860|Active Comparator|Treatment as usual|Usual treatment of sleep disorders consist of adequate sleep hygiene entails the behaviors, practices, rituals, and habits.
16314140|NCT04578860|Experimental|Music Intervention|Using the app Music Care
16314141|NCT04578860|Placebo Comparator|White Noise|Using an app producing white noise (like rain, storm, fan, wind...)
16314142|NCT04578847|Experimental|The TKI dose reduction|Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
16314145|NCT04578821|Experimental|Deney group|"Education Program:The education program consists of theoretical didactic education, case discussion, film and video screening in class, Web-based laboratory work, SSI practice, poster preparation and awareness activities for a total of 12 weeks and 2 hours per week (24 hours per week).
~Theoretical didactic education, film screening, video screening, Web-based laboratory work, Social Security Institution study, poster preparation, poster presentation at University Campus."
16314146|NCT04578821|No Intervention|Kontrol group|The control group participated in the courses and practices included in the routine curriculum.
16314147|NCT04578795|Experimental|Pt underwent single use flexible ureteroscopy|Patients with renal stones who will operated by single use flexible ureteroscopy
16314148|NCT04578782|Experimental|BOTOX|155 UI of Botox were injected according to the approved PREEMPT protocol (the only FDA-approved injection pattern for chronic migraine), in 31 sites. From visit 5, the PREEMPT 'follow-the-pain' paradigm was applied in patients falling in the 'non-responder' or 'partial responder' classes after the first BoNT-A injection, with the possibility to increase the doses up to 195 UI in maximum 39 sites. The injections were every 3 months for 4 cycles
16314149|NCT04578769|Active Comparator|conventional myotomy|conventional myotomy for achalasia type I, II and III
16314150|NCT04578769|Experimental|short myotomy|modified myotomy (short myotomy) for achalasia type I and II
16314151|NCT04578769|Experimental|full-thickness myotomy|modified myotomy (full-thickness myotomy) for achalasia type I and II
16314152|NCT04578769|Experimental|tailored myotomy|modified myotomy (tailored myotomy) for achalasia type III
16314153|NCT04578756|Experimental|Cariprazine Dose 1|Participants with Schizophrenia 13 to 17 years will receive cariprazine.
16314154|NCT04578756|Experimental|Cariprazine Dose 2|Participants with Bipolar I Disorder, 10 to 12 years (weighing <=40 kg) will receive cariprazine.
16314155|NCT04578756|Experimental|Cariprazine Dose 3|Participants with Bipolar I Disorder, 10 to 12 years (weighing >40 kg) will receive cariprazine.
16314156|NCT04578756|Experimental|Cariprazine Dose 4|Participants with Bipolar I Disorder, 13 to 17 years will receive cariprazine.
16314157|NCT04578743|Experimental|Graded Exercise|ClearPlay(TM): a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, will provide a telemetry-based graded exercise program for 20 minutes each day, identifying a heart rate target that will be advanced weekly for up to 8 weeks as symptoms resolve.
16314158|NCT04578743|Experimental|Passive Stretching|ClearPlay(TM): we have created a passive stretching program (placebo arm) downloadable to an Apple i-touch or i-phone device, that will provide a telemetry-based guided passive stretching program for 20 minutes each day for up to 8 weeks as symptoms resolve.
16314159|NCT04578717|Experimental|Air-abrasion + Etch & rinse adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by etch&rinse adhesive application using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
16314197|NCT04578535|Experimental|Part 2 Treatment Arm 4: HYQVIA|Participants from part 2 of study in treatment arm 4 will receive SC infusion of HYQVIA 0.25 g/kg at week 1 and ramp up to full TDL (1.0 g/kg) at week 8.
16314160|NCT04578717|Experimental|Air-abrasion + Self-etch adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by self-etch adhesive application which was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
16314161|NCT04578717|Experimental|Etch & rinse adhesive|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
16314162|NCT04578717|Experimental|Self-etch adhesive|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
16314163|NCT04578704|Experimental|Vacuum formed retainer group|It will be constructed following manufacturer's instructions for the thickness.
16314164|NCT04578704|Experimental|Fixed bonded retainer group|fixed bonded wire will be bonded on individual tooth extended distal to extraction space that were previously closed by fixed appliances treatment.
16314165|NCT04578704|Experimental|Vacuum formed retainer and fixed bonded retainer|Double regime retainer that will be consisted of bonded retainer and vacuum formed retainer for upper and lower arch.
16314166|NCT04578691|Experimental|"Anatase Spine Surgery Navigation System"|"Using Anatase Spine Surgery Navigation System in pedicle screw placement in spine surgery"
16314167|NCT04578691|Active Comparator|Medtronic Stealthstation S7 Treatment Guidance System|Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery
16314168|NCT04578678||Apathy Group|Patients diagnosed with apathy
16314169|NCT04578678||Dysarthria Group|Patients diagnosed with dysarthria
16314170|NCT04578678||No Apathy and Dysarthria Group|Patients diagnosed with neither apathy nor dysarthria
16314171|NCT04578678||Apathy and Dysarthria Group|Patients diagnosed with apathy as well as dysarthria
16314172|NCT04578665|Experimental|Healthy Participants Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
16314173|NCT04578665|Experimental|Healthy Participants Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
16314174|NCT04578665|Experimental|Clinical Populations Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
16314175|NCT04578665|Experimental|Clinical Populations Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
16314176|NCT04578652|Active Comparator|MET|MET (850 mg po bid - standard of care) + Fiber placebo daily
16314177|NCT04578652|Active Comparator|FIBER|Fiber supplementation [35g fiber daily] + MET placebo po bid
16314178|NCT04578652|Experimental|FIBER + MET|Fiber supplementation [35g fiber daily] + MET 850 mg po bid
16314179|NCT04578639|Experimental|Rituximab|Rituximab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial dose; 1000 mg Subsequent doses; 500 mg
16314180|NCT04578639|Active Comparator|Ocrelizumab|Ocrelizumab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial and subsequent doses; 600 mg
16314181|NCT04578626|Experimental|dry needling group|Dry needling treatment on right or left side of the face (depending on randomization)
16314182|NCT04578626|No Intervention|control group|No treatment on left or right side of the face (depending on randomization)
16314183|NCT04578613|Experimental|ICP-022|ICP-022 will be orally administered until disease progression or unacceptable toxicity.
16314184|NCT04578613|Active Comparator|Chlorambucil combined with Rituximab|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles.
16314185|NCT04578600|Experimental|Treatment (lenalidomide, oral azacitidine, obinutuzumab)|Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16314186|NCT04578587|Active Comparator|Rater 1|Rater 1
16314187|NCT04578587|Active Comparator|Rater 2|Rater 2
16314188|NCT04578574|Experimental|BI-TDCS Stimulation Group|Participants in this group will receive the BI and TDCS interventions for 10 sessions over two weeks.
16314189|NCT04578574|Sham Comparator|BI-TDCS (Sham) Stimulation Group|Participants in this group will receive the BI and TDCS (Sham) interventions for 10 sessions over two weeks.
16314190|NCT04578561||Prophylactic mesh|Patients who received a prophylactic mesh after emergency surgery due to high risk of incisional hernia.
16314191|NCT04578561||Suture|Patients who's laparotomies closure was using only suture without any abdominal wall reinforcement
16314192|NCT04578548|Experimental|GLPG2737|GLPG2737 will be administered orally once daily with food for 52 weeks.
16314193|NCT04578548|Placebo Comparator|Placebo|Matching placebo will be administered orally once daily with food for 52 weeks.
16314194|NCT04578535|Experimental|Part 1 Treatment Arm 1: HYQVIA|Participants from part 1 of study in treatment arm 1 will receive subcutaneous (SC) infusion of HYQVIA 0.1 g/kg at week 1 and ramp up to full TDL (0.4 g/kg) at week 8.
16314195|NCT04578535|Experimental|Part 1 Treatment Arm 2: HYQVIA|Participants from part 1 of study in treatment arm 2 will receive SC infusion of HYQVIA 0.2 g/kg at week 1 and ramp up to full TDL (0.4 g/kg) at week 5.
16314196|NCT04578535|Experimental|Part 1 Treatment Arm 3: HYQVIA|Participants from part 1 of study in treatment arm 3 will receive SC infusion of HYQVIA 0.4 g/kg at week 1 without ramp-up dosing.
16314198|NCT04578535|Experimental|Part 2 Treatment Arm 5: HYQVIA|Participants from part 2 of study in treatment arm 5 will receive SC infusion of HYQVIA 0.5 g/kg respectively at week 1 and ramp up to full TDL (1.0 g/kg) at week 5.
16314199|NCT04578535|Experimental|Part 2 Treatment Arm 6: HYQVIA|Participants from part 2 of study in treatment arm 6 will receive SC infusion of HYQVIA 1.0 g/kg at week 1 without ramp-up dosing.
16314200|NCT04578509||Salicov|Ambulatory adults or children requiring screening for SARS-CoV-2 by nasopharyngeal swab
16314201|NCT04578509||SalicovII (ancillary study)|Ancillar study : Children and teachers / staff from middle and high schools in Ile de France Saliva samples is collected as part of care. Only a self-rated questionnaire is collected.
16314202|NCT04578496|Experimental|Afamelanotide|
16314203|NCT04578483||PCA group|Patients receiving patient-controlled analgesia (PCA) will be allocated to PCA group.
16314204|NCT04578483||ERDS group|Patients receiving one dose of extended-release dinalbuphine sebacate (ERDS) by ultrasound-guided muscle injection will be allocated to ERDS group.
16314205|NCT04578483||PRN group|Patients receiving analgesics other than ERDS and PCA will be allocated to PRN group.
16314206|NCT04578470|No Intervention|Group C|Patients with replete VitaminD levels (≥30ng/ml) will be serving as a control in group C. Group C will not receive any Vitamin D intervention for the entire 12- month study period but will receive dietary interventions.
16314207|NCT04578470|Experimental|Group A|Group A will be prescribed Vitamin D supplementation in the form of daily 2000 IU cholecalciferol (two tablets)for 13 weeks, and daily1000 IU cholecalciferol(1tablet) for another 13 weeks and then treatment will be discontinued but dietary interventions will continue across the 12-month study period.
16314208|NCT04578470|Placebo Comparator|Group B|Group B will be prescribed placebo of Vitamin D with two tablets daily for 13 weeks then 1 tablet daily for13 weeks then no treatment for 26 weeks but dietary interventions will continue across the 12-month study period.
16314209|NCT04578457|Active Comparator|Hearing Aid without NR(0) enabled|Hearing Aid without Noise Reduction (NR 0) enabled serves as reference condition.
16314210|NCT04578457|Experimental|Hearing Aid with NR (1)|Hearing Aid with Noise Reduction I (NR) enabled.
16314211|NCT04578457|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
16314212|NCT04578457|Experimental|Hearing Aid with NR(3)|Hearing Aid with Noise Reduction III (NR) enabled.
16314213|NCT04578431|Experimental|Intervention groups|The participants will be given a beverage containing four artificial sweeteners (intervention) at baseline
16314214|NCT04578418|Active Comparator|Collagen + heavy slow resistance group|Daily collagen supplementation + heavy slow resistance training three times weekly for 12 weeks.
16314215|NCT04578418|Experimental|Placebo + heavy slow resistance group|Daily placebo supplementation + heavy slow resistance training three times weekly for 12 weeks.
16314216|NCT04578405|Active Comparator|Extracorporeal anastomosis|
16314217|NCT04578405|Experimental|Intracorporeal anastomosis|
16314218|NCT04578392|Active Comparator|high ligation of ileocolic artery|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
16314219|NCT04578392|Active Comparator|mesenteric sparing for a primary ileocolic resection|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
16314220|NCT04578366|Experimental|Shockwavetherapy Group/Experimental group|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
16314221|NCT04578366|Active Comparator|Conventional Group|Conventional therapy hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
16314222|NCT04578353|Experimental|AquaPass System|Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
16314223|NCT04578327|Experimental|Aim 1|Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
16314224|NCT04578327|Experimental|Aim 3|Data from Specific Aim 3 will be used to test the following hypotheses: H3a. The maximum number of channels elicits more embodiment than the minimum number. H3b. The sensory feedback from passive spatial locations of the hand increases the embodiment compared to sensory feedback just from the grasping spatial locations.
16314225|NCT04578314|Experimental|Relating module + Treatment as usual|Participants in this arm will receive 16 weekly sessions with Relating Therapy (RT) over 5 months in addition to their treatment as usual.
16314226|NCT04578314|Active Comparator|Treatment as usual|Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include Cognitive Behavior Therapy or psychodynamic interventions.
16314227|NCT04578301||Surgery|Patients with and without liver cirrhosis undergoing surgery.
16314228|NCT04578288|Active Comparator|Standard Blood Pressure management|The standard blood pressure management is maintenance of intraprocedural pre-recanalization SBP between 140-180 mmHg for all patients who receive endovascular thrombectomy for acute ischemic stroke in anterior circulation.
16314229|NCT04578288|Experimental|Individualized Blood Pressure management|The study intervention would be maintaining the intraprocedural pre-recanalization blood pressure in individualized SBP target ranges depending on the systolic blood pressure of the patient at presentation (=baseline SBP or bSBP).
16314230|NCT04578262|Experimental|Epley Manoeuvre|Epley manoeuvre in participants with Multiple Sclerosis who suffer from benign paroxysmal positional vertigo. Only one administration.
16314231|NCT04578262|Sham Comparator|Sham Manoeuvre|The second group will received a sham manoeuvre. However after the experimental intervention ends, this groups will also receive Epley manoeuvre.
16314232|NCT04578249|Placebo Comparator|Clear goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, or CABG MVR surgery will be given clear goggles to wear at nighttime.
16314233|NCT04578249|Experimental|Blue-light blocking goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, or CABG MVR surgery will be given blue-light blocking goggles to wear at nighttime.
16314234|NCT04578236|Experimental|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
16314235|NCT04578236|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
16314236|NCT04578223||Study group|Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.
16314237|NCT04578223||Control group|Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.
16314238|NCT04578210|Experimental|Arm A: allogeneic T memory cells|patients will receive memory T cells
16314239|NCT04578210|Experimental|Arm B: allogeneic NK cells|patients will receive NK cells
16314240|NCT04578184|Other|Epithelial thickness map evaluation in keratoconus patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
16314241|NCT04578184|Other|Epithelial thickness map evaluation in healthy cornea patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
16314242|NCT04578171||Study population|Subjects with severe asthma treated with mepolizumab
16314243|NCT04578158|Active Comparator|Standard of care|This arm will receive the standard COVID-19 care as per the hospital physician guidelines.
16314244|NCT04578158|Experimental|Quercetin Phytosome|This arm will receive standard COVID-19 care + Quercetin Phytosome
16314245|NCT04578145|Other|Female sex workers (FSW)|Female sex workers (FSWs) community is the only group which has implemented the study intervention. This group has been underlined as the one of key affected populations (KAPs) that hold an increasing number of HIV incidence and prevalence recently in Indonesia even though it is approximately 226,791 FSWs by 2016 and around 5,254,065 clients access their services per year (MoH, 2017). The condition will be worst because the transmission definitely will continue to clients' sexual partner and moreover, their babies if their HIV status has not been known earlier. It means that lowering the transmission of HIV infection for FSWs, it will simultaneously lower its transmission to their sexual partners and furthermore their babies.
16314246|NCT04578132||Genitourinary cancer patients that suffered COVID-19|Patients diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ) that suffered from COVID-19 infection prior to cancer treatment, during treatment, or after treatment.
16314247|NCT04578119|No Intervention|Conventional Intubating Technique|'Conventional technique' means that endotracheal intubation is performed with the videolayngoscope blade lifting up the epiglottis.
16314248|NCT04578119|Experimental|Sliding Intubating Technique|'Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
16314249|NCT04578106|Experimental|Omission of surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
16314250|NCT04578106|No Intervention|Surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
16314253|NCT04578080|Experimental|Anodal-tDCS & PT|"Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere.
~Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
16314254|NCT04578080|Experimental|Cathodal-tDCS & PT|"Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the supraorbital area of affected hemisphere, Cathodal on the motor area (M1) of unaffected hemisphere.
~Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
16314255|NCT04578080|Active Comparator|Sham-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area of affected hemisphere, Cathodal on the supraorbital area of affected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity.
16314256|NCT04578067|Experimental|Intervention|culturally tailored intervention package on changes in lifestyle-habits
16314257|NCT04578067|No Intervention|Control|
16314258|NCT04578041|Experimental|Arm 1: TRPMS + Aerobic Physical Activity Program|
16314260|NCT04578028|Experimental|ONO-2808 Part A - Fasted|Single ascending dose of ONO-2808 or placebo orally under fasted conditions
16314261|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part A- Fasted|Single ascending dose of ONO-2808 or placebo orally under fasted conditions
16314262|NCT04578028|Experimental|ONO-2808 Part A - Fed|Single dose of ONO-2808 or placebo orally under fed conditions
16314263|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part A - Fed|Single dose of ONO-2808 or placebo orally under fed conditions
16314264|NCT04578028|Experimental|ONO-2808 Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
16314265|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
16314266|NCT04578028|Experimental|ONO-2808 Part C|Multiple ascending doses of ONO-2808 or placebo orally
16314267|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part C|Multiple ascending doses of ONO-2808 or placebo orally
16314268|NCT04578028|Experimental|ONO-2808 Part D|Single or multiple doses of ONO-2808 or placebo in Japanese healthy volunteers
16314269|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part D|Single or multiple doses of ONO-2808 or placebo in Japanese healthy volunteers
16314270|NCT04578015|Active Comparator|Metronidazole 500 mg|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
16314271|NCT04578015|Placebo Comparator|Placebo|Participants in this arm will receive placebo
16314272|NCT04577963|Experimental|Part 1|Approximately 6-12 patients will be enrolled to receive fruquintinib in combination with tilelizumab and assessed for DLTs during the 28-day DLT observation period
16314273|NCT04577963|Experimental|Part 2|"Approximately 60 patients with TNBC will be enrolled, up to 30 patients in each cohort. Patients will be enrolled to one of the following two cohorts:
~Cohort A (TNBC, IO-Treated): Patients must have advanced TNBC who have progressed on at least one cytotoxic therapy in the metastatic setting. Patients must have also received prior therapy with an immune checkpoint inhibitor.
~Cohort B (TNBC, IO-Naïve): Patients must have advanced TNBC who have progressed on at least one cytotoxic therapy in the metastatic setting. Patients must not have received prior therapy with an immune checkpoint inhibitor."
16314274|NCT04577950|Experimental|Arm with procedure: identification of lymphatic drainage of the uterus following 3 sites injections|A radiocolloid (Nanocoll® marked with Technetium 99), a fluorochrome (ICG) and a blue dye (Bleu Patenté®) will be injected in submucosal tissue to see the differences in lymphatic drainage between three different injection sites. Indeed, ICG will be injected under the endometrium, whereas Nanocoll® will be injected in the cervix and Bleu Patenté® in the uterine isthmus, at the transition between the cervix and the uterine corpus.
16314275|NCT04577937|Experimental|PSG in LAM patients|Patients affected by LAM underwent whole-night PSG
16314276|NCT04577924||Road traffic injury victims|"All RTI patients presenting to ED within 24 hours of injury is included in the study..
~Individual's not consenting to be part of the study or withdrawing consent later on would be excluded. We also would exclude cases where pre-hospital care provider could not be traced or where reliable data patient could not be collected even after repeated interview."
16314277|NCT04577885|Experimental|experimental group|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
16314278|NCT04577872|Experimental|Supine group (n=22)|The 22 participants with lower muscle strength (under 60 microvolt) comprised the supine group.
16314279|NCT04577872|Experimental|Sitting group (n=19)|The 19 participants with higher muscle strength (over 60 microvolt) formed the sitting group.
16314280|NCT04577872|No Intervention|Control group (n=14)|The control group comprised 7 individuals with lower muscle strength (under 60 microvolt) and 7 with higher muscle strength (over 60 microvolt)
16314281|NCT04577859|Active Comparator|Study group|Those randomized to the study group will receive the esophageal cooling device- the ensoETM probe, during AF ablation treatment, under general anaesthetic. The cooling device is set to 4 degrees covering ablation of the left atrial posterior wall.
16314282|NCT04577859|Active Comparator|Control group|Those randomized to the control group will receive standard of care, which is an esophageal temperature monitoring probe during their AF ablation procedure, under general anaesthetic. The esophageal temperature probe is sited close to the level of ablation (the probe should be at the esophageal level where, opposite this, the ablation catheter is at, in the endocardial aspect of the posterior left atrium).
16314283|NCT04577846|Active Comparator|Intervention Arm|The intervention arm will be administered, either Cefazolin iv every 8 hours while NPO or cefalexin 500 mg q8 hours per oral if tolerating a diet.
16314284|NCT04577846|Placebo Comparator|Control|Controls will be provided with initially IV placebo while NPO and then with a placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
16314285|NCT04577833|Experimental|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
16314286|NCT04577833|Experimental|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
16314287|NCT04577833|Experimental|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
16314288|NCT04577833|Experimental|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
16314289|NCT04577820|Experimental|garetosmab|
16314290|NCT04577807|Experimental|Arm 1: PVSRIPO Only|PVSRIPO (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions given every 3 or 4 weeks
16314291|NCT04577807|Experimental|Arm 2: PVSRIPO and anti-PD-1|PVSRIPO (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions and anti-PD-1 therapy given every 3 or 4 weeks as per the anti-PD-1 approved package insert
16314292|NCT04577794|Experimental|GLPG3970|Participants will receive GLPG3970 solution, orally, once daily for 6 weeks
16314293|NCT04577794|Placebo Comparator|Placebo|Participants will receive placebo solution, orally, once daily for 6 weeks.
16314294|NCT04577781|Experimental|GLPG3970|Participants will receive GLPG3970 solution, orally, once daily for 6 weeks.
16314295|NCT04577781|Placebo Comparator|Placebo|Participants will receive placebo solution, orally, once daily for 6 weeks.
16314296|NCT04577768|Experimental|HD-tDCS 2 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 2 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
16314297|NCT04577768|Experimental|HD-tDCS 1.5 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 1.5 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
16314298|NCT04577768|Sham Comparator|Control|Single session of 20-min of sham HD-tDCS. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
16314299|NCT04577755|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with complete response, partial response, or stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
16314300|NCT04577729|Experimental|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
16314301|NCT04577729|Placebo Comparator|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
16314302|NCT04577716||Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak
16314303|NCT04577716||No Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak
16314304|NCT04577716||Pre-EVAR Group|Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care
16314305|NCT04577703|Experimental|CT053PTSA (dose escalation)|"Patients were treated in 5 dose cohorts of 15 mg, 30 mg, 60 mg, 100 mg, and 150 mg QD capsules.
~Patients receive treatment with CT053PTSA once on Cycle 0 Day 1 following a 7-day treatment-free withdrawal period to observe the safety and pharmacokinetic of CT053PTSA.
~After that, Patients receive treatment with CT053PTSA per orally, beginning on Cycle 1 Day 1 for 28 day following a 7-day treatment-free withdrawal period to observe efficacy of CT053PTSA and determine to continue taking medicine or not. Each cycle had 28 days."
16314306|NCT04577690|Experimental|PECS block|A PECS block of 0.25 % bupivacaine with epinephrine 1:200000 (below the toxic dose limit of 3 mg/kg) in divided doses to cover the fascial planes identified in PECS I and PECS II. At the completion of surgery, the wound will be infiltrated with up to 0.2 ml/kg of 0.25 % bupivacaine into the wound.
16314307|NCT04577690|Active Comparator|Infiltration|At the completion of surgery, the EP cardiologist will infiltrate the wound with up to 0.8 ml/kg of 0.25 % bupivacaine with epinephrine 1:200000.
16314308|NCT04577677|Experimental|optimization of control anesthetic condition|
16314309|NCT04577677|Experimental|understanding tDCS effect on motor learning|
16314310|NCT04577677|Experimental|understanding tDCS effects on cortical excitability|
16314311|NCT04577677|Experimental|optimizing peripheral nerve stimulation protocols|
16314312|NCT04577677|Experimental|Effect peripheral nerve stimulation on motor learning|
16314313|NCT04577664|Active Comparator|TT group|
16314314|NCT04577664|Active Comparator|ST group|
16314315|NCT04577651|Experimental|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with a 16-contact Directional Lead
16314316|NCT04577638|Experimental|Nivolumab and accelerated IMRT|
16314317|NCT04577625|Active Comparator|L. reuteri Low Dose|L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.
16314318|NCT04577625|Active Comparator|L. reuteri High Dose|L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.
16314319|NCT04577625|Placebo Comparator|Placebo|The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.
16314320|NCT04577612|Experimental|Group 1|150 mg CBD
16314321|NCT04577612|Experimental|Group 2|300 mg CBD
16314322|NCT04577612|Experimental|Group 3|600 mg CBD
16314323|NCT04577612|Placebo Comparator|Group 4|Placebo MCT oil
16314324|NCT04577599|Other|Single Arm|Mobile Low-dose Computed Tomography (LDCT) Screening
16314325|NCT04577586||Water|Patients who ingested only water as an oral contrast
16314326|NCT04577586||Milk|Patients who ingested milk as an oral contrast
16314327|NCT04577586||Mannitol|Patients who ingested mannitol as an oral contrast
16314328|NCT04577573|Active Comparator|No cognitive feedback|Perform task without cognitive feedback.
16314329|NCT04577573|Active Comparator|Intermediate feedback.|Perform task with intermediate feedback.
16314330|NCT04577573|Experimental|Enhanced feedback|Perform task with virtual reality and/or haptic feedback.
16314331|NCT04577560|Experimental|MII with PB biopsy|Five selected MII will undergo sequential polar biopsy; on day 0 [PB1] (36-42 hours post trigger injection) and if fertilization occurred on day 1 [PB2] (17-20 hours post ICSI). On day 5, 6 or 7, the resulting blastocyst will be biopsied.
16314332|NCT04577560|Experimental|MII with no PB biopsy|MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
16314333|NCT04577547|Experimental|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
16314334|NCT04577547|Experimental|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
16316183|NCT04565145|Placebo Comparator|Placebo|Three placebo capsule per day for one week
16314335|NCT04577547|Experimental|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
16314336|NCT04577547|Experimental|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
16314337|NCT04577547|Experimental|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
16314338|NCT04577547|Experimental|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
16314339|NCT04577547|Experimental|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
16314340|NCT04577547|Experimental|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
16314341|NCT04577534|Experimental|Tocilizumab (TCZ)|Participants will receive one infusion of iv TCZ (according to weight of patient)
16314342|NCT04577534|No Intervention|standard of care (no TCZ)|Participants will receive standard of care
16314343|NCT04577508|Experimental|Functional Remediation|Functional Remediation
16314344|NCT04577508|Other|Control|Treatment as usual
16314345|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
16314346|NCT04577469|Experimental|500 mg sulfadoxine / 25 mg pyrimethamine tablet|500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once.
16314347|NCT04577469|Active Comparator|G-COSPE® tablets|G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once.
16314348|NCT04577443|Active Comparator|Adenosine|
16314349|NCT04577443|Placebo Comparator|Saline|
16314350|NCT04577430|Experimental|Loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 0.5 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the operation finished.
16314351|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the surgery finished.
16314352|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 1 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 1 μg/kg per hour during the operation until 0.5 h before the surgery finished.
16314353|NCT04577430|Placebo Comparator|Normal saline|
16314354|NCT04577417||ADHD|Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date
16314355|NCT04577417||Control|Adolescents, male or female, ages 13-19, with normal health status and development
16314356|NCT04577404|Experimental|MT-1186|Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
16314357|NCT04577391|Experimental|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the use of involved side as maximum as possible. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating). In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook the role of the child's dominant hand.
16314358|NCT04577391|Active Comparator|Bimanual training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
16314359|NCT04577378|Active Comparator|13 cis retinoic acid doses orally|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
16314360|NCT04577378|Sham Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
16314361|NCT04577378|No Intervention|control|No intervention
16314362|NCT04577352|Experimental|Vatiquinone|Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.
16314363|NCT04577352|Placebo Comparator|Placebo|Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.
16314364|NCT04577339||Adult patients with acute abdominal conditions|"All adult patients >=16years of age on all general adult wards (excluding maternity) between 2013 and 2020 with the following inclusion and exclusion criteria:
~Inclusion criteria:
~Must have an acute intestinal condition, based on their ICD-10 codes and OPSC-4 codes
~Must be >= 16 years of age at the time of admission
~Have at least one full set of vital signs recorded on the day of admission
~Have at least one full set of routine blood tests recorded on the day of admission
~Exclusion criteria:
~Maternity admissions during/after pregnancy
~Patients admitted or undergoing abdominal surgery for a second time or more"
16314478|NCT04576650|Experimental|Summit system|Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
16314365|NCT04577326|Experimental|Engineered Autologous T Cells|Following eligibility screening and enrollment, patients will undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMCs), to enable generation of M28z1XXPD1DNR. Following successful M28z1XXPD1DNR CAR T-cell manufacturing, patients will be reevaluated for eligibility. A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m2 will be administered 2-7 days before the infusion. A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. All patients will be monitored in the hospital for a minimum of 48 h following the administration of CAR T cells.
16314366|NCT04577313|Active Comparator|Continuous Counseling|Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.
16314367|NCT04577313|Active Comparator|Fixed Counseling|Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.
16314368|NCT04577300|Experimental|Dual Implantation|Two NT-501 devices will be implanted in the study eye.
16314369|NCT04577300|Experimental|Single Implantation|One NT-501 device will be implanted in the study eye.
16314370|NCT04577300|Sham Comparator|Sham Implantation|No NT-501 devices will be implanted in the study eye.
16314371|NCT04577287|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the supraorbital area of affected hemisphere, Cathodal on the motor are (M1) of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
16314372|NCT04577287|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor are (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
16314373|NCT04577274|Experimental|smoothie with regular formulas (SM)|Participants were given 300 kcal smoothie with regular formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
16314374|NCT04577274|Experimental|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal smoothie with low carbohydrate formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
16314375|NCT04577274|Active Comparator|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal Glucerna within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
16314376|NCT04577261||FNS Participants|Participants who will undergo surgery to treat a fractured femoral neck using the FNS (Femoral Neck System)
16314377|NCT04577235|Experimental|Survivors group|Lung ultrasound score and computed tomography score were evaluated in the surviving group
16314378|NCT04577235|Experimental|Non survivors group|Lung ultrasound score and computed tomography score were evaluated in the non surviving group
16314379|NCT04577222|Experimental|Adipose Flap|Covering neurovascular bundle with fat
16314380|NCT04577222|No Intervention|Control|No adipose flap
16314381|NCT04577209|Experimental|Pediatric Patients|Participants undergoing anesthesia-related aerosol generating medical procedures (AGMPs) and pediatric otolaryngologic surgeries will have a local exhaust ventilation system to the exposure seen by the medical providers during the AGMPs and surgeries.
16314382|NCT04577196||Briefing supported by the trauma dashboard|During the entire chain of transmission (from the initial phone call to the end of the briefing to the trauma team) the trauma leader will be provided with a trauma dashboard to synthesize and disseminate the available information about the arriving patient.
16314383|NCT04577196||Briefing without the trauma dashboard|The transmission chain will not be supported by any specific tool.
16314384|NCT04577183|Experimental|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
16314385|NCT04577170||Fabry disease|
16314386|NCT04577170||Healthy|age and sex matched
16314387|NCT04577157|Experimental|Intervention Arm|"The participants in the intervention group will receive Health@click (seven-item multifaceted educational and reminder module) through WhatsApp. This will be included daily notes for medication reminders, voice messages, Graphics-based Reminders (GBR), Twice-weekly Graphics-based Messages (GBM), and once-weekly lifestyle advice through video in addition to standard care (as being practiced routinely in the hospitals). Besides this, a 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects and interaction with different foods, and psychological support to the participants who feel the need."
16314388|NCT04577157|No Intervention|Control Arm|Participants in the control group will receive no intervention except in standard care (as per being practiced routinely in the hospitals).
16314389|NCT04577144||Individuals who participated in the RECOVER study|Individuals who enrolled in the Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery (RECOVER) study. Individuals who received at least one injection in a SUBLOCADE Phase III program were eligible to participate in the original study.
16314390|NCT04577131|Experimental|With check-ins|Daily blood pressure monitoring with weekly check-ins
16314391|NCT04577131|No Intervention|Without check-ins|Daily blood pressure monitoring without weekly check-ins
16314479|NCT04576637|Experimental|Neurophysiological monitoring during induction|
16316777|NCT04560985|Active Comparator|Hydrophobic sealant|Helioseal-F Sealant ®
16314392|NCT04577118|Other|iotaSOFT Insertion System|The iotaSOFT Insertion System is a surgical device that aids the surgeon in implanting cochlear electrode arrays by controlling the speed and distance of implant insertion. All subjects enrolled in the trial will have the iotaSOFT Insertion System used during surgery.
16314393|NCT04577105||Suspected, probable, or confirmed COVID-19 case|Patients who come to the emergency room with symptoms compatible with a suspected, probable, or confirmed case of SARS-CoV2 infection, in which a chest computed tomography (CT) scan was requested for suspected COVID-19 pneumonia, will be evaluated. On April 1 and August 28, 2020.
16314394|NCT04577092|Active Comparator|Motor-Cognitive|"In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
~In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed."
16314395|NCT04577092|Active Comparator|Motor-Motor|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion. In cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
16314396|NCT04577079||IPMF Screened|Patient screened and assessed by intelligent patient flow management system.
16314397|NCT04577066|Experimental|Group 1 (GA2)|Volunteers will be exposed to GA2-infected mosquito bites.
16314398|NCT04577066|Active Comparator|Group 2 (GA1)|Volunteers will be exposed to the GA1-infected mosquito bites.
16314399|NCT04577066|Placebo Comparator|Group 3 (Placebo)|Volunteers will be exposed to uninfected mosquito bites.
16314400|NCT04577053|Experimental|PEMF Therapy|Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
16314401|NCT04577053|No Intervention|Control|Control group will not receive treatment.
16314402|NCT04577040||1|Tadalafil in moderate puts
16314403|NCT04577040||2|Tadalafil in severe puts
16314404|NCT04577040||3|Tadalafil with sildosin in moderate luts
16314405|NCT04577040||4|Tadalafil with sildosin in severe luts
16314406|NCT04577027|Experimental|vitiligo patients|Thirty Patients complaining of generalized non segmental vitiligo will be recruited in this study. They will be chosen from the attendants of the out-patient clinics of Dermatology, Assiut university hospital. six patches will be selected in each patient.
16314407|NCT04577014|Experimental|Phase I: Safety Run-In / Dose Level 0|A safety run-in (dose level 0 in Table 1, below) will be performed and enroll 6 patients with advanced high-grade sarcoma who are treatment naïve. Cycle one will consist of gemcitabine plus docetaxel at the institution's standard dose and schedule: 900 mg/m2 of gemcitabine on days 1 and 8, and 75 mg/m2 of docetaxel on day 8. Intravenous Retifanlimab at a flat dose of 210 mg will be administered every 3 weeks starting on C2D1 for a total of two cycles (cycles 2 and 3).
16314408|NCT04577014|Experimental|Phase I: Dose De-escalation Level 1|"If ≤ 1 patient out of 6 at dose level 0 has a dose-limiting toxicity during this safety run-in, then the dose de-escalation portion of the protocol will commence.
~Dose Level 1:
~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 900 mg/m2 Docetaxel (Day 8) - 75 mg/m2"
16314409|NCT04577014|Experimental|Phase I: Dose De-escalation Level -1|"Dose Level -1:
~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 750 mg/m2 Docetaxel (Day 8) - 60 mg/m2"
16314410|NCT04577014|Experimental|Phase I: Dose De-escalation Level -2|"Dose Level -2:
~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 675 mg/m2 Docetaxel (Day 8) - 50 mg/m2"
16314411|NCT04577014|Experimental|Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma|"(UPS/MFS)
~After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment."
16314412|NCT04577014|Experimental|Liposarcoma/LPS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment.
16314413|NCT04577014|Experimental|Leiomyosarcoma/LMS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment.
16314480|NCT04576624|Experimental|Lifestyle Intervention|Subjects in the Lifestyle Intervention group will, in six months, receive sixteen group sessions and six individualized treatment sessions.
16314481|NCT04576624|Sham Comparator|Social Activities|Social Activities Group will receive twenty-two group sessions
16314414|NCT04577014|Experimental|Vascular Sarcoma|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment.
16314415|NCT04577014|Experimental|Other Soft tissue sarcoma/STS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment.
16314416|NCT04577001|Experimental|Letrozole Group|Subjects with hepatopulmonary syndrome will get the study drug letrozole
16314417|NCT04577001|Placebo Comparator|Placebo Group|Subjects with hepatopulmonary syndrome will get the study placebo
16314418|NCT04576988|Experimental|Sotatercept plus background PAH theraphy|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy
16314419|NCT04576988|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered (SC) every 21 days plus background PAH therapy
16314420|NCT04576975|Experimental|Ketamine|This group will receive a bolus dose of Ketamine [Ketamine HCL - Sterop, Belgium] (0.3 mg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which Ketamine infusion (500 mg vial diluted over 50 cc infusion syringe, concentration 10 mg/ml) will start with rate of 0.3 mg/kg/hr till 10 Minutes before the end of the surgery
16314421|NCT04576975|Experimental|Dexmedetomidine|This group will receive a bolus dose of Dexmedetomidine [Precedex® -Hospira, USA] (0.5 µcg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which, the Dexmedetomidine infusion (200 µcg vial diluted over 50 cc infusion syringe, concentration 4 µcg/ml) will start with rate of 0.5 µcg/kg/hr till 10 Minutes before the end of the surgery
16314422|NCT04576975|Placebo Comparator|Normal Saline 0.9%|This group will receive a bolus dose of NS 0.9% over 10 minutes by 20 ml syringe infused before induction. After which, NS 0.9% (50 ml over 50 cc syringe) will be infused.
16314423|NCT04576962||Children aged 14 years or younger|All children in Indiana aged 14 years and younger who received the first dose of HPV vaccine during the 2017 and 2018 calendar years. This is a non-interventional study, with data to be analyzed at the county level only.
16314424|NCT04576949|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
16314425|NCT04576949|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
16314426|NCT04576949|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
16314427|NCT04576936|Experimental|AIRVO Device|All participants are assigned to this single-arm: Enrolled participants will be given a MyAIRVO2 Device and device stand, and asked to use their device daily, for 12 months
16314428|NCT04576923|Experimental|Liver Incytes|Patients with known or suspected Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) will be scanned with Liver Incytes.
16314429|NCT04576910|Experimental|"Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
16314430|NCT04576910|Experimental|"Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
16314431|NCT04576910|Experimental|"Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
16314432|NCT04576910|Experimental|"Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
16314433|NCT04576910|Experimental|"Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
16314434|NCT04576897|Experimental|Liver Incytes|Patients with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplantation will be scanned with Liver Incytes.
16314435|NCT04576884||Group 1|participants of less than 18 years old
16314436|NCT04576884||Group 2|participants aged from 18 years to 40 year
16314437|NCT04576884||Group 3|participants aged from 41 years to 60 years
16314438|NCT04576884||Group 4|participants over 60 years old
16314439|NCT04576871|Experimental|All Subjects|
16314440|NCT04576858||Cohort 1: Surgical resection + perioperative chemotherapy|
16314441|NCT04576858||Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery|
16314442|NCT04576858||Cohort 3: Definitive chemoradiotherapy|
16314443|NCT04576858||Cohort 4: Chemotherapy with the aim to prolong life expectancy|
16314444|NCT04576858||Cohort 5: Non-chemotherapeutic palliation|E.g. Palliative radiotherapy
16314473|NCT04576676||Essential Tremor and Parkinson's Disease|"Subjects must be 50 years of age or older.
~Subjects must have been diagnosed with Essential Tremor
~Subjects must have been diagnosed with Parkinson's Disease preceded by at least 3 years of enrollment in study
~Subjects must live within 3 hours of UTSW
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
16314474|NCT04576663|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
16314475|NCT04576663|Experimental|0.3125 μg/kg/min group|A maintenance dose of phenylephrine (0.3125 μg/kg/ min) infusion simultaneous with subarachnoid block
16314445|NCT04576845||Study Group|The study will be performed on Caucasian origin children who are among 2 to 6 years of age. The study group will be composed of children (n=31) who had CMA (Ig E-mediated and/or non-Ig E-mediated and/or mixed type) proved with oral food challenge tests in their early childhood (in ages of 0-2). The inclusion criteria to the study group will be to undergo a Cow's milk elimination (CME) diet or took a hypoallergenic formula in 0-2 years of age for at least 3 months or longer due to CMA allergy and improved afterward, and/or to eliminate other nutrients (e.g., eggs, potatoes, wheat flour, soybean, etc.) other than cow's milk between the ages of 0-2 for at least 3 months or longer, and/or to add these nutrients back to their diet in the last 3 months, and/or not receiving hypoallergenic formula for the last 3 months, not to be on the CME diet at present. Thus, no children in the study and control groups will be on a dietary restriction during the study.
16314446|NCT04576832|Experimental|Cohort A (MT group)|Participants will receive 4 weeks of mindfulness training and then followed by 5 months of mindfulness app usage.
16314447|NCT04576832|Active Comparator|Cohort B (Wait-list group)|Participants will begin with 4 weeks of no training interval followed by 4-weeks of mindfulness training and then followed by 4 months of mindfulness app usage.
16314448|NCT04576819||Sepsis cohort|"Inclusion criteria
~Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)
~Treatment with an institutional, evidence-based guideline management bundle for sepsis
~Within 24 hrs of sepsis recognition
~Exclusion criteria:
~alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),
~uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),
~advanced directives limiting resuscitative efforts,
~organ transplant recipient on immunosuppressive agents,
~known pregnancy,
~inability to obtain informed consent,
~HIV/AIDS with CD4 count < 200,
~absolute neutrophil count < 500"
16314449|NCT04576806|Active Comparator|Body temperature fluid bolus of crystalloid|Fluid bolus at 38 degrees celsius of 500ml crystalloid over 15 minutes
16314450|NCT04576806|Experimental|Room temperature fluid bolus of crystalloid|Fluid bolus at 22 degrees celsius of 500ml crystalloid over 15 minutes
16314451|NCT04576793|Experimental|Cognitive impairment|"Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties
~Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties
~Amnestic Alzheimer's disease - a typical version of Alzheimer's disease with memory difficulties"
16314452|NCT04576793|Active Comparator|No cognitive impairment|Healthy controls
16314453|NCT04576780||Referred Patients with Large, Complex Colorectal Polyps|Patients referred from outside community care hospitals or ambulatory endoscopy centers to the therapeutic endoscopy group at St. Michaels Hospital via the new integrated management pathway for endoscopic resection of a large or complex colorectal polyp.
16314454|NCT04576767||Experimental group|interventions:general anesthesia drugs:propofol、muscle relaxant、pain relievers(fentanbyl、sufentanil)
16314455|NCT04576767||control group|interventions:intraspinal anesthesia drugs:ropivacaine、pain relievers(fentanbyl、sufentanil)
16314456|NCT04576754|Experimental|WB001|
16314457|NCT04576754|Sham Comparator|Comparison Condition|
16314458|NCT04576741|Experimental|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
16314459|NCT04576741|Experimental|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
16314460|NCT04576728|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
16314461|NCT04576728|Placebo Comparator|Placebo|Human albumin 1%
16314462|NCT04576715|Experimental|TEaM Intervention Group|Dedicated Provider Education plus Information Technology Support. The IT support includes addition of an eMR concussion screening, followed by an alert to the provider, followed by a structured assessment / evaluation template.
16314463|NCT04576715|Active Comparator|Control Group|Standard medical protocol for the management of mTBI in children. This group will not receive interventional Provider Training on the TEaM concussion evaluation examination and utilization of the eMR template.
16314464|NCT04576702|Experimental|Investigational aIIV group|aIIV will be administered as a single dose intramuscularly on Day 1
16314465|NCT04576702|Active Comparator|licensed IIV type 1 group|IIV will be administered as a single dose intramuscularly on Day 1
16314466|NCT04576702|Active Comparator|licensed aIIV group|aIIV will be administered as a single dose intramuscularly on Day 1
16314467|NCT04576702|Active Comparator|licensed IIV type 2 group|IIV will be administered as a single dose intramuscularly on Day 1
16314468|NCT04576689|Experimental|Low dose|One (1) IBE-814 IVT Implant (70 μg Dexamethasone) Route of administration: intravitreal injections
16314469|NCT04576689|Experimental|High dose|Two (2) IBE-814 IVT Implant (140 μg Dexamethasone) Route of administration: intravitreal injections
16314470|NCT04576676||Essential Tremor|"Subjects must be 50 years of age or older.
~Subjects must have been diagnosed with Essential Tremor
~Subjects must live within 3 hours of UTSW
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
16314471|NCT04576676||Parkinson's Disease|"Subjects must be 50 years of age or older.
~Subjects must have been diagnosed with Parkinson's Disease
~Subjects must live within 3 hours of UTSW
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
16314472|NCT04576676||Healthy Individuals|"Healthy individuals living within 3 hours of UTSW
~Subjects must be 50 years of age or older
~You are healthy and have not being diagnosed with any neurological disease
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
16314476|NCT04576663|Experimental|0.625 μg/kg/min group|A maintenance dose of phenylephrine (0.625 μg/kg/ min) infusion simultaneous with subarachnoid block
16314477|NCT04576663|Experimental|0.9375 μg/kg/min group|A maintenance dose of phenylephrine (0.9375 μg/kg/ min) infusion simultaneous with subarachnoid block
16314482|NCT04576624|No Intervention|Passive Control|Control group will receive patient education materials with each assessment
16314483|NCT04576611|Experimental|face-to-face|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using face-to-face modality guided by a health professional.
16314484|NCT04576611|Experimental|self-managed|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using self-managed modality through BackFit App.
16314485|NCT04576598|Experimental|Self-management group to increase physical activity levels|This group will perform a self-management program along 6 months. This program will aim to increase the level of physical activity and adherence to healthier lifestyle habits and will be carried out through several sessions that will incorporate: education, goal setting, identification of barriers, self-control and feedback.
16314486|NCT04576598|Active Comparator|Control group|This group will participate in the initial educational session and will be given a leaflet with recommendations for physical activity to follow throughout the six months.
16314487|NCT04576585|Experimental|Appetite lexicon training group|They will get appetite lexicon training in week three.
16314488|NCT04576585|Active Comparator|taste Lexicon training|They will get taste lexicon training In week three.
16314489|NCT04576559|Experimental|Modified dental visual aids|
16314490|NCT04576559|Active Comparator|Regular dental visual aids|
16314491|NCT04576546|Active Comparator|comparator group|myo-inositol treatment
16314492|NCT04576546|Experimental|study group|D-chiro-inositol treatment
16314493|NCT04576533|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
16314494|NCT04576533|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
16314495|NCT04576520|Experimental|pharmacopuncture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
16314496|NCT04576520|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
16314497|NCT04576507|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
16314498|NCT04576494|Experimental|5q-SMA type 2 and type 3 adults|5q-SMA type 2 and type 3 adults
16314499|NCT04576481|Active Comparator|Group 1: Text Messaging|Consist of daily text messages on shared reading
16314500|NCT04576481|Experimental|Group 2: Text Messaging + Coaching|Will consist of Group 1 plus personalized coaching.
16314501|NCT04576481|Experimental|Group 3: Text Messaging + Coaching + Lottery|Will consist of Group 2 plus availability of a weekly lottery.
16314502|NCT04576468|Experimental|open flap debridement|envelope full thickness flap reflection, removal of granulation tissue then suturing with simple loop sutures.
16314503|NCT04576468|Experimental|perforated membrane (PM)|envelope full thickness flap reflection, removal of granulation tissue placing resorbable membrane after perforating it over the vertical defect then suturing with simple loop sutures.
16314504|NCT04576468|Experimental|leucocyte platelet rich fibrin (L-PRF)|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF in the defect then suturing with simple loop sutures.
16314505|NCT04576468|Experimental|L-PRF + PM|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF covered by resorbable membrane after perforating it in the defect then suturing with simple loop sutures.
16314506|NCT04576455|Experimental|Giredestrant|
16314507|NCT04576455|Active Comparator|Physician's Choice of Endocrine Monotherapy|The physician's choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.
16314508|NCT04576442|Experimental|Asthma-PASS Intervention|Collaboration with PCPs to optimize management. Community Health Worker (CHW) to ensure PCP plan is followed. Two asthma education sessions with children/caregivers focusing on self-efficacy and physical activity promotion. Promotion of asthma awareness in school. School personnel training in asthma
16314509|NCT04576442|Active Comparator|Asthma Management Comparison Group|Includes two sessions of basic asthma education and PCP notification of child's asthma severity level.
16314510|NCT04576429|Experimental|experimental group|
16314511|NCT04576429|Active Comparator|comparator group|
16314512|NCT04576416|Experimental|Intervention|During the three months the intervention group will receive access to the AI augmented digital educational platform and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
16314513|NCT04576416|No Intervention|Control|The control group continues its standard clinical practice without access to the E-app, but does register skin lesions throughout the full 3 month period.
16314514|NCT04576403|Active Comparator|Intervention group|Activated mittens
16314515|NCT04576403|Sham Comparator|Control group|Deactivated mittens
16314516|NCT04576390|Active Comparator|Group O|On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
16314517|NCT04576390|Active Comparator|Group P|On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
16314520|NCT04576364|Active Comparator|12-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 12-hour postpartum Mgso4
16314521|NCT04576364|Active Comparator|24-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 24-hour postpartum Mgso4
16314753|NCT04574856|Experimental|Patients with Newly Diagnosed Glioblastoma|Patients will receive dose-intensified, adaptive photon radiation therapy
16314522|NCT04576351||1|"Sub cohort 1:
~Participants in the WHO NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients.
~Eligibility: consenting adults (age ≥18) hospitalized with definite COVID-19 included in the WHO COVID-19 Study. Participants invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected."
16314523|NCT04576351||2|"Sub cohort 2:
~Patients with COVID-19 and neurological symptoms related to COVID-19 admitted to the Norwegian Departments of Neurology or other relevant Departments (both hospitalized and outpatient visits) and persons with neurological symptoms participating in other COVID-19 studies and not already participating in the WHO NOR Solidarity multicenter trial."
16314524|NCT04576338||College Students|The cohort consists of Black and White college students at a university in a southeastern state in America.
16314525|NCT04576325|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
16314526|NCT04576325|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
16314527|NCT04576312|Experimental|Cohort 1|Single dose of UNI911 inhalation (4 mL 0.1% ~ 3,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
16314528|NCT04576312|Experimental|Cohort 2|Single dose of UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
16314529|NCT04576312|Experimental|Cohort 3|Single dose of UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
16314530|NCT04576312|Experimental|Cohort 4|Single dose of UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
16314531|NCT04576312|Experimental|Cohort 5|UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 2,5 days.
16314532|NCT04576312|Experimental|Cohort 6|UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
16314533|NCT04576312|Experimental|Cohort 7|UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
16314534|NCT04576312|Placebo Comparator|Placebo (applicable for cohorts 1-5)|Placebo, administered in a double-blinded fashion (except for the first subjects of cohorts 1-4) at the same dose and frequency as UNI911 inhalation and intranasal spray.
16314535|NCT04576299||Healthcare workers.|"Survey developed specifically for the objective of this study: Healthcare worker perception of patient safety in times of pandemic.
~The application will be done through a digital questionnaire in the surveymonkey platform (Link of the instrument: https://es.surveymonkey.com/r/COVIDSP)"
16314536|NCT04576286|Experimental|Holmium en bloc resection|Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency
16314537|NCT04576286|Active Comparator|bipolar en bloc resection|bipolar en bloc tumor resection of urinary bladder tumors
16314538|NCT04576273||Non-parasitic|
16314539|NCT04576273||Parasitic|
16314540|NCT04576260|Experimental|CBT-I Group|Participants in the CBT-I group will undertake weekly sessions for a duration of 8 weeks with a trained psychologist through Zoom or Skype Calls.
16314541|NCT04576260|No Intervention|Control group|The control group will be asked to maintain the usual lifestyle for the duration of the study
16314542|NCT04576247|Experimental|Combined aerobic and resistance exercise|12 weeks of supervised resistance exercise and unsupervised aerobic exercise.
16314543|NCT04576234|Experimental|intermittent entral feeding group|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest) by using syringe pump and Feeds were administered according to guidelines as the head of the patient's bed was elevated at least 30 degrees from the horizontal before initiating feeding, the feeding schedule was started at a rate of 50 ml/hr in adults to promote tolerance,the administration rate of isotonic formulas increased in 20-25 ml/hr increments every eight hours until the desired rate was achieved, the tube was flushed regularly with 20 to 30 ml of warm water every four hours during continuous feeding and before and after intermittent feeding and medication administration, the gastric residual volume was checked every 4-6 hr routinely
16314544|NCT04576234|Experimental|, feeding bag group|Feeding bag group received hospital blended formual which was 300 ml of feeds every 2hrs with 4hrs rest at night and given in 10 minutes with following the same guidelines in the intermittent enteral feeding group
16314545|NCT04576221|Experimental|stacked breathing group|experimental group received staked breathing exercise for 7 days , 3 sessions per day, 7-8 times per session
16314546|NCT04576221|Experimental|CPAP group|experimental group received NIV with CPAP mask
16314547|NCT04576208|Experimental|Cohort 1|TAK-788 160 mg, capsules, orally, once daily (QD) with or without a low-fat meal until disease progression or as assessed by the investigator during every 3-week cycle.
16314548|NCT04576208|Experimental|Cohort 2|TAK-788 160 mg, capsules, orally, QD with or without a low-fat meal and antidiarrheal prophylaxis administered during the first 8 weeks of treatment until disease progression or as assessed by the investigator during every 3-week cycle.
16314549|NCT04576195|Experimental|Real PENS|One single session of PENS
16314550|NCT04576195|Sham Comparator|Sham PENS|One single session of Sham-PENS
16314551|NCT04576182|Experimental|Supportive-Expressive|Participants will receive supportive-expressive treatment for 16 weeks.
16314552|NCT04576182|Experimental|Emotion-Focused|Participants will receive Emotion-Focused treatment for 16 weeks.
16314553|NCT04576169|Experimental|Central or Radial Tear: Arthroscopic debridement|Arthroscopic debridement
16314554|NCT04576169|Placebo Comparator|Central or Radial Tear: Sham surgery|Diagnostic arthroscopy only (placebo surgery).
16314555|NCT04576169|Experimental|Ulnar Tear: Arthroscopic or open repair|Arthroscopic or open repair
16314556|NCT04576169|Active Comparator|Ulnar Tear: Physiotherapy|Diagnostic arthroscopy and physiotherapy
16314557|NCT04576156|Experimental|Imetelstat|Participants will receive imetelstat at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
16314558|NCT04576156|Active Comparator|Best Available Therapy (BAT)|Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
16314559|NCT04576143|Active Comparator|epirubicin/CTX × 4 - docetaxel × 4, every 3 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 21 days); Cycle 5-8: Docetaxel i.v. 100mg/m2 (One cycle = 21 days) .
16314560|NCT04576143|Experimental|epirubicin/CTX × 4 - paclitaxel × 4, every 2 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 14 days); Cycle 5-8:Paclitaxel i.v. 175mg/m2 (One cycle = 14 days) .
16314561|NCT04576130|Experimental|ICD-implantation|Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
16314562|NCT04576130|No Intervention|Standard care|Guideline directed medical therapy
16314565|NCT04576104|Active Comparator|Arm I (megestrol acetate)|Prior to standard of care surgery, patients receive megestrol acetate PO BID for 4 weeks in the absence of disease progression or unacceptable toxicity.
16314566|NCT04576104|Experimental|Arm II (megestrol acetate, metformin hydrochloride)|Prior to standard of care surgery, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 4 weeks in the absence of disease progression or unacceptable toxicity.
16314568|NCT04576078|Experimental|NEFOPAM 60mg PO/ 8 hours|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
16314569|NCT04576078|Placebo Comparator|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
16314570|NCT04576065|No Intervention|Usual Care|Patients randomized to usual care will follow-up with primary care providers and specialists as recommended by hospital providers, or seek medical care as needed after hospital discharge.
16314571|NCT04576065|Experimental|Intervention|Patients randomized to intervention will have 6 months of access after hospital discharge for telehealth visits with a nurse practitioner and an activity tracker providing data to the nurse practitioner about subject's daily level of activity.
16314572|NCT04576052||antibiotic-coating|patients who have been treated with an antibiotic-coated nail for tibia-fracture
16314573|NCT04576052||non-coated|patients who have been treated with a non-coated nail for tibia fracture
16314574|NCT04576039|Experimental|presenting with thickened endometruim|women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.
16314575|NCT04576026|Experimental|Ketone esters|Ketone esters will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
16314576|NCT04576026|Active Comparator|Placebo|Iso-caloric carbohydrate drink will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
16314577|NCT04576013|Experimental|Active PNS during training|Individuals in this group will receive active PNS while participating in 2 hours of motor training of the affected arm.
16314578|NCT04576013|Active Comparator|Active PNS before training|Individuals in this group will receive 2 hours of active PNS before participating in 2 hours of motor training of the affected arm.
16314579|NCT04576013|Sham Comparator|Sham PNS during training|Individuals in this group will receive 2 hours of sham PNS while participating in 2 hours of motor training of the affected arm.
16314580|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
16314581|NCT04575974||Adolescents 13-19 years|All adolescents between 13-19 years of age in North Trøndelag county were invited to participate in HUNT 3 and followed up after 11 years.
16314582|NCT04575961|Other|Pembrolizumab + Chemotherapie|pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin or carboplatin monotherapy)
16314583|NCT04575948|Experimental|Moringa Oleifera mouth wash|According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
16314584|NCT04575948|Placebo Comparator|Base formula of mouth wash|Base formula of mouthwash
16314585|NCT04575948|Active Comparator|Chlorhexidine|Commercial 0.12% chlorhexidine digluconate mouthwash
16314586|NCT04575935|Experimental|Arm A (MIS, standard of care chemotherapy)|Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing an open procedure, patients may undergo laparotomy instead. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
16314587|NCT04575935|Active Comparator|Arm B (laparotomy, standard of care chemotherapy)|Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
16314588|NCT04575922|Experimental|Nivolumab+Ipilimumab+Radiation Therapy (RT)|"Study cycles are 6 weeks long, participants will receive:
~Cycle 1: Nivolumab every 2 weeks during cycle, Ipilimumab 1x on Day 1 of cycle, and Radiation Therapy every other weekday or 2 days for a total of 3 treatments during week 1 of Cycle 1 only.
~Cycles 2-4: Nivolumab every 2 weeks during each cycle, Ipilimumab 1x on Day 1 of each cycle
~Cycles 5-Disease Progression: Nivolumab every 2 weeks during each cycle"
16314589|NCT04575909|Experimental|Recognition, Production Implicit-Explicit|Treatment will begin with 6 visits of emotional prosody recognition treatment followed by 6 visits of emotional prosody production treatment (1-3 implicit, 4-6 explicit).
16314590|NCT04575909|Experimental|Recognition, Production Explicit-Implicit|Treatment will begin with 6 visits of emotional prosody recognition treatment followed by 6 visits of emotional prosody production treatment (1-3 explicit, 4-6 implicit).
16314591|NCT04575909|Experimental|Production Implicit-Explicit, Recognition|Treatment will begin with 6 visits of emotional prosody production treatment (1-3 implicit, 4-6 explicit) followed by 6 visits of emotional prosody recognition treatment.
16314592|NCT04575909|Experimental|Production Explicit-Implicit, Recognition|Treatment will begin with 6 visits of emotional prosody production treatment (1-3 explicit, 4-6 implicit) followed by 6 visits of emotional prosody recognition treatment.
16314593|NCT04575896|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive glecaprevir/pibrentasvir 300 mg/120 mg once daily by mouth for 2 weeks
16314594|NCT04575883|Experimental|MedBIKE HIIT|MedBIKE HIIT Exercise Program
16314595|NCT04575870||Treatment Group 1: 90 min waiting period|Participants undergo their planned tracheobronchoscopy + 90 minute waiting period prior to modified functional endoscopic swallowing exam
16314596|NCT04575870||Treatment Group 2: 66 min waiting period|Participants undergo their planned tracheobronchoscopy + 66 minute waiting period prior to modified functional endoscopic swallowing exam
16314597|NCT04575870||Treatment Group 3: 46 min waiting period|Participants undergo their planned tracheobronchoscopy + 46 minute waiting period prior to modified functional endoscopic swallowing exam
16314598|NCT04575870||Treatment Group 4: 28 min waiting period|Participants undergo their planned tracheobronchoscopy + 28 minute waiting period prior to modified functional endoscopic swallowing exam
16314599|NCT04575870||Treatment Group 5: 13 min waiting period|Participants undergo their planned tracheobronchoscopy + 13 minute waiting period prior to modified functional endoscopic swallowing exam
16314602|NCT04575844|No Intervention|Control|24 weeks of observation
16314603|NCT04575844|Experimental|Exercise Alone|24 weeks of treatment
16314604|NCT04575844|Experimental|Liraglutide Alone|24 weeks of treatment
16314605|NCT04575844|Experimental|Exercise + Liraglutide|24 weeks f treatment
16314606|NCT04575831|Experimental|Intervention|The intervention arm will receive a 12-week multimodal intervention featuring exercise, nutrition, and palliative symptom management.
16314607|NCT04575818|Experimental|GLPG4059 SAD|Single doses of GLPG4059 at up to 6 dose levels in ascending order
16314608|NCT04575818|Placebo Comparator|Placebo SAD|Single doses of placebo
16314609|NCT04575818|Experimental|GLPG4059 rBA/FE oral suspension fasted|Single dose of GLPG4059 in fasted state
16314610|NCT04575818|Experimental|GLPG4059 rBA/FE tablet fed|Single dose of GLPG4059 in fed state
16314611|NCT04575818|Experimental|GLPG4059 rBA/FE tablet fasted|Single dose of GLPG4059 in fasted state
16314612|NCT04575805|Experimental|Internet-delivered Combined Cognitive Bias Modification|CBM Version 1 is the combination of internet-delivered Cognitive Bias Modification-Interpretation and internet-delivered Cognitive Bias Modification-Attention interventions taking place over 4 weeks (eight sessions, twice per week).
16314613|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Interpretation|CBM Version 2 is an internet-delivered Cognitive Bias Modification-Interpretation intervention taking place over 4 weeks (eight sessions, twice per week).
16314614|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Attention|CBM Version 3 is an internet-delivered Cognitive Bias Modification-Attention intervention taking place over 4 weeks (eight sessions, twice per week).
16314615|NCT04575805|No Intervention|Wait-List Control|This arm is wait-list control group which will also receive internet-delivered Combined Cognitive Bias Modification intervention after the follow-up assessment
16314616|NCT04575792||C group|C group: control group, children who do not practice oral habits.
16314617|NCT04575792||E group|E group: exposed group, children who practicing oral habits.
16314618|NCT04575779||Group A|Cyclosporin of a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
16314619|NCT04575779||Group B|Administer cyclosporin daily dose of 3 mg/kg/day in a continuous infusion over 23 h every 24 h.
16314620|NCT04575766|Experimental|Dose escalation study of FT-7051|
16314621|NCT04575740|Experimental|Positive Airway Pressure Device|All participants will receive PAP therapy
16314622|NCT04575727|Experimental|Health Volunteers|In the first stage, five healthy human subjects will receive a microdose (10 µg) of [11C]MPC6827, immediately followed by whole body PET/CT to determine dosimetry and perform an initial safety evaluation of the radiotracer. A dose of 20 mCi [11C]MPC6827 will be administered and serial whole body PET scans will be acquired up to 2 hours post injection.
16314623|NCT04575727|Experimental|Patients with Neurodegenerative Disorders|Up to 30 patients with neurodegenerative disorders will receive a microdose (10 µg) of [11C]MPC6827 and be imaged dynamically for up to 90 minutes using PET/CT for research purposes.
16314624|NCT04575714||Acute low back pain|Adult patients with acute low back pain
16314625|NCT04575701||Ulcerative Colitis (UC)|This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
16314626|NCT04575701||Crohn's disease (CD)|This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
16314627|NCT04575701||IBD unclassified|This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
16314628|NCT04575688|Active Comparator|Periarticular Injection|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a periarticular injection by the surgeon using 10 milliliters of Exparel mixed with 10 milliliters of bupivicaine 0.5 percent at the end of the procedure.
16314754|NCT04574843|Experimental|Embolization arm|Intervention: Embolization of middle meningeal artery Device: Onyx, squid, Phil
16314629|NCT04575688|Active Comparator|Popliteal Block|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a popliteal block by the anesthesiologist using 30 milliliters of bupivicaine 0.5 percent in the pre-operative area, prior to surgery, using an ultrasound machine for guidance.
16314630|NCT04575675|Experimental|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
16314631|NCT04575675|Placebo Comparator|Standard of care|Standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
16314632|NCT04575662|Experimental|STAR Treatment|Patients performing STAR treatment
16314633|NCT04575636|Other|Lymphedema patients|MRL examination in lymphedema patients
16314634|NCT04575636|Other|Healthy volunteers|MRL examination in healthy volunteers
16314635|NCT04575623||Study group|It will consist of 120 patients suffering from migraine according to international classification of headache
16314638|NCT04575597|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314639|NCT04575597|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314640|NCT04575597|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314641|NCT04575597|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314642|NCT04575597|Experimental|Part 2: Molnupiravir 800 mg|800 mg Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
16314643|NCT04575597|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314644|NCT04575584|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314645|NCT04575584|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314646|NCT04575584|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314647|NCT04575584|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314648|NCT04575584|Experimental|Part 2: Molnupiravir|Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
16314649|NCT04575584|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
16314650|NCT04575558|Experimental|Hydroxychloroquine + Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD, both for 7 days
16314651|NCT04575558|Placebo Comparator|Hydroxychloroquine + Placebo tablets|Hydroxychloroquine 400mg PO BID 2 times a day + Placebo, both for 7 days
16314652|NCT04575545||HIV positive patients|
16314653|NCT04575545||Patients taking PrEP|
16314654|NCT04575519|Active Comparator|Control group|Standard of Care (SoC) TB treatment + placebo twice daily during first 4 weeks of TB treatment followed by placebo once daily for an additional 4 weeks.
16314655|NCT04575519|Experimental|SoC TB + ASA group|Standard of Care (SoC) TB treatment + acetylsalicylic acid 300mg twice daily during first 4 weeks of TB treatment followed by aspirin 300mg once daily for an additional 4 weeks.
16314656|NCT04575519|Experimental|SoC TB + IBU group|Standard of Care (SoC) TB treatment + ibuprofen 400mg twice daily during first 4 weeks of TB treatment followed by ibuprofen 400mg once daily for an additional 4 weeks
16314657|NCT04575506|No Intervention|Control group|
16314658|NCT04575506|Active Comparator|Obesity-Non-hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
16314659|NCT04575506|Experimental|Obesity-Hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
16314660|NCT04575493|Experimental|Test Group|No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
16314661|NCT04575493|Active Comparator|control group|No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
16314662|NCT04575480|Active Comparator|Group 1|Group 1 will undergo SWL with 3 days between each session.
16314663|NCT04575480|Active Comparator|Group 2|Group 2 will undergo SWL with 7 days between each session
16314664|NCT04575480|Active Comparator|Group 3|Group 3 will undergo SWL with 14 days between each session.
16314665|NCT04575467|Experimental|CBL-514 320 mg|
16314666|NCT04575467|Experimental|CBL-514 480 mg|
16314667|NCT04575467|Experimental|CBL-514 640 mg|
16314668|NCT04575467|Experimental|CBL-514 800 mg|
16314669|NCT04575454|Other|Comatose or post-comatose patients|
16314670|NCT04575441|Experimental|Pilates Ball Exercises|Various exercises are conducted with using pilates ball. Sensory feedbacks like proprioception and vestibulation are given. Many physical fitness parameters like balance, coordination, speed and agility are used in this exercise program. Children are taken to the program for 40 min, twice a week during 6 weeks.
16314671|NCT04575441|No Intervention|Without exercise|The children in this group are not included in any kind of exercise/sport program during 6 weeks.
16314672|NCT04575428|Experimental|Splanchnic nerve block|
16314755|NCT04574817|Experimental|HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
16314673|NCT04575415||Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
16314674|NCT04575415||Arm 2:Bevacizumab plus Afatinib/Dacomitinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.
16314675|NCT04575415||Arm 3:Bevacizumab plus Osimertinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
16314676|NCT04575402||CSMC prostate cancer patients receiving ADT|Prostate cancer patients recruited from oncology clinic at Cedars-Sinai Medical Center.
16314677|NCT04575402||Veterans with prostate cancer|Prostate cancer patients recruited from the Veteran Affairs Oncology Clinic (Durham, NC).
16314678|NCT04575363|Experimental|pancreatic adenocarcinoma patient|patient with pancreatic ductal adenocarcinoma
16314679|NCT04575350||Cohort|no intervention.
16314680|NCT04575337||AD group|Dementia is diagnosed according to the 2011 NIA-AA criteria.
16314681|NCT04575337||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
16314682|NCT04575337||pre-MCI group|β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment; not up to MCI or cognitive impairment.
16314683|NCT04575337||Other neurodegenerative diseases|Frontotemporal Dementia; or Parkinson's disease
16314684|NCT04575337||Cognitive normal group|Individuals are with normal cognitive function and ≥ 60 years old.
16314685|NCT04575324|Experimental|Intervention Arm|Participants will receive the telemedicine linkage intervention.
16314686|NCT04575324|No Intervention|Control Arm|Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
16314687|NCT04575311|Active Comparator|Active: Dose Escalation|Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 or matching placebo will be random.
16314688|NCT04575311|Placebo Comparator|Placebo: Dose Escalation|Participants will receive matching placebo as a single oral dose. Assignment to receive AB680 or matching placebo will be random.
16314689|NCT04575285|Experimental|Electroencephalogram (EEG)|All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.
16314690|NCT04575272|Experimental|Continuous Deep Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately deep to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
16314691|NCT04575272|Active Comparator|Continuous Superficial Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately superficial to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
16314692|NCT04575259|Experimental|ANAVEX2-73 Active|Oral capsules
16314693|NCT04575233|Experimental|Laparoscopic Transversus Abdominis Plane (L-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under laparoscopic control
16314694|NCT04575233|Active Comparator|Ultrasound Transversus Abdominis Plane (U-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under ultrasound control
16314695|NCT04575220|Experimental|tele-exercise|Subjects will perform three sessions/week of home exercise using bicycles for 12 weeks
16314696|NCT04575207|Experimental|caFFR-guided|Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR > 0.80.
16314697|NCT04575207|Active Comparator|FFR-guided|Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR > 0.80.
16314698|NCT04575194|Active Comparator|Liraglutide 3 mg|Patients will be prescribed sc liraglutide 3 mg/day along with a dietary and physical activity intervention.
16314699|NCT04575194|Active Comparator|Naltrexone/bupropion 32/360 mg|Patients will be prescribed oral naltrexone/bupropion 32/360 mg/day along with a dietary and physical activity intervention.
16314700|NCT04575181|Experimental|NNC0286-0965|NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial
16314701|NCT04575181|Active Comparator|Insulin glargine|Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial
16314702|NCT04575168||Positive for COVID-19|Subjects positive for COVID-19 as indicated by the Standard of Care test.
16314703|NCT04575168||Negative for COVID-19|Subjects negative for COVID-19 as indicated by the Standard of Care test.
16314726|NCT04574973|Experimental|Anodal tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
16314704|NCT04575155|Experimental|TEAM Strategy|Patients randomized to the TEAM intervention arm will receive at least one call from a Walgreens pharmacist to help them with their complex Rx regimens. Pharmacists will have read/write EHR access with established Epic security points. Through shared access to patients' medical records, pharmacists can perform comprehensive medication therapy management services, document and communicate patients' Rx challenges for review and action by primary care providers. After the pharmacist calls the patient for a Comprehensive Medication Review, they will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit.
16314705|NCT04575155|No Intervention|Enhanced Usual Care|Patients randomized to enhanced usual care will have the medical record available to a Walgreens pharmacist with 'read only' access. All patients at the five targeted health centers already have read-only access in place. This means the Walgreens pharmacist will have the capability to review a patient's record as necessary. The pharmacist may refer to the EHR as needed and in a reactive manner; such as if a patient were to request a medication requiring review for billing purposes (i.e. verify insurance, prior authorizations), or if a patient safety concern was raised (e.g. potential drug-drug or drug- disease interaction, therapeutic duplication, etc.). Similarly, read only EHR access means pharmacists must continue to use existing communication channels (e.g. phone, fax) to contact prescribers.
16314706|NCT04575142|Experimental|CO2 laser device group|Participants who will be undergoing laser treatment for their vocal nodes with a specific laser device. AcuPulse Duo, a CO2 laser is absorbed by water found in soft tissues and is independent of tissue color. It is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. The absence of a long healing process means that most patients can resume their normal activities even on the same day The CO2 laser is the preferred laser for use in the operating room.
16314707|NCT04575129||Study Group|No intervention will be applied
16314708|NCT04575116|Experimental|Tafamidis Free acid tablet then tafamidis meglumine capsule|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
16314709|NCT04575116|Experimental|Tafamidis meglumine capsule then Tafamidis Free acid tablet|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
16314710|NCT04575103|Active Comparator|Antipsychotics|Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.
16314711|NCT04575103|No Intervention|Control|Healthy controls, not treated with antipsychotics.
16314712|NCT04575090||Sub-Study 1|Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
16314713|NCT04575090||Sub-Study 2|"Subjects will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.
~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
16314714|NCT04575064|Other|Standard of Care (SoC)|This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
16314715|NCT04575064|Experimental|Remdesivir + SoC|Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
16314716|NCT04575051|Active Comparator|Residents|Residents will be exposed to the Consult Model and then the Engage Model. Hearing Specific Quality of Life and Satisfaction with Social Participation are the outcome measures. Hearing Specific Quality of Life is measured using the HHIE with a range of scores from 0-40 with a lower score revealing less handicap. Satisfaction with Social Participation is measured using the Satisfaction with Participation in Discretionary Social Activities Short form 7a with a range of scores from 7-35 with a higher score meaning higher satisfaction.
16314717|NCT04575051|Active Comparator|Family|Families will be surveyed related to burden during the Consult and Engage Model of Care. Family Burden will be measured using the Zarit Burden scale with a range of scores from 0-16 and a lower scoring revealing less burden.
16314718|NCT04575051|Active Comparator|Staff|Staff of the Assisted Living/Personal Care Facilities will be surveyed related to work satisfaction during the Consult and Engage Model of Care. Staff work satisfaction will be measured with the Michigan Organizational Assessment Questionnaire (MOAQ) with a range of scores from 3-18 and a lower score revealing higher satisfaction.
16314719|NCT04575038|Experimental|Brequinar 100 mg|Brequinar oral capsules 100 mg x 5 days
16314720|NCT04575038|Placebo Comparator|Placebo|Placebo for Brequinar capsules x 5 days
16314721|NCT04575025||Tabrecta tablets|Patients administered Tabrecta by prescription
16314722|NCT04575012|Experimental|Deferred invasive strategy|
16314723|NCT04575012|Other|Early invasive strategy|
16314724|NCT04574999|Experimental|0.005% Estriol group|0.005% Estriol (50 μg/g) gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
16314725|NCT04574999|Placebo Comparator|Placebo group|Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
16314813|NCT04574336|Experimental|Surgical Treatment|Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method
16314727|NCT04574973|Experimental|Cathodal tDCS|Subjects will receive 20 minutes of active, excitatoryinhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
16314728|NCT04574973|Experimental|Dual tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere and inhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
16314729|NCT04574973|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the affected upper extremity.
16314730|NCT04574960|Experimental|Neoadjuvant Chemotherapy Arm|Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).
16314731|NCT04574960|Active Comparator|Adjuvant Chemotherapy Arm (Standard of Care)|"Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy.
~Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin.
~Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles.
~Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles."
16314732|NCT04574947|Active Comparator|Intravenous lidocaine|
16314733|NCT04574947|Experimental|Topical lidocaine|
16314734|NCT04574947|Placebo Comparator|Placebo|
16314735|NCT04574934|Experimental|the study group|study group received the traditional physical therapy program plus aquatic therapy
16314736|NCT04574934|No Intervention|the control group|control group received traditional physical therapy program only.
16314737|NCT04574921|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
16314738|NCT04574921|Sham Comparator|Sham|Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
16314739|NCT04574908|Active Comparator|Blinded Ward 1|Continuous ward monitoring with hallway monitor screens covered. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.
16314740|NCT04574908|Experimental|Unblinded Ward 2|Continuous ward monitoring with hallway monitor screens accessible for viewing but with alarm limits more narrow. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will be able to view the hallway monitors showing the vital signs in all of the rooms and/or log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.
16314741|NCT04574908|Active Comparator|Blinded Ward 2|Continuous monitoring accessible to clinicians with pre-specified alerts at Systolic Blood Pressure alert <70, no Mean Arterial Pressure alert, heart rate >150 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <80%. Every 4 hourly checks by nursing teams unless otherwise ordered. These alarms are consistent with current standard of care.
16314742|NCT04574908|Experimental|Unblinded Ward 1|Continuous monitoring accessible to clinicians with pre-specified alerts at Mean Arterial Pressure (MAP) <65 mmHg, heart rate >110 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <90%. Every 4 hourly checks by nursing teams unless otherwise ordered.
16314743|NCT04574895|Other|VTE risk prediction scores|Patients in the intervention arm will have their VTE risk prediction scores presented to the study team daily on weekdays via an automated report, which will list patients in descending order of risk severity for review by the VTE research team each weekday. Starting with the highest risk patients, the VTE research team will review each patient and clinical situation, and then the VTE research team will directly discuss risks/benefits of prophylactic anticoagulation with the admitting team. Patients with a risk score <1% will not be reviewed, and the investigators anticipate most of the intervention arm patients will fall into this category (based on our previous data, the investigators anticipate >90% of all patients will score <1%). The VTE risk report will be re-calculated based on updated EHR data every day at midnight.
16314744|NCT04574895|No Intervention|Standard of care|Patients randomized to the control arm will continue to receive current standard of care anticoagulation practice, which is at the discretion of the admitting team. In general, nearly no pediatric patients are offered prophylactic anticoagulation unless a previous VTE has been identified. This currently is at the discretion of the provider and no risk scoring is used. VTE risk prediction scores will be calculated and stored for analysis, these will not be visible to the study team in real time.
16314745|NCT04574882||Case|Patients ages 40-74 with and without CHD (IICD 10: I63, I20-I25 ) within the last 6 months who receive care in the University of Pennsylvania Health System (UPHS).
16314746|NCT04574882||Control|Patients aged 40-74 who have non-cardiovascular-related chief compliant.
16314747|NCT04574869|Experimental|RLS-0071 administered as Single-Ascending Low Dose|Patients will receive a single low-dose infusion of RLS-0071 or placebo.
16314748|NCT04574869|Experimental|RLS-0071 administered as Single-Ascending High Dose|Patients will receive a single high-dose infusion of RLS-0071 or placebo.
16314749|NCT04574869|Placebo Comparator|Placebo administered as Single-Ascending Doses|Placebo will be administered at the same volume and duration of IV infusion corresponding to the dosing cohort schedules.
16314750|NCT04574869|Experimental|RLS-0071 administered as Multiple-Ascending Low Doses|Patients will receive treatment with RLS-0071 low dose or placebo approximately 3 days (i.e., q8 hours [± 1 hour] for 9 consecutive doses).
16314751|NCT04574869|Experimental|RLS-0071 administered as Multiple-Ascending High Doses|Patients will receive treatment with RLS-0071 high dose or placebo approximately 3 days (i.e., q8 hours [± 1 hour] for 9 consecutive doses).
16314752|NCT04574869|Placebo Comparator|Placebo administered as Multiple-Ascending Doses|Placebo will be administered approximately 3 days (i.e., q8 hours [± 1 hour] for 9 consecutive doses).
16314756|NCT04574804|Experimental|online training program|online training program Participants receive access to online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis, which they will be instructed to and encourage to complete over the 6 intervention period.
16314757|NCT04574804|No Intervention|control group|control group Participants do NOT receive access to the online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis during the intervention period.
16314758|NCT04574791|No Intervention|Multimodal Pain Regimen|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol.
16314759|NCT04574791|Experimental|Multimodal Pain Regimen + Tizanidine|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge
16314760|NCT04574778|Active Comparator|Group 1: IV acetaminophen and oral placebo|Group 1 will receive 1000 mg of IV acetaminophen approximately 30 minutes prior to skin closure and will receive oral placebo in the holding area prior to surgery
16314761|NCT04574778|Active Comparator|Group 2: oral acetaminophen|Group 2 will receive 1000 mg of PO acetaminophen in the holding area and will not receive an IV placebo.
16314762|NCT04574765||Healthcare Worker|Individuals who work within a food production, healthcare, research or clinical organization of participating institutions.
16314763|NCT04574726|Experimental|virtual environment|Balance test in virtual environment with a virtual reality software executed in a 6DOF Occulus Quest helmet and a motion capture software with a Kinect Azure DK camera.
16314764|NCT04574726|Active Comparator|reel environment|Balance test in real environment with a motion capture software and a Kinect Azure DK camera.
16314765|NCT04574713|Experimental|Candesartan 8 mg|
16314766|NCT04574713|Experimental|Candesartan 16 mg|
16314767|NCT04574713|Placebo Comparator|Control group|
16314768|NCT04574700|Experimental|knee joint mobilization and traction|Tibiofemoral, Tibiofibular joint anterioposterior mobilization, keltonborn knee traction Transcutaneous electrical nerve stimulation(TENS) and quadriceps strengthening
16314769|NCT04574700|Active Comparator|Post isometric relaxation|Post isometric relaxation on hamstring, TENS and quadriceps strengthening.
16314770|NCT04574687|Active Comparator|Neurodevelopmental Techniques|Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
16314771|NCT04574687|Experimental|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
16314772|NCT04574674|Experimental|Flexibility exercise group|"Participants will be asked to follow a 12-week flexibility exercise training programme. Participants will be asked to perform a minimum amount of flexibility exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.
~Participants will perform 6 flexibility exercises per week (2 different for legs, 1 shoulder and arms, 1 chest, 1 back and 1 core). Passive static stretching exercises will be performed."
16314773|NCT04574674|Experimental|Resistance exercise group|"Participants will be asked to follow a 12-week home-based exercise programme. Participants will be asked to perform a minimum amount of resistance exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.
~Participants in the resistance exercise group will be asked to perform a total of 6 exercises per week (2 different leg exercises, 1 shoulder exercise, 1 chest exercise, 1 back exercise and 1 core exercise). Body weight and resistance bands exercises will be used. Participants will be asked to perform each set to complete as many repetitions as possible until fatigue."
16314774|NCT04574661|Active Comparator|Static stretching|Static stretching to lower limb muscles
16314775|NCT04574661|Experimental|Intermittent occlusion|Intermittent occlusion to lower limb
16314776|NCT04574648|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the non-adherence information such that community pharmacists can view the information prior to dispensing medications.
16314777|NCT04574648|No Intervention|Standard care (ADE information retained locally)|Patients in the control arm will have their information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their information will not be visible to other providers via PharmaNet.
16314778|NCT04574635||Cohort 1 (surgery patients)|Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
16314779|NCT04574635||Cohort 2 (post-operative radiation +/- chemotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
16314780|NCT04574635||Cohort 3 (definitive chemoradiotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
16314781|NCT04574635||Cohort 4 (systemic treatment patients)|Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
16314814|NCT04574336|Active Comparator|Non-surgical treatment|Treatment of humeral shaft fracture with sling and/or functional brace
16314782|NCT04574622|Experimental|Five true ESWT sessions|"A total of five sessions (1x/week) were conducted.
~A total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
16314783|NCT04574622|Experimental|Three true ESWT sessions and two sham ESWT sessions|"A total of three true ESWT (week 1, 3 and 5) and two sham ESWTs in (week 2 and 4) were conducted.
~For true ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars.
~For sham ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle with a 1 cm gap between between the probe and subject's skin. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
16314784|NCT04574609|No Intervention|no hypnotherapy|"A control group of patients receiving the usual management for PAC and chemotherapy sessions."
16314785|NCT04574609|Experimental|hypnotherapy|"A hypnotherapy group of patients benefiting from hypnotherapy sessions prior to PAC and chemotherapy cures in addition to the usual management."
16314786|NCT04574596||3GCR ceftriaxone-resistant-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
16314787|NCT04574596||3GCS ceftriaxone-susceptible-E. coli|Positive blood culture for above susceptible e coli. Observational there will be no intervention
16314788|NCT04574583|Experimental|1/Sequential Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN M7824 +CV301
16314789|NCT04574583|Experimental|2/Combination Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN Escalating doses of SX-682 + M7824 + CV301
16314790|NCT04574583|Experimental|3/Disease-Specific Expansion|RP2D of SX-682 + M7824 + CV301
16314791|NCT04574570|Other|interventional patient|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
16314792|NCT04574544|Experimental|Zinc supplementation|The 25 supplemented children had received an oral dose of 10 mg of zinc sulphate per day for 14 days
16314793|NCT04574544|Experimental|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
16314794|NCT04574518|Experimental|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
16314795|NCT04574518|Other|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
16314796|NCT04574505|Experimental|NUT|1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
16314797|NCT04574505|Placebo Comparator|Placebo|1 tablet of Placebo per day + standard diet for 8 weeks
16314799|NCT04574479|Placebo Comparator|Placebo|Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
16314800|NCT04574479|Experimental|Fascia iliaca block|Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
16314801|NCT04574466|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by a physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
16314802|NCT04574466|Experimental|Problem Management Plus|"The participants who are assigned to the intervention group will receive five sessions of PM+, a psychological intervention which has been developed by the WHO. PM+ is a new short, transdiagnostic (i.e., not specifically aimed at treating a certain mental disorder) program aiming to reduce common mental health symptoms and improve psychosocial functioning.
~PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, and accessing social support. These elements have been recommended in recent WHO guidelines. PM+ has proven to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan."
16314803|NCT04574453|Experimental|Iracross|1 course of IRACROSS (crosslinked 2% Hyaluronic Acid) at baseline, consisting of a mono-dose intra-articular administration (2ml).
16314804|NCT04574453|Active Comparator|Iraline|1 course of IRALINE (linear 2% Hyaluronic Acid); each course consists of 3-5 intra-articular administrations (2ml) at weekly intervals (from week 1 to 3, 4 or 5, depending on each patient's need)
16314805|NCT04574440||multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap during surgery. The patient's surgery and subsequent medical care will not be altered.
16314806|NCT04574414||Children with Attention Deficit Hyperactivity Disorder|Cases
16314807|NCT04574414||Children without Attention Deficit Hyperactivity Disorder|Population controls
16314809|NCT04574388|Active Comparator|open label placebo|participants will take open label placebo pills TID and in conjunction with other PRN analgesics
16314810|NCT04574388|No Intervention|treatment as usual|participants will take PRN analgesics as usual
16314811|NCT04574362|Active Comparator|Rimegepant 75mg|One 75mg oral disintegration tablet
16314812|NCT04574362|Placebo Comparator|Placebo|Matching placebo
16314815|NCT04574323|Experimental|Paleolithic lifestyle group|The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
16314816|NCT04574323|Other|Standard diet group|This group is on a standard diet while receiving radiotherapy.
16314817|NCT04574310||Frozen embryo transfer (FET)|Collect retrospectively data on embryo implantation rate
16314818|NCT04574310||Intracytoplasmic sperm injection (ICSI)|Collect retrospectively data on embryo implantation rate
16314819|NCT04574310||oocyte donation|Collect retrospectively data on embryo implantation rate
16314820|NCT04574284|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16314821|NCT04574284|Experimental|TQB2450|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
16314822|NCT04574284|Experimental|Anlotinib|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16314823|NCT04574271|Experimental|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
16314824|NCT04574271|Active Comparator|Usual dietary advice and exercise prescription|Generalized dietary advice and exercise prescription in elder subjects.
16314825|NCT04574245||Resectable group|
16314826|NCT04574245||Potentially resectable group|
16314827|NCT04574245||Unresectable group|
16314828|NCT04574232|Other|athletic subjects|athletic subjects who may need intra-articular knee infiltration
16314829|NCT04574219|Other|Feasibility/Acceptability|This arm will be used to assess the feasibility and acceptability of using FaceTime during induction.
16314830|NCT04574219|Other|Coaching prior to surgery|
16314831|NCT04574219|Other|Coaching day of surgery|
16314832|NCT04574206|Experimental|Elaborative Reminiscence (ER)|ER is a communication strategy used between a caregiver and child to support children's cognitive and emotional development. ER involves a caregiver and child jointly reminiscing about a past event that they personally experienced, to co-create a coherent narrative that describes the event from both their perspectives. ER consists of two crucial elements, the use of elaborative language (e.g. open ended questions, contributing new information to the conversation) and specific talk focused on recollections of the past as opposed to observations of the present.
16314833|NCT04574206|Sham Comparator|Present Tense Talk (PTT)|PTT is an active control intervention, designed to ensure that caregivers/ guardians in this group spend a similar amount of time engaging in conversation with their children but do not use elaborative reminiscing language. The focus will be on describing activities as they are happening in real time; PTT caregivers will be asked to avoid reference future or past events .
16314834|NCT04574193|Experimental|Continuing Care App|Participants will receive the Continuing Care app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy).
16314835|NCT04574193|Active Comparator|Treatment As Usual|Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.
16314836|NCT04574180|Active Comparator|Group 1|Zirconia crown anterior (NuSmile, Houston, Texas, USA).
16314837|NCT04574180|Active Comparator|Group 2|Zirconia crown posterior (NuSmile, Houston, Texas, USA).
16314838|NCT04574180|Active Comparator|Group 3|Stainless steel crown (3M-ESPE, St. Paul, Minnesota, USA)
16314839|NCT04574180|Active Comparator|Group 4|Strip Crown (3M-ESPE, St. Paul, Minnesota, USA)
16314840|NCT04574167|Experimental|tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes)
16314841|NCT04574167|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
16314842|NCT04574154|Experimental|FIB|ultrasound guided Fascia Iliaca Block
16314843|NCT04574154|Experimental|ESPB|ultrasound guided Erector Spinae Plane Block
16314844|NCT04574141|Experimental|spray before tablet|
16314845|NCT04574141|Experimental|tablet before spray|
16314846|NCT04574128|Experimental|Retransfusion of cardiotomy blood or not|Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
16314847|NCT04574128|No Intervention|No retransfusion of cardiotomy blood|
16314848|NCT04574115|Experimental|Study Eye|study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.
16314849|NCT04574115|Active Comparator|Control Eye|Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
16314850|NCT04574102|Experimental|Study Eye|Omega Refractive capsule, model V, with an FDA approved intraocular lens.
16314851|NCT04574102|Active Comparator|Control Eye|FDA approved Intraocular Lens
16314852|NCT04574089|Experimental|Baofukang Suppository 7 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days
16314853|NCT04574089|Experimental|Baofukang Suppository 14 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days
16314855|NCT04574063|No Intervention|Breast cancer risk leaflet only|
16314856|NCT04574063|No Intervention|Breast cancer risk leaflet PLUS SNPs|
16314861|NCT04574050|Experimental|SELF-BREATHE|Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
16314862|NCT04574050|No Intervention|Control|standard / currently available NHS care
16314863|NCT04574037||follow up of stroke patients with a upper limb deficit|Usual follow up of stroke patients with a upper limb deficit
16314864|NCT04574024|Experimental|Cohort A: Treatment with NBT-NM108�|Patients will receive NBT-NM108 at 60 g/day for 8 weeks.
16314865|NCT04574024|Placebo Comparator|Cohort B: Non-treatment|Patients will not receive NBT-NM108.
16314866|NCT04574011|Experimental|Fluid challenge responder|If the ratio of the stroke volume change after passive leg raising is the same or larger than 10%, the patient is assigned to RESPONDER group.
16314867|NCT04574011|Experimental|Fluid challenge non-responder|If the ratio of the stroke volume change after passive leg raising is less than 10%, the patient is assigned to RESPONDER group.
16314868|NCT04573985|Experimental|Serious Game Eurekoi intervention|1 session in group using the serious game eurekoi
16314869|NCT04573985|No Intervention|Control group|no intervention
16314870|NCT04573972|Active Comparator|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
16314871|NCT04573972|Experimental|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
16314872|NCT04573959|Experimental|SV-3 Capsule Endoscopy|CapsoCam SV-3 Capsule Endoscopy system will perform in a manner consistent with the performance of the CapsoCam SV-3 capsule endoscopy systems.
16314873|NCT04573946|Placebo Comparator|Vitamin D placebo + fish oil placebo|
16314874|NCT04573946|Active Comparator|Vitamin D placebo + fish oil|
16314875|NCT04573946|Active Comparator|Vitamin D + fish oil placebo|
16314876|NCT04573946|Active Comparator|Vitamin D + fish oil|
16314877|NCT04573920|Experimental|Atrasentan|Once daily oral administration of 0.75 mg atrasentan for 52 weeks.
16314878|NCT04573907|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
16314879|NCT04573907|Active Comparator|Reference formulation of Levothyroxine|Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
16314880|NCT04573894||Positives blood cultures|Collection of clinical and biological data of patients with blood cultures positives for potential contaminants, as well as PCT levels measurements, from January 2016 to May 2019 at the Nancy CHRU
16314881|NCT04573881|Experimental|Treatment Group|This is a single arm study that intends to treat all enrolled subject with the histotripsy device.
16314882|NCT04573855|Experimental|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
16314883|NCT04573855|No Intervention|Control|
16314884|NCT04573829|Experimental|Non-drug approaches at home|Non-drug approaches at home three visits per week during six months and psycho-education for the caregivers one time per week for six months.
16314885|NCT04573803|Experimental|MAST DURATION - <3 months|TBI patients with early seizures (within first 7 days following trauma) will receive a short course of up to 3 months of either Phenytoin Sodium or Levetiracetam.
16314886|NCT04573803|Experimental|MAST DURATION - >6 months|TBI patients with early seizures (within first 7 days following trauma) will receive a longer course of at least 6 months of either Phenytoin Sodium or Levetiracetam.
16314887|NCT04573803|Experimental|MAST PROPHYLAXIS - Phenytoin Sodium|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Phenytoin Sodium as seizure prophylaxis.
16314888|NCT04573803|Experimental|MAST PROPHYLAXIS - Levetiracetam|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Levetiracetam as seizure prophylaxis. Dosing will be as prescribed clinically by the treating physician.
16314889|NCT04573803|No Intervention|MAST PROPHYLAXIS - no treatment|TBI patients, without an acute symptomatic seizure, will not receive any anti-epileptic drug.
16314890|NCT04573790||Trained in eFONA|Trained participants completed our eFONA workshop within the last six month prior to participating in this study
16314891|NCT04573790||Untrained in eFONA|Untrained participants had never taken part in our institutional eFONA workshop
16314892|NCT04573777|Experimental|Intervention Repatha|
16314893|NCT04573764|Active Comparator|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|
16314894|NCT04573764|Placebo Comparator|Placebo|
16314895|NCT04573751|Sham Comparator|Standard therapy|No intracoronary epinephrine and verapamil
16314896|NCT04573751|Active Comparator|Epinephrine|Intracoronary bolus epinephrine injection requires two ampoules each of 1:1,000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline solution (to 20 μg/mL epinephrine solution); therefore, a 5-mL syringe contains 100 μg of epinephrine. Intracoronary epinephrine will be administered at a dose of 100 μg and at a lower dose of 80 μg in patients with blood pressure >160 mmHg
16314897|NCT04573751|Active Comparator|Verapamil|Intracoronary verapamil is administered at a dose of 0.5 mg.
16314898|NCT04573751|Active Comparator|Epinephrine + verapamil|Intracoronary administration of epinephrine at a dose of 80-100 μg and verapamil at a dose of 0.5 mg.
16314899|NCT04573738|Experimental|Robotic transanal surgery|Robotic assisted transanal total mesorectal excision for rectal cancer patients
16314900|NCT04573738|Active Comparator|Laparoscopic transanal surgery|Laparoscopic transanal total mesorectal excision for rectal cancer patients
16314901|NCT04573725|Experimental|5 mg|Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
16314902|NCT04573725|Experimental|10 mg|Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
16314903|NCT04573725|Experimental|30 mg|Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
16314904|NCT04573725|Placebo Comparator|Placebo|Period in which participants received single placebo prior to bedtime
16314905|NCT04573712|Experimental|Fatigue Severity Scale scores assessment|Fatigue Severity Scale scores assessment
16314906|NCT04573673|Experimental|PTNS verum|Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.
16317439|NCT04556123|Active Comparator|Decongestion based on clinical judgement|
16314907|NCT04573673|Sham Comparator|PTNS placebo|Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).
16314908|NCT04573660||XIENCE PRIME BTK|Participants in the XIENCE PRIME BTK arm will receive XIENCE PRIME BTK
16314909|NCT04573660||Absolute Pro LL|Participants in the Absolute Pro LL arm will receive Absolute Pro LL
16314910|NCT04573660||Supera 7.5 Outer Diameter (OD)|Participants in the Supera 7.5 OD arm will receive Supera 7.5 OD
16314911|NCT04573660||Xpert Pro|Participants in the Xpert Pro arm will receive Xpert Pro
16314912|NCT04573660||Pacel Pacing Catheters|Participants in the Pacel Pacing Catheters arm will receive Pacel Pacing Catheters (pacel bipolar pacing catheter [BPC] or pacel flow directed bipolar pacing catheter [FDPC])
16314913|NCT04573660||Amplatzer Vascular Plugs|Participants in the Amplatzer Vascular Plugs (AVP) arm will receive Amplatzer Vascular Plugs (AVP I/ AVP II/ AVP 4)
16314914|NCT04573660||Pressure Wire|Participants in the Pressure Wire arm will receive Pressure Wire X
16314915|NCT04573660||Multilink BMS|Participants in the Multilink BMS arm will receive either MULTI-LINK 8/ MULTILINK 8 Long Length (LL)/ MULTILINK 8 Small Vessel (SV)
16314916|NCT04573647||Treatment group|All participants in this trial will be in the treatment group. They will administer Oxervate following the FDA approved guidelines: 1 drop to the affected eye 6 times per day for 8 weeks.
16314917|NCT04573634||Health Care Workers|Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
16314918|NCT04573634||Eligible Patients|Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
16314919|NCT04573634||Quarantining Individuals|Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
16314920|NCT04573621|Active Comparator|Pelvic drain|Placement of a pelvic drain
16314921|NCT04573621|Experimental|No pelvic drain|No pelvic drain placed
16314922|NCT04573608|Experimental|Papacarie-Duo|
16314923|NCT04573608|Active Comparator|Atraumatic Restorative Treatment|
16314924|NCT04573582|Experimental|Enasidenib (CC-90007) tablet|Participants will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
16314925|NCT04573556||Lemborexant|Participants with insomnia will initiate treatment with lemborexant 5 milligram (mg), tablet, orally as per the clinical judgment of the treating physician as part of routine clinical care. Dosage and administration of lemborexant tablet will be according to package insert and actual dosing and frequency will be decided by physician including dose escalation from initial dose of 5 mg up to 10 mg once daily. All participants will be observed prospectively for up to 24 weeks.
16314926|NCT04573543||Patients with Non-alcoholic fatty liver disease|120 patients diagnosed with NAFLD
16314927|NCT04573543||Controls|40 healthy controls
16314928|NCT04573530|Experimental|We Walk Plus Intervention|The intervention group will receive a Fitbit, SMS and will be assigned to a private Fitbit community (4-5 participants per group) for 12 weeks. During the intervention, participants will receive weekly personalized SMS on their mobile phones including encouraging messages, reminders, and tips to increase steps, and weekly step goals. The investigators will use a secure, web-based platform, iCardia, to support continuous real-time remote monitoring of activity data from Fitbit devices and personalized communication via SMS based on incoming data. The investigators will set up the Fitbit networking settings on participants' phones to give notifications when there are posts to this group. Individual goals and a weekly team goal of steps will be set up by the research team. Each member will be awarded a badge upon reaching each individual's weekly goal. Teams will also be awarded badges when all team members reach their individual weekly goals.
16314929|NCT04573530|No Intervention|Attention control group|The attention control group will also receive a Fitbit and will be asked to continue with normal daily activities. During the initial in-person session, they will receive the same PA recommendations as the intervention group to walk at least 30 minutes for 5 days or more a week or 10,000 steps a day. However, a plan for improving PA will not be discussed.
16314930|NCT04573517|Experimental|Early amniotomy|Subjects randomized to this arm will undergo amniotomy within 2 hours of removal of Foley balloon.
16314931|NCT04573517|Active Comparator|Delayed amniotomy|Subjects randomized to this arm will undergo amniotomy at least 4 hours after removal of Foley balloon.
16314932|NCT04573504|Experimental|Antibiotic Group|The antibiotic regimen chosen is based on the Royal College of Obstetricians and Gynecologists' recommendations (Augmentin and Flagyl or Clindamycin and Flagyl if they are allergic to Penicillin). The dosage for the antibiotics are the following: Flagyl 500mg po BID (twice a day) X 5 days, Clindamycin 400 mg po TID (three times a day) X 5 days, Augmentin 875mg po BID X 5 days.
16314933|NCT04573504|Placebo Comparator|Placebo Group|Women randomized not to receive antibiotics will be given placebo tablets postpartum, so they will all have an identical experience to the women in the experimental (antibiotic) group.
16314934|NCT04573491|Experimental|Pharmacogenetic test|Medication review including results from pharmacogenetic testing
16314937|NCT04573465|Experimental|Phone Coaching Condition|Participants will receive weekly, 10-15 minute phone coaching from a trained peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. Coaches will adhere to an ACT-based protocol that includes reinforcing adherence, identifying and problem solving non-adherence, strengthening and generalizing ACT skills, and using ACT skills to increase commitment to ongoing program adherence.
16314938|NCT04573465|Experimental|Text Message Coaching Condition|Participants assigned to the text messaging condition will receive weekly text messages from their peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. These text messages will reflect content delivered in the phone coaching group, but through a briefer protocol that accounts for the abbreviated, asynchronous nature of texting. Text messages will similarly focus on reinforcing adherence, problem solving non-adherence, strengthening ACT skills, and using ACT to increase program adherence. However, these areas will be covered in short messages and with limited exchanges between participants and coaches due to the asynchronous nature of texting.
16317497|NCT04555746|No Intervention|Control|Waiting list
16314939|NCT04573465|Active Comparator|No Coaching Condition|Participants will be asked to use ACT Guide, an online program for general mental health, over the course of 10 weeks while receiving no coaching.
16314940|NCT04573452||Normal pregnancy group|
16314941|NCT04573452||Placenta accreta at 32 weeks group|
16314942|NCT04573452||Placenta accreta at 37 weeks group|
16314943|NCT04573426||Overweight/Obese+Drug+Stigma|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
16314944|NCT04573426||Overweight/Obese+Drug+Control|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
16314945|NCT04573426||Overweight/Obese+Placebo+Stigma|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
16314946|NCT04573426||Overweight/Obese+Placebo+Control|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
16314947|NCT04573426||Normal Weight+Placebo+Stigma|40 participants with normal weight will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
16314948|NCT04573413|Experimental|r-TMS group|The interventions have a total administration time of 75 minutes per day. For rTMS stimulation, the coil will be positioned tangentially on the target area. Each rTMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The CCT (i.e. visual scanning treatment) involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities.Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the rTMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
16314949|NCT04573413|Sham Comparator|SHAM group|SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the experimental group.
16314950|NCT04573387|Active Comparator|Fixed-time drainage|Drainage will be removed after 48 hours.
16314951|NCT04573387|Experimental|Exhaustive drainage|Drainage will be removed when postoperative hematoma volume is minimized with repeated urokinase injection into hematoma cavity through catheter.
16314952|NCT04573374|Active Comparator|Biodentine|Biodentine (BD; Septodont, St Maur-des-Fosses, France) is a calcium silicate capping material. Biodentine is mixed according to manufacturer's instructions and placed in a 2-3 mm layer above the pulp tissue using an amalgam carrier and gently packed using a condenser. Initial setting is achieved after 12 minutes.
16314953|NCT04573374|Active Comparator|Portland cement|Preparation of Portland cement: Industrial Portland cement is mixed with Bisthmus oxide or Barium sulphate radio-opacifier in a 3:1 ratio. The mix is sieved through silk sieve then sterilized in hot air oven at 135 ֯C for 2 hours. Portland cement is mixed in a 3:1 powder: distilled water ratio and placed in the pulp chamber and condensed against a moist cotton pellet. A small cotton pellet moistened with saline is placed in the pulp chamber against PC for 5 seconds to ensure water uptake then removed
16314954|NCT04573361|No Intervention|Group Control|Patients having no access to chiropractic treatment during the trial
16314955|NCT04573361|Experimental|Group Chiropractic Care one session|Patients having access to in-person chiropractic treatment once during the trial
16314956|NCT04573361|Experimental|Group Chiropractic Care multiple sessions|Patients having access to in-person chiropractic treatment more than once during the trial
16314957|NCT04573348||Groups 1-4|no intervention will be performed in this study, only blood drawn
16314964|NCT04573309|Experimental|ALXN1840|Participants will be administered ALXN1840 at a dose of 15 milligrams (mg)/day on Day 1 through Day 28 and then increased to 30 mg/day on Day 29 through Day 39
16314965|NCT04573296|Experimental|Participants using Vitadio Health|Participants in the intervention arm undergo a 6-month digitally administered behavioral change programme consisting of nutrition/lifestyle education, diet and activity monitoring, remote dietitian's support and promoting self-management and long-term self-sufficiency. In addition, they undergo regular face-to-face medical assessment.
16314966|NCT04573296|Active Comparator|Participants assigned to conventional lifestyle intervention programme|Participants in the control group undergo a 6-month high-intensity lifestyle intervention programme consisting of face-to-face nutrition/lifestyle education, diet monitoring and regular medical assessment.
16314967|NCT04573270|Experimental|COVID-19 Patients Experimental|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
16314968|NCT04573270|Placebo Comparator|COVID-19 Patients Placebo|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
16314969|NCT04573270|Experimental|Healthcare Providers Experimental|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
16314970|NCT04573270|Placebo Comparator|Healthcare Providers Placebo|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
16314971|NCT04573257||normotensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
16314972|NCT04573257||Prehypertension group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
16314973|NCT04573257||hypertensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
16314974|NCT04573231|Experimental|18F-DCFPyL PSMA-based PET/CT|"18F-DCFPyL whole body PET/CT scan
~Review of relevant imaging and medical record information
~Blood draw for circulating tumor cells (CTCs)
~Analysis of diagnostic tissue specimens"
16314975|NCT04573218|Placebo Comparator|Group A|Glucose.
16314976|NCT04573218|Active Comparator|Group B|250 mg Oil Palm Phenolics.
16314977|NCT04573205|Experimental|> 50 years|"Healthy individuals > 50 years of age divided into age groups 50-59 years, 60-69 years and >70 years, approximately 20 participants in each group.
~Vaccinated with 4 doses FSME immune Adult intramuscular injection according to the recommended primary vaccine Schedule in Sweden for individuals > 50 years of age, at time 0, 1, 2 and 7 months."
16314978|NCT04573205|Active Comparator|< 40 years|Healthy individuals < 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
16314979|NCT04573192|Experimental|Phase 1 part: Dose Finding|"Phase I part:
~Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels.
~The RD will be confirmed following a traditional 3+3 design.
~Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
~The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1."
16314980|NCT04573192|Experimental|Phase II part: Signal Seeking|"118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle.
~Treatment Arm 1: L19TNF plus Lomustine
~Treatment Arm 2: Lomustine"
16314981|NCT04573166|Experimental|CURB procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation (CURB)
16314982|NCT04573153|Experimental|Treatment Arm|Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
16314983|NCT04573153|Placebo Comparator|Placebo Arm|Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
16314985|NCT04573114||Stroke subjects|
16314986|NCT04573114||Healthy|
16314987|NCT04573101|No Intervention|Before intervention|Participants answer questionnaire before any stimulus is given.
16314988|NCT04573101|No Intervention|After intervention|Participants answer questionnaire after the series of stimulus is given.
16314989|NCT04573101|Experimental|N1 (Ney - Improvisation- Saba Re)|Improvisation with Ney, on Saba maqam on Re.
16314990|NCT04573101|Experimental|O1 (Oud - Improvisation- Saba Re)|Improvisation with Oud, on Saba maqam on Re.
16314991|NCT04573101|Experimental|Q1(Qanun - Improvisation- Saba Re)|Improvisation with Qanun, on Saba maqam on Re.
16314992|NCT04573101|Experimental|N2 (Ney - Improvisation- Saba Sol)|Improvisation with Ney, on Saba maqam on Sol.
16314993|NCT04573101|Experimental|O2 (Oud - Improvisation- Saba Sol)|Improvisation with Oud, on Saba maqam on Sol.
16314994|NCT04573101|Experimental|Q2 (Qanun - Improvisation- Saba Sol)|Improvisation with Qanun, on Saba maqam on Sol.
16314995|NCT04573101|Experimental|N3 (Ney - Improvisation- Kurd Re)|Improvisation with Ney, on Kurd maqam on Re.
16314996|NCT04573101|Experimental|O3 (Oud - Improvisation- Kurd Re)|Improvisation with Oud, on Kurd maqam on Re.
16314997|NCT04573101|Experimental|Q3 (Qanun - Improvisation- Kurd Re)|Improvisation with Qanun, on Kurd maqam on Re.
16314998|NCT04573101|Experimental|N4 (Ney - Improvisation- Kurd Sol)|Improvisation with Ney, on Kurd maqam on Sol.
16314999|NCT04573101|Experimental|O4 (Oud - Improvisation- Kurd Sol)|Improvisation with Oud, on Kurd maqam on Sol.
16315000|NCT04573101|Experimental|Q4 (Qanun - Improvisation- Kurd Sol)|Improvisation with Qanun, on Kurd maqam on Sol.
16315001|NCT04573101|Experimental|N5 (Ney - Known music- Kurd Re)|Known music with Ney, on Kurd maqam on Re. (El Rabii)
16315002|NCT04573101|Experimental|O5 (Oud - Known music- Kurd Re)|Known music with Oud, on Kurd maqam on Re. (El Rabii)
16315003|NCT04573101|Experimental|Q5 (Qanun - Known music- Kurd Re)|Known music with Qanun, on Kurd maqam on Re. (El Rabii)
16315004|NCT04573101|Experimental|N6 (Ney - Known music- Kurd Sol)|Known music with Ney, on Kurd maqam on Sol. (El Rabii)
16315005|NCT04573101|Experimental|O6 (Oud - Known music- Kurd Sol)|Known music with Oud, on Kurd maqam on Sol. (El Rabii)
16315006|NCT04573101|Experimental|Q6 (Qanun - Known music- Kurd Sol)|Known music with Qanun, on Kurd maqam on Sol. (El Rabii)
16315007|NCT04573101|Experimental|N7 (Ney - Known music- Saba Re)|Known music with Ney, on Saba maqam on Re. (Howa Sahih)
16315008|NCT04573101|Experimental|O7 (Oud - Known music- Saba Re)|Known music with Oud, on Saba maqam on Re. (Howa Sahih)
16315009|NCT04573101|Experimental|Q7 (Qanun - Known music- Saba Re)|Known music with Qanun, on Saba maqam on Re. (Howa Sahih)
16315010|NCT04573101|Experimental|N8 (Ney - Known music- Saba Sol)|Known music with Ney, on Saba maqam on Sol. (Howa Sahih)
16315011|NCT04573101|Experimental|O8 (Oud - Known music- Saba Sol)|Known music with Oud, on Saba maqam on Sol. (Howa Sahih)
16315012|NCT04573101|Experimental|Q8 (Qanun - Known music- Saba Sol)|Known music with Qanun, on Saba maqam on Sol. (Howa Sahih)
16315013|NCT04573088|Experimental|ABICOL|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
16315014|NCT04573088|No Intervention|CONTROL|No acceptance-based intervention or other discussion related to the patients' fears and worries will be applied.
16315015|NCT04573075|Other|no outlet|no outlet is used after colorectal resection and forming of a primary anastomosis
16315016|NCT04573075|Active Comparator|loop ileostomy|loop ileostomy is applied after colorectal resection and forming of a primary anastomosis
16315017|NCT04573075|Experimental|ghost ileostomy|ghost ileostomy or ghost stoma (synonyms) is performed after colorectal resection and forming of a primary anastomosis
16315018|NCT04573062||Post COVID patients|Individuals whom have previously had COVID -19 infection.
16315019|NCT04573049|Experimental|Levosimendan|Levosimendan 0.1µg/kg/min will last for 24h after the valve is released.
16315020|NCT04573049|Placebo Comparator|Placebo|5% glucose 0.1µg/kg/min administration will continue for 24h after the valve is released.
16315021|NCT04573036|Experimental|HRS4800 tablets cohort 1|
16315022|NCT04573036|Experimental|HRS4800 tablets cohort 2|
16315023|NCT04573036|Experimental|HRS4800 tablets cohort 3|
16315024|NCT04573036|Experimental|HRS4800 tablets cohort 4|
16315025|NCT04573036|Experimental|HRS4800 tablets cohort 5|
16315026|NCT04573036|Placebo Comparator|Placebo tablets|
16315027|NCT04573023|Experimental|JR-141 2.0 mg/kg/week|
16315028|NCT04573023|Other|administered as the standard of care: idursulfase (ELAPRASE®)|standard of care-controlled study
16315029|NCT04573023|Other|Rescue arm|
16315030|NCT04572997|Experimental|Full analysis set (FAS)|The full analysis set (FAS) consisted of all patients who received at least one dose of study drug.
16315031|NCT04572984|Experimental|EBUS-TBNA-TBMCB|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was followed by endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMCB)
16315032|NCT04572984|No Intervention|EBUS-TBNA|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed
16315033|NCT04572945||1- Cases: Diabetic patients with CKD.|classified according to estimated GFR into 5 stages according to KIDGO 2012 classification.
16315034|NCT04572945||2- Controls: Diabetic patients without CKD.|defined as patients who have normal kidney function test, normal urine analysis and normal ultrasound findings.
16315035|NCT04572932|Active Comparator|group 1:Probiotic arm|first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks
16315036|NCT04572932|Active Comparator|Group 2:Placcebo arm|the second group received only itopridehcl 50mg by the same dose for four weeks.
16315037|NCT04572919|Active Comparator|group A|Patients were randomly assigned to undergo lateral advancement flap
16315038|NCT04572919|Active Comparator|group B|Patients were randomly assigned to undergo classic Limberg flap
16315039|NCT04572906|Experimental|NTX-001|NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.
16315040|NCT04572906|No Intervention|Standard of Care|standard suture neurorrhaphy
16315042|NCT04572880|Active Comparator|Trabeculectomy|
16315043|NCT04572880|Active Comparator|XEN®|
16315044|NCT04572880|Active Comparator|Preserflo®|
16315045|NCT04572867|Experimental|Aquapheresis|Per protocol, if randomized to Aquapheresis arm (AQ), all diuretics are discontinued and AQ will be administered as per established protocol. BMP and CBC will be checked prior to initiation and as needed, 7-10 days, 30, 60 and 90 days post discharge. Note, aquapheresis rate is to be decreased by 100 cc/hr if Hgb increases by 1gm/dL, and stopped if rate is decreased to 50 cc/hr or reaches euvolemia, whichever comes first.
16315046|NCT04572867|Active Comparator|IV Diuretics|Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If a patient in IV arm is refractory to maximum 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
16315047|NCT04572854|Experimental|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
16315048|NCT04572854|Other|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
16315049|NCT04572841|Experimental|SAR441344|SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)
16315050|NCT04572841|Placebo Comparator|Placebo|Matching placebo
16315051|NCT04572828|Active Comparator|Group 1: Waiting 1 Minute After Paracervical Block|
16315052|NCT04572828|Active Comparator|Group 2: Waiting 3 Minute After Paracervical Block|
16315053|NCT04572828|Placebo Comparator|Group 3: Control Group|
16315057|NCT04572802||control group|Coronary heart disease population: after coronary angiography, Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease
16315058|NCT04572802||experimental group (course of disease <5 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).Retrospective examination of patients' data, recording patients' laboratory tests and drug use, taking blood to measure orphanin, and evaluating the severity of coronary artery occlusion with Gensini score.
16315059|NCT04572802||experimental group(course of disease 5-10 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).
16315060|NCT04572802||experimental group(course of disease10-20 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 10 -20years).Finally, the data were obtained to evaluate the relationship between the course of diabetes and the severity of coronary heart disease, as well as the relationship between the course of diabetes and OFQ in patients' blood.
16315063|NCT04572776|Experimental|Resiniferatoxin|Single dose of Resiniferatoxin (25 mcg in 3 mL) injected epidurally
16315064|NCT04572776|Active Comparator|Standard of Care|Standard of care treatment as determined by the investigator
16315065|NCT04572763|Experimental|Dose Escalation Copanlisib + Venetoclax|"Phase 1
~Dose escalation will occur using a 3+3 design
~Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle
~Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting"
16315066|NCT04572763|Experimental|Recommended phase II dose (RP2D) Copanlisib + Venetoclax|Patients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
16315067|NCT04572750|Experimental|EMPOWER-ED|Individuals will be given access on their preferred platform to an electronic self-help app focused on reducing benzodiazepine use
16315068|NCT04572750|No Intervention|Control|Individuals will be provided care as usual
16315069|NCT04572737|Experimental|Experimental|Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
16315070|NCT04572724|Experimental|Sacubitril/Valsartan treatment group|"Sacubitril/Valsartan will be administered step by step with a titrated dose. When patients switching to Sacubitril/Valsartan from RAS inhibitor, a washout period of at least 36 hours is required to decrease the risk of angioedema.
~All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis."
16315071|NCT04572724|Active Comparator|RAS inhibitor treatment group|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis.
16315072|NCT04572698|Experimental|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
16315073|NCT04572698|Active Comparator|EYLEA|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
16315074|NCT04572685|Experimental|LY03010 Process 1|"Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.
~LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process"
16315075|NCT04572685|Experimental|LY03010 Process 2|"Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.
~LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1."
16315076|NCT04572685|Experimental|INVEGA SUSTENNA|INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study
16315077|NCT04572672|Active Comparator|Purse lip breathing with number counting arm|"1) Position: The patient lies down in a semi-supine position, the bed is adjusted by 45-60 degrees, 2) Pursed-lip breathing and number counting one and two during inspiration, and 3) Number counting, one, two, three, and four during exhalation for the first 15 minutes (min) of each hour, total study time was 3 hours or until the patient was discharged from the ER."
16315078|NCT04572672|No Intervention|Control arm|The patients who were allocated to the control group received usual nursing care i.e. bed rest in a supine position in a quiet area. Patients were advised to limit their activity. The frequency of the vital signs monitoring and pharmacologic treatment were the same as the intervention group.
16315079|NCT04572659|Experimental|Group intervention|
16315080|NCT04572659|Experimental|Couple intervention|
16315081|NCT04572659|No Intervention|No intervention|
16315082|NCT04572646|Other|NRT proposition and exhaled CO measurement|
16315083|NCT04572633|Experimental|Treatment Group|This is a single are arm study that intends to treat all enrolled subjects with the histotripsy device.
16315084|NCT04572620||group 1(rituximab)|
16315085|NCT04572620||group 2 (abatacept)|
16315086|NCT04572607|No Intervention|Control group 1|
16315087|NCT04572607|No Intervention|Control group 2|
16315088|NCT04572607|No Intervention|Control group 3|
16315089|NCT04572607|No Intervention|Control group 4|
16315090|NCT04572607|No Intervention|Control group 5|
16315091|NCT04572607|No Intervention|Control group 6|
16315092|NCT04572607|No Intervention|Control group 7|
16315093|NCT04572607|Experimental|Honey group 1|
16315094|NCT04572607|Experimental|Honey group 2|
16315095|NCT04572607|Experimental|Honey group 3|
16315096|NCT04572607|Experimental|Honey group 4|
16315097|NCT04572607|Experimental|Honey group 5|
16315098|NCT04572607|Experimental|Honey group 6|
16315099|NCT04572594||Inflammatory myofibroblastic tumor|tissue of Inflammatory myofibroblastic tumor lession
16315102|NCT04572568||experimental group|"Treatment applied accordingly with the following standard criteria , patients are selected into this group:
~Ruptured lesion：
~Lesions not at the brainstem, thalamus, basal ganglia, or deep location，craniotomy can be performed;
~Target embolization of aneurysms and arteriovenous fistulas should be applied;
~Stereotactic radiosurgery for patients with a volume less than 10ml and not in the acute phase(< 3months) of intracranial hemorrhage.
~Unruptured lesion:
~Lesion is not located in the deep brain tissue, and is not located in an important functional area or the fiber bundle is more than 5mm away from the lesion, then surgery or combined surgery can be performed;
~If there are bleeding-related risk factors (aneurysm or high-flow fistula), relevant risk factors should be actively treated with embolization;
~Patients with no indications for craniotomy and poor symptom controlled, or with appropriate volume for radiosurgery or hybrid surgery (embolization +radiosurgery)."
16315103|NCT04572568||control group|Patients who received treatment that did not meet the standard group treatment plan were included in this control group.
16315104|NCT04572555|Experimental|Heat Treatment Group|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak. The subjects were instructed on the application of the thermophores. Thermoforming was applied wrapped in towels in order to shield the subjects from the effects of direct heat. In a study, heat packs that had a temperature of 38.9 °C were used for treatment of dysmenorrhea. In this study, the temperature of the water used in the thermoforming process was 45 °C. Considering the risk of the thermophores cooling down and the shielding provided by the towels, the water temperature was kept higher compared to those in other studies. The temperature of the water was measured using a liquid thermometer. Heat treatment was applied for 20 minutes without interruptions.
16315105|NCT04572555|No Intervention|Control Group|No Intervention
16315106|NCT04572542|Experimental|Camrelizumab + Apatinib + nab-paclitaxel|Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer
16315107|NCT04572516|Experimental|Topical group|Topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
16315108|NCT04572516|Experimental|Injection group|20 units of BTX_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
16315109|NCT04572503|Experimental|Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty In Management of Mild and Moderate Obstructive Sleep Apnea Syndromea using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
16315110|NCT04572490||Narrow platform implant|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
16315111|NCT04572490||Regular platform implants|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
16315112|NCT04572477|Other|[18F]THK-5351|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.
~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.
~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.
~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
16315113|NCT04572477|Other|[18F]AV-45|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.
~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.
~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.
~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
16315114|NCT04572464|Experimental|Experimental|Mindfulness Based Guided Meditation
16315116|NCT04572425|Active Comparator|Guided imagery|10 minutes of guided imagery (using Apple iPad and headphones, subject watches 10 minute video of a guided-imagery session depicting a peaceful walk through a forest with instrumental background music and 2-dimensional imagery)
16315117|NCT04572425|Experimental|Virtual reality|10 minutes of virtual reality (using study-administered Facebook Oculus Go VR headset with headphones, subject engages with VR application Forest of Serenity (Holosphere VR®, Birmingham, UK) that features a forest environment with voice narration that can be played in a seated or fixed position.
16315118|NCT04572412|Experimental|Low Dose Radiotherapy|Low Dose Radiotherapy
16315119|NCT04572399|Experimental|Endotracheal UV Light|Mechanically ventilated patients who will receive UV Light therapy
16315120|NCT04572386|Active Comparator|Light cure universal bond|light cured 3m single bond universal
16315121|NCT04572386|Active Comparator|self cure universal bond|self-cure universal bond (Palfique, Tokuyama, Japan)
16315122|NCT04572373||SMOFlipid group|"TPN and SMOFlipid support were indicated for patients who received NPO for more than 3 days, such as those with repeated laparotomy, staged biliary reconstruction, massive nasogastric (NG) drainage (>500 mL/day), ileus, diarrhoea, poor digestion (NG extraction >50 mL/time), and chylous ascites.
~Furthermore, SMOFlipid was discontinued when the platelet count decreased to 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10-14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more."
16315123|NCT04572373||non SMOFlipid group|On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group and the SMOFlipid group , respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.
16315124|NCT04572360|Experimental|Cardiorespiratory Exercise plus Chinese Herbal Medicines Group|"Includes:
~1.12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities.
~2.Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
16315125|NCT04572360|Experimental|Cardiorespiratory Exercise Group|"Includes:
~A 12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities."
16315126|NCT04572360|Experimental|Chinese Herbal Medicines Group|"Includes:
~Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
16315127|NCT04572360|No Intervention|Waiting List Group|The waiting list control sign will be adopted to conceal allocation results from the patients and further to reduce selection and confounding bias and increase their adherence to the study. Patients in the waiting list control group will receive no treatment in the study period (including a 12-week intervention period and a 12-week follow-up period). However, they will receive Chinese herbal medicines after the completion of the study (i.e., after the 3rd wave of measurements in the 25th weeks).
16315128|NCT04572347||Nurses working in PUTH|Participants will be recruited from Peking University Third Hospital through cluster sampling. Female registered nurses, licensed practical nurses and/or midwives with informed consent are included in this study. The exclusion criteria are student nurses and training nurses.
16315129|NCT04572334|Other|visual acuity and refractive outcome for Tecnis Eyhance|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
16315130|NCT04572334|Other|visual acuity and refractive outcome for Tecnis ZCB00|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
16315131|NCT04572308|Experimental|CD7 CAR-T|Patients will be treated with CD7 CAR-T cells
16315132|NCT04572295|Experimental|Part 1 Dose Escalation: E7090 + Fulvestrant or Exemestane|Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 milligram (mg), intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later, or along with exemestane 25 mg tablet, orally, once daily in 28 days cycle. Each cycle length equals to (=) 28 days.
16315133|NCT04572295|Experimental|Part 2 Monotherapy: E7090|Participants will receive E7090 tablets, orally, once daily in 28 days cycle. Each cycle length =28 days.
16315134|NCT04572295|Experimental|Part 3 Dose Expansion: E7090 + Fulvestrant or Exemestane|"Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 mg, intramuscular injection on Days 1 and 15, or along with exemestane 25 mg, tablet, once daily in 28 days cycle. Each cycle length =28 days.
~The dose of E7090 for Part 3 in combination with fulvestrant or exemestane will be determined based on the safety, tolerability, pharmacokinetic (PK), and biomarker data obtained from Part 1."
16315135|NCT04572282|Experimental|Mentora|Remote symptoms monitoring with mobile app
16315136|NCT04572269||Subjects with OSA|Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI >5)
16315137|NCT04572256|Experimental|Montelukast|Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
16315138|NCT04572256|Placebo Comparator|Placebo|Patients will receive an oral placebo daily for 6 months after surgery.
16315139|NCT04572243|Experimental|Lorcaserin (Core Study and Open-label Extension Phase)|Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
16315140|NCT04572243|Placebo Comparator|Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)|Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
16315141|NCT04572217|Experimental|Medication Group|"Adolescent patients post vertical sleeve gastrectomy who have had inadequate weight loss, who consented for use of off-label medications prescribed at the discretion (one or both) of physician.
~Patients will be followed every 2-12 weeks over one year.
~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
16315142|NCT04572217|No Intervention|Non-Medication Group|"Adolescent patients post vertical sleeve gastrectomy who had inadequate weight loss and did not consent for use of off-label medications.
~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
16315143|NCT04572204||Conservative group|
16315144|NCT04572204||interventional group|
16315145|NCT04572178|Experimental|Cash payment and brief behavioral counseling|The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
16315146|NCT04572165||semaglutide|New users of Ozempic® or Rybelsus®
16315147|NCT04572165||Active comparator|First-time ever users of an active comparator drug
16315149|NCT04572139||Young participants|18-45 years old
16315150|NCT04572139||Old participants|55-80 years old
16315151|NCT04572139||Oldest old participants|over 80 years old
16315152|NCT04572126|Experimental|Mindfulness Group|Participants in the mindfulness group will receive mindfulness based instructions.
16315153|NCT04572126|Active Comparator|Control Group|Participants in the control group will receive instructions to cope with cravings how they normally would.
16315154|NCT04572113||No collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are not wearing a cervical collar
16315155|NCT04572113||DJO collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a DJO cervical collar
16315156|NCT04572113||Miami J collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a Miami J cervical collar
16315157|NCT04572100|Experimental|Group A - Low Risk|Participants who have low-risk cancer and significant reduction (greater than 50%) in tumor size following induction therapy will be assigned to this group.
16315158|NCT04572100|Experimental|Group B - Intermediate Risk|Participants who have low-risk cancer and intermediate reduction (30-50%) in tumor size or high-risk cancer with significant reduction (greater than or equal to 50%) in tumor size following induction therapy will be assigned to this group.
16315159|NCT04572100|Experimental|Group C - High-Risk|Participants who have high-risk cancer and less than a 50% reduction in their tumor size following induction therapy will be assigned to this group.
16315160|NCT04572100|Experimental|Induction Therapy (Carboplatin and Paclitaxel)|All study participants will be assigned to this group to first receive induction therapy using a combination of carboplatin and paclitaxel. Participant response to this phase of therapy will determine which group (low-risk, intermediate risk or high-risk) the participant will be in.
16315161|NCT04572087|Experimental|Cognitive Control Training + Verum stimulation|This arm consists of the cognitive control training (six sessions) combined with 2mA anodal tDCS over the right dlPFC (F4) during the training for 20 minutes.
16315162|NCT04572087|Active Comparator|Cognitive Control Training + Sham stimulation|This arm consists of cognitive control training (six sessions) with sham-tDCS. 2 mA Sham-tDCS (40 seconds of tDCS) is applied to the right dlPFC (F4) before the trainings starts.
16315163|NCT04572074|Active Comparator|Arm 1 (Guided imagery)|10 minutes of guided imagery experience
16315164|NCT04572074|Experimental|Arm 2 (Virtual reality)|10 minutes of virtual reality experience
16315165|NCT04572048|Other|Single-day NRP training|This group will follow the single-day NRP training course that is currently the standard. It usually takes 8 hours to complete this training course and the nurses are released from their clinical duty to attend the training course.
16315166|NCT04572048|Experimental|Longitudinal one year NRP Training|This group will follow the longitudinal NRP training course. The longitudinal NRP training course will consist of nine 30-minute modules that will be taught every 6-8 weeks over a period of one year. The nurses will attend the different modules of the training course at their work place and during their work shift so they will have to be released from their clinical duty only 30 minutes at a time.
16315167|NCT04572035|Experimental|Exercise only|Undergraduate peer-facilitators part of a curricular kinesiology program will facilitate a personalized group-based exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised group-based moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
16315168|NCT04572035|Experimental|Exercise + Self-compassion|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks).
16315169|NCT04572035|Experimental|Exercise + Behavioural Coaching|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
16315170|NCT04572022|Experimental|Intervention group rehabilitation teaching video instructions|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions module.
16315171|NCT04572022|No Intervention|Control group|Control group receive proximal humerus fracture standard care only.
16315172|NCT04572009|Experimental|Augmented physician|Medical decision assisted by the bio-mathematical model to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
16315173|NCT04572009|Placebo Comparator|Control|Unassisted medical decision to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
16315174|NCT04571996|Experimental|ODM-104 and Panadol Zapp|
16315175|NCT04571970|Experimental|Single Arm|6.5 × 10^10 GC/g brain mass of RGX-121
16315176|NCT04571957||Donors with NASH|Donors with NASH underwent donor optimization protocol
16315177|NCT04571957||Donors without NASH|Donors without NASH
16315180|NCT04571918|Experimental|Group A: Biodegradable spacer|Intervention group
16315181|NCT04571918|Active Comparator|Group B: control group|Control group
16315182|NCT04571905|Other|Syntellix Treatment Arm|General anaesthesia, open fracture reduction, insertion of the appropriate screw with x-ray control and documentation intraoperatively, cast immobilisation Use of bioresorbable Magnezix CS or CBS Screws, if intraoperatively suitable bioresorbable screws not available, use of conventional ostesynthesis screws
16315183|NCT04571892|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
16315184|NCT04571879|Experimental|Arm 1|"Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr.
~Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg)."
16315185|NCT04571879|Experimental|Arm 2|"Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg).
~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
16315186|NCT04571879|Placebo Comparator|Arm 3|"Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization
~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
16315187|NCT04571866|Experimental|Beta-glucan bread|Participants will receive a standardised meal consisting of beta-glucan-enriched bread (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participants will be asked to spend approximately 10 minutes consuming the standardised meal.
16315188|NCT04571866|Sham Comparator|Control bread|Participants will receive a standardised meal consisting of a wheat bread with no additives (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participant will be asked to spend approximately 10 minutes consuming the standardised meal.
16315189|NCT04571853|Experimental|PNE-explained group|The participants in the PNE-explained group will be explained the fact sheets with an explanatory video (due to COVID-19 circumstances) conducted by the therapist M.S. The video will last one hour approximately and it contains a presentation by Mayte Serrat with a view of the fact sheets. This group will be given one week to watch the video and comprehend its content.
16315190|NCT04571853|Active Comparator|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
16315191|NCT04571853|Active Comparator|TAU group|Participants allocated into this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professional.
16315192|NCT04571840|Active Comparator|mpMRI|Multiparametric MRI
16315193|NCT04571840|Experimental|bpMRI|Biparametric MRI
16315194|NCT04571827|Experimental|Placebo Effect|"Group with positive expectation: it is a very effective technique that achieves excellent results in the improvement of the cervical musculature
~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
16315195|NCT04571827|Experimental|Nocebo Effect|"Group with negative expectation: this is a technique that will cause discomfort in the area of intervention of the cervical muscles after applying it .
~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
16315196|NCT04571827|Experimental|Neutral Effect|"Group with neutral expectations: It's a physical therapy technique used to treat neck pain and we're investigating its effects
~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
16315197|NCT04571814|Experimental|Parent and child intervention|Both parent and child will receive a computerized intervention to reduce error sensitivity.
16315198|NCT04571814|Experimental|Parent intervention and child control|Parent will receive a computerized intervention to reduce error sensitivity and child will receive an active control (a computerized program targeting health behaviors).
16315199|NCT04571814|Experimental|Parent control and child intervention|Child will receive a computerized intervention to reduce error sensitivity and parent will receive an active control (a computerized program targeting health behaviors).
16315200|NCT04571814|Active Comparator|Parent and child control|Both parent and child will receive an active control (a computerized program targeting health behaviors).
16315201|NCT04571801|Active Comparator|1|Standard diagnostics
16315202|NCT04571801|Experimental|2|Standard diagnostics + NGS
16315203|NCT04571788||FCB group|FCB group received FCB implantation
16315204|NCT04571788||Control group|Control group undergoes silicone scleral pad surgery
16315205|NCT04571775|Active Comparator|Qi-Shield user group|
16315206|NCT04571775|Sham Comparator|Sham Qi-Shield user group|
16315207|NCT04571775|No Intervention|No Qi-Shield device group|
16315208|NCT04571762|Experimental|Single arm|Patients with low-risk, intermediate-risk and low-volume metastatic prostate cancer eligible for stereotactic body radiotherapy will be recruited.
16315209|NCT04571749|Experimental|Customized Or to ICU handoff protocol|Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.
16315210|NCT04571736|Active Comparator|access to the internet information platform|usual preoperative information and access to the internet information platform
16315211|NCT04571736|No Intervention|usual preoperative information|medical information delivered to the patient before any surgery
16315212|NCT04571723|Active Comparator|Established Diabetes Prevention Program|This arm will receive the established diabetes prevention program curriculum.
16315213|NCT04571723|Active Comparator|Health Mindset modified Diabetes Prevention Program|This arm will receive the modified curriculum with the added health mindset information.
16315214|NCT04571710|Experimental|Treatment group|Intervention: Drug: SHR1258 400mg
16315216|NCT04571684|Experimental|Intervention Arm (HITSystem 2.1)|Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed.
16315217|NCT04571684|No Intervention|Control Arm (Standard of care)|Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up.
16315218|NCT04571671||Study group|Women with Müllerian anomalies who have received an oocyte donation. The diagnosis of Müllerian anomalies is established when a cavity is demonstrated uterine abnormality with any of the defects described in the American classifications or European in transvaginal ultrasound, hysteroscopy or hysterosalpingography (HSG). The differential diagnosis in case of doubts is established with 3D ultrasound, MRI or hystero / laparoscopy. All the septa have been resected prior to performing the OVODON cycle.
16315219|NCT04571671||Control group|Patients who receive donated oocytes and who do not present Müllerian anomalies. An absence of AM, a transvaginal ultrasound, an HSG or a normal hysteroscopy with a uterine cavity with a normal shape and absence of intracavitary images is considered
16315220|NCT04571658||NEPTUNE Match Participants|"Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas.
~NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years."
16315221|NCT04571645|Experimental|Dociparstat sodium (DSTAT)|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Dociparstat 4 mg/kg IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
16315222|NCT04571645|Placebo Comparator|Placebo|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Placebo IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
16315223|NCT04571632|Active Comparator|Immediate treatment arm:|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1, approximately 2 hours after the last SBRT fraction, intratumoral injection of ipilimumab (Yervoy®, 50mg/10mL solution) at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) and avelumab (Bavencio®, 200mg/10mL solution) at maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) will be performed. Subject will also receive a standard 200mg (fixed dose) intravenous infusion of pembrolizumab (Keytruda®, 100 mg/4mL solution).
~On day 2, autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered. Previously cryopreserved CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be thawed before administration.
~On day 21 and every 21 days thereafter, IT injection of ipilimumab and avelumab and IV pembrolizumab at the same dose as on day 1 will be performed. Treatment will be discontinued upon disease progression"
16315224|NCT04571632|Active Comparator|Contemporary control arm|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1 and every + 21 days thereafter, subjects will receive a standard 200mg (fixed dose) IV pembrolizumab (Keytruda®, 100 mg/4mL solution) dose.
~On disease progression, intratumoral administration as in the immediate-treatment arm will be conducted. Thus, intratumoral injection of ipilimumab at a maximum total dose of 10 mg and avelumab at maximum total dose of 40 mg will be performed. Administration of pembrolizumab at a dose of 200 mg will be continued.
~Tumor response assessments by whole body PET/CT will be scheduled in week 12 and every 12 weeks thereafter during the treatment phase; . Baseline scan will be performed during screening period Procurement of tumor tissue by fine needle aspirates will be performed at the time of every intra-tumoral study drug administration"
16315225|NCT04571619|Active Comparator|Pain Coping Skills Training|
16315226|NCT04571619|No Intervention|Usual Care|
16315227|NCT04571619|Active Comparator|Buprenorphine|
16315228|NCT04571619|No Intervention|No Buprenorphine|
16315229|NCT04571606|Active Comparator|Liposomal Bupivacaine|Pre-operative ultrasound guided interscalene nerve block with 10 mL 1.3% liposomal bupivacaine (Exparel) and 10 mL 0.5% bupivacaine
16315230|NCT04571606|Active Comparator|Peripheral Nerve Catheter|Pre-operative ultrasound guided interscalene nerve block with 20 mL of 0.25% bupivacaine and placement of peripheral nerve catheter with 10 mL/hr 0.2% bupivacaine infusion via OnQ pump.
16315295|NCT04571112|Experimental|NBM ON|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.
~The NBM ON arm will have constant NBM stimulation for 8 weeks."
16315231|NCT04571593|Experimental|Digital Yoga Nidra|"Participants will voluntarily complete a ~30-minute remote Yoga Nidra practice, synchronously (through Zoom Wednesdays at 10 pm ET) or asynchronously (through YouTube, using the Zoom recording, any time they like).
~They may voluntarily repeat this practice as often as they like. Recordings are updated weekly, to reflect the ongoing Zoom class. Yoga Nidra scripts from Satyananda Saraswati's Yoga Nidra book (1976) are used for this class."
16315232|NCT04571580|Placebo Comparator|placebo|
16315233|NCT04571580|Experimental|reteplase 9mg|
16315234|NCT04571580|Experimental|reteplase 18mg|
16315235|NCT04571567|Experimental|Secukinumab|300mg subcutaneously
16315236|NCT04571528|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
16315237|NCT04571528|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
16315238|NCT04571528|Active Comparator|Physiotherapy part of VIRTUA FIBROWALK|The physiotherapy part of the VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
16315239|NCT04571515|Experimental|MR-107A-01 15 mg once in a 24-hour period|Oral tablet one day of dosing
16315240|NCT04571515|Experimental|MR-107A-01 10 mg once in a 24-hour period|Oral tablet one day of dosing
16315241|NCT04571515|Experimental|MR-107A-01 15 mg twice in a 24-hour period|Oral tablet one day of dosing
16315242|NCT04571515|Experimental|MR-107A-01 10 mg twice in a 24-hour period|Oral tablet one day of dosing
16315243|NCT04571515|Placebo Comparator|Placebo twice in a 24-hour period|Placebo tablet one day of dosing
16315244|NCT04571502|Experimental|Full Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the experimental arm will have access to use CareHeroes AND the newly developed AAC app. Provider will receive information via the AAC app.
16315245|NCT04571502|Active Comparator|Minimal Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the minimal intervention arm will have access to use CareHeroes but only a paper version of the newly developed AAC app.
16315246|NCT04571489|Experimental|Gimatecan group|All patients will receive gimatecan (0.8mg/m2, on days 1 to 5, PO, every 4 weeks) until progressive disease (PD).
16315247|NCT04571489|Placebo Comparator|placebo group|All patients will receive tegafur, gimeracil and oteracil potassium (40-60mg, twice daily, on days 1 to 14 , PO, every 3 weeks) or gemcitabine (1000mg/m2, on days 1、8, IV, every 3 weeks) until progressive disease (PD).
16315248|NCT04571476|Experimental|UTB-VBN-EBUS group|Ultrathin bronchoscope with a 3.0-mm outer diameter and a 1.7-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN and EBUS.
16315249|NCT04571476|Active Comparator|TB-VBN-EBUS-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN-EBUS and a 1.95-mm outer diameter guide sheath.
16315250|NCT04571476|Active Comparator|TB-VBN-EBUS-non-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using conventional biopsy forceps and cytology brush with the guidance of VBN and EBUS, but without guide sheath.
16315251|NCT04571463||HUCS A|Mothers visiting the prenatal care units within the Helsinki area.
16315252|NCT04571463||HUCS HAL|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area.
16315253|NCT04571463||PHHYKY A|Mothers visiting the prenatal care units within the Lahti area.
16315254|NCT04571463||PHHYKY HALSO|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area.
16315255|NCT04571450|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
16315256|NCT04571437|Active Comparator|Chemo endocrine treatment (A)|Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously
16315257|NCT04571437|Active Comparator|Endocrine treatment only (B)|Letrozole 2.5mg PO daily
16315258|NCT04571424|Experimental|Cohort 1: BIIB133 Dose 1|Participants will receive single IV infusion of BIIB133 Dose 1.
16315259|NCT04571424|Experimental|Cohort 2: BIIB133 Dose 2|Participants will receive single IV infusion of BIIB133 Dose 2.
16315260|NCT04571424|Placebo Comparator|Cohort 1-2: Placebo|Participants will receive single IV infusion of matching placebo to BIIB133.
16315261|NCT04571385|Experimental|Part 1: AP30663|Participants will receive single dose of AP30663.
16315262|NCT04571385|Placebo Comparator|Part 1: Placebo|Participants will receive placebo matched to AP30663.
16315263|NCT04571385|Experimental|Part 2: AP30663|Participants will receive a single dose of one of the multiple dose levels of AP30663.
16315264|NCT04571385|Placebo Comparator|Part 2: Placebo|Participants will receive placebo matched to AP30663.
16315265|NCT04571372||Patients with severe aortic stenosis or severe aortic regurgitation|Patients with severe aortic stenosis or severe aortic regurgitation
16315266|NCT04571346|Active Comparator|the classical TOT procedure|performing the trans-obturator procedure through the standard vertical incision
16315267|NCT04571346|Experimental|2 paramedian vertical incisions|performing the trans-obturator procedure through a new technique of 2 paramedian vertical incisions
16315268|NCT04571333|Experimental|Mi2000 Cochlear Implant surgery|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
16315296|NCT04571112|Sham Comparator|NBM OFF|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.
~The NBM OFF arm will have NBM stimulation turned off for 8 weeks."
16315297|NCT04571073|Experimental|Treatment arm|The only arm in the study was the intervention arm as this is a pilot study.
16315269|NCT04571320|Experimental|Summer STRIPES|Up to two weeks of daily high school orientation (four hours per day) immediately prior to the start of ninth grade, staffed by peer interventionists (2:1 ratio + extra interventionist in case of absences) and a school staff member. Two sessions of summer parent training. During the school year, ninth grade students will continue to meet weekly with their peer interventionists in a group setting under the supervision of the school staff sponsor. School year follow-up component of summer STRIPES will occur for 16 weeks and will include weekly 30 minute meetings between peer and target students. Parent components during the school year will include optional monthly group problem solving sessions with the school staff sponsor and school mental health liaison and a weekly phone call (up to five minutes) from the school staff sponsor to discuss home contingency management.
16315270|NCT04571320|Active Comparator|Enhanced School Services as Usual|Students who are assigned to the SSU plus group will be referred to their identified school counselor for referral to services available in the school setting. The counselor will be provided with a report from the student's intake assessment that summarizes the student's symptoms and presenting problems. The student will also receive new school supplies at the beginning of ninth grade. In our past trials, SSU plus students typically received subject-specific tutoring or after-school homework help. We will systematically track services received by students in the SSU plus condition.
16315271|NCT04571294|Experimental|group A|PALN removal
16315272|NCT04571294|No Intervention|group B|No PALN removal
16315273|NCT04571268||Healthy validation subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for the purpose of developing and validating the biomechanical models used to track scapular motion
16315274|NCT04571268||Healthy comparison subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for comparison of shoulder motion and muscle activation patterns with RCT subjects
16315275|NCT04571268||RCT subjects|Subjects who have sustained a major rotator cuff tear
16315276|NCT04571255|Experimental|Intervention group|Participants in the intervention group will receive a minimum of 3 and a maximum of 6 music therapy sessions (i.e. Music-Assisted Relaxation) during a two weeks time frame.
16315277|NCT04571255|No Intervention|Control Group|Treatment as usual.
16315278|NCT04571242|Active Comparator|DTM-SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and participants tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
16315279|NCT04571242|Active Comparator|Conventional SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and subjects tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
16315283|NCT04571203|Experimental|Phase I Study of Combined DD Kidney and HCT Transplant|Single arm Phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion
16315284|NCT04571190|Experimental|Prenatal MBSR|The prenatal MBSR program consists of nine two-hour sessions including teachings in mindfulness meditation and yoga. The program is taught by an experienced MBSR instructor with relevant clinical expertise.
16315285|NCT04571190|No Intervention|Usual care|Standard clinical practice, usual care (TAU), imply routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Usual care include a multidisciplinary approach involving preventive counselling by midwifes, physicians and social workers throughout the pregnancy and follow-up until the early post-partum period.
16315286|NCT04571164|Experimental|LY03003|
16315287|NCT04571164|Placebo Comparator|Placebo|
16315288|NCT04571151|Active Comparator|Lexette + Sorilux|"Halobetasol Propionate Topical Foam (Lexette Foam) + Calcipotriol Foam (Sorilux Foam) for 2 weeks
~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.
~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g."
16315289|NCT04571151|Placebo Comparator|Lexette + Vehicle|"Halobetasol Propionate Topical Foam (Lexette Foam) + Vehicle Foam for 2 weeks
~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.
~Vehicle Foam would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application."
16315290|NCT04571151|Active Comparator|Sorilux|"Calcipotriol Foam (Sorilux Foam) for 6 weeks
~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.
~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 6 weeks. SORILUX Foam contains calcipotriene 50 mcg/g."
16315291|NCT04571151|Placebo Comparator|Vehicle|"Vehicle Foam for 6 weeks.
~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.
~Vehicle Foam would be applied over the affected area twice daily for 6 weeks."
16315292|NCT04571138|Experimental|SCRI-CAR22v2|Patients will receive SCRI-CAR22v2 in either Phase I or Phase II
16315302|NCT04571034|Experimental|Medium-Intensity Roller Massage|Healthy adults receiving medium-intensity roller massage.
16315303|NCT04571034|Experimental|High-Intensity Roller Massage|Healthy adults receiving high-intensity roller massage.
16315304|NCT04571021|Experimental|I-DEPT|Novel triage. The triage nurse can adjust the triage category one level of urgency down or one or two levels up.
16315305|NCT04571021|Active Comparator|DEPT|Existing triage algorithm
16315306|NCT04571008|Placebo Comparator|Placebo|At least 16 weeks of placebo.
16315307|NCT04571008|Experimental|NMN supplementation|At least 16 weeks of NMN.
16315308|NCT04570995|Active Comparator|fish oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing fish oil encapsulated in soft gel capsules.
16315309|NCT04570995|Placebo Comparator|safflower oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing a placebo oil product (safflower oil) encapsulated in soft gel capsules.
16315310|NCT04570982||Convalescent Plasma with SOC|All patients will receive CPT and SOC
16315311|NCT04570969|No Intervention|standard of care|Peri-operative analgesia by opioids
16315312|NCT04570969|Experimental|Peri operative regional analgesia|Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters
16315313|NCT04570956|Experimental|Oral Tamoxifen 10 mg/day|Oral Tamoxifen 10 mg/day
16315314|NCT04570956|Experimental|Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day|"Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day
~+oral placebo"
16315315|NCT04570956|Experimental|Control|Oral and gel placebo
16315316|NCT04570943|Experimental|Gabrinox followed by stereotactic radiotherapy|"Gembrax:
~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest
~Folfirinox:
~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
16315317|NCT04570930|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of Health- Related Quality of Life (HRQOL) and receive personalized pushes over a six-month (180 day) period.
16315318|NCT04570930|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period (without the personalized feedback).
16315319|NCT04570917|Experimental|Intervention group (INT)|An online learning module targeted to reduce ageism will be delivered to the INT group.
16315320|NCT04570917|Active Comparator|Control group (CON)|An online learning module on diversity and cultural competence will be delivered to the CON group.
16315321|NCT04570904||Early HCWs|Health Care Workers vaccinated early prior to the influenza season
16315322|NCT04570904||Late HCWs|Health Care Workers vaccinated just prior to the influenza season
16315323|NCT04570904||Inpatients|Inpatients recruited for evaluation of new approaches to influenza diagnosis
16315324|NCT04570891|Experimental|FICB|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
16315325|NCT04570891|Placebo Comparator|Control|No regional block is provided at the end of surgery.
16315326|NCT04570878|Experimental|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
16315327|NCT04570878|Active Comparator|Control|No regional block is provided at the end of surgery.
16315328|NCT04570865|Experimental|Dapagliglozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
16315329|NCT04570852|Experimental|Intensive monitoring of patients|State of the art biochemical assessment of patients with acute pancreatitis including multi-OMICS focusing on transcriptomics and proteomics.
16315330|NCT04570839|Experimental|Dose Escalation Cohorts.|Up to 5 sequential dose escalation cohorts of COM701 in combination with fixed doses of BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks until a maximum tolerated dose or recommended dose for expansion is identified.
16315331|NCT04570839|Experimental|Cohort 1 Expansion Cohort A (ovarian cancer)|Single arm: subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with COM701 in combination with BMS-986207 and nivolumab. The study drugs will be administered IV every 4 weeks.
16315332|NCT04570839|Experimental|Cohort 2 Expansion Cohort (endometrial cancer).|Single arm: subjects with MSS-endometrial cancer will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
16315333|NCT04570839|Experimental|Cohort 3 Expansion Cohort (basket cohort - high PVRL2 tumors).|Single arm: subjects with tumor types with high expression of PVRL2 will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
16315334|NCT04570839|Experimental|Cohort 4 Expansion Cohort (Head and Neck cancer).|"Two arms: subjects with head and neck cancer. Equal number of subjects in each of the 2 arms. One arm will enroll subjects who have not previously received treatment with an immune checkpoint inhibitor, the other arm will enroll subjects who have received prior treatment with an immune checkpoint inhibitor.
~All subjects will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks."
16315335|NCT04570826|Experimental|Meditation program|The experimental group participated in the Meditation program during one month, eight sessions with a total of sixteen hours.
16315336|NCT04570826|Active Comparator|Scientific descriptions about meditation|The control group received scientific descriptions about meditation.
16315337|NCT04570813|Experimental|artistic activities|"participants will do a 3-month cycle of weekly artistic activities at the MAMAC Museum, which are structured 2-h-long art-based workshops"
16315338|NCT04570813|No Intervention|No artistic activities|The control group is composed of participants who do not take part in art-based activities,
16315339|NCT04570787|Active Comparator|No Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.
16315464|NCT04569968|Experimental|Expiratory muscle training group|Daily expiratory muscle training for four weeks will be applied.
16315340|NCT04570787|Active Comparator|Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.
16315341|NCT04570774|Experimental|Facilitatory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
16315342|NCT04570774|Active Comparator|Facilitatory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and sham high-frequency rTMS over the ipsilateral cerebellar hemisphere.
16315343|NCT04570774|Experimental|Inhibitory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
16315344|NCT04570774|Active Comparator|Inhibitory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and sham rTMS over the ipsilateral cerebellar hemisphere.
16315345|NCT04570761|Experimental|ON-Stim|acoustic stimulation
16315346|NCT04570761|Sham Comparator|OFF-Stim|no acoustic stimulation
16315347|NCT04570748|Experimental|Group A|Direct anterior hip arthroplasty with capsule repair.
16315348|NCT04570748|Active Comparator|Group B|Surgery that the surgeon will not perform capsule repair after performing an initial capsulectomy during total hip arthroplasty
16315349|NCT04570735||patients with type 2 diabetes and diabetic kidney disease|
16315350|NCT04570735||patients with type 2 diabetes and no diabetic kidney disease|
16315351|NCT04570735||patients with obesity, no diabetes and no kidney disease|
16315352|NCT04570722|Other|Single arm study|Patients with a history of axillary surgical lymph node procedures (SLNP) presenting for routine radiographic scan will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Patients will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt.
16315353|NCT04570709|No Intervention|Control|Patients in the control arm will receive standard of care.
16315354|NCT04570709|Experimental|Intervention|Patients in the intervention arm will receive the PACT intervention provided by a multidisciplinary team of RNs, OTs, and PTs.
16315355|NCT04570696||Adult haemophilia patients|Adult (≥ 18 years old) haemophilia patients, only men
16315356|NCT04570683|Active Comparator|AFL monotherapy|Singe dose AFL as monotherapy, 100 mJ
16315357|NCT04570683|Active Comparator|AFL+nivolumab|Single dose AFL 100 mJ followed by immediate intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
16315358|NCT04570683|Active Comparator|nivolumab monotherapy|Intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
16315359|NCT04570670|Experimental|Test (BLS-11)|A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1
16315360|NCT04570670|Active Comparator|Reference (Tecfidera)|A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1
16315361|NCT04570657|Experimental|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
16315362|NCT04570657|Experimental|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
16315363|NCT04570657|Placebo Comparator|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
16315364|NCT04570644|Other|Part A|"24 subjects randomized to receive treatment: (A-B) = Single 17.1 mg oral inhaled dose of ALZT-OP1a (cromolyn) via dry powder inhaler and a single oral 10 mg tablet of ALZT-OP1b (ibuprofen) on Day 1. On Day 2, subjects would receive two 17.1 mg doses of ALZT-OP1a via dry powder inhaler and two 10 mg tablets of ALZT-OP1b (ibuprofen), within two minutes of each other.
~(B-A) = Two 17.1 mg doses of ALZT-OP1a (cromolyn) and two doses of 10 mg ALZT-OP1b (ibuprofen) on Day 1 and single 17.1 mg dose of ALZT-OP1a cromolyn 17.1 mg and a single 10 mg dose of ALZT-OP1b (ibuprofen) on Day 2.
~All subjects will have plasma and CSF collected for PK analysis."
16315365|NCT04570644|Other|Part B|"PD - 32 subjects (AD only) will be enrolled in the PD portion of the study. Twenty-four (24) subjects will be assigned to Treatment Group 1 to receive a single (17.1 mg) inhaled dose of ALZT-OP1a (cromolyn) plus a single (10 mg) oral dose of ALZT-OP1b (ibuprofen) daily for 60 days.
~All subjects will have plasma and CSF collected for PD biomarker analysis. Eight (8) A subjects will be assigned to Treatment Group 2 (Control Group) and will not be administered study drug."
16315366|NCT04570631|Experimental|Safety Lead-in|Participants will receive escalating doses of eftozanermin alfa in combination with bortezomib and dexamethasone to determine recommended phase 2 dose (RP2D).
16315367|NCT04570631|Experimental|Dose Expansion|Participants will receive eftozanermin alfa at RP2D determined in Safety Lead-in part in combination with bortezomib and dexamethasone.
16315368|NCT04570618|Sham Comparator|Standard of Care|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines.
16315369|NCT04570618|Experimental|Standard of Care + AlgoDx Sepsis Prediction Algorithm|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines, and sepsis prediction algorithm alerts are unblinded to clinical staff.
16315370|NCT04570605|Active Comparator|Standard Urotherapy|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management.
16315371|NCT04570605|Experimental|Standard Urotherapy + PTENS|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management AND use parasacral percutaneous TENS as additional treatment.
16315372|NCT04570592|Placebo Comparator|Granisetron|Granisetron 1 mg (1ml) + Normal saline 1ml
16315373|NCT04570592|Experimental|Granisetron and Dexamethasone|Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)
16315465|NCT04569968|No Intervention|Control group|Nothing will be applied except for the hospital conventional physiotherapy program.
16315374|NCT04570579||Observational cohort|"This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day (postoperative day 1), 1 week (postoperative week 1), 1 month (postoperative month 1) and 3 months (postoperative month 3) following surgery."
16315375|NCT04570566|Experimental|titanium mish|horizontal alveolar ridge augmentation with non-resorbable titanium mish .evaluation after 4 months
16315376|NCT04570566|Experimental|pericardium membrane|horizontal alveolar ridge augmentation with resorbable pericardium membrane then .evaluation after 4 month.
16315377|NCT04570553|Experimental|V-care uterine manipulator|Patients in the V-care uterine manipulator arm will undergo standard staging surgery utilizing a V-care uterine manipulator in the standard fashion
16315378|NCT04570553|Active Comparator|Sponge stick|Patients in the sponge stick arm will undergo standard staging surgery utilizing a non-invasive sponge stick for cervical delineation.
16315379|NCT04570540||OSA|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9.
16315380|NCT04570540||OSA+SH|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
16315381|NCT04570540||OHS|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during wakefulness, defined by a PCO2>45mmHg as measured by arterialized capillary blood gas analysis.
16315382|NCT04570527||Obesity|BMI>=25
16315383|NCT04570527||Non-Obesity|BMI<25
16315384|NCT04570514||Obesity|Patients with Obesity. BMI>=25
16315385|NCT04570514||Non-Obesity|Patients without Obesity. BMI<25
16315386|NCT04570501|Experimental|Angiotensin (1-7)|Participants receive treatment for 7 days.
16315387|NCT04570501|Placebo Comparator|Placebo|Participants receive treatment for 7 days.
16315388|NCT04570488|Experimental|Intervention|Display of risk score/ colored flag in Epic patient list column; will be viewable to all frontline workers
16315389|NCT04570488|No Intervention|Control|"No display (hidden) of risk score/ colored flag in Epic patient list column; not viewable to all frontline workers"
16315390|NCT04570475|Experimental|vitamin D+multivitamin|
16315391|NCT04570475|Active Comparator|placebo+multivitamin|
16315392|NCT04570462|Experimental|Experimental Arm- Induction of Mild Hypothermia Protocol|Determination of metabolic rate by the metabolic cart (noninvasive connection of the device to the ventilator for 20 minutes). Initiate hypothermia (established Northwell hypothermia status post cardiac arrest protocol) using the Arctic Sun. The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.
16315393|NCT04570449|Experimental|Fluoxetine|"Participants instructed to take fluoxetine 20 mg capsule orally daily for 8 weeks in the following schedule:
~Week 1 = 1 pill (20 mg), Week 2 = 2 pills (40 mg), Weeks 3-6 = 3 pills (60 mg), Week 7 = 2 pills (40 mg), Week 8 = pill (20 mg)"
16315394|NCT04570449|Placebo Comparator|Placebo|"Participants instructed to take fluoxetine placebo capsule matching fluoxetine orally daily for 8 weeks in the following schedule:
~Week 1 = 1 pill, Week 2 = 2 pills, Weeks 3-6 = 3 pills, Week 7 = 2 pills, Week 8 = pill"
16315395|NCT04570436|Experimental|gabapentin 600 mg|single dose
16315396|NCT04570436|Active Comparator|diazepam 20 mg|single dose
16315397|NCT04570436|Placebo Comparator|placebo|single dose
16315398|NCT04570436|Experimental|gabapentin 1200 mg|single dose
16315399|NCT04570436|Experimental|gabapentin 1800 mg|single dose
16315400|NCT04570423|Experimental|Cohort 1: ≥12 to <17 years|Participants will receive a SC injection of eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
16315401|NCT04570423|Experimental|Cohort 2: ≥6 to <12 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
16315402|NCT04570423|Experimental|Cohort 3: ≥2 to <6 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
16315403|NCT04570423|Experimental|Cohort 4: ≥1 month to <2 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
16315404|NCT04570410|Experimental|Subgroup1:Patients who can tolerate cisplatin chemotherapy|"GC plus Tislelizumab Participants receive GC (Gemcitabine plus cisplatin), in combination with Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.
~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W
~Biological: GC GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks"
16315405|NCT04570410|Experimental|Subgroup2:Patients who cannot tolerate cisplatin chemotherapy|"Tislelizumab Participants receive Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.
~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W"
16315408|NCT04570384|Active Comparator|IV L-Citrulline (Turnobi) Arm|Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
16315409|NCT04570384|Placebo Comparator|Placebo Arm|Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
16315410|NCT04570371|Experimental|Intervention|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches in which the intervention will be implemented per the study schedule.
16315411|NCT04570371|No Intervention|Control Arm|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches. The control arm consists of all patients receiving surgery in implementation tranches in which the intervention has not been implemented yet (per the study schedule).
16315412|NCT04570358|Experimental|Static stretching|An 8-week home-based static stretching training for the calf muscles will be performed by group A. Altogether, 10 stretches are performed per leg 4 times a week.
16315413|NCT04570358|No Intervention|Control|While group A performs the 8-week static stretching training, group B acts as control group performing its daily life activities as usual.
16315414|NCT04570358|Experimental|Proprioceptive neuromuscular facilitation stretching|After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
16315415|NCT04570358|No Intervention|Follow-up|While group B performs the 8-week proprioceptive neuromuscular facilitation stretching, group A is in its follow-up period performing its daily life activities as usual.
16315416|NCT04570345|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
16315417|NCT04570345|Active Comparator|Aspirin with P2Y12 receptor inhibitor|Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
16315418|NCT04570332|Experimental|Single Arm|Patients will be treated with the combination of BO-112 and pembrolizumab. IT administration of BO-112 will be performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. The order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 23-gauge needles.
16315419|NCT04570319|Experimental|Probiotic Bths-08|a capsule containing the probiotic blend (nutritional complement)
16315420|NCT04570319|Placebo Comparator|Placebo|a capsule containing placebo comparator
16315421|NCT04570306||Belimumab-treated SLE patients|SLE patients with active disease who will be started on add-on treatment with belimumab on top of standard of care.
16315422|NCT04570293|Experimental|The LMP group|The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
16315423|NCT04570293|Placebo Comparator|The control group|The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
16315424|NCT04570280|Placebo Comparator|Range of Motion Exercises|The patients in the control group will be given the practice of range of motion exercises for 12 weeks, 3 days a week for 50 minutes (1 day accompanied by a physiotherapist).
16315425|NCT04570280|Active Comparator|Range of Motion and Resistive Exercises Group|Patients in this group will be given joint range of motion and resistive exercises with sandbag to the lower extremity for 12 weeks, 3 days a week for 50 minutes (1 day in the presence of a physiotherapist). For the exercises with resistance, the repetition maximum will be calculated and the intensity of the exercises will be adjusted in accordance with the DeLorme protocol.
16315426|NCT04570280|Active Comparator|Range of Motion and Aerobic Exercises Group|Joint range of motion exercises and aerobic exercises on the treadmill will be given to the aerobic exercise arm, 3 days a week for 12 weeks (1 day in the presence of a physiotherapist). For aerobic exercises, the maximum heart rate of the patients will be calculated during exercise and the exercise intensity will be determined by increasing the target heart rate level during the exercise.
16315427|NCT04570267|Experimental|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
16315428|NCT04570267|Experimental|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
16315429|NCT04570267|Placebo Comparator|Placebo|One dose of placebo administered subcutaneously on Day 1
16315430|NCT04570254|Experimental|Patients with septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.
~With the following specifications:
~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.
~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.
~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.
~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.
~The dose of pentoxifylline that all patients will receive is as follows:
~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
16315431|NCT04570254|Experimental|Patients without septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.
~With the following specifications:
~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.
~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.
~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.
~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.
~The dose of pentoxifylline that all patients will receive is as follows:
~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
16315432|NCT04570241|Active Comparator|Group A-Malaria toolkit|School children shall be trained on key malaria messages with a malaria toolkit. From the training received, the pupils will carry out awareness-raising in communities with key messages learnt.
16315466|NCT04569942|Active Comparator|Vasopressor|a restricted fluids and early vasopressor strategy
16315433|NCT04570241|No Intervention|Group B-No malaria toolkit|"School children shall not be trained on key malaria messages with a malaria toolkit. Pupils will not carry out awareness-raising in communities with key messages.
~."
16315434|NCT04570228|Active Comparator|Treatment group|Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
16315435|NCT04570228|Sham Comparator|Sham control group|A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
16315436|NCT04570215|Active Comparator|Gotcha! Therapy Application|"Participants will receive the Gotcha therapy daily for six weeks.Participants are required to use the app everyday for a maximum of 45 minutes. After this time they enter a twelve week block with no therapy or maintenance of therapy (see Gotcha maintenance arm).
~This aim of this arm is to invesitgate the efficacy of the Gotcha therapy for proper-noun anomia in mild-moderate patients with dementia (Alzheimer's disease, vascular dementia and mixed)"
16315437|NCT04570215|Active Comparator|Gotcha! Therapy Application: Maintenance|"Participants will receive the Gotcha therapy for six weeks as described in the Gotcha arm. After this time they enter a twelve week block of maintenance of therapy gains made in the initial six week therapy block.
~The maintenance block consists of a weekly test of the Gotcha outcome measure to monitor the therapy gains made during the therapy block. If any previously correctly named person is incorrectly named during these weekly tests then the participant must complete a 'top-up' therapy session. They will then be tested again the following week.
~The aim of this arm is to compare Gotcha maintenance with Gotcha, to see if extra testing and therapy is required to maintain gains made during an initial intense therapy block."
16315438|NCT04570202|No Intervention|Usual Care|Subject from this group are screened positive for psychological distress but they will only receive standard of care.
16315439|NCT04570202|Experimental|Eye Movement Desensitization & Reprocessing Group|Subject from this group are screened positive for psychological distress. They will receive 12 sessions of Eye Movement Desensitization & Reprocessing therapy by a trained therapist over three months in addition to standard of care.
16315440|NCT04570189||Phase I|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with the Auscul-X, a conventional stethoscope and an electronic stethoscope (Littmann 3200).
16315441|NCT04570189||Phase II|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
16315442|NCT04570176|Experimental|Urologic tumor group|patients with adrenal adenoma, muscle-invasive bladder cancer or renal cell carcinoma are included in the experiment.
16315443|NCT04570150|Active Comparator|Sugammadex|
16315444|NCT04570150|Placebo Comparator|Neostigmine|
16315445|NCT04570137|Experimental|1|This arm received the arabinoxylan/ß-glucan mix first.
16315446|NCT04570137|Experimental|2|This arm received the inulin/oligofructose mix first.
16315447|NCT04570124|Experimental|Remote Surveillance|Women will use the home blood pressure monitoring device to record their blood pressure everyday for the first postpartum week, and then weekly until postpartum week 6.
16315448|NCT04570111|Active Comparator|Standard Care Diet|After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
16315449|NCT04570111|Experimental|Macro-Optimized Diet (MOD)|After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
16315450|NCT04570085|Experimental|Caffeine|after a 3 weeks up titration period, 1 capsule of 200 mg twice a day during 27 weeks (ie 400mg/day)
16315451|NCT04570085|Placebo Comparator|placebo|after a 3 weeks up titration period, 2 capsules per day during 27 weeks
16315452|NCT04570072|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10^10 colony forming unit per 2g sachet.
16315453|NCT04570072|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
16315454|NCT04570059|Experimental|Intervention program|Intervention group
16315455|NCT04570059|Active Comparator|Usual Care|Control group
16315456|NCT04570033|Experimental|patients with hyperparathyroidism|We prospectively enrolled 65 consecutive patients with primary hyperparathyroidism (PHPT) who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study
16315457|NCT04570020||Clinically-Selected Scleral Lens|The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.
16315458|NCT04570020||OCT-Selected Scleral Lens|The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.
16315459|NCT04569994|Experimental|Part 1|Healthy volunteers will receive either NNC0363-0845 or placebo
16315460|NCT04569994|Experimental|Part 2|Participants with T1D will receive either NNC0363-0845 or insulin degludec
16315461|NCT04569994|Experimental|Part 3|Participants with T1D will receive NNC0363-0845
16315462|NCT04569981|Active Comparator|Climbing Group (CG)|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
16315463|NCT04569981|Active Comparator|Unsupervised active group (UAG)|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
16315467|NCT04569942|Active Comparator|Fluids|a larger intravenous (IV) fluid volume and later vasopressor strategy
16315468|NCT04569929|Active Comparator|control|conventionally manufactured Polymethyl Methacrylate (PMMA) mandibular implant overdentures
16315469|NCT04569929|Experimental|intervention|digital light processed (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdentures
16315470|NCT04569916|Experimental|treatment group|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
16315471|NCT04569903|Experimental|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
16315472|NCT04569890|Experimental|CZP|Certolizumab pegol: subcutaneous CZP at 200mg twice a week.
16315473|NCT04569890|Active Comparator|GC+HCQ|"Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.
~Glucocorticoid: continuous usage GC at 10mg a day from Week 0 to Week 52.
~At 24 week, non-responders (ΔDAS28<0.6) will switch to the other group. Participants switched to CZP group will taper their dose of GC gradually, if they have an improvement in disease activity (two successive DAS28<2.6). If participants have a disease flare (increased DAS28>0.6) during a reduction in corticosteroid dose, then they will resume their previous dose. Weekly step-down GC scheme: 10mg-7.5mg-5mg-2.5mg-0mg."
16315474|NCT04569877|Experimental|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution
16315475|NCT04569877|Placebo Comparator|Placebo nebuliser solution|Placebo nebuliser solution
16315476|NCT04569864|Experimental|Mild hypothermia (30-32°C)|During aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest.
16315477|NCT04569864|Active Comparator|Moderate hypothermia (26-28°C)|During aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest.
16315478|NCT04569838|Experimental|Bendamustine hydrochloride injection|Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle (6-8 cycles maximum) for non-hodgkin's lymphomas or chronic lymphocytic leukemia. After 6-8 cycles, the course of treatment could be added based on patient's benefit and investigator's determination.
16315479|NCT04569825|Active Comparator|Local Nasal Steroid|Application of Local Nasal Steroid for the COVID-19 patients with anosmia
16315480|NCT04569825|Placebo Comparator|Normal Saline|Application of Normal Saline for the COVID-19 patients with anosmia
16315481|NCT04569812|Experimental|Standard CPR|After Informed Consent Document (ICD) signature, participants were randomised (to the Standard CPR group) to perform standard CPR (30:2) in a flowchart-assisted resuscitation for 5min in a manikin model
16315482|NCT04569812|Experimental|Chest compressions only|After ICD signature, participants were randomised (to the CC only CPR group) to perform chest compressions only in a flowchart-assisted resuscitation for 5min in a manikin model
16315484|NCT04569786|Experimental|Part 1: 5.00x10⁵ plaque forming units (pfu) (Panel A)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel A) will receive a single dose of V590 5.00x10⁵ pfu or placebo on Day 1.
16315485|NCT04569786|Experimental|Part 1: 2.40x10⁶ pfu (Panel B)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel B) will receive a single dose of 2.40x10⁶ pfu or placebo on Day 1.
16315486|NCT04569786|Experimental|Part 1: 1.15x10⁷ pfu (Panel C)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel C) will receive a single dose of 1.15x10⁷ pfu or placebo on Day 1.
16315487|NCT04569786|Experimental|Part 1: 5.55x10⁷ pfu (Panel D)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel D) will receive a single dose of V590 5.55x10⁷ pfu or placebo on Day 1.
16315488|NCT04569786|Experimental|Part 2: 5.00x10⁵ pfu (Panel E)|Participants in this ≥ 55 years old SARS CoV-2 seronegative cohort (Panel E) will receive a single dose of V590 5.00x10⁵ pfu or placebo on Day 1.
16315489|NCT04569786|Experimental|Part 2: 2.40x10⁶ pfu (Panel F)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel F) will receive a single dose of 2.40x10⁶ pfu or placebo on Day 1.
16315490|NCT04569786|Experimental|Part 2: 1.15x10⁷ pfu (Panel G)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel G) will receive a single dose of V590 1.15x10⁷ pfu or placebo on Day 1
16315491|NCT04569786|Experimental|Part 2: 5.55x10⁷ pfu (Panel H)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel H) will receive a single dose of V590 5.55x10⁷ pfu or placebo on Day 1.
16315492|NCT04569786|Experimental|Part 3: 5.55x10⁷ pfu (Panel I)|Participants in this 18 to 54-year-old SARS-CoV-2 seropositive cohort (Panel I) will receive a single dose of V590 5.55x10⁷ pfu or placebo on Day 1.
16315493|NCT04569773||Participants undergoing surgery for clinical|Participants will be undergoing surgery for clinical stage I endometrioid endometrial cancer
16315494|NCT04569760|Experimental|Cannabinoid Oil - Oral Preparation|"50mg CBD: 2mg of THC in each 1ml drop in MCT Oil, flexibly dosed at 200-800 mg per day.
~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (the maximum of 800 mg/day total dose of High CBD).
~The dose will be titrated in increments of 200 mg (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach 800 mg/day/week by Week 4."
16315495|NCT04569760|Placebo Comparator|Placebo Oil - Oral Preparation|"MCT Oil
~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (a volume equivalent to the maximum of 800 mg/day total dose of High CBD).
~The dose will be titrated in incremental volumes equivalent to 200 mg of active product (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach the volume equivalent to 800 mg/day/week by Week 4."
16315538|NCT04569383|Experimental|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
16315539|NCT04569370||Scoring Factor|Intervention: Procedure: Laparoscopic cholecystectomy
16315496|NCT04569747|Experimental|PERTUZUMAB + TRASTUZUMAB + ADJUVANT ENDOCRINE THERAPY|"Study treatment will be administered in 21-day (3- week, +/- 3 days) cycles for one year (18 cycles).
~Trastuzumab + Pertuzumab SC fixed dose combination
~Hormonal therapy- oral, daily per cycle (may add LHRH agonist per investigator discretion)"
16315497|NCT04569734|Experimental|Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score >2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
16315498|NCT04569721|Experimental|CT guided splanchnic cryoablation|Obese patients with type 2 diabetes receiving CT guided splanchnic cryoablation.
16315499|NCT04569708|Experimental|Children and adolescents with epilepsy and controls|Closed loop auditory stimulation during nap
16315504|NCT04569682|Active Comparator|transrenal artery perfusion group|
16315505|NCT04569682|Experimental|transrenal vein perfusion group|
16315506|NCT04569669|Experimental|Patients diagnosed with Coronary Artery Disease（CAD）by CCTA|Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.
16315507|NCT04569656|Experimental|treatment|6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg
16315508|NCT04569643||Main|Patients with cerebral small vessel disease and periodic limb movement index equal or more than 15 movements per hour of sleep.
16315509|NCT04569643||Control|Patients with cerebral small vessel disease and periodic limb movement index less than 15 movements per hour of sleep.
16315510|NCT04569630|Experimental|Intervention group|
16315511|NCT04569617|Active Comparator|upper limb endurance protocol|UL endurance protocol - elbow flexion
16315512|NCT04569617|Active Comparator|upper limb strength protocol|UL strength protocol - elbow flexion
16315513|NCT04569617|Active Comparator|lower limb endurance protocol|LL endurance protocol - knee extension
16315514|NCT04569617|Active Comparator|lower limb strength protocol|LL strength protocol - knee extension
16315515|NCT04569604||Postsurgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years after neck surgery
16315516|NCT04569604||Non-surgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years without neck surgery
16315517|NCT04569604||Pseudohypoparathyroidism|Patients with the diagnosis of Pseudohypoparathyroidism
16315518|NCT04569604||Healthy controls|25 controls from the background population matched on age (±3 years), gender and level of education with the 25 patients with postsurgical hypoparathyroidism
16315520|NCT04569578|Experimental|Policy|The policy will be implemented on preschool level.
16315521|NCT04569578|No Intervention|Regular practice|The control preschool will continue their regular practice.
16315522|NCT04569565|Experimental|PleurX catheter intervention|Participants will undergo placement and follow up monitoring of PleurX catheter.
16315523|NCT04569539|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane
16315524|NCT04569500|Experimental|PETAL program|Patients with total laryngectomy and their close relatives, benefiting from the therapeutic education program PETAL
16315525|NCT04569500|No Intervention|Usual care|Patients with total laryngectomy and their close relatives, benefiting from the usual care
16315526|NCT04569487|Active Comparator|Sarcopenic population|"Diagnosed sarcopenia following definition of the EWGSOP2:
~Muscle strength assessed by the handgrip test <27 kg
~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA <7.0 kg/m2"
16315527|NCT04569487|Active Comparator|Non sarcopenic population|"Non-sarcopenic population adapted from the EWGSOP2:
~Muscle strength assessed by the handgrip test ≥ 27 kg
~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2"
16315528|NCT04569474|Experimental|Dressing Group|use of sterile transparent dressing
16315529|NCT04569474|No Intervention|Standard Group|non-sterile transparente dressing
16315531|NCT04569448|Experimental|Patient|Individuals diagnosed with Bipolar Disorder Type I and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
16315532|NCT04569435|Experimental|ANX005|IV
16315533|NCT04569422||ephedrine drop|
16315534|NCT04569409|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
16315535|NCT04569409|Placebo Comparator|Vehicle sheet|Hydrogel sheet without allogenic mesenchymal stem cell
16315536|NCT04569396||Non-Alcoholic Fatty Liver Disease|A total of 72 severely or morbidly obese patients with non-alcoholic fatty liver disease and associated co-morbidities like diabetes and hypertension were enrolled into the study.
16315537|NCT04569383|Experimental|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
16315541|NCT04569357|Experimental|Prospecta|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
16315542|NCT04569357|Placebo Comparator|Placebo|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
16315543|NCT04569344||Patients with Covid-19|Patients with laboratory test positive for SARS-CoV-2 virus
16315544|NCT04569344||Patients without Covid-19|Patients who do not have a laboratory test positive for SARS-CoV-2 virus
16315545|NCT04569331|No Intervention|Control group|"Patients undergoing anterior rectal resection with protective ileostomy will follow routine clinical practice.
~During hospital admission for ileostomy closure surgery, the stoma therapist reinforces the information on the possibility of anterior resection syndrome (ARS) and hygienic-dietary measures. At the level of the ARS, the patient is informed of the possibility of increased frequency of bowel movements, evacuation dysfunction, such as urgency to defecate or feeling of incomplete emptying. At the level of diet, an astringent diet is recommended during the first week after ileostomy closure to avoid liquid stools. It is also recommended at the level of perineal hygiene to use a cleanser with a pH similar to that of the skin, applying the least possible force on the skin, dry gently after each bowel movement and apply a skin protection product to avoid dermatitis associated with incontinence."
16315546|NCT04569331|Experimental|Stimulation of efferent loop and rehabilitation pelvic floor|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened every 48-hours the first two weeks and once daily the thrid week.
~Rehabilitation of pelvic floor: 3 months after the ileostomy closure surgery, patient will be referred to the pelvic floor unit for pelvic floor rehabilitation."
16315547|NCT04569318|Experimental|Treatment Arm|Treatment with treatment beam.
16315548|NCT04569305|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
16315549|NCT04569305|Active Comparator|Conventional treatment|Simple moist gauze dressing applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of treatment was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
16315550|NCT04569292||Cancer patients|"confirmation of COVID-19 in the laboratory (RT-PCR techniques);
~suspected cases of COVID-19; clinically diagnosed based on symptoms (fever> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a COVID-19 subject positive;
~asymptomatic cases; diagnosed based on positive swab results but without symptoms"
16315551|NCT04569279|Active Comparator|Warfarin arm|Patients randomly assigned to (W) group will receive an adjusted dose of warfarin with targeted INR of 2.0 to 3.0.
16315552|NCT04569279|Experimental|Rivaroxaban arm|Patients randomly assigned to (R) group will receive 20mg rivaroxaban daily if CrCl>50 mL/min using Cockcroft-Gault equation or 15mg rivaroxaban daily if CrCl 30-50 mL/min.
16315553|NCT04569266|No Intervention|No specific exercise rehabilitation treatment|"Patients will not benefit from any specific exercise rehabilitation treatment until 6 months post-ICU. They will then be proposed to follow the treatment protocol if efficacy is demonstrated, once their follow-up in the study is completed."
16315554|NCT04569266|Experimental|specific exercise rehabilitation treatment|"Patients will receive a prescription for exercise rehabilitation, at the rate of 2 sessions of approximately 1 hour each per week for 10 weeks.
~Continuous endurance training will start at 60-70% of the patient's maximum power. For patients who are unable to maintain continuous re-training, interval training sequences (30 seconds of effort followed by 30 seconds of rest) may be offered.
~Initially, the effort will be 15 minutes, then gradually increase to reach an exercise duration of 40 minutes or 45-60 minutes for endurance or interval training respectively.
~The power can be adjusted as the patient progresses to reach the target heart rate and dyspnea at 4-6 on the BORG scale.
~All patients will be offered lower limb and upper limb strengthening exercises. Each exercise will consist of 3-4 sets of 6-12 repetitions."
16315555|NCT04569240|Other|Dexcom G6 continuous glucose monitor|All patients will have a Dexcom G6 continuous glucose monitor placed pre-operatively. The glucose readings will be collected for 10 days or upon discharge from the ICU and data will be compared with arterial blood glucose readings or venous Accu-Check Inform II glucose readings
16315556|NCT04569227|Experimental|Active EC-18|
16315557|NCT04569227|Placebo Comparator|Placebo|
16315558|NCT04569214|Placebo Comparator|A - Placebo Control|4 tablets of placebo
16315559|NCT04569214|Experimental|B - PAZ320 Low Dose|2 tablets of PAZ320 and 2 tablet of placebo
16315560|NCT04569214|Experimental|C - PAZ320 High Dose|4 tablet of PAZ320
16315561|NCT04569188|Experimental|convalescent plasma|Cohort of elderly patients treated with convalescent plasma
16315562|NCT04569175|Experimental|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product)
16315563|NCT04569136|Experimental|Intervention group|"Educating the patient about mastitis and self-management strategies
~Treating with therapeutic ultrasound
~Administering and teaching breast massage"
16315564|NCT04569136|Sham Comparator|Sham group|"Educating the patient about mastitis and self-management strategies
~Receiving sham ultrasound
~Administering and teaching breast massage"
16315565|NCT04569136|Other|Usual care group|Receiving usual obstetric care, which may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff
16315566|NCT04569123|Active Comparator|Vibration|The device will deliver imperceptible vibration for the treatment group.
16315567|NCT04569123|Sham Comparator|No Vibration|The device will deliver no vibration for the control group.
16315568|NCT04569110||Pleural infection|Patients with clinically confirmed ongoing pleural infection.
16315569|NCT04569110||Negative control|Patients without pleural infection.
16315570|NCT04569097|Experimental|Patient group|lingual strengthening
16315571|NCT04569097|No Intervention|Healthy controls|Healthy normal swallow
16315574|NCT04569071|Experimental|Sinovation Laser Ablation System treatment|Sinovation Laser Ablation System treatment
16315575|NCT04569058|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
16315576|NCT04569045|Experimental|HA + Lidocaine|Sodium Hyaluronate with Lidocaine Hydrochloride
16315577|NCT04569045|Active Comparator|HA|Sodium Hyaluronate
16315580|NCT04569019||Health care workers|The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants
16315581|NCT04568993|Experimental|proximal phalangeal level|injection in the the tendon sheet over proximal phalanx of finger
16315582|NCT04568993|Active Comparator|volar MCP level|injection above the A1 pulley volar to the MCP joint
16315586|NCT04568967|Experimental|intervention arm|"The intervention arm for this trial consists of testing expectorated sputum and concentrated urine with Ultra and urine with FujiLAM, regardless of presence of TB compatible symptoms.
~To fulfil exploratory objectives we will also collect tongue and stool/rectal swabs in this arm for Xpert Ultra testing."
16315587|NCT04568967|No Intervention|control arm|"The control arm for this trial will consist of:
~Sputum Ultra whenever the patient has cough, fever, weight loss or night sweats and/or Ultra on any tissue (including lymph nodes) from patients with suspected extrapulmonary TB.
~& Urine Alere TB-LAM, if patients have signs and symptoms of TB (pulmonary and/or extrapulmonary), or with advanced HIV disease,or who are seriously ill, or else irrespective of signs and symptoms of 3 TB and with a CD4 cell count of less than 200 cells/mm .
~These testing guidelines are the current WHO recommended TB testing practices for HIV positive inpatients (as of Q1 2020)."
16315588|NCT04568954|Experimental|Xpert MTB/RIF Ultra using GeneXpert Omni Arm|GeneXpert Omni platforms using Xpert MTB/RIF Ultra® cartridges placed at primary health care clinics combined with rapid communication of results and same day TB treatment initiation
16315589|NCT04568954|No Intervention|Standard of care Arm|Standard of care may vary by clinics. Dependent on availability of transport and stock of Xpert cartridges standard of care will be a combination of smear microscopy and off-site Xpert MTB/RIF Ultra® testing.
16315590|NCT04568941|Experimental|Preoperative Vacuum-Assisted Biopsy|Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
16315591|NCT04568941|Experimental|Preoperative Core Needle Biopsy|Preoperative core needle biopsy was performed within 10 days before final surgery. The needle biopsy were performed with 3 needles.
16315592|NCT04568941|Experimental|Intraoperative Excisional Biopsy|The tumor was excised intraoperatively.
16315593|NCT04568928|Experimental|OLTP/PE+FES first, then OLTP/PE+sham FES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE+FES).
~One week break. 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton combined with SHAM functional electrical stimulation (OLTP/PE + shamFES).
~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression. For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. For the sham FES, all parameters will be the same except that a subthreshold current intensity (i.e. not producing palpable muscle contraction) will be delivered. FES timing and duration is already built into the device."
16315594|NCT04568928|Experimental|OLTP/PE+shamFES first, then OLTP/PE+FES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined with SHAM functional electrical stimulation (OLTP/PE+ shamFES).
~One week break. 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE + FES).
~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression. For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. For the sham FES, all parameters will be the same except that a subthreshold current intensity (i.e. not producing palpable muscle contraction) will be delivered. FES timing and duration is already built into the device."
16315595|NCT04568928|Active Comparator|OLTP/PE noFES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined (OLTP/PE) One week break 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton (OLTP/PE)
~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression."
16315596|NCT04568915|Experimental|Dry Needling-Group|Tens, Stretching, Strengthening(girdle), Neck Isometrics, DN
16315597|NCT04568915|Active Comparator|Maitland-Group|Tens Stretching, Strengthening(girdle), Neck Isometrics, Maitland joint mobilization
16315601|NCT04568889|Experimental|Government/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
16315602|NCT04568889|Experimental|Government/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
16315603|NCT04568889|Experimental|Government/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
16315604|NCT04568889|Experimental|Government/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
16315605|NCT04568889|Experimental|Researchers/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
16315606|NCT04568889|Experimental|Researchers/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
16315607|NCT04568889|Experimental|Researchers/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
16315608|NCT04568889|Experimental|Researchers/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
16315609|NCT04568889|Experimental|Government/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
16315610|NCT04568889|Experimental|Government/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
16315611|NCT04568889|Experimental|Government/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
16315612|NCT04568889|Experimental|Government/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
16315613|NCT04568889|Experimental|Researchers/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
16315614|NCT04568889|Experimental|Researchers/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
16315615|NCT04568889|Experimental|Researchers/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
16315616|NCT04568889|Experimental|Researchers/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
16315617|NCT04568876|Active Comparator|PEA Group|Normast® MPS (mPEA and umPEA 300mg + 600mg) oral suspension: 2700mg/die in 3 doses for 28 days, in add-on to standard therapy
16315618|NCT04568876|Other|Control Group|Standard therapy only
16315619|NCT04568863|Experimental|Melatonin|(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
16315620|NCT04568863|Placebo Comparator|Placebo|(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
16315621|NCT04568837|Experimental|Corticosteroid|Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery
16315622|NCT04568837|No Intervention|Control|Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery.
16315623|NCT04568824|Experimental|GraphoLearn reading intervention|GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
16315624|NCT04568824|Active Comparator|Vektor math control|We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.
16315625|NCT04568811|Experimental|Adenovirus Type-5 Vectored COVID-19 Vaccine|
16315626|NCT04568798|Active Comparator|Sana Device|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
16315627|NCT04568798|Sham Comparator|Sana Sham Device|The sham treatment device is designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
16315628|NCT04568785|Experimental|Brief Intervention group|Intervention consisted of a standardized Brief Intervention, which varied depending on the reason the patient had given for refusing the vaccination.
16315629|NCT04568785|Active Comparator|Control group|the control group intervention was the normal advice that professionals used to give their patients
16315630|NCT04568772|Active Comparator|Atovaquone/Proguanil 250/100 mg|A single oral administration of atovaquone/proguanil 250/100 mg
16315631|NCT04568772|Experimental|Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
16315632|NCT04568772|Experimental|Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
16315633|NCT04568772|Experimental|Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
16315634|NCT04568759|Active Comparator|Standard care group|Observation or brace plus conventional physiotherapy exercises on video
16315635|NCT04568759|Experimental|GPR group|GPR interventions added to standard care (observation or brace)
16315636|NCT04568746|Other|patients with qSOFA ≥ 2|adult patients with a qSOFA score ≥ 2 at the screening in the emergency department, will be referred to the emergency vital room
16315637|NCT04568746|Other|patients with qSOFA <2|adult patients with a qSOFA score < 2 at the screening in the emergency department, will be referred to the box
16315638|NCT04568733|No Intervention|Resting|
16315639|NCT04568733|Experimental|Pilates exercise session|
16315640|NCT04568733|Active Comparator|Treadmill walking at 3.2 kph|
16315641|NCT04568733|Active Comparator|Treadmill walking at 4.8 kph|
16315642|NCT04568720||Shanghai General Hospital|
16315643|NCT04568707|Experimental|Covid-19 infection|Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
16315644|NCT04568694|Experimental|Delayed Lung Transplantation|Patients that received lung(s) delayed for transplantation
16315645|NCT04568694|Active Comparator|Conventional Lung Transplantation|Reference Therapy
16315646|NCT04568681||Patients with dystonia|Patients with dystonia who have clinically been deemed candidates for DBS surgery.
16315647|NCT04568668|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
16315648|NCT04568668|No Intervention|Standard care (ADE information retained locally)|Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their adverse drug event information will not be visible to other providers via PharmaNet.
16315649|NCT04568655||COVID-19 patients need noninvasive ventilation|
16315650|NCT04568642|Active Comparator|Conventional|Device: conventional FiO2 will be selected by the clinician according to the SpO2 target
16315651|NCT04568642|Experimental|Closed-loop|Device: conventional FiO2 will be selected by the closed-loop algorithm according to the SpO2 target
16315652|NCT04568629||Palliative Care Clinicians|Clinicians working in an adult palliative care service
16315653|NCT04568616|Experimental|Treatment|Letrozole 2.5mg tablet administered once daily for 4 to ~12 weeks (window of + 4 weeks for surgical scheduling flexibility) final dose taken the day of surgery.
16315654|NCT04568603|Experimental|Methadone + ISL|Methadone-maintained participants (20 to 200 mg once daily [QD] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9 and ISL 60 mg once on Day 2.
16315655|NCT04568590|Experimental|Vaccine Hesitant|Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.
16315656|NCT04568577|Experimental|tensioned tape|The tensioned tape group will apply weekly with gradual tension calculated by measuring the initial length of the tape. From the first week of application, there will be a 5% increase in tension up to the fifth week.
16315657|NCT04568577|Active Comparator|tape without tension|The tensionless tape group will receive the application of the tape weekly without tensioning during the five weeks.
16315684|NCT04568369|Sham Comparator|Sham group|In the sham condition, a sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
16315660|NCT04568538|Experimental|İntervention group|"Randomization with a sealed envelope will be applied to mothers who have 2-4 months old babies who apply to Akdeniz University Hospital Pediatric Outpatient Clinic for health control and who accept the study. A pre-test application will be made in the intervention group. The Researcher will fill in the Personal Information Form and the Shaken baby syndrome assessment survey at this stage.
~The training prepared to prevent shaken baby syndrome, which was prepared immediately after the end of the pre-test application, will be given to the mothers in the intervention group. The training will be given with mothers using one-to-one face-to-face interview method. Necessary equipment will be provided for training. At the end of the training, the questions of the mothers will be answered and a booklet prepared to prevent shaken baby syndrome will be given and tele-consultancy will be provided for 2 months."
16315661|NCT04568538|No Intervention|Control group|No application will be made to the mothers in the control group after the pre-test application. After 2 months, the final test application will be made. After the last test, the mothers in the control group will be given a training and a booklet prepared to prevent shaken baby syndrome.
16315662|NCT04568525|Active Comparator|COVID - 19 patients|
16315663|NCT04568525|Active Comparator|COVID - 19 and pneumonia patients|
16315664|NCT04568525|Active Comparator|Health patients|
16315665|NCT04568512|Placebo Comparator|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
16315666|NCT04568512|Active Comparator|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
16315667|NCT04568499||Suspected and Confirmed COVID-19 cases|Suspected and confirmed COVID-19 cases (age 5 years and above) identified at health facilities or via mobile teams in Juba, South Sudan and in Eastern Democratic Republic of the Congo.
16315668|NCT04568486|Other|Rural-dwelling older adults (seed) and Key players (alter|Rural-dwelling older adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. This group will be paired with their key players (identified during interviews) to receive the diabetes education. The pair complete the intervention as a dyad.
16315669|NCT04568473|Experimental|PRG Barrier Coat (SHOFU Inc., Japan)|"BioSmart Light Cured Protective Shield with bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology.
~S-PRG filler possesses a three-layer structure with a stabilized glass-ionomer-like structure surrounding multifunctional glass fillers, and is subsequently protected by a surface modified layer."
16315670|NCT04568473|Experimental|EMBRACE™ Varnish (Pulpdent Corporation, USA)|"Resin-based 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release.
~The incorporation of CXP™ (xylitol-coated calcium and phosphate) in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish"
16315671|NCT04568473|Active Comparator|Duraphat® (Colgate Palmolive Company, New York, NY)|It is attributed to the reactivity of the fluoride by adsorbing to the surface and attracting calcium ions forming loosely-bound calcium fluoride (CaF2)- like reservoir which is also considered responsible for the anticaries mechanism and protection against cariogenic acid attack.
16315672|NCT04568460|Experimental|Intervention Group Sessions|Intervention group sessions will be delivered by lay health counselors. The sessions will reflect principles of co-learning, participatory design, and empowerment to promote engagement of young people in critical thinking and problem solving - including modeling, roleplaying, and interactive activities.
16315673|NCT04568460|No Intervention|Standard of Care|This is the standard of care arm. Participants newly diagnosed with HIV will get a referral to the local primary health care setting of their choice for further management, including ART.
16315674|NCT04568447|Experimental|IMOOVE|Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.
16315677|NCT04568421||Treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
16315678|NCT04568421||Not treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases not treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
16315680|NCT04568395|Experimental|PLWH smoker|PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control
16315683|NCT04568369|Experimental|Treatment group|Patients will engage in a four-week treatment protocol (20 treatments). This was chosen as it is the midpoint between typical depression and migraine protocol durations. If available, patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. If not available, a standardized atlas brain with Montreal neurologic institute (MNI) coordinates will be used for navigation. The DLPFC will be located through MNI coordinates (-48, 26, 36) vs. (-41, 21, 38). The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, with a frequency of 10 Hz, 10 trains of 60 pulses/train (total of 600 pulses) and inter-train interval of 45s.
16315685|NCT04568356|Experimental|Antigen rapid test for COVID-19|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
16315686|NCT04568343|Experimental|small bowel bleeding patient|with suspicious small bowel bleeding,patient will recieve Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule later for evaluations
16315687|NCT04568330|Other|Best support care (BSC)|Interventions for comparison group (group C) who received BSC alone were (1) informed of potential presentations of HFSR, (2) asked for wearing waterproof gloves before execute household or work with water, (3) provided the method of contacting with healthcare specialists for confirming early diagnosis of HFSR, and (4) asked for self-report when they occurred symptoms of HFSR.
16315688|NCT04568330|Experimental|BSC plus moisture cream|The A group with BCS plus moisturizing cream received the interventions as the comparison group, was given the moisturizing cream (dimethicone, fragrance free, Aveeno, United States) for 9 times and was instructed how to use the cream. The education of usage included (1) using the cream twice a day from 3 days before starting sorafenib and each week post starting sorafenib, (2) scooping out nut-sized cream with a unique spoon each time, (3) gently applied the cream evenly on symmetrical palms below wrists and symmetrical soles below ankles each time, (4) wore unique cotton gloves immediately after the appalment of cream for 30 minutes each time.
16315689|NCT04568330|Active Comparator|10% urea-based cream|The B group with BCS plus 10% urea-based cream had the similar interventions as the A group with BCS plus moisturizing cream except being given the cream container with different component (10% urea; Sipharr, Taiwan). The outlook of the containers with the two kinds of cream was the same. All the cream looks white and grey.
16315690|NCT04568317|Experimental|Smartwatch group|iCBT intervention 'Space from Depression' with smartwatch as an additional means to self-report data on mood, sleep and physical activity in the 'Space from Depression' program (n=35).
16315691|NCT04568317|Active Comparator|Treatment as usual group|iCBT intervention 'Space from Depression' (n=35).
16315692|NCT04568304|Experimental|Toripalimab Injection + chemotherapy group|
16315693|NCT04568304|Placebo Comparator|Placebo + chemotherapy group|
16315694|NCT04568291|Active Comparator|routine treatment|routine treatment
16315695|NCT04568291|Experimental|model treatment|model treatment
16315696|NCT04568278|Experimental|Intervention Group|a mobile application using the PRO-CTCAE along with usual care
16315697|NCT04568278|No Intervention|Controlled Group|Usual care
16315698|NCT04568265|Experimental|APG-1387 12 mg combined with entecavir 0.5 mg|
16315699|NCT04568265|Experimental|APG-1387 20 mg combined with entecavir 0.5 mg|
16315700|NCT04568265|Experimental|APG-1387 30 mg combined with entecavir 0.5 mg|
16315701|NCT04568265|Experimental|entecavir 0.5 mg|
16315702|NCT04568252|Experimental|Intervention|Millimetric wave emission bracelet.
16315703|NCT04568252|Sham Comparator|Control|Placebo bracelet.
16315704|NCT04568239||M184V + group and M184 - group|
16315705|NCT04568226|Experimental|ConquerFear Intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
16315706|NCT04568226|Active Comparator|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
16315707|NCT04568213|Experimental|Hypochlorous Gel Application|
16315708|NCT04568200|Experimental|durvalumab and neoadjuvant therapy|durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
16315709|NCT04568200|Placebo Comparator|normal saline and neoadjuvant therapy|normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
16315710|NCT04568187|Active Comparator|cryolipolysis machine on Left inner thigh|Zeltiq machine as intervention procedure was carried out on left inner thigh (treated side) for 1 hour through cool sculpting procedure with CIF (Cooling Intensity Factor: -73 mW/cm2).
16315711|NCT04568187|Sham Comparator|radiofrequency on right thigh|The radio frequency method was applied on right thigh (control side) as sham procedure for 30 minutes through 3000 Hz- amplitude modulated frequency at once.
16315712|NCT04568174|Active Comparator|PPSGG|sterile liquid, one 1-hour infusion in SAD and multiple infusions in MAD. In SAD multiple cohorts being tested. Dosage and regime in MAD to be defined based on SAD outcome.
16315713|NCT04568174|Placebo Comparator|Placebo|standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
16315714|NCT04568161|Experimental|pre and post chemotherapy assessments|The patients will be assessed before and after chemotherapy treatment.
16315715|NCT04568135||survey|
16315716|NCT04568122|Experimental|Saliva test|Participants perform each test assay, noting the results for comparison by technician, and completing survey questionnaires.
16315717|NCT04568109|Experimental|Exposure-based cognitive-behavior therapy|Patients are treated in accordance with a manualized protocol (Gloster et al., 2011)
16315718|NCT04568109|No Intervention|Wait-List control condition|Patients are assessed prior to and after a 12-week waiting period. Patients are treated after this 12-week delay.
16315719|NCT04568096|Active Comparator|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
16315720|NCT04568096|Placebo Comparator|The standard therapy|The infected patients will receive the standard therapy for COVID-19 for 14 days
16315721|NCT04568083||Ticagrelor cohort|Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
16315722|NCT04568083||Non-ticagrelor cohort|Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.
16315723|NCT04568070|Experimental|Stroke|Stroke patients who applied to the Physical Medicine and Rehabilitation outpatient clinic, met the inclusion criteria and volunteered to participate in the study
16315724|NCT04568057|Active Comparator|NIR Transcranial phototherapy device|The active transcranial phototherapy device. 1068 nm NIR Transcranial phototherapy PBM-T device An air-cooled LED helmet with a peak wavelength of 1068 nm, spectral width of 60 nm, and a 6-minute internal timer was used. The average optical power output of the combined arrays is circa 3.8 Watts, 12mw/sq. cm. The total energy to be delivered to the cranium is 1368J (3.8 x 360) per treatment session.
16315725|NCT04568057|Placebo Comparator|Placebo Device.|Placebo cranial device. The external appearance of the device is identical to that of the active device but no NIR light is emitted.
16315726|NCT04568044||Group A: Mild to moderate COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness.
~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
16315727|NCT04568044||Group B: Severe to critical COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness.
~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
16315728|NCT04568044||Group C: Controls (non-pregnant)|"Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness.
~A blood sample will be taken on 1 day and at 1 time point."
16315729|NCT04568044||Group D: Pregnant or postnatal with COVID-19|"Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only.
~For most participants in this group, blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months).
~However, for pregnant women admitted to hospital with severe COVID-19, we will aim to collect earlier timepoints (day 1-3, day 5-7 and then day 7-14). Thereafter, we will follow the above mentioned the long-term schedule (i.e. 1, 4, 8, 12 months)."
16315730|NCT04568044||Group E: Pregnant or postnatal with influenza|"Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only.
~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
16315731|NCT04568044||Group F: Pregnant and have received the influenza vaccine|"Current pregnant and due to receive the influenza vaccine (age 18-50 years old). Singleton pregnancies only.
~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
16315732|NCT04568044||Group G: SARS-CoV-2 vaccinated pregnant/postnatal women|"Current pregnant or postnatal (within 6 weeks of birth) and due to receive the SARS-CoV-2 vaccine (age 18-50 years old). Singleton pregnancies only.
~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
16315733|NCT04568044||Group H: SARS-CoV-2 vaccinated non-pregnant women|"Non-pregnant and due to receive the SARS-CoV-2 vaccine (age 18-50 years old).
~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
16315734|NCT04568031|Active Comparator|Part I|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
16315735|NCT04568031|Placebo Comparator|Part II|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
16315736|NCT04568018||1 cohort|"Patients with mild ARDS, who are on spontaneous breathing.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
16315737|NCT04568018||2 cohort|"Patients with moderate ARDS, who are on spontaneous breathing.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
16315738|NCT04568018||3 cohort|"Patients with mild ARDS, receiving NIV and high-flow oxygen therapy.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
16315739|NCT04568018||4 cohort|"Patients with moderate ARDS, receiving NIV and high-flow oxygen therapy.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
16315740|NCT04567992|Experimental|SCPB|
16315741|NCT04567992|Placebo Comparator|Control|
16315742|NCT04567979||Patients with solid tumors|Patients with solid tumors under chemotherapy and / or radiotherapy treatment at our center.
16315743|NCT04567979||Healthcare workers|Healthcare workers at the chemotherapy and radiotherapy unit in our center.
16315744|NCT04567966|Experimental|Cortical bone plate|A cortical plate was harvested from the external oblique ridge and split in half. Then one plate was fixed at a distance from the atrophied ridge and autogenous bone chips were used to fill the gap between the plate and the ridge.
16315745|NCT04567966|Active Comparator|Cortico-cancellous block graft|A cortico-cancellous block graft was harvested from the symphysis of the mandible and fixed to the atrophied ridge.
16315746|NCT04567953|Experimental|Saliva and NP paired specimen collection|
16315747|NCT04567940|Experimental|Intervention group|Behavioural multicomponent intervention
16315748|NCT04567940|No Intervention|Control group|Usual care
16315749|NCT04567914||Adolescent idiopathic scoliosis|Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness of AIS patients diagnosed by a specialist. Spirometry evaluation was performed by the investigator
16315750|NCT04567914||Adolescent healthy individuals|Healthy adolescents aged 10-18 were selected. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness. Spirometry evaluation was performed by the investigator.
16315751|NCT04567901||Trauma Patients|The enrolled patients experienced trauma from different injuries and were hospitalized for treatment and admitted to the ICU. 700 older trauma patients (age equal to or more than 65 years) were finally included in the study.
16315752|NCT04567888|Active Comparator|Happify Teens|Happify Teens is a digital well-being intervention that can be accessed via mobile application or web browser
16315753|NCT04567888|No Intervention|Waitlist Control|Waitlist Control Condition
16315754|NCT04567875||CRPC patients|CRPC patients without evidence of distant metastasis are eligible
16315755|NCT04567849|No Intervention|Control|No intervention control group
16315756|NCT04567849|Experimental|Nudge: call provider|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call their recent Women's Health provider (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
16315757|NCT04567849|Experimental|Nudge: call tele-nurse|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call Geisinger's nurse triage hotline (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
16315758|NCT04567836||The asymptomatic medical staff cohort|"The cohort of asymptomatic / paucisymptomatic operators will include the cohort of operators who will test positive in the serological analysis.
~From the entire population of hospital workers (over 3000), three controls will be identified for each operator who tested positive for the serological test that were analyzed on the same day and were negative for the serological test."
16315759|NCT04567836||The symptomatic medical staff cohort|The cohort of symptomatic hospital workers who tested positive for the swab includes 250 operators.
16315760|NCT04567823|Experimental|Microalgae I|Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
16315761|NCT04567823|Experimental|Microalgae II|Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
16315762|NCT04567823|Placebo Comparator|Smoothie|Smoothie (without microalgae) and standardised background diet (defined menu plans)
16315763|NCT04567823|No Intervention|Control|no intervention (no smoothie, no menu plans)
16315764|NCT04567810|Experimental|Part A: 2 mg preparation|Participants receive a single 2 mg dose of anti-SARS-CoV-2 IgY.
16315765|NCT04567810|Experimental|Part A: 4 mg preparation|Participants receive a single 4 mg dose of anti-SARS-CoV-2 IgY.
16315766|NCT04567810|Experimental|Part A: 8 mg preparation|Participants receive a single 8 mg dose of anti-SARS-CoV-2 IgY.
16315767|NCT04567810|Placebo Comparator|Part A: placebo preparation|Participants receive placebo matching anti-SARS-CoV-2 IgY.
16315768|NCT04567810|Experimental|Part B: 6 mg total daily dose|Participants receive a 2 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
16315769|NCT04567810|Experimental|Part B: 12 mg total daily dose|Participants receive a 4 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
16315770|NCT04567810|Experimental|Part B: 24 mg total daily dose|Participants receive a 8 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
16315771|NCT04567810|Placebo Comparator|Part B: 0 mg total daily dose|Participants receive placebo matching anti-SARS-CoV-2 IgY three times daily for 14 days.
16315772|NCT04567797|Experimental|Exoskeleton|To compare the efficacy of four different exoskeleton devices, all participants will be asked to finish simulated construction tasks with each exoskeleton. Additionally, all participants will be asked to finish the same tasks without wearing an exoskeleton for reference.
16315773|NCT04567784|Placebo Comparator|Control|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
16315774|NCT04567784|Experimental|CBD 800mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
16315775|NCT04567771|Experimental|Treatment (radiation therapy, questionnaires)|Patients undergo standard of care proton or intensity modulated radiation therapy. Patients also complete quality of life questionnaires and adverse event assessments over 10-15 minutes each at baseline, at the end of radiation therapy, and at 1 month, 1 year, and 3 years post-radiation therapy.
16315776|NCT04567758|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
16315777|NCT04567758|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
16315778|NCT04567745|Other|Cognitive diagnosis|
16315779|NCT04567732|Experimental|Filtered Autologous Adipose Tissue|based on randomization one of the two knees will be treated with a single injection of Filtered Autologous Adipose Tissue
16315780|NCT04567732|Placebo Comparator|Placebo|based on randomization one of the two knees will be treated with a single injection of Placebo
16315781|NCT04567719||Changes in Taste Perception After Exposure to Chemotherapy|A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
16315783|NCT04567693|Experimental|Early 1|Advance to spaced-out appointments at month 6 after a single viral load is measured.
16315784|NCT04567693|Experimental|Early 2|Advance to spaced-out appointments at month 6 after two viral loads are measured.
16315785|NCT04567693|No Intervention|Usual Care|Do not advance to spaced-out appointments during study period
16315816|NCT04567433||CHEST Study|Participants in the CHEST trial long term sepsis cohort
16315817|NCT04567433||ARISE Study|Participants in the ARISE study long term follow-up cohort
16315818|NCT04567433||ADRENAL study|Participants in the ADRENAL study
16315786|NCT04567680|Experimental|Acceptance and Commitment Therapy to Improve Social Support|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
16315787|NCT04567680|Active Comparator|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
16315788|NCT04567667|Experimental|Group 1|
16315789|NCT04567667|Experimental|Group 2|
16315790|NCT04567641||Enteral Nutrition|
16315791|NCT04567641||Parenteral nutrition|
16315792|NCT04567628||TDM Cohort|Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment will be observed retrospectively.
16315793|NCT04567628||Historical Cohort|Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment will be observed retrospectively.
16315794|NCT04567615|Experimental|Arm A : Nivolumab|
16315795|NCT04567615|Experimental|Arm B : Nivolumab + Relatlimab Dose 1|
16315796|NCT04567615|Experimental|Arm C : Nivolumab + Relatlimab Dose 2|
16315798|NCT04567576||Exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed infection by 2019-nCoV (COVID-19) who at the time of diagnosis (of infection) receive pharmacological treatment with disease modifying antirheumatic drugs (DMARDs).
16315799|NCT04567576||Un-exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed 2019-nCoV (COVID-19) infection who at the time of diagnosis (of infection) are not receiving pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs).
16315800|NCT04567563|Active Comparator|Remote Ischemic Condition|
16315801|NCT04567563|No Intervention|Standard of Care|
16315802|NCT04567550|No Intervention|Observation Control Arm|Observation Control
16315803|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
16315804|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
16315805|NCT04567537|Active Comparator|Scars|One half or side of the hypertrophic scar will be randomized to receive laser treatment only. The other side will be left untreated, and each subject will act as their own control.
16315806|NCT04567537|Active Comparator|Scleroderma|One half or side of the sclerodermoid lesion will be randomized to receive laser treatment only. The other side will be left untreated, and each subject will act as their own control.
16315807|NCT04567524|Active Comparator|Arm 1|"• LYN-005: Size 00EL capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone.
~AND
~• IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient."
16315808|NCT04567524|Placebo Comparator|Arm 2|"• LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate.
~AND
~• IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets."
16315809|NCT04567511|Experimental|Single Arm|Patients with mild hemophilia A (without inhibitors) will be treated with prophylactic emicizumab. The clinical hemostatic efficacy and safety will be assessed. Secondary outcomes will assess changes in quality of life and joint health in treated patients.
16315810|NCT04567498|Experimental|Presumptive TB patients (395 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
16315811|NCT04567498|Experimental|Residents of area with high risk of TB (1383 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
16315812|NCT04567472|Experimental|Online HEADS: UP|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
16315813|NCT04567459|No Intervention|control group: chemotherapy|No intervention
16315814|NCT04567459|Experimental|experimental group: chemotherapy and nutrition support|Premium amino acids 1pc bid for 6 months
16315815|NCT04567446||Patients who will start cancer treatment|"Collection of biological samples (stool, blood, saliva) and data from patients included in the study will be performed:
~By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).
~Collection of biological resources (all samples will be collected in fresh):
~Stool: collected at diagnosis, before initiating anticancer treatment, during treatment
~Blood: 40 mL collection before, 3 and 6 months of treatment cancer
~Saliva: 5 mL collection before initiation of treatment cancer
~Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
16315822|NCT04567394|Experimental|Intervention|Participants randomized to the Intervention group will complete questionnaires at baseline, 1 month, 3 months, and 6 months and will receive 4 weeks of the PNC-txt intervention.
16315823|NCT04567394|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will complete questionnaires at baseline, 1 month, 3 months, and 6 months.
16315824|NCT04567381|Active Comparator|Treatment as Usual|Treatment as Usual (TAU)/Control. Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
16315825|NCT04567381|Experimental|Enhanced Services|Enhanced Services/Treatment (ES). Participants randomized to the ES intervention will receive intensive community-based case management.
16315826|NCT04567355|Experimental|Migraine Manager|The Migraine Manager portal intervention is comprised of 16 modules that are assigned in an individually tailored manner to participants based on their answers to a brief assessment battery. Once assessments are completed, a treatment plan consisting of recommended modules is automatically generated for patient and parent guidance, and the user is directed to the list of recommended modules. Participants will also complete online daily diaries for eight weeks.
16315827|NCT04567355|No Intervention|Attention Control|Participants in this arm will complete the online daily diaries for eight weeks (i.e., equal time as the Migraine Manager arm) through the portal but will be restricted from receiving intervention content; they will also receive equal number of communications via the portal as the Migraine Manager arm. Data from migraine daily diaries will not be available to AC participants or their clinicians as this would likely be used clinically and lead to contamination of the control arm resulting from varying levels of intervention across participants based on their data.
16315828|NCT04567342|Experimental|Arm 1|
16315829|NCT04567342|Experimental|Arm 2|
16315830|NCT04567342|Experimental|Arm 3|
16315831|NCT04567342|Experimental|Arm 4|
16315832|NCT04567329|Experimental|NOV03|100% perfluorohexyloctane 4 times daily (QID)
16315833|NCT04567329|Placebo Comparator|Saline solution|0.6% sodium chloride solution 4 times daily (QID)
16315834|NCT04567316|Experimental|[14C]-radiolabelled BI 1358894|[14C]-radiolabelled BI 1358894 (part 1)
16315835|NCT04567316|Experimental|BI 1358894|BI 1358894 (part 2)
16315836|NCT04567303|Experimental|Part 1: Intravitreal Injections|RO7250284 administered in ascending dose levels through IVT injections.
16315837|NCT04567303|Experimental|Part 2: Port Delivery System with High Dose|RO7250284 administered at a high dose through the PDS implant.
16315838|NCT04567303|Experimental|Part 2: Port Delivery System with Low Dose|RO7250284 administered at a low dose through the PDS implant.
16315839|NCT04567290|Experimental|Chewed ticagrelor|"Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff.
~Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed"
16315840|NCT04567290|Active Comparator|Swallowed ticagrelor|"Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water.
~Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed"
16315841|NCT04567277|Experimental|Early VPS|
16315842|NCT04567264|Experimental|With stimulation|Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.
16315843|NCT04567251|Experimental|Namzaric® arm|Arm 1 will take daily Namzaric® for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
16315844|NCT04567251|Placebo Comparator|Placebo arm|Arm 2 will take daily placebo for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
16315845|NCT04567238|Experimental|Reduced Use Condition|Participants in the reduced use condition will be provided mobile contingency management, in which they are paid to provide marijuana saliva readings that suggest they have been abstinent from marijuana use.
16315846|NCT04567238|No Intervention|Control Condition|Participants in the control condition will be asked to provide marijuana saliva readings, but they are not paid for abstinent readings. Instead, their payments are yoked to the average amount of payment made by two participants in the reduced use condition.
16315847|NCT04567225|Experimental|Early Glargine|All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.
16315848|NCT04567225|Active Comparator|Standard practice (Late Glargine)|Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.
16315849|NCT04567212||Male-group|in this group we will enroll only male with asthma
16315850|NCT04567212||Female-group|in this group we will enroll only female with asthma
16315886|NCT04566978|Experimental|Cohort 3|Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
16315887|NCT04566978|Experimental|Cohort 4|Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
16315945|NCT04566653||dialysis-dependent|chronic kidney disease patients with hyperkalaemia and dialysis-dependent
16315851|NCT04567199||Cytosorb recipients|"Patients receiving Cytosorb due to septic shock.
~SOFA score, Changes in catecholamine support after CytoSorb initiation Survival to discharge ICU Survival >28d Thromboembolic events
~General data:
~Need of catecholamines Type of extra-corporal treatments Anticoagulation medication Concomitant allogenic blood products Concomitant factor concentrates Bleeding events Vital signs Underlying Disease SAPSII, SAPSIII, SOFA Scores (on 1st day of treatment) Type of Pathogen (gram+, gram-, fungi) Sepsis Multi Organ Failure
~Data records:
~Myoglobin, CK (creatine kinase), CK-MB, Fibrinogen D-dimers, Antithrombin III, Procalcitonin Creatinin, urea, Natrium, Potassium, Bilirubin, GOT (glutamate-oxalacetate transaminase), GPT, GGT (glutamate-pyruvate transaminase), PT (prothrombin time) aPTT (activated partial thromboplastin time) CRP (C reactive protein) Blood count Further parameters if of interest"
16315852|NCT04567199||Non Cytosorb recipients|"Patients not receiving Cytosorb due to septic shock.
~Patients not treated with CytoSorb under suspicion for inflammation, septic shock or SIRS will be searched for same characteristics as the first group.
~These groups will be matched when parameters like epidemiology, infectious parameters, prognostic scores, age, gender amount of catecholamines fit best.
~Parameters as in Group of Cytosorb recipients"
16315853|NCT04567173|Experimental|Anti-SARS-CoV-2 convalescent plasma|About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
16315854|NCT04567173|No Intervention|Standard of care|Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways
16315855|NCT04567160|Active Comparator|Propofol group|Induction and maintenance of general anesthesia using propofol
16315856|NCT04567160|Active Comparator|Sevoflurane group|Induction and maintenance of general anesthesia using sevoflurane
16315857|NCT04567147|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.
16315858|NCT04567147|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
16315859|NCT04567121|Other|Intensive intervention group|intensive life-style and care intervention
16315860|NCT04567121|Other|Standard intervention group|standard life-style and care intervention
16315861|NCT04567108|Active Comparator|Maintain SSBs (Control)|Instruction to maintain baseline intake of SSBs
16315862|NCT04567108|Experimental|Substitute Aspartame ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame
16315863|NCT04567108|Experimental|Substitute Sucralose ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose
16315864|NCT04567108|Experimental|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water
16315865|NCT04567082||Cancer group|
16315866|NCT04567082||Control group|
16315867|NCT04567069|Experimental|DC vaccine|Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
16315868|NCT04567069|Experimental|DC vaccine + CTL (cytotoxic lymphocyte)|Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
16315869|NCT04567069|Experimental|DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)|Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
16315870|NCT04567056||Cancer group|Patients with verified head and neck squamous cell carcinomas
16315871|NCT04567056||Control group|Matched control group without active or earlier cancer and a normal ENT examination.
16315872|NCT04567043|Experimental|Mindfulness-Oriented Recovery Enhancement+JITAI|Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
16315873|NCT04567043|Active Comparator|Supportive Psychotherapy|Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
16315874|NCT04567030|Experimental|Experimental group A (AI Group: EG-A)|Behavioral: AI intervention For the EG-A, a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
16315875|NCT04567030|Experimental|Experimental group B (AI with humanized Group: EG-B)|"Behavioral: AI intervention For the EG-B,a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
~The humanized counseling will also send to patients' mobile phone about each patients oral hygiene condition and advises."
16315876|NCT04567030|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
16315877|NCT04567004|Other|Control|The control arm will show the products with no label.
16315878|NCT04567004|Experimental|Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
16315879|NCT04567004|Experimental|Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
16315880|NCT04567004|Experimental|Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
16315881|NCT04566991|Experimental|Deferoxamine lower dose|Deferoxamine 32 Milligram Per Kilogram (mg/kg)
16315882|NCT04566991|Experimental|Deferoxamine higher dose|Deferoxamine 48 mg/kg
16315883|NCT04566991|Placebo Comparator|Placebo|normal saline
16315884|NCT04566978|Experimental|Cohort 1|Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
16315885|NCT04566978|Experimental|Cohort 2|Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
16315888|NCT04566965||Full-Time CCHMC Employees|All CCHMC full-time residents and fellows who have some direct contact with patients and their families as part of normal workplace duties.
16315889|NCT04566952|Experimental|Anlotinib combined With dose-reduced olaparib|Anlotinib-olaparib combination therapy until disease progression
16315890|NCT04566926|Experimental|Part 1: Cohort 1 (Placebo or JNJ-64140284)|Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.
16315891|NCT04566926|Experimental|Part 1: Cohort 2 (Placebo or JNJ-64140284)|Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
16315892|NCT04566926|Experimental|Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)|Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.
16315893|NCT04566926|Experimental|Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)|Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.
16315894|NCT04566913|Experimental|Patients recruited from Cairo University|"After Cone beam CT assessment , The patient is assigned for nonsurgical periodontal phase then an impression is taken for stent formation to facilitate tissue thickness measurement .
~> After 2 weeks , the patient is assigned for surgical phase to extract the palatal and apical aspect of the tooth and leave the buccal portion .
~Socket preservation is attempted in the socket , using 'genbioss ' bone graft. Modified free gingival graft is done on the pontic site to cover the buccal root shield and the bone graft .
~Post operative instructions include :
~Analgesics (Prufen 400 mg ) three times for three days
~Antibiotic (Augmentin 1gm ) twice daily for one week The patient will be assured to contact the operator of any unexpected complications occured ."
16315895|NCT04566900|Experimental|Active Treatment|Subjects will be given a choice of videos consisting of still images set to music. Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range. Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.
16315896|NCT04566900|Sham Comparator|Placebo|Video and music progression will be random and will not depend on brain activity. Any progression will be by random chance alone.
16315897|NCT04566887|Experimental|Acalabrutinib with R-CHOP chemotherapy|Acalabrutinib 100mg twice per day orally with standard of care R-CHOP chemotherapy by IV every 21 days for a maximum of six cycles.
16315898|NCT04566874|Other|Spira-A with HCT/p DBM|Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM
16315899|NCT04566874|Active Comparator|Medtronic PEEK ALIF with Infuse|Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)
16315900|NCT04566861|Experimental|Anxious pregnant women - intervention group|100 pregnant women who have at least mild anxiety will be randomized to the intervention group where they will receive six one-on-one core sessions of Cognitive Behavioral Therapy during pregnancy (plus possible booster sessions)
16315901|NCT04566861|No Intervention|Anxious pregnant women - enhanced usual care group|100 pregnant women who have at least mild anxiety will be randomized to the enhanced usual care group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
16315902|NCT04566861|No Intervention|Non-anxious pregnant women - healthy control|100 pregnant women who do not have symptoms of anxiety or depression be followed in the healthy control group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
16315903|NCT04566848||Gastrointestinal cancers|Patients with advanced stage colorectal cancer, gastric cancer and pancreatic cancer who develop malignant ascites
16315904|NCT04566848||Control|Patients with intraabdominal ascites with benign reasons (liver cirrhosis, Congestive heart failure, etc.) .
16315905|NCT04566835|Experimental|Education Group|Taking the Health Promotion Program with cartoons and comics for Children with Asthma
16315906|NCT04566835|Other|Control Group|Taking standart care
16315907|NCT04566822|Experimental|High-touch intervention|"6 live video coaching sessions
~Coaching/feedback is tailored to the individual and adaptive to their progress
~Member can send the Coach messages between sessions, but the Coach will not respond until the live session"
16315908|NCT04566822|Experimental|medium-touch intervention|"3 live video coaching sessions
~2 live videos are optional (recommended for end of Weeks 3 and 5, but member can take advantage of them anytime)
~2-4 pre-recorded video sessions at end of the week. Pre-recorded videos provided in the absence of live sessions
~Chat messaging between sessions with 24-48 hour response time"
16315909|NCT04566822|Experimental|low-touch intervention|"1 Live video coaching session (week 1)
~Chat messaging with 24-48 hour response time"
16315910|NCT04566822|Sham Comparator|Sleep education control|"Weekly sleep education for six weeks
~No interaction with coach"
16315911|NCT04566809|Experimental|Experimental group: FES+CBA|FES+CBA participants executed FES and CBA treatment which means that during the stimulation they manipulated different tools. In particular, for the first ten sessions the participants were invited to manipulate specific objects: squares, rectangles and pyramids of different sizes; touch on plastic test tubes coated with materials of different consistency; these two exercises were performed both with open and closed eyes. Finally, for the last ten sessions the participants were asked to execute specific tasks, depending on person's life before the lesion.
16315912|NCT04566809|Active Comparator|Control Group: FES|FES participants received only FES to improve their manipulating skills without the interaction with objects, but only with the muscle contraction induced by the devices.
16315913|NCT04566796|Active Comparator|(Group N)|patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
16315914|NCT04566796|Experimental|(Group S)|the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
16315915|NCT04566783||Women and men fulfilling PGAD-criteria|"Inclusion criteria:
~- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum & Nathan (2001).
~Exclusion criteria:
~- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.
~Age:
~- 18 - 65 years of age
~Gender:
~- Female and male subjects"
16315916|NCT04566783||Controls|"Inclusion criteria:
~- Age and education matched healthy controls."
16315917|NCT04566770|Experimental|MID A|20 participants(18-49), Ad5-nCoV , two doses, Intramuscular administration
16315918|NCT04566770|Placebo Comparator|MID B|10 participants(18-49), Ad5-nCoV-placebo , two doses, Intramuscular administration
16315919|NCT04566770|Experimental|MIN A|100 participants(6-17), Ad5-nCoV , two doses, Intramuscular administration
16315920|NCT04566770|Placebo Comparator|MIN B|50 participants(6-17), Ad5-nCoV-placebo , two doses, Intramuscular administration
16315921|NCT04566770|Experimental|OLD A|100 participants(56 years of age and above), Ad5-nCoV , two doses(Low dose), Intramuscular administration
16315922|NCT04566770|Experimental|OLD B|100 participants(56 years of age and above), Ad5-nCoV , two doses(Middle dose), Intramuscular administration
16315923|NCT04566770|Placebo Comparator|OLD C|50 participants(56 years of age and above), Ad5-nCoV-placebo , two doses, Intramuscular administration
16315924|NCT04566770|Experimental|EBOV A|34 participants, Ad5-nCoV , two doses, Intramuscular administration
16315925|NCT04566770|Placebo Comparator|EBOV B|17 participants, Ad5-nCoV , two doses, Intramuscular administration
16315926|NCT04566757|Experimental|Umbilical Cord Plasma Infusion|Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months
16315927|NCT04566744|Experimental|Physical tool use, tool making and construction|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a physical tool, making a physical tool or building a construction. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools as well as when we build constructions.
16315928|NCT04566744|Experimental|Use of modern physical tools and stone tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a modern physical tool or a stone tool. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools irrespective of whether they are modern or old (i.e., stone tools).
16315929|NCT04566744|Experimental|Use of modern physical, arbitrary and digital tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when watching video clips of individuals using either a modern physical tool, an arbitrary tool (e.g., a washing machine) or a digital tool (e.g., a touchscreen). Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we observe others using different kinds of tools, which have appeared progressively over technological evolution.
16315930|NCT04566744|Experimental|Physical tool use and Internet|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when estimating the capacity to solve a mechanical problem with modern physical tools either alone or with the help of a Internet Tutorial. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we imagine and estimate solving a mechanical problem alone or with the help of the Internet;
16315931|NCT04566731|Active Comparator|tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of tDCS for 20 minutes using a montage in which an anode (1.5 mA) is placed over F7 (left frontotemporal lobe) and the cathode will be place on O1 (left occipital) using the 10-20 EEG mapping system. Subjects will participate in a modified constraint-induced language therapy.
16315932|NCT04566731|Sham Comparator|Sham tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham tDCS for 20 minutes using a montage in which an anode is placed of F7 and cathose is placed over O1. Subjects will participate in a modified constraint-induced language therapy,
16315933|NCT04566718||Group A|Obese women who have been treated with metformin for one year prior to the study.
16315934|NCT04566718||Group B|Obese women who have been treated with metformin for at least three years prior to the study.
16315935|NCT04566705||Women with uterine rupture|Women with uterine rupture
16315936|NCT04566705||Women without uterine rupture|Women without uterine rupture
16315937|NCT04566692|Experimental|Treatment-experienced Cohort|Treatment-experienced participants will receive IGSC 20% at 2 different dosing frequencies using a subcutaneous (SC) infusion pump during 2 treatment periods (16 weeks per treatment period). In treatment period 1, treatment-experienced participants will receive 16 weekly IGSC 20% doses from Week 0 to Week 15. For participants entering study on intravenous immune globulin (IVIG), IGSC 20% will be dosed at 1.37 times the equivalent weekly dose and participants entering on subcutaneous immunoglobulin (SCIG) will receive the same milligram/kilogram (mg/kg) equivalent weekly dose as given prior to entry, without using a dose adjustment factor (DAF). In treatment period 2, treatment-experienced participants will receive biweekly IGSC 20 % (i.e, IGSC 20% every 2 weeks) for a total of 9 doses, with the first IGSC 20% dose administered at Week 16 and the final dose given at Week 32.
16315938|NCT04566692|Experimental|Treatment-naïve Cohort|Treatment-naïve participants will receive a loading dose of 150 mg/kg/day IGSC 20% for 5 consecutive days (Week 0, Days 1 to 5) followed by weekly maintenance infusions of 150 mg/kg IGSC 20% starting Week 1 (Day 8) through Week 32. IGSC 20% infusion will be administered using an SC infusion pump.
16315939|NCT04566679|Experimental|Butyrate|oral butyrate (500mg) once or twice per day
16315940|NCT04566679|Placebo Comparator|Placebo|oral placebo once or twice per day
16315941|NCT04566666|Placebo Comparator|Placebo of SCD-044 product|Placebo of SCD-044 study drug
16315942|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 tablets at Dose 1
16315943|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 tablets at Dose 2
16315946|NCT04566653||non-dialysis-dependent|chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent
16315947|NCT04566627|Experimental|YSLQQ group|"Schools in this group implemented Yo Sé Lo Que Quiero program. This is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
16315948|NCT04566627|No Intervention|Control Group|Schools in this group implemented the usual preventive actions to reduce substance use. Usually, these actions are not manualized.
16315949|NCT04566614||Biliary Tract Cohort|Patients with suspected biliary tract cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
16315950|NCT04566614||Bladder Cancer Cohort|Patients with suspected bladder cancer (localised and metastatic) will be offered ctDNA to support their diagnosis, in cases where cystoscopy and biopsy are difficult to obtain due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. A positive ctDNA result will be supportive of a diagnosis of bladder cancer, their treatment may be prioritised and decided based on this result in conjunction with radiological findings, patient presentation and after discussion between the treating physician and patient
16315951|NCT04566614||Pancreatic Cancer Cohort|Patients with suspected pancreatic cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
16315952|NCT04566614||Gastrointestinal Stromal Tumour Cohort|Those with suspected Gastrointestinal Stromal Tumour Cohort (GIST) are eligible for this study. KIT and PDGFR mutation detected using ctDNA in conjunction with radiological features will be supportive of a diagnosis of GIST. This may allow for the use of directed targeted therapy, or prioritise surgical resection in some cases. Patients with histological diagnosis will not be eligible for this study. However, patients with inadequate tissue for KIT/PDGFR analysis will be eligible for PREVAIL-ctDNA to confirm the diagnosis of GIST and help guide treatment decisions
16315953|NCT04566614||Lung Cancer Cohort|The use of ctDNA in the diagnosis and adaptive management of patients with lung cancer is well established, however not funded by NHS. As aerosol-generating bronchoscopy procedures have reduced due to the COVID-19 pandemic, patients with suspected lung cancer may be offered ctDNA to support the diagnosis. A positive ctDNA result in conjunction with radiological findings will assist in prioritising those suitable for upfront surgical resection, radiotherapy or systemic anti-cancer treatment. It may provide sufficient genotypic information to guide standard of care targeted therapies (usually two tests are required - biopsy and then next generation sequencing of extracted DNA), including in patients without sufficient tissue for EGFR and ALK testing which can be detected using ctDNA. The use of ctDNA to guide treatment decisions in this cohort will not require signed consent as it is considered a standard approach (not yet NHS funded)
16315954|NCT04566614||Colorectal Cancer Cohort|Patients with suspected colorectal cancer will often be referred following either suspicion on imaging or faecal immunochemical testing (FIT). FIT testing results will be used to prioritise patients for screening colonoscopy, in conjunction with the PREVAIL-imaging risk stratification pathway
16315960|NCT04566588|Experimental|Early apical release holmium enucleation of the prostate|Early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
16315961|NCT04566588|Active Comparator|Classic holmium enucleation of the prostate|Classic holmium enucleation of the prostate (HoLEP), as a surgical treatment for benign prostatic hyperplasia
16315962|NCT04566562||Study Group|Brain scans, cognitive tests, blood biomarkers
16315963|NCT04566549|Placebo Comparator|Placebo group|Shampoo base without probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance.
16315964|NCT04566549|Active Comparator|Test group|Shampoo base with probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance、Heat-killed Lactobacillus paracasei powders (5x10^8 cells/ g-shampoo).
16315965|NCT04566536||Surgery|Patients ≥ 18 years old scheduled for robotic surgery (all specialties except ENT)
16315966|NCT04566523||Control Group|Chronic respiratory patients who undergo a home-based exercise training program with a rehabilitation coach supervision.
16315967|NCT04566523||Tele Group|Chronic respiratory patients who undergo a home-based exercise training program online.
16315968|NCT04566510|Experimental|Royal Guard|alpha-cypermethrin + pyriproxyfen (PPF)
16315969|NCT04566510|Active Comparator|PermaNet 3.0|deltamethrin + piperonyl butoxide (PBO)
16315970|NCT04566497|Experimental|Experimental|no systematic stress testing during follow-up
16315971|NCT04566497|Active Comparator|Active Comparator|systematic annual stress testing during follow-up
16316025|NCT04566055||Prospective observational cohort|
16315972|NCT04566484|Experimental|BBV87vaccine(BBV87 20 µg/ BBV87 40 µg)|"The test article, inactivated Chikungunya virus vaccine 'BBV87', is available in a 2 mL clear glass USP Type 1 vial that contains a single dose of 0.5 mL of the vaccine as singlehuman dose (SHD). Vials are stoppered and sealed with tear-down aluminum seals.
~• Route: BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm. 0.5 mL of the investigational vaccine (BBV87 20 µg/ BBV87 40 µg) will be administered."
16315973|NCT04566484|Placebo Comparator|Normal Saline|Each 0.5 ml vial of placebo will contain normal saline.The placebo will be given to participants intramuscularly in the deltoid region of the upper arm.0.5 mL of placebo will be administered.
16315974|NCT04566471||PPP and GPP|Palmoplantar pustulosis (PPP) and Generalized pustular psoriasis (GPP) are rare chronic inflammatory skin diseases, characterized by repeated episodes of sterile pustules in several months or years, associated with erythrokeratodermia generally. Both two diseases are easy to cause skin rupture, leading to bleeding and pain.
16315975|NCT04566458||Single arm|Her2 positive mBC patients who have received at least 3 lines of treatment in the metastatic setting.
16315976|NCT04566445|Experimental|GT005 Medium Dose|Approximately 60 subjects are planned, with subjects randomised to GT005 Medium Dose.
16315977|NCT04566445|Experimental|GT005 High Dose|Approximately 60 subjects are planned, with subjects randomised to GT005 High Dose.
16315978|NCT04566445|No Intervention|Untreated control|Approximately 60 subjects are planned, with subjects randomised to untreated control.
16315979|NCT04566432||Immune checkpoint inhibitors|
16315980|NCT04566432||Targeted therapy|Targeting ALK, ROS1, MET ex14 skipping
16315981|NCT04566419|Active Comparator|Control group|Oxygen delivered by Venturi Mask
16315982|NCT04566419|Experimental|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
16315983|NCT04566380|Experimental|ONO-4538 group|Specified Dosage and Duration of Treatment
16315984|NCT04566367|Active Comparator|Standard White Light Imaging|In this group the participants will be examined by white light endoscopy first and secondly with blue laser imaging technique during the same gastroscopy.
16315985|NCT04566367|Experimental|Blue Light Imaging|In this group the participants will be examined by blue laser imaging technique first and secondly with standard white light during the same gastroscopy.
16315986|NCT04566354|Other|Sprint exercise|Three bouts of 30-s sprint exercise with 20 min rest in between. Three fat biopsies obtained ar rest before first sprint, 15 min after and 120 min after third sprint Blood samples from stomach vein and arteria during the whole experiment
16315987|NCT04566341||Feasibility of OCT TCE in identifying signs of PD|Participants that fulfill our Inclusion/Exclusion criteria will be asked to swallow our Capsule Imaging device.
16315988|NCT04566328|Active Comparator|Arm A (daratumumab, lenalidomide, dexamethasone)|INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
16315989|NCT04566328|Experimental|Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16315990|NCT04566328|Active Comparator|Arm C (daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity."
16315991|NCT04566315|Other|ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS|SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
16315992|NCT04566302|Experimental|SECM Skin Imaging|The SECM skin imaging procedure will be very similar to that by the FDA approved RCM devices. First, the skin lesion (such as a mole) will be identified on a forearm of the subject. The lesion will be imaged first with a dermatoscope, and then with the SECM device. A dermatoscope is a hand-held device used for the visual observation of the epidermis. It is a superior surface contact microscope used to examine skin lesions.
16315993|NCT04566289||PiCSO treatment group|PiCSO treatment as per IFU
16315994|NCT04566276|Experimental|Adult Cohort 1: 10 µg|12 healthy adults aged 18-55 years will receive 10 µg of the vaccine IM
16315995|NCT04566276|Experimental|Adult Cohort 2: 25 µg|12 healthy adults aged 18-55 years will receive 25 µg of the vaccine IM
16315996|NCT04566276|Experimental|Adult Cohort 3: 50 µg|12 healthy adults aged 18-55 years will receive 50 µg of the vaccine IM
16315997|NCT04566276|Experimental|Elderly Cohort 1 :10 µg|12 elderlies aged 56-75 years will receive 10 µg of the vaccine IM
16315998|NCT04566276|Experimental|Elderly Cohort 2: 25 µg|12 elderlies aged 56-75 years will receive 25 µg of the vaccine IM
16315999|NCT04566276|Experimental|Elderly Cohort 3: 50 µg|12 elderlies aged 56-75 years will receive 50 µg of the vaccine IM
16316000|NCT04566276|Experimental|Phase 2: ChulaCov19 vaccine Dose 50 ug|adults between 18 and 59 years of age will receive 2 IM ChulaCov19 vaccine Dose 50 ug vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
16316001|NCT04566276|Other|Phase 2: Placebo|adults between 18 and 59 years of age will receive 2 IM saline vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
16316002|NCT04566263|Other|Successful embolization of intracranial aneurysms|Successful embolization of intracranial aneurysms defined by angiographic occlusion of greater than or equal to 90% at 6 months.
16316026|NCT04566042|Experimental|ACT video game|
16316066|NCT04565756|Experimental|Dose Escalation Cohort 2|Each subject will receive a mid-dose 1 mg/mL (0.1%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
16316003|NCT04566250|Active Comparator|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:
~A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 20mg PO daily x 30 tabs (to be taken only while utilizing Naproxen). In the case of a Naproxen intolerance, a prescription for Meloxicam 15mg PO BID PRN x 60 tabs will be given.
~A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.
~Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
16316004|NCT04566250|Other|Standard of Care|The control group is standard of care, which typically includes a prescription for an opioid.
16316005|NCT04566237|Experimental|24 months follow up after vitrectomy|Objective Scatter Index (OSI) and Average Lens Density (ALD) at inclusion, then 3 months, 12 months and 24 months after vitrectomy
16316006|NCT04566224|Experimental|Macintosh 2 group|Using Macintosh size 2 blade for direct laryngoscope intubation according to randomization
16316007|NCT04566224|Active Comparator|Macintosh 3 group|Using Macintosh size 3 blade for direct laryngoscope intubation according to randomization
16316008|NCT04566211|Experimental|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
16316009|NCT04566211|Active Comparator|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
16316011|NCT04566172|Experimental|Prehabilitation program|Patient undergoing thoracic or upper abdominal surgery as part of their regular medical care will be approached. Participants will receive a prehabilitation program that includes an inspiratory muscle training that they will do leading up to the day of their surgery.
16316012|NCT04566159|Experimental|CBI + CHW|2 Session Computer Delivered Intervention with use of Nicotine Replacement Therapy and Community Health Worker Follow Up
16316013|NCT04566159|Other|Routine Care|Routine Tobacco Cessation Advice to Stop Smoking and Nicotine Replacement Therapy as offered by the inpatient team
16316014|NCT04566146|Other|45 patients with subacromial impingement syndrome|Forty-five patients between the age 18 and 45 years old, will be referred by orthopaedist as subacromial impingement syndrome (stage Ⅰ and ⅠⅠ Neer's classification)
16316016|NCT04566120|Experimental|Cinnamon extract mouthwash|Participants will be exposed to cinnamon extract mouthwash and will be instructed to use 10 ml of cinnamon extract mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
16316017|NCT04566120|Active Comparator|Chlorohexidine based mouthwash|Participants will be exposed to chlorohexidine based mouthwash. and will be instructed to use 10 ml of 0.12% chlorhexidine based mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
16316018|NCT04566107|No Intervention|Enhanced Usual Care|The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
16316019|NCT04566107|Experimental|mHealth|The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
16316020|NCT04566107|Experimental|mHealth Plus|The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
16316021|NCT04566081|Active Comparator|iTALKbetter: deterministic|"Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.
~iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again."
16316022|NCT04566081|Active Comparator|iTALKbetter: reactive|"Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.
~iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements."
16316023|NCT04566068|Experimental|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors. Interventionists will participate in weekly supervision. Approximately half of participants will be asked to wear sleep trackers for one-week prior to starting the intervention (T0) and one-week after completing the intervention (T1).
16316024|NCT04566068|Placebo Comparator|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
16316029|NCT04566016|Experimental|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1).
16316030|NCT04566016|Active Comparator|General anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
16316034|NCT04565977||Retrospective Cohort|All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
16316035|NCT04565964|Other|Health behaviors|Health behavior intervention for one month will be provided to every participant. We will teach children's guardians (care-giver) how to change the health behaviors to clean indoor environment, including the health behaviors in bedroom, kitchen room, restroom, refrigerator, washing machine, and incense burning hall.
16316036|NCT04565951|Experimental|treatment arm|Participants in this arm will receive the intervention, PsychArmor S.A.V.E.
16316037|NCT04565951|Sham Comparator|sham arm|"Participants in this arm will receive a sham training, not the intervention, consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
16316038|NCT04565938|Experimental|one-step self-etch adhesive with enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive with enamel etching
16316039|NCT04565938|Experimental|one-step self-etch adhesive without enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive without enamel etching
16316040|NCT04565938|Experimental|two-step etch-and-rinse adhesive|Non carious cervical lesions which will receive composite-resin restorations, with a two step etch-and-rinse adhesive
16316041|NCT04565925|Experimental|Sildenafil 20mg TID then Placebo TID|Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
16316042|NCT04565925|Experimental|Placebo TID then Sildenafil 20mg TID|Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
16316043|NCT04565912|Experimental|Sage extract mouthwash|Natural product mouthwash
16316044|NCT04565912|Active Comparator|Chlorohexidine mouthwash|Synthetic mouthwash
16316045|NCT04565899|Experimental|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
16316046|NCT04565899|Other|Usual care|Care received before active implementation begins, which includes passive access to tools in the EHR.
16316047|NCT04565886|Sham Comparator|control|Non-surgical mechanical instrumentation 3x. Each time the laser will be held in place but will not be activated.
16316048|NCT04565886|Experimental|laser|Non-surgical mechanical instrumentation 3x with adjunctive diode laser application according to the protocol of the Department of Periodontology, University of Bern
16316049|NCT04565873||P1|Primigravida in group 1
16316050|NCT04565873||M1|Multipara in group 1
16316051|NCT04565873||P2|Primigravida in group 2
16316052|NCT04565873||M2|Multipara in group 2
16316053|NCT04565860|Active Comparator|X-tra fil (bulk-filling) (X-traB)|X-tra fil composite placed as bulk-filling
16316054|NCT04565860|Active Comparator|X-tra fil (incremental) (X-traI)|X-tra fil composite placed as incremental
16316055|NCT04565860|Active Comparator|Filtek Bulk (bulk-filling) (FBB)|Filtek Bulk composite placed as bulk-filling
16316056|NCT04565860|Active Comparator|Filtek Bulk (incremental) (FBI)|Filtek Bulk composite placed as incremental
16316057|NCT04565847|Active Comparator|Healthy Control - Active Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
16316058|NCT04565847|Placebo Comparator|Healthy control - Placebo Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized 0.9% Saline given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
16316059|NCT04565834||Suicidal patients|Patients who have made at least one attempt to commit suicide.
16316060|NCT04565834||Control group|"This group will consist of two types of people:
~75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and
~150 patients suffering from depression but have never attempted to commit suicide."
16316061|NCT04565821|Experimental|Feasibility of trans-nasal IPD probe|The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability
16316062|NCT04565795|Experimental|Placement of ureteral stent post ureteroscopy|Subjects with unilateral ureteral or renal stone fragments who have undergone an uncomplicated ureteroscopy (UURS)
16316063|NCT04565769||Cancer patients with metastatic melanoma|Forty two cancer patients with metastatic melanoma included prior to treatment with ICI.
16316064|NCT04565769||Healthy controls|Forty two age- and gender- matched healthy controls.
16316065|NCT04565756|Experimental|Dose Escalation Cohort 1|Each subject will receive a low-dose 0.5 mg/mL (0.05%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
16316067|NCT04565756|Experimental|Dose Escalation Cohort 3|Each subject will receive a high-dose 1.5 mg/mL (0.15%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
16316068|NCT04565756|Experimental|Dose Expansion Cohort|The highest well-tolerated dose of EXN407 will be evaluated where subjects will receive EXN407 at the selected dose or placebo twice a day for up to 84 days resulting in a total of 168 doses
16316069|NCT04565743|Active Comparator|Intervention|Multiprofessional education for health professionals in primary care on secondary prevention of osteoporotic fractures. Identification and referral of patients with recent osteoporotic fracture.
16316070|NCT04565743|No Intervention|Control|No intervention from study. No restrictions regarding education or the local organization of care for the prevention of osteoporotic fractures.
16316071|NCT04565730|Active Comparator|Grup I= General anesthesia group|After applying standard ASA monitoring; 2-2,5 mg/kg propofol, and 0,6 mg/kg rocuronium IV will be performed for general anesthesia induction, and then orotracheal intubation will be performed. The patients will be placed in the supine position. General anesthesia will be maintained with sevoflurane in the mixture of oxygen-fresh air. Controlled mechanical ventilation will be initiated with a tidal volume of 8-10 ml/kg at 12 breaths per minute (I:E ratio 1:2), a fresh gas flow rate of 2 L per min, end tidal CO2 value at 30-35 mmHg, and peak airway pressure of maximally 30 cm H2O. All patients will undergo cesarean delivery surgery with the same technique by the same surgical team.
16316072|NCT04565730|Active Comparator|Grup II= Spinal anesthesia group|A standardized spinal anesthesia will administrated to the patients. After skin disinfection, 25G needle will used for puncture at the level of L2-L3 or L3-L4. After observing the cerebrospinal fluid, 15 mg bupivacaine (marcain spinal heavy) will be administered into the subarachnoid space. The level of anesthesia below T6 will be controlled.
16316077|NCT04565704|Experimental|Development of novel optical imaging technologies|Consented participants will allow their endoscopist to collect 3 additional biopsies from the participants. These biopsies will be used to develop our imaging techniques at our lab. We will use the standard of care histology images from the endoscopy procedure as a control comparison.
16316078|NCT04565691|Experimental|Bacteremia inducing arm|As mentioned the participants will be their own controls at the different time-points.
16316079|NCT04565678|Experimental|Treatment Sequence 1: ABCD|Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
16316080|NCT04565678|Experimental|Treatment Sequence 2: BDAC|Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
16316081|NCT04565678|Experimental|Treatment Sequence 3: CADB|Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
16316082|NCT04565678|Experimental|Treatment Sequence 4: DCBA|Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
16316086|NCT04565652|Experimental|ICD Defibrillation|Detection of ICD shock during elective ICD implant using the investigational device
16316087|NCT04565639|Experimental|Experimental Power Hand Orthosis|Participants will test the improved grip strength using the powered hand orthosis system.
16316088|NCT04565639|Experimental|Experimental Power Hand Orthosis - Tasks of Daily Living|Participants will test the improved ability to perform tasks of daily living using the powered hand orthosis system.
16316089|NCT04565626|Experimental|Intervention|Participants will receive additional exercise by independent use of a peddle bike on the weekends. This is in addition to their usual physiotherapy
16316090|NCT04565626|No Intervention|Control|This arm will receive usual physiotherapy
16316091|NCT04565613|No Intervention|Standard care group|The participants will receive feeding as per standard of care (without protein or any other supplementations).
16316092|NCT04565613|Experimental|Study interventional group|The participants will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds.
16316093|NCT04565600|Experimental|Etoricoxib|Prophylactic etoricoxib (60 mg) was administered orally at each course of docetaxel-containing chemotherapy, which started from the day of chemotherapy and was performed once per day for 8 days (day 1-8).
16316094|NCT04565600|No Intervention|Control|No prophylactic regimen was given.
16316095|NCT04565587|Other|Videofluoroscopy|All participants will undergo a Videofluoroscopy when swallowing different viscosity levels of the thickener Tsururinko Quickly (japanese thickener)
16316096|NCT04565574|Experimental|Part A: E7090 35 mg (Fasted + Fed + Fed)|Participants will receive E7090 35 milligram (mg) tablet, orally on Day 1 of Treatment Period 1 in fasted state, followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fed state (high-fat meal). A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
16316097|NCT04565574|Experimental|Part A: E7090 35 mg (Fed + Fasted + Fed)|Participants will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 1 in fed state (high-fat meal), followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fasted state. A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
16316098|NCT04565574|Experimental|Part B: E7090 35 mg + Rabeprazole 20 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rabeprazole 20 mg tablets, orally, once daily on Days 7 to 10, and then followed by E7090 35 mg tablet and rabeprazole 20 mg tablets, orally on Day 11 in fasted state.
16316099|NCT04565574|Experimental|Part C: E7090 35 mg + Rifampin 600 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rifampin 600 mg capsules, orally, once daily on Days 7 to 12, then followed by E7090 35 mg tablet and rifampin 600 mg capsules, orally on Day 13 in fasted state, and then by rifampin 600 mg capsules, orally, once daily on Days 14 to 18.
16316100|NCT04565561||Neovas BRS group|Neovas BRS group, n=20
16316101|NCT04565561||DCB group|DCB group, n=20
16316102|NCT04565548|Experimental|Intervention|Participants will receive the newly developed theory-guided program for 12 weeks.
16316103|NCT04565548|Active Comparator|Control|Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.
16316104|NCT04565535|Experimental|Intervention arm|Liver donors undergoing lifestyle optimisation
16316105|NCT04565535|No Intervention|Control arm|Liver donors who continue normal lifestyle.
16316106|NCT04565522||Hemodialysis or peritoneal dialysis patients|Hemodialysis or peritoneal dialysis Covid negative patients
16316107|NCT04565522||dialysis staff healthcare professionals|dialysis staff Covid negative healthcare professionals
16316108|NCT04565509|Active Comparator|General Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
16316109|NCT04565509|Active Comparator|Focus/Targeted Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
16316110|NCT04565509|Active Comparator|Best Message Alone|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
16316111|NCT04565509|Active Comparator|Best Message + Augmented Message or Implementation Strategy|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
16316112|NCT04565496|Experimental|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
16316114|NCT04565457|Experimental|Participants Scanned|All participants will be scanned with a CBCT system equipped with 2D antiscatter grid technology, referred to as research CBCT. Each participant will also be scanned with a standard clinical CBCT as part of their standard clinical care, which will serve as the baseline, or control.
16316115|NCT04565444|Experimental|Ketone|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and carbohydrate control.
16316116|NCT04565444|Experimental|Ketone + Protein|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and 10g of whey protein.
16316117|NCT04565444|Experimental|Protein|Carbohydrate control and 10g of whey protein.
16316118|NCT04565431||Group 1: Multiple Sclerosis|"Individuals with RRMS who are going to be starting Tysabri as determined by Neurologist as part of clinical care.
~Intervention: Drug: Tysabri"
16316119|NCT04565431||Group 2: Healthy Controls|Healthy individuals who are age, gender and education matched to the MS group.
16316120|NCT04565418|Experimental|Exercise training|12 week high-intensity interval training (3 sessions per week): Before and after exercise, subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws and indirect calorimetry.
16316121|NCT04565405|Experimental|AB (Detergent (A) followed by sterile water (B))|"Sequence: Detergent (A) followed by sterile water (B)
~The inner cannula will be cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the first visit, and then cleaned with sterile water in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
16316145|NCT04565353|Experimental|No Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot.
16316182|NCT04565145|Experimental|Kava Pharmacokinetics Group|75 mg kava dietary supplement capsules per day for one week.
16316122|NCT04565405|Experimental|BA (Sterile water (B) followed by detergent (A))|"Sequence: Sterile water (B) followed by detergent (A)
~The inner cannula will be cleaned with sterile water in the first visit, and then cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
16316123|NCT04565392|Experimental|famotidine|A 20-milligram tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
16316124|NCT04565392|Placebo Comparator|Placebo|A placebo tablet to match a 20-milligram (mg) tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
16316125|NCT04565379|Active Comparator|NuSepin® 0.1 mg|NuSepin® 0.1 mg/kg in 100 ml normal saline infusion
16316126|NCT04565379|Active Comparator|NuSepin® 0.2 mg|NuSepin® 0.2 mg/kg in 100 ml normal saline infusion
16316127|NCT04565379|Placebo Comparator|Placebo|100 ml normal saline infusion
16316128|NCT04565366||Spinal Cord Injury|Individuals recently admitted to hospital and diagnosed with acute, traumatic spinal cord injury.
16316129|NCT04565366||Trauma Control|Individuals recently admitted to hospital and diagnosed with an acute, traumatic injury that is not spinal cord injury.
16316130|NCT04565366||Healthy Control|Generally healthy individuals not recently diagnosed with an acute, traumatic injury (including spinal cord injury).
16316131|NCT04565353|No Intervention|Holdout control|Participants will only receive the standard appointment reminders from their providers.
16316132|NCT04565353|Experimental|Default Reservations Opt-Out Condition|"The day before their scheduled appointment, participants receive a text reading: A flu shot has been reserved for you to receive at your appointment tomorrow. Reply Y if you want this shot held for you, N if you don't. The text will include a picture of a vial that says Your Flu Shot on it."
16316133|NCT04565353|Experimental|Default Reservations Opt-In Condition|"The day before their scheduled appointment, participants receive a text reading: Reply Y if you would like to receive a flu shot at your appointment tomorrow, N if not. The text will include a picture of vial with no text on it."
16316134|NCT04565353|Experimental|Intergroup Competition Treatment Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind another region in flu shot rate last year (your region and another region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
16316135|NCT04565353|Experimental|Intergroup Competition Control Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind the target flu shot rate of 70% last year (your region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
16316136|NCT04565353|Experimental|Flu Shot for You Symbolic Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity to dedicate getting the flu shot to someone by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
16316137|NCT04565353|Experimental|Flu Shot for You Herd Immunity Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity of getting the flu shot to protect a vulnerable loved one by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
16316138|NCT04565353|Experimental|Flu Shot for You Control Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also receive a reminder message on the day of the appointment. They will not receive any further information, nor will they be asked to respond with initials of an individual.
16316139|NCT04565353|Experimental|Prosocial Condition|The day before their scheduled appointment, participants will receive a message describing the pro-social benefits of getting a flu shot, and a reminder to ask for their flu shot. The described pro-social benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting loved ones from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting loved ones from serious complications from the flu). Participants will also receive a reminder message on the day of the appointment.
16316140|NCT04565353|Experimental|Self-Oriented Condition|The day before their scheduled appointment, participants will receive a message describing the self-oriented benefits of getting a flu shot, and a reminder to ask for their flu shot. The described self-oriented benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting oneself from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting oneself from serious complications from the flu).
16316141|NCT04565353|Experimental|Information Vivid Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain vivid information about getting the flu. Participants will also receive a reminder message the day before the appointment.
16316142|NCT04565353|Experimental|Information Basic Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain basic information about getting the flu. Participants will also receive a reminder message the day before the appointment.
16316143|NCT04565353|Experimental|Information Control Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain information about exercising. Participants will also receive a reminder message the day before the appointment.
16316144|NCT04565353|Experimental|Sharing Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
16316180|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
16316146|NCT04565353|Experimental|Healthy Habits Easy Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of easy health behaviors (e.g., whether they walked 500 feet yesterday, at least two serving of fruits and vegetables in the last week, and slept at least 6 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
16316147|NCT04565353|Experimental|Healthy Habits Difficult Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of difficult health behaviors (e.g., whether they walked 3 miles yesterday, ate 4-6 servings of fruits and vegetables yesterday, and slept at least 9 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
16316148|NCT04565353|Experimental|Healthy Habits Control Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot.
16316149|NCT04565353|Experimental|Just-In-Time Reminders 24-Hour Condition|Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 24 hours before their appointment.
16316150|NCT04565353|Experimental|Just-In-Time Reminders 15-Minute Condition|Just-In-Time Reminders 15-Minute Condition: Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 15 minutes before their appointment.
16316151|NCT04565340||Induction of labor with Foley catheter|Induction of labor with Foley catheter
16316152|NCT04565340||Induction of labor with Propess|Induction of labor with Propess
16316153|NCT04565327|Experimental|Cohort A: Single Dose/Image|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one minute then undergo MRI over 5 minutes at baseline
16316154|NCT04565327|Experimental|Cohort A: Multiple Dose/Images|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute then undergo MRI over 5 minutes at baseline and 4 weeks after beginning treatment
16316155|NCT04565314|Experimental|Plumpy'Mum|Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area.
16316156|NCT04565301|Placebo Comparator|Group C|The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
16316157|NCT04565301|Active Comparator|Group D|The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
16316158|NCT04565301|Active Comparator|Group N|The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
16316161|NCT04565275|Experimental|ICP-192|"Dose Escalation Phase ICP-192
~Dose Expansion Phase ICP-192"
16316162|NCT04565262|Experimental|NAs+IFN-α|NAs+IFN-α/ 96w
16316163|NCT04565262|Other|NAs+(IFN-α+ NAs )|NAs/48w+(IFN-α+ NAs)/96w
16316167|NCT04565236|Experimental|Part A: PTPs <12 years of age|Previously treated severe hemophilia A patients (PTPs) <12 years of age
16316168|NCT04565236|Experimental|Part A: PTPs ≥12 to 65 years of age|Previously treated severe hemophilia A patients (PTPs) ≥12 to 65 years of age
16316169|NCT04565236|Experimental|Part B: PUPs/MTPs <6 years of age|Previously untreated/minimally treated severe hemophilia A patients (PUPs/MTPs) <6 years of age
16316170|NCT04565223|Experimental|Cognitive behavioral therapy (CBT)|"5 sessions of Cognitive behavioral therapy for insmonia and an extra session for benzodiazepine withdrawal (if necessary).
~The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal"
16316171|NCT04565223|No Intervention|Usual care|Usual care from GPs or nurses
16316172|NCT04565210|Experimental|Oriental music|Infants assigned to this group will be exposed to oriental music.
16316173|NCT04565210|Active Comparator|Western music|Infants assigned to this group will be exposed to western music.
16316174|NCT04565210|Placebo Comparator|Silence / control|Infants assigned to this group will be exposed to the same protocol but using a track of silence.
16316175|NCT04565197|Experimental|Group intervene with convalescent plasma|"Review effect of Plasma therapy as clinical trial among hospitalized patients with COVID-19 infection.
~Transfuse 2 aliquots of plasma (200 mL x 2) per patient.
~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)
~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
16316176|NCT04565184|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
16316177|NCT04565184|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
16316178|NCT04565171|Experimental|Participants with renal impairment|Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.
16316179|NCT04565171|Experimental|Participants with normal renal function|Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.
16316184|NCT04565132|Experimental|HD-tDCS|Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.
16316185|NCT04565119||Severe traumatic brain injury (TBI)|This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
16316186|NCT04565093|Experimental|iPACK|In this group, participants will receive a peripheral nerve anesthetic block that is iPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) to cover posterior knee pain after total knee arthroplasty (TKA). This anesthetic block will be performed by assigned anesthesiologist under ultrasound guidance.
16316187|NCT04565093|Placebo Comparator|Periarticular local infiltration analgesia (LIA)|In this group, participants will receive a mixture of bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) that will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This local anesthetic infiltration is commonly performed by the operating orthopedic surgeon during TKA for postoperative pain control.
16316188|NCT04565080||FMD Patients|adult FMD patients who participated in protocol 07-N-0190
16316189|NCT04565080||PD Patients|adult PD patients who participated in protocol 01-N-0206
16316190|NCT04565067||1|COVID-19 recovered adult patients
16316191|NCT04565054|Experimental|Abemaciclib plus ET|Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
16316192|NCT04565054|No Intervention|Standard-of-care ET|"Standard-of-care ET according to clinical guidelines.
~Premenopausal patients:
~Either aromatase inhibitor + GnRH agonist
~or Tamoxifen +/- GnRH-agonist (as per investigator´s decision) or
~Postmenopausal patients:
~Either Aromatase inhibitor
~or Tamoxifen OR"
16316193|NCT04565041|Experimental|Social Support|
16316194|NCT04565028|Experimental|Contingency Management (CM)|Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
16316195|NCT04565015|Experimental|GC5107|Immune Globulin Intravenous (Human), 10% Liquid
16316196|NCT04565002|Experimental|EG|The TEDS protocol will consist of the following parameters: a) frequency of 30 Hz; b) pulse width of 0.4 ms; c) respiratory rate of 15 irpm; d) holding time of 1 s; e) rise time of 1 s; f) 2 s descent time; and g) 2 s non-stimulus time. Phrenics equipment (Dualpex 961, Quark®) will be used. The positioning of the electrodes will be performed according to a study by Cancelliero et al. (2012), who proposed the placement of two electrodes in the right and left paraxiphoid regions, and two others in the direction of the axillary midline, over the seventh intercostal space, also on the right and left sides.
16316197|NCT04565002|No Intervention|CG|The control group will undergo the same assessments as the experimental group, but the TEDS will not be applied.
16316198|NCT04564989||HPV+ OPSCC Patients|Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
16316199|NCT04564976|Experimental|Social Support|
16316202|NCT04564950||Control|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
16316203|NCT04564950||Periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
16316204|NCT04564950||Coronary heart disease|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
16316205|NCT04564950||Coronary heart disease + periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
16316206|NCT04564937|Experimental|SCT510A dose level 1 treatment|SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously
16316207|NCT04564937|Experimental|SCT510A dose level 2 treatment|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously
16316208|NCT04564937|Experimental|SCT510A dose level 3 treatment|SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously
16316209|NCT04564937|Experimental|SCT510A dose level 4 treatment|SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously
16316210|NCT04564924||MRI & DXA patients|No intervention
16316211|NCT04564924||MRI & DXA volunteers|No intervention
16316212|NCT04564911|Experimental|Flash Glucose Monitoring and Education|Participants randomised to the experimental arm will receive an education package and wear the flash glucose monitoring system. They will use sensor glucose data for self-management.
16316213|NCT04564911|Active Comparator|Capillary Glucose Monitoring and Education|Participants randomised to the control arm will receive an education package and self-manage their glucose levels utilising a standard capillary blood glucose device, and keeping a glucose diary for the duration of the intervention period.
16316214|NCT04564898|Experimental|trifluridine/tipiracil plus capecitabine and bevacizumab|
16316215|NCT04564885|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis at 2 contiguous levels
16316216|NCT04564885|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc at 2 contiguous levels
16316217|NCT04564872|Experimental|HSK7653 10 mg|
16316218|NCT04564872|Experimental|HSK7653 25 mg|
16316219|NCT04564872|Active Comparator|Linagliptin 5 mg|
16316220|NCT04564859|Experimental|Noninvasive Ventilation group|Noninvasive Ventilation group initial setting： Insp. Pressure：12 ~ 16 centimeter of water Exp. Pressure ： 4 ~ 6 centimeter of water FiO2：Keep oxygen saturation measured by pulse oximeter：> 92% By condition, gradually tap 2~3 centimeter of water inspiratory positive airway pressure Keep Tidal volume：6~10 ml/kg
16316221|NCT04564859|Active Comparator|Heated Humidified High-Flow Nasal Cannula group|Heated Humidified High-Flow Nasal Cannula group initial setting： Flow setting: 50 L/m FiO2：Keep oxygen saturation measured by pulse oximeter > 92% temperature:37 ℃ By condition, gradually tap Flow 5 L/m
16316816|NCT04560673|Experimental|Group II (neurofeedback training)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks.
16316222|NCT04564846|Placebo Comparator|Placebo|Subjects will be administered a single capsule of placebo( fish oil); placebo will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
16316223|NCT04564846|Active Comparator|ORMD-0801|Subjects will be administered a single 8mg capsule of ORMD-0801; study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
16316224|NCT04564833|Experimental|Low Dose RBT-1|45 mg SnPP/240 mg FeS
16316225|NCT04564833|Experimental|High Dose RBT-1|90 mg SnPP/240 mg FeS
16316226|NCT04564833|Placebo Comparator|Placebo|Normal saline
16316227|NCT04564807|Active Comparator|Web-Based Insomnia Education Program|Adult heavy drinkers with insomnia.
16316228|NCT04564807|Experimental|SHUTi Intervention|Adult heavy drinkers with insomnia.
16316229|NCT04564768|Experimental|Intervention group|Online Mindfulness-Based Cancer Recovery
16316230|NCT04564768|No Intervention|Control group|Treatment as usual
16316233|NCT04564729|Experimental|Decision Aid|The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.
16316234|NCT04564729|No Intervention|Control|Subjects in the control group will undergo standard care and discharge practices. Baseline pain and psychosocial factors will be documented as well as postoperative pain and analgesic consumption.
16316235|NCT04564716|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
16316236|NCT04564716|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
16316237|NCT04564703|Experimental|cohort 1|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
16316238|NCT04564703|Experimental|cohort 2|Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
16316239|NCT04564703|Experimental|cohort 3|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
16316240|NCT04564690|Experimental|QUARTET®|Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks
16316241|NCT04564690|Experimental|Control|Consumption of three regular hen eggs per day for three weeks
16316242|NCT04564677||Patients eligible for laparoscopic ventral mesh rectopexy|Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)
16316243|NCT04564664|Other|High-flow nasal cannula oxygen therapy|
16316244|NCT04564664|Other|Standard oxygen therapy|
16316245|NCT04564651|Experimental|platelet transfusion treatment|
16316246|NCT04564651|No Intervention|standard medical treatment|
16316247|NCT04564625||Fracture and Vitamin D assessment|All patients between 18 and 25 years treated for fractures at Methodist Dallas Medical Center (MDMC) with an index admission vitamin D assessment will be enrolled. This study will consider any patients with an index admission occurring between February 2016 and February 2020. No changes to care or intervention will occur and this study will be conducted completely via chart review. The aim is to identify 100 subjects with a one-year follow-up appointment for their injury to determine the rate of nonunion and vitamin D levels. As patients receive vitamin D supplementation as standard of care if index values are low, impact will be assessed through relative deficiency and clinical outcomes. Data collected from subjects without need for supplementation may be used to generate a threshold.
16316248|NCT04564612|Experimental|Part 1|Participants will receive single oral dose of BIIB091 on Day 1 of each study period, in fasted state, for up to 5 periods. There will be a minimum 7-day washout between Day 1 of each study period.
16316249|NCT04564612|Experimental|Part 2: Cohort A|Participants receiving single oral dose of BIIB091 on Day 1 of Period 1A in fed state will receive single oral dose of BIIB091 on Day 1 of Period 2A in fasted state. Participants receiving single oral dose of BIIB091 on Day 1 of Period 1A in fasted state will receive single oral dose of BIIB091 on Day 1 of Period 2A in fed state. Participants will then receive rabeprazole 20 milligram (mg) tablets, orally, twice daily (BID) for 3 days (Days -3, -2, and -1) of Period 3A in fed state followed by combination of rabeprazole 20 mg tablets, orally and BIIB091, orally, on the 4th day (Day 1) of Period 3A in fasted state. There will be a minimum 7-day washout between Day 1 of each study period.
16316250|NCT04564612|Experimental|Part 2: Cohort B|Participants will receive single oral dose of BIIB091 on Day 1 of Period 1B in fasted state followed by itraconazole 100 mg capsules, orally, BID for 1 day (Day -4) of Period 2B in fed state followed by itraconazole 100 mg capsules, orally, once daily (QD) for 2 days (Days -3, -2) of Period 2B in fed state followed by itraconazole 100 mg capsules, orally, QD for 1 day (Day -1) of Period 2B in fasted state. Participants will then receive combination of itraconazole 100 mg capsules, orally and BIIB091, orally on 5th day (Day 1) of Period 2B in fasted state followed by itraconazole 100 mg capsules, orally on 6th day (Day 2) of Period 2B in fed state. There will be a minimum 7-day washout between Day 1 of each study period.
16316251|NCT04564612|Experimental|Part 3|Participants will receive BIIB091, orally, QD or BID for at least 7 days in fasted or fed state.
16316252|NCT04564599||alcohol- and drug-related motor vehicle collisions|Number of alcohol- and drug-related motor vehicle collisions
16316253|NCT04564599||auto-ped alcohol- and drug-related collisions|Number of auto-ped alcohol- and drug-related collisions
16316289|NCT04564339|Placebo Comparator|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
16318615|NCT04548414||Control group|The recruited volunteers in this group are healthy.
16316254|NCT04564586|Other|Enhanced Intervention Group (EIG)|The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
16316255|NCT04564573||antidepressant treatment group|participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
16316256|NCT04564573||non-antidepressant treatment group|participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
16316257|NCT04564560||Patients treated with Zenith Alpha Spiral-Z®|Patients that from January 2017 until December 2019 received endovascular aortic repair with the Zenith Alpha Spiral-Z® at St. Olavs Hospital
16316258|NCT04564547|Experimental|Group 1: ISL 20 mg + MK-8507 100 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) [Part 1].
16316259|NCT04564547|Experimental|Group 2: ISL 20 mg + MK-8507 200 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
16316260|NCT04564547|Experimental|Group 3: ISL 20 mg + MK-8507 400 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
16316261|NCT04564547|Active Comparator|Group 4: BIC/FTC/TAF|Participants receive placebo to ISL + placebo to MK-8507 QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).
16316262|NCT04564534||Study cohort|"Adult (>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.
~The MoCA will be administered by trained professionals with MoCA certification.
~Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure."
16316263|NCT04564521|Experimental|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
16316264|NCT04564521|Active Comparator|Normal saline|Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
16316265|NCT04564495|Experimental|Live zoom exercise classes|Participants will engage in a live zoom exercise session. Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
16316266|NCT04564495|Active Comparator|Recorded zoom exercise classes|Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks, using a pre-recorded class that they can do according to their own schedule. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
16316267|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CRT)|
16316268|NCT04564482|Other|Short-course preoperative radiotherapy (SCPRT)|
16316269|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CROSS protocol)|
16316270|NCT04564456|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16316271|NCT04564456|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
16316272|NCT04564443|Experimental|(Medaxis Debritom+™) micro jet lavage|Medaxis Debritom+™ is a high-quality, micro water jet debridement device designed to remove fibrin, necrotic tissue, and biofilm from wound surfaces by mechanical cleaning and stimulation of the diabetic foot wound
16316273|NCT04564443|Active Comparator|Sharp Surgical Debridement|Use of a surgical scalpel or curette to remove fibrin, necrotic tissue and biofilm from wound surfaces by mechanically cleaning the wound
16316274|NCT04564430|Placebo Comparator|Control group|IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
16316275|NCT04564430|Experimental|Intervention group|Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
16316276|NCT04564417|Experimental|Monotherapy dose escalation: W0180|Participants will receive W0180 in a 21-day cycle until the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) for the single-agent identified.
16316277|NCT04564417|Experimental|Combination dose escalation: W0180+Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) followed by W0180 in a 21-day Cycle until the MTD in combination is identified or an RDE in combination is established.
16316278|NCT04564417|Experimental|Dose expansion|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion Q3W followed by an RDE dose of W0180 in a 21-day cycle.
16316279|NCT04564391|Active Comparator|Whey protein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of whey protein (=60 g / day)
16316280|NCT04564391|Active Comparator|Casein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of casein (=60 g / day)
16316281|NCT04564391|Active Comparator|pea protein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of pea protein (=60 g / day)
16316282|NCT04564391|Placebo Comparator|placebo arm|Three weeks, twice daily supplementation with 30 g of placebo (=60 g / day)
16316283|NCT04564378||Mild Fuchs Dystrophy|
16316284|NCT04564378||Severe Fuchs Dystrophy|
16316285|NCT04564365||with beta-blocker|
16316286|NCT04564365||without beta-blocker|
16316287|NCT04564352||2|Adansonia digitata (Baobab)
16316288|NCT04564339|Experimental|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
16316290|NCT04564339|Experimental|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
16316291|NCT04564339|Placebo Comparator|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
16316292|NCT04564326|Active Comparator|Group C|Patients will be assigned to receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
16316293|NCT04564326|Experimental|Group P|Patients will be assigned to receive Pericapsular Nerve Group Block (PENG Block) before positioning the patient for spinal anesthesia.
16316294|NCT04564326|Experimental|Group F|Patients will be assigned to receive Fascia Iliaca Block (F.I Block) before positioning for spinal anesthesia.
16316295|NCT04564313|Experimental|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
16316296|NCT04564300|Experimental|Oral contraceptive users|
16316297|NCT04564300|Active Comparator|Non-oral contraceptive users|
16316298|NCT04564287||Patient|Patients with history of Covid-19 infection and persistent neurological symptoms
16316299|NCT04564274||1|patients with rare and common diseases
16316302|NCT04564248|Experimental|website access for families|
16316303|NCT04564248|No Intervention|standard care|
16316304|NCT04564235|Experimental|Indication for a genome-wide analysis in the proband|
16316305|NCT04564222|Experimental|Micronutrient Enriched Crackers (MECs)|"Micronutrient Enriched Crackers (MECs) are a deep-fried snack product rich in iron, zinc, calcium, and vitamin A made from chicken liver and chicken eggshell powder.
~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
16316306|NCT04564222|Placebo Comparator|Placebo|"Placebo Crackers are a deep-fried snack product made from the basic cracker ingredients (mainly wheat flour) with the addition of Pangium edule seeds to provide a color similar to the intervention product (MECs).
~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
16316307|NCT04564209|Experimental|Treatment|The treatment group will be exposed to the infographic intervention when they present for clinic/study visits. During their visit with the provider, the provider offer health education while using infographics.
16316308|NCT04564209|No Intervention|Control|The control groups will receive standard health education.
16316309|NCT04564196||Induction of Labor|"Samples collected from women who present for induction of labor.
~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
~Samples will be collected at the following time points for patients presenting for induction of labor:
~A) Baseline: At presentation to labor and delivery unit and prior to initiation of augmentation of labor. A total of 1 sample.
~B) End of 1st stage of labor: At complete cervix dilatation and prior to starting to push. A total of 1 sample will be taken.
~C) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
16316310|NCT04564196||Spontaneous Labor|"Samples will be collected from women who present in spontaneous labor
~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
~Samples will be taken at the following endpoints:
~A) End of 1st stage of labor: At completely cervix dilated and prior starting pushing. A total of 1 sample will be taken.
~B) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
16316311|NCT04564183||Full Cohort|Entire study population
16316312|NCT04564183||Sub-Cohort|Randomly selected sub-cohort from the larger group of all participants
16316313|NCT04564170||ED|Patients with Eating Disorders
16316314|NCT04564170||HC|Healthy Controls without eating disorders
16316315|NCT04564157|Experimental|Adjuvant treatment + Adjuvant maintenance treatment|"Adjuvant treatment:
~Paclitaxel: 200mg/m2 infusion over 3 hours
~Carboplatin: AUC5 at the end of the Paclitaxel infusion
~Nivolumab: 360 mg intravenous Q3W
~It has to start within 3-10 weeks from surgery and the first administration has to be done within 1-3 days from randomization. 4 cycles will be administered at 21day intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment. Patients must discontinue treatment if there is evidence of disease relapse.
~After the 4 cycles of chemo-immunotherapy the patient will receive:
~Adjuvant maintenance treatment: Nivolumab: 480 mg IV Q4W It will start after 4 weeks from day 1 cycle 4 of adjuvant treatment. 6 cycles will be administered every 28 days. A CT-SAN must be done within +/- 7 days from day 28 of the 3rd cycle of adjuvant maintenance treatment and within +/- 7 days at the end of the 6th cycle. Patients must discontinue treatment if there is evidence of disease relapse at 3rd cycle CT-SCAN."
16316316|NCT04564157|Active Comparator|Control arm: Adjuvant treatment|"Adjuvant treatment:
~Paclitaxel: 200mg/m2 infusion over 3 hours
~Carboplatin: AUC5 at the end of the Paclitaxel infusion Adjuvant treatment has to start within 3-10 weeks from surgery and the first administration and has to be done within 1-3 days from randomization. 4 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment.
~Observation: 2 observation visits will be done at 3 months and at 6 months from day 21 of cycle 4 of adjuvant treatment."
16316317|NCT04564144|Experimental|Volunteers receiving the prepared orodispersible tablets|6 human volunteers will receive the prepared orodispersible tablets plus a commercial one all containing Meclizine HCl in a parallel manner.
16316354|NCT04563871|Experimental|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
16316355|NCT04563858||Cardiac patients|
16318656|NCT04548102|Experimental|Fetal Movement Counting|Fetal movement counting
16316318|NCT04564131|Experimental|reflexology practice|"Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism.
~Experimental group participants will be given 10 sessions of reflexology massage twice a week for 5 weeks. A total of three follow-ups will be performed in the 1st session, the 5th session and the 10th session. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied."
16316319|NCT04564131|Experimental|Control|Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism. 1. 3. 5. A total of three follow-ups will be done once in the week. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied.
16316320|NCT04564118||Group 1|retrospective data on treatment from EMC
16316321|NCT04564118||Group 2|Treatment assignment using medicBC CDSS platform in the same cohort of patients
16316322|NCT04564105|Other|Staff of the ICU|The whole staff (nurses and doctors) of the ICU will be recruited to this trial. When they give their informed consent, video-recording of the intubations will be started. After 20 videos, simulations will be run. Also simulations will be recorded. Thereafter 20 further real-life intubations will be recorded. Staff intubating patients before and after won't be same but they will be adjusted for experience related to intubations.
16316323|NCT04564092|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.
16316324|NCT04564066|Experimental|efgartigimod IV|intravenous infusions of efgartigimod
16316325|NCT04564066|Experimental|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
16316326|NCT04564053|Experimental|LNA043|LNA043
16316327|NCT04564053|Placebo Comparator|placebo|
16316328|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 1|"Part 1: Participants will receive Treatment A (100 mg AT suspension in water via NG administration) in Period 1, Treatment B (100 mg acalabrutinib capsule suspension via NG administration) in Period 2, and Treatment C (100 mg AT suspension in water via NG administration plus 20 mg rabeprazole) in Period 3.
~Part 2: Participants will receive Treatment D (100 mg AT suspension in water via NG administration) in Period 1 and Treatment A in Period 2."
16316329|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 2|"Part 1: Participants will receive Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3.
~Part 2: Participants will receive Treatment A in Period 1 and Treatment D in Period 2."
16316330|NCT04564027|Experimental|Cohort A|Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
16316331|NCT04564027|Experimental|Cohort B|Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
16316332|NCT04564014|Experimental|ISSS Intervention|The intervention group will receive 5 weekly ISSS sessions in addition to the information about mental health, depression, anxiety and available treatment and community resources also recived by the control group.
16316333|NCT04564014|Active Comparator|Wait-list control group|Members will receive information about mental health, depression, anxiety and available treatment and community resources but not ISSS during the intervention period.
16316334|NCT04564001|Experimental|A ( Infliximab)|Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
16316335|NCT04564001|Experimental|B (Tocilizumab)|Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
16316336|NCT04563975|Experimental|Chemotherapy and programmed death 1 inhibitor|Docetaxel /nab-paclitaxel in combination with Toripalimabs
16316337|NCT04563962|Experimental|Contingency Management-ART|Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
16316338|NCT04563962|Active Comparator|Contingency Management-Methamphetamine|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
16316339|NCT04563949||PLA-|PLA- initially and repeat testing 1-2 years later
16316340|NCT04563949||PLA+|Not eligible for the study
16316341|NCT04563936|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
16316342|NCT04563936|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
16316343|NCT04563923|Experimental|Drug|"Patients in this group will additionally receive 3 s.c. injections of avdoralimab every week during 12 weeks
~They receive 0.05% Clobetasol propionate cream as follows:
~Patients of less than 45kg of body weight: 2 tubes of 10g/d
~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
16316344|NCT04563923|Other|Conventional therapy|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:
~Patients of less than 45kg of body weight: 2 tubes of 10g/d
~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
16316345|NCT04563910||less than 2 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
16316346|NCT04563910||2-5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
16316347|NCT04563910||more than 5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
16316348|NCT04563897||HBV/HCV|
16316349|NCT04563897||Fatty liver disease|
16316350|NCT04563897||Liver background after systematic treatment|
16316351|NCT04563897||normal hepatic background|
16316352|NCT04563884||Patients with deafness|Patients aged 12 months to 17 years with deafness
16316353|NCT04563884||Controls|Normal-hearing patients aged 12 months to 17 years
16316356|NCT04563845|Experimental|Part 1: Sentinal Cohort 1|Participants will be randomized in a 3:1 ratio to evaluate QD dosing of GSK3640254 or placebo. Participants will be administered GSK3640254 500 milligram (mg) or placebo with approximately 240 milliliters (mL) of water following ingestion of a moderate fat meal.
16316357|NCT04563845|Experimental|Part 1: Sentinal Cohort 2|Participants will be randomized in a 3:1 ratio to evaluate BID dosing of GSK3640254 or placebo. The maximum dose would be GSK3640254 500 mg BID or placebo BID with approximately 240 mL of water following ingestion of a moderate fat meal.
16316358|NCT04563845|Placebo Comparator|Part 2: Main QTc Study|Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin [400 mg] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.
16316359|NCT04563832|Other|Control group|standardized respiratory management.
16316360|NCT04563832|Experimental|Experimental group|same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)
16316361|NCT04563819||Newborns with DDH|Newborns (born 1988-90) with sonographic hip dysplasia (DDH)
16316362|NCT04563819||Newborns without DDH|Newborns (born 1988-90) without sonographic hip dysplasia (DDH)
16316363|NCT04563819||Hip dysplasia at skeletal maturity|Subjects that show signs of acetabular dysplasia at skeletal maturity (age 17-19 years), in 2007-09, when hip radiographs and salivary samples were collected.
16316364|NCT04563806|Experimental|Device feasibility (MRI-guided surgery)|Patients undergo standard of care spine surgery with MRI-based image guidance.
16316365|NCT04563793||Superion IDS|All patients to receive IDS for the treatment of their moderate Lumbar Spinal Stenosis Symptoms.
16316366|NCT04563767||Infinitome|All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
16316367|NCT04563754|Experimental|mHRME and HRA|"5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.
~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
16316368|NCT04563741|Experimental|MOVE!+UP (intervention)|usual care enhanced with MOVE!+UP (intervention)
16316369|NCT04563741|Active Comparator|MOVE! (control condition)|usual care enhanced with MOVE! (control condition)
16316370|NCT04563728|Active Comparator|Camera Group|"1) The camera(s) will be a stationary device installed by the study technician on the ceiling of a common living area of the participant's home. The camera(s) will record video and audio data to be stored in our secure data base. The cameras will be purchased from YI Technology (see more details in Section 1.7). A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Highlighted video and audio data will be reviewed daily by the study technician. If there is evidence of abuse, exploitation, and neglect on these video and audio data, a report will be made to APS and the IRB."
16316371|NCT04563728|Active Comparator|Mock Camera Group|"2) The mock camera(s) will be a stationary device installed on the ceiling of a common living area of the participant's home. They will not record video or audio but will be installed with a sensor chip and a Wi-Fi connection, which will notify the study team if the device has been touched, tampered, altered, or disrupted power sources. After installing the device, the study technician and study coordinator will test the anti-tampering sensor to ensure potential future tampering will be detected. A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Daily check-ins to assess whether elder abuse may have been experienced by the participant will occur by phone or other preferred mode of communication. In the event of reported abuse, exploitation, and neglect, despite not being mandatory reporters, we will report to NJ APS and the IRB."
16316372|NCT04563728|No Intervention|Usual Care|Each participant will receive educational packages about elderly community-living.
16316375|NCT04563702|Experimental|Low Dose VXA-CoV2-1|Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29
16316376|NCT04563702|Experimental|High Dose|High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
16316377|NCT04563689|Experimental|actve|oral rinse
16316378|NCT04563689|Placebo Comparator|placebo|distilled water,
16316379|NCT04563663|Experimental|One session|One session of talus posteriorization.
16316380|NCT04563663|Experimental|Two sessions|Two sessions of talus posteriorization.
16316381|NCT04563663|Experimental|Three sessions|Three sessions of talus posteriorization.
16316382|NCT04563663|Experimental|Four sessions|Four sessions of talus posteriorization.
16316383|NCT04563650|Experimental|COVID-19 positive resident|
16316384|NCT04563650|Active Comparator|COVID-19 negative resident|
16316385|NCT04563637||Computer Based Vision|A 15 second long video will be obtained at the research site using a smart phone or tablet. Then subjects will undergo a whole body dual energy x-ray absorptiometry scan . Then the subject will go home and take a second 15 second long video. The videos will then be analyzed by computer based vision application and the body fat percentage measured by dual energy x-ray absorptiometry scan will be compared.
16316386|NCT04563624|Experimental|ceramic cad cam blocks|
16316387|NCT04563624|Active Comparator|composite cad cam blocks|
16316388|NCT04563611|No Intervention|Muscle strength|Participants hamstring muscle strengths will be evaluated with ISOMED 2000 isokinetic dynamometer
16316389|NCT04563611|No Intervention|Hamstring Flexibility|In this study, Individuals' evaluations of hamstring flexibility will be assessed by the active knee extension test (ICC: 0.96) with maximum hip flexion.
16316418|NCT04563494|Active Comparator|IV Dexmethsone and oral placebo|
16316419|NCT04563494|Active Comparator|Oral dexamethasone and IV placebo|
16316390|NCT04563611|No Intervention|Cognitive Function|The lower (reaction time and visual-perceptual ability) and upper level (working memory, inhibitory control, and cognitive flexibility) cognitive functions of the individuals participating in the study will be evaluated with the computer assisted CNSVS test battery
16316391|NCT04563611|No Intervention|Injury risk|Injury risk analysis of individuals will be made using the strength differences between the two sides, H: Q ratios (conventional and functional ratio) and functional movement screen (FMS), which will be obtained from the isokinetic measurement results.
16316392|NCT04563611|Experimental|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. The hands and arms will be positioned on the chest and held by the physical therapist at the heels of the individuals. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed
16316393|NCT04563611|Experimental|Supine Sliding Leg Curls|The persons will be started to exercise in the hook position, with hands-on their back, with their knees next to the body, in a flexion position of approximately 60 °. Participants will be asked to first build a bridge, then maintain this position and slowly slide the slippery apparatus under their feet to bring their knees to full extension.
16316394|NCT04563611|Experimental|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
16316395|NCT04563611|No Intervention|Agility|Agility performances of individuals will be evaluated with the Agility T-test.
16316396|NCT04563598||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
16316397|NCT04563598||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
16316398|NCT04563585||Muscle strength|Maximal voluntary isometric (MVIC) knee flexion and extension strength were measured using a handheld dynamometer (HDD) (Lafayette Instrument Company, Lafayette, IN).
16316399|NCT04563585||Lower Extremity Vertical Power|Lower extremity vertical power was identified through the use of the VertiMetric (Lafayette Instrument Company, Lafayette, IN) according to protocols suggested by Ambegaonkar et al.
16316400|NCT04563585||Trunk Extension Endurance|Trunk extension endurance was measured using the Biering-Sorensen test as previously described
16316401|NCT04563585||Upper Limb Performance|The Davies test (DT) was used to assess upper body agility and stabilization.The Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) was utilized to assess shoulder performance function and stability according to protocol suggested by Goldbeck and Davies.
16316402|NCT04563585||Lower Limb Performance|The Shark Skill Test (SST) was developed in order to assess lower extremity agility and neuromuscular control.
16316403|NCT04563572|Experimental|PPG Smartwatch|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.
~CardioWatch 287 is a novel non-invasive monitoring device manufactured by the MMT company. The device monitors heart rhythm, heart rate (HR) and respiratory rate (RR) based on peripheral PPG signal.
~In this arm, we will test the quality of the algorithm integrated into the smartwatch."
16316404|NCT04563572|Experimental|PPG Bracelet|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.
~A PPG-sensor is also integrated into a bracelet Basler Band manufactured by the MMT company, which is a simplified multisensory device.
~In this arm, we will test the quality of the algorithm integrated into the bracelet."
16316405|NCT04563559|Other|DEXTENZA vs prednisolone acetate 1%)|Subjects will randomly receive Dextenza or prednisolone acetate 1% in the first eye after surgery. At the time of the second eye surgery, the other eye will receive the drug that the first eye did not receive. Subjects will receive both drugs during the course of the study and therefore there is only 1 ARM for this study.
16316406|NCT04563546|Other|MI Patients in northern Tanzania|Patients presenting to KCMC emergency department with acute MI
16316407|NCT04563533|Experimental|adults of phase I|Healthy people aged 18-59
16316408|NCT04563533|Experimental|teenagers of phase I|Healthy people aged 6-17
16316409|NCT04563533|Placebo Comparator|elderly of phase I|Healthy people 60 years old and above
16316410|NCT04563533|Experimental|Toddler of phase I|Healthy people aged 2-5
16316411|NCT04563533|Placebo Comparator|Infants of phase I|6 weeks old-2 years old healthy person
16316412|NCT04563533|Experimental|elderly of phase II|Healthy people 60 years old and above
16316413|NCT04563533|Placebo Comparator|Toddler of phase II|Healthy people aged 2-5
16316414|NCT04563533|Experimental|Infants of phase II|6 weeks old-2 years old healthy person
16316415|NCT04563520|Experimental|Experimental treatment|"Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a good' response in bleed event response efficacy as stated above at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI."
16316416|NCT04563507|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
16316417|NCT04563507|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
16316422|NCT04563468|Experimental|Strength inspiratory muscle training group|Strength IMT
16316423|NCT04563468|Sham Comparator|Endurance inspiratory muscle training group|Endurance IMT
16316424|NCT04563442||covid 19|complications and comorbidities
16316425|NCT04563429|Experimental|Treatment Group|
16316426|NCT04563429|No Intervention|Control Group|
16316427|NCT04563416||Patients who need undergo magnifying endoscopy|
16316428|NCT04563403|Experimental|Treatment with Multiple Stimuli|Projection-based augmented reality therapy (P-ARET) with Multiple Stimuli (MS) (P-ARET MS). Intervention group that receives P-ARET treatment varying the stimuli available in the system (different cockroaches in colour, size, etc).
16316429|NCT04563403|Experimental|Treatment with Single Stimuli|Projection-based augmented reality therapy (P-ARET) with Single Stimuli (SS) (P-ARET SS). Intervention group that receives P-ARET treatment using a single stimulus (one cockroach).
16316430|NCT04563390|Experimental|Projection-based augmented reality exposure therapy|Intervention group that receives the projection-based augmented reality to carry out the exposure therapy for cockroach phobia.
16316431|NCT04563390|Experimental|In vivo exposure|Intervention group that receives traditional in vivo exposure therapy for cockroach phobia.
16316432|NCT04563390|No Intervention|WL Control|Waiting list control group.
16316433|NCT04563377|Experimental|ChAdOx1.HTI and MVA.HTI vaccination|"1x dose of ChAdOx1.HTI at 5 x 10^10 vp
~1x dose of MVA.HTI at 2 x 10^8 pfu"
16316434|NCT04563364|Experimental|Hospital-Home|This group will receive an interdisciplinary intervention of education to parents for get better outcomes of motor development.
16316435|NCT04563364|Active Comparator|Control Intervention|Control group will receive a conventional treatment given by the institutions
16316436|NCT04563351|Active Comparator|conventional inferior alveolar nerve block (IANB)|37 patients received Inferior Alveolar Nerve Block (IANB) for dental treatment of mandibular posterior teeth.
16316437|NCT04563351|Experimental|Intraligamentary Anesthesia (ILA)|35 patients received Intraligamentary Anesthesia (ILA) for dental treatment of mandibular posterior teeth.
16316438|NCT04563338|Experimental|Arm A (Liver Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
16316439|NCT04563338|Experimental|Arm B (Lung Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
16316440|NCT04563338|Experimental|Arm C (Lung Cancer)|Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
16316441|NCT04563325|Active Comparator|Experimental|"< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).
~=/> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).
~Treatment will be adjusted according to microbiological findings."
16316442|NCT04563325|Active Comparator|Standard|"IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:
~< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).
~>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).
~Treatment will be adjusted according to microbiological findings."
16316443|NCT04563312|No Intervention|Balance Assessment|The Flamingo Balance Test and Y Balance Test were used to evaluate static and dynamic balance, respectively.
16316444|NCT04563312|No Intervention|Coordination Assessment|Coordination was assessed using the Hexagon Test.
16316445|NCT04563312|No Intervention|Lower Extremity Functional Performance Assessment|Lower extremity functional performance was evaluated using the Single Leg Hop Test.
16316446|NCT04563312|Experimental|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
16316447|NCT04563299|Experimental|Dextenza|Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
16316448|NCT04563299|Active Comparator|Topical Corticosteroids|Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
16316449|NCT04563273|Experimental|Healthy people aged 18-45|Healthy people aged 18-45 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
16316450|NCT04563273|Experimental|Healthy people aged 46-65|Healthy people aged 46-65 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
16316451|NCT04563273|Experimental|Healthy people aged 11-17.|Healthy people aged 11-17 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
16316452|NCT04563273|Experimental|Healthy people aged 6-10|Healthy people aged 6-10 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
16316453|NCT04563260|Placebo Comparator|Control group|Control group receives the intravenous normal saline 2 mL.
16316454|NCT04563260|Experimental|Palonosetron group|Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.
16316455|NCT04563247||Asymptomatic frontline HCWs for COVID 19|All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.
16316456|NCT04563234|Experimental|COFLEX training|Neurocognitive training, delivered via a mobile device app
16316457|NCT04563234|Active Comparator|Crossword group|Access to crossword puzzles via a mobile device app
16316458|NCT04563221|Experimental|Balloon occlusion microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.
16316459|NCT04563221|Experimental|Standard microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.
16316460|NCT04563208|Placebo Comparator|Arm A: Placebo|Placebo administered
16316461|NCT04563208|Active Comparator|Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)|Ribavirin/Nitazoxanide (RBV/NTZ) administered
16316462|NCT04563195|Other|open label|open label study; all subjects will receive the same drug at the same dose
16316463|NCT04563182||Muscle strength|GMed strength was assessed with the use of a Lafayette Manual Muscle Tester (Lafayette Instruments; Lafayette, Indiana, USA).
16316464|NCT04563182||Horizontal Jumping Performance|Lower extremity horizontal jumping was measured using the single leg hop (SLH) test as previously described
16316465|NCT04563182||Vertical Jumping Performance|To measure the single-leg vertical jump (SLVJ), the participants stood on the ground with their foot flat distributing their weight evenly on both feet.
16316466|NCT04563182||Dynamic Balance|The Y-Balance Test (YBT) was used to dynamic balance
16316467|NCT04563182||Static Balance|The Stork balance test (SBT) was used to measure static balance performance
16316468|NCT04563169|Experimental|Video consultation|Patients in the video consultation group will receive video consultations.
16316469|NCT04563169|No Intervention|Face-to-Face consultation|Patients in the usual care group will receive face-to-face consultations.
16316470|NCT04563156||Severe Covid-19 Survivors|Severe Covid-19 survivors previously admitted in the hospital
16316472|NCT04563130|Experimental|Cryocompression|Patients will be randomized to receive cryocompression on one hand and foot using ice bags and compression socks.
16316473|NCT04563130|No Intervention|Control|Patients will be randomized to receive no intervention on the opposite hand and foot.
16316474|NCT04563117||Automatic registration|
16316475|NCT04563117||Point-based registration|
16316476|NCT04563091|Experimental|Interventional group|"The study population will consist of 6 evaluable, outpatient patients with chronic kidney failure who need to perform hemodialysis thrice weekly for their survival.
~In the case of drop out of a patient will be enrolled another patient to arrive at 6 patients evaluable both at the end of Period A and at the end of Period B of the study"
16316477|NCT04563078|Experimental|Transcranial Magnetic Stimulation (TMS)|TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
16316478|NCT04563078|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS)|Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
16316479|NCT04563065|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy (11,13) and published by Barakat model (10).
~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.
~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
16316480|NCT04563065|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
16316481|NCT04563052|Experimental|Education|Air pollution educational module exposure.
16316482|NCT04563039|Experimental|Acoustic Enhancer with Ureteroscopic Laser Lithotripsy|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer
16316483|NCT04563039|Active Comparator|Standard Ureteroscopic Laser Lithotripsy|Standard Ureteroscopic Laser Lithotripsy
16316484|NCT04563026|Experimental|DUR-928 (30 mg)|
16316485|NCT04563026|Experimental|DUR-928 (90 mg)|
16316486|NCT04563026|Placebo Comparator|(Placebo) Sterile Water for Injection|
16316487|NCT04563013|Sham Comparator|Sham tVNS|The participants under conventional radiochemotherapy were applied with sham tVNS at the earlobe for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
16316488|NCT04563013|Active Comparator|tVNS|The participants under conventional radiochemotherapy were applied with transcutaneous vagus nerve stimulation at the tragus for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
16316489|NCT04563000|Experimental|Vitamin C|Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
16316490|NCT04563000|Placebo Comparator|Placebo|Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
16316491|NCT04562987|Active Comparator|Core|All participants will receive the Core component, which includes access to weekly telecoaching, weekly emails from the interventionist, a smartphone app, and a Fitbit monitor. Telecoaching will include discussion of general cancer-related and wellness topics, and the smartphone app will have basic activity monitoring features.
16316492|NCT04562987|Experimental|Move|Telecoaching calls for Move participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on reducing prolonged sitting. Smartphone app features include activity monitoring that visualizes progress toward Move-based goals and goal achievement badges specific to Move.
16316493|NCT04562987|Experimental|Exercise|Telecoaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
16316494|NCT04562987|Experimental|Combo (Move+Exercise)|Includes telecoaching that encourages behavior adoption and goal setting focused on reducing prolonged sitting and engaging in 30+ minutes of physical activity per day. Participants are able to visualize progress toward Move and Exercise goals and are eligible to receive achievement badges for Move and Exercise.
16316495|NCT04562974|Experimental|One group of 30 healthy subjects|Perception and memory tasks inside a MRI-scanner for all participants
16316496|NCT04562961|Experimental|Schizophrenia caregiver (relative)|
16316497|NCT04562935||Pediatric intensive care|Children admitted to a pediatric intensive care unit before one year of age and admitted for to days or more and treated with mechanical ventilation and alive at follow
16316498|NCT04562922|Experimental|Lifemel|"LifeMel is bee-honey obtained using Zuf Globus Ltd technology: it is produced in Israel and distributed by VitalMel in Italy. In Italy Ministry of Health has listed it as a food supplement.
~Two tea spoons (5 g each) of honey were administered to subjects on each day of the chemotherapy treatment."
16316499|NCT04562909||Premature children|Premature children born before than 32 weeks were included.
16316500|NCT04562909||Healthy Control Group|Age matched healthy controls
16316501|NCT04562896|No Intervention|No Device|Participants will be evaluated without a CDO.
16316502|NCT04562896|Experimental|CDO-A|The first design variant will be designated CDO-A
16316503|NCT04562896|Experimental|CDO-B|The second design variant will be designated CDO-B
16316504|NCT04562896|Experimental|CDO-C|The third design variant will be designated CDO-C
16316505|NCT04562883|Experimental|Single Culture|"Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the washing dish containing Maturation Medium and wash them thoroughly. Then transfer COCs one by one to the Culture dish with Maturation Medium."
16316506|NCT04562883|Experimental|Group Culture|"Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the washing dish containing Maturation Medium (Group Culture) by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the IVM dish with Maturation Medium (Group Culture)."
16316507|NCT04562870|Experimental|Arm S: Selinexor|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Selinexor 60 mg oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
16316508|NCT04562870|Active Comparator|Arm PC: Physician's Choice Treatment|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Physician's choice treatment which will be administered as per clinical practice.
16316509|NCT04562857|Active Comparator|obstructive sleep apnea|interval exercises (intervention) on bicycle for patients with AF and OSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
16316510|NCT04562857|Active Comparator|Central sleep apnea|interval exercises (intervention) on bicycle for patients with AF and CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
16316511|NCT04562844|Experimental|Social cognition|
16316512|NCT04562831|Experimental|Newly diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)
~Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)
~Placebo"
16316513|NCT04562831|Experimental|Earlier diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)
~Placebo"
16316514|NCT04562818||Daunorrubicin|Patient treated with daunorrubicin
16316515|NCT04562818||Idarrubicin|Patient treated with idarrubicin
16316516|NCT04562805|Experimental|DynamX Bioadaptor|Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor
16316517|NCT04562805|Active Comparator|Medtronic Resolute Onyx Stent|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
16316519|NCT04562779|Experimental|XR Naltrexone|Participants will receive a single dose of extended-release, injectable naltrexone prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
16316520|NCT04562779|Experimental|IV Ketamine|Participants will receive a single dose of intravenous ketamine (0.5mg/kg over 40 minutes) prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
16316521|NCT04562779|Active Comparator|Linkage|Participants will receive no single-dose addiction medication prior to hospital discharge, but will receive enhanced linkage to follow-up addiction care.
16316522|NCT04562766|Experimental|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
16316523|NCT04562766|Placebo Comparator|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
16316524|NCT04562753|Active Comparator|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
16316525|NCT04562753|Active Comparator|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
16316526|NCT04562740|Experimental|ABLUMINUS DES|"ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.
~Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions."
16316527|NCT04562727|Experimental|Only MWA|Only preform MWA, chemotherapy isn't necessary
16316528|NCT04562727|Active Comparator|MWA combined with perioperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed before MWA and after MWA
16316529|NCT04562727|Experimental|MWA combined with postoperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed after MWA
16316530|NCT04562714|Experimental|Intervention (FGM + DSME)|Study participants randomized to the intervention arm will be provided with a FreeStyle Libre flash glucose monitor (FGM) system to use for 16 weeks in Phase 1. Study participants will receive one training session on proper use of the FGM and encouraged to test at least 4 times per day: fasting and post-meals. Participants will also receive six diabetes self-management education (DSME) sessions, consisting of four individual in-clinic sessions and two telephone sessions.
16316531|NCT04562714|Other|Control (DSME alone)|Study participants in the control arm will receive six diabetes self-management education sessions matched to time and location of the intervention group. The sessions will consist of four individual in-clinic sessions and two telephone sessions over 16 weeks. Control participants will be encouraged to self-monitor blood glucose four times daily (fasting and post-meals) as per existing diabetes self-care guidelines
16316532|NCT04562688|Experimental|Arm A|Participants assigned to Arm A will engage in CICADAS app only for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
16316533|NCT04562688|Experimental|Arm B|Participants assigned to Arm B will engage in PEERS + CICADAS for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
16316534|NCT04562688|Experimental|Arm C|Participants assigned to Arm C will engage in PEERS + Active Comparator for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
16316535|NCT04562675|Experimental|Intervention group (IG)|LHA intervention group (IG)
16316536|NCT04562675|Placebo Comparator|Control group (CG)|brochure-only control group (CG)
16316537|NCT04562662|Experimental|Intervention group|Single arm (all participants receive interventions)
16316538|NCT04562649|Experimental|Intervention|Wise App that delivers medication adherence reminders and community health worker sessions
16316539|NCT04562649|No Intervention|Control|Standard of care
16316540|NCT04562636|Experimental|Environment-focused Meatless Monday messages|Four environmental messages from the Meatless Monday campaign.
16316541|NCT04562636|Experimental|Health-focused Meatless Monday messages|Four health messages from the Meatless Monday campaign.
16316542|NCT04562636|Other|Neutral Message|Four neutral messages about checking one's credit score.
16316543|NCT04562623||Cohort A : High grade serous ovarian carcinoma|
16316544|NCT04562623||Cohort B :Breast carcinoma SBR grade II or III|Breast carcinoma SBR grade II or III superior to 3 cm
16316545|NCT04562623||Cohort C : Extended Breast carcinoma In situ|Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy
16316546|NCT04562610|Active Comparator|Group A: All oral pre-operative analgesics|"Group A patients will be administered the following medications in the preoperative holding area:
~Acetaminophen 1,000 mg by mouth prior to operation
~Celecoxib 200mg by mouth prior to operation
~Tranexamic acid 2 grams by mouth prior to operation
~Gabapentin 600mg by mouth prior to operation"
16316547|NCT04562610|Active Comparator|Group B: Intravenous agents|"Group B patients will receive:
~Acetaminophen (Ofirmev) 1,000mg intravenous prior to operation
~Celecoxib 200mg by mouth prior to operation
~Tranexamic acid 2grams intravenous at start of operation
~Gabapentin 600 mg by mouth prior to operation"
16316548|NCT04562597|Placebo Comparator|Dose Response Curve Placebo|5-10 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
16316549|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 50 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
16316550|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 100 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
16316551|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 150 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
16316552|NCT04562597|Experimental|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteine dose is identified, 10-15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.
16316553|NCT04562597|Placebo Comparator|Placebo|10-15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.
16316554|NCT04562584|Experimental|MyHomeDoc|Comparison of MyHomeDoc pulse oximetry readings with arterial blood saturation laboratory analysis in the same subject
16316555|NCT04562571|Experimental|Charter & patient information leaflets|A public commitment charter promoting antibiotic stewardship, signed by the general practitioner (GP) and displayed in the practice waiting room; a non-prescription pad, to be distributed to patients when an antibiotic is not needed; and a patient information leaflet to be used when antibiotics were prescribed
16316556|NCT04562571|No Intervention|Control|No intervention, eligible general practitioners randomised in the control group not informed of the intervention
16316557|NCT04562558|Experimental|Arm1-Methotrexate|Patients receive methotrexate intramuscularly（50mg） on Days 1, 3, 5, 7 (4 doses per cycle) with Leucovorin (15mg) on Days 2, 4, 6, 8. Repeat every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment. If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
16316558|NCT04562558|Experimental|Arm 2-Dactinomycin|Patients will receive IV pulse actinomycin-D (1.25mg/m2，2mg max dos) every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment.If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
16316559|NCT04562545|Active Comparator|Maximum Bite Advancement|
16316560|NCT04562545|Experimental|Incremental Bite Advancement|
16316561|NCT04562532|Experimental|Firehawk group|Participants implant Firehawk stent(s)
16316562|NCT04562532|Active Comparator|2nd generation DES|Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)
16316563|NCT04562519|Experimental|diabetic HD group|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
16316564|NCT04562519|Active Comparator|Nondiabetic goup|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
16316565|NCT04562506|Active Comparator|Real rTMS stimulation|real deep excitatory, high frequency rTMS with H-coil stimulation
16316566|NCT04562506|Sham Comparator|Sham rTMS stimulation|sham high frequency H-coil stimulation
16316567|NCT04562493|Active Comparator|Magnesium sulphate group|Effect of transforaminal Magnesium sulphate on oxidative stress markers and radicular pain
16316568|NCT04562493|Experimental|Ozone Group|Effect of transforaminal Ozone on oxidative stress markers and radicular pain
16316569|NCT04562493|Other|Steroid group|Effect of transforaminal steroids on oxidative stress markers and radicular pain
16316570|NCT04562480|Experimental|Treatment (hypofractionated radiation therapy, resection)|Patients undergo hypofractionated radiation therapy QD (except weekends and holidays) over 3 weeks for a total of 15 fractions. Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
16316571|NCT04562467|Experimental|Icosapent Ethyl + Standard of Care|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT
16316572|NCT04562467|No Intervention|Standard of Care|Standard of care therapy (including statin therapy as per inclusion criteria)
16316573|NCT04562454|Experimental|Normal group|Specific diet with CGM for 5days
16316574|NCT04562454|Experimental|T1DM group|Specific diet with CGM for 5days
16316575|NCT04562454|Experimental|T2DM group|Specific diet with CGM for 5days
16316576|NCT04562454|Experimental|other type of diabetes group|Specific diet with CGM for 5days
16316577|NCT04562441|Experimental|Axitinib and Avelumab|"Axitinib: 5 mg bd po Day 1 to Day 28
~Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks"
16316578|NCT04562428|Experimental|XSLJZ|Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
16316579|NCT04562428|Placebo Comparator|XSLJZ Placebo|10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
16316580|NCT04562415|Active Comparator|Active rTMS group|chronic ischemic stroke patients receiving active low frequency repetitive transcranial magnetic stimulation therapy and physical therapy
16316581|NCT04562415|Active Comparator|Active cTBS group|chronic ischemic stroke patients receiving active continuous theta burst stimulation therapy and physical therapy
16316582|NCT04562415|Sham Comparator|Sham cTBS group|chronic ischemic stroke patients receiving sham continuous theta burst stimulation therapy and physical therapy
16316583|NCT04562402|Active Comparator|Phacoemulsification with endoscopic cyclophotocoagulation|Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.
16316584|NCT04562402|Active Comparator|Phacoemulsification alone|Cataract extraction via phacoemulsification.
16316585|NCT04562389|Experimental|Phase 1a: Cohort 1: Selinexor 40 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 40 milligrams (mg) of selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg twice a day (BID).
16316586|NCT04562389|Experimental|Phase 1a: Cohort 2: Selinexor 60 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 60 mg of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
16316587|NCT04562389|Experimental|Phase 1a: Cohort -1: Selinexor 20 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 20 mg of selinexor oral tablet twice weekly (BIW) of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
16316588|NCT04562389|Experimental|Phase 1b: RP2D: Selinexor and Ruxolitinib 15/20 mg|Participants with MF will receive recommended safe dose (estimated in Phase 1a) of selinexor oral tablets on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
16316589|NCT04562389|Experimental|Phase 2: Selinexor RP2D and Ruxolitinib 15/20 mg|Participants with MF will receive recommended safe dose (estimated in Phase 1b) of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
16316590|NCT04562389|Active Comparator|Phase 2: Ruxolitinib 15/20 mg|Participants with MF will receive ruxolitinib oral tablets 15 or 20 mg BID.
16316591|NCT04562376|Experimental|Group A|The program consists of high-intensity resistance training for 60 minutes twice a week for group A during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group A will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
16316592|NCT04562376|Active Comparator|Group B|The program consists of high-intensity resistance training for 60 minutes once a week for group B during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group B will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
16316597|NCT04562350|Experimental|Intervention group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Anoia in the course of 2020-21.
16316598|NCT04562350|No Intervention|Control group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Osona in the course of 2020-21.
16316599|NCT04562337|Experimental|SHR1316+Chemotherapy +Radiotherapy|Paiticipant receive SHR-1316 、Chemotherapy and Radiotherapy
16316658|NCT04561817|Active Comparator|PI3K/AKT mutations (altered)|Participants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
16316604|NCT04562311|Experimental|Chidamide with Immunotherapy|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
16316606|NCT04562272|Active Comparator|Mechanical unloading|Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment
16316607|NCT04562272|No Intervention|Standard care|Standard treatment of AMI after PCI according to guidelines.
16316608|NCT04562259||patients with Kimmerle's anomaly|patients who have a complete or incomplete bony bridge over the posterior arch of the first cervical vertebra
16316609|NCT04562246||PCR positive subjects|Patients who receive positive test result from RT-PCR for SARS-CoV-2.
16316610|NCT04562233|Experimental|Intervention arm|Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each onto Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30-45-minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20-25-minute workout; 5-10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location incase of an emergency.
16316611|NCT04562233|Other|Control Arm|"The attention control arm will include a printed, individualized resistance-based physical activity program.
~Participants randomized to the control arm will also be given a printed or digital individualized, resistance-based physical activity program and told to aim to for three exercise sessions per week. Control participants will follow the same measurement schedule as intervention participants."
16316614|NCT04562207|Experimental|Patients|Addition of a nasopharyngeal swab before surgery
16316615|NCT04562194|Other|Intervention|NeVa Stent Retriever
16316616|NCT04562181|Experimental|Interventions|Anesthesia will be induced with bolus infusion using propofol, sufentanil and cis-atracurium intravenously. The patients will be intubated subsequently. TOF (T4/T1) will be calculated continuously using muscle relaxation monitoring. Anesthesia are maintained with a combination of sevoflurane, propofol, sufentanil and cis-atracurium. Anti-emetic and opioids will be routinely administrated prior to abdominal closure. Neostigmine will be administrated for reversing the residual neuromuscular blockade after the patient get his breath. Tracheal extubating is indicated by a TOF value above 70% in addition to other physical signs.
16316617|NCT04562168|Experimental|Diagnostic Test: ML model|The diagnostic capacity of the ML model will be compared with that of the general practitioners and with dermatologist.
16316618|NCT04562155|Experimental|BAY1817080 dose A BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
16316619|NCT04562155|Experimental|BAY1817080 dose B BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
16316620|NCT04562155|Experimental|BAY1817080 dose C BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
16316621|NCT04562155|Placebo Comparator|Placebo|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
16316622|NCT04562129|Experimental|Treatment|HD IL2 (600,000 units/kg/dose IV) will be given during week 1 of the 2 initial cycles or each course. Ipilimumab will be given concurrently at the low dose of 1 mg/kg during week one of the 2 initial cycles of each course for up to 2 doses, total. Nivolumab will be given on during week one of the 3rd cycle of each course. No systemic treatment will be administered during the 4th cycle. Patients without evidence of disease progression (RECIST v.1.1) or limiting toxicities will be offered additional courses of treatment for up to a maximum of 3 courses, total.
16316623|NCT04562116|Experimental|CYP 450 Substrates plus Nemolizumab|Participants will receive 1 single oral dose of selected, commercially available, cytochrome P450 substrates (CYP450-S) on Day 1 and after a 1-week washout period, participants will receive a 60 milligram (mg) loading dose of nemolizumab via 2 consecutive subcutaneous (SC) 30-mg injections at the Week 1 visit, followed by a single 30-mg injection once in every 4 weeks (Q4W) at Week 5 and Week 9. Participants will receive a second oral dosing of CYP450-S at Week 10.
16316624|NCT04562103|Experimental|Epinephrine QLB|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
16316625|NCT04562103|Active Comparator|Plane QLB|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
16317346|NCT04556773|Experimental|Module 3: T-DXd + capivasertib|T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
16316628|NCT04562064||keratoconus group|patients with keratoconus implanted with the Myoring 360 degree, KeraRing 355 degree, KeraRing one segment, KeraRing two segments ICRS .corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system .pentacam data that will be included
16316629|NCT04562051||stratified prophylaxis group|The process of stratified prophylaxis was as follows. 1) If the recipient's HBsAb level is more than 100 IU/L and the donor is HBV DNA-, the recipient will not receive any preventive measures; 2) If the recipient's HBsAb is more than 100 IU/L and the donor is HBV DNA+, the recipient receives antiviral treatment for 1 month; 3) If the recipient's HBsAb is between 10 and 100 IU/L, the recipient is treated with single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status; 4) If the recipient's HBsAb is less than 10 IU/L, the recipient will receive single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status.
16316630|NCT04562051||Routine prophylaxis group|Transplant centers adopted routine prophylaxis based on clinical experience
16316631|NCT04562038|Experimental|YC-PEM e-PRO|Participants are administered an electronic patient-reported outcome measure to obtain information about parent priorities, and they obtain a summary report of their responses to share with their early intervention team for discussion during the annual IFSP meeting.
16316632|NCT04562038|No Intervention|Family Assessment|Participants are scheduled to complete a semi-structured family interview to obtain information about parent priorities, for use during the annual IFSP meeting
16316633|NCT04562025|Experimental|UC-MSCs treatment group|"Conventional treatment plus UC-MSCs:
~Participants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2，week3)."
16316634|NCT04562025|Placebo Comparator|Placebo control group|"Conventional treatment plus Placebo:
~Without UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2，week3."
16316635|NCT04561999||Patients with Superficial Lymphadenopathy|
16316636|NCT04561986|Active Comparator|Arm A: Standard of care (SOC) + tocilizumab (TCZ)|SOC, as below + TCZ (162 mg every week, subcuataneous administration)
16316637|NCT04561986|No Intervention|Arm B: SOC|Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + prednisolone (not less than 5 mg/day), all oral administration
16316638|NCT04561960|Active Comparator|Control|"Participants will be trained to perform oral hygiene using the modified bass technique.
~The participants will be asked to brush their teeth twice daily using a manual tooth brush and fluoridated toothpaste containing 1450ppm of fluoride"
16316639|NCT04561960|Experimental|Miswak|Participants will be trained to chew and condition a miswak stick Participants will be asked to use the miswak stick twice daily
16316640|NCT04561960|Experimental|Miswak Paste|"Participants will be trained to perform oral hygiene using the modified bass technique.
~The participants will be asked to brush their teeth twice daily using a manual tooth brush a non-fluoridated toothpaste containing miswak extract"
16316641|NCT04561947|Active Comparator|TT+CTG|The combined connective tissue graft (CTG) with tunnel technique (TT)
16316642|NCT04561947|Experimental|TT+CGF|The combined concentrated growth factor (CGF) membrane with tunnel technique (TT)
16316643|NCT04561934|Experimental|resin modified glassionomer cement|Application of Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE)
16316644|NCT04561934|Active Comparator|silver diamine flouride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
16316645|NCT04561921|Experimental|megnesium sulphate|Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.
16316646|NCT04561921|Active Comparator|mepivacaine HCl|Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block
16316647|NCT04561908|Experimental|Transcatheter microguidewire drilling|"Through femoral vein, 6F MP1 guidecatheter was introduced into right atrium and engaged on fossa ovalis. Through guidecatheter, the hard back-end of microguidewire (0.014-inch BMW; Abbott, Plymouth, Minnesota, USA) was advanced to drill through fossa ovalis in the aid of a balloon (3.0 mm×15 mm; NC TREK, Abbott, Plymouth, Minnesota, USA). Over the fixed guidewire, the balloon crossed and overrode atrial septum with proximal portion in guidecatheter-tip, and the guidecatheter was advanced gently to slip into left atrium during balloon dilation."
16316648|NCT04561895||control group|healthy volunteers with absence of NAFLD
16316649|NCT04561895||test group|patients with confirmed NAFLD diagnosis
16316650|NCT04561882|Experimental|Transcatheter exclusion of atrial septal aneurysm|Transcatheter reconstruction of atrial septum might be achieved with PFO occluder through transseptal perforation in patients with ASA.
16316651|NCT04561856|Active Comparator|Group1|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume intravenously.
16316652|NCT04561856|Active Comparator|Group2|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume perinural plus 2 ml of normal saline intravenously.
16316653|NCT04561856|Placebo Comparator|Group3|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 2 ml of normal saline intravenously.
16316654|NCT04561843||case group|Women complaining of any of the pelvic floor disorder symptoms such as: Pelvic organ prolapse (POP), Stress urinary incontinence (SUI), urgency symptoms of obstructed defecation, fecal incontinence (FI), pelvic pain, and/or sexual problems.
16316655|NCT04561843||control group|Women not complaining of any of the pelvic floor disorder symptoms
16316656|NCT04561830|Active Comparator|group 1|underwent laparoscopic-assisted excision of mesorectum
16316657|NCT04561830|Active Comparator|group 2|open excision of mesorectum
16316659|NCT04561817|Active Comparator|Without PI3K/AKT mutations (non-altered)|Participants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
16316660|NCT04561804||LISESTYLE INTERVENTION|LOW CARB LOW GLYCEMIC LOAS DIET
16316661|NCT04561804||WEGHT LOSS SURGERY|SLEEVE OR MINBYPASS SURGERY
16316662|NCT04561791|Experimental|Feasibility of TCE & Prevalence of BE|"Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment
~Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH"
16316663|NCT04561778|Active Comparator|HOT-CRT|Subjects randomized to HOT-CRT will undergo CRT as described below. His bundle pacing lead will be placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and LV timing may be optimized to achieve maximal resynchronization. This will be at the discretion of the implanting physician. Only FDA approved leads and devices will be used.
16316664|NCT04561778|Active Comparator|Biventricular Pacing|Subjects randomized to biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.Only FDA approved leads and devices will be used.
16316665|NCT04561765|Experimental|iCanCope|In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
16316666|NCT04561765|Experimental|iCanCop+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
16316667|NCT04561765|No Intervention|Control Group|The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
16316668|NCT04561752|Experimental|Treatment Sequence A-B|Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
16316669|NCT04561752|Experimental|Treatment Sequence B-A|Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
16316670|NCT04561739|Experimental|Drug-coated balloon|
16316671|NCT04561739|Active Comparator|Drug-eluting stent|
16316672|NCT04561726|Experimental|Study Group|"All of the 20 participants in the study group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
~Additionally, CTM was applied to the volunteers in study group for 6 weeks, 2 sessions in a week.CTM applied to lumbosacral area (basic region), lower toracal, scapular, interscapular and cervical regions, respectively."
16316673|NCT04561726|Active Comparator|Exercise Group|All of the 20 participants in the exercise group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
16316674|NCT04561713|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|Children aged 8 to 12 diagnosed with ADHD
16316675|NCT04561713|Sham Comparator|Control|Control group of healthy ADHD children matched in age, gender and laterality to children in ADHD group
16316676|NCT04561700|Experimental|Reporting of sucking patterns captured by Instrumented Bottle|Weekly reporting on objective measurements of sucking activity during oral feeding
16316677|NCT04561700|Sham Comparator|Control|Weekly reporting on traditional measurements of sucking activity during oral feeding (no objective measurements reported)
16316678|NCT04561687|Active Comparator|Azelastine and Nasal Budesonide|Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
16316679|NCT04561687|Active Comparator|Montelukast and Nasal budesonide|Montelukast 5mg 6-14years old and 10mg for older
16316680|NCT04561687|Placebo Comparator|Nasal Budesonide and Placebo|Placebo once daily
16316681|NCT04561674|Experimental|Experimental Group|"The patients in the experimental group participated in Web-Based Patient Education with Colostomy and Ileostomy on computer between the third and seventh days after surgery.
~The cards with the website address, username and the website QR code were given to the patients in order to be able to receive education after discharge.The patient and her family received the training from any computer or smartphone connected to the internet."
16316682|NCT04561674|No Intervention|Control group|The clinical routine was applied to the control group.
16316683|NCT04561661|Active Comparator|Conservative treatment|Fracture treated with closed reduction, custom made orthosis and early mobilization.
16316684|NCT04561661|Active Comparator|Surgery|Fractures treated with closed reduction, percutaneous pinning (k-wires) and plaster.
16316685|NCT04561648|Experimental|High Dose of Unfractionated Heparin|100 IU/Kg of Unfractionated Heparin
16316686|NCT04561648|Active Comparator|Standard Dose of Unfractionated Heparin|5000 IU of Unfractionated Heparin.
16316770|NCT04561037|Experimental|Study Group|Study group patients received PEMFT, using EMG 8400 PEMF device (made in Italy, by EME) in addition to physical therapy treatment program.
16316687|NCT04561635|Experimental|Intervention group|The intervention group was supplemented with three sachets of MMS each week for every other day for a period of 12 months. Each sachet containing 1 g consisting of ten vitamins and five minerals. It was to be sprinkled over a cooked meal or dissolved in a drink for the child. Written instruction for using and storing the MMS in simple language with visuals was given prior to the supplementation. The intervention group also received health and nutrition advice at 3, 6 and 9 months after supplementation begins.
16316688|NCT04561635|No Intervention|Control group|The control group received health and nutrition advice that were similar to intervention group and delivered by the investigator at 3, 6 and 9 months after the study began.
16316689|NCT04561622||Bipolar patients|Bipolar patients (type I,II, NOS) of the bipolar disorder expert center of CHU Grenoble Alpes.
16316690|NCT04561622||Healthy controls|Volunteers without any psychiatric disease matching inclusion criteria
16316691|NCT04561609|Active Comparator|CO2 treated|Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs
16316692|NCT04561609|Placebo Comparator|control|Patients receiving placebo treatment with air on lower limbs
16316693|NCT04561596|Experimental|Autohypnosis|
16316694|NCT04561596|Other|Control|
16316695|NCT04561583|Other|LED light source system for endoscope|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).Test grop use LED light source system for endoscope
16316696|NCT04561583|Other|Pinpoint Endoscopic Fluorescence Imaging System|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).control group use Pinpoint Endoscopic Fluorescence Imaging System (Model: PC9000)
16316697|NCT04561570||Study Group: Vivity ACRYSOF IQ IOL|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
16316698|NCT04561570||Control Group: ACRYSOF IQ IOL|Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
16316699|NCT04561557|Experimental|CAR T cells therapy，Dose level 1: 0.5 × 10^6 CAR-T cells/Kg|"The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting toxicity (DLT) occurs and at least one subject benefits from the treatment, there will be two options for the investigator based on the available data: 1) three more subjects will be enrolled in the 0.5 × 10^6 CAR-T cells/Kg group and DLT will be evaluated in a total of six subjects; 2) another three subjects will be treated with 1 × 10^6 CAR-T cells/Kg instead of 0.5 × 10^6 CAR-T cells/Kg.
~If DLT occurs in one of the first three subjects, three more subjects will be enrolled in this cohort to reach the total subjects of six."
16316700|NCT04561557|Experimental|CAR T cells therapy，Dose level 2: 1 × 10^6 CAR-T cells/Kg|If neither DLT nor efficacy is shown in the first three subjects, the dose of CAR-T cells will be increased to 1 × 106 CAR-T cells/kg to assess DLT.
16316701|NCT04561557|Experimental|CAR T cells therapy，Dose level 3: 0.25 × 10^6 CAR-T cells/Kg|If DLT occurs in two subjects, whether to test the safety and efficacy in 0.25 × 10^6 CAR-T cells/kg group will be determined by the investigator based on the initial data of efficacy, PK and PD.
16316702|NCT04561544|Experimental|Intervention in Fall 2020|Participants will receive the intervention in Fall 2020
16316703|NCT04561544|Other|Intervention in Spring 2021|Control in Fall 2020
16316704|NCT04561531|Experimental|Intermittent bolus|In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
16316705|NCT04561531|Experimental|Traditional continuous drip|In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
16316708|NCT04561505|Active Comparator|Holmium laser enucleation of prostate|patients that undergo Holmium laser enucleation of prostate (HoLEP) procedure
16316709|NCT04561505|Active Comparator|monopolar transurethral resection of prostate|patients that undergo monopolar transurethral resection of prostate
16316710|NCT04561492|Experimental|[68Ga]Ga-PentixaFor|
16316711|NCT04561479|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training, inspiratory muscle training and progressive resistance training
16316712|NCT04561479|Sham Comparator|Control Group|Control group will receive alternative upper extremity exercises and breathing exercises.
16316713|NCT04561466|Experimental|treatment group|"14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.
~Befizal® 200 mg will be tested for one year"
16316714|NCT04561453||Resected Biliary Duct Cancer|
16316715|NCT04561440||molecular karyotyping|
16316716|NCT04561440||cytogenic karyotyping|
16316717|NCT04561427||Pediatric Patients with narcolepsy|"Patients between 0 and 18 years old
~Patients diagnosed with primary or secondary narcolepsy
~From both gender"
16316771|NCT04561024||RT-PCR Positive Patients|RT-PCR confirmed patients positive for SARS-CoV-2
16316772|NCT04561024||Negative patients|RT-PCR confirmed patients negative for SARS-CoV-2 or patients with CXR performed before the emergence of COVID-19 pandemic
16316718|NCT04561414|Other|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope
16316719|NCT04561414|Other|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)
16316720|NCT04561401|Experimental|rTMS + IPRP|25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
16316721|NCT04561401|Active Comparator|IPRP|Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
16316723|NCT04561375|Active Comparator|Intervention Group|30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
16316724|NCT04561375|Placebo Comparator|Control Group|placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia
16316725|NCT04561362|Experimental|Cohort A-1 BT8009 Monotherapy Dose Escalation|Participants will receive increasing doses of BT8009. It is expected that approximately 34 participants will participate in this dose escalation arm.
16316726|NCT04561362|Experimental|Cohort A-2 BT8009 and Nivolumab Dose Escalation|Participants will receive increasing doses of BT8009 and a standard dose of nivolumab. It is expected that approximately 20 participants will participate in this dose escalation arm
16316727|NCT04561362|Experimental|Cohort B-1 - Dose expansion (BT8009 alone)|Participants will receive a selected dose of BT8009. It is expected that approximately 40 participants will participate in this dose expansion arm
16316728|NCT04561362|Experimental|Cohort B-2 - Dose expansion (BT8009 and nivolumab)|Participants will receive a selected dose of BT8009 and a standard dose of nivolumab. It is expected that approximately 40 participants will participate in this dose expansion arm.
16316729|NCT04561362|Experimental|Cohort C - Renal Insufficiency (BT8009 alone)|Participants will receive a selected dose of BT8009. It is expected that approximately 12 participants will participate in this arm.
16316730|NCT04561349|Experimental|Task-oriented training (TOT)|Task-oriented training consisted of different functional tasks for lower limbs to improve balance and walk
16316731|NCT04561349|Active Comparator|Conventional rehabilitation treatment|Conventional rehabilitation treatment includes mat activities and range of motion (ROM) of all limbs, Lower limb strengthening and stretching, walking, cycling
16316732|NCT04561336|Experimental|avelumab plus cetuximab|avelumab at a dose of 10 mg/kg once every 2 weeks plus cetuximab at a starting dose of 400 mg/m2 by i.v.infusion over 120 minutes at first dose and at the dose of 250 mg/ m2 by i.v.infusion over 60 minutes for subsequent infusions every week.
16316733|NCT04561310|Experimental|Post facilitation stretch|Post facilitation stretch with Maitland mobilization
16316734|NCT04561310|Active Comparator|Active release technique|Active release technique with Maitland mobilization
16316735|NCT04561297|Experimental|Biopsied Patients|Patients scheduled for a breast biopsy will have breast tissue dielectric constant measurements made prior to the biopsy
16316736|NCT04561284|Experimental|Indigestible fiber supplementation|Participants will receive an indigestible fiber supplementation (classified) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals.
16316737|NCT04561284|Placebo Comparator|Placebo supplementation|Participants will receive placebo supplementation (Maltodextrin) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals. The amount of maltodextrin taken will be isocaloric with the amount of indigestible fiber.
16316738|NCT04561271|Experimental|foot reflexology|patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music
16316739|NCT04561271|Sham Comparator|toucher massage|patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
16316740|NCT04561258|Experimental|Low Dose Cohort|A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
16316741|NCT04561258|Experimental|High Dose Cohort|A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
16316742|NCT04561245|Experimental|ALT-801 (Part 1)|Escalating doses of ALT-801 administered once
16316743|NCT04561245|Placebo Comparator|Placebo (Part 1)|Placebo administered once
16316744|NCT04561245|Experimental|ALT-801 (Part 2)|Escalating doses of ALT-801 administered once weekly for 12 weeks
16316745|NCT04561245|Placebo Comparator|Placebo (Part 2)|Placebo administered once weekly for 12 weeks
16316773|NCT04561011|Experimental|Persons with Mild Traumatic Brain Injury (mTBI)|
16316746|NCT04561232|Other|Locomotor Learning|"This study has three phases. The first phase of the study will be the observation of early spontaneous leg movements which will be measured monthly from 1-4 months of age.
~The prone locomotor intervention phase using the Self-Initiated Prone Progression Crawler (SIPPC) will occur from 5-9 months of post-term age, or end earlier if the child achieves the ability to crawl six feet. Treatment will occur at an intensity of 3 times per week for 15-30 minutes. Infants will use the SIPPC for the duration of each therapy session
~The upright locomotor intervention phase using DWS will occur from 9-18 months of age, or begin earlier if the child achieves the ability to crawl six feet before 9 months of age, and end earlier if the child achieves independent walking before 18 months of age. Treatment will occur at an intensity of 3 times per week for 30 minutes. Infants will receive dynamic weight support (DWS) for the duration of the 30-minute therapy session."
16316747|NCT04561219|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
16316748|NCT04561219|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days
16316749|NCT04561206|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
16316750|NCT04561193||Retrospective Cohort|Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.
16316751|NCT04561180|Placebo Comparator|Arm 1: SOC + DEX + EG-009A placebo|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A placebo for 3 additional weeks.
16316752|NCT04561180|Experimental|Arm 2: SOC + DEX + Low Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A Low dose for 3 additional weeks.
16316753|NCT04561180|Experimental|Arm 3: SOC + DEX + High Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A High dose for 3 additional weeks.
16316754|NCT04561167|Experimental|Cuspal reduction in MOD Cavity in endodontically treated teeth|Cavity design is of prime importance for the restoration of endodontically treated teeth. The cavity design plays an important role in the protection of the remaining tooth structure as well as the restoration. Cuspal reducuction and further coverage by the CAD/CAM generated indirect resin composite restoration has been proved in literature by the retrospective study done by (Chrepa V et al 2014) which studied 189 posterior endodontically treated teeth receiving indirect composite onlays with a median follow up time of 37 months and suggested this type of restoration as a viable option with 100% tooth survival and 96.8% restoration survival.
16316755|NCT04561167|Active Comparator|No cuspal reduction in endodontically treated teeth|In the present study, choosing the comparator to be the cavity design without cuspal reduction and further coverage (inlay) is done as an attempt to reduce the application of inlays in endodontically treated teeth. In accordance to the in-vitro study done by (M. D. Al Amri et al 2016) which tested the fracture resistance of endodontically treated mandibular first molars with conservative access cavity and different restorative techniques, catastrophic failures were highest in the composite group (100%), followed by the inlay and the amalgam groups (91.67%) and this was referred to the adhesive bonding mechanism of the composite restoration and the wedging effect of the inlay and the amalgam restorations (Rivera EM andWalton RE 2015)
16316756|NCT04561154|Experimental|patient hospitalized between march 1 and june 30, 2020|patient hospitalized between march 1 and june 30, 2020
16316757|NCT04561128|Experimental|SHR-1819|Experimental: SHR-1819
16316758|NCT04561128|Placebo Comparator|Placebo|Placebo comparator: placebo
16316759|NCT04561115|Active Comparator|Gamunex-C|Participants will receive Gamunex-C by means of an infusion pump at an individualized dose (based on historical IVIG treatment dose) between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. The subject's usual mg/kg dose (given on either a 3 or 4 week repeating schedule) will be the same mg/kg dose and schedule that the subject was receiving prior to entering screening. This mg/kg dose and schedule will be used throughout the study duration. Note that the weight of the subject will be measured at each visit and if the subject's weight changes, the actual weight at each visit will be used to calculate amount of drug (mg) to be administered. Gamunex-C will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
16316760|NCT04561115|Experimental|IVIG-PEG|Following treatment with Gamunex-C, participants will receive IVIG-PEG by means of an infusion pump at an equivalent dose between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. IVIG-PEG will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
16316761|NCT04561102||COVID-19 asymptomatic population|COVID-19 asymptomatic Rollins College community
16316762|NCT04561089||COVID-19 asymptomatic population|COVID-19 asymptomatic Illumina personnel
16316763|NCT04561076|Experimental|Sequence 1|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
16316764|NCT04561076|Experimental|Sequence 2|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
16316765|NCT04561076|Experimental|Sequence 3|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
16316766|NCT04561063|No Intervention|Arm A: No pharmacological intervention (PPE only)|No intervention
16316767|NCT04561063|Active Comparator|Arm B: Nitazoxanide (NTZ)|Nitozoxanide administered
16316768|NCT04561063|Active Comparator|Arm C: Sofosbuvir/daclatasvir (SOF/DCV).|Sofosbuvir/daclatasvir administered
16316769|NCT04561037|Active Comparator|Control Group|Control group patients received traditional physical therapy treatment. The traditional physical therapy treatment program consisted of TMJ mobilization techniques include distraction, anterior glide, anterior glide with pre-positioned mouth opening, medial/lateral glides, caudal-anterior-medial (CAM) glide, and CAM glide with pre-positioned mouth opening and isometric exercises against resistance for muscles of mastication.
16316776|NCT04560985|Experimental|Hydrophilic sealant|UltraSeal XT hydro™ sealant ®
16316778|NCT04560972|Experimental|Treatment (LB-100, carboplatin, etoposide, atezolizumab)|"INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
16316779|NCT04560959|Experimental|tACS arm|The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.
16316780|NCT04560946|Experimental|PACT|Personalized Augmented Cognitive Training (PACT)
16316781|NCT04560946|Active Comparator|ETAU|Enhanced Treatment As Usual (ETAU)
16316782|NCT04560920|Experimental|Experimental|This group will contribute PGD and it will be available in the study visit.
16316783|NCT04560920|No Intervention|Control|This group will contribute PGD but it will not be available during a study visit, it will be available to the provider in a subsequent visit.
16316784|NCT04560907|Experimental|Aquablation|
16316785|NCT04560907|Active Comparator|HoLEP|
16316786|NCT04560894|Experimental|SCT-I10A+SCT510|
16316787|NCT04560894|Active Comparator|Sorafenib|
16316788|NCT04560881|Experimental|Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
16316789|NCT04560881|Placebo Comparator|Placeboof Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
16316790|NCT04560868|Active Comparator|Control|
16316791|NCT04560868|Experimental|Experimental|
16316792|NCT04560855||Covid19 Patients|Patients diagnosed as COVID-19 positive and managed on an outpatient basis.
16316793|NCT04560842|Experimental|Conventional oxygen devise|Chose devise to keep patient's SpO2 > 92%
16316794|NCT04560842|Active Comparator|High flow nasal cannula|High flow oxygen device
16316795|NCT04560816|Experimental|Treatment Sequence 1|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: ALXN1840.
~Period 2: Placebo-matching ALXN1840.
~Period 3: Moxifloxacin."
16316796|NCT04560816|Experimental|Treatment Sequence 2|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: ALXN1840.
~Period 2: Moxifloxacin.
~Period 3: Placebo-matching ALXN1840."
16316797|NCT04560816|Experimental|Treatment Sequence 3|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Placebo-matching ALXN1840.
~Period 2: ALXN1840.
~Period 3: Moxifloxacin."
16316798|NCT04560816|Experimental|Treatment Sequence 4|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Placebo-matching ALXN1840.
~Period 2: Moxifloxacin.
~Period 3: ALXN1840."
16316799|NCT04560816|Experimental|Treatment Sequence 5|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Moxifloxacin.
~Period 2: ALXN1840.
~Period 3: Placebo-matching ALXN1840."
16316800|NCT04560816|Experimental|Treatment Sequence 6|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Moxifloxacin.
~Period 2: Placebo-matching ALXN1840.
~Period 3: ALXN1840."
16316801|NCT04560803|Experimental|Epidermal Grafting|This irradiated area of the skin will be treated with autologous epidermal grafts
16316802|NCT04560803|No Intervention|No treatment|This irradiated area will not receive any treatment
16316803|NCT04560790|Experimental|BD111 Adults single group Dose|Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
16316804|NCT04560777|Experimental|experimental arm|CO-OP intervention
16316805|NCT04560764|Experimental|Virtual Reality + Action Observation Therapy|Participants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
16316806|NCT04560764|Sham Comparator|Virtual Reality + Landscape video|Participants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
16316807|NCT04560751||Lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.
16316808|NCT04560738|Experimental|Administration of [14C]-CC-92480|[14C]-CC-92480 will be administered as an oral solution. A single oral dose of [14C]-CC-92480, containing approximately 2 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
16316809|NCT04560725|Experimental|[68Ga] P137|Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo [68Ga]P137 PET/CT scans.
16316810|NCT04560712|Experimental|Arm I (acupuncture, usual care)|Beginning the day after surgery, patients undergo acupuncture sessions over 25 minutes QD for up to 7 days. Patients also undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
16316811|NCT04560712|Active Comparator|Arm II (usual care)|Patients undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
16316812|NCT04560699|Active Comparator|Physiotherapeutic group|medical care and physiotherapeutic treatment
16316813|NCT04560699|Active Comparator|medical care group|Medical care
16316814|NCT04560686|Experimental|Treatment (bintrafusp alfa, surgical resection)|Patients receive bintrafusp alfa IV on days 1, 15, and 29 in the absence of unacceptable toxicity. Within 4-6 weeks after last dose of bintrafusp alfa, patients undergo surgery at the discretion of the treating surgeon. Within 8 weeks after surgery, patients may receive chemotherapy or undergo radiation therapy at the discretion of the treating physician.
16316815|NCT04560673|Experimental|Group I (neurofeedback training, duloxetine)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
16316817|NCT04560673|Experimental|Group III (duloxetine)|Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
16316818|NCT04560660|Experimental|Ketamine and prolonged exposure (PE)|Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
16316819|NCT04560660|Placebo Comparator|Midazolam and prolonged exposure (PE)|Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
16316820|NCT04560647||Psoriasis|Subjects diagnosed with psoriasis.
16316821|NCT04560647||Control|Subjects who do not have psoriasis.
16316822|NCT04560634||Normal Diastolic Function|Diastolic Function within normal values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
16316823|NCT04560634||Impaired Diastolic Function|Diastolic Function with pseudonormal pattern or impaired values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
16316824|NCT04560621|Experimental|MAPS+|
16316825|NCT04560621|No Intervention|Standard of Care|
16316827|NCT04560582||Kidney Transplant Patients with Failed Allograft|All participants are assigned to a single cohort of kidney transplant patients with failed allograft requiring dialysis.
16316828|NCT04560569|Experimental|Group A|ABT weekly and 3BNC117 bi-weekly
16316829|NCT04560569|Experimental|Group B|both ABT and 3BNC117 treatment bi-weekly
16316830|NCT04560556||POC Testing Alone|POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
16316831|NCT04560556||POC and 4th Generation Testing|POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
16316832|NCT04560556||4th Generation Testing Alone|4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
16316833|NCT04560543|Experimental|McCall suture|
16316834|NCT04560543|No Intervention|standard cuff closure|
16316835|NCT04560517||Anorexia Nervosa|
16316836|NCT04560517||Healthy Control Subjects|
16316839|NCT04560491||Frozen section|Patients underwent intraoperative sentinel node examination by frozen section
16316840|NCT04560491||Scrape cytology|Patients underwent intraoperative sentinel node examination by scrape cytology
16316841|NCT04560478|Active Comparator|Pro Seal Sealant|ProSeal Sealant was applied to the facial surfaces of the maxillary anterior teeth (canine to canine)
16316842|NCT04560478|Active Comparator|MI Varnish|MI Fluoride Varnish was applied to the maxillary anterior teeth (canine to canine)
16316843|NCT04560465|Experimental|group A: Cases that had tranexamic acid infusion|Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
16316844|NCT04560465|Placebo Comparator|Group B: Control|control were given perioperative placebo at the rate of 100mls per hour
16316845|NCT04560439|Experimental|Treatment (METFIT program)|Patients undergo METFIT program for 16 sessions over 6 months.
16316846|NCT04560426|Experimental|Naked eyes & Instrument assistance|Identify the parathyroid glands through the experience of surgeons and assistance of instrument.
16316847|NCT04560426|No Intervention|Naked eyes only|Identify the parathyroid glands only through the experience of surgeons.
16316848|NCT04560400|Sham Comparator|No Concussion Conventional KD|Participants without concussion history perform conventional King-Devick Test.
16316849|NCT04560400|Active Comparator|No Concussion Reverse KD|Participants without concussion history perform reverse King-Devick Test.
16316850|NCT04560400|Sham Comparator|Single Concussion Conventional KD|Participants with 1 concussion history perform conventional King-Devick Test.
16316851|NCT04560400|Active Comparator|Single Concussion Reverse KD|Participants with 1 concussion history perform reverse King-Devick Test.
16316852|NCT04560400|Sham Comparator|Multiple Concussion Conventional KD|Participants with 2 or more concussion history perform conventional King-Devick Test.
16316853|NCT04560400|Active Comparator|Multiple Concussion Reverse KD|Participants with 2 or more concussion history perform reverse King-Devick Test.
16316854|NCT04560387|Experimental|Interventional|"Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight.
~Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI > 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI > 35 kg/m2 and a presence of metabolic or other complications)."
16316855|NCT04560387|No Intervention|Conservative|Routine treatment of obesity
16316856|NCT04560374|Experimental|Experimental Group|Crochet octopus was delivered to the hands of the neonates in the experimental group 10 minutes before heel lance process and they were contacted with the crochet octopus up to 10 minutes after the procedure.
16316857|NCT04560374|No Intervention|Control Group|Control group neonates were performed all the process without delivering them any crochet octopus.
16316878|NCT04560192|Active Comparator|Intervention group|Treatment with the mindfulness based emotion regulation therapy (MBERT) in block 1, no study-treatment in block 2 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy).
16316879|NCT04560192|Other|Treatment as usual (TAU)|No study-treatment in block 1 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy), treatment with the mindfulness based emotion regulation therapy (MBERT) in block 2.
16316880|NCT04560192|No Intervention|Control condition|Healthy subjects will get a single TSST session.
16316858|NCT04560361|Experimental|Electroacupuncture group|Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and use a 0.30×40mm acupuncture needle to penetrate the skin 10mm obliquely through the fixed insulating gasket at Ashi point; According to the above operation, the SJ6 and GB34 point of the affected side are directly penetrated into the skin 15-20mm. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-5mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture treatment for 30 minutes.
16316859|NCT04560361|Sham Comparator|Sham electroacupuncture group|Participants randomly assigned to the sham electroacupuncture (SA) group received sham electroacupuncture by using placebo blunt needles at the same acupoints. After disinfecting the skin and placing the sterile insulating adhesive pads on unilateral Zhigou, Yanglingquan and Ashi points, placebo blunt needles are inserted through the pads and reach the insulating adhesive layer, causing the participants to feel the needle resistance (a sensation of needle insertion). Other procedures, electrode placements, parameter of electroacupuncture apparatus and treatment settings are the same as in the EA group, but with no skin penetration or electricity output.
16316860|NCT04560348|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program An 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure games, and one adventure day camp (2 sessions). One session per week, 3 hours for each session. A variety of cognitive behavioral skills are taught in lectures and these skills are practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. The adventure training includes a day adventure camp and five 40-minute adventure games in the beginning of each workshop. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework are used in the intervention program.
16316861|NCT04560335|Experimental|Coach to fit|CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about 15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.
16316862|NCT04560335|Other|Treatment as usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
16316863|NCT04560322|Experimental|Venetoclax-Obinutuzumab +/- Acalabrutinib|"A treatment cycle is defined as 28 consecutive days. Participants with undetectable MRD (uMRD) at 1 year will complete an additional 1 year of VO then stop therapy.
~Participants with high detectable MRD at 1 year will complete an additional 1 year of VO plus acalabrutinib then stop therapy.
~Participants with low detectable MRD at 1 year will complete an additional 1 year of VO alone. If this eradicates MRD, they will stop therapy. If there is still residual MRD, they will complete an additional 1 year of IVO then stop therapy.
~If progression occurs on VO, I will be added and IV will be administered indefinitely. After 2 years, V may be stopped and I continued as monotherapy at investigator discretion.
~Infused Study Drug: Obinutuzumab on Days 1, 2, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 1-6
~Oral Study Drugs: Venetoclax daily starting on Cycle 1 Day 22
~Oral Drug: acalabrutinib daily for Days 1-28 (if applicable)"
16316864|NCT04560309|Experimental|Glutamine|Intravenous L-alanyl-L-glutamine 0.5 mg/kgbw
16316865|NCT04560309|Placebo Comparator|Control|Intravenous NaCl 0.9%
16316866|NCT04560296|Experimental|Nurse-led e-Health program|The intervention group will consist of 80 participants who will engage in Nurse-led e-Health program.
16316867|NCT04560296|Active Comparator|usual self-management and follow up with doctors/nurse|The participants will receive the usual self-management and follow up with doctors/nurse as planned.
16316868|NCT04560283|Experimental|Experimental group receiving HYALOGYN®|
16316869|NCT04560283|Placebo Comparator|Control group undergoing expectant management|
16316870|NCT04560270|Experimental|Only arm|Blood samples to analyze ctDNA
16316871|NCT04560257|Experimental|Group intervene with HFNC|Review effect of HFNC as clinical trial among hospitalized patients with COVID-19 infection.
16316872|NCT04560244|Experimental|SHR 1701+radiotherapy|SHR-1701 Simultaneously Combined with High Fractionation and Low-dose Radiotherapy
16316873|NCT04560231|Experimental|Group intervene with Remdesivir|Review effect of Remdesivir as clinical trial among hospitalized patients with COVID-19 infection. 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
16316874|NCT04560218|Experimental|Uterotonic agents group A|Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab
16316875|NCT04560218|Experimental|Uterotonic agents group B|Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab
16316876|NCT04560218|No Intervention|Uterotonic agents group C|Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab
16316877|NCT04560205|Experimental|Group intervene with Tocilizumab|"Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection.
~Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers."
16316881|NCT04560179|Experimental|Treatment Arm|The phase 1 trial will last up to 14 days, with each infant receiving a specified dose of tobramycin solution for inhalation every 12 hours, administered via vibrating mesh nebulizer. The drug dosage (78mg, 150mg, 216mg, or 300mg) will be determined as per the inter-patient dose escalation 3+3 design protocol. During the trial, each infant will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Clinical data will also be recorded daily throughout the trial.
16316882|NCT04560179|No Intervention|Observational Arm|Enrolled infants who are ineligible to participate in the phase-1 trial (lack of parental consent, research tracheal aspirate negative for a pathogenic GNR) will undergo collection of clinical and respiratory mechanics data for 14 days after ineligibility to participate in the phase-1 trial is established.
16316884|NCT04560153|Experimental|patient living with HIV|
16316885|NCT04560140|Experimental|Intervention group|Eligible participants will be randomly assigned to receive usual care with the novel 24-week Narrative and Skills-building Intervention.
16316886|NCT04560140|No Intervention|Usual care group|Participants will receive usual stroke care.
16316887|NCT04560127|Experimental|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
16316888|NCT04560114|Experimental|Essential oils|Inhalation will be carried out via an inhaler stick containing essential oils (Mentha x Piperita; Citrus Limon; Zingiber Officinale)
16316889|NCT04560088|Experimental|Mindfulness|Mindfulness using an individual mobile health mindfulness-based intervention training. These sessions are intended to act as a general introduction to mindfulness meditation and incorporate techniques such as breath awareness and body scanning.
16316890|NCT04560088|Active Comparator|Breathing|Breathing control intervention will use an individual breathing app. The intervention is designed to be structurally equivalent to the mindfulness-based study intervention on key common factors of psychosocial interventions: (a) the number of sessions, (b) the length of sessions, and (c) delivery format.
16316891|NCT04560075|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages will receive a monthly check-in text prompt. Based on their response, the participants then receive either general psychoeducational videos and prompts to continue to monitor mental health or are then prompted to endorse stressors and symptoms they are experiencing to prompt awareness of treatment targets in daily life.
16316892|NCT04560075|Active Comparator|Psychoeducational Videos (PE) Only|Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
16316893|NCT04560062||Population in Quito|576 randomly chosen patients with diabetes in District 17D06, Quito (Ecuador)
16316894|NCT04560062||Population in Esmeraldas|576 randomly chosen patients with diabetes in Eloy Alfaro District, Esmeraldas (Ecuador)
16316895|NCT04560049|Experimental|Phenolisation|Surgical pit excision and phenolisation of sinus tract
16316896|NCT04560049|Active Comparator|Silver Nitrate Irrigation|Surgical pit excision and silver nitrate irrigation of sinus tract
16316897|NCT04560036|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
16316898|NCT04560023|Experimental|Exposition to multimedia content|Ad hoc design multimedia content in a tablet (video with sound and subtitles).
16316899|NCT04560023|No Intervention|Standard procedures|Standard procedures.
16316900|NCT04560010|Experimental|Group 1|TXA
16316901|NCT04560010|No Intervention|Group 2|no TXA
16316902|NCT04559997|Experimental|Exercise+FU|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 6 years.
16316903|NCT04559997|Active Comparator|Exercise|After 3 weeks of intensive treatment, no special exercises are performed as a control.
16316904|NCT04559997|No Intervention|Controll|No intervention.
16316905|NCT04559984|Experimental|JUVÉDERM VOLUX®|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional touch-up treatment at week 4 if agreed upon by both the participant and Treating Investigator.
16316906|NCT04559984|Other|Control- No treatment|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
16316907|NCT04559971|Experimental|1.0mg/kg|Drug: SLN124
16316908|NCT04559971|Placebo Comparator|Placebo|
16316909|NCT04559971|Experimental|3.0mg/kg|Drug: SLN124
16316910|NCT04559971|Experimental|Optional Cohort|An additional dose level may be explored
16316911|NCT04559958||non-dialysis CKD group|Participants with estimated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2 more than three months and without regular dialysis will be enrolled in non-dialysis CKD group.
16316912|NCT04559958||ESRD group|Participants with eGFR ≤15 mL/min/1.73 m2 and underwent regular dialysis will be recruited in ESRD group.
16316913|NCT04559958||control group|Participants with eGFR ≧60 mL/min/1.73 m2 and without evidence of kidney damage such as albuminuria or abnormal findings on renal imaging will be enrolled in control group.
16316914|NCT04559945|Experimental|Aveir Leadless Pacemaker|VVIR pacing
16316915|NCT04559932|Experimental|Intervention|The knowledge and self-efficacy pre-tests will be completed at the start of the course and the post-test will be completed after the course at the end of the day. Study participants will complete tests independently using paper and pencil. Six weeks and six months post course completion, the knowledge and self-efficacy tests will be completed using REDcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases or via telephone as per participant preference. Study participants will be sent a link to complete the tests online for the subsequent study visits. Study participants will receive 2 reminder emails (1 week apart) and 1 reminder phone call after the email reminders (if applicable) to complete the tests. Monthly telephone calls by the RA will be made to review the HCP experience logs.
16316916|NCT04559932|No Intervention|Control|Study participants in the control arm will be offered complementary attendance in the Health Tech Junior enterostomy and vascular access competency based training course while awaiting their session. This is being done to minimize the potential confound of generalized improvements in self-efficacy that may occur as a result of participating in an 8 hour learning opportunity at SickKids. The control group will also complete the tracheostomy course during session 3 and 4 but this will occur outside the window of data collection for the study procedures. Data collection intervals as described above for the intervention group will be followed for the control group.
16316917|NCT04559919||Adults with epilepsy|"Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion.
~Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect."
16316918|NCT04559906|Experimental|Group A|Spray and Stretch technique Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
16316919|NCT04559906|Active Comparator|Group B|Sustain pressure release Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
16316920|NCT04559893|Experimental|Collaborative Care|Intervention is administered to patients in this arm. Care to be delivered via collaborative care.
16316921|NCT04559893|No Intervention|Control|Patients in this arm will receive enhanced usual care.
16316922|NCT04559880|Experimental|Tranexamic Acid|"Intra-procedural tranexamic acid (TXA) - 1 gram, IV
~Post-procedural tranexamic acid (TXA) - 1 gram, oral, three times per day for 5 days"
16316923|NCT04559867|Active Comparator|Needle Knife Fistulotomy|The study doctor will gain access to the bile ducts using the cutting technique called a needle knife fistulotomy. When using this technique, the study doctor makes a cut directly into the bile duct.
16316924|NCT04559867|Active Comparator|Sphincterotomy|The study doctor will gain access to the bile ducts using the cutting technique called a sphincterotomy. Using this method, a heated metal wire cuts the opening to the bile duct after a wire has been passed into it.
16316925|NCT04559854|Experimental|Mindful After Cancer|Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.
16316926|NCT04559841|Active Comparator|bone substitute; NanoBone® (group 1, control group)|a synthetic bone substitute consisting of nanocrystalline hydroxyapatite and silica fabricated in a sol-gel process.
16316927|NCT04559841|Experimental|simvastatin + NanoBone (group 2, test group)|medications used to treat hypercholesterolemia
16316928|NCT04559828|Active Comparator|Pomace olive oil|50 g of pomace olive oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
16316929|NCT04559828|Active Comparator|High-oleic sunflower oil|50 g of high-sunflower oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
16316930|NCT04559815||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
16316931|NCT04559802|Experimental|Transmucosal (Non-Submerged)|Flaps will be adapted to the healing abutments for a trans-mucosal healing up on closure
16316932|NCT04559802|Active Comparator|Submerged|Flaps will be advanced to achieve primary wound closure.
16316933|NCT04559789|Experimental|Digital Lifestyle Intervention|Participants randomized to the intervention arm will receive access to a digital intervention consisting of the MindMate cognitive health app and Neurotrack's personalized health coaching platform.
16316934|NCT04559789|Active Comparator|Health Education|Participants randomized to the control arm will receive digital health education materials that mirror the content in the app.
16316935|NCT04559776|Experimental|typically developing toddlers|toddlers with a typical development and with less than 3 years old and less than 6 months of independent walking
16316936|NCT04559776|Experimental|unilateral cerebral palsy toddlers|toddlers with a unilateral cerebral plasy and with less than 3 years old and less than 6 months of independent walking
16316937|NCT04559763||Healthy Adult Volunteers|
16316938|NCT04559750|Experimental|Internet-delivered CBT|10 weeks of CBT delivered via the Internet.
16316939|NCT04559737|No Intervention|Usual Care|Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. Fixed scheduled follow-up visits will be scheduled at 1-month (telephone encounter), 3-months (in-person or video encounter), and 1-year (in-person or video encounter). This sequence of follow-up visits reflects current real-world practice. Patients are eligible for additional visits when self-initiated. Sleep questionnaires will be delivered at 1, 3, and 6 months and at 1 year.
16316940|NCT04559737|Active Comparator|Case Management|Patients will undergo the same follow-up process as described in the Usual Care Pathway. A population CM dashboard (Somnoware, Inc.) will be used to automatically identify PAP strugglers (defined as <70% nights with ≥4 hours use during the preceding month) for 1 year. Video encounters will be triggered for these select patients for troubleshooting. Additionally, throughout this 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the case manager convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year.
16316941|NCT04559724|Experimental|Indego-Assisted Gait Rehabilitation|"Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC):
~subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program;
~Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program.
~During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion."
16316942|NCT04559711|Experimental|Intervention arm|Strengthening coverage and quality of nutrition services including MMS during ANC
16316943|NCT04559711|No Intervention|Comparison arm|Existing provision of nutrition services during ANC.
16316944|NCT04559698|Experimental|immediate training group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the immediate training group will take part in the first 11-week course.
16316945|NCT04559698|Experimental|waitlist control group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the waitlist control group will take part in the second 11-week course.
16316946|NCT04559685|Experimental|Arm A Dose-escalation|In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed SONALA-001 dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.
16316947|NCT04559685|Experimental|Arm B Time-escalation|In Arm B, the time-escalation cohort, the SONALA-001 and power/energy dose combination will be fixed. Participants will be enrolled into two time cohorts (2 days and 6 days post-SDT).
16316948|NCT04559672||Laminoplasty Group|Patients who underwent cervical laminoplasty surgery due to myelopathy.
16316949|NCT04559672||Laminectomy and Fusion Group|Patients who underwent cervical laminectomy and fusion surgery due to myelopathy.
16316950|NCT04559646||"Group A Haemoblock"|"100 patients. Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
16316951|NCT04559646||"Group B Control"|100 patients. Saline solution will be used after pocket formation during pacemaker implantation.
16316952|NCT04559633|Experimental|Anxious school refusal|Adolescents with anxious shool refusal will beneficiate of cognitive and behavioral therapy (CBT) in order to help them to return back to school
16316953|NCT04559620|Experimental|Maternal voice|Mother's voice will be played for 1 week between week 2 and 3 of life
16316954|NCT04559620|No Intervention|Control|NO intervention between week 2 and 3
16316955|NCT04559607|Experimental|Experimental group: TACE+Camrelizumab+Apatinib|Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
16316956|NCT04559607|Active Comparator|Control group: TACE|TACE
16316957|NCT04559581||Patients newly initiating Nintedanib|
16316958|NCT04559568|Experimental|LY3522348 (Part A)|LY3522348 administered orally.
16316959|NCT04559568|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
16316960|NCT04559568|Experimental|LY3522348 (Part B)|LY3522348 administered orally. Some participants will also receive midazolam.
16316961|NCT04559568|Placebo Comparator|Placebo (Part B)|Placebo administered orally. Some participants will also receive midazolam.
16316962|NCT04559542||Female material art athletes|Females practicing material art during recruitment time, in Oslo-area in Norway
16316963|NCT04559529|Experimental|Levetiracetam (LEV), then Placebo|Participants will first receive two 250mg LEV capsules on the same day. After one week, they will receive two placebo capsules on the same day.
16316964|NCT04559529|Experimental|Placebo, then Levetiracetam (LEV)|Participants will first receive two placebo capsules on the same day. After one week, they will receive two 250mg LEV capsules on the same day.
16316965|NCT04559516|Experimental|Mobile application-based home exercise intervention|"The exercise program will be administered over 12 weeks through the Ethica mobile app. Participants will perform exercise sessions at home guided by instructional video accessed via Ethica, six days per week. The program will include a combination of education, endurance, strength, and respiratory muscle training.
~The Ethica mobile app will provide a daily alert and a daily exercise video. There will be background monitoring of step counts and actigraphy will be monitored for one week intervals at baseline, at week six, and at week twelve."
16316966|NCT04559516|Active Comparator|Standard care|No supervised exercise session will be performed. Symptoms and quality of life will be monitored in the same manner as the intervention group, and participants will receive the same educational message alerts through the Ethica app as the exercise intervention group.
16316967|NCT04559503|Experimental|İntervention Group|Progressive relaxation exercises were applied once a day for four weeks in the intervention group in addition to the standard treatments. The patients were called 3 times each week on the telephone, and it was monitored whether they continued to do the exercises.
16316968|NCT04559503|No Intervention|Control group|The control group received standard treatment.
16316969|NCT04559490||Standard formula|Participants receiving intact protein lactose-based formula, exclusively for at least 3 months.
16316970|NCT04559490||Sensitive|Participants receiving intact protein glucose/sucrose- based formula, exclusively for at least 3 months.
16316971|NCT04559477|Experimental|Static extension endurance exercise|static back extension endurance exercise
16316972|NCT04559477|Active Comparator|Dynamic extension endurance exercise|dynamic back extension endurance exercise
16316973|NCT04559464|Other|AeriSeal and Zephyr Valve Treatment|"Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-).
~Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR)."
16316974|NCT04559438|Experimental|Rotary Neoniti GPS|Glide path preparation using Rotary Neniti GPS file (Neolix, châtres-la-Forêt, France).
16316975|NCT04559438|Active Comparator|Stainless steel K-files|Glide path preparation using manual stainless steel K-files #10, #15 (Dentsply Maillefer, Ballaigues, Switzerland).
16316976|NCT04559425||Prospective observational cohort 1|Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
16316977|NCT04559425||Prospective observational cohort 2|Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
16316978|NCT04559412|Experimental|Sofusa Enbrel|Enbrel® administered by the Sofusa® DoseConnect™ delivery system
16316979|NCT04559386|Experimental|Overall trial|People who complete the questionnaire.
16316980|NCT04559373|Experimental|Virtual Reality and Field Practice Training (VRFT)|Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.
16317098|NCT04558398|Experimental|High-intensity interval training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
16316981|NCT04559360|Active Comparator|Active group - PRESTOapp users|Once users are recruited, an independent researcher will randomize the participants using a 1:1 sequential method in two groups of 76 individuals and will assign a 6-digit identification code (IC) to each participant. The IC will be given to the participant on a reminder card and will be used to access the app guaranteeing its confidentiality. The name of the subjects and their respective code will be stored in independent servers for methodological, security and legal reasons. The intervention group will be asked to use the app for a period of 2 months. The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
16316982|NCT04559360|No Intervention|Control group|The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
16316983|NCT04559347|Experimental|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic
16316984|NCT04559347|Active Comparator|Continuous catheter infusion ropivacaine|Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic
16316985|NCT04559334|Other|open label|All participants will receive Tetrasodium EDTA Catheter Lock Solution (KiteLock™ 4% Sterile Catheter Lock Solution)
16316986|NCT04559321|Active Comparator|Holmium laser|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser.
16316987|NCT04559321|Experimental|Trilogy|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with LithoClast Trilogy EMS and 1.5 mm x 440 mm probe
16316988|NCT04559308|Experimental|metformin arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.
16316989|NCT04559308|Active Comparator|control arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.
16316990|NCT04559295|Experimental|Stem Cells (BMC)|Subjects in the BMC arm received an injection of bone marrow concentrate
16316991|NCT04559295|No Intervention|Control|Subjects in the control arm received no treatment for their condition
16316992|NCT04559282|Experimental|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
16316993|NCT04559282|Experimental|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
16316994|NCT04559269||Cohort 1|Cohort of 98 patients suffering from sleep disorders hospitalized between September 2017 and January 2019 in the Sleep Medicine Center of the Croix Rousse Hospital (Lyon) for objective sleepiness evaluation with polysomnography and MWT.
16316997|NCT04559217|Experimental|Single arm with 68Ga-DOTATATE|all participants will undergo a PET scan with 68Ga-DOTATATE
16316998|NCT04559204|Experimental|experimental group|408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
16316999|NCT04559204|Active Comparator|control group A|408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
16317000|NCT04559204|Active Comparator|control group B|408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
16317001|NCT04559191|No Intervention|HbA1c-guided group|Glycemic control is controlled by guideline-recommended HbA1c control.
16317002|NCT04559191|Active Comparator|CGM-guided group|Glycemic control is controlled by CGM-guided control.
16317003|NCT04559165|Experimental|sericin and chitosan cream|Apply sericin and chitosan cream on pressure ulcer 2 times/day for 21 days.
16317004|NCT04559165|Active Comparator|Cavilon cream|Apply cavilon cream on pressure ulcer 2 times/day for 21 days.
16317005|NCT04559152|Experimental|Zinc Supplementation Group|Zinc capsule (20mg) was taken in the morning after meals once daily for 12 weeks. All subjects in this arm were also given iron and folic acid tablets in accordance with the Indonesian government program.
16317006|NCT04559152|Placebo Comparator|Placebo Group|Placebo (sugar tablet) was taken in the morning after meals once daily for 12 weeks. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Each placebo tablet was inserted into a capsule of the same shape and color with zinc capsule
16317007|NCT04559139|Active Comparator|Arm I (surgery, adjuvant therapy)|Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine IV over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16317008|NCT04559139|Experimental|Arm II (neoadjuvant therapy, surgery, adjuvant therapy)|Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized), then undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16317013|NCT04559113|Experimental|Group intervene with Methylprednisolone|"Review effect of Methylprednisolone as clinical trial among hospitalized patients with COVID-19 infection.
~Anyone of the following Corticosteroids dose will be given to moderate disease patients of COVID-19
~0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or
~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day. *Note: in Diabetic patients' dose of methyl prednisolone should be divided in doses preferably 40mg BD."
16317014|NCT04559100||Severe and critical COVID-19 survivors|"Radiological alterations assessed by chest radiography and/or thoracic computed tomography Lung function alterations assessed by spirometry, diffusing capacity for carbon monoxide, 6 minute walk.
~Quality of life alterations: saint george respiratory questionnaire"
16317015|NCT04559087|Experimental|Natural Orifice Specimen Extraction Surgery|
16317016|NCT04559087|Sham Comparator|Conventional laparoscopy|
16317017|NCT04559074|Experimental|Interventional|Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
16317018|NCT04559074|No Intervention|Observational|This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.
16317019|NCT04559048||FK506-treated group|In FK506-treated group, the patients who underwent liver transplant are treated with FK506 immunosuppressive therapy.
16317020|NCT04559048||control group without FK506 treatment|In control group, the patients who underwent liver transplant are treated without FK506.
16317021|NCT04559035|Other|Betadine|"Intervention - twice-a-day nasal lavage Twice-a-day virucidal group: Participants randomized to betadine will receive 2 gallon jugs of distilled water, two NeilMed Sinus Irrigation bottles and 28 salination packets (with some extras), OR one Navage unit with 28 SaltPods (and some extras), and a cardboard receptacle labeled used saline containers to keep track of adherence.
~Those randomized to receive betadine will also receive one bottle of povidone-iodine, a one-sheet instruction with photographs demonstrating how to add ½ tsp betadine in addition to the salination packet to the sinus irrigation bottle or Navage unit reservoir prior to SaltPod, along with a ½ tsp measuring spoon."
16317022|NCT04559035|Other|Baking Soda|"Twice-a-day alkalinized group: Participants randomized to alkalinization will receive 2 gallon jugs of distilled water, two Neilmed bottles with 28 saline packets, OR one Navage unit with 28 SaltPods, and a cardboard receptacle labeled used saline containers to keep track of adherence. Those randomized to alkalinization will also receive a box of baking soda, ½ tsp measuring spoon and instructions on how to add the baking soda."
16317023|NCT04559022|Other|Fat Grafting for Acne Scar Treatment|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
16317024|NCT04558996||OBS COVID 3|"Objective/s The purpose of this study was to test if pregnant patients with COVID-19 have more obstetrical morbidity than those non-infected.
~Determine the variables that are associated with more maternal and neonatal morbidity.
~Quantify the risk of adverse pregnancy outcomes (e.g., miscarriage, stillbirth, growth restriction) and neonatal outcomes (e.g., NICU, prematurity, death, birth defects).
~Design Longitudinal cohort case study to quantify the obstetrical and perinatal morbi-mortality throughout all hospitals in Spain with a universal, consecutive PCR based screening program.
~Recruitment: 1st March 2020 to 30 September 2020. Spanish sites collected in Appendix 1."
16317025|NCT04558996||OBS COVID 4|Substudy 4. Epidemiological prevalence study Objective/s Determine the prevalence of SARS_COV2 infection in Spanish pregnant women Design Cross-sectional study. The nQuery Advisor Release 7.0 software was used to calculate the sample size, based on the available data. As we do not have data on the prevalence of COVID-19, we set an expected percentage of 50% (a situation that maximizes the sample size) of asymptomatic women during delivery. We determined the sample size for a COVID-19 delivery prevalence study with an expected prevalence of 50%, a 95% confidence level and 5% accuracy, resulting in a sample size of 1056 pregnant women.
16317026|NCT04558983||Retinitis Pigmentosa|Patients with Retinitis Pigmentosa
16317027|NCT04558957|Experimental|FLEBOGRIF|Interventions will be performed using Flebogrif catheter.
16317028|NCT04558944|No Intervention|Control group|This group received pain and pruritus medication as needed, received the usual physical therapy as per the protocol of our burn unit, as well as compression garments, silicone sheets and gels and moisturizing cream twice a day. Additionally, the patients were advice on reducing sun exposure and applying +50SPF sunblock on a daily basis.
16317029|NCT04558944|Experimental|Extracorporeal Shock Wave Therapy group|This group received the same treatment as the control group plus Extracorporeal Shock Wave Therapy (The DermaPACE® System, SANUWAVE Health Inc., USA) with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
16317030|NCT04558931|Experimental|A - Isatuximab/CellProtect|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).
~CellProtect will be given IV infusion at the dose of 3x10^7 cells/kg day 29 , 43 and 3-10x10^7 on day 57.
~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
16317031|NCT04558931|Active Comparator|B - Isatuximab|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).
~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
16317096|NCT04558411|Experimental|Assessment + Intervention Group|This group will receive assessments and the 14 brief intervention videos.
16317099|NCT04558372|Experimental|Group 1- 43 COVID-19 patients|COVID-19 patients breath normally via disposable non-rebreathing mask
16317034|NCT04558905|Active Comparator|Usual Medical Care Model|All the patients will receive face-to-face medical visits
16317035|NCT04558905|Experimental|Hybrid Medical Care Model|The patients will receive alternating face-to-face medical visits and video medical consultations
16317036|NCT04558892|Experimental|Nephrotic syndrome - fixed dose (NS-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
16317037|NCT04558892|Experimental|Nephrotic syndrome - adjusted dose (NS-AD)|Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
16317038|NCT04558892|Active Comparator|Control - fixed dose (C-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
16317039|NCT04558879|Experimental|Cardiovascular training|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and through a linear progression will reach vigorous intensity; then, this intensity will be maintained until the end of the intervention. Each session will include five minutes of warm-up and cool-down performed at the beginning and the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool down. CT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
16317040|NCT04558879|Experimental|Resistance training|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
16317041|NCT04558866|Experimental|ExBAT Arm|Testosterone Cypionate 400 mg IM on Day 1 and Darolutamide 1,200mg/day (two 300 tablets every 12 hours) p.o. for 28 days, from day 29 to day 56 followed by a washout period of 7 days (63-day cycles), until loss of benefit (disease progression and/or limiting toxicity).
16317042|NCT04558853|Experimental|Autologous NK cells|"The investigation product is a cell suspension based on ex vivo expanded NK cells from patients with MM. The treatment is strictly autologous. The IP is given as three infusions with escalating doses.
~Mode of administration Intravenous infusions. Dose levels
~First infusion; 5x10^6 cells/kg body weight
~Second infusion; 50x10^6 cells/kg body weight
~Third infusion; 100x10^6 cells/kg body weight"
16317045|NCT04558827|Experimental|Low Carb / Time Restricted Feeding|Participants will eat a low carbohydrate diet (30-60 grams) in a time restricted feeding window (2 meals within 8 hours) daily for the duration of the study (6 months).
16317046|NCT04558814|Other|Systemic lupus erythematosus patients|Evaluation of serum galectin-9 level
16317047|NCT04558814|Other|Control group|Evaluation of serum galectin-9 level
16317048|NCT04558801|Experimental|Mobile application-based lifestyle change program|"This arm receives the mobile application-based lifestyle change program at baseline. The mobile application-based lifestyle change program consists of twice a week content for the first 6 months, continuing with less frequent content for the following 6 months. The follow-up period is 6 months. Weight is measured and blood samples (lipids, glucose and metabolic syndrome measures) are collected at 0, 6, 12, and 18 months.
~The mobile application-based counselling contains aspects of cognitive behavior therapy and persuasive system design and consists of twice a week reminders, tasks, self-monitoring, and reflection."
16317049|NCT04558801|Active Comparator|"The waiting-list control"|"The waiting-list control arm will receive mobile application-based lifestyle change program after 6 months, following same principles as Mobile application-based lifestyle change program-arm, excluding follow-up period (6 months of waiting list, 6 months of more intense and 6 months of less intense application use)."
16317050|NCT04558788||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
16317051|NCT04558788||Colitis|Patients with active colitis
16317052|NCT04558788||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
16317053|NCT04558775||Observational Cohort|
16317054|NCT04558762||Women who had a MUS inserted.|Women who underwent surgery with insertion of a MUS due to SUI 2006-2010 in Sweden with the MUS coming out retropubic (TVT) or through foramen obturatorium (TOT).
16317055|NCT04558762||Controls|Women who have not had a MUS inserted due to stress urinary incontinence. Matched in age.
16317056|NCT04558749||Study group|The study population comprised women that will attend their routine visit to the antenatal clinic. The study population will be recruited by using simple random sampling method after verbal consent will be obtained. Resident in the Department of Obstetrics and Gynaecology who will be trained to administer the questionnaire will interview women. Face masks will be provided to the study population during the process of data collection.
16317097|NCT04558398|Experimental|Resistance exercise training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
16317202|NCT04557618|Experimental|Auricular VNS Stimulation|Participants receive twice daily auricular vagal nerve stimulation
16317057|NCT04558736|Experimental|Haploidentical HCT|"To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.
~Cells for infusion are prepared using the CliniMACS System."
16317058|NCT04558723|Experimental|ICD group|Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.
16317059|NCT04558723|No Intervention|Optimal HF care group|Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.
16317060|NCT04558710||CGM|CGM users
16317061|NCT04558710||SMBG|Non-CGM users
16317062|NCT04558697|Experimental|Shepherd's Purse extractum oleosum vagitories|Vagitories containing Calendulae extractum oleosum 5,5% (w/w), Bursae pastoris extractum oleosum 5,5% (w/w), Matricariae extractum oleosum 5,5% (w/w), Hyperici extractum oleosum 5,5% (w/w) and Millefolii extractum oleosum 5,5% (w/w) as active component
16317063|NCT04558697|Experimental|Tea tree oil vagitories|Vagitories containing tea tree oil, 200 mg per each vagitorie as active component
16317064|NCT04558697|Experimental|Hyperici extractum oleosum vagitories|Vagitories containing Hyperici extractum oleosum 32% (w/w) as active component
16317065|NCT04558697|Active Comparator|Vagitories - Probiotic|Commercially available vagitories with probiotic
16317066|NCT04558684|Experimental|radiotherapy, chemotherapy and PD1 inhibitor|Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
16317067|NCT04558645||Patients with type 1 diabetes mellitus|Patients with Type 1 diabetes mellitus willing to participate in the study
16317068|NCT04558645||Healthy controls|Healthy controls without chronic disease willing to participate in the study
16317069|NCT04558619|Other|Kōmmour Prenatal|
16317070|NCT04558606|Experimental|Sonic toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).
~Each patient is instructed by the hygienist in the correct use of the sonic toothbrush"
16317071|NCT04558606|Active Comparator|Manual toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).
~Each patient is instructed by the hygienist in the correct use of the manual toothbrush"
16317072|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
16317073|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
16317074|NCT04558580|No Intervention|Standard of Care|
16317075|NCT04558580|Experimental|Rufinamide|
16317076|NCT04558567|Other|Open-Label|
16317077|NCT04558554|Experimental|Pharmacy-based PrEP delivery|Participants in this experimental arm (which includes all participants) will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) at community pharmacies in Kenya.
16317078|NCT04558541|Experimental|Sensitivity to phonological rules: Children|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
16317079|NCT04558541|Experimental|Sensitivity to semantic category cues: Children|Arm 1.Referential cue during OR learning.
16317080|NCT04558515||Case|Symptomatic patients positive for malaria by PCR
16317081|NCT04558515||Control|Symptomatic patients negative for malaria by PCR
16317082|NCT04558502|Experimental|minocycline-based bismuth quadruple regimen|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and bismuth potassium citrate 200 mg twice daily for 14 days.
16317083|NCT04558502|Active Comparator|clarithromycin-based bismuth quadruple regimen|Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and bismuth potassium citrate 200 mg twice daily for 14 days.
16317084|NCT04558489|Experimental|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
16317085|NCT04558476|Experimental|Convalescent Plasma|2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
16317086|NCT04558476|Other|Standard of care|Standard of care according the last gold standards
16317087|NCT04558463|Experimental|Favipiravir|The favipiravir group received loading dose and maintenance dose of Favipiravir for 2 up to 7 days in addition to standard therapy
16317088|NCT04558463|Active Comparator|Oseltamivir|The oseltamivir group was given oseltamivir for 7 days.
16317089|NCT04558450|Other|Group 1|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit
16317090|NCT04558450|Other|Group 2|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit
16317091|NCT04558450|Other|Group 3|Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization
16317092|NCT04558450|Other|Group 4|4) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative
16317093|NCT04558424|Experimental|Intervention group|This group will consist of 50 patients who will be treated with zinc and vitamin C at a dose of 220 mg and 1 gram orally daily for 10 days in addition to their standard treatment
16317094|NCT04558424|Placebo Comparator|Placebo group|This group will consist of 50 patients who will receive placebo at a dose same dose for 10 days in addition to their standard treatment.
16317095|NCT04558411|No Intervention|Control Group (assessment only)|This group will receive assessments only.
16317100|NCT04558372|Experimental|Group 2- 40 non COVID-19 patients|Non COVID-19 patients breath normally via disposable non-rebreathing mask
16317101|NCT04558372|Experimental|Group 3- suspected COVID-19 patients|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
16317102|NCT04558359|Active Comparator|Standard of Care Cohort|Patients in this group will receive standard of care treatment.
16317103|NCT04558359|Experimental|Angiotensin II Cohort|Patients in this group will receive angiotensin II.
16317104|NCT04558346|Placebo Comparator|Placebo|"Placebo (40ug/kg) will be self-administered twice daily for 14 days.
~ONLY THE PART B (ACUTE) SUBJECTS WILL BE RANDOMIZED AND MAY RECEIVE PLACEBO."
16317105|NCT04558346|Experimental|Ghrelin (OXE-103)|"OXE-103 (40ug/kg) will be self-administered twice daily for 14 days.
~PART A (POST-ACUTE) SUBJECTS WILL BE OFFERED EXPERIMENTAL TREATMENT WITHOUT RANDOMIZATION.
~PART B (ACUTE) SUBJECTS WILL BE DOUBLE-BLIND RANDOMIZED TO EXPERIMENTAL OR PLACEBO TREATMENT."
16317106|NCT04558333||LTx (lung transplant) patients|identification of possible biomarkers
16317107|NCT04558307||Observational Intervention|Rapid SARS-CoV-2 testing strategy
16317108|NCT04558307||Behavioral Intervention|Community-driven messages to promote COVID-19 testing
16317111|NCT04558281|Experimental|Active Treatment|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
16317112|NCT04558281|Placebo Comparator|Placebo|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline
16317113|NCT04558268|Experimental|treatment group|
16317114|NCT04558268|Placebo Comparator|placebo group|
16317115|NCT04558242|Active Comparator|Genix LLLT Therapeutic Cap|This is a low-level light device containing 150, 650 nanometer LEDs and 50, 940 nanometer LEDs of equal energy output, fixed at 10 milliwatts in a low profile helmet.
16317116|NCT04558242|Sham Comparator|Sham Non-therapeutic Placebo Cap|Sham Placebo Cap low profile helmet containing no low-level light.
16317117|NCT04558229|No Intervention|Standard of Care Clinician Counseling|
16317118|NCT04558229|Experimental|Additional Standardized Counseling|
16317119|NCT04558216|Experimental|Vonoprazan single doses / rifampin single doses|Participants will be administered a single oral dose of 20 mg of vonoprazan oral tablets on Day 1 and Day 17. Participants will also be administered single daily doses of 600 mg rifampin oral capsules on Days 3 through 18.
16317120|NCT04558190|Experimental|Lipid infusion + MitoQ|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion
16317121|NCT04558190|Placebo Comparator|Lipid infusion + placebo|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion
16317122|NCT04558190|No Intervention|Control|Subjects undergo a hyperinsulinemic isoglycemic clamp
16317123|NCT04558190|Other|Lipid infusion + beta2-agonist|Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol
16317124|NCT04558177|Experimental|Stimulation Group|Will receive ~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator
16317125|NCT04558177|Sham Comparator|Device placed only, no stim|Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped
16317126|NCT04558164|Experimental|Active TBS|Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80% of motor threshold (MT).
16317127|NCT04558164|Sham Comparator|Sham TBS|Sham stimulation will be delivered at 10% of motor threshold (MT), with all other parameters matching the active TBS condition.
16317130|NCT04558138|Experimental|Discharge day of surgery|Patient discharges day of surgery and given surveys to complete at home on post operative day (POD) #1 and #7.
16317131|NCT04558138|No Intervention|Discharge post operative day 1|Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
16317134|NCT04558112|Experimental|100 mg L-DOPA|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
16317135|NCT04558112|Placebo Comparator|Placebo|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
16317136|NCT04558099|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
16317137|NCT04558099|No Intervention|Wait-list control|Usual practice
16317138|NCT04558086|Experimental|Reduce pain and fear|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
16317139|NCT04558086|Experimental|control group|To develop the intervention strategies of hospitalized school-age children with IV placement, using photo book to further examine the effectiveness of reducing IV pain and fear.
16317203|NCT04557618|Sham Comparator|Sham Auricular VNS Stimulation|Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied
16317140|NCT04558073|Experimental|Body Project (BP)|The BP intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
16317141|NCT04558073|Experimental|Healthy Weight Program (HW)|The HW intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
16317142|NCT04558073|No Intervention|Waiting-list (WL)|The waiting list will consist of two assessments each separated by a one-month interval. Following this waiting time, participants will receive the BP intervention.
16317143|NCT04558060|Experimental|Virtual Standardized Patient|Training for 45 minutes at each training time point with a computer program that presented a virtual human patient and two simulated patient encounters. The virtual standardized patient involves a branching story line. Participants select 1 of 3 computer-generated response options at each conversational pause: 1) a response that is consistent with the principles and skills of MI, 2) an MI inconsistent response, or 3) a response that is mixed - partly consistent and partly inconsistent with MI.
16317144|NCT04558060|Active Comparator|Academic Study|Study of a summary handout of motivational interviewing concepts and techniques for 45-minutes.
16317145|NCT04558034|Active Comparator|Interventioncryotherapy/control|Subjects will have one mitt/one slipper and serve as their own control
16317146|NCT04558034|No Intervention|standard of care|Subjects will have two mitts/slippers
16317147|NCT04558021|Experimental|Intervention Arm-I|Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
16317148|NCT04558021|Placebo Comparator|Intervention Arm-II|10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
16317149|NCT04558008|Experimental|Online MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
16317150|NCT04558008|No Intervention|Wait-list control|Usual practice
16317151|NCT04557995|Experimental|Erythropheresis treatment|Erythropheresis treatment was was added to routine treatment
16317152|NCT04557995|No Intervention|Routine treatment|Oxygen delivery and basic care
16317153|NCT04557982||Children aged 3 < 4 years|Children aged 3 < 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
16317154|NCT04557982||Children aged 4 < 5 years|Children aged 4 < 5 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
16317155|NCT04557982||Children aged 5 < 6 years|Children aged 5 < 6 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
16317156|NCT04557969||1/ Cohort 1|Patients with histologically confirmed or clinical presentation suspicious of GIST
16317157|NCT04557956|Active Comparator|ARM I (tazemetostat) phase II|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients may crossover to Arm II after completion of radiation therapy.
16317158|NCT04557956|Experimental|ARM II (tazemetostat, dabrafenib, trametinib) phase I/phase II|Patients receive tazemetostat orally PO BID, dabrafenib PO BID, and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16317159|NCT04557943|Active Comparator|Sodium Hyaluronate|Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
16317160|NCT04557943|Experimental|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:
~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
16317161|NCT04557930|No Intervention|Usual Care Control|The control arm occurs prior to receipt of the video game intervention. Each hospital group 'crosses over' from control to intervention at a randomized time point.
16317162|NCT04557930|Experimental|Video Game Intervention|Each hospital group 'crosses over' from control to intervention at a randomized time point by receiving a study iPad and playing the video game loaded on the iPad.
16317163|NCT04557904|Experimental|Group A: Craniocervical flexion exercises|Exercise protocol were performed over a 4 week duration under the command of a supervisor. Subjects were asked not to obtain any other particular intervention for cervical ache. Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible.
16317204|NCT04557605|Active Comparator|No face mask|Progressive step-exercise cycling test to exhaustion wearing no face mask
16317164|NCT04557904|Experimental|Group B: Scapular stabilization exercises|Group B performed scapular stabilization workout for 30 minutes per session, three days a week for four weeks. The scapular stabilization exercises were made up of four stages
16317165|NCT04557878|Experimental|Hypertonic Dextrose Solution|
16317166|NCT04557878|Active Comparator|Liquid Phase Concentrated Growth Factor (LPCGFs)|
16317167|NCT04557865|Experimental|Participants receving 18F-PMPBB3 (APN-1607) PET imaging|Single arm, open label
16317168|NCT04557852||Anterior transvaginal mesh group|Women received anterior transvaginal mesh surgery without concomitant mid-urethral sling surgery.
16317169|NCT04557839|Active Comparator|Traditional physical therapy balance exercise|Traditional physical therapy including balance exercise on mate and swiss ball.
16317170|NCT04557839|Experimental|proprioception based balance training|proprioception based balance training with eye open and close on soft , firm and foam surface.
16317171|NCT04557826|Experimental|RD19 Experimental Device|RD19 Experimental Device used twice/day for 3 minutes each use at least 4 hours, and preferably 8-12 hours, apart
16317172|NCT04557813||IC before start of any treatment|Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
16317173|NCT04557813||IC after start of any treatment|IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.
16317174|NCT04557813||Deceased patients|Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.
16317175|NCT04557800|Experimental|DNL151|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
16317176|NCT04557800|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
16317177|NCT04557787|Active Comparator|Intermittent catheter; SpeediCath® standard Female|Standard of care
16317178|NCT04557787|Experimental|New intermittent catheter variation 1 for females|Intermittent catheter variation 1 for females. The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
16317179|NCT04557787|Experimental|New intermittent catheter variation 2 for females|Intermittent catheter variation 2 for females. The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
16317180|NCT04557774||Liver cirrhosis group|All included patients were asymptomatic at the baseline with no evidence of neurological impairment. Patients with a history of moderate alcohol drinking plus hepatitis B/C virus infection, medication for sedation, MELD (Model for End-stage Liver Disease) score of more than 20, OHE, seizure, head trauma, stroke, dementia, Parkinson's disease, or any kind of focal neurologic deficits were excluded. Any patients who were suspected of alcohol induced direct neurologic damages such as Wernicke's encephalopathy, alcohol induced spinal cord disease, or alcohol induced peripheral nerve disease were excluded. After evaluating the data including the laboratory findings, image findings, endoscopic findings, and medical records of all these patients, as well as liver biopsy findings for some patients, we sub-classified these 88 patients into two groups: alcoholic LC and viral LC. Finally, 80 patients (viral: 37; alcohol: 43) with compensated LC were prospectively considered in this study.
16317181|NCT04557761|Experimental|Closure with microMend® Arm|The microMend® wound closure product will be used to close the Subject's laceration. The wound will be covered with a non-stick dressing.
16317182|NCT04557761|Active Comparator|Closure with Sutures Arm|The Subject's laceration will be closed with sutures. The standard method for suture closed wounds will be followed in accordance with regular institutional policies and procedures.
16317183|NCT04557748||Prospective Observational Cohort Study|Men and women with lower urinary tract symptoms.
16317184|NCT04557748||Prospective Observational Cohort Study Controls|Men and women who do not have urinary dysfunction.
16317185|NCT04557748||Central Sensitization Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
16317186|NCT04557748||Central Sensitization Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
16317187|NCT04557748||Physical Activity and Sleep Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
16317188|NCT04557748||Physical Activity and Sleep Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
16317189|NCT04557748||Organ-Based Study|Women enrolled in the Prospective Observational Cohort Study with urinary urgency, with and without urgency incontinence.
16317190|NCT04557748||Organ-Based Study Controls|Women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency pr urgency incontinence.
16317191|NCT04557748||Qualitative Assessment of Patients with Urinary Urgency Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency who have treatment plans prescribed at the baseline visit.
16317192|NCT04557735|Experimental|Ravulizumab plus Best Supportive Care|Participants will receive ravulizumab plus Best Supportive Care as background therapy.
16317193|NCT04557722|Active Comparator|Group 1: 0-30° technique.|Procedure: 0-30° Biplanar Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
16317194|NCT04557722|Active Comparator|Group 2: new 0-90° technique.|Procedure: new 0-90° Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
16317195|NCT04557709||Observational (chart review)|Patients' medical charts are reviewed.
16317198|NCT04557657|Experimental|Control Group Resin cement|Control group Using resin cement
16317199|NCT04557657|Active Comparator|Intervention Group Active Cement|Intervention Group Using active cement bio activa
16317200|NCT04557644|Active Comparator|medical staff treating patients with scabies|
16317201|NCT04557644|Active Comparator|family infested with scabies|
16317205|NCT04557605|Experimental|Disposable face mask|Progressive step-exercise cycling test to exhaustion wearing a 3-ply disposable face mask
16317206|NCT04557605|Experimental|Cloth face mask|Progressive step-exercise cycling test to exhaustion wearing a cloth face mask
16317207|NCT04557579||Bifocal group|Patients in bifocal group implanted with Restor +2.5D IOL (Alcon, Fort Worth, TX, USA) in bilateral eyes
16317208|NCT04557579||Extended depth of focus group|Patients in extended depth of focus group implanted with EDOF Symfony IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
16317209|NCT04557579||Monofocal group|Patients in monofocal group implanted with Sensar AR40e IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
16317210|NCT04557566|Active Comparator|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
16317211|NCT04557566|No Intervention|Control|Wait list control
16317212|NCT04557553|Experimental|Lagenbone|Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
16317213|NCT04557540|Experimental|Arm I (Fasting WORD)|Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
16317214|NCT04557540|Experimental|Arm II (The WORD)|Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
16317215|NCT04557527|Other|control|Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.
16317216|NCT04557527|Active Comparator|treatment|Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.
16317217|NCT04557514|Active Comparator|platelet rich plasma injection in post burn facial scar|"prp in subgroup allocation 1:1 Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes
~Do not chill the blood at any time before or during platelet separation.
~Centrifuge the blood using a 'soft' spin.
~Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).
~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.
~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.
~Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube."
16317218|NCT04557514|Active Comparator|fat injection in post burn facial scar|After aspiration of the fatty tissue, it is important that nonviable components of the aspirate, such as oil, blood, and local anesthetics are removed and, at the same time, the quality, integrity, and viability of the adipocytes and the inherent mesenchymal stem cells in the aspirate be maintained. Processing techniques are sedimentation , filtering and washing There is no consensus as to the optimal method of fat graft preparation.
16317219|NCT04557501|Active Comparator|Control - SOC Treatment|Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.
16317220|NCT04557501|Experimental|Experimental - PSMAiTx|Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.
16317221|NCT04557488|Experimental|Music therapy|The treatment group will receive social skill intervention using music therapy in groups of eight. A certified music therapist with prior experience with children with ASD and ID will be the trainer for the treatment group. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to facilitate the group activities, manage unexpected situations, and ensure the safety of the participants.
16317222|NCT04557488|Experimental|Behavioral-based social skill training|The control group will receive behavioral-based social skill training in groups of eight. The trainer will be a registered social worker with experience in providing social skill training for children with ASD and ID. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to provide support.
16317223|NCT04557475|Experimental|ASA Group|Receives standard of care and intervention.
16317224|NCT04557475|No Intervention|SOC Group|Receives standard of care (SOC), only
16317225|NCT04557462|Experimental|LNP023|All participants are receiving 200 mg b.i.d
16317226|NCT04557449|Experimental|1A Monotherapy Escalation Arm 1|PF-07220060 Monotherapy Escalation
16317227|NCT04557449|Experimental|1A Monotherapy Escalation Arm 2|PF-07220060 Monotherapy Escalation
16317228|NCT04557449|Experimental|1A Monotherapy Escalation Arm 3|PF-07220060 Monotherapy Escalation
16317229|NCT04557449|Experimental|1A Monotherapy Escalation Arm 4|PF-07220060 Monotherapy Escalation
16317230|NCT04557449|Experimental|1B Combination Dose Finding Arm 1|PF-07220060 with Letrozole combination Escalation
16317231|NCT04557449|Experimental|1B Combination Dose Finding Arm 2|PF-07220060 with Letrozole Combination Escalation
16317232|NCT04557449|Experimental|1C Combination Dose Finding Arm 1|PF-07220060 with Fulvestrant Combination Escalation
16317233|NCT04557449|Experimental|1C Combination Dose Finding Arm 2|PF-07220060 with Fulvestrant Combination Escalation
16317234|NCT04557449|Experimental|2B Combination Dose Expansion|PF-07220060 with Letrozole Combination Expansion
16317235|NCT04557449|Experimental|2C Combination Dose Expansion|PF-07220060 with fulvestrant Combination Expansion
16317236|NCT04557449|Experimental|1D Monotherapy Food Effect|PF-07220060 Monotherapy Food Effect
16317237|NCT04557449|Experimental|1A Monotherapy Escalation Arm 5|PF-07220060 Monotherapy Escalation
16317238|NCT04557436|Other|Standard of care|"Follow-up period:
~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.
~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.
~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m
~Physical examination, ECOG
~Laboratory tests
~Vital signs (temperature, BP, HR, respiratory rate, weight)
~Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)
~Chimerism and MRD in blood and bone marrow (if sampled)
~Adverse events
~Concomitant treatments"
16317239|NCT04557423|Active Comparator|Evidence-Based Intervention|Culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided.
16317240|NCT04557423|Experimental|HPV Self-Sampling|Previously tested evidence-based intervention (i.e. culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided). Participants will also receive a self-sampling kit.
16317241|NCT04557410|Experimental|Receiving Supplement|Participants receive supplement PolyMVA. Dose is 2 teaspoons twice a day.
16317242|NCT04557397|Other|Part A|Subjects will receive fruquintinib, alone and with itraconazole.
16317243|NCT04557397|Other|Part B|Subjects will receive fruquintinib, alone and with rifampin.
16317244|NCT04557384|Experimental|Ramucirumab|Ramucirumab given subcutaneously (SC).
16317245|NCT04557371|Experimental|Developmental Serum|The participants will apply a developmental serum topically to the face twice daily (morning and evening) to freshly cleansed with normal moisturizing routine for 21 days.
16317246|NCT04557371|Experimental|Developmental Lotion|The participants will apply a developmental lotion topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
16317247|NCT04557371|Experimental|Developmental Cream|The participants will apply a developmental cream topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
16317248|NCT04557358||Rheumatic diseases outpatients|"All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic.
~In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)"
16317249|NCT04557345||Biological prostheses INC|"Prosthetic valve manufactured in the National Institute of Cardiology Ignacio Chávez."
16317250|NCT04557345||Imported Biological aortic prostheses|St Jude EPIC and Carpentier-Edwards Perimount
16317251|NCT04557345||Mechanical prostheses|St Jude Masters HP, Carbomedics Standart, ON-X Life Technologies, Edwards Mira, Carbomedics Orbis, Medtronic Hall and Medtronic ATS.
16317252|NCT04557345||Control|In subjects who come to donate blood products altruistically, in the blood bank service of the INC, with prior informed consent, the subjects will be matched with PO patients of CVA by age and gender.
16317253|NCT04557332|Experimental|Mobile app|In this arm, participants received a mobile app to support ART medication adherence.
16317254|NCT04557332|No Intervention|Control|In this arm, participants received care as usual.
16317255|NCT04557319|Experimental|GNR-038, 25 МЕ/kg|Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion
16317256|NCT04557319|Experimental|GNR-038, 50 МЕ/kg|Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion
16317257|NCT04557319|Experimental|GNR-038, 100 МЕ/kg|Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion
16317258|NCT04557306|Experimental|CBT101 q2w|CBT101 (2-6 x 10^9 cells), every 2 weeks
16317259|NCT04557306|Experimental|CBT101 q4w|CBT101 (2-6 x 10^9 cells), every 4 weeks
16317260|NCT04557293|Experimental|CPAP Treatment|Patients with OSA will undergo cognitive assessment before starting CPAP treatment and after six months of CPAP use.
16317261|NCT04557293|No Intervention|Control Group|We will enrol a control group of subjects without sleep disorders and comparable to OSA patients for age and schooling. Control group will undergo cognitive assessment.
16317262|NCT04557280|Experimental|Treatment A: liquid formulation via auto-injector|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an auto-injector forming an integral ready-to-use single-dose drug delivery system.
16317263|NCT04557280|Experimental|Treatment B: liquid formulation via syringe|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe.
16317264|NCT04557280|Experimental|Treatment C: lyophilizate-based formulation via syringe|Selatogrel will be administered as a reconstituted lyophilizate-based formulation for injection.
16317265|NCT04557267|Experimental|Group A (dosage A)|The lower dose of the active drug
16317266|NCT04557267|Experimental|Group B (dosage 2)|The middle dose of the active drug
16317267|NCT04557267|Experimental|Group C (dosage 3)|The higher dose of the active drug
16317268|NCT04557267|Placebo Comparator|Group D (placebo)|Placebo
16317269|NCT04557254||silver-triclosan graft implantation (SynG group)|
16317270|NCT04557254||standard Dacron graft implantation (DacrG group)|
16317271|NCT04557241|Experimental|Brief Intervention arm|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process (as described in the Intervention section). This arm will introduce the intervention and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection.
16317272|NCT04557241|Placebo Comparator|Placebo Control arm|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (As described in the Placebo Control section). This arm will introduce the control infographic and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection."
16317273|NCT04557228|Placebo Comparator|Placebo|Study participants will receive 4 weeks of supplementation with 400mg placebo supplements
16317274|NCT04557228|Experimental|Phosphatidylserine Supplementation|Study participants will receive 4 weeks of supplementation with 400mg phosphatidylserine supplements.
16317275|NCT04557215|Active Comparator|Standard dose for IBS-D|Rifaximin 550 mg
16317276|NCT04557215|Placebo Comparator|Traveler's diarrhea dose + placebo|Rifaximin 200 mg + placebo
16317277|NCT04557215|Experimental|Traveler's diarrhea dose + NAC|Rifaximin 200 mg plus N-acetylcysteine (NAC) 600 mg days
16317278|NCT04557202|Active Comparator|Group A|Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively
16317279|NCT04557202|Placebo Comparator|Group B|62 patients who underwent non-stented ureteroscopy and laser and received placebo.
16318692|NCT04547855|Experimental|experimental group|anlotinib combined with dose-dense temozolomide
16317280|NCT04557189|Experimental|Group A|Prophylaxis with ondansetron placebo intravenous (IV) immediately before induction and 4 mg TAK 951 subcutaneous (SC) approximately 30 to 45 minutes before the end of surgery (wound closure).
16317281|NCT04557189|Experimental|Group B|Prophylaxis with 4 mg ondansetron IV immediately before induction and TAK-951 placebo SC approximately 30 to 45 minutes before the end of surgery (wound closure).
16317282|NCT04557176|Experimental|POC CRP-based TB screening|Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
16317283|NCT04557176|No Intervention|Symptom-based TB screening|Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
16317284|NCT04557163|Experimental|Subjects receiving TS-142 and itraconazole|Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.
16317285|NCT04557150|Experimental|Part I: Dose Escalation|Participants will receive RO7425781 as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
16317286|NCT04557150|Experimental|Part II: Dose Expansion|Dose Expansion cohorts with IV and/or SC administration will be initiated at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) determined from Part I: Dose Escalation.
16317287|NCT04557137||NET|"Study A:
~A cross-sectional study that investigates 250 patients (Cohort A) with neuroendocrine neoplasia, encompassing both patients with neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).
~Study B:"
16317288|NCT04557137||Newly diagnosed NET|A prospective study that investigates 30 newly diagnosed NET patients over three months (Cohort B) who are offered palliative treatment with somatostatin analogues.
16317289|NCT04557124|Experimental|USS|social cognitive training
16317290|NCT04557124|Active Comparator|MovingForward|problem solving training
16317291|NCT04557098|Experimental|Part 3: Teclistamab|Participants in all cohorts will receive teclistamab SC at an RP2D.
16317292|NCT04557085|Placebo Comparator|Placebo|Placebo
16317293|NCT04557085|Experimental|Cenobamate 100 mg/day|Cenobamate 100 mg/day
16317294|NCT04557085|Experimental|Cenobamate 200 mg/day|Cenobamate 200 mg/day
16317295|NCT04557085|Experimental|Cenobamate 400 mg/day|Cenobamate 400 mg/day
16317296|NCT04557072||The selective alpha-blockade group|Patients treated with selective alpha-blockade before pheochromocytoma surgery
16317297|NCT04557072||The non-selective alpha-blockade group|Patients treated with non-selective alpha-blockade before pheochromocytoma surgery
16317298|NCT04557059|Active Comparator|Interventional Cohort (Group 1): RT+ LHRHa|Participants who are PSMA-PET-positive will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation on Day 1 and at Day 85, or as a 6-monthly depot preparation on Day 1.
16317299|NCT04557059|Experimental|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants who are PSMA-PET-positive receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation on Day 1 and at Day 85, or as a 6-monthly depot preparation on Day 1. Participants will also receive 240 milligram (mg) of apalutamide starting at Day 1 as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
16317300|NCT04557059|No Intervention|Observational Cohort(Group3) PSMA-PET Negative Particitpans|Participants who are PSMA-PET-negative at screening,, will be enrolled in the Observational Cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year.
16317301|NCT04557046|Other|Group A: Sample Collection|Nasal Swab and Saliva Sample Collection
16317302|NCT04557046|Other|Group B: Sample Collection|Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection
16317303|NCT04557046|Other|Group C: Sample Collection|Nasal Swab, Throat Swab and Saliva Sample Collection
16317304|NCT04557046|Other|Group D: Sample Collection|Nasopharyngeal Swab and Saliva Sample Collection
16317305|NCT04557046|Other|Group E: Sample Collection|Nasal swab
16317306|NCT04557033|Experimental|Mindful Meditation|"The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.
~The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
~Participants will be asked to complete brief surveys before and after the intervention activity."
16317307|NCT04557020|Experimental|Arm A|
16317308|NCT04557020|Active Comparator|Arm B|
16317309|NCT04557007||Treatment-naive NSCLC patients|Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
16317310|NCT04556994|Active Comparator|Phase 1 Cardiac Rehabilitation|Phase 1 Cardiac Rehabilitation
16317311|NCT04556994|Experimental|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Phase 1 Cardiac Rehabilitation with lower limb paddling
16317312|NCT04556981|Experimental|M72/AS01E vaccine|
16317313|NCT04556981|Placebo Comparator|Placebo|
16317344|NCT04556773|Experimental|Module 1: T-DXd + capecitabine|T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
16317345|NCT04556773|Experimental|Module 2: T-DXd + durvalumab + paclitaxel|T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
16317314|NCT04556955|Placebo Comparator|post isometric relaxation and exercises|Group A included Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier and conventional exercise program ; this program included Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions).This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the End of treatment, i.e. ROM, pain intensity by NPRS and PPT , functional disability.
16317315|NCT04556955|Experimental|Graston technique and exercises|Group B included Graston Technique to Upper Trapezius and Levator Scapulae.This instrumented-assisted soft tissue massage applied with deeper pressure to the area of concern.The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions). This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the END of treatment , i.e. ROM, pain intensity by NPRS and PPT , functional disability.
16317316|NCT04556942|Experimental|Group 1 (Immediate Group)|"Group 1:
~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:
~Flow mediated dilation measurement
~Blood pressure, pulse, blood oxygenation saturation measurement
~Fit bit tracker counting steps and distance during 7 days
~SGRQ (St Georg Respiratory Questionnaire)
~Withdrawal of a blood sample for preservation for later examinations
~This group will receive endobronchial valve placement (EVP) within 1-2 weeks after T0.
~At T1 which will be 4-6 weeks after EVP the measurements done at T0 will be repeated."
16317317|NCT04556942|Other|Group 2 (Delayed Group)|"Group 2:
~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:
~Flow mediated dilation measurement
~Blood pressure, pulse, blood oxygenation saturation
~Fit bit tracker counting steps and distance during 7 days
~SGRQ (St Georg Respiratory Questionnaire)
~Withdrawal of a blood sample for preservation for later examinations
~This group will receive endobronchial valve placement (EVP) 6-8 weeks after T0. A few days before that the investigators repeat the measurement taken at T0."
16317318|NCT04556929|Experimental|Intraoperative imaging of 5-ALA during tumour resection|Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.
16317319|NCT04556916|Experimental|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
16317320|NCT04556916|Experimental|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
16317321|NCT04556903|Experimental|Bilateral Arm Training|Bilateral Arm Training
16317322|NCT04556903|Active Comparator|modified constrained induce movement therapy|modified constrained induce movement therapy
16317323|NCT04556890|Experimental|Active rTMS/Active iTBS DFPLC/Sham Pain M1|
16317324|NCT04556890|Experimental|Sham rTMS/ Active iTBS Pain|
16317325|NCT04556890|Experimental|Active rTMS/Active iTBS|
16317326|NCT04556877||Intraabdominal pressure under 12 mmHg|Patients with intraabdominal pressure under 12 mmHg
16317327|NCT04556877||Intraabdominal pressure between 12-20 mmHg|Patients with intraabdominal pressure between 12-20 mmHg
16317328|NCT04556877||Intraabdominal pressure over 20 mmHg|Patients with intraabdominal pressure over 20 mmHg
16317329|NCT04556864||Description Group|"For each patient included in the study, the secondary variables will be noted in the patient's data collection logbook.
~This is followed by radial artery cannulation (if absent), and connection to the HemoSphere/EV1000 platform
~After the daily visit, the PI/collaborating investigators (CI) will measure the clinical, treatment, and mechanical ventilation parameters of the patient during the last 24 hours.
~Daily arterial analysis will be requested
~This information collection process will be followed for 5 days. At the end of the information collection period, the IP will perform two downloads, the engineering download, and the standard download in which the values are monitored every 20 seconds.
~These will be noted in the secondary variables of the data collection logbook, along with the patients' ICU discharge date.
~In-hospital mortality will be monitored during admission to a conventional hospital ward.
~Records will be closed upon discharge of the patient."
16317330|NCT04556851|Experimental|HSK7653 10 mg|
16317331|NCT04556851|Experimental|HSK7653 25 mg|
16317332|NCT04556851|Placebo Comparator|Placebo|
16317336|NCT04556825|Experimental|Study group|Arthroscopic treatment with PRP injection
16317337|NCT04556825|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
16317338|NCT04556812|Experimental|Study group|"underwent four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
16317339|NCT04556812|Placebo Comparator|Control group|traditional soft tissue surgery
16317340|NCT04556799|Experimental|Study group|3D osteotomy template for derotation osteotomy with the aid of computer-assisted simulated surgery technique
16317341|NCT04556799|Experimental|Control group|traditional osteotomy technique
16317342|NCT04556786|Experimental|Transitions of care|The study participants in this aim received usual care plus medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist.
16317343|NCT04556786|No Intervention|Usual care|The study participants in this arm received usual care.
16317347|NCT04556773|Experimental|Module 4: T-DXd + anastrozole|T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
16317348|NCT04556773|Experimental|Module 5: T-DXd + fulvestrant|T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
16317349|NCT04556760|Experimental|Cohort 1|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (72 mg AZD9567 followed by 40 mg prednisolone [AB sequence group] or 40 mg prednisolone followed by 72 mg AZD9567 [BA sequence group]).
16317350|NCT04556760|Experimental|Cohort 2|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (40 mg AZD9567 followed by 20 mg prednisolone [AB sequence group] or 20 mg prednisolone followed by 40 mg AZD9567 [BA sequence group]).
16317351|NCT04556760|Active Comparator|Cohort 3|Participants will be randomised in a ratio of 1:1 to receive placebo and prednisolone over two 72 hour periods in a cross over design (placebo followed by 5 mg prednisolone [AB sequence group] or 5 mg prednisolone followed by placebo [BA sequence group]).
16317352|NCT04556747|Other|VR - Distraction|
16317353|NCT04556747|Other|VR - Biofeedback|
16317354|NCT04556734|Experimental|Etrasimod 2 mg|
16317355|NCT04556734|Experimental|Etrasimod 3 mg|
16317356|NCT04556734|Placebo Comparator|Placebo|
16317357|NCT04556721|Experimental|Sugammadex|After surgery and general anesthesia, a clinically-appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade. Either 2 mg/kg or 4 mg/kg dosing will be used based on the level of neuromuscular blockade at the time of reversal. Administer as single IV bolus injection infused over 10 seconds into existing IV line. Dose is based on actual body weight (mg/kg).
16317358|NCT04556708|Active Comparator|saline control group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
16317359|NCT04556708|Active Comparator|ozone group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozoned water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
16317360|NCT04556708|Active Comparator|chlorhexidine group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
16317361|NCT04556695||Questionnaire survey|An initial online questionnaire, based on the International Sedentary Assessment Tool (ISAT), will be distributed to General Practice Specialty Trainees (GPSTs) and General Practitioners (GPs) throughout Northern Ireland.
16317362|NCT04556695||Accelerometer study|A purposive sample of questionnaire respondents will be asked to participate in the accelerometer study. This purposive sample will be based on responses to the online questionnaire. The aim will be to obtain a varied sample, based on questionnaire responses, by selecting individuals with a range of demographic characteristics and self-reported levels of sedentary behaviour. Some participants will also be asked to complete a further online survey, while wearing the accelerometer, regarding their health, wellbeing, burnout and fatigue.
16317363|NCT04556695||Semi-structured interview study|A purposive sample comprising participants of the accelerometer study will be asked to participate in semi-structured interviews. This purposive sample will be based on the accelerometer data. The aim will be to obtain a varied sample, based on accelerometer data, by selecting individuals with a range of different levels of sedentary behaviour, demographic and workplace characteristics. The final number of participants will depend on the saturation of information.
16317366|NCT04556669|Experimental|CD22（aPD-L1）CAR-T cells|
16317369|NCT04556643|Experimental|Intervention Group|Two sessions will be given to pregnant women in Intervention group. One session breathing exercises training will be given during first stage of labor by the investigator. During training all participants in Intervention group will be instructed to perform breathing exercises during the second stage of labor.
16317370|NCT04556643|No Intervention|Control Group|Usual hospital delivery protocol will be followed.
16317410|NCT04556344|Experimental|Emotional skills|3 individual sessions in which patients are going to learn how to identify, understand, express and regulate emotions
16318903|NCT04546347|Experimental|AZD9833 Oral Solution|Dose 1 AZD9833 oral solution
16317371|NCT04556617|Experimental|PLX2853 + Abiraterone Acetate + Prednisone|"Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled.
~Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled."
16317372|NCT04556617|Experimental|PLX2853 + Olaparib|"Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.
~Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled."
16317373|NCT04556604||1|First cycle of the audit on consenting practice pre intervention
16317374|NCT04556604||2|Second cycle of the audit on consenting practice to assess change following intervention
16317375|NCT04556604||3|Third cycle of the audit on consenting practice to assess long term compliance
16317376|NCT04556591|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of health related quality of life (HRQOL) over a three-month (90 day) period (without the personalized feedback).
16317377|NCT04556591|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of health related quality of life (HRQOL) and receive personalized pushes over a three-month (90 day) period.
16317378|NCT04556578|Experimental|High-flow ECCO2R|Extracorporeal support using high flow circulation
16317379|NCT04556565||General population|A representative sample of the general adult population (including those tele-working and working outside of home)
16317380|NCT04556565||Cases and contacts|Recently isolated or quarantined COVID-19 cases and close contacts
16317381|NCT04556565||Healthcare workers|Healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers)
16317382|NCT04556552|Experimental|Active non-invasive Vagal nerve stimulation (VNS)|Active non-invasive Vagal Nerve Stimulation (nVNS) with opioid cues.
16317383|NCT04556552|Sham Comparator|Sham stimulation|Sham stimulation of vagus with opioid cues
16317384|NCT04556539|Experimental|SC10914 group|
16317387|NCT04556513||Patient|Patient hospitalized in ICU for PCR-proven SARS-COV-2 infection
16317388|NCT04556461|Experimental|Tralokinumab|Tralokinumab 600mg loading dose s.c., followed by 300mg every other week.
16317389|NCT04556448|Experimental|Aligners|Invisalign treatment
16317390|NCT04556448|Active Comparator|Traditional braces|Clear braces
16317391|NCT04556435||LC Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.
16317392|NCT04556435||Control Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).
16317393|NCT04556422|Active Comparator|Sauna alone|Sauna exposure for 30 minutes
16317394|NCT04556422|Experimental|Exercise and Sauna|Cycling exercise for 15 minutes followed by sauna for 15 minutes
16317395|NCT04556409|Experimental|low intensity pulsed ultrasound|20 women were treated by low intensity pulsed ultrasound (5 min, 0.5 w/cm2, 1MHZ with 20% duty cycle, 3 times/ week for 4 weeks plus static abdominal and pelvic floor exercises.
16317396|NCT04556409|Experimental|low level laser therapy|20 women were treated by low level laser therapy (Gallium Aluminum Arsenide Laser), 808nm, 4J/cm2, pulsating signal, 60 seconds for each point, 30 Mw/cm2, 3 times/week for 4 weeks plus static abdominal and pelvic floor exercises.
16317397|NCT04556409|Placebo Comparator|static abdominal and pelvic floor exercises|20 women were the control group who received only static abdominal and pelvic floor exercises. , 3 times/week for 4 weeks.
16317398|NCT04556396|Experimental|Intervention arm|This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
16317399|NCT04556396|No Intervention|Retrospective arm|This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.
16317400|NCT04556383|Experimental|GB004 Dose A|GB004 dose A for oral administration for 36 weeks
16317401|NCT04556383|Experimental|GB004 Dose B|GB004 dose B for oral administration for 36 weeks
16317402|NCT04556383|Placebo Comparator|Placebo|Placebo for oral administration for 36 weeks
16317403|NCT04556383|Experimental|Open-Label GB004 Dose A|GB004 dose A for oral administration for 24 weeks
16317404|NCT04556370|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
16317405|NCT04556370|Experimental|0.025 μg/kg/min group|A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
16317406|NCT04556370|Experimental|0.050 μg/kg/min group|A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
16317407|NCT04556370|Experimental|0.075 μg/kg/min group|A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block
16317408|NCT04556357|Active Comparator|Control group|Phenylephrine infusion simultaneous with subarachnoid block
16317409|NCT04556357|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with subarachnoid block
16317411|NCT04556344|Sham Comparator|Short free talk and relaxation|3 individual sessions in which patients are going to follow relaxation instructions after a non-directive talk about their current or past experience of cancer.
16317412|NCT04556305|Experimental|Mind - BrainHQ cognitive training intervention|The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
16317413|NCT04556305|Experimental|Move - lifestyle physical activity intervention|"The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit active minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings."
16317414|NCT04556305|Experimental|MindMoves - cognitive training and lifestyle physical activity|Participants who are assigned to this condition will complete both the Move lifestyle physical activity program and the Mind BrainHQ cognitive training intervention simultaneously for 24 weeks (see Move and Mind descriptions). Participants will receive both a Fitbit and iPad tablet to complete the combined MindMoves intervention.
16317415|NCT04556305|No Intervention|Usual Care|Participants in the usual care group do not receive any Mind- or Move-related intervention, and will receive their usual care from their cardiology provider.
16317416|NCT04556292|Experimental|SC10914 group|
16317417|NCT04556279||hyperaldosteronism surgical treatment|Hypertensive patients with primary hypersldosteronism, treated with surgery
16317418|NCT04556279||hyperaldosteronism medical treatment|Hypertensive patients with primary hypersldosteronism, treated with aldosterone blockade.
16317419|NCT04556279||hypertensive control|Hypertensive patients shown not to have primary hyperaldosteronism
16317420|NCT04556266|Experimental|Cohort -1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 1 x 10^4 cells/kg"
16317421|NCT04556266|Experimental|Cohort 1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 1 x 10^5 cells/kg"
16317422|NCT04556266|Experimental|Cohort II|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 2 x 10^5 cells/kg"
16317423|NCT04556266|Experimental|Cohort III|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 4 x 10^5 cells/kg"
16317424|NCT04556253|Experimental|treatment arm|Subjects will receive AK104 by intravenous administration.
16317425|NCT04556227|Experimental|Simultaneous Cycle/Cognitive Training|After discharge from the hospital the group will engage in recumbent cycling with simultaneous cognitive training on a tablet.
16317426|NCT04556227|No Intervention|Usual Care|After discharge from the hospital the group will complete baseline activies.
16317427|NCT04556214|Experimental|Liver Transplant|The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
16317428|NCT04556201|Experimental|Thulium Fiber Laser lithotripsy|Subjects who have a medical indication for ureteroscopy, percutaneous nephrolithotomy (PCNL) or mini PCNL
16317429|NCT04556188||Cases|RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital
16317430|NCT04556188||RHD controls|RHD patients not offered Cardiac surgery
16317431|NCT04556188||Anticoagulation controls|Norwegian patients on anticoagulant therapy due to mechanical valve implants
16317432|NCT04556175|Experimental|Oral Health|Motivational interviewing sessions will involve in-person visits by Community Health Workers focused on the mitigation of behavioral risk factors for early childhood caries, with two sessions provided before childbirth and four more sessions at 6, 12, 18 and 24 months after childbirth. Children receive up to 4 fluoride varnish applications during the study. Early cohort of enrollees will be followed up in a 7th visit solely for oral health assessment.
16317433|NCT04556175|Active Comparator|Healthy Lifestyle|Didactic educational sessions delivered in-person by Community Health Workers cover nutrition and diet, physical activity, breastfeeding/formula feeding, substance use, mental/emotional health, personal and family goals, prenatal/postpartum health care access, labor and delivery, family support, infant/child care, oral health, and development milestones. Children receive up to 2 fluoride varnish applications during the study. Early cohort enrollees will be followed up in a 7th visit solely for oral health assessment.
16317434|NCT04556149||Case|Inpatients with confirmed COVID-19 with pulmonary symptoms
16317435|NCT04556149||Matched Control|Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms
16317436|NCT04556136|Experimental|Standing Phototherapy Kiosk (SPK)|Volunteers assigned to this group were administered phototherapy treatments in a standing phototherapy kiosk once every other week, for 10 weeks. The treatment usually lasts no more than 10 minutes and is based on the Fitzpatrick skin type classification tool, which is self-reported via the computer touch screen in the kiosk.
16317437|NCT04556136|Active Comparator|Oral Supplement|Volunteers assigned to this group were provided with a 10-week supply (70 pills) of a vitamin D3 supplement. Consented subjects were instructed to take one 600 IU pill by mouth each day for ten weeks. They were instructed to take this with a meal. This dose is the RDA for adults between 18 and 70 years old according to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.
16317438|NCT04556123|Experimental|BIS-guided decongestion|
16317440|NCT04556110|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
16317441|NCT04556110|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
16317442|NCT04556097|Experimental|Early Training|Nurse care managers will be randomized to either early or delayed adapted Care Ecosystem training. The Early Training arm will be the first group to receive training and the first to have the opportunity to use the training in a clinical setting. We anticipate that each nurse care manager will manage 10 PWLD and we anticipate a 50% response rate/data availability, yielding 75 patients per arm.
16317443|NCT04556097|Active Comparator|Delayed Training|The Delayed Training arm will be the second group of nurse care managers to receive training.
16317444|NCT04556084|Experimental|Blinatumomab|Up to 2 cycles of continuous infusion blinatumomab will be given based on the end of Cycle 1 disease response. Cycle 2 of blinatumomab can be given to subjects who have achieved remission (< 5% marrow blasts) after Cycle 1 but have persistent disease identified by multi-parameter flow cytometry (minimal residual disease (MRD) positive ≥ 0.01%) after Cycle 1.
16317445|NCT04556071|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until disease progression
16317446|NCT04556058|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
16317447|NCT04556058|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
16317448|NCT04556045|Experimental|Radiation therapy + exercise therapy (RT+ET) group|The RT+ET group will receive the exercise intervention. At their baseline visit, they will meet with the exercise physiologist, each participant will be provided a personalized exercise prescription to follow at home and will be asked to record what they do in between daily radiation treatment visits on the exercise tracking log provided to them. Participants will exercise between 1 and 7 times/week depending on the patient's tolerance to the treatment and exercise prescription. The exercise physiologist will meet with the participant at every radiation treatment visit for a brief 15-30 minute exercise counseling check in. After the participant's five radiation treatments, the exercise physiologist will follow-up with the participants via phone call once per week for 4 weeks during the follow-up period.
16317449|NCT04556045|Experimental|Radiation therapy (RT) group|The RT group will continue with their usual care. The study team will provide patients with an educational pamphlet at the end of their baseline visit. Additionally, the participant's medical record will be reviewed for serious adverse events during their time on study. Baseline and final measurements will be obtained.
16317450|NCT04556032|Experimental|L-Ergothioneine 10 mg/d|Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.
16317451|NCT04556032|Experimental|L-Ergothioneine 25 mg/d|Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.
16317452|NCT04556032|Placebo Comparator|Placebo|Participants will receive placebo orally once daily for 16 weeks.
16317453|NCT04556006|No Intervention|Control|The patients in the control group received only the standard care provided by the clinicians. After the collection of post-test data, the content of the training was also explained to these patients and the study was completed by giving them the training guide.
16317454|NCT04556006|Active Comparator|İntervention|The training program was applied by the researcher who also work as an academic nurse. The contact information of the patients was obtained and the contact information of the researcher was also given to the patients. In order to consolidate the information given, the training guide was given to the patients in the intervention group. After the training, the patients in the intervention group were contacted again in the 2nd week by using face-to-face interview and in the 4th-8th and 12th weeks by phone calls. During these interviews, the questions of the patients, if any, were answered and the problems they faced regarding the disease management were tried to be solved. In the last interview, an appointment day was determined to meet face-to-face at home, workplaces or hospital according to the preferences of the patients.
16317455|NCT04555993|Active Comparator|Transversus abdomis plane block|Patients will receive Transversus abdomis plane block
16317456|NCT04555993|Experimental|Erector spinae plane block|Patients will receive Erector spinae plane block.
16317457|NCT04555980|Experimental|Warm patch|the injection site was covered with warm patch.
16317458|NCT04555980|Placebo Comparator|Cotton patch|the injection site was covered with cotton patch.
16317459|NCT04555967||Transcatheter aortic valve implantation|
16317460|NCT04555941|Experimental|active iTBS|The patient is treated with iTBS stimulation according to protocol with an active coil.
16317461|NCT04555941|Sham Comparator|Sham iTBS|The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.
16317462|NCT04555915||Intervention group|Intervention Group of the SafeboosC Phase III Trial
16317463|NCT04555915||Control group|Control Group of the SafeboosC Phase III Trial
16317464|NCT04555902|Active Comparator|Standard Mailer and Small Gift|A postcard encourages mammograms and includes a small gift.
16317465|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and Small Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; a small gift is included.
16317466|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and No Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; the small gift is not included.
16317467|NCT04555889|Experimental|lung recruitment maneuver (LRM) group|The lung recruitment maneuver (LRM) will be done by increasing of PEEP 0,2 cm H2O every 3 minutes, until reach the opening pressure. After that PEEP decrease gradually until get the closing pressure. Than the investigators will back to the opening pressure for 3 minutes, and the final PEEP will be put backo 0,2 above closing pressure.
16317468|NCT04555889|No Intervention|without lung recruitment maneuver (LRM) group|Another group get standart protocol only.
16317469|NCT04555876|Experimental|high tone external muscle stimulation|"- HiTop 191 appliance (gbo Medizintechnik AG, Rimbach, Germany) Device HiToP® 4 touch gbo Medizintechnik AG, this modern high-tech design with brushed aluminum surface and the 15 TFT LC D full color touch screen monitor offer to the health care professional an indispensable feature."
16317470|NCT04555876|Experimental|stationary bicycle|supervised regular aerobic exercise program on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.
16317471|NCT04555863|Experimental|haMSter app|Patients receiving the app for personal use for 6 months
16317472|NCT04555850|Experimental|Recombinant Human Thymosin β4 0.5ug/kg|10 subjects in this group will receive NL005 for 0.5ug/kg respective.Continuous administration for 10 days.
16317473|NCT04555850|Experimental|Recombinant Human Thymosin β4 2.0ug/kg|10 subjects in this group will receive NL005 for 2.0ug/kg respective.Continuous administration for 10 days.
16317474|NCT04555850|Experimental|Recombinant Human Thymosin β4 5.0ug/kg|10 subjects in this group will receive NL005 for 5.0ug/kg respective.Continuous administration for 10 days.
16317475|NCT04555850|Other|Placebo|Two subjects in each dose group (0.5/2/5ug/kg) were given placebo for 10 days.A total of six participants were given a placebo.
16317476|NCT04555837|Experimental|Treatment (alisertib, pembrolizumab)|Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16317477|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 1 group|Two subjects in this group will receive NL005 for 0.05ug/kg respective in D1.
16317478|NCT04555824|Experimental|Dose 2 groupRecombinant Human Thymosin β4|Two subjects in this group will receive NL005 for 0.25ug/kg respective in D1.
16317479|NCT04555824|Experimental|Dose 3 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 0.5ug/kg respective in D1.
16317480|NCT04555824|Experimental|Dose 4 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 2ug/kg respective in D1.
16317481|NCT04555824|Experimental|Dose 5 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 5ug/kg respective in D1.
16317482|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 6 group|Eight subjects in this group will receive NL005 for 12.5ug/kg respective in D1.
16317483|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 7 group|Eight subjects in this group will receive NL005 for 25ug/kg respective in D1.
16317484|NCT04555824|Placebo Comparator|Placebo|Two subjects in each dose group（0.5/2/5/12.5/25ug/kg）were given placebo respective in D1. A total of 10 subjects were given placebos.
16317485|NCT04555811|Experimental|FT596 + Rituximab Dose Level 1: 9x10^7 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
16317486|NCT04555811|Experimental|FT596 + Rituximab Dose Level 2: 3x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
16317487|NCT04555811|Experimental|FT596 + Rituximab Dose Level 3: 9x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
16317488|NCT04555798|Placebo Comparator|Group A|Group A continue on the same conventional way of management as mentioned above with conventional way of ventilation and broad spectrum antibiotics coverage
16317489|NCT04555798|Active Comparator|Group B|group B who connected to (A-VECMO).with venous access from femoral vien and arterial cannulation using the femoral artery
16317490|NCT04555785|Experimental|Platelet transfusion with Wilate ®|
16317491|NCT04555785|Placebo Comparator|Platelet transfusion with Placebo|
16317492|NCT04555772||Healthy Group|Patients who had been treated and recovered physically and gained cognitive functions completely.
16317493|NCT04555772||Sequel Group|Patients who could not gain their physical and cognitive functions.
16317494|NCT04555772||Exitus Group|Patients who did not respond to the treatments and lost their lives within 28 days of admission.
16317495|NCT04555759|Experimental|Patient with spinal cord injuries|
16317496|NCT04555746|Experimental|Physical activity|Physical activity
16317498|NCT04555733|Experimental|Cohort 1: Lemborexant 5 mg|Participants will receive a single dose of lemborexant 5 milligram (mg) tablet, orally on Day 1.
16317499|NCT04555733|Experimental|Cohort 2: Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1 followed by a washout period of approximately 14 days further followed by multiple doses of lemborexant 10 mg tablets, orally, once daily from Day 15 through Day 28.
16317500|NCT04555733|Experimental|Cohort 3: Lemborexant 25 mg|Participants will receive a single dose of lemborexant 25 mg (1*5 mg tablet and 2*10 mg tablet), orally on Day 1.
16317501|NCT04555720|Experimental|Interdisciplinary Care|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participant's doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
16317502|NCT04555720|No Intervention|Standard of Care|If assigned to standard of care, group participants will have a normally scheduled visit with neurologist.
16317503|NCT04555707|Experimental|Otezla + Enstilar|
16317504|NCT04555694|Active Comparator|Restasis and Lotemax|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes and Lotemax ophthalmic solution twice a day in both eyes.
16317505|NCT04555694|Active Comparator|Restasis and Dextenza|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes, as well as receiving Dextenza insertion in both lower lids.
16317506|NCT04555694|Active Comparator|Restasis|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes
16317507|NCT04555668|Experimental|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch
16317508|NCT04555668|Active Comparator|Hamstring Stretch Program|Hamstring Stretch Program and Knee -flexor eccentric training
16317509|NCT04555655|Experimental|Chicken extract supplement|
16317510|NCT04555655|Experimental|Peptides supplement|
16317511|NCT04555655|Placebo Comparator|Placebo|
16317512|NCT04555642||therapy group|lymphoma patients planned chemotherapy or immunotherapy scheme
16317513|NCT04555642||healthy control group|Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.
16317514|NCT04555629|Experimental|Advanced Cognitive Stimulation Therapy Hong Kong|"Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. It has also been translated and adapted for the Hong Kong Chinese population.
~ACST-HK will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee, or care home staff."
16317515|NCT04555629|No Intervention|Treatment as usual|Standard care in care homes
16317516|NCT04555616|Placebo Comparator|Control Group|Alzheimer's disease patients and caregivers.
16317517|NCT04555616|Experimental|Standard Environmental Design|Alzheimer's disease patients and caregivers.
16317518|NCT04555616|Experimental|Individualized Environmental Design Protocol|Alzheimer's disease patients and caregivers.
16317519|NCT04555590|No Intervention|Pre H-HOPE Cohort|The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).
16317520|NCT04555590|Experimental|H-HOPE Cohort|The H-HOPE Cohort will receive the H-HOPE intervention.
16317521|NCT04555577|Experimental|Stage I (nedisertib, radiation therapy, temozolomide)|"CONCURRENT: Patients undergo standard of care radiation therapy daily (Monday-Friday) for 30 fractions. Patients also receive nedisertib PO on each day of radiation therapy and given 1-2 hours before each treatment fraction. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
~ADJUVANT: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16317522|NCT04555577|Experimental|Stage II (nedisertib, radiation, temozolomide, surgery)|"CONCURRENT: Patients receive nedisertib and undergo standard of care radiation therapy as in Stage I. Within 1-14 days after the completion of radiation therapy, patients undergo surgical resection.
~ADJUVANT: Patients receive temozolomide as in Stage I."
16317523|NCT04555564|Experimental|Technicium 99 MAA|Participants will receive bronchial artery administration of Technicium 99 MAA
16317525|NCT04555538||Atrial Fibrillation Group|
16317526|NCT04555538||Non-Atrial Fibrillation Group|
16317527|NCT04555525|Experimental|sarecycline|weight-based dose per label by mouth once daily for 12 weeks
16317528|NCT04555525|Other|Centrum Adult Multivitamin|one tablet by mouth daily for 12 weeks
16317529|NCT04555512|Active Comparator|Standard-care interval-training group|Subjects will complete a standard interval-training program that remains constant for the entire 12 weeks of cardiac rehabilitation.
16317530|NCT04555512|Experimental|Progressive interval-training group|Subjects will complete an interval-training program during which the number of intervals and the duration of each interval are changed across the 12-week cardiac rehabilitation program.
16317531|NCT04555499||Suspected stroke|Patients with suspected stroke who are evaluated by paramedics
16317532|NCT04555486|Experimental|DCR-PHXC|Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.
16317533|NCT04555486|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.
16317785|NCT04553692|Experimental|IGM-8444 + FOLFIRI Escalation|IGM-8444 will be administered intravenously in combination with FOLFIRI.
16317534|NCT04555460|Active Comparator|Decompressive surgery|Decompressive surgery was performed with a large hemicraniectomy that removed, ipsilateral to the stroke, a bone flap as large as possible including temporal, frontal, parietal, and some occipital squama.
16317535|NCT04555460|Active Comparator|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke. Administration of intravenous mannitol (0.25 to 0.5 g/kg) or furosemide was given only in patients whose condition was rapidly worsening because of brain edema, without additional recommendations on loading doses.
16317536|NCT04555447|Experimental|Healthy-agavins|Agavins are branched neo-fructans and were supplemented for a 5-week dose-escalation period in lean participants
16317537|NCT04555447|Placebo Comparator|Healthy-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in lean participants
16317538|NCT04555447|Experimental|Obese-agavins|Agavins are branched neo-fructans that were supplemented for a 5-week dose-escalation period in obese participants
16317539|NCT04555447|Placebo Comparator|Obese-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in obese participants
16317540|NCT04555434|Experimental|Probiotics group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
16317541|NCT04555434|Placebo Comparator|Placebo group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
16317542|NCT04555421|Experimental|Lumen device usage and diet guidelines|
16317543|NCT04555408|Active Comparator|blue light group|The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
16317544|NCT04555408|Active Comparator|bright light group|The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
16317545|NCT04555408|Placebo Comparator|dim light group|The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
16317546|NCT04555395||gonadal|
16317547|NCT04555395||extra-gonadal|
16317548|NCT04555395||chemotherapy|
16317549|NCT04555395||without chemotherapy|
16317550|NCT04555382||AKI group|this group are included patients who have not occured acute kidney injury at first, however acute kidney injury are occured soon afterwards during the observation period.
16317551|NCT04555382||non-AKI group|this group are included patients who have not occured acute kidney injury during the observation period.
16317552|NCT04555369|Experimental|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
16317553|NCT04555343|Experimental|Intervention- TXA|"Drug: one-time intravesical administration of 1gm of TXA instilled via urinary catheter, instilled for 15min before continuous bladder irrigation treatment beings.
~1gm of TXA will be mixed with 100cc NS"
16317554|NCT04555330|Experimental|Visual Feedback|Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level and motivation to move. This information will be visible to the health personnel, the patients and visitors.
16317555|NCT04555330|Other|Control Group|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.No feedback on physical activity is provided.
16317556|NCT04555317|No Intervention|Standard of Care|No intervention. Standard of care cancer pathway followed.
16317557|NCT04555317|Active Comparator|Musculoskeletal Health Package|3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
16317558|NCT04555304|Experimental|KH903 + Paclitaxel|IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
16317559|NCT04555304|Active Comparator|Placebo + Paclitaxel|IV Placebo IV paclitaxel 80 mg/m²
16317560|NCT04555291|Experimental|Drug Ropivacaïne 2 mg/ml|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
16317561|NCT04555291|Placebo Comparator|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
16317562|NCT04555278|Experimental|Active rTMS + Motor control exercises|Active (real) repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
16317563|NCT04555278|Sham Comparator|Sham rTMS + Motor control exercises|Sham repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
16317564|NCT04555278|Experimental|Active rTMS|Active (real) repetitive transcranial magnetic stimulation (20 minutes).
16317565|NCT04555278|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (20 minutes).
16317566|NCT04555265|Other|Thermal ablation group|Patients with hepatocellular carcinoma treated by thermal ablation
16317567|NCT04555252||Cephalic Duodenopancreatectomy|Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.
16317568|NCT04555239|Active Comparator|Standard of Care, Upper Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
16317569|NCT04555239|Active Comparator|Standard of Care, Lower Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
16317570|NCT04555239|Experimental|FDM, Upper Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
16317571|NCT04555239|Experimental|FDM, Lower Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
16317572|NCT04555226|Active Comparator|Standard treatment group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
16317573|NCT04555226|Experimental|Experimental group|Open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
16317574|NCT04555213|Experimental|Dose Escalation Cohort 1 - NOX66 400mg|NOX66 400 mg suppository OD
16317575|NCT04555213|Experimental|Dos Escalation Cohort 2 - NOX66 600mg|NOX66 600 mg suppository OD
16317576|NCT04555213|Experimental|Dose Escalation Cohort 3 - NOX66 800mg|NOX66 800 mg daily (400 mg suppository BID)
16317577|NCT04555213|Experimental|Dose Escalation Cohort 4 - NOX66 1200mg|NOX66 1200 mg daily (600 mg suppository BID)
16317578|NCT04555213|Experimental|Dose Escalation Cohort 5 - NOX66 1800mg|NOX66 1800 mg daily (600 mg suppository TID)
16317579|NCT04555213|Experimental|Dose Expansion - NOX66 Recommended Phase 2 Dose|Dose Expansion: NOX66 RP2D
16317580|NCT04555187||Covid19-positive|Covid19 test positive. age >= 18 y.
16317581|NCT04555187||Covid19-negative|Covid19 test negative. age >=18y
16317582|NCT04555174||Orsiro Mission DES|All subjects will be implanted with the Limus Eluting Orsiro Mission Stent System and followed up until 60 months.
16317583|NCT04555161|Experimental|Aria CV Pulmonary Hypertension System|Treatment with the Aria CV Pulmonary Hypertension System
16317584|NCT04555148|Placebo Comparator|Placebo|Saline
16317585|NCT04555148|Experimental|Low dose Treatment|Low dose treatment
16317586|NCT04555148|Experimental|Medium dose Treatment|Medium dose Treatment
16317587|NCT04555148|Experimental|High dose Treatment|High dose Treatment
16317588|NCT04555135|Experimental|Colonoscopy Procedure with EndoVigilant Software|Colonoscopy Procedure is performed with EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
16317589|NCT04555135|No Intervention|Colonoscopy Procedure without EndoVigilant Software|Colonoscopy Procedure is performed without EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
16317590|NCT04555122|Experimental|Intervention Group|Advertisements will be sent to participants mobile devices to attempt to increase adherence to stay-at-home orders and social distancing. There are 3 types of advertisements. This will occur for 7 days.
16317591|NCT04555122|No Intervention|Control Group|Control Group will be people who will not receive any advertisements.
16317592|NCT04555109||COVID-19 Convalescents|The cohort will include up to 1000 persons recovered from COVID-19, ages 17 - 65, that will provide a written consent form to participate in the study, complete questionnaires and provide a blood sample.
16317593|NCT04555096|Experimental|Active GC4419|Arm A
16317594|NCT04555096|Placebo Comparator|Placebo|Arm B
16317595|NCT04555083||CAI group|Case group is CAI group that recruit patients complain of ankle insatiability and giving way mainly
16317596|NCT04555083||control group|control group recruits participants with non injured ankle, matched with case group in gender and dominant limb
16317597|NCT04555057|Experimental|Music therapy group|"One day before surgery, the participants of music therapy group choose the music they want to listen in the operating room. The total playing time of the selected music is recommended between 5 and 10 minutes.
~On the day of surgery, after entering the operating room, listen to personally selected music through the speaker. After the music is over, start anesthesia induction."
16317598|NCT04555057|No Intervention|Control group|The participants of control group wear earmuff to block noise after entering the operating room until induction of anesthesia. All other treatments proceed as conventional treatments.
16317601|NCT04555031|Experimental|kalifilcon A lenses|
16317602|NCT04555031|Active Comparator|Dailies Total 1|
16317603|NCT04555031|Active Comparator|Precision 1|
16317604|NCT04555031|Active Comparator|Biotrue ONEday|
16317605|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
16317606|NCT04554992|Experimental|Treatment|All subjects recruited will be transfused with COVID 19 convalescent plasma. A prospective comparison with matched historical controls receiving standard care will be employed.
16317607|NCT04554979||Group 1|Duration of COVID-19 symptoms less than 12 days
16317608|NCT04554979||Group 2|Duration of COVID-19 symptoms equal or more than 12 days
16317609|NCT04554966|Experimental|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
16317610|NCT04554966|Experimental|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
16317611|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
16317612|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
16317613|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
16317614|NCT04554966|Experimental|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
16317615|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
16317616|NCT04554940|Experimental|Vosoritide + Standard of Care|Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of vosoritide at 30μg/kg (ages 0 - <2 years old) or 15 μg/kg (ages >2 years old)
16317617|NCT04554940|No Intervention|Standard of Care Alone|Institutional standard of care monitoring and treatment for cervicomedullary compression
16317618|NCT04554927|Experimental|WEB-application|
16317619|NCT04554927|Active Comparator|Standard accompaniment|
16317620|NCT04554914|Experimental|EBV+ PID LPD|Participants with newly diagnosed or relapsed/refractory EBV+ PID LPD will receive IV tabelecleucel.
16317621|NCT04554914|Experimental|EBV+ AID LPD|Participants with newly diagnosed or relapsed/refractory EBV+ AID LPD will receive IV tabelecleucel.
16317622|NCT04554914|Experimental|EBV+ PTLD CNS|Participants with newly diagnosed or relapsed/refractory EBV+ PTLD CNS will receive IV tabelecleucel.
16317623|NCT04554914|Experimental|EBV+ PTLD (ineligible for first-line therapy or CD20 negative)|Participants with EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease will receive IV tabelecleucel.
16317624|NCT04554914|Experimental|EBV+ sarcoma, including LMS|Participants with newly diagnosed or failed systemic first-line therapy for EBV+ sarcoma will receive IV tabelecleucel.
16317625|NCT04554914|Experimental|CAEBV/ HLH|Participants with newly diagnosed or previously treated CAEBV or EBV viremia with HLH will receive IV tabelecleucel.
16317626|NCT04554901|Other|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
16317627|NCT04554888|Experimental|Doxepin Application|During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.
16317628|NCT04554888|Experimental|Itch Induction|After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.
16317629|NCT04554875||Cohort 1|Derivation Cohort of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
16317630|NCT04554875||Cohort 2|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
16317631|NCT04554875||Cohort 3|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
16317632|NCT04554875||Cohort 4|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
16317633|NCT04554862|Active Comparator|the intervention group (M) magnesium sulfate|a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
16317634|NCT04554862|Active Comparator|the intervention group (K) ketorolac|a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
16317635|NCT04554836|Experimental|FOLFIRI + cetuximab|"Patients in Arm A will receive FOLFIRI + cetuximab until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first. The recurrence of RAS-mutation without PD to switch back to FOLFIRI. In case of repeated conversion to RAS wild-type without PD, treatment will shift to FOLFIRI + cetuximab again, and so on. Switches of treatment will proceed until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.
~[FOLFIRI = Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)]"
16317636|NCT04554836|Other|FOLFIRI|Patients in Arm B will continue therapy with FOLFIRI until PD, unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.
16317637|NCT04554823|Placebo Comparator|Control Group|Will attend lectures on health education.
16317638|NCT04554823|Experimental|Exercise Group|Will be subjected to a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and Will attend lectures on health education.
16317639|NCT04554810|Active Comparator|Intervention group|Intervention group participants are the refugees who received the medication management review service and pharmacist's counselling. They have been assessed at baseline and at follow-up after 3 months) home visits.
16317640|NCT04554810|No Intervention|Control group|Control group participants are the refugees who did not received the medication management review service and no pharmacist's counselling wsa provided to them during the study period. They have been assessed at baseline and at follow-up (after 3 months) home visits.
16317641|NCT04554797|Experimental|Regional Hypothermia group|
16317642|NCT04554797|No Intervention|Control group|
16317643|NCT04554784|Active Comparator|Conventional|Conventional pain treatment.
16317644|NCT04554784|Active Comparator|Bowen|Patients will be referred to Occupational Therapist for Bowen therapy.
16317645|NCT04554771|Experimental|ADAM12 high with tocilizumab and standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
16317646|NCT04554771|Active Comparator|ADAM12 high with standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
16317647|NCT04554771|Experimental|ADAM12 low with tocilizumab and standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
16317679|NCT04554498|Experimental|Hemodiafiltration with ATA filter|patients with clinical history of hypersensitivity to polisulfone/poliethersulfone dialysis filters or hypersensitivity to drugs or generic allergens.
16317648|NCT04554771|Active Comparator|ADAM12 low with standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
16317649|NCT04554758|Experimental|Sleeve gastrectomy|200 obesity patients who undergo laparoscopic sleeve gastrectomy
16317650|NCT04554758|Experimental|Roux-en-Y gastric bypass|200 obesity patients who undergo laparoscopic Roux-en-Y gastric bypass
16317651|NCT04554732|Experimental|Part 1 - Initial group treatment|For part 1 of the study, subjects will be enrolled into a prospective single arm phase where all of them get the study treatment. We plan to enroll up to 25 subjects to have 20 evaluable subjects to this phase.
16317652|NCT04554719|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated malignant tumors who have completed 18F-FDG PET/CT imaging, focusing on malignant tumors with poor results of FDG PET/CT imaging, such as brain tumors, liver tumors, digestive system tumors and peritoneal, greater omentum, and mesenteric metastatic tumors. Patients undergo 68Ga-DOTA-FAPI PET/MR imaging within one week.
16317653|NCT04554706|Experimental|a JITAI interactive narrative condition (Narrative JITAI)|This arm is an exploratory condition, which tested whether story-based JITAI would be an effective way to deal with rumination.
16317654|NCT04554706|Experimental|a JITIAI non-interactive condition|This arm uses the regular JITAI ( mobile phone delivered) intervention to provide treatment for ruminative thoughts.
16317655|NCT04554706|No Intervention|a wait-list control condition|Participants in this arm will be put on a waitlist without receiving active treatment upon the end of the study.
16317656|NCT04554693|Experimental|Metronidazole|Metronidazole
16317657|NCT04554693|Placebo Comparator|Placebo|Halal and Kosher certified gelatin placebo capsules
16317658|NCT04554680|Experimental|Treatment Group|Patients with progressive, metastatic or locally advanced, unresectable radioiodine (RAI)-refractory thyroid cancer of follicular cell origin with mutation involving MAPK signalling pathway, including BRAFV600E mutation or RAS mutation.
16317659|NCT04554667|Experimental|Exercise Intervention|Single exercise arm
16317660|NCT04554654||frozen embryo transfer cycles|patients undergoing frozen embryo transfer with artificial hormone replacement
16317661|NCT04554641|Experimental|BioKult Advanced|This is a single arm study, all participants will take Bio-kult Advanced for 56 days (+/- 2days). Participants will be required to take 4 capsules daily.
16317662|NCT04554628|Active Comparator|Urinary human neutrophil gelatinase-associated lipocalin|Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
16317663|NCT04554628|Active Comparator|Urinary human kidney injury molecule 1 (U-KIM1)|Urinary human kidney injury molecule 1 (U-KIM1) measurement group
16317664|NCT04554615|Active Comparator|Conventional Insulin Therapy|CIT was provided as a continuous infusion of 50 IU of Actrapid HM in 50 ml of 0.9% sodium chloride using a pump, Infusion was adjusted to achieve BG level in range of 180-200 mg/dl.
16317665|NCT04554615|Active Comparator|Intensive Insulin Therapy|IIT was provided as an insulin infu-sion at rate of 1 mU/kg/min and was adjusted to achieve target BG level in range of 80-110 mg/dl.
16317666|NCT04554602||Patient with endometriosis or suspicion of endometriosis|"Information and collection of the non-objection before inclusion
~Interrogation, clinical examination, EHP30 and SF36 form at inclusion
~MRI, pelvic ultrasound (coupled with fusion ultrasound)
~Laparoscopy if indicated after MRI, ultrasound and fusion ultrasound
~Monitoring by form and fusion ultrasound at 6 months and then once a year for 3 years"
16317667|NCT04554602||Patient with other gynaecological pathology|"Information and collection of the non-opposition before inclusion
~Interrogation, clinical examination, EHP30 and SF36 form at inclusion
~MRI, pelvic ultrasound (coupled with fusion ultrasound)
~laparoscopy if indicated after MRI, ultrasound and fusion ultrasound"
16317668|NCT04554589|Active Comparator|intervention group|receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .
16317669|NCT04554589|Placebo Comparator|placebo group|receive normal saline 2 ml IV every 8 hours daily .
16317670|NCT04554576|Experimental|6-week self-management and remote feedback for 6 months|All participants will receive the 6-week self-management program and after, half the group will be randomized to an every 6th week healthcare provider feedback phone or video visit session for 6 months (4 visits over 24 months).
16317671|NCT04554576|Active Comparator|6-week self-management and control group for 6 months|All participants will receive the 6-week self-management program and after, half will be randomized to a 6 month control grup
16317672|NCT04554563|Experimental|Training group|4-week core stability training
16317673|NCT04554563|No Intervention|Control group|Standard physical therapy
16317674|NCT04554537|Placebo Comparator|Brain Health Workshop|The BHW training has been used in multiple prior studies as a comparison training program in cognitive training trials It consists of sessions of fact-based information about the brain but does not train cognitive strategies. Topics include neuroanatomy, neuroplasticity, and effects of TBI on cognitive functioning. Other sessions focus on diet, exercise, sleep, and social functioning and their relationships to brain health. Participants are encouraged to share how the topics impact their lives. Participants are given take-home reading materials on related topics that were then discussed at the last session. At home, they were instructed to watch assigned videos but had no other homework.
16317675|NCT04554537|Experimental|SMART|"SMART emphasizes top-down processing by targeting focused attention, assimilation of information, and mental flexibility and innovation, all higher-order cognitive functions driven by the frontal lobes. SMART was delivered in small groups (n = 2 to 8) consisting of two 3-hour sessions over two days, followed by one 3-hour session a month later. Overall, sessions focused on strategic attention, integrative reasoning, and cognitive control functions (Chapman, 2014). Training consists of initial sessions of skills training with the one-month follow-up session being a booster session consisting of review. We modified the training such that all sessions included skills training with briefer review. The first two sessions consisted of strategic attention and integrated reasoning and the final session discussed innovation."
16317676|NCT04554524|Experimental|Chemotherapy+Pembrolizumab|Chemotherapy combined with pembrolizumab.
16317677|NCT04554511||Training cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
16317678|NCT04554511||Validation Cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
16317680|NCT04554498|Active Comparator|Hemodiafiltration with Helixone filter|no history of hypersensitivity to polisulfone/poliethersulfone dialysis filters is assessed; no history of hypersensitivity to drugs or generic allergens is assessed.
16317681|NCT04554485|Experimental|Blinatumomab followed by high-dose chemotherapy|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
16317682|NCT04554472||Study group|Patients with a distal radius fracture requiring surgery who meet the exclusion and inclusion criteria
16317683|NCT04554459|Experimental|ponatinib plus reduced-intensity chemotherapy|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
16317684|NCT04554446|Experimental|T-MSAT(Motion style acupuncture treatment using Traction)|T-MSAT group receives 3 sessions of T-MSAT; on 2nd, 3rd, 4th day after hospitalization. A trained doctor of Korean medicine with clinical experience conducted the T-MSAT. And T-MSAT group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
16317685|NCT04554446|Active Comparator|Korean medicine treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
16317686|NCT04554433|Active Comparator|Intervention|A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
16317687|NCT04554433|No Intervention|Control|B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .
16317688|NCT04554420|Experimental|Youth Participatory Action Research-Mental Health Curriculum|Youth will be engaged with youth participatory approaches in learning about the intersection of mental health and systemic/community level issues.
16317689|NCT04554407|Experimental|Treatment Group|All participants receive the SOMAVAC® 100 Sustained Vacuum System
16317690|NCT04554394|Experimental|CellFX Treated Wart Lesion|CellFX device using pre-defined energy protocols
16317691|NCT04554381|Experimental|JL1|JL1 on acute leukemia
16317692|NCT04554381|Experimental|JL1 and acute leukemia|Assesment of JL1 expression on acute leukemia
16317693|NCT04554368||IA-CEFDCT group|95 patients who underwent IA-CEFDCT and MT for acute anterior stroke.
16317694|NCT04554355|Experimental|Intervention group|Participants in this group will receive a three-month PA intervention (60 minutes/session, two sessions/week).
16317695|NCT04554355|No Intervention|Control group|No intervention will be provided, participants in this group need to attend the regular school activities as normal.
16317696|NCT04554342|Experimental|healthy participants starting with candy V01|healthy participants testing a candy in 5 different variations by (unstimulated and stimulated) salivary flow rate (before and after comparison)
16317697|NCT04554342|Experimental|healthy participants starting with candy V02|
16317698|NCT04554342|Experimental|healthy participants starting with candy V03|
16317699|NCT04554342|Experimental|healthy participants starting with candy V04|
16317700|NCT04554342|Experimental|healthy participants starting with candy V05|
16317701|NCT04554329|Active Comparator|bandage contact lens|A bandage contact lens was applied on the eye at the end of the surgery, and the eye was not covered with a patch.
16317702|NCT04554329|Active Comparator|eye patching|Antibiotic eye ointment was applied on the eye, and the eye was covered with a patch at the end of the surgery.
16317703|NCT04554316|Active Comparator|Parallel placement|Steri-strips will be placed in-line (parallel) with the surgical incision.
16317704|NCT04554316|Active Comparator|Perpendicular placement|Steri-strips will be placed perpendicular to the surgical incision.
16317705|NCT04554303||S-amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
16317706|NCT04554303||Amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
16317707|NCT04554290||positive temporal artery biopsy|all adult patients with significant inflammation shown on temporal artery biopsy
16317708|NCT04554277|No Intervention|Control|Usual management of heart failure. The sST-2 level will be blunted.
16317709|NCT04554277|Experimental|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
16317710|NCT04554238|Experimental|Armeo spring group|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.
16317711|NCT04554238|Active Comparator|Occupational Therapy group|It consists of 5 weeks of intervention, with 3 treatment sessions per week, 40 minutes each time. The patient performs active exercises of the paretic upper limb: bimanual play activities, weight bearing, reaches in various planes of motion that favor shoulder flexion, elbow extension, forearm supination, and dissociated finger movements. In addition to passive mobilizations of the shoulder, elbow and wrist and tactile and proprioceptive sensory stimulation and the use of paretic limbs as support or carrying out prehensions.
16317712|NCT04554225||Pulmonary disease patients|Patients with COPD or other pulmonary disease starting to use ambulatory oxygen therapy
16317717|NCT04554199|Experimental|EEG and MMSE measurements before receiving RPD|EEG and MMSE were measured for all participant before wearing the removable partial dentures.
16317718|NCT04554199|Experimental|EEG and MMSE measurements after receiving RPD|EEG and MMSE were measured for all participant after wearing the removable partial dentures
16317719|NCT04554186|Experimental|Serratus anterior plane block|20 patients will receive SAP block with 0.4 ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
16317720|NCT04554186|Active Comparator|Thoracic Paravertebral block|20 patients will receive TPVB 0.4ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
16317721|NCT04554186|Placebo Comparator|Control group|20 patients will receive Fentanyl patch 50 microgram
16317722|NCT04554173||surgical resection neurogenic tumors|
16317723|NCT04554147|Experimental|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.
~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
16317724|NCT04554121|Experimental|Brain Basics|Brain Basics is a cognitive remediation intervention that emphasizes training in early auditory processing.
16317725|NCT04554121|Active Comparator|Brain Training|Brain Training is a cognitive remediation intervention that targets a range of cognitive abilities
16317726|NCT04554108|Active Comparator|Intravenous antibiotic treatment|Intravenous antibiotic treatment started during an initial hospitalization of 3 days, with continuation of oral antibiotic therapy at home for a total duration of antibiotic therapy of 3 weeks
16317727|NCT04554108|Experimental|oral antibiotic treatment|Oral antibiotic treatment started in hospital then continued at home for a total duration of 3 weeks of antibiotic therapy
16317728|NCT04554082||Preoperative Clinical characteristics and metabolic biomarkers|BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery
16317729|NCT04554082||9 months' Postoperative metabolic biomarkers|BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy
16317730|NCT04554056|Experimental|MW05 300μg/kg|Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
16317731|NCT04554056|Experimental|MW05 500μg/kg|Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
16317732|NCT04554056|Active Comparator|PEG-rhG-CSF|Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
16317742|NCT04554017|Experimental|Intervention arm - All participant (Single arm)|Participants received education or health talks on dietary and physical activity behaviours linked to hypertension
16317743|NCT04554004|Experimental|Study group|All consecutive patients undergoing outine CT angiography and dynamic CT-myocardial perfusion imaging(MPI) will be potentially eligible for inclusion in the trial. Assessment of coronary stenosis severity using invasive fractional flow reserve (FFR) and the status of myocardial microcirculation perfusion including coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed as part of invasive coronary angiography(CAG).
16317744|NCT04553991|Active Comparator|QL block group|For the ultrasound-guided quadratus lumborum block group, the patient was placed in lateral position . QL was identified medial to the aponeurosis of transversus abdominis muscle. Then the needle was inserted from supero-anterior to postero-inferior and advanced using in plane technique till the needle tip reached the anterolateral border of the QL at its junction with transversalis fascia.An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
16317745|NCT04553991|Active Comparator|TAP block group|For the ultrasound-guided TAP block,The probe was placed in the mid-axillary line above the level of the anterior superior iliac spine, then slided cranially till the three abdominal wall muscles identified (External oblique muscle (EAO), internal oblique muscle (IOM) and transverse abdominis muscle (TAM)). The needle was advanced using in-plane technique till it reached the transvers abdominis plane. An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
16317746|NCT04553978|Experimental|Treatment A|"After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.
~Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary."
16317784|NCT04553692|Experimental|IGM-8444 Single Agent Alternate Dosing Escalation|IGM-8444 will be administered intravenously as a single agent on an alternate dosing schedule.
16319083|NCT04545099|Active Comparator|Neostigmine|Administration of Neostigmine
16317747|NCT04553978|Experimental|Treatment B|"At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.
~Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary."
16317748|NCT04553952||Gummy smile (GS(+))|
16317749|NCT04553952||Gumms smile(GS(-))|
16317750|NCT04553939|Experimental|Toripalimab in Combination With Gemcitabine Therapy|
16317751|NCT04553913|Experimental|cooling device placed|A basic medical grade cooling pad will be secured to the non operative leg. Intermittent coolness will be assessed and subject will inform recovery room staff when sensation returns.
16317752|NCT04553887|Experimental|Cohort 1|Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
16317753|NCT04553887|Experimental|Cohort 2|NSCLC Patients with uncommon EGFR Mutation
16317754|NCT04553861||Healthy subjects|Healthy subjects without blood pressure difference on both arm
16317755|NCT04553848|Experimental|Augmented Reality+ Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
16317756|NCT04553848|Active Comparator|Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
16317757|NCT04553848|Active Comparator|Over ground training/standard of care|Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.
16317758|NCT04553835|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
16317759|NCT04553835|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
16317760|NCT04553835|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
16317761|NCT04553835|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
16317762|NCT04553822|Experimental|Assisted autogenous drainage group (DAA)|The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes.
16317763|NCT04553822|Experimental|Group prolonged slow expiration (ELPr)|This technique is applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume.
16317764|NCT04553822|Active Comparator|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer.
16317765|NCT04553809|Active Comparator|Kontrol|Patients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
16317766|NCT04553809|Experimental|Intervention|Patients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
16317767|NCT04553796||diabetic participants|HBA1C : 6.5% or higher Fasting Plasma Glucose : 126 mg/dl or higher Oral Glucose Tolerance Test : 200 mg/dl or higher Random Plasma Glucose Test : greater than or equal to 200 mg/dl
16317768|NCT04553796||prediabetic participants|HBA1C : 5.7% to 6.4% Fasting Plasma Glucose : 100 mg/dl to 125 mg/dl Oral Glucose Tolerance Test : 140 mg/dl to 199 mg/dl
16317769|NCT04553796||non diabetic participants|HBA1C : less than 5.7% Fasting Plasma Glucose : less than 100 mg/dl Oral Glucose Tolerance Test : less than 140 mg/dl
16317770|NCT04553770|Active Comparator|Arm A (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
16317771|NCT04553770|Experimental|Arm B (trastuzumab deruxtecan, anastrozole)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle and anastrozole PO QD on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
16317772|NCT04553757||Observational (survey)|Patients complete a seizure assessment survey over 5 minutes at each clinic visit.
16317773|NCT04553744||Observational (survey)|Participants complete an online survey over 5-10 minutes asking how they would manage lymph node basins in the extremity sarcoma.
16317774|NCT04553731|Experimental|mHealth group|
16317775|NCT04553731|No Intervention|general care|
16317776|NCT04553718|Experimental|experimental|
16317777|NCT04553705|Experimental|Omega-3/thymoquinone supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA) (3% thymoquinone) per day for one month.
~In addition to the standard care"
16317778|NCT04553705|Experimental|Omega-3/thymoquinone / Indian Costus supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.
~In addition to the standard care"
16317779|NCT04553705|Experimental|Omega-3/thymoquinone / Quinine pills|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.
~In addition to the standard care"
16317780|NCT04553705|Experimental|Omega-3/thymoquinone / Anise seed capsule|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.
~In addition to the standard care"
16317781|NCT04553705|Experimental|Omega-3/thymoquinone / Deglycyrrhizinated Licorice|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.
~In addition to the standard care"
16317782|NCT04553705|Active Comparator|Active Comparator: standard care|The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia
16317783|NCT04553692|Experimental|IGM-8444 Single Agent Escalation|IGM-8444 will be administered intravenously as a single agent.
16317786|NCT04553692|Experimental|IGM-8444 Single Agent Expansion|IGM-8444 will be administered intravenously as a single agent in disease specific cohorts.
16317787|NCT04553692|Experimental|IGM-8444 + FOLFIRI Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI.
16317788|NCT04553692|Experimental|IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI and bevacizumab (and approved biosimilars).
16317789|NCT04553692|Experimental|IGM-8444 + Birinapant Escalation|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
16317790|NCT04553692|Experimental|IGM-8444 + Birinapant Expansion|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
16317791|NCT04553692|Experimental|IGM-8444 + Venetoclax Escalation|IGM-8444 will be administered intravenously in combination with Venetoclax.
16317792|NCT04553692|Experimental|IGM-8444 + Venetoclax Expansion|IGM-8444 will be administered intravenously in combination with Venetoclax.
16317793|NCT04553666|Experimental|Intervention Group|Four 200mg EGCG pills and one 250mg Vitamin C pill taken one time each day
16317794|NCT04553666|No Intervention|Usual Care Group|No study pills
16317795|NCT04553653|No Intervention|Baseline|Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
16317796|NCT04553653|Experimental|Intervention arm|The intervention arm will be enrolled after the checklist implementation.
16317797|NCT04553640|Experimental|Group A/Intervention Curriculum|Virtual patient (VP) cases and feedback available through solving VP cases and participants' self-report on the diagnosis of dizzy patients in the emergency department.
16317798|NCT04553640|Active Comparator|Group B/Control curriculum|Online articles on dizziness AND regular emergency department clinical rotations
16317799|NCT04553627|Experimental|Interventional cohort|Zeltiq system is a thermoelectric device that applies controlled cooling ot skin. The CoolAdvantage applicators use gentle vacuum pressure to draw tissue into the cup shaped applicator. A gelpad is applied to skin to improve thermal coupling between participant and the applicator cooling surface.
16317800|NCT04553614|Active Comparator|Exercise Referral Scheme|The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
16317801|NCT04553614|Experimental|Home-based HIIT|Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
16317802|NCT04553601|Experimental|8F-FDG PET/CT and PET/CT-guide targeted biopsy|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time.
16317803|NCT04553588|Active Comparator|Opioid Disposal Pouch|an opioid disposal pouch to inactivate and dispose of unused opioid medication within the first 30 days after surgery
16317804|NCT04553588|No Intervention|Usual Care|usual medication disposal includes multiple options as desired by patient; for example, flushing down toilet, giving to local pharmacist, giving to police department etc.
16317805|NCT04553575||CoViD-19 patients cohort|Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
16317806|NCT04553562|Experimental|Acupuncture group|For acupuncture group, sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads. The participants will be treated three times a week, on alternate days, for 6 successive weeks; 18 sessions for each patient in total.
16317807|NCT04553562|Sham Comparator|Sham acupuncture group|For the sham acupuncture group, aterile adhesive pads will be placed after skin disinfection on the acupoints and needles with a blunt tip will be inserted at the same acupoints in the acupuncture group without penetrating the skin.No manipulation of needles will be conducted. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
16317808|NCT04553562|No Intervention|Waiting list group|For the waiting list group, patients will receive no treatment in the first 6 weeks and will receive the same treatment used in the acupuncture group according to patients' preference.
16317809|NCT04553549||Transradial approach|"The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
16317810|NCT04553536|Active Comparator|Opioid analgesics|Mu-opioid receptor agonists (remifentanil, sulfentanil) will be used as the only analgesic(s) in the surgery.
16317811|NCT04553536|Experimental|Ketamine|Esketamine will be used as the only anagesic in the surgey.
16317812|NCT04553523|Other|Single Arm|Subjects with mild to moderate POAG undergoing cataract surgery & implantation of the Hydrus Microstent
16317813|NCT04553510|Experimental|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
16318201|NCT04551144||transwomen|Subjects starting estradiol therapy as part of standard of care for gender incongruence
16317814|NCT04553510|Active Comparator|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
16317815|NCT04553497|Active Comparator|Rehabilitation and interferential current therapy|Flipping a coin was used for simple randomization (tails - interferential current). In this arm, interferential current therapy was applied to the patients in addition to the rehabilitation program.
16317816|NCT04553497|Sham Comparator|Rehabilitation and sham interferential current therapy|Flipping a coin was used for simple randomization (heads - sham). In this arm, sahm interferential current therapy was applied to the patients in addition to the rehabilitation program.
16317817|NCT04553484|Experimental|Measuring cardiovascular performance and blood flow|
16317818|NCT04553471|Experimental|SBRT|5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
16317819|NCT04553458||Favorable outcome|Cure or stable disease
16317820|NCT04553458||Unfavorable outcome|Progressive (deteriorate/Recurrence) or Death
16317821|NCT04553445|Experimental|Chronotype|Determination whether monthly migraine load is affected by exercise in sync with chronotype
16317822|NCT04553445|Experimental|Green exercise|Determination whether monthly migraine load is affected by exercise in a natural environment
16317823|NCT04553432|Experimental|Omnigen + OmniLenz|Omnigen amniotic membrane 17mm disk with 6mm central aperture place under 18mm OmniLenz bandage contact lens
16317824|NCT04553432|Active Comparator|OmniLenz|Bandage contact lens alone
16317825|NCT04553419|Experimental|Cephalexin|Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
16317826|NCT04553419|Placebo Comparator|Placebo|The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
16317827|NCT04553406|Experimental|SPR720 low dose|SPR720 500 mg (2 capsules of 250 mg SPR720 and 2 capsules of placebo) administered orally once daily for 28 days
16317828|NCT04553406|Experimental|SPR720 high dose|SPR720 1000 mg (4 capsules of 250 mg SPR720) administered orally once daily for 28 days
16317829|NCT04553406|Placebo Comparator|Placebo|4 capsules of placebo once daily for 28 days
16317830|NCT04553406|Active Comparator|Standard of Care (SOC)|"Clarithromycin 500-1000 mg plus ethambutol HCl 15 mg/kg po once daily or Azithromycin 250-500 mg plus ethambutol HCl 15 mg/k po once daily. Optional rifampin 600 mg or rifabutin 300 mg po once daily may be added to the SOC regimen for up to 28 days.
~Additional SOC treatments may be considered in consultation with the medical monitor."
16317831|NCT04553393|Active Comparator|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.
16317832|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
16317833|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
16317834|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine|The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance
16317835|NCT04553380|Experimental|community patient group|The community doctor adjusts the basic insulin dosage daily according to the fasting blood glucose of the patient under the guidance of the specialist.
16317836|NCT04553380|Active Comparator|inpatient group|Endocrinologists in the in-patient department use the same basic insulin dose adjustment regimen to treat patients.
16317837|NCT04553367|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
16317838|NCT04553367|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
16317839|NCT04553328|Active Comparator|Group T|Group (T) received ultrasound guided (US) combined ipsilateral transverse abdominis plane (TAB) and ilioinguinal- iliohypogastric (ILIH) nerve block
16317840|NCT04553328|Active Comparator|Group I|Group (I) received US guided ipsilateral illioinguinal- illiohypogastric nerve block only.
16317841|NCT04553315|Experimental|intervention group|Intervention group was received Chest mobility exercises with Incentive spirometer and segmental breathing exercise and breath stacking technique . The patient in the intervention group was instructed to perform the exercises 3 times per day, 7-8 times per session for one week. Ensure that the patient fully hydrated by maintaining normal daily water requirement in the form of (30-35ml/kg/day) with restriction of intravenous fluids.
16317842|NCT04553315|Experimental|control group|control group will receive only routine hospital care
16317843|NCT04553302||Psoriatic Arthritis|Patients diagnosed with PsA according to CASPAR criteria by the rheumatologist were included.
16317844|NCT04553302||Rheumatoid Arthritis|Patients diagnosed with RA according to ACR / EULAR 2010 criteria by the rheumatologist were included.
16317845|NCT04553302||Asymptomatic Healthy Group|Participants had any neurological and/or rheumatological diseases, no complaints about the upper extremity. Participants diagnosed with OA according to traditional clinical criteria were excluded from the study.
16317935|NCT04552756|Experimental|Patients irradiated for high-grade glioma|Participants who receive radiotherapy or radiochemotherapy for glioblastoma (grade IV), anaplastic astrocytoma (grade III) or anaplastic oligodendroglioma (grade III).
16317846|NCT04553289|Experimental|exercising into pain|The participants will train during 12 with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. One exercise will be performed with pain ranging between 4 and 7 on a NPRS (Numeric Pain Rating Scale) and the rest of the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. At week 9, patients will continue to exercise with pain between 0 and 2 in all exercises. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
16317847|NCT04553289|Active Comparator|exercising with no/slight pain|The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
16317848|NCT04553263|Experimental|Contrave|Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
16317849|NCT04553263|Experimental|Bupropion|Participants will receive daily extended-release oral bupropion (Wellbutrin XL) at a dose of 450 mg. The dose will be titrated: 150 mg on Days 1 and 2, 300 mg on Days 3 and 4, and 450 mg on Day 5. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone. A reduction to 300 mg will permitted to alleviate medication-related adverse effects if they occur.
16317850|NCT04553263|No Intervention|Treatment As Usual|Participants will complete inpatient treatment as usual and will not receive any medication. This arm serves as a TAU control to compare outcomes versus Bupropion and Contrave arms.
16317851|NCT04553250|Active Comparator|Conventional technique|"In this group, double-staple colorectal anastomosis will be performed following the technique described by Lee et al: Prior to firing the endostapler, a suture will be placed on the rectal stump that includes both dog ears. After the punch comes out of the endostapler, the point will be tied, which will invaginate the two corners of the staple line on the same punch. Subsequently, the endostapler will be closed and fired, including the dog ears in the anastomotic rims"
16317852|NCT04553250|Active Comparator|Lateral invagination technique|In this group, the circular endostapler will be fired in a conventional way, that is, without having invaginated the two corners of the staple line.
16317853|NCT04553237||Patients over 90 years old|
16317854|NCT04553237||Patients between 70 and 89 years of age.|
16317855|NCT04553224|Other|All Subjects|Clinical and instrumental measurements
16317856|NCT04553211|Experimental|Expedited Partner Therapy (EPT)|Participants in the EPT arm will receive up to five partner antibiotic treatment packets to deliver to their recent sexual partners following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The intervention will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
16317857|NCT04553211|No Intervention|Control|Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
16317858|NCT04553198|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 3 weeks.
16317859|NCT04553198|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 3 weeks.
16317860|NCT04553185||Parkinson's disease patients|Patients with idiopathic or familial Parkinson's disease
16317861|NCT04553172||Affected family members|Affected family members
16317862|NCT04553172||Affected PM|Affected PM
16317863|NCT04553159|Experimental|Adipose Derived Stem Cell(ADSC) arm|"Participants allocated to this arm will have tumescent liposuction performed on them to obtain lipoaspirate. The lipoaspirate will then be processed to obtain the stromal vascular fraction. This Adipose derived stromal vascular fraction which contains stem cells will then be infiltrated into the keloid tissue as a single dose infiltration.
~This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6)."
16317864|NCT04553159|Active Comparator|Triamcinolone Acetanoide (TAC) arm|Participants in this arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid. This will be a single dose infiltration of 40mg/cubic centimetres of keloids.
16317865|NCT04553146|Experimental|Interventional arm|immediate implant placement in posterior sites using a custom-made sealing socket abutment combined to alveolar ridge preservation
16317866|NCT04553133|Experimental|PF-07104091|CDK2 monotherapy dose escalation
16317867|NCT04553133|Experimental|PF-07104091 + palbociclib + fulvestrant|CDK2 + palbociclib + fulvestrant
16317868|NCT04553133|Experimental|PF-07104091 + palbociclib + letrozole|CDK2 + palbociclib + letrozole
16317869|NCT04553133|Experimental|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 monotherapy dose expansion (SCLC)
16317870|NCT04553133|Experimental|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 monotherapy dose expansion (ovarian)
16317871|NCT04553133|Experimental|PF-07104091 monotherapy dose expansion (TNBC)|PF-07104091 monotherapy dose expansion (TNBC)
16317872|NCT04553133|Experimental|PF-07104091 + palbociclib + fulvestrant (post CDK4/6)|PF-07104091 + palbociclib + fulvestrant (post CDK4/6)
16317873|NCT04553133|Experimental|PF-07104091 + palbociclib + fulvestrant (CDK4/6 naive)|PF-07104091 + palbociclib + fulvestrant (CDK4/6 naive)
16317874|NCT04553133|Experimental|PF-07104091 + palbociclib + letrozole (CDK4/6 naive)|PF-07104091 + palbociclib + letrozole (CDK4/6 naive)
16317972|NCT04552574|No Intervention|Control group|No intervention for 4 weeks.
16317973|NCT04552561|Experimental|My MS Toolkit|10 Participants asked to use My MS Toolkit and meet weekly with a study coach via telephone.
16317875|NCT04553120|Experimental|Alternating treatments condition - 10 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
16317876|NCT04553120|Experimental|Alternating treatments condition - 9 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
16317877|NCT04553120|Experimental|Alternating treatments condition - 13 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
16317878|NCT04553120|Experimental|Alternating treatments condition - 12 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
16317879|NCT04553107|Experimental|Deprescribing Intervention|
16317880|NCT04553107|Active Comparator|Usual Care|
16317881|NCT04553094|No Intervention|Group 1|No physical training
16317882|NCT04553094|Experimental|Group 2|Endurance training
16317883|NCT04553094|Experimental|Group 3|Muscle building training
16317884|NCT04553094|Experimental|Group 4|Training combining endurance + muscle building
16317885|NCT04553081|Active Comparator|Dovato|We aim to include 120 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=40) or to switch to the dual regimen DTG/3TC (Dovato) (N=80).
16317886|NCT04553081|Active Comparator|Biktarvy|We aim to include 120 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=40) or to switch to the dual regimen DTG/3TC (Dovato) (N=80).
16317889|NCT04553055||community pharmacists|
16317890|NCT04553042|Experimental|Treatment Sequence ABC|Participants will receive a single dose of seltorexant as formulation (Test 1) (Treatment A) in Treatment Period 1, followed by a single dose of seltorexant as formulation (Test 2) (Treatment B) in Treatment Period 2, followed by a single dose of seltorexant as formulation (Reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
16317891|NCT04553042|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
16317892|NCT04553042|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
16317893|NCT04553042|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
16317894|NCT04553042|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
16317895|NCT04553042|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
16317896|NCT04553029||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
16317897|NCT04553029||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
16317898|NCT04553029||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
16317899|NCT04553029||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
16317900|NCT04553016|Experimental|1: Vaccine|"At Week 0, volunteers receive 5.0 x 10^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM). The dose is divided in 2 and administered in the deltoid muscle of each arm.
~At week 4,1.0 x 10^8 Plaque forming units (PFU) of MVA.tHIVconsv3 (M3) administered IM and 0.9 x 10^8 PFU of MVA.tHIVconsv4 (M4) are administered IM simultaneously, one into the deltoid muscle of each arm."
16317901|NCT04553016|Placebo Comparator|2. Placebo|Normal sterile saline (0.9% Sodium Chloride solution) administered IM as Placebo, the volume is matched to that of the vaccines and administered in the deltoid muscle of each arm at Week 0 and at week 4 .
16317902|NCT04553003|Experimental|glucocorticoid+hepatoprotectant group|glucocorticoid 0.4mg/kg/d+hepatoprotectant for 7d
16317903|NCT04553003|Active Comparator|hepatoprotectant group|hepatoprotectant for 7d
16317904|NCT04552990|Experimental|Tumor Excision, No Illumination|The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.
16317905|NCT04552990|Experimental|PDT treatment with jet-injections|Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.
16317906|NCT04552977|Experimental|fluzoparil+temozolomide|Participants receive fluzoparil and temozolomide
16317907|NCT04552964|Other|Single arm|This will be a single centre, single-arm, prospective pilot study.
16317908|NCT04552951|Active Comparator|Active|Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed
16317909|NCT04552951|No Intervention|Control|No vitamin D
16317910|NCT04552938||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA between June 2018 and May 2019.
16317911|NCT04552925|Active Comparator|Exercise Group|Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
16317912|NCT04552925|Experimental|EMG-BF Group|EMG-BF group will receive the same exercises as with the other group, but deltoid re-education exercises were performed under the guidance of EMG-BF device. All subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
16317917|NCT04552886|Experimental|Dendritic cell vaccine: Starting dose|This arm will evaluate the safety of administering a total dendritic cell dose of 3.5 x 10^6. A total of 3-6 patients will be enrolled with this dose. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
16317918|NCT04552886|Experimental|Dendritic cell vaccine dose de-escalation|If unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 1.75 X 10^6.
16317919|NCT04552886|Experimental|Dendritic cell vaccine dose escalation one|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 7.0 X 10^6.
16317920|NCT04552886|Experimental|Dendritic cell vaccine dose escalation two|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 7.0 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1.4 X 10^7.
16317921|NCT04552873|Experimental|EXPERIMENTAL GROUP|the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)
16317922|NCT04552873|Placebo Comparator|CONTROL GROUP|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
16317923|NCT04552860|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
16317924|NCT04552847|Experimental|Patients|"In the main part of the trial (part A) 75 patients with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/CT scan.
~In part B of the trial 10 up to 20 patients with with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/MR scan."
16317925|NCT04552821||Control|Non-sepsis and non-ARDS adults receiving mechanical ventilation
16317926|NCT04552821||Sepsis complicated with mild ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for mild ARDS
16317927|NCT04552821||Sepsis complicated with moderate/severe ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for moderate/severe ARDS
16317928|NCT04552808|Experimental|Yimitasvir Phosphate Capsules|The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A
16317929|NCT04552795|Experimental|Open-Label 3TC|12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
16317930|NCT04552782|Experimental|Alcohol CBM + PTSD CBM|
16317931|NCT04552782|Experimental|Alcohol CBM + PTSD Sham|
16317932|NCT04552782|Experimental|Alcohol Sham + PTSD CBM|
16317933|NCT04552782|Sham Comparator|Alcohol Sham + PTSD Sham|
16317934|NCT04552769|Experimental|Abemaciclib|Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops
16317936|NCT04552743|Experimental|MGTA-145 and Plerixafor HSC Mobilization|Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.
16317937|NCT04552717|Experimental|Intervention|"Participants will complete a web based pre-assessment and then given access to the app My Grief for three months followed by a web based post-assessment and an interview via telephone regarding their experiences of using the app, and follow-up questionnaires."
16317938|NCT04552717|No Intervention|Waitlist controll|Participants will get access to the app after three months.
16317939|NCT04552704|Experimental|Phase I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 with standard of care (i.e., steroids per treating physician and best supportive care) in the absence of disease progression or unacceptable toxicity.
16317940|NCT04552704|Experimental|Phase II, Arm I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
16317941|NCT04552704|Placebo Comparator|Phase II, Arm II (placebo)|Patients receive placebo IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
16317942|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation, Parent Education|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum) and Parent Education
16317943|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum), but no Parent Education
16317944|NCT04552678|Experimental|Healthy Eating, Active Play, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, and Parent Education
16317945|NCT04552678|Experimental|Healthy Eating + Active Play|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, but no Parent Education
16317946|NCT04552678|Experimental|Healthy Eating, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, and Parent Education
16317947|NCT04552678|Experimental|Healthy Eating + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, but no Parent Education
16317948|NCT04552678|Experimental|Healthy Eating + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, and Parent Education
16317949|NCT04552678|Experimental|Healthy Eating Only|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, but no Parent Education
16317950|NCT04552678|Experimental|Active Play, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, and Parent Education
16317951|NCT04552678|Experimental|Active Play + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, but no Parent Education
16317952|NCT04552678|Experimental|Active Play + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, and Parent Education
16317953|NCT04552678|Experimental|Active Play Only|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, but no Parent Education
16317954|NCT04552678|Experimental|Self-Regulation + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, and Parent Education
16317955|NCT04552678|Experimental|Self-Regulation Only|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, but no Parent Education
16317956|NCT04552678|Experimental|Food Literacy + Parent Education|Classrooms receive the core Food Literacy Curriculum, and parents are invited to complete web-based education modules.
16317957|NCT04552678|Experimental|Food Literacy Only|Classrooms only receive the core Food Literacy Curriculum, and no other intervention materials or parent education.
16317958|NCT04552665||Adults|Patients who have cardiac arrhythmia
16317959|NCT04552652|Experimental|High-intensity interval training - telerehabilitation|12 weeks of high-intensity interval training. Three sessions per week will be performed (36 total sessions).
16317960|NCT04552652|Active Comparator|Moderate-intensity continuous training - telerehabilitation|12 weeks of moderate-intensity continuous training. Three sessions per week will be performed (36 total sessions).
16317961|NCT04552639|Active Comparator|Treatment as usual|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, excluding the NEAT group.
16317962|NCT04552639|Experimental|Treatment as usual and NEAT group|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, alongside NEAT group.
16317963|NCT04552626|Experimental|Prolonged sitting (social breaks)|
16317964|NCT04552626|Experimental|Prolonged sitting with step-up exercise break|
16317965|NCT04552626|Experimental|Prolonged sitting with simple resistance activity breaks|
16317966|NCT04552613|Experimental|Standard programme group|EGFR-TKI targeted therapy
16317967|NCT04552613|Active Comparator|controlled programme group|EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
16317968|NCT04552600|Experimental|NuvastaticTM 1000 mg|NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.
16317969|NCT04552600|Active Comparator|Placebo|NuvastaticTM (without active) will be given orally, three times per day for 12 months
16317970|NCT04552587|Experimental|HEART|Patients and caregivers will complete a HEART visit virtually or in person. The visit includes a needs assessment that generates a tailored care plan with messages, referrals and educational materials for discussion with a nurse. Caregivers will receive brief training about the HEART App and then use the App for 4 weeks with bi-weekly real-time prompts and feedback.
16317971|NCT04552574|Experimental|Intervention group|All subjects will intake HMR(Home meal replacement)-type omega-3-balanced-diet for 4 weeks.
16317974|NCT04552548|No Intervention|Control group|the patients will receive regular analgesics (1 µg /kg fentanyl with induction and 15mg/kg paracetamol before extubation)
16317975|NCT04552548|Active Comparator|TAP group|the patients will receive bilateral TAP block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
16317976|NCT04552548|Active Comparator|quadratus lumborum group|the patients will receive bilateral quadratus lumborum block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
16317977|NCT04552535||Second line (2L) afatinib|Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
16317978|NCT04552535||Second line (2L) chemotherapy|Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
16317979|NCT04552522|Experimental|Shrimp allergy with Intend to eat shrimp|Case shrimp Immunoglobulin E mediated allergy and intend to eat shrimp and start oral immunotherapy for shrimp
16317980|NCT04552522|No Intervention|Shrimp allergy with avoid shrimp|Case shrimp allergy with avoid shrimp
16317981|NCT04552509|Other|Observation|Observational study of patient efficacy and side effects
16317982|NCT04552483|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
16317983|NCT04552483|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days.
16317984|NCT04552470|Placebo Comparator|Placebo|
16317985|NCT04552470|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
16317986|NCT04552470|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
16317987|NCT04552470|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
16317988|NCT04552457|Experimental|No activity restrictions|
16317989|NCT04552457|Active Comparator|Activity restrictions|
16317990|NCT04552444||the death group|Through the corresponding treatment, the patients who died within 28 days
16317991|NCT04552444||the survival group|Through the corresponding treatment, the patients who survived within 28 days
16317992|NCT04552431|Placebo Comparator|Placebo|Men assigned to placebo
16317993|NCT04552431|Experimental|Ciprofloxacin alone|Men assigned to Ciprofloxacin alone
16317994|NCT04552431|Experimental|Tamsulosin alone|Men assigned to Tamsulosin alone
16317995|NCT04552431|Experimental|Combination of ciprofloxacin and tamsulosin|Men assigned to a combination of ciprofloxacin and tamsulosin
16317996|NCT04552418|Experimental|Potato-based dietary starch supplement|Patients undergoing cancer treatment with dual immune checkpoint inhibitors (ICI) will receive potato-based dietary starch supplements.
16317997|NCT04552405|Other|FAP patients|FAP patients who underwent prophylactic total colectomy
16317998|NCT04552379|Active Comparator|Interferon|Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
16317999|NCT04552379|No Intervention|Standard of Care|Standard of Care; following national guidelines regarding self-isolation and infection prevention
16318000|NCT04552366|Experimental|Group A: Intramuscular administration|24 subjects. 5E10 VP of Ad5-nCoV on Day 0 and on Day 56.
16318001|NCT04552366|Experimental|Group B: Mixed administration|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0 and a mucosal administration of 2E10 VP on Day 28.
16318002|NCT04552366|Experimental|Group C: Mucosal administration, high dose|24 subjects. A mucosal administration of 2E10 VP of Ad5-nCoV on Day 0 and Day 28.
16318003|NCT04552366|Experimental|Group D: Mucosal administration, low dose|24 subjects. A mucosal administration of 1E10 VP of Ad5-nCoV on day 0 and Day 28.
16318004|NCT04552366|Active Comparator|Group E: Intramuscular administration, one dose|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0.
16318005|NCT04552366|Experimental|Group F: Intramuscular administration, two doses|24 subjects. Two intramuscular administrations of 5E10 VP of Ad5-nCoV at left and right arms on day 0.
16318006|NCT04552353|Experimental|Vaway Lyo-Injection|Voriconazole, 200 mg/vial
16318007|NCT04552353|Active Comparator|Vfend Lyo-Injection|Voriconazole, 200 mg/vial
16318008|NCT04552327|Experimental|Solcera|
16318009|NCT04552327|Placebo Comparator|Placebo|
16318010|NCT04552327|Active Comparator|Solaraze|
16318011|NCT04552314||patients after primary MMC-augmented trabeculectomy|
16318012|NCT04552301|Experimental|Cognitive Processing Therapy and Targeted Asthma Education|Intervention group - Cognitive Processing Therapy and Targeted Asthma Education
16318013|NCT04552301|Active Comparator|Psychotherapy and General Asthma Education|Control group - Psychotherapy and General Asthma Education
16318015|NCT04552275|Other|HALT Cohort|Patients who develop HALT
16318016|NCT04552275|Other|Control Group|Patients who do not develop HALT
16318017|NCT04552262|Experimental|BAY2327949 / Placebo|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
16318018|NCT04552262|Experimental|Placebo / BAY2327949|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
16318019|NCT04552249||Group 1|
16318020|NCT04552249||Group 2|
16318021|NCT04552249||Group 3|
16318022|NCT04552249||Group 4|
16318023|NCT04552249||Group 5|
16318024|NCT04552249||Group 6|
16318025|NCT04552223|Experimental|Nivolumab Plus Relatlimab Group|Participants in this group will receive Nivolumab and Relatlimab administered together on Day 1 of every 4 week cycle. Both drugs will be administered until disease progression or intolerable toxicity for up to 24 months.
16318026|NCT04552197|Experimental|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
16319586|NCT04541589|Active Comparator|Arm 2|Arm 2 - Iscalimab Dose 2 and Placebo
16318027|NCT04552197|Experimental|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
16318028|NCT04552197|Experimental|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
16318029|NCT04552197|Active Comparator|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
16318030|NCT04552197|Experimental|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
16318031|NCT04552197|Experimental|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
16318032|NCT04552184|Active Comparator|GPOEM|
16318033|NCT04552184|Sham Comparator|SHAM|
16318034|NCT04552171|Experimental|Access to Game Plan app and 24-hour helpline|Participants in this condition will be provided access to the Game Plan app and encouraged to use it after they complete their baseline assessments and STI testing has been completed. These participants will also be provided with access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not.
16318035|NCT04552171|No Intervention|Access to a 24-hour helpline|"Participants in this condition will be provided access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not. Use of this comparison condition is intended to provide a real-world test of the added benefit of using Game Plan, above and beyond the current standard of care for HIV/STI self-testing, which involves providing users with access to a 24-hour helpline."
16318036|NCT04552158|No Intervention|controlled group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management only
16318037|NCT04552158|Experimental|experimental group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management and nutritional management in the form of the Mediterranean diet
16318038|NCT04552145|Active Comparator|surgery|Decompression surgery
16318039|NCT04552145|Active Comparator|physiotherapy|Physical therapy program
16318040|NCT04552132|Experimental|GentleWave|Patients randomly assigned to the GentleWave group will receive irrigation and activation of irrigants with the GentleWave device (multisonic energy) by Sonendo.
16318041|NCT04552132|Active Comparator|EndoActivator|Patients randomly assigned to the EndoActivator group will receive irrigation via a side-vented needle and activation using the EndoActivator (sonic energy) by Dentsply Sirona.
16318042|NCT04552119||HEALICOIL Knotless Suture REGENESORB|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless REGENESORB
16318043|NCT04552119||HEALICOIL Knotless PEEK|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless PEEK
16318044|NCT04552106|Active Comparator|Group 1|10 subjects
16318045|NCT04552106|Active Comparator|Group 2|10 subjects
16318046|NCT04552106|Active Comparator|Group 3|10 subjects
16318047|NCT04552106|Active Comparator|Group 4|10 subjects
16318048|NCT04552106|Active Comparator|Group 5|10 subjects
16318049|NCT04552093|Experimental|Colorectal liver metastases|Patients with potentially resectable colorectal liver metastases will undergo hepatic artery infusion pump placement. Subsequent hepatic artery infusion of floxuridine via the HAIP as well as standard of care Dutch systemic chemotherapy (FOLFOX or FOLRIRI) will be administered in a combined chemotherapy schedule.
16318050|NCT04552080|Active Comparator|Test: Amoxicillin|
16318051|NCT04552080|Placebo Comparator|Comparator: Placebo|
16318052|NCT04552067|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
16318053|NCT04552067|Active Comparator|Enoxamed|patients are given a curative dose of Enoxaparin (ENOXA)
16318054|NCT04552054|Active Comparator|CT guided localization|Computerized Tomography(CT)-guided percutaneous lung puncture staining marker localization
16318055|NCT04552054|Experimental|MR+3D guided localization|Mixed reality(MR)+3D printing-guided percutaneous lung puncture staining marker localization
16318056|NCT04552041|Experimental|Prospecta|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
16318057|NCT04552041|Placebo Comparator|Placebo|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
16318058|NCT04552015|Other|volunteers|two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection
16318059|NCT04552002|Experimental|Synbiotic group|"Intervention group:
~Will receive synbiotic supplements: one capsule/day. Each capsule contains 20 billion CFU multi-strain probiotics + prebiotics (inulin and oligosaccharides) for a duration of 6 months."
16318060|NCT04552002|No Intervention|Placebo group|Will receive a placebo. The placebo will be similar to the synbiotic supplements in appearance.
16318061|NCT04551989||Participants with EGPA who have received NUCALA treatment|Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.
16318062|NCT04551976|Experimental|Mindful Video Game Then Laundry Group|Receive mindfulness prompt and play their video game first and fold laundry second.
16318063|NCT04551976|Experimental|Mindful Laundry Then Video Game Group|Receive mindfulness prompt and fold laundry first, play their video game second.
16318064|NCT04551976|No Intervention|Control Video Game Then Laundry Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will play their video game first and fold laundry second.
16318065|NCT04551976|No Intervention|Control Laundry Then Video Game Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will fold laundry first and will play their video game second.
16318066|NCT04551963|Experimental|Zanubrutinib + Moderate CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg twice daily (BID) + fluconazole (days 4 - 10), zanubrutinib 320 mg once daily (QD) (days 13 - 19), zanubrutinib 80 mg BID + diltiazem (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
16318067|NCT04551963|Experimental|Zanubrutinib + Strong CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg QD + voriconazole (days 4 - 10), zanubrutinib 320 mg QD (days 13 - 19), zanubrutinib 80 mg QD + clarithromycin (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
16318068|NCT04551950|Experimental|Cohort 1A:M7824+cisplatin/carboplatin+paclitaxel+bevacizumab|
16318069|NCT04551950|Experimental|Cohort1B:M7824+cisplatin or carboplatin+paclitaxel|
16318070|NCT04551950|Experimental|Cohort 2: M7824+cisplatin+ radiotherapy|
16318071|NCT04551937|Placebo Comparator|Control|4-5 week period where participant will consume control beverage
16318072|NCT04551937|Experimental|Prebiotic|4-5 week period where participant will consume the intervention beverage
16318073|NCT04551924|Experimental|dose 1|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
16318074|NCT04551924|Experimental|dose 2|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
16318075|NCT04551924|Experimental|dose 3|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
16318076|NCT04551924|Experimental|dose 4|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
16318077|NCT04551924|Active Comparator|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
16318078|NCT04551911|Experimental|30 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
16318079|NCT04551911|Placebo Comparator|0 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
16318080|NCT04551898|Experimental|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
16318081|NCT04551898|Experimental|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
16318082|NCT04551898|Experimental|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
16318083|NCT04551898|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
16318084|NCT04551885|Experimental|FT516 in combination with avelumab|
16318085|NCT04551872|Experimental|Obese High Risk|200 participants with BMI ≥30 and 10-year ASCVD risk ≥20%
16318086|NCT04551872|Experimental|Obese Low Risk|200 participants with BMI ≥30 and 10-year ASCVD risk <7.5%
16318087|NCT04551872|No Intervention|Non-Obese High Risk|100 participants with BMI 18-25 and 10-year ASCVD risk ≥20%
16318088|NCT04551872|No Intervention|Non-Obese Low Risk|100 participants with BMI 18-25 and 10-year ASCVD risk <7.5%
16318089|NCT04551859|Other|Sacrospinofixation|After accepting the surgeon's proposal to perform a sacrospinofixation to treat the pelvic organ prolapse, participation in this study will be proposed to the patient. It will not change the management or the course of the surgery
16318090|NCT04551846|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
16318091|NCT04551846|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
16318092|NCT04551833|Experimental|Group (T) : 30 patients (Tramadol group)|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 1.5 mg/kg Tramadol.
16318093|NCT04551833|Experimental|Group (D) : 30 patients (Dexamethasone group):|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 8mg of Dexamethasone
16318094|NCT04551820||Regular Hours|These subjects have undergone a cholecystectomy during regular hours at the Institution.
16318095|NCT04551820||After Hours|These subjects have undergone a cholecystectomy during after hours at the Institution.
16318096|NCT04551807|Active Comparator|Modified natural cycle|corpus luteum present
16318097|NCT04551807|Active Comparator|Programmed cycle|corpus luteum absent
16318098|NCT04551794|Experimental|Online self-help program with additional peer support|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
16318099|NCT04551794|No Intervention|No intervention: waitlist-control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 9 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
16318100|NCT04551794|Experimental|Online self-help program with therapeutic guidance|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences and difficulties concerning the program on a weekly basis with a therapeutic guide on the phone.
16318101|NCT04551781|Experimental|steroid|20 mg prednisolone for 14 days
16318102|NCT04551781|Placebo Comparator|control|controll
16318103|NCT04551768|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
16318104|NCT04551768|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
16318105|NCT04551755|Active Comparator|Ivermectin plus Doxycycline plus standard care|Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours 2) Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes 3) Standard symptomatic and supportive treatment; Tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements
16318106|NCT04551755|Placebo Comparator|Placebo plus standard care|"1) Standard symptomatic and supportive treatment with placebo; Standard treatment includes tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements.
~Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days"
16318107|NCT04551729|Active Comparator|Fluid restriction|Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
16318108|NCT04551729|Experimental|Liberal fluid intake|Patient will receive a lifestyle advice for liberal fluid intake for 3 months.
16318109|NCT04551703|Experimental|Adrenaline saline irrigation|Adrenaline saline irrigation will be prepared by adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000
16318110|NCT04551703|No Intervention|Normal saline irrigation|Normal saline bag will be used for irrigation during the procedure
16318111|NCT04551677|Experimental|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
16318112|NCT04551677|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to <9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
16318113|NCT04551677|Experimental|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged >=65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
16318114|NCT04551664|Experimental|EVT group|Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.
16318115|NCT04551664|Active Comparator|Best medical management group|Patients in this group will receive best medical management alone.
16318116|NCT04551651|Active Comparator|ApplTree reminder app intervention|A reminding app developed with features that, based on previous research, will increase use and ease of use for individuals with ABI when setting smartphone reminders.
16318117|NCT04551651|Active Comparator|Google Calendar reminder app intervention|A widely available calendar app that can be used to set reminders.
16318118|NCT04551638||Online Videogame Players|One cohort of healthy young adults players of online video games.
16318119|NCT04551612||Patients with cholesteatoma|Patients with cholesteatoma in one ear that will compared with the other healthy one.
16318120|NCT04551599|Experimental|Part 1: Sequence 1|"Healthy, young, adult participants will receive danicopan once each Period as follows:
~Period 1: Danicopan administered under fed conditions.
~Period 2: Danicopan administered under fasted conditions.
~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
16318121|NCT04551599|Experimental|Part 1: Sequence 2|"Healthy, young, adult participants will receive danicopan once each Period as follows:
~Period 1: Danicopan administered under fasted conditions.
~Period 2: Danicopan administered under fed conditions.
~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
16318122|NCT04551599|Experimental|Part 2|Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.
16318123|NCT04551586|Experimental|Sequence 1|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).
~Period 2: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).
~Period 3: ACH-0145228 as power-in-capsule under fasted conditions (reference).
~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
16318124|NCT04551586|Experimental|Sequence 2|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).
~Period 2: ACH-0145228 as power-in-capsule under fasted conditions (reference).
~Period 3: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).
~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
16318125|NCT04551586|Experimental|Sequence 3|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: ACH-0145228 as power-in-capsule under fasted conditions (reference).
~Period 2: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).
~Period 3: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).
~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
16318126|NCT04551573|Experimental|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
16318127|NCT04551573|Experimental|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
16318128|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
16318129|NCT04551547|Experimental|Experimental Vaccine-low dosage|low dosage inactivated SARS-CoV-2 vaccine
16318130|NCT04551547|Experimental|Experimental Vaccine-medium dosage|medium dosage inactivated SARS-CoV-2 vaccine
16318131|NCT04551547|Placebo Comparator|Placebo|No active ingredient in the placebo
16318132|NCT04551534|Experimental|DNL201|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
16318133|NCT04551534|Placebo Comparator|Placebo|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
16318134|NCT04551521|Experimental|BRAF V600E/K|
16318135|NCT04551521|Experimental|ERBB2|
16318136|NCT04551521|Experimental|ALK|
16318137|NCT04551521|Experimental|PI3K/AKT|
16318138|NCT04551521|Experimental|PI3K-AKT-TAX|
16318139|NCT04551521|Experimental|MAPK|
16318140|NCT04551521|Experimental|Immune evasion|
16318142|NCT04551482|Experimental|Oxytocin|Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
16318143|NCT04551482|Placebo Comparator|Placebo|Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
16318144|NCT04551469|Experimental|Treatment Arm|30 minutes of listening to music
16318145|NCT04551469|No Intervention|Standard of Care|actual sounds of the intensive care unit environment
16318146|NCT04551456|Placebo Comparator|Placebo Infusion PBS|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.
~Assigned Interventions:
~Biological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo"
16318147|NCT04551456|Experimental|Single dose Infusion WJMSCs|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.
~Biological/Vaccine:
~WJMSCs Vs.placebo"
16318148|NCT04551456|Experimental|Infusion WJMSCs multiple doses|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.
~Biological/Vaccine:
~WJMSCs Vs.placebo"
16318149|NCT04551443|Placebo Comparator|Placebo PBS|Standard therapy+Intravenous infusion PBS in patients with AMI
16318150|NCT04551443|Active Comparator|WJMScs|Standard therapy+Intravenous infusion WJMSCs in patients with AMI
16318151|NCT04551430|Experimental|Cohort A: Cabozantinib|Patients randomized to Cohort A will take cabozantinib at a dose of 60 mg by mouth once each day of each 28-day cycle. At time of progression, patients will continue on cabozantinib daily but will reduce their dose to 40 mg. They will cross over into Cohort B and initiate treatment.
16318152|NCT04551430|Experimental|Cohort B: Cabozantinib + Nivolumab + Ipilimumab|"Patients randomized to Cohort B will take cabozantinib at a dose of 40 mg by mouth once each day. Nivolumab will given IV at a dose of 3 mg/kg over approximately 30 minutes every 3 weeks for 4 doses, followed by 480 mg over approximately 30 minutes every 4 weeks until treatment discontinuation. Ipilimumab will be given IV at a dose of 1 mg/kg over approximately 30 minutes every 3 weeks for 4 doses.
~Participants who cross-over from Cohort A into Cohort B They will cross over into Cohort B will initiate treatment with nivolumab at a dose of 3 mg/kg IV over approximately 30 minutes and ipilimumab at a dose of 1 mg/kg IV over approximately 30 minutes. Nivolumab and ipilimumab will be given every 3 weeks for 4 doses. Nivolumab will then be continued at a dose of 480 mg IV over approximately 30 minutes every 4 weeks, with cabozantinib to continue at 40 mg every day."
16318153|NCT04551417|Active Comparator|Dorsal onlay graft urethroplasty|
16318154|NCT04551417|Experimental|Ventral onlay graft urethroplasty|
16318155|NCT04551404|Experimental|Study Intervention(s) A|"TRNS bilateral temporal regions combined with AS for 20 minutes
~Sham-tRNS bilateral temporal regions combined with Sham-AS for 20 minutes"
16318156|NCT04551404|Experimental|Study Intervention(s) B = Control Intervention|"TRNS bilateral temporal regions for 20 minutes
~Sham-tRNS bilateral temporal regions for 20 minutes"
16318157|NCT04551391||Case|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:
~Previous (within 3 years) eGFR >45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND
~Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND
~Increasing creatinine >= 27μmol/L above index value within 48 hours"
16318158|NCT04551391||Control|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR > 60).
~This group will be recruited contemporaneously with, and matched to, AKI participants by:
~Age (± 5 years)
~Sex
~AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not"
16318159|NCT04551378||Observational (survey)|Patients and survivors complete a survey online over 20-30 minutes at baseline about COVID-19 specific psychological distress, health care utilization, health behavior, social and financial disruptions, HRQoL, their social support, perceived benefits under times of stress, and the ability to manage stress. Patients and survivors may be contacted again at 6 months and 1 year for COVID-19 research.
16318160|NCT04551365|Experimental|Obese patients I|Undergoing lifestyle changes (rehabilitation) along daily intake of chitosan supplement, 4 capsules twice daily at main meals.
16318161|NCT04551365|Placebo Comparator|Obese patients II|Undergoing lifestyle changes (rehabilitation) along daily intake of placebo, 4 capsules twice daily at main meals.
16318162|NCT04551365|Experimental|Control I|Daily intake of chitosan supplement, 4 capsules twice daily at main meals.
16318163|NCT04551365|Placebo Comparator|Control II|Daily intake of placebo 4 capsules twice daily at main meals.
16318164|NCT04551352|Experimental|Part I: Single Participant Cohorts (IV)|Part I is a dose escalation in single participant cohorts. RO7293583 will be administered intravenously (IV) every three weeks (Q3W). The starting dose will be 0.045mg and the maximum dose explored will be 1.5mg.
16318198|NCT04551157|Experimental|Video Viewing|Participants will receive the intervention where they will view two patient information videos. The first video will be viewed within the first week of their inpatient stay and the second video will be viewed just before discharge.
16318199|NCT04551157|No Intervention|Treatment as usual|No change to routine care.
16318165|NCT04551352|Experimental|Part II: Multiple Participant Cohorts (IV/SC)|Multiple ascending dose-escalation of RO7293583 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation will be determined by Part I and RO7293583 will be administered IV or SC every 3 weeks. Dose-escalation will be undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. Fractionated, step up or subcutaneous dosing may be implemented. The maximum dose explored will be 600mg IV and 160mg SC.
16318166|NCT04551339|Active Comparator|High dose Zinc (PreserVision AREDS formulation soft gels or tablets)|Subjects will have a high dose Zinc supplementation in combination with Copper, Vitamin C/E and beta-carotene
16318167|NCT04551339|Active Comparator|Multivitamin with 11mg of zinc|Subjects in this arm will have a multivitamin supplement with 11mg of zinc
16318168|NCT04551326|Experimental|hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
16318176|NCT04551287||Training dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
16318177|NCT04551287||SYSMH internal validation dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
16318178|NCT04551287||TAHGMU external validation dataset|600 slides from 600 eligible individuals were obtained in the Third Affiliated Hospital of Guangzhou Medical University (TAHGMU, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
16318179|NCT04551287||GWCMC external validation dataset|600 slides from 600 eligible individuals were obtained in Guangzhou Women and Children Medical Center (GWCMC, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
16318180|NCT04551287||Prospective validation dataset|A prospective validation dataset was conducted to distinguish the diagnostic performance of the cytotechnician, CAISS, and CAISS-assisted groups, in which 2,780 eligible slides from 2,780 individuals were obtained and prospectively labeled between August 28, 2020 and October 16, 2020 at SYSMH.
16318181|NCT04551287||Randomized controlled trial|a prospective randomized controlled trial was conducted to compare the performance of the cytotechnician, CAISS, and CAISS-assisted groups in SYSMH. Here, 618 slides were collected between August 13, 2020, and December 14, 2020, to build the SYSMH randomized controlled trial. The remaining 608 slides after quality control were randomly assigned (1:1:1) to the CAISS group (n = 201), the cytotechnician group (n = 203), and the CAISS-assisted combination group (n = 204).
16318182|NCT04551274|Experimental|Music Therapy|Participants in the music therapy group will complete a 4 week music therapy program, with a minimum of 2 sessions per week.
16318183|NCT04551274|No Intervention|Control|Control group participants will not experience any intervention
16318184|NCT04551261|Experimental|Part A|Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
16318185|NCT04551261|Experimental|Part B|Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
16318186|NCT04551248||PCV13 recipients (children)|Children < 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018 under the national childhood immunization program in South Korea.
16318187|NCT04551248||PPSV23 recipients (elderly adults)|Persons 65 years or older who had received at least one dose of PPSV23 between January, 2014 and December, 2018 under the national immunization program in South Korea.
16318188|NCT04551248||Influenza vaccine recipients (elderly adults)|Persons 65 years or older who had received at least one dose of influenza vaccine (as comparator) between January, 2014 and December, 2018 under the national immunization program in South Korea.
16318191|NCT04551209|Experimental|Apical patency group|Patients in which apical patency is maintained.
16318192|NCT04551209|No Intervention|Non- apical patency group|Patients in which apical patency is not maintained
16318193|NCT04551196|Active Comparator|Alternating Regimen|A regimen of acetaminophen and ibuprofen alternating doses every 3 hours.
16318194|NCT04551196|Active Comparator|Combined Regimen|A regimen of acetaminophen and ibuprofen dosed together every 6 hours.
16318195|NCT04551183|Experimental|OnlyGroup|Patients are their own witnesses
16318196|NCT04551170|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
16318197|NCT04551170|Placebo Comparator|Placebo|Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
16318200|NCT04551144||Transmen|Subjects starting testosterone therapy as part of standard of care for gender incongruence
16319852|NCT04539769|Active Comparator|BI group|Conventional Billroth I reconstruction
16318204|NCT04551118|Experimental|tACS group|Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
16318205|NCT04551118|Experimental|tDCS group|Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
16318206|NCT04551118|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current continued less than 30s.
16318207|NCT04551105|Active Comparator|First session: manual review first and then review with CADx|"Each rater will interpret the Dataset A cases in different random order without any assistance of artificial assistance first, and then interpret the Dataset B cases in different random order with BR-USCAD DS."
16318208|NCT04551105|Active Comparator|First session: review with CADx first and then manual review|"Each rater will interpret the Dataset A cases in different random order with BR-USCAD DS first, and then interpret the Dataset B cases in different random order without any assistance of artificial assistance."
16318209|NCT04551105|Active Comparator|Second session: manual review first and then review with CADx|"At least 4 weeks after first session for memory washing out. Each rater will interpret the Dataset A cases in different random order without any assistance of artificial assistance first, and then interpret the Dataset B cases in different random order with BR-USCAD DS."
16318210|NCT04551105|Active Comparator|Second session: review with CADx first and then manual review|"At least 4 weeks after first session for memory washing out. Each rater will interpret the Dataset A cases in different random order with BR-USCAD DS first, and then interpret the Dataset B cases in different random order without any assistance of artificial assistance."
16318211|NCT04551092|Experimental|Single|Single group to receive intervention
16318212|NCT04551079|Experimental|TAK-994 Dose A+ Placebo + TAK-994 Dose B|TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
16318213|NCT04551079|Experimental|TAK-994 Dose B + TAK-994 Dose A + Placebo|TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
16318214|NCT04551079|Experimental|Placebo + TAK-994 Dose B+ TAK-994 Dose A|TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose B tablets orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
16318219|NCT04551040|Experimental|Primary Cohort|Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.
16318220|NCT04551027|Experimental|compensatory cognitive treatment|compensatory cognitive treatment intervention, focusing on learning cognitive strategies to overcome cognitive deficits.
16318221|NCT04551027|No Intervention|control group|standard ambulatory treatment
16318222|NCT04551014|Experimental|With EverLift|Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.
16318223|NCT04551014|Experimental|Without EverLift|Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.
16318224|NCT04551001|Experimental|Cold forcep|Cold forcep polypectomy performed for polyps <=3mm.
16318225|NCT04551001|Experimental|Cold snare|Cold forcep polypectomy performed for polyps <=3mm.
16318227|NCT04550975|Experimental|Advanced Cognitive Stimulation Therapy|Advanced Cognitive Stimulation Therapy (ACST), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. ACST will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee or care home staff.
16318228|NCT04550975|No Intervention|Treatment as usual|Standard care in care homes
16318229|NCT04550962||Participants with asthma|Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
16318230|NCT04550949|Experimental|QL1206|QL1206 injection(120mg)was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
16318231|NCT04550949|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
16318232|NCT04550923|Experimental|Investigational device (non-rigid) group|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
16318233|NCT04550923|Active Comparator|Control device (rigid) group|Use rigid (PEEK) interbody fusion device .
16318234|NCT04550910|Other|Arm A|40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy
16318235|NCT04550910|Experimental|Arm B|28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy
16318236|NCT04550897|Experimental|BM7PE treatment|"The BM7PE treatment will be administered as a 20-minute i.v. infusion. The treatment is repeated after 2 weeks (day 15). The patients will be treated as in-patients and will stay at the hospital until toxicity have decreased to grade 2 and or plasma AST and or ALT levels has started to decrease. For at least a minimum of 3 days.
~The dose administered to the patient will be 2.5, 5.0, 7.5, 10.0, 15.0 and 20.0 μg/kg body weight."
16318237|NCT04550845|Experimental|Specific Aim 1|In specific aim 1, twelve focus group interviews (AA and rural White men with localized prostate cancer and caregivers, N = 50 dyads or N = 100 participants) will be conducted to explore comprehension of prognostic genomics as well as facilitators and barriers to genomic health literacy and to assess the acceptability and value of the revised PCLA education video.
16318238|NCT04550845|Experimental|Specific Aim 2|In specific aim 2, participants will be randomized into intervention versus control group. Twenty focus groups (AA and rural White men with localized prostate cancer and caregivers, N = 80 dyads or N = 160 participants) will be conducted to culturally conceptualize the study intervention and to provide qualitative contextual evaluation. The design for this aim is a randomized controlled, parallel group, repeated measures, non-blinded trial, with a nurse-delivered tailored prostate cancer education, communication coaching, and the prognostic genomics revised Prostate Cancer Literacy Video compared to the prognostic genomics revised Prostate Cancer Literacy Video.
16318239|NCT04550832|Active Comparator|Arm1(D0)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will not administered
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
16318240|NCT04550832|Experimental|Arm2(D400)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 400 mg orally once daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
16318241|NCT04550832|Experimental|Arm3(D800-OD)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 800 mg orally once daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
16318242|NCT04550832|Experimental|Arm4(D1200)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 1200 mg orally once daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
16318243|NCT04550832|Experimental|Arm5(D800-BD)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 800 mg orally twice daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
16318244|NCT04550819|Experimental|IEBSs in malignant extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with malignant extrahepatic biliary stricture
16318245|NCT04550819|Active Comparator|CPBSs in malignant extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with malignant extrahepatic biliary stricture
16318246|NCT04550819|Experimental|IEBSs in benign extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with benign extrahepatic biliary stricture
16318247|NCT04550819|Active Comparator|CPBSs in benign extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with benign extrahepatic biliary stricture
16318248|NCT04550806||GDM|
16318249|NCT04550806||non-GDM|
16318250|NCT04550793||Intervention|The stroke patients who receive botulinum toxin injection at affected brachialis and/or biceps brachials.
16318251|NCT04550793||Control|The stroke patients who do not receive botulinum toxin injection at affected brachialis and/or biceps brachials in the past 3 months.
16318253|NCT04550767||local infections|local infections
16318254|NCT04550767||systemic infections|systemic infections
16318256|NCT04550741|Experimental|Telerehabilitation|Experimental group of 100 patients using the M-Réhab BPCO telerehabilitation solution. The solution will be provided during the fourth and final week of RR's stay during which patients will be trained to use all of the solution's features. Patients will carry out the entire post-rehabilitation using the remote rehabilitation solution and will benefit from medical assessments by teleconsultation at 1, 3, 6 and 12 months as well as assessments at 3, 6 and 12 months by filling. electronic auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
16318381|NCT04549896|Experimental|CT scan|CT scan with a last generation 256 slice machine of occluded coronary artery before CTO PCI
16318257|NCT04550741|No Intervention|Standard chronic care|following usual standard chronic care. Patients will receive during the last week of stay in the center, the usual advice to continue physical activity and nutritional advice at home. The evaluations at 3, 6 and 12 months will be done by electronic filling of auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
16318258|NCT04550728|Experimental|FES+robot|Participants in this group will have FES during ankle robot training
16318259|NCT04550728|Active Comparator|Robot|Participants in this group will have ankle robot training only
16318260|NCT04550715|Experimental|Brief intervention (BI) then Portal|The BI will be delivered at intake and the portal will occur for 4 weeks starting at intake.
16318261|NCT04550715|Experimental|Brief intervention (BI) then Enhanced Usual Care (EUC)|The BI will be delivered at intake and EUC will be added 4 weeks later.
16318262|NCT04550715|Experimental|Enhanced Usual Care (EUC) then Portal|EUC will be delivered at intake and the portal will occur for 4 weeks starting at intake.
16318263|NCT04550715|Active Comparator|Enhanced Usual Care (EUC) then EUC|EUC will be delivered at intake and delivered again 4 weeks later.
16318264|NCT04550702||Women received Mirabegron|Women with overactive bladder syndrome received Mirabegron
16318265|NCT04550689|Active Comparator|Xenograft|
16318266|NCT04550689|Active Comparator|Allograft|
16318267|NCT04550676|Experimental|High intensity interval training|
16318268|NCT04550676|Active Comparator|Continuous moderate intensity exercise|
16318269|NCT04550663|Experimental|KD-025 CAR-T cells|NKG2D-based CAR-T cells infusion
16318270|NCT04550650|No Intervention|Controll|No intervention
16318271|NCT04550650|Experimental|Training grp|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
16318272|NCT04550650|Experimental|PNF|2 years long, You have only treated patients with the PNF technique.
16318273|NCT04550650|Experimental|Spinning group|Patients developed endurance for 2 years. They worked using a spinning bike.
16318274|NCT04550650|Experimental|Balance|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance
16318275|NCT04550637||Anticoagulant therapy after percutaneous left atrial appendage|Oral apixaban
16318276|NCT04550624|Experimental|Interventional Arm|This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with advanced cholangiocarcinoma (CCA) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
16318277|NCT04550611|Experimental|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|will receive blood group -specific MP-IVIG in a regimen of 2 g/kg bodyweight, usually as 0.4 g/kg bodyweight per day for five consecutive days within two weak of onset of symptoms.
16318278|NCT04550611|Experimental|plasmapheresis|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
16318279|NCT04550598|Experimental|HD-tCES|The experiment group will receive active HD-tCES.
16318280|NCT04550598|Sham Comparator|Sham HD-tCES|The sham control group will receive sham HD-tCES.
16318281|NCT04550559|Active Comparator|Group 1|The patients in group 1 were instructed to masturbate at least 3-4 times a week
16318282|NCT04550559|Other|Group 2|The patients in group 2 were prescribed oral tamsulosin 0.4 mg once daily
16318283|NCT04550559|No Intervention|Group 3|The patients in group 3 acted as controls and received only standard medical therapy
16318284|NCT04550546|Experimental|Nystatin treatment|Participants will be given 1-week supply of nystatin suspension (6ml 600,000 U/mL) and be instructed to rinse the mouth with nystatin for 1 minute and spit out the suspension, at a frequency of four times a day, for a duration of 1 week. Participants will be instructed to spit the suspension after the oral rinse and do not swallow the suspension, and they will be instructed to avoid eating, drinking and brushing their teeth for 30 minutes.
16318285|NCT04550520|Experimental|study part 1: healthy adult volunteers|22 Healthy volunteers: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
16318286|NCT04550520|Experimental|study part 2: adult patients with primary polydipsia or central diabetes insipidus|If results of study part 1 suggest that glucagon stimulates copeptin (proof of concept),10 patients with primary polydipsia and 10 patients with central diabetes insipidus will be additionally included (study part 2): The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
16318287|NCT04550507|Experimental|Group A: Mindful Sensory Awareness|Group A: Mindful Sensory Awareness receives the mindful sensory awareness intervention during the first 8-week period, and receives no active intervention delivery during the second 8-week period.
16318288|NCT04550507|Other|Group B: Mindful Sensory and Body Awareness|Group B: Mindful Sensory and Body Awareness receives no active intervention delivery during the first 8-week period, and during the second 8-week period receives an intervention combining the mindful sensory awareness content received by Group A with the mindful body awareness check-in approach.
16318289|NCT04550494|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and 4 hours after talazoparib dose on day 1 of cycle 2, and an optional biopsy either at the restaging follow up or at the time of disease progression.
16318290|NCT04550481|Experimental|Prevention (lisinopril)|Patients receive lisinopril PO QD for 24 weeks in absence of unacceptable toxicity.
16318291|NCT04550468|Experimental|Low-Carb High-Fat Breakfast|Participants will follow a daily low carbohydrate high fat breakfast intervention for 3 months.
16318292|NCT04550468|Active Comparator|"Low fat Standard Care Control Breakfast"|"Participants will follow a daily low fat standard care control breakfast intervention for 3 months."
16318293|NCT04550455|Experimental|Cladribine Tablets|All participants will receive cladribine tablets according to the current United States Federal Food and Drug Administration (FDA) package guidelines.
16318294|NCT04550442|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO daily on days 1-14 and azacitidine IV over 15 minutes or SC on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
16318295|NCT04550429|Active Comparator|60 mmHg MyoSure Hysteroscopic Morcellator Device|The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
16318296|NCT04550429|Sham Comparator|80 mmHg MyoSure Hysteroscopic Morcellator Device|This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study
16318297|NCT04550416|Experimental|ProMark Information and Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
16318298|NCT04550416|No Intervention|Standard Practice|Physicians will care for online virtual patients as they normally would in practice.
16318299|NCT04550377|Active Comparator|Cannabidiol Group 1|40 participants will be titrated to a maximum dose of oral cannabidiol 800 mg daily over 2 weeks for a total of 8 weeks treatment.
16318300|NCT04550377|Active Comparator|Cannabidiol Group 2|40 participants will be titrated to a maximum dose of oral cannabidiol 400 mg daily over 2 weeks for a total of 8 weeks treatment.
16318301|NCT04550377|Placebo Comparator|Placebo Group|40 participants will be given a placebo for a total of 8 weeks treatment.
16318302|NCT04550351|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
16318303|NCT04550351|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
16318304|NCT04550351|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
16318305|NCT04550338|Experimental|Tranexamic Acid Treatment|
16318306|NCT04550338|Placebo Comparator|Placebo Treatment|
16318307|NCT04550325|Experimental|Immune gamma globulin (IgG)|Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion
16318308|NCT04550299|Active Comparator|Group A|single bundle technique with the use of bioabsorbable implants
16318309|NCT04550299|Active Comparator|Group B|single bundle technique with the use of Bio-Intrafix
16318310|NCT04550299|Active Comparator|Group C|double bundle technique with the use of bioabsorbable implants
16318311|NCT04550299|Active Comparator|Group D|double bundle technique with the use of Bio-Intrafix
16318312|NCT04550286|Experimental|Intervention Group|"Intervention points in time include:
~Baseline measure
~Installation of the study app
~Advice on general enhancements regarding study environment and behavior (BCT 4.1)
~Students are to develop up to three action plans (BCT 1.4) and coping plans (BCT 1.2) to reduce smartphone interference during exam preparation periods by putting the smartphone away
~Students receive weekly questionnaire (t1-t3) and one questionnaire after their first exam (t4). All these questionnaires concern their academic performance and well-being. A short questionnaire (t5) asks for the participants' exam grades approx. 2 months after their exam. A time period of 2 months has been chosen to ensure that universities have enough time to announce the grades.
~During the whole period of the study, the mobile application tracks the students' smartphone behavior (i.e., daily smartphone use, daily screen activations, and specific app usage)."
16318313|NCT04550286|Active Comparator|Control Group|Control points in time include all parts except for number 4. Here students in the control group will receive questionnaires on general health behavior in order to achieve an equal questionnaire completion time compared to the intervention group.
16318314|NCT04550273|Experimental|study group|The study group (n=20) will receive three sessions of aerobic walking exercise per week for 3 months in addition to the traditional medical treatment
16318315|NCT04550273|No Intervention|control group|The control group (n=20) will receive no training
16318318|NCT04550247||Nivolumab treatment|Administered according to the market authorization in France
16318319|NCT04550234|Experimental|Treatment 1|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1.
16318320|NCT04550234|Experimental|Treatment 2|Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1.
16318321|NCT04550234|Experimental|Treatment 3|Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1.
16318322|NCT04550234|Experimental|Treatment 4|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1.
16318323|NCT04550234|Experimental|Treatment 5|Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1.
16318324|NCT04550221|Experimental|Intervention|The Shauriana intervention is aimed at promoting sexual health and preventing HIV through a comprehensive prevention toolbox including PrEP. Components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions.
16318325|NCT04550221|Active Comparator|Standard care|Standard care includes clinic-based HIV counseling and testing, screening for symptoms of sexually transmitted infections (STI), and individual counseling about HIV prevention methods. Standard of care counseling for HIV prevention in Kenya includes general information about HIV transmission and discussions of risk reduction including condom use. PrEP counseling sessions focus on PrEP knowledge, adherence tips, and strategies to address adherence barriers.
16318382|NCT04549896|Active Comparator|Control|No CT scan before CTO PCI
16318326|NCT04550208||Healthy basketball or volleyball players|Basketball and volleyball players Landing biomechanics of different landing tasks is investigated in a population of volleyball and basketball players
16318327|NCT04550195|Experimental|Part A Single Ascending Dose (SAD) Cohort A1|
16318328|NCT04550195|Experimental|Part A SAD Cohort A2|
16318329|NCT04550195|Experimental|Part A SAD Cohort A3|
16318330|NCT04550195|Experimental|Part A SAD Cohort A4|
16318331|NCT04550195|Experimental|Part A SAD Cohort A5|
16318332|NCT04550195|Experimental|Part A SAD Cohort A6|
16318333|NCT04550195|Experimental|Part B Multiple Ascending Dose (MAD) Cohort B1|
16318334|NCT04550195|Experimental|Part B MAD Cohort B2|
16318335|NCT04550195|Experimental|Part B MAD Cohort B3|
16318336|NCT04550195|Experimental|Part B MAD Cohort B4|
16318337|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C1|
16318338|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C2|
16318339|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C3|
16318340|NCT04550182|Experimental|Individual positioning schedule|Pressure ulcer prevention cares are provided according to the positioning schedule for every patient.
16318341|NCT04550182|No Intervention|Standard care|Pressure ulcer prevention cares are provided according to usual practice of the ICU. Frequency and modality of positioning applied to the patients are collected.
16318342|NCT04550169||Intensive Care Coordination|Intensive Care Coordination along with Standard of Care
16318343|NCT04550169||Control|Standard of Care alone
16318344|NCT04550156|No Intervention|Control Arm|Patients are treated according to current local standards
16318345|NCT04550156|Experimental|Colorectal Bundle Arm|Patients are treated according to the colorectal bundle
16318346|NCT04550143||Septic Shock|
16318347|NCT04550130|Experimental|low dose (1.8 L)|Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
16318348|NCT04550130|Experimental|high dose (3.6 L)|Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.
16318349|NCT04550117|Experimental|Intraspinal Pressure Monitoring|A fiberoptic pressure monitoring device will be placed into the subarachnoid space at the site of traumatic spinal cord injury
16318350|NCT04550104|Active Comparator|Radiotherapy only|
16318351|NCT04550104|Experimental|Olaparib + radiotherapy|
16318352|NCT04550104|Experimental|AZD1390 + radiotherapy|
16318353|NCT04550104|Experimental|TBD1 + radiotherapy|DDRi to be decided
16318354|NCT04550104|Experimental|TBD2 + radiotherapy|DDRi to be decided
16318355|NCT04550104|Experimental|TBD3 + radiotherapy|DDRi to be decided
16318356|NCT04550078|Active Comparator|Calcium Carbonate|800 mg calcium as calcium carbonate in capsules consumed orally once with a standardized meal.
16318357|NCT04550078|Experimental|Calcium-enriched permeate|800 mg calcium as calcium permeate in capsules consumed orally once with a standardized meal.
16318358|NCT04550078|Placebo Comparator|Maltodextrin|0 mg calcium as placebo capsules with maltodextrin consumed orally once with a standardized meal.
16318359|NCT04550065|Experimental|Intervention arm|Digital game
16318360|NCT04550039|Experimental|Body-weight-supported treadmill training|Participants complete prescribed gait training program for at least three weeks or until they discharge.
16318361|NCT04550039|Experimental|EksoNR exoskeleton|Participants complete prescribed gait training program for at least three weeks or until they discharge.
16318362|NCT04550026|Experimental|Inhalation of HTP|Inhalation of HTP for 30 minutes
16318363|NCT04550026|Active Comparator|Sham inhalation of HTP|Sham usage of HTP for 30 minutes
16318364|NCT04550013|Active Comparator|Heavy-Slow Resistance training|Heavy-Slow Resistance training. Three times weekly for 12 weeks.
16318365|NCT04550013|Experimental|Low-Load Blood Flow Restriction training|Low-Load Blood Flow Restriction training. Three times weekly for 12 weeks
16318366|NCT04549987|Experimental|Without changing working archwire|Extraction space closed using the same working archwire throughout 3 visits after insertion
16318367|NCT04549987|Experimental|With changing working archwire|The extraction space closed having the working archwire changed monthly.
16318368|NCT04549974|Experimental|Passive heat exposure|
16318369|NCT04549961||patients admitted to intensive care units|all patients that are present on an intensive care unit on nutritionday
16318370|NCT04549948|Experimental|0.017X0.025 Stainless Steel Archwire|Leveling of COS using 0.017X0.025 Stainless Steel (SS) Archwire A reverse COS using 0.017X0.025 SS was used to correct the excessive COS in the lower arch.
16318371|NCT04549948|Experimental|0.019X0.025 Stainless Steel Archwire|A reverse COS using 0.019X0.025 SS was used to correct the excessive COS in the lower arch.
16318372|NCT04549948|Experimental|0.021X0.025 TMA archwire|A reverse COS using 0.021X0.025 TMA archwire was used to correct the excessive COS in the lower arch.
16318373|NCT04549935|Active Comparator|Group A Dextenza|Drug: Dextenza 0.4mg Opthalmic Insert The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion, The attributes of the insert reduce risks for improper corticosteriod tapering and unwanted peaks and troughs in drug concentration.
16318374|NCT04549935|Active Comparator|Group B Topical Prednisolone|Drug: Topical Prednisolone Standard of care topical drop treatment
16318375|NCT04549922|Placebo Comparator|Placebo|1.2 mL Normal Saline, single dose subcutaneous, after randomization
16318376|NCT04549922|Active Comparator|ISIS 721744|1.2 mL ISIS 721744, single dose subcutaneous, after randomization
16318377|NCT04549909||preimplantation genetic testing for aneuploidy (PGT-A) Group|Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) (transfer of own frozen embryo)
16318378|NCT04549909||endometrial receptivity array (ERA) Group|Patients who have undergone frozen embryo transfer (FET) with endometrial receptivity array (ERA) test (embryos from own or donated oocytes)
16318379|NCT04549909||CONTROL OWN (CO) Group|Control group of FET from own oocytes (without ERA or PGT-A)
16318380|NCT04549909||CONTROL DONATED(CD) Group|Control group of FET from donated oocytes (without ERA or PGT-A)
16318383|NCT04549883|Experimental|Performing after session|LB control during hip extension after intervention
16318384|NCT04549870|Active Comparator|Roflumilast|Roflumilast 500 microgram daily (capsule)
16318385|NCT04549870|Placebo Comparator|Placebo|Placebo (capsule)
16318386|NCT04549857|Experimental|intervention group|The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.
16318387|NCT04549857|Placebo Comparator|Placebo group|The placebo group only used base oil (sweet almond oil).
16318388|NCT04549857|No Intervention|Control group|No intervention
16318389|NCT04549844|Active Comparator|the intervention group (G A)|Group general anaesthesia plus peribulbar block : Total 35 cases who will receive general anesthesia with peribulbar block (bupivacaine 0.5 % xylocaine 2% hyaluronidase with total volume 0.06 mg \kg (bupivacaine : (xylocaine :hyaluronidase ) 1:1) Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
16318390|NCT04549844|Placebo Comparator|the control group (G B )|"General group: Total 35 cases who will receive general anesthesia only, i.e., without peribulbar block. (Fentanyl 1µg\kg, atracurium 0.5 mg\kg and propofol 2mg \kg.
~After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane."
16318391|NCT04549831||SARS-CoV-2 PCR positive individuals|Adult (> o equal to 18 years) SARS-CoV-2 PCR positive individuals with different clinical outcome: from asymptomatic to severely affected COVID-19 patients.
16318392|NCT04549818|Experimental|sacral neuromodulation|Sacral neuromodulation group, will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
16318393|NCT04549818|No Intervention|medical therapy|this group will be treated with sustained release morphine tablets for pain control
16318394|NCT04549805||Patients without myocardial injury|Patients without myocardial injury will be recruited in a 2:1 fashion stratified by peak high-sensitivity cardiac troponin I concentration above and below a threshold of 5 ng/L.
16318395|NCT04549792|Experimental|Open Label|
16318396|NCT04549779|Experimental|Group I (low volume)|patients will receive 5 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
16318397|NCT04549779|Experimental|Group II (intermediate volume)|patients will receive 10 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
16318398|NCT04549779|Experimental|Group III (high volume)|patients will receive 15 ml levobupivacaine 0.25% ultrasound-guided interscalene brachial plexus block.
16318399|NCT04549753|Experimental|tDCS stimulation group|Patients receive four sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system.
16318400|NCT04549727||infants with surgical NEC|Infants who undergo surgery for NEC disease
16318401|NCT04549727||Infants with GI surgical diseases other than NEC|Infants who undergo surgery for other GI diseases than NEC
16318402|NCT04549714|Experimental|High AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
16318403|NCT04549714|Experimental|Middle AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
16318404|NCT04549714|Experimental|Low AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
16318405|NCT04549701|Experimental|CAVAL US group|Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.
16318406|NCT04549701|Active Comparator|Standard of care group|Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.
16318407|NCT04549688|Experimental|Focal therapy|
16318408|NCT04549675|Experimental|Arm 1 Sun Safe Partners Online Intervention|Web-based intervention called Sun Safe Partners Online. Website developed by the study team. Participants received individual username and password to login.
16318409|NCT04549675|Active Comparator|Generic Online Sun Safety Information intervention|Publicly online available skin cancer and sun protection information emailed to participants in 4 seperate email links.
16318410|NCT04549662|Experimental|Group A|Powdered formula containing whey protein and arginine (Active A) and lipid bolus containing omega 3 fatty acids. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
16318411|NCT04549662|Active Comparator|Group B|Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
16318551|NCT04548869|Experimental|CDX-0159|20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159
16318412|NCT04549662|Placebo Comparator|Comparator|Powdered formula containing whey protein (Active B) and placebo oil. Participants will mix the powder (Active B) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
16318413|NCT04549649|Experimental|Group A (Experimental oocyte triggering approach)|0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) associated with two ampoules of Ovitrelle (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be administered subcutaneously simultaneously for final oocyte triggering.
16318414|NCT04549649|No Intervention|Group B (Routine oocyte triggering approach)|Two ampoules of Ovitrelle® (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be injected subcutaneously for final oocyte triggering.
16318415|NCT04549636||healthy COVID-19+|Individuals who recently recovered from COVID-19 and who have no history of lung disease
16318416|NCT04549636||asthmatic COVID-19+|Individuals who recently recovered from COVID-19 and who have asthma
16318417|NCT04549636||healthy COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
16318418|NCT04549636||asthmatic COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have asthma
16318419|NCT04549623|Experimental|Group ETCO2|Novel end-tidal carbon dioxide monitoring device is used for sedation.
16318420|NCT04549623|Experimental|Group Reg|Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.
16318421|NCT04549610|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a one week HMB supplementation.
~HMB will be administered in the form of blinded capsules containing 0.5 g HMB free acid per capsule. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 8 capsules (4 x 2 capsules) of HMB in a split dose per day. On training days the supplements will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals during the day."
16318422|NCT04549610|Placebo Comparator|Placebo treatment|The experimental procedure for each participant in this group includes a one-week placebo (PLA) administration. PLA (corn starch) will be placed in the blinded capsules form. PLA will be ingested with at least 250 mL of water. Each participant in this group will ingest 8 placebo capsules a day. On training days the PLA capsules will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals.
16318423|NCT04549597|Experimental|Cohort 1: Straight Switch|Patients stop taking phosphate binders and start tenapanor 30 mg twice daily
16318424|NCT04549597|Experimental|Cohort 2: Decrease Phosphate Binder by 50%|Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
16318425|NCT04549597|Experimental|Cohort 3: Phosphate Binder Naive|Phosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID
16318426|NCT04549584||metaplastic breast cancer|Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
16318427|NCT04549584||non-metaplastic breast cancer|Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer
16318478|NCT04549311|Active Comparator|Antibiotic 1 arm (amoxicillin + clavulanic acid)|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.
~Patients randomized to the antibiotic 1 arm will receive a prescription for amoxicillin + clavulanic acid (875 mg amoxicillin and 125 mg clavulanic acid BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
16318437|NCT04549545|Active Comparator|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (24 months)."
16318438|NCT04549545|Sham Comparator|Sham Control Procedure|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
16318439|NCT04549532|Experimental|T-MD Intervention Group|Participants will be prescribed 1+ interventions tailored to affected domains.Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.Autonomic-Graded aerobic exercise. Perform daily aerobic exercise, goal 80% HR max on a stationary bike/treadmill/walking/jogging.
16318440|NCT04549532|Active Comparator|Behavioral Management|Participants in control group will receive standardized behavioral management strategies including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion. Clinicians will discuss and review a behavioral strategies handout with each participant and answer any questions they may have about the information in the handout. Contact time between clinicians and patients will be similar to avoid effects associated with more or less contact time.
16318441|NCT04549519||Stable group|Participants display knee valgus less or equal to 15° at 45° knee flexion in the descending phase of the squat on both legs
16318442|NCT04549519||Unstable group|Participants display knee valgus greater than 15° at 45° knee flexion in the descending phase of the squat on one leg or both legs
16318443|NCT04549506||ASD group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. All ASD participants were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders 5th Edition's (DSM-5) diagnostic criteria (APA, 2013) and conﬁrmed by clinical consensus. ASD individuals were recruited from a community autism program and referred to children's health doctors and child psychiatrists. Exclusion criteria for all participants were neurological abnormalities, a history of epilepsy or seizures, head trauma and IQ <75. The subjects did not participate in any intervention or drug programs during the experimental period.
16318444|NCT04549506||Control group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. The participants in the age- and sex-matched control group were recruited from the local community, and screened for major psychiatric illnesses by conducting structured interviews.
16318445|NCT04549493|Active Comparator|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, & Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
16318446|NCT04549493|Active Comparator|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
16318447|NCT04549493|Active Comparator|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
16318448|NCT04549480|Experimental|Bosutinib capsule|Bosutinib pediatric capsule to healthy participants
16318449|NCT04549480|Active Comparator|Bosutinib tablet|Bosutinib tablet to healthy participants
16318450|NCT04549467|Experimental|Dolutegravir + lamivudine|Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD
16318451|NCT04549467|Active Comparator|Dolutegravir + emtricitabine/tenofovir (FTC/TDF)|Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
16318546|NCT04548934|Active Comparator|No PPE|Cardiopulmonary resuscitation without wearing personal protective equipment (PPE)
16318547|NCT04548934|Experimental|PPE|Cardiopulmonary resuscitation while wearing personal protective equipment (PPE)
16318452|NCT04549454|Experimental|Intervention App|Students in arm of the study will have a parent who has access to the following content in the parent app: (a) FITSTART+ PBI materials (personalized normative feedback quiz, information on college student drinking, and alcohol-specific advice for parents of first year students); (b) general advice for parents of college students (e.g., improving communication; reducing conflict); (c) information about university resources; and (d) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
16318453|NCT04549454|Placebo Comparator|Control App|Students in this arm of the study will have a parent who has access to the following content in the parent app: (a) general advice for parents of college students (e.g., improving communication; reducing conflict); (b) information about university resources; and (c) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
16318454|NCT04549441||WALANT|The participants undergo distal radius plating surgery via wide-awake local anesthesia no tourniquet technique. In this group, mean arterial pressure, heart rate, and numeric rating scale for pain were measured by nursing staff in the operation theatre seven times perioperatively, namely before surgery (T0) and at the time of injection of local anesthesia (T1), skin incision (T2), fracture reduction (T3), plating and screwing (T4), skin closure (T5), surgery completion (T6).
16318455|NCT04549441||GA|The participants undergo distal radius plating surgery via general anesthesia induced by an anesthesiologist. The anesthesia team continuously monitored patients' intraoperative physiological status. MAP and HR in group B were marked after induction (T1) and at the other six same time points as in the group WALANT.
16318456|NCT04549428|Experimental|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1,200 mg by intravenous infusion every 21 days on an outpatient basis until progression, intolerance or loss of clinical benefit, according to the its approved prescribing information. Palliative radiation therapy will be delivered concomitant to the 2nd dose of atezolizumab as a single fraction of 8 Gy
16318457|NCT04549415|Active Comparator|metformin|Metformin, 1000 mg b.i.d, 12 months
16318458|NCT04549415|Active Comparator|lifestyle modification|Lifestyle modification Standard Principles
16318459|NCT04549402|Experimental|Mirror Therapy group|The intervention will consist of the visualization of movement through the Mirror Therapy VR® application, broadcast on a mobile device and visualized with virtual reality glasses. The knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (walking and feeding, respectively).
16318460|NCT04549402|Active Comparator|Video group|The intervention will consist of the visualization of movement through the reproduction of an immersive 360º video broadcast on a mobile device and viewed with virtual reality glasses. Knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
16318461|NCT04549402|No Intervention|Control group|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
16318462|NCT04549389|Active Comparator|Group A|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (1/week) by using Dornier Aries 2 shockwave machine (energy level 7)
16318463|NCT04549389|Active Comparator|Group B|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (2/week) by using Dornier Aries 2 shockwave machine (energy level 7)
16318464|NCT04549376|Experimental|PVP-I 0.4% NI|Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
16318465|NCT04549376|Experimental|PVP-I 0.5% NI|Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
16318466|NCT04549376|Experimental|PVP-I 0.6% NI|Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
16318467|NCT04549376|Experimental|PVP-I NS 0.5% NS|Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
16318468|NCT04549376|Experimental|PVP-I 0.6% NS|Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
16318469|NCT04549376|Placebo Comparator|DW NI|Arm-6 will receive distilled water through nasal irrigation
16318470|NCT04549376|Placebo Comparator|DW NS|Arm-7 will receive distilled water through nasal spray
16318471|NCT04549363|Experimental|Participants undergoing IC|IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.
16318472|NCT04549363|Experimental|Participants undergoing SK|SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
16318473|NCT04549337|Experimental|4X4|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up with a heart rate of 60-70% of HRmax followed by 4 intervals of 4 minutes at an intensity that will induce at least 85% of HRmax (we will start with 75% of watt max).
~Each interval is separated by 3-minute active pauses, biking at 50-70% of HRmax. Following this a 3-minute cooldown (at warm up intensity) will be performed."
16318474|NCT04549337|Active Comparator|6X1|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up on 30% of watt-max followed by 6 intervals of 1 minute at 100% of the watt-max.
~Each interval is interspersed by 3-minute active pauses at 30% of watt-max. Following this a 7-minute cooldown (at warm up intensity) will be performed."
16318475|NCT04549337|Active Comparator|10-20-30|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up at 60-70% of HRmax followed by 3 intervals of 5 minutes interspersed by 3 minutes on 50-70% of HRmax.
~Each interval consists of 5 minutes of 5 repeated 30-20-10 intervals, consisting of 30 seconds at easy pace, 20 seconds at medium pace and 10 seconds at all-out. Following this a 7-minute cooldown (at warm up intensity) will be performed."
16318548|NCT04548921||Participants with Friedreich's Ataxia|Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age
16318479|NCT04549311|Active Comparator|Antibiotic 2 arm (ciprofloxacin + metronidazole)|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.
~Patients randomized to the antibiotic 2 arm will receive a prescription for ciprofloxacin + metronidazole (ciprofloxacin 500 mg and metronidazole 500 mg BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
16318480|NCT04549311|No Intervention|No antibiotics|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.
~In the comparator arm, patients will not receive any antibiotics. Otherwise, all participants will be treated identically according to the institution's standard practices."
16318481|NCT04549298||Patients with grade 2 and 3 LV diastolic dysfunction|Patients with high filling pressure
16318482|NCT04549298||Patients with normal and grade 1 LV diastolic dysfunction|Patients with normal filling pressure
16318483|NCT04549285|Experimental|hCT-MSC infusion|Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.
16318484|NCT04549272||Patients with Patent Foramen Ovale|
16318485|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM + Tech Detailing|
16318486|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM|
16318487|NCT04549259|Experimental|Social Support + Stigma Reduction + Technology Detailing|
16318488|NCT04549259|Experimental|Social Support + Stigma Reduction|
16318489|NCT04549259|Experimental|Social Support + SBCM + Technology Detailing|
16318490|NCT04549259|Experimental|Social Support + SBCM|
16318491|NCT04549259|Experimental|Social Support + Technology Detailing|
16318492|NCT04549259|Experimental|Social Support|
16318493|NCT04549259|Experimental|Stigma Reduction + SBCM + Technology Detailing|
16318494|NCT04549259|Experimental|Stigma Reduction + SBCM|
16318495|NCT04549259|Experimental|Stigma Reduction + Technology Detailing|
16318496|NCT04549259|Experimental|Stigma Reduction|
16318497|NCT04549259|Experimental|SBCM + Technology Detailing|
16318498|NCT04549259|Experimental|SBCM|
16318499|NCT04549259|Experimental|Technology Detailing|
16318500|NCT04549259|No Intervention|HIV Information Only|This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.
16318501|NCT04549220||Delivery (Birth) Cohort|All women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age delivering a live infant or stillbirth at Kawempe Referral Hospital over a 6-month pilot phase will be invited to participate in the study until a sample size of at least 5000-6000 women is achieved.
16318502|NCT04549220||Active Surveillance Cohort|This is expected to improve capacity for managing and investigating infants <3 months of age presenting with suspected sepsis at Kawempe Neonatal Intensive Care Unit (NICU), Postnatal Ward, and Acute Paediatric Wards and Mulago Hospital Paediatric Acute Care Unit, through provision of supplies for blood culture, CSF culture and nasopharyngeal swabs. Mothers/caretakers of Neonates that are diagnosed with GBS through this active case surveillance will be invited to participate in the study and will be enrolled following written informed consent.
16318503|NCT04549207|Active Comparator|Standard BMA frequency|Continue standard BMA frequency (every 4 or 12 weeks) as administered previously. If a change in BMA frequency (every 4 weeks to every 12 weeks OR every 12 weeks to every 4 weeks) was prescribed by the physician, this would still be considered on protocol treatment.
16318504|NCT04549207|Active Comparator|De-escalate BMA to once every 24 weeks|Bone modifying agent once every 24 weeks.
16318505|NCT04549194|Experimental|Tyrosine - External Operation|1-month L-Tyrosine treatment following 4-month external operation
16318506|NCT04549194|Experimental|Placebo - External Operation|1-month Placebo treatment following 4-month external operation
16318507|NCT04549194|Experimental|Tyrosine - Rear Base|1-month L-Tyrosine treatment following 4 months at rear base
16318508|NCT04549194|Experimental|Placebo - Rear Base|1-month Placebo treatment following 4 months at rear base
16318509|NCT04549181|No Intervention|Phase I: Qualitative|Rural HF dyads will participate in a one-time telephone-based semi-structured interview to explore the types of HF-related problems that rural HF dyads experience and how these problems are managed.
16318510|NCT04549181|Experimental|Phase II: Problem-Solving for Rural HF Dyads|The dyadic problem-solving intervention will be provided by a HF specialist nurse. The nurse will conduct the initial telehealth (virtual, telephone) session and provide dyads with an intervention booklet containing examples of common HF-related problems experienced by rural dyads and suggested management strategies tailored to the rural sociocultural context. The nurse will lead dyads in a card sorting task intended to help dyads prioritize current HF-related problems and will guide dyads in developing management strategies for the highest priority problem. Dyads will utilize these strategies until the next session at which time the nurse will guide dyads in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Dyads will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, including those specific to the rural population.
16318549|NCT04548895||LTCF residents and involved health practitioners|"The intervention will take place in nursing homes, assisted living facilities and long-term care facilities (LTCF) in the United States (henceforth collectively referred to as LTCF).
~Staff who work in the participating LTCF ≥ 20 hours/week and who have direct contact with the residents are also eligible to participate and to employ the biometric monitoring equipment in their private residences."
16318550|NCT04548882|Experimental|Calypso Knee System|Calypso Knee System
16318582|NCT04548674|Experimental|Nano Group|Whiteness HP 35% + NANO
16318514|NCT04549142||Pregnant women- high level pollution|Exposed to high levels of pollution (PM2.5)
16318515|NCT04549142||Pregnant women- low level pollution|Exposed to low levels of pollution (PM2.5)
16318516|NCT04549142||Non-pregnant women-high level pollution|Exposed to high levels of pollution (PM2.5)
16318517|NCT04549142||Non-pregnant women-low level pollution|exposed to low levels of pollution (PM2.5)
16318518|NCT04549129|Experimental|Intervention group|Participants randomized to the intervention group will receive breastfeeding education and teaching of hand expression using a breastfeeding education video and associated breastfeeding website, as well as hands-on teaching of hand expression techniques during their 36 week visit.
16318519|NCT04549129|Active Comparator|Control group|Participants randomized to the control group will receive usual breastfeeding education during their 36-week visit.
16318520|NCT04549116|Experimental|Investigational|Progesterone-IBSA 25mg, twice daily (BID) subcutaneous (SC) injection every 12 hours and Crinone Placebo, once daily (QD) intravaginally.
16318521|NCT04549116|Active Comparator|Comparator|Crinone 8%, 90 mg, QD intravaginally and Progesterone-IBSA Placebo, BID SC Injection every 12 hours
16318524|NCT04549090||No QL block group|These patients will not be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
16318525|NCT04549090||QL block group|These patients will be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
16318526|NCT04549077||Cystic Fibrosis Patients|Patients with Cystic Fibrosis.
16318527|NCT04549077||Historical Controls|Patients diagnosed with solid tumors, who have had a normal chest CT scan during screening for possible metastasis
16318528|NCT04549064||Patients with pancreatic cancer|Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.
16318529|NCT04549064||Healthy Control|healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.
16318530|NCT04549051|Experimental|Tenex plus local anesthetic|Use of the TENEX device for sectioning of the CHL
16318531|NCT04549051|Other|Local Anesthetic|Only Local anesthetic will be injected into the CHL. This arm will have the option to cross over into Tenex arm at 1 month
16318532|NCT04549038|Experimental|Cases|Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
16318533|NCT04549038|No Intervention|Controls|Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
16318534|NCT04549025|Experimental|JTX-4104|Drug: JTX-4014
16318535|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 1)|"Drug: JTX-4014
~Drug: Vopratelimab Other Name: JTX-2011"
16318536|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 2)|"Drug: JTX-4014
~Drug: Vopratelimab Other Name: JTX-2011"
16318537|NCT04549012|Active Comparator|group A|will receive oxytocin
16318538|NCT04549012|Active Comparator|group B|will receive tranexamic acid plus oxytocin
16318539|NCT04548999|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
16318540|NCT04548999|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
16318541|NCT04548986|Other|single arm|single arm study
16318542|NCT04548973|Experimental|Esketamine Group|At the beginning of the operation, 0.25mg/kg ketamine was administered intravenously, and normal saline was diluted to 2mL to assist sedation and analgesia
16318543|NCT04548973|Placebo Comparator|Control Group|At the beginning of the operation, 2ml normal saline was given intravenously
16318544|NCT04548960|Other|cancer patients|cancer patients To explore the phenomena of resistance during the therapeutic response and/or the progression of the pathology, the investigatorswill used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) from blood and tumor samples and immunological profil by ELISA
16318545|NCT04548947|Experimental|Cold snare polypectomy with a submucosal injection|The procedure will include a cold snare polypectomy with a submucosal injection done prior to the resection.
16318583|NCT04548674|No Intervention|Negative Control|Without intervention
16318552|NCT04548856|Other|IA-Microsurgical clipping group (ruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of an acutely ruptured cerebral aneurysm
16318553|NCT04548856|Other|IB-Microsurgical clipping group (unruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of unruptured cerebral aneurysm
16318554|NCT04548856|Other|IIA-Endovascular embolization group (ruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of an acutely ruptured cerebral aneurysm
16318555|NCT04548856|Other|IIB-Endovascular embolization group (unruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of unruptured cerebral aneurysm
16318556|NCT04548843|Experimental|Cohort 1 & Cohort 2|"3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells).
~3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells)."
16318557|NCT04548830|Experimental|Transbronchial cryobiopsy|All study participants will undergo transbronchial biopsies via our proposed standardized cryo-biopsy protocol in place of the traditional forceps transbronchial biopsy that is typically used at MSK.
16318558|NCT04548817||Neurocutaneous Melanocytosis|Participants will have Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
16318559|NCT04548804|Experimental|Control|Control subjects receiving body-surface potential mapping (BSPM) and CT-scan.
16318560|NCT04548804|Experimental|Diseased|Diseased subjects receiving body-surface potential mapping (BSPM) and CT-scan. Outcome measures from these procedures will be compared to controls.
16318561|NCT04548791|Experimental|Cohort 1|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, and 60 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 20 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
16318562|NCT04548791|Experimental|Cohort 2|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
16318563|NCT04548791|Experimental|Cohort 3|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
16318564|NCT04548778||exocrine pancreatic insufficiency (PEI)|Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
16318565|NCT04548778||no exocrine pancreatic insufficiency (no PEI)|No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
16318566|NCT04548765|Active Comparator|Standard Letter|The standard letter describes the importance of getting screened and instructs recipients how to use the FIT kit for screening at home.
16318567|NCT04548765|Experimental|Letter with Risks|The standard letter is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; it also explains why test kits are being sent to disarm skepticism about the program.
16318568|NCT04548765|Experimental|Letter with Risks and Options|In addition to the enhancements added by the letter with risks, the letter also includes a table comparing FIT kit and colonoscopy. Presenting different screening options allows recipients to make the choice that best suits them. In addition, presenting multiple options increases the chance that recipients get screened in one way or another.
16318569|NCT04548765|Experimental|Letter with Risks, Options, and Consequences for Inaction|In addition to the enhancements added by the letter with risk, the comparison table includes comparisons of the consequences of getting screened vs. waiting for symptoms to appear.
16318572|NCT04548726||Sapien 3|Patients with aortic stenosis treated with Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) TAVI
16318573|NCT04548726||Myval|Patients with aortic stenosis treated with Myval (Meril Life Sciences Pvt. Ltd., India) TAVI
16318574|NCT04548713|Experimental|4% EDTA CVC Lock|Patients in this group will be given 4% EDTA as their CVC locking solution.
16318575|NCT04548713|Active Comparator|Standard of Care Saline CVC Lock|Patients in this group will be given standard of care saline as their CVC locking solution.
16318576|NCT04548700|Experimental|Dose-finding and dose-expansion|"Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.
~Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle)."
16318577|NCT04548687|Active Comparator|carbon dioxide insufflation|patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities, supplemented with carbon dioxide insufflation during surgery + standard methods of deaeration of cardiac cavities
16318578|NCT04548687|Other|no carbon dioxide|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
16318579|NCT04548674|Placebo Comparator|Positive Control Group|Whiteness HP 35%
16318580|NCT04548674|Experimental|Laser Group|Whiteness HP 35% + Laser
16318581|NCT04548674|Experimental|CPP Group|Whiteness HP 35% + CPP
16318588|NCT04548635|Experimental|VR-PAT|Virtual Reality administered during burn dressing changes
16318589|NCT04548635|No Intervention|Control|Dressing changes performed without Virtual Reality (other distraction methods available in the home allowed).
16318590|NCT04548622|Experimental|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
16318591|NCT04548609|Experimental|Inhibitory Control/ Fear Extinction|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16318592|NCT04548609|Experimental|Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16318593|NCT04548583|Experimental|remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline
~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)"
16318594|NCT04548583|Experimental|remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.
~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
16318595|NCT04548583|Placebo Comparator|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.
~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
16318596|NCT04548570||approximation of both recti group|
16318597|NCT04548570||non approximation of both recti group|
16318598|NCT04548557|No Intervention|Control|They will not receive any intervention
16318599|NCT04548557|Experimental|IVIG group|They will reveive intravenous immunoglobulin therapy
16318600|NCT04548544|Experimental|TARA training|
16318601|NCT04548544|No Intervention|Control|
16318602|NCT04548531|No Intervention|Usual Care Arm|This arm will be a usual care arm. Patients may call to schedule a colonoscopy or other tests as desired.
16318603|NCT04548531|Experimental|Shared Decision Making Arm|This is the intervention arm. Patients will receive a shared decision making information sheet in the mail and will be able to receive decision coaching from study staff to support selection of an option if desired.
16318604|NCT04548518|Active Comparator|GPO Tri Fluvac vaccine|408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.
16318605|NCT04548518|Active Comparator|Licensed Influenza vaccine|408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
16318606|NCT04548479|Active Comparator|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure (PEP) breathing
16318607|NCT04548479|No Intervention|INS group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Inspiratory incentive spirometry breathing
16318608|NCT04548466|No Intervention|CONTROL group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
16318609|NCT04548466|Experimental|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
16318610|NCT04548453|Experimental|Uterine EMG during labor|Multichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor.
16318611|NCT04548440|Experimental|Preoperative Sintilimab plus Nab-paclitaxel and Cisplatin|"Patients receive the following regimen every 3 weeks:
~Sintilimab 200mg IV on Day 1; Albumin-bound paclitaxel 125 mg/m2 IV on Day 1 and Day 8; Cisplatin 75mg/m2 IV on Day 1; Standard hydration regimen on Day 0-3
~After 2-4 cycles, radiological evaluation and multidisciplinary assessment will be performed. If radical resection is possible, surgery is to be performed 3-6 weeks after the last chemotherapy session. In the case of a R0 resection, the investigator will decide whether to perform adjuvant therapy depending on the patient's condition; in the case of R1 or R2 resection, concurrent chemoradiotherapy is recommended. If the multidisciplinary assessment considers that radical resection is not possible, radical concurrent chemoradiotherapy is performed."
16318612|NCT04548427|Experimental|CKD-352|
16318613|NCT04548427|Active Comparator|Diquafosol Sodium 3%|
16318614|NCT04548414||Sepsis group|The patients in this group are diagnosed sepsis with the sepsis 3.0 definition.
16318616|NCT04548401||Antiplatelet-N group|Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy
16318617|NCT04548401||Antiplatelet-Y group|Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)
16318618|NCT04548388|Experimental|Bobath approach|Bobath approach
16318619|NCT04548388|Experimental|whole body vibration|whole body vibration
16318620|NCT04548362|Experimental|Meat meals|This arm contains a 4-way cross-over intervention study with meats
16318621|NCT04548362|Experimental|Starchy meals|This arm contains a 4-way cross-over intervention study with
16318622|NCT04548349|Experimental|Altreno Group|
16318623|NCT04548349|Experimental|BPO Group|
16318624|NCT04548349|No Intervention|Control Group|During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.
16318625|NCT04548336|Experimental|Motor Imagery|
16318626|NCT04548336|Experimental|Action Observation|
16318627|NCT04548336|Placebo Comparator|Placebo group|
16318628|NCT04548323||Motor Imagery in Sedentary subjects|
16318629|NCT04548323||Motor Imagery active subjects|
16318630|NCT04548310||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
16318631|NCT04548310||Healthy group|Healthy individuals without chronic disease
16318632|NCT04548297||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
16318633|NCT04548297||Healthy group|Healthy individuals without chronic disease
16318634|NCT04548284|Experimental|Periorbitally Injected Glucocorticoids|Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
16318635|NCT04548284|No Intervention|Observe|Observe and wait.
16318636|NCT04548271|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
16318637|NCT04548258|Experimental|electric welded metal framework|using electric welding device to intraorally join metal framework where the study aim to save time and cost and eliminate lab errors
16318638|NCT04548258|Experimental|conventional cast metal technique|using the conventional casting technique to join metal framework and compare it with the electric welding technique
16318639|NCT04548245||Term|
16318640|NCT04548245||Preterm|
16318641|NCT04548219|Experimental|Mirikizumab (Reference)|Reference formulation of mirikizumab administered as a subcutaneous (SC) injection.
16318642|NCT04548219|Experimental|Mirikizumab (Test)|Test formulation of mirikizumab administered as a SC injection.
16318643|NCT04548206|Experimental|Pilates training|60 minutes of Pilates training will be performed for 8 weeks.
16318644|NCT04548206|Placebo Comparator|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
16318645|NCT04548193|Experimental|Arm A (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM A: Patients receive mailed educational materials about the importance of consuming cruciferae, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
16318646|NCT04548193|Active Comparator|Arm B (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM B: Patients receive mailed educational materials about general fruit and vegetable intake, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
16318647|NCT04548180||TBI BIAFAC|100 TBI subjects with BIAFAC will be enrolled. No intervention
16318648|NCT04548154|Experimental|Proximal Resistance Training|Participants will receive 6 one-on-one supervised intervention visits and 8 telerehabilitation visits over 10 weeks. For the first 4 weeks intervention frequency will start with 1x/ week in clinic and 1x/ week via telerehabilitation, and the participant will be asked to perform exercises 2x/ week independently. For the final 6 weeks there will be 1x week supervised visits (weeks 6 and 8 in person, and weeks 5,7, 9, and 10 via telerehabilitation) and the participant will be asked to perform exercises 3x/ week independently.
16318649|NCT04548141|Experimental|Active adults|Adults coming for a visit for sports activity participation and submitted the SAPHIR questionnaire
16318650|NCT04548128||Treatment Arm|The treatment arm will have the HM3 LVAS implanted utilizing a technique other than full median sternotomy (e.g. thoracotomy).
16318651|NCT04548115|Experimental|ARTISAN Condition|Participants assigned to this arm will engage in ARTISAN, a 5-weekly, 15-hour group-based arts and heritage intervention programme with specific intervention components including curated museum tours, facilitated storytelling and professionally-led art-making. The weekly intervention covers the five ARTISAN themes of national heritage, social bonds, adversity and resilience, dreams and aspiration, and community art exhibition.
16318652|NCT04548115|Experimental|Intergenerational Participatory Arts Condition|Participants assigned to this arm will engage in the participatory arts-making component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based professionally-led art-making that covers the five ARTISAN themes.
16318653|NCT04548115|Experimental|Intergenerational Art-space Condition|Participants assigned to this arm will engage in the cultural space component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based a group-based curated museum tour that covers the five ARTISAN themes.
16318654|NCT04548115|Experimental|Inter-generational Storytelling Condition|Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.
16318655|NCT04548115|Experimental|Control Condition|Participants assigned to this arm will engage in a 5-weekly, 5-hour, group-based physical activity session conducted in the community.
16318657|NCT04548102|No Intervention|standard antenatal follow up care|Women in the control group received the antenatal hospital standard care.
16318658|NCT04548089|Experimental|Immediate Intervention Group|Participants assigned to the immediate intervention group will engage in a 4-week 2.5-hour Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) with intervention elements of brief psycho-education, weekly mindfulness meditation, facilitated creative art making, reflective writing, group sharing and discussion.
16318659|NCT04548089|Experimental|Waitlist Control Group|Participants assigned to the wait-list control group will not receive Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) until one month after baseline assessment.
16318660|NCT04548063|Experimental|6,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 6,000 words.
16318661|NCT04548063|Experimental|4,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 4,000 words.
16318662|NCT04548063|Experimental|2,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 2,000 words.
16318663|NCT04548050||mothers informed by untrained nurse|
16318664|NCT04548050||mothers informed by trained nurse|
16318665|NCT04548050||mothers informed by nurses trained 6 months ago|
16318666|NCT04548037||Patients with transient global amnesia|
16318667|NCT04548037||Healthy volunteers|
16318668|NCT04548011|Experimental|Three times a week group|Twenty participants in three times a week group will receive acupuncture treatment 3 times per week (every other day) for 4 weeks, 12 sessions totally. The acupuncture operation as above. Participants will not be not allowed to take any other medication or accept any treatment for FD. should not be accepted during the study. In case of unbearable symptoms, the assistant researchers will detailly document.
16318669|NCT04548011|Experimental|Once a week group|Twenty participants in once a week group will receive acupuncture treatment 1 time per week for 4 weeks (Weekly fixed day), 4 sessions totally. Other inventions will be same as the Three times a week group.
16318670|NCT04548011|No Intervention|Waiting for treatment group|After the health education（such as dietary adjustment for FD patients）, the participants will be followed up for 4 weeks. At the end of the follow-up, the patients could be given free acupuncture treatment (the invention will be similar with that of the Three times a week group) for 4 weeks at will.
16318671|NCT04547998|Experimental|Spray-On Skin™ Cells 1:20 with NB-UVB|Skin cell suspension at expansion ratio 1:20 (donor area : recipient area), prepared using the RECELL System, will be applied to an ablated (de-epithelialized) area of depigmentation, followed by targeted phototherapy using NB-UVB. Each participant receive treatment of a portion of a single bisected depigmented lesion or all of a single with cell suspension prepared at 1:20.
16318672|NCT04547998|Active Comparator|NB-UVB only|Each subject will serve as their own control, with a portion of the depigmented lesion receiving no RECELL treatment but receiving the same targeted NB-UVB as the investigational treatment area.
16318673|NCT04547985|Placebo Comparator|Placebo|23 randomized patients will take placebo daily for 8 weeks.
16318674|NCT04547985|Active Comparator|Naltrexone|23 randomized patients will take naltrexone daily for 8 weeks
16318675|NCT04547972|Active Comparator|Higher-load limbs|This treatment arm will have participants performing resistance training with loads of ~80% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
16318676|NCT04547972|Active Comparator|Lower-load limbs|This treatment arm will have participants performing resistance training with loads of ~30% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
16318677|NCT04547959|Experimental|C-CURVE PEEK|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in PEEK or Titane is used
16318678|NCT04547959|Experimental|C-CURVE Titane|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in PEEK or Titane is used
16318679|NCT04547946||dabrafenib + trametinib|Patients administered dabrafenib and trametinib
16318680|NCT04547933||OAB-wet|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency and urinary incontinence (UI) were allocated to the overactive bladder syndrome (OAB) -wet group.
16318681|NCT04547933||OAB-dry|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency but without incontinence were allocated to the OAB-dry group.
16318682|NCT04547933||UI|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of UI but without urgency were allocated to the UI group.
16318683|NCT04547933||Nocturia|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 2 episodes of nocturia but without urgency and UI were allocated to the nocturia group.
16318684|NCT04547933||Frequency|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 8 episodes of daytime frequency but without urgency, UI and nocturia were allocated to the frequency group.
16318685|NCT04547933||Normal|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women without urgency, UI, nocturia nor frequency were allocated to the normal group.
16318686|NCT04547907|Experimental|nab-PHP|Albumin binding paclitaxel + trastuzumab+ patuzumab
16318687|NCT04547907|Active Comparator|TCbHP|Docetaxel + carboplatin + trastuzumab + patuzumab
16318688|NCT04547894|Experimental|ASC09F|ASC09F one tablet at a time, once per day, up to 7 days.
16318693|NCT04547842|Active Comparator|Group M: patients receive Mirtazapine|the patient will receive an oral disintegrating tablet (ODT) of mirtazapine 30 mg with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 min as a placebo 1 h preoperatively
16318694|NCT04547842|Active Comparator|Group D: patients receive Dexamethasone|the patient will receive a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 min, 1 h preoperatively.
16318695|NCT04547829|Experimental|PEG-rhG-CSF|pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection
16318696|NCT04547816|Experimental|biofeedback and tibial neuromodulation (BFB+TNM)|
16318697|NCT04547816|Experimental|BFB+TNM + pelvic floor muscles training (PFMT)|
16318698|NCT04547816|Experimental|BFB+TNM+PFMT+diet modification|
16318699|NCT04547803|Experimental|Video Visit and Standard of Care|Participants will participate in a video visit and standard of care
16318700|NCT04547803|Active Comparator|Standard of Care|Participants will participate in standard of care for discharged patients.
16318701|NCT04547790|Experimental|Psyllium group|Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.
16318702|NCT04547790|Experimental|Wheat Dextrin group|Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.
16318703|NCT04547777|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours
16318704|NCT04547764|Experimental|TAP group|
16318705|NCT04547764|Active Comparator|Vitapex group|
16318706|NCT04547751||Adult|Patients aged 18yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
16318707|NCT04547751||Minor|Patients aged 14-17yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
16318708|NCT04547738||Tuberculosis (TB) index patients|- Patients (older than 5 years) diagnosed with TB before initiation of TB treatment
16318709|NCT04547738||TB contacts|- Children (5-17 years old), who had contact with TB index patients
16318710|NCT04547725|Experimental|CRS-IP (Arm-A)|Stage IV gastric cancer with limited peritoneal carcinomatosis (peritoneal carcinomatosis index [PCI] ≤ 10)
16318711|NCT04547725|Experimental|CRS-IP (Arm-B)|Stage IV gastric cancer with positive peritoneal wash cytology (CY1/P0)
16318714|NCT04547699|Placebo Comparator|HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein,
16318715|NCT04547699|Experimental|CYK+ high HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma),and 5ng/mL LIF (SRP9001 Sigma).
16318716|NCT04547699|Active Comparator|CYK+low HSA|A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF (SRP9001 Sigma).
16318717|NCT04547686|Experimental|Smoke-Free Homes intervention|Participants in the intervention condition will receive the expanded Smoke-Free Homes intervention. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
16318718|NCT04547686|Active Comparator|Control|The usual care/control arm will receive mailed information on the QL (quitline), and a connection to the QL at their request. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
16318719|NCT04547673||NPC group|Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
16318720|NCT04547673||Non-NPC group|Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
16318721|NCT04547660|Experimental|Convalescent Plasma|Transfusion of 2 aliquots of 300 ml of frozen convalescent plasma, 2 days apart, thawed at 37 degrees Celsius before infusion. Best supportive care except for investigational interventions.
16318722|NCT04547660|Active Comparator|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
16318723|NCT04547634|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
16318724|NCT04547634|No Intervention|Control|Subjects will be told to continue with their normal activity of daily living. After the intervention in the experimental group, the control group will be offered intervention.
16318725|NCT04547621|Experimental|HSRT+IMRT+Temozolomide|"Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.
~Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.
~Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy."
16318726|NCT04547608|Other|group PRi|received immediate injection of rocuronium after propofol administration,
16318727|NCT04547608|Other|group PRd|rocuronium injection when bispectral index score became below 60 after propofol administration
16318728|NCT04547595|No Intervention|CONTROL|Standard care
16318729|NCT04547595|Active Comparator|Hypnosis|Standard care + intervention
16318730|NCT04547582|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
~Participants in this study receive spinal cord stimulation will be trans-tibial amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
16318731|NCT04547569|Experimental|Adaptation to altered auditory feedback|fMRI measurement of brain activity during speech production under altered auditory feedback
16318732|NCT04547569|Experimental|Speech production|fMRI measurement of brain activity during normal speech production
16318733|NCT04547569|Experimental|Vibrotactile discrimination|fMRI measurement of brain activity during a vibrotactile discrimination task
16318734|NCT04547556|Experimental|Intervention|
16318735|NCT04547556|No Intervention|Standard of Care|
16318736|NCT04547543|Other|Video consultation|Patients in this group will have a continuous positive pressure follow-up visit by videoconsultation
16318737|NCT04547543|No Intervention|Face-to-face consultation|Patients in this group will have a continuous positive pressure follow-up visit by face-to-face consultation
16318738|NCT04547530|Active Comparator|Vitamin D|"Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.
~If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.
~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
16318739|NCT04547530|Placebo Comparator|Placebo|"Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.
~If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.
~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
16318740|NCT04547504|Active Comparator|Pembrolizumab|Pembrolizumab
16318741|NCT04547504|Active Comparator|Chemotherapy-Pembrolizumab|Chemotherapy and Pembrolizumab
16318742|NCT04547491|Other|GDT group|Cardiac optimization with goal-directed therapy, liberal use of vasopressor agents.
16318743|NCT04547491|Experimental|HPI group|Hemodynamic management HPI-based, protocol-based use of fluids, vasopressors and inotropes.
16318744|NCT04547452|Experimental|Sintilimab Combined with SBRT|"Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.
~Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year."
16318745|NCT04547452|Active Comparator|Sintilimab|Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
16318746|NCT04547439|Active Comparator|Control|Placebo
16318747|NCT04547439|Active Comparator|Melatonin|Melatonin
16318748|NCT04547426|Active Comparator|red wine and snuff|regular red wine and moist snuff
16318749|NCT04547426|Active Comparator|red wine and nicotine-free snuff|regular red wine and nicotine-free snuff
16318750|NCT04547426|Active Comparator|non alcoholic red wine and regular moist snuff|non alcoholic red wine and regular moist snuff with nicotine
16318751|NCT04547426|Placebo Comparator|non-alcoholic red wine and nicotine-free snuff|Non-alcoholic red wine and nicotine-free snuff
16318752|NCT04547413|No Intervention|Control Arm|"Control Arm will will complete a total of three visits:
~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment
~Monthly: Prevention Maintenance Intervention Messages from months 2-11
~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey
~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
16318753|NCT04547413|Active Comparator|Intervention Arm|"Intervention Arm will will complete a total of four visits:
~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment
~Visit 2 (Day 2-30): Group Intervention Session, Feedback form, and post-intervention knowledge assessment (for intervention arm only)
~Monthly: Prevention Maintenance Intervention Messages from months 2-11
~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey
~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
16318754|NCT04547400||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
16318755|NCT04547400||Healthy group|Healthy individuals without chronic disease
16318756|NCT04547387||Carotid Artery Stenting|Consecutive patients with symptoms or signs of ischemic cerebral injury eligible for endovascular carotid artery revascularization using direct carotid artery access and MicroNET covered carotid stent plaque exclusion under cerebral protection by temporary flow reversal
16318757|NCT04547374||Cohort 1 - GaH Intervention|Cohort 1 - GaH intervention group
16318758|NCT04547374||Cohort 2 - Standard-of-care control group|"Cohort 2 - Standard-of-care control group
~*Importantly, these individuals are eligible for referral to GaH at the discretion of their physicians.*"
16318759|NCT04547361|Experimental|Cohort 1: Dose 1 E2511 or Placebo|Participants will receive Dose 1 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
16318760|NCT04547361|Experimental|Cohort 2: Dose 2 E2511 or Placebo|Participants will receive Dose 2 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
16318761|NCT04547361|Experimental|Cohort 3: Dose 3 E2511 or Placebo|Participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 (Treatment Period 1) under fasted condition followed by Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 7 (Treatment Period 2) under fed condition. A washout period of 6 days will be maintained between the doses.
16318762|NCT04547361|Experimental|Cohort 4: Dose 4 E2511 or Placebo|Participants will receive Dose 4 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
16318763|NCT04547361|Experimental|Cohort 5: Dose 5 E2511 or Placebo|Participants will receive Dose 5 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
16318764|NCT04547361|Experimental|Cohort 6: Dose 6 E2511 or Placebo|Participants will receive Dose 6 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
16318765|NCT04547361|Experimental|Cohort 7: Dose 3 E2511 (Elderly Participants) or Placebo|Elderly participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
16318766|NCT04547348|Experimental|Denosumab treated group|Participants will receive a 60 mg subcutaneous injection of Prolia upon randomization and on week 28 after the first injection provided remission of the Charcot foot has not been achieved by then
16318800|NCT04547049|Active Comparator|Non-first-degree donor|Each patient receive graft from a non-first degree donor aged ≤40
16318767|NCT04547348|Placebo Comparator|Placebo treated group|Participants will receive an injection of placebo produced by the same provider as the prolia drug of equivalent volume at the same time points as the treated group
16318768|NCT04547335||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
16318769|NCT04547322|Experimental|VR application group|The experimental group received VR application in the preoperative period for 10 minutes.
16318770|NCT04547322|No Intervention|Control group|The control group received the routine procedure in the unit clinic where the study was conducted. The routine procedure of the unit includes patients are taken to the operating room on a stretcher and wait on the stretcher in the surgery waiting room until the operation room is prepared.
16318771|NCT04547309|Experimental|68Ga/18F-HER2 Affibody PET/CT scan|
16318772|NCT04547296|Experimental|BRS group|After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
16318773|NCT04547296|Experimental|ARS group|After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
16318774|NCT04547283|Active Comparator|Usual Care|Participants randomized to this arm will remain in their clinician's team standard practice and their natural choice of position, which is anticipated to favor a supine (rather than prone) position.
16318775|NCT04547283|Experimental|Awake-Prone Positioning Strategy|Participants randomized to this arm will receive guidance from their Inpatient treatment team to assume the prone position for as much time as is tolerable during hospitalization.
16318776|NCT04547257|Experimental|Treatment|Extracorporeal therapy with Seraph 100 blood filter
16318777|NCT04547257|No Intervention|Control|patients receive antibiotics only as standard of care
16318778|NCT04547244||T2DM patients with CRTd with automatic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.
16318779|NCT04547244||T2DM patients with CRTd with echocardiographic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.
16318780|NCT04547231||Deferral of PCI group|Patients with a vessel determined to defer revascularization after FFR measurement who undergo CCTA within 90 days before FFR measurement will be included.
16318781|NCT04547231||PCI group|Patients with a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) with available coronary CT angiography within 90 days before FFR measurement will be included.
16318782|NCT04547218||Elderly patients|"Above 65 year old patients undergoing elective surgery Inclusion criteria I. Geriatric patients ( age more than 65 y/o) II. All elective surgeries under GA
~Exclusion criteria I. Refuse to participate in the study II. Patients with cognitive disorders such as dementia and Alzheimer's disease"
16318783|NCT04547205|Experimental|AK109|
16318784|NCT04547192|No Intervention|Pre TIF introduction|Emergency Health Service prior to introduction of TIF.
16318785|NCT04547192|Experimental|Post introduction of TIF|Emergency Health Service after introduction of TIF.
16318786|NCT04547179|Experimental|BLAfit® usage|In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.
16318787|NCT04547179|Experimental|fremanezumab-vfrm|Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
16318788|NCT04547179|Placebo Comparator|Saline injection|This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
16318789|NCT04547166|Experimental|HLX10 + HLX04|
16318790|NCT04547166|Placebo Comparator|placebo + Avastin ®|
16318791|NCT04547153|Experimental|LD-FUD|5-Fu 200mg/m2/day continuously for 20 days; Docetaxel 25mg/m2, days 1, 8 and 15; Repeated every four weeks.
16318792|NCT04547140|Experimental|Liquid Alpha1-Proteinase Inhibitor+Standard Medical Treatment|Participants will receive the first Intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) (120 milligram per kilogram [mg/kg]), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16318793|NCT04547140|Placebo Comparator|Placebo+Standard Medical Treatment|Participants will receive IV infusions of 0.9% Normal Saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16318794|NCT04547127|Experimental|Convalescent anti-SARS-CoV-2 MBT Plasma + SMT|Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16318795|NCT04547127|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
16318796|NCT04547114||SARS-CoV-2- infected|Detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
16318797|NCT04547114||non infected|Lack of detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
16318798|NCT04547101|Experimental|AK104|
16318799|NCT04547088|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy. Every patient will receive Apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
16318801|NCT04547049|Active Comparator|First-degree donor|Each patients receive graft from a first-degree donor aged >50
16318802|NCT04547036||Endothelial cell count measurment|
16318803|NCT04547023|Experimental|Fasting before gestational diabetes screen|Fasting for at least 6 hours prior to the 1-hour gestational diabetes screen.
16318804|NCT04547023|Active Comparator|Fed before gestational diabetes screen|Liberal per oral intake within 2 hours of the 1-hour gestational diabetes screen.
16318805|NCT04547010|Experimental|Intervention group|In four weeks of intervention study the participants instructed to receive (60 mg) of soy-isoflavone supplement per day, after this period the Bone Mineral Density was assessed by Dual X-ray Absorptiometry scan to evaluate the effect of soy-isoflavone supplement on Bone mineral density.
16318806|NCT04546997||Patients with ocular blunt trauma|Patients with previous ocular blunt trauma in one eye.
16318807|NCT04546997||Control Group|Healthy fellow eyes without actual and previous ocular trauma
16318808|NCT04546984|Experimental|Single dose of HEC96719 （Part 1，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
16318809|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 1）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
16318810|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 2）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
16318811|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 3）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
16318812|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 4）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
16318813|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 5）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
16318814|NCT04546971|Active Comparator|Brief intervention|A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.
16318815|NCT04546971|Experimental|Brief Intervention plus Telehealth Counseling|A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.
16318816|NCT04546958|Active Comparator|Nutritional counseling arm|Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
16318817|NCT04546958|Experimental|Nutritional counseling plus whey protein supplements arm|Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.
16318818|NCT04546945||control cases|normal healthy person
16318819|NCT04546945||Patients|Patients with hematologic malignancies. Newly diagnosed.
16318820|NCT04546932|Experimental|Lung-protective mechanical ventilation|Vt=7 ml/kg IBW; an intraoperative 10 cmH2O in PEEP, recruitment maneuvers applying a stepwise increase in PEEP.
16318821|NCT04546932|No Intervention|Conventional mechanical ventilation|the tidal volume was set at 10 ml/kg IBW without PEEP and (recruitment maneuvers) RM
16318822|NCT04546906|Experimental|CD22 CAR-T|Patients will be treated with CD22 CAR-T cells
16318823|NCT04546893|Experimental|1904B CAR-T|Patients will be treated with CD19 CAR-T cells
16318824|NCT04546880|Experimental|Group 1:Breathing and Stabilization Exercise Group|Breathing exercises combined with stabilization exercises
16318825|NCT04546880|Active Comparator|Group 2: Stabilization Exercise Group|Only Stabilization exercises therapy
16318826|NCT04546867|Other|Sonography arm|Sonography is being performed by expericenced investigators to visualize a pancreatic stent in the pancreatic duct. If the stent is being visualized, an endoscopy will be performed to remove the stent. Otherwise, x-ray will be needed to confirm the sonographic finding of a dislodged pancreatic stent with no further need of intervention. If x-ray finds a pancreatic stent in situ opposingly to ultrasound, an endoscopy will be performed to confirm the stents position and eventually remove it.
16318827|NCT04546854|Experimental|Conservative - Binding Appeal|
16318828|NCT04546854|Experimental|Liberal - Individulizing Appeal|
16318829|NCT04546841|Experimental|Vaccination|"A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.
~Part I: Age 18-55 at the time of screening, n=12
~Part II: Age 56-74 years at the time of screening, n=12
~Part III: Age ≥ 75 years at the time of screening, n=12"
16318830|NCT04546828|Experimental|Gemcitabine, Cisplatin, and Nab-Paclitaxel|"Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:
~Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:
~Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days"
16318831|NCT04546815||Gram-positive cocci infection|No intervention. The clinical data of patients (including demographic information, details of anti-infective therapy, imaging and laboratory testings) will be collected and analyzed.
16318832|NCT04546802|Active Comparator|Immediate treatment|This group will undergo immediate treatment of the HCV once HCC complete response (CR) has been confirmed
16318833|NCT04546802|Active Comparator|Delayed treatment|This group will delay commencement of the HCV treatment until 6 months after HCC complete response (CR) has been confirmed
16318834|NCT04546789|Experimental|Group 1: Normal Hepatic Function|Healthy participants who have normal hepatic function with sex, age (± 10 years; >= 18 years old and =< 79 years old), and weight (± 10 percent; >= 50 kilogram (kg) and =< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
16318835|NCT04546789|Experimental|Group 2: Mild Hepatic Impairment|Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
16318836|NCT04546789|Experimental|Group 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).
16318837|NCT04546776||Faecal and saliva sampling|A minimum of 4 and a maximum of 8 sample sets will be asked for over the study period
16318838|NCT04546763||Paroxysmal Atrial Fibrillation Patients|This will be a single arm study of patients with paroxysmal atrial fibrillation. Subjects will be wearing the Study Watch and Zio XT Patch concurrently for up to 14 days.
16318839|NCT04546750||Patients without Varicose Veins|Individuals who do not have varicose veins of lower legs: C0, C1 classes according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
16318840|NCT04546750||Patients with Varicose Veins|Individuals who have varicose veins of lower legs: C2 Ep class according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
16318841|NCT04546724|Active Comparator|VLA1553|
16318842|NCT04546724|Placebo Comparator|Placebo|
16318844|NCT04546698||Multiple Sclerosis patients with an acute relapse|Multiple Sclerosis diagnosed according to Mc Donald's criteria with an acute relapse
16318845|NCT04546698||Multiple sclerosis pataients treated with Natalizumab|Multiple Sclerosis patients diagnosed according to Mc Donald's criteria and treated with Natalizumab since 6 cures
16318846|NCT04546698||Healthy people|
16318847|NCT04546685|Other|Usual Care (waitlist)|Participants will continue their usual clinical care.
16318848|NCT04546685|Experimental|Single-Session Pain Relief Skills Class (Empowered Relief)|A 2-hour class that will be delivered by a clinical psychologist via videoconference to participant cohorts.
16318849|NCT04546672|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
16318850|NCT04546672|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+Glycopyrrolate 0.2 mg per 1 mg of neostigmine administered) IV once at the end of surgery
16318851|NCT04546659|Experimental|Group A|Osteoarthritic patient receiving Conventional therapy and Retrowalking
16318852|NCT04546659|Active Comparator|Group B|Osteoarthritic patient receiving Conventional therapy
16318853|NCT04546646|Experimental|GROUP A (Elastic Band Exercises)|Warm up: for 10 min, Exercise: Lower limb exercises using elastic band for 30 min. Cool down: Self-stretches 5 min.
16318854|NCT04546646|No Intervention|GROUP - B (No Intervention)|Routine activities of daily living
16318859|NCT04546607|Experimental|Nuvastatic TM|Nuvastatic TM (C5OSEW5050ESA) capsule 1000 mg administered orally 3 times a day for 9 weeks.
16318860|NCT04546607|Placebo Comparator|Placebo|Excipient, without Nuvastatic TM (C5OSEW5050ESA) capsule administered orally 3 times a day for 9 weeks.
16318861|NCT04546594||Orthopedic surgery|
16318862|NCT04546594||Thoracic surgery|
16318863|NCT04546594||Gynecological surgery|
16318864|NCT04546581|Experimental|Intervention Group|Participants in this group will receive the investigational product and standard of care (SOC).
16318865|NCT04546581|Placebo Comparator|Control Group|Participants in this group will receive a placebo and standard of care (SOC).
16318866|NCT04546568|Experimental|Servo control - Leoni plus CLAC|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.
~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
16318867|NCT04546568|Active Comparator|Servo control - IntellO2 Precision Flow, Vapotherm|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.
~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
16318868|NCT04546555|Placebo Comparator|No pacing|
16318869|NCT04546555|Experimental|Bachmann's bundle pacing|
16318870|NCT04546555|Experimental|Bachmann's bundle and His bundle pacing|
16318871|NCT04546555|Experimental|Bachmann's bundle, His bundle and nocturnal pacing|
16318873|NCT04546529|Active Comparator|TsMS active|Patients undergoing real Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
16318874|NCT04546529|Sham Comparator|TsMS sham|Patients undergoing placebo Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
16318875|NCT04546516||HYAcorp Lips|HYAcorp Lips is indicated for the restoration of volume and contour of the lips.
16318876|NCT04546516||HYAcorp Face|HYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
16318877|NCT04546503|Active Comparator|Continuous Regional Analgesia group|Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4 + perinerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H
16318878|NCT04546503|Experimental|Control Group|group with general anesthesia and without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4
16318879|NCT04546490|Experimental|Pressure release|It will be applied with the patient in a supine position. The therapist will clamp his first and second fingers over the Myofascial Trigger Point located on the upper trapezium, it will be marked previously. The pressure will increase as the therapist perceives a reduction in the resistance offered by the soft tissue under his finger within a period of 90 seconds.
16318880|NCT04546490|Experimental|Ischemic pressure|Patient in supine position, the therapist performs pressure with first and second finger in PGM marked previously, this is performed until the patient tolerance, when the patient refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier. Repeat the process for 90 seconds.
16318881|NCT04546490|No Intervention|Control Group|Patient in supine position on the stretcher, the therapist performs a clamp with the first and second finger on the upper trapezius muscle without making any pressure on it during 90 seconds
16318882|NCT04546477|Other|Single Arm|"135 patients stratified in 2 groups:
~90 FEM-POP patients: SFA-P1
~45 Isolated POP Patients: P1, P2, P3 only"
16318883|NCT04546464|Experimental|Experimental Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately
~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
16318884|NCT04546464|No Intervention|Standard care|
16318885|NCT04546451|Experimental|Music practice|Patients will receive Music Practice interventions of 45 minutes twice a week over 6 months, provided by a professional musician
16318886|NCT04546451|Experimental|Psychomotor therapy|Patients will receive Psychomotor interventions of 45 minutes twice a week over 6 months, provided by a professional psychomotor therapist
16318887|NCT04546451|Active Comparator|Social animation|Patients will receive Social animation interventions of 45 minutes twice a week over 6 months, provided by professional psychologists
16318888|NCT04546438|Experimental|MiraDry® treatment|"The miraDry System is a noninvasive method that utilizes microwave energy to destroy the sweat glands at the dermal-fat interface.
~Each participant will be scheduled one MiraDry ® treatment with the possiblity of a second intervention approximately three months apart if the primary objective is not fullfilled efter the first."
16318889|NCT04546425|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
16318890|NCT04546425|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
16318891|NCT04546412||Fresh oocytes|Sibling oocytes not subjected to vitrification prior to assessment
16318892|NCT04546412||Vitrified-thawed oocytes|Sibling oocytes subjected to vitrification using the Cryotop® - Open System and thawing prior to assessment
16318900|NCT04546360||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement based on two-dimensional shear wave elastography, gallbladder wall thickness, spleen thickness, spleen long diameter and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, albumin, prothrombin time, international normalized ratio).
16318901|NCT04546347|Experimental|14CAZD9833 Infusion NMT 22.8 kBq/5mL|Dose 1 14CAZD9833 Solution for Infusion
16318902|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet type A
16318904|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 1|Dose 1 AZD9833 film-coated tablet type B
16318905|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 2|Dose 2 AZD9833 film-coated tablet type A
16318906|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 2|Dose 2 AZD9833 film-coated tablet type B
16318907|NCT04546334|Experimental|Group A|Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block
16318908|NCT04546334|Experimental|Group B|Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment.
16318909|NCT04546334|Experimental|Group C|Patients that will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment.
16318910|NCT04546321||HIE group (I)|All fullterm newborn admitted to the NICU with Hypoxic Ischemic Encephalopathy during the study period
16318911|NCT04546321||TTN group(II)|All fullterm babies with Transient Tachypnea of the Newborn admitted to the NICU during the study period
16318912|NCT04546308|Experimental|Exercise training|The participants will undergo 8 weeks of whole-body resistance exercise training followed by a 4-week detraining. The central hemodynamic and muscle stiffness variables will be measured pre, post-training, and post-detraining.
16318913|NCT04546308|No Intervention|Sedentary control|The participants will undergo 12 weeks of intervention without exercise training. The central hemodynamic and muscle stiffness variables will be measured pre, 8th, and 12th week.
16318914|NCT04546295|Experimental|Brushlink|
16318915|NCT04546295|Active Comparator|Water-flosser|
16318916|NCT04546295|Placebo Comparator|Interproximal Brush|
16318917|NCT04546282||Osimertinib treated patients|Patients with metastatic adenocarcinoma of the lung for whom a 3rd generation TKI therapy is proposed and a search for resistance mutation by blood analysis as part of the usual management.
16318918|NCT04546269|Experimental|Fully-guided|Single-tooth implant placed using a fully computer-guided approach
16318919|NCT04546269|Active Comparator|Conventionally guided|Single-tooth implant placed using a conventionally guided approach
16318920|NCT04546256|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16318921|NCT04546256|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
16318922|NCT04546243||osteosarcoma patients receiving resections|
16318923|NCT04546243||osteosarcoma patients receiving radiotherapy|
16318924|NCT04546230|Experimental|E group|Low-Thoracic Epidural Anesthesia
16318925|NCT04546230|Active Comparator|G group|General Anesthesia
16318926|NCT04546217|Experimental|Treadmill training +Transfer package (TT+TP)|"The TT+TP group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist. In combination with the gait training, participants in this group will also receive a group of behavioral strategies called the Transfer Package (TP). Each intervention session will last 1.5h, 1h for the gait training and 30 minutes dedicated for the transfer package.
~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
16318927|NCT04546217|Active Comparator|Treadmill training (TT)|"The TT group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist.
~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
16318928|NCT04546178|Experimental|PE+ intervention group|This group will participate in 15 sessions of PE+ therapy and participate in frequent symptom assessments; this is the same group of participants as the pre-intervention scores group, but they have crossed over from pre-intervention phase into intervention (active) phase.
16318929|NCT04546178|Active Comparator|Pre-intervention scores group (TAU)|This group will participate in symptom assessments but will not receive the PE+ intervention until the begin the active part of the trial. Participants in this group have been diagnosed with a psychotic disorder, have also experienced adversity, and use substances. This group will receive medication for psychosis as well as access to standard education programs and clinical care; thus treatment as usual (TAU).
16318930|NCT04546165|Active Comparator|manipulation group|manipulation plus exercise
16318931|NCT04546165|Active Comparator|myofascial release group|suboccipital inhibition plus exercise
16318932|NCT04546165|Active Comparator|exercise group|only exercise
16318933|NCT04546152||HYAPROF® SOFT|HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.
16318934|NCT04546152||HYAPROF® BALANCE|HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
16318935|NCT04546139||amateur badminton player|
16318936|NCT04546139||elite badminton player|
16318937|NCT04546126|Experimental|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take
~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
16318938|NCT04546126|Experimental|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
16318939|NCT04546126|Experimental|Adrenal pathology (Group 4)|Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
16318964|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track B|Adjusted Margin or / Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)
16318965|NCT04545944|Experimental|Midazolam single doses / Vonoprazan multiple doses|Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10
16318940|NCT04546113|Active Comparator|Paravertebral Block|If the patient is randomized to group Paravertebral Block, the anesthesiologist performs TPVB before induction of general anesthesia. The patient is positioned in lateral décubitus position. The anesthetist performs the bilateral paravertebral block with ultrasound identification of the paravertebral space at the T4-T5 level. Slow injection of 0.3 to 0.35 ml / kg of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of NaCl 0.9%) after aspiration test.
16318941|NCT04546113|Experimental|Erector Spinae Plane Block|"If the patient is randomized to group Erector Spinae Plane Block, the anesthesiologist performs the ESPb block before induction of general anesthesia. The patient is positioned in a right lateral decubitus position. The anesthesiologist performs the erector block of the spine ESP with ultrasound identification at the T4-T5 level (identify the 1st rib on ultrasound then the space T4 to T5). Slow injection of 20 ml of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of 0.9% NaCl) after aspiration test.
~The patient is then turned in left lateral decubitus position and the contralateral block is performed according to the same procedure."
16318942|NCT04546100|Experimental|Maternal-Infant Exercise Program|"In the postpartum period, give the intervention group Maternal-Infant Exercise Program and encourage them to do exercise. The Parent-Child Exercise Program can be divided into three stages. Videos will be provided in each stage. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
16318943|NCT04546100|Placebo Comparator|Regular postpartum exercise guidance|"Another group will receive Regular postpartum exercise guidance. The guidance includes chest exercises, neck exercises, leg exercises, hip exercises, abdominal exercises, vagina contraction exercises, and uterine contraction exercises, starting from the third day after delivery to one month after delivery. The detail information will refer to the General Hospital of Tri-Services Provided the postpartum health education manual-postpartum exercise (p.8-10)"
16318945|NCT04546074|Experimental|Treatment|
16318946|NCT04546061|Experimental|Project Uplift Intervention|A 6-month long intervention for young adult sexual and gender minorities, ages 18-35.
16318947|NCT04546048|Experimental|Exercise group (EG)|The exercise group (EG) were received an 8-week resistance training program in addition to standard post-transplant physiotherapy follow-up.
16318948|NCT04546048|No Intervention|Control Group (CG)|"The control group (CG) were received only standard physiotherapy program.
~The usual post-transplant care consisting of preoperative patient education, respiratory physiotherapy program, active/active assistive exercises of cervical, upper and lower extremities, and early mobilization.
~Patients were instructed about the postoperative physiotherapy process including all details within the preoperative education. Respiratory physiotherapy consisted of positioning, lung expansion exercises and bronchial hygiene techniques.
~They were allowed to pursue their normal daily activities and mobilized as early as possible when clinically stable."
16318949|NCT04546035|Experimental|500 pulses|In this group, patients received one single rESWT session consisting of 500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
16318950|NCT04546035|Experimental|1,000 pulses|In this group, patients received one single rESWT session consisting of 1,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
16318951|NCT04546035|Experimental|1,500 pulses|In this group, patients received one single rESWT session consisting of 1,500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
16318952|NCT04546035|Experimental|2,000 pulses|In this group, patients received one single rESWT session consisting of 2,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
16318953|NCT04546022|Other|GSP measurement|For the GSP measurement, subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes. Sixty minutes after- G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of GSP value.
16318956|NCT04545996|Active Comparator|Cervical Rang of Motion Exercises.|Cervical exercises for mechanical neck pain.
16318957|NCT04545996|Experimental|Cervical Exercises.|Cervical exercises for the management of mechanical neck pain.
16318958|NCT04545983|Active Comparator|ACD|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
16318959|NCT04545983|Experimental|ACDA|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
16318960|NCT04545970|Active Comparator|Anti-aging Serum|"Dosage form: Serum composed of water, thickener, and bioactive ingredients including antioxidants and peptides.
~Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.
~Study Duration: 12 weeks."
16318961|NCT04545970|Placebo Comparator|Placebo Serum|"Dosage form: Serum composed of water and thickener. Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.
~Study Duration: 12 weeks."
16318962|NCT04545957|Experimental|Phase I MRI Simulation|"This research study involves a screening period to determine eligibility.
~- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data."
16318963|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track A|MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment
16318966|NCT04545931|Experimental|Posterior tibial nerve stimulation|First arm will undergo posterior tibial nerve stimulation ( one session per week for 12 weeks )
16318967|NCT04545931|Experimental|Desmopressin|Second arm will receive medical treatment (desmopressin 0.2 mg . single evening dose ) for 12 weeks
16318968|NCT04545918||Infertile Female|90 female patients with infertility undergoing an ovarian stimulation with use of exogenous gonadotropins.
16318969|NCT04545905||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Gaoua, Banfora, and Orodara districts.
16318970|NCT04545892|Experimental|Capsaicin|From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
16318971|NCT04545879|Experimental|Raw garlic juice|Raw garlic juice treatment group
16318972|NCT04545866|Experimental|budesonide with surfactant|Infants randomized to the intervention arm receive a dose of surfactant (poractant alfa; Curosurf) mixed with budesonide (Pulmicort nebulizing suspension) within 50 hours of birth and administered via endotracheal tube.
16318973|NCT04545866|Active Comparator|surfactant alone|Infants randomized to the active control arm receive a dose of surfactant (poractant alfa; Curosurf).
16318974|NCT04545840||Study group|Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
16318975|NCT04545814|Experimental|Stereotactic Radiosurgery|SRS will be delivered utilizing gamma knife or linear accelerator-based techniques.
16318976|NCT04545801|Active Comparator|Ketamine Group|Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia
16318977|NCT04545801|Placebo Comparator|Placebo Group|
16318978|NCT04545788|Active Comparator|A|4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx: Moxifloxacin) A group is the control group which includes injectable drugs (AM).
16318979|NCT04545788|Experimental|B|4-6 INH EMB PZA Pto LZD Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, LZD: Linezolid, Cfz: Clofazimine, Mfx: Moxifloxacin) B group is the experimental groups which is total oral short-term therapy.
16318980|NCT04545788|Experimental|C|4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (BDQ: Bedaquiline, LZD: Linezolid, Mfx: Moxifloxacin, CS: Cycloserine, Cfz: Clofazimine) C group is another experimental groups which is also total oral short-term therapy, and includes new anti-TB drugs: BDQ.
16318981|NCT04545762|Experimental|Treatment Regimen|"Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices
~CAR-T cell manufacturing (estimated ~13-14 days)
~Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.
~CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes."
16318982|NCT04545749|Experimental|Group A (Low dose)|20 subjects will be enrolled to receive low dose of UB-612 vaccine.
16318983|NCT04545749|Experimental|Group B (Medium dose)|20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
16318984|NCT04545749|Experimental|Group C (High dose)|20 subjects will be enrolled to receive high dose of UB-612 vaccine.
16318985|NCT04545736|Experimental|Metformin|Oral administration of metformin
16318986|NCT04545723|No Intervention|Control group|In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
16318987|NCT04545723|Active Comparator|Intervention group|In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
16318988|NCT04545710|Experimental|Single Arm, POC|"Single arm, POC Safety and Efficacy
~Osimertinib 80 mg QD Abemaciclib 150mg BID"
16318989|NCT04545697|Experimental|Patient Decision Support|Instructions will be provided for installation and use of a smartphone recording app 7-60 days before an oncology consultation. Participants will share the recording with the Patient Support Corps (PSC), who will summarize the recording, send it to the participant's oncologist for review, then return an annotated summary to the participant within a week of the consultation.
16318990|NCT04545684|Experimental|Mental practice|
16318991|NCT04545684|Placebo Comparator|Placebo group|
16318992|NCT04545671||Patients already implanted with study lens|No intervention as patients are already implanted.
16318993|NCT04545645|Active Comparator|Neural Stress Provoked by the Median Nerve|
16318994|NCT04545645|Experimental|Neural stress provocation with cognitive auditory distraction|
16318995|NCT04545645|Experimental|Providing neural stress with a motor distraction|
16318996|NCT04545645|Experimental|Neural stress provocation with both distractions|
16318997|NCT04545632||Patients|Patients receiving chemotherapy with ethanol-containing docetaxel
16318998|NCT04545619|Experimental|Paroxysmal and Early Persistent AFIB|
16318999|NCT04545606|Experimental|In-person CBT for insomnia in children with autism|In-person cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted at the Thompson Center. In-person treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
16319020|NCT04545489|Active Comparator|Education control group|Participants randomized to the education control group will have 4 visits over 12 months and will receive education materials related to CVD risk reduction.
16319195|NCT04544371||obese patients|patients with body mass index >30 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area semi-sitting and right lateral positions
16319000|NCT04545606|Experimental|Remote CBT for insomnia in children with autism|Remote/videoconferenced cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
16319001|NCT04545606|Experimental|Remote behavioral SHARE for insomnia in children with autism|Remote/videoconferenced behavioral sleep hygiene and related education (SHARE) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep and related health related concerns/interests.
16319002|NCT04545593|Experimental|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) consists of 10 sessions focused on mental health (PM) and 36 sessions focused on physical health (SB), along with a group maintenance component.
16319003|NCT04545593|Active Comparator|Enhanced Usual Care|The Enhanced Usual Care condition includes written materials on depression and anxiety and 4 calls to participants over the course of 6 months to assess symptoms and safety.
16319006|NCT04545567|Experimental|RocketAP|Adolescents will be assessed for a 48-70 hour period on the Rocket AP. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the USS Virginia system under the same conditions.
16319007|NCT04545567|Active Comparator|USS Virginia|Adolescents will be assessed for a 48-70 hour period on the USS Virginia system. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the Rocket AP system under the same conditions.
16319008|NCT04545554|Experimental|Romosozumab|
16319009|NCT04545541|Experimental|Nebulised heparin|"Participants assigned to nebulised UFH will receive nebulised UFH in addition to the standard care required as determined by the treating team. Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days."
16319010|NCT04545541|No Intervention|Control group|"Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin (Australia, Ireland).
~Participants assigned to placebo will receive Nebulised 0.9% Sodium Chloride (5 mL) administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days (USA)."
16319011|NCT04545528||Test group|100 Patients that were referred to our stone clinic for follow up with risk factors for stone recurrence like metabolic syndrome and diabetes, uric acid stones etc. In addition to seeing our urologist and nephrologist these patients will also be referred to a nutritionist in order to balance risk factors and will be followed for one year with our usual blood tests and imaging
16319012|NCT04545528||Control group|100 Patients that were referred to our stone clinic for follow up without risk factors for stone recurrence will see our urologist and nephrologist and will be followed for one year with our usual blood tests and imaging
16319013|NCT04545515|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
16319014|NCT04545502||Gelsoft Plus - Straights and Bifurcated|Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
16319015|NCT04545502||Gelsoft Plus - Extra-Anatomical|Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
16319016|NCT04545502||Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall|Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
16319017|NCT04545502||Gelweave - Abdominal, Thoracic, Thoracoabdominal|"Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:
~Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.
~Thoracic aorta or arteries arising from the thoracic aorta.
~Abdominal and thoracic aorta requiring a thoracoabdominal repair"
16319018|NCT04545502||Gelweave - Valsalva|Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.
16319019|NCT04545489|Experimental|Nurse-led intervention group|Participants randomized to the nurse-led intervention will have 4 visits over 12 months with study staff. In addition, they will also receive focused communication from the intervention nurse, with additional BP monitoring support and medication management for 12 months.
16319080|NCT04545138|Active Comparator|treadmill training group|Treadmill training as an active control.
16319021|NCT04545476|Experimental|APIS Biomaterial on the Head|Participants in this group will receive the experimental APIS Biomaterial on the Head. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
16319022|NCT04545476|Experimental|APIS Biomaterial on the Lower Extremities|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
16319023|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
16319024|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
16319025|NCT04545463|Active Comparator|Insoluble Fibre|Cookies with insoluble fibre (wheat bran)
16319026|NCT04545463|Active Comparator|Soluble Fibre|Cookies with soluble fibre (Psyllium plantago)
16319027|NCT04545463|Experimental|FIBRACEP|Cookies with FIBRACEP
16319028|NCT04545450|Active Comparator|Testosterone Undecanoate plus dutasteride|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day
16319029|NCT04545450|Placebo Comparator|Testosterone Undecanoate plus placebo|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill
16319030|NCT04545437||ICU|Patients treated on a general adult intensive care unit
16319031|NCT04545424|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
16319032|NCT04545424|Active Comparator|Usual Temperature Management|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
16319033|NCT04545411|Active Comparator|Treatment A|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 35mg in 1mL solution REMD-477
16319034|NCT04545411|Placebo Comparator|Treatment B|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 1mL solution Placebo
16319035|NCT04545398|Experimental|Pasture-raised|The meal contains grass/pasture fed beef
16319036|NCT04545398|Experimental|Grain-fed|The meal contains grain-fed beef
16319037|NCT04545398|Placebo Comparator|Meat Alternative|The meal contains a meat alternative
16319038|NCT04545398|Experimental|Lamb|The meal contains lamb
16319041|NCT04545372|Experimental|the study group|the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.
16319042|NCT04545372|No Intervention|the control group|control group (GB)was treated only by the disease modifying drug (interferon beta-1a)
16319043|NCT04545359|Experimental|Neurofeedback Group|Participants from this group perform actual neurofeedback training, i.e they are instructed to control -- decrease -- in real-time a sound that is inversely related to the amplitude of their own alpha activity, obtained from Melomind EEG signals.
16319044|NCT04545359|Sham Comparator|Control Group|Participants from this group perform sham neurofeedback based on the feedback sounds generated by the participants from the Neurofeedback Group at the same step of the training program.
16319045|NCT04545346|No Intervention|Wait-listed control|Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.
16319046|NCT04545346|Experimental|Low Glutamate diet|Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
16319047|NCT04545333||ALL|patients diagnosed with acute lymphoblastic leukemia
16319048|NCT04545333||CLL|patients diagnosed with chronic lymphocytic leukemia
16319049|NCT04545333||MM|patients diagnosed with multiple myeloma
16319050|NCT04545333||NHL|patients diagnosed with non-Hodgkin lymphoma
16319051|NCT04545320|Placebo Comparator|Usual care control group|Subjects in the usual care control group will receive a health education program to provide the usual care information. This program will include 3-month biweekly sessions (70 minutes each session, total 6 sessions) for obesity-related health briefing, dietary caloric restriction advice, lifestyle counselling/consultation and stretching exercise.
16319052|NCT04545320|Experimental|HIIT group|A 3-month intervention of HIIT will be given to participants allocated to this group. The once-a-week HIIT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform brisk walking for four 4-min bouts at 85%-95% maximal heart rate (HRmax) with a 3-min active recovery walk at 50%-70% HRmax between each session. There will be a 5-min warm-up and cool-down in each exercise session. The duration of each exercise session will be 35 minutes. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
16319053|NCT04545320|Experimental|MICT group|A 3-month intervention of MICT will be given to participants allocated to this group. The once-a-week MICT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform mild walking exercise for ~47 minutes at an intensity of 65-75% HRmax. This exercise volume matches the HIIT volume. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
16319081|NCT04545112|Experimental|XABG|
16319082|NCT04545099|Experimental|Sugammadex|Administration of Sugammadex
16319054|NCT04545307|Experimental|Allogenic transplant of BM-MSCs|"Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo button (pellet) is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
16319055|NCT04545294|Experimental|Active theta (6Hz) in-phase tACS|θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.
16319056|NCT04545294|Sham Comparator|Sham tACS|During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
16319057|NCT04545268|Sham Comparator|Control group|
16319058|NCT04545268|Experimental|NMES group|
16319059|NCT04545255|Active Comparator|active|A shockwave device with a probe that conveys shockwave energy
16319060|NCT04545255|Sham Comparator|sham|A shockwave device with specially designed probe which has the shockwave energy blocked
16319061|NCT04545242|Active Comparator|Dexamethasone (low dose)|Dexamethasone: 6 mg/iv/day during 10 days.
16319062|NCT04545242|Active Comparator|Dexamethasone (moderate dose)|Dexamethasone: 20 mg/iv/ daily from day of randomization (day 1) during 5 days, followed by 10 mg/iv/ daily from Day 6 to Day 10 of randomization.
16319063|NCT04545229|Experimental|Active VR-PAT|Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
16319064|NCT04545229|Experimental|Passive VR-PAT|Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
16319065|NCT04545229|No Intervention|Standard Care Control|Standard care control group used regular distraction such as background music or no distraction.
16319066|NCT04545216||UT4M 40|athletes participating to the 40 km mountain race.
16319067|NCT04545216||UT4M 160|athletes participating to the 160 km mountain race.
16319068|NCT04545216||UTV 55|athletes participating to the 55 km mountain race.
16319069|NCT04545203|Experimental|Slow-Stroke Back Massage Group|
16319070|NCT04545203|No Intervention|Control group|
16319071|NCT04545190|Active Comparator|Glucose|"Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml).
~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).
~Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade.
~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only)"
16319072|NCT04545190|Placebo Comparator|Placebo|"Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml).
~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).
~Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade.
~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only)"
16319073|NCT04545177|Experimental|Tissue Preservation System (TPS)|Tumor tissue will be obtained, processed, and then transported remotely to undergo multiple tests, including gene panel DNA sequencing, DNA methylation array, and bulk as well as single-cell transcriptome analyses (RNA-seq)
16319074|NCT04545164|No Intervention|Usual Care|Participants in the usual care arm will receive no specific trial intervention. Usual care includes tests routinely available at Zomba Central Hospital, including (but not limited to) conventional (plain film) chest X-ray, urine Alere LAM and sputum Xpert Mtb/Rif on treating clinician request.
16319075|NCT04545164|Experimental|DCXR-CAD and FujiLAM and usual care|Participants randomized to the intervention arm will receive TB screening using DCXR-CAD and urine FujiLAM. The CAD score and FujLAM results will be appended into their medical notes for treating clinicians to see. If patients have a CAD score above a pre-determined threshold the study team will attempt to collect sputum for Xpert Mtb/Rif. Chest X-ray images will be available for clinicians to view. This is in addition to usual care (detailed above).
16319076|NCT04545164|Other|Diagnostic cohort|Patients in the observational enhanced diagnostic arm will receive an enhanced package of diagnostics. This is a smaller arm (1 in 9 of all clusters) and is observational only - participants in this arm do not contribute to trial outcomes.
16319077|NCT04545151|Experimental|Verapamil SR|Eligible participants will be randomised into the verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
16319078|NCT04545151|Placebo Comparator|Placebo|"Eligible participants will be randomised into the Placebo arm and receive instructions on frequency of administration (daily intake).
~40 participants on the control arm are expected to complete the trial."
16319079|NCT04545138|Experimental|cognitive training during treadmill training group|Cognitive training combine treadmill training is an intervention that can challenge participants by practicing different tasks simultaneously.
16319084|NCT04545086|Experimental|VBE Group|Video Based Education was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
16319085|NCT04545086|Experimental|MT Group|Music Therapy was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
16319086|NCT04545086|No Intervention|Control Group|Routine Information was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation was done.
16319087|NCT04545073||Post-refractive trifocal IOL|
16319088|NCT04545060|Experimental|VIR-7831|
16319089|NCT04545060|Placebo Comparator|Placebo|
16319090|NCT04545047||Exposed|Veterans who received COVID-19 convalescent plasma therapy within 30 days of first SARS-CoV-2 positive test and associated hospital admission
16319091|NCT04545047||Unexposed|Veterans who did not receive COVID-19 convalescent plasma therapy within 30 days of first SARS-CoV-2 positive test and associated admission
16319092|NCT04545034|Experimental|Water aerobic exercise protocol|Walter aerobic exercise session would be used to treat blood pressure in elderly hypertensive people.
16319093|NCT04545034|No Intervention|Control Group|No exercise intervention would be used.
16319094|NCT04545021||Cognitive Behavioral Stress Management (CBSM) - PC Survivor|Participant receives standard cognitive behavioral stress management from the Parent study NCT03344757.
16319095|NCT04545021||CBSM - PC Survivor Partner|The survivor partner does not receive any intervention.
16319096|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor|Participant receives culturally adapted cognitive behavioral stress management from the Parent study NCT03344757.
16319097|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor Partner|The survivor partner does not receive any intervention.
16319098|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 600 mg three times daily
16319099|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine|N-Acetyl Cysteine 1,200 mg three times daily
16319100|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
16319101|NCT04545008|Experimental|High Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 1,800 mg three times daily
16319102|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
16319103|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
16319104|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
16319105|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
16319106|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
16319107|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
16319108|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
16319109|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily
16319110|NCT04544995|Experimental|Participants receiving Niraparib +Dostarlimab|Participants will receive Niraparib and Dostarlimab.
16319111|NCT04544982|Active Comparator|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
16319112|NCT04544982|Placebo Comparator|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
16319113|NCT04544969||Chemotherapy|Patients treated with palliative chemotherapy
16319114|NCT04544956|Experimental|Participants receiving 300 mg GSK3228836|Eligible participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
16319115|NCT04544943|Experimental|Cohort 1|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The total body surface area (BSA) dosed will be either 9% or 27% BSA. Part A will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control, applied at 9% or 27% BSA.
16319116|NCT04544943|Experimental|Cohort 2|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients in Cohort 2. Part B will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control.
16319117|NCT04544930|Experimental|therapist-guided|Therapist-guided Internet treatment based on cognitive behavior therapy (ICBT).
16319118|NCT04544917|Experimental|SmartManage Group|Participants in this group will receive ten 90-minute weekly therapist delivered SmartManage group sessions via video conference. Participants will have access to the SmartManage web platform, which will also guide the live intervention sessions.
16319119|NCT04544917|Active Comparator|Educational Control Group|Participants in this group will view ten weekly control content video recorded sessions.
16319120|NCT04544904|No Intervention|Usual Care|Patients will receive the usual care.
16319121|NCT04544904|Experimental|PAARx|Patients will be prescribed technology-based physical activity programming.
16319122|NCT04544904|Experimental|PAARx and JM|Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.
16319123|NCT04544878||Pediatric patients|All term children from birth to 18 years of age admitted in the PICU
16319124|NCT04544878||Adult patients|All patients >18 years of age
16319125|NCT04544865|Experimental|Gastric and thoracic staple line reinforcement|ECHELON ENDOPATH Staple Line Reinforcement is used during a gastric or thoracic procedure.
16319126|NCT04544852|Placebo Comparator|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge."
16319127|NCT04544852|Active Comparator|Targeted intervention programme|"Intervention B involves a targeted intervention programme tackling issues relating to a lack of education, inconvenience and cost would improve screening rates amongst the spouses."
16319128|NCT04544839|Experimental|ADLC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the ADLC (test) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the ADLC group will receive the LOC attachments.
16319129|NCT04544839|Active Comparator|LOC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the LOC (control) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the LOC group will receive the ADLC attachments.
16319130|NCT04544826|Experimental|Cohort 1: JNJ-77474462 (Low Dose) or Placebo|Participants will receive single low dose of JNJ-77474462 or matching placebo as subcutaneous (SC) injection.
16319131|NCT04544826|Experimental|Cohort 2: JNJ-77474462 (Medium Dose) or Placebo|Participants will receive single medium dose of JNJ-77474462 or matching placebo as SC injection.
16319132|NCT04544826|Experimental|Cohort 3: JNJ-77474462 (High Dose) or Placebo|Participants will receive single high dose of JNJ-77474462 or matching placebo as SC injection.
16319133|NCT04544813|Experimental|Cohort A: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 subcutaneously (SC).
16319134|NCT04544813|Experimental|Cohort B: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
16319135|NCT04544813|Experimental|Cohort C: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
16319136|NCT04544813|Experimental|Cohort D: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
16319137|NCT04544813|Experimental|Cohort E: JNJ-77474462 IV (Wave 1)|Participants will receive single dose of JNJ-77474462 intravenously (IV).
16319138|NCT04544813|Experimental|Cohort F: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
16319139|NCT04544813|Experimental|Cohort G: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
16319140|NCT04544813|Experimental|Cohort H: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
16319141|NCT04544813|Experimental|Cohort I: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
16319142|NCT04544813|Active Comparator|Cohort J: Anakinra SC|Participants will receive a SC injection of anakinra once daily for 3 days.
16319143|NCT04544787|Experimental|Group 1: One Dose of Novel OPV2 Candidate 1|Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
16319144|NCT04544787|Experimental|Group 2: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
16319145|NCT04544787|Experimental|Group 3: One Dose of Novel OPV2 Candidate 2|Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
16319146|NCT04544787|Experimental|Group 4: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
16319147|NCT04544787|Experimental|Group 5: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
16319148|NCT04544787|Experimental|Group 6: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
16319149|NCT04544787|Placebo Comparator|Group 7: Two Doses of Placebo|Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
16319150|NCT04544774||Allergic rhinitis patients|Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.
16319151|NCT04544761||1-5 Years post|Persons with Spinal Cord Injury occurring between 1-5 years prior
16319152|NCT04544761||5-15 Years post|Persons with Spinal Cord Injury occurring between 5-15 years prior
16319153|NCT04544761||>15 Years post|Persons with Spinal Cord Injury occurring at least 15 years prior
16319154|NCT04544748|Other|Cohort 1|GNR-051 (0.1 mg/kg)
16319155|NCT04544748|Other|Cohort 2|GNR-051 (0.3 mg/kg)
16319156|NCT04544748|Other|Cohort 3|GNR-051 (1 mg/kg)
16319157|NCT04544748|Other|Cohort 4|GNR-051 (3 mg/kg)
16319158|NCT04544748|Other|Cohort 5|GNR-051 (10 mg/kg)
16319159|NCT04544735|Experimental|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will will integrate two key components: pelvic health PT interventions (i.e., vaginal dilators, Pelvic Floor Muscle Training) and coping skills training for managing symptoms and improving treatment adherence. The intervention aims to improve women's sexual function after pelvic radiation
16319160|NCT04544722|Experimental|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
16319161|NCT04544722|Active Comparator|Lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
16319162|NCT04544709|Other|Discogenic Low Back Pain|Patient with Refractory Discogenic Low back pain who will be scheduled for platelet rich plasma injection as standard of care.
16319163|NCT04544696||Patients with chronic non cancer pain|Patients with chronic non cancer pain, treated with opioids and having completed the POMi questionnaire
16319196|NCT04544358|Experimental|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
16319164|NCT04544683|Other|Cervical Pain for 6 months or less and scheduled for TFESI|Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
16319165|NCT04544657||stroke group|
16319166|NCT04544657||normal group|
16319167|NCT04544644|Experimental|treatment arm|AK104+anlotinib
16319168|NCT04544631|Experimental|Active VR|"Participants in the active VR group played a virtual reality game entitled Virtual River Cruise. In this game, an otter floats down a river on a boat and players activate snow-blowing statues along the shore by focusing on them. The statues will emit snow if they are correctly aimed at by the child, and a thermometer placed in the front of the boat shows decreased temperatures as more snowflakes are blown. As feedback to reinforce continued engagement, a scoreboard placed beside the thermometer will show children the number of statues he/she has activated. Additionally, as the temperature drops, snow and ice will start piling up on the boat and its surroundings, providing an enhanced cooling experience for pediatric burn patients. Children interact with the immersive virtual reality environment by tilting their head, minimizing potential interference with the dressing change procedure."
16319169|NCT04544631|Experimental|Passive VR|Participants in the passive VR group were immersed in the same virtual reality environment as the active VR group, without any interactions with the VR game.
16319170|NCT04544631|No Intervention|Standard Care Control|Participants in the standard group received routinely used distraction tools provided in the clinical setting, such as iPads, music, books, and/or talking.
16319171|NCT04544618|Experimental|Active intervention group|Participants will be exposed to a virtual reality simulation of the operating room environment for a minimum of ten minutes.
16319172|NCT04544618|Placebo Comparator|Control intervention group|Participants will explore a non-surgery related virtual reality simulation, pre-programmed to the virtual reality headset for a minimum of ten minutes.
16319173|NCT04544618|No Intervention|Treatment as usual group|Participants will receive standard of care with no additional intervention aside from information received at their surgical oncology appointment and optional preoperative education classes (available to all patients).
16319174|NCT04544592|Experimental|UCD19 CART infusion|Lymphodepleting chemotherapy following by infusion of UCD19 CAR-T
16319175|NCT04544579||Ascending aortic dissection patients|Ascending aortic dissection patients
16319176|NCT04544566|Experimental|Test product A new adhesive material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
16319177|NCT04544566|Experimental|Test product B new adhesion material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
16319178|NCT04544566|Active Comparator|Comparator|The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
16319179|NCT04544553|Other|SMS reminder|This arm receive SMS reminder for the follow-up of DR Screening
16319180|NCT04544553|Other|No SMS reminder|This arm did not receive SMS reminder for the follow-up of DR Screening
16319181|NCT04544540|Experimental|One-Unit|Patients will be randomized to receive 1-unit of red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 1-unit
16319182|NCT04544540|Experimental|Two-Unit|Patients will be randomized to receive 2-unit sof red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 2-units
16319183|NCT04544501|Experimental|Culturally-Targeted Video|
16319184|NCT04544501|Active Comparator|FORCE Fact Sheet|
16319185|NCT04544475|Experimental|Investigational|
16319186|NCT04544475|Active Comparator|Standard of Care|
16319187|NCT04544462||Infertile patients|Patients attending an IVF center for infertility treatment
16319188|NCT04544449|Experimental|fenebrutinib|Participants will receive oral fenebrutinib and intravenous (IV) ocrelizumab-matching placebo.
16319189|NCT04544449|Active Comparator|ocrelizumab|Participants will receive intravenous (IV) ocrelizumab and oral fenebrutinib-matching placebo.
16319194|NCT04544371||normal weight patients|patients with body mass index =18-24.9 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area in semi-sitting and right lateral positions
16319197|NCT04544358|No Intervention|Control|Randomized to wait list, received BAILAMOS© program after data collection.
16319198|NCT04544345|Experimental|His bundle pacing, AV optimized|Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.
16319199|NCT04544345|Sham Comparator|Backup VVI pacing|Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.
16319200|NCT04544332||Unsweetened Supplement|Infants will receive 10 exposures to the unsweetened small quantity lipid nutritional supplement (SQ-LNS) at home
16319201|NCT04544332||Sweetened Supplement|Infants will receive 10 exposures to the sweetened small quantity lipid nutritional supplement (SQ-LNS) at home
16319202|NCT04544319|Experimental|Arm I|Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
16319203|NCT04544319|Experimental|Arm II|Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg
16319204|NCT04544306|No Intervention|Control arm|Standard of Care (intravenous antimicrobial therapy according to the American Heart Association Guideline 2015)
16319205|NCT04544306|Experimental|Partial oral treatment arm|The mode of antimicrobial delivery is switched to oral therapy after at least 10 days of IV therapy, guided by antimicrobial susceptibility
16319206|NCT04544293|Experimental|Molgramostim|Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
16319207|NCT04544293|Placebo Comparator|Placebo|Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
16319208|NCT04544280|Experimental|Intervention|
16319209|NCT04544267|Experimental|QIV-HD|One injection of QIV-HD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
16319210|NCT04544267|Active Comparator|QIV-SD|One injection of QIV-SD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
16319211|NCT04544254|Active Comparator|Bilateral transversus thoracis muscle plane block|Regional block will be performed after induction of anesthesia by anesthesiologist on duty who is not part of investigators for this study. The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided
16319212|NCT04544254|Placebo Comparator|Control|Needle will be put in the superficial skin on the same area as transversus thoracis muscle plane block area without any drugs injected into the injection area
16319213|NCT04544241|Experimental|Clergy Wives and Widows|We will provide cancer survivorship and caregiving leadership education and activities for African American Clergy Wives and Widows by creating an educational partnership program aimed towards church-based health education on cancer survivorship and caregiving
16319214|NCT04544228|Experimental|ketamine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml ketamine
16319215|NCT04544228|Experimental|Neostigmine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml neostigmine
16319216|NCT04544228|Active Comparator|Control|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml normal saline.
16319217|NCT04544215|Experimental|MPCs-derived exosomes Dosage 1|low-dose group
16319218|NCT04544215|Experimental|MPCs-derived exosomes Dosage 2|high-dose group
16319219|NCT04544215|Placebo Comparator|No exosomes|No MPCs-derived exosomes
16319223|NCT04544176||Exposed Cohort|This group will include patients attending radiology outpatient appointments in 2020 in our period of interest from the peak of the first wave of the pandemic, who were subsequently tested for SARS-COV2 within 28-days of their attendance.
16319224|NCT04544176||Unexposed Cohort|This group will form the control group and comprises all individuals who attended radiological appointments during the same period for each hospital in 2019 but not 2020.
16319225|NCT04544163|Experimental|Magnesium sulphate- Fentanyl|30 mg per kg MgSo4 infusion in 100 ml saline over 10 minutes
16319226|NCT04544163|Experimental|Fentanyl 4 mic|4 mic per kg fentanyl i.v
16319227|NCT04544163|Active Comparator|Fentanyl|2 mic per kg fentanyl i.v
16319228|NCT04544163|Experimental|Lidocaine- Fentanyl|Lidocaine 1.5 mg/kg
16319229|NCT04544137|Experimental|BOKS + SFSP|Children randomized to the BOKS + SFSP will be invited to attend the one-hour BOKS program four days per week for eight weeks during the summer. The BOKS program will be run by Lifespan employed staff in the hour before the SFSP lunch service at two community locations.
16319230|NCT04544137|No Intervention|SFSP|Children randomized to the SFSP alone group will be asked to participate in the SFSP as they would have otherwise.
16319231|NCT04544124|Experimental|Contingency management for treatment attendance|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
16319232|NCT04544124|No Intervention|Treatment-as-usual|Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
16319233|NCT04544111|Experimental|Cohort A-BRAF WT tumors|Cohort A (BRAF WT tumors): trametinib (T) 2mg by mouth daily plus PDR001 400mg IV every 4 weeks
16319342|NCT04543344|Experimental|High Dose|Repeated multiple doses
16319234|NCT04544111|Experimental|Cohort B-BRAF Mutant|Cohort B (BRAF Mutant, resistant to previous BRAF inhibitors): dabrafenib (D) 150 mg twice daily (OR at dose the patient previously tolerated) plus PDR001 400mg IV every 4 weeks.
16319235|NCT04544098|Experimental|PRRT with 177Lu-DOTATATE|Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
16319236|NCT04544085|No Intervention|control group|Patients in the control group will not receive any noise management intervention
16319237|NCT04544085|Experimental|experimental group|Patients in the experimental group will receive noise management. The intervention measures mainly include the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.We will strengthen the education of medical staff to ensure the effective implementation of the noise management.
16319238|NCT04544059|Experimental|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
16319239|NCT04544046|Active Comparator|Usual Care|Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.
16319240|NCT04544046|Experimental|Supportive Oncology Care at Home|"The research study procedures include:
~Remote monitoring of symptoms, vitals, and body weight
~Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms)
~Data collection from medical record"
16319241|NCT04544033||mild group|"Amendment to MOH COVID-19 Protocol:
~Patient with mild clinical symptoms & clinically table.
~CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line."
16319242|NCT04544033||moderate group|"Amendment to MOH COVID-19 Protocol:
~Patient with non-specific and specific respiratory infection (pneumonia).
~CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening)."
16319243|NCT04544033||severe group|"Amendment to MOH COVID-19 Protocol:
~Patients with respiratory distress (RR > 30/min, Sa02 < 92 at room air).
~Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours.
~CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening)."
16319244|NCT04544020||subjects|subjects with alcoholic hepatitis receiving NG feeding
16319246|NCT04543994|Experimental|Remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.
~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)."
16319247|NCT04543994|Experimental|Remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.
~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
16319248|NCT04543994|Placebo Comparator|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall.
~If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.
~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
16319249|NCT04543968|Experimental|EVOO intake|"MD patients will receive EVOO daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving EVOO as their dietary supplements for another 6 months.
~Doses of EVOO intake: (1) Toddlers,1-3 y, 25 ml/day; (2) Kindergarten kids, 4-6 y, 30 ml/day; (3) Primary school age, 7-12y, 40 ml/day; (4) Secondary school age, 13-17y, 50 ml/day"
16319250|NCT04543968|Experimental|EVOO intake and withdraw|"MD patients will receive EVOO daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving EVOO as their dietary supplements for another 6 months.
~Doses of EVOO intake: (1) Toddlers,1-3 y, 25 ml/day; (2) Kindergarten kids, 4-6 y, 30 ml/day; (3) Primary school age, 7-12y, 40 ml/day; (4) Secondary school age, 13-17y, 50 ml/day"
16319251|NCT04543955|Experimental|Arm 1: Low-Dose Telotristat|Participants in this group will receive 750mg Telotristat per day.
16319252|NCT04543955|Experimental|Arm 2: High-Dose Telotristat|Participants in this group will receive 1500mg Telotristat per day.
16319253|NCT04543942|Experimental|Males|Participants in this group will be adult male heavy drinkers.
16319254|NCT04543942|Experimental|Females|Participants in this group will be adult female heavy drinkers. Data will be segregated by menstrual cycle phase - the late follicular or mid-luteal phase.
16319255|NCT04543929|Active Comparator|exercise|exercise prescription + standard of care
16319256|NCT04543929|No Intervention|no exercise|no exercise prescription + standard of care
16319257|NCT04543916|Experimental|Dose Level 1|Venetoclax 50mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
16319258|NCT04543916|Experimental|Dose Level 2|Venetoclax 100mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
16319259|NCT04543916|Experimental|Dose Level 3|Venetoclax 200mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
16319260|NCT04543916|Experimental|Dose Level 4|Venetoclax 400mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
16319261|NCT04543916|Experimental|Dose Level 5|Venetoclax 600mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
16319262|NCT04543916|Experimental|Phase 2 Expansion Cohort|Venetoclax recommended phase 2 dose (RP2D) by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
16319263|NCT04543903|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16319264|NCT04543890|Active Comparator|Hyperfrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
16319265|NCT04543890|Experimental|Hypofrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/15 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
16319266|NCT04543877|Experimental|Inulin and Ty21a Vaccine|Participants will consume 12 grams/day of inulin for 4 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 6 weeks.
16319267|NCT04543877|Placebo Comparator|Maltodextrin and Ty21a Vaccine|Participants will consume 12 grams/day of maltodextrin (control) for 4 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 6 weeks.
16319268|NCT04543864|Experimental|electric welded metal framework|
16319269|NCT04543864|Experimental|conventional casted metal framework|
16319270|NCT04543851|Experimental|CARA positioning|Planning and Treatment using the CARA Device
16319271|NCT04543838|Experimental|EEG & SSEP monitoring|Intervention will include standard of care pain management during the postoperative period. Participants in this arm will receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP). EEG will be used to manage blood pressure.
16319272|NCT04543838|Active Comparator|Standard of Care|Control will include standard of care pain management during the postoperative period. Participants in this arm will not receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP).
16319273|NCT04543825|Experimental|CPET|Patients with cirrhosis who have been wait listed for liver transplant or are undergoing liver transplant evaluation and will undergo cardiopulmonary exercise testing (CPET).
16319274|NCT04543812|Experimental|PBF-1681 (ferric citrate)|PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
16319275|NCT04543812|Placebo Comparator|Placebo|Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
16319276|NCT04543799||A1|"Group A1 consists of patients with prostate cancer receiving ADT as part of their standard care for either locally advanced or metastatic disease.
~Group A1 consists of a combination of two groups; B1, metastatic patients receiving ADT both with and without an oral AR targeted agent, and not receiving radiotherapy and B2, locally advanced patients receiving ADT alongside radiotherapy"
16319277|NCT04543799||A2|patients with localised prostate cancer receiving radiotherapy only
16319278|NCT04543786|Experimental|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation on lower back for 30-60 minutes for 5 consecutive days.
16319279|NCT04543773|Experimental|rTMS|Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
16319280|NCT04543760|Other|[PP sequence 1] - Wash-out - [SP sequence 2]|
16319281|NCT04543760|Other|[SP sequence 1] - Wash-out - [PP sequence 2]|
16319282|NCT04543747||Patients implanted with HVAD System|Patients who require treatment with HVAD for use as bridge to cardiac transplantation (BTT) or destination therapy (DT) within the re-examination period are eligible for enrollment into the MCS Korea PMS. Patient consent may be obtained prior to HVAD implant or after receiving HVAD implant. Waiver of consent may be allowed if allowed by site's Institutional Review Board (IRB) or Ethics Committee (EC).
16319283|NCT04543721||24-h-ABPM|
16319284|NCT04543708|Active Comparator|Incision drainage|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Incision drainage arm will benefit from drainage of the tonsillar abscess under local anesthesia and then be hospitalized for intravenous antibiotics. If the incision drainage fails, they will get a tonsillectomy under general anesthesia."
16319285|NCT04543708|Active Comparator|Tonsillectomy|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Tonsillectomy arm will benefit from tonsillectomy under general anesthesia and then be hospitalized for intravenous antibiotics."
16319286|NCT04543695|Active Comparator|adjuvant chemotherapy group|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
16319287|NCT04543695|Experimental|consolidation chemotherapy group|concurrent chemoradiotherapy → consolidation chemotherapy → TME (experimental group)
16319288|NCT04543695|Experimental|induction chemotherapy group|induction chemotherapy → concurrent chemoradiotherapy →TME ( experimental group).
16319289|NCT04543682|Experimental|First intervention group (0.125 ng/kg/min Iloprost)|The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS, Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.
16319290|NCT04543682|Experimental|Second intervention group (0.25 ng/kg/min Iloprost)|The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS, Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.
16319291|NCT04543682|Other|Control intervention group|Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS).
16319292|NCT04543669|Experimental|Adacel®|All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
16319293|NCT04543656|Experimental|AI-Based Lifestyle Recommendations Group|Participants in this group receive AI-based, personalized lifestyle recommendations based on analysis of their activity tracker and blood pressure data.
16319294|NCT04543656|Active Comparator|Control Group|Participants in this group do not receive the lifestyle recommendations, but are provided with an identical activity tracker and blood pressure monitor.
16319297|NCT04543630|Active Comparator|Particulated autogenous bone|Particulated autogenous bone is considered the gold standard for sinus floor augmentation. The bone will be harvested locally
16319298|NCT04543630|Experimental|Advanced platelet-rich fibrin|Advanced platelet-rich fibrin will be be obtained through a blood sample from the participant
16319299|NCT04543617|Experimental|Arm A: Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab.
16319300|NCT04543617|Experimental|Arm B: Tiragolumab Placebo + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab matching placebo.
16319301|NCT04543617|Placebo Comparator|Arm C: Tiragolumab Placebo + Atezolizumab Placebo|Participants will receive matching placebos to tiragolumab and atezolizumab.
16319302|NCT04543604|Experimental|Test group1 - Leaflet with visual aid|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. Along, pictograms were supplemented to display the prevalence of disease with and without the known indicator.
16319303|NCT04543604|Experimental|Test group2 - Leaflet with visual aid (L-NVA)|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. No pictograms were supplemented.
16319304|NCT04543604|No Intervention|• Control group - No leaflet (NL)|Only verbal information was provided to the patient during initial interview.
16319305|NCT04543591|Experimental|Ravulizumab|
16319306|NCT04543591|Placebo Comparator|Placebo|
16319307|NCT04543578||Patients unfit for Surgery with mild-moderate acute cholecyst|Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.
16319308|NCT04543578||Patients unfit for Surgery with severe acute cholecystitis|Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.
16319309|NCT04543578||Patients suitable for Surgery with high and intermediate risk|"Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.
~High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.
~Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP."
16319310|NCT04543578||Patients suitable for Surgery with low risk|"Admission in Surgery Department. According to the AC severity:
~Mild-moderate AC: check de ASA/Charlson comorbidity index.
~ASA I-II/Charlson <6: laparoscopic cholecystectomy
~ASA > =III/Charlson >=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)
~Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy."
16319311|NCT04543565|Experimental|Trial group|subject in this group will receive Pradefovir mesylate tablet and the placebo of tenofovir disoproxil fumarate tablet, once daily for 96 weeks
16319312|NCT04543565|Active Comparator|Control group|subject in this group will receive tenofovir disoproxil fumarate tablet and the placebo of Pradefovir mesylate tablet, once daily for 96 weeks.
16319313|NCT04543552||Bladder Scan|Subjects who are scheduled to undergo urodynamic studies.
16319314|NCT04543539||IN.PACT™ AV Access PAS Primary Cohort|The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
16319315|NCT04543539||IN.PACT™ AV Access PAS Extended Cohort|The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
16319316|NCT04543526||Obese patients|Obese patients eligible for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.
16319317|NCT04543513|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
16319318|NCT04543500|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
16319319|NCT04543500|Active Comparator|Sham Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left postcentral gyrus. Participants in this arm will receive sham feedback while attempting to modulate their neural activity during an emotional cognitive control task.
16319320|NCT04543487|Experimental|Control Group|Group name
16319321|NCT04543474|Active Comparator|Group 1|Patients starting with a low lactose diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low FODMAP diet for 3 weeks
16319322|NCT04543474|Active Comparator|Group 2|Patients starting with a low FODMAP diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low lactose diet for 3 weeks.
16319343|NCT04543331||treatment naïve patients|Patients being the first time treated for nAMD
16319344|NCT04543331||pre-treated patients|Patients already being treated for nAMD
16319345|NCT04543318|Experimental|Deep temporal nerves group|this group will use deep temporal nerves for reactivation of affected upper facial nerve branch
16319323|NCT04543448|Other|Traditional Rehabilitation|Traditional Rehabilitation program was included strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs in all individuals. Indıvıduals participated in 2 training sessions per week for 4 weeks. Each training session consisted of a 5-minute non-balance coordination exercise, a 30-minute balance and coordination exercise, a 10-minute stretching and strengthing.
16319324|NCT04543448|Experimental|Cervical Mobilization|Cervical Mobilization program, cervical mobilization techniques were applied to the patients for 30 minutes in addition to the traditional program. Cervical mobilization includes suboccipital relaxing techniques, myofascial muscle relaxing techniques for Levator scapula, trapezius, scalenes muscles. These techniques were applied bilaterally.
16319325|NCT04543422|Experimental|Green tea extracts|Patients in this arm received green tea extract capsules
16319326|NCT04543422|Placebo Comparator|Placebo|Patients in this arm received placebo treatment
16319327|NCT04543409|Experimental|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
16319328|NCT04543409|Placebo Comparator|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
16319329|NCT04543396|Experimental|Physical Thearpy + Resistance Training|Subjects will receive standard of care treatments from their physical therapist. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
16319330|NCT04543396|No Intervention|Physical Thearpy|Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
16319331|NCT04543396|Experimental|Chiropractic Care + Resistance Training|Subjects will receive standard of care treatments from their chiropractor. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
16319332|NCT04543396|No Intervention|Chiropractic Care|Subjects will receive standard of care treatments from their chiropractor. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
16319333|NCT04543383|Experimental|Part 1: Group 1|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: ABC1, BC1A, C1AB, BAC1, C1BA and AC1B in period 1, period 2 and period 3 respectively where, Treatment A= Dose 1 of JNJ-70033093 +Dose 3 of 4F-PCC; Treatment B=Dose 2 of JNJ-70033093+Dose 3 of 4F-PCC; Treatment C1=Dose 2 of JNJ-70033093+Placebo with a washout period of 14 days to 21 days between Day 1 of each study period.
16319334|NCT04543383|Experimental|Part 1: Group 2|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: ABC2, BC2A, C2AB, BAC2, C2BA and AC2B in period 1, period 2 and period 3 respectively where, Treatment A= Dose 1 of JNJ-70033093 +Dose 3 of 4F-PCC; Treatment B=Dose 2 of JNJ-70033093+Dose 3 of 4F-PCC; Treatment C2=Dose 1 of JNJ-70033093+Placebo with a washout period of 14 days to 21 days between Day 1 of each study period.
16319335|NCT04543383|Experimental|Part 2: Group 1|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E in period 1, period 2 and period 3 respectively where, Treatment D=Dose 1 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment E=Dose 2 of JNJ-3093+Dose 4 of rFVIIa; Treatment F1=Dose 2 of JNJ-70033093+Placebo with a washout period of 4 days between Day 1 of each study period.
16319336|NCT04543383|Experimental|Part 2: Group 2|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and IV injection of the reversal agent Recombinant Human Factor VIIa (rFVIIa) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E in period 1, period 2 and period 3 respectively where, Treatment D=Dose 1 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment E=Dose 2 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment F2=Dose 1 of JNJ-70033093 +Placebo with a washout period of 4 days between Day 1 of each study period.
16319337|NCT04543370|Experimental|Treatment A|2 mg midazolam on Day 1 and 36 mg deflazacort on Day 2.
16319338|NCT04543370|Experimental|Treatment B|2000 mg edasalonexent TID on Day 1 to Day 11 with 2 mg midazolam on Day 10 and with 36 mg deflazacort on Day 11.
16319339|NCT04543357||All participants|Household contacts of a participant in study C3391003
16319340|NCT04543344|Experimental|Low Dose|Repeated multiple doses
16319341|NCT04543344|Placebo Comparator|placebo|Repeated multiple doses
16319346|NCT04543318|Active Comparator|Masseteric nerve group|this group will use masseteric nerve for reactivation of affected upper facial nerve branch (gold standard)
16319347|NCT04543305|Experimental|PRT1419|PRT1419 will be administered orally
16319348|NCT04543292|Experimental|MATFILL|Prosthetic chimney filling with MATFILL prior to other sealing materials to protect the screww head.
16319349|NCT04543279|Experimental|Part A: Fostamatinib|The starting dose of fostamatinib is 100 mg twice daily (BID). After the first cycle, if no major dose related safety issue is observed and the platelet count is less than 50K/microL, then the fostamatinib dose will be increased to 150 mg BID for the next 2 cycles; otherwise the dose may be continued at 100 mg BID.
16319350|NCT04543279|Experimental|Part B: Fostamatinib + Ruxolitinib|"After 3 cycles of fostamatinib monotherapy, all patients with a sustained platelet count ≥ 50K/microL, will continue on the current fostamatinib dose plus ruxolitinib at the recommended dose per standard prescribing guidelines for an additional 9 cycles.
~Patients who do not reach platelet count of at least 50K/microL but who achieve clinical benefit per the treating provider may continue on single agent fostamatinib for up to 12 total treatment cycles. If these patients achieve a sustained platelet count of ≥ 50K/microL at any point prior to Cycle 10 Day 1, then they may be eligible to enroll in Part B of the study and continue treatment with fostamatinib and ruxolitinib for the remainder of the study."
16319351|NCT04543266||Patients with Progressive Disease|Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease
16319352|NCT04543266||Patients without Progressive Disease|Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease
16319355|NCT04543227||Retrospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries between August 2015 - August 2019.
16319356|NCT04543227||Retrospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure between August 2015 - August 2019.
16319357|NCT04543227||Prospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries after July 2020.
16319358|NCT04543227||Prospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure after July 2020.
16319359|NCT04543201|Experimental|Early STructured Advanced care Referrals by Telehealth|"Early START visit using checklist over telephone or zoom:
~A telehealth visit conducted within 4 months of patient diagnosis, with the goal of encouraging patients to discuss and document their end-of-life wishes prior to the onset of cognitive impediments common among patients with late-stage high grade glioma."
16319360|NCT04543188|Experimental|PF-07284890 (Part A monotherapy)|Monotherapy dose escalation of PF-07284890
16319361|NCT04543188|Experimental|PF-07284890+binimetinib (Part A combo-therapy)|Combination dose escalation of PF-07284890 + binimetinib
16319362|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 1)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or Non-Small Cell Lung Cancer (NSCLC), with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
16319363|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 2)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
16319364|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 3)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
16319365|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 4)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and prior BRAF inhibitor utilization
16319366|NCT04543188|Experimental|Expansion Phase (Part B Cohort 5)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
16319367|NCT04543188|Experimental|Drug-Drug Interaction Substudy|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
16319368|NCT04543175||Chemotherapy breast cancer patients|Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.
16319369|NCT04543162||patients with Mild Traumatic Brain Injury|patients with Mild Traumatic Brain Injury
16319370|NCT04543149||Case|Patients with idiopathic granulomatous mastitis
16319371|NCT04543149||Control|Healthy volunteers
16319372|NCT04543136|Active Comparator|SpeediCath® standard Male|Standard of care
16319373|NCT04543136|Experimental|New intermittent catheter variation 1 for male|New intermittent catheter variation 1 for male.
16319374|NCT04543136|Experimental|New intermittent catheter variation 2 for male|New intermittent catheter variation 2 for male
16319375|NCT04543123|Sham Comparator|sham tDCS treatment group|the current rose slowly for 30 seconds, descended for 30 seconds, and then remained at zero for 29 minutes
16319376|NCT04543123|Experimental|active tDCS treatment group|2mA of current was delivered during the 30 minutes of treatment
16319377|NCT04543110|Experimental|Single Arm|Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
16319378|NCT04543097|No Intervention|Usual care|Participants randomised to the usual care arm will continue to receive care as usual for their health and vocational needs. For most patients, this will comprise usual clinical care, without formal vocational advice.
16319379|NCT04543097|Experimental|Usual care plus vocational support|Vocational support following a stepped care model based on the principles of case management in addition to usual primary care.
16319380|NCT04543084|Other|Single-Subject Design|Each participant will go through a baseline phase and then an intervention phase.
16319382|NCT04543058|Experimental|BeatPark Experimental Group|Group of participants who will make its self-rehabilitation in walking program using BeatPark application, delivering synchronized music adapted to the patient walking progression.
16319383|NCT04543058|Active Comparator|Control Group with Music at Random Tempo|Group of participants who will make its self-rehabilitation in walking program using an application delivering music at random tempo.
16319384|NCT04543058|Active Comparator|Control Group without Music|Group of participants who will make its self-rehabilitation in walking program using an application without music.
16319385|NCT04543045||Stage 1|20 patients will be interviewed once, which will be approximately 60 minutes in duration. The interviews will be audio recorded.
16319386|NCT04543045||Stage 2|Five patients who participated in stage 1 will take part in a cognitive interview, which will be approximately 60 minutes in duration.The interviews will be audio recorded.
16319387|NCT04543032|Experimental|study group|the patients in this group will receive sensorimotor training for 6 weeks in addition to medical care.
16319388|NCT04543032|No Intervention|control group|the patients in this group will receive medical care only.
16319389|NCT04543006|Other|Covid-19|only arm: Covid-19 proven by PCR
16319390|NCT04542993|Active Comparator|Resveratrol and Zinc Picolinate combination therapy|Resveratrol and Zinc Picolinate combination therapy
16319391|NCT04542993|Placebo Comparator|Resveratrol Placebo and Zinc Placebo combination therapy|Placebo Resveratrol and Placebo Zinc combination therapy
16319392|NCT04542980||SARS-CoV2 Positive|"Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.
~A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus."
16319393|NCT04542980||Control|Control tear and serum samples will be selected from Namida Lab's own biorepository.
16319394|NCT04542967|No Intervention|Control group|They will receive the standard care for critically ill inpatients.
16319395|NCT04542967|Experimental|Convalescent plasma group.|They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.
16319396|NCT04542941|Active Comparator|Intervention arm|The participants will receive COVID Convalescent Plasma in addition to the standard of care received by all COVID 19 patients
16319397|NCT04542941|No Intervention|Control arm|The participants under this arm will receive the COVID 19 standard of care
16319398|NCT04542928|Placebo Comparator|routine care|The controlled group will receive routine functional treatment activities, a facial cleansing instruction and five facial cleansing videos.
16319399|NCT04542928|Experimental|experimental group|experimental group is required to receive a nurse leading 50- minute face care group every two weeks
16319400|NCT04542915||U.S. licensed dental hygienists|Dental hygienists licensed in the United States. No intervention will be administered.
16319401|NCT04542902|Experimental|Allergic asthma patients|Allergic asthma patients and sensitization to house dust mites (D. pteronyssinus) allergen.
16319402|NCT04542902|Experimental|Severe eosinophilic asthma patients|
16319403|NCT04542902|Active Comparator|Healthy subjects as a control group|Healthy subjects without allergic and other chronic respiratory diseases (control group).
16319404|NCT04542889|Experimental|Absolute coronary resistances and IMR after angioplasty|Patients with STEMI by acute occlusion of a large caliber coronary artery that had been admitted to hospital less than 12 hours and revascularized by primary angioplasty with good final result.
16319405|NCT04542876|Experimental|Ayurveda|Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.
16319406|NCT04542863|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans.
16319408|NCT04542837|Experimental|KN046 plus Lenvatinib|
16319409|NCT04542824|Experimental|epcoritamab|Open label, single arm trial where epcoritamab will be administered
16319410|NCT04542811|Experimental|Intervention group|Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
16319411|NCT04542811|No Intervention|Control Group|Control group will take only their migraine prophylaxis treatment. Participants will followed-up 3 months.
16319412|NCT04542798|Experimental|NPPG (neuropatic pain group) PRF|Pulsed radiofrequency neuromodulation of dorsal root ganglia
16319413|NCT04542798|Active Comparator|NPPG (neuropatic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
16319414|NCT04542798|Experimental|NMPG (nociceptive/mechanic pain group) WCRF|Water cooled radiofrequency of the medial branch of the dorsal nerve
16319415|NCT04542798|Active Comparator|NMPG (nociceptive/mechanic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
16319416|NCT04542785|Experimental|Lenient rate control|Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
16319417|NCT04542785|Active Comparator|Strict rate control|Treating physicians will target a resting heart rate a mean resting heart rate < 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
16319418|NCT04542772|Experimental|Mirror Therapy + Standard of Care|Participants in this group will receive standard of care based on their needs along with mirror therapy education.
16319419|NCT04542772|Active Comparator|Standard of Care|Participants in this group will receive only standard of care based on their needs.
16319420|NCT04542759|Active Comparator|Besifloxacin|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
16319421|NCT04542759|Placebo Comparator|Hydroxypropyl methylcellulose|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
16319422|NCT04542746|Experimental|Minimally invasive surgical technique|The intra-bony defects of subjects allocated in test group were treated with a combination of minimally invasive surgical technique (MIST) and enamel matrix derivative( EMD).
16319423|NCT04542746|Active Comparator|Conventional open flap debridement with papilla preservation|The intra-bony defects of control group were treated using a combination of conventional open flap debridement with papilla preservation (COFD+PP) and EMD.
16319424|NCT04542733|Active Comparator|mTORi with reduced-dose tacrolimus|Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.
16319425|NCT04542733|Active Comparator|reduced-dose tacrolimus|Patient will receive tacrolimus with target concentration of 3-6 ng/mL with or without leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter. Duration for this regimen would be at least 3 months.
16319426|NCT04542720|Experimental|Decompression|
16319427|NCT04542720|Active Comparator|Extension Fusion|
16319428|NCT04542707|Active Comparator|Joint manipulation|Grade V-Thrust manipulation with audible sound and without audible sounds of T7, MTP 2 and MCP2 joints.
16319429|NCT04542707|Active Comparator|Exercise|Aerobic, anaerobic, and yoga exercises
16319430|NCT04542707|Active Comparator|Soft tissue massage|Instrument assisted soft tissue massage
16319431|NCT04542694|Experimental|Favipiravir (Areplivir)|"Arm 1 (n=100) receives the study drug Areplivir film-coated tablets:
~on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient."
16319432|NCT04542694|Active Comparator|Standard of care|"Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes.
~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
16319433|NCT04542681|Placebo Comparator|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo (0.9% normal saline) (n=10)
16319434|NCT04542681|Active Comparator|MANP - 1st Cycle|Subjects will receive a single SQ injection of 2.5 μg/kg MANP (n=10)
16319435|NCT04542681|Active Comparator|MANP - 2nd Cycle|Subjects will receive a single SQ injection of 5 μg/Kg MANP (n=10)
16319436|NCT04542668|Other|Cycling as first intervention|Cycling -> Running -> Inotropy -> Resting
16319437|NCT04542668|Other|Running as first intervention|Running -> Cycling -> Inotropy -> Resting
16319438|NCT04542655|Other|Cycling first|Ergometer cycling then treadmill running then rest
16319439|NCT04542655|Other|Running first|Treadmill running then ergometer cycling then rest
16319440|NCT04542642|Active Comparator|reSET-O|Prescription Digital therapeutic
16319441|NCT04542642|Experimental|PEAR-008|Investigational Digital Therapeutic
16319442|NCT04542629|Experimental|RITUXIMAB|rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses
16319443|NCT04542629|Active Comparator|KETOGENIC DIET|"The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.
~Diets that produce a state of ketosis are referred to as ''ketogenic"
16319444|NCT04542629|Active Comparator|TRACE ELEMENTS|. Essential trace elements that include zinc, copper, magnesium, and selenium
16319445|NCT04542629|Active Comparator|CORTICOSTEROID|corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month
16319446|NCT04542616|Active Comparator|Baerveldt 350|The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
16319447|NCT04542616|Active Comparator|Ahmed ClearPath 250|The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
16319448|NCT04542603|Experimental|treatment naivete women with stage 1-4 newly diagnosed ovarian|
16319449|NCT04542564|Experimental|telemedicine group|The HT app (HealthCap) allows patients to record their home BP measurements (HBPM) and can automatically provide mean BP values from the previous 7 or 30 days. 1-2 week prior to a scheduled physician, HealthCap and a research assistant will remind patients to take dual BP readings both in the morning and evening for 1 week for doctors' management. The mean values of the 7-day home BP will be checked before the index consultation. If the home BP control was optimal (i.e. ≤135/85 mmHg), other important parameters will be checked automatically by a questionnaire in the app: (i) if they have good drug compliance and if they experienced any side effects,(ii) if they have symptoms suggestive of target organ damages such as chest pain or hemiplegia, and (iii) if they have any problem(s) that need to consult a physician. If no complaints are identified, the patient can collect medications directly from the clinic and the physician appointment will be deferred for 3 months
16319450|NCT04542564|Placebo Comparator|usual care|Patients in the usual care group will be asked to refrain from downloading or using any health care apps related to HT
16319451|NCT04542551|Active Comparator|Without stricture - dilation with 60-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 60-Fr dilator
16319452|NCT04542551|Sham Comparator|Without stricture - dilation with 15-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 15-Fr dilator (sham)
16319587|NCT04541576|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
16319453|NCT04542551|Active Comparator|Non severe stricture - dilation with 60-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 60-Fr dilator
16319454|NCT04542551|Active Comparator|Non severe stricture - dilation with 46-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 46-Fr dilator
16319455|NCT04542551|Active Comparator|Severe stricture - dilation with 51-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 51-Fr dilator
16319456|NCT04542551|Active Comparator|Severe stricture - dilation with 42-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 42-Fr dilator
16319457|NCT04542538||COVID-19 critical care patients|All patients who have received intensive care with COVID-19 in Sweden until May 27, 2020. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
16319458|NCT04542538||Sepsis critical care patients|All patients who have received intensive care with severe sepsis or septic shock in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
16319459|NCT04542538||ARDS critical care patients|All patients who have received intensive care with ARDS in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
16319460|NCT04542499|Experimental|Tavapadon|Participants will receive a tavapadon tablet titrated 5 to 15 milligrams (mg) once daily (QD) orally for 27 weeks.
16319461|NCT04542499|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
16319462|NCT04542486|Experimental|The conventional approach:|Gingivoplasties and removal of excess gingival tissues through the conventional scalpel technique using a reverse bevel.
16319463|NCT04542486|Active Comparator|The intervention approach:|"Gingivoplasties and elimination of excess gingival tissues through the use of Thermacut burs."
16319464|NCT04542473|Active Comparator|Pancreatic Enzymes (PE)|"Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day:
~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)
~---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667"
16319465|NCT04542473|Placebo Comparator|Placebo-PE|"Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands:
~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)
~----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil"
16319466|NCT04542473|Active Comparator|Ursodeoxycholic acid (UA)|The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
16319467|NCT04542473|Placebo Comparator|Placebo-UA|The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
16319468|NCT04542460|No Intervention|Optimal Medical Treatment|CTO patients receiving optimal medical treatment
16319469|NCT04542460|Active Comparator|Optimal Medical Treatment and PCI|CTO patients receiving PCI in ajunction to optimal medical treatment
16319470|NCT04542447|Active Comparator|Nuvastatic + standard treatment|5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
16319471|NCT04542447|Placebo Comparator|Placebo|5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
16319472|NCT04542434|Experimental|Niclosamide|
16319473|NCT04542434|Placebo Comparator|Placebo|
16319474|NCT04542421|Experimental|Lung ultrasound Implementation arm|Hospitalists undergo training to use lung ultrasound in their patients hospitalized with COVID
16319475|NCT04542408|Experimental|Intensive anticoagulation strategy|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC
16319476|NCT04542408|Other|Moderate anticoagulation strategy|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban
16319477|NCT04542395|Experimental|Increasing Uptake of COVID-19 Testing and Vaccination|"This is a pre-experimental one group pretest-posttest design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
16319478|NCT04542382|Experimental|Placebo and Rosuvastatin|Subjects will be dosed with placebo tablet and Rosuvastatin 10mg tablet
16319479|NCT04542382|Experimental|Eltrombopag and Rosuvastatin|Subjects will be dosed with Eltrombopag 75mg tablet and Rosuvastatin 10mg tablet
16319556|NCT04541797|Placebo Comparator|Control|Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
16319726|NCT04540588|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16319480|NCT04542369|Experimental|ES-SCLC|Induction therapy: BGB-A317 200mg, qd, ivgtt, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles. Maintenance therapy: BGB-A317 200mg, qd, ivgtt, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death).
16319481|NCT04542356|Experimental|experimental group|patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
16319482|NCT04542356|Placebo Comparator|control group|patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC<1✕109/L
16319483|NCT04542343|Experimental|Risk Reduction of COVID-19 Among African American Parishioners|"This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators."
16319484|NCT04542330|Active Comparator|BCG-Denmark|"Participants that are randomized to the active comparator arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.
~Each 0.1 ml dose of vaccine contains between 200,000 to 800,000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
16319485|NCT04542330|Placebo Comparator|Control|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
16319488|NCT04542304|Active Comparator|Metolazone then placebo|Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
16319489|NCT04542304|Placebo Comparator|Placebo then Metolazone|Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.
16319490|NCT04542291|Experimental|Dapagliflozin|"Dapagliflozin is an oral drug which will be administered on an outpatient basis. Dosing will start at 5 mg daily and will increase to 10 mg daily after 2 weeks (after consulation with a study endrocrinologist) if the patient is tolerating the 5 mg dose. Dapagliflozin will be given for a total of 8 weeks (2 weeks at 5 mg and 6 weeks at 10 mg)
~Treatment with dapagliflozin will be initiated on Cycle 1 Day 1 of standard of care chemotherapy.
~Participants will use the BIOSENSE meter once daily"
16319491|NCT04542278|Active Comparator|Steroids|Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care
16319492|NCT04542278|No Intervention|No Steroids|Pre-operative Standard of Care
16319493|NCT04542265|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
16319494|NCT04542265|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
16319495|NCT04542265|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil A + vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
16319496|NCT04542265|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
16319497|NCT04542252|Experimental|Group 1|SyB V-1901 alone, Simultaneous administration of SyB V-1901 and cyclosporine, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
16319498|NCT04542252|Experimental|Group 2|Simultaneous administration of SyB V-1901 and cyclosporine, SyB V-1901 alone, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
16319499|NCT04542239||Infants with GER|Infants (N=25) meeting inclusion/exclusion criteria
16319500|NCT04542239||Controls without GER|Infants (N=10) meeting inclusion/exclusion criteria, but no GER
16319501|NCT04542226||Adult patients hospitalized with COVID-19|Patients eligible for enrollment into the study
16319502|NCT04542213|Experimental|DPP4 inhibitor + insulin|Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
16319503|NCT04542213|Active Comparator|Insulin scheme alone|Patients assigned to this group will receive only a basal-bolus insulin scheme
16319504|NCT04542161|Active Comparator|NAC 900mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
16319505|NCT04542161|Active Comparator|NAC 3600mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
16319506|NCT04542161|Placebo Comparator|NAC 0mg/day (Placebo)|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
16319510|NCT04542135|Active Comparator|Sulindac|sulindac 150 mg
16319511|NCT04542135|Placebo Comparator|Placebo|placebo pill
16319512|NCT04542122|No Intervention|Choices then judgements|
16319513|NCT04542122|Active Comparator|Judgements then choices|Switch in the order of clinical cases in the survey
16319557|NCT04541797|Experimental|Intervention|Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
16319622|NCT04541316||Mid term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-4 months post implantation
16319514|NCT04542109|Experimental|READyR A|Group A will start the READyR intervention immediately after the baseline Session 1. The READyR program consists of a 3-session, values-based needs assessment intervention designed to match objectively-assessed in-home activity patterns with subjective reports of participants' care values. The goal of the intervention is to address unmet dementia-related care needs and help couples prepare for the future, and reduce strain on their relationship, and help maintain their health and well-being. Session 2 will occur approximately 3 weeks after Session 1, and Session 3 will occur approximately 3 weeks after Session 2. Session 3 also includes follow-up assessments.
16319515|NCT04542109|Active Comparator|READyR B (wait list comparison)|Group B - the wait list comparison group - will have a 60-minute support session (comparator intervention) about 3 weeks after the baseline Session 1. The support session will include general information about dementia-related care needs that does not take into account the individual participant's care values or objective in-home activity patterns. They will also receive a check-in call approximately 3 weeks later, with follow-up assessments. Group B will begin the READyR intervention sessions following completion of follow-up assessments.
16319516|NCT04542096||Group1|Patients receiving invasive respiratory therapy (intubated)
16319517|NCT04542096||Group2|Patients receiving non-invasive respiratory therapy.
16319518|NCT04542083||COVID-19 period|Admissions from January to December 2020
16319519|NCT04542083||Control period|Admissions from January 2018 to December 2019
16319520|NCT04542070|Experimental|Participants receiving CAB LA + RPV LA regimen|Participants will be offered the option to start with a month long oral lead in or to start long acting intramuscular injections (OLI or D2I). On Day 1, participants who choose to participate in OLI will be administered CAB 30 milligrams (mg) + RPV 25 mg once daily orally for one month. At the Month 1 visit, last dose of oral CAB + RPV will be given followed by the first CAB LA 600 mg + RPV LA 900 mg intramuscular (IM) injection (within 2 hours of the final oral dose). The second IM injection with CAB LA 600 mg and RPV LA 900 mg will be administered at Month 2 followed by the same Q2M until Month 12. In D2I, at Day 1, eligible participants will receive the first injection of CAB LA 600 mg + RPV LA 900 mg as initial loading dose. The second and third injections (CAB LA 600 mg + RPV LA 900 mg) will be administered at Month 1 and Month 3 followed by the same Q2M until Month 11.
16319521|NCT04542070|Active Comparator|Participants receiving BIK|Participants will receive BIK, that is a combination of Bictegravir (BIC) 50 mg + Emtricitabine (FTC) 200 mg + Tenofovir alafenamide (TAF) 25 mg orally, administered once daily until Month 12.
16319522|NCT04542057|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
16319523|NCT04542057|Placebo Comparator|Arm 2|Placebo Nebulized BID
16319524|NCT04542031|Other|Survey|Survey to be distributed at 6 and 12 months
16319525|NCT04542018|Experimental|Study patients with IBS-D|Patients with diarrhea-predominant IBS who will undergo a low FODMAP diet for 4 weeks
16319526|NCT04542005|Experimental|q3h albuterol|Using q3h as discharge criteria from hospital
16319527|NCT04542005|No Intervention|q4h albuterol|Using q4h as discharge criteria from hospital
16319528|NCT04541992||Airborne Group|Participants in this group will be tested for balance and agility within a 20 minute time frame.
16319529|NCT04541979|Active Comparator|Aerosolized DNase I|
16319530|NCT04541979|Placebo Comparator|NaCl|
16319531|NCT04541966||Nuchal translucency> = 99th percentile and <3.5mm|Nuchal translucency> = 99th percentile and <3.5mm
16319532|NCT04541966||Nuchal translucency> = 3.5 mm|Nuchal translucency> = 3.5 mm
16319533|NCT04541953|Active Comparator|Telerehabilitation|
16319534|NCT04541953|Active Comparator|In-Person Rehabilitation|
16319535|NCT04541940|Active Comparator|Telerehabilitation|
16319536|NCT04541940|Active Comparator|In-Person Rehabilitation|
16319537|NCT04541927||BCL11B|BCL11B intragenic pathogenic variant
16319538|NCT04541914|Experimental|Validation group|Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)
16319539|NCT04541901|Experimental|Deep massage and Cold water immersion|
16319540|NCT04541901|Active Comparator|Superficial Massage and Water immersion in room temperature|
16319541|NCT04541901|No Intervention|Control/Rest|
16319542|NCT04541888|Experimental|Experimental Group|322 subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
16319543|NCT04541888|Placebo Comparator|Control group|322 subjects will be treated with Placebo : 0 g: 0mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
16319544|NCT04541875||Cystic fibrosis|"Patients aged 18+ and diagnosed with cystic fibrosis.
~Patients will answer the MAR-Scale once every three months for a year."
16319545|NCT04541875||Hemophilia A or B|"Patients aged 18+ and diagnosed with hemophilia A or B.
~Patients will answer the MAR-Scale once every three months for a year."
16319546|NCT04541875||Idiopathic pulmonary fibrosis|"Patients aged 18+ and diagnosed with idiopathic pulmonary fibrosis.
~Patients will answer the MAR-Scale once every three months for a year."
16319547|NCT04541875||Myasthenia gravis|"Patients aged 18+ and diagnosed with myasthenia gravis.
~Patients will answer the MAR-Scale once every three months for a year."
16319548|NCT04541875||Sickle cell disease|"Patients aged 18+ and diagnosed with sickle cell disease.
~Patients will answer the MAR-Scale once every three months for a year."
16319549|NCT04541862||Critically ill patients|
16319550|NCT04541849||Critically ill patients|
16319551|NCT04541836||healthy control|healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.
16319552|NCT04541836||PSP|"Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP as possible or probably PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later."
16319553|NCT04541823|Experimental|Desflurane|Patients allocated to this arm will receive desflurane during the maintenance of anesthesia.
16319554|NCT04541823|Placebo Comparator|Propofol|Patients allocated to this arm will receive propofol during the maintenance of anesthesia
16319555|NCT04541810||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
16319558|NCT04541784|Active Comparator|3 counselling sessions with gynaecology-oncology nurses|Patients randomized to the control group will receive standardized care, 3 counselling sessions with a gynaecology-oncology nurse and written information at three points in time during 6 months after diagnosis/surgery.
16319559|NCT04541784|Experimental|Mobile app and 3 counselling sessions (WOMAN-PROIII)|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III. Counselling sessions will take place at 3 points in time during 6 months after diagnosis/surgery. Additionally, the gynaecology-oncology nurse will instruct the patient to use the mobile app. It includes a diary for symptom assessment and gives graphical feedback. Further, the app includes disease and treatment related information. If a symptom occurs the app will give an evidence-based recommendation (Kobleder et al., 2016). The patients can use the app whenever they want for a period of six months."
16319560|NCT04541771|Experimental|drug group|The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
16319561|NCT04541771|Placebo Comparator|control group|this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed
16319562|NCT04541758|Experimental|surgical treatment|Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
16319563|NCT04541758|Experimental|Conservative treatment|analgesic treatment and chest strap fixation
16319564|NCT04541732|Experimental|Thoracic epidural block|Patients will receive thoracic epidural block following induction of general anaesthesia
16319565|NCT04541732|Active Comparator|Bilateral quadratus lumborum block|Patients will receive Ultrasound-guided bilateral quadratus lumborum block following induction of general anaesthesia
16319566|NCT04541719|Active Comparator|Patient-controlled remifentanil analgesia|Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery
16319567|NCT04541719|Placebo Comparator|Epidural analgesia|Patients will received continuous epidural analgesia starting from labour pain until delivery
16319568|NCT04541706|Experimental|Lorlatinib|The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
16319569|NCT04541693|Other|Hip revision|Revision to cup and stem, cup only or stem only.
16319570|NCT04541680|Experimental|Nintedanib|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
16319571|NCT04541680|Placebo Comparator|Placebo|Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.
16319572|NCT04541667|Active Comparator|Air for luminal inflation|Patients randomized into this arm will have luminal inflation using air.
16319573|NCT04541667|Active Comparator|Carbon Dioxide for luminal inflation|Patients randomized into this arm will have luminal inflation using carbon dioxide.
16319574|NCT04541654||Variant in the TP53 Gene in blood or saliva|Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history
16319575|NCT04541641|Experimental|osteotome group|
16319576|NCT04541641|Experimental|New Reverse Drilling technique|
16319577|NCT04541628|Experimental|SIG-001|B-Domain Deleted Human Factor VIII (BDD-hFVIII) Producing Spheres
16319578|NCT04541615|Active Comparator|Group 1: Online didactic to proficiency PBP+|Group 1 Pre-trained group will receive information on how to optimally perform the ORSI chicken anastomosis task and the material will be delivered online via the ORSI e-learning platform. They will be given access to the material two weeks before their training. Unlike the other groups, Group 1 will be required to study the material to a pre-defined performance benchmark or proficiency level. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
16319579|NCT04541615|Active Comparator|Group 2: Online didactic PBP+|The Pre-trained group (Group 2) will receive the exact same information as Group 1 on how to optimally perform the ORSI chicken anastomosis task but they are not required to study the material to a pre-defined proficiency benchmark. The time they spend on the task and effort expended will be logged. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
16319580|NCT04541615|Active Comparator|Group 3: Standard training group|The standard trained group will receive face-to-face lectures on how to perform the ORSI chicken anastomosis task. It will not differ from what they would normally receive during a traditional surgery training course when they arrive at the ORSI academy for their training. The content of the face-to face lecture is the same as in the e-learning courses. After the face-to face lecture, the participants have to perform the orsi chicken anastomosis task.
16319581|NCT04541615|Active Comparator|Group 4: Apprenticeship Group|The apprenticeship trained group will not receive face-to-face lectures or e-learning on how to perform the ORSI chicken anastomosis task. They will however receive hands-on practical one-to-one training during a traditional surgical training course, with deliberate practice. During this course, clinicians will train the participants on how to perform the orsi anastomosis task. They will also receive published materials describing how best to perform the task and mentoring on suturing and knot tying by a task expert who will guide their performance.
16319582|NCT04541602||Dysphagia-positive|"critically ill patients more than 17 years of age
~matching study inclusion criteria
~confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later
~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
16319583|NCT04541602||Dysphagia-negative|"critically ill patients more than 17 years of age
~matching study inclusion criteria
~newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later
~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
16319584|NCT04541602||Controls|"healthy volunteers without any neuromuscular disease
~swallowing dysfunction ruled out using FEES"
16319585|NCT04541589|Active Comparator|Arm 1|Arm 1 - Iscalimab Dose 1
16319588|NCT04541563|Experimental|Immediate Treatment Arm|The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
16319589|NCT04541563|Sham Comparator|Delayed Treatment Arm|In the delayed treatment arm, the participants will receive a sham device that looks exactly the same, but only provides treatment for 2 seconds. At week 4, sham arm participants will be unblinded and shipped an active device (limited to Level 2 output even if a participant raises the dial beyond that). The delayed arm participants will continue with active devices for the remaining 4 weeks of the trial.
16319590|NCT04541550|Experimental|Low Dose AMP-001|12.5 mg AMP-001 in 3 ml Saline
16319591|NCT04541550|Experimental|Medium Dose AMP-001|25 mg AMP-001in 3 ml Saline
16319592|NCT04541550|Experimental|High Dose AMP-001|50 mg AMP-001 in 3 ml Saline
16319593|NCT04541537|Experimental|Sorbstar®|Odour sampling : rub hands with Sorbstars® before and post-surgery
16319594|NCT04541537|Experimental|Dog Detection|Odour sampling :sleep over a night with a compress on the affected breast before and after surgery
16319595|NCT04541511|Experimental|Healthy subject|"Healthy subject will be asked to performed two 6-minutes walking test : one in a corridor and one on the non-motorized treadmill.
~Oxygen saturation, heart rate and Borg score will be collected before and after each test."
16319596|NCT04541511|Experimental|Patients|Patients will be asked to to performed a 6-minutes walking test on the non-motorized treadmill and to answer a questionnaire regarding the acceptability and ease of use of the new method.
16319597|NCT04541498||Population of Poland|Exposure to short term long term effects of air pollution and climate change
16319598|NCT04541498||Patients with Acute Coronary and Cerebral Syndromes|Exposure to short term long term effects of air pollution and climate change
16319599|NCT04541485|Experimental|Experimental: Cohort 1 (96 mg)|24 mg/0.1 mL x 4 sites
16319600|NCT04541485|Experimental|Experimental: Cohort 2 (288 mg)|72 mg/0.3 mL x 4 sites
16319601|NCT04541485|Experimental|Experimental: Cohort 3 (480 mg)|120 mg/0.5 mL x 4 sites
16319602|NCT04541485|Experimental|Experimental: Cohort 4 (672 mg)|168 mg/0.7 mL x 4 sites
16319603|NCT04541485|Experimental|Experimental: Cohort 5 (960 mg)|240 mg/1.0 mL x 4 sites
16319604|NCT04541459|Sham Comparator|Sham Qi-Shield user group|
16319605|NCT04541459|Active Comparator|Qi-Shield user group|
16319606|NCT04541446|Experimental|Residents to receive Dynamic Haptic Robotic Training|
16319607|NCT04541446|Experimental|Residents to receive Advanced Dynamic Haptic Robotic Training|
16319608|NCT04541433|Experimental|AZD9833 monotherapy|Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
16319609|NCT04541420||Eribulin|Eribulin 1.4mg/m2 d1,8 iv q3w
16319610|NCT04541407|Experimental|Exon 19 deletions or L858R point mutations in exon 21|Will include patients with exon 19 deletions or L858R point mutations in exon 21 of the epidermal growth factor receptor (EGFR) gene. Temozolomide plus Osimertinib will be the study drug combination administered. Osimertinib will be given at a fixed dose of 80 mg daily for dose level 1, with a potential to increase to 160 mg daily for dose level 2. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level.
16319611|NCT04541407|Experimental|Patients with anaplastic lymphoma kinase (ALK) fusions|Will include patients with anaplastic lymphoma kinase (ALK) fusions. Temozolomide plus Lorlatinib will be the study drug combination administered. Lorlatinib will be given at a fixed dose of 100 mg daily. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level depending on tolerability.
16319612|NCT04541394|Experimental|MolecuLight group|Patients with infected wounds received MolecuLight photography during debridement operation to evaluate the adequacy of remission of infected biofilm and facilitate wound healing
16319613|NCT04541394|No Intervention|Control group|Patients with infected wounds received debridement operation by surgeon's clinical experiences to decide the extension of wounds
16319614|NCT04541381|No Intervention|Control Group (No PGx Test)|Participants assigned to the control group will not take a genotyping/PGx test during the start of treatment and will instead receive standard chemotherapy without their doctors receiving any genetic information based on the participants' PGx test results. Blood samples for participants in this group will be stored and tested for genotyping six months later after treatment (or earlier if the participant experiences side effects).
16319615|NCT04541381|Experimental|Pharmacogenomics (PGx Testing) Group|Participants enrolled in the pharmacogenomics (PgX) testing group will give a blood sample for immediate genotyping/PGx testing. Once the results from these tests are in, cancer doctors caring for each participant will have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription based on genetic information found in their PGx test results.
16319616|NCT04541368|Experimental|Administration of CS1 Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16319617|NCT04541355|Experimental|Cohort A: Weekly Cisplatin + STS|Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients receive cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every 7 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
16319618|NCT04541355|Experimental|Cohort B: High Dose Cisplatin + STS|Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients receive high-dose cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16319619|NCT04541342|Experimental|osteoarthritic with genu varus|initial arthroscopy and high tibial osteotomy to be followed later by a second look arthroscopy with plate removal
16319620|NCT04541329|Experimental|Tildrakizumab treatment|
16319621|NCT04541316||Short term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-5 weeks post implantation
16319656|NCT04541082|Experimental|ONC206|
16319623|NCT04541316||Long term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 6-8 months post implantation
16319624|NCT04541303|Experimental|Intervention|Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
16319625|NCT04541303|Placebo Comparator|Placebo|Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.
16319626|NCT04541290|Experimental|Treatment|Women with stage 1-2 lymphedema due to breast cancer treatment
16319627|NCT04541277|Experimental|Tislelizumab with DAN hypmethylation agent +/- chemotherapy|"Decitabine, 20 mg/m2/d, IV, on days 1-5; or Azacitidine, 75 mg/m2/d,SC, on days 1-7.
~Aclamycin hydrochloride, 20 mg/d, IV, on day 1, 3, and 5 (For relapse/resistance AML, on days 1-5.); or idarubicin hydrochloride,10 mg/d, IV, on day 1, 3, and 5.
~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cytarabine,100 mg, IV, q12h/d. For patients with one of the following conditions, cytarabine,10 mg, SC, q12h/d: (1) There are obvious heart, lung, and kidney complications; (2) Bone marrow is hypoproliferative; (3) Age> 75 years old; (4) Age> 60 years old who are unfit for standard-dose chemotherapy.
~Recombinant human granulocyte colony stimulating factor injection, 5 μg/kg, SC, from day 0 to stop of chemotherapy after the WBC count exceeds 10.0×10^9/L; or Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC, on day 0.
~Tislelizumab,200 mg, IV, on the next day after chemotherapy was stopped."
16319628|NCT04541264||Model reconstruction cohort|160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.
16319629|NCT04541264||Internal validation cohort|40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group.
16319630|NCT04541264||External validation cohort|100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group.
16319631|NCT04541251|Experimental|Camrelizumab + Nab-paclitaxel + Carboplatin|
16319632|NCT04541238||Novel template report|"The last 100 consecutive and anonymized MRI investigations for primary perianal fistula reported according to standard practice by dedicated radiologists (the last 10 reports from each of 10 international centers) are reviewed blindly and independently by two experienced radiologists (based on case load, years of experience and publications on anal fistula) using a novel template incorporating 8 key descriptors.
~A third independent experienced radiologist will resolve any disagreement and assess the presence of descriptors in the original report compared to the novel template."
16319633|NCT04541225|Experimental|Phase 1 Dose Escalation|NUV-422 administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
16319634|NCT04541225|Experimental|Phase 2 Dose Expansion|NUV-422 administered at the recommended Phase 2 dose (RP2D).
16319637|NCT04541199|Active Comparator|Conventional|
16319638|NCT04541199|Experimental|Closed-loop|
16319639|NCT04541186|Active Comparator|Main Study|The cohort will include subjects with SHTG without concurrent fibrate therapy and will consist of 5 treatment groups to compare 4 dose levels/regimens of BIO89-100 versus placebo.
16319640|NCT04541186|Active Comparator|Fibrate Expansion Study|The cohort will include subjects with SHTG on stable background fibrate therapy and with a baseline MRI PDFF ≥6%, and will consist of 2 treatment groups comparing one dose regimen of BIO89 100 versus placebo.
16319641|NCT04541173|Active Comparator|Arm A|TARE alone
16319642|NCT04541173|Experimental|Arm B|TARE then Bevacizumab and Atezolizumab
16319643|NCT04541160||Suspected community-acquired pneumonia patients|Suspected community-acquired pneumonia patients that will be evaluated by an imaging method
16319644|NCT04541147|Experimental|Dexamethasone plus analgesics|oral dexamethasone of 0.5mg/kg/day (max of 8mg/day), administered on post-operative days 1,3,5,7 in addition to standardized course of analgesics (opioids/acetaminophen/NSAIDs).
16319645|NCT04541147|Active Comparator|analgesics alone|standardized course of analgesics (opioids/acetaminophen/NSAIDs)
16319646|NCT04541134|Other|Group 1|
16319647|NCT04541134|Other|Group 2|
16319648|NCT04541121|Experimental|3D printed model|Mother is given 3D printed model of fetus' face
16319649|NCT04541121|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
16319650|NCT04541108|Experimental|BMS-986299, Relatlimab, Ipilimumab, & Nivolumab|Patients with HNSCC who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile dextrose) or subtherapeutic microdoses of BMS-986299, relatlimab, ipilimumab as single agents or combined with nivolumab. Each microdose is simultaneously injected in a columnar fashion through each of 8 or 5 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
16319651|NCT04541108|Experimental|TAK-676, Carboplatin, 5-FU, & Paclitaxel|Patients with HNSCC who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-676, carboplatin, 5-fluorouracil (5-FU), or paclitaxel as single agents or in combination. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
16319652|NCT04541108|Experimental|MK-0482, MK-4830, & Pembrolizumab|Patients with HNSCC or STS who are scheduled for surgical biopsy or tumor resection surgery will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 8 needles into a single solid tumor or effaced metastatic lymph node.
16319653|NCT04541095|Experimental|EX_IMF group|Infants will receive infants formula with large amounts of beta-palmitate (EX_IMF).
16319654|NCT04541095|Active Comparator|ST_IMF group|Infants will receive infants formula with low amounts of beta-palmitate (ST_IMF).
16319655|NCT04541095|No Intervention|HM group|Infants will receive human milk (HM).
16319657|NCT04541069|Experimental|Social Communication and Emotional Skill Development (SCESD)|This arm will get the intervention which is the Early Childhood Development (ECD) training.
16319658|NCT04541069|No Intervention|Control|This arm will not get any intervention.
16319659|NCT04541056|Experimental|Goal Management Training (GMT)|"GMT will be administrated in a group-based format over 6 sessions (minimum two weeks between each session). Homework assignments between sessions are included. Following the fourth session, text messages reading Stop! (a key instruction in GMT) will be sent to all GMT participants every day to maximize adherence to training (28 per participant). Homework assignment will also include the logging of automatic thoughts and an examination of the relationship between situations, thoughts, and accompanying emotions."
16319660|NCT04541056|Active Comparator|Waitlist/Brain Health Workshop (BHW)|The adults participating in the control condition will approximately one year from waitlist, be offered a psycho-educative training program, the BHW, in groups aimed at providing a better understanding of cognitive sequelae after treatment for childhood ALL.
16319661|NCT04541043|Experimental|active treatment|Nefecon 16 mg once daily by mouth for 9 months
16319662|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
16319663|NCT04541017|Experimental|Arm I (magrolimab, mogamulizumab), Phase Ib and Phase II|Patients receive magrolimab IV over 2-3 hours weekly during cycles 1-2, then Q2W during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16319664|NCT04541017|Active Comparator|Arm II (mogamulizumab), Phase II|Patients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have PD or have received at least 6 full treatment cycles and have SD may crossover to Arm I.
16319665|NCT04541004|Experimental|HDM SLIT Tablet|House dust mite (HDM) Sublingual allergy immunotherapy tablet
16319666|NCT04540991|Active Comparator|Ankylos dental implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Ankylos dental implants (Dentsplay Sirona, Charlotte, USA) areused in the first group of patients.
16319667|NCT04540991|Active Comparator|Dentium SuperLine implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Dentium SuperLine implants (Dentium Co., Seoul, Korea) is used in the second group of patients-.
16319668|NCT04540965|Experimental|Telaglenastat and Famotidine|Famotidine
16319669|NCT04540965|Placebo Comparator|Telaglenastat and Placebo for Famotidine|Placebo for famotidine
16319670|NCT04540952|Experimental|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
16319671|NCT04540952|Active Comparator|Control|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
16319672|NCT04540939|Experimental|Mindfulness-Based Cognitive Therapy|
16319673|NCT04540939|Experimental|Muscle Relaxation Therapy|
16319674|NCT04540926|Experimental|COVID-19 Pneumonia control group|COVID-19 pneumonia patients with standar treatment: enoxaparin 0.5 mg/kg S.C. once, Clarithromycin 500 mg twice an metylprednisolone 0.5 mg/kg once endovenous.
16319675|NCT04540900|Active Comparator|KB301|non-integrating HSV-1 vector expressing human type III collagen injection
16319676|NCT04540900|Placebo Comparator|Placebo|sterile isotonic saline injection
16319677|NCT04540887|Experimental|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
16319678|NCT04540874|Experimental|Treatment group|
16319679|NCT04540874|Placebo Comparator|Placebo group|
16319683|NCT04540835|Experimental|Teethmate|Half of the cavities will be applied Teethmate Desensitizer following manufacturer instructions before restoration
16319684|NCT04540835|No Intervention|Negative Control|Half of the cavities will be restored without application of Teethmate Desensitizer
16319685|NCT04540822|Experimental|peripheral venous catheter with compress|Insertion of a peripheral venous catheter with a compress inserted below the catheter-extension tube junction
16319686|NCT04540822|Active Comparator|peripheral venous catheter without compress|Insertion of a peripheral venous catheter without any compress inserted below the catheter-extension tube junction.
16319687|NCT04540809||Psoriatic arthritis group (PsAG)|The evaluation was made using dynamometer, goniometer, mobile application, and Purdue pegboard test.
16319688|NCT04540796|Experimental|Part A: Dose Escalation|Participants will receive once weekly dose or may receive every 2 weeks (Q2W) administration of JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
16319689|NCT04540796|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
16319690|NCT04540783|Active Comparator|Group 1 - G1|bitemporal anodal stimulation and cathodal stimulation at supraorbital region.
16319691|NCT04540783|Active Comparator|Group 2 - G2|dorsolateral prefrontal anodal stimulation and cathodal stimulation at contralateral supraorbital region.
16319692|NCT04540783|Sham Comparator|Group 3 - G3|sham anodal stimulation over bitemporal or dorsolateral prefrontal cortex (randomized) and sham cathodal over the orbitofrontal region.
16319693|NCT04540770|Placebo Comparator|Part A 1 (1 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
16319694|NCT04540770|Placebo Comparator|Part A 2 (3 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
16319695|NCT04540770|Placebo Comparator|Part A 3 (5 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
16319696|NCT04540770|Experimental|Part B 1 (Selected Dose)|"At the end of Part A, the SRC will review the accumulated unblinded data of safety, tolerability, PK (any available data), and immunogenicity (any available data) to select a dose to initiate Part B in MS subjects. Part B will be conducted in multiple-dose, uncontrolled, and open-label manner to explore the safety, tolerability, PK, and immunogenicity in MS subjects. Only one cohort will be enrolled to receive 3 repeated doses of the selected HuL001 dose, which will be administered bi-weekly.
~A total of 6 MS subjects will be enrolled in this multiple-dose cohort."
16319697|NCT04540757||Surgery|Surgery and systemic anti-cancer therapy (with or without radiotherapy) given in any order
16319698|NCT04540757||No surgery|Radiotherapy and systemic anti-cancer treatment given in any order (with or without adjuvant immunotherapy if indicated).
16319699|NCT04540744|Experimental|Treatment Sequence AB|Participants will receive a single oral dose of fixed dose combination (FDC) of macitentan/tadalafil (10 milligram [mg]/20 mg) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of a free combination of 10 mg macitentan and 20 mg tadalafil in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
16319700|NCT04540744|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
16319701|NCT04540731||NAFLD and diabetes/NASH and fibrosis|Patients with NAFLD and type 2 diabetes (or insulin-resistance) or with any stage of fibrosis in the inclusion visit will be followed over time in a prospective cohort study with scheduled visits. Patients without diabetes/insulin-resistance or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study.
16319702|NCT04540731||NAFLD without diabetes/NASH without fibrosis|Patients without diabetes (or insulin-resistance) or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study
16319703|NCT04540718|No Intervention|Control|Participants in this group continues with their sedentary behavior
16319704|NCT04540718|Active Comparator|Exercise only|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and will sit in the exercise laboratory for 15 minutes whilst the experimental group uses the sauna.
16319705|NCT04540718|Experimental|Exercise and sauna|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and incorporates sauna bathing (heat therapy) immediately after exercise.
16319706|NCT04540705|Experimental|Part 1A (Part 1): Nivolumab + Bempegaldesleukin + Axitinib|
16319707|NCT04540705|Experimental|Part 1B (Part 1): Nivolumab + Bempegaldesleukin + Cabozantinib|
16319708|NCT04540705|Experimental|Arm A (Part 2): Nivolumab + Bempegaldesleukin + Cabozantinib|
16319709|NCT04540705|Experimental|Arm B (Part 2): Nivolumab + Cabozantinib|
16319710|NCT04540692|Active Comparator|Start with Cyclophosphamide + Doxorrubicin|Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.
16319711|NCT04540692|Experimental|Start with Docetaxel or Paclitaxel|Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.
16319712|NCT04540679|Active Comparator|Inpatient - Standard Care Delayed Platform|Patient will receive standard inpatient care and provided access to the platform 6 weeks after inpatient discharge with support provided by the VIP coach.
16319713|NCT04540679|Active Comparator|Inpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the inpatient program
16319714|NCT04540679|Active Comparator|Outpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the outpatient program. If patient is transitioning from the inpatient program, their access to the platform will be guided by which group they were originally assigned to (i.e. if a 6 week delay is applicable).
16319715|NCT04540666|Experimental|VR group|VR program will be displayed throughout the surgery.
16319716|NCT04540666|Placebo Comparator|Non-VR group|VR program will be turned off throughout the surgery.
16319717|NCT04540653|Other|Standard vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, aged ≥50 years old, using a standard vaccination schedule (three doses of 20 μg, in months 0, 1, 6).
16319718|NCT04540653|Experimental|Reinforced vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, in individuals aged ≥50 years, using a reinforced vaccination schedule (three doses of 40 μg, in months 0, 1, 6).
16319719|NCT04540640|Experimental|Subnormothermic Perfusion|Kidneys retrieved for transplantation will undergo subnormothermic oxygenated perfusion using the study device and perfusion solution for at least 1 hour prior to transplantation into the recipient.
16319720|NCT04540627|Placebo Comparator|Placebo|Sodium Chloride 0.9% Solution (Normal Saline)
16319721|NCT04540627|Active Comparator|Palivizumab (Synagis™)|Sterile vial 50mg/0.5mL
16319722|NCT04540614|Experimental|Intervention|70 participants receiving active comparator treatment plus experimental
16319723|NCT04540614|Active Comparator|Control|70 participants receiving active comparator treatment
16319724|NCT04540601|Active Comparator|Cancer patients, randomized A|Patients in high-dose antiresorptives with bone metastases
16319725|NCT04540601|No Intervention|Cancer patients, randomized B|Drug Holiday as standard operation procedure
16319853|NCT04539769|Experimental|BII group|Billroth II reconstruction with 100-cm long biliopancreatic limb
16319727|NCT04540575|Active Comparator|Mother Provides MOM|Receive Rush NICU standard of care lactation support
16319728|NCT04540575|Experimental|NICU Acquires MOM|Receive economic interventions in addition to Rush NICU standard of care lactation support
16319729|NCT04540562|Experimental|Intervention|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
16319730|NCT04540549|Experimental|intervention group|Jogging or cycling ≥5 days/week, 30-60 min/d
16319731|NCT04540549|No Intervention|control group|The control group was encouraged to maintain their lifestyle.
16319732|NCT04540523|Experimental|Exergaming intervention group|30 minutes of exergaming per session and 5 sessions of exergaming play per week for a 6-month period.
16319733|NCT04540523|Active Comparator|Traditional Physical Activity|Phone consultations and workshops for parents to offer 5 times, 30 minutes per session; traditional physical activity at home for 6 months.
16319734|NCT04540523|No Intervention|Attention control group|Continue with usual activities at home with emailed physical activity tips.
16319735|NCT04540510|Active Comparator|OPEP therapy added to standard pneumonia care|The intervention group will be asked to use an OPEP device twice daily, with the help of study investigators, for a total of at least 5 minutes per session. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the pneumonia.
16319736|NCT04540510|Active Comparator|Standard pneumonia care|The control group will continue to receive the usual care that their hospital team prescribe for them to treat the pneumonia.
16319737|NCT04540497|Experimental|VIB0551|Inebilizumab administered as an IV infusion.
16319738|NCT04540497|Placebo Comparator|Placebo|Placebo administered as an IV infusion.
16319739|NCT04540484||ALGH Physicians|Attending physicians on the medical staff, fellow physicians, and resident physicians that work at Advocate Lutheran General Hospital (ALGH) from March 1st, 2020 and forward.
16319740|NCT04540484||Household Members|Household members above age 18 who lived in household of ALGH physician who tested positive for COVID-19 IgG antibodies, and who lived with that physician for at least 2 consecutive weeks.
16319741|NCT04540471|Experimental|MT group|The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
16319742|NCT04540471|Placebo Comparator|Control group|control groups will receive comprehensive in-patient education program for 12 consecutive weeks
16319743|NCT04540458|Other|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
16319744|NCT04540458|Other|Placebo|Mother or Mother/Father is given printed picture of 3D ultrasound of fetus
16319745|NCT04540445||Concussed Cohort|The concussed cohort will consist of children ages 5-17 diagnosed with a concussion within 72 hours following injury and recruited from a pediatric emergency department.
16319746|NCT04540445||Healthy Matched Controls|The healthy matched control cohort consists of children 5-17, who are age and gender matched to concussed subjects who will be recruited from affiliated pediatric primary care and adolescent clinics.
16319751|NCT04540419|Experimental|Ad5-nCoV single dose|375 subjects, Ad5-nCoV containing 5E10 vp, single dose
16319752|NCT04540419|Placebo Comparator|Placebo single dose|125 subjects, Placebo containing 0 vp, single dose
16319753|NCT04540406|Experimental|NBT-NM108 + Usual Care|
16319754|NCT04540406|Active Comparator|Usual Care Only|
16319755|NCT04540393|Experimental|Arm A|Single arm
16319756|NCT04540367|No Intervention|No Intervention: Control|Participants in this group performed the exercises without the blood flow restriction therapy cuff
16319757|NCT04540367|Experimental|Experimental: BFR|Participants in this group performed the exercises with the blood flow restriction therapy cuff
16319758|NCT04540354|Experimental|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
16319759|NCT04540354|Active Comparator|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
16319760|NCT04540341|Experimental|Mulligan mobilization group|Painless movement
16319761|NCT04540341|Experimental|Core stabilization group|Abdominal drawing-in maneuver
16319762|NCT04540341|Active Comparator|conventional therapy group|Ultrasound TENS Hotpack
16319763|NCT04540328|Other|Non-surgical peridontal treatment|Patients with chronic periodontitis received non-surgical periodontal treatment, including scaling and root planing and polishing within 14 days under local anesthesia with manual and ultrasonic devices and standardized oral hygiene instructions including methods of tooth-brushing and interdental cleaning were also given to each one. A professional supragingival plaque control was applied on a regular basis every month.
16319854|NCT04539769|Experimental|RY group|Roux-en-Y reconstruction with 100-cm long Roux limb
16320119|NCT04537949|Experimental|Part A participants aged 56 to 85 years (optional)|Escalating dose levels
16319764|NCT04540315|Experimental|Intervention - MobiMD app|Intervention group will receive notifications to their smart device through MobiMD app. Participants will be asked to fill out reports and upload all clinically relevant data using the app. Engaging with the app will be in addition to the standard of care follow-up.
16319765|NCT04540315|No Intervention|Standard of Care|The standard of care control group will receive conventional postoperative care. Participants will receive reported outcome survey by email.
16319766|NCT04540302|Experimental|AVF Peripheral study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
16319767|NCT04540302|Other|AVF Peripheral control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
16319768|NCT04540302|Experimental|AVG Anastomosis|All subjects in this single arm cohort will receive treatment with the WRAPSODY Endovascular Stent Graft
16319769|NCT04540302|Experimental|AVF/AVG Central study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
16319770|NCT04540302|Other|AVF/AVG Central control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
16319771|NCT04540289|Active Comparator|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
16319772|NCT04540289|Experimental|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
16319773|NCT04540263||Sleeve Gastrectomy|Patients who underwent Sleeve gastrectomy operation
16319774|NCT04540263||Gastric Bypass|Patients who underwent Gastric Bypass operation
16319775|NCT04540250||Study group of Rheumatoid arthritis patients|RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.
16319776|NCT04540237||Case|Patients with idiopathic granulomatous mastitis
16319777|NCT04540237||Control|Healthy volunteers
16319778|NCT04540224||Luminal A|Breast cancer patients with Luminal A phenotype
16319779|NCT04540224||Luminal B|Breast cancer patients with Luminal B phenotype
16319780|NCT04540224||Triple Negative|Breast cancer patients with Triple negative phenotype
16319781|NCT04540224||Control|Healthy volunteers
16319782|NCT04540211|Experimental|Atezolizumab + Tiragolumab + PC|Participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
16319783|NCT04540211|Placebo Comparator|Placebo + PC|Participants will receive atezolizumab matching placebo and tiragolumab matching placebo on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
16319784|NCT04540198|Experimental|GamePlan4Care (GP4C)|Participants in this arm will have access to full functionality and content of the online system GamePlan4Care (GP4C) including educational resources, skills training, and support tailored to their unique caregiving needs. Additional individualized feedback will be automatically generated based on responses to online questions and will include links to relevant site educational/skill-building content. Participants will be assigned a Dementia Care Specialist who will facilitate caregiver interactions with the online material and provide skills training via telephone or web-video conference. Study participants assigned to GP4C will receive 9 automated emails and 4 phone calls over a 6-month period.
16319785|NCT04540198|Active Comparator|Resources4Care (R4C)|"Participants in this arm will receive access to Resources4Care (R4C), a feature-limited version GamePlan4Care system. R4C will serve as an online hub for articles and videos about Alzheimer's disease and dementia. Educational topics will included information on: 1) Alzheimer's Disease & Dementia, 2) Caregiving, 3) Caregiver Stress and 4) Home Safety. R4C will present a page on each topic with active links to two additional online sources on the same topic. Study participants assigned to R4C will receive two emails from their DCS encouraging the caregiver to review specific education materials. Each email will be followed by brief check-in calls (15-min each) at three months and five months after randomization."
16319786|NCT04540185|Experimental|Standard dose bivalent oral polio vaccine|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
16319787|NCT04540185|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|Saline administered orally on a sugar lump
16319788|NCT04540185|Experimental|Standard dose of NA-831|Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally
16319789|NCT04540185|Placebo Comparator|Comparable Placebo- 30mg|30 mg of placebo in a capsule administered orally
16319790|NCT04540185|Experimental|Standard dose of bivalent OPV and NA-831|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally
16319791|NCT04540185|Placebo Comparator|Comparable Placebo|Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally
16319792|NCT04540172|Experimental|Music Therapy|music therapy was applied in the practice room. Environmental noise was reduced as much as possible; the room was dimly lit. The students were asked to close their eyes after sitting comfortably in a chair and focus on the music by asking them to imagine a different memory and place that would relax them instead of the thoughts that occupied their minds. The music was played through a portable computer for 15 minutes under the supervision of the researchers using an mp3 player program on the computer.
16319821|NCT04540003|No Intervention|Control Arm: Standard of care|Of the eight schools assigned to the control condition, four will be in the South East area of the city closer to Nelson Mandela Park PS and four will be in the South West area of the city closer to St. Josephs Health Center. The eight schools will be subject to standard of care which is: when a child is identified by the SST (no pediatrician present), students identified with developmental concerns are advised to access a pediatric/developmental assessment in the community.
16319888|NCT04539483|Experimental|HDIT101|Topical application of HDIT101 solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
16319793|NCT04540172|Experimental|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercises were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association. Warning messages were hung on the door of the room, environmental noise was reduced as much as possible, and the room was provided with dim lighting. The students were asked to close their eyes and breathe deeply after sitting comfortably in a chair. After taking two deep breaths, they were told to dangle their arms and relax as much as possible. The hands, shoulders, neck, chest, abdomen, hips, legs, feet, toes, and facial muscles were made to relax while they breathed and relaxed while exhaling. They were asked to store the experience into their memories thoroughly so that they could recall this feeling for comfort during the day."
16319794|NCT04540172|No Intervention|Control|No additional method was applied in the control group.
16319795|NCT04540159||Case|Advanced stage Colorectal cancer patients with intraabdominal ascites
16319796|NCT04540159||Control|Liver cirrhosis and congestive heart failure patients with intraabdominal ascites
16319797|NCT04540146||Case|End Stage Colorectal Cancer patients with intraabdominal ascites
16319798|NCT04540146||Control|Congestive heart failure and liver cirrhosis patient who had intraabdominal ascites
16319799|NCT04540133|Experimental|dexamethasone 0.5mg/5ml solution in Mucolox™ (group A)|Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
16319800|NCT04540133|Active Comparator|dexamethasone 0.5mg/5ml solution (Arm B)|Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks
16319801|NCT04540120|Experimental|dapansutrile capsules|Subjects will receive 4 x 250mg dapansutrile capsules BID for 14 days with an initial (first) dose of 8 x 250mg (2000 mg) administered at the study site on Day 1 (Day 1 dose may be 3000 mg).
16319802|NCT04540120|Placebo Comparator|placebo capsules|Subjects will receive 4 placebo capsules BID for 14 days with an initial (first) dose of 8 capsules administered at the study site on Day 1.
16319803|NCT04540107|Experimental|Group I (MRI, MRSI)|Patients undergo MRI and MRSI scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
16319804|NCT04540107|Experimental|Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)|Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate IV over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
16319805|NCT04540094|Experimental|5% Human Albumin Solution|Participants allocated to the treatment arm will receive intravenous 5% Human Albumin Solution (HAS) administered as the sole intravenous fluid during the initial 6-hour resuscitation period. The clinician can deliver up to 10ml/kg in the first 3 hours using 250ml boluses of HAS based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). After 3 hours further HAS boluses up to 6 hours post-randomisation will be at clinical discretion and will be documented in the CRF. Patients in the albumin arm should not receive balanced crystalloid as a resuscitation fluid in the first 6 hours.
16319806|NCT04540094|Active Comparator|Intravenous balanced crystalloid|Participant allocated to the usual care arm will receive intravenous balanced crystalloid administered as the sole intravenous fluid during the initial 6 hour resuscitation period. The clinician can deliver up to 30ml/kg in the first 3 hours using 250ml boluses of balanced crystalloid based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). Thereafter, further crystalloid boluses up to 6 hours will be at the discretion of the clinical team and will be documented in the CRF. Patients in the balanced crystalloid arm should not receive albumin as a resuscitation fluid in the first 6 hours.
16319807|NCT04540081|Experimental|CLOVER arm|This arm will contain clinics that utilize the CLOVER intervention
16319808|NCT04540081|No Intervention|Standard of Care arm|This arm will contain clinics that do not utilize the CLOVER intervention
16319809|NCT04540068||Patients with Lumbar Disc Herniation|Patients with a lumbar disc herniation on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
16319810|NCT04540068||Patients with Lumbar Spinal Stenosis|Patients with a lumbar spinal stenosis on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
16319811|NCT04540055||Paravertebral (Group P)|Patients underwent MRM under the combination of general anesthesia and paravertebral block.
16319812|NCT04540055||General Anesthesia (Group G)|Patients underwent MRM under general anesthesia.
16319813|NCT04540042|Experimental|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
16319814|NCT04540042|Placebo Comparator|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
16319815|NCT04540042|Experimental|SelK2 (Part 2)|I.V., single-dose (Day 1)
16319816|NCT04540042|Placebo Comparator|Placebo (Part 2)|I.V., single-dose (Day 1)
16319817|NCT04540029||COVID-19 Exposed Pregnancy (CEP)|Women who were pregnant and delivered during the outbreak of COVID-19 pandemic in Italy, and their infants.
16319818|NCT04540029||Non-Exposed Pregnancy (NEP)|Women who were pregnant and delivered during an anticipated COVID-19 free period in Italy, and their infants.
16319819|NCT04540016|Other|Arm Ⅰ|25 mg of 80 µCi [14C]HSK7653.
16319820|NCT04540003|Experimental|Access to School Based Health Centre|Of the eight school in the intervention arm, four schools will be linked to a school based health center (SBHC) at Sprucecourt or Nelson Mandela Park Public Schools (established in partnership with the department of Pediatrics at St. Michael's hospital) and four schools will be linked to a SBHC at Parkdale Public School (established in partnership with St. Joseph's Health Centre). SBHC pediatricians will attend School Support Team (SST) meetings at all intervention schools and students with developmental concerns identified at the SST meetings will be referred to the SBHC.
16319847|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
16319848|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
16319849|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 3|MPH966
16319850|NCT04539782|Experimental|Physiotherapy intervention|Pelvic floor muscle training given by a physiotherapist in four sessions and follow up phone calls twice in 14 weeks
16319822|NCT04539990|Experimental|Behavioral Sleep Treatment|"Parents of children with autism will come to two group meetings (up to 5 families in each group) where they will be receive information regarding sleep hygiene and behavioral techniques for reducing sleep onset delays and night awakenings. The program will last 8 weeks. Meetings will be held on week 1 and week 3. In addition parents will receive a weekly phone call where they will be asked about their ability to implement the behavioral techniques.
~Sleep of the children will be measured using questionnaires, sleep diaries and with a Fitbit sensor before and after the program."
16319823|NCT04539977|Experimental|ES-SCLC|"Induction therapy: TQB2450 1200mg, d1, q3w, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles.
~Maintenance therapy: TQB2450 1200mg, d1, q3w, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
16319824|NCT04539977|Experimental|LS-SCLC|"Neoadjuvant therapy: TQB2450 1200mg, d1, q3w, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles.
~Surgery or/and radiotherapy: the patients will receive surgery or/and radiotherapy, or multi-disciplinary treatment.
~Adjuvant therapy: TQB2450 1200mg, d1, q3w, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
16319825|NCT04539964|Experimental|Treatment|Active stimulation for 1 min once per day
16319826|NCT04539964|Sham Comparator|Control|Non-active stimulation for 1 min once per day
16319827|NCT04539951|Active Comparator|serotonin treatment|In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
16319828|NCT04539951|Active Comparator|sequenced treatment alternatives|If participants in In Experimental phase I do not achieve remission, they will be will be randomly assigned to the second-step treatment (Experimental phase II). The second-step therapy will consist of five treatment options including higher-than-usual-maximal dosage of sertraline, switching to fluvoxamine, switching to venlafaxine, augmentation with memantine, and augmentation with aripiprazole.
16319829|NCT04539938|Experimental|Single Arm|Tucatinib + trastuzumab deruxtecan
16319830|NCT04539925||Industrial area|
16319831|NCT04539925||Non-industrial area|
16319832|NCT04539912|Experimental|angulated screw-retained group(AG)|
16319833|NCT04539912|Active Comparator|cemented group (CG)|
16319834|NCT04539899|Experimental|VR+|For patients in the experimental group, using the virtual reality helmet, the caregiver will position the helmet on the patient when she is placed on the gynecological examination table. He or she will make sure that the patient can see and hear the current sequence. The caregiver can then proceed with the different steps of the IUD insertion. Once the procedure is completed, the caregiver will indicate to the patient that she can remove the headphones.
16319835|NCT04539899|No Intervention|VR-|For patients in the control group, without a helmet, the course of the consultation will not be modified.
16319836|NCT04539886|Experimental|CellFX System|The CellFX System consists of a electrical pulse console combined with a handpiece coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm). Based on the size of the SH lesion and treatment tip used, a predetermined treatment energy setting is selected to deliver a sequence of electrical pulses to the SH lesion area directly beneath the treatment tip.
16319837|NCT04539886|Active Comparator|Intralesional Electrodesiccation|Intralesional Electrodesiccation involves using a Hyfrecator electrosurgical unit and a non-insulated epilation needle electrode to apply a high-frequency electric current within the lesion.
16319838|NCT04539873|Active Comparator|COLHICINE PLUS STANDARD TREATMENT|Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
16319839|NCT04539873|Placebo Comparator|STANDARD TREATMENT|In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment
16319840|NCT04539860||Healthy Controls|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
16319841|NCT04539860||Patients|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
16319842|NCT04539847|Experimental|High-end hearing aid|Patients will be fitted with premium level hearing aid technology
16319843|NCT04539847|Experimental|Basic hearing aid|Patients will be fitted with basic level hearing aid technology
16319844|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).
16319845|NCT04539808|Experimental|Treatment (mFOLFIRINOX, chemotherapy)|"mFOLFIRINOX REGIMEN: Oxaliplatin intravenously (IV) over 2 hrs, leucovorin calcium IV over 2 hrs, and irinotecan hydrochloride IV over 90 minutes on day 1. Also receive fluorouracil IV over 46 hrs starting on day 1. Repeats every 14 days for up to 4 cycles. Those with response and no disease progression may receive an additional 2 months.
~GA REGIMEN: Those with disease progression or toxicity to mFOLFIRINOX switch to GA regimen comprising gemcitabine hydrochloride IV over 30-60 mins and nab-paclitaxel IV over 30-40 mins on days 1, 8, and 15. Repeats every 28 days for 2 cycles.
~LOSARTAN: Cycle 1 day 1, start losartan potassium orally once daily until end of RT.
~RT/SURGERY: Short-course RT for 10 fractions over 5 days weekly or long-course RT with 15-25 fractions over 5 days weekly along with oral capecitabine twice daily on Monday-Friday or fluorouracil IV over 5-7 days weekly until completion of RT. Patients then undergo surgery 1-4 weeks following RT"
16319846|NCT04539795|Placebo Comparator|Placebo oral tablet|placebo
16319855|NCT04539756|Active Comparator|Active control condition|Participants in the active control condition will receive the same number of text message reminders and will complete the same number of writing activities as the intervention group. The writing activity for the active control condition will ask them to list their activities for that day.
16319856|NCT04539756|Experimental|Positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
16319859|NCT04539704|Experimental|Healthy Adults-magnet|Healthy adults with magnet and/or sham
16319860|NCT04539704|Sham Comparator|Healthy Adults-sham|Healthy adults with magnet and/or sham
16319861|NCT04539691|Experimental|Magnet group|"Women wearing magnet
~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
16319862|NCT04539691|Sham Comparator|Sham group|"Women wearing sham
~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
16319863|NCT04539665|Experimental|Intervention Arm|Prospective study arm involving an extended mesenteric ileocolic excision.
16319864|NCT04539665|No Intervention|Control Arm|Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.
16319865|NCT04539652|Experimental|Experimental group|
16319866|NCT04539639|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+Placebo 75mg Bid
16319867|NCT04539639|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 100mg Bid
16319868|NCT04539639|Experimental|Jaktinib 100mg Bid|Jaktinib 100mg Bid+ Placebo 75mg Bid
16319869|NCT04539639|Placebo Comparator|placebo|Placebo 100mg Bid+ Placebo 75mg Bid
16319870|NCT04539626|Experimental|Estrogen Therapy|"Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg
~Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)"
16319871|NCT04539626|No Intervention|Control Group|Patients who will receive conventional COVID-19 treatment
16319872|NCT04539613||group1|Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added
16319873|NCT04539613||group2|Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)
16319874|NCT04539600|Experimental|induction chemotherapy + anti-PD-1 antibody|Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.
16319875|NCT04539587||adjuvant hormonal therapy for breast cancer|Women more than 18 years old, with hormone receptor-positive early BC, with completed surgery as well as chemotherapy and/or radiotherapy, if indicated, and had begun their hormonal therapy for less than 6 months.
16319876|NCT04539574|Experimental|Diagnostic (7T MRI)|Patients undergo 7T MRI over 60 minutes.
16319877|NCT04539561|Experimental|Pigmentation|Treatment of Hand Pigmentation Using PiQo4 Laser System
16319878|NCT04539548|Experimental|Dextenza|1 dosing group - Approximately 30 subjects treated with Dextenza
16319879|NCT04539548|Active Comparator|Prednisolone|1 dosing group - Approximately 30 subjects treated with Prednisolone
16319880|NCT04539535|Experimental|Down syndrome|We did the General Movements Assessment on standard mattress and experimental mattress in infants with Down syndrome on the same day.
16319881|NCT04539535|Experimental|Typically infants|We did the General Movements Assessment on standard mattress and experimental mattress in typically infants on the same day.
16319882|NCT04539522|Experimental|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
16319883|NCT04539522|Active Comparator|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
16319884|NCT04539509|Active Comparator|Monitoring|Participants will be given a heart rate monitor to wear on their wrist for the duration of the study (i.e. until recovered, or 8 weeks post-injury, whatever comes first).
16319885|NCT04539509|Placebo Comparator|Monitoring + Treadmill Test|In addition to wearing the heart rate monitor, participants will undergo a treadmill test at each appointment.
16319886|NCT04539509|Experimental|Monitoring + Treadmill Test + Specific Exercise Prescription|In addition to wearing the heart rate monitor, and completing a treadmill test at each appointment, participants will receive an exercise prescription based on the results of the treadmill test. They will be prescribed 30 minutes of structured aerobic exercise, 5 times per week, at a heart rate determined by their treadmill test.
16319887|NCT04539496|Experimental|dose confirmation and the phase II study|To determine the MTD and RP2D of XZP-3287; To determine the RP2D of XZP-3287 combined with endocrine therapy; To determine the efficacy and safety of XZP-3287 in HR positive HER2 negative advanced breast cancer
16319919|NCT04539288||Gestational diabetes mellitus|Women who were diagnosed GDM in 24-28 gestation weeks.
16319889|NCT04539483|Placebo Comparator|Placebo to HDIT101|Topical application of placebo solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
16319890|NCT04539470|Experimental|Cohort A: UTTR1147A Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive UTTR1147A dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
16319891|NCT04539470|Experimental|Cohort B: UTTR1147A Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive UTTR1147A dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
16319892|NCT04539470|Experimental|Cohort C: UTTR1147A Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive UTTR1147A dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
16319893|NCT04539457|No Intervention|Usual care|Neither the 'Desktop Helper (version 10)' will be integrated in the EMR system nor the 'e-learning' will be offered to GPs. However, to prevent attenuation of usual care, GPs will be free to adjust any medication on their own initiative or to use any other aid to decrease inappropriate prescribing in COPD patients.
16319894|NCT04539457|Active Comparator|Only desktop helper|Only the 'Desktop Helper (version 10)' will be integrated in the EMR system. Specifically, GPs will receive a notification about the 'Desktop Helper (version 10)'. This notification will inform general practitioners about the option in the Medicom Smart Module to identify COPD patients with comorbidities who have one or more 'medication-comorbidity clashes' (i.e. undesired interactions between medications for COPD and comorbid conditions).
16319895|NCT04539457|Active Comparator|Only E-learning|Only the 'e-learning' will be offered to GPs. Herein, GPs, will be invited to perform an e-learning module which provide information about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
16319896|NCT04539457|Active Comparator|Both dekstop helper and e-learning|Both 'Desktop Helper (version 10)' will be implemented in the EMR system. GPs will subsequently be notified about the possibility to detect COPD patients with 'medication-comorbidity clashes'. The implementation of the 'Desktop Helper (version 10), will be accompanied by e-learning offered to GPs. about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
16319897|NCT04539444|Experimental|CD19/22 CART cells combined with PD-1 inhibitors|Patients will receive PD-1 inhibitor on the first day after CART cell infusion
16319898|NCT04539431||Retrospective|The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.
16319899|NCT04539431||Prospective|A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.
16319900|NCT04539418|Active Comparator|Vitamn K2 Treated patients|Vitamin K2 will be given to patients randomized to ARM 1 three times a week at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
16319901|NCT04539418|Placebo Comparator|Placebo Group|Placebo will be given to patients randomized three times a week to ARM 2 at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
16319902|NCT04539405||Memsorb|M for memsorbTM group with the minimal gas flow possible (sevoflurane administration at 0.2L.min-1) with the ventilator Draeger A-500 Perseus,
16319903|NCT04539405||Dräegersorb|D for DraegersorbTM group with gas flow at 2L.min-1 (classical sevoflurane administration) with the same ventilator Draeger A-500 Perseus.
16319904|NCT04539392||Infertile couple|
16319905|NCT04539379|Active Comparator|magnesium sulfate|intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..
16319906|NCT04539379|Active Comparator|labetolol|The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.
16319908|NCT04539353||chronic pain|Patients with chronic pain, regardless of the cause of the pain.
16319909|NCT04539340|Other|Cohort 1 GNR-055 (0.3 mg/kg)|GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055
16319910|NCT04539340|Other|Cohort 2 GNR-055 (0.5 mg/kg)|GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055
16319911|NCT04539340|Other|Cohort 3 GNR-055 (1 mg/kg)|GNR-055 (1 mg/kg) Single intravenous administration GNR-055
16319912|NCT04539340|Other|Cohort 4 GNR-055 ( 2 mg/kg)|GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055
16319913|NCT04539340|Other|Cohort 5 GNR-055 (3 mg/kg)|GNR-055 (3 mg/kg) Single intravenous administration GNR-055
16319914|NCT04539314|Placebo Comparator|Control group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)
16319915|NCT04539314|Active Comparator|Dexmedetomidine 0.5 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 0.5 μg / kg as an adjuvant
16319916|NCT04539314|Active Comparator|Dexmedetomidine 1 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 1 μg / kg as an adjuvant
16319917|NCT04539301||Derivation cohort|In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.
16319918|NCT04539301||Validation cohort|"In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:
~estimated anticoagulant level = conversion factor for this anticoagulant × heparin anti-Xa activity
~The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed."
16319920|NCT04539275|Experimental|Convalescent Plasma|The study intervention consists of intravenous administration of 200-500mL of convalescent plasma administered in two equally divided doses, less than 12 hours apart.
16319921|NCT04539275|Placebo Comparator|Masked Saline Placebo|The study intervention consists of intravenous administration of 200-500mL of 0.9% saline administered in two equally divided doses, less than 12 hours apart.
16319922|NCT04539262|Experimental|Remdesivir (RDV), Part A|Participants will receive 31 mg inhaled RDV administered daily for 5 days
16319923|NCT04539262|Experimental|RDV + Placebo, Part A|Participants will receive 31 mg inhaled RDV administered for 3 days followed by placebo through Day 5
16319924|NCT04539262|Placebo Comparator|Placebo, Part A|Participants will receive placebo administered daily for 5 days
16319925|NCT04539262|Experimental|RDV, Part B|Participants will receive 62 mg inhaled RDV administered daily for up to 5 days
16319926|NCT04539262|Experimental|RDV + Placebo, Part B|Participants will receive 62 mg inhaled RDV administered for up to 3 days followed by placebo through Day 5
16319927|NCT04539262|Placebo Comparator|Placebo, Part B|Participants will receive placebo administered daily for 5 days
16319928|NCT04539262|Experimental|RDV, Part C|Participants will receive 39 mg inhaled RDV administered daily for 5 days
16319929|NCT04539262|Placebo Comparator|Placebo, Part C|Participants will receive placebo administered daily for 5 days
16319930|NCT04539249|Experimental|Magnesium sulphate|Combination of intravenous magnesium sulphate, intravenous paracetamol and rectal diclofenac
16319931|NCT04539249|Active Comparator|Pentazocine|Combination of intramuscular pentazocine, intravenous paracetamol and rectal diclofenac
16319933|NCT04539223|Active Comparator|Drug (Evolocumab)|Individuals randomized to this arm will administer Evolocumab subcutaneously (SC) every two weeks (Q2W) for 26 weeks.
16319934|NCT04539223|No Intervention|No Drug (Standard of Care)|Individuals randomized to this arm will not administer a placebo.
16319935|NCT04539210|Experimental|Electric Welded Metal Framework|A preexisting or prepared flat surface area of the welding abutment of implant at central incisor position at one side (right or left) will serve as the welding point. A titanium bar will be shaped following the curvature of the implants positioned. At this point, temporary titanium implant abutments will be welded with the titanium bar in the oral cavity, using the Syncrystallization Unit. Finally, the prosthetic framework, created by welding the titanium bar to the implant abutments, will be removed and opaque will be applied in order to avoid metal shining through the acrylic resin. The framework is picked up to denture with hard liner, and screwed to the denture.
16319936|NCT04539210|Experimental|cast metal framework|On a verified analogue model, occlusion blocks will be constructed for adjustment of vertical dimension and bite registration. Afterwards, CCM abutments will be fastened over the analogues of the placed implants, followed by waxing, spruing and casting. The resultant cast metal framework will be inserted inside the patient's mouth on the right or left installed implants to insure passivity of fit. In case of framework misfit, separation will be performed using a disc, followed by intraoral splinting and soldering. After framework soldering, another try-in will be done to insure framework fit.
16319937|NCT04539197||IgG4-RD group|300 IgG4-RD were enrolled and followed up for more than 6 months. Peripheral blood of all patients were collected at baseline, disease remission and relpase for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline, each follow up were collected.
16319938|NCT04539197||other autoimmune disease group|200 patients( RA, SLE, pSS, BD, et al) were enrolled in this study. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
16319939|NCT04539197||IgG4-RD mimicker group|60 IgG4-RD mimickers (pancreatic cancer, cholangiocarcinoma, vasculitis, lymphoproliferative diseases, inflammatory bowel disease, kimura disease) were collected. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
16319940|NCT04539197||healthy control group|100 healthy controls were collected. Peripheral blood of healthy controls were collected at baseline for plasmablast/plasma cells detection. Demographic features of healthy controls were collected.
16319941|NCT04539184|Experimental|Motion Style Acupuncture treatment|Motion Style Acupuncture treatment (2-3 times/week, 2 weeks)
16319942|NCT04539184|Active Comparator|Acupuncture treatment|Acupuncture treatment (2-3 times/week, 2 weeks)
16319943|NCT04539171|Experimental|Intervention|Pain neuroscience education (Health education) and Physical exercise program: 6 weekly sessions (2 hours each), and a reminder session one month later
16319944|NCT04539171|No Intervention|Control|Standard of care.
16319945|NCT04539158|Active Comparator|single-DCCV group|"Patients randomized to single-DCCV will be given a single 200J shock using the primary (or right anterior-left posterior) pair of pads."
16319946|NCT04539158|Experimental|dual-DCCV group|"Patients assigned to dual-DCCV will receive two simultaneous 200J shocks (from both the primary and secondary set of defibrillator pads), totaling 400J delivered."
16319947|NCT04539145|Experimental|Chocolate PTA balloon|
16319948|NCT04539145|Other|POBA|Intervention with regular baloon
16319949|NCT04539132|Experimental|Intervention Group|"The intervention group will participate in the 6-month interdisciplinary comprehensive rehabilitation program. The ABI Wellness (ABIW) program aimed at this population would be 7 hours a week (2 days per week will be scheduled for the intervention group), consisting of around 4 hours of cognitive training (through specified drills, cognitive exercises focused on executive functioning), 1 hour of physical exercise, 1 hour of mindfulness sessions (meditation) and scheduled break times."
16319950|NCT04539132|No Intervention|Control Group|"The non-intervention group or control group will have all the same pre-tests administered as the intervention group, however, will not participate in the cognitive program. The control group will be required to complete the assessment periods only, however, keep a record of their daily activities in a log format which is presented in the materials included herein. No other intervention or programming will be provided."
16319951|NCT04539119|Experimental|Entecavir and Tenofovir|
16319952|NCT04539119|Active Comparator|Entecavir|
16319953|NCT04539093||End-stage heart failure patients requiring lvad support|Patients with end-stage heart failure with reduced ejection fraction, requiring mechanical circulatory support.
16319954|NCT04539080||Pre-operative transversus abdominis plane block|
16319955|NCT04539080||Post-operative transversus abdominis plane block|
16319956|NCT04539067|Experimental|HMG group|Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG
16319957|NCT04539067|Experimental|H FSH plus HHMG|Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation
16319958|NCT04539054|Experimental|Pre-Workout Condition|This condition consisted of the ingestion of one serving of the pre-workout supplement.
16319959|NCT04539054|Experimental|Caffeine Condition|This condition consisted of the ingestion of 6 mg of caffeine per kg of body mass.
16319960|NCT04539054|Placebo Comparator|Placebo condition|This condition consisted of the ingestion of a placebo.
16319961|NCT04539041|Experimental|Cohort A NIO752|4 injections of NIO752 at dose A
16319962|NCT04539041|Experimental|Cohort B NIO752|4 injections of NIO752 at dose B
16319963|NCT04539041|Placebo Comparator|Placebo|4 injections of placebo
16319964|NCT04539041|Experimental|Cohort C NIO752|4 injections of NIO752 at dose C
16319965|NCT04539041|Experimental|Cohort D NIO752|4 injections of NIO752 at dose D
16319966|NCT04539041|Experimental|Cohort E NIO752|4 injections of NIO752 at dose E
16319967|NCT04539041|Experimental|Cohort F NIO752|4 injections of NIO752 at dose F
16319968|NCT04539015||Group-I|Patients randomized to the Group-I will receive PREVENA Plus, which is currently being used at our institution (Prevena, KCI) and it is FDA-approved device. Dressings will be applied under sterile conditions at the end of the surgery while still in the operating room and will continuously apply for 5 days.
16319969|NCT04539015||Group-II|"Subjects randomized to SOC surgical incision dressing arm will receive SOC dressing for 4 days immediately following surgery. The closed incision will be covered with materials which may include sterile gauze pieces, surgical tape and tegaderm.
~Any material used for the SOC dressing will be documented."
16319970|NCT04539002|Experimental|MS: Cycle|Twenty-two participants in the clinical trial arm will be randomized to MS:Cycle: an aerobic exercise intervention on a stationary ergometer. Participants will exercise thrice weekly for 30 minutes with graded supervision for 24 weeks.
16319971|NCT04539002|Active Comparator|MS: Take Control|Twenty-two participants in the clinical trial arm will be randomized to MS: Take Control (MSTC): a monthly, hour-long MS education control group led by a trained facilitator.
16319972|NCT04538989|Experimental|RZ358 Cohort 1|
16319973|NCT04538989|Experimental|RZ358 Cohort 2|
16319974|NCT04538989|Experimental|RZ358 Cohort 3|
16319975|NCT04538989|Experimental|RZ358 Cohort 4|
16319976|NCT04538976|No Intervention|Control|Patients in the control group will receive standard care.
16319977|NCT04538976|Active Comparator|Sildenafil|Patients in the Sildenafil group will receive standard care and targeted Sildenafil-treatment.
16319978|NCT04538963|Experimental|Banded Tooth|This tooth will have an orthodontic band and glass ionomer cement placed as an intervention for interproximal incipient caries.
16319979|NCT04538963|No Intervention|Non-banded Tooth|This tooth will be monitored per standard of care; encourage good dental hygiene at home.
16319980|NCT04538950|Other|Checkpoint Inhibitor (ICI)|Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.
16319981|NCT04538937||Subjects with eosinophilia and respiratory manifestation|
16319982|NCT04538937||Healthy subjects|
16319983|NCT04538924|Other|MINOCA (group I) - conventional MI treatment|Traditional MI treatment with optimal doses of statin, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), beta-blockers (BB) and dual antiplatelet therapy (DAPT).
16319984|NCT04538924|Other|MINOCA (group II)|Treatment with a low-dose statin and ACEI/ARB. In case of vasospasm, calcium channel blockers.
16319985|NCT04538911|Experimental|Experimental group|80 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
16319986|NCT04538911|Other|control group|80 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
16319987|NCT04538885|No Intervention|control group|No intervention
16319988|NCT04538885|Experimental|experimental group|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)
16319989|NCT04538872|Experimental|MS group implicit|
16319990|NCT04538872|Experimental|MS group explicit|
16319991|NCT04538872|Active Comparator|HC group implicit (Healthy Controls)|
16319992|NCT04538872|Active Comparator|HC group explicit (Healthy controls)|
16319993|NCT04538846|Experimental|Culinary Art Therapy Group|Patients with eating disorders that will participate in a weekly session of culinary art therapy group.
16319994|NCT04538846|No Intervention|No Culinary Art Therapy Intervention|Patients with eating disorders that are not scheduled to come to the outpatients ward on the day of intervention.
16319995|NCT04538833|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin-bound paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
16319996|NCT04538833|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel application, (placebo as a single infusion)
16320040|NCT04538508|Active Comparator|Control|Participants that perform supervised exercises for three weeks
16319997|NCT04538820|Active Comparator|control|patients with BMI=18.5-24.9 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
16319998|NCT04538820|Active Comparator|4 mg|patients with BMI>30 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
16319999|NCT04538820|Active Comparator|8 mg|patients with BMI>30 kg/m2 will be received 8 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
16320000|NCT04538807||Lumbar disc herniation|Patients are complaining of lower extremity radiating pain due to lumbar disc herniation.
16320001|NCT04538794|Experimental|CDX-0159|CDX-0159 every 4-8 weeks
16320002|NCT04538794|Placebo Comparator|Normal Saline|Normal saline every 4-8 weeks
16320003|NCT04538781||Same Day Discharge|Patients undergoing a-fib ablation procedures who were closed with VASCADE MVP and were discharged the same day.
16320004|NCT04538768|Experimental|Mesh Augmentated|
16320005|NCT04538768|Other|Direct Suture|
16320006|NCT04538755|Placebo Comparator|Placebo|Placebo capsule 4 hours before sleep
16320007|NCT04538755|Active Comparator|DAW2020|DAW2020 capsule 4 hours before sleep
16320008|NCT04538742|Experimental|Module 1- T-DXd and Durvalumab|T-DXd and Durvalumab
16320009|NCT04538742|Experimental|Module 2- T-DXd and Pertuzumab|T-DXd and Pertuzumab
16320010|NCT04538742|Experimental|Module 3- T-DXd and Paclitaxel|T-DXd and Paclitaxel
16320011|NCT04538742|Experimental|Module 4- T-DXd and Durvalumab and Paclitaxel|T-DXd and Durvalumab and Paclitaxel
16320012|NCT04538742|Experimental|Module 0- T-DXd|T-DXd
16320013|NCT04538742|Experimental|Module 5 - T-DXd and Tucatanib|T-DXd and tucatinib
16320014|NCT04538742|Experimental|Module 6 - T-DXd and Tucatinib|T-DXd and tucatinib in patients with active brain metastases (Part 2 Only)
16320015|NCT04538742|Experimental|Module 7 - T-DXd|T-DXd monotherapy in patients with active brain metastases (Part 2 Only)
16320016|NCT04538716|Experimental|SVF-gel|Transconjunctival blepharoplasty associated with associated with stromal vascular fraction gel (SVF-gel)
16320017|NCT04538716|Experimental|fat transposition|Transconjunctival blepharoplasty associated with fat transposition
16320018|NCT04538690|No Intervention|Control Group|Age and sex matched non interventional, healthy control group
16320019|NCT04538690|Experimental|Exercise Group|Individuals who are taken part of shoulder exercises with painful shoulder disorders.
16320020|NCT04538677||F2F-Group|Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.
16320021|NCT04538677||VC-group|Patients who preferred a video consult were seen over a video connection.
16320022|NCT04538664|Experimental|Arm A: Amivantamab + Chemotherapy|"Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.
~Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles.
~Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3."
16320023|NCT04538664|Experimental|Arm B: Chemotherapy Alone|"Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.
~Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles."
16320024|NCT04538638|Active Comparator|Mesenteric Sparing ileocolic resection|Standard procedure for CD, ileocolic resection without removal of the mesentery.
16320025|NCT04538638|Active Comparator|Central mesenterectomy ileocolic resection|Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.
16320026|NCT04538625|Placebo Comparator|Placebo|Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.
16320027|NCT04538625|Experimental|Crofelemer|Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.
16320028|NCT04538612|Experimental|measure capillary refill time|
16320029|NCT04538599|Experimental|RD13-01 cell infusion|
16320030|NCT04538573|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during during burn treatment, dressing changes and hydrotherapy.
16320031|NCT04538573|Active Comparator|Standard Treatment|Standard treatment during burn treatment, dressing changes and hydrotherapy.
16320032|NCT04538560|Experimental|Polar body biopsy group|The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
16320033|NCT04538560|No Intervention|Control group|The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.
16320034|NCT04538547|Experimental|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
16320035|NCT04538547|Active Comparator|Non Accelerated Radiotherapy|Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.
16320036|NCT04538534|Experimental|nicardipine and isosorbide dinitrate|"A Cocktail of 1 mg of Isosorbide Dinitrate associated to 1 mg of nicardipine will be put in a syringe than diluted in saline serum to have a volume of 3cc.
~The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization."
16320037|NCT04538534|Active Comparator|isosorbide dinitrate|Isosorbide Dinitrate: 1 mg will be diluted in saline solution as to have a 3cc volume The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization
16320038|NCT04538521|Experimental|Niacin in early-stage mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
16320039|NCT04538508|Experimental|Diathermy|Participants that receive 10 sessions of radiofrequency diathermy of 12 minutes of duration
16320043|NCT04538469||Group 1|Admitted prior to COVID visitation restrictions introduced
16320044|NCT04538469||Group 2|Admitted following the introductions of visitation restrictions due to COVID 19 pandemic
16320045|NCT04538456||used electronic Patient Reported Outcome Measures|Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.
16320046|NCT04538456||never used electronic Patient Reported Outcome Measures|Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.
16320047|NCT04538443||hemodialysis group|One hundred children with ESRD who are treated with hemodialysis and their caregivers will participate in this study. They will be recruited from Nephrology Unit at Abo-Elreesh Hospital, Cairo University
16320048|NCT04538430|Other|Axial Low Back Pain|Patient diagnosed with axial low back pain not responding to conservative measures and no symptoms of radiculopathy, that is scheduled to have a SPRINT percutaneous peripheral nerve stimulator placed as standard of care.
16320049|NCT04538417|Other|Residual Limb Pain in affected amputated limb|Patient has residual limb pain in amputated limb and is scheduled to receive standard of care treatment of cooled radiofrequency ablation.
16320050|NCT04538391|Active Comparator|bupivacaine group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.
16320051|NCT04538391|Active Comparator|meloxicam group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.
16320052|NCT04538391|Active Comparator|placebo group|included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.
16320053|NCT04538378|Experimental|1/Arm 1|Combination of durvalumab and olaparib
16320054|NCT04538365|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
16320055|NCT04538365|Experimental|Hand antisepsis with triclosan solution|Effectiveness of pre-surgical hand washing in reducing bacterial load using triclosan 0.5% solution
16320056|NCT04538352|Experimental|Once-weekly sc semaglutide combined with once-daily insulin|Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
16320057|NCT04538352|Experimental|MDI requiring multiple daily injections of insulin|Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.
16320058|NCT04538326|Other|Single|Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
16320059|NCT04538313|Experimental|High dose group|10^10 TIL
16320060|NCT04538313|Experimental|Low dose group|10^9 TIL
16320061|NCT04538313|Experimental|Extension set|The number of TIL is decided by dose escalation experiment.
16320062|NCT04538300|Active Comparator|Group Gum|"Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
~Degree of nausea and Abramowitz Emezis score were evaluated as the interventions. If PONV persists second chewing gum was gived. 15 minutes later PONV was evaluated. If PONV was persisted ondansetron 4 mg, then dexamethasone 4 mg , then propofol 10 mg intravenously were given, respectively."
16320063|NCT04538300|Active Comparator|Group Control|In Group Control, Degree of nausea and Abramowitz Emezis score were evaluated as the interventions in recovery room. If patients with moderate and severe nausea were given 4 mg ondansetron intravenously. If PONV continues, we planned to give dexamethasone 4 mg and propofol 10 mg intravenously, respectively.
16320064|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1010|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010
16320065|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1020|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020
16320066|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1030|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1030
16320067|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1021|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1021
16320068|NCT04538274|Experimental|Patient researcher intervention|Intervention conducted by trained patient researchers to restart CPAP in addition to usual care
16320069|NCT04538274|No Intervention|Usual care|Usual care
16320070|NCT04538261|Sham Comparator|Control|Non-inflation of the balloon device
16320071|NCT04538261|Experimental|Intervention|Inflation of the balloon device
16320072|NCT04538248||Continuous|Continuous
16320073|NCT04538248||Discontinuous|Discontinuous
16320074|NCT04538235||Bi-block (Serratus and erector spinae block) group|"The Bi-block consisted in performing an ESP block followed by a SAP block on the side ipsilateral to the thoracic surgery. For the ESP block, 40 ml of Ropivacaine 2mg/ml were injected under the erector spinae muscle plane, at the level of the 4th thoracic vertebra. For the SAP block, 40 ml of Ropivacaine 2 mg/ml were injected under the serratus anterior muscle plane. The cumulative dose of Ropivacaine did not exceed 3 mg/kg.
~Regional anesthesia was performed before surgery."
16320075|NCT04538235||Thoracic Epidural Analgesia (TEA) group|"The thoracic epidural was performed according to a standardized protocol, with a Tuohy needle via the median puncture technique, at the level of T4-T5 intervertebral space. After a test dose of 2 to 3 ml of Lidocaine, 5 to 10 ml of a mixture of Ropivacaine 2 mg/ml and Sufentanil 0.5 µg / mL were injected. Epidural continuous administration was performed with the same mixture of anesthetic connected to a CADD Solis ™ pump set according to a PCEA protocol adapted to the patient's weight (continuous flow rate from 3 to 6 ml/h, self-administered bolus dose from 3 to 5 ml, refractory period 30 min).
~Regional anesthesia was performed before surgery."
16320076|NCT04538209||canditates for variceal eradication|patients with documented liver cirrhosis (Based on clinical, laboratory and ultrasonographic findings) undergoing either primary or secondary prophylaxis variceal eradication at endoscopy unit of El-Rajhi hospital, Assuit University
16320077|NCT04538196|Experimental|R Education|Invervention: Resident who receives education on documentation and coding at the beginning of the surgical rotation
16320078|NCT04538196|No Intervention|R no Education|Resident who does not receive information on documentation and coding at the beginning of the surgical rotation
16320079|NCT04538183|Experimental|WO 5000|Body lotion pH 4 for topical application
16320080|NCT04538183|Experimental|WO 5001|Body lotion pH 5.8 for topical application
16320081|NCT04538183|No Intervention|No product use|Untreated control area
16320082|NCT04538170||ORC|Group orchidectomy following cancer
16320083|NCT04538170||GAC|Group sex reassignment surgery
16320084|NCT04538157|Experimental|Comprehensive Geriatric Assessment|Specialist co-ordinated care (known as comprehensive geriatric assessment, or CGA) was developed to address medical, social, mental health, and physical needs with the help of a skilled multi-disciplinary team.
16320085|NCT04538157|No Intervention|Usual Care|Usual Care
16320086|NCT04538144||Younger participants|Individuals aged 18-39 years
16320087|NCT04538144||Older participants|Individuals aged 65 years or older
16320088|NCT04538131|Active Comparator|conventional SCS|
16320089|NCT04538131|Experimental|sensor-driven position-adaptive SCS|
16320090|NCT04538118||Patient with a shoulder problem|Patients with shoulder problems between 18-65 years of age and being volunteered
16320091|NCT04538105|Sham Comparator|Sham Injection|20cc of Normal Saline 0.9%
16320092|NCT04538105|Experimental|Articular Branch Block (ABB)|20cc of 0.5% Bupivacaine with epinephrine 1:200,000
16320093|NCT04538092|No Intervention|Control|Standard post op complex spine orders placed for patients undergoing deformity correction
16320094|NCT04538092|Experimental|ERAS|Enhanced recovery after surgery protocol is applied to the patients undergoing deformity correction
16320095|NCT04538079||Feasibility/Accuracy/Reproducibility|The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
16320096|NCT04538079||Prediction of Circulatory Failure|Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
16320097|NCT04538066|Active Comparator|Bryostatin 1|20ug Bryostatin will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
16320098|NCT04538066|Placebo Comparator|Placebo|Placebo will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
16320099|NCT04538053|Active Comparator|Intervention|Children will receive high-dose oral cefalexin 37.5 mg/kg/dose (max 1.5 g) four-times daily (QID) for 2 to 4 days followed by oral cefalexin 25 mg/kg/dose (max 1 g) QID for a total course of 3 weeks
16320100|NCT04538053|Active Comparator|Standard Therapy|Children will receive IV cefazolin 50 mg/kg/dose (max 2 g) three-times daily (TDS) for 2 to 4 days followed by oral cefalexin 25 mg/kg/dose (max 1 g) four-times daily (QID) for a total course of 3 weeks
16320101|NCT04538040|Experimental|Biktarvy + Doravirine Switch|bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day
16320102|NCT04538027|Active Comparator|6 weeks|Microdiscectomy was done at 6 weeks of starting symptoms
16320103|NCT04538027|Active Comparator|3 months|Microdiscectomy was done at 3 months of starting symptoms
16320104|NCT04538027|Active Comparator|6 months|Microdiscectomy was done at 6 months of starting symptoms
16320105|NCT04538014|Experimental|Lu AF88434|
16320106|NCT04538001|Experimental|Balloon implantation|Arthroscopic implantation of this sub-acromial balloon
16320107|NCT04538001|Active Comparator|Rotator cuff repair|Partial rotator cuff repair
16320108|NCT04537988|Experimental|Feasibility and usability intervention trial|Pre-post evaluation of a 3-month pilot-trial of an electronic health (eHealth) intervention
16320109|NCT04537975|Active Comparator|C2Rx|Hemofiltration device
16320110|NCT04537975|Active Comparator|Standard of Care (SOC)|Standard of Care based on protocol inclusion/exclusion criteria
16320111|NCT04537962|Placebo Comparator|Colgate Periogard and Peroxyl®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution
16320112|NCT04537962|Placebo Comparator|Colgate Periogard®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution;
16320113|NCT04537962|Placebo Comparator|Colgate Peroxyl®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution
16320114|NCT04537962|Placebo Comparator|Colgate Total 12®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate
16320115|NCT04537962|Active Comparator|Toothpaste with sodium monofluorophosphate|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing only 1.1% fluoride, water, glycerin, cellulose, sodium lauryl sulfate, and sodium bicarbonate
16320116|NCT04537962|Active Comparator|Toothpaste with sodium fluoride and zinc|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.32% fluoride, 0.96% zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and sodium saccharin
16320117|NCT04537962|Active Comparator|Toothpaste with tin fluoride|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum
16320118|NCT04537949|Experimental|Part A participants aged 18 to 55 years|Escalating dose levels
16320120|NCT04537936|Experimental|Meaning Centered Psychotherapy for Latinos (MCP-L)|
16320121|NCT04537936|Active Comparator|Control|
16320126|NCT04537910|Experimental|LY3819253|LY3819253 administered subcutaneously (SC).
16320127|NCT04537910|Placebo Comparator|Placebo|Placebo administered SC.
16320132|NCT04537871||Observational (physical assessment)|Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
16320133|NCT04537858|Experimental|Virtual reality therapy first|Subjects with COVID-19 who will start the first day of the protocol with Virtual Reality tasks in the morning and then in the second period, in the afternoon, will perform the conventional exercises (n = 25)
16320134|NCT04537858|Experimental|Conventional therapy first|Subjects with COVID-19 who will start the first day with conventional exercises in the morning and in the second period, in the afternoon, will perform activity with virtual reality (n = 25).
16320135|NCT04537845||with cancer pain|
16320136|NCT04537845||without cancer pain|
16320137|NCT04537832||Group 1|Subjects from 6 through 60 months of age (at baseline) who have SCN1A+ Dravet Syndrome. Clinical, neurocognitive, laboratory, the burden of disease, and health care resource utilization will be assessed.
16320138|NCT04537819|Experimental|The main group|"1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Imupret oral drops in the age-related dosage of 6 times per day for 6 days with the subsequent transition to the regime of 15 drops / 3 times in a day according to the patient's condition.
~6. Paracetamol as antipyretic, if necessary."
16320139|NCT04537819|Other|The comparison group|1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Paracetamol as antipyretic, if necessary.
16320140|NCT04537806|Experimental|Brexanolone|Participants receiving mechanical ventilation as standard of care will receive brexanolone as a single, continuous, intravenous (IV) infusion for 60 hours.
16320141|NCT04537806|Placebo Comparator|Placebo|Participants receiving mechanical ventilation as standard of care will receive matching placebo as a single, continuous, IV infusion for 60 hours.
16320142|NCT04537793|Experimental|Part A: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
16320143|NCT04537793|Experimental|Part B: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
16320144|NCT04537780|Placebo Comparator|group 1|(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..
16320145|NCT04537780|Experimental|Group 2|"Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.
~The treatment duration will be 12 weeks."
16320146|NCT04537767|Experimental|ES group|Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
16320147|NCT04537767|Placebo Comparator|control group|Patients randomly assigned to the control group were treated with placebo.
16320148|NCT04537754|Experimental|clinician|Comparison of LED and diode laser
16320149|NCT04537741|Experimental|NSTEMI scheduled for angiography|
16320150|NCT04537728|Experimental|My Healthy Brain Version 2|an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of CD
16320151|NCT04537715|Experimental|Part 1: Tazemetostat and Itraconazole Drug Interaction Cycle 1|"Subjects in Part 1 of the study will receive a single oral 400 mg dose of Tazemetostat on Day 1, 15 and 36. The subjects will receive Tazemetostat (oral 400 mg dose) tablets to be taken twice daily from Day 3 - 14 and Day 21 - 35. In addition, the subjects will receive oral 200 mg itraconazole daily from Day 18 - 38.
~Subjects may discontinue from the study after completion of Cycle 1 or can continue treatment (Cycle 2+ onwards) until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. For subjects continuing Tazemetostat treatment at the recommended therapeutic dose (oral 800 mg Tazemetostat twice daily [12 hours apart]), Cycle 2 will begin on day 40 (Cycle 2 Day 1) and each subsequent cycle from Cycle 2+ onwards will be of 28-day duration. Safety and tolerability will be assessed throughout the subject's participation."
16320152|NCT04537715|Experimental|Part 2:Tazemetostat and Rifampin Drug Interaction Cycle 1|"Subjects in Part 2 of the study will receive a single oral 800 mg dose of Tazemetostat on Day 1, 15 and 24. The subjects will receive Tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 3 - 14 and Day 17 - 23. In addition, the subjects will receive oral 600 mg rifampin daily from Day 17 - 25.
~Subjects may discontinue from the study after completion of Cycle 1 or can continue treatment (Cycle 2+ onwards) until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. For subjects continuing Tazemetostat treatment at the recommended therapeutic dose (800 mg Tazemetostat twice daily [12 hours apart]), Cycle 2 will begin on day 27 (Cycle 2 Day 1) and each subsequent cycle from Cycle 2+ onwards will be of 28-day duration. Safety and tolerability will be assessed throughout the subject's participation."
16320212|NCT04537208|Experimental|Group 2 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1
16320213|NCT04537208|Experimental|Group 3 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1
16320153|NCT04537702|Active Comparator|Tradition Counseling Group (TG)|After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor. TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree. The TG subjects will then meet with the genetic counselor. After counseling, participants will be given the option to undergo a multi-gene panel genetic test. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
16320154|NCT04537702|Experimental|Streamlined Group (SG)|"After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. All subjects will then have the option to opt out and receive formal genetic counseling prior to making a decision about testing. If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form. As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. SG subjects will complete an FHQ within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree. Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education."
16320155|NCT04537689|Experimental|Ixekizumab|"Participants will be offered ixekizumab as first-line systemic treatment for moderate to severe PsO. The indication for ixekizumab will be equivalent to current registered indications. Standard dose of subcutaneous ixekizumab for moderate to severe PsO will be given at 160 mg at week 0, followed by ixekizumab 80mg at weeks 2, 4, 6, 8, 10 and 12, then 4 weekly thereafter, for a total duration of 6 months.
~Ixekizumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO.
~Relapses will be managed as per standard care."
16320156|NCT04537689|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.
~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
16320157|NCT04537676||DFU Participants|A cohort of 200 DFU patients who have been prescribed the Podimetrics System by their healthcare providers will be recruited upon providing informed consent. Potential participants will be asked to indicate their interest in participating in this patient empowerment study during their initial phone consultation for mat set-up with the Podimetrics care-management team. Participants will be followed for one year and answer a set of identical questionnaires at three time points: at baseline, at 6-month and at 12-month post enrollment.
16320158|NCT04537663|Experimental|Bacille Calmette-Guérin (BCG)|Intradermal injection of BCG-Vaccine SSI [Statens Serum Institut]) - Danish strain 1331.
16320159|NCT04537663|Placebo Comparator|Placebo|Intradermal injection of sterile 0.9% NaCl.
16320160|NCT04537637||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
16320162|NCT04537611|Experimental|dHb contrast compared to gadolinium contrast imaging|Subjects will be referred for a clinical gadolinium contrast perfusion exam. Gas manipulation will be supplied by a programmable computer-controlled gas delivery system while subjects are in the MRI scanner. In addition to their prescribed clinical scans, two additional scans will be obtained: 1) a structural sequence (, followed by 2) a BOLD-EPI sequence while inducing changes of PO2. PO2 will be held at a baseline of 45-50 mmHg for 60s. For 10 s, the lung PO2 will be transiently raised to peak PO2 of 90-120 mmHg (normoxia) within 2 s transition, and then returned to baseline. Alternatively, the baseline may be at normoxia and the gas challenges will target PO2 of 45-50 mmHg. A total of 4 such ventilatory challenges will be applied over 6 min while maintaining normocapnia.
16320163|NCT04537598|Active Comparator|patient controlled analgesia|30 patients will receive only postoperative IV PCA alone for postoperative analgesia.
16320164|NCT04537598|Active Comparator|Patient controlled analgesia and ESPB|30 patients will receive postoperative IV PCA in addition to ESPB for postoperative analgesia.
16320165|NCT04537585|Experimental|Tomeka|Number of participants with treatment-TOMEKA® usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour
16320166|NCT04537585|Experimental|"Vernonia amygdalina"|"Number of participants with Vernonia amygdalina herbs usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour"
16320167|NCT04537572|Other|Sample Collection Method|All subjects will provide samples via traditional phlebotomy, finger-stick, and saliva collection.
16320168|NCT04537559||Per and post COVID-19 period|Patients hospitalized between 1.3.2020 and 31.7.2020
16320169|NCT04537559||Pre COVID-19 period|Patients hospitalized between 1.3.2019 and 31.7.2019
16320170|NCT04537546|Experimental|Elasto compression belt|all patients must wear the belt 2 months after laparoscopic digestive surgery.
16320171|NCT04537533|Experimental|first group|1st group (A) will include 30 patients: each one will receive 15mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 10mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
16320172|NCT04537533|Active Comparator|second group|2nd group (B) will include 30 patients: : each one will receive 5mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 1mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
16320173|NCT04537533|Placebo Comparator|Third group|3rd group (C){controlled group} will include 30 patients: each one will receive saline (placebo) injection and infusion all through the operation.
16320174|NCT04537520|Experimental|Experimental Group|treatment with the device Kerecis Omega3 Wound
16320175|NCT04537520|No Intervention|Control Group|treatment with SOC treatment
16320214|NCT04537208|Experimental|Group 4 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1
16320215|NCT04537208|Placebo Comparator|Group 5 (18 - 49 years of age)|1 injection of placebo at Day 1
16320216|NCT04537208|Experimental|Group 6 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1 and Day 22
16320176|NCT04537507||Patients underwent coronary angiography|We reviewed medical notes of patients hospitalized for coronary angiography because of exacerbated angina (recurrent chest pain, classical stable angina, long history of chest pain/angina or other symptoms such as dyspnea). We excluded patients with acute coronary syndromes (ACS), Tako-tsubo cardiomiopathy and history of ischemic heart disease, as well as those referred for coronary angiography before heart valve surgery. Prior cardiosurgical valve replacement was also the exclusion criterion.
16320177|NCT04537494|Active Comparator|Prevention|Oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks
16320178|NCT04537494|Other|Treatment-as-needed|Supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age
16320179|NCT04537481|Experimental|Normal fertilization group|Sperm samples from the successful fertilization IVF cycles were collected.
16320180|NCT04537481|Experimental|Low fertilization group|Sperm samples from the low fertilization IVF cycles were collected.
16320181|NCT04537468|Other|Skin sample collection|Skin sample collection for gene expression analyses.
16320182|NCT04537455|Experimental|Abnormal cardiac conduction|patients with abnormal cardiac conduction will undergo an ultra-high frequency electrocardiogram
16320183|NCT04537442|Experimental|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
16320184|NCT04537429|Experimental|Eptinezumab|
16320185|NCT04537416||Women with recurrent pregnancy loss|consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss
16320186|NCT04537403|Experimental|Aim 1A|Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery
16320187|NCT04537403|Experimental|Aim 1B|Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery
16320188|NCT04537390|Other|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
16320189|NCT04537377|Experimental|VTX-801|
16320190|NCT04537364||pediatric patients with CAKUT|"This cohort is composed of pediatric children diagnosed of CAKUT from Shanghai peri-conceptional parent-offspring cohort (SPCC) clinic research related outpatient and high-risk newborns referral outpatient, and those who are enrolled in nephrology department and urinary surgery department with CAKUT diagnosis.
~By diagnostic tests for predicting renal parenchymal damage in this cohort, data of kidney images, urinary biomarkers and disease genes can be collected."
16320191|NCT04537351|Experimental|CYP-001|The investigational medicinal product used in this study is known as CYP-001. The active agent in CYP-001 is Cymerus™ MSCs. CYP-001 is supplied as 100 million Cymerus MSCs formulated in 20 mL cryoprotectant medium. On D1 and D3, each participant randomised to receive CYP-001 will receive an IV infusion of 2 million Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells per infusion).
16320192|NCT04537351|No Intervention|Standard of care|Control participants will be randomised to received standard of care treatment.
16320193|NCT04537338||Active / Recovered Cases|"Active Cases:
~Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.
~Most of the cases of Covid-19 are treated at CCSS hospitals or clnics.
~Recovered cases:
~Are subjects previously diagnosed with Covid-19 via a positive PCR test who were considered recovered because they had two consecutive negative PCR tests."
16320194|NCT04537338||Community control group|The community control group will be frequency-matched on age, sex and area of residence. Two controls per case will be selected as follows
16320195|NCT04537338||Household survey|"Are a household contact of a person diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.
~A household will be defined as a group of persons living together who share a kitchen. To be considered eligible for inclusion a contact must have spent at least one night per week in the living area since onset in the index case."
16320196|NCT04537325|Active Comparator|RenalGuard group|
16320197|NCT04537325|No Intervention|Control group|
16320198|NCT04537312|Experimental|Supportive care (RNSM, surveys)|RNMS Surveys
16320199|NCT04537299|Experimental|Treatment Group|Subjects will receive treatment drug (Fisetin)
16320200|NCT04537299|Placebo Comparator|Placebo Group|Subjects will receive placebo
16320201|NCT04537286|Experimental|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
16320202|NCT04537273||Localy advanced Cervical Cancer|Patients with Localy advanced Cervical Cancer confirmed by pathology, clinical exams and computed tomography scan, treated with concurrent chemoradiotherapy.
16320203|NCT04537260|No Intervention|Control Arm (Standard of Care)|The control group took the knowledge-based survey about induction of labor prior to meeting their provider (midwife or obstetrician) on the day of scheduled induction. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction with the labor and delivery process.
16320204|NCT04537260|Experimental|Intervention Arm (Educational video)|The intervention group had the opportunity to watch the 3-minute educational video. The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8. After watching the video, the participant was asked to take the knowledge-based survey. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction.
16320205|NCT04537247|Experimental|Open partial nephrectomy (Group A)|patients in this group will have open partial nephrectomy for their renal tumors.
16320206|NCT04537247|Experimental|Robotic partial nephrectomy (group B)|patients in this group will have robotic partial nephrectomy for their renal tumors.
16320207|NCT04537234|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
16320208|NCT04537234|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
16320209|NCT04537221||No transfusions|Patients receiving no perioperative blood transfusions (PBT)
16320210|NCT04537221||Transfusions|Patients receiving perioperative blood transfusions (PBT)
16320211|NCT04537208|Experimental|Group 1 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1
16320217|NCT04537208|Experimental|Group 7 (18 - 49 years of age)|2 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1 and Day 22
16320218|NCT04537208|Experimental|Group 8 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1 and Day 22
16320219|NCT04537208|Experimental|Group 9 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1 and Day 22
16320220|NCT04537208|Experimental|Group 10 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 2 without adjuvant at Day 1 and Day 22
16320221|NCT04537208|Placebo Comparator|Group 11 (18 - 49 years of age)|2 injections of placebo at Day 1 and Day 22
16320222|NCT04537208|Experimental|Group 1 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1
16320223|NCT04537208|Experimental|Group 2 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1
16320224|NCT04537208|Experimental|Group 3 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1
16320225|NCT04537208|Experimental|Group 4 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1
16320226|NCT04537208|Placebo Comparator|Group 5 (50 years of age and older)|1 injection of placebo at Day 1
16320227|NCT04537208|Experimental|Group 6 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1 and Day 22
16320228|NCT04537208|Experimental|Group 7 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1 and Day 22
16320229|NCT04537208|Experimental|Group 8 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1 and Day 22
16320230|NCT04537208|Experimental|Group 9 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1 and Day 22
16320231|NCT04537208|Placebo Comparator|Group 11 (50 years of age and older)|2 injections of placebo at Day 1 and Day 22
16320232|NCT04537195|Experimental|Intervention Group|ADSMP-C
16320233|NCT04537195|No Intervention|Control Group|Wait-list control group
16320234|NCT04537182|Experimental|LVRS treatment group|A bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) is performed under general anesthesia with double lumen endobronchial intubation. Unilateral treatment is accepted in cases with severe adhesions or intraoperative instability making a bilateral procedure unsafe.
16320235|NCT04537182|Active Comparator|BLVR study group|Unilateral bronchoscopic lung volume reduction with endobronchial valves (EBV) is performed using a flexible bronchoscope under general anesthesia and under full attendance of an anesthesiologist. Valves are placed unilaterally in segmental or subsegmental bronchi in the target lobe with the goal of complete atelectasis.
16320236|NCT04537169||Mild congenital ptosis|children with mild congenital ptosis
16320237|NCT04537169||Moderate congenital ptosis|children with moderate congenital ptosis
16320238|NCT04537169||Severe congenital ptosis|children with severe congenital ptosis
16320239|NCT04537156|Experimental|HPV vaccine (6,11,16,18,31,33,45,52,58 Types)|Participants in this arm would receive 270μg/0.5ml HPV vaccines (6,11,16,18,31,33,45,52,58 Types).
16320240|NCT04537156|Active Comparator|HPV vaccine (16,18 Types)|Participants in this arm would receive 60μg/0.5ml HPV vaccines (16,18 Types).
16320241|NCT04537143||Control|Non-AMD eyes
16320242|NCT04537143||AMD|AMD eyes
16320243|NCT04537130|Experimental|Experimental|The investigational medical product, the IN01 vaccine, will be administered in two phases to those patients in the experimental arm: the induction phase and the maintenance phase. During the induction phase IN01 vaccine will be administered on day 1 and will be repeated on Day 14, Day 28, Day 42 and day 56. During the maintenance phase, the vaccination will be administered every 2 months with the same dosage and administration mode as during induction.
16320244|NCT04537130|No Intervention|Control|The patients enrolled in the control arm of the study will receive standard of care.
16320245|NCT04537117||Pediatric dentists|Pediatric dentists following Facebook groups for pediatric dentists and practicing dentistry nowadays
16320246|NCT04537091|Experimental|ESWT group: rESWT|rESWT treatment was applied to patients
16320247|NCT04537091|Experimental|PRP group: PRP injection|PRP treatment was applied to patients
16320248|NCT04537078|Active Comparator|the progestin primed double stimulation group|luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphastonat 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness ≥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.
16320249|NCT04537078|Active Comparator|the flexible GnRh antagonist|This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle >18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle >18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
16320250|NCT04537065||preterm infants without ROP|
16320251|NCT04537065||preterm infants with regressed ROP|
16320252|NCT04537065||preterm infants with threshold ROP|
16320253|NCT04537065||full-term infants|
16320254|NCT04537052|Experimental|Onl Femoral vein|Ultrasound-guided controlled injection begins, and the venous diameter and gap between valves are reduced
16320255|NCT04537039|Other|All the participants.|This study only includes 1 arm.
16320256|NCT04537026|Experimental|Transforaminal epidural Amniotic Fluid injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position will be confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. Then 3 mL of Amniotic Fluid will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
16320257|NCT04537026|Active Comparator|Transforaminal epidural dexamethasone injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. 1 mL of dexamethasone sodium phosphate (10 mg/mL) combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
16320258|NCT04537013|Active Comparator|Control Arm|Patients with small chondral lesions of the knee
16320259|NCT04537013|Experimental|Investigational Group|Patients with large chondral lesions of the knee
16320260|NCT04537000|No Intervention|control group|The strategies of red blood cell transfusion for the pediatric patients in this group will be made by the attending doctors in charge based on the current transfusion guidelines. The attending doctors decide when to start blood red cell transfusion and order the volume of the blood red cell as the usual clinical practice.
16320261|NCT04537000|Experimental|study group|For study group, the clinical condition score must be identified every time red blood cell transfusion is considered. The strategies of red blood cell transfusion for the pediatric patients in this group, including the trigger and the volume, will be made based on the comparison between the clinical condition score and the Hb concentration.
16320262|NCT04536987|Experimental|low-dosage robot therapy|12 sessions of robotic therapy over 4-5 weeks
16320263|NCT04536987|Experimental|hi-dosage robot therapy|24 sessions of robotic therapy over 8-10 weeks
16320264|NCT04536961|Experimental|Part A: Reference Treatment|
16320265|NCT04536961|Experimental|Part A Prototype|
16320266|NCT04536961|Experimental|Part C Reference Treatment|
16320267|NCT04536961|Experimental|Part C: Prototype|
16320268|NCT04536961|Experimental|Part B: Treatment 1|
16320269|NCT04536961|Experimental|Part B: Treatment 2|
16320270|NCT04536961|Experimental|Part B: Treatment 3|
16320271|NCT04536961|Experimental|Part B: Treatment 4|
16320272|NCT04536961|Experimental|Part B: Treatment 5|
16320273|NCT04536948|Experimental|Group 1|Cooling gel application
16320274|NCT04536948|Active Comparator|Group 2|Cold pack was applied
16320275|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 1|
16320276|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 2|
16320277|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 3|
16320278|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 4|
16320279|NCT04536922|Experimental|iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
16320280|NCT04536909||Non-surgical|A non-surgical group for comparison, they will conduct a training program tailored for the kyphoscoliotic patients. The inclusion criteria is the same as for the surgical group.
16320281|NCT04536909||Surgical|Patients operated with correction of kyphotic- or scoliotic deformity.
16320282|NCT04536896|Active Comparator|Traditional face-to-face teaching method|In this arm, participants underwent a 6-hour traditional face-to-face lecture on breastfeeding education in a classroom at a university. Course was divided into 4 1.5-hour sessions during a time span of two weeks.
16320283|NCT04536896|Experimental|Breastfeeding smartphone app|In this group, participants downloaded a smartphone application which contained an online breastfeeding education course. Participants freely navigated through the smartphone app during a time span of two weeks.
16320284|NCT04536883|Experimental|Microscopy confocal|"The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins.
~After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing"
16320285|NCT04536870|Experimental|STAREE Statin group|Participants in STAREE trial randomised to statin
16320286|NCT04536870|Experimental|STAREE Placebo group|Participants in STAREE trial randomised to placebo
16320287|NCT04536857||Parkinson's Disease|Subjects who have a PD diagnosis
16320288|NCT04536857||Multiple System Atrophy|Subjects who have an MSA diagnosis
16320289|NCT04536857||Progressive Superanuclear Palsy|Subjects who have a PSP diagnosis
16320290|NCT04536857||Age-matched controls|Subjects who do not have a diagnosed neurological disorder
16320291|NCT04536844|Experimental|Telehealth follow-up group|Rheumatoid arthritis patients in remission who will be followed by an electronic app
16320292|NCT04536844|Placebo Comparator|Conventional follow-up group|Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic
16320293|NCT04536831|Experimental|Vitamin D group|Consisted of 48 patients selected on admission via lottery method those will be given Vitamin D mega dose
16320294|NCT04536831|Placebo Comparator|Normal Saline group|Consisted of 48 patients selected on admission via lottery method those will be given Normal saline
16320295|NCT04536818||Time to surgery ≤12 hours|Waiting time to surgery ≤12 hours from hospital presentation.
16320296|NCT04536818||Time to surgery >12 hours|Waiting time to surgery >12 hours from hospital presentation.
16320297|NCT04536805|Experimental|Metformin + SBRT at total dose of 30 Gray (Gy)|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10)"
16320298|NCT04536805|Experimental|Metformin + SBRT at total dose of 36 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12)"
16320299|NCT04536805|Experimental|Metformin + SBRT at total dose of 25 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10)"
16320300|NCT04536792|Experimental|Part 1: Single Ascending Dose (SAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.
16320301|NCT04536792|Experimental|Part 2: Multiple Ascending Dose (MAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days or using an alternative dosing regimen for 28 days under fasted conditions.
16320302|NCT04536792|Experimental|Part 3: Sickle Cell Disease (SCD) Phase|Participants will receive a range of selected ascending doses of AG-946, orally, QD or using an alternative dosing regimen for 28 days.
16320303|NCT04536779|Experimental|Individuals with low mobility (Disabled and Elder)|minimum 8-10 training sessions in at least three months.
16320304|NCT04536766|Experimental|Enhanced Sleep Health Education|50 families will be randomly assigned to receive sleep health education delivered in two telephone sessions by Beds for Kids staff members, in addition to receiving the standard Beds for Kids program (bed, bedding, written sleep education materials). The first session will occur approximately 2-3 days before bed delivery. The second 15-20-minute session will occur approximately one week following bed delivery. Sleep health education training and supervision of Beds for Kids staff members will be provided by board-certified Behavioral Sleep Medicine providers. Sleep health information will be manualized and will consist of evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs.
16320305|NCT04536766|Active Comparator|Beds for Kids Standard Program|50 families will be randomly assigned to the standard Beds for Kids program, which includes a bed, bedding, and written sleep education materials.
16320306|NCT04536753||Suspected large for gestational age (LGA)|Women with pregnancies suspected to be complicated by fetuses weighing more than the 90th centile on customised growth chart and induced for this reason prior to 287 days as the main indication without diabetes.
16320307|NCT04536753||Women with diabetes (DM)|Women with diabetes in pregnancy induced at between 259 and 266 days if on treatment and 273 days if gestational diabetes managed with diet alone.
16320308|NCT04536753||Control|All other women induced at or after 280 days of gestation
16320309|NCT04536740|Other|PDL-treated PWS|PWS treated with PDL before will be treated with PDT
16320310|NCT04536740|Experimental|without treatment PWS|PWS without treatment before will be treated with PDT
16320311|NCT04536727|Experimental|Intervention|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content.
16320312|NCT04536727|Placebo Comparator|Wait list|Participants randomized to the wait list group, receive the 8-week Fit & Strong! intervention after the intervention group has completed it.
16320313|NCT04536714|Experimental|Intervention group|34 participants. Received Pythagorean Self-Awareness program
16320314|NCT04536714|No Intervention|Control group|35 participants. Received usual care
16320315|NCT04536701|Experimental|Dementia/Caregiver Dyad|All dementia/caregiver dyads will have in-home acoustic monitoring to classify mood and will be provided mindfulness-based stress reduction recommendations via a smart phone.
16320316|NCT04536688|Experimental|RGLS4326 1 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses
16320317|NCT04536688|Experimental|RGLS4326 0.3 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses
16320318|NCT04536688|Experimental|RGLS4326 0.1 or 0.5 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses
16320319|NCT04536675|Experimental|VI/UME|Anoro (Vilanterol 25mcg/Umeclinidium 62.5mcg) in Ellipta device Inhaled through mouth once daily
16320320|NCT04536675|Placebo Comparator|Control|Placebo (including lactose monohydrate) in Ellipta device Inhaled through mouth once daily
16320321|NCT04536662|Experimental|Group hydrocortisone|
16320322|NCT04536662|Experimental|Group Prednisone|
16320323|NCT04536662|Experimental|Group Dexamethasone|
16320324|NCT04536649|Experimental|Standard-dose Photon Radiotherapy|The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)
16320325|NCT04536649|Experimental|Standard-dose Proton Radiotherapy|The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
16320326|NCT04536649|Experimental|Standard-dose Proton Radiotherapy plus Carbon-Ion Boost|The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
16320327|NCT04536636|Active Comparator|Control|The patients on this arm received usual medical care
16320328|NCT04536636|Active Comparator|DHA supplementation|The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)
16320364|NCT04536389||group B|women with normal uterine cavity with hysteroscopically detected cervical abnormality.
16320329|NCT04536623|Experimental|SIESTA-Rehab Protocol|This inpatient rehabilitation floor will be trained to implement the SIESTA-Rehab protocol. Nurses will be empowered to reduce unnecessary disruptions and subjects will be screened for sleep-disordered breathing. Subjects will utilize wearable sensor technology.
16320330|NCT04536623|No Intervention|Standard of Care|This inpatient rehabilitation floor will continue to implement usual care.
16320331|NCT04536610|Experimental|Experimental group|Providing structured OP education in addition to the informative leaflet. (The leaflet contained the same information as the OP education program)
16320332|NCT04536610|Active Comparator|Control group|Giving only the informative leaflet. (The leaflet contained the same information as the OP education program)
16320333|NCT04536597|Experimental|Quince seed jelly group|
16320334|NCT04536597|Experimental|Breast milk group|
16320335|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
16320336|NCT04536584|Experimental|Arm A: personalized coaching for physical activities|This arm consists of providing patients with a personalized coaching focused on exercise and physical activity, with or without connected watch.
16320337|NCT04536584|Active Comparator|Arm B: standard supportive approach|The standard supportive approach will consist in recommendations made during visits with the oncologist. The delivery of post-treatment care by oncologists and their team systematically provide exercise advice patients including recommendations for strength training and aerobic activity.
16320338|NCT04536571|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
16320339|NCT04536571|Active Comparator|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
16320340|NCT04536558|Experimental|olanzapine plus fosaprepitant-based triple regimen|Olanzapine（5mg p.o. d1-d5）plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
16320341|NCT04536558|Placebo Comparator|Placebo plus fosaprepitant-based triple regimen|Placebo plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
16320342|NCT04536532|Experimental|HEC121120 tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
16320343|NCT04536532|Placebo Comparator|HEC121120 placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
16320344|NCT04536532|Active Comparator|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
16320345|NCT04536532|Placebo Comparator|entecavir placebo tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
16320346|NCT04536519|Active Comparator|Lateral Heel Wedged Insole Alone with physical therapy|"the lateral heel wedged insole (19) comprised non-custom, high density based on insoles of ethyl-vinyl acetate distributed bilaterally, preferably, covered in leather, were used in the study. The insole were equipped with a lateral wedge of 50 to 60.
~In the case of unilateral knee osteoarthritis, the non-wedge insole were used to compensate for possible leg length discrepancy in the contra-lateral leg. Shoes used was based on gymnast type to keep wedge insole in place. This further finalized individual to individual with unanimous decisions of Cordwainers, orthotics, and principal researcher, physiotherapist."
16320347|NCT04536519|Active Comparator|Lateral aand medial Heel Wedged Insole with physiotherapy|medial arch support part were combine with aforementioned lateral heel wedged support, full length support. There is a debate, however, 4 to 6 mm of full length support is considered to be effective for required alteration in mechanics
16320348|NCT04536506|Experimental|Treatment group|Bobath group received 45 min of sessions three times weekly for 12 weeks.
16320349|NCT04536506|Active Comparator|Control group|Vojta group received the following three times weekly for 12 weeks.
16320350|NCT04536493|Active Comparator|1 application|Patients receive single dose LET
16320351|NCT04536493|Active Comparator|3 applications|Patients receive 3 doses of LET
16320352|NCT04536480|Experimental|Control: 12 hour eating period|Control: Habitual daily eating period (no meal time restrictions)
16320353|NCT04536480|Experimental|Time Limited Eating|Time Limited Eating: 8-hour eating period (16 hours of daily fasting).
16320354|NCT04536467|Other|Goserelin arm|3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
16320355|NCT04536467|Other|control Arm|Standard chemotherapy
16320356|NCT04536454|Experimental|[18F]FPyGal|"Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.
~After the end of the neo-adjuvant therapy a tracer injection with [18F]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes."
16320357|NCT04536441|Experimental|Treatment|Ultra Brief Online Mindfulness-based Intervention
16320358|NCT04536441|Placebo Comparator|Control|This arm requires participants to answer questions about themselves.
16320359|NCT04536428|Experimental|ClearEndoclip|This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.
16320360|NCT04536428|Active Comparator|EZ clip|This arm is a group in whom EZ clip would be used for the treatment of bleeding.
16320361|NCT04536415|Experimental|Oseltamivir Phosphate 75 mg capsules (Yangtze River)|During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.
16320362|NCT04536415|Active Comparator|Tamiflu capsules 75 mg (Genentech, Inc.)|During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.
16320363|NCT04536389||group A|women with normal uterine cavity and normal cervix by office hysteroscopy.
16320365|NCT04536376|Experimental|Resilience Program|a 4 week program focused on improving resilience
16320366|NCT04536363|Active Comparator|Standard therapeutic protocol|"Dexamethasone (4mg ampoule, intravenous)
~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)
~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)
~Enoxaparin (40mg prefilled syringe)
~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)
~Low molecular weight heparin (5000IU prefilled syringe)"
16320367|NCT04536363|Experimental|Standard Therapeutic Protocol + PGE1 Analog|"Analog of PGE1 + Standard therapeutic protocol
~Standard medical treatment:
~Dexamethasone (4mg ampoule, intravenous)
~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)
~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)
~Enoxaparin (40mg prefilled syringe)
~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)
~Low molecular weight heparin (5000IU prefilled syringe)"
16320368|NCT04536350|Experimental|Aviptadil Treatment|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
16320369|NCT04536350|Placebo Comparator|Placebo Treatment|Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
16320370|NCT04536337|Experimental|ALG-000184|Oral tablet(s) of ALG-000184 in HV or CHB subjects once daily for up to 4 weeks
16320371|NCT04536337|Placebo Comparator|Placebo|Oral tablet(s) of placebo in HV or CHB subjects once daily for up to 4 weeks
16320372|NCT04536311|Experimental|Paravertebral block in surgical stabilization of rib fractures under awake or appropriate sedation|patients receive internal fixation for multiple rib fractures using paravertebral nerve block anesthesia in awareness status and keep spontaneous breath
16320373|NCT04536298|Active Comparator|Vitamin D|Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
16320374|NCT04536298|Placebo Comparator|Placebo|Placebo
16320375|NCT04536272|Active Comparator|Target of 2-2.5 times baseline aPTT (usual care, about 60-75)|Administration of heparin during ECLS with an aPTT target of 2-2.5 times baseline.
16320376|NCT04536272|Active Comparator|Target of 1.5-2.0 times baseline aPTT (45-60 sec.)|Administration of heparin during ECLS with an aPTT target of 1.5-2.0 times baseline.
16320377|NCT04536272|Active Comparator|LMWH guided by weight and renal function.|Administration of LMWH guided by weight and renal function during ECLS.
16320378|NCT04536259|Experimental|Video Default|"The case and response options participants in this group will be asked to consider is provided below.
~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.
~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.
~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
16320379|NCT04536259|Experimental|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.
~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.
~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.
~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
16320380|NCT04536259|Experimental|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.
~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.
~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.
~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
16320381|NCT04536246|Active Comparator|BQT Group|Procedure on this arm = bone quadriceps tendon reconstruction
16320382|NCT04536246|Other|SBHT Group|Procedure on this arm = single-bundle hamstring tendon reconstruction
16320383|NCT04536233|Placebo Comparator|control group|
16320384|NCT04536233|Experimental|experimental group|
16320385|NCT04536220||pancreatic mass diagnosed benign|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
16320386|NCT04536220||pancreatic mass diagnosed malignant|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
16320387|NCT04536207|Experimental|the study group|Group (A) the study group received cryotherapy
16320388|NCT04536207|No Intervention|the control group|Group (B) the control group not received cryotherapy
16320391|NCT04536181|Placebo Comparator|3 months group|Subjects will receive 12-weeks of placebo following randomization
16320392|NCT04536181|Experimental|6 months group|12 Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone.
16320393|NCT04536155||patient with chronic pain|
16320394|NCT04536142||Brain tumors|Subjects with operable supratentorial brain tumors
16320395|NCT04536142||Healthy subjects|Healthy subjects
16320396|NCT04536129|Experimental|Group A: glaucoma|OSD patients with glaucoma
16320397|NCT04536129|Active Comparator|Group B: no glaucoma|OSD patients without glaucoma
16320398|NCT04536116|Experimental|MRI simulation|MRI simulation with a Virtual Reality headset
16320399|NCT04536116|No Intervention|Standard medical care|Standard medical care
16320400|NCT04536103||Cleveland Clinic Foundation (CCF) Volunteers|The group will be used for evaluating differences between standard T1rho and T2 imaging vs accelerated T1rho and T2 imaging techniques that will be developed from this study.
16320401|NCT04536103||Traveling Volunteers|The group will be recruited at CCF and be scanned at CCF, University of California San Francisco, University of Kentucky and Albert Einstein College of Medicine.
16320402|NCT04536103||ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).
16320403|NCT04536103||Group Matched to ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).Traveling Volunteers share the same inclusion and exclusion criteria as this group, therefore subjects can participate the study and serve as subjects within both groups
16320404|NCT04536090|Experimental|Isoquercetin (IQC-950AN)|1000 mg Isoquercetin b.i.d. on day 1, then 500 mg Isoquercetin b.i.d. for 27 more days, plus standard of care (as defined below)
16320405|NCT04536090|No Intervention|Standard of care|This arm will receive standard of care based on national guidelines. This may change as new information regarding best practice emerges.
16320406|NCT04536077|Experimental|CDX-1140 Monotherapy|Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.
16320407|NCT04536077|Experimental|CDX-1140 + CDX-301|Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.
16320408|NCT04536051|Experimental|Group 1a: single dose ChAdOx & paracetamol|Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol
16320409|NCT04536051|Active Comparator|Group 1b: single dose MenACWY & paracetamol|Participants will receive a single dose of MenACWY plus paracetamol
16320410|NCT04536051|Experimental|Group 1c: two dose ChAdOx & paracetamol|Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol
16320411|NCT04536051|Active Comparator|Group 1d: two dose MenACWy/saline & paracetamol|Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol
16320412|NCT04536038|No Intervention|Opt-in|Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the study, or to call or email the study coordinator with questions or for assistance in enrolling.
16320413|NCT04536038|Experimental|Opt-out|Patients randomized to opt-out framing will receive an email that frames participation in the study as part of the standard of care, and will be informed that a study coordinator will be calling them in the coming days to start enrollment in the study unless they opt out of participation.
16320414|NCT04536025||Prosthetists|Up to 24 prosthetists who are actively providing prosthetic care to people with lower limb amputation will be recruited for participating in focus groups to describe their decisional needs for providing prostheses to people with lower limb amputation.
16320415|NCT04536025||People with lower limb amputation|An estimated 14 people within 1 year from lower limb amputation, receiving their first prosthesis will be recruited for individual semi-structured interviews to describe their decisional needs for provision of a prosthesis.
16320416|NCT04536025||Expert working group|The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
16320417|NCT04536012|No Intervention|Control|Via the Way to Health platform, all patients will receive daily text messages that inform them of their previous day's step count for 24 weeks.
16320418|NCT04536012|Experimental|Intervention|"Participants have a 4-week ramp-up towards their step goal and are asked to maintain the goal for the rest of the study. They receive daily texts informing them if they met their step goal and biweekly texts to encourage walking for exercise.
~Participants are entered into a game. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level. Participants start in the middle of 5 levels.
~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. Every 8 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.
~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
16320419|NCT04535999|Experimental|Open Label|Secukinumab
16320420|NCT04535986|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
16320421|NCT04535986|Placebo Comparator|Arm 2|Placebo Nebulized BID
16320422|NCT04535973||study group|female postmenopausal women with burning mouth syndrome
16320423|NCT04535973||control group|female postmenopausal women without burning mouth syndrome
16320424|NCT04535960|Experimental|Liraglutide|Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks
16320425|NCT04535960|Experimental|Empagliflozin|Empagliflozin Tablets Total Dose 25mg daily for 6 weeks
16320426|NCT04535947|Placebo Comparator|Vehicle|Vehicle
16320427|NCT04535947|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Active
16320428|NCT04535934||1 dose/week followed by 4 doses/week|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 1 dose/week followed by 4 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
16320429|NCT04535934||3 doses/week followed by 7 doses/week.|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 3 doses/week followed by 7 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
16320430|NCT04535921||Prostatectomy|FCR7 questionnaire pre and postoperative
16320431|NCT04535921||Cystectomy|FCR7 questionnaire pre and postoperative, 6 months follow
16320432|NCT04535921||Nephrectomy|FCR7 questionnaire pre and postoperative
16320433|NCT04535921||Orchidectomy|FCR7 questionnaire pre and postoperative
16320434|NCT04535908|Experimental|Hypofractionated radiotherapy|
16320435|NCT04535895|Experimental|Simultaneous integrated boost arm|
16320436|NCT04535869|No Intervention|A)standard therapy group|No intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol
16320437|NCT04535869|Active Comparator|B)Standard Therapy group plus Ant-HCV drugs|Intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol plus sofosbuvir 400 mg and Daclatasvir 200mg
16320438|NCT04535856|Experimental|Low-dose group|"Low-dose group (5 x 10^7cells):
~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 2 vials for low-dose group"
16320439|NCT04535856|Experimental|High-dose group|"High-dose group (1 x 10^8 cells):
~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 4 vials for High-dose group"
16320440|NCT04535856|Placebo Comparator|Control group (placebo)|"Control group (placebo):
~No Drug substance: 4 vials for Place group"
16320441|NCT04535843||myasthenia gravis|300 MG patients are anticipated for precision diagnosis and disease monitoring.
16320442|NCT04535830|Experimental|Flash glucose monitor system(FSL)|Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month.
16320443|NCT04535830|No Intervention|Self-monitoring blood glucose(SMBG)|People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month.
16320444|NCT04535817|Experimental|Treatment Group|Subjects will receive subcutaneous treatment of 300mg of omalizumab during the 24-week treatment period. One injection will be administered every 4 weeks.
16320445|NCT04535804|Active Comparator|Aspirin group|100 mg of low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
16320446|NCT04535804|Placebo Comparator|placebo group|100 mg of placebo was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
16320447|NCT04535791|Experimental|cholecalciferol (Vitamin D)|cholecalciferol 4,000 IU orally daily for 30 days
16320448|NCT04535791|Placebo Comparator|Starch|Starch 500 mg orally daily for 30 days
16320449|NCT04535778|Experimental|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. Participants will also have access to the standard charity resources.
16320450|NCT04535778|Active Comparator|Standard charity resources|Participants will be directed to the standard resources provided by the charities involved in the study.
16320451|NCT04535765|Experimental|experimental group|The experimental group began to perform warm water sitz bath 6 hours after the operation (the day of the operation).Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
16320452|NCT04535765|Other|control group|The control group began to perform warm water sitz bath at 8:00 in the morning on the first day after the operation as usual.Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
16320453|NCT04535752|Experimental|ANX009, Single Ascending Doses|Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.
16320454|NCT04535752|Placebo Comparator|Placebo, Single Ascending Doses|Single doses of matching placebo
16320455|NCT04535752|Experimental|ANX009, Multiple Ascending Doses|ANX009 once daily on Days 1-14
16320456|NCT04535752|Placebo Comparator|Placebo, Multiple doses|Matching placebo once daily on Days 1-14
16320457|NCT04535739|Experimental|PCI group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。
16320458|NCT04535739|Other|control group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。
16320459|NCT04535713|Experimental|Single arm|A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.
16320460|NCT04535700|Experimental|pioglitazone|
16320461|NCT04535700|Other|Standard of care treatment|
16320462|NCT04535687|Experimental|Treatment group|Fluzoparib alone
16320463|NCT04535674|No Intervention|Standard of Care|
16320464|NCT04535674|Experimental|Standard of Care + Asunercept 25 mg|
16320465|NCT04535674|Experimental|Standard of Care + Asunercept 100 mg|
16320466|NCT04535674|Experimental|Standard of Care + Asunercept 400 mg|
16320467|NCT04535661||non CRE|Children with a negative culture for CRE during their stay in PICU are defined as non CRE.
16320468|NCT04535661||CRE colonization|Children who have a positive culture for CRE during their stay in PICU but lack of clinical symptoms are defined as CRE colonization.
16320469|NCT04535661||CRE infection|Children who have a positive culture for CRE during their stay in PICU combined with clinical symptoms are defined as CRE infection.
16320470|NCT04535635|Experimental|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
16320471|NCT04535635|Placebo Comparator|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
16320472|NCT04535622|Experimental|Exercise group|A structured exercise instruction for facedown posture-related pain will be provided to the patients, and patients will go through three times of self-exercise sessions everyday according to the training provided.
16320473|NCT04535622|No Intervention|Control group|Patients are going to maintain face-down posture but no specific exercise instruction will be provided.
16320476|NCT04535596|Experimental|Conventional Exercises|12 week long strength training exercise with the higher loading (%70-80 of 1 Repetitive Maximum)
16320477|NCT04535596|Experimental|Blood Flof Restriction Exercises|12 week long strength training exercise with the lower loading (%20-30 of 1 Repetitive Maximum) by using cuff around the thigh
16320479|NCT04535570||Pre Transplant|All 20 patients will have the energy expenditure measured in the pre-transplantation in order to compare with post-transplant data.
16320480|NCT04535570||Post Transplant|All 20 patients will have the energy expenditure measured in the post transplantation in order to compare with the pre-transplant data.
16320483|NCT04535531|Experimental|SB206 10.3% berdazimer|SB206 10.3% berdazimer topically once daily
16320484|NCT04535531|Placebo Comparator|vehicle gel|Vehicle gel topically once daily
16320485|NCT04535518|Active Comparator|the standard group|"IVIG 2 g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
16320486|NCT04535518|Experimental|the standard + infliximab group|"IVIG 2 g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
~Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours."
16320488|NCT04535492|Other|Colorectal Cancer Screening Recommended|The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
16320489|NCT04535492|Other|Lung Cancer Screening Recommended|The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults ages 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
16320490|NCT04535492|Other|Breast Cancer Screening Recommended|The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
16320491|NCT04535479|Experimental|Individuals with spasticity resulting from stroke|This is an experimental intervention in which individuals will receive dry needling to relieve spasticity in the target muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
16320492|NCT04535479|Experimental|Individuals with no known neurological injury|This is an experimental intervention in which individuals will receive dry needling of an arm or leg muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
16320497|NCT04535440||Rectal varices with bleed|
16320498|NCT04535440||Rectal varices without bleed|
16320499|NCT04535427|Placebo Comparator|Control|Participants in this arm will receive placebo per day.
16320500|NCT04535427|Experimental|Low dose L-arginine|Participants in this arm will receive 9g (3g tid) L-arginine per day.
16320501|NCT04535427|Experimental|High dose L-arginine|Participants in this arm will receive 15g (5g tid) L-arginine per day.
16320504|NCT04535401|Experimental|Treatment (elimusertib, FOLFIRI)|Patients receive elimusertib PO BID on days 1, 2, 15, and 16 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity.
16320505|NCT04535388|Other|LK scleral lens|LK scleral lens (Lucid Korea LTD, Seoul, Republic of Korea) are worn for 12 weeks.
16320506|NCT04535375|Other|Preterm infants < 28 weeks gestational age|For infants born before 28 0/7 weeks, standard of care consists of brain ultrasound performed on admission, day 1, day 2, day 3, day 7, and then weekly until discharge.
16320507|NCT04535375|Other|Preterm infants born between 28 0/7 and 31 6/7 weeks|For infants born between 28 0/7 and 31 6/7 weeks, brain ultrasound is performed on admission, once between day 1 and 3, once between day 7 and 10, and then 2-weekly until discharge or transfer.
16320508|NCT04535362|Active Comparator|menthol cigarettes|Will smoke only menthol cigarettes for two weeks
16320509|NCT04535362|Active Comparator|non menthol cigarettess|Will only smoke non menthol cigarettes for two weeks
16320510|NCT04535349|Other|No cardiac ATTR amyloidosis|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).
~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up."
16320511|NCT04535349|Other|Cardiac ATTR amyloidosis, no treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).
~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.
~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
16320512|NCT04535349|Other|Cardiac ATTR amyloidosis, treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).
~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.
~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
16320513|NCT04535336|Experimental|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included 3 phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained an certified by the PI, 3 times per week and 40 minutes per session for 6 months.
16320514|NCT04535336|Active Comparator|Control|Participants in the control group continued with their daily activities as usual.
16320515|NCT04535323|Experimental|Treatment Group|Platelet rich plasma will be administered in an array of 6 locations inside the vagina. Each array will receive 5 injections of 0.2 ml PRP. An additional 5 injections of 0.2 ml PRP will be injected at the entrance of the vagina for a total of 7 ml PRP.
16320516|NCT04535310|Experimental|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
16320517|NCT04535284|Experimental|Coaching|"Health Coaching-in-Context includes coaching by trained coaches up to 10 sessions over teleconference."
16320518|NCT04535284|No Intervention|Usual Care|The usual care group does not get any intervention but continues with any of their usual activities that would otherwise would have been provided to them.
16320519|NCT04535271|Experimental|Single arm|Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8
16320520|NCT04535258|Other|First-movers|The first four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
16320521|NCT04535258|Other|Second-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
16320522|NCT04535258|Other|Third-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
16320523|NCT04535258|Other|Fourth-movers|After three months, the last four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
16320524|NCT04535245||LCI testing|LCI testing will be performed on all study subjects
16320525|NCT04535219|Experimental|Group A|Participants will have vascular function assessed following total sleep deprivation
16320526|NCT04535219|No Intervention|Group B|Participants will have vascular function assessed following a full night of sleep
16320527|NCT04535219|Experimental|Group C|Participants will have vascular function assessed following total sleep deprivation preceded by exercise
16320528|NCT04535219|No Intervention|Group D|Participants will have vascular function assessed following a full night of sleep
16320529|NCT04535206||With AT-Ⅲ, PC, PS activity decreased|Any decreased in AT-Ⅲ, PC, PS activity before catheter intubation is regarded as the exposure group
16320530|NCT04535206||AT-Ⅲ, PC, PS activity are at normal value|The activities of AT-Ⅲ, PC and PS are all at normal values before catheter intubation
16320531|NCT04535193|Other|Low likelihood of coronary heart disease|Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration.
16320532|NCT04535193|Other|Heart Failure + left ventricular function (LVEF ≤ 35%)|Thorax and total body imaging for quantification of myocardial sympathetic innervation. PET imaging to 100 minutes post-administration
16320533|NCT04535180||Hemophilia|
16320534|NCT04535167|Experimental|PF-07304814|"Part 1:
~Cohort 1-5
~Part 2:
~Cohort 6-9"
16320535|NCT04535167|Placebo Comparator|Placebo|"Part 1:
~Cohort 1-5
~Part 2:
~Cohort 6-9"
16320536|NCT04535141|Experimental|Olanzapine Arm|Olanzapine 5mg tablet with chemotherapy, and 3 days after
16320537|NCT04535141|Placebo Comparator|Placebo Arm|
16320538|NCT04535128||COVID-19 Positive|Patients with positive COVID-19 PCR
16320539|NCT04535115|Experimental|Group 1|Starting LRM (Lung Recruitment Maneuver)
16320540|NCT04535115|Experimental|Group 2|Starting VtC (Tidal Volume Challenge)
16320541|NCT04535102|Experimental|Polatuzumab + BR (minimum 3 cycles)|Patients will be treated with a minimum of 3 cycles up to a maximum six cycles to optimize response prior to ASCT (stem cell transplant) per investigator discretion
16320542|NCT04535089|Active Comparator|dexmedetomdine|IV bolus dose of 0.5ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5ug/kg/h
16320543|NCT04535089|Active Comparator|lidocaine|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
16320544|NCT04535076|Experimental|Transcatheter Aortic Valve Implantation|
16320545|NCT04535076|Active Comparator|Surgical Aortic Valve Replacement|
16320546|NCT04535063|Other|severe pneumonia arm|patients with severe COVID19 pneumonia defined by: spontaneous breathing patients with respiratory failure requiring O2 nasal cannula more than 3 L/min or reservoir oxygen mask and SaO2 less than 95% or patients with critical pneumonia define by mechanical ventilation with less than 300 mmHg PaO2/FiO2 or shock or multi-organic dysfunction
16320547|NCT04535050|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization
16320548|NCT04535050|Sham Comparator|Sham control|Subjects are treated with renal angiography
16320549|NCT04535037|Experimental|DTPa-HBV-IPV/Hib Investigational Group|All subjects in this group receive 3 doses (2 primary doses and 1 booster dose) of DTPa-HBV-IPV/Hib vaccine co-administered with 3 doses of pneumococcal 13-valent conjugate vaccine at 2, 4, and 12 months of age.
16320550|NCT04535037|Active Comparator|DTaP5-HBV-IPV-Hib Comparator Group|All subjects in this group receive 3 doses (2 primary doses and 1 booster dose) of DTaP5-HBV-IPV-Hib vaccine co-administered with 3 doses of pneumococcal 13-valent conjugate vaccine at 2, 4, and 12 months of age.
16320551|NCT04535024|Experimental|Treatment Arm|"A total of 60 MSS oligometastatic colorectal cancer patients will receive multisite SABR followed by Sintilimab within one week from completion.
~The dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
16320552|NCT04535011|No Intervention|Usual Care|No prevention or educational information verbally or written coinciding with current usual care
16320553|NCT04535011|Experimental|PPKAY|One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use
16320554|NCT04535011|Experimental|PPKAY with Standard Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use.
~Weekly standard text booster until final follow-up (e.g., Reducing your alcohol intake to less than 4 drinks per day reduces your risk of alcohol-related consequences)"
16320555|NCT04535011|Experimental|PPKAY with Personalized Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use Weekly personalized text booster until final follow-up (e.g., Remember to reduce your alcohol less than 4 drinks to achieve your goal of… [being a better husband].)"
16320556|NCT04534998|Experimental|Robotic-assisted partial nephrectomy|Partial nephrectomy will be performed using a robotic-assisted laparoscopic approach.
16320557|NCT04534998|Active Comparator|Open partial nephrectomy|Partial nephrectomy will be performed using an open retroperitoneal approach.
16320558|NCT04534985|Experimental|Time Restricted Feeding|Instructed to eat within an 8-hr window, beginning within 3 hrs of waking. In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
16320559|NCT04534985|Active Comparator|Healthy Eating Advice without Time Restricted Feeding|Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
16320560|NCT04534972|No Intervention|Pre-Implementation|The control (pre-implementation) group will be burn patients admitted to the burn unit in ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
16320561|NCT04534972|Active Comparator|Post-Implementation Targeting Normoxia in Burn ICU|The intervention (post-implementation) group will be patients admitted to the burn unit in ICU during the targeting normoxia intervention period of the stepped-wedge design implementation process (up to 19 months).
16320562|NCT04534959|No Intervention|Pre-Implementation|The control (pre-implementation) group will be trauma patients admitted to the surgical/trauma ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
16320563|NCT04534959|Experimental|Post-Implementation Targeting Normoxia in Trauma ICU|The intervention (post-implementation) group will be patients admitted to the surgical/trauma ICU during the targeted normoxia intervention period of the stepped-wedge implementation process (up to 25 months).
16320564|NCT04534933|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
16320565|NCT04534933|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure in double lung ventilation and 6ml/kg PBW in one lung ventilation. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
16320566|NCT04534907|Active Comparator|VR(ERP）|The combination of exposure and response prevention (ERP) and VR will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
16320567|NCT04534907|Active Comparator|traditional ERP|The traditional ERP will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
16320568|NCT04534894||DM group and DCM group|DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction
16320569|NCT04534881|Active Comparator|progesterone|subjects on active drug (progesterone)
16320570|NCT04534881|Placebo Comparator|placebo|subjects on placebo
16320571|NCT04534868|Other|Patient Acceptance and satisfaction for teledermoscopy|"The aim of the first part of the study is to evaluate patients' skin monitoring habits, their knowledge of skin cancer, and their preconceptions about new telemedicine tools such as teledermoscopy. This is a written quantitative questionnaire with answers to tick.
~An explanatory folder will be given to patients and they will be asked to read it beforehand in order to allow a good understanding of the terms used and the goal of the project. This part will include 70 to 100 patients.
~The second part of the study is a qualitative study and the aim of it is to evaluate the satisfaction, acceptance and future expectations of those who have benefited from teledermoscopy. Individual and anonymous interviews, lasting 15 to 20 minutes, intended for patients who have benefit of teledermoscopy at the office. An explanatory folder will also be given to the patients concerned in order to explain to them the procedure of the interview. This part will include 8 to 10 patients."
16320572|NCT04534855|Experimental|Treprilimab treatment group|Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity
16320573|NCT04534842|Experimental|SYNB1618|Dose ramp of SYNB1618
16320574|NCT04534829|Experimental|Ultrasound-Guided SIJ RFA|"Utilizing short axis views, the S1, S2 and S3 foramen and tubercles would be localized and marked by a surgical skin marker. Then, the ultrasound transducer will be moved laterally to achieve a long axis view between the S1 and S2 tubercle. Local skin and subcutaneous tissue freezing would be performed with Lidocaine 1% utilizing a 30-gauge needle. An 18-gauge radiofrequency (RF) cannula will be directed utilizing an in-plane approach toward the S2 and S3 lateral branches between the S2 and S3 tubercles. A small amount of 1% lidocaine will be injected in order to provide comfort.
~The RF generator will be set to continuous monopolar RF ablation and the needle will be heated to 80 degrees Celsius for 90 seconds. The needle will then be repositioned proximally to obtain a slightly larger burn in a similar fashion previously described. A similar approach will be utilized for the S1 lateral branch RF ablation between the S1 and S2 tubercles."
16320575|NCT04534829|Active Comparator|Fluoroscopic-Guided SIJ RFA|An anterior-posterior approach is used to identify the S1-S3 foramen. A 3-inch spinal needle would be used for marking. Local tissue freezing would be accomplished with Lidocaine 1% and a 30-G needle. An 18-G RF cannula will be positioned over the 12 o'clock position of the S1 foramen and a second cannula placed in the 2 o'clock or 10 o'clock position for the right and left respectively (4-5 mm distance between the cannula). A small amount of 1% lidocaine will be injected for comfort. A lateral projection is taken to ensure the needles are not placed into the foramen. The RF generator will be set to continuous bipolar RF ablation and heated to 80 degrees Celsius for 90 seconds. Then another 18-G RF cannula will be positioned at the 4 o'clock or 8 o'clock position (4-5 mm distance between the cannula) to achieve the second RF ablation. The third RF ablation will be performed with the RF cannula at the 6 o'clock position. An identical fashion is utilized at the S2 and S3 foramen.
16320576|NCT04534816|Experimental|Indocyanine Green|patients abdominal injuries and repair will be investigated using Indocyanine Green
16320577|NCT04534803|Experimental|BCG Vaccine|Participants randomized to the BCG arm will receive BCG vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
16320578|NCT04534803|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm.
16320579|NCT04534790|No Intervention|Not radiotherapy|control group
16320580|NCT04534790|Experimental|Radiotherapy|patientis with treatment with radiotherapy 1 Gy to Whole lung.
16320581|NCT04534777||Consciousness disorder patients|"The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.
~Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years."
16320582|NCT04534764|Experimental|TEST/CONTROL|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Test/Control)
16320583|NCT04534764|Experimental|CONTROL/TEST|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Control/Test)
16320584|NCT04534751|Experimental|Intervention Group- Clotting Factor Concentrates|"Fibryga + Octaplex (Fibrinogen + PCC)
~Fibrinogen Concentrate 4g (Fibryga) + Prothrombin Complex Concentrate 2000 IU (Octaplex) in the first and second massive hemorrhage protocol (MHP) packs."
16320585|NCT04534751|Active Comparator|Control Group: Standard FP transfusion|Frozen Plasma (FP)
16320586|NCT04534738|Experimental|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
16320587|NCT04534738|No Intervention|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
16320588|NCT04534725|Experimental|prophylaxis|"This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.
~Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections."
16320649|NCT04534257|Experimental|Angioplasty with SELUTION Sirolimus DCB|Subjects with infra-inguinal occlusive lesions will be treated with SELUTION Sirolimus DCB
16320650|NCT04534244|No Intervention|Control group|Treatment of the tributary veins by phlebectomy
16320651|NCT04534244|Experimental|Experimental group|Endovenous steam treatment of the tributary veins
16320589|NCT04534725|Experimental|Post-Exposure Prophylaxis|"This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days
~Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections."
16320590|NCT04534725|Experimental|Moderate COVID-19 infection|"This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks
~Participants will be followed for 60 days to assess effectiveness and safety."
16320591|NCT04534725|Experimental|Severe COVID-19 infection|"This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.
~Participants will be followed for 60 days to assess effectiveness and safety."
16320592|NCT04534712||PROGRESSION|Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
16320593|NCT04534712||NON PROGRESSION|Cohort B with those who improved by two points on the ordinal scale without any further progression
16320594|NCT04534699|Experimental|Hepatic Impaired|KBP-5074 0.5mg tablet orally, Single dose
16320595|NCT04534699|Experimental|Matched-control Healthy|KBP-5074 0.5mg tablet orally, Single dose
16320596|NCT04534686|Experimental|CogXergaming|CogXergaming based cognitive-motor balance training will be delivered to group A using the commercially available Wii-Fit Nintendo and a mouse in conjunction with cognitive training. All participants will undergo 18 sessions of training in a tapering manner for six weeks with 60-90 minutes of training per session, i.e., 3 sessions each week till the 6th week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 to 6 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
16320597|NCT04534686|Experimental|Matter of Balance Training|Participants in group B will undergo matter of balance training for 8 weeks (one session a week for 2 hours/day).
16320598|NCT04534673|Experimental|Intervention group|Pegylated interferon lambda + Standard of care treatment
16320599|NCT04534673|No Intervention|Control group|Standard of care treatment
16320600|NCT04534660|Experimental|Nasolabial Fold|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.
~The study treatment facial areas are the Right and Left nasolabial fold. The Treating Investigator will inject SMI-01 into the mid to deep dermis for correction of moderate to severe wrinkle and folds. The Treating Investigator will determine the appropriate volume of SMI-01 to be injected during initial and touch-up treatment(s)."
16320601|NCT04534660|Experimental|Cheek Augmentation|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.
~The midface constitutes the area of the face below the eyes and between the nose and the left or right ear. The study treatment facial areas are the Right and Left cheeks. The Treating Investigator will inject SMI-01 deeply (subcutaneous and/or supraperiosteal plane) for cheek augmentation to correct age-related volume deficiency in the midface, i.e., zygomaticomalar region, anteromedial cheek, and/or submalar region"
16320602|NCT04534634|Experimental|Experimental group|IFN-α combined with CAR T-cells therapy
16320603|NCT04534634|No Intervention|Control group|CAR T-cells therapy
16320604|NCT04534621||Brazilian chiropractors|A cross-sectional survey will be performed with this population (Brazilian chiropractors) to assess outcomes regarding what is the current impact and what measures they have implemented while facing the COVID-19 pandemic.
16320605|NCT04534608||Asymptomatic children w/out an underlying condition|
16320606|NCT04534608||Asymptomatic children with underlying condition(s)|
16320607|NCT04534608||Children with COVID-19 symptoms w/out an underlying condition|
16320608|NCT04534608||Children with COVID-19 symptoms with underlying condition(s)|
16320609|NCT04534595||Students attending SBHCs|The students enrolled in 5 schools with the school based health clinic implemented would be studied in terms of their experience during the COVID-19 pandemic.
16320610|NCT04534582|Experimental|HLX14 group|HLX14 are given subcutaneous injection at a single dose of 60 mg.
16320611|NCT04534582|Active Comparator|EU-Prolia® group|EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
16320612|NCT04534556|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
16320613|NCT04534556|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
16320614|NCT04534543|Other|Imaging|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
16320706|NCT04533828|Experimental|68Ga-FAPI-04 PET/CT scanning|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
16321242|NCT04530240||ERA-1 Group|Before the introduction of the MELD≥30 allocation scheme August 2010 - July 2014
16320615|NCT04534530||Experimental|"The experimental group systematic screening for ischemic heart disease will be identified during the screening period by performing at least one systematic screening examination, regardless of the frequency, for ischemic heart disease in patients. diabetics at very high cardiovascular risk, without known coronary heart disease, by at least one non-invasive functional cardiovascular exploration outside the resting ECG."
16320616|NCT04534530||Control|"The control group Absence of systematic screening for ischemic heart disease will be identified during the pre-selection period by the absence of a non-invasive functional cardiovascular exploration (examinations mentioned above) in T2D with very high cardiovascular risk, with no known coronary heart disease, apart from performing a resting ECG"
16320617|NCT04534517|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age will be recruited. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
16320618|NCT04534504|Experimental|SG-uncut JJB|For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
16320619|NCT04534504|Active Comparator|SG-JJB|For SG-JJB procedure, after SG was finished, the jejunum was transected 20-cm distal to Treiz ligament. After that, another 200-cm jejunum was measured and side-to-side jejunojejunal anastomosis was made. The anastomotic and mesenteric defects were closed by hand suture.
16320620|NCT04534491|Experimental|Oxytrol|Subjects decided to purchase Oxytrol.
16320621|NCT04534478|Active Comparator|Control Group|Prednisone 0.75mg / Kg / d 4 weeks; 0.5mg / Kg / d 4 weeks; 20mg / d 4 weeks; 10mg / d 6 weeks; 5mg / d 6 weeks (6m)
16320622|NCT04534478|Active Comparator|Experimental group|Prednisone 0.5mg / Kg / d 3 weeks, 20mg / day 3 weeks; 15mg / day 2 weeks; 10mg / day 2 weeks, 5mg / day 2 weeks and discontinue.
16320623|NCT04534465|Experimental|Dosing arm 1|MiraLAX Sachet (17g) + Flavor blend (2g mannitol total)
16320624|NCT04534465|Experimental|Dosing arm 2|MiraLAX Sachet (17g) + Flavor blend + additional 2g mannitol (4g mannitol total)
16320625|NCT04534465|Experimental|Dosing arm 3|MiraLAX Sachet (17g) + Flavor blend + additional 4g mannitol (6g mannitol total)
16320626|NCT04534465|Experimental|Dosing arm 4|MiraLAX Sachet (17g) + Flavor blend + additional 6g mannitol (8g mannitol total)
16320627|NCT04534465|Experimental|Dosing arm 5|MiraLAX Sachet (17g) + Flavor blend + additional 8g mannitol (10g mannitol total)
16320628|NCT04534452|Experimental|Phenylephrine HCl|Subjects have a documented and/or self-reported history of allergic rhinitis with nasal congestion for at least 2 years.
16320629|NCT04534439|Experimental|APX-115|Oral administration of APX-115 400mg, daily
16320630|NCT04534439|Placebo Comparator|Placebo|Oral administration of APX-115-matching placebo 400mg, daily
16320631|NCT04534426|Active Comparator|Postoperative topical arnica montana cream|In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
16320632|NCT04534426|Active Comparator|Postoperative topical mucopolysaccharide polysulfate cream|In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
16320633|NCT04534426|Other|Control group|In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
16320634|NCT04534400||Patients with SARS-CoV-2 infection|
16320635|NCT04534400||Patients with Postoperative hypoxemic respiratory failure|
16320636|NCT04534387|Experimental|Experimental Group|This group will receive the Spanish-Language Hearing Loss Toolkit materials.
16320637|NCT04534387|Active Comparator|Active Control Group|This group will receive standard of care Spanish language information from the American Speech-Language-Hearing Association (ASHA) Audiology Series
16320638|NCT04534374|Experimental|Resistance exercise|The experimental intervention is a session of resistance exercise described in the intervention section.
16320639|NCT04534374|Active Comparator|Stretching exercise|The active control intervention is a session of stretching exercise described in the intervention section.
16320640|NCT04534348||Control|All central-line-associated blood stream infections (CLABSI) diagnosed during the year previous the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
16320641|NCT04534348||CUROS|All central-line-associated blood stream infections (CLABSI) diagnosed during the year after the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
16320642|NCT04534309|Other|Self-Directed Weight Loss with year-long weight tracking|Written Weight Loss Material.
16320643|NCT04534309|Other|App-Directed Weight Loss with year-long weight tracking|Smart phone Weight Loss App.
16320644|NCT04534309|Other|Coach-Directed Weight Loss with year-long weight tracking|Behavioral Lifestyle Weight Loss Intervention with Smart phone Weight Loss App.
16320645|NCT04534296|Experimental|Early Mobilization Group (EM group)|Early mobilization will be performed in this arm. Critically ill children will be assessed for appropriate activity within 24 hours of intubation. When the safe criteria is met, early mobilization goals will be set according to the children's clinical conditions, developmental maturity, strength and endurance. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily.
16320646|NCT04534296|Active Comparator|Routine Care Group (RC group)|Routine care strategy without early mobilization will be performed in this arm. It includes the clinical status management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
16320647|NCT04534283|Experimental|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
16320648|NCT04534270|Experimental|Dapagliflozin treatment|
16320652|NCT04534218|Experimental|Experimental|"REGORAFENIB:
~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).
~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.
~METRONOMIC CHEMOTHERAPIES:
~Capecitabine: 625mg/m²/orally twice daily continuously for 6 months
~Cyclophosphamide: 50 mg per os, daily, for 6 months
~ASPIRIN:
~75 mg orally and daily until progression"
16320653|NCT04534205|Experimental|Part A (Safety run-In) - BNT113 + Pembrolizumab|Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
16320654|NCT04534205|Experimental|Part B (Randomized phase) - BNT113 + Pembrolizumab|BNT113 in combination with pembrolizumab.
16320655|NCT04534205|Active Comparator|Part B (Randomized phase) - Pembrolizumab monotherapy|Pembrolizumab monotherapy.
16320656|NCT04534192|Experimental|JADE balloon|Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C & D lesions in patients with chronic limb threatening ischemia.
16320657|NCT04534179|Experimental|Vacuum myofascial therapy and physical activity|The protocol would last 5 weeks, group received fifteen 30-minute sessions of vacuum myofascial therapy and fifteen sessions physical activity program similar to the control group per week.
16320658|NCT04534179|Active Comparator|Physical activity Program|The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 30 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
16320659|NCT04534153|Experimental|Fexofenadine without SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
16320660|NCT04534153|Experimental|Fexofenadine and 3 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
16320661|NCT04534153|Experimental|Fexofenadine and 30 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
16320662|NCT04534140|Experimental|HBKB Capsule|Experimental group participants will take one capsule of the HBKB botanical dietary supplement orally, once daily
16320663|NCT04534140|Placebo Comparator|HBKB Capsule Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
16320664|NCT04534127|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16320669|NCT04534101||Inpatient Subjects|Inpatients will be presented with an informed consent. If they sign the consent, they will then be given a VR headset pre- programmed with content that they may use for the duration of their stay. GI patients headsets will be collected when they are discharged. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford. Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered. Patient who are hospitalized for chronic pain will be allowed to take the VR headset home for month and be asked to return it at their followup outpatient visit.
16320670|NCT04534101||Outpatient Subjects|Outpatient: Patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient GI appointment will be presented with an informed consent. If they sign the consent, they will be given the VR headset to use prior to their procedure. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford Medicine Box.Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered.
16320671|NCT04534088|Active Comparator|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|The VR tool was an attention control and was not weight related.
16320672|NCT04534088|Experimental|Standard Behavioral Weight Loss plus Weight-Related VR app|The Intervention's VR tool was designed to enable practice of behavioral skills taught in weekly group meetings, including managing social and home environmental cues for eating and activity.
16320673|NCT04534075|Experimental|Additional dietary fiber through Psyllium husk|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. Altogether the fifteen capsules contains 5.5 g dietary fiber in psyllium husk.
16320674|NCT04534075|Placebo Comparator|Placebo (no additional dietary fiber)|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. The capsules contain placebo (maltodextrin) and have a similar look as in the experimental arm.
16320675|NCT04534062|Experimental|Group A|Participants in Group A will perform PNF D2 flexion and extension with free weights (PNF D2 FW) The intensity of exercise will be determined for each individual by using maximum repetition test (1 repetition maximum 1-RM). The intensity will be kept 50 % of the maximal load. 3 sets of PNF D2 FW Flexion (flexion-abduction and external rotation) and PNF D2 FW Extension (extension-adduction-internal rotation) respectively will be performed on each upper limb with 10 repetitions per set. All exercises will be performed with a rest interval of 30 seconds to 1 minute between the sets.
16320707|NCT04533815|Experimental|LOCK sleep intervention|Nursing home staff receive the LOCK sleep intervention training and thus provide to nursing home residents with dementia the LOCK sleep intervention
16320768|NCT04533399|Experimental|Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
16320769|NCT04533399|Placebo Comparator|Cohort 2 (HIV positive) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
16320676|NCT04534062|Experimental|Group B|Participants in this group will perform 3 sets of PNF D2 flexion (flexion-abduction and external rotation) and extension (extension-adduction-internal rotation) respectively with elastic bands after assessing the 1-RM test starting with a lightest resistance and gradually progressing to the higher level. Subsequently, 71% to 86% of 1-RM will be taken as a target range of the resistance for the training that will be applied through Elastic Resistance Band in accordance with values that are provided on the Thera-Band website. Moreover, each set will consist of 10 repetitions for both D2 flexion and Extension and a resting interval of 60 seconds between two consecutive sets. The procedure will be repeated for both limbs.
16320677|NCT04534062|Experimental|Group C|The participants in the Group C or control group will perform the PNF D2 flexion and extension without any resistance. Three sets consist of 10 repetitions of each pattern for both upper limbs will be performed with an interval of 60 seconds between two consecutive sets.
16320678|NCT04534049|Experimental|Intensive strength training (IST)|
16320679|NCT04534049|Experimental|Strength Endurance training (SET)|
16320680|NCT04534049|Other|Flexibility training (FT)|
16320681|NCT04534036|Active Comparator|Multi-Strain Synbiotic (PDS-08)|PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
16320682|NCT04534036|Placebo Comparator|Placebo|Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
16320683|NCT04534023|Experimental|trial group|
16320684|NCT04534023|Placebo Comparator|control group|
16320685|NCT04534010|Experimental|NACgraft patients|uni- or bilateral engraftment surgery will be performed
16320686|NCT04533997|Active Comparator|Intravenous furosemide|
16320687|NCT04533997|Experimental|Hypertonic saline solution plus intravenous furosemide|
16320688|NCT04533984|Experimental|Intervention with 28-day self-injection of Forteo|The active study medication FORTEO is recombinant human parathyroid hormone analog, [rhPTH]. The study medication Forteo (teriparatide [rDNA origin] injection) (Eli-Lilly, Indiana, USA), will be self-administered via a blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20 mcg dose of the medication daily for 28 days. Following this period the participant will receive standard physical therapy until full-return to duty.
16320689|NCT04533984|Placebo Comparator|Placebo with 28-day self injection of inactive substance|Participants will self-administered a placebo substance normal in a replica, blinded, injection pen via in the abdominal wall or thigh daily for 28 days. Following this period the participant will receive standard physical therapy until full-return to duty.
16320690|NCT04533971|Experimental|WBC group|"Criteria
~documented diagnosis of MS,
~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3
~no contraindications for WBC treatments found in the medical examination
~no other serious chronic diseases identified that may affect the results of the tests carried out
~readiness to participate in daily WBC
~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
16320691|NCT04533971|No Intervention|Control Group|"Criteria
~documented diagnosis of MS,
~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3
~no contraindications for WBC treatments found in the medical examination
~no other serious chronic diseases identified that may affect the results of the tests carried out
~readiness to participate in daily WBC
~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
16320692|NCT04533958|Experimental|HypnoVR Arm|During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
16320693|NCT04533958|No Intervention|Control Arm|Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)
16320694|NCT04533945|Other|FreeStyle Libre Device|Inpatients admitted to the medical-surgical units that are eligible for the trial will have the FreeStyle Libre device will be placed by the inpatient diabetes team at the discharge and glucose log will be obtained in 2 weeks followed by Hba1c in 3 months.
16320695|NCT04533932||Elastography|
16320696|NCT04533919||Basic science (dorsal root ganglia collection)|Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
16320697|NCT04533906|Experimental|Carrageenan|Subjects sucking carageenan containing lozenge
16320698|NCT04533893||BLS Training Group (Students without prior BLS Training)|"After completing training mode of the serious game module, participants were asked to choose the self-test mode of the serious game module.
~the participants were asked to practice their hands-on skills in simulation center under the supervision of educators. After familiarization with the system using self-training mode, the participants were asked to proceed the BLS Hands-on training app with the simulator under the supervision of the educator.
~Conventional OSCE score of each participant was obtained by watching the recorded sessions of BLS trainings."
16320699|NCT04533880|Placebo Comparator|Control|The control group will receive autologous bone obtained from the BTBPB graft harvest
16320700|NCT04533880|Active Comparator|Autologous Bone + DBM|Autologous bone plus demineralized bone matrix
16320701|NCT04533880|Active Comparator|Autologous Bone + Calcium Phosphate Cement|Autologous bone plus calcium phosphate cement
16320702|NCT04533867||Ondansetron|In Group B (n = 50): Intravenous injection of ondansetron 0.1 mg/kg diluted up to 5 mL with normal saline solution in a maximum dose of 8 mg is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
16320703|NCT04533867||Palonosetron|The antiemetics used are palonosetron in Group A (n = 50): Intravenous injection of Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
16320704|NCT04533841|Active Comparator|Misoprostol + propranolol|Patient who receive misoprostol then after 30minutes receive propranolol
16320705|NCT04533841|Placebo Comparator|Misoprostol + placebo|Pt who will receive misoprostol then after 30minutes receive placebo
16320767|NCT04533399|Placebo Comparator|Cohort 1 (HIV negative) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
16320708|NCT04533789|Experimental|the control group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
16320709|NCT04533789|Experimental|virtual reality|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min.
16320710|NCT04533789|Experimental|Task oriented|Group 3 the study group received the same physical therapy program 30 min. plus task oriented training for 30 min.
16320711|NCT04533776|Experimental|PEER-INTERACTION GROUP SUPPORT|"All the sessions of the research took place in a classroom in the hospital. The sessions lasted an average of 90 minutes with two 45-minute sections. During the break, which lasted about 20 minutes, gluten-free products were offered. During the break, adolescents were given the opportunity to chat and interact with each other.
~Peer interactive group support was implemented for 3 months with an interval of one week. A total of 6 sessions were held with the study group. Adolescents in the study group were contacted by phone before each session. The day before the session, a text message was sent to all participants informing the location and time of the meeting. The contents of the first and second sessions in relation to the study were created beforehand. However, contents of the third, fourth, fifth and sixth sessions were prepared after the first two sessions."
16320712|NCT04533776|Experimental|routine health care- control group|Peer interactive group support was not provided to the control group.
16320713|NCT04533763|Experimental|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
16320714|NCT04533763|Active Comparator|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
16320715|NCT04533750|Experimental|Treatment (peposertib, IMRT)|Patients receive peposertib PO QD and undergo IMRT daily Monday-Friday for 7 weeks in the absence of disease progression or unacceptable toxicity.
16320716|NCT04533737|Experimental|Arm 1 (brodalumab + dummy 1)|"Participants receive:
~Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.
~Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
16320717|NCT04533737|Active Comparator|Arm 2 (guselkumab + dummy 2)|"Participants receive:
~Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.
~Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
16320718|NCT04533724|Experimental|Study group|Recruit 30 outpatient/inpatient schizophrenia patients (dominant negative symptoms) in Shanghai Mental Health Center .
16320719|NCT04533724|No Intervention|Healthy control group|15 cases of normal healthy people (control group) with similar eating habits and ages in the same region were matched with study group.
16320720|NCT04533711|Experimental|OA-PCP|Participants assigned to the OA-PCP intervention will receive an initial physical activity (PA) coaching call then, 5 more calls over the course of 12 months. Participants, if they agree, will also receive monthly check-in emails between phone calls.
16320721|NCT04533711|Placebo Comparator|Attention Control|Participants assigned to the Attention Control group will receive the same number of phone calls over the course of 12 months, focused on understanding osteoarthritis (OA) and current information on treatment options. Participants, if they agree, will also receive monthly check-in emails between phone calls.
16320722|NCT04533698||Resternotomy|
16320723|NCT04533698||No resternotomy|
16320724|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
16320725|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) a pre-commitment prompt
16320726|NCT04533685|Active Comparator|Direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
16320727|NCT04533685|Active Comparator|Direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling
16320728|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment + Pre-Appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
16320729|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) a pre-commitment prompt
16320730|NCT04533685|Active Comparator|No direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
16320731|NCT04533685|Active Comparator|No direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling for a flu vaccine appointment
16320732|NCT04533685|No Intervention|Control Arm|Participants will not receive any reminder/recall messages regarding influenza vaccination via the patient portal or other intervention components
16320733|NCT04533672|Experimental|Single study arm|
16320734|NCT04533659|Active Comparator|Control group|This group will receive 4-week diabetes nutrition education with digital self-monitoring for diet and blood glucose.
16320735|NCT04533659|Experimental|Intervention group|This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
16320736|NCT04533646|Experimental|Fixed Dosing, Followed by Carbohydrate Counting|Dosing of premeal insulin with fixed doses
16320737|NCT04533620|Active Comparator|Standardized CIRT|Patients will receive standardized CIRT with a dose of 63 GyE/21 fx.
16320738|NCT04533620|Experimental|Individualized CIRT|A previously predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
16320739|NCT04533607|Active Comparator|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
16320740|NCT04533607|No Intervention|Waitlist control|Services as usual.
16320741|NCT04533594|Experimental|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
16320742|NCT04533581|Experimental|ME-401|
16320743|NCT04533568|Experimental|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
16320744|NCT04533568|Experimental|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
16320745|NCT04533555|Experimental|Universal genetic testing|Detection of genetic risk using a broad panel of cancer risk genes.
16320746|NCT04533555|Active Comparator|Standard|We will refer a subset of patients who meet guideline criteria based on age, cancer type, and family history, for genetic counseling and testing.
16320747|NCT04533542||Arm I (3 video or telephone conferences)|Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
16320748|NCT04533542||Arm II (2 video or telephone conferences)|Participants attend up to 2 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on a nicotine-free condition and 3 randomly assigned conditions (combinations of carrier concentration and nicotine form).
16320751|NCT04533516|Experimental|Manual Therapy additional over Inspiratory muscle training|Participants receive manual therapy protocol session three times a week for 12 weeks. The manual therapy protocol session lasts 30 minutes and included of the following manual therapy techniques: suboccipital decompression, gliding of the cervical vertebral articulations in the anterior/posterior direction, myofascial release of sternocleidomastoid and trapezius muscles, gliding of sternoclavicular joint in the anterior/posterior direction, myofascial release of intercostal muscles and paravertebral muscles, diaphragmatic release, rib raising, mobilization of scapulothoracic joint, and gliding of the thoracic vertebral articulations in the anterior/posterior direction. And all participants receive inspiratory muscle training.
16320752|NCT04533516|Active Comparator|Inspiratory Muscle Training|Participants receive only inspiratory muscle training by using Threshold Inspiratory Muscle Training device. Training load is 40% of the measured maximum inspiratory pressure, weekly. Participants receive inspiratory muscle training session for 30 min-per day, 7 days per week, for 12 weeks.
16320753|NCT04533503||HF-OCT imaging|Enrolled subjects who meet lesion-specific eligibility criteria and undergo HF-OCT imaging
16320754|NCT04533490|Experimental|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 (200mg ivgtt q3w) from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
16320755|NCT04533477|Experimental|Routine surgery with reconstructing FCS|The participants undergo FCS reconstruction during the routine standardized surgery.
16320756|NCT04533477|Active Comparator|Routine surgery|The participants undergo routine standardized surgery.
16320757|NCT04533464|Experimental|MultiStem|
16320758|NCT04533464|Placebo Comparator|Placebo|
16320759|NCT04533451|Experimental|Group A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16320760|NCT04533451|Experimental|Group B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV per institutional guidelines on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16320763|NCT04533425||Patients with syncope|Patients who present to the ED with syncope
16320764|NCT04533412|Experimental|Targeted self-management barrier support|Intervention group - Targeted self-management barrier support, home-based pulmonary rehabilitation, and emergency medication with community health workers
16320765|NCT04533412|Active Comparator|Guided COPD education|Control group - Guided COPD education with a COPD educator
16320766|NCT04533399|Experimental|Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
16320770|NCT04533386|Experimental|BSMM|Intervention arm will include motivational interview-consistent discussion with a peer change agent and use of a mobile application to record and review sexual risk behaviors with participants.
16320771|NCT04533373|Experimental|Neurotized Patients|Neurotization will be performed at the time of reconstruction.
16320772|NCT04533373|No Intervention|Non-Neurotized Patients|No Neurotization will be performed at the time of reconstruction.
16320773|NCT04533360||Community Cohort 1|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
16320774|NCT04533360||Community Cohort 2|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
16320775|NCT04533360||Healthcare Provider Cohort 1|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
16320776|NCT04533360||Healthcare Provider Cohort 2|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
16320777|NCT04533347|Active Comparator|Tafenoquine|Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10
16320778|NCT04533347|Placebo Comparator|Placebo|Placebo two tablets 1x/day on Days 1,2,3 and 10
16320779|NCT04533334||Pediatric|FOB measurement of the distance between carinae and right upper lobe and carinae and labium oris in paediatric population
16320780|NCT04533321|Other|Patients genotyped positive for MET-N375S polymorphism|will be treated with orally administered daily dose of afatinib (Gilotrif®) in a fasting state (1 hour before or 2 hours after meals).
16320781|NCT04533308|Experimental|VR intervention|Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).
16320782|NCT04533308|No Intervention|Control|Patients in the control group will not receive any psychological interventions.
16320783|NCT04533295|Experimental|Acupuncture and IVF|Acupuncture and IVF
16320784|NCT04533295|Sham Comparator|Sham acupuncture and IVF|Sham acupuncture and IVF
16320785|NCT04533282||Acute IHD with STEMI and PCI|"Acute ischemia in IHD is represented by the recruitment of patients presenting with ST-elevation myocardial infarction (STEMI patients) to the Meilahti Cardiac Care Unit (CCU) and admitted for Percutaneous Coronary Intervention (PCI) revascularization. The informed consent and blood samples from these patients will be collected during the first 72 hours after PCI, during their stay either in CCU or medical ward.
~Inclusion of this cohort to the IHD-EPITRAN opens the possibility to identify novel circulative epitranscriptomic biomarkers representing acute ischemic myocardial damage as well as particularly insightful comparison of acute and chronic states of IHD when compared against the second study cohort."
16320786|NCT04533282||Chronic IHD and elective CABG|"The second study cohort composes of patients with stable IHD phenotype with angina pectoris or exertional dyspnea provoked by either moderate or severe physical exertion, corresponding either NYHA or CCS classes II to IV, respectively, destined to undergo an elective coronary artery bypass grafting (CABG) operation as method for revascularization. The duration of stable symptoms must exceed a month in order to exclude acute events.
~The obtained blood samples from this main cohort of the IHD-EPITRAN project provides insightful overview into the circulation-borne RNAs' epitranscriptomic landscape for identification of novel biomarkers for stable IHD. Furthermore, availability of right atrial appendage tissue pieces following CABG surgery from this patient cohort gives invaluable organ-specific information in its own right as well as a crucial reference point, against of which the alterations observed in circulation can be compared."
16320787|NCT04533282||Elective aortic valve stenosis (AVS) replacement therapy|"The third study cohort consists of patients admitted for surgical (open heart surgery) valve replacement due to aortic valve calcification and critical stenosis with no IHD as a comorbidity. As to elective CABG patients, here patients are also required to be either moderately or severely symptomatic equaling NYHA or CCS II to IV classes, respectively.
~This cohort will provide insights into how the pathological pressure overloaded left ventricular remodelling is reflected to the epitranscriptomes of the supposedly relatively spared right atrial appendage tissue and blood RNA. Comparison of this data to the data of the first two IHD study cohorts opens the window to assess the possible differences for these differing pathologies, thus functioning as an active control cohort."
16320788|NCT04533282||IHD-negative healthy controls verified by coronary CT|The fourth study cohort shall consist of patients referred to Meilahti Heart Unit's Coronary Artery Computerised Tomography (CT) Angiogram imaging in order to investigate the possibility of atherosclerotic coronary artery disease (i.e. IHD) behind symptoms such as pressing chest pain (i.e. angina pectoris) or abnormal dyspnea provoked by exertion. Based on the results from CT angiogram, only those patients' blood samples are selected for further study that show negative results for IHD (no visualisation of either atherosclerotic strands or plaques in coronary arteries). This patient cohort functions as a critical IHD-healthy control group in the IHD-EPITRAN project (i.e. negative control).
16320789|NCT04533269|Experimental|Active|Arnica montana and Ledum palustre infused Pad
16320790|NCT04533269|Placebo Comparator|Placebo|Pad (Matching appearance with Active)
16320791|NCT04533243|Experimental|2.5ug/h transdermal fentanyl|
16320792|NCT04533243|Active Comparator|Oral immediate-released morphine|
16320793|NCT04533230|Experimental|Educational intervention with prescription feedback|The manager and physicians at each intervention center will participate in a brief educational intervention about benzodiazepines and benzodiazepine-like hypnotics and receive 12 months of targeted feedback on prescription of these drugs. The education will cover national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics.
16320794|NCT04533230|Active Comparator|Information on guidelines|The manager and physicians at each center in the active control group will receive written information on national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics. These centers will not receive the onsite educational intervention or 12 months of targeted prescription feedback.
16320836|NCT04532931|Experimental|Arm E|SOC plus Sofosbuvir/daclatasvir
16320837|NCT04532918|Experimental|Verinurad + allopurinol|The subjects will receive single oral dose of verinurad 7.5 mg and allopurinol 300 mg under fasted condition.
16321270|NCT04530032|Experimental|TBI KD|TBI subjects on a ketogenic diet
16320795|NCT04533230|No Intervention|No active intervention: standard care|The manager and physicians at each primary health care center in the passive control group will receive no active intervention. The passive control group will consist of primary health care centers that are not actively participating in the study. Data will be gathered from regional registers and databases. Thus, there will be no need to contact or communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
16320796|NCT04533217|Active Comparator|Vertebroplasty|Patients treated with vertebroplasty in addition to regular medical treatment.
16320797|NCT04533217|No Intervention|Regular treatment|Patients treated with regular medical treatment.
16320798|NCT04533204|Experimental|Mnemonic strategy training|Training using mnemonic strategies
16320799|NCT04533204|Active Comparator|Spaced retrieval training|Training using spaced retrieval
16320800|NCT04533178|Active Comparator|Restriction of sports activities|No sports during the 6 week treatment period
16320801|NCT04533178|Experimental|Restriction of sports activities and soft spinal brace|No sports and use of a soft spinal brace 16 hours per day during the 6 week treatment period
16320802|NCT04533165|Experimental|Virtual exercise program|This arm will receive the virtual exercise program.
16320803|NCT04533139||Vaccine, pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
16320804|NCT04533139||Vaccine, post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
16320805|NCT04533139||Vaccine, not receiving transplant|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
16320806|NCT04533113|Experimental|VitreBond LC|VitreBond LC used as a liner after selective carious tissue removal.
16320807|NCT04533113|Experimental|Biodentine|Biodentine used as a liner after selective carious tissue removal.
16320808|NCT04533113|Experimental|Theracal|Theracal used as a liner after selective carious tissue removal.
16320809|NCT04533087||Candida blood stream infection|
16320810|NCT04533087||Aspergillosis|
16320811|NCT04533087||Rare mold infections|
16320812|NCT04533074|Experimental|Single-visit regeneration protocol|
16320813|NCT04533074|Active Comparator|Multiple-visits regeneration protocol|
16320814|NCT04533061||Lung Transplant, Vaccine|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
16320815|NCT04533061||Healthy Control, Vaccine|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
16320816|NCT04533048|Experimental|MW33|
16320817|NCT04533048|Experimental|Placebo|
16320818|NCT04533035||Single cohort|30 patients undergoing hallux valgus surgery
16320819|NCT04533022|Experimental|C21|
16320820|NCT04533009|Active Comparator|tramadol/acetaminophen|Tramadol-paracetamol two tablets 37,5mg/325mg twice daily up to five days for patients undergoing spinal surgery
16320821|NCT04533009|Placebo Comparator|placebo|Placebo two tablets twice daily up to five days for patients undergoing spinal surgery
16320822|NCT04532996|Experimental|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 20-24 sessions.
16320823|NCT04532983|Active Comparator|fixation group|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic),
16320824|NCT04532983|Active Comparator|non fixation group|group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.
16320825|NCT04532970|Placebo Comparator|Standard|"Eligible patients will be randomized to one of the treatment arms, which will involve 5 phone-delivered counseling sessions over a 9 week treatment phase. SC will be based on the 2008 PHS Clinical Practice Guideline (Fiore et al., 2008) and on SC in our ongoing two-site trials (R01DA025078; R01CA165001) This intervention arm will begin with a pre-quit session designed to help participants prepare for their Target Quit Day (TDQ). The TQD session will occur at week 1. The SC arm will focus on self-monitoring, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, relapse prevention, and homework. The pre-quit session prepares participants for their TQD by reviewing their experience with quitting, beliefs about smoking/quitting, perceived barriers to cessation, and creating a quit plan to identify smoking triggers and implement alternative strategies to manage those triggers without smoking."
16320826|NCT04532970|Experimental|BAPS|Key components of BAPS include activity monitoring and rewarding activity scheduling, assessment of personal goals and values, assessment and altering of avoidance behavior and other maladaptive coping strategies, and contingency management. BAPS focuses on reducing stress pile-up and loss of pleasure that accompanies the cessation process and on identifying and establishing environmental/social changes to promote abstinence. BAPS addresses smoking as a behavior that prevents and restricts opportunities for contact with healthy rewarding behaviors. These changes are achieved through altering daily routines previously associated with smoking in ways that increase pleasure and mastery across life domains, reducing rumination, and increasing behavioral skills to prevent return to smoking as a means of avoiding stressors.
16320827|NCT04532957|Experimental|Group 1|Multiple doses 100mg Healthy subjects receive multiple doses of KBP-7072 (100mg) or Placebo (100mg) QD capsules daily for a total of 10 days
16320828|NCT04532957|Experimental|Group 2|Multiple doses 200mg Healthy subjects receive multiple doses of KBP-7072 (200mg) or Placebo (200mg) QD capsules daily for a total of 10 days
16320829|NCT04532957|Experimental|Group 3|Multiple doses dose tbd Healthy subjects receive multiple doses of KBP-7072 (tbd) or Placebo(tbd) QD capsules daily for a total of 10 days
16320830|NCT04532944|Other|patients with MS|20 relapsing-remitting and 20 progressive MS patients
16320831|NCT04532944|Other|healthy controls|15 age- and sex-matched healthy controls
16320832|NCT04532931|Placebo Comparator|Arm A|Paracetamol (SOC)
16320833|NCT04532931|Experimental|Arm B|SOC plus Artesunate-Amodiaquine
16320834|NCT04532931|Experimental|Arm C|SOC plus Pyronaridine-Artesunate
16320835|NCT04532931|Experimental|Arm D|SOC plus Favipiravir plus Nitazoxanide
16320838|NCT04532918|Experimental|Verinurad + allopurinol + cyclosporine|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and cyclosporine 600 mg under fasted condition.
16320839|NCT04532918|Experimental|Verinurad + allopurinol + rifampicin|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and rifampicin 600 mg under fasted condition.
16320840|NCT04532905|Sham Comparator|without previous strength training experience|control (untrained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
16320841|NCT04532905|Experimental|with previous strength training experience|experimental (trained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
16320842|NCT04532892|Placebo Comparator|Placebo|Morning and night tablets with no active ingrédients. Morning and night tablets are different.
16320843|NCT04532892|Experimental|Dietary supplément|Morning and night tablets with active ingrédients. Morning and night tablets are different.
16320844|NCT04532879|Experimental|All patients enrolled|"Bowel habits before and after the HygiRelief procedure will be assessed.
~Samples will be sent for microbiome evaluation."
16320845|NCT04532866|Experimental|Isolation and Confinement|Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.
16320846|NCT04532866|No Intervention|Control Group|Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.
16320847|NCT04532853||COPD patients|
16320848|NCT04532840|Active Comparator|Group A: (control group)|This group includes 30 patients will receive routine medical treatment and routine physical therapy as (Exercising, Positioning and splinting, Pressure Therapy and Massage).
16320849|NCT04532840|Experimental|Group B: (Study group)|This group includes 30 patients will receive cryotherapy (at least 10 minutes at -14 degree , 2 sessions per week , for 10 weeks ) in addition to routine medical and physical therapy treatment.
16320850|NCT04532827|Experimental|Case formulation with web-program|"The intervention will start with two video meetings with a psychologist to build up and present an individual case formulation, based on behavioral analysis, and to build up a shared decision of individual goals for the web program. The intervention continues with web program consisting of six manualized web-based modules, each at two-week intervals based on relational frame theory (RFT) and acceptance and commitment therapy (ACT).
~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
16320851|NCT04532827|No Intervention|Treatment as usual|"Treatment as usual includes all the routine care that individual receives when he or she is presenting his or her symptoms at the primary or the occupational health care unit (corresponds primary care level treatment) or other unit that recommends the study for the participant. In practice, TAU may vary between the study participants based on their individual needs e.g. treatments for co-morbid somatic diseases or psychiatric disorders that this study will not interfere.
~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
16320852|NCT04532814|Other|Lean|Control
16320853|NCT04532814|Experimental|Obese|
16320854|NCT04532801|Experimental|kisspeptin-10|kisspeptin infusion
16320855|NCT04532801|Placebo Comparator|placebo|placebo
16320856|NCT04532788|Active Comparator|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.
~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
16320857|NCT04532788|Active Comparator|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.
~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
16320858|NCT04532775|Other|group C|"This study was conducted on 100 patients. Patients were divided according to the injected drugs into two equal groups (50 patients each):
~1- Group (C): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of normal saline (0.9 %) with a total volume of 4 ml."
16320859|NCT04532775|Other|group M|2- Group (M): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of preservative free magnesium (200 mg) with a total volume of 4 ml. Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol). Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
16320860|NCT04532762|Experimental|Coldamaris akut|One puff (140µl) into each nostril
16320861|NCT04532762|Placebo Comparator|Placebo|One puff (140µl) into each nostril
16320864|NCT04532736|Experimental|Methotrexate|10 mg Emthexate, PO, once a week during 8 weeks
16320865|NCT04532736|Active Comparator|Methylprednisolone|8 mg/day Prednol, PO, for 8 weeks
16320866|NCT04532736|Active Comparator|Control|200 mcg/day, intranasal mometasone furoate, for 8 weeks
16320867|NCT04532723|Experimental|ExoAtlet II|Safety/feasibility of utilizing the ExoAtlet II in a clinical setting with a group of individuals with SCI
16320868|NCT04532710|Placebo Comparator|Placebo low dose|Application of 2 placebo eye drops once daily for 8 days.
16320869|NCT04532710|Active Comparator|Tacrosolv low dose|Application of 1 Tacrosolv eye drop once daily for 8 days.
16320870|NCT04532710|Placebo Comparator|Placebo high dose|Application of 1 placebo eye drop once daily for 8 days.
16320871|NCT04532710|Active Comparator|Tacrosolv high dose|Application of 2 Tacrosolv eye drops once daily for 8 days.
16320872|NCT04532697|Active Comparator|Chinese Medicine|Uncaria Rhynchophylla (Gou-Teng)
16320873|NCT04532697|Placebo Comparator|Placebo treatment|Placebo
16320874|NCT04532684|Active Comparator|Duloxetine|33 patients received 60 mg/day of duloxetine HCL orally for 12 weeks
16320875|NCT04532684|Active Comparator|Pregabalin|33 patients received 300 mg/day of pregabalin orally for 12 weeks
16320876|NCT04532671|Other|Poly ether ether ketone (PEEK)|Poly ether ether keton (PEEK) is acknowledged as a high-performance polymer in engineering & medical applications due to its favorable mechanical and chemical properties.
16320877|NCT04532671|Other|CADCAM poly ether ether ketone (PEEK)|PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks.
16320878|NCT04532671|Active Comparator|indirect resin composite|In CAD/CAM resin composite blocks, properties of flexibility and ease of use similar to that of resin composite are combined with durability and surface finish properties similar to that of ceramics
16320879|NCT04532658|Experimental|Intervention arm|Surgeons randomly assigned to the intervention arm
16320880|NCT04532658|No Intervention|Control arm|Surgeons randomly assigned to the control arm
16320881|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
16320882|NCT04532619|Experimental|Intervention|6 weeks of Fathering Through Change videos and 3 individual coaching calls.
16320883|NCT04532619|No Intervention|Control|Links to parenting websites
16320884|NCT04532606|Experimental|Remimazolam group|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain Bispectral Index (BIS) value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
16320885|NCT04532606|Active Comparator|Propofol group|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
16320886|NCT04532593|Experimental|Stem cell group|
16320887|NCT04532593|Placebo Comparator|Control|
16320888|NCT04532580||AI- Aided performances|
16320889|NCT04532580||AI- Unaided performances|
16320890|NCT04532567|Experimental|GLPG1205 dose A|Participants will receive a single dose with dose A of GLPG1205 on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
16320891|NCT04532567|Placebo Comparator|Placebo dose A|Participants will receive a single dose placebo on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
16320892|NCT04532567|Experimental|GLPG1205 dose B|Participants will receive 14 days q.d. dosing with dose B of GLPG1205 on Days 1 to 14.
16320893|NCT04532567|Placebo Comparator|Placebo dose B|Participants will receive 14 days q.d. dosing placebo on Days 1 to 14.
16320894|NCT04532554|Experimental|Growth hormone|Recombinant GH will be used for those patients
16320895|NCT04532554|Placebo Comparator|Placebo|Saline will be used
16320896|NCT04532541||Patients with childhood onset SLE|Participants in this group were derived from patients diagnosed with SLE at an age of less than 18 years old, and these patients were hospitalized in our center. Peripheral blood was collected from the patient and their biological parents for gene analysis to obtain the overall incidence of monogenic lupus in the cohort.
16320897|NCT04532528||Patients receiving standard of care (SOC)|(without advanced educational Intervention)
16320898|NCT04532528||Patients receiving SOC with advanced educational intervention|
16320900|NCT04532502||Study group|All female assistants in anesthesia
16320901|NCT04532489|Other|Group 1|These subjects, 6 planned (3 male, 3 female), will be to obtain normal tissue distribution of [18F]NP-59 and confirm calculated radiation dosimetry and optimal uptake time.
16320902|NCT04532476|Experimental|Laser treated side|Group of 22 participants whose mucose around right maxillary permanent molar was treated with laser.
16320903|NCT04532476|Placebo Comparator|Placebo side|Placebo side was LEFT side.It was treated the same way as right with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so participants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.
16320904|NCT04532463||Amphotericin B,Flucytosine, Fluconazole|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
16320905|NCT04532424|Experimental|Targeting insistence on sameness|
16320906|NCT04532424|Experimental|Targeting stereotyped motor behaviors|
16320907|NCT04532411||Pre-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing prior to implementation of the Hexapod personal protective booths.
16320908|NCT04532411||Post-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing after implementation of the Hexapod personal protective booths.
16320909|NCT04532398|Other|Swallowing test|
16320910|NCT04532385|Experimental|GTE|Green tea extract, 400 mg every 12 hours for 12 weeks
16320911|NCT04532385|Placebo Comparator|Placebo|Calcined magnesia, 400 mg every 12 hours for 12 weeks
16320912|NCT04532372|Experimental|Phase I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Patients may receive SOC drugs in addition to leflunomide.
16320913|NCT04532372|Experimental|Phase II Arm I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
16320914|NCT04532372|Placebo Comparator|Phase II Arm II (placebo, SOC)|Patients receive placebo PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
16320915|NCT04532346|Experimental|Hydroxychloroquine|Hydroxychloroquine in a dose of 10 mg/kg*d, p.o., bid for 12 months. The maximum daily dose is 400mg.
16320916|NCT04532346|No Intervention|control|control group which do not take hydroxychloroquine for treatment.
16320917|NCT04532333|Experimental|Bivalirudin|Bivalirudin at full dose Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
16320918|NCT04532333|Active Comparator|Heparin|Heparin first dose at 0.6mg/kg(75U/kg) Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
16320919|NCT04532307|Experimental|Standard of Care SOC|Youth friendly services at Isisekelo Sempilo clinics
16320920|NCT04532307|Experimental|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples for gonorrhea, chlamydia and trichomonas
16320921|NCT04532307|Experimental|Peer-support (Thetha-Nami)|Peer support and needs assessment from an area-based peer navigator
16320922|NCT04532307|Experimental|SOC + SRH + peer-support|Combination of all arms
16320923|NCT04532294|Experimental|BGB-DXP593: Dose Level A|Participants will receive BGB-DXP593 10 mg/kg on Day 1
16320924|NCT04532294|Experimental|Placebo: Dose Level A|Participants will receive placebo to match (PTM) BGB-DXP593 10 mg/kg on Day 1
16320925|NCT04532294|Experimental|BGB-DXP593: Dose Level B|Participants will receive BGB-DXP593 30 mg/kg on Day 1
16320926|NCT04532294|Experimental|Placebo: Dose Level B|Participants will receive placebo to match (PTM) BGB-DXP593 30 mg/kg on Day 1
16320927|NCT04532294|Experimental|BGB-DXP593: Dose Level C|BGB-DXP593 at a higher dose determined from the two previous dose levels on Day 1
16320928|NCT04532294|Experimental|Placebo: Dose Level C|Placebo to match (PTM) BGB-DXP593 at a higher dose determined from the two previous dose levels on Day 1
16320929|NCT04532281|Experimental|Administration of Murine CD19 CAR T-cells|
16320930|NCT04532268|Experimental|Administration of Humanized CD19 CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16320931|NCT04532242|Experimental|fMRI Participants|Participants will be scanned in an fMRI session lasting approximately 45-50 minutes and will be shown negative images for which they will have to take on a cognitive reappraisal tactic. All participants will be taken through the scanner with the same reappraisal protocol for each participant.
16320932|NCT04532229|Experimental|Experimental|Nimotuzumab+CRT(concurrent IMRT and TMZ)
16320933|NCT04532216|Experimental|Study group|
16320934|NCT04532216|Other|Control group|
16320935|NCT04532203|Experimental|Administration of CAR T-cells|Dose escalation follows the standard 3+3 doseescalation design. A total of 3 dose levels are set for subjects.
16320936|NCT04532190|Experimental|Active rTMS|Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
16320937|NCT04532190|Sham Comparator|Sham rTMS|For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
16320938|NCT04532177|Experimental|Active|
16320939|NCT04532164|Experimental|Photoallergic reaction test|During the Induction Phase, participants received Butenafine HCl 1% on the treated irradiated skin test site followed by UV irradiation and on the treated non-irradiated skin test site without UV radiation, two times per week for three consecutive weeks. After 10 days of Rest Phase, during the Challenge Phase, participants received same procedure on the two virgin sites (treated sites) as in Induction Phase, and two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Test sites were evaluated at 24, 48, and 72 hours after irradiation using the same grading scale used during Induction Phase.
16320940|NCT04532151|Other|Early SSc group|"Patients with SSc according to the criteria ACR / EULAR 2013, without scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements.
~Patients will be reassessed at M24. The participation of each subject will be 24 months, with two visits of one hour.
~The clinical data corresponding to the current practice will be collected in a study specific case report form."
16320941|NCT04532151|Other|Established SSc group|"Patients with SSc according to criteria ACR / EULAR 2013 with scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements. The participation of each subject will be one hour.
~The clinical data corresponding to the current practice will be collected in a study specific case report form."
16320942|NCT04532151|Other|Control group:|"Patient without systemic sclerosis Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The participation of each subject will be one hour.
~The clinical data corresponding to the current practice will be collected in a study specific case report form."
16320943|NCT04532138|Active Comparator|C-MAC Video laryngoscope awake intubation|In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using Videolaryngoscope (C-MAC) with Hyperangulated blade (D-blade) Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied.
16321074|NCT04531254||Masking at all times|Children in this group will be asked to wear a face mask/covering in the classroom and common areas during the simulation
16320944|NCT04532138|Experimental|VS-CMAC Rigid Fiberoptic Stylet awake intubation|"In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
~Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied."
16320945|NCT04532125|Experimental|ARGX-117 IV|Subjects receiving ARGX-117 IV
16320946|NCT04532125|Placebo Comparator|Placebo IV|Subjects receiving placebo IV
16320947|NCT04532125|Experimental|ARGX-117 PH20 SC|Subjects receiving ARGX-117 PH20 SC
16320948|NCT04532125|Placebo Comparator|Placebo PH20 SC|Subjects receiving placebo PH20 SC
16320949|NCT04532112|Experimental|Intubated Subjects with the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by anesthesiologists trained in device use.
16320950|NCT04532112|Placebo Comparator|Intubated Subjects without the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by same cohort of anesthesiologists trained in device use.
16320951|NCT04532099|Other|LID018869, then AOHP (Part A)|Lehfilcon A contact lenses worn first, followed by senofilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
16320952|NCT04532099|Other|AOHP, then LID018869 (Part A)|Senofilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
16320953|NCT04532099|Active Comparator|Biofinity (Part B)|Comfilcon A contact lenses worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of the wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
16320954|NCT04532073|Experimental|Eurythmy therapy exercises|As part of the ENTAiER trial: In group sessions á 5 patients with a qualified therapist: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by an eurythmy manual and an exercise video. This supplements the regular care.
16320955|NCT04532073|Experimental|Tai Chi exercises|As part of the ENTAiER trial:In group sessions of 5 patients each with a qualified teacher: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by a Tai Chi Manual and an exercise video. This complements the regular care
16320956|NCT04532073|Active Comparator|Standard Care Only|"As part of the ENTAiER trial:Brochure with detailed description of various evidence-based measures for fall prevention, prepared for the specific age group (https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf)
~- Recommendation to visit the family doctor and discuss fall prophylaxis with her"
16320957|NCT04532060|Experimental|Antimicrobial Photodynamic Therapy|Patients treated with Antimicrobial Photodynamic Therapy
16320958|NCT04532060|Experimental|Nystatin|Patients treated with Nystatin antifungal drug.
16320959|NCT04532047|Experimental|Experimental: in utero enzyme replacement therapy|ERT will be delivered in utero. Typically, the target of the procedure to administer in utero ERT will be the umbilical vein near the insertion of the umbilical cord into the placenta. The dose of the ERT will be dependent on the specific disease process and enzyme being replaced, and the estimated weight of the fetus. The dosage will be the same as the recommended weight-based postnatal dosing, adjusted for estimated fetal weight. IUERT will be repeated every 2-4 weeks, which is an interval consistent with the standard of care for IUTs (every 2-4 weeks) to avoid excessive access through the umbilical vein. This interval is also consistent with the half-life of each relevant enzyme.
16320960|NCT04532034|Experimental|Peer-Delivered Decision Support Intervention|
16320961|NCT04532021||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
16320962|NCT04532021||control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
16320963|NCT04532008|No Intervention|Control Group|No intervention
16320964|NCT04532008|Experimental|Treatment Group|Experimental group received 12 session of group based depression treatment, a matched savings program, financial literacy training, agricultural training, and a cash transfer.
16320967|NCT04531969|Active Comparator|Inpatient group|Spa therapy,HP application, deep heater application, and TENS.
16320968|NCT04531969|Active Comparator|Outpatient group|Spa therapy,HP application, deep heater application, and TENS.
16320969|NCT04531956|No Intervention|Before group|In the before group (BG) GPs will execute care as usual in the decision-making process for a diagnostic trajectory for memory complaints.
16320970|NCT04531956|Active Comparator|After group|In the after group (AG), a patient decision aid will be added to the decision-making process provided by the GP.
16320971|NCT04531943||TGWSM Using Estrogen|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of only estrogen.
16320972|NCT04531943||TGWSM Using Estrogen plus Progesterone|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of estrogen and progesterone.
16321076|NCT04531241|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to sequence, Test/Control.
16320973|NCT04531943||Cisgender MSM|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of cisgender MSM.
16320974|NCT04531943||TGWSM Initiating Feminizing Hormone Therapy|Cohort 2 participants are in the longitudinal portion of the study and are TGWSM who are planning to initiate feminizing hormone therapy. Individuals in Cohort 2 will participate in study activities for 18 months.
16320975|NCT04531930||Surgery Group|Colorectal surgery
16320976|NCT04531930||Enhanced Colonoscopy Group|Enhanced colonoscopic treatment and surveillance
16320977|NCT04531930||Self Choice Group|The patients choose the interventional methods, even do nothing.
16320978|NCT04531917|Experimental|Pain Neuroscience Education + Behavioural Graded Activity|Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.
16320979|NCT04531917|Active Comparator|Usual care|"Patients allocated to the control group will receive an information leaflet from Kom op tegen kanker regarding Pain in and after cancer."
16320980|NCT04531891|Experimental|All-out, high-intensity, intermittent exercise protocol|
16320981|NCT04531891|Experimental|5 min, high-intensity, intermittent exercise protocol|
16320982|NCT04531878|Experimental|BSEP trafficking abnormal group|Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
16320983|NCT04531865|Experimental|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
16320984|NCT04531865|Placebo Comparator|Rituximab Only|First course Course Rituximab at Randomization. Addition of Maintenance Placebo tablets matching Mycophenolate mofetil from 4 Month onwards.
16320985|NCT04531852||At risk older adults|Home-dwelling older adults entitled to preventive home visit, who had a risk profile for loss of physical function and disability identified through a multi-domain screening instrument
16320986|NCT04531839|Experimental|Intervention period|The 1.5-year period during which all six participating centers receive evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation, and collaborative learning
16320987|NCT04531839|No Intervention|Baseline period|The 2-year period before the collaborative quality improvement intervention
16320988|NCT04531826|Active Comparator|Group A|Five-strand hamstring autograft group
16320989|NCT04531826|Placebo Comparator|Group B|Quadripled hamstring autograft group
16320990|NCT04531813|Experimental|Cumulative Irritation Test|Participants received butenafine HCl 1% cream on the skin test site, 0.3% solution of sodium lauryl sulfate on the skin Positive Control test site, and a blank patch on the skin Negative Control test site daily (excluding weekends) for 21 days, or 15 applications.
16320991|NCT04531800|Experimental|Study Group|The necrotic bone was removed with rotating burs, curettage was performed, and the surface of the bone was smoothened. CGF was then applied to the surgical area in the study group (n=14), and the area was primarily closed after additional releasing incisions were made to the periosteum to assure tension-free soft tissue closure.
16320992|NCT04531800|Experimental|Control Group|The surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy, in the control group (n=14).
16320993|NCT04531787||Vaccine, Pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
16320994|NCT04531787||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
16320995|NCT04531787||Vaccine, Healthy Controls|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
16320996|NCT04531774|Experimental|RECHARGE|4 1-hour sessions of RECHARGE are delivered online using Skype for Business within 2 weeks.
16320997|NCT04531774|Active Comparator|Online self-study of stress management strategies|Self study during 2 weeks.
16320998|NCT04531761|Experimental|Immediate Access to Parent Support Program|
16320999|NCT04531761|No Intervention|Waitlist Control|
16321000|NCT04531748|Active Comparator|Toremifene + Melatonin|"100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening), 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
~60mg oral toremifene daily days 1-14."
16321001|NCT04531748|Active Comparator|Melatonin + Placebo|100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening) and 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
16321002|NCT04531748|Placebo Comparator|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions
16321003|NCT04531735||Group 1|COVID positive infants
16321004|NCT04531735||Group 2|RSV positive infants
16321005|NCT04531722|Experimental|drug-resistant temporal lobe epilepsy|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe. The electro-physiological data that will be gathered is not altered and this methodology will not impact standard clinical care, except and will not to extend the duration in the OR - the measurements will occur during the clinical electrocorticography (ECoG; intracranial electroencephalography (iEEG)) procedure by 15 min.
16321006|NCT04531709||Recently diagnosed TGCT|
16321007|NCT04531709||Long-term survivors of TGCT|
16321008|NCT04531696|Other|Standard|"UPTIDER consists of 8 substudies:
~Pilot phase
~Invasive Lobular Carcinoma (ILC) substudy
~Inflammatory Breast Cancer (IBC) substudy
~Molecular heterogeneity and treatment response substudy
~Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy
~Metabolomics substudy
~Liquid biopsy substudy
~Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different."
16321077|NCT04531241|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to sequence, Control/Test.
16321009|NCT04531683|Experimental|electroacupuncture|patients will receive electroacupuncture at 3 acupoints (Bladder meridian of foot-taiyang 33 and 35（BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 8 weeks(24 times in total), followed with 24-weeks follow up. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 × 40 mm at SP 6. Standardised electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
16321010|NCT04531683|Sham Comparator|sham electroacupuncture|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
16321011|NCT04531683|Other|life style counselling group|patients randomised to this group will receive a one-time life style counselling at the enrolment to improve their daily behaviour to expedite the recovery of their mixed urinary incontinence. Then the patients will be followed up for 20 weeks.
16321012|NCT04531670|Experimental|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
16321013|NCT04531670|Active Comparator|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
16321014|NCT04531657||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
16321015|NCT04531657||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
16321016|NCT04531644|Experimental|Study|the patients in this group will be treated with double stimulation
16321017|NCT04531644|Active Comparator|Control|the patients in this group will be treated with conventional ovarian stimulation
16321018|NCT04531631|Other|Group 1|receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3
16321019|NCT04531631|Other|Group 2|receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3
16321020|NCT04531618|Experimental|Family Nurture Intervention (FNI)|Receives a FNI session over Zoom in the Well Baby Nursery and 3 subsequent Zoom sessions over the next 3 months.
16321021|NCT04531618|No Intervention|Standard of Care (SC)|SC receives the regular standard of care in the Well Baby Nursery and no intervention.
16321022|NCT04531605|Experimental|Intervention|"12-week program of combined life-skills training and financial incentives (YBank program) described in more detail below.
~Life-skills training: Every 4 weeks through the 12 week program, life-skills training sessions will be delivered during peer-group sessions at the clinic. Topics include economic empowerment, financial literacy, healthy relationships, and anti-retroviral therapy (ART) adherence.
~Financial incentives: The incentives program combines an immediate financial reward with a long-term savings opportunity. For clinic attendance, 500 RWF (~$0.50) will be deposited into participants' mobile money short-term account, where funds will be immediately accessible, and 1500 RWF (~$1.50) will be deposited into their savings account upon completing the program. If participants demonstrate a suppressed viral load at a clinic appointment, an additional 1000 RWF (~$1) will be deposited to their short-term account and 3000 RWF (~$3) into their saving account."
16321027|NCT04531566|Experimental|Oral Feed Intervention Group|
16321028|NCT04531566|Active Comparator|Usual care|
16321029|NCT04531553|Active Comparator|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of bupivacaine 0.25% then bupivacaine 0.1% infused at a rate of 6 mL/h for 48 hours.
16321030|NCT04531553|Active Comparator|ESPB with bupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of bupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted bupivacaine 0.1%, infused at a rate of 6 mL/h for 48 hours.
16321031|NCT04531553|Active Comparator|ESPB with bupivacaine and dexometedomidne|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of bupivacaine 0.25% plus 0.5mic/ml dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted bupivacaine 0.1% and dexmedetomidine 0.5 μg/mL infused at a rate of 6 mL/h for 48 hours.
16321032|NCT04531540|Experimental|Repeated Insult Patch Test|During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.
16321075|NCT04531254||No mask/masking when physical distancing is not maintained|Children in this group will not be asked to wear a mask (JK-Grade 4) or only asked to wear a mask when physical distancing in the classroom cannot be maintained (Grade 5-Grade 12) during the simulation
16321033|NCT04531527|Experimental|Phototoxicity reaction test|Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
16321034|NCT04531514|Experimental|Sensitivity to phonological rules & referents: Toddlers|Arm 1: OR condition with a referent; Arm 2: OR condition without a referent; Arm 3: Family Resemblance condition with a referent; Arm 4: Family Resemblance condition without a referent.
16321035|NCT04531501||Patients suspected to have Covid-19|Individuals suspected to have COVID-19 who are admitted to Gloucestershire Hospitals NHS Foundation Trust facilities for treatment for COVID-19. Individuals with full mental capacity.
16321036|NCT04531501||Patients tested positive for Covid-19|Individuals tested positive for COVID-19 at Northern Care Alliance NHS Group using an NHS NPS test who are accessible within 24 hours and consent to providing a saliva sample and further NPS sample for Chronomics.
16321037|NCT04531488|Experimental|Powered Mobility Training Simulator|Powered mobility simulator- the McGill Immersive Wheelchair Simulator (MiWe) was developed for adults. In a previous study the simulator was found valid for use with children. Participants were provided a laptop, joystick and the software program- MiWe- to practice at home or school
16321038|NCT04531488|Active Comparator|Training with Powered Wheel Chair|Participants were provided with a powered wheelchair to practice at home or school
16321039|NCT04531475|Experimental|X842 50 mg QD|X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
16321040|NCT04531475|Experimental|X842 100 mg QD|X842 100 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
16321041|NCT04531475|Experimental|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.
16321042|NCT04531462|Experimental|Empagliflozin|
16321043|NCT04531462|Placebo Comparator|Placebo|
16321044|NCT04531436|Experimental|Intervention|Brief mindful eating intervention
16321045|NCT04531423|Experimental|SSRI + golimumab|Participants will be administered with SSRI+golimumab . Golimumab will be administered at the dose of 50mg every month during the acute phase.
16321046|NCT04531423|Active Comparator|SSRI +placebo|Participants will be administered with SSRI+placebo
16321047|NCT04531410|Experimental|Linoleic|Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)
16321048|NCT04531410|Active Comparator|Oleic|Oleic acid 13 g and 600 algal DHA
16321049|NCT04531397|Placebo Comparator|ACEI treatment|Drug: ACEI will be given once daily
16321050|NCT04531397|Experimental|Dapagliflozin+ACEI treatment|Drug: ACEI, will be given once daily Drug: Dapagliflozin, will be given once daily
16321051|NCT04531384|Experimental|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 weekly individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants.
16321052|NCT04531384|Other|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions, which consisted of weekly group and/or individual therapy, as determined by the clinical team.
16321053|NCT04531371|Experimental|dexemedetomidine|dexemedetomidine was administered intravenously after induction of general anesthesia.
16321054|NCT04531371|Active Comparator|magnesium sulphage|magnesium sulphate was infused through out the surgery after induction of general anaesthesia.
16321055|NCT04531371|Placebo Comparator|saline|nothing was given just saline during the operation.
16321056|NCT04531358|Active Comparator|Callergin|One puff (140 microliter) into each nostril
16321057|NCT04531358|Active Comparator|Alpin Alpensalz|One puff (140 microliter) into each nostril
16321058|NCT04531358|Experimental|no treatment|Patients do not receive a treatment
16321059|NCT04531345||Case Group|Patients with Covid 19 PCR (+) results
16321060|NCT04531345||Control Group|Healthy volunteers
16321061|NCT04531332|Experimental|Continuous infusion|Patients will be received linezolid 600 mg intravenous Loading dose over 30 to 60 minutes followed by 1200 mg/ day by Continuous infusion (50 mg /hr)
16321062|NCT04531332|Active Comparator|Intermittent dosing|Patients will be received Linezolid 600 mg intravenous twice daily over 30 to 60 minutes
16321063|NCT04531319||Case Group|Covid 19 (+) patients
16321064|NCT04531319||Control Group|Healthy volunteers
16321065|NCT04531306|Active Comparator|Pre-tape|
16321066|NCT04531306|Experimental|With tape 1|
16321067|NCT04531306|Experimental|With tape 2|
16321068|NCT04531306|Experimental|Post-tape|
16321069|NCT04531293|Other|Total-breath method followed by standard method|Total Lung Capacity (TLC) measurement performed on device EasyOne Pro (TM) according to total-breath method followed by TLC measurement performed on device MasterScreen (TM) according to standard method.
16321070|NCT04531293|Other|Standard method followed by total breath method|Total Lung Capacity (TLC) measurement performed on device Masterscreen (TM) according to standard method followed by TLC measurement performed on device EasyOne Pro (TM) according to total-breath method.
16321071|NCT04531280|Experimental|Home hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
16321072|NCT04531267|Active Comparator|Individualized nutrition|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
16321073|NCT04531267|No Intervention|Control group|Participants do not receive any supplements, they stay with the original medication plan.
16321078|NCT04531228|Experimental|Experimental: TACE-HAIC plus lenvatinib|chemo-lipiodolization, followed by FOLFOX-based chemotherapy artery infusion (HAIC). Lenvatinib was administrated two or four days after TACE-HAIC.
16321079|NCT04531215|Active Comparator|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
16321080|NCT04531215|Active Comparator|ultrasound guided erector spinae|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
16321081|NCT04531202||Patients with confirmed or suspected of coronavirus infe|Clinical and laboratory data will be collected throughout the acute illness period. Research data will be integrated with information available from hospital and regulatory files.
16321082|NCT04531176|Experimental|Obesity-centric approach + AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
16321083|NCT04531176|Experimental|Obesity-centric approach without AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
16321084|NCT04531176|Active Comparator|Usual care approach (Comorbidity-centric approach)|Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.
16321085|NCT04531163|Experimental|Interventional|"First arm is experimental, given (NAC) for 2 months in 1200mg/day dosing.
~Both arms are assigned to pre-treatment analytical tests and post treatment all test analysis are repeated to compare drug effect with placebo group."
16321086|NCT04531163|No Intervention|Non-interventional|Second arm has no intervention. It is only used to compare results of analytical tests with the first interventional arm.
16321087|NCT04531150|Experimental|Cohort 1|Subjects will be randomized to receive either placebo or 20 mg INV-101
16321088|NCT04531150|Experimental|Cohort 2|Subjects will be randomized to receive either placebo or 80 mg INV-101
16321089|NCT04531150|Experimental|Cohort 3|Subjects will be randomized to receive either placebo or 160 mg INV-101
16321090|NCT04531150|Experimental|Cohort 4|Subjects will be randomized to receive either placebo or 320 mg INV-101
16321091|NCT04531150|Experimental|Cohort 5|Subjects will be randomized to receive either placebo or 500 mg INV-101
16321092|NCT04531137|Experimental|CLA-fortified milk powder|Respondents will receive CLA-fortified milk powder containing 3.4 gram for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
16321093|NCT04531137|Other|Placebo|Respondents will receive a placebo milk powder for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
16321094|NCT04531124||control group without an integrated management|
16321095|NCT04531124||observational group with an integrated management|
16321096|NCT04531098|Experimental|Sci-B-Vac-SciGen|The tri-antigenic HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
16321097|NCT04531098|Active Comparator|Engerix-B|The mono-antigenic HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
16321098|NCT04531098|Experimental|Sci-B-Vac-BTG|The tri-antigenic HepB vaccine, Sci-B-Vac-OLD BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-OLD BTG was supplied in a final volume of 1.2 ml vials
16321099|NCT04531085|Active Comparator|RCT operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
16321100|NCT04531085|Active Comparator|RCT Non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
16321101|NCT04531085|Other|Patient preference operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
16321102|NCT04531085|Other|Patient preference non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
16321103|NCT04531072|Experimental|ATVr-arm|10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
16321104|NCT04531072|Active Comparator|AL-arm (Control)|10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
16321105|NCT04531059|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 300mg bid Tetracycline 500mg qid Metronidazole 400mg qid
16321106|NCT04531059|Experimental|Minocycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 300mg bid Minocycline 100mg bid Metronidazole 400mg qid
16321107|NCT04531046|Experimental|axicabtagene ciloleucel|Single infusion administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg
16321108|NCT04531033|Placebo Comparator|Placebo|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
16321109|NCT04531033|Experimental|Low dose 10 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
16321179|NCT04530643|Experimental|HY209 0.5%|multiple dose of HY209 0.5% gel
16321110|NCT04531033|Experimental|High dose 15 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
16321111|NCT04531020||Patients at PACU|Patients undergoing elective surgical or diagnostic intervention admitted to PACU after postanaesthesia recovery
16321112|NCT04531007|Experimental|Intermediate LMS stenosis|Patients with intermediate left main stem stenosis with additional severe downstream lesion will be subject to physiology (FFR and iFR) at multiple sites along the target vessels before and after PCI of the severe lesion located in the downstream vessel. Intravascular imaging (IVUS and OCT) will be performed for additional evaluation of the left main stem stenosis.
16321113|NCT04530981|Experimental|Repaglinide 0.5 mg + Ripretinib 150 mg QD|A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
16321114|NCT04530968||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
16321115|NCT04530968||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
16321116|NCT04530968||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
16321117|NCT04530968||Healthy controls (HCs)|Healthy controls (HCs)
16321118|NCT04530955|No Intervention|Control Arm|"Patients randomized to the Control Arm that have been implanted with the valve-gated pump will be started on an equivalent dose (without change to the medication concentration) as prior to implant. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be modified, the dose can be modified as clinically indicated. Multiple dosing decreases may be performed if the patient is clinically demonstrating a reduction in spasticity that is profound and negatively impacting function, or if the patient is demonstrating signs of baclofen overdose.
~The criteria for dosing decrease will be clinical discretion."
16321119|NCT04530955|Active Comparator|Study Arm|"Patients randomized to the Study Arm will be started on a 20% dose reduction (without change to the medication concentration) through the newly implanted valve-gated pump. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be increased or decreased, the dose can be increased/decreased as clinically indicated. If the dose increases with the valve-gated pump reach the patients' baseline dose and the patient's spasticity is worse than his or her spasticity at baseline, then the patient will be considered a primary endpoint failure.
~The criteria for dosing increase will be clinical discretion."
16321120|NCT04530942|Experimental|Active DBS then Sham DBS|After 6 months open-lable period, some patients will take DBS ON for one week with the optimal stimulation parameters and then take DBS OFF for one week.
16321121|NCT04530942|Experimental|Sham DBS then Active DBS|After 6 months open-lable period, some patients will take DBS OFF for one week and then take DBS OFF for one week with the optimal stimulation parameters.
16321122|NCT04530929|Active Comparator|Group PROBIOTIC|The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
16321123|NCT04530929|Placebo Comparator|Group PLACEBO|Placebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
16321124|NCT04530916|Experimental|Blueberry|22 g blueberry powder per day
16321125|NCT04530916|Placebo Comparator|Control|22 g placebo control powder per day
16321126|NCT04530903|Experimental|Group Clonidine|Group Clonidine will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine and 75 µg of clonidine per side.
16321127|NCT04530903|Placebo Comparator|Control|Group Control will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine per side; 0.5 ml of 0.9% NaCl will be added to each syringe to homogenise the volume in order to remain blind.
16321128|NCT04530890|Experimental|One arm only|Only one arm with blood samples
16321129|NCT04530877|Experimental|Exclusive enteral nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
16321130|NCT04530877|Active Comparator|Infliximab|the participants with active CD accept anti-TNF therapy (Infliximab) at 0week, 2week, 6week, 14week. Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
16321131|NCT04530864|Experimental|DEXTENZA Insert|This prospective study will use a self controlled design for 35 eyes. Patients scheduled to undergo routine cataract surgery in at least one of their eyes will have their pre-surgical measurements performed, IOL calculated and surgery planned. Then they will receive insertion of an intracanalicular dexamethasone insert into the inferior punctum. At 2 weeks (+/- 2 days) post-insertion, patients will return for an identical set of measurements. The IOL will be calculated and the surgery planned based on post-insert data. The insert will be removed if present (manually or via saline irrigation). This self controlled design allows for greater control of potential confounders tied to participants' systemic and ocular health.
16321132|NCT04530851|No Intervention|Conventional care|This group is conventional care of pregnant women after Cesarean section
16321133|NCT04530851|Experimental|ERAS protocol|This protocol for improve outcome of pregnant women after Cesarean section
16321134|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (subcutaneous)|20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
16321135|NCT04530838|Active Comparator|13-valent pneumococcal conjugate vaccine (subcutaneous)|13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
16321136|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (intramuscular)|20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)
16321180|NCT04530643|Placebo Comparator|Placebo|multiple dose of Placebo
16321181|NCT04530630|Experimental|Biktarvy|Participants receive a Biktarvy tablet orally once daily with or without food.
16321137|NCT04530825|No Intervention|Providers|"All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline
~A subset of 5-10 providers will be recruited via email, at the baseline training,or by using snowball-sampling approach within the clinic to participate in qualitative in-depth interviews"
16321138|NCT04530825|No Intervention|Parents|-Semi-structured interviews
16321139|NCT04530825|Active Comparator|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail
~Up to 10 patients will also take part in semi-structured interviews
~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
16321140|NCT04530825|Experimental|Patients - PREVENT tool|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail
~Up to 10 patients will also take part in semi-structured interviews
~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
16321143|NCT04530799||IAPA+|Influenza patients who develop IAPA during ICU admission
16321144|NCT04530799||IAPA-|Influenza patients admitted to the ICU not developing IAPA
16321145|NCT04530786||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
16321146|NCT04530786||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
16321147|NCT04530773|Experimental|GROUP1|
16321148|NCT04530773|Experimental|GROUP2|
16321149|NCT04530773|Experimental|GROUP3|
16321150|NCT04530773|Experimental|GROUP4|
16321151|NCT04530773|Experimental|GROUP5|
16321152|NCT04530760||intraabdominal hypertension group|patients with intraabdominal hypertension defined as intravesical pressure more than 12 mmHg
16321153|NCT04530760||control group|patients with no intraabdominal hypertension
16321156|NCT04530721||stroke group|
16321157|NCT04530721||normal group|
16321158|NCT04530708|No Intervention|A: Standard of care|Normal standard of care and follow-up.
16321159|NCT04530708|Experimental|B: Thoracic radiotherapy|Addition of thoracic radiotherapy to 36 Gy after medical treatment.
16321160|NCT04530695|Experimental|Arm A: Deep Cleaning|participants with periodontitis will undergo treatment by scaling and root planing (SRP)
16321161|NCT04530695|No Intervention|Arm B: No cleaning|participants with periodontitis will undergo no periodontal treatment
16321162|NCT04530682||SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs)|200 SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the COVID-RIC-1 cohort.
16321163|NCT04530682||Control group|100 health professionals participating in the COVID-BIOTOUL cohort will be selected to be matched on age, gender, and the time between the date of infection with Covid-19 and the first serology of CIR patients.
16321164|NCT04530669|Experimental|study group|"in the active arm patients will receive high tone power therapy in addition to the physical therapy conventional selected exercise program"
16321165|NCT04530669|Sham Comparator|control group|"the sham arm will receive the same physical exercise program with sham high tone power therapy."
16321166|NCT04530656|Experimental|Middle-dose vaccine (18-55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
16321167|NCT04530656|Experimental|Middle-dose vaccine (> 55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
16321168|NCT04530656|Experimental|High-dose vaccine (18-55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
16321169|NCT04530656|Experimental|High-dose vaccine (> 55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
16321170|NCT04530656|Experimental|High-dose vaccine (18-55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
16321171|NCT04530656|Experimental|High-dose vaccine (> 55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
16321172|NCT04530656|Placebo Comparator|Middle-dose placebo (18-55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
16321173|NCT04530656|Placebo Comparator|Middle-dose placebo (> 55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
16321174|NCT04530656|Placebo Comparator|High-dose placebo (18-55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
16321175|NCT04530656|Placebo Comparator|High-dose placebo (> 55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
16321176|NCT04530656|Placebo Comparator|High-dose placebo (18-55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
16321177|NCT04530656|Placebo Comparator|High-dose placebo (> 55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
16321178|NCT04530643|Experimental|HY209 0.3%|multiple dose of HY209 0.3% gel
16321182|NCT04530617|Active Comparator|Camostat mesilate|100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
16321183|NCT04530617|Placebo Comparator|Camostat Placebo|Matched placebo
16321184|NCT04530617|Active Comparator|Artemisia annua|Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
16321185|NCT04530617|Placebo Comparator|Artemisia annua Placebo|Matched placebo
16321186|NCT04530604|Experimental|Defibrotide|
16321187|NCT04530591||Patient Participants|"This group of participants will complete a survey about their opioid use history and their preferences for a device-based intervention. They will then participate in a semi-structured interview to provide feedback on non-functional, looks-like prototypes of such a device."
16321188|NCT04530578|Experimental|NEBULIZED HEPARIN|"Nebulized Heparin (UNF)5000 IU in Saline Solution1 ml every 8 hours plus Enoxaparine 40mg /d or 60mg/d, adjusted by BMI and calculated creatinine clearance .
~Device to nebulize without producing aerosolization:
~To nebulized heparin we have a modified a fullface snorkel mask, in which instead of the discharge valve a connector for the Venturi has been placed, and in the air outlet / inlet of the snorkel it has been adapted a connector made with 3D printing for the insertion of a disposable antiviral filter (filters commonly used in Mechanical Respiratory Assistance devices).
~The mask is made of materials that allow its sterilization with the STERRAT Hydrogen Peroxide plasma system, available at the institution."
16321189|NCT04530578|Active Comparator|Enoxaparine|Enoxaparin 40mg/d or 60mg/d adjusted by BMI and calculated creatinine clearance
16321195|NCT04530552|Experimental|Treatment (apalutamide)|The first 40 patients taking part in this trial receive apalutamide PO TIW for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Based on PSA levels of the first 40 patients, the next group of 40 patients receive apalutamide either QW or QD for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Patients may receive apalutamide for up to 12 weeks before prostate surgery (in the event surgery is delayed).
16321196|NCT04530539|Experimental|Experimental- Melatonin|Patients will receive melatonin
16321197|NCT04530539|Experimental|Experimental- Vit C|Patients will receive vitamin C
16321198|NCT04530539|Placebo Comparator|Control|Patients will receive placebo
16321199|NCT04530513|Experimental|Dose Level 1|
16321200|NCT04530513|Experimental|Dose Level 2|
16321201|NCT04530513|Experimental|Dose Level 3|
16321202|NCT04530513|Experimental|Dose Level 4|
16321203|NCT04530513|Experimental|De-escalation Level|
16321204|NCT04530500||Arm 1|Males first tested positive for SARS-CoV-2 at the site (medical center) with CAG length <24 (based on the CoVAST Test)
16321205|NCT04530500||Arm 2|Males first tested for SARS-CoV-2 at the site (medical center) with CAG length >=24 (based on the CoVAST Test)
16321206|NCT04530487|Experimental|Treatment (conditioning regimen, HSCT)|"CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.
~TRANSPLANT: Patients undergo HSCT on day 0.
~GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90."
16321207|NCT04530474|Experimental|Ivermectin|Single dose of 0.15-2 mg/kg/dose to a maximum of 12 mg
16321208|NCT04530474|Placebo Comparator|Placebo|Single dose of 2-4 placebo pills
16321209|NCT04530448|Active Comparator|Standard of Care|Standard of Care treatment
16321210|NCT04530448|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
16321211|NCT04530435|Experimental|Treatment group|"The participants will be handed three airway resistances equivalent to a resistance of 10-20 cm H2O alongside one PEP flute. Two videos will guide the participants in use of the PEP flute; one with instructions of the rationale and how to use the flute, including how to choose the suitable resistance and one video, which gives instructions of hygienic maintenance.
~Participants in the intervention group will be advised to continue use of their PEP flute in the active intervention period of 30 days or at least if they still have respiratory symptoms. They will receive daily text-messages to prompt their reporting and to use the PEP flute according to instructions."
16321239|NCT04530279||Burn centre|Burn assessments performed in the national burn centre
16321240|NCT04530266|Active Comparator|Persons with knee osteoarthritis|
16321212|NCT04530435|No Intervention|Control group|The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
16321213|NCT04530422|Experimental|• Group I (Sofosbuvir plus Ledipasvir)|Patients assigned to this group (125 patients) were received Sofosbuvir plus Ledipasvir, once daily for 15 to 21 days as minimum and maximum duration of therapy, respectively.
16321214|NCT04530422|Active Comparator|Group II (Oseltamivir plus HCQ & Azithromycin)|"Patients in this group (125 patients) were received the local medical committee of Almaza Fever Hospital guided standard treatment protocol for COVID-19:
~Oseltamivir 150 mg q 12 hours for 10 days ;
~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and
~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.
~Additional conservative medications were also given. Patients were evaluated as scheduled on day 0, 5 & 11 clinically"
16321215|NCT04530409|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
16321216|NCT04530409|Active Comparator|Late CS|Dexamethasone is to be used lately upon the deterioration of cases
16321217|NCT04530396|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
16321218|NCT04530396|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
16321221|NCT04530370|Experimental|Recovered covid 19 plasma|
16321222|NCT04530370|Placebo Comparator|controlled|
16321223|NCT04530357|Experimental|Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16321224|NCT04530357|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16321225|NCT04530357|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16321226|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16321227|NCT04530357|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder
16321228|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
16321229|NCT04530344|Experimental|Cohort A : ruxolitinib cream|Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
16321230|NCT04530344|Placebo Comparator|Cohort A : Vehicle|Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
16321231|NCT04530344|Experimental|Cohort B : roxolitinib cream|Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
16321232|NCT04530331|Experimental|Intervention group|Providing nutrition education.
16321233|NCT04530331|No Intervention|Control group|Without any intervention.
16321234|NCT04530318|Experimental|TolDec|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
16321235|NCT04530318|Placebo Comparator|Placebo|Placebo of dendritic cells
16321236|NCT04530292|Experimental|intervention by a pediatric nurse at the child's home|"The pediatric nurse will visit the patient's home 3 times during the first six months of the discovery of diabetes in children. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit can be organized according to the needs of families.
~The pediatric nurse will ensure the implementation of learning in terms of drug therapy (modality of insulin administration, adaptation of insulin doses) and diet, according to the knowledge acquired during the initial hospitalization. She will offer her help to the families to make a connection with the school and after-school activities of the child.
~In addition to these visits, the child and his family will come to the hospital as part of the regular medical follow-up: consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes."
16321237|NCT04530292|No Intervention|Classic strategy (for retrospective group)|The child and his family benefited from a consultation with a pediatric nurse at 1 month of the discovery of T1D and had medical consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes. The data from this group were collected in a previous study (collection of retrospective data) for children whose parents were in a precarious social situation and whose management was traditional.
16321238|NCT04530279||Referring hospital|Burn assessments performed in referring hospitals
16321243|NCT04530240||ERA-2 Group|After the introduction of the MELD≥30 allocation scheme August 2014 - July 2018
16321244|NCT04530227|Experimental|Camrelizumab combined with chemotherapy|"Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy.
~Interventions:
~Biological: Camrelizumab"
16321245|NCT04530201|Other|Sample collection|Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.
16321246|NCT04530188|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
16321247|NCT04530188|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already used in our ICU
16321248|NCT04530175||patients with hemodialysis|patient treated with intermittent hemodialysis for chronic renal failure
16321252|NCT04530136|Experimental|Ruconest|Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
16321253|NCT04530136|Other|Standard of Care|SOC
16321254|NCT04530123|Placebo Comparator|Cohort 1: Placebo (2 Infusions)|Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
16321255|NCT04530123|Experimental|Cohort 1: TAK-101 2 mg/kg (1 Infusion) + Placebo (1 Infusion)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
16321256|NCT04530123|Experimental|Cohort 1: TAK-101 2 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
16321257|NCT04530123|Placebo Comparator|Cohort 2: Placebo (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
16321258|NCT04530123|Experimental|Cohort 2:TAK-101 4 mg/kg (1 Infusion)+placebo (1 Infusion)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
16321259|NCT04530123|Experimental|Cohort 2: TAK-101 4 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
16321260|NCT04530123|Experimental|Cohort 2: TAK-101 1 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
16321262|NCT04530097|Experimental|RFA+MLT|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
16321263|NCT04530097|No Intervention|RFA|Radiofrequency ablation was performed immediately after enrollment, and a placebo treatment program was given for 6 months after 1 week after radiofrequency.
16321264|NCT04530084|Experimental|Diagnosed with open angle glaucoma|
16321265|NCT04530071|Experimental|CordSTEM-DD(0.7x10^7 cells|Tissuefill+saline+CordSTEM-DD(0.7x10^7 cells)
16321266|NCT04530071|Experimental|CordSTEM-DD(2.1x10^7 cells)|Tissuefill+saline+CordSTEM-DD(2.1x10^7 cells)
16321267|NCT04530058|Placebo Comparator|Control|
16321268|NCT04530058|Experimental|Metformin|
16321269|NCT04530045||critically ill patients|Critically ill patients receiving continuous infusion of piperacillin/tazbactam or cefepim and dosage of plasma concentration of the B lactam administered
16321271|NCT04530032|Sham Comparator|TBI SD|TBI subjects on a standard (normal) diet
16321272|NCT04530019||MR Group|Following standard MRI-guided Brachytherapy, patients will have images analyzed for quantification of residual tumor versus fibrosis. We will pilot-test an endovaginal coil, a deflectable MR stylet, real-time planning software, and auto-segmentation of normal and tumor tissue.
16321273|NCT04530006|Experimental|GBM Patients|"This cohort of patients will be asked to orally ingest 200mg dose of FDA approved drug amantadine hydrochloride. This will be done at the following timepoints:
~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.
~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days
~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
16321274|NCT04529993|Experimental|Interstitial pulmonary fibrosis|
16321275|NCT04529993|Experimental|Chronic obstructive pulmonary disease|
16321276|NCT04529993|Experimental|Healthy volunteers|
16321279|NCT04529954|Experimental|Open-Label Safety|Participants roll-over from DA071976
16321280|NCT04529941|Experimental|Experimental Group|Will receive stimulation ScNS at 3.5mA output
16321281|NCT04529941|Sham Comparator|Control Group|Does not receive therapy
16321282|NCT04529928|Experimental|Implanted|Subjects successfully implanted with the Carillon Mitral Contour System
16321283|NCT04529915||Lung cancer|
16321284|NCT04529915||Healthy|
16321285|NCT04529902||Tumor necrosis factor inhibitors|Reference group
16321286|NCT04529902||Abatacept|Exposure group
16321287|NCT04529876||Tofacitinib|Reference group
16321288|NCT04529876||Abatacept|Exposure group
16321289|NCT04529863||Tocilizumab|Reference group
16321290|NCT04529863||Abatacept|Exposure group
16321291|NCT04529850|Experimental|Open Label Active Arm|90mg GC4419 by IV
16321292|NCT04529811|Experimental|Formulation 1 - Low Dose|Rifaximin Formulation 1 Capsules
16321293|NCT04529811|Experimental|Formulation 1 Capsules - Mid Dose|Rifaximin Formulation 1 Capsules
16321294|NCT04529811|Experimental|Formulation 1 Capsules - High Dose|Rifaximin Formulation 1 Capsules
16321295|NCT04529811|Experimental|Formulation 1 Capsules - Max Dose|Rifaximin Formulation 1 Capsules
16321296|NCT04529811|Placebo Comparator|Formulation 1 Capsules - Placebo|Placebo Formulation 1 Capsules
16321297|NCT04529811|Experimental|Formulation 2 - Low Dose|Rifaximin Formulation 2 Capsules
16321298|NCT04529811|Experimental|Formulation 2- Mid Dose|Rifaximin Formulation 2 Capsules
16321299|NCT04529811|Experimental|Formulation 2 - High Dose|Rifaximin Formulation 2 Capsules
16321300|NCT04529811|Experimental|Formulation 2 - Max Dose|Rifaximin Formulation 2 Capsules
16321301|NCT04529811|Placebo Comparator|Formulation 2 - Placebo|Placebo Formulation 2 Capsules
16321302|NCT04529811|Experimental|Formulation 3 - Low dose|Rifaximin Formulation 3 Capsules
16321303|NCT04529811|Experimental|Formulation 3 - Mid dose|Rifaximin Formulation 3 Capsules
16321304|NCT04529811|Experimental|Formulation 3 - High dose|Rifaximin Formulation 3 Capsules
16321305|NCT04529811|Experimental|Formulation 3 - Max dose|Rifaximin Formulation 3 Capsules
16321306|NCT04529811|Placebo Comparator|Formulation 3 - Placebo|Placebo Formulation 3 Capsules
16321307|NCT04529785|Active Comparator|SVC only|Patients in Group 1 will receive an SVC isolation only
16321308|NCT04529785|Active Comparator|SVC isolation with substrate modification and VoM inf|Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion
16321311|NCT04529759|Active Comparator|Control Infant Formula|Feed ad libitum
16321312|NCT04529759|Experimental|Experimental Infant Formula|Feed ad libitum
16321313|NCT04529746|Experimental|EVERYbody Project: Professional facilitator version|"The EVERYbody Project is a dissonance body image intervention created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and through an iterative process of student-driven feedback. The Body Project manual (Stice et al., 2006) was adapted to retain key dissonance activities while expanding the gender focus, adding an exploration of the diversity characteristics within appearance ideals, and adjusting activities to be inclusive of diversity characteristics. Several adapted versions of the intervention were piloted with groups of college students and further adapted based on feedback.
~Facilitators received 16 hours of training on the EVERYbody Project manual and facilitation guidelines."
16321314|NCT04529746|No Intervention|Waitlist control group|Participants allocated to the waitlist completed assessments at time points parallel to those in the EVERYbody Project condition and were offered the EVERYbody Project upon completing the one-month follow-up assessment.
16321315|NCT04529720||acellular pertussis vaccine|Antibody persistence at 5 years after a single dose vaccination of acellular pertussis vaccines (Pertagen;Boostagen;Adacel)
16321316|NCT04529707|Experimental|Sleep Intervention|All participants will engage in a 10-week, parent mediated sleep intervention with weekly education sessions.
16321317|NCT04529694|Active Comparator|Cognitive-only Intervention|This condition includes cognitive interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
16321349|NCT04529512|Experimental|Receiving DEXTENZA® 1 month prior to surgery|Participants to receive DEXTENZA® 1 month prior to surgery
16321318|NCT04529694|Active Comparator|Behavioral-only Intervention|The condition includes behavioral interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
16321319|NCT04529681|Experimental|Intervention Group|Intervention group will be equipped with Stroke Riskometer Apps and informational leaflets. In the beginning of the study, investigators will guide the participants to download and install the Stroke Riskometer Apps and how to use the application to measure, monitor and self-manage the stroke risk. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
16321320|NCT04529681|Other|Control Group|Control group will be given the informational leaflets consist of stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
16321321|NCT04529668|Experimental|group I|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
16321322|NCT04529668|Active Comparator|group II|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
16321323|NCT04529655||Sepsis|Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment
16321324|NCT04529642||Stroke Group|Inclusion criteria were as follows: age above 18, Mini-Mental State Examination ≥ 24, ability to provide written informed consent and to understand the test instructions, and the presence of a single stroke. Exclusion criteria were as follows: more than one stroke, stroke area other than the cerebral cortex, or concomitant neurological disease and pathology of the locomotor system. This group has been analysed also dividing the subjects according to the stroke phase in 3 subgroups: Acute phase group, Subacute phase group, Chronic stroke group
16321325|NCT04529642||Healthy Group|Healthy subjects age matched with the stroke group
16321326|NCT04529629||primary aldosteronism|
16321327|NCT04529629||pheochromocytoma|
16321328|NCT04529629||adrenocortical carcinoma|
16321329|NCT04529603|Experimental|Arm 1|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
16321330|NCT04529590||Patients with cardiovascular events after 18 years|"Analyzing metabolic markers screened and optimized by multivariate statistical with plasma metabolic profiles from peripheral blood samples of different groups.
~Positive patients' samples will be collected at baseline."
16321331|NCT04529590||Patients without cardiovascular events after 18 years|For negative patients' samples will be collected at baseline as negative control.
16321332|NCT04529577|Experimental|His-bundle pacing first|Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
16321333|NCT04529577|Experimental|RV apical pacing first|Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
16321334|NCT04529564||EAP patients|The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in South Korea and Taiwan during 2018 to 2019.
16321335|NCT04529551|Experimental|1601A, 1601B product use order|Subjects will use 1601A for 1 week and then 1601B for 1 week.
16321336|NCT04529551|Experimental|1601B, 1601A product use order|Subjects will use 1601B for 1 week and then 1601A for 1 week.
16321337|NCT04529538|Experimental|Group1: nOPV1 (IPV History)|20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of novel OPV type 1 (nOPV1) containing 10^6.5 CCID50/dose.
16321338|NCT04529538|Active Comparator|Group 2: mOPV1 (IPV History)|20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of mOPV1 containing 10^6.0 CCID50/dose.
16321339|NCT04529538|Experimental|Group 3: nOPV1 (OPV History)|50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV1 containing 10^6.5 CCID50/dose, given 28 days apart.
16321340|NCT04529538|Active Comparator|Group 4: mOPV1 (OPV History)|25 healthy adults fully vaccinated against polio by OPV will be administered 2 doses of mOPV1containing ≥ 10^6.0 CCID50/dose, given 28 days apart
16321341|NCT04529538|Experimental|Group 5: nOPV3 (IPV History)|20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of nOPV3 containing 10^6.5 CCID50/dose.
16321342|NCT04529538|Active Comparator|Group 6: mOPV3 (IPV History)|20 healthy adults fully vaccination against polio by exclusively IPV will be administered 1 vaccination of mOPV3 containing ≥ 10^5.8 CCID50/dose.
16321343|NCT04529538|Experimental|Group 7: nOPV3 (OPV History)|50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV3 in a dose of 10^6.5 CCID50/dose, given 28 days apart.
16321344|NCT04529538|Active Comparator|Group 8: mOPV3 (OPV History)|25 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of mOPV3 containing ≥ 10^5.8 CCID50/dose, given 28 days apart.
16321345|NCT04529525|Active Comparator|Ivermectin|"The dose of ivermectin in patients who are randomized to the active substance depends on the weight of the patient:
~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
16321346|NCT04529525|Placebo Comparator|Placebo|"The dose of placebo in patients who are randomized to the this depends on the weight of the patient:
~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
16321347|NCT04529512|Experimental|Receiving DEXTENZA® 1-3 days prior to surgery|Participants to receive DEXTENZA® 1-3 days prior to surgery
16321348|NCT04529512|Experimental|Receiving DEXTENZA® 1-2 weeks prior to surgery|Participants to receive DEXTENZA® 1-2 weeks prior to surgery
16321566|NCT04528186||1|Low eating index scores(50-70)
16321350|NCT04529512|No Intervention|Not receiving the DEXTENZA® implant|Participants will not receive the DEXTENZA® implant
16321351|NCT04529499|Experimental|favipiravir + supportive care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets. Tablet Strength 200 mg. Dosage: 1,800 mg BID on Day 1 + 800 mg BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
16321352|NCT04529499|Placebo Comparator|Placebo with Standard of Care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets Dosage: 9 tablets for BID on Day 1 + 4 tablets BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
16321353|NCT04529486|Experimental|Group 1: Kinesio taping|Kinesio taping was applied to the study group to improve posture and improve function in the shoulder area. Measurements were carried out for the study group before and after application (with tape on). The tape was then removed and the measurements were repeated after 1 week.
16321354|NCT04529486|No Intervention|Group 2: Control|No application was made to the control group.
16321355|NCT04529473|Placebo Comparator|Placebo|1 capsule per day, consumed orally, before breakfast for the duration of the study.
16321356|NCT04529473|Experimental|Eubacterium hallii|1 capsule per day, consumed orally, before breakfast for the duration of the study.
16321357|NCT04529460||Previously COVID-19 positive|Previously confirmed PCR positive for COVID-19 And/or positive COVID-19 antibody test in the past six months
16321358|NCT04529460||Previously COVID19 negative|No previous symptoms of COVID-19
16321359|NCT04529447||Patient satisfaction survey|Jaseng Hospital of Korean medicine conducted a pen and paper survey on patient satisfaction with regard to its COVID-19 response in inpatients hospitalized and outpatients visiting during March 23-25, 2020.
16321360|NCT04529434|Experimental|Arm 1|Households living in novel-design houses.
16321361|NCT04529434|Other|Arm 2|Households living in traditional African houses.
16321362|NCT04529421||Students, Higher Education Institution 1|All first, second, and third year students at Higher Education Institution 1 who agree to take part in study.
16321363|NCT04529421||Students, Higher Education Institution 2|All first, second, and third year students at Higher Education Institution 2 who agree to take part in study.
16321364|NCT04529421||Students, Higher Education Institution 3|All first, second, and third year students at Higher Education Institution 3 who agree to take part in study.
16321365|NCT04529421||Students, Higher Education Institution 4|All first, second, and third year students at Higher Education Institution 4 who agree to take part in study.
16321366|NCT04529421||Students, Higher Education Institution 5|All first, second, and third year students atHigher Education Institution 5 who agree to take part in study.
16321367|NCT04529421||Students, Higher Education Institution 6|All first, second, and third year students at Higher Education Institution 6 who agree to take part in study.
16321368|NCT04529421||Students, Higher Education Institution 7|All first, second, and third year students at Higher Education Institution 7 who agree to take part in study.
16321369|NCT04529421||Students, Higher Education Institution 8|All first, second, and third year students at Higher Education Institution 8 who agree to take part in study.
16321370|NCT04529421||Students, Higher Education Institution 9|All first, second, and third year students at Higher Education Institution 9 who agree to take part in study.
16321371|NCT04529421||Students, Higher Education Institution 10|All first, second, and third year students at Higher Education Institution 10 who agree to take part in study.
16321372|NCT04529421||Students, Higher Education Institution 11|All first, second, and third year students at Higher Education Institution 11 who agree to take part in study.
16321373|NCT04529421||Students, Higher Education Institution 12|All first, second, and third year students at Higher Education Institution 12 who agree to take part in study.
16321374|NCT04529421||Students, Higher Education Institution 13|All first, second, and third year students at Higher Education Institution 13 who agree to take part in study.
16321375|NCT04529421||Students, Higher Education Institution 14|All first, second, and third year students at Higer Education Institution 14 who agree to take part in the study.
16321376|NCT04529408||COVID-19 Follow up clinic|Patients attending routine post-COVID-19 follow up clinic
16321377|NCT04529408||Pulmonary Disease clinic|Patients attending routine outpatient appointment for pulmonary disease
16321378|NCT04529395|Experimental|Aromatherapy group|
16321379|NCT04529395|Active Comparator|Control group|
16321380|NCT04529382||Cohort 1: Unanticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 1 will be FNAIT cases that were not antenatally treated with by maternal IVIg administration (or other forms of fetal therapy).
16321381|NCT04529382||Cohort 2: Anticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 2 will be FNAIT cases which were anticipated antenatally by maternal IVIg administration according to our local protocol.
16321382|NCT04529369|Experimental|Prominent middle lobe BPH satisfactory channel after MLO PVP|
16321383|NCT04529369|Active Comparator|Prominent middle lobe BPH unsatisfactory channel after MLO PVP|
16321384|NCT04529356|Sham Comparator|Simple acetaminophen treatment|Acetaminophen will be taken when patients suffered from headache during the study. No specific dosage and frequency was required for this group as long as the participants record the exact drug usage.
16321385|NCT04529356|Active Comparator|Simple acetaminophen combined with low-frequency rTMS|Apart from acetaminophen usage, low frequency TMS (1HZ) will be used in patients three times a month for 6 months.
16321386|NCT04529356|Experimental|Simple acetaminophen combined with high-frequency rTMS|Apart from acetaminophen usage, high frequency TMS (10HZ) will be used in patients three times a month for 6 months.
16321387|NCT04529343|Experimental|Virtual Reality Group|To the virtual reality group; In addition to upper extremity exercises applied 2 days a week, upper extremity rehabilitation via virtual reality glasses will be performed 3 days a week for 6 weeks and each session will be 45 minutes.
16321388|NCT04529343|Active Comparator|Control Group|Upper extremity exercises will be applied to the participants in the control group 2 days a week for 6 weeks.
16321389|NCT04529330||fractures with blister appeared|tibial plateau fractures with blister observed
16321390|NCT04529330||fractures without blister appeared|tibial plateau fractures without blister observed
16321391|NCT04529317|No Intervention|Regular diet|The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed.
16321392|NCT04529317|Experimental|Quinoa diet|With the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).
16321393|NCT04529304|Experimental|Visual EEG|Individual dosing of anesthetic medications based on EEG AND other standardized clinical observations (BP, HR)
16321394|NCT04529304|Experimental|Blinded EEG|Individual dosing of anesthetic medications based on standardized clinical observations (BP, HR).
16321395|NCT04529291|Other|Group with walking disorder|This Group with walking disorder corresponds to patient reporting walking disorders due to his illness.
16321396|NCT04529291|Other|Group without walking disorder|This Group without walking disorder corresponds to patients not reporting walking disorders due to his illness.
16321397|NCT04529278|Experimental|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).
~The daily dose is then 1.8 mg until week W26."
16321398|NCT04529265|Experimental|Methylene Blue group|The first dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration at 8:00AM on the postoperative first day within one hour; The third dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration at 8:00AM on the postoperative second day within one hour.
16321399|NCT04529265|Placebo Comparator|Control group|The first dosage: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: normal saline in total 50 ml volume intravenous administration at 8:00AM on the postoperative first day within one hour; The third dosage: normal saline in total 50 ml volume intravenous administration at 8:00AM on the postoperative second day within one hour.
16321400|NCT04529252||Spinocerebellar Ataxia and Other Nucleotide Repeat Diseases|Participants with a clinical diagnosis of spinocerebellar ataxia and other nucleotide repeat diseases (not including Huntington's Disease) with or without a genetic mutation and unaffected family members (grandparents, parents, brothers, sisters, cousins, uncles and aunts) who may or may not carry a genetic mutation for the disease.
16321401|NCT04529252||Control Group|Participants with no known medical or family history of inherited neurodegenerative forms of spinocerebellar ataxia or nucleotide repeat diseases (not including Huntington's Disease) and spouses or caregivers of patients with spinocerebellar ataxia and nucleotide repeat diseases (not including Huntington's Disease) will serve as controls in the study.
16321402|NCT04529239||Low to Moderate Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
16321403|NCT04529239||High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
16321404|NCT04529239||Very High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
16321405|NCT04529226|Experimental|Clozapine|Pharmaceutical Form: Tablet ATC Code: N05AH02
16321406|NCT04529226|Active Comparator|Control|Usual antipsychotic medication used in the treatment of treatment-resistant psychosis.
16321407|NCT04529213|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel
16321408|NCT04529213|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel
16321409|NCT04529213|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
16321410|NCT04529200|Experimental|1. Comprehensive fall prevention protocol group (CARE)|every week protocol change for every patient according to 1 repetition maximum
16321411|NCT04529200|Active Comparator|2. Conventional balance training group|conventional protocol commonly used for rehabilitation
16321412|NCT04529187|Active Comparator|DEX group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a dexmedetomidine infusion in a rate of of 0.7 ug.kg-1.hr-1will be initiated. After 5 minutes of dexmedetomidine therapy a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
16321413|NCT04529187|Active Comparator|MID group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a single dose of midazolam (2 mg intravenously) will be given to each participant in this arm. After 5 minutes of midazolam administration a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
16321414|NCT04529174|Active Comparator|Active HDL supplement|25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.
16321415|NCT04529174|Placebo Comparator|Placebo|25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.
16321416|NCT04529161|Experimental|Group A|Diet followed by routine eating
16321417|NCT04529161|Experimental|Group B|Routine eating followed by diet
16321567|NCT04528186||2|High eating index scores(Above 70)
16321418|NCT04529148|Experimental|The treatment group|Ginkgo biloba dropping pills (63mg / pill), oral, 5 pills each time, three times a day,12 weeks totally. ( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
16321419|NCT04529148|Placebo Comparator|The control group|Mimetic drug of ginkgo biloba dropping pills (63mg / pill),oral, 5 pills each time, three times a day,12 weeks totally.( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
16321420|NCT04529135|Experimental|Dexmedetomidine|IV,0.2~0.8 µg/kg/hr
16321421|NCT04529135|Active Comparator|Remifentanil|IV,0.05~0.2 µg/kg/min
16321422|NCT04529096|Experimental|LY3016859|LY3016859 administered intravenously (IV).
16321423|NCT04529096|Placebo Comparator|Placebo|Placebo administered IV.
16321424|NCT04529083|Experimental|Intervention|Mixed Reality System for virtual mirror therapy
16321425|NCT04529070|Experimental|Intervention + Standard of care|Nightmare Rescripting and Rehearsal: a 10 minute intervention for Primary Care plus Sleep Hygiene handout.
16321426|NCT04529070|Active Comparator|Standard of care|Standard of Care Sleep Hygiene handout alone.
16321427|NCT04529057|Experimental|Tooth-borne (Hyrax) expander|
16321428|NCT04529057|Experimental|Tooth tissue-borne (KBME) expander|
16321429|NCT04529057|Experimental|Bone-borne (MIDME) expander|
16321430|NCT04529044|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30-40 minutes during weeks 1, 8, 16, and 24 in the absence of disease progression or unacceptable toxicity.
16321431|NCT04529031|Active Comparator|RFPP group intervention|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices.
16321432|NCT04529031|Sham Comparator|attentional control condition (group process)|Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy. Parents will receive 4 sessions of relaxation techniques.
16321433|NCT04529018|Experimental|Healthy Volunteers|A group of 5 healthy volunteers will be tested with the PET radiotracer [18F]CETO to assess safety of tracer administration, and evaluate uptake by the normal adrenal glands.
16321434|NCT04529018|Experimental|Patients with primary aldosteronism|A group of 6 patients with Primary Aldosteronism (3 with unilateral and 3 with bilateral disease) will be tested with up to two administrations of the PET radiotracer [18F]CETO, to assess safety of tracer administration, evaluate the ability of [18F]CETO to distinguish between unilateral and bilateral cases of PA, and determine the effect of Dexamethasone in improving the quality of PET-CT images acquired following administration.
16321435|NCT04529005|Experimental|Angiotensin II (Giapreza)|
16321436|NCT04528992|Experimental|Physical Therapy with BFR|Participants will begin BFR therapy as early as 2 weeks after surgery. The initial 2 weeks after surgery, or prior to initiation of BFR will consist of the physical therapy following the surgeon's postoperative protocol.
16321437|NCT04528992|Active Comparator|Physical Therapy without BFR|Participants will undergo standard physical therapy following the surgeon's postoperative protocol.
16321438|NCT04528979|Experimental|Primary root canal treatment|Primary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
16321439|NCT04528979|Experimental|Secondary root canal treatment|Secondary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
16321440|NCT04528966|Experimental|Treatment Group|Group that have received whole-body vibration treatment in addition to conventional physiotherapy
16321441|NCT04528966|Active Comparator|Control group|Group that have received conventional physiotherapy only
16321442|NCT04528953|Experimental|interval group|
16321443|NCT04528953|Experimental|Qigong exercise|
16321444|NCT04528953|Active Comparator|continuous walking|
16321445|NCT04528927|Experimental|HCQ+Azithromycin|"Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
~Usual standard treatment"
16321446|NCT04528927|Experimental|HCQ+Azithromycin+Zinc|"HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
~Zinc: 220 mg per day for 10 days
~Usual standard treatment"
16321447|NCT04528927|Experimental|Azithromycin+Doxycycline|"Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
~Doxycycline: 200 mg per day for 10 days.
~Usual standard treatment"
16321448|NCT04528914|Experimental|Low-FODMAP diet|37 participants.
16321449|NCT04528914|No Intervention|Regular diet|"37 participants. The regular diet will reflect the habitual FODMAP intake in a normal diet.
~Diets in both groups will be matched in terms of total energy, fat, protein, carbohydrates and dietary fiber with the usual participant's diet."
16321450|NCT04528888|Active Comparator|LMWH group|The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). Patients in this group will be administered enoxaparin at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment with enoxaparin will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered subcutaneously, daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
16321451|NCT04528888|Experimental|LMWH + steroids group|"The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization).
~Patients in this group will receive enoxaparin and methylprednisolone. Enoxaparin will be administered at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14."
16321860|NCT04526301||Tablo Hemodialysis System|Home dialysis treatment with the Tablo Hemodialysis System
16321452|NCT04528888|Experimental|UFH + steroid group|The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
16321453|NCT04528862|Experimental|Nature|
16321454|NCT04528862|Sham Comparator|Urban|
16321455|NCT04528849|Active Comparator|Early dose increment|Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction
16321456|NCT04528849|Active Comparator|Late dose increment|Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction
16321457|NCT04528836|Experimental|Dose Escalation Level 1|Level 1 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
16321458|NCT04528836|Experimental|Dose Escalation Level 2|Level 2 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
16321459|NCT04528836|Experimental|Dose Escalation Level 3|Level 3 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
16321460|NCT04528836|Experimental|Dose Escalation Level 4|Level 4 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
16321461|NCT04528836|Experimental|Dose Escalation Level 5|Level 5 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
16321462|NCT04528836|Experimental|Dose Escalation Level 6|Level 6 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
16321463|NCT04528836|Experimental|Expansion Cohort A: Advanced KRAS G12C NSCLC|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
16321464|NCT04528836|Experimental|Expansion Cohort B: Advanced KRAS G12C non-NSCLC|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
16321465|NCT04528836|Experimental|Expansion Cohort C: Advanced solid tumor with other MAPK-|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
16321466|NCT04528836|Experimental|Expansion Cohort D: Advanced EGFR-mutant NSCLC|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
16321467|NCT04528823|No Intervention|Standard care (control arm)|Strategy 1: Symptoms screen, CXR and TST (standard)
16321468|NCT04528823|Active Comparator|GeneXpert (GX)|Strategy 2: Symptoms screen, Genexpert and TST
16321469|NCT04528823|Active Comparator|CXR for all/NoTST|Strategy 3: Symptoms screen, CXR but NO TST
16321470|NCT04528810||Child injuries|pediatric patients under the age of 18 years newly diagnosed with injuries in the emergency department
16321471|NCT04528797|Experimental|Levothyroxine|Levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
16321472|NCT04528797|Experimental|Methylprednisolone|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later.
16321473|NCT04528797|Experimental|Combination|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later plus levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
16321474|NCT04528797|No Intervention|Control|No levothyroxine or methylprednisolone administered.
16321475|NCT04528784|Experimental|Intervention|Transcutaneous tibial nerve stimulation will be applied as follows: 18 sessions of 30 minutes duration, delivered three times a week over a 6 week period using TENS device with 10 Hertz (Hz), and pulse width 200µs. The intensity of stimulation will be at the sensory and motor threshold by tingling sensation on sole of the foot with flexion of big toe and /or fanning of other toes.
16321478|NCT04528758|Experimental|Dosimetry group|Patients in the dosimetry group will be imaged with the radio-pharmaceutical Rhodamine 6G at different time points. 0-120, 30-150, 60-180
16321479|NCT04528758|Active Comparator|Stable Heart Patients|Stable heart patients will be given a rest/stress PET/CT with Rhodamine 6G myocardial perfusion study to determine myocardial blood flow
16321480|NCT04528745||Patients with cancer receiving cytostatic treatment|Consecutive patients referred for cytostatic treatment or in treatment with cytostatic agents for colorectal or pancreatic cancer
16321481|NCT04528732|No Intervention|Usual Care|Usual care consists of the traditional clinic intervention that focuses on testing services, ART treatment, and information about disease management.
16321482|NCT04528732|Experimental|Group-Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
16321483|NCT04528732|Experimental|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
16321484|NCT04528719|Experimental|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
16321485|NCT04528719|Experimental|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
16321486|NCT04528719|Experimental|Cohort 3: Dose B in Younger Adults|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
16321487|NCT04528719|Experimental|Cohort 4: Dose C in Younger Adults|Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.
16321488|NCT04528719|Experimental|Cohort 5: Dose D in Children|Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
16321489|NCT04528719|Experimental|Cohort 6: Dose B in Children|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
16321490|NCT04528719|Experimental|Cohort 7: Dose A in Older Adults|Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
16321491|NCT04528719|Experimental|Cohort 8: Dose B in Older Adults|Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
16321492|NCT04528719|Experimental|Cohort 9: Dose C in Older Adults|Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
16321493|NCT04528719|Experimental|Cohort 10: Dose E in Older Adults|Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
16321494|NCT04528719|Experimental|Cohort 11: Dose F in Older Adults|Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
16321495|NCT04528719|Experimental|Cohort 12: Dose E in Women of Child-Bearing Potential|Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.
16321496|NCT04528719|Experimental|Cohort 13: Dose F in Women of Child-Bearing Potential|Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.
16321497|NCT04528719|Experimental|Cohort 14: Dose A in Women of Child-Bearing Potential|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
16321498|NCT04528719|Experimental|Cohort 15: Dose B in Japanese Older Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
16321499|NCT04528706|Experimental|MIN-102|
16321500|NCT04528693|Experimental|Intervention|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will perform, for a period of 3 months, 3 times a week, strength training, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software.
16321501|NCT04528693|No Intervention|Control|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will be asked to maintain their current level of physical activity and their diet for a period of 3 months.
16321502|NCT04528680|Experimental|SC9/ABX|Infusion of albumin-bound paclitaxel immediately followed by sonication using the SC9 device and microbubbles in order to open the blood-brain barrier.
16321503|NCT04528667|Experimental|STI-5656|STI-5656 (abivertinib maleate) capsules administered orally 100 mg QD for 7 days, in addition to standard of care
16321504|NCT04528667|Placebo Comparator|Placebo|Placebo capsules administered orally daily for 7 days, in addition to standard of care
16321505|NCT04528654|Experimental|Intervention App Group|The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
16321506|NCT04528654|No Intervention|Educational Control Group|The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.
16321507|NCT04528641|Experimental|Arm 1 - Low dose|Arm-1 Healthy adult volunteers aged 18-55y will receive IM single dose of 5e10vp. N=15
16321508|NCT04528641|Experimental|Arm 2 - Intermediate dose|Arm-2 Healthy adult volunteers aged 18-55y will receive IM single dose of 1e11vp. N=15
16321509|NCT04528641|Experimental|Arm 3 - High dose|Arm-3 Healthy adult volunteers aged 18-55y will receive IM single dose of 2e11vp. N=15
16321510|NCT04528641|Experimental|Arm 4 - Low dose|Arm-4 Healthy elderly volunteers aged 65-85y will receive IM single dose of 5e10vp. N=15
16321511|NCT04528641|Experimental|Arm 5 - Intermediate dose|Arm-5 Healthy elderly volunteers aged 65-85y will receive IM single dose of 1e11vp. N=15
16321512|NCT04528641|Experimental|Arm 6 - High dose|Arm-6 Healthy elderly volunteers aged 65-85y will receive IM single dose of 2e11vp. N=15
16321513|NCT04528628|Experimental|MDD with melancholic features|
16321514|NCT04528628|Experimental|MDD with atypical features|
16321515|NCT04528628|Experimental|MDD with anxious distress|
16321516|NCT04528628|Experimental|MDD (overall)|
16321517|NCT04528615|Experimental|CCK In-Person Sessions|This group received the in-person CCK intervention.
16321518|NCT04528615|Active Comparator|CCK Printed Materials|This group received select printed CCK materials.
16321519|NCT04528602|Experimental|Control (Extended leg position) Group|In the control (Extended leg position) group of the study, diaper change will be performed after the legs of the babies are brought to extension.
16321520|NCT04528602|Experimental|Experimental (Legs are flexed toward abdomen) Group|In the experimental (Legs are flexed toward abdomen) group, the diaper change will be performed after the legs of the babies are brought closer to the abdomen while maintaining their flexion leg position.
16321521|NCT04528589||Mothers|Women with adverse childhood experiences referred for treatment in gestational week 20-30
16321522|NCT04528589||Therapists|Clinicians with experience of providing psychotherapy to women with adverse childhood experiences referred for treatment during pregnancy
16321523|NCT04528576|Experimental|DragonFly-M|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Meditech Co., Ltd
16321524|NCT04528563|Experimental|Ketorolac Tromethamine|IV ketorolac tromethamine, 0.5 mg/kg to a maximum of 30 mg plus IV morphine placebo;
16321525|NCT04528563|Active Comparator|Morphine Sulfate|IV morphine 0.1 mg/kg to a maximum of 5 mg plus IV ketorolac placebo
16321861|NCT04526288|Active Comparator|Arm A (alloHCT)|Patients undergo alloHCT.
16321526|NCT04528550|Experimental|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection in acute phase. Each included patient will receive a single dose of 100 million autologous bone marrow-derived mononuclear cells.
16321527|NCT04528550|Placebo Comparator|Control|Included patients will receive the same amount of saline through lumbar injection.
16321528|NCT04528511||Low burden of new-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value<10.87% (previously established) will be divided into the low burden group.
16321529|NCT04528511||High burden of new-onset atrial fibrillation|For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.
16321530|NCT04528485|Experimental|Sea swimming|8 sessions over 4 weeks of swimming-based activities in the sea
16321531|NCT04528472|Experimental|Acupuncture Treatment|Acupuncture Treatment: main point: DU20, DU24, MS7, LI4, ST40 Oral Medicine Rehabilitation Treatment
16321532|NCT04528472|Experimental|Regular Treatment|Acupuncture Treatment Oral Medicine Rehabilitation Treatment
16321533|NCT04528459|Active Comparator|Traditional fluoroscopy|Cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw (current standard of care).
16321534|NCT04528459|Experimental|Stryker© ADAPT™ platform|Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.
16321537|NCT04528433|Experimental|Medical-education-community Collaborated Intervention|
16321538|NCT04528433|Active Comparator|routine clinical care|
16321539|NCT04528420|Experimental|Optimised arm|Patients will be taken care of early and optimally way.
16321540|NCT04528420|No Intervention|Standard arm|Patients will be monitored as in standard practice
16321541|NCT04528394|Experimental|Photon combined with Carbon ion|The participants received photon: 56 Gy/28 Fx for high-risk area(CTVhigh), 50.4 Gy/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
16321542|NCT04528394|Experimental|Proton combined with Carbon ion|The participants received proton: 56 GyE/28 Fx for high-risk area(CTVhigh), 50.4 GyE/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
16321543|NCT04528381|Other|Laparoscopy|Diagnostic and therapeutic laparoscopy
16321544|NCT04528368|Experimental|Convalescent Plasma + Standard treatment|Participants will receive the standard treatment and convalescent plasma
16321545|NCT04528368|No Intervention|Standard treatment|Participants will receive the standard treatment
16321546|NCT04528329|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
16321547|NCT04528329|Active Comparator|Late CS|Dexamethasone is to be used lately upon the deterioration of cases
16321548|NCT04528316|Active Comparator|Control Group/Pilates Core Stability Exercises program Group|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks
~Stages: Three stages:
~Stage I: Warm-up: consists of four Pilates motions:
~Breathing:
~Rolling back:
~Coccyx-curl:
~Hundred breathing:
~Stage II: Work-out: consists of twelve Pilates motions:
~Single leg stretch:
~Straight leg raise:
~Basic bridge:
~Bridging variation:
~Quadruped:
~Clap with seal motion
~Mermaid twist:
~Swimming:
~Double leg stretch:
~Shoulder bridge:
~Swan dive:
~Leg full front:
~Stage III: Cool-down: consists of three Pilates motions:
~Rest position:
~Cat with arm/leg extension:
~Breathing:"
16321549|NCT04528316|Experimental|Balance Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Balance Program
16321550|NCT04528316|Experimental|Coordination Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Coordination Exercises.
16321551|NCT04528303|Experimental|Whole genome sequencing|
16321552|NCT04528303|Active Comparator|Whole exome sequencing|
16321553|NCT04528290|Experimental|Group A (reference): Current ozanimod capsule formulation|Single oral dose of ozanimod 0.92 mg
16321554|NCT04528290|Experimental|Group B (test): Ozanimod granule formulation|Single oral dose of ozanimod 0.92 mg using Sprinkle capsule. Ozanimod Sprinkle Capsule will be opened, and the entire contents sprinkled onto a teaspoon (5 mL) of applesauce.
16321555|NCT04528277|Experimental|LGTB treatment group|The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw).
16321556|NCT04528277|No Intervention|LGTB no treatment group|The LGTB no treatment group will not take any medication related to preventive treatment of tuberculosis.
16321557|NCT04528277|No Intervention|non-LGTB group|The non-LGTB group will not take any medication related to preventive treatment of tuberculosis.
16321558|NCT04528264|Experimental|Ultrasound guided|Intraoperative high frequency ultrasound used to guide the reduction of depressed zygomatic arch.
16321559|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction of zygomatic arch fracture will be conducted without any intraoperative imaging.
16321560|NCT04528238|Experimental|Relaxing Visual Immersion|The patients will benefit a Relaxing Visual Immersion during the intravenous treatment for their cancer.
16321561|NCT04528238|No Intervention|No sensitive stimulation|The patients will not receive Relaxing Visual Immersion during the intravenous treatment for their cancer.
16321562|NCT04528212|Experimental|Group I|Glimepiride (4 mg) per Day
16321563|NCT04528212|Experimental|Group II|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
16321564|NCT04528212|Experimental|Group III|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
16321565|NCT04528199|Experimental|[18F]FLOR (FC303)|[18F]FLOR (FC303) PET/CT imaging.
16321568|NCT04528173|Active Comparator|Traditional Care Group (TCG)|Traditional anesthetic with opioids group will receive institutional standard clinical care for tonsillectomy, including a standardized opioid dose at the beginning of the case and again at the end if needed. Dexmedetomidine and Ketorolac will not be used intra-operatively in this cohort to prevent confounding.
16321569|NCT04528173|Experimental|Opioid-Free Group (OFG)|Opioid-Free group will receive institutional standard clinical care for tonsillectomy, without opioids, but including Dexmedetomidine and Ketorolac.
16321570|NCT04528160|Experimental|Pain neuroscience education and exercise|"This group will receive an 8-week intervention (1 session per week) of pain neuroscience education and exercise.
~PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will include mobility, balance and strength exercises."
16321571|NCT04528160|Active Comparator|Usual care|This group will receive usual care administered by general practitioners at primary care.
16321572|NCT04528147|Experimental|Yi Jin Jing Tiger Roaring Speech Rehabilitation|Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.
16321573|NCT04528147|Experimental|Conventional Speech Rehabilitation|"Patients will receive speech rehabilitation recommended by The Parkinson's Foundation.
~Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total."
16321574|NCT04528134|Experimental|Extended Contact RMGI Varnish/5% Sodium Fluoride Varnish|This group will receive extended contact (XT) varnish on their upper left and lower right teeth, and traditional 5% sodium fluoride varnish on their upper right and lower left teeth.
16321575|NCT04528134|Experimental|Placebo Varnish/Extended Contact RMGI Varnish|This group will receive placebo varnish on their upper left and lower right teeth, and extended contact (XT) varnish on their upper right and lower left teeth.
16321576|NCT04528134|Active Comparator|5% Sodium Fluoride Varnish/Placebo Varnish|This group will receive traditional 5% sodium fluoride varnish on their upper left and lower right teeth, and placebo varnish on their upper right and lower left teeth.
16321577|NCT04528121|Experimental|study group|(CoDuSe) exercise inform of core stability, dual tasking, and sensory strategies the conventional selected exercise program inform of static and dynamic balance training exercises
16321578|NCT04528121|Experimental|control group|the conventional selected exercise program inform of static and dynamic balance training exercises
16321579|NCT04528108|Experimental|ZYZQ Group|ZYZQ group is the experimental group which is treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine for 3 months.
16321580|NCT04528108|Active Comparator|GXN Group|GXN group is the active Comparator group which is treated with Gong Xue Ning capsules for 3 months
16321581|NCT04528095|Experimental|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml
16321582|NCT04528095|Experimental|Clozapine+Amisulpride|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d
16321583|NCT04528095|Experimental|Clozapine+Gingke biloba|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Gingke biloba 120-360mg/d
16321584|NCT04528095|Experimental|MECT|MECT:The treatment lasted for 4 months,16 times in total
16321585|NCT04528095|Experimental|MST|MST:The treatment lasted for 4 months,16 times in total
16321586|NCT04528095|Experimental|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
16321589|NCT04528069|Experimental|PanOptix Toric Trifocal IOL|PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
16321590|NCT04528056|Experimental|Ambrisentan+Sulfasalazine|
16321591|NCT04528056|Active Comparator|Ambrisentan+Sulfasalazine's placebo|
16321592|NCT04528056|Experimental|Ambrisentan's placebo+Sulfasalazine|
16321593|NCT04528056|Placebo Comparator|Ambrisentan's placebo+Sulfasalazine's placebo|
16321594|NCT04528043||critically ill patients|critically ill patients admitted in one of the 5 ICUs of the university hospital of Nancy during the year 2016 with documented third group enterobacteriaceae infection and/or colonization with third group enterobacteriaceae
16321595|NCT04528030|Other|Treatment starting with an on ON cycle|The treatment will start ON cycle for 6 hours, followed by OFF cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
16321596|NCT04528030|Other|Treatment starting with an on OFF cycle|The treatment will start OFF cycle for 6 hours, followed by ON cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
16321597|NCT04528017|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16321598|NCT04528017|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16321599|NCT04528004|Experimental|Nicotinamide riboside|"Participants randomized to Nicotinamide Riboside (NR) and scheduled to receive an LVAD will receive nicotinamide riboside (NR) capsules according to the following administration schedule:
~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
16321708|NCT04527276|Active Comparator|Chlorhexidine|5 ml of 0,12 % Chlorhexidine (CHX) solution is applied to the intervention group for oral care
16321709|NCT04527276|No Intervention|Placebo Group|Group of patients who received standard oral care
16321600|NCT04528004|Placebo Comparator|Placebo|"Participants randomized to Placebo and scheduled to receive an LVAD will receive Placebo capsules according to the following administration schedule:
~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
16321603|NCT04527978|Other|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16321604|NCT04527978|Other|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
16321605|NCT04527965|Experimental|Customized diet to reduce liver fat|Ad libitum diet high in plant-derived PUFA and lower in carbohydrates
16321606|NCT04527965|Experimental|Healthy Nordic diet|Ad libitum diet, based on Nordic foods, higher in carbohydrates (high fiber/low GI) and lower in fat but rich in monounsaturated fatty acids (MUFA) and PUFA
16321607|NCT04527965|Active Comparator|Control|Ad libitum diet in accordance with the Nordic Nutrition Recommendations
16321608|NCT04527952|Experimental|Time-restricted feeding (TRF)|Participants will eat the majority of their calories in the day. More specifically participants will consume 70% of their total calories before 5 pm and the remaining 30% after 5 pm.
16321609|NCT04527952|Active Comparator|Intermittent fasting (IF)|This involves eating all of one's meals within a specific time (e.g. 8 hours) frame and fasting for the remaining hours (16 hours) in a day.
16321610|NCT04527952|Active Comparator|Alternate day fasting (ADF)|This involves complete fasting (i.e. no food or caloric containing beverages, only water consumption) for roughly an entire 36-hour period, followed by an ad libitum feeding day.
16321611|NCT04527939|Active Comparator|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
16321612|NCT04527939|Sham Comparator|magnification chromoendoscopy.|magnification chromoendoscopy.
16321613|NCT04527926|Experimental|STEPuP Intervention|STEPuP interventions
16321614|NCT04527926|Active Comparator|Usual Care|Standard of Care
16321615|NCT04527913|Experimental|Control group|15 patients receiving oral hygiene instructions as determined by their group allocation (use of manual toothbrush alone)
16321616|NCT04527913|Experimental|Test group 1|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus dental floss)
16321617|NCT04527913|Experimental|Test group 2|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus interdental brushes)
16321618|NCT04527913|Experimental|Test group 3|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus rubber interdental picks)
16321619|NCT04527900|Experimental|Concurrent chemoradiation|Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
16321620|NCT04527887|Active Comparator|Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)|intracanalicular dexamethasone insert
16321621|NCT04527887|Placebo Comparator|ProLong™ collagen plugs|collagen plug
16321622|NCT04527874|Experimental|Intervention|Clusters in the intervention arm receive the VITAL intervention (see intervention)
16321623|NCT04527874|No Intervention|Control|Clusters in the control arm continue standard of care.
16321624|NCT04527861|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
16321625|NCT04527861|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（3~5 ports）.
16321626|NCT04527848|Experimental|small amount of undiluted C3F8|
16321627|NCT04527848|Active Comparator|large amount of diluted C3f8|
16321628|NCT04527848|Active Comparator|small amount of undiluted SF6|
16321629|NCT04527848|Active Comparator|large amount of diluted SF6|
16321630|NCT04527835||patients suspected for viral myocarditis|All patients admitted with unexplained heart failure in the last 3 months will be investigated for viral myocarditis by the use of 12 lead ECG, echocardiography, Cardiac MRI , coronary angiography, Endomyocardial biopsy ( optional ), serological tests including ELIZA,Extraction of nucleic acid, Determination of viral genome by using PCR., Quantitative real-time PCR to assess viral load, Immunohistochemistry analysis of EMB.
16321631|NCT04527822|Experimental|Discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
16321632|NCT04527822|Active Comparator|Standard Care|
16321633|NCT04527809|Experimental|tDCS-active|tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area.
16321710|NCT04527263|Active Comparator|group A|subjected to institutional protocol of diagnosis of acute appendicitis
16321711|NCT04527263|Active Comparator|group B|subjected to institutional protocol of diagnosis of acute appendicitis plus measurement of urinary 5-HIAA
16321634|NCT04527809|Sham Comparator|tDCS-sham|tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
16321635|NCT04527796|Other|rehabilitation|All included patients get an pre-intervention and a post intervention analysis
16321636|NCT04527783|Experimental|experimental group|"Each subject will perform a variety of VR exercises to reduce impairments in their finger range of motion, speed and strength.
~It includes a glove-shaped sensor device and a software application."
16321637|NCT04527783|Active Comparator|control group|Each subject will perform usual care rehabilitation aimed at improving manual dexterity
16321638|NCT04527770|Active Comparator|dexamethasone group|sonar guided median nerve hydrodissection by lidocaine and dexamethasone
16321639|NCT04527770|Active Comparator|midazolam group|sonar guided median nerve hydrodissection by lidocaine and dexamethasone
16321640|NCT04527757||Paediatric patients with inhalation induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
16321641|NCT04527757||Paediatric patients with intravenous induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O). For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
16321642|NCT04527744|Experimental|the Yonsei point group|Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifacies) will be initially injected at the Yonsei point.
16321643|NCT04527744|Active Comparator|the levator labii superioris alaeque nasi muscle group|For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
16321644|NCT04527718|Experimental|Cohort 1|611 dose 1 (45mg) plus placebo
16321645|NCT04527718|Experimental|Cohort 2|611 dose 2 (150mg) plus placebo
16321646|NCT04527718|Experimental|Cohort 3|611 dose 3 (300mg) plus placebo
16321647|NCT04527718|Experimental|Cohort 4|611 dose 4 (450mg) plus placebo
16321648|NCT04527718|Experimental|Cohort 5|611 dose 5 (600mg) plus placebo
16321649|NCT04527705|Active Comparator|1-vist endodontic retreatment|Non-surgical root canal retreatment performed in one visit
16321650|NCT04527705|Active Comparator|2-vist endodontic retreatment|Non-surgical root canal retreatment performed in two visits
16321651|NCT04527692||Child|Children/adolescents from 1 to 18 years of age with a serious illness requiring follow-up by a regional pediatric palliative care resource team and/or temporarily hospitalized.
16321652|NCT04527692||Parents|Adult person with parental authority over a child between the ages of 1 and 18 who is a carrier of a serious illness and requires follow-up by a regional pediatric palliative care resource team and/or is temporarily hospitalized.
16321653|NCT04527679|Experimental|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.
~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
16321654|NCT04527666||Anticoagulation group|Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.
16321655|NCT04527666||Control group|Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.
16321656|NCT04527653|Experimental|Tixel Treatment|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology
16321657|NCT04527640|Experimental|Synbiotic Arm|Patients receiving synbiotics: Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 Colony Forming Unit (CFU) and Fructooligosaccharides (FOS) 60 mg, 2 capsules/day for 60 days
16321658|NCT04527640|Placebo Comparator|Placebo Arm|Patients receiving placebo capsules containing saccharum lactis (2 capsules/day for 60 days)
16321659|NCT04527627|Experimental|Experimental Group (EG)|The nursing empowerment intervention will be administered in the experimental group
16321660|NCT04527627|No Intervention|Control Group (CG)|The nursing empowerment intervention will not be administered in the control group
16321663|NCT04527601||ELGAN admissions during peak three months of COVID-19 pandemic|
16321664|NCT04527601||ELGAN admissions in the three corresponding months of 2019|
16321665|NCT04527575|Experimental|"EpiVacCorona (An Open Study)"|Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
16321666|NCT04527575|Experimental|"EpiVacCorona (A Simple, Blind, Randomized Study)"|Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)
16321667|NCT04527575|Placebo Comparator|"Placebo (A Simple, Blind, Randomized Study)"|Group 3: Тhe use of placebo (sodium chloride, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)
16321668|NCT04527562|Active Comparator|TRAETMENT GROUP|Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
16321712|NCT04527250|Experimental|Experimental:1mg|ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
16322345|NCT04522843||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
16321669|NCT04527562|Placebo Comparator|CONTROL /PLACEBO GROUP|"COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.
~Standard care of enrolled study patients will consist:
~Isolation facility
~Symptomatic treatment with Paracetamol, Fexofenadine
~Steam inhalation/Gurgle of Lukewarm water.
~Ensuring of hand wash (20 seconds each time) and ideally wearing mask.
~Monitoring by the attending nurses."
16321670|NCT04527549|Experimental|Arm A (dabrafenib, trametinib, hydroxychloroquine)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16321671|NCT04527549|Active Comparator|Arm B (dabrafenib, trametinib, placebo)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16321672|NCT04527536||early-set BMJ group|Infants were admitted to our hospital at 4-7 days of age and were followed up to 28 days. Other pathological jaundice factors were excluded.Those who met the criteria were the early-onset BMJ group.
16321673|NCT04527536||late-onset BMJ group|Infants were admitted to our hospital after 7 days of age and were followed up to 28-42 days or until the jaundice disappeared. Other pathological jaundice factors were excluded..Those who met the criteria were late-onset BMJ
16321674|NCT04527536||healthy control|During the same period, the healthy newborns who were born in the obstetrics department of our hospital. These newborns were mainly breastfed or breastfed, and grew well. They were enrolled at 7-14 days of age and were followed up to 28-42 days without pathological jaundice.
16321675|NCT04527523||Endothelial Dysfunction Cohort|All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.
16321676|NCT04527510||double reading|Each patient will have the following: Screening whole breast ultrasound.
16321677|NCT04527510||second-reading|Each patient will have the following: Screening whole breast ultrasound.
16321678|NCT04527510||concurrent-reading|Each patient will have the following: Screening whole breast ultrasound.
16321679|NCT04527484|Active Comparator|Group A|SHR-1314 Vial
16321680|NCT04527484|Active Comparator|Group B|SHR-1314 PFS
16321681|NCT04527471|Active Comparator|Ensifentrine + Standard of Care|30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection
16321682|NCT04527471|Placebo Comparator|Placebo + Standard of Care|15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection
16321683|NCT04527458||Hospitalisations|All hospitalised COVID patients
16321684|NCT04527458||Critical care|All hospitalised COVID patients in critical care
16321685|NCT04527445|Experimental|Reduced Radiation Fluoroscopy|Reduced radiation fluoroscopy technique is performed by the C-arm set at 1 pulses-per-second and reduction of current.
16321686|NCT04527445|Active Comparator|Conventional Fluoroscopy|The standard of care is the conventional fluoroscopy, the C-arm is set at 30 pulses-per-second and the current set as the default.
16321687|NCT04527432|Other|All participants|Survey at 6 and 12 months time with optional antibody tests
16321688|NCT04527419|Active Comparator|Systematically mediastinal lymph node dissection group|Patient would receive systematically mediastinal lymph node dissection in surgery.
16321689|NCT04527419|Experimental|No systematically mediastinal lymph node dissection group|Patient would not receive systematically mediastinal lymph node dissection in surgery.
16321690|NCT04527406|Experimental|Early surgical group|The subjects in this group received early surgical treatment, and they are arranged to be admitted to the hospital for surgical treatment after admission. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction.
16321691|NCT04527406|Active Comparator|Traditional surgical treatment|This group of subjects received conservative treatment with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5.
16321692|NCT04527393|Experimental|individualized opioid analgesia regimen group|The dose of oral morphine for patients in the individualized group is determined according to the results of fentanyl test.
16321693|NCT04527393|Active Comparator|conventional opioid analgesia regimen group|Patients in the conventional group are given routine dose of oral morphine.
16321696|NCT04527367||VHD patients|Patients with moderate and severe valvular heart diseases
16321697|NCT04527354|Experimental|Treamid 50 mg|1 tablet of Treamid 50 mg once a day during 4 weeks of treatment period.
16321698|NCT04527354|Placebo Comparator|Placebo|1 tablet of Placebo once a day during 4 weeks of treatment period
16321699|NCT04527341||cardiac surgery patients in ICU|
16321700|NCT04527328|Experimental|AKST1210 apheresis device|The AKST1210 column will be connected to the dialysis circuit during each dialysis session.
16321701|NCT04527328|Placebo Comparator|Control column|A sham control with no effect on the dialyzed blood will be used.
16321702|NCT04527315||COVID-19 ICU Patients|
16321703|NCT04527315||Control|
16321704|NCT04527302|Active Comparator|active tDCS+exposure based CBT|the exposure and response prevention (ERP) treatment combined with an anode transcranial direct current stimulation over the mPFC will be applied twice a week for the fist two weeks. For the next four weeks, the active tDCS+ERP will be applied once a week. 8 times in total
16321705|NCT04527302|Sham Comparator|sham tDCS +exposure based CBT|the exposure and response prevention (ERP) treatment combined with an sham transcranial direct current stimulation over the mPFC will be applied twice a week for the fist two weeks. For the next four weeks, the sham tDCS+ERP will be applied once a week. 8 times in total
16321706|NCT04527289|Experimental|Amantadine Group|Group, I are patients who will receive amantadine (100mg) as add on therapy to the standard regimen.
16321707|NCT04527289|Placebo Comparator|Placebo Group|Group II are patients who will be managed with the standard regimen.
16321713|NCT04527250|Experimental|Experimental:2mg|ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
16321714|NCT04527250|Experimental|Experimental:5mg|ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
16321715|NCT04527250|Experimental|Experimental:10mg|ASC41 two tablets (10mg) single oral dose at Day 1.
16321716|NCT04527250|Experimental|Experimental:20mg|ASC41 four tablets (20mg) single oral dose at Day 1.
16321717|NCT04527250|Placebo Comparator|Placebo:1mg|ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
16321718|NCT04527250|Placebo Comparator|Placebo:2mg|ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
16321719|NCT04527250|Placebo Comparator|Placebo:5mg|ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
16321720|NCT04527250|Placebo Comparator|Placebo:10mg|ASC41 placebo two tablets (10mg) single oral dose at Day 1.
16321721|NCT04527250|Placebo Comparator|Placebo:20mg|ASC41 placebo four tablets (20mg) single oral dose at Day 1.
16321722|NCT04527237|Experimental|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total.Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.
~Application to acupressure points in a certain order; Baihui, Susanli, Hegu, Shenmen and Quchi will be held.
~After 2-3 minutes of approach to the patient and proper positioning, 20 seconds of preparation of each of the notes will be prepared and then 2 minutes acupressure application will be applied to each point."
16321723|NCT04527237|Placebo Comparator|placebo|The false acupressure application steps (temperature of the environment, patient's position, application time, frequency and repetition, evaluation period etc.) will be the same as the acupressure application steps. Unlike acupressure, it will only be in contact with wearing gloves to reduce the electrical effect of touch, away from the actual acupressure points. Touching any part of the body or making skin contact can be an effect alone, as well as other meridians and points are located near the existing meridian and selected points, and entering their area of influence, pressing or scrubbing can cause other effects to be activated.
16321724|NCT04527224|Experimental|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
16321725|NCT04527211|Experimental|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
16321726|NCT04527211|Placebo Comparator|Placebo|Oral administration of placebo of similar characteristics every week for seven weeks
16321727|NCT04527198|Experimental|group 1|Major patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)
16321728|NCT04527185|Experimental|Endotoxin|Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.
16321729|NCT04527185|Placebo Comparator|Placebo|Administered one time during the laboratory session.
16321730|NCT04527172||systemic lupus patients|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
16321731|NCT04527172||Healthy subjects|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
16321732|NCT04527159|Other|desensitizing agents (Fluoraphat Pro and VivaSens®)|"22 participants above the age of 18 years who presented to dental clinics in Riyadh Elm University with dentine hypersensitivity were randomly selected to participate in the study.
~Each participant has at least two teeth with natural hypersensitivity which was not caused by any iatrogenic causes or bad oral habits, so there are 44 cases divided into two groups according to the material used, each group has 22 teeth, that make it applicable to apply the studied material with every patient on individual tooth with the same variables of the oral mouth. When teeth in the hypersensitivity group were evaluated for the level of DH, all teeth were found to have Grade 4 sensitivity."
16321733|NCT04527146|Experimental|IMAGINE-PD/Virtual|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via virtual visit with a genetic counselor.
16321734|NCT04527146|Experimental|IMAGINE-PD/Telephone|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via telephone with a genetic counselor.
16321735|NCT04527146|Experimental|Virtual/Telephone|Pre-test genetic counseling virtual visit with a genetic counselor. Genetic results disclosure via telephone with a genetic counselor.
16321736|NCT04527146|Active Comparator|Virtual/Virtual|Pre-test genetic counseling and genetic results disclosure via virtual visit with a genetic counselor.
16321737|NCT04527133|Experimental|Stage 1/Group 1|Intravenous Aprotinin in addition to standard care: 1 000 000 KIU IV daily during 3 days
16321738|NCT04527133|Experimental|Stage 2/Group 2|Inhaled Aprotinin in addition to standard care: 625 KIU 4 times per day during 5 days
16321739|NCT04527133|Experimental|Stage 2/Group 3|Intravenous Aprotinin in addition to standard care that includes Favipiravir: 1 000 000 KIU IV daily during 5 days
16321740|NCT04527120|Other|Model A first and then B|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
16321780|NCT04526873|No Intervention|Control|No intervention control group
16321781|NCT04526873|Experimental|Postcard: non-telehealth, photo|This group receives a postcard that does not include telehealth information and features a stock photo
16322346|NCT04522830|Experimental|BTL-TML-COVID|BTL-TML-COVID
16321741|NCT04527120|Other|Model B first and then A|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
16321742|NCT04527107|Experimental|THR-149 dose level 1|
16321743|NCT04527107|Experimental|THR-149 dose level 2|
16321744|NCT04527107|Experimental|THR-149 dose level 3|
16321745|NCT04527107|Active Comparator|aflibercept|
16321746|NCT04527107|Experimental|THR-149 selected dose level|
16321747|NCT04527094||AI_PRF|Adults patients undergoing general anesthesia
16321748|NCT04527081|Experimental|Group A|
16321749|NCT04527081|Experimental|Group B|
16321750|NCT04527081|Experimental|Group C|
16321751|NCT04527068|Experimental|Bevacizumab +Tripleitriumab|Participants receive bevacizumab 7.5mg/kg and tripleitriumab 240mg in day 1 intravenously every 3week until disease progression or unacceptable toxicity
16321752|NCT04527055|Active Comparator|The 14-day bismuth-based quadruple therapy group|The patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
16321753|NCT04527055|Active Comparator|The 10-day bismuth-based quadruple therapy group|The patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
16321754|NCT04527055|No Intervention|The non-H. pylori-infected control|Age- and sex-matched patients who do not have H. pylori infection by endoscopic gastric biopsy are enrolled as the non-H. pylori-infected control.
16321755|NCT04527055|Active Comparator|The probiotic therapy group|"The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of >= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
16321756|NCT04527055|No Intervention|The non-probiotic control group|The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the non-probiotic control therapy and they do not ingest probiotic powder.
16321757|NCT04527029||limb deformity children|the imaging of limb deformity diagnosis by AI
16321760|NCT04527003|Placebo Comparator|Group A - Placebo|Norethindrone acetate (5mg daily) + Placebo
16321761|NCT04527003|Active Comparator|Group B - Low Dose CBD|Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
16321762|NCT04527003|Active Comparator|Group C - High Dose CBD|Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
16321763|NCT04526990|Experimental|Experimental group|20000 participants, Ad5-nCoV , single dose, Intramuscular administration
16321764|NCT04526990|Placebo Comparator|Placebo group|20000 participants, placebo, single dose, Intramuscular administration
16321767|NCT04526964|Other|Intervention Group (IGr)|Participants of the intervention group (IGr) receive self-management support and skills training based on the modular self-management curriculum during the inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up and a supplementary app.
16321768|NCT04526964|No Intervention|Control Group (CGr)|Participants in the control group (CGr) receive the standard follow-up procedures (care as usual).
16321769|NCT04526951|Active Comparator|Tenecteplase|The total dose of tenecteplase is 0.25 mg/kg body weight, maximum 25 mg. The total dose will be given as an intravenous bolus
16321770|NCT04526951|Active Comparator|acetylsalicylic acid|one tablet of aspirin 300 mg Other Name: Aspirin
16321772|NCT04526925|Active Comparator|standard CPET|Standard CPET will be performed without in-line filter
16321773|NCT04526925|Experimental|standard CPET with in-line filter|An in-line filter will be placed on the mouthpiece during standard CPET
16321774|NCT04526912|Experimental|VIB7734 Dose|Participants will receive a single subcutaneous dose of VIB7734.
16321775|NCT04526912|Placebo Comparator|Placebo|Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.
16321776|NCT04526899|Experimental|BNT111 + cemiplimab|
16321777|NCT04526899|Experimental|BNT111 monotherapy|
16321778|NCT04526899|Experimental|Cemiplimab monotherapy|
16321857|NCT04526327|Other|exercise group|Female and male patients over 70 years of age with osteoporosis and sarcopenia
16321782|NCT04526873|Experimental|Postcard: non-telehealth, salience/humorous cartoon|This group receives a postcard that does not include telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
16321783|NCT04526873|Experimental|Postcard: telehealth, photo|This group receives a postcard that does includes telehealth information and features a stock photo
16321784|NCT04526873|Experimental|Postcard: telehealth, salience/humorous cartoon|This group receives a postcard that includes telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
16321785|NCT04526873|Experimental|Phone call|This group receives a phone call
16321786|NCT04526860|No Intervention|Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
16321787|NCT04526860|Other|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
16321788|NCT04526847|Experimental|Intervention|"Intermittent energy restricted (IER) group:
~IER group will receive 5:2 diet pattern (5 day without energy restriction and 2 days with 75% energy restriction, net weekly energy deficit ~25%)"
16321789|NCT04526847|Active Comparator|Calorie Restricted Diet (CER)|"Continuous energy restricted (CER) group:
~CER group with a low-calorie diet (daily energy deficit ~25%) over the course of six months."
16321790|NCT04526834|Experimental|CD30 positive NHL subtypes|"(ALCL, PTCL-NOS, ENKTCL, DLBCL-NOS, PMBCL)
~Dose Level 1
~Dose Level 2
~Dose Level 3"
16321791|NCT04526821|Experimental|Bovine Lactoferrin|Bovine Lactoferrin plus standard measures of personal protection.
16321792|NCT04526821|Placebo Comparator|Maltodextrin|Maltodextrin plus standard measures of personal protection.
16321793|NCT04526808|Experimental|FODMAP diet|
16321794|NCT04526795|Experimental|Treatment (pegcrisantaspase, fludarabine, cytarabine)|"INDUCTION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-11 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-10. Treatment repeats every 5 weeks for up 3 cycles in the absence of disease progression or unacceptable toxicity."
16321795|NCT04526782|Experimental|Cohort 1 (1rst line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
16321796|NCT04526782|Experimental|Cohort 2 (2nd line) - A|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
16321797|NCT04526782|Active Comparator|Cohort 2 (2nd line) - B|Docetaxel 75 mg/kg (D1=D22)
16321798|NCT04526769||COVID-19 Patients|All patients aged 18 years and above who present to Fairview/UMN ERs or ICUs with confirmed or suspect COVID-19 based on the attending physician's judgment will be included.
16321799|NCT04526756|Experimental|Intervention group|patients in this group will receive mechanical thrombectomy and standardized drug treatment of acute ischemic stroke
16321800|NCT04526756|No Intervention|control group|patients in this group will receive standardized drug treatment of acute ischemic stroke
16321801|NCT04526743||BS patients|Candidates to primary BS undergoing laparoscopic gastric bypass (LGBP) or laparoscopic sleeve gastrectomy (LSG) from September 2020 to September 2021. Patients will be evaluated prior to BS and at 4 months, 1, 3 and 5 years after BS.
16321802|NCT04526743||no BS patient|A control group of subjects with obesity not candidates to BS matched with the intervention group for age, sex and BMI prior to BS. Patients will be evaluated once.
16321803|NCT04526730|Experimental|Neoadjuvant Treatment|"Neoadjuvant Phase: (3 x 4-week cycles, total 12 weeks): At every cycle, intratumoral tavo-EP will be administered (on Days 1 and 8) concurrently with 480 mg nivolumab IV infusion on Day 8 of each cycle (tavo-EP will be administered prior to nivolumab infusion).
~Definitive Surgery Phase: Surgery may be scheduled about 2-4 weeks after the last dose of nivolumab following radiologic and clinical assessment at that point. Pathologic response will be determined by institutional pathologist.
~Adjuvant Phase: Adjuvant therapy with nivolumab monotherapy will begin approximately 2-4 weeks following definitive surgery; recovery from surgery is required (Day 1 of Cycle 4 will be determined by the treating investigator once the subject is cleared to initiate systemic therapy). Nivolumab (480 mg IV infusion on Day 1 of each 4-week cycle) will be administered for up to 9 cycles during the Adjuvant phase."
16321804|NCT04526717|Other|MPT0B640|There is single Arm in this clinical trials.
16321805|NCT04526704|Experimental|Treatment Continuation Cohort|Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
16321806|NCT04526704|Experimental|Treatment-Free/Re-Treatment Cohort|Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
16321808|NCT04526678|Experimental|Iron supplements|The intervention group will ingest 27 mg iron supplement per day for three months while the control group will not ingest iron supplements.
16321809|NCT04526678|No Intervention|Control group|The control group will not ingest iron supplements.
16321810|NCT04526665|Experimental|Elafibranor 80mg|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
16321811|NCT04526665|Placebo Comparator|Placebo|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
16321814|NCT04526639|Experimental|Virtual Reality games for training executive functions|Virtual Reality games for training three core executive functions
16321815|NCT04526639|Placebo Comparator|Control VR Game on Playground|A relaxing virtual reality game for control group to play in VR playground without training their executive functions
16321816|NCT04526626|Experimental|High ligation and stripping|High ligation and stripping of long saphenous vein is the traditional standard procedure for the treatment of varicose veins
16321823|NCT04526600|No Intervention|No fidget|
16321824|NCT04526600|Experimental|With fidget|The participant is given a specially designed fidget ball
16321825|NCT04526587||Basic science (medical chart review, biospecimen collection)|Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
16321828|NCT04526561|Active Comparator|Hidradenitis suppurativa TDAP|Axillary hidradenitis suppurativa reconstructed with TDAP
16321829|NCT04526561|Active Comparator|Hidradenitis suppurativa Limberg|Axillary hidradenitis suppurativa reconstructed with a Limberg flap
16321830|NCT04526561|Active Comparator|Breast reconstruction TDAP|Breast reconstruction performed with TDAP
16321831|NCT04526561|Active Comparator|Breast reconstruction latissimus dorsi|Breast reconstruction performed with latissimus dorsi
16321832|NCT04526535||No B-lines|Patients with no significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction
16321833|NCT04526535||B lines|Patients with significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (pending establishing an optimal cut-off point)
16321834|NCT04526509|Experimental|Substudy 1: GSK3901961 in previously treated advanced SS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
16321835|NCT04526509|Experimental|Substudy 1: GSK3901961 in previously treated metastatic NSCLC|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as a single IV infusion after completing lymphodepleting chemotherapy.
16321836|NCT04526509|Experimental|Substudy 2: GSK3845097 in previously treated advanced SS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as a single IV infusion after completing lymphodepleting chemotherapy.
16321837|NCT04526496|Experimental|Single Ascending Doses|50mg-600mg
16321838|NCT04526496|Experimental|Multiple Ascending Doses|dose to be determined
16321839|NCT04526483|Experimental|laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D|
16321840|NCT04526470|Experimental|Alpelisib + Paclitaxel|"Phase IB is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D of alpelisib will be determined based on the MTD and toxicity profiles.
~In phase II part, RP2D from the phase IB part will be applied as follows: alpelisib ( ) mg PO bid daily + paclitaxel ( ) mg/m² IV on D1, 8, and 15 every 4 weeks."
16321841|NCT04526457|Other|Standard of Care|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH and randomized to standard of care with lipid testing only.
16321842|NCT04526457|Other|Genetic Testing|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH randomized to genetic testing
16321843|NCT04526444|Experimental|Ftiness tracker|Participants in the group A will be provided the fitness tracker Mi Smart Band 5 with the computational algorithm PAI.
16321844|NCT04526444|Experimental|Home training platform and fitness tracker|Participants in group B will be provided with both the fitness tracker Mi Smart Band 5 with the computational algorithm PAI and access to Les Mills On Demand to perform training classes from home.
16321845|NCT04526444|Experimental|Peer support, home training platform and fitness tracker and|Participants in group C will be offered the fitness tracker Mi Smart Band 5 with the computational algorithm PAI, Les Mills On Demand and additional peer support via social media.
16321846|NCT04526431||Tacrolimus once-daily|Patients receiving tacrolimus as a once-daily formulation (Envarsus)
16321847|NCT04526431||Tacrolimus bid|Patients receiving tacrolimus as a twice-a-day formulation.
16321848|NCT04526418|Experimental|24/7 EEG™ SubQ System|To demonstrate the electrographic seizure recording effectiveness of the 24/7 EEG™ SubQ system by comparison to simultaneous inpatient video-EEG data.
16321849|NCT04526392||Questionnaire|Patients will choose how they wish to complete the Pubertal Course Questionnaire: electronically (web link), on paper, by telephone, or face-to-face at a follow-up consultation.
16321850|NCT04526379|Experimental|children with PWS|Evaluation of cognitive abilities of children with PWS by several cognitive tasks and neuropsychological tests.
16321851|NCT04526379|Other|non affected children|Evaluation of cognitive abilities of children with PWS compared to a non-pathologic population of children by several cognitive tasks and neuropsychological tests
16321853|NCT04526353|Experimental|Oxybutynin during 9 months.|0.1mg / kg 2x / day from inclusion and for 9 months.
16321854|NCT04526353|No Intervention|No oxybutynin|No treatment affecting bladder function
16321855|NCT04526340|Experimental|Nutrient day|on the nutrient day the subjects will take the testing food/nutrient capsules with 500 ml water
16321856|NCT04526340|Placebo Comparator|Control day|on the control day the subjects will take 500 ml water without nutrient/food capsules
16321862|NCT04526288|Experimental|Arm B (CPX-351, alloHCT)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment may repeat for an additional cycle for a total of 2 cycles (on days 1 and 3 only of cycle 2) in the absence of disease progression or unacceptable toxicity. Within 60 days after completion of CPX-351, patients undergo alloHCT.
16321863|NCT04526262|Experimental|BBB disruption|All participant in this arm will undergo 2 sessions of transcranial magnetic resonance guided focused ultrasound blood brain barrier disruption every 3 months.
16321864|NCT04526236|Placebo Comparator|Methadone 0|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered the placebo drug.
16321865|NCT04526236|Experimental|Methadone 1|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.05 mg/kg.
16321866|NCT04526236|Experimental|Methadone 2|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.1 mg/kg.
16321867|NCT04526236|Experimental|Methadone 3|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.2 mg/kg.
16321868|NCT04526223|Experimental|treatment group|MF patients exposure to ruxolitinib during transplantation
16321869|NCT04526210|Experimental|Treatment A|Participants will receive bupropion.
16321870|NCT04526210|Experimental|Treatment B|Participants will receive bupropion with ALXN1840.
16321871|NCT04526197|Experimental|Treatment A|Participants will receive celecoxib.
16321872|NCT04526197|Experimental|Treatment B|Participants will receive celecoxib with ALXN1840.
16321873|NCT04526184|Active Comparator|healthy group|25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.
16321874|NCT04526184|Active Comparator|patient group|25 individuals will be selected randomly from 103 patients with COPD from hospital records.
16321875|NCT04526171|Experimental|Vaparshun|In intervention clusters, two full day events, with a gap of 4 weeks between the two events, were organized at cluster level. Eligible households with a government or contract tor built toilet were invited to enroll for a toilet makeover. Intervention activities, delivered at cluster level, included films on toilet improvement, comfort and convenience of toile use, addressing pit filling anxiety and celebrating proud toilet owners by providing certificates and acknowledging them during the events.
16321876|NCT04526171|No Intervention|Control Arm|No intervention was delivered to clusters in the control arm.
16321877|NCT04526158|Experimental|Mobile+Group LAMP Mindfulness-Based Intervention|8 weekly interactive online group sessions and access to mobile app
16321878|NCT04526158|Experimental|Mobile LAMP Mindfulness-Based Intervention|8 weekly asynchronous sessions, delivered on mobile app
16321879|NCT04526158|No Intervention|Usual Care|The Usual Care arm will not get access to either intervention
16321880|NCT04526145|Experimental|Stress and emotion Management for Black/African Americ|Four weekly sessions delivered in a group format via Zoom teleconference. The following topics are listed in the workbook: Planning Your Information Diet; My Spheres of Influence Worksheet; Practical Wisdom for Tolerating Uncertainty; Reducing Anxiety With Thought Challenging; Reducing Anxiety Through Distraction Activities; Starting a Planning Practice; Starting a Daily Gratitude Practice; Starting a Daily Breathing Practice; Improving the Quality of Your Social Connections; Developing a Regular Exercise Routine; and Creating Your Stress-Resilience Action Plan. Each session will begin with a 15-30 minute check in on what went well, challenges, and Coronavirus Anxiety workbook. The Coronavirus Anxiety Workbook topics are complementary and the sessions will tie together the themes of comprehensive stress and emotional management through blood pressure knowledge/self-monitoring, diet, interpersonal communication skills building, and sleep hygiene.
16321881|NCT04526132|Experimental|Experimental: group1|Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
16321882|NCT04526132|Placebo Comparator|Experimental: group2|Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
16321883|NCT04526119|Experimental|Z-338|
16321884|NCT04526119|Placebo Comparator|Placebo|
16321885|NCT04526106|Experimental|Part 1: Dose Escalation|Multiple doses of RLY-4008 for oral administration.
16321886|NCT04526106|Experimental|Part 2: Dose Expansion|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
16321887|NCT04526080|Experimental|TheraBionic Arm|Self-administered from the device that delivers low levels of radiofrequency electromagnetic fields into the body with a spoon-shaped antenna placed in the mouth.
16321888|NCT04526080|Placebo Comparator|Placebo Arm|Placebo device that looks and sounds like the active device.
16321889|NCT04526067|Active Comparator|Cognitive Adaptation Training (CAT)|A home delivered adherence intervention used by managed care used to improve outcomes across multiple conditions.
16321890|NCT04526067|Active Comparator|Remote Cognitive Adaptation Training (R-CAT)|A primarily remotely delivered workable adherence intervention used by managed care used to improve outcomes across multiple conditions.
16321891|NCT04526054|Other|anosmic or normosmic COVID-19 patients|Patients will undergo ENT exams, olfactometry and MRI.
16321892|NCT04526041|Other|Professional beatboxer singer|1 professional beatboxer singer will be asked to produced different sounds while undergoing the different procedures. Researchers wil then select the most interesting sounds to be studied.
16321893|NCT04526041|Other|Experimented beatboxer singer|10 experimented beatboxer singer will be asked to reproduced the sounds record by the first subject (professional singer) while undergoing the different procedures.
16321894|NCT04526028||Palbociclib combined with Fulvestrant|
16321895|NCT04526028||Fulvestrant|
16321925|NCT04525768||Portal caver cavernoma Group|Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation.
16321956|NCT04525521||Non-Atopic Individuals|Individuals with no history of atopic dermatitis, food allergy, asthma, or allergic rhinitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
16321896|NCT04526015|Experimental|Ilioinguinal iliohypogastric Block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
16321897|NCT04526015|Other|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
16321898|NCT04526002|Experimental|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
16321899|NCT04525989|Experimental|Proton therapy|5 x 5 Gy External radiation therapy with Protons
16321900|NCT04525989|Active Comparator|Photon therapy|5 x 5 Gy External radiation therapy with Photons
16321901|NCT04525963|Experimental|Experimental: Intervention Arm|":In the experimental group,the operating room nurse, who is given intervention training , will be provided to visit the patient before surgery. After the verbal training of the operating room nurse, a printed booklet will be left for the patient to read.
~Assigned Interventions The level of anxiety experienced by the patients increases the postoperative perception and analgesic need, increasing the sequence and anesthetic substance. For these reasons, there is a need for studies to reduce pain distribution and severity by directly dealing with pre- and postoperative anxiety and anxiety levels. Similarly, the role of the operating room nurse in reducing patient anxiety is increasingly recognized. It is observed that the pre-operative visit and education reduce the pre-operative anxiety level in patients undergoing surgical intervention, and the pre-operative visit of the operating room nurse is on the agenda."
16321902|NCT04525963|No Intervention|No Intervention|There will be no intervention in the control group. The procedures of the institution will be applied before and after the operation.
16321903|NCT04525950|Experimental|Navio|Using the new technology during surgery
16321904|NCT04525950|Active Comparator|Conventional|Using the conventional surgical instruments
16321905|NCT04525937||Patients with Severe Aortic Stenosis with Disparities|Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year
16321906|NCT04525937||Medical Providers with Disparities|Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis
16321907|NCT04525924|Experimental|Bright light therapy|Bright light therapy (BLT) will be given via a lightbox device in the morning for 30 minutes after waking up. Duration of therapy will be 7 consecutive days.
16321908|NCT04525911||Symptomatic COVID-19 infection confirmed or probable|Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)
16321909|NCT04525898|Active Comparator|Methadone Group|The methadone group will receive a dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
16321910|NCT04525898|Placebo Comparator|Control Group|The control group will be administered an equal volume of saline in an identical appearing syringe.
16321911|NCT04525885|Experimental|Gefapixant 45 mg twice daily (BID)|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
16321912|NCT04525885|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks). This arm is not included in protocol amendment 5 or later.
16321913|NCT04525885|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
16321914|NCT04525872|Experimental|Premature infants|Premature infants who are expected to receive TPN for a minimum of 5 days and infants with gastrointestinal surgical problems (e.g., ileal atresia, gastroschisis), expected to receive TPN for a minimum of 5 days
16321915|NCT04525859|Experimental|Safety|Six patients will be enrolled in the Phase 1 safety cohort. Patients will have an IR guided biopsy and FNA. Up to four core biopsies and FNAs at one site will be performed prior to intratumoral (IT) administration of Poly-ICLC. Pleural fluid will be collected for research analysis if available. Poly-ICLC will be injected in 2 locations within the pleura. Patients will undergo surgery 21±7 days after the biopsy and Poly-ICLC intratumoral (IT) injection. The type of surgery that will be performed is at the discretion of the thoracic surgeon and per the standard of care. This includes pleurectomy/decortication or extrapleural pneumonectomy. Patients will be evaluated per the standard of care post-operatively. On day 7±4 days a final toxicity assessment, physical exam and research blood will be collected. All post-operative care and monitoring thereafter is as per standard of care.
16321916|NCT04525859|Experimental|Expansion Cohort|If at most one (1) patient in the Phase 1 safety cohort experiences a DLT then a total of thirteen (13) additional patients will be enrolled into the Phase 1b Expansion Cohort. Patients in the Expansion Cohort will receive the same dose and schedule of Poly-ICLC as in the Phase 1 safety cohort. Patients will be followed for safety and tolerability, as well as efficacy. If a total of 4 or more patients experience DLTs then the study will be closed due to excessive toxicity.
16321917|NCT04525846|Experimental|PFMT group|Researcher was trained and test pelvic floor muscle strength by urogynecologist with Brink scores, participants PFMT group were educated by VDO and recieved program of PFMT after consented form 4 weeks reassess Brink score for check compliance of PFMT and followed up by telephone weekly about compliance of PFMT, general symptom, notice self recording book total 12 weeks and evaluate urinary incontinence by UDI-6 questionaires at third trimester
16321918|NCT04525846|Experimental|non PFMT|Randomized to non PFMT group watchful waiting until 36-38 week gestation follow up and evaluate UI by UDI6 questionaires at third trimester sames as intervention group
16321919|NCT04525820|Experimental|High Dose Vitamin D|"Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D.
~The medication be administered orally"
16321920|NCT04525820|Placebo Comparator|Placebo|Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)
16321921|NCT04525807||Multiomics arm|Guide therapy based on multi-omics
16321922|NCT04525794|Experimental|BRight DCB|
16321923|NCT04525781||1|
16321924|NCT04525768||JAK2 mutation Group|Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation.
16321926|NCT04525755|Experimental|Varenicline (.5mg BID)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
16321927|NCT04525755|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
16321928|NCT04525755|No Intervention|Control Group|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group.
16321929|NCT04525742|Other|Parents who have a disabled child or children|Parents having disabled child or children will be included in the research and it will be wanted to complete the survey questionary
16321930|NCT04525729|Experimental|Rituximab+RASi(ACEI and/or ARB)|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). Add 1 g rituximab at 6 months.
16321931|NCT04525729|Other|RASi(ACEI and/or ARB）|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject.
16321932|NCT04525716||COVID-19|Patients with confirmed COVID-19 infection
16321933|NCT04525716||Non-COVID-19|Patients without confirmed COVID-19 infection
16321934|NCT04525703|Experimental|Pathways for Parents|
16321935|NCT04525690|Experimental|HCV Screening Default-1 Hospital Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening
16321936|NCT04525690|Experimental|HCV Screening Default-2 Hospitals Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening.
16321937|NCT04525664|Experimental|Participants who test positive for Helicobacter pylori|Participants who test positive for Helicobacter pylori by fecal antigen testing will be offered treatment with triple therapy (clarithromycin 500 mg per os twice daily, amoxicillin 1 g per os twice daily, omeprazole 40 mg per os twice daily) for 14 consecutive days. Two to four weeks following the completion of treatment, participants will repeat fecal antigen testing to confirm whether they eradicated the Helicobacter pylori.
16321938|NCT04525664|Experimental|Patients with dyspepsia and negative for Helicobacter pylori|Participants who report chronic dyspepsia but are negative for Helicobacter pylori by fecal antigen testing will receive daily omeprazole (20 mg per os) for one month. Their symptoms will be reassessed after completion of the month treatment.
16321939|NCT04525651|Experimental|Digital Acupuncture Instrument Group|The needles will be stimulated manually to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness) and then paired electrodes from the digital acupuncture instrument will be attached to the needle handles and another two adjunct acupoints by the research assistant. The electric current will be increased until the needles begin to vibrate slightly.
16321940|NCT04525651|Active Comparator|Manual Acupuncture Group|Patients in the MA group will undergo similar procedures as the EA group except that no current will be output from the instrument.
16321941|NCT04525651|Sham Comparator|Sham Acupuncture Group|Patients in the SA group will receive non-invasive acupuncture to avoid de qi.
16321942|NCT04525638|Experimental|177Lu-DOTATATE + Nivolumab|Patients will receive 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion and 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
16321943|NCT04525612|Experimental|68Ga-BNU-PSMA|Each subject receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT imaging within the specificed time.
16321950|NCT04525586||It's just an observational study, no interventions|children with recurrent wheezing
16321951|NCT04525560|Experimental|PEG-ELS-S|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
16321952|NCT04525560|Active Comparator|PEG-ELS-L|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
16321954|NCT04525534||Placenta accreta spectrum|Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
16321955|NCT04525534||Phenotypically-matched controlled group|Mother-infant dyads admitted for delivery without placenta accreta spectrum
16321957|NCT04525521||Individuals with Atopic Dermatitis|Individuals with history of atopic dermatitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
16321958|NCT04525508||Normal glucose tolerance (NGT)|Those of the study population with one normal Oral glucose tolerance test (OGTT)
16321959|NCT04525508||Dysglycemia|Those of the study population with one dysglycemia (IFG and/or IGT)
16321960|NCT04525508||Diabetic OGTT|Those of the study population with one Diabetic OGTT
16321961|NCT04525495|Experimental|Dopamine treatment|
16321962|NCT04525482|No Intervention|Control Group|No intervention was implemented
16321963|NCT04525482|Experimental|Intervention Group|Early goal-directed sedation programs was implemented
16321964|NCT04525469|Experimental|Narrative Exposure Therapy|NET is a fully-manualized evidence-based treatment for PTSD. Participants will receive 6 weekly 60-minute individual sessions of NET.
16321965|NCT04525456|Experimental|Reduxium|1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days
16321966|NCT04525443||Patients with active SARS-CoV-2 infection.|Patients admitted for COVID-19 at Hospital Clínico San Carlos with positive SARS-CoV-2 polymerase chain reaction (PCR).
16321967|NCT04525443||Patients with past, not active, SARS-CoV-2 infection.|Patients with past infection (not active), demonstrated by serology and PCR.
16321968|NCT04525443||People without concurrent or past SARS-CoV-2 infection|Health personnel from the Cardiology Service of Hospital Clínico San Carlos who demonstrate by serology that they have not had SARS-CoV-2 infection.
16321969|NCT04525430|Experimental|Group 1|only childbirth education group
16321970|NCT04525430|Experimental|Group 2|childbirth education and was subjected to a birth plan group
16321971|NCT04525430|No Intervention|Group 3|standard care group
16321972|NCT04525417|Other|hospital healthcare workers|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
16321973|NCT04525417|Other|private health professionals|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
16321974|NCT04525404||Troponin Substudy|Participants with new COVID-19 infection will undergo high-sensitivity Troponin testing; participants with elevated Troponin will undergo MRI, bloodwork, and olfaction testing at Baseline, then repeat MRI, bloodwork and all functional testing at the Recovered (ie 12weeks post diagnosis) phase. Participants with normal Troponin will undergo only olfaction testing and bloodwork at baseline, then MRI, bloodwork and all functional testing at the Recovered phase.
16321975|NCT04525404||Late Cross-Sectional Substudy|Participants with a COVID-19 diagnosis at least 3 months prior to enrollment will undergo MRI, bloodwork and all functional testing at the Recovered phase only.
16321976|NCT04525391|Experimental|Durvalumab+AZD2811 to SCLC patients|"Dosage and Schedule: AZD2811 500mg and durvalumab 1500mg via IV administered on Day 1 for every 3weeks (fixed dosing for subjects > 30 kg body weight for durvalumab). One cycle is consisted of 3 weeks.
~The drug products must be dosed consecutively using different infusion lines. The sequence of infusions is as follows: durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. A waiting time interval of at least 30 minutes between the end of durvalumab infusion and start of AZD2811 infusion should be adhered to."
16321977|NCT04525378|No Intervention|Control|Patients will receive standard care.
16321978|NCT04525378|Experimental|MSC - low dose (2.5x10ˆ7)|Patients will receive standard care plus cell therapy.
16321979|NCT04525378|Experimental|MSC - intermediate dose (5x10ˆ7)|Patients will receive standard care plus cell therapy.
16321980|NCT04525378|Experimental|MSC - high dose (10x10ˆ7)|Patients will receive standard care plus cell therapy.
16321981|NCT04525365|Experimental|Pleural aspiration|Pleural aspiration under sedation
16321982|NCT04525365|Active Comparator|Closed Thoracostomy|Actual management
16321983|NCT04525352|Experimental|Experimental - RP-L401|RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene
16321984|NCT04525326|Experimental|standard chemotherapy plus Cetuximab|
16321985|NCT04525326|Experimental|standard chemotherapy plus Bevacizumab|
16321986|NCT04525313||training set|58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2013.01 and 2017.12.
16321987|NCT04525313||validation set|another 58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2018.01 and 2022.12.
16321988|NCT04525300|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
16321989|NCT04525300|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
16321990|NCT04525287||Severe COVID-19|Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.
16321991|NCT04525287||Mild COVID-19|The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.
16321992|NCT04525274|Placebo Comparator|control group|patient will receive 40 ml bupivacaine 0.25% + 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
16321993|NCT04525274|Active Comparator|dexmedetomidine group|patient will receive 40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
16321994|NCT04525274|Active Comparator|ketamine group|patient will receive 40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
16321995|NCT04525248|Active Comparator|High resection|Laparoscopic total colectomy + High resection of rectum
16321996|NCT04525248|Experimental|Low resection|Laparoscopic total colectomy + Low resection of rectum
16321997|NCT04525235|Active Comparator|Rifampicin standard dose|rifampicin standard dose + phenotyping cocktail
16321998|NCT04525235|Experimental|Rifampicin high dose|rifampicin high dose + phenotyping cocktail
16322039|NCT04524936||obese patient with non-alcoholic fatty liver disease|
16322040|NCT04524936||obese patient without non-alcoholic fatty liver disease|
16321999|NCT04525222|Experimental|Arm I (Actify, text messages)|Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text messages.
16322000|NCT04525222|Active Comparator|Arm II (Current Standard Care, text messages)|Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text messages.
16322001|NCT04525196|Experimental|Physical activity.|Patients will benefit a physical activity program during their dialysis session.
16322002|NCT04525196|No Intervention|No physical activity.|Patients will have access to their dialysis sessions without additional physical activity.
16322003|NCT04525183|Experimental|Run In|"Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study
~Participants will receive a 6-week Acceptance and Commitment Therapy (ACT) intervention (REVITALIZE)."
16322004|NCT04525183|Experimental|Enhanced Usual Care (EUC)|Participants randomized to EUC will receive educational materials developed by the National Comprehensive Cancer Network (NCCN) about fatigue and exercise during cancer treatment.
16322005|NCT04525183|Experimental|REVITALIZE ACT Intervention|Participants randomized to the REVITALIZE acceptance and commitment therapy (ACT) will receive 6 weekly sessions lasting approximately 60-75-minutes over a 6-8 week period, delivered face-to-face using iPads, computers or tablets, and a HIPAA-compliant platform (Zoom for Healthcare). If participants have difficulty connecting to the platform, telephone sessions are permitted.
16322006|NCT04525170|Experimental|HPT treated|daily wear Hexafocon A rigid contact lens treated with Hydra PEG surface coating
16322007|NCT04525170|Experimental|untreated|daily wear Hexafocon A rigid contact lens
16322008|NCT04525157|Experimental|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
16322009|NCT04525157|Placebo Comparator|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
16322010|NCT04525157|Experimental|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.
~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
16322011|NCT04525144|Experimental|Tebonin Forte|120mg, twice a day, 52 weeks
16322012|NCT04525144|No Intervention|Control|
16322013|NCT04525131|Experimental|CPX-POM|IV over 20 minutes once per day
16322014|NCT04525105||Study group|wıth URGE INCONTINANCE
16322015|NCT04525105||Control group|not urge incontinance
16322016|NCT04525092|Active Comparator|Conventional Hemodialysis|Participants will receive intermittent HD for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode HD).
16322017|NCT04525092|Experimental|Pre-dilution Hemodiafiltration|Participants will receive intermittent pre-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode pre-dilution HDF).
16322018|NCT04525092|Experimental|Post-dilution Hemodiafiltration|Participants will receive intermittent post-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode post-dilution HDF).
16322019|NCT04525079|Experimental|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
16322020|NCT04525079|Experimental|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
16322021|NCT04525079|Experimental|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
16322022|NCT04525079|Experimental|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
16322023|NCT04525066|Experimental|Treatment Group - Receiving Hyaluronic Acid Injection|Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
16322024|NCT04525066|Placebo Comparator|Control Group - Not Receiving Hyaluronic Acid Injection|Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
16322025|NCT04525040|Experimental|Intervention arm|Children in this arm were given ProbioKid®; one capsule daily, for 6 weeks.
16322026|NCT04525040|Other|Pragmatic arm|Children in this arm received standard of care as usual without a preventive intervention
16322027|NCT04525027||survivors|
16322028|NCT04525027||non survivors|
16322029|NCT04525014|Experimental|RRx-001, Temozolomide and Irinotecan|
16322030|NCT04524988|Active Comparator|Fundamentals of Laparoscopic Surgery (FLS)|This group will undergo 2.5h of training on the current standard laparoscopic simulation trainer (FLS), including the following tasks: peg transfer, intracorporeal knot tying and ligating loop.
16322031|NCT04524988|Experimental|Essentials in Minimally Invasive Gynecology (EMIG)|This group will undergo 2.5h of training on a new gynecology-specific laparoscopic simulation trainer (EMIG), including the following tasks: peg transfer, intracorporeal knot tying and running suture.
16322032|NCT04524975|Experimental|CD-008-0045 60 mg/day|Patients assigned to the CD-008-0045 60 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast, lunch, and dinner for 8 weeks
16322033|NCT04524975|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner, and 1 placebo capsule before lunch for 8 weeks.
16322034|NCT04524975|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, lunch, and dinner for 8 weeks.
16322035|NCT04524962|Experimental|Descartes 30|
16322036|NCT04524949|Experimental|IMCY-0098, low dose|The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).
16322037|NCT04524949|Experimental|IMCY-0098, high dose|The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).
16322038|NCT04524949|Placebo Comparator|Placebo|Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.
16322041|NCT04524936||control group|
16322042|NCT04524923||cohort group|Ninety-seven typically developing preschool children of both genders with age ranges from three to five years will be included in this study. Visual motor integration, quality of life and cognitive function were assessed by the Peabody Developmental Motor Scale, the Pediatric Quality of Life Inventory™ and the Pediatric Quality of Life Inventory™ cognitive functioning scale respectively
16322043|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
16322044|NCT04524897|Other|The use of Triamcinolone Injection|Triamcinolone acetate (40 mg/mL)
16322045|NCT04524884|Experimental|Cohort A|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination.
16322046|NCT04524884|Experimental|Cohort B|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.
16322047|NCT04524884|Experimental|Cohort C|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will be removed from the study, if the tumor is evaluated as unresectable cases and patients have no potential benefits by clinical examination.
16322048|NCT04524871|Active Comparator|Stage 1: Atezolizumab + Bevacizumab|Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16322049|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tiragolumab|Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16322050|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tocilizumab|Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16322051|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + SAR439459|Participants will receive atezolizumab plus bevacizumab plus SAR439459 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16322052|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + TPST-1120|Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16322053|NCT04524871|Experimental|Stage 1: RO7247669 + Bevacizumab|Participants will receive RO7247669 plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
16322054|NCT04524858|Experimental|ATI-450|Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
16322055|NCT04524845|Experimental|Rebel Reliever|Rebel Reliever (RR) (Thuasne, Levallois Perret, France) with bilateral rigid frames and two hinges. The valgus correction was set by adjusting the medial and lateral frame lengths to a difference of two or three points as dictated by the participant's feeling and comfort. Six straps maintained the brace in place
16322056|NCT04524845|Experimental|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France) made mainly from textile. Upper and lower straps were adjusted to the participant's feeling and comfort.
16322057|NCT04524845|Active Comparator|Unloader One|Unloader One (UO) (Össur, Reykjavik, Iceland), with unilateral frame and one hinge. Upper and lower straps were adjusted to the setting recommended by the fitting instructions and confirmed by the participant's sensation.
16322058|NCT04524845|No Intervention|No orthosis|Control condition without brace
16322059|NCT04524832|Experimental|Semaglutide D 50 mg|Participants will receive once daily semaglutide D formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
16322060|NCT04524832|Experimental|Semaglutide C 50 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
16322061|NCT04524832|Experimental|2 x Semaglutide C 25 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 2 x 25 mg (week 13-16)
16322062|NCT04524832|Experimental|Semaglutide E 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 16 weeks: A) Semaglutide C formulation: 2.4 mg (week 1-2), 5.6 mg (week 3-4) and 11.2 mg (week 5-8). B) Semaglutide E formulation: 25 mg (week 9-12) and 50 mg (week 13-16)
16322063|NCT04524832|Experimental|Semaglutide F 50 mg|Participants will receive once daily semaglutide F formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
16322064|NCT04524819||COPD participants|Saliva and Sputum will be collected from patients when they are unwell with a flare up of the COPS and when they are well
16322065|NCT04524806|Active Comparator|2 mm-thick splint group (2 mm-TSG)|The group which applied the 2 mm thick stabilization splint
16322066|NCT04524806|Active Comparator|4 mm-thick splint group (4 mm-TSG)|The group which applied the 4 mm thick stabilization splint
16322067|NCT04524793|Other|Endovenous Microwave Ablations|Patients that have undergone Endovenous Microwave Ablation from ECO (Nanjing ECO Microwave System Co., Ltd) to treat primary great and short saphenous vein reflux
16322068|NCT04524780|Experimental|left atrial appendage radiography|
16322070|NCT04524767|Experimental|SBIRT|SBIRT will involve screening with the Patient Health Questionnaire-9 (PHQ-9); brief intervention with Motivational Interviewing (MI); and referral to specialty treatment, as needed for subjects with persistent depressive symptoms.
16322071|NCT04524767|Active Comparator|Referral As Usual|Referral as Usual will involve distributing depression educational materials (e.g., from the National Institute of Mental Health) and contact information for treatment providers in our target community
16322072|NCT04524741|Experimental|left atrial appendage radiography|
16322073|NCT04524741|Experimental|intracardiac echocardiography guidance|
16322074|NCT04524728||Cohort A|Patients that received palbociclib combined with letrozole 2.5 mg
16322075|NCT04524728||Cohort B|Patients that received palbociclib combined with fulvestrant 500 mg
16322076|NCT04524715|Experimental|Active Treatment Group|LLLT Treatment using an UltraSlim red/IR LED device along with all standard treatment measures for COVID19.
16322077|NCT04524715|Sham Comparator|Control Group|Treatment using a Sham comparator along with all standard treatment measures for COVID19.
16322078|NCT04524702|Experimental|Treatment (paricalcitol, hydroxychloroquine, chemotherapy)|Beginning day -14, patients receive paricalcitol IV three times weekly and hydroxychloroquine PO BID. Patients also receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on days 1, 8, 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16322081|NCT04524676|Experimental|Individualized Treatment Group|
16322082|NCT04524663|Experimental|Camostat mesilate|Patients will receive camostat mesilate for 10 days in addition to standard of care treatment.
16322083|NCT04524663|Placebo Comparator|Placebo|Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment.
16322084|NCT04524650||stage 0|without liver function injury or splenomegaly
16322085|NCT04524650||stage 1|occurrence of liver function injury (ALT or AST > 2 ULN (upper limit of normal)
16322086|NCT04524650||stage 2|occurrence of splenomegaly or reduced platelet count (<150 X10^9/L)
16322087|NCT04524650||stage 3|occurrence of portal hypertension and/or gastroesophageal varices
16322088|NCT04524637||Traumatic brain injury|Patients who are delivered within 24 hours after head trauma and sustain isolated traumatic brain injury are included in this study.
16322089|NCT04524624|Experimental|AI-based CDSS|"Automatically identifying acute ischemic stroke lesions on DWI.
~Classification of stroke subtypes and mechanisms.
~Evidence-based alerts and guidelines for early stroke management.
~Guideline-recommended secondary stroke prevention strategies."
16322090|NCT04524624|No Intervention|Usual Care|Usual Care
16322094|NCT04524598|Experimental|Limbix Spark|A 5 week CBT-based intervention
16322095|NCT04524598|Active Comparator|Psychoeducation|5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention
16322096|NCT04524585|Experimental|Partial NMB|
16322097|NCT04524572|Experimental|Individual Challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure
16322098|NCT04524572|Experimental|friend challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure in comparison to the group average of all participants randomized to the friend challenge.
16322099|NCT04524572|Experimental|Team challenge|participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their teams' daily step counts and physical activity expenditure in comparison to the group average of other teams.
16322100|NCT04524559|Placebo Comparator|conventional physical therapy training|received 90 minutes conventional physical therapy training focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms.
16322101|NCT04524559|Experimental|oral stimulation|received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time. The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol
16322102|NCT04524533|Experimental|Intervention group|Participants randomized into the intervention arm will watch smoking cessation videos (ready to quit or not ready to quit) during a dental cleaning clinic visit, receive a brochure about EBTs, and participate in a 4-week text message program which consists of automated and tailored text messages to motivate EBT utilization. After the 4-week program, the intervention group will receive monthly assessment text messages.
16322103|NCT04524533|Active Comparator|Control group|Participants randomized into the control arm will watch a control video during a dental hygiene visit and receive a brochure about EBTs, and a 4-week assessment-only text message program.
16322104|NCT04524507|Experimental|High-Titer (CCP1)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
16322105|NCT04524507|Active Comparator|Standard-Titer (CCP2)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.
16322106|NCT04524494||RAS- active medication|Patients taking RAS- active medication (ACE- Inhibitor, Angiotensin II AT1 Antagonist (Sartan)) on a daily Basis for at least 6 months for medical reasons
16322107|NCT04524494||no RAS- active medication|Patients not taking RAS- active medication
16322111|NCT04524468||hemodialysis patients|end-stage renal disease patients on hemodialysis
16322112|NCT04524468||peritoneal dialysis patients|end-stage renal disease patients on peritoneal dialysis
16322113|NCT04524455|Experimental|Blinatumomab and AMG 404|
16322114|NCT04524442|Experimental|GEP-NET|One dose of arginine/lysine solution administered intravenously over a 4-hour period
16322115|NCT04524429||Pre-operative Group|This is the group of participants who suffer from obesity and are awaiting bariatric surgery.
16322116|NCT04524429||Post-operative Group|This is the group of participants who suffer from obesity and have received bariatric surgery.
16322117|NCT04524403|Experimental|Miricorlilant - 600 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 600 mg miricorilant once daily for 26 weeks.
16322118|NCT04524403|Experimental|Miricorlilant - 900 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 900 mg miricorilant once daily for 26 weeks.
16322119|NCT04524403|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive placebo once daily for 26 weeks.
16322120|NCT04524390|Experimental|Maralixibat|Maralixibat oral solution administered twice daily, up to 600 microgram per kilogram, for 26 weeks and in the OLE for all patients.
16322121|NCT04524390|Placebo Comparator|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.
16322122|NCT04524377|Experimental|DBS for Parkinsons Disease|
16322123|NCT04524364|Other|Participants with Paroxysmal Atrial Fibrillation (PAF)|Participants with PAF and who are candidates for catheter ablation will be enrolled.
16322124|NCT04524351|Active Comparator|Posiphen, 80mg|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
16322125|NCT04524351|Active Comparator|Posiphen, 40mg|Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
16322126|NCT04524351|Active Comparator|Posiphen, 20mg|Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
16322127|NCT04524351|Active Comparator|Posiphen, 10mg|Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
16322128|NCT04524351|Active Comparator|Posiphen, 5mg|Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
16322129|NCT04524351|Placebo Comparator|Placebo|Placebo Oral Capsule, taken once per day for 25±2 days.
16322130|NCT04524338|Experimental|At Home tDCS Users|Participants conducting tDCS at home
16322131|NCT04524325|Active Comparator|Trans men|transgender men taking physiologic doses of testosterone for gender affirming hormone therapy
16322132|NCT04524325|No Intervention|control|cisgender women not receiving testosterone and with normal sex hormone levels
16322133|NCT04524312|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
16322134|NCT04524312|Active Comparator|K-Mod|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Bioimplanti K-MOD prosthesis
16322135|NCT04524299|Experimental|Concurrent chemotherapy Twice a Week|During the period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.
16322136|NCT04524299|Active Comparator|Concurrent chemotherapy Once a Week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours.
16322137|NCT04524286||Public - Childbearing Women|Childbearing women living in three deprived areas in a city in the South of England.
16322138|NCT04524286||Staff - Midwives|Midwives working in caseloading teams providing continuity of care to women living in three deprived areas in a city in the South of England.
16322139|NCT04524273|Experimental|Inebilizumab, (AChR-Ab+) MG|"Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the randomized controlled period.
~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183."
16322140|NCT04524273|Placebo Comparator|Placebo, (AChR-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 and on Day 183 of the randomized controlled period.
~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183."
16322141|NCT04524273|Experimental|Inebilizumab, (MuSK-Ab+) MG|"Participants will receive inebilizumab administered IV on Days 1 and 15 of the randomized controlled period.
~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183"
16322142|NCT04524273|Placebo Comparator|Placebo, (MuSK-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 of the randomized controlled period.
~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183"
16322143|NCT04524260|Active Comparator|Painting art therapy|Intervention group
16322144|NCT04524260|Sham Comparator|Usual Care|Control group
16322145|NCT04524247|Experimental|PMEG FEVAR|The only arm of this study will be enrolled subjects who undergo physician modified endografting as a treatment of their thoracoabdominal aortic aneurysms or complex abdominal aortic aneurysms.
16322146|NCT04524221|Experimental|PTG-100|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
16322147|NCT04524221|Placebo Comparator|Placebo|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
16322148|NCT04524208|Experimental|Treatment-Arm|
16322149|NCT04524195|Experimental|[18F]F-AraG|A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.
16322152|NCT04524169|Experimental|Thymosin Alpha 1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
16322153|NCT04524169|No Intervention|Standard Care|Participants under the regularly treatment
16322154|NCT04524156|Active Comparator|COVIS 19 positive|
16322155|NCT04524156|Sham Comparator|COVID 19 negative|
16322158|NCT04524130|Experimental|Lidocaine and Ketamine|Participants in this arm will receive intra-operative lidocaine and ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
16322159|NCT04524130|Active Comparator|Lidocaine|Participants in this arm will receive only intra-operative ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
16322160|NCT04524130|Placebo Comparator|Placebo|Participants in this arm will receive normal saline, same volume as lidocaine and ketamine.
16322161|NCT04524117||Group A(vulnerable plaque group)|Lipid plaques with fibrous cap thickness less than 65um, erosion and coronary artery dissection detected by OCT are defined as vulnerable plaque.
16322162|NCT04524117||Group B(stable plaque group)|Lipid plaques with fibrous cap thickness more than 65um detected by OCT are defined as vulnerable plaque.
16322163|NCT04524104|Experimental|Lumen treatment|Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at baseline and 14 weeks. Participant will receive an encrypted study iPad enabled with Lumen at baseline. They will complete 8 PST sessions beginning with 4 weekly and then 4 biweekly intervals (i.e., on weeks 1, 2, 3, 4, 6, 8, 10, 12) over 12 weeks on their assigned iPad. Participants will also complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 14), that is, 8 time series. Additionally, participants will complete depressive and anxiety symptoms questionnaire and user experience surveys at all PST sessions.
16322164|NCT04524104|No Intervention|Waitlist Control|"Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at Baseline and 14 weeks.
~Participant will receive an encrypted study iPad at baseline. Participants will complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 14), that is, 8 time series.
~Participants in the waitlist control arm will only complete assessments but will have the option to receive Lumen at the end of the study. The PST module on the study iPad will be disabled until their 14-week assessment is completed, at which time they will have the option to complete 8 PST sessions on their assigned iPads."
16322165|NCT04524078|Experimental|Intensive integrated intervention care program|intensive integrated intervention care program [ICP] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
16322166|NCT04524078|No Intervention|Non intensive integrated intervention care program|
16322167|NCT04524065|Experimental|Early intervention group|The 14 early rehabilitation sessions(10=physical therapy, 4=occupational therapy) occurred per week over a 2-week period (excluding weekends) in the early rehabilitation group for 15 minutes each.
16322168|NCT04524065|No Intervention|Control group|The control group received 2 sessions(physical therapy) per week over a 2-week period for 10 minutes each.
16322169|NCT04524052|Experimental|cohort 1 (144 mg)|Arms (both) 0.1 mL/site*2 sites Hips (both) 0.2 mL/site*2 sites
16322170|NCT04524052|Experimental|cohort 2 (432 mg)|Arms (both) 0.3 mL/site *2 sites Hips (both) 0.6 mL/site*2 sites
16322171|NCT04524052|Experimental|cohort 3 (960 mg)|Arms (both) 0.8 mL/site*2 sites Hips (both) 1.2 mL/site*2 sites
16322172|NCT04524052|Experimental|cohort 4 (1200 mg)|Arms (both) 1.0 mL/site *2 sites Hips (both) 1.5 mL/site*2 sites
16322173|NCT04524039|Experimental|iTBS stimulation|iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
16322174|NCT04524039|Sham Comparator|sham iTBS stimulation|sham iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
16322175|NCT04524026|Experimental|Intervention|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before gonadotrophin releasing hormone(GnRH) agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
16322176|NCT04524026|No Intervention|Control group|recFSH from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
16322177|NCT04524013||School aged children|
16322178|NCT04524013||Pregnant women|
16322179|NCT04524000|Experimental|Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)|Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).
16322180|NCT04524000|Experimental|Cohort 2: CDK4/6 inhibitor naive (Part 2)|Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
16322181|NCT04524000|Experimental|Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)|Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
16322182|NCT04523987|Experimental|gemcitabine and nab-paclitaxel chemotherapy|Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.
16322183|NCT04523974||Preemptive and Precise Intervention|Preemptive surgical intervention will be performed on enrolled CKD-SHPT patients. Safety and efficacy of this intervention will be evaluated during peri-operative period, and long-term outcomes will be analyzed during 1-year follow-up.
16322184|NCT04523961|Active Comparator|2.5 g of lidocaine 23% / tetracaine 7% ointment|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion for 60 minutes.
16322185|NCT04523961|Active Comparator|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion for 60 minutes.
16322186|NCT04523948||Cohort One|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
16322187|NCT04523948||Cohort Two|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
16322188|NCT04523948||Cohort Three|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
16322189|NCT04523948||Cohort Four|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
16322190|NCT04523948||Cohort Five|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
16322193|NCT04523922|Experimental|Oxytocin Treatment Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.
~40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session."
16322194|NCT04523922|Active Comparator|Placebo Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).
~Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session."
16322195|NCT04523909||Thoracic aortic surgery patients|
16322196|NCT04523896|Experimental|HDR brachytherapy + SABR|"High-Dose-Rate prostate brachytherapy: a single fraction of 15 Gy to the whole prostate.
~Between 2-4 weeks after the brachytherapy session, SABR treatment will be delivered:
~5 sessions of 5 Gy in consecutive days (i.e monday to friday) to a total dose of 25 Gy to the whole prostate."
16322197|NCT04523883|Experimental|concurrent PD-1|Concurrent Immunotherapy With Postoperative Radiotherapy
16322198|NCT04523883|Active Comparator|Radiotherapy alone|Postoperative Radiotherapy alone
16322199|NCT04523870|Experimental|Botanical extract|
16322200|NCT04523870|Experimental|Major compound of the extract|
16322201|NCT04523870|Placebo Comparator|Placebo|
16322202|NCT04523857|Experimental|A (Abema)|Abemaciclib (150 mg BID)
16322203|NCT04523857|Experimental|B (Abema + HCQ)|"Abemaciclib (100 mg or 150 mg BID*) + Hydroxychloroquine (600 mg BID)
~*Abemaciclib dose will be determined by safety cohort"
16322204|NCT04523844|Active Comparator|Brinzolamide-brimonidine fixed combination|One drop of the brinzolamide-brimonidine fixed combination is instilled in the eyes of patients two hours before the intravitreal injection
16322205|NCT04523844|No Intervention|No topical IOP-lowering medication|No IOP-lowering drops are instilled before the intravitreal injections
16322206|NCT04523831|Active Comparator|Ivermectin and Doxycycline|Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
16322207|NCT04523831|Placebo Comparator|Placebo|Standard treatment
16322208|NCT04523818|Experimental|Treatment (CXRT, chemotherapy, surgery)|Patients receive CXRT consisting of radiation therapy 5 days a week (Monday through Friday) for 2 weeks (10 treatments) and standard of care chemotherapy consisting of capecitabine PO BID or fluorouracil IV continuous Monday to Friday of each radiation week. About 2 weeks later, patients receive standard of care chemotherapy for up to 2 months in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery 3-8 weeks post-chemotherapy completion.
16322209|NCT04523805|Experimental|AUTJUDO-O1|"The judo sessions are performing in a large and well-ventilated space suitable for athletic activities in general and for judo in particular, such that the safety of the participants was maintained. Each participant is outfitted with a judogi (a traditional uniform consisting of a cotton jacket and trousers and a belt).
~The sessions are 75 minutes in duration and were held once a week. Two judo teachers, with degrees in pedagogy and sports sciences and 7th and 6th degree black belts, respectively, led each session, and at least four volunteer judo instructors are present to lend support. The sessions are divided into warm-up, main exercise and cool-down activities. The instructional methodology apply the principles of gradual progression and the main exercise content of the sessions includes: different types of movements and falling techniques, ground control techniques, judo techniques and games."
16322347|NCT04522830|Placebo Comparator|Placebo|Placebo
16322348|NCT04522817|Experimental|CLBS119 Active Treatment|Single administration of CLBS119
16322210|NCT04523792|Experimental|Opioid withdrawal patients|Subjects with opioid use disorder seeking treatment and/or experiencing symptoms of opioid withdrawal receive acute administration of SUBOXONE sublingual film followed by SUBLOCADE administration in the 1) ED, 2) Clinical Decision Unit or 3) Inpatient unit combined with 6 months of treatment with SUBLOCADE in the outpatient treatment clinic.
16322211|NCT04523779|Experimental|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
16322212|NCT04523779|No Intervention|Enhanced Usual Care|EUC participants will receive anxiety education materials, a note in their medical record indicating the presence of elevated anxiety symptoms, and 4 brief monthly check-in calls with project staff. The primary outcome, anxiety symptoms, will be evaluated at 4-, 8- and 12-month follow-ups. Due to ethical concerns of withholding needed treatment, EUC participants will NOT be restricted from receiving mental health services including psychotherapy during the study period. The investigators fully expect that EUC participants may receive anxiety treatments (e.g., antianxiety and antidepressant medications or psychotherapy).
16322213|NCT04523766|Active Comparator|Mindfulness of Breath|
16322214|NCT04523766|Experimental|Mindful Interoceptive Mapping|
16322215|NCT04523740|Experimental|Placebo replacement|Participants will discontinue the paracetamol treatment, and be administered 6 to 8 tablets of placebo per day
16322216|NCT04523740|Active Comparator|Usual care with paracetamol|Participants will continue the paracetamol treatment, and be administered 6 to 8 tablets of 500mg paracetamol per day
16322217|NCT04523727|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 36 weeks at a starting dose based on body weight categories.
16322218|NCT04523714|Active Comparator|Web-based CBT-CP|Interactive Mobile health (mHealth) program in which participants complete eight, approximately weekly sessions focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
16322219|NCT04523714|Active Comparator|Virtual coach-led CBT-CP|Live, coach-led program delivered by telephone or videoconference consisting of eight, approximately weekly sessions focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
16322220|NCT04523714|No Intervention|Usual Care plus information|Receipt of a bound copy of the 2020 edition of the American Chronic Pain Association Resource Guide to Chronic Pain Management and any pharmacologic and nonpharmacologic treatments available to them without restriction.
16322221|NCT04523701|Experimental|Experimental Intervention (treatment)|"Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic).
~SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the white test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution."
16322222|NCT04523701|No Intervention|Control Intervention|Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)
16322223|NCT04523688|Experimental|Experimental treatment|"Induction phase: 4 weekly doses of dendritic cell vaccine (10x10exp6 cells) intradermally administered (weeks 1-4).
~Maintenance phase: 28 days cycles with vaccine administration (start on week 7) and adjuvant temozolomide (150-200mg/m2/day) assumed orally from day 1 to 5 q28 (start on week 5). The combined maintenance treatment will continue until disease progression, unacceptable toxicity or withdrawal of consent by the patient, or up to a maximum of 1 year of treatments.
~After disease progression or the end of maintenance phase, is foreseen a one-year follow-up phase for each subject."
16322224|NCT04523675|Experimental|EXP-NAC|Participated in daily training sessions and three games, and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
16322225|NCT04523675|Experimental|EXP-Pla|Participated in daily training sessions and three games, and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
16322226|NCT04523675|Active Comparator|CON-NAC|Participated in daily training sessions only and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
16322227|NCT04523675|Active Comparator|CON-Pla|Participated in daily training sessions only and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
16322228|NCT04523662|Experimental|Carrelizumab treatment group started during radiotherapy|
16322229|NCT04523662|Experimental|Start the carrelizumab treatment group within 3 days after the|
16322230|NCT04523649|Experimental|Home-based atrial fibrillation screening group|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
16322231|NCT04523649|No Intervention|Control group|Conventional medical care
16322232|NCT04523636|Active Comparator|Custom Splint|Custom Splint- Thermoplastic device fabricated by occupational therapist
16322233|NCT04523636|Active Comparator|Prefabricated Splint|Prefabricated Splint- Commercially available from Restorative Care of America, Inc (RCAI)
16322234|NCT04523623|Experimental|Ibuprofen Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
16322235|NCT04523623|Experimental|Oxycodone Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
16322236|NCT04523610|Experimental|Program Users - Quantitative|The Telehealth Intervention Program (TIP-OA) for older adults was created during the COVID-19 pandemic to support the health of older adults who are isolated or have mental health/cognitive issues. Within the TIP-OA program, trained volunteers provide friendly phone calls once a week to older adults (age 60+). 200 participants will be recruited for the quantitative component of the study.
16322237|NCT04523610|Other|Program Users - Qualitative|Interviews will be conducted with 25 participants regarding their perceptions and experiences in the TIP-OA program.
16322238|NCT04523610|Other|Volunteers - Qualitative|15 volunteers taking part in the semi-structured interviews and 16 volunteers participating in the focus groups. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
16322239|NCT04523610|Other|Stakeholders - Qualitative|18 stakeholders (clinicians, community partners, TIP-OA team members) will participate in focus groups and interviews. Specifically, 10 clinicians will participate in one focus group and 8 community partners/team members will participate in interviews. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
16322240|NCT04523597||toracic hyperkyphosis|children with COBB angle ≥ 45˚
16322241|NCT04523597||control|children with kyphosis index < 13 measured using the flexicurve ruler
16322242|NCT04523584||Hepatic Steatosis|<5% liver fat fraction by MRI PDFF
16322243|NCT04523584||No Hepatic Steatosis|>5% liver fat fraction by MRI PDFF
16322244|NCT04523571|Experimental|Low-dose, 18-55 years of age|
16322245|NCT04523571|Experimental|High-dose, 18-55 years of age|
16322246|NCT04523571|Placebo Comparator|Placebo, 18-55 years of age|
16322247|NCT04523571|Experimental|Low-dose, 65-85 years of age|
16322248|NCT04523571|Experimental|High-dose, 65-85 years of age|
16322249|NCT04523571|Placebo Comparator|Placebo, 65-85 years of age|
16322250|NCT04523558|Experimental|Bilateral implantation of LuxSmart hydrophobic IOL|"Cataract surgery will be carried out using standard phacoemulsification technique with a 2.2 mm incision. Investigators will target a 5.5 mm diameter capsulorhexis to allow the optic to be fully overlapped by the anterior capsular rim.
~The intended target of the post-operative refraction will be emmetropia. The patient will be implanted with LuxSmart hydrophobic IOLs in both eyes and followed up for 6 months"
16322251|NCT04523532|Experimental|Group 1: Folate + hazelnut oil|Group 1 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of vegetables rich in folate - 191µg and additionally received 01 capsule containing 25 mg hazelnut oil per day.
16322252|NCT04523532|Placebo Comparator|Group 2: Folate|Group 2 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of folate-rich vegetables - 191 µg and 01 placebo capsule.
16322253|NCT04523532|Experimental|Group 3: Moderate folate + hazelnut oil|Group 3 = in this group, individuals received, during the period of 08 weeks daily, with 300 g of vegetables containing 94 µg of folate and 01 capsule containing 25 mg of hazelnut oil per day.
16322254|NCT04523532|No Intervention|Group 4: Control|Group 4 = in this group, individuals received weekly visits during the 08 week period to maintain their eating habits.
16322255|NCT04523519|Experimental|Video directly observed therapy with contingency management|Video directly observed therapy with contingency management, in addition to Integrated Next-Step Counseling.
16322256|NCT04523519|Placebo Comparator|Integrated Next-Step Counseling|
16322257|NCT04523506|Experimental|the temporomandibular joint (TMJ) group|This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The TMJ group will be injected with two units of Botox into four different injection points to each masseter (16 units of Botox total) at the initial visit. No additional Botox will be injected in subsequent visits. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1
16322258|NCT04523506|Experimental|the perioral group|Biological/Vaccine: Botulinum toxin(Botox) This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The perioral group will be injected with two units of Botox into eight different injection points (16 units of Botox total) around the lips (in the orbicularis oris). Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3.
16322259|NCT04523493|Active Comparator|Experimental group|Toripalimab combined with Lenvatinib
16322260|NCT04523493|Placebo Comparator|Control group|Placebo combined with Lenvatinib
16322261|NCT04523480|Experimental|Testopel 75mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.
16322262|NCT04523480|Active Comparator|Compounded testosterone pellets 100mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.
16322263|NCT04523480|Active Comparator|Compounded Testosterone pellets 200mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.
16322264|NCT04523467|Experimental|Combined group|Anti-angiogenic targeted drug + Rg3 + TACE
16322265|NCT04523467|Active Comparator|Single group|TACE alone
16322266|NCT04523441||Parents|man or woman
16322267|NCT04523441||Professionals|health professionals in charge of monitoring children
16322268|NCT04523428|Experimental|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
16322269|NCT04523415||patients wiht CT data|all patients with CT data are enrolled with this research, and the classification about proximal humeral fractures are identified.
16322465|NCT04521959|Active Comparator|Normal aerobik ve direnç egzersiz grubu|Normal şartlarda aerobik ve direnç egzersizi uygulanacak
16322270|NCT04523402|Experimental|Neoadjuvant chemotherapy following liver section|"1. GEMOX chemotherapy:
~It is performed within one week after the identification of ICC;
~Day1 Oxaliplatin 85mg/m2 + gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2;
~Three weeks is a course of treatment;
~A total of 3 courses.
~2. Liver resection: It is performed 1 month after chemotherapy"
16322271|NCT04523402|No Intervention|Liver resection|"Liver resection:
~It is performed within one week after the identification of ICC."
16322272|NCT04523389||colorectal cancer|
16322273|NCT04523376|Experimental|Sickle Cell Disease|Patients with Sickle Cell Disease (SCD) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
16322274|NCT04523376|Experimental|Beta Thalassemis Major|Patients with Beta Thalassemis Major (BTM) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
16322275|NCT04523363|Experimental|Metformin|Study subjects will be randomized to the metformin medication arm. They will take a 500 mg tablet orally twice a day starting at 14 weeks of pregnancy until delivery.
16322276|NCT04523363|No Intervention|Standard of Care|Study subjects will be randomized to standard of care and receive routine prenatal care without further intervention for their prediabetes.
16322277|NCT04523350|Experimental|Instylla HES|
16322278|NCT04523350|Active Comparator|Control|TAE or cTACE
16322279|NCT04523337|Experimental|MISSION-CJ|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services.
16322280|NCT04523337|Experimental|Enhanced Usual Care|Usual care provided by the mental health residential rehabilitation treatment programs, with patients in both groups are enrolled in, in addition to peer support and community outreach case management. Patients receive 2 Peer Support Curriculum sessions per week (24 sessions total). Patients will receive unstructured community outreach and linkage support while enrolled in the mental health residential rehabilitation program. After discharge, patients will continue to receive 1 hour of weekly linkage support per week.
16322281|NCT04523324|Active Comparator|RIV4 (Flublok Quadrivalent)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
16322282|NCT04523324|Active Comparator|IIV4 (Vaxigrip Quadrivalent)|VaxigripTetra™ by Sanofi, Inc., 15µg of HA per strain, egg-based
16322283|NCT04523311|Experimental|Hypnosis + usual care|An online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis. Participants will continue with whatever usual care they receive/undertake.
16322284|NCT04523311|Other|Waitlist control + usual care|The control group will receive no intervention beyond whatever usual care they receive/undertake. After the study is complete, they will be offered the option of participating in the hypnosis intervention.
16322285|NCT04523298|Experimental|Laser|
16322286|NCT04523298|Active Comparator|PFE|
16322287|NCT04523285|Experimental|TQB3728 tablets|TQB3728 tablets administered orally, once a week in 28-day cycle.
16322288|NCT04523272|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16322289|NCT04523272|Active Comparator|Sunitinib Malate Capsules|Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).
16322290|NCT04523246|Experimental|Shingrix|Shingrix Dosage: two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90).
16322291|NCT04523246|Placebo Comparator|Normal Saline|Sterile Normal Saline Solution, two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90)
16322292|NCT04523233||Neural tube defects (NTDs)|NTDs are a group of birth defects in which an opening in the spine or cranium remains from early in human development. Neural tube defects may be diagnosed during the ultrasound scan that is carried out around week 12 of the pregnancy or, more likely, during the anomaly scan that is carried out at around weeks 19 to 20.
16322293|NCT04523233||Control group|The control group will be included pregnant women with healthy fetuses (n = 70), who were matched for gestational weeks and maternal age and underwent amniocentesis because of age-related risk or increased risk in the triple test.
16322294|NCT04523220|Experimental|BAY1213790 low dose|Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
16322295|NCT04523220|Placebo Comparator|Placebo low dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
16322296|NCT04523220|Experimental|BAY1213790 high dose|Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
16322297|NCT04523220|Experimental|Placebo high dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
16322298|NCT04523207|Experimental|Apalutamide + Androgen Deprivation Therapy (ADT)|In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
16322299|NCT04523194||Acute Coronary Syndrome|Patients diagnosed with acute coronary syndrome.
16322300|NCT04523194||Stable Angina|Patients diagnosed with stable angina.
16322301|NCT04523181|Active Comparator|Antroquinonol with SOC|Antroquinonol in a dose of 100 mg (1 capsule) administered twice daily (BID) orally, for 14 days.
16322302|NCT04523181|Placebo Comparator|Placebo with SOC|placebo (1 capsule) administered twice daily (BID) orally, for 14 days.
16322469|NCT04521907||Group 2|Group 2 includes patients who underwent cataract surgery with secondly IOL implantation
16322303|NCT04523168|Experimental|Chronic Refractory Angina|Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.
16322304|NCT04523155|Experimental|Treatment Sequence AB|Participants randomized to sequence AB will receive 3 months of meals, followed by a 3 month washout period and a 3 month intervention period with no meals.
16322305|NCT04523155|Experimental|Treatment Sequence BA|Participants randomized to sequence BA will receive 3 months of no meals followed by a 3 month washout period and a 3 month intervention period with meals.
16322306|NCT04523142|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
16322307|NCT04523129|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
16322308|NCT04523129|Placebo Comparator|Vehicle Ophthalmic solution|Vehicle only
16322309|NCT04523103|No Intervention|Control group|Standard ICSI procedure. The MII oocytes that failed fertilization in IVF cycles were injected with activating sperm.
16322310|NCT04523103|Experimental|A1 assisted activation|The MII oocytes that failed fertilization in ICSI cycles were activated in calcium ionophore A23187 activation solution for two times.
16322311|NCT04523103|Experimental|A2 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 solution for two times.
16322312|NCT04523103|Experimental|A3 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. Mechanical activation was done for the MII oocytes, and then the oocytes were transferred into the calcium ionophore A23187 solution for two times.
16322313|NCT04523090|Experimental|Nitazoxanide|Nitazoxaninde, 1000mg (2pills), oral, twice daily for 7 days. To be taken with food.
16322314|NCT04523090|Placebo Comparator|Placebo|Placebo, 2 pills, oral, twice daily for 7 days. To be taken with food.
16322315|NCT04523077||Oral lichen planus|Female patients of the Department of Oral Medicine with oral lichen planus
16322316|NCT04523077||Control|Female patients of the Department of Oral Medicine without oral lichen planus or other immune disorders
16322317|NCT04523064|Active Comparator|SGLT2i (empagliflozin)|Empagliflozin 25 mg 1 time day for three months
16322318|NCT04523064|No Intervention|Standard of care|Standard care treatment of diabetes patients in our center
16322319|NCT04523038||Low albumin|Patients presenting with low albumin levels preoperatively (<3,5 mg/l)
16322320|NCT04523038||Normal albumin|Patients presenting with normal or high albumin levels preoperatively (>3,5 mg/l)
16322321|NCT04523025||Low NLR-ratio|Patients with low NLR ratio (NLR<3)
16322322|NCT04523025||High NLR-ratio|Patients with high NLR ratio (NLR≥3)
16322323|NCT04523012||HIV patients|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
16322324|NCT04522999|Experimental|Photobiomodulation|Valeda™ Light Delivery System
16322325|NCT04522986|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
16322326|NCT04522973|Other|Within group four condition comparison|Participants will receive each of the four conditions. Order of conditions will be assigned using a Latin square model.
16322327|NCT04522960|Experimental|Patients with dementia or mild cognitive impairment due to AD|Dementia or MCI due to AD according to NIA-AA research criteria.
16322328|NCT04522960|Active Comparator|Healthy volunteers|Age-and-gender matched healthy controls.
16322329|NCT04522947|Experimental|fMRI|Participants are delivered sips of appetizing tastes (milkshake) and tasteless solution throughout the task while in the MRI scanner.
16322330|NCT04522934|Experimental|Pain Neuroscience Education|Patients received 24 sessions, in a 8-week period, of multimodal physiotherapy along with four sessions of pain neuroscience education.
16322331|NCT04522934|Active Comparator|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy along with four sessions of biomedical education.
16322332|NCT04522921|No Intervention|Control Group (CG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and regular follow-up.
16322333|NCT04522921|Experimental|Follow-up group (FUG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and increased follow-up.
16322334|NCT04522921|Experimental|Intervention group (IG)|A higher protein diet (25E%/day) for the 10 weeks they attend the camp and increased follow-up.
16322335|NCT04522908|Experimental|Cabozantinib - Single Arm|Single Arm with Cabozantinib starting dose 40 mg for 4 weeks and dose escalation to 60 mg afterwards.
16322336|NCT04522895|Experimental|Consolidation Arm|Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
16322337|NCT04522895|Experimental|Salvage Arm|"Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
~DLI as standard of care can be given to patients optionally after cycle 4, 6 and 8 in case of HLA-identical donors at a dose of 1-5 x10^6 CD3/kg (1st DLI), 5 x10^6 - 5x107 CD3/kg (2nd DLI) and 5x10^7 - 5x10^8 CD3/kg (3rd DLI) or at lower dosages in case of unrelated, mismatched or haploidentical donors. Additional DLI may be given due to the treating physician's decision in case of urgent medical need, but only beyond the fourth cycle of Enasidenib."
16322338|NCT04522882|Experimental|At home clinical data collection|Clinical data will be collected during 7 days: physical activity, sleep duration, chronotype, food and medication intake, glucose level and insulin administration.
16322339|NCT04522869|Experimental|Umbilical cord blood - derived mesenchymal stem cells|17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery
16322340|NCT04522869|No Intervention|Control group|17 patients with BA will be conducted Kasai operation only
16322341|NCT04522856||A|Local
16322342|NCT04522856||B|Nested
16322343|NCT04522843||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
16322344|NCT04522843||Colitis|Patients with active colitis
16322349|NCT04522804|Experimental|Treatment: all patients|"Subjects will participate in a total of five group sessions. There will be 6 subjects per group and one therapist will be assigned to each subject for a total of 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are Preparatory sessions followed by three Integration sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session."
16322350|NCT04522791|Experimental|RFB+VSOP|"For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.
~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
16322351|NCT04522791|Active Comparator|IR+VSOP|The control IR strategy will be used, set-up of which will be the same as the RFB + VSOP intervention group with IR replacing RFB. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
16322352|NCT04522791|Placebo Comparator|IR only|Participants randomized to this condition will receive weekly in-person check-in visits, and perform daily 10-minute IR, so that the number of treatment contacts (though not duration) will be equivalent. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
16322353|NCT04522778|Experimental|Device|Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear throughout the duration of the study.
16322354|NCT04522778|Active Comparator|Traditional Securement Dressing|Those is the non-device arm will continue to wear a traditional central line securement dressing as is the standard of care.
16322355|NCT04522765||Health|Healthy individuals with no known medical condition and taking no regular medication
16322356|NCT04522765||Acute kidney injury|Individuals with acute kidney injury as defined by KDIGO criteria
16322357|NCT04522765||Chronic kidney disease|Individuals with chronic kidney disease as defined by KDIGO criteria
16322358|NCT04522765||Small vessel vasculitis|Individuals with active small vessel vasculitis an diagnosed by a specialist physician
16322359|NCT04522765||Kidney transplant recipient|Individuals who have received a kidney transplant
16322360|NCT04522765||Kidney donor|Individuals who have donated a kidney for transplantation
16322361|NCT04522752||Gastric Polyp|The included subjects were patients with benign epithelial gastric polyps confirmed by gastroscopy and biopsy pathology. The size and pathology type of polyps were identified. Gastroscopy and biopsy were followed up six, twelve and eighteen months later to observe the relationship between the size, pathology types of polyps and the development of gastric polyps. Other factors including the relationship between helicobacter pylori infection and polyp type were also observed.
16322362|NCT04522739|Experimental|Spironolactone|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for12 months.
16322363|NCT04522739|Placebo Comparator|Placebo|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
16322364|NCT04522726|Experimental|Treatment group A|"Treatment group A received Weiyang Yupingfang Granules orally for 1 month on the Sanfu days and on theSanjiudays each year for a total of 2 months a year."
16322365|NCT04522726|Experimental|Treatment group B|Treatment group A received Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months a year.
16322366|NCT04522713|Experimental|Large-group transdiagnostic course|6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
16322367|NCT04522674|Experimental|Autologous platelet rich plasma|0.5 mL of activated autologous PRP will be injected by fluoroscopic guidance into the affected lumbar facet joint (s) depending on the number of affected levels. A max of 4 joints will be injected per patient.
16322368|NCT04522661|Experimental|Early Vitrectomy Group|Vitrectomy surgery plus intravitreal antibiotics
16322369|NCT04522661|Active Comparator|Control Group|Intravitreal antibiotics
16322370|NCT04522648|Experimental|Intervention (INT)|INT participants will be asked to perform self-measurements of arm circumference at five points along the arm at home every three months. Additional measurements can be performed if the participants experience signs of BCRL. Participants will report the self-measurements in cm and mm in an online questionnaire, or over the phone to a physiotherapist navigator, along with reporting sign and symptoms of BCRL.
16322371|NCT04522648|No Intervention|Control (CON)|The CON group will follow the usual post-operative care. CON participants will be prompted every 6 months by an online questionnaire to report if they have been diagnosed with BCRL and if so, month of initiation of treatment.
16322372|NCT04522635|Active Comparator|albumin|albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
16322373|NCT04522635|Placebo Comparator|normal saline|0.9% sodium chloride (normal saline (NS)) given intravenously at the start of IHD
16322374|NCT04522622|Experimental|Teriparatide|Patients receive teriparatide 20 micrograms once daily for 18 months
16322375|NCT04522622|Other|Controls|Controls receive no treatment with teriparatide
16322376|NCT04522609|No Intervention|Control group|Guideline recommended pharmacologic therapy
16322377|NCT04522609|Experimental|NMES group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
16322378|NCT04522596|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day for 14 days.
16322379|NCT04522596|Placebo Comparator|Placebo|Placebo inhaled once a day for 14 days.
16322380|NCT04522583||Troponin-positive ED patients|All patients admitted to the ED at the Hillel Yaffe Medical Center in Hadera, Israel, in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (>0.014 nanogram/milliliter).
16322381|NCT04522570|Active Comparator|laser ablation|Percutaneous Laser Ablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
16322467|NCT04521920|Experimental|Medication and telemedicine follow up|All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine
16322382|NCT04522570|Active Comparator|cryoablation|Percutaneous cryoablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
16322383|NCT04522570|Active Comparator|Radiofrequency ablation|Percutaneous radio frequency ablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
16322384|NCT04522557|Experimental|Experimental: Participants with breast cancer enrolled in grou|
16322385|NCT04522544|Experimental|SIRT|Y-90 SIRT + Tremelimumab + Durvalumab
16322386|NCT04522544|Experimental|TACE|TACE + Tremelimumab + Durvalumab
16322387|NCT04522531|Experimental|Exercise performed on stabil ground|Open cinetic chain shoulder exercise will performed on stabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
16322388|NCT04522518||DD group|160 pairs of children with disabilities 6-12 years of age and their caregivers (n=320)
16322389|NCT04522518||TD group|160 pairs of typically developing children 6-12 years of age and their caregivers (n=320)
16322390|NCT04522492|Experimental|internet CBT|Internet delivered cognitive behavioral therapy, thru 2 booster sessions. Each session will last 50 minutes. Fist session will involve: psychoeducation about the symptoms, evaluation of the skin picking habit, reinforcement of the habit reversal strategies. After 1 week, the second session will be applied, consisting of: strategies to cope with anxiety (breathing and muscle relaxation techniques) and to cope with depressive status (cognitive restructuring techniques).
16322391|NCT04522492|Active Comparator|Quality of life promotion|The therapist will send to the patient 2 videos with strategies to improve quality of life during the pandemia (1 video about social support and one video about sleep hygiene). After 1 week, the therapist will send to the patient another 2 videos with strategies do improve quality of life (dietary guidance and guidance on physical activity)
16322392|NCT04522479|No Intervention|prolonged protocol of early follicular phase|Inject a full dose of GnRH-a in 1st-3rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
16322393|NCT04522479|Experimental|prolonged protocol of middle luteal phase|Inject a full dose of GnRH-a in 21st-23rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
16322394|NCT04522466|Experimental|Patients infected by SARS-CoV-2 treated by Hydroxychloroquine|Blood sample on patients infected by SARS-CoV-2 treated by Hydroxychloroquine
16322395|NCT04522453|Active Comparator|paper mental health Gap Action Program-Intervention Guide|This arm will be training and supervision as usual employing the standard paper version of the mental health Gap Action Program-Intervention Guide. Primary care workers will be trained to use the paper version of this tool and will use the paper version when evaluating patients.
16322396|NCT04522453|Experimental|digital mental health Gap Action Program-Intervention Guide|This arm will be training and supervision in an experimental approach using a digital version of version of the mental health Gap Action Program-Intervention Guide. The digital version allows for interactive decision making on diagnoses and care, and it allows for entering of patient data. Primary care workers in this arm will be trained to use the digital version of this tool and will use the digital version when evaluating patients.
16322397|NCT04522440|Experimental|Inpatients in hospice Ward|Inpatients in hospice Ward with pain control problems
16322398|NCT04522427|Experimental|Multifocal and Extended Depth-of-Focus intraocular lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
16322399|NCT04522427|Active Comparator|Monofocal intraocular Lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
16322400|NCT04522414||Preterm infant|
16322401|NCT04522401||People aged 65 and over|"People aged 65 and over who have had a gerontological evaluation Bien vieillir at the St-Etienne University Hospital Day Hospital."
16322402|NCT04522388|Experimental|Treatment|Nutritional shakes, Ensure Enlive, twice per day orally in patients awaiting lung transplant
16322403|NCT04522375|Experimental|FP-045|FP-045 at one of 3 dose levels to sequential cohorts of adolescent, followed by pediatric subjects
16322404|NCT04522362|Sham Comparator|Control task-|The Control Task was implemented to ensure the specificity of the psychological stress effects had on study outcomes. Therefore, the Control Task had a similar procedure and the same duration of the TSST, lacking except for only the psychologically stressful component. The control task consisted of (a) Participants had a 5-min a preparation section and anticipation phase (5 min ), (b) a reading task where they had to. Then, all participants had to be read a simple text in a low voice (5 min), and (c) an arithmetic section where they were asked to perform an easy mathematical calculation (5 mins).
16322468|NCT04521907||Group 1|Group 1 includes patients who underwent cataract surgery with primary IOL implantation
16322405|NCT04522362|Experimental|Experimental Task- Trier Social Stress Task|"The Trier Social Stress Task (TSST) is a standardized, 15-minute laboratory task designed to induce psychological stress in laboratory settings (Kirschbaum, Pirke, & Hellhammer, 1993). The TSST consists of three continuously successive phases: (a) an anticipation period (5 min); (b) a free speech task (5 min); and (c) a mental arithmetic task (5 min). As is standard in the TSST procedure, participants were told by a research staff member that they would provide a brief speech about their dream job in front of a critical audience. At the end of the speech, a member of the audience instructed the participant to conduct serial subtractions as accurately and quickly as possible."
16322406|NCT04522349|Active Comparator|Greifer then Axon-Hook|T0 + 2 weeks: evaluation with Greifer. T1 + 2 weeks: evaluation with Axon-Hook
16322407|NCT04522349|Active Comparator|Axon-Hook then Greifer|T0 + 2 weeks: evaluation with Axon-Hook. T1 + 2 weeks: evaluation with Greifer
16322408|NCT04522336|Experimental|Treatment (pembrolizumab, chemoradiotherapy)|See Detailed Description
16322409|NCT04522323|Experimental|Dose Exploration|The Dose exploration Phase is made up of Part A and Part B. Part A will evaluate the safety and tolerability of MEDI5752 in combination with Axitinib (2 patients), and Part B will evaluate the safety and tolerability of MEDI5752 in combination with Lenvatinib (~27 patients)
16322410|NCT04522323|Experimental|Dose Expansion|Evaluate safety and anti-tumor activity of MEDI5752 in combination with Lenvatinib (~41 patients )
16322411|NCT04522297|Experimental|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
16322412|NCT04522297|Active Comparator|Nor-epinephrine|Intravenous infusion norepinephrine
16322413|NCT04522284|Experimental|CURATE.AI|"- Cohort 1: Capecitabine in solid tumours. In this cohort, participants will receive the treatment in three-week cycles. Only the dose of capecitabine will be modulated with CURATE.AI, based on measurements of the tumour marker (CEA/CA19-9). CT scans for radiological assessment will be performed according to standard of care, usually after every 2 to 3 cycles of chemotherapy for Cohort 1 only.
~Cohort 2: Ibrutinib in Waldenström macroglobulinaemia In this cohort, participants will receive the treatment in four-week cycles. The total cumulative dose of Ibrutinib will be modulated with CURATE.AI, based on measurements of the tumour marker (IgM paraprotein)."
16322414|NCT04522271|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5 g/m2 of an individually optimized resistant starch for approximately 5 months
16322415|NCT04522271|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 5 months
16322416|NCT04522258|Placebo Comparator|Placebo|Refined cereal flour
16322417|NCT04522258|Active Comparator|Dietary fiber|Fermentable cereal bran
16322418|NCT04522245|Placebo Comparator|Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
16322419|NCT04522245|Experimental|Noom Health Weight Program|
16322420|NCT04522232|Placebo Comparator|group A|women that underwent conventional Total laparoscopic hysterectomy
16322421|NCT04522232|Experimental|group B|women that underwent Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
16322422|NCT04522219|Experimental|Case group|Diagnosis of adnexal torsion confirmed by the surgical intervention: woman allocated to case group
16322423|NCT04522219|Experimental|Control group|Diagnosis of adnexal torsion not confirmed by the surgical intervention: woman allocated to control group
16322424|NCT04522206|Experimental|Patients undergoing elective spine surgery|
16322425|NCT04522193|Experimental|Experimental group|All children born at the Lille University Hospital during the investigation period with esophageal atresia type III or IV
16322426|NCT04522180|Experimental|IONIS-GHR-LRx Dose 1|Single dose of IONIS-GHR-LRx Dose 1 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
16322427|NCT04522180|Experimental|IONIS-GHR-LRx Dose 2|Single dose of IONIS-GHR-LRx Dose 2 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
16322428|NCT04522180|Experimental|IONIS-GHR-LRx Dose 3|Single dose of IONIS-GHR-LRx Dose 3 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
16322429|NCT04522167|Experimental|FYB203 (Proposed aflibercept biosimilar)|Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.
16322430|NCT04522167|Active Comparator|Eylea® (Aflibercept)|Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.
16322432|NCT04522141|Experimental|Self-control treatment group|The self-control treatment group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit as well as a short interventional input targeting self-control.
16322433|NCT04522141|Active Comparator|Control group|The control group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit.
16322434|NCT04522128|Active Comparator|Feedback Intervention|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.
~Participants randomly allocated to the feedback intervention will then be provided with graphs showing WHOQOL COMBI facet scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important."
16322466|NCT04521946|Experimental|Treatment (chemotherapy, HCT)|Patients receive thiotepa IV over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil PO every 8 hours or IV from days 0-40 and tapered to day 90.
16322435|NCT04522128|Experimental|Extended Intervention|"All participants will complete an online questionnaire (as described above).
~Participants randomly allocated to the extended intervention will then be provided with graphs to highlight differences between their actual WHOQoL COMBI scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important.
~Participants will then receive an online intervention that will provide them with behaviour change techniques to help them address the discrepancies in the relevant quality of life domains."
16322436|NCT04522128|Other|Waitlist Control|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.
~Participants randomly allocated to the waitlist control group will then receive their WHOQoL COMBI scores only, with no information about differences between quality of life and importance or intervention materials."
16322437|NCT04522115|Experimental|aerobic training|Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.
16322438|NCT04522115|Experimental|Resistance training|Resistance exercise training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
16322439|NCT04522102|Experimental|Intervention|Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).
16322440|NCT04522102|No Intervention|Comparator|Avoid antiplatelet therapy.
16322445|NCT04522076||COVID-19 with pneumonia|patients with positive COVID 19 by PCR and pneumonia by CT
16322446|NCT04522076||COVID-19 without pneumonia|patients with positive COVID 19 by PCR and absent of pneumonia by CT
16322447|NCT04522076||Patients with pneumonia and without COVID 19|patients with negative COVID 19 by PCR and with pneumonia by CT
16322448|NCT04522076||Patients without pneumonia and COVID 19|Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital
16322449|NCT04522050|Other|Induction chemotherapy + IMRT and concurrent gemcitabine|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m²,d1) every 3weeks for 2 cycles before radiotherapy, and then receive intensity modulated radiotherapy (IMRT) concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. Patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
16322450|NCT04522037||interventional group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic treatment for COVID-19 disease dyspnea.
16322451|NCT04522037||control group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 not receiving morphinic treatment for COVID-19 disease dyspnea.
16322452|NCT04522024|Active Comparator|Mei Mini Maze|Mei Mini Maze procedure (Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side)
16322453|NCT04522024|Experimental|Mei Mini Maze plus epicardial cryoablation|Epicardial focal cryoablation during Mei Mini Maze procedure
16322454|NCT04522011||Group A|D1/2 radical gastrectomy combines intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
16322455|NCT04522011||Group B|D1/2 radical gastrectomy combines postoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
16322456|NCT04522011||Group|without hyperthermic intraperitoneal chemotherapy
16322457|NCT04521998|Experimental|electroacupuncture|The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.
16322458|NCT04521998|Experimental|Transcutaneous electrical nerve stimulation|The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.
16322459|NCT04521985||thoracolumbar kyphosis|patients undergoing thoracolumbar kyphosis surgery
16322460|NCT04521972|Active Comparator|Group 1|Natural non-augmented labor with room lights ON. This is what is currently done in the hospital, and thus does not change any current medical practices.
16322461|NCT04521972|Active Comparator|Group 2|Augmented labor with room lights ON. This group will be a subgroup of Group 1 (Natural non-augmented labor with room lights ON), as labor-augmentation cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
16322462|NCT04521972|Experimental|Group 3|Natural non-augmented labor with reduced or red room lights.
16322463|NCT04521972|Experimental|Group 4|Augmented labor with reduced or red room lights. This group will be a subgroup of Group 3, as augmented labor cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
16322464|NCT04521959|Active Comparator|Blood Flow Restricted Aerobic and Resistance Exercise Group|kan akımı kısıtlanarak.direnç ve bisikletle aerobik egzersiz uygulanacak
16322470|NCT04521907||Group 3|Group 3 includes patients who underwent cataract surgery without IOL implantation.
16322471|NCT04521894||Primary PCa without metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies.
16322472|NCT04521894||Primary PCa with metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies. And the 18F-PSMA-PET/CT scan confirmed metastases.
16322473|NCT04521894||Oligometastatic PCa group|"Oligometastaticis a subgroup of metastatic patients with a limited number of secondary lesions (threshold ranging from 3 to 5) in one or few organs."
16322474|NCT04521894||Biochemical recurrence Group|Proven biochemical recurrence after radical therapy (PSA >0.2 ng/mL after radical prostatectomy, PSA ≥2 ng/mL above the nadir after external-beam radiotherapy) or persisting PSA after radical treatment with rising PSA values.
16322475|NCT04521894||Control Group|Prostate cancer benign prostatic hypertrophy or normal prostate.
16322478|NCT04521868|Experimental|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia.
16322479|NCT04521868|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
16322480|NCT04521855||Caregivers|Caregivers (family environment or close entourage) for adults and children with cerebral palsy.
16322481|NCT04521842|Placebo Comparator|Standard size femoral head implant|Participants qualified to undergo total hip replacement who will receive standard femoral head size implant
16322482|NCT04521842|Active Comparator|Large size femoral head|Participants qualified to undergo total hip replacement who will receive large femoral head size implant
16322483|NCT04521829|Experimental|VR-enhanced treadmill walking|Participants will be tested during 2 sessions of VR-enhanced treadmill walking.
16322484|NCT04521816|Experimental|Intervention--PACT Intensive Management|"The intervention is the PACT Intensive Management Program (PIM) provides a standardized menu of services, ranging from chart review assessment or in-home assessment, to a time limited intensive care management intervention. The following PIM features are standardized across the PIM demonstration sites:
~A) Chart review assessment template in the EMR; B) Comprehensive assessment template of unmet needs and modifiable risk factors in EMR; C) Transitions in care process (eligibility criteria, clinical protocols); D) Diagnostic home visits process (eligibility criteria, clinical protocols); E) Core risk stratification/Triage process; F) Discharge criteria and note template in EMR; G) Standardized interdisciplinary team (IDT) meeting note procedure and template in EMR."
16322485|NCT04521816|No Intervention|Usual care|High-Risk patients receiving care in PACT.
16322486|NCT04521803|No Intervention|Arm 1: Standard of care (RIF10)|Dosing of the daily oral RHZE fixed dose combination (FDC) will be according to WHO weight bands
16322487|NCT04521803|Experimental|Arm 2: High-dose RIF (RIF35)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used39
16322488|NCT04521790||Arrhythmic (A)|"Arrhythmic Group. To oversimplify, specific subgroups of patients will be considered.
~Group 1: major ventricular arrhythmias (haemodynamically unstable VT, hu-VT; ventricular fibrillation, VF).
~Group 2: other ventricular arrhythmias (high-burden premature ventricular complexes = hb-PVC; nonsustained VT = NSVT; haemodynamically stable VT = hs-VT).
~Group 3: bradyarrhythmias (2nd type II or 3rd degree atrioventricular block = advanced AVB; critical sinus pauses = SND).
~Group 4: supraventricular arrhythmias (atrial fibrillation = AF; atrial flutter = AFlu; atrial tachycardia = AT)."
16322489|NCT04521790||Nonarrhythmic (NA)|"Nonarrhythmic Group. To oversimplify, specific subgroups of patients will be considered.
~Heart failure presentation (and subtypes)
~Chest pain presentation (and subtypes)
~Asymptomatic presentation/screening (and subtypes)"
16322490|NCT04521790||Subgroups|"For specific study aims, different patient subgroups will be compared. The main groups are hereby reported:
~A. Arrhythmic myocarditis subgroups (1-4). B. Non-arrhythmic myocarditis subgroups (i.e.: fulminant, acute coronary syndrome-like, pericarditis-like, heart failure, nonischaemic dilated /hypokinetic cardiomyopathies of unknown aetiology…).
~C. Infectious vs. autoimmune vs. toxic myocarditis. D. Myocarditis treated by aetiology-based treatment vs. isolated cardiac medical treatment.
~E. Myocarditis at different disease stages: acute, hyperacute, fulminant, chronic active, post-inflammatory, or active vs. previous vs. non-myocarditis.
~F. Myocarditis presenting as organ-specific diseases vs. in the context of a genetic disorder or systemic disease.
~G. Myocarditis vs. peri-myocarditis/myo-pericarditis. H. Other subgroups."
16322491|NCT04521777|Experimental|Supportive care (exercise intervention)|Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
16322492|NCT04521764|Experimental|Treatment (MV-s-NAP)|Patients receive MV-s-NAP intratumorally (IT) on day 1 in the absence of disease progression or unacceptable toxicity. After 1 cycle of treatment, patients who experience disease progression proceed to follow-up. Patients who achieve CR, PR, or SD receive MV-s-NAP IT every 21 days for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity.
16322523|NCT04521595|Experimental|weigh smart intervention|open treatment arm to receive group based lifestyle intervention via telehealth.
16322493|NCT04521751|Experimental|EMP16-02 120 mg orlistat/40 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.
~Dosage: 120 mg O/40 mg A (given as 2 capsules EMP16-02-60/20). Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).
~Duration: 26 weeks."
16322494|NCT04521751|Experimental|EMP16-02 150 mg orlistat/50 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.
~Dosage: 150 mg O/50 mg A (given as 1 capsule EMP16-02-90/30 and 1 capsule EMP16-02-60/20).
~Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).
~Duration: 26 weeks."
16322495|NCT04521751|Placebo Comparator|Placebo|"Dosage form: Matching, oral capsule. Identical in appearance but contain only cellulose.
~Dosage: Placebo (given as 2 placebo capsules) Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).
~Duration: 26 weeks."
16322496|NCT04521738|Experimental|SAR441255|Single dose, subcutaneous, escalating dose
16322497|NCT04521738|Placebo Comparator|Placebo|Single dose, subcutaneous, matched volume
16322498|NCT04521725|No Intervention|Group1: ECG+SpO2 only|Traditional ECG (heart rate) and SpO2 (pulse oximetry) monitoring for resuscitation only.
16322499|NCT04521725|Active Comparator|Group 2: ECG+SpO2+RFM|Addition of Respiratory Function Monitor to ECG and SpO2 during resuscitation.
16322500|NCT04521725|Active Comparator|Group 3: ECG+SpO2+RFM+NIRS|Addition of cerebral NIRS and Respiratory Function Monitor to ECG and SpO2 during resuscitation.
16322501|NCT04521712|Experimental|Postpartum GDM|Women with GDM diagnosed early (< 20 weeks gestation) or with routine 3rd trimester screening (>=24 weeks) will be enrolled in this longitudinal study. All enrolled women will complete a oral glucose tolerance test and wear a continuous glucose monitor for 10 days at the 3 designated study time points (0-4 days, 4-6 weeks, and 6 months after delivery).
16322504|NCT04521686|Experimental|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738 Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
16322505|NCT04521673||infectious uveitis|Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap
16322506|NCT04521673||Control group|Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases
16322507|NCT04521660|Experimental|Intervention group|Patients in the intervention group will wear virtual reality glasses during coronary angiography.
16322508|NCT04521660|No Intervention|Control group|Patients in the control group will not wear virtual reality glasses. They will be given standard care and treatment during the procedure.
16322509|NCT04521647|Experimental|menthol flavor|Participants will receive 5% nicotine in an e-cigarette
16322510|NCT04521647|Experimental|tobacco flavor|Participants will receive 5% nicotine in an e-cigarette
16322511|NCT04521634||Acute Stroke + Diabetes|People who have experienced and acute stroke and also have diabetes
16322512|NCT04521634||Acute stroke|People without diabetes who have experienced and acute stroke
16322513|NCT04521621|Experimental|Part 1, Cohort A: Triple-Negative Breast Cancer|This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322514|NCT04521621|Experimental|Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322515|NCT04521621|Experimental|Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322516|NCT04521621|Experimental|Part 2 Dose Level 1, Solid Tumors+Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322517|NCT04521621|Experimental|Part 2 Dose Level 2, Solid Tumors+Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322518|NCT04521621|Experimental|Part 2 Dose Level 3, Solid Tumors+Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322519|NCT04521621|Experimental|Part 2, Cohort D: Hepatocellular Carcinoma (HCC)|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322520|NCT04521621|Experimental|Part 2, Cohort E: Gastric Carcinoma|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
16322521|NCT04521608|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants enrolled in the intervention arm will be offered a Home-based pulmonary rehabilitation program with health coaching.
16322522|NCT04521608|No Intervention|Control- Choice|This arm receives the standard of care which includes the choice of PR at a facility or through telehealth. Center based PR involves attending a medical center gym where they can do exercises and receive disease specific education. Telehealth PR is delivered virtually through the computer or telephone.
16322524|NCT04521582|Experimental|Active Group|Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within ~1 week and measure blood pressure again. If found high, the participant will be referred to the nearest Health Post. At the Health Posts, if FB-CHWs confirms the diagnosis of hypertension, they will prescribe amlodipine 5 mg/d according to the study protocol and ask the patient to return in ~2 weeks. If blood pressure is controlled (<140/90 mmHg) after ~2 weeks, FB-CHWs will refill amlodipine 5 mg/d for 3 months. If not, FB-CHWs will increase the dose to 10 mg/d and follow up in ~2 weeks. If still not controlled with amlodipine 10 mg, FB-CHWs will refer the patient to the Regional Hospital in Pokhara. In addition, FCHVs will visit patients' homes 3 times (at 3-, 6-, and 9-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.
16322525|NCT04521582|Active Comparator|Comparison Group|"Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within a week or so and measure the blood pressure again. If found high, the participant will be referred to a healthcare facility (the usual care) which can diagnose and manage hypertension. In addition, FCHVs will visit patients' homes once (around 3-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment."
16322526|NCT04521569|Experimental|EVLP with Regadenoson|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the study drug, Regadenoson.
16322527|NCT04521569|Placebo Comparator|EVLP with Steen solution|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the same volume of Steen solution.
16322528|NCT04521556|Active Comparator|Epidural anesthesia and analgesia|"Epidural catheter insertion: Th 9 - Th 10 or Th 10 - Th 11 using the midline approach.
~Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml).
~Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml)."
16322529|NCT04521556|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
16322530|NCT04521530|Experimental|immediate functional loading with temporary crowns|patients were rehabilitated with immediate functionally loaded implants.
16322531|NCT04521530|Experimental|immediate non functional loading with temporary crowns|patients were rehabilitated with immediate non-functionally loaded implants.
16322532|NCT04521517|Experimental|Pamphlet with timing of family planning|"Pamphlet with timing of family planning and Routine service"
16322533|NCT04521517|No Intervention|Only routine service|Receive only routine service
16322534|NCT04521504|Experimental|Biofeedback|Patients were treated with an experimental rehabilitation protocol, based on shoulder kinematic biofeedback.
16322535|NCT04521504|No Intervention|Control|Patients were treated with a standard rehabilitation protocol, based on hospital guidelines.
16322536|NCT04521491|Experimental|FOLFOX4|Patients who will receive FOLFOX4 chemotherapy after liver resection
16322537|NCT04521491|No Intervention|placebo|No adjuvant therapy after liver resection
16322541|NCT04521465||NovaTears® + Omega-3|
16322542|NCT04521452|Experimental|Evogliptin Group|evogliptin 5mg daily
16322543|NCT04521452|No Intervention|Non-evogliptin Group|DM medications except evogliptin and other DPP-4 inhibitors
16322544|NCT04521439|Experimental|MS Patients Group|
16322545|NCT04521439|Sham Comparator|Healthy Volunteers Group|
16322546|NCT04521426||Lung Fibrosis|"probable or confirmed diagnosis of interstitial pulmonary fibrosis (IPF) or other fibrotic lung disease of unknown origin.
~being listed for lung transplantation"
16322547|NCT04521426||COPD standard therapy|"COPD: GOLD stage III or IV
~being listed for lung transplantation
~did not underwent LVR surgery or endoscopic LVR
~not being treated with chronic NIV"
16322548|NCT04521426||COPD with long-term NIV|"COPD: GOLD stage III or IV
~being listed for lung transplantation
~did not underwent LVR surgery or endoscopic LVR
~being treated with chronic NIV before lung transplantation (at least 1 months, at least 4 hours per day)."
16322549|NCT04521413|Experimental|A1: Monotherapy Escalation|Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
16322550|NCT04521413|Experimental|A2: Monotherapy Biomarker|Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
16322551|NCT04521413|Experimental|A3: Monotherapy Expansion|Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
16322552|NCT04521413|Experimental|B1: Combination Escalation|Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
16322553|NCT04521413|Experimental|B2: Combination Expansion|Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
16322554|NCT04521400|Experimental|Arm1|Lopinavir /Ritonavir +high dose Interferon-β 1a
16322555|NCT04521400|Experimental|Arm2|Lopinavir /Ritonavir + Low dose Interferon-β 1a
16322556|NCT04521387|Experimental|N1 Platelet Rich Plasma (PRP)|2ml of autologous platelet rich plasma injection
16322557|NCT04521387|Active Comparator|N2 Corticosteroid (CS)|2ml of 7mg Betamethasone injection
16322558|NCT04521387|Active Comparator|N3 Hyaluronic Acid (HA)|2ml of 40mg hyaluronic acid with mannitol injection
16322559|NCT04521387|Placebo Comparator|N4 Saline (NaCl)|2ml saline (0,9%NaCl) injection
16322560|NCT04521374|Experimental|Standard Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 16g protein.
16322561|NCT04521374|Experimental|Standard Protein Fortified Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 25g protein.
16322562|NCT04521374|Experimental|Texture Modified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 340kcal, 16g protein.
16322563|NCT04521374|Experimental|Texture Modified Protein Fortified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 350kcal, 25g protein.
16322566|NCT04521348|Experimental|RAIR-DTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
16322567|NCT04521348|Experimental|MTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
16322568|NCT04521348|Experimental|ATC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
16322569|NCT04521348|Experimental|DTC unsuitable for RAI arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
16322570|NCT04521335|Experimental|Treatment: all patients|disulfiram and copper gluconate in combination
16322571|NCT04521322|Placebo Comparator|Control|Participants in this arm will receive a nasal spray with placebo
16322572|NCT04521322|Experimental|Experimental|Participants in this arm will receive a nasal spray with Iota-Carrageenan
16322573|NCT04521309|No Intervention|Control|Standard care only n = 10 patients.
16322574|NCT04521309|Experimental|IVIG dose: 0.15 g/kg|Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients
16322575|NCT04521309|Experimental|IVIG dose: 0.20 g/kg|Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
16322576|NCT04521309|Experimental|IVIG dose: 0.25 g/kg|Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
16322577|NCT04521309|Experimental|IVIG dose: 0.30 g/kg|Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
16322578|NCT04521296|Experimental|DWJ1248|Camostat mesylate
16322579|NCT04521296|Placebo Comparator|Placebo|Placebo
16322580|NCT04521244|Experimental|Thrust joint lumbar manipulation|Thrust joint lumbar manipulation (Lumbar rotation manipulation) ,Moist Hot pack
16322581|NCT04521244|Active Comparator|Lumbar mobilization|Lumbar mobilization (Stretch rotation mobilization), Moist Hot pack
16322582|NCT04521231|Experimental|Blinatumomab: Dose escalation|Cohorts of at least 3 participants each will be treated with escalating doses of blinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.
16322583|NCT04521231|Experimental|Blinatumomab: Dose expansion|Participants will be administered the recommend phase 2 dose (RP2D) determined from dose escalation stage to further assess safety, pharmacokinetics (PK), pharmacodynamic (PD), and efficacy.
16322584|NCT04521218|Experimental|Thrust joint Manipulation|Thrust joint Manipulation, heat application, Strengthening exercise and home plan
16322585|NCT04521218|Active Comparator|Reverse Sustained Natural apophyseal glides|Reverse Sustained Natural apophyseal glides (SNAG), heat application, Strengthening exercise and home plan.
16322586|NCT04521205|Experimental|Standardized FMT|The patients will receive standardized FMT. The FMT was given by capsule. It was given three times a week.
16322587|NCT04521205|Placebo Comparator|Without FMT|The patients will receive FMT with blank capsule.
16322588|NCT04521192|Experimental|TR sequence group|
16322589|NCT04521192|Experimental|RT sequence group|
16322590|NCT04521179|Experimental|KN026 combined with KN046|KN026 combination therapy
16322591|NCT04521166|Experimental|Setting 1|Hearing aid features presented in this arm include omnidirectional microphone settings and fast-acting compression
16322592|NCT04521166|Experimental|Setting 2|Hearing aid features presented in this arm include omnidirectional microphone settings and slow-acting compression
16322593|NCT04521166|Experimental|Setting 3|Hearing aid features presented in this arm include directional microphone settings and fast-acting compression
16322594|NCT04521166|Experimental|Setting 4|Hearing aid features presented in this arm include directional microphone settings and slow-acting compression
16322595|NCT04521153|Experimental|Experimental group|Preoperative camrelizumab combined with apatinib mesylate (q2w, 2 cycles) → radical surgery → postoperative TACE treatment → sequential camrelizumab and apatinib mesylate (q3w, at least 6 cycles) (Note: Surgery within 2-4 weeks after the last administration of neoadjuvant therapy, postoperative TACE treatment at least 4 weeks after surgery, and camrelizumab combined with apatinib mesylate within 2 weeks after TACE treatment)
16322596|NCT04521153|Active Comparator|Control group|Radical surgery→postoperative TACE treatment
16322597|NCT04521140|Experimental|PKP with Dextenza (study)|"Patients undergoing PKP will receive Dextenza insert with:
~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
16322598|NCT04521140|Other|PKP without Dextenza (Controlled)|"Patients undergoing PKP will receive:
~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
16322599|NCT04521140|Experimental|DSEK with Dextenza (study)|"Patients undergoing DSEK will receive Dextenza insert with:
~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
16322600|NCT04521140|Other|DSEK without Dextenza (Controlled)|"Patients undergoing DSEK will receive:
~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
16322643|NCT04520841|Active Comparator|Standard dry dressing in lower limb amputation|Standard dressing in lower limb amputation: a dry sterile dressing is applied on the surgical wound at the end of surgery
16322601|NCT04521140|Experimental|DMEK with Dextenza (study)|"will receive Dextenza insert with: topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
16322602|NCT04521140|Other|DMEK without Dextenza (Controlled)|"Patients undergoing DMEK will receive:
~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
16322603|NCT04521127|Active Comparator|Kinesio Taping Group|Kinesio taping will be applied to trapezius muscle
16322604|NCT04521127|Active Comparator|Dry needling Group|Dry needling will be applied to trigger point on trapezius muscle
16322605|NCT04521127|No Intervention|Control Group|Control group will not receive any additional intervention
16322606|NCT04521114|Experimental|Phase II: 700 mg PRO 140 SC weekly|"Drug: 700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
~Other names:
~PRO 140"
16322607|NCT04521114|Placebo Comparator|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
16322608|NCT04521101|Other|VAST Course|
16322609|NCT04521088||visitors of the outpatient clinic for COVID-19|visitors of the outpatient clinic for COVID-19
16322610|NCT04521075|Experimental|Treatment Arm|Combination treatment: anti PD1 + FMT by capsules
16322611|NCT04521062|Other|Dilapan S|Placement of dilators
16322612|NCT04521049|Active Comparator|saxagliptin|patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of <50 mL/min/1.73 m2
16322613|NCT04521049|No Intervention|control|patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
16322614|NCT04521036|Experimental|Convalescent plasma|Standard of care plus 500 mL of convalescent plasma from COVID-19 recovered donors
16322615|NCT04521036|No Intervention|Standard of care|Standard of care (Supportive care, oxygen, antibiotics, no convalescent plasma)
16322616|NCT04521023|Experimental|A|
16322617|NCT04521023|Active Comparator|B|
16322618|NCT04521010||Staff absenteeism|A retrospective analysis of above-mentioned data, covering the period January-April 2019 and January-April 2020, was carried out. The evaluation of the staff's absence included all workers employed under an employment contract: 713 workers in 2019 and 747 workers in 2020.
16322619|NCT04521010||healthcare services|The variable number of employees was a result of the employment dynamics in the subsequent 2 years, due to variable quantity of healthcare services that were contracted with the national payer and changes in the form of employment of some hospital workers
16322620|NCT04520997|Experimental|Down-up|Participants in this group will receive injections in the chin area at baseline and in the nasolabial folds (NLFs) and marionette lines (MLs) at week 3.
16322621|NCT04520997|Experimental|Top-down|Participants in this group will receive injections in the nasolabial folds (NLFs) and marionette lines (MLs) at baseline and in the chin area at week 3.
16322622|NCT04520984|Experimental|Arm 1|Intervention
16322623|NCT04520984|Other|Arm 2|Standard Care
16322624|NCT04520971|Experimental|780G closed-loop|780 closed-loop insulin delivery system
16322625|NCT04520971|Active Comparator|standard of care|standard of care treatment (continue with current treatment of insulin pump without closed-loop or multiple daily insulin injections).
16322626|NCT04520958|Experimental|Mindfulness of Breath|
16322627|NCT04520958|Experimental|Mindfulness of Pain|
16322628|NCT04520958|Active Comparator|Cognitive-Behaviorally Based Pain Psychoeducation|
16322629|NCT04520945|Active Comparator|Active Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
16322630|NCT04520945|Placebo Comparator|Placebo Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
16322631|NCT04520932|Experimental|RFA treatment efficacy|PNETs ablation by radiofrequency treatment (1 to 3 sessions)
16322632|NCT04520906|Experimental|single-arm|Subjects will be treated with microwave ablation.
16322633|NCT04520893|Experimental|VCV pause|volume controlled ventilation with pause time 30%
16322634|NCT04520893|Active Comparator|VCV|volume controlled ventilation (without pause)
16322635|NCT04520893|Active Comparator|PCV-VG|pressure controlled ventilation - volume guaranteed
16322636|NCT04520880||Critically ill SARS-Cov2 patients|Critically ill patients with acute hypoxemic respiratory failure defined as those admitted to ICU and receiving mechanical ventilation (invasive or non-invasive) or high-level supplemental oxygen (via a high-flow nasal cannula or non-rebreathing face mask at a flow rate of 15 L per min or greater), at or during hospitalization
16322637|NCT04520880||Hospitalized non-critically ill SARS-Cov2 symptomatic patients|Hospitalized non-critically ill SARS-Cov2 symptomatic patients
16322638|NCT04520867||Qualifying Subjects|Patients seen in the EGMDC for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro
16322639|NCT04520854|Experimental|2-week Telehealth Protocol|Participants randomized to this arm will receive 5 live-video sessions. The first 2 live-video sessions will occur during the first week, last 20 minutes each and separated by 48-72 hours. The last 3 live-video sessions will occur during the second week, last 30-minutes each and separated by 24-48 hours.
16322640|NCT04520854|Active Comparator|2-week Usual Care|The usual care group will be used to reflect the current care provided to patients after discharged from the emergency department for an ankle sprain.
16322641|NCT04520841|Active Comparator|Standard dry dressing in total hip or knee arthroplasty|Standard dressing in total hip or knee arthroplasty surgery revision: a dry sterile dressing is applied on the surgical wound at the end of surgery
16322642|NCT04520841|Experimental|Prevena in total hip or knee arthroplasty|"Prevena incision management system in total hip or knee arthroplastsy surgery revision:
~The Prevena incision management system is applied on the surgical wound at the end of surgery"
16322644|NCT04520841|Experimental|Prevena in lower limb amputation|"Prevena incision management system in lower limb amputation:
~The Prevena incision management system is applied on the surgical wound at the end of surgery"
16322645|NCT04520828|Experimental|Postural repositioning|
16322646|NCT04520802||POCD|Patients with postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
16322647|NCT04520802||no POCD|Patients without postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
16322648|NCT04520789|Sham Comparator|RD control group|Conventional Surgery for Retinal Detachment
16322649|NCT04520789|Experimental|RD treatment group1|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study
16322650|NCT04520789|Active Comparator|RD treatment group2|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study, postoperative intervention
16322651|NCT04520776|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis
16322652|NCT04520776|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc
16322653|NCT04520763|Experimental|Respiratory Muscle Exercises|Two respiratory muscle exercises
16322654|NCT04520763|No Intervention|Control|The control intervention consists of quiet sitting for 15 min
16322655|NCT04520750|Experimental|Open label treatment arm|PTX-022 QTORIN
16322656|NCT04520737|Active Comparator|16W group|Multimodal prehabilitation program (MPP) will be implemented during 16 weeks, 12 weeks during chemotherapy (CT) and 4 weeks while waiting for surgery.
16322657|NCT04520737|Active Comparator|4W group|Multimodal prehabilitation program (MPP) will start at the end of preoperative chemotherapy (CT) until surgery (4 weeks in total).
16322658|NCT04520724|Experimental|Study group|"30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (ca. 300 kcal; no less than 12 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (12 g of fiber/per roll) for 8 weeks.
~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
16322659|NCT04520724|Placebo Comparator|Placebo group|"30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (ca. 300 kcal; no less than 6 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (6 g of fiber/per roll) for 8 weeks.
~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
16322660|NCT04520698|Experimental|Nursing Home-level UPLIFT-AD intervention|The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
16322661|NCT04520698|No Intervention|Usual Care|
16322662|NCT04520685|Experimental|Arm 1: 12 weeks of study drug then 15 weeks of placebo|Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.
16322663|NCT04520685|Experimental|Arm 3: 15 weeks of placebo then 12 weeks of study drug|Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks.
16322664|NCT04520685|Experimental|Arm 3: 27 weeks of study drug|Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment.
16322665|NCT04520659|Experimental|Group 1: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
16322666|NCT04520659|Placebo Comparator|Group 1: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16322667|NCT04520659|Experimental|Group 2: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
16322668|NCT04520659|Placebo Comparator|Group 2: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16322669|NCT04520646|Experimental|empagliflozin|empagliflozin is added on the basis of the original treatment
16322670|NCT04520633||control level stable|severe asthma for which the control level is stable (variation in ACT score <3 between M0 and M6) contributing to the test-retest
16322671|NCT04520633||biologic initiation|introduction or modification of biotherapy at M0
16322672|NCT04520620|Experimental|enoxaparin treatment|"Patients infected by SARS-CoV-2 in intensive care unit with enoxaparin treatment will be included.
~They will have enoxaparin pharmacokinetic and ultrasound of the lower limbs at 7, 14 and 21 days after inclusion."
16322673|NCT04520607|Experimental|Arm 1|Subjects assigned to this arm will receive one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study); performed on Day 1, at Week 48 and every 52 weeks thereafter.
16322674|NCT04520607|Experimental|Arm 2|Subjects assigned to this arm will receive one intra-articular injection of 0 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study) on Day 1, followed by one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle at Week 48 and every 52 weeks thereafter.
16322675|NCT04520594|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5g/m2 of an individually optimized resistant starch for approximately 6 months
16322676|NCT04520594|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 6 months
16322677|NCT04520581|No Intervention|Control|Use in the shape of an endotracheal tube.
16322678|NCT04520581|Experimental|"Group O"|"Just before the induction of medicine is injected, the assistant makes endotracheal tube into O shape."
16322718|NCT04520256|Experimental|Exercise|
16322679|NCT04520568|Active Comparator|HFNC group|For HFNC group, F&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).
16322680|NCT04520568|Placebo Comparator|control group|induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.
16322681|NCT04520555|Experimental|Laryngeal mask airway group|Flexible laryngeal mask airway is inserted for general anesthesia
16322682|NCT04520555|Active Comparator|intubation group|Endotracheal intubation was performed for general anesthesia
16322683|NCT04520542|Experimental|acupressure|The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention. Each acupressure point was massaged for 30 seconds to provide circulation before the pressure. After the massage, consecutive pressures were applied for 90 seconds. In each intervention, a total of 8-minute sessions were applied to 4 points as 2 minutes for each point. Consecutive pressures were applied on a frequency that did not disturb the women, did not cause pain, and had a soothing effect. Until the end of the intervention it was continued 2 times a week, 16 times in total in 8 weeks.
16322684|NCT04520542|No Intervention|Control Group|no intervation
16322685|NCT04520529|Other|Patients with primary cutaneous lymphoma|
16322686|NCT04520516|Experimental|tVNS active device|VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
16322687|NCT04520516|Sham Comparator|Sham tVNS device|Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
16322688|NCT04520503||Pre EEG group|This cohort includes all participants in this study. EEG sensor will be attached to the patient's forehead before induction of anesthesia. Patterns of EEG and data will be obtained
16322689|NCT04520490|Active Comparator|Exenatide once weekly extended-release|Weekly subcutaneous injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (2mg) for 24 weeks in randomized intervention.
16322690|NCT04520490|Placebo Comparator|Matching placebo|Weekly subcutaneous injections of placebo for 24 weeks.
16322691|NCT04520464|Active Comparator|Self-test for cervical sample|First sequence will start with self-test. Second sequence will start with traditional method.
16322692|NCT04520464|Active Comparator|Traditional provider for cervical sample|First sequence will start with traditional method. Second sequence will start with self-test method.
16322693|NCT04520451|Experimental|PRN1008 plus glucocorticoids|PRN1008 tablets, 400 mg twice daily from Week 0 to Week 12 plus glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 2 weeks on study)
16322694|NCT04520451|Active Comparator|Glucocorticoids|Glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 12 weeks on study)
16322695|NCT04520438|Experimental|NSPT + L-PRF|Scaling and root planing associated to Leucocyte and Platelet rich Fibrin Membrane and irrigation with exudate of L-PRF.
16322696|NCT04520438|Other|NSPT alone|Only Scaling and root planing
16322697|NCT04520425|Experimental|Intervention|Participants will receive 5 standardized osteopathic manipulative treatments, two weeks apart. (To be considered a study completer, a participant must complete at least 3 of these treatments.) In addition to assessments at intake and during treatments, 1 and 3 months after their last treatment patients will be asked to provide follow-up data. Assessments include the HIT-6, MIDAS, and MSQ surveys, treatment satisfaction assessments, and a headache diary. Participants will also consent to an electronic medical record extraction of medication and healthcare services utilization.
16322698|NCT04520412|Experimental|GV-971|
16322699|NCT04520412|Placebo Comparator|Placebo|
16322700|NCT04520399||violence|
16322701|NCT04520399||non-violence|
16322702|NCT04520386|Experimental|Open label single arm|1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval
16322703|NCT04520373|Experimental|Treatment Group 1: AD-MSC Injection|Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
16322704|NCT04520373|Active Comparator|Treatment Group 2: Best Medical Management|Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
16322705|NCT04520360|Experimental|Types of Carisbamate|"A single 300 mg oral dose of the Oral Suspension Type 1 under fasting conditions
~A single 300 mg oral dose of Oral Suspension Type 2 under fasting conditions
~A single 300 mg oral dose of Oral Suspension Type 2 under fed conditions
~A single oral dose of the 300 mg Oral Tablet under fasting conditions
~A single oral dose of the 300 mg Oral Tablet under fed conditions"
16322706|NCT04520334|Other|Zhineng Qigong|Zhineng Qigong intervention
16322707|NCT04520321|Placebo Comparator|Vehicle (placebo)|Placebo weekly x 4
16322708|NCT04520321|Experimental|Low dose|TTHX1114(NM141) low-dose weekly x 4
16322709|NCT04520321|Experimental|Mid-dose|TTHX1114(NM141) mid-dose weekly x 4
16322710|NCT04520321|Experimental|High-dose|TTHX1114(NM141) high-dose weekly x 4
16322711|NCT04520308|Experimental|dupilumab|
16322712|NCT04520295||HER2 positive cohort|
16322713|NCT04520269|Experimental|Patient with (cfDNA) 1q21.3 copy number amplification|The phase Ib segment will be carried out in a standard 3+3 design. In the phase II portion, 2 parallel cohorts will be enrolled (Cohort A: 1q21.3 amplified breast cancers, Cohort B: 1q21.3 amplified other solid tumors).
16322714|NCT04520256|Experimental|Core Program Only|
16322715|NCT04520256|Experimental|Social Support|
16322716|NCT04520256|Experimental|Dysregulated Eating|
16322717|NCT04520256|Experimental|Social Support, Dysregulated Eating|
16322721|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise|
16322722|NCT04520256|Experimental|Feedback|
16322723|NCT04520256|Experimental|Social Support, Feedback|
16322724|NCT04520256|Experimental|Dysregulated Eating, Feedback|
16322725|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback|
16322726|NCT04520256|Experimental|Exercise, Feedback|
16322727|NCT04520256|Experimental|Social Support, Exercise, Feedback|
16322728|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback|
16322729|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback|
16322730|NCT04520256|Experimental|VR|
16322731|NCT04520256|Experimental|Social Support, VR|
16322732|NCT04520256|Experimental|Dysregulated Eating, VR|
16322733|NCT04520256|Experimental|Social Support, Dysregulated Eating, VR|
16322734|NCT04520256|Experimental|Exercise, VR|
16322735|NCT04520256|Experimental|Social Support, Exercise, VR|
16322736|NCT04520256|Experimental|Dysregulated Eating, Exercise, VR|
16322737|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, VR|
16322738|NCT04520256|Experimental|Feedback, VR|
16322739|NCT04520256|Experimental|Social Support, Feedback, VR|
16322740|NCT04520256|Experimental|Dysregulated Eating, Feedback, VR|
16322741|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback, VR|
16322742|NCT04520256|Experimental|Exercise, Feedback, VR|
16322743|NCT04520256|Experimental|Social Support, Exercise, Feedback, VR|
16322744|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback, VR|
16322745|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback, VR|
16322746|NCT04520243|Experimental|English alphabet illiterate group|Individuals with no self-reported understanding of English alphabet and recognition of <6/10 Sloan Letters
16322747|NCT04520243|Active Comparator|English alphabet literate group|Individuals with self-reported understanding of English alphabet and recognition of ≥6/10 Sloan Letters
16322748|NCT04520230|Experimental|Group 1|Group 1: 15 patients with COPD who will receive inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination (160/4.5mcg) 2 inhalations bid).
16322749|NCT04520230|Experimental|Group 2|Group 2: 15 patients with COPD who will receive inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg inhaled capsule once daily+ Budesonide inhalation 200 mcg twice daily).
16322750|NCT04520230|Experimental|Group 3|Group 3: 15 patients with COPD who will receive long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC). (Tiotropium 18 mcg inhaled capsule once daily+ Formoterol 12 mcg inhaled capsule twice daily)
16322751|NCT04520217|Experimental|4% Imipramine Cream on UVB-Treated Areas|"2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.
~2g of base cream will be applied to the UVB-treated areas on volar forearm and back.
~No cream will be applied to a UVB-treated area on the back"
16322752|NCT04520178|Active Comparator|Low-dose 5HTP|50mg 5-HTP in combination with 50mg carbidopa
16322753|NCT04520178|Active Comparator|High-dose 5HTP|100mg 5-HTP in combination with 50mg carbidopa
16322754|NCT04520178|Sham Comparator|Carbidopa|50mg carbidopa only
16322755|NCT04520178|Placebo Comparator|Placebo|
16322756|NCT04520152|Experimental|Treatment group|Bronchoscopic LTD placement
16322757|NCT04520139|Experimental|Phase 1 Dose Escalation|Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.
16322758|NCT04520139|Experimental|Phase 2 Dose Expansion|Patients will be randomized to receive NAC at the maximum tolerated dose or placebo.
16322759|NCT04520126|Active Comparator|olive extract 1|Fifteen patients will be randomized to receive two Olivomed soft capsules bid for three months (10 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another 3 months.
16322760|NCT04520126|Placebo Comparator|placebo 2|Fifteen patients will be randomized to receive two placebo soft capsules bid for three months. Then they will be crossed over to receive two Olivomed soft capsules bid for three months (10 mg hydroxytyrosol po twice daily)
16322761|NCT04520113|Active Comparator|Standard Tracing|"Households of tuberculosis index patients receive standard household contact tracing during regular weekday business hours."
16322762|NCT04520113|Experimental|Holiday Tracing|Households of tuberculosis index patients in rural South Africa receive household contact tracing during holidays (Christmas and Easter).
16322763|NCT04520113|Experimental|Evening / Weekend Tracing|Households of tuberculosis index patients in urban South Africa receive household contact tracing during evenings and weekends.
16322764|NCT04520100|No Intervention|MRI without intervention|No hypnosis during MRI and care by regular MR technologist
16322765|NCT04520100|Active Comparator|MRI with clinical hypnosis and regular MR tech|Hypnosis during MRI and care by regular MR technologist
16322766|NCT04520100|Active Comparator|MRI with care by MR Tech trained in empathic communication|No hypnosis during MRI and care by MR technologist who have been trained in emphatic communication
16322767|NCT04520087|Experimental|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
16322768|NCT04520074|No Intervention|Follow-up|No interevention
16322769|NCT04520074|Experimental|three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
16322770|NCT04520061|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
16322771|NCT04520061|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
16322772|NCT04520048|Experimental|Women with gestational hypertension and/or preeclampsia|Pregnant patients from the 20th week of amenorrhea with the initial diagnosis of gestational hypertension and/or preeclampsia. Patients in a stable state undergoing follow-up consultation (day hospital and week hospitalisation)
16322773|NCT04520035|Experimental|neoadjuvant chemotherapy with camrelizumab|"paclitaxel and cisplatin
~Carilizumab 200 mg, every 3 weeks, 2 cycles.
~Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
~Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles"
16322774|NCT04520022|Experimental|FURESTEM-CD Inj|
16322775|NCT04520009||Activity Restriction|Discharge orders for activity restriction
16322776|NCT04520009||Activity As Tolerated|Discharge orders written for activity as tolerated
16322777|NCT04519996|Experimental|US Internal Jugular Vein Collapsibility Index|The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility.
16322778|NCT04519996|Experimental|US Inferior Vena Cava Collapsibility Index|The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration.
16322779|NCT04519983|Experimental|Upfront TKI + Salvage SRT|Patients With Brain metastases of EGFR-mutant Non-small Cell Lung Cancer should receive receive Osimertinib as upfront treatment. SRT(32-40 Gy/4-5f) given to progressive or recurrent intracranial lesions as salvage therapy after intracranial failure.
16322780|NCT04519970|Active Comparator|Highest Tier of Case Management (Piggyback) and Biktarvy|The most intensive tier of case management. Includes three appointment reminders; check ins twice per week; travel compensation; housing support; food insecurity support; follow ups for missed appointments and off pill counts; connections with substance use programs; meetings with the benefits department for health insurance needs; childcare support to make appointments; mental healthcare referrals; open pool appointments as back-up options in case of rescheduling needs; late doctor's appointments and prescription pick up for those working during the day; meetings with the health educators to discuss HIV and ART; and re-motivation of HIV treatment every 3 months.
16322781|NCT04519970|Active Comparator|Middle Tier of Case Management (Got Your Back) and Biktarvy|The middle tier (Got Your Back) will work closely with the CORE case managers to augment their work in housing support, transportation assistance, mental healthcare referrals, childcare assistance, substance use program referrals, food insecurity support and health insurance needs. The retention specialist will additionally provide this middle tier 2 reminders for appointments; check ins once per week; follow ups for missed appointments or off pill counts; support with scheduling appointments for limited availability; meetings with the health educators for information on HIV or ART; and re-motivation for treatment at the 6 and 9 month marks of participation.
16322782|NCT04519970|Active Comparator|Lowest Tier of Case Management (Backbone) and Biktarvy|The top tier (Backbone) will need the least amount of support and also have a CORE Center case manager for a majority of the support in housing, food, insurance, transportation, childcare, substance use, and mental healthcare. The retention specialist will still provide an appointment reminder; check ins every other week; text checkups after missed appointments or off pill counts; support with scheduling for appointments or prescription pick up for limited availability; and re-motivation of treatment for HIV at the 9 month mark of study participation.
16322783|NCT04519944||NVAF patients undergoing PCI|Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
16322784|NCT04519931|Experimental|Stress ball|
16322785|NCT04519931|No Intervention|Control group|
16322786|NCT04519918|No Intervention|Standard ICSI procedure|a single spermatozoon was injected into the ooplasm.
16322787|NCT04519918|Experimental|Chemical oocyte activation|After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
16322788|NCT04519918|Experimental|Mechanical oocyte activation|Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
16322789|NCT04519905|Experimental|chemoradiotherapy|50.4Gy/28Fx; Paclitaxel plus carboplatin
16322790|NCT04519905|Active Comparator|radiotherapy|61.2Gy/34Fx
16322791|NCT04519892|Experimental|Receiving PDRC and coach guidance|Intervention group: Receiving PDRC + coach guidance.
16322792|NCT04519892|Active Comparator|Receiving PDRC without coach guidance|Control group: Receiving PDRC only.
16322793|NCT04519879|Experimental|Arm IA (white mushroom extract)|Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
16322794|NCT04519879|Active Comparator|Arm IB (clinical observation)|Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
16322795|NCT04519879|Experimental|Arm IIA (white mushroom extract)|Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
16322796|NCT04519879|Active Comparator|Arm IIB (active surveillance)|Patients undergo active surveillance for 48 weeks.
16322797|NCT04519866|Experimental|Electroacupuncture|In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
16322798|NCT04519866|Active Comparator|Manual acupuncture|In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
16322799|NCT04519853|Experimental|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 30% carbohydrate, 20% protein.
16322800|NCT04519827|Experimental|New Rice-based hydrolysate|The TEST formula is a new Rice-based hydrolysate with new ingredient.
16322801|NCT04519827|Placebo Comparator|Amino-acid based formula|The PLACEBO is an Amino-acid based formula.
16322802|NCT04519814|Experimental|all eligible patients|A total of 40 eyes in 40 consecutive patients, 22 years of age or older, with primary open-angle glaucoma (HPG + NPG), who did not reach target pressure, agree to participate in the study, and will be able to complete clinical follow-up and evaluation.
16322803|NCT04519801|Other|REHAB|Standard post-operative rehabilitation regimen (REHAB) (Control)
16322804|NCT04519801|Experimental|REHAB + BFR|Standard rehabilitation regimen with BFR therapy (REHAB + BFR) (Experimental)
16322805|NCT04519788|Active Comparator|AT-301B|AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0)
16322806|NCT04519788|Placebo Comparator|AT-301A|AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0)
16322807|NCT04519775|Experimental|HOBSCOTCH-V (virtual)|"Participants will receive the HOBSCOTCH intervention consisting of 1:1 sessions delivered once per week, including:
~1 pre-HOBSCOTCH Session (on webcam)
~1 educational session (on webcam)
~6 telephone sessions
~1 wrap-up session (webcam or telephone)
~Participants will also receive 3 booster sessions, via webcam or telephone, once per month."
16322808|NCT04519775|Other|Control|Participants will be wait listed and will receive HOBSCOTCH-V (above) following a 6 month wait period.
16322809|NCT04519762|Sham Comparator|Control group|Management of sepsis/ septic shock via fluids, antibiotics, vasopressors and inotropes.
16322810|NCT04519762|Active Comparator|Study group|Management of sepsis/ septic shock in addition to management of hypophosphatemia.
16322811|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A|Single IV administration of 4D-310 Dose Level 1 - AAV NAb Titer Group A patients
16322812|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV NAb Titer Group B|Single IV administration of 4D-310 Dose Level 1 - AAV NAb titer Group B patients
16322813|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV NAb Titer Group A|Single IV administration of 4D-310 Dose Level 2 - AAV NAb titer Group A patients
16322814|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV NAb Titer Group B|Single IV administration of 4D-310 at Dose Level 2 in AAV NAb titer Group B patients
16322815|NCT04519749|Experimental|4D-310 Dose Expansion|Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
16322816|NCT04519736|Active Comparator|Harmony Dye-VL 500-600nm|The left side of the face will be treated with the Single Band Alma Harmony Dye-VL 500-600nm device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
16322817|NCT04519736|Active Comparator|Palomar MaxG|Right side of the face will be treated with the Dual Band Palomar MaxG device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
16322818|NCT04519723|Other|Alma Harmony Laser System|There is only one arm. Three hand modules; Dye-VL 500-600nm, High Power QSW 1064nm, and High power Pixel ER:YAG 2940nm laser module with rollers will be utilized in combination in a series of treatments intended to improve skin color, tone, texture and laxity. Subjects will receive up to four treatments administered in intervals of 28 +/- 2 days. Treatment duration of approximately 60 minutes.
16322819|NCT04519710|Experimental|multiple sclerosis or other inflammatory neurological disease|HBV negative
16322820|NCT04519710|Experimental|systemic vasculitis|HBV negative
16322821|NCT04519710|Experimental|an autoimmune disease|HBV negative
16322822|NCT04519697|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
16322823|NCT04519697|Placebo Comparator|Placebo|Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula.
16322824|NCT04519684|Experimental|Mesenchymal stem cells|Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
16322825|NCT04519684|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s).
16322826|NCT04519671|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
16322827|NCT04519671|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)
16322828|NCT04519658|Experimental|CIN-107 Dose 1|
16322829|NCT04519658|Experimental|CIN-107 Dose 2|
16322830|NCT04519658|Experimental|CIN-107 Dose 3|
16322831|NCT04519658|Placebo Comparator|Placebo|
16322836|NCT04519632||Children|Children and young people aged 6-18 years, Qualitative interviews
16322838|NCT04519606||One-lung ventilation|During one-lung ventilation, the dependent lung (non-operation lung) will be mechanically ventilated with a fixed positive end-expiratory pressure (PEEP) of 4 cmH2O and the peak pressure below 30 cmH2O. Tidal volumes will be titrated from the initial 4 ml/kg predicted body weight (PBW) to 7 ml/kg PBW. Optimal lung compliance is determined by the levels of upper reflection point of the pressure-volume loop closed to 30 cmH2O. Chest tomography will be undertaken with the optimal tidal volume during OLV phase and when the independent lung is completely recruited using the stepwise PEEP increase method.
16322839|NCT04519593|Experimental|Laparoscopic myomectomy with temporary blood supply occlusion|Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
16322840|NCT04519593|Active Comparator|Conventional laparoscopic myomectomy|Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.
16322841|NCT04519580||Patients with suspected polymyalgia rheumatica|The study investigates patients with suspected polymyalgia rheumatica (PMR). For Patients where the PMR diagnosis is dismissed, the study terminates after the first visit. Patients diagnosed with PMR will be treated with prednisolone with taper corresponding to usual care. At baseline all patients will have medical history taken, physical examination, blood drawn, Synacthen® test, PET/CT, and ultrasound performed. Physical examination, PET/CT, and ultrasound are repeated after 8 weeks of prednisolone treatment while the patients iare on 10 mg prednisolone as well as after prednisolone taper two weeks later, where Synachten® test is also performed. After 10 weeks prednisolone is restarted at 10 mg and the patient is followed by their general practitioner or at the department of rheumatology, where prednisolone is tapered according to usual care. Patients are invited to a follow up visit after one year.
16322842|NCT04519567|Experimental|CTI-1601|
16322843|NCT04519567|Placebo Comparator|Placebo|
16322844|NCT04519554|Other|5FR + 7FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 5FR then 7 FR
16322845|NCT04519554|Other|7FR + 5FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 7FR then 5FR
16322846|NCT04519541|Experimental|Neurolyser XR treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
16322847|NCT04519528||Patients|Minors who required veno-venous or veno-arterial ECMO, in pediatric intensive care unit at Necker Enfants Malades hospital between 2014 and 2019.
16322848|NCT04519515|Experimental|Treatment With Juvederm Vollure Right|Injection of Juvederm Vollure on one half of the face, placebo on the other side
16322849|NCT04519515|Experimental|Treatment Juvederm Vollure Left|Injection of Juvederm Vollure on one half of the face, placebo on the other side
16322850|NCT04519502||Randomly Selected Delivery Dates 2019|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.
16322851|NCT04519502||Randomly Selected Delivery Dates 2020|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020
16322852|NCT04519502||Confirmed COVID-19 Infections|Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.
16322853|NCT04519489|Experimental|PAP therapy with telemonitoring|This arm will consist of 86 subjects.
16322854|NCT04519489|Other|Control group|This arm will consist of 43 subjects.
16322855|NCT04519476|Experimental|Selinexor/Lenalidomide/Steroids|All subjects enrolled will receive: 1) selinexor, PO, at 60 mg once weekly on days 1-28 of a 28-day cycle, 2) lenalidomide, PO, 10 mg daily on days 1-21 of 28-days cycle and 3) methylprednisolone at the same dose and schedule as the last lenalidomide-containing regimen if it contained steroids. If patient's qualifying lenalidomide-containing regimen contained different type of steroid (e.g. prednisone, dexamethasone, etc.) then patient on this study will receive methylprednisolone at the equivalent dose and schedule.
16322856|NCT04519463|Experimental|Xylocaine|30 patients who receive Xylocaine 10% nasal spray
16322857|NCT04519463|Placebo Comparator|Saline|30 patients who receive saline nasal spray
16322858|NCT04519450||ICU patients without an with chronic respiratory diseases|The group will consist of >50 patients admitted to the intensive care unit, of which at least 20 with chronic respiratory diseases. Patients of both sexes, patients with and without chronic respiratory diseases, and also patients requiring mechanical ventilation were included and their demographic characteristics and outcomes registered. All patients will sign an informed consent form before inclusion in the prospective observational study.
16322859|NCT04519437|Experimental|REGN10933+REGN10987|
16322860|NCT04519437|Placebo Comparator|Placebo|
16322861|NCT04519424|Experimental|CSL324|CSL324 administered intravenously
16322862|NCT04519424|Placebo Comparator|Placebo|Normal saline administered intravenously
16322863|NCT04519411|Experimental|Intubated pediatric patients with COVID-19 respiratory failure|
16322864|NCT04519398||COVID-19 patients with proved venous thrombosis|"1st group includes COVID-19 patients with proved
~venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis occurring in more atypical places such as in the veins of the brain, liver, kidney, mesenteric vein and the veins of the arms)
~or arterial thrombosis (heart attacks, strokes)"
16322865|NCT04519398||Asymptomatic COVID-19 & those with mild or moderate disease|2nd group encompasses asymptomatic patients and those with mild or moderate disease, according to current guidelines, without thrombosis: no symptoms or evidence of lower respiratory disease by clinical assessment or imaging and a SpO2 > 94%
16322866|NCT04519398||Severe disease, according to Guidelines, without thrombus|3rd group includes severe disease, according to current guidelines, without thrombosis: respiratory frequency > 30 breaths per minute, SpO2 < 94%, PaO2/FiO2 < 300 mmHg, or lung infiltrates >50%
16322867|NCT04519385|Experimental|Tocilizumab|Tocilizumab
16322868|NCT04519385|Active Comparator|Dexamethasone|Dexamethasone therapy
16322869|NCT04519359|Experimental|Stop Arm|Stop NAs therapy
16322870|NCT04519359|No Intervention|Continue Arm|Continue NAs therapy
16322901|NCT04519112|Active Comparator|Mannual control navigation group|PVC ablation with mannual navigation
16322871|NCT04519346|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with migraine pain
16322872|NCT04519333|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with neck pain related to cervical disc herniation
16322873|NCT04519320|Other|SARS-COV 2 Patients|
16322874|NCT04519307||Group 1|The newborns with covid 19 infection
16322875|NCT04519307||Group 2|The newborns with no covid 19 infection
16322878|NCT04519281||Group (A)|consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid
16322879|NCT04519281||Group (B)|consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).
16322880|NCT04519268||Elective Surgical Adult Patients|Adult patients scheduled for an elective general surgical operation.
16322881|NCT04519255||Screening of clinically cured patients with severe COVID-19|①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
16322882|NCT04519255||Screening of clinically cured patients with mild COVID-19|①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
16322883|NCT04519255||Healthy people who are not infected with COVID-19|① Volunteers who are not infected with COVID-19; ②Age > 18 years, age < 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
16322884|NCT04519242|Active Comparator|Patients enrolled in the ORIF group|Open reduction and internal fixation (ORIF), ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation, TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.
16322885|NCT04519242|Active Comparator|Patients enrolled in the PA group|PA will be done by removal of the articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).
16322886|NCT04519229||Children in fostercare in CPP-treatment|Children in foster care taking part in Child-Parent Psychotherapy
16322887|NCT04519216|Active Comparator|Traditional education|Participants in the control group will complete an online unfolding case scenario. Then these same participants will participate in a videoconferencing case based lecture with the academic pediatric fellow
16322888|NCT04519216|Experimental|Telesimulation|Participants in the intervention group will complete an online unfolding case scenario. Then these participants will complete a telesimulation case with a standardized patient via video conferencing.
16322889|NCT04519203|Active Comparator|SPI group|Group of patients where opioid consumption will be guided using SPI target
16322890|NCT04519203|Active Comparator|Control Group|Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period
16322891|NCT04519177|Experimental|Experimental (Early Education)|Firefighters in station randomized to the experimental (early education) will receive the sleep health education program (SHEP) including screening for common sleep disorders. Those found at high risk will be given information about seeking further evaluation, diagnosis and treatment, if necessary.
16322892|NCT04519177|No Intervention|Control (Later education)|Firefighters in station randomized to the control condition will not receive SHEP prior to the data collection.
16322893|NCT04519164|Experimental|Eplerenone|Participants will receive eplerenone, ranging from 25-100mg daily for one year.
16322894|NCT04519164|Active Comparator|Chlorthalidone with potassium chloride|Participants will receive chlorthalidone (6.25-25mg daily for one year) along with potassium chloride (up to 20 mEq daily for one year)
16322895|NCT04519151|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
16322896|NCT04519138|Experimental|Endodrill Model X|Three consecutive samples will be taken using the Endodrill Model X instrument.
16322897|NCT04519138|Active Comparator|Endoscopic ultrasound guided fine-needle aspiration/biopsy|Three consecutive samples will be taken using the the standard method fine-needle aspiration/biopsy.
16322898|NCT04519125|Experimental|Intervention|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
16322899|NCT04519125|Placebo Comparator|Placebo|(1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
16322900|NCT04519112|Experimental|Remote magnetic navigation group|PVC ablation with RMN
16322902|NCT04519086|Experimental|Low-dose CT for acute appendicitis in patients with BMI >30|Low-dose computed tomography (CT) vs. standard CT for diagnosing acute uncomplicated appendicitis in patients with BMI > 30 Laparoscopic appendectomy
16322903|NCT04519073|Placebo Comparator|Placebo|0.5 mL of diluent (phosphate buffer)
16322904|NCT04519073|Experimental|V-306 low dose|V-306 at 15 µg
16322905|NCT04519073|Experimental|V-306 intermediate dose|V-306 at 50 µg
16322906|NCT04519073|Experimental|V-306 high dose|V-306 at 150 µg
16322907|NCT04519060|No Intervention|No eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care.
16322908|NCT04519060|Experimental|Eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care and the application of eye shields. They will be worn until four (4) hours after the last dose of dilating eye drops.
16322909|NCT04519047|Experimental|Rejoint|Rejoint+PRP
16322910|NCT04519047|Active Comparator|Control|Saline+PRP
16322911|NCT04519034||Audit 1|All vitamin D results performed since January 2020 (N= ~15000) together with age, weight and height if available, ethnicity and other relevant laboratory markers (Ca, adjusted calcium, PTH, Mg, phosphate, liver and renal profile, Covid-19 screening, CRP, Haematinics, FBC)
16322912|NCT04519034||Audit 2|All Covid-19 screening results together with vitamin D, ethnicity, age, weight, height, length of stay in hospital including ICU (if applicable), type of illness, recovered or not, associated health conditions, CRP, Ferritin, Haematinics, vitamin A and E, procalcitonin, LDH, INR, fibrinogen, FBC, D-dimers, CK, Troponin-T, cytokines, renal function and electrolytes from patients tested at GSTT NHS Trust.
16322913|NCT04519008|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
16322914|NCT04519008|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
16322915|NCT04518995|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
16322916|NCT04518995|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
16322917|NCT04518995|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
16322918|NCT04518982|Experimental|The experimental group|
16322919|NCT04518982|Placebo Comparator|The control group|
16322920|NCT04518969|No Intervention|Control|Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed……
16322921|NCT04518969|Experimental|Cytosorb|"CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed…… Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.
~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.
~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
16322922|NCT04518956|Experimental|Inter maxillary fixation and exposure to shockwave therapy|
16322923|NCT04518956|Experimental|Inter maxillary fixation and exposure to low intensity pulsed|
16322924|NCT04518956|Active Comparator|Inter maxillary fixation only|
16322925|NCT04518943|Experimental|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
16322926|NCT04518943|Experimental|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
16322927|NCT04518943|Experimental|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
16322928|NCT04518943|Experimental|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
16322929|NCT04518943|Experimental|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
16322930|NCT04518943|Experimental|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
16322931|NCT04518943|Experimental|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
16322932|NCT04518943|Experimental|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
16322933|NCT04518943|Experimental|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
16322934|NCT04518943|Experimental|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
16322935|NCT04518943|Experimental|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
16322936|NCT04518943|Experimental|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
16322937|NCT04518943|Experimental|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
16322938|NCT04518943|Experimental|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
16322939|NCT04518943|Experimental|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
16322940|NCT04518943|Experimental|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
16322941|NCT04518930|Experimental|high fat|30 participants will be provided with (33) g of roasted, not salted peanuts after-lunch as snack.
16322942|NCT04518930|Experimental|high protein|30 participants will be provided with (148) g of Plain Greek yogurt after-lunch as snack.
16322943|NCT04518930|No Intervention|control|30 participants who will not be provided with any type of snacks after lunch
16322944|NCT04518917||Parkinson disease plus dementia|Participants will have a diagnosis of Parkinson disease plus dementia.
16322945|NCT04518904||Group of poor prognosis|In this group,the patients had suffered from systemic infection,pulmonary complications or died.
16322946|NCT04518904||Group of good prognosis|In this group,the patients were safely discharged without complications.
16322947|NCT04518891|Experimental|Cognitive Functional Therapy (CFT) Group|"There will be 3 main components in the intervention:
~Making sense of pain: the cognitive component will focus on identifying the factors that contribute to pain during examination. This will include discussion on the multidimensional nature of persistent pain, individual beliefs, and how emotions and behaviours regarding movement and lifestyle can reinforce a vicious cycle of pain and disability.
~Controlled exposure: specific functional training is designed to normalise maladaptive or provocative movement and posture. functional integration is directed at activities of daily life that are avoided by the patient. This will vary among individuals but should include basic activities such as rolling in bed, sitting, sitting to standing, walking, bending and lifting.
~Lifestyle change: Physical activity and lifestyle. Patients will be advised to gradually increase physical activity based on their preference, while also focusing on sleep hygiene, stress and management strategies."
16322948|NCT04518891|Sham Comparator|Sham intervention|Placebo group will be treated with detuned photobiomodulation device (904Nm Ibramed Infrared - no-visible beam), without any emission of therapeutic dose. Nine sites will be applicate on the patient's lumbar region: three central sites on top of the spinous processes (between T11 and T12, L2 and L3, L5 and S1); in the same direction, but laterally, three sites on the left and three on the right. Three minutes of fake stimulation will be administered, summing up 27 minutes. In addition, a neutral talking control therapy of at least 15 minutes will be provided to patients in each session. Maladaptive beliefs will not be challenged; however, the therapists will be trained to show interest and warmth, empathy and encouraging participants to discuss neutral topics such as hobbies, sports, and current affairs. No advice or problem solving will be given, and any attempt to talk about emotional issues will be kindly discouraged and the talking will be redirect to neutral tropics.
16322949|NCT04518878|Experimental|Fixed Low-dose Eltrombopag and rhTPO|Fixed Low-dose Eltrombopag and rhTPO
16322950|NCT04518865|Experimental|pre-pubertal group.|The patients were allocated into the pre-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS II and CVMS III
16322951|NCT04518865|Experimental|post-pubertal group|The patients were allocated into the post-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS V and CVMS IV
16322952|NCT04518852|Experimental|Treatment group|The participants will receive the combined treatment of local therapy (TACE, oxaliplatin and epirubicin), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
16322953|NCT04518839||Group with regional anaesthesia|
16322954|NCT04518839||Group with general anaesthesia|
16322955|NCT04518826||FFR|In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR <0.9, the operator will dilate the DES-ISR lesion again before another FFR is measured. If FFR>=0.9, DEB will be used and final FFR will be measured at the end of the procedure.
16322956|NCT04518826||CAG|In angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.
16322957|NCT04518813|Experimental|RSP-24|Subjects will perform calibrations on the IMD (Prototype 0.5) for 41 days over a 60 day period.
16322958|NCT04518800|Experimental|Jin Youli(PEG-rhG-CSF)|PEG-rhG-CSF Secondary Prevention：patients with pancreatic cancer who met the eligibility criteria were given secondary prophylactic administration of the Jin Youli(PEG-rhG-CSF).
16322961|NCT04518774|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 3 cycles of ex-vivo expanded allogeneic γδT cells treatments, at four-weeks' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
16322962|NCT04518761||Prospective group|
16322963|NCT04518761||Retrospective group|
16322964|NCT04518748|Experimental|Y-90 SIRT followed by SBRT|Y-90 SIRT followed by SBRT
16322965|NCT04518735||Patients on previous oral anticoagulant treatment|Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication
16322966|NCT04518735||Patients on previous antiplatelet therapy|Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication
16322967|NCT04518735||Patients without antithrombotic therapy|Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy
16322968|NCT04518709|Experimental|Posterior Annulus Elevation Technique Group|In patients who were determined in the treatment group, after the conventional procedure for mitral valve repair was completed, a posterior mitral valve elevation technique will be performed.
16322969|NCT04518709|Placebo Comparator|Without Posterior Annulus Elevation Technique Group|No additional procedure will be done after conventional mitral valve repair
16322970|NCT04518696|Experimental|suprachoroidal buckling treatment group|suprachoroidal buckling for therapy of rhegmatogenous retinal detachment
16322971|NCT04518683|Experimental|Groupe 1 - Study group|"The home program (outside of the sessions with the physiotherapist) will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes (time corresponding to 1 programe). The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.
~The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
16322972|NCT04518683|Active Comparator|Groupe 2 - Control group|"The home program (outside of the sessions with the physiotherapist) will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist.
~This training will work on pelvic floor strength, relaxation and endurance. The program includes 3 levels of difficulty"
16323124|NCT04517799|Placebo Comparator|placebo|placebo arm
16323693|NCT04513535|Experimental|manual therapy combination 6|glenohumeral mobilization, sleeper stretch
16322973|NCT04518657|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and oneonone video chats with a behavioral coach.The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory.Each course consists of an introduction,the primary content,and a take home message.The interactive courses include embedded,supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps,and these steps will be entered into the website so progress can be monitored.The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries.The chats are conducted facetoface through an online videoconferencing platform.The chats occur 7 times during the first 2 months,4 times during the second 2 months,and twice during the final 2 months of the intervention.
16322974|NCT04518657|Sham Comparator|Wellness for MS (WellMS)|Provides an internet website and oneonone video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity.The materials are transformations of brochures provided by the National MS Society,including Gait or Walking Problems:The Basic Facts;MS and Your Emotions;Pain:The Basic Facts; Solving Cognitive Problems;Taming Stress in MS;Food for Thought:MS and Nutrition;and Vitamins,Minerals,and Herbs:An Introduction.The delivery of the internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition,and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
16322975|NCT04518631|Experimental|8-week mindfulness program|8-week .b Foundations course
16322976|NCT04518631|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
16322977|NCT04518618|Experimental|Group F|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml).
16322978|NCT04518618|Experimental|Group FN|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml) plus 20 ugs naloxone.
16322979|NCT04518605|Experimental|Low protein breakfast|Subject will eat a low protein breakfast and maintain their habitual physical activity.
16322980|NCT04518605|Experimental|High protein breakfast|Subject will eat a high protein breakfast and maintain their habitual physical activity.
16322981|NCT04518605|Experimental|Low protein breakfast and exercise training|Subject will consume a low protein breakfast (bread, jam, juice) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
16322982|NCT04518605|Experimental|High protein breakfast and exercise training|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr) with oats) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
16322983|NCT04518592||Severe Major Depressive Disorder|
16322984|NCT04518592||control , healthy|
16322985|NCT04518579|Active Comparator|Group (EP)|Group (EP) received epidural (fentanyl and bupivacaine) - propofol based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
16322986|NCT04518579|Active Comparator|Group (EH)|Group (EH) received epidural (fentanyl and bupivacaine)- inhalational based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
16322987|NCT04518566|No Intervention|Placebo|Patients in control arm will have FitBit. However, there are no personalised nudges given to the patients in the control arm. Occasional reminders to encourage adherence to wearing of the FitBit will be sent.
16322988|NCT04518566|Experimental|Nudges|Patients in the intervention arm will be given a FitBit device and will be encouraged to wear it as often as possible. Using FitBit built-in tracking technologies such as PurePulse and SmartTrack54, patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the adaptive intervention platform as developed in Phase 2 for real-time tracking.
16322989|NCT04518553|Active Comparator|active control|antiviraltherapy using HA using antiviralHA drugs of HA to decrease HBV-DNA load. In this group, patients with chronic hepatitis B just take antiviral drug of HAs to control hepatitis B viral without active interference.
16322990|NCT04518553|Experimental|active interference|HA+plasma purification as active interference. HA antiviral therapy using HA plus plasma purification every three months.DFT as plasma purification mode will be used. DFT therapy time lasts 2.5-3 hours each time.After three months, DFT therapy will be used if patients' HBV-DNA loads are higher than cut-off normal level.
16322991|NCT04518540|Experimental|lipoic acid group|The patients will take lipoic acid by intravenous. At the same time, the patients will take take riluzole tablets orally everyday.
16322992|NCT04518540|Experimental|control group|The patients will take riluzole tablets orally everyday.
16322993|NCT04518527|Active Comparator|true taping+ exercise|The true taping method was applied to the first group according to the method determined by Kase. According to this method, a 2-inch (5 cm) wide beige-colored Kinesio tape (Kinesio® Tex Gold FP) was measured from the second-third metacarpal base to the lateral epicondyle while the elbow was extended and the wrist was in the neutral position and the tape was applied in the shape of a 'Y'. In a position where the wrist-ankle extensors were most tense (wrist-ankle extension - forearm pronation), the anchor point of the tape was applied to the insertion of the muscle without creating any tension. Then, the tape was applied to the medial and lateral edges of the wrist extensors by applying a 15-25% tension towards the origin of the muscle. Both ends of the Y-shaped tape were terminated without tension on the lateral epicondyle.
16322994|NCT04518527|Placebo Comparator|sham taping+exercise|In the placebo group, the 10 cm I-shaped tape was placed 5 cm inferior to the lateral epicondyle using the same Kinesio tape in the study group. It was applied transversely, starting from the painless side of the midline on the forearm extensor face directing towards the lateral side of the forearm without a tension.
16322995|NCT04518514|Experimental|Preoperative evaluation and risk assessment via telemedicine|
16322996|NCT04518501|Experimental|study group|Fuzuloparib Capsules plus table Arsenic Trioxide po
16323125|NCT04517786|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
16322997|NCT04518488|Active Comparator|Prehabilitation group|The prehabilitation group will receive a set of exercises designed to strengthen both limbs. The exercises will be taught and illustrated by a trained physiotherapist and are to be done daily during the period prior to surgery. The participant will be coached and supported for the exercise program, twice a week during the pre-operative period.
16322998|NCT04518488|Other|Informational support group (control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period. The intervention will be in the form of telephone or video calls by a trained health professional. These calls will be scheduled twice a week during the pre-operative period.
16322999|NCT04518475|Experimental|efficacy of eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.
~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.
~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
16323000|NCT04518475|Active Comparator|efficacy of eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.
~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
16323001|NCT04518462|Experimental|EXPAREL arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL mixed with 20 mL saline
16323002|NCT04518462|Experimental|EXPAREL admix arm|subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL admixed with 20 mL (50 mg) 0.25% bupivacaine HCl.
16323003|NCT04518462|Active Comparator|Bupivacaine HCl Arm|subjects randomized to this treatment arm will receive 40 mL (100 mg)0.25% bupivacaine HCl.
16323004|NCT04518449||SMA group|the medial border along the left side of superior mesenteric artery (SMA)
16323005|NCT04518449||SMV group|the medial border along the left side of superior mesenteric vein (SMV)
16323006|NCT04518423||Elderly people over the age of 65 years|The study group will comprise community dwelling elderly individuals over the age of 65 years who get around by themselves. The subjects will be followed up for 5 years to investigate the frailty and disability development, and survival.
16323022|NCT04518397|Experimental|Theatre participants|Girls in this arm will participate in the theatre intervention.
16323023|NCT04518371|Experimental|Indirect Restoration|Milled Resin Composite Block, Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments (inorganic pigments such as ferrous oxide or titanium dioxide).
16323024|NCT04518371|Active Comparator|Direct Restoration|"3M™ Filtek™ One Bulk Fill Restorative is a visible light activated, restorative composite optimized to create fast and easy restorations.
~It is composed of fillers which are a combination of a non-agglomerated/non-aggregated 20 nm silica filler, 4 to 11 nm zirconia filler, zirconia/silica cluster filler and ytterbium trifluoride filler consisting of 100nm particles. The inorganic filler loading is about 76.5% by weight (58.5% by volume)."
16323025|NCT04518358|Experimental|Evaluation of Expert Guiding Technology|
16323126|NCT04517773||study group|Oncological patients
16323127|NCT04517747|Experimental|Ramucirumab plus TAS-102|Ramucirumab 8 mg/kg i.v. on day 1 and day 15 of a 28-day cycle and TAS-102 35 mg/m2/dose p.o. twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle Each cycle will be repeated after 28 days (from day 1) for a maximum of 4 cycles.
16323128|NCT04517734||Pregnant Adolescents|
16323026|NCT04518345|Experimental|Treatment (dubermatinib)|"FLT3 AML WITH RELAPSED/REFRACTORY DISEASE:
~INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission."
16323027|NCT04518319|Experimental|omega-3 polyunsaturated fatty acids|Patients randomized to the omega-3 polyunsaturated fatty acids will receive treatment with 1200mg per day plus on-going olanzapine.
16323028|NCT04518319|Experimental|Xbox aerobic exercise|Patients randomized to the Xbox aerobic exercise will do Xbox aerobic exercise 30min per day plus on-going olanzapine.
16323029|NCT04518319|Experimental|transcranial direct current stimulation|Patients randomized to the transcranial direct current stimulation will be applied for transcranial direct current stimulation 5 session/week at 2mA, 20min plus on-going olanzapine. The anodal electrode will be placed over the left dorsolateral prefrontal cortex.
16323030|NCT04518319|Experimental|olanzapine|Patients randomized to the olanzapine will receive conventional treatment-olanzapine.
16323031|NCT04518306|Experimental|Triple ¼ (GMRx2)|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
16323032|NCT04518306|Active Comparator|Triple ½ (GMRx2)|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
16323033|NCT04518306|Placebo Comparator|Placebo|Placebo
16323034|NCT04518293|Experimental|Triple - TAI|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
16323035|NCT04518293|Active Comparator|Dual - TA|Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
16323036|NCT04518293|Active Comparator|Dual - TI|Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
16323037|NCT04518293|Active Comparator|Dual - AI|Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
16323038|NCT04518280|Experimental|Consolidation cohort|A total of 65 patients will receive 5*5Gy short-course radiotherapy, followed by 6 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery.
16323039|NCT04518280|Experimental|Induction cohort|A total of 65 patients will firstly receive 2 cycles of CAPOX chemotherapy and PD-1 antibody, then receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery.
16323040|NCT04518267||Civilian group|Participants with civilian status
16323041|NCT04518267||Military group|Participants with military status
16323042|NCT04518254|Experimental|Tyrosine - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure
16323043|NCT04518254|Experimental|Tyrosine - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure
16323044|NCT04518254|Experimental|Placebo - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure
16323045|NCT04518254|Experimental|Placebo - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
16323046|NCT04518241|Experimental|Condition 1|Core, fixed compensation, TMQQ, MI sessions
16323047|NCT04518241|Experimental|Condition 2|Core, lottery prize, TMQQ, MI sessions
16323048|NCT04518241|Experimental|Condition 3|Core, fixed compensation, MI sessions
16323049|NCT04518241|Experimental|Condition 4|Core, lottery prize, MI sessions
16323050|NCT04518241|Experimental|Condition 5|Core, fixed compensation, TMQQ
16323051|NCT04518241|Experimental|Condition 6|Core, lottery prize, TMQQ
16323052|NCT04518241|Experimental|Condition 7|Core, fixed compensation
16323053|NCT04518241|Experimental|Condition 8|Core, lottery prize
16323129|NCT04517734||Pregnant Women Carrying Multiple Fetuses|
16323380|NCT04515758|Experimental|Exercise and Cognitive Training|Each participant (in a group setting) completes 30 minutes of cognitive training and 1 hour of exercise two days/week.
16323067|NCT04518215|Experimental|ESPB group|Erector Spinae Plain Block
16323068|NCT04518215|Active Comparator|IV Analgesia group|Intra-Venous Analgesia
16323069|NCT04518202|Experimental|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
16323070|NCT04518202|Placebo Comparator|Sham patch|Sham patch applied at 6 hours before the scheduled office hysteroscopy.
16323071|NCT04518189|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
16323072|NCT04518189|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
16323073|NCT04518176|Experimental|study group|patients with twin pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
16323074|NCT04518176|Active Comparator|control group|patients with twin pregnancy undergoing cesarean section received oxytocin only.
16323075|NCT04518163|Experimental|study group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus 1gm tranexamic acid by intravenous infusion
16323076|NCT04518163|Active Comparator|control group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus saline by intravenous infusion
16323077|NCT04518150|Experimental|study group|patients with placenta previa undergoing cesarean section underwent bilateral uterine artery ligation plus insertion of Bakri balloon
16323078|NCT04518150|Active Comparator|control group|patients with placenta previa undergoing cesarean section underwent insertion of Bakri balloon
16323079|NCT04518137|Experimental|ATG-008|Enrolled patients will be treated with ATG-008 at an oral fixed milligram (mg) dose of 30 mg QD
16323080|NCT04518124|Experimental|Propranolol|
16323083|NCT04518098|Experimental|Intervention group|"For the intervention group, it consists of leg muscle strengthening and balance training exercises that progress in difficulty. The balance component of the exercise will include knee bend, backwards walking, sideways walking, heel toe stand, heel toe walk, and one-leg stand, as outlined by the Otago program (31). The strength training component will target the lower body muscles by performing isotonic contraction of quadriceps muscles using an exercise band. During the familiarization session, the training load will be tailored and adjusted for each participant to ensure optimal benefit from the exercise.
~Once the familiarization is completed and participants are comfortable with the exercise routines and techniques, they will continue the online strength and balance training for 3 months (20-30 minutes per scheduled session, three times a week), supervised by the CEP."
16323084|NCT04518098|No Intervention|Control group|Participants in the CG will not receive the intervention, and will be advised to carry out their usual daily activities. Data collection for CG participants will also occur at baseline and at 3- and 6-month follow-up by a research nurse blinded to study group allocation. As with the IG, the research nurse will call CG group participants weekly to ask if a fall has occurred.
16323085|NCT04518085|Experimental|Hypnosis + iACT|Single 20 minute medical hypnosis session delivered pre-surgery plus internet-based acceptance and commitment therapy delivered post-surgery
16323086|NCT04518085|Active Comparator|Mindfulness + treatment as usual (TAU)|Single 20 minute mindfulness session delivered pre-surgery plus treatment as usual post-surgery
16323087|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
16323088|NCT04518072||Control group|No prostate cancer (50)
16323089|NCT04518059||Parkinsonism Group|Participants with Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)
16323090|NCT04518059||Control Group|Participants without parkinsonism
16323091|NCT04518046|Experimental|Phase 1: Dose Escalation|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.
16323092|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort A|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment
16323093|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort B|Patients with favorable-risk RCC with clear cell component for first-line treatment.
16323094|NCT04518033|Experimental|Face covering use|Participants will be provided various commercially available face coverings
16323095|NCT04518020|Active Comparator|Short implant|Short implant 6 mm installed
16323096|NCT04518020|Other|Conventional implant + bone augmentation|Standard length implant 13 mm in conjunction with maxillary sinus floor augmentation serves as a control group
16323097|NCT04518007|Active Comparator|hyperbaric oxygen therapy (HBOT) active treatment|The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes, of 100% oxygen at 2 ATA and 5-minute air breaks every 20 minutes.
16323130|NCT04517721|Experimental|Treatment group|"The 4C's-TBuRP for adult burn survivors comprises of two phases:
~Phase 1: Discharge planning/ preparation and day of discharge (Comprehensive assessment and evaluation, Education, guidance, and counselling, Treatment and procedures, Case management (referral for nursing follow-up), multi-disciplinary follow-up and Surveillance)
~Phase 2: Follow-up Phase (2 WeChat Telehealth, 6 structured telephone follow-ups and daytime patient/ family-initiated telephone service; home visit based on meeting criteria) over an 8-week follow-up with delivery of rehabilitation care across the spectrum by trained nurse case managers ongoing assessment, intervention using the Omaha System and delivery of evidence-based care."
16323098|NCT04518007|Sham Comparator|sham|All the conditions provided in the HBOT intervention will be provided in the sham intervention. However, in contrast to the HBOT, where the pressure will go up to 2 ATA, in the sham condition the pressure will go up to 1.1 ATA during the first five minutes of the session with noise of circulating air, and then decrease slowly during the next half hour to 1.0 ATA and the oxygen level will be 21% The initial 1.1 ATA level will provide a minimal pressure sensation in the ears, with the same nurse advice on pumping the ears. In the last five minutes of the session, the air will be circulated again with its related noises. Sham and HBOT sessions will never be adjacent, so subjects from the two groups cannot meet and discuss the session and its effects.
16323099|NCT04517994|Experimental|Active Treatment|The intervention includes components from empirically validated interventions for intimate relationship difficulties and PTSD. This includes core themes of trust, self-esteem, power and control, conflict-management skills, and communication skills training.
16323100|NCT04517994|Active Comparator|Supportive Treatment|Broadly based on the principles and techniques of client centered (Rogerian) therapy, and the fundamental principles and practices for experiential group psychotherapy as specified by Yalom. The group also draws upon the work of Murphy's Supportive Therapy protocol specifically for group intervention with domestic abuse perpetrators.
16323101|NCT04517981||Drug intervention|Antidepressant
16323102|NCT04517981||Psychological intervention|Cognitive behavior therapy, sand table therapy
16323103|NCT04517981||Comprehensive intervention|Psychological intervention, community intervention combined with drug intervention
16323104|NCT04517968|Experimental|immediate implant with customized healing abutment|
16323105|NCT04517942|Experimental|EVERYbody Project: Peer facilitator version|"This dissonance-based body image program was created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and piloted in an initial randomized-controlled trial. Based on the Body Project (Stice et al., 2006), it retains key dissonance activities while adapting exercises to have a more inclusive focus (e.g., expanding the gender focus, exploring diversity characteristics within appearance ideals, adjusting activities to be inclusive of diversity).
~Around 10% of the original EVERYbody Project manual was modified to create the Peer Facilitator version for the current trial. Changes focused on adding individual exercises to draw out the critique of diversity in cultural ideals, refining prompts to be more suitable for peer facilitation, and flagging sections of the manual for more expert peer facilitation.
~Peer facilitators received 16 hours of training on the EVERYbody Project manual and peer facilitation guidelines (e.g., group management, handling problems, etc.)."
16323106|NCT04517942|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists (2015 ), and (2) The Mask You Live In (2015). Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.
~Peer facilitators received brief (1 hour) training on the video group manual."
16323107|NCT04517929|No Intervention|control group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia.
16323108|NCT04517929|Experimental|intervention group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia and group psychotherapy.
16323109|NCT04517916||Zephyr Valve treatment|Patients undergoing the Zephyr Valve treatment for emphysema/COPD
16323110|NCT04517903|Experimental|exploratory phase|eye rubbing questionnaire at baseline and 15 days later
16323111|NCT04517903|Experimental|Confirmatory phase|eye rubbing questionnaire at baseline and at 6 month follow-up
16323112|NCT04517890|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
16323113|NCT04517890|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
16323114|NCT04517877|Experimental|Caring Light Training|Caring Light mobile app with coping skills training.
16323115|NCT04517877|Active Comparator|Educational Training|Traditional educational program.
16323116|NCT04517864|Experimental|Treatment Arm: PF-06651600|ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm
16323117|NCT04517864|Other|Control Arm (Placebo) followed by active therapy extension|matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24
16323118|NCT04517851|Experimental|Treatment (elotuzumab)|Patients receive elotuzumab IV over 1-4 hours on days 1, 8, 15, and 22 of cycles 1-2. Beginning in cycle 3, patients receive elotuzumab IV over 1-4 hours on day 1. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16323119|NCT04517838||Basic Science (biospecimen collection)|Patients undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence for patients with stage I-III, or progressive disease for patients with stage IV. Patients with stage IV HER2 positive breast cancer with no disease progression >= 2 years on the same line of therapy, undergo blood sample collection at baseline anytime during their treatment with anti-HER2 therapies, 8 and 16 weeks after the first blood draw, and at the time of invasive disease recurrence. Patients also undergo tumor tissue collection for the evaluation of gene expression and DNA variants.
16323120|NCT04517825||Target Population|HIV positive individuals attending Bugoye ART clinic
16323121|NCT04517812|Experimental|Intervention group|The intervention group will carry out a 12-week exercise-based intervention delivered via the VirtualRehab platform. The exercise-games have been designed from conventional physiotherapy exercises for stroke rehabilitation. A personalised training programme will be created for individual participants by a qualified physiotherapist member of the research team. Each participant will be asked to undertake their set exercise-based training programme for one hour a day, six days a week for 12 weeks.
16323122|NCT04517812|No Intervention|Control group|The control group will undertake the measurement battery and provide the demographic details.
16323123|NCT04517799|Experimental|cannabidiol|cannabidiol arm
16323131|NCT04517721|Active Comparator|Control group|Participants in the control group will receive the care at the discharge planning phase and thereafter continue to utilise the exiting service available at the hospital, that is, medical review in the hospital.
16323132|NCT04517708|Experimental|Intervention group|"Regarding the intervention group, patients were treated with the intervention regimen, which consisted of:
~Nutritional counseling
~Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months."
16323133|NCT04517708|No Intervention|Control group|Patients had diets based on their demands
16323134|NCT04517695||COVID-19 ICU Patients|Patients who are admitted to the ICU with a confirmed SARS-CoV-2 infection
16323135|NCT04517695||ICU Patients with bacterial infection|Patients who are admitted to the ICU with a confirmed bacterial infection
16323136|NCT04517682||Positive for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a positive result.
16323137|NCT04517682||Negative for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a negative result.
16323138|NCT04517656|Experimental|patients with hematologic malignancy|Adult patient, over 18 years old, suffering from a malignant hemopathy (without exception) for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated
16323139|NCT04517643|Experimental|Therasphere Therapy|All participants will receive the Therasphere Therapy.
16323140|NCT04517630||Severe pneumoniae|Evaluate the progression to AKI during first 30 days of recruitment
16323141|NCT04517617||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
16323142|NCT04517604|Experimental|iTBS+yoga|Participants will receive 6 sessions of intermittent theta burst stimulation (iTBS) and the LoveYourBrain Yoga program. The LoveYourBrain Yoga program was specifically designed for people with TBI.
16323143|NCT04517591|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
16323144|NCT04517591|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels and health nutrition.
16323145|NCT04517565|Experimental|Patients with SWS or high-risk facial port-wine birthmark|All patients with SWS brain involvement (based on previous imaging) or facial port-wine birthmark indicating a high risk for SWS brain involvement will undergo a brain MRI and neuro-psychology testing.
16323146|NCT04517552||Experimental: [11C] CS1P1|
16323147|NCT04517539|Experimental|SBRT+GM-CSF+INF-αb|Metastasis lesion will be treated with a SBRT of 30Gy/5F from day 1 to day 5 . Injection of Immunological Agenthuman recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.Subcutaneous injection of Peginterferon alfa-b2(90ug) will be executed in day8. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Injection of Peginterferon alfa-b2(90ug) will be executed in day8 of this cycle.
16323148|NCT04517526|Experimental|1|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles , followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites
16323149|NCT04517500|Experimental|Home-base pulmonary rehabilitation with mindful breathing modu|Subjects will complete in a home-based pulmonary rehabilitation program and in addition will complete a mindful breathing practice using a module on a computer tablet.
16323150|NCT04517500|Active Comparator|Home-base pulmonary rehabilitation|Subjects will complete 12 week home-based pulmonary rehabilitation with health coaching
16323151|NCT04517487|Active Comparator|VMT recipients|"In order to prevent transfer of pathogens, sperm, or antibiotic-resistant commensals we will establish a vaginal fluid bank in which samples from suitable donors will be kept for future use:
~Donors will be screened using a questionnaire addressing risk factors for potentially transmissible infections, undergo screening for cervico-vaginal infections, cervical cytology screening, and serology analysis for transmittable infections {see detailed screening in Lev-Sagie et al. Nat Med. 2019;25(10):1500-1504. doi: 10.1038/s41591-019-0600-6.}
~The collected samples for VMT will be examined for bacteria,viruses and sperm.
~Before transplantation, patients will be treated with intravaginal antibiotics. A frozen specimen will be thawed at room temperature and will be placed in the patient's vagina.
~Following VMT, patients will be evaluated every 14 days for the first 2 months, then every month for additional 10 months."
16323152|NCT04517487|Placebo Comparator|Placebo|"Vaginal fluid of all recipients will be collected before initiation of the study using the same protocol, will be clearly labeled and will be kept frozen in similar conditions. These samples will be used in the placebo arm for autologous vaginal fluid transplantation.
~Before transplantation, patients will be treated with intravaginal antibiotic.
~Following Placebo, patients will be evaluated every 14 days for the first 2 months, then every month for additional 2-4 months.
~After 4-6 months, patients who initially received placebo will be offered a VMT in case they are still symptomatic and fulfill inclusion criteria, in an open-label phase."
16323153|NCT04517474|Experimental|CANreduce with psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
16323154|NCT04517474|Experimental|CANreduce without psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use without psychological support
16323155|NCT04517474|No Intervention|Treatment as usual|Users will be prompt to a web with a list of the treatment centers nearby their postal code
16323156|NCT04517461||Head and neck free flap surgery patients|Patients undergoing head and neck microvascular free flap surgery at Skåne University Hospital, Lund, Sweden.
16323177|NCT04517292|Active Comparator|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
16323157|NCT04517435|Experimental|ME-401 + R-CHOP|Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
16323158|NCT04517422|Experimental|Probiotics|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS)status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
16323159|NCT04517422|Placebo Comparator|Placebo|The control study product is identical in packaging and formulation except that Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483 (probiotic bacteria) are not present. The Control product only contains maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
16323160|NCT04517409|Experimental|GDHT|After hepatic resection (Dynamic phase), the patients received an initial hemodynamic assessment based on PPV, CI and MAP. First, preload was optimized by fluid loading until PPV was <14% or VVS <12%, subjects were given 4 ml kg-1 boluses colloid solution every 5 minutes. At this point, the patient's individual preload optimized CI was determined and used as the hemodynamic goal until the end of surgery. Only if this value was below 2.5 L/min/(m2), inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If PPV and CI were within the target range but MAP was below 65 mmHg or PPV/VVS>1,2, vasopressors were started. After the initial assessment, patients were reassessed every 15 minutes intraoperatively to maintain values.
16323161|NCT04517409|Other|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.
~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment"
16323162|NCT04517396|Experimental|Fenofibrate + Usual Care|The randomized intervention will be Fenofibrate, in combination with usual care. Dosing: 145 mg of Tricor or a dose-equivalent preparation
16323163|NCT04517396|Placebo Comparator|Placebo + Usual Care|The randomized intervention will a matching placebo, in combination with usual care.
16323164|NCT04517383|Experimental|POS group|Patients in the POS group will undergo EVT under general anesthesia. After the surgery is done, patients will keep being intubated and mechanically ventilated for 6h, during which period the patients will be sedated with propofol (TCI 1.0~3.0μg/ml) and Dexmedetomidine (0.2~0.7μg/kg/h) to maintain a BIS value of 50~70 and Ramsay sedation score of 5 ~ 6. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs.
16323165|NCT04517383|Active Comparator|Con group|Patients in the Con group will undergo EVT under general anesthesia and will be routinely recovered and extubated immediately after the surgery is done. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs for at least 7h after the surgery. In case the patient shows agitation after extubation, i.e., the Ramsay sedation score is 1, 0.02 ~ 0.1mg/kg of midazolam will be given. If the patient's Ramsay sedation score keeps being 1 and more than 0.2mg/kg of midazolam is given within 1 h, dexmedetomidine or propofol will be administered to calm the patient. Any patients in the Con group receiving dexmedetomidine or propofol within 24h after extubation will be excluded.
16323166|NCT04517370|Active Comparator|Laser treatment|Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.
16323167|NCT04517370|Sham Comparator|Sham treatment|"Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.
~Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study ."
16323170|NCT04517344|Experimental|Arm 1, HFNC 1 L/kg/min|The infant that is randomized to the HFNC therapy arm 1 will be placed on high flow at 1 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%. If FiO2 requirement exceeds 50%, the patient will be excluded from the study.
16323171|NCT04517344|Experimental|Arm 2, HFNC 1.5 L/kg/min|The infant that is randomized to the HFNC therapy arm 2 will be placed on high flow at 1.5 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%. If FiO2 exceeds 50% requirement, patient will be excluded from the study.
16323172|NCT04517344|Experimental|Arm 3, HFNC 2 L/kg/min|The infant that is randomized to the HFNC therapy arm 3 will be placed on high flow at 2 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%. If FiO2 exceeds 50% requirement, patient will be excluded from the study.
16323173|NCT04517331|Active Comparator|Group S (single injection TPVB group)|Patients received bilateral single injection ultrasound-guided TPVB at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
16323174|NCT04517331|Active Comparator|Group D (double injection TPVB group)|Patients received bilateral double injection ultrasound-guided TPVB at the level of T2-T3 and T4-T5 with 10 mL bupivacaine 0.375% per injection (20 mL bupivacaine 0.375% per side as the single injection group).
16323175|NCT04517305||Pyrotinib plus vinorelbine|Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
16323176|NCT04517292|Experimental|Eribulin,cisplatin|EP (Eribulin and cisplatin combination)
16323178|NCT04517279|Experimental|Invest in My Recovery Bank|The Invest in My Recovery Bank arm is an intervention focused on enhancing the recovery capital of individuals in early psychosis care. The intervention is provided by a peer provider, operating on the coordinated specialty care team
16323179|NCT04517279|Active Comparator|Usual Care|The peer providers operating under the Usual Care condition will continue to provide peer support services to individuals within the coordinated specialty care team.
16323180|NCT04517266|Experimental|experimental group|whole breast/chest wall irradiation + SVC irradiation
16323181|NCT04517266|Active Comparator|controlled group|whole breast/chest wall irradiation + IMI+SVC irradiation
16323182|NCT04517253|Experimental|Baricitinib|Baricitinib administered orally either by tablet or suspension.
16323183|NCT04517227|Experimental|single arm|All patients enrolled with receive the sequential therapy of TACE, ablation and durvalumab.
16323184|NCT04517214|Experimental|Toripalimab Combined with GP Arm|Systemic chemotherapy for 6 cycles: Toripalimab 240mg d1+Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Toripalimab with Capecitabine: Toripalimab 240mg d1+Capecitabine 1000mg/m2 bid d1-14, q3w
16323185|NCT04517214|Active Comparator|GP Arm|Systemic chemotherapy for 6 cycles: Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Capecitabine: Capecitabine 1000mg/m2 bid d1-14, q3w
16323186|NCT04517201|Experimental|AI group|iGMS+iNCDSS group (Artificial intelligence assisted insulin titration system group)
16323187|NCT04517201|Active Comparator|Control group|iGMS+routine treatment group (Physicians decided insulin titration group)
16323188|NCT04517188|Experimental|Halodine Nasal Antiseptic|"Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
~Single topical administration"
16323189|NCT04517175||Myelodysplastic syndrome (MDS) patients|MDS patients will be divided according to prognostic parameters in sub-cohorts.
16323190|NCT04517175||Acute myeloid Leukemia (AML) patients|AML patients will be divided according to prognostic parameters in sub-cohorts.
16323191|NCT04517175||Myelodysplastic syndrome/neoplasm (MDS/MPN) patients|MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.
16323192|NCT04517162|Active Comparator|Active comparator or polymerized type I collagen|1.5 mL of polymerized type I collagen every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
16323193|NCT04517162|Placebo Comparator|Placebo comparator o placebo|1.5 mL of placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
16323194|NCT04517149|Experimental|4D-125 Dose Exploration|"Dose 1 and Dose 2
~4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1."
16323195|NCT04517149|Experimental|4D-125 Dose Expansion|4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1.
16323196|NCT04517149|Other|Observational|Natural History
16323197|NCT04517123|No Intervention|Control - Usual Care|Usual Care
16323198|NCT04517123|Experimental|Intervention - Prone Positioning|Prone Positioning
16323199|NCT04517110|Experimental|Pregabalin + Usual Care|300 mg pregabalin taken orally within 2 hours before surgery and 75 mg pregabalin taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
16323200|NCT04517110|Placebo Comparator|Placebo + Usual Care|Placebo taken orally within 2 hours before surgery and placebo taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
16323201|NCT04517097||patient group|patients treated in the french anti-cancer center of the study
16323202|NCT04517097||salaried staff group|all salaried staff of the french anti-cancer center of the study
16323203|NCT04517058|Experimental|"Cognitive type depression group"|HAMD-17 greater than 7 with negative HRV changes
16323204|NCT04517058|Active Comparator|"Somatic type depression group"|HAMD-17 greater than 7 with positive HRV changes
16323205|NCT04517045|Sham Comparator|Conventional treatment group|Control the primary disease, prevent infection, reduce gastrointestinal decompression, and actively maintain organ function.
16323206|NCT04517045|Experimental|Conventional treatment plus L92 group|Conventional treatment combined with L92
16323207|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction group|Conventional treatment combined with Dachengqi Decoction
16323208|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction plus L92 group|Conventional treatment combined with L92 and Dachengqi Decoction
16323209|NCT04517019|Experimental|Arm A (Tracker/daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients phyiscal activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
16323210|NCT04517019|Experimental|Arm B (Tracker/no daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.
~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
16323211|NCT04517019|No Intervention|Arm C (no activity tracker)|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
16323212|NCT04517006|No Intervention|Track activities|For three weeks research subjects will be keeping track of the things they do without altering their routine in any way.
16323213|NCT04517006|Experimental|Self-focused acts|"For three weeks research subjects will be treating themselves by doing things that they enjoy. These acts don't have to be large or costly, but they should be over and above what they typically do. They are asked to do one (or more) things they enjoy each day for the first three days of each week and report them."
16323350|NCT04515992|Experimental|High Intensity Body-weight Circuit (HIBC)|The at home HIBC intervention program involved the use of both bodyweight and suspension training equipment (TRX® Fit System) with modified movements. The TRX® system was used to modify squats and rows while attached to the top of a door frame.
16323214|NCT04517006|Experimental|Prosocial acts|For three weeks research subjects are asked to perform acts of kindness, meaning behaviors that benefit someone else and are over and above what they typically do (i.e., they are not expected of them). These acts should also involve some sacrifice by them (e.g., in effort, energy, time, or money) and be completed for the first three days of each week.
16323217|NCT04516980||Participants with ankle sprain.|Participants with ankle sprain
16323218|NCT04516980||Participants without ankle sprain|Participants without ankle sprain
16323221|NCT04516954|Experimental|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
16323222|NCT04516941|Active Comparator|Edoxaban|Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
16323223|NCT04516941|Active Comparator|Colchicine|Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days).
16323224|NCT04516941|No Intervention|No Edoxaban and No Colchicine|No intervention
16323225|NCT04516941|Active Comparator|Edoxaban and Colchicine|"Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
~Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days)."
16323226|NCT04516915|Experimental|IMU-838 + Oseltamivir|Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
16323227|NCT04516915|Active Comparator|Oseltamivir|Oseltamivir (75mg BID) for 14 days
16323228|NCT04516902|Experimental|100 μg LSD + MDMA placebo|100 μg LSD + MDMA placebo
16323229|NCT04516902|Experimental|LSD placebo +100 mg MDMA|LSD placebo +100 mg MDMA
16323230|NCT04516902|Experimental|100 μg LSD + 100 mg MDMA|100 μg LSD + 100 mg MDMA
16323231|NCT04516902|Placebo Comparator|LSD placebo+ MDMA placebo|LSD placebo+ MDMA placebo
16323232|NCT04516889|Experimental|Intervention|The intervention arm will undergo the modified sutured SFIOL technique with double Prolene sutures instead of a single Prolene suture
16323233|NCT04516876|Experimental|Camp-based bimanual intensive training(BIT)|
16323234|NCT04516863|Active Comparator|Patients with depression|"Major depression according to DSM-V and ICD-10 (ICD F32.1, F32.2, F32.3, F33.1, F33.2, F33.3)
~Hamilton Depression Rating Scale > 17"
16323235|NCT04516863|Active Comparator|Healthy controls|- Mental health
16323236|NCT04516850||Patients tested for COVID-19|The nasopharyngeal swabs taken from patients tested for Covid-19 who resulted infected and non-infected will be analyzed to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2.
16323237|NCT04516850||Patients with mild-moderate and severe SARS-CoV-2 infection|Formalin-fixed paraffin will be analysed to determine the association between polymorphism of the HSD3B1 gene and outcomes in COVID-19 affected patients
16323238|NCT04516837|Experimental|eltrombopag plus rhTPO|Combination of eltrombopag and rhTPO
16323239|NCT04516837|Active Comparator|eltrombopag|Eltrombopag monotherapy
16323240|NCT04516824||Trauma,Spine cases,Arthroplasty,Arthroscopy, Miscellaneous|
16323241|NCT04516811|Experimental|Arm 1|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
16323242|NCT04516811|Placebo Comparator|Arm 2|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines.
16323243|NCT04516798|Experimental|Experiment|Local and whole body vibration were applied
16323244|NCT04516785||Intervention|FIT and urine VOC samples followed by colonoscopy
16323245|NCT04516772|Other|Visian TICL|STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.
16323246|NCT04516759|Experimental|AZD1656 (plus Usual Hospital Care)|50mg film-coated tablets at a dose of 100mg BID
16323247|NCT04516759|Placebo Comparator|Matched Placebo (plus Usual Hospital Care)|Matched placebo tablets
16323248|NCT04516746|Experimental|AZD1222|Approximately 20,000 participants randomized to the AZD1222 arm
16323249|NCT04516746|Placebo Comparator|Placebo|Approximately 10,000 participants randomized to the saline placebo arm
16323250|NCT04516733|Other|single arm|patient with glioblastoma
16323251|NCT04516720||Primary Nervous System Tumors arm|"The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.
~Clinical Data and Questionnaires:
~For the retrospective part
~Patient identification based on data from the Medical Information Department (DIM) of the ICM;
~Verification of the eligibility criteria;
~Inclusion of patients in a coded form in BDD-NO;
~Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created
~Collection of clinical data from each patient's medical record
~For the prospective part
~Inclusion of patients in a coded form in BDD-NO;
~Collection of clinical data from each patient's medical record."
16323252|NCT04516694|No Intervention|Control|Usual care reflects the standard treatment currently provided to T1D patients. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
16323351|NCT04515979|Experimental|vactosertib+Pembrolizumab|Vactosertib (5days on and 2days off) Pembrolizumab 200mg Q3Weeks
16323381|NCT04515758|Active Comparator|Exercise Training Only|Each participant (in a group setting) completes 1 hour of exercise two days/week (separate days than the experimental group).
16323253|NCT04516694|Experimental|Gain-framed incentive|"Participants will start off with nothing at the beginning of the treatment period. For each day that participants' meet goals, value will be added to their incentive balance.
~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
16323254|NCT04516694|Experimental|Loss-framed incentive|"Participants will start off at the maximum incentive balance at the beginning of the treatment period and for each day that participants' fail to meet goals, value will be subtracted from their incentive balance over the 12-week.
~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
16323255|NCT04516681|Experimental|Combined Ascorbic Acid with chemotherapy group|Ascorbic Acid with FOLFOXIRI with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
16323256|NCT04516681|Active Comparator|Chemotherapy alone group|standard FOLFOXIRI treatment
16323257|NCT04516655|Experimental|C-R-MTX|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles
16323258|NCT04516629||Experimental|subjects with sub-health status
16323259|NCT04516616|Experimental|Study group|Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.
16323260|NCT04516603|Experimental|Fampridine SR|"Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.
~The single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t½ = 3.61 h) between experimental and control intervention."
16323261|NCT04516603|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of the identical additives formulated for oral administration.
16323262|NCT04516590||autoimmune antigen negative|treated with anti-epilepsy drugs
16323263|NCT04516590||autoimmune antigen positive|whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom
16323264|NCT04516577||Shanghai Pulmonary Hospital|Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.
16323265|NCT04516577||Peking Union Medical College Hospital|Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.
16323268|NCT04516551|Experimental|anti-CD19 allo-CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage.
~dosage: the number of anti CD19+CD22 CAR T cells
~-1(if needed) 1×10^6/KG
~3×10^6 /KG 6×10^6 /KG 1×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion."
16323269|NCT04516538|Experimental|Young people|Men or Women under 35 years old
16323270|NCT04516538|Experimental|Old people|Men or Women between 60 and 80 years old
16323271|NCT04516538|Experimental|Very old people|Men or Women over 80 years old
16323272|NCT04516512|Experimental|Investigated arm|Participants included in the study who met inclusion criteria
16323273|NCT04516499||f-FTLD mutation carriers|All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.
16323274|NCT04516499||Non-mutation carriers from families with f-FTLD mutations|All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.
16323275|NCT04516473||Experimental/Body Contouring Intervention|These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.
16323276|NCT04516473||Control/Post Massive Weight Loss Matched Control|"These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study.
~The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions."
16323277|NCT04516460|Experimental|PuraStat|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection
16323278|NCT04516447|Experimental|Combination with carboplatin|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)
16323279|NCT04516447|Experimental|Combination with PLD|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 50 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle
16323280|NCT04516447|Experimental|Combination with paclitaxel|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles, and (2) paclitaxel 80 mg/m^2 administered intravenously over 60 minutes (± 10 minutes) on Days 1, 8, and 15 of each 28-day cycle
16323281|NCT04516447|Experimental|Combination with gemcitabine|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles, and (2) gemcitabine 1000 mg/m^2 intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle
16323694|NCT04513522|Experimental|Nivolumab + ipilimumab|
16323282|NCT04516434|Experimental|Intraurethral Electrical Stimulation|"This procedure is specific to the urethral stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the urethra and positioned with the electrode contact 10-14 mm from the bladder neck to stimulate the proximal urethra. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be 2-20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to the proximal urethra at strong desire to void during cystometry. The participant will then be given permission to void at maximum cystometric capacity with continuous intraurethral stimulation."
16323283|NCT04516434|Experimental|Intravesical Electrical Stimulation|This procedure is specific to the bladder stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the bladder through the urethra and the electrode contacts will be positioned to be floating within the bladder. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be set at 20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to bladder sensory nerves for up to 60 minutes prior to the start of urodynamic studies.
16323284|NCT04516421|Experimental|Experimental group|The experimental group will receive a 12-weeks intervention, with each day a pack of supplementation containing 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
16323285|NCT04516421|Placebo Comparator|Control (Placebo) group|The control (placebo) group will receive a 12-week oat drink, with each day a pack of oat tea containing 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
16323286|NCT04516408|Experimental|Recombinant zoster vaccine|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the vaccine 2 months apart.
16323287|NCT04516408|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the placebo (sterilized water) 2 months apart.
16323288|NCT04516395|Experimental|Optimal antibiotic combination regimens|The patients in the groups will be given the optimal antibiotic combination regimens.
16323289|NCT04516395|Other|Standard antibiotic regimens|The patients in the groups will be given the standard antibiotic regimens.
16323290|NCT04516382|Experimental|Intravenous|PTG-300 Intravenous
16323291|NCT04516382|Experimental|Subcutaneous Low Concentration|PTG-300 Subcutaneous Low Concentration
16323292|NCT04516382|Experimental|Subcutaneous High Concentration|PTG-300 Subcutaneous High Concentration
16323293|NCT04516382|Experimental|Intramuscular|PTG-300 Intramuscular
16323294|NCT04516369|Experimental|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
16323295|NCT04516356|Experimental|Intervention Arm|Korean hand acupressure will be applied to the experimental group 30 minutes before the induction of anesthesia. After determining the pressure / therapy points associated with nausea and vomiting on the patient's hand, a massage will be made for 3-5 minutes with a diagnostic stick. The seeds will then be fixed at these points with a paper patch. Seeds will not be removed for 24 hours. It will be massaged for 3-5 minutes by pressing the seeds every 3-4 hours and making a curling motion at the same time. At the end of the 24th hour, the application will be terminated.
16323296|NCT04516356|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
16323297|NCT04516343|Experimental|User testing|Two sessions of user-centric testing.
16323298|NCT04516343|Experimental|Therapist-guided training|Therapist-guided gait training with the RAAD.
16323299|NCT04516343|Experimental|Assistance training|Assistance training with the RAAD
16323300|NCT04516343|Experimental|Therapist supervised resistance training|Resistance training with the RAAD under therapist supervision.
16323301|NCT04516343|Experimental|Parent supervised resistance training|Resistance training under parent supervision.
16323302|NCT04516330|Active Comparator|unifocal breast cancer|patients having unifocal breast cancer
16323303|NCT04516330|Active Comparator|multicentric breast cancer|patients having multicentric breast cancer
16323304|NCT04516317||Group intravenous artesunate (around 300 patients)|Period 2011-2019
16323305|NCT04516317||Group intravenous quinine (around 300 patients)|Period 2000-2010
16323306|NCT04516304|Placebo Comparator|Placebo|Placebo
16323307|NCT04516304|Experimental|Experimental|S-equol
16323308|NCT04516291|Placebo Comparator|Placebo|No drug
16323309|NCT04516291|Experimental|Vupanorsen 80 mg every 4 weeks|80 milligrams (mg) given subcutaneously every 4 weeks.
16323310|NCT04516291|Experimental|Vupanorsen 60 mg every 2 weeks|60 mg given subcutaneously every 2 weeks.
16323311|NCT04516291|Experimental|Vupanorsen 120 mg every 4 weeks|120 mg given subcutaneously every 4 weeks.
16323312|NCT04516291|Experimental|Vupanorsen 80 mg every 2 weeks|80 mg given subcutaneously every 2 weeks.
16323313|NCT04516291|Experimental|Vupanorsen 160 mg every 4 weeks|160 mg given subcutaneously every 4 weeks.
16323314|NCT04516291|Experimental|Vupanorsen 120 mg every 2 weeks|120 mg given subcutaneously every 2 weeks.
16323315|NCT04516291|Experimental|Vupanorsen 160 mg every 2 weeks|160 mg given subcutaneously every 2 weeks.
16323316|NCT04516278|Experimental|Biological: bevacizumab|ONS-5010
16323317|NCT04516265|Active Comparator|NGT Group|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
16323318|NCT04516265|Active Comparator|Video-based training group|Trunk training will be done with games developed for the use of children with cerebral palsy.
16323319|NCT04516265|Active Comparator|Video-based training group with theratogs|Video-based trunk training (45 minutes) will apply with Theratogs to the group
16323320|NCT04516252|Experimental|Intervention|Half of the BodyWorks families will be randomized to the intervention group, and will receive a PAT for the children, the parents, and the dogs at the beginning of the cycle; the children will respond to EMA surveys using a cell phone; the children and the parents will receive the Canine health literacy module in addition to the BW curriculum.
16323321|NCT04516252|Active Comparator|Control|Half of the BodyWorks participants will be randomized to the control group and will receive a PAT at the beginning of the cycle for the children, the parents, and the dogs, and the children will respond to EMA surveys using cell phones.
16323322|NCT04516239|Active Comparator|LDH THA|large diameter head total hip arthroplasty
16323323|NCT04516239|Active Comparator|HR|metal-on-metalhip resurfacing
16323324|NCT04516226|Experimental|Vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of PPROM diagnosis.
16323325|NCT04516226|No Intervention|No vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to not undergo vaginal cleansing.
16323326|NCT04516213|Experimental|Enteral formula tube feeding|Enterally fed children, ages 1-4, with established enteral feeding access
16323327|NCT04516200|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation will be applied to study group only . Anodal transcranial stimulation will be applied on left somatosensory cortex while the cathodal one will be applied on right supra-orbital area with frequency of 2m.A for 20 minutes.Stimulation will be applied three times per week for two months.
16323328|NCT04516200|Placebo Comparator|traditional physical therapy program|traditional physical therapy program will be applied to both the control group and study group. It will be consist of sensory re-education training and balance training.Exercises will be applied three times per week for two months
16323329|NCT04516174|Experimental|Dex+TAPB group|Patients in Dex+TAPB group will receive the bilateral transversus abdominis plane block with 0.25% ropivacaine 20ml each side before anesthesia and combined with continuous infusion of dexmedetomidine during operation.
16323330|NCT04516174|Placebo Comparator|Control group|Patients in control group will receive the bilateral transversus abdominis plane block with saline 20ml each side before anesthesia and don't receive the infusion of dexmedetomidine during operation.
16323331|NCT04516161||Radium-223 dichloride (Xofigo, BAY88-8223)|Patients with mCRPC who received treatment of Ra-223.
16323332|NCT04516148|Experimental|Antibiotics|Patients randomized to the treatment arm of the study will have orders placed by a physician on the clinical team, with preparation and delivery of the antibiotics dose by the pharmacy following standard procedures. Antibiotic administration will occur after induction of anesthesia, with delivery by the Anesthesia staff no more than one hour prior to incision. Those with known allergy to beta-lactams will receive clindamycin instead of cefazolin.
16323333|NCT04516148|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the study will receive no perioperative antibiotic administration and will proceed with routine pre-operative care.
16323334|NCT04516135|Experimental|Arm A (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
16323335|NCT04516135|Active Comparator|Arm B (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
16323336|NCT04516122||Observational (biospecimen collection, DXA scan)|Patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and at 12 months.
16323337|NCT04516109|Active Comparator|Arthrosocpic labral repair|Patients undergoing arthroscopic labral repair with the use of the modified hip capsule slotted cannula.
16323338|NCT04516109|Active Comparator|Arthroscopic bone grafting|Patients undergoing arthroscopic bone grafting of subchrondral cyst with the use of the modified bone graft delivery tool set and modified hip capsule slotted cannula.
16323339|NCT04516096|Experimental|AMX-0035 long term treatment extension|AMX0035 administered twice daily p.o.
16323340|NCT04516070|Experimental|Treatment (SRS)|Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
16323341|NCT04516057|Experimental|Nabilone Arm|Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.
16323342|NCT04516057|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive placebo capsules.
16323343|NCT04516044||Video game|Patients treated by physicians who were randomized to either play an adventure-based video game that used narrative engagement to recalibrate physician heuristics in trauma triage or a puzzle-based video game that used analogical encoding to recalibrate physician heuristics in trauma triage.
16323344|NCT04516044||Control|Patients treated by physicians who were randomized either to nothing at all or to a text-based educational program.
16323345|NCT04516031|Active Comparator|Mesh-only repair|
16323346|NCT04516031|Active Comparator|Transversus Abdominis Muscl|
16323347|NCT04516018|Experimental|Cold acclimation arm|An oral glucose tolerance test will be performed on day 1 of the study. The next day (day 2), subjects will be exposed to shivering thermogenesis for at least 1 hour. The day after, an oral glucose tolerance test will be performed (day 3). The following 9 days, subjects will be exposed daily to shivering thermogenesis for at least 1 hour (day 4-12). On the last day (day 13), an oral glucose tolerance test will be performed.
16323348|NCT04516005|Experimental|foot reflexology|Foot reflexology was performed in every participant in the foot reflexology group after resting for 5 minutes in a sitting position by the same researcher who was trained and certified by the Department of Thai Traditional and Alternative Medicine, Ministry of Health.
16323349|NCT04516005|No Intervention|control|The control group received conventional treatment including anti-HT medications according to the standard HT guideline's recommendations. In the end of the follow-up visit, every participants were informed to adhere to their medication and were encouraged to have healthy lifestyles including salt restriction, regular exercise, and consuming healthy diets.
16323695|NCT04513509|Experimental|rate control|
16323352|NCT04515966|Active Comparator|Ultrasound-guided steroid injection|Participants with CTS who meet the inclusion criteria are randomized to two groups. One group (or arm) will receive an ultrasound-guided steroid injection in the vicinity of the median nerve within the carpal tunnel. A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine is injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
16323353|NCT04515966|Active Comparator|Wrist splint|Participants in this arm are treated with a wrist splint.
16323354|NCT04515953|Active Comparator|Control|Standard practice of pain management for post-TKA
16323355|NCT04515953|Experimental|ND-340|ND-340 90mg~320mg at dose escalations
16323356|NCT04515927|Experimental|subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.|
16323357|NCT04515914||Decitabine therapy|The patients are treated with decitabine at least 1 cycles
16323358|NCT04515914||non-Decitabine therapy|The Patients are diagnosed as MDS and do not be treated with decitabine therapy
16323359|NCT04515901|Experimental|SPGB|Via a soft tip 20-gauge long IV catheter attached to a 3 mL syringe will be filled with 2 mL of 2% viscous lidocaine. The 2% viscous lidocaine will be administered according to the method of Barre.
16323360|NCT04515901|Placebo Comparator|Placebo|It will be adminstered the same as the experimental arm but with methylcellulose and cherry flavouring to match odour and taste.
16323361|NCT04515888||target population|The target population of the study consists of breast cancer female patients over 50 years old followed for an invasive carcinoma expressing hormone receptors, non metastatic, undergoing adjuvant hormone therapy.
16323362|NCT04515888||control population|The control group will be composed of patients followed for an in situ carcinoma treated by surgery +/- radiotherapy, without hormone therapy.
16323363|NCT04515875|Experimental|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
16323364|NCT04515875|Placebo Comparator|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
16323365|NCT04515862|Experimental|intervention|Intervention group: Mothers in the intervention group were included in the breastfeeding training program with the group training method. The training program was developed by the researchers, and the content of the program was evaluated with the expert opinion of academicians, obstetricians, nurses and breastfeeding counselor midwives working on breastfeeding.
16323366|NCT04515862|No Intervention|control|Control Group:Routine obstetric care and treatment procedures were applied to the mothers in the control group. In the hospital where the study was conducted, all mothers are routinely evaluated for breastfeeding by an infant nurse.
16323372|NCT04515836|Experimental|Treatment Arm|Olaparib will be given orally to patients in 28-day cycles. Patients will attend the clinic on days 1 (first day of treatment) and 15 of the first cycle following the beginning of study treatment and then every 4 weeks (day 1 of every cycle) until discontinuation of treatment.
16323373|NCT04515810|Experimental|PACT Intervention|"PACT is grounded in decision-making research that indicates individuals often make decisions with the input of social informants or influences.10 PACT will utilize mHealth technology to provide the following empirically based features to meet patients' reported need to incorporate loved ones into the advance care planning (ACP) decision-making process and thus bolster their social networks: Pick one's team of loved ones to be involved in ACP through its shareability feature; Address common barriers of traditional family meetings (e.g., distance of loved ones, domineering family members) by exploiting the ubiquitous access of an online application with the ability to control online ACP meetings; Complete advance directives with the engagement and, if desired, input of loved ones through structured question prompts; Team up with loved ones to share one's wishes both informally through care preference messages and formally through shared advance directive forms."
16323374|NCT04515810|No Intervention|Control condition|Usual, standard care.
16323375|NCT04515797|Experimental|Treatment with Direct Acting Antiviral for HCV|4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant
16323376|NCT04515784|Experimental|Active|Active arm- START-PTSD
16323377|NCT04515784|No Intervention|Control|Control arm
16323658|NCT04513769|Experimental|Study participants|This is a single-arm study so all participants receive the same intervention.
16323382|NCT04515745||ILI/Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration (SSA) databases.
16323383|NCT04515745||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to SSA databases.
16323384|NCT04515732|Experimental|3a (apremilast intervention)|Apremilast in standard dosis (gradual increase 0-30 mg x 2 daily over the first 6 days, hereafter 30 mg x 2 daily) for 6 months, followed by 6 months observation.
16323385|NCT04515732|No Intervention|3b (non-intervention)|Observation
16323386|NCT04515719|Experimental|Belimumab 2mg/kg|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Belimumab 2mg/kg is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
16323387|NCT04515719|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
16323388|NCT04515706|Experimental|Iguratimod|Iguratimod 25 twice a day (bid) on Week 1-48.
16323389|NCT04515706|Placebo Comparator|Placebo|Placebo twice a day (bid) on Week 1-24, and Iguratimod 25 twice a day (bid) on Week 25-48.
16323390|NCT04515693|Experimental|Maximal Assist group|Subjects with acute stroke who ambulate with Maximal assistance of 1.
16323391|NCT04515693|Experimental|Moderate Assist group|Subjects with acute stroke who ambulate with Moderate assistance of 1.
16323392|NCT04515693|Experimental|Minimal Assist group|Subjects with acute stroke who ambulate with Minimal assistance of 1.
16323393|NCT04515693|Experimental|Supervision/Modified Independence/Independence|Subjects who walk without physical assistance of a helper.
16323394|NCT04515667|Experimental|Mindfulness|
16323395|NCT04515667|Placebo Comparator|Control|
16323396|NCT04515654|Experimental|Audience participants|Community members viewed the performance (intervention) and completed pre/post stigma questionnaire
16323397|NCT04515641|Experimental|Moderate Hepatic Impairment|Participants receive a single dose of ISL 60 mg.
16323398|NCT04515641|Experimental|Healthy Controls|Participants receive a single dose of ISL 60 mg.
16323399|NCT04515628|Experimental|Period A: Rosuvastatin|
16323400|NCT04515628|Experimental|Period B: Branebrutinib|
16323401|NCT04515628|Experimental|Period C: Branebrutinib + Rosuvastatin and Branebrutinib|
16323402|NCT04515628|Experimental|Period D: Branebrutinib|
16323403|NCT04515615|Experimental|Camrelizumab and chemotherapy|Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Three weeks as a course of treatment, a total of 8 courses.
16323404|NCT04515602|Experimental|Part 1 Arm I (low/medium tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
16323405|NCT04515602|Active Comparator|Part 1 Arm II (low/medium tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
16323406|NCT04515602|Experimental|Part 2 Arm I (high tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
16323407|NCT04515602|Active Comparator|Part 2 Arm II (high tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
16323408|NCT04515589||Main study cohort|The main study cohort in this single-arm cohort is 250 adults with rheumatoid arthritis
16323409|NCT04515576|Experimental|LY3493269|LY3493269 administered Subcutaneous (SC).
16323410|NCT04515576|Active Comparator|Dulaglutide|Dulaglutide administered SC.
16323411|NCT04515576|Placebo Comparator|Placebo|Placebo administered SC.
16323412|NCT04515563|Placebo Comparator|Control Group|Subjects in the care control group will perform once-a-week stretching exercise intervention. Each session lasts for 75 minutes and covers the major muscle groups.
16323413|NCT04515563|Experimental|Low-frequency, moderate-intensity walking group|A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 150-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 150 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
16323414|NCT04515563|Experimental|High-frequency, moderate-intensity walking group|Intervention of high-frequency, moderate-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 50-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 50 minutes of exercise time. If needed, there will be one 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
16323690|NCT04513535|Experimental|manual therapy combination 3|cervical manipulation, sleeper stretch
16323415|NCT04515563|Experimental|Low-frequency, vigorous-intensity walking group|Intervention of low-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 75-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 75 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
16323416|NCT04515563|Experimental|High-frequency, vigorous-intensity walking group|Intervention of high-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 25-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 25 minutes of exercise time. If needed, there will be a 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
16323417|NCT04515550||Huntington's disease (HD)|people with HD
16323418|NCT04515550||Controls without HD|people without HD
16323419|NCT04515537||conventional therapy plus AFA|Patient using conventional therapy plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
16323420|NCT04515537||conventional therapy plus SVF|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue, evaluted for period of 6 months
16323421|NCT04515537||conventional therapy plus SVF and AFA|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
16323423|NCT04515511|Experimental|standard care|ICU septic shock patients with refractory hypotension with indwelling pulmonary artery catheter received five sequential intravenous boluses of 100 mL 4% gelatin. Cardiac output measured by thermodilution of PAC before fluid challenge (baseline) and three minutes after each bolus. Fluid responsiveness (FR) was defined as an increase in CO greater than 10% after 500 mL fluid infusion. The smallest volume which can perform an effective fluid challenge was analyzed.
16323424|NCT04515498||CloudCath System|Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis
16323425|NCT04515485||Patients undergoing laparoscopy|The participants are patients that have undergone the laparoscopic surgery.
16323426|NCT04515472|Active Comparator|Healthy Volunteer Male|Healthy male currently on no testosterone treatment
16323427|NCT04515472|Active Comparator|Healthy Volunteer Female|Healthy female currently on no estrogen treatment
16323428|NCT04515472|Active Comparator|MTF group|MTF transgender currently on estrogen treatment
16323429|NCT04515472|Active Comparator|FTM group|FTM transgender group currently on testosterone treatment
16323430|NCT04515459|Other|Patients treated for bone or soft-tissue sarcoma of the limbs|
16323431|NCT04515446|Other|TROD + PCR diagnosis|For each patient positive for flu with a rapid diagnostic test, sequential nasopharyngeal (NP) samples will be collected for quantitative PCR every day from D1 to D8 or until discharge (if before D8). Sequential quantitative PCR will quantify influenza virus load in the upper airways.
16323432|NCT04515433|Experimental|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
16323433|NCT04515433|Placebo Comparator|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
16323434|NCT04515420||Group A|"Group A for patients that will need an infusion of NA solution to meet the desired CPP.
~Group A will be further divided into three sub-groups: A1 for patients that will receive NA in the dose of 0.06-0.12 μg/kg/min, A2 for patients that will receive a dose of 0.13-0.2 μg/kg/min, and A3 for patients that will receive a dose of NA > 0.2 μg/kg/min."
16323435|NCT04515420||Group B|Group B for patients that will not receive NA infusion.
16323436|NCT04515407|Other|Order 1|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 1 will be: Seated@Rest, Seated@Active, Walking.
16323437|NCT04515407|Other|Order 2|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 2 will be: Seated@Active, Walking, Seated@Rest.
16323438|NCT04515407|Other|Order 3|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 3 will be: Walking, Seated@Rest, Seated@Active.
16323440|NCT04515381|Experimental|Therapeutic touch group|Each student from the Therapeutic touch (TT) group was given TT sessions via Krieger-Kunz method in a total of 8 times in the manner of twice a week for one group (Monday - Wednesday) and another group (Tuesday - Thursday) for a duration of 1 month (4 week). TT application procedure: The procedure was explained to the student, the student person was concentrated, concentrated practitioner for TT application, the student's entire body was evaluated from head to foot with the practitioner's hands at a distance of about 2 inc, hands were moved regularly and rhythmically to prevent imbalances in the energy field, the energy field was re-evaluated from top to bottom and rebalanced if there was a blocked area, finally, the student was left to rest and response to the treatment was observed. The TT sessions of 20 minutes were applied on the students and they were given a short rest at the end of the session
16323441|NCT04515381|Placebo Comparator|Placebo group|For students in the placebo group, the similar duration (20 minutes) and frequency (2 sessions a week, total of 8 sessions) of TT was applied with hands at a certain distance from the body (approximately 5 cm) and they were moved without a specific order. The application was performed by the other researcher in a separate room to the placebo group.
16323442|NCT04515381|Other|Control group|There was no attempt being made towards the students within the control group. At the end of the 4th week, all students were asked to repeat measurements
16323443|NCT04515368|Experimental|Fendrix|Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.
16323444|NCT04515368|Experimental|Bexsero|Bexsero (Meningococcal group B subunit / Outer Membrane Vesicles, GlaxoSmithKline); 0.5 mL. intramuscular. stat.
16323445|NCT04515368|Experimental|Fluad|Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.
16323446|NCT04515368|Experimental|Seasonal Trivalent Influenza Vaccine|Seasonal Trivalent Influenza Vaccine ('ÄòSTIV'Äô, split virion inactivated, Northern Hemisphere 2016-17, Sanofi Pasteur); 0.5 mL. intramuscular. stat.
16323447|NCT04515355|Experimental|People with MS (PwMS)|People with MS recruited to take part and will be randomised to receive the intervention of online programme of support.
16323448|NCT04515355|No Intervention|People with MS (PwMS) - standard care|People with MS recruited to take part and will be randomised to receive the usual standard of care.
16323449|NCT04515342||Participants|This is a cross-sectional study involving approximately 150 patients. They undergo a physical examination, fill out a questionnaire, have blood samples drawn, undergo a Dual Energy X-ray Absorptiometry (DXA) scan and different physical procedures to assess muscle strength and muscle function.
16323450|NCT04515329|Experimental|Cyclosporine + Artificial Tears|Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control).
16323451|NCT04515329|Other|Artificial Tears|Preservative-free artificial tear drops 4 times a day (Control).
16323452|NCT04515316|Experimental|healthy adults|Any adult, who is at least eighteen (18-70) years old.
16323453|NCT04515316|Experimental|Patients with intractable epilepsy|Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.
16323454|NCT04515290|Experimental|TSG-01-H|Two tablets of TSG-01 per time.
16323455|NCT04515290|Experimental|TSG-01-L|One tablet of TSG-01 and One tablet of Placebo per time.
16323456|NCT04515290|Placebo Comparator|Control|Two tablets of Placebo per time.
16323457|NCT04515277|Active Comparator|40 g (D1)|40 g gum acacia powder (D1). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
16323458|NCT04515277|Active Comparator|20 g (D2)|20 g gum acacia powder (D2). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
16323459|NCT04515277|Other|No treatment (NT)|0 g gum acacia powder. Standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
16323460|NCT04515238|Experimental|BZAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated
~Induction: 6 cycles (q 28d) of Obinutuzumab + Zanubrutinib + Venetoclax
~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Zanubrutinib + Venetoclax
~Maintenance treatment will be continued until (whichever occurs first):
~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity
~maintenance cycle 8
~progression of CLL or start of a subsequent therapy unacceptable toxicity"
16323461|NCT04515225||HIV-infected patients|All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination
16323462|NCT04515212|Active Comparator|Healthy Volunteers|
16323463|NCT04515212|Experimental|Traumatic Brain Injury Patients|
16323467|NCT04515173|Experimental|Artificial intelligence group|On the basis of conventional drug therapy combined with psychotherapy robot psychotherapy, the corresponding intelligent psychotherapy module and intensity were recommended according to the results of intelligent psychological evaluation. Each module was set once a week, 50 minutes each time, a total of 12 times.
16323468|NCT04515173|Other|General group|The subjects in this group only received routine drug therapy and routine outpatient follow-up evaluation
16323469|NCT04515147|Experimental|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
16323470|NCT04515147|Experimental|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
16323471|NCT04515147|Experimental|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.
~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
16323472|NCT04515147|Experimental|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
16323473|NCT04515147|Active Comparator|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
16323474|NCT04515147|Active Comparator|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
16323475|NCT04515147|Experimental|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
16323476|NCT04515147|Active Comparator|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
16323477|NCT04515147|Experimental|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
16323478|NCT04515147|Active Comparator|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
16323479|NCT04515121|Experimental|HD-tCES & lower limb rehabilitation|The experiment group will receive HD-tCES combined with lower limb rehabilitation of affected side.
16323480|NCT04515121|Sham Comparator|Sham HD-tCES & lower limb rehabilitation|The sham control group will receive sham HD-tCES combined with lower limb rehabilitation of affected side.
16323481|NCT04515108||Group 1 (Pregnants with COVID-19)|Study group included pregnant women with clinically confirmed COVID-19.
16323482|NCT04515108||Group 2 (Pregnants without COVID-19)|Control group consisted of healthy pregnant women in the same number and same gestational week with the Study group.
16323483|NCT04515095|Experimental|Water-only Fasting Group|Participants who voluntarily elect and are approved to water-only fast.
16323484|NCT04515069|Active Comparator|Traditional technique for tooth preparation.|Tooth preparation performed directly on the tooth structure
16323485|NCT04515069|Active Comparator|Aesthetic preevaluative temporary technique|Aesthetic pre-evaluative temporary (APT) was fabricated according the planned wax-up. Once the APT was approved both aesthetically and functionally, tooth preparation was performed through the APT.
16323486|NCT04515056|Experimental|Papain dosage|In the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm). The two areas will be located 4 cm apart. Three areas will be exposed to 10, 50 or 100 µg of papain, while the last area will be used as control (exposed to a vehicle).
16323487|NCT04515056|Experimental|Papain SPT|Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
16323488|NCT04515043|Experimental|INVAC-1|All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
16323489|NCT04515004|Experimental|Intervention|All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.
16323490|NCT04514991|Experimental|Foundation|Subjects assigned to this group will receive Foundation in the bone defect before suturing the surgical site.
16323491|NCT04514991|No Intervention|Control|
16323492|NCT04514978|Experimental|Blood donation and transfusion|Donation and reinfusion of 1 unit whole blood and 130 mL packed red blood cells, respectively. Blood samples were collected at 8 weeks prior to donation for 12 subjects and 2 weeks prior to donation by 12 subjects. Blood samples were collected 3, 7, 14, 21, and 28 days after donation and 3, 6, 24 hours and 2, 3 and 6 days after reinfusion of blood.
16323493|NCT04514978|No Intervention|Control group|Blood samples collected with same frequency as described in the intervention arm.
16323494|NCT04514965||PBC patients offered bezafibrate treatment|"All patients started on bezafibrate treatment are offered inclusion in the study.
~First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion.
~At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus."
16323495|NCT04514939||Group A - Leg elevation|Patients will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
16323496|NCT04514939||Group B- Non Leg elevation|Patients will lie in their hospital bed without leg elevation
16323497|NCT04514926||Healthy Controls|Participants with no history of asthma or other lung diseases.
16323498|NCT04514926||Asthmatics newly prescribed therapeutic proteins|Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.
16323499|NCT04514926||Asthmatics already being treated with therapeutic proteins|Participants with asthma who have already started on therapeutic proteins.
16323500|NCT04514913||Healthy Controls|Participants with no history of asthma or other lung diseases.
16323501|NCT04514913||Asthmatics without mucus plugs|Participants with asthma and no evidence of mucus plugging.
16323502|NCT04514913||Asthmatics with mucus plugs|Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
16323503|NCT04514900|Active Comparator|Video Chat +Personalized Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
16323504|NCT04514900|Active Comparator|Video Chat + Basic Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive basic feedback weekly on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
16323505|NCT04514900|Active Comparator|Discussion Board for Social Support + Basic Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly basic feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
16323541|NCT04514640|Experimental|General Meditation|"Participants will be asked to meditate every day during the daytime for at least 10 min/session. Participants can use any general meditation including the Daily Calm which can be found on the homepage or by clicking on the meditate tab in the app. Participants will be asked to not choose any sleep meditations or Sleep Stories."
16323691|NCT04513535|Experimental|manual therapy combination 4|thoracic manipulation, glenohumeral mobilization
16323506|NCT04514900|Active Comparator|Discussion Board for Social Support+Personalized Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring from a trained interventionist. Participants will be asked to weigh daily on a digital scale, which will be provided.
16323507|NCT04514887|Experimental|Mild Hyperventilation|In this study arm, patients were mildly hyperventilated intraoperatively so their end-tidal CO2 levels are brought down to 30-32 mmHg.
16323508|NCT04514887|No Intervention|Control|In this study arm patients' ventilation is managed according to guidelines with end-tidal CO2 levels kept in the normal range of 35-40 mm Hg
16323509|NCT04514861|Other|Tissue Oxygen Dynamics with Lumee Oxygen and TcPO2|Monitoring local subcutaneous tissue oxygen dynamics using the Wireless Lumee Oxygen Platform in correlation to TcPO2 measurements in the arm and foot
16323510|NCT04514848|Experimental|Individuals accessing screening for syphilis and HIV|Individuals at risk for syphilis and HIV (e.g. gay and bisexual men, indigenous communities experiencing a resurgence of syphilis, persons who inject drugs, etc) will undergo testing with both POCT and standard laboratory testing. Individuals testing positive for syphilis or HIV on the POCT will be informed that this is a preliminary positive and standard testing will be done. Individuals testing positive for syphilis on POCT may be offered treatment at the time of testing.
16323511|NCT04514835|Experimental|Cisplatin+Capecitabine+Sintilimab|Cisplatin+Capecitabine+Sintilimab
16323512|NCT04514822|Other|N0 stage|patients without malignant lymph nodes
16323513|NCT04514822|Other|Non-N0 stage|patients with malignant lymph nodes
16323514|NCT04514809|Experimental|Experimental|It consists of 15 mothers who meet the inclusion criteria
16323515|NCT04514809|Experimental|Control Groups|It consists of 15 mothers who meet the inclusion criteria
16323516|NCT04514796|Experimental|40 mg/0.4 mL of SB5|100 mg/mL of SB5
16323517|NCT04514796|Active Comparator|40 mg/0.8 mL of SB5|50 mg/mL of SB5
16323518|NCT04514783|Other|Group 2|Use of scalpel and a spoon-shaped metal instrument (curette).
16323519|NCT04514783|Experimental|Group 1|Use of Debritom+ micro water jet technology
16323520|NCT04514770|Active Comparator|early amniotomy|"Group A:
~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.
~Early amniotomy was performed for the participant of the first group at 3 cementer cervical dilatation with Kocher's forceps provided the head is well fitted to the cervix."
16323521|NCT04514770|Active Comparator|Late amniotomy|"Group B:
~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.
~late amniotomy was performed for the participant of the second group at 7 cementer cervical dilatation."
16323522|NCT04514757|Experimental|Intervention Group|Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to ear at 20 Hz, 200 microseconds at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 6 days post-operatively or discharge.
16323523|NCT04514757|Sham Comparator|Control Group|Sham tVNS will be performed by attaching the Parasym device to the ear and setting output to 0. Stimulation will continue until 6 days post-operatively or discharge.
16323524|NCT04514744|Experimental|Unilateral Immobilization|One leg will undergo 8 days of single-leg immobilization, by means of a removable knee brace.
16323525|NCT04514744|Experimental|Unilateral Resistance Exercise|One leg will undergo 4 sessions of unilateral resistance exercise, over the course of 8 days. Specifically, participants will be asked to perform leg press and leg extension.
16323526|NCT04514731|Experimental|Group M|Patients in the magnesium sulfate group received magnesium sulfate 50 mg/kg for 15 minutes after spinal anesthesia and then 15 mg/kg/hour by continuous intravenous infusion until the end of surgery
16323527|NCT04514731|Placebo Comparator|Group S|Patients in the saline group received the same volume of isotonic saline over the same period with magnesium infusion protocol
16323528|NCT04514718|Active Comparator|low energy holmium laser|30 watts
16323529|NCT04514718|Active Comparator|high energy holmium laser|80-100 watts
16323530|NCT04514705|Experimental|Intervention Group|The exercises performed will attend the musculoskeletal dimension of the body, which includes the muscular strength / endurance indexes, which is part of the functional-motor dimension of physical fitness related to health. The protocol will be applied in the form of sessions lasting approximately 50 minutes, performed three times a week on alternate days, for a period of 6 weeks, totaling 20 sessions. For aerobic exercises, a treadmill will be used and for anaerobic exercises, four exercises involving muscle mobility / strength in upper and lower limbs will be performed at weight training station.
16323531|NCT04514692|Experimental|Phase I -Dose finding, Cohort 1|Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
16323532|NCT04514692|Experimental|Phase I -Dose finding, Cohort 2|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
16323533|NCT04514692|Experimental|Phase I -Dose finding, Cohort 3|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
16323534|NCT04514692|Experimental|Phase II-G-CSF|Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
16323535|NCT04514679||Healthy Lifestyles Program|Usual care in the Healthy Lifestyles Program.
16323536|NCT04514679||Obesity Medicine Program|Usual care in the Obesity Medicine program.
16323537|NCT04514666|Experimental|Liver/kidney transplant|The breath of patients undergoing liver or kidney transplant will be sampled and analysed
16323538|NCT04514653|Active Comparator|Ranibizumab control|Control treatment arm
16323539|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
16323540|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
16323542|NCT04514640|Experimental|Sleep Meditation|"Participants will be asked to meditate every day just before going to bed for at least 10 min/session. Participants can use any sleep meditations which can be found by clicking on the meditate tab and then sleep. Particpiants will be asked to not choose any general meditations including the Daily Calm or Sleep Stories."
16323543|NCT04514640|Experimental|Sleep Stories|"Participants will be asked to listen to a Sleep Story every day just before going to bed for at least 10 min/session. Participants can listen to any Sleep Story which can be found by clicking on the sleep tab. Participants will be asked to not choose any general meditations including the Daily Calm or sleep meditations."
16323544|NCT04514627|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
16323545|NCT04514627|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
16323546|NCT04514614|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
16323547|NCT04514601||Pre-Intervention Group|The verbal and written handover of these patients was observed. This included 146 general orthopaedic admissions patients and 43 trauma patients. All patient data was anonymised.
16323548|NCT04514601||Post-Intervention Group|The verbal and written handover of these patients was observed after the introduction of the intervention. This included 81 general orthopaedic admissions patients and 47 trauma patients. All patient data was anonymised.
16323549|NCT04514588|Other|caffeine consumption and metabolism|Participants will take part in two trials. Each trial will last one day at least one week apart. During the first trial half of the participants will consume caffeine (5mgr/kgr) and the rest only water. During the second trial a crossover design will be applied
16323550|NCT04514588|Other|control|Control group will consume only water (not coffee) and the same parameters will be recorded as previously
16323551|NCT04514575||High-FFP|Patients transfused with an FFP:RBC ratio of 2:3 to 3:3 (0.7 - 1.0)
16323552|NCT04514575||Low-FFP|Patients transfused with an FFP:RBC ratio at or below 1:3 (0.0 - 0.3).
16323553|NCT04514562|Other|Intervention|NeVa Stent Retrievers
16323554|NCT04514549||Cohort 1|will enroll approximately 5 patients with pronounced respiratory dysfunction. Patients may be enrolled with tremors and or seizures. All patients will be observed via Emerald to capture sleep staging, movement and breathing for up to approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. MC10 nPoint data will be captured for at least two 24-hour periods in each of the 4 weeks to assess patch placements for breathing detection. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 1 progresses.Preliminary results from Cohort 1 will determine if Emerald will continue to be evaluated and will inform on MC10 nPoint optimizations for Cohort 2. If preliminary results indicate Emerald is not an effective device, then Emerald will be discontinued
16323555|NCT04514549||Cohort 2|will enroll approximately 15 patients. Patients with pronounced respiratory dysfunction, tremors, seizures, and/or other expanded features of Rett syndrome deemed appropriate may be enrolled. If Emerald is continued, all patients are observed via Emerald to capture sleep staging, movement and breathing up to for approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 2 progresses.
16323556|NCT04514536|Experimental|Health monitoring|Subjects have to monitor their health autonomously using the monitoring platform (connected health devices and app on the touchpad).
16323557|NCT04514523|Experimental|Implementation Arm|
16323560|NCT04514497|Experimental|Cohort I (elimusertib, irinotecan)|Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16323561|NCT04514497|Experimental|Cohort II (elimusertib, topotecan)|Patients receive topotecan IV over 30 minutes on days 1-5 and elimusertib PO BID on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16323563|NCT04514471|Experimental|Unventilated Filter Cigarette|Conventional cigarette with approximately 6-7% (non-menthol) and 5-6% filter ventilation (menthol).
16323564|NCT04514471|Active Comparator|Ventilated Filter Cigarette|Conventional cigarette with approximately 22-26% (non-menthol) and 35-38% filter ventilation (menthol).
16323565|NCT04514458|Experimental|EHR-based alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
16323566|NCT04514458|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
16323567|NCT04514432||When music was available|3 month period during which music was available to patients experiencing agitation
16323568|NCT04514432||When music was not available|3 month period during which music was not available to patients
16323569|NCT04514419|Experimental|Trastuzumab + HS627 + Docetaxel|Trastuzumab HS627 Docetaxel
16323570|NCT04514419|Experimental|Trastuzumab + Pertuzumab + Docetaxel|Trastuzumab Pertuzumab Docetaxel
16323571|NCT04514406||APERTO OTW DCB|Dialysis patients treated with APERTO OTW following (re)stenosis of central veins
16323597|NCT04514224||Healthy Start Program 3|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
16323692|NCT04513535|Experimental|manual therapy combination 5|thoracic manipulation, sleeper stretch
16323572|NCT04514393|Experimental|methotrexate, ibrutinib, and temozolomide (MIT regimen)|Methotrexate will be given on day 1 of each 28-day cycle；Ibrutinib will be given day 1-28 of each 28-day cycle; Temozolomide will be given day 1-5 of each 28-day cycle. Methotrexate and Temozolomide are given for up to 4 cycles; Ibrutinib is continued until disease progression, intolerable toxicity, or death.
16323573|NCT04514380||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon A.
16323574|NCT04514380||Group N|Patients did not drink carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon B.
16323575|NCT04514367|Experimental|ANX005|IV
16323576|NCT04514354|Experimental|GEST Visit|As described in the detailed study description, the GEST Visit included measures of cardiovascular health at Hartford Hospital. These measures included BMI, waist circumference, exhaled carbon monoxide (CO), vascular health (i.e., carotid intimal medial thickness and arterial stiffness), HRV, resting BP, the GEST, and blood draws pre- and post-GEST to obtain SCD and CVD biomarkers.
16323577|NCT04514354|No Intervention|CONTROL Visit|On either Visit 3 or 4, subjects performed the CONTROL Visit. Resting auscultatory blood pressure was measured according to AHA standards. At the conclusion of CONTROL, subjects were fitted for the ABP monitor. Subjects were instructed to proceed with normal activities, not to exercise, and to keep their arm still and extended at their side when each ABP measurement was being taken. Subjects carried a standard journal, recording activities performed during each measurement, any unusual physical or emotional events, and sleep and wake times. The following morning, subjects detached the monitor and returned it that day to the study investigators.
16323578|NCT04514328|Experimental|one group|patients with mild or moderate Alzheimer disease
16323579|NCT04514315||Minimally invasive aortic valve surgery|Patients undergoing minimally invasive aortic valve surgery
16323580|NCT04514315||Minimally invasive mitral valve surgery|Patients undergoing minimally invasive mitral valve surgery
16323581|NCT04514315||Conventional aortic valve surgery|Patients undergoing conventional aortic valve surgery
16323586|NCT04514289||assesment SLND with enjection by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.
16323587|NCT04514289||assesment SLND with hysterescopy by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The second one which ICG has injected the uterine cavity during hysteroscopy. Our aim is to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy.
16323588|NCT04514276|Experimental|consecutive fetoneonatal healthcare|inclusion criteria: pregnant woman having higher risk of early fetal growth restriction, preeclempsia living in studyregion (east-Saxony or east Thuringia) the fetoneonatal pathway consists of four consecutive parts: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
16323589|NCT04514276|No Intervention|standard fetoneonatal healthcare|inclusion criteria: due to health insurance data by AOK PPLUS & ikk classics propsensityscorematched pregnant women living in west Saxony and Thuringia, being not part of the intervention group receiving standard health care.
16323590|NCT04514263||Oral Biopsy|Patients with oral lesions undergoing diagnostic or therapeutic biopsies either for benign lesions or potentially malignant disorders or malignant lesions or salivary glands diseases.
16323591|NCT04514237|Experimental|Part 1: Regimens AB(CD)|Participants received 50 milligrams (mg) BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 1, followed by 50 mg BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
16323592|NCT04514237|Experimental|Part 1: Regimens BA(CD)|Participants received 50 milligrams (mg) BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 1, followed by 50 mg BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
16323593|NCT04514224||Healthy Start Program 1|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
16323594|NCT04514224||Community Health Center 1|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
16323595|NCT04514224||Healthy Start Program 2|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
16323596|NCT04514224||Community Health Center 2|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
16323598|NCT04514224||Community Health Center 3|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
16323599|NCT04514224||Healthy Start Program 4|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
16323600|NCT04514224||Community Health Center 4|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
16323601|NCT04514224||Healthy Start Program 5|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
16323602|NCT04514224||Community Health Center 5|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
16323603|NCT04514224||Healthy Start Program 6|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
16323604|NCT04514224||Community Health Center 6|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
16323605|NCT04514211||Propofol|General anesthesia using propofol infusion
16323606|NCT04514211||Sevoflurane|General anesthesia using sevoflurane
16323607|NCT04514185|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
16323608|NCT04514185|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
16323609|NCT04514172|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
16323610|NCT04514172|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
16323611|NCT04514159|Experimental|ZN-c5 + abemaciclib combination therapy|Participants will take abemaciclib (150mg) orally twice a day and ZN-c5 (dose escalation) orally once or twice a day to determine the safety, tolerability, and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D).
16323612|NCT04514146||Water-only Fasting Group|Overweight and obese, non-diabetic participants undergoing elective water-only fasting treatment
16323613|NCT04514133|Experimental|Action Civics program|Students in this arm will take part in an Action Civics (AC) program. AC delivers action civics programming to young people from diverse backgrounds nationwide. AC offers a school-based action civics curriculum in which classes collectively choose a local issue, learn strategies and skills for taking civic action, develop an action plan, and take action on their selected local issue. Students, as a class, tackle topics ranging from health-related (e.g., health of school lunches) to safety-related (e.g. lack of crosswalks) to community social issues (e.g., community-police relations).
16323614|NCT04514133|No Intervention|No Action Civics program|Students in this arm will receive no intervention.
16323615|NCT04514120|Experimental|Stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and/or with Allergic Fungal Rhinosinusitis and stable condition
16323616|NCT04514120|Experimental|Non-stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and with Allergic Fungal Rhinosinusitis who are experiencing an exacerbation
16323617|NCT04514107|Active Comparator|Control|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD). n=1740
16323618|NCT04514107|Experimental|Intervention|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD) and Wolbachia-infected Aedes aegypti (wMel) mosquitoes. n=1740
16323619|NCT04514094|Experimental|Silver Diamine Fluoride|"Gross debris will be removed with cotton pellets to allow better SDF contact with denatured dentin.
~Cotton rolls will be used to protect surrounding gingival tissues and mucous membranes to avoid pigmentation or irritation.
~Affected tooth surfaces will be dried with a gentle flow of air.
~1-2 drops only of SDF will be used for the whole visit.
~SDF will then be directly applied to affected tooth surfaces only using a micro sponge brush.
~At least one minute will be needed to allow drying of SDF.
~Excess SDF will finally be removed with cotton rolls to minimize systemic absorption.
~When possible, isolation will be continued for up to three minutes.
~After 2-4 weeks: reapplication will be done only to lesions that do not appear arrested (dark and hard)."
16323620|NCT04514094|Active Comparator|Atraumatic Restorative Treatment|"Caries removal by hand instruments with care not to expose the pulp.
~Maximum excavation from the periphery of lesions will be done, to minimize leakage at the restoration margins.
~Cotton roll isolation will then be carried out.
~Cavities will be restored by glass ionomer cement.
~Hand pressure should be applied by a gloved and petroleum jelly coated finger, then, excess material will be removed."
16323621|NCT04514081|Experimental|Chidamide+Decitabine+Camrelizumab|
16323622|NCT04514081|Active Comparator|Decitabine+Camrelizumab|
16323623|NCT04514068|Experimental|Unilateral electroacupuncture of p6 acupoint|
16323624|NCT04514068|Experimental|Bilateral electroacupuncture of p6 acupoint|
16323625|NCT04514068|Sham Comparator|Sham acupuncture of p6 acupoint|
16323626|NCT04514055|Experimental|De-epithelialized connective tissue graft wall|"Simplified papilla preservation flap will be applied in the narrow interproximal spaces (≤2 mm), where an oblique incision starting from the gingival margin at the buccal-line angle of the involved tooth reaching the mid-interproximal portion of the papilla under the contact point of the adjacent tooth will be performed using a 15c blade.
~A free gingival graft will be obtained from the hard palate and de-epithelized extra-orally.
~A Coronally advanced flap will be performed. The de-epithelialized FGG will be sutured coronally using a 6-0 vicryl suture to the anatomical papillae of the two teeth adjacent to the defect and apically to the periosteum left in place apical to the exposed bone.
~The flap will be sutured using internal Horizontal mattress suture at the base of the simplified papilla and a vertical mattress suture will be placed in a more coronal position so complete soft tissue closure can be obtained."
16323627|NCT04514042|Active Comparator|Standard procedure|Patients with Zenker's diverticulum treated with flexible endoscopy septotomy.
16323628|NCT04514042|Experimental|Investigational procedure|Patients with Zenker's diverticulum treated with peroral endoscopic myotomy.
16323629|NCT04514029|Experimental|Simvastatin and Dexamethasone|Simvastatin 40 mg/day will be started at least 5 days prior to apheresis and will be continued until day +30 after infusion. Intrathecal dexamethasone 8 mg will be administered on days (related to CAR-T infusion) -1, +6, +13, (+/- 2 days).
16323630|NCT04514016||HIV positive participants with positive COVID-19 results|Participants in this group will have a RT-PCR and Coronavirus Disease (COVID) -19 specific antibody testing at baseline, 1 month and 3 month visits.
16323631|NCT04514016||HIV positive participants with negative COVID-19 results|Participants in this group will have a RT-PCR and COVID-19 specific antibody testing at baseline only.
16323632|NCT04514003||SARS-CoV-2 PCR positive cases|Antibody tests will be performed every 6 months for 2 years
16323633|NCT04514003||SARS-CoV-2 PCR negative cases|Antibody tests will be performed at baseline
16323634|NCT04514003||Population controls|A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
16323635|NCT04513990|Experimental|Diagnostic (biospecimen collection)|Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.
16323636|NCT04513977|No Intervention|Usual care|For older adults with cancer with G8 score 14 or less. Randomized to usual oncology care.
16323637|NCT04513977|Experimental|Geriatric Oncology Supportive Clinic|For older adults with cancer with G8 score 14 or less. Randomized to attend Geriatric Oncology Supportive Clinic
16323638|NCT04513964||Control|Patient not suffering from COVID-19
16323639|NCT04513964||COVID-19|Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
16323640|NCT04513951|Experimental|mFOLFOXIRI + Cetuximab + Avelumab|"Avelumab, 800 mg intravenous [IV] dose over 60 minutes, day 1, followed by
~Cetuximab, 500 mg/m2 IV dose over 2 hours at cycle 1 (if well tolerated, it is administered over 90 minutes at cycle 2 and over 60 minutes by cycle 3), day 1, followed by
~Irinotecan 150 mg/ m2 IV dose over 60 minutes day 1, followed by
~Oxaliplatin 85 mg/m2 IV dose over 2 hours, day 1 in two-way with
~L-Leucovorin 200 mg/ m2 IV dose over 2 hours, day 1 followed by
~5-fluoruracil 2400 mg/m2 IV dose 48 h-continuous infusion, starting on day 1; to be repeated every 14 days for a maximum of 12 cycles. If no progression occurs during the induction treatment, patients will receive maintenance with 5-FU/LV plus cetuximab and avelumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus cetuximab and avelumab will be repeated biweekly until disease progression, unacceptable toxicity, patient's refusal or consent withdrawal."
16323641|NCT04513925|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
16323642|NCT04513925|Active Comparator|Durvalumab|Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.
16323645|NCT04513899|Experimental|Community Health Worker/Registered Nurse (CHW/RN)|Nurse-led Community Health Worker (CHW/RN) program delivered DOT for HCV treatment.
16323646|NCT04513899|Active Comparator|Clinic-based Standard of Care (cbSOC)|Standard of care for HCV treatment delivered by a clinic-based MD or clinic-based NP at the clinic site
16323647|NCT04513886|Active Comparator|Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes, a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate.
16323648|NCT04513886|Experimental|no Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique, collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes no suture was performed.
16323649|NCT04513873|Experimental|Equipment Intervention Group|"The intervention group had equipment that looks like a blood tube in front of them during the blood collection process to divert their attention from the blood collection process to the equipment. This equipment was with a fixed arm on the right and a moving arm on the left with a total height of 80 cm as well as a red light-emitting diode(LED) to stimulate the blood collection. It had some answers to common questions of parents as well as the key concerns of the children like  Will it hurt me?. The equipment was made a musical device by loading the most popular children's songs into its database."
16323650|NCT04513873|No Intervention|No Intervention Group|Standard blood collection procedures were applied to the control group.
16323651|NCT04513847||Control|Psoriasis patients treated with non-biologic
16323652|NCT04513847||Non-Control|Psoriasis patients treated with biologic
16323653|NCT04513834|Experimental|Multi-faceted intervention|Patient education material on PPI deprescribing will be sent to the patients and their general practitioner (GP) will receive an educational outreach visit by a Delegue d'Assurance Maladie (DAM, healthcare representative )
16323654|NCT04513834|Active Comparator|Educational outreach visit to GPs|GP will receive the educational outreach visit by a DAM (healthcare representative). Their patients will not receive any patient education material.
16323655|NCT04513834|No Intervention|Control|Neither the patients nor their GP will receive any information.
16323656|NCT04513808|Active Comparator|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.
16323657|NCT04513808|Active Comparator|Sevoflurane intravenous anesthesia|Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary
16323659|NCT04513756|Experimental|Active Treatment Group|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques.
16323660|NCT04513756|No Intervention|Treatment As Usual Group|CRA comprising of nine sessions will not be provided to this group. However, patients who will be already receiving treatment from any psychiatric or some other rehabilitation facility will be advised to continue their routine treatment.
16323661|NCT04513743|Experimental|Healthy adults|UNEEG™ medical 24/7 EEG™ SubQ
16323662|NCT04513730|Experimental|pelvic suspension device|A device will be built with the function of keeping the user in position of pelvic suspension promoting lumbar traction that will consist of a structure of pvc pipes and connections and padded material.
16323663|NCT04513717|Active Comparator|RT + ADT for 24 months (De-Intensification)|Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.
16323664|NCT04513717|Experimental|RT + ADT for 12 months (De-Intensification)|Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity.
16323665|NCT04513717|Active Comparator|RT + ADT for 24 months (Intensification)|Patients undergo RT over 4-9 weeks and receive ADT as in Arm I.
16323666|NCT04513717|Experimental|RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)|Patients undergo radiation therapy over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide, abiraterone acetate and prednisone PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
16323667|NCT04513704|Experimental|Oral Semaglutide A|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 2 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
16323668|NCT04513704|Experimental|Oral Semaglutide B|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 4 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
16323669|NCT04513704|Experimental|Oral Semaglutide C|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 6 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
16323670|NCT04513704|Experimental|Oral Semaglutide D|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-dose fasting time of 2 hours followed by a post-dose overnight fast.
16323671|NCT04513704|Active Comparator|Oral Semaglutide E|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days). Participants will be instructed to take the trial product in the morning after an overnight fast and wait 30 minutes before taking any food, water or other oral medication in accordance with the approved dosing schedule for oral semaglutide.
16323672|NCT04513691||Sample|Asymptomatic newborns 35 weeks or greater GA born at Banner - University Medical Center Phoenix whose mothers were determined or suspected to have CAM.
16323673|NCT04513678|Experimental|ImmunOncoTool Condition|The ImmunOncoTool condition includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention.
16323674|NCT04513678|No Intervention|Control|Participants in the control condition are not assigned an intervention. They receive standard of care.
16323675|NCT04513665|Experimental|Stage 1|Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants.
16323676|NCT04513665|Experimental|Stage 2|If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy.
16323677|NCT04513652|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
16323678|NCT04513652|Placebo Comparator|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
16323679|NCT04513639|Experimental|Arm A|Patients will be followed with MRD assessment every 4 month and start 2.L treatment at loss of MRD negative complete response.
16323680|NCT04513639|Active Comparator|Arm B|Patients will be followed up by standard criteria and start 2.L treatment at progressive disease.
16323681|NCT04513626|Other|Delayed switch|the maintaining of their current ART followed by a switch to doravirine/raltegravir at W48 (delayed switch group).
16323682|NCT04513626|Experimental|Immediate switch|Immediate switch to doravirine/raltegravir
16323683|NCT04513613||Subjects with a clinical indication for PVI|Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).
16323684|NCT04513587|Experimental|CBT-Based Weight Loss Model|CBT- Based weight loss model
16323685|NCT04513587|Active Comparator|Control|Usual Care
16323686|NCT04513548|Experimental|Ligelizumab|
16323687|NCT04513548|Placebo Comparator|Placebo|
16323688|NCT04513535|Experimental|manual therapy combination 1|Cervical manipulation, Thoracic manipulation
16323689|NCT04513535|Experimental|manual therapy combination 2|Cervical manipulation, glenohumeral mobilization
16323696|NCT04513483|Experimental|CPAP treatment for 12 months|CPAP treatment for 12 months
16323697|NCT04513483|Placebo Comparator|Placebo|observation
16323698|NCT04513470|Experimental|COVID-19|Five subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
16323699|NCT04513457||Liver resection and Neoadjuvant chemotherapy|Liver resection and Neoadjuvant chemotherapy
16323700|NCT04513457||Liver resection and Adjuvant chemotherapy|Liver resection and Adjuvant chemotherapy
16323701|NCT04513457||Liver resection, Neoadjuvant and Adjuvant chemotherapy|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy
16323702|NCT04513457||Liver resection|Liver resection
16323703|NCT04513444|Other|Standard arm (A): music listening therapy|
16323704|NCT04513444|Experimental|Experimental arm (B): music listening and hypnosis therapy|
16323705|NCT04513431|Experimental|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
16323706|NCT04513418|Experimental|Interventional group|Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion from the start of neoadjuvant chemoradiotherapy until surgery. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.
16323707|NCT04513418|No Intervention|Control group|Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.
16323708|NCT04513405|Other|subjects with skin tears (Group A)|"A sample of peripheral venous blood will be taken to measure the levels of estrone and estradiol.
~A skin biopsy on the intact skin area near the skin tear will be performed."
16323709|NCT04513405|Other|subjects without skin tears (Group B)|"A sample of peripheral venous blood will be taken to measure the levels of estrogen.
~A skin biopsy (thin layer) on the intact skin area of the arm will be performed in order to evaluate skin estrogen receptors."
16323710|NCT04513392|Active Comparator|KTP laser treatment|All participants will complete a paper Voice Handicap Index-10 (VHI-10) questionnaire and laryngeal stroboscopy examination at baseline. Local anesthesia will be administered as per standard of care for in-office laryngeal procedures. KTP laser will be utilized to ablate the lesion of interest. Immediately following the procedure, participants will complete a VAS pain scale on paper. Participants will be asked to exercise 3 days of absolute voice rest following the procedure. All patients will have follow-up clinic appointments on POD 7, POD 30, and POD 90 after surgery. At each of the follow-up visit, the patients will fill out a paper VHI-10 questionnaire and undergo stroboscopic examination to assess vocal fold vibratory properties and closure, as well as residual lesions. During the first week post procedure, the participants will continue to complete a daily VAS at home for pain assessment.
16323711|NCT04513392|Experimental|BL laser treatment|The only difference in study procedures between the experimental arm and the control arm is that the experimental arm will use the BL laser. The post-operative instructions and follow-up schedule are identical.
16323712|NCT04513379|Experimental|Trial|EFV 400mg
16323713|NCT04513379|Active Comparator|Control|EFV 600mg
16323714|NCT04513366|Experimental|SEL-212A|"SEL-212A Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)
~Other Names:
~Pegadricase, pegsiticase Drug: SEL-110.36 (0.1 mg/kg) SEL-110.36, ImmTOR"
16323715|NCT04513366|Experimental|SEL-212B|"SEL-212B Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)
~Other Names:
~Pegadricase, pegsiticase Drug: SEL-110.36 (0.15 mg/kg) SEL-110.36, ImmTOR"
16323716|NCT04513366|Placebo Comparator|Placebo|Normal saline
16323717|NCT04513353|Experimental|Digital Healthcare System Rehabilitation|
16323718|NCT04513353|Active Comparator|Conventional Rehabilitation|
16323719|NCT04513340|Experimental|Treatment A|Treatment A will be given under fed conditions by intra-oral single dose administration
16323720|NCT04513340|Experimental|Treatment B|Treatment B will be given intra-orally and orally under fed conditions by single dose administration
16323721|NCT04513340|Experimental|Treatment C|Treatment C will be given orally under fed conditions by single dose administration
16323722|NCT04513340|Experimental|Treatment D|Treatment D will be given orally under fasting conditions by single dose administration
16323723|NCT04513327|Experimental|Digital Healthcare System Rehabilitation|
16323724|NCT04513327|Active Comparator|Conventional Rehabilitation|
16323727|NCT04513301|Active Comparator|Sintilimab alone|Sintilimab (200 mg q3w ×2cycle)
16323728|NCT04513301|Experimental|Sintilimab+Radiotherapy|Sintilimab (200 mg q3w ×2cycle)+RT 50-60Gy/25-30f
16323729|NCT04513288|Experimental|Experimental group|Enteral administration of citrulline for 5 days. L-citrulline (Protéocit®). This commercial form consists only of L-citrulline. Each patient will receive 10 grams per day in 2 doses (1 stick/ 12H = 5 grams / 12H). These sticks contain a powder to be resuspended in 50 mL of water for injection (ppi) for 1 stick. They will be delivered in a 50 mL syringe allowing administration of the product through the nasogastric tube. The solution will be prepared just before administration.
16323730|NCT04513288|Placebo Comparator|Control group|Enteral administration of iso-nitrogenous placebo for 5 days. The placebo used will consist of a mixture of 4 non-essential amino acids. 5 g of L-citrulline provides 1.2 g of nitrogen. For the mixture to be iso-nitrogenous, each of the 4 amino acids will need to provide 0.3 g of nitrogen. The mixture will therefore consist of 21.6% alanine, 32.3% aspartate, 18.2% glycine and 27.9% proline for a total of 8.83 g of amino acids per sachet. 2 administrations (2 sticks) daily for 5 days.
16323731|NCT04513275||schizophrenia patient group|Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years
16323732|NCT04513262||Video-assisted surgery|Patients undergoing video-assisted major abdominal surgery (VAS) in Trendelenburg position. The decision regarding the type of VAS was made by the attending surgeon prior to study inclusion. Twenty-five consecutive patients undergoing classic laparoscopic surgery and twenty-five patients undergoing robotic-assisted surgery will be included in the study.
16323733|NCT04513236|No Intervention|Control|No Airtime Incentive was given for completing the survey
16323734|NCT04513236|Experimental|Pre-survey incentive|0.1X incentive before the survey, 1X afterwards
16323735|NCT04513236|Experimental|Post-survey incentive|1X incentive after the survey
16323736|NCT04513223|Experimental|SHR-A1811|
16323737|NCT04513210||Changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital with changes in the ultrasound on admission, suggesting pneumonia.
16323738|NCT04513210||No changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital without changes in the ultrasound on admission, suggesting pneumonia.
16323739|NCT04513184|Active Comparator|Standard therapy (ST) only|Control. Standard care and treatment only
16323740|NCT04513184|Experimental|DXM|Nasal dexamethasone plus Standard care and treatment
16323741|NCT04513171|Experimental|Y-shape pegylated somatropin low dose|
16323742|NCT04513171|Experimental|Y-shape pegylated somatropin middle dose|
16323743|NCT04513171|Experimental|Y-shape pegylated somatropin high dose|
16323744|NCT04513171|Active Comparator|Norditropin-1|
16323745|NCT04513171|Experimental|Y-shape pegylated somatropin optimal dose|
16323746|NCT04513171|Active Comparator|Norditropin-2|
16323747|NCT04513158|Experimental|Treatment Arm|Study is single arm all patients hospitalized meeting inclusion/exclusion criteria and providing informed consent to receive one unit (approximately 200 mL) of convalescent plasma with data collected daily on routine (non-research) clinical assessments/physical exams and lab results.
16323748|NCT04513145|Experimental|Treatment Group (Ropivacaine)|The treatment group will consist of patients undergoing total knee arthroplasty who receive standardized 100 cc periarticularinjection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients will then receive 10cc of ropivacaineinto their adductor canal.This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
16323749|NCT04513145|Placebo Comparator|Control Group (Saline)|The control group will consist of patients undergoing total knee arthroplasty who receive a standardized periarticular injection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients randomized in this group will then receive 10cc of saline into their adductor canal. This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
16323750|NCT04513132|Active Comparator|active-CHR|Participants will be intervened with deep transcranial magnetic stimulation (dTMS).
16323751|NCT04513132|Sham Comparator|sham-CHR|Participants, as a control group, will receive sham stimulation.
16323752|NCT04513106|Experimental|Advance care planning programme|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
16323753|NCT04513106|Placebo Comparator|Attention control|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
16323754|NCT04513093|Experimental|İntervention Group|"The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
~The Bristol Stool Scale and Constipation Severity Scale were re-applied to the individuals in the intervention before, during the second week of practice and at the end of practice (fourth week)."
16323755|NCT04513093|No Intervention|Control Group|"No application was applied to the individuals in the control group. Bristol Stool Scale and Constipation Severity Scale were applied to the individuals in the control group at the same time as (at the beginning, second week and fourth week) the intervention group."
16323756|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
16323757|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
16323758|NCT04513080|Experimental|Phase 1, Level 2: MBP with weekly VCP|Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).
16323759|NCT04513080|Experimental|Phase 1 Level 2: MBP with monthly VCP|Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).
16323760|NCT04513080|Experimental|Phase 2 Level 1: Message-Based Psychotherapy (MBP)|Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.
16323761|NCT04513080|Experimental|Phase 2, Level 1: Video-Chat Psychotherapy (VCP)|Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.
16323762|NCT04513080|Experimental|Phase 2, Level 2: MBP with monthly VCP|"Phase 2: This intervention will serve as the switch arm for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist."
16323763|NCT04513080|Experimental|Phase 2, Level 2: MBP with weekly VCP|Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
16323764|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
16323765|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
16323766|NCT04513067|Experimental|Stage 1: Single agent|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels of 20, 30, 60, 90 and 120 mg/kg will be evaluated.
16323767|NCT04513067|Experimental|Stage 2: Combination Therapy|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels from 20 mg/kg to the MTD obtained from Stage 1 in combination of a fixed dose of 200 mg intravenous pembrolizumab given on the same day following YQ23 administration and every 3 weeks thereafter.
16323768|NCT04513054|Other|Takotsubo Case Arm|A patient that has been diagnosed with Takotsubo Cardiomyopathy from 2010 onwards.
16323769|NCT04513041|Experimental|Pinhole/Tunnel|Participants will receive Pinhole surgical technique for treatment of soft tissue recession at one side of the mouth and Tunnel technique for treatment of soft tissue recession at the other side of the mouth
16323770|NCT04513028|Experimental|Treatment|"All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.
~Pembrolizumab: 200 mg/100mL IV in three week intervals
~Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days"
16323771|NCT04513015|Experimental|Antioxidant diet|Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment
16323772|NCT04513015|Active Comparator|Normal diet|Group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex).
16323773|NCT04513002|Other|Group 1: Triheptanoin and no Placebo|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.
~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.
~Group 1: 10%, 20%, 30%, 30%, 30% (no placebo). Group 2: placebo, 10%, 20%, 30%, 30% Group 3: placebo, placebo, 10%, 20%, 30%"
16323774|NCT04513002|Other|Group 2: Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.
~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.
~Group 1: 10%, 20%, 30%, 30%, 30% (no placebo). Group 2: placebo, 10%, 20%, 30%, 30% Group 3: placebo, placebo, 10%, 20%, 30%"
16323775|NCT04513002|Other|Group 3: Placebo, Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.
~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.
~Group 1: 10%, 20%, 30%, 30%, 30% (no placebo). Group 2: placebo, 10%, 20%, 30%, 30% Group 3: placebo, placebo, 10%, 20%, 30%"
16323776|NCT04512989||Patients undergoing cardiac surgery|
16323777|NCT04512976|Experimental|24 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
16323778|NCT04512976|Experimental|30 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
16323779|NCT04512976|Experimental|38 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
16323780|NCT04512963|Experimental|SAD Phase including Food Interaction|Single Ascending Dose (SAD) study with up to 6 cohorts + Food interaction phase on two cohorts
16323781|NCT04512963|Experimental|MAD Phase|Multiple Ascending Dose (MAD) study with up to 2 cohorts
16323782|NCT04512950|Active Comparator|Ringer's lactate|administered as infusions or boluses as per the treating physician
16323783|NCT04512950|Active Comparator|0.9% Saline|administered as infusions or boluses as per the treating physician
16323784|NCT04512937|Experimental|All patients|All patients will be subjects to the intervention of computer navigation-assisted surgery
16323785|NCT04512924|Active Comparator|Group 1|
16323786|NCT04512924|Experimental|Group 2|
16323787|NCT04512911|Active Comparator|Patients who didn't fail AAD|This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications
16323788|NCT04512911|Active Comparator|Patients who failed AAD|This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation
16323789|NCT04512898|Experimental|Patient with IBS|Patients with IBS and positive H. pylori.
16323790|NCT04512885||Patients with type 1 diabetes|
16323791|NCT04512885||Health professionals|
16323792|NCT04512872|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in PFS
16323793|NCT04512872|Active Comparator|EU-approved Prolia|60 mg/mL single dose administration, Solution for injection in PFS
16323794|NCT04512859|Experimental|Stellate Ganglion Block|"Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.
~Patients were then assessed using transcranial Doppler"
16323795|NCT04512859|Placebo Comparator|No Stellate Ganglion Block|"patients will receive a stellate ganglion block with 0.9% saline 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.
~Patients were then assessed using transcranial Doppler"
16323796|NCT04512846||CK-SBRT with TACE group|The hepatocellular carcinoma patients (5-10cm）who received SBRT with TACE.
16323797|NCT04512846||CK-SBRT group|The hepatocellular carcinoma patients (5-10cm）who received SBRT alone.
16323798|NCT04512820|Experimental|TRUCLEAR TREATMENT|patients up to 10 weeks of gestation with missed miscarriage undergoing evacuation of products of conception using the TRUCLEAR tissue removal system under direct hysteroscopic visualization
16323799|NCT04512794|Other|Non-randomized|All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
16323800|NCT04512781|Active Comparator|Conventional Legacy Cannula Design (Control)|During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.
16323801|NCT04512781|Experimental|Cannula Design Test #1 (Randomized)|During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
16323802|NCT04512781|Experimental|Cannula Design Test #2 (Randomized)|During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
16323803|NCT04512768|Active Comparator|Standard ICBT|Participants in the Standard ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia.
16323804|NCT04512768|Experimental|Sleep-Enhanced ICBT|Participants in the Sleep-Enhanced ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. In addition, participants in the Sleep-Enhanced ICBT condition will also receive a newly developed lesson designed to target insomnia.
16323805|NCT04512742|Other|Leishmania infected-Phlebotomus duboscqi human challenge|There is no clear indication in the medical literature to determine which of the major sand fly vectors of Leishmania major - Phlebotomus papatasi or Phlebotomus duboscqi, will be most effective at transmitting infection to a human host. Both species have a similar mode of feeding and can support L. major development. In our previous study, FLYBITE, no significant difference in biting rates on humans was observed. Based on pre-clinical data , Phlebotomus duboscqi was determined to be the lead candidate for use in this study. If all the 6 participants have developed lesions within the 6-month follow up after Leishmania challenge, the challenge phase of the study is completed. If only 5 participants have developed lesions, then a further 6 participants will undergo Leishmania challenge by P. duboscqi. If only 4 or less subjects in the first cohort develop lesions, then the investigators will switch vector to P. papatasi and a further 6 subjects will undergo Leishmania challenge.
16323806|NCT04512716|Experimental|B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell Lym|Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
16323807|NCT04512703||Healthy Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
16323808|NCT04512703||Arrhythmia Monitoring Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
16323809|NCT04512703||Front Position Devices|All devices placed in the front position
16323810|NCT04512703||Side Position Devices|All devices placed in the side position
16323811|NCT04512690|Experimental|Epidural electrical stimulation of the cervical spinal cord|Individuals with prior subcortical stroke and hemiparesis of the upper extremity.
16323812|NCT04512677|No Intervention|No Interventions: Control|Conventional clinical treatment and using the ventilatory weaning protocol and standard extubation with the spontaneous breathing test (SBT) with the T-piece in 30 minutes.
16323813|NCT04512677|Experimental|Experimental: Intervention|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
16323814|NCT04512664|Active Comparator|short term group|cold treatment for 4 hours
16323815|NCT04512664|Experimental|long term group|cold treatment for 48 hours
16323816|NCT04512651|Experimental|Intervention Group (IG)|The GI dancers, submitted to tibiotarsal thrust manipulation
16323817|NCT04512651|Sham Comparator|Control Group (CG)|For the CG was performed the simulation of the technique, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
16323818|NCT04512638|Active Comparator|Conservative treatment|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minor debridement. Primary wound closure is not part of this treatment strategy.
16323819|NCT04512638|Experimental|Minimally invasive approach + LPRF|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
16323820|NCT04512638|Experimental|Primary surgical management|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
16323821|NCT04512625|No Intervention|Control group|Sensitivity level scores were evaluated on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation.
16323842|NCT04512469|Experimental|Treatment Group - Mesh|The treatment group will undergo standard running fascial closure with PDS plus a low molecular weight mesh extending 3 cm from the fascial incision.
16323843|NCT04512456|Experimental|Active HIV-infected patients|Exercise training
16323822|NCT04512625|Experimental|Group GL (Gluma desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
16323823|NCT04512625|Experimental|Group SF (SheildForce desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
16323824|NCT04512625|Experimental|Group TS (Telio CS desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
16323825|NCT04512612|Active Comparator|Dye based Chromoendoscopy|The patients enrolled in this group will undergo pan-colonic chromoendoscopy evaluation.
16323826|NCT04512612|Active Comparator|High Definition White Light Endoscopy|The patients enrolled in this group will undergo high definition white light endoscopy based evaluation
16323827|NCT04512599|Experimental|Single Arm|Open-label consumption of prebiotic bar(s); 1 bar for 3 days; followed by 2 bars for 7 days
16323828|NCT04512586|Experimental|His-pacing plus AV node ablation|"A His-pacing lead in combination with a backup RV pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. A standard DDD pacemaker or CRT-P device from Medtronic will be used.
~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed."
16323829|NCT04512586|Active Comparator|Pulmonary vein isolation|Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.
16323830|NCT04512560|Experimental|Structured Remote Surgical Coaching|Participants randomized to the intervention group will participate in a 3-month SRSC program in addition to CST. Participants will be asked to provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon prior to the coaching session. Each coach will review the video recording and will identify key themes for discussion. Coaching sessions will be structured using the modified PRACTICE model, will be conducted outside of the clinical environment, and will employ facilitative coaching methods to encourage participants to define specific intra-operative problems and conceptually troubleshoot various solutions.
16323831|NCT04512560|Active Comparator|Conventional Surgical Training|Participants randomized to the control group will continue of their usual general surgery residency training including attending scheduled teaching sessions, and continuing with assigned responsibilities on the ward and in the OR.
16323832|NCT04512547|Experimental|Obese Asthmatics|Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
16323833|NCT04512547|Active Comparator|Obese Non-Asthmatics|The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.
16323834|NCT04512534|Experimental|Sinitilimab+Chidamide|Anti-PD-1 antibody Sintilimab 200mg intravenously every 3 weeks; HDAC inhibitor Chidamide 30mg orally twice every week
16323835|NCT04512521||eosinophilic asthma|
16323836|NCT04512508|Other|Group 1, HIV negative patients.|Only HIV negative patients
16323837|NCT04512508|Other|Group 2, HIV positive patients|Only HIV positive patients
16323838|NCT04512495|Other|Patients with sarcoma|
16323839|NCT04512482|Experimental|Experimental: Bromelain, Then Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
16323840|NCT04512482|Placebo Comparator|Experimental: Placebo, Then Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the bromelain rinse, following the same protocol and series of intraoral photographs.
16323841|NCT04512469|No Intervention|Control Group|The control group will undergo standard running fascial closure with PDS .
16323844|NCT04512456|No Intervention|Inactive HIV-infected patients|No intervention.
16323845|NCT04512456|No Intervention|Healthy subjects|No intervention.
16323846|NCT04512443||1|42 women (treated with Daflon 1000 mg (study group))
16323847|NCT04512443||2|41 women (placebo (control group))
16323848|NCT04512430|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment: (Atezolizumab: 1200 mg, IV infusion+Bevacizumab: 15mg/Kg mg, IV infusion+Carboplatin: AUC6, IV infusion+Pemetrexed: 500 mg/m2, IV infusion) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery.Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3).
~Adjuvant treatment: Atezolizumab: 1200 mg, IV infusion Q4W (+/- 3 days) for 6 months (6 cycles) Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+7 days) from surgery and for 6 months (6 cycles)."
16323849|NCT04512417|Experimental|Combined radiotherapy group|
16323850|NCT04512417|Experimental|Immunotherapy alone group|
16323851|NCT04512404||hypercholesterolemia|"3-hydroxy-3-methylglutaric acid coenzyme A (HMG Co-A) reductase inhibitor Types of drug, dosage and frequency is according to the treating physician. This is an observational study.
~Duration of treatment: 3-5 months"
16323852|NCT04512391||Erector Spinae|patients who are administered ultrasound guided ESPB at T4 vertebrae level with long acting local anesthetic (%0,25 bupivacaine) and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
16323853|NCT04512391||Control|patients who are not administered any regional analgesic technique and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
16323854|NCT04512378|Experimental|IU Group Treatment|Clinical intervention arm
16323855|NCT04512365|Placebo Comparator|Placebo oral capsule|Participants will receive a placebo at their first or second laboratory visit.
16323856|NCT04512365|Experimental|THC|Participants will receive THC (7.5 mg) at their first or second laboratory visit.
16323857|NCT04512352|Experimental|Treatment group|Online curriculum has been delivered to this group of participants on an Internet-based platform
16323858|NCT04512352|No Intervention|Wait-list control group|Participants in wait-list control group would not have access to the online curriculum until the intervention process for treatment group is finished.
16323859|NCT04512339|Active Comparator|Dupilumab|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive dupilumab injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
16323860|NCT04512339|Placebo Comparator|Placebo|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive placebo injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
16323861|NCT04512326||Total or subtotal colectomy|Total or subtotal colectomy with ileorectal or ileosigmoid anastomosis
16323862|NCT04512313|Active Comparator|Group receiving rocuronium 0,3 mg/kg|Rocuronium 0,3 mg/kg at induction
16323863|NCT04512313|Active Comparator|Group receiving rocuronium 0,9 mg/kg|Rocuronium 0,9 mg/kg at induction
16323864|NCT04512287|Experimental|Experimental: Autologous PRP followed by Placebo Group|Participants in this group will receive the autologous intervention first, followed by the placebo intervention 6 months later.
16323865|NCT04512287|Experimental|Experimental: Placebo followed by Autologous PRP Group|Participants in this group will receive the placebo intervention first, followed by the Autologous PRP intervention 6 months later.
16323866|NCT04512274|Experimental|Test Article|
16323867|NCT04512274|No Intervention|Negative Control|
16323868|NCT04512261|Experimental|Tucatinib + Pembrolizumab + Trastuzumab|Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
16323869|NCT04512248|Experimental|Quit and Stay Quit Monday Model|
16323870|NCT04512248|No Intervention|Usual Care|
16323871|NCT04512235|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 77 deaths have been observed.
16323872|NCT04512235|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 77 deaths have been observed.
16323873|NCT04512235|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) according to institutional SoC. Patients will have a planned first-line PCD treatment with a CyBorD regimen according to institutional SoC and initiate their PCD treatment within 7 days of receiving the first dose of study drug. Patients can refer to the package insert or Summary of Product Characteristics (SmPC) for contraindications, warnings and precautions for anti-PCD medications.
16323874|NCT04512209|Experimental|DCE-MRI|
16323875|NCT04512196|Experimental|Super-oxidised Solution|Peritoneal lavage with super-oxidised solution of at least 10 cc/kg and wound lavage with super-oxidised solution 1 cc/kg
16323876|NCT04512196|Placebo Comparator|Normal Saline|Peritoneal lavage with normal saline 0.9% of at least 10 cc/kg and wound lavage with normal saline 0.9% 1 cc/kg
16323877|NCT04512183|Experimental|High-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to high-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a reflective debriefing session.
16323878|NCT04512183|Active Comparator|Low-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to low-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a feedback session.
16323879|NCT04512170|Experimental|A single dose HEC585（pilot trial arm）|Healthy subjects receive a single dose of HEC585
16323880|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 1）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
16323881|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 2）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
16323882|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 3）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
16323883|NCT04512170|Experimental|Single dose of HEC585 （Part 2，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
16323884|NCT04512170|Experimental|two-period study at 400 mg dose group (part 3，Fed)|Healthy subjects receive Single/multiple doses of HEC585 or matching placebo in two cycles.
16323885|NCT04512157|Experimental|PATHS, Intervention preschools|These preschools implement PATHS for one school year
16323886|NCT04512157|No Intervention|Waitlist control preschools|Preschool as usual, which does have some social emotional learning but not PATHS specifically
16323887|NCT04512144|Experimental|Intervention|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a three month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
16323888|NCT04512144|No Intervention|Control|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
16323889|NCT04512131||Intermittent hemodialysis|patients who are going to undergo intermittent hemodialysis or patients who are going to switch dialysis mode to intermittent hemodialysis from continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate® platelet function analysis will be checked just before dialysis initiation and immediately after dialysis termination
16323890|NCT04512131||continuous renal replacement therapy|patients who are going to undergo continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate platelet function analysis will be checked within 24 hours after dialysis initiation and 48 hours after taking first blood sample
16323891|NCT04512105|Experimental|Dose Level -1 (DL-1)|"Patients receive Pitavastatin (PIT) 1 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.
~The 1 mg/day dose level will be held in reserve to allow dose reduction in those patients who cannot tolerate DL1."
16323892|NCT04512105|Experimental|Dose Level 1 (DL1)|"Patients receive Pitavastatin (PIT) 2 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.
~This is the starting dose level for the study."
16323893|NCT04512105|Experimental|Dose Level 2 (DL2)|"Patients receive Pitavastatin (PIT) 4 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.
~If DL1 is well tolerated, the next cohort will progress to this dose level."
16323894|NCT04512092|Experimental|CMT-C group|Compassion Mind Training for Caregivers (CMT-C) is a 12-session structured program to be delivered in a group format, aiming to cultivate a compassionate-self and compassionate care practices in residential youth care.
16323895|NCT04512092|No Intervention|Control group|This group did not receive any mind training or group intervention during the study.
16323896|NCT04512079|Active Comparator|Prophylactic Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
16323897|NCT04512079|Active Comparator|Full Dose Enoxaparin|Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
16323898|NCT04512079|Experimental|Apixaban|Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
16323903|NCT04512053|Experimental|TAS-303|
16323904|NCT04512053|Placebo Comparator|Placebo|
16323905|NCT04512040|Experimental|Yoga Dyads AD patients and Caregivers|Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
16323906|NCT04512027|Experimental|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class+Stand of care|Tablet chewed for 5 days along and given alongside standard of care
16323907|NCT04512027|No Intervention|Standard of Care|All patients will receive currently practiced standard of care medicines
16323908|NCT04512014||major liver surgery|Patients undergoing major liver surgery
16323909|NCT04512001|Experimental|MSB11456|
16323910|NCT04512001|Active Comparator|RoActemra®|
16323911|NCT04511988|Experimental|Experimental|blood sample (20 ml) and biopsy
16323912|NCT04511975|Experimental|IBI188 + azacitidine|Participants will receive IBI188 in combination with azacitidine
16323913|NCT04511962||Fast track group|Participants randomised to the fast track group will receive the pulmonary rehabilitation intervention 14 ± 7 days after randomisation.
16323914|NCT04511962||Wait list group|Participants randomised to the wait-list group will receive the pulmonary rehabilitation intervention 56 ± 7 days after randomisation.
16323915|NCT04511949|Other|No arm|No arm
16323916|NCT04511936|Active Comparator|i-Lumen AMD Active|
16323917|NCT04511936|Sham Comparator|i-Lumen AMD Sham|
16323918|NCT04511923|No Intervention|Standard Care|Standard care
16323919|NCT04511923|Experimental|Heparin|Standard care plus nebulised unfractionated heparin 25000 units every 6 hours for 10 days
16323920|NCT04511910||Early surgery Group 1|The surgery is performed within the first 3 days
16323921|NCT04511910||Early surgery Group 2|Surgery is performed between the fourth and seventh day
16323922|NCT04511910||Early surgery Group 3|Surgery is performed more than 7 days from the onset of symptoms
16323923|NCT04511897|Experimental|Experimental group|oral An'ningpai Enteric Soft Capsules (300 mg,three times daily) for 12 months.
16323924|NCT04511897|No Intervention|Control group|No experimental durgs used.
16323926|NCT04511858|Experimental|Running endurance|Athletes wiil run for 5 hours in a row.
16323927|NCT04511858|Experimental|Cycling endurance|Athletes wiil cycle for 5 hours in a row.
16323928|NCT04511845|Experimental|Dose escalation cohort of SPYK04|Patients will receive SPYK04 at escalated dose.
16323929|NCT04511845|Experimental|Expansion part in NSCLC, ovarian cancer and other solid tumors|Patients will receive SPYK04 at the recommended dose.
16323930|NCT04511832|Experimental|Acupuncture to NSAIDs|
16323931|NCT04511832|Experimental|NSAIDs to Acupuncture|
16323932|NCT04511832|Experimental|Combined both acupuncture and NSAIDs|
16323933|NCT04511819|Experimental|Losmapimod|COVID-19 patients with PCR confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 14 days.
16323934|NCT04511819|Placebo Comparator|Placebo|COVID-19 patients with PCR confirmation will receive Placebo twice daily given as two tablets per dose by mouth; for a total of 4 tablets daily for 14 days.
16323935|NCT04511806||Primary Subjects|Children (age 0-21) with a cancer predisposition syndromes (CPS).
16323936|NCT04511806||Relatives of Children with CPS|Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members.
16323937|NCT04511793|Experimental|Hepatic Artery Infusion (HAI)|The Medtronic Synchromed II pump with the Codman® Catheter will be used to create the investigational device. The Medtronic Synchromed II pump is a surgically implantable device that allows for the delivery of high doses of chemotherapy directly to the liver, in order to treat cancer. The device is surgically implanted into a subcutaneous pocket in the abdominal wall, and the catheter is inserted into the arterial system of the liver, allowing for chemotherapeutic delivery.
16323938|NCT04511780||Caregivers|• Caregivers (doctors senior and junior, nurses, aid nurses) involved in the staff (permanent or transient, full or partial time) of ICU patients during Covid-19 outbreak
16323939|NCT04511767||ASD group|the autism spectrum disorder group
16323940|NCT04511767||GDD group|the global developmental disorder group
16323941|NCT04511767||LD group|the language disorder group
16323942|NCT04511754|Experimental|Experiential Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the experiential training condition, the trainees will receive information about the skills with examples and will have opportunity to practice using short video clips of actors portraying clients. The trainees will be asked to respond to the short clips using the skills they learned. A trainer (a graduate student in clinical psychology) will pause and process the trainees' reactions after they respond to each practice video clip and will provide feedback to the trainees about their performance on the practice.
16323943|NCT04511754|Active Comparator|Standard Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the standard training condition, the trainee will receive a lecture about the skills including rationale and research background, examples, and opportunities to ask questions. The standard training condition will not include opportunities for practice or live discussion and feedback from the trainer.
16323944|NCT04511741||invasive mechanical ventilation|
16323945|NCT04511741||non invasive mechanical ventilation|
16323946|NCT04511728|Experimental|HSK3486|
16323947|NCT04511728|Active Comparator|Propofol|
16323948|NCT04511715|Active Comparator|Intravitreal Bevacizumab IVB group|
16323949|NCT04511715|Sham Comparator|undergo regular follow-up for Diabetic Retinopathy|
16323950|NCT04511702|Experimental|Pegloticase 60 Minute Infusion with methotrexate (MTX)|Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
16323951|NCT04511702|Experimental|Pegloticase 45 Minute Infusion with methotrexate (MTX)|Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
16323952|NCT04511702|Experimental|Pegloticase 30 Minute Infusion with methotrexate (MTX)|Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
16323953|NCT04511689||test group|bone grafting with gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
16323954|NCT04511689||control group|bone grafting with xenogenic deproteinized bone matrix mixed with autobone
16323955|NCT04511663|Active Comparator|intervention group|The intervention group received assertive community treatment, in which the team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers.
16323956|NCT04511663|Other|control group|The control group received basic public health services which is regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge.
16323957|NCT04511650|Experimental|Razuprotafib|
16323958|NCT04511650|Placebo Comparator|Placebo|
16323959|NCT04511637|Experimental|Test C: 15 mg ODT with water, then 15 mg film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
16323960|NCT04511637|Experimental|Test C: 15 mg film-coated tablet, then 15 mg ODT with water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
16323961|NCT04511637|Experimental|Test D: 15 mg ODT without water, then 15 film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
16323962|NCT04511637|Experimental|Test D: 15 mg film-coated tablet, then 15 mg ODT without water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
16323963|NCT04511624|Experimental|Cohort 1|IBI112 SC dose1
16323964|NCT04511624|Experimental|Cohort 2|IBI112 SC dose2
16323965|NCT04511624|Experimental|Cohort 3|IBI112 SC dose3
16323966|NCT04511624|Experimental|Cohort 4|IBI112 IV dose4
16323967|NCT04511624|Experimental|Cohort 5|IBI112 IV dose3
16323968|NCT04511624|Experimental|Cohort 6|IBI112 SC dose5
16323969|NCT04511624|Experimental|Cohort 7|IBI112 IV dose5
16323970|NCT04511611|Experimental|Test A: 10 mg ODT with water, then 10 mg film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
16323971|NCT04511611|Experimental|Test A: 10 mg film-coated tablet, then 10 mg ODT with water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
16323972|NCT04511611|Experimental|Test B: 10 mg ODT without water, then 10 film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
16323973|NCT04511611|Experimental|Test B: 10 mg film-coated tablet, then 10 mg ODT without water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
16323974|NCT04511598|Experimental|Bellus 3D Face Camera Pro|"Every single patient will be diagnosed using 3D imaging system Bellus 3D Face Camera Pro to be compared to the direct measurements obtained from direct anthropometry."
16323975|NCT04511598|Experimental|Planmeca ProMax 3D Proface|"Every single patient will be diagnosed using 3D imaging systems Planmeca ProMax 3D Proface to be compared to the direct measurements obtained from direct anthropometry."
16323976|NCT04511585|Experimental|GLMC experimental arm|GLMC experimental arm receiving a 24-month (6 weeks each year) multilevel and TPB-based program aiming to promote PA practice
16323977|NCT04511585|No Intervention|the control arm|the control arm that do not receive any intervention
16324014|NCT04511299|Experimental|Fish oil-enriched intravenous lipid emulsion|SMOFlipid 20%, given for 3 consecutive days with 1-4 g/kg/day.
16324015|NCT04511299|Active Comparator|Standard intavenous lipid emulsion|Lipofundin 20%, given for 3 consecutive days with 1-4 g/kg/day.
16323978|NCT04511572|No Intervention|Standard Care: burr hole surgery|Patients who have had burr hole evacuation for symptomatic chronic subdural hematomas will be followed in the outpatient clinic after hospital discharge at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
16323979|NCT04511572|Active Comparator|embolisation middle meningeal artery|Besides standard treatment those patient who are allotted to the intervention group will receive embolization of the middle meningeal artery until 72 hours after burr hole evacuation. After hospital discharge follow-up is at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
16323980|NCT04511559||chronic gastritis|This group will include 80 patients with chronic gastritis and the diagnoses will be based on the British Society of Gastroenterology guidelines.
16323981|NCT04511559||Moderate to severe atrophy/intestinal metaplasia/|This group will include 80 patients with Moderate to severe atrophy/intestinal metaplasia/ and the diagnoses will be based on British Society of Gastroenterology guidelines.
16323982|NCT04511559||gastric cancer|This group will include 380 patients with gastric cancer and the diagnoses will be based on British Society of Gastroenterology guidelines.
16323983|NCT04511546|Experimental|BPET Scan|
16323984|NCT04511533|Experimental|Treatment Arm|The recommended dosage of dacomitinib is 45 mg taken orally once a day at approximately the same time each day, until disease progression, participant refusal/lost to follow-up, or unacceptable toxicity occurs.
16323985|NCT04511520|Experimental|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
16323986|NCT04511520|Experimental|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
16323987|NCT04511520|No Intervention|Control|Standard follow-up at the participating heart center
16323988|NCT04511507||liver failure|patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption
16323989|NCT04511494|Active Comparator|OIT peanut|Children with peanut allergy receiving peanut OIT. Peanut challenge are done before randomization and one and three years after inclusion.
16323990|NCT04511494|No Intervention|Peanut avoidance|Children with peanut allergy not undergoing OIT peanut. Peanut challenge are done Before randomization and one and three years after inclusion.
16323991|NCT04511494|No Intervention|Healthy controls|Control Group with non-allergic, age-matched children. No challenges are performed in this group.
16323992|NCT04511481||platinum-resistant group|
16323993|NCT04511481||platinum-sensitive group|
16323994|NCT04511468|Experimental|Experimental Group|A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention
16323995|NCT04511468|Placebo Comparator|Control group|Placebo with standard healthy lifestyle intervention
16323996|NCT04511455|Experimental|Experimental|"Cabozantinib peroral 60 mg/day
~A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib.
~The study treatment will be limited to a maximum of 12 months (including interruptions)."
16323997|NCT04511442||Bariatric surgery|Women with obesity, with a bariatric surgery
16323998|NCT04511442||Control|Women with obesity, without a bariatric surgery
16323999|NCT04511429||Kidney transplant patients|Patients submitted to kidney transplantation.
16324000|NCT04511429||Liver transplant patients|Patients submitted to liver transplantation.
16324001|NCT04511429||Oncological patients|Oncological patients submitted to chemotherapy.
16324002|NCT04511416|Active Comparator|Intervention|Metformin
16324003|NCT04511416|Placebo Comparator|Placebo|Placebo
16324004|NCT04511390|Experimental|Transparent, reusable respirator|Transparent, reusable elastomeric respirator that has been designed to fit multiple different face sizes and shapes.
16324005|NCT04511377|Experimental|Digital Healthcare System Rehabilitation|Rehabilitation using Uincare Homeplus
16324006|NCT04511377|Active Comparator|Conventional Rehabilitation|Rehabilitation using Brochure
16324007|NCT04511364|Experimental|AGN1 treated patients|Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
16324008|NCT04511351|Experimental|RT+GDP+Chidamide|IMRT followed by GDP chemotherapy with chidamide during radiation and chemotherapy phase
16324009|NCT04511351|No Intervention|RT+GDP|IMRT followed by GDP chemotherapy without chidamide during radiation and chemotherapy phase
16324010|NCT04511338|Experimental|Circuit A|Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline
16324011|NCT04511338|Experimental|Circuit B|Circuit (B) includes dialyzer with Endexo and the Streamline bloodline
16324012|NCT04511325|Other|Potato Regimen Arm|All participants will be randomly assigned to receive the potato regimen daily for the 12-week treatment period, separated by a 2-week washout.The potato regimen (75 grams of baked white russet potato with the skin) and refined grain (100 grams of long grain white rice) regimen will be matched for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day.
16324013|NCT04511325|Other|Refined Grain Regimen Arm|All participants will be randomly assigned to the calorie-matched refined grain daily for the 12-week treatment period, separated by a 2-week washout.The refined grain (100 grams of long grain white rice) regimen will be matched to the potato regimen for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day. Long-grain boiled white rice also has a similar glycemic index to that of a baked white potato.
16324016|NCT04511286|Experimental|Internet-delivered exposure-based treatment|Eight weeks of therapist-guided exposure-based treatment delivered via the Internet.
16324017|NCT04511260|Experimental|VRF Treatment|"A treatment of the vaginal canal using the NuEra Tight VRF small area handpiece. A treatment of the introitus and vestibule using the NuEra Tight VRF small area hand piece (optional).
~Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment."
16324018|NCT04511247|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
16324019|NCT04511247|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
16324020|NCT04511234|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
16324021|NCT04511234|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
16324022|NCT04511221|Placebo Comparator|Placebo|15 mg capsule containing rice maltodextrin and medium chain coconut triglycerides
16324023|NCT04511221|Active Comparator|Bifidobacterium animals subsp. lactis BL04|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 with rice maltodextrin and medium chain coconut triglycerides as a filler material
16324024|NCT04511221|Experimental|Bifidobacterium animals subsp. lactis BL04+PreforPro|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 and 1x10^6 PFU of PreforPro (Commercial phage preparation) with rice maltodextrin and medium chain coconut triglycerides as a filler material
16324027|NCT04511195|Experimental|Sphaeralcea angustifolia standardized extract|Patients with diagnosis of knee osteoarthritis will be included in the experimental group and assigned the treatment consisting of a topical administration of a gel elaborated with the pharmaceutical formulation prepared with a standardized extract from S. angustifolia, which will be administered three times a day for four weeks.
16324028|NCT04511195|Active Comparator|Diclofenac 2 %|Patients with diagnosis of knee osteoarthritis will be included in the control group and assigned the treatment consisting of a topical administration of a gel elaborated with 2% diclofenac, which be administered three times a day for four weeks
16324029|NCT04511182|Experimental|exercise intervention group|Patients will receive standard medications plus EBCR 。Education covering topics related to AMI and exercise for AMI will be implemented and any consultations on exercise prescription and disease management will be explained by a cardiac rehabilitation team consisting of cardiologists, cardiology nurses and physiotherapists.
16324030|NCT04511182|No Intervention|Usual care group（control）|Patients will receive standard medications according to national guidelines, as well as education and consultations as intervention group. However，no exercise prescription is given,
16324031|NCT04511169|Experimental|remainder|The participants who are inactive for more than 48 hours after recieving new content will recieve a remainder, in the format of a text message and an email.
16324032|NCT04511169|No Intervention|non-remainder|The participants who are inactive for more than 48 hours after recieving new content will NOT recieve a remainder, in the format of a text message and an email.
16324033|NCT04511156|Experimental|Foundational Helping Skills|The Foundational Helping Skills training will be intervention to be evaluated in this study. The Foundational Helping Skills is a flexible curriculum, with an approximate 3-day (20 hour) duration to be modified based on context and personnel. The Foundational Helping Skills is a human-centered design competency-based training in foundational helping skills. The training curriculum has been developed in a modular format, with each module relating to specific foundational helping skills (e.g., non-verbal communication, confidentiality, etc). The training curriculum can be found. The general training outline includes two days of foundational helping skill modules, brief role-play competency assessments at the end of each foundational helping skills training day to inform trainers which competencies need remediation, and a half-day of training that involves a remediation of the specific foundational helping skills that have been identified via the brief role-play assessments.
16324037|NCT04511117|Active Comparator|Control Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by composite restorations.
16324038|NCT04511117|Experimental|Endocrown Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by endocrown restorations.
16324039|NCT04511104|Active Comparator|Standard of Care|"Standard of care treatment:
~- including passive / assisted / active movements, stretching, functional exercise, scar treatment
~Duration: up to 8 weeks"
16324040|NCT04511104|Experimental|Exercise|"Standard of care + added exercises
~Exercise type: resistance and aerobic exercise
~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)
~Duration: up to 8 weeks"
16324041|NCT04511091||Vats Group|patients underwent planned VATS lobectomy for NSCLC from the Italian VATS Group Database (a validated, risk-adjusted, prospective, outcomes-based program with 50 participating hospitals in Italy) were included in the analysis.
16324042|NCT04511078|Experimental|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
16324074|NCT04510831|Experimental|Refined maize|Two portions of porridge prepared with refined maize flour with extrinsic addition of labelled FeSO4 (isotopic iron 54)
16324075|NCT04510831|Experimental|T.molitor native chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) native chitin and extrinsic addition FeSO4 (isotopic iron 58)
16324076|NCT04510831|Experimental|T.molitor reduced chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) reduced chitin and extrinsic addition FeSO4 (isotopic iron 58)
16324043|NCT04511065|Experimental|Intervention Group|The intervention group will be provided with a survey to determine areas of interest to guide the 7-week literacy intervention plan of completing a newsletter. Students will complete the newsletter virtually using secure Zoom meetings 2x per week for 30 minutes per session. The results of the GORT 5 and TOC will be used to determine the baseline reading skills of the students and each researcher will use the results of the assessments to guide the intervention with the newsletter topic that is chosen by the student. For example, if the GORT 5 notes deficiency with reading accuracy, the focus of the intervention will be ensuring that reading accuracy is a focus of the summary that is crafted by the student for the newsletter.
16324044|NCT04511065|No Intervention|Control Group|The control group will not participate in the newsletter creation for the 7-week study period. These students will engage in the after-school programs at the Center, some of which may be literacy-based, but not the prescriptive model that is being followed by the researchers.
16324047|NCT04511039|Experimental|Treatment Arm|Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16324048|NCT04511026|Experimental|Lymphoseek/SPECT-CT/Indocyanine|The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.
16324049|NCT04511013|Experimental|Arm I (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16324050|NCT04511013|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.
16324051|NCT04511000|Experimental|Experimental group|
16324052|NCT04511000|Active Comparator|Comparator group|
16324053|NCT04510987|Experimental|Experimental: Treatment 1|Participants in Groups 1-4 and Group 6 will receive a single dose of BAY2433334 on one occasion. Participants in Group 5 will receive a single dose of BAY2433334 on a dialysis-free day.
16324054|NCT04510987|Experimental|Experimental: Treatment 2|Participants in Group 5 will receive a single dose of BAY2433334 on a day with dialysis treatment.
16324055|NCT04510974||Cervical SCI|Ages between 21-70 years old Injured between C1-T1 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
16324056|NCT04510974||Thoracic SCI|Ages between 21-70 Injured between T6-T12 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
16324057|NCT04510974||Able-bodied Control|Ages between 21-70
16324058|NCT04510961|Active Comparator|Paraffin baths therapy (PBT) :group A|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks.
16324059|NCT04510961|No Intervention|Control group (B)|receive routine skin care program ; lifestyle change, emollients and moisturizers
16324060|NCT04510948|Experimental|Intervention (Implementing Patient Priorities Care)|Patient Priorities Care requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences (collectively referred to as health priorities). Participants will be contacted by a trained priorities facilitator in-person or over the phone to elicit their health priorities. This information will be documented in the PPC- GOALS AND PREFERENCES form in the EHR and shared with the clinicians who will then use the Patient Priorities Care approach with patients to inform and guide treatment decisions.
16324061|NCT04510948|No Intervention|Usual Care (Not implementing PPC)|Patients will receive routine clinical care.
16324062|NCT04510935|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
16324063|NCT04510935|Active Comparator|local anesthesia|In this group, patients will receive radiofrequency ablation under local anesthesia.
16324064|NCT04510922|Experimental|Droxidopa|100-600mg droxidopa TID
16324065|NCT04510909|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
16324066|NCT04510896|No Intervention|Pre-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
16324067|NCT04510896|Experimental|Post-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
16324068|NCT04510883|Experimental|PACO|Participants are asked to use the intervention for eight weeks.
16324069|NCT04510883|Other|Waiting list + PACO|Participants receive the same intervention, but only after a waiting period of four weeks.
16324070|NCT04510870|Experimental|Experimental group|"infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)
~infusion is NaCl"
16324071|NCT04510870|Experimental|NaCl infusion group|"infusion is NaCl
~infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)"
16324072|NCT04510844|Experimental|Study Drug Group|Participants who will receive a shot of the Evolocumab at Visit 3 and self-administer the rest of the shots at visit 4-7.
16324073|NCT04510844|Placebo Comparator|Placebo group|Participants who will receive a Placebo shot at Visit 3 and self-administer the rest of the shots at visit 4-7.
16324077|NCT04510818|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
16324078|NCT04510805|Experimental|Intervention Arm|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.
~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
16324079|NCT04510805|No Intervention|Control Arm|Usual standard of care. Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.
16324080|NCT04510779|Experimental|Heart Failure Patients|This will be a single arm study of heart failure patients with acute decompensation
16324081|NCT04510766||Part A|Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
16324082|NCT04510766||Part B|"FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for liquid biopsy will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent
~(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of liquid biopsy for future analysis."
16324083|NCT04510740||Hepatocellular Carcinoma (HCC)|Patients with Hepatocellular Carcinoma (HCC)
16324084|NCT04510740||Cholangiocarcinoma (CCC)|Patients with Cholangiocarcinoma (CCC)
16324085|NCT04510727|Experimental|OCT Guided C&D Group|Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C&D.
16324086|NCT04510714|Experimental|Microwave ablation arm|Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation
16324087|NCT04510688||Managed Access Program (MAP) patients|Patients with RCC treated with cabozantinib under a Managed Access Program (MAP) prior to Cabometyx® marketing authorization
16324088|NCT04510688||Real World (RW) patients|Patients with RCC treated with cabozantinib as routine clinical prescription (Real World), with treatment started after Cabometyx® marketing authorization
16324089|NCT04510675|Experimental|Test Article|
16324090|NCT04510675|Sham Comparator|Negative Control|
16324091|NCT04510662|Experimental|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
16324092|NCT04510662|No Intervention|Control|Patients in this group will receive standard care.
16324093|NCT04510649|Experimental|Surufatinib and Rabeprazole (Part A)|Part A: Surufatinib 300 mg on study days 1 and 11 Rabeprazole 40 mg on study days 5 - 11
16324094|NCT04510649|Experimental|Surufatinib and Rifampin (Part B)|Part B: Surufatinib 300 mg on study days 1 and 12 Rifampin 600 mg on study days 5-15
16324095|NCT04510636|Experimental|Pembrolizumab and Bendamustine|"The study drugs will be given in 3 week periods called cycles.
~Pembrolizumab is available in powder form or as a liquid for infusion. Pembrolizumab at a dose of 200 mg will be given over 30 minutes, once every cycle for up to 35 cycles (approximately 24 months).
~Bendamustine is available in powder form for injection. Bendamustine at a dose of 90 mg/m2 will be given over 60 minutes, on Days 1 and 2 of every cycle for up to 6 cycles."
16324096|NCT04510623||COVID-19 Patients on ARBs|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.
16324097|NCT04510623||COVID-19 Patients on ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.
16324098|NCT04510623||COVID-19 Patients on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.
16324099|NCT04510623||COVID-19 Patients not on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.
16324100|NCT04510610|Experimental|Camrelizumab plus decitabine|Decitabine 10 mg/day, days 1-5; Camrelizumab 200 mg, day 8, every 3 weeks.
16324101|NCT04510597|Active Comparator|Arm 1: Continued Systemic Therapy Only|"Nivolumab 240 mg IV 1 q 2 weeks
~OR
~Nivolumab 480 mg IV 1 q 4 weeks
~OR
~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID
~OR
~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
16324102|NCT04510597|Experimental|Arm 2: Nephrectomy and Continued Systemic Therapy|"Continued systemic therapy as above, plus:
~Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization."
16324104|NCT04510571|Active Comparator|Protaper Next|Protaper Next group (n=25): The instrumentation of mesial and distal canals were done according to manufacturer's recommendations using X1 and X2 (25.06) at a rotational speed of 300 rpm. Then X3 and X4 (40.06) instruments were used to enlarge distal canals in order to compare the results with the Reciproc Blue group. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
16324182|NCT04510077|Experimental|Prevention (SmartQuit)|Patients use the SmartQuit program to learn and practice skill modules as often as they wish over 6 months.
16324246|NCT04509557|Experimental|125mCi|Using a drug product for which dose is determined (125±13 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
16324105|NCT04510571|Active Comparator|Reciproc Blue|Reciproc Blue group (n=25) : The canals were shaped with in accordance with the manufacturer's recommendations. R25 (25.08) instrument was introduced into the canal with slow pecking movement within a 3 mm range each time. The flutes and remnants were cleaned after 3 pecking moves. Then R40 instrument (40.06) was selected to shape the distal canals as the #20 K file was passively introduced to the working length. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
16324106|NCT04510558|Experimental|Intervention (mesh)|Insertion of a non-resorbable mesh in the subway position.
16324107|NCT04510558|Sham Comparator|Control (no mesh)|No insertion of mesh.
16324108|NCT04510545||Treatment Group|All patients will undergo CAD of any diminutive polyps found in the rectosigmoid on colonoscopy
16324109|NCT04510532||Patients with Breast Cancer who use pyrotinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
16324110|NCT04510532||Patients with Breast Cancer who use apatinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given apatinib as having HER2-negative breast cancer with no metastasis.
16324111|NCT04510532||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
16324112|NCT04510506|Experimental|Artificial Pancreas Therapy|Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.
16324113|NCT04510506|No Intervention|Usual Care + CGM|Participant will use their usual diabetes care along with a study CGM.
16324114|NCT04510493|Active Comparator|active treatment arm|Treatment with Canakinumab i.v. administered over 2 hours
16324115|NCT04510493|Placebo Comparator|placebo treatment arm|placebo treatment
16324116|NCT04510480||cardiac arrest|"Out of hospital cardiac arrest patients (Historical cohort) from 1st January 2009 and 30th June 2020.
~Out of hospital cardiac arrest patients from 1st July 2020 and 31st December 2025."
16324117|NCT04510467||case group|RMD patients with COVID 19 infection
16324118|NCT04510467||control group|RMD patients without COVID 19 infection
16324119|NCT04510454|Experimental|RT-PCR and ddPCR sampling analyses|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
16324120|NCT04510428|Experimental|OSIG-Eye Drop|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
16324121|NCT04510428|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
16324122|NCT04510415|Experimental|Olmutinib 600mg|HM61713 600 mg (1 x 400 mg + 1 x 200 mg tablets) once daily (QD)
16324123|NCT04510402|Experimental|Safety Analysis|Evaluate safety of PVP-I nasal swabs single daily application
16324124|NCT04510402|Experimental|Tolerability analysis|Investigate the dosing of PVP-I nasal swabs daily single dosing versus double dosing
16324125|NCT04510389|Placebo Comparator|Placebo|volunteers will receive 28 sachets containing 30g of maltodextrin to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
16324126|NCT04510389|Experimental|Whey|volunteers will receive 28 sachets containing 30g of whey protein to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
16324127|NCT04510376|Experimental|Test article|
16324128|NCT04510376|Active Comparator|Histamine Positive Skin Test Control|
16324129|NCT04510376|Placebo Comparator|Aqueous Negative Control|
16324130|NCT04510350||MS CIS+|
16324131|NCT04510350||Healthy volunteers|
16324132|NCT04510337|Active Comparator|Standard rocuronium|patients received rocuronium 0.6mg/kg
16324133|NCT04510337|Experimental|Magnesium|patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes
16324134|NCT04510324|Active Comparator|Red meat patties|Participants will be randomized to group 1: Red meat, ''Costco Kirkland Signature 1/4 lb Ground Beef Patties'' (Beef burger). Participants will be given two patties per day.
16324135|NCT04510324|Experimental|Plant-based patties|"Participants will be randomized to group 2: plant-based burger which contains no animal products. The Plant-based burger selected is ''Beyond Burger (https://www.beyondmeat.com/products/the-beyond-burger/ ). Participants will be given two patties per day."
16324136|NCT04510311|Experimental|PET/CT scan with radiotracer [18F]3F-PHPG|Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.
16324137|NCT04510311|Active Comparator|Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG|FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
16324138|NCT04510298|Experimental|SP-624|SP-624 oral capsule, 20 mg once daily
16324139|NCT04510298|Placebo Comparator|Placebo|Placebo oral capsule, once daily
16324140|NCT04510285|Experimental|Trastuzumab and Pembrolizumab|"Trastuzumab will be administered on an every 3 week dosing schedule, with initial loading dose of 8 mg/kg as a 90 minute infusion, followed by trastuzumab 6 mg/kg every 3 weeks.
~The planned dose of pembrolizumab for this study is 200 mg every 3 weeks."
16324141|NCT04510272|Experimental|High risk critically ill patients|Critically ill patients requiring vasopressor support or mechanical ventilation will receive aloud real time ICU diary reading intervention
16324142|NCT04510259|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthesize the whole upper limb.
16324143|NCT04510246|Experimental|Intervention|Practitioners randomised to the intervention arm will receive the standard of care surveillance letter if the notification is new. Both new and repeat notifications will receive further enhanced case support during the project if required. Support can be provided at the first phone call, or if accepted and required, in a 12-week period during which the DoH health care worker can do follow-up calls with the GP or directly with the patient to inform the patient and enhance linkage back to their GP. At the end of the 12-week period, a follow-up call we be carried out for the project evaluation.
16324144|NCT04510246|No Intervention|Control|All practitioners randomised to this arm will be contacted by telephone approximately 12 weeks after an HCV notification has been made from the laboratory to the Department of Health.This is not current standard practise and will be performed by the DoH HCV health worker for the project evaluation purpose. At this phone call consent will be sought for the GP to provide information on their clinical management of the notified patient. The details of the clinical management survey are provided as Appendix B. Details provided or missing from the standard DoH surveillance form would be confirmed with the GP at this phone call. Three attempts will be made to contact the practitioner to complete the survey within a 30-day period before they are determined to be unable to be contacted.
16324145|NCT04510233|Experimental|Ivermectin nasal spray|Ivermectin administered as nasal spray (one ml in each nostril two times daily)
16324146|NCT04510233|Experimental|Ivermectin oral|Ivermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.
16324147|NCT04510233|Experimental|standard care|COVID-19 cases will receive standard of care [oxygen via masks or ventilators]
16324148|NCT04510220|Experimental|Subjects diagnosed with relapsing forms of multiple sclerosis|We plan to enroll 10 subjects with relapsing MS. All enrolled subjects will receive Ofatumumab 20 mg every 4 weeks, subcutaneously for 9 months during the study. Loading doses will be administered initially at 1, 7 and 14 days. During the study period, all enrolled subjects will undergo five PET scans using [F-18] PBR06 at 0, 5, 28, 90 and 273 days after starting treatment with Ofatumumab.
16324149|NCT04510207|Experimental|Investigational Vaccine1|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 & D21.
16324150|NCT04510207|Experimental|Investigational Vaccine 2|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 & D21.
16324151|NCT04510207|Placebo Comparator|Placebo|Participants will receive 2 doses of Placebo according to the immunization schedule of D0 & D21.
16324152|NCT04510194|Experimental|Treatment Arm - Metformin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the metformin alone.
16324153|NCT04510194|Placebo Comparator|Treatment Arm - Placebo Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the placebo.
16324154|NCT04510194|Experimental|Treatment Arm - Ivermectin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the ivermectin alone.
16324155|NCT04510194|Experimental|Treatment Arm - Fluvoxamine Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the fluvoxamine alone.
16324156|NCT04510194|Experimental|Treatment Arm - Metformin and Fluvoxamine Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and fluvoxamine.
16324157|NCT04510194|Experimental|Treatment Arm - Metformin and Ivermectin Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and ivermectin.
16324158|NCT04510181|Experimental|Amino acid-based blend|The amino acid-based blend will be administered PO daily for the study duration
16324159|NCT04510168||MRI Only|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at least 50-60 people with dementia (as determined by the ongoing NOMAS procedures).
16324160|NCT04510168||MRI and PET|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at 20 participants with dementia and 40 participants without (as determined by the ongoing NOMAS procedures). In addition to MRI, participants in this group will have three PET studies.
16324161|NCT04510155|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
16324162|NCT04510155|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
16324163|NCT04510129||head and neck squamous cell carcinoma (HNSCC)|
16324164|NCT04510129||non-small-cell lung cancer (NSCLC)|
16324165|NCT04510129||small cell lung cancer (SCLC)|
16324166|NCT04510129||urothelial carcinoma (UCC)|
16324167|NCT04510129||gastric or gastroesophageal junction adenocarcinoma|
16324168|NCT04510129||cervical cancer|
16324169|NCT04510129||esophageal squamous cell carcinoma (ESCC)|
16324170|NCT04510129||triple-negative breast cancer (TNBC)|
16324171|NCT04510129||hepatocellular carcinoma (HCC)|
16324172|NCT04510129||renal cell carcinoma (RCC)|
16324173|NCT04510129||colorectal cancer (CRC)|
16324174|NCT04510116|Experimental|AIM preventive intervention|Families were assigned to receive a 6 session, 12 hour prevention program in their community.
16324175|NCT04510116|No Intervention|Control|Families were assigned to no intervention control.
16324176|NCT04510103|Other|Regression Group|The Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then entered a 2-week regression period (no moisturizer usage).
16324177|NCT04510103|Other|Non-Regression Group|The Non-Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then underwent a physical insult (tape stripping) on the lower legs and continued using the moisturizer for 4 additional days.
16324178|NCT04510090|Experimental|EP547 Single Dose|Single doses of EP547
16324179|NCT04510090|Experimental|EP547 Multiple Doses|Multiple doses of EP547
16324180|NCT04510090|Placebo Comparator|Placebo Single Dose|Single doses of placebo
16324181|NCT04510090|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo
16324183|NCT04510064|Experimental|Treatment group|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every two weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
16324184|NCT04510051|Experimental|Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)|Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
16324185|NCT04510038|Experimental|Active Colchicine Arm|Arm of Covid-19 hospitalized patients (with evidence of cardiac injury) treated with colchicine plus current standard of care.
16324186|NCT04510038|Active Comparator|Control Group|Arm of Covid-19 hospitalized patients (with evidence of cardiac injury) treated with current standard of care only.
16324187|NCT04510025||Non-COVID|We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects ( no serological evidence of previous infection or active symptoms).
16324188|NCT04510025||COVID-19|Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).
16324189|NCT04510012||Mild COVID-19|SARS-Cov-2 infected individuals with mild symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 1-2)
16324190|NCT04510012||Moderate COVID-19|SARS-Cov-2 infected individuals with moderate symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 3-4)
16324191|NCT04510012||Severe COVID-19|SARS-Cov-2 infected individuals with severe symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 5-8)
16324192|NCT04509999|Experimental|Standard of care and Experimental treatment of Bicalutamide|Each subject will be administered bicalutamide 150 mg daily at 1:1 randomization for up to 4 weeks.
16324193|NCT04509999|Placebo Comparator|Standard of Care and Placebo|Each subject will be administered placebo as formulated at 1:1 randomization for up to 4 weeks.
16324194|NCT04509973|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
16324195|NCT04509973|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
16324196|NCT04509960|No Intervention|proseal laryngeal mask insertion|no intervention
16324197|NCT04509960|Experimental|proseal laryngeal mask insertion with laryngoscope|with the help of direct laryngoscopy
16324201|NCT04509934|Active Comparator|Group 1|Connective Tissue Manipulation was performed to participants in Group 1, starting at the end of the menstrual cycle, 5 days a week and for 1 cycle (approximately 3 weeks) until the beginning of the next period.
16324202|NCT04509934|Active Comparator|Group 2|In Group 2, Connective Tissue Manipulation was started with the completion of menstrual cycle performed to participants for 5 days a week and until the other menstrual cycles. At the end of the menstrual cycle, it was restarted and a total of 2 cycles were applied until the second menstrual cycle started (approximately 6 weeks).
16324203|NCT04509921|No Intervention|symptoms group|The asthma treatment adjustments guided by GINA guidelines
16324204|NCT04509921|Experimental|BHR group|The asthma treatment adjustments additionally taking account to the results of the bronchial hyperresponsiveness test
16324205|NCT04509895|Experimental|lateral extensile approach in calcaneal fractures fixation|Lateral extensile approach is the standard approach for intra-articular calcaneal fractures .
16324206|NCT04509895|Experimental|minimally invasive sinus tarsi approach in calc.fixation|Sinus tarsi approach become one of the most frequently applied minimally invasive approaches.
16324207|NCT04509882|Experimental|bear bile pill|Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI).
16324208|NCT04509882|Placebo Comparator|placebo|Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI).
16324209|NCT04509869|Experimental|pre-operative and postoperative|the patients who will undergo the operation to treat the pain
16324210|NCT04509856|No Intervention|Control Group|Routine diabetes education will given to the patients included in the Control Group by a diabetes education nurse. The diabetes education nurse has been working for 10 years in the same center.
16324211|NCT04509856|Experimental|Intervention Group|Intervention Group will take their diabetes education by teach-back educational strategy.
16324212|NCT04509830|Experimental|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator will be performed.cuff weights will be used with 80% of 1 repetition maximum at 3 sets of 8 repetitions with 10-15 second rest between repetitions and 1-2 minute rest between sets.
16324338|NCT04508881|Active Comparator|intraluminal stenting|stenting of the valve tube by prolene suture
16324339|NCT04508868|Experimental|Brief Behavioral Activation with Mental Imagery|Four weekly sessions of Brief Behavioral Activation with Mental Imagery.
16324213|NCT04509830|Active Comparator|quadriceps strengthening, stretch for hamstring,cuff muscles|"quadriceps strengthening: multi-angle isometric exercise from sitting position will be performed. cuff weights will be used with 3 sets of 12 repetitions at 40% of 1 reprtition maximum.
~self stretch for hamstring and cuff muscles from supine position. the procedure will be repeated 4 times."
16324214|NCT04509817|Experimental|Acupuncture+Usual care|Subjects in experimental group will receive a standardized acupuncture treatment, 10 times per 4 weeks for 16 weeks with a total of 40 sessions in addition to usual care.
16324215|NCT04509817|Active Comparator|Usual care|Subjects in control group will receive usual care only.
16324216|NCT04509791|Placebo Comparator|placebo|placebo arm
16324217|NCT04509791|Active Comparator|2.5 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
16324218|NCT04509791|Active Comparator|1.5 mg ATG/kg|the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio
16324219|NCT04509791|Active Comparator|0.5 mg ATG/kg|The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio
16324220|NCT04509791|Active Comparator|0.1 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
16324221|NCT04509778||SHARP|ShangHai At Risk for Psychosis
16324222|NCT04509765|Experimental|Patients with Hematologic Malgnancies|
16324223|NCT04509752||Dysphagia clinicians|Clinicians from swallowing centers (from all over the world)
16324224|NCT04509739|Experimental|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.
~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
16324225|NCT04509726|Experimental|EBV TCR-T|
16324226|NCT04509713||infected/positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
16324227|NCT04509713||uninfected/negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
16324228|NCT04509700|Experimental|parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
16324229|NCT04509700|Experimental|parsaclicib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
16324232|NCT04509661|Experimental|Experimental group|Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.
16324233|NCT04509661|Placebo Comparator|Control group|Placebo treatment for the airway limitation.
16324234|NCT04509648|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will receive 5.2 Gy in 5 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular/infraclavicular region, internal mammary nodes, and any part of the axillary bed at risk) and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast.
16324235|NCT04509635|Experimental|Arm A|Using treatment of cetuximab plus chemotherapy. Cetuximab: 500 mg/m2 IV over 2 hours, day 1, every 2 weeks. Chemotherapy: detailed regimen is determined by a multi-disciplinary team.
16324236|NCT04509635|Active Comparator|Arm B|Using treatment of chemotherapy alone. Chemotherapy: detailed regimen is determined by a multi-disciplinary team
16324237|NCT04509622|Experimental|Venetoclax + Low-Dose Cytarabine (LDAC)|Participants will receive venetoclax once daily (QD) on days 1 through 28 plus LDAC QD on days 1 through 10 during the 28-day treatment cycles.
16324238|NCT04509609||LGMD 2E with a genetic diagnosis|Any patient affected by LGMD 2E with a genetic diagnosis
16324239|NCT04509596|Experimental|daily dose of DZD1516|daily dose of DZD1516
16324240|NCT04509583|Experimental|PROFortil group|"Men with increased sperm DNA fragmentation (>=30%) will be indicated for multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months then checked again post-treatment for DF).
~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
16324241|NCT04509583|Other|Vitamin E group|"Any case with high DNA fragmentation index (DFI >=30%) will be randomized indicated only Vitamin E (Enat 400 once per day) in 3 months then checked again post-treatment for (DFI).
~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
16324242|NCT04509570|Other|Treatment: ILI(Intralesional injection)|5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
16324243|NCT04509557|Experimental|50mCi|Using a drug product for which dose is determined (50±5 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
16324244|NCT04509557|Experimental|75mCi|Using a drug product for which dose is determined (75±8 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
16324245|NCT04509557|Experimental|100mCi|Using a drug product for which dose is determined (100±10 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
16324247|NCT04509557|Experimental|150mCi|Using a drug product for which dose is determined (150±15 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
16324248|NCT04509531|Experimental|Experimental: SA, ITP and Resilience|1 hour Wise intervention (based on SA, ITP and resilience) consisting on several tasks to be completed online individually.
16324249|NCT04509531|Other|Standard preventive intervention|1 hour educational intervention (about internet risks such as sexting and grooming) consisting on several tasks to be completed online individually.
16324250|NCT04509518|Experimental|Study group|Participants in the study group received exercise therapy program plus additional TENS therapy
16324251|NCT04509518|Other|Control group|Participants in the study group received exercise therapy program plus sham TENS
16324252|NCT04509466|Experimental|dose escalation (part 1)|"dose escalation (part 1):Patients with treatment-naïve, relapsed or refractory extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles. The starting dose of liposomal mitoxantrone hydrochloride is 12mg/m2.dose expansion, treatment-naïve patients (part 2):Patients with treatment-naïve extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles.
~dose expansion, relapsed or refractory patients (part 2):Patients with relapsed or refractor extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles."
16324253|NCT04509453|Experimental|McGRATH|
16324254|NCT04509453|Active Comparator|Macintosh|
16324255|NCT04509440|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 3 ml). The injection was done using Lyftgot technique. The subcutaneous injections were done at sensory nerves fascial penetration points and tender areas around the anserine bursa anatomical region.
16324256|NCT04509440|Active Comparator|Corticosteroid group|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
16324259|NCT04509414|Experimental|dexmedetomidine|2ug/kg intranasal atomized dexmedetomidine
16324260|NCT04509414|Active Comparator|midazolam|0.2mg/kg intranasal atomized midazolam
16324261|NCT04509401|Active Comparator|Interventional|High dose of Vitamin B6 with Magnesium. Vitamin B6 will be given orally 150 mg for ages 2-3 years, 200 mg for ages 4-6 years,300 mg for ages 7-8 years and Magnesium will be given orally 50 mg for 2-3 years, 100 mg for ages 7-8 years for three months.
16324262|NCT04509401|Placebo Comparator|Control|Control group will receive oral placebo in the same manner, schedule and time frame.
16324263|NCT04509388|Placebo Comparator|Commercially Available Sports Drink A|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes
16324264|NCT04509388|Experimental|Commercially Available Sports Drink B|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes.
16324265|NCT04509388|Experimental|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available sports water, with small amounts of flavouring, sweetener and electrolytes), but with the addition of a small amount of amino acids (~0.7 g/100 ml).
16324266|NCT04509375||Study Group|Premature babies in the first 28 postnatal days of life, with less than 32 gestational weeks or less than 1500 grams of birth weight, with documented anemia by current accepted transfusion guidelines of Turkish Neonatal Society
16324267|NCT04509349|Active Comparator|Real tACS|For transcranial stimulation, a stimulation method called high-definition tACS (HD-tACS) will be applied to target the primary motor cortex (M1), an area of the brain that is involved in controlling movement, using gel electrodes placed on the scalp. Participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage, to create focused stimulation over the M1 region. A stimulator will be connected to the electrodes to deliver a low-intensity stimulating current to the scalp.
16324268|NCT04509349|Placebo Comparator|Sham tACS|For the transcutaneous ACS, the procedure for real and sham stimulation will be identical to HD-tDCS, but ACS will be delivered to the upper arm contralateral to hand attached to the accelerometer.
16324269|NCT04509336|Experimental|orphenadrine group|orphenadrine
16324270|NCT04509336|Active Comparator|Baclofen group|Baclofen
16324271|NCT04509323|Experimental|Experimental：Huperzine A for Injection+Basic treatment|Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days； Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
16324272|NCT04509323|No Intervention|Control：Basic treatment|Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
16324340|NCT04508868|Placebo Comparator|Minimal Attention Control Intervention|Four weeks with weekly follow-up calls.
16324411|NCT04508296|Experimental|EVLWI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI > 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI < 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL
16324273|NCT04509310|Experimental|Active Bodysuits|The potential materials that can provide support are 3D printable rigid materials, semirigid foam padding, Velcro tape and stretchable wide waistbands. The 3D printable materials can be very versatile in terms of properties and can be further finished with an epoxy resin or thermoplastics. Different compositions and structures of knitted fabrics will be used in different areas of the proposed bodysuits to provide a close fit, high breathability and effective pain management due to extra support. The fastening system includes a magnetic zipper and pulley system that can be adjusted by pulling on knobs. The pulley system contains a microadjustable dial, super-strong lightweight lacing, and low friction lacing guides.
16324274|NCT04509297|Experimental|High protein milk|Experimental: High protein milk consumption This arm involved High protein milk whole consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
16324275|NCT04509297|Placebo Comparator|Placebo|This arm involved consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime. drink r
16324276|NCT04509284|Experimental|Training|Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
16324277|NCT04509284|Other|Control|Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
16324278|NCT04509271||Normal aged|
16324279|NCT04509271||MCI due to AD|
16324280|NCT04509271||Mild AD|
16324281|NCT04509271||Moderate AD|
16324282|NCT04509271||Severe AD|
16324283|NCT04509271||Dementia with Lewy body|
16324284|NCT04509271||Frontotemporal dementia|
16324285|NCT04509258|Placebo Comparator|control group|this group will have the standard and routine therapy of treatment of acute Aluminium Phosphide poisoning immediately after admission according to PCCA guidelines
16324286|NCT04509258|Active Comparator|N- acetyl cysteine grouo|N-acetyl cysteine will be given at dose of 300mg/kg/d IV in the first day then 150 mg/kg/d IV in addition to standard of care according to PCCA guidelines
16324287|NCT04509258|Active Comparator|Acetyl L-carnitine group|Acetyl L-carnitine will be given at dose of 50 mg/kg IV once to be followed by additional doses of 15 mg/kg IV q4hr infused over 30 min. standard of care according to PCCA guidelines will also be provided
16324288|NCT04509258|Active Comparator|Medicated paraffin oil group|Gastric decontamination with sodium bicarbonate (NaHCO3; 44 mEq, orally) and medicated paraffin oil (200 mL) will be administered in addition to standard of care according to PCCA guidelines
16324289|NCT04509245|Experimental|Effects of a digitally assisted lifestyle intervention|Testing the effects of a low-calorie diet in connection with app-based digital education and behavioral change program on glucose metabolism and disease management.
16324290|NCT04509232|Experimental|group A|- 38% Silver diamine fluoride will be applied to carious lesions by microbrush on the affected surface application time should be 1 min, Application time will be shorter in very young patients.
16324291|NCT04509232|Experimental|group B|"-38% Silver diamine fluoride will be applied by the same protocol as in group A
~Then Glass Ionomer restoration is applied as follows
~Self cure glass ionomer restoration is applied not light cured as light causes oxidation of silver and the filling appears darker.
~Glass ionomer won't be applied immediately after SDF placement it will be applied at time ranging from 2 hours to two days.
~Conditioning of the base of the cavity is done by 3M ESPE conditioner for 10 seconds then rinsing the cavity for 10 to 20 secs.
~Applying High strength hand mix chemical self cure glass ionomer."
16324292|NCT04509219|Experimental|Participants treated with MP pulse|Selected participants will be given MP pulse treatment
16324293|NCT04509206|Experimental|Intervention|Subjects will undergo four nutritional educational classes, lasting 1 hour long, conducted over a two month period. These classes will occur on zoom and subjects will be located in their home.
16324294|NCT04509193||Group A|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban
16324295|NCT04509193||Group B|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin
16324296|NCT04509180|Experimental|Catheter ablation group|Patients undergoing catheter procedure will be put under conscious sedation and local anesthesia. Pulmonary vein isolation and posterior wall isolation will be performed with a radiofrequency ablation catheter (20-45W, open-tip irrigation). Ablation index will be used for the lesion formation guidance (450-500 on anterior aspects; 350-400 on the posterior aspects). A wide antral circumferential ablation will be performed for pulmonary veins and a box lesion set for the posterior left atrial wall. Voltage mapping and signal analysis performed by the operator will be used to assess electrical isolation of the pulmonary veins and posterior wall and to identify gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
16324297|NCT04509180|Active Comparator|Convergent group|Patients undergoing convergent procedure will be put under general anesthesia. A minimally invasive epicardial radiofrequency ablation (30W, 90s) of posterior wall will be performed through a subxiphoid window. Monitoring of the esophageal temperature will be performed with an esophageal temperature probe set at 38°C. Next, an endocardial radiofrequency ablation (20-40W, open-tip irrigation; ablation index 450-500 anteriorly and 350-400 posteriorly) of pulmonary veins in a wide antral circumferential fashion will be performed. Voltage mapping and signal analysis performed by the operator will be used to assess the electrical isolation of the pulmonary veins and posterior wall and to identify the gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
16324298|NCT04509167|Experimental|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
16324299|NCT04509154|Experimental|Multimodal pain therapy|"The treatment will last 6 weeks maximum 8 weeks. The three questionnaires will be completed by all study subjects in a maximum time of 10 minutes. Immediately after receiving the two face-to-face sessions; 6 weeks after (8 weeks maximum after treatment) and three months just after having completed treatment.
~The pain management application includes automatic monitoring, skills training, social support, education, goal setting and achievement of 4 components: exercises, psychological well-being, pharmacological and health assets interventions. Every week participants have a look at digital presentations about every component, doing then 3 activities related to each of them.This program will be."
16324300|NCT04509154|Experimental|Standardized treatment.|Both groups (control and intervention) received two face-to-face health education sessions led by nurses and physicians, and had access to a non-interactive web page with material for pain management from a self-help approach.
16324301|NCT04509141|Active Comparator|acupuncture|acupuncture three times a week
16324302|NCT04509141|Active Comparator|standard treatment for migraine by neurologist|standard treatment for migraine that was given by a neurologist
16324303|NCT04509128||A|Subjects hospitalized for a COPD acute exacerbation, undergoing arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, at admission and discharge.
16324304|NCT04509128||B|Subjects referred for pulmonary rehabilitation (PR) after a hospitalized COPD exacerbation, undergoing pulmonary function test, arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, before and after PR.
16324305|NCT04509115||Patients given short-acting opioid prescription|Patients not currently using opioids who receive a new short-acting opioid prescription for acute pain will be recruited.
16324306|NCT04509102|Active Comparator|Active|Subjects randomized to Adderall will take an tablet/capsule by mouth daily.
16324307|NCT04509102|Placebo Comparator|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar.
16324308|NCT04509089|Experimental|Experimental|Congestive heart failure patients scheduled for pulmonary artery catheterization (Swan-Ganz)
16324309|NCT04509076|Experimental|PrEP iT! (plus usual PrEP care)|The PrEP iT! intervention is a mobile-optimized website with components tailored for young men who have sex with men on PrEP.
16324310|NCT04509076|Placebo Comparator|Usual PrEP care only|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
16324311|NCT04509063|Other|Detailed information about screening harms|
16324312|NCT04509063|Other|Non-detailed information about screening harms|
16324313|NCT04509050||Part A|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
16324314|NCT04509050||Part B|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
16324315|NCT04509037||Liposuction Assisted Breast Reduction|
16324316|NCT04509037||Open Incision Breast Reduction|
16324317|NCT04509024|Experimental|Incidental training|Participants undergo novel non-linguistic incidental category learning training.
16324318|NCT04509024|Active Comparator|explicit training|Participants undergo traditional explicit language learning.
16324319|NCT04509011|Experimental|Fluobeam® LX|Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands
16324320|NCT04509011|No Intervention|Control|In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).
16324321|NCT04508998|Experimental|Patients with microvascular angina|Patients with clinical features of microvascular angina screened for the main PRIZE trial however not possessing the PHACTR1 GG minor allele single nucleotide polymorphism
16324322|NCT04508985|Experimental|Intervention|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
16324323|NCT04508985|Other|Continuation of standard of care|No intervention, Continuation RAAS inhibitor [continued standard of care].
16324324|NCT04508959||Screened patients|All individuals screened using the hospital's microbiology laboratory.
16324325|NCT04508959||Outpatient (Emergency Department) cases|All individuals seen in the emergency department who test positive for COVID-19.
16324326|NCT04508959||Inpatient (General Medical or Intensive Care) cases|All individuals admitted to a general or intensive care bed who test positive for COVID-19.
16324327|NCT04508946|Active Comparator|Hydrocortisone Monotherapy|Hydrocortisone Monotherapy
16324328|NCT04508946|Experimental|triple therapy regimen (vitamin c - thiamine- hydrocortisone)|triple therapy regimen (vitamin c - thiamine- hydrocortisone)
16324331|NCT04508920||Basal|"All adults (age >18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.
~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2019 ( without covid-19 )"
16324332|NCT04508920||Ourbreak|"All adults (age >18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.
~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2020 ( ongoing covid-19 )"
16324333|NCT04508907|Experimental|Arm 1: Pre-emptive Treatment Arm|Single arm study were all recipients of HCV viremic organs will receive combination therapy.
16324334|NCT04508894|Placebo Comparator|Control group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline
16324335|NCT04508894|Active Comparator|Ketamine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline plus 1 mg\kg ketamine
16324336|NCT04508894|Active Comparator|Dexmedetomidine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5% bupivacaine and 20 ml 0.9% normal saline plus 1µg\kg dexmedetomidine
16324337|NCT04508881|Active Comparator|External ligation|External ligation of the valve tube by vicryl sutures
16324341|NCT04508855||Cancer patients with atrial fibrillation|"All patients will be assigned to receive subcutaneous LMWH in therapeutic doses
~More specifically the regimens will be as follows:
~Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux <50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, >100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; <50kg, 5000IU, 50-70kg, 7.500 IU, >70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients"
16324342|NCT04508842|Experimental|CD19/CD22-Dual-STAR-T|CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
16324343|NCT04508829|Experimental|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or TPF regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3+5-FU 750mg/m2, CIV, 120h, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
16324344|NCT04508816|Experimental|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or GP regimen (Gemcitabine 1.0g/m2, D1, 8 + DDP 25mg/m2 , D1-3, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
16324345|NCT04508803|Experimental|The main research|Patients diagnosed with HER2 negative metastatic breast cancer with BRCA1/2, PALB2, CHEK2 pathogenic/suspected pathogenic germline mutation are recruited.
16324346|NCT04508803|Experimental|Ancillary Exploration research 1|Patients diagnosed with HER2 negative metastatic breast cancer with DDR gene (include ATM、ATR、BAP1、BARD1、BLM、BRIP1、CHEK1、CDK12、FANCA、FANCC、FANCD2、FANCE、FANCF、FANCM、MRE11A、NBN、PTEN、RAD50、RAD51C、RAD51D、WRN)pathogenic/suspected pathogenic germline mutation except BRCA1/2, PALB2 and CHEK2 are recruited.
16324347|NCT04508803|Experimental|Ancillary Exploration research 2|Patients diagnosed with HER2 positive metastatic breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation are recruited.
16324348|NCT04508803|Experimental|Ancillary Exploration research 3|Patients diagnosed with brain metastases breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation who has not undergone or progressed after brain radiotherapyare recruited.
16324349|NCT04508790|Experimental|Treatment (leflunomide, pomalidomide, dexamethasone)|Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16324352|NCT04508751|Other|Healthy Pregnancy|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
16324353|NCT04508751|Other|Pregnant Mothers with gestational diabetes|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
16324410|NCT04508296|Experimental|GEDVI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI > 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL
16324442|NCT04508075|Experimental|SARS-CoV-2 Vaccine|Participants receive 2 doses of SARS-CoV-2 Inactivated Vaccine with 14 days interval, intramuscularly
16324354|NCT04508751|Other|Pregnant Mothers with infants diagnosed with IUGR|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
16324355|NCT04508738|Experimental|ERP Intervention|Combination of different methods to improve recovery.
16324356|NCT04508738|No Intervention|Control|Passive recovery by sitting on a chair
16324357|NCT04508738|Placebo Comparator|Placebo|A combination of methods similar to the ERP intervention but at an intensity / mixture supposed to be ineffective at improving recovery.
16324358|NCT04508725|Experimental|Doppler Ultrasound|Patients receiving standard of care anti-angiogenesis inhibitor plus immune checkpoint inhibitor will have power doppler imaging at baseline, 3 weeks and 6 weeks.
16324359|NCT04508699|Experimental|Developmental language disorder|Children with language impairment but in the absence of cognitive deficits
16324360|NCT04508699|Active Comparator|Typical language|Children with typical language development and typical cognitive development
16324361|NCT04508686|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
16324362|NCT04508660|Experimental|Subjects with facial redness|Topical application twice daily for 4 weeks
16324363|NCT04508647|Experimental|Treatment|Treatment-Naive Stage II (non-contiguous), Stage III, Stage IV FL + MZL will receive Ublituximab 900mg IV weekly x 4 doses. End of treatment assessment 8 weeks post last dose of single agent ublituximab will be performed. Patients who achieve less than a complete response will receive a combination of ublituximab AND umbralisib for a total of 12 cycles. (In the combination arm ublituximab will be administered on day 1,8 and 15 on cycle 1 and on day 1 on each cycle thereafter. Umbralisib will be administered at 800 mg daily for 12 cycles)
16324364|NCT04508634|Experimental|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
16324365|NCT04508634|Active Comparator|Metformin Group|Metformin Group
16324366|NCT04508621|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
16324367|NCT04508621|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
16324368|NCT04508608||Ischemic cardiomyopathy group - 1 (ICM-1)|"Inclusion criteria:
~History of myocardial infarction (MI) or revascularization (CABG or PCI);
~> 75% stenosis of left main or proximal left anterior descending artery (LAD) and/ or stenosis of > 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);
~LV ejection fraction (EF) <40% and increase in LV volumes according to echocardiography (ECHO)
~Exclusion criteria:
~Presence of contraindications to the stress test with inotropic stimulation;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
16324369|NCT04508608||Ischemic cardiomyopathy group - 2 (ICM-2)|"Inclusion criteria:
~History of myocardial infarction (MI) or revascularization (CABG or PCI);
~> 75% stenosis of left main or proximal LAD and/ or stenosis of > 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);
~LV EF <40% and increase in LV volumes according to echocardiography (ECHO)
~Exclusion criteria:
~Presence of contraindications to the stress test with inotropic stimulation;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
16324370|NCT04508608||Control group for GBPS.|"Inclusion criteria:
~Absence of obstructive coronary artery lesion;
~Absence of history of MI and revascularization.
~Exclusion criteria:
~Presence of contraindications to the stress test with inotropic stimulation;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
16324371|NCT04508608||Control group for CFR.|"Presence of obstructive coronary artery lesion;
~Indications for coronary artery bypass grafting
~Exclusion criteria:
~Presence of contraindications to the adenosine stress test;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
16324372|NCT04508582||Women with Pre-eclampsia|De novo hypertension after 20 weeks gestation with evidence of end organ dysfunction.
16324373|NCT04508582||Women with Pregnancy-induced hypertension|De novo hypertension after 20 weeks gestation without evidence of end organ dysfunction.
16324374|NCT04508582||Healthy pregnant controls|Low risk women at booking as per NICE guidelines without any medical condition throughout pregnancy
16324375|NCT04508569|Experimental|Big Decisions|
16324376|NCT04508569|Active Comparator|Youth Voices|
16324377|NCT04508543||Minority (Case)|Self-identified as being a member of group traditionally underrepresented in the medical profession relative to the proportion in the general population: African-American/Black, Mexican-American, Native American (American Indians, Alaska Natives, and Native Hawaiians), and mainland Puerto Rican.
16324378|NCT04508543||Caucasian (Control)|Self-identified as Caucasian and Non-Hispanic
16324379|NCT04508530|Experimental|Panzyga|Panzyga 10% IVIG
16324380|NCT04508530|Placebo Comparator|Placebo|Placebo
16324443|NCT04508075|Placebo Comparator|Placebo|Participants receive 2 doses of placebo with 14 days interval, intramuscularly
16324444|NCT04508062|Active Comparator|pectopexy group|this group will only have pectopexy operation
16324381|NCT04508504|Experimental|Preop PENG Block|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL 0.5% ropivacaine in a manner consistent with Girón-Arango et al 2018 (PMID:30063657). Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence, in 5 mL increments with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
16324382|NCT04508504|Placebo Comparator|Placebo|Patients in the placebo group will receive a subcutaneous injection of 5 mL 0.9% normal saline. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, 1-2 cm beneath the skin, remaining in the subcutaneous tissue. 5 mL of 0.9% normal saline is injected, with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
16324383|NCT04508491|Experimental|Rhythm control|Rhythm control with medication or any procedure
16324384|NCT04508491|Active Comparator|Rate control|Rate control with medication or any procedure
16324385|NCT04508478|Experimental|Aerobic training|
16324386|NCT04508478|Active Comparator|Resistance training|
16324387|NCT04508478|Placebo Comparator|Control|
16324388|NCT04508465||OMEGA|Patients who have undergone major emergency abdominal surgery including the stomach, small or large bowel, or rectum for conditions such as perforation, ischemia, abdominal abscess, bleeding or obstruction.
16324389|NCT04508452|Experimental|mXELOXIRI+Bev reintroduction|"Patients will receive mXELOXIRI+BEV as first-line therapy (to be repeated every 2 weeks for a maximum of 12 cycles), followed to initiate a MDT to determine whether to perform a surgery or receive maintenance therapy. Maintenance treatment: CAP+BEV. The following CAP+BEV therapy will be repeated in 2-week cycles.
~At the time of disease progression, patients will be re-introduced XELOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 12 cycles. If no progression occurs during XELOXIRI plus bev, patients will receive maintenance CAP+BEV at the same dose used in the last cycle of the induction treatment."
16324390|NCT04508439|Experimental|Prophylactic enexaparin|Enoxaparin dose of 1mg / kg / dose twice daily
16324391|NCT04508439|Active Comparator|Therapeutic Enoxaparin|Enoxaparin dose of 1mg / kg / dose daily
16324392|NCT04508426|Experimental|Mass Balance|
16324393|NCT04508413|Other|KB295|
16324394|NCT04508400|Experimental|a single dose of fosaprepitant|Participants received a single dose of fosaprepitant (age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
16324395|NCT04508400|Placebo Comparator|a single dose of matched placebo|Participants received a single dose of matched placebo for fosaprepitant administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
16324396|NCT04508387|Active Comparator|Group HH (heated-humidified) patients|Group HH (heated-humidified) patients were administered 95% humidified CO2 insufflation at 37°C. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
16324397|NCT04508387|Placebo Comparator|Group CD (cold-dry) patients|Group CD (cold-dry) patients were administered dry CO2 via insufflator at room temperature (21°C). All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
16324398|NCT04508374|Experimental|1470 nm diode laser treatment of right HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the right side, while the HS tunnel on the left side will be left as an untreated control.
16324399|NCT04508374|Experimental|1470 nm diode laser treatment of left HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the left side, while the HS tunnel on the right side will be left as an untreated control.
16324400|NCT04508348|Active Comparator|Exclusive Human Milk|Group One will receive an exclusive human milk diet throughout the 28-day feeding period or until hospital discharge
16324401|NCT04508348|Other|Maternal human milk or Formula|Group Two (Control Group) will receive maternal human milk or formula (per standard of care).
16324402|NCT04508322|Active Comparator|Group 1|Early treatment HGA (9 years)
16324403|NCT04508322|Active Comparator|Group 2|Late treatment HGA (11 years)
16324404|NCT04508322|Active Comparator|Group 3|Treatment FA
16324412|NCT04508257|Experimental|Investigational Formula (Stage 1&2)|Investigational formula contains DHA，ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants.
16324413|NCT04508257|Active Comparator|Control formula (Stage 1&2)|Control formula have comparable macronutrients and micronutrients, but does not contain DHA，ARA and MFGM.
16324414|NCT04508257|Other|Breast feeding|Breast fed of human milk
16324415|NCT04508244|Active Comparator|TBI with positive troponin|Patients will receive IV propranolol for 6 days
16324416|NCT04508244|Placebo Comparator|TBI with negative troponin (a)|Patients will receive IV placebol for 6 days
16324417|NCT04508244|Experimental|TBI with negative troponin (b)|Patients will receive IV propranolol for 6 days
16324418|NCT04508231||Hormonal treatment|The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria.
16324419|NCT04508231||Controls|Data for control subjects are retrieved from medical records of healthy non-obese females and males who underwent an initial assessment for gender dysphoria in our department, but not yet receiving hormonal treatment at the time of the present study.
16324420|NCT04508218|Experimental|Protein+ Exercise group|Received oral protein supplementation, exercise program and traditional burn care
16324421|NCT04508218|Experimental|Protein group|Received oral protein supplementation and traditional burn care
16324422|NCT04508218|Experimental|Exercise group|Received exercise program and traditional burn care
16324423|NCT04508218|Other|Control group|Received traditional burn care
16324424|NCT04508205|Experimental|Subjects with redness and bumps and/or blemishes|Topical administration twice daily for 12 weeks
16324425|NCT04508192|Experimental|Copenhagen Adduction|The CA is a high-intensity partner exercise where the player is lying on their side using the elbow of the lower forearm to support their body and the other arm placed along their body. The upper arm is supported by the partner who places their one hand under the knee and the other under the ankle, holding the leg approximately in the height of their hip. The player performs a 3-second concentric movement lifting their body until it reaches a straight line. At the same time, the other leg is adducted so that it touches the other leg. A 3-second eccentric adduction then follows with the body lowered halfway to the ground and the foot of the lower leg touching the ground without supporting the body.
16324426|NCT04508192|Active Comparator|Adductor Squeeze|The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees. The player lies supine with the ball placed between the knees with the knees and hips flexed and the feet flat on the surface with the first toe is pointed straight forward.the player is asked to press against the ball as hard as they can The contraction is held for 10 seconds
16324427|NCT04508179|Experimental|7HP349 Capsules|Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (2-period cross-over)
16324428|NCT04508179|Placebo Comparator|Placebo Capsules|Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)
16324429|NCT04508166|Experimental|Dexmedetomidine|Sublingual dose of dexmedetomidine
16324430|NCT04508166|Active Comparator|Gamma-hydroxybutyrate|Oral dose of gamma-hydroxybutyrate
16324431|NCT04508166|Placebo Comparator|Placebo|Oral (saline) and sublingual (orodispersible tablet) doses
16324432|NCT04508153|Other|Leva PDHS arm|"Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.
~Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks."
16324433|NCT04508153|Other|Kegel arm|Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
16324434|NCT04508140|Experimental|Single Arm|The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
16324435|NCT04508127||Active Procedure|The patients will receive targeted Percutaneous Spinal Cord Stimulation at suitable DRG with Axium SCS system as part of their standard treatment for lumbar pain. The lead placement will happen in 2 stages. First stage involves placement of leads and an externalised device and is a trial stage. Patient deemed to have a good response to first stage will proceed to the second stage to have the permanent implant. Again this is part of our standard care. Normally our drop out rate after first stage is less than 10% and these patients will not have subsequent tests including PET-CT scan and questionnaires.
16324436|NCT04508114|No Intervention|control group|Participants in the control group will not receive the ATP testing result (pretest) immediately until finished the research.
16324437|NCT04508114|Experimental|experimental group|Participants in the experimental group will be informed the ATP testing result (pretest) and receive the explanation by research assistant.
16324438|NCT04508101||drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty with suction drainage positioning
16324439|NCT04508101||non-drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty without suction drainage positioning
16324440|NCT04508088||Crohn Disease|"This group will be 10 adolescent girls, ages 13-20, who have been recently (within 12 months) diagnosed with Crohn Disease.
~All participants will have a single study visit during which the listed diagnostic testing will be performed."
16324441|NCT04508088||Control|"Controls will be matched for age, Tanner staging, and both height percentile and BMI percentile.
~All participants will have a single study visit during which the listed diagnostic testing will be performed."
16324445|NCT04508062|Active Comparator|Pectopexy and uterosacral ligaments plication group|this group will have pectopexy operation with bilateral uterosacral ligaments plication
16324447|NCT04508036||Study Group|Premature newborns born before 32nd gestational week and weighing less than 1500 grams.
16324450|NCT04508010|Experimental|IVR survey|Participants will receive an IVR survey
16324451|NCT04508010|Experimental|CATI survey|Participants will receive a CATI survey
16324452|NCT04507984||Children with hypercholesterolemia (Slovenia)|Children (aged 5 years) with total cholesterol measurement at primary care pediatricians at the programed visit prior to school entry.
16324453|NCT04507984||Children with hypercholesterolemia (Lower Saxony, Germany)|Children (aged 2-6 years) with LDL-cholesterol measurement during the compulsory routine check-ups and at any voluntary visits to the primary care pediatricians.
16324454|NCT04507984||Children referred for FH genetic analysis (Slovenia and LS)|Children referred for familial hypercholesterolemia genetic analysis to the tertiary center, according to the screening algorithm.
16324455|NCT04507984||Parents and siblings of children with confirmed FH (Slovenia)|Parents or siblings of index cases with completed familial hypercholesterolemia genetic analysis, according to the screening algorithm.
16324456|NCT04507971|Experimental|MET-3 2.5 g daily for 4 weeks|MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
16324457|NCT04507971|Experimental|MET-5 2.5 g daily for 4 weeks|MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
16324458|NCT04507958||Electronic auscultation|
16324459|NCT04507958||Conventional ausculatation|
16324460|NCT04507945|Experimental|living quality|
16324461|NCT04507945|Experimental|complication|
16324462|NCT04507932|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
16324463|NCT04507906|Other|Nivolumab + Anlotinib Arm|
16324464|NCT04507893||SARS-COV-2 PNEUMONIA CONFIRMED BY PCR ON NASOPHARYNGEAL SWAB|Hospitalized patients affected by COVID-19 interstitial pneumonia (with positive PCR on naso-pharyngeal swab)
16324465|NCT04507893||NEGATIVE SARS-COV-2 PNEUMONIA|Hospitalized patients affected by negative COVID-19 interstitial pneumonia (with negative PCR on naso-pharyngeal swab)
16324466|NCT04507880|Experimental|RTSA group|Participants with a complex proximal humerus fracture given a RTSA
16324467|NCT04507880|Active Comparator|Hemiarthroplasty group|Historical cohort of participants, operated with a hemiarthroplasty of the shoulder
16324468|NCT04507867|Sham Comparator|control group|Patients who received the standard diet
16324469|NCT04507867|Experimental|Intervention group|Patients who received the nutritional support system (NSS) and the standard diet
16324470|NCT04507854|Experimental|Operated athletes|
16324472|NCT04507828|Experimental|Combined DIBH-Expiration Planning Technique|Patients will undergo a 4D scan as well as a DIBH scan and an expiration breath hold scan. In order to develop a combined DIBH-Expiration treatment plan, the DIBH scan, the expiration phase of the 4D scan or the expiration breath hold scan will be used. If the radiation plan meets the coverage goals and normal tissue constraints, the patient will receive treatment using the new DIBH Planning Technique. If coverage and normal tissue constraints are not met per protocol, the patient will be treated per standard of care and not on protocol. Patients treated on protocol will undergo radiation treatment with SBRT for a total of 3 fractions and will receive each fraction no more frequently then every other day. Patients will then be evaluated at 1 month after SBRT completion and every 3 months for 2 years
16324473|NCT04507815|Experimental|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
16324474|NCT04507815|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This ramp up/down method is done at the end of the stimulation period, as well. This method mimics the physical sensation of stimulation typically encountered at the very beginning and end of the intervention period.
16324475|NCT04507802|Experimental|Non invasive ventilation via helmet|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
16324476|NCT04507802|No Intervention|Non invasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
16324477|NCT04507789|Experimental|exercise intervention group|This group will be taken an exercise intervention during their radiotherapy programme.
16324478|NCT04507789|Active Comparator|routine radiotherapy protocol|This group will not be taken into an exercise intervention during their radiotherapy programme.
16324479|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
16324481|NCT04507750|Experimental|camrelizumab+apatinib mesylate|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
16324482|NCT04507737|Experimental|Critical Care Outreach Team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Critical Care Outreach Team Model consisting of an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
16324483|NCT04507737|No Intervention|Medical Emergency team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Medical Emergency Team Model, consisting of an ICU-trained Doctor as well as an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
16324484|NCT04507711|Experimental|0 ng/ml|Blood specimen which was added of 0 ul of palonosetron
16324485|NCT04507711|Experimental|5 ng/ml|Blood specimen which was added of 0.2 ul of palonosetron
16324486|NCT04507711|Experimental|50 ng/ml|Blood specimen which was added of 2 ul of palonosetron
16324487|NCT04507711|Experimental|100 ng/ml|Blood specimen which was added of 4 ul of palonosetron
16324488|NCT04507698|Experimental|Supervised Exercise Arm|If participants are placed in the Supervised Exercise Group, they will attend supervised group exercise sessions, which are individually tailored to the participants physical condition, at least once a week, every week for the first year of the study. They will be asked to exercise 3 times a week.
16324489|NCT04507698|No Intervention|Self-Directed Exercise Arm|If Participants are placed in the Self-directed Exercise Group, they will receive usual medical care (standard of care) and be asked to follow their usual exercise and lifestyle routine. They will receive supportive care in the form of newsletters, covering a variety of topics including pain management, bone health, goal setting, taking control of life, and more.
16324490|NCT04507685|Experimental|Low Glycaemic Diet (LG)|Low carbohydrate, low saturated fat diet
16324491|NCT04507685|Active Comparator|Control Diet|High unrefined carbohydrate, low fat diet
16324492|NCT04507672|Placebo Comparator|saline group|Use saline for fluid resuscitation during the first 72 hours after enrollment
16324493|NCT04507672|Experimental|Acetated Ringer's solution group|Use acetated Ringer's solution for fluid resuscitation during the first 72 hours after enrollment
16324494|NCT04507659|Active Comparator|Jaktinib 100mg|100 mg bid.po
16324495|NCT04507659|Active Comparator|Jaktinib 75mg|75 mg bid.po
16324496|NCT04507659|Placebo Comparator|Placebo|Placebo bid.po
16324497|NCT04507646|Experimental|True auricular acupuncture|Effective auricular acupuncture
16324498|NCT04507646|Sham Comparator|Sham auricular acupuncture|Ineffective auricular acupuncture
16324499|NCT04507633|Experimental|ROMA therapy|ROMA therapy combines four elements including reminiscence, reality orientation, music, and art in the intervention.
16324500|NCT04507633|No Intervention|control group|usual care
16324501|NCT04507620||cervical neck collar|
16324502|NCT04507620||head blocks strapped on the backboard|
16324503|NCT04507607|Experimental|Pregnant women with CHB|Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.
16324504|NCT04507607|Active Comparator|women with CHB|Nonpregnant women taking TAF for antiviral therapy were regularly rechecked for liver function, viral load, and antigens.
16324505|NCT04507594||Patients undergoing Thoracic Surgery|
16324506|NCT04507568|Experimental|Person-Centered Model-of-Care|Patients randomized to the person-centered model-of-care will have a 30 minute education session with a radiation therapist in addition to the standard of care, radiation therapy procedures.
16324507|NCT04507568|Other|Standard Model-of-Care|Patients randomized to the standard model of care will be treated as per standard of care.
16324508|NCT04507555|Experimental|Intervention|
16324509|NCT04507555|Active Comparator|Standard Care|
16324510|NCT04507555|No Intervention|Observational|
16324511|NCT04507542|Experimental|Enriched Music-Supported Therapy group|Participants in the eMST-group will follow a 10-week program of Enriched Music-Supported Therapy. The program comprises 3 individual self-training sessions and 1 group session per week (total program duration: 40 hours).
16324512|NCT04507542|Active Comparator|Control group|Participants in the control intervention group will follow the Graded Repetitive Arm Supplementary Program (GRASP, Harris et al., 2009). They will be asked to complete 4 weekly one-hour session for 10 weeks (total program duration: 40 hours).
16324513|NCT04507529|Experimental|Peer-mentoring|Peer-mentoring
16324514|NCT04507516||Water-only Fasting Cohort|Obese/overweight, non-diabetic patients undergoing elective water-only fasting treatment.
16324515|NCT04507490|Experimental|Whole body vibration 6 Hz|application of whole body vibration in the following parameters:frequency 6 Hz, amplitude 4 mm, five cycles lasting 1 minutes and interval between cycles of 1 minute
16324516|NCT04507490|Experimental|Whole body vibration 25 Hz|application of whole body vibration in the following parameters: 25 Hz frequency, 4 mm amplitude, five cycles lasting 1 minute and interval between 1 minute cycles
16324517|NCT04507490|Sham Comparator|Whole body vibration sham|application of whole body vibration in the following parameters: The sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to that of the connected platform for a time equivalent to that of the treatment protocol.
16324518|NCT04507477|Experimental|Rituximab + Ex-vivo lung perfusion|Donor lungs deemed suitable for such patients will undergo ex vivo lung perfusion (EVLP) as per standard practice. In clinical practice almost all adult donor lungs are EBV seropositive. If in the rare case the donor lung is EBV seronegative, then the lung transplant candidate/recipient will no longer need to be part of the study. Therefore, for EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours. Lungs will then be transplanted as per standard procedure.
16324519|NCT04507464|Experimental|Ecological Momentary Intervention|Participants will receive real time physical activity notifications via a wearable activity tracker and smartphone application.
16324520|NCT04507464|No Intervention|Physical Activity Guidelines|Participants will be sent general guidelines for disruption of sedentary time.
16324521|NCT04507451|Experimental|Trained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle training. This program will be delivered 5 days a week.
~Inspiratory muscle training (IMT): using a threshold IMT device with mouthpiece, 5 sets of 6 breaths, intensity is prescribed at 60% of maximal inspiratory pressure for the first set, and then increased to the highest tolerable intensity to allow completion of the 6th breath Expiratory muscle training (EMT): using a bottle filled with water, starting at 5cm and then increased to 8 cm gradually, 5 sets of 6 breaths
~Training program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
16324522|NCT04507451|Placebo Comparator|Untrained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle exercises that are not planned to train muscles. This program will be delivered 5 days a week.
~Inspiratory exercises: fractionated inspiration, 5 sets of 6 breaths Expiratory exercises: using a bottle filled with water (1 cm)
~Exercises program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
16324525|NCT04507425|Active Comparator|Not Intubated|Patients admitted with a trauma injury who do not need to be intubated to receive treatment. Intubated means putting a tube down your throat to keep your airway from collapsing. Participants will be randomized to receive one of the three interventions in this arm.
16324526|NCT04507425|Active Comparator|Intubated Patients Undergoing Extubation|Patients admitted with a trauma injury who had to be intubated for treatment of their injury. Interventions administered after the tube is extubated (removed from throat). Participants will be randomized to receive one of the three interventions in this arm.
16324527|NCT04507412|Experimental|arm A|• 9 mg of i.v. dexamethasone
16324528|NCT04507412|No Intervention|arm B|• no steroid supplementation
16324529|NCT04507399|Experimental|Protein Beverage|Whey Protein Beverage
16324530|NCT04507399|Experimental|Control Beverage|Whey Permeate Beverage
16324531|NCT04507386|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
16324532|NCT04507386|No Intervention|Control|The control group will receive regular medical care and advice on healthy lifestyle, including physical activity and healthy eating recommendations
16324533|NCT04507373|Placebo Comparator|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
16324534|NCT04507373|Active Comparator|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
16324535|NCT04507360|Experimental|Engagement Strategy - 1|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
16324536|NCT04507360|Experimental|Engagement Strategy - 2|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
16324537|NCT04507347|Experimental|Test product|Eligible participants will be randomized to receive test product, TRC041266 1500 mg twice daily for 48 weeks.
16324538|NCT04507347|Placebo Comparator|Placebo product|Eligible participants will be randomized to receive matching placebo twice daily for 48 weeks.
16324539|NCT04507321|Experimental|GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension|Participants will receive a single oral dose of GSK3640254 200 milligram (mg) (2×100 mg) tablets with a moderate fat meal. Participants will then be administered a 100 microgram (mcg) dose (approximately 3.7 kilobecquerel; 100 nano Curie) of [14C]-GSK3640254 as an IV infusion for 1 hour on Day 1 in treatment Period 1, On Day 1 in treatment Period 2, participants will receive a single oral dose of 85 mg (approximately 3.15 megabecquerel; 85 micro Curie) [14C]-GSK3640254 administered as an oral suspension with a moderate fat meal. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
16324541|NCT04507295|Active Comparator|volume controlled group|"15 patients in is this group will be ventilated during capnothorax using volume controlled ventilation with the following parameters:
~FIO2 of 60 %.
~Tidal Volume (TV) of 6-8 ml/kg.
~Respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.
~inspiratory to expiratory ratio (I: E) 1:2.
~using a minimal Positive End Expiratory Pressure (PEEP) of 2 cm H2O."
16324542|NCT04507295|Active Comparator|pressure controlled group|"15 patients in is this group will be ventilated during capnothorax using pressure controlled ventilation with the following parameters:
~FIO2 60 %.
~inspiratory pressure adjusted to fulfil the required TV according to the weight of the patient (6-8 ml /kg) then the insufflation pressure will be added to the driving pressure.
~respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.
~I:E ratio of 1:1.5 .
~Using a minimal PEEP of 2 cm H2O."
16324543|NCT04507282||COVID 19 positive patients|
16324548|NCT04507243|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
16324549|NCT04507243|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
16324550|NCT04507217|Experimental|BM without prior radiotherapy|"No Prior Systemic treatment for Stage IV NSQ-NSCLC
~With asymptomatic untreated BM"
16324551|NCT04507217|Experimental|BM with prior radiotherapy|"No Prior Systemic treatment for Stage IV NSQ-NSCLC
~With Clinical stable BM with prior radiotherapy"
16324552|NCT04507204|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
16324553|NCT04507204|Active Comparator|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
16324554|NCT04507178|No Intervention|prophylactic dose LMWH|Patients assigned to the control group will receive standard care according to current protocol with a prophylactic dose of LMWH (nadroparin once daily 2850 AxaIE subcutaneously) starting within 24 hours after coiling, continued until discharge or when mobilized for at least six hours a day.
16324555|NCT04507178|Active Comparator|therapeutic dose LMWH|In the intervention group, the standard prophylactic dose will be replaced by a higher dose of LMWH (nadroparin; twice daily 5700 IE) starting within 24 hours after coiling and continued for 21 days after initial SAH. After this, patients will continue with standard care (prophylactic dose until discharge or when mobilized for more than six hours per day).
16324556|NCT04507165|Experimental|opioid-free general anesthesia|under opioid-free general anesthesia
16324557|NCT04507165|Active Comparator|opioid based general anesthesia|under opioid based general anesthesia
16324558|NCT04507152|Experimental|Blood flow restriction resistance training|
16324559|NCT04507152|Active Comparator|Resistance training|
16324560|NCT04507126|Experimental|BCG Immunization|All participants will receive two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 1.8-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
16324561|NCT04507113|Experimental|Lumbar radiculopathy|Patients with acute lumbar radiculopathy (less than 3 months of evolution)
16324562|NCT04507100|Experimental|Lifestyle and environment intervention|Schools will receive the components of Salud Escolar
16324563|NCT04507100|No Intervention|Wait-list control|Wait-list control of schools without intervention.
16324564|NCT04507087|Experimental|Intervention|See detailed preregistration: https://osf.io/xrckh/registrations
16324565|NCT04507087|Sham Comparator|Control|See detailed preregistration: https://osf.io/xrckh/registrations
16324566|NCT04507074|Experimental|Patients With Obesity|40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and chronic low back pain.
16324567|NCT04507074|Active Comparator|Normal-Weight Patients|20 subjects aged 35-60 with normal body weight (BMI ≤ 24.9 and ≥ 18.5 kg/m2) suffering from chronic low back pain.
16324568|NCT04507061|Experimental|runcaciguat|Participant randomized to this arm will be up-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
16324569|NCT04507061|Placebo Comparator|Placebo|Participant randomized to this arm will be sham-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
16324570|NCT04507048|Active Comparator|Passive intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
16324571|NCT04507048|Experimental|Active intervention|"A standardized oral explanation will be given to the patient by a dermatologist, together with the administration of a booklet containing written information of 2 clinical rules for detection of melanoma, as the ABCDE and the ugly duckling rules."
16324572|NCT04507035|Experimental|Anlotinib group|After 2 cycles of anlotinib treatment, we evaluate the therapeutic effect of tumor treatment: If it achieve downgrading and is operable, surgical treatment will be performed; if it is still inoperable and could accept radiotherapy, radiotherapy and chemotherapy will be combined with oral chemotherapy of anlotinib until the end of radiotherapy. Efficiency and side effects will be evaluated within 3 months after therapy. Finally, the survival is in follow-up.
16324573|NCT04507022|Experimental|HRT Plus Aromatase Inhibitor|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups:
~Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2.
~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
16324574|NCT04507022|Active Comparator|HRT Only|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2.
~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
16324575|NCT04507009|Active Comparator|Control|Traditional treatment group which alvogyl applied to the socket after irrigation
16324576|NCT04507009|Experimental|Ozone|Ozone group which Ozone (O3) applied after irrigation of the socket
16324577|NCT04507009|Experimental|CGF +Ozone|CGF + Ozone group which concentrated growth factor (CGF) after Ozone (O3) applied followed by irrigation of the socket.
16324608|NCT04506827|Active Comparator|Control group|patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation
16324609|NCT04506827|Experimental|Test group 1|patients in the test group 1 received TCP with particle size from 250 to 1000 µm
16324578|NCT04506996|Experimental|Intervention Group - Receiving Text Messages|"The 16-weeks text-messaging intervention centered around 8 goal topics: eating only when hungry, increasing PA, eating a lower fat diet, eating less sugar and reducing calories from beverages, exercising more, eating a balance diet, portion control, and making healthier food choices in social situations.
~Messaging
~Sun evening: asked to pick 1 of 3 goal topics
~Mon morning: received a goal to focus on for the week
~Mon evening: asked whether plans were made to reach the goal
~Wed morning: received a tip to help reach goal
~Wed evening: reminded that if having cravings, text tip to automatically receive a tip
~Fri morning: received end of the week congratulations, encouragement to keep goals in mind over the weekend
~Fri evening: asked for weight, congratulated if lost weight, or encouraged if no weight lost"
16324579|NCT04506996|Active Comparator|Control Group - Written Messages|"Participants in the control group, received a printed copy of the same messages that the intervention group received. However, the first eight-weeks' worth of messages and craving tips were given after the baseline assessment, and the rest were given after the first follow-up assessment (~ 8 weeks post randomization).
~The messages for each week were clearly laid out and labeled. Participants were given spaces to record their answers (i.e. to which goal they were selecting for each week). The study staff reviewed the first week's messages together with the study participants to get the participants comfortable with the format that the printed messages were presented in."
16324580|NCT04506983|Experimental|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).
16324581|NCT04506970||Intrauterine Growth Restriction|Pregnant women carrying a fetus identified with intrauterine growth restriction during the third trimester (>28 weeks gestation)
16324582|NCT04506970||Normal pregnancy|Pregnant women identified with an uncomplicated pregnancy during the third trimester (>28 weeks), matched for fetal sex and gestational age with women enrolled in the IUGR group.
16324583|NCT04506944||General population|Whole population of scrub typhus endemic villages
16324584|NCT04506944||hospital case population|cases recruited at study clinics who are not enrolled in general population cohort
16324585|NCT04506944||Serological cohort|random subset of 4000 participants above the age of 10 drawn from general population cohort
16324586|NCT04506931|Experimental|Short Message Service (SMS) survey|Participants will receive an SMS survey
16324587|NCT04506931|Experimental|Interactive Voice Response (IVR) survey|Participants will receive an IVR survey
16324588|NCT04506931|Experimental|Computer Assisted Telephone Interviews (CATI) survey|Participants will receive a CATI survey
16324589|NCT04506918|Experimental|IVR survey|Participants will receive an IVR survey
16324590|NCT04506918|Experimental|SMS survey|Participants will receive an SMS survey
16324591|NCT04506905|Experimental|Part 1 (Panel A) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
16324592|NCT04506905|Experimental|Part 1 (Panel B) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
16324593|NCT04506905|Experimental|Part 1 (Panel C) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
16324594|NCT04506905|Experimental|Part 2 (Panel D) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
16324595|NCT04506905|Experimental|Part 2 (Panel E) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
16324596|NCT04506905|Experimental|Part 2 (Panel F) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
16324597|NCT04506905|Experimental|Part 2 (Panel G) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
16324598|NCT04506905|Placebo Comparator|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
16324599|NCT04506905|Placebo Comparator|Part 2 (Panels D, E, F, G) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
16324600|NCT04506892||Adept Meditators|Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.
16324601|NCT04506879|Other|Popliteal Sciatic Nerve block|Patients will lie on their chest on the examination couch with both feet rested on the pillow to relax their lower extremity. Ultrasound scan of the nerves in popliteal fossa will be identified and then local anesthetic agents [1.5% lidocaine with 1:200,000 adrenaline and 0.5ml of 8.4% sodium bicarbonate (total 30ml)] will be injected close to the nerves (Common peroneal nerve and tibial nerve). The injections below the bifurcation near the two nerves are expected to produce quicker block than the injections above the bifurcation.
16324602|NCT04506866|Other|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
16324603|NCT04506866|Other|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
16324604|NCT04506866|Other|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
16324605|NCT04506853|Other|Study Procedure|
16324606|NCT04506840|Experimental|Training group|Participants will participate in a program of physical exercise during the adjuvant chemotherapy treatment
16324607|NCT04506840|No Intervention|Not training group|Participants will not do any intervention, they only will be perform the pre and post-tests.
16324610|NCT04506827|Experimental|Test group 2|patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid
16324611|NCT04506814|Active Comparator|Endocardial PVI|Endocardial complete PVI
16324612|NCT04506814|Experimental|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip
16324613|NCT04506801|Placebo Comparator|Placebo|liquid oral formulation 9 drops once a day
16324614|NCT04506801|Experimental|Probiotic|The probiotic contained Lactobacillus acidophilus LA3; 1 · 1011 CFU / g, Bifidobacterium animalis subsp. Lactis BLC1; 1.5 · 1011 CFU / g and Lactobacillus casei BGP93 2 · 1011cfu / g in the form of a liquid oral formulation
16324615|NCT04506775|Experimental|Wrist one|Wrist one will have both the ViTrack wrist cuff on one wrist
16324616|NCT04506775|Active Comparator|Wrist Two|Wrist two and the radial artery catheter in the opposite wrist.
16324617|NCT04506762|No Intervention|Control|Standard of care for peri operative analgesia
16324618|NCT04506762|Experimental|Intervention|Bilateral ESP catheters for peri operative regional analgesia
16324619|NCT04506749|Experimental|Experimental group|"Consumption of antioxidant boiled ham, 100 grams daily to consume during the day.
~Consumption time: 8 weeks."
16324620|NCT04506749|Placebo Comparator|control group Placebo|Consumption of extra boiled ham, 100 grams daily to consume during the day. Consumption time: 8 weeks.
16324621|NCT04506736|Active Comparator|SPV spontanous ventilation|The patients will be ventilated using volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
16324622|NCT04506736|Active Comparator|OLA open lung ventilation|The patients will undergo ARM followed by personalized PEEP.
16324623|NCT04506723|Experimental|Patients with urolithiasis|Patients with confirmed urolithiasis who is assigned to PCNL.
16324624|NCT04506723|Active Comparator|Patients without urolithiasis|Patients with renal tumor without urolithiasis in history who is assigned to partial or radical nephrectomy due to renal tumor.
16324625|NCT04506710||Patients with low-risk prostate cancer|Histologically confirmed low-risk prostate cancer (PSA up to 10 ng / ml; Gleason (3 + 3) = 6 (ISUP 1); tumor stage T2a (low- risk according to the D'Amico scale))
16324626|NCT04506697|Experimental|Patients with LUTS|Patients who are indicated for uroflowmetry
16324627|NCT04506671|Experimental|Cryoablation group|Patients with T1b renal tumor and ECOQ>20
16324628|NCT04506671|Active Comparator|Partial nephrectomy group|Patients with T1b renal tumor
16324629|NCT04506658|Experimental|Intervention group|
16324630|NCT04506658|Sham Comparator|Control group|
16324631|NCT04506645|Experimental|REGN5381|Single dose REGN5381 administered via IV infusion
16324632|NCT04506645|Other|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
16324633|NCT04506619||SHP607 250 mcg/kg/24 hours|Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
16324634|NCT04506619||SHP607 400 mcg/kg/24 hours|Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
16324635|NCT04506619||Standard Neonatal Care|Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
16324636|NCT04506606|Experimental|Afferent effect on hemodynamics|Evaluate impact of group III/IV muscle afferents on femoral blood flow
16324637|NCT04506606|Experimental|Afferent effect on fatigue|Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force
16324638|NCT04506606|Experimental|Effect of cardiac rehab|Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
16324639|NCT04506580|Experimental|Dermabond group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using DERMABOND™ PRINEO™
16324640|NCT04506580|No Intervention|Subcuticular group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using 3-0 Dermalon with subcuticular suture method
16324641|NCT04506567|Experimental|Dose- Fractionated Cohort|
16324642|NCT04506567|Experimental|Multiple Dose Cohort|
16324643|NCT04506554|Experimental|AMVAC + nivolumab|This will be a single-arm, open-label, multicenter phase 2 study of neoadjuvant nivolumab with AMVAC. Approximately 70 evaluable patients will be enrolled into this study. Eligible patients will be those with diagnosis of muscle invasive urothelial carcinoma of the bladder who are cT2 or cT3 but not clinical N1 at diagnosis. Clinical stage is confirmed by transurethral resection of bladder tumor (TURBT#1).
16324644|NCT04506541|Experimental|Kangaroo Care Group|"The pregnant women who were in the kangaroo care group of the study and who were 36-38 weeks of gestation were given 20 minutes of kangaroo care and breastfeeding training by the researcher. A video about kangaroo care and breastfeeding was sent to pregnant women to remind them two weeks after the training. Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room. In the first, third, sixth, and ninth months after the discharge of the mothers who started applying kangaroo care, kangaroo care application status, breastfeeding status, baby's growth, and development status were evaluated. In each follow-up, the baby's height, weight, and head circumference were measured with a standard measuring tool."
16324645|NCT04506541|No Intervention|Control Group|The pregnant women in the control group were not trained other than breastfeeding training given in the hospital. In the maternity room, routine care practices were performed after delivery of the pregnant women. As in mothers in the kangaroo care group, in the first, third, sixth, and ninth months after the discharge of mothers, kangaroo care application situations, breastfeeding conditions, growth, and development of the baby were evaluated.
16324646|NCT04506528||Patients with COVID-19|The cohort analyzed for the first paper will be those who have met COVID-19 criteria and who have been hospitalized. COVID-19 criteria for inclusion in the study include: ICD-10-CM diagnosis of COVID-19, COVID-19 PCR lab test, and/or COVID-19 antibody lab test.
16324647|NCT04506502|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
16324648|NCT04506489||Psychological investigation|
16324649|NCT04506476|Experimental|Activity tracker with weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients physical activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
16324650|NCT04506476|Experimental|Activity tracker without Weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.
~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
16324651|NCT04506476|No Intervention|Control arm with no activity tracker|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
16324658|NCT04506450|Active Comparator|Peripheral nerve block|The participant will receive a combination of lumbar plexus block, sciatic nerve block, lateral femoral cutaneous nerve block and lateral branch of iliohypogastric nerve block
16324659|NCT04506450|Active Comparator|Spinal anesthesia|The participant will receive a combination of spinal anesthesia and lumbar plexus block
16324660|NCT04506437|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
16324661|NCT04506437|Active Comparator|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
16324662|NCT04506424|Experimental|CT-Based Program for First Year of CI Use|"The Flat Panel CT scan will take place after a CI has been implanted and prior to the CI device activation.
~The CI device will be activated using a CT-based program. The participant may continue to use this program for 1 year. Speech and music perception abilities will be monitored at regular intervals (approx. at 1, 3, 6, and 12 months post-activation).
~After the 1 year of experimental program use, the participant may be switched over to a program that uses only the clinical default settings for 1 month; after which the participant will again complete the speech and music test battery.
~At the end of the 13 month study the participant may choose whether to use the CT-based program or the clinical default program moving forward."
16324663|NCT04506411|Experimental|TPG|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
16324664|NCT04506411|Active Comparator|STE|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
16324665|NCT04506411|Placebo Comparator|Control|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
16324666|NCT04506398||Retrospective cohort|20 HCC patients experienced post-transplant HCC
16324667|NCT04506398||Perspective cohort|20 HCC patients who underwent liver transplant, the patients would be recruited if recurrence would be diagnosed >6 months after liver transplant
16324668|NCT04506385|Active Comparator|A|L. delbrueckii LDD01
16324669|NCT04506385|Active Comparator|B|Bifidobacterium longum DLBL
16324670|NCT04506385|Active Comparator|C|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: low dosage
16324671|NCT04506385|Active Comparator|D|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: high dosage
16324672|NCT04506372|Experimental|Intervention group|Perioperative withdrawal of ACEI/ARB.
16324673|NCT04506372|Active Comparator|Control group|Perioperative continuation of ACEI/ARB.
16324674|NCT04506359|No Intervention|control group|Control Group: Usual care +case manager care, UC group or Control group
16324675|NCT04506359|Experimental|experimental group|The experimental group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1) - usually patients visited hospital in 2 weeks, 1 month, 2 months, 3 months and 6 months (T2-6) after surgery. Patients will receive (a) nurse-guided touch-screen computer screening (assessment) for their psychological and physical distress and care needs during current week; (b) the screening /assessment results will immediately show as the outcome (we are developing a calculation system to sum those scores).
16324676|NCT04506346||OSAHS|patients with OSAHS, undergoing UPPP
16324677|NCT04506333|Experimental|Small Cuff|"Participants with an upper-arm circumference of 6.3-9.4 may be placed in the small cuff arm."
16324678|NCT04506333|Experimental|Medium Cuff|"Participants with an upper-arm circumference of 9.0-14.6 may be placed in the medium cuff arm."
16324679|NCT04506333|Experimental|Lage Cuff|"Participants with an upper-arm circumference of 12.2-17.7 may be placed in the large cuff arm.
~The large cuff arm will use an adaptive study design. Per the AAMI/ESH/ISO standards, at least 1/6 of participants must fall into each cuff size arm for that cuff size, and of the participants assigned to each cuff size, at least 40% of those must fall in the upper and lower half of the cuff's size range. However, we do not anticipate many participants in our age range falling in the upper half of the large cuff size range (upper arm circumference > 14.95).
~Because of this, our plan is to validate the large cuff, but if enrolling a patient with a large cuff would require additional patients be enrolled to reach 1/6 of the total sample, the large cuff will be dropped from consideration and the validation completed with only the small and medium cuffs."
16324680|NCT04506320||Patients with Multiple myeloma|Adult with diagnosis of multiple myeloma treated with Allo-HSCT from related - HLA identical or volunteer unrelated donor or haploidentical related donor performed from January 1, 2009 to december 31, 2018
16324681|NCT04506307|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.
16324713|NCT04506047||Acute Myocardial Infarction|Consecutive patients with acute myocardial infarction
16324682|NCT04506294|Experimental|eScreen Group|After randomization at baseline, use eScreen system (child screening component and parent information component) for 6 weeks.
16324683|NCT04506294|No Intervention|Usual Care Group|Treatment as usual from baseline. Optional access to the game only (no screening, no parent information component) after completion of T3 assessment (~12 weeks)
16324684|NCT04506281|Experimental|Neoadjuvant treatment|"Gemox chemotherapy:
~Day1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.
~Lenvatinib (8mg/d) for 9 weeks of continuous use.
~Toripalimab (240mg, once every 3 weeks), used 3 times. Evaluate the resectability of the operation within 2-4 weeks after the end of the neoadjuvant treatment course, and implement radical resection. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses"
16324685|NCT04506281|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients undergoing resection use capecitabine 2500mg/m2 twice a day, stopping for 1 week as a course of treatment, totaling 8 courses.
16324686|NCT04506268|Experimental|Opt-in Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and invites them to enroll.
16324687|NCT04506268|Experimental|Opt-out Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and informs them that they have been conditionally enrolled.
16324688|NCT04506255|Experimental|Silicone tape|Adult subjects will act as their own control and will be randomized to have silicone tape applied to one half of their abdominoplasty incision. Patients will apply silicone tape on a daily basis, with each piece lasting 24 hours. Tape may be removed for showers and replied after drying. Total length of treatment will be two and a half months.
16324689|NCT04506255|No Intervention|No dressing|Control treatment using the current standard of care at our institution to the other half, which is no dressing after the initial two week post-op period, will be used on the other half of the incision for comparison. Each individual patient will act as their own control.
16324690|NCT04506242|Experimental|apatinib+ Neoadjuvant/Adjuvant camrelizumab|"Neoadjuvant: Prior to surgery, participants receive 3 cycles (cycle length: 2 weeks) of camrelizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with apatinib ,5 days on 2days off].
~Adjuvant: 4-8 weeks following surgery, participants receive up to 12 cycles (cycle length: 2 weeks) of camrelizumab [200 mg, IV; given on cycle day 1]. Participants who can not able to benefit from immunotherapy will not receive camrelizumab adjuvant therapy."
16324691|NCT04506229||COVID-19 positive|
16324692|NCT04506229||COVID-19 negative|
16324693|NCT04506216|Experimental|cohort|adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
16324694|NCT04506203|Experimental|Air test|
16324697|NCT04506177||Permanent Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) suture for vaginal mesh attachment
16324698|NCT04506177||Delayed Absorbable Monofilament Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using delayed absorbable monofilament (polydioxanone, PDS) suture for vaginal mesh attachment
16324699|NCT04506164|Other|Stepped-wedge|This stepped-wedge trial relies on sequential roll-out of eScreening to participating sites over time, while using other sites as controls until they begin implementation.
16324700|NCT04506151|Experimental|Sleep-Opt|12-week intervention that includes self-monitoring, goal setting, motivational enhancement.
16324701|NCT04506151|Active Comparator|Healthy Living|12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.
16324702|NCT04506138|Experimental|Camrelizumab plus Chemotherapy|
16324703|NCT04506125|Experimental|Liberal Group|transfusion of an erythrocyte concentrate in case of haemoglobin below 9.5 g/dL
16324704|NCT04506125|Active Comparator|Restrictive group|transfusion of an erythrocyte concentrate in case of haemoglobin below 7.5 g/dL
16324705|NCT04506112|Experimental|TranS-C + Usual Care|Participants in this group will receive TranS-C and will continue with care in cardiac rehabilitation as usual.
16324706|NCT04506112|No Intervention|Usual Care|Participants in this group will receive only usual care and thus will continue with care in cardiac rehabilitation as usual.
16324709|NCT04506086|Experimental|Blinatumomab|
16324710|NCT04506073|Experimental|MSC+placebo|2 treatment doses + 1 placebo 3 months apart
16324711|NCT04506073|Experimental|MSC|3 treatment doses 3 months apart
16324712|NCT04506073|Placebo Comparator|Placebo|3 placebo doses 3 months apart
16324714|NCT04506034|Experimental|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
16324715|NCT04506034|Active Comparator|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
16324716|NCT04506034|Placebo Comparator|IV saline infusion|received i.v. saline infusion.
16324717|NCT04506021||Bicarbonate Ringer's Solution|"According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution.
~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
16324718|NCT04506021||Other Crystalloid|"According to the choices of patients' immediate family members, patients will be divided into Other Crystalloid.
~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
16324719|NCT04506008|Experimental|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy followed by immediate surgical resection
16324720|NCT04505995|Experimental|Intervention group|
16324721|NCT04505982||Tocilizumab intravenous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, intravenous
16324722|NCT04505982||Tocilizumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, subcutaneous
16324723|NCT04505982||Sarilumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with sarilumab, subcutaneous
16324724|NCT04505969||SCD patients and healthcare professionals|
16324725|NCT04505956|Experimental|Moses Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.
16324726|NCT04505956|Active Comparator|Standard Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
16324727|NCT04505943|Experimental|isonicotinic acid hydrazide|2vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
16324728|NCT04505943|Active Comparator|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 12 hours before IUD insertion.
16324729|NCT04505943|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 12hours before IUD insertion.
16324730|NCT04505930|Experimental|Intervention Group with active education|The study team provides participants in the intervention group with interventional education, using interactive video watch and dynamic discussion.
16324731|NCT04505930|Active Comparator|Control Group with handouts|The study team provides the participants in the control group with education, using only handouts of vaccinations including HPV, but not using interactive video watch and dynamic discussion
16324732|NCT04505917|Experimental|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
16324733|NCT04505917|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
16324734|NCT04505917|Placebo Comparator|placebo|Placebo Comparator: placebo 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
16324735|NCT04505904|Experimental|Syntocinon First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.
16324736|NCT04505904|Placebo Comparator|Placebo First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received placebo at visit one, and syntocinon at visit two.
16324737|NCT04505891|No Intervention|Usual care|
16324738|NCT04505891|Active Comparator|Education alone|
16324739|NCT04505891|Active Comparator|Education and follow-up|
16324740|NCT04505878|Experimental|Vitamin C Arm|Ascorbic Acid will be administered at a dose of 1500 mg in 100 mL of saline over 30 minutes intravenously once every 6 hours for a total of 72 hours
16324743|NCT04505852|Experimental|EMBRACE USERS|Embrace wristband users
16324744|NCT04505839|Experimental|STP1002|
16324747|NCT04505813|Experimental|Safety Evaluation Phase|Treatment with NEXI-002 T cells, derived from PBMCs of the patient
16324748|NCT04505813|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI- 002 T cell product at the dose established from the Safety Evaluation Phase.
16324749|NCT04505800|Experimental|Tryptophan supplement|"Pure L-tryptophan in capsules (500mg/capsule)
~3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
16324750|NCT04505800|Placebo Comparator|Maltose|"Placebo is maltose powder capsule (500mg/capsule)
~3g maltose powder per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
16324751|NCT04505787|Experimental|Esflurbiprofen hydrogel patch|"Esflurbiprofen hydrogel patch 165 mg (EFHP) (Teikoku Seiyaku Co.), transdermal patch containing 165 mg S-flurbiprofen, once daily consecutive application over 14 days; each patch to be applied for 24 h, application site: outer ankle (same site and position for all applied patches)"
16324752|NCT04505787|Active Comparator|Froben|"Froben 100 mg comprimidos revestidos (Abbott Laboratórios, Lda., Portugal), immediate release tablets containing 100 mg flurbiprofen, oral multiple dose administration of 1 tablet three times daily (TID) over 4 consecutive days after a light meal"
16324757|NCT04505761|Experimental|Intervention group|Participants will receive Virtual Reality as an add-on to standard physiotherapy after COVID-19.
16324758|NCT04505748|Experimental|Self-transfusion group|Patients to whom a self-transfusion device has been used after total knee arthroplasty.
16324759|NCT04505748|No Intervention|Control group|Patients to whom conventional drains have been used after total knee arthroplasty.
16324760|NCT04505735||Normal Control|Adults with no history of memory complaints, diagnosis of MCI, or dementia from a physician
16324761|NCT04505735||Adults with Mild Cognitive Impairment|Adults with cognitive decline verified by a study partner or cognitive impairment verified by the study physician. The cognitive decline has had limited impact on functional activities; general cognition and functional performance are sufficiently preserved such that a diagnosis of dementia cannot be made by the enrolling physician
16324764|NCT04505696|Other|Speech-Language Pathology Introduction and scope|Demographic Information Section on Knowledge & Awareness Section on Practices
16324765|NCT04505683|Experimental|test drug arm|Benapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
16324766|NCT04505683|Active Comparator|active control arm|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
16324769|NCT04505657|Experimental|Celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
16324770|NCT04505657|Active Comparator|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
16324771|NCT04505657|Active Comparator|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
16324772|NCT04505644|Experimental|lidocaine patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
16324773|NCT04505644|Active Comparator|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
16324774|NCT04505644|Placebo Comparator|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
16324775|NCT04505618|Other|Controls|Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.
16324776|NCT04505618|Other|Diabetics with and without Diabetic Retinopathy Only|Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.
16324777|NCT04505618|Other|Hypertension Only|Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
16324778|NCT04505618|Other|Diabetics w/ or w/o Diabetic Retinopathy & Hypertension|Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
16324779|NCT04505605||Patient hospitalized without being transferred in the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 (day of the enrollment = the day of hospitalization in the healthcare institution). The total volume of blood collected as part of the research is therefore 5 ml.
16324780|NCT04505605||Patient directly hospitalized in the ICU|A blood sample on a dry tube with a 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 and D3 of the admission to intensive care. The total volume of blood collected for research is therefore 10 ml.
16324815|NCT04505397|Experimental|Single Ascending Dose Level 3|4 Subjects will receive one dose of 50 mg and 2 subjects will receive one dose of placebo
16325437|NCT04501341|Experimental|BM-MNC experimental|Autologue bone marrow mononuclear cell
16324781|NCT04505605||Patient transferred from an other hospital service to the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test that will be taken at D1 and D3 of the patient's admission to the intensive care unit, even if it has already been included in the study during the patient's admission to the unit (D1 hospitalization). The total volume of blood collected for the research is therefore 15 ml.
16324782|NCT04505592|Experimental|Tenecteplase|First 20 patients randomized to treatment will receive tenecteplase 0.25 mg/kg (maximum 25 mg). Last 20 patients randomized to treatment will receive tenecteplase 0.50 mg/kg (maximum 40 mg).
16324783|NCT04505592|Placebo Comparator|Placebo|Placebo control
16324784|NCT04505579||Tether|Patients who have received The Tether HUD for treatment of idiopathic scoliosis.
16324785|NCT04505566|Experimental|Adult Type II Diabetics - Moderate NPDR - Ketorolac|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy and HbA1c ≥ 8 randomized to Ketorolac treatment.
16324786|NCT04505566|Placebo Comparator|Adult Type II Diabetics - Moderate NPDR - Placebo|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy randomized to placebo treatment.
16324787|NCT04505566|Other|Adult Type II Diabetics - No Diabetic Retinopathy (DR)|23 Adult type II diabetic patients with no diabetic retinopathy as a control group.
16324788|NCT04505566|Other|Adult Type 2 Diabetics-Proliferative Diabetic Retinopathy(PDR)|23 Adult type II diabetic patients with proliferative diabetic retinopathy as a control group.
16324789|NCT04505566|Other|Age-matched Non-diabetics|We will also enroll 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole. Removed aqueous fluid that is typically discarded will instead be collected and stored at -80° C. Aqueous fluid will be tested for inflammatory markers as detailed below to provide a reference level for cross-comparison analysis.
16324790|NCT04505553|Experimental|Arm I (acupuncture, acupressure, cryotherapy)|Patients undergo acupuncture during chemotherapy infusion on day 1 and fluorouracil pump disconnect on day 3 of each biweekly chemotherapy infusion over 12 weeks. Patients also undergo self-administered acupressure over 11 minutes daily for 12 weeks and undergo standard of care oral cryotherapy.
16324791|NCT04505553|Active Comparator|Arm II (cryotherapy)|Patients undergo standard of care oral cryotherapy.
16324792|NCT04505540|Active Comparator|Bridge Clinic|Medication assisted treatment supervised by addiction bridge clinic until stabilized in treatment.
16324793|NCT04505540|Active Comparator|Local Waivered Physcian|Medication assisted treatment supervised by local waivered physician.
16324794|NCT04505527|Active Comparator|Recurrent fallers - control group|In this control arm, older adults will have a typical forward walking training that mirror the lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min forward walking. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
16324795|NCT04505527|Experimental|Recurrent fallers - intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
16324796|NCT04505527|Experimental|Older non-fallers intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
16324797|NCT04505527|Active Comparator|Younger adult control group|Outcome measures from a young healthy group will also be measured as a reference. Will be used to compare outcome measured between older and young adults. Young adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
16324798|NCT04505514|Experimental|Intravenous Iron Group|
16324799|NCT04505514|Active Comparator|Oral Iron Group|
16324800|NCT04505501|Experimental|N-803|N-803 at 6mcg/kg every 3 weeks for 3 doses plus ART (n=10)
16324801|NCT04505501|No Intervention|Control|ART alone (n=5)
16324802|NCT04505488|Experimental|Intervention Group|The intervention group will receive a parent manual, a resource packet, and 12 weekly sessions delivered by the clinician and peer leader.
16324803|NCT04505488|No Intervention|Control Group|The control group will receive a parent manual and a resource packet. Four phone check-ins will be conducted across 12-14 weeks to address questions by the research team.
16324804|NCT04505475||Direct oral anticoagulants|Patients taking dabigatran, ravaroxaban or apixaban
16324805|NCT04505475||Vitamin K antagonists|Patients taking acenocoumarol with therapeutic INR levels (2.0-3.5)
16324806|NCT04505462|Experimental|Study diet|7-day therapeutic diet intervention as experimental group
16324807|NCT04505462|No Intervention|Usual diet|7-day usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet
16324808|NCT04505449||Left heart catheterization|Symptomatic patients who underwent left heart catheterization and coronary angiography.
16324809|NCT04505436|Experimental|HM15211|
16324810|NCT04505436|Placebo Comparator|Placebo|
16324811|NCT04505410|Experimental|Tofacitinib plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
16324812|NCT04505410|Active Comparator|Tofacitinib only group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks.
16324813|NCT04505397|Experimental|Single Ascending Dose Level 1|4 Subjects will receive one dose of 10 mg and 2 subjects will receive one dose of placebo
16324814|NCT04505397|Experimental|Single Ascending Dose Level 2|4 Subjects will receive one dose of 25 mg and 2 subjects will receive one dose of placebo
16324816|NCT04505397|Experimental|Single Ascending Dose Level 4|4 Subjects will receive one dose of 100 mg and 2 subjects will receive one dose of placebo
16324817|NCT04505397|Experimental|Single Ascending Dose Level 5|4 Subjects will receive one dose of 200 mg and 2 subjects will receive one dose of placebo
16324818|NCT04505397|Experimental|Single Ascending Dose Level 6|4 Subjects will receive one dose of 300 mg and 2 subjects will receive one dose of placebo
16324819|NCT04505397|Experimental|Single Ascending Dose Level 7|4 Subjects will receive one dose of 400 mg and 2 subjects will receive one dose of placebo
16324820|NCT04505397|Experimental|Single Ascending Dose Level 8|4 Subjects will receive one dose of 600 mg and 2 subjects will receive one dose of placebo
16324821|NCT04505397|Experimental|Single Ascending Dose Level 9|4 Subjects will receive one dose of 800 mg and 2 subjects will receive one dose of placebo
16324822|NCT04505397|Experimental|Single Ascending Dose Level 10|4 Subjects will receive one dose of 1000 mg and 2 subjects will receive one dose of placebo
16324823|NCT04505397|Experimental|Multiple Ascending Dose Level 1|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
16324824|NCT04505397|Experimental|Multiple Ascending Dose Level 2|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
16324825|NCT04505397|Experimental|Multiple Ascending Dose Level 3|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
16324826|NCT04505397|Experimental|Multiple Ascending Dose Level 4|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
16324827|NCT04505384|Experimental|Left bundle branch pacing|Left bundle branch pacing
16324828|NCT04505384|Active Comparator|Biventricular pacing|Biventricular pacing
16324829|NCT04505371|No Intervention|Control - Standard Care|The control intervention is referral to standard evidence-based cessation services available nationally to Veterans, including the National VA Quitline and SmokefreeVET texting program.
16324830|NCT04505371|Experimental|Intervention - Wellness Intervention for Smokers with HIV|The experimental WISH intervention is an HIV-specific comprehensive wellness program designed to offer integrated phone and text counseling regardless of readiness to quit.
16324831|NCT04505358|Experimental|30 mg PU AD 3:2 ratio|will be administered orally, as 30 mg active dose strength tablets qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
16324832|NCT04505358|Placebo Comparator|30 mg Placebo 3:2 ratio|will be administered orally, as 30 mg placebo tablets (placebo has no active ingredients) qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
16324833|NCT04505345|Experimental|Virtual reality cognitive training|Virtual reality cognitive training consists of a behavioral intervention of 10 sessions of training using virtual reality exercises depicting daily life activities from the Systemic Lisbon Battery aiming cognitive impairments.
16324834|NCT04505345|Other|Treatment-as-usual|Treatment-as-usual for alcohol use disorder (AUD) in our partner institution, a therapeutic community for rehabilitation of AUD, is conducted according to the Minnesota Model requiring alcohol abstinence.
16324835|NCT04505332|Other|orthopedists|orthopedists working actively and performing arthroplasty every day
16324836|NCT04505319|Experimental|DEFINISSE CORE FILLER|"Cross linked sodium hyaluronate 25 mg/ml with 0,3% lidocaine hydrochloride will be inject during the first visit and a touch up after one month if indicated by the physician.
~The filler will inject in the face."
16324837|NCT04505306|Active Comparator|Subthreshold Laser 30%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 30% EndPoint algorithm.
16324838|NCT04505306|Active Comparator|Subtreshold Laser 50%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 50% EndPoint algorithm.
16324839|NCT04505306|Active Comparator|Micropulse Laser|Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle.
16324840|NCT04505293|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ upon arrival to the casualty unit at MRRH following CT. Patients will be scanned using the InfraScanner 2000™ following each subsequent CT as allowed by patient or representative. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
16324841|NCT04505280|Active Comparator|Active|%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks
16324842|NCT04505280|Placebo Comparator|Placebo|0.9% saline injections to greater occipital nerve and cervical region once a week for 4 weeks
16324843|NCT04505267|Experimental|Treatment (NBTXR3, RT)|Patients receive NBTXR3 IT or intranodally on day 1. Within 15 days, patients undergo RT 5 times weekly (Monday-Friday) over 3 weeks for a total of 10-15 fractions.
16324844|NCT04505254|Experimental|Treatment (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16324845|NCT04505241|Experimental|Adaptive Goal-Setting|Participants in this condition will receive daily step goals calculated as the 60th percentile of their last 9 days of available daily steps data. Goals will be transmitted over text message, and will be accompanied by information about the participant's steps on the previous day and whether they met their goal the previous day.
16324846|NCT04505241|Experimental|Static Goal-Setting|Participants in this condition will receive daily a uniform daily goal of 10,000 steps per day. Participants will receive daily texts including information about the participant's steps on the previous day, whether they met their goal the previous day, and encouraging them to continue striving for 10,000 steps each day.
16324847|NCT04505228|Experimental|Research group|The patients receiving Atropine and the extra Chinese herb formulas treatment
16324848|NCT04505228|Active Comparator|Control group|The patients receiving the basic treatment of atropine
16324849|NCT04505215|Experimental|Mulligan Technique|In addition to the exercises applied to the participants in the control group, the participants in this group used Mobilization with movement, which was performed with the principle of painless movement 3 times a week for a total of 12 times a week for 4 weeks. Mobilization with movement has been performed by a certified physiotherapist who has been practicing this technique for 10 years.
16324850|NCT04505215|Experimental|Muscle Energy Technique|In addition to the exercises applied to the participants in the control group, the Janda method (Post Isometric Relaxation Technique) from Muscle Energy Technique (3 times a week) was used 3 times a week for 4 weeks.
16324851|NCT04505215|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the forearm extensors were shown to the participants in the control group for 4 weeks every day of the week.
16324852|NCT04505202|Experimental|Experimental group|0.12% chlorhexidine gluconate
16324853|NCT04505202|Placebo Comparator|Placebo group|sodium bicarbonate
16324854|NCT04505189|Experimental|Treatment|Psilocybin
16324855|NCT04505176||1|20 patients being in the HHHNFC. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
16324856|NCT04505176||2|20 patients in the CPAP group. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
16324857|NCT04505163|Active Comparator|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
16324858|NCT04505163|Experimental|Cryoballoon PVI + Posterior Wall Isolation|Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
16324859|NCT04505150|Experimental|Monitoring of lifestyle change activities|The intervention arm will involve (i) the delivery of a blended learning education program and (ii) weekly phone calls to participants. The lectures will be delivered to 10 teams, comprised of about 15 participants in each team and lead by a volunteer team leader using the ORCD's laptop, overhead projector and the sound system in local clubs, school premises or participants' houses. The ORCD investigator including the physician and an information technology person will facilitate the education programs. The interpretations or additional explanations will be made by the physician following WHO guidelines and recommendations[36]. The investigator will maintain a folder for each team and will communicate at least with the team leaders by phone calls once every week to remind them to adhere to lifestyle modification intervention program. The weekly monitoring program will continue until the study ends.
16324860|NCT04505150|No Intervention|lifestyle change activities: non-monitoring|The control group will only receive the printed materials, no active monitoring
16324861|NCT04505137|Experimental|GMA301 1500mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 1500 mg single Intravenous dose of GMA301 Injection.
16324862|NCT04505137|Experimental|GMA301 2000mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 2000 mg single intravenous dose of GMA301 Injection.
16324863|NCT04505124|Experimental|FutureMe|"Participants use the FutureMe app for 12 weeks. The app has the following functionality:
~Opportunity to personalize one's avatar
~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)
~Feedback on health behaviors represented through a Future-self avatar (consequential and visual feedback)
~Individualized shopping tipps"
16324864|NCT04505124|Active Comparator|Control|"Participants use the a control app for 12 weeks. The control app has the following functionality:
~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)
~Feedback on health behaviors represented through conventional dashboards (numeric & text feedback)
~Individualized shopping tipps"
16324865|NCT04505111|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
16324866|NCT04505111|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
16324867|NCT04505098|Active Comparator|Intervention|
16324868|NCT04505098|No Intervention|Usual Care|
16324869|NCT04505085|Experimental|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
16324932|NCT04504734|Active Comparator|Bucillamine high dose|Bucillamine 200 mg 3 times a day (TID)
16324933|NCT04504734|Placebo Comparator|Placebo|Placebo, 3 times a day (TID)
16324934|NCT04504721|Experimental|Light therapy group|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
16324870|NCT04505085|Experimental|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
16324871|NCT04505085|Experimental|Active Dads Healthy Families: Fitness + Parenting|The intervention will include physical activity opportunities and social support for fathers at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
16324872|NCT04505072|Experimental|PR-ESSENCE treatment|PR-ESSENCE treatment 10 weeks
16324873|NCT04505072|Active Comparator|Control|Treatment as usual 10 weeks
16324874|NCT04505059|Experimental|Precision cardiac anesthesia|Remifentanil (TCI) for intra-operative analgesia Propofol (TCI) for intra-operative sedation
16324875|NCT04505059|Active Comparator|Conventional cardiac anesthesia|Institutional standard of care.
16324876|NCT04505033|Experimental|50 mg s.c|
16324877|NCT04505033|Placebo Comparator|50 mg placebo|
16324878|NCT04505033|Experimental|150 mg s.c.|
16324879|NCT04505033|Placebo Comparator|150 mg placebo|
16324880|NCT04505033|Experimental|300 mg s.c.|
16324881|NCT04505033|Placebo Comparator|300 mg placebo|
16324882|NCT04505033|Experimental|450 mg s.c.|
16324883|NCT04505033|Placebo Comparator|450 mg placebo|
16324884|NCT04505020|Experimental|3D Print + Conventional imaging|Patients in this group allocation will receive a 3D reconstruction of their hip in addition to conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
16324885|NCT04505020|Other|Conventional Imaging|Patients in this group allocation will receive conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
16324886|NCT04505007|No Intervention|Usual clinical care|In this arm, patients with devices and heart failure will undergo usual clinical care. This consists of follow-up as deemed necessary by their primary care providers.
16324887|NCT04505007|Experimental|Specialized clinic|"In this arm, patients with devices and heart failure will be enrolled in a specialized clinic with the following aims:
~Referral to a heart failure nurse practitioner to undergo optimization of medical therapy.
~Optimization of device programming with reduction of ventricular pacing where possible, rate responsiveness when indicated.
~For those patients with CRT - ECG optimization using a previously tested protocol will be performed. This will consist of attempts to achieve the shortest QRS duration with the following guidelines:
~Two BV fusion patterns in leads V1 and V2: QRS normalization or a new or an increased R wave.
~QRS difference ≤-25 ms. Remodelling probability increases as QRS difference takes on larger negative values (QRS difference = BV paced QRS - LBBB QRS duration, in ms)."
16324888|NCT04504994|Experimental|exclusion BPD|cyberball exclusion condition - BPD patients
16324889|NCT04504994|Experimental|over-inclusion BPD|cyberball over-inclusion condition - BPD patients
16324890|NCT04504994|Experimental|exclusion healthy controls|cyberball exclusion condition - healthy controls
16324891|NCT04504994|Experimental|over-inclusion healthy controls|cyberball over-inclusion condition - healthy controls
16324892|NCT04504981|Other|Y2Prevent Intervention|Y2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans.
16324893|NCT04504968|Experimental|Intervention group|Multimodal intervention:
16324894|NCT04504968|Placebo Comparator|Usual care group|Usual care group
16324895|NCT04504955||Atopic Dermatitis|Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
16324896|NCT04504942|Experimental|Leronlimab 525mg|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
16324897|NCT04504929|Sham Comparator|Sham tape|participants received sham taping during pitching, and removed after pitching
16324898|NCT04504929|Experimental|Dynamic tape|participants received dynamic taping during pitching, and removed after pitching
16324899|NCT04504916|Experimental|Zilovertamab vedotin|Participants will receive zilovertamab vedotin at 2.5 mg/kg given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.
16324900|NCT04504903|Experimental|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will participate in 12 weekly group sessions to discuss thoughts, feelings, and behaviors that promote work success in the community
16324901|NCT04504903|Active Comparator|Psychoeducation|Veterans in the control group will participate in 12 weekly group sessions in which they will learn more about their mental health conditions.
16324902|NCT04504890||Adults - Diagnosis|Adults seeking treatment for an attention-related disorder
16324903|NCT04504890||Adults - Prescribed|Adults who have been diagnosed with ADHD and prescribed medication treatment for the disorder
16324904|NCT04504890||Children - Diagnosis|Children seeking treatment for an attention-related disorder
16324905|NCT04504890||Children - Prescribed|Children who have been diagnosed with ADHD and prescribed medication treatment for the disorder
16325251|NCT04502602|Experimental|Dose Level -1|Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
16324906|NCT04504877|Experimental|cannabidiol plus general clinical supportive measures|The participants will receive CBD 300mg/daily plus general measures (supporting motivational videos, fitness videos). All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as well as five collections of saliva, in a collecting tube, to assess viral load. They will also be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
16324907|NCT04504877|Other|general clinical supportive measures|The participants will receive general measures (supporting motivational videos, fitness videos) alone. All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern in a collecting tube to assess viral load. Also, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
16324908|NCT04504864|Experimental|low-dose aspirin|Management policy is to use 50 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 50mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke. But this dose is rarely used clinically, especially in East Asia area.
16324909|NCT04504864|Active Comparator|conventional-does aspirin|Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
16324910|NCT04504851|Active Comparator|Arm A (Standard of Care)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid
16324911|NCT04504851|Experimental|Arm B (Standard of Care plus Rosuvastatin)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol PLUS rosuvastatin, then 16 weeks rifampicin, isoniazid
16324912|NCT04504825|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
16324913|NCT04504825|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
16324914|NCT04504825|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) according to institutional SoC. Patients will have a planned first-line PCD treatment with a CyBorD regimen according to institutional SoC and initiate their PCD treatment within 7 days of receiving the first dose of study drug. Patients can refer to the package insert or Summary of Product Characteristics (SmPC) for contraindications, warnings and precautions for PCD medications.
16324915|NCT04504812|Active Comparator|Phase 1: Best Practices|Participants will receive an intervention from the best practices.
16324916|NCT04504812|Active Comparator|Phase 1: Best Practices + Duloxetine|Participants will receive Duloxetine in addition to an intervention from the best practices.
16324917|NCT04504812|Active Comparator|Phase 1:Best Practices + Duloxetine + Pain coping skills|Participants will receive Duloxetine and pain coping skills training in addition to an intervention from the best practices.
16324918|NCT04504812|Active Comparator|Phase 2: Intra-Articular Injection (HA+)|Participants will receive an intra-articular injection of hyaluronic acid mixed with steroid and bupivacaine.
16324919|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Long Acting Blocks|Participants will receive a nerve blocking procedure, long-acting local anesthetic, and steroid injection.
16324920|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Nerve Ablation|Participants will receive a nerve ablation procedure and steroid injection.
16324921|NCT04504786|Experimental|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included three phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained and certified by the PI, 3 times per week and 40 minutes per session for 6 months.
16324922|NCT04504786|Active Comparator|Control|Participants in the control group continued with their daily activities as usual.
16324923|NCT04504773|Experimental|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
16324924|NCT04504760|Experimental|ONO-2910 (Part A and B)|
16324925|NCT04504760|Placebo Comparator|Placebo (Part A)|
16324926|NCT04504760|Experimental|ONO-2910 (Part C and D)|
16324927|NCT04504760|Placebo Comparator|Placebo (Part C and D)|
16324928|NCT04504747||RH+|Prospective blood and biopsie analyses
16324929|NCT04504747||HER2+|Prospective blood and biopsie analyses
16324930|NCT04504747||TN|Prospective blood and biopsie analyses
16324931|NCT04504734|Active Comparator|Bucillamine low dose|Bucillamine 100 mg 3 times a day (TID)
16324935|NCT04504721|No Intervention|Waiting list group|Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.
16324936|NCT04504708|Experimental|ZX-101A Dose Level 1|Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle
16324937|NCT04504708|Experimental|ZX-101A Dose Level 2|2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
16324938|NCT04504708|Experimental|ZX-101A Dose Level 3|3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
16324939|NCT04504708|Experimental|ZX-101A Dose Level 4|4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
16324940|NCT04504708|Experimental|ZX-101A Dose Level 5|5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
16324941|NCT04504695||Thrombectomy group|Major patients requiring management for endovascular thrombosis
16324942|NCT04504695||Aneurysm group|Major patients requiring management for an intracranial aneurysm
16324943|NCT04504682|Experimental|Ambulation|Participants in this arm will be encouraged to ambulate with epidural in place.
16324944|NCT04504682|No Intervention|No Ambulation|This arm will undergo our current standard of care.
16324947|NCT04504656||1|open surgery
16324948|NCT04504656||2|minimally invasive surgery
16324949|NCT04504643|Experimental|Technology-assisted circuit training|Multicomponent circuit training using FItLight Trainer™ as an embodied tool to perform motor task. The circuit training is composed by aerobic, muscular, coordination and balance exercises.
16324950|NCT04504643|Experimental|Conventional circuit training|Multicomponent circuit training composed by aerobic, muscular, balance and coordination exercises. Coordination exercises wll be charged of simple dual task cognitive exercises (counting backwards, or making some easy math calculations, repeating words backward, finding words of the same family).
16324951|NCT04504643|Experimental|Nordic Walking|The training sessions are performed in a natural parc, which offers pathways of different lengths and levels of difficulty that will increase over the weeks.
16324952|NCT04504630|Active Comparator|Active HD-tDCS|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting dorsal anterior cingulate region for 20 minutes) across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
16324953|NCT04504630|Sham Comparator|Sham HD-tDCS|Participants will receive 10 sessions of sham stimulation across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
16324954|NCT04504617|Experimental|Intervention Group|This group will consist of six kebeles with a total of 90 pairs of mothers and their children that will receive the nutrition education intervention to enhance complementary feeding practices first. The six lessons will be delivered in a period of 6 weeks. Before the intervention this groups will be assessed with the baseline assessment. After the intervention, this group will be assessed in three time points (post-intervention, follow-up 1 and follow-up 2).
16324955|NCT04504617|Active Comparator|Delayed Intervention Group|This arm will consist of the six kebeles with a total of 90 pairs of mothers and their children that will not receive the intervention immediately. This group will first complete the baseline and the second assessment. After the second assessment, this group will receive the nutrition education intervention to enhance complementary feeding practices. After the intervention, this group will be assessed in two additional time points (post-intervention and follow-up 1).
16324956|NCT04504604|Active Comparator|Cholangiocarcinoma|Eligible patients that present with Cholangiocarcinoma.
16324957|NCT04504604|Active Comparator|Cancer of Unknown Primary (CUP)|Eligible patients with cancer of unknown primary site (CUP).
16324958|NCT04504604|Active Comparator|Other remaining rare cancers (solid tumors & lymphomas)|Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).
16324959|NCT04504578|Experimental|patients with progressive keratoconus with thin corneas|patients with progressive keratoconus with thin corneas , with thickness less than 400 micron ,will do conventional cross linking but with putting contact lens over the cornea ( will receive Contact lens assisted corneal cross liking )
16324960|NCT04504565|Experimental|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTC-3PRGD2, patients underwent single-photon emission computed tomography/COMPUTED tomography (SPECT/CT) examination.
16324961|NCT04504552|Experimental|Single Arm Avelumab|Avelumab monotherapy on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
16324962|NCT04504539|Experimental|mOPV with FIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
16324963|NCT04504539|Experimental|bOPV with FIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
16324964|NCT04504539|Experimental|mOPV with fIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
16324965|NCT04504539|Experimental|bOPV with fIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
16324966|NCT04504526|Experimental|68Ga-Pentixafor, PET/CT|PET/CT perform after injecting 68Ga-Pentixafor
16324967|NCT04504500|No Intervention|Observation phase|Routine practice assessment
16324968|NCT04504500|Active Comparator|Intervention phase|Clinical practice assessment after the application of the trial's educational, behavioral and organizational interventions
16324969|NCT04504487|Experimental|Early drain removal - POD3|Drain removal on POD3 if drain bilirubin is less than 3mg/dl and serous in nature.
16324970|NCT04504487|Placebo Comparator|Routine Drain Removal|Drain removed routinely when the output is less than 100ml and serous in nature
16324971|NCT04504461||Laparoscopic Inguinal Hernioplasty. Ambulatory|Laparoscopic Inguinal Hernioplasty performed in ambulatory surgery center
16325438|NCT04501341|Experimental|UC-MSC|Umbilical cord mesenchymal stem cell
16324972|NCT04504461||Laparoscopic Inguinal Hernioplasty. Hospital Stay|Laparoscopic Inguinal Hernioplasty that have to stay at least 24 hours at the hospital
16324973|NCT04504448|Experimental|HNC664 capsules|HNC664 capsules,single ascending doses Single dose
16324974|NCT04504448|Placebo Comparator|HNC664 placebos|HNC664 placebos,single ascending doses Single dose
16324975|NCT04504448|Experimental|HNC664 capsules FED|HNC664 capsules,food effect,Single dose
16324980|NCT04504422|Experimental|Primary motor cortex|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
16324981|NCT04504422|Experimental|Left dorsolateral prefrontal cortex|The anodic electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
16324982|NCT04504422|Experimental|Ventromedial prefrontal cortex|The anodic electrode is positioned in the ventromedial prefrontal cortex (Fpz) and the cathode electrode on the left dorsolateral prefrontal cortex (F4). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
16324983|NCT04504422|Sham Comparator|Sham stimulation|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA during first 30 seconds, decreases to 0 mA over 30 seconds, and then stops supplying for 19 minutes.
16324984|NCT04504409|Active Comparator|Exercise group (ExG)|The exercise program consisted of; Codman , wand, stretching and strengthening exercises [25] applied twice a day, 5 times a week and duration of 3 weeks in all groups. All exercises were performed for 10 repetitions and 3 sets. Patients performed exercises with under supervision of physiotherapist in the clinic settings. In ExG, patients received only this exercise protocol for 3-weeks.
16324985|NCT04504409|Experimental|KT application combined with exercise (KTG)|Before KT application, their skin was shaved, cleaned with alcohol, and dried. Prior to application, the patient was seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side. KTs (Ares®) tape was used. The first strip was a Y-strip representative of the supraspinatus, which was applied from its insertion to origin with paper off tension. A Y-strip refers to a section of tape that has a portion cut down the middle to produce 2 tails. In KTG, patients wore the KT for a 3-week duration (renewed twice a week periodically in this time).
16324986|NCT04504409|Active Comparator|DN combined with exercise (DNG)|The MTrP dry needling procedure employed was similar to the MTrP injection described by Hong. The MTrP was located by palpating the taut band and identifying the point of maximal tenderness. This was then firmly compressed by the index finger or middle finger of the nondominant hand to direct the placement of the needle tip while inserting the needle. The needle was inserted into the skin at a point above the taut band, approximately 1 cm from the MTrP region. After penetration of the needle into the subcutaneous layer, it was kept there and obliquely (about 45 degrees) directed to the MTrP region under the fingertip of the non-dominant hand. Then, the needle was inserted rapidly into the MTrP region and withdrawn rapidly. In DNG, patients received DN for a 3-week duration (twice a week periodically in this time).
16324994|NCT04504357|No Intervention|Arm A- No intervention|Participants randomized to Arm A will receive no research intervention.
16324995|NCT04504357|Experimental|Arm B- U=U app|"Participants randomized to Arm B will receive controlled exposure to the tablet-based U=U app."
16324996|NCT04504357|Active Comparator|Arm C- clinical exposure demonstration|Participants randomized to Arm C will be shown U=U videos in clinic waiting rooms and the tablet-based app will be integrated into routine counseling
16324997|NCT04504344|Experimental|Active tDCS|Active tDCS
16324998|NCT04504344|Sham Comparator|Sham tDCS|Sham tDCS
16325252|NCT04502602|Experimental|Dose Level 1|Neratinib 160 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
16324999|NCT04504331|Experimental|Cohort 1: Infigratinib (100mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 100 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
16325000|NCT04504331|Experimental|Cohort 1: Infigratinib (125mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 125 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + + 20 mg/ day tamoxifen
16325001|NCT04504331|Experimental|Cohort 1: Infigratinib (75mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 75 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
16325002|NCT04504318|Experimental|Apixaban|Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
16325003|NCT04504318|Active Comparator|Enoxaparin|Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
16325004|NCT04504305|Active Comparator|Neuropaway|
16325005|NCT04504305|Placebo Comparator|Microcystalline cellulose|
16325006|NCT04504292|Experimental|Oral sulfate solution (SuPREP arm)|"Per the package insert: The dose for colon cleansing requires administration of two bottles of SUPREP Bowel Prep Kit. Each bottle is administered as 16 oz of diluted SUPREP solution with an additional 1quart of water taken orally. The total volume of liquid required for colon cleansing (using two bottles) is 3 quarts (approximately 2.8 L) taken orally prior to the colonoscopy outlined below under frequency.
~Two 6 oz bottles of oral solution: Each 6 oz bottle contains: sodium sulfate 17.5 g, potassium sulfate 3.13 g, magnesium sulfate 1.6 g."
16325007|NCT04504292|Active Comparator|Polyethelene Glycol (GoLytely arm)|Polyethylene Glycol Bowel Prep Kit
16325008|NCT04504279|Experimental|FB-401|FB-401 applied topically for 16 weeks.
16325009|NCT04504279|Placebo Comparator|Placebo|Placebo applied topically for 16 weeks.
16325010|NCT04504266|No Intervention|Control Arm|Recommendations to follow Mediterranean diet and exercise regularly before surgery.
16325011|NCT04504266|Experimental|Prehab|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
16325016|NCT04504227|Placebo Comparator|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
16325017|NCT04504227|Experimental|Slightly thick liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
16325018|NCT04504227|Experimental|Mildly thick liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
16325019|NCT04504227|Experimental|Moderately thick liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
16325020|NCT04504214|Experimental|Experimental group (EG)|An Experimental Group (EG) of post-stroke subjects having vibration stimulation sessions in addition to traditional rehabilitation
16325021|NCT04504214|Sham Comparator|Control Group (CG)|A Control Group (WG) of post-stroke subjects having placebo/sham vibration sessions (same vibrators used but without the eccentric mass), in addition to traditional rehabilitation
16325022|NCT04504201||Early Breast Cancer Patients|Early breast cancer patients (Stage I-III) who have completed primary treatment with a current Body mass index (BMI) over 30.
16325023|NCT04504201||Medical Oncology Clinicians|Oncology providers associated with community-based practices
16325024|NCT04504188|Experimental|Heart Rate Monitor Enhanced Treatment Optimization|Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.
16325025|NCT04504175|Experimental|Acute|Acute phase: ketamine infusions twice a week for 4 weeks
16325026|NCT04504175|Experimental|Continuation|Continuation: for remitters/ responders, 4 weeks of weekly ketamine infusions
16325027|NCT04504162||outpatient|Patients visiting a psychiatric hospital
16325028|NCT04504149|Experimental|PRIMED|Shared decision making session
16325029|NCT04504149|No Intervention|Usual Care|The investigators will characterize usual care using chart review and administrative data to identify medications (prescribed, filled), number of mental health sessions received, types of providers seen, and the content of treatment sessions as captured in chart notes.
16325030|NCT04504136|Experimental|Healthy Controls|Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).
16325031|NCT04504136|Experimental|Inflammatory Bowel Disease|Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.
16325032|NCT04504136|Experimental|Rheumatoid/Psoriatic Arthritis|Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.
16325033|NCT04504123|Experimental|Doxycycline|Participants received doxycycline hyclate 50 mg capsule orally once a day for 6 months
16325034|NCT04504123|Placebo Comparator|Placebo|Participants received placebo (inactive) capsule orally once a day for 6 months
16325035|NCT04504110|Experimental|Epithelial ovarian cancer|68Ga-FAPI-04 and 18F-FDG PET/CT
16325036|NCT04504097|Experimental|HIV self-testing + m-Health|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics. We will provide a 24-hour contact number to text, managed through WelTel system that will flag these messages in real-time. Participants will also receive a weekly bidirectional SMS hosted by WelTel to check how they are.
16325253|NCT04502602|Experimental|Dose Level 2|Neratinib 200 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
16325037|NCT04504097|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics
16325038|NCT04504097|No Intervention|Standard of Care|Participants will receive information about HIV testing, care and support services at MARPI clinics and provide a pamphlet of information about HIV & HIV prevention strategies.
16325039|NCT04504084|Experimental|Decision aid group|Shared decision making using decision aid
16325040|NCT04504084|No Intervention|Controlled group|Standard oral explanation the details of treament options
16325041|NCT04504071|Other|Dacomitinib Arm|This is a single arm study.
16325042|NCT04504058||UFACH|Unsaturated Fatty Acid in Clinical High-risk
16325043|NCT04504045|Experimental|Metformin|Patients will receive metformin 1000-2000 mg daily for 12 weeks.
16325046|NCT04504019|Experimental|USCTR Procedure|Participants will undergo the USCTR procedure with SX-One MicroKnife®
16325047|NCT04504019|Active Comparator|mOCTR Procedure|Participants will undergo the traditional mOCTR procedure.
16325048|NCT04504006||Cohort A|PMMR + TCL, followed by systematic lymphadenectomy in node positive patients.
16325049|NCT04504006||Cohort B|Therapy according to actual guidelines
16325050|NCT04503993|Experimental|Hepatitis B Healthy Planet Arm|This is a single arm study where all patients eligible patients will receive a hepatitis B order set
16325051|NCT04503980|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
16325052|NCT04503967|Experimental|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line treatment of Gastric and Esophageal Cancer patients
16325053|NCT04503954|Experimental|Self-management group|Self-management group Chronic disease self-management program is conduct training skills, person how to live together with personal chronic disease to make life quality better.
16325054|NCT04503954|Placebo Comparator|Control group|Control group will continue general psychiatric intervention.
16325055|NCT04503941|Experimental|Active Comparator|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
16325056|NCT04503941|Placebo Comparator|The control group|False Needle treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
16325057|NCT04503928|Experimental|Experimental: Kansui 1g per day x 7 days|Study participants will be given 1 g of Euphorbia kansui Pill for a total of 7 consecutive daily doses.
16325058|NCT04503915|Experimental|Constant group|Women will receive oral estradiol valerate (Progynova®; Bayer Schering Pharma AG, Berlin, Germany) 3 mg bid for 14 days for endometrial priming from the second or third day of the menstrual cycle.
16325059|NCT04503915|Active Comparator|Step -up group|Women will receive estradiol valerate 2mg once daily for 4 days from the second to fifth day,followed by 2mg bid for 4 days from the sixth to ninth day and then 3mg bid for 6 days from tenth to fifteenth day of menstrual cycle.
16325060|NCT04503902|Experimental|JS001+Donafenib|Donafenib 100mg QD/100 mg BID/200 mg BID orally + JS001 240mg Q3W iv
16325061|NCT04503889|Experimental|Real taVNS intervention|taVNS will be administered to cymba conchae of both ears using ECO2-TENS device
16325062|NCT04503889|Sham Comparator|Sham|aVNS will be administered to lobes of both ears using ECO2-TENS device
16325063|NCT04503876|Active Comparator|Decremental PEEP titration following an ARM|PEEP will be titrated in a stepwise decremental fashion following a standardized alveolar recruitment maneuver (ARM). The ARM is a progressive increase of intra-thoracic pressure (pressure controlled mode), with a constant driving pressure of 10 cmH2O and PEEP steps (10-15-20-25-30-35 and 40 cmH2O), reaching a maximum pressure of 50 cmH2O, allowing full recruitment. PEEP steps will be conducted every 2 cmH2O (from 20 to 6 cmH2O), every 5 minutes.
16325064|NCT04503876|Active Comparator|Incremental PEEP titration without any previous ARM|PEEP will be titrated in a stepwise incremental fashion without any previous alveolar recruitment maneuver (ARM). PEEP steps will be conducted every 2 cmH2O (from 6 to 20 cmH2O), every 5 minutes.
16325065|NCT04503863|Experimental|Experimental 1|Single administration of middle dose NPC-22
16325066|NCT04503863|Experimental|Experimental 2|Single administration of high dose NPC-22
16325067|NCT04503863|Placebo Comparator|Experimental 3|Single administration of placebo dose NPC-22
16325068|NCT04503850||Group A Mirabegron|50 patients receiving Mirabegron 50 mg once daily & alpha blocker
16325069|NCT04503850||Group B alpha blocker only|50 patients receiving alpha blocker only
16325070|NCT04503837|Experimental|Intervention|Personalized Mobile Phone Video Recording in addition to Standard care
16325071|NCT04503837|No Intervention|Control|Standard care alone
16325072|NCT04503824||Group IIa: 13 papular OLP|
16325073|NCT04503824||Group IIb: 13 atrophic OLP|
16325074|NCT04503824||Group IIc: 13 erosive OLP|
16325075|NCT04503824||Group I: 13 healthy individuals|
16325076|NCT04503811||Frail Older People|The first phase of the data collection process will include one to one interviews with up to twenty (20) frail older people. The pre-selected inclusion criteria for this category of participants include; older people (aged 65 years and over); individuals diagnosed with frailty and receiving (part of their) care services at the Day Hospital; the capacity to give free and fully informed consent; ability to use the English language, as well as judgement by the clinical staff and/or nominated manager that the potential participant can take part in an in-depth interview.
16325077|NCT04503811||Day Hospital Staff|The second phase of the data collection process will entail one to one interviews with up to ten (10) Staff at the Day Hospital. The study will include staff that routinely work with frail older people at the Day Hospital including nurses (registered and unregistered), doctors, physiotherapists, occupational therapists and therapy assistants that can give free and fully informed consent. Furthermore, the study will include both part-time and full-time staff with a minimum of six months of work experience with frail older people.
16325078|NCT04503798|Experimental|Online Goal Management Training (GMT)|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
16325079|NCT04503798|No Intervention|Treatment-as-usual control group|Participants randomized to this arm will receive no additional information or access to the intervention program. They will continue to receive treatment-as-usual from their care providers.
16325080|NCT04503785||Dysphagia|Patients with Esophageal dysphagia
16325082|NCT04503759||Foot and Ankle Surgery using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
16325083|NCT04503746|Placebo Comparator|Placebo|Placebo twice a day
16325084|NCT04503746|Experimental|ALH-L1005 600 mg|ALH-L1005 300 mg twice a day
16325085|NCT04503746|Experimental|ALH-L1005 1,200 mg|ALH-L1005 600 mg twice a day
16325086|NCT04503733|Experimental|Q4W GMA301 IV injections (300 mg)|
16325087|NCT04503733|Experimental|Q4W GMA301 IV injections (600 mg)|
16325088|NCT04503733|Experimental|Q4W GMA301 IV injections (1000 mg)|
16325089|NCT04503720|Experimental|CLoWI|"CLoWI (ropivacaine) and PCA (normal saline)
~The local anaesthetic infusion will be administered via 2 catheters using a ON-Q® (Halyard) delivery system that will be placed under direct vision by the surgeon at the time of wound closure. 40 mls of 0.25% ropivacaine are infiltrated in the preperitoneal plane. 0.5% ropivacaine will be infused at a rate of 4mls/hour (2mls/hour in each catheter).
~The dosage 40 mls of 0.25% ropivacaine and 0.5% ropivacaine at 4mls/hr (20mg/hr) over 4 days will be less than the recommended toxic dose of 3-4 mg/kg."
16325090|NCT04503720|Active Comparator|PCA|"PCA (Morphine) and CLoWI (normal saline)
~Morphine will be administered via the standard PCA protocol in accordance to the hospital's Acute Pain Service Programme:
~Concentration: 1mg/ml
~Bolus (Loading): 1mg
~Lockout Interval: 5 minutes
~Maximum hourly dose of 10mg"
16325091|NCT04503707||Follitropin Delta|Treatment according to routine clinical practice.
16325092|NCT04503694|Experimental|Single arm|"Eligible subjects will be treated according to the following plan:
~Induction systemic period 1: Consists of treatment with nivolumab (240 mg intravenously on day 1 and 14) and regorafenib (80 mg/day orally from day 1 to 14)
~Standard SCRT: Consists of 25 Gy delivered in 5 fractions (from day 21 to 25)
~Induction systemic period 2: Consists of treatment with nivolumab (240 mg intravenously on day 28, 42 and 56) and regorafenib (80 mg/day orally from day 28 to 49)
~Surgery: Surgical resection will be performed according to the principles of TME (between day 74 and 87, i.e., between 7 to 8 weeks after completion of SCRT)
~Adjuvant chemotherapy: Administration of adjuvant chemotherapy will be left to the discretion of the treating physician The study also includes translational procedures (collection of tumour biopsies, blood and stool samples at pre-specified time points) for exploratory molecular and immune contexture analyses. These are mandatory for all study subjects."
16325093|NCT04503681|Active Comparator|Standard introduction video|
16325094|NCT04503681|Experimental|Enhanced compassion video|
16325095|NCT04503668|Active Comparator|Nk1-RA|Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
16325096|NCT04503668|Experimental|Olanzapine|Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.
16325097|NCT04503655|Experimental|Intervention group|"The randomized centres in this group will be follow a training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
16325098|NCT04503655|No Intervention|Control group|The randomized centres in this group will not change their practices.
16325099|NCT04503642||Intervention Group|The intervention consisted in the closure of the abdominal wall and skin by a second surgical team which included a board-certified surgeon and a resident.
16325100|NCT04503642||Baseline Group|During the baseline period, closure of the abdominal wall was performed by the main surgical team, the same team that performed the whole surgery.
16325101|NCT04503629|Experimental|Anaprazole Sodium 20mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
16325102|NCT04503629|Experimental|Anaprazole Sodium 40mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
16325103|NCT04503629|Active Comparator|Rabeprazole sodium 10mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
16325104|NCT04503616|Experimental|HSCT Patients|Adult patients with hematological malignancies undergoing HLA-haploidentical HSCT from first-or second-degree family donors.
16325105|NCT04503603|Experimental|Lanadelumab|Participants will receive single dose of lanadelumab 300 milligram (mg) IV infusion on Day 1 followed by second dose on Day 4.
16325106|NCT04503603|Placebo Comparator|Placebo|Participant will receive single dose of placebo matching to lanadelumab IV infusion on Day 1 followed by second dose on Day 4.
16325107|NCT04503590|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
16325108|NCT04503577||Bladder cancer patients|
16325254|NCT04502602|Experimental|Dose Level 3|Neratinib 240 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
16325111|NCT04503538|Other|CAR-T cell therapy and Telemedicine|All outpatient CAR-T patients will require assessments for cytokine release syndrome and neurotoxicity three times daily (every 8 hours)
16325112|NCT04503525||COVID 19 hospitalized patients|COVID 19 infected patients admitted in conventional hospitalization for less than 72 hours
16325113|NCT04503512|Active Comparator|Non removal of fat pad|Non removal of fat pad
16325114|NCT04503512|Active Comparator|Removal of fat pad|Removal of fat pad
16325115|NCT04503499|Experimental|Study Group|The group to which the manuel therapy will be applied.
16325116|NCT04503499|No Intervention|Control Group|The control group where only the evaluations will be made.
16325117|NCT04503473|Experimental|High Intensity Stepping Training|The primary goal will be to perform continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). We will also record Ratings of Perceived Exertion (RPE) every 3-5 minutes, with goals of 15-18. Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
16325118|NCT04503473|Active Comparator|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions. The type of therapeutic activities is based on published normative data of typical activities performed during clinical physical therapy sessions with focus on strengthening activities (25% of session); balance activities (25%); locomotor activities (25%), and combined stretching exercises (10-15%) and transfers (10-15%). Intensity of activities will be targeted at 30-40% of their HR reserve in attempts to maintain consistent intensities between training groups.
16325119|NCT04503460|Experimental|Single treatment arm|"All participants who are deemed eligible for inclusion in the study following screening will be enrolled into a single experimental arm which will comprise the following sequential stages:
~Baseline sampling; participants only use 'as required' ipratropium bromide when needed (1 week)
~Salmeterol xinafoate monotherapy 50 μg twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)
~Washout period; participants only use 'as required' ipratropium bromide when needed (2 weeks)
~Salmeterol xinafoate 50 μg / fluticasone propionate 250 μg combination therapy twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)"
16325120|NCT04503421|Experimental|BFR|"Patient will use the following rehabilitation protocol while incorporating blood flow restriction therapy:
~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only
~Sling immobilization with active wrist and shoulder ROM
~Active extension of biceps to 30 degrees, No active flexion
~6-9 weeks full active extension in brace
~Maintain wrist and shoulder flexibility
~Begin rotator cuff/deltoid isometrics, progress active extension in brace
~Weeks 9-12: Gently advance ROM to tolerance
~Discontinue sling
~Begin active flexion and extension against gravity.
~Advance strength to light resistance, maintain flexibility/ROM
~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
16325121|NCT04503421|No Intervention|Control (no BFR)|"patients will use following rehabilitation protocol without the use of blood flow restriction therapy:
~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only
~Sling immobilization with active wrist and shoulder ROM
~Active extension of biceps to 30 degrees, No active flexion
~6-9 weeks full active extension in brace
~Maintain wrist and shoulder flexibility
~Begin rotator cuff/deltoid isometrics, progress active extension in brace
~Weeks 9-12: Gently advance ROM to tolerance
~Discontinue sling
~Begin active flexion and extension against gravity.
~Advance strength to light resistance, maintain flexibility/ROM
~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
16325122|NCT04503408||cystic fibrosis with abnormal glucose tolerance|cystic fibrosis with abnormal glucose tolerance Cystic fibrosis patients with descripted that impaired glucose tolerance or cystic fibrosis related diabetes by oral glucose tolerance test
16325123|NCT04503408||cystic fibrosis with normal glucose tolerance|cystic fibrosis with normal glucose tolerance Cystic fibrosis patients with descripted that normal glucose tolerance by oral glucose tolerance test
16325124|NCT04503395|Experimental|ESAR|Endovascular Aneurysm Repair + Heli-FX EndoAnchors
16325125|NCT04503395|Active Comparator|FEVAR|Fenestrated EndoVascular Aneurysm Repair
16325126|NCT04503382|Experimental|Kindness media|Short videos of kindness media. As part of a program entitled EnSpire®, this media consists of short videos that display acts of kindness and compassion that are edited together into a single reel.
16325127|NCT04503382|Active Comparator|Standard television|Children's commercial programming--as the control condition, participants watched commercial children's programming such as Disney, Nickelodeon, etc.
16325128|NCT04503369||EMS crews|Crews of Emergency Medical Services
16325129|NCT04503356|Active Comparator|OMNI as a standalone procedure|
16325130|NCT04503356|Active Comparator|OMNI combined with cataract surgery|
16325131|NCT04503343|Other|intervention group|subjects are randomly divided into the intervention group. and they will be given a one-time non-drug intervention(mindfulness training, relaxation training or electrical cerebellar stimulation).
16325132|NCT04503343|No Intervention|control group|subjects are randomly divided into the control group and regularly followed up.
16325133|NCT04503330|Experimental|Patients with iatrogenic PUJO|patients with iatrogenic PUJO or long segment ureteric stricture disease for safety and efficacy of using buccal graft for repair
16325134|NCT04503317|Active Comparator|active acupuncture low level laser and nasal laser|active acupuncture low level laser and aerobic exercises
16325135|NCT04503317|Experimental|aerobic exercises|aerobic exercises
16325173|NCT04503070||Baseball Batters|Participants must be healthy volunteers who accept all provisions of the study and agree to complete the program in its entirety. Participants should have their own bat and relative experience of at least 2 years of hitting a baseball. Ages accepted will be 16-40.
16325174|NCT04503057||COVID-19 positive|Positive COVID-19 patients with pulmonary infection, ALI or ARDS
16325136|NCT04503304|Experimental|HAS group|"hip abductors strengthening group
~Hip abduction -standing[Ferber et al.,2015].
~Sidelying hip abduction(clamshell)[Schache et al.,2016].
~lateral leg raise: in brief, the patients lie down on bed on the unaffected side, with the resistance band positioned around the distal thigh of the affected limb.;later, they raise the above lower limbs upwards for about 30 degrees, stay for 5- 10 s and slowly lay down[Xie et al.,2018].
~pelvic lift training, specifically, patients stand single-leg off the side at a 10-cm step. Later, they begin with the other limb that is lower than the step level, and contract the stance-limb hip abductor to raise the free leg to the step level while keeping the stance knee extended[Xie et al.,2018].
~Stretching Hamstrings [Fukuda et al.,2012]. Number of sets = 3, Repetitions =10 repetitions for each set"
16325137|NCT04503304|Active Comparator|KES group|"knee extensors strengthening group
~Isometric quadriceps setting
~Knee extensions from sitting with knee bend to 90
~Terminal knee extension from sitting.
~Stretching Hamstrings Number of sets = 3, Repetitions =10 repetitions for each set"
16325138|NCT04503291|Experimental|supra-papillary metal stent group|The distal ends of metal stents are located above the major papilla in the common bile duct.
16325139|NCT04503291|Active Comparator|trans-papillary metal stent group|The distal ends of metal stents are located below the major papilla in the duodenum.
16325140|NCT04503278|Experimental|Part 1 CLDN6 CAR-T|Dose escalation in lymphodepleted patients until the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
16325141|NCT04503278|Experimental|Part 2 Vaccine-modulated|Dose escalation until the MTD and/or RP2D.
16325142|NCT04503265|Experimental|AMXI-5001 Treatment|Single Arm Study, all participants will receive AMXI-5001.
16325143|NCT04503252||Study population: patients with CSAI caused by MSSA|Inpatients with CSAI caused by MSSA treated or intended to receive cefazolin within the next 24-48 hours (at least 10 (maximum of 20) critically-ill patients, at least 10 (maximum of 20) patients with an estimated glomerular filtration rate of <60ml/min, at least 10 patients with BSI).
16325144|NCT04503252||Sub-study: Torque Teno virus (TTV) viremia|TTV viral load may indicate the immunological status of the host. The TTV sub-study is to to describe the viral kinetics of TTV in CSAI patients.
16325145|NCT04503252||Sub-study: cefazolin concentrations in sweat|Out of the study population (patients with CSAI) a total of 15 CSAI patients will be included for the substudy investigating cefazolin concentrations in sweat as a non-invasive therapeutic drug monitoring.
16325146|NCT04503239||Prediabetes (both IGT and IFG)|Device: G6 Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325147|NCT04503239||Type 2 Diabetes on 1 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325148|NCT04503239||Type 2 Diabetes on 2 or more OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325149|NCT04503239||Type 2 Diabetes using Basal insulin with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325150|NCT04503239||Type 2 Diabetes in GLP-1 with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325151|NCT04503239||Type 2 Diabetes using intense insulin treatment-Multiple Dail|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325152|NCT04503239||Type 2 Diabetes in MDI or basal insulin plus GLP-1|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325153|NCT04503239||Type 2 Diabetes on 0 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325154|NCT04503239||High Risk to Develop Prediabetes / Type 2 Diabetes|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
16325155|NCT04503200|Active Comparator|Double guidewire|
16325156|NCT04503200|Active Comparator|Transpancreatic precut|
16325157|NCT04503187||Chronic Stroke|Participants who suffered a single event of cerebral vascular accident at least six months ago before study enrollment.
16325158|NCT04503187||Multiple Sclerosis|Participants who has been diagnosed with multiple sclerosis
16325159|NCT04503187||Healthy control|Age-matched healthy adults who are self-reported healthy and has no known musculoskeletal, neuromuscular, and cardiovascular diseases.
16325160|NCT04503174||Pump Naiive|New to insulin pump use
16325161|NCT04503174||6-13 YO|Subjects between the age of 6-13 years old.
16325162|NCT04503174||14-17 YO|Subjects between the age of 14-17 years old.
16325163|NCT04503174||Adults (18+)|Subjects are 18 years old and older.
16325164|NCT04503174||CGM Naiive|Subjects have not used CGM in the 30 days prior to enrollment.
16325165|NCT04503174||HbA1c more than or equal to 8.5%|Subjects have an HbA1c of more than or equal to 8.5% in the 3 months prior to enrollment.
16325166|NCT04503174||HbA1c less than or equal to 8.5%|Subjects have an HbA1c of less than or equal to 8.5% in the 3 months prior to enrollment.
16325167|NCT04503161|Experimental|Hydrogel recipient|
16325168|NCT04503148|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
16325169|NCT04503148|Active Comparator|inhalation group|Patients receiving inhalation anesthesia using sevoflurane or desflurane
16325170|NCT04503109|Other|Nalu SCS System|All eligible subjects will receive the Nalu Neurostimulation System
16325171|NCT04503096|Experimental|High-dose accelerated rTMS|
16325172|NCT04503083||Migraine patients|"Excellent responder, a patient who experiences a >75% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;
~Responder, a patient who experiences a >50% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;
~Non responder, a patient who experiences a decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days ranging from 26 to 49% during the last 4 weeks of treatment as compared to baseline;
~Full non responder, a patient who experiences a <25% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline."
16325175|NCT04503057||COVID-19 negative|Negative COVID-19 patients with pulmonary infection, ALI or ARDS
16325176|NCT04503044||CT Lung Cancer Screening Patients|All CT Lung Cancer Screening patients at LHMC from January 1st, 2012 to September 30th, 2014 with an in-network PCP that had baseline CT scans will be scored. A subset of these patients with T4 screening scans will be scored for progression.
16325177|NCT04503031|Active Comparator|cylindrical tube group|The patient in cylindrical tube group (n=26) were intubated with cylindrical shaped endotracheal tube.
16325178|NCT04503031|Experimental|tapergaurd tube group|The patient in taperguard tube group (n=26) was intubated with TaperGuard endotracheal tube.
16325179|NCT04503018||Interviewed -implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
16325180|NCT04503018||Questionnaires - implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
16325181|NCT04503018||Questionnaires - controls|Patients who have had immediate breast reconstruction without complications
16325182|NCT04503005|Active Comparator|Effect of fasting duration|study the effect of different daily fasting duration on body composition and blood lipid and inflammatory markers in healthy adults.
16325183|NCT04503005|Other|Effect of time restricted eating protocol on chronotype|study the effect of 2 month of time restricted eating on the chronotype profile of healthy adults.
16325184|NCT04502992|Other|Single Arm (pre-post, quasi-experimental)|Pre-post intervention, single arm. (Intervention was 4 weeks of Acceptance and Committment therapy, 2 times per week, 90 min per session, in a group setting).
16325185|NCT04502979|Experimental|Responsive Feeding|Intervention families will receive approximately 4 hours of ASL and development specific content related to language and feeding during home visits and phone calls. The initial in-home session with families will focus on teaching ASL signs indicative of hunger, thirst, and satiety. A video and placemat of mealtime signs will be left with families at the completion of the first visit. The remaining sessions, in-home over the next 3 months and by phone monthly thereafter for 6 months total, will focus on reinforcing ASL signing in addition to focused education on particular aspects of language development (receptive language preceding expressive language and increasing intentional communication), feeding development (such as hunger and fullness cues, fear of new foods, the importance of repeated food exposures, variations in intake from meal-to-meal, and the propensity to reject bitter tastes [many vegetables]55], and appropriate portion sizes and variety for healthy growth.
16325186|NCT04502979|No Intervention|Routine Care|No intervention is provided to the families in this group; however, portions of the intervention lessons will be made available after completion of data collection.
16325187|NCT04502966|Experimental|Grazax® +Dupixent®|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:
~Once daily tablet of Grazax® sublingual immunotherapy and
~Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
16325188|NCT04502966|Experimental|Grazax® + Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:
~Once daily tablet of Grazax® sublingual immunotherapy and
~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
16325189|NCT04502966|Placebo Comparator|Grazax® Placebo +Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:
~Once daily tablet of placebo for Grazax® sublingual immunotherapy and
~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
16325190|NCT04502953|Active Comparator|Vertical plication|Vertical plication of the rectovaginal septum was done
16325191|NCT04502953|Active Comparator|Horizontal plication|Horizontal plication of the rectovaginal septum was done
16325192|NCT04502940||Mild pancreatitis|Patients with mild acute biliary pancreatitis according to Atlanta classification
16325193|NCT04502940||Moderate Pancreatitis|Patients with moderate acute biliary pancreatitis according to Atlanta classification
16325194|NCT04502940||Severe pancreatitis|Patients with severe acute biliary pancreatitis according to Atlanta classification
16325195|NCT04502940||Control|Healthy volunteers
16325196|NCT04502927|Other|Stroke patients with hand spasticity (n=20)|
16325197|NCT04502927|Other|Healthy volunteers (n=10)|
16325198|NCT04502914|Experimental|The experimental group|The experimental group will consist of wounds treated with the open-to-air strategy.
16325199|NCT04502914|Other|The control group|The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
16325200|NCT04502901|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects once a day for 14 days. The applied dosage cohorts are 2.5mg, 5mg, 10mg and 20mg.
16325201|NCT04502901|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects once a day for 14 days.
16325203|NCT04502875|Experimental|Treatment Arm|Intracavernosal infusion of Platelet Rich Plasma
16325204|NCT04502875|Active Comparator|Control Arm|Intracavernosal infusion of Platelet Poor Plasma
16325205|NCT04502862|Experimental|Dupilumab|2 x dupilumab injections as loading dose on Day 1, followed by 1 dupilumab maintenance dose injection every 2 weeks (Q2W) during 12 weeks
16325206|NCT04502862|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 12 weeks
16325207|NCT04502849||"Group Bypass (A)"|50 patients with indications for bypass surgery (chronic lower limb ischemia, stage 2b-4 Fontaine).
16325208|NCT04502849||"Group Endovascular (B)"|50 patients with indications for endovascular angioplasty and stenting (chronic lower limb ischemia, stage 2b-4 Fontaine).
16325209|NCT04502849||"Group Hybrid (C)"|50 patients with indications for hybrid surgery (endovascular angioplasty/stenting and bypass surgery; chronic lower limb ischemia, stage 2b-4 Fontaine).
16325210|NCT04502849||"Group Conservative (D)"|50 patients without indications surgery (conservative treatment, chronic lower limb ischemia, stage 2b-4 Fontaine).
16325211|NCT04502849||"Group Healthy volunteers (E)"|50 healthy subjects.
16325212|NCT04502836|Experimental|preliminary psychological intervention|Participants in this group will receive a psychological intervention providing knowledge and tools for problems solving one hour prior to the ACTH LRH test.
16325213|NCT04502836|No Intervention|control group|Participants in this group will not receive any psychological intervention prior to the test.
16325214|NCT04502823|No Intervention|Control Group|"Clinical practice: Management by Doppler and CTG findings.
~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:
~Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended at at ≥37 weeks.
~Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
16325215|NCT04502823|Experimental|Intervention Group|Management based on sFlt-1/PlGF values
16325216|NCT04502810|Experimental|High-level laser therapy|Real high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
16325217|NCT04502810|Sham Comparator|Sham High-level laser therapy|Sham high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
16325218|NCT04502797|Experimental|Interventional: Electronic Patient Visit Assessment (ePVA)|Participants diagnosed with head and neck cancer randomized to Electronic Patient Visit Assessment intervention
16325219|NCT04502797|No Intervention|Usual care|Participants diagnosed with head and neck cancer randomized to usual care.
16325220|NCT04502784||Chronic Kidney Disease|This group will consist of 10 patients who have previously been diagnosed with chronic kidney disease and are receiving intravenous iron due to anaemia.
16325221|NCT04502784||Intestinal failure|This group will consist of 10 patients who have previously been diagnosed with intestinal conditions and are receiving intravenous iron due to anaemia.
16325222|NCT04502784||Healthy Volunteers|This group will consist of 20 healthy volunteers. This group will act as a comparator for the CKD and intestinal failure groups.
16325223|NCT04502771||Antifungal treatment|Patients receiving antifungal treatment during their stay in Intensive Care Unit
16325224|NCT04502758|Active Comparator|Sequential bilateral accelerated theta burst stimulation|Three sessions of Sequential bilateral accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
16325225|NCT04502758|Sham Comparator|Sham seqential billateral accelerated theta burst stimulation|Three sessions of Sequential bilateral sham accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
16325226|NCT04502745|Experimental|Treatment Group|During clinically indicated surgery for subdural hematoma, the patient will undergo a single burr hole evacuation with the MICAS device with endoscopic assistance.
16325227|NCT04502732||Observational|NSSM and GEBT
16325228|NCT04502719||Screened|Patients with liver cirrhosis screened for malnutrition.
16325240|NCT04502680|Experimental|Eribulin Mesylate|Patients receive eribulin mesylate following standard adjuvant chemotherapy.
16325241|NCT04502680|No Intervention|Observation|Observation. No intervention.
16325242|NCT04502667|Experimental|cholecalciferol (Vitamin D)|Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
16325243|NCT04502667|No Intervention|Control|No intervention
16325244|NCT04502654||Pilot group|As a pilot Group for observating variable rehabilitation under individual baselines.
16325245|NCT04502641|Experimental|Arm I|Patients receive induction chemotherapy with docetaxel-based, with or without cisplatin or fluorouracil. Treatment repeats every 21 days for 3 courses. Then, patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
16325246|NCT04502641|Active Comparator|Arm II|Patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
16325247|NCT04502628|Experimental|HBOT group|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished.
16325248|NCT04502615|Experimental|Sand|Participants perform 5 single leg hops onto a Sand surface from a 30cm height
16325249|NCT04502615|Active Comparator|Artificial grass|Participants perform 5 single leg hops onto a grass surface from a 30cm height
16325250|NCT04502615|Active Comparator|Firm Ground|Participants perform 5 single leg hops onto a firm ground surface from a 30cm height
16325255|NCT04502602|Experimental|Dose Level 4|Neratinib 240 mg and Niraparib 300 mg by mouth once daily for 28 day cycles.
16325256|NCT04502602|Experimental|Phase 1b: Platinum Resistant Expansion Cohort|This portion of the study provides for cohort expansion to observe for 4 month or greater progression-free survival in patients with platinum resistant ovarian cancer treated at the recommended phase 2 dose (RP2D) determined in Phase I.
16325257|NCT04502589|Active Comparator|perampanel by itself|
16325258|NCT04502589|Active Comparator|Perapanel with Disulfiram|
16325259|NCT04502576|Active Comparator|High-flow nasal cannula|"High-flow nasal cannula will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge. Weaning from high-flow will be considered as standardized criteria are met."
16325260|NCT04502576|Experimental|Helmet noninvasive ventilation|"Patients will receive continuous helmet pressure support ventilation for at least 16 hours/day the first 2 calendar days. Continuous noninvasive ventilation without interruptions will be strongly encouraged in the first 24 hours of treatment. The ventilator will be set in pressure support mode. Use of continuous positive airway pressure by flow generators and Venturi systems instead of pressure support ventilation will be allowed in case of shortage of ventilators. Maintenance of positive end-expiratory pressure ≥ 8-10 during the treatment is mandatory.
~After weaning and during any interruption from noninvasive ventilation, patients will undergo low-flow or high-flow oxygen, according to the decision of the attending physician.
~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge."
16325261|NCT04502563|Experimental|Active arm|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
16325262|NCT04502563|Sham Comparator|Control|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
16325263|NCT04502550||Parkinson's Disease patients with DBS, no stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.
~A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Experiments will be completed with DBS off."
16325264|NCT04502550||Essential Tremor patients with DBS|"This cohort will serve as a control group (no basal ganglia pathology). A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a TCI system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Experiments will be completed with DBS off."
16325265|NCT04502550||Parkinson's Disease patients with DBS, Gpi stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.
~A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Participants will be stimulated at the Gpi via DBS leads during propofol induced loss of consciousness."
16325266|NCT04502550||Parkinson's Disease patients with DBS, Gpe stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.
~A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Participants will be stimulated at the Gpe via DBS leads during propofol induced loss of consciousness."
16325267|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpe stimulation|"A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Participants will be stimulated at the Gpe via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
16325268|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpi stimulation|"A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Participants will be stimulated at the Gpi via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
16325269|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, no stimulation|"A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Participants will not receive any stimulation via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
16325270|NCT04502537||Roxadustat|treatment with roxadustat
16325271|NCT04502537||erythropoietin|treatment with erythropoietin
16325300|NCT04502264|Experimental|Botulinum toxin, hand robot training, occupational therapy|Patient would receive Botulinum toxin (Injections of 100~400U of Botox in the upper limb muscle with a 2ml/100U dilution), robot-assisted therapy (Hand of Hope training), and standard occupational therapy.
16325272|NCT04502524|Experimental|Arm I (New website program, handout, text message)|Participants complete the new website smoking cessation program which provides values driven, mindfulness based coping skills and utilizes non-judgmental acceptance of uncomfortable internal states like cravings. Participants will also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with all session handouts and available resources provided by the VA for continued support for smoking cessation.
16325273|NCT04502524|Active Comparator|Arm II (Standard care VA website, handout, text message)|Participants use the standard of care website, which provides educational materials about cessation treatments, tools to cope with urges and relapse, how to stay motivated, and brief tips on coping with physical and mental health problems. Participants also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with a handout of available resources provided by the VA for continued support for smoking cessation.
16325274|NCT04502511||Adult critically ill patients in the ICU|Acutely admitted to the ICU
16325275|NCT04502498||60 patients with local advanced bladder cancer|Local advanced bladder cancer patients candidate for radical cystectomy
16325276|NCT04502485|Experimental|Gastric water exchange|Air will be minimally insufflated to partially open the lumen and any residual fluid will be suctioned when the scope passes through the esophagus. Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further. Air will be opened when the scope enter the prepylorus area where there is usually an air pocket. The scope will enter the duodenal bulb and 2nd portion of duodenum where withdrawal inspection will start.
16325277|NCT04502485|Active Comparator|Traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
16325278|NCT04502472|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Patients hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome and meet eligibility criteria
16325279|NCT04502459|Active Comparator|Cement only|The tourniquet was inﬂated just before cement application and deﬂated after its hardening
16325280|NCT04502459|Active Comparator|Skin to Cement|Inﬂation of tourniquet before skin incision and its deﬂation after hardening of cement
16325281|NCT04502459|Active Comparator|Skin to Skin|Inflate of tourniquet before incision and deflate following completion of skin closure
16325282|NCT04502446|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
16325283|NCT04502433|No Intervention|Control cohort|"Approximately 28 patients will be included in this main control cohort.
~The above-mentioned control cohort population will continue receiving the SoC"
16325284|NCT04502433|Experimental|Poractant alfa treated cohort|42 patients will be treated with CUROSURF® (poractant alfa).
16325285|NCT04502420||Abdominal surgery|People who to be operated in the abdomen are investigated before and after surgery.
16325286|NCT04502407|Experimental|De-intensified Cisplatin-based Chemoradiation|This is a non-randomized study, with all patients undergoing de-intensified post-operative cisplatin-based chemoradiation. Dosage level and duration of administration will be determined by whether the patient is high risk or not as assessed by the treating investigator.
16325287|NCT04502394|Experimental|Cohort 1 (R/R DLBCL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
16325288|NCT04502394|Experimental|Cohort 2 (R/R CLL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
16325289|NCT04502381|Experimental|Intervention arm|The study participants in the intervention arm will receive nebulization with amphotericin B deoxycholate (10 mg twice a day every alternate day, as described below) along with intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
16325290|NCT04502381|Active Comparator|Conventional arm|Participants will receive treatment with only intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
16325291|NCT04502342|Active Comparator|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
16325292|NCT04502342|Experimental|Cospherunate/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
16325293|NCT04502342|Experimental|Cospherunate/Phytomedicine/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Phytomedicine tablet 350 mg at the rate of 2 tablets orally twice daily for 6 days, and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
16325294|NCT04502329|Experimental|IER|Intermittent Energy Restriction
16325295|NCT04502329|No Intervention|CER|Continous Energy Restriction
16325296|NCT04502303|Experimental|Crohn's disease: patients with intestinal stricture|Patients with intestinal strictures confirmed by other modalities, e.g. CT, MR, ultrasound, and endoscopy, will be recruited in the study.
16325297|NCT04502290|Experimental|Combined non-invasive brain and Functional Electrical Stimulation|In this arm of the study participants will receive repeated non-invasive brain stimulation synchronously paired with FES
16325298|NCT04502277|Experimental|Flucanazole|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
16325299|NCT04502277|Active Comparator|Diflucan|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
16325301|NCT04502264|Active Comparator|Botulinum toxin, occupational therapy|Patient would receive Botulinum toxin (Injections of 100~400U of Botox in the upper limb muscle with a 2ml/100U dilution) and standard occupational therapy.
16325302|NCT04502251|Active Comparator|LDN + tDCS|Low Dose Naltrexone and Transcranial Direct Current Stimulation
16325303|NCT04502251|Sham Comparator|LDN + Sham tDCS|Low Dose Naltrexone and Sham Transcranial Direct Current Stimulation
16325304|NCT04502251|Placebo Comparator|Placebo + tDCS|Placebo and Transcranial Direct Current Stimulation
16325305|NCT04502251|Other|Placebo + Sham tDCS|Placebo and Sham Transcranial Direct Current Stimulation
16325306|NCT04502225|Experimental|Elevation of the whole bed (tilt)|Tilt of the whole bed so that the participant's head is raised by 9 and/or 12 inches.
16325307|NCT04502225|Experimental|Elevation of the trunk|Elevation of the trunk by tilting just the head of the bed so that the participant's head is raised by 9 and/or 12 inches.
16325308|NCT04502225|Experimental|Elevation of the whole bed (tilt) - In home|Tilt of the whole bed so that the participant's head is raised by 8 inches.
16325309|NCT04502225|Experimental|Elevation of the trunk - In home|Elevation of the trunk by raising the head 8 inches on a wedge pillow.
16325310|NCT04502212|Experimental|Insonification|All subjects enrolled will receive a 3-day, 15 minute per day ultrasound insonification targeting the portis hepatis (liver).
16325311|NCT04502186|Experimental|Raising Our Spirits Together Intervention|
16325312|NCT04502186|Other|Enhanced Control Condition|
16325313|NCT04502173||Training|Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.
16325314|NCT04502173||Managing PPH|Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.
16325315|NCT04502121|Experimental|Intervention group (IG)|
16325316|NCT04502121|No Intervention|Standard of Care (SOC)|
16325317|NCT04502108||Employees|Employees of the Department of Health Professions, Bern University of Applied Sciences
16325318|NCT04502108||Students|Students of the Department of Health Professions, Bern University of Applied Sciences
16325319|NCT04502095|Experimental|Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
16325320|NCT04502095|Active Comparator|Group II (standard of care)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.
16325321|NCT04502082|Experimental|ET140203 TCells|ET140203 T Cells
16325322|NCT04502069|Experimental|Open label opaganib|opaganib dosed at 500 mg Q12 hours
16325323|NCT04502056|Experimental|AMA RI - B- B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
16325324|NCT04502056|Experimental|AMA RI - B - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
16325325|NCT04502056|Experimental|AMA RI - W - W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
16325326|NCT04502056|Experimental|AMA RI - W - W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
16325327|NCT04502056|Experimental|AMA DP - B- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
16325328|NCT04502056|Experimental|AMA DP - B- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
16325329|NCT04502056|Experimental|AMA DP - W- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
16325330|NCT04502056|Experimental|AMA DP - W- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
16325331|NCT04502056|Placebo Comparator|Control: AMA RI - B - B|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.
~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA"
16325332|NCT04502056|Placebo Comparator|Control: AMA RI - W - W|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.
~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA"
16325333|NCT04502056|Placebo Comparator|Control: AMA DP - B - B|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.
~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
16325334|NCT04502056|Placebo Comparator|Control: AMA DP - W - W|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.
~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA
~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
16325335|NCT04502043|Experimental|Exercise therapy|Exercise therapy consists of improving dynamic hip joint stability by means of hip-specific and functional lower limb strengthening, core stability and postural balance exercises.
16325336|NCT04502030|Experimental|Panzyga|
16325337|NCT04502030|Placebo Comparator|Placebo|
16325338|NCT04502017|Active Comparator|Standard Antithrombotic Therapy|OAC for 6 weeks followed by DAPT until 6 month-follow-up, then aspirin alone
16325339|NCT04502017|Active Comparator|Genetic-Tailored AntiThrombotic Strategy|OAC for 6 weeks followed by DAPT (clopidogrel responders) or aspirin plus half-dose OAC (clopidogrel non-responders) until 6 month-follow-up, then aspirin alone
16325340|NCT04502017|Active Comparator|Half-Dose NOAC|Half Dose of Novel OAC
16325341|NCT04502004|No Intervention|Control Group (CG)|"Receive the recommendations of the Clinical Practice Guidelines which consist of: advice on smoking cessation smoking, leaflet with information (tobacco components, treatments to reduce withdrawal syndrome).
~Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
16325342|NCT04502004|Experimental|Experimental Group (EG)|"Receive codes to download the App NoFumo+ . Is a mHealth that offer a CBT program. Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
16325343|NCT04501991||Patients with Type 2 Diabetes|Patients with type 2 diabetes and a scheduled visit during the lockdown for COVID-19
16325346|NCT04501965|Active Comparator|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
16325347|NCT04501965|Experimental|Quinquina/Azythromycin|Patients receive 3.5g tea bags of Cinchona/Stevia powder orally at the rate of 3 tea bags per day for 10 days
16325348|NCT04501965|Experimental|4plants/Azythromycin|Participants received 4Plants powder in a 3.5g tea bag orally three times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
16325349|NCT04501952|Experimental|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
16325350|NCT04501952|Placebo Comparator|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
16325351|NCT04501939|Experimental|Cirmtuzumab + Venetoclax|All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.
16325352|NCT04501926||Controls|Asthma patients who did not report asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
16325353|NCT04501926||Cases|Asthma patients that reported asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
16325354|NCT04501913||Observational (remote telemonitoring)|Patients undergo remote perioperative telemonitoring with home monitoring devices activity monitor beginning 7 days before surgery and up to 30 days after hospital discharge.
16325355|NCT04501900|Active Comparator|prolonged DAPT group|
16325356|NCT04501900|No Intervention|standard DAPT group|
16325357|NCT04501887||Matched therapy|Molecular profiling performed with actionable molecular alterations detected and target therapy was then conducted
16325358|NCT04501887||Unmatched therapy|Molecular profiling performed with actionable molecular alterations detected but therapy was conducted based on the guideline treatment
16325359|NCT04501887||No marker|Molecular profiling performed without any actionable molecular alterations detected, tranditional therapy based on the guideline was then conducted
16325360|NCT04501874|Active Comparator|EMB-001 Active|EMB-001 Combination product of 720 mg metyrapone/24 mg oxazepam mg by mouth twice per day for 12 weeks followed by a 1 week taper
16325361|NCT04501874|Placebo Comparator|EMB-001 Placebo|EMB-001 Placebo by mouth twice per day for 12 weeks followed by a 1 week taper
16325362|NCT04501861|Active Comparator|The use of vasopressin compared with norepinephrine|The investigator hypothesize that the use of vasopressin compared with norepinephrine induces a lower mPAP-to-MAP ratio, in cardiac surgical patients with and without pulmonary hypertension who require intraoperative vasopressor support.
16325363|NCT04501861|Active Comparator|The use of norepinephrine compared with vasopressin|The investigators will compare GLS between patients who received norepinephrine versus vasopressin intraoperatively.
16325364|NCT04501848||Study|parents of obstructive sleep disordered breathing (OSDB) children before and after surgical treatment
16325365|NCT04501848||Control|A group of parents to healthy children comprised the control group.
16325366|NCT04501835||Cardiac implantable electronic device infections|Patients hospitalised in Nancy University Hospital for suspected cardiac implantable electronic device infections
16325367|NCT04501822||Covid19 pneumonia patients|The study includes men and women ≥18 years old with documented COVID-19 pneumonia
16325368|NCT04501809|Active Comparator|Group I (Misoprostol group):|seventy-nine patients will receive a loading dose of moistened misoprostol tablets ( Cytotec pfizer 400 mg) inserted vaginally and it will be followed by maintenance dose (200 mg) after six hours and repeated every 4 hours till the start of effective uterine contraction with maximum five doses in 24 hours duration .
16325369|NCT04501809|Active Comparator|Group II (Combined group):|seventy- nine patients will get intracervical Foleys Catheter insertion .a 16F (french units) Foley catheter will be introduced into the cervical canal to induce cervical ripping. The catheter will be fixed through inflation of the balloon with 30 milliliters of sterile solution when the catheter will be beyond the internal cervical os. After six hours of Foleys catheter fixation, we will start infusion of 10 international units (IU) of oxytocin on 500 ml ringer lactate by rate 125 ml\hr followed by one hour rest to allow diuresis. Increased gradually of oxytocin dose by 5 IU each time until achieving regular uterine contraction, maximum five doses in twenty -four hours duration.
16325370|NCT04501796|Experimental|NT-I7|NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
16325371|NCT04501796|Placebo Comparator|Placebo|Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
16325372|NCT04501783|Experimental|TL-FVP-t (favipiravir) Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC); Days 2-10: 800 mg BID plus SOC.
16325373|NCT04501783|Active Comparator|Standard of Care Arm|Standard of Care including etiotropic therapy according to MoH of Russian Federation Recomendations for COVID-19 (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine, or mefloquine in recomended regimen) up to10 days
16325374|NCT04501770|Experimental|M802|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with M802 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
16325375|NCT04501744|Experimental|M701|Patients will undergo a 2-week screening period and a 4-week core treatment period, and eligible patients who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
16325376|NCT04501731||Young PFT survivors|
16325377|NCT04501731||Age-matching controls|
16325378|NCT04501718|Experimental|Test group|
16325379|NCT04501705|Experimental|test group|
16325380|NCT04501692|Experimental|VivaSight|Intubated with a VivaSight-SL endotracheal tube.
16325381|NCT04501692|Active Comparator|Conventional|Intubated by videolaryngoscopy.
16325382|NCT04501679|Experimental|Nemolizumab|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (>=) 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
16325383|NCT04501679|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing >= 90 kg will receive two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
16325384|NCT04501666|Experimental|Nemolizumab 30 milligram (mg)|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W) and participants >= 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W up to 24 weeks.
16325385|NCT04501666|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive matching placebo of two SC injections at baseline, then one SC injection Q4W and participants weighing >= 90 kg will receive matching placebo of two SC injections at baseline, then two SC injections Q4W up to 24 weeks.
16325386|NCT04501653|Experimental|Psilocybin first|Participants will receive 25 mg of psilocybin at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the control drug (methylphenidate) at their second drug exposure neuroimaging session.
16325387|NCT04501653|Active Comparator|Methylphenidate first|Participants in this group will be randomized to receive 40 mg of methylphenidate at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the active comparator (psilocybin) at their second drug exposure neuroimaging session.
16325392|NCT04501627||Participants with RE|Participants diagnosed with RE who have received 20 milligram (mg) of vonoprazan in routine clinical practice, will be observed prospectively. Data will be collected from participants' medical records, self-reported questionnaires and recorded information on symptom via diaries.
16325436|NCT04501354|Experimental|UC-Mesenchymal Stem Cell|Allogeneic Mesenchymal Stem Cell from umbilical cord
16325394|NCT04501601|Experimental|Experimental: weight loss program kit|weight loss program kit
16325395|NCT04501588|Experimental|Parent Learning Style 1|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
16325396|NCT04501588|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
16325397|NCT04501588|Active Comparator|Learning Style 1 (Parent)|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
16325398|NCT04501588|Active Comparator|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
16325399|NCT04501575|Experimental|Osteopathic consultation|It consists of 1 session. Each osteopathic session is based on a structural evaluation and treatment tailored to the participant-specific complains
16325400|NCT04501575|Sham Comparator|Osteopathic sham consultation|Osteopathic Sham treatment was applied using manual contact on specific bony surfaces using very light pressure. The practitioner was counting the seconds up to 1 minute between the areas where to apply the light touch without any intention to treat or diagnose.
16325401|NCT04501575|No Intervention|Usual Care|Participants will be on a waiting list, and meanwhile, they are advised to deal with their pain in the way they would, but without using any sort of Manual Therapy.
16325402|NCT04501562||Subject|
16325403|NCT04501536|Experimental|High Frequency|Participants will receive therapy 4 times a week for 10 weeks for 30 minutes per session.
16325404|NCT04501536|Experimental|Low Frequency|Participants will receive therapy 1 time a week for 10 weeks for 2 hours per session.
16325405|NCT04501523|Experimental|A|ctDNA positive, non-pCR Intervention: Tislelizumab(anti-PD1 antibody) combined with capecitabine
16325406|NCT04501523|Active Comparator|B|ctDNA positive, non-pCR Intervention: capecitabine(standard care)
16325407|NCT04501523|Experimental|C|ctDNA positive, pCR Intervention: capecitabine
16325408|NCT04501523|No Intervention|D|Follow up(standard care)
16325409|NCT04501510||HumerusFracture|Patients with humerus fracture
16325410|NCT04501510||RadiusFracture|Patients with radial bone fracture
16325411|NCT04501497||NSCLC cohort (N=800)|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
16325412|NCT04501497||ED-SCLC cohort (N=400)|Patients with extensive disease small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
16325413|NCT04501484|Experimental|Treatment Group|Participants will undergo a thalamotomy contralateral to their previous treatment with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel).
16325414|NCT04501471|Experimental|SAAF-T|Participants received a 5 session, 10-hour family centered prevention program designed to prevent substance use, conduct problems, and risky sexual behavior
16325415|NCT04501471|Placebo Comparator|Fuel for Families|Participants received a 5 session, 10 hour family centered program that focused on healthy nutrition and exercise.
16325416|NCT04501458|Experimental|Functional community health units|Community health units with active community health workers.
16325417|NCT04501458|No Intervention|Non functional community health units|Community health units without active community health workers.
16325418|NCT04501458|Experimental|Health facilities with oxygen capacity|Health facility with regular oxygen capacity.
16325419|NCT04501458|No Intervention|Health facilities without oxygen capacity|
16325420|NCT04501445|Experimental|Rounding Summary|Surrogates who were assigned to the intervention group received a written rounding summary every day or every other day that the patient is in the ICU.
16325421|NCT04501445|No Intervention|Usual Care|
16325422|NCT04501432||Cardiac Rehabilitation|Participants will be recruited from a group of patients who regularly attended group-based cardiac rehabilitation exercise training at the study site until COVID-19 restrictions (national lockdown) came into force on 10th March 2020.
16325423|NCT04501419|Experimental|Trained radiologists|Trainers will successfully train Nigerian radiologists
16325424|NCT04501419|Experimental|Patients with a suspicious breast mass|Women that present to the hospital with a suspicious breast mass
16325425|NCT04501406|Active Comparator|Pioglitazone|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving pioglitazone 15mg/day.
16325426|NCT04501406|Placebo Comparator|Placebo|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving placebo.
16325427|NCT04501393|No Intervention|0 ml/kg|The participants will not be asked to drink anything at 2 hours prior to planned procedure.
16325428|NCT04501393|Active Comparator|3 ml/kg|The participants will be asked to drink 3ml/kg of clear liquid at 2 hours prior to planned procedure.
16325429|NCT04501393|Active Comparator|7 ml/kg|The participants will be asked to drink 7 ml/kg of clear liquid at 2 hours prior to planned procedure.
16325430|NCT04501393|Active Comparator|10 ml/kg|The participants will be asked to drink 10 ml/kg of clear liquid at 2 hours prior to planned procedure.
16325431|NCT04501380|Experimental|1st regimen|30 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
16325432|NCT04501380|Experimental|2nd regimen|30 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
16325433|NCT04501367|Experimental|DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
16325434|NCT04501367|Experimental|Second DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
16325435|NCT04501367|Experimental|Topical Prednisolone Acetate 1% Group|Patients undergoing vitrectomy with internal limiting membrane peel
16325439|NCT04501328|Experimental|CIC+VA-CRAFT|Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
16325440|NCT04501328|Active Comparator|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
16325441|NCT04501315||ICU TBI|Patients treated on the ICU with brain injury
16325442|NCT04501315||ICU tumor|Patients treated on the ICU because of intracranial tumor
16325443|NCT04501315||ICU surgery|Patients treated on the ICU following surgery without brain injury
16325444|NCT04501315||ICU control|Patients treated on the ICU without TBI, tumor or surgery
16325445|NCT04501289|Experimental|Low dose magnesium sulphate|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive low dose magnesium sulphate
16325446|NCT04501289|Experimental|Magnesium sulphate Pritchard regimen|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive Pritchard regimen of magnesium sulphate
16325447|NCT04501276|Experimental|ADG116 Dose Escalation Level 1|
16325448|NCT04501276|Experimental|ADG116 Dose Escalation Level 2|
16325449|NCT04501276|Experimental|ADG116 Dose Escalation Level 3|
16325450|NCT04501276|Experimental|ADG116 Dose Escalation Level 4|
16325451|NCT04501276|Experimental|ADG116 Dose Escalation Level 5|
16325452|NCT04501276|Experimental|ADG116 Dose Escalation Level 6|
16325453|NCT04501276|Experimental|ADG116 Dose Escalation Level 7|
16325454|NCT04501276|Experimental|ADG116 Dose Escalation Level 8|
16325455|NCT04501276|Experimental|ADG116 Dose Escalation Level 9|
16325456|NCT04501250|Experimental|Rinsulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
16325457|NCT04501250|Active Comparator|Humulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
16325458|NCT04501237|No Intervention|Bruxers without sleep hygiene instructions|
16325459|NCT04501237|Experimental|Bruxers with sleep hygiene instructions|
16325460|NCT04501224|Experimental|switch to tenofovir alafenamide fumarate|Patients will switch to tenofovir alafenamide fumarate treatment, 25mg，once a day
16325461|NCT04501224|Active Comparator|Continue with the original regimen|Patients will continue with the original regimen treatment, entecavir, 0.5mg once a day, or tenofovir disoproxil fumarate 300mg once a day
16325462|NCT04501211|Other|Patch arm|Transdermal Granisetron patch to be given for application for 24 weeks with 2 weeks on and one week off pattern for a total of 24 weeks
16325463|NCT04501198|Experimental|Moxibustion with characteristic lifestyle intervention of TCM|Participants will receive moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine.In this study, xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course, and the intervention of Xiusheng Decoction and Traditional exercises will last for 8 weeks.While the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
16325464|NCT04501198|Experimental|moxibustion with lifestyle intervention|Participants will receive moxibustion combined with lifestyle intervention. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course,while the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
16325465|NCT04501198|Other|lifestyle intervention|Participants will receive lifestyle intervention which includes modern dietary exercise modifications. Participants will receive this treatment for a 8-session treatment course and 4-session follow-up course.
16325466|NCT04501185||UTS Stem|The subjects who received UTS Stem in total hip arthroplasty.
16325467|NCT04501185||UTF-reduced Stem|The subjects who received UTF-reduced Stem in total hip arthroplasty.
16325468|NCT04501172||Study group|People who use social networks, with permanent residence in Greece, aged above 18 years old and adequate literacy of Greek language
16325469|NCT04501159||End-stage renal disease (ESRD)|Patients with end-stage renal disease undergoing regular haemodialysis 3 times weekly.The investigation will measure cardiac output (CO), oxygen saturation (SaO2), arterial blood gases (ABG) and white blood cell (WBC) count during HD to assess changes in haemodynamics, pH, leukostasis and hypoxia. Patients undergoing regular HD will be recruited with arterial blood samples for gas analysis drawn over three consecutive HD treatments. Arterial samples will be taken at the start, 15 minutes and end of HD treatment for ABG and WBC analysis. Dialysis membrane, ultrafiltration volume, serum and dialysate bicarbonate levels will also be recorded. Regression analysis will be performed with pH, ABG and SaO2. A subset of patients will be used to assess an if cardiac output, WBC or pH better predicts PaO2 during HD.
16325470|NCT04501133|Experimental|Healthy Participants|Healthy participants without motor disorders and medications influencing brain functions will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG is recorded.
16325471|NCT04501133|Experimental|Patients|Participants with Parkinson's Disease or essential tremor will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG and EEG are recorded.
16325472|NCT04501120|Experimental|APG2575 single agent|APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
16325473|NCT04501120|Experimental|APG2575+ reduced-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT.
16325474|NCT04501120|Experimental|APG2575+ standard-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT.
16325475|NCT04501120|Experimental|APG2575+ AZA|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA.
16325542|NCT04500574|Experimental|Latanoprost contact lens|The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
16325476|NCT04501107|Experimental|BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Subcutaneous administration of Biochaperone insulin lispro formulation made from a freeze-dried of BioChaperone reconstituted with Humalog® at a dose of 0.2 U/Kg Body Weight (BW).
16325477|NCT04501107|Experimental|Ready-to-use BioChaperone insulin lispro (IMP2)|Subcutaneous administration of ready-to-use Biochaperone insulin lispro formulation at a dose of 0.2 U/Kg BW.
16325478|NCT04501107|Active Comparator|US-approved Humalog® (IMP3)|Subcutaneous administration of US-approved Humalog® at a dose of 0.2 U/Kg BW.
16325479|NCT04501107|Active Comparator|EU-approved Humalog® (IMP4)|Subcutaneous administration of EU-approved Humalog® at a dose of 0.2 U/Kg BW.
16325481|NCT04501081||1|DFNA patients and their family members (affected)
16325482|NCT04501081||2|DFNA patients and their family members (unaffected)
16325483|NCT04501068||Ambu AuraGain|Ambu® AuraGainTM Patients undergoing anesthesia in which airway management includes a Ambu® AuraGainTM supraglottic airway and fulfill the inclusion criteria of the study.
16325484|NCT04501055|Experimental|Perineal nerve block|Man receive the perineal nerve block before under the transperineal prostate biopsy
16325485|NCT04501055|Active Comparator|Periprostatic block|Man receive the periprostatic block before under the transperineal prostate biopsy
16325486|NCT04501042||Obese patients tissue proved NASH|age >20，morbid obesity who will receive bariatric surgery, tissue proved NASH
16325487|NCT04501042||Obese patients tissue proved NAFL|age >20，morbid obesity who will receive bariatric surgery, tissue proved NAFL
16325488|NCT04501042||NASH (before bariatric surgery)|age >20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected before bariatric surgery.
16325489|NCT04501042||NASH (after bariatric surgery)|age >20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected after bariatric surgery.
16325490|NCT04501029|Experimental|Gimatecan group|In Phase Ib study, patients will receive gimatecan at different dose level (0.4mg/m2, 0.6mg/m2,0.8mg/m2, oral, every 4 weeks) until progressive disease (PD).In Phase II study, patients will receive gimatecan at recommended phase II dose level.
16325491|NCT04501016|Experimental|Tailored Intervention|Tailored behavioral counseling combined with tobacco cessation pharmacotherapy.
16325492|NCT04501003|Other|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm.
16325493|NCT04500990||Single agent PD-1/PD-L1 inhibitor|Patients will receive single agent PD-1/PD-L1 inhibitor in a predefined group.
16325494|NCT04500990||Combined immunotherapy|Patients will receive combined immunotherapy in a predefined group. PD-1/PD-L1 inhibitor will be combined with target therapy, such as lenvatinib, enrotinib, herceptin et al.
16325495|NCT04500977|Experimental|Training community health promotion leaderss|Community women are trained in leadership and community-based health promotion skills
16325496|NCT04500964||failed transcather aortic valve (Stenotic)|
16325497|NCT04500964||failed transcather aortic valve (Regurgitation)|
16325498|NCT04500964||failed transcather aortic valve (Regurgitation and stenotic))|
16325499|NCT04500951|Experimental|Optimized resting environment|"The optimized resting environment will consist of the following complex intervention.
~Technically assisted noise control in regards of alarms in the patient room
~Visual signing reminding staff that the patient is not to be disturbed during rest
~Individual optimization of room environment according to information received from relatives
~Individual optimization of room environment and positioning according to systematized knowledge on best practice in the intervention ward including auditory and visual stimuli"
16325500|NCT04500951|Other|Standard resting environment|Standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward.
16325501|NCT04500925||UPSCALED|
16325502|NCT04500925||NOT UPSCALED|
16325503|NCT04500912|Active Comparator|Supraflex Cruz stent|Randomization to Supraflex Cruz stent
16325504|NCT04500912|Active Comparator|Ultimaster Tansei stent|Randomization to Ultimaster Tansei stent
16325505|NCT04500899|Experimental|Mydfrin|Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.
16325506|NCT04500886|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24 hours after the end of chemotherapy, 6mg for patients with body weight ≥ 45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
16325507|NCT04500886|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24 hours after the end of chemotherapy, 300ug for patients with body weight ≥45kg and 150ug for patients with body weight less than 45kg, Once a day for 3-5 days until the absolute count of neutrophils ≥2×109/L.
16325508|NCT04500860||Group A Tadalafil 5 mg|50 patients subjected to Daily dose of tadalafil 5mg
16325509|NCT04500860||Group B placebo|50 patients subjected to placebo daily
16325510|NCT04500847|Active Comparator|Group 1|25 MCI and early AD subjects
16325511|NCT04500847|Placebo Comparator|Group 2|10 MCI and early AD subjects
16325512|NCT04500834|Experimental|Positive reactions, Concordance with reference allergen|All subjects will be patch tested with 11 experimental and 11 reference allergens. Rates of positive reactions will be evaluated using Cohen's kappa calculation.
16325513|NCT04500821|Experimental|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
16325514|NCT04500808|Experimental|Part 1: Double Blind Phase|Participants will receive macitentan or matching placebo from Day 1 up to Day 13 under fed conditions and will be up-titrated starting with 2 once daily (QD) dosing of Dose 1 from Days 1 to 2 followed by 3 qd doses of Dose 2 of macitentan from Days 3 to 5, followed by qd doses of Dose 3 macitentan from Days 6 to 13.
16325543|NCT04500574|Placebo Comparator|Topical Latanoprost|The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.
16325515|NCT04500808|Experimental|Part 2: Open Label Phase: Treatment Sequence AB|Participants will receive Dose 3 of macitentan under fasted conditions (Treatment A) in period 1 followed by Dose 3 of macitentan under fed condition (Treatment B) in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
16325516|NCT04500808|Experimental|Part 2: Open Label Phase: Treatment Sequence BA|Participants will receive Treatment B in period 1 followed by Treatment A in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
16325517|NCT04500795|Experimental|Embolization Group|Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
16325518|NCT04500795|No Intervention|Control Group|All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.
16325519|NCT04500782||Patients|Group of patients with CP aged 4 to 10 years.
16325520|NCT04500769|Experimental|Acute Resistance Exercise|Participants will perform four exercises: squat, knee extension, leg press, and lat pulldown at 80% of 1-RM determined during a previous visit.
16325521|NCT04500756|Active Comparator|Metformin group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
16325522|NCT04500756|Placebo Comparator|Placebo Group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
16325523|NCT04500743|Active Comparator|Dienogest|
16325524|NCT04500743|Active Comparator|GnRH analogue|
16325525|NCT04500730|Experimental|Shaoyao Gancao Decoction Jiawei|"Shaoyao Gancao Decoction Jiawei by adding Pueraria montana, Salvia Miltiorrhiza, into Shaoyao Gancao.
~The medication will be taken twice daily for 28 consecutive days. Each prescription will consist of 4 herbal granules."
16325526|NCT04500717|Active Comparator|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
16325527|NCT04500717|Experimental|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
16325528|NCT04500704|Active Comparator|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
16325529|NCT04500704|Experimental|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
16325530|NCT04500691||FBSS patients|FBSS patients who are treated with high frequency Spinal Cord Stimulation
16325531|NCT04500678|Experimental|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
16325532|NCT04500678|No Intervention|Observation|Observed without metformin
16325533|NCT04500665|Experimental|Colchicine|Colchicine 0.3 mg once daily
16325534|NCT04500665|Placebo Comparator|Placebo|Placebo once daily
16325535|NCT04500626|Experimental|HBOT|These patients will receive hyperbaric oxygen therapy (HBOT) in addition to usual treatment for COVID-19. HBOT sessions will be 75 minutes in length at a pressure of 2.0 ATA.
16325536|NCT04500626|No Intervention|Control|These patients will receive usual treatment for COVID-19, including oxygenation at normal atmospheric pressure (normobaric oxygenation).
16325537|NCT04500613|Active Comparator|ESPB with Bupivacaine and Dexamethasone|12 pediatric spinal fusion surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.25% bupivacaine with 2mg preservative free dexamethasone with a maximum of 30 mL total per side, depending on the patient's weight.
16325538|NCT04500613|Placebo Comparator|No ESPB|12 pediatric spinal fusion surgery patients will be randomized to not receive an intraoperative ultrasound-guided bilateral ESPB. These patients will still receive the standard anesthesia regimen during and after surgery.
16325539|NCT04500600||Observational (questionnaire)|Patients complete an online questionnaire over 10 minutes regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
16325540|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - NHL|Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Mantle Cell Lymphoma (MCL), large cell lymphoma (LCL), and peripheral T-cell lymphoma (PTCL). Subjects must have relapsed or be refractory to at least 2 prior lines of therapy and have either failed or were not eligible for any available therapies expected to provide clinical benefit.
16325541|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - AML|Subjects with relapsed and/or primary refractory AML as defined by WHO 2016 revised criteria, who have either relapsed or are refractory to previously available therapy.
16325544|NCT04500561|Experimental|YY-20394|YY-20394 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons
16325547|NCT04500535||Cohort 1|Immuno-oncology (IO)-naïve patients
16325548|NCT04500535||Cohort 2|IO-experienced patients for whom last IO discontinuation was not primarily related to IO-toxicity
16325549|NCT04500535||Cohort 3|IO-experienced patients for whom last IO discontinuation was primarily due to IO-toxicity
16325550|NCT04500522|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (INH) 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
16325551|NCT04500522|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
16325552|NCT04500509|Experimental|Group A|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure
16325553|NCT04500509|Placebo Comparator|Group B|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure
16325554|NCT04500496|Experimental|INH|3 tablet of INH 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
16325555|NCT04500496|Active Comparator|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
16325556|NCT04500483||Burn outpatients|Burn patients treated for minor burns in an outpatient setting
16325557|NCT04500483||ICU survivors|Critically ill patients who survived ICU stay and are admitted in a general ward
16325558|NCT04500470|Experimental|Group A|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
16325559|NCT04500470|Placebo Comparator|Group B|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table vaginal placebo by the patient 12 hours before the procedure
16325560|NCT04500457|Experimental|Intervention|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 3 days at home (5 treatment sessions total).
16325561|NCT04500457|No Intervention|Wait-List Control|Participants in this condition will not receive treatment.
16325562|NCT04500444|Experimental|Blood-Flow Restriction Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The blood flow restriction protocol will be applied to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. Before the first application, patients will be evaluated by a specialist physician using ultrasonography and it will be ensured that the arterial blood flow is not restricted as the blood flow restriction restricts only venous blood flow. The pressure threshold at this point is the level to be used in subsequent training sessions and the same person (physician) will be bandaging in the same way during all subsequent training sessions.
16325563|NCT04500444|Sham Comparator|Control Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The sham blood flow restriction protocol will be applied which consists of loose bandaging to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. The same person (physician) will be bandaging in the same way during all subsequent training sessions. The pressure feeling of the patient must correspond to level 0 -not tight at all- before starting the exercise training.
16325564|NCT04500431|Experimental|spCART-269|spCART-269 administered by intravenous (IV) infusion
16325565|NCT04500418|Active Comparator|Cenicriviroc (CVC)|Approximately 122 patients. Day 1: CVC 450 mg (300 mg AM; 150 mg PM; if patients receive their first dose on Day 1 past 2 PM, then their evening dose will be 300 mg and their next dose will be the following AM.) Days 2-28: CVC BID 150 mg (AM/PM). Every dose should be taken with food (within 30 min).
16325566|NCT04500418|Placebo Comparator|Placebo|Approximately 61 patients. A matching placebo will be given to the patients in the Placebo group at an equal volume and at the same schedule.
16325567|NCT04500392|Active Comparator|Control group|Oxygen(up to 6L/min) supplied with a regular nasal catheter
16325568|NCT04500392|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
16325569|NCT04500366|Active Comparator|Socialization|Participants randomized to the socialization arm will receive once-weekly phone calls from medical student volunteers for a total of 12-weeks (n=35). This program pairs health professional student volunteers with older adults in the community to provide social comfort while heightened physical distancing measures are in place during the current COVID-19 pandemic. Attendance and duration of the phone calls will be logged.
16325570|NCT04500366|Experimental|Multi-Modal Frailty Rehabilitation|Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all through a videoconferencing system.
16325571|NCT04500353|Active Comparator|Routine face mask application|Routine application of a face mask shortly after birth to deliver continuous positive airway pressure (CPAP)
16325615|NCT04500041|Active Comparator|Casting|Subjects will be treated with serial casting
16325572|NCT04500353|Experimental|Selective face mask application|Selective application of a face mask to give positive pressure ventilation (PPV) for apnoea or bradycardia [heart rate (HR) < 100 beats per minute (bpm)] at any time in the delivery room (DR); or to give CPAP for signs of respiratory distress after 5 minutes of life
16325573|NCT04500340|Experimental|Group Cognitive Behavioral Therapy (Group CBT)|Intervention Group will receive ten-session group CBT for test anxiety. Two sessions will be carried out each week.
16325574|NCT04500340|No Intervention|Control Group|The Control group will be waiting for the control group who will receive intervention if they demand after final assessment for outcome measure.
16325575|NCT04500327|Experimental|CPAP users|The Drive app will be used by CPAP users to identify any major issues with the usability and functionality of the app when used with CPAP therapy.
16325576|NCT04500314|Experimental|Whole body vibration plus routine physical therapy|
16325577|NCT04500314|Active Comparator|Routine physical therapy|
16325578|NCT04500301|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
16325579|NCT04500288|Experimental|LEFT Device Arm|Subjects in this arm will wear the LEFT device for 1 month
16325580|NCT04500275|Experimental|Vancomycin group|"i. Timing of application: the Vancomycin (China Chemical & Pharmaceutical Co., Ltd., CCPC, Taiwan R.O.C.) paste will be spread on sternal edge immediately after sternotomy and before sternal closure.
~ii. Regimen: The Vancomycin paste will be prepared using 2.5 g of Vancomycin powder mixed with 2 ml normal saline for each time. A total of 5 g of Vancomycin powder will be applied during the cardiac surgery."
16325581|NCT04500275|Placebo Comparator|Placebo group|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.
16325582|NCT04500262|Active Comparator|Open-tip pulsed needle biopsy|
16325583|NCT04500262|Active Comparator|Conventional core needle biopsy (CNB)|
16325584|NCT04500249|Experimental|CPB|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique
16325585|NCT04500249|Experimental|CPB with SPI guided analgesia|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
16325586|NCT04500249|Experimental|CPB plus SPI guided analgesia plus carotid artery block|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique combined ith US-guided carotid artery block alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
16325587|NCT04500236|Active Comparator|General Anesthesia (GA)|Patients undergoing thyroid or breast cancer surgery under general anesthesia
16325588|NCT04500236|Placebo Comparator|Hypno-analgesia (Hyp)|Patients undergoing thyroid or breast cancer surgery under Hypno-analgesia; i.e.hypnosis combined with the use of analgesics.
16325589|NCT04500223|Experimental|Cervical Cranioflexion exercise plus cardiopulmonary exercise|subjects who received Cervical Cranioflexion exercise plus cardiopulmonary exercise
16325590|NCT04500223|Active Comparator|Cervical stretch exercise plus cardiopulmonary rehabilitation|subjects who received Cervical stretch exercise plus cardiopulmonary rehabilitation
16325593|NCT04500184||Exercise group|patients who underwent cardiac rehabilitation
16325594|NCT04500184||Control group|patients who did not undergo cardiac rehabilitation
16325595|NCT04500171|Active Comparator|English Original Assessment Tools|Short-Test of Functional Health Literacy in Adults ColoCARE Instruction Sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
16325596|NCT04500171|Active Comparator|Samoan Original Assessment Tools|Samoan Short-Test of Functional Health Literacy in Adults ColoCARE Instruction sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
16325597|NCT04500171|Experimental|English Modified Assessment Tools|Short-Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
16325598|NCT04500171|Experimental|Samoan Modified Assessment Tools|Samoan Short Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
16325599|NCT04500158|Experimental|Local anesthesia|Participants will receive local anesthesia in addition to the standard care general anesthesia
16325600|NCT04500158|No Intervention|Standard care|Participants will receive standard care general anesthesia
16325601|NCT04500145|Active Comparator|SIB-IMRT|patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.
16325602|NCT04500145|Other|routine|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
16325603|NCT04500132|Experimental|EC-18 Arm|EC-18 QD
16325604|NCT04500132|Placebo Comparator|Placebo Arm|Placebo EC-18 QD
16325605|NCT04500119|Experimental|Behavioral Testing|Behavioral and Neuronal Recordings
16325606|NCT04500106||Participants With Nurse Support, Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, using video devices.
16325607|NCT04500106||Participants With Nurse Support, Not Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, not using video devices.
16325608|NCT04500093|Experimental|Capsulotomy with Repair|Repair after capsulotomy in direct anterior hip arthroplasty
16325609|NCT04500093|Active Comparator|Capsuloectomy|Capsuloectomy in direct anterior hip arthroplasty
16325610|NCT04500080|Experimental|PE intervention|Aerobic, resistance, and neuromotor exercise
16325611|NCT04500067|Experimental|Study Group (IVIG)|Patients receive IVIG (trade name - Bioven) with base therapy
16325612|NCT04500067|No Intervention|Control group|Patients receive base therapy only
16325613|NCT04500054|Experimental|Music Intervention Group|The music intervention group listened to the music by the researchers for the duration of 15 minutes one hour before the surgery as well as the standard care.
16325614|NCT04500054|No Intervention|No Intervention Group|The control group patients received standard care only.
16325616|NCT04500041|Active Comparator|Bracing|Subjects will be treated with full-time orthotics (braces)
16325617|NCT04500028|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) ( inserted by the study nurse 4 hours before IUD insertion.
16325618|NCT04500028|Placebo Comparator|Placebo Comparator|one tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
16325619|NCT04500015|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
16325620|NCT04500015|Placebo Comparator|Placebo Comparator|3 tablet of placebo self-administered by the patient 12 hours before IUD insertion
16325621|NCT04500002|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
16325622|NCT04500002|Active Comparator|Misoprostol|Misoprostol Alone 800 mcg every three hours up to maximum three doses
16325623|NCT04499989|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
16325624|NCT04499989|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo Comparator self-inserted by the patient 12 hours before IUD insertion.
16325625|NCT04499976|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily dose, 900 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
16325626|NCT04499976|Placebo Comparator|Placebo Comparator|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
16325627|NCT04499963|Experimental|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
16325628|NCT04499963|No Intervention|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
16325629|NCT04499950|Experimental|SLOW-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose <5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave [as per the Food and Drug Administration (FDA) recommended administration] starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6.
16325630|NCT04499950|Active Comparator|FAST-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL)
16325635|NCT04499924|Experimental|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
16325636|NCT04499924|Experimental|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
16325637|NCT04499924|Active Comparator|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
16325638|NCT04499924|Experimental|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
16325639|NCT04499911|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 5 ml). The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
16325640|NCT04499898|Experimental|carvedilol|Carvedilol
16325641|NCT04499898|Active Comparator|Band Ligation|Band Ligation
16325642|NCT04499885|Active Comparator|Paraffin oil gastric lavafe|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
16325643|NCT04499885|Active Comparator|Saline gastric lavage|Gastric lavage with saline and sodium bicarbonate
16325644|NCT04499872||Patient/family Participant|Advance Care Plan with the Trajectory Touchpoint Technique
16325645|NCT04499859|Experimental|ezetimibe 10 mg plus rosuvastatin 5 mg|Rosuzet 5/10 mg , once a day for 24 months
16325646|NCT04499859|Active Comparator|rosuvastatin 20 mg only|Any brand drugs of rosuvastatin 20mg, once a day for 24 months
16325647|NCT04499846||Diabetic patients following education|Patients will followed an educational intervention about physiopathology of diabetes and mechanisms of action of statins. A questionnaire will allow to measure compliance to the treatment.
16325648|NCT04499833|Experimental|"liver transplant outside the Milan Criteria"|"patients with hepatocellular carcinoma, outside the Milan Criteria, that complied with the proposed HepatoPredictTool, submitted to liver transplant"
16325649|NCT04499820|Experimental|NUTROF Group|vitamin and DHA supplementation
16325650|NCT04499820|Placebo Comparator|MERALUT Group|vitamin A, natural flavonoids, lutein and zeaxanthin and no DHA
16325651|NCT04499807|Other|Smart Watch|The patients will wear the Smart Watch to generate data to assess their rhythm as confirmed by the ILR done during the same time.
16325652|NCT04499794||FISH diagnosed EML4-ALK fusion positive NSCLC group|
16325653|NCT04499794||FISH diagnosed EML4-ALK fusion negative NSCLC group|
16325654|NCT04499781|Experimental|HIV-infected youth: Intervention|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).
~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
16325655|NCT04499781|Active Comparator|HIV-infected youth: control|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).
~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
16325656|NCT04499768||control|the age-related cataract patients
16325657|NCT04499768||DR group|the cataract patients with mild/moderate NPDR
16325658|NCT04499755|Experimental|Nucleo CMP forte|Nucleo CMP forte twice daily for 6 weeks with supportive treatment.
16325659|NCT04499755|No Intervention|Supportive treatment|Supportive treatment only.
16325660|NCT04499729|Active Comparator|Treatment as Usual (TAU)|TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
16325661|NCT04499729|Experimental|IntelliCare|Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
16325662|NCT04499716|Active Comparator|Arm 1: ITO group|Arm 1: IPACK combined with femoral triangle and obturator nerve blocks
16325663|NCT04499716|Experimental|Arm 2 : Quadri-block group|Arm 2 : Femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks
16325664|NCT04499703||Group 1|Subjects with normal macular thickness in one or both eyes.
16325665|NCT04499703||Group 2|Subjects with center-involving macular edema due to wAMD in one or both eyes
16325666|NCT04499703||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes
16325667|NCT04499690||Global CALM Training Program Clinicians|Clinicians engaging in the CALM Training Program.
16325668|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r)|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
16325669|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
16325670|NCT04499677|Experimental|Favipiravir placebo + Lopinavir/ritonavir (LPV/r)|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
16325671|NCT04499677|Placebo Comparator|Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
16325672|NCT04499664||Blood donors|Healhy young male bloddonors, aged 30-45
16325673|NCT04499651|No Intervention|Control|All people who are living with HIV who are currently in custody in the Los Angeles County Jail are provided with Transitional Case Management and may also receive Whole Person Care related services regardless of participation in this study. Participants recruited from clinics who do not enroll in the study will be offered HIV/HCV care that follows the national HIV/HCV care guidelines, as provided by participating study clinics. Participants recruited from non-medical community agencies who do not enroll in the study and do not have a regular provider will receive a referral list of HIV/HCV care facilities that follow the national HIV/HCV care guidelines.
16325674|NCT04499651|Active Comparator|Navigation|"Participants will be paired with a navigator and will complete the following didactic sessions in one-on-one format:
~Session 1: Intervention Overview and Basic HIV/HCV Knowledge and Skills Builder
~Session 2: Rapport Building
~Session 3: Society and Self and the Role of Disclosure
~Session 4: Accompaniment 1
~Session 5: Goal-Setting, Problem-Solving and a Disclosure Toolkit
~Session 6: Accompaniment 2
~Session 7: Accompaniment 3 (ONLY if needed)
~Weekly check-in calls following Session 2 for six months"
16325675|NCT04499638||Non type 2 diabetic patient|Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered
16325676|NCT04499638||Diabetic type 2 patient|Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered
16325677|NCT04499625|Other|Control - Lateral window|Standard surgical technique to access maxillary sinus for sinus floor augmentation procedure.
16325678|NCT04499625|Experimental|Test - Hydrodynamic transalveolar approach|Novel transalveolar approach (using an ultrasonic device) to access maxillary sinus for sinus floor augmentation procedure.
16325679|NCT04499612||"Group Single-chamber CIED (A1)"|50 patients with permanent atrial fibrillation and indications for cardiac implantable electronic device implantation (single-chamber system).
16325680|NCT04499612||"Group Dual-chamber CIED (A2)"|50 patients with atrioventricular block/sick sinus syndrome and indications for cardiac implantable electronic device implantation (dual-chamber system).
16325774|NCT04499053|Experimental|durvalumab (MEDI4736)|Durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
16325681|NCT04499612||"Group Dual-chamber CIED + Atrial fibrillation (A3)"|50 patients with atrioventricular block/sick sinus syndrome, paroxysmal or persistent atrial fibrillation and indications for cardiac implantable electronic device implantation (dual-chamber system).
16325682|NCT04499612||"Group CIED Replace (B)"|50 patients with cardiac implantable electronic device implantation 6-12 years ago (single- or dual-chamber system).
16325683|NCT04499612||"Group Conservative (C)"|50 patients with atrioventricular block/sick sinus syndrome/atrial fibrillation and without indications for cardiac implantable electronic device implantation (conservative group).
16325684|NCT04499599|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
16325685|NCT04499599|Placebo Comparator|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
16325686|NCT04499599|Experimental|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
16325687|NCT04499586|Experimental|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Administration of Raltitrexed and Irinotecan weekly followed by a 2 week 'rest' period with no drug given. Raltitrexed is given by IV infusion at a dose of 3mg/m2. Irinotecan is given by IV infusion at a dose of 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7).Radiation: 45-55Gy/25-30Fx
16325688|NCT04499573|Experimental|intervention/treatment|"Intervention:
~Patient (cohort 1 and 2) or donor (cohort 3) leukapheresis
~Drug therapy:
~Fludarabine 120 mg/m2
~Cyclophosphamide 750 mg/m2
~Etoposide 450 mg/m2
~Cytarabine 900 mg/m2
~Dexamethasone 30 mg/m2
~Tocilizumab 8 mg/kg BW
~Biological:
~Cohort 1 and 2: autologous CD19/CD22 CAR-T lymphocytes, dose 0.15 - 1.5х106/kg
~Cohort 3: allogeneic CD19/CD22 CAR-T lymphocytes, dose 0.1х106/kg + allogeneic HSCT from a haploidentical or matched related donor"
16325689|NCT04499560|Experimental|Intervention|Participants consume 2 ounces of the supplement each morning for 60 days.
16325690|NCT04499560|No Intervention|Control|Participants do not make any changes to their health related routines
16325691|NCT04499547|Experimental|Physical activity intervention|Will receive twice-weekly, YouTube-delivered aerobic and muscle-strengthening physical activity videos for 8 weeks.
16325692|NCT04499547|No Intervention|General health education control|Will receive twice-weekly, YouTube-delivered videos with general health education information for 8 weeks.
16325693|NCT04499521|Experimental|Arm A: BrachyGel in fractions 3 and 5|BrachyGel VHPS in fractions 3 and 5 and standard packing in fractions 2 and 4
16325694|NCT04499521|Experimental|Arm B: BrachyGel in fractions 2 and 4|BrachyGel VHPS in fractions 2 and 4 and standard packing in fractions 3 and 5
16325695|NCT04499508|Experimental|Treatment with Optima Balt Coils|The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.
16325696|NCT04499482|Experimental|Foods containing 10 g soy flour|Participants will receive foods containing 10 g of soy flour to be consumed everyday for one week.
16325697|NCT04499482|Experimental|Foods containing 20 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week.
16325698|NCT04499482|Experimental|Foods containing 30 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week.
16325699|NCT04499469|Experimental|Spreader Graft|Placement and attachment with 5.0 polydioxanone (PDS) suture 2 grafts in the middle third of the nose
16325700|NCT04499469|No Intervention|Without Spreader Graft|No engraftment in the middle third
16325701|NCT04499456|Active Comparator|Control|Waiting list control receiving the PNF after the last assessment
16325702|NCT04499456|Experimental|Single PNF|Receives PNF after the first assessment only
16325703|NCT04499456|Experimental|Boosted PNF|Receives PNF after every assessment
16325704|NCT04499443|Experimental|Single-dose experimental group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2，Day4 and Day6. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
16325705|NCT04499443|Placebo Comparator|Single-dose control group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
16325706|NCT04499443|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, Day8 and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
16325707|NCT04499443|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
16325708|NCT04499443|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
16325775|NCT04499040|Experimental|patients with SD/THE|
16325776|NCT04499040|Placebo Comparator|control group|
16325777|NCT04499014|Experimental|ultrasound|ultrasound : a frequency of 1 MHz and an intensity of 1 W/cm2, 5 days a week, a total of 10 sessions
16325709|NCT04499443|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
16325710|NCT04499430||1|"Group 1: 29 weeks and six days of gestation and earlier
~Group 1a: complementary feeding began chronologically in the sixth month
~Group 1b: Complementary feeding corrected at sixth month"
16325711|NCT04499430||2|"Group 2: Those whose gestational age is between 30 weeks and 33 weeks and sixth days
~Group 2a: complementary feeding began chronologically in the sixth month
~Group 2b: complementary feeding started in the sixth month, corrected"
16325712|NCT04499430||3|"Group 3: Those whose gestational age is between 34 weeks and 37 weeks and sixth day
~Group 3a: complementary feeding began chronologically in the sixth month
~Group 3b: complementary feeding started in the sixth month, corrected"
16325713|NCT04499417|Experimental|Experimental-Condition|"8 weeks x weekly 20 minutes whole-body-workouts with simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
16325714|NCT04499417|Sham Comparator|Sham-Condition|"8 weeks x weekly 20 minutes whole-body-workouts without simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are not actually stimulated by EMS."
16325715|NCT04499404|Experimental|Intervention group|Participants receive breastfeeding-related information from WeChat
16325716|NCT04499404|Active Comparator|Control group|Participants receive non-breastfeeding information from WeChat
16325717|NCT04499391|Experimental|ECHO plus|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Participants in this arm will receive a 2 month (8 sessions total) refresher course in Fall 2021. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
16325718|NCT04499391|Active Comparator|ECHO|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
16325719|NCT04499378||SARS-CoV-2|Patients with a positive SARS-CoV-2 PCR test upon admission to the emergency department.
16325720|NCT04499378||H1N1 influenza|Patients with a positive Influenza H1N1 PCR test upon admission to the emergency department.
16325721|NCT04499365|Experimental|Experimental: 68Ga-DOTA/NOTA-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
16325722|NCT04499352|Experimental|treatment arm A|
16325723|NCT04499352|Experimental|treatment arm B|
16325724|NCT04499339|Experimental|All eligible patients|
16325725|NCT04499326|Experimental|Intervention|Patients undergoing catheter ablation of VT
16325726|NCT04499326|Active Comparator|Comparator|Patients undergoing AAD therapy for VT
16325727|NCT04499313|Active Comparator|Group A: Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization, followed by a tapering dose according to the patient's condition.
16325728|NCT04499313|Active Comparator|Group B: Methylprednisolone|Methylprednisolone Sodium Succinate at a dose of 0.5mg/kg (Injectable solution)
16325729|NCT04499300||Covid positive|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection.
16325730|NCT04499300||Sub-group: deceased patients|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, with death as outcome.
16325731|NCT04499300||Sub-group: patients who survived|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, who survived the infection.
16325732|NCT04499287|Placebo Comparator|Control|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) added to the apple juice (active) and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption . One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption
16325733|NCT04499287|Active Comparator|Fiber|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. 9 grams of soluble viscous fiber from psyllium husk (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) was mixed with the apple juice. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption. One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo).
16325778|NCT04499014|Experimental|phonophoresis|an intensity of 1 W/cm2 and a frequency of 1 MHz and phonophoresis with 0.1% dexamethasone pomade,5 days a week, a total of 10 sessions
16325734|NCT04499287|Experimental|Walk|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes. Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo comparator). One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) added to the apple juice and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (active comparator).
16325735|NCT04499274|Experimental|0 ng/ml|Blood specimen which was added 0 ul of ondansetron
16325736|NCT04499274|Experimental|100 ng/ml|Blood specimen which was added 0.10 ul of ondansetron
16325737|NCT04499274|Experimental|200 ng/ml|Blood specimen which was added 0.20 ul of ondansetron
16325738|NCT04499274|Experimental|300 ng/ml|Blood specimen which was added 0.30 ul of ondansetron
16325739|NCT04499261|Experimental|laparoscopic surgery|The laparoscopic view is caudal to cephalic, which is consistent with the direction of hepatic transection. In addition, the high-definition magnified view and ability to change perspectives with the laparoscope are conducive to subtle manipulation, and compression of the carbon dioxide pneumoperitoneum can reduce venous bleeding. Therefore, laparoscopic surgery may have certain advantages in the treatment of paracaval-originating lesions.
16325740|NCT04499261|Active Comparator|Open surgery|Open surgery is the traditional surgical method for resection of paracaval-originating lesions.
16325745|NCT04499235|Experimental|Mometasone furoate + AKST4290|Subjects will receive mometasone furoate concurrently with AKST4290, 400 mg twice daily, until disease control is reached.
16325746|NCT04499235|Placebo Comparator|Mometasone furoate + Placebo|Subjects will receive mometasone furoate concurrently with placebo until disease control is reached.
16325747|NCT04499222|Experimental|Portex|usage of PORTEX POLAR [Smiths Medical International, Hythe, United Kingdom] nasotracheal tube
16325748|NCT04499222|Active Comparator|Mallinckrodt|usage of Mallinckrodt TaperGuard [Covidien, Ireland] nasotracheal tube
16325749|NCT04499209|Experimental|Period 1- XG005|XG005 capsule in 4 dose level
16325750|NCT04499209|Active Comparator|Period 2- Naproxen and Pregabalin|Combination of Naproxen and Pregabalin
16325751|NCT04499209|Placebo Comparator|Period 1- Placebo|XG005 matching placebo
16325752|NCT04499183|Experimental|non-digestible carbohydrates|fructo- and galacto-oligosaccharides
16325753|NCT04499183|Placebo Comparator|placebo|maltodextrin
16325754|NCT04499170|Experimental|Muscle energy technique (G1)|Group Elderly (G1)
16325755|NCT04499170|Active Comparator|Muscle energy technique (G2)|Group of young people (G2)
16325756|NCT04499157|Experimental|MEMOPTIC added to the usual treatment of glaucoma|MEMOPTIC added to the usual treatment of glaucoma
16325757|NCT04499157|Active Comparator|usual treatment of glaucoma|usual treatment of glaucoma
16325758|NCT04499144|Experimental|modified buccal flap and subepithelial connective palatal flap|
16325759|NCT04499131|Experimental|I: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and vaginal natural micronized progesterone 400mg/12h
16325760|NCT04499131|Experimental|II: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/24h
16325761|NCT04499131|Experimental|III: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/12h
16325762|NCT04499131|Experimental|IV: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and a combination of subcutaneous natural progesterone 25mg/24h + vaginal natural micronized progesterone 400mg/24h
16325763|NCT04499131|Experimental|V: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and intramuscular natural progesterone 50mg/24h
16325764|NCT04499131|Active Comparator|Natural menstrual cycle|Natural menstrual cycle (without any exogenous steroid hormone Treatment)
16325765|NCT04499118|Experimental|Arm a(HR+/HER2-,HRD-）|Participants receive AT regimen for neoadjuvant therapy
16325766|NCT04499118|Experimental|Arm b(TNBC, HRD-)|Participants receive TP regimen for neoadjuvant therapy
16325767|NCT04499118|Experimental|Arm c(HER2-,HRD+)|Participants receive AT regimen for neoadjuvant therapy
16325768|NCT04499118|Experimental|Arm d(HER2-, HRD+)|Participants receive TP regimen for neoadjuvant therapy
16325769|NCT04499105|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem cell + Nacl 0.9%
16325770|NCT04499092|Active Comparator|Multifunction treatment|Patients that will receive a simulataneous multifunction treatment
16325771|NCT04499092|Experimental|Sequential treatment|Patients will receive a sequential function by function treatment
16325772|NCT04499079|No Intervention|Probation Referral Practice as Usual|Data are collected regarding standard probation practice and outcomes before implementation of the Learning Health System.
16325773|NCT04499079|Experimental|Learning Health System|Participating counties receive a system-level intervention, a Learning Health System, designed to improve youth connection to substance use treatment.
16325779|NCT04499014|Placebo Comparator|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week, a total of 10 sessions
16325780|NCT04498988||Substance use disorder (SUD) group|In the substance use disorder (SUD) group, participants had a diagnosis of alcohol and/or tobacco use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) but no lifetime non-substance-related addictive disorder (ND).
16325781|NCT04498988||Non-substance-related addictive disorder (ND) group|In the non-substance-related addictive disorder (ND) group, participants were included who fulfilled two or more criteria for a DSM-5 gambling disorder or for an addictive behavior related to Internet use (not for gambling, gaming, or shopping), gaming, or shopping assessed with adapted criteria from DSM-5 substance use disorder (SUD). Participants in the ND group had no lifetime SUD.
16325782|NCT04498988||Control group|The control participants had no current or lifetime substance use disorder (SUD) or non-substance-related addictive disorder (ND).
16325783|NCT04498975||Patients with IHD|No intervention
16325784|NCT04498962|Experimental|chronic stable angina|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with chronic stable angina will be treated by Danzhu Fuyuan Granule in addtion to routine care
16325785|NCT04498962|Experimental|Vascular Dementia|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Vascular Dementia will be treated by Danzhu Fuyuan Granule in addtion to routine care
16325786|NCT04498962|Experimental|Idiopathic Membranous Nephropathy|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Idiopathic Membranous Nephropathy will be treated by Danzhu Fuyuan Granule in addtion to routine care
16325787|NCT04498962|No Intervention|Healthy population|Comparator: Healthy population with no treatment
16325788|NCT04498949|Experimental|Exprimental|"The unified protocol modules are as follows:
~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
16325789|NCT04498949|Active Comparator|Treatment as usual|Treatment as usual care, Recieve consulting not included unified protocol Recieve supportive cares
16325790|NCT04498936|Experimental|Sofosbuvir/Ledipasvir|This group will receive a fixed combination of Sofosbuvir/Ledipasvir (400 mg and 90 mg, orally) once daily for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
16325791|NCT04498936|Experimental|Nitazoxanide|This group will receive nitazoxanide (500 mg, orally) four times per day for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
16325792|NCT04498936|No Intervention|Standard care treatment|This group will receive only the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
16325793|NCT04498923||Bupivacaine with dexamethasone|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.
~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone was injected for one plexus or peripheral nerve."
16325794|NCT04498923||Bupivacaine with dexamethasone and epinephrine|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.
~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone 0,02% and epinephrine 0,00018% was injected for one plexus or peripheral nerve."
16325797|NCT04498897|Active Comparator|Test group|Vortioxetine + Acamprosate
16325798|NCT04498897|Placebo Comparator|Placebo Group|Placebo + Acamprosate
16325799|NCT04498884|Experimental|Rinsulin® mix 30/70|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
16325800|NCT04498884|Active Comparator|Humulin® M3|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
16325801|NCT04498858||Patient|
16325802|NCT04498845|Active Comparator|Basic intervention group|Participants in the basic intervention group will have a 1-hour in-home assessment plan and family educational session.
16325803|NCT04498845|Experimental|Intermediate intervention group|Participants in the intermediate intervention group will have a 1-hour in-home assessment plan and educational session and refer worker to a 1-hr worker take home prevention educational session.
16325804|NCT04498845|Experimental|Advanced intervention group|Participants in the advanced intervention group will have a 1-hour in-home assessment plan and educational session, refer worker to a 1-hr worker take home prevention educational session, and provision of D-LEAD all-purpose cleaner and laundry detergent.
16325805|NCT04498832|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
16325806|NCT04498832|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
16325807|NCT04498819|Experimental|Single Arm|Only one arm, one intervention; this is a feasibility study.
16325808|NCT04498806|Experimental|Intervention|Pre-op appointment, patient will receive Fitbit device to track physical activity.
16325809|NCT04498793|Experimental|PD-1 group|"Participants receive tislelizumab every 3 weeks (Q3W) + nab-paclitaxel weekly x 4 cycles, followed by tislelizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 14 cycles of tislelizumab Q3W plus capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.
~Each cycle is 21 days."
16325810|NCT04498793|Active Comparator|Control group|"Participants receive nab-paclitaxel weekly x 4 cycles followed by (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.
~Each cycle is 21 days."
16325882|NCT04498260|Experimental|Local steroid-triamcinolone acetonide|Local steroid (triamcinolone acetonide) injection to the ulcer immediately after ESD. Total amount of injected triamcinolone is 100 mg.
16325811|NCT04498767|Active Comparator|Arm 1: Standard of Care + palliative RT|"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
~Systemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy."
16325812|NCT04498767|Experimental|Arm 2: Standard of Care + SBRT|"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size & location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
~Patients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation."
16325815|NCT04498741|Experimental|EDP-938 and tacrolimus interaction (Part 1)|
16325816|NCT04498741|Experimental|EDP-938 and dabigatran interaction (Part 2)|
16325817|NCT04498741|Experimental|EDP-938 and rosuvastatin interaction (Part 3)|
16325818|NCT04498741|Experimental|EDP-938 and midazolam interaction (Part 4)|
16325819|NCT04498715|Experimental|OSTEOSYNTHESIS+SYSTEMIC ZOLEDRONIC ACID|After osteosynthesis, systemic Zoledronic acid 4mg will be given intravenously on day 7 post operation.
16325820|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)|During osteosynthesis, cerament BVF will be used for the augmentation of the screw.
16325821|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)+LOCAL ZOLEDRONIC ACID|During osteosynthesis, 5 or 10 mL cerament BVF mixed with 1 or 2 mg Zoledronic acid will be used for the augmentation of the screw.
16325822|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)+SYSTEMIC ZOLEDRONIC ACID|During osteosynthesis, cerament BVF will be used for the augmentation of the screw. Then systemic Zoledronic acid 4mg will be given intravenously on day 7 post operation.
16325823|NCT04498702|Experimental|APL-1202 treatment|
16325824|NCT04498689|Experimental|camrelizumab + nab-paclitaxel + gemcitabine|PD-1 Monoclonal Antibody Camrelizumab at 200 mg on Day 1 and 15 nab-paclitaxel at 100 mg/m2 on Day 1, 8, and 15; gemcitabine at 1000 mg/m2 on Day 1, 8, and 15
16325825|NCT04498676|Experimental|Test product|
16325826|NCT04498663|Experimental|Therapeutic Interview Condition|The therapeutic interview for chronic pain will be a one-session interview lasting approximately 90 minutes. The goals of the therapeutic interview are to promote awareness of the role of trauma and interpersonal stress in pain, to encourage experience of emotions associated with interpersonal stressors and conflicts, and to encourage more adaptive interpersonal communication in current relationships.
16325827|NCT04498663|No Intervention|Waitlist Control Condition|Participants in the waitlist control condition will receive a delayed interview (after 5-week follow-up assessment), if they choose to do so.
16325828|NCT04498650|Placebo Comparator|Placebo|
16325829|NCT04498650|Experimental|300 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-24: 300 mg BID
16325830|NCT04498650|Experimental|600 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-12: 300 mg BID Dose in weeks 12-24: 600 mg BID
16325831|NCT04498637||Physiotherapy students|Students enrolled in the Physiotherapy Bachelor´s Degree of the University of Cadiz, Spain
16325832|NCT04498637||Nursing students|Students enrolled in the Nursing Bachelor´s Degree of the University of Cadiz, Spain
16325833|NCT04498624|Active Comparator|inverted flap|
16325834|NCT04498624|Active Comparator|peeling internal limiting membrane (ILM)|
16325835|NCT04498611|Experimental|breast DCIS patients|Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.
16325836|NCT04498598|Experimental|A/Z Airway|Patients under general anesthesia for surgical procedures who need airway management for ventilation.
16325837|NCT04498585|Experimental|Intervention|Participants who will be receiving standard ICU care and additionally the VR stimulation during their ICU stay.
16325838|NCT04498585|No Intervention|Control|Patients in the ICU who will be receiving standard ICU care during their ICU stay. Participants in this arm will not be receiving VR stimulation.
16325839|NCT04498572|Experimental|research group|active exercises and dry needling for the Gluteus medius muscle
16325840|NCT04498572|Sham Comparator|control group|active exercises and sham dry needling for the Gluteus medius muscle
16325841|NCT04498559||Patients undergoing total hip replacement|Patients at HSS Main Campus undergoing primary total hip replacement surgery, age range between 18 and 80 years old, and English speaking
16325842|NCT04498533|Active Comparator|B (brace) group|The patients in the B group were informed about the application of the forearm strap (counterforce brace). Patients were advised to wear the counterforce brace for three weeks continuously.
16325843|NCT04498533|Active Comparator|KT (kinesio tape) group|In the KT group, a standard 2-inch (5 cm) Kinesio®Tex tape (Kinesio Holding Corporation, Albuquerque, New Mexico, USA) was used with techniques of muscle inhibition and fascia correction. Kinesio tape was applied once a week for four weeks.
16325883|NCT04498260|Active Comparator|Oral steroid-predonisolone|(predonisolone) administration three days after ESD. Predonisolone is administered over 8 weeks, started at 30 mg/day and tapered 30, 30, 25, 25, 20, 15, 10 and 5 every 7 days, totaling 8 weeks of treatment.
16325844|NCT04498520|Experimental|Treatment (abexinostat tosylate, palbociclib, fulvestrant)|Patients receive abexinostat PO BID on days 1-4, 8-11, and 15-18, palbociclib PO QD on days 1-21, and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16325845|NCT04498494||myocarditis|The diagnosis of acute myocarditis was confirmed by a recent history of gastrointestinal/upper respiratory tract infection and/or complaints of cardiac symptoms and increasing cardiac markers and/or presentation with a new abnormality of the 12-lead ECGcombined with at least one of the following: ⅰ) Active or borderline biopsy according to the Dallas criteria (13); ⅱ) positive infectious origin of ventricular dysfunction; ⅲ) delayed enhancement on cardiac MRI consistent with myocarditis; or ⅳ) serological tests, ECGs, ultrasonic cardiogram (UCG), coronary angiography and ventriculography to exclude acute myocardial infarction (AMI), stress cardiomyopathy, congenital heart disease, myocarditis secondary to sepsis, valve disease, hyperthyroidism, autoimmune disease and rheumatic fever
16325846|NCT04498494||fulminant myocarditis|In patients with acute myocarditis, a diagnosis of FM was determined upon identification of one or more of the following: Haemodynamic instability due to cardiogenic shock or arrhythmia; left ventricular dysfunction and low cardiac output syndrome requiring inotropes or mechanical circulatory support; mechanical ventilation; and/or cardiac arrest (CA)
16325847|NCT04498481||Breast cancer patients|HR+/HER2- advanced/metastatic breast cancer patients in the USA.
16325848|NCT04498468|Experimental|Treatment Arm|Commercially available Sustained Release Dexamethasone, 0.4 mg intracannalicular insert (DEXTENZA® - Ocular Therapeutix, Bedford, MA)
16325849|NCT04498468|Sham Comparator|Control Arm|Commercially available EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL) (Vera90™ - Elkridge, MD)
16325850|NCT04498455|Placebo Comparator|Placebo|Dietary Supplement: Placebo
16325851|NCT04498455|Active Comparator|Prebiotin|Dietary Supplement: Prebiotin (oligofructose enriched inulin)
16325852|NCT04498442|No Intervention|Yoga Practitioners|Yoga practitioners arm is the observational arm of the study, wherein participants who follow Isha school of yoga and have completed either of the three courses : Inner Engineering Online (IEO), Inner Engineering Completion (Shambhavi Mahamudra kriya) or Shakthi Chalana Kriya can be included in this group. The participant are advised to continue with their routine yoga practice with no change in the duration of practice or frequency of their practices. Participants of this group have expertise in yoga practice and have been practicing yoga for more than 6 weeks before study enrollment.
16325853|NCT04498442|Active Comparator|Control Yoga|"Control Yoga is the active comparator arm of the study. Participants who are randomly allocated to this group, practice Simha Kriya, a deep breathing exercise taught by the Isha School of yoga."
16325854|NCT04498442|Placebo Comparator|Control Idle|Control Idle is the active comparator arm of the study. Participants who are randomly allocated to this group, are advised to either read a book for 15 minutes each day or sit idle for 15 minutes. This is the true control group for the study
16325855|NCT04498429|Experimental|Integrated Manual and Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Integrated/Manual Cueing intervention.
16325856|NCT04498429|Experimental|Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Verbal Cueing intervention
16325857|NCT04498416||Group 1 Post-Traumatic Stress Disorder (PTSD)|children with an identified traumatic history
16325858|NCT04498416||Group 2 Pathology|children with psychological follow-up treatment for a psychiatric disorder, without traumatic history;
16325859|NCT04498416||Group 3 Control|children without traumatic experience and without psychiatric or psychological follow-up treatment.
16325860|NCT04498403|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied twice daily (BID)
16325861|NCT04498390|Experimental|LY3493269|LY3493269 administered orally.
16325862|NCT04498390|Placebo Comparator|Placebo|Placebo administered orally.
16325863|NCT04498377|Experimental|F-652|
16325864|NCT04498377|Placebo Comparator|Placebo|
16325865|NCT04498364|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 8 hours of treatment.
16325866|NCT04498351|Placebo Comparator|cotrol group|
16325867|NCT04498351|Active Comparator|dexmedetomidine group|
16325868|NCT04498351|Active Comparator|magnesium sulphate group|
16325869|NCT04498351|Active Comparator|dexmedetomidine and magnesium sulphate group|
16325870|NCT04498338|Experimental|Neural mobilization and conventional physical therapy|Neural mobilization combined with conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) were performed three times/week for 6 successive weeks.
16325871|NCT04498338|Active Comparator|Conventional physical therapy program|Conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) was performed three times/week for 6 successive weeks.
16325872|NCT04498325|Experimental|NT-I7 (Phase I)|"In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
~NT-I7 will be given by intramuscular injection on Day 0
~Participants will also be given standard of care treatment for COVID-19"
16325873|NCT04498325|Experimental|NT-I7 (Pilot)|"NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0
~Participants will also be given standard of care treatment for COVID-19"
16325874|NCT04498325|Placebo Comparator|Placebo (Pilot)|"Placebo will be given by intramuscular injection on Day 0
~Participants will also be given standard of care treatment for COVID-19"
16325875|NCT04498312|Experimental|Shock wave group|Received Extracorporeal shock wave therapy twice/week for 4 weeks
16325876|NCT04498312|Experimental|Manual lympharic group|Received manual lymphatic drainage twice a week for four weeks
16325877|NCT04498286||Amsterdam MS Cohort|
16325878|NCT04498273|Active Comparator|Apixaban 2.5mg|Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
16325879|NCT04498273|Active Comparator|Apixaban 5mg|Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
16325880|NCT04498273|Active Comparator|Aspirin|Antiplatelet agent: low dose aspirin 81mg po qd
16325881|NCT04498273|Placebo Comparator|Placebo|Placebo
16326015|NCT04497402||female matched COVID19-free patients|
16325884|NCT04498247|Experimental|Part 1: Panels A, B|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.
16325885|NCT04498247|Experimental|Part 2A: Panels C-E|Participants in this 18 to 55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.
16325886|NCT04498247|Experimental|Part 2A: Panel F|Participants in this 18 to 55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.
16325887|NCT04498247|Experimental|Part 2B: Panels G, H|Participants in this >55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.
16325888|NCT04498247|Experimental|Part 2B: Panels I, J|Participants in this >55 year old cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.
16325889|NCT04498247|Experimental|Part 2B: Panels K, L|Participants in this >55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.
16325890|NCT04498234|Experimental|GROUP(A) (CONTROL GROUP)|Patients will receive standard regimen of anesthesia .
16325891|NCT04498234|Experimental|Group B|Patients will receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4.
16325892|NCT04498234|Experimental|Group C|Patients will receive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
16325893|NCT04498221|Experimental|Imaging Phase|During routine examination under anaesthetic 4 x peritumoural injection of Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
16325894|NCT04498221|Experimental|Surgical Phase|Excision of contralateral nodes identified on imaging *(fhSPECT or SPECT/CT*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
16325895|NCT04498208|Experimental|Personalized prehabilitation|Patients will participate in a personalized health optimization program combining one-on-one coaching, tailored to each patient's physical, nutritional, well-being and cognitive status baseline. Prehabilitation will last from a minimum of 14 days to a maximum of 42 days before surgery
16325896|NCT04498208|No Intervention|Standard prehabilitation|Patients in the control group will be provided with standard instructions in a hard-copy form specific to prehabilitation before surgery associating physical, nutritional, stress-reduction and cognitive recommendations without any personalized coaching for at least 14 days prior to surgery.
16325897|NCT04498195|Experimental|Increase physical activity and exercise|
16325898|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.0014%)|Low Dose
16325899|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.003%)|High Dose
16325900|NCT04498182|Placebo Comparator|Vehicle|AR15512 Ophthalmic Solution Vehicle
16325901|NCT04498169|Experimental|Once Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
16325902|NCT04498169|Experimental|Twice Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.
16325903|NCT04498156||CKD-Patients|Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
16325904|NCT04498156||Physicians treating CKD|Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
16325905|NCT04498143|Experimental|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|SAVE is a ~30-minute, self-administered, web-based program that uses components of cognitive behavior therapy and dialectical behavior therapy designed to decrease self-injurious behaviors in youth. The Project SAVE SSI has 4 general content sections: (1) explaining the science behind how changing your actions (i.e. decreasing self-injurious behaviors) can positively impact your emotions over time; (2) providing scientific evidence and testimonials from other teens that have successfully decreased their self-injurious behaviors and noticed positive change as a result; (3) evidence-based tips for overcoming common obstacles to decreasing self-injurious behaviors in day to day life; and (4) offering an opportunity for youth to share their own thoughts and advice on what they have learned with other teenagers who are facing similar challenges.
16325906|NCT04498143|Active Comparator|"Supportive Therapy (Share Your Feelings) SSI"|Supportive Therapy SSI (Schleider & Weisz, 2018): ~30-minute, self-administered, web-based program that uses components of supportive therapy to encourage feelings sharing. The supportive therapy SSI encourages participants in the control group to identify and express their feelings by (1) explaining why sharing feelings is natural, important, and helpful and (2) including testimonials from teens who have shared their feelings with close others.
16325907|NCT04498130|Experimental|12-Week Home Exercise Group|The 12-week theory-based physical activity intervention will involve mailing participants an exercise manual with health and exercise information (i.e. information about exercising safely, modules related to the social cognitive theory, weekly goal setting worksheets, exercise-tracking logs, etc.), a resistance band, and a standard Omron pedometer. Participants will receive a weekly 30-minute Zoom--based group meetings to discuss different strategies to begin and maintain a consistent exercise routine and access to a social media page to facilitate social support and interaction among the group participants. Participants will be able to join the group if they would like, but it will not be required. Participants will be encouraged to connect with each other to promote social support and social modeling. Lastly participants will receive a weekly exercise video to follow along with on their own time and tailored weekly step goals.
16325908|NCT04498130|Active Comparator|Educational Comparison Group|The education group participants will receive the same exercise manual, fitness items, exercise videos, and same weekly tailored step goal as the 12-week intervention group. This group will not have weekly zoom discussions, or be a part of the same social media page as the 12-week intervention group. Instead, the education group will be contacted by research staff once a week via telephone to discuss their manuals and activity for the week, and to ensure they have been safely engaging in exercise. A separate social media page will be created for this group, where pre-existing materials related to physical activity recommendations, benefits, other resources, and more will be shared.
16325909|NCT04498117|Experimental|Cohort 1- Surgery Active|Six (6) 21-day cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
16325910|NCT04498117|Placebo Comparator|Cohort 1 - Primary Surgery Control|Six (6) 21-day cycles of chemotherapy with placebo comparator given with chemotherapy at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
16325911|NCT04498117|Experimental|Cohort 2 - NACT + Interval Surgery Active|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
16325912|NCT04498117|Placebo Comparator|Cohort 2 - NACT + Interval Surgery Control|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with placebo comparator given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
16325913|NCT04498104||Borderline Personality Disorder|Borderline personality disorder diagnosed participants
16325914|NCT04498104||Control|Healthy participants
16325915|NCT04498091||A|Type 2 MI with COVID-19
16325916|NCT04498091||B|Type 2 without COVID-19
16325917|NCT04498091||C|Type 2 MI with pneumonia without COVID-19
16325918|NCT04498091||D|Type 2 MI without pneumonia and without COVID-19
16325919|NCT04498078|Experimental|Creatine|Twenty grams per day b.i.d.
16325920|NCT04498065||A|COVID positive and Troponin positive
16325921|NCT04498065||B|COVID positive and Troponin negative
16325922|NCT04498052|Experimental|Patients eligible for LDCT lung cancer screening|"This population will consist of patients eligible for, or potentially eligible for, LDCT lung cancer screening according to USPSTF guidelines, who are seen by a pilot user of the intervention. The inclusion criteria are (i) >= 55 years and <= 80 years old at the time of the visit; (ii) does not already have lung cancer; and (iii) meets USPSTF smoking criteria for LDCT screening (30+ pack-year smoking history and current smoker or quit in the past 15 years) or may meet the criteria if a complete smoking history were taken.
~USPSTF guidelines may change during the study. In particular, it is anticipated that the guidelines may update during the study whereby the minimum age is reduced to 50 (from 55) and the minimum smoking history is reduced to 20 years (from 30). In the event that the USPSTF guidelines change, the intervention will be updated to match the change to the guidelines. We may also update the study evaluation to match the updated USPSTF guidelines."
16325923|NCT04498039|Experimental|Active|Electrical stimulation to the tongue is delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Active subjects will be able to feel the sensation.
16325924|NCT04498039|Sham Comparator|Control|Electrical stimulation to the tongue will be delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Control subjects will be informed that while they may not feel the electrotactile stimulation, they are in-fact receiving a low level signal.
16325925|NCT04498026|Experimental|Adherus Dural Sealant System|Device: Adherus Dural Sealant, In situ polymerizing sealant
16325926|NCT04498026|Active Comparator|DuraSeal Exact Dural Sealant System|Device: DuraSeal Exact (P080013b)
16325927|NCT04498013|Experimental|Treatment group|Patients will be treated with Cyclodynon 1 tablet per day 6 month in addition to lifestyle modification
16325928|NCT04498013|Other|Control group|Lifestyle modification only
16325929|NCT04497987|Experimental|LY3819253 (Part 1)|LY3819253 administered intravenously (IV).
16325930|NCT04497987|Placebo Comparator|Placebo (Part 1)|Placebo administered IV.
16325931|NCT04497987|Experimental|LY3819253 (Part 2 - Prevention)|LY3819253 administered IV to prevention cohort.
16325932|NCT04497987|Experimental|LY3819253 + LY3832479 (Part 2 - Prevention)|LY3819253 + LY3832479 administered IV to prevention cohort.
16325933|NCT04497987|Placebo Comparator|Placebo (Part 2 - Prevention)|Placebo administered IV to prevention cohort.
16325934|NCT04497987|Experimental|LY3819253 (Part 2 - Treatment)|LY3819253 administered IV to treatment cohort.
16325935|NCT04497987|Experimental|LY3819253 + LY3832479 (Part 2 - Treatment)|LY3819253 + LY3832479 administered IV to treatment cohort.
16325936|NCT04497987|Experimental|LY3819253 (Part 3 - Treatment)|LY3819253 administered IV.
16325937|NCT04497987|Experimental|LY3819253 + LY3832479 (Part 3 - Treatment)|LY3819253 + LY3832479 administered IV.
16325938|NCT04497974|Active Comparator|Regular dietary sweetness exposure - Control|Regular dietary sweetness exposure (RSE) - The RSE group consumes a diet with 25 - 30 % energy from sweet tasting foods, for 6 months.
16325939|NCT04497974|Experimental|Low dietary sweetness exposure - Experimental|Low dietary sweetness exposure (LSE) - The LSE group consumes a diet with 10 - 15 % energy from sweet tasting foods, for 6 months.
16325940|NCT04497974|Experimental|High dietary sweetness exposure - Experimental|High dietary sweetness exposure (HSE) - The HSE group consumes a diet with 40 - 45 % energy from sweet tasting foods, for 6 months.
16325941|NCT04497961|Experimental|Lenalidomide maintenance|Those randomized to lenalidomide maintenance will receive a maintenance dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.
16325942|NCT04497961|Experimental|Daratumumab maintenance|Those randomized to receive daratumumab maintenance will receive 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.
16325943|NCT04497948|Other|Single Arm|Single Arm
16325944|NCT04497935||1LPEG|Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.
16325945|NCT04497935||2LPEG|Patients receiving 2LPEG who had a colonoscopy in the morning were asked to follow a similar day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, the first 1L dose was consumed over a 1-hour period, followed by the second dose at 11:00 pm. For 2LPEG patients with procedures in the afternoon, they took Dose 1 at 7:00 am and Dose 2 at 10:00 am. Any patient receiving 2LPEG was also told to consume 1L of clear liquids during the preparation procedure.
16325946|NCT04497922|Active Comparator|Treatment as usual in emergency department|Individuals triaged to a pod in the emergency department without rooms that are fitted with a virtual display screen
16325947|NCT04497922|Experimental|Virtual white board|Individuals triaged to a pod in the emergency department in a room that is fitted with a virtual display screen
16325948|NCT04497909|Experimental|Pre-clerkship cohort|First- and second-year medical students
16325949|NCT04497909|Experimental|Clerkship cohort|Third- and fourth-year medical students
16325950|NCT04497909|Experimental|Resident cohort|Medical residents
16325951|NCT04497883|Experimental|Cohort A: Non-Hispanic, Caucasian group|Non-Hispanic, Caucasian group participants will receive 400 milligram (mg) maribavir tablets orally once on Day 1 during treatment period 1.
16325952|NCT04497883|Experimental|Cohort B: Japanese Descent|Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1 followed by 200 mg or 800 mg maribavir tablets orally once on Day 1 during treatment period 2 followed by 800 mg or 200 mg maribavir tablets orally once on Day 1 during treatment period 3 in cross-over fashion. A washout period of 72 hours will be maintained between treatment period 1, 2, and 3.
16325953|NCT04497870|Active Comparator|540 mg|Peppermint oil at a dose of 180 mg thrice daily orally
16325954|NCT04497870|Experimental|900 mg|Peppermint oil at a dose of 180 mg five times daily orally
16325955|NCT04497857|Placebo Comparator|CSC-SD|Standard clinic-based CSC model treatment. Treatment will be delivered largely in clinic for 12 months.
16325956|NCT04497857|Experimental|CSC-TH|Telehealth based CSC model treatment. Treatment will be delivered largely through telehealth for 12 months.
16325957|NCT04497844|Experimental|Niraparib with Abiraterone Acetate plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
16325958|NCT04497844|Experimental|AA plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
16325959|NCT04497831|Experimental|Study Drug|Morphine hydrochloride
16325960|NCT04497831|Placebo Comparator|Placebo|Placebo
16325961|NCT04497818||Netizens|Netizens of Al Qassim province of Saudi Arabia were the target population for this cross sectional study. Sample size is (n=385) estimated based on the population size in Al Qassim province (Confidence Interval 95%, Design effect 1 & hypothesized % frequency of outcome factor of 50%). Assessment of Fear of COVID-19 was estimated using FEAR OF COVID-19, a 5 item Likert Scale. Assessment of Dental Anxiety was estimated using Modified Dental Anxiety 5 item Likert Scale. An online Survey form (Arabic 7 English) was developed using Google form application. The Google form link was shared to the netizens of Al Qassim province, across all relevant Social media platforms. Statistical analysis is done using SPSS 22.00 software program.
16325962|NCT04497805|Experimental|ALLO-ASC-SHEET|ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
16325963|NCT04497805|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
16325964|NCT04497792|Experimental|Treatment group|The treatment group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will receive empagliflozin additionally to previously taken hypoglycemic treatment.
16325965|NCT04497792|Other|Control group|patients continue previously prescribed medication intake
16325966|NCT04497779||Screening (biospecimen collection, medical record review, CCP)|"PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed.
~CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed.
~CCP RECIPIENTS: Patients undergo collection of blood samples at baseline, 12-24 hours after each CCP infusion, and 7 days after last CCP infusion. Patients' medical records are reviewed."
16325967|NCT04497766|Experimental|Nebulized magnesium sulphate|100mg of mgso4 in 20ml of normal saline via ultrasonic nebulizer
16325968|NCT04497766|Experimental|Intravenous magnesium sulphate|Magnesium sulphate according to weight will be given intravenously.
16325969|NCT04497753||Can't fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.
~Record whether the subject feels bitterness, if there is no feeling, the test is over."
16325970|NCT04497753||Can fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.
~Record whether the subject feels bitterness, If there is a sensation, put the adhesive strip on the upper edge of the subject's mask and put on the hood to carry out the above fitness test again.
~Record whether the subject feels bitterness, if not, the test is over. If there is any sensation, ask the subject to change to a medical surgical mask, and put an adhesive strip on the upper edge of the mask, and put on the hood to carry out the above fitness test again."
16325971|NCT04497727||Patients undergoing routine colonoscopy|Patients with and without hypertension who routinely undergo colonoscopy
16325972|NCT04497714||Cervical lymph nodes tuberculosis|The patients with Cervical lymph nodes tuberculosis
16325973|NCT04497714||Cervical lymphoma|The patients with
16325974|NCT04497714||Cervical lymph node metastasis|The patients with
16325975|NCT04497714||Cervical Reactive hyperplasia|The patients with
16325976|NCT04497701|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24~72 hours after the end of chemotherapy, 100µg/kg, once in each chemotherapy cycle.
16325977|NCT04497701|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24~72 hours after the end of chemotherapy, 100µg/kg/d, and stop using it until the ANC value exceeds the lowest value for 2 consecutive days> 0.5×10^9/L.
16325978|NCT04497688|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®) 48 hours after the end of chemotherapy, 6mg for patients with body weight≥45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
16325979|NCT04497675||Can't fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.
~Record whether the subject feels bitterness, if not, let the subject puts on the hood, carry out the fitness test again and record the results."
16325980|NCT04497675||Can fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.
~If the subject feels bitterness, stick the adhesive strip on the upper edge of the subject's mask and perform the direct spray test again. Record whether the subject feels bitterness, if not, ask the subject to put on the hood, carry out the fitness test again and record it. If there is a feeling, ask the subject to change to a medical surgical mask and put an adhesive strip on the upper edge of the mask, then conduct the direct spray test again, and record the test results."
16325981|NCT04497662|Experimental|KPL-404 (IV Administration)|
16325982|NCT04497662|Experimental|KPL-404 (SC Administration)|
16325983|NCT04497649|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir with standard of care treatment
16325984|NCT04497649|No Intervention|Standard of care treatment|Standard of care treatment
16325985|NCT04497623|Experimental|Intervention arm|Patients with indication for volume-controlled mechanical ventilation
16325986|NCT04497610||Positive TeraSystem test|Patients having positive PCR tests will undergo TeraSystem test
16325987|NCT04497610||Negative TeraSystem test|Patients having negative PCR tests will undergo TeraSystem test
16325990|NCT04497571|Experimental|Piezoelectric osteotomy|Implant placement by piezoelectric osteotomy
16325991|NCT04497571|Active Comparator|Conventional drilling|Implant placement by conventional drilling
16325992|NCT04497558|Experimental|ERA group|In the experimental group, those patients undergo endometrial receptivity array. According to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out.
16325993|NCT04497558|No Intervention|Control group|In the control group, those patients do not receive any treatment before next cycle of transfer. In the control group, no intervention will be performed.
16325994|NCT04497545|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual therapy and 30 minutes of therapy on the Luna EMG device.
16325995|NCT04497545|Other|Control Group|A four-week rehabilitation program (Monday to Friday) involving one hour of individual therapy and 30 minutes on lower limb rotor
16325996|NCT04497532|No Intervention|Control|
16325997|NCT04497532|Experimental|Diet|
16325998|NCT04497506|Experimental|Self-affirmation and Incremental theory of personality|1 hour Wise intervention (based on SA and ITP) consisting on several tasks to be completed online individually.
16325999|NCT04497506|Other|Standard preventive intervention|1 hour educational intervention (about stress management) consisting on several tasks to be completed online individually.
16326002|NCT04497480|Experimental|experimental group|
16326003|NCT04497480|No Intervention|controlled group|
16326004|NCT04497454|Active Comparator|ARDSNet|ARDSNet protocol (low PEEP-FiO2 table). Ventilatory mode: volume-controlled ventilation Tidal volume (VT) will be adjusted to 4-6 mL/Kg of PBW and Plateau pressure < 30 cmH2O for the at least the first 12 hours after inclusion in the protocol pH should be maintained between 7.35-7.45 Oxygenation (SpO2) target ranges 90-95% Maximum respiratory rate = 35 breaths/min PEEP and FIO2 adjusted according to the low PEEP-FiO2 Table.
16326005|NCT04497454|Experimental|EIT-Group|The goal is to maintain driving pressure (DP) < 16 cmH2O. Ventilatory mode: pressure-controlled ventilation After a recruitment a maneuver, PEEP will be chosen according to a PEEP titration maneuver monitored with electrical impedance tomography Plateau pressure may exceed 30 cmH2O and VT may exceed 6 mL/Kg if DP < 16 cmH2O pH should be maintained between 7.15-7.40 Oxygenation (SpO2) target ranges 90 -95% Maximum respiratory rate = 50 bpm
16326006|NCT04497441||Netizens|Internet users in Al Qassim province region are the target study population for this study. This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms.
16326007|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to S1|Adaptation to Altered Sensory Feedback + cTBS to S1
16326008|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to A1|Adaptation to Altered Sensory Feedback + cTBS to A1
16326009|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to M1|Adaptation to Altered Sensory Feedback + cTBS to M1
16326010|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + Sham cTBS|Adaptation to Altered Sensory Feedback + Sham cTBS
16326011|NCT04497415|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
16326012|NCT04497415|No Intervention|Assessment only|Control
16326013|NCT04497402||female COVID19 patients|
16326014|NCT04497402||male COVID19 patients|
16326017|NCT04497389|Experimental|Intervention|10ml intravenous hAF QD for 5 consecutive days
16326018|NCT04497389|No Intervention|Standard of Care|10 mL normal saline QD for 5 days
16326019|NCT04497376|Experimental|Upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo ethanol infusion in the vein of Marshall (EI-VOM) followed by the '2C3L' ablation step which includes bilateral circumferential PV antral ablation and linear ablations across the left atrial roof, mitral isthmus (MI), and cavo-tricuspid isthmus (CTI).
16326020|NCT04497376|Active Comparator|Pulmonary vein antral isolation (PVI)|Patients randomized to PVI arm will undergo right PV antrum ablation, followed by the left PVA ablation. Radio frequency should be applied 1 cm proximal to the PV ostia in a wide-area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished.
16326021|NCT04497363|Experimental|Focused Ultrasound|On the day of the ultrasound appointment, patients will undergo ten minutes of ultrasound targeting the anterior cingulate. The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
16326022|NCT04497350|Experimental|Transcranial Magnetic Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
16326023|NCT04497350|Experimental|Theta Burst Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
16326026|NCT04497311||SARS-CoV-2|Patients with a SARS-CoV-2 polymerase chain reaction positive test upon admission to the emergency department.
16326027|NCT04497311||H1N1 influenza|Patients with an influenza H1N1 polymerase chain reaction positive test upon admission to the emergency department.
16326028|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - Low dose|Volunteers will receive two administrations of the low dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28
16326029|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - High dose|Volunteers will receive two administrations of the high dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28.
16326030|NCT04497298|Experimental|One COVID-19 vaccine candidate (TMV-083/V-591) - High and placebo|Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
16326031|NCT04497298|Placebo Comparator|Placebo|Volunteers will receive physiological saline solution (0.9% NaCl), administered by intra muscular (i.m.) injection
16326032|NCT04497272|Other|The metabolomic signature of COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
16326033|NCT04497259|Experimental|Interventional|Patients in the teleconsultation arm will benefit from a tele-evaluation (a questionnaire filled through a chatbot link) and teleconsultation (skype-like connection) at 6 and 9 months after surgery.
16326034|NCT04497259|Experimental|Control|Patients in the consultation arm will benefit from a tele-evaluation (a questionnaire filled at home after the file was sent by secured mail) and a classical face to face consultation at 6 and 9 months after surgery.
16326035|NCT04497246||Elderly patients|Elderly patients (over 65 years old) hospitalized for COVID-19 within the CHU Brugmann Hospital
16326036|NCT04497246||Health Care professionals|Health Care professionals working within the CHU Brugmann Hospital
16326037|NCT04497233||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
16326038|NCT04497220|Placebo Comparator|Nocebo Group|Participants in this group will receive the control treatment
16326039|NCT04497220|Experimental|Positive Connotation Group|Participants in this group will receive the experimental treatment.
16326040|NCT04497207||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:
~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
16326041|NCT04497207||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
16326042|NCT04497207||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
16326043|NCT04497181|Experimental|Experimental group|
16326044|NCT04497181|Sham Comparator|Control group|
16326045|NCT04497168|Experimental|Citalopram|20mg daily
16326046|NCT04497168|Placebo Comparator|Placebo|matching placebo pills
16326047|NCT04497155||Prehospital norepinephrine|Trauma patients that received norepinephrine in the prehospital setting.
16326048|NCT04497155||Prehospital no norepinephrine|Trauma patients that did not receive norepinephrine in the prehospital setting.
16326131|NCT04496583|Experimental|Preload Responsiveness Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a state of preload responsiveness
16326477|NCT04494048||Endoscopic Bariatric Therapies (EBT).|patients undergoing Endoscopic Bariatric Therapies
16326049|NCT04497142|Experimental|Perampanel|"Participants will take a predetermined first dose of perampanel on the day before their tumor surgery
~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).
~After surgery participants will take perampanel at a predetermined dose once a day for as long as they do not have serious side effects and their disease does not get worse, up to a maximum of 12 months. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone."
16326050|NCT04497142|Active Comparator|Standard of Care|"Participants will receive standard of care medication before surgery.
~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).
~After surgery participants will take standard of care medications as predetermined by their doctor. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone.
~Participants will be followed up to 12 months after completing surgery."
16326051|NCT04497129|Experimental|ROMTech PortableConnect|Rehabilitation Using the ROMTech PortableConnect Device
16326052|NCT04497129|Active Comparator|Traditional Rehabilitation & Continuous Passive Motion Device|Combination of OPPT and HHPT in conjunction with CPM device usage
16326053|NCT04497116|Experimental|RP-3500|"Phase 1:
~Multiple doses of RP-3500 for oral administration alone or in combination with a talazoparib"
16326054|NCT04497116|Experimental|Expansion cohorts with RP-3500|"Phase 2:
~Expansion cohorts with RP-3500"
16326055|NCT04497103|Active Comparator|control|The traditional rehabilitation program conducted for 40-min sessions, three times per week for 8 weeks for all children.
16326056|NCT04497103|Experimental|task oriented training|Task-oriented training TOT group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
16326057|NCT04497103|Experimental|Xbox kinect|Xbox training group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
16326058|NCT04497090|Active Comparator|Fixed-EPAP|EPAP was kept fixed at the prescribed level throughout the night
16326059|NCT04497090|Experimental|Auto-EPAP|EPAP was continuously adjusted using the experimental approach aimed at abolishing tidal expiratory flow limitation
16326060|NCT04497077|Experimental|single dose tart cherry capsule|single dose tart cherry capsule
16326061|NCT04497077|Experimental|double dose tart cherry capsule|double dose tart cherry capsule
16326062|NCT04497077|Experimental|single dose tart cherry juice|single dose tart cherry juice
16326063|NCT04497077|Experimental|double dose tart cherry juice|double dose tart cherry juice
16326064|NCT04497077|Experimental|single placebo capsule|single placebo capsule
16326065|NCT04497077|Experimental|single placebo juice|single placebo juice
16326066|NCT04497064||Athlete|those who identified as participating in athletic competitions at DI, intramural, club or competitive levels
16326067|NCT04497064||non-athletes|those who did not identify as participating in athletic competitions at DI, intramural, club or competitive levels
16326068|NCT04497051||Embolized patients|subjects receiving preoperative embolization for aggressive spinal debulking surgery
16326069|NCT04497038|Experimental|Cabozantinib|Cabozantinib 20-60 mg by mouth once daily.
16326070|NCT04497025|Experimental|Immersive virtual reality-based vestibular training.|"Subjects in this group will receive the same intervention than the other group of study, but they will wear a 3D head mounted display (Oculus Quest glasses) and will receive real-time gaming feedback in terms of visual and audio output while using the training system.
~Participants will receive a total of 20 sessions (3 sessions of 50 minutes per week, 7 weeks). These sessions will be divided in 10 initial sessions (based on the three first blocks of Cawthorne-Cooksey protocol) and 10 advanced sessions in which vestibular exercises are gradually get more complicated by modifiying the following exercise parameters: base of support width, standing on unstable surface, alternatives single leg support, tandem position, increased velocity of head movements, higher head range motion and coordinated movements with arms and trunk.
~Same location, tailoring parameters and physical therapist supervision than conventional vestibular training."
16326071|NCT04497025|Active Comparator|Conventional vestibular training.|"Subjects in the control group will receive a total of 20 sessions of 50 minutes (3 sessions per week, 7 weeks). They will receive traditional Cawthorne-Cooksey vestibular rehabilitation exercises. This program improves vestibular compensation through a mechanism of neuroplasticity known as adaptation, habituation and substitution. Just like the virtual reality intervention it will be divided in 10 initial sessions and 10 advanced sessions. For the advanced phase of intervention exercises parameters were the same described for the virtual vestibular rehabilitation intervention.
~A physical therapy with at least two years of expertise in vestibular rehabilitation will adjust the difficulty level. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain)."
16326072|NCT04497012|Active Comparator|Low Iron Sulfate Supplementation|Participants will be given 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
16326073|NCT04497012|Active Comparator|High Iron Sulfate Supplementation|Participants will be given 6 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
16326074|NCT04496999|Experimental|Midostaurin with HDM201 dose escalation.|Midostaurin 50mg bid d1-28 (morning, evening) and HDM201
16326132|NCT04496570|Active Comparator|Periodontitis patients|gingival crevicular fluid and saliva collection were taken before and after nonsurgical periodontal treatment
16326133|NCT04496570|No Intervention|Healthy individuals|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
16326075|NCT04496986||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
16326076|NCT04496986||Cardiovascular Surgical Patients Postoperative Exam|All remaining participants without preoperative dysphagia will be seen for a postoperative exam performed within 48 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow up clinic visit.
16326077|NCT04496960|Placebo Comparator|Placebo group|Receiving placebo
16326078|NCT04496960|Experimental|Subjects with SS|Receiving tofacidinib
16326079|NCT04496947|Experimental|Stress Reduction|8 week stress reduction course
16326080|NCT04496947|No Intervention|Control|No intervention
16326081|NCT04496934|Experimental|Intervention|Exercise intervention
16326082|NCT04496934|Active Comparator|Control|The control group is a waiting list group. The participants will receive exercise intervention after twelve weeks of treatment as usual.
16326083|NCT04496921|Active Comparator|Vitamin K supplement, dose #1|Vitamin K supplementation with dose #1
16326084|NCT04496921|Active Comparator|Vitamin K supplement, dose #2|Vitamin K supplementation with dose #2
16326085|NCT04496908|Active Comparator|Early Amniotomy|Women in the Early AROM group will under amniotomy one hour from Foley Catheter expulsion. Labor augmentation will continue per study protocol. Refer to Appendix A for protocol regimen.
16326086|NCT04496908|Active Comparator|Delayed Amniotomy|Women in the Delayed AROM group will undergo amniotomy at the discretion of the obstetrician or labor provider. No specific instructions will be given.
16326089|NCT04496882|Experimental|Switching therapy cohort|single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks
16326090|NCT04496882|No Intervention|Historical continuing therapy cohort|By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)
16326091|NCT04496856|Experimental|Collagen|Participants of this arm are going to consume 30 g of collagen peptides daily for 30 days
16326092|NCT04496856|Experimental|Whey Protein|Participants of this arm are going to consume 30 g of whey protein daily for 30 days
16326093|NCT04496843||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings HWA09 Device and overnight PSG
16326094|NCT04496830|Experimental|Relapsing Remitting Multiple Sclerosis|"Blood sample collection
~Vital signs, weight, height and BMI.
~Complete neurological examination documented in NeurEx (recorded with an iPAD).
~Clinical data questionnaire
~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).
~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).
~Optical Coherence Tomography (OCT)
~CSF Analysis"
16326095|NCT04496830|Experimental|Progressive Multiple Sclerosis|"Blood sample collection
~Vital signs, weight, height and BMI.
~Complete neurological examination documented in NeurEx (recorded with an iPAD).
~Clinical data questionnaire
~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).
~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).
~Optical Coherence Tomography (OCT)
~CSF Analysis"
16326096|NCT04496830|Experimental|Non-Inflammatory Neurological Diseases|"Clinical data questionnaire
~CSF Analysis"
16326097|NCT04496830|Experimental|Other Non-Inflammatory Neurological Diseases|"Clinical data questionnaire
~CSF Analysis"
16326098|NCT04496817|Experimental|Enriched Egg Group|Participants will consume 2 medium sized docosahexaenoic acid and lutein enriched eggs daily (at least 5 days per week) for 6 weeks.
16326099|NCT04496817|Placebo Comparator|Regular Egg Group|Participants will consume 2 medium sized non-enriched eggs daily (at least 5 days per week) for 6 weeks.
16326100|NCT04496804|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an Internet website and one-on-one video chats with a behavioral coach. The Internet website involves content delivered through interactive video courses. The interactive video courses are based on elements of social cognitive theory. Each courses consists of an introduction, the primary content, and a take home message. The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic. A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention, discussion of website material, supportive accountability, and reporting of adverse events/injuries. The chats are conducted face-to-face through Skype. The chats occur 7 times during the first 2 months, 4 times during the second 2 months, and twice during the final 2 months of the intervention.
16326134|NCT04496557|Experimental|Patients diagnosed with PTSD|7-15 men and women with PTSD will be recruited from the community and from local clinical programs through a multi-modal outreach program.
16326135|NCT04496544||Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with drug-coated devices (drug-eluting stent ± drug-coated balloon, bare metal stent with drug-coated balloon, or drug-coated balloon alone)
16326286|NCT04495335|Experimental|Test Group (TG)|The study included test group with Photobiomodulation treatment after dental implant surgery
16326101|NCT04496804|Sham Comparator|Wellness for MS (WellMS)|Provides an Internet website and one-on-one video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity. The materials are transformations of brochures provided by the National MS Society, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
16326102|NCT04496791|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing instrument (HI) with modified precalculation.
16326103|NCT04496791|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent RIC device from Phonak which will be fitted to the participants individual hearing loss.
16326104|NCT04496778|Active Comparator|low level laser plus exercise|acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
16326105|NCT04496778|Placebo Comparator|sham laser plus exercise|placebo acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
16326106|NCT04496765||< 40 years|Patients with rectal cancer ageing 40 years or less
16326107|NCT04496765||> 40 years|Patients with rectal cancer ageing more than 40 years
16326108|NCT04496739|Active Comparator|Group I (educational materials)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
16326109|NCT04496739|Experimental|Group II (educational materials, decision support, interview)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
16326110|NCT04496726|Experimental|Cranberry and Quillaja|one 450mg cranberry capsule and one 50mg quillaja capsule in the morning and evening for 14 days.
16326111|NCT04496713|No Intervention|Telemedicine - Phone|Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
16326112|NCT04496713|Experimental|Telemedicine - Audio/Video|Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
16326113|NCT04496700|Experimental|Group 1 - Shooting test|All participants in this group were tested for shooting abilities before and after blood donation. No variation within the group.
16326114|NCT04496700|Experimental|Group 2 - VO2max|"All participants in this group were tested for physical abilities before and after blood donation. Method: Bruce protocol.
~No variation of protocol within the group."
16326115|NCT04496700|Experimental|Group 3 - Feasability|"All participants in this group were tested for feasability before and after blood donation. Method: Hiking uphill with 20 kg backpack.
~No variation of method within the group."
16326116|NCT04496674|Experimental|Treatment with bispecific Ab CC-1|administration of bispecific PSAMxCD3 Ab CC-1.
16326117|NCT04496661|Experimental|tDCS over M1 and PES|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
16326118|NCT04496661|Experimental|tDCS over DLPFC and PES|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
16326119|NCT04496661|Sham Comparator|Sham tDCS and PES|Sham tDCS and PES stimulation. Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. The currents will be turned off automatically after 30 seconds. Duration: 30 minutes.
16326120|NCT04496648|Active Comparator|Percutaneous Coronary Intervention|Conventional PCI and optimal medical therapy
16326121|NCT04496648|Placebo Comparator|Sham-percutaneous coronary intervention|Sham-PCI and optimal medical therapy
16326122|NCT04496635|No Intervention|Baseline phase|Patients included in the VINCat program, and operated on colorectal surgery between 2007 and 2015 in Catalonia
16326123|NCT04496635|Experimental|Implementation phase|Patients included in the VINCat program, and operated on colorectal surgery between 2016 and 2018 in Catalonia
16326124|NCT04496622|Experimental|Whole Body Vibration Technique|WBV training with the frequency of 16-25 Hz along with conventional treatment.
16326125|NCT04496622|Active Comparator|WBV Technique|WBV training with the frequency of 26-35 Hz along with conventional treatment.
16326126|NCT04496609|Experimental|Stimulation-automated rehabilitation/automated rehabilitation|"Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days
~Washout 30 days
~Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
16326127|NCT04496609|Experimental|Automated rehabilitation/Stimulation-automated rehabilitation|"Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days
~Washout 30 days
~Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
16326128|NCT04496596|Experimental|Suramin|
16326129|NCT04496596|Placebo Comparator|Placebo|
16326130|NCT04496583|Active Comparator|Fluid Balance Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a predetermined negative balance
16326212|NCT04495881|Experimental|sitagliptin|sitagliptin 100mg
16326136|NCT04496544||Non-Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with non-drug-coated devices (bare metal stent ± percutaneous transluminal balloon angioplasty or percutaneous transluminal balloon angioplasty alone)
16326137|NCT04496531|Experimental|Active|Active group members use a device providing perceivable electrical stimulation
16326138|NCT04496531|Sham Comparator|Sham|Group members use a device providing a non-perceivable stimulus
16326139|NCT04496518||Patients with ICD/CRT device with iATP programmed on|Patients implanted with an iATP-capable device with iATP on in at least one device detection zone will be enrolled in the iATP PAS. Patients must also be enrolled in the CareLink network for remote monitoring. All patients must have provided signed informed consent.
16326140|NCT04496505|Sham Comparator|Control Arm|Participants will use a sham device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
16326141|NCT04496505|Experimental|Treatment Arm|Participants will use a device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
16326142|NCT04496492|Experimental|Tocotrienol|Subjects receiveTocotrienol 200 mg/twice daily before surgery
16326143|NCT04496479|Experimental|LYG-LIV0001|Open label group of subjects with end stage liver disease receiving increasing doses of the experimental therapy.
16326144|NCT04496453|Experimental|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
16326145|NCT04496440||Trial Group|Contracture correction therapy
16326146|NCT04496440||Control Group|No new intervention, patients continued with the previous treatment.
16326147|NCT04496401|Experimental|Tacrolimus then Envarsus|Tacrolimus will be started on the day of surgery. After a stable trough level is achieved (on postoperative day 7-17) the first PK profile will be measured. Subsequently, the switch to ENVARSUS® will be performed
16326148|NCT04496388|Experimental|Aerobic exercise|Aerobic exercise is lasting for nearly 50 minutes each time, including warm-up and stretching for 10 minutes after exercise.
16326149|NCT04496388|Experimental|Aerobic exercise combined with resistance exercise|Aerobic exercise is lasting for nearly 20 minutes each time, and add resistance exercise for 20 minutes. Additional warm-up 10 minutes and stretching for 5 minutes.
16326150|NCT04496388|Experimental|Aerobic exercise combined with interval training|Aerobic exercise is lasting for nearly 20 minutes each time, and add moderal intensity interval training for 10 minutes. Additional warm-up 10 minutes and stretching for 15 minutes.
16326151|NCT04496388|Placebo Comparator|Placebo|No exercise intervention.
16326152|NCT04496375||Institut Paoli Calmettes Outpatients|Patients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic
16326153|NCT04496362|Experimental|subcutaneous heparin anticoagulation|Experimental arm
16326154|NCT04496362|No Intervention|systemic intravenous anticoagulation|SOC arm
16326157|NCT04496323||LOW|Golf Skill level high, handicap below 11.5
16326158|NCT04496323||HIGH|Golf Skill level low, handicap 18.5 - 26.4
16326159|NCT04496310|Experimental|Telemedicine|"Baseline: in office clinical assessment of all patients (collection of seizure diary).
~Followup: scheduled 6-month consultations through a telemedicine device providing remote outcome assessment, counselling and follow-up. If required, on call video consultations available by contacting a provider through telemedicine, 3-hr/week."
16326160|NCT04496310|No Intervention|Usual care|"Baseline: in office clinical assessment of all patients (collection of seizure diary).
~Followup: scheduled 6-month in-office consultations with outcome assessment, counselling and follow-up. On-call consultations are possible if needed by the patient, by contacting a clinician through an in-office phone call, 3-hr/week."
16326161|NCT04496284|Experimental|Vitrification via slush nitrogen|Blastocyst stage embryos will be vitrified via slush nitrogen
16326162|NCT04496284|No Intervention|Vitrification via liquid nitrogen|Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.
16326163|NCT04496271|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing aid with modified precalculation.
16326164|NCT04496271|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent Receiver In Canal hearing aid by Phonak which will be fitted to the participants individual hearing loss.
16326165|NCT04496258|Experimental|Positive VR Scene|Participants will explore a virtual reality (VR) environment of a beach scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
16326166|NCT04496258|Experimental|Neutral VR Scene|Participants will explore a virtual reality (VR) environment of a neutral office scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
16326167|NCT04496245|Active Comparator|Wait-list control|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
16326168|NCT04496245|Experimental|Initial treatment wtih OM85|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
16326169|NCT04496232|No Intervention|Normal SDF|Using routine semen processing method
16326170|NCT04496232|Active Comparator|Physiological ICSI (PICSI)|Sperm selection using PICSI dishes for selecting sperm with lower DNA fragmentation index for ICSI
16326171|NCT04496232|Active Comparator|Second ejaculate|Using the second ejaculate as a way of reducing SDF in the semen sample used for ICSI
16326172|NCT04496219|Experimental|Arm I (acupuncture, BCG)|Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management.
16326255|NCT04495569|Experimental|Group/Cohort B|A single intramuscular injection of SYN023 at 0.3mg/kg combined with the Chinese licensed Vero Cell Rabies Vaccine (following the PEP (Post-exposure Prophylaxis) recommendation)
16326173|NCT04496219|Active Comparator|Arm II (BCG, standard of care)|Patients receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management. Patients may undergo acupuncture therapy after completion of intravesical BCG therapy.
16326174|NCT04496193|Experimental|Group lower dose ropivacaine with dexamethasone|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + dexamethasone 0.8 ml (4mg) at the end of surgery
16326175|NCT04496193|Active Comparator|Group higher dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.5% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
16326176|NCT04496193|Placebo Comparator|Group lower dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
16326177|NCT04496180|Experimental|PREVENA (CiPNT)|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply all parts just after the surgical procedure.
~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.
~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.
~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.
~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
16326178|NCT04496180|Active Comparator|Simple dressing|Simple dressing; standard, waterproof dressing applied to wound
16326179|NCT04496167|Experimental|EN3835|EN3835 up to 1.74mg.
16326180|NCT04496167|Placebo Comparator|Placebo|Placebo
16326181|NCT04496154|Experimental|Omega-3 fatty acids|3 oral softgels (600 mg EPA and 300 mg DHA / softgel), Triple Strength Omega-3 from Webber Naturals
16326182|NCT04496141||With COVID-19 infection|Subjects with a positive SARS-CoV-2 PCR
16326183|NCT04496141||Without COVID-19 infection|Subjects with COVID-19 negative serum
16326184|NCT04496115|Experimental|Mindfulness Intervention|Mindfulness training
16326185|NCT04496115|No Intervention|Control|Standard of Care
16326186|NCT04496102|Active Comparator|Cemented TKA|Cemented TKA (Triathlon, Stryker) include patellar resurfacing
16326187|NCT04496102|Experimental|Cementless TKA|Cementless TKA (Triathlon Tritanium, Stryker) include patellar resurfacing
16326188|NCT04496089|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
16326189|NCT04496063|Experimental|Group 1 Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
16326190|NCT04496063|Placebo Comparator|Group 2 Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
16326191|NCT04496050||one|there is only one patient group. This group of patients, given the same dose and at the same time, is examined by ultrasonography to determine the thickness of the pyloric muscle.
16326192|NCT04496037||Standard of care (SOC)|See NCT03994783
16326193|NCT04496037||Rituximab + SOC (SOCR)|See NCT03994783
16326194|NCT04496011|Experimental|Experimental Group|In this group the exercise program will be based on the protocol of Control Group, without the exception of walking training, adding aerobic capacity training using the bicycle ergometer, model CBL11 Classic® from ACT®.
16326195|NCT04496011|No Intervention|Group Control|"In this group the exercise program is based on the standard physiotherapy protocol that is part of the care routines performed at the bone marrow transplant service.
~It includes essential components of a rehabilitation program: range of motion, balance training, gait and strength of the upper and lower limbs"
16326196|NCT04495998|Other|Motor Neurological Soft Signs|motor test and an interview for the participants
16326197|NCT04495985||Thyrogen (rh-TSH)|Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
16326198|NCT04495985||Withdrawal from thyroid hormone|Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
16326199|NCT04495972|Active Comparator|Experimental arm: Intestinimonas|Intestinimonas in capsules
16326200|NCT04495972|Placebo Comparator|Placebo arm: Placebo|Placebo in capsules
16326201|NCT04495959||F18-DCFPyL PET/MRI DWB scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
16326202|NCT04495946|Experimental|Sepsis Transition and Recovery (STAR) Program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
16326203|NCT04495946|Active Comparator|Usual Care|Standard of care received through Atrium Health facilities for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
16326204|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|SARS-CoV-2 Sclamp antigen 5 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart.(Cohorts 1 & 4)
16326205|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|SARS-CoV-2 Sclamp antigen 15 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 2 & 5)
16326206|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|SARS-CoV-2 Sclamp antigen 45 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 3 & 6)
16326207|NCT04495920|Experimental|Test product|
16326208|NCT04495907||Group I|Group I- Asymptomatic patients with SARS-CoV-2 Infection
16326209|NCT04495907||Group II|Group II-Symptomatic patients with SARS-CoV-2 Infection
16326210|NCT04495894|Experimental|Preoperative Ketorolac|Participants randomized to receive ketorolac prior to surgery for stage I/II NSCLC and stage III RCC. Participants will receive standard-of-care surgery. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered.
16326211|NCT04495894|No Intervention|Control Group|Participants randomized to the control group receiving the standard of care during surgery for stage I/II NSCLC and stage III RCC. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered. The concurrent control group is to obtain untreated biologic samples for biologic correlative studies and secondary endpoints.
16326213|NCT04495868|Experimental|Bacteriostatic Normal Saline then 1% Lidocaine|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of bacteriostatic normal saline followed by an intradermal administration of 1% lidocaine.
16326214|NCT04495868|Active Comparator|1% Lidocaine then Bacteriostatic Normal Saline|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of 1% lidocaine followed by an intradermal administration of bacteriostatic normal saline.
16326216|NCT04495842|Experimental|Intervention|Participants receive an active essential oil blend to inhale for 15 minutes. The blend contains plant based oils sourced from flowers and citrus plants.
16326217|NCT04495842|Placebo Comparator|Control|Participants receive an inert comparison to inhale for 15 minutes.
16326218|NCT04495829||Phorcides|Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software.
16326219|NCT04495816|Active Comparator|Omega-3|1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
16326220|NCT04495816|Sham Comparator|Placebo/Control|2 softgels per day for 6 weeks
16326221|NCT04495803|Experimental|Experimental|After an initial assessment to confirm eligibility, the experimental group will receive 8 weekly sessions (2 hours long) of our augmented group CBT for perinatal anxiety during a global pandemic (n=6 per group). Participants will be re-assessed at post-treatment and at a 3-month follow-up to determine the effectiveness of the treatment and whether these effects are maintained in the long-term.
16326222|NCT04495777||students|students were assessed in order to have a risk for TMD in order to their status of having parafunctional habits and neck pain
16326225|NCT04495738|Active Comparator|Control Feeding Group|Ready to feed milk-based product
16326226|NCT04495738|Experimental|Experimental Feeding Group|Ready to feed milk-based product with oligosaccharides
16326227|NCT04495738|Other|Human Milk (HM) Reference Group|HM from infant's own mother and as needed supplemental infant formula and toddler milk-based product
16326228|NCT04495725|Placebo Comparator|Voucher for a Discounted Placebo Product|Voucher for a Discounted Placebo Soft-Gel Capsule Product
16326229|NCT04495725|Experimental|Voucher for a Discounted High THC:Low CBD Product|Voucher for a Discounted 4.3mg THC/0.7mg CBD Soft-Gel Capsule Product
16326230|NCT04495725|Experimental|Voucher for a Discounted Equal THC:CBD Product|Voucher for a Discounted 2.5mg THC/2.5mg CBD Soft-Gel Capsule Product
16326231|NCT04495725|Experimental|Voucher for a Discounted Low THC:High CBD Product|Voucher for a Discounted 0.2mg THC/4.8mg CBD Soft-Gel Capsule Product
16326232|NCT04495712|Active Comparator|Spironolactone|Patients randomized to active therapy with spironolactone
16326233|NCT04495712|Placebo Comparator|placebo|patients randomized to placebo
16326234|NCT04495699||Observation|Patients who elect to have observation of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
16326235|NCT04495699||Stone treated|Patients who elect to have intervention of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
16326236|NCT04495686|Experimental|Caregiver PWD-ADRD TCCI|Participants in the Caregiver PWD-ADRD telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
16326237|NCT04495686|No Intervention|Caregiver for PWD-ADRD (BMT)|Participants in the Caregiver PWD-ADRD best medical treatment (BMT) group will not receive care coordination.
16326238|NCT04495686|Experimental|Caregiver for PWD-TBI TCCI|Participants in the Caregiver PWD-TBI telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
16326239|NCT04495686|No Intervention|Caregiver for PWD-TBI (BMT)|Participants in the Caregiver PWD-TBI best medical treatment (BMT) group will not receive care coordination.
16326240|NCT04495673|Experimental|tDCS with Cognitive Training|DLPFC stimulation with tDCS with simultaneous cognitive training
16326241|NCT04495673|Active Comparator|Sham tDCS with Cognitive Training|Sham tDCS with simultaneous cognitive training
16326242|NCT04495660|Experimental|Severe/profoundly deaf children 10-24 months old|The cohort 1 includes patients aged 10-24 months old about to be implanted
16326243|NCT04495660|Experimental|Severe/profoundly deaf children 3-7 years old|The cohort 2 includes 3-7 years old cochlear implanted patients (implanted before 24 months of age)
16326244|NCT04495660|Other|Normally hearing children 10-24 months old|The cohort 1 includes patients aged 10-24 months matched in age and sex with normally hearing children
16326245|NCT04495660|Other|Normally hearing children 3-7 years old|The cohort 2 includes 3-7 years old matched in sex and age with cochlear implanted patients
16326246|NCT04495647|Experimental|WB-EMS_frail|
16326247|NCT04495647|Active Comparator|WB-EMS_robust|
16326248|NCT04495647|Active Comparator|WB-EMS_young|
16326249|NCT04495634|Experimental|Head Trauma or Brain Bleed|Medically stable patients who have undergone conventional head CT imaging undergo imaging within 24 hours using the s-HCT system.
16326250|NCT04495621|Experimental|MEN1611|MEN1611 + Cetuximab
16326251|NCT04495608|Experimental|fluconazole|Fluconazole 50mg capsule (1, 2, 3 or 4 pills to take daily during 18 weeks, corresponding respectively to 50, 100, 150 or 200 mg of fluconazole).
16326252|NCT04495608|Placebo Comparator|placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
16326253|NCT04495582||Non-Interventional Study group|Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
16326254|NCT04495569|Experimental|Group/Cohort A|A single intramuscular injection of SYN023 at 0.3mg/kg
16326773|NCT04492033|Experimental|ABL001 and Paclitaxel (P2)|1 cycle = 4weeks
16326256|NCT04495556||Typical|Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
16326257|NCT04495556||Atypical|Patients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS.
16326258|NCT04495543|Experimental|Brief-Skills for Safer Living (Brief-SfSL)|Participants with current suicidal ideation (Beck Suicide Scale >10) will undergo Brief-SfSLtherapy
16326259|NCT04495530||Patient|Patients will be considering commencing or discontinuing parenteral nutrition, or will be receiving home parenteral nutrition
16326260|NCT04495530||Carer|Carers will be those caring for a patient with advanced cancer who is considering commencing or discontinuing parenteral nutrition, or already receiving parenteral nutrition. Carers will also be recruited if they previously cared for a person with advanced cancer receiving parenteral nutrition in the last 12 months
16326261|NCT04495504|Experimental|Ropivacaine group|Administration of a bolus dose of ropivacaine, followed by a continuous infusion of ropivacaine during the first 48 hours postoperatively.
16326262|NCT04495491||Pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
16326263|NCT04495491||plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
16326264|NCT04495491||mixed mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
16326265|NCT04495478|Experimental|Ramucirumab - Intravenous (IV)|Ramucirumab administered IV.
16326266|NCT04495478|Placebo Comparator|Placebo - IV|Placebo administered IV.
16326267|NCT04495478|Experimental|Ramucirumab - Subcutaneous (SC)|Ramucirumab administered SC.
16326268|NCT04495478|Placebo Comparator|Placebo - SC|Placebo administered SC.
16326269|NCT04495465|Experimental|Experimental group: manual therapy + shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of extracorporeal radial shock waves therapy on painful points of neck muscles at 2 bars and 10 Hetzs.
16326270|NCT04495465|Placebo Comparator|Control group: manual therapy + placebo shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
16326271|NCT04495452||Study Participants|"We will be enrolling 200 participants, this will provide a large enough sampling to assure there are at least 25 patients with significant respiratory depression and 25 with insignificant respiratory depression.
~The genetic data from participants with the most respiratory depression defined as having a 20-40% decrease from initial respiratory parameters will be compared with genetic data from participants with the least respiratory depression defined as having no change or less than 10% decrease from initial respiratory parameters."
16326272|NCT04495439|Other|Treatment with ISS Sleeve|The biocompatible, resorbable ISS sleeve is used for augmentation to enhance screw anchorage. It is melted into the trabecular bone structure of the osteoporotic vertebra using ultrasound. A standard pedicle screw is inserted into the sleeve.
16326273|NCT04495439|Other|Treatment with PMMA|The bone cement Polymethylmethacrylat (PMMA) that is injected into the osteoporotic vertebra.PMMA augmentation of pedicle screws is done using standard cannulated and perforated pedicle screws. The cancellous bone surrounding the screw is enhanced with PMMA bone cement to increase screw anchorage.
16326274|NCT04495426||Presence of symptomatic ataxic disease|Presence of symptomatic ataxic disease with definite molecular diagnosis of SCA10 or whose first-degree relative has a molecular diagnosis of SCA10.
16326275|NCT04495426||Premanifest for SCA10|Asymptomatic participants of either sex aged ≥18 with definite molecular diagnosis of SCA10 (Premanifest carriers)
16326276|NCT04495426||At risk for SCA10|Asymptomatic participants of either sex, aged ≥18 whose first-degree relative has a molecular diagnosis of SCA10 (50%-at-risk relatives*).
16326277|NCT04495426||Non-carrier for SCA10 (Control)|At risk participants who test negative for the SCA10 mutation will serve as non-carriers. Exclusion criteria described above also applies to non-carrier subjects. If the number of non-carriers were less than 10, we will recruit additional participants from normal population to supplement the controls.
16326278|NCT04495400||Percutaneous Screw Fixation|Patients who have had a Percutaneous Screw fixation procedure.
16326279|NCT04495400||Open Fixation|Patients who have had an Open Fixation procedure.
16326280|NCT04495387||patients with colon cancer|
16326281|NCT04495387||patients with breast cancer|
16326282|NCT04495374|Placebo Comparator|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
16326283|NCT04495374|Experimental|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
16326284|NCT04495361|Experimental|Online learning portal|Final year medical students will use an online learning portal in which three case scenarios of under five pneumonia patients will be displayed each month. Based on history and examination, the user will diagnose and manage the patient.
16326285|NCT04495348||Open-label arm|Participants are switched to doravirine and then switched back to INSTI-based therapy.
16326478|NCT04494035|Experimental|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
16326287|NCT04495335|Active Comparator|Control Group (CG)|The control group consisted of laser application without energy delivery to the tissue.
16326288|NCT04495322|Experimental|10 mg TG-1000|Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.
16326289|NCT04495322|Experimental|20 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.
16326290|NCT04495322|Experimental|40 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
16326291|NCT04495322|Experimental|80 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
16326292|NCT04495322|Experimental|120 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
16326293|NCT04495322|Experimental|160 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
16326294|NCT04495322|Experimental|X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.
16326295|NCT04495322|Experimental|X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.
16326296|NCT04495309|No Intervention|Standard|Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)
16326297|NCT04495309|Experimental|Experimental|Standard of care (standard systemic therapy) + study intervention
16326298|NCT04495296|Experimental|TST001 Injection|TST001 Injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
16326299|NCT04495283|Experimental|PGB and APAP administered IV (Group A)|Group A receives the first infusion of PGB plus APAP IV prior to surgery. All subsequent Group A combination infusions should be timed from the first pre-surgical infusion.
16326300|NCT04495283|Experimental|APAP IV infusion (Group B)|Group B receives first infusion prior to surgery then receives the first infusion from the last suture. All subsequent Group B APAP infusions should be timed from the first post-surgical infusion.
16326301|NCT04495283|No Intervention|Placebo (Group C).|Saline Solution
16326302|NCT04495270||Clinical observation|All study patients were examined by 1 endodontist clinically and radiographically at baseline and after follow up of endodontic treatment.
16326303|NCT04495257|Experimental|Dose Level 1 (DL1)|DL1 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.1mg/kg for the induction phase. After 4 cycles, participants will be treated with 360mg of nivolumab and APX005M every 3 weeks.
16326304|NCT04495257|Experimental|Dose Level 2 (DL2)|DL2 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.3mg/kg for the induction phase. After 4 cycles we will treat with 360mg of nivolumab and APX005M every 3 weeks.
16326305|NCT04495244||Investigational Population|"Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation.
~Inclusion criteria
~Women with suspected Invasive Breast Cancer (tumours of any size and/or DCIS).
~Individuals with an abnormal or suspicious screening mammogram recalled for further evaluation.
~Suspected Invasive Breast Cancer (tumours of any size and/or DCIS).
~Willing to give written Informed Consent and provide whole blood samples
~Age 30-75 years
~Exclusion criteria
~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
~Inoperable (T4 category) or inflammatory breast cancer
~Previous history of cancer previously at any site
~Previous history of breast cancer
~Concomitant or other concurrent anti-cancer therapy
~Male
~No histopathological diagnosis"
16326306|NCT04495244||Borderline (Atypica and LCIS) Population|"Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria
~Abnormal screening mammogram with suspected benign breast disease or proliferative changes
~Willing to give Written Informed Consent and provide whole blood samples
~Aged 30-75 years
~Exclusion criteria
~Existing cancer diagnosis
~Male
~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
~Previous history of any cancer
~Previous history of breast cancer
~Concomitant or other concurrent anti-cancer therapy"
16326307|NCT04495244||Control Population|"Healthy Controls Inclusion criteria
~Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography
~Willing to give Written Informed Consent and provide whole blood samples
~Aged 30-75 years
~Exclusion criteria
~Cancer diagnosis
~Male
~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
~Previous history of any cancer
~Concomitant or other concurrent anti-cancer therapy"
16326308|NCT04495218||Patient with a diagnosis of incomplete form of albinism|
16326309|NCT04495205|Experimental|Non-eugenol containing periodontal packs with PRF|Non-eugenol containing periodontal packs with PRF after gingival de-pigmentation
16326310|NCT04495205|Placebo Comparator|Non-eugenol containing periodontal packs|Non-eugenol containing periodontal packs after gingival de-pigmentation
16326311|NCT04495192||Patients affected by severe Acquired Brain Injury|All patients admitted in the participant IRU with a history of sABI and fulfilling our inclusion and exclusion criteria will be recruited.
16326312|NCT04495179|Experimental|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
16326313|NCT04495179|Experimental|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
16326479|NCT04494022|No Intervention|Cross-sectional image only|Image set which consists of a Cross-sectional image only.
16326314|NCT04495166|Experimental|Motherly app with brief psychotherapy|Participants in this arm will receive intervention via Motherly 1.0, an app that delivers behavioral activation strategies and psychoeducational content to promote changes in sleep, nutrition, and physical activity habits. It has also functionalities that help participants to engage in prenatal care, breastfeeding, and social support, and to stimulate child development. In addition will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
16326315|NCT04495166|Active Comparator|Educational app (Active control)|Participants in this arm will have access to a psychoeducational app (active control) which delivers content about gestation, maternal health and mental health, and child development. In addition, they will undergo will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
16326317|NCT04495140|Experimental|Oral [14C]PF-06882961, 50 mg|In this arm, a single oral dose of [14C]PF-06882961, 50 mg will be administered as a liquid formulation.
16326318|NCT04495140|Experimental|Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug|In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961, 100 ug, will be administered via intravenous infusion.
16326319|NCT04495127|Experimental|Selumetinib|
16326320|NCT04495114|No Intervention|Control Arm|Modern fasting guidelines without the carbohydrate load preoperatively.
16326321|NCT04495114|Experimental|Intervention Arm|40g carbohydrate load preoperatively.
16326322|NCT04495101|Experimental|Prolastin 120 mg/kg + Standard Medical Treatment|Subjects will receive Prolastin, two intravenous infusion (IV) doses of 120 milligram per kilogram (mg/kg), based upon the subject's body weight, on Day 1 and Day 8. Subjects will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16326323|NCT04495101|Active Comparator|Standard Medical Treatment|Subjects will receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16326324|NCT04495088|Experimental|A (experimental arm)|The experimental arm A starts with 6 cycles of mFOLFOX or 4 cycles of XELOX. Surgery is scheduled four or six weeks after day 1 of the last mFOLFOX or XELOX cycle, respectively. No postoperative chemotherapy is planned
16326325|NCT04495088|Active Comparator|B (control arm)|In the standard arm B, patients undergo surgical resection of the primary tumor followed by stage- (risk-)adapted adjuvant chemotherapy 4-8 weeks after surgery according to recommendations of the S3 guidelines in analogy to colon cancer. Details of the recommended protocols are provided in the protocol.
16326326|NCT04495075|Experimental|Visuomotor Therapy|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. A target sine wave with a maximum amplitude of 30% MVIC and a minimum amplitude of 5% MVIC and a frequency of 0.128 Hz was visually presented to the patient.31 The patient was instructed to match their torque to the presented target throughout the duration of testing. Each visuomotor therapy trial was 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes.
16326327|NCT04495075|Active Comparator|Passive Motion|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. The dynamometer then passively moved the patient from 80º to 120º of knee flexion for 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes. The patient was provided visual feedback of their knee position throughout the trials. The patient was instructed to relax their knee throughout the intervention.
16326328|NCT04495036||dermatology patients|
16326329|NCT04495036||physicians and medical staff|
16326330|NCT04495023||Group 1 (Kidney transplanted patients)|Group 1: Kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy All kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
16326331|NCT04495023||Group 2 (Non-transplanted patients)|Group 2 : Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
16326332|NCT04495010|Experimental|Neoadjuvant treatment + Adjuvant treatment|
16326333|NCT04495010|Experimental|Adjuvant treatment|
16326334|NCT04495010|Experimental|Neo treat with patho response-driven Adju treat or observation|Neoadjuvant treatment with pathologic response-driven Adjuvant treatment or observation
16326335|NCT04494997||Dentists|Practicing Dental Health Professionals who are either General Dentists &/or Specialists Dentists are part of the Cohort. They should have held or currently hold Social Media account for their Professional purpose. They should have used or currently using their Social Media account for Professional purpose. The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media &/Or email to seek responses. The link will be available for single response for a single respondent.
16326336|NCT04494984|Active Comparator|Active|Subjects will receive a 1st intravenous dose of 4 mg/kg INM005 (Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM005. Each dose will be separated by 48 h (± 2 h).
16326337|NCT04494984|Placebo Comparator|Placebo|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 48 h (± 2 h).
16326338|NCT04494958|Experimental|Palbociclib + Binimetinib|
16326339|NCT04494945|Other|Screening (genetic testing)|Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
16326340|NCT04494932|Experimental|Biceps Tenodesis|
16326341|NCT04494932|Active Comparator|SLAP Repair (Control)|
16326342|NCT04494919||Ultrafine Endoscope Assisted|The self-expanding metal stent (SEMS) implantation was conducted using an ultrafine endoscope (UFE) (GIF-XP260NS; Olympus, Tokyo, Japan). The UFE researched the stricture, and a guidewire was inserted into the endoscopic working channel. The guidewire was left. And the endoscope was withdrawn. The normal colonoscope was exchanged under the reverse guidance of the guidewire. Finally, a metal, uncovered SEMS was placed along the guidewire.
16326343|NCT04494906|Experimental|Interactive stepping exercise group|Participants will execute interactive stepping exercise 2 times per week for 8 weeks (16 sessions).
16326344|NCT04494906|Active Comparator|Square stepping exercise group|Participants will execute square stepping exercise 2 times per week for 8 weeks (16 sessions).
16326345|NCT04494893||Cohort 1|Exposed to coronavirus disease
16326346|NCT04494893||Cohort 2|Active coronavirus disease
16326347|NCT04494893||Cohort 3|Recovered from coronavirus disease
16326348|NCT04494880|Experimental|Treatment Group (Marcaine 1 Breast)|Marcaine will be injected into one randomized breast and saline into the other in the treatment group.
16326349|NCT04494880|No Intervention|Control Group (Marcaine 2 Breasts)|Marcaine will be injected into both breasts as is currently the standard of care.
16326350|NCT04494867|Experimental|Core warming|Patients receive the Attune Medical Esophageal Heat Transfer Device (EnsoETM) and undergo core warming
16326351|NCT04494867|Active Comparator|Standard of Care|Patients receive standard temperature management and treatment
16326352|NCT04494841|Experimental|DuoTherm VibraCool Back Device|Patients will be offered a pain relief belt device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate. They will be able to choose from 8 patterns of vibration with the multiple motors (50, 100, 200Hz), and hot or cold, and will wear the device for 20 minutes.
16326353|NCT04494828|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/ kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
16326354|NCT04494828|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
16326355|NCT04494815|Experimental|Treatment A+Treatment B+Treatment C|"Treatment A: Single 20 mg oral suspension dose of SR419 + single active control placebo capsule.
~Treatment B: Single SR419 placebo oral suspension + single 300 mg oral capsule of active control.
~Treatment C: Single SR419 placebo oral suspension + single active control placebo capsule."
16326356|NCT04494815|Experimental|Treatment A+Treatment C+Treatment B|
16326357|NCT04494815|Experimental|Treatment B+Treatment A+Treatment C|
16326358|NCT04494815|Experimental|Treatment B+Treatment C+Treatment A|
16326359|NCT04494815|Experimental|Treatment C+Treatment A+Treatment B|
16326360|NCT04494815|Experimental|Treatment C+Treatment B+Treatment A|
16326361|NCT04494802|Placebo Comparator|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
16326362|NCT04494802|Experimental|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
16326363|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 24hrs|Receive 50mcg doses of fludrocortisone every 24hrs
16326364|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 12hrs|Receive 50mcg doses of fludrocortisone every 12hrs
16326365|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 6hrs|Receive 50mcg doses of fludrocortisone every 6hrs
16326366|NCT04494789|Placebo Comparator|Control Arm|Receives standard treatment without fludrocortisone dosing regime
16326367|NCT04494763|Experimental|Propanolol|Dose: 1 to 8 mg/kg/day in 1 to 2 divided doses adjusted to achieve target reduction in resting heart rate by 25% from baseline Frequency: once to Twice daily Route of Administration: Oral Duration: 18 months
16326368|NCT04494763|Placebo Comparator|Placebo|Placebo in a similar manner
16326369|NCT04494737|Active Comparator|Active Comparator: Program 1|Mindfulness Training program is based on mindfulness based stress reduction developed by Kabat-Zinn, but the didactic content is focused on attention training and meta-awareness. Participants will be taught formal open awareness meditation, gentle yoga, and a 'body scan' meditation during weekly classes. Importantly, there is no retreat day included in the program.
16326370|NCT04494737|Active Comparator|Active Comparator: Program 2|Stress Management Education (SME) is designed to control for non-specific factors such as contact hours, stress education, and gentle exercise. Stress education classes will consist of teaching about the effects of stress on health and optimizing one's personal health care, understanding positive coping behavior, optimizing nutrition to decrease stress, and exercise and strength training.
16326371|NCT04494724|Experimental|Clazakizumab|Clazakizumab - 25mg in 50 milliliters (mL) of 0.9% saline, IV infusion over 30 minutes.
16326372|NCT04494724|Placebo Comparator|Placebo|Placebo - 50 mL 0.9% saline, IV infusion over 30 minutes.
16326373|NCT04494711|Experimental|Physical functional literacy|5 week physical literacy program for adults with multiple chronic conditions
16326374|NCT04494698|Active Comparator|DuoTherm VibraCool Back Device|A low back pain relief device incorporating multiple speeds and patterns of vibration and optional heat, cold, or pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice daily for 20 minutes.
16326375|NCT04494698|Sham Comparator|Posture Plate|a sham placebo sculpted metal plate attached with a plain belt, without the pocket or potential for heat, cold, or pressure. No motors are attached to this unit, so while support is possible there are no active pain relief modalities. Patients will be instructed to use the Posture Plate twice a day for 20 minutes.
16326376|NCT04494685|Experimental|Robotic rehabilitation|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland).
16326377|NCT04494685|Active Comparator|Conventional physiotherapy|The protocol will be based on lower limb exercises, aiming at maintaining and gaining muscle strength through passive, assisted or active mobilization, when possible, on the affected side.
16326378|NCT04494672|Experimental|Intramedullary nailing with ADAPT system (arm-A)|A commercial product, namely ADAPT will be used as investigation product in arm-A
16326379|NCT04494672|Active Comparator|Intramedullary nailing without ADAPT system (arm-B)|No aid in performing intramedullary nailing for proximal femoral fractures will be implemented in arm-B
16326380|NCT04494659|Experimental|Single arm|single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16
16326381|NCT04494646|Experimental|Bardoxolone Methyl|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
16326382|NCT04494646|Placebo Comparator|Placebo|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
16330214|NCT04468516|Experimental|Treatment|Intervention is applied to the C1 of the spine.
16326383|NCT04494633|Experimental|Intervention|Participants will complete the pre-assessments, use the intervention, complete the assessments, wait 4 weeks, and complete the assessment a 3/final time.
16326384|NCT04494633|Other|Wait Group|Participants will complete the pre-assessments, wait, complete the assessments, use the intervention, complete the assessment a 3/final time.
16326385|NCT04494620|No Intervention|Control Arm|Standard of Care
16326386|NCT04494620|Active Comparator|Intervention Arm|Visual Inspection of Oral Cavity for Precancers and Cancer
16326387|NCT04494607|Experimental|Test arm|Determination of Glycemic and Insulinemic curves under different alimentary intake
16326388|NCT04494594|Sham Comparator|Control|
16326389|NCT04494594|Active Comparator|Intervention|
16326390|NCT04494581||Pregnant and postpartum women|Pregnant and postpartum women over 18, meeting inclusion and exclusion criteria.
16326391|NCT04494581||healthcare workers|Health professionals over 18, working in maternity wards included.
16326392|NCT04494568|Experimental|HIFU intervention|patients will benefit of an HIFU Treatment of their rectal endometriosis
16326393|NCT04494555|Experimental|Adaptable Prosthetic Socket|Using measurements of limb-socket displacements from sensors embedded within the socket wall, adaptable sockets make small adjustments to socket size so as to maintain consistent displacements while prosthesis users are active. They do not require the user to stop activity or to touch or modify the prosthesis, and they do not distract users from their objectives.
16326394|NCT04494542|Experimental|Sustained Low Efficiency Dialysis|Sustained Low Efficiency Dialysis
16326395|NCT04494542|Active Comparator|Continuous Renal Replacement Therapy|continuous renal replacement therapy
16326396|NCT04494529|Placebo Comparator|Single-Dose (12 mg betamethasone + placebo)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.
~Participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection instead of the standard 2nd dose of 12 mg of betamethasone (i.e. they will receive the experimental single-dose regimen, total 12 mg of betamethasone only from the first injection)."
16326397|NCT04494529|Active Comparator|Double-Dose (12 mg betamethasone + 12 mg betamethasone)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.
~Participants randomized to the Double-Dose arm will receive the standard 2nd dose of 12 mg of betamethasone injected intramuscularly (i.e. they will receive the standard double-dose regimen, total 24 mg of betamethasone)."
16326398|NCT04494516||Pre-trial|This cohort of participants will be recruited preceding evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with design of the intervention and implementation strategy. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
16326399|NCT04494516||Post-trial|This cohort of participants will be recruited after evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with future scale up and dissemination of the intervention. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
16326400|NCT04494503|Experimental|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 400mg, 600mg, 800mg dose levels respectively, every 28 days as a cycle.
16326401|NCT04494503|Experimental|APG-2575+Rituximab in Relapse/Refractory CLL/SLL|"Stage 1:APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg. Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1. Every 28 days as a cycle.
~Stage 2: APG-2575 MTD/RP2D combined with rituximab. Every 28 days as a cycle."
16326402|NCT04494503|Experimental|APG-2575+ibrutinib in Relapse/Refractory CLL/SLL|"Stage 1: APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg.Ibrutinib 420mg orally once daily during C1D8-28 and following cycles. Every 28 days as a cycle.
~Stage 2: APG-2575 MTD/RP2D combined with ibrutinib. Every 28 days as a cycle."
16326403|NCT04494490|No Intervention|Usual Care Condition|"During the usual care condition the therapists will be instructed to act as usual, that is, to read the guidelines on low back pain if they have read previous published guidelines and not read these guidelines if they have not read any other guidelines."
16326404|NCT04494490|Active Comparator|CPG+PIPT Condition|An active Clinical Practice Guidelines (CPG) implementation strategy will be utilized with an education component in Psychologically Informed Physical Therapy (PIPT) with peer opinion leaders and a monthly audit/feedback on CPG adherence rates and patient outcomes
16326405|NCT04494477|Experimental|The IN•clued program|The IN•clued program for youth consists of a three-hour in-person workshop for youth which includes lessons about safe sex practices and self-efficacy at healthcare centers, exam room roleplays, and a discussion on patient rights. Youth receive a Zine, or a magazine-style booklet, that they may take home. They also receive a list of local healthcare providers that highlights those that have participated in the IN•clued healthcare provider workshop or have had training on working with the LGBTQ population. Program youth can also receive text messages with health tips and reminders to visit a healthcare center.
16326406|NCT04494477|No Intervention|Control|"The youth control group receives a 10-minute presentation and a list of local sexual healthcare providers, with no indication of which providers have been trained to be more LGBTQ friendly and accepting. This 10-minute presentation is a part of a longer three-hour activity unrelated to sexual health or accessing sexual healthcare. During the three-hour session, the list of approved activities includes but is not limited to:
~Films by, and for, LGBTQ youth about sexual orientation and gender identity;
~Community scavenger hunts;
~Poetry slams;
~Discussions about relationships; and
~Activities related to the appreciation of individuals' unique strengths."
16326443|NCT04494256|Experimental|Cohort D1|Participants with ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326407|NCT04494464||Patients with LDL cholesterol ≥250 mg/dL|Patients older than 18 years old and have a serum LDL-C≥250 mg/dL between January 2010 and December 2016. Patients with a serum TSH≥10 mIU/mL, patients with glomerulonephritis or nephrotic syndrome, patients with ALT or AST higher than 3 times of normal limits and patients with serum triglyceride >400 mg/dL were excluded.
16326408|NCT04494451|Experimental|Vitamin C + Standard Medical Treatment|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol along with iv antibiotics
16326409|NCT04494451|Active Comparator|Standard Medical Treatment|iv antibiotics alone
16326410|NCT04494438|No Intervention|Steroid tapering.|
16326411|NCT04494438|Experimental|Rituximab|Single administration of Rituximab 375 mg/mq at a rate of 0.5 to 1.5 ml/min over approximately 6 hours, following the infusion of 2.5-5 mg of intravenous chlorfenamine maleate (based on the local protocol and patient tolerance), methylprednisolone (2 mg/Kg) in normal saline and oral paracetamol (8 mg/kg).
16326412|NCT04494425|Experimental|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
16326413|NCT04494425|Active Comparator|Standard of Care|Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
16326414|NCT04494412|Experimental|Hospitalized neonates and infants with influenza infection|Preterm neonates and infants who have reached Post-Menstrual Age (PMA) of at least 28 weeks and have a confirmed complicated influenza infection will be included. Participants will receive daily IV infusion of zanamivir for up to 5 days. This initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests warrant further treatment. The initial dose of IV zanamivir will be determined by PMA/corrected age and body weight. The maintenance dose and interval between the initial dose and subsequent twice-daily maintenance dose will be further determined by Principal Investigator based on renal function.
16326415|NCT04494399|Active Comparator|Treatment group|5-day course of daily subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and oral ribavirin 400mg twice daily plus standard care
16326416|NCT04494399|No Intervention|Control group|Standard care alone
16326417|NCT04494386|Experimental|ULSC in Phase 1 Open Label|"Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:
~In Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen."
16326418|NCT04494386|Experimental|ULSC in Phase 2a Randomized|"Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:
~In Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability."
16326419|NCT04494386|Placebo Comparator|Placebo in Phase 2a Randomized|"Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:
~In Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
16326420|NCT04494373|Experimental|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
16326421|NCT04494373|Active Comparator|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
16326423|NCT04494347|Experimental|Treatment Group|This is not a randomized study. Patients who are clinically indicated for both procedures will be offered the option to enroll in this registry for a combined procedure. Otherwise, they will undergo TMVr and LAAO in two separate session as clinically indicated (standard of care).
16326424|NCT04494334||Healthy Volunteers|These will be age matched healthy volunteers (n=15) who will not undergo bronchoscopy
16326425|NCT04494334||Probable Idiopathic Pulmonary Fibrosis|Patients with probable IPF, who will be having bronchoscopy as part of their clinical diagnostic work up
16326426|NCT04494334||Sarcoidosis,|Patients with sarcoidosis who will be having bronchoscopy as part of their clinical diagnostic work up
16326427|NCT04494321|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
16326428|NCT04494321|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
16326429|NCT04494321|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
16326430|NCT04494308||exacerbated|COPD patients admitted to the hospital for an exacerbation occurred within the past 10 days.
16326431|NCT04494308||stable|COPD stable patients with no exacerbations in the past 3 months
16326432|NCT04494295||AURORA|Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma
16326433|NCT04494282|Active Comparator|Same day|The ERP will be performed the same day of the endoscopic drainage of PP
16326434|NCT04494282|Active Comparator|Other day|The ERP will be performed 6 weeks after the endoscopic drainage of PP.
16326435|NCT04494269|Active Comparator|Subjects with normal hepatic function|Single dose of Tegoprazan 50mg
16326436|NCT04494269|Experimental|Subjects with mild hepatic impairment|Single dose of Tegoprazan 50mg
16326437|NCT04494269|Experimental|Subjects with moderate hepatic impairment|Single dose of Tegoprazan 50mg
16326438|NCT04494269|Experimental|Subjects with severe hepatic impairment|Single dose of Tegoprazan 50mg
16326439|NCT04494256|Experimental|Cohort A|Participants with ALS will receive BIIB105 Dose 1, intrathecally (IT), as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326440|NCT04494256|Experimental|Cohort B|Participants with ALS will receive BIIB105 Dose 2, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326441|NCT04494256|Experimental|Cohort C1|Participants with ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326442|NCT04494256|Experimental|Cohort C2|Participants with polyQ-ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326444|NCT04494256|Experimental|Cohort D2|Participants with polyQ-ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326445|NCT04494256|Placebo Comparator|Cohorts A-D2|Participants with ALS and polyQ-ALS will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
16326446|NCT04494243|Experimental|AD-214/Rabeprazole|Period 1 : Test Drug(AD-214 10/600mg) Period 2 : Reference Drug(Rabeprazole 10mg)
16326447|NCT04494243|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole 10mg) Period 2 : Test Drug(AD-214 10/600mg)
16326448|NCT04494230||Attention deficit hyperactivity disorder (ADHD) only|the diagnosis of ADHD
16326449|NCT04494230||Attention deficit hyperactivity disorder (ADHD) andSpecificand|the diagnosis of ADHD and SLD
16326450|NCT04494230||ADHD and oppositional defiant disorder (ODD)|the diagnosis of ADHD and ODD
16326451|NCT04494230||ADHD and Anxiety Disorder|the diagnosis of ADHD and Ank. Dis.
16326452|NCT04494230||Typical Development Children|no mental symptoms described by their teachers or parents and showing healthy development
16326453|NCT04494204|Experimental|Intervention|2 tablets Immunofree 500 mg tablets thrice a day for 10 days and 1 capsule Reginmune 750 mg twice a day for 10 days
16326454|NCT04494204|Active Comparator|Comparator Agent|As per standard National Clinical Management Protocol for COVID-19 by Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services, (EMR Division), Version 3, 13.06.20
16326455|NCT04494191|Experimental|T test|Test drug (AphroFemine) 1 tablet contains 100 mg Flibanserin
16326456|NCT04494191|Active Comparator|B reference|Reference drug (Addyi) 1 tablet contains 100 mg Flibanserin
16326457|NCT04494178|Experimental|2.0g G-PUR® oral - Placebo|
16326458|NCT04494178|Experimental|Placebo - 2.0g G-PUR® oral|
16326459|NCT04494165|Experimental|Aromatherapy Group|In addition to the standard physical therapy session, 30 patients in this group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
16326460|NCT04494165|Placebo Comparator|placebo group|In addition to the standard physical therapy session, 31 patients in this group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
16326461|NCT04494165|No Intervention|control group|30 patients in this group received standard physical therapy sessions, and no massage was applied.
16326462|NCT04494152||Critically ill patients|Adult critically ill patients hospitalised in the intensive care unit.
16326463|NCT04494139|Active Comparator|Canteen Only|Train canteen staff and implement canteen intervention in the canteen space: interventions targeting food quality and quantity, intervention targeting food choice at point of sale, interventions target improved supply, interventions targeting price and promotional material.
16326464|NCT04494139|Experimental|Behavioral and Canteen intervention|The behavioral intervention will be comprised of a combination of intensive education sessions and goal setting and monitoring based on a validated worksite curriculum tailored to local needs. The curriculum includes 24 sessions: 16 core weekly sessions during the first four months of the intervention followed by 8 weekly maintenance sessions (text messages). Each session will be facilitated by a nutritionist/dietitian and a peer educator; and will last one hour. Broadly, the curriculum covers the subject matters of importance of healthy weight, eating a healthy diet, increasing physical activity, stress management, and challenges of lifestyle changes. Participants will be encouraged to keep food and activity diaries throughout the course of the study. During the maintenance period, the focus will be on overcoming declines in motivation and on maintaining long-term healthy behaviors.
16326465|NCT04494126|Experimental|Tranexamic acid|Experimental: TXA Group One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
16326466|NCT04494126|Placebo Comparator|Placebo|Placebo Comparator: Control Group Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
16326468|NCT04494100|Active Comparator|CONTROL|Troncular blocks using a long-acting LA + Tourniquet
16326469|NCT04494100|Experimental|WALANT|Troncular blocks using a long-acting LA + WALANT technique using a short-term LA with epinephrine a vasoconstrictor agent
16326470|NCT04494087|Active Comparator|Hernia video|The video of the intervention group will provide a short (< 5 min) summary explaining the basic principles of endoscopic extraperitoneal hernia repair, its possible complications and the postoperative course. After carefully watching the video, participants should be able to correctly answer to a multiple-choice test consisting of 12 questions related to the aforementioned topics.
16326471|NCT04494087|Placebo Comparator|Mock video|"This video is a general documentation of the typical day of surgery in the day clinic. The information is essentially limited to the pictorial representation of the individual wards which the patient will pass through during the operation (arrival at the clinic, admission, transport to the operating theatre, recovery room, discharge).
~The video explicitly does not transport any information that could be helpful for answering the quiz questions or for medical understanding of the operation itself."
16326472|NCT04494087|Sham Comparator|Control group|The link of the third group leads to a digital version of the information sheet, which has already been discussed with all patients during the informed consent discussion. The digital version of the informed consent form allows the patient to read the information again. The third group thus corresponds to the standard of care.
16326473|NCT04494074|Experimental|Fever Control by external cooling|External cooling during 48 hours to obtain normothermia
16326474|NCT04494074|No Intervention|Fever respected, no cooling|Fever respect without any antipyretic therapy
16326475|NCT04494061||HSCT - Hematopoetic Stem Cell Proliferation|Patients who received hematopoietic stem cell transplant
16326476|NCT04494061||IHSCP - Impaired HSC proliferation|Patients with impaired hematopoietic stem cell proliferation
16326480|NCT04494022|Active Comparator|Cross-sectional image with CEUS|The same participants with Arm1. But image set will consist of a Cross-sectional image and CEUS.
16326481|NCT04494009|Experimental|INCMGA00012 군|INCMGA00012 500 mg iv every 4 weeks for up to 12 months
16326482|NCT04494009|No Intervention|Observation arm|followed up every 12 weeks for up to 12 months
16326483|NCT04493996|Experimental|Cognitive training group|
16326484|NCT04493996|No Intervention|Control group|
16326485|NCT04493983|Other|Investigation|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
16326486|NCT04493957|Experimental|educational intervention|"Patients and caregivers included in the ACCOMPAGNE Education Program group will benefit from seven group workshops spread over three half-days (once a week over 3 consecutive weeks), animated in pairs, each lasting approximately one and a half hours. and using educational pedagogical methods."
16326487|NCT04493957|Active Comparator|Control group|"Patients and caregivers included in the Control group will receive the usual recommendations for driving, issued by their referring doctor in memory consultation during the diagnostic announcement process or during the follow-up of their illness."
16326488|NCT04493944|Experimental|Intervention group (with culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study, and will participate in a culinary workshop with a chef (3 hours).
16326489|NCT04493944|No Intervention|Control group (without culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study.
16326490|NCT04493931|Experimental|Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg|This is a fixed sequence (Sequence AB) cohort. Participants will receive gepotidacin 1500 milligrams (mg) single dose (SD) on Day 1 of Period 1 (Treatment A); and Cimetidine 400 mg 4 times daily on Days 1 through 4 of Period 2 and gepotidacin 1500 mg single dose (Treatment B). Gepotidacin will be administered 1 hour after the first dose of cimetidine on Day 2 of Period 2. There will be a washout of at least 3 days between Treatment A and Treatment B, and a follow-up visit 5 to 7 days after the last dose of cimetidine.
16326491|NCT04493931|Experimental|Cohort 2: Gepotidacin 1500 mg + Rifampicin 600 mg|This is a fixed sequence (Sequence CDE) cohort. Participants will receive gepotidacin 1500 mg single dose on Day 1 of Period 1 (Treatment C), rifampicin 600 mg (administered in the evenings) once daily for 7 days (Days 1 through 7 of Period 2, to elicit maximal enzyme induction) (Treatment D); and gepotidacin 1500 mg single dose administered in the morning on Day 8 and rifampicin 600 mg administered in the evening on Days 8 and 9 of Period 2 (Treatment E). There will be a washout of at least 3 days between Treatment C and Treatment D, and a follow-up visit 7 to 10 days after the last dose of rifampicin.
16326492|NCT04493931|Experimental|Cohort 3: Digoxin 0.5mg+Midazolam 2mg then Gepotidacin 3000mg|Participants will receive digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 1 on Day 1 then gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 2 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G). There will be a washout of at least 10 days between treatments. In Sequence 2, these regimens are reversed. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
16326493|NCT04493931|Experimental|Cohort 3: Gepotidacin 3000mg then Digoxin 0.5mg+Midazolam 2mg|Participants will receive gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 1 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G) followed by digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 2 on Day 1. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
16326494|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fed then fasted then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
16326495|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fasted then fed then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fasted conditions in Period 1 (Treatment I), then a single dose of gepotidacin 1500 mg under fed conditions in Period 2 (Treatment H), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
16326496|NCT04493931|Placebo Comparator|Cohort 4: Placebo fed then fasted then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fed conditions in Period 1, then a single dose of placebo under fasted conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
16326497|NCT04493931|Placebo Comparator|Cohort 4: Placebo fasted then fed then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fasted conditions in Period 1, then a single dose of placebo under fed conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
16326498|NCT04493918|Experimental|MSC Group|Mesenchymal Stem Cell + NaCl 0,9% 2ml
16326499|NCT04493892|Experimental|Educational Intervention|All participants receive educational information on the potential health risk of endocrine disruptor chemicals in hair care products, specifically phthalates. Provide information on how to reduce exposure.
16326500|NCT04493879|Experimental|Bioptron Light Therapy (BLT) group|Received Bioptron Light Therapy (BLT) ten minutes every day for one month plus the routine medical treatment of oral mucositis(Analgesics, anti-inflammatory medication and antimicrobial therapy for any new mouth infections
16326501|NCT04493879|Experimental|Routine medical care group|Received only the routine medical care of oral mucositis for one month this consists of analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections
16326502|NCT04493853|Experimental|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
16326503|NCT04493853|Placebo Comparator|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
16326504|NCT04493840|Experimental|Shenfu Injection|
16326505|NCT04493840|Placebo Comparator|5% Glucose Injection|
16326506|NCT04493814||Cohort|All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
16326507|NCT04493801||with nasoseptal flap|patient who undergo a pituitary gland surgery with nasoseptal flap
16326508|NCT04493801||without nasoseptal flap|patient who undergo a pituitary gland surgery without nasoseptal flap
16326509|NCT04493788||PCOS group|
16326510|NCT04493788||Control group|
16326511|NCT04493762||PSO/PSA|Patients diagnosed with psoriasis or psoriatic arthritis
16326512|NCT04493762||RA|Patients diagnosed with rheumatoid arthritis
16326513|NCT04493749||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
16326514|NCT04493749||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
16326515|NCT04493736||Case|Any person receiving services from a mental health provider who is able to either consent or for whom parental consent is able to be obtained.
16326516|NCT04493723||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
16326517|NCT04493697|Active Comparator|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
16326518|NCT04493697|Placebo Comparator|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
16326519|NCT04493684|Experimental|Part 1: Cohort 1: Participants receiving GSK3739937|Part 1 cohort 1 may contain up to 4 escalating doses (Period 1- 10 milligram [mg], Period 2- 80 mg, and Period 3- 320 mg, Period 4- 800 mg) of GSK3739937.
16326520|NCT04493684|Placebo Comparator|Part 1: Cohort 1: Participants receiving Placebo|In this cohort, participants will be randomized to receive placebo.
16326521|NCT04493684|Experimental|Part 1: Cohort 2: Participants receiving GSK3739937|Part 1 cohort 2 may contain up to 3 escalating doses ( Period 1- 30 mg, Period 2- 160 mg, and Period 3- 640 mg) of GSK3739937.
16326522|NCT04493684|Placebo Comparator|Part 1: Cohort 2: Participants receiving Placebo|In this cohort, participants will be randomized to receive placebo.
16326523|NCT04493684|Experimental|Part 2: Cohort 3: Participants receiving GSK3739937|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 25 mg GSK3739937 for 14 days.
16326524|NCT04493684|Placebo Comparator|Part 2: Cohort 3: Participants receiving Placebo|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
16326525|NCT04493684|Experimental|Part 2: Cohort 4: Participants receiving GSK3739937|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 50 mg GSK3739937 for 14 days.
16326526|NCT04493684|Placebo Comparator|Part 2: Cohort 4: Participants receiving Placebo|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
16326527|NCT04493684|Experimental|Part 2: Cohort 5: Participants receiving GSK3739937|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 100 mg GSK3739937 for 18 days.
16326528|NCT04493684|Placebo Comparator|Part 2: Cohort 5: Participants receiving placebo|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 18 days.
16326529|NCT04493684|Experimental|Part 2: Cohort 6: Participants receiving GSK3739937|Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 7 participants will be randomized to receive three 500 mg doses of GSK3739937 administered at once weekly intervals over two weeks.
16326530|NCT04493684|Placebo Comparator|Part 2: Cohort 6: Participants receiving placebo|Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 3 participants will be randomized to receive three doses of placebo administered at once weekly intervals over two weeks.
16326531|NCT04493684|Experimental|Part 3: Cohort 7: Participants receiving treatment sequence ABC|Participants will receive Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 1; Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 2; and Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 3.
16326532|NCT04493684|Experimental|Part 3: Cohort 7: Participants receiving treatment sequence BCA|Participants will receive Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 1; Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 2; and Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 3.
16326533|NCT04493684|Experimental|Part 3: Cohort 7: Participants receiving treatment sequence CAB|Participants will receive Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 1; Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 2; and Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 3.
16326534|NCT04493671|Active Comparator|SAD (Part 1): Cohort 1, TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 6 will receive TBAJ-876 10mg under fasting conditions.
16326535|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 1, placebo for TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 10mg under fasting conditions.
16326536|NCT04493671|Active Comparator|SAD (Part 1): Cohort 2, TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 6 will receive TBAJ-876 25mg under fasting conditions.
16326537|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 2, Placebo for TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 25mg under fasting conditions.
16326538|NCT04493671|Active Comparator|SAD (Part 1): Cohort 3, TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 6 will receive TBAJ-876 50mg under fasting conditions.
16326539|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 3, Placebo for TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 50mg under fasting conditions.
16326540|NCT04493671|Active Comparator|SAD (Part 1): Cohort 4, TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 6 will receive TBAJ-876 100mg under fasting conditions.
16326541|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 4, Placebo for TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 100mg under fasting conditions.
16326542|NCT04493671|Active Comparator|SAD (Part 1): Cohort 5, TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 6 will receive TBAJ-876 200mg under fasting conditions.
16326543|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 5, Placebo for TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 200mg under fasting conditions.
16326544|NCT04493671|Active Comparator|SAD (Part 1): Cohort 6, TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 6 will receive TBAJ-876 400mg under fasting conditions.
16326545|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 6, Placebo TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 400mg under fasting conditions.
16326546|NCT04493671|Active Comparator|SAD (Part 1): Food effect Cohort, TBAJ-876|In food-effect cohort with 10 subjects, n=8 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive the chosen dose of TBAJ-876 under fed conditions.
16326547|NCT04493671|Placebo Comparator|SAD (Part 1): Food effect Cohort, Placebo|In food-effect cohort with 10 subjects, n=2 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive matching placebo for the chosen dose of TBAJ-876 under fed conditions.
16326548|NCT04493671|Active Comparator|MAD (Part 2): Cohort 1, TBAJ-876 Dose 1|In cohort 1 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
16326549|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 1, Placebo|In cohort 1 with 12 subjects, n=3 is expected to receive the matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
16326550|NCT04493671|Active Comparator|MAD (Part 2): Cohort 2, TBAJ-876 Dose 2|In cohort 2 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
16326551|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 2, Placebo|In cohort 2 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
16326552|NCT04493671|Active Comparator|MAD (Part 2): Cohort 3, TBAJ-876 Dose 3|In cohort 3 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements
16326553|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 3, Placebo|In cohort 3 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
16326554|NCT04493658||Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and a diagnosis of Sjogren's syndrome made according to the 2016 revised criteria
16326555|NCT04493658||Non-Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and no diagnosis of Sjogren's syndrome based on 2016 revised criteria.
16326556|NCT04493658||Control|Normal individuals with no previous diagnosis of dry eye or Sjogren's syndrome
16326559|NCT04493619|Experimental|PLX2853 Phase 2a Monotherapy|Up to 26 evaluable subjects with ARID1A mutation-positive advanced gynecological malignancies will be enrolled.
16326560|NCT04493619|Experimental|PLX2853 + Carboplatin Phase 1b/2a Combination Therapy|"Phase 1b (PLX2853 + carboplatin combination): Up to 15 evaluable subjects with platinum-resistant EOC will be enrolled.
~Phase 2a (PLX2853 + carboplatin combination): Up to 26 evaluable subjects with platinum-resistant EOC will be enrolled."
16326561|NCT04493606|Experimental|Intervention Patients|SCI patients receiving the physical activity coaching (Objective 1)
16326562|NCT04493606|No Intervention|Control Patients|SCI patients that did not want to receive physical activity coaching (Objective 1)
16326563|NCT04493606|Experimental|Intervention- Interventionists|Interventionists receiving physical activity coaching training (Objective 2)
16326564|NCT04493593|Experimental|Space for Sleep Group|SilverCloud internet-delivered CBT intervention for Insomnia
16326565|NCT04493580|Experimental|iDBT Treatments|15 weekly DBT sessions. During each session, participants will be sent 30-40 PowerPoint slides including general information on particular topic, overview of skills, and homework sheets to be completed and returned to therapists. Therapists involved will be a psychiatry resident, a psychologist, and a registered nurse who will also facilitate the in-person groups. The content and format of the online program will directly corresponded with that of the in-person group. Participants will be asked to send their homework sheets back to therapists by a specific day each week. The following day, the therapist will email feedback regarding the homework submitted and send next week's PowerPoint slides, information sheets, and homework. In order to be eligible to receive the materials, participants are required to send in homework prior to deadline. If homework was not returned, reminder email will be sent. If more than two sessions are missed, participants are excluded from the program.
16326601|NCT04493359|No Intervention|Maintenance therapy|Renin-angiotensin system inhibitors will be kept during in-hospital stay
16326602|NCT04493333|Experimental|Vaginal DHEA|Vaginal insert with 6.5 mg vaginal DHEA self-administered once daily at bedtime for 12 weeks
16326603|NCT04493333|Active Comparator|Vaginal Polycarbophil Moisturizer|Prefilled vaginal applicator with 2.5 g of polycarbophil vaginal moisturizing gel, self-administered two times per week at night for 12 weeks
16326604|NCT04493320|Experimental|L-DOPA, Then Placebo|"Step 1 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.
~Participants will then enter a 1 week taper period.
~Step 2 (3 Weeks): Participants will receive L-DOPA matching placebo tablets daily.
~Participants will then enter a 1-week taper period."
16326566|NCT04493580|Active Comparator|In-Person DBT Treatments|Weekly skills-building groups titled Managing Powerful Emotions (MPE) includes Mindfulness, Distress Tolerance, Emotion Regulation, and Interpersonal Effectiveness. Personality Disorders Service offers more advanced therapy groups for individuals who have successfully completed MPE and wish to continue seeking treatment modalities. Chrysalis Day Treatment Program (CDTP) is for an individual who has progress through two prior phases. In phase one, individuals will participate in a DBT-informed skill-building group (MPE). Once completed, the individual will progress to phase two which includes attending a psychotherapy group, incorporating DBT skills-building. Finally, in phase three, individuals who wish to participate in a more advanced and complex psychological treatment program, apply to participate in CDTP. The CDTP is an intensive day treatment program integrating DBT skills-building, psychodynamic psychotherapy, and a range of other group therapy modalities.
16326567|NCT04493567|Experimental|Part A: 1 x BMS-986036 via auto-injector or pre-filled syringe|
16326568|NCT04493567|Experimental|Part B: 2 x BMS-986036 via auto-injector or pre-filled syringe|
16326569|NCT04493554|Experimental|Vasopressin|Vasopressin (20 IU) intranasally
16326570|NCT04493554|Placebo Comparator|Placebo|Placebo intranasally
16326571|NCT04493541|Experimental|BMS-986256|
16326572|NCT04493541|Placebo Comparator|Placebo|
16326573|NCT04493528|Active Comparator|Needle Infiltration anesthesia|Patients received one needle injection of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326574|NCT04493528|Experimental|Needle-free infiltration anesthesia|Patients received one NFLJI (needle-free liquid jet injection) of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326575|NCT04493528|Active Comparator|Needle mental nerve block|Patients received one needle injection of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326576|NCT04493528|Experimental|Needle-free mental nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326577|NCT04493528|Active Comparator|Needle mandibular nerve block|Patients received one needle injection of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326578|NCT04493528|Experimental|Needle-free mandibular nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326579|NCT04493528|Active Comparator|Needle infraorbital nerve block|Patients received one needle injection of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326580|NCT04493528|Experimental|Needle-free infraorbital nerve block|Patients received one NFLJI (needle-free liquid jet injection) of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
16326581|NCT04493515|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
16326582|NCT04493515|Placebo Comparator|Oral Placebo|Placebo orally (24 IU, identical ingredients, except the active agent)
16326585|NCT04493489|Placebo Comparator|BCG|After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
16326586|NCT04493489|Experimental|Propranolol plus BCG|After TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
16326587|NCT04493476|Active Comparator|Chineese Herbal formula|The study group will be given capsules containing Chinese herbal formula extract - Traditional Chinese MedicinalSubstances
16326588|NCT04493476|Placebo Comparator|placebo|The control group tested will receive placebo capsules. Containing starch.
16326589|NCT04493463|Experimental|methylprednisolone + ropivacaine + saline|The local infiltration solution in the methylprednisolone plus ropivacaine with saline group (treatment group) will consist of 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
16326590|NCT04493463|Active Comparator|ropivacaine + saline|The local infiltration solution in the ropivacaine plus saline group (control group) will consist of 15 ml of 1% ropivacaine and 15ml saline.
16326591|NCT04493450||Smartphone-users|Cancer patients who use smartphones
16326592|NCT04493437|Experimental|Telerehabilitation group A|Device: Telerehabilitation Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
16326593|NCT04493437|Experimental|Telerehabilitation group B|"Device: Telerehabilitation + rehabilitation at health care center Telerehabilitation: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
~Rehabilitation at health care center: The rehabilitation will consist of four closed group sessions focusing on patient education. The groups will consist of both patients and relatives. The program at the health care center will not include any psychological tests or data control. Duration is 4 x 2 hours sessions over a period of 1 month."
16326595|NCT04493411|Experimental|Multiple Myeloma Patients|Patients with pathologically confirmed myeloma scheduled to undergo induction therapy followed by bone marrow transplantation.
16326596|NCT04493398|Active Comparator|Titanium curette and ultrasonic.|Debridement of mandibular furcations with conventional ultrasonic/curette (control).
16326597|NCT04493398|Experimental|Erythritol air-polishing.|Treatment of mandibular furcations with erythritol powder/air-polishing system (test)
16326598|NCT04493372|Experimental|Individuals with spinal cord injury|
16326599|NCT04493372|Experimental|Individuals without spinal cord injury|
16326600|NCT04493359|Experimental|Switch therapy|Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
16326605|NCT04493320|Experimental|Placebo, Then L-DOPA|"Step 1 (3 Weeks): Participants will receive 3 L-DOPA matching placebo tablets daily. Participants will then enter a 1-week taper period.
~Step 2 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.
~Participants will then enter a 1-week taper period."
16326606|NCT04493281|Experimental|MT-1186|Healthy subjects were administered a single dose of Edaravone oral suspension
16326607|NCT04493281|Active Comparator|MCI-186|Healthy subjects were administered a single dose of Edaravone intravenous formulation
16326608|NCT04493255|Experimental|E7090|Participants will receive 100 microcurie (μCi) of [14C]E7090 as a single 35 milligram (mg), capsule, orally on Day 1.
16326609|NCT04493242|Placebo Comparator|Placebo|Normal saline 100 mL
16326610|NCT04493242|Experimental|Experimental Dose 1|Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.
16326611|NCT04493242|Experimental|Experimental Dose 2|Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles.
16326612|NCT04493229|Experimental|Oxytocin|Oxytocin IM injection will be given per randomization prior to first outpatient physical therapy session
16326613|NCT04493229|Active Comparator|Placebo|Placebo IM injection will be given per randomization prior to first outpatient physical therapy session
16326614|NCT04493216|Experimental|Blinded GSK3640254 100 mg + GSK3640254 matching placebo + Open Label ABC/3TC or FTC/TAF|
16326615|NCT04493216|Experimental|Blinded GSK3640254 150 mg + Open Label ABC/3TC or FTC/TAF|
16326616|NCT04493216|Experimental|Blinded GSK3640254 200 mg + GSK3640254 matching placebo + Open Label ABC/3TC or FTC/TAF|
16326617|NCT04493216|Active Comparator|Open Label DTG + Open Label ABC/3TC or FTC/TAF|
16326618|NCT04493203|Experimental|Nivolumab plus Axitinib|"Nivolumab 480mg, IV, every 4 weeks, for up to two years.
~Axitinib 5mg, PO, BID, for up to two years."
16326622|NCT04493177|Experimental|Gestational diabetes intervention|All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
16326623|NCT04493177|Experimental|No diabetes intervention|Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
16326624|NCT04493177|Active Comparator|No diabetes no intervention|Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
16326625|NCT04493164|Experimental|Treatment (CPX-351, ivosidenib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and ivosidenib PO QD on days 1-28. Patients who do not achieve complete remission may receive a second cycle of induction therapy in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission proceed to consolidation.
~CONSOLIDATION: Patients receive CPX-351 IV over 90 minutes on days 1 and 3, and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ivosidenib PO QD for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who are experiencing clinical benefit and who have not experienced excessive toxicity after completion of 2 years of maintenance may be eligible to continue therapy after discussion with the principal investigator."
16326626|NCT04493151|Experimental|Imipenem-Cilastatin-Relebactam|Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.
16326627|NCT04493138|Experimental|Treatment (azacitidine, quizartinib)|Patients receive azacitidine SC or IV over about 30 minutes on days 1-5 and quizartinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16326628|NCT04493125|Experimental|Mosapride group|Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
16326629|NCT04493125|Placebo Comparator|Placebo group|Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery
16326630|NCT04493099|Experimental|Treatment (decitabine, alvocidib hydrochloride, venetoclax)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10, or 1-14, and venetoclax PO QD on days 1-14 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive decitabine IV over 1 hour on days 1-5, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10 or 1-14, and venetoclax PO QD on days 1-10. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
16326631|NCT04493073|Active Comparator|Trabectulectomy with mitomycin|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India) 10 mg vial 2 mg/ml concentration
16326632|NCT04493073|Active Comparator|Trabectulectomy with Ologen implants|Ologen Collagen Implant (Aeon Astron Europe, Netherlands) - three-dimensional collagen- GAG implant >90% lyophilized porcine atelocollagen and <10% lyophilized porcine GAG 12 mm in diameter with 1 mm of thickness and 6 mm in diameter with 2 mm of thickness
16326633|NCT04493060|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21. Patients also receive dostarlimab IV over 30 minutes on day 1 Q3W for cycles 1-4 and Q6W for subsequent cycles. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16326634|NCT04493047|Experimental|Counselling on pneumonia prevention|Recruited caregivers will be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject.
16326635|NCT04493034|Experimental|Art Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
16330447|NCT04466969||Treated by potassium binders|Patients who have been treated by Potassium Binders
16326636|NCT04493034|Experimental|Music Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
16326637|NCT04493034|No Intervention|Standard Of Care|A list of support services is provided. No requirement to attend sessions and no home assignments
16326638|NCT04493021|Experimental|Treatment with Dermal Cooling System|Dermal Cooling System will be used in all eligible subjects.
16326639|NCT04493008|Other|MIU students and patents|Educational session
16326640|NCT04492995|Active Comparator|Radiotracer + TUMIR|TUMIR = transvaginal ultrsound-guided myometrial injection
16326641|NCT04492995|Experimental|(Radiotraces + ICG) + TUMIR|ICG =indocyanine green TUMIR = transvaginal ultrsound-guided myometrial injection
16326642|NCT04492982|Active Comparator|Yoga|60 minute sessions of guided yoga in small group format
16326643|NCT04492982|Active Comparator|Distress Tolerance|60 minutes sessions of guided didactic distress tolerance skill building in small group format
16326644|NCT04492982|No Intervention|Treatment as Usual|Those recruited through Student Health and Wellness will complete the university standard BASICS intervention.
16326645|NCT04492956|Experimental|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
16326646|NCT04492956|Placebo Comparator|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
16326647|NCT04492930|Active Comparator|Comparator|Time restricted eating
16326648|NCT04492930|Experimental|Intervention|Time restricted eating
16326649|NCT04492917|Experimental|Cranial Technique CV4|"All subjects received a combination of active technique (CV4) and the corresponding sham technique (shamCV4).
~CV4: the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension.The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
~ShamCV4: sham intervention was performed placing the hands in the same position of the corresponding active technique, applying a light touch"
16326650|NCT04492917|Active Comparator|Sacral Technique ST|"All subjects received a combination of active technique (ST) and the corresponding sham technique (shamST).
~ST: The subject was lying in supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point.
~ShamST: sham intervention was performed placing the hands in the same position of the corresponding active technique, applying a light touch"
16326651|NCT04492904||COVID-19 Positive (Case)|Participants who were present for COVID-19 screening and their test results will later indicate positive of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
16326652|NCT04492904||COVID-19 Negative/Other respiratory diseases (Control)|Participants who were present for COVID-19 screening and their test results will later indicate negative of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days
16326655|NCT04492878|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|
16326656|NCT04492852|Experimental|Interventional Arm 1|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
16326657|NCT04492852|Active Comparator|Interventional Arm 2|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
16326658|NCT04492839|Experimental|Intestial adsorbent arm|This is a single arm study, all participants will receive the class IIa intestinal adsorbent medical device
16326659|NCT04492826||Infected patients|patients with bone flap surgeries
16326660|NCT04492813|Experimental|Obese patients|Severe and morbidly obese patients (35²≤BMI <55)
16326661|NCT04492813|Active Comparator|Non Obese patients|Patients with normal weight or slightly overweight (19 <BMI <30).
16326662|NCT04492800|Other|Paxman Scalp Cooling Device|Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
16326663|NCT04492787|Experimental|Changkang Granules|Changkang Granules
16326664|NCT04492787|Placebo Comparator|Changkang Placebo Granules|Changkang Placebo Granules
16326665|NCT04492774|Experimental|GOLDIC serum|Epidural ultrasound guided injections
16326666|NCT04492774|Active Comparator|Steroid|Epidural ultrasound guided injections
16326667|NCT04492774|Active Comparator|Manual therapy|veno-lymphatic spinal drainage
16326668|NCT04492748|Experimental|Collagen and PRP injections|Ultrasound guided injections
16326669|NCT04492748|Active Comparator|Collagen injections|Ultrasound guided injections
16326670|NCT04492748|Active Comparator|PRP injections|Ultrasound guided injections
16326942|NCT04490798||Headache|Patients with headache treated following the Acupuncture Treatment Clinic Pathway.
16326675|NCT04492709|Experimental|Treatment|The subjects will receive oral midazolam solution of 2 mg as a single dose on 2 occasions, 6 days apart (Days 1 and 7). The first dose will be prior to dosing with oral AZD5718 tablet and the second dose after five administrations of AZD5718 under fasted conditions.
16326676|NCT04492696|Active Comparator|Crashcourse|"CC uses an approach to providing concussion education informed by user-centered formative design research studies. The program features an interactive choose your own adventure approach to navigate the learner through the content, and is guided by near-peer Division I collegiate football athletes"
16326677|NCT04492696|Active Comparator|CDC Video|CDC-Vi is an online learning module developed by the CDC and the National Federation of State High School Associations Learning Center. Learners progress through the curriculum sequentially completing each unit before proceeding to the next. The primary narrator of CDC-Vi is Dr. Mick Koester, Chair of the NFHS Sports Medicine Advisory Committee
16326678|NCT04492696|Active Comparator|CDC Written|"CDC-Wr consists of educational PDFs available for download from the CDC website, as part of the CDC's Heads Up brain injury awareness initiative. The PDFs used for the CDC-Wr condition were specific to high school athlete concussion education"
16326679|NCT04492683|Experimental|Disease group|One active patch and one control patch applied to subjects with clinical symptoms suggestive of non-IgE mediated CMA
16326680|NCT04492683|Experimental|Control group|One active patch and one control patch applied to subjects without any history of allergic disease
16326681|NCT04492670|Experimental|Tui-na and oral Chinese medicine|8 sessions of 20 minutes Tui-na for 4 weeks and take study medication (Herbal granules) twice daily concomitantly for 4weeks
16326682|NCT04492670|Other|Tui-na|8 sessions of 20 minutes Tui-na for 4 weeks
16326683|NCT04492644||elderly inpatients|Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.
16326684|NCT04492631|Experimental|Probiotic|Powdered probiotic with a carrier.
16326685|NCT04492631|Placebo Comparator|Placebo|Carrier only.
16326686|NCT04492618|Experimental|Necrobiosis Lipoidica|Adults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
16326690|NCT04492592|Experimental|Workshop Only|2 session weekend face:face workshop for adolescent-mother pairs
16326691|NCT04492592|Experimental|Workshop + SMS/Texting|2 session weekend face:face workshop for adolescent-mother pairs followed by 8 weeks of supplementary text messages (NOTE: there was no 'SMS/texting-only' arm of this study)
16326692|NCT04492592|No Intervention|Control|No intervention provided.
16326693|NCT04492579|Experimental|Supplementation of Gentle-UHT donor milk|Supplementation of Gentle-UHT donor milk in addition to mother's own milk, as recommended by the health care providers.
16326694|NCT04492566|Experimental|AID Evaluation|"After completing a 1-2 week CGM run-in period, subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present.
~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
16326695|NCT04492553|Experimental|Testogel|All patients will be treated with Testogel. Starting dose is 1 sachet of gel daily applied to the skin of arms, thighs or abdomen. Dose adjustments are made after serum-levels of testosterone. All patients will be treated for a total of 52 weeks, unless they exit the study early because of side-effects or other reasons.
16326696|NCT04492540|Other|aerobic exercises and diet recommendations|the aerobic exercises in form of treadmill training intensity of exercises moderate intensity, target heart rate (THR) will be 50-60% of heart maximum (HR MAX), time of session 40 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
16326697|NCT04492540|Other|diet recommendations|the control group will receive diet recommendations for 12 weeks
16326698|NCT04492527|Experimental|Telehealth coaching sessions|Receives the Telehealth-delivered coaching sessions.
16326699|NCT04492514|Experimental|Mavrilimumab|Mavrilimumab treatment infusion
16326700|NCT04492514|Placebo Comparator|Placebo|Placebo infusion
16326701|NCT04492501|No Intervention|Supportive Arm|As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 < 80mmHg) and corticosteroids. All patients of Cytokine release storm (CRS) received either Methylprednisolone 1 mg/kg or Dexamethasone 6-12mg/day irrespective of disease severity.
16326702|NCT04492501|Experimental|TPE arm|addition to standard care TPE will be performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access will be achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume will be calculated as per Nadler's formula. Anticoagulant acid dextrose ratio will be 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation will be monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume will be removed during each procedure. Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures will be performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE will be continued till recovery.
16326703|NCT04492501|Experimental|TPE in combination with other investigational treatments|During TPE, Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively plus 200-400 ml of convalescent plasma. A predefined number of patients will also receive mesenchymal stem cell therapy and/or Remdesivir
16326943|NCT04490798||Shoulder pain|Patients with shoulder pain treated following the Acupuncture Treatment Clinic Pathway.
16326704|NCT04492501|Experimental|Either alone or combination of MSC, Remdesivir and Tocilizumab|A predefined number of patients will receive either alone Tocilizumab, Remdesivir and Mesenchymal stem cell therapy or their combination
16326705|NCT04492488|Experimental|Solid Tumors|Phase I Dose Escalation: MRG002 will be administrated by an IV infusion of escalating doses (starting dose of 2.2 mg/kg, followed by 2.6 mg/kg) on Day 1 of every 3 weeks (21-day cycle).
16326706|NCT04492488|Experimental|Locally Advanced or Metastatic Gastric/GEJ Cancer|MRG002 will be administrated by an IV infusion on Day 1 of every 3 weeks (21-day cycle).
16326707|NCT04492475|Experimental|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
16326708|NCT04492475|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
16326709|NCT04492462|Experimental|Formal Physical Therapy|
16326710|NCT04492462|Experimental|Self-directed Physical Therapy|
16326711|NCT04492449||Obese pregnants group|Obese pregnants exposure of coronavirus infection.
16326712|NCT04492449||Normal pregnants group|Normal pregnants exposure of coronavirus infection.
16326713|NCT04492449||children with congenital malformations|Child with congenital malformations
16326714|NCT04492449||children without congenital malformations|Child without congenital malformations
16326715|NCT04492436|Experimental|Low Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
16326716|NCT04492436|Experimental|High Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
16326717|NCT04492436|Placebo Comparator|Placebo|Reconstituted lyophilized placebo with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
16326718|NCT04492423||Prasugrel|Patients taking prasugrel
16326719|NCT04492423||Ticagrelor|Patients taking ticagrelor
16326720|NCT04492410|Experimental|Experimental arm|screening using a rapid serological test with a drop of blood from a finger prick.
16326721|NCT04492397|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
16326722|NCT04492397|Active Comparator|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
16326725|NCT04492358|Experimental|colchicine + prednisone|Prednisone should be administered for 3 consecutive days (60 mg/d) together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function) for 3 days and maintained for 14 days in total (0.5 mg/d).
16326726|NCT04492358|Active Comparator|Standard treatment|The standard treatment used in each site will be administered to the patients assigned to the control group.
16326727|NCT04492345|Experimental|Experimental|Patient with conventional rehabilitation session and isokinetic reeducation during 7 weeks
16326728|NCT04492345|Other|Control|Patient with conventional rehabilitation session during 7 weeks
16326729|NCT04492332|Sham Comparator|normal controls with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
16326730|NCT04492332|Sham Comparator|normal controls without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
16326731|NCT04492332|Active Comparator|BTSS patients with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
16326732|NCT04492332|Active Comparator|BTSS patients without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
16326733|NCT04492319|Active Comparator|control group|
16326734|NCT04492319|Active Comparator|neostigmine group|
16326768|NCT04492059|Experimental|Blood flow restriction augmented physical therapy|The group will undergo traditional physical therapy with the augment of blood flow restriction therapy under the supervision of trained physical therapists.
16326769|NCT04492059|Active Comparator|Traditional physical therapy|The group will undergo traditional physical therapy without the augment of blood flow restriction therapy under the supervision of trained physical therapists.
16326770|NCT04492046||Complex Decongestive physiotherapy|All participants included in the study were included in a treatment protocol consisting of Complex Decongestive physiotherapy.
16326771|NCT04492033|Experimental|ABL001 and Paclitaxel (P1b)|
16326738|NCT04492280|Active Comparator|1. Group H|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®, E.I.P.I.co. under license of Pfizer) at dose 50mg every 6 hours by Intra venous route.
16326739|NCT04492280|Active Comparator|2. Group HF|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®) at dose of 50mg every 6 hours by Intra venous route and Fludrocortisone (Cortilon®, Amoun) 50 Microgram once daily by nasogastric tube for one week
16326740|NCT04492280|Placebo Comparator|3. Group C|These patients will receive standard therapy for sepsis.
16326741|NCT04492254|Experimental|Enoxaparin|(40 mg o/d if < 100 kg, 40 mg b/d if ≥ 100 kg)
16326742|NCT04492254|No Intervention|Current standard of care (no enoxaparin)|Standard of care
16326743|NCT04492241|Experimental|Study Arm|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
16326744|NCT04492241|Placebo Comparator|Control Arm|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
16326745|NCT04492228|Experimental|Ketogenic diet group|patients with COVID-19 feeding with a ketogenic diet (4.1 formula)
16326746|NCT04492228|No Intervention|Standard diet group|patients with COVID-19 feeding with a standard diet
16326747|NCT04492215|Experimental|Physicians trained in motivational interviewing|Patients followed by general practitioners trained in motivational interviewing
16326748|NCT04492215|No Intervention|Physicians did not trainned in motivational interviewing|Patients followed by general practitioners who did not receive motivational interviewing.
16326749|NCT04492202||First group|Physiotherapists will be included in this group.
16326750|NCT04492202||Second group|Doctors will be included in this group.
16326751|NCT04492202||Third group|Nurses will be included in this group.
16326752|NCT04492202||Fourth group|Other health professionals will be included in this group.
16326753|NCT04492176|Experimental|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%，ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.
16326754|NCT04492176|No Intervention|before treatment|the patient did not receive laser treatment
16326755|NCT04492163|Experimental|Experimental: TTFields|Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.
16326756|NCT04492150|Experimental|study group|women who will receive 250 mL/hour of dextrose 5% with normal saline in a 1:1 ratio.
16326757|NCT04492150|Active Comparator|control group|women who will receive 250 mL/hour of normal saline for the whole duration of induction
16326758|NCT04492137|Experimental|Ultra Early NKF group|Patients submitted to Ultra early NKF in a consecutive fashion by an expert endoscopist
16326759|NCT04492137|No Intervention|Standard cannulation techniques group (including double-guidewire-assisted cannulation)|Patients submitted to standard cannulation techniques (including double-guidewire-assisted cannulation) in a consecutive fashion by an expert endoscopist
16326760|NCT04492111|Experimental|X-space group|Each patient of the experimental group will receive one X-space implant.
16326761|NCT04492111|Active Comparator|2P group|Each patient of the control group will receive one 2P implant. Bone System Cylindric implants. Surface Ecotek.
16326762|NCT04492098||study group|women with spontaneous miscarriage
16326763|NCT04492085||Primary hospital or clinics|
16326764|NCT04492085||Secondary hospital|
16326765|NCT04492085||Tertiary hospital|
16326766|NCT04492072|Experimental|Oxytocin with Mechanical Dilation|"If the patient is randomized to Cook Balloon and Oxytocin - The balloon inflated to 60cc will be placed and oxytocin 2 mu/min will be initiated, and increased incrementally by 2mu/min every 30 minutes. If the cook cannot be placed initially, it will be reattempted and placed within 6 hours of oxytocin starting. The Cook catheter will remain in place until spontaneously expelled, or if not, after 12 hours of placement.
~If a Cook Balloon is not available, a Foley catheter can be used in its place as alternate and equivalent form of mechanical dilation."
16326767|NCT04492072|Active Comparator|Misoprostol with Mechanical Dilation|If the patient is randomized to Misoprostol and Cook balloon - she will be given 25mcg of misoprostol orally or buccal and a Cook Balloon inflated to 60cc will be placed. She will subsequently receive 50mcg oral or buccal misoprostol every 4 hours up to 4 doses. If regular contractions occur (three or more contractions in a 10-minute period), the patient will be switched to Oxytocin 2 mu/min, and increased incrementally by 2mu/min every 30 minutes. If the cook balloon cannot be placed initially, it will be reattempted and placed within 6 hours of induction start. The Cook catheter will remain in place until spontaneously expelled, or at the fourth misoprostol administration. At this point, oxytocin will be started if not already initiated and artificial rupture of membranes will occur
16326772|NCT04492033|Experimental|ABL001 and Irinotecan (P1b)|1 cycle = 4weeks
16326774|NCT04492020|Experimental|Treatment Sequence A|Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
16326775|NCT04492020|Experimental|Treatment Sequence B|Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
16326776|NCT04492007|Experimental|PRISMS|In addition to usual care, participants assigned to this arm will have access to our Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) program.
16326777|NCT04492007|No Intervention|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
16326778|NCT04491994|No Intervention|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
16326779|NCT04491994|Experimental|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
16326780|NCT04491981|Experimental|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using a high viscosity glass ionomer cement (RIVA Self Cure - SDI)
16326781|NCT04491981|Experimental|Composite resin|Repair of restorations in primary molars using a composite resin (Filtek Bulk Fill- 3M ESPE)
16326782|NCT04491968|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
16326783|NCT04491968|Other|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
16326789|NCT04491916|Experimental|Iron Treatment|Treatment with iron sucrose with orginal guideline from ferritin>500ng/ml, or TSAT>20% to ferritin>800ng/ml, or TSAT>50%.
16326790|NCT04491903|Experimental|REBOA|
16326800|NCT04491851|Experimental|LM3 group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
16326801|NCT04491851|Experimental|NODAGA group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
16326802|NCT04491838|Experimental|Process A|Randomized 1:1
16326803|NCT04491838|Experimental|Process B|Randomized 1:1
16326804|NCT04491825||Mycosis fungoides (MF)|
16326805|NCT04491825||Eczema (Atopic Dermatitis)|
16326806|NCT04491825||Chronic Plaque-Psoriasis|
16326807|NCT04491825||Healthy Control Skin|
16326808|NCT04491812|Experimental|Kinesiotaping|kinesiotaping of the triceps muscle applied to the study group alongside the physical therapy program
16326809|NCT04491812|Placebo Comparator|physical therapy program|the control group recieved only the physical therapy program
16326810|NCT04491799||Nosocomial diarrhea|Patients who are hospitalized and develop diarrhea after 72 hours of hospitalization.
16326811|NCT04491786|Experimental|GAPA|Participants will treated with preoperative 600 mg of gabapentin plus nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
16326944|NCT04490785|Experimental|patients under aortic surgery with CPB|Patients under aortic surgery with CPB will have MRI and postoperative dosage of released troponin
16326812|NCT04491786|No Intervention|Non-GAPA|Participants will treated with nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
16326813|NCT04491773||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for more than 6 months
16326814|NCT04491773||Control Group|Healthy controls without previous surgery of radical prostatectomy.
16326815|NCT04491760|Experimental|Inspiratory muscle training|Inspiratory muscle training (IMT) will be perform for 15 minutes each time, twice a day, training every day from 12h to 24h after primary percutaneous coronary intervention (PCI) to 30 days since randomized.
16326816|NCT04491760|No Intervention|Control group|Participants will receive standard care according to the current guideline and clinical practice after primary PCI.
16326817|NCT04491734|Other|Tolerability Arm|Single arm study of active study product
16326818|NCT04491721||Rituximab Biosimilar HLX01 in Combination With CHOP|Rituximab Biosimilar HLX01 in Combination With CHOP,in Previously Untreated Subjects With CD20+ DLBCL.
16326819|NCT04491721||MabThera in Combination With CHOP|MabThera in Combination With CHOP，in Previously Untreated Subjects With CD20+ DLBCL.
16326820|NCT04491708|Experimental|Apparatus Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
16326821|NCT04491708|Experimental|Mat Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
16326822|NCT04491695|Experimental|Tirofiban+Oral antiplatelet therapy|Patients will receive Tirofiban in the first 72 hours and bridge to oral antiplatelet therapy thereafter.
16326823|NCT04491695|Active Comparator|Oral antiplatelet therapy|Patients will receive oral antiplatelet therapy alone.
16326824|NCT04491682|Experimental|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months.Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.
~Due to personal reasons, it may not be possible to accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
16326825|NCT04491656|Active Comparator|7 minutes group|surgeries performed with this group would wait 7 minutes after lidocaine+epinephrine injection prior to skin incision
16326826|NCT04491656|Active Comparator|30 minutes group|surgeries performed with this group would wait 30 minutes after lidocaine+epinephrine injection prior to skin incision
16326827|NCT04491643|Experimental|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months. Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.
~Due to personal reasons, patients may not accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
16326828|NCT04491630|Active Comparator|Self-Hypnosis (SH)|
16326829|NCT04491630|Active Comparator|Mindfulness meditation (MM)|
16326830|NCT04491630|Active Comparator|Christian prayer (CP)|
16326831|NCT04491630|No Intervention|Control condition (CN)|Participants in the CN condition will not be instructed to use any particular coping strategy to cope with the painful stimulation provided by the Cold Pressor Arm Wrap. Participants in the CN condition will listen to a 20-minute natural history audio recording. The option for this recording is supported by: (a) previous research showing that individuals who were asked to listen to it found it to be a neutral, yet relaxing, passage; (b) the use of this passage as an effective control condition in previous studies.
16326832|NCT04491617|Active Comparator|Standard Opioid Protocol (Control)|Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery
16326833|NCT04491617|Experimental|Restrictive Opioid Protocol (Intervention)|Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire
16326834|NCT04491604|Placebo Comparator|Placebo|Matching masked inactive topical gel
16326835|NCT04491604|Active Comparator|B-VEC-03|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
16326836|NCT04491591|Experimental|BREASTChoice|"After consent, the participant will be randomized
~Depending on the clinic work-flow, the patient will be sent the link to the BREASTChoice tool by email or MyChart message
~1) prior to their visit with the surgeon;
~2) at the time of their visit with the surgeon;
~3) after the surgeon appointment
~Will receive an online survey to complete after viewing the BREASTChoice tool assessing socio-demographics, knowledge, health literacy, decisional conflict, patient engagement, health-related quality of life, preferred decision role, and usability of the website.
~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
16326945|NCT04490772||Patients with Covid-19|COVID-19 patients presented with gastrointestinal manifestations
16326946|NCT04490759||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System
16326947|NCT04490746||active|patients with active tuberculosis
16326948|NCT04490746||latent|patients with latent tuberculosis infection
16326949|NCT04490746||negtive control|healthy volunteers
16326837|NCT04491591|Active Comparator|Attention Control Website|"After consent, the participant will be randomized
~Depending on the clinic work-flow, the patient will be sent the link to the website by email or MyChart message
~1) prior to their visit with the surgeon;
~2) at the time of their visit with the surgeon;
~3) after the surgeon appointment
~Will receive an online survey to complete after viewing the website assessing socio-demographics, knowledge, preferences, health literacy, decisional conflict, measure of patient engagement, health-related quality of life, preferred decision role, consult time, and usability of the website.
~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
16326838|NCT04491591|Experimental|Clinicians|"Will receive a brief virtual training on how BREASTChoice functions and the features, including placement of the patient tool summary in the electronic health record
~Will complete pre-post trial survey about shared decision making"
16326839|NCT04491578|Experimental|Advance care planning programme|
16326840|NCT04491578|Placebo Comparator|Attention control|
16326841|NCT04491565|No Intervention|standard education|
16326842|NCT04491565|Active Comparator|educational video|
16326843|NCT04491552||Patients monitored with TruGraf and TRAC testing|Subjects will have TruGraf and TRAC testing at study enrollment (Baseline) and thereafter every 3 months. In addition subjects will have TRAC testing at any time there is a suspicion of acute rejection.
16326844|NCT04491539|No Intervention|Adaptation|Site will inform the adaptation of the FRESH intervention.
16326845|NCT04491539|Experimental|First Receipt|Site will received the adapted FRESH intervention first.
16326846|NCT04491539|Experimental|Second Receipt|Site will received the adapted FRESH intervention second.
16326847|NCT04491526|Experimental|Tamsulosin Arm|p.o.
16326848|NCT04491526|Placebo Comparator|Placebo Arm|p.o.
16326849|NCT04491513||Overall cohort|Pateints that underwent both CTA and CAG in the work-up for TAVI
16326850|NCT04491500||study group|This is a self-control study. Subjects who plan togo to 4000m altitude to work for two weeks will be enrolled. And before and after they arrive high altitude, they will have visual acuity, OCTA, and intraocular pressure; blood pressure, blood oxygen measurement.
16326851|NCT04491487|Experimental|Experimental group|
16326852|NCT04491487|No Intervention|Control group|
16326853|NCT04491474|Active Comparator|Group 1|bilateral great occipital nerve blockade and bilateral isotonic injection into the supraorbital region.
16326854|NCT04491474|Active Comparator|Group 2|bilateral supraorbital nerve blockade and bilateral isotonic injection into the great occipital nerve region
16326855|NCT04491474|Active Comparator|Group 3|bilateral great occipital nerve blockade and bilateral supraorbital nerve blockade
16326856|NCT04491474|Sham Comparator|Group 4|saline injection to bilateral great occipital nerve and supraorbital nerve region
16326857|NCT04491461|Active Comparator|Herbal tea blend|1 cup of herbal tea blend containing Rosehip and other berry extracts.
16326858|NCT04491461|Sham Comparator|Warm water|1 cup of warm water.
16326859|NCT04491435|Experimental|Interventional|4 weeks use of mucin-based saliva substitute
16326860|NCT04491435|Placebo Comparator|Control|4 weeks use of xylitol-based mouthwash
16326861|NCT04491422|Active Comparator|Integrated Next Steps Counseling using poi|At quarterly visits, intervention arm participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine TFV levels <1000 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing.
16326862|NCT04491422|No Intervention|Standard adherence counseling|Control arm participants will receive standard adherence counseling.
16326863|NCT04491409||Observational (standard of care, medical chart review)|Patients undergo standard of care treatment and their medical records are reviewed at 30 days and at 1 year after surgery.
16326864|NCT04491396|Other|GYYB|This is a single-arm pre-post design.
16326865|NCT04491383|Experimental|Tocovid Suprabio (HOV-12020)|200mg, twice 1 day, 12 months
16326866|NCT04491383|Placebo Comparator|Placebo|200mg, twice 1 day, 12 months
16326867|NCT04491370|Experimental|Polatuzumab vedotin|"Evaluable patients for safety Patients receiving 1 dose of Polatuzumab Vedotin will be evaluable for safety.
~Evaluable patients for response Only in patients who are in PR or SD prior to PV and received a minimum of 3 doses will be evaluable.
~Evaluable patients for EFS, PFS, OS All patients who have completed conditioning and autoSCT will be evaluable for EFS, PFS, and OS."
16326868|NCT04491357|Experimental|Intervention arm|Intervention arm will receive 1 ampoule of intravenous calcium gluconate within 4 hours of skin closure post total thyroidectomy
16326869|NCT04491357|Placebo Comparator|Placebo arm|Placebo arm will receive 100ml of normal saline within 4 hours of skin closure post total thyroidectomy
16326870|NCT04491344||Overweight and obese children|Overweight and obese children and adolescents visiting the adiposity outpatient clinic.
16326871|NCT04491331||Non-anesthetized volunteers|Hemodynamic parameters will be measured in supine position. Volunteers will be turned into prone position. After a five-minute stabilization phase will be monitored CI, MAP, heart rate (HR), stroke volume variation SVV, systemic vascular resistance index (SVRI) by non-invasive measurements using a ClearSight (Edwards) in two prone positions (lying on support system allowing a free abdomen and then lying flat without any device). Furthermore, the width of the inferior vena cava and vena jugularis interna, vena saphena and vena cephalica will be measured by ultrasound. The measurement will be performed in inspiration and in expiration phase.
16326872|NCT04491318||Experimental group|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
16326873|NCT04491305||Women with pathohistological confirmation|Women aged between 18 and 50 with surgically proven endometriosis.
16326874|NCT04491292||Observational (questionnaire)|Participants complete 2 online questionnaires over 10 minutes each at baseline and at 3 months after the pandemic ends.
16326950|NCT04490733|Experimental|Experimental group|Participants in the experimental group will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
16326951|NCT04490733|No Intervention|Control group|Participants in control group will receive usual care.
16326875|NCT04491279|Experimental|Neuropilates class.|"Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (chartered physiotherapist and pilates instructor).
~Pitched at a beginner level focused on the core elements of neuropilates and progressing week on week as appropriate.
~Includes a warm up, cool down and neuropilates exercises in line with the teaching of APPI (the Australian Physiotherapy and Pilates Institute). Exercises may be completed on mats, chairs, gym balls, plinths and in standing, depending upon the ability level of the participant.
~Two classes running with 8 participants in each based on their initial assessment into the higher and lower functionally independent participants.
~Participants will be given a home exercise programme weekly based on exercises from the class and will be asked to complete these independently at home twice more during the week and to keep a training diary."
16326876|NCT04491279|Active Comparator|Generalised exercise class.|"Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility.
~Exercises will be more functional and generic than in the pilates classes and will be conducted in a circuit style, including mobility practice, sit to stand practice, cycling with the motomed, and general upper and lower limb strengthening. Warm up and cool downs will also be a feature of this class.
~Participants will be also be given a home exercise programme based on exercises completed in the class and will be asked to complete these exercises twice more during the week and to keep a training diary."
16326877|NCT04491266|Experimental|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
16326878|NCT04491266|Placebo Comparator|placebo|maltodextrins
16326879|NCT04491253|Experimental|Intervention|The intervention is defined as informational support (transmission of information for health care, knowledge of DM2, nutrition, physical activity), instrumental (physical care) and emotional (management of anxiety, empowerment and decision-making).
16326880|NCT04491253|No Intervention|Control|Control group will receive usual care treatment at the diabetes mellitus nursing consultation in primary care.
16326881|NCT04491240|Experimental|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
16326882|NCT04491240|Experimental|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
16326883|NCT04491240|Placebo Comparator|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
16326884|NCT04491227||Kidney disease in COVID-19|"Chronic Kidney Disease (CKD): Known diagnosis of chronic kidney disease; prior evidence of markers of kidney damage for 3 months (microalbuminuria, proteinuria >300mg/24 hrs or abnormalities in imaging tests) or the presence of glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months calculated with CKD-EPI equation, with or without other signs of kidney damage as described above.
~ESKD: Patients that are dialysis dependent.
~Suspected AKI: Oliguria (<200 mL/6 hours) and any AKI-related clinical signs or symptoms (see table 1) or urinalysis/dipstick abnormality. All suspected AKI cases must be confirmed prior to enrollment.
~Confirmed AKI: Meeting of at least one of the modified KDIGO Criteria
~Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours
~Increase or decrease in serum creatinine > 50% from reference in 7 days
~Urine output < 400 ml/day
~Functioning Kidney transplant:"
16326885|NCT04491188|Experimental|Probiotic|1 x10-9 CFU Bacillus subtilis DE111 was consumed daily for 28-days
16326886|NCT04491188|Placebo Comparator|Placebo|Maltodextrin placebo was consumed for 28-days
16326887|NCT04491175|Active Comparator|DuoTherm|A low back pain relief device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice a day for 20 minutes.
16326888|NCT04491175|Sham Comparator|Posture Plate|a sham placebo sculpted metal plate attached with a plain belt, without the pocket or potential for heat, cold, or pressure. No motors are attached to this unit, so while support is possible there are no active pain relief modalities. Patients will be instructed to use the Posture Plate twice a day for 20 minutes.
16326889|NCT04491162|Active Comparator|Conventional gait therapy|Conventional gait therapy.
16326890|NCT04491162|Experimental|BWST training|Conventional gait therapy + Body weight support treadmill training
16326891|NCT04491149|Experimental|women using virtual glass during amniocentesis/foeticide|
16326892|NCT04491149|No Intervention|women undergoing amniocentesis/foeticide|
16326893|NCT04491136|Experimental|ACEI/ARB treatment in 6 months/ARNI treatment in next 6 months|"Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers treatment in the first 6 months
~Angiotensin receptor neprilysin inhibitor treatment in next 6 months"
16326894|NCT04491110|Experimental|Experimental: Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
16326895|NCT04491110|Sham Comparator|Sham Comparator: Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
16326896|NCT04491097|Experimental|Experimental: Panavia V5 resin cement|Resin cement with non-MDP monomer
16326897|NCT04491097|Active Comparator|Experimental: Panavia F2.0 resin cement|Resin cement with MDP monomer
16326898|NCT04491084|Experimental|FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140), and SBRT|"Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease. Subjects on Arm 1 with extensive disease will initially receive SBRT to a single site of disease but may receive additional cycles of FLT3 ligand, anti-CD40 antibody, and SBRT at later time points."
16326899|NCT04491084|Active Comparator|Standard care|Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease.Subjects on Arm 2 with extensive disease are expected to receive some form of standard systemic therapy (e.g., docetaxel). Subjects on Arm 2 with limited disease may also receive standard systemic therapy following completion of SBRT to all sites of evident disease, at the discretion of the treating physicians.
16326900|NCT04491071||Volunteers|volunteers over 18 years of age
16326901|NCT04491058||Carpal tunnel syndrome patients|
16326902|NCT04491058||Healthy|
16326988|NCT04490473|Other|volunteer group|Only volunteer participants will be included in the research. Survey forms will be sent to individuals online. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
16326903|NCT04491045|Experimental|Community-Engaged Learning Collaborative (CELC)|The CELC arm is an integration of community engagement and learning collaborative approach which involves province-wide collaborative meetings for commune health stations (6 CHSs for each province) randomized into the CELC implementation condition. CELC CHSs will meet monthly initially for 3 months, followed by bi-monthly meetings for 12 months to engage in continuous quality improvement process, track implementation goals, problem solve implementation barriers, and engage in cross-site learning. This is in addition to usual implementation condition (supervision, workshops, technical assistance, and evidence-based toolkit)
16326904|NCT04491045|Experimental|Enhanced Supervision (ES)|This is an evidence-based training approach which involves 6-9 months of ongoing group supervision support from psychiatric hospital mental health specialist (psychiatrist, psychiatric nurse, or psychologist) for each community health station randomized to the ES condition. Supervision approach is structured and involves observation of sessions, feedback on fidelity and quality. Supervision support will be provided biweekly initially and monthly after completion of one practice case. This is in addition to usual implementation condition (workshops, technical assistance, and evidence-based toolkit)
16326905|NCT04491045|Active Comparator|Usual Implementation (UI)|"Usual Implementation (UI) Control intervention that will be enhanced usual implementation and includes hybrid training workshops on basic implementation and training supports for Multicomponent Collaborative Care for Depression program, which is an evidence-based stepped collaborative care intervention for integrating depression care into primary care settings. It consists of six components: routine screening, diagnostic assessment, psychoeducation, antidepressant medication, adherence management, behavior activation therapy.
~This implementation and training supports includes a series of online training modules, weekly webinars, and 3 one-day in-person workshops on collaborative care for depression (MCCD), limited technical assistance, and toolkit."
16326906|NCT04491032|Active Comparator|Low Volume|Caudal anesthesia will be performed with 0.8 ml/kg of the local anesthetic solution
16326907|NCT04491032|Active Comparator|High Volume|Caudal anesthesia will be performed with 1.25 ml/kg of the local anesthetic solution
16326908|NCT04491019|Experimental|Balance exercise group|Balance exercises will be carried out with a physiotherapist.
16326909|NCT04491019|Experimental|Strengthening exercise group|Strengthening exercises will be performed with a physiotherapist.
16326910|NCT04491006|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
16326911|NCT04491006|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
16326912|NCT04491006|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
16326913|NCT04490993|Experimental|APL-1202 treatment|
16326914|NCT04490993|Placebo Comparator|Placebo|
16326915|NCT04490980|Experimental|Observed group|
16326916|NCT04490980|No Intervention|Control group|
16326917|NCT04490967|Experimental|Silymarin and salicylic acid|There will be one group of patients, that will use salicylic acid peeling on the right side of the face and topical Silymarin cream on the left side
16326918|NCT04490954|Other|Patients examined with MRI/CT|
16326919|NCT04490954|Other|Patients examined with biological electrical impedance|
16326920|NCT04490941|Experimental|Intervention group|
16326921|NCT04490941|Other|Control group|
16326922|NCT04490928||complete revascularization|All patients who underwent complete myocardial revascularization
16326923|NCT04490928||incomplete revascularization|All patients who did not complete myocardial revascularization
16326924|NCT04490928||without revascularization|All patients who were not revascularized
16326925|NCT04490915|Experimental|Crinecerfont|Capsule, administered orally, twice daily for 24 weeks, followed by active treatment for 1 year.
16326926|NCT04490915|Placebo Comparator|Placebo|Capsule, administered orally, twice daily for 24 weeks, followed by active treatment for 1 year.
16326927|NCT04490902|Active Comparator|Single graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from single donors.
16326928|NCT04490902|Experimental|Dual graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from different donors.
16326929|NCT04490889||Patients with PGT indication|Patients undergo in vitro fertilization with PGT-A or for PGT-SR indication
16326930|NCT04490876||Retinal Detachment with PVR|Proliferative vitreoretinopathy (PVR), a major complication of rhegmatogenous retinal detachment (RRD), is an abnormal process whereby proliferative, contractile cellular membranes form in the vitreous and on both sides of the retina, resulting in tractional retinal detachment with fixed retinal folds. Patients with RD complicated by PVR will be included, and the proposed intervention will be performed.
16326931|NCT04490863|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
16326932|NCT04490850|Experimental|Participants|Blood sample
16326933|NCT04490837||COVID-19 positive|Patients with clinical, radiological and/or PCR positive for COVID-19 infection
16326934|NCT04490837||Normal|Normal human serum from blood donnors before COVID-19 pandemia
16326935|NCT04490837||Pathological controls|Patients with other positive virological serologies
16326936|NCT04490824|Active Comparator|Treated Then Control Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale KELEA Excellerated Water for 2 days followed by inhaling water without an elevated level of KELEA for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
16326937|NCT04490824|Placebo Comparator|Control Than Treated Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale water without an elevated level of KELEA for 2 days followed by inhaling KELEA Excellerated water for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
16326938|NCT04490798||Lumbar back pain|Patients with lumbar back pain treated following the Acupuncture Treatment Clinic Pathway.
16326939|NCT04490798||Musculoskeletal pain|Patients with musculoskeletal pain treated following the Acupuncture Treatment Clinic Pathway.
16326940|NCT04490798||Cervicalgia|Patients with cervicalgia treated following the Acupuncture Treatment Clinic Pathway.
16326941|NCT04490798||Knee osteoarthritis|Patients with knee osteoarthritis treated following the Acupuncture Treatment Clinic Pathway.
16326954|NCT04490707|Experimental|Azacitidine plus Lenalidomide (AZA+LEN)|"Arm 1(AZA+LEN): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA combined with LEN: AZA 50mg/m² per day for days 1-5 and LEN 10mg per day orally for days 6-26 , every 28 days for up to 12 cycles or progression.
~AZA -Azacitidine, LEN- Lenalidomide"
16326955|NCT04490707|Experimental|Azacitidine(AZA)|"Arm 2 (AZA): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA 50mg/m² per day for days 1-5, every 28 days for up to 12 cycles or progression.
~AZA -Azacitidine"
16326956|NCT04490707|No Intervention|Observation|Arm 3(Observation): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter observation.
16326957|NCT04490694|Experimental|TACE Combined with Lenvatinib|
16326958|NCT04490681|Experimental|Ertugliflozin|Ertugliflozin 5mg
16326959|NCT04490681|Placebo Comparator|placebo|Placebo
16326960|NCT04490668||Human albumin support|Patients who received intravenous human albumin after gastric cancer surgery
16326961|NCT04490668||No human albumin support|Patients who did not receive intravenous human albumin after gastric cancer surgery
16326962|NCT04490655|Experimental|Active somatosensory training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that focuses on the retraining of both motor and somatosensory functions, for a maximum of one hour per session.
16326963|NCT04490655|Active Comparator|Motor-based training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that is purely motor based, for a maximum of one hour per session.
16326964|NCT04490642||Concomitant bladder and bowel Dysfunction|25 patients with concomitant bladder and bowel dysfunction.
16326965|NCT04490642||Those without concomitant bladder and bowel dysfunction|25 patients without concomitant bladder and bowel dysfunction.
16326966|NCT04490629|Other|DURAFORM|DURAFORM was used in repairing cerebral dura mater.
16326967|NCT04490629|Experimental|Lyoplant Onlay|Lyoplant Onlay was used in repairing cerebral dura mater.
16326968|NCT04490616|Experimental|RR-GR|MCI patients with social cognition deficits will receive 4 weeks of rTMS stimulation
16326969|NCT04490616|Other|SR-GR|MCI patients with social cognition deficits will receive 2 weeks of placebo treatment, followed by 2 weeks of real rTMS stimulation
16326970|NCT04490603|No Intervention|Conventional group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided in the same way as the conventional method of injecting drugs in Seoul National University Hospital Pain Center.
16326971|NCT04490603|Experimental|VR group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided with virtual reality experience. Conditions are the same in both arms except for virtual reality experience.
16326972|NCT04490590|Experimental|Chidamide+ Etoposide capsule|"Chidamide: 30mg, twice a week(BIW), PO.
~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle. Patients receive the other treatment of chidamide and etoposide capsule, and those who have achieved PD(progressive disease) will give the other treatment."
16326973|NCT04490577|Experimental|Pilates training group|"In the Pilates group, the exercises were performed with Reformer® for eight weeks, twice in a week, one hour per day."
16326974|NCT04490577|Experimental|Whole-body vibration (WBV) group|"In the WBV group, the training was given Power Plate® for eight weeks, twice in a week, and 30 minutes in a day."
16326975|NCT04490577|No Intervention|Control group|The control group did not receive any training.
16326976|NCT04490564||HNSCC, NSCLC, melanoma Patients|
16326977|NCT04490564||Healthy volunteers|In case of healhty volunteers, only peripheral blood samples will be collected.
16326978|NCT04490551|Experimental|Intervention group|This group will be screened with the risk-based model. The input of the model will be gathered with the FIT, a validated questionnaire, and from data of the Dutch general population registry. The threshold of the model will be set at a calculated risk of 0.10. To comply with ethical guidelines, all participants in this group with a FIT result of >=15 mcg Hb/g faeces and a calculated risk of <0.10 will also be offered a colonoscopy.
16326979|NCT04490551|Active Comparator|Control group|This group will be screened with the FIT. The threshold of the FIT will be set at >= 15 mcg Hb/g faeces.
16326980|NCT04490538||Critically ill patients|Critically ill patients hospitalised at the intensive care unit indicated to echocardiographic examination.
16326981|NCT04490525|Experimental|Intervention|The intervention group will participate in the telerehabilitation program (please see detailed description of telerehabilitation program and technologies). The two steps in the telerehabilitation program last up to six months depending on how fast the titration of medicine in step one will be conducted. The intervention group will spend 5-10 minutes every day on monitoring themselves. Every month, an online questionnaire has to be filled in which will take up to 5 minutes. At enrolment, after titration of medicine, and the end of rehabilitation, the patient will fill in an online questionnaire. This will take 5 minutes each time. Selected patients and relatives will be asked if they wish to participate in interviews after participation in the trial. Each interview will last less than one hour. Number of interviews will be decided when data saturation has been achieved.
16326982|NCT04490525|No Intervention|Control|The control group will follow a conventional rehabilitation program (Egstrup et al 2015). The control subjects will participate in medicine titration for 1- 3 months and conventional rehabilitation for 3 months. The participation in the control group will last up to six months. The exact period depends on how fast the titration of medicine is conducted. At enrolment, after titration of medicine, and end of rehabilitation, the patient will fill in a questionnaire. This will take 5 minutes each time.
16326983|NCT04490512|Experimental|FluBHPVE6E7|Multiple administration of FluBHPVE6E7
16326984|NCT04490512|Placebo Comparator|Placebo|Multiple administration of buffer solution
16326985|NCT04490499|Experimental|HBVAXPRO™|Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).
16326986|NCT04490486|Experimental|Group 1: (UCMSCs)|Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.
16326987|NCT04490486|Placebo Comparator|Group 2: (Placebo)|Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3.
16326989|NCT04490460|Placebo Comparator|First 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. Double blind 50% Placebo capsules identical to those containing WB-0031 and 50% WB-0031
16326990|NCT04490460|Active Comparator|Second 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. All participants receiving WB-0031.
16326991|NCT04490447||Bronchiectasis|"Patient meets diagnose of bronchiectasis refering to BTS guideline 2010 will be included."
16326992|NCT04490447||Healthy control|Healthy volunteers will be included.
16326993|NCT04490434|Experimental|Cohort 1, A (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
16326994|NCT04490434|Experimental|Cohort 1, B (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
16326995|NCT04490434|Experimental|Cohort 2, C (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
16326996|NCT04490434|Experimental|Cohort 2, D (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
16326997|NCT04490434|Experimental|Cohort 3, E (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
16326998|NCT04490434|Experimental|Cohort 3, F (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
16326999|NCT04490421|Experimental|Experimental|Experimental:Camrelizumab combined with Apatinib, Etoposide and Cisplatin
16327000|NCT04490408|Active Comparator|long surgical bypass|long surgical bypass for multilevel lower limb ischemia
16327001|NCT04490408|Experimental|Hybrid approach|surgical bypass and endovascular treatment for multilevel lower limb ischemia
16327002|NCT04490395|Experimental|Engage PA|
16327003|NCT04490395|Other|Treatment as usual plus fitness tracker|
16327004|NCT04490382|Experimental|Patients undergoing Neuromodulation|Patients, who have had a lower limb amputation and undergoing neuromodulation as part of standard of care.
16327005|NCT04490369||Group 1- short interval|Less than or equal to six minutes between receiving sedation and the start of the procedure
16327006|NCT04490369||Group 2- long interval|Greater than or equal to seven minutes between receiving sedation and the start of the procedure
16327007|NCT04490356|Experimental|Legacy Intervention|Older adults who have successfully completed a lifestyle intervention (lost at least 3% body weight and increased short physical performance battery (SPPB) score by 1 point or 6-minute walk test (6MWT) by 50 meters) will be enrolled in a tele-nutrition and tele-exercise intervention.
16327008|NCT04490317||Acute CO poisoning|A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
16327009|NCT04490304|Other|posterior soft tissue repair durability|
16327010|NCT04490278|Experimental|Patients with PICS|
16327011|NCT04490265|Experimental|Problem-Solving Treatment|Our PST is 12-weeks and teaches patients strategies to address real-life problems.20 Sessions are once a week for one hour except for the first session, which is two hours. The treatment has four main goals: 1. Safety planning; 2. Problem-orientation-addressing how patients approach problems; 3. Planful problem-solving or a logical approach to address problems; 4. Behavioral activation of daily activities. Patients are provided weekly worksheets on problem-solving and receive weekly assessment of emotional state and suicidal ideation monitoring.
16327012|NCT04490265|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was … ) in order to help identify experiences for discussion in session. Participants will be informed that the control condition is supportive and non-directive, and that providers will not engage in problem-solving. Providers will be taught to use reflective listening, clarification, empathy, and validation. The control consists of 12 weekly sessions delivered via telephone or video."
16327013|NCT04490252|No Intervention|Free diet|Free diet
16327014|NCT04490252|Experimental|FMD|Fasting mimetic diet for 5 days, next cycle after 25 days of free diet
16327015|NCT04490239|Experimental|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.
~Acute phase:
~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.
~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.
~Chronic phase:
~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
16327016|NCT04490226|Experimental|fasting, active|36 hours fasting, PAL 1.6
16327017|NCT04490226|Experimental|ketogenic diet, active|24 hours of ketogenic diet (liquid meals), PAL 1.6
16327018|NCT04490226|Experimental|exogeneous ketone bodies, active|24 hours of ketone body supplements (Beta-Hydroxybutyrate as Ca-Mg-salt) additional to a normal diet (liquid meals), PAL 1.6
16327019|NCT04490226|Experimental|fasting, inactive|36 hours fasting, PAL 1.3
16327020|NCT04490213||hydrofibre, Aquacel|Study participants were previously treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
16327021|NCT04490213||polyurethane foam, Allevyn|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
16327022|NCT04490213||porcine xenograft, Mediskin|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
16327074|NCT04489836|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
16327023|NCT04490200|Experimental|Novel chitosan semi facial respirator (VESTA)|VESTA is a semi facial respirator that follows the same technical specifications of a N95 class PFF2 respirator. However, the VESTA respirator has nanoparticles in the filtering element, which is manufactured with a product of 50 gsm melt blown polypropylene-treated with an electrostatic charge. This filtering element deposits nanoparticles of polymeric biodegradable material known as chitosan. Chitosan can act as a surface for adsorption and viral inactivation.
16327024|NCT04490200|Active Comparator|Conventional N95 semi facial respirator|The N95 PFF2 respirators are manufactured from TNT as defined in ABNT NBR 15052: 2004 and in the resolution of ANVISA RDC No. 356. The filtering element is usually formed by a layer of thin polypropylene fibers arranged at random. This configuration influences the particles (which constitute aerosols) to move along an extensive and tortuous path in relation to their size; thus, increasing the probability of them coming into contact with the fibers and being retained. A number of mechanisms influence the interception of particles by the fibers of the filter element. In addition to the mechanical interception mechanisms, the presence of charges on the surface of the filter material can enhance the association of particles with its fibers and optimize the efficiency of the respirator.
16327025|NCT04490187|Experimental|Active tDCS stimulation|tDCS will be applied over the left motor cortex at 1 mA for 30 min. The current will be ramped up to 1 mA over 45-60 s, held for 30 min, and ramped down to 0 mA over 45-60 s.
16327026|NCT04490187|Sham Comparator|Sham tDCS stimulation|tDCS will be ramped up and held for only 60 s before it is slowly ramped down. This procedure, called the Fade-in-Short Stimulation-Fade out, has shown its reliability as an effective sham technique through making the same tolerability and transient scalp sensation as active stimulation in both adults (Ambrus 2012) and children (Ciechanski 2017).
16327027|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
16327028|NCT04490161|Experimental|Interventional|Subjects will receive reinstallation of CSF intravenously.
16327029|NCT04490161|No Intervention|Observational|Subjects will not receive study intervention; CSF will be sampled and analyzed in comparison to the Interventional arm,
16327030|NCT04490148|Active Comparator|remote PFT (rPFT) longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment.
16327031|NCT04490148|Experimental|remote PFT (rPFT) + Nurse Coaching longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment, and receive monthly coaching from an ALS nurse.
16327032|NCT04490135|Experimental|Carers group intervention|caregivers entered into the 8 week CARERS intervention (N=264) Group intervention, 8 x 2 hour sessions. Session 1-4 PST training, session 5-8 Simulation with standardized patients training Pre- post evaluations completed
16327033|NCT04490135|No Intervention|Wating list control|Caregivers waiting for entry into active arm of CARERS intervention.During this time usual care allowed with no other intervention. Study measures administered at intake and immediately prior to starting the CARERS group. (N=83)
16327034|NCT04490122||Inhalational|will receive inhalational anesthesia
16327035|NCT04490122||Total intravenous|will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.
16327036|NCT04490109|Experimental|B244 Suspension O.D. 5.0|One arm of 192 Subjects will be receiving a dose of B244 O.D. 5.0 suspension
16327037|NCT04490109|Experimental|B244 Suspension O.D. 20.0|Second arm of 192 subjects will receive a dose of B244 O.D. 20.0 suspension
16327038|NCT04490109|Placebo Comparator|Placebo|Third arm of 192 subjects will receive a vehicle dosing.
16327039|NCT04490096|Other|[11C]-PBR28 ALS|Neuroinflammatory pathways have been implicated in a variety of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), but the vast majority of this evidence is from animal or ex vivo human studies. In vivo measurement of the 18 kDa translocator protein (TSPO) has become possible with [11C]-PBR28 PET imaging. Briefly, TSPO expression is increased when microglial are activated. Cross-sectional studies have demonstrated that [11C]-PBR28 uptake is elevated in ALS compared to controls, is correlated with upper motor neuron severity, and that microglial activation is associated with more severe upper motor neuron disease and faster disease progression. We are only aware of a single 6-month study of 10 patients evaluating longitudinal change of [11C]-PBR28 in ALS. We hypothesize that we will observe increased [11C]-PBR28 uptake over a 6-month period in motor cortex and prefrontal cortex in ALS. This portion of the study will be performed at UPenn only.
16327040|NCT04490057|Experimental|12 wks NRT+CM / 12 wks NRT+CM|Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.
16327041|NCT04490057|Experimental|12 wks NRT+CM/ 12 wks VAR or bupropion+CM|Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.
16327042|NCT04490057|Experimental|12 wks NRT+CM/12 wks NRT+CM plus|Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.
16327043|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT|Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.
16327044|NCT04490057|Experimental|12 wks NRT/ 12 wks VAR or bupropion|Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.
16327045|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT+CM|Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.
16327046|NCT04490044|Active Comparator|1|Participants in Arm 1 will be posted the Under & Over study pack (1) and asked to complete the Under & Over tool daily for up to 30 minutes per day, 5 days per week for 3 months. They will be instructed to follow the instruction booklet and complete each pattern in the specific order described in the booklet.
16327075|NCT04489836|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
16327076|NCT04489823|Experimental|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
16327047|NCT04490044|Active Comparator|2|Participants in Arm 2 will be posted the Under & Over study pack (2) and asked to complete the Under & Over tool daily for as long or short as they choose or are able to. They will be asked to complete 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to complete. They will also be encouraged to create their own patterns. These participants will have access to a section of the study website where they will be able to upload photographs of their patterns and see other participants' patterns over the 3-month period.
16327048|NCT04490044|Placebo Comparator|3|Participants in Arm 3 will be posted the Under & Over study pack (3). For the first three months of the study they will be asked to complete the c9HPT 5 days a week. After three months, they will be able to complete the Under & Over tool daily for as long or short as they choose. Similar to Arm 2, They will be asked to do this 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to
16327049|NCT04490031|No Intervention|Midazolam group|Standard sedation for ERCP in UKMMC
16327050|NCT04490031|Experimental|Ketamine group|
16327051|NCT04490018|Experimental|Group 1 (investigational group - sequential administration)|MenACYW conjugate vaccine on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
16327052|NCT04490018|Active Comparator|Group 2 (control group - sequential administration)|Nimenrix® on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
16327053|NCT04490018|Experimental|Group 3 (investigational group - concomitant administration)|MenACYW conjugate vaccine + 9vHPV* + Tdap-IPV vaccines on Day 01: n=116
16327054|NCT04490005||Acute brain injury|"Intensive care unit (ICU) admission after ABI, including traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH)
~• Age 18 years old."
16327055|NCT04489992||Standard radiology studies with AI|"The experiment is conducted on three types of studies:
~Chest Computed tomography and Low-Dose Computed Tomography for lung cancer detection (hereinafter referred to as CT/LDCT) with artificial intelligence results;
~Chest X-ray for lung pathology detection (hereinafter referred to as XR) with artificial intelligence results;
~Mammography for breast cancer detection (hereinafter referred to as MG) with artificial intelligence results;"
16327056|NCT04489992||Standard radiology studies without AI|"The experiment is conducted on three types of studies:
~Chest Computed tomography and Low-Dose Computed Tomography for lung cancer detection (hereinafter referred to as CT/LDCT) without artificial intelligence results;
~Chest X-ray for lung pathology detection (hereinafter referred to as XR) without artificial intelligence results;
~Mammography for breast cancer detection (hereinafter referred to as MG) without artificial intelligence results;"
16327057|NCT04489979||Analgetics only|Children with epididymitis / orchitis treated by analgetics only.
16327058|NCT04489979||Analgetics and antibiotics|Children with epididymitis / orchitis treated by analgetics and antibiotics.
16327059|NCT04489966|Experimental|Aerobic training group|The aerobic training group was performed 3 times/week for 60 minutes/session(including 5 minutes of warm-up, 50 minutes aerobic rhythmic exercise and 5 minutes to relax) for moderate(60 to 70% of participants' HRmax) aerobic rhythmic exercise. All patients received an open class, relate to diabetes health education. The intervention lasted for 6 months.
16327060|NCT04489966|No Intervention|Control group|Patients in control group remained the original lifestyle unchanged. All patients received an open class, relate to diabetes health education.
16327061|NCT04489966|Experimental|Intervention group|The intervention was aerobic rhythmic exercise, with intensive training under the guidance and supervision of a professional.The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 5-10 minutes flexibility exercises). Participants were educated on aerobic exercises (aerobic dancing) with music.The intervention lasted for one year.
16327062|NCT04489966|No Intervention|Compared group|The control group was instructed to maintain their usual habits and received no structured exercise intervention. But the form, frequency and time of movement of each participant must be recorded.Participants receive an open diabetes health education class once a month, which is taught by a specially trained diabetes nurse.
16327063|NCT04489953|Active Comparator|Clinical and Immunologic criteria|In the clinical and immunologic monitoring criteria was based on the 2010 WHO guidelines. Whereby children were monitored using clinical presentation and CD4 count to define treatment failure.
16327064|NCT04489953|Active Comparator|Clinical, Immunologic and Virologic criteria|In the Clinical, Immunologic and Virologic criteria was based on a confirmed viral load of > 1000 HIV RNA copies/ml; as well as clinical and immunologic criteria
16327065|NCT04489940|Experimental|Bintrafusp alfa|
16327066|NCT04489901|Experimental|Extra Virgin Olivei oil group|The women in the experimental (olive oil) group were asked to apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
16327067|NCT04489901|No Intervention|Control group|The women in the control group did not undergo any intervention.
16327068|NCT04489888|Experimental|Pembrolizumab + Carboplatin + Paclitaxel|Participants will receive pembrolizumab plus carboplatin plus paclitaxel. Pembrolizumab will be administered via intravenous (IV) infusion at a dose of 200 mg on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Carboplatin will be administered via IV infusion at area under curve (AUC) 5 mg/mL/minute on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months). At investigator's choice, paclitaxel will be administered via IV infusion at a dose of 100 mg/m^2 on Day 1 and Day 8 of each 21-day cycle for up to 6 cycles (up to ~4 months) or at a dose of 175 mg/m^2 on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months).
16327069|NCT04489875|Experimental|Chewing gum|the patients in this arm will receive the post-operative oral feeding along with chewing gum which they'll be required to chew for at least 15 minutes before their meal 3 times a day
16327070|NCT04489875|No Intervention|No chewing gum|The patients in this arm will only receive the post-operative oral feeding
16327071|NCT04489862|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
16327072|NCT04489849|Experimental|Apixaban|Apixaban 2.5mg BID
16327073|NCT04489849|Active Comparator|Control|Other treatment except oral anticoagulant
16327077|NCT04489810|Placebo Comparator|Meal A + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal A
16327078|NCT04489810|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
16327079|NCT04489810|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
16327080|NCT04489810|Experimental|Meal B + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal B
16327081|NCT04489797|Experimental|Arm A|Participants will receive single oral dose of acalabrutinib capsule with 100 mL of water.
16327082|NCT04489797|Experimental|Arm B|Participants will receive single oral dose of acalabrutinib capsule taken with 100 mL of COCA-COLA along with 20 mg rabeprazole.
16327083|NCT04489784|Experimental|Treatment|Laser treatment on ballerina's feet.
16327088|NCT04489745|Experimental|SBRT and ADT|Patients undergo SBRT to a dose of 40 Gy in 5 fractions to prostate, and optional 25 Gy in 5 fractions to SVs and Pelvic LNs, with 9 months of Androgen Deprivation Therapy
16327089|NCT04489732|Experimental|Treatment with MSCs|A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia
16327090|NCT04489719||Observational (biospecimen collection)|Patients receive standard of care radium Ra 223 dichloride given by IV bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
16327091|NCT04489706|Experimental|P53 mutation arm|patients of recurrent and metastatic ovarian cancer and endometrial cancer associated with P53 mutation
16327092|NCT04489693|Active Comparator|Ambulatory Care Coordinator Team (ACCT)|Patients randomized to ACCT receive care from different doctors in clinic and in the hospital. ACCT patients who have been hospitalized twice, had 4 emergency department (ED) visits in the last year or are referred by their primary care physician are offered ACCT care coordination services (ACCT-CC) from nurses and social workers who manage their care with the larger clinical team. Patients are graduated from ACCT if the ACCT team thinks they are no longer high risk.
16327093|NCT04489693|Active Comparator|Comprehensive Care Physician (CCP)|Patients randomized to the CCP group are assigned to a Comprehensive Care Physician and are asked to see their assigned CCP for their primary care. The patients receive their care from the same CCP in the outpatient clinic and also if they were to be hospitalized.
16327094|NCT04489693|Active Comparator|Comprehensive Care, Community & Culture Program (C4P)|Patients randomized to C4P receive care from a CCP in both the hospital and the clinic as well as the following: 1) systematic screening of 17 domains of unmet social needs, 2) access to a community health worker and 3) access to community-based arts and culture programming.
16327095|NCT04489680|Experimental|Surgical Trainees undergoing Cleft Palate Training|26 UK specialty trainees performed a vomerine mucosal flap and intra-velar veloplasty in a one-hour workshop. Pre- and post-simulation questionnaires assessing cleft knowledge and surgical confidence were compared for statistical significance.
16327096|NCT04489667|Other|+STEP Implementation|All patients will receive +STEP as new standard of care at their clinic. This intervention will include staff training, PROs as part of routine care to screen for substance use and mental health disorders, and telemedicine for health care delivery.
16327097|NCT04489654|Active Comparator|study|Test group will receive immediate implant with modified socket shield and deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) put in the buccal gap
16327098|NCT04489654|No Intervention|control|Control group will receive an immediate implant with modified socket shield technique but without deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) in the buccal gap
16327099|NCT04489641|Experimental|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau et al., 2010). This intervention is provided by clinical psychologist in primary care."
16327100|NCT04489641|Active Comparator|Treatment as usual (TAU)|Medication provided by a general practitioner.
16327101|NCT04489628|Active Comparator|Vitamin D|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
16327102|NCT04489628|Placebo Comparator|Placebo|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
16327103|NCT04489602||Intervention|Each patient complete ObsQoR-10F questionnaire 3 times (before delivery, on Day 1, on Day 2)
16327104|NCT04489589|Experimental|Midodrine|Midodrine 10mg PO/NG q8h
16327105|NCT04489589|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
16327106|NCT04489576|Active Comparator|Group (1): Treatment with keratin cure hair|Group (1): Patients will be treated with Keratin cure ® hair treatment. It will be applied once with use of a flat iron.
16327107|NCT04489576|Active Comparator|Group (2): Treatment with Qod max keratin hair|Group (2): Patients will be treated with QOD Max ® keratin hair treatment. It will be applied once with use of a flat iron.
16327108|NCT04489576|Placebo Comparator|Group (3): Treatment without keratin hair treatment|Group (3): Patients will be treated without keratin hair treatment, but the same steps of keratin application will be followed.
16327109|NCT04489563|Other|Aged persons|A feasibility test of 20-30 minutes in aged persons with an adapted Kinect-based system, i.e. i-ACT.
16327135|NCT04489368||Study Group|Patients undergoing NA-CCRT followed by Surgery
16327110|NCT04489537|Experimental|MarzAA|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route, administered on-demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis
16327111|NCT04489537|Active Comparator|Standard of Care|Standard of care administered on-demand during bleeding episodes
16327112|NCT04489524|Experimental|individualized counselor-led MI sessions and NRT|The intervention (4 individualized counselor-led MI sessions and nicotine replacement therapy [NRT]) consisted of four 60-min in-person sessions of AMI counseling and a packet of self-help smoking cessation materials. Participants were provided NRT packs and counseled on their use.
16327113|NCT04489524|Active Comparator|general health education, self-help materials, and NRT|Participants in this condition were provided with four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco. Strategies for quitting smoking were also provided to participants in this group as well as a supply of NRT and counseling on its use.
16327114|NCT04489511|Experimental|Dose 1|STG-001 given orally at Dose 1 once a day for 28 days
16327115|NCT04489511|Experimental|Dose 2|STG-001 given orally at Dose 2 once a day for 28 days
16327116|NCT04489498||Children with stiff cerebral palsy|Children with stiff cerebral palsy, aged 1 to 13 years
16327117|NCT04489498||Normal children|Normal children, aged 1 to 13 years
16327118|NCT04489485||Primary Care Providers (PCP)|20 PCP who provide well child care to teens 12-18. After randomization, 10 PCPs in the enhanced care group will use the Teen Depression Module for care.
16327119|NCT04489485||Standard care teens|All teens coming for routine well child care to the control group PCPs will have routine depression screening and Youth Health Questionnaire without goals to inform treatment as usual. They will be offered a goals text messaging conversation. Suicide screening will be at the discretion of the PCP.
16327120|NCT04489485||Enhanced care teens|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, as well as Youth Health Questionnaire with goals and then they will receive treatment guided by the Teen Depression Module and offered a depression text messaging conversation. Suicide screening will be conducted.
16327121|NCT04489485||Standard care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the control group PCPs will complete a Pediatric Symptom Checklist and Short Moods and Feelings Questionnaire, plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
16327122|NCT04489485||Enhanced care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the enhanced group PCPs will complete a Pediatric Symptom Checklist plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
16327123|NCT04489472|Experimental|PCD Group|
16327124|NCT04489472|Placebo Comparator|Control Group|
16327125|NCT04489459|Active Comparator|colistin-tigecycline|this group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12h
16327126|NCT04489459|Active Comparator|colistin-meropenem|received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
16327127|NCT04489446|Experimental|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
16327128|NCT04489446|Placebo Comparator|Control|Patients allocated to this arm will receive a placebo that will be similar in form to sildenafil pills in the interventional arm. These doses will be scheduled every 8 hours and wil be administered orally por up to seven consecutive days.
16327129|NCT04489420|Experimental|Intravenous IV ( Recurrent and Surgical ) GBM|Cohort 1A ( recurrent GBM) will receive CYNK-001 at a dose of 1.2 x 10^9 cells intravenous ( IV) on Days 0, 7, and 14 and will include up to 6 subjects. The subjects will be followed for a 42 day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose). No other treatment interventions are planned between the last day of CYNK-001. In the event of DLTs, Cohort 1C ( recurrent GBM dose-De escalation) will receive CYNK-001 at a dose of 600 x 10^6 cells (IV) on Days 0, 7, 14, and will include up to 6 subjects who will be followed for a 42-day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose. Cohort 1B (surgical cohort) will receive CYNK-001 at the maximum safe dose (MSD) (either 1.2x10^9 cells or 600x10^6 cells) (IV) at Days 0, 7, 14, and will include up to 6 subjects. The tumor resection surgery will be performed after the last CYNK-001 infusion during the DLT period.
16327130|NCT04489420|Experimental|Intratumoral IT ( Recurrent and Surgical ) GBM)|The cohort 2A or cohort 2C (recurrent GBM) IT route of administration can be started only after the safety results were acceptable from the completion of cohort 1A or Cohort 1C (IV route of administration). The Treatment Period for the IT cohorts will begin with having the Ommaya catheter placement per institutional policy, which is planned to occur within one week prior to the CYNK-001 administration on Day 0. Cohort 2A will be treated with CYNK-001 IT at 200 x 10^6 ± 50 x 10^6 cells IT on Day 0, 7 and 14 includes up to 6 recurrent GBM subjects Cohort 2C ( dose de-escalation) will be treated with CYNK-001 200 x 106 ± 50 x 106 cells IT on Day 0, and Day 7 ( only two days dosing) and include up to 6 recurrent GBM subjects. Cohort 2B ( the surgical IT cohort) will be treated with CYNK-001 at the maximum safe dose ( MSD) (either 200 x 10^6 ± 50 x 10^6 cells on Days 0, 7 and 14 or at 200 x 10^6 ±50x10^6 cells on Days 0 and 7) and include up to 6 surgical GBM subjects
16327131|NCT04489407|Experimental|rPPG Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with the rPPG app.
16327132|NCT04489407|Other|Conventional Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with conventional vital sign monitors and manual respiratory rate counts.
16327133|NCT04489381|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
16327134|NCT04489381|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
16327136|NCT04489355||CABG|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG)
16327137|NCT04489355||CABG with SVR|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR)
16327138|NCT04489355||CABG with mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with and mitral repair (MR)
16327139|NCT04489355||CABG with SVR and mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
16327140|NCT04489329|Experimental|Single Arm|Participant swallows and retrieves capsule in stool before and after ingestion of a probiotic. Capsule and stool samples are analyzed for presence of probiotic strain and compared to baseline.
16327141|NCT04489316|No Intervention|Control|Subjects in the Control group will proceed through the standard pediatric oncology curriculum. They will not receive any sessions in narrative medicine. They will take the pretest and the post-test.
16327142|NCT04489316|Experimental|Intervention|Subjects in the Intervention group will receive 2-3 sessions in narrative medicine. They will also take the pretest and the postest.
16327143|NCT04489303|Experimental|Virtual Patient Behavioral Response Training|Caring Response mobile app with a behavioral training.
16327144|NCT04489303|Active Comparator|Educational Training|Traditional educational program.
16327145|NCT04489290|Experimental|D005 Vaginal Mousse|
16327146|NCT04489290|Placebo Comparator|Placebo|
16327147|NCT04489277||Patients with Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure with silent brain infarction
16327148|NCT04489277||Patients without Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure without silent brain infarction
16327149|NCT04489264||ASCT group|patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
16327150|NCT04489264||Observation group|patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up
16327151|NCT04489251||PH subjects|"Pediatric subjects ages 2-17 years
~Subjects undergoing a clinically indicated cardiac catheterization.
~Subjects with proven or being evaluated for pulmonary hypertension in WHO classification group 1 or 3†
~Subjects will be categorized as PAH subjects if they meet the hemodynamic criteria: pulmonary artery pressure >20mmHg, pulmonary vascular resistance index >3 Woods units*m2, and wedge pressures <15mmHg."
16327152|NCT04489251||Control subjects|"Pediatric subjects ages 2-17 years
~Subjects undergoing a clinically indicated cardiac catheterization.
~Subjects can be categorized as control subjects if they do not have PH on catheterization and do not meet any exclusion criteria."
16327153|NCT04489238||Young onset Colorectal Cancer Participants|(Stool collection on newly diagnosed patients in this cohort) Participants will include patients under the age of 50 who are diagnosed with colorectal adenocarcinoma.
16327154|NCT04489238||Average onset Colorectal Cancer Participants|"(Stool collection cohort only) 166 colorectal cancer patients 50 year-old or older will serve as controls.
~Stool collection cohort only."
16327155|NCT04489225||Observational|This single arm observational study includes all patients implanted with a Medtronic Cobalt™ XT ICD or CRT-D MRI SureScan™ (with Attain StabilityQuad™ MRI SureScan™ Model 4798 Lead (ASQ)), who are enrolled in the Medtronic CareLink (CL) Network and Product Surveillance Registry (PSR). Patients will be followed per the standard of care practices of their care provider. All patients must provide a signed informed consent.
16327156|NCT04489212|Experimental|Treatment (follow-up, observation)|Patients who have recurrence or progression during treatment or observation have medical charts are reviewed every 6 months for 5 years. Patients who complete adjuvant treatment are followed for observation 3 days after radiation therapy, 1 month after radiation therapy, every 3 months after radiation therapy for 2 years, every 6 months for 1 year, and then annually for 2 years.
16327157|NCT04489199||Stroke patient|Patient included in the Dijon Stroke Registry.
16327158|NCT04489186|Experimental|All subjects|Single arm feasibility study with a wearable device intervention for cardiorespiratory and activity monitoring in subjects with cystic fibrosis.
16327159|NCT04489173|Experimental|Treatment|Treatment with TAS102
16327160|NCT04489160|Experimental|C1-inhibitor|One dose 6000 IU C1-inhibitor intravenously
16327161|NCT04489160|Placebo Comparator|Placebo|0.9% saline
16327162|NCT04489147|Active Comparator|metformin|Group A ( involve 200 patients ) will receive metformin 850 mg twice daily along the cycle of ICSI
16327163|NCT04489147|No Intervention|No Metformin|Group B ( involve 200 patients) will not receive metformin
16327164|NCT04489134|Experimental|A D B C|Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°03:Administration of a 2 mg dose of LCP-tacro Period n°04:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
16327165|NCT04489134|Experimental|B A C D|Period n°01: Administration of a 2 mg dose of LCP-tacro Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro
16327166|NCT04489134|Experimental|C B D A|Period n°01: Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro Period n°03:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
16327167|NCT04489134|Experimental|D C A B|Period n°01:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°02:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro
16327207|NCT04488887||Choroidal neovascularization group|Patients with active choroidal vascularization without scarring will be recruited
16327168|NCT04489121|Experimental|omalizumab preseasonal treatment|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season. Rescue medication could be used during pollen seasons.
16327169|NCT04489121|No Intervention|control|No preseasonal treatment was performed. Rescue medication could be used during pollen seasons.
16327170|NCT04489108|Experimental|Tranexamic Acid with Standard Medical Treatment|Arm A will Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours along with standard medical and interventional (Endoscopy) therapy.
16327171|NCT04489108|Active Comparator|Placebo + Standard Medical treatment|Arm B will receive similar volume of isotonic solution (saline) along with standard medical and interventional (Endoscopy) therapy.
16327172|NCT04489095|Experimental|Electrophysiology Study pre and Post TAVR|In all patient's undergoing TAVR after informed consent will undergo an electrophysiology study pre and post device deployment in order to determine the need for permanent pacemaker implantation or further testing/monitoring.
16327173|NCT04489082|Experimental|Near Infrared Laser Therapy|"On the days of each near-infrared therapy session, patients will undergo 10 minutes of transcranial infrared laser stimulation.
~The laser dose for all conditions will be a 3.4 W continuous laser wave, at a 1064 wavelength, with irradiance (power density) at 250 milli-Watts/cm2. All groups will have treatment once a week (10 minutes per session) for 5-6 weeks. For Alzheimer's, the site targeted will be the right prefrontal cortex. Parkinson's patients will have laser delivered to the brain stem, bilateral temporal lobes. TBI/CTE patients will have the laser stimulation site dependent on location of injury. Patients with depression/anxiety will have laser stimulation applied to the prefrontal area of the head."
16327174|NCT04489069|Other|Clinical, neuropsychological and MRI evaluations|
16327175|NCT04489056||Study group|This group will consist of 50 pregnant women, who experienced pPROM between 22+5 and 28+0 gestational weeks, either presenting at the primary study site, or being referred from other hospitals, and delivered at preterm by cesarean section.
16327176|NCT04489056||Control group|This group will consist of 50 pregnant women, who are scheduled for elective cesarean section at the outpatient department of the primary study site, between a 32+0 and 37+0 gestational weeks, and delivered at term by cesarean section.
16327177|NCT04489043|Experimental|Exercise and healthy life style recommendations|A planned exercise programme to test the impact of this treatment. An Oral Glucose Tolerant Test (OGTT) at intermediate time points in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
16327178|NCT04489017|Experimental|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day for 24 weeks
16327179|NCT04489017|Placebo Comparator|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day for 24 weeks
16327180|NCT04489004|Experimental|Driver ablation+CPVI|Driver ablation plus CPVI (circumferential pulmonary vein isolation)
16327181|NCT04489004|Active Comparator|Stepwise ablation|Stepwise ablation
16327182|NCT04488991||the woman who has just HPV infection|the woman who is between 30-65 years old, who is participate this research, and has just HPV infection in cervix.
16327183|NCT04488991||the woman who has just nabothian cyst|the woman who is between 30-65 years old, who is participate this research, and has just nabothian cyst in cervix.
16327184|NCT04488991||the woman who has both nabothian cyst and HPV infection|the woman who is between 30-65 years old, who is participate this research, and has both nabothian cyst in cervix.
16327185|NCT04488978|Experimental|Irbesartan low/Amlodipine low|Irbesartan low & Amlodipine low, once daily for 8 weeks
16327186|NCT04488978|Experimental|Irbesartan low/Amlodipine high|Irbesartan low & Amlodipine high, once daily for 8 weeks
16327187|NCT04488978|Experimental|Irbesartan high/Amlodipine low|Irbesartan high & Amlodipine low, once daily for 8 weeks
16327188|NCT04488978|Experimental|Irbesartan high/Amlodipine high|Irbesartan high & Amlodipine high, once daily for 8 weeks
16327189|NCT04488978|Active Comparator|Amlodipine low|Amlodipine low, once daily for 8 weeks
16327190|NCT04488978|Active Comparator|Amlodipine high|Amlodipine high, once daily for 8 weeks
16327191|NCT04488978|Active Comparator|Irbesartan low|Irbesartan low, once daily for 8 weeks
16327192|NCT04488978|Active Comparator|Irbesartan high|Irbesartan high, once daily for 8 weeks
16327193|NCT04488965|Experimental|Autologous neural cell ecosystems - ANCE|The patient will undergo first surgery under general anesthesia for the collection of the cortical biopsy (5x5x5 mm biopsy of non-dominant frontal cortex). After the production of ANCE from the cortical biopsy, which last 8 to 12 weeks, the patient will undergo a second neurosurgery, for the stereotaxic reimplantation of ANCE under general anesthesia.
16327194|NCT04488952|Experimental|nerve block combined with general anesthesia group|Patients in this group receive nerve block combined with general anesthesia.
16327195|NCT04488952|Experimental|spinal anesthesia group|Patients in this group receive spinal anesthesia.
16327196|NCT04488952|Placebo Comparator|control group|This group is used to obtain the learning effect.
16327197|NCT04488939|Experimental|Bilateral treatment|
16327198|NCT04488926|Active Comparator|Group 1|Normast® MPS (mPEA and umPEA 300mg + 600mg) microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
16327199|NCT04488926|Placebo Comparator|Group 2|Placebo microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
16327200|NCT04488913|Other|Standard of Care Treatment|Exposure to traditional evaluation for suspected acute coronary syndrome (ACS) with ECG, 0- and 3-hour troponin testing using the 99th percentile as the upper reference limit, and application of the History, EKG, Age, Risk factors, and troponin (HEART) score.
16327201|NCT04488913|Active Comparator|RACE-IT pathway|Exposure to new protocol for suspected ACS, which includes the use of 0- and 1-hour ECG and high-sensitivity troponin testing and application of the HEAR score (a modification of the HEART score)
16327202|NCT04488900|Experimental|CKD-508 single dose|Single dose administration of CKD-508
16327203|NCT04488900|Experimental|CKD-508 multiple dose|Multiple dose administration of CKD-508
16327204|NCT04488900|Placebo Comparator|Placebo|Matching placebo
16327205|NCT04488887||Diabetic retinopathy Group|Patients with non-proliferative and proliferative diabetic retinopathy with clear media will be recruited.
16327206|NCT04488887||Myopia Group|Patients with different grades of myopia, with accurate segmentation will be recruited
16327208|NCT04488887||Healthy controls|Healthy individuals without retinal disorders will be included for comaprison
16327209|NCT04488874|Experimental|Sodium Lactate|Intravenous Molar Sodium Lactate is administered during the first surgical incision. The dose is 2.5mL/kg.
16327210|NCT04488874|Active Comparator|Mannitol 20%|Intravenous mannitol 20% is administered during the first surgical incision. The dose is 5mL/kg (1g/kg).
16327211|NCT04488861||IVF-conceived|Those who have conceived by IVF (for whatever indication); target 80 participants of which it is anticipated 20 would have conceived by frozen embryo transfer IVF.
16327212|NCT04488861||Spontaneously conceived|Those who have conceived spontaneously (within 12 months and without use of hormonal or other contraception); target 20 participants
16327213|NCT04488861||Ovulation induction-conceived|Those who have conceived by ovulation induction (after more than 12 months); target 20 participants.
16327214|NCT04488848|Placebo Comparator|continous glucose|continous glucose infusion (60 grams over 3 hours)
16327215|NCT04488848|Experimental|bolus (excursion)|3 x 20 grams of glucose as a bolus over 6 minutes at t0, 60 minutes and 120 minutes
16327216|NCT04488835|Experimental|TENS Therapy Group|patients in this group received TENS therapy in addition to routine physical therapy
16327217|NCT04488835|Experimental|PEMFT group|patients in this group received PEMFT therapy in addition to routine physical therapy
16327218|NCT04488822|Experimental|Pexidartinib|
16327219|NCT04488809|Experimental|Deep Water Running|Participants in this group will perform running in a vertical position in water. The sessions will be held in deep pool where the feet of the participants will not touch the ground.
16327220|NCT04488809|Active Comparator|Treadmill Running|Participants in this group will perform running on a treadmill.
16327221|NCT04488809|No Intervention|Control|Participants in this group will not interfere regular exercise for 8 weeks.
16327222|NCT04488796|Experimental|Assigned Strategies: Opt-in|"Participants in this group will be assigned two behavioural strategies under the theme of moving more and will be asked to Place a check in the box [agree] if you will breakup your sitting throughout your work hours by X this week. The strategy statement is followed up by; OR, click the next button at the bottom. Within the opt-in condition, the default is to not participate (by clicking next): participants are not required to explicitly state they do not want to do the strategy"
16327223|NCT04488796|Experimental|Assigned Strategies; Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Active choice condition, participants will be required to either, Place a check in one box: I will break up my sitting throughout my work hours by [strategy] this week or, I will not break up my sitting throughout my work hours by [strategy] this week."
16327224|NCT04488796|Experimental|Assigned Strategies; Enhanced Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Enhanced Active Choice condition, participants will to required to choose between two alternatives: I will break up my sitting throughout my work hours this week by [strategy] to reduce my risk of diabetes, mental health issues and other detrimental health outcomes and I want to win the eGiftcard or, I will not break up my sitting time during my work hours by [strategy] this week even if it means I increase my risk of developing diabetes, mental health issues and other detrimental health outcomes and I don't care about winning an eGiftcard"
16327225|NCT04488796|Experimental|Choice of Assignment; Opt-in|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
16327226|NCT04488796|Experimental|Choice of Assignment; Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
16327227|NCT04488796|Experimental|Choice of Assignment; Enhanced Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
16327228|NCT04488783|Experimental|Glioblastoma patients|newly diagnosed GB who underwent at least partial resection of the tumor surgically
16327229|NCT04488770|Experimental|Part 1 (SAD) Cohort 1:Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
16327230|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 1:Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
16327231|NCT04488770|Experimental|Part 1 (SAD),Cohort 2: Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 500 mg, 750 mg and 900 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
16327232|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 2: Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
16327270|NCT04488575|Experimental|EDP1815|Patients will receive EDP1815 in addition to standard of care
16327271|NCT04488575|Placebo Comparator|Placebo|Patients will receive placebo in addition to standard of care
16327233|NCT04488770|Experimental|Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg|In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.
16327234|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 3: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
16327235|NCT04488770|Experimental|Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg|GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
16327236|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 4: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
16327237|NCT04488770|Experimental|Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg|GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
16327238|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 5: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
16327239|NCT04488770|Experimental|Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg|GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.
16327240|NCT04488770|Placebo Comparator|Part 2(MAD),Cohort 6: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
16327241|NCT04488757|Other|Study Arm|All participants enrolled in the study will undergo baseline fMRI and baseline and follow-up (4-month post-baseline) assessment of stress physiology (i.e., allostatic load). Treatment as usual information will be gathered for all participants to assess observational intervention response.
16327242|NCT04488744|Experimental|nicotine infusion 0.2mg|"nicotine infusion
~0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) The day order will be randomized over 5 days."
16327243|NCT04488744|Experimental|nicotine infusion 2.0mg|0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries),
16327244|NCT04488744|Experimental|nicotine infusion 1.0mg|1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries)
16327245|NCT04488744|Experimental|nicotine infuison 1.0mg|1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
16327246|NCT04488744|Placebo Comparator|Saline|saline delivered over 2minutes ,2.5minutes,10 minutes
16327247|NCT04488731||NW/MCC|Normal body mass index (BMI) / with moderate coffee consumption
16327248|NCT04488731||NW/HCC|Normal body mass index (BMI) / with heavy coffee consumption
16327249|NCT04488731||OW/MCC|Overweight / with moderate coffee consumption
16327250|NCT04488731||OW/HCC|Overweight / with heavy coffee consumption
16327251|NCT04488718|Experimental|EnergieShake® Junior Powder Complete (test)|EnergieShake® Junior Powder Complete will be consumed by children, as a supplement to normal diet, over a period of 7 day period to determine its acceptability (liking, compliance) and tolerance (gastro-intestinal tolerance). The dose will be the same as currently consumed product (all children recruited to the study will be consuming an oral nutritional supplement).
16327252|NCT04488705|Experimental|Single ascending dose|
16327253|NCT04488705|Experimental|Repeat dose - 7 days|
16327254|NCT04488705|Experimental|Repeat dose - 14 days|
16327255|NCT04488705|Experimental|Repeat dose - 7 days with SABA|
16327256|NCT04488692|Experimental|Model 1|Participants will receive 2 sessions of functional training per day, 15-min per session.
16327257|NCT04488692|Active Comparator|Model 2|Participants will receive 1 session of functional training and 1 session of sham intervention (therapist visiting and education) per day, 15-min per session.
16327258|NCT04488679|Experimental|PRF along with MTA|10 ml of the participant blood will be drawn into 10 ml test tubes without an anticoagulant and centrifuged immediately .centrifugation will be done using a tabletop centrifuge for 12 min at 2700 rounds per minute. The resultant product will exhibit three layers. platelet-poor plasma at the surface, PRF clot in the middle, and red blood cells at the bottom. Sterile tweezers inserted into a test tube to retrieve the PRF clot. The prepared fibrin membrane will be gently packed over the pulp
16327259|NCT04488679|Active Comparator|MTA direct pulp capping|MTA is primarily calcium oxide in the form of tricalcium silicate, dicalcium silicate and tricalcium aluminate. Bismuth oxide is added for radiopacity, MTA is considered a silicate cement rather than an oxide mixture, a so its biocompatibility is due to its reaction products. MTA elevates the expression of transcription factors, induces dentin bridge formation, possesses biocompatibility9, and sustains a high pH for a longer duration and a close physiochemical seal with dentin that forms an insoluble barrier to prevent microleakag
16327260|NCT04488666|Experimental|npSIMS|Group will receive the Aatru Medical npSIMS device
16327261|NCT04488653|Experimental|Oligopin®|Oligopin® contains French Maritime Pine Bark Extract
16327262|NCT04488653|Placebo Comparator|Placebo|Placebo is a mixture of different inert compounds
16327263|NCT04488640||Thyroid fine needle aspiration biopsy group|A group of 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis.
16327264|NCT04488640||Thyroid core needle aspiration biopsy group|A patient group with 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis and who underwent a core needle biopsy again. A total thyroidectomy was performed in 88 of these patients. Surgical pathology results, core needle results and TIRADS scores were compared.
16327265|NCT04488627||Critically ill patients|Critically ill patients hospitalised in the intensive care unit indicated to echocardiographic examination.
16327266|NCT04488614||Early Stage Breast Cancer (Stage I and II)|Consecutive early stage breast cancer patients who are treated according to the national guidelines. Observation over 11 years.
16327267|NCT04488601|Experimental|Rapamycin 5|Rapamycin 5 mg/week
16327268|NCT04488601|Experimental|Rapamycin 10|Rapamycin 10 mg/week
16327269|NCT04488601|Placebo Comparator|Placebo 1|Placebo once per week
16327272|NCT04488562||Patients with COVID-19|Patients with proven COVID-19 and abnormalities on chest X-Ray/HRCT, admitted at the hospital. Patients are included around the time of discharge from the hospital or at their regular outpatient clinic visit 6 weeks after discharge, depending on the clinical status of the patient at time of discharge.
16327273|NCT04488536||Frail patients|Clinical Frailty Scale level 5-9
16327274|NCT04488536||Nonfrail patients|Clinical Frailty Scale level 1-4
16327275|NCT04488523|Experimental|Family-based Telehealth Treatment|A family-based telehealth intervention.
16327276|NCT04488497|Experimental|Peer coach guided online learning program|
16327277|NCT04488497|Placebo Comparator|Self-administered online learning program|
16327278|NCT04488484|Other|Arm|"Serology test results
~The Paris Saint- Joseph Hospital Group staff was submitted to a 2 times serology test: the 1st took place between April, 20th to May, 12th and the second, between May, 26th to June, 12th. The employees presenting positive antibodies titers to SARS-CoV-2 will be contacted and asked for a 12 month follow-up study organized by the Occupational Health Team and the team of COVID-19 Serology referents appointed to carry out and coordinate the procedure. Each enrolled member will receive a letter with containing an information letter describing the study with a written consent form and a questionnaire enabling the data to be collected individually on the COVID-19 infection."
16327279|NCT04488471||high-risk group|IBD patients who were high risk of infection and were shielding
16327280|NCT04488471||low-risk group|IBD patients who were low risk of infection and were following standard quarantine guidance
16327281|NCT04488471||young people from affiliated study|32 IBD patients from an affiliated study
16327282|NCT04488458|Experimental|MBEC and MIC susceptibility testing|"For all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin, fusidic acid, ciprofloxacin/levofloxacin and clindamycin.
~MBEC cut-off for replacement with 2nd or 3rd line antibiotic: RIF MBEC/MIC > 8; LEV MBEC/MIC > 5; FUS MBEC/MIC > 3; CLI MBEC/MIC > 4; LIN MBEC/MIC > 2; T/S MBEC > MIC
~Second line of treatment:
~RIF and Fusidic acid 500 mg TID (ter in die) RIF and Clindamycin 450 - 600 mg TID LEV and Fusidic acid 500 mg TID LEV and Clindamycin 450 mg TID
~Third line of treatment:
~Linezolid 600 mg BID (bis in die) Sulfamethoxazole/Trimethoprim 800/160 mg TID Clindamycin 450 mg TID and Fusidic acid 500 mg TID"
16327283|NCT04488458|Active Comparator|MIC susceptibility testing|If the causative bacterium is susceptible according to MIC diagnostics, the patient will follow the first line of treatment: Rifampicin 750-900 mg/day + Levofloxacin 750 mg BID
16327284|NCT04488445|Experimental|Strength Training|The intervention group performs a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 RM) and 3 minutes of resting time between sets.
16327285|NCT04488445|Placebo Comparator|Stretching|The control group performs 3 exercises of stretching and balance during one minute each and three sets. One minute of resting time between sets.
16327289|NCT04488406||Graves' Orbitopathy|Graves' Orbitopathy patients who undergoing orbital decompressive surgery
16327290|NCT04488406||Control Patients|Patients undergoing eye surgery for unrelated reasons
16327291|NCT04488393||Pregnancies with multiple gestations|
16327292|NCT04488380|Experimental|high-viscosity glass ionomer restoration|One of the carious mandibular 2nd molar teeth (according to randomisation) will be restored with high-viscosity glass ionomer restoration (Equia, GC)
16327293|NCT04488380|Experimental|nano-hybrid composite resin|One of the carious mandibular 2nd molar teeth will be restored with nano-hybrid composite resin (GrandioSO, Voco)
16327294|NCT04488367|Experimental|Early TXA|Experimental group will receive 10 mg/kg IV TXA while in the Emergency Department, and repeat preoperative and postoperative doses.
16327295|NCT04488367|Other|Control|Control group will receive 100 mL 0.9% normal saline in the Emergency Department, and 10 mg/kg IV TXA before skin incision and again in post anesthesia care unit.
16327296|NCT04488354|Experimental|CLBR001 treated patients|Patients who have been administered with CLBR001
16327297|NCT04488341|Other|aerobic exercises in addition to diet|The study group will receive aerobic exercises in addition to diet recommendations
16327298|NCT04488341|Other|diet recommendations|control group will receive diet recommendations
16327299|NCT04488328|Experimental|Magnetic Therapy Group|patients received the routine medical treatment (Bisphosphonates, Calcium, and Vitamin D) in addition to pulsed magnetic therapy on the pelvic region for 12 weeks
16327300|NCT04488328|Experimental|Exercise group|patients received the routine medical treatment in addition to moderate-intensity aerobic exercise for 12 weeks
16327301|NCT04488328|Experimental|Combined Magnetic Therapy and Exercise Therapy group|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
16327302|NCT04488315|Experimental|The dexamethasone plus ropivacaine group|
16327303|NCT04488315|Experimental|The dexamethasone lipid microsphere plus ropivacaine group|
16327304|NCT04488315|Active Comparator|The ropivacaine group|
16327305|NCT04488302||Implant group|Patients with 1 or more implants with CBCT, ultrasound and open-bone images
16327306|NCT04488289|Other|Parallel measurement of blood pressure|Office blood pressure, self-directed and ambulatory blood pressure measurement.
16327307|NCT04488276||Pregnant women|Non smoking pregnant and post-partum women
16327308|NCT04488276||Smoking fathers|Expectant or new fathers who smoke
16327309|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
16327310|NCT04488250|Other|Low-to-mid functioning HIV/AIDS patients|Low-to-mid functioning HIV/AIDS patients greater than 18 years of age with stroke co-morbidity.
16327311|NCT04488250|Other|Stroke survivors|Stroke survivors greater than 18 years of age with hemiplegia with and without HIV/AIDS.
16327395|NCT04487782||Low SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be Caucasian/White.
16327312|NCT04488224|Experimental|Patients receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.
~Participants in this arm undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. These participants do not require an additional conventional CBCT as the SOC conventional CBCT images are used to benchmark the experimental Nano-X CBCT scans for evaluation of the primary outcome measure."
16327313|NCT04488224|Experimental|Patients not receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.
~Participants in this arm do not undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. As such these participants will receive an additional conventional CBCT scan on standard equipment which used to benchmark the experimental NAno-X CBCT scans for evaluation of the primary outcome measure."
16327314|NCT04488211||Prospective survey respondents|Invitations to participate in the survey will be emailed on three occasions to selected fertility specialists worldwide who are affiliated to a public or private fertility clinic.
16327315|NCT04488198|No Intervention|Control group|20 CIBD patients do not receive acupuncture or placebo-acupuncture.
16327316|NCT04488198|Active Comparator|Acupuncture group|20 CIBD patients receive 8 sessions of acupuncture therapy with 0,3 x 30mm needles (asia-med special number 16).
16327317|NCT04488198|Placebo Comparator|Placebo group|20 CIBD patients receive 8 sessions of sham acupuncture with placebo-needles 0,3 x 30mm (Streitberger).
16327318|NCT04488185|Experimental|Secukinumab 300mg|Randomized in a 2:1 ratio to secukinumab or placebo
16327319|NCT04488185|Placebo Comparator|Placebo|Randomized in a 2:1 ratio to secukinumab or placebo
16327320|NCT04488172|Experimental|Epilepsy subjects|Receiving multi-vitamins supplementation (B6, B9, D, E, Q10) for 6 months trial
16327321|NCT04488159|Experimental|Immunoscore stratification|"Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly, standardised physical excise (stair walking excise twice a week for 12 weeks), which will be monitored by an electronic sports device.
~Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)
~Immunoscore high (I high; I4): no adjuvant treatment."
16327322|NCT04488159|Active Comparator|TNM stratification|"TNM-based low-risk (pT1, pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)
~TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)"
16327323|NCT04488133|Experimental|Nusinersen 12 mg|Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
16327324|NCT04488120|Experimental|Occlutech septal occluder ( Figulla Flex II)|Occlutech septal occluder (Figulla Flex II)
16327325|NCT04488120|Active Comparator|Amplatzer Septal Occluder (ASO)|St. Jude AGA septal occluder (Amplatzer ASO)
16327326|NCT04488107|Experimental|Dose escalation cohort of FCN-437c|"This study plans to start escalating from 50 mg QD, through 100 mg, 200 mg, 300 mg, 450 mg, to 600 mg.
~Participants will receive FCN-437c in sequential 28-day cycles which are made up of monotherapy QD for 21 days followed by a 7 day rest period.
~Participants must be histologically or cytologically diagnosed with ER+/ HER2- advanced breast cancer."
16327327|NCT04488107|Experimental|Dose expansion cohort of FCN-437c + letrozole|"The dose expansion stage will be initiated after escalating to MTD.
~Six patients will be treated with FCN-437c combined with letrozole.
~DLT assessment and PK blood collection will be completed in the first 28-day cycle.
~If DLT does not occur in the first three patients, 15 additional patients were enrolled to complete the expansion study of MTD group.
~If one DLT occurs in the first three patients, three additional patients will be enrolled onal patients were enrolled and completed the MTD group.
~Patients will be evaluated every 8 weeks until disease progression, intolerable toxicity, death, investigator's decision or patient's voluntary withdrawal from the study."
16327328|NCT04488094|Experimental|Heart transplantation|Patients suspected of having acute heart allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
16327329|NCT04488094|Experimental|Liver transplantation|Patients suspected of having acute liver allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
16327330|NCT04488081|Active Comparator|Remdesivir plus standard of care|"See the Full EUA Prescribing Information for complete dosage, administration, and preparation instructions.
~Remdesivir is available as a concentrated solution.
~The recommended dose for adults weighing 40 kg and higher is a single loading dose of 200 mg on Day 1 followed by once- daily maintenance doses of 100 mg from Day 2.
~The optimal duration of treatment for COVID-19 is unknown.
~For patients requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO), the recommended total treatment duration is 10 days.
~For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days.
~Administer remdesivir via IV infusion over 30 to 120 minutes."
16327331|NCT04488081|Experimental|Pulmozyme plus remdesivir|Nebulized aerosol medication that is inhaled recombinant DNAse. Dosing for high-flow nasal cannula (HFNC) 2.5 mg/2.5 mL nebulized BID; for mechanical ventilation (MV) 5.0 mg/10 mL nebulized BID. Treatment course is 14 days total (return to room air or baseline oxygen use for 24hours, or until hospital discharge, whichever comes first)
16327349|NCT04488016|Experimental|Cohort 1- Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC. In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
16327332|NCT04488081|Experimental|IC14 plus remdesivir|Monoclonal antibody that blocks CD14, a cell surface and soluble protein that acts as a cofactor in triggering innate immune inflammation to pathogen- and damage-associated molecular patterns. Dosing: 4 mg/kg/day on Day 1, then 2 mg/kg/day on Days 2-4 as an IV infusion over 2 hours via peripheral or central vein. Additional Exclusions: Pre-existing thrombocytopenia (platelets <50,000/mm3); presence of serious coexisting infection, defined as HIV infection not virally suppressed and with pre-hospitalization CD4 counts ≤ 500 cell/mm3; or active tuberculosis or a history of inadequately treated tuberculosis; or active hepatitis B or hepatitis C viral infection (for questions, consult chaperones).
16327333|NCT04488081|Experimental|Celecoxib & Famotidine plus remdesivir|Histamine-2 (H2) receptor antagonist and inverse agonist acts via a well-documented mechanism of action involving histamine H2 receptor blockade as well as interference with mast cell autocrine amplification of activation and degranulation which may reduce the proinflammatory response. The course of treatment is a total of 21 days. High dose 80 mg PO/PNGT four times daily (QID) for 7 days. Upon completion of the high dose, subjects should receive a lower 40 mg PO twice daily (BID) for a course of 14 days. Subjects will continue regimen upon discharge should it occur prior to 21 days from initiation of medication.
16327334|NCT04488081|Experimental|Narsoplimab plus remdesivir|4 mg/kg, given as a 30-minute intravenous infusion (up to maximum of 370 mg/ infusion) twice weekly. If weekend narsoplimab administration is not feasible, administration day can be worked around as long as the intervals do not exceed 2-3 days
16327335|NCT04488081|Experimental|Aviptadil plus remdesivir|100μg (microgram) in 1ml normal saline per dose. Drug solution is provided in a syringe for convenient filling of nebulizer and should be used neat (undiluted)1 ml total per dose for intubated and non-intubated subjects. Drug should be administered gradually, and it will take approximately 5 minutes to administer. Drug should be administered q8H, for a maximum of 14 days(maximum 42 doses)
16327336|NCT04488081|Experimental|Cyclosporine plus remdesivir|Dosing: 5mg/kg/ day given PO/NGT in two doses daily for 5 days while hospitalized as inpatients. Prior and after administration through an NGT/OGT, flush the NGT or OGT with 5-10ml of water. See instructions for dose adjustment based on CsA levels.
16327337|NCT04488068|Experimental|Magnetic Stimulation|Patients will be subjected to TPMS.
16327338|NCT04488068|No Intervention|Sham TPMS|Patients will be subjected to sham TPMS
16327339|NCT04488055|Experimental|Crisis Line Facilitation (CLF)|This single-session intervention addresses the individuals' perceived barriers and facilitators of crisis line use during periods of suicidal crisis.
16327340|NCT04488055|Active Comparator|Enhanced Usual Care (EUC)|Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with the NSP Lifeline and a list of outpatient mental health and substance use resources and encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms.
16327341|NCT04488042|Experimental|Stapler-less|after the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
16327342|NCT04488042|Active Comparator|Conventional Stapler|no reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
16327343|NCT04488029|Experimental|Experimental Group|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Research staff will remotely setup a PCT account for the subjects, and provide instructions for logging into the PCT application. During the treatment period, patients will be instructed to use PCT for at least 30 minutes a day and at least 5 days a week. Performance data (accuracy and latency) will be reported by the PCT software to the treating clinician and will be used to modify task assignment over time. PCT tracks usage of the program so that research staff can access automated reporting of subject use to monitor participant adherence to the treatment program.
16327344|NCT04488029|Active Comparator|Control Group 1 [Conventional Workbook Therapy]|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Subjects in the control group will be told they will have access to 3-months of PCT after their participation in the study has concluded. Subjects in this group will be provided with a standard regime of paper workbooks and instructions to complete approximately 30 minutes a day at least 5 days a week.
16327345|NCT04488016|Experimental|Cohort 1 -Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
16327346|NCT04488016|Experimental|Cohort 2- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
16327347|NCT04488016|Experimental|Cohort 3- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
16327348|NCT04488016|Experimental|Cohort 4 - Part 1|Subjects will be randomized to one of 4 sequences: ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
16327350|NCT04488016|Experimental|Cohort 2 - Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC.In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
16327351|NCT04488003|Experimental|Part A: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
16327352|NCT04488003|Experimental|Part B: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
16327353|NCT04488003|Experimental|Part B: Physician's choice of treatment|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice). If a patient progresses on physician's choice of treatment, crossover to the ulixertinib arm is permitted.
16327354|NCT04487990|No Intervention|Control group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l.
16327355|NCT04487990|Experimental|Intervention group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l associated with unfractionated heparin at 10U / Kg / h.
16327356|NCT04487977||Surveyed professionals|
16327357|NCT04487964|Active Comparator|the conventional therapy according to the MOH protocol.|Patients who are receiving conventional therapy according to the MOH protocol.
16327358|NCT04487964|Active Comparator|conventional therapy +Liquorice cap and Boswellia Serrata gum|Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy
16327359|NCT04487951||Moderate|Moderate: moderate COVID -19 pneumonia
16327360|NCT04487951||Severe|_severe COVID-19 pneumonia
16327361|NCT04487938||Tobacco use and/or alcohol consumption|
16327362|NCT04487938||No tobacco use and/or alcohol consumption|
16327363|NCT04487925|Experimental|Intervention group: up to 3 modified natural cycles|Patients will receive up to 3 modified natural cycles in stead of a conventional ovarian hyperstimulation
16327364|NCT04487925|No Intervention|Control group: conventional ovarian stimulation|Patients will receive a conventional ovarian stimulation with corifollitropin alfa.
16327365|NCT04487912|Active Comparator|Injection of 99m-Tc Tilmanocept|
16327366|NCT04487912|Active Comparator|Injection of 99m-Tc Nanocolloid|
16327367|NCT04487899||Instructors group|Group of flight instructors at the reactor school.
16327368|NCT04487899||Students group|Group of students at the reactor school.
16327369|NCT04487886|Experimental|Duvelisib|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.
16327370|NCT04487886|Placebo Comparator|Placebo|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.
16327371|NCT04487873||Bronchiectasis|Having been diagnosed with non-cystic fibrosis bronchiectasis
16327372|NCT04487873||Healthy individuals|Healthy individuals without chronic disease
16327373|NCT04487860|Experimental|AS012 dose regimen I|Oral
16327374|NCT04487860|Experimental|AS012 dose regimen II|Oral
16327375|NCT04487860|Experimental|AS012 dose regimen III|Oral
16327376|NCT04487860|Experimental|AS012 dose regimen IV|Oral
16327377|NCT04487860|Placebo Comparator|Placebo|Oral
16327381|NCT04487834|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
16327382|NCT04487834|Experimental|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
16327383|NCT04487821|Experimental|Experimental Group|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. This contained 4 types of progressive activities. Respectively every type contains 2 to 4 tasks, performed in sets of 10 repetitions for 4 weeks.
~Results were obtained by using Balance scoring system, and physical performance test for speed and agility"
16327384|NCT04487821|No Intervention|Control Group|"Control group: (Group B) Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. They were asked to perform the regular drills.
~Results were obtained using Balance Error scoring system and physical performance test for speed and agility."
16327385|NCT04487808|Active Comparator|Average American Diet|Diet representative of average American intake in terms of diet quality measured by the Healthy Eating Index-2015.
16327386|NCT04487808|Active Comparator|Average American Diet + Pecans|Diet that approximates average American intake in terms of diet quality measured by the Healthy Eating Index-2015, but includes 2 oz./day of pecans.
16327387|NCT04487808|Active Comparator|Healthy Diet + Pecans|High diet quality, measured by Healthy Index-2015 score >95, and includes 2 oz./day of pecans.
16327388|NCT04487795||under 18 years old|
16327389|NCT04487795||18-40 years old|
16327390|NCT04487795||41-60 years old|
16327391|NCT04487795||over 60 years old|
16327392|NCT04487782||High SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be African-American/Black.
16327393|NCT04487782||High SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be Caucasian/White.
16327394|NCT04487782||Low SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be African-American/Black.
16327517|NCT04487002|Experimental|group A|underwent localized resection
16327396|NCT04487756|Experimental|Atezo+DCvac|"- Induction (4 cycles, every 3 weeks): Carboplatin area under the curve (AUC) 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle) Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)
~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks) DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33."
16327397|NCT04487743|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
16327398|NCT04487743|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
16327399|NCT04487730|Experimental|"Engage & Connect Psychotherapy"|"Engage & Connect, a modified adapted version of Engage. Its principal intervention is social reward exposure - facilitating engagement in rewarding and meaningful social activities with significant others. In Engage-S therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding social activities of their choice."
16327400|NCT04487730|Active Comparator|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
16327404|NCT04487704|Other|Camrelizumab in the treatment of liver cancer|Camrelizumab intravenous infusion (no need for prophylactic administration), no less than 30 min
16327405|NCT04487691|Experimental|Platelet Lysate|Inhaled nebulized platelet lysate (PL), 2-ml 1x per day for 8 weeks.
16327406|NCT04487691|Active Comparator|Saline|Inhaled nebulized normal sterile saline, 2-ml 1x per day for 8-weeks.
16327407|NCT04487678|Experimental|Low-dose KE|141 mg/kg bodyweight of ketone esters
16327408|NCT04487678|Experimental|High-dose KE|282 mg/kg bodyweight of ketone esters
16327409|NCT04487665||positive COVID-19|patient diagnosed by nasopharyngeal positive COVID-19
16327410|NCT04487652|Placebo Comparator|Placebo spray|Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray
16327411|NCT04487652|Experimental|CoQ10 spray|The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.
16327412|NCT04487639|Experimental|Cohort : patients needing oncofertility preservation|
16327413|NCT04487626|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
16327414|NCT04487613|Active Comparator|Moringa oleifera leaf|Participants received Moringa oleifera leaf 450 mg capsule orally twice daily for 3 days.
16327415|NCT04487613|Placebo Comparator|Placebo|Participants received placebo capsule orally twice daily for 3 days.
16327416|NCT04487600|Experimental|Active Voiding Trial|At the completion of surgery, a Foley catheter was left in place. When the patient was determined to be ambulatory by the recovery room nurse, the bladder was backfilled with 300cc of sterile normal saline. Voiding 200cc or (2/3) of the backfill amount was considered passing.
16327417|NCT04487600|No Intervention|Passive Voiding Trial|At the completion of surgery, a Foley catheter was removed in the operating room. Study participants were allowed six hours to void spontaneously, with 200cc being considered adequate consistent with institution standard practice. At the completion of six hours, if spontaneous voiding has not occurred, a bladder scan was performed and additional time was allowed based on bladder volume with criteria previously established as institution standards based on published practices.
16327418|NCT04487587|Active Comparator|Active|Cediranib 20mg tablet OD (5 days out of 7) and Olaparib 300mg tablet BD (continuous) + standard of care
16327419|NCT04487587|Placebo Comparator|Placebo|Placebo Cediranib 20mg tablet OD (5 days out of 7) and Placebo Olaparib 300mg tablet BD (continuous) + standard of care
16327420|NCT04487574|Experimental|XC221|"XC221 100 mg orally.
~1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period."
16327421|NCT04487574|Placebo Comparator|Placebo|"Placebo orally.
~1 tablet of Placebo 2 times a day during 14 days of treatment period"
16327422|NCT04487561|Other|aspirative drainage|Drainage is the usual treatment after axillary lymphadenectoma for breast cancer
16327423|NCT04487561|Active Comparator|Hemopatch|The hemopatch group will be the group without drainage and with a product patch
16327426|NCT04487535|Other|Standard Total Knee Arthroplasty Surgery|Surgery performed by one orthopedic surgeon
16327427|NCT04487522||Retromuscular ventral hernia repair|These subjects will undergo an open, a laparoscopic, or a robotic-assisted retromuscular ventral hernia repair.
16327428|NCT04487522||Retromuscular TAR ventral hernia repair|These subjects will undergo an open or a robotic-assisted retromuscular transversus abdominis release (TAR) ventral hernia repair.
16327429|NCT04487483|Experimental|Sleep App|"Participants in this condition will receive full free access to the Pro version of the sleep app and asked to use the app every day for three months."
16327430|NCT04487483|No Intervention|Control|Participants in this condition will be asked to continue their life as normal and abstain from downloading or using any sleep aid and/or sleep tracker app for three months.
16327431|NCT04487470|Experimental|Flavored Filtered Cigars|Half of the group will be randomized to start with flavored filtered cigars (FCs) at the second visit and cross over to unflavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
16327432|NCT04487470|Experimental|Unflavored Filtered Cigars|Half of the group will be randomized to start with unflavored FCs at the second visit and cross over to flavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
16327433|NCT04487457||Cancer|Patients receiving chemotherapy alone after immunotherapy for NSCLC or bladder cancer or ENT cancer
16327434|NCT04487444|Experimental|Ta1 treatment arm|Ta1 at a dose of 1.6 mg will be administered SC in 1 mL of diluent daily for a total of 1 week, in addition to standard of care.
16327435|NCT04487444|No Intervention|Control arm|No treatment will be provided in addition to standard of care.
16327436|NCT04487431|Experimental|BAY1817080 Part A|Healthy male participants will receive BAY1817080 given as an oral solution (study Part A)
16327437|NCT04487431|Experimental|[14C]BAY1817080 Part B|Healthy male participants will receive BAY1817080 blended with [14C]BAY1817080 given as an oral solution (study Part B).
16327438|NCT04487418|Experimental|Surgery group with electro cautery|Surgery will be performed with electro cautery.
16327439|NCT04487418|Experimental|High level diode laser surgery|High power diode laser surgery will be performed.
16327440|NCT04487405||Group A|Symptomatic with adnexal mass
16327441|NCT04487405||Group B|Asymptomatic with adnexal mass
16327442|NCT04487405||Group C|Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant
16327443|NCT04487392|Active Comparator|Estrogen vaginal cream group (group A)|22 participants will be included in this group. The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home.
16327444|NCT04487392|Experimental|Photobiomodutation group (group B)|22 participants will be included in this group. The participants selected for group B will be undergo photobiomodulation with red LED.
16327445|NCT04487379||Group with edentulous ridge|This group had edentulous ridge planning to receive a dental implant and had ultrasound and cone-beam computed tomography images of the ridge.
16327446|NCT04487366|Active Comparator|Double Operator Ultrasound-Guided Regional Anesthesia|resident control block needle and ultrasound probe and asistant operator inject the solution. resident reach the target area created in the phantom model using a block needle with ultrasound guidance
16327447|NCT04487366|Active Comparator|Jedi Grip|resident control block needle, ultrasound probe and syringe independently with jedi grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject and aspirate the solution.
16327448|NCT04487366|Active Comparator|On-lock grip|resident control block needle, ultrasound probe and syringe independently with on-lock grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
16327449|NCT04487366|Active Comparator|Bedforth alternative grip|resident control block needle, ultrasound probe and syringe independently with bedforth's alternative grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
16327450|NCT04487353|Experimental|Experiment I Group|"After 4 hours of theoretical training, 35 students will be followed by a computer-aided and guided virtual birth practice. After 4 hours of theory training, the information form (DEDBF) to be prepared by the researchers for use in this research will be applied as the first test.
~After the virtual birth application is watched to the experimental groups, the DEDBF questions will be changed and the posttest will be done. Also, at this stage, Cognitive Load Scale and Feel of Inventory will be applied to the experimental groups after the application.
~In all three groups, DEDBF will be applied again after 6 weeks, and the effectiveness of the application of virtual birth will be examined in remembering and recalling the information."
16327451|NCT04487353|Experimental|Experiment II Group|"After 4 hours of theoretical training, 35 students will be shown a computer-free and non-guided virtual birth practice. After 4 hours of theory training, the information form (DEDBF) to be prepared by the researchers for use in this research will be applied as the first test.
~After the virtual birth application is watched to the experimental groups, the DEDBF questions will be changed and the posttest will be done. Also, at this stage, Cognitive Load Scale and Feel of Inventory will be applied to the experimental groups after the application.
~In all three groups, DEDBF will be applied again after 6 weeks, and the effectiveness of the application of virtual birth will be examined in remembering and recalling the information."
16327452|NCT04487353|No Intervention|Control Group|"Virtual birth practice will not be shown to 35 students who will only receive 4 hours of theory training. After 4 hours of theory training, the information form (DEDBF) to be prepared by the researchers for use in this research will be applied as the first test. No application will be made to the control group, The DEDBF questions will be replaced and a post-test will be done after 4 hours of theory training.
~In all three groups, DEDBF will be applied again after 6 weeks, and the effectiveness of the application of virtual birth will be examined in remembering and recalling the information."
16327453|NCT04487327|Experimental|Dry Needling within the Myofascial Trigger Point|Randomized to receive DN at the site of the MTrP
16327454|NCT04487327|Active Comparator|Dry Needling away from Myofascial Trigger Point Site|Randomized to receive DN 2 cm away from the site of the MTrP but within the same muscle
16327455|NCT04487314||Patients without Chronic Venous Disease|Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
16327456|NCT04487314||Patients with Chronic Veinous Disease|Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer).
16327457|NCT04487288|Experimental|CEUS with fusion|Control group: The historic cohort is used to compare the results of the biopsy using fusion only technique from 2013 to 2019.
16327458|NCT04487275|Experimental|Drug|MLC901 capsules three times per day over 6 months
16327459|NCT04487275|Placebo Comparator|Placebo|Placebo capsules three times per day over 6 months
16327460|NCT04487262|Active Comparator|Day O chest tube removal|"Chest tubes maybe removed ten hours after arrival at the intensive care provided standardized removal criteria are fulfilled:
~blood loss through chest tubes less than 200 ml during the last four hours
~no air leak
~the patient extubated and mobilized It remains at the discretion of the attending cardiac surgeon to postpone chest tube removal in cases of increased bleeding risk, due to circumstances which develop during the perioperative period"
16327523|NCT04486963|Experimental|Sanhuangjingshimingwan group|Sanhuangjingshimingwan,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
16327461|NCT04487262|Active Comparator|Day 1 chest tube removal|"Chest tubes are removed in the early morning of the first postoperative day, provided standardized removal criteria are fulfilled:
~blood loss through chest tubes less than 200 ml during the last four hours
~no air leak
~the patient extubated and mobilized It remains at the discretion of both the attending surgeon and anestesiologist to remove chest tubes prematurely in cases of drain-induced, severe analgetic resistant, intractable pain resistant to analgetic treatment."
16327462|NCT04487249|Experimental|Vision Therapy|Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.
16327463|NCT04487249|No Intervention|Observation|Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.
16327464|NCT04487236|Experimental|ZN-A-1041 50mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
16327465|NCT04487236|Experimental|ZN-A-1041 100mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
16327466|NCT04487236|Experimental|ZN-A-1041 200mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
16327467|NCT04487236|Experimental|ZN-A-1041 400mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
16327468|NCT04487236|Experimental|ZN-A-1041 600mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
16327469|NCT04487236|Experimental|ZN-A-1041 800mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
16327470|NCT04487236|Experimental|ZN-A-1041 1000mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
16327471|NCT04487236|Experimental|ZN-A-1041 level 1+Capecitabine 1000 mg/m2|"Phase 1b:
~ZN-A-1041 level 1+Capecitabine 1000 mg/m2; ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.
~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle."
16327472|NCT04487236|Experimental|ZN-A-1041 level 2+Capecitabine 1000 mg/m2|"Phase 1b:
~ZN-A-1041 level 2+Capecitabine 1000 mg/m2; ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.
~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle."
16327473|NCT04487236|Experimental|ZN-A-1041 level 3 +Capecitabine|"Phase 1c:
~The actual dose levels of ZN-A-1041 to be used in the combination Capecitabine will be determined based on the MTD identified in the Phase 1b study."
16327474|NCT04487210|Experimental|Phase 1a (Low Dose)|15 subjects will be enrolled to receive Low-dose S-protein with adjuvant MVC-COV1901.
16327475|NCT04487210|Experimental|Phase 1b (Medium Dose)|15 subjects will be enrolled to receive Medium-dose S-protein with adjuvant MVC-COV1901.
16327476|NCT04487210|Experimental|Phase 1c (High Dose)|15 subjects will be enrolled to receive High-dose S-protein with adjuvant MVC-COV1901.
16327477|NCT04487197||Cohort 1|"Adult patients (age ≥ 18 years),
~kidney or pancreas or pancreatic islets transplantation
~transplanted patients (period: 01.01.2020 to 30.06.2020)"
16327478|NCT04487197||Cohort 2|"Adult patients (age ≥ 18 years),
~kidney or pancreas or pancreatic islets transplantation
~Transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020."
16327479|NCT04487184|Active Comparator|Facilitation|From origin to insertion
16327480|NCT04487184|Experimental|Relaxation|From insertion to origin
16327481|NCT04487184|Placebo Comparator|Cross|Cross the muscle fiber
16327482|NCT04487184|Sham Comparator|Control|No tape
16327483|NCT04487158|Active Comparator|Small Changes|
16327484|NCT04487158|Experimental|INSPIRE|
16327485|NCT04487145|Experimental|HIV-infected children on EFV-based ART (E3)|30 HIV-infected children age 3 - 10 years on EFV-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
16327486|NCT04487145|Experimental|HIV-infected children on DTG-based ART (D3)|30 HIV-infected children age 11 - 17 years on DTG-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
16327487|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L1)|20 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take one oral dose DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
16327488|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L3)|30 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
16327489|NCT04487145|Active Comparator|HIV-uninfected children (C1)|20 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 1st dose. Control group for L1.
16327490|NCT04487145|Active Comparator|HIV-uninfected children (C3a)|30 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 3rd dose. Control group for E3 and L3.
16327491|NCT04487145|Active Comparator|HIV-uninfected children (C3b)|30 HIV-uninfected children age 11-17 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. Control group for D3.
16327492|NCT04487132|Active Comparator|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan provided to the controlled group
16327493|NCT04487132|Active Comparator|Recess or lunch time activities|Preparing the playground by offering adequate spaces and games provided to the experimental group
16327518|NCT04486989|Experimental|Cardiovascular Conditioning Protocol|Participants will complete a sub maximal cardiovascular training program twice per week for a period of 4 weeks.
16327519|NCT04486989|Active Comparator|Voice Production Exercises|Participants will complete voice production exercises twice per week for a period of 4 weeks.
16327520|NCT04486976|Experimental|Normal|
16327494|NCT04487106|Experimental|Treatment (azacitidine, venetoclax, trametinib)|"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
16327495|NCT04487093|Experimental|neoantigen vaccine + EGFR-TKI|
16327496|NCT04487093|Experimental|neoantigen vaccine + anti-angioge|
16327497|NCT04487080|Experimental|Treatment Arm A (Open-label): Amivantamab and Lazertinib|Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.
16327498|NCT04487080|Active Comparator|Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.
16327499|NCT04487080|Experimental|Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib|Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
16327500|NCT04487067|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
16327501|NCT04487054|No Intervention|Usual care|Subjects in the ICU with a poor prognosis will receive usual care in time period one.
16327502|NCT04487054|Experimental|Usual care plus palliative care|Subjects in the ICU with a poor prognosis will receive usual care plus targeted pro-active palliative care intervention within 48 hours of ICU admission in time period two.
16327503|NCT04487041|Active Comparator|Young HIV negative group|HIV uninfected participants that are 18-35 years of age will receive the standard dose flu vaccine. Participants who did not respond to the standard dose flu vaccination, as defined by less than a four-fold increase in flu antibody titer from baseline, will then receive the high dose flu vaccination 1 year after initial standard dose flu vaccination. Participants who respond to the standard dose flu vaccination will not receive the high dose flu vaccination.
16327504|NCT04487041|Experimental|Young HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 18-35 years of age, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
16327505|NCT04487041|Experimental|Old HIV negative group|HIV uninfected participants that are 65 years and older will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
16327506|NCT04487041|Experimental|Old HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 65 years and older, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
16327507|NCT04487028||Thoracic Surgical Patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
16327508|NCT04487015|No Intervention|Part I: Non-Digital (Control)|Participants who currently receive performance nutrition support, via a qualified practitioner as indicated by a member of the sports science team at their sporting organisation, will be assigned to the non-digital approach (control). These participants will not receive any intervention from the research team for the duration of this study (6 weeks).
16327509|NCT04487015|Experimental|Part I: MP+ Call + MesC [6 weeks]|For part one of study, participants who currently do not receive performance nutrition support, will be given access to an app-based menu planner (MP) for 6 weeks with coach support that gives ad-hoc messaging and calls.
16327510|NCT04487015|Experimental|Part II: Stage 1- MP [1week]|For the pilot SMART trial (part two of study), participants (not the same participants as part one) who currently do not receive performance nutrition support, will be given access to a menu planner app (MP) for 4 weeks. In the first 1 week, participants will only receive MP.
16327511|NCT04487015|Experimental|Part II: Stage 2 - R1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1week, this group of participants are considered responders (R1) so they continue with MP only for another 1 week.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
16327512|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to continue with MP only for another 1 week.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
16327513|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP + Call + MesC [1 week]|"For participants in Part II: Stage 1- MP [1 week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to have MP and additional coach support for another 1 week. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
16327514|NCT04487015|Experimental|Part II: Stage 3 - R2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered responders (R2) so they continue with MP only for 2 weeks.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
16327515|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to use MP only for another 2 week.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
16327516|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP + Call + MesC [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to have MP and additional coach support for another 2 weeks. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
16327524|NCT04486963|Placebo Comparator|Sanhuangjingshimingwan Placebo group|Sanhuangjingshimingwan placebo,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
16327525|NCT04486950|Experimental|Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes|TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.
16327526|NCT04486950|Experimental|Cohort 2 (High Dose): TAK-951 1 mg Infusion Over 60 Minutes|TAK-951 1 milligram (mg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
16327527|NCT04486950|Experimental|Cohort 3: TAK-951 1 mg Infusion Over 120 Minutes|TAK-951 1 mg or TAK-951 placebo-matching, infusion, intravenously, over a period of 120 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
16327528|NCT04486937|Experimental|SC10914|400mg TID，oral admination on an fasting state
16327529|NCT04486924|Experimental|Globe Mapping and Ablation System|
16327530|NCT04486911|Experimental|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
16327531|NCT04486898|Experimental|Music group|Music group will be receiving music intervention 3 times a day for 30 minutes per session for the duration of five (5) weeks period.
16327532|NCT04486898|No Intervention|Usual care|Those who will be in this group will be ask to continue doing their actual activities and not to partake in any kind of music listening or therapy for the 5 week period.
16327533|NCT04486872|Experimental|anti-CD19 and anti-CD20 dual specific CAR-T Cells|
16327536|NCT04486846|Experimental|eVisit|The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.
16327537|NCT04486833|Experimental|Phase 1|"Up to 3 sequential dose escalation cohorts will be treated with GPX-001 intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet.
~The first group will receive GPX-001 IV infusion at 0.06 mg/kg, the next group 0.09 mg/kg and the third will receive 0.12 mg/kg. Additional GPX-001 dose levels may be evaluated until RP2D is identified."
16327538|NCT04486833|Experimental|Phase 2 Combination|Patients will receive the RP2D of GPX-001 intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet starting on Day 10. The 21-day treatment cycle will continue until second progression event (PFS2) or unacceptable toxicity.
16327539|NCT04486833|Active Comparator|Phase 2 Active Comparator|Patients will continue on monotherapy osimertinib 80 mg fixed dose oral daily tablet until second progression event (PFS2).
16327540|NCT04486820||Chordoma|Patients diagnosed with chordoma
16327541|NCT04486794|Experimental|Treatment at baseline|
16327542|NCT04486794|Active Comparator|Treatment at Month 1|
16327543|NCT04486781|Experimental|Combination Therapy|All study participants will receive Pembrolizumab + sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. Pembrolizumab will be given at Day 1 of each 3 week cycle. The study drug (sEphB4-HSA) will be given at Day 1, 8, and 15 of each 3 week cycle.
16327544|NCT04486755|Experimental|Dose Level 1|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
16327545|NCT04486755|Experimental|Dose Level 2|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
16327546|NCT04486755|Experimental|Dose Level 3|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
16327547|NCT04486742|Experimental|Itch CBT Arm|Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.
16327548|NCT04486742|No Intervention|Usual Care Arm|Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.
16327549|NCT04486716|Experimental|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
16327550|NCT04486703|Experimental|Exercise with music group|physical therapy program combined with music therapy
16327551|NCT04486703|Experimental|Exercise group|physical therapy program without music
16327552|NCT04486690|Experimental|propofol group|"Propofol infusion, 25-150mic/kg/min.
~Fentanyl infusion, 1-2 mcg/kg/h.
~Atracurium infusion, 3-12 mic/kg/min"
16327553|NCT04486690|Active Comparator|ketofol group|"Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.
~Fentanyl infusion, 1-2 mcg/kg/h.
~Atracurium infusion, 3-12 mic/kg/min"
16327556|NCT04486664|Experimental|Mediterranean diet|Mediterranean diet twice per day for four weeks
16327557|NCT04486664|Placebo Comparator|Conventional diet|Conventional diet for four weeks
16327558|NCT04486651|Experimental|HX008 plus Irinotecan|Participants recieve HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
16327559|NCT04486651|Placebo Comparator|Placebo plus Irinotecan|Participants recieve placebo intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
16327560|NCT04486638||Pregnant women and their offspring(s)|Women and their offspring(s) exposed to Dengvaxia during pregnancy
16327561|NCT04486625|Experimental|Cohort 1|Normal renal function
16327562|NCT04486625|Experimental|Cohort 2|Severe renal impairment (not on dialysis)
16327563|NCT04486612||hypotension|
16327564|NCT04486612||non-hypotension|
16327565|NCT04486599|Experimental|Electromagnetic Navigation|The patient have to low Flow Vascular Abnormality diagnosed by Duplex Ultrasound and MRI. Decision of Ultrasound Guided Percutaneous Foam Sclerotherapy taken in multidisciplinary staff meeting
16327566|NCT04486586|Experimental|Active tDCS plus Speech-Language Therapy first|Active tDCS will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to sham tDCS after a washout period.
16327567|NCT04486586|Sham Comparator|Sham plus Speech-Language Therapy first|Sham will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to an active tDCS after a washout period.
16327568|NCT04486573|Other|CMRI|"Clinical data will be collected regarding cardiac risk factors, cancer type, and cancer treatment.
~CMRI will be performed:
~Within 2 weeks before the first fraction of radiation therapy (RT)
~Within 1 week of the final fraction of RT (before or after)
~Any patient with a pre-RT and post-RT MRI scan will be considered evaluable.
~Pre- and post-RT CMRI parameters will be compared.
~3D reconstructed CMR images will be co-registered with RT treatment plans to assess for spatial associations."
16327569|NCT04486560|Experimental|Single Arm: Cryoprobe|Everyone who enrolls in this study will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe.
16327570|NCT04486547|No Intervention|Follow up Posttest and HbA1c|56.0% of the adolescents with type 1 diabetes were aged 12-14 years and 52.0% were male in the control group (n=25)
16327571|NCT04486547|Experimental|Information Motivation Behavioral Skills Based Intervention|52.0% of the adolescents with type 1 diabetes were aged 15-18 years and 52.0% were female(n=25)
16327572|NCT04486534||Case group|36 patients between the ages of 18-65, who have been followed up for at least 3 months with the diagnosis of unilateral transtibial amputation and who have been using prostheses for at least 3 months
16327573|NCT04486534||Control group|36 age and body mass index (BMI)-matched healthy controls
16327574|NCT04486521||Experimental|anti-IL-6 drugs (tocilizumab and siltuximab)
16327575|NCT04486521||Active Comparator 1|Anti-IL-6 drugs (tocilizumab and siltuximab) and corticosteroids combination
16327576|NCT04486521||Active Comparator 2|corticosteroids alone
16327577|NCT04486508|Experimental|Intermediate dose anticoagulation|Intermediate dose anticoagulation will be the the tested regimen. The anticoagulation regimen will be modified according to weight/ body mass index, and creatinine clearance level (Cl Cr). Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according to Cockcroft-Gault Formula.
16327578|NCT04486508|Active Comparator|Standard Prophylaxis|Standard prophylaxis dose anticoagulation will be the anticoagulation of choice in the control arm. Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according Cockcroft-Gault Formula.
16327579|NCT04486508|Experimental|Atorvastatin 20|Atorvastatin 20 mg daily will be the statin therapy of choice in the intervention arm
16327580|NCT04486508|Placebo Comparator|Atorvastatin 20 mg Matched placebo|Matching placebo will be used for the control arm
16327581|NCT04486482|Other|KB109 + Self Supportive Care (SSC)|
16327582|NCT04486482|Other|Self Supportive Care (SSC) Alone|
16327583|NCT04486469|Experimental|Subjects with Irritable bowel syndrome|Experimental group is formed with 24 patients diagnosed with IBS treated in the digestive system service of the Virgen de la Arrixaca and Reina Sofía General University Hospitals.
16327584|NCT04486443|Experimental|Intervention Group|Patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour. All forms were applied to the group before the music therapy, respectively. Prior to musical therapy, the patient's preferred classical music (Rast or Hejaz modes) was asked by the specialist and 10 minutes of music therapy was performed according to patient's choice. Clinical data and pain scores were obtained 5, 30 and 60 minutes after music therapy. 6 sessions of music therapy were applied on different days. Patient Follow-up Form was recorded before and after each therapy. The forms were evaluated 3 times, before the application, after the 3rd and 6th application.
16327585|NCT04486443|No Intervention|control group|The control group consisted of patients who only received analgesic treatment and underwent routine nursing care, and didn't have any interventions. All forms were assessed 3 times, before application, after the 3rd application and after the 6th application. The Patient Information Form and K-MASF were applied only once.
16327586|NCT04486430|Experimental|Neu2000KWL 2750mg dose group|Low dose group
16327587|NCT04486430|Experimental|Neu2000KWL 5250mg dose group|Middle dose group
16327588|NCT04486430|Experimental|Neu2000KWL 6000mg dose group|High dose group
16327589|NCT04486430|Placebo Comparator|Placebo|Placebo
16327590|NCT04486404||Group 1|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra and Ec.
16327591|NCT04486404||Group 2|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra, Ch and Ec.
16327592|NCT04486391|Experimental|Tislelizumab|Tislelizumab monotherapy for up to 45 months
16327593|NCT04486391|Experimental|Salvage chemotherapy|Salvage chemotherapy for up to 45 months
16327594|NCT04486378|Experimental|RO7198457|Participants will receive a recommended dose of RO7198457.
16327595|NCT04486378|Other|Observational Group|Observational group will undergo watchful waiting, which is the standard of care in this setting.
16327596|NCT04486378|Experimental|Biomarker Cohort|15 patients
16327597|NCT04486378|Experimental|Exploratory Cohort|20 patients
16327598|NCT04486365|Active Comparator|Bifocal bone transport|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
16327946|NCT04483947|Experimental|Cohort 2|15 participants will receive AZD2693 dose 2 and 5 participants will receive placebo
16327599|NCT04486365|Active Comparator|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments between osteotomy and defect.
16327600|NCT04486352|Experimental|Atezolizumab and Bevacizumab Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with no specified gene signatures will be enrolled in this cohort. Twenty patients will be enrolled. Once twenty patientsare enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
16327601|NCT04486352|Experimental|Atezolizumab and Ipatasertib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with PIK3CA/AKT1/PTEN-altered tumors will be enrolled in this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
16327602|NCT04486352|Experimental|Atezolizumab and Talazoparib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with tumors that have a ≥16%genomic loss of heterozygosity (LOH) will be assigned to this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
16327603|NCT04486339|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.
16327604|NCT04486326|Experimental|crofelemer|125mg bid
16327605|NCT04486326|Placebo Comparator|placebo|bid
16327606|NCT04486313|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
16327607|NCT04486313|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
16327608|NCT04486300|No Intervention|Season of presentation|Comparison of number of presented cases in each season
16327609|NCT04486300|Active Comparator|Intervention|Surgical intervention of failed Pneumatic cases is done
16327610|NCT04486287|Experimental|Sintilimab Arm|Sintilimab after Stereotactic Ablation Brachytherapy.
16327611|NCT04486274|Experimental|non MOSE arm|Three needle passes will be performed for each mass
16327612|NCT04486274|Experimental|MOSE arm|The endoscopist will perform biopsy until a macroscopic visible core (MVC) will be obtained and specimen will be placed in a container (Container A-MOSE). If the needle passes performed are less than 3 (1 or 2 passes) the specimens acquired in the remnant passes to join standard care of 3 passes, according to ESGE guidelines, will be placed in a second container (Container B).
16327613|NCT04486261|Experimental|High-intensity strength training|"16 weeks of high-intensity strength training two times per week.
~Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient)
~Interventions:
~Other: high-intensity strength training Drug: Usual care"
16327614|NCT04486261|No Intervention|Control|"Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient).
~Intervention:
~Drug: Usual care"
16327615|NCT04486235|Experimental|Intervention|Receive experiential pamphlet
16327616|NCT04486235|No Intervention|Control|No materials, usual care
16327617|NCT04486222|Experimental|Experimental Group|The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.
16327618|NCT04486222|Active Comparator|Standard Treatment Group|The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.
16327619|NCT04486222|Sham Comparator|Sham Control|The sham control group would receive an rTMS course with sham high-frequency stimulation (10Hz) at left DLPFC (40 trains, 1600 pulses) followed by sham low-frequency (1Hz) inhibition at right DLPFC (10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't sham-R't sham-1.5 hr-L't sham-R't sham), five days a week, and two weeks in total.
16327620|NCT04486222|Experimental|Open-label Experimental Group|"Partial unblinding (control group or not control group, rather than experimental group, standard treatment group and sham control group) would be done at the end of the third week. If the participant were in control group and HAM-D 17 scores neither decreased for ≥ 50% nor were ≤ 7 points at the end of the third week, he or she would enter an extending open-label trial, that participants would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total."
16327621|NCT04486196|Experimental|Control (No Laser) Group|The final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water.
16327622|NCT04486196|Experimental|Laser Disinfection (LD) Group|After final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water, root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle. This cycle was applied 4 times for each root canal. The optical fiber (Medency) was inserted 1 mm short of the apex and the root canals were slowly (at a speed of 2mm/s) irradiated from apical to coronal in continuous circling movements to treat all dentinal tubules in one cycle for each power.
16327623|NCT04486183|Experimental|Intervention|The data were collected by the researcher at the waiting room of the blood collection unit at a close distance to the lavatory. The capillary first and second blood drop values taken from the patients after fasting and at two hours following OGTT and capillary and venous blood glucose values were compared.
16327705|NCT04485637|Other|Communication with basic table|Blood pressure communication showing a basic table representing only the normal range of blood pressure readings
16327947|NCT04483947|Experimental|Cohort 3|15 participants will receive AZD2693 dose 3 and 5 participants will receive placebo
16327624|NCT04486170|No Intervention|Control group: Current hospital education practices|The control group will receive standard of care postpartum educational materials provided by the nursing and resident physician staff. The will be asked to complete a brief questionnaire to determine if they would be interested in receiving education in a video formal.
16327625|NCT04486170|Experimental|Intervention group: Standardized video and pamphlet|The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
16327626|NCT04486157|Experimental|IN-A012|Intravenous administration of IN-A012
16327627|NCT04486157|Active Comparator|Akynzeo capsules|Single oral administration of Akynzeo capsules
16327628|NCT04486144|Experimental|COVID19 Positive: Intervention Group (Receive extract)|These are patients that are COVID19 positive who elect to try the extract.
16327629|NCT04486144|No Intervention|COVID19 Positive: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 positive who do NOT elect to try the extract
16327630|NCT04486144|Experimental|COVID19 Exposed: Intervention Group (Receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to try the extract.
16327631|NCT04486144|No Intervention|COVID19 Exposed: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to NOT try the extract.
16327632|NCT04486118|Active Comparator|CA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:
~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
16327633|NCT04486118|Placebo Comparator|nonCA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:
~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
16327634|NCT04486105|Placebo Comparator|control|vehicle only for one week
16327635|NCT04486105|Experimental|40g sucrose ingestion|40g sucrose treatment on top of habitual diet for one week
16327636|NCT04486105|Experimental|80g sucrose ingestion|80g sucrose treatment on top of habitual diet for one week
16327637|NCT04486105|Experimental|120g sucrose ingestion|120g sucrose treatment on top of habitual diet for one week
16327638|NCT04486092|Experimental|Valproic Acid|
16327639|NCT04486079|Experimental|Carbohyrate loading|Group A will receive 400ml of the carbohydrate rich drink, Nutricia preOp 2 hours before operation. This is the intervention group.
16327640|NCT04486079|No Intervention|Fasting|Group B will be prepared before the operation with a 24-hour fasting. This is the current clinical standard.
16327641|NCT04486066|Experimental|Mindfulness-Based Stress Reduction (MBSR)|In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
16327642|NCT04486066|Experimental|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 sessions in a group format, while retaining all essential elements.
16327643|NCT04486066|Other|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
16327644|NCT04486053||Patients with flexor tendon injury|Patients between the ages of 6-18 who have applied to orthopedics emergency department due to hand injury and have been operated with flexor tendon injury, for the last 3 years, were retrospectively scanned from hospital record. Eligible patients for the study were informed about the study by telephone and requested to come hospital for further evaluations including sensory, motor and functional assessments.
16327645|NCT04486040|Active Comparator|Drainage group|Patients with drainage after hip revision arthroplasty
16327646|NCT04486040|Active Comparator|No-drainage group|Patients without drainage after hip revision arthroplasty
16327647|NCT04486027||Healthy|Healthy individuals not smoking, not using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, not receiving chemotherapy, not being hypothyroidic
16327648|NCT04486027||Active Rheumatoid Arthritis|Active Rheumatoid Arthritis meeting American College of Rheumatology (ACR) RA remission criteria
16327649|NCT04486027||Rheumatoid Arthritis in remission|Rheumatoid Arthritis in remission meeting American College of Rheumatology (ACR) RA remission criteria
16327650|NCT04486014|Experimental|Erector spinae plane block (ESP)|Patients would receive erector spinae plane block
16327651|NCT04486014|Experimental|Serratus anterior plane block (SAP)|Patients would receive serratus anterior plane block
16327652|NCT04486001|Experimental|Treatment Group|This is single arm study with only comparison to non-treated cohorts at site.
16327653|NCT04485988||No-beta blocker|
16327654|NCT04485988||beta blocker|
16327655|NCT04485962|Experimental|Fibroblasts and keratinocytes treated patients|Fibroblasts and keratinocytes treated patients
16327768|NCT04485104|Experimental|Standard of care (SOC) plus GWP42003-P|
16327769|NCT04485104|Active Comparator|SOC|
16327656|NCT04485949|Experimental|IGV-001|Participants will be implanted with IGV-001 on Day 1 and explanted with IGV-001 on Day 3 (within approximately 48 hours after implantation). After 6 weeks, participants will receive radiotherapy (RT) per institutional standards for 5 days per week along with temozolomide 75 mg/m^2 orally, once daily (QD) for up to 12 weeks followed by temozolomide 150 to 200 mg/m^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 40).
16327657|NCT04485949|Placebo Comparator|Placebo|Participants will be implanted with placebo on Day 1 and explanted with placebo on Day 3 (within approximately 48 hours after implantation). After 6 weeks, participants will receive RT per institutional standards for 5 days per week along with temozolomide 75 mg/m^2 orally, QD for up to 12 weeks followed by temozolomide 150 to 200 mg/m^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 40).
16327658|NCT04485936|Experimental|Epitomee Device|the participants receive the device which is non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of early satiation and prolonged satiety
16327659|NCT04485910|Active Comparator|Single step media|Embryos cultured in single step media
16327660|NCT04485910|Active Comparator|Sequential media|Embryos cultured in sequential media
16327661|NCT04485897|Experimental|icare HOME|
16327662|NCT04485884|Experimental|Group A|IN-C005 dose A
16327663|NCT04485884|Experimental|Group B|IN-C005 dose B
16327664|NCT04485884|Experimental|Group C|IN-C005 dose C
16327665|NCT04485884|Experimental|Group D|IN-C005 dose D
16327666|NCT04485884|Experimental|Group E|IN-C005 dose E
16327667|NCT04485884|Experimental|Group F|IN-C005 dose F
16327668|NCT04485871|Experimental|Omega-3 fatty acids|3.6 g EPA:DHA / day (2:1)
16327670|NCT04485845|Active Comparator|metformin treated group|A group of patients treated with a daily dose of metformin
16327671|NCT04485845|Experimental|vildagliptin treated group|A group of patients treated with a daily dose of vildagliptin
16327672|NCT04485832|Active Comparator|Intervention|
16327673|NCT04485832|Active Comparator|Control|
16327674|NCT04485819||Cleavage stage transfer|Poor responders who transfer their embryos in cleavage stage on day 3
16327675|NCT04485819||Blast stage transfer|Poor responders who transfer their embryos on blast stage on day 5/6
16327676|NCT04485806|Other|GPS / LM versus SPL/LM|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with light mineral oil (LM).
16327677|NCT04485806|Other|GPS/PO versus SPL/PO|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with paraffin oil (PO).
16327678|NCT04485806|Other|GPS/PO versus GPS/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 3D dishes (GPS).
16327679|NCT04485806|Other|SPL/PO versus SPL/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 2D dishes (SPL).
16327680|NCT04485793|Active Comparator|Active Comparator|Dietary supplement
16327681|NCT04485793|Placebo Comparator|Placebo comparator|Placebo
16327682|NCT04485780|Placebo Comparator|Botulinum toxin injection during surgery|Patients in this group underwent Botulinum toxin injection during surgery
16327683|NCT04485780|Experimental|Botulinum toxin injection one week before surgery|Patients in this group underwent Botulinum toxin injection at the outpatient clinic one week before surgery
16327684|NCT04485767|Experimental|Progressive Resistance Training Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend structured progressive resistance exercise training sessions 2 times/week for six months.
16327685|NCT04485767|Active Comparator|Flexibility and Balance Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend flexibility and balance exercises training sessions 2 times/week for six months.
16327686|NCT04485754|Experimental|Telemedicine FU|Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
16327687|NCT04485754|Active Comparator|Office FU|Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
16327688|NCT04485728|Experimental|Sleep Improvement Intervention|
16327689|NCT04485728|No Intervention|Standard of Care (Control)|
16327690|NCT04485715|Experimental|AI-aided group|
16327691|NCT04485715|No Intervention|control group|
16327692|NCT04485702|Active Comparator|MELT-100|3mg midazolam and 25mg ketamine sublingual tablet
16327693|NCT04485702|Active Comparator|IV midazolam|2mg Intravenous midazolam
16327694|NCT04485702|Active Comparator|IV ketamine|6mg Intravenous ketamine
16327695|NCT04485689|Experimental|Capsaicin - alone|5x7 cm2 capsaicin patch
16327696|NCT04485689|Placebo Comparator|Placebo - alone|5x7 cm2 placebo patch alone
16327697|NCT04485689|Experimental|Capsaicin - ice|5x7 cm2 capsaicin patch - plus ice
16327698|NCT04485689|Placebo Comparator|Placebo - ice|5x7 cm2 placebo patch - plus ice
16327699|NCT04485676||Dalbavancin|"Patients to be included in this study have been treated with Dalbavancin according to clinician's judgement and clinical practice according national or international guidelines.
~Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Information about dosing treatment will be collected."
16327700|NCT04485663|Experimental|ALG-010133|Subcutaneous injections of ALG-010133 in HV or CHB subjects up to every 7 days for up to 12 weeks
16327701|NCT04485663|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects up to every 7 days for up to 12 weeks
16327702|NCT04485650|Experimental|Music group|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group. The number of participants:30
16327703|NCT04485650|Active Comparator|Sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
16327704|NCT04485650|Other|Non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
16327948|NCT04483934|Experimental|Patients treated with dermal fibroblasts|Cultured dermal fibroblasts and LED phototherepy
16327706|NCT04485637|Other|Communication with enhanced table|Communication showing an enhanced table (Fig 1B) with more reference information for interpreting blood pressure readings, including how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
16327707|NCT04485637|Other|Communication with enhanced graph|Communication showing an enhanced graph (adapted from Blood Pressure UK) for interpreting blood pressure readings, showing the same color-coded ranges as the enhanced table, with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
16327708|NCT04485624||Attendees at Paediatric Emergency Department 1 (PED1)|These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large district general hospital.
16327709|NCT04485624||Attendees at Paediatric Emergency Department 2 (PED2)|These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large children's hospital.
16327710|NCT04485611|Experimental|Prehabilitation|This pilot cohort will undergo an intervention and will be followed for up to 6 months. The study does not include a comparator group.
16327711|NCT04485585|Experimental|Sequence T/M/T+M|"A total of 36 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(T, M, T+M) assigned to on sequence group in Period 1, Period 2, and Period 3.
~Period 1(T): BR9006-1 (Tamsulosin HCL 0.2mg) - 1 capsule QD, five-day repeated-dose
~Period 2(M): BR9006-2 (Mirabegron 50mg) - 1 tablet QD, eleven-day repeated-dose
~Period 3(T+M): BR9006-1 (Tamsulosin HCL 0.2mg) 1 capsule + BR9006-2 (Mirabegron 50mg) 1 tablet QD, five-day repeated-dose
~Washout period between Period 1 and Period 2: five days
~Washout period between Period 2 and Period 3: none"
16327712|NCT04485572||Straight Leg Raise test and Bragard test|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
16327713|NCT04485572||Fajersztajn test (F) and Sicard test (S)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
16327714|NCT04485572||Passive Neck Flexion test (PNF)and Kernig test (K)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
16327715|NCT04485572||Slump test (ST) and Dejerine triad (DT)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
16327716|NCT04485559|Experimental|Treatment (trametinib, everolimus)|Patients receive dosing per their assigned dose level. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16327717|NCT04485546|Experimental|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj|
16327718|NCT04485533|Experimental|VisuXL® Gel/HYLO®|Patients treated with VisuXL® ophthalmic gel for the first 30 days (1 treatment period) and with HYLO® for the second 30 days (2 treatment period).
16327719|NCT04485533|Active Comparator|HYLO®/VisuXL® Gel|Patients treated with HYLO® for the first 30 days (1 treatment period) and with VisuXL® ophthalmic gel for the second 30 days (2 treatment period).
16327720|NCT04485520|Experimental|Carica Papaya extract|Carica Papaya at 3%
16327721|NCT04485520|Active Comparator|Chlorhexidine|0.12% chlorhexidine mouthwash formulation (commercially available)
16327722|NCT04485507|Experimental|Nature-VR|Viewing 3D pictures of natural environments
16327723|NCT04485507|Active Comparator|Urban-VR|Viewing 3D pictures of urban environments
16327724|NCT04485494||Professional Rugby Athletes|These are the cohort of players that consent to the study and have a preseason baseline blood sample taken. If the participant from this cohort then receives a concussion they are assessed by the World Rugby's Head Injury Assessment (HIA) and then enter into the return to play (RTP) protocol which means they cannot play a competitive game for 6 days.
16327725|NCT04485481|Experimental|Experimental: Cohort 1:1 - 1:6 ADX-914|ADX-914 single SC dose
16327726|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 1:1 - 1:6 placebo|Placebo single SC dose
16327727|NCT04485481|Experimental|Experimental: Cohort 2:1- 2:3|ADX-914 multiple SC dose once every 2 weeks for 6 weeks
16327728|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 2:1- 2:3|Placebo multiple SC dose once every 2 weeks for 6 weeks
16327729|NCT04485468||Parkinson's disease patients|Parkinson's disease patients and over 18 years old
16327730|NCT04485455|Experimental|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
16327731|NCT04485429|Experimental|Methylprednisolone + Standard treatment|Participants will receive the standard treatment and methylprednisolone.
16327732|NCT04485429|Experimental|Full-dose heparin + Standard treatment|Participants will receive the standard treatment and full-dose heparin,
16327733|NCT04485429|Experimental|Methylprednisolone + Full-dose heparin + Standard treatment|Participants will receive the standard treatment, methylprednisolone and full-dose heparin
16327734|NCT04485429|No Intervention|Standard treatment|Participants will receive the standard treatment
16327735|NCT04485416|Experimental|Treatment group|Subjects will receive eltrombopag
16327736|NCT04485403|Experimental|Ibuprofen|Depending on body weight, patients will be divided into two groups. Women with a body weight <70 kg will be taking a daily dose of 800 mg ibuprofen orally. Women ≥ 70 kg will take a dose of 1200 mg ibuprofen orally. Before and after 3 weeks of treatment, all subjects will have a full hormonal, biochemical and clinical profile.
16327737|NCT04485390||First responder group|Cardiac arrest victims in remote areas resuscitated by the first responders before the arrival of the EMS.
16327738|NCT04485390||EMS groups|Cardiac arrest victims in remote areas resuscitated by the EMS.
16327739|NCT04485351||Diabetic patients from the University Hospital of Nancy|
16327740|NCT04485325|Active Comparator|Tofacitinib|Tofacitinib (Xeljanz®; 5 mg twice daily, p.o.)
16327741|NCT04485325|Active Comparator|Etanercept|Etanercept (Enbrel®; 50 mg once per week, s.c.)
16327742|NCT04485312|Active Comparator|caries preventive protocol|preventive protocol for special needs ( tooth brushing , topical fluoride and mouth wash)
16327743|NCT04485312|Other|chlorhexidine varnish added to the caries preventive protocol|chlorhexidine varnish preventive caries protocol for special needs
16327856|NCT04484506|Experimental|Stage I/II nasal ENKTL|2-3 cycles of induction pegaspargase-COEP chemotherapy followed by concurrent chemoradiotherapy, then by 1-2 cycles of pegaspargase-COEP chemotherapy as consolidation
16327744|NCT04485299|Experimental|bifluorid 10 varnish|Bifluorid 10 (NaF and CaF) lead to reduce the dentin hypersensitivity, the sodium fluoride (NaF) dissociates and releases F ions, that diffuse through the tubules and then precipitates as calcium fluoride as a consequence of the high of calcium content in saliva and dentinal fluid ,The calcium fluoride (CaF) present in the varnish composition diffuses into the tubules and block the canal with a semi-permanent protective layer.The calcium fluoride is added to block the dentin tubules mechanically, by the combination with the calcium fluoride resulted from the sodium fluoride reaction to the calcium of dentin.
16327745|NCT04485299|Active Comparator|sodium fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
16327746|NCT04485286|Experimental|Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy|Lung cancer or pancreatic cancer patients will receive [68Ga]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
16327747|NCT04485273|Active Comparator|Dexmedetomedine Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected, in addition to dexmedetomedine.
16327748|NCT04485273|Placebo Comparator|Control Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected.
16327750|NCT04485247|Active Comparator|Conventional group|conventional laparoscopic appendectomy with 3-ports
16327751|NCT04485247|Experimental|TULAA group|An operator extracts and ligates appendix through umbilical port.
16327752|NCT04485234||All patients|All lesions undergo assessment with coronary pressure sensor and either Doppler velocity or coronary thermodilution
16327753|NCT04485221||Children with a TECPR2 mutation|"Children with a TECPR2 mutation, age 18 months to 12 years old.
~Assessments will include collection of genetic mutation reports, functional assessments, and questionnaires. There will be a singular blood draw and skin biopsy."
16327754|NCT04485208|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the thalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
16327755|NCT04485195|Active Comparator|Vernakalant|Patients randomized to this arm will receive an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump.82 For patients ≤ 100 kg the infusion is prepared by adding 25 mL of BRINAVESS 20 mg/mL to 100 mL of diluent creating a total volume of 125 mL at a concentration of 4 mg/mL. For patients > 100 kg the infusion is prepared by adding 30 mL of BRINAVESS 20 mg/mL to 120 mL of diluent creating a total volume of 150 mL at a concentration of 4 mg/mL. For patients weighing ≥ 113 kg, the maximum initial dose is 339 mg (84.7 mL of 4 mg/mL solution).
16327756|NCT04485195|Active Comparator|Procainamide|Patients randomized to this arm will receive a continuous infusion of IV procainamide with a dose of 15 mg/kg in 500 mL of normal saline given over 60 minutes (maximum dose 1,500 mg), by a pre-programmed pump. While the CAEP Best Practices Checklist suggests an infusion time of 30-60 minutes, we believe that a 60-minute period will avoid some adverse events.
16327757|NCT04485182||First|Patients receiving Transcutaneous Electrical Nerve Stimulation + underwater massage + spine gymnastics +
16327758|NCT04485182||controll group|Patients receiving Transcutaneous Electrical Nerve Stimulation + spine gymnastics
16327759|NCT04485169|Experimental|TPE Arm|In addition to standard care TPE was performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access was achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume was calculated as per Nadler's formula. Anticoagulant acid dextrose ratio was 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation was monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume was removed during each procedure. Replacement fluid was fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures were performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE was continued till recovery
16327760|NCT04485169|No Intervention|NON TPE arm|Only supportive treatment offered including Vit C, Zinc, Vit D, famotidine, Enoxaparin and Methylprednisolone
16327761|NCT04485156|Active Comparator|Arm 1 (Conventional treatment group)|"Will be treated as recommended by Korean Guidelines For Tuberculosis as well as WHO guidelines (e.g. isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months followed by isoniazid, rifampicin, (and ethambutol)) Duration of the treatment
~- 6 months in total"
16327762|NCT04485156|Experimental|Arm 2 (High-dose rifampicin group)|"High-dose rifampicin, isoniazid, and pyrazinamide
~Rifampicin: 30mg/kg
~Isoniazid: 300mg/day
~Pyrazinamide: 1000mg/day (<50kg), 1500mg/day (50-70kg), 2000mg /day (>70kg), till culture conversion Duration of the treatment
~Till 12 weeks after culture conversion on liquid media"
16327763|NCT04485143||experimental group|Non-invasive Wearable Device
16327764|NCT04485130|Experimental|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
16327765|NCT04485130|Placebo Comparator|Placebo|This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
16327766|NCT04485117|Active Comparator|Sevoflurane Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane anesthesia under BIS monitoring.
16327767|NCT04485117|Active Comparator|Propofol Group|Laryngeal mask airway is inserted and anesthesia is maintained with propofol infusion under BIS monitoring.
16327770|NCT04485091|Experimental|Group A: 20% TCM and PBM|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with photobiomodulation (PBM) with red spectrum LED (660nm) on the back of the hands.
16327771|NCT04485091|Placebo Comparator|Group B: 20% TCM and PBM placebo|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with simulated photobiomodulation on the back of the hands.
16327772|NCT04485078||Axial spondyloarthritis patients|QST with clinical scales
16327773|NCT04485078||Healthy controls|QST
16327774|NCT04485065|Experimental|IBI188+azacitidine|
16327775|NCT04485052|Experimental|IBI188+azacitidine|Participants receive IBI188 every four weeks(Q4W) by intravenous(IV) and azacitidine daily in Day1-7 of each four weeks(Q4W) by subcutaneous(IH)
16327776|NCT04485039|Other|ABCDE|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet."
16327777|NCT04485039|Other|ACEBD|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate"
16327778|NCT04485039|Other|ADBEC|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet"
16327779|NCT04485039|Other|AEDCB|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 500 mg lanthanum carbonate chewable tablet.
~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 1334 mg calcium acetate
~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 1600 mg sevelamer carbonate"
16327780|NCT04485026|Experimental|Local Consolidative Radiation Therapy Arm|Definitive external beam radiation therapy will be delivered to all sites of progressive disease for all patients. The technique used to deliver radiation therapy will be determined by the treating radiation oncologist.
16327781|NCT04485026|Active Comparator|Standard of Care - Control Arm|Second line systemic therapy is at the discretion of the treating medical oncologist.
16327782|NCT04485013|Experimental|Phase 1a, Monotherapy Dose Escalation|
16327783|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)|Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)
16327784|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)|Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)
16327785|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)|Cohorts will enroll subjects with advanced/metastatic colorectal cancer (CRC)
16327786|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (CRC)|Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR colorectal cancer (CRC)
16327787|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC)|Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR (KRAS wild type) colorectal cancer (CRC)
16327788|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)|Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
16327789|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)|Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
16327790|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (TNBC)|Cohorts will enroll subjects with advanced/metastatic triple negative breast cancer (TNBC)
16327791|NCT04485000|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1) in addition to receiving standard postnatal care.
16327792|NCT04485000|Other|Waitlist Cpntrol|The waitlist control group will receive standard postnatal care for 12 weeks and will participate in the online 1-day CBT-based workshop at T2 (12 weeks post baseline).
16327793|NCT04484987|Other|TRE group|Time-restricted eating group
16327794|NCT04484987|Other|Control group|Time-unrestricted eating group
16327795|NCT04484974|Experimental|Pecan snack condition|In this crossover condition, a mid morning snack consisting of 300 kcal of lightly salted roasted pecan nuts will be administered.
16327796|NCT04484974|Active Comparator|Pretzel snack condition|In this crossover condition, a mid morning snack consisting of 300 kcal of lightly salted pretzels will be administered.
16327797|NCT04484961|No Intervention|Control - Routine Rehab|Participants in this group received standard ACL rehab with no blood flow restriction therapy.
16327798|NCT04484961|Experimental|Experimental - BFR|Participants in this group received standard ACL rehab with the addition of blood flow restriction therapy.
16327799|NCT04484948|Experimental|Systemic sclerosis group|Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria
16327801|NCT04484922|Experimental|Dexmedetomidine|
16327802|NCT04484922|Placebo Comparator|Control|
16327803|NCT04484909|Experimental|Treatment (NBTXR3, radiation therapy)|Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity.
16327949|NCT04483921|Experimental|Exercise|Participants will complete a prescribed exercise bout.
16327804|NCT04484896|Experimental|Gain-frame Message|"Short messaging service (SMS) message: Dear group O/A Rh-D negative blood donor:
~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to save lives. Thank you for your support.
~Please bring your identification (ID) card and show this message to our staff. Thank you."
16327805|NCT04484896|Experimental|Loss-frame Message|"SMS message: Dear group O/A Rh-D negative blood donor:
~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to prevent the loss of life. Thank you for your support.
~Please bring your ID card and show this message to our staff. Thank you."
16327806|NCT04484896|Experimental|Information Message|"SMS message: Dear group O/A Rh-D negative blood donor:
~Hello! The inventory of group O/A Rh-D negative blood product is low at present, if you can, please consider donating blood again. Thank you for your support.
~Please bring your ID card and show this message to our staff. Thank you."
16327807|NCT04484896|No Intervention|Control group|Donors in this group were not received SMS reminders.
16327808|NCT04484870|Experimental|Danshu capsule group|The patients in Danshu group were treated with Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets)，The course of treatment was 6 months
16327809|NCT04484870|Active Comparator|ursodeoxycholic acid group|UDCA group, 250mg/ was taken orally twice a day (0.25g/, Losan Pharma GmbH company). The course of treatment was 6 months
16327810|NCT04484857|Experimental|Roxadustat|
16327811|NCT04484844|Experimental|Shield Force Plus Varnish|Shield force plus (SFP), Self-reinforcing (SR) monomer technology supplied in the form of one component self-etching light-cured dental adhesive, which is characterized by an SR monomer component that penetrates the tooth substrate. Multi-point interactions with apatite calcium and three-dimensional cross-linking occur reactions.it forms a thin even, hard coating on the tooth surface that gives the tooth substrate a superior binding power.
16327812|NCT04484844|Active Comparator|Sodium Fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
16327813|NCT04484831|Experimental|ABT Weight Loss Intervention|Adolescent participants will attend sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
16327814|NCT04484831|Placebo Comparator|Enhanced Care|Adolescent participants will receive handouts on elements of a healthy lifestyle and will participate in a midpoint one-on-one nutrition consultation with a registered dietitian.
16327815|NCT04484818|Active Comparator|Arm A (ADT, placebo)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
16327816|NCT04484818|Experimental|Arm B (ADT, darolutamide)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive darolutamide QID for 52 weeks in the absence of disease progression or unacceptable toxicity.
16327817|NCT04484805|No Intervention|Baseline|The subject wears their usual socket with an ambient temperature sensor and step counter for approximately one month.
16327818|NCT04484805|Experimental|ICE Unit|"The subject wears the experimental socket with an ICE Unit, which includes a TEC and will be actively cooling the leg whenever the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
16327819|NCT04484805|Sham Comparator|Sham Unit|"The subject wears the experimental socket with a Sham Unit, which excludes a TEC and will not be actively cooling the leg when the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
16327820|NCT04484792|Experimental|Group A|
16327821|NCT04484792|Experimental|Group B|
16327822|NCT04484792|Placebo Comparator|Group C|
16327823|NCT04484779|Experimental|IIM System|The IIM system is comprised of an insulin lispro pen and/or an insulin glargine pen (both U-100), an investigational mobile medical application (MMA) that transmits data to cloud storage, an investigational Bluetooth Low Energy® (BLE)-paired insulin data transmission (IDT) module and a compatible commercially available BLE-paired blood glucose meter (BGM).
16327824|NCT04484766||Patient after pre-eclampsia|Patients with pre-eclampsia who were treated at the University Hospital of Jena between 1999-2009.
16327825|NCT04484766||Patients after PETN treatment|Patients of the PETN pilot study, with PETN and patients who received PETN as an individual therapy trial
16327826|NCT04484753|Other|Home Exercise Sheet|The participant took the sheet with the description of the exercises to his address.
16327827|NCT04484753|Other|Ipelvis mobile application|The participant received the app and performs home exercises guided by the app.
16327828|NCT04484753|Active Comparator|Home exercise sheet + Pelvic Physiotherapy|The participant did group physical therapy and used the exercise sheet at home on other days.
16327829|NCT04484753|Active Comparator|Ipelvis mobile application + Pelvic Physiotherapy|The participant did group physical therapy and used the mobile application on other days.
16327830|NCT04484740|Experimental|Gepotidacin|
16327857|NCT04484506|Experimental|Stage III/IV or primary extra-nasal ENKTL|6-8 cycles of pegaspargase-COEP chemotherapy with or without local radiotherapy and/or consolidative autologous stem cell transplantation
16327858|NCT04484493|Experimental|mometasone nasal spray|Patients will receive topical corticosteroid nasal spray (mometasone furoate nasal spray) in appropriate dose of 2 puff in each nostril (100 µg once daily) beside olfactory training.
16327859|NCT04484493|No Intervention|control|Patients will not receive topical corticosteroid nasal spray but only olfactory training.
16327831|NCT04484727||ICU-patients in ventilator treatment|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each is performed and data on airway pressure and tidal volume changes collected. The data is transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.
~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes, suctioning, inhalation, CO2 insufflation etc. is performed, and repeated during the whole period of ventilator treatment."
16327832|NCT04484727||Surgery-patients during general anaesthesia|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each, is performed in the same way as described for ICU patients. Data of airway pressure and volumes are transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.
~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes or suctioning is performed, and before and after implementation of pneumoperitoneum."
16327833|NCT04484714|Experimental|Behavioural: Exercise|"Participants will take part in a twelve week resistance and aerobic exercise program twice per week delivered virtually.
~Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises"
16327834|NCT04484701||PSMA-11 PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
16327835|NCT04484675|Active Comparator|Group IH(inhaled milrinone)|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
16327836|NCT04484675|Active Comparator|Group Iv(Intravenous milrinone)|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
16327837|NCT04484662|Other|Potted Mint Plants Intervention|We will measure 2 indoor environments (living room and bedroom) for placing potted plants. We will analyze the effect of potted mint plants on indoor air quality, fungal and bacterial concentration, and explore the correlation between the intervention of potted mint plants and cardiovascular health.
16327838|NCT04484649|Experimental|Intervention|Sleeping Healthy/Living Healthy
16327839|NCT04484649|Active Comparator|Control|Attention Control
16327840|NCT04484636|Other|Hepatocellular Cancer|molecular profiling - hepatocellular cancer (HCC)
16327841|NCT04484636|Other|Cholangiocarcinoma|molecular profiling - intra- and extrahepatic cholangiocellular carcinoma (CCA)
16327842|NCT04484636|Other|Gallbladder Cancer|molecular profiling - gallbladder carcinoma (GBCA)
16327843|NCT04484636|Other|Pancreatic Cancer|molecular profiling - pancreatic cancer (PanCa)
16327844|NCT04484636|Other|Oesophageal Cancer + Stomach Cancer|molecular profiling - esophagogastric cancer (EC/GC)
16327845|NCT04484623|Experimental|Arm A: Belantamab mafodotin plus Pomalidomide and Dexamethasone|
16327846|NCT04484623|Experimental|Arm B: Bortezomib plus Pomalidomide and Dexamethasone|
16327847|NCT04484610|Experimental|Appropriate Opioid Quantities|Pharmacists in the intervention regions are invited to complete an eLearning program to promote the practice change intervention of assessing and dispensing appropriate quantities of opioids prescribed for acute pain.
16327848|NCT04484610|No Intervention|Usual Practice|Pharmacists in the comparison regions are not targeted for the practice change intervention (they are not invited nor provided access to the eLearning program).
16327849|NCT04484584||Complex Decongestive Therapy Group (CDT)|"Complex Decongestive Therapy Group: The treatment was applied by a specialist therapist who received CDT training. The study group rehabilitation and CDT application is 1 hour. CDT Treatment Protocol:
~Deep abdominal technique application Neck region CDT application (supraclavicular fossa circular motion-Eflöraj) Circular movements on ipsilateral Axillar lymph nodes Circular movements on bottle neck cubital fossa Front arm bucket pumping pump push MLD application of dorsal and palmar face of the hand to ulnar and radial bundles
~Bandage Treatment (Fingers and hand and forearm bandage): Patients can stay for 6-8 hours or until the next day.
~Patients can do exercises in bandages. The patient is given home education.
~The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home. Orthopedic rehabilitation is the same as the control group."
16327850|NCT04484584||Orthopedic Rehabilitation Group (OR)|"Orthopedic Rehabilitation Group: The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home.
~Orthopedic Rehabilitation Treatment Protocol:
~Exercises to be done at 4 to 6 weeks: Wrist NEH (at the pain limit),active exercise,Grasp exercise
~Exercises to be done at 6 to 8 weeks: Wrist NEH (at the pain limit),Active assistive / active exercise, Grasp exercise,Supination-pronation exercise. (Opposite baths and classical massage are recommended from orthopedics)
~Exercises to be done at 8 to 10 weeks: Stretching exercises,Finger strengthening spring with Digiflex spring, Power web combo hand finger arm amplifier, Msd theraflex hand exercise dough, Theraband flevbar exercise bar.
~Exercises to be done at 10 to 12 weeks Wrist strengthening exercises, Resistant exercises to all muscles."
16327851|NCT04484571|Experimental|Robotic treatment|Patients receive 4 weeks of elbow rehabilitation treatment provided by the NEEM robotic elbow exoskeleton
16327852|NCT04484571|Active Comparator|Conventional treatment|Patients receive 4 weeks of elbow conventional rehabilitation treatment matched in time
16327853|NCT04484545||Alive or Dead with COVID-19 diagnosis|Patients selected in phase 1 of study according to Health Protection Scotland criteria for diagnosis of COVID-19 infection Patients selected for phase 2 (validation phase) by PCR result
16327854|NCT04484532|Experimental|Supportive Care (trivalent influenza vaccine)|Within 14 days of baseline influenza titer, patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time, patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course, and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.
16327855|NCT04484519||Cognitively unimpaired|
16327860|NCT04484480|Experimental|Balance training|Patients included in the study group, who received 3-month proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
16327861|NCT04484480|No Intervention|Control group|Patients included in the control group who did not received any intervention
16327862|NCT04484467|Experimental|Food supplement Standart Zdorovya GASTRO|"In the intervention group (Group 1), the supplement Standart Zdorovya GASTRO (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days."
16327863|NCT04484467|Placebo Comparator|Placebo|In the control group (Group 2), placebo (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days.
16327864|NCT04484454|Experimental|Omega 3 Oil Supplementation|Following all necessary screening, patients will be provided with the ProdromeNeuro Omega-3 oil supplement and instructed to consume the equivalent of 1 cc of the oil supplement per day for the first month, followed by 2 cc of the supplement/day for the second month, and finally ending with 4 cc/day of the supplement for the third month. Neurocognitive assessment and serology testing will take place at baseline, end of month 1, end of month 2, end of month 3, and one month post intervention-termination.
16327865|NCT04484441||Fetal surgical intervention group|Pregnant adult women carrying a fetus with a diagnosed congenital anomaly and scheduled to undergo fetal surgical intervention at Mayo Clinic.
16327866|NCT04484441||Control group - normal pregnancy|Pregnant adult women with normal ultrasound findings. These women will be matched with the subjects enrolled in the intervention cohort for parity, maternal age, ethnicity, fetal sex and gestational age at time of surgical intervention.
16327867|NCT04484428|Experimental|Treatment Arm A|K-285
16327868|NCT04484428|Active Comparator|Treatment Arm B|Menthol
16327869|NCT04484415|Experimental|Cevira® treatment|The Cevira® treatment is an integrated combination of drug and device
16327870|NCT04484415|Placebo Comparator|Placebo ointment|The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.
16327871|NCT04484402|Experimental|mesenchymal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells
16327872|NCT04484402|Experimental|limbal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells
16327873|NCT04484402|Active Comparator|control|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment
16327874|NCT04484389|Experimental|Study Group|Individual exercises will be applied to individuals with Chronic disease.
16327875|NCT04484389|Active Comparator|Control Group|Group to be given an exercise brochure
16327876|NCT04484376||Other invasive candida infection|Patients with invasive candida infection due a Candida specie othr than Candida Auris.
16327877|NCT04484376||Candida Auris related invasive infection|Candida Auris related invasive candida infection.
16327878|NCT04484350|Experimental|Intensive Blood Pressure management|Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
16327879|NCT04484350|Active Comparator|Standard Blood Pressure management|Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
16327880|NCT04484337|Experimental|Part 1:Cohort 1: CAB 400 mg/mL IM gluteal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via IM gluteal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via IM gluteal injection at Week 4.
16327881|NCT04484337|Active Comparator|Part 1:Cohort 1: CAB 200 mg/mL IM gluteal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 3 mL CAB 200 mg/mL via IM gluteal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 2 mL CAB 200 mg/mL via IM gluteal injection at Week 4.
16327882|NCT04484337|Experimental|Part 1:Cohort 2: CAB 400 mg/mL SC abdominal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via SC abdominal injection. Participants will receive a second injection of CAB 200 mg given as 1 x 0.5 mL CAB 400 mg/mL via SC abdominal at Week 4.
16327883|NCT04484337|Active Comparator|Part 1:Cohort 2: CAB 200 mg/mL SC abdominal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 300 mg as 1x 1.5 mL CAB 200 mg/mL via SC abdominal injection. Participants will receive a second injection of CAB 100 mg as 1 x 0.5 mL CAB 200 mg/mL SC abdominal at Week 4.
16327884|NCT04484337|Experimental|Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL or 400 mg given as 1 x 1 mL CAB 400 mg/mL formulation via IM (lateral thigh) injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via IM (lateral thigh) at Week 4.
16327885|NCT04484337|Active Comparator|Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 600 mg given as 1 x 3 mL or 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (lateral thigh) injection. Participants will receive a second injection of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (lateral thigh) at Week 4.
16327913|NCT04484181|Active Comparator|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer was based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
16327886|NCT04484337|Experimental|Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 400 mg as 1 x 1 mL CAB 400 mg/mL via IM (gluteal injection). Participants will receive a second injection of 200 mg as 1 x 0.5 mL CAB 400 mg/mL via SC (abdominal) at Week 4.
16327887|NCT04484337|Active Comparator|Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (gluteal injection). Participants will receive a second injection of 100 mg as 1 x 0.5 mL CAB 200 mg/mL via SC (abdominal) at Week 4.
16327888|NCT04484337|Experimental|Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 800 mg as 1 x 2 mL CAB 400 mg/mL via IM (gluteus medius) injection. Participants will receive a second injection of CAB 400 mg/mL formulation via IM (gluteal injection) 12 weeks apart. The determination of the dose of the second injection will be governed by the Study Team safety and PK Review (STR).
16327889|NCT04484337|Active Comparator|Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (gluteus medius) injection. Participants will receive a second injection of CAB 200 mg/mL formulation via IM (gluteal injection) 12 weeks apart. The determination of the dose of the second injection will be governed by the STR.
16327890|NCT04484337|Experimental|Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of CAB 400 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.
16327891|NCT04484337|Active Comparator|Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of CAB 200 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.
16327892|NCT04484324|Experimental|60 seconds|60 seconds stretching group Stretching exercises for upper Trapezius and Levator the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times.
16327893|NCT04484324|Experimental|30 seconds|The same procedures while the therapist will maintain the stretch for 30 seconds.
16327894|NCT04484324|Experimental|15 seconds|The same procedures while the therapist will maintain the stretch for 15 seconds.
16327895|NCT04484324|Placebo Comparator|control|The therapist maintains the same manual contact without stretching force
16327896|NCT04484298|Experimental|reference group|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.
~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
16327897|NCT04484298|Experimental|TRINITRINE|0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered sublingually and CO was evaluated.
16327898|NCT04484285|Active Comparator|Younger Cohort|Healthy individuals aged 18 - 40
16327899|NCT04484285|Active Comparator|Older Cohort|Healthy individuals aged 65 - 85
16327900|NCT04484272|Active Comparator|Control Group|
16327901|NCT04484272|Experimental|Experimental Group|
16327902|NCT04484259|Experimental|Ticagrelor|ticagrelor 60 mg bid monotherapy
16327903|NCT04484259|Active Comparator|Aspirin plus Clopidogrel|aspirin 81 mg qd plus clopidogrel 75 mg qd
16327904|NCT04484259|Active Comparator|Aspirin plus Ticagrelor|aspirin 81 mg qd plus ticagrelor 60 mg bid
16327905|NCT04484233||Control Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management.
16327906|NCT04484233||Clinical Decision Support Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management helped by dedicated clinical decision support systems for patient blood management (iAnemia, Intelligence Anesthesia).
16327911|NCT04484194|Experimental|eHA Screening|Patients receiving eHA screening tool.
16327912|NCT04484181|Experimental|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
16327945|NCT04483947|Experimental|Cohort 1|15 participants will receive AZD2693 dose 1 and 5 participants will receive placebo
16327914|NCT04484168|Active Comparator|Terminal Interruption of the Reflux Source (TIRS|These patients will have foam sclerotherapy of the veins in the immediate vicinity of their venous ulcer and thereafter be managed in compression bandaging and followed up fro 6 months or until the ulcer has healed
16327915|NCT04484168|Active Comparator|Axial Ablation|These patients will undergo endovenous ablation of the great or small saphenous veins, or other large superficial veins exhibiting significant reflux
16327916|NCT04484155|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
16327918|NCT04484129||Close contacts of MDR-TB patients|"Close contacts of MDR-TB who met the inclusion and exclusion criteria were enrolled. Routine follow-up is scheduled at week 8, 20, 32, and 80. During the visit, participants with suspected tuberculosis symptoms will have detailed clincial assessent, weight measurement, sputum smear, sputum culture and drug sensitivity examination, imaging examinations, etc. For patients diagnosed with TB, the trial ends. Proper treatment will be started. For all paricipants who are not diagnosed with tuebrculosis in previous follow-up, the last follow-up of this study is all face-to-face visits. Sputum smear, sputum culture and chest imaging screening will be performed when necessary to exclude the possibility of tuberculosis infection. In addition, If the participants has suspected TB symptoms or is diagnosed with TB in another hospital, the researchers can be contacted for follow-up at any time."
16327919|NCT04484116||Succesful surgery|PTH 24 hours after surgery <150pg/mL
16327920|NCT04484116||Unsuccessful surgery|PTH 24 hours after surgery >150pg/mL
16327921|NCT04484103||251 patients from the MRI-FIRST trial|The mpMRIs were performed at 16 centers with 1.5T or 3T MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced imaging.
16327922|NCT04484090|Experimental|Vertica|Treatment with Vertica RF device for improving erectile function for men with erectile dysfunction
16327924|NCT04484064|No Intervention|Standard care|"Patients in the standard care arm will use an electronic adherence monitor (MEMS®) without any feedback (electronic data will be blinded to patients, clinicians and investigators until the analysis)"
16327925|NCT04484064|Experimental|Adherence program|"Patients in the adherence program will use the MEMS® and the pharmacist will provide an electronic feedback on medication adherence since the last visit. The identified determinants of medication adherence will be discussed with the patient."
16327926|NCT04484051|Active Comparator|Active comparator: Genotropin|Subcutaneous injections Genotropin, 0.6-0.8 mg/day. Participants start with 0.2 mg/day and the dose increases with 0.2 mg/day per month to a maximum dose of 0.6-0.8 mg/day.
16327927|NCT04484051|Placebo Comparator|Placebo comparator: Placebo|Placebo for 12 months.
16327928|NCT04484038|Other|IMRT, any mode|"External radiation therapy with 6-18 MV photons on the 62.5 Gy prostate bed in 25 2.5 Gy fractions (EQD2 71 Gy).
~Serving per fraction: 2.5 Gy Total fractions: 25 No. fractions / week: 5 Total treatment time: 5 weeks Total nominal dose: 62.5 Gy EQD3 (TRT): 68.75 Gy EQD1.5 (CaP): 71.43 Gy EQD2 (CaP): 68.75 Gy EQD10 (TRA): 65.10 Gy"
16327932|NCT04484012|Experimental|Treatment (CD19 CAR T cells, acalabrutinib)|Patients receive acalabrutinib PO BID on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells IV on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.
16327933|NCT04483986|Active Comparator|Study group|This arm is going to include the patients who are performed rectus reapproximation.
16327934|NCT04483986|No Intervention|Control group|This arm is going to include the patients who are not performed rectus reapproximation.
16327938|NCT04483960|No Intervention|Antiviral - Standard of care|Standard of care without nafamostat mesilate
16327939|NCT04483960|Experimental|Antiviral - nafamostat mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
16327940|NCT04483960|No Intervention|Antibody - Standard of care|No hyperimmune globulin
16327941|NCT04483960|Experimental|Antibody - hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation
16327942|NCT04483960|Active Comparator|Anticoagulation - standard dose thromboprophylaxis|Patients will be administered a standard thromboprophylactic dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site.
16327943|NCT04483960|Experimental|Anticoagulation - intermediate dose thromboprophylaxis|Patients will be administered an intermediate dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.
16327944|NCT04483960|Experimental|Anticoagulation - therapeutic anticoagulation|Therapeutic anticoagulation administered with LMWH daily until hospital discharge, admission to ICU or for a maximum of 28 days from randomisation. Choice of LMWH according to availability and local practice at the participating site
16330483|NCT04466683|Experimental|High radiation arm|A single dose of 100 cGY delivered to the whole thorax
16327950|NCT04483921|No Intervention|Sedentary|Participants will rest quietly in a seated position for the equivalent amount of time prescribed for the exercise condition.
16327951|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test > 12days (d) ago and no symptoms (~250 participants).
~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
16327952|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (~100 participants).
~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
16327953|NCT04483908||Cohort 3|Subjects with PCR negative test > 5d (~100 participants). Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
16327954|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (~100 participants).
~Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
16327955|NCT04483895|Active Comparator|The OHL method|the ETT insertion depth was estimated according to the OHL method.
16327956|NCT04483895|Active Comparator|The 7-8-9 method|the ETT insertion depth was estimated according to the 7-8-9 method.
16327957|NCT04483882|Sham Comparator|Phase I- Visually Obscured Healthy Subjects|Tactile label to be evaluated by healthy subjects without visual defect. Subjects in visually obscuring lenses but without peripheral neuropathies or other tactile deficits will evaluate the tactile labeling product for efficacy in drug identity and dosing definition. .
16327958|NCT04483882|Active Comparator|Phase II- Low Vision Over 50 years of age|Subjects with documented Low Vision of 20/70 or less or visual field less than 20 degrees will be asked to evaluate tactile labeling product for efficacy in drug identity and dosing definition.
16327959|NCT04483856|Experimental|DermoRelizema cream|The treatment will be applied since about 7 (±3) days prior to RT start and will continue until 14 days post RT end
16327960|NCT04483856|Active Comparator|Dexeryl|The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
16327961|NCT04483843||CPE patients|All patients prehospitally treated for cardiogenic pulmonary edema in the pre-hospital emergency setting in the Central Bohemian region, Czech Republic.
16327962|NCT04483830|Placebo Comparator|group A|patient with the early stages of COVID-19 to received an oral dose of placebo twice a day for 21 days
16327963|NCT04483830|Active Comparator|group B|patient in the early stages of COVID-19 to received an oral dose of 500LRU of sulodexide twice a day for 21 days.
16327964|NCT04483817|Experimental|A: Transcutaneous tibial nerve stimulation|The transcutaneous electrostimulation of the posterior tibial nerve (ETNTP) will be applied to group A: place two surface electrodes, one 32 mm in diameter, 5 cm cephalad of the internal malleolus and 1 cm medial posterior of the tibia; and another 50x50 mm electrode in the calcaneous. The flexion of the first toe will indicate the correct placement of the electrodes. Stimulation is performed according to the Stoller method with a stimulator programmed at 20Hz and 200 µs, with a continuous current, 12 sessions, 2 weekly are completed. The intensity of the current will be tolerance by the subject.
16327965|NCT04483817|Active Comparator|B: Percutaneous tibial nerve stimulation|The percutaneous electrostimulation of the posterior tibial nerve (EPNTP) will be applied to group B: inserting a 0.25x30mm surgical steel needle at a 60º angle, 5 cm cephalad to the malleolus and 1 cm posterior of the tibia , and a surface electrode of 50x50 mm in the calcaneous. The flexion of the first finger will indicate its correct placement. The stimulation parameters will also follow the Stoller method.
16327966|NCT04483804||disease free survival|Time from randomization to relapse or death due to disease progression
16327967|NCT04483804||non-disease free survival|Time of metastasis or death
16327968|NCT04483778|Experimental|SCRI-CARB7H3(s)|Autologous CD4+ and CD8+ T-cells genetically modified to express an B7H3-specific CAR
16327969|NCT04483778|Experimental|SCRI-CARB7H3(s)x19|Autologous CD4+ and CD8+ T-cells genetically modified to a bispecific B7H3xCD19 CAR
16327970|NCT04483765||post-spinal hypotension|Patients with a fall in SBP by 25% of the preoperative baseline or an absolute value <90 mm of Hg; MAP ≤65 mmHg after spinal anesthesia
16327971|NCT04483765||post-spinal normotension|Patients with Fall of SBP<%25 of the preoperative value or absolute value >90 mm Hg, MAP>65 mmHg
16327972|NCT04483752|Other|Patients hospitalised for SARS CoV-2 infection.|
16327973|NCT04483739|Experimental|Krd Induction|4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
16327974|NCT04483739|Experimental|Isa-KRd induction|"Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4.
~Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22"
16327975|NCT04483739|Experimental|KRd post ASCT consolidation|4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
16327976|NCT04483739|Experimental|Isa-KRd post ASCT consolidation:|4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
16327977|NCT04483739|Experimental|KRd light consolidation|12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
16327978|NCT04483739|Experimental|Isa-KRd light consolidation|Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
16328013|NCT04483453|Experimental|EXPL feeding regimen|Lower protein / lower estimated glycemic index regimen
16327981|NCT04483713|Active Comparator|Educational Workshop|Will receive theoretical and practical training in EBP through a workshop in a structured model with themes related to the introduction to EBP, with the final proposal of a practical class that aims to structure and describe an individual case through an exercise formulated to go through the phases of a project of EBP, to base this exercise we will use a finished and consolidated project, this will be used as a template of the exercise, the description of this exercise is in the programmatic content.
16327982|NCT04483713|Active Comparator|Educational Workshop plus J. H. N. EBP Guide Tools|"Will receive the same training as group Educational Workshop, plus the presentation and availability of the Johns Hopkins Nursing Evidence-based Practice guide tools to be used in the practice class for the structuring and individual description of the EBP exercise case. The same theme of the case will be used in both groups."
16327983|NCT04483700|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
16327984|NCT04483700|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
16327985|NCT04483700|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
16327986|NCT04483700|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.
~After study-wide unblinding, participants will receive filgotinib 200 mg."
16327987|NCT04483700|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.
~After study-wide unblinding, participants will receive filgotinib 100 mg."
16327988|NCT04483687|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
16327989|NCT04483687|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
16327990|NCT04483687|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
16327991|NCT04483687|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.
~After study-wide unblinding, participants will receive filgotinib 200 mg."
16327992|NCT04483687|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.
~After study-wide unblinding, participants will receive filgotinib 100 mg."
16327993|NCT04483674|Experimental|Biktarvy|Patients will receive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks
16327994|NCT04483648|Experimental|Exercise Group|A progressive home-based cervical stabilization exercise program was delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) in a weekly basis.
16327995|NCT04483648|No Intervention|Control Group|Patients in control group did not receive any exercise intervention.
16327996|NCT04483635|Placebo Comparator|Placebo|"10 placebo tablets taken orally at baseline, followed by 1 placebo tablet once a week for 16 weeks
~Note that the study may be prolonged according to the overall infection rate monitored monthly."
16327997|NCT04483635|Experimental|Vitamin D3|"10 tablets containing 10,000 IU (total : 100,000 IU) of Vitamin D3 taken orally at baseline, followed by 10,000 IU once a week for 16 weeks.
~Note that the study may be prolonged according to the overall infection rate monitored monthly."
16327998|NCT04483609||pre-test Group|10 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
16327999|NCT04483609||Validation and Reliability Group|80 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
16328000|NCT04483596||M|will receive 5 mg melatonin orally at 9 p.m. the night before surgery and another 5 mg melatonin with 15 ml of plain water 30 min before operation and 5 mg melatonin at 9 p.m. in the day of operation and for the first three postoperative days
16328001|NCT04483596||C|received a placebo in the form of one tablet of 500 mg paracetamol that packaged the same way as melatonin at the same times
16328002|NCT04483583|Active Comparator|ABCD-GENE >10 - Clopidogrel|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
16328003|NCT04483583|Experimental|ABCD-GENE >10 - Ticagrelor|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
16328004|NCT04483583|Active Comparator|ABCD-GENE <10 - Clopidogrel|Patients with an ABCD-GENE<10 will be treated with clopidogrel (75 mg/qd) for 30 days.
16328005|NCT04483570||Secondary Tethered Cord Syndrome|Children with signs of progressive deterioration in urological or neuroorthopedic system, and suspected Secondary Tethered Cord Syndrome (STCS) following primary untethering surgery.
16328006|NCT04483544|Experimental|Treatment|PD-1 inhibitor pembrolizumab, in combination with the PARP inhibitor olaparib
16328007|NCT04483518||HBV patients|HBV patients with HBsAg positive and/or HBV DNA positive
16328008|NCT04483505|Experimental|Rogaratinib + palbociclib + fulvestrant|
16328009|NCT04483492||1|newborns under 32 weeks with respiratory support if they are decided to start caffeine treatment
16328010|NCT04483479|Experimental|Active Treatment|Orally Administered ENT-01 25mg Tablet Once Daily (Dose dependent on ENT-01-030 dose level stratification)
16328011|NCT04483466|Experimental|Treatment with methotrexate|134 participants will be treated with methotrexate
16328012|NCT04483466|Placebo Comparator|Placebo methotrexate|76 will receive placebo
16328014|NCT04483453|Active Comparator|CTRL feeding regimen|Standard protein / standard glycemic index regimen
16328015|NCT04483440|Experimental|4D-110 Dose 1|4D-110 IVT injection
16328016|NCT04483440|Experimental|4D-110 Dose 2|4D-110 IVT injection
16328017|NCT04483427|Experimental|OSA patients after multilevel surgery|
16328018|NCT04483414|Experimental|Patients with suspected BCR or metastatic prostate cancer|Patients with suspected BCR or metastatic prostate cancer
16328019|NCT04483401|No Intervention|Waitlist|"Waitlist Participants are first allocated to a waitlist condition. After the first MRI scan, participants wait for 12 weeks and have a second MRI scan."
16328020|NCT04483401|Experimental|Treatment arm|Upon completion on the waitlist time of 12 weeks, participants then are allocated to the treatment group. Participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a third MRI scan.
16328021|NCT04483388|Other|Group AB|After randomization, 6 children composed the AB sequence were initially submitted to experimental training with virtual reality and after a week, a period considered washout, the conventional training.
16328022|NCT04483388|Other|Group BA|After randomization 6 children composed the BA sequence were initially submitted to conventional training and after a week, a period considered washout, the experimental training with virtual reality.
16328023|NCT04483375|Experimental|anti-SARS-CoV-2 monoclonal antibody(SCTA01)|SCTA01: single dose on Day0
16328024|NCT04483375|Placebo Comparator|Placebo|Placebo: single dose on Day0
16328025|NCT04483362|Experimental|Physical Activity|Behavioural change techniques to promote physical activity
16328026|NCT04483349||Observational (survey administration)|Patients and healthcare providers complete a survey over 10-15 minutes.
16328027|NCT04483336|Experimental|Virtual reality Distraction.|Subjects watched a video cartoon using virtual reality goggles as a distraction technique during the administration of local anesthesia.
16328028|NCT04483336|Active Comparator|TV screen Distraction|Subjects watched a video cartoon on a regular TV screen as a distraction technique during the administration of local anesthesia.
16328029|NCT04483323|Active Comparator|Group I: Intraarticular group ( IA )|Patients will receive 20 ml of 0.25% bupivacaine intra-articularly through the surgical port
16328030|NCT04483323|Experimental|Group II: Erector Spinae Plane Block group ( ES )|Patients will receive an ultrasound guided erector spinae plane block using 20 ml of 0.25% bupivacaine at the level of T2 transverse process
16328031|NCT04483310|Experimental|MR therapy|MR therapy is a psychological treatment for SP, comprised of the following steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
16328032|NCT04483310|Active Comparator|Control intervention|The control intervention was identical, except participants engaged in deep breathing; entailing slow deep breaths, while repeatedly counting from 1-10. This is an active control (breathing-distraction exercise) rather than a placebo.
16328033|NCT04483297|Experimental|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation
16328034|NCT04483297|Other|Control|Local Autologous Bone + Posterior Fixation
16328035|NCT04483284|Experimental|TACE combined with Camrelizumab|Camrelizumab（200mg q3w ivgtt）combined with TACE,the interval between TACE treatment and Carilizumab is not less than 7 days.
16328036|NCT04483271|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 2 months.
16328037|NCT04483271|No Intervention|Control group|No intervention was given
16328038|NCT04483258|Active Comparator|Sedation with Insufflation|Sedation induction via oxygen mask %8 sevoflurane and reducing %3 concentration after rediotherapy start
16328039|NCT04483258|Active Comparator|İntravenous sedation|Midazolam+ Ketamine sedation
16328040|NCT04483245||controls|persons free of hemorrhage or haemostasis disorder
16328041|NCT04483245||Haemorrhagic|Acute hemorrhagic patient
16328042|NCT04483245||ECMO|ECMO surgery patient with hemorrhagic complication
16328043|NCT04483245||polytrauma|
16328044|NCT04483245||Platelet disorder|Patient with an identified platelet disorder or treated with antiplatelet agents
16328045|NCT04483232||Healthy Subjects|
16328046|NCT04483232||Patients with ear infections|
16328047|NCT04483219|Experimental|TKI ± anti-PD-1 antibody|According to response to TKI, the combination of anti-PD-1 treatment would be determined.
16328048|NCT04483206|Experimental|Treatment (Melphalan-based autologous transplant)|Patients receive high dose (100 mg/m2) melphalan IV over 30 minutes on day -3 and PK-directed melphalan IV over 30 minutes on day -1 to achieve set cumulative melphalan exposure levels. Patients then undergo stem cell infusion on day 0.
16328049|NCT04483193||Critically ill patients|Critically ill patients hospitalised at the intensive care unit.
16328050|NCT04483180|Placebo Comparator|Control|Beverage containing a sucrose solution. Same aspect and flavor than the experimental beverages. About 1/4 of participants will start with this beverage first.
16328051|NCT04483180|Experimental|Sucralose / acesulfame K|Beverage containing a blend of sweeteners based on sucralose and acesulfame K. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
16328052|NCT04483180|Experimental|Stevia rebaudioside A / thaumatin|Beverage containing a blend of sweeteners based on stevia rebaudioside A and thaumatin. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
16328053|NCT04483180|Experimental|Mogroside V / stevia rebaudioside M|Beverage containing a blend of sweeteners based on mogroside V and stevia rebaudioside M. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
16328054|NCT04483167|Experimental|99mTccAbVCAM1-5|"Healthy volunteers and asymptomatic patients
~Pré-screening of the volunteers by the CIC or the Vascular Surgeon and sending or handing over the newsletter
~Visit 0 Selection: Validation of IC / NIC + Consent collection + additional exams
~Visit 1 Inclusion: J0 Scintigraphic imaging following injection 99mTc-cAbVCAM1-5 (370 MBq - 550 MBq - 750 MBq depend of the SAE or AE )
~Visit 2: Follow-up visit (Day 14 +/- 7 days post injection)
~Visit 3: End of the study, follow-up visit (70 days +/- 10 days post injection)"
16328203|NCT04482309|Experimental|Arm 5|Cohort 5: Ovarian cancer
16328055|NCT04483141||non-communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (hetero-assessment of pain).
16328056|NCT04483141||communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (including hetero-assessment and auto-assessment of pain)
16328057|NCT04483128|Sham Comparator|Sham IFC therapy: Control group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).
~IFC parameters:
~Carrier frequency of 4000 Hz
~Amplitude modulated frequency of 65 Hz (AMF)
~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.
~NO intensity (0 mA)
~Session duration: 25 minutes"
16328058|NCT04483128|Experimental|IFC therapy: Experimental group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).
~IFC parameters:
~Carrier frequency of 4000 Hz
~Amplitude modulated frequency of 65 Hz (AMF)
~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.
~Intensity will depend on subjet's tolerance but without generating visible muscle twitches.
~Session duration: 25 minutes"
16328065|NCT04483102|Experimental|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
16328066|NCT04483102|Active Comparator|Standard cold preservation of liver|This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.
16328067|NCT04483076|Experimental|Arm A|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm A will receive three more cycles of SOX (six cycles of neoadjuvant chemotherapy with SOX in total) followed by D2 gastrectomy.
16328068|NCT04483076|Active Comparator|Arm B|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm B will receive D2 gastrectomy (three cycles of neoadjuvant chemotherapy with SOX in total).
16328069|NCT04483063|Experimental|Extended shoulder group|2% chlorhexidine gluconate skin cleanser over the not only the operative shoulder and axilla but also the chest, back, neck, and face
16328070|NCT04483063|Experimental|Shoulder group|2% chlorhexidine gluconate skin cleanser over the operative shoulder and axilla
16328071|NCT04483063|No Intervention|Control group|Skin prepare with soap as usual
16328072|NCT04483050|Experimental|experimental group|
16328073|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the morning (Observation Group)|routine bowel preparation before colonoscopy in the morning
16328074|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the afternoon (Random)|routine bowel preparation before colonoscopy in the afternoon
16328075|NCT04483037|Experimental|two dose in the same day, colonoscopy in the afternoon (Random)|experimental group
16328076|NCT04483024|Placebo Comparator|Placebo|Maltodextrin
16328077|NCT04483024|Active Comparator|Glucosamine|Glucosamine hydrochloride
16328078|NCT04483024|Experimental|Collagen hydrolysate|2g of hydrolyzed collagen II
16328079|NCT04483024|Experimental|Collagen hydrolysate + chicken extract|2g of hydrolyzed collagen II with chicken extract
16328080|NCT04483011|Experimental|RiaGev|RiaGev, 2000mg, BID
16328081|NCT04483011|Active Comparator|Comparator|Comparator matched to RiaGev, BID
16328082|NCT04482998||Steroids only - early|treatment was initiated within 7 days of acoustic trauma.
16328083|NCT04482998||Early combined steroid and hyperbaric oxygen therapy|treatment was initiated within 7 days of acoustic trauma.
16328084|NCT04482998||Delayed combined steroid and hyperbaric oxygen therapy|treatment was initiated after 7 days of acoustic trauma.
16328085|NCT04482998||Early sequential steroid followed by HBO therapy|treatment was initiated within 7 days of acoustic trauma.
16328086|NCT04482998||Delayed sequential steroid followed by HBO therapy|treatment was initiated after 7 days of acoustic trauma.
16328087|NCT04482998||Hyperbaric oxygen therapy only|
16328088|NCT04482998||No treatment|
16328089|NCT04482998||Steroid only - delayed|treatment was initiated after 7 days of acoustic trauma.
16328090|NCT04482985|Active Comparator|Meclizine responders|
16328091|NCT04482985|Active Comparator|Meclizine non responders|
16328092|NCT04482972||DCB|DCB group: Patients treated with drug coated balloon (DCB) only angioplasty (all-comers: STEMI, NSTEMI, Stable angina)
16328093|NCT04482972||DES|DES group: Patients treated with drug eluting stent (DES) angioplasty (all-comers:STEMI, NSTEMI, Stable angina)
16328094|NCT04482959|Experimental|Carbetocin group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute.
16328095|NCT04482959|Placebo Comparator|• Control group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of sodium chloride 0.9% IV over 1 minute.
16328204|NCT04482309|Experimental|Arm 6|Cohort 6: Pancreatic cancer
16328096|NCT04482946|Experimental|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
16328097|NCT04482933|Experimental|Experimental: HSV G207|All subjects will receive G207 at 1 x 10^8 plaque-forming units (pfu), intratumorally via controlled rate infusion through up to 4 silastic catheters over a 6 hour period. The subject will then receive a single 5 Gy dose of radiation to the tumor within 24 hours of virus inoculation.
16328098|NCT04482920||Transgender males|Transgender males who are clinically ready to start testosterone
16328099|NCT04482920||Transgender females|Transgender females who are clinically ready to start estradiol
16328100|NCT04482907|Active Comparator|Group receiving dill|They took 3 meals a day, 3x300 mg dry dill powder by mouth. They bought dry dill powder for 90 days.
16328101|NCT04482907|Placebo Comparator|Group receiving placebo|They took 3 meals a day and 3 cellulose placebo capsules by mouth. They took placebo capsules for 90 days.
16328102|NCT04482894|Experimental|Palliative Care Intervention|Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.
16328103|NCT04482894|No Intervention|Standard Clinical Care|Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.
16328104|NCT04482881|Active Comparator|women receiving isosorbide mononitrates lower dose|women who will receive isosorbide mononitrates lower dose
16328105|NCT04482881|Active Comparator|women receiving isosorbide mononitrates higher dose|women who will receive isosorbide mononitrates higher dose
16328106|NCT04482881|Active Comparator|Women receiving misoprostol|Women who will receive misoprostol
16328107|NCT04482868|Placebo Comparator|open reduction group|
16328108|NCT04482868|Experimental|percutaneous group|
16328109|NCT04482855|Experimental|Group 1 (laser group)|Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
16328110|NCT04482855|No Intervention|Group 2 (wait-list control group)|Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
16328111|NCT04482842|Experimental|Gene-guided Warfarin|
16328112|NCT04482842|Other|Routine use|
16328113|NCT04482829|Experimental|Experimental Group|On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.
16328114|NCT04482829|Other|Control Group|All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.
16328115|NCT04482816|Experimental|Physiological pacing|"Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle.
~If hisian pacing is not achieved (QRS is not shortened > 20% or QRS is not <130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection <85ms).
~Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria."
16328116|NCT04482816|Active Comparator|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
16328117|NCT04482803|Experimental|Carbon nanoparticles labelled lymph nodes group|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes before NST.
16328118|NCT04482790|Active Comparator|Conventional celluloid matrix|Conventional celluloid matrix technique in management of black triangle
16328119|NCT04482790|Experimental|Bioclear cervical matrix|Bioclear cervical matrix with injection molding technique in management of black triangle
16328120|NCT04482764|Other|cyanotic breath holding spells|drug, valproic acid: 5mg/kg/d for 6 months
16328121|NCT04482751||Infertile women|the group consists of 80 infertile patients undergoing IVF
16328122|NCT04482738||Lean subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
16328123|NCT04482738||Obese subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
16328205|NCT04482309|Experimental|Arm 7|Cohort 7: Rare tumors
16328136|NCT04482712|Placebo Comparator|Placebo|Administration of placebo daily during hospitalization
16328137|NCT04482712|Active Comparator|Rapamycin|Administration of rapamycin (sirolimus) 1mg daily during hospitalization
16328138|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 1)|Dose level 1 is 40 x 10^6
16328139|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 2)|Dose level 2 is 160 x 10^6
16328140|NCT04482699|Active Comparator|RAPA-501 cells|RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)
16328141|NCT04482699|Placebo Comparator|Placebo-control Cohort|Placebo
16328144|NCT04482673|Experimental|COVID-19 Negative Active Treatment|Participants will be randomized to vitamin D3 (6000 IU) per day for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
16328145|NCT04482673|Placebo Comparator|COVID-19 Negative Placebo|Participants in this arm would receive placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
16328146|NCT04482673|Experimental|COVID-19 Positive Active Treatment|Participants will be randomized to vitamin D3 as a bolus (20,000 IU) per day for 3 days followed by high dose vitamin D (6000 IU) per dayfor 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
16328147|NCT04482673|Placebo Comparator|COVID-19 Positive Placebo|Participants in this arm would receive placebo as a bolus followed by daily placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
16328148|NCT04482660|Experimental|PET|
16328149|NCT04482647|Experimental|Supportive Care (video, breathing techniques, meditation)|Patients view an instructional video on breathing techniques and meditation. Patients then perform breathing techniques over 3 minutes and meditation over 2 minutes BID for 28 days.
16328150|NCT04482634|Active Comparator|Tele-rehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection.
16328151|NCT04482634|Active Comparator|Home exercise group|This group will perform the exercises at their home on their own, the first exercise program will be given at hospital and the patients will be followed up regular weekly by phone call.
16328152|NCT04482621|Active Comparator|Decitabine + Standard of Care (SOC)|Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
16328153|NCT04482621|Placebo Comparator|Standard of Care (SOC) + Placebo|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
16328154|NCT04482608||pMMR/MSS mCRC patients|The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
16328155|NCT04482608||dMMR/MSI-H mCRC patients|The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
16328156|NCT04482595|Experimental|BIO 300 Oral Suspension (genistein 1500 mg)|BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
16328157|NCT04482595|Placebo Comparator|Placebo|BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
16328158|NCT04482582|Experimental|Image-guided percutaneous ICN (pICN): Group A|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to percutaneous image-guided cryoneurolysis (pICN) group within 72 hours of presentation.
16328159|NCT04482582|Active Comparator|Standard-of Care : Group B|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to standard-of-care group within 72 hours of presentation.
16328160|NCT04482569|Experimental|Single Ascending Dose Study|Six XNW4107 doses ( 50-1250 mg ), each administered as a single dose with 60-minute IV infusion
16328161|NCT04482569|Experimental|Multiple Ascending Dose Study|Three XNW4107 doses (167-500 mg), each administered as 60-minute IV infusion every 6 hours for 7 days
16328162|NCT04482569|Experimental|Multiple Dose Study of XNW4107 +Imipenem/Cilastatin|500 mg XNW4107 co-administered with imipenem/cilastatin as 60-minute IV infusion every 6 hours for 14 days
16328163|NCT04482556|Other|Q-NRG+ Indirect Calorimetry Device|Q-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion.
16328164|NCT04482556|Other|V(max) Encore Indirect Calorimetry Device|V(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion.
16328165|NCT04482543|Active Comparator|Intra-silicone oil injection of 250 µg methotrexate|
16328166|NCT04482543|No Intervention|No intra-silicone oil injection of methotrexate|
16328167|NCT04482530|Experimental|Original recipe|Normal fruit paste
16328168|NCT04482530|Experimental|maltodextrin recipe|fruit pastes in which some of the simple sugars in the recipe will be replaced by maltodextrin with a low glycemic index (DE12).
16328169|NCT04482530|Experimental|fructose recipe|fruit pastes in which some of the simple sugars in the recipe (25% min) will be replaced by fructose
16328170|NCT04482530|Experimental|isomaltulose recipe|fruit pastes with some of the sugars will be replaced (25% min) by isomaltulose
16328171|NCT04482530|Experimental|mixed recipe|fruit pastes with some of the sugars will be replaced (25% min) by fructose / isomaltulose
16328172|NCT04482517|Other|Density Gradient Centrifugation (DGC)|Using the routine DGC sperm processing only
16328173|NCT04482517|Active Comparator|Physiological ICSI (PICSI)|Using PICSI dish for selecting sperm with lower sperm DNA fragmentation
16328174|NCT04482517|Active Comparator|Magnetic Activated Cell Sorting (MACS)|Using MACS for selecting sperm with lower sperm DNA fragmentation
16328175|NCT04482517|Active Comparator|Testicular sperm (Testi)|Using testicular sperm not ejaculated sperm
16328176|NCT04482504||healthy pregnant women|"200 healthy pregnant women in 36.-38. Week of pregnancy. The investigators involve every healthy pregnant woman in 36.-38. week of pregnancy.
~Exclusion criteria:
~Unwilling to participate
~Minors (under 18 years old)
~e) Unfamiliar with slovak language f) Multiple pregnancy g) Musculoskeletal and neurological abnormalities"
16328177|NCT04482504||non-pregnant women|"30 non-pregnant healthy control women The investigators involve every healthy non-pregnant woman.
~Exclusion criteria:
~Unwilling to participate
~Minors (under 18 years old)
~e) Unfamiliar with slovak language f) Pregnancy g) Musculoskeletal and neurological abnormalities"
16328178|NCT04482478|Experimental|EDL(Extract of Dolichos lablab Linne)|The randomly assigned target was given a Extract of Dolichos lablab Linne (EDL) 715 mg/day for 12 weeks.
16328179|NCT04482478|Placebo Comparator|Placebo comparator|The randomly assigned target was given a placebo for 12 weeks.
16328180|NCT04482465|Other|pilot study 1 arm|50 subjects with no AMD or early AMD, aged over 55, at moderate-to-high risk for AMD based on a simplified AMD risk assessment scale score > or = 10, not taking vitamin D or trace nutriënt containing supplements
16328181|NCT04482439|Experimental|Vivity mini-monovision|Subjects will have bilateral Vivity IOL implanted, with a target of slight myopia in the non-dominant eye.
16328182|NCT04482413|Experimental|Treatment|treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10^8 cells / 20 mL of saline with 30% auto-serum.
16328183|NCT04482413|Active Comparator|Active Control|Active control group will receive 5 mg of Donepezil and AstroStem Placebo.
16328184|NCT04482400|Experimental|NEAT!2|Participants randomized to this arm will use the NEAT!2 app and receive biweekly coaching calls during weeks 4-12 after surgery, and monthly maintenance calls between months 3-6.
16328185|NCT04482400|Active Comparator|MyKneeGuide|Participants randomized to this arm will use the MyKneeGuide app/website and receive biweekly coaching calls during week 4-12 after surgery, and monthly maintenance calls between months 3-6.
16328186|NCT04482387|Other|subjects recruited to visual acuity testing|All recruited subjects will have the intervention (Digivis visual acuity self-testing) and the standard clinical visual acuity assessment in clinic.
16328189|NCT04482348|Active Comparator|the mind is a great story teller-positively framed|explanations for more pain than expected
16328190|NCT04482348|Active Comparator|the mind is a great story teller-negatively framed|explanations for more pain than expected
16328191|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-positive frame|explanations for more pain than expected
16328192|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-negative frame|explanations for more pain than expected
16328193|NCT04482348|Active Comparator|"mixed emotion and cognition (mind and body work together)"|explanations for more pain than expected
16328194|NCT04482348|Active Comparator|"physically based explanations over-excited state"|explanations for more pain than expected
16328195|NCT04482348|Active Comparator|"physically based explanations overstimulated"|explanations for more pain than expected
16328196|NCT04482335||Main Study|Participants complete questionnaires and agree to have their retrospective and prospective medical data used as part f this research project. All participants will take part in this arm.
16328197|NCT04482335||Biosample Sub-Study|A subset of the participants will take part of this. Participants will agree to have blood samples taken at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to provide urine samples.
16328198|NCT04482335||Synovial Biopsy and Synovial Fluid Sub-Study|A subset of the participants will take part of this. Participants will agree to synovial biopsies at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to donate waste synovial fluid.
16328199|NCT04482309|Experimental|Arm 1|Cohort 1: Biliary tract cancer
16328200|NCT04482309|Experimental|Arm 2|Cohort 2: Bladder cancer
16328201|NCT04482309|Experimental|Arm 3|Cohort 3: Cervical cancer
16328202|NCT04482309|Experimental|Arm 4|Cohort 4: Endometrial cancer
16328206|NCT04482296|No Intervention|SSRI with placebo|50 patients who will receive placebo with SSRIs for 8 weeks
16328207|NCT04482296|Active Comparator|SSRI with zinc sulfate|50 patients who will receive SSRIs with zinc sulfate for 8 weeks
16328208|NCT04482270|Experimental|Fezolinetant: Mild Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328209|NCT04482270|Experimental|Fezolinetant: Moderate Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328210|NCT04482270|Experimental|Fezolinetant: Normal Hepatic Function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328211|NCT04482257|Experimental|T-R|Subjects will receive Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV
16328212|NCT04482257|Experimental|R-T|Subjects will receive Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV
16328213|NCT04482244|Experimental|Cannabidiol|"After screening procedures confirm participation in the research study, participants will be randomized one of two groups:
~Participants in the experimental arm will complete questionnaires and then receive a single dose of CBD prior to diagnostic CT scan.
~Cannabidiol: Oral, per protocol dosage, single dose
~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
16328214|NCT04482244|Placebo Comparator|Placebo|"After the screening procedures confirm participation in the research study, participants will be randomized one of two groups:
~Participants in the placebo arm will complete questionnaire and then receive a single dose of placebo prior to diagnostic CT scan.
~Placebo: Oral, per protocol dosage, single dose
~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
16328215|NCT04482205||precovid group|those who were operated from fJanuary first to March 15
16328216|NCT04482205||covid|those operated from March 16, to May 31, 2020
16328217|NCT04482192|Active Comparator|Thoracic paravertebral block group|Continuous thoracic paravertebral block with 1% lidocaine infusion for 3 postoperative days through a paravertebral catheter inserted intraoperatively by the surgeon.
16328218|NCT04482192|Active Comparator|Systemic analgesia group|patients in this group will receive paracetamol and ketorolac by intravenous infusion every 6 hours for 3 postoperative days
16328219|NCT04482179|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
16328220|NCT04482179|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
16328221|NCT04482166|Experimental|Candidates|Training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
16328223|NCT04482127|Experimental|SubEpithelial connective graft|"SCTG harvested from palatal tissue by single line incision technique, blade will be oriented perpendicular to the palatal tissue surface. A single incision will be made down to the bone in a horizontal direction approximately 2 to 3 mm apical to the gingival margin of the maxillary teeth. A partial thickness dissection will then be made within the single incision, leaving an adequate thickness of the palatal flap intact to minimize the chance of sloughing of the overlying tissue. Careful manipulation of the graft with tissue forceps will be required and care must be taken to prevent compression or tearing of the graft.
~The fatty tissue (yellow in color) will be eliminated and some contouring of the graft will be done to fit the prepared envelope. The harvested SCTG will be placed at the extraction sites in a supra-periosteal partial dissection (pouch II technique) prepared at the buccal aspect without using vertical incisions and without flap elevation."
16328224|NCT04482127|No Intervention|Atraumatic extraction|Extraction with Periotomes and Luxators keeping the buccal plate of bone intact
16328225|NCT04482114|Other|ultra-low dose CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
16328226|NCT04482101|Experimental|Ah-Plus sealer|"Root canal sealer which is a resin-based formula with excellent radiopacity , low shrinkage , low solubility and outstanding flow characteristics .
~It features a 1:1 , paste-to-paste mixing system for fast , easy preparation and less waste . It is biocompatible and silver free ."
16328227|NCT04482101|Experimental|Endosequence BC sealer|"It is a root canal sealer which is premixed ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications.
~It is insoluble , radiopaque and aluminum-free material based on calcium silicate composition , which requires the presence of water to set and hardens . It does not shrink during setting and demonstrate excellent physical properties ."
16328228|NCT04482088|Experimental|OTC & OTEE|Every participant will receive 10 weeks of occupational therapy in a clinic environment (OTC) followed by 10 weeks of occupational therapy in an equine environment
16328229|NCT04482075|Other|SEGMENTAL STABILISATION TRAINING (SST)|Segmental Stabilisation Training is an established treatment technique for chronic low back pain
16328256|NCT04481854|Experimental|left paratracheal pressure group|Patients of this group will recieve left paratracheal pressure during direct laryngoscopy.
16328233|NCT04482036|Placebo Comparator|Dementia Collaborative Care|"Patient and caregivers assigned to the three in-person assessments and no mobile application group will complete the following:
~The caregiver will be asked to complete three in-person assessments that involve answering survey questions and an interview.
~Some of the questions asked will be related to Behavioral and/or Psychological Symptoms the patient experiences.
~The caregiver will be asked to answer questions about the patient, the patient's experience with the research study and the caregiver's own experience with the research study.
~If the patient's symptoms or the caregiver's distress answers reach a high enough level, a member of the research study team and clinical team will contact the caregiver to ask more questions and check in on the patient and caregiver's safety.
~The research study team will also notify Dr. Bateman (the person responsible for the research)."
16328234|NCT04482036|Active Comparator|Dementia Collaborative Care Plus BrainCare Notes Application|"Patient and caregivers assigned to the three in-person assessments and mobile application group will complete the same tasks that Group 1 (control group) will complete with the addition of the following:
~The caregiver will be asked to monitor the patient and complete 5 to 10-minute long surveys (the neuropsychiatric inventory questionnaire) sent to the caregiver through the mobile application or in-person at each follow-up visit.
~The caregiver will be asked to monitor and complete these surveys at different times for a period of 6 months."
16328235|NCT04482023||Nurses COVID 19|Nurses from any unit of the Consortium Parc Taulí Corporation who have been in direct care of patients diagnosed with COVID 19 between March 9, 2020 and May 15, 2020
16328236|NCT04482010|No Intervention|Classic HIV care|Participants diangosed HIV positive at the time of the community-based activities conducted by ARCAD Santé PLUS. They will be referred to the referral centers (CSRéf) for the classic HIV care in the Malian public health system.
16328237|NCT04482010|Other|Community-based HIV care|Participants diagnosed HIV positive at the time of the community-based activities by ARCAD Santé PLUS. They will receive community-based HIV care by the NGO at the gold-mining site.
16328239|NCT04481984|Experimental|Exercise group|The training including isometric and stretching hand exercise was applied once by a physiatrist. A hand exercise ball was used for isometric exercise. Patients performed both stretching exercises and isometric exercises according to the training and printed materials. The home-based exercise program was implemented 7 days per week during an 8-week period. In addition, patients received recommendations such as avoiding cold exposure and trauma.
16328240|NCT04481984|Other|Control group|Patients received care advice including avoiding cold exposure and trauma.
16328241|NCT04481971|Experimental|40 mg|
16328242|NCT04481971|Experimental|20 mg|
16328243|NCT04481971|Placebo Comparator|Placebo|
16328244|NCT04481958|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
16328245|NCT04481945|Active Comparator|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
16328246|NCT04481945|Experimental|bioceramic sealer and silver nanoparticles|silver nanoparticles are antibacterial ions that can interact with multiple targets in the bacterial cell
16328247|NCT04481945|Experimental|bioceramic sealer and chitosan|chitosan has an excellent antibacterial, antiviral and antifungal properties, as an antibacterial, it works better on gram negative than gram positive
16328248|NCT04481932|Experimental|Trastuzumab combined with Pyrotinib and chemotherapy|The dosage of the above drugs can be adjusted according to the adverse reactions of the subjects. The subject continued to use the drug until the full cycle or the disease progressed or the toxicity was intolerable or withdrawn, or the researcher judged that the medication must be terminated.
16328249|NCT04481919|Active Comparator|Protocolized spot urine sodium guided diuretic therapy|Patients will have a spot urine sodium and urine creatinine obtained. The urine and creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance. Performed 3 times per day, diuretic dosing will be individualized based on the proportion of 24-hour diuresis achieved since the prior IV diuretic dose. Every 24 hours new goals for urine output and net negative fluid balance are established based on the study and treatment team's assessment of residual congestion until protocol completion.
16328250|NCT04481919|No Intervention|Guideline-based care|Patients will be placed on guideline-based diuretic dosing consistent with usual practice. The initial dose will be two times their home dose and will be subsequently adjusted by the treating team based on renal function and symptom severity. The treating team can increase or decrease the frequency and dose of diuretic based on urine output and clinical assessment. Patients in this arm also have urine collected 3 times per day by the bedside nurse to mirror the intervention arm.
16328251|NCT04481906||Women 20 years and older with cystocele|Women 20 years and older with cystocele
16328252|NCT04481893|Experimental|using a virtual reality headset|
16328253|NCT04481867|Active Comparator|intervention arm :densah bur group|at the maxillary molar area for implant placement ,,just after making initial drilling perforation close to the sinus floor, the direction of the drill is reversed and the cutting speed is raised to 1200 rpm, then 2 successive densah burs are used to elevate sinus membrane 2 mm and to prepare implant hole to the selected implant size .for both groups the selected implant size, 4.2 mm width and 10 mm. length
16328254|NCT04481867|Other|control group :osteotome group|at the maxillary molar area for implant placement .a set of concave osteotomes with different dimensions sequentially used to widen the osteotomy site by surgical mallet. Osteotome 2.5 mm is inserted into the osteotomy firstly to a depth of 1 mm away from the sinus floor with light malleting by the nylon cap mallet then 3 mm osteotome is used to fracture up the sinus floor and finally 3.5 mm osteotome is tapped gently to elevate the sinus floor to the desired depth of the implant in the maxillary sinus.
16328255|NCT04481854|Experimental|Cricoid pressure group|Patients of this group will recieve cricoid pressure during direct laryngoscopy.
16328257|NCT04481841|Experimental|experimental group|"On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
16328258|NCT04481841|Active Comparator|control group|oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
16328259|NCT04481828||open gastrectomy|The first group (Group 1; n: 30) consisted of patients who underwent open surgery
16328260|NCT04481828||laparoscopic gastrectomy|The second group (group 2; n:30) consisted of patients who underwent laparoscopic gastrectomy
16328261|NCT04481815|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
16328262|NCT04481815|Sham Comparator|R-MTX|Control arm will be treated with R-MTX regimen(Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved CR or PR with additional WBRT, they processed to Lenalidomide maintenance for 4 cycles.
16328263|NCT04481802|Experimental|RadiaAce gel|RadiaAce Gel is a clear, non-oily Hydrogel wound dressing for the management of Radiation Dermatitis which provides optimal moist wound environment necessary to the healing process. RadiaAce gel contains Acemannan, a high molecular polysaccharide obtained from the inner gel of Aloe Vera leaves and it is considered the main functional component of Aloe vera (Sahu et al. 2013).
16328264|NCT04481802|Active Comparator|Biafine|one of the standard skin care in radiation oncology, this treatment was chosen as the comparator.
16328265|NCT04481789|Experimental|Rosuvastatin, Sildenafil, and MT-1186|"Group 1 of Cohort 1:
~A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively."
16328266|NCT04481789|Experimental|Furosemide and MT-1186|"Group 2 of Cohort 1:
~A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6."
16328267|NCT04481789|Experimental|MT-1186|"Cohort 2:
~A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule."
16328268|NCT04481776|Experimental|Breakfast consumption|Participants will be asked to consume a standardised breakfast at home before 09:00 for seven consecutive days. The energy content of the breakfast will be 25% of individual measured resting metabolic rate. Prior to the experimental conditions, the participants will select one wholegrain, high-fibre ready-to-eat cereals (with the option of adding raisins) and fruit juice from a limited selection. Thus, breakfast composition will be controlled within participants, but not between participants to account for individual preferences. To ensure that the correct amount of each breakfast item is consumed, food items will be provided to the participants in pre-packaged containers and the participants will be provided with a marked beaker to measure their milk and juice each morning. The only exception is that parents will be asked to provide the 1.8% milk.
16328269|NCT04481776|Experimental|Breakfast omission|Participants were asked to abstain from all energy-providing nutrients before 10:30 for seven consecutive days.
16328270|NCT04481763|Other|camrelizumab + radiotherapy|This is a open-labeled, single-arm, Investigator-initiated clinical trial ,Compared with historical data
16328271|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S1)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
16328272|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S2)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
16328273|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S3-1)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
16328274|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S3-2)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
16328275|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S4)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
16328276|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S5)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
16328277|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S6)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
16328278|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S7)|Healthy Caucasian male subjects receive a single dose of MT-1186 or matching placebo.
16328279|NCT04481750|Experimental|Multiple doses MT-1186 (Part 2, Cohort M1)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo.
16328280|NCT04481750|Experimental|Multiple doses MT-1186 (Part 2, Cohort M2)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo
16328281|NCT04481737|Experimental|PDTA-IIMR|
16328282|NCT04481737|Active Comparator|Peer support|
16328283|NCT04481724|Experimental|gamma-linolenic acid (GLA) supplementation|Sonova GLA safflower oil (840 mg GLA per day)
16328284|NCT04481724|Placebo Comparator|placebo control|1500 mg 'light' olive oil per day
16328285|NCT04481711|Experimental|Study group|Twenty-nine patients (female/male: 24/5) with grade 4 osteoarthritis were included in the study group. These patients underwent total knee arthroplasty
16328286|NCT04481711|No Intervention|Control group|Twenty-two patients (female/male:13/9) with <grade 4 osteoarthritis were included in the control group.
16328287|NCT04481698||Mesoglycan|All patients received the standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy)
16331901|NCT04456309||Intracardiac thrombus|stroke patients with intracardiac thrombus
16328288|NCT04481698||Control|standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners)
16328289|NCT04481685|Active Comparator|ATI-450|Treated with 50 mg dose of ATI-450, orally, twice daily for 14 days
16328290|NCT04481685|Placebo Comparator|Placebo|Treated with matched placebo, orally, twice daily for 14 days
16328291|NCT04481672|Experimental|Magnesium Sulfate|"Starting the night before surgery participants will receive intravenous infusion of magnesium over approximately 36 hours. Dosage amounts will vary among participants as the study is determining the highest dose of magnesium that can be administered safely without severe or unmanageable side effects. The first 5 participants of the study will all receive the same dose of magnesium. The decision to test other doses of magnesium in 5 additional participants will depend on magnesium levels and dose tolerance outcomes in the first 5 participants.
~Participants will be followed for 4 days and undergo blood test to measure magnesium levels at the time of hospital admittance, the morning prior to the surgery, twice immediately after surgery, and twice a day for 3 days after the surgery."
16328292|NCT04481659|Experimental|A group|Patients who are initially staged as T1-2, according to MRI and intraluminal ultrasound, are assigned to the direct surgery group (determined by the multidisciplnary team [MDT] group)
16328293|NCT04481659|Experimental|B group|Patients who are initially staged as T3M0, according to MRI and intraluminal ultrasound, should undertake preoperative chemoradiotherapy (determined by the MDT group). The operation was performed 8-12 weeks after the end of the chemoradiotherapy.
16328294|NCT04481646||1|Patients admitted to hospital with COVID-19 symptoms will be approached to undertake a face mask sample and nasopharyngeal swab at two time points 12 hours apart on a single day whilst in hospital. Medical records will be accessed for basic clinical, demographic and microbiological data.
16328295|NCT04481646||2|Healthcare workers who have report COVID-19 symptoms will be asked to undertake a face mask sample and nasophayngeal swab on days 1,3,5,7,10,14 and 21 of the study, for part of which they will be quarantined at home.During this time they will complete a simple symptom diary. Medical records will be accessed for basic clinical, demographic and microbiological data.
16328296|NCT04481646||3|Healthcare workers from different areas of the hospital will be approached as part of a screening programme. They will be asked to undertake a single face mask and swab sample. Basic clinical and environmental data will be collected about each participant so they exposure risk can be stratified.
16328297|NCT04481633|Other|Patient treated with Hydroxy-chloroquine|patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)(HC+ group, n=400)
16328298|NCT04481633|Other|Patient without treatment with Hydroxy-chloroquine|patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants
16328299|NCT04481607|Experimental|TQB3454 tablets|TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
16328300|NCT04481594|Experimental|HPN-01|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01. One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01.
~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 once daily for a consecutive 14 days."
16328301|NCT04481594|Placebo Comparator|Placebo|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01 placebo.
~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 placebo once daily for a consecutive 14 days."
16328302|NCT04481581|Experimental|Intervention arm- Oxygen titration with electronic alerts|Oxygen titration will be done based on electronic alerts and decisions support tool by Respiratory Therapists, if FiO2=> 0.4 and SpO2 =>94% for more than 45 minutes
16328303|NCT04481581|No Intervention|Control Arm- Oxygen titration by one time physician orders|Oxygen titration will be done ventilator management guidelines for the medical intensive care unit. Titration is done by one-time orders.
16328304|NCT04481568|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and nurse assistants who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff: mental health assistants with high school level education, who receive training in de-escalation and crisis prevention techniques and provide direct personal care to psychiatric patients. On the intervention unit, these PES purposefully engage patients with BPSD. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients. IV. Staff Training (please refer to NCT# 04179721 for more details on staff support and training).
16328305|NCT04481568|Active Comparator|The attention control condition|The attention control condition will consist of a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 nursing assistants (1:8 ratio), that primarily cohorts older patients with geriatric syndromes.
16328306|NCT04481555|No Intervention|"Eosinophil_Control/Azithro_Control"|"Azithromycin: patients are given placebo
~ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose."
16328307|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Control:"|"a. Azithromycin: placebo b. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months): i. If blood eosinophil ≥ 300 cells/μL, ICS in usual dose next 3 months. Blood eosinophils are measured every 3 months.
~ii. If blood eosinophil <300 cells/μL, ICS is discontinued."
16328308|NCT04481555|Experimental|"Eosinophil_Control/Azithro_Active group"|Azithromycin: 250 mg azithromycin three times weekly. b. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose, where the medical treatment for severe COPD is unchanged throughout the entire project period
16328309|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Active:"|"Azithromycin: 250 mg azithromycin three times weekly.
~ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months):"
16328378|NCT04480957|Experimental|Escalation Cohort dose 4 of ARCT-021, 21 - 55 years|Escalation Cohort dose 4 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328310|NCT04481516||Yoga|Single arm only representing cohort of NHS health care workers with possible Covid-19 related stress and anxiety disorder. Participants act as their own controls pre and post regular practice of yoga technique.
16328311|NCT04481490||Home-based|Cardiac rehabilitation (including exercise training) delivered in a home-based setting, facilitated remotely by Mayo Clinic staff.
16328312|NCT04481490||Center-based|Cardiac rehabilitation (including exercise training) delivered in a center-based setting, facilitated in person by Mayo Clinic staff.
16328313|NCT04481477||Patients COVID-19|Patients over the age of 18 who were admitted with a diagnosis of COVID-19 to any CCSPT unit between March 13, 2020 and April 30, 2020 and were discharged with a recovery result
16328314|NCT04481451|Experimental|Erector spinae supplemental block|Single-shot T9/T10 operative side erector spinae block using ropivacaine 0.2%, 0.5ml/kg.
16328315|NCT04481451|Active Comparator|Quadratus lumborum supplemental block|Single-shot T9/T10 operative side quadratus lumborum (type 1) block using ropivacaine 0.2%, 0.5ml/kg.
16328316|NCT04481438|Experimental|exercise group|exercise group will receive acupunch exercise
16328317|NCT04481438|No Intervention|control group|control group will maintain the regular activities of their original daily lives
16328318|NCT04481425|Other|intervention group|Text messages will be sent to the subjects through the investigator, including giving popularization of psychiatric knowledge, coping skills, emotional regulation strategies, and brief care. Two or three times a week for two months.
16328319|NCT04481425|No Intervention|control group|Subjects both collected in the outpatient department and the ward were randomly divided into the control group and regularly followed up.
16328320|NCT04481412|Experimental|Study group|(30) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
16328321|NCT04481412|Active Comparator|Control group|(30) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
16328322|NCT04481399|Experimental|FSI-ECD|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. The FSI-ECD will be delivered in weekly 90-minute home visiting sessions for 12 consecutive weeks.
16328323|NCT04481399|Other|Control|The control is standard maternal and child health home visiting delivered by community health workers. Families will receive three 90-minute home visiting educational sessions focused on nutrition, hygiene, and post-natal care.
16328324|NCT04481386|Experimental|Active arm|Participants with a diagnosis of retinal detachment or vitreous haemorrhage, who are scheduled for vitrectomy surgery with a vitreous substitute
16328325|NCT04481373|Experimental|THRIVE|Acceptance and Commitment Therapy plus Education about HIV A master's level mental health professional will provide the 4-5 hour intervention for out-of-care PWH during a hospitalization. There are two important components to the intervention: Acceptance and Commitment Therapy (ACT) content, targeting avoidance with acceptance-based coping and active engagement in values-based living, and HIV education.
16328326|NCT04481373|Other|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
16328327|NCT04481360||patients with covid 19 pneumonia|clinical presentation & outcome of covid 19 pneumonia
16328328|NCT04481347||Patients undergoing general anesthesia|Patients eligible for interventional neuroradiology or surgery performed under general anesthesia. Patients will be included if they are admitted for a non-emergency scheduled procedure.
16328329|NCT04481334|Experimental|One group|One group pre-test, post-test design
16328330|NCT04481321||Patient with benign gynaecologic disease|Patients consulting for endometriosis, pelvic pain, abnormal uterine bleeding and/or infertility, or for a pelvic mass,
16328331|NCT04481295|Active Comparator|High SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 94-96%, and a flow of 10 L/min).
16328332|NCT04481295|Active Comparator|Low SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 84-86%, and a flow of 10 L/min).
16328333|NCT04481282|Experimental|Terbutaline plus Danazol group|Terbutaline 2.5mg tid po plus danazol 200mg bid po for 12weeks
16328334|NCT04481269|Experimental|Research Group|Research group uses surface-modified composite coated orthopedic implants
16328335|NCT04481269|Active Comparator|Controls Group|Controls group uses conventional orthopedic implants
16328336|NCT04481256|Experimental|1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy|"Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
~External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy"
16328337|NCT04481243|Experimental|Experimental|Children will receive Pneumovax 23 vaccination.
16328338|NCT04481230|Experimental|99mTc-NTP 15-5 (level 1)|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
16328339|NCT04481230|Experimental|99mTc-NTP 15-5 (level 2)|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
16328340|NCT04481230|Experimental|99mTc-NTP 15-5 (level 3)|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
16328341|NCT04481217|Experimental|Schizophrenia|Patients included will be diagnosed with schizophrenia or schizoaffective disorder, and experience AVH at the time of the inclusion (n= 350). All will be inpatients.
16328342|NCT04481204|Active Comparator|Control arm GroupI(mFOLFIRINOX)|Patients receive mFOLFIRINOX for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
16328343|NCT04481204|Active Comparator|Control arm GroupII(chemotherapy, FOLFIRINOX)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
16328379|NCT04480957|Experimental|Expansion cohort dose regimen 1, 21 - 55 years.|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328344|NCT04481204|Active Comparator|Control arm GroupIII(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
16328345|NCT04481204|Active Comparator|Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
16328346|NCT04481204|Active Comparator|Control arm GroupV(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
16328347|NCT04481204|Active Comparator|Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
16328348|NCT04481191|Experimental|Concomitant RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
16328349|NCT04481191|Active Comparator|Staggered RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
16328350|NCT04481178||patients with nevus of Ota|patients with nevus of Ota who had been treated with laser at Siriraj hospital
16328351|NCT04481165||Adolescents with anorexia nervosa|Adolescents from 12 to 25 year old, cared for anorexia nervosa at the Maison de Solenn (Cochin hospital, Paris, France) et for whom antidepressive agents have been prescribed
16328352|NCT04481139|Experimental|SHR0302 dose1|SHR0302 dose1 for 24 weeks
16328353|NCT04481139|Experimental|SHR0302 dose2|SHR0302 dose2 for 24 weeks
16328354|NCT04481139|Experimental|SHR0302 dose3|SHR0302 dose3 for 24 weeks
16328355|NCT04481139|Placebo Comparator|Placebo|Placebo for 12 weeks
16328356|NCT04481113|Experimental|Treatment (abemaciclib, niraparib)|Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
16328357|NCT04481100|Experimental|Experimental Group|Itraconazole capsule 100mg twice daily for 6 weeks concurrent with chemoradation.
16328358|NCT04481087|Experimental|Clearfil Universal Bond Quick, self-etch mode (CU-SE)|
16328359|NCT04481087|Experimental|Clearfil Universal Bond Quick, selective etch mode (CU-SLE)|
16328360|NCT04481087|Experimental|Clearfil Universal Bond Quick, etch&rinse mode (CU-ER)|
16328361|NCT04481087|Experimental|Clearfil SE Bond (CSE)|
16328362|NCT04481087|Experimental|Tetric N-Bond (TB)|
16328363|NCT04481074|Experimental|Inspiratory muscle training group|Group intervention: home-based interval inspiratory muscle training during 8 weeks, two sessions with two sets of 30 breaths with one minute rest between them. Load set is determinated weekly, aiming 50% of actual PImax and according to Borg Score.
16328364|NCT04481061|Other|Decision Making About Genetic Results|Adolescents between 13-21 and parent (if applicable) will make decisions about learning results using an electronic decision tool. Results that match their choices will be returned.
16328365|NCT04481048|Experimental|N-Acetylcysteine (NAC)|"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.
~Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg
~*Max dose not to exceed 2700mg/day (1350mg BID)"
16328366|NCT04481048|Placebo Comparator|Placebo|Each subject will be dosed with placebo for 8 weeks.
16328367|NCT04481035|Experimental|N-Acetylcysteine|Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
16328368|NCT04481035|Placebo Comparator|Placebo|Participants will be dosed three times per day with a placebo for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
16328369|NCT04481022|Other|group will receive proximal control exercises|
16328370|NCT04481009|Experimental|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
16328371|NCT04481009|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
16328372|NCT04481009|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
16328373|NCT04480996||Road traffic accidents with medicines|Road traffic accidents cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Drugs Responsible for Cognitive and Psychomotor Side Effects
16328374|NCT04480970|Experimental|Nasogastric tube placement|
16328375|NCT04480957|Experimental|Escalation Cohort dose 1 of ARCT-021, 21 - 55 years|Escalation Cohort dose 1 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328376|NCT04480957|Experimental|Escalation Cohort dose 2 of ARCT-021, 21 -55 years|Escalation Cohort dose 2 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328377|NCT04480957|Experimental|Escalation Cohort dose 3 of ARCT-021, 21 - 55 years|Escalation Cohort dose 3 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328464|NCT04480463|Active Comparator|Aflibercept|
16328380|NCT04480957|Experimental|Expansion cohort dose regimen 2, 21 - 55 years.|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328381|NCT04480957|Experimental|Expansion cohort dose regimen 1, 56 - 80 years|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328382|NCT04480957|Experimental|Expansion cohort dose regimen 2, 56 - 80 years|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
16328383|NCT04480931|Experimental|mHealth Intervention Group|This group will be provided with the mobile health app (including introductory videos on how to use its features).
16328384|NCT04480931|Sham Comparator|Control Group|This group will receive an educational brochure about physical activity during pregnancy.
16328385|NCT04480918||Major Depressive Episode|After referral to the University of Iowa's Interventional Psychiatry Clinic, the patient will be clinically evaluated and, if appropriate, commence the procedural-based treatment course.
16328386|NCT04480905|Sham Comparator|Sham tape group|in supine, full knee extension position, apply the sham tape from the anterior inferior iliac crest to the middle of the lower leg
16328387|NCT04480905|Experimental|Dynamic tape group|in supine, full knee extension position, apply the dynamic tape from the anterior inferior iliac crest to the middle of the lower leg
16328388|NCT04480879|Experimental|AZD8154 nebuliser suspension|The study subjects will receive 1 mg delivered dose of AZD8154 nebuliser suspension
16328389|NCT04480879|Experimental|AZD8154 Monodose|The study subjects will receive 1 mg capsule delivered dose of AZD8154 Monodose DPI formulation
16328390|NCT04480879|Placebo Comparator|AZD8154 Placebo Monodose DPI|The study subjects will receive AZD8154 placebo Monodose DPI formulation dosed to correspond to 1 mg delivered dose AZD8154 Monodose DPI formulation
16328391|NCT04480866|Other|First-void urine collection|Women self-collect three first-void urine samples (random order) at home.
16328392|NCT04480853|Experimental|Fingolimod|Open label Fingolimod 0.5 mg capsule taken once daily, oral.
16328393|NCT04480840|Placebo Comparator|Placebo|
16328394|NCT04480840|Experimental|PLN-74809 Dose Level 1|Dose: 40 mg;
16328395|NCT04480840|Experimental|PLN-74809 Dose Level 2|Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
16328396|NCT04480840|Experimental|PLN-74809 Dose Level 3|Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
16328397|NCT04480827|Experimental|Part 1: Mild Hepatic Impairment (Cohort A)|8 mild hepatic impaired subjects
16328398|NCT04480827|Experimental|Part 1: Moderate Hepatic Impairment (Cohort B)|8 moderate hepatic impaired subjects
16328399|NCT04480827|Experimental|Part 1: Severe Hepatic Impairment (Cohort C)|8 severe hepatic impaired subjects
16328400|NCT04480827|Experimental|Part 1: Healthy Volunteers (Cohort D)|up to 24 matched healthy volunteers
16328401|NCT04480827|Experimental|Part 2: Hepatic Impairment cohort|up to 8 hepatic impaired subjects (mild, moderate or severe)
16328402|NCT04480827|Experimental|Part 2: Healthy Volunteers cohort|up to 8 matched healthy volunteers
16328403|NCT04480814||Metastatic Breast Cancer|
16328404|NCT04480814||Healthy volunteers|
16328405|NCT04480801|Experimental|thermal evaluation and foot care|Participants in the experimental group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone. Thermal evaluation will be done. The application of the thermal evaluation, the foot areas to be applied and how to record the results of the application will be taught to the patient and / or their relatives. In addition, the thermal evaluation video will be uploaded to the phone of the patient and / or their relative. While the participants in the experimental group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions, Thermal evaluation registration form, Daily step number registration form will be provided and participants will be invited to check every 2 months.
16328406|NCT04480801|Other|foot care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone.While the participants in the control group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions will be provided and participants will be invited to check every 2 months.
16328407|NCT04480788|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
16328408|NCT04480775|Experimental|bupivacaine group|28 Patients will receive 18 ml of bupivacaine 0.5 % plus 1ml 0.9% saline in TAP block divided equally on both sides
16328409|NCT04480775|Active Comparator|triamicinolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (20 mg of triamcinolone in 1ml 0.9% saline divided equally on both sides in TAP block
16328410|NCT04480775|Active Comparator|methylprednisolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (40 mg of methylprednisolone in 1ml 0.9% saline ) on both sides in TAP block.
16328411|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 1|A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo
16328412|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 2|A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo
16328413|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 3|A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo
16328414|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 4|A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo
16328415|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 5|A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo
16328416|NCT04480749|Other|Routine Testing|Among men in the control group, they will receive a list of local clinics that can provide free syphilis testing.
16328417|NCT04480749|Experimental|Self-Testing|In the intervention arm we will provide a treponemal rapid syphilis test kit to all individuals in the intervention arm of the pilot, delivered through MSM community facilitators. This is similar to existing rapid treponemal test kits that are available at many clinical facilities. Kits will be accompanied by simplified pictorial instructions on finger prick blood sample collection.
16328425|NCT04480723|Other|Participants with Low or Intermediate Probability of PH|Participants who underwent a work-up for the suspicion of PH that includes transthoracic echocardiography (TTE) and who were considered to have a low or intermediate probability of PH according to TTE (local interpretation) will be enrolled. Blood samples will be taken and a cardiac magnetic resonance imaging (MRI) will be performed to evaluate the presence of Pulmonary Hypertension (PH). The TTEs that were performed by local standards will be collected and undergo central interpretation using European society of Cardiology / European respiratory society (ESC/ERS) guidelines to confirm the local interpretation.
16328426|NCT04480710|Experimental|CRV431|CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions
16328427|NCT04480710|Placebo Comparator|Placebo|Placebo, softgel capsule, QD, 28 days, fasted conditions
16328428|NCT04480697|Experimental|SAD 10mg|A single oral dose of 10 mg
16328429|NCT04480697|Experimental|SAD 20mg|A single oral dose of 20 mg. Food effect will also be assessed at the same dose level.
16328430|NCT04480697|Experimental|SAD 40mg|A single oral dose of 40mg
16328431|NCT04480697|Experimental|SAD 80 mg|A single oral dose of 80 mg
16328432|NCT04480697|Experimental|SAD 120 mg|A single oral dose of 120 mg
16328433|NCT04480697|Experimental|SAD 150 mg|A single oral dose of 150 mg
16328434|NCT04480697|Experimental|MAD 10mg|Dose regimen is once daily 10 mg for 14 consecutive days.
16328435|NCT04480697|Experimental|MAD 30mg|Dose regimen is once daily 30 mg for 14 consecutive days.
16328436|NCT04480697|Experimental|MAD 90 mg|Dose regimen is once daily 90mg for 14 consecutive days.
16328437|NCT04480671|Other|Sacrocolpopexy|This group will only receive the sacrocolpopexy for their pelvic organ prolapse repair.
16328438|NCT04480671|Active Comparator|Sacrocolpopexy and concomitant level III support procedure|This randomized group will receive an additional vaginal repair for level III support at the conclusion of the sacrocolpopexy.
16328439|NCT04480658|Experimental|Bryophyllum pinnatum|Bryophyllum pinnatum (BP) muscle relaxing substance
16328440|NCT04480645|Experimental|Treatment|Radioactive bandage applied to surface of the body worn for approximately one week.
16328441|NCT04480632|Experimental|ABO compatible convalescent plasma|A 500 ml dose of convalescent plasma (from a single donor or two 250 ml units from one or two donations) collected by apheresis will be administered. In case of plasma storage, plasma unit will be thawed following parameters of blood bank. Administration will take place slowly and over the course of four hours. When two 250 ml units are administered, second unit must be administered after the first unit in a period not exceeding 12 hours.
16328442|NCT04480632|No Intervention|Usual care|Usual medical care for critically ill patients at ICU
16328443|NCT04480619|Experimental|Ga-68 AIP-301 Positron Emission Tomography|Companion Ga-68 PET diagnostic for tumor targeted therapy
16328444|NCT04480606|Experimental|Home exercise group|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group.
16328445|NCT04480606|No Intervention|Control Group|The control group will be asked to remain isolated as they are and the exercise program will not be implemented.
16328446|NCT04480593|Active Comparator|Control|standard care.
16328447|NCT04480593|Experimental|EPP-AF 400mg/day|Green propolis extract (EPP-AF) at a dose of 400mg / day in addition to the standard treatment.
16328448|NCT04480593|Experimental|EPP-AF 800mg/day|Green propolis extract (EPP-AF) at a dose of 800mg / day in addition to the standard treatment.
16328449|NCT04480580||Hospitalized patients|
16328450|NCT04480567|Experimental|Dose 1 of BMN 307|
16328451|NCT04480567|Experimental|Dose 2 of BMN 307|
16328452|NCT04480567|Experimental|Dose 3 of BMN 307|
16328453|NCT04480554|Experimental|Methadone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
16328454|NCT04480554|Experimental|Buprenorphine/naloxone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
16328455|NCT04480554|Experimental|XR-Naltrexone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
16328456|NCT04480541|Experimental|Roadmap 2.0 + Fitbit Charge 3|"Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.
~Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
16328457|NCT04480528|Experimental|BFRT Group|This group will receive physical therapy plus active BFRT.
16328458|NCT04480528|Sham Comparator|Standard of Care Group|This group will receive physical therapy plus sham BFRT.
16328459|NCT04480502|Experimental|Envafolimab|Patients treated with 300 mg of single agent envafolimab every three weeks
16328460|NCT04480502|Experimental|Envafolimab + Ipilimumab|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 300 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
16328461|NCT04480489|Experimental|Group A|In Group A, students will first perform Task 1 (walk from anesthesia lounge to the day surgery unit) using intervention 1 (using the virtual reality video) first, then Task 2 (walk from anesthesia lounge to the pre-operative clinic) using intervention 2 (using the traditional 2D video).
16328462|NCT04480489|Active Comparator|group B|In Group B, students will first perform Task 1 (follow route 1: walk from anesthesia lounge to the day surgery unit) using intervention 2 (using the traditional 2D video) first, then Task 2 (follow route 2: walk from anesthesia lounge to the pre-operative clinic) using intervention 1 (using the virtual reality video).
16328463|NCT04480463|Experimental|SCD411|
16328465|NCT04480450|Active Comparator|IVIg/SCIg < 12 Months Arm|Patients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
16328466|NCT04480450|Active Comparator|IVIg/SCIg > 12 Months Arm|Patients with CIDP successfully treated with IVIg/SCIg for more than 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
16328467|NCT04480450|Active Comparator|Corticosteroid Arm|Patients with CIDP successfully treated with corticosteroids. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
16328468|NCT04480437|Experimental|Study Intervention|mp-BUS data collection
16328469|NCT04480424|Experimental|GAMUNEX-C + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of GAMUNEX-C on Day 1 up to a total net dose of 2 grams per kilogram (g/kg), based on participant's body weight (maximum dose = 160 g for participants over 80 kg), administered in divided doses as infusions of 500 milligrams per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16328470|NCT04480424|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
16328471|NCT04480411|Experimental|COVID-19 Patients|Patients that are admitted to the hospital with COVID 19.
16328472|NCT04480398||Ayurveda|Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol.
16328473|NCT04480398||Control|Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines.
16328474|NCT04480385|Experimental|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last 7 days through post-operative monitoring room (continuous comparison with reference monitor), general ward (comparison with spot-check monitoring) and patient's home
16328475|NCT04480372|Experimental|NSCLC (cohort 1) and inoperable MPM (cohort 2)|"Cohort 1 consists of NSCLC patients. Cohort 2 consists of MPM patients.
~Patients will be treated with gemcitabine at the dose of 1000 mg/m2 i.v. on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
~The trial treatments will be continued for max. 2 years or until discontinuation criteria are met (see Ch. 9.3), whichever occurs first. The follow-up phase will last up to 5 years from treatment start."
16328476|NCT04480359|Active Comparator|Bawei Shenqi group|participants should administrate both Bawei Shenqi Pill and Meloxicam tablets
16328477|NCT04480359|Placebo Comparator|placebo group|participants should administrate both Bawei Shenqi Pill placebo and Meloxicam tablets
16328478|NCT04480346|Experimental|CHP treatment|Participants assigned to this arm received the treatment described in another section.
16328479|NCT04480346|No Intervention|Community Care|Participants randomly assigned to this condition received information about service providers in the community, but no services from the investigators.
16328480|NCT04480333|Experimental|Drug: NA-831 - 0.10 mg/kg|3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
16328481|NCT04480333|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
16328482|NCT04480333|Experimental|Drug: NA-831 - 0.20 mg/kg|6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
16328483|NCT04480333|Placebo Comparator|Comparable Placebo- 0.20 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
16328484|NCT04480333|Experimental|Drug: GS-5734 - 1.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
16328485|NCT04480333|Placebo Comparator|Comparable Placebo- 1.00 mg.kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
16328486|NCT04480333|Experimental|Drug: GS-5734 - 2.00 mg/kg|6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
16328487|NCT04480333|Placebo Comparator|Comparable Placebo - 2.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
16328488|NCT04480333|Experimental|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
16328489|NCT04480333|Placebo Comparator|Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg|3 Subjects - inhaled formulation of placebo once/day for 5 days
16328490|NCT04480333|Experimental|Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)|6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
16328491|NCT04480333|Placebo Comparator|Placebo- 0.20 mg/kg + 2.00mg/kg|3 Subjects- inhaled formulation of placebo once/day for 5 days
16328492|NCT04480320|Experimental|Pericapsular nerve group block|
16328493|NCT04480320|Placebo Comparator|Saline placebo group|
16328494|NCT04480307|Experimental|temelimab 18 mg/kg|Monthly IV repeated dose
16328495|NCT04480307|Experimental|temelimab 36 mg/kg|Monthly IV repeated dose
16328496|NCT04480307|Experimental|temelimab 54 mg/kg|Monthly IV repeated dose
16328497|NCT04480307|Placebo Comparator|Placebo|Monthly IV repeated dose
16328508|NCT04480281|Active Comparator|Lidocaine Group|Bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
16328509|NCT04480281|Placebo Comparator|Placebo Group|Equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
16328510|NCT04480255|Active Comparator|Group 1: Standard of Care|Parents of infants born from date July 2020-December 2020
16328511|NCT04480255|Active Comparator|Group 2: NICU2HOME+ app|Parents of infants born from mid Jan 2021-May2021
16328512|NCT04480242||Asthma Research in Children and Adolescents - Spanish Cohort|Groups defined according to treatments prescribed during regular clinical practice and to the exposure to inhalation techniques monitoring
16328513|NCT04480229|Experimental|Intervention Group|After the first treatment, every week the patients were called and consulted by telenursing. During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled. The study ended with the fourth cycle chemotherapy. A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients. Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
16328514|NCT04480229|No Intervention|No Intervention: Control Group|"During their first treatment the Patient Identification Form was filled and they were trained, which is the routine practice of the clinic. Patients were informed about the Symptom follow-up form, asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom. When the patients came to the second treatment, the first follow-up of the patients was done. The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews. The Symptom Follow-up Form given to the patients in the previous chemotherapy treatment was collected and the same new form was given. They were requested to bring this form in their next treatment. The same protocol was followed during the third and fourth chemotherapy treatment"
16328515|NCT04480203|Active Comparator|Cognitive based stress management (CBSM)|Cognitive based digital intervention.
16328516|NCT04480203|Active Comparator|Mindfulness based intervention (MBI)|Mindfulness based digital intervention.
16328517|NCT04480203|Placebo Comparator|Control|Control arm. No intervention.
16328518|NCT04480190|Experimental|Research Treatment|Gemcitabine/Cisplatin/ChemoRT
16328519|NCT04480177|Other|insole group|the control group receives insole only.
16328520|NCT04480177|Experimental|exercise group|the experimental group receives exercise and insole.
16328521|NCT04480164|Experimental|NDMC 40 mg/day|Oral administration of two NDMC 20mg capsules per day over 6 weeks
16328522|NCT04480164|Experimental|NDMC 60 mg/day|Oral administration of three NDMC 20mg capsules per day over 6 weeks
16328523|NCT04480164|Experimental|NDMC 120 mg/day|Oral administration of six NDMC 20mg capsules per day over 6 weeks
16328524|NCT04480164|Placebo Comparator|Placebo|Oral administration respectively, according to the experimental arm considered, of two, three or six placebo capsules per day over 6 weeks
16328525|NCT04480151||IMPELLA™ alone as bridge to LVAD|patients assisted by IMPELLA™ pump alone during the days preceding the implantation of long term LVAD (at least 48 hours for patients for whom an ECLS was previously used)
16328526|NCT04480151||ECLS alone or with IMPELLA™ as bridge to LVAD|patients assisted by ECLS (ExtraCorporeal life support) alone or simultaneously with IMPELLA™ until the implantation of LVAD
16328527|NCT04480138|Experimental|Pegylated Interferon-α2b + Standard of care|"Test :- Pegylated Interferon-α2b + Standard of care (SOC)
~Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial."
16328528|NCT04480138|Active Comparator|Standard of Care|"Control: Standard of care
~Standard of care treatment will be provided as per regulatory recommendation and approval."
16328529|NCT04480125|Experimental|Aza+Chida|Azacitidine ivgtt D1-7 Chindamide 30mg,PO,twice a week Every 21 days for total 6 courses
16328530|NCT04480112|Experimental|Group A Intervention|Participants in Group A will receive an intervention designed to provide participants with more social interaction during a time of social distancing and highly limited in-person social interactions
16328531|NCT04480112|Active Comparator|Group B Control|Participants in Group B will not receive any new interventions.
16328532|NCT04480099|Active Comparator|CHOP|Patients in this arm will receive conventional CHOP regimen for 6 cycles
16328533|NCT04480099|Experimental|CHOP+X|Patients in this arm will receive targeted drug in combination with conventional CHOP regimen for 6 cycles, based on NGS results
16328534|NCT04480086|Experimental|Segment A: Mivebresib Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of mivebresib to identify the safe dosing regimen and schedule.
16328535|NCT04480086|Experimental|Segment A: Mivebresib Monotherapy|Participants will receive the identified safe dosing regimen of mivebresib as monotherapy.
16328536|NCT04480086|Experimental|"Segment B: Ruxolitinib + Mivebresib Add-on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as add-on therapy."
16328537|NCT04480086|Experimental|Segment C: Mivebresib + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.
16328538|NCT04480086|Experimental|Segment D: Mivebresib + Ruxolitinib|Participants who have never received JAKi will receive mivebresib and ruxolitinib.
16328539|NCT04480073|Other|edentulous patients with atrophic jaws|patients presenting with severely atrophic edentulous sites in the upper and lower jaw, and requesting implant-supported prosthetic restorations, will be enrolled in this study.
16328563|NCT04479917|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg 2 tablets
16328540|NCT04480047|Experimental|Tetranite Stabilized Dental Implants with Provisional Crown|Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.
16328541|NCT04480034||Group Pisa|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Bariatrica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy (Head Prof. Marco Anselmino) will be collected in a prospective database, to monitor the postoperative course.
16328542|NCT04480034||Group Padova|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOSD Week Surgery, Azienda Ospedaliera, Università di Padova, Italy (Head Dr. Mirto Foletto) will be collected in a prospective database, to monitor the postoperative course.
16328543|NCT04480034||Group Bologna|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Chirurgia Bariatrica, Azienda Ospedaliera Universitaria di Bologna, Italy (Head Dr. Paolo Bernante) will be collected in a prospective database, to monitor the postoperative course.
16328544|NCT04480034||Group Bergamo|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale e Oncologica, Policlinico San Marco di Zingonia, Bergamo, Italy (Head Prof. Stefano Olmi) will be collected in a prospective database, to monitor the postoperative course.
16328545|NCT04480034||Group Tor Vergata|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit U.O.S.D. Chirurgia Mininvasiva e dell'Apparato Digerente, Università Tor Vergata, Rome, Italy (Head Prof. Paolo Gentileschi) will be collected in a prospective database, to monitor the postoperative course.
16328546|NCT04480034||Group Torino|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria Citta della Salute e della Scienza, Università di Torino, Italy (Head Prof. Mario Morino) will be collected in a prospective database, to monitor the postoperative course.
16328547|NCT04480034||Group Milano|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Milano, Italy (Head Dr. Giuseppe Marinari) will be collected in a prospective database, to monitor the postoperative course.
16328548|NCT04480034||Group Rome|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, University La Sapienza of Rome, Italy (Head Prof. Gianfranco Silecchia) will be collected in a prospective database, to monitor the postoperative course.
16328549|NCT04480021|Experimental|Multiuser Interactive Health Response Application (MITHRA)|Randomization is at the level of the Community Based Organization (CBO). CBOs randomized to MITHRA will have access to the MITHRA app on tablets. MITHRA app will include depression screening and behavioral activation modules.
16328550|NCT04480021|Placebo Comparator|Enhanced Usual Care (EUC)|CBOs randomized to EUC will receive standardized monthly group education (45 min) regarding the symptoms of depression
16328551|NCT04480008|Experimental|Resilient Living Program|All participants will be in the Resilient Living Program arm. Study participation involves participating in a 12-week stress management and resilience training program. This will involve four virtual sessions (video or phone) and answering questions about their health, well-being, and quality of life. There will also be online modules to watch and an accompanying journal (with prompts) to keep.
16328552|NCT04479995|Experimental|Horizon Program|"Eight weekly, audio recorded telehealth videoconferencing sessions. Sessions are 90 minutes.
~Questionnaire assessments at 8 and 16 weeks after end of videoconferencing sessions"
16328553|NCT04479995|Experimental|Usual Care|"Standard medical visits to address chronic GVHD, with an additional standardized booklet, in electronic or paper format, containing information on the management of chronic GVHD and stem cell transplant survivorship recommendations.
~Questionnaire assessment at 8 weeks and 16 weeks after Horizons Program group starts"
16328554|NCT04479969|Other|Intervention|This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing.
16328555|NCT04479956|Experimental|Surgical Ligation|Conventional surgical procedures will carried out through a 3-4 cm incision in the groin. The trunk of GSV and the tributaries will be ligated and divided.
16328556|NCT04479956|Experimental|Microwave group|The microwave treating wire (Microwave Intracavity Coagulation System; Shanghai Medical Electronics, Shanghai, China) will be inserted into the GSV until it reached the medial aspect of ankle, guided by a light that illuminated the tip of the wire. Then, GSV will be ablated using pulse mode at 20-30 W. The treating wire will be withdrawn at 2-4 mm/s, with the ablation time lasting 2 s (energy delivery to the GSV was estimated at around 80 J/cm); the treatment parameters will be based on a previous report. Tumescence will be used in all patients with 0.9% saline containing 20 mL 2% lidocaine with 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L 0.9% saline.
16328557|NCT04479956|Experimental|Laser ablation group|"Endovenous Laser Ablation (EVLA) uses a laser Fiber, which is inserted into the abnormal vein via a small skin puncture.using 1470 nm laser and a radial fiber for less discomfort. Two weeks later the branch vessels have reduced in size"
16328558|NCT04479956|Experimental|Radiofrequency ablation group|inserts a small catheter into the diseased vein through a small incision, using ultrasound guidance for an accurate and live view. Consistent and uniform heat is delivered to contract the collagen in the vein walls, causing them to collapse and close. After the vein is closed the treated vein is gradually absorbed into surrounding tissue.
16328559|NCT04479943|No Intervention|Pre-intervention/control|160 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months prior to implementation of the unit-based MOVIN intervention.
16328560|NCT04479943|Experimental|Post-intervention|160 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months after MOVIN has been implemented on the unit.
16328561|NCT04479930|Experimental|HappyAir Group|The HappyAir app comprises two main parts: an educational program providing patients useful information and advice about their illness and data collection related to physical activity and disease.
16328562|NCT04479930|No Intervention|Control group|The control group only underwent the scheduled check-ups
16328564|NCT04479917|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet+ Placebo 10mg tablet
16328565|NCT04479917|Experimental|TPN171H 20mg group|TPN171H 10mg 2 tablets + Placebo 5mg tablet
16328566|NCT04479917|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg 2 tablets
16328567|NCT04479904|Experimental|famitinib|
16328568|NCT04479891|Experimental|pyrotinib alone, pyrotinib + itraconazole|Sequential treatments of pyrotinib alone followed by pyrotinib + itraconazole, with a washout period in between.
16328569|NCT04479865|Experimental|Sequence 1|Period 1, Aricept 5mg → DA-5207 150mg; Period 2, Aricept 5mg → Aricept 10mg
16328570|NCT04479865|Experimental|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 150mg
16328571|NCT04479865|Experimental|Sequence 3|Period 1, Aricept 5mg → DA-5207 170mg; Period 2, Aricept 5mg → Aricept 10mg
16328572|NCT04479865|Experimental|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 170mg
16328573|NCT04479852|Experimental|SP-624|Daily oral capsule, 20 mg/day
16328574|NCT04479852|Placebo Comparator|Placebo|Daily oral capsule
16328575|NCT04479839||Microcuff ETT|Patients intubated with microcuff ETT
16328576|NCT04479839||Non-microcuff ett|Patients intubated with regular ETT
16328577|NCT04479813|Experimental|No conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
16328578|NCT04479813|Experimental|No conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
16328579|NCT04479813|Experimental|Remote pre-conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
16328580|NCT04479813|Experimental|Remote pre-conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
16328581|NCT04479800|Experimental|Treatment A - Fasting|No food prior to dosing
16328582|NCT04479800|Experimental|Treatment B - Fed|High-fat/high-calorie meal prior to dosing
16328583|NCT04479800|Experimental|Treatment C - Fed|Low-fat/low-calorie meal prior to dosing
16328584|NCT04479787|Active Comparator|Spinal Cord Stimulation (SCS)|An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
16328585|NCT04479787|Active Comparator|Comprehensive Medical Management (CMM)|CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
16328586|NCT04479774|Experimental|Experimental Group (Group A)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.
~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
16328587|NCT04479774|Other|Control group: (Group B)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.
~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
16328588|NCT04479761|Experimental|Virtual Reality|Participants will be wearing a virtual reality headset and observing 2 types of scenes: abstract (a display of stars) or contextual (a subway station).
16328589|NCT04479748|Other|Dextenza insert|Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).
16328590|NCT04479748|Other|Fellow-eye|The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.
16328591|NCT04479735|Experimental|VR goggle with venipuncture|Virtual reality goggles SamsungGearVR supplied by KindVR will be placed on patients at least 2 min prior to venipuncture. All patients will also receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture.
16328592|NCT04479735|No Intervention|no VR goggle with venipuncture|Patients will receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture but NO virtual reality goggles.
16328593|NCT04479722|Experimental|Microport CardioAdvance LAAC system|Subject implant Microport CardioAdvance LAAC system to occlude LAA through percutaneous intervention.
16328594|NCT04479722|Active Comparator|Watchman LAAC system|Subject implant Watchman LAAC system to occlude LAA through percutaneous intervention.
16328595|NCT04479696|Experimental|Arm I (NIRS)|Patients receive standard of care verbal and written education materials. Patients also receive a customized video which includes a description of each of their tumor, functional areas of the brain affected, and possible symptoms from the tumor and radiation treatment based on the neuro-imaging features. Patients and their caregivers watch the video together or separately over 1.5-3 minutes before the end of the first week of radiation treatment. Within 2 weeks after watching the NIRS video, patients complete an optional survey over 5-10 minutes.
16328596|NCT04479696|Active Comparator|Arm II (standard of care)|Patients receive standard of care verbal and written education materials.
16328597|NCT04479683|Other|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
16328714|NCT04478721|Experimental|Temocillin|Patients enrolled in this arm, will receive 2g each 8 hours of intravenous temocillin.
16328598|NCT04479683|Experimental|FTH (full-time hospitalisation) then day hospitalization)|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.
~During this phase, all children are evaluated once a week on a somatic level."
16328599|NCT04479657|Experimental|QingFei Granule+Cefuroxime group|Cefuroxime：30mg/kg/d,bid QingFei Granule: tid
16328600|NCT04479657|Active Comparator|Cefuroxime group|Cefuroxime：30mg/kg/d,bid
16328601|NCT04479644|Experimental|Cohort 1|BRII-198 dose level 1 or placebo
16328602|NCT04479644|Experimental|Cohort 2|BRII-198 dose level 2 or placebo
16328603|NCT04479644|Experimental|Cohort 3|BRII-198 dose level 3 or placebo
16328604|NCT04479631|Experimental|Cohort 1|BRII-196 dose level 1 or placebo
16328605|NCT04479631|Experimental|Cohort 2|BRII-196 dose level 2 or placebo
16328606|NCT04479631|Experimental|Cohort 3|BRII-196 dose level 3 or placebo
16328607|NCT04479618|Active Comparator|Usual practice (negative control)|After a member of the UHWI surgical team performs the initial cleansing/debriding, the control group (1) will have their ulcer dressed as usually done at UHWI. Wounds are dressed with saline-soaked gauze, covered with dry gauze. One wrap of stretch gauze will hold the dressing in place. Patients will clean the wound by vigorously wiping with gauze soaked in homemade normal saline (1 tsp salt/500ml water bottle), center to edges, at each dressing change, unless already very clean. Clean wounds will simply be irrigated with normal saline at each dressing change. Patients experienced with using papaya for debridement of their ulcers may apply it only to the open wound, avoiding contact with the periwound, to remove slough or eschar. If patients observe green exudate, they are permitted to add one teaspoon of vinegar to their bottle of saline. Dressings in group (1) will be changed daily. The dressings will be soaked off if they become adherent.
16328608|NCT04479618|Experimental|improvised dressings (experimental)|After initial cleansing/debriding, patients in the improvised dressing group (2) will then have a thin layer zinc oxide paste applied to the dried periwound, carefully avoiding the open wound. A piece of a clean new plastic bag (food-grade World Star 1 mil LD bags, or the equivalent, purchased from the Papine Market across John Golding Road from the University of the West Indies), cut slightly larger than the ulcer will be gently conformed to the moist wound contours and sealed onto the zinc oxide paste. The bag will be fenestrated with a small slit using a number 11 scalpel or clean scissors prior to placing it on the ulcer in order to allow excess fluid to escape. The edges of the slit will be approximated. Clean gauze will be placed lightly over the slit to capture escaping fluid. One wrap of stretch gauze will hold the dressing in place. Patients will be instructed to change the dressings daily, irrigating with normal saline at each dressing change.
16328609|NCT04479618|Active Comparator|advanced dressings (positive control)|"After initial cleansing/debriding, the advanced dressing group (3) will have a cut piece of a 4x24 standard (pink) polymeric membrane dressing roll large enough to extend at least 0.5 cm beyond all open and closed (inflamed or damaged) wound edges applied as per the Instructions for Use (the periwound is blotted dry, but the wound bed remains moist from the final saline rinse). One wrap of stretch gauze will hold the polymeric membrane dressing in place. The approximate open wound edges will be marked on the dressing backing. As per the manufacturer's instructions for use, patients will change the dressings when saturation reaches any of the wound edges, as indicated by a change in color on the backing of the dressing, visible through the stretch gauze. Routine rinsing will not be performed; the wounds will be rinsed at dressing changes only if visible loose debris is present."
16328610|NCT04479605||Patients with advanced cancer|Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E & F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G & H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
16328611|NCT04479605||Caregivers|Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
16328612|NCT04479605||Oncologists|The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
16328613|NCT04479579|Experimental|Apixaban|apixaban for extended prophylaxis against VTE after discharge
16328614|NCT04479566|Experimental|lithium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
16328615|NCT04479566|Placebo Comparator|calcium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
16328616|NCT04479553||Qizhi Tongluo Capsules|Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.
16328617|NCT04479540|Experimental|Hospitalized SARS Cov-2|Hospitalized patients diagnosed with SARS Cov-2 infection
16328647|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19
~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-
~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
16328715|NCT04478721|Active Comparator|Meropenem|Patients enrolled in this arm, will receive 1g each 8 hours of intravenous meropenem.
16328618|NCT04479527|Experimental|the group of HAIC combined with carilizumab and apatinib mesylate treatment|"cTACE or DEBTACE+FOLFOX scheme HAIC, arterial chemotherapy scheme: OXA 65-85mg/m2 arterial H0-4 pump, calcium folinate 200mg/ m2 intravenous pump H2-4, 5-FU 1g-1.5g/ m2 arterial H4-24 pump, once every 6-8 weeks, the interventional treatment times are determined by researchers according to the patient's condition, and two times are adjacent.
~Apatinib mesylate tablets, 250mg/ time, once a day. Take it about half an hour after a meal (the daily medication time should be as same as possible), and take it with warm boiled water.
~Karelizumab, 200mg, was given intravenously for 30 minutes (including the flushing time, the whole infusion time was not shorter than 20 minutes and not longer than 60 minutes), and the medication period was q3w(±3 days)."
16328619|NCT04479514|Experimental|Preventative Skin Care Routine|"Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.
~Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment."
16328620|NCT04479501||Asthma group|Patients with asthma
16328623|NCT04479475|Experimental|Supportive care through community support persons|Participants will attend 2-hour weekly group sessions for four weeks to build social support systems. Participants will also report back on social activities that they participated in with their partner each week for the four-week intervention.
16328624|NCT04479449|Experimental|SP-8203|SP-8203 80 mg (40 mg/dose twice a day for three days)
16328625|NCT04479449|Placebo Comparator|Placebo|Placebo group: twice a day for three days
16328626|NCT04479436|Experimental|Cohort 1: HER3 High (IHC 3+, 2+)|Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen.
16328627|NCT04479436|Experimental|Cohort 2: HER3 Low/Negative (IHC 1+, 0)|Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen.
16328628|NCT04479423|Experimental|Soda water|400ml soda water was drunk to obtain good vision before undergoing MCE examination.
16328629|NCT04479423|No Intervention|water|900ml clear water(100 ml water of simethicone solution was not included) was drunk to obtain good vision before undergoing MCE examination.
16328630|NCT04479410||Drug resistant epilepsy patients|Patients with drug resistant epilepsy underwent epilepsy surgery
16328631|NCT04479397|Active Comparator|Sling Arm|This arm of the study will receive a sling for 3 weeks in postoperative care.
16328632|NCT04479397|Experimental|No Sling Arm|This arm of the study will not receive a sling during the postoperative care,
16328633|NCT04479384|Experimental|Intervention group|Thoracic manipulation T1-T5 if somatic dysfunction. Intrathoracic fascia stretch x 3. Recoil sternum x 3. Cranial base release - 4 steps.
16328634|NCT04479384|No Intervention|Control group|Supine position 10 minutes on the bench.
16328635|NCT04479371|Experimental|Liposomal bupivacaine|a penile block administered with novel liposomal bupivacaine during hypospadias repair
16328636|NCT04479371|Active Comparator|Standard Penile Block|Standard weight based bupivacaine penile block during hypospadias repair
16328637|NCT04479358|Active Comparator|Sub-study A, Tocilizumab-Free Standard of Care|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive no tocilizumab.
16328638|NCT04479358|Experimental|Sub-study A, Tocilizumab 40mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 40mg.
16328639|NCT04479358|Experimental|Sub-study A, Tocilizumab 120mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 120mg.
16328640|NCT04479358|Active Comparator|Sub-study B, Tocilizumab 400mg or 8mg/kg Standard of Care|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab dose (400mg or 8mgkg).
16328641|NCT04479358|Experimental|Sub-study B, Tocilizumab 40mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 40mg.
16328642|NCT04479358|Experimental|Sub-study B, Tocilizumab 120mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 120mg.
16328643|NCT04479332|Experimental|Resuscitation Area|Critical patient is assigned to the resuscitation area for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1-2 licensed physicians, 2-3 nurses (1 for preparing intubation materials and acts as the assist, 1-2 for administering medications and documentation); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside resuscitation area, 1 at nurses' station), 4 nurses (2 inside resuscitation area, 2 at the sterile area)
16328644|NCT04479332|Experimental|Negative Pressure Isolation Room|Critical patient is assigned to the negative pressure isolation room for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1 licensed physician, 2 nurses (1 for preparing intubation materials, acts as the assist, and for administering medications; 1 for documentation at the anteroom); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside negative pressure isolation room, 1 at nurses' station), 5 nurses (2 inside negative pressure isolation room, 1 at the anteroom, 2 at the sterile area)
16328645|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT
~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-
~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
16328646|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT
~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
16328648|NCT04479306|Experimental|Arm A (osimertinib, alisertib)|Patients receive osimertinib PO QD on days 1-28 and alisertib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm B.
16328649|NCT04479306|Experimental|Arm B (osimertinib, sapanisertib)|Patients receive osimertinib PO QD on days 1-28 and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm A.
16328650|NCT04479280||Covid19 positive patients|
16328651|NCT04479280||Covid19 negative patients|
16328652|NCT04479267|Experimental|Treatment (polatuzumab vedotin, R-CHP)|Patients receive prednisone PO, prednisolone IV, or methylprednisolone IV on days 1-5. Patients also receive rituximab IV, polatuzumab vedotin IV over 30-90 minutes, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16328653|NCT04479254|Experimental|Indirect Calorimetry- Directed Nutrition|Enteral Nutrition (EN) will be the preferred route of nutrition, and will be initiated within the first 24-48 hours of ICU admission. Caloric requirements will be measured by indirect calorimetry IC as soon as possible after recruitment and will be repeated in every 24 hrs. The amount of delivery is gradually increased to avoid the possibility of gastrointestinal intolerance. If EN fails to reach caloric goals or not feasible supplementary Parenteral nutrition(PN) will be initiated after 5-7days
16328654|NCT04479254|Active Comparator|Standard weight-based equation- Directed Nutrition|Enteral Nutrition (EN) will be initiated within the first 24-48 hours of ICU. Admission. Enteral nutrient delivery is gradually increased to avoid the possibility of gastrointestinal intolerance so that a few days are required to achieve the caloric target. PN will be started after 5-7 days if EN is not feasible. Energy and protein goals will be calculated by the standard weight-based equation of 25 kcal/kg BW body weight and 1.2-2.5 g/kg body weight, respectively.
16328655|NCT04479241|Experimental|PVSRIPO|
16328656|NCT04479228|Experimental|NAGI bi-flanged metal stent (BFMS)|The WON will be punctured using a standard 19-gauge FNA needle and the aspirate was sent for biochemical and microbial analysis. A 0.025-inch (Visiglide; Olympus Corporation, Tokyo, Japan) or 0.035-inch stiff guidewire (Jag Wire; Boston Scientific) passed through the needle into the cyst cavity to form at least 1 to 2 loops under fluoroscopic guidance. A 6F cystotome (Endo-flex GmbH Dusseldorf, Germany) will be passed over the guidewire for creating a fistula. Subsequently, a 6-mm balloon dilator (Hurricane; Boston Scientific Corporation or Titan balloon, Wilson Cook) will be used to further dilate the fistula tract. After this, the stent delivery catheter is advanced over the guidewire across the PFC wall and the BFMS (Nagi; Taewoong Medical, Gyeonggi-do, South Korea) deployed using sonographic, fluoroscopic and endoscopic visualization.
16328657|NCT04479228|Experimental|Plastic stents|Double-pigtail plastic stents will be used. A minimum of one 10Fr pigtail plastic stent will be placed. After initial EUS-guided access, the ostomy will be dilated first, using a cystotome, and secondly with a balloon dilation. The plastic stent will be inserted and delivered following the routine technique of each interventional endoscopist. The number of the plastic stents and the size of the balloon used to dilate the ostomy will depend on the WON size and content.
16328658|NCT04479202|Experimental|berberine group (B group)|Patients in the B group were given berberine hydrochloride tables 0.3g tid orally or tube feed daily, until the 14th day of the study. Other treatments include general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support.
16328659|NCT04479202|Sham Comparator|control group (C group)|Patients in the C group were given montmorilonite orally if they presence of diarrhea. The other treatments were the same as in B group.
16328662|NCT04479163|Experimental|Plasma|Convalescent plasma with an IgG titer against SARS-CoV2
16328663|NCT04479163|Placebo Comparator|Placebo|Normal Saline 0.9%
16328664|NCT04479150||Pandemic Covid-positive cohort|All Covid-positive patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
16328665|NCT04479150||Pandemic Covid-negative cohort|All Covid-negative patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
16328666|NCT04479150||Control cohort|Pre-pandemic cohort: all patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2019.
16328667|NCT04479111|Experimental|LISRH group|Following the principle of complete mesocolic excision(CME), Ileocecus-Sparing Right colectomy refers to the resection of the most portion of the ascending colon, hepatic flexure and mid to distal transverse colon. The extent of lymph node dissection and length of distal resection margin are similar to conventional right hemicolectomy. The length of proximal resection margin varies.
16328668|NCT04479098|Experimental|Exercise training|Postmenopausal breast cancer survivors undergoing tamoxifen treatment, who will do the evaluations before the beginning and after 12 weeks of exercise training and subsequently 12 weeks of detraining.
16328669|NCT04479085|Experimental|experimental group|The nursing attempt to organize the home environment for the experimental group will take 4 months. During this period, two home visits and two telephone calls will be made. During the first home visit, training will be organized to regulate the home environment. Temperature and humidity changes of the houses will be monitored during the operation with the heat-moisture meter device. During the first home visit, a temperature-humidity meter device, symptom log and temperature-humidity log tracking chart will be provided. Children in this group will be given an anti-allergic duvet cover. Home environment arrangements of mothers and changes in the quality of life of children will be examined at the beginning and end of the study. Children's symptoms will be monitored weekly for 4 months.
16328670|NCT04479085|Other|control group|The nursing initiative to regulate the home environment for the control group will take 4 months. During this time, two home visits will be made. During the first home visit, temperature-humidity meter device, symptom log and temperature-humidity log monitoring chart will be provided.Home environment arrangements of mothers and changes in the quality of life of children will be examined at the beginning and end of the study. Children's symptoms will be monitored weekly for 4 months.
16328671|NCT04479072|Active Comparator|Intervention Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.
16328672|NCT04479072|Placebo Comparator|Placebo Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill
16328673|NCT04479072|No Intervention|Observational Arm|60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.
16328674|NCT04479059|Experimental|İntracavitary fluid flushing|
16328675|NCT04479059|No Intervention|Control group|
16328676|NCT04479046|Active Comparator|Stainless steel crowns|3M ESPE
16328677|NCT04479046|Experimental|Zirconia crowns|Nu Smile
16328678|NCT04479046|Experimental|PMMA crowns|Dental Direkt
16328679|NCT04479033|No Intervention|Control|Participants assigned to the control group had screened positive for cognitive impairment but refused the intervention. They were provided with a GP referral letter and information on helplines and caregiver support. Follow-up interviews were scheduled at week 24.
16328680|NCT04479033|Experimental|Intervention|Weekly meeting/communication sessions with members of intervention team for a total of 24 weeks.
16328681|NCT04479007||Mechanically ventilated patients|Critically ill patients of 18 years or older who receive invasive mechanical ventilation for acute respiratory failure and have an indication for an intervention in the airways.
16328682|NCT04478994|Active Comparator|TEPEZZA 20mg/kg|Approximately 15 participants will receive 8 infusions of TEPEZZA q3W for a total of 21 weeks. TEPEZZA 10mg/kg will be administered on Day 1 and TEPEZZA 20mg/kg will be administered q3W for the remaining 7 infusions.
16328683|NCT04478994|Placebo Comparator|Placebo|Approximately 10 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
16328684|NCT04478981||SELENON- or LAMA2-related muscular dystrophy|Participants diagnosed with congenital myopathy/muscular dystrophy due to mutations in the SEPN1 (SELENON) or LAMA2 gene
16328685|NCT04478968||Active AVF|Patients after kidney transplantation with functioning AVF
16328686|NCT04478968||No AVF|Patients after kidney transplantation without AVF (thrombosed AVF, history of HD with catheter, history of PD, preemptive transplantation)
16328687|NCT04478955||normal|no make up
16328688|NCT04478955||eyeliner only|three days a week at least for 6 months
16328689|NCT04478955||mascara only|three days a week at least for 6 months
16328690|NCT04478955||eyeliner and mascara|three days a week at least for 6 months
16328691|NCT04478942|Active Comparator|oral misoprostol|At time of delivery, participants randomly assigned to either oral misoprostol will receive 50 mcg of Misoprostol every 4 hours up to 6 doses, OR until simplified Bishop score >6 (whichever is achieved first).
16328692|NCT04478942|Active Comparator|intravenous oxytocin|At time of delivery, participants randomly assigned to intravenous oxytocin, will be administered the drug per standard of labor and delivery titrations.
16328693|NCT04478929||gastroscopy clinic patients|NBT gastroscopy clinic invited participants. Patients are already due to attend the clinic, and we are inviting them to share their gastroscopy data with our research study.
16328694|NCT04478916||Geriatric evaluation Group|Geriatric evaluation of the proportion of elderly patients in which the treatment is modified based on the complete geriatric assessment (CGA)
16328695|NCT04478916||Control Group|
16328696|NCT04478903||primary caregiver of patients aged 70 and over|
16328697|NCT04478890||Observational Group|Characterize right ventricular function while undergoing LVAD implantation
16328698|NCT04478851|Experimental|Intervention|All participants will be involved in group exercise classes, twice a week for 12 weeks.
16328699|NCT04478838|Experimental|Extended Dosing Group|Participants taking olanzapine or risperidone will be switched to an alternate day dosing schedule.
16328700|NCT04478838|No Intervention|Treatment as Usual group|Participants will continue to take their olanzapine or risperidone following the same prescribed daily schedule.
16328701|NCT04478825|Experimental|BBT-401-1S|BBT-401-1S, rectal administration
16328702|NCT04478812|Experimental|Single Group Assignment|
16328703|NCT04478799|Experimental|Group A (Transcutanous Posterior Tibial Nerve Stimulation)|Patients belonging to the group A received Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
16328704|NCT04478799|Sham Comparator|Group B (Sham Control)|Patients belonging to the group B received Sham Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
16328705|NCT04478786||Focus Groups 1-4|An anticipated 3-8 participants who meet the inclusion criteria of being aged 18 or over, a employee of the local ambulance service, are employed as an operational ambulance crew member, irrespective of title and to have had experienced an out of hospital resuscitation where MCCD was used, irrespective of the type of device or their level of involvement, and who also volunteer and agree to take part in the online focus group.
16328706|NCT04478773|Experimental|Experimental|Patient will receive MRI
16328707|NCT04478760||Masculinising therapy|Healthy transgender (including non-binary) adults who are on testosterone-containing hormone therapies.
16328708|NCT04478760||Feminising therapy|Healthy transgender (including non-binary) adults who are on oestrogen-containing hormone therapies.
16328709|NCT04478747|Active Comparator|Transvaginal mesh|BSC mesh (A.M.I., Feldkirch, Austria) is attached to the sacrospinosus ligaments and to the apical part of the vagina.
16328710|NCT04478747|Active Comparator|Colposacropexy with the apical fixation only|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina.
16328711|NCT04478747|Active Comparator|Colposacropexy with the apical and the levator fixation|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina with fixation reaching to the level of the levator planes.
16328720|NCT04478695|Experimental|Cohort 1|
16328721|NCT04478695|Experimental|Cohort 2|
16328722|NCT04478682|Experimental|WhatsApp Messaging Application|Continuous breastfeeding support will be provided for the first 6 months through WhatsApp messaging application. Mothers will be contacted once a week through WhatsApp and feedback will be received on the breastfeeding process. The questions of the mother regarding breastfeeding will be answered by text / voice message or video call.
16328723|NCT04478682|No Intervention|Standard breastfeeding support|She will receive standard breastfeeding support after delivery. Breastfeeding will not receive continuous breastfeeding support for the first 6 months after discharge.
16328724|NCT04478656|Experimental|BBV121-2.5 µg|BBV121: Each 0.5ml vial contain purified10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
16328725|NCT04478656|Placebo Comparator|Placebo|Each 0.5ml vial contain purified 2.5 µg, 5 µg or 10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
16328726|NCT04478656|Experimental|BBV121-5 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
16328727|NCT04478656|Experimental|BBV121-10 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5ml
16328728|NCT04478643|Placebo Comparator|PLACEBO|"Collection of microbiological samples from the two deepest sites in two different quadrants.
~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).
~Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
16328729|NCT04478643|Experimental|PROBIOTIC (L. Reuteri)|"Collection of microbiological samples from the two deepest sites in two different quadrants.
~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).
~Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
16328730|NCT04478630|Active Comparator|Peppermint Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of peppermint essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4).The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening).The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
16328731|NCT04478630|Active Comparator|Ginger Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of ginger essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy.The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
16328732|NCT04478630|Placebo Comparator|Pure Vanilla Extract (placebo-control)|Usual care plus a personal pocket diffuser prepared with 14 drops of pure vanilla extract (placebo). Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
16328733|NCT04478617|Experimental|Metronidazole|
16328734|NCT04478617|No Intervention|Control|
16328735|NCT04478604||pregnant women|last trimester pregnant women and gave birth in the same hospital
16328736|NCT04478591||Patients with multiple sclerosis using ocrelizumab.|Patients with multiple sclerosis using ocrelizumab for a minimum of one year.
16328737|NCT04478578||Patients with febrile illness|Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study.
16328738|NCT04478552|Experimental|Intervention group|
16328739|NCT04478552|Placebo Comparator|Control group|
16328740|NCT04478539|Experimental|COVID-19 patients admitted to the ICU|"COVID-19 patients will be treated with the Prismaflex® oXiris® system in the ICU.
~Treatment will be initiated within 4 - 12 hours after admission upon establishing control of the haemostasis, ACT = Activated Coagulation Time of 180 seconds"
16328768|NCT04478344|Experimental|Ultrasound guided hydrodissection to superior cluneal nerve|Ultrasound guided perineural injection with 5% dextrose 4 c.c. + 1% xylocaine 1 c.c. to superior cluneal nerve of affected side.
16328769|NCT04478331|No Intervention|CONTROL|The Control group will receive the usual care. In the physical activity (PA) field, this includes two individual motivational interviews with a PA professional, and a group workshop during the first year after BS. PA recommendations will be explained to each participant, and their achievement will be encouraged and supported during these sessions. No face-to-face PA sessions will be offered as part of the usual care.
16328741|NCT04478526|Experimental|e-CBT|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session were designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
16328742|NCT04478526|Experimental|Pharmacotherapy|Biweekly meeting with psychiatrist with GAD-7, DASS-42 and Q-LES-SF. Pharmacotherapy class decided according to protocol developed in accordance with Canada's best practice guidelines for GAD treatment. At second appointment, medication will be maintained and optimized, regardless of response. At third appointment, optimized if partial response or switched according to protocol if no response. Partial response is improvement of 20% or more in GAD-7. If switched, 6-week protocol will recommence with new medication. At fourth appointment, dosage optimized if responding well to medication and improvement greater than 50% within primary arm, or 20% if secondary arm, patient will remain on said medication for remainder of 12-week study. If not improving more than 20%, medication switched according to protocol and 6-week protocol will recommence. If primary arm and 20-50% improvement after six weeks on new medication, augmented with olanzapine, risperidone or benzodiazepines.
16328743|NCT04478526|Experimental|e-CBT + Pharmacotherapy|Participants will commence both treatments described above simultaneously.
16328744|NCT04478513|Experimental|Smokers|Pre-specified group of participants.
16328745|NCT04478513|Experimental|Non-smokers|Pre-specified group of participants.
16328746|NCT04478500|Active Comparator|Minocycline Group|Subjects will be randomized to receive Minocycline 100mg twice daily
16328747|NCT04478500|Placebo Comparator|Placebo Group|Subjects will be randomized to receive placebo.
16328748|NCT04478487|Experimental|Study Participants|all preterm infants ≤ 32 weeks and 0 days gestational age (GA) with a birth weight 700 g to 1500 g at the hospital, who are enterally fed human milk in the neonatal intensive care unit (NICU) for at least 7 days. Various blending ratios of the fortifier with either the mother's expressed milk or donor milk will be used to deliver macro and micronutrients based on established guidelines to be adjusted according to the infant's tolerance for volume and calories. The estimated time for each subject's participation is approximately from 1 week through 8 weeks, depending on the weight and age at enrollment. Historic control cases treated by another human milk based human milk fortifier will be obtained from medical records, matched on birth weight and gender, with sample size twice (n=80) that of the study population.
16328749|NCT04478474||Eligible|Retrospective chart review of all pediatric patients who underwent allogeneic stem cell transplant between June 29, 2011 and December 31, 2019 at Westchester Medical Center (WMC). Children, adolescent, and young adult patients, ages 0-≤26 years, who have received an allogeneic stem cell transplantation on the pediatric bone marrow transplant service including matched unrelated donor, matched sibling donor, haploidentical donor, umbilical cord donor, who received ganciclovir prophylaxis for ≥14 days.
16328750|NCT04478461|Experimental|MW11 injection|1, 3, 10 mg/kg and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W.
16328751|NCT04478448|Experimental|T test|Test drug (Flupirava) 1 tablet contains 200 mg Favipiravir
16328752|NCT04478448|Active Comparator|B reference|Reference drug (Avigan) 1 tablet contains 200 mg Favipiravir
16328753|NCT04478435|Active Comparator|1 Hour post intervention|Ultrasound assessment done 1 hour after ingestion of glucose loaded drink
16328754|NCT04478435|Placebo Comparator|2 hours post intervention|Ultrasound assessment done 2 hour after ingestion of glucose loaded drink
16328755|NCT04478422|Experimental|Muscle strengthening with vascular occlusion|Quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, with partial occlusion to blood flow. The occlusion equipment will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017).
16328756|NCT04478422|Active Comparator|Conventional muscle strengthening|Conventional quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, without occlusion to blood flow.
16328757|NCT04478409||Children or adult with Familial Mediterranean fever|"Considering 5 clearly pathogenic (homozygous) genotypes, 15 possibly pathogenic genotypes (5 pathogenic mutations in the heterozygous state, 10 possibly pathogenic mutations in the homozygous or heterozygous state), a number of 80 patients will be necessary to cover the correlation analysis genotype / phenotype.
~The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients."
16328758|NCT04478409||Healthy blood donor|Healthy blood donor
16328759|NCT04478370|Experimental|An. minimus|"This arm will be divided into 2 groups; the low-exposure groups and the high-exposure group.
~In the low-exposure group, participants will be exposed to 5 mosquito bites at weekly intervals from day 14 to day 56 (seven challenges with 5 mosquito bites/challenge over six weeks, yielding a total of 35 mosquito bites).
~In the high-exposure group, participants will be exposed to 5 mosquito bites on day 14 and then to 50 mosquito bites at weekly intervals from day 21 to day 56 (one challenge with 5 mosquito bites and six challenges with 50 mosquito bites/challenge over 6 weeks, yielding a total of 305 mosquito bites)."
16328760|NCT04478370|Experimental|An. maculatus|Same as above
16328761|NCT04478370|Experimental|An. dirus|Same as above
16328762|NCT04478370|Experimental|Ae. aegypti|Same as above
16328763|NCT04478370|Experimental|Ae. albopictus|Same as above
16328764|NCT04478357|Other|Treatment A|4 mg fesoterodine ER tablet manufactured at Zwickau.
16328765|NCT04478357|Other|Treatment B|4 mg fesoterodine ER tablet manufactured at Freiburg
16328766|NCT04478357|Other|Treatment C|8 mg fesoterodine ER tablet manufactured at Zwickau
16328767|NCT04478357|Other|Treatment D|8 mg fesoterodine ER tablet manufactured at Freiburg.
16328770|NCT04478331|Experimental|ACTI-VISIO|The two PA sessions per week will be delivered via videoconferencing (developed by Mooven™). The PA program consists in tailored adapted PA sessions led by a professional specialized in adapted PA. These sessions were specifically designed to be appropriate for the population and were developed in collaboration with the authors to ensure standardization of the recommended volume of PA. The PA sessions will be given live, individually at the beginning and then in groups of four women. During sessions, the professional and the participants will interact simultaneously, and the execution of the exercises will be monitored and adapted live by the professional. To ensure the safety of the PA, a rating of perceived exertion will be requested after each session on a 10-point scale. If the RPE exceed 7, the professional specialized in adapted PA will adjust the training load. In addition to the exercises, the sessions will also include advice and tips for reaching the recommended PA level.
16328771|NCT04478331|Experimental|ACTI-MOBIL|The PA sessions will be delivered by an eHealth platform (developed by BePatient™) associated with an activity bracelet. The researchers enrich PA content on the platform and ensure standardization of the recommended volume of PA. The platform consists of tips for reaching the PA level, PA questionnaires, PA feedback measured by the activity bracelet, and a video demonstration of PA sessions performed by a peer. The PA sessions are automatically broadcasted twice a week for 12 weeks. To ensure the safety of the PA, the sessions were designed to be appropriate for this population and the RPE will be measured after each session on a 10-point scale. If the RPE exceeds 7 for 3 consecutive sessions, the training load will be adjusted. The platform will also include a variety of content, including dietary tips, obesity-related facts, information about surgery, and frequently asked questions.
16328772|NCT04478318|Experimental|uEXPLORER/mCT|Each patient will undergo a scan on a total-body PET/CT scanner (uEXPLORER) and then undergo an additional scan on a conventional PET/CT scanner (mCT). The first scan will take place 90 minutes after injection with 18F-FDG and the second scan will be 120 minutes after injection with 18F-FDG.
16328773|NCT04478318|Experimental|mCT/uEXPLORER|Each patient will undergo a scan on a conventional PET/CT scanner (mCT) and then undergo an additional scan on a total-body PET/CT scanner (uEXPLORER) . The first scan will take place 90 minutes after injection with 18F-FDG and the second scan will be 120 minutes after injection with 18F-FDG.
16328774|NCT04478305|Other|Intervention group|Patient will be provided with study medication. To be taken once a day for 16 weeks (112 days). Active drug brand name - Duavive/Duavee. Dose consisting of 1 pill of 0.45mg conjugated estrogens and 20mg bazedoxifene as bazedoxifene acetate.
16328775|NCT04478292|Experimental|Group A|"Group A1： tumor is completely resected at diagnosis and receives no adjuvant chemotherapy（well differentiated fetal [WDF] histology HB) ；
~Group A2：tumor is completely resected followed by 2 cycles of standard dose cisplatin monotherapy （non-well differentiated fetal histology HB)"
16328776|NCT04478292|Experimental|Group B|"Patients will be randomized to one of 2 arms: Arm CDDP or Arm CDDP plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy (6 cycles of standard dose cisplatin monotherapy with or without STS). All the patients in 2 arms will receive 6 cycles chemotherapy in total.
~Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.
~Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
16328777|NCT04478292|Experimental|Group C|"Patients in Group C will have locally advanced tumors including PRETEXT I-III tumors with a positive VPEFR annotation factor and all PRETEXT IV tumors.
~Patients will be randomized to one of 2 arms: Arm C5VD or Arm C5VD plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy. All the patients in 2 arms will receive 6 cycles chemotherapy in total.
~Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.
~Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
16328778|NCT04478292|Experimental|Group D|"These patients have metastatic disease, suspected HB patients ≥ 8 years of age, or have an AFP ≤ 100 at diagnosis.
~Patients will receive initial chemotherapy according to the cisplatin-intensive SIOPEL-4 induction regimen. Resection (including transplant) of the primary tumor should be completed after induction Block 3, but primary tumor resection can be planned any time after completing induction therapy.
~Following 3 blocks of induction chemotherapy, patients will be stratified into 2 risk groups: Group D1 includes patients who either have a chemotherapy-induced lung CR or are rendered a lung CR by surgical metastasectomy. These patients will have chemotherapy consolidation with carboplatin/doxorubicin. In Group D2, patients will have not yet achieved a lung CR at the end of induction Block 3. These patients will get intensified consolidation therapy of carboplatin/doxorubicin with vincristine/irinotecan.
~Resection of pulmonary nodules should be considered in Group D2."
16328779|NCT04478279|Experimental|Dose Escalation|This cohort only patients diagnosed with locally advanced or metastatic melanoma, carcinoma or sarcoma of any tumor type who are refractory or intolerant to all available therapies. ST101 will be administered intravenously (IV), initially once per week.
16328780|NCT04478279|Experimental|Dose Expansion HR+ Breast|This cohort must have progressed after 1-2 hormone based therapies. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
16328781|NCT04478279|Experimental|Dose Expansion Melanoma|This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
16328782|NCT04478279|Experimental|Dose Expansion GBM|Primary (de novo) GBM that has recurred or progressed (per modified RANO criteria) after 1 standard treatment regimen. Standard therapy is defined as maximal surgical resection, radiotherapy, and concomitant temozolomide with radiotherapy or adjuvant chemotherapy with temozolomide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
16328783|NCT04478279|Experimental|Dose Expansion CRPC|CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
16328784|NCT04478266|Experimental|Amcenestrant with Letrozole-matching placebo Arm|Participants in Amcenestrant with Letrozole-matching placebo Arm will be administered: Amcenestrant dose, once daily, continuously. Letrozole-matching placebo, once daily, continuously. Palbociclib dose once daily, days 1-21 of every 28-day cycle. Goserelin once every 4 weeks in pre/peri menopausal women and men
16328785|NCT04478266|Active Comparator|Letrozole with Amcenestrant matching placebo Arm|Participants in Letrozole with Amcenestrant-matching placebo Arm will be administered: Letrozole dose, once daily, continuously. Amcenestrant-matching placebo, once daily, continuously. Palbociclib dose once daily, days 1-21 of every 28-day cycle Goserelin once every 4 weeks in pre/peri menopausal women and men
16328786|NCT04478253|Experimental|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
16328787|NCT04478253|No Intervention|Usual care|Insertion of the drain according to the usual management protocol
16328788|NCT04478240|Experimental|Intervention (access to PeerLearning.net)|Teachers and students in intervention schools will be given access to PeerLearning.net software for the purposes of instruction for the 2021-2022 school year.
16328789|NCT04478240|No Intervention|Passive Control (no intervention)|Teachers and students in control schools will conduct instruction as usual without PeerLearning.net.
16328790|NCT04478227|Experimental|Arm A|"Arm A will include acquired bone marrow failure (BMF) disorders including aplastic anemia, refractory cytopenia of childhood/Myelodysplastic Syndrome(MDS) without monosomy 7 and 5q deletion abnormalities, toxin induced myelosuppression due to infection and inherited cytopenia with or without involvement of other cell lines who are transfusion dependent and or showing progression to bone marrow failure.
~Arm A: Start at 5 microgram/kg/dose per week along with standard of care and escalate with 2.5 microgram/kg/dose increments (per week at physician's discretion depending on the clinical and laboratory response) (Maximum: 20 microgram/kg/dose) based on response for at least 24 weeks or until hematopoietic response is seen, whichever comes first. If patient shows response, therapy will be continued for a total of 52 weeks."
16328791|NCT04478227|Experimental|Arm B|"Arm B will include children with chemo and or radiotherapy induced thrombocytopenia/cytopenia and children undergoing stem cell transplantation (SCT).
~Arm B: Starting dose 2 microgram/kg/dose per week with increments at 1 microgram/kg/dose (Maximum: 10 micrograms/kg/dose) depending on the laboratory response."
16328792|NCT04478201|Experimental|Back lying sleep position|sleep on the back
16328793|NCT04478201|Experimental|Side lying sleep position|sleep on the side
16328794|NCT04478188||Cardiogenic Shock Patients Needing TMCS|Heart failure patients who undergo TMCS insertion for acute decompensated heart failure and cardiogenic shock.
16328795|NCT04478175|Other|Patients with advanced gastrointestinal (GI) cancers|"All patients will receive usual care including:
~Chemotherapy at the investigator's choice,
~Outpatient clinical visits according to the regular schedule,
~Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8 weeks.
~Nutritional support will consist of:
~A nutrition assessment by a dieticianat W4 and W8 (plus additional visits if required),
~Nutritional intervention ± oral supplementation, enteral tube feeding, and/or parenteral nutrition).
~Physical activity support will consist of:
~A physical condition assessment by a APA profesional including physical tests (6-minute walking test, handgrip test, chair stand fitness test, get-up and go test, balance in single-leg and bipodal stance) at baseline, W4 and W8,
~Personalized counselling for unsupervised home-based exercises"
16328796|NCT04478162|Experimental|Experimental|Newborn to be premature (28-34 Gestation Weeks), The baby is admitted to the neonatal intensive care unit,sleeps for at least 7 days, Any screened newborn gastrointestinal, neurological, and Genetic the absence of disease, Mother and father being open to communication and cooperation, Mother and father volunteering to participate in the research, Being a literate mother and father, The mother has primiparous and first maternity experience, Having the first parenting experience in your father, Your mom and dad being 19 and over, Participation of parents in the initiative group in training and practices for the FICare model, Participation in routine care in parents in the NICU to the parents in the control group, Baby nurses in charge of a 4-hour training on the Family Integrated Care model, Mothers and fathers in the venture group stay at least 6-8 hours a day in hospital, Mothers and fathers in the intervention group to perform at least 3 treatments a day with a nurse,
16328797|NCT04478162|No Intervention|Control Groups|Babies in the control group will be monitored in routine service care. There will be no intervention
16328798|NCT04478149|Experimental|Active Cameras|active cameras in the room
16328799|NCT04478149|Sham Comparator|Inactive Cameras|camera in the room, not activated
16328800|NCT04478136||Major bleeders (MB)|Additional blood to be drawn from patients on ECMO who have a major bleeding event.
16328801|NCT04478136||Non-major bleeders (NMB)|
16328802|NCT04478123|Experimental|romiplostim|"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.
~Regardless of the conditioning regimen received, all patients will receive romiplostim 3.0 mcg/kg SC on Day +1 and romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. No patient will receive more than six doses of romiplostim, even if platelets have not corrected by Day +42."
16328803|NCT04478110|Experimental|Interactive education with linkage to care|Main intervention components included interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care
16328804|NCT04478110|Active Comparator|general health education|Receive a group education session focused on general health education and primary prevention issues.
16328805|NCT04478097|Experimental|Reference-Reference-Test|
16328806|NCT04478097|Experimental|Reference-Test-Reference|
16328807|NCT04478097|Experimental|Test-Reference-Reference|
16328808|NCT04478084|Experimental|Group 1: pediatric participants; VRVg-2|VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
16328809|NCT04478084|Active Comparator|Group 2: pediatric participants; Verorab|Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
16328810|NCT04478084|Experimental|Group 3: adult participants; VRVG-2 + ERIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7
~+ ERIG at D0"
16328811|NCT04478084|Active Comparator|Group 4: adult participants; Verorab + ERIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7
~+ ERIG at D0"
16328812|NCT04478084|Experimental|Group 5: adult participants; VRVG-2 + HRIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
~+ HRIG at D0"
16328813|NCT04478084|Active Comparator|Group 6: adult participants; Verorab + HRIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
~+ HRIG at D0"
16328816|NCT04478058|Experimental|e-CBT|Weekly e-CBT sessions will occur through Online Psychotherapy Tool (OPTT) and consist of slides and interactive therapist videos. Content and format mirrors live CBT. Slides will highlight a different topic each week and include general information, overview of skills, and homework. Homework will be submitted through OPTT and reviewed by administrators with personalized feedback within three days. Weekly homework submission will be mandatory before beginning the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment. After each cycle of e-CBT, patients and healthcare providers involved in e-CBT will be recruited for focus groups once they have completed their 12-week program. Qualitative data will be gathered through 10 focus groups. The focus group prompts will pertain to experience and expectations of service. Patients will be contacted six months after treatment to complete DASS 21 and Q-LES-Q-SF questionnaires.
16328817|NCT04478058|Active Comparator|Live CBT|The content and format of live CBT will be mirrored by the e-CBT group over the course of 12 weeks. The sessions will highlight a different topic each week and include general information, an overview of skills, and homework on that topic. Live CBT homework will be reviewed by the CBT group organizer and provided at the beginning of the next CBT session. Weekly homework submission for feedback will be mandatory before being eligible for the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment for both live and e-CBT. All live and e-CBT patients will be contacted six months after the completion of their CBT to complete final DASS 21 and Q-LES-Q-SF questionnaires. This will allow for the examination of the longevity of e-CBT compared to live CBT.
16328818|NCT04478032|Sham Comparator|sham stimulation|20 patients will be randomly allocated into this group,they will receive sham stimulation.
16328819|NCT04478032|Active Comparator|real stimulation dTMS targeting the ACC|20 patients will be randomly allocated into this group,they will receive real stimulation.
16328820|NCT04478019|Other|Control > Active Intervention|Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
16328821|NCT04478019|Other|Active Intervention > Control|Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).
16328822|NCT04478006||Childhood Leukemia|Peripheral blood and bone marrow samples are collected for genetic analysis, invitro drug sensitivity test and animal experiment.
16328823|NCT04477993|Experimental|Experimental Group - ruxolitinib|Ruxolitinib 5 mg PO b.i.d. for 14 days
16328824|NCT04477993|Placebo Comparator|Placebo Group|
16328825|NCT04477980||Culture positive empyema|Patients with empyema confirmed by a positive pleural fluid culture, irrespective of its gross fluid appearance
16328826|NCT04477980||Culture negative empyema|Patients with empyema confirmed by a gross pus appearance AND a negative pleural fluid culture
16328827|NCT04477954|Experimental|Experimental HBOT|Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
16328828|NCT04477954|No Intervention|Standard care|
16328829|NCT04477928||Newborn/Delayed Entry Group|Children 0-5.99 years old
16328830|NCT04477928||DGE- Opt In Group|36 weeks gestation up until onset of active labor
16328831|NCT04477915|Experimental|Core stabilization Exercise|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises. Exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
16328832|NCT04477915|Experimental|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles. exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
16328833|NCT04477915|No Intervention|Control|Control Group
16328834|NCT04477889||COVID-19 Cohort|Patients treated at MHS facilites for COVID-19
16328835|NCT04477850|Experimental|Luspatercept Administration|Starting dose of 1.0mg/kg subcutaneous injection every 3 weeks
16328836|NCT04477837||direct oral anticoagulant (DOAC) No.1|Apixaban 5mg, oral, twice daily for at least four months
16328837|NCT04477837||direct oral anticoagulant (DOAC) No.2|Rivaroxaban 20mg, oral, once daily for at least four months
16328838|NCT04477837||direct oral anticoagulant (DOAC) No.3|Edoxaban 60mg, oral, once daily for at least four months
16328839|NCT04477837||direct oral anticoagulant (DOAC) No.4|Dabigatran 150mg, oral, twice daily for at least four months
16328840|NCT04477811|Active Comparator|vitamin k1|vitamin k1 will be given 10 mg thrice a week for 3 months
16328841|NCT04477811|Active Comparator|vitamin k2|vitamin k2 (menaquinone) will be given 90 ug per day orally
16328842|NCT04477811|Placebo Comparator|placebo|placebo will be given daily per oral for 3 months
16328843|NCT04477798|Experimental|PCT-DIA/MS|PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules
16328845|NCT04477772|Experimental|1mg/kg, Q3W until to 2 years|
16328846|NCT04477772|Experimental|3mg/kg, Q3W until to 2 years|
16328847|NCT04477772|Experimental|10mg/kg, Q3W until to 2 years|
16328848|NCT04477759|Experimental|50 Gray (Gy) Radiation Therapy|50 Gy of ionizing radiation therapy will be administered in 15 fractions.
16328849|NCT04477759|Experimental|55 Gray (Gy) Radiation Therapy|55 Gy of ionizing radiation therapy will be administered in 15 fractions.
16328850|NCT04477759|Experimental|60 Gray (Gy) Radiation Therapy|60 Gy of ionizing radiation therapy will be administered in 15 fractions.
16328851|NCT04477733|Experimental|Butorphanol group|
16328852|NCT04477733|Placebo Comparator|control group|
16328853|NCT04477707||Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO or FIGARO.
16328854|NCT04477707||Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO or FIGARO.
16328855|NCT04477694||type II diabetic patients|
16328856|NCT04477694||non-diabetic patients|
16328857|NCT04477681||Patients in therapeutic failure or relapse|Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant)
16328858|NCT04477668|Experimental|Helmet group|Patients will be allocated to helmet non-invasive ventilation
16328859|NCT04477668|No Intervention|Control group|Patients will be allocated to standard of care
16328860|NCT04477655|Active Comparator|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Continuous monitoring of vital signs. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%. Prone positioning will be allowed as a rescue therapy.
16328861|NCT04477655|Experimental|Awake prone positioning|Oxygen therapy through high flow nasal cannula (HFNC). Patients will be asked to remain in prone position throughout the day as long as possible, with breaks according to tolerance. Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%.
16328862|NCT04477642|Experimental|AbataceptTreatment Arm|Enrolled patients who will receive treatment with abatacept
16328863|NCT04477629|Experimental|Belatacept|Participants will receive Belatacept along with an upfront tacrolimus taper Participants will also receive mycophenolate mofetil and corticosteroids are part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice.
16328864|NCT04477616|Experimental|Experimental: Experimental/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 (chemotherapy day was recorded as day 1). If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
16328865|NCT04477616|Active Comparator|Comparator: Comparator/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 (chemotherapy day was recorded as day 1). If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
16328866|NCT04477603|Experimental|Subjects receiving the Impella ECP|
16328867|NCT04477590|No Intervention|NO EXERCISE TRAINING|25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
16328868|NCT04477590|Experimental|EXERCISE TRAINING FED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
16328869|NCT04477590|Experimental|EXERCISE TRAINING FASTED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
16328870|NCT04477577|Experimental|New Parent Intervention|
16328871|NCT04477577|Active Comparator|Safety Control|
16328872|NCT04477564||Unprovoked proximal deep vein thrombosis|
16328873|NCT04477564||Provoked distal deep vein thrombosis|
16328874|NCT04477564||age-matched control group with no history of vein thrombosis|
16328875|NCT04477551|Experimental|Diode laser (device) with scaling and root planing|Diode laser (device) with conventional scaling and root planing
16328876|NCT04477551|Active Comparator|Conventional scaling and root planing|Conventional scaling and root planing
16328877|NCT04477538||Participants with prepectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
16328878|NCT04477538||Participants with postpectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
16328879|NCT04477525|Experimental|ESP nerve block|
16328880|NCT04477525|No Intervention|Standard of Care|Standard of care includes IV opioids, NSAIDs (commonly ketorolac), +/- acetaminophen. No regional anesthesia will be given to control patients.
16328881|NCT04477512|Experimental|Level 1: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 20 mg.
16328882|NCT04477512|Experimental|Level 2: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 40 mg.
16328883|NCT04477512|Experimental|Expansion: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be dependent on recommended dose found in first part of study
16328884|NCT04477486|Experimental|Ibrutinib + Venetoclax|Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.
16328885|NCT04477473||Vulnerable subjects|Patients under long-term non-invasive ventilation (respiratory support) at home for chronic respiratory failure
16328886|NCT04477460||Infants with BRUE receiving thickened feeds|
16328887|NCT04477460||Infants with BRUE not receiving thickened feeds|
16328888|NCT04477421|Active Comparator|FS-LASIK Group|100 eyes of 50 patients underwent bilateral FS-LASIK (Femtosecond laser Insitu Keratomileusis)
16328889|NCT04477421|Experimental|FS-SMILE|100 eyes of 50 patients who underwent bilateral FS-SMILE (femtosecond small incision lenticule extraction)
16328890|NCT04477408|Other|plantar exercise group|"plantar sensitive exercises
~Plantar sensitive exercises:
~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
16328891|NCT04477395|Experimental|SRP plus fish oil|Patients will receive scaling and root planing (SRP) supplemented with the dietary fish oil rich in omega-3 PUFAs: 2.6 g of EPA and 1.8 g DHA daily for 6 months.
16328892|NCT04477395|Active Comparator|SRP alone|Patients will receive scaling and root planing (SRP) only.
16328893|NCT04477369|Other|Sequence A|7 subjects assigned to Sequence A will receive a single dose of 300mg DWJ1439 in period 1, 300mg DWC202003 in period 2 and 300mg DWJ1464 in period 3.
16328894|NCT04477369|Other|Sequence B|7 subjects assigned to Sequence B will receive a single dose of 300mg DWJ1464 in period 1, 300mg DWC202004 in period 2 and 300mg DWC202003 in period 3.
16328895|NCT04477369|Other|Sequence C|7 subjects assigned to Sequence C will receive a single dose of 300mg DWC202003 in period 1, 300mg DWJ1439 in period 2 and 300mg DWC202004 in period 3.
16328896|NCT04477369|Other|Sequence D|7 subjects assigned to Sequence D will receive a single dose of 300mg DWC202004 in period 1, 300mg DWJ1464 in period 2 and 300mg DWJ1439 in period 3.
16328897|NCT04477356|Active Comparator|Swim-up technique (SU)|The SU method's principle is that the normal and highly motile sperm will move against the gravity and separate from the dead or abnormal sperms to swim up to the upper media culture layer.
16328898|NCT04477356|Active Comparator|Density gradient centrifugation technique (DG)|The DG method is based on the density in which mature and normal sperms are capable of passing through filtration layer to be isolated from dead or abnormal sperms in semen.
16328899|NCT04477343|Experimental|Experimental: SX-682 and Nivolumab|"SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill
~Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion"
16328900|NCT04477330|Experimental|Priming+HIISTT|Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
16328901|NCT04477330|Sham Comparator|Sham+HIISTT|Sham tDCS before high intensity interval speed based treadmill training
16328902|NCT04477317|Experimental|Experimental|4% Articaine Hydrochloride with 1:100,000 Adrenaline (Alexadricaine, Alexandria Co., Egypt).
16328903|NCT04477317|Active Comparator|Control|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin (Mepicaine-L, Alexandria Co., Egypt)
16328904|NCT04477304|Experimental|Behavioral Intervention Arm|Clinicians in clinics randomized to the intervention group will be prompted with an EHR nudge when the prescribing history for the patient falls into one of the following three categories: Opioid naïve, At-risk for long-term use, or Long-term opioid recipient. These EHR-based nudges include elements of accountable justification, defaults and precommitments. Clinicians will also receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
16328905|NCT04477304|No Intervention|Control|Clinicians in clinics randomized to the control group will receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
16328906|NCT04477291|Experimental|Dose Escalation and Expansion|Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.
16328907|NCT04477278|Experimental|Audio-Guided Mindfulness Intervention|Brief, 8-minute, audio-guided mindfulness intervention delivered prior to osteopathic manipulation.
16328908|NCT04477278|Active Comparator|History of Osteopathy|Brief, 8-minute, audio-guided history of osteopathy delivered prior to osteopathic manipulation.
16328909|NCT04477265|Experimental|combination of drug and exercise|Participant will be prescribed with oral medication in combination with biofeedback-assisted pelvic floor muscle training (PFMT) during the first month, participant will continue to have biofeedback assisted PFMT for another 2 months
16328910|NCT04477265|Active Comparator|drug only|Participant will be prescribed with oral medication for 3 months
16328911|NCT04477265|Active Comparator|exercise only|Participant will be doing biofeedback-assisted pelvic floor muscle training for 3 months
16328912|NCT04477252|Experimental|App group|Use of the Mobile App for the daily performance (Monday to Friday) of lumbopelvic stability exercises apart from the usual physiotherapy treatment for 3 months.
16328913|NCT04477252|Active Comparator|conventional physiotherapy|usual physiotherapy treatment for 3 months
16328914|NCT04477239|Placebo Comparator|Placebo|Oral administration of one capsule of Placebo
16328915|NCT04477239|Active Comparator|Purified gluten (10 mg)|Oral administration of capsules containing 10 mg of purified gluten.
16328916|NCT04477239|Active Comparator|Purified gluten (50 mg)|Oral administration of capsules containing 50 mg of purified gluten.
16328917|NCT04477239|Active Comparator|Purified gluten (100 mg)|Oral administration of capsules containing 100 mg of purified gluten.
16328918|NCT04477239|Active Comparator|Purified gluten (500 mg)|Oral administration of capsules containing 500 mg of purified gluten.
16328919|NCT04477239|Active Comparator|Purified gluten (1000 mg)|Oral administration of capsules containing 1000 mg of purified gluten.
16328920|NCT04477200|Experimental|Phase 0|Mycophenolate mofetil, administered at 4 dose levels (2 participants will be assigned to each dose level): 500mg, 1000mg, 1500mg and 2000mg, orally, twice daily for one week prior to re-resection or biopsy. The re-resection or biopsy of tumor is part of standard of care.
16328921|NCT04477200|Experimental|Phase 1|Mycophenolate mofetil, 250-2000mg orally twice daily, for one week prior to and concurrent with re-irradiation. Radiation therapy of 40.5 Gy in 15 fractions.
16328922|NCT04477187|Experimental|Single Group|All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.
16328923|NCT04477174||Group A|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores. After 2 weeks, the participants match again.
16328924|NCT04477174||Group B|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores.
16328925|NCT04477161|Experimental|Ketone Intervention|Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
16328926|NCT04477148|Active Comparator|Metallic Reusable(MR)|Patients in this group were intubated with reusable metallic blades
16328927|NCT04477148|Active Comparator|Metallic Disposable(MD)|Patients in this group were intubated with disposable metallic blades
16328928|NCT04477148|Active Comparator|Plastic Disposable(PD)|Patients in this group were intubated with disposable plastic blades
16328929|NCT04477135|Other|perinatologists|perinatologists working actively and performing ultrasonography every day
16328930|NCT04477122|Experimental|Blue|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes (2000 shots approximately) of extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles at 2 bars and 10 Hertzs. Participants will wear splint 23 hours/day
16328931|NCT04477122|Placebo Comparator|Red|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes of placebo extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles. Participants will wear splint 23 hours/day
16328932|NCT04477109|Active Comparator|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and a relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. the device will be applied on specific acupuncture points (N acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time, once per day, 3 times per week for three months
16328933|NCT04477109|Sham Comparator|sham laser application in addition to diet recommendations|while the control group will stick to the same line of treatment but with sham laser application
16328934|NCT04477096|Other|single arm for each part: two arms|"PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.
~PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days."
16328935|NCT04477083|Active Comparator|inhalable hydroxychloroquine (HCQ).|supportive and symptomatic treatment and inhalable hydroxychloroquine (HCQ).
16328936|NCT04477083|Placebo Comparator|Placebo|supportive and symptomatic treatment
16328937|NCT04477070|Experimental|Air-polishing with ultrasonic debridement|Air-polishing with ultrasonic debridement
16328938|NCT04477070|Active Comparator|Conventional scaling and root planing.|Conventional scaling and root planing.
16328939|NCT04477057|Other|one arm|one arm
16328940|NCT04477044|No Intervention|No GoPro|No GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
16328941|NCT04477044|Experimental|GoPro|GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
16328942|NCT04477018|Experimental|Iron and Vitamin C|28 mg iron bis-glycinate chelate and 240 mg vitamin C
16328943|NCT04477018|Active Comparator|Iron|28 mg iron bis-glycinate chelate
16328944|NCT04477018|Placebo Comparator|Placebo|Matched placebo tablets
16328945|NCT04476992|Active Comparator|NO High Concentration|Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
16328946|NCT04476992|Experimental|NO High Concentration + Continuous Low Concentration|"Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
~This arm will receive in addition a continuous low flow of Nitric Oxide at 20 ppm among the high concentration treatments."
16328947|NCT04476979|Active Comparator|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
16328948|NCT04476979|Experimental|Dexamethasone + Tocilizumab|"Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
~+Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3"
16328949|NCT04476966|Experimental|T test|Test drug (Bladogra)1 extended release tablet contains 25 mg Mirabegron
16328950|NCT04476966|Active Comparator|B reference (first dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (first dose)
16328951|NCT04476966|Active Comparator|B reference (second dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (second dose)
16328952|NCT04476953|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
16328953|NCT04476953|Placebo Comparator|Placebo Group|Subjects will receive placebo
16328954|NCT04476940|Experimental|COVID BF-Support|COVID-19 breastfeeding guideline education and support for pregnant women.
16328955|NCT04476927|Experimental|DiaNose procedure|all subjects will be required to undergo the DiaNose exhalation test.
16328956|NCT04476914||Family Member|Family members of ICU patients admitted with respiratory failure from COVID-19
16329436|NCT04473612||Neuromuscular low physical status group|Patients diagnosed of Neuromuscular disease with low physical status
16328957|NCT04476901|Placebo Comparator|Genotype A administered with placebo Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.
16328958|NCT04476901|Experimental|Genotype A administered with hMSC Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.
16328959|NCT04476901|Placebo Comparator|Genotype B administered with placebo Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.
16328960|NCT04476901|Experimental|Genotype B administered with hMSC Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.
16328961|NCT04476901|Placebo Comparator|Genotype C administered with placebo Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.
16328962|NCT04476901|Experimental|Genotype C administered with hMSC Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.
16328963|NCT04476888|Experimental|Treatment arm/CP recipient|"Patients with severe/critical COVID 19 who will receive 500 ml of Convalescent plasma (CP), obtained from donors who have been recovered from SARS-CoV-2 infection.
~These patients may or may not get other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
16328964|NCT04476888|Other|Control arm|"Patients with severe/critical COVID 19 who will not receive Convalescent plasma (CP). These will be those who were recruited during the period before CP becomes available or for whom no compatible CP is available.
~These patients will receive one or more of the other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
16328965|NCT04476875|Active Comparator|Open outpatient clinic programme (OOCP)|OOCP patients had no scheduled appointments but were allowed acute appointments with their rheumatologist, and had access to nurse-led consultations and telephone helpline.
16328966|NCT04476875|No Intervention|Traditional scheduled routine follow up (TSRF)|Appointments for the TSRF group were scheduled according to routine procedures.
16328967|NCT04476862||Cerliponase alfa patients|Patients who are currently on or plan to start taking cerliponase alfa within 60 days of signing the study informed consent form.
16328968|NCT04476849|Experimental|Fezolinetant: Mild renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328969|NCT04476849|Experimental|Fezolinetant: Moderate renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328970|NCT04476849|Experimental|Fezolinetant: Severe renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328971|NCT04476849|Experimental|Fezolinetant: Normal renal function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
16328972|NCT04476836|Experimental|AAT group|Animal-assisted therapy will be provided one 1-hour session per week for 48 weeks.
16328973|NCT04476836|No Intervention|control group|routine care
16328974|NCT04476810|Experimental|combined (phaco-kdb)|Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Consecutive patients with medically-treated glaucoma and visually-significant cataract underwent combined surgery. Subgroup analysis of glaucoma subtypes was performed.
16328975|NCT04476797|Experimental|Arm A Active GC4711|
16328976|NCT04476797|Placebo Comparator|Arm B Placebo|
16328979|NCT04476771|No Intervention|TAU + waiting list|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
16328980|NCT04476771|Experimental|TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
16328981|NCT04476758||Fungal Infection Group|Have had a fungal species isolated from sputum and/or BAL culture on >= 2 separate occasions in the 18 months preceding study visit and do not have a diagnosis of ABPA (N=10).
16328982|NCT04476758||Control Group|Have never previously isolated fungus from sputum, BAL, or OP swab (N=10).
16328983|NCT04476758||ABPA Group|"Previous diagnosis of ABPA as defined by CFF guidelines, regardless of the amount of fungal infection or history thereof.
~• ABPA Minimum diagnostic criteria per CFF: Acute or subacute deterioration, total serum IgE > 500 IU per mL, immediate cutaneous reactivity to Aspergillus or in vitro IgE antibody to A. fumigatus, and either a new or recent chest imaging change that has not responded to antibiotics and standard physiotherapy OR precipitin to A. fumigatus or IgG antibody to A. fumigatus1 (N=5). Culture positive sputum is not required for ABPA diagnosis and is not taken into account for the diagnosis per CFF guidelines."
16328984|NCT04476745|Experimental|Experimental: VD3 group|Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
16328985|NCT04476745|No Intervention|Control group|Control group No intervention was given
16328986|NCT04476732|Experimental|Paraben-free then Paraben-containing|Paraben free facial lotion is applied twice a day for 1 week and measurements are taken. Then, paraben-containing facial lotion is applied twice a day for 1 week and measurements are taken.
16328987|NCT04476719|Experimental|Atafenovir 200 mg Kapsül|Capsules containing 207.009 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride (Atabay-Turkey).
16328988|NCT04476719|Active Comparator|Arbidol 100 mg Kapsül|Capsules containing 103.504 umifenovir hydrochloride monohydrate equivalent to 100 mg umifenovir hydrochloride (OTC-Pharma Russia).
16328989|NCT04476693|Experimental|Breakfast Consumption (BC)|"The consumption of a standardised breakfast followed by a standardised lunch 3-h after the last mouthful of breakfast meal. All the ingredients of the breakfast and lunch provided will be weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period will be provided to avoid carry-over effects between conditions.
~The standardised lunch will consist of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
16328990|NCT04476693|Experimental|Breakfast omission (BO)|"Participant will consume water, the individual volume of which was calculated based on the liquid content of the breakfast. A standardised lunch will be consumed 3-h after the last mouthful of water. All the ingredients of the breakfast and lunch provided were weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period was provided to avoid carry-over effects between conditions.
~The standardised lunch consists of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
16328991|NCT04476680|Active Comparator|Military recruits|Vitamin D supplementation (1000 IU/day D3 for 4 weeks, and 400 IU/d D3 as a maintenance dose)
16328992|NCT04476680|No Intervention|No intervention|
16328993|NCT04476667|Experimental|e-Psychotherapy|Participants will receive a 9-week program with CBT, mindfulness, and problem-based therapy, in addition to TAU. The content will be customized to reflect challenges faced through the COVID-19 pandemic and developed into interactive and engaging modules. All sessions and interactions will occur through Online Psychotherapy Tool (OPTT), a secure online platform. Participants will be assigned to a team of psychiatrists and social workers (SWs). The SW working with each patient will assign a pre-designed therapy module to that patient on a specific day of the week through OPTT. Participants will then be able to access the therapy content at any time throughout the week. Each module will highlight a different topic and include general information, an overview of skills, and homework that is to be completed by a specific day that week. This homework will be directly submitted through OPTT to the clinician who will provide personalized feedback to the patient.
16328994|NCT04476667|No Intervention|Treatment as Usual|The control group will receive treatment as usual during the first 9 weeks; if they still present significant symptoms (less than 50% response to treatment from baseline), they will be offered the e-psychotherapy program.
16328995|NCT04476654|No Intervention|Fact Sheet Arm|Komen print materials about genetic counseling and testing will be given to women.
16328996|NCT04476654|Active Comparator|YouTube Video Arm|Participants in this arm will receive the culturally tailored video either via a Youtube link or a DVD.
16328997|NCT04476641|Experimental|DC-CIK|
16328998|NCT04476628|Other|Budesonide 5MR then 1MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.
~st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~nd time period: 5MR administration method once daily for 8 weeks in duration.
~rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~th time period: 1MR administration method once daily for 8 weeks in duration."
16328999|NCT04476628|Other|Budesonide 1MR then 5MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.
~st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~nd time period: 1MR administration method once daily for 8 weeks in duration.
~rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~th time period: 5MR administration method once daily for 8 weeks in duration."
16329000|NCT04476615|Experimental|FMD|Fasting-Mimicking diet (ProLon®)
16329001|NCT04476615|Placebo Comparator|Placebo|Low-energy bars (L-Nutra®) supplementation
16329002|NCT04476602||COVID-19 (SARS-CoV-2) patients|adults 18 or older, ambulatory , with COVID-19 (SARS-CoV-2)
16329003|NCT04476589||COVID-19 Disorders of Consciousness|Patients with COVID-19 and disorders of consciousness
16329004|NCT04476576|Experimental|Aerobic|3 months program, 3 times/week aerobic ambulatory program.
16329005|NCT04476576|Active Comparator|Flexibility|3 months program, 3 times/week flexibility ambulatory program
16329006|NCT04476563||ChILI|Patients who are already on CPI therapy and have developed liver injury
16329007|NCT04476563||Control|Patients with cancer who are starting on checkpoint inhibitors
16329008|NCT04476537|Experimental|Intervention Arm|Individuals who meet the eligibility criteria based on their provided tissue sample will be followed by the investigators to obtain medical information every 4 weeks. This follow-up will consist of a review of medical records, contact with the participant's treating physician, or personal contact between the participant and the investigators at Columbia University Irving Medical Center (CUIMC). During the study, their tumor tissue will be evaluated to identify medications that may help treat the cancer. The results of these tests will be reviewed by experts on a Precision Medicine Tumor Board (PMTB) and these experts may recommend a specific treatment to the participant or participant's physician.These participants will continue to be followed until death or withdrawal of consent from the study.
16329009|NCT04476537|No Intervention|Observation Arm|Individuals who do not meet the eligibility criteria based on their provided tissue sample will be provided follow-up with their treating physicians up to every 4 weeks to gather clinical information related to their disease.
16329010|NCT04476524||Study Arm|Patients who present with AF as the primary diagnosis to the ER will have their chart reviewed
16329011|NCT04476524||Historical Cohort|Historical control arm will be selected from chart review of emergency department prior to the commencement of this study after propensity matching with age and sex.
16329012|NCT04476511|Active Comparator|Slower Loading Dose|30.000IU cholecalciferol once weekly for ten weeks
16329013|NCT04476511|Active Comparator|Moderate Loading Dose|30.000IU cholecalciferol twice weekly for five weeks
16329014|NCT04476498|No Intervention|Standard pull-PEG|"Standard pull-PEG
~In this group the participants receive a conventional pull-PEG as firstly described by Ponsky and Gauderer."
16329015|NCT04476498|Active Comparator|Pull-PEG with gastropexy|"Pull-PEG with gastropexy
~In this group the participants firstly receive a gastropexy with the Funada style gastropexy device. Afterwards a conventional pull-PEG will be inserted."
16329016|NCT04476485||experimental group|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy.
16329017|NCT04476472|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
16329018|NCT04476459|Experimental|camrelizumab in combination with apatinib|Apatinib should be given at a fixed time. On the day of camrelizumab infusion, Apatinib should be taken 30 minutes after the end of camrelizumab infusion
16329020|NCT04476433|No Intervention|Control Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
16329021|NCT04476433|Experimental|Experimental Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.
16329022|NCT04476420|Active Comparator|Steroid group|Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
16329023|NCT04476420|Experimental|Nigella Sativa oil group|Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
16329024|NCT04476407|Experimental|G1|subjects with nomal renal function
16329025|NCT04476407|Experimental|G2|subjects with mild renal impairment
16329026|NCT04476407|Experimental|G3|subjects with moderate renal impairment
16329027|NCT04476394|Experimental|1|Administered orally once
16329028|NCT04476381|Experimental|Dry needling of a trigger point in the infraspinatus muscle|Insertion a a acupuncture type needle into a trigger point in the infraspinatus muscle on the painful side to decrease the stiffness and tone and increase the elasticity
16329029|NCT04476368|Experimental|yoga|Participants in yoga group will be recruited during prenatal yoga classes at two locations: Maribor and Ljubljana. Women will be instructed to attend one class per week. Classes will consist of pregnancy-adapted yoga practices according to the system Yoga in Daily Life. They will be 90 min in duration and will consist of initial relaxation (10 to 15 min), followed by yoga postures (asanas) and stretching exercises (45 to 60 min), and final breathing (pranayama), concentration (dharana), and meditation (dhyana) techniques (20 to 30 min). Two certified yoga instructors will lead yoga classes. Measurements will be performed before and after yoga session.
16329030|NCT04476368|Active Comparator|control|Control group will consist of healthy pregnant women attending regular prenatal visits at the departments of perinatology of the university medical centers Maribor and Ljubljana. Only women not attending any formal prenatal exercise program will be offered entrance in the study. Measurements in this group will be performed before and after a 20-30 minute walk.
16329031|NCT04476355|No Intervention|control group|In the same ICU, the former(2019-12~2020-12) patients were the control group, data collected through case system.
16329032|NCT04476355|Experimental|experimental group|In the same ICU, the patients in the study period were the experimental group
16329033|NCT04476342|Experimental|MICPB group|The experimental group is minimal invasive cardiopulmonary bypass (MICPB) group, with built-in micro-thrombotic oxygenator and mini cardioplegia (MP) formula (15ML15% KCl+10ml compound potassium, calcium and magnesium +25ml normal saline).
16329034|NCT04476342|No Intervention|CCPB group|The control group was conventional cardiopulmonary bypass (CCPB) group, using ordinary oxygenator, microemboli filter, and 4:1 cardioplegia solution.
16329035|NCT04476329|Active Comparator|A|"Arm A: Regorafenib Cycle 1:
~80 mg daily Week 1
~120 mg daily Week 2
~160 mg daily week 3 then 1 week off followed by Cycle 2+ (160 mg for 21 days/1 week off) Subsequent Treatment Cycles
~160 mg daily for 21 days, then 1 week off."
16329036|NCT04476329|Active Comparator|B|"Arm B: Regorafenib Cycle 1:
~160 mg daily for 21 days/then 1 week off Subsequent Treatment Cycles
~160 mg daily for 21 days, then 1 week off"
16329037|NCT04476303|Experimental|SAD (#6 Cohort)|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo once.
16329038|NCT04476303|Experimental|SAD (#1 Cohort) - Food effect evaluation|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo for two periods at 7 days interval, with both fasting and after high fat meal.
16329039|NCT04476303|Experimental|MAD (#4 Cohort)|Drug: BEY2153 or placebo subjects will receive multiple ascending dose of BEY2153 or placebo for 7 days.
16329040|NCT04476277|Experimental|1|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
16329041|NCT04476264||transscleral IOL fixation|the use of a novel adjustable single 8-0 polypropylene suture for scleral fixation without conjunctival dissection
16329042|NCT04476251|Experimental|Arm 1|E7 TCR T Cell Therapy
16329043|NCT04476238|Experimental|Inosine|2 grams of inosine dissolved in 250 ml of tap water
16329044|NCT04476238|Placebo Comparator|Water|250 ml of tap water only
16329045|NCT04476225||Individuals with Hirschsprung Disease|Individuals with Hirschsprung disease
16329046|NCT04476225||Unaffected Relatives|Unaffected relatives of individuals with Hirschsprung disease
16329047|NCT04476212|Experimental|Intervention|In the experimental arm, the surgical wound will be irrigated using an antibiotic solution (amoxicillin-clavulanate) for topical prophylaxis
16329048|NCT04476212|No Intervention|Control|In the control arm, the surgical wound will be irrigated with saline, which is our routine at present.
16329049|NCT04476199|Experimental|Treatment with VEN-DEC|Venetoclax will be given with a 3-day ramp up beginning with 100 mg dose on Day 1, with 200mg on Day 2, to reach the final dose of 400 mg on Day 3 of Cycle 1. Venetoclax will be continued at 400 mg daily. Tumor lysis prophylaxis will be administered from day -4, cycle 1 (oral uric acid reducing agent and hydration with at least 1.5 L/day).Decitabine will be administered at the dose of 20 mg/sqm intravenously from day 1 to day 5 every 28 days (VEN-DEC) for 2 cycles.
16329050|NCT04476186|Active Comparator|treatment group|200 mg of oral acyclovir 5 timed per day for 5 days per week for maximum 1 month
16329051|NCT04476186|Placebo Comparator|controlled group|KOH 10 % solution local application with apiece of cotton 2 time per day maximum for 1 month
16329052|NCT04476173|Experimental|Methoxyflurane|Patients treated with inhaled methoxyflurane (3 mg)
16329053|NCT04476173|Active Comparator|Morphine|Patients treated with intravenous morphine (5 mg)
16329054|NCT04476160|Experimental|Cinnamon|In this group, children will receive an intervention with 3000mg / day cinnamon along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
16329055|NCT04476160|No Intervention|Control|In this group, children will receive a placebo intervention along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
16329056|NCT04476147||Participates|This is an observational study
16329057|NCT04476134||patients with adverse events|patients underwent adverse events after cardiac surgery
16329058|NCT04476121|Experimental|PRF application|Patients with alveolar osteitis in which PRF application was performed.
16329059|NCT04476121|Active Comparator|Aspirin application|Patients with alveolar osteitis in which Nipas was used.
16329060|NCT04476108|Experimental|LY3016859|LY3016859 administered intravenously (IV).
16329061|NCT04476108|Placebo Comparator|Placebo|Placebo administered IV.
16329062|NCT04476095|Experimental|Active PBMT|Active PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
16329063|NCT04476095|Placebo Comparator|Placebo PBMT|Placebo PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
16329064|NCT04476082||Initial Diagnosis|Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.
16329065|NCT04476082||Ongoing Cytostatic Treatment|Patients with a malignant condition of the gastrointestinal tract already receiving cytostatic treatment.
16329066|NCT04476069|Experimental|Ibuprofen|30 minutes before extraction, once/day orally
16329067|NCT04476069|Placebo Comparator|Placebo|30 minutes before extraction, once/day orally
16329068|NCT04476056|Experimental|Chronic Pancreatitis + Malnutrition|Malnourished patients with chronic pancreatitis will receive intensified nutritional therapy for 6 months.
16329073|NCT04476030|Experimental|Experimental: SAGE-217 + Assigned ADT|Participants will receive SAGE-217 capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
16329074|NCT04476030|Active Comparator|Active Comparator: Placebo + Assigned ADT|Participants will receive SAGE-217-matching placebo capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
16329075|NCT04476017|Experimental|Part A: SAGE-718|Participants will receive SAGE-718 tablets, once daily with food in the morning for 14 days.
16329076|NCT04476017|Experimental|Part B: SAGE-718|Participants will receive SAGE-718 tablets, once daily with food in the morning for 28 days.
16329077|NCT04476004|Experimental|experimental group|EMG group
16329078|NCT04476004|Active Comparator|control group|exercise group
16329079|NCT04475991|Active Comparator|Currently used therapy (CT) only|"Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present."
16329080|NCT04475991|Experimental|Maraviroc+CT|"Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
16329081|NCT04475991|Experimental|Favipiravir+CT|"Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
16329082|NCT04475991|Experimental|Maraviroc+Favipiravir+CT|"Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients"
16329083|NCT04475978|Experimental|IVUS group|
16329084|NCT04475978|Placebo Comparator|Angio group|
16329085|NCT04475965|Experimental|Group 1 20% maximal voluntary isometric contraction|Patients in group 1 received a five-series Isometric Contraction of shoulder external rotators at 20% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
16329086|NCT04475965|Active Comparator|Group 2 80% maximal voluntary isometric contraction|Patients in group 2 received a five-series Isometric Contraction of shoulder external rotators at 80% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
16329087|NCT04475952||Oropharyngeal squamous cell carcinoma|
16329088|NCT04475952||Oesophageal squamous cell carcinoma|
16329089|NCT04475952||Control|
16329090|NCT04475939|Experimental|Participants receiving niraparib plus pembrolizumab|Eligible participants will receive niraparib along with pembrolizumab.
16329091|NCT04475939|Placebo Comparator|Participants receiving placebo plus pembrolizumab|Eligible participants will receive matching placebo along with pembrolizumab.
16329092|NCT04475926||LGMD2E/R4 Cohort|Patients with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
16329093|NCT04475926||LGMD2D/R3 Cohort|Patients with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
16329094|NCT04475926||LGMD2C/R5 Cohort|Patients with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
16329095|NCT04475913|Active Comparator|(CIG Axial)|received 4 axial implants and conventional impression
16329096|NCT04475913|Experimental|(DIG Axial)|received 4 axial implants and digital impression
16329097|NCT04475913|Active Comparator|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
16329098|NCT04475913|Experimental|(DIG Tilted)|received two anterior axial implants and two distal tilted implants, and digital impression
16329099|NCT04475900||Healthy|Healthy eyes without any signs of ocular diseases
16329100|NCT04475900||Ectasia|ectasia suspects early, moderate and advanced keratoconus
16329101|NCT04475900||Glaucoma|Normal Tension glaucoma Primary Open-Angle Glaucoma
16329102|NCT04475887|Active Comparator|Group A|IV administration of iron-III-carboxymaltose according to iron deficit every 4 weeks.
16329103|NCT04475887|Placebo Comparator|Group B|IV administration of 1000ml 0.9% NaCl every 4 weeks.
16329104|NCT04475874|Active Comparator|supervised stretching exercises :group A|The intervention group A practiced a 30 to 45-minute supervised active stretching program three times a week for four weeks
16329105|NCT04475874|Active Comparator|non-supervised active stretching home program: group B|practiced non-supervised active stretching home program
16329106|NCT04475874|No Intervention|Standard of care: group c|control group
16329107|NCT04475861|Experimental|L-arginine supplements|The enrolled subjects will then be randomized into two groups. Study Group: will take a supplementation pill containing 5 g L-arginine (0.5g/ pill, GNC, USA) All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
16329108|NCT04475861|No Intervention|nutritional supports|"The enrolled subjects will then be randomized into two groups. Control group: will take a supplementation pill containing 5 g whey protein (5g/ pack, Santosa,Taiwan).
~All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians."
16329109|NCT04475848|Experimental|Part 1: SAD/FE|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of RO6953958 while fasted. Participants in the fed (FE) cohort will return to receive the same single oral dose of RO6953958 repeated in the fed state.
16329110|NCT04475848|Placebo Comparator|Part 1: SAD placebo|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of a placebo while fasted/fed.
16329111|NCT04475848|Experimental|Part 2: MAD|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 once daily (QD) for 10 days.
16329112|NCT04475848|Placebo Comparator|Part 2: MAD placebo|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 QD for 10 days.
16329113|NCT04475835|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during PCI
16329114|NCT04475835|Active Comparator|Heparin|Heparin 100U/kg
16329115|NCT04475822|Experimental|Intermittent fasting|During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
16329321|NCT04474262|Active Comparator|Albumin with placebo|Group A will be given albumin 8g/l of ascitic tap along with placebo for 7 days. Standard albumin therapy will continue (40gm/week)
16329116|NCT04475822|Experimental|Low carb diet|According to the definition of low carbon diet given by R. D. Feinman et al. (Nutrition, 2015), the daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
16329117|NCT04475822|Experimental|Low carbon diet and intermittent fasting group|Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
16329118|NCT04475809|Placebo Comparator|Group C|high intra-abdominal pressure
16329119|NCT04475809|Active Comparator|Group L|low intra-abdominal pressure
16329120|NCT04475809|Active Comparator|Group LR|low intra-abdominal pressure with pulmonary recruitment maneuver group
16329121|NCT04475809|Active Comparator|Group LS|low intra-abdominal pressure with intraperitoneal saline infusion group
16329122|NCT04475796|Active Comparator|Early group|
16329123|NCT04475796|Active Comparator|Delayed group|
16329124|NCT04475783|Experimental|Sirolomus DCB group|Intervention with Sirolimus-coated balloon catheter
16329125|NCT04475783|Active Comparator|Paclitaxel DCB group|Intervention with Paclitaxel-coated balloon catheter
16329126|NCT04475770|Experimental|Real SNAGs|Real SNAGs group consists of 16 participants, where the Mulligan concept lumbal SNAGs is applied and evaluations are made before and after.
16329127|NCT04475770|Sham Comparator|Sham SNAGs|The Sham SNAGs group consists of 16 participants who performed the same positioning as the Real SNAGs group and evaluated twice with a similar interval without any intervention to the spine.
16329128|NCT04475744|No Intervention|Control arm|POI women radomized to control arm will undergo a 3-month follow up for: AFC, AMH, FSH and E2 determinations.COS will be initiated if growing antral follicles detected. In the second phase, POI women allocated to control group after completed the follow up period will undergo the 4-step ASCOT technique, as described in the previous phase but only one ovary will be injected, then they will undergo a 6-month follow up period as described above.
16329129|NCT04475744|Experimental|4-step ASCOT arm|POI women randomized to the 4-step ASCOT technique will receive a direct ovarian injection of G-CSF mobilized and activated PRP. For each patient, both ovaries will be directly injected with the G-CFS activated PRP (4-step ASCOT). Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 6 months and COS initiated if growing antral follicles detected.
16329130|NCT04475731|Experimental|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).
~Patients will receive the study drug until disease relapse or progression."
16329131|NCT04475718|Other|Fourth Trimester Mobile Tool|Fourth Trimester Mobile Tool
16329132|NCT04475705|Active Comparator|Sevoflurane group|patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
16329133|NCT04475705|Active Comparator|propofol group|patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
16329134|NCT04475692|Experimental|Intervention|"Conventional care will continue.
~Participants (and proxy, where relevant) will be trained to use the intervention platform (GripAble). Participants will be loaned a GripAble device and advised to continue a self-selected training dose throughout the intervention period.
~Weekly follow-up phone calls will be conducted, remote tech support will be available. Adherence with the intervention will be remotely monitored via an inbuilt data capture system.
~At 3months post stroke, the intervention period will conclude, outcome measures will be implemented. Participants will be invited to complete a post intervention survey and interview. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.
~At 6months post stroke, follow-up outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
16329135|NCT04475692|Active Comparator|Control|"Baseline data collection and outcome measures will be completed.
~Conventional care will continue, no restrictions/specifications will be placed on this.
~At 3months post stroke, UL outcome measures will be implemented. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.
~At 6months post stroke, follow-up UL outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
16329136|NCT04475679|Experimental|Adhese Universal DC|
16329137|NCT04475679|Active Comparator|Adhese Universal|
16329138|NCT04475666|Active Comparator|Replenish protein group|The subjects randomized to this group will receive the standard amount of proteins (maximum 1.2 g/kg/day) from the primary polymeric formula AND supplemental protein at 1.2 g/kg/day
16329139|NCT04475666|Active Comparator|Standard protein group|The subjects randomized to this group will receive standard prescription without supplemental proteins (maximum1.2 g/kg/day) from the primary polymeric formula. No supplemental protein will be allowed
16329140|NCT04475653|Active Comparator|Group coaching|Performing physical activities with Activity tracker, coaching included
16329141|NCT04475653|Active Comparator|Group Independant|Performing physical activities with Activity tracker, coaching NOT included
16329142|NCT04475653|Other|Controls|Controls from former study (see Study description)
16329143|NCT04475640||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood or saliva sample for genetic testing.
16329144|NCT04475627||Participants randomised to 1.5T then 3T|Participants randomized to be scanned at 1.5T first followed by 3T
16329145|NCT04475627||Participants randomised to 3T then 1.5T|Participants randomized to be scanned at 3T first followed by 1.5T
16329146|NCT04475614|No Intervention|informative|The patients in this group received only verbal and written information about their condition.
16329147|NCT04475614|Experimental|oral probiotics|The patients in this group, beside verbal and written information about their condition, received also oral probiotics. They were instructed to melt one lozenge in the mouth in the evening, after tooth brushing and flossing, for one month.
16329148|NCT04475614|Experimental|low level laser treatment|The patients in this group, beside verbal and written information about their condition, received a total of ten low level laser treatments, for ten days consecutively excluding weekends.
16329149|NCT04475614|Experimental|B-vitamin injections|The patients in this group, beside verbal and written information about their condition, received a total of nine B vitamin injections, every other day, intra muscular.
16329150|NCT04475601|Experimental|Enzalutamide+Standard of Care|Up to 5 days with 4x40 mg enzalutamide tablets orally once daily
16329151|NCT04475601|No Intervention|Standard of Care|Standard of care
16329152|NCT04475588|Experimental|Arm A - Itolizumab + BSC|
16329153|NCT04475588|Active Comparator|Arm B - Best supportive care (BSC)|
16329154|NCT04475575|Other|COVID-19 suspected|Participants where included if an oropharyngeal and nasopharyngeal swab was collected for RT-PCR and serology testing had been performed, or if participants have had a confirmed COVID-19 diagnosis in the previous days or weeks with an indication for re-testing via PCR and serology testing at the moment of inclusion
16329155|NCT04475562|Other|COVID-19 suspected|Participants were recruited at the outpatient clinic for MUMC+ employees with COVID-19 symptoms or at the nursing unit where a SARS-CoV-2 patient was admitted.
16329156|NCT04475549|Experimental|IW-6463|
16329158|NCT04475523|Experimental|CI-8993 dose escalation|Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours at planned step-doses and subsequent full doses. The planned schedule of administration is every 2 weeks. The MTD of full doses of CI-8993 will be determined based on the occurrence of DLTs 28 days from the first full dose. Eligible patients may receive CI-8993 at the dose and schedule, according to their assigned cohorts, until disease progression or unacceptable toxicity.
16329159|NCT04475510|Experimental|Antiplatelet treatment discontinuation|At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
16329160|NCT04475497|Experimental|Blood mangement group|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels <11.0. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
16329161|NCT04475497|Active Comparator|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
16329162|NCT04475484||School-age children|School-age children from primary school to high school (about age 6 to 18) in the Academy of Lyon
16329163|NCT04475458||LANDMARK|The children who underwent circumcision received general anesthesia plus dorsal penis nerve block performed by the surgeon with a landmark technique.
16329164|NCT04475458||ULTRASOUND|The children who underwent circumcision received sedation (in spontaneous breathing) plus ultrasound-guided dorsal penis nerve block.
16329165|NCT04475445|Experimental|Ultrasound guided transforaminal epidural steroid injection|
16329166|NCT04475445|Experimental|Interlaminar epidural steroid injection|
16329169|NCT04475419|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe)
16329170|NCT04475419|Active Comparator|preformed metal crowns|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
16329171|NCT04475406|Sham Comparator|Control group|Standard implant, intra-bone length ≥8 mm (30 implants)
16329172|NCT04475406|Active Comparator|Test group|Extra Short implant, intra-bone length ≤6 mm (30 implants)
16329173|NCT04475393|Experimental|Carmat TAH|Subjects implanted with Carmat TAH
16329174|NCT04475380||All-comer patients requiring PCI|All-comer patients requiring percutaneous coronary intervention (PCI) for the treatment of significant coronary artery of bypass graft lesions that are suitable for treatment with Xience Sierra DES
16329175|NCT04475367|Experimental|hypertensive patients using HyperCrossApp|"Interdisciplinary health care
~+ HyperCross App"
16329176|NCT04475367|Active Comparator|hypertensive patients without using HyperCrossApp|Interdisciplinary health care
16329177|NCT04475354||Cervical cancer patients and their partners|520 cervical cancer patients will complete questionnaires, online food diary and wear a fitbit after diagnosis, after 6 months, and after 1, 2, 5 and 10 years. In addition, a subsample (n=116) will donate blood samples and a scalp hair sample after diagnosis and 6, 12 and 24 months. We expect 312 partners of cervical cancer patients to included in the study and complete questionnaires after diagnosis, after 6 months, and after 1, 2, 5 and 10 years
16329178|NCT04475341|Active Comparator|BMS without BMAC|
16329179|NCT04475341|Experimental|BMS with BMAC|
16329180|NCT04475328|Experimental|AngongNiuhuang|Drugs : AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
16329181|NCT04475328|Placebo Comparator|Placebo of AngongNiuhuang|Drugs : Placebo of AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
16329182|NCT04475315|Experimental|Papillary Muscle Sling Group|Participants in the papillary muscle sling group will receive the sling technique performed in conjunction with their standard of care (SOC) Coronary Artery Bypass Grafting (CABG) surgery.
16329183|NCT04475315|Active Comparator|Controls Group|Participants in the control group will receive their SOC CABG surgery only, without any additional intervention.
16329184|NCT04475302|Experimental|Intervention arm|In the identified hotspots, BCG vaccine will be offered to all the elderly between 60 - 80 years of age. Those who get vaccinated will be followed for a period of 6-months.
16329185|NCT04475302|No Intervention|Control arm|"in the hotspots, those who do not agree for vaccination, will be considered as controls. They will have an entry and exit interview at baseline and end of study period
~in situations where we are unable to enrol the required number of controls from the vaccination hotspot zones, then hotspots in the neighbouring area / wards where BCG is not offered will be taken as control sites. Elderly between 60-80 years in those areas would be considered as control sites for the study. The elderly participants will be approached for an entry and exit interview, if they agree. If they do not agree for an exit interview at the end of 6-months, then the status of those in the control group would be collected either from the corporation records / other medical database."
16329186|NCT04475289||Patients with an coronary artery anomaly (focus on ACAOS)|Patients eligible for study participation have a CAA and a prior, clinically indicated testing (noninvasive and/or invasive measurement) at our institution to evaluate the hemodynamic significance of this coronary anomaly. They will be approach either after start of this study (retrospective inclusion) or before their testing (prospective inclusion).
16329187|NCT04475276|Placebo Comparator|Placebo|Life style modification with the placebo will be given for 12 weeks
16329188|NCT04475276|Experimental|Alphalipoic acid|Life style modification with Alpha lipoic acid in a dose of 600mg twice daily will be prescribed orally for 12 weeks
16329189|NCT04475263||Carbon monoxide exposure|Confirmed exposure to carbon monoxide
16329190|NCT04475250|Experimental|Tetragraph|
16329191|NCT04475237||Healthy mandibles|Belgian adults (between 20 and 60 years old), 50/50 male/female, with no major mandibular problems/deformities
16329192|NCT04475224|Other|Open-label|
16329193|NCT04475198|Experimental|Single Ascending Dose: Cohort 1|5 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
16329194|NCT04475198|Experimental|Single Ascending Dose: Cohort 2|10 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
16329195|NCT04475198|Experimental|Single Ascending Dose: Cohort 3|15 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
16329196|NCT04475198|Experimental|Single Ascending Dose: Cohort 4|22 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
16329197|NCT04475198|Experimental|Single Ascending Dose: Cohort 5|33 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
16329198|NCT04475185|Experimental|MakAir|
16329199|NCT04475172|Experimental|Fusio™ Flowable Self-Adhesive Flowable Composite|"2-Cavity preparation steps:
~patients will be given local anesthesia as required,the operative field will be isolated with rubber dam before starting.
~Conventional design Class V cavity will be prepared on the buccal surface of tooth by No. #330 bur (0.8 mm in diameter and 1.6 mm in length) , tooth surfaces will be kept moist to protect them against dehydration.
~2% chlorhexidine gluconate disinfecting solution .
~wash the dentin surface with water spray and air dry with maximum air pressure for 5 s.
~A) Intervention: Fusio™ Flowable (Self adhesive flowable composite):
~Simply syringe into the preparation 1 mm increments, agitate with tip or brush for 20 s, and light-cure.No need for an etchant or an adhesive."
16329200|NCT04475172|Active Comparator|Conventional flowable composite [Tetric Evo Flow (FF)].|"Tetric Evo Flow (Conventional flowable composite):
~After cleaning cavities, apply conditioning material (phosphoric acid etching 37% ) and apply bonding agent (ExciTE® F) according to the instructions for use of the product.
~Apply Tetric EvoFlow in layers of 1mm. Polymerize each layer separately following the instructions for use of this product. . Hold the light emission window as closely as possible to the surface of the restorative material.
~All 20 Class V restorations will be prepared, restored, finished, and polished by one operator. Each of the 10 patients had one (FL) restoration and the other restoration will be filled with (FF)."
16329201|NCT04475159|Experimental|PIPAC arm|Together with neoadjuvant systemic therpay PIPAC will be performed twice and regional chemotherpay will be administered before planned CRS/HIPEC
16329202|NCT04475146||Standard information and video visualization|Standard information and video visualization
16329203|NCT04475146||Standard information, no video|Standard information, no video
16329204|NCT04475133|Experimental|Low-frequency and high-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.
~The parameters are continuous stimulation of low frequency (2 hz) and high intensity (slightly painful) during 16 minutes."
16329205|NCT04475133|Experimental|High-frequency and low-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.
~The parameters are high frequency (100 hz) and low intensity trains. There are 5 trains, 5 second active current and 55 second without current per train.
~The current is off on the first 11 minutes and the next 5 minutes it will be on. The total time is 16 minutes."
16329206|NCT04475133|Sham Comparator|Control group|The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve without current during 16 minutes.
16329207|NCT04475120|Experimental|Liposomal Lacroferrin|Thirty-two patients (14 hospitalised and 18 in home-based isolation) belonging to the first group received oral and intranasal liposomal bLf. BLf capsules for oral use containing 100 mg of bLf encapsulated in liposome while bLf nasal spray had about 8 mg/ml of bLf encapsulated in liposome. BLf, contained in both products, was tested by SDS-PAGE and silver nitrate staining and its purity was about 95%. The bLf iron saturation was about 5% as detected via optical spectroscopy at 468 nm based on an extinction coefficient of 0.54 (100% iron saturation, 1% solution). The scheduled dose treatment of liposomal bLf for oral use was 1gr per day for 30 days (10 capsules per day) in addition to the same formulation intranasally administered 3 times daily (a total of about 16 mg/nostril)
16329208|NCT04475120|Active Comparator|SOC therapy|Thirty-two hospitalized patients belonging to the second group were only treated with SOC regimen according to the national guidelines at the time of the enrollment: lopinavir/ritonavir cps 200/50 mg, 2x2/day (alternatively darunavir 800 mg 1 cp/day+ritonavir 100 mg 1 cp/day or darunavir/cobicistat 800/150 mg 1 cp/day), chloroquine 500 mg, 1x2/day or hydroxychloroquine cp 200 mg, 1x2/day. SOC regimen lasted from 5 to 20 days, with timing to be established according to clinical course.
16329209|NCT04475120|No Intervention|Home-based isolation|Twenty-eight patients, in home-based isolation, belonging to the third group did not receive any therapy.
16329210|NCT04475120|No Intervention|Healthy volunteers|A control group, comprising 32 healthy volunteers, did not receive any treatment or placebo.
16329211|NCT04475107|Experimental|Arm A|Pyramax (Pyronaridine 180mg/ Artesunate 60mg)
16329212|NCT04475107|Placebo Comparator|Arm B|Placebo
16329213|NCT04475094||COHORT|All patients will have had a clinically-indicated PET revealing at least one reversible perfusion defect followed by a research-indicated cardiac PET study between 3 and 8 weeks post-successful coronary artery stenting.
16329214|NCT04475081|Experimental|MMR vaccination|Subjects will be randomized to receive the MMR Vaccine subcutaneously
16329215|NCT04475081|Placebo Comparator|Placebo control|Subjects will be randomized to receive sterile saline given subcutaneously
16329216|NCT04475068||Moderate to severe ARDS patients due to COVID-19 infection|Mechanically ventilated patients with moderate to severe ARDS due to COVID-19 infection admitted to the COVID Intensive Care Unit of Rebagliati Hospital.
16329217|NCT04475055||Community sample|Participants will take part in the DIPS-interview and in an online survey.
16329218|NCT04475042|Active Comparator|Group A|Dapagliflozin - washout period - placebo
16329219|NCT04475042|Active Comparator|Group B|Placebo - washout period - Dapagliflozin
16329220|NCT04475029|Experimental|Methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
16329221|NCT04475029|Active Comparator|Morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
16329222|NCT04475016|Experimental|Neoadjuvant Therapy|TIP (Paclitaxel + Ifosfamide + Cisplatin) & Nimotuzumab & Triprilimab
16329223|NCT04474964|Experimental|Low Dose Craniospinal Irradiation|WNT subgroup medulloblastoma patients accrued in the study will be treated with Low-dose Craniospinal Irradiation (18Gy/10fx) plus focal conformal tumor-bed boost (36Gy/20fx) for total primary-site dose of 54Gy/30fx over 6-weeks. Followed by adjuvant multi-agent systemic chemotherapy which will be initiated 4-6 weeks after completion of radiotherapy provided the ANC >1500 and platelet count >1,00,000. A total of 6 cycles of alternating chemotherapy every 4-weekly will be planned as per our standard practice using CET protocol.
16329224|NCT04474951|Experimental|Anemia|Metastatic patients with grade 1 anemia and on treatment with anti-CDK 4/6 or PARP Inhibitors (10 patients) or on adjuvant therapy with hormonal therapy (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; hemoglobin levels will be assessed every 4 weeks for a maximum period of 6 months.
16329225|NCT04474951|Experimental|Fatigue|Patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing fatigue not associated to anemia or with anemia grade 1 (10 patients) or associated to anemia grade 2 (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; the assessment of fatigue will be performed at every chemotherapy cycle, for a maximum period of 6 months.
16329226|NCT04474951|Experimental|Nausea|20 patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing nausea of any grade (without vomiting) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Peppermint Fluid Extract, associated to antiemetic therapy prescribed as per clinical practice; the assessment of nausea will be performed at every chemotherapy cycle, for a maximum period of 6 months.
16329227|NCT04474938|Experimental|Dara-BD|Daratumumab combined with bortezomib and dexamethasone
16329228|NCT04474925|Active Comparator|Surgical Resection followed by SRS (Non-Experimental)|Surgical Resection followed by SRS within 3 weeks of surgery date.
16329229|NCT04474925|Experimental|SRS followed by Surgical Resection (Experimental)|SRS followed by surgery within 1 week of radiotherapy end date.
16329230|NCT04474912||Control group|Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis
16329231|NCT04474912||Rheumatoid arthritis group|Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
16329232|NCT04474912||Osteoarthritis group|Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands
16329233|NCT04474899|Experimental|Phase 1|Moxonidine 0.4mg/daily
16329234|NCT04474899|Experimental|Phase 2|Amlodipine 5mg
16329237|NCT04474873|No Intervention|Group 1:Conventional intravenous analgesia|Conventional intravenous analgesia applied according to surgeon's preference
16329238|NCT04474873|Active Comparator|Group 2:ESPB|A 6-13 MHz linear probe was used for ultrasound-guided ESPB (Logiq e, General Electric, USA,) performed at the T11 level. The transverse process was detected by sliding the transducer 3-4 cm laterally from the midline, and after identification of the transverse process, a 20-gauge 100mm insulated echogenic needle (Vygon locoplex, France) was used
16329239|NCT04474860||Malignant Hyperthermia|Samples from Chinese whose malignant hyperthermia susceptibility had been confirmed after a positive clinical manifestation of malignant hyperthermia and samples from their blood relations will receive genetic testing.
16329240|NCT04474847|Experimental|Blinded Abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
16329241|NCT04474847|Placebo Comparator|Blinded Placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
16329242|NCT04474834||PRS|Providing polygenic risk score (PRS)
16329243|NCT04474821|Experimental|Prevention (HPV educational program)|Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.
16329244|NCT04474808|Experimental|L-arginine-containing foot cream|The participants apply one foot (randomized assignment) with the L-arginine-containing foot cream twice a day (morning and evening) over a period of six weeks.
16329322|NCT04474262|Experimental|Albumin with Midodrine|GROUP B will be given midodrine 7.5 mg to 10 mg tds (keeping the target MAP above 70 mmhg)for 7 days plus albumin same as in other group.
16329245|NCT04474808|Active Comparator|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the Urea-containing foot cream twice a day (morning and evening) over a period of six weeks.
16329249|NCT04474769|Experimental|Educational intervention|Intervention group's preceptors is given an eight-hour education entity about orientation and preceptorship. The objective is to enhance preceptors' knowledge and skills about the orientation and to give preceptors means to precept new graduate nurses better.
16329250|NCT04474769|No Intervention|No intervention|Nursing units at the control group continue to precept as before.
16329251|NCT04474756|Experimental|Mandibular Advancement Devices Narval™|The tested device Narval™ will be a custom-made adjustable bi-block mandibular advancement device, that is made with semi-rigid plastic materials (bio-compatible polymer) and customized using a high-precision computer-aided design (CAD)/computer-aided manufacturing (CAM) ) (ResMed, Narval CC™). The Mandibular Advancement Devices will be gradually adjusted to provide mandibular advancement over a 15-mm range. Each Mandibular Advancement Device will be ﬁtted by a dental specialist with an initial advancement of about 60 % of maximal jaw protrusion. During titration, mandibular advancement will be adjusted at the discretion of the dental specialist.
16329252|NCT04474756|Active Comparator|Mandibular Advancement Devices TALI ™|"The control device TALI ™ is a mandibular advancement orthesis, customized and manufactured by the laboratoire TALI, of the bi-bloc type consisting of rigid gutters thermo-formed on the plaster dental arches and articulated by two links of variable size allowing to adjust the advance in steps of 1 millimeter. This orthesis is manufactured on molding from bio-compatible plastic materials. The different sizes of rods proposed allow mandibular advances of 4 mm to 16 mm. Two clinical studies evaluated the effectiveness of the AMC / AMO orthosis (initial version of the TALI orthesis, with non-curved links) in patients with OSA. They have already demonstrated the effectiveness of the TALI orthesis by decreasing AHI and drowsiness; most patients preferred to use the orthesis (76.4% vs. 9.1%)11."
16329253|NCT04474743||Liver Cirrhosis|Patients diagnosed with liver cirrhosis.
16329254|NCT04474743||Chronic Pancreatitis|Patients diagnosed with chronic pancreatitis.
16329255|NCT04474743||Short Bowel Syndrome|Patients diagnosed with short bowel Syndrome.
16329256|NCT04474743||Control Patients|Otherwise healthy patients visiting hospital with other non-severe diseases.
16329257|NCT04474743||Healthy Controls|Healthy subjects recruited from the general population.
16329258|NCT04474730|Active Comparator|Watch Only|
16329259|NCT04474730|Experimental|Watch+App|
16329260|NCT04474717|Other|The natural history of COPD|Monitoring risk factors, chronic respiratory symptoms and respiratory function in the natural history of chronic obstructive pulmonary disease
16329261|NCT04474717|Experimental|Study of systemic inflammation and molecular mechanisms|Study of systemic inflammation and molecular mechanisms underlying the comorbid course of COPD and atherosclerosis
16329262|NCT04474717|Other|non-coding miRNAs|Investigation of the role of non-coding miRNAs in the epigenetic regulation of signaling pathways involved in the pathogenesis of COPD and atherosclerosis
16329263|NCT04474717|Other|Exhaled breath condensate|A study of the clinical and biochemical COPD phenotype with systemic inflammation and comorbidity
16329264|NCT04474704|Experimental|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
16329265|NCT04474704|Other|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
16329266|NCT04474691|Experimental|Visual-acoustic biofeedback|
16329267|NCT04474691|Active Comparator|Traditional articulation treatment|
16329268|NCT04474678|Other|All Patients|Since this is a single-group study, all patients are within the same arm
16329269|NCT04474665|Other|Implant placement accuracy|Blueprint planning software will be used to plan reverse shoulder replacement surgery. Accuracy of the placement compared to the plan will be assessed post-surgery.
16329270|NCT04474639||with diastolic dysfunction|patients with diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e' >=8, and lateral e'>=10 and left atrium <34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
16329271|NCT04474639||without diastolic dysfunction|patients without diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e'<8, and lateral e'<10 and left atrium >=34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
16329272|NCT04474626|Experimental|ISOQUERCETIN|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits
~- ISOQUERCETIN: Oral Study Drug, 1 time per day, per predetermined dosed per 28 treatment cycle.
~This will continue for up to 337 days."
16329273|NCT04474613|Experimental|Liquid biopsy|A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
16329274|NCT04474600|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
16329275|NCT04474600|Active Comparator|Inhalation group|Patients receiving inhalation anesthesia using desflurane
16329276|NCT04474587||OHS-NIV|Patients with obesity-hypoventilation syndrome (OHS) treated with non-invasive ventilation (NIV).
16329324|NCT04474236||COVID-19 patients|Adult (> 18 years) with Proven COVID-19 (specific PCR from respiratory track sample)
16329277|NCT04474561|Other|Reduced sulfur diet intervention (INT)|"The INT group will receive conventional management plus a reduced sulfur diet and diet counselling by an RD. Implementation of the diet will be delivered directly by the RD and will provide each patient with an individualized plan. A reduced sulfur diet includes reducing foods, additives and beverages high in sulfate/sulfur.
~The reduced sulfur diet eating plan, resources on reduced sulfur eating, and RD counselling session will be designed and reviewed by experts in nutrition, dietary design, education resources and dietary behaviour change"
16329278|NCT04474561|No Intervention|Conventional management (CM)|The CM group will receive one session with RD on reduced sulfur diet at the end of 8 weeks.CM groups will receive conventional management .
16329279|NCT04474548|Experimental|Ultrasound|"For participants randomly assigned to ultrasound use, a bedside ultrasound will be performed using the trans-abdominal probe during and/or immediately after placement of the IUD. The distance from the IUD arms to the fundus will be measured with the ultrasound, and the IUD will be defined as being in place when the distance from the top of the IUD to the fundus is measured to be 3mm or less. If the distance is greater than 4mm, the provider may reposition the IUD manually or with a ring forceps."
16329280|NCT04474548|No Intervention|No ultrasound|For participants randomly assigned to no ultrasound use, provider will insert the IUD with a ring forceps and will use palpation of the fundus to determine whether or not the IUD is likely in place.
16329281|NCT04474522|Active Comparator|intervention group using morphology and NIPGT-A|Both morphology and NIPGT-A result will be used to prioritize the sequence of embryo transfer in the intervention group.
16329282|NCT04474522|No Intervention|control group based on morphology alone|Morphology only will be used to prioritize the sequence of embryo transfer in the intervention arm.
16329283|NCT04474509|Experimental|FACT Module Engagement|During this module, patients will have the opportunity to increase their motivation to change and encourage the engagement in committed actions, consistent with their life values. Patients are invited to reflect on what is important in their lives, which values make their life worth living, and which actions they could take to live a meaningful life, in accordance with personal values. The use of metaphors and experiential exercises will facilitate the process of exploring personal values, identifying life directions and related behaviors. For example, the 80th Birthday Party metaphor requires participants to imagine there is a party in honor of their birthday and the time comes when people are starting to give speeches and try to answer the question about what they want to hear people at the party say. This exercise help patients in wondering what person they want to be with themselves and others.
16329284|NCT04474509|Experimental|FACT Module Openness|"Participants attending this module are guided to recognize and distancing themselves to stressful thoughts, feelings and sensations. They will learn to read suffering as part of human experience, without self-judgment and self-condemnation. Rather, therapist will encourage the patient's assumption of an open and acceptable approach to internal experiences. Throughout the module, therapist will help patients to reflect on their usual, but ineffective efforts to solve personal problems, and encourage the adoption of new responsive strategies based on acceptance and defusion from personal distress.
~An example of metaphor used during the Module is The Passenger on a bus. In this metaphor patient have to imagine to be a driver bus and his every thought is a passenger that gets on and off the bus. This exercise help patients to accept, defuse from, and reduce the power of their thoughts."
16329285|NCT04474509|Experimental|FACT Module Awareness|The module comprises meditation exercises and experiences aimed to learn how to act intentionally with awareness about personal thought and sensations without automatically reacting. Participants are supported to recognize their actions and the context where they occur and learn to choose to respond with action consistent with their values and not automatically. Therapist will propose breathing exercises, body scan and others mindfulness experiences. Participants will be encouraged to sitting comfortably, close the eyes, feel themselves in contact with the present moment they are living, paying attention to their breath, noticing the rhythm and any other aspect of the experience of breathing. Then, the therapist guides the participant's attention on the body, noting any part of their body from the head to feet. Then, the sounds around, any noises that could distract their attention on themselves.
16329286|NCT04474496||Marshallese adults in the U.S.|Marshallese persons 18 years of age or older currently residing in the United States
16329287|NCT04474483|Placebo Comparator|Control|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
16329288|NCT04474483|Experimental|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
16329289|NCT04474470|Experimental|Dose escalation of NT219 as a single agent|
16329290|NCT04474470|Experimental|Dose escalation of NT219 in combination with ERBITUX®|
16329291|NCT04474470|Experimental|Expansion cohort of NT219 in combination with ERBITUX®|
16329292|NCT04474457||COVID-19/Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
16329293|NCT04474444||Hear and treat|phone call, treatment, not attended
16329294|NCT04474444||See and treat|Ambulance crew attended
16329295|NCT04474431|Other|Patients admitted in the ICU of hospital of Rouen|Patients admitted in the intensive care unit (ICU) of the teaching hospital of Rouen.
16329296|NCT04474405|Experimental|Brain flortaucipir PET scan|Subjects receiving a brain PET scan after flortaucipir administration
16329297|NCT04474405|Experimental|Whole body flortaucipir PET scan|Subjects receiving a whole body PET scan after flortaucipir administration
16329298|NCT04474405|Other|MRI and Amyloid Extension Cohort|Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
16329325|NCT04474223|Experimental|Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms|
16329437|NCT04473612||Neuromuscular high physical status group|Patients diagnosed of Neuromuscular disease with high physical status
16329438|NCT04473612||Control group|Healthy subjects
16329299|NCT04474392||At-Risk (N=180)|"No evidence of inflammatory arthritis on clinical examination AND
~At elevated risk for RA based on familial or serologic risk
~Familial risk includes having a first degree relatives (FDRs) with RA
~Serologic risk includes asymptomatic serum ACPA positivity
~There will be 1 study visit per year for 3 years; for a subset of 30 of these participants, there will be an additional 3 quarterly visits in one year.
~Study Procedures (Baseline & Follow-up):
~Questionnaires
~Physical and joint exam
~Measurement of participants' height, weight
~Blood and sputum collection"
16329300|NCT04474392||Healthy Controls (N=120)|"No history of RA
~No FDRs with RA
~No systemic use of immunosuppressants for autoimmune disease
~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.
~Study Procedures (Baseline & Follow-up):
~Questionnaires
~Physical and joint exam
~Measurement of participants' height, weight
~Blood and sputum collection"
16329301|NCT04474392||RA Diagnosis (N=40)|"Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR
~Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)
~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.
~Study Procedures (Baseline & Follow-up):
~Questionnaires
~Physical and joint exam
~Measurement of participants' height, weight
~Blood and sputum collection"
16329302|NCT04474379|Experimental|Strategy Training|Consists of 8-90 minute sessions over 4 weeks. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the therapist teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based) and instructs in their use before and during the training games. In sessions 3-8, the tester tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. After completing the training games, the therapist and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the therapist helps the participant develop written action plans to do so. Plans and goals are reviewed and modified, if necessary, at each session.
16329303|NCT04474379|No Intervention|Process Training|Consists of 8, 90 minute sessions over 4 weeks. In sessions 1 and 2, the therapist teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3-8, the tester tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the therapist. Feedback on accuracy is provided after each training game. This is typical of a process training approach and expects that practice of the training tasks will improve prospective memory ability per se or that participants will develop effective strategies for completing prospective memory tasks on their own. At the end of each session, the therapist reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Goals are reviewed and modified if necessary.
16329304|NCT04474366|Sham Comparator|Saline|Control group will receive an injection of 20ml of saline between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of saline between the pectoralis minor and pectoralis major muscles bilaterally.
16329305|NCT04474366|Experimental|Ropivacaine|Intervention group will receive an injection of 20ml of 0.2% Ropivacaine between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of 0.2% Ropivacaine between the pectoralis minor and pectoralis major muscles bilaterally (Not to exceed 225mg or 3.5mg/kg).
16329306|NCT04474353|Experimental|Novo-TTF|"Day 1: Subjects will wear the Optune (TTFields device) for ≥ 18 hours/day. They will take off the device when receiving stereotactic radiosurgery and brain MRI scans.
~Days 1 to 8: Subjects will take oral temozolomide 75 mg/m2/day Days 2 to 8: Subjects will receive stereotactic radiosurgery (total of 35 Gy) divided equally over 5 days
~• After the interventional treatment, subjects will receive standard of care adjuvant chemotherapy and routine surveillance brain MRI scans."
16329307|NCT04474340|Experimental|CCP patients|"Patient has to fulfil the inclusion/exclusion criteria of the ward or the ICU
~Valid consent.
~Request the CCP from the central blood bank (200-250 ml/dose - can be repeated again in 12 hours) this is through the local hospital blood bank.
~How to transfuse CCP:
~Dose required is 200-250 ml/hr (one dose, can be repeated in 12 hrs), max total 500ml.
~Premedication prior to administration of CCP (Acetaminophen, diphenhydramine,steriods) or according to hospital guidelines."
16329308|NCT04474340|No Intervention|Control|Standard COVID-19 treatment.
16329309|NCT04474327|Experimental|Intervention group|"The intervention group will receive Montelukast Sodium for 10 days in addition to the conventional antibiotic therapy regimen and other supportive measures according to the policy of neonatal units and patients' needs. Montelukast sodium will be given at a dose according to body weight (1.5 kg to 2 kg, will be given 1.5 mg; greater than 2 kg, 2 mg will be given) this dose was calculated according to ( Kim et al. (2015). Four mg of the drug will be dissolved in four ml milk and 1.5 - 2 ml milk only will be given once daily at 9 pm via an orogastric tube or by oral administration for 10 days and patients of this group will be closely observed for development of Montelukast side effects as diarrhea, colic, vomiting, fever and cough (Adelsberg et al. 2005)."
16329310|NCT04474327|No Intervention|Control group|The control group will receive antibiotics and other supportive measures according to the policy of neonatal units and patients' needs.
16329311|NCT04474314|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
16329312|NCT04474314|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
16329313|NCT04474314|Placebo Comparator|Placebo|Oral administration of once daily Placebo
16329314|NCT04474301||Observational (survey administration)|Patients complete a survey over 10 minutes.
16329315|NCT04474288||Person Under Investigation (PUI)|PUI's are subjects who were admitted to the hospital with symptoms suspicious for COVID-19.
16329316|NCT04474288||Asymptomatic Person under Screening (APS)|APS's are those patients who do NOT meet the criteria to be a suspect COVID- 19 patient but are being tested because they are being admitted, are required for testing by state mandate, or are having a procedure, etc.
16329317|NCT04474275||Study group 1|Primiparous women who gave birth with ceserean section
16329318|NCT04474275||Study group 2|Primiparous women who gave birth with vaginal route delivery without episiotomy
16329319|NCT04474275||Study group 3|Primiparous women who gave birth with vaginal route delivery with episiotomy
16329320|NCT04474275||Control group|Nulliparous women
16329326|NCT04474210|Experimental|Part A: Group 1|Participants with severe renal impairment and/or kidney failure (estimated glomerular filtration rate [eGFR] less than [<] 30 milliliter[mL]/minute but not yet on hemodialysis) will receive a single oral dose of JNJ-56136379.
16329327|NCT04474210|Active Comparator|Part A: Group 2|Healthy participants with normal renal function (eGFR greater than or equal to [>=] 90 mL/minute), will receive a single oral dose of JNJ-56136379.
16329328|NCT04474210|Experimental|Part B: Group 3 (Optional)|Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379.
16329329|NCT04474210|Experimental|Part B: Group 4 (Optional)|Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379.
16329330|NCT04474210|Experimental|Part B: Group 5 (Optional)|Participants with kidney failure (eGFR: <15 mL/minute and on hemodialysis; pharmacokinetic [PK] to be evaluated during non-dialysis days) will receive a single oral dose of JNJ-56136379.
16329331|NCT04474197|Experimental|VX-864|Subjects will be randomized to receive different dose levels of VX-864.
16329332|NCT04474197|Placebo Comparator|Placebo|Subjects will receive placebo matched to VX-864.
16329333|NCT04474184|Experimental|Aim 1 (focus group)|Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
16329334|NCT04474184|Experimental|Aim 2 (vaginal kit)|Participants receive a tampon kit for collection of vaginal samples.
16329335|NCT04474171|Experimental|SCI&U Intervention|The SCI&U online platform has a resource library, secure videoconferencing, and tools to support one-on-one health coaching. Health coaches are certified in motivational interviewing and have lived in the community with SCI for more than five years. In the first session, participants identify priority issues related to their health and target management of secondary conditions specific to SCI. They will work through goal setting, problem solving activities and create action plans for behaviour change, which will be securely stored. The intervention will be a maximum of 14 sessions over 6 months. Each session will cover a health-related topic (bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression) and a self-management skill topic (action planning, goal setting, problem-solving, mood management, navigating the health care system and communicating with health care providers) with an expected duration of 30 to 45 minutes.
16329336|NCT04474171|No Intervention|Waitlist Control|Usual health care and be offered the SCI&U program at the end of the 12-month follow-up period (wait-list control)
16329337|NCT04474158|Experimental|Creating Peace|Creating Peace uses a group discussion format with activities that explore race, gender, sexual identity, and social class. Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
16329338|NCT04474158|Active Comparator|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
16329339|NCT04474145|Active Comparator|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.
~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
16329340|NCT04474145|Active Comparator|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
16329341|NCT04474132|Other|single group|binary: positive or negative result
16329342|NCT04474119|Experimental|Experimental arm|KN046 plus Carboplatin and Paclitaxel
16329343|NCT04474119|Placebo Comparator|Control arm|Placebo plus Carboplatin and Paclitaxel
16329344|NCT04474106|Experimental|ESWT|The extracorporeal shockwave therapy is applied once at the level of lesion and 5 segments above and below; or below the occiput (in lesions higher than C6) and above the sacrum (in lesions lower than T12). In addition, the ESWT is applied to the soles of both feet on the medial side of the plantar surface. The ESWT is applied as soon as possible within 48 hours post-injury.
16329345|NCT04474106|Sham Comparator|Control|In the control group, the same procedure is performed, but without the device emitting extracorporeal shock waves using a dummy head.
16329346|NCT04474093|Active Comparator|Zirconium-reinforced glass ceramics (ZRGC)|12 posterior single tooth crowns made from monolithic zirconium-reinforced glass ceramics(ZRGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
16329374|NCT04473950|Experimental|Pain Group|Patients with chronic pain who are maintained on methadone for opioid use disorder
16329375|NCT04473950|Placebo Comparator|No Pain Group|Patients who are maintained on methadone for opioid use disorder but who do not have chronic pain.
16332559|NCT04451863|Active Comparator|Low THC + High BCP|5 mg THC, 0 mg myrcene, 7.5 mg BCP
16329347|NCT04474093|Active Comparator|Lithium disilicate glass ceramics (LGC)|Group 2: 12 posterior single tooth crowns made from monolithic lithium disilicate glass ceramics(LGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
16329348|NCT04474093|Active Comparator|Resin infiltrated glass ceramics (RIGC)|12 posterior single tooth crowns made from monolithic resin infiltrated glass ceramics(RIGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
16329349|NCT04474080|Experimental|Virtual Peer Support Platform|"The intervention program content will be informed by the BASICS-a guide for supporting resilience against burnout, developed by the Ontario Medical Association Physician Health Program, as well as the Person-Environment-Occupation (PEO) model, a transactive approach to modelling occupational performance issues in the field of Occupational Therapy. The BASICS highlights six fundamental domains will underly the focus of group therapy sessions, where participants will be encouraged to consider how they may incorporate healthy physical and emotional practices both on their own (Person), and during the practice of medicine (Occupation), in addition to identifying barriers to adopting these practices within the healthcare environment (Environment)."
16329350|NCT04474080|Active Comparator|Control period|Residents receive a 30 minutes break during their weekly academic half-day.
16329351|NCT04474067||• Asymptomatic or Pre-symptomatic Infection|Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.
16329352|NCT04474067||Mild COVID-19|"Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.
~According to NIH classification"
16329353|NCT04474067||Moderate COVID-19|COVID-19 patients who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.
16329354|NCT04474067||Severe COVID-19|COVID-19 patients who have respiratory frequency >30 breaths per minute, SpO2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, or lung infiltrates >50%
16329355|NCT04474067||Critical COVID-19|COVID-19 patients who have respiratory failure, septic shock, and/or multiple organ dysfunction.
16329356|NCT04474067||Sepsis|A control group of patients with sepsis-related cytokine storm
16329357|NCT04474067||CAR-T CRS|A control group of patients with cytokine release syndrome due to CAR-T therapy
16329358|NCT04474041|Experimental|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
16329359|NCT04474028||Hood group|The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood.
16329360|NCT04474028||Direct spray group|The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively.
16329361|NCT04474015|Active Comparator|Part A, Group 1|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 1 will receive forearm stimulation at 0.75 Hz with an oscillating direct current (DC) waveform while awake.
16329362|NCT04474015|Active Comparator|Part A, Group 2|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 2 will receive forearm stimulation at 0.75 Hz with a modified alternating current (AC) waveform while awake.
16329363|NCT04474015|Active Comparator|Part A, Group 3|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 3 will receive forearm stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform while awake.
16329364|NCT04474015|Active Comparator|Part B, Group 4|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). roup 4 will receive scalp stimulation at 0.75 Hz with an oscillating direct current (DC) waveform during sleep.
16329365|NCT04474015|Active Comparator|Part B, Group 5|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 5 will receive scalp stimulation at 0.75 Hz with a modified alternating current (AC) waveform during sleep.
16329366|NCT04474015|Active Comparator|Part B, Group 6|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 6 will receive scalp stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform during sleep.
16329367|NCT04474015|Active Comparator|Part C, Group 7|Pulsed Stimulation: Group 7 (Part C)will receive a series of brief stimulations of up to 500 millisecond duration and of up to 5 milliamperes of current, using either metal electrodes or sponge electrodes as stimulating electrodes.
16329370|NCT04473989|Placebo Comparator|Placebo|Injection product without active teriparatide
16329371|NCT04473989|Experimental|PTH 40ug/w|Injection product with active teriparatide
16329372|NCT04473963|Experimental|EGF-Guided Ablation Therapy|"Subjects randomized to therapy will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software)."
16329373|NCT04473963|No Intervention|Control - No Ablation Therapy|"Subjects randomized to control will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end."
16329376|NCT04473937|Experimental|Radiotherapy|"Participants must have received CAR-T infusion within the last 90 days prior to completing a study screening and enrollment process.
~Participants will be enrolled within 28 days after screening is complete and radiotherapy will occur within 14 days after study enrollment.
~Radiotherapy will be administered based on a dose and schedule pre-determined by the study doctor."
16329377|NCT04473924|Experimental|Body surface area-based mycophenolate dosing|Intervention group will receive mycophenolate mofetil 750 mg/m^2/day divided into twice daily dosing.
16329378|NCT04473924|Active Comparator|Standard (fixed) dosing|Active comparator group will receive standard fixed dosing of mycophenolate mofetil 1000 mg twice daily.
16329379|NCT04473911|Experimental|Regimen 1: Fludarabine, Cyclophosphamide, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician
~Pre- stem cell transplant:
~Fludarabine predetermined dose, intravenously, 4 times per cycle
~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
~Total body irradiation (TBI) once during treatment cycle
~Post stem cell transplant:
~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.
~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
16329380|NCT04473911|Experimental|Regimen 2: Fludarabine, Melphalan, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician
~Pre- stem cell transplant:
~Fludarabine predetermined dose, intravenously 3 times per cycle
~Melphalan, infusion, determined dosage, once per cycle
~Total body irradiation (TBI) once per cycle.
~Post stem cell transplant
~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:
~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
16329381|NCT04473898|Sham Comparator|Patient Education Group|Information training about COViD-19 and its symptoms, hygiene education, family education
16329382|NCT04473898|Experimental|Aerobic Training Group|Teaching and regular follow-up of aerobic exercises shown online
16329383|NCT04473898|Experimental|Aerobic + Respiratory Training Group|Teaching and regular follow-up of aerobic and respiratory exercises shown online
16329384|NCT04473885|Experimental|Perturbation-based balance training group|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
16329385|NCT04473885|No Intervention|Control group|Participants in the control group will remain their regular activity without additional training.
16329386|NCT04473872|Active Comparator|Neurodevelopmental treatment program group|"When applying NGT, which is described as a problem solving approach, the treatment program appropriate for their functional levels will be determined for each patient, taking into account the individual needs and wishes of the patient. Principles to be considered while applying the treatment program:
~Inhibition of normal / ineffective movements
~Facility of normal / effective movements Sensory-motor stimulation
~Correct placement of body segments Neurodevelopmental treatment physiotherapy session for 5-days in a week, over 6-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities."
16329387|NCT04473872|Experimental|diaphragmatic breathing|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises. Diaphragmatic breathing; To give the patient a supine position, a pillow is placed under his knees and head. The patient is asked to place his right hand on the upper abdomen and his left hand on the upper part of his chest. The patient is told to take a slow and deep breath through the nose until four counts, and to hold the air in for the time it has inhaled, and then the patient shrinks her lips like a whistle and exhales from using her breath for a long time. Exercises are performed two hours after meals, in short, 2-3 minutes in the beginning, in 10 of the patients, on average 30 minutes per day.
16329388|NCT04473872|Experimental|respiratory muscle training with the THRESHOLD IMT device|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and respiratory muscle training with the THRESHOLD IMT device. T-IMT is an instrument that provides the same pressure in each breath for the strength and endurance of the inspiratory muscles, regardless of the patient's rapid or slow breathing. This device provides a constant pressure in inspiration with its flow-free one-way valve. It also has an adjustable device pressure. The tool consists of pressure section, mouthpiece and nose clip. During application, constant pressure is applied to the inspiration phase. The training group is started from 40% of MIP and inspiratory muscle training is given. In practice, patients are asked to sit in a loose position on the upper chest and shoulders. After eight breathing cycles, 1-2 respiratory controls are requested
16329389|NCT04473859|Experimental|FSR Peptide 20 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
16329390|NCT04473859|Experimental|FSR peptide 50 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
16329391|NCT04473859|Experimental|FSR peptide 100 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
16329392|NCT04473859|Experimental|FSR peptide 200 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
16329393|NCT04473859|Placebo Comparator|Placebo only|Each subject will have two punch biopsies. Placebo will be applied to both punch biopsies.
16329394|NCT04473846|Experimental|PF group|The first group will undergo general anesthesia using Fentanyl and Propofol.
16329395|NCT04473846|Experimental|PFK group|The second group will receive a mixture that consists of Fentanyl, Propofol, and Ketamine. In addition, Lidocaine will be added to reduce the pain on injection caused by Propofol.
16329435|NCT04473625||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329396|NCT04473833|Experimental|Participants in the Kentucky Ovarian Cancer Screening Program|Participants from the Kentucky Ovarian Cancer Screening Program who choose to participate in this trial will undergo further serial transvaginal ultrasonography (TVS) screening.
16329397|NCT04473820|Active Comparator|Vapocoolant spray|
16329398|NCT04473820|Active Comparator|Lidocaine-Prilocaine cream|
16329399|NCT04473807|Other|DASH-AF|Patients with history of highly symptomatic persistent or paroxysmal AF who are scheduled for sotalol therapy once in sinus rhythm will be enrolled in this study.
16329400|NCT04473781|Experimental|Treatment (interstitial brachytherapy)|Patients undergo interstitial brachytherapy for 1-2 fractions in the absence of disease progression or unacceptable toxicity. Patients who undergo 2 fractions may receive both fractions in the same day or on 2 separate days over 2 weeks.
16329401|NCT04473768||NTS bloodstream infection|growth of NTS in blood culture
16329402|NCT04473768||NTS/Pf malaria co-infection|concurrence of current Pf malaria infection and NTS bloodstream infection
16329403|NCT04473768||Other pathogen bloodstream infections|growth of a pathogen other than NTS in blood culture
16329404|NCT04473768||Severe Pf malaria mono-infection|defined according to WHO-criteria
16329405|NCT04473768||Other causes of febrile illness requiring hospital admission|"Current Pf malaria infection: see above
~Recent Pf malaria infection: see above
~Non-confirmed bloodstream infection without Pf malaria: no growth in blood culture and negative results in all Pf malaria tests
~If feasible, severe bacterial localized infections such as pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection, will be assessed and clinically defined"
16329406|NCT04473755||ADHD|This group will include participants who meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
16329407|NCT04473755||Non-ADHD|This group will include participants who do not meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
16329408|NCT04473742|Experimental|Patients exposed to silica|
16329409|NCT04473742|Active Comparator|Patients exposed to asbestos fibres|
16329410|NCT04473729|Experimental|Children with an autism spectrum disorder|The intervention as described above with children with an ASD.
16329411|NCT04473729|Experimental|Children with Hearing Loss|
16329412|NCT04473729|Experimental|Typically developing children with normal hearing acuity|
16329413|NCT04473716|Experimental|Inductive therapy with Toripalimab, Paclitaxcel and Cisplatin|Pre-operative inductive therapy will be used with the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of paclitaxcel and cisplatin in patients with locally advanced OSCC. After inductive therapy, the patients will receive radical surgery and post-operative radiotherapy/chemoradiotherapy.
16329414|NCT04473703||observation group|A total of 300 patients are expected to include in this group. And the cardiac adverse reactions related to immune checkpoint inhibitor will be observed.
16329415|NCT04473690|Experimental|Low Dose KBP-COVID-19 and adjuvant|"Two age groups.
~Part A (18-49 years).
~Part B (50-85 years).
~All subjects in these groups will receive the low dose of KBP-COVID-19"
16329416|NCT04473690|Experimental|High Dose KBP-COVID-19 and adjuvant|"Two age groups.
~Part A (18-49 years).
~Part B (50-85 years).
~All subjects in these groups will receive the high dose of KBP-COVID-19"
16329417|NCT04473690|Placebo Comparator|Placebo|"Two age groups.
~Part A (18-49 years).
~Part B (50-85 years).
~All subjects in these groups will receive placebo"
16329418|NCT04473677||Fecal Occult Blood Test|People in this group will detect hemoglobin in stool before colonoscopy by the new qFIT.
16329419|NCT04473664|Experimental|Hepatic-impaired Participants|Participants with moderate HI as defined by NCI-ODWG criteria.
16329420|NCT04473664|Experimental|Healthy Control Participants|Healthy participants with normal hepatic function matched as a group by sex, age (±10 years), and weight (±20%).
16329421|NCT04473651|Experimental|Part A: Single dose of Lu AG06479 or Placebo|
16329422|NCT04473651|Experimental|Part B: Repeated dose of Lu AG06479 and Food interaction|"Sequence B1: Fed - Fasting- Fasting
~Sequence B2: Fasting- Fed - Fasting
~Sequence B3: Fasting- Fasting - Fed"
16329423|NCT04473638||Arthroscopic|Deltoid Arthroscopic Repair in Ankle Fractures
16329424|NCT04473625||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329425|NCT04473625||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329426|NCT04473625||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329427|NCT04473625||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329428|NCT04473625||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329429|NCT04473625||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329430|NCT04473625||Kidney/Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329431|NCT04473625||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329432|NCT04473625||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329433|NCT04473625||Pancreas|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329434|NCT04473625||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
16329439|NCT04473599|Active Comparator|Uniform Random|Participants will receive supportive text-messages for a period of 2 months. These text-messages have two categories: behavioral activation (BA) and coping skills. In this arm, participants will receive one of these types of messages daily on a random schedule in random time periods throughout the day.
16329440|NCT04473599|Experimental|Reinforcement Learning|In this arm we will test a reinforcement learning (RL) algorithm with a learned decision mechanism for the timing and type of text-messages. The algorithm learns from previous data (which messages were sent, what was the participants' mood) to maximize an increase in participants' mood.
16329441|NCT04473586|Other|Sample tested in less than one-hour|Buccal samples will be collected and analyzed on the Spartan Cube CYP2C19 System immediately (<1hr). The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
16329442|NCT04473586|Other|Samples tested greater than 24 hours|Buccal samples will be collected, stored and then analyzed on the Spartan Cube CYP2C19 System greater than 24 hours after collection. The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
16329443|NCT04473573|Other|Lot to Lot Reproducibility|The purpose of this arm is to provide evidence to support that each lot of manufactured reagents for the Spartan Cube CYP2C19 Test produce the same result. Each participant, over the course of the study at the various sites, will be tested using 3 different lots of manufactured Spartan CYP2C19 Test Kits.
16329444|NCT04473573|Other|Site to Site Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when tested at different locations, produce the same result.
16329445|NCT04473573|Other|Operator Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when collected and tested by different operators, produce the same result.
16329446|NCT04473560||Catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with catheter-directed thrombectomy along with anticoagulation therapy
16329447|NCT04473560||No catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with anticoagulation therapy alone
16329448|NCT04473534|Experimental|Arm of CBT-I treatment|Web cognitive behavioral therapy was administered before starting CPAP use by a psychologist expert in behavioral sleep medicine and expert in CBT-I. CBT-I was administered according to the same model and standard visual approach in patients with insomnia. Five sessions are scheduled: sleep psycho-education, sleep restriction, stimulus control, sleep hygiene and challenging beliefs and perception of sleep.
16329449|NCT04473534|Experimental|Arm of psycho-education session|Single session of psycho-education about sleep, OSA, insomnia and interaction among them will be administered by web before beginning CPAP use
16329450|NCT04473534|No Intervention|Arm of control TAU (Treatment As Usual)|The control group will receive TAU. Each patient will start to use CPAP after the diagnosis according to AASM (American Academy of Sleep Medicine) guideline.
16329451|NCT04473521|No Intervention|No Adhesive|No adhesive will be applied.
16329452|NCT04473521|Active Comparator|Super Poligrip Free (SPF)|The denture adhesive of 1.00grams (g) +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilised using this adhesive up to 2 times (maximum [max] 3 adhesive applications per day) at examiner's discretion.
16329453|NCT04473521|Experimental|Investigational Adhesive|The denture adhesive of 1.00g +/- 0.05g will be applied only to the maxillary denture only in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
16329454|NCT04473521|Experimental|Investigational Adhesive + Hot drink|The denture adhesive of 1.00g +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Hot drinks will be provided within 1 hour of completing lunch and dinner and must be consumed within 30 minutes. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
16329455|NCT04473508|Experimental|Treated|active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)
16329456|NCT04473508|Placebo Comparator|Control|Local administration of Placebo ( Saline Solution)
16329457|NCT04473495||video|patients who enjoyed an educational video
16329458|NCT04473495||control|patients who didn't enjoy any educational video
16329459|NCT04473482|Experimental|MAIN-ART Behavior Tool|The Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
16329460|NCT04473482|No Intervention|Routine care|Patients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.
16329461|NCT04473469|Experimental|Cystometrogram|The bladder will be filled to different volumes and electrical stimulation will be applied to the pudendal nerve via the implanted neurostimulator.
16329462|NCT04473456|No Intervention|Serial arm|In the serial group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
16329463|NCT04473456|Active Comparator|Simultaneous arm|In the simultaneous group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
16329464|NCT04473443||Cohort A|Patients with a challenging anatomy, including bicuspid aortic valve, severely calcified aortic valves or small aortic roots
16329465|NCT04473443||Cohort B|Consecutive patients eligible for TAVI with Acurate TM and Lotus Edge TM valve
16329466|NCT04473430|Experimental|Dexcom G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia < 55 mg/dL within the preceding 20 minutes)."
16329467|NCT04473430|Active Comparator|Point-Of-Care Blood Glucose (POC BG) monitoring|Patients will receive conventional/point-of-care blood glucose monitoring
16329468|NCT04473417|Experimental|Part A, Sequence I|Period I: Forxiga® → DA-2811, Period II: DA-2811 → Forxiga®
16329469|NCT04473417|Experimental|Part A, Sequence II|Period I: DA-2811 → Forxiga®, Period II: Forxiga® → DA-2811
16329470|NCT04473417|Experimental|Part B, Sequence I|Period I: DA-2811 under fasting state → DA-2811 under fed state, Period II:DA-2811 under fed state → DA-2811 under fasting state
16329471|NCT04473417|Experimental|Part B, Sequence II|Period I: DA-2811 under fed state → DA-2811 under fasting state, Period II: DA-2811 under fasting state → DA-2811 under fed state
16329472|NCT04473404|Experimental|Probiotic - low dose|Powdered probiotic with a carrier.
16329473|NCT04473404|Experimental|Probiotic - high dose|Powdered probiotic with a carrier.
16329474|NCT04473404|Placebo Comparator|Placebo|Carrier only.
16329475|NCT04473391|Experimental|Robot-assisted Rehabilitation|Participants will receive Functional Electrical Stimulation (FES) training with a lower extremity cycle-ergometer (MOTOmed Viva 2, Reck GmbH., Germany) and a 6-channel FES Device (TrainFES, Biomedical Devices SpA, Chile). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 3 sessions per week for 8 weeks, each lasting about 45 minutes.
16329476|NCT04473378||FreeStyle Libre sensor cohort|Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
16329477|NCT04473365||Without parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 1 will constitute those without parasite co-infection
16329478|NCT04473365||With parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 2 will constitute those with parasite co-infection
16329479|NCT04473352||Single Group|Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
16329480|NCT04473339|Experimental|HRR mt 1|Patients are HRR mutated type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
16329481|NCT04473339|Experimental|HRR mt 2|Patients are HRR mutated type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
16329482|NCT04473339|Experimental|HRR wt 3|Patients are HRR wild type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
16329483|NCT04473339|Experimental|HRR wt 4|Patients are HRR wild type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
16329484|NCT04473326|Experimental|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
16329485|NCT04473326|No Intervention|Control Arm|Up to daily, untailored text messages.
16329486|NCT04473287|Experimental|intervention group|Reflexology was applied to the intervention group during the procedure for 45 minutes.
16329487|NCT04473287|No Intervention|control group|Reflexology was not applied to the control group during the procedure. The control group received standard care and treatment.
16329488|NCT04473274|Experimental|Pioglitazone group|Participants will receive pioglitazone 15mg to 30mg daily oral or enteral during hospitalization for up to 30 days in addition to standard of care
16329489|NCT04473274|No Intervention|Matching cohort group|Participants will standard of care
16329490|NCT04473261|Experimental|Iodine Complex (Capsule form)|Iodine Complex) capsule (200mg) will be given three times a day
16329491|NCT04473261|Experimental|Iodine Complex (Syrup form)|Iodine Complex syrup form (40ml) will be given three times a day
16329492|NCT04473261|Placebo Comparator|Standard Care Alone|Placebo as empty capsule. Treatment will be given for all 4 arms will be receiving standard care as per version 3.0 of clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan COVID-19 guidelines of the study setting.
16329493|NCT04473261|Experimental|Iodine Complex (Nasal Spray)|Iodine complex throat spray of 2 puffs three times a day.
16329494|NCT04473248|Experimental|Method 1- Nasopharyngeal Swab in transfer liquid|A nasopharyngeal swab will inoculate a proprietary solution which will be transferred to the Spartan COVID-19 System for analysis
16329495|NCT04473248|Experimental|Method 2- Dipping of specialized swab in VTM|A nasopharyngeal swab will inoculate VTM solution. A modified traditional Spartan Swab will be dipped into the inoculated VTM solution and then transferred to the Spartan COVID-19 System for analysis.
16329496|NCT04473248|Experimental|Method 3: Direct input of VTM|Using the VTM from Method 2, pipette 10uL of VTM, inoculated with sample, into the Spartan COVID-19 System for analysis.
16329497|NCT04473248|Experimental|Method 4: Collection of nasal sample.|Using a modified tip of the Spartan swab, a nasal sample will be taken from the patient and directly placed into the Spartan COVID-19 System for analysis.
16329498|NCT04473235|Experimental|Literacy training|The basic-literacy training will be given for two hours/day for four days/week for 6 months. At baseline, participants will be randomized into four classes of 30. An expert in adult education will oversee the classes and meet the teachers periodically, and each class will count with a certified and experienced lead teacher and teacher aid. The intervention group will receive literacy training based on analytical and phonemic methods for enabling reading and writing
16329499|NCT04473235|Active Comparator|Non-literacy training|The comparator group will have access to non-literacy classes offered at the adult school, including geography, history, informatics, and sciences, but no literacy-training, for two hours/day for four days/week for 6 months. After 6 months, the groups switch, so the comparator receives the specific reading and writing training, and the intervention group receives the lessons on other themes.
16329500|NCT04473222|Experimental|Sleep Well! Intervention|Participants in this condition will begin the Sleep Well! intervention after initiating baseline, daily diary, and actigraph procedures. Sleep Well! will be provided over approximately 6-8 weeks and will include 3 sessions. Intervention sessions will typically last about an hour, but session length may vary.
16329527|NCT04473014||Negative Mood|This group will be exposed to a negative mood induction prior to heat pain.
16329528|NCT04473014||Neutral Mood|This group will be exposed to a neutral mood induction prior to heat pain.
16329501|NCT04473222|Other|Enhanced Usual Care|The enhanced usual care condition will occur between 6 and 8 weeks. At randomization to this condition, participants will be provided with an evidence-based sleep guidelines for young children from the CHOP Parent Family Education manual. Participants in this condition will also be able to consult with their primary care physician for management of child sleep. Consistent with usual care in the CHOP system, the primary care physician may manage the sleep concern or choose to make a referral to the CHOP sleep center or to other behavioral health services internal or external to the CHOP system. Of note, the CHOP Parent Family Education handouts provide contact information for the CHOP Sleep Center and direct readers to follow-up with their primary care provider for further guidance.
16329502|NCT04473209|Active Comparator|diabetic group|diabetic patients with chronic periodontitis
16329503|NCT04473209|Active Comparator|non-diabetic group|non diabetic patients with chronic periodontitis
16329504|NCT04473196|Active Comparator|Weightbearing|Immediate weightbearing after surgery
16329505|NCT04473196|Active Comparator|Non weightbearing|nonweightbearing x 6 weeks post surgery
16329506|NCT04473183||General Healthy Population|Participants in this group are part of the general healthy population of adults 18 years-of-age and older, not known to be exposed to the virus as reported by potential participants and who have not sought medical help in the previous 4 months.
16329507|NCT04473183||Medical School Residents|Participants in this group are medical school residents.
16329508|NCT04473183||Individuals who are HIV positive|Participants in this group are HIV positive.
16329509|NCT04473170|Experimental|Group A|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
16329510|NCT04473170|Active Comparator|Group B|COVID-19 Standard care.
16329511|NCT04473144|No Intervention|Control|Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery.
16329512|NCT04473144|Sham Comparator|Ulistin|"In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
~Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery."
16329513|NCT04473131||COVID-19 positive|"Inclusion criteria:
~Male or female aged over 18 years
~Admitted patients to ICU with a suspicious COVID19 infection
~Tested positive for SARS-CoV-2
~Exclusion criteria:
~Burn and trauma
~Any immunological diseases, or immunosuppressive medications
~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)
~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
16329514|NCT04473131||COVID-19 negative|"Inclusion criteria:
~Male or female aged over 18 years
~Admitted patients to ICU
~Tested negative for SARS-CoV-2
~Exclusion criteria:
~Burn and trauma
~Any immunological diseases, or immunosuppressive medications
~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)
~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
16329515|NCT04473131||Heathy volunteers|"Inclusion criteria:
~Male or female aged over 18 years
~Normal clinical examination
~Exclusion criteria:
~Person with an infectious syndrome during the last 90 days
~Extreme physical stress within the last week
~Person receiving within the last 90 days, a treatment based on: antivirals; antibiotics; antiparasitics; antifungals; non-steroidal anti-inflammatory drugs; immunosuppressive therapy; corticosteroids; therapeutic antibodies; chemotherapy
~Person with history of: innate or acquired immune deficiency; hematological disease; solid tumor; severe chronic disease; surgery or hospitalization within the last 2 years; pregnancy within the last year; participation to a phase I clinical assay during the last year; participation to a phase I clinical assay during the last year; pregnant or breastfeeding women; a person with restricted liberty or under legal protection
~Sample collection time points: 1 (day of blood sample donation)"
16329516|NCT04473118||Healthcare workers|All healthcare workers exposed directly or not to suspected or infected COVID-19 patients such as nurse; paramedic; senior physician; resident/ trainee physician; respiratory therapist; perfusionist; physiotherapist; dietitian; technician lab; technician imaging; pharmacist; occupational therapist; speech therapist
16329517|NCT04473079|Experimental|Experimental group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus probiotic formulation (commercially-available as Lacidofil) for 12 weeks.
16329518|NCT04473079|Placebo Comparator|Placebo group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus placebo for 12 weeks.
16329519|NCT04473066||Adenotonsillectomy (AT)|Children diagnosed with moderate-to-severe OSA (OAHI ≥3/h) and tonsillar hypertrophy (tonsil grade ≥2) at the age of 5-12 years old and underwent AT since 2012.
16329520|NCT04473066||Refused AT|Children diagnosed with moderate-to-severe OSA and tonsillar hypertrophy but refused AT in the same period.
16329521|NCT04473066||Normal control|Children reported to have no habitual snoring (less than 3 nights per week) and confirmed to have no OSA (OAHI <1/h) by overnight sleep study in the same period.
16329522|NCT04473053|Experimental|Nafamostat|It is intended that the licensed dose (0.2mg/kg/hr) in Japan will be used. Patients randomised to Nafamostat will receive a continuous intravenous infusion at 0.2 mg/kg/hr for 7 days. If a participant is discharged from hospital or can no longer receive this treatment, the treatment will be stopped.
16329523|NCT04473053|Experimental|TD139|"Patients will inhale 5mg x 2 (10 mg) twice daily for the first 48 hrs and then subsequently 5mg x 2 (10 mg) once daily for the remaining 12 days. Unless a participant is discharged from hospital or can no longer use an inhaler - in which case treatment will be stopped at such time.
~CE marked inhalers will be provided by the Manufacturer. All patients will receive guidance on how to use the inhaler by an appropriately trained member of the research team. Two individual inhalers will be used by each patient over the course of the 14 day study period (each inhaler will be used by one patient for 7 days) and will be thoroughly cleaned with an antiseptic wipe before and after each use."
16329524|NCT04473053|Active Comparator|Standard of Care|All treatment arms will be compared to the Standard of Care arm.
16329525|NCT04473027||Patients with advanced melanoma|Patients receiving anti-PD-1 monotherapy (Nivolumab or Pembrolizumab) in the first-line setting
16329526|NCT04473014||Positive Mood|This group will be exposed to a positive mood induction prior to heat pain.
16329529|NCT04473001||Surgical patients|Adult patients admitted for major abdominal-, orthopedic or arterial vascular surgery.
16329530|NCT04472988|Experimental|Eye Movement Desensitization and Reprocessing|"30 participants will be randomly allocated to the EMDR group. They will receive a 90 minutes session of EMDR each week for twelve weeks. The sessions will be conducted by clinicians or psychotherapists specialized in EMDR, and the participants will be randomly allocated to them.
~EMDR is a structured, goal-oriented, short-term intervention organized around traumatic or stressful memories. This method was discovered in 1981 by F. Shapiro and represented an evidence-based treatment, one of the two first-line trauma treatment recommended for use with adults (NICE, 2005; World Health Organization, 2013). EMDR proved effective by hundreds of researches and has also been shown to be useful in alleviating physical symptoms such as pain or increased autonomic activity. But to our knowledge, research on EMDR efficacy in the treatment of autoimmune thyroiditis has not been previously reported."
16329531|NCT04472988|Placebo Comparator|Placebo|30 participants will be randomized to the placebo group. The placebo goup will receive an intervention that does not include working on past traumatic memories, it will be more focused on present and future.
16329532|NCT04472988|Active Comparator|Treatment as Usual|30 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
16329533|NCT04472975||Multiple sclerosis (MS) cohort|Individuals with multiple sclerosis without any exposure to disease-mofidying drugs (DMDs) and with exposure to one or more DMDs.
16329534|NCT04472962|Active Comparator|Low-carbohydrate-high-protein pre-exercise meal|
16329535|NCT04472962|Active Comparator|High-carbohydrate-low-protein pre-exercise meal|
16329536|NCT04472949|Experimental|Durvalumab & thoratic radiotherapy|"Patients will start with an induction phase (part 1). Patients with CR; PR or SD after the induction phase, will transfer to the maintenance phase (part 2). Patients with PD after the induction phase will transfer to the follow-up phase.
~Induction phase (part 1):
~Patients will receive durvalumab in combination with carboplatin and etoposide for 4 cycles of 21 days:
~Maintenance phase (part 2):
~Patients will receive durvalumab treatment up to PD or max. 2 years, i.e. 26 maintenance cycles, in combination with tRT:
~Follow up phase:
~Patients will be followed up for 24 months, every 8 weeks."
16329537|NCT04472936|Active Comparator|Group A|Double venous femoral access will be obtained. A duodecapolar catheter placed around tricuspid annulus will be used to prove isthmus block after CTI ablation.
16329538|NCT04472936|Experimental|Group B|Ablation will be performed similar as described in the Group A. After the ablation line is over, PRI on the surface ECG will be used to prove isthmus block after CTI ablation.
16329539|NCT04472923|Active Comparator|Control group|Patients belonging to the control group received conventional physical therapy program in the form of diet and Kegel exercises.
16329540|NCT04472923|Experimental|Study group|Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training
16329541|NCT04472910|Experimental|Neo-adjuvant mFFX|Neo-adjuvant mFFX up to 6 cycles, surgery, adjuvant chemotherapy for up tp 6 cycles, follow up
16329542|NCT04472897|Experimental|Part A: Participants receiving GSK2556286|Participants will be randomized to receive one of the ascending doses of GSK2556286 in any of the 8 cohorts (Cohort 1A to 8A). In each dosing cohort, 6 participants will receive a single oral dose of GSK2556286 on Day 1 under fasting conditions (Cohort 1A to 6A) and under fed conditions (Cohort 7A and 8A). The starting dose in Part A will be 25 milligrams (mg) and no dose escalation to the next dose will be higher than 3-folds. One cohort (Cohort 7A) will investigate the effect of food administration (high fat meal) on safety, tolerability and PK after a single dose of GSK2556286. Based on emerging data, a second food effect cohort (Cohort 8A) may also be included using a higher dose of GSK2556286.
16329543|NCT04472897|Placebo Comparator|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 8 cohorts (Cohort 1A to 8A). In each dosing cohort, 2 participants will receive a single oral dose of matching placebo on Day 1 under fasting conditions (Cohort 1A to 6A) and under fed conditions (Cohort 7A and 8A).
16329544|NCT04472897|Experimental|Part B: Participants receiving GSK2556286|Participants will be randomized to receive one of the multiple-ascending doses of GSK2556286 in any of the 4 cohorts (Cohort 1B to 4B). In each dosing cohort, 6 participants will receive a single oral dose of GSK2556286 on Day 1 up to 14 days under either fasting or fed conditions, dependent on the results from Part A. Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B.
16329545|NCT04472897|Placebo Comparator|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts (Cohort 1B to 4B). In each dosing cohort, 2 participants will receive a single oral dose of matching placebo on Day 1 up to 14 days under either fasting or fed conditions, dependent on the results from Part A.
16329546|NCT04472884|Experimental|mWACh-PrEP|
16329547|NCT04472884|Other|Standard of Care|
16329548|NCT04472871||patients with atrial fibrillation and heart failure|Patients with cardiac function ejection fraction less than 35% and underwent Left atrial appendage closure in the period covered by the study
16329549|NCT04472871||patients with atrial fibrillation without heart failure|Patients with cardiac function ejection fraction more than 35% and underwent Left atrial appendage closure in the period covered by the study
16329550|NCT04472858|Experimental|Cholangiocarcinoma|Cholangiocarcinoma
16329551|NCT04472858|Experimental|Squamous cell carcinoma of the head and neck|Squamous cell carcinoma of the head and neck（HNSCC）
16329552|NCT04472858|Experimental|Endometrial cancer|Endometrial cancer
16329553|NCT04472845|Experimental|1 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be of 26Gy in 5 fractions over 1 week in the study arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 34Gy.Supraclavicular fossa(SCF) and axilla level III will be treated in patients with T3-4 disease with lymphovascular invasion, grade 3 or N2 disease and T3-4 disease treated with neoadjuvant chemotherapy after adequate axillary dissection. Level I and II axilla will only be irradiated in patients with inadequate axillary dissection(<10 lymph nodes). Internal mammary node (IMNs) radiation will be done in T3-4 central and inner quadrant lesions and patients with N2 disease. IMNs will be irradiated with a separate single field. The first five intercostal spaces will be included in the IMN target volume.
16329554|NCT04472845|Active Comparator|2 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be 34Gy in 10 fractions over 2 weeks in the control arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 42 Gy.
16329555|NCT04472832|Placebo Comparator|Treatment A|Participants will receive a single oral dose of mitapivat-matching placebo under fasted conditions on Day 1 of each of 4 periods.
16329556|NCT04472832|Experimental|Treatment B|Participants will receive a single oral dose of mitapivat 100 milligrams (mg) and placebo under fasted conditions on Day 1 of each of 4 periods.
16329557|NCT04472832|Experimental|Treatment C|Participants will receive a single oral dose of mitapivat 100 mg and placebo under high-fat meal conditions on Day 1 of each of 4 periods.
16329558|NCT04472832|Experimental|Treatment D|Participants will receive a single oral dose of mitapivat 300 mg under fasted conditions on Day 1 of each of 4 periods.
16329559|NCT04472819|Experimental|SHR2285 Part 1A|Participant received one of 7 dose levels of SHR2285 tablet as single-dose oral administration
16329560|NCT04472819|Placebo Comparator|Placebo Part 1A|Single ascending doses of placebo orally
16329561|NCT04472819|Experimental|SHR2285 Part 1B|Participant received one dose of SHR2285 tablet as single-dose oral administration
16329562|NCT04472819|Placebo Comparator|Placebo Part 1B|Single doses of placebo orally
16329563|NCT04472819|Experimental|SHR2285 Part 2|Participant received one of 4 dose levels of SHR2285 tablet as multi-dose oral administration
16329564|NCT04472819|Placebo Comparator|Placebo Part 2|Multiple ascending doses of placebo orally
16329565|NCT04472806|Experimental|chemotherapy+Endostar+Toripalimab(JS001)|
16329566|NCT04472793||Full-Time CCHMC Employees|
16329567|NCT04472780|Experimental|HBOT Group|will benefit from HBOT
16329568|NCT04472780|No Intervention|Control group|will benefit from the conventional treatment
16329569|NCT04472767|Experimental|Cabozantinib with Ipilimumab/Nivolumab and TACE|"Subjects receive Cabozantinib 40 mg daily on days 1-28 of a 28 day cycle, this is to be started 7-14 days after the last TACE procedure.
~Nivolumab 480 mg IV on day 1 of a 28 day cycle (cycle 2 and beyond), this is to be started 7-14 days after the last TACE procedure.
~Nivolumab: 3mg/kg IV on day 1 of a 21 day cycle x 1 dose.
~Ipilimumab: 1 mg/kg on day 1 of a 21 day cycle x 1 dose
~TACE: Within 3-4 weeks of cycle 1 day 1; may be done up to 3 times (9-12 weeks total), the intervals between each TACE treatment can vary based on investigator's discretion"
16329570|NCT04472754||A(healthy control group)|patients who did not have ischemic stroke and whose TCM constitution was dialectically peaceful;
16329571|NCT04472754||B|Patients with no ischemic stroke and whose TCM constitution was dialectical with damp phlegm constitution
16329572|NCT04472754||C|patients with ischemic stroke diagnosed with phlegm dampness syndrome
16329573|NCT04472754||D|patients with ischemic stroke diagnosed as non-phlegm dampness syndrome
16329574|NCT04472741|Other|FUSE|wide angle colonoscope
16329575|NCT04472741|Other|HD Pentax i10 colonoscopes|SFV instrument
16329576|NCT04472741|Other|Endocuff|Cuff on SFV
16329577|NCT04472728|Experimental|BIO101|BIO101 350 mg bid
16329578|NCT04472728|Placebo Comparator|Placebo|Placebo
16329579|NCT04472715|Experimental|follicular unit extraction|extraction of hair follicle unit from donar area and tranplant it into recepient bald area
16329580|NCT04472715|Experimental|foolicular unit extraction and platelet rich plasma|the same procedure mentioned above coupled with session of platelet rich plasma before and after transplantation
16329581|NCT04472702|Experimental|Subjects with knee OA using ultrasound for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to ultrasound (N=45) cRFA treatment arm.
16329582|NCT04472702|Experimental|Subjects with knee OA using fluoroscopy for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to fluoroscopic (N=45) cRFA treatment arm.
16329583|NCT04472689|Active Comparator|Lidocaine group|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
16329584|NCT04472689|Placebo Comparator|Control group|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation.
16329585|NCT04472676|Experimental|LY3473329 (Part A)|LY3473329 administered orally.
16329586|NCT04472676|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
16329587|NCT04472676|Experimental|LY3473329 (Part B)|LY3473329 administered orally.
16329588|NCT04472676|Experimental|Placebo (Part B)|Placebo administered orally.
16329589|NCT04472663||Cohort 1|Retrospective Long-term Chart Review
16329590|NCT04472663||Cohort 2|Prospective-Retrospective Chart Review and Humanistic Burden
16329591|NCT04472650|Experimental|Sitravatinib Free Base + Malate Salt|"Period 1: sitravatinib free base capsule on Day 1 of the 15 day cycle
~Period 2: sitravatinib malate salt capsule on Day 1 of the 15 day cycle"
16329592|NCT04472650|Experimental|Sitravatinib Malate Salt + Free Base|"Period 1: sitravatinib malate salt capsule on Day 1 of the 15 day cycle
~Period 2: sitravatinib free base capsule on Day 1 of the 15 day cycle"
16329593|NCT04472637|Experimental|Atorvastatin|They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.
16329594|NCT04472637|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 24 weeks.
16329595|NCT04472624|Experimental|Fasting arm|Participants will be fasting during 72 hours
16329596|NCT04472624|Experimental|Diet arm|Participants will be using ketogenic diet for 14 days
16329597|NCT04472611|Experimental|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
16329598|NCT04472611|No Intervention|Standard of care (SOC)|Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization
16329601|NCT04472585|Active Comparator|Ivermectin alone|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
16329602|NCT04472585|Active Comparator|Ivermectin with Zinc|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
16329603|NCT04472585|Placebo Comparator|Placebo|Placebo drug plus standard care
16329604|NCT04472585|Active Comparator|Ivermectin (oral) alone|Oral ivermectin 0.2mg/kg/day
16329605|NCT04472585|Active Comparator|Ivermectin (oral) with Zinc|Oral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
16329606|NCT04472585|Active Comparator|Zinc Alone|20mg Zinc Sulphate 8 hourly plus standard care
16329607|NCT04472559|Experimental|Self-acupressure|
16329608|NCT04472559|No Intervention|Control|
16329609|NCT04472546|Other|Control subject group|"Divided in 5 subgroups :
~A': associated to acne of the face subgroup
~B' : associated to atopic dermatitis of the upper limb subgroup
~C' : associated to vulgar plaque psoriasis subgroup
~D' : associated to telangiectasic erythrocouperosis papule of the face (rosacea) subgroup
~E' : associated to seborrheic dermatitis of scalp subgroup"
16329610|NCT04472546|Other|Subject group with dermatitis|"Divided in 5 subgroups :
~A : acne of the face subgroup
~B : Atopic dermatitis of the upper limb subgroup
~C : Vulgar plaque psoriasis subgroup
~D : Telangiectasic erythrocouperosis papule of the face (rosacea) subgroup
~E : Seborrheic dermatitis of scalp subgroup"
16329611|NCT04472533||CTEPH|Patients diagnosed with chronic thromboembolic pulmonary hypertension
16329612|NCT04472533||CTED|Patients diagnosed with chronic thromboembolic disease but no evidence of pulmonary hypertension
16329613|NCT04472533||Control|Healthy control subjects
16329614|NCT04472520|Experimental|Subject getting an ECG|Subjects getting an ECG will have AliveCore tracings obtained in 3 configurations; between right hand and left hand, between left hand and left lower leg (thigh, calf, and foot) and between right hand and left lower leg (thigh, calf, and foot).These configurations will be obtained with the participant lying in bed and in a sitting position.
16329615|NCT04472494|Experimental|Abatacept + Standard of care|
16329616|NCT04472494|Placebo Comparator|Placebo infusion + Standard of care|
16329617|NCT04472481|Other|group II|50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months
16329618|NCT04472468|Experimental|Treatment (pericardiotomy)|"Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.
~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.
~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.
~Standard pericardiocentesis with prolonged drainage is performed afterwards.
~Pericardial drain is removed when output is less than 100cc/day"
16329619|NCT04472468|No Intervention|Control (standard pericardiocentesis)|"Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.
~Pericardial drain is removed when output is less than 100cc/day"
16329620|NCT04472455||Screen Negative Group|All women who screen negative at Visit 1.
16329621|NCT04472455||Screen Positive Group|All women who screened positive at Visit 1 and were invited to Visit 2
16329622|NCT04472455||10% Of Screen Negative Group|10% of women who screened negative at Visit 1 and were invited to Visit 2
16329623|NCT04472442|Experimental|High Intensity Training with Intermittent Hypoxia|The primary goal will be provide acute intermittent hypoxia (9% PO2; 1 min on 1 min off) prior to stepping training while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
16329624|NCT04472442|Sham Comparator|High Intensity Training with Sham Hypoxia|The primary goal will be provide sham intermittent hypoxia (20% PO2) prior to performing continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
16329625|NCT04472429|Placebo Comparator|Group A : carboplatin+paclitaxel+placebo|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle
16329626|NCT04472429|Experimental|Group B : carboplatin+paclitaxel+retifanlimab|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle
16329627|NCT04472416|No Intervention|Standardized analgesic protocol alone|Abdominal VAC dressing change using an standardized analgesic protocol alone.
16329628|NCT04472416|Experimental|VRD + standardized analgesic protocol|Abdominal VAC dressing change using standardized analgesic protocol + virtual reality device
16329629|NCT04472403||PFLL Group|"Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/m2) on day 1 and day 28, every 60 days.
~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
16329630|NCT04472403||Non-PFLL Group|"Patients were treated with other platinum-based chemotherapy every 21 days including:
~PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.
~GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.
~TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1.
~TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5.
~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
16329631|NCT04472390||Tapering|TNF-α inhibitors
16329633|NCT04472377|Experimental|study population|"We enroll a total of 1,200 women, as follows,
~120 cases with no history or current cervical intraepithelial lesion or malignancy.
~180 cases with a history of abnormal Pap test including ASCUS, CIN1, or atypical glandular cell.
~240 cases with a history of atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.
~240 cases with current ASCUS, CIN1, or atypical glandular cell.
~420 cases with current abnormal Pap test as atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma."
16329634|NCT04472364|Experimental|HemoPill|All participants will receive the blood detection capsule HemoPill Acute ®.
16329635|NCT04472351|Experimental|ASCEND-I|Computerized WM training with Rehacom will be implemented in daily 30-minute sessions that are scheduled prior to the participant's occupational therapy (OT) session as an adjunct to routine rehabilitation. Tasks are tailored to the participant's current ability level and are adaptive to performance changes. During these sessions, the study staff member will use guided questioning to help the participant anticipate challenges, reflect on performance, and link computerized exercises to the Multicontext sessions. The Multicontext treatment sessions will be delivered within the participant's OT session by an OT. The Multicontext approach helps individuals to self-discover WM-related error patterns and learn to anticipate WM performance challenges through repeated practice using functionally-relevant activities. The OT conducts guided questioning pre- and post-task to help the participant anticipate challenges and self-discover WM strategies.
16329636|NCT04472351|No Intervention|Enhanced Usual Care|The control condition will account for the time spent with rehabilitation therapists and study staff and provide more general cognitive stimulation. The control group will receive usual, standard of care occupational therapy during OT by inpatient rehabilitation staff who are not trained in the Multicontext approach. The standard OT session often focuses on cognition in a non-standardized and non-targeted manner without the targeting of WM and guided self-discovery of the Multicontext approach. To control for the cognitive training element of ASCEND, individuals randomized to the control condition will meet with a study staff member for 30 minutes of general cognitive stimulation that includes word-searches, crossword puzzles, and/or jigsaw puzzles.
16329638|NCT04472325||Atypical Parkinson's Disease patients|This group consists of patients includes 35 patients with Progressive Supranuclear Paralysis (PSP), 35 patients with Multiple System Atrophy (MSA), and 35 patients with Cortico-Basal Degeneration (CBD).
16329639|NCT04472325||Idiopathic Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD)
16329640|NCT04472325||Healthy volunteers|"The 96 healthy volunteers should meet the following criteria:
~Between 50-80 years old
~Right-handed
~MMSE score greater than or equal to 26
~Able to understand study requirements and give informed consent"
16329641|NCT04472312||Cirrhotic patients undergoing a liver transplantation|The investigators aim to conduct a prospective observational, non-interventional study including all cirrhotic patients undergoing a liver transplantation with a planned use of vasopressin during the surgery.
16329642|NCT04472299|Experimental|Experimental|Participants in this group will receive the intervention.
16329643|NCT04472299|No Intervention|Control|Participants in this group will receive no intervention.
16329644|NCT04472286||Pediatric Cancer Survivors|Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.
16329645|NCT04472273||high-flow nasal cannula group|Group 1
16329646|NCT04472273||classic nasal cannula group|Group 2
16329651|NCT04472247||Critical Care Patients|Critical care patients requiring mechanical ventilation via an endotracheal tube, with invasive hemodynamic monitoring via an arterial line, and receiving intravenous sedation by continuous infusion (propofol, midazolam).
16329652|NCT04472234|Other|BPA level|BPA (Bisfenol A) in urine, blood and follicle fluid samples
16329653|NCT04472221|Experimental|Vascular Access Venous Hypertension|Swollen upper limb with synthetic Arteriovenous graft
16329654|NCT04472208|Experimental|Ambulatory Monitoring Solution|The evaluable device is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
16329655|NCT04472195|Experimental|Experimental|The experimental group will review a pre-induction airway management plan for their upcoming case and undergo a scripted 10-minute RCDP session with an airway coach within 1 hour of patient intubation. The intubation approach (DL vs. video assisted DL) will be chosen by the primary case attending and communicated to the airway coach to simulate the planned laryngoscopy attempt. The experimental group will then proceed with their scheduled case with a member of the research team observing the laryngoscopy attempt(s) to capture data.
16329656|NCT04472195|No Intervention|Control|The trainees in the control group will have no interventions by the research team, only observation of the intubation and documentation of the same details.
16329657|NCT04472182|Experimental|Fluoride varnish with xylitol coated calcium and phosphate|
16329658|NCT04472182|Active Comparator|Conventional Fluoride varnish|
16329659|NCT04472169||Severe haemophila A patients with or without inhibitors|
16329660|NCT04472156|Experimental|Transfer of mosaic embryo|Women will have a mosaic embryo transferred to their uterus after in vitro fertilization (IVF) with pre implantation genetic testing completed at Colorado Center for Reproductive Medicine.
16329661|NCT04472143|Experimental|Granisetron Transdermal Delivery System|The patch will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days
16329662|NCT04472130||Early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset less than 5 years
16329663|NCT04472130||Non-early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset more than 5 years
16329664|NCT04472130||Multiple System Atrophy|100 patients with Multiple System Atrophy based on Second consensus statement on the diagnosis of MSA
16329665|NCT04472130||Progressive Supranuclear Palsy|100 patients with Progressive Supranuclear Palsy based on Clinical research criteria for diagnosis of PSP
16329666|NCT04472130||Alzheimer's Disease|100 patients with Alzheimer's Disease by Diagnostic and Statistical Manual of Mental disorder, Fifth edition (DSM-5) criteria
16329667|NCT04472130||Motor Neuron Disease|200 patients with Motor Neuron Diseases by revised El Escorial criteria or Awaji ALS criteria
16329668|NCT04472130||Small Vessel Disease|200 patients with cerebral Small Vessel Diseases
16329669|NCT04472130||Frontotemporal Dementia|100 patients with Frontotemporal Dementia by International consensus criteria for behavioral variant FTD (FTDC) or Primary Progressive Aphasia by Gorno-Tempini
16329670|NCT04472130||Healthy Control|200 age and sex matched healthy controls
16329671|NCT04472117|Experimental|Usual care and usual care plus video|Phase I (completed 3/31/2021): A sample of patients in phase I will complete a qualitative interview prior to or after surgery. Twenty-five patients (15 pre-operatively and a separate 10 post-operatively) will be selected to participate in an in-person/phone interview. Phase II: A separate group of women will compose phase II. All patients (N = 100) in phase II will complete discrete-choice surveys. Patients in phase III of the study will be randomized evenly to usual care plus video or usual care only.
16329672|NCT04472104|Active Comparator|MBCT-S|Mindfulness-Based Cognitive Therapy for sexuality (MBCT-S) which incorporates several empirically supported therapeutic approaches, integrating elements of education, mindfulness meditation skills, and sex therapy.
16329673|NCT04472104|Active Comparator|SexEd|Sexuality education on sexual desire, sexual distress, and sexual pain.
16329674|NCT04472091|Experimental|Genicular artery embolization|"Participants will undergo the genicular artery embolization (GAE) procedure for the treatment of moderate to severe knee osteoarthritis. A total of 30 patients will be enrolled in the single treatment arm of the study.
~The study will involve a screening period in which patient eligibility is determined. Once eligibility is confirmed, patients will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ). Following treatment, patients will undergo follow-up at 1, 6, 12, and 24 months post GAE."
16329675|NCT04472065|Active Comparator|Subjects receiving Probiotic Dietary Supplement|
16329676|NCT04472065|Placebo Comparator|Subjects receiving Placebo|
16329677|NCT04472052||Appendectomy|Patients who required appendectomy for suspected acute appendicitis
16329678|NCT04472039||Studygroup|Retrospective analysis of OCT, IOP and distance corrected visual acuity from the patients history.
16329680|NCT04472000|Experimental|Vitamin C|Patients who are assigned to the experimental treatment group will be given extended release capsules with 500 mg of ascorbic acid orally two times daily, packed in PET/PP-bottles identical as used for the licenced product.
16329681|NCT04472000|Placebo Comparator|Placebo|The control intervention of this study consists of treatment with no active substance (placebo) but in the same schedule as the experimental treatment (verum).
16329682|NCT04471987|Experimental|Treatment|"The study will take place in two stages:
~In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.
~Following successful identification of the RD, the study will proceed with a dose expansion part and 40 patients will be treated at the RD dose level."
16329683|NCT04471974|Experimental|Safety Cohort|Patients receive 96mg pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16329684|NCT04471974|Experimental|Cohort A: Transdifferentiated mCRPC|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16329685|NCT04471974|Experimental|Cohort B: mCRPC without evidence of transdifferentiation|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16329686|NCT04471961|Experimental|Children with cancer (Proband) with theirs parents|
16329687|NCT04471948|Experimental|Fractional picosecond laser 1,064 nm laser|1 arm The subjects with enlarged pores were treated with fractional picosecond laser 1,064 nm laser
16329688|NCT04471935|Other|At home Speech Hero therapy|
16329689|NCT04471922|Experimental|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
~"
16329690|NCT04471922|Placebo Comparator|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
16329691|NCT04471922|Active Comparator|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
16329692|NCT04471909|Experimental|Chronic Dissection|
16329693|NCT04471909|Experimental|Aneurysm|
16329694|NCT04471909|Experimental|Penetrating Aortic Ulcer and/or Intramural Hematoma|
16329695|NCT04471896|Experimental|Treatment Arm|Participants will receive an infrared therapy device for use at home for 60 days. Participants will use the device every day for 10-20 minutes during the intervention period.
16329696|NCT04471857|Experimental|Hypnosis|A brief session of hypnosis just before child starts with anorectal manometry
16329697|NCT04471857|No Intervention|Control|No hypnosis session, standard care
16329700|NCT04471831|Experimental|Stroke survivors with COVID19|The active intervention group
16329701|NCT04471831|Placebo Comparator|Non-stroke individuals with COVID19|Matching for age, sex and co-morbid status with the stroke survivors
16329702|NCT04471818|Experimental|Ketamine|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
16329703|NCT04471818|Placebo Comparator|Placebo|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
16329704|NCT04471805|Sham Comparator|Women Sham 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
16329705|NCT04471805|Experimental|Women tDCS 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
16329706|NCT04471805|Sham Comparator|Women Sham 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (4 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
16329707|NCT04471805|Experimental|Women tDCS 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16329708|NCT04471805|Sham Comparator|Men Sham 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
16329709|NCT04471805|Experimental|Men tDCS 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
16329710|NCT04471805|Sham Comparator|Men Sham 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (4 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
16329711|NCT04471805|Experimental|Men tDCS 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16329712|NCT04471792|Experimental|Creatine monohydrate|Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.
16329713|NCT04471792|Placebo Comparator|Cellulose|These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.
16329714|NCT04471779|Experimental|Disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.
16329779|NCT04471324|Experimental|EBUS cryo probe|Patients receive a transbronchial cryobiopsy using an eBUS cryo probe
16329715|NCT04471779|No Intervention|Non-disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.
16329716|NCT04471766|Experimental|Certified cloth face mask plus preventive information|Certified cloth face mask
16329717|NCT04471766|Active Comparator|Information on COVID-19 prevention|Advice on how to prevent COVID-19 according to the government´ policy.
16329718|NCT04471753||Patients with disorders of consciousness|Patients with medical diagnosis of prolonged disorders of consciousness (≥28 days) were included in neurosurgery, neurology, and neurorehabilitation units.
16329719|NCT04471740|Experimental|Normal-pressure hydrocephalus only|Patients suffering from normal-pressure hydrocephalus with NO sleep apnea
16329720|NCT04471740|Active Comparator|Normal-pressure hydrocephalus with sleep apnea|Patients suffering from normal-pressure hydrocephalus with sleep apnea
16329721|NCT04471727|Experimental|Part 1 (Dose Escalation)|HPN328 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
16329722|NCT04471727|Experimental|Part 2 (Dose Expansion)|HPN328 is IV administered once weekly for about 1 hour at the recommended phase 2 dose (2) established in Part 1.
16329723|NCT04471714|Experimental|Control|Control participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
16329724|NCT04471714|Experimental|Spinal Cord Injury|Participants with a spinal cord injury will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
16329725|NCT04471688||patients|Preoperative patients needing transfusions
16329726|NCT04471675|Experimental|Experimental: solid tumors|Albumin-bound docetaxel by intravenous infusion.Patients receive albumin-bound docetaxel once every three weeks (a Cycle), starting at a dose of 50mg/m2.
16329727|NCT04471649||Experimental|Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen.
16329728|NCT04471649||Active Comparator|Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen
16329729|NCT04471636|Experimental|Telemedicine Care|Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.
16329730|NCT04471636|No Intervention|Control|Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.
16329731|NCT04471623|Experimental|DeTAP Study App and Home Devices|Monitoring of OAC administration, OAC adherence, and clinical status through combined decentralized technologies
16329732|NCT04471610|No Intervention|Control group|Group A: Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. The diagnostic and therapeutic decisions in the control Group and in the Intervention group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.
16329733|NCT04471610|Experimental|POC-available group|Group B:Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The blood collection (10 ml of Lithium Heparin blood) for these tests will be done in the morning together with the regularly blood collection. The study team does the the analysis on the study devices. The result of the test will be provided directly to the responsible physician. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.
16329734|NCT04471597|Placebo Comparator|Control group|patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.
16329735|NCT04471597|Active Comparator|bupivacaine group|patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.
16329736|NCT04471584|Active Comparator|Abbott Confirm Rx|All patients randomized to this group will be implanted Abbott Confirm RX
16329737|NCT04471584|Active Comparator|Medtronic Reveal LINQ|All patients randomized to this group will be implanted Medtronic Reveal LINQ
16329738|NCT04471584|Active Comparator|Biotronik Biomonitor|All patients randomized to this group will be implanted Biotronik Biomonitor
16329739|NCT04471571|Active Comparator|Resin infiltration group|Enamel lesions for this group will be treated only by resin infiltration.
16329740|NCT04471571|Experimental|Microabrasion + resin infiltration group|Enamel lesions for this group will be treated first by microabrasion followed by resin infiltration.
16329741|NCT04471558||Music group|A part of the care is realized with music.
16329742|NCT04471558||Control group|The entire care is realized without music.
16329743|NCT04471545|Experimental|Interventional group|Intervention arm: PECS II block with ropivacaine
16329744|NCT04471545|Placebo Comparator|Control group|Control arm: PECS II block with placebo (saline)
16329745|NCT04471532|Experimental|Behavior change intervention|A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
16329746|NCT04471532|No Intervention|Control|No attention
16329747|NCT04471519|Experimental|BBV152A - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
16329748|NCT04471519|Experimental|BBV152B - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
16329749|NCT04471519|Experimental|BBV152C - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152C], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
16329750|NCT04471519|Active Comparator|Placebo - Phase I|0.5 mL of Placebo will be administered intramuscularly twice at Day 0 and Day 14.
16329751|NCT04471519|Experimental|BBV152A - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28.
16329752|NCT04471519|Experimental|BBV152B - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28
16329753|NCT04471506|Other|study group will receive interval training and diet advices|exercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program)17.
16329754|NCT04471506|Other|diet recommendations|The control group will receive diet recommendations. The volunteers will follow diet recommendations for 12 weeks
16329755|NCT04471480|Experimental|group A，TCCA|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +anlotinib 10mg, PO, d1-14, q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab plus anlotinib for maintenance therapy until PD or intolerable toxicity
16329756|NCT04471480|Experimental|group B，TCC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab for maintenance therapy until PD or intolerable toxicity
16329757|NCT04471480|Other|group C，TC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w
16329758|NCT04471467||group F|Using tracheal tube fixation method （According to the needs of the surgery, the surgeon who did not participate in the trial）
16329759|NCT04471467||group N|No tracheal tube fixation （According to the needs of the surgery, the surgeon who did not participate in the trial）
16329760|NCT04471441|Experimental|CertiroBell Tablet|De novo liver transplant recipients will be randomized after liver transplant operation.
16329761|NCT04471441|Active Comparator|Mycophenolate mofetil Tablet/Capsule|De novo liver transplant recipients will be randomized after liver transplant operation.
16329762|NCT04471428|Experimental|Atezolizumab + Cabozantinib|Participants will receive atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on days 1-21 of each cycle.
16329763|NCT04471428|Active Comparator|Docetaxel|Participants will receive docetaxel on Day 1 of each 21-day cycle.
16329764|NCT04471415|Experimental|Part 1a & Part 1b|"Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2 via intravenous injection
~Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 at 10 mg via subcutaneous injection"
16329765|NCT04471415|Experimental|Part 2|"Cohort 1a: Phase 1 single-agent safety expansion at the of intravenous DRP-104 in patients with advanced solid tumors (N=14 up to 20 patients);
~Cohort 1b: Phase 1 single-agent safety expansion at the of subcutaneous DRP-104 in patients with advanced solid tumors (N=14 up to 20 patients);
~Cohort 2: Phase 2a expansion at the of DRP-104 at the recommended selected route of administration (intravenous or subcutaneous) in patients with locally advanced or metastatic NSCLC whose tumors contain a KEAP1 mutation, NFE2L2 mutation and/or STK11 mutation (N=55 patients)
~Cohort 3: Phase 2a expansion at the MTD of DRP-104 at the recommended selected route of administration (intravenous or subcutaneous) in recurrent, unresectable or metastatic SCCHN (N=15-25 patients)."
16329766|NCT04471415|Experimental|Part 3|Dose escalation of DRP-104 at 1 dose level below declared MTD at the selected recommended route of administration (intravenous or subcutaneous) in combination with atezolizumab in patients with advanced solid tumors previously treated with an anti-PD-1, anti PD-L1, and/or anti-CTLA-4 antibody (up to approximately (N=12 patients).
16329767|NCT04471415|Experimental|Part 4|Dose expansion at the MTD of DRP-104 at the selected recommended route of administration (intravenous or subcutaneous) with atezolizumab (N=14 patients).
16329768|NCT04471402||All subjects recruited|"All subjects recruited will be given 3mcg/kg intranasal Precedex through an atomiser, divided equally between two nostrils. They will be observed and sedation score will be recorded every 5 minutes according to the University of Michigan Sedation Scale (UMSS). Pulse oximetry and Blood pressure cuff will be applied whenever they accept these monitoring.
~A buccal swab sample will be taken from all children and the identified genes will be analysed and compared between the different responders (fast, normal, slow or non-responders)."
16329769|NCT04471389||Hanzhong adolescent hypertension cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas was recruited in 1987. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
16329770|NCT04471389||Mei county adult salt-sensitive hypertension cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
16329771|NCT04471376|Active Comparator|Sugammadex group|
16329772|NCT04471376|No Intervention|control group|
16329773|NCT04471363||Cancer Specific Exercise Education|This subsample of participants will watch an audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
16329774|NCT04471363||Control|All participants will be asked to indicate their exercise knowledge, self-efficacy, beliefs and intentions.
16329775|NCT04471337|Experimental|Arm A: Moderately impaired renal function|Participants with moderately impaired renal function will receive multiple doses of BAY1817080.
16329776|NCT04471337|Experimental|Arm B: Normal renal function matched to Arm A|Participants with normal renal function matched to Arm A will receive multiple doses of BAY1817080.
16329777|NCT04471337|Experimental|Arm C: End stage renal disease on dialysis|Participants with ESRD requiring dialysis will receive single dose of BAY1817080.
16329778|NCT04471337|Experimental|Arm D: Normal renal function matched to Arm C|Participants with normal renal function matched to Arm C will receive single dose of BAY1817080.
16329780|NCT04471311|No Intervention|Primary closure of midline laparotomy|Primary closure of midline laparotomy
16329781|NCT04471311|Experimental|Sub-lay mesh supported closure|Sub-lay permanent mesh supported the closure
16329782|NCT04471298|Active Comparator|Active dosage group 1|Qishenyiqi dripping pills, 3.12g, oral, three times a day
16329783|NCT04471298|Active Comparator|Active dosage group 2|Qishenyiqi dripping pills, 4.68g, oral, three times a day
16329784|NCT04471298|Active Comparator|Active dosage group 3|Qishenyiqi dripping pills, 6.24g, oral, three times a day
16329785|NCT04471298|Placebo Comparator|Control dosage group 1|Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day
16329786|NCT04471298|Placebo Comparator|Control dosage group 2|Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day
16329787|NCT04471298|Placebo Comparator|Control dosage group 3|Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day
16329788|NCT04471285|Active Comparator|true acupuncture|patient will get treatment according to the point the will help the symphysiolysis according to the Alternative medicine
16329789|NCT04471285|Sham Comparator|Sham acupuncture|patient will get treatment according to the point the will NOT help the symphysiolysis according to the Alternative medicine
16329790|NCT04471272|Experimental|RFA using gradual RF energy delivery mode|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
16329791|NCT04471259||Patients' injured side|The Biodex, AOFAS, VAS were tested on the patients' injured side
16329792|NCT04471259||Patients' uninjured side|The Biodex, AOFAS, VAS were tested on the patients' uninjured side
16329793|NCT04471246|Experimental|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
16329794|NCT04471246|Active Comparator|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
16329795|NCT04471233|Experimental|Multimodal analgesia regimen including pregabalin|For the pregabalin group, patient will be provided with an oral preoperative pregabalin dose of 150mg on the day of surgery. Patient will continue pregabalin 75mg two times a day, for two weeks postoperatively. For both the intervention and control groups, the operative technique and additional perioperative analgesic modalities will follow a standard protocol
16329796|NCT04471233|Active Comparator|Multimodal analgesia regimen not including pregabalin|For the non-pregabalin group, patient will be undergo total knee arthroplasty with the same operative technique and additional perioperative analgesic modalities will follow a standard protocol
16329797|NCT04471220|Active Comparator|Low FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 10 L/min).
16329798|NCT04471220|Active Comparator|Low FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 40-50 L/min).
16329799|NCT04471220|Active Comparator|High FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 10 L/min).
16329800|NCT04471220|Active Comparator|High FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 40-50 L/min).
16329801|NCT04471207|Experimental|Intelligent Biometrics - Prolonged Exposure (Therapist Guided).|In the therapist-guided group, Study Therapists will virtually accompany patients during IVEs and use actionable biometric and subjective data during IVEs (e.g., HR, GSR, SUDS) to modify the assignments in real-time.
16329802|NCT04471207|Active Comparator|Intelligent Biometrics - Prolonged Exposure (Record Only).|In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.
16329803|NCT04471194|Experimental|Self-Sampling Intervention|Participants in this group will receive cervical and colorectal cancer self-sampling kits, instructions for completing the self-sampling kits, and educational materials about cervical and colorectal cancer.
16329804|NCT04471194|No Intervention|Control|Participants in this group will receive a standardized letter informing them that they are out-of-date for both cervical and colorectal cancer screenings and should schedule an appointment with their provider to receive these screenings.
16329805|NCT04471181||All patients with ruptured abdominal aortic aneurysms|"All patients will undergo CTA to confirm the diagnosis. The use of balloon for aortic clamp in case of haemodynamic instability can be used.
~All patients included in the research study must undergo standard EVAR with a bifurcated graft or an aorto-uni-iliac and a femoral to femoral crossover. In aneurysms with short proximal neck down to 4mm, or in cases where completion angiography indicates type Ia endoleak, the Heli-FX EndoAnchor system is recommended to be used, as indicated. All patients will have plain abdominal x-rays on discharge. Participants will undergo CTA in 3months and annually post-op.. In case of an adverse event before the 3 months follow up CTA, a more urgent imaging might be requested and proceed to appropriate action according to the findings."
16329806|NCT04471168|Experimental|Cryo-Auriculotherapy|Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
16329807|NCT04471168|Sham Comparator|Control group|Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
16329808|NCT04471155|Active Comparator|Holep|patient underwent laser prostatectomy
16329809|NCT04471155|Active Comparator|open prostatectomy|patient underwent open prostatectomy
16329810|NCT04471142|Experimental|Group A|Intervention group with preventive application of compressive bandages in addition to suction drain (routine adopted at the institution).
16329811|NCT04471142|No Intervention|Group B|Group control. The patient will follow the institution's routine with only the suction drain.
16329812|NCT04471129|Other|High-Flow Oxygen Therapy, followed by Non-Invasive Ventilation|oxygenation first by High-Flow Oxygen Therapy, then by O2C, then by Non-Invasive Ventilation
16329813|NCT04471129|Other|Non-Invasive Ventilation, followed by High-Flow Oxygen Therapy|oxygenation first by Non-Invasive Ventilation, then by O2C, then by High-Flow Oxygen Therapy
16329919|NCT04470375|Experimental|VR pain education|Students receiving the 45 minute pain education through Virtual Reality
16329814|NCT04471116|Active Comparator|Therapy group|Patients in the therapy group took 1 sachet of OMNi-BiOTiC® FLORA plus + (= 2 g) dissolved in 1/8 l of water once a day
16329815|NCT04471116|No Intervention|Control group|Patients in the control group received no additional medication.
16329816|NCT04471103|Experimental|Real-Time Delphi Method|The Real-Time Delphi Method involves a single-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant once they have rated an outcome. They can then modify how they rated the outcome based on this feedback if they wish. Participants can also re-visit and re-rate outcomes as many times as they wish when the survey is live. Duration will span approximately 5 weeks.
16329817|NCT04471103|Active Comparator|Multi-round Delphi Method|The Multi-Round Delphi Method involves a three-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant at the end of Round 1 and the end of Round 2. Participants can then modify how they rated the outcome based on feedback, in Rounds 2 and 3, if they wish. Each survey Round will run for 3 weeks approximately. In between survey Rounds, there will be a downtime of approximately 10 days before providing feedback and a further 7 days before starting the next round. Duration will span approximately 14 weeks.
16329818|NCT04471077||Favorable outcome of bariatric surgery|Excess weight loss above 50%
16329819|NCT04471077||Unfavorable outcome of bariatric surgery|Excess weight loss below 50%
16329820|NCT04471064|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg; multiple dose phase
16329821|NCT04471064|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg; multiple dose phase
16329822|NCT04471064|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg; multiple dose phase
16329823|NCT04471064|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg; multiple dose phase
16329824|NCT04471064|Experimental|XY0206-150mg|Drug:XY0206;Dosage form:Tablet;Dosage：150mg; multiple dose phase
16329825|NCT04471064|Experimental|XY0206-200mg|Drug:XY0206;Dosage form:Tablet;Dosage：200mg; multiple dose phase
16329826|NCT04471064|Experimental|XY0206-250mg|Drug:XY0206;Dosage form:Tablet;Dosage：250mg; multiple dose phase
16329827|NCT04471051||COVID19 Convalescent Plasma Treatment|Hospitalized COVID19 patients who receive COVID19 Convalescent Plasma under Expanded Access protocol NCT04372368.
16329833|NCT04471025|Active Comparator|Group I|USG guided infraclavicular block with single operator jedi grip technique
16329834|NCT04471025|Active Comparator|Group 2|USG guided infraclavicular block with conventional double operator technique
16329835|NCT04471012|Experimental|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.
~The experimental group was given a Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet during their first counseling session."
16329836|NCT04471012|No Intervention|Standard Care|The progress of the participants in the control group was tracked routinely without any specific implementation. At the end of the study, the control group was also given the same booklet.
16329837|NCT04470999|Experimental|Single arm|Venous blood and apheresis collection will be conducted
16329838|NCT04470973||Cefuroxime/Amikacin|20 patients will be included in the cefuroxime cohort and 20 patients in the amikacin cohort.
16329839|NCT04470960|Experimental|participating community centers|Training course for the community center health coordinators Professional guidance for the CC health coordinators
16329840|NCT04470947||Next generation functional drug screening|
16329841|NCT04470947||Comprehensive genomic profiling|
16329842|NCT04470947||Physician's choice|
16329843|NCT04470921||Choice for Opportunistic Salpingectomy|Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.
16329844|NCT04470908|Experimental|Zanubrutinib + Rifabutin|"Day 1: zanubrutinib
~Days 3 to 10: rifabutin
~Day 11: zanubrutinib and rifabutin"
16329845|NCT04470895||Usual falling patients|"a group enrolling the patients who completed the inclusive criteria and have had at least one fall in the last 12 months in addition to the possible fall causing the index fracture.
~These patients must answer positively the following question Have you fallen in the last 12 months, regardless of the current fracture?"
16329846|NCT04470895||Unusual falling patients|"a group enrolling the patients who also completed the inclusive criteria, but are defined as unsual falling patients. These patients must answer negatively the following question: Have you fallen in the last 12 months, regardless of the current fracture?"
16329850|NCT04470869|Experimental|OLAF group|The interventional group (OLAF) benefit from a psychiatric follow up, from virtual visiting of the patient and video interview with ICU team.
16329851|NCT04470869|Placebo Comparator|Control|The control group contains the relatives of patients hospitalized after the confinement measure but before the OLAF intervention. This group benefit from phone contact with the ICU team at the admission in ICU then two contact per week minimum to one contact per day maximum during the stay, excepting the specific phone calls associated with favorable or unfavorable evolution.
16329852|NCT04470856|Experimental|septic shock patients|"Intubated patients with septic shock receive an end-expiratory occlusion test (EEOT) and, after the test, they receive a 500 ml-fluid challenge.
~During these phases the carotid doppler changes will be recorded."
16329853|NCT04470843|Active Comparator|Acetazolamide|Group 1 (acetazolamide): Patients undergoing RALP with the peri-operative use of one-time 250 mg dose of acetazolamide
16329854|NCT04470843|Placebo Comparator|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
16329855|NCT04470830||Participants With Essential Hypertension|Participants diagnosed with essential hypertension who have been treated with azilsartan medoxomil/chlorthalidone FDC as an early therapy for participants whose blood pressure is not properly controlled by monotherapy or who require administration of multiple drugs in order to reach the target blood pressure, will be observed prospectively over a period of 5 years.
16329856|NCT04470817||Participants With Essential Hypertension|Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
16329857|NCT04470804|Experimental|Sirolimus on newly diagnosed primary acquired PRCA|A prospective research of the sirolimus efficiency on newly diagnosed primary acquired PRCA patients. Sirolimus dosage: 2mg QD with plasma concentration 4-15ng/mL. Medication time should last at least 6 months
16329858|NCT04470804|Active Comparator|Cyclosporine A on newly diagnosed primary acquired PRCA|Cyclosporine A (CsA) efficiency on newly diagnosed primary acquired PRCA patients. CsA dosage: 4mg/kg QD. Medication time should last at least 6 months
16329859|NCT04470791|Experimental|F(ab')2 antivenom plus local cryotherapy.|Group A: patients with a Crotalus snakebite, and grade II envenomation received F(ab')2 antivenom therapy and application of local cryotherapy.
16329860|NCT04470791|Active Comparator|F(ab')2 antivenom.|Group B: patients who received only F(ab')2 antivenom therapy.
16329861|NCT04470778|Experimental|BMS-986256|
16329862|NCT04470778|Experimental|BMS-986256 + Famotidine|
16329863|NCT04470765|Active Comparator|Active Treatment|Active Zida device to be delivered for use by patient
16329864|NCT04470765|Sham Comparator|Sham Treatment|Identical Sham device to be delivered for use by patient
16329865|NCT04470752|Placebo Comparator|Placebo|InOrpha solution/ml, three times daily with meals for the Treatment period, 7 or 30 days.
16329866|NCT04470752|Experimental|Capsaicin|InOrpha solution plus 1 mcg Capsaicin/ml, three times daily with meals for the Treatment period of 7 or 30 days.
16329867|NCT04470739|Active Comparator|Infants born to COVID-19 positive mothers|Infants, born to COVID-19 positive mothers, will be evaluated for cardiothymic index in their first chest X-ray.
16329868|NCT04470739|No Intervention|Infants born to COVID-19 negative mothers|Infants, born to COVID-19 negative mothers, will be evaluated for cardiothymic index in their first chest X-ray.
16329869|NCT04470726|Experimental|AIV001 Treatment Dose 1|Intradermal/intratumoral, Dose 1
16329870|NCT04470726|Experimental|AIV001 Treatment Dose 2|Intradermal/intratumoral, Dose 2
16329871|NCT04470726|Experimental|AIV001 Treatment Dose 3|Intradermal/intratumoral, Dose 3
16329872|NCT04470713||Group A - Retrospective data collection|Participants with a confirmed diagnosis, either deceased patients or patients whose survival status is not known at enrollment.
16329873|NCT04470713||Group B - Prospective data collection|Participants who are alive at enrollment. Data collection is retrospective for the time between birth and enrollment visit, and data collection is prospective from the enrollment visit onwards. Visits are performed as per local standard of care.
16329874|NCT04470700||subjects with greater than 3years delay|Subjects with delay in treatment of Urinary incontinence greater than three years
16329875|NCT04470700||subjects with less than three years delay|Subjects with delay in treatment of Urinary incontinence lesser than three years
16329876|NCT04470687|Experimental|Carotid plaque or stenosis ultrasound enhanced UF assesment|symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy
16329877|NCT04470674|Active Comparator|Arm A (Durvalumab)|Durvalumab 1500 mg IV every 4 weeks for 13 cycles.
16329878|NCT04470674|Experimental|Arm B (Durvalumab plus chemotherapy)|Durvalumab 1500 mg IV plus carboplatin AUC 5 IV and pemetrexed 500 mg/m2 IV every 3 weeks for 4 cycles followed by durvalumab and pemetrexed every 3 weeks for 13 more cycles.
16329879|NCT04470648||hosted in the center and HCWs at the epidemic period|"people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time.
~People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic"
16329880|NCT04470635||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
16329881|NCT04470635||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
16329882|NCT04470635||Healthy children with gingivitis|Systemically healthy children with gingivitis
16329883|NCT04470635||Healthy children and healthy gingiva|Systemically healthy children with healthy gingiva
16329886|NCT04470609|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
16329887|NCT04470609|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
16329888|NCT04470609|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
16329889|NCT04470609|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
16329947|NCT04470180|Experimental|Virtual Teach-to-Goal (V-TTG)|They will be randomized to receive education via a virtual learning module.
16329890|NCT04470583||Mild/moderate COVID-19 affected pregnant and postnatal women|Pregnant and postnatal women who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-50 years old.
16329891|NCT04470583||Severe/Critical COVID-19 affected pregnant and postnatal women|"Pregnant and postnatal women who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-50 years old.
~These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards."
16329892|NCT04470583||Mild/moderate COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-60 years old.
16329893|NCT04470583||Severe/Critical COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-60 years old. These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards.
16329894|NCT04470570|No Intervention|Control Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder only.
16329895|NCT04470570|Experimental|Cross-Education Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side.
16329896|NCT04470570|Experimental|Cross-Education + Blood-Flow Restriction Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side with blood-flow restriction simultaneously.
16329897|NCT04470557||Patients with COVID-19|The patients will be subjected to to laboratory analyses, a number of hematological, immunological and biochemical parameters like total leucocytic count and differential count of CBC, ESR, D- dimer levels in plasma, CRP, serum urea and creatinine levels, serum levels of AST, ALT liver enzymes, serum ferritin levels Also, CT scan of chest, clinical assessment and the severity and course of the disease.
16329898|NCT04470544|Placebo Comparator|Placebo + Standard of Care|Standard of Care will be defined by the investigators in collaboration with the sponsor on the basis of the best available evidence at the time of study initiation with placebo.
16329899|NCT04470544|Experimental|Camostat + Standard of Care|Patient will receive SOC tablets and Camostat mesilate 200 mg four times a day after each meal with Standard of Care treatment.
16329900|NCT04470531|No Intervention|Control|"Arm A :No Intervention/control: Standard treatment
~Antibiotics for secondary bacterial infection as per institutional guidelines
~Supplemental oxygen (to keep saturations between 90% to 96%)
~Intravenous hydration (to maintain euvolumia)
~Thrombo-prophylaxis as per local guidelines
~Paracetamol (oral or I/V 1gram QDS as required or regular)
~To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
16329901|NCT04470531|Experimental|intervention /experimental|"Arm B: Experimental Arm received oral co-trimoxazole + standard therapy
~The following treatments are recommended as standard therapy:
~Antibiotics for secondary bacterial infection as per institutional guidelines
~Supplemental oxygen (to keep saturations between 90% to 96%)
~Intravenous hydration (to maintain euvolumia)
~Thrombo-prophylaxis as per local guidelines
~Paracetamol (oral or I/V 1gram QDS as required or regular)
~To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
16329902|NCT04470518|Active Comparator|Intervention: Diagnostic algorithm|diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
16329903|NCT04470518|No Intervention|Usual care|"In the control arm, patients will receive 'usual care' left at the discretion of the treating physician.
~Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools.
~They are expected (but not forced) to follow the Belgian guidelines (as described in BAPCOC National guidelines and the RIZIV consensus meeting Rational use of antibiotics in children)."
16329904|NCT04470492|Experimental|Experiment|
16329905|NCT04470492|Other|Control|
16329906|NCT04470479|Experimental|Pilocarpine Hydrochloride|Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
16329907|NCT04470479|Placebo Comparator|placebo|Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks
16329908|NCT04470466|Active Comparator|short pulse and Q-switched ND-YAG laser with topical carbon|
16329909|NCT04470466|Active Comparator|Fractional CO2 Laser|
16329910|NCT04470453|Experimental|Patients with active rheumatoid arthritis|30 patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
16329911|NCT04470453|Experimental|Patients with rheumatoid arthritis into remission|30 patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
16329912|NCT04470427|Experimental|mRNA-1273|"Part A: Participants will receive 1 intramuscular (IM) injection of 100 microgram (ug) mRNA-1273 on Day 1 and on Day 29.
~Part B: Participants who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29, if the participant chooses. Participants who choose to be unblinded and was only able to receive 1 dose of mRNA-1273 due to administrative reasons, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1, if the participant chooses."
16329913|NCT04470427|Placebo Comparator|Placebo|Part A only: Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29, if the participant chooses.
16329914|NCT04470414||Recovered COVID-19 patients|Patients recovered from COVID-19 infection within three months before the start of the study.
16329915|NCT04470401|Placebo Comparator|Placebo|Abobotulinumtoxina 400 IU in 2cc of saline solution
16329916|NCT04470401|Experimental|Abobotulinumtoxina - 400IU|placebo (2cc of saline solution)
16329917|NCT04470388|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 capsule Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days.
16329918|NCT04470388|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days.
16330142|NCT04468997|Experimental|601 dose level 6 treatment|
16329920|NCT04470362|Placebo Comparator|Control group|The control group will receive an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing quadriceps power and strength.
16329921|NCT04470362|Experimental|Study group|"Participants in the study group will perform the same exercise parameters used in the control group but in a different manner.
~The isokinetic exercise will be done with a closed eye to improve the proprioception function. This exercise will be performed for 6 sets.
~Additional training will be performed by the application of three vibrators above and on both sides of the knee joint to improve the function of the Pacinian and Meissner corpuscles which is one of the included receptors in the sensation of the fatigue."
16329922|NCT04470349||LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
16329923|NCT04470349||Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
16329924|NCT04470336|Active Comparator|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
16329925|NCT04470336|Other|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
16329926|NCT04470336|Placebo Comparator|Placebo|Three capsules post-breakfast Three capsules post-dinner
16329927|NCT04470323||COVID19 patients|Patients admitted to Assiut university Hospitals diagnosed as COVID19 positive patients by PCR.
16329928|NCT04470323||healthy volunteer|as negative control for each sample
16329929|NCT04470310|Active Comparator|glimepiride|glimepiride 1mg monotherapy and glimepiride 2mg monotherapy
16329930|NCT04470310|Active Comparator|alogliptin|alogliptin 25mg monotherapy
16329931|NCT04470310|Active Comparator|alogliptin - pioglitazone|Alogliptin 25mg+pioglitazone 15mg combination
16329932|NCT04470297|Placebo Comparator|Placebo|A placebo with the same physical characteristics of the experimental drug pill will be administered at the same time and daily schedule as the experimental intervention for 10 days.
16329933|NCT04470297|Experimental|Ramelteon|A pill containing ramelteon 8mg will be administered daily at bedtime for 10 days.
16329934|NCT04470284|Active Comparator|SMBP_only|Standard treatment with SMBP
16329935|NCT04470284|Experimental|SMBP_mobile_app|SMBP with mobile App based feed-back algorithm
16329936|NCT04470271||Patients under routine hepatitis C care|Patients who are routinely followed at the treating institution. Investigators will evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
16329937|NCT04470271||Patients with hepatitis C lost of follow-up|Patients who were lost of follow-up. Participants will be contacted to evaluate if the continued HCV care at another institution, were not routinely followed by a liver-specialist or if they died. Investigators will also evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
16329938|NCT04470258|Other|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|A realistic simulation will be carried out, centered on the heuristic evaluation, by a multiprofessional team (N= 6), to evaluate the performance of the new equipment in the execution of the pre-defined skills. The prototype will be tested on a mannequin by the research team and on healthy volunteers by health professionals, where physiological parameters and interface comfort will be evaluated.
16329939|NCT04470258|Other|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The second phase will consist of a clinical trial, in the application of the non-invasive respiratory device in 10 patients with respiratory failure by COVID-19, to assess its clinical effectiveness, through the analysis of the physiological variables and patient comfort.
16329940|NCT04470245|Active Comparator|Healthy volunteers|
16329941|NCT04470245|Active Comparator|Patients undergoing surgery|We will include adults (over 18 years of age) undergoing surgical decompression of the ulnar nerve at the elbow for cubital tunnel syndrome.
16329942|NCT04470232||Patients with coxofemoral pathologies|"For the transcultural validation, a french version of the 2 self-assessment questionnaires, SUSHI-score and the HOOs-12 score will be produced.
~For the psychometric validation, 120 patients with coxofemoral pathologies will pass the two questionnaires. The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
16329943|NCT04470219|Experimental|intervention group|Participants receive rehabilitation as usual and training how to use RemindMe by personnel from the research group and an occupational therapist working at the rehabilitation clinic. The participants will use RemindMe for two months. The participants choose activities that he/she wishes to remember to carry out with support by RemindMe. An individual follow-up session will be conducted once a week by the occupational therapist to evaluate if the chosen activities were performed and discuss strategies for the continued use of RemindMe. After two months the participants decide if he/she wants to continue to use RemindMe.
16329944|NCT04470219|No Intervention|control group|The control group receive treatment as usual by the rehabilitation personnel, for example, occupational therapists give interventions that provide support for memory, it could be a paper calendar or other memory devices or strategies.
16329945|NCT04470193|Experimental|MyChildCMC Intervention Group|Parents/patients randomized into the MyChildCMC Intervention Group will use the MyChildCMC app to monitor their child's daily symptoms for the duration of the study period (3 months). The MyChildCMC app includes a daily form consisting of 12 questions assessing child's vitals, pain, seizures, mood, and feeding as well as caregiver worry for the day. Daily reminders are sent to the parent to fill out the vitals form in the app. Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
16329946|NCT04470193|No Intervention|Standard of Care Group|Parents/patients randomized into the Standard of Care Group do not use the MyChildCMC app to monitor their child's daily symptoms and are instructed to continue with regular care for their child and to continue monitoring their child's symptoms on their own without the use of the app for the duration of the study period (3 months). Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
16329948|NCT04470180|Active Comparator|standardized brief intervention|Intervention that mimics usual care to deliver inhaler technique education.
16329949|NCT04470167|Experimental|TPX-115|Subjects receive ultrasound-guided intratendinous injection of TPX-115
16329950|NCT04470167|Placebo Comparator|Placebo|Subjects receive ultrasound-guided intratendinous placebo injection
16329951|NCT04470154|Experimental|Stage I: HSK21542 0.05 μg/kg,0.15 μg/kg,0.30 μg/kg,0.80 μg/kg|
16329952|NCT04470154|Placebo Comparator|Stage I: Placebo 0.05 μg/kg,0.15 μg/kg,0.30 μg/kg,0.80 μg/kg|
16329953|NCT04470154|Experimental|Stage II: HSK21542 0.3 μg/kg,0.6 μg/kg|
16329954|NCT04470154|Placebo Comparator|Stage II: Placebo 0.3 μg/kg,0.6 μg/kg|
16329955|NCT04470141|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
16329956|NCT04470128|Experimental|Stage I: HSK21542 0.5 μg/kg|
16329957|NCT04470128|Experimental|Stage I: HSK21542 1 μg/kg|
16329958|NCT04470128|Experimental|Stage II : HSK21542 0.5 μg/kg|
16329959|NCT04470128|Experimental|Stage II : HSK21542 1 μg/kg|
16329960|NCT04470128|Active Comparator|Stage II : fentanyl 1 μg/kg|
16329961|NCT04470115|Active Comparator|General anesthesia|Patients will receive general endotracheal anesthesia with propofol, fentanyl, sevoflurane and rocuronium.
16329962|NCT04470115|Experimental|Regional anesthesia|Patients will receive femoral and lateral femoral cutaneous nerves block under ultrasonographical guidance before operation.During surgical procedure they will receive deep sedation with propofol.
16329963|NCT04470102|Other|isolated septal myectomy|Isolated extended septal myectomy
16329964|NCT04470102|Active Comparator|"Septal myectomy+ edge-to-edge"|advanced septal myectomy in combination with mitral valve repair using the edge-to-edge technique
16329965|NCT04470089|Experimental|Myramistin 0.005%|
16329966|NCT04470089|Experimental|Myramistin 0.01%|
16329967|NCT04470089|Experimental|Myramistin 0.02%|
16329968|NCT04470089|Placebo Comparator|Placebo|
16329969|NCT04470076|Experimental|neoadjuvant afatinib combination with chemotherapy|"Neoadjuvant treatment (chemotherapy+afatinib) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment (including dynamic 18F-FDG PET/CT) will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) Adjuvant treatment (afatinib): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the first week (+ 7 days) from surgery and up to 2 years."
16329973|NCT04470050|Experimental|Cohort 1- 30 Micrograms|Sublingual film containing 30 Micrograms Dexmedetomidine
16329974|NCT04470050|Experimental|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
16329975|NCT04470050|Experimental|Cohort 3- 90 Micrograms|Sublingual film containing 90 Micrograms Dexmedetomidine
16329976|NCT04470050|Experimental|Cohort 4- 120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
16329977|NCT04470050|Experimental|Cohort 5- 180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
16329978|NCT04470050|Placebo Comparator|Cohort 6- Placebo|Sublingual placebo film
16329979|NCT04470037|Experimental|DAAOI-P|DAAOI-P 250-1500mg
16329980|NCT04470037|Placebo Comparator|Starch pill|
16329981|NCT04470024|Experimental|Arm 1|Vax + delayed anti-PD-1
16329982|NCT04470024|Experimental|Arm 2|Vax + anti-GITR + delayed anti-PD-1
16329983|NCT04470011||Patients who initiated HIV treatment|
16329984|NCT04470011||Service providers at study facilities|
16329985|NCT04469998|Experimental|AXR-270 Low Dose|AXR-270 Low Dose administered once daily
16329986|NCT04469998|Experimental|AXR-270 High Dose|AXR-270 High Dose administered once daily
16329987|NCT04469998|Placebo Comparator|AXR-270 Vehicle|AXR-270 Vehicle administered once daily
16329988|NCT04469972|Experimental|Implementation in the intervention group|This group of elderly were subjected to a pursed-lip breathing exercise (using a windmill toy), a diaphragmatic breathing exercise and a coughing exercise three times a week (Mondays, Tuesdays and Thursdays) for 12 weeks in groups of 5-6 individuals (2 groups of 6 persons, and 4 groups of 5 persons: 6 groups in total) between 10:00 and 15:30, at the same time of the day for each group in 30-minute sessions. All breathing exercises were taught to the elderly individuals on the first day of implementation and demonstrated again prior to practice by the researcher throughout the implementation phase.
16329989|NCT04469972|No Intervention|Implementation in the control group|None of the elderly in the control group were subjected to breathing exercises. They continued their daily lives as normal.
16329990|NCT04469959|Experimental|L-Dopa First / Placebo Second|"STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and placebo tablets at 1pm and 5pm. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, with placebo at 1pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2.
~Step 2 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets at 9am, 1pm, and 5pm over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn."
16329991|NCT04469959|Placebo Comparator|Placebo First / L-Dopa Second|"Step 1 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets at 9am, 1pm, and 5pm over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2.
~Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and placebo tablets at 1pm and 5pm. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, with placebo at 1pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued."
16329992|NCT04469946|Experimental|Exploratory|Participants were fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Pre-intervention measures were obtained within one week of the hearing aid fit and post-intervention measures were obtained after two months of daily hearing aid use.
16329993|NCT04469920|Experimental|Group 1- mild hepatic impairment without evidence of PHT|Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
16329994|NCT04469920|Experimental|Group 2- mild hepatic impairment with evidence of PHT|Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
16329995|NCT04469920|Experimental|Group 3-moderate hepatic impairment|Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
16329996|NCT04469920|Experimental|Group 4- severe hepatic impairment|Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
16329997|NCT04469920|Experimental|Group 5-cholestatic liver disease|Subjects with cholestatic liver disease
16329998|NCT04469920|Experimental|Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH|Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
16329999|NCT04469920|Experimental|Group 7- normal hepatic function|Subjects with normal hepatic function
16330000|NCT04469907|Experimental|Treatment - AZD9977|There are 4 cohorts in this arm based on renal function (mild, moderate, severe, and normal). Each cohort will have 8 participants.
16330001|NCT04469894||Niemann-Pick Type A|Also referred to as Infantile Neurovisceral ASMD
16330002|NCT04469894||Niemann-Pick Type A/B|Also referred to as Intermediate form or Chronic Neurovisceral ASMD
16330003|NCT04469894||Niemann-Pick Type B|Also referred to as Chronic Visceral ASMD
16330004|NCT04469894||Niemann-Pick Type C (Early Infantile)|Onset at less than 2 years of age
16330005|NCT04469894||Niemann-Pick Type C (Late Infantile)|Neurodegenerative form (late-infantile) onset at 2-6 years of age
16330006|NCT04469894||Niemann-Pick Type C (Juvenile)|Neurodegenerative form (juvenile) onset at 6-15 years of age
16330007|NCT04469894||Niemann-Pick Type C (Adult)|Psychiatric neurodegenerative form (adult) onset at greater than 15 years of age
16330008|NCT04469881|Experimental|Virtual Reality|Wear VR glasses and watch movies during surgery
16330009|NCT04469868|Experimental|No opioids prescriptions at discharge|Patients will receive non-opioid analgesia, mostly over the counter, medications such as acetaminophen or ibuprofen. Opioids may be prescribed if the patients experience break through pain and call the office.
16330010|NCT04469855||Ozempic®|Japanese people with type 2 diabetes being treated in normal clinical practice conditions
16330011|NCT04469842|Experimental|Immunosuppression with Extended-Release Tacrolimus|"LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).
~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
16330012|NCT04469842|Active Comparator|Immunosuppression with Intermediate Release Tacrolimus|"IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).
~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
16330013|NCT04469829|Experimental|secukinumab|patients with psoriasis and metabolic syndrome candidate for treatment with secukinumab standard doses
16330014|NCT04469829|Active Comparator|methotrexate|patients with psoriasis and metabolic syndrome candidate for treatment with methotrexate dosed 15 mg/week
16330015|NCT04469816|Experimental|Behavioral: Family Check-Up 4 Health|Families will receive the FCU4Health program 3 times annually in a health maintenance model. The FCU4Health coordinator reviews the assessment results with the parents, using motivational interviewing strategies to create a tailored plan to address family needs. This plan may include referrals to community resources or parenting modules that focus on family management.
16330016|NCT04469816|Experimental|Control-Services as Usual|"Families will continue with their medical standard of care and referrals for services as appropriate from the healthcare staff in their respective FQHCs or primary healthcare clinics.
~Families will receive brochures about the community programs to which families in the FCU4Health arm are referred."
16330017|NCT04469803|Experimental|No nap, brief nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
16330018|NCT04469803|Experimental|No nap, longer nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
16330019|NCT04469803|Experimental|Brief nap, no nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
16330020|NCT04469803|Experimental|Brief nap, longer nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
16332560|NCT04451863|Active Comparator|High THC + Low BCP|15 mg THC, 0 mg myrcene, 0.5 mg BCP
16330021|NCT04469803|Experimental|Longer nap, brief nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
16330022|NCT04469803|Experimental|Longer nap, no nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
16330023|NCT04469790|No Intervention|SIT|Continuous sitting for 3 hours
16330024|NCT04469790|Experimental|SIT+WALK|Interrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
16330025|NCT04469790|Experimental|EX|Perform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
16330026|NCT04469777|Experimental|Systemic erythropoietin injections|20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
16330028|NCT04469751|Experimental|patients undergoing neurosurgery|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
16330029|NCT04469738|Experimental|SCS off|
16330030|NCT04469738|Experimental|SCS on|
16330031|NCT04469725|Experimental|Thymic carcinoma|enrolled subjects will receive KN046 every 2 weeks.
16330032|NCT04469712||SASI Bipartition|Subjects submitted to SASI Bipartition
16330033|NCT04469712||Roux-en-Y gastric bypass|Subjects submitted to gastric bypass
16330034|NCT04469699|Experimental|Treatment arm|Stereotactic biopsy followed by stereotactical photodynamic therapy
16330035|NCT04469699|Other|Control arm|Stereotactic biopsy
16330036|NCT04469686|Experimental|Twice Daily - Active|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure suppository applicator
16330037|NCT04469686|Experimental|Once Daily - Active|Once daily 90 mg hydrocortisone acetate and once daily placebo suppository administered with Sephure suppository applicator
16330038|NCT04469686|Placebo Comparator|Placebo|Twice daily placebo suppository administered with Sephure suppository applicator
16330039|NCT04469673|Experimental|JS002|Participants received one of 3 dose regimens of JS002 administered as multiple subcutaneous doses.
16330040|NCT04469673|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
16330041|NCT04469647||High-risk|Employees at high-risk of Coronavirus exposure areas (physicians, nurses, respiratory therapists, radiology technologists, lab technologists, housekeepers)
16330042|NCT04469647||Low-risk|Employees working at lower risk areas such as (administration, HR, Public relations)
16330043|NCT04469634|Experimental|antibody response and memory B-cell|Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
16330044|NCT04469621|Experimental|SAR443122|SAR443122 dose 1, twice daily for 14 days
16330045|NCT04469621|Placebo Comparator|Placebo|matching placebo
16330046|NCT04469608|Experimental|TCM clinical daycare model for depression patients|Tai Chi and Acupuncture and Yoga and Mindfulness
16330047|NCT04469608|No Intervention|Depression patients|Tai Chi and acupuncture and yoga and mindfulness are not added
16330048|NCT04469595|Active Comparator|ILUVIEN Arm|Intravitreal ILUVIEN
16330049|NCT04469595|Active Comparator|Aflibercept Arm|Intravitreal aflibercept
16330050|NCT04469569|Other|Delayed Intervention|Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4
16330051|NCT04469569|Other|Early Intervention|Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4
16330052|NCT04469556|Active Comparator|Modified Folfirinox|"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.
~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
16330053|NCT04469556|Active Comparator|Gemcitabine/nab-Paclitaxel|"Gemcitabine/nab-Paclitaxel administered intravenously.
~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
16330054|NCT04469543||MTHFR polymorphism|
16330055|NCT04469530|Experimental|Maintenance regimen|"Maintenance chemotherapy regimen administered as a 12-month course of continuous sirolimus with celecoxib and low-dose oral etoposide alternating every 21 days with low-dose oral cyclophosphamide following the completion of standard therapy"
16330056|NCT04469530|No Intervention|Observation|"Observation alone following the completion of standard therapy"
16330057|NCT04469517||HHT|patients with HHT
16330058|NCT04469517||control|persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
16330059|NCT04469504|Experimental|PREHAB|
16330060|NCT04469504|Active Comparator|control group|
16330061|NCT04469491|Experimental|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; +/- dexamethasone; + appropriate O2 support)
16330062|NCT04469491|Active Comparator|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics;+/- dexamethasone; + appropriate O2 support).
16330063|NCT04469478|Experimental|Virtual Reality for imaging review|Each participant (patient and caregiver(s)) will undergo standard 2D imaging review on a computer screen, followed by 3D imaging review in virtual reality during their radiation oncology consultation
16330064|NCT04469465|Experimental|Danicopan + C5 Inhibitor|Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
16330065|NCT04469465|Placebo Comparator|Placebo + C5 Inhibitor|Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).
16330066|NCT04469452||Healthy Adults (19-99yrs)|Healthy adults already enrolled in separate studies using indirect calorimetry to measure RMR within our lab will be recruited for this study. Fifty participants (25 male, 25 female) will be heterogeneous in age, body composition, and physical activity based on the inclusion and exclusion of their respective studies. To test reliability, 25 of the 50 participants will repeat RMR measurements within 1 week of initial measurements.
16330067|NCT04469439||Surgical group|Individuals with cystic fibrosis and chronic rhinosinusitis who undergo endoscopic sinus surgery
16330068|NCT04469439||Medical group|Individuals with cystic fibrosis and chronic rhinosinusitis who do not undergo endoscopic sinus surgery
16330069|NCT04469426|Experimental|Informational online app group|Participants will have access to an interactive online peer support app developed by the research team.
16330070|NCT04469426|No Intervention|Booklet only|Participants will only have access to the educational booklet on LARS developed by the colorectal research team.
16330071|NCT04469413||standard IV intermittent bolus infusion group|
16330072|NCT04469413||continuousIV intermittent bolus infusion group|
16330073|NCT04469400|No Intervention|Group1|Researchers conduct health education on patients, including dietary guidance, physical activity guidance, psychological behavior counseling, etc.
16330074|NCT04469400|Experimental|Group2|In addition to education, the subjects will consume 2 composite protein solid drinks per day, in conjunction with the three-meal diet to increase satiety and intake of sufficient nutrients
16330075|NCT04469400|Experimental|Group3|In addition to education, the subjects will consume 2 nutrition bars daily to replace the staple food of daily lunch and dinner to help reduce carbohydrate intake and intake of sufficient nutrients
16330076|NCT04469387|Active Comparator|NS Group|NS Group includes patients who simply receive responsible segments fused (L4-S1).
16330077|NCT04469387|Experimental|LD Group|LD Group includes patients who receive responsible segments fused (L4-S1) plus limited decompression at adjacent segment (L3/4).
16330078|NCT04469374|Experimental|Jumping exercise|10 rest-inserted jumps performed three times per week
16330079|NCT04469374|Sham Comparator|Balance exercise|Single-leg balances for 60 seconds on each leg
16330080|NCT04469361||Ballerinas|Balerina students who have trained at least for 4 years
16330081|NCT04469361||Female students|Female students with sedentary lifestyle
16330082|NCT04469348|Experimental|Healthy volunteers|"Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus.
~If contamination of S. Aureus: they will have 12 follow-up visits (1 per month)
~If no contamination of S. Aureus: their participation stops"
16330083|NCT04469335|Experimental|mobile neurofeedback|
16330084|NCT04469335|Sham Comparator|sham control|
16330085|NCT04469335|Experimental|medication +mobile neurofeedback|
16330086|NCT04469335|Sham Comparator|medication + sham control|
16330087|NCT04469322|Experimental|Pharmacogenetic Test Guided|Treating physician for this group receives a detailed pharmacogenetic report for the patient, prioritizing 53 psychoactive medications into 4 use categories: preferential use, use as directed, may have significant limitations, and may have severe adverse reactions.
16330088|NCT04469322|Sham Comparator|Treatment As Usual|Treating physician receives a sham report listing the names of all drugs and treats patients according to standard of care.
16330089|NCT04469309|Experimental|Group I|Group I will receive Brandoff Exercises
16330090|NCT04469309|Active Comparator|Group II|Group II will receive Somersault exercises
16330091|NCT04469296|No Intervention|control arm|In the control arm, patients will continue their usual diet without further recommendation.
16330092|NCT04469296|Experimental|"specific diet arm Ketogenic arm"|In the specific diet arms, the study diet will be calculated with a dietician, for the ketogenic diet, an iso-caloric ketogenic will be proposed and explained to the patient Each diet will be respected by the patient during 9 days +/- 1 day.
16330093|NCT04469296|Experimental|"specofoc diet arm protein restricted diet"|"In the specific diet arms, the study diet will be calculated with a dietician, for the protein restricted diet, a 20% protein restriction as compared to the usual diet will be calculated and the diet will be explained to the patient.
~Each diet will be respected by the patient during 9 days +/- 1 day."
16330094|NCT04469283||caffeine efficacy|Collection of preliminary data on caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
16330095|NCT04469270|Experimental|Engensis|16 (ea) 0.25mg (0.5 mL) injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
16330096|NCT04469270|Placebo Comparator|Placebo|16 0.5 mL injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
16330097|NCT04469257|Experimental|Sunbathing|During the activities for the intervention group, the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open. Sunbathing sessions were held between 10:30 and 11:30 to prevent elderly individuals from being affected by extreme temperatures, and UV index values were monitored during the time and duration of the event at WHO website (http://www.who.int/uv/resources/link/indexlinks/en/, Access date: July 1, 2018). During the hours of the day when UV index was > 6-7, elderly individuals were not taken out. After each sunbathing session, elderly individuals in the intervention group were evaluated for sensitivity and erythema that may occur in the exposed body areas
16332561|NCT04451863|Active Comparator|High THC + High BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
16330098|NCT04469257|No Intervention|Control|Elderly individuals in the control group were not invited to the activities held in the nursing home garden. There were no restrictions on them for not going out in the sun or spending time inside the nursing home
16330099|NCT04469231|Experimental|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.
16330102|NCT04469192|Experimental|cryotherapy + education|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
16330103|NCT04469192|Active Comparator|education alone|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
16330108|NCT04469166|Active Comparator|Tourniquet|Group of tourniquet
16330109|NCT04469166|Active Comparator|No tourniquet|Group of no tourniquet
16330110|NCT04469153||SARS-COV 2 positive patient|57 SARS-COV-2 positive patients followed during the SARS-COV 2 epidemic in the internal medicine department of the Croix-Rousse hospital. For each patient ferritin and glycosylated ferritin was analysed one time (biological analysis) at the entry of the hospitalization.
16330111|NCT04469140||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
16330112|NCT04469140||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
16330113|NCT04469140||Cohort 3|Subjects with GA enrolled in another trial
16330114|NCT04469127|Experimental|Arm 1|Single Arm study
16330115|NCT04469114|Experimental|Tofacitinib|Tofacitinib 10mg twice daily for 14 days or until hospital discharge
16330116|NCT04469114|Placebo Comparator|Placebo|Placebo twice daily for 14 days or until hospital discharge
16330121|NCT04469088|Experimental|Dry Needling Group|
16330122|NCT04469088|Active Comparator|Manual Therapy Treatment|
16330124|NCT04469062|Experimental|Mirikizumab|Mirikizumab administered intravenously (IV) and subcutaneously (SC).
16330125|NCT04469062|Active Comparator|Vedolizumab|Vedolizumab administered IV.
16330126|NCT04469062|Placebo Comparator|Placebo|Placebo administered SC and IV.
16330127|NCT04469049|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 90-minute weekly group sessions.
16330128|NCT04469036|No Intervention|Telephone consultation|Telephone consultation to a pediatric trauma specialist
16330129|NCT04469036|Experimental|Virtual Pediatric Trauma Center|The Virtual Pediatric Trauma Center (VPTC), uses live video, or telehealth, to bring the expertise of a Level I pediatric trauma center virtually to patients at a hospital emergency department.
16330130|NCT04469023|Experimental|TS-142 2.5 mg|Period in which participants received multiple-dose of 2.5 mg TS-142 prior to bedtime
16330131|NCT04469023|Experimental|TS-142 5 mg|Period in which participants received multiple-dose of 5 mg TS-142 prior to bedtime
16330132|NCT04469023|Experimental|TS-142 10 mg|Period in which participants received multiple-dose of 10 mg TS-142 prior to bedtime
16330133|NCT04469023|Experimental|Placebo|Period in which participants received single placebo prior to bedtime
16330134|NCT04469010|Experimental|Iron and Vitamin C|28mg iron bis-glycinate chelate and 240mg vitamin C
16330135|NCT04469010|Active Comparator|Iron|28mg iron bis-glycinate chelate
16330136|NCT04469010|Placebo Comparator|Placebo|Matched placebo tablets
16330137|NCT04468997|Experimental|601 dose level 1 treatment|
16330138|NCT04468997|Experimental|601 dose level 2 treatment|
16330139|NCT04468997|Experimental|601 dose level 3 treatment|
16330140|NCT04468997|Experimental|601 dose level 4 treatment|
16330141|NCT04468997|Experimental|601 dose level 5 treatment|
16330145|NCT04468971|Placebo Comparator|Arm 1|Excipient
16330146|NCT04468971|Experimental|Arm 2|CK0802: 1x10^8 cells
16330147|NCT04468971|Experimental|Arm 3|CK0802: 3x10^8 cells
16330153|NCT04468945|Experimental|mirror box therapy|The objects use for task-specific mirror therapy are duster, glass, the wooden block of different sizes and shapes, beads, coin, paper cards and spongy ball. In all these activities shoulder horizontal flexion-extension, adduction-abduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed automatically.
16330154|NCT04468945|Experimental|Repetitive Facilitation Exercise|Treatment involved rapid passive stretching of the muscles of the targeted joints in conjunction with tapping and rubbing the skin to assist in the generation of a contraction.Shoulder horizontal flexion-extension , adduction-abduction ,elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed
16330155|NCT04468932|Experimental|Active TMS first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week TMS intervention. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week sham TMS period prior to their final assessment.
16330156|NCT04468932|Experimental|Sham treatment first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week sham TMS period. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week TMS intervention prior to their final assessment.
16330157|NCT04468919|Experimental|BCI-FIT multi-modal configuration|For this single case research design with alternating treatments with baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with their existing alternative access method (baseline) and then with the multi-modal configurations optimized from the BCI-FIT algorithms (experimental). Outcome measures are typing accuracy, typing speed and user experience.
16330158|NCT04468919|Experimental|Adaptive signal modeling|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks when the BCI-FIT adaptive modeling is on and when the BCI-FIT adaptive modeling is off. Outcome measures are typing accuracy, typing speed and user experience.
16330159|NCT04468919|Experimental|Active querying techniques|For this single case research design with alternating treatments with baseline, 5 healthy control volunteers and 5 participants with severe speech and physical impairment who have AUC scores between 79-80% will complete copy spelling tasks with BCI-FIT active querying technique on and with BCI-FIT active querying technique off. Outcome measures are typing accuracy, typing speed and user experience.
16330160|NCT04468919|Experimental|Language modeling|For this single case research design with alternating treatments, 5 healthy control volunteers and 5 participants with severe speech and physical impairment, each with a healthy-control partner for partner input will complete a story retell task with BCI-FIT language modeling features on and with BCI-FIT language modeling features off. Outcome measures are information transfer rate and user experience.
16330161|NCT04468906|Experimental|"Biceps self-locking T tenotomy"|
16330162|NCT04468906|Active Comparator|Biceps tenodesis (control)|
16330163|NCT04468893|Experimental|Positive Psychology Intervention with chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression with the support of a chat service provided by therapists.
16330164|NCT04468893|Active Comparator|Positive Psychology Intervention without chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression without the support of the chat service.
16330165|NCT04468880|Other|Group (A1 → A2)|Group (A1 → A2) receiving control milk A1A2 in period 1 then the milk evaluated A2A2 in period 2
16330166|NCT04468880|Other|Group (A2 → A1)|Group (A2 → A1) receiving the milk evaluated A2A2 in period 1 then the control milk A1A2 in period 2
16330167|NCT04468867|Experimental|Patient group|
16330168|NCT04468854|Experimental|Experimental intervention|In the experimental phase we will administer 500 mg Luteolin (2x250 mg capsules) per day formulated for oral administration for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning). The last intake on visits 2 resp. 4 is important as the participants then have to recall the learned material from visits 1 resp. 3 during a steady-state status of Luteolin.
16330169|NCT04468854|Placebo Comparator|Control Intervention|Control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning) with water.
16330170|NCT04468841|Experimental|Prospective Group|Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
16330211|NCT04468542|Placebo Comparator|Saline injection|2-cc injection of normal saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
16330212|NCT04468529|Experimental|Investigational drug group|Injectable Neucardin + standard basic therapeutic medication
16330213|NCT04468529|Placebo Comparator|Placebo group|placebo + standard basic therapeutic medication
16330171|NCT04468841|Experimental|Retrospective Group|Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of ctDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
16330172|NCT04468815|Experimental|Treatment A: BMS-986278 suspension, fasted|
16330173|NCT04468815|Experimental|Treatment B: BMS-986278 tablet, fasted|
16330174|NCT04468815|Experimental|Treatment C: BMS-986278 tablet, fed|
16330175|NCT04468815|Experimental|Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted|
16330176|NCT04468789||Comparison group|Patients eligible for six-month dispensing receiving care at comparison sites.
16330177|NCT04468789||Intervention group|Patients eligible for six-month dispensing receiving care at intervention sites.
16330178|NCT04468776|Active Comparator|Medication (zolpidem or trazodone)|Zolpidem or trazodone, as prescribed by physician
16330179|NCT04468776|Active Comparator|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|Internet-based CBT-I program
16330180|NCT04468776|Experimental|Combination|Medication (zolpidem or trazodone) as prescribed by physician and Internet-based CBT-I program
16330181|NCT04468750|Experimental|Kinesiotape|Kinesiotape (Nasara, Korea) was applied for three times a week (Monday, Wednesday, and Friday) for three weeks.
16330182|NCT04468724|Experimental|IMMEDIATE|People who are included in the Immediate Arm receive the Makasi intervention right away or in a six-week time if they are not available on the spot
16330183|NCT04468724|Other|DIFFERED|People who are included in the Differed Arm receive the Makasi intervention three months after inclusion
16330184|NCT04468711|Active Comparator|treatment group|vitamin D plus topical 1% hydrocortisone cream twice daily
16330185|NCT04468711|Placebo Comparator|placebo group|placebo plus plus topical 1% hydrocortisone cream twice daily
16330186|NCT04468698||Global cohort|A global cohort is built merging data from three studies
16330187|NCT04468685|Experimental|Ondansetron|Ondansetron intraperitoneal in the gall bladder bed
16330188|NCT04468685|Placebo Comparator|Saline|Normal saline intraperitoneal in the gall bladder bed
16330189|NCT04468672|Active Comparator|Day worker|Men and women who work only day shift for at least 3 consecutive days of the week
16330190|NCT04468672|Active Comparator|Night worker|Men and women who work only night shift for at least 3 consecutive days of the week
16330191|NCT04468659|Experimental|A45 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 milligram per kilogram (mg/kg), administered as intravenous (IV) infusion, every two weeks through 8 weeks, then 10 mg/kg, administered as IV infusion, every two weeks through 96 weeks, and 10 mg/kg, administered as IV infusion, every four weeks through 216 weeks.
16330192|NCT04468659|Placebo Comparator|A45 Trial: Placebo|Participants will receive placebo (0.9 percent [%] sodium chloride solution), administered as IV infusion, every two weeks through 96 weeks then every four weeks through 216 weeks.
16330193|NCT04468659|Experimental|A3 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 mg/kg, administered as IV infusion, every four weeks through 8 weeks, then 10 mg/kg, administered as IV infusion, every four weeks through 216 weeks.
16330194|NCT04468659|Placebo Comparator|A3 Trial: Placebo|Participants will receive placebo (0.9% sodium chloride solution), administered as IV infusion, every four weeks through 216 weeks.
16330195|NCT04468646|Placebo Comparator|Placebo|matching placebo drug
16330196|NCT04468646|Experimental|NK-1R antagonist group|80 mg daily
16330197|NCT04468633|Active Comparator|Baerveldt 350 implant|
16330198|NCT04468633|Active Comparator|Ahmed ClearPath 350 implant|
16330199|NCT04468620|Experimental|ASSET Intervention|13-session group intervention
16330202|NCT04468594|Experimental|rigid tape|the rigid tapping technique using zinc oxide tape and protective tape (reference). With the participant assuming a relaxed standing position, the tape was applied bilaterally starting from the first to the last thoracic vertebra. A second tape was then applied to form a position of scapular depression and retraction. This tape was applied bilaterally and extended from the midpoint of the spine of the scapula to the last thoracic vertebra (figure ). This taping was applied for 12 weeks and changes every 3 days
16330203|NCT04468594|Experimental|scapular stabilizing exercises|scapular stabilizing exercises in the form of (1)wall slides with squat, (2) Wall push-ups with ipsilateral leg extension, (3) lawnmower with diagonal squat, (4) resisted retraction to scapula with opposite leg squat (5) robbery with squat. ten repetitions / exercises/ session were perform
16330204|NCT04468594|Active Comparator|control|a standard physical therapy protocol will be introduced. This protocol consisted of (1) progressive strengthening exercises for rotator cuff muscles. The resistance was applied first by a red-colored elastic Thera-band. Then progressed, using the green-colored band. Each exercise was performed 10 times /session, (2) Self-stretching exercises for levator scapula, posterior deltoid, pectoralis minor, and latissimus dorsi muscles. Five repetitions of stretching were performed for each muscle per session
16330205|NCT04468581||Community sample|We plan to recruit a representative sample of the Singapore population.
16330206|NCT04468568|Experimental|Experimental|Intravenous Atosiban.
16330207|NCT04468568|Active Comparator|Control|Intravenous Terbutaline.
16330208|NCT04468555|Experimental|Global postural reeducation|Patients completed 3 sessions of global postural reeducation for 3 weeks.
16330209|NCT04468555|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
16330210|NCT04468542|Experimental|Bupivacaine/triamcinolone injection|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
16330215|NCT04468516|Placebo Comparator|Placebo|Intervention is applied in reduced intensity to the trapezius muscle.
16330216|NCT04468516|No Intervention|Waitlist period|Participants will have a 1 month waitlist period where no intervention takes place.
16330217|NCT04468503|Active Comparator|1 g per kg body weight per day|"Protein will be receive by patients that is 1g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.
~Base line characters(BMI, nitrogen Balance, Protein biomarker, LFTs, RFTs, GCS)"
16330218|NCT04468503|Active Comparator|2 g per kg body weight per day|"Protein will be receive by patients that is 2g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.
~Base line characters(BMI, nitrogen Balance, Protein bio marker, LFTs. , RFTs, GCS)"
16330221|NCT04468477|Active Comparator|Patients attending cardiac outpatient clinic|
16330222|NCT04468464|Active Comparator|Control Group|Occlusal Splint
16330223|NCT04468464|Experimental|Study Group|Osteopathic Manuel Therapy
16330224|NCT04468451|Experimental|ROC-48 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 48 hours for a total of 12-week intervention.
16330225|NCT04468451|Active Comparator|ROC-24 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 24 hours for a total of 12-week intervention.
16330226|NCT04468451|Active Comparator|Control group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. The participant's clinical occupational therapist will be responsible for the regular therapy. The dosage will be their regular dosage for a total of 12-week intervention.
16330227|NCT04468438||50 patients with LN with regular menstrual cycle|1- First group of50 patients with regular menstrual cycle
16330228|NCT04468438||50 patients with LN with amenorrhea|2- Second group of 50 patients with amenorrhea.
16330229|NCT04468425|Experimental|Pharmacokinetic Study|"Period 1 (Day 1) and 2 (Day 8 - Day 21) separated by 7-day washout period. Period 1: A single 5 mg tofacitinib tablet will be administered orally on Day 1.
~Period 2: Repeat dosing of Tofacitinib Citrate Topical Gel 3.2% to approximately 10% BSA in the morning of Day 8 and twice daily from Day 9 to Day 20 with the last dose in the morning of Day 21."
16330230|NCT04468399||Patients who initiated HIV treatment|
16330231|NCT04468399||Service providers at study facilities|
16330232|NCT04468373|Experimental|WA-NG (NG-IMT) Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
16330237|NCT04468347|Experimental|Alzheimer's disease (AD)|Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
16330238|NCT04468347|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
16330239|NCT04468347|Experimental|Subjective memory complainers (SMC)|Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
16330240|NCT04468347|Experimental|Cognitively normal (CN)|Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
16330241|NCT04468334|Experimental|LARIAT + PVI Treatment Group|"Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
~Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n<65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n<20)"
16330242|NCT04468321|Experimental|Apple Watch|Patients will be provided with the Apple Watch Series 6 with Irregular Rhythm Detection and ECG capabilities.
16330243|NCT04468321|Placebo Comparator|Withings Move|Patients will be provided with the Withings Move with activity tracking.
16330244|NCT04468308||Senile Cataract|Patient with senile cataract, whose cataract surgery was postponed in the COVID-19 pandemic
16330245|NCT04468295|Experimental|0.018-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.018-inch slot orthodontic bracket system.
16330246|NCT04468295|Active Comparator|0.022-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.022-inch slot orthodontic bracket system.
16330247|NCT04468282|Experimental|VGB-ST|"Name of the compound: Vigabatrin ORPHELIA Pharma (VGB-ST) Pharmaceutical form: Soluble tablet Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.
~Batch N°: 16.92.042 (expiry date: 31.05.2017)"
16330248|NCT04468282|Active Comparator|Sabril|"Name of the compound: Sabril (vigabatrin) Pharmaceutical form: granules (sachet) Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.
~Batch N°: 6810 (expiry date: 31.05.2019)"
16330249|NCT04468269|Experimental|balance training with sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group. For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability.
16330250|NCT04468269|Experimental|balance training without sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group.For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability
16330251|NCT04468256||Cardiomyopathy|Heart Hive registered participants with self-reported cardiomyopathy
16330252|NCT04468256||Participants without Heart Disease|Heart Hive registered participants without cardiomyopathy or other heart disease.
16330253|NCT04468243|Experimental|Nurse-led|Nurse-led (group A). Patients randomized to group A will be taken to an available consultation room within the clinic and provided brief diabetes education which includes understanding what it means to have diabetes, healthy eating, and physical activity. Patients will also receive instructions on how to use a glucometer and how to take Metformin.
16330254|NCT04468243|No Intervention|Usual Care|Usual Care (Control; group B). Patients randomized to usual care will be informed of their HbA1c value, will continue to receive usual cancer care, and will be encouraged to follow-up with their PCP for T2D management. The RA will ensure that oncology visit clinic notes and the results of the HbA1c testing are relayed to the patient's PCP office. Patients who do not have a PCP identified will be referred to an appropriate provider.
16330255|NCT04468230|Experimental|Nicotine Transdermal Patch Administration|Each patient will complete two 14-day treatment conditions, one each for 7 mg and 14 mg nicotine transdermal patch administration with a washout period in between (≥ 14 days and up to 21 days).
16330256|NCT04468217||Subjects with positive test to SARS-COV2|Employees of critical services companies and healthcare workers with a positive test to SARS-COV2.
16330257|NCT04468217||Subjects with negative test to SARS-COV2|Employees of critical services companies and healthcare workers with a negative test to SARS-COV2.
16330258|NCT04468204|Experimental|SinuSonic Device|SinuSonic device used for 1 min three times a day for 8 weeks.
16330259|NCT04468204|Sham Comparator|Sham|Sham SinuSonic device used for 1 min three times a day for 8 weeks.
16330260|NCT04468191|Experimental|Experimental, then sham|Patients with ALS in the experimental, then sham arm will undergo an expiratory muscle strength training (EMST) session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 0% resistance.
16330261|NCT04468191|Experimental|Sham, then experimental|Patients with ALS in the sham, then experimental arm will undergo an expiratory muscle strength training (EMST) session with a device set to 0% resistance during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment.
16330262|NCT04468178|Experimental|Shoulder prosthesis system GLOBAL ICON from DePuy|The GLOBAL ICON stemless is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
16330263|NCT04468178|Active Comparator|SIMPLICITY shoulder prosthesis system from Wright Medical|The SIMPLICITY is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
16330264|NCT04468152|Experimental|Case|
16330265|NCT04468152|No Intervention|Control|
16330266|NCT04468139|Experimental|Quercetin|Quercetin 500 g of quercetin Quercetin will be administered orally once daily, in the morning before breakfast for 5-10 days or patient improves or discharged
16330267|NCT04468126|Active Comparator|standard oxygen group|In order to maintain SpO2 between 92 and 96%
16330268|NCT04468126|Experimental|high-flow nasal cannula oxygen group|At least 50 L/min adjusted in order to maintain SpO2 between 92 and 96 %
16330269|NCT04468113||US-guided core biopsy and clip placement|Female patients with sonographically suspicious, intramammary foci, scheduled for ultrasound-guided core biopsy and marking of the lesion with the Tumark® Vision Clip
16330270|NCT04468100|Experimental|Tigerase®|Dornase alfa
16330271|NCT04468100|Active Comparator|Pulmozyme®|Dornase alfa
16330272|NCT04468087|Experimental|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
16330273|NCT04468087|Experimental|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
16330274|NCT04468087|Experimental|Sofusbuvir + Daclatasvir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofosbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
16330275|NCT04468087|Placebo Comparator|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
16330276|NCT04468087|Placebo Comparator|Placebo Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
16330277|NCT04468087|Placebo Comparator|Placebo Sofusbuvir + Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
16330278|NCT04468074|Experimental|Therapy Group|"Therapy Group participants start the treatment period with three 1 ½ hour introductory sessions:
~An education session on the science behind chronic pain and a basic overview of the VR therapy.
~A session to customize the VR experience to match the participant's own pain experience.
~A training session on the use of the VR hardware and software.
~Upon completion, participants begin using the VR therapy app at home once a day, 5 times a week (minimum), for a total of 8 weeks. The VR app contains different training exercises. A workbook provides a schedule and background on each of the training sessions.
~Therapy Group participants may continue their other pain treatment regimes, and are asked to notify the research team of any changes."
16330279|NCT04468074|No Intervention|Standard of Care (SOC) Group|The SOC Group (no-intervention) completes a daily pain survey. SOC Group participants are asked to maintain their pain treatment regimes, and are asked to notify the research team of any changes.
16330280|NCT04468061|Experimental|Sacituzumab Govitecan + Pembrolizumab|"Participants will receive Sacituzumab Govitecan + Pembrolizumab at a pre-determined dose during a 21 day cycle.
~Sacituzumab Govitecan will be given on days 1 and 8 of the 21 day cycle Pembrolizumab will be given on day 1 of the 21 day cycle."
16330281|NCT04468061|Experimental|Sacituzumab Govitecan|"Participants will receive Sacituzumab Govitecan at a pre-determined dose during a 21 day cycle.
~Sacituzumab Govitecan will be given on days 1 and 8 of a 21-day cycle"
16330282|NCT04468061|Experimental|Retreatment|"Participants randomized to the combination arm (Sacituzumab Govitecan + Pembrolizumab) who stop with CR after at least 24 weeks of treatment may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment. This is termed the Second Course Phase and is only available if the study remains open and the subject meets conditions:
~."
16330283|NCT04468048||Music|"Subjects will put on headphones containing music from the album Nada Himalaya performed by S. G. Sachchidananda. The music will start playing 10 minutes before the colonoscopy procedure and will stop once subjects have woken up from sedation. Subjects will be instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure."
16330284|NCT04468048||Control|Subjects will put on headphones, but there will be no music playing. Subjects are instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure.
16330285|NCT04468022|Active Comparator|Toric Trifocal IOL|Twenty patients (20) underwent Toric Trifocal IOL surgery (first group)
16330286|NCT04468022|Active Comparator|Toric Trifocal IOL RELEX SMILE|Twenty patients (20) underwent Toric Trifocal IOL and RELEX SMILE surgery (second group)
16330287|NCT04468009|No Intervention|Standard of care|Standard of care for Covid-19
16330288|NCT04468009|Experimental|PCC-19|Treatment with convalescent plasma
16330289|NCT04467996|Active Comparator|6 hour IUBT placement|
16330290|NCT04467996|Active Comparator|18 hour IUBT placement|
16330291|NCT04467983|Active Comparator|Denosumab alone|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
16330292|NCT04467983|Active Comparator|Combination therapy|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
16330293|NCT04467970|Experimental|Unicompartmental Knee Replacement|
16330294|NCT04467970|Experimental|High Tibial Osteotomy|
16330295|NCT04467957|Experimental|CF Cohort|16 Cystic Fibrosis Patients will undergo MRI imaging before and 6 months after initiation of triple-combination modulator therapy. Initiation of triple -combination modulator therapy will be determined by clinician and family prior to study enrollment. Hyperpolarized Xenon 129 will be administered through inhalation at two MRI imaging study visits.
16330296|NCT04467957|Experimental|Control Cohort|10 Healthy control study participants matched for age and gender will undergo one MRI imaging study visit. Hyperpolarized Xenon 129 will be administered through inhalation at one MRI imaging study visit.
16330297|NCT04467944||NS Group|Patients without pre-existing degeneration at L3/4 segment will be classified into control group (NS group).
16330298|NCT04467944||D Group|Patients with pre-existing disc factors (Pfirrmann grade≥3, Hiz or vacuum sign) at L3/4 segment will be classified into group D.
16330299|NCT04467944||C Group|Patients with pre-existing canal stenosis factors (cerebrospinal fluid occlusion≥1) at L3/4 segment will be classified into group C.
16330300|NCT04467931||1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
16330301|NCT04467931||1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB|Among Veterans with treated hypertension who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
16330302|NCT04467931||2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
16330303|NCT04467931||2.2 COVID-19 Hospitalized, ACEI vs. ARB|Among Veterans with treated hypertension who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
16330304|NCT04467918|Experimental|Cannabidiol (CBD)|50 cases in the CBD group plus pharmacological and clinical measures. Patients in the investigational treatment group will receive CBD within 24 hours after randomization, with a daily dose of 300mg / day (two 150mg doses; 1mL of the formulation) for 14 days.
16330305|NCT04467918|Placebo Comparator|Placebo (PLB)|50 in the placebo group plus pharmacological and clinical measures. Patients in the placebo group will also receive, within 24 hours after randomization, 1mL of the same investigational medication vehicle (medium / coconut chain triglyceride oil - MCT) for 14 days
16330306|NCT04467905|Placebo Comparator|Placebo|Patients will receive a total of 200 μL of placebo ((i.e. 100 μL in each nostril) via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
16330307|NCT04467905|Experimental|Etripamil|Patients will receive a total of 200 μL of etripamil Nasal spray 70 mg via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
16330308|NCT04467892|Active Comparator|Group A|. Group A 120 patients, received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
16330309|NCT04467892|Active Comparator|Group B|group B 120 patients, included received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
16330312|NCT04467866|Experimental|ROC-Stand(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
16330313|NCT04467866|Experimental|ROC-Stand(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
16330314|NCT04467866|Active Comparator|Control(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. The other occupational therapist will be responsible for regular therapy.
16330315|NCT04467866|Active Comparator|Control(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. The other occupational therapist will be responsible for regular therapy.
16330316|NCT04467853|Experimental|chimeric Antigen Receptor T cell LCAR-C18S Cells|
16330317|NCT04467840|Experimental|Opaganib|In addition to standard of care, opaganib will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. When required this may be made into a suspension form and may be administered by nasogastric tube.
16330318|NCT04467840|Placebo Comparator|Placebo|In addition to standard of care, a matching placebo will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. Where required this may be made into a suspension form and may be administered by nasogastric tube.
16330319|NCT04467827||Group A1 male|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
16330320|NCT04467827||Group A2 female|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
16330321|NCT04467827||Group B1 male|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
16330322|NCT04467827||Group B2 female|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
16330323|NCT04467827||Group C1 male|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
16330324|NCT04467827||Group C2 female|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
16330325|NCT04467814|Experimental|Intervention|
16330326|NCT04467814|Active Comparator|Usual Care|
16330327|NCT04467801|Experimental|Treatment|"Ipatasertib, 400 mg once daily, Oral, Days 1-14 of each 21 day cycle (2 weeks on and 1 week off).
~Docetaxel, 75 mg/m2, Intra-venous, Day 1 of each 21 day cycle."
16330328|NCT04467788|Active Comparator|Computer-aided session|Training on ergonomic principles in dentistry will be given to the participants through Computer-Aided sessions, including explaining videos on proper postures in dental practice .
16330329|NCT04467788|Active Comparator|Clinical Simulation Session|Training on ergonomic principles in dentistry will be given to the participants through clinical simulation sessions showing the proper postures in dental practice.
16330330|NCT04467762||Meningoencephalitis (ME-PED)|"pediatric patients between 0 and 17 years of age
~admission to hospital with suspected meningoencephalitis
~confirmed meningoencephalitis within 24 hours after admission"
16330331|NCT04467762||Sepsis-associated encephalopathy (SAE-PED)|"pediatric patients between 0 and 17 years of age
~admission to hospital with suspected sepsis
~confirmed sepsis within 24 hours after admission or time of diagnosis"
16330332|NCT04467762||Control group (CON-PED)|"pediatric patients between 0 and 17 years of age
~exclusion of neurocognitive impairment
~admission to hospital for minor surgery (e.g. herniotomy, adenoidectomy, fractures treated by osteosynthesis) or for hemangioma treated by propranolol"
16330333|NCT04467749|Experimental|Suspension Wheel|Participants will be given a set of in-wheel suspension wheels to use in their normal daily routine for three months.
16330334|NCT04467736|No Intervention|Control|No further treatment after alveolar ridge preservation
16330335|NCT04467736|Active Comparator|Test|In case the test group comes out, instructions for the daily application of hyaluronic acid (Gengigel Forte©) will be given. Hyaluronic acid will be administered by the patient 3 times per day during 7 days.
16330336|NCT04467723|Experimental|Treatment|"Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.
~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:
~Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID"
16330337|NCT04467710||Success of LCBDE|Patients with a fully laparoscopic surgical treatment of common bile duct stones
16330338|NCT04467710||Failure of LCBDE|Patients with a laparoscopic cholecystectomy but an endoscopic treatment of common bile duct stone with an ERCP performed intra, per or postoperatively
16330339|NCT04467697|Experimental|SOV2012-F1-treated|Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 600 mg SOV2012-F1 per day (300 mg in the morning and 300 mg in the evening) based on plasma T after 14 and 42 days of treatment.
16330340|NCT04467684|Experimental|Cohort 1|Cohort 1: 100 mg CB-0406 (n=6)
16330341|NCT04467684|Experimental|Cohort 2|Cohort 2: 200 mg CB-0406 (n=6). Dose initiated following review of all safety data from Cohort 1 by a Safety Review Committee
16330342|NCT04467684|Experimental|Cohort 3|Cohort 3: 400 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 2 by a Safety Review Committee.
16330343|NCT04467684|Experimental|800 mg|Cohort 4: 800 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 3 by a Safety Review Committee.
16330344|NCT04467684|Experimental|1000 mg|Cohort 5: 1000 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 4 by a Safety Review Committee
16330345|NCT04467684|Placebo Comparator|Matched placebo|Two subjects in each Cohort (1, 2, 3, 4, 5) are randomized to matched placebo
16330346|NCT04467671|Experimental|Tissue Engineered Vascular Grafts|
16330347|NCT04467658||ADHD|
16330348|NCT04467658||NT NeuroTypical|
16330349|NCT04467658||ADHD NOS|
16330350|NCT04467645|Experimental|Reflexology|Reflexology Application: A total of twelve 30-minute reflexology sessions (2 per week)were administered to each patient.
16330351|NCT04467645|No Intervention|No intervention|No intervention was applied to the postmenopausal women in the control group.
16330352|NCT04467632|Experimental|Patients affected with idiopathic Parkinson Disease|
16330353|NCT04467619|Active Comparator|Early Illusory Movements|"Phase 1: A patient enrolled in group A will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist from the start of the study (Day 1), and also FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 15).
~Phase 2: From Day 16 onwards, the patient will undergo standard rehabilitation only according to the instructions of the attending surgeon and performed by an independent physiotherapist for 14 days (Day 30)."
16330354|NCT04467619|Active Comparator|Deferred Illusory Movements|"Phase 1: A patient enrolled in group B will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist, from the start of the study (Day 1) for 14 days (Day 15).
~Phase 2: Then, from Day 16 onwards, in addition to standard physiotherapy, FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 30)."
16330355|NCT04467606|Experimental|Experimental|The experimental group will receive a discharge planning which use the strategy of motivational interviewing.
16330356|NCT04467606|No Intervention|Control|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
16330357|NCT04467593|Experimental|Cohort A1|Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)
16330358|NCT04467593|Experimental|Cohort A2|The highest whole-body hyperthermia duration with acceptable side effects from cohort A1 will be applied to three additional patients with advanced solid cancer, once a week and for 15 days in total.
16330359|NCT04467593|Experimental|Cohort B1|Three pancreatic cancer patients will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15) using the device and in combination with the standard of care chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nab-paclitaxel or gemcitabine alone).
16330360|NCT04467593|Experimental|Cohort B2|The highest whole-body hyperthermia duration with acceptable side effects from cohort B1 will be applied in combination with chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nabpaclitaxel or gemcitabine alone) to three additional pancreatic cancer patients, once a week and for 15 days in total.
16330361|NCT04467580|Experimental|Patients with stenosing CD|Patients with stenosing CD will be recruited in each investigation center, during a preoperative consultation for an already decided and planned intestinal resection (digestive surgery or hepato-gastro department) -enterology).
16330362|NCT04467567|Experimental|patients treated with lutathera|Patients undergoing treatment with Lutathera® and who accept to participate in the study, regardless of the cycle of treatment, 1, 2, 3 or 4.
16330363|NCT04467554|Experimental|Measurements and T-chair training|This group will receive three measurements sessions and training with a new developed device (15 therapy sessions in total).
16330364|NCT04467554|No Intervention|Measurements|This group will receive three measurements sessions.
16330365|NCT04467541|Experimental|Inactivated enterovirus type 71 vaccine|Inactivated enterovirus type 71 vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
16330366|NCT04467528|Experimental|Electroacupuncture combined with conventional drug therapy|"Conventional drug therapy:
~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial
~For participants with abdominal distension:
~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min
~For participants with post-operative ileus:
~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min
~32# acupuncture needle used and twice daily for three days"
16330367|NCT04467528|Active Comparator|Conventional drug therapy|"Conventional drug therapy:
~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
16330369|NCT04467502|Experimental|CBT with VRET|
16330370|NCT04467502|Active Comparator|CBT with imaginal ET|
16330377|NCT04467476|Active Comparator|tDCS (anodal)|tDCS: 20 minutes, 2mA, over the motor cortex representation of lower limbs.
16330378|NCT04467476|Sham Comparator|tDCS (sham)|tDCS: 20 minutes (but 30s ON), 2mA, over the motor cortex representation of lower limbs.
16330379|NCT04467463|Experimental|GPN|administrated bilateral greater palatine nerve block using levobupivacaine 0.25%
16330380|NCT04467463|Experimental|SMN|administrated bilateral suprazygomatic nerve block using levobupivacaine 0.25%.
16330381|NCT04467450|Experimental|Botox injection|half of the hemiplegic patients will be injected by botulinum toxin A in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
16330382|NCT04467450|Active Comparator|methyl prednisolonate injection|the other half of the hemiplegic patients will be injected by methylprednisolonate in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
16330383|NCT04467437|Active Comparator|Intensive Training Only|Physical and gait training that targets rehabilitation of walking function.
16330384|NCT04467437|Active Comparator|Intensive Training Combined with Spinal Stimulation|Transcutaneous spinal stimulation combined with physical and gait training that targets rehabilitation of walking function.
16330385|NCT04467424|Experimental|Pediatric anesthesia with ketofol|ketamine, propofol
16330386|NCT04467424|Experimental|Pediatric anesthesia with ketofol plus lidocaine|ketamine, propofol, lidocaine
16330387|NCT04467411||Breast Cancer Group|Breast Cancer Group
16330388|NCT04467411||Healthy Volunteer|Healthy Volunteer Group
16330389|NCT04467398||Tuohy needle group|The participants who undergo the trigeminal nerve block using 22 guage Tuohy needle.
16330390|NCT04467398||Quincke needle group|The participants who undergo the trigeminal nerve block using 22 guage Quincke needle.
16330391|NCT04467385|Experimental|Experimental Group|Virtual Reality training(VR) + Sensory Integration therapy + conventional therapy
16330392|NCT04467385|Experimental|Control Group|VR training + conventional therapy
16330393|NCT04467372|Experimental|Tart cherry juice concentrate|tart cherry juice
16330394|NCT04467372|Experimental|Freeze dried tart cherry powder|tart cherry capsules
16330395|NCT04467372|Experimental|Juice placebo|kool-aid
16330396|NCT04467372|Experimental|Capsule placebo|maltodextrin
16330397|NCT04467359|Experimental|The experimental group|ERAS intervention group
16330398|NCT04467359|Placebo Comparator|The control group|Sports medicine rehabilitation nursing group
16330399|NCT04467346|Experimental|Ped-TMZ|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
16330400|NCT04467346|Active Comparator|Temodal capsule|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition
16330401|NCT04467333||All lung cancer patients|There will not be an intervention.
16330402|NCT04467320|Experimental|Intervention Group|Receiving the Teaching Recovery Techniques intervention (delivered online).
16330403|NCT04467320|Active Comparator|Care-As-Usual Group|Receiving care-as-usual.
16330404|NCT04467307|Active Comparator|Foreign body aspiration.|Patients undergoing bronchoscopy with suspicion of foreign body aspiration. There is a foreign body in the bronchoscopy performed on these patients and it is the treated group.
16330405|NCT04467307|Active Comparator|Group with no foreign body aspiration|Patients undergoing bronchoscopy with suspicion of foreign body aspiration, but there is no foreign body in bronchoscopy.
16330406|NCT04467281|Experimental|89Zr-DFO-daratumumab PET/CT|"Pre treatment evaluation: 1) Standard of Care (SoC) labs, imaging, blind bone marrow biopsy. 2) Baseline research 89 Zr DFO daratumumab PET/CT 3) Possible biopsy of 89 Zr DFO daratumumab avid lesion Treatment: Daratumumab containing combination therapy (up to 12 cycles, 4 weeks/cycle). SoC labs, imaging, and blind bone marrow biopsies until complete response (CR) is suspected or 12 cycles are completed.
~Post treatment evaluation:1) SoC labs, imaging, and blind bone marrow biopsy 2) SoC minimal residual disease (MRD) analysis by next generation sequencing 3) Follow up research 89 Zr DFO daratumumab PET/CT 4) Possible biopsy of 89 Zr DFO daratumumab avid lesion"
16330407|NCT04467268|Experimental|Sleep extension intervention|"Intervention group participants met with an experienced sleep scientist to discuss and agree changes to their sleep and personal schedules. Discussions lasted 60-90 minutes, were informed by actigraphic sleep assessments from the baseline period, and aimed to increase TST by ≥1 hour/night. The structure and content of the About Sleep, Sleep Hygiene and Thoughts and Sleep components of the online Sleepful application, a self-help sleep management programme. Advice was supported by the provision of self-help booklets addressing sleep hygiene and the management of pre-sleep cognitions which had been successfully trailed in an intervention for insomnia symptoms. Finally, to capitalize on the participant's motivation at recruitment, and optimize adherence, the newly agreed sleep schedule was written into an agreement which the participant was asked to sign, simulating a 'therapeutic contract'. Schedules were reviewed by telephone at the end of the first week and revised if required."
16330408|NCT04467268|No Intervention|Control group|Participants in the control group were asked to continue with their habitual sleep schedule.
16330409|NCT04467255|Active Comparator|group a|aerobic training
16330410|NCT04467255|Active Comparator|group b|endurance training
16330411|NCT04467242||COPD patients|COPD patients with severe emphysema and right heart dysfunction
16330412|NCT04467229|Experimental|Focus group with chronically painful adolescents|Adolescents with chronic pain
16330413|NCT04467216|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks
16330414|NCT04467216|No Intervention|Control Group|This arm will be doing existing forms of motor-cognitive training in 30 minutes session, twice a week for 8 weeks
16330415|NCT04467203|Experimental|Fadanafil fast to fat meal|"Seven subjects in group A will receive treatment in the following order:
~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-> At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal"
16330481|NCT04466696||t4 colorectal cancer treated with standards of care|retrospective from January 2010 to December 2015
16330416|NCT04467203|Experimental|Fadanfil fat meal to fat|"Seven subjects in group B will receive treatment in the following order:
~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
16330417|NCT04467177|Experimental|Glucose group|Neonates will receive 30% oral glucose
16330418|NCT04467177|Placebo Comparator|Placebo group|Neonates will receive sterile water
16330419|NCT04467164|Experimental|Exhalatory-gated tVNS|exhalatory-gated tVNS on the left auricle
16330420|NCT04467164|Active Comparator|Inhalatory-gated tVNS|inhalatory-gated tVNS on the left auricle
16330421|NCT04467151|Experimental|anti-SARS-CoV-2 plasma|Patients receive one dose (250-300ml) of anti-SARS-CoV-2 convalescent plasma
16330422|NCT04467151|Placebo Comparator|Placebo|Patients receive one dose (250-300ml) of placebo (albumin 5%)
16330423|NCT04467138||Inflammatory bowel disease|Patients with either Crohn's disease (CD, n=22), and Ulcerative colitis (UC, n=19).
16330424|NCT04467138||Chronic intestinal failure|Patients with intestinal failure (CIF, n=20)
16330425|NCT04467125|Experimental|EMLA|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
16330426|NCT04467125|Active Comparator|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.
16330427|NCT04467099||Os Trigonum Excision with Tear|Participants with flexor hallucis tendon tear
16330428|NCT04467099||Os Trigonum Excision without Tear|Participants without flexor hallucis tendon tear
16330429|NCT04467086|No Intervention|Control Arm - Usual Care|"Participants in the control group will receive usual intravenous sedation according to practices already in place at each participating site (3 quaternary hospitals). The choice of agent, route of delivery, method of monitoring, and target levels of sedation will be determined by the treating team; however, we will recommend best practice clinical guidelines be followed. Current guidelines recommend analgesia first sedation titrated to relief of pain and dyspnea and sedative infusions if need for anxiety or agitation titrated to a prescribed level of sedation using a validated sedation scale. Patients may receive adjunct sedative/analgesic medications (e.g., enteral benzodiazepines) but propranolol use in the control group will be considered a protocol violation."
16330430|NCT04467086|Experimental|Intervention Arm - Propranolol hydrochloride|"Participants in the control arm will received sedation as described for the control arm, but with the addition of propranolol hydrochloride (titrated up as described under Intervention Description) and a corresponding reduction in sedatives as appropriate and described under Intervention Description."
16330431|NCT04467073|Experimental|Stepped-Care Online Reciprocal Imitation Training (Online RIT)|"Participants completed four telehealth modules over a period of 5 weeks (~1 per week, 1 week to practice). Two variables were selected as tailoring variables for this stepped-care model. Fidelity (RIT-PFF) and self-efficacy (EIPSES) at 5 weeks were used to determine which participants were in need of a step up in care, in the form of remote parent coaching.
~Parents who demonstrated ≥80% on the RIT-PFF, and who reported gains on the EIPSES continued to have access to Online RIT and practiced on their own for the next 5 weeks, but did not receive any remote coaching. Parents who demonstrated <80% fidelity on the RIT-PFF and/or who didn't report increases in the EIPSES were directed into coaching. Coaching involved videoconferences once per week (wks. 6-10) with a parent coach (PI), and followed the occupational performance coaching model. Sessions included review of successes and challenges, parent practice with feedback, problem solving, and planning."
16330432|NCT04467073|No Intervention|Wait List Control|Participants provided with information about available community resources after randomization. These participants were given the opportunity to engage in the stepped-care format of Online RIT after the post-intervention data collection time point; however their data was included exclusively in control group analyses.
16330433|NCT04467060|Experimental|Anaprazole Sodium enteric-coated tablet|Single ascendinng dose (2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg), fasting oral administration.
16330434|NCT04467060|Placebo Comparator|Placebo|single dose, fasting oral administration
16330435|NCT04467047|Experimental|Intervention|Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
16330436|NCT04467034|Experimental|Receives Stanford tobacco education curriculum|Stanford Tobacco Prevention Toolkit is administered.
16330437|NCT04467034|No Intervention|Does not receive Stanford tobacco education curriculum|Receives another curriculum or no tobacco education.
16330438|NCT04467021|Experimental|Arm A (intensive systolic blood pressure management)|Patients receive intensive systolic blood pressure management for 6 months. Patients receive increased blood pressure medication every 2 weeks while systolic blood pressure is 120 mmHg or higher. Patients also monitor blood pressure at home 1 day a week (4 times in 1 day) every 2 weeks, and upload the recorded blood pressure readings to the provider and to a central blood pressure monitoring team. Patients with changes in blood pressure medications monitor blood pressure readings on 3 days in 1 week (4 times in 1 day).
16330439|NCT04467021|Active Comparator|Arm B (usual blood pressure management)|Patients receive standard blood pressure management for 6 months. Patients receive blood pressure medications per doctor's instruction. Patients also monitor blood pressure at home 1 day (4 times in 1 day) every 2 weeks, and upload the recorded blood pressures to a central monitoring team.
16330440|NCT04467008||One group of patients|
16330441|NCT04466995|Experimental|laparoscopic gynecologic surgery|25 laparoscopic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
16330442|NCT04466995|Other|laparotomic gynecologic surgery|25 laparotomic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
16330443|NCT04466969||HF|"Patients with HF with reduced Ejection Fraction (HFrEF) is enrolled if patients meet following criteria within 6 months:
~Ejection Fraction ratio（EF） ≤40%
~New York Heart Association(NYHA) class II-IV"
16330444|NCT04466969||stages of CKD (stage 3b)|"CKD is diagnosed based on the following e Glomerular Filtration Rate (eGFR) categories:
~Stage 3b: 30 mL/min/1.73m2 ≤ eGFR <45 mL/min/1.73m2"
16330445|NCT04466969||Stages of CKD (stage 4)|"CKD is diagnosed based on the following eGFR categories:
~15 mL/min/1.73m2 ≤ eGFR <30 mL/min/1.73m2"
16330446|NCT04466969||stages of CKD (stage 5)|"CKD is diagnosed based on the following eGFR categories:
~eGFR <15 mL/min/1.73m2"
16330448|NCT04466956|Active Comparator|Virtual reality for reduction of pain and anxiety during MVA|15 participants randomised to use VR headset during MVA and complete questionnaire and short interview regarding experience
16330449|NCT04466956|No Intervention|Control group- no VR|15 participants randomised to not use VR headset during MVA and complete questionnaire and short interview regarding experience
16330450|NCT04466943|Experimental|group A|Moderate neuromuscular blockade (NMB) , defined as a 1±2 twitch response to the train-of four (TOF) by stimulation of the ulnar nerve. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
16330451|NCT04466943|Experimental|group B|Deep NMB, defined by (0 twitch count in the TOF, 1±2 twitch responses in the post-tetanic count. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
16330452|NCT04466917|Experimental|ABP 215|"Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles.
~All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles."
16330453|NCT04466917|Active Comparator|Bevacizumab|"Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles.
~All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles."
16330454|NCT04466904|Experimental|IBI362 low dose cohort|Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.
16330455|NCT04466904|Experimental|IBI362 medium dose cohort|Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
16330456|NCT04466904|Experimental|IBI362 high dose cohort|Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
16330457|NCT04466891|Experimental|ZW25 (Zanidatamab) Monotherapy|
16330458|NCT04466865|Experimental|Best Case/Worst Case communication tool|The participant's enrolled nephrologist will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the participant.
16330459|NCT04466865|No Intervention|Usual Care|"Usual care conversations are typically focused on mode and timing of dialysis, management of electrolytes and scheduling of laboratory testing. Conservative management or a treatment option of no dialysis is rarely mentioned."
16330460|NCT04466852|Active Comparator|cardio-relay Family Clinic|Patients discharged from INC hospital and identified as belonging to a Family Clinic randomized to cardio-relay receive instruction for telemedicine consultations. These are based on their own devices, when available, or provided by their local community agents associated in the study.
16330461|NCT04466852|No Intervention|control Family Clinic|Patients discharged from INC hospital and identified as belonging to a Family Clinic randomized to the control group or belonging who consent to participate in follow-up
16330462|NCT04466852|Active Comparator|cardio-relay Basic Clinic|Patients discharged from INC hospital and identified as belonging to a Basic Clinic randomized to cardio-relay receive instruction for telemedicine consultations. These are based on their own devices, when available, or provided by their local community agents associated in the study.
16330463|NCT04466852|No Intervention|control Basic Clinic|Patients discharged from INC hospital and identified as belonging to a Basic Clinic randomized to the control group or belonging who consent to participate in follow-up
16330464|NCT04466839||parkinsonian patients|Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.
16330465|NCT04466826|Experimental|Minors with chronic migraines|
16330466|NCT04466813|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
16330467|NCT04466813|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
16330468|NCT04466800|Experimental|Intervention group_rehabilitation program|multidisciplinary and personalized rehabilitation program
16330469|NCT04466800|No Intervention|Control group|Usual care of each site, including delivery of an information sheet concerning recommended physical activity (based on WHO recommendations) and nutrition. One month after inclusion, patients of this group will be offered a rehabilitation program (as described in the intervention group, but with only one session with a physical activity educator at home) and one dietitian consultation.
16330470|NCT04466787|Experimental|Spectral Photon Counting Computed Tomography (SPCCT)|The randomized SPCCT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
16330471|NCT04466787|Active Comparator|Dual Energy CT (DECT)|The randomized DECT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
16330472|NCT04466774|Experimental|Dip Home-Based Dipstick Analyzer|Each participant will test their urine sample using the HBDA. device
16330473|NCT04466761|Experimental|Experimental: Cohort 1-4|60% of subjects per cohort will consume 30-90 grams of dietary supplement daily for 4 weeks, with each successive cohort dosage increasing according to a Fibonacci dose escalation.
16330474|NCT04466761|Placebo Comparator|Placebo: Cohort 1-4|40% of subjects per cohort will consume 30-90 grams of daily placebo for 4 weeks with each successive cohort dosage increasing in parallel to the experimental arm.
16330475|NCT04466748|Experimental|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration."
16330476|NCT04466748|Placebo Comparator|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
16330477|NCT04466735|Experimental|Active group|Participants will be on the active intervention for 6 months
16330478|NCT04466735|Placebo Comparator|Placebo Group|Participants will be on the placebo intervention for 6 months
16330479|NCT04466735|Active Comparator|Open phase on active product|At the end of the 6-month randomized controlled phase, participants will be unblinded and invited to continue on the active product for an additional 3 months.
16330480|NCT04466696||t4 colorectal cancer treated with ERAS protocol|prospective from January 2016 to May 2020
16330482|NCT04466683|Experimental|Low radiation arm|A single dose of 35 cGY delivered to the whole thorax
16330484|NCT04466683|No Intervention|Control arm|Patients will receive no radiation therapy but will have research samples collected and best supportive care
16330485|NCT04466670|No Intervention|phase 1|Observational arm
16330486|NCT04466670|Experimental|phase 2A|Acetylsalicylic acid
16330487|NCT04466670|Experimental|phase 2B|inhaled unfractionated heparin
16330488|NCT04466670|Placebo Comparator|Placebo|Placebo arm for Phase 2A
16330489|NCT04466657|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
16330490|NCT04466657|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus daily antioxidant supplement composed of two proprietary formulations that include reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
16330491|NCT04466644||The regulars of IVF clinics in the USA|Mainly asymptomatic individuals composed by patients who are attending their regular medical consultation and/ clinic staff of the participant sites, located in two areas of the USA with different pandemic status, and undergoing PCR and ELISA tests for diagnosis of COVID-19 before initiating the work after the lockdown.
16330492|NCT04466631||Observative longitudinal|The participants won't receive any support during the post surgery period.
16330493|NCT04466618|Placebo Comparator|Saline|Saline infusion
16330494|NCT04466618|Active Comparator|Exendin-9,39|Exendin-9,39 infusion
16330495|NCT04466618|Active Comparator|Saline + Intralipid/Heparin|Induction of acute insulin resistance during Saline infusion
16330496|NCT04466618|Active Comparator|Exendin-9,39 + Intralipid/Heparin|Induction of acute insulin resistance during Exendin-9,39 infusion
16330497|NCT04466605|Experimental|Tele-Yoga Therapy|All patients randomized to the intervention group had one to one yoga sessions with yoga therapist twice a week for 45 minutes on secure virtual platform. Patients were encouraged with home practice to follow everyday at least for 30-mins.
16330498|NCT04466605|Active Comparator|Usual Care|Patients randomized to usual care continued to receive care for their chronic musculoskeletal pain from their primary care physician. There was no attempt by to influence clinical management unless an emergency arose
16330499|NCT04466592|Experimental|Supportive intervention|A research psychologist will support participants, promoting their competences in the recover of work and social activities, such as the compliance.
16330500|NCT04466579|Experimental|BIS monitoring|Study subjects randomized in this study arm will have the depth of anesthesia controlled with the BIS monitor.
16330501|NCT04466579|Active Comparator|Standard care|Study subjects randomized in this study arm will receive standard anesthesiology care according to the usual procedures used at the study centre.
16330502|NCT04466566|Placebo Comparator|Saline|Saline will be infused during the study
16330503|NCT04466566|Active Comparator|Exendin-9,39|Exendin-9,39 will be infused during the study
16330504|NCT04466553||NICO BrainPath™ Patients|"50 patients will be enrolled in Group A NICO BrainPath™ system.
~The NICO BrainPath™ System has been proposed to reduce high morbidity and mortality associated with ICH through minimally invasive clot evacuation. Previous, single-center trials concluded evacuation of ICH using the BrainPath™ system as being safe and effective. Additionally, previous studies concluded that lesser ICH removal was correlated with mortality benefit and that the NICO BrainPath™ system approach was shown to be safe and effective with a high rate of clot evacuation and functional independence. This system warrants further research because of the need to optimize clinical outcome in these patients and to better define the role of hematoma evacuation in the care of these patients."
16330505|NCT04466553||Standard of Care|50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care (e.g. no surgical intervention). These patients will be matched to the surgical patients based on age, gender, and location of hemorrhage.
16330506|NCT04466540|Experimental|Hydroxychloroquine (HCQ)|HCQ group participants will receive a dose of 400mg twice daily (BID) in the first day, and a dose of 400 mg once daily (OD) from the second day of treatment, in a total of 7 days.
16330507|NCT04466540|Placebo Comparator|Placebo|The placebo group will follow the same regimen of administration
16330508|NCT04466527|Experimental|Treatment|Subjects in this arm will undergo laser treatment on their active acne vulgaris lesions. Subjects will serve as their own control.
16330509|NCT04466514|Experimental|Treatment A - Fasting|Fasting conditions
16330510|NCT04466514|Experimental|Treatment B - Fed|High-fat/high-calorie breakfast
16330511|NCT04466514|Experimental|Treatment C - Fed|Low-fat/low-calorie breakfast
16330512|NCT04466501|Experimental|ACR LAB for Professional User|
16330513|NCT04466488|No Intervention|Standard of care study arm|"The standard TPT implementation is for a clinician to screen for TB and to consider TPT for those who do not have presumptive TB. Clinicians in the study district (and most districts in South Africa) have received training and job aids to assist in appropriate application of the TPT initiation algorithm. Prescribing for TPT and ART is done by writing, by hand, the prescription in the patient's paper file. As part of this study, all study clinic providers will have access to standard Department of Health printed material and clinical training."
16330514|NCT04466488|Experimental|Choice Architecture study arm|"In the choice architecture implementation strategy, all opt-out clinic providers and pharmacists will be trained on the approach. The fundamental tenant of this approach is that TPT will be prescribed with any ART initiation and any ART re-prescribing for 3-12 months of TPT (adherent to current guidelines) if TPT has not been previously prescribed. This will be facilitated by co-prescribing ART and TPT. That is when ART is being prescribed TPT is meant to be prescribed at the same time of the clinic visit.
~The simultaneous prescribing will be facilitated through the introduction of an ink stamp or pre-printed sticker to use for quick entry of the ART prescription along with TPT and cotrimoxazole. The stamp/sticker for ART prescription, the prescription for TPT and for cotrimoxazole will be automatically included. Active canceling of these prescriptions (and indicating the reasons) will be needed to not have TPT dispensed."
16330516|NCT04466436||CABG group|
16330517|NCT04466436||spine group|
16330518|NCT04466423|Experimental|Small group intervention|Those randomized to the immediate intervention arm will be asked to meet approximately every other week for 6 months, covering 12 sessions. We will ask each group to meet in a relatively private setting (e.g., a restaurant near campus or a reserved meeting room), rather than more public spaces (e.g. river room, cafeteria) where interruptions are more likely.
16330519|NCT04466423|Placebo Comparator|Control|"Participants randomized to Arm 2 (delayed intervention) will be wait listed to begin sessions 6 months after the start of the study. This participation will be optional."
16330524|NCT04466397||3D printed implants reconstruction group|The patients with large bone defects who treated by 3D printed individualized porous implants
16330525|NCT04466384|Other|Propofol|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Propofol will be started at a concentration of 0.5 µg/ml followed by incremental increases in the target effect-site concentrations of 1.5, 2, 2.5, 3, 4, 6, and 8 µg/ml until a MOAA/S score less than 2 is reached.
16330526|NCT04466384|Other|Propofol with Remifentanil|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Approximately 2 minutes before starting propofol, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, remifentanil will be given by a continuous infusion. Within approximately 7 minutes, the infusion rate of Remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml throughout the study.
16330527|NCT04466371||MIU students and staff members|All students and staff members in MIU
16330528|NCT04466358|Experimental|Modified CLOSE protocol|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol, confirmed with multipolar circular mapping catheter.
16330529|NCT04466358|Active Comparator|High density mapping guided pulmonary vein isolation|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol and confirmed with high density mapping of each pulmonary vein antrum, with additional ablation lesions at sites of gap or dormant conduction.
16330530|NCT04466345|Experimental|Semaglutide|Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
16330531|NCT04466345|Placebo Comparator|Placebo|Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
16330532|NCT04466332|Experimental|Saline ECG with Pilot Tip Location System|PICC insertion using electrocardiographic guidance Pilot Tip Location System (TLS), ECG signal transmission is with saline water
16330533|NCT04466332|Experimental|Guidewire ECG with Sherlock Tip Confirmation System|PICC insertion using electrocardiographic guidance Sherlock 3CG Tip Confirmation System (TCS), ECG signal transmission is with guidewire
16330534|NCT04466319|Experimental|intervention arm|The individuals in the intervention group in the rocking chair three times a day, 20 minutes, a total of 60 minutes after the first day after surgery.They did this intervention until they first defecation .
16330535|NCT04466319|No Intervention|Control arm|The individuals in the control group sat in a standard chair in the same time as the intervention group in the non-rocking chair.
16330536|NCT04466293|No Intervention|Standard of care study arm|"Providers will receive training on benefits, indications, and contra-indications for TPT. Providers will use the standard approach of the default being to not prescribe. Only if providers specifically write for TPT will it be dispensed by a pharmacy or the provider."
16330537|NCT04466293|Experimental|Choice Architecture study arm|"Clinic staff will be responsible for strategy delivery for all patient interactions. Research staff will provide training and guidance for the choice architecture arm. Research staff will also work with the clinics to develop appropriate clinical stationary, ink stamps, stickers, or EMR modifications for prescribing, and reminder systems (e.g. written by pharmacy in clinic file, post-it on clinic file, post-it on lab results). The goal of this approach is for TPT prescribing to occur routinely and as part of ART prescribing. This is in contrast to considering prescribing only at the end of a long algorithm that includes TB and other assessments. With this approach, a patient will automatically be prescribed TPT unless the clinician specifically decides patients are not candidates due to active TB treatment or other clinical reasons."
16330538|NCT04466280|Active Comparator|Control Group|Participants in this group use personal protective equipment in the face of patients with COVID-19
16330539|NCT04466280|Experimental|Intervention Group 1|In this group, participants will receive 200 mg of hydroxychloroquine tablets daily in addition to personal protective equipment.
16330540|NCT04466280|Experimental|Intervention Group 2|In this group, participants, while observing and using complete personal protective equipment, will apply a thin layer of Dentol gel to the vestibular area of the mouth daily, every 6 to 8 hours.
16330541|NCT04466254|Experimental|Arm A|CPGJ602 325mg/m2 IV Q2W； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks.
16330542|NCT04466254|Experimental|Arm B|CPGJ602 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
16330543|NCT04466254|Active Comparator|Arm C|cetuximab 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
16330544|NCT04466241|Active Comparator|Lopinavir/ritonavir|Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
16330545|NCT04466241|Experimental|Lopinavir/ritonavir + telmisartan|"Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
~Telmisartan 40 mg : 1 tablet daily from Day 1 to Day 10"
16330546|NCT04466241|Experimental|Lopinavir/ritonavir + atorvastatin|"Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
~Atorvastatin 20 mg : 1 tablet daily from Day 1 to Day 10"
16330547|NCT04466228|Experimental|Stim1 high dose|This group will receive high dose non-invasive transcranial electrical stimulation
16330548|NCT04466228|Experimental|Stim2 low dose|This group will receive low dose non-invasive transcranial electrical stimulation
16330549|NCT04466228|Sham Comparator|Sham control|This group will receive sham control non-invasive transcranial electrical stimulation
16330550|NCT04466215|Active Comparator|CORT118335|900 mg (6 x 150 mg) tablets daily taken orally for one week
16330551|NCT04466215|Placebo Comparator|Placebo|Six placebo tablets taken orally for one week
16330552|NCT04466202|Experimental|Music Group with Structured Verbal Training|Music with structured verbal training was applied during transrectal ultrasound guided prostate biopsy.
16330553|NCT04466202|No Intervention|Control Group|The control group did not listen to music during the procedure, and they received routine training.
16330554|NCT04466189||Pancreatic Cancer Patients Treated With Proton Beam Therapy|Pancreatic Cancer Patients Treated With Proton Beam Therapy
16330555|NCT04466176|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16330556|NCT04466176|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
16330557|NCT04466163|Experimental|Schema Therapy and the Healthy Adult|For this study the ST-HA protocol outlined by Broersen & Claassen (2019) will be followed, consisting of ten one-and-a-half hour individual sessions across ten weeks with daily homework assignments (30-60 minutes). The ST-HA protocol is based on three pillars, aimed at improving self-compassion, well-being and positive affect. First psycho-education about compassionate affect regulation is given and patients learn to recognize the importance of self-caring behavior in stimulating the soothing- affect system to buffer against stress. The second pillar of the ST-HA protocol concerns the development of personal values and committed action as well as getting insight in values of important others. The third pillar concerns developing self-compassion
16330558|NCT04466163|No Intervention|Baseline|Outcome variables will be measured repeatedly in a pre-treatment baseline condition (2-5 weeks). Patients are randomly assigned to a pre-treatment/baseline phase. In the present study a restricted randomisation is chosen (Heyvaert & Onghena, 2014a). A minimum length of the phases is decided a priori in order to prevent for the assignment of too few measurements per phase and to ensure that the full treatment protocol can be offered
16330559|NCT04466150|Active Comparator|Ocrelizumab treated|Participants age 18-50 with a first clinical presentation of MS or high-risk CIS diagnosed within 90 days of screening will be treated with ocrelizumab (300 mg IV x 2 doses given 2 weeks apart) at disease origin and with maintenance ocrelizumab 600 mg every 6 months through 30 months with a final study visit at 3 years
16330560|NCT04466150|No Intervention|Observational study cohort|Subjects enrolled into an observational study matched for the same disease duration and who are either untreated or treated with alternate MS disease modifying therapies will serve as a parallel reference group
16330561|NCT04466137|Experimental|YPEG-rhG-CSF 2mg|YPEG-rhG-CSF 2mg
16330562|NCT04466137|Experimental|YPEG-rhG-CSF 33μg/kg|YPEG-rhG-CSF 33μg/kg
16330563|NCT04466137|Active Comparator|Positive Control Group|rhG-CSF/PEG-rhG-CSF
16330564|NCT04466098|Experimental|Mesenchymal Stromal Cells|Three fixed doses of MSC approximately 48 hours apart.
16330565|NCT04466098|Placebo Comparator|Placebo|Three fixed doses of placebo control approximately 48 hours apart.
16330566|NCT04466085|Experimental|Population I|In population I, there were 150 subjects who injected with 2 doses of low-dose test vaccine into the deltoid muscle of the upper arm according to the 0 and 1 month immunization schedule.
16330567|NCT04466085|Experimental|Population II|In population II, there were 150 subjects who injected with 2 doses of high-dose test vaccine in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
16330568|NCT04466085|Placebo Comparator|Population Ⅲ|In population Ⅲ, there were 150 subjects who injected with 2 doses of placebo in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
16330569|NCT04466085|Experimental|Population Ⅳ|In population Ⅳ, there were 150 subjects who injected with 3 doses of low-dose test vaccine in the upper arm deltoid muscle according to the 0, 1, and 2 month immunization schedule.
16330570|NCT04466085|Experimental|Population Ⅴ|In population Ⅴ, there were 150 subjects who injected with 3 doses of high-dose test vaccine into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
16330571|NCT04466085|Placebo Comparator|Population Ⅵ|In Population Ⅵ, there were 150 subjects who injected with 3 doses of placebo into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
16330572|NCT04466072||High Ventricular Arrhythmia burden group|"Inclusion criteria for all groups:
~age >18 years-old
~competent and willing to provide consent
~presence of implantable cardioverter-defibrillator
~diagnosis of cardiomyopathy
~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment
~Inclusion criteria for high ventricular arrhythmia burden group:
~• at least one episode of sustained VT/VF or VT/VF requiring ICD therapies within the preceding 3 months as assessed on device interrogation at the time of study enrollment
~Both groups will have stool sample collected for microbial analysis. This is anticipated twice for the high ventricular arrhythmia (VA) burden group. Once at the time of diagnosis of VA and later after the clinically indicated treatment for the VA."
16330573|NCT04466072||Control group|"Inclusion criteria for all groups:
~age >18 years-old
~competent and willing to provide consent
~presence of implantable cardioverter-defibrillator
~diagnosis of cardiomyopathy
~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment
~Inclusion criteria for control group:
~• no VT/VF on device interrogation for a period of at least 3 months preceding study enrollment
~Both groups will have stool sample collected for microbial analysis. This is anticipated only once for the control group."
16330574|NCT04466046|Active Comparator|midazolam with ramosetron (MR)|Midazolam 0.05mg/kg is given to the patients intravenously before anesthesia induction and ramosetron 0.3mg is received 10 minutes before surgery.
16330575|NCT04466046|Active Comparator|midazolam with palonosetron (MP)|Midazolam 0.05mg/kg is given to the patients intravenously before anesthesia induction and palonosetron 0.075mg is received immediately before anesthesia.
16330576|NCT04466033|Experimental|Magneto Microcatheter|
16330577|NCT04466020||Patients with Chronic Breathlessness|Patients with Chronic Breathlessness
16330578|NCT04466007|Placebo Comparator|Control arm|0.9% physiological saline
16330579|NCT04466007|Experimental|Low dose treatment arm|Low dose allogeneic mesenchymal stem cells derived from adipose tissue
16330580|NCT04466007|Experimental|High dose treatment arm|High dose allogeneic mesenchymal stem cells derived from adipose tissue
16330581|NCT04465994||primary repair|Patients with acute achilles tendon ruptures who received the treatment of primary repair.
16330582|NCT04465994||gastrocnemius turn-down flaps|Patients with acute achilles tendon ruptures who received the treatment of gastrocnemius turn-down flaps.
16330583|NCT04465981||Patients with lab-confirmed COVID-19|Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
16330584|NCT04465981||Patients who are suspected to have or are confirmed to not have COVID-19|Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
16330585|NCT04465968|Experimental|CRT + Durvalumab ± Surgery + Durvalumab|Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.
16330586|NCT04465955|Experimental|NGM621 Treatment Group A (every 4 weeks)|NGM621 single IVT injection
16330587|NCT04465955|Experimental|NGM621 Treatment Group C (every 8 weeks)|NGM621 single IVT injection
16330588|NCT04465955|Sham Comparator|Sham Group B (every 4 wks) & D (every 8 wks)|Sham
16330589|NCT04465916|Experimental|Experimental Arm|Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
16330590|NCT04465916|Placebo Comparator|Control Arm|Control Arm: Placebo + NA daily (12 patients)
16330591|NCT04465903||Dysphagia patients|The first group consists of 85 dysphagia patients who have at least six months of dysphagia complaints. The participants will given the Turkish version of Sydney Swallow questionnaire (SSQ-T), consisted of 17 questions, eating assessment tool-10 and two scales evaluated with FEES. After the two weeks, 30 participants will given the SSQ-T for sampling.
16330592|NCT04465903||Healthy adults|The second group consists of 85 healty participants will given the SSQ-T consists of 17 questions, eating assessment tool-10.
16330593|NCT04465890|Experimental|Single dose ASC22 injection 0.3mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,0.3mg/kg dose of the drug once.
16330594|NCT04465890|Experimental|Single dose ASC22 injection 1.0mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,1.0mg/kg dose of the drug once.
16330595|NCT04465890|Experimental|Single dose ASC22 injection 2.5mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,2.5mg/kg dose of the drug once.
16330596|NCT04465890|Experimental|Multiple dose ASC22 injection 1.0mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks
16330597|NCT04465890|Experimental|Multiple dose ASC22 injection 2.5mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 2.5mg/kg, up to 24 weeks
16330598|NCT04465890|Placebo Comparator|Placebo sodium chloride injection A|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (1.0mg/kg).
16330599|NCT04465890|Placebo Comparator|Placebo sodium chloride injection B|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (2.5mg/kg).
16330600|NCT04465877|Experimental|JTT-662 Dose 1|JTT-662 Tablets Dose 1 by mouth once daily from Day 1 to Day 28
16330601|NCT04465877|Experimental|JTT-662 Dose 2|JTT-662 Tablets Dose 2 by mouth once daily from Day 1 to Day 28
16330602|NCT04465877|Experimental|JTT-662 Dose 3|JTT-662 Tablets Dose 3 by mouth once daily from Day 1 to Day 28
16330603|NCT04465877|Placebo Comparator|Placebo|Placebo Tablets by mouth once daily from Day 1 to Day 28
16330604|NCT04465864|Other|Insertion visit 4 days prior|Intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
16330605|NCT04465864|Other|Surgical 1 visit day 0|Intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
16330606|NCT04465851|Active Comparator|FS65_Curc|Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day
16330607|NCT04465851|Placebo Comparator|FS65_Plac|Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose])
16330608|NCT04465851|Placebo Comparator|FS0_Plac|Placebo (Ferrous Sulphate placebo [cellulose]) and Placebo (Curcumin placebo [cellulose])
16330609|NCT04465851|Placebo Comparator|FS18_Plac|Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose])
16330610|NCT04465851|Active Comparator|FS18_Curc|Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day
16330611|NCT04465838||Psoriasis|This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
16330612|NCT04465825|Active Comparator|Interspersing HITT in exercise|We will test whether introducing HITT into an acute exercise bout will increase overall energy expenditure or time to fatigue.
16330613|NCT04465825|No Intervention|Acute exercise bout with no HITT|Exercise will occur at 50% peak without introducing HITT.
16330614|NCT04465812|No Intervention|Standard health counseling at baseline|Standard health counseling at baseline
16330637|NCT04465643|Other|Immunotherapy with Nivolumab and Ipilimumab|Nivolumab 4.5 mg/kg every 3 weeks (Q3W) x 2 Ipilimumab 1 mg/kg Q3W x 2 Nivolumab monotherapy 4.5mg/kg Q3W concurrent with standard therapy Nivolumab monotherapy should be held for at least 2 weeks before and 2 weeks after surgery
16330638|NCT04465630|Other|Pseudophakic eyes with Open Angle Glaucoma|Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.
16330639|NCT04465591||Myocardial infarction|Recruited patients with STEMI or NSTEMI and elevated Troponin T
16330848|NCT04464239|Experimental|Part A: Cohort 2: TS-142 30 mg|Single dose of TS-142 30 mg or placebo in a fasted condition.
16330615|NCT04465812|Experimental|Self-monitoring and personalized feedback on smartphone app|"Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;
~Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index > 15 to assess detail clinical status and recommend outpatient visit if necessary;
~Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS>49 or SDS>52 to assess detail clinical status and recommend outpatient visit if necessary;
~Patients will complete cognitive training games every week on app;
~Medical staff will send health information on app"
16330616|NCT04465799|Experimental|ENTREN Programme|This intervention consists in a total of 12 biweekly sessions: 9 sessions of 2-hr only for children, with a further three 3-hr sessions attended by both families and children together: nutrition, physical activity sessions, and a closing event session. Children content was developed based a cognitive-behavioural perspective, and included motivational interviewing tools. The aim of the children's programme is, to promote healthy eating habits, problem awareness, motivation to change unhealthy behaviours, health commitment, emotional regulation, social skills and self-esteem. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
16330617|NCT04465799|Experimental|ENTREN-F Programme|ENTREN-F has the same children's intervention than ENTREN. It has extra 6 2-hr sessions to work on family environment and communication, plus three 2-hr sessions attended by both families and children together. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
16330618|NCT04465799|Other|Control group|The intervention of this group consists in usual treatment in Primary Care provided by Endocrinology Services. 3 monthly face-to-face consultations and continuous online monitoring are provided to these families, oriented to promote healthy habits of nutrition and physical activity for 6 months. It works from an exclusively behavioural perspective. A token economy is used with the families as a system of contingency management based on the systematic reinforcement of target behaviour.
16330619|NCT04465773|Experimental|pupillometry|General anesthesia for scheduled gynecological surgery Propofol target concentration adjusted to maintain bispectral index between 45 and 55 for 10 minutes Remifentanil target concentration 1 ng/ml for 10 minutes Tetanic stimulations of 10-20-30-40-50-60 milliamps (5 seconds per stimulation, 2 minutes between stimulations) Continuous pupillometry VideoAlgesiGraph
16330620|NCT04465760|Experimental|Supportive Care (xisomab 3G3)|Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.
16330621|NCT04465734|Experimental|A (treatment group)|HLX10 in combination with HLX04
16330622|NCT04465734|Sham Comparator|B (control group)|sorafenib
16330623|NCT04465721|Active Comparator|HABIT Group|Participants randomized to the HABIT group will maintain their habitual eating schedule (≥13-h).
16330624|NCT04465721|Experimental|TRE Group|Participants randomized to TRE will reduce their eating window to a self-selected eating window (≤10-h).
16330625|NCT04465708|Other|Homework, Organization, and Planning Skills (HOPS)|"The Homework, Organization, and Planning Skills (HOPS) intervention is delivered through a series of 16 frequent but brief sessions between the school professional and student. For the purposes of this study, the school professional will be called a school partner. Each session is approximately 20 minutes. The three main skill areas covered as part of the program are: (1) school materials organization, (2) homework management and (3) time management and planning. A reward system is utilized in effort to change behavior patterns by making rewards available when a student engages in productive organizing and planning behaviors. The intervention also includes two parent meetings and one teacher meeting."
16330626|NCT04465708|No Intervention|Treatment-As-Usual Waitlist (WL-TAU)|The Treatment-As-Usual Waitlist (WL-TAU) will be enacted for study participants attending the enrolled schools assigned to this arm. After providing post data (and in some cases, follow-up data as well), participants will then receive the HOPS intervention.
16330627|NCT04465695|Experimental|IFN beta-1b and clofazimine|A 3-day course of 3 doses of subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) consecutively on day 1 to day 3 and oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
16330628|NCT04465695|Active Comparator|Clofazimine|A 3-day course of oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
16330629|NCT04465695|No Intervention|Control|Standard care alone
16330630|NCT04465682|Experimental|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm. Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user
16330631|NCT04465669|Active Comparator|Orsiro|Implantation of a Orsiro® biolimus a9 eluting coronary stent (drug-eluting stent, DES)
16330632|NCT04465669|Active Comparator|Resolute Integrity|Implantation of a Resolute Integrity® zotarolimus eluting coronary stent (drug-eluting stent, DES)
16330633|NCT04465656||[PCR-COVID 19-Pos] group|Having a microbiological diagnosis confirming COVID-19 infection (ie positive RT-PCR on nasopharyngeal swab) and/or clinical/CT signs
16330634|NCT04465656||[PCR-COVID 19-Neg] group|Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
16330635|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Pos] group|"Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
~Having been tested positive in a serological test for COVID-19 at M3"
16330636|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Neg] group|"Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
~Having been tested negative in a serological test for COVID-19 at M3"
16330849|NCT04464239|Experimental|Part B: Cohort 4: TS-142 20 mg|Daily doses of 20 mg TS-142 or placebo for 7 days before bedtime.
16330640|NCT04465591||Myocardial injury|Recruited patients with myocardial injury based on elevated Troponin T and associated with renal failure, severe infection, strenouos exercise, atrial fibrillation, myocarditis, takotsubo cardiomyopathy or other similar conditions
16330641|NCT04465578|Active Comparator|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
16330642|NCT04465578|Active Comparator|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
16330643|NCT04465565|Experimental|Intravenous fluid administration|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin
16330644|NCT04465565|No Intervention|Control Group|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons
16330645|NCT04465552||Hospitalized COVID-19 Patients|
16330646|NCT04465539|Placebo Comparator|control group|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
16330647|NCT04465539|Experimental|Hydroxyethyl starch group):|Patients will start therapy with Hydroxyethyl starch instead of normal saline (6% hetastarch 600/0.75 in 0.9% sodium chloride) with a dose of 500 cc in 6 hours. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
16330648|NCT04465539|Experimental|Combined Hydroxyethyl starch and hydrocortisone group|Patients will start therapy with combined Hydroxyethyl starch (Voluven®, fresenius kabi, Germany) and hydrocortisone (SOLU-CORTEF 100 mg ampoule) instead of normal saline of normal saline as follow: Hydroxyethyl starch dose is 6% hetastarch 600/0.75 in 0.9% sodium chloride with a dose of 500 cc in 6 hours. Hydrocortisone dose is 200-300 mg /day intravenously until normalization of blood pressure. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
16330649|NCT04465513|Active Comparator|Best Standard of Care + CARDIO|Combination of CARDIO and Best Standard of Care
16330650|NCT04465513|Placebo Comparator|Best Standard of Care|Placebo and Best Standard of Care
16330651|NCT04465500|Other|Treatment|
16330652|NCT04465487|Experimental|REGN6569+cemiplimab|REGN6569 lead-in
16330653|NCT04465461|Experimental|Treatment|Patients exhibiting baseline collateral ventilation by Chartis® balloon catheter assessment who undergo video-assisted thoracoscopic surgery (VATS) fissure completion surgery, confirmation of fissure completion by computerized tomography (CT) scan and confirmation of conversion to collateral ventilation negative by Chartis® balloon catheter assessment post VATS surgery and subsequent Zephyr Valve insertion.
16330654|NCT04465448||healthy volunteers|
16330655|NCT04465448||group case|
16330656|NCT04465435||SUN-participants|"University students enrolled in a selected university in Stockholm, studying on a full-time educational program with at least one academic year left before graduation.
~There is no intervention. The exposures are repeated measures, 5 times (every three months), using web-based self-report questionnaires during one academic year. Also weekley SMS are used to measure depression, anxiety and pain intensity."
16330657|NCT04465422|Experimental|Intervention Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.
~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance."
16330658|NCT04465422|Active Comparator|Control Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.
~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.
~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc."
16330659|NCT04465409|Experimental|Presbyopic adults|"Presbyopic adults, male or female between 40-65 years of age who need from +1.25 D to +3.50 D of reading addition in the non-dominant eye to improve near visual acuity by at least one line or more.
~In this investigation, CorVision® will be implanted in the non-dominant eye to improve near vision and the dominant eye is left intact or corrected by a standard refractive surgery to emmetropia. In brief, subjects will undergo laser corneal surgery on their non-dominant eye to create an anterior stromal pocket into which the investigational device will be implanted."
16330660|NCT04465396|Experimental|Sequence AB|Cohort 1 participants will receive 3 milligram (mg) of Teduglutide and Cohort 2 participants will receive 4 mg of Teduglutide subcutaneous (SC) injection using syringe on Day 1 of treatment period I (Sequence A) followed by SC pen injector on Day 1 of treatment period II (Sequence B). A washout period of 7 days will be maintained between the treatment period I and II.
16330718|NCT04464980|Experimental|Retention: SL-BUP high dose + MMR|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
16330661|NCT04465396|Experimental|Sequence BA|Cohort 1 participants will receive 3 mg of Teduglutide and Cohort 2 participants will receive 4 mg of Teduglutide SC pen injector on Day 1 of treatment period I (Sequence B) followed by SC injection using syringe on Day 1 of treatment period II (Sequence A). A washout period of 7 days will be maintained between the treatment period I and II.
16330662|NCT04465383|Experimental|Digital Sedation|Digital Sedation with rescue intravenous sedation (propofol) if needed upon patient request
16330663|NCT04465383|Active Comparator|Intravenous sedation|Control arm with conventional Intravenous sedation
16330664|NCT04465357|Experimental|Erenumab-Aooe 140 MG/ML [Aimovig]|Participants received 140 mg/mL administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for three months (12 weeks).
16330665|NCT04465344|Experimental|IOL implantation experimental|Experimental arm: Trifocal intraocular lens Isatis TF
16330666|NCT04465344|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens Isatis
16330667|NCT04465331||patients with knee arthrosis|Painful Knee Osteoarthritis with presence of osteophytes on radiography
16330668|NCT04465318|Experimental|E-cigarettes (EC)|EC + Counseling
16330669|NCT04465318|Active Comparator|Nicotine Replacement Therapy (NRT)|NRT + Counseling
16330670|NCT04465305|Experimental|enraped group|patients with a new treatment of tarlov cysts
16330671|NCT04465305|Active Comparator|plasty group|patients with traditional treatment of tarlov cysts
16330672|NCT04465292|Experimental|Intervention|Participants will receive Tildrakizumab 100mg at Weeks 0, 4, 16; three doses; a 16-week treatment course and 24-week followup
16330673|NCT04465279|Experimental|Trifocal Diffractive Intraocular Lens (FineVision)|36 eyes having implantation of trifocal diffractive IOL (FineVision)
16330674|NCT04465266|Experimental|50 mg Tolperisone|50 mg tablets (2 days SD, 2 days TID)
16330675|NCT04465266|Experimental|100 mg of Tolperisone|100 mg tablets (2 days SD, 2 days TID)
16330676|NCT04465266|Experimental|200 mg Tolperisone|200 mg tablets (2 days SD, 2 days TID)
16330677|NCT04465253|Experimental|Health services research (discussion, interview)|Patients participate in a discussion with an occupational therapist via videoconferencing over 15 minutes QW for 4 weeks about their experience with lymphedema and the occupational services they received. After 4 weeks, some patients may also participate in an interview with an occupational therapist via videoconferencing over 60 minutes. During the first week of the study, patients also receive occupational therapy per standard of care.
16330678|NCT04465240|Experimental|Virtual reality simulation of neighborhood disadvantage|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood representative of disadvantage they were assigned to. Then they will watch a video again during a recovery period.
16330679|NCT04465240|Active Comparator|Virtual reality simulation of neighborhood affluence|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood, representative of affluence they were assigned to. Then they will watch a video again during a recovery period.
16330680|NCT04465214||1/Cohort 1|Participants with a diagnosis of cancer who are under active treatment on a protocol at NIH
16330681|NCT04465201|Experimental|Subjects receiving the Impella/Impella® Hemodynamics platform|
16330682|NCT04465188|Experimental|Experimental arm|Surgical procedure to prevent retinal detachment in the unaffected eye
16330683|NCT04465188|No Intervention|Control arm|Standard procedure of clinical practice without any surgical procedure for the unaffected fellow eye.
16330684|NCT04465175|Active Comparator|Second dose magnesium sulphate|Second dose magnesium sulphate 50 mg/kg infused over one hour
16330685|NCT04465175|Placebo Comparator|Placebo|Normal saline (2.5 ml/kg) infused over one hour
16330686|NCT04465162|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy QD 5 times weekly over 3.5-5 weeks.
16330687|NCT04465149|Experimental|Patients|Patients who required germectomy of mandibular third molars. Each patient received local anaesthesia on one side with articaine inoculated with plexus technique while on the other side with mepivacaine using inferior alveolar nerve block technique.
16330688|NCT04465136|Experimental|Received CES intervention|CES with the frequency of 0.5 Hertz; current of 100~600micro-ampere, for 60 minutes, everyday for 6 weeks, total 42 sessions intervention
16330689|NCT04465123|Experimental|Furosemide with spironolactone or hydrochlorothiazide|"IV furosemide dosage will be adjusted according to the protocol as follows. Level 1: previous oral furosemide dose ≤80 mg/day; furosemide 80 mg IV bolus every 6 hours Level 2: previous oral furosemide dose 81-160 mg/day; furosemide 160 mg IV bolus every 6 hours Level 3: previous oral furosemide dose >160 mg/day; furosemide 250 mg IV bolus every 6 hours Furosemide dosage will be adjusted to keep urine output between 3,000 and 5,000 ml/day and >600 ml during 6 hours after furosemide administration.
~If the urine output <3,000 ml/day or <600 ml per 6 hours, furosemide dosage will be increase 1-level up per protocol above.
~If the urine output >5,000 ml/day, furosemide dosage will be reduced 1-level down per protocol above.
~Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels."
16330690|NCT04465123|Active Comparator|Furosemide with placebo|"IV furosemide dosage will be adjusted according to the pre-defined protocol as shown in the experimental group.
~Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels."
16330691|NCT04465110|Experimental|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 7 days
16330692|NCT04465110|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 7 days
16330693|NCT04465097|Experimental|Tucidinostat and Exemestane|Patients receive exemestane from week 1 to week 26 and Tucidinostat BIW from week 3 to week 26. Courses continue in the absence of disease progression or unacceptable toxicity. If the patient is premenopausal, leuprorelin or goserelin will be prescribed.
16330694|NCT04465084|Other|Case|Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
16330695|NCT04465084|Other|Witness|"Person matched to a case on age (+/-3 years) and education level"
16330696|NCT04465071|No Intervention|Standard Treatment|Post-Cataract surgery standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
16330697|NCT04465071|Other|Standard Treatment plus lubricating drops|Lubricant eye-drops (0.3% cross linked sodium hyaluronate, AEONTM Protect Plus and phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vita-mins A and E (AEONTM Repair) for 6 weeks post-Cataract surgery, in addition to the standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
16330698|NCT04465045||Unique cohort|All women, 18 to 43 years, operated from laparoscopy-hysteroscopy for unexplained infertility in montpellier university hospital
16330699|NCT04465032|Active Comparator|Autologous gut microbiome transplantation|Three autologous (own) fecal transplantations (at baseline, 3 and 6 weeks)
16330700|NCT04465032|Experimental|Allogenic gut microbiome transplantation|Three allogenic (lean donor) fecal transplantations (at baseline, 3 and 6 weeks)
16330701|NCT04465019||TBI Group|Subjects in the TBI group included patients who suffered a TBI and who used the EKSO® bionic exoskeleton during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
16330702|NCT04465019||CVA Group|Subjects in the CVA group included all patients in the hospital that used the EKSO® during their rehabilitation process during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
16330703|NCT04465006|Experimental|Hippotherapy Simulator Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
16330704|NCT04465006|Experimental|Conventional Exercise Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
16330705|NCT04464993|Experimental|CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
16330706|NCT04464993|Experimental|CORE + text|CORE components + The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV app) that will provide simple adaptive content based upon length of most recent SST bout and time of day. These prompts will specifically target outcome expectations around SST and MVPA.
16330707|NCT04464993|Experimental|CORE + Lockout|CORE components + Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided with a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
16330708|NCT04464993|Active Comparator|CORE + Earn|CORE components + the investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
16330709|NCT04464993|Active Comparator|CORE + Text + Earn|"Intervention components will be delivered as described in simpler factorial conditions.
~App shows progress toward SST goal or if goal is exceeded. Can earn additional SST through exercise based on 3:1 ratio , simple adaptive content (by SST bout, time of day). Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation."
16330710|NCT04464993|Active Comparator|CORE + Text + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...
~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Simple adaptive content (by SST bout, time of day)."
16330711|NCT04464993|Active Comparator|CORE + Earn + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...
~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio."
16330712|NCT04464993|Active Comparator|CORE + Earn + Lockout + Text|"Intervention components will be delivered as described in simpler factorial conditions, and...
~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio). Simple adaptive content (by SST bout, time of day)."
16330713|NCT04464980|Experimental|Retention: SL-BUP standard dose + MM|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330714|NCT04464980|Experimental|Retention: SL-BUP high dose + MM|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330715|NCT04464980|Experimental|Retention: XR-BUP + MM|Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330716|NCT04464980|Experimental|Retention: XR-NTX + MM|Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330717|NCT04464980|Experimental|Retention: SL-BUP standard dose + MMR|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
16330788|NCT04464681|Placebo Comparator|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
16330875|NCT04464031|Experimental|Alert group|
16330719|NCT04464980|Experimental|Retention: XR-BUP + MMR|Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
16330720|NCT04464980|Experimental|Retention: XR-NTX + MMR|Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
16330721|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with SL-BUP + MM|Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330722|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with XR-BUP + MM|Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330723|NCT04464980|Experimental|Discontinuation: Discontinue XR-BUP with XR-BUP + MM|Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330724|NCT04464980|Experimental|Discontinuation: Discontinue XR-NTX with XR-NTX + MM|Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
16330725|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with SL-BUP + MMD|Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
16330726|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with XR-BUP + MMD|Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
16330727|NCT04464980|Experimental|Discontinuation: Discontinue XR-BUP with XR-BUP + MMD|Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
16330728|NCT04464980|Experimental|Discontinuation: Discontinue XR-NTX with XR-NTX + MMD|Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
16330729|NCT04464967|Experimental|Phase 1, Cohort 1|SNK01 (low dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
16330730|NCT04464967|Experimental|Phase 1, Cohort 2|SNK01 (high dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
16330731|NCT04464967|Experimental|Phase 1, Cohort 3|SNK01 (low dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
16330732|NCT04464967|Experimental|Phase 1, Cohort 4|SNK01 (high dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
16330733|NCT04464967|Experimental|Phase 2, Expansion Cohort 1|SNK01 (TBD RP2D) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
16330734|NCT04464967|Experimental|Phase 2, Expansion Cohort 2|SNK01 (TBD RP2D) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
16330735|NCT04464954|Experimental|Auricular semi-permanent (ASP gold) needles|
16330736|NCT04464954|Experimental|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|
16330737|NCT04464954|Experimental|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|
16330738|NCT04464941|Experimental|oral health promotion program|"The oral health promotion program was a composite intervention with both group and individual components. The group intervention consisted of:
~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:
~1. Instruction in the Bass tooth-brushing method 2. Individual behavioral modification method"
16330739|NCT04464941|No Intervention|Usual care group|
16330740|NCT04464928||User interests|Facebook advertisements arm
16330741|NCT04464928||User characteristics|Google advertisements arm
16330742|NCT04464915|Experimental|Isopropyl alcohol swab every 10 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes for a total of one hour.
16330743|NCT04464915|Experimental|Isopropyl alcohol swab every 20 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 20 minutes for a total of one hour.
16330744|NCT04464915|No Intervention|No treatment arm|No intervention administered.
16330745|NCT04464902|Other|knee extension constraint rehabilitation group|
16330746|NCT04464902|Other|placebo group|
16330747|NCT04464902|Other|control group|
16330748|NCT04464889|Experimental|MDG1021|Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
16330749|NCT04464876|Experimental|Treatment|SATURN TA TMVR Device implanted
16330750|NCT04464863||Cases|Acute stroke patients during the first week of evolution
16330751|NCT04464863||Control|Age and sex 1:1 healthy participants
16330752|NCT04464850|Experimental|Intravenous iron|Iron sucrose 200 mg every 2 weeks Folic acid 5 mg/day B6 10 mg/day
16330753|NCT04464850|Active Comparator|Oral iron|Ferrous fumarate 600 mg/day Folic acid 6.5 mg/day B6 15 mg/day
16330754|NCT04464824||patient over 75 years of age with an emergency room visit|Patients over 75 years of age, with a visit to the emergency department between April 1, 2019 and September 30, 2019, with a non-hospitalization at the end of their visit to the emergency department.
16330755|NCT04464811||Heart failure with diuretic resistance|This group includes acute heart failure patients who has diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have received oral furosemide before. Diuretic resistance was defined as urine output <250 hr at 2 hours after furosemide administration.
16330756|NCT04464811||Heart failure without diuretic resistance|This group includes acute heart failure patients who do not have diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide before. Patients will be defined not to have diuretic resistance if their urine output ≥250 hr at 2 hours after furosemide administration.
16330757|NCT04464798|Experimental|Cohort A- Monotherapy in R/R lymphoma subjects|Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
16330758|NCT04464798|Experimental|Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects|"Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.
~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.
~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
16330759|NCT04464798|Experimental|Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects|"Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.
~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6."
16330760|NCT04464798|Experimental|Cohort D - Monotherapy in other lymphomas subtype subjects|"Subjects with other lymphoma subtype who have been allocated to Cohort D will receive CC-220 monotherapy (MonoT).
~- Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles."
16330761|NCT04464798|Experimental|Cohort E - CC-220 and rituximab in B-cell lymphoma subjects|"Subjects with aggressive B-cell lymphoma who have been allocated to Cohort E will receive CC-220 in combination with rituximab
~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
16330762|NCT04464798|Experimental|Cohort F - CC-220 and rituximab in FL and MZL subjects|"Subjects with follicular lymphoma (FL) (1 to 3a) and marginal zone lymphoma (MZL) who have been allocated to Cohort F Part 2 will receive CC-220 in combination with rituximab.
~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2"
16330763|NCT04464798|Experimental|Cohort G -CC-220 and obinutuzumab in FL and MZL subjects|"Subjects with FL (1 to 3a) and MZL who have been allocated to Cohort G will receive CC-220 in combination with obinutuzumab.
~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15 and on D1 of every 28-day cycle from C2 to C6."
16330764|NCT04464785||Treatment|Subjects who receive the CentriMag Circulatory Support System
16330765|NCT04464759|Experimental|Phase 1a: Nivolumab and Hydroxychloroquine (HCQ)|"Dose escalation:
~Dose Level 1: HCQ 400 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks
~Dose Level 2: HCQ 600 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks
~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
16330766|NCT04464759|Experimental|Phase 2: Nivolumab and Hydroxychloroquine (HCQ)|"HCQ 400-600 mg (maximum tolerated dose from Phase 1a) orally every 12 hours and nivolumab 480 mg IV every 4 weeks
~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
16330767|NCT04464759|Experimental|Phase 1b: Nivolumab + Ipilimumab +Hydroxychloroquine (HCQ)|"HCQ 400-600 mg orally every 12 hours and nivolumab 3 mg/kg IV plus ipilimumab 1 mg/kg IV every 3 weeks x4 cycles
~Then 6 weeks after the last dose of ipilimumab/nivolumab begin maintenance nivolumab 480 mg IV every 4 weeks
~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
16330768|NCT04464746|No Intervention|Control|usual medical follow-up
16330769|NCT04464746|Active Comparator|Intervention|Implementation of a specific program to improve therapeutic adherence
16330770|NCT04464733|Experimental|Treatment group A|
16330771|NCT04464733|Experimental|Treatment group B|
16330772|NCT04464733|Experimental|Treatment group C|
16330773|NCT04464733|Experimental|Treatment group D|
16330774|NCT04464733|Experimental|Treatment group E|
16330775|NCT04464733|Experimental|Treatment group F|
16330776|NCT04464733|Experimental|Treatment group C-|
16330777|NCT04464733|Experimental|Treatment group G|
16330778|NCT04464733|Experimental|Treatment group H|
16330779|NCT04464733|Experimental|Treatment group I|
16330780|NCT04464733|Experimental|Treatment group J|
16330781|NCT04464720|Other|Intervention after One Week|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for one week prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional two weeks.
16330782|NCT04464720|Other|Intervention after Two Weeks|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for two weeks prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional one week.
16330783|NCT04464707|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
16330784|NCT04464707|Placebo Comparator|Placebo|Matching placebo
16330785|NCT04464694|Experimental|Ranibizumab|Single intravitreal injection of ranibizumab (0.5 mg) 3~7 days before vitrectomy
16330786|NCT04464694|Sham Comparator|Sham injection|Sham injection 3~7 days before vitrectomy
16330787|NCT04464681|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
16330789|NCT04464668||Wave 1 Only: Clinics using CARES Intervention|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics to implement the Colorectal Cancer Awareness, Research, Education & Screening (CARES) intervention.
16330790|NCT04464668||Wave 1 Only: Control Clinics|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics as control (usual care) clinics.
16330791|NCT04464668||All Clinics|For Wave 2, the 7 clinics in the control group will roll out as intervention clinic, thus, all 14 clinics will be exposed to the intervention by year 2.
16330792|NCT04464655||Healthy Volunteers|Age: >18 y, No known current or pre-existing medical conditions that would affect the cardiovascular or respiratory system.
16330793|NCT04464655||Patients|Age: > 18y, Clinically indicated CMR exam
16330794|NCT04464642|Experimental|group A|"group A is a control arm who will get conventional drug (methotrexate). 25 mg subcutaneous weekly . at 3 months if DAS-28 not fall by at least 1.2, drug is to be changed and regarded as therapy failure. if at least 1.2 improvement of DAS-28 occur,then therapy is continued for 6 monyhs"
16330795|NCT04464642|Experimental|group B|"group B will get tofacitinib 10 mg weekly. if DAS-28 not improved at least 1.2 at 3 months, it is regarded as therapy failure. if improved at least 1.2, then therapy continued for 6 months"
16330796|NCT04464629|Experimental|Intracanalicular Sustained Release Dexamethasone, 0.4 mg|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of post-surgical inflammation and pain associated with ocular surgery.
16330797|NCT04464629|Active Comparator|topical prednisolone acetate 1%.|
16330798|NCT04464616|Placebo Comparator|control group|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + normal saline (0.5 ml).
16330799|NCT04464616|Experimental|Dexmedetomidine group):|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 5 μg dexmedetomidine in a volume of (0.5 ml).
16330800|NCT04464616|Experimental|Dexamethasone group|spinal anaesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 2 mg dexamethasone in a volume of 0.5 ml).
16330801|NCT04464603|Experimental|Arm A (InterFACE)|"Participants that will use the mHeath InterFACE tool during the simulation-based pediatric scenario.
~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
16330802|NCT04464603|Active Comparator|Arm B (Conventional methods)|"Participants that will use conventional methods during the simulation-based pediatric scenario.
~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
16330803|NCT04464577|Experimental|Arm A: BMS-986235+Fluconazole|
16330804|NCT04464577|Experimental|Arm B: BMS-986235+ Bupropion|
16330805|NCT04464577|Experimental|Arm C: BMS-986235+ Itraconazole|
16330806|NCT04464564|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
16330807|NCT04464564|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
16330808|NCT04464551|Experimental|[14C]D-0316|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (75mg, 50µCi) of [14C]D-0316 to healthy Chinese male subjects
16330809|NCT04464538|Placebo Comparator|Health information|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
16330810|NCT04464538|Experimental|Group education session and individualised coaching (online)|Participants assigned to the WALC-R intervention will attend a virtual baseline educational group session which will include a maximum of five people. The aim of the sessions will be to introduce the basics of the benefits of walking for exercise and why exercise is beneficial, as well as to give information, support and motivation to help participants to independently walk more in their daily routines.The group session will also include goal setting, in which participants will be encouraged to set their own daily walking targets to increase their habitual levels of walking. All participants will be given a pedometer to self-monitor how far they walk and a diary to record activity context throughout the intervention daily. Participants will meet briefly (20-30 minutes) via the internet with an assigned coach every 2 weeks.
16330811|NCT04464525|Experimental|Omecamtiv mecarbil|All subjects will be assigned to OM
16330812|NCT04464512|No Intervention|Standard (control) treatment|"The control group receives 1mcg/kg fentanyl followed by fentanyl 0.5-1mcg/kg q10 minute PRN, ketorolac 0.5mg/kg up to 30mg max IV, and acetaminophen 1000mg IV for pain control intraoperatively. The patient is then treated with hydromorphone 0.005mg/kg q10minutes the post-anesthesia recovery. The patient would then receive hydromorphone 0.005 mg/kg q1hr PRN, 1 gram acetaminophen IV scheduled q6hr, and methocarbamol 750mg QID following discharge from the PACU and transfer to the hospital floor. The patient is converted to oxycodone 10mg (Roxicodone) q4hr PRN and 975 mg PO APAP scheduled for pain control on postoperative day number 1 or when appropriate for PO intake. The patients receives their home dose of suboxone onpostoperative day number 1 or when appropriate for PO intake.
~On postoperative day number 2 number 3, patients are transitioned to an increased dose of their Suboxone for pain control in preparation for discharge."
16330813|NCT04464512|Active Comparator|Treatment Group|Buprenorphine-sufentanil group receives sufentanil 0.03mcg/kg followed by sufentanil 0.01-0.03 mcg/kg q10 min PRN, IV ketorolac 0.5mg/kg up to 30mg max and IV acetaminophen 15mg/kg up to 1000mg for pain control intraoperatively. In the PACU, IV buprenorphine 0.3mg IV q30 minutes would be given as the first line choice for pain control for 3 doses. IV PCA sufentanil is used as a second line therapy if patient comfort is not achieved by IV buprenorphine alone. The patient receives 0.3 mg buprenorphine IV Q6hr PRN, scheduled IV acetaminophen 1 gram for 24 hrs and methocarbamol 750mg QID after discharge from the PACU and transfer to the floor. The patient is converted to buprenorphine2mg q6hr PRN and 975 gram PO APAP scheduled for pain control on postoperative day 1. The patient receives their home dose of Suboxone starting on postoperative day 1 if tolerating PO intake. On postoperative day 2, patients would be transitioned to an increased dose of their Suboxone.
16330814|NCT04464499||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
16330815|NCT04464499||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
16330847|NCT04464239|Experimental|Part A: Cohort 1: TS-142 10 mg|Single dose of TS-142 10 mg or placebo in a fasted condition
16330816|NCT04464486|Experimental|COVID-19 Symptom Augmented SCH Intervention|The SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants receive automated self-management support messages for symptoms reported and a Nurse Practitioner monitors and responds to alerts for COVID-19 symptoms and poorly controlled or worsening cancer symptoms. Participants in this group complete baseline and monthly measures.
16330817|NCT04464486|No Intervention|Enhanced Usual Care|Participants in the control group are given information by research staff reviewing COVID-19 symptoms, home precautions, and instructions on what to do to address concerns that arise. Participants in this group complete baseline and monthly measures.
16330818|NCT04464473|Experimental|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold.
16330819|NCT04464473|Experimental|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
16330820|NCT04464473|Active Comparator|S1-TMS|Transcranial magnetic stimulation to primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
16330821|NCT04464460|Experimental|Cohort 1: TAK-671 Low Dose|TAK-671 low dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
16330822|NCT04464460|Experimental|Cohort 2: TAK-671 High Dose|TAK-671 high dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
16330823|NCT04464447|Other|Group-based Acceptance and Commitment Therapy|Group-based Acceptance and Commitment Therapy (ACT) for adolescents presenting with multiple functional somatic syndromes.
16330824|NCT04464434|Experimental|Upfront autologous HSCT|
16330825|NCT04464434|Active Comparator|Immunosuppressive therapy|"12 monthly i.v. pulses CYC 750 mg/m2 (= 9 g/m2 cumulative) followed by at least 12 months of oral MMF daily (3 grams as maximum daily dosage) or mycophenolic acid (up to 2.160 grams daily).
~Hyperhydration, alkalinisation of the urine and mesna is recommended, and will be given according to local protocols in order to prevent haemorrhagic cystitis."
16330826|NCT04464421|Experimental|Contingency management (CM)|Participants will receive physical rewards urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment (MAT)) during their first four visits after initiation of MAT.
16330827|NCT04464421|Experimental|BSM|BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants will have one-on-one behavioral intervention sessions at each of the first four visits after initiation of MAT.
16330828|NCT04464408|Experimental|Favipiravir|Favipiravir: 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (Maximum days of therapy is 7 days)
16330829|NCT04464408|Placebo Comparator|Placebo|9 tablets by mouth twice daily for one day, followed by 4 tablets twice daily (Maximum days of therapy is 7 days).
16330830|NCT04464395|Experimental|CPI-006 Dose Escalation|CPI-006 + Standard of Care
16330831|NCT04464395|Other|Control Arm|Standard of Care Only
16330832|NCT04464382|Experimental|Outpatient appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.
~Patients after surgery will go to the anesthetic recovery room without requiring hospital admission. The degree of satisfaction of the quality of the service and the care that must be completed before discharge and after surgery will be recorded.
~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
16330833|NCT04464382|Active Comparator|Hospitalization appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.
~Patients after surgery will go to the anesthetic recovery room and then be admitted to hospital beds, to be discharged within approximately 12 hours.
~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
16330834|NCT04464369|Placebo Comparator|Placebo|Placebo t.i.d.
16330835|NCT04464369|Active Comparator|Itopride|Itopride co 100 mg t.i.d.
16330836|NCT04464343||Posterior cruciate ligament injury group|According to the previous clinical diagnosis, volunteers who has never suffered the Posterior cruciate ligament injury.
16330837|NCT04464343||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
16330838|NCT04464330||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, patients who has suffered the Anterior Cruciate Ligament injury.
16330839|NCT04464330||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
16330840|NCT04464317||Patient who has had cardiovascular surgery|Undergone an elective, urgent, and/or emergent cardiovascular surgery via endovascular or open (sternotomy and/or extended thoracotomy) technique at the University of Florida Health.
16330843|NCT04464291|Experimental|Patients with pneumococcal infection|There will be assessing the prevalence of Streptococcus pneumoniae serotypes in the nasopharynx in healthy people; in middle ear liquid in patients with acute otitis media; in sputum and epithelial lining fluid in patients with community-acquired pneumonia; in spinal fluid in patients with invasive pneumococcal indection
16330844|NCT04464278||Case group: weight loss ≥ 5%|
16330845|NCT04464278||Control group: weight loss ≤ 5%|
16330846|NCT04464265|Experimental|Functional Magnetic Resonance Imaging|"While music is played Noninvasive functional magnetic resonance (fMRI) imaging will be performed at the University of Michigan Health System, University Hospital, Department of Radiology.
~The fMRI is done under anesthesia using propofol. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations of 1.2, 1.6, 2.0, and 2.4 μg/ml in a stepwise fashion."
16330876|NCT04464031|No Intervention|Control group|
16330851|NCT04464213|Experimental|Single dose experiments|
16330852|NCT04464213|Experimental|Multi-dose experiments|
16330853|NCT04464200|Experimental|19(T2)28z1xx CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the RP2D. There are 5 planned flat-dose levels: 25x10^6, 50 x 10^6, 100 x 10^6, 150 x 10^6, and 200 x 10^6 CAR T cells and one de-escalation dose: 12.5 x 10^6 CAR T cells. A standard 3+3 dose escalation design will be implemented starting from dose 1.
16330854|NCT04464187||Participants exposed to Orilissa|Pregnant participants exposed to Orilissa from 14 days after last menstrual period (LMP) or at any point during pregnancy.
16330855|NCT04464187||Participants not exposed to Orilissa|Pregnant participants with endometriosis or other conditions based on approved indications and prescribing patterns of Orilissa not exposed to Orilissa from 14 days after LMP or at any point during pregnancy.
16330856|NCT04464174|Experimental|Ipatasertib plus capecitabine|Arm A: Ipatasertib (GDC-0068) 400 milligrams (mg) tablets administered orally once a day (noon) on Days 1-14 of each 21-day cycle plus capecitabine 1000 mg/m2 tablets orally twice a day (morning and evening; equivalent to 2000 mg/m2 total daily dose), for 14 days (followed by a 7-day rest period) every 21-day cycle.
16330857|NCT04464174|Experimental|Ipatasertib plus Eribulin|Arm B: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle.
16330858|NCT04464174|Experimental|Ipatasertib plus carboplatin plus gemcitabine|Arm C: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus carboplatin AUC5 on Day 1 administered intravenously plus gemcitabine 1000 mg/m2 administered intravenously over 30 minutes on Days 1 and 8, every 21-day cycle.
16330859|NCT04464161|Experimental|Arm 1|The treatment arm will receive 6 week supply of daily Ensure protein drinks, while the control arm will be instructed to continue their current diet. This includes 2 weeks pre-operatively and 4 weeks post-operatively.
16330860|NCT04464161|No Intervention|Arm 2|The control group will be instructed to continue to their regular diets.
16330861|NCT04464148|Experimental|Pregnenolone 250 BID > Pregnenolone 400 BID|For week 0-5 participants will receive pregnenolone 250 mg twice a day (total 500 mg/day). For weeks 6-8 participants will receive 400 mg twice a day (800 mg/day), if the drug is well tolerated.
16330862|NCT04464135|Experimental|WE+AA group|Water containing 1% of AA was used during insertion of colonoscopy using water exchange method.
16330863|NCT04464135|Active Comparator|WE group|Water exchange colonoscopy was used for standard screening or surveillance colonoscopy.
16330864|NCT04464122||Neuroendocrine toumor group|30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.
16330865|NCT04464122||Control group|Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)
16330866|NCT04464109|Active Comparator|Retro-scleral placement of the implant|"Surgical steps;
~Two anterior scleral relaxing incisions
~A 360° scleral incision around the optic nerve to disinsert it
~Two posterior scleral relaxing incisions
~The implant is inserted posterior to posterior scleral edges
~The posterior sclera is closed then the anterior sclera is overlapped and closed.
~The implant is completely seated in the intraconal space"
16330867|NCT04464109|Active Comparator|Intrascleral placement of the implant|"Anterior and posterior sclerotomies with the implant partly in the scleral shell and partly in the intraconal space.
~Anterior relaxing sclerotomies not reaching the optic nerve
~A 360° scleral incision around the optic nerve.
~The anterior sclera flaps are overlapped and closed
~Part of the implant remains in the scleral shell, while the remaining part is sitting in the intraconal space."
16330868|NCT04464070|Experimental|niacin|"Blood (10 ml) will be drawn from the subject. Immediately before or after the blood draw the subject will collect a urine (3-10 ml) sample. After the baseline blood draw and the urine sample is collected the subject will take 500 mg of niacin. The niacin will not be an extended release formulation. Subjects will be encouraged to drink plenty of water during the study. Subjects are instructed to collect urine 1, 2, 4, 6, 8, and 10 hours after niacin administration. Subjects will collect their urine in separate plastic tubes that will be provided to them.
~Approximately 1-2 h after niacin administration a second blood sample (10 ml) will be drawn from the subject."
16330869|NCT04464070|Experimental|niacin + low-dose aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of low-dose aspirin (81 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
16330870|NCT04464070|Experimental|niacin + regular-strength aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of regular-strength aspirin (325 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
16330871|NCT04464070|Experimental|deuterated PGD2|"Volunteers will come to the clinical research center. Volunteers will provide a urine sample. The volunteers will be fitted to record an electrocardiogram (ECG) and blood pressure. ECG will be recorded continuously. Blood pressure will be taken at baseline and every 10 minutes thereafter for one hour. The solution with deuterated PGD2 (10 microgram) will be infused over the course of 30 min. Volunteers will be monitored for 1 h after the end of the infusion, and volunteers will start collecting urine in intervals up to 10 h.
~Infusion of the deuterated PGD2 solution will be performed in the presence of a physician. The injection solution will be prepared by Vanderbilt University Medical Center (VUMC) Investigational Drug Services. The solution will be sterile and pyrogen free."
16330872|NCT04464057|Experimental|experimental group|The patients in the experimental group would be given early oral feeding within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
16330873|NCT04464057|No Intervention|control group|The control group would be given early oral feeding within 4-5 days after intestinal anastomosis. Start taking it at 4-5 days after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
16330874|NCT04464044|Experimental|DDT2 Toric|Verofilcon A toric contact lenses worn in both eyes
16330877|NCT04464018|Experimental|Working group|Working group (hybrid simulation method) after the theoretical lecture, the application with hybrid simulation method is made by videotaping. Repeat the same practice after 1 Week
16330878|NCT04464018|No Intervention|Control group|Control group (Low reality simulation method) after the theoretical lecture, the application with low reality simulation method is made. Repeat the same practice after 1 Week Control group received only general care
16330879|NCT04464005|Experimental|Pads with cold magnesium sulfate 33% solution|
16330880|NCT04464005|Placebo Comparator|Pads with cold water|
16330881|NCT04463992|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
16330882|NCT04463992|Active Comparator|Behavioral:Program participants|The control group arm will receive usual care as provided by their local oncologists.
16330883|NCT04463979||Cerebellar Tumors|Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection.
16330884|NCT04463979||Brain Tumors|Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
16330885|NCT04463966|Active Comparator|Study|Tranexamic acid 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
16330886|NCT04463966|No Intervention|Control|control group will not be given tranexamic acid
16330887|NCT04463953|Experimental|ZID regimen|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15.
16330888|NCT04463940||Umbilical cord arterial blood|participant's umbilical cord arterial blood will be obtained
16330889|NCT04463940||Umbilical cord venus blood|participant's umbilical cord Venus blood will be obtained
16330890|NCT04463940||Maternal blood|participant's blood will be obtained
16330891|NCT04463927|Experimental|Intervention Group|The non-nutritive sucking is applied to the group during the examination for retinopathy of prematurity
16330892|NCT04463927|No Intervention|Control Group|The non-nutritive sucking is not applied to the control group.
16330893|NCT04463914|Other|Group A- Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
16330894|NCT04463914|Experimental|Group B- Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
16330895|NCT04463914|Experimental|Group C- Moodivate + EHR|Participants randomized to the Moodivate + EHR condition will receive similar instructions as those randomized to Moodivate, but will also be instructed that their PCP will have access to metrics related to their app utilization and may choose to follow-up with them regarding treatment utilization and response. The PCP for each participant randomized to this condition will be provided EHR access to Moodivate metrics which will include metrics related to change in mood, frequency of app utilization, and frequency of activity completion. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
16330896|NCT04463901|Active Comparator|Group CAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then conjunctival autograft without limbal tissue will be used to cover the bare sclera.
16330897|NCT04463901|Active Comparator|Group LCAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft will be used to cover the bare sclera.
16330898|NCT04463888|Experimental|Robot training with Smart Home-based Exoskeleton Robot System|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based robot assisted tenodesis-grip training per day, 5 days a week, for 4 weeks .
16330899|NCT04463888|Active Comparator|control group|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based specific motor task training per day, 5 days a week, for 4 weeks .
16330900|NCT04463849|Experimental|COVID-19 positive patients|Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
16330901|NCT04463849|Other|Healthy volunteers|Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
16330999|NCT04463082|Experimental|Weight category 30-50kg|Pediatric patients with a weight of 30-50kg will be enrolled in this arm.
16331508|NCT04459195|Experimental|5 Minute Static stretching|Stretching applications will be applied to the first group for 5 minutes.
16330902|NCT04463849|Other|Type 2 diabetes patients|Patients with established Type 2 diabetes, not affects by COVID-19. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
16330903|NCT04463797|Experimental|Square-stepping exercise group|Square-stepping exercise
16330904|NCT04463797|Active Comparator|Control group|Whole-body stretching and upper extremity strengthening
16330905|NCT04463784|Experimental|Efavirenz 400MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 400mg per day as antiretroviral treatment.
16330906|NCT04463784|Active Comparator|Efavirenz 600MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 600mg per day, per standard dose.
16330907|NCT04463771|Experimental|Group A - retifanlimab|Select participants will be administered retifanlimab intravenously
16330908|NCT04463771|Experimental|Group B - retifanlimab|Select participants will be administered retifanlimab intravenously
16330909|NCT04463771|Experimental|Group C - retifanlimab + epacadostat|Participants will be administered retifanlimab intravenously in combination with oral epacadostat (IDO1 inhibitor)
16330910|NCT04463771|Experimental|Group D - retifanlimab + pemigatinib|Select participants will be administered retifanlimab intravenously in combination with oral pemigatininb (FGFR 1,2,3 inhibitor)
16330911|NCT04463745||Liver Transplant Recipients|adult patients undergoing liver transplantation
16330912|NCT04463732||Healthy group|Subjects are above 20 years old. Their condition is healthy with no history of inspiratory disease. They can cooperate with the measurements of this study.
16330913|NCT04463719|Experimental|Intervention group|Counseling using the electronic conversation aid
16330914|NCT04463719|Active Comparator|Control Group|Routine counseling only
16330915|NCT04463706||COVID19 REDISSEC|Patients admitted (confirmed cases) by CoVid-19, excluding paediatric population. No losses are expected. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene [RdRp or S gene] or PCR positive for at least 2 genes used for screening [E or N gene].
16330916|NCT04463706||COVID19 Basque Country|All people from thw Basque Country positive to CoVid-19. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene [RdRp or S gene] or PCR positive for at least 2 genes used for screening [E or N gene], or, as well and in the general population of the Basque Country, by detection of COVID-19 IgM or IgG antibodies.
16330917|NCT04463693|Experimental|Intervention|Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula
16330918|NCT04463680|Experimental|Intervention|Will receive 2 week regimen of rifampin 600mg per day
16330919|NCT04463667|Experimental|The effects of exercise intervention on fatty liver|The effects of exercise intervention on fatty liver and the improvement of the above-mentioned various metabolic indicators, including improvement of sleep patterns and changes of intestinal microflora.
16330920|NCT04463654|Experimental|Zero Self-Harm|When randomized to the Zero Self-Harm app the participants will receive an introduction to the app through videos in the app, which explains, amongst others, how to review previous crisis situations and possible strategies for future crisis. This will ensure the navigation and knowledge of the technicalities of the app, in addition to ensure the app can be used privately without personal guidance from e.g a therapist.
16330921|NCT04463654|No Intervention|Treatment as usual|The control group will continue their present course of treatment and/or counseling at non-profit organizations, service centers in the municipalities, at outpatient treatment services for psychiatric disorders and/or care, attention at emergency departments. They will receive no treatment on the nature of NSSI. Participants in the control group will be offered a possibility to download the Zero Self-Harm app after they have completed the last questionnaire at six months, which will be stressed at the initial appointment as well as after collection of all data.
16330922|NCT04463641|Experimental|Axone 4LV Lead|Subjects implanted with the Axone 4LV Lead
16330923|NCT04463628||Questionnaire and/or interview|An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences).
16330924|NCT04463615|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
16330925|NCT04463602|Experimental|Desidustat + Standard of Care|"Test: Desidustat + Standard of care
~Desidustat 100 mg for the duration of 14 days along with the recommended standard of care at the time of conduct of trial."
16330926|NCT04463602|Active Comparator|Standard of Care|"Control: Standard of care
~Standard of care treatment for the duration of 14 days at the time of conduct of trial."
16330927|NCT04463576||Experimental|A total of 5 676 hospital discharge prescriptions, defined as the list of medications prescribed at discharge from hospital or after a hospital visit, whether new or renewed, will be selected.
16330928|NCT04463563|Active Comparator|NIRS group. Brain oxygen saturations group.|A monitor by means of non-invasive stickers will display cerebral oximetry (brain oxygen saturations) throughout the heart surgery.This gives a direct reading of brain frontal lobe oxygen levels. The baseline is recorded before the patient goes to sleep (anaesthetised) and throughout the surgery and time on cardiopulmonary bypass if the brain oxygen levels fall below baseline then various physiological changes are made to restore oxygen to baseline.
16330929|NCT04463563|No Intervention|Standard Patient Monitoring|No cerebral monitoring. Standard patient monitoring according to normal practice at Castle Hill Hospital apply.
16330930|NCT04463550||Patients GFAP-IgG positive in serum and/or CSF|Patients developing clinical autoimmune encephalitis or meningoencephalomyelitis with anti-GFAP antibodies, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis or the National Reference Center for Centre de référence for Neuro-inflammatory diseases of the brain and the spinal cord at the Neurological Hospital of Bron.
16330931|NCT04463537|Experimental|experiment group|"Firstly, patients selected with convenience sampling. In the sampling method, the order of the patients' enrollment to the emergency room was used. Then, patient's age, sex and presence of otitis media were recorded in the Personal Information Form.
~After recording, measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.
~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale. The auricle on the same side was used during both measurements."
16330932|NCT04463524||Test|They will receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
16330933|NCT04463524||Control|They will not receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
16330934|NCT04463511|Experimental|PB BCC: Polyethylene Bag Before Cord Clamping|Immediately after delivery, while still attached to placental circulation, infants will be placed in a PB. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire for ongoing care. In the case of caesarean section a sterile bag will be used and prepared observing sterile techniques. A member of the neonatal team donned in sterile gown and gloves will assist the obstetrician in placing the infant in the PB.
16330935|NCT04463511|No Intervention|PB ACC: Polyethylene Bag After Cord Clamping|Infants will not be placed in a PB immediately after birth. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire where they will be placed in a PB.
16330936|NCT04463498|Experimental|n=20, Sleep-school 8 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
16330937|NCT04463498|Experimental|n=20, Sleep-school 8 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
16330938|NCT04463498|Active Comparator|n=40 8-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
16330939|NCT04463485|Experimental|Delayed Clamping|The intervention group was waited 60 seconds for umbilical cord clamping in the second stage of labor.
16330940|NCT04463485|No Intervention|Early Clamping|No interventions have been assigned.
16330941|NCT04463472|Experimental|Low-dose group|
16330942|NCT04463472|Experimental|High-dose group|
16330943|NCT04463459|No Intervention|Chemotherapy + Placebo|Patients receiving chemotherapy This group will be received chemotherapy and placebo
16330944|NCT04463459|Active Comparator|Chemotherapy + Vitamin C + Vitamin E|Patients receiving vitamin C and E with Chemotherapy This group will be received vitamin C (500 mg) twice daily and vitamin E (400 mg) once daily with chemotherapy for 6 weeks
16330945|NCT04463446|Experimental|The app arm|Use of CHD app
16330946|NCT04463446|Active Comparator|Nurse-led intervention arm|Nurse-led intervention
16330947|NCT04463433|Experimental|Parent-child Relationship Intervention|The intervention involves five 2h weekly group sessions in which exercises in mindfulness are practiced and associated ABCDE theory is taught to improve emotional regulation and parent-child communication under COVID-2019.
16330948|NCT04463433|Experimental|Couple Relationship Intervention|The intervention involves four 2h weekly group sessions in which express feelings and wants clearly are practiced and associated Satir communication model is taught to improve couple conflict resolution and communication under COVID-2019.
16330949|NCT04463420|Experimental|Test Group|Intervention group: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days / PHR160 spray one hour oral puff with Demyar ten times a day for ten days in a row, for ten days.
16330950|NCT04463420|Placebo Comparator|Control Group|Control group: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days Daily / 25 mg prednisolone daily for 5 days / placebo spray one hourly oral puff ten times a day for ten days in a row, for ten days
16330951|NCT04463407|No Intervention|Control group|Participants keep their normal routine without intervention.
16330952|NCT04463407|Experimental|Experimental group|Participants receive a single nutritional intervention previous to a critical period.
16330953|NCT04463394|Experimental|Vasopressin|Participants undergoing cardiac catheterization
16330954|NCT04463381||Group 1|sharp choledochotomy by a scalpel or scissor
16330955|NCT04463381||Group 2|choledochotomy by a diathermy hook
16330956|NCT04463381||Group 3|choledochotomy by an ultrasonic device
16330957|NCT04463368|Experimental|Arm A|Patients will be treated with IHP followed by 4 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
16330958|NCT04463368|Experimental|Arm B|Patients will be treated with 1 course of ipilimumab 3mg/kg and nivolumab 1mg/kg followed by IHP after 3 weeks and then another 3 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
16330959|NCT04463355|No Intervention|Control group: usual verbal instructions|In this group, caregivers receive, after completing the test and prior to discharge, the usual verbal information and recommendations about AGE following the guidelines of the Spanish Society of Pediatric Emergencies. The instructions are always given by one of the main investigators to provide homogeneity in the information
16330960|NCT04463355|Experimental|Intervention group: video discharge instructions|Additionally to the verbal information, patients are shown a short 2-minute video providing the same information about AGE that would be given by verbal information.
16330961|NCT04463342|Experimental|Non Coated Glass Ionomer|A faster, easier procedure is great, but you want assurance that reducing chair time doesn't mean compromising on performance. KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.This advancement is the latest in 3M's 30-year history of developing proven and trusted glass ionomers.
16330962|NCT04463342|Active Comparator|Conventional Glass Ionomer with Coat|"A bulk-fill, packable and fast-setting conventional glass ionomer. Because it's less technique sensitive than a composite it's ideal for difficult-to-isolate posterior restoration. High compressive strength and marginal integrity make it a glass ionomer of choice for posterior restorations.Ketac Conditioner Dentin Pretreatment is required; Ketac Glaze Light-Cured Varnish applied on the top of the restoration to avoid moisture contamination."
16330963|NCT04463329|Active Comparator|Group C|conventional two-operator axillary brachial plexus blockage
16330964|NCT04463329|Active Comparator|Group J|axillary brachial plexus block with single operator using Jedi grip
16330965|NCT04463303||group 1|patient who will develop weaning induced pulmonary adema
16330966|NCT04463303||group 2|patient who will nor develop weaning induced pulmonary adema
16330967|NCT04463290||Knee Osteoarthritis Patients Group|Patients suffering from primary knee osteoarthritis
16330968|NCT04463290||Control Group|Healthy people without suffering from primary knee osteoarthritis
16330969|NCT04463277|Experimental|Calorie Restriction|
16330970|NCT04463277|Experimental|Time Restricted Feeding|
16330971|NCT04463277|Experimental|Time Restricted Feeding with Calorie Restriction|
16330972|NCT04463277|No Intervention|Control|
16330973|NCT04463264|Experimental|NTX active treatment|Intervention: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
16330974|NCT04463264|Placebo Comparator|Intervention: placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
16330975|NCT04463251|Experimental|RPH-104 80 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites
16330976|NCT04463251|Experimental|RPH-104 160 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites
16330977|NCT04463251|Placebo Comparator|Placebo|subjects will receive subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites
16330978|NCT04463238|Experimental|Cartilage membrane surgery|"The test group applied the guidance provided by Shaanxi Baiao Regenerative Medicine Co., Ltd.
~Cartilage regeneration membrane combined with microfracture surgery."
16330979|NCT04463238|Other|Microfracture|The control group was treated with microfractures widely recognized at home and abroad.
16330980|NCT04463225|Other|Intervention condition|Participants assigned to the intervention condition will be invited to engage with an internet-based intervention three times during the course of the study.
16330981|NCT04463225|No Intervention|Control|The control group will not be offered the internet-based intervention.
16330982|NCT04463212||Patient|Diagnosis of probable SVCR evoked, faced with a single or repeated episode of unusual thunderclap or rapidly progressive headache, and demonstration of diffuse vasospasms via sectional imaging (angiography, angio-MRI or cerebral arteriography) or an increase in transcranial doppler speeds
16330983|NCT04463212||Subject control|Subject without SVCR (current and history)
16330984|NCT04463199|Experimental|Experimental|Experimental group received craniocervical flexion training for 4 weeks and postural advice
16330985|NCT04463199|No Intervention|Control Group|Control group received only postural advice
16330986|NCT04463186|Experimental|Experimental|subjects participated in three experimental trials: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Strength was measured before (pre), immediately after (post), and at 10- and 20- minutes post stretching.
16330987|NCT04463173|Experimental|High fat food oral administration|Anaprazole 40mg, single dose, oral administration 30 minutes after breakfast with high fat food.
16330988|NCT04463173|Experimental|Fasting oral administration|Anaprazole 40mg, single dose, oral administration before breakfast.
16330989|NCT04463160|Experimental|"prevention program for prediabetes Say No to Diabetes"|
16330990|NCT04463160|No Intervention|No prevention program|
16330991|NCT04463147|Other|new residents|new residents in ultrasound-guided central vascular catheterization.
16330992|NCT04463147|Other|experienced residents or ICU practitioners|experienced residents or ICU practitioners in ultrasound-guided central vascular catheterization.
16330993|NCT04463134||Treatment group|They will start pharmacological treatment according to guidelines and sensitivity
16330994|NCT04463134||Observation group|They will not start pharmacological treatment. They will be monitored on symptoms, sputum conversion and radiological progression
16330995|NCT04463121|Experimental|Acute CNT pacing signals testing|"Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals.
~Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well.
~A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions."
16330997|NCT04463082|Experimental|Weight category 10-20kg|Pediatric patients with a weight of 10-20kg will be enrolled in this arm.
16330998|NCT04463082|Experimental|Weight category 20-30kg|Pediatric patients with a weight of 20-30kg will be enrolled in this arm.
16331145|NCT04461899|Other|sclerotherapy|a sclerotherapy will be done in patients
16331000|NCT04463069|Experimental|intervention group|Participants in the intervention group participated in the APA intervention consisting of simple and fun endurance and strength-building exercise at a frequency of two sessions per week.
16331001|NCT04463069|No Intervention|control group|Participants in the control group received no intervention in the study time period.
16331002|NCT04463056|Experimental|Elizaria®|International nonproprietary name: eculizumab
16331003|NCT04463056|Active Comparator|Soliris®|International nonproprietary name: eculizumab
16331004|NCT04463043|Experimental|SelfBACK app|The selfBACK app in addition to usual care
16331005|NCT04463043|Active Comparator|e-Help webpage|The e-Help webpage in addition to usual care
16331006|NCT04463043|Active Comparator|Usual care|Usual care only
16331007|NCT04463030|Active Comparator|Liposomal vitamin C, 1 gram|Participants will consume 1 gram on study day
16331008|NCT04463030|Active Comparator|Liposomal vitamin C, 2 grams|Participants will consume 2 grams on study day
16331009|NCT04463030|Active Comparator|Liposomal vitamin C, 5 grams|Participants will consume 5 grams on study day
16331010|NCT04463030|Placebo Comparator|Placebo|Participants will consume placebo on study day
16331011|NCT04463017|Active Comparator|Active Treatment: HU6|Planned doses of HU6; N = 74
16331012|NCT04463017|Placebo Comparator|Placebo Comparator|Non-active study drug N = 14
16331013|NCT04463004|Active Comparator|Intervention|Treatment infusion
16331014|NCT04463004|Placebo Comparator|Control|Placebo infusion
16331015|NCT04462978||Non IgE-mediated food allergy|Children with non IgE-mediated food allergy
16331016|NCT04462965|Experimental|Test group|Toripalima Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
16331017|NCT04462965|Placebo Comparator|Placebo group|Placebo Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
16331018|NCT04462952|Experimental|Adavosertib monotherapy|Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
16331019|NCT04462939|Experimental|Healthy lactating women - Supplement|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
16331020|NCT04462939|Placebo Comparator|Healthy lactating women - Placebo|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
16331021|NCT04462926|Experimental|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
16331022|NCT04462913||Healthy control|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
16331023|NCT04462913||Patients with sports injuries|According to the previous clinical diagnosis, patients who has suffered the sports injuries(including hip, knee, and ankle joint diseases).
16331024|NCT04462913||Patients with degenerative osteoarthritis|According to the previous clinical diagnosis, patients who has suffered the degenerative osteoarthritis.
16331025|NCT04462887|Experimental|Nursing intervention program|The nursing intervention program consisting of 3 parts: (1) Structural Informational (SI) booklet, (2) Nursing Telephone Support (NTS) protocol, and (3) Nurse Pager 24/7.
16331026|NCT04462887|No Intervention|Usual Care Group|Usual care participants received treatment as usual from their health care providers.
16331027|NCT04462861|Experimental|CVAD securement device|Patients with a pre-existing CVAD who will trial the new securement dressing
16331028|NCT04462848|Experimental|anti-SARS-CoV-2 human convalescent plasma|single transfusion of human convalescent plasma
16331029|NCT04462822|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16331030|NCT04462822|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
16331031|NCT04462809|Experimental|Cohort A, Malignant pleural mesothelioma|Malignant pleural mesothelioma
16331032|NCT04462809|Experimental|Cohort B1:Malignant peritoneal mesothelioma non-resected|Malignant peritoneal mesothelioma with non-resected or incompletely resected disease
16331033|NCT04462809|Experimental|Cohort B2:Malignant peritoneal mesothelioma (resected)|Malignant peritoneal mesothelioma with completely resected disease.
16331034|NCT04462796|Experimental|Magnesium Citrate|Magnesium Citrate given orally taken once daily for 8 weeks
16331035|NCT04462783|Experimental|Patient's symptom data without pulse oximeter|Some patients may not be given a pulse oximeter to enter heart rate and O2 saturation into the CovidX application.
16331036|NCT04462783|Experimental|Patient's symptom data with a pulse oximeter|Some patients will be given (or may have) a pulse oximeter in order to enter heart rate and O2 saturation data into the CovidX application.
16331037|NCT04462770|Active Comparator|Active arm with EPX-100 (Clemizole HCl)|EPX-100 oral solution 5 mg/mL starting at 2.0 mg/kg/day increasing 2 mg/kg/day every 7 days until the maximum tolerated dose is found. Those intolerant of the 2.0 mg/kg/day starting dose will drop to a dose of 1.0 mg/kg/day and increasing by 0.5 mg/kg every 7 days or to MTD. The titration period can extend beyond 4 weeks for participants who do not reach their MTD. This will be determined per Primary Investigator discretion.
16331038|NCT04462770|Placebo Comparator|Placebo arm|Color- and taste-matched placebo oral solution dosed to match the active arm.
16331039|NCT04462757|Active Comparator|Subcutaneous Arm|100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
16331040|NCT04462757|Active Comparator|Intravenous Arm|100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.
16331146|NCT04461886|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
16331041|NCT04462731|Experimental|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
16331042|NCT04462731|Active Comparator|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
16331043|NCT04462718|Active Comparator|CONTROL GROUP:|You will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks.
16331044|NCT04462718|Experimental|EXPERIMENTAL GROUP|"After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
~The treatment is administered with a pulsatile short-wave equipment and inductive electrodes of 100 W peak power, with a frequency of application of twice daily with a dose submitis (grade I), for 10 min, with a frequency of repetition of the impulses of 46 Hz and a pulse duration of 0.2 ms."
16331045|NCT04462705|Active Comparator|Usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.
~- At D + 1 post-surgical:
~- First lift with verticalization.
~- A session with the Cliniflo® in a seated position.
~- Walk at least 100 m with the help of the physiotherapist.
~At- D+2 and D+3 post-surgical Same session as on D+1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3"
16331046|NCT04462705|Experimental|abdominal massage and usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.
~- At D + 1post-surgical:
~- First lift with verticalization.
~- A session with the Cliniflo® in a seated position.
~- Walk at least 100 m with the help of the physiotherapist.
~At- D + 2 and D + 3 post-surgical Same session as on D + 1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3
~In this experimental arm, a abdominal massage will be performed in addition to the usual physiotherapeutic intervention (respiratory and walking exercices).
~The sessions take place on D+1, D+2 and D+3 post-surgical The first session is performed at least 20 hours after surgery (incision begins) Never within an hour of a meal. The session is timed."
16331047|NCT04462679|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
16331048|NCT04462666|Experimental|HZG intervention|During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.
16331049|NCT04462666|Active Comparator|Etoricoxib intervention|During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.
16331050|NCT04462666|Placebo Comparator|Placebo intervention|During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.
16331051|NCT04462653|Experimental|use two kinds of device successively|the same participant use a Wearable Dynamic ECG Recorder and 12-lead ECG to record heart rate and atrial fibrillation
16331052|NCT04462640||regurgitation|45 infants aged 0 to 5 months suffering from regurgitation
16331053|NCT04462640||colic|45 infants aged 0 to 5 months suffering from colic
16331054|NCT04462627|Experimental|Covid 19 positive patients|
16331055|NCT04462627|Experimental|Covid 19 negative patients|
16331056|NCT04462627|Experimental|Untested healthy volunteers|
16331057|NCT04462614|Experimental|single-arm study|Chronic hemodialysis patients for at least 3 months at Reims University Hospital, treated by long-term anticoagulation with VKA and dialysed with the HeprAN ™ membrane
16331058|NCT04462601||Patients with Sjögren Syndrome|
16331059|NCT04462588||Medical Treatment Group|Medical treatment group of uncomplicated acute appendisitis
16331060|NCT04462588||Surgery|Operated group of uncomplicated acute appendisitis
16331061|NCT04462575|Experimental|Onlay bone block covered using collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block) covered by collagen membrane, stabilized by resorbable suture and fixed by tacs.
16331062|NCT04462575|Active Comparator|Onlay bone block without collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block).
16331063|NCT04462562|Experimental|quantitative ultrasound imaging parameters|"quantitative ultrasound imaging parameters
~tissue attenuation imaging (TAI) parameter
~tissue scatter-distribution imaging (TSI) parameter
~Hepatorenal index (semi-auto, EzHRI)"
16331064|NCT04462549|Experimental|Resource Facilitation|This group is receiving Resource Facilitation
16331065|NCT04462549|No Intervention|Control|Not receiving Resource Facilitation
16331066|NCT04462536|Placebo Comparator|Placebo|Vehicle only
16331067|NCT04462536|Experimental|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
16331189|NCT04461600|Experimental|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
16331068|NCT04462523|Experimental|Group 1 Pre-surgery Dextenza insert|Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
16331069|NCT04462523|Experimental|Group 2 Surgery Day Dextenza insert|Ten patients will receive dexamethasone intracanalicular insert on the day of surgery. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
16331070|NCT04462523|Experimental|Group 3 Post op Day 1 Dextenza insert|Ten patients will receive DEXTENZA insert Day 1 post-operatively. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops
16331071|NCT04462523|Active Comparator|Group 4 Topical steroid|Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
16331072|NCT04462510|Experimental|Illioinguinal/Illiohypogastric Block|A single shot 20ml of 0.25% Ropivacaine was used to block illioinguinal/illiohypogastric nerves using ultrasound right before incision was given
16331073|NCT04462510|Experimental|Wound infiltration|Surgeon infiltrated the wound using 20ml of 0.25% Ropivacaine right after the skin was closed.
16331076|NCT04462484|No Intervention|Control group|No intervention
16331077|NCT04462484|Experimental|Intervention group|Videoconference
16331078|NCT04462471|Experimental|Participants with thyroid cancer|Eligible participants will have a diagnosis of BRAF mutant RAIR thyroid cancer
16331079|NCT04462445|Experimental|pazopanib|Pazopanib 800 mg (2x400mg ) taken orally daily as per clinical practice
16331080|NCT04462432||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
16331081|NCT04462432||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
16331082|NCT04462419||Diagnostic (18F-fluciclovine, PET/MRI imaging)|Patients receive fluciclovine IV and undergo brain dynamic PET/MRI imaging over 50 minutes.
16331083|NCT04462406|Experimental|Arm A (active surveillance)|Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance.
16331084|NCT04462406|Active Comparator|Arm B (nivolumab, pembrolizumab, ipilimumab)|Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity.
16331085|NCT04462406|Other|Standard of Care (nivolumab, pembrolizumab, ipilimumab)|Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity.
16331086|NCT04462354|Active Comparator|Pancreatogastric anastomosis.|
16331087|NCT04462354|Experimental|Blumgart Anastomosis|
16331088|NCT04462341|Active Comparator|Manual brushing only|Participants brushed with a manual toothbrush and fluoridated toothpaste twice a day for 6 weeks
16331089|NCT04462341|Experimental|Manual brushing + water flossing|Participants brush twice a day and water flossed once a day for 6 weeks.
16331090|NCT04462328|Experimental|Phase I Dose Level 1: Durvalumab + Acalabruitinib|"Acalabrutinib 100 mg twice per day by mouth on days 1-28
~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
16331091|NCT04462328|Experimental|Phase I Dose Level 2: Durvalumab + Acalabruitinib|"Acalabrutinib 200 mg twice per day by mouth on days 1-28
~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
16331092|NCT04462328|Experimental|Expansion Cohort: Durvalumab + Acalabrutinib|"Acalabrutinib 100 mg or 200 mg (depends on tolerable dose found in Phase I portion of study) twice per day by mouth on days 1-28
~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
16331093|NCT04462315||Everolimus Arm|Everolimus Eluting Coronary Stent System
16331094|NCT04462315||Non-drug eluting stent Arm|Cobalt chromium balloon-expandable stent
16331095|NCT04462302|Experimental|Internet-based program + Pain Education|If you are in this group, in additional to your usual care, you will be provided access to the 8-session Internet-based pain program plus pain education. You will need to complete your sessions within 10 weeks of being provided your log-in code. You will be allowed to revisit sessions that you have completed during this 10 weeks. After completion of the study, you will still be provided access to the 8-session Internet-based pain program.
16331096|NCT04462302|No Intervention|Pain Education Only|If you are in this group, in addition to your usual care, you will be provided pain education at your initial clinic visit. After you have completed the 6-month follow up assessment, you will be provided a secure log-in code and invited to complete the 8 sessions of this Internet-based pain program on your own.
16331097|NCT04462289|No Intervention|Usual Care|Randomly assigned sample who will receive usual care for tobacco cessation treatment
16331098|NCT04462289|Experimental|Proactive Outreach|Randomly assigned sample who will receive a proactive offer of tobacco treatment
16331099|NCT04462276|Experimental|Arm A: Atezolizumab + thoracic radiotherapy|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W) Thoracic radiation therapy (TRT), 30 Gy in 10 fractions
16331100|NCT04462276|Experimental|Arm B: Atezolizumab|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
16331101|NCT04462263|Experimental|Single Dose HTL0014242|The study consists of up to 5 dosing groups, with 2 to 3 subjects per dosing group. Each subject will receive a single oral dose of HTL0014242 in the form of solid suspension capsules (1, 5, 10, and 30mg) as required. HTL0014242 will be administered in up to 5 single dose groups, with 120mg administered in the first dosing group.
16333097|NCT04447989|Placebo Comparator|Cohort 3, placebo|Placebo (IV or enteral) every 8 hours for 28 days
16331102|NCT04462250|Active Comparator|Control|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points but there will be no reward provided.
16331103|NCT04462250|Active Comparator|Contingency Management - Virtual Pet|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which can be used in the care of a virtual pet.
16331104|NCT04462250|Active Comparator|Contingency Management - Monetary|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which will be paid out at the end of the one-week trial in the form of a monetary reward.
16331105|NCT04462237|Experimental|collagen matrix + platelet-derived growth factor|Root coverage procedure using collagen matrix + platelet-derived growth factor for the treatment of multiple adjacent gingival recessions
16331106|NCT04462237|Active Comparator|collagen matrix alone|Root coverage procedure using collagen matrix alone (without the use of the platelet-derived growth factor) for the treatment of multiple adjacent gingival recessions
16331107|NCT04462211|Experimental|Management pharmacological protocol and bundle's|"The elaboration of the protocol according to the evidence-based approach, updated evidence found from both search engines such as MEDLINE, EMBASE, Cochrane Library, OVID and ScIELO will be used through the research question using the PICO method (Patient interest, Intervention, Comparation and Outcome).
~the ready-made protocol will be adjusted to the pharmacological options that are available in the hospital."
16331108|NCT04462198|Experimental|PIPE-505|
16331109|NCT04462198|Placebo Comparator|Diluent alone|
16331110|NCT04462185||Prospective Cohort|This is a prospectively enrolling cohort study and 3000 patients (1500 GGO and 1500 solid / semi solid nodules) with radiologic diagnosis of indeterminate pulmonary nodule (5-30 mm) will be recruited. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, a genomic and transcriptomic landscape analysis, at each visit.
16331113|NCT04462159|Experimental|Risk Reduction Program|All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component.
16331116|NCT04462133|Active Comparator|Empirical therapy for H. pylori infection|The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication
16331117|NCT04462133|Experimental|Tailored therapy for H. pylori infection|The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.
16331118|NCT04462107||Surveys|All participants will complete questionnaires at several time points, ranging from baseline to 3 months post partum.
16331119|NCT04462094|Active Comparator|End-of-surgery|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at the end of surgery
16331120|NCT04462094|Placebo Comparator|Induction|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at induction
16331121|NCT04462042|Active Comparator|Photon radiotherapy|Conventional photon radiation is delivered by volumetric arc therapy/intensity modulated radiotherapy/helical tomotherapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases >2 cm is 57.5 Gy in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy.
16331122|NCT04462042|Experimental|Proton radiotherapy|Proton radiation is delivered by spot scanning. Proton plans will be produced by single field optimisation/single field uniform dose or multifield optimisation/intensity modulated proton therapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases >2 cm is 57.5 Gy(RBE) in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy(RBE) in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy(RBE).
16331228|NCT04461353|Active Comparator|Hydroxychloroquine Sulfate|The study drug AHCQ will be administered by inhalation through the mouth. The starting dose will be 20 mg (Cohort A1) with a proposed subsequent dose of 50 mg (Cohort A2). At each dose level 8 participants (including at least 3 female participants and 3 participants older than 50 years old) will be enrolled. Six participants will receive the active study drug and 2 participants will receive placebo.
16331123|NCT04462029|Other|sequence 1|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 1: R - T1 - T2"
16331124|NCT04462029|Other|sequence 2|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 2: R - T2 - T1"
16331125|NCT04462029|Other|sequence 3|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 3: T1 - R - T2"
16331126|NCT04462029|Other|sequence 4|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 4: T1 - T2 - R"
16331127|NCT04462029|Other|sequence 5|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 5: T2 - R - T1"
16331128|NCT04462029|Other|sequence 6|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 6: T2 - T1 - R"
16331129|NCT04462016|Active Comparator|Reference drink|Healthy volunteers' blood glucose response to reference drink (glucose)
16331130|NCT04462016|Experimental|Test drink|Healthy volunteers' blood glucose response to test drink (calamansi)
16331131|NCT04462003|Active Comparator|Apixaban|50 patients with DVT with malignancy were randomized to apixaban 10 mg twice daily dose for 7 days followed by apixaban 5 mg twice daily
16331132|NCT04462003|Active Comparator|Enoxaparin|50 patients with DVT with malignancy were randomized to enoxaparin (1mg/Kg/SC every 12 h)
16331133|NCT04461990||Luminal|"Luminal A：ER+ and/or PR+,HER2- Luminal B：ER+ and/or PR+,HER2+
~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
16331134|NCT04461990||HER2 overexpression|"ER- PR-,HER2+
~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
16331135|NCT04461990||Triple negative|"ER- PR-,HER2-
~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
16331136|NCT04461977|Experimental|A - true acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen 2011) and on previous studies (Jeong, 2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment."
16331137|NCT04461977|Sham Comparator|B - sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet."
16331138|NCT04461964|Experimental|treatment group|Eligible participants will be identified by their treating physician and referred to the study research coordinator for enrollment. NYU standard practice in relation to pre-operative and intra-operative imaging studies will be explained. The role of the MvIGS system in this study will then also be explained. In each subject, they will perform posterior instrumentation utilizing the MvIGS spine navigation system for pedicle screw guidance and record data for intraoperative study endpoints
16331139|NCT04461951||Community dwelling seniors|Participants are visited at the research facility in their residence town by a trained team. Informed consent form is completed at the research facility prior to data collection. In those individuals without capacity to give full informed consent, proxy consent is collected from relatives or caregivers. This 2-hours interview includes a face-to-face administration of a neuropsychological battery of tests and questionnaires to inquire about socio-demographic, occupational, and social-economic data, education, medical conditions and drug use, lifestyle habits, functional status, and dietary behaviours.
16331140|NCT04461938|Other|Fasting|All study participants follow the same dietary intervention; thus, no randomization will take place.
16331141|NCT04461925|Experimental|Experimental group|"On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day 1, Day 4, Day 7."
16331142|NCT04461925|Active Comparator|Control Group|Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies
16331143|NCT04461912|Experimental|Cataract|Participants with diverse types and severities of cataract, that should realize phacoemulsification surgery
16331144|NCT04461912|Placebo Comparator|Control|Participants on which the presence of cataract have been excluded
16331147|NCT04461873|Experimental|Reiki|Reiki was applied to this arm by the researcher who completed her second level education according to the Usui method, for 45 minutes once a week for 6 weeks and by touching the 9 main points in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again. After the 6-week Reiki application, all the caregivers of the intervention group were asked about their experience and opinions regarding the application by the individual in-depth interview method during the home visit.
16331148|NCT04461873|Placebo Comparator|Sham Reiki|Four student nurses who did not receive Reiki training and were trained about application by the investigator applied sham by gesturing and mimic imitation through touching 9 points for 45 minutes/week for 6 weeks in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again.
16331149|NCT04461847|Experimental|patients underwent ESM|
16331150|NCT04461847|Active Comparator|patients underwent SM|
16331151|NCT04461821||obstructive bronchitis/bronchiolitis|
16331152|NCT04461821||pneumonia|
16331153|NCT04461821||asthma|
16331154|NCT04461821||neurological diseases|
16331155|NCT04461821||type 1 diabetes (T1D)|
16331156|NCT04461821||pharmacotherapy with bronchodilators|
16331157|NCT04461821||pharmacotherapy with antibiotics|
16331158|NCT04461821||pharmacotherapy with antiviral medication|
16331159|NCT04461821||pharmacotherapy with antifungal medication|
16331160|NCT04461821||pharmacotherapy with antiepileptic medication|
16331161|NCT04461821||pharmacotherapy with immuno suppressants and immune-modulati|
16331162|NCT04461821||pharmacotherapy with anesthesia (including sedating, analges|
16331163|NCT04461808|Experimental|Tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.
~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
16331164|NCT04461808|Active Comparator|Digital Mammography|"Women will be screened for digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.
~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
16331165|NCT04461795|Experimental|AJOVY (fremanezumab-vfrm)|Participants received 225 mg/1.5 mL solution via single-dose prefilled syringe administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for 12 weeks.
16331166|NCT04461782|Experimental|Lactobacillus plantarum|"Oral intake 1 cap daily
~1E+09 cfu/cap of Lactobacillus plantarum"
16331167|NCT04461769|Experimental|Slow Oscillation Synchronization with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
16331168|NCT04461769|Sham Comparator|Sham Control|No current delivered.
16331169|NCT04461756|Experimental|inhaled THC/CBD (PPP001)|
16331170|NCT04461743||Patients with normal lac|
16331171|NCT04461743||Patients with abnormal lac|
16331172|NCT04461730||Parkinson disease|
16331173|NCT04461730||essential tremor|
16331174|NCT04461730||dystonia|
16331175|NCT04461730||OCD|
16331176|NCT04461730||healthy volunteers|
16331177|NCT04461717||MicroNet covered stenting (interventional)|MicroNet covered stent implantation for increased risk arterial lesions beyond the carotid bifurcation
16331178|NCT04461691|Other|Heart Failure|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
16331179|NCT04461691|Other|Normal cardiac function|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
16331180|NCT04461678|Experimental|screening population|
16331181|NCT04461665|No Intervention|Control|Enroll 6 months old breast feeding infant, who have not supplement vitamin D at pediatric clinic.
16331182|NCT04461665|Experimental|VitD supplement|Enroll 4 months old breast feeding infant, and provide 10 μg vitamin D daily for 2 months.
16331183|NCT04461652|Experimental|New method|One thoracic tube (28fr drainage tube) was inserted through intercostal incision, and one microtubule (7fr × 20cm) was punctured through the middle line of clavicle
16331184|NCT04461652|Placebo Comparator|Traditional method|Two conventional chest tubes (28fr or 24fr) were placed through intercostal incision
16331185|NCT04461639||Damoctocog alfa pegol|Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.
16331186|NCT04461626||Persona fixed bearing knee system|Persona fixed bearing knee system (All patients will received Persona fixed bearing knee system)
16331187|NCT04461613|Experimental|Group 1|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 1 will receive an original International Physical Activity Questionnaire short form (IPAQ-sf). Group 1 will be asked to fill it out with information about physical activities in the last 7 days.
~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 1 will be asked to fill a revised version of IPAQ-sf to describe physical activities in the last 7 days."
16331188|NCT04461613|Experimental|Group 2|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 2 will receive a revised version of International Physical Activity Questionnaire short form (IPAQ-sf). Group 2 will be asked to fill it out with information about physical activities in the last 7 days.
~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 2 will be asked to fill an original IPAQ-sf to describe physical activities in the last 7 days."
16331190|NCT04461587|Experimental|Pirfenidone [Esbriet]|"Pirfenidone recommended daily dose for patients is 801 mg three times a day with food, for a total of 2403 mg/day. Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:
~Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)
~Days 8 to 14: a dose of 534 mg administered three times a day (1602 mg/day)
~Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day) It will be provided in 267mg capsules. Treatment will be for a minimum of 12 months. Treatment duration will continue until last patient enrolled received 12 months of treatment."
16331191|NCT04461574|Placebo Comparator|Cervex Brush|
16331192|NCT04461574|Active Comparator|Orcellex Brush|
16331193|NCT04461561|Experimental|ELNEC-PPC WBT pluss usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
16331194|NCT04461561|No Intervention|Usual care only|Participants nurses deliver usual care as his/her role appropriate to neonates, infants, toddlers, preschoolers, school age, also to adolescents in selected unit of perinatal, neonatal, and settings which can be pediatric.
16331195|NCT04461548|Experimental|Experimental group 1: Best Possible Self|Participants are asked to think and write about their best possible future self and to imagine this positive future subsequently.
16331196|NCT04461548|Experimental|Experimental group 2: Best Possible Self + next steps|Participants are asked to think and write about their best possible future self and what the next steps could be to reach that best possible future. Subsequently, participants are asked to imagine this positive future.
16331197|NCT04461548|Experimental|Experimental group 3: Self-compassion|Participants are asked to think and write about a self-compassion exercise and to imagine this content subsequently.
16331198|NCT04461548|Active Comparator|Active control group|Participants are asked to think and write about a neutral task that is comparable to the experimental groups.
16331199|NCT04461535|Experimental|AVS with ACTH stimulation|Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.
16331200|NCT04461535|No Intervention|AVS without ACTH stimulation|Patients divided into AVS without ACTH stimulation group take the same procedure of AVS with a continuous saline infusion.
16331201|NCT04461522||Exposed group|
16331202|NCT04461522||Control group|
16331203|NCT04461509|Experimental|18F-PSMA|10 mCi ±20% F18-PSMA injection
16331204|NCT04461496|Active Comparator|Hybrid revascularization|50 hybrid procedure
16331205|NCT04461496|Experimental|Full metall jacket|50 total endovascular interventions
16331206|NCT04461483|Experimental|Part 1, Cohort 1; TAK-935 200 mg|Part 1, Cohort 1; TAK-935 200 mg, tablets, orally once on Days 1 in fasted state.
16331207|NCT04461483|Experimental|Part 1, Cohort 2; TAK-935 600 mg|Part 1, Cohort 2; TAK-935 600 mg, tablets, orally once on Days 1 in fasted state.
16331208|NCT04461483|Experimental|Part 1, Cohort 3; TAK-935 1200 mg|Part 1, Cohort 3; TAK-935 1200 mg, tablets, orally once on Days 1 in fasted state.
16331209|NCT04461483|Placebo Comparator|Part 1, Cohort 1-3; Placebo|Part 1, Cohort 1-3; TAK-935 placebo-matching tablets, orally once on Days 1 in fasted state.
16331210|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 100 mg|Part 2, Cohort 4: TAK-935 100 mg, tablets, orally twice on Days 1-7 in fasted state with multiple doses with titration.
16331211|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 200 mg|Part 2, Cohort 4: TAK-935 200 mg, tablets, orally twice on Days 8-14 in fasted state with multiple doses with titration.
16331212|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 300 mg|Part 2, Cohort 4: TAK-935 300 mg, tablets, orally twice on Days 15-21 in fasted state with multiple doses with titration.
16331213|NCT04461483|Placebo Comparator|Part 2, Cohort 4: Placebo|Part 2, Cohort 4: TAK-935 placebo-matching tablets, orally twice on Days 1-21 in fasted state.
16331214|NCT04461470||London|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
16331215|NCT04461470||All United Kingdom|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
16331216|NCT04461457|Experimental|Intraperitoneal Radioimmunotherapy boost|Four groups of 3 patients with recurring ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one IP dose of 211astatine-MX35 F(ab'2). Starting at 50 MBq/L. Dose escalation 100 Mbq/L, 200 MBq/L and finally 300 MBq/L.
16331217|NCT04461444|Other|Group ALMS et BBS|
16331218|NCT04461431|Experimental|Knee joint lateral reconstruction group|
16331219|NCT04461418|Active Comparator|Dexamethasone|Dose starting at 4 mg daily (for patients randomized to the Dexamethasone arm).
16331220|NCT04461418|Active Comparator|Prednisone|Dose starting at 25 mg/day (a calculation of equipotent steroid equivalencies will be used).
16331221|NCT04461405|Experimental|Intervention Arm|INTEGRATE-D is a step-by-step blueprint that will assist practices with employing American Diabetes Association recommendations for integrating medical and psychosocial care. INTEGRATE-D consists of a set of implementation strategies that enable clinical teams to put evidence-based care in place. The intervention consists of training and education; audit and feedback materials; a facilitation implementation protocol; and health information technology support materials.
16331222|NCT04461405|No Intervention|Control Arm|Usual care
16331223|NCT04461392|Experimental|Oncology patients|Patients diagnosed with cancer and treated with chemotherapy and/or radiotherapy
16331224|NCT04461379|Experimental|BCG Vaccine|A single dose BCG vaccine intradermally 0.1 ml.
16331225|NCT04461379|Placebo Comparator|Placebo|A single dose intradermally 0.1 ml of NaCl 0.9% solution
16331226|NCT04461366|Experimental|monopolar radiofrequency (MRF) group|Monopolar Radiofrequency Diathermy (LVT-250, Korea) was used at average energy160-180 W, main power 50/60 Hz, 40˚C ~ 45˚C Temperature, RF output 470 kHz, 20 mm electrode size.
16331227|NCT04461366|Active Comparator|Pulsed dye laser (PDL) group|Flash lamp pulsed dye laser; Candela SPTL-1 (Candela Corp., Wayland, Mass.) with the following parameters: (585nm wavelength, 450 msec pulse duration, 6.5 to 7.5 J/cm² energy density and 5or 7mm spot size).
16331229|NCT04461353|Placebo Comparator|Placebo|Placebo will be administered by inhalation through the mouth. It will be administered in both Cohort A1 and Cohort A2. Six participants will receive the active study drug and 2 participants will receive placebo.
16331230|NCT04461340|Experimental|Group A|20 patients will receive sirolimus ( oral dose of 6 mg on day 1 followed by 2 mg daily for 9 days) plus national standard of care therapy against COVID 19
16331231|NCT04461340|No Intervention|Group B|20 patients will receive only national standard of care therapy against COVID 19
16331232|NCT04461327|Experimental|Major Depressive patients|"3 groups:
~Women having recently attempted suicide (less than 72 hours).
~Women having a past suicide attempt (more than 72 hours).
~Women without lifetime history of suicidal behaviour."
16331233|NCT04461314|Other|Peer-led counselling|"About 50 university students trained as peer telephone counsellors through a structured training programme.
~About 200 Drug-abusing youth and young adults received telephone-based, Peer-led Brief Motivational Interviewing (BMI)"
16331234|NCT04461301|Experimental|Intervention|Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
16331235|NCT04461301|No Intervention|Control|Perioperative care of the control group will be based on standardized, multi-element, ERAS recommendations as already implemented in the different participating clinics.
16331236|NCT04461288|Experimental|Pride Posts|This six month intervention will be conducted on the Facebook platform. Participants will receive regular social media posts tailored to the sexual and gender minority communities (LGBTQ+). Weekly live sessions with a tobacco expert will be available. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
16331237|NCT04461288|Experimental|Pride Posts Plus|This six month intervention will include all elements of the Pride Posts arm. In addition, the intervention will include gamification, gaming elements designed to encourage participation in the program and behavior change. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
16331238|NCT04461288|Active Comparator|Usual Care Condition|Participants in this arm will be provided with a referral to smokefree.gov, a federally-funded website which provides support and digital-based interventions to assist in smoking cessation activities. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
16331239|NCT04461275|Experimental|ERAS 2.0 group|Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol.
16331240|NCT04461262|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
16331241|NCT04461262|Other|Standard Care|Foley catheter, uncoated
16331242|NCT04461249||Latanoprost group|Latanoprost 0.005 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
16331243|NCT04461249||Travoprost group|Travoprost 0.004 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
16331244|NCT04461249||Tafluprost group|Tafluprost 0.0015 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
16331245|NCT04461236|Experimental|Isoleucine|Type 2 Diabetics randomized to isoleucine group
16331246|NCT04461236|Placebo Comparator|Placebo|Type 2 Diabetics randomized to placebo group
16331247|NCT04461236|No Intervention|Healthy|gender-, age-, BMI-matched controls for baseline measurements only. No supplementation provided.
16331248|NCT04461210||Vulvodynia|Women with localized, provoked vulvodynia
16331249|NCT04461210||Health Controls|Women without vulvar pain or other vulvar disorders.
16331250|NCT04461197|Experimental|ESWT + orthotic insole|(shock waves + orthotic insole +Stretches of the posterior muscle chain)
16331251|NCT04461197|Placebo Comparator|ESWT + flat insole|(shock waves + flat insole + Stretches of the posterior muscle chain)
16331252|NCT04461184|Experimental|Internet wellness intervention for aging|Feasibility components will be evaluated with a 5-point Likert scale may include open ended items for more detailed feedback. Participants will be asked to visit NDSU at the beginning and end of the intervention, and at 1-month follow-up. After written informed consent, each participant will complete a descriptive questionnaire at the beginning of the intervention period, and a health-related questionnaire at the beginning and end of the intervention, and at follow-up that includes self-rated health, current smoking status, smoking history, alcohol use, morbid conditions, functional disability, and depression status. Standing height and waist circumference will be collected with a tape measure. Body weight and composition will be measured with the InBody 570. Anthropometric and body composition assessments will be collected pre, post, and follow up.
16331253|NCT04461171|Experimental|ERAS|Administration of a perioperative non-narcotic, multimodal pain management pathway.
16331254|NCT04461171|No Intervention|Non-ERAS (Conventional)|Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
16331255|NCT04461158|Experimental|Interventional Group|
16331256|NCT04461145|Other|ACL group|
16331257|NCT04461132|Active Comparator|Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included manual lymphatic drainage on the leg, skin care, bandaging and exercise.
16331341|NCT04460586|Experimental|Omadacycline IV followed by PO|Omadacycline 100mg IV, Omadacycline 300 mg tablet
16331258|NCT04461132|Sham Comparator|Shame Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included shame manual lymphatic drainage on the leg, skin care, bandaging and exercise. Shame manual lymphatic drainage include light touches instead of real manual lymphatic drainage techniques
16331259|NCT04461119|Experimental|Evenamide 7.5 mg bid|Evenamide capsules 7.5 mg BID for a total of 28 dosing days
16331260|NCT04461119|Experimental|Evenamide 15 mg bid|Evenamide capsules 15.0 mg BID for a total of 28 dosing days
16331261|NCT04461119|Placebo Comparator|Placebo|Matching placebo capsules BID for a total of 28 dosing days
16331262|NCT04461106|Active Comparator|Social Marketing Campaign|Select egg hubs will receive social marketing campaign which aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women.
16331263|NCT04461106|No Intervention|No Social Marketing Campaign|Other egg hugs will not receive social marketing campaign.
16331264|NCT04461093|Experimental|Group I|"Group I (n=45)
~Acupressure wristband
~IV Dexamethasone 8mg
~IV Ondansetron 4mg"
16331265|NCT04461093|Active Comparator|Group II|"Group II (n=45)
~1. IV Palonosetron 0.075mg"
16331266|NCT04461080|Experimental|Integrated care promoter|Patients who are randomized to the intervention group will be connected with a trained Integrated Care Promoter. The ICP could have a background as a social worker, health promoter or community worker. All ICPs will receive 1 week training to assist participants with social needs.
16331267|NCT04461080|Active Comparator|Information on community resources|Patients randomized to the control group will receive a list of tailored written information.
16331268|NCT04461067|Experimental|Gastric antrum measurement|
16331269|NCT04461041|Active Comparator|Empagliflozin|Single 10 mg tablet, administered orally once daily for 6 months
16331270|NCT04461041|Placebo Comparator|Placebo|Single 10 mg tablet, administered orally once daily for 6 months
16331271|NCT04461028|Other|GROUP 1 liposomal Bupivacaine|Will receive a 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
16331272|NCT04461028|Other|GROUP 2 Bupivacaine with dexamethasone|Will receive 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
16331273|NCT04461015|Other|0.4mU Insulin|During the euglycemic clamp insulin will be infused at 0.4mU/Kg/Min
16331274|NCT04461015|Other|0.8mU Insulin|During the euglycemic clamp insulin will be infused at 0.8mU/Kg/Min
16331275|NCT04461002||Cohort|Retrospective cohort
16331276|NCT04460989||standard implant|arthroplasty with a standard implant
16331277|NCT04460989||personalized implant|arthroplasty with a customized implant
16331278|NCT04460976|Experimental|Experimental group|Experiment group that receives the psychoeducation direct after the baseline measurement.
16331279|NCT04460976|Other|Control group|Standard care / treatment as usual. Comparison group alos receives Prisma psychoeducation after the three-month follow-up time period.
16331280|NCT04460963|Other|Biological evaluation|Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up
16331282|NCT04460924||MSM HIV-uninfected and ART naïve|Men who have sex with men without HIV infection, not receiving ART
16331283|NCT04460924||MSM HIV-infected starting ART|Men who have sex with men with HIV infection, starting ART
16331284|NCT04460924||MSM HIV-infected on ART with >500 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with >500 CD4 T cells/uL
16331285|NCT04460924||MSM HIV-infected on ART with <350 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with <350 CD4 T cells/uL
16331286|NCT04460924||MSM HIV negative patients starting PEP with INST|Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir
16331287|NCT04460911||PAL + FUL|Patients who initiated palbociclib-fulvestrant combination therapy as first-line or beyond therapy in the advanced or metastatic setting.
16331288|NCT04460911||FUL Mono|Patients who received fulvestrant monotherapy as first-line or beyond therapy in the advanced or metastatic setting.
16331289|NCT04460898||Breast Cancer Patients|HR+/HER2- metastatic breast cancer patients in the US.
16331290|NCT04460885|Experimental|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
16331291|NCT04460885|Active Comparator|Insulin glargine|Insulin glargine + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
16331292|NCT04460872|Experimental|testosterone enanthate|Testosterone enanthate via i.m. injection (100 mg/week)
16331293|NCT04460872|Experimental|locomotor training, testosterone enanthate|Treadmill and overground walking training and testosterone enanthate via i.m. injection (100 mg/week)
16331294|NCT04460872|No Intervention|non-interventional control|Non-interventional control group
16331295|NCT04460859||Intubated mechanically ventilated ARDS patients|Intubated mechanically ventilated patients with moderate to severe ARDS according to the Berlin definition
16331296|NCT04460846|Active Comparator|Alkaline water|Participants will consume 1.5 liters per day
16331297|NCT04460846|Placebo Comparator|Reverse osmosis water|Participants will consume 1.5 liters per day
16331298|NCT04460833|Experimental|Test group|All children will have the 6 feedback modalities + the control given randomly
16331299|NCT04460820|Experimental|Doxorubicin Hydrochloride Liposome Injection|50mg/m2 ,IV on Day 1 of each cycle
16331300|NCT04460820|Active Comparator|Doxorubicin Hydrochloride Liposome Injection(Caelyx®)|50mg/m2 ,IV on Day 1 of each cycle
16331301|NCT04460807|Experimental|Exemestane|"Standard chemotherapy: paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.
~+
~Exemestane: single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
16331302|NCT04460807|Placebo Comparator|Placebo|"Standard chemotherapy : paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.
~+
~Placebo: single oral tablet until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
16331303|NCT04460794|Experimental|Ballet-inspired workout programme (Group A)|Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
16331304|NCT04460794|Other|Usual care (Group B)|Control participants will continue their usual activities and exercises during the study period. In addition, they will be provided with an information sheet about recommendations with pictorial demonstrations on basic stretching and leg exercises for stroke survivors.
16331305|NCT04460781||1|Pregnant women from the VAP00003 Study and their offspring - Pregnant women from the VAP00003 Study (NCT03694392) between September 2018 and May 2020 (2 influenza seasons), and infants born from this cohort of pregnant women
16331306|NCT04460755|Active Comparator|Control group|A group of participants that will be using toothpaste without tooth whitening ingredients.
16331307|NCT04460755|Experimental|Whitening toothpaste 1|A group of participants that will be using urea peroxide whitening toothpastes.
16331308|NCT04460755|Experimental|Whitening toothpaste 2|A group of participants that will be using hydrogen peroxide whitening toothpastes.
16331309|NCT04460755|Experimental|Whitening toothpaste 3|A group of participants that will be using whitening toothpastes that contain abrasive ingredients.
16331310|NCT04460755|Experimental|Whitening toothpaste 4|A group of participants that will be using whitening toothpastes that contain enzymes as whitening ingredients.
16331311|NCT04460755|Experimental|Whitening toothpaste 5|A group of participants that will be using toothpastes that contain an activated charcoal.
16331312|NCT04460742|Experimental|CAPABLE Transitions|Older adults admitted to University of Rochester Medicine Home Care with and without dementia will receive care as usual as well as CAPABLE-trained occupational therapy, registered nurse, and handyman services delivered over 3-4 months.
16331313|NCT04460742|Active Comparator|Care As Usual|Older adults admitted to University of Rochester Medicine Home Care (a Medicare-certified home health agency) with and without dementia will receive care as usual.
16331314|NCT04460729|Experimental|Cohort 1|Participants who are asymptomatic and without prior brain therapy
16331315|NCT04460729|Experimental|Cohort 2|Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease
16331316|NCT04460703|Sham Comparator|Control|Control message about birdfeeding
16331317|NCT04460703|Active Comparator|Baseline message|These participants will be assigned a message about the benefits of vaccination. All other treatment arms include this baseline language.
16331318|NCT04460703|Experimental|Personal freedom|Experimental message arm.
16331319|NCT04460703|Experimental|Economic freedom|Experimental message arm.
16331320|NCT04460703|Experimental|Social benefit, self-interest|Experimental message arm.
16331321|NCT04460703|Experimental|Social benefit, community interest|Experimental message arm.
16331322|NCT04460703|Experimental|Economic benefit|Experimental message arm.
16331323|NCT04460703|Experimental|Social pressure- guilt|Experimental message arm.
16331324|NCT04460703|Experimental|Social pressure- embarrassment|Experimental message arm.
16331325|NCT04460703|Experimental|Social pressure- anger|Experimental message arm.
16331326|NCT04460703|Experimental|Trust in science|Experimental message arm.
16331327|NCT04460703|Experimental|Not bravery arm|Experimental message arm.
16331328|NCT04460690|Experimental|Rapid Onsite COVID-29 Testing|Community participants provide a saliva sample for a simple test to detect high concentrations of SARS-CoV-2 in saliva with assays that require no specialized equipment and can be completed in one hour.
16331329|NCT04460677|Experimental|Emotional Support Plan (ESP) + Weekly Monitoring|This will involve weekly assessments without prompting to use the plan.
16331330|NCT04460677|Experimental|Emotional Support Plan (ESP) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day randomly, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt
16331331|NCT04460664||Subjects admitted to floor|COVID-19 patients admitted to the floor as initial place of hospitalization
16331332|NCT04460664||Subjects admitted or transferred to ICU|COVID-19 patients admitted to the ICU as initial place of hospitalization or transferred to ICU from floor
16331333|NCT04460651|Active Comparator|Active treatment|Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.
16331334|NCT04460651|Placebo Comparator|Placebo|Participants in this arm will receive Placebo with the same dose scheme as the active comparator:
16331335|NCT04460638||Covid+ hospitalization group|Patients hospitalized with SARS-CoV2 infection
16331336|NCT04460638||Covid+ outpatient group|Patients or caregivers followed on an outpatient basis for an SARS-CoV2 infection
16331337|NCT04460638||Covid- group|Caregivers not infected with an SARS-CoV2
16331338|NCT04460638||Non-SARS pathology group|Individuals not infected with SARS-CoV2 but with another acute and/or infectious non-SARS pathology
16331339|NCT04460612|Placebo Comparator|Placebo Sock|Placebo Socks will be placed on participants feet either first or second for 60 minutes
16331340|NCT04460612|Active Comparator|Active IR Sock|Active IR socks will be placed on participants feet either first or second
16331345|NCT04460547||Completed Interventional studies|Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
16331346|NCT04460547||Completed Observational studies|Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
16331347|NCT04460534|Experimental|COHORT|Cohort
16331348|NCT04460521|Experimental|NAC Group|Participants in this group will given an N-acetylcysteine 500mg oral tablet daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
16331349|NCT04460521|Placebo Comparator|Placebo Group|Participants in this group will be given a placebo table to be taken orally daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
16331350|NCT04460508|Experimental|Mecapegfilgrastim|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle.
16331351|NCT04460508|Active Comparator|rhG-CSF|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle.
16331352|NCT04460495|Experimental|Feasibility (ASL,pH-Weighted amine CEST, O2-Weighted SAGE-EPI)|Participants undergo ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI , while breathing normal room air (21% oxygen). Patients then undergo another ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI while breathing medical grade air (100% oxygen). Total ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI imaging scan time is 60 minutes.
16331353|NCT04460482|Active Comparator|NIRS-guided PCI|Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
16331354|NCT04460482|Active Comparator|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
16331355|NCT04460456|Experimental|SBT6050 Monotherapy|Escalating doses of SBT6050 in Part 1 followed by expansion in Part 2 at the recommended dose determined in Part 1.
16331356|NCT04460456|Experimental|SBT6050 and pembrolizumab|Escalating doses of SBT6050 in combination with pembrolizumab in Part 3 followed by expansion in Part 4 at the recommended dose determined in Part 3.
16331357|NCT04460456|Experimental|SBT6050 and cemiplimab|SBT6050 in combination with cemiplimab in Part 5 at the recommended dose determined in Parts 1 and 3.
16331358|NCT04460443|Experimental|Sofosbuvir and ledipsavir|Sofosbuvir and ledipsavir plus standard of care treatment.
16331359|NCT04460443|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir plus standard of card treatment..
16331360|NCT04460443|No Intervention|Standard treatment|Standard treatment alone
16331361|NCT04460430|Experimental|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
16331362|NCT04460417|Experimental|Enhanced care|Participants will take part in an approximate one-hour health and smoking feedback session at the University of Chicago in Dr. King's Clinical Addictions Research Laboratory (CARL). The session will follow the Courage to Quit™ (CTQ) Roadmap program (developed by Dr. King with the Respiratory Health Association). This roadmap shorter version of the larger CTQ program has been specifically designed as an inpatient bedside or outpatient brief intervention guide to assess smoking cessation motivation, consequences of smoking, facts and myths about smoking, barriers to making a change, approved medications, de-bunking myths about medications or treatments without scientific evidence (e-cigarette, laser treatments, herbals, etc.), and gaining social support.
16331363|NCT04460417|Active Comparator|Treatment as Usual|"Participants will receive the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information."
16331364|NCT04460391|Experimental|experimental group|Early standing training and routine rehabilitation
16331365|NCT04460391|Active Comparator|control group|Conventional rehabilitation，Muscle training and breathing training
16331366|NCT04460378|Experimental|Cognitive Behavioral Therapy|Manualized Cognitive Behavioral Therapy starting at the patients' home.
16331367|NCT04460365|Active Comparator|Active|Softgel capsules: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin once a day with a meal for 18 months
16331368|NCT04460365|Placebo Comparator|Placebo|Identical capsule containing no active ingredients
16331369|NCT04460352|Active Comparator|Control arm (A)|"Neoadjuvant chemoradiotherapy followed by esophagectomy.
~Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
~Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy.
~Esophagectomy: Within 8 weeks of termination of chemoradiotherapy,"
16331370|NCT04460352|Experimental|Experimental arm (B)|"Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer.
~Radiotherapy: Two alternative schemes:
~1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.
~2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.
~Chemotherapy: Three alternative regimens:
~1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy.
~2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5.
~2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5."
16331371|NCT04460326|Active Comparator|Group 1 insulin glargine and Novolog|Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal BG is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
16331372|NCT04460326|Experimental|Group 2 insulin glargine and Fiasp|Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
16331373|NCT04460313|Other|prospective cohort|Nasopharyngeal sample for each enrrolled children
16331405|NCT04460001|Active Comparator|Ranibizumab|intravetreal injection of Ranibizumab alone for treatment of patients with macular oedema after CRVO once per month and follow up
16331374|NCT04460300|Experimental|Aromatherapy-inhalation group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.
~In this method, 5 drops of lavender oil is dropped directly on a sterile gauze and individuals is allowed to breathe from a distance of 10 cm for 5 minutes."
16331375|NCT04460300|Experimental|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.
~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
16331376|NCT04460300|No Intervention|Control group|Interviews is held with the control group while performing the routine treatment and care of the clinic. No intervention is made by the researchers to the control group during the interview.
16331377|NCT04460287|Placebo Comparator|Milk Drink Unfortified (Negative Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days.
16331378|NCT04460287|Active Comparator|Milk Drink Unfortified Plus Fish Oil (Positive Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
16331379|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Wet Mixing Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
16331380|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Dry Blending Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
16331381|NCT04460274||Model Building|Number of Covid-19 cases from December 31, 2019 to June 1, 2020 were used to build ARIMA model using Hyndman-Khandakar algorithm.
16331382|NCT04460274||Model Validation|Number of Covid-19 cases from June 2, 2020 to June 15, 2020 were used to forecast cases using the ARIMA model
16331383|NCT04460261|Experimental|COPD Group|Patients with COPD
16331384|NCT04460261|Experimental|Non-COPD Group|Non-COPD
16331385|NCT04460248|Experimental|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|
16331386|NCT04460235||Vaccination|All patients will be vaccinated
16331387|NCT04460222|Experimental|Rotational Thromboelastometry (ROTEM)|To prevent bleeding during invasive procedure, cirrhotic children in the ROTEM group will receive prophylactic transfusion based on the following protocol:- EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg
16331388|NCT04460222|Active Comparator|Conventional Transfusion|"To prevent bleeding during the procedure, cirrhotic children in the conventional group will receive prophylactic transfusion if either FFP, Platelet or Cryoprecipitate is deranged based on the following protocol
~If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg
~If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg
~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
16331389|NCT04460183|Experimental|Investigational arm|Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.
16331390|NCT04460183|Active Comparator|Control arm|Participants will receive institutional SOC for the treatment of COVID-19
16331391|NCT04460118||screw group|coracoid bone block fixed by the screw
16331392|NCT04460118||button group|coracoid bone block fixed by the suture-button
16331393|NCT04460105|Experimental|Lanadelumab|Participants receive 300 milligram (mg) of lanadelumab intravenous (IV) infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
16331394|NCT04460105|Placebo Comparator|Placebo|Participants will receive placebo matching IV infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
16331395|NCT04460092|Experimental|"Group A"|"In the first three days, participants in group A will inject 90-degree insulin injections using 5-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 8 mm to inject insulin."
16331396|NCT04460092|Experimental|"GroupB"|"In the first three days, participants in group B will inject 90-degree insulin injections using 8-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 5mm to inject insulin."
16331397|NCT04460066|Experimental|PD-L1 group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
16331398|NCT04460066|Placebo Comparator|placebo group|All patients will receive 6 cycles of placebo ( IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
16331399|NCT04460053|Experimental|Neurofilament light protein measurement|Neurofilament light protein measurements in peripheral blood pre- peri- and postoperatively.
16331400|NCT04460040|Experimental|Intervention|Exercise in moderate intensity tailored individually to 20 kcal/kg/week (range 1500-2000 kcal/week) with a free choice to exercise at home/gym on a treadmill or outdoors.
16331401|NCT04460027|Experimental|W-SUDs|
16331402|NCT04460027|No Intervention|Wait List Control|
16331403|NCT04460014|Experimental|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.
~Options to engage in self-administered/guided booster sessions per intrusive memory."
16331404|NCT04460014|Placebo Comparator|Attention placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
16331406|NCT04460001|Active Comparator|Ranibizumab and triamcinolone acetate|intravetreal injection of Ranibizumab and triamcinolone acetate for treatment of patients with macular oedema after CRVO once per month and follow up
16331407|NCT04459988||Patients with MS|Patients with MS who have been newly prescribed Ocrevus
16331408|NCT04459988||Healthy Controls|Healthy Controls
16331409|NCT04459975||AKI (-)|patients treated in ICU for COVID-19 infection and without occurrence of AKI (define as creatinine > 1,5x baseline according with KDIGO guidelines)
16331410|NCT04459975||AKI (+)|"patient treated in ICU for COVID-19 infection and with occurrence of AKI among which:
~• Severe AKI patients (define as creatinine > 3x baseline or need for renal replacement therapy according with KDIGO guidelines) who will participate to biocollection and to post-mortem biopsy (if death)."
16331411|NCT04459962|Experimental|Study Arm|Breath Test and Cheek Swab collection
16331412|NCT04459949|Active Comparator|Sharkskin Arm|
16331413|NCT04459949|Placebo Comparator|Grieshaber Arm|
16331414|NCT04459936|Experimental|Management by Rheumatologist|Treatment of modifiable risk factors for cardiovascular disease managed by the Rheumatologist according to national guideline.
16331415|NCT04459936|Active Comparator|Management by General Practitioner|Treatment of modifiable risk factors for cardiovascular disease managed by the General Practitioner according to national guideline.
16331416|NCT04459923|Active Comparator|Epidural Catheter Group|Patients will be applied with epidural catheter at T 5-6 level and the patient will be injected with an epidural solution containing 15 ml 0.125% bupivacaine through this epidural catheter
16331417|NCT04459923|Active Comparator|Erector Spina Block Catheter Groups|Patients will be applied with an erector spina plane block catheter at the T 5-6 level, erector spina plane block will be applied by ultrasound guidance and when the first local anaesthetic dosage block needle is identified under the erector spina muscle 30 ml 0.25% bupivacaine (15 ml bupivacain + 15 ml saline) will be injected.
16331418|NCT04459910||Multidirectional|Arthroscopic lateral ligament repair combined with deltoid arthroscopic ligament repair.
16331419|NCT04459897||diagnosed or treated for granulomatous hepatitis fol|The cohort is composed by patient diagnosed or treated for granulomatous hepatitis followed in the internal medicine and / or Hepato-gastroenterology departments (Croix-Rousse Hospital, Edouard-Herriot Hospital, Lyon Sud Hospital Center).
16331420|NCT04459871|Experimental|The experimental group|The topical recombinant human thrombin(rhThrombin) was prepared into 1000IU/mL solution with 10ml normal saline and used in combination with absorbable gelatin spongeat at appropriate bleeding evaluation site(s).
16331421|NCT04459871|Placebo Comparator|The control group|The placebo was prepared into a solution with 10mL normal saline and used in combination with absorbable gelatin sponge at appropriate bleeding evaluation site(s).
16331422|NCT04459858||rotator cuff lesion|patients treated for traumatic or degenerative rotator cuff lesion
16331423|NCT04459845|Active Comparator|Parent Child Interaction Therapy|Parents and children will receive 12 weekly sessions of PCIT.
16331424|NCT04459845|Active Comparator|Child Parent Psychotherapy|Parents and children will receive 12 weekly sessions of CPP
16331425|NCT04459832|Experimental|15 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 15 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
16331426|NCT04459832|Experimental|30 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 30 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
16331427|NCT04459832|Experimental|60 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 60 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
16331428|NCT04459832|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end
16331429|NCT04459780|Experimental|Group 1 : 20 subjects with plaque psoriasis|Intervention: skin biopsies and blood sample
16331430|NCT04459780|Experimental|Group 2 : 10 subjects with atopic dermatitis|Intervention: skin biopsies
16331431|NCT04459767|Experimental|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
16331432|NCT04459767|Experimental|Vupanorsen 160 mg|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
16331433|NCT04459767|Placebo Comparator|Placebo|"Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water.
~Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water."
16331434|NCT04459754|Experimental|Fuzheng Yiliu group|
16331435|NCT04459754|No Intervention|control group|
16331436|NCT04459741|Experimental|HIV+ Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
16331437|NCT04459741|Other|HIV+ Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
16331438|NCT04459741|Experimental|HIV- Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
16331439|NCT04459741|Other|HIV- Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
16331440|NCT04459728|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
16331443|NCT04459702|Experimental|Dual Therapy|Dual Therapy utilizing hydroxychloroquine and azithromycin.
16331444|NCT04459702|Experimental|Quadruple Therapy|Quadruple therapy utilizing hydroxychloroquine, lopinavir, ritonavir, and azithromycin
16331445|NCT04459676|Active Comparator|ANG-3777 + SOC|"ANG-3777 Administered IV for 30 min and SOC
~Repeat within 24 hours after previous dosing for a total of 4 days"
16331446|NCT04459676|Placebo Comparator|Standard of Care + Placebo|Standard of Care + Placebo
16331447|NCT04459663|Experimental|JS001 combined with Axitinib|JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy
16331448|NCT04459650|Experimental|Female Breast Cancer Pts|Participants include female breast cancer patients who either receive endocrine therapy and suffer from endocrine induced alopecia or suffer from post chemotherapy induced alopecia.
16331449|NCT04459637||Asymptomatic group|Definition of asymptomatic disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
16331450|NCT04459637||Mild group|Definition of mild disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
16331451|NCT04459637||general-type group|Definition of general-type disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
16331452|NCT04459637||severe group|Definition of severe disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
16331453|NCT04459637||critical group|Definition of critical disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
16331454|NCT04459624|Active Comparator|ESP block|Intervention: Erector Spina Plane Block will administer with 20 ml of % 0.25 bupivacaine
16331455|NCT04459624|Active Comparator|QLB 2 block|Intervention: Quadratus Lumborum Block 2 will administer with 20 ml of % 0.25 bupivacaine
16331456|NCT04459611|Experimental|sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
16331457|NCT04459611|Experimental|sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
16331458|NCT04459598|Experimental|Efavirenz 600 mg + Quizartinib 60 mg|Participants who are randomized to receive efavirenz 600 mg once daily (QD) for 34 days and a single, oral dose of quizartinib 60 mg will be administered on Day 15 concurrently with efavirenz.
16331459|NCT04459598|Active Comparator|Quizartinib 60 mg|Participants who are randomized to receive a single, oral dose of quizartinib 60 mg.
16331460|NCT04459585|Experimental|Dabigatran + Quizartinib|Participants who will receive a single oral dose of 150mg dabigatran etexilate on Day 1 of Period 1 and then will receive a single oral dose of 60mg quizartinib 2 hours prior to the administration of a single oral dose of 150mg dabigatran etexilate on the morning of Day 5 of Period 2.
16331461|NCT04459572|Other|Sepsis and sepstic shock|The study consists patients and healty-control group. Patients divided into 3 groups based on severity: sepsis, severe sepsis and septic shock
16331462|NCT04459559|Experimental|Intervention|Using the Tactile Cueing Device
16331463|NCT04459546|Experimental|Study group|Study group intervention consists patient education, training booklet and 3 month follow-up.
16331464|NCT04459546|No Intervention|Control group|Control group received only general care
16331465|NCT04459533||TOF group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, for whom a NMB monitor use (TOF) was reported in the electronic health records (EHR).
16331466|NCT04459533||Control group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, with no NMB monitor use reported in the EHR
16331467|NCT04459520|Experimental|Testing Unavailable Group|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, but that COVID-19 testing is not available. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
16331468|NCT04459520|Active Comparator|Positive Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a positive COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
16331469|NCT04459520|Placebo Comparator|Negative Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a negative COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
16331471|NCT04459494|Experimental|Test group|Patients undergoing dental implant treatment without flap removal (Test Group)
16331472|NCT04459494|Active Comparator|Control group|Patients who will receive dental implants by removing conventional full thickness flaps (Control group)
16331473|NCT04459481|Experimental|70-degree bending angle group|intubation with a 70-degree bending angle
16331474|NCT04459481|Experimental|90-degree bending angle group|intubation with a 90-degree bending angle
16331475|NCT04459468||HCC for Lipiodol TACE|These patients will standard of care Lipiodol TACE treatment. No research intervention is planned
16331476|NCT04459468||Healthy controls|Healthy controls from public database
16331477|NCT04459468||HCC patients|HCC patients will be used for biomarker validation.
16331478|NCT04459455|Experimental|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people from the US who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
16331479|NCT04459455|Placebo Comparator|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
16331480|NCT04459442|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
16331481|NCT04459442|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth.
16331482|NCT04459429|Experimental|NHF by smaller cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the smaller cannula
16331483|NCT04459429|Experimental|NHF by larger cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the larger cannula
16331484|NCT04459416|Experimental|Usual Care plus Acupuncture|Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. to prevent severe pain. If acupuncture does not prevent severe pain, the participant will receive opioid medication as backup pain relief.
16331485|NCT04459416|Active Comparator|Usual Care|Will receive only the usual pain management approach, which includes opioid medication when needed for severe pain, according to the routine guidelines for their care.
16331486|NCT04459390||COVID19 with comorbidities|"Patients with COVID19 with at least one of the following comorbidities:
~Hypertension
~Diabetes
~Cardiovascular disease
~Chronic pulmonary disease
~Obesity
~Chronic liver disease
~Chronic kidney disease
~Collagen vascular disease
~Autoimmune disease
~Malignancy"
16331487|NCT04459390||COVID19 without comorbidities|Patients with COVID19 without any of the previously mentioned comorbidities
16331488|NCT04459377|Placebo Comparator|Placebo|Sodium Chloride solution (9mg / ml) 0.2ml / kg slow intravenous injection (2ml / min).
16331489|NCT04459377|Active Comparator|K1|S-Ketamine (0.125 mg / kg body weight). (0.625mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
16331490|NCT04459377|Active Comparator|K2|S-Ketamine (0.25 mg / kg body weight). (1.25mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
16331491|NCT04459338|Placebo Comparator|Saline|Saline infused during the hyperglycemic clamp with escalating doses of glucagon
16331492|NCT04459338|Active Comparator|Exendin-9,39|Exendin-9,39 infused during the hyperglycemic clamp with escalating doses of glucagon
16331493|NCT04459325|Experimental|Study drug and best available care|Best available care and Tigerase®/nebulised dornase alfa [2.5 mg BID] for 7 days
16331494|NCT04459325|Other|Control group (best available care)|Patients will receive the usual care in accordance with good practice.
16331495|NCT04459299||STEMI patients with clinical indication for primary PCI|Subjects with a clinical indication of STEMI.
16331496|NCT04459286|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
16331497|NCT04459286|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets
16331498|NCT04459273|Experimental|Basic science (68GA-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV then 20-90 minutes later undergo PET/CT.
16331499|NCT04459260|Experimental|Cognitive Behavior Therapy|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on cognitive behavior therapy and includes both cognitive interventions, e.g., cognitive restructuring and behavioral experiments, and behavioral interventions, behavioral activation. The treatment was manualized by Egan et al. (2016) and has been tested in several clinical trials, both via the Internet and face-to-face.
16331500|NCT04459260|Active Comparator|Unified Protocol|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on a transdiagnostic approach derived from cognitive behavior therapy called Unified Protocol, focusing on the shared emotional aspects underlying depression and anxiety disorders. The treatment was manualized by Ellard et al. (2010) and has been tested in several clinical trials, but so far not over the Internet.
16331501|NCT04459247|Experimental|Intervention|Vitamin D high dose
16331502|NCT04459247|No Intervention|Control arm|No Vitamin D supplementation
16331503|NCT04459221|Experimental|Facilitating access to HPV vaccination|
16331504|NCT04459221|No Intervention|promotion of HPV vaccination|
16331505|NCT04459208|Active Comparator|Manta|plug-based vascular closure
16331506|NCT04459208|Active Comparator|ProGlide|suture-based vascular closure
16331507|NCT04459195|Experimental|2 Minute Static stretching|Stretching applications will be applied to the first group for 2 minutes .
16331509|NCT04459182|Active Comparator|Endothelial dysfunction (DE+)|obsese patient with OSA (AHI>15) and endothelial dysfunction
16331510|NCT04459182|Sham Comparator|No endothelial dysfunction (DE-)|obsese patient with OSA (AHI>15) and no endothelial dysfunction
16331511|NCT04459156|Experimental|Healthy Participants|healthy control subjects
16331512|NCT04459156|Experimental|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
16331513|NCT04459130|Experimental|Child Obesity Program|"Firstly, overweight and obese students will be determined by measuring their height and weight. While selecting children for the experimental group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Experiment group. Child Obesity Program (COP) will be applied to students in the experimental group for 10 weeks. Before the program is implemented, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed.
~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales
~- Children's Dietary Self- Efficacy Scale-CDSS
~- Food Behavior Scale
~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)
~-Daily Food Consumption Form
~-Drink Consumption Form
~Health Perception Form
~Follow-ups will be performed in the 6th and 12th months after the intervention"
16331514|NCT04459130|No Intervention|Control Grup|"Firstly, overweight and obese students will be determined by measuring their height and weight. When selecting children for the control group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Control group. First, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed. The control group will be trained for a daily healthy diet and physical activity.
~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales
~- Children's Dietary Self- Efficacy Scale-CDSS
~- Food Behavior Scale
~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)
~-Daily Food Consumption Form
~-Drink Consumption Form
~Health Perception Form
~Follow-ups will be performed in the 6th and 12th months after the intervention"
16331515|NCT04459117|Active Comparator|Acetaminophen|The active product is a 10 ml polyethylene ampoule of acetaminophen containing 100 mg of acetaminophen, solution for infusion, B BRAUN.
16331516|NCT04459117|Placebo Comparator|NaCL 0.9%|The placebo product is a polyethylene ampoule of 10ml of NaCL 0.9%, B BRAUN. Polyethylene ampoule of active and placebo products are with the same appearance, in accordance with Good Manufacturing Practices Drugs for Clinical Trials.
16331517|NCT04459104|Experimental|chronic low back patients|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
16331518|NCT04459104|Experimental|breast cancer survivors having chronic pain|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
16331519|NCT04459104|Active Comparator|healthy pain-free controls|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
16331522|NCT04459078|Experimental|Camrelizumab combined with Albumin Paclitacxel and Apatinib.|Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days,, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity.
16331523|NCT04459065|Experimental|Low dose intermediate time|Participants will receive an i.v. infusion of 50 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
16331524|NCT04459065|Experimental|High dose intermediate time|Participants will receive an i.v. infusion of 100 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
16331525|NCT04459065|Experimental|Optimal dose early time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on results from cohorts 1 and 2). Participants will undergo lung cancer resection surgery 1-3 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
16331526|NCT04459065|Experimental|Optimal dose late time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on cohorts 1 and 2). Participants will undergo lung cancer resection surgery 7+ days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
16331529|NCT04459039|Experimental|Fluid restriction|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
16331530|NCT04459039|Placebo Comparator|Non-fluid restriction|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously
16331531|NCT04459026|Experimental|group A - combination|Group A patients will receive intra-abdominal instillation 0.75% Ropivacaine 2 mg / kg in 200 ml of NaCl through the trocars and 2) Infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 1 mg / kg in 20 ml of NaCl
16331532|NCT04459026|Experimental|Group B - infiltration|Group B patients will receive infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 3 mg / kg in 20 ml of NaCl.
16331533|NCT04459026|Active Comparator|Group C - instillation|Group C patients will receive intra-abdominal instillation 0.75% Ropivacaine 3 mg / kg in 200 ml of NaCl through the trocars.
16331534|NCT04459013||Patient of the orthodontic consultation|
16331535|NCT04459000|Active Comparator|STARs Only|Consenting research participant who receive prenatal care services in the STAR clinic, but are not randomized to receive mABC home visiting services.
16331536|NCT04459000|Experimental|STARS + mABC|Consenting research participant who receive prenatal care services in the STAR clinic, and are randomized to receive mABC home visiting services.
16331537|NCT04459000|No Intervention|Control Group/CHOUM Only|These are research participants who were eligible to receive care in the STAR clinic, but did not opt to receive that care.
16331539|NCT04458974|Experimental|Experimental group (Exp)|Active tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation)
16331540|NCT04458974|Sham Comparator|Sham-tDCS (Sham)|Sham tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation
16331541|NCT04458974|Other|Control group (Control)|Conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation) without tDCS.
16331542|NCT04458961|Active Comparator|One-stage|
16331543|NCT04458961|Active Comparator|Two-stage|
16331544|NCT04458948|Experimental|Hydroxychloroquine and Azithromycin|All subjects receive Hydroxychloroquine and Azithromycin.
16331545|NCT04458935||Participants|Participants with retinal hemangioblastoma (RH) managed with trans-scleral cryotherapy at the NIH.
16331546|NCT04458922|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16331547|NCT04458909|Experimental|Arm I (nivolumab, gemcitabine, cisplatin, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 30-60 minutes or carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 4 weeks, patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16331548|NCT04458909|Active Comparator|Arm II (gemcitabine, cisplatin, carboplatin)|Patients receive gemcitabine and cisplatin or carboplatin as in Arm I.
16331549|NCT04458896|Experimental|Stand When You Can|The intervention is grounded in Social Cognitive Theory and the Social Ecological Model (SEM). Multiple levels of the SEM will be targeted (individual, environmental, and organizational) over 6 weeks.
16331550|NCT04458883|Experimental|Myocardial Infarction Group|Patients diagnosed with a myocardial infarction
16331551|NCT04458883|Experimental|Healthy Volunteers|Healthy Volunteers
16331552|NCT04458870|Experimental|Acceptance and Commitment Therapy|
16331553|NCT04458857|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
16331554|NCT04458857|Placebo Comparator|Placebo|Matching placebo
16331555|NCT04458844|Experimental|Fundamental Movement Skill (FMS) Training|Exercise 2 x per week focusing on Fundamental Movement Skill Development
16331556|NCT04458844|Experimental|FMS and strength|Replacement of 50% FMS training with integrated strength training.
16331557|NCT04458844|No Intervention|Control|No intervention.
16331559|NCT04458818|Experimental|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
16331560|NCT04458805|Experimental|NX-13 250mg|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
16331561|NCT04458805|Placebo Comparator|Placebo|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
16331562|NCT04458792|Experimental|Experimental: Biological collection|"For all the patients include in the study :
~Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue)
~MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery
~circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery
~radiotherapy toxicity : Blood samples collected before the radiotherapy
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16331563|NCT04458779|Experimental|CPAP group|Subjects will receive CPAP treatment in addition to optimal standard therapy for acute stroke.
16331564|NCT04458779|No Intervention|Usual-care group|Subjects will receive optimal standard therapy for acute stroke.
16331565|NCT04458766|Experimental|Interventions|"All subjects in this trial will receive the following interventions:
~Pre-Intervention (Days 0-14): Subjects given access to Wellth application reminders, no incentives provided. A virtual check in with the study team will occur at the end of the pre-intervention period (14 days).
~Intervention (Days 15-74): Subjects will use Wellth app for 60 days, with incentives provided at the 30- and 60-day mark. At the end of the intervention period (Day 60), the subject will attend a clinic visit with the medical provider and a fasting lipid panel and MMAS will also be collected at this time.
~Post-intervention (Days 74-134): Subjects will continue to use the Wellth app and receive reminders, but with no incentives provided, for 60 days. A clinic visit, fasting lipid profile, and MMAS will also be collected following the post-intervention period."
16331566|NCT04458753|Experimental|Lumbar focused + knee focused exercise group|Will receive strengthening of back , abdominal, and quadriceps muscles, and stretching if calf and Hamstring muscles
16331567|NCT04458753|Active Comparator|Knee focused exercise group|Will receive strengthening of quadriceps and stretching of calf and Hamstring muscles
16331568|NCT04458740||Patient|Patients with a diagnosis of colorectal cancer after 65 years.
16331569|NCT04458740||The spouse and /or children and /or parents|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
16331570|NCT04458727||Patients who used supportive measures during home training|
16331571|NCT04458727||patients who did not use supp. measures during home training|
16331572|NCT04458714|Active Comparator|CO2 group (treatment arm)|This arm included 32 patients who were randomized for using CO2 as the contrast medium for aortoiliac angiolplasty.
16331573|NCT04458714|Active Comparator|ICM group (control arm)|This arm involved 32 patients who were randomized for using iodine contrast medium (ICM) for aortoiliac angiolplasty.
16331574|NCT04458688||African Americans with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as African American.
16331575|NCT04458688||Caucasian American with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as Caucasian American.
16331576|NCT04458675|Experimental|Active|Activr capsule
16331577|NCT04458675|Placebo Comparator|Placebo|Placebo capsule
16331578|NCT04458662||Eumenorrheic women|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).
~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.
~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.
~In both studies, eumenorrheic participants were evaluated at three specific moments of the menstrual cycle: Early-follicular phase (EFP), late-follicular phase (LFP) and mid-luteal phase (MLP);"
16331579|NCT04458662||Oral contraceptive users|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).
~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.
~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.
~Oral contraceptive users performed the trial at two moments: Withdrawal phase (WP) and active pill phase (APP)."
16331580|NCT04458662||Postmenopausal women|"he project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).
~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.
~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.
~Postmenopausal women were tested only once, since their hormonal status does not fluctuate."
16331581|NCT04458649||No increased risk of hypoglycemia|Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
16331582|NCT04458649||Increased risk of hypoglycemia|"Infants considered at increased risk for hypoglycemia after birth including the following criteria:
~Infant born to a diabetic mother
~Very large for gestational age (VLGA) infant with weight >97%"
16331583|NCT04458636|Active Comparator|Standard care|Blinded prednisolone 30mg orally once per day for 14 days
16331584|NCT04458636|Placebo Comparator|Biomarker care|Blinded prednisolone 30mg orally once per day for 14 days if peripheral eosinophil count is equal or greater than 2%. Placebo equivalent if peripheral blood eosinophil count is <2%.
16331587|NCT04458610|Experimental|Treatment (zanubrutinib, rituximab)|See Detailed Description.
16331588|NCT04458584||Ligament Reconstruction - Tendon Interposition (LRTI)|Patients undergoing thumb basal joint arthroplasty using LRTI procedure as treatment of osteoarthritis.
16331589|NCT04458584||Suture Suspensionplasty (SS)|Patients undergoing thumb basal joint arthroplasty using suture suspensionplasty (SS) procedure as treatment of osteoarthritis.
16331590|NCT04458584||Arthroscopic Trapeziectomy (AT)|Patients undergoing thumb basal joint arthroplasty using arthroscopic trapeziectomy (AT) procedure as treatment of osteoarthritis.
16331591|NCT04458558|Experimental|Medical abortion patients|Oral mifepristone 200 mg followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone).
16331592|NCT04458545|Placebo Comparator|Placebo Vaccine|
16331593|NCT04458545|Experimental|Low Dose Vaccine (100 μg)|
16331594|NCT04458545|Experimental|High Dose Vaccine (400 μg)|
16331595|NCT04458532|Experimental|(A) breast cancer after completion of chemo|300 min/wk for 16 weeks, followed by 16 weeks of usual care.
16331596|NCT04458532|Experimental|(B) breast cancer after completion of chemo|150 min/wk for 32 weeks.
16331597|NCT04458532|Experimental|(C) breast cancer after completion of chemo|300 min/wk for 32 weeks.
16331598|NCT04458532|Active Comparator|(D) breast cancer after completion of chemo|150 min/wk for 16 weeks, followed by 16 weeks of usual care.
16331599|NCT04458519|Experimental|Probiorinse|Nasal irrigations with Probiorinse (2.4 Billion CFU (Colony-Forming Units) of Lactococcus Lactis W136, (NPN: 80085895)) twice-daily for a period of fourteen days
16331600|NCT04458519|Active Comparator|Saline solution|Nasal irrigations with saline (NeilMed Sinus Rinse, (NPN: 80027142)) twice-daily for a period of fourteen days
16331601|NCT04458506|Experimental|Rapid Maxillary Expander (RME)|36 patients will be treated with RME in order to correct their unilateral posterior cross bite
16331602|NCT04458506|Active Comparator|Quad Helix (QH)|36 patients will be treated with QH in order to correct their unilateral posterior cross bite
16331603|NCT04458493|Experimental|control|no supplement will be provided on the day of the experiment
16331604|NCT04458493|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 400ml, 20% solution)
16331605|NCT04458480||Exposed Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
16331606|NCT04458480||Control Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
16331607|NCT04458467|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout).
16331608|NCT04458467|Experimental|Automated Boluses|Patients will receive intermittent boluses of Ropivacaine 0.2% (8 mL automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
16331609|NCT04458454||Examination of relaxin levels|This is a pilot study of 1 group of patients. The analysis of relaxin levels in serum and follicular fluid obtained on the day of puncture of the follicles in patients undergoing treatment in the IVF protocol is carried out.
16331610|NCT04458441|Active Comparator|warm skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.
16331611|NCT04458441|No Intervention|cold skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be used in the skin cleaning of the baby without any heating procedure.
16331612|NCT04458428|No Intervention|Control|No other non-standard of care activities will be performed
16331613|NCT04458428|Experimental|Intervention|Will be signed up for the automated short message service (SMS)
16331614|NCT04458415|Experimental|TPR Arm|Surgeon will use the Traxi Panniculus Retractor to retract the panniculus during cesarean section.
16331615|NCT04458415|Active Comparator|Silk Tape Arm|Surgeon will use silk tape to retract the panniculus during cesarean section.
16331616|NCT04458402|Experimental|Hypofractionated Whole-Pelvis Radiotherapy|Hypofractionated WPRT Cohort 1: 41.25 Gy in 15 fx Cohort 2: 38 Gy in 10 fx
16331617|NCT04458389|Experimental|TY101|"Dose escalation：Humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg (fix dose) until disease progresses or unacceptable tolerability occurs.
~Dose expansion：After completion of the DLT observation, the sponsor and principal investigator will select a possible dose（RP2D）for dose expansion to further confirm the efficacy and safety of RP2D."
16331618|NCT04458376|Experimental|Follows the internet-based self-help program|
16331619|NCT04458363|Experimental|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria) convalescent plasma will be administered
16331620|NCT04458350|Experimental|Digital Promotions Group|Eligible zip codes (n=96) will be randomized using stratified randomization at the state level. The intervention will last 13 weeks (Summer 2020 market season) and consist of receiving digital ads on the Fresh EBT app and Facebook for SNAP fruit and vegetable incentive programs at farmers' markets.
16331621|NCT04458350|No Intervention|Control Group|No intervention administered. Eligible zip codes (n=96) will be randomized using stratified randomization at the state level.
16331622|NCT04458337||SARS-CoV-2 patients undergoing a surgical procedure|The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery.
16331623|NCT04458324|Experimental|NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
16331624|NCT04458324|Placebo Comparator|NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
16331625|NCT04458324|Sham Comparator|sham NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
16331626|NCT04458324|Active Comparator|sham NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
16331813|NCT04456920|Experimental|Experimental group 1|PRO (Patient Reported Outcomes) gathered via a phone consultation
16331627|NCT04458311|Experimental|Phase I|Increasing doses of tildrakizumab in combination with a fixed dose of abiraterone to establish the recommended phase II dose in patients with metastatic castration resistant prostate cancer..
16331628|NCT04458311|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
16331629|NCT04458298|Experimental|Cohort A: OP-101 2 mg/kg|Participants will receive a single intravenous (IV) infusion of OP-101 2 milligram per kilogram (mg/kg) on Day 1.
16331630|NCT04458298|Experimental|Cohort B: OP-101 4 mg/kg|Participants will receive a single IV infusion of OP-101 4 mg/kg on Day 1.
16331631|NCT04458298|Experimental|Cohort C: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Day 1.
16331632|NCT04458298|Placebo Comparator|Cohort D: Placebo|Participants will receive a single IV infusion of matching placebo on Day 1.
16331633|NCT04458285|Experimental|Sacubitril/valsartan|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous angiotensin converting enzyme inhibitor(ACEI), ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
16331634|NCT04458285|Active Comparator|Valsartan|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
16331635|NCT04458272|Experimental|DS-1001b|
16331643|NCT04458246|Experimental|Intervention|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will receive an online home-based aerobic training, three times a week, during 3 months.
16331644|NCT04458246|No Intervention|Control|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will be advised to maintain their daily routine.
16331645|NCT04458233|Active Comparator|long axis|
16331646|NCT04458233|Active Comparator|short axis|
16331649|NCT04458207|Experimental|Experimental group (EG), the immediate rehabilitation group|The experimental group will begin with the rehabilitation immediately after the first measurement of cognitive tests (pre-test). Three months after complete rehabilitation the first post-test (post-test 1) will be conducted on all participants. Participants will be recalled after about a year for a long-term follow up (post-test 2). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at different time points (i.e., pre-test, post-test 1 and post-test 2).
16331650|NCT04458207|Active Comparator|Control group (CG), the test-retest group|The control group will be tested with the cognitive tests two times (pre-test + post-test 1) at an interval of about three months or more inbetween tests and before the onset of the prosthodontic rehabilitation. Three months after complete rehabilitation the post-test (post-test 2) will be conducted on all participants. Further, participants will be recalled after about a year for a long-term follow up (post-test 3). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at these time points (i.e., pre-test, post-test 1, post-test 2 and post-test 3).
16331651|NCT04458194|Active Comparator|Standard Care|Cancer survivor-caregiver dyads receive their standard care
16331652|NCT04458194|Experimental|Partnered yoga|Cancer survivor-caregiver duads receive 8 virtual Zoom yoga sessions (75 minutes/session, 2 times a week for 4 weeks) together
16331653|NCT04458194|Experimental|Non-partnered yoga|Cancer survivors receive 8 virtual Zoom yoga sessions (75 minutes/session, 2 times a week for 4 weeks) along; caregivers do not receive virtual Zoom yoga sessions.
16331654|NCT04458181|Experimental|Treatment Group|Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.
16331655|NCT04458181|No Intervention|Control Group|There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.
16331656|NCT04458168|Experimental|Recently completed treatment|25 women who have just completed treatment
16331657|NCT04458168|Experimental|No recurrence of ovarian cancer for at least one year|25 women who have not experienced a recurrence of their ovarian cancer at least one year after their initial diagnosis
16331658|NCT04458168|Experimental|Recurrence of ovarian cancer|25 women who have experienced a recurrence of their ovarian cancer after primary treatment
16331659|NCT04458155||Chest pain patients|"Patients are eligible for participation if they are admitted to:
~The cardiac emergency department (ED) because of chest pain for ruling out acute coronary syndrome by troponin analysis
~The Coronary Care Unit (CCU) with a NSTEMI or post-percutaneous coronary intervention (PCI) STEMI.
~Troponin analysis will be performed according to standard protocol. From every included patient two capillary blood samples and an extra venous blood sample will be drawn during regularly ordered blood work to evaluate HS cTnI levels obtained with the POC instrument."
16331660|NCT04458142|Experimental|Single buccal infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine).
~Injecting by a small amount of solution in the superficial mucosa. After a few seconds, the needle was slowly advanced in the mucobuccal fold toward the apex of the molar and 1.8 ml of 4% articaine using short 30-gauge needle was slowly given.
~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed by inquiring about the area of numbness from the participant, no pain during pricking the palatal mucosa. The cases in which palatal anesthesia will not be reported by the patient will be given supplemental palatal infiltration with 0.2 to 0.3 mL articaine.
~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
16331661|NCT04458142|Active Comparator|Buccal and intrapapillary infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine) Injecting a small amount of solution in the superficial mucosa,then needle will slowly advanced in the mucobuccal fold toward the apex of the molar and 1.5 ml of 4% articaine was slowly given. The remaining 0.3ml solution will be given equally into the distal, mesial intrapapillary and palatal sites respectively until blanching of the palate is observed extending more than halfway along the palatal gingival margin.
~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed.
~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
16331662|NCT04458129|Experimental|Polyethylene glycol treatment|Study participants will take a 3-month laxative treatment with polyethylene glycol for 3 months.
16331663|NCT04458116|Experimental|Tumeric Group|participants will receive capsules containing 1.5 grams of turmeric 95% curcumin
16331664|NCT04458116|Placebo Comparator|Placebo Group.|will receive capsules containing corn starch.
16331665|NCT04458103|Experimental|prospective interventional cohort|The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
16331666|NCT04458103|No Intervention|retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.
16331667|NCT04458090|Experimental|Intervention|Receive hospice patient decision aid
16331668|NCT04458090|No Intervention|Control|Does not receive hospice decision aid
16331669|NCT04458077|Experimental|Mobile-phone-based SEIL Intervention|This group will receive the Discover Learning 10-session intervention through a mobile-phone based platform over the course of 10 weeks (1 session per week).
16331670|NCT04458064|Active Comparator|i gel|I gel LMA was inserted for all patients
16331671|NCT04458064|Active Comparator|Air Q LMA|Air Q LMA was inserted for all patients
16331672|NCT04458051|Experimental|SAR442168|Dose 1 of oral SAR442168 daily
16331673|NCT04458051|Placebo Comparator|Placebo|Placebo to match the SAR442168 daily
16331674|NCT04458038|Experimental|intervention arm|
16331675|NCT04458025|Active Comparator|Standard rehabilitation program|Standard postoperative 4 weeks immobilization rehabilitation program with a sling in adduction and internal rotation
16331676|NCT04458025|Experimental|Early rehabilitation program|Early rehabilitation program will start passive mobilization during second week after surgery, including controlled external rotation movements
16331677|NCT04457999|Experimental|Lipiflow treatment|Lipiflow thermal pulsation prior to cataract surgery
16331678|NCT04457986|Experimental|Erector spina plane block (ESP)|Patients will receive Erector spina plane block (ESP) with bupivacaine for postoperative analgesia
16331679|NCT04457986|Experimental|Modified thoracolumbar interfacial plane block (MTI)|Patients will receive Modified thoracolumbar interfacial plane block (MTI) with bupivacaine for postoperative analgesia
16331680|NCT04457986|Active Comparator|Intravenous patient controlled analgesia (IV-PCA)|Patients will receive Intravenous patient controlled analgesia (IV-PCA) with tramadol for postoperative analgesia
16331681|NCT04457973|Experimental|Active tDCS|
16331682|NCT04457973|Placebo Comparator|Sham tDCS|
16331685|NCT04457934||IBD patients|"Patients with IBD will undergo preparation for Standard endoscopy with PLENVU, since it is considered to be less affecting for patients. IBD patients have to undergo endoscopy often and mostly suffer from non-efficient preparation.
~Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and will follow the Guidelines for preparation of endoscopy.
~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
16331686|NCT04457934||Screening patients|"Screening patients will undergo Standard endoscopy to prevent colon Cancer. Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and nd will follow the Guidelines for preparation of endoscopy.
~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
16331687|NCT04457921|Experimental|Deep tissue massage|deep tissue massage applied group
16331688|NCT04457921|No Intervention|Standard of care|group without deep tissue massage
16331689|NCT04457908|Other|intelligent|receive the neurological function assessment by artificial intelligence
16331690|NCT04457908|No Intervention|manual|receive the neurological function assessment by doctor
16331691|NCT04457895|Experimental|Experimental arm|"For experimental arm patients, there will be a 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga (the first on site and by videoconference for the others).
~Starting the first day of the yoga practice there will be one daily 15 min session at home with My Yoga Guide and the audio guide during 12 weeks."
16331692|NCT04457895|Placebo Comparator|control arm|The control arm patients will have standard care. They will be proposed to participate in the physical therapy - yoga - educational program after the end of the study.
16331693|NCT04457882|Experimental|Without Drainage Tube|No place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
16331694|NCT04457882|Active Comparator|With Drainage Tube|Place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
16331695|NCT04457869|Experimental|Single arm|
16331696|NCT04457856|Experimental|TJ003234|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
16331697|NCT04457856|Placebo Comparator|Placebo|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
16331698|NCT04457843||COPD patients|
16331699|NCT04457830|Experimental|Single arm|
16331700|NCT04457817|Experimental|CRI Monitoring/Management|These patients are COVID-19 positive; ages > 18 and < 70 years old; require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.
16331701|NCT04457817|No Intervention|Standard of Care|These patients are COVID-19 positive; ages > 18 and < 70 years old; require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). This cohort will receive the standard of care.
16331702|NCT04457804|Experimental|Online ACT workshop for Emotional Eating|All participants will be assigned to 2, 1.5 hour interventions using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
16331703|NCT04457791|Experimental|Intervention phase|From week 5-8, participants will receive the intervention, namely personalized dietary advice.
16331704|NCT04457791|No Intervention|Observational phase|From week 1-4, participants will not receive any intervention, but just will be observed, to form as their own control
16331707|NCT04457765|Experimental|group 1|All participants will have PVP-I at 1.25% administered as an intranasal topical preparation prior undergoing rhinoplasty
16331708|NCT04457752|Active Comparator|Dual Layer Amniotic Membrane (DLAM) + SOC|DLAM (Up to 10 weekly DLAM applications) + Standard of Care (sharp debridement, offloading, and proper moisture balance).
16331709|NCT04457752|No Intervention|Standard of Care|Standard of Care: sharp debridement, offloading, and proper moisture balance.
16331710|NCT04457726|Experimental|Recipients with severe COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have severe COVID-19.
16331711|NCT04457726|Experimental|Recipients with mild to moderate COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have mild to moderate COVID-19.
16331712|NCT04457700||Triple-negative and HER2 Positive breast cancer|Patients with triple-negative or HER2 Positive breast cancer, axillary lymph node metastasis who underwent NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis. CT-based radiomics will be uesd in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.
16331713|NCT04457674|Other|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.
16331714|NCT04457674|Other|Sleep Hygiene Education (SHE)|SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.
16331715|NCT04457661|Experimental|TCI711 probiotic|Taking one capsule (containing 10^10 of Bacillus coagulans TCI711) daily for one month
16331716|NCT04457648|Placebo Comparator|Conventional|
16331717|NCT04457648|Active Comparator|Manuka Honey|
16331718|NCT04457635|Experimental|Brief psychotherapy (brief PsT)|The focus was on normalizing, accepting and coping with their present mental health complaints and their hindrance for work participation. Primarily, there was no intention to process previous pathogenic experiences. The standard duration was set on six sessions.
16331719|NCT04457635|Active Comparator|Short psychotherapy (short-PsT)|With more extended focus, there was besides coping of mental health and challenges concerning WP, an emphasis on both an extensive anamnesis and possibility to establish a so-called central theme based on previous or current challenging issues such as trauma, difficult childhood conditions, and personality-related issues. Additional aims of the intervention could include reducing symptoms and problematic behaviour and an improvement of home situation, with deeper focus on cognitive maladaptive coping strategies or dynamic repetitions. The number of sessions was aimed to be 20 on average
16331720|NCT04457622|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses
16331721|NCT04457609|Placebo Comparator|Control Group|Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin
16331722|NCT04457609|Experimental|Experiment Group|Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment
16331723|NCT04457596|Active Comparator|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
16331724|NCT04457596|Experimental|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
16331725|NCT04457583|Experimental|Intervention|Procedure: Inspiratory muscle training with powerbreathe with a linear pressure resistance using an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, 30 exercises daily for 12 weeks.
16331726|NCT04457583|No Intervention|Control|Procedure: Training with the same equipment but without load-generating resistance.
16331783|NCT04457154||Registry Population|Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)
16331727|NCT04457570||exposed patients|"The exposed patients are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an exposed patient if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection."
16331728|NCT04457570||control patients|"The control patients  are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection"
16331729|NCT04457557|Experimental|Low concentration|Interscalene block with 0.15% ropivacaine 15 ml
16331730|NCT04457557|Active Comparator|Usual concentration|Interscalene block with 0.5% ropivacaine 15 ml
16331731|NCT04457544||Retrospective patients|The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
16331732|NCT04457544||Prospective patients|Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.
16331733|NCT04457531|Experimental|LiuWeiLuoBi Group|Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.
16331734|NCT04457531|Other|Control Group|Patients will receive the standard medical treatment for 12 weeks.
16331735|NCT04457492|Experimental|Acute Facial Nerve Injury with Intact Facial Nerve|"40 sessions of FES (in a 14 week period)
~Assessments will be taken during the beginning, middle, and end of each study arm."
16331736|NCT04457492|Experimental|Facial Nerve Grafting After Surgical Excision|"40 sessions of FES (in a 14 week period)
~Assessments will be taken during the beginning, middle, and end of each study arm."
16331737|NCT04457492|No Intervention|Standard of Care Group|"No FES
~Assessments will be taken at the same intervals as the interventions group."
16331738|NCT04457466||Healthy musicians|Men and women aged 18-60, who must be enrolled in a music conservatory performance program or be professionally active, and must speak and understand English.
16331739|NCT04457466||Healthy non-musicians|Men and women aged 18-60, must speak and understand English and not have any kind of musical training.
16331740|NCT04457466||Musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must be enrolled in a music conservatory performance program or be professionally active and must speak and understand English.
16331741|NCT04457466||Non-musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must not have any kind of musical training and must speak and understand English.
16331742|NCT04457453|Active Comparator|control group|intubation with direct laryngoscope in sniffing position
16331743|NCT04457453|Experimental|direct laryngoscope in Trendelenburg and Sellick position|intubation with direct laryngoscope in Trendelenburg and Sellick position
16331744|NCT04457453|Experimental|video laryngoscope in Trendelenburg and Sellick position|intubation with video laryngoscope in Trendelenburg and Sellick position
16331747|NCT04457427|No Intervention|Tracheostomy, no DPS|5 patients undergoing tracheostomy for failure to wean will receive no additional intervention.
16331748|NCT04457427|Experimental|Trachesotomy with immediate DPS stimulation and monitoring|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate stimulation and monitoring.
16331749|NCT04457427|Active Comparator|Trachesotomy with DPS monitoring, stimulation on day 5|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate monitoring followed by stimulation on day 5 post-procedure.
16331750|NCT04457401|Experimental|Probiotic|1 capsule daily for 8 weeks, containing 3 x 10^9 colony forming units/capsule of a Bifidobacterium strain
16331751|NCT04457401|Placebo Comparator|Placebo|1 capsule daily for 8 weeks containing the same carrier material and is similar in size, shape and taste to probiotic
16331752|NCT04457388|Experimental|Tele-Yoga Therapy|Individualised Yoga therapy based on participant's clinical condition and personal needs. Twice a week sessions were carried out by trained and experienced Yoga therapist via video conference with each therapy for individualized based on each participant.
16331753|NCT04457375||Healthy Adults|Healthy
16331754|NCT04457362|Experimental|Experimental Cohort|Patients with clinically diagnosed wrist pathology undergoing wrist arthroscopy
16331755|NCT04457349|Experimental|Therapeutic Plasma Exchange (TPE)|Each patient will undergo two sessions. TPE will be done through filtration technique using a plasma filter at a dose of (1-1.5) plasma volume/session. Fresh frozen plasma or albumin 5% will be used to replace plasma.
16331760|NCT04457323|Experimental|Test|S-Metoprolol XR 25 mg Film Coated Tablets (first four weeks) S-Metoprolol XR 50 mg Film Coated Tablets (second four weeks)
16331761|NCT04457323|Active Comparator|REFERENCE|Beloc® (Metoprolol) Zok 50 mg Controlled Release Film Tablets (first four weeks) Beloc® (Metoprolol) Zok 100 mg Controlled Release Film Tablets (second four weeks)
16331784|NCT04457141|Other|first:shod ,second:minimalist shoes|"The first group will race with conventional shoes and then minimalist shoes. The group run 5 minutes for warming and then 30 seconds at 9km/h, 30 seconds at 11km/h and 30 seconds at 13km/h.
~They have a washout period of 10 minutes between both interventions."
16331762|NCT04457310|Experimental|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
16331763|NCT04457310|Experimental|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
16331764|NCT04457310|Experimental|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
16331765|NCT04457310|Experimental|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
16331766|NCT04457310|Placebo Comparator|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
16331767|NCT04457297|Experimental|trifluridine and tipiracil|
16331768|NCT04457297|Placebo Comparator|Placebo|
16331769|NCT04457284|Experimental|temozolomide, cisplatin and nivolumab|Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).
16331770|NCT04457271|Experimental|Goal Management Training (GMT)|Participants in this arm will attend 9 weekly, 2-hour group GMT appointments.
16331771|NCT04457271|No Intervention|Wait List|Participants in this arm will receive no treatment for approximately 21 weeks (at which point, they will be offered the same, standard GMT treatment).
16331772|NCT04457258|Experimental|Diagnostic (68Ga-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV, and then undergo PET/CT over 20-90 minutes.
16331773|NCT04457245|Active Comparator|Arm I (dRT)|150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
16331774|NCT04457245|Experimental|Arm II (18F-DCFPyL, PET/CT, dRT)|162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.
16331775|NCT04457232|Experimental|Basic Science (68Ga-FAPi-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.
16331776|NCT04457219|Active Comparator|Conventional dressing with 120 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 2 hours, as per protocol. This is the standard radial care currently in use at Liverpool Heart and Chest Hospital.
16331777|NCT04457219|Experimental|Conventional dressing with 60 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
16331778|NCT04457219|Experimental|Haemostatic dressing with 60 minutes external compression|A haemostatic absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. This consists of a mineral-based dressing that accelerates local haemostasis. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
16331779|NCT04457193||post-ablation Barrett's patients|The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
16331780|NCT04457180|Experimental|Treament|"In phase A, subjects receiving a single dose of Repaglinid orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16
~# In addition, In phase B, subjects receiving a single dose of Repaglinid (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13."
16331781|NCT04457167|Experimental|Robotic surgery|Robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
16331782|NCT04457167|Active Comparator|Non robotic surgery|Non-robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
16331785|NCT04457141|Other|first:minimalist shoes ,second:shod|"The second group will race with minimalist shoes and then conventional shoes. The group run 5 minutes for warming and then 30 seconds at 9km/h, 30 seconds at 11km/h and 30 seconds at 13km/h.
~They have a washout period of 10 minutes between both interventions."
16331786|NCT04457128|Experimental|Secular Image|Secular Image
16331787|NCT04457128|Experimental|Non-secular image|non-secular images
16331788|NCT04457128|Experimental|Secular message|secular messages
16331789|NCT04457128|Experimental|Non-secular message|non-secular messages
16331790|NCT04457115|Experimental|TPV Block|Thoracic paravertebral block performed at thoracic level T2-T3 and T4-T5 with administration of Ropivacaine 0.7% 8 ml for each level.
16331791|NCT04457115|Experimental|ESP Block|Erector spinae plane block performed at thoracic level T2 and T5 with administration of Ropivacaine 0.5% 12 ml for each level.
16331792|NCT04457102|Active Comparator|Arm N°1 - Standard treatment-Breast DIBH|Patients will be treated during spontaneous breath hold wich is considered as the gold-standard radiotherapy treatment for left breast cancer.
16331793|NCT04457102|Experimental|Arm N°2 - Interventional -Breast MANIV DIBH|Irradiation will take place during DIBH induced by MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 40-50 seconds to allow the complete delivery of a treatment beam.
16331794|NCT04457102|Experimental|Arm N°3 - Interventional -Liver/Lung MANIV DIBH|Irradiation will take place during DIBH induced by the MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 40-50 seconds to allow the complete delivery of a treatment beam [13]. Prior to treatment, a radio-opaque fiducial will be implanted in the tumor by an interventional radiologist, to facilitate the tumor position monitoring from onboard imaging. Residual tumor baseline shift and motion will thus be measured during beam delivery, and used to recompute the optimal safety margins that ensure an adequate dose coverage of at least 90% of tumors, according to literature recommendations [24]. We will also compare these safety margins computed under MANIV condition with those routinely applied in free-breathing condition (from a matched retrospective cohort) to estimate the gain in terms of margin reduction.
16331795|NCT04457102|Experimental|Arm N°4 - Interventional -Liver/Lung MANIV VC|Patients will be ventilated by VC mode during their treatment. For each fraction, the treatment time, the number of reconstructions of the tracking model and the correlation errors of the model will be collected. The same information will be extracted from a matched retrospective cohort treated by tracking in spontaneous breathing.
16331796|NCT04457102|Other|Arm N°5 -Liver/Lung MANIV DIBH for PT|Data on tumor position and its residual motion from patients included in the arm n°3 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCLouvain - IREC) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare [25], coupled with log-file acquisitions [26]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach.
16331797|NCT04457089|Experimental|Simvastatin|
16331798|NCT04457076|Experimental|LevoCept|LevoCept™ Intrauterine Contraceptive
16331799|NCT04457063|Experimental|penetrating keratoplasty|A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction
16331800|NCT04457050|Experimental|Non-Diabetic Hepatitis C infected patients|"clinical examination,
~measurement of weight (Kg), height (meter), and waist circumference (cm).
~Calculation of the body mass index.
~Ultrasound abdominal examination.
~Laboratory Investigations including Complete blood count, Serum aspartate and alanine aminotransferases, serum albumin, serum bilirubin, serum gamma-glutamyl transpeptidase, and international normalization ratio. HCV-RNA quantification before treatment and 12 weeks after the end of therapy.. Serum lipid profile, fasting and post-prandial blood sugar, glycated hemoglobin A1c also included.
~Treatment of all patients with the available generic direct antivirals in Egypt (sofosbuvir/ledipasvir ± ribavirin or sofosbuvir plus daclatasvir ± ribavirin).
~Evaluation of insulin resistance using the homeostasis model assessment of insulin resistance before and 12 weeks after end of treatment.
~measurement of serum levels of resistin before and at 12 weeks after treatment."
16331801|NCT04457037|Experimental|MSC|Patients with trophic ulcers received standard treatment and MSC
16331802|NCT04457011|Experimental|High dose group|High dose Susu Xiao'er Zhike Granules, 1 bag, bid
16331803|NCT04457011|Experimental|Middle dose group|Middle dose Susu Xiao'er Zhike Granules, 1 bag, bid
16331804|NCT04457011|Placebo Comparator|Extremely-low dose group|Extremely-low dose Susu Xiao'er Zhike Granules, 1 bag, bid
16331805|NCT04456998|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) over 24 weeks
16331806|NCT04456998|Placebo Comparator|Placebo|Placebo inhaled orally BID over 24 weeks
16331807|NCT04456985|Active Comparator|Intervention group|Before the operation, the patient took 20ml of brown sugar aqueous solution containing folic acid and VitB12 for 3 days (folic acid concentration is 0.4mg / d for 2 year old children + 1.2μg / d of VitB12, dissolved in 20ml brown sugar water once a day). Postoperatively, PAED scores were performed at the time of awakening, extubation and every 10min within 30min after extubation. 10 points is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
16331808|NCT04456985|Placebo Comparator|Placebo group|The patients in the placebo group took 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation. Postoperatively, PAED scores were performed at the time of recovery, extubation, and every 10 minutes within 30 minutes after extubation. The PAED scores of all children were measured by the same person. (The total score is 0-20, and the score ≥10 is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
16331809|NCT04456972|Experimental|One arm only|
16331810|NCT04456959||Adult R/R ALL patients who have received InO|Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.
16331814|NCT04456920|Experimental|Experimental group 2|e-PRO self-completed via connected objects (tablet/phone)
16331815|NCT04456920|No Intervention|Control group|group without e-PROs (standard care)
16331816|NCT04456907|Experimental|PPR group|Receive PRP injection
16331817|NCT04456907|Sham Comparator|Saline group|Receive saline injection
16331818|NCT04456881|Experimental|anatomical reconstruction group of Patellofemoral ligament|
16331819|NCT04456868|Active Comparator|Healthy volunteers|Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
16331820|NCT04456868|Experimental|Anhedonic drug-resistant bipolar depression patient|Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
16331821|NCT04456868|Active Comparator|Non-anhedonic drug-resistant bipolar depression Pat|Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
16331822|NCT04456868|Active Comparator|Mild to moderate Parkinson's disease patient|Adult patients at least 18 years of age with mild to moderate Parkinson's disease
16331823|NCT04456855||Locoregional surgery|
16331824|NCT04456855||No surgery|
16331825|NCT04456829|Experimental|Resveratrol drink|
16331826|NCT04456829|Placebo Comparator|Placebo drink|
16331827|NCT04456816|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
16331828|NCT04456816|Experimental|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
16331829|NCT04456803|Experimental|Ferric citrate tablet|Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.
16331830|NCT04456803|Active Comparator|Sevelamer carbonate tablet|Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.
16331831|NCT04456777|Experimental|1group|patients with vortioxetine
16331832|NCT04456777|Placebo Comparator|2 group|patients without vortioxetine
16331833|NCT04456764|Experimental|SaFTiE|The SaFTiE intervention includes: [a] real-time text-message assessments of fatigue and sleep during and between scheduled shift work; [b] tailored text-message alerts that promote adopting evidence based strategies for mitigating fatigue when high levels of fatigue or sleepiness are reported; [c] a mobile app that delivers goal setting, summary data of sleep/fatigue indicators from all study participants, and video interviews of EMS clinicians focused on sleep and fatigue.
16331834|NCT04456764|Placebo Comparator|Attention Placebo Control|The attention placebo control includes: [a] real-time text-message assessments of teamwork during and between scheduled shift work; [b] text-message alerts that promote techniques for mitigating poor teamwork when episodes of poor teamwork are reported; [c] a mobile app that delivers goal setting, summary data of teamwork indicators from all study participants, and video interviews of EMS clinicians focused on teamwork.
16331835|NCT04456751||No redo op|Patients with a single cardiac operation under extracorporeal bypass
16331836|NCT04456751||Redo op|Patients with a redo cardiac operation under extracorporeal bypass
16331837|NCT04456738|Experimental|Parent Training|16 weeks of parent training in a group context with 5 to 10 relative and non-relative foster caregivers
16331838|NCT04456738|No Intervention|Services as Usual|Foster care services as usual
16331839|NCT04456725|Active Comparator|Control|Usual care group
16331840|NCT04456725|Experimental|Intervention|Intensive management utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring.
16331841|NCT04456712|Experimental|ciprofloxacin for diabetic patients|50 diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
16331842|NCT04456712|Experimental|levofloxacin for diabetic patients|50 diabetic patients received intravenous levofloxacin 750mg/24 hours.
16331843|NCT04456712|Experimental|ciprofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
16331844|NCT04456712|Experimental|levofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous levofloxacin 750mg/24 hours.
16331845|NCT04456699|Experimental|Olaparib + Bevacizumab|Olaparib (300 mg twice daily [BID] oral) + Bevacizumab (5 mg/kg intravenous [IV] once every 2 weeks [Q2W]) until progressive disease or end of study
16331846|NCT04456699|Experimental|Olaparib|Olaparib (300 mg BID) oral, until progressive disease or end of study
16331847|NCT04456699|Active Comparator|Bevacizumab + 5-FU|Bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W) until progressive disease or end of study
16331848|NCT04456686|Experimental|LY3016859|LY3016859 given intravenously (IV).
16331849|NCT04456686|Placebo Comparator|Placebo|Placebo given IV.
16331852|NCT04456660|No Intervention|Control group|
16331853|NCT04456660|Active Comparator|sFlt-1 & Doppler group|
16331854|NCT04456647||Parenteral nutrition|
16331855|NCT04456634|Experimental|AL&RUX|"Oral administration of:
~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
16331856|NCT04456634|Placebo Comparator|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
16331857|NCT04456621|Experimental|PBT arm|
16331858|NCT04456608|Experimental|Low and High n-3 PUFA|Individuals with low or high n-3 PUFA RBC concentration will be given aspirin (81 mg of aspirin once a day, for 6 days)
16331859|NCT04456595|Experimental|Adult - Vaccine|Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
16331860|NCT04456595|Experimental|Elderly - Vaccine|Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
16331861|NCT04456595|Placebo Comparator|Adult - Placebo|Participants aging 18-59 years receiving two doses with 14-days interval of placebo
16331862|NCT04456595|Placebo Comparator|Elderly - Placebo|Participants aging 60 years or above receiving two doses with 14-days interval of placebo
16331863|NCT04456582|Experimental|Amyloidosis transthyretin with cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
16331864|NCT04456582|Experimental|Amyloidosis transthyretin without cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
16331865|NCT04456582|Placebo Comparator|Healthy subjects|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
16331866|NCT04456569|Experimental|GAE + Standard of Care|Participants in this arm will receive geniculate artery embolization and standard of care.
16331867|NCT04456569|No Intervention|Standard of Care|Participants in this arm will receive standard of care only.
16331868|NCT04456543|Experimental|Pressure monitoring group|In the pressure monitoring group, garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg for 2 months. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
16331869|NCT04456543|Active Comparator|conventional treatment group|In the conventional treatment group, non-surgical standard treatment of burn scars except for pressure monitoring was performed in the same manner. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
16331870|NCT04456530|Experimental|Testosterone Group|Participants receiving two IM Testosterone injections.
16331871|NCT04456530|Placebo Comparator|Control Group|Participants receiving two IM Normal Saline Injections.
16331872|NCT04456517|Experimental|Ranolazine, Then Placebo|- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
16331873|NCT04456517|Experimental|Placebo, Then Ranolazine|- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
16331874|NCT04456504|Experimental|Healthcare worker|Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.
16331878|NCT04456478|Active Comparator|pH 7.38 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02
16331879|NCT04456478|Experimental|pH 7.22 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.22 ± 0.02
16331880|NCT04456452|Experimental|Ampion|Ampion
16331881|NCT04456452|Other|Standard of Care|Standard of Care
16331882|NCT04456426||Patients treated with COVID-19|All populations of patients admitted with COVID-19 in healthcare institutions involved. No intervention but standard care designed by national guidelines will be provided.
16331883|NCT04456413|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
16331884|NCT04456413|Active Comparator|Best Supportive Care|Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.
16331885|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.
~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.
~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
16331886|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
16331887|NCT04456387|Experimental|Arm 1-on demand treatment|Part A-Participants will receive on-demand treatment with Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection for 6 months.
16331888|NCT04456387|Experimental|Arm 2- prophylaxis treatment|"Part B-Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
~12 Participants of them will receive PK assessment at ED1 and ED35(Participants will be tested for PK assessment at timepoints throughout the study based on exposure days (ED). One ED is equivalent to a 24 hours period in which drug is dosed.)，measured by one-stage assay, they would not be given prophylaxis treatment until the completion of PK blood collection."
16331889|NCT04456374||Under-12 (U12) players|
16331890|NCT04456374||Under-14 (U14) players|
16331891|NCT04456374||Under-16 (U16) players|
16331892|NCT04456374||Under-18 (U18) players|
16331893|NCT04456361|Experimental|COVID-19 patients|Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
16331894|NCT04456348||positive|Subjects have gait disorder according to intelligent gait assessment at baseline.
16331895|NCT04456348||negative|Subjects don't have gait disorder according to intelligent gait assessment at baseline.
16331896|NCT04456335||Caries-free|Caries-free children
16331897|NCT04456335||Early childhood caries|Children with early childhood caries
16331898|NCT04456322|Experimental|RT plus Nimotuzumab|Patients with pretreatment plasma EBV DNA<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy ( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
16331899|NCT04456322|Active Comparator|RT plus Cisplatin|Patients with pretreatment plasma EBV DNA<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
16331900|NCT04456309||Atrial fibrillation|stroke patients with atrial fibrillation
16331905|NCT04456283||Incomplete pathological response with less than 12 LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
16331906|NCT04456283||Incomplete pathological response with 12 or more LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
16331907|NCT04456283||Complete pathological response with less than 12 LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
16331908|NCT04456283||Complete pathological response with 12 or more LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
16331909|NCT04456270||Primary care patients with current asthma|Male and female primary care patients aged ≥18 years of age with clinically diagnosed asthma.
16331910|NCT04456257|Experimental|Fractional Picosecond 1,064 nm laser|The subjects with abdominal striae alba were treated with a fractional picosecond 1,064 nm laser
16331911|NCT04456244||Group 1:Transtibial Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
16331912|NCT04456244||Group 2:Transfemoral Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
16331913|NCT04456231||QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. In Addition, this Group will receive a health app for better preparation and more Information regarding preparation and endoscopy itself.
16331914|NCT04456231||no QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. This Group will have no app and will have to receive Information in traditional ways.
16331915|NCT04456218|Experimental|Biliary stone|Participants who meet the criteria of biliary stone enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
16331916|NCT04456218|Experimental|Biliary stricture|Participants who meet the criteria of biliary neoplasm enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
16331917|NCT04456205||Dual Therapy|Dual Therapy (long-acting muscarinic antagonist [LAMA] + long-acting beta-agonist [LABA])
16331918|NCT04456205||Triple Therapy|Triple Therapy (inhaled corticosteroid [ICS]/ long-acting beta-agonist [LABA] + long-acting muscarinic antagonist [LAMA])
16331919|NCT04456192|Experimental|Women with Obesity|23 healthy, obese (BMI ≥ 30 kg/m2; waist circumference > 80) women, aged 34-62, screened at the outpatient clinic of the Department of Internal Medicine, Metabolic Disorders, and Hypertension, University of Medical Sciences, Poznań, Poland were enrolled based on the inclusion criteria and the willingness to participate in the research.
16331920|NCT04456192|Active Comparator|Normal-weight Women|"8 healthy, normal-weight (≤ 24.9 and ≥ 18.5 kg/m2) women, aged 34-62 were enrolled to intervention from the announcement.
~Random selection for groups was not applicable due to the planned body mass difference in the studied groups."
16331921|NCT04456166||Patient who received carbohydrate loading|Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting
16331922|NCT04456153|Experimental|standard of care therapy with atovaquone|The first treatment group will receive continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days.
16331923|NCT04456153|Placebo Comparator|standard of care therapy with matching placebo|The second treatment group will receive continued standard of care therapy together with matching placebo.
16331924|NCT04456140|Experimental|Prevention (pre-genetic test counseling, genetic testing)|Patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. Patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.
16331925|NCT04456127|No Intervention|Standard of Care|Scar section does not receive CO2 laser therapy.
16331926|NCT04456127|Experimental|Factional CO2|Scar section receives fractional CO2 laser therapy.
16331927|NCT04456114|Experimental|Acid etched brackets|Stainless steel bracket base etched with 10% Hydrofluoric acid for 1 minute
16331928|NCT04456114|Active Comparator|Sandblasted brackets|Stainless steel bracket sandblasted base
16331929|NCT04456101||Control group|healthy volunteers without COVID-19
16331930|NCT04456101||Severe/Critical COVID-19 rehabilitation group|Patients recovering from severe/critical COVID-19
16331931|NCT04456101||mild/moderate COVID-19 rehabilitation group|Patients recovering from mild/moderate COVID-19;
16331932|NCT04456101||asymptomatic COVID-19 rehabilitation group|Asymptomatic COVID-19 patients with laboratory test for SRARS-COV2 turning negative
16331933|NCT04456088|Experimental|Phase 1- Nitric oxide treatment- 80ppm|
16331934|NCT04456088|Experimental|Phase 2- Group 1- Nitric oxide treatment- 150ppm|
16331935|NCT04456088|No Intervention|Phase 2- Group 2- control|Standard of Care
16331936|NCT04456062|Experimental|Caring Contacts Group|
16331937|NCT04456062|No Intervention|Standard Treatment Group|
16331938|NCT04456049|Experimental|Enzalutamide (Xtandi®)|Interventional treatment
16331939|NCT04456049|Active Comparator|Standard of care (SOC)|Supportive treatment
16331941|NCT04456010||Infertile couple|Infertile couple who had a fertility treatment prescribed during the past 9 months which was not completed yet.
16331942|NCT04455984||Neoadjuvant chemoradiotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery
16333695|NCT04444050|Experimental|Part 3 J-MAD: Optional (to be determined) Panel|
16331943|NCT04455984||Neoadjuvant chemotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery
16331944|NCT04455971||OM Group|People who participate in the practice of orgasmic meditation (OM)
16331945|NCT04455958|Experimental|Group I (lopinavir/ritonavir)|Patients receive lopinavir/ritonavir PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
16331946|NCT04455958|Placebo Comparator|Group II (placebo)|Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
16331947|NCT04455945||Open|Patients with open surgery for rectal cancer planned in our department.
16331948|NCT04455945||Laparoscopic|Patients with laparoscopic surgery for rectal cancer planned in our department.
16331949|NCT04455932|Experimental|HCC surveillance with US and aNC-MRI|
16331950|NCT04455919|Experimental|Yoga|Yoga classes once a week for eight weeks
16331951|NCT04455919|Other|Wait-list control|The delayed intervention group was to benefit from the intervention after week 8.
16331952|NCT04455893|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
16331953|NCT04455893|Experimental|Combined 2: Stratified only|Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
16331954|NCT04455880|Active Comparator|GDM with insulin therapy|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
16331955|NCT04455880|Active Comparator|GDM treated with only diet (without any medical therapy)|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
16331956|NCT04455880|Active Comparator|Non-diabetic Controls|Singleton non diabetic healthy pregnancies above 36 gestational weeks
16331957|NCT04455867||UHN Toronto Rehab|Participants with prediabetes of T2DM undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as per the site's standard protocol (Diabetes Exercise and Healthy Lifestyle Program).
16331958|NCT04455867||Sunnybrook Health Sciences Centre|Participants with prediabetes or T2DM receiving care from an outpatient service at Sunnybrook Health Sciences Centre.
16331959|NCT04455841|Experimental|Treatment Group A (TGA)|INCB000928 will be administered once daily( QD).
16331960|NCT04455841|Experimental|Treatment Group B (TGB)|INCB000928 will be administered in combination with ruxolitinib.
16331961|NCT04455828||Hospitalized Heart Failure subjects|Subjects hospitalized for heart failure exacerbation will be enrolled, prior to discharge from hospital, to wear the WHOOP device for 90 days.
16331962|NCT04455828||Non-hospitalized Heart Failure subjects|Subjects who have not been hospitalized in the past 1 year, but have a diagnosis of heart failure, will be enrolled during routine outpatient care to wear the WHOOP device for 90 days.
16331963|NCT04455815|Experimental|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
16331964|NCT04455815|No Intervention|Control arm|Patient to receive best supportive care.
16331965|NCT04455802|Active Comparator|Morphine|Infants randomized to the morphine arm will start at a dose of 0.06 mg/kg/dose every 4 hours. A buprenorphine placebo will also be given at the same frequency as a faux drug.
16331966|NCT04455802|Experimental|Buprenorphine|"Infants randomized to the buprenorphine arm will be started on a dose of 10 mg/kg/dose every 8 hours. A morphine placebo will also be given at the same frequency as a faux drug.
~Patients can only be randomized to only one arm."
16331967|NCT04455789|Experimental|conventional mechanical ventilation|routine mechanical ventilation will be adjusted based on conventional mechanical ventilation settings with tidal volume of 8 ml/kg and PEEP level of 5
16331968|NCT04455789|Experimental|mechanical ventilation adjusted according to driving pressure|routine mechanical ventilation adjusted based on driving pressure during lateral position. After patients are put to lateral position incremental increase in PEEP will be applied and the driving pressures will be recorded for each PEEP level and the patients will be ventilated with this PEEP during anesthesia. the other setting will be same with conventional group. tidal volume of 8 ml/kg
16331969|NCT04455763|Experimental|SVF|Thumb carpometacarpal injection with adipose-derived SVF combined with splinting
16331970|NCT04455763|Active Comparator|Splint|Thumb carpometacarpal osteoarthrosis treated with splinting only
16331973|NCT04455737||Patients with indigo carmine stained specimen|Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
16331974|NCT04455737||Patients with unstained specimen|Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
16331975|NCT04455724|Experimental|Negative Pressure Incisional Woundth Therapy|A PREVENA™ PEEL & PLACE™ system kit will be applied to the surgical wound and assembled in the operating room following closure by primary intent. The system will be set for a negative pressure of -125mmHg. The dressing will be left in place for 7 days post-operation, during which the patient may be discharged from hospital. The dressing will only be removed or changed if the treating physician has suspicion of one of the complications included in the primary composite outcome or is planning re-intervention on the surgical site.
16331976|NCT04455724|Active Comparator|Standard sterile dressing|A sterile island dressing will be applied to the surgical wound in the operating room following closure by primary intent, which will be removed on post-operative day 2 and left open to air unless there is ongoing discharge.
16331977|NCT04455711|Placebo Comparator|Remifentanil group|Emerge with continuous infusion of remifentanil 1.5 ng/ml
16331978|NCT04455711|Experimental|Lidocaine group|Emerge with continuous infusion of remifentanil 1.5 ng/ml with IV bolus of lidocaine 1.5 mg/kg
16331979|NCT04455698|Experimental|Remote Telegenetics: TELEPHONE (ARM A)|"Remote Phone Telegenetics:
~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - TELEPHONE."
16331980|NCT04455698|Experimental|Remote Telegenetics: VIDEOCONFERENCING (ARM B)|"Remote Videoconferencing Telegenetics:
~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - VIDEOCONFERENCING."
16331981|NCT04455698|Experimental|USUAL CARE (ARM C)|"Usual Care:
~Participants will receive referrals to genetic counseling providers, initiating services on their own. At 6 months, if participants have not sought and received genetic counseling services, they will be offered randomization to ARM A/ARM B."
16331982|NCT04455672|Experimental|interventional group|patient using two types of splints (3d Anterior Rrepositioning Splint then printed stabilizing splint)
16331983|NCT04455672|Active Comparator|control group|patient using two types of splints (3d printed stabilizing splint then Anterior Rrepositioning Splint)
16331984|NCT04455659|Experimental|TENS + Conventional physical therapy exercise|
16331985|NCT04455659|Active Comparator|conventional physical therapy exercise|
16331986|NCT04455633|Experimental|LX9211 low dose|LX9211, once daily
16331987|NCT04455633|Experimental|LX9211 high dose|LX9211, once daily
16331988|NCT04455633|Placebo Comparator|Placebo|Placebo, once daily
16331989|NCT04455620|Experimental|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
16331990|NCT04455607|Experimental|experimental group|Random perturbation training
16331991|NCT04455607|Active Comparator|control group|Block perturbation training
16331992|NCT04455594|Experimental|Almonertinib|Almonertinib 110mg QD
16331993|NCT04455594|Active Comparator|Investigator-choice therapy (Erlotinib or Chemotherapy)|Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
16331994|NCT04455581|Experimental|Treatment group|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
16331995|NCT04455568||experimental group|Non-invasive Wearable Device, use ECG Wisdom bracelet
16331996|NCT04455555|Experimental|rotigotine treatment group|rotigotine sustained release microspheres therapy by injection
16331997|NCT04455555|Placebo Comparator|placebo comparator|placebo comparator/null microspheres
16331998|NCT04455542||LMND-ALS|The main clinical manifestations were muscle weakness with atrophy and bundle fibrillation, the pyramidal tract sign was relatively mild, and extensive neurogenic damage with CMAP amplitude decreased could be seen in patients with electromyography.
16331999|NCT04455542||UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
16332000|NCT04455542||FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy
16332001|NCT04455529||ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
16332002|NCT04455516||repair group|The first operation in these patients was meniscus repair
16332003|NCT04455516||nonfailure group|These patients had a successful first operation
16332004|NCT04455516||failure group|In these patients, the first meniscus repair operation failed
16332005|NCT04455503|Experimental|Cohort A: Nivolumab and EVX-02A|EVX-02A administered IM.
16332006|NCT04455503|Experimental|Cohort B: Nivolumab and EVX-02B|EVX-02B administered IM.
16332007|NCT04455503|Experimental|Cohort C: Nivolumab and EVX-02A OR Nivolumab and EVX-02B|The selected delivery methodology either EVX02A or EVX-02B.
16332008|NCT04455490||Delayed wound healing|Patients with delayed wound healing after Achilles tendon suture who were treated at Peking University Third Hospital
16332010|NCT04455438|Experimental|SBRT Level 1|The starting dose level will be SBRT 30 Gy in 5 fractions (level 1 or L1).
16332011|NCT04455438|Experimental|SBRT Level 2|If the starting dose is tolerated in the first 5 patients, the next dose will be SBRT 40 Gy in 5 fractions (level 2 or L2)
16332012|NCT04455438|Experimental|SBRT Level 3|If the second dose is tolerated in the next 5 patients, the next dose will be SBRT 50 Gy in 5 fractions (level 3 or L3)
16332013|NCT04455412|No Intervention|control group|Conventional ICSI procedure was done for first portion of sibling oocytes
16332014|NCT04455412|Experimental|Study group 1|Laser assisted drilling ICSI procedure was done for second portion of sibling oocytes
16332015|NCT04455412|Experimental|Study group 2|Laser assisted thinning ICSI procedure was done for Third portion of sibling oocytes
16332016|NCT04455399|Other|Intravitreal injection guide|Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye
16332017|NCT04455399|Other|Dual blade eyelid speculum|Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus
16332018|NCT04455386||stable|The anterior drawer test and/or talar tilt test are negative and the ankle joint is stable.
16332019|NCT04455386||slightly instable|The anterior drawer test and/or talar tilt test are slightly positive and the ankle joint is partially instable.
16332020|NCT04455386||obviously instable|The anterior drawer test and/or talar tilt test is significantly positive, with significantly instable. The ankle joint is completely instable and can featured with dimple sign.
16332021|NCT04455373||orthopedic surgery group|Planned tumor resection
16332022|NCT04455373||traumatic surgery group|Patients with traumatic vascular injury
16332023|NCT04455360|Experimental|EMDR R-TEP intervention|Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.
16332024|NCT04455360|No Intervention|Standard care|Patients will receive standard post-hospital discharge care.
16332025|NCT04455334|Other|healthy|year 1 study
16332026|NCT04455334|Other|stroke|year 1 study
16332027|NCT04455334|Active Comparator|active control group|year 2 study
16332028|NCT04455334|Experimental|Error-augmented treadmill training|year 2 study
16332029|NCT04455334|Experimental|Error-augmented concept combined physical therapy group|year 3 study
16332030|NCT04455334|Active Comparator|conventional physical therapy group|year 3 study
16332031|NCT04455321|Active Comparator|Vicryl|Single layer locked uterine closure with vicryl suture material
16332032|NCT04455321|Experimental|rapide vicryl|Single layer locked uterine closure with rapide vicryl suture material
16332033|NCT04455308|Experimental|Subjects with chilblains|
16332034|NCT04455308|Active Comparator|Subjects without chilblains|
16332035|NCT04455295|Experimental|Active Stimulation 0.5|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
16332036|NCT04455295|Placebo Comparator|Lobe Control|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the earlobe. Stimulation 30 second on/30 seconds off for five cycles.
16332037|NCT04455295|Placebo Comparator|Sham Stimulation|0.5mA, 5Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
16332038|NCT04455295|Placebo Comparator|Nonstimulation|Placement of electrode without any stimulation.
16332039|NCT04455269|Experimental|Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)|"The quadrants allocated to FM-EPAPT underwent the following steps:
~Decontamination of soft tissues with air-polishing and erythritol powder;
~Supra-gingival removal biofilm with air-polishing and erythritol powder;
~Sub-gingival removal of biofilm with air-polishing and erythritol;
~Calculus removal with a piezoceramic scaler."
16332040|NCT04455269|Active Comparator|Ultrasonic debridement and abrasive paste (US+P)|"The quadrants allocated to US+P treatment underwent the following steps:
~Full-mouth ultrasonic debridement with piezoceramic scaler;
~Plaque removal and polishing with soft rubber cup and low-RDA polishing paste"
16332041|NCT04455256||recurrent pregnancy loss group|Women between the ages of 18 and 45 who had a history of miscarriage under 3 weeks and above 22 weeks were included in this group.
16332042|NCT04455256||women who had healthy birth|Women between the ages of 18-45 who have not had a history of pregnancy loss and who have had at least one healthy birth and no known chronic diseases are included in this group.
16332043|NCT04455243|Experimental|Intervention group|
16332044|NCT04455243|Placebo Comparator|Control group|
16332045|NCT04455230|Experimental|Participants who have received gene therapy vector (FLT190)|
16332046|NCT04455204||non-pregnant women (group 1)|20 non-pregnant women who serve as a control group (group 1)
16332047|NCT04455204||pregnant women (group 2)|20 pregnant women with normal pregnancy at their third trimesters (group 2)
16332048|NCT04455204||pregnant women with Preeclampsia (group 3)|20 pregnant women with Preeclampsia in their third trimester (group 3) will be screened to fit the inclusion and exclusion criteria.
16332049|NCT04455191|Experimental|Thawing Embryos in Advance|Thawing embryos one day in advance (16:00), 18h before embryos transfer (10:00).
16332050|NCT04455191|Experimental|Thawing Embryos on the Day of Transfer|Thawing embryos on the day of transfer (8:00), 2h before embryos transfer (10:00).
16332051|NCT04455178|Experimental|Spironolactone|Spironolactone 20mg once daily
16332052|NCT04455178|Active Comparator|Indapamide|Indapamide 1.5mg once daily
16332053|NCT04455165||RVAo MITAVA|Patient operated since 2009 for aortic valve replacement through right anterior minithoracotomy approch in Dijon Burgundy University Hospital
16332054|NCT04455152|Experimental|Self-control|two-week period of practicing self-control (attempting to avoid eating sweet foods) and self-monitoring success in doing so
16332055|NCT04455152|No Intervention|wait list|waiting 2 weeks after baseline assessment before gaining access to web-based self-help
16332056|NCT04455139|Active Comparator|Treatment 1a|IVitC melphalan (randomized) in case of vitreous relapse only
16332057|NCT04455139|Experimental|Treatment 1b|IVitC topotecan (randomized) in case of vitreous relapse only
16332058|NCT04455139|Active Comparator|Treatment 2a|IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
16332059|NCT04455139|Experimental|Treatment 2b|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
16332060|NCT04455139|No Intervention|Treatment 2c|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
16332061|NCT04455139|No Intervention|Treatment 3a|sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
16332062|NCT04455139|No Intervention|Treatment 3b|sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment
16332063|NCT04455126|Experimental|Preservative-free tafluprost|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
16332064|NCT04455113||Normo-phosphatemia|238 patients included in this group. Phosphorus level >2.5 mg/dl
16332065|NCT04455113||Hypophosphatemia|79 patients included in this group. Phosphorus level <2.5 mg/dl
16332067|NCT04455087||before intervention|1000 patients befor sensitization
16332068|NCT04455074|Experimental|PD patients with motor fluctuations|FN scale is an autoquestionnaire consisting of 20 questions, to be answered in On-med and OFF-med condition
16333159|NCT04447469|Active Comparator|10 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
16332069|NCT04455048|Experimental|Intervention Group|A single-session manipulation with a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied each week for two weeks.
16332070|NCT04455048|Sham Comparator|Control Group|A sham manipulation without a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied.
16332071|NCT04455035|Active Comparator|Retrospective Group(Control)|
16332072|NCT04455035|Experimental|Prospective Group|
16332073|NCT04455022||Any infant who will have a blood culture collected.|During the study period educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
16332074|NCT04455009|Experimental|100mg Caffeine Formula|10kcal drink containing a total of 100 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
16332075|NCT04455009|Experimental|140mg Caffeine Formula|10kcal drink containing a total of 140 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
16332076|NCT04455009|Placebo Comparator|Placebo Formula|non-caloric/non-caffeinated drink
16332077|NCT04454996|Experimental|Non-erosive reflux disease test group|
16332078|NCT04454996|Placebo Comparator|Non-erosive reflux disease control group|
16332079|NCT04454996|Experimental|Diarrhea-type irritable bowel syndrome test group|
16332080|NCT04454996|Placebo Comparator|Control group with diarrheal irritable bowel syndrome|
16332081|NCT04454996|No Intervention|Healthy control group|
16332082|NCT04454983|Experimental|Lipiflow - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
16332083|NCT04454983|Experimental|iLux - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
16332084|NCT04454970|Experimental|Urethral catheterisation device (UCD)|First attempt of urethral catheterisation using the Urethrotech(R) Urethral catheterisation device (UCD)
16332085|NCT04454970|Active Comparator|Bardia Aquafil Foley catheter|First attempt of urethral catheterisation using the Bardia Aquafil Foley catheter
16332086|NCT04454957|Experimental|Mastering Diabetes|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
16332087|NCT04454957|No Intervention|Usual care|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen not to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
16332088|NCT04454944|No Intervention|Control|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. Participants in the control arm will receive no other intervention.
16332089|NCT04454944|Experimental|No subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm will receive an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
16332090|NCT04454944|Experimental|Subsidy, no distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas (LPG) purchases.
16332091|NCT04454944|Experimental|Subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas) (LPG) purchases an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
16332092|NCT04454931||Intensive care patients who underwent neurosurgery|Cerebral oxygenation status will be monitored during and after endotracheal suctioning in each patient included in the study. Non-invasive regional oximetry probes are placed in the frontal region of the patient and the patient will be positioned at the head height of 15 degrees with a 3-motor angle determining bearing system. Then, when the patient's need for endotracheal suctioning arises, endotracheal suctioning will be performed and the cerebral oxygenation status before the procedure, 1 minute, 5 minutes and 30 minutes after the procedure will be recorded on the monitor of the non-invasive regional oximeter device operating with NIRS technology. The same procedure will be applied to the patient at head heights of 30 and 45 degrees. Cerebral oxygenation status measured at each head height will be compared with appropriate statistical methods and the most appropriate head height will be determined.
16332093|NCT04454918|Experimental|TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg|TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 mcg (approximately 1 mcCi), infusion, intravenously, once on Day 1 of Period 1, followed by a washout period of at least 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 mcCi), solution, orally, once on Day 1 of Period 2.
16332094|NCT04454905|Experimental|Camrelizumab combination with Apatinib|Camrelizumab 200mg, every 3 weeks, intravenous infused. Apatinib 250mg, once a day, orally. Until progression or unacceptable toxicity events develop.
16332095|NCT04454892||Amyotrophic lateral sclerosis patients|Although previous studies have provided reference for the diagnosis and treatment of ALS, the etiology of ALS is still unknown, and the relevant clinical features and natural history of ALS still lack the verification of large samples. Therefore, the research on the natural history of ALS is of great significance to further increase the understanding of ALS and provide new evidence for the diagnosis and treatment of ALS
16332096|NCT04454879|Experimental|standard roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
16332097|NCT04454879|Experimental|lower roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.
16332176|NCT04454359|Placebo Comparator|CTR|Control will ingest an isocaloric placebo consisting of 1) 30 g maltodextrin, twice daily, following the same schedule, and 2) 7.5 mL corn oil, once daily.
16332177|NCT04454346|Experimental|double Foley Catheter|
16332098|NCT04454866|Placebo Comparator|Control group|For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
16332099|NCT04454866|Experimental|Single injection group|For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
16332100|NCT04454866|Experimental|Continuous infusion group|For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
16332101|NCT04454853||Lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in lung cancer.
16332102|NCT04454853||Lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in lung cancer.
16332103|NCT04454853||Suspected lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in suspected lung cancer.
16332104|NCT04454853||Suspected lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in suspected lung cancer.
16332105|NCT04454840|Experimental|Biological+Riluzole|Plasma from healthy young people treatment + Riluzole
16332106|NCT04454840|Active Comparator|Riluzole|Riluzole
16332107|NCT04454814|Active Comparator|Rotary Engine-driven Instruments|The instrumentation protocol with Protaper Universal rotary files was began with an S1 file with a brushing movement to the two thirds of the working length and then an SX file was introduced to the two thirds of the working length with a brushing movement Afterwards, S1, S2, F1, F2 files in mesial roots and F4 files in distal roots were used to the working length, respectively. Protaper F2 instrument was then used to complete the canal preparation in mesial roots and Protaper F4 instrument was used to complete the canal preparation in distal roots.
16332108|NCT04454814|Active Comparator|Reciprocal Engine-driven Instruments|The instrumentation of the root canal in the Reciproc Blue group began with a R25 instrument with a slow in-and-out pecking movement.According to the manufacturer instructions, a #10 K-file was inserted to the canal to check the canal is free to 1 mm beyond the prepared canal section. After each 3 pecks or when a resistance was encountered the instrument was pulled out of the canal. Afterward, the R25 instrument was inserted in to root canal until approximately two thirds of the working length.RB R25 instrument was then used to complete the canal preparation in mesial roots and RB R40 instrument was used to complete the canal preparation in distal roots.
16332109|NCT04454788|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
16332110|NCT04454788|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
16332111|NCT04454775||group I|50 cases who received raloxifene and calcium therapy
16332112|NCT04454775||group II|30 cases who received only calcium therapy
16332113|NCT04454762|Experimental|Cabozantinib|40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.
16332114|NCT04454749||Stimulated cycles|Ovarian stimulation will be performed by standard protocols. Stimulation medication dosage will be individualised prior to stimulation start according to the ovarian reserve parameters and during ovarian stimulation according to the ovarian response and the measured levels of E2 and progesterone (P4), in order to avoid progesterone elevation during late follicular phase. Final oocyte maturation will be achieved by administration of either 10.000 IU of hCG, 0.3 mg of GnRH agonist (Triptorelin) or dual trigger (hCG and GnRH-analogue), as soon as ≥ 3 follicles ≥ 17 mm are present. Oocyte retrieval will be carried out 36 hours after administration of the trigger. Embryos will undergo PGT-A at blastocyst stage and be vitrified thereafter.
16332115|NCT04454749||Artificial (HRT) Cycles|"Start of estradiol valerate 4mg on day 2 of the cycle for three days. Increase E2 to 6mg on day 4 of E2 treatment. E2 dose may be increased according to clinician discretion based on endometrial thickness. Maximum time of E2 exposure will be 14 days. Transvaginally scan to monitor endometrial development and to exclude the presence of a dominant follicle. Serial measurements of serum LH, estradiol and progesterone levels. Commence the initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue estradiol administration 6mg (3 tablets daily).
~Blastocyst transfer is scheduled on the 5th full day of progesterone administration, following the initial initiation of progesterone."
16332116|NCT04454749||Spontaneous natural cycles|"Ultrasound scans to monitor follicular growth and serial measurements of serum LH, estradiol and progesterone levels to determine the timing of ovulation. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter.
~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/ml confirming ovulation (day 0). This is considered as day 0 with initiation of vaginal progesterone 100mg (vaginal suppository) at 2200H. The following day (day 1) increases progesterone administration to 100mg vaginally three times daily (8 hourly) and continues this regime until 7 weeks gestation as per clinic protocol.
~Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
16332117|NCT04454736|Experimental|SBGmentdis|Children and adolescents with mental disorders at the Department of Child and Adolescents Psychiatry in Salzburg, Austria
16332118|NCT04454736|Experimental|SBGhealthy|Healthy children and adolescents from schools in Salzburg, Austria
16332119|NCT04454736|Experimental|VIEhealthy|Members from the Vienna Boys Choir, Austria
16332120|NCT04454723|Experimental|Tranfusions and blood collection|"Patients enrolled will receive one unit each of blood and/or platelet transfusions once a week based on trigger symptoms of anemia and/or thrombocytopenia, along with blood sample collections.
~Data on patient demographics, disease, and length of hospice stay will also be collected."
16332121|NCT04454710|Active Comparator|Real Pulsed Radiofrequency|The participant will receive real pulsed radiofrequency for 2 minutes at a frequency of 2 pulses per second (2Hz) while lie in the supine position with their leg of interest partially flexed about 45 degrees and externally rotated. The full procedure will take eight minutes, composed of four sessions of 2 minutes in which the temperature was maintained below 42°C.
16332122|NCT04454710|Sham Comparator|Sham Pulsed Radiofrequency|Identical to the real pulsed radiofrequency, except the participants will only receive the initial 2 seconds of ramp-up, after which the device will switch-off for the rest of the session and will turn-on again at the end of the session.
16332123|NCT04454697|Experimental|Intervention|Patient receive personalized 3D-printed GWR
16332124|NCT04454697|Active Comparator|Control|Patient receive standardized radiation protection tooth splints
16332125|NCT04454684|Experimental|AN-R: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
16332126|NCT04454684|Experimental|BED: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
16332127|NCT04454684|Experimental|Caregivers: Psychotherapy|Psychotherapy alone
16332135|NCT04454645|Experimental|Modified ABC|12-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
16332136|NCT04454645|Active Comparator|Modified DEF|12-session home visiting intervention designed to increase parental playful interactions that stimulate infant cognitive and motor development
16332137|NCT04454632|Experimental|Mirror therapy group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the mirror therapy group bilateral exercised with the affected arm behind the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation.
16332138|NCT04454632|Experimental|Visual feedback group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the visual feedback group bilateral exercised by seeing both arms in the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
16332139|NCT04454632|No Intervention|Control group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the control group bilateral exercised without a mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
16332140|NCT04454619|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
16332141|NCT04454619|Experimental|Hand antisepsis with Clorhexidina and solution|chlorhexidine gluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.
16332142|NCT04454606|Experimental|Fit test|All the subjects will be tested for fit test
16332143|NCT04454593||Lateral patellar compression syndrome|Patients diagnosed with lateral patellar compression syndrome between February 2016 and April 2019
16332144|NCT04454593||patellar dislocation|Patients diagnosed with patellar dislocation between February 2016 and April 2019
16332145|NCT04454593||meniscus tear|Patients diagnosed with meniscus tear between February 2016 and April 2019
16332146|NCT04454580||treated patients|hypomethylating agent (azacitidine or decitabine) in combination with venetoclax
16332147|NCT04454567|Experimental|ABI-H0731 + SOC NrtI|Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).
16332148|NCT04454567|Placebo Comparator|Placebo + SOC NrtI|Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.
16332178|NCT04454346|Experimental|Single Foley Catheter|
16332179|NCT04454346|Experimental|Cook Baloon|
16332149|NCT04454541|Active Comparator|Greater occipital nerve block with ultrasound|A-Greater occipital nerve block The ultrasound-guided GONB was performed to more accurately locate the nerve. The patient was asked to lie prone on the table. To locate the nerve, we searched for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp was cleaned with iodine. After that, the skin was sterilized, and the probe was sheathed in a sterile plastic package GONB was performed by applying the injection to the medial of the artery. A 22-gauge needle was advanced beneath the lateral border of the probe using real-time ultrasound guidance and an in-plane technique. In all patients the occipital nerve was seen medial to the artery. The injected side was determined by the patients' clinical symptoms and according to the painful side reported in their headache diaries. The patients were required to lie down for 30 minutes after the injection to avoid dizziness.
16332150|NCT04454541|Experimental|Multifidus cervicis plane block with ultrasound guided|Patients placed in a lateral position with their affected side upwards. Several gel cushions were placed under their head, neck, and arm to put the neck in a stable and slightly anterior flexion position spinal level was determined by identifying the transverse process of the seventh and sixth cervical vertebrae (C7 and C6). The seventh cervical transverse process (C7) differs from the levels above by having a rudimentary anterior tubercle and a prominent posterior tubercle. After aseptic preparation of the injection area, lidocaine 1% was used to anesthetize the skin. Under continuous ultrasound guidance, the needle (22-G, 0.7 mm × 60 mm, Plexufx, B-BRAUN, Tokyo, Japan) was introduced in-plane through the skin and advanced into the fascial plane between the multifidus cervicis and semispinalis cervicis muscles for the MCP block.
16332151|NCT04454528|Active Comparator|Arm 1|Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
16332152|NCT04454528|Active Comparator|Arm 2|Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
16332153|NCT04454528|Active Comparator|Arm 3|Arm 3 will receive pembrolizumab on day -14. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
16332154|NCT04454528|Other|Arm 4|Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
16332155|NCT04454515|Experimental|dexmedetomidine|patient recieving dexmedetomidine
16332156|NCT04454515|Placebo Comparator|placebo|patients receiving placebo
16332157|NCT04454502|Experimental|Experimental|"In the first stage of data collection, the information in the Mother-Preterm Introductory Information Form study and control groups before colostrum administration, and the information in Preterm Follow-up Form including questions related to physiological parameters, body measurements and nutrition will be obtained. In the second stage, oral colostrum, will be administered once every 3 hours and for at least 5 days until the newborn begins oral feeding. In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered in approximately 1 minute for infants weighing between 1001-1500 g. The third stage, the effectiveness of the first breastfeeding will be evaluated by the observers in experimental group using the Bristol Breastfeeding Assessment Tool. In the last stage, one week after the first breastfeeding sucking / breastfeeding experience will be evaluated again."
16332158|NCT04454502|No Intervention|Control Groups|The infants in the control group will be followed up by oral care with sterile physiological saline in routine care of the service
16332159|NCT04454489|Experimental|Quad-shot palliative radiotherapy and Immunotherapy|Systemic therapy (ICI) and radiotherapy will be administered according to the standard of care, according to the treating medical oncologist and radiation oncologist, respectively
16332161|NCT04454463||Adult patients with NAFLD|1500 patients 18 years and older at the time of enrollment.
16332162|NCT04454463||Pediatric patients with NAFLD|750 patients 2 years or older and up to 17 years old at the time of enrollment.
16332163|NCT04454450|Experimental|Imaged prior to primary debulking surgery|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).
16332164|NCT04454450|Experimental|Imaged pre/postneoadjuvant chemotherapy (NACT)|In patients triaged to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), PET/MRI will be obtained at two time points, i.e. first within 30 days preceding NACT/ multi-region laparoscopic tissue sampling (already being done under IRB# 06-107) and, second, any time after completion of NACT and before multi-region tissue collection at the time of interval debulking surgery (already being done under IRB# 06-107).
16332165|NCT04454437|Other|Arm A|
16332166|NCT04454424|Experimental|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
16332167|NCT04454424|Experimental|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
16332168|NCT04454424|Experimental|Arm C: Child-Pugh C|Participants with severely impaired hepatic function (Child-Pugh C)
16332169|NCT04454424|Experimental|Arm D: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
16332170|NCT04454424|Experimental|Arm E: Normal hepatic (Matched to C)|Participants with normal hepatic function matched to Arm C
16332171|NCT04454411|Experimental|Buprenorphine|Participants assigned to treatment with extended-release buprenorphine
16332172|NCT04454411|Active Comparator|Naltrexone|Participants assigned to treatment with extended-release naltrexone
16332173|NCT04454398|Experimental|COVI-GUARD|COVI-GUARD (STI-1499) administered via a single IV push injection at a dose of 10 mg, 30 mg, 100 mg, or 200 mg, in addition to standard of care
16332174|NCT04454398|Placebo Comparator|Placebo|Placebo administered via a single IV push injection, in addition to standard of care
16332175|NCT04454359|Experimental|EXP|EXP group will ingest a supplement consisting of 1) flavored whey protein isolate with added pure leucine (3 g) diluted in water, twice daily, before breakfast and before bedtime; doses are adjusted per body weight as follows: 20 g, 25 g or 30 g per category of <65 kg, 65-75 kg and >75 kg of body weight respectively. 2) fish oil containing vitamin D, provided as 7.5 mL liquid oil providing 1500 IU vitamin D3 + 1125 mg EPA + 750 mg DHA, to be ingested once daily.
16332180|NCT04454333||Hospitalized caused by COVID-19|A total of 466 patients hospitalized with the diagnosis of SARS-COV-2 at the University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital were retrospectively screened. 212 of these patients did not answer the calls, 34 of them could not be reached because they gave the wrong phone number beforehand. 4 of the patients called by the phone had communication problems due to language problems and 10 people did not want to fill the questionnaire. 206 of them were contacted by the phone and their pain and myalgia in the head, neck-back, waist, shoulder and hip regions before, during and after SARS-COV-2, their anxiety and depression levels after SARS-COV-2, and their quality of life were questioned.
16332181|NCT04454307|Experimental|Tramadol|tramadol 100 mg twice daily for 10 days
16332182|NCT04454307|Active Comparator|standard care|standard care plus (placebo twice daily for 10 days).
16332183|NCT04454294|Experimental|Control|The first method; There is no application in maintaining the drain opening, but if there are necessary medical indications such as clot formation, blood accumulation in the drainage connections, lack of drainage, this group is intervened by milking method. In our study, this group will be taken as a control group, there will be a situation that requires intervention in the first 6 hours, and if the milking method is used, it will be excluded from the sample.
16332184|NCT04454294|Experimental|Experimental Group (Absorption Group)|The second method used to maintain the drain opening is the suction method. In this study, this group will be taken as the first experimental group. The suction method is a continuous use until the patient's drainage requirement and the physician's request is terminated by ensuring that the pressure is between 5 and 15 kPa (kilopascals) or 10-20 cm H20 after the appropriate negative pressure tracking system of the patient, who is accepted with intensive care under water drainage system, is established. system.
16332185|NCT04454294|Experimental|Experimental Group (Milking Group)|The third method is milking. In our study, this group will be taken as the 2nd experimental group. In the milking method, the process starts from the area close to the drain entry point. The latex tube is folded into 12 cm long pieces and gripped with two hands. The nurse repeats the process 3 times by compressing the parts gripped by the hand. This process is then used at intervals every hour to repeat the distal part.
16332186|NCT04454281|Experimental|Naloxone HCl Low dose: 0.02 mg|This arm will receive 0.02 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
16332187|NCT04454281|Experimental|Naloxone HCl High dose: 0.08 mg|This arm will receive 0.08 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
16332188|NCT04454268|Other|hydatid cyst|
16332189|NCT04454255|Experimental|Primo-FunSpeech|Participants will begin the study by a period using FunSpeech (45 days) followed by a control period without the game (45 days). This sequence will be repeated once.
16332190|NCT04454255|Experimental|Primo-control|Participants will begin the study by a control period without the game (45 days) followed by a period using FunSpeech (45 days). This sequence will be repeated once.
16332191|NCT04454242|Experimental|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 8 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.
~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
16332192|NCT04454242|Active Comparator|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 8 weeks will be trained with a 1-minute rest cycle in 5 breaths.
~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
16332193|NCT04454229|Experimental|Direct oral antibiotic challenge|Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.
16332194|NCT04454229|Active Comparator|Standard of care|Standard of care: skin testing and, if negative, oral challenge.
16332195|NCT04454203|Experimental|Mepivacaine Block Group|Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.
16332196|NCT04454203|Placebo Comparator|Saline Sham Group|Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.
16332197|NCT04454190||Glaucoma - Slow progressors|Rates of MD change slower than -0.50 dB/year Rates of global RNFL thickness change slower than -1.0 µm/year
16332198|NCT04454190||Glaucoma - Fast progressors|Rates of MD change faster -0.50 to -2.00 dB/year Rates of global RNFL thickness change -1.0 to -4.0 µm/year
16332199|NCT04454190||Glaucoma - Catastrophic progressors|Rates of MD change faster than -2.00 dB/year Rates of global RNFL thickness change faster than -4.0 µm/year
16332200|NCT04454177||SMART watch|Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement
16332201|NCT04454164|Experimental|PRP group|Intraarticular 5 ml single PRP injection
16332202|NCT04454164|Placebo Comparator|Saline group|Intraarticular 5 ml single saline injection
16332203|NCT04454164|Experimental|Multiple PRP group|Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)
16332204|NCT04454164|Placebo Comparator|Multiple saline group|Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)
16332205|NCT04454151|Experimental|Azithromycin|1x250
16332206|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
16332207|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
16332208|NCT04454125|Active Comparator|Routine Care|
16332209|NCT04454125|Experimental|AQI Intervention|
16332210|NCT04454112|Experimental|24-hour esophageal pH monitoring|24-hour esophageal pH monitoring was conducted using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands). This system consists of a portable data logger (MMS Investigation and Diagnostic Software®) and a disposable catheter which contains two pH electrodes (Unisensor, Attikon, Switzerland). Before recording, the pH electrode was calibrated in the special buffer solutions at pH values of 1 and 2.
16332211|NCT04454099||Fecal Occult Blood Test|People in this group will use four kind of fecal occult blood test, including quantitative and qualitative method, to detect Hb in stool before colonoscopy.
16333160|NCT04447469|Active Comparator|6 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
16332212|NCT04454086|Experimental|Supportive care (exercise program, counseling)|Patients undergo aerobic exercise over 10-30 minutes and resistance exercise comprising 1-3 sets of 8-12 repetitions of 10 different exercises over 1 hour for 24 weeks. Patients also receive behavioral activity counseling once a week and nutritional counseling over 30 minutes for 10 sessions after center-based exercise sessions during months 1-2.
16332213|NCT04454073||Bipolar patients|In euthymic state or with mild to moderate symptoms
16332214|NCT04454060||Extracapsular method group|consecutive 43 patients who received extracapsular method treatment for refractory tennis elbow
16332215|NCT04454047||Extracapsular method group|50 patients with refractory tennis elbow who received extracapsular arthroscopic surgery.
16332216|NCT04454034||Group1|The refractory elbow RA who undergo arthroscopic synovectomy
16332217|NCT04454008|Experimental|Intervention|The intervention group will receive 12 sessions of executive function family training, including executive function training for children and parenting guidance for parents.
16332218|NCT04454008|Active Comparator|waiting|The waiting group will receive routine clinical intervention, including health education, family support and guidance from outpatient clinic.
16332219|NCT04453982||Human milk donors|
16332220|NCT04453969||Breastfeeding mothers positive for COVID-19|
16332221|NCT04453956|Sham Comparator|Control group|Patients will receive colonoscopy without assistance of EndoAngel's any function.
16332222|NCT04453956|Experimental|Polyp detection function group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection function.
16332223|NCT04453956|Experimental|Quality monitoring function group|Patients will receive colonoscopy with the assistance of EndoAngel's quality monitoring function.
16332224|NCT04453956|Experimental|Polyp detection plus quality monitoring functions group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection plus quality monitoring function.
16332225|NCT04453943|Experimental|Group A - SCI|Ten individuals with SCI at the T1-T10 level will be recruited (Group A). These individuals can have incomplete or complete paraplegia.
16332226|NCT04453943|Experimental|Group B - Subjects without disability|Twenty individuals without disability will be recruited (Group B). Individuals with SCI who have experience in using some kind of walking assistive devices in the recent past will be preferably recruited.
16332227|NCT04453930|Experimental|Camrelizumab+Irinotecan+Platinum→Camrelizumab+apatinib|Participants received intravenous infusions of Camrelizumab 200 mg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) or Cisplatin 30 milligrams per square meter (mg/m^2) followed by Irinotecan 65 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4/5/6). On Days 8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6), Cisplatin 30 mg/m^2 and Irinotecan 65 mg/m^2 was administered. Thereafter, participants received maintenance (Cycle onward) Camrelizumab 200 mg on Day 1 of every 21-day cycle with Apatinib 250mg until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
16332228|NCT04453917|Experimental|Patients with active PML|Patients with neurological symptoms (< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV
16332229|NCT04453904|Experimental|"sequential radiochemotherapy in a sanwich mode"|Two courses of TC regimen chemotherapy (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) will be given first, followed by external pelvic radiation (± vaginal brachytherapy), and then four courses of the same regime consolidation chemotherapy.
16332230|NCT04453904|Active Comparator|concurrent chemoradiotherapy followed by chemotherapy|External pelvic radiation (± vaginal brachytherapy) will be given after operation. On the first day and the 29th day of radiotherapy, concurrent intravenous cisplatin (50mg/m2) will be given. After the concurrent radiochemotherapy, four courses of TC regimen (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) chemotherapy will be given.
16332231|NCT04453865|Experimental|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, & Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz & Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
16332232|NCT04453865|Other|Online Resources and Referrals (ORR)|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
16332233|NCT04453852|Experimental|Group A|Spike antigen (25ug) + 15 mg Advax-2 adjuvant
16332234|NCT04453852|Placebo Comparator|Group B|Saline
16332235|NCT04453826|Experimental|Camrelizumab plus chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.
16332236|NCT04453826|Active Comparator|Chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy.
16332237|NCT04453813|Experimental|Toripalimab plus concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.
16332238|NCT04453813|Active Comparator|Concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy alone.
16332239|NCT04453800|Experimental|Group A ：low dose sofadil|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
16332240|NCT04453800|Experimental|Group B: Medium dose group|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
16332282|NCT04453488|Placebo Comparator|Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
16332241|NCT04453800|Experimental|Group C: high dose group|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
16332242|NCT04453800|Placebo Comparator|Group D: placebo group|Saline was administered intravenously
16332243|NCT04453787|Experimental|Arch support orthoses with forefoot medial wedge|The intervention of this group include orthoses with arch support and added forefoot medial wedge.
16332244|NCT04453787|Experimental|Arch support orthoses|The intervention of this group include orthoses with arch support.
16332245|NCT04453787|Sham Comparator|Flat insole|This group will wear a flat insole. It is made from ethylene-vinyl acetate copolymer with 4mm thickness. It only provide shock absorbtion.
16332246|NCT04453774|Experimental|Covi19 patients receiving intervention|We will collect self-reported symptoms via a questionnaire, temperature and oxygen saturation will be entered by the patient and passive near continuous sensing of heart rate, audio for cough detection, respiratory rate, cough and physical activity from a smart watch. The smart watch then transmits this sensor data to the paired smartphone.
16332247|NCT04453761|Experimental|Drugs Group|Thiamine IV
16332248|NCT04453761|Placebo Comparator|Placebo|NaCl IV
16332249|NCT04453748||COVID-19 convalescents|People who recovered from COVID-19: have no symptoms and no SARS-Cov2 RNA in PCR
16332250|NCT04453735|Active Comparator|Intervention|Atorvastatin mylan 40 mg once daily
16332251|NCT04453735|No Intervention|Control|No statin therapy
16332252|NCT04453722||Oxalert in monitor only mode|Randomization will be to Oxalert in monitor-only mode
16332253|NCT04453722||Oxalert in monitor in normal mode|Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.
16332254|NCT04453709|Experimental|Problem Management Plus for Immigrants at family settings|PMP-I intervention aims to develop skills in coping adaptively in a new culture, seeking help and support for mental health problems, and other life skills opportunities that can help to improve their quality of life. PMP-I intervention includes stress management through breathing exercises and yoga, problem solving, behavioral activation, and skills to strengthen social support.
16332255|NCT04453709|Active Comparator|Talk program with Community Support Service Pamphlet (CSS)|Family receives pamphlet including list of community support service institutions that provide various health and well-being services.
16332256|NCT04453696||Communication before operation|Communication was established before the operation.
16332257|NCT04453696||Communication after operation|Communication was established after the operation.
16332258|NCT04453696||Communication before and after operation|Communication took place both before and after the operation.
16332259|NCT04453696||No communication|No communication.
16332260|NCT04453683|Active Comparator|Group I ( Air Q)|nsertion of proper size Air-Q. ILA
16332261|NCT04453683|Active Comparator|Group II (ILMA)|nsertion of proper size ILMA
16332262|NCT04453670||COVID-19 non-survivors|ICU adults who died from severe COVID-19 and in whom autopsy could be performed
16332263|NCT04453657|Experimental|Intervention|There is only one arm in this study. All recruited and consented participants will fill out a pre-survey, engage with the digital toolkit for 15 weeks, then fill out a post-survey.
16332264|NCT04453644|Experimental|Group A (Hamstrings)|Hamstring stretching would be done then isometric strength would be measured.
16332265|NCT04453644|Experimental|Group B (Calf)|Calf stretching would be done then isometric strength would be measured.
16332266|NCT04453631|Experimental|active tDCS + CBT-UP|Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
16332267|NCT04453631|Active Comparator|sham tDCS + CBT-UP|Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
16332268|NCT04453631|Active Comparator|active tDCS + Psychoeducation|Active tDCS combined with psychoeducation (control condition for CBT-UP).
16332269|NCT04453631|Placebo Comparator|sham tDCS + Psychoeducation|Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
16332270|NCT04453618|Experimental|Food effect|Healthy subjects receive a single dose of SYHA1402 (100mg) in either a fasted state or with a meal.
16332271|NCT04453618|Experimental|Multiple doses 25mg|Healthy subjects receive multiple doses of SYHA1402 (25mg) or Placebo(25mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
16332272|NCT04453618|Experimental|Multiple doses 50mg|Healthy subjects receive multiple doses of SYHA1402 (50mg) or Placebo (50mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
16332273|NCT04453618|Experimental|Multiple doses 150mg|Healthy subjects receive multiple doses of SYHA1402 (150mg) or Placebo (150mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
16332274|NCT04453605||Patients with neo-diagnosed type 2 diabetes|Patients referring for the first time to the outpatient diabetes clinic in the department of Internal Medicine between January 2008 and December 2015 and matching the inclusion criteria.
16332275|NCT04453579||116 patients completed a survey|116 patients were assessed during the Italian lockdown by means of a telephone interview performed by a trained researcher. The interview was composed of socio-demographic items (e.g. employed before and during the lockdown, own accommodation during lockdown etc.) and questions about physical and mental health in relation to the COVID-19 emergency
16332276|NCT04453566||Elite Athletes|Elite Athletes
16332277|NCT04453553|Active Comparator|Standard of care|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
16332278|NCT04453553|Experimental|Near Patient Testing|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
16332279|NCT04453514|Experimental|Trauma-informed yoga video recording|Participants will complete a single trauma-informed yoga practice using a 45-minute guided video recording.
16332280|NCT04453501||Azithromycin or non-azithromycin group|Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
16332281|NCT04453488|Experimental|RUTI® vaccine|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
16332283|NCT04453475|Experimental|Partial digital group: depression|"Burg
~Online depression session as a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
16332284|NCT04453475|Experimental|Partial digital group: social work (social medicine)|"NOR
~Online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
16332285|NCT04453475|Experimental|Partial digital group: depression + social work|"JUL
~Online depression session as a flipped classroom and an online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
16332286|NCT04453475|Active Comparator|Control group: only digital training before rehabilitation|"MOE
~Online tobacco cessation a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
16332287|NCT04453462|Active Comparator|Local direct median nerve block|
16332288|NCT04453462|Active Comparator|Brachial plexus block|
16332289|NCT04453449||No sedation|Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).
16332290|NCT04453449||Sedation|Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).
16332291|NCT04453436||Virologic failure|Viral load above detection limits at window period
16332292|NCT04453436||Virologic Success|Viral load bellow detection limits at window period
16332293|NCT04453423|Other|First-line Treatment|
16332294|NCT04453423|Experimental|Maintenance Treatment A|
16332295|NCT04453423|Experimental|Maintenance Treatment B|
16332296|NCT04453423|Experimental|Maintenance Treatment C|
16332297|NCT04453384|Experimental|Treatment arm|"Administrations of XAV-19
~Phase 2a: XAV-19 at 0.5 mg/kg at D1 and D5(Group 1) or at 2 mg/kg at D1 and D5 (Group 2), or at 2 mg/kg at D1 (groupe 3)
~Phase 2b: Selected dose from Phase 2a : one administration at 2 mg/kg on day1"
16332298|NCT04453384|Placebo Comparator|Placebo arm|"same administration as treatment arm
~Phase 2a: two administrations of placebo (day 1 and day 5) for Group 1 and 2, one administration of placebo on day 1 for Group 3
~Phase 2b: one administration of placebo on day 1"
16332299|NCT04453371|Experimental|Study group|Thrombolysis
16332300|NCT04453371|Placebo Comparator|Control group|Ringer's solution infusion
16332301|NCT04453358|Active Comparator|Interactive coaching|Airway clearance therapy using goal setting and interactive feedback.
16332302|NCT04453358|Active Comparator|Standard of care coaching|Standard of care airway clearance therapy.
16332303|NCT04453345|Experimental|TPM regimen|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
16332304|NCT04453332|Active Comparator|Oral hormone therapy|Estradiol 1mg and micronized natural progesterone 200mg 14 days a month (oral)
16332305|NCT04453332|Active Comparator|Non-oral hormone therapy|Percutaneous estradiol gel 1.5mg and micronized progesterone 200mg vaginal 14 days a month (non-oral)
16332306|NCT04453319|Experimental|Application of the device (PICO)|PICO® is a disposable, single-use pump without a canister that generates an effective, non-adjustable, negative pressure of -80 mmHg and that can be used for up to 7 days.(-1113) It incorporates leak detection and low battery indicators and is connected to a 4-layer absorbent dressing that primarily removes wound exudates through evaporative loss. The mechanism of action has been postulated to occur because of the combined effects of a reduction in the frequency of dressing changes, a reduction in stress concentration in the tissue surrounding the incision, and an enhancement in the appositional strength of the incision line, thus reducing dead space and minimizing the risk of wound contamination.(14) PICO® has also been demonstrated to enhance lymphatic clearance and decrease the risk of hematomas or seromas
16332307|NCT04453319|No Intervention|Conventional Dressing of the femoral wound|Conventional Dressing of the femoral wound
16332308|NCT04453306|Placebo Comparator|placebo|"Patients with the same characteristics as the intervention group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.
~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
16332309|NCT04453306|Experimental|intervention|"Patients with the same characteristics as the placebo group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.
~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
16332310|NCT04453293|Experimental|BCG vaccine|Freeze-dried Glutamate Bacillus Calmette-Guérin (BCG) (Tokyo 172) vaccine
16332311|NCT04453293|Placebo Comparator|Placebo|Vaccine diluent [sodium glutamate]
16332312|NCT04453280||Cohort 1 - Prague and Central Bohemian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
16332313|NCT04453280||Cohort 2 - South Moravian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
16332314|NCT04453267||Patient Arm.|"Consecutive patients undergoing elective percutaneous coronary intervention (PCI) or isolated coronary artery bypass grafting (CABG) for symptomatic stable angina (SA) despite optimal medical therapy at the University Hospital Southampton NHS Foundation Trust will be prospectively enrolled (n=86).
~No interventions administered. 40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
16332315|NCT04453267||Age and gender matched controls|"Age and gender-matched patients being investigated for chest pain with unobstructed coronary arteries, defined as coronary stenosis ≤ 30% in any major epicardial vessel on CT or invasive coronary angiography, will also be recruited as controls (n=86).
~40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
16332316|NCT04453254|Active Comparator|Whole Food Meal|A whole meal consisting of 1 cup 2% milk, 1 cup Kashi Go Lean Original cereal, ¼ cup of almonds, ¼ cup of strawberries, and ¼ cup of raspberries.
16332401|NCT04452838|Other|Cohort 2 Sequence 4 (Part B)|Treatment sequence F, E, H, and G
16332317|NCT04453254|Active Comparator|Supplement Food Meal|A supplemental meal equivalent consisting of 1 cup 2% milk, 20 g whey protein, ½ EAS Myoplex bar, and ½ Balance bar.
16332318|NCT04453241|Experimental|NBP615|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
16332319|NCT04453241|Active Comparator|GARDASIL|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
16332320|NCT04453228||2017-2018 snow season|Injured skiers in the 2017-2018 snow season
16332321|NCT04453228||2018-2019 snow season|Injured skiers in the 2018-2019 snow season
16332322|NCT04453215|Experimental|mild group|patients with mild systemic lupus erythematosus
16332323|NCT04453215|Experimental|moderate group|patients with moderate systemic lupus erythematosus
16332324|NCT04453215|Experimental|severe group|patients with severe systemic lupus erythematosus
16332325|NCT04453202|Experimental|Cohort 1 Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an Ad26-based RSV vaccine on Day 1.
16332326|NCT04453202|Experimental|Cohort 1 Group 2: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 1) on Day 1.
16332327|NCT04453202|Experimental|Cohort 1 Group 3: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 2) on Day 1.
16332328|NCT04453202|Experimental|Cohort 1 Group 4: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 3) on Day 1.
16332329|NCT04453202|Placebo Comparator|Cohort 1 Group 5: Placebo|Participants will receive IM injection of placebo on Day 1.
16332330|NCT04453202|Experimental|Cohort 2 Group 6: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
16332331|NCT04453202|Experimental|Cohort 2 Group 7: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 1) on Day 1.
16332332|NCT04453202|Placebo Comparator|Cohort 2 Group 8: Placebo|Participants will receive IM injection of placebo on Day 1.
16332333|NCT04453202|Experimental|Cohort 3 Group 9: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
16332334|NCT04453202|Experimental|Cohort 3 Group 10: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 2) on Day 1.
16332335|NCT04453202|Experimental|Cohort 3 Group 11: Placebo|Participants will receive IM injection of placebo on Day 1.
16332336|NCT04453189|Experimental|Treatment Sequence: AB(Part 1) followed by C(Part 2-Optional)|Participants will received Treatment A (single dose of JNJ-64417184 in fed condition on Day 1) in period 1 followed by Treatment B (lansoprazole on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5) in period 2 of part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
16332337|NCT04453189|Experimental|Treatment Sequence: BA(Part 1) followed by C(Part 2-Optional)|Participants will receive Treatment B in period 1 followed by Treatment A in period 2, Part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
16332338|NCT04453176||"operating block admission on foot"|Patient going to the oparating block on foot
16332339|NCT04453176||standard operating block admission|Patient going to the operating room in a conventional way (stretcher)
16332340|NCT04453163|Experimental|RAAC program|"If the patient is under the RAAC group, he/she will then be received in consultation by a RAAC specialist nurse, between the anesthesia / radiology consultation and the intervention. This RAAC nurse will explain the procedure and show him/her an information video on vertebroplasty. Information about managing anxiety and pain will also be provided. In addition, the day after the patient leaves the clinic, the RAAC nurse will call him/her to inquire."
16332341|NCT04453163|Other|Standard management program|"If the patient is under the control group, he/she will be taken care of according to the standard protocol after a surgery in percutaneous vertebroplasty. The patient will not have a consultation with the specialized nurse."
16332342|NCT04453150|Experimental|Standard hypocaloric diet|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits 3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
16332343|NCT04453150|Experimental|Intermittent fasting 16/8 (early fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 12 am. to 8 pm.), maintaining 16 fasting hours (from 8 pm. to 12 am. the following day).
16332344|NCT04453150|Experimental|Intermittent fasting 16/8 (late fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
16332345|NCT04453150|Experimental|Alternate-day fasting|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
16332346|NCT04453150|Experimental|Ketogenic diet|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein.
16332347|NCT04453137|Active Comparator|Humira 40 mg/mL (Adalimumab Originator)|During the LeadIn Period, patients will receive Humira (initial dose of 80 mg [2 × 40 mg] administered subcutaneously [SC], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index [PASI] ≥ 75 [PASI75]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.
16332348|NCT04453137|Active Comparator|IC - Humira 40 mg/mL (Adalimumab Originator)|patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)
16332349|NCT04453137|Experimental|IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)|"patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:
~Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections),
~Sw2-Humira (40 mg every other week) for 4 weeks (2 injections),
~Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections)."
16332350|NCT04453137|Experimental|AVT02 40 mg/mL (Adalimimab Biosimilar)|At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 [PASI50]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.
16332351|NCT04453124|No Intervention|Soap and Water|Standard of care using soap and water
16332352|NCT04453124|Experimental|Ficus Septica Sap|Ficus Septica Sap, topical cream, 50ul, daily, for 2 days
16332353|NCT04453124|Active Comparator|Chlorhexidine (Topical)|Chlorhexidine, topical solution, 50ul, daily, for 2 days
16332354|NCT04453111|Experimental|Hyaluronic Acid (HA) + P-MMSCs|Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
16332355|NCT04453111|Experimental|Hyaluronic Acid (HA) + BM-MMSCs|Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
16332356|NCT04453111|Active Comparator|Hyaluronic Acid (HA)|Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients
16332357|NCT04453098|Experimental|Re group|high-Resistance-moderate-endurance, participants performed 10 repetitions at 70% of one maximal repetition in resistance and 30% of VO2-peak for endurance training
16332358|NCT04453098|Experimental|rE group|moderate-resistance (30%) - high-Endurance (70%)
16332359|NCT04453098|Experimental|re group|moderate-resistance (30%) - moderate-endurance (30%).
16332360|NCT04453098|No Intervention|control group|no intervention
16332361|NCT04453085|Experimental|JR-171|Until the dose determination, subjects will intravenously receive either the low dose or high dose of JR-171 (the same dose as at Week 12 of the JR-171-101 study). Thereafter, all subjects will receive the optimal dose of JR-171 determined based on the results of JR-171-101 study.
16332362|NCT04453072|Experimental|Supportive Care (app, scales, coaching, questionnaire)|Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.
16332363|NCT04453046|Experimental|Hemopurifier and Pembrolizumab|In this clinical trial, the exosome-depleting device, the Hemopurifier, will be combined with standard of care therapy, Pembrolizumab. The purpose of the combination is to more effectively reduce immune suppression and provide a combined benefit of immune restoration for patients with recurrent/metastatic HNSCC. Therapy with the Hemopurifier will be initiated on the same day as and prior to Pembrolizumab infusion. The Hemopurifier treatment will be 4h. The subject treated with the Hemopurifier will remain in the Hemopurifier treatment area for the duration of the treatment. Pembrolizumab infusion will take place shortly after Hemopurifier treatment and may take place through the next day if needed.
16332364|NCT04453033|Active Comparator|Investigational Device|The Celeste device resembles a large tablet. It has a protective cover that folds into a stand and is magnetically attached to the back of the device. It produces a low intensity of specific bandwidths of light believed to be responsible for circadian and alerting responses in humans. The overall emission produces a pleasing soft glow of light.
16332365|NCT04453033|Sham Comparator|Control Device|The Control device is identical in appearance to Celeste. When turned on, the device emits a soft diffused light that is indistinguishable in color from the Active Device. However, this device produces a different amount of the specific wavelengths thought to be effective in the Active Device.
16332366|NCT04453020|Experimental|LHA DBS|Subjects will receive bilateral DBS of the LHA
16332554|NCT04451863|Active Comparator|Low THC + Low myrcene|5 mg THC, 0.5 mg myrcene, 0 mg BCP
16332373|NCT04452981|Active Comparator|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
16332374|NCT04452981|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
16332375|NCT04452968|Experimental|intermittent fasting|"Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
~Women were told about timed restricted feeding. They were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours."
16332376|NCT04452968|Active Comparator|caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
16332378|NCT04452929|Active Comparator|Randomized treatment phase: Erenumab|Erenumab 140 mg single subcutaneous injection at baseline
16332379|NCT04452929|Placebo Comparator|Randomized treatment phase: Placebo|Saline placebo single subcutaneous injection at baseline
16332380|NCT04452929|Other|Open-label extension treatment phase: Erenumab|Erenumab 140 mg monthly subcutaneous injection for six months after completion of the randomized, double-blinded, placebo-controlled study phase during the open-label extension
16332381|NCT04452916|Active Comparator|Fasting|Starts immediately with 5 days of Buchinger fasting
16332382|NCT04452916|Placebo Comparator|Waiting list control|Starts with 5 days of Buchinger fasting after a waiting period of 12 weeks
16332383|NCT04452903|Experimental|Reassurance intervention|The physiotherapist in the intervention group (n=15) will participate in a 3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
16332384|NCT04452903|No Intervention|Control|The physiotherapist in the control group (n=15) receives no training.
16332385|NCT04452890|Experimental|Sonourethrography|Ultrasound of the urethra (Sonourethrography - SUG): In this procedure, a Foley catheter is inserted into the top of the urethra and physiological serum is instilled into the urethra while a linear 7.5 MHz ultrasound probe is placed sagitally on the course of the urethra to detect a narrowing of the urethra.
16332386|NCT04452877|Experimental|Dabrafenib in combination with trametinib|Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
16332387|NCT04452864|Experimental|Study Intervention|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
16332388|NCT04452864|Active Comparator|Active Control Group|This control study arm will watch documentaries at home for three months (each day for 20 minutes) , instead of performing the CCT and serve as active control group. This group will also train with the CCT tasks after these three months.
16332389|NCT04452864|Other|Wait-List Control|This control study arm will start with the CCT with a delay of three months and serve as wait-list control group.
16332390|NCT04452851|Experimental|Treadmill test with BREATHE|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).
16332391|NCT04452851|Active Comparator|Treadmill test with BiPAP|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).
16332392|NCT04452851|Placebo Comparator|Treadmill test with placebo inhaler|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).
16332393|NCT04452851|Experimental|Activity of Daily Living with BREATHE|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
16332394|NCT04452851|Experimental|Activity of Daily Living with BREATHE during recovery|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
16332395|NCT04452851|No Intervention|Activity of Daily Living|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
16332396|NCT04452838|Other|Cohort 1 Sequence 1 (Part A)|Treatment Sequence A,B,C and D
16332397|NCT04452838|Other|Cohort 1 Sequence 2 (Part A)|Treatment Sequence B, A,C and D
16332398|NCT04452838|Other|Cohort 2 Sequence 1 (Part B)|Treatment Sequence E, F, G, and H
16332399|NCT04452838|Other|Cohort 2 Sequence 2 (Part B)|Treatment Sequence E, F, H and G
16332400|NCT04452838|Other|Cohort 2 Sequence 3 (Part B)|Treatment Sequence F, E, G, and H
16332402|NCT04452825|Experimental|Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
16332403|NCT04452825|Experimental|Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
16332404|NCT04452812|Experimental|Convalescent plasma|"Best available treatment + convalescent plasma
~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.
~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
16332405|NCT04452812|Placebo Comparator|Best available treatment|"Best available treatment + Placebo (0.9% saline solution)
~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.
~Placebo will consist on 2 doses of 200 ml of 0.9% saline solution separated on a 12 hour interval."
16332406|NCT04452799|Experimental|expermintal|1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days
16332407|NCT04452799|Active Comparator|standard|standard care therapy in quarantine hospitals
16332408|NCT04452786|Other|Endoscopic sleeve gastroplasity operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
16332409|NCT04452786|Other|Laparoscopic sleeve gastrectomy operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
16332410|NCT04452773|Experimental|Manremyc|Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast
16332411|NCT04452773|Placebo Comparator|Placebo|Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast
16332412|NCT04452760|Active Comparator|Control group|Only testing sessions
16332413|NCT04452760|Experimental|Progressive resistance training group|10-weeks of progressive resistance training group. Leg press, leg extension, calf raises, hip extension exercises.
16332414|NCT04452747|Active Comparator|Dino-first|Labour will be induced by the use of the vaginal Dinoprostone system (Propess®) first.
16332415|NCT04452747|Active Comparator|Balloon-first|Labour will be induced by the use of a cervix dilatation balloon first.
16332416|NCT04452734|Active Comparator|Control Group|
16332417|NCT04452734|Experimental|Study Group|
16332418|NCT04452721||Retrospective cohort|340 to 400 patients
16332419|NCT04452721||Validation cohort|120 patients
16332420|NCT04452708||HFNC at 30-60L/min|HFNC at 50-60L/min with humidification at 37C (Airvo 2, Fisher & Paykel, Auckland, New Zealand) will be applied for patients with moderate type 1 respiratory failure
16332421|NCT04452708||NIV|NIV (Respironics V60) via oronasal mask (Quattro, ResMed) will be reserved for patients with type 2 respiratory failure
16332422|NCT04452708||Conventional nasal oxygen|Oxygen 1-5 L/min via nasal cannula for those with mild type 1 respiratory failure
16332423|NCT04452695||Intervention arm|Patients presenting to the emergency department are triaged using a novel robotic telehealth triage system. Once triage is complete, patients complete a quantitative assessment to measure their acceptance and willingness to interact with the robotic telehealth system.
16332424|NCT04452682||Era of COVID 19|Total number of cases admitted during first six months of 2020
16332425|NCT04452682||Era of Non COVID 19|Total number of cases admitted the first six months of 2019
16332426|NCT04452669|Experimental|Study Treatment|Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
16332427|NCT04452669|Placebo Comparator|Placebo Control|Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
16332428|NCT04452656|Active Comparator|bilateral erector spinae plane block|The patient WILL receive bilateral erector spinae plane block.
16332429|NCT04452656|No Intervention|NO BLOCK|The patient will not receive Erector spinae plane block
16332430|NCT04452643|Active Comparator|Bacmune (MV130)|Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
16332431|NCT04452643|Placebo Comparator|Placebo|Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
16332432|NCT04452630||Covid 19 Patients|patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
16332433|NCT04452591|Experimental|Single Arm|"Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease.
~CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments.
~Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter."
16332434|NCT04452578|Experimental|Experimental: Recipient of HCV positive heart graft|A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.
16332435|NCT04452565|Active Comparator|Active Comparator: NA-831 alone|Arm 1: NA-831 30 mg orally twice a day for one day, followed by 30 mg once day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule
16332436|NCT04452565|Active Comparator|Active Comparator: NA-831 plus Atazanavir Sulfate|"Arm 2: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.
~AND Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets."
16332437|NCT04452565|Active Comparator|Active Comparator: NA-83 plus Dexamethasone|"Active Comparator: NA-831 30 mg capsule plus Dexamethasone 4 mg Arm 3: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.
~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
16332438|NCT04452565|Active Comparator|Active Comparator: Atazanavir and Dexamethasone|"Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets.
~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
16332439|NCT04452552|Experimental|ultra-sound cavitation|cavitation40 KHz applied for 30 min, once time weekly for 8 weeks.
16332440|NCT04452552|Experimental|radiofrequency|radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks
16332441|NCT04452539||Paediatric cardiac surgery patients|All patients undergoing paediatric cardiac surgery
16332442|NCT04452526|Experimental|ARM I (EARLY INTERVENTION) (educational material, reminders)|Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
16332443|NCT04452526|Experimental|ARM II (DELAYED INTERVENTION)(education, reminder, usual care)|Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
16332446|NCT04452487||Patient 2019|Patients hospitalized in selected centers during march and june 2019
16332447|NCT04452487||Patient 2020|Patients hospitalized in selected centers during march and june 2020 (during COVID-19 pandemia)
16332448|NCT04452487||Patient 2021|Patients hospitalized in selected centers during march and june 2021
16332449|NCT04452474|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
16332450|NCT04452474|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy
16332451|NCT04452461|Other|Single Arm Intervention|"Chemotherapy: 6 cycles (three months) of IV combination chemotherapy with mFOLFIRINOX on day 1 followed by one week of rest (14-day cycle). Alternatively, patients will receive three months of gemcitabine / nab-paclitaxel.
~Re-staging CT scan with Carbohydrate Antigen (CA) 19-9 serum test.
~Radiation therapy with SBRT for 5 days.
~Re-staging CT scan with CA 19-9 serum test one week following the last day of SBRT . Staging laparoscopy to rule out occult metastatic disease is optional based on surgeon's preference.
~Pancreatectomy 4 weeks following the last day of SBRT as per standard of care.
~Adjuvant chemotherapy: as per standard of care.
~Clinical assessment and CT scan with CA 19-9 serum test at 4-month intervals until identification of cancer recurrence.
~Follow up of patients after 2 years every six months for up to 5 years following the initiation of treatment will be performed off-protocol as per standard of care."
16332452|NCT04452448|Experimental|Laser in situ keratomileusis|A prospective clinical study including 20 eyes of 10 cases undergoing laser in situ keratomileusis (LASIK)
16332453|NCT04452435|Experimental|C21 100 mg twice daily|Oral C21 treatment 100 mg twice daily for 7 days
16332454|NCT04452435|Placebo Comparator|Placebo|Oral placebo treatment 100 mg twice daily for 7 days
16332455|NCT04452409|Active Comparator|study (low level laser plus Mediterranean diet)|Active infra -red laser in addition to diet
16332456|NCT04452409|Other|control (Mediterranean diet only)|diet
16332457|NCT04452396|Experimental|patients|patients undergoing CGM monitoring
16332458|NCT04452383|Active Comparator|propofol (P)|patients will receive only propofol intravenous for sedation
16332459|NCT04452383|Active Comparator|propofol ketamine (pk)|patients will receive ketamine in addition to propofol intravenous for sedation
16332460|NCT04452370|Experimental|oral Etoposide+Anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
16332461|NCT04452357|Experimental|PLDR Chemoradiation|"Patients will receive pulse-low-dose rate radiation, along with gemcitabine chemotherapy.
~6 patients each will be accrued at two dose levels. PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows: Dose level 1: 56 Gy; Dose level 2: 66 Gy"
16332462|NCT04452344|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.
16332463|NCT04452344|Active Comparator|Non-Opioid|Combination of ibuprofen 400 mg/acetaminophen 500 mg
16332464|NCT04452331|Experimental|OAA Intervention|Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
16332465|NCT04452331|Sham Comparator|OAA Physician Aware Control|Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
16332466|NCT04452331|Placebo Comparator|OAA Physician Unaware Control|Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
16332467|NCT04452318|Experimental|REGN10933 + REGN10987|
16332468|NCT04452318|Placebo Comparator|Placebo|
16332469|NCT04452305|Experimental|Spermatogonial Stem Cell Transplant & Testicular Tissue Graft|Stem cell transplantation Testicular tissue grafting
16332470|NCT04452292|Active Comparator|No TP53/Rb1 Co-Mutation|HG-LCNEC tumor lacking the TP53/Rb1 co-mutation (non-small cell-like).
16332471|NCT04452292|Experimental|TP53/Rb1 Co-Mutation Present|HG-LCNEC tumor with the TP53/Rb1 co-mutation.
16332555|NCT04451863|Active Comparator|Low THC + High myrcene|5 mg THC, 12.0 mg myrcene, 0 mg BCP
16332556|NCT04451863|Active Comparator|High THC + Low myrcerne|15 mg THC, 0.5 mg myrcene, 0 mg BCP
16332472|NCT04452279|Experimental|Ocular Surface Disease post-stenting|Eyes will undergo phacoemulsification cataract surgery combined with iStent or iStent inject implantation according to standard clinical practice. From baseline through 3 months postoperatively, participants will complete subjective and objective assessments of ocular surface disease.
16332473|NCT04452266||case group|Women with Lynch Syndrome and endometrial Cancer matched on age of endometrial cancer diagnosis
16332474|NCT04452266||control group|Women with Lynch Syndrome, without Cancer at Lynch Syndrome Diagnostic matched on their age at Lynch Diagnostic
16332475|NCT04452253|Active Comparator|PS128|"The PS128, which belongs to Lactobacillus plantarum subsp. plantarum, 2 caps daily use.
~Sub-project 2 (Open label) for IT specialists also take the same probiotics."
16332476|NCT04452253|Active Comparator|PS23 live|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
16332477|NCT04452253|Active Comparator|PS23 heat-treated|PS23 heat-treated, 2 caps daily use.
16332478|NCT04452253|Placebo Comparator|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
16332479|NCT04452227||eumenorrheic healthy women|women with a regular menstrual cycle for three months, predictable, and a period between 24-38 days that lasts less than 8 days.
16332480|NCT04452214|Experimental|CAN04 and pembrolizumab|Subjects will receive weekly doses of CAN04 in combination with pembrolizumab given as standard regimen
16332481|NCT04452201|Experimental|Guided Participation (GP)|A GP intervention is participatory formal and informal education to support learning of a practice beyond what could occur as efficiently and effectively without guidance. GP uses strategies for teaching-learning that make best use of the family's situation and opportunities, tailored to the parents' needs. The overall goal of the GP intervention is to support parent couples in effectively communicating for parenting work, including care-giving and maintaining the couple's relationship
16332482|NCT04452201|No Intervention|Usual Care (UC)|The UC group will receive standard of care
16332483|NCT04452188|Experimental|Normoxia|"On bypass, goal PaO2 on cardiopulmonary bypass of 60-100 mm Hg using lower fraction of inspired oxygen (FiO2) (blended sweep gas) via oxygenator
~Post-bypass, goal of PaO2 <100 mm Hg by anesthesia and in ICU via oxygen titration via mechanical ventilator for 24 hours post-op."
16332484|NCT04452188|Active Comparator|Standard of care|Frequent blood gases will be checked per protocol on bypass and correlated with the blood parameter monitoring system to maintain a PaO2 of 200-300 per standard practice
16332485|NCT04452175|Experimental|HIGH 5%|
16332486|NCT04452175|Active Comparator|LOW 1.7%|
16332487|NCT04452162|Other|Salivary Gland Tumor|
16332488|NCT04452149|Placebo Comparator|Observation Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care for heart failure management without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 7 months.
16332489|NCT04452149|Experimental|Intervention Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed using an integrated device diagnostic-based risk stratification algorithm combined with a clinical medication plan.
16332490|NCT04452123|Experimental|Argon plasma|Patients with endometrioma treated with laparoscopic argon plasma energy.
16332491|NCT04452123|Experimental|Stripping and suture/coagulation|Patients with endometrioma treated with laparoscopic excision with suture or gentle coagulation of the rest of ovary.
16332492|NCT04452110||Group I|In volunteers in Group 1, values obtained using a linear probe will be compared.
16332493|NCT04452110||Group II|In volunteers in Group 2, values obtained using a hockey stick probe will be compared.
16332494|NCT04452097|Experimental|Phase 1 Low-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.
16332495|NCT04452097|Experimental|Phase 1 Middle-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.
16332496|NCT04452097|Experimental|Phase 1 High-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.
16332497|NCT04452097|Experimental|Phase 2a Treatment Group|Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.
16332498|NCT04452097|Placebo Comparator|Phase 2a Control Group|Eligible subjects will receive a single infusion of placebo control and standard of care treatment.
16332499|NCT04452084|Active Comparator|Control|
16332500|NCT04452084|Experimental|Experimental Procedure|
16332501|NCT04452071||prepubertal|patients born in 2012-2011
16332502|NCT04452071||pubertal|patients born in 2010-2009-2008-2007
16332503|NCT04452071||postpubertal|patients born in 2006-2005-2004-2003
16332504|NCT04452058||Internal cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to December 31,2019. Patients with single pulmonary lesion underwent preoperative chest CT scan and histologically confirmed precancerous lesions or early stage lung adenocarcinoma after thoracic surgery was included.
16332505|NCT04452058||External cohort 1|The same inclusion/exclusion criteria were applied for another independent centers, Sun Yat-sen Memorial Hospital ,Guangdong Province, China, forming an external validation cohort of 73 patients
16332506|NCT04452058||External cohort 2|The same inclusion/exclusion criteria were applied for another independent centers, Zhoushan Lung Cancer Institution, Zhejiang Province, China, forming second external validation cohort of 30 patients
16332507|NCT04452058||Immune Cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to May 31,2020. Patients with advanced lung cancer underwent preoperative chest CT scan and histologically confirmed NSCLC before receiving immunotherapy was included.
16332508|NCT04452045|Experimental|SweetDreams|Access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
16332509|NCT04452045|No Intervention|Waitlist Control|Wait list condition with future access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
16332557|NCT04451863|Active Comparator|High THC + High myrcene|15 mg THC, 12.0 mg myrcene, 0 mg BCP
16332558|NCT04451863|Active Comparator|Low THC + Low BCP|5 mg THC, 0 mg myrcene, 0.5 mg BCP
16332510|NCT04452032|Experimental|Single arm|"The first phase of the study will consist of an evaluation of the initial dental state of each subject based on stomatological examination, orthopantomogram, bitewing radiographs, evaluation of potential risks of caries and fractures. Dental decalcification, dental care and/or avulsion if necessary, and afterwards, a dental splint will be performed before the start of RT treatment.Based on our predictive model, every tooth which potentially will receive more than 40 Gy and for which long term survival is compromised will be avulsed at least 2 weeks before the start of RT.
~After RT, the subject will have clinical follow-up with dental evaluation every 6 months for 36 months in order to identify possible dental events. At each consultation, a stomatological examination will be performed as well as bitewing radiographs. Orthopantomogram will be done once a year. Periapical X-rays will be performed if there is a dental complain or to refine a lesion visible on orthopantomogram."
16332511|NCT04452019|Active Comparator|Standing frame|Use of standard standing frame
16332512|NCT04452019|Experimental|Innowalk|Use of a new Device; Innowalk Pro
16332513|NCT04452006|Experimental|Part A (SAD) - A1, ACT-541478 10 mg fasted|SAD = single ascending dose
16332514|NCT04452006|Experimental|Part A (SAD) - A2, ACT-541478 30 mg fasted|SAD = single ascending dose
16332515|NCT04452006|Experimental|Part A (SAD) - A3 (Period 1), ACT-541478 100 mg fasted|SAD = single ascending dose
16332516|NCT04452006|Experimental|Part A (SAD) - A3 (Period 2), ACT-541478 100 mg fed|SAD = single ascending dose
16332517|NCT04452006|Experimental|Part A (SAD) - A4, ACT-541478 300 mg fasted|SAD = single ascending dose
16332518|NCT04452006|Experimental|Part A (SAD) - A5, ACT-541478 1000 mg fasted|SAD = single ascending dose
16332519|NCT04452006|Experimental|Part B - B1-3, ACT-541478 low or high dose|
16332520|NCT04452006|Experimental|Part C (MAD) - C1, ACT-541478 30 mg, fasted|MAD = multiple ascending dose
16332521|NCT04452006|Experimental|Part C (MAD) - C2, ACT-541478 100 mg, fasted|MAD = multiple ascending dose
16332522|NCT04452006|Experimental|Part C (MAD) - C3, ACT-541478 300 mg, fasted|MAD = multiple ascending dose
16332523|NCT04452006|Experimental|Part C (Elderly) E1, ACT-541478, fasted|
16332524|NCT04451993||OSAS PATIENTS|mild, moderate and severe OSAS patients
16332525|NCT04451993||HEALTHY INDIVIDUALS|healthy individuals without chronic disease
16332526|NCT04451980||HIV+ non-diabetics|HIV-infected participants with hemoglobin A1c (HbA1c) <5.7% or fasting glucose <100 mg/dl.
16332527|NCT04451980||HIV+ pre-diabetics|HIV-infected participants with HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dl.
16332528|NCT04451980||HIV+ diabetics|HIV-infected participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
16332529|NCT04451980||HIV-negative diabetics|HIV-negative participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
16332530|NCT04451967||Transfer after thrombolysis|
16332531|NCT04451967||Transfer after DAPT|
16332532|NCT04451967||Direct transfer|
16332540|NCT04451941|Experimental|RecoveriX with individual EEG calibration|RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
16332541|NCT04451941|Sham Comparator|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
16332542|NCT04451928||Preterm delivery|Pregnant women who give birth before 37th gestational week
16332543|NCT04451928||Term delivery|Pregnant women who will give birth 37th and after gestational week
16332544|NCT04451915|Experimental|Early management GDM group|defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
16332545|NCT04451915|Experimental|Late management GDM group|early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
16332546|NCT04451889|Experimental|Confocal laser endomicroscopy diagnostic study|"Cohort 1: COVID-19 patients. Cohort 2: patients with lung diseases unrelated to COVID-19.
~All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special Alveoflex miniprobe during the hospitalisation period. Records will be done and analysed prospectively with the included software for the endomicroscopic system.
~Using Alveoflex is a minimally invasive intervention."
16332547|NCT04451863|Placebo Comparator|Placebo|0 mg THC, 0 mg myrcene, 0 mg BCP
16332548|NCT04451863|Active Comparator|Low strength THC|5 mg THC, 0 mg myrcene, 0 mg BCP
16332549|NCT04451863|Active Comparator|Higher strength THC|15 mg THC, 0 mg myrcene, 0 mg BCP
16332550|NCT04451863|Active Comparator|Low strength myrcene|0 mg THC, 0.5 mg myrcene, 0 mg BCP
16332551|NCT04451863|Active Comparator|High strength myrcene|0 mg THC, 12.0 mg myrcene, 0 mg BCP
16332552|NCT04451863|Active Comparator|Low strength BCP|0 mg THC, 0 mg myrcene, 0.5 mg BCP
16332553|NCT04451863|Active Comparator|High strength BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
16332562|NCT04451837|Active Comparator|semaglutide|Patients randomized to add semaglutide (Ozempic) will receive injection training at the study site and inject 0.25 mg subcutaneously once weekly during the first four weeks, followed by 0.5 mg weekly for the subsequent four weeks and finally 1.0 mg weekly throughout the study.
16332563|NCT04451837|Active Comparator|dapagliflozin|Those randomized to dapagliflozin will receive 10 mg orally once daily in addition to metformin.
16332564|NCT04451824|Experimental|Intervention with Routine Use of Red Light|Routine Use of red light (635nm) for 30 minutes on patients is to be observed in relation to its effect(s) in achieving circumferential reduction of the thighs, hips and waist of the patient, and a contour reduction of any protrusion of fat.
16332565|NCT04451811|Experimental|OPL-002 SDD 20 mg|20 mg SDD formulation of OPL-002
16332566|NCT04451811|Experimental|OPL-002 5 mg Tablet|5 mg tablet formulation of OPL-002
16332567|NCT04451811|Experimental|OPL-002 20 mg Tablet|20 mg tablet formulation of OPL-002
16332568|NCT04451798|Experimental|Intervention|Impella implantation and hemodynamic measurement
16332569|NCT04451785|Active Comparator|Healthy individuals|20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
16332570|NCT04451785|Experimental|Patients with hereditary spherocytosis|60 patients with hereditary spherocytosis will be included in this study.
16332571|NCT04451772|Experimental|Part 1: Elsubrutinib Dose A and Upadacitinib Dose A|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).
16332572|NCT04451772|Experimental|Part 2: Elsubrutinib Dose A and Upadacitinib Dose B|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.
16332573|NCT04451772|Experimental|Part 3: Elsubrutinib Dose A and Upadacitinib Placebo|Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.
16332574|NCT04451772|Experimental|Part 4: Elsubrutinib Placebo and Upadacitinib Dose A|Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.
16332575|NCT04451759|Active Comparator|healthy controls|
16332576|NCT04451759|Experimental|Anorexia|
16332577|NCT04451759|Experimental|Obesity|
16332578|NCT04451746|Other|Tableted hormonal drugs for contraception|Tableted hormonal drugs for contraception, 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
16332579|NCT04451720|Experimental|Risankizumab|In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.
16332580|NCT04451720|Experimental|Placebo|In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.
16332581|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
16332582|NCT04451694||Covid-19 unit outgoing patients|nutritional evaluation and intervention
16332583|NCT04451681|Other|Ankylosing spondylitis|A total of 42 patients, who were diagnosed with AS with modified New York Criteria, and who agreed to participate in the study, will be included in this group.
16332584|NCT04451681|Other|Control|A total of 42 control participants between the ages of 18-65 who agreed to participate in the study will be included in this group.
16332585|NCT04451668|Experimental|FT218|once nightly sodium oxybate extended release oral solution (FT218)
16332586|NCT04451655|Experimental|Interventional|
16332587|NCT04451642||Peripheral nerve block Group|Every patient scheduled during 2011-2019 for the surgery needed a peripheral nerve block were enrolled.
16332588|NCT04451629|Experimental|Exercises group|intervention group çalışma grubundaki kadın öğrencilere 8 hafta süresince haftada 4 kez 40 dakika boyunca pelvik taban ve core egzersizleri uygulatılacak
16332589|NCT04451629|No Intervention|control group|students will be watched without any intervention
16332590|NCT04451616||Group A - study group - patients with metabolic syndrome|"Patients with metabolic syndrome will be included.
~Procedures:
~blood sample collection
~hair sample collection
~urine sample collection
~body composition analysis
~questionnaires
~blood pressure, pulse and blood oxygen saturation measurement"
16332591|NCT04451616||Group B - control group - patients without metabolic syndrome|"Patients without metabolic syndrome will be included.
~blood sample collection
~hair sample collection
~urine sample collection
~body composition analysis
~questionnaires
~blood pressure, pulse and blood oxygen saturation measurement"
16332592|NCT04451603||Surgical resection|
16332593|NCT04451603||Y-90 therapy|
16332594|NCT04451603||Systemic Therapy|
16332595|NCT04451590|Experimental|VR-based Simulation (Intervention)|Students will receive training on traumatic airway management using VR-based simulation.
16332596|NCT04451590|Other|Mannequin-based Simulation (Control)|Students will receive training on traumatic airway management using mannequin-based simulation.
16332597|NCT04451577||EMPLOYEES WITHOUT COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.
~Negativity to COVOD-19 will be tested by peripheral blood samples every month for 6 months (or until seroconversion). If they are positive for anti- covid 19 antibodies, a test for positivity of the virus will be carried out. T"
16332598|NCT04451577||EMPLOYEES WITH COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.
~employees that are Sars-Cov-2 positive both symptomatic and asymptomatic, there will be at least 2 peripheral blood samples (5 and 3 ml) at every control visit until ascertained negativity. They will also undergo a pharyngeal swab for viral titers and microbiota analysis at enrollment and at negativity. In addition, a sample of saliva/sputum will be collected for most of the employees at positivity and at every control visit.
~For employees hospitalized but not requiring intensive care the following samples will be collected:
~an aliquot of samples from the respiratory tract (e.g., bronchial aspirate, bronchoalveolar lavage) residual from the normal clinical practice
~saliva/sputum
~pharyngeal swab not used for diagnosis both at admission and at the first check up
~blood sample in EDTA for plasma and peripheral blood mononuclear cell (PBMC)"
16332599|NCT04451564|Experimental|MORE Mindfulness oriented recovery enhancement group|MORE Mindfulness oriented recovery enhancement group
16332600|NCT04451564|No Intervention|Control|wait-list
16333696|NCT04444037||OCT-guided PCI|PCI procedure was done with intra-coronary imaging OCT.
16332601|NCT04451538|Experimental|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g [12 spoon, 500 kcal]/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoon, 440 kcal]/day, twice a day).
16332602|NCT04451538|Placebo Comparator|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
16332603|NCT04451525||Patients with Acute Ischemic Stroke|
16332604|NCT04451512||CSP|
16332605|NCT04451512||HSP|
16332606|NCT04451499|Experimental|Intervention group -smartphone app|"All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
~All the participants will get access to our study's smartphone app site."
16332607|NCT04451499|No Intervention|Control group|All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
16332608|NCT04451486|Experimental|Treatment dose 1|1x10*5 CD61-Lin- cells /0.25mL DPBS
16332609|NCT04451486|Experimental|Treatment dose 2|1x10*6 CD61-Lin- cells /0.25mL DPBS
16332610|NCT04451486|Experimental|Treatment dose 3|1x10*7 CD61-Lin- cells /0.25mL DPBS
16332611|NCT04451473|Experimental|ERAS- Group|Patients underwent surgery for lung cancer accepted the enhanced recovery after surgery (ERAS).
16332612|NCT04451473|Other|Control- Group|Patients underwent surgery for lung cancer without enhanced recovery after surgery (ERAS).
16332613|NCT04451460||Hyponatremia|Hyponatremic small cell cancer patients
16332614|NCT04451460||Normonatremia|Normonatremic small cell cancer patients
16332615|NCT04451447|Experimental|white test arm|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
16332616|NCT04451447|Other|Saline test arm|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
16332617|NCT04451434|Experimental|Danicopan 200 mg Fasted|Fasting participants will receive a single dose of 200 mg danicopan.
16332618|NCT04451434|Experimental|Danicopan 200 mg Fed|Fed participants will receive a single dose of 200 mg danicopan.
16332619|NCT04451434|Experimental|Danicopan 400 mg Fed|Fed participants will receive a single dose of 400 mg danicopan.
16332620|NCT04451421|Experimental|Standing Angle|Assist the electric hospital bed to conduct different Angle standing training, starting from 20 degrees, every five minutes to rise 5 degrees, the maximum rise to 80 degrees
16332621|NCT04451408|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV).
16332622|NCT04451408|Experimental|LY3372993 (Part B)|LY3372993 administered IV in Japanese Participants.
16332623|NCT04451408|Placebo Comparator|Placebo (Part A)|Placebo administered IV.
16332624|NCT04451408|Placebo Comparator|Placebo (Part B)|Placebo administered IV in Japanese Participants.
16332625|NCT04451395|Experimental|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet..The supplement is provided within the parent trial.
~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
16332626|NCT04451395|No Intervention|Standard of care|Daily iron and folic acid supplementation provided through the existing public health system.
16332627|NCT04451382||OnabotulinumtoxinA (BoNTA)|DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
16332628|NCT04451382||Percutaneous tibial nerve stimulation (PTNS)|DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.
16332629|NCT04451369|No Intervention|Control group|Group without prehabilitation program before surgery
16332630|NCT04451369|Experimental|Prehabilitation group|Group will follows a prehabilitation program before surgery
16332631|NCT04451343||Patients|Patients with a diagnosis of colorectal cancer before 65 years.
16332632|NCT04451343||Family|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
16332633|NCT04451330|Experimental|Trifarotene (CD5789) Cream + Doxycycline|Participants will apply trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.
16332634|NCT04451330|Placebo Comparator|Trifarotene Vehicle + Doxycycline Placebo|Participants will apply vehicle trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of placebo doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.
16332635|NCT04451317||Experimental|Patients involved in a Sport-Health initiative Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
16332636|NCT04451317||Control|Healthy sport subjects. Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
16332637|NCT04451291|Experimental|Decidual Stromal Cells (DSC)|Participants will receive one dose of DSC at 1x10^6/kg. A second dose may be given sometime between Day 5 and Day 8 if the participant's condition improves.
16332638|NCT04451239|Other|COVID-19 keratoconjunctivitis|cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
16332639|NCT04451226|Experimental|Fezolinetant|Participants will receive fezolinetant once daily for 52 weeks.
16332640|NCT04451213|Experimental|experimental|
16332641|NCT04451200|Experimental|busulfan treatment|Personalized BU administration
16332646|NCT04451174|Experimental|Treatment|Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8.
16332647|NCT04451174|No Intervention|Control|
16332651|NCT04451148||Obese subjects|Subjects with obesity
16332652|NCT04451148||Obese plus metabolic syndrome subjects|Subjects with obesity and metabolic syndrome
16332653|NCT04451148||Healthy controls|Otherwise healthy subjects
16332654|NCT04451135|Experimental|Patients with Treatment-Resistant Depression|
16332655|NCT04451122|Other|Treatment of ocular demodicosis|
16332656|NCT04451109||Cases in which Dilapan-S was used for cervical ripening.|Every participating site will select 50 cases of pregnant women who underwent cervical ripening by Dilapan-S prior to induction of labor. These cases has to fulfill inclusion/exclusion criteria defined in the protocol.
16332657|NCT04451096|Active Comparator|Probiotic with prebiotic|Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
16332658|NCT04451096|Placebo Comparator|Placebo|Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
16332659|NCT04451083|Experimental|FOY-305|
16332660|NCT04451070||Family Medicine resident physicians|Family Medicine resident physicians at David Grant Medical Center who started their Family Medicine residency at David Grant Medical Center between June 2018 - June 2019 and are scheduled to graduate from Family Medicine residency between June 2021 - June 2022.
16332661|NCT04451057|Experimental|high flow nasal nasal cannula|Patients allocated for this arm are received high flow nasal cannula therapy after extubation.
16332662|NCT04451057|Active Comparator|low flow nasal cannula|Patients allocated for this arm are received conventional oxygen therapy after extubation.
16332663|NCT04451044|Experimental|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
16332664|NCT04451044|Active Comparator|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
16332665|NCT04451031|Experimental|LiFT Program|LiFT is a two-module curriculum workshop for youth and their parenting adults. Topics for youth include communication skills, condom use, and skill building to access sexual healthcare resources. For parenting adults, topics include building a climate of trust and open communication with youth about sexual health. Trained and certified facilitators deliver each 2.5 hour module over one or two sessions. Youth and parents participated in simultaneous but separate programming in community locations such as schools or health care settings. They received participant guides that encourage communication between them. They could opt-in to receive 12 weekly texts that offered additional resources. Parenting adults received a phone call from the facilitator a month after the workshop to reinforce the skills learned during the program.
16332666|NCT04451031|No Intervention|Comparison Group|The comparison group received business as usual. The youth and parents enrolled in the study could receive the existing services available within the broader community, which may have included sexual education delivered in the local school system. Study staff collected data throughout the study to track access to other TPP programming offered at the study sites.
16332667|NCT04451005||Elderly patients with sarcopenia|Elderly patients with sarcopenia
16332668|NCT04450979|Active Comparator|Bioactive hydrolysate|20 g of hydrolysed rice protein
16332669|NCT04450979|Placebo Comparator|Placebo|20 g micro crystalline cellulose
16332670|NCT04450966|No Intervention|Usual Care|Clinicians randomized to this arm will not receive training in delivery of cSBI until study completion, and their participating patients will receive usual care.
16332671|NCT04450966|Experimental|Computer-facilitated screening and brief intervention|Clinicians randomized to this arm will receive training in delivery of cSBI and their participating patients will then receive the experimental intervention.
16332672|NCT04450953|Experimental|Eplerenone group A (cross over design)|Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 2-month wash-out period, then a 6-month period without eplerenone, until the end of the study.
16332673|NCT04450953|Active Comparator|Eplerenone group B (cross over design)|Eplerenone-free for 6 months, followed by a 2-month wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
16332674|NCT04450940|Experimental|PACV|The PACV arm received the PACV survey at baseline in order to assess the impact of administration on vaccine hesitancy. All participants received the PACV at 6-month follow up.
16332675|NCT04450940|Sham Comparator|Placebo|The placebo arm received a placebo survey on general childhood health topics at baseline. All participants received the PACV at 6-month follow up.
16332677|NCT04450914|Other|Health Systems - First Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the first step, health systems will be assigned to usual care (passive implementation of CV Prevention Choice).
16332678|NCT04450914|Other|Health Systems - Second Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the second step, health systems (in an order to be determined by randomization and staggered over time) will move into active implementation.
16332679|NCT04450914|Other|Health Systems - Third Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions.In the third step, all health systems will move to maintenance implementation.
16332680|NCT04450901|Experimental|Cohort A1 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 0.5 mg/kg
16332681|NCT04450901|Experimental|Cohort A2 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 2 mg/kg
16332682|NCT04450901|Experimental|Cohort A3 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 5 mg/kg
16332683|NCT04450901|Experimental|Cohort A4 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 10 mg/kg
16332684|NCT04450901|Experimental|Cohort B1|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).
~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
16332685|NCT04450901|Experimental|Cohort B2|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).
~YBL-006 will be administered once every 3 weeks (Q3W). Dose: 300 mg"
16332686|NCT04450901|Experimental|Cohort B2 reserve|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).
~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 300 mg"
16332687|NCT04450901|Experimental|Cohort B3|"Tumor type: Metastatic NSCLC (Non-small-cell lung carcinoma), unresectable or metastatic, MSI-H (microsatellite instability-high) or dMMR (Deficient MisMatch Repair), recurrent or metastatic HNSCC (Head and neck squamous cell carcinoma), non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer.
~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
16332688|NCT04450888|Other|Model A|Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
16332689|NCT04450888|Other|Model B|Average CVD-free life expectancy gain per year.
16332690|NCT04450888|Other|Model C|Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
16332691|NCT04450888|Other|Model D|Average CVD-free life expectancy loss that can be reclaimed per year.
16332692|NCT04450875|Experimental|Experimental group (with diet)|It consisted in the administration of nutritional therapy with foods high in methionine according to the National Nutrient Database For Standard Reference (USDA) and adapted to the consumption and usual cost in the Mexican diet.
16332693|NCT04450875|No Intervention|Control|The control group continued with their usual diet for the same period of 3 months as the experimental group.
16332694|NCT04450862|Experimental|Intervention arm|Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky & Mooney, 1990).
16332695|NCT04450862|No Intervention|Control arm|A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention.
16332696|NCT04450849|Experimental|collagen membrane associated to anorganic bone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio) associated to anorganic bovine bone matrix + collagen (Bio-Oss® Collagen) . The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
16332697|NCT04450849|Active Comparator|collagen membrane alone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio). The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
16332698|NCT04450836|Experimental|Arm A (R-TT)|Regorafenib followed by trifluridine-tipiracil.
16332699|NCT04450836|Experimental|Arm B (TT-R)|Trifluridine-tipiracil followed by Regorafenib.
16332700|NCT04450810||Control|Evaluation of serum and salivary NLRP3
16332701|NCT04450810||Periodontitis|Evaluation of serum and salivary NLRP3
16332702|NCT04450810||Diabetes|Evaluation of serum and salivary NLRP3
16332703|NCT04450810||Periodontitis + diabetes|Evaluation of serum and salivary NLRP3
16332704|NCT04450797|Active Comparator|US -G VPS placement|
16332705|NCT04450797|Active Comparator|Stereotactic navigation for VPS placement|
16332706|NCT04450784||Secondary Acute Myeloid Leukemias (AML) of the child|
16332801|NCT04450069|Experimental|Dose Escalation|CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
16334135|NCT04441099|Experimental|Expansion Cohort 2 (EC2)|Dose to be determined based on DEC and SEC.
16332707|NCT04450771|Experimental|Family-based Treatment for ARFID(FBT-ARFID)|FBT-ARFID is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior. Early sessions focus on inciting parents to make changes and include a family meal that allows therapists to observe & consult directly to mealtime behaviors. FBT-ARFID for children 12 and under is manualized and consists of 2 phases. The first phase is focused on parents taking charge & changing the eating behaviors of their child that are maintaining ARFID. The second phase focuses on the child taking up in an age-appropriate way managing their eating consistent with the changes the parents have employed in phase 1. Fourteen 1-hour sessions will be conducted approximately weekly over 4 months. Throughout medical monitoring and weekly dietary consultation are available to the family.
16332708|NCT04450771|Active Comparator|Manualized Non-Specific Usual Care for ARFID(NSC)|A manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model that has been used in other RCTs with eating disorders as a comparison. NSC consists of sessions with the child alone and 5 parent-only meetings. Sessions are 1-hour. NSC matches FBT-ARFID for time and therapist attention. The focus of the NSC intervention is psychoeducation about health & social impacts of restrictive eating and supporting parent & child exploration of motivation to change eating patterns & choices they make about changes to eating. The therapist does not initiate behavioral or cognitive interventions. Feelings about eating and making changes are explored in both the child and parent sessions. Medical and dietary advice are provided weekly.
16332709|NCT04450758||resection|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
16332710|NCT04450758||bridge to sugery|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
16332711|NCT04450745|Experimental|Exercise in hypoxia|Patients randomized to this arm will have training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above see level( indoor air composition: 15,4% of O2 and 84,7% of N)
16332712|NCT04450745|Experimental|Exercise in normoxia|Patients randomized to this arm will have the same training program in normoxic conditions
16332718|NCT04450719||Group 1: Patients with lung cancer|Exercise capacity [6-minute walk test (6-MWT)], pulmonary functions [spirometry], respiratory [maximal inspiratory and expiratory pressures (MIP-MEP), mouth pressure device] and peripheral muscle strength [dynamometer], physical activity level [metabolic holter], dyspnea [Modified Medical Research Council dyspnea scale (MMRC)] and quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] were evaluated in patients with lung cancer. Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
16332719|NCT04450719||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were performed in healthy individuals.
16332720|NCT04450706|Experimental|Treatment: all patients|"Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first uninformed line of therapy.
~Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line."
16332721|NCT04450706|Experimental|Physician Questionnaire|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
16332722|NCT04450693|Experimental|TTAX01|TTAX01 plus standard of care
16332723|NCT04450693|Other|Control|Standard care alone
16332724|NCT04450667|No Intervention|Fasting|"Patient will be nil per os from midnight before their cesarean section"
16332725|NCT04450667|Active Comparator|Rehydration|Patient will receive 400 mL of Nutricia Preop ® 2 hours before their cesarean section
16332726|NCT04450654|Experimental|Gamunex-C IVIG|Gamunex-C IVIG dosed at 2g/kg will be given on week 0 and week 4.
16332727|NCT04450654|Placebo Comparator|Placebo|Albumin in a 1% solution at an equivalent volume to the corresponding Gamunex-C IVIG dose will be given at week 0 and week 4.
16332728|NCT04450641|Experimental|Treatment|Treatment group used GuessWhat during the 4 week intervention period.
16332729|NCT04450641|Other|Control|Participants in control group received standard treatment as usual.
16332730|NCT04450628|No Intervention|Surgeon blinded|"During blinded cases no adjustment will be made to the surgical procedure based on EndoFLIP results, as the operating surgeon will not be informed of the measured values.
~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
16332731|NCT04450628|Experimental|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.
~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
16332732|NCT04450615|Experimental|Training group|"The first part of the program aims in pelvic and hip mobility and includes the following exercises, glute bridge, single-leg glute bridge, side-lying clam, side plank and side plank with hip abduction, on stable surface.
~The second part consists of exercises for deep and superficial trunk muscles. In the first exercise the participants learn to activate the transversus abdominis muscle from the crook-lying position, by performing abdominal hollow. Other exercises include the front plank, trunk curl-up, trunk curl-up on stable surface and curl-up on unstable surface (Swiss ball).
~The third part of the program consists of exercises for strengthening the lumbar multifidus muscle. The participants will perform prone trunk extension, superman exercise, quadruped diagonal arm and leg lift, single leg supine bridge and supine bridge on unstable surface (Swiss ball)."
16332733|NCT04450615|No Intervention|Control group|The participants of this group will follow their typical daily routine
16332734|NCT04450602|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR (Patent Pending) active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
16332735|NCT04450602|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
16332736|NCT04450589|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
16332737|NCT04450589|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
16332738|NCT04450563|Active Comparator|Placebo + closed-loop insulin system|
16332739|NCT04450563|Experimental|Empagliflozin 2.5 mg + closed-loop insulin system|
16332740|NCT04450563|Experimental|Empagliflozin 5 mg + closed-loop insulin system|
16332741|NCT04450550|Active Comparator|Active|
16332742|NCT04450550|Sham Comparator|Sham|
16332743|NCT04450537|Experimental|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
16332744|NCT04450537|No Intervention|Sun Safety Control|Participants will be exposed 10 sun safety messages
16332745|NCT04450524|Experimental|Hypnosis|Hypnosis formed from hypnotic induction (an adapted version from Harvard Group Scale of Hypnotic Susceptibility) together with hypnotic suggestions about a future where they will control their eating behaviors by choosing the low-calorie food instead of dense calorie one.
16332746|NCT04450524|Experimental|Food Inhibition Training|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press or not a button when the pictures are framed in a bold frame (dense calorie food).
16332747|NCT04450524|Placebo Comparator|Control|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press the button to indicate the position of the picture - left or right.
16332748|NCT04450511|Active Comparator|Group 1: Bladder Training (BT)|BT, consisting of four stages, did not contain any PFM training programs in all groups. In these stages, including urgency suppression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women were encouraged to pause/stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
16332749|NCT04450511|Experimental|Group 2: Bladder Training+Magnetic Stimulation|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is inserted by this magnetic ﬁeld, an eddy current ﬂow is generated. This eddy current stimulates nerve or muscle of the pelvic ﬂoor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
16332750|NCT04450498|Experimental|Walvax MPV ACYW® vaccine group|
16332751|NCT04450498|Active Comparator|Sanofi Pasteur Menactra® vaccine group|
16332752|NCT04450485|Active Comparator|Medial para-patellar approach|Fast track protocol applied total knee arthroplasty patients operated by using medial para-patellar approach
16332753|NCT04450485|Active Comparator|Mini mid-vastus approach|Fast track protocol applied total knee arthroplasty patients operated by using mini mid-vastus approach
16332754|NCT04450446||cerebral hemorrhage|
16332755|NCT04450446||thromboembolism|
16332756|NCT04450446||no thromboembolism and cerebral hemorrhage|
16332757|NCT04450433||Baseline table of patients|
16332758|NCT04450433||Differential metabolites of two groups of control patients|
16332759|NCT04450433||Functional verification of differential metabolites|
16332760|NCT04450420|Experimental|Simulation based curriculum|"Three phases:
~Self-study of an eBook - Participating trainees will be required to learn material pertaining to tunnel construction and general surgical principles during SICS from an eBook that has been developed by HelpMeSee.
~Instructor led teaching - didactic training, lab activities to gain familiarity with instruments, simulator based training through deliberate practice, and debriefing with instructor.
~Instructor supervised performance of surgery on patients in the operating room."
16332761|NCT04450420|Active Comparator|Standard training|Current standard curriculum for resident training.
16332764|NCT04450394|Experimental|LY3209590 Algorithm 1|LY3209590 administered subcutaneously (SC).
16332765|NCT04450394|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
16332766|NCT04450381|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
16332767|NCT04450368||Cases with Air Trapping|20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
16332768|NCT04450368||Cases without Air Trapping|20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
16332769|NCT04450368||Healthy Controls|Non COPD patients and non-smokers
16332770|NCT04450355|Experimental|Nefopam group|At the end of induction, the nefopam group will receive intravenous nefopam 20mg mixed with 50ml of normal saline, and at the end of surgery, this group will receive intravenous nefopam 60mg mixed with 50ml of normal saline at a rate of 2ml/hr.
16332771|NCT04450355|Placebo Comparator|Control group|The control group will receive intravenous normal saline 50ml at the end of induction and receive intravenous normal saline 50ml at a rate of 2ml/hr at the end of surgery.
16332772|NCT04450342|Experimental|ARCR augmented with REGENETEN™ Bioinductive Implant|During the ARCR procedure, the REGENETEN™ Bioinductive Implant is covering the tendon and attached to the bone and the tendon with small anchors.
16332773|NCT04450342|Sham Comparator|ARCR alone|The rotator cuff is repaired during arthoscopic standard procedure. No product is added for healing
16332774|NCT04450342|Other|ARCR revision group|ARCR revision group allows treatment of subjects having recurrent tears, ARCR supplemented with REGENETEN
16332775|NCT04450329|Experimental|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
16332776|NCT04450329|Active Comparator|Eylea (Aflibercept)|"Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
~At Week 32, subjects in Eylea group will re-randomized into SB15 or Eylea group. After re-randomization, subjects transited to SB15 group will receive SB15 2 mg (0.05 mL) once every 8 weeks until Week 48 and subjects remaining in Eylea group will continue to receive Eylea 2 mg (0.05 mL) once every 8 weeks until Week 48."
16332777|NCT04450316|Active Comparator|Low-dose naltrexone|4.5mg of naltrexone to be taken one hour prior to bedtime nightly for 8 weeks.
16332778|NCT04450316|Placebo Comparator|Placebo|Placebo tablet (sugar-pill) to be taken one hour prior to bedtime nightly for 8 weeks.
16332779|NCT04450303|Experimental|Telehealth Therapy|
16332780|NCT04450290|Experimental|single arm - treatment|All subjects will be implanted with the investigational device.
16332781|NCT04450264|Other|Breast Cancer Education Program|
16332782|NCT04450251||Pregnant women, at least 24 weeks gestation|
16332783|NCT04450238||Study Group|"All participants are inpatients at the clinic Stillachhaus in Germany. They are receiving treatment for a variety of psychological disoders, mostly depressive disoders."
16332784|NCT04450212|Experimental|Phase I, Buccal Swab Collection for DNA Isolation|Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
16332785|NCT04450212|Experimental|Phase II, Vitamin K (Vitacost) Supplementation|Subjects from Phase I with a homozygous CYP4F2*1 (n=14) or CYP4F2*3 (n=14) genotype are selected to receive daily vitamin K supplementation, for 10-days. Blood and urine samples are collected sequentially, at baseline, and during the supplementation period.
16332786|NCT04450199|Active Comparator|Vitamin D|12 over encapsulated 50,000 IU Vitamin D2
16332787|NCT04450199|Placebo Comparator|Placebo|12 over encapsulated placebo tablets
16332788|NCT04450186|Experimental|EEG/fMRI neurofeedback|Healthy volunteers
16332789|NCT04450173|Experimental|Treatment (obinutuzumab, venetoclax, ibrutinib)|Patients receive obinutuzumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, and 24. Patients also receive venetoclax PO QD on days 1-28 (days 4-28 of cycle 1) and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16332790|NCT04450160|Placebo Comparator|Standard of Care|Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.
16332791|NCT04450160|Experimental|AEO with Standard of Care|Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).
16332792|NCT04450147|Experimental|Tai Chi and Qigong|50mins x 12 weeks of virtually-delivered group tai chi/qigong
16332793|NCT04450147|Active Comparator|Walking and Stretching|50mins x 12 weeks of virtually-delivered group walking and stretching
16332794|NCT04450134|Placebo Comparator|Placebo|6 weeks high-intensity interval training + placebo intake
16332795|NCT04450134|Experimental|Blockade|6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
16332796|NCT04450121|Active Comparator|GA (n =22)|Patients will be intubated using Air-Q airway
16332797|NCT04450121|Active Comparator|GF (n =22)|Patients will be intubated using Fekry airway
16332798|NCT04450095|Active Comparator|Treated group|Tab. Volibris 10mg given once a day for 5 days, starting 48 hours before surgery (in addition for the standard treatment for partial nephrectomy)
16332799|NCT04450095|No Intervention|Control group|Treated with the standard treatment for partial nephrectomy
16332800|NCT04450082||One anastomosis gastric bypass|One anastomosis gastric bypass in Sleeve Gastrectomy failure
16332802|NCT04450056||Mother-infant pairs|Mothers with a term-born (>37 weeks gestation) infant whom they are exclusively or predominantly breastfeeding at 1 month postpartum. Mothers must be enrolled in the MaPPS Trial (ClinicalTrials.gov Identifier: NCT03287882).
16332803|NCT04450043|Experimental|Run In|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
16332804|NCT04450043|Experimental|Intervention|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
16332805|NCT04450043|Active Comparator|Control|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
16332806|NCT04450030||Intravenous methyl prednisolone|Patients receiving an additional course of intravenous methyl prednisolone for treatment of a steroid-refractory MS relapse
16332807|NCT04450030||Immunoadsorption|Patients receiving 6 courses of immunadsorption treatment for treatment of a steroid-refractory MS relapse
16332808|NCT04450017||Clinical Features of Severe Patients With COVID-19|Critical ill patients with COVID-19 admitted to the ICU. The demographic, clinical data, laboratory data, and Instrumental data will be analysed.
16332809|NCT04450004|Experimental|Vaccine (3.75 µg) unadjuvanted|• Group 1: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine
16332810|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with CpG 1018|• Group 2: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
16332811|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with AS03|• Group 3: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
16332812|NCT04450004|Experimental|Vaccine (7.5 µg) unadjuvanted|• Group 4: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
16332813|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with CpG 1018|• Group 5: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
16332814|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with AS03|• Group 6: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
16332815|NCT04450004|Experimental|Vaccine (15 µg) unadjuvanted|• Group 7: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
16332816|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with CpG 1018|• Group 8: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
16332817|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with AS03|• Group 9: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
16332818|NCT04449991|Experimental|Intervention arm: Repeat kidney biopsy at M12|Patients will undergo repeat kidney biopsy at month 12 from baseline.
16332819|NCT04449991|No Intervention|Control arm: No repeat kidney biopsy|Patients will not undergo repeat kidney biopsy at month 12 from baseline.
16332820|NCT04449965|Experimental|PVP-I sinus rinses and throat gargles|Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
16332821|NCT04449965|Placebo Comparator|Placebo sinus rinses and throat gargles|Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
16332822|NCT04449965|Experimental|PVP-I gel forming nasal spray|0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.
16332823|NCT04449952|Experimental|AFEO-Containing Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive AFEO-containing mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 milliliter (mL) of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
16332824|NCT04449952|Experimental|Listerine Cool Mint Mouth Rinse (Marketed product)|Participants with Diabetes (Type 1 and 2) will be randomized to receive Listerine cool mint mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
16332825|NCT04449952|Experimental|5 Percent (%) Hydroalcohol Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
16332826|NCT04449939|Experimental|Group 1|Single dose of KY1005 by i.v. infusion
16332827|NCT04449939|Experimental|Group 2|Single lower dose KY1005 by s.c. injection
16332828|NCT04449939|Experimental|Group 3|Single higher dose KY1005 by s.c. injections
16332829|NCT04449926|Experimental|BCG Vaccinated|"Experimental: BCG Group FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area. A follow up booster dose will be given one month after the initial dose."
16332832|NCT04449900||The exudative CCH group|Treatment naïve patients with exudative CCH which caused subfoveal retinal detachment and/or intraretinal fluid
16332833|NCT04449900||The healthy eye control group|In the healthy eye control group, all eyes should have no ocular diseases and the best-corrected visual acuity (BCVA) should be 20/20 or better.
16332834|NCT04449887|Experimental|The treatment group|The subjects in this group were treated with Xiangsha Liujunzi granule for 4 weeks
16332835|NCT04449874|Experimental|Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)|"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.
~Participants with select solid tumors will be treated with GDC-6036 PO QD in Stage II."
16332836|NCT04449874|Experimental|Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.
16332837|NCT04449874|Experimental|Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)|Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.
16332838|NCT04449874|Experimental|Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)|Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.
16332839|NCT04449874|Experimental|Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.
16332840|NCT04449874|Experimental|Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.
~Participants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II."
16332841|NCT04449861|Experimental|Durvalumab plus 4-6 cycles chemotherapy|Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
16332842|NCT04449848|Experimental|Sitting after intra tympanic injection|Patients with Sudden hearing loss sitting after intra tympanic injection of steroids
16332843|NCT04449822|Active Comparator|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
16332844|NCT04449822|Active Comparator|Colonic stenting|The colonic stent placement
16332845|NCT04449809|Experimental|Exercise|Exercise program
16332846|NCT04449783||study patients|Patients undergoing elective cancer surgery, who will receive pre-operative screening including reporting symptoms and nose and throat swabbing 48 hours prior to surgery
16332847|NCT04449757|Experimental|bicarbonated ringer's solution|We apply bicarbonated ringer's solution as resuscitation fluid to patients with septic shock.
16332848|NCT04449757|Experimental|lactated ringer's solution|We apply lactated ringer's solution as resuscitation fluid to patients with septic shock.
16332849|NCT04449744|Active Comparator|MySafeRx Group A-(coaching + medication dispenser)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
16332850|NCT04449744|Experimental|MySafeRx Group B-(coaching + dispenser based on clinical need)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a manual lockbox, and a standardized protocol for supervising self-administration of medication via videoconferencing. Participants will be assessed bi-weekly by their clinical team for substance abuse, coaching and medication adherence, compliance with urine drug screen policies, safety/ risk or mental health concerns, and diversion. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study.
16332851|NCT04449731||Adult population (> 18 years old)|Around 30000 adults (> 18 years old) from 22 different countries.
16332852|NCT04449718|Experimental|Experimental|Patients will receive 200,000 IU of vitamin D3 on admission + conventional care
16332853|NCT04449718|Placebo Comparator|Placebo|Patients will receive an equivalent amount of a placebo solution on admission + conventional care
16332854|NCT04449692|Experimental|80 µg s.c. dasiglucagon|80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
16332855|NCT04449692|Experimental|120 µg s.c. dasiglucagon|120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
16332856|NCT04449692|Active Comparator|15 g oral carbohydrate (dextrose tablets)|15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l
16332857|NCT04449679|Experimental|Health Services Research (RT-CAMSS)|Patients receive RT-CAMSS over 2 months or until chemotherapy is discontinued, whichever is earlier. RT-CAMSS consists of text messages addressing knowledge about specific cancer type and chemotherapy, side-effect prevention, suggestions of lifestyle behavioral changes and emotional support, and preparation for surgery. Patients then record their symptoms through answering a series of questionnaires and receive tailored feedback according to their answers, including a consultation with a nurse.
16332858|NCT04449666||Experimental group|Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage
16332859|NCT04449666||Control group|Healthy adults controlled for age, gender and educational status
16332860|NCT04449653||Lupus Cases|Individuals who are diagnosed with System Lupus Erythematosus and consent to the study will be placed in this cohort. Upon enrollment they will be given the opportunity to invite a non-SLE-diagnosed friend to enroll in the study as a healthy control. These individuals will answer weekly questions and receive a smartwatch to measure their physical activity.
16332861|NCT04449640||Uterine rupture|Women who had uterine rupture during pregnancy.
16332862|NCT04449627||Naturalistic cohort|Patients who were hospitalised between March and June from Covid19, who did not require treatment in intensive care, who at 8 weeks post discharge have symptoms of anxiety or depression. All patients are offered access to an audio based self help programme based on applied relaxation and mindfulness based cognitive therapy.
16333023|NCT04448470||patients with a clinical suspicion of sleep apnea (n=150)|patients with a clinical suspicion of sleep apnea
16332863|NCT04449614||1|"Inclusion criteria: All consenting Infants and children who have had A Congenital Pulmonary Airway Malformation (CPAM) surgically removed by thoracoscopy over a 10 year period (2008-2017) in a regional centre.
~Exclusion criteria: Non consenting participants"
16332864|NCT04449601||Group 1 (with hypertension )|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
16332865|NCT04449601||Group 2( without hypertension)|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
16332866|NCT04449588|Experimental|Treatment group|
16332867|NCT04449588|Experimental|Control group|
16332868|NCT04449575||Health care workers with hand eczema|Swabs will be taken from eczema lesions on dominating hand (if possible) and nostril
16332869|NCT04449575||controls (health care workers without hand eczema)|swabs will be taken from healthy skin on dominating hand and nostril
16332870|NCT04449549|Experimental|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28- day cycles.
16332871|NCT04449536|Experimental|Mesna|Administration of a single oral dose of 400 mg, 800 mg, 1200 mg or 1600 mg
16332872|NCT04449510|Other|E-liquid pH 5, 7, or 9|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned e-liquid pH.
16332873|NCT04449510|Other|1 of the other 2 remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
16332874|NCT04449510|Other|Remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining assigned e-liquid pH.
16332875|NCT04449497||Bereaved caregivers|Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
16332876|NCT04449497||Country experts|Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
16332877|NCT04449484|Experimental|MEDI1341|3 doses given at 4 week intervals
16332878|NCT04449484|Placebo Comparator|Placebo|3 doses given at 4 week intervals
16332879|NCT04449471|Experimental|Naproxen Tablet|Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
16332880|NCT04449458|Experimental|Positively Me|Positively Me is a 12-session (8 [1.5] hour main sessions plus four booster sessions) intervention guided by Social Cognitive Theory to promote smoking cessation in people with certain health conditions.
16332881|NCT04449458|Sham Comparator|Positively Living|Positively Living is a modified updated version of a healthy living intervention based on Social Cognitive Theory that is designed for people with certain health conditions and attention-matched to the experimental condition (8 [1.5] hour main sessions plus four booster sessions).
16332882|NCT04449445|Other|Standard enteral tube feeds|Patients will be instructed to continue a normal diet before surgery. Post-operatively, patients will receive standard of care isocaloric and iso-nitrogenous standard enteral tube feeds
16332883|NCT04449445|Experimental|Nestle IMPACT AR|Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
16332884|NCT04449432|Experimental|GROWell (Interactive Obesity Treatment Approach)|With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
16332885|NCT04449432|Active Comparator|Attention Support Control|The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
16332886|NCT04449419||very severe COPD|Patients diagnosed with COPD and FEV1 less than 30
16332887|NCT04449419||Severe COPD|Patients diagnosed with COPD and FEV1 less than 50
16332888|NCT04449419||Moderate COPD|Patients diagnosed with COPD and FEV1 less than 80
16332889|NCT04449419||Mild COPD|Patients diagnosed with COPD and FEV1 80 or more.
16332890|NCT04449419||CONTROL|Non-copd control group
16332891|NCT04449419||Exacerbated Patients|Patients 48 hours after hospital admission for COPD exacerbation.
16332892|NCT04449406||Individuals at risk of developing PDAC|"Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study)
~Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry)
~Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available)."
16332893|NCT04449393|Experimental|Emdogain® FL|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
16332894|NCT04449393|Placebo Comparator|Control group|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation, followed by rinsing with saline.
16332895|NCT04449380|Experimental|IFNβ 1a|
16332896|NCT04449380|Active Comparator|Standard care|
16332897|NCT04449367||Randomized and Single-Arm Trials|a sham comparator (no intervention)
16332898|NCT04449354|Other|Quality of Life assessment|HidraWear AX Garment
16332899|NCT04449341|Experimental|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
16332900|NCT04449341|No Intervention|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
16332901|NCT04449328|Experimental|Patient with first stroke causing hemiplegic|"Patient with first stroke causing hemiplegic will be included.
~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:
~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))
~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
16332902|NCT04449328|Sham Comparator|healthy subjects|"Healthy subjects will be included.
~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:
~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))
~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
16332903|NCT04449315|Experimental|Peppermint and Lavender Essential Oil|Young Living Essential oil of Peppermint and Lavender will be used to patients who meet the inclusion criteria.
16332904|NCT04449302|Experimental|Immediate molar implant with customized healing abutment|Patients will receive an immediate mandibular molar implant with customized healing abutment
16332905|NCT04449302|Active Comparator|Immediate molar implant with submerged healing|Patients will receive an immediate mandibular molar implant with submerged healing
16332906|NCT04449289|Active Comparator|Intravenous lidocaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
16332907|NCT04449289|Active Comparator|Epidural ropivacaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
16332910|NCT04449263|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (test) the control Lens B for 2 weeks in this randomized, cross-over bilateral dispensing study.
16332911|NCT04449263|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) and Lens A (Test) for 2 weeks in this randomized, cross-over bilateral dispensing study.
16332912|NCT04449263|Active Comparator|Habitual Lenses|All subjects will wear their habitual lenses for two weeks prior to randomization of Test lens A and control lens B.
16332913|NCT04449250|Active Comparator|CTx-1301 Fasted|Subjects will receive CTx-1301 in a fasted state.
16332914|NCT04449250|Active Comparator|CTx-1301 Fed|Subjects will receive CTx-1301 in a fed state (high fat meal).
16332915|NCT04449237|Other|volunteer|40 volunteer will not accept any treatment
16332916|NCT04449237|Placebo Comparator|patients with unmodified music group|40 participants in this group will listen to music without any modification
16332917|NCT04449237|Experimental|patients with modified tinnitus relieving music|40 participants in this group will listen to the music modified according to the matched dominant tinnitus pitch
16332918|NCT04449224||RA patients who start bDMARD|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a biologic disease modifying antirheumatic drug (bDMARD) including Adalimuab, Etanercept, Tocilizumab or Abatacept after shared-decision making.
16332919|NCT04449224||RA patients who start small molecule inhibitor|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a small molecular inhibitor including Tofacitinib or Baricitinib after shared-decision making.
16332920|NCT04449211|Experimental|Participants with massive bone defect|"Adult participants with health insurance regardless of sex having bone defect greater than 5cm due to trauma or tumour resection agree to participate the research.
~The customised 3D-Printed implant is manufactured and undergoes post-processing treatment before being ready for implantation surgery."
16332921|NCT04449198|Experimental|Individuals with type 1 diabetes|Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
16332922|NCT04449198|No Intervention|Healthy Controls|Healthy individuals who participate will receive no intervention and serve as controls.
16332923|NCT04449185|Experimental|HP eradication group|"HP eradication group
~Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days"
16332924|NCT04449159|Placebo Comparator|Placebo|
16332925|NCT04449159|Experimental|Vinh Wellness Collagen|
16332926|NCT04449146|Experimental|shoulder localizer ultrasound|The localizer ultrasound of the shoulder is performed on an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer. The Protocol plans to acquire different landmarks on the scapula: lower angle, coracoid, scapula spine and bilateral acromioclavicular joint (definition of the coronal plan). These acquisitions are carried out by the probe connected to a Tablet (Microsoft surface Pro 3) which allows to locate the probe and by extension of the probe the location of the points selected by ultrasound.
16332927|NCT04449133|Experimental|Treatment Group 1|AD128 for 7 days, then, after a wash-out period of 7-10 days, placebo for 7 days
16332928|NCT04449133|Experimental|Treatment Group 2|Placebo for 7 days, then, after a wash-out period of 7-10 days, AD128 for 7 days
16333024|NCT04448470||healthy subjects (n=10)|healthy subjects
16333025|NCT04448457|Experimental|SSTS group|Patients received sufentanil nanotab patient controlled analgesia (PCA) system (Zalviso) 15 mcg with 20 min of lockout interval during 48 hours postoperatively
16332929|NCT04449120|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one-month. Three visits will be scheduled for participants assigned to this group:
~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
16332930|NCT04449120|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group received the written nutrition educational information as well as four online cooking classes (one cooking class per week) during the one-month intervention period. Three visits will be scheduled for participants assigned to this group:
~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected.
~Participants will attend 4 culinary workshops between visit 2 and 3. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
16332931|NCT04449107|Experimental|Intervention Arm|The intervention arm in addition to the standard counselling will include receiving text messages, voice messages, pictorial messages and video messages regarding vaccination once a week till the child turns 14 weeks
16332932|NCT04449107|No Intervention|Control Arm|The control group will receive one-time standard verbal counselling at the time of initial visit for on-time EPI vaccines at 10 and 14 weeks of age as recommended by EPI, government of Pakistan.
16332933|NCT04449068||Evaluation of patients with Tourette's Gilles Syndrome|Neurological and neuropsychological evaluations of patients with Tourette's Gilles syndrome treated with high frequency bilateral stimulation of the anterior part of the internal pallid globus
16332934|NCT04449055|Experimental|Study arm|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TBS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use.
16332939|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD|Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.
16332940|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
16332941|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
16332942|NCT04449029|Experimental|Cohort 1: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
16332943|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.
16332944|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
16332945|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
16332946|NCT04449029|Experimental|Cohort 2: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
16332947|NCT04449016|Experimental|Caucasian|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
16332948|NCT04449016|Experimental|Hispanic|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
16332949|NCT04449003||Adolescents with Tourette Syndrome|Adolescents (aged 13-17 years) with Tourette Syndrome
16332950|NCT04449003||Adolescents without any neurologic or psychiatric diagnoses|Adolescents (aged 13-17 years) without any neurologic or psychiatric diagnoses
16332951|NCT04448990|Experimental|tVNS|Stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) bilaterally at the cymba conchae of the auricles for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
16333026|NCT04448457|Active Comparator|Oxycodone group|Patients received oxycodone extended-release tablet (OxyContin) 10 mg every 12 hours systematically plus Oxycodone 5 mg every 6 hours if numeric rating scale is above 3 during the 48 hours postoperatively
16332952|NCT04448990|Sham Comparator|Sham|Same stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) to bilaterally to the earlobes for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
16332953|NCT04448977||Multiple Sclerosis group 1|Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
16332954|NCT04448977||Multiple Sclerosis group 2|Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
16332955|NCT04448977||Healthy Controls|Healthy individuals who are age, gender and education matched to the other groups.
16332956|NCT04448964|Experimental|Part 1: Treatment Sequence ABC|Participants will receive a single dose of JNJ-70033093 spray-dried dispersion (SDD) tablet under fasted conditions (Treatment A) in Treatment Period 1, followed by JNJ-70033093 SDD tablet in fed conditions (Treatment B) in Treatment Period 2, and then JNJ-70033093 SDD granule capsule under fasted conditions (Treatment C) in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332957|NCT04448964|Experimental|Part 1: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332958|NCT04448964|Experimental|Part 1: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332959|NCT04448964|Experimental|Part 1: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332960|NCT04448964|Experimental|Part 1: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment C in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332961|NCT04448964|Experimental|Part 1: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332962|NCT04448964|Experimental|Part 2: Treatment Sequence DE|Participants will receive Treatment D (single dose of JNJ-70033093 SDD tablet in fed conditions) in Treatment Period 1, and then Treatment E (single dose of JNJ-70033093 SDD granule capsule under fasted conditions) in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332963|NCT04448964|Experimental|Part 2: Treatment Sequence ED|Participants will receive Treatment E in Treatment Period 1, and then Treatment D in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
16332964|NCT04448951||sepsis/septic shock|target population
16332965|NCT04448951||non-septic critically ill|demographically-matched control group
16332966|NCT04448951||healthy control|control group
16332967|NCT04448938||optic neuritis|
16332968|NCT04448938||control|
16332969|NCT04448925|Experimental|Recovery duration 15 seconds|Resting for 15 sec
16332970|NCT04448925|Experimental|Recovery duration 30 seconds|Resting for 30 sec
16332971|NCT04448925|Experimental|Recovery duration 45 seconds|Resting for 45 sec
16332972|NCT04448912||Non-trauma damge control surgery|Patients with non-traumatic abdominal emergencies undergoing damage control surgery.
16332973|NCT04448912||Non-trauma conventional surgery|Patients with non-traumatic abdominal emergencies undergoing conventional surgery with primary abdominal closure.
16332974|NCT04448899|Active Comparator|Ivabradine|"Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.
~Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study."
16332975|NCT04448899|Placebo Comparator|Control|Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.
16332976|NCT04448886|Experimental|Sacituzumab Govitecan + Pembrolizumab|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits. Each Cycle =21 Days
~Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle
~Pembrolizumab (iv) fixed dose administered once per cycle"
16332977|NCT04448886|Experimental|Sacituzumab Govitecan|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.
~- Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle"
16332978|NCT04448886|Experimental|Retreatment|"Participants randomized to the combination arm (sacituzumab govitecan + pembrolizumab) may elect to stop pembrolizumab and/or sacituzumab govitecan with confirmed CR after at least 24 weeks of treatment. These participants would still be required to undergo regular disease restaging every 9-12 weeks.
~Participant who stop pembrolizumab and/or sacituzumab govitecan with CR may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment.
~This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets the following conditions"
16332979|NCT04448873|Active Comparator|Maintenance treatment group|After at least 2 years of remission of KHE, the participant receives sirolimus as usual. The serum concentration is supposed to be 5-7 ng/ml. If the effect or side effects of sirolimus require discontinuation, it is allowed to modify intervention, and if so, the patient stays in the maintenance group.
16333095|NCT04447989|Placebo Comparator|Cohort 2, placebo|Placebo (IV or enteral) every 8 hours for 28 days
16332980|NCT04448873|Experimental|Guided discontinuation group|"After at least 2 years of remission of KHE, the discontinuation measurement should be guided by the clinician with the following principles:
~10% monthly reduction of the previous dose at most.
~At least 5 half-lives between each reduction (2 weeks).
~Blood concentration should be monitored monthly. Adjustment can be suggested according to the linear relationship between the dose and the blood concentration.
~At least 6 months for the duration of guided discontinuation.
~Regular assessments and evaluations should be done.
~If the condition relapses or worsens during this process, dose of sirolimus should be adjusted to the previously effective dose. After a 3-month stabilization phase, 5% monthly reduction of the previous dose could be considered."
16332981|NCT04448860|Experimental|Retinitis Pigmentosa patients|Patients with Retinitis Pigmentosa (RP) at different stages of impairment of the visual field, acuity and sensitivity to contrasts 15 patients will be included in phase 1 versus 36 in phase 2 (15 in step 1 and 21 in step 2).
16332982|NCT04448860|Other|healthy volunteers patients|36 patients will be included just in phase 2 (15 in step 1 and 21 in step 2).
16332983|NCT04448847|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
16332984|NCT04448847|Experimental|Bif195 arm|Active trial product with minimum 100 billion CFU daily dose
16332986|NCT04448821|Experimental|Sequence A|Period 1: metformin; Period 2: metformin + nilotinib
16332987|NCT04448821|Experimental|Sequence B|Period 1: metformin + nilotinib; Period 2: metformin
16332988|NCT04448808|Experimental|BX-1 (dronabinol)|BX-1
16332989|NCT04448808|Placebo Comparator|Placebo|Placebo of BX-1
16332990|NCT04448769|Other|Anti-SARS-CoV-2 IgT seropositivity|Analysis of the serology result: The ELISA method allows semi-quantitative detection of total IgT antibodies. A positive sample will be defined by a ratio ≥ 1.0.
16332991|NCT04448756|Experimental|M5049 50 mg|
16332992|NCT04448756|Experimental|M5049 100 mg|
16332993|NCT04448756|Placebo Comparator|Placebo|
16332994|NCT04448743||Covid-19 patients|
16332995|NCT04448743||patients with coronary artery disease|
16332996|NCT04448743||healthy volunteers|
16332997|NCT04448730||Group 1 (normal weight with PCOS )|35 cases
16332998|NCT04448730||overweight PCOS|38 cases
16332999|NCT04448717||Children and adolescents|Children and adolescents in primary and secondary schools (aimed sample size: 2500)
16333000|NCT04448717||Parents|Parents of participating children (aimed sample size: 3000)
16333001|NCT04448717||School personnel|School personnel (teaching, administrative, maintenance, etc.) (aimed sample size: 2500)
16333002|NCT04448691|Other|CCTA|Suspected coronary disease patients enrolled in EVINCI trial with CCTA where recalled for follow up CCTA and blood sampling
16333003|NCT04448678|Experimental|HIEP intervention|Participants will be randomized to receive the insurance navigation intervention from patient navigators, which includes four, one hour long, educational learning sessions. Randomization will be done by age at diagnosis and site.
16333004|NCT04448678|Active Comparator|Usual Care|"Participants will be randomized to receive standard navigation provided by patient navigators (usual care)."
16333005|NCT04448665||patients with suspected infection|The hospitalized patients in whom, based on clinical signs and symptoms, an infection is suspected, and an administration of antimicrobial agents as empiric therapy is necessary.
16333006|NCT04448652||+NSAIDs|Patients undergoing elective colorectal cancer resection before april 1st 2016 were treated with paracetamol tablets 1000 mg and ibuprofen tablets 400 mg four times a day from the day of the operation and until discharge.
16333007|NCT04448652||-NSAIDs|Patients undergoing elective colorectal cancer resection from april 1st 2016 were only treated with paracetamol tablets 1000 mg four times a day from the day of the operation and until discharge.
16333008|NCT04448639||STEMI|Patients with ST-elevation myocardial Infarction (STEMI) (TS) who undergo urgent coronary angiography within 12 hours of symptom onset.
16333009|NCT04448639||TS|Patients with Takotsubo Syndrome (TS) who undergo urgent coronary angiography within 12 hours ofsymptom onset.
16333010|NCT04448626||Healthy subject|Healthy subject
16333011|NCT04448626||Stable COPD patients|Stable COPD patients
16333012|NCT04448626||Exacerbation COPD patients|Exacerbation COPD patients
16333013|NCT04448587|Experimental|Sitagliptin|
16333014|NCT04448561|Experimental|ASP8062 in combination with morphine|Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
16333015|NCT04448561|Placebo Comparator|Placebo in combination with morphine|Participants received ASP8062 matching placebo tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 matching placebo dose.
16333016|NCT04448535|Experimental|Gingko Biloba|oral intake of gingko biloba for 4 weeks
16333017|NCT04448522|Experimental|Reduced dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 63.6 Gy
16333018|NCT04448522|Active Comparator|Conventional dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 69.96 Gy
16333019|NCT04448509|Other|Healthy donor|Healthy donor
16333020|NCT04448496|Experimental|Arms|Diabetic macular edema Dexamethasone 0.7mg is injected into the vitreous cavity. Center-involved macular edema secondary to diabetic retinopathy for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
16333021|NCT04448483|Experimental|Group A|Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
16333022|NCT04448483|Experimental|Group B|Patients belonging to group B will follow an observation period (max. 3 months) before starting intervention I. We will recruit about 15 patients for group B (randomization will take into account the two to one study design) in order to have about 10 patients in Group B that will complete the study.
16333027|NCT04448444|Experimental|Motor Program Activating Therapy (MPAT)|The MPAT was chosen for our clinical experience - it was developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centred. Then somatosensory (manual and verbal) stimuli are applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when the patient is lying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to use the acquired motor skills automatically in daily life.
16333028|NCT04448444|Experimental|Vojta Reflex Locomotion (VRL)|VRL was developed by prof. Vojta and is standardly used in the Czech Republic. In this therapy, patients should be set up into the precisely given initial position with defined angular setting of extremities. In each position (supine, prone, lying on the side, and low kneeling position), activation points (zones) are stimulated with precise localization and pressure direction. Such stimulation activates one of the global movement patterns (reflex turning and reflex creeping) corresponding to the initial position. In addition to motor involuntarily reaction, also sensory and autonomic response is activated.
16333029|NCT04448444|No Intervention|healthy controls|sex and age matched healthy controls
16333030|NCT04448431|Experimental|Vortioxetine|8 weeks treatment
16333031|NCT04448431|Active Comparator|Desvenlafaxine|8 weeks treatment
16333032|NCT04448405||Patients followed by the CRIAVS|Patients followed by the CRIAVS (resource center for workers working with authors of sexual violence) in CHU Motpellier from June to October 2020
16333033|NCT04448392|Other|Neonatal HSV disease requiring suppressive therapy|All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.
16333034|NCT04448379|Experimental|Dose Escalation Cohort|"Two dose levels of JMT101 combined with afatinib or osimertinib will be tested according to the 3 + 3 dose-escalation design.
~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
16333035|NCT04448379|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
16333036|NCT04448366|Experimental|Cognitive behavioral therapy group|Patients in this group will undergo a total of 7 sessions of CBT in 5 months in addition to usual care.
16333037|NCT04448366|No Intervention|Usual care|Patients in this group will undergo usual care only.
16333038|NCT04448353||Development / training|Selected by stratified partitioning
16333039|NCT04448353||Sequestered / test|Selected by stratified partitioning
16333040|NCT04448340||Parkinson Disease Dementia|the PDD group comprised of 58 patients fulfilling the Criteria for probable PDD of the Movement Disorders Society
16333041|NCT04448340||Dementia with Lewy Bodies|the DLB group comprised of 40 patients, according to the recent revised criteria for probable DLB
16333042|NCT04448327|Experimental|Active tVNS|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
16333043|NCT04448327|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
16333045|NCT04448288|Experimental|Hamstring Group|Pretest-posttest experimental design. Subjects participated in three experimental trials on three different days. On day-I for static-stretching for 2 minutes (SS2), day-II for 4 minutes (SS4), and day-III for 8 minutes (SS8). Testing was conducted before (pre), immediately after (post), and at 10 and 20 min post stretching. MVCF was measured using strain gauze as main outcome measure. The SS trials involved varied repetitions of 30-s static-stretches and 20-s relax period. MVC force was assessed.
16333046|NCT04448275|Experimental|study group|received conventional selected exercise program and in addition to Neurodynamics Nerve flossing for femoral nerve
16333047|NCT04448275|Experimental|control group|received conventional selected exercise program in form of: Ultrasound therapy The flexibility exercises for iliopsoas & quadriceps in heamophilic patient The iliopsoas & quadriceps muscles strength exercise
16333048|NCT04448262||G1 Asthma|Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
16333049|NCT04448262||G2 Diabetes|Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
16333050|NCT04448262||G3 Asthma plus diabetes|Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
16333051|NCT04448249|Experimental|Interventional group|After inclusion, eligible patients are randomly assigned to one of the following groups: the control group of patients keeps a traditional follow-up (AH then consultation with a MD within approximately two to six months) and the interventional group meets an APN between the AH and the MD consultation, within one to three months
16333052|NCT04448249|No Intervention|Control group|After inclusion, eligible patients are randomly assigned to one of the following groups: the control group of patients keeps a traditional follow-up (AH then consultation with a MD within approximately two to six months) and the interventional group meets an APN between the AH and the MD consultation, within one to three months
16333053|NCT04448236|Experimental|BFR-RE intervention group|"The participants will have the standardised 2 week resistance training with BFR-device with details as follows:
~Cuff size: medium
~Restriction time: 5- 10 mins (stop after finishing 4 sets of training or terminating by Physiotherapists)
~Applied location: alternate quadriceps in consecutive day
~Applied pressure: 80% limb occlusion pressure (LOP)"
16333054|NCT04448236|No Intervention|Control group|"Same standardized 2-week in-patient rehabilitation and same amount of the above-mentioned resistance training without the BFR device."
16333055|NCT04448223|Experimental|CKD-351|CKD-351
16333056|NCT04448223|Active Comparator|Latanoprost+Dorzolamide|Latanoprost(50ul/ml) Dorzolmamide(20mg/ml)
16333057|NCT04448210|Experimental|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
16333096|NCT04447989|Active Comparator|Cohort 3, sildenafil|Sildenafil (2 mg/kg IV or 4 mg/kg enteral) every 8 hours for 28 days
16333058|NCT04448210|No Intervention|Wait-list control|The wait-list control group did not receive the intervention between the pre-test and post-test assessments. After completing the post-test questionnaire, youth in the wait-list control group had the option to receive access to the intervention (DigiKnowIt News).
16333059|NCT04448184|No Intervention|Prophylactic Platelet Transfusion|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
16333060|NCT04448184|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.
16333061|NCT04448171|Active Comparator|Activated TENS Unit with standard pain control measures|Activated TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
16333062|NCT04448171|Placebo Comparator|Sham TENS Unit with standard pain control measures|Sham TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
16333063|NCT04448158||5 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 5 years
16333064|NCT04448158||10 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 10 years
16333065|NCT04448145||COVID-19 Positive|Participants who have been diagnosed with COVID-19 or experienced symptoms of COVID-19.
16333066|NCT04448145||COVID-19 Negative|Participants who have never tested positive for COVID-19.
16333067|NCT04448132|Experimental|IPV-Al AJV|One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.
16333068|NCT04448119|Experimental|Chemoprophylaxis|Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
16333069|NCT04448119|Placebo Comparator|Placebo|Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.
16333070|NCT04448106|Experimental|Phase 2 Arm 1 - OA Knee|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.
~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
16333071|NCT04448106|Active Comparator|Phase 2 Arm 2 OA Knee|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
16333072|NCT04448106|Experimental|Phase 2 Arm 3 - OA Hip|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.
~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
16333073|NCT04448106|Active Comparator|Phase 2 Arm 4 - OA Hip|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
16333074|NCT04448106|Experimental|Phase 2 Arm 5 - OA Shoulder|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.
~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
16333075|NCT04448106|Active Comparator|Phase 2 Arm 6 - OA Shoulder|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
16333076|NCT04448093|Experimental|Treatment group|Treated group (53) that answered quality of life questionnaires before, after and with 45 days of treatment.
16333077|NCT04448093|No Intervention|Group control|Untreated group (68) that answered quality of life questionnaires before, after and with 45 days of treatment.
16333078|NCT04448080|Experimental|Topical Anesthesia|topical tetracaine eye drops (3 times, given in 1 minute intervals) followed by topical Xylocaine 2% Gel (alcohol-free formulation), given in 1 minute intervals for a total of 5 minutes
16333079|NCT04448080|Active Comparator|Analgosedation|Remifentanil 1mg i.v., and, Thiopental i.v., adapted to patients' weight, age, and hepatic and renal function; usually, a bolus of 150-250mg
16333080|NCT04448067|Experimental|LOW Lentil Intake|Consumption of meals containing 60 g of lentils 5 out of 7 days per week for 8 weeks.
16333081|NCT04448067|Experimental|HIGH Lentil Intake|Consumption of meals containing 120 g of lentils 5 out of 7 days per week for 8 weeks
16333082|NCT04448067|Sham Comparator|CONTROL|Consumption of meals matched in total energy and protein to the lentil meals but containing 0 g of lentils 5 out 7 days per week for 8 weeks
16333083|NCT04448041||Ghana|
16333084|NCT04448041||India|
16333085|NCT04448041||Philippines|
16333086|NCT04448041||Zambia|
16333087|NCT04448028|Placebo Comparator|Intervention group|Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esomeprazole 20mg on day 2, 4, 6, 8, 11, 14, to minimize the risk for gastric acid rebound symptoms.
16333088|NCT04448028|Active Comparator|Control group|Patients randomized to the control group continue their pre-existing PPI therapy with esomeprazole 20mg/day (day 15 to 360). During the first 14 days (dose tapering phase) patients in the control group receive esomeprazole 20mg/day on day 1 to 14.
16333089|NCT04448015|Experimental|Enhanced Perinatal Care|Pregnant women enrolled in the study will receive enhanced perinatal care from community healthcare providers that have participated in the perinatal OUD education curriculum.
16333090|NCT04448002|Experimental|AIM2ACT|AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.
16333091|NCT04448002|Active Comparator|mHealth Attention Control Condition|The mHealth attention control condition is the active comparator arm in the trial that accounts for staff attention and novelty of technology based asthma management intervention.
16333092|NCT04447989|Active Comparator|Cohort 1, sildenafil|Sildenafil (0.5 mg/kg IV or 1 mg/kg enteral) every 8 hours for 28 days
16333093|NCT04447989|Placebo Comparator|Cohort 1, placebo|Placebo (IV or enteral) every 8 hours for 28 days
16333094|NCT04447989|Active Comparator|Cohort 2, sildenafil|Sildenafil (1 mg/kg IV or 2 mg/kg enteral) every 8 hours for 28 days
16333098|NCT04447976||Patients undergoing ERCP by formally trained Endoscopists|No intervention has been used and this is an observational study of evaluation of a TIP duodenoscope performance overall.
16333099|NCT04447963|Experimental|Non-invasive treatment of wrinkles and rhytids|"The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete three (3) treatment visits and two follow-up visits.
~At the baseline visit health status will be assessed and, if needed, additional tests will be performed. Inclusion and exclusion criteria will be verified and informed consent will be signed.
~The treatment administration phase consists of three (3) treatment visits, delivered 1 week apart.
~At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device."
16333100|NCT04447950|Experimental|Study group|Posterior QL block with 20-40 cc of Bupivocaine in posterior border of Quadratum Lumborum muscle at the end of the operation.
16333101|NCT04447950|Placebo Comparator|Placebo group|Posterior QL block with 40 cc of Saline in posterior border of Quadratum Lumborum muscle at the end of the operation.
16333102|NCT04447937||Multiple Sclerosis and Related Diseases|Individuals with one or more immunoglobulin level results and medical histories available for data collection will be included. Subjects will be 18 years of age or older at the time of data collection.
16333103|NCT04447924|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
16333104|NCT04447924|Experimental|Bif195 arm|Active trial product with minimum 15 billion CFU daily dose
16333105|NCT04447911|Experimental|Empagliflozin|Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
16333106|NCT04447911|Placebo Comparator|Placebo|Placebo (Lactose tablet) per os once daily for 30 days
16333107|NCT04447898|Experimental|Low dose|10 μg + Montanide™ ISA 51 VG
16333108|NCT04447898|Experimental|High dose|50 μg + Montanide™ ISA 51 VG
16333109|NCT04447885|Experimental|Experimental blanket|This blanket is the weight being tested which cannot be disclosed without unblinding participants.
16333110|NCT04447885|Active Comparator|Control blanket|This blanket is the control weight which cannot be disclosed without unblinding participants.
16333111|NCT04447872|Active Comparator|Luteal phase ovarian stimulation (LPOS)|Patients will present in the luteal phase, and will begin 150 IU hMG and 300 IU recombinant FSH daily, as well as oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH can then be titrated per patient response. Gonadotropin releasing hormone antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started per criteria. Once patients are ready for ovulation trigger, 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU), will be administered. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
16333112|NCT04447872|Active Comparator|Luteal estradiol priming protocol|In the luteal phase, the patient will begin Estradiol patches 0.1mg QOD. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for three days. With menses, she will begin 150 IU hMG, 300 IU recombinant FSH daily, and oral Clomiphene citrate 100mg qd (for five days). FSH can be titrated per patient response. GnRH antagonist will be started per criteria. 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU) will be administered for ovulation trigger. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
16333113|NCT04447859|Active Comparator|label recommended titration|eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy)
16333114|NCT04447859|Experimental|Slow semaglutide titration|A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached)
16333115|NCT04447846|Experimental|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
16333116|NCT04447833|Experimental|Mesenchymal Stromal Stem Cell Treatment|Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg.
16333117|NCT04447820|Experimental|K-877-ER Dose A|K-877-ER dose A administered once daily
16333118|NCT04447820|Experimental|K-877-ER Dose B|K-877-ER dose B administered once daily
16333119|NCT04447820|Experimental|K-877-IR|K-877-IR administered twice daily.
16333120|NCT04447807|Experimental|Group A: Metacognitive Training Intervention|"Participants of this group will under go Metacognitive Training (MCT) in group format for the duration of 8 weeks. The intervention will be helf once a week, with an estimate duration of 1-2 hours. The MCT intervention focuses on rehabilitating Social Cognition and teaching skills of inter-personal relations, as well as functional remediation aspects.
~We estimate a total of 45 participants in this group."
16333121|NCT04447807|Experimental|Group B: Treatment as Usual|Participants of this group will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School, although they will not be part taking in any group rehabilitation format We estimate a total of 45 participants in this group.
16333122|NCT04447794|Active Comparator|Step Away App|Participants randomly assigned to this arm will access the Step Away smartphone-based mobile application immediately upon enrollment.
16333123|NCT04447794|Experimental|Step Away Chatbot|Participants randomly assigned to this arm will access the Step Away mobile, text-based, interactive AI chatbot immediately upon enrollment.
16333124|NCT04447794|No Intervention|Step Away App Delay|Participants randomly assigned to this arm will be provided access to the Step Away smartphone-based mobile application three months after enrollment.
16333125|NCT04447781|Experimental|Group 1 (Part A)|"Number of Subjects: 20 subjects
~ID Injection of INO-4800 1mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
16333126|NCT04447781|Experimental|Group 2 (Part A)|"Number of Subjects: 20 subjects
~ID Injection of INO-4800 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
16333127|NCT04447781|Experimental|Group 3 (Part B)|"Number of Subjects: 90 subjects
~ID Injection of INO-4800 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
16333128|NCT04447781|Placebo Comparator|Group 4 (Part B, Placebo)|"Number of Subjects: 30 subjects
~ID Injection of Placebo (SSC) 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
16333129|NCT04447768|Experimental|Venetoclax and Obinutuzumab|All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
16333130|NCT04447755|Experimental|Lenvatinib|Participants receive lenvatinib 14 mg/m^2 once daily (QD) orally until progressive disease or unacceptable toxicity (up to approximately 1 year).
16333131|NCT04447729|Experimental|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
16333132|NCT04447716|Experimental|Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)|Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16333133|NCT04447703|Experimental|Aim I (Interview)|Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinical for 2 weeks. After 2 weeks, provides discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
16333134|NCT04447703|Active Comparator|Aim II: Arm I (Genetic Counseling, Genetic Testing)|Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
16333135|NCT04447703|Experimental|Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)|Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
16333136|NCT04447664|Experimental|Telemedicine arm|
16333137|NCT04447664|No Intervention|Control arm|
16333139|NCT04447625|Active Comparator|CE patients receiving OAA|Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
16333140|NCT04447625|Experimental|CE patients receiving OAA and IAI|Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
16333141|NCT04447612|Experimental|Durvalumab arm|"Induction phase: Durvalumab 1500mg via intravenous infusion every 4 weeks, with chemotherapy gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.
~Concurrent phase: Durvalumab 1500mg via intravenous infusion every 4 weeks for 2 cycles, with cisplatin 100mg/m2 via intravenous infusion every 3 weeks for 3 cycles.
~Maintenance phase: Durvalumab 1500mg daily via intravenous infusion every 4 weeks for 8 cycles."
16333142|NCT04447612|Active Comparator|Standard of care arm|"Induction phase: Chemotherapy with gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.
~Concurrent phase: Cisplatin 100mg/m2 on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles."
16333143|NCT04447599|Experimental|Photographs|Photographs
16333144|NCT04447586|Active Comparator|Patients following Command A and B|This group of patients followed the Commands A and B with this specific order, and performed 3 exhalation attempts for each command.
16333145|NCT04447586|Active Comparator|Patients following Command B and A|This group of patients followed the Commands B and A with this specific order, and performed 3 exhalation attempts for each command.
16333146|NCT04447586|Active Comparator|intervention group|"Intervention group was requested to exhale as indicated by the right command, performing 3 sets of 10 repetitions."
16333147|NCT04447586|No Intervention|control group|"Did not perform exhalation attempts by the right command."
16333148|NCT04447573|Experimental|BCMA CAR-T cells|Patients will be treated with BCMA CAR-T cells
16333149|NCT04447560|Experimental|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol before and after the plane block and two researchers will measure the radius and area of those vessels separately.
16333150|NCT04447547|Experimental|SL1904B CAR-T|Patients will be treated with CD19 CAR-T cells
16333151|NCT04447534|Experimental|Chloroquine|Chloroquine alone
16333152|NCT04447534|Experimental|Chloroquine with zinc|Chloroquine with zinc
16333153|NCT04447508|Experimental|Exercise class and motivational interviewing|Patients receiving the intervention will be enrolled in an online instructor led group exercise class and five online one on one motivational interviewing sessions.
16333154|NCT04447508|No Intervention|Usual care|Participants in the control group will receive an exercise booklet and educated on the benefits of exercise for low back pain. They will be advised to exercise for the duration of the study
16333155|NCT04447495||SARS-CoV-2 positive|We will enroll patients within a larger clinical validation study of the iAMP® test against the gold standard (the CDC-recommended test) until we have prospectively collected a total of 100 positive cases.
16333156|NCT04447495||Controls|Current SARS-CoV-2 positivity in the region is approximately 20%, therefore, approximately 400 negative control samples will be needed.
16333157|NCT04447482|Experimental|Treatment Group|4D electromagnetic navigation bronchoscopy (4D-ENB) for lung biopsy. Guidance based on tip tracked surgical tools and images calculated from CT.
16333158|NCT04447482|Active Comparator|Control Group|Bronchoscopic lung biopsy taken while using X-ray fluoroscopy.
16334174|NCT04440826|Experimental|Processed Food Meal|Highly processed foods - grilled cheese and drink meal
16333161|NCT04447469|Placebo Comparator|Placebo (Cohort 1)|Non-mechanically ventilated participants administered placebo as a single IV infusion
16333162|NCT04447469|Active Comparator|10 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
16333163|NCT04447469|Active Comparator|6 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
16333164|NCT04447469|Placebo Comparator|Placebo (Cohort 2)|Mechanically ventilated participants administered placebo as a single IV infusion
16333165|NCT04447456||Surgery|
16333166|NCT04447456||Radiotherapy|
16333167|NCT04447443|Experimental|Prebiotic Fiber|
16333168|NCT04447443|Placebo Comparator|Maltodextrin|
16333169|NCT04447430|Experimental|bright light group|treat patients with bright light (10000 lux)
16333170|NCT04447430|Placebo Comparator|dim red light group|treat patients with dim red light (100 lux)
16333171|NCT04447417|Experimental|Dupilumab|Double dose on Day 1 and followed by single dose every 14 ±2 or 3 days through week 14. - Type: Experimental
16333172|NCT04447417|No Intervention|Healthy volunteers|Healthy volunteers are matched by age, gender, body location and study site to AD patients. They will receive no treatment with dupilumab but will be monitored in the same way as atopic dermatitis patients during the study.
16333173|NCT04447404|Experimental|DUR-928|
16333174|NCT04447404|Placebo Comparator|Placebo|
16333175|NCT04447391|Experimental|Exercise group|Exercise group who performed a combined exercise and 300 kcal/day deficit diet during 12 weeks.
16333176|NCT04447391|Placebo Comparator|Control group|Control group who performed 300 kcal/day deficit diet during 12 weeks.
16333177|NCT04447378|Experimental|Fondaparinux|Subcutaneous injection of fondaparinux 2.5 mg once daily would be given over 10 days for post partum thromboprophylaxis
16333178|NCT04447365||control|10 patients who have had no device-monitored for ventricular tachycardia/ ventricular fibrillation the 3 months prior to recruitment will comprise a group of controls
16333179|NCT04447365||high burden of ventricular arrhythmias|. 20 patients will comprise a group of patients with high burden of ventricular arrhythmias, defined as patients with at least one sustained episode of VT/VF requiring ICD therapies in the 3 months preceding study enrollment.
16333180|NCT04447352|Active Comparator|Arm A - FLOT|"Patients randomized to treatment Arm A already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
16333181|NCT04447352|Experimental|Arm B - FLOT/HIPEC|"Patients randomized to treatment Arm B already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery including Intraoperative Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) during gastric-/ esophagogastric resection using Cisplatin 75mg/m². Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
16333182|NCT04447339||Open|Prophylactic NSM cases by Open approach
16333183|NCT04447326|Experimental|IC＋CCRT＋Toripalimab＋Endostar|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.
16333184|NCT04447326|Active Comparator|IC＋CCRT|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w.
16333185|NCT04447313|Experimental|Arm I (ACT)|Participants receive ACT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
16333186|NCT04447313|Active Comparator|Arm II (SBT)|Participants receive SBT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
16333187|NCT04447300|Active Comparator|Standard power application|
16333188|NCT04447300|Active Comparator|High power application|
16333189|NCT04447287|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants will receive multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. Titration may be extended based on a participants tolerability; however, participants must be on a stable dose of buprenorphine/naloxone by day 5. Participants will be on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants will receive a single oral dose of ASP8062 concomitantly with buprenorphine/naloxone and undergo repeat intensive safety assessment on day 12 with continued safety and pharmacokinetic assessments up to day 23. The stable dose of buprenorphine/naloxone will be down titrated from days 19 through 26.
16333190|NCT04447287|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. Titration may be extended based on a participants tolerability; however, participants must be on a stable dose of buprenorphine/naloxone by day 5. Participants will be on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants will receive a single oral dose of placebo ASP8062 concomitantly with buprenorphine/naloxone and undergo repeat intensive safety assessment on day 12 with continued safety and pharmacokinetic assessments up to day 23. The stable dose of buprenorphine/naloxone will be down titrated from days 19 through 26.
16333191|NCT04447274|Experimental|Camrelizumab and Apatinib|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16333192|NCT04447261|Experimental|BI 1356225|
16333193|NCT04447261|Placebo Comparator|Placebo|
16333194|NCT04447235|Placebo Comparator|ARM A: Placebo|Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
16333195|NCT04447235|Experimental|ARM B: Ivermectin plus losartan|Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
16333196|NCT04447222||Observational (survey)|Participants complete a survey online over 35-45 minutes about their experiences regarding the COVID-19 pandemic.
16333197|NCT04447209||Child Health Clinic (CHC)|"Children attending CHC for routine vaccinations and follow-up in a tertiary center Parents will be counselled on food groups based on Infant and Young Children feeding practices.
~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.
~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
16333198|NCT04447209||Community Children|"Children of urban poor families living in low-cost flats around Kuala Lumpur. Parents will be counselled on food groups based on Infant and Young Children feeding practices.
~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.
~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
16333199|NCT04447196||CCHS|20 patients presenting with central hypoventilation syndrome during spontaneous breathing and with Non Invasive Ventilation
16333200|NCT04447183|Experimental|Test group|The test group of patients who took thyroid hormone medicine and were euthyroid [i.e. their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
16333201|NCT04447183|Experimental|Control group|The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e. their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
16333202|NCT04447170||Laparoscopic repair|Patients undergoing laparoscopic treatment
16333203|NCT04447170||Open repair|Patients undergoing open treatment
16333204|NCT04447157||Microspherophakia|This is a non-interventional study(NIS). All the patients diagnosed as microspherophakia are included in the study and recieved intraocular lens implantation
16333205|NCT04447144||COVID-19 mild severity|"Definition of mild cases according to MOH:
~Age < 60
~Temperature <38.5
~arterial oxygen saturation (SaO2) >92%
~Heart Rate <110
~Respiratory Rate <25 /min.
~Neutrophil / lymphocyte ratio on complete blood count (CBC) < 3.1
~No co-morbidities that necessitates hospital admission: Pregnancy, severe uncontrolled Diabetes, Chronic lung disease, Chronic kidney disease, Chronic liver disease, Serious heart diseases (arrythmia, Ischemic heart disease, uncontrolled hypertension), immunocompromised: prolonged use of corticosteroids and other immunosuppressive drugs/ organ transplantation/ HIV/ Immunodeficiency, Obesity (BMI > 40)"
16333206|NCT04447144||COVID-19 moderate severity|Any patient not fulfilling the above mild criteria is considered having moderate disease as well as any positive pulmonary imaging findings
16333207|NCT04447131||COVID-19|Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
16333208|NCT04447131||Healthy Individuals|Asymptomatic and with negative SARS-CoV-2 serology
16333209|NCT04447131||Influenza|Positive for influenza vírus. Negative for SARS-CoV-2.
16333210|NCT04447131||Respiratory symptoms but negative for influenza or COVID-19|Negative for influenza vírus. Negative for SARS-CoV-2. But with respiratory symptoms
16333213|NCT04447105|Experimental|TIVA group|Patients receiving total intravenous anesthesia with propofol.
16333214|NCT04447105|Active Comparator|Desflurane group|Patients receiving inhalation anesthesia with desflurane.
16333215|NCT04447092|Experimental|Gemcitabine/Nab-paclitaxel|Gemcitabine/Nab-paclitaxel + pembrolizumab
16333216|NCT04447092|Experimental|FOLFIRINOX|FOLFIRINOX + pembrolizumab
16333217|NCT04447079||'Before' and 'After' Arm|"Before Arm - This refers to the rate of Emergency Department visits in the pre-intervention period (12 months).
~After Arm - This refers to the rate of Emergency Department visits in the post-intervention period (12 months) following the START of intervention."
16333218|NCT04447066||Patients hospitalized at the rehabilitation department|
16333219|NCT04447053|Experimental|Belimumab + SOC|Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.
16333220|NCT04447053|No Intervention|SOC only|Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.
16333221|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
16333222|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
16333223|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
16333224|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
16333225|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
16333226|NCT04447040|Placebo Comparator|Placebo|Placebo tablets administered as a single two-tablet dose.
16333227|NCT04447027|Experimental|1- Experimental Treatment: Dose Escalation|Lenalidomide by oral intake at escalating doses of 5, 10, 15, or 20 mg/day on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle, to determine MTD
16333228|NCT04447027|Experimental|2 - Experimental Treatment: Dose Expansion|Lenalidomide by oral intake at MTD on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle
16333229|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
16333230|NCT04447001|Experimental|Tai Chi Prime (TCP)-session 1|This arm will receive Tai chi prime as an intervention. TCP is a combination of two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
16333231|NCT04447001|No Intervention|Wait list control-session 2|Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time. At week 7, pre-test measures from wait-list group will be used as a control and compared with the post intervention measures of the experimental group.
16333232|NCT04446988|Experimental|Ultrasound(US)|Sacroiliac joint injection using ultrasound
16333233|NCT04446988|Experimental|Fluoroscopy(FL)|Sacroiliac joint injection using fluoroscopy
16333234|NCT04446975|No Intervention|BPA Off|No BPA message is displayed to providers.
16333235|NCT04446975|Experimental|BPA On|BPA message is displayed to providers based on patient opioid intake as reported in the EHR.
16333236|NCT04446962|Active Comparator|Arm A: R-MPV with Lenalidomide|Lenalidomide in association with R-MPV as a targeted induction treatment
16333237|NCT04446962|Active Comparator|Arm B: R-MPV with Ibrutinib|Ibrutinib in association with R-MPV as a targeted induction treatment
16333238|NCT04446949||Undocumented migrants|
16333239|NCT04446949||Immigrants with Norwegian ID|
16333240|NCT04446949||Norwegian residents|
16333241|NCT04446936||Propeller flaps|Patients who undergone propeller flap surgery
16333242|NCT04446936||Random flaps|Patients who undergone random flap surgery
16333243|NCT04446923|Experimental|Hand antisepsis by scrub|Hand antisepsis by scrub using propan-ol-1 60%
16333244|NCT04446923|Active Comparator|Hand antisepsis by rub|Hand antisepsis by rub using propan-ol-1 60%
16333245|NCT04446910|Experimental|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to encourage attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
16333246|NCT04446910|Active Comparator|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
16333247|NCT04446897|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
16333248|NCT04446897|Active Comparator|standard treatment|standard treatment according to clinical protocols
16333249|NCT04446884|Experimental|mesenchymal stem cells|Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
16333250|NCT04446884|Active Comparator|control|Patients with Stress urinary incontinence receiving standard treatment
16333251|NCT04446871|Placebo Comparator|Standard care|Placebo
16333252|NCT04446871|Experimental|Methylene blue|Methylene blue
16333253|NCT04446858||With TIPS|Prospective cohort that received TIPS
16333254|NCT04446858||Without TIPS|Prospective cohort that did not receive TIPS
16333255|NCT04446845|Experimental|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|"A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.
~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.
~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)"
16333256|NCT04446845|Active Comparator|Conventional Stimulation (Elonva+rFSH) in follicular phase|A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
16333257|NCT04446832||Liver transplantation candidates|
16333258|NCT04446819|Other|Cohort|Patients diagnosed with solid tumors who are about to received albumin-binding paclitaxel monotherapy are recruited. Dominant hands and non-dominant hands are treated with small-size compression gloves and suitable-size compression gloves, respectively, during the administration of albumin-binding paclitaxel.
16333259|NCT04446780||Women who underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery with mediolateral episiotomy
16333260|NCT04446780||Women who did not underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery without mediolateral episiotomy
16333261|NCT04446767|Experimental|Bioptron light therapy and medical care|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks plus medical care in the form of Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
16333262|NCT04446767|Active Comparator|medical care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
16333263|NCT04446741||Acute Myeloid Leukemia (AML)|Newly diagnosed or relapsed/resistant AML
16333264|NCT04446728|Active Comparator|Strategy I.Training|Sites randomized to Strategy I will receive a three hour training webinar in preparing for implementation of the PAT in their center.
16333265|NCT04446728|Active Comparator|Strategy II.Training+Implementation Enhanced Resources (TIER)|Sites randomized to Strategy II will identify a Champion for screening and will participate in a monthly consultation call in addition to completing the three hour training webinar for implementing the PAT in their center.
16333266|NCT04446715|Experimental|Sufentanil Group|Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia
16333267|NCT04446715|Experimental|Meperidine Group|Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia
16333290|NCT04446559|No Intervention|Semi-recumbent in bed position|The patient will benefit from conventional positioning techniques in the ICU bed. With the help of the medical monitoring software present in the wards, we will note the different nursing care given to the patient during the 3 hours following the morning arterial gasometry.
16333291|NCT04446546||Cold Stored Allograft Vascular Access|
16333268|NCT04446689|Active Comparator|Biofeedback|The intervention group will develop an activity with self-monitoring called Cardiovascular Biofeedback or Cardiac Frequency Variability (CFV). This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph. This photoplethysmograph verifies blood flow alterations through an optical method. Cardiac frequency oscillations may be estimated both by the quantity of blood infrared lights absorbed or reflected, and by variations in blood volume and pressure. Captured physiological signs will be recorded during ten minutes by the Software Emwave Pro Plus®, which is adapted to biofeedback training.
16333269|NCT04446689|No Intervention|activity without self monitoring|"The placebo group will develop an activity without self monitoring. In order to keep blindness between the groups the activities will be processed by an electronic device - the on line app Jigsaw Puzzles. This app consists of a puzzle with different levels of difficulties, and is played in a tablet.
~Each participant will be performing in the study during four weeks, with two encounters each week (total: four weeks). While the participant will be performing its activity he/she will be monitored by the researchers through CFV (Cardiac Frequency Variability) - with no visualization of the computer monitor.
~The control group will answer the research protocol in two moments (D1 and D8), to evaluate"
16333270|NCT04446676|Active Comparator|Stem stabilization|Group of patients with stem endoprosthesis stabilization
16333271|NCT04446676|Active Comparator|Sleeve stabilization|Group of patients with sleeve endoprosthesis stabilization
16333272|NCT04446663|Experimental|Toripalimab+induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.
~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT .
~Toripalimab 240mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy"
16333273|NCT04446663|Active Comparator|induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.
~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT ."
16333274|NCT04446650|Experimental|Fedratinib Administration|The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.
16333275|NCT04446637|Experimental|Ipratropium/Levosalbutamol|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
16333276|NCT04446637|Active Comparator|Salbutamol + Ipratropium|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
16333277|NCT04446624|No Intervention|Treatment as usual (TAU)|Patients in the TAU group will receive the treatment routinely offered to patients undergoing RT for breast cancer.
16333278|NCT04446624|Experimental|Music therapy intervention (PSY)|Patients in the PSY group will participate to a short-term group psychotherapy with elements of music therapy; meetings will be 1 / week, for a total of 6 weeks. Beginning of psychotherapy intervention will be 1-2 weeks after recruitment at T0 and will therefore cover the entire duration of the RT cycle.
16333279|NCT04446611|Experimental|Test at 1st ANC + Test-of-Cure (Treatment 1)|Single point-in-time diagnostic screening plus test-of-cure three weeks post-treatment
16333280|NCT04446611|Experimental|Test at 1st ANC + 30-34 gestation (Treatment 2)|Repeated diagnostic screening at first antenatal care and 30-34 weeks gestation
16333281|NCT04446611|No Intervention|Syndromic Management (Control)|Syndromic management (standard of care) at every antenatal care visit per South African National Guidelines.
16333282|NCT04446598|Experimental|Laser group|In the laser group, the patients received two sessions of Er:YAG intraurethral laser in non-ablative SMOOTH™ mode, with 1 month interval between sessions.
16333283|NCT04446598|Active Comparator|Tadalafil group|The tadalafil group was treated with daily oral administration of tadalafil, at a dose of 5 mg/day, which lasted consecutively for two months.
16333284|NCT04446585|No Intervention|Control sites|"For all 1-1-2 calls with suspected cardiac arrest to the emergency dispatch center will activate a two-tiered response consisting of dispatch of an ambulance with an emergency medical technician, a physician-staffed mobile emergency care unit, and citizen first responders through the Heart Runner app.
~The medical dispatcher offers telephone assisted cardiopulmonary resuscitation (CPR) to bystanders. Furthermore, if more than two bystanders are present and an AED is accessible within 1½ minute travel distance (depending on the type of terrain), then one bystander is guided to localize and retrieve the AED."
16333285|NCT04446585|Experimental|Intervention sites|"As a supplement to the standard care as described in the control arm, the following will be supplied:
~Strategical deployment of AEDs with 24:7 availability and 1½ minute walking distance to every residence within the area. The AEDs will be registered with the AED network and thus linked to the emergency dispatch center.
~The emergency dispatch center will retrieve data from used AEDs.
~For each interventional area, approximately 120 residents will receive a course in CPR and AED use and subsequently be recruited as citizen responders so that they can be activated through the HeartRunner app in case of a nearby cardiac arrest."
16333286|NCT04446572|Experimental|Repetitive Abortion (RA) group|Starting at day 0, women of the RA (n=21) group consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
16333287|NCT04446572|Experimental|Infertility (INF) group|Starting at day 0, women of the INF group (n=23) consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
16333288|NCT04446572|No Intervention|Control group|The control group (n = 14) included fertile women having at least two children after uncomplicated term pregnancies.
16333289|NCT04446559|Experimental|Sitting in a chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
16333292|NCT04446533|Experimental|Hydrogen Peroxide and Hyaluronic acid (BMG0703)|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.
~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.
~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.
~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
16333293|NCT04446533|Active Comparator|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.
~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.
~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.
~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
16333294|NCT04446533|Placebo Comparator|Placebo product|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.
~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.
~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.
~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
16333295|NCT04446520|Experimental|autogenic drainage and traditional physiotherapy|autogenic drainage technique plus traditional physiotherapy (localized breathing exercise, diaphragmatic breathing and splinted coughing)
16333296|NCT04446520|Active Comparator|traditional physiotherapy|traditional physiotherapy (localized breathing exercise, diaphragmatic breathing, and splinted coughing)
16333297|NCT04446507|Experimental|Group 1|Subjects in severe renal impairment group will be enrolled and dosed consecutively (i.e. first 8 subjects of group 1 will receive 2 mg dose, followed by another 8 subjects who will receive 4 mg dose).
16333298|NCT04446507|Experimental|Group 2|Subjects (Normal renal function eGFR ≥90) will be matched according to age (± 10 years), sex, and weight (± 10 kg) with participants in Group 1 (Severe renal impairment not on HD) on a one to one basis based on demographic characteristic. Here, 8 participants will be administered single dose of 2 mg Saroglitazar Magnesium and 8 participants will be administered single dose of 4 mg Saroglitazar Magnesium.
16333299|NCT04446494|Experimental|Axillary dissection with DEPART technique|In the experimental group, 1 ml (2.5 mg) indocyanine green (ICG) and methylene blue (MB) was intradermally injected into the internal bicipital sulcus of ipsilateral arm. During axillary dissection, the identified arm sentinel nodes were carefully injected with 0.1 ml methylene blue (MB) using a 1-cc syringe with a 32-gauge needle. MB could then flow from the nodes along several lymphatic channels toward the infraclavicular nodes. Subsequent-echelon nodes and lymphatics were identified. Sentinel lymph nodes (SLNs) were removed after the identification of the arm sentinel nodes and the procedure of MB injection. When patients harbored positive SLNs, axillary lymph node dissection (ALND) was performed subsequently. All discernible arm lymphatics and lymph nodes were preserved, except that gross arm lymph nodes (major axis larger than 10 mm or node firm on palpation) were sent for immediate partial frozen section (pFS) to determine their resection during ALND.
16333300|NCT04446494|No Intervention|Standard axillary dissection|In the control group (no intervention), ALND was performed with complete resection of at least Berg's levels I and II. Resection of level III was performed only in cases with gross disease in level II and/or III
16333301|NCT04446481|Experimental|MCI patients|Vets with mild cognitive impairment
16333302|NCT04446481|Active Comparator|NC|Normal healthy Veterans
16333303|NCT04446468|Experimental|PEACE|The PEACE intervention will be delivered by a trained mental health staff member, such as a study psychologist, mental health nurse, social worker, or psychiatrist. The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide. Patients in this arm will also continue to receive standard post-discharge psychiatric care.
16333304|NCT04446468|Experimental|Control|Those randomized to the control arm will receive standard psychiatric hospital discharge care alone. Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
16333305|NCT04446455|Experimental|Functional Power + Cognitive Training|Training sessions began with approximately 30 minutes of cognitive training using a desktop computer followed by 40 minutes of functional power training.
16333306|NCT04446455|Active Comparator|Functional Power Training|Training sessions began with 40 minutes of functional power training.
16333697|NCT04444037||Angiography-guided PCI|PCI procedure was done without any intra-coronary imaging assistance, guided by angiography alone
16333307|NCT04446442|Experimental|Full Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1 mA will be administered over 20 minutes to the right crusI/II area of the cerebellum with a 15 second fade in period at the beginning and a 15 second fade out period at the end. During the tDCS administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
16333308|NCT04446442|Sham Comparator|Sham Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1mA increased over 15 seconds and immediately decreased over 15 seconds to provide sensation associated with tDCS. During the sham administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
16333309|NCT04446429|Active Comparator|Usual Care|Usual care as determined by the PI
16333310|NCT04446429|Experimental|Proxalutamide + Usual Care|Proxalutamide + Usual care as determined by the PI
16333311|NCT04446416|Experimental|Bevacizumab plus NaviFUS System|"Device: NaviFUS System BBB Disruption by FUS in recurrent GBM Microbubbles (MB) (SonoVue®) 0.1 mL/kg and optimal ultrasound exposure doses (based on the acoustic emission feedback FUS power control algorithm) generated from the NaviFUS System every 2 weeks to transiently open the BBB.
~Drug: Bevacizumab 10 mg/kg every 2 weeks for up to 36 weeks or until evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent."
16333312|NCT04446403|Experimental|circumflex|patients will undergo ultrasound guided SSN+circumflex
16333313|NCT04446403|Experimental|posterior cord|patients will undergo ultrasound guided SSN+circumflex
16333314|NCT04446390|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care). Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash,0.12% concentration) for one minute per day; such the regimen will be repeated one week every month.
~Chew xylitol gum 2 pieces four times per day for 5 minutes after meals."
16333315|NCT04446390|Active Comparator|preventive regimen using Fluoride based toothpaste(colgate)|preventive regimen using Fluoride based toothpaste (colgate cavity protection). Participants will be using a fluoride-based toothpaste (colgate cavity protection), (1450 ppm sodium fluoride) Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash, 0.12% concentration) for one minute per day; such a regimen will be repeated for one week every month. hew xylitol gum 2 pieces four times per day for 5 minutes after meals.
16333316|NCT04446377|Experimental|LAM-002A|LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
16333317|NCT04446377|Placebo Comparator|Placebo|(microcrystalline cellulose) in 5 capsules BID for 10 days
16333318|NCT04446364|Experimental|Aloe vera group|Gel cavity disinfection
16333319|NCT04446364|Active Comparator|Chlorohexidine group|2% cavity disinfection
16333320|NCT04446351|Experimental|Participants receiving GSK6097608 (Arm A)|Participants will be administered an IV infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
16333321|NCT04446351|Experimental|Participants receiving GSK6097608 plus dostarlimab (Arm B)|Participants will be administered an IV infusion of GSK6097608 every 3 weeks in escalating doses followed by an IV infusion of dostarlimab (every 3 weeks for 4 doses and every 6 weeks thereafter).
16333322|NCT04446338||Healthcare Worker|Staff of the Department of Ophthalmology, University Tuebingen, Germany
16333323|NCT04446312|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
16333324|NCT04446312|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
16333325|NCT04446299|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
16333326|NCT04446299|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
16333327|NCT04446273|Experimental|PRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The PRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist).
16333328|NCT04446273|Active Comparator|DRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The DRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).
16333329|NCT04446260|Experimental|Part 1 Dose escalation|
16333330|NCT04446260|Experimental|Part 2 Indication expansion|
16333331|NCT04446234|Experimental|Risperidone|Risperidone tablet
16333332|NCT04446234|Experimental|Aripiprazole|Aripiprazole tablet
16333333|NCT04446234|Experimental|Ziprasidone|Ziprasidone tablet
16333334|NCT04446234|Experimental|Amisulpride|Amisulpride tablet
16333335|NCT04446234|Experimental|Quetiapine|Quetiapine tablet
16333336|NCT04446195|No Intervention|Control group|The control group received routine intestinal preparation education.
16333337|NCT04446195|Active Comparator|Experimental group|The experimental group was treated with routine intestinal preparation education and individualized intervention.
16333339|NCT04446169||SARS-CoV 2 Patients|Patients with previous nasopharyngeal swab positive for SARS-CoV-2, subsequently negativeized in two detections
16333340|NCT04446143|Other|Application of mindfulness meditation prior to UDS|Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete.
16333341|NCT04446143|Active Comparator|No meditation prior to UDS|The control group will be seated in a quiet empty room where they wait for 10 min.
16333342|NCT04446130|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed T-ALL/LBL and T/M-MPAL patients.
16333343|NCT04446117|Experimental|Experimental Arm|Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
16333344|NCT04446117|Active Comparator|Control Arm|Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
16333345|NCT04446104|Experimental|Hydroxychloroquine|Participants will receive hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
16333346|NCT04446104|Experimental|Ivermectin|Participants will receive ivermectin tablet 12mg single dose
16333347|NCT04446104|Experimental|Zinc/ Vitamin C|Participants will receive zinc tablet 80 mg/vitamin C 500mg daily for 42 days
16333348|NCT04446104|Experimental|Povidone-iodine throat spray|Participants will receive povidone-iodine throat spray (3 times daily) for 42 days
16333349|NCT04446104|Active Comparator|Vitamin C|Participants will receive vitamin C tablet 500mg daily for 42 days
16333350|NCT04446091|Experimental|Two-drug group|Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
16333351|NCT04446091|Experimental|Three-drug group|Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
16333352|NCT04446078|Experimental|PEEK - All-on-4|Patients rehabilitated with a PEEK-acrylic resin prosthesis supported by immediate function dental implants inserted through the All-on-4 concept
16333353|NCT04446065|Experimental|Previfenon®|Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
16333354|NCT04446065|Placebo Comparator|Placebo|Participants will receive coded non-transparent bottles of placebo, each containing 90 starch capsules (250 mg plus excipients) under the same dosage, frequency and duration that Previfenon@ arm.
16333355|NCT04446052|Placebo Comparator|Placebo|
16333356|NCT04446052|Active Comparator|GM-CSF priming|
16333357|NCT04446039||1. Escitalopram Cohort|
16333358|NCT04446039||2. Paroxetine Cohort|
16333359|NCT04446039||3. Fluoxetine Cohort|
16333360|NCT04446039||4. Mirtazapine Cohort|
16333361|NCT04446039||5. Duloxetine Cohort|
16333362|NCT04446039||6. Sertraline Cohort|
16333363|NCT04446039||7. Venlafaxine Cohort|
16333364|NCT04446039||8. Tianeptine Cohort|
16333365|NCT04446039||9. Vortioxetine Cohort|
16333366|NCT04446039||10. Desvenlafaxine Cohort|
16333367|NCT04446039||11. Bupropion Cohort|
16333368|NCT04446026|Experimental|teneligliptin|
16333369|NCT04446026|Placebo Comparator|placebo|
16333370|NCT04446013|Experimental|Group General Anesthesia|C-Section under general anesthesia
16333371|NCT04446013|Experimental|Grup Spinal Anesthesia|C-Section under spinal anesthesia
16333372|NCT04446000|Experimental|CSL730 (dose 1 with premedication)|administered as a single dose by subcutaneous (SC) injection or by SC infusion
16333373|NCT04446000|Experimental|CSL730 (dose 2 with premedication)|administered as a single dose by SC injection or by SC infusion
16333374|NCT04446000|Experimental|CSL730 (dose 3 with premedication)|administered as a single dose by SC injection or by SC infusion
16333375|NCT04446000|Experimental|CSL730 (dose 1 without premedication)|administered as a single dose by SC injection or by SC infusion
16333376|NCT04446000|Experimental|CSL730 (dose 2 without premedication)|administered as a single dose by SC injection or by SC infusion
16333377|NCT04446000|Experimental|CSL730 (dose 3 without premedication)|administered as a single dose by SC injection or by SC infusion
16333378|NCT04446000|Experimental|CSL730 (dose 4 without premedication)|administered as a single dose by SC injection or by SC infusion
16333379|NCT04446000|Experimental|CSL730 (dose 5 without premedication)|administered as a single dose by SC injection or by SC infusion
16333380|NCT04446000|Experimental|CSL730 (dose 6 without premedication)|administered as a single dose by SC injection or by SC infusion
16333381|NCT04446000|Experimental|CSL730 (dose 7 without premedication)|administered as a single dose by SC injection or by SC infusion
16333382|NCT04446000|Placebo Comparator|Placebo|A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion
16333383|NCT04445987|Experimental|Long-term safety of ARQ-154|Open-label, Long-term Safety of ARQ-154
16333384|NCT04445974|Active Comparator|Expand Your Horizons: More than my skin|Participants allocated to the intervention condition will be asked to follow the adapted instructions for 'Expand Your Horizon'. Participants will be asked to complete three 15 min writing exercises over approximately six days. Participants who complete the first exercise on Qualtrics will be sent links to and asked to complete the second and third writing exercises.
16333385|NCT04445974|Experimental|Control writing activity|Participants in the control condition will be asked to complete three 15 minute creative writing exercises online via Qualtucs over approximately six days. Participants completing the first writing exercise will be sent links to the second and third writing exercises.
16333386|NCT04445948|Active Comparator|Triple Therapy|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days.
16333387|NCT04445948|Active Comparator|Sequential Therapy|Received the sequential therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 g tablets twice daily for 5 days, then esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus metronidazole 500 milligrams tablets twice daily plus clarithromycin 500 milligrams tablets twice daily after meal for another 10 days.
16334060|NCT04441580|Active Comparator|standard colonoscopy arm|Patients undergoing colonoscopy with standard colonscopy
16333388|NCT04445948|Active Comparator|Triple Therapy plus Lactoferrin|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days. in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner for 14 days.
16333389|NCT04445948|Active Comparator|Sequential Therapy plus Lactoferrin|Received the sequential therapy in the form of esomeprazole 40 milligrams once daily 30 minutes before breakfast plus amoxicillin 1 gram twice daily for 5 days, then esomeprazole 40 mg once daily 30 minutes before breakfast plus metronidazole 500 milligrams twice daily plus clarithromycin 500 milligrams twice daily after meal for another 10 days in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner throughout the 15 days.
16333390|NCT04445935|Active Comparator|Standard treatment|"In this arm the patients will be treated according to our standard anticoagulation protocol.
~The patients will not be treated with Bivalirudin (the investigational drug)."
16333391|NCT04445935|Experimental|Bivalirudin arm|The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
16333392|NCT04445922|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
16333393|NCT04445922|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
16333394|NCT04445909||VA-ECMO patients|VA-ECMO support because of low cardiac output.
16333395|NCT04445896||Study Participants|Patients with a diagnosis of a life-limiting illness who have previosuly had a discussion with a healthcare professional about the care they would want at the end of life
16333396|NCT04445883|Experimental|Study Group A|Study group A will include patients from the medical unit on 6S100 in addition to the Rehab units on 6N400/500. Participants in Study Group A will be receiving mealtime assistance from volunteers via the Eating Matters Program.
16333397|NCT04445883|No Intervention|Control Group B|Control Group B will include participants from the Rehab Unit on 4N400 and the Medical unit on 6S200.
16333398|NCT04445857|Active Comparator|Group 1|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.
16333399|NCT04445857|Active Comparator|Group 2|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.
16333400|NCT04445857|Placebo Comparator|Group 3 (control group)|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.
16333401|NCT04445844|Experimental|Treatment (pelareorep, retifanlimab)|Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16333402|NCT04445831|Placebo Comparator|Placebo|Placebo administered at predefined time points over a 48-week period.
16333403|NCT04445831|Experimental|ACI-35.030 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
16333404|NCT04445831|Experimental|ACI-35.030 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
16333405|NCT04445831|Experimental|ACI-35.030 - High dose|Active vaccine administered at predefined time points over a 48-week period.
16333406|NCT04445831|Experimental|JACI-35.054 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
16333407|NCT04445831|Experimental|JACI-35.054 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
16333408|NCT04445818|Experimental|More Appreciation|"A 6-minute engaging video will be shown, illustrating examples where a mother initially withholds her appreciation for her son's effort in school and later express it. The video will also capture the effect on the child and the family. Attributional discussion questions will follow to elicit positive outcomes of expressing appreciation and the negative outcomes of withholding appreciation (e.g., What may be the long-term effects of showing appreciation on your child, family, or on yourself?). Key points will be summarised and reinforced to enhance behavioural intention (Schwarzer & Luszczynska, 2008). Then the participants will be asked to plan by indicating when (e.g., Saturday afternoon), what (e.g., child helping a younger sibling prepare for a dictation test), and how (e.g., I can see that you gave up your leisure time to help your sister with the spelling. Thank you!) they would express appreciation to their children."
16333409|NCT04445818|Experimental|Less Criticism|"Participants will watch a 6-minute video showing examples of a father criticising his son, which will be replaced by positive communication later, and the different reactions evoked in the child and the family. Then, participants will have an attributional discussion on the negative effects of criticism (e.g., negative effect on self-worth and motivation) and positive outcomes of using constructive feedback (e.g., promptly identifying undesirable behaviours without relating to personal traits or abilities). In small groups, they will work out alternatives (i.e., constructive feedback; termed positive reminder in the intervention) to criticism, and each plan and write down when (e.g., after school), what (e.g., low test marks), and how (e.g., How do you prepare for the tests?)"
16333410|NCT04445818|Experimental|Fruit and Vegetable|This workshop will emphasise the importance of consuming at least 5 portions of fruit and vegetable daily for a healthy diet, and aim to boost participants' self-efficacy in achieving this. Participants will be presented with examples of one portion of fruit or vegetable, and then create their own recipes. They will also consider how to overcome obstacles of consuming more portions. Each participant will set goals and write down plans on when, where, what, and how they would increase their fruit and vegetable intake of their children and family as a whole.
16333411|NCT04445805|Active Comparator|CBTI Treatment Group|Telemedicine Cognitive Behavioral Therapy for Insomnia (CBTI)
16333412|NCT04445805|Experimental|Perinatal-enhanced behavioral therapy for insomnia|Telemedicine Mindfulness Based Therapy for Insomnia (MBTI)
16333413|NCT04445805|Placebo Comparator|Attention Control Treatment Group|Minimal intervention control
16333414|NCT04445792|Experimental|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
16333415|NCT04445792|Other|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
16333416|NCT04445792|Experimental|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
16333417|NCT04445792|Other|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
16333418|NCT04445792|Experimental|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
16333419|NCT04445792|Other|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
16333420|NCT04445779|Experimental|CoQ10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure.
16333421|NCT04445779|Placebo Comparator|Placebo|Patients will receive per-orally placebo in three divided doses.
16333422|NCT04445753|Experimental|Tai Chi program|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
16333423|NCT04445753|Other|Control group|Individuals in the control group will be trained on heart failure. The only attempt to be made to the control group will be education.
16333424|NCT04445740|Experimental|Intervention|Participants will receive an intervention and will participate in assessments
16333425|NCT04445740|No Intervention|Control|Participants will not receive an intervention, but will participate in assessments
16333426|NCT04445727|Experimental|vitamin c|daily dose of 1000 mg vitamin c in order to regenerate collagen
16333427|NCT04445727|Experimental|spinal manipulation|Spinal manipulation in cervical and dorsal with high speed and short amplitude techniques
16333428|NCT04445727|Experimental|Transcutaneous electrical nerve stimulation (TENS)|electrotherapy for an analgesic purpose
16333429|NCT04445727|Experimental|manual therapy|manual muscle treatment for epicondyl musculature
16333430|NCT04445714|Other|dapagliflozin and saxagliptin|Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
16333431|NCT04445701|Experimental|AO-176 Dose Escalation Monotherapy|The dose escalation monotherapy cohorts will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
16333432|NCT04445701|Experimental|AO-176 + DEX Expansion Cohort|Once the monotherapy RP2D has been established, an expansion cohort of AO-176 + dexamethasone will be enrolled.
16333433|NCT04445701|Experimental|AO-176 + DEX + BORT Dose Escalation|Following evaluation of AO-176 + dexamethasone, dose escalation cohorts of AO-176 + dexamethasone + bortezomib will be enrolled. Each dose escalation cohort will initially recruit 3 patients in a standard 3+3 design; cohorts will be expanded in the event of a DLT. The Phase 2 portion of the study will further evaluate the RP2D of AO-176 + DEX + BORT.
16333434|NCT04445688|Experimental|AD036|AD036 oral capsule administered before sleep
16333435|NCT04445688|Active Comparator|Atomoxetine|Atomoxetine oral capsule administered before sleep
16333436|NCT04445688|Placebo Comparator|Placebo|Placebo oral capsule administered before sleep
16333437|NCT04445675|Experimental|Experimental|The support for breastfeeding and the feeding of infants' with breast milk will be conducted in one stage for the experimental group. (1) breastfeeding support education. The content of the support for breastfeeding and the feeding of infants' with breast milk and the materials used were determined by the researchers in accordance with the literature. The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding. Breastfeeding support will be provided in the postpartum service and lactation outpatient clinic of the relevant hospital.
16333438|NCT04445675|No Intervention|Control Groups|The infants in the control group will be followed up in routine service. No intervention will be made.
16333439|NCT04445662|Active Comparator|Control (n=200)|"Varenicline
~Tobacco coaching
~Saliva cotinine monitoring with fixed payments ($10) regardless of results"
16333440|NCT04445662|Experimental|Financial incentives (n=200)|"Varenicline
~Tobacco coaching
~Saliva cotinine monitoring with escalating payments ($25-70) for levels <30 ng/ml"
16333441|NCT04445649||ICU patients|Patients with impaired consciousness admitted to intensive care unit after severe brain injury
16333442|NCT04445636|Experimental|Dexmedetomidine group|A group which will receive dexamedetomidine as an adjunct to bupivacaine used in caudal anesthesia.
16333443|NCT04445636|Experimental|Morphine group|A group which will receive morphine as an adjunct to bupivacaine used in caudal anesthesia.
16333444|NCT04445623|Active Comparator|prasugrel hydrochloride|film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
16333445|NCT04445623|Placebo Comparator|placebo|film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
16333446|NCT04445610||A|mild
16333447|NCT04445610||B|moderate
16333448|NCT04445610||C|severe
16333449|NCT04445597|Other|COVID-19 positive or negative patients|Hospitalised patients with or without COVID-19 (with or without olfactory dysfunctions)
16333450|NCT04445571|Active Comparator|INSURE|Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.
16333451|NCT04445571|Active Comparator|LISA|Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.
16333452|NCT04445558|Experimental|Membrane PEPA®|Patient will use the membrane PEPA® for the dialysis
16333453|NCT04445558|Active Comparator|Standard membrane of dialysis|Patient will use a standard membrane for the dialysis
16333454|NCT04445545|Experimental|Experimental group 1 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in continuous emission (duty cycle 100%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
16333455|NCT04445545|Experimental|Experimental group 2 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 50 J / cm2 in continuous emission (duty cycle 100%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
16333456|NCT04445545|Experimental|Experimental group 3 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in pulsed emission (duty cycle 25%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
16333457|NCT04445545|Experimental|Experimental group 4 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in pulsed emission (duty cycle 25%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
16333458|NCT04445545|Active Comparator|Control group|The group will receive only passive static stretching exercises of 5 sets of 30 seconds.
16333459|NCT04445532||hepatobiliary tumor patients|benign or malignant hepatobiliary tumors patients
16333460|NCT04445532||Benign Hepatobiliary Disease|chronic hepatitis, cirrhosis, and healthy control
16333461|NCT04445519|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes
16333462|NCT04445519|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
16333463|NCT04445519|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
16333464|NCT04445506||SARS-CoV2 patients that received dexamethasone|
16333465|NCT04445493||Device: MindRhythm Harmony|Passive recording of the head pulse
16333466|NCT04445480|Experimental|Popliteal block group|
16333467|NCT04445480|Active Comparator|Control group|
16333468|NCT04445467|Experimental|Favipiravir|1800 mg Favipiravir twice daily on Day 1 followed by 800 mg Favipiravir twice daily for the next 13 days.
16333469|NCT04445467|Placebo Comparator|Placebo|Matched Placebo
16333470|NCT04445454|Experimental|MSC therapy for severe COVID-19 infection|After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.
16333471|NCT04445428|Experimental|Intervention|Standard dose bivalent oral polio vaccine, 0.1ml, and information regarding prevention of COVID-19
16333472|NCT04445428|Other|Control|Information regarding prevention of COVID-19
16333473|NCT04445402||Heme/Non-Sickle Cell Disease|Subjects with a diagnosis of hemoglobinapathy except Sickle Cell Disease
16333474|NCT04445402||Heme/Sickle Cell Disease|Subjects with a diagnosis of Sickle Cell Disease
16333475|NCT04445402||Neuro-Oncological Disease|Oncology diagnosis with involvement of the neurological system
16333476|NCT04445402||Oncology/Non-Neuro-Oncological|Subjects with any oncology diagnosis except those that involve the neurological system.
16333477|NCT04445402||Transplant patients|Subjects who have received or are intending to have a stem cell transplant for treatment of disease.
16333478|NCT04445389|Experimental|GX-19: Dose A|Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
16333479|NCT04445389|Experimental|GX-19: Dose B|Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
16333480|NCT04445389|Placebo Comparator|GX-19: Dose C|Dose C of GX-19 will be intramusculary administered via PharmaJet® Needle Free Delivery on day 1 and day 29.
16333481|NCT04445389|Placebo Comparator|Placebo: Dose A, B, or C|Placebo will be intramusculary administered on day 1 and day 29 via EP or PharmaJet® Needle Free Delivery
16333482|NCT04445376|Experimental|Intervention Group (Ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
16333483|NCT04445376|Experimental|Intervention (Non ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
16333484|NCT04445363|Experimental|Cohort 1,0.5% Bid|Jacatinib hydrochloride cream 0.5% concentration, twice daily
16333485|NCT04445363|Experimental|Cohort 1,1.5% Bid|Jacatinib hydrochloride cream 1.5% concentration, twice daily
16333486|NCT04445363|Experimental|Cohort 1,2.5% Qd|Jacatinib hydrochloride cream 2.5% concentration, once daily
16333487|NCT04445363|Experimental|Cohort 1,2.5% Bid|Jacatinib hydrochloride cream 2.5% concentration, twice daily
16333488|NCT04445363|Placebo Comparator|Dose extension: Placebo|Placebo, twice daily
16333489|NCT04445363|Experimental|Dose extension: 1.5% Bid|Jacatinib hydrochloride cream 1.5% concentration, twice daily
16333490|NCT04445363|Experimental|Dose extension: 2.5% Bid|Jacatinib hydrochloride cream 2.5% concentration, twice daily
16333491|NCT04445350|Experimental|External focus of attention training program|The intervention group receives a strength and neuromuscular training program. The training instructions have an external focus of attention.
16333492|NCT04445350|Active Comparator|Internal focus of attention training program|The control group receives a strength and neuromuscular training program. The training instructions have an internal focus of attention.
16333493|NCT04445337|Experimental|Open Label SGB|Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml will be used for SGB block.
16333519|NCT04445155|Experimental|Modified DECIDE|DECIDE has two primary components: 1) three parent training sessions designed to help patients effectively ask questions and participate in decisions about care: and 2) a 12-hour workshop and up to 4 individual coaching sessions for providers to improve perspective-taking, reduce attributional errors, and increase receptivity to parent participation
16333520|NCT04445155|No Intervention|Usual Care|Usual Care consists of standard outpatient mental health care, including individual treatment for the adolescent (i.e., therapy, and/or medication) or family treatment for adolescents and parents, delivered in a variety of settings (e.g., clinics, schools, homes).
16333521|NCT04445142||epiretinal membrane group|Patients developed secondary fovea epiretinal membrane
16334207|NCT04440631||Antibiotic therapy including rifampicin|
16333494|NCT04445324|Experimental|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
16333495|NCT04445324|Active Comparator|Control Group (pharmacotherapy and/or psychotherapy N=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
16333496|NCT04445311|Experimental|Ivermectin group|group that will receive ivermectin plus standard of care ttt
16333497|NCT04445311|No Intervention|Control group|group that will receive standard of care ttt
16333498|NCT04445298||Pregnant women with expected delivery in the fall or winter|We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February). We will then follow their infant offspring.
16333499|NCT04445298||Pregnant women with expected delivery in the spring or summer|We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August). We will then follow their infant offspring.
16333500|NCT04445298||Infants born in the fall or winter|The infants born to the enrolled mothers will be followed. These are infants born in the fall (September, October, November) or winter (December, January, February).
16333501|NCT04445298||Infants born in the spring or summer|The infants born to the enrolled mothers will be followed. These are infants born in the spring (March, April, May) or summer (June, July, August).
16333502|NCT04445285|Experimental|Treatment Arm|Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
16333503|NCT04445285|Placebo Comparator|Placebo Arm 0.9% sodium chloride|Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
16333504|NCT04445272|Experimental|Tocilizumab|"Patients will receive IV tocilizumab as per clinical practice and at the discretion of treating investigator, following the posology indicated in the SmPC, or the recommendations proposed by the Spanish Ministry of Health:
~The recommended posology by the SmPC is 8 mg per kg in patients weighing greater than or equal to 30 kg or 12 mg per kg in patients weighing less than 30 kg. If no clinical improvement in the signs and symptoms up to 3 additional doses of tocilizumab may be administered. The interval between consecutive doses should be at least 8 hours.
~The recommendations of the Spanish Ministry of Health:
~Patients more than 80 kg: first dose 600 mg; second dose 600 mg. Patients less than 80 kg: first dose 600 mg; second dose 400 mg.
~A third dose might be considered 16 to 24 hours after if: fever persists or a worsening of the laboratory parameters
~Given the exceptionality of the situation modification of doses according to the physician experience will be allowed."
16333505|NCT04445259||Critically Ill Patients with COVID-19|We plan to recruit patients who are admitted to intensive care units with COVID-19 diagnosis.
16333506|NCT04445246|Experimental|Inhaled Iloprost therapy|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization
16333507|NCT04445233||COV Participants|COVID-positive index cases (COV): Participants who are greater than or equal to 18 years of age who test positive for COVID-19 by positive NP swab
16333508|NCT04445233||COV-HC Participants|Household contact of COVID-positive index case (COV-HC): Household contacts greater than 1 year of age currently living in the same home as the COVID-positive index case
16333509|NCT04445220|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
16333510|NCT04445220|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
16333511|NCT04445220|No Intervention|Case controls|Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.
16333512|NCT04445194|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
16333513|NCT04445194|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
16333514|NCT04445194|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
16333515|NCT04445181||Patients with T2D|Active patients (defined as patients seen by an LMC endocrinologist between January 1, 2019 and December 31, 2019) with T2D (Type 2 Diabetes). Among the patients with T2D, those identified with CKD will be included in the renal registry.
16333516|NCT04445181||Healthcare providers|Healthcare providers caring for patients with CKD and T2D.
16333517|NCT04445168|No Intervention|Usual Care|Participants assigned to usual care may receive advice from their primary care physician to increase their physical activity. They will receive handouts about every 6 weeks on general health topics.
16333518|NCT04445168|Experimental|Intervention|Participants assigned to the intervention arm will receive telephone-based motivational interviews with trained interventionists to encourage increases in physical activity.
16334208|NCT04440631||Non-rifampicin antibiotic therapy|
16333522|NCT04445129||Narcolepsy Type 1 Participants|Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
16333523|NCT04445129||Healthy Participants|Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
16333524|NCT04445116|Experimental|Endeavor group|25 participants will fill out questionnaires and complete a neuropsychological evaluation. During study participation, participants will target using Endeavor™ action video game to complete 25-30 minutes at-home sessions 5 days a week for a total of 8 weeks via an iOS application.
16333525|NCT04445103||History of malaria|Individuals with a history of malaria infection
16333526|NCT04445103||Controls|Individuals without a history of malaria infection
16333527|NCT04445103||Symptomatic malaria|Patients with symptomatic malaria infection (complicated and uncomplicated)
16333528|NCT04445090|Experimental|Single Rising Dose part: BI 1569912|
16333529|NCT04445090|Placebo Comparator|Single Rising Dose part: Placebo|
16333530|NCT04445090|Experimental|Bioavailability and Food effect part: BI 1569912|This part follows the SRD part; open-label, randomised, single-dose, intraindividual, six-sequence, three-way crossover
16333531|NCT04445077|Experimental|Intervention group|The education will be delivered weekly with 60-90 minutes per lecture for eight lectures. Multiple teaching methods will be used, including lectures, structured handouts, video, role play, case study and discussion. During the study period, the research team will provide ongoing support and consultation through electronic communication and bimonthly field visits.
16333532|NCT04445077|Other|Control group|Printed materials will be given to the participants in the control group for their self-study.
16333533|NCT04445064|Experimental|IO102 vaccine|
16333534|NCT04445064|No Intervention|Control group|
16333535|NCT04445051|Active Comparator|Standard of care|SpeediCath® standard Male and Female
16333536|NCT04445051|Experimental|New intermittent catheter variation 1 for male and female|New intermittent catheter variation 1 for male and female
16333537|NCT04445051|Experimental|New intermittent catheter variation 2 for male and female|New intermittent catheter variation 2 for male and female
16333538|NCT04445038|Experimental|610 group|Participants will be administered with 0.03mg/kg, 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg of 610 by subcutaneous injection. Subjects will be followed for 84 days.
16333539|NCT04445038|Placebo Comparator|controll group|Participants will be administered with 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg placebo once by subcutaneous injection. Subjects will be followed for 84 days.
16333540|NCT04445025|Experimental|Test group|Subjects will receive the medication elagolix
16333541|NCT04445025|Active Comparator|Control group|Subjects will receive leuprolide acetate
16333542|NCT04445012||Aortic Valve Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
16333543|NCT04445012||Mitral Valve Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
16333544|NCT04445012||Aortic Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe aortic regurgitation, using the BSE gradings [Wharton 2014].
16333545|NCT04445012||Mitral Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral stenosis, using the BSE gradings [Wharton 2014].
16333546|NCT04445012||Mixed Valve Disease (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mixed valve disease. Overall classification based on the most severe disease using the BSE gradings [Wharton 2014].
16333547|NCT04445012||Ventricular Septal Defects (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe ventricular septal defects, using gradings from [Samaan 1970].
16333548|NCT04445012||Aortic Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe aortic stenosis
16333549|NCT04445012||Pulmonary Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe pulmonary stenosis.
16333550|NCT04445012||Patent Ductus Arteriosus (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe patent ductus arteriosus, graded using ductal size [Arlettaz 2017].
16333551|NCT04445012||No Disease (Paediatric Patients)|264 paediatric patients with no heart disease. Note that we are only taking recordings from those who have been referred for an echocardiogram with a suspected heart condition but are subsequently found to have no heart disease.
16333552|NCT04444999|Experimental|Endovascular abdominal aortic aneurysm repair|a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA).
16333553|NCT04444986|Experimental|FAVIR then AVIGAN|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
16333554|NCT04444986|Experimental|AVIGAN then FAVIR|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
16333555|NCT04444973||Invasive RV assessment|RV conductance catheter assessment of RV performance
16333556|NCT04444960||Intracoronary physiology and imaging-guided group|
16333557|NCT04444960||Angiography-guided group|
16333558|NCT04444934||Patients with not-surely pathologic diaphragmatic peritoneum|The definition of not-surely pathologic diaphragmatic peritoneum was given in association with the presence of flat dyschromic areas.
16333559|NCT04444934||Patients with certainly pathologic diaphragmatic peritoneum|The definition of certainly pathological diaphragmatic peritoneum was given when isolated or confluent thick nodules were visualized at the intra-operative inspection.
16333656|NCT04444245|Experimental|ARM 4 Intra-ovarian guided placement|Specifically designed 23 gauge modified oocyte harvester needle for ultrasound guided placement
16333562|NCT04444895|Experimental|Lanadelumab|Rollover participants from SHP643-303 (NCT04206605) will receive 300 milligram (mg) of lanadelumab solution in prefilled syringe subcutaneously (SC) for 26 weeks once every 2 weeks (Q2W) or once every 4 weeks (Q4W) if well controlled during SHP643-303 (NCT04206605) with up to 13 doses.
16333563|NCT04444869|Other|Open label single-arm study|All patients will receive concurrent cisplatin and radiation therapy with radiation dose de-escalation to clinically and radiologically uninvolved lymph nodes.
16333564|NCT04444856||NovoSeven|Women with severe postpartum haemorrhage treated with NovoSeven
16333565|NCT04444856||Standard of care|Women with severe postpartum haemorrhage treated with standard of care
16333566|NCT04444843|Other|Mycophenolate Mofetil Capsules|The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring. It is not allowed to switch to other MPAs. When MMF is discontinued but is not switched to other MPA, the patients will be followed until the end of study.
16333567|NCT04444830|No Intervention|Standard|"To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed a standard postoperative regimen of Acetaminophen 650 mg PO q 6-8 hours + Ibuprofen 600 mg PO q 6-8 hours + rescue narcotics (Oxycodone 5-10 mg PO q 4-6 hours or if allergic to Oxycodone, Norco 5-10mg/325mg PO q 4-6 hours) for breakthrough pain"
16333568|NCT04444830|Experimental|Sprix|To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed regimen of Sprix 30.5mg Intranasal q 6-8 hour up to 4 times daily + Acetaminophen 650 mg PO q 6- 8 hours + rescue narcotics (as above) for breakthrough pain during the day of surgery and the following 4 postoperative days.
16333569|NCT04444817||Tacrolimus-based immunosuppression|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started.
16333570|NCT04444804||Rivaroxaban|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
16333571|NCT04444804||Low-molecular-weight heparin (LMWH) and Phenprocoumon|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
16333572|NCT04444791||Cohort|This cohort study only set up one group. The habits and health status of mothers and their offspring will be followed up and observed. The participants will be divided into more than one group according to the variables (e.g. age, physical activity, dietary patterns, sleep quality.).
16333573|NCT04444778|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
16333574|NCT04444778|No Intervention|Conservative treatment|Diet and general life style recommendations.
16333575|NCT04444765||Patients with bicarbonate-based intermittent dialysis|Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).
16333576|NCT04444765||Patients with acetate free biofiltration dialysis|Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification
16333577|NCT04444752|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection
16333578|NCT04444752|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection
16333579|NCT04444752|Experimental|CBP-201 Dose 3|CBP-201 Dose 3 subcutaneous (SC) injection
16333580|NCT04444752|Placebo Comparator|placebo|subcutaneous (SC) injection
16333581|NCT04444726|Experimental|"Phototherapy PUVA +traditional medical treatmentn"|"patient sock his hands in a bath containing water with the constitution of psoralen meladinine  capsule for 20 minutes then irradiated at the UVA device for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
16333582|NCT04444726|Experimental|Tap Water Iontophoresis + Traditional medical treatment|"Tap-water iontophoresis was given 3 times weekly for 10 min The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30mA. Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
16333583|NCT04444726|Active Comparator|traditional medical treatment|"Traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
16333586|NCT04444687||SARS-CoV-2-positive 01|SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
16333587|NCT04444687||SARS-CoV-2-positive 02|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
16333588|NCT04444687||SARS-CoV-2-positive 03|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
16333589|NCT04444687||Control|Control patients, SARS-CoV-2-negative
16333590|NCT04444674|Experimental|Group 1- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
16333591|NCT04444674|Placebo Comparator|Group 1- placebo|Participants (HIV-negative) will receive two doses of Normal saline (0.9%) in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
16333592|NCT04444674|Experimental|Group 2a- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
16333593|NCT04444674|Placebo Comparator|Group 2a- placebo|Participants (HIV-negative) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
16333594|NCT04444674|Experimental|Group 2b- IP|Participants will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
16333595|NCT04444674|Placebo Comparator|Group 2b- placebo|Participants will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
16333596|NCT04444674|Experimental|Group 3- IP|Participants (HIV-positive) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
16333597|NCT04444674|Placebo Comparator|Group 3- placebo|Participants (HIV-positive) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
16333598|NCT04444661||HIT-resistance exercise|High Intensity Resistance Exercise
16333599|NCT04444661||Non exercising control|Control group that maintained life style and physical activity habits
16333600|NCT04444648||One groupe without distinction of age, sexe, and pathology.|"Patients with strok in coma, with or without wake up, and with disorder of consciousness. No limit in age (maybe give the younger age).
~We obtain this data from medical record. Every assessment was made of clinical purposes.
~We use the Glasgow coma recovery scale for assessment of behavior to check the variation of wakefulness. The scale was performed by the nursing staff every 2 to 8 hours depending on the severity of the medical condition.
~The continuous analysis of neurophysiologic data was based on EEG with a bipolar montage composed of the less noisy electrodes per recording period.
~The EEG features will include: spectral analysis (relative and absolute power in 4 canonical bands: Delta/Theta/Alpha/Beta) and complexity analysis (DFA, determinism, SVD entropy and permutation entropy).
~The patient outcome at the ICU and hospital discharges were collected from the medical files."
16333601|NCT04444635|Active Comparator|Serratus Anterior Plan block plus fentanyl infusion|The patients will receive serratus anterior block in addition to continous intraoperative fentanyl infusion.
16333602|NCT04444635|Active Comparator|Fentanyl infusion only|The patient will receive fentanyl infusion only.
16333603|NCT04444622|Experimental|AlloStim|"AlloStim is administered in three cycles:
~Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®
~Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®
~Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®"
16333604|NCT04444609||COVID -19 with chronic lung disease|"Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)
~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
~Mild/Moderate ( n =30) (absence of severe criteria)"
16333605|NCT04444609||COVID-19 without chronic lung disease|"Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)
~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
~Mild/Moderate ( n =30) (absence of severe criteria)"
16333606|NCT04444609||Chronic Lung disease|"Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)
~Asthma (defined as severe) - (n=20)
~CF (FEV1% predicted baseline <50%) - (n=20)
~COPD (FEV1% predicted baseline <50%) - (n=20)
~Idiopathic Pulmonary Fibrosis (n=20)"
16333607|NCT04444609||Healthy volunteers|Healthy subjects with no COVID-19 (n=30)
16333608|NCT04444596|Other|Swab|Conjunctival swab and nasopharyngeal swab for SARS-COV 2
16333609|NCT04444583||HFpEF|HF patients with preserved ejection fraction (HFpEF)
16333610|NCT04444583||HFrEF|HF patients with reduced ejection fraction (HFrEF)
16333611|NCT04444570||Control group|14 days before the date of the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom)
16333612|NCT04444570||Study group|Right after the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
16333613|NCT04444557||Turkish hemodialysis patients|Turkish patients undergoing in-center hemodialysis
16333614|NCT04444557||Temporarily protected Syrian hemodialysis patients|Temporarily protected Syrian patients undergoing in-center hemodialysis
16333615|NCT04444531||Ozone autohemotherapy plus standard treatment|
16333616|NCT04444531||Standard treatment alone|
16333617|NCT04444518|Experimental|VAX-MOM Intervention|
16333618|NCT04444518|Active Comparator|Standard of Care|
16333619|NCT04444492|Experimental|Ranibizumab+Laser-arm|Ranibizumab injections and additional targeted laser
16333620|NCT04444492|Active Comparator|Ranibizumab-arm|Only Ranibizumab injections
16333621|NCT04444479|Experimental|PICC catheter placement|Study subjects in whom placement of the PICC catheter is indicated
16333622|NCT04444466|Experimental|UCB8600|Study participants randomized to this arm will receive various single doses and multiple doses of UCB8600 administered to various cohorts.
16333693|NCT04444050|Experimental|Part 3 J-MAD: Panel 2|
16333694|NCT04444050|Experimental|Part 3 J-MAD: Panel 3|
16333623|NCT04444466|Placebo Comparator|Placebo|Study participants randomized to this arm will receive various single doses and multiple doses of Placebo administered to various cohorts.
16333624|NCT04444453|Experimental|Pedometer|Admitted patients who receive a pedometer to wear during their hospital stay to measure steps ambulated
16333625|NCT04444453|No Intervention|Control|Patients admitted to hospital who do not receive a pedometer, but receive all other usual standard of care
16333626|NCT04444440|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
16333627|NCT04444440|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
16333628|NCT04444427|Experimental|Part 1: Dose Escalation|Dose escalation cohorts are planned to determine the maximum tolerated dose or recommended phase 2 dose of GLR-2007, as well as expansion cohorts and a Phase 2 cohort.
16333629|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort A|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their non-small cell lung cancer (NSCLC) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
16333630|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort B|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their brain metastases of breast or NSCLC origin will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
16333631|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort C|Participants experiencing their first recurrence glioblastoma multiforme (GBM) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
16333632|NCT04444414|Experimental|Manual Therapy group|Bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
16333633|NCT04444414|Other|Control group|They received no treatment, they just went to the evaluations.
16333634|NCT04444388|Experimental|Cocoa group|5 g/day of flavonoid-rich defatted cocoa for 10 weeks
16333635|NCT04444388|Placebo Comparator|Placebo group|5 g/day of maltodextrin for 10 weeks
16333636|NCT04444375||obese, non-obese|obese and non-obese diabetic patients
16333637|NCT04444362|Experimental|Inspiratory Muscle Training|The Inspiratory Muscle Training group received respiratory muscle training, in addition to routine preparation, including laboratory and radiological examinations and preoperative education.
16333638|NCT04444362|No Intervention|Control|The control group received routine preparation, including laboratory and radiological examinations and preoperative education.
16333639|NCT04444349|Experimental|Coenzyme Q10 group|Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
16333640|NCT04444349|Sham Comparator|Control|Participants in the experimental group will be given 10mg of placebo each time (3 times a day).
16333641|NCT04444323|Experimental|3D Telemedicine|Single arm. All patient seen face-to-face and then with 3D telemedicine.
16333642|NCT04444297|Active Comparator|2D telemedicine|2D telemedicine first, followed by crossover to 3D telemedicine with no washout period
16333643|NCT04444297|Experimental|3D Telemedicine|3D telemedicine first, followed by crossover to 2D telemedicine with no washout period
16333644|NCT04444284|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
16333645|NCT04444284|Placebo Comparator|Dosage Group 1: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
16333646|NCT04444284|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
16333647|NCT04444284|Placebo Comparator|Dosage Group 2: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
16333648|NCT04444284|Experimental|Dosage Group 3: RSV Vaccine Dosage 3|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
16333649|NCT04444271|Experimental|Mesenchymal stem cells|10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
16333650|NCT04444271|Placebo Comparator|Placebo|Only supportive care will be given to 10 patients
16333651|NCT04444258|Experimental|Experimental I Group|After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
16333652|NCT04444258|No Intervention|Control Group|FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
16333653|NCT04444245|Experimental|ARM 1 Platelet Rich Plasma|Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. (Emcyte II Pure PRP) Endovaginal ultrasound guided intra-ovarian placement into ovarian parenchyma, preferably both if accessible.
16333654|NCT04444245|Experimental|ARM 2 emulsified tSVF and PRP|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue into tSVF (Tulip Nanofat device). Blending of Nanofat with PRP at a 3:1 ratio.
~Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible."
16333655|NCT04444245|Experimental|ARM 3 emulsified tSVF and PRP, enriched with cSVF|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP tSVF preparation: Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue (Tulip Nanofat device).
~cSVF preparation: lipoaspiration as above. Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocol. Quantification of viable nucleated cell count with flow cytometry. Addition of pellet of viable nucleated cells to tSVF.
~Blending of tSVF/cSVF emulsion with PRP at a 3:1 ratio. Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible.
~Intervention:"
16333657|NCT04444232|Experimental|Health services research (educational video, survey)|Participants view an educational video on cancer and cancer screening options over 12 minutes. Participants also complete a phone survey over 10-15 minutes before attending the video session and 2 months after the video session.
16333658|NCT04444219|Other|Breakfast meal_1|100 g white bread, 40 g yellow cheese and Κing Oyster mushrooms (test meal)
16333659|NCT04444219|Other|Breakfast meal_2|100 g white bread, 40 g yellow cheese and 6-7 cherry tomatoes (control meal)
16333660|NCT04444206|Experimental|CL and CCI screening|The Cervical lenght (CL) and the Consistence Cervix Index (CCI) will be evaluated by transvaginal ultrasound. CL and CCI measurements will be expected in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy, in accordance with current national guidelines.
16333661|NCT04444206|No Intervention|No CL and CCI screening|The investigators collect data of these pregnant women without any additional ultrasound examination
16333662|NCT04444193|Experimental|Durvalumab and Lenvatinib|Combination therapy of Lenvatinib 80-120mg daily orally and durvalumab 1500mg by IV infusion every 4 weeks
16333663|NCT04444180||Clinical high risk for psychosis (CHR)|No intervention. Just use virtual hand illusion (VHI) paradigm to observe the outcome of individuals with CHR at one-year follow-up node and analyze the predictive role of self-representation in transition into psychosis.
16333664|NCT04444180||First episode of schizophrenia (FES)|In contrast to FES, it is anticipated to observe CHR individuals with similar behavioral performance to FES may presented higher risk of transition.
16333665|NCT04444180||Healthy control (HC)|In contrast to HC, it is anticipated to observe CHR individuals with similar behavioral performance to HC may presented lower risk of transition.
16333666|NCT04444167|Experimental|AK104 and Lenvatinib|AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
16333667|NCT04444154|Active Comparator|Control group|oral hygiene advice given orally
16333668|NCT04444154|Active Comparator|Group with active participation|oral hygiene advice given orally and demonstration of brushing methods in the sink with active participation
16333669|NCT04444154|Experimental|Group with video and quizz|oral hygiene advice given orally and an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
16333670|NCT04444141|Experimental|AK104|AK104 450mg IV every 2 weeks (Q2W)
16333671|NCT04444102|No Intervention|Control group (CG)|Those subjects randomized to the CG will be offered reading options that do not evoke high emotional distress. They will spend an hour reading.
16333672|NCT04444102|Experimental|Stretching protocol 1, Mild Stretching Group (MSG)|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 50% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch and then corrected to 50%. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 50% with some feedback from the instructor.
16333673|NCT04444102|Experimental|Stretching protocol 2, Intense Stretching Group (ISG):|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 100% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 100% with some feedback from the instructor.
16333674|NCT04444089|Experimental|conventional group, CG|receives Ringer's lactate solution at a rate of 4 ml/kg/h for the first-10 kg of body weight, 2 ml/kg/h for the second-10 kg of body weight, and 1 ml/kg/h for each further kg of body weight. The deficit volume is calculated as the maintenance volume multiplied by fasting hours and given as follows: 50% of the volume in the first hour, 25% of the volume in the second hour, and 25% of the volume in the third hour, in addition to the aforementioned maintenance volume
16333675|NCT04444089|Experimental|restricted group, RG|Patients in the RG receives Ringer's lactate solution at a rate of 3 ml/kg/h from the start to the end of surgery.
16333676|NCT04444076|Experimental|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a bovine mesh that will be implanted following supraspinatus tendon repair.
16333677|NCT04444076|No Intervention|Standard of Care|Supraspinatus tendon repair.
16333678|NCT04444063|Experimental|NIPSA technique with Allograft plus PRF|Non-incised papilla preservation technique to treat intraosseous bony defects with the addition of Allograft plus PRF
16333679|NCT04444063|Active Comparator|NIPSA technique|Non-incised papilla preservation technique to treat intraosseous bony defects without the addition of Allograft plus PRF
16333680|NCT04444050|Experimental|Part 1 Single Ascending Dose (SAD): Panel 1|
16333681|NCT04444050|Experimental|Part 1 SAD: Panel 2|
16333682|NCT04444050|Experimental|Part 1 SAD: Panel 3|
16333683|NCT04444050|Experimental|Part 1 SAD: Panel 4|
16333684|NCT04444050|Experimental|Part 1 SAD: Panel 5|
16333685|NCT04444050|Experimental|Part 1 SAD: Panel 6|
16333686|NCT04444050|Experimental|Part 1 SAD: Optional Split-dose Panel|
16333687|NCT04444050|Experimental|Part 2 Multiple Ascending Dose (MAD): Panel 1|
16333688|NCT04444050|Experimental|Part 2 MAD: Panel 2|
16333689|NCT04444050|Experimental|Part 2 MAD: Panel 3|
16333690|NCT04444050|Experimental|Part 2 MAD: Panel 4|
16333691|NCT04444050|Experimental|Part 2 MAD: Optional (to be determined) Panel|
16333692|NCT04444050|Experimental|Part 3 MAD in Japanese Participants (J-MAD): Panel 1|
16333698|NCT04444024||NTC/-HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to normal TC/ none hypertension(NTC/-HTN) group.
16333699|NCT04444024||NTC/+HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to normal TC/ hypertension(NTC/+HTN) group.
16333700|NCT04444024||BHTC/-HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to borderline-high TC/ none hypertension (BHTC/-HTN) group.
16333701|NCT04444024||BHTC/+HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to borderline-high TC/ hypertension (BHTC/+HTN) group.
16333702|NCT04444024||HTC/-HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to high TC/ none hypertension(HTC/-HTN) group.
16333703|NCT04444024||HTC/+HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 80 mmHg belong to high TC/ hypertension(HTC/+HTN) group.
16333704|NCT04444011|Experimental|Anaprazole Sodium enteric-coated tablet|Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), one tablet each time.
16333705|NCT04444011|Experimental|Amoxicillin capsules|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 capsules each time."
16333706|NCT04444011|Experimental|Clarithromycin tablet|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 tablets each time."
16333707|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin|"Cohort 1: Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods ( only once on the morning of D5 of treatment periods).
~Cohort 2: Administered orally on an empty stomach once on the morning of D1 of treatment periods"
16333708|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin+Bismuth|Administered orally on an empty stomach once on the morning of D1 of treatment periods in cohort 2
16333709|NCT04443998|Experimental|Bone reduction forceps|
16333710|NCT04443972|Experimental|PD VitalOs cement® alone|class II furcation defects that will be treated with PD VitalOs cement® alone
16333711|NCT04443972|Experimental|PD VitalOs cement® plus Bone graft and membrane|PD VitalOs cement® and Hydroxyapatite bone graft and biodegradable collagen membrane in the treatment of class II furcation defects.
16333712|NCT04443959|Experimental|MBTI Treatment|Telemedicine-assisted digital mindfulness-based therapy for insomnia (MBTI).
16333713|NCT04443946|Active Comparator|Group-P|Group-P: (Propofol group): 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
16333714|NCT04443946|Experimental|Group-PAS|Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 2.5 mg kg-1 h-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
16333715|NCT04443946|Experimental|Group-PS|Group-PS: (Propofol and Sevoflurane group): 2.5 mg kg-1 h-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time.
16333716|NCT04443946|Experimental|Group-S|Group-S: (Sevoflurane group): 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
16333717|NCT04443946|Experimental|Group-PSu|Group-PSu: (Propofol and Sufentanil group): 5 mg kg-1 h-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
16333718|NCT04443933||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
16333719|NCT04443933||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
16333720|NCT04443920|Active Comparator|Tranexamic acid (TXA)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of 15 mg/kg of Tranexamic acid (TXA) before the release of the tourniquet. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
16333721|NCT04443920|Placebo Comparator|Placebo Normal Saline (NS)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of placebo (Normal Saline) in the volume calculated to be equal to the volume of 15 mg/kg of TXA. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
16333722|NCT04443907|Experimental|OTQ923 or HIX763|Single intravenous infusion of either OTQ923 or HIX763, Part A - Adults treated with OTQ923; Part B - Adults treated with HIX763 Part C - Children age 2-17 - either OTQ923 or HIX763 based on review of data from Part A and/or Part B by Health agency after a formal interim analysis.
16333723|NCT04443894|Active Comparator|PECS block|
16333724|NCT04443894|Active Comparator|local infiltration|
16333725|NCT04443881|Experimental|Anakinra Arm|Standard of care plus Anakinra (100mg) administered as 4-times daily i.v. infusions for a maximun of 15 days
16333726|NCT04443881|No Intervention|Control Arm|Standard of care
16333727|NCT04443868|Experimental|Nitric Oxide Releasing Solution|Daily nasal irrigation (240mL) 14.4ppm
16333728|NCT04443868|Placebo Comparator|Placebo Isotonic Saline|Daily nasal irrigation (240mL) 0.9% saline
16333729|NCT04443855|Active Comparator|Water quality|90 clusters, approx. 720 newborns
16333730|NCT04443855|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
16333731|NCT04443855|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
16333732|NCT04443855|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
16333733|NCT04443855|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
16333734|NCT04443855|Active Comparator|Nutrition+ Combined WASH|90 clusters, approx. 720 newborns
16333735|NCT04443855|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
16333736|NCT04443842|Experimental|Intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentive, social incentives and weekly feedback on performance for 6 months.
16333802|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 72Units|Botulinum Toxin Type A (Botulax®) 72Units total dose administered intramuscularly to the bilateral masseter muscles.
16333737|NCT04443842|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
16333738|NCT04443829|Experimental|CD19CAR T-cells|Treatment with the ATIMP: CD19CAR T-cells
16333739|NCT04443790|Active Comparator|Obesecure Capsules (Test Group)|A dose of 500mg capsule twice daily of Polyherbal formulation Obesecure was given in the test group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
16333740|NCT04443790|Placebo Comparator|Plasicure (Control Group)|A dose of 500mg capsule twice daily of Placebo as Plasicure was given in the control group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
16333741|NCT04443777|Active Comparator|Sulphonylurea Group|Gliclazide 60 mg (Diamicron® MR) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
16333742|NCT04443777|Placebo Comparator|Placebo Group|Placebo (starch, sodium lauryl sulfate and Aerosil) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
16333743|NCT04443751|Experimental|SHR-1702 monotherapy|SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.
16333744|NCT04443725|Experimental|Hydroxychloroquine plus Sofosbuvir/Daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days, Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days
16333745|NCT04443725|Active Comparator|Standard of care|Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days
16333746|NCT04443686|Experimental|ALA / Fractions of Radiotherapy|Subjects will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed.
16333747|NCT04443673|Experimental|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
16333748|NCT04443673|No Intervention|Control|Participants will receive the habitual treatment for their severe condition.
16333749|NCT04443660||Group A|without medical history or risk factors, with a normal pregnancy
16333750|NCT04443660||Group B|without medical history or risk factors, developing a pregnancy complication
16333751|NCT04443660||Group C|with risk of complication, having a normal pregnancy
16333752|NCT04443660||Group D|with a risk of complication, developing a pregnancy complication
16333753|NCT04443647|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
16333754|NCT04443647|Placebo Comparator|Placebo|Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
16333755|NCT04443634|Experimental|Adductor 20|Ultrasound guided adductor canal block will be performed with injection of 20 ml bupivacaine
16333756|NCT04443634|Experimental|Adductor 30|Ultrasound guided adductor canal block will be performed with injection of 30ml bupivacaine
16333757|NCT04443634|Experimental|Adductor /Saphenous|Ultrasound guided adductor canal block will be performed by injection of 20 ml bupivacaine , combined with ultrasound guided saphenous nerve block at the distal third of the thigh in the intermuscular plane between Vastus Medialis and Sartorius muscle with injection of 10ml bupivacaine 0.5%.
16333758|NCT04443621||participants with early stage dementia|Subjects with diagnosed any type of dementia at an early phase (MMSE score 20 - 25 points) - for longitudinal study (three phasis).
16333759|NCT04443621||participants without dementia|Subjects without dementia with MMSE score 26 - 30 points (for validation of ACE-III).
16333760|NCT04443608|Active Comparator|Veltassa|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
16333761|NCT04443608|Placebo Comparator|Placebo|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
16333762|NCT04443595|Experimental|Experimental|Treatment of Acute Severe Pancreatitis with DPN
16333763|NCT04443569|Experimental|Lidocaine Patch Group|This group will be women who were randomized to receive a lidocaine patch for postoperative pain following cesarean delivery in addition to routine postoperative pain management.
16333764|NCT04443569|No Intervention|Control Group|This group will be women randomized to routine postoperative pain management following cesarean delivery.
16333765|NCT04443556|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|Standart postoperative analgesia + Continue Rhomboid Intercostal and Subserratus Plane Block
16333766|NCT04443556|Other|Control Group|Standart postoperative analgesia
16333767|NCT04443543|Experimental|Arm 1|"Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
16333768|NCT04443543|Experimental|Arm 2|"Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
16333769|NCT04443530||Coronary artery stenosis|Patients with coronary artery disease
16333770|NCT04443517|Experimental|Maintenance-Alpha Optimization / Wake from Propofol|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive individualized titration of anesthetic gas and opioid. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
16333881|NCT04442750|Experimental|B (0.375%) group|patients will receive a single shot erector spinae block with 30 ml 0.375% bupivacaine followed by general anesthesia
16333771|NCT04443517|Active Comparator|Maintenance-Alpha Optimization / Wake from Volatile|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive real-time monitoring of alpha recordings and individualized titration of desflurane and opioid. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
16333772|NCT04443517|Active Comparator|Maintenance-Routine Care / Wake from Propofol|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
16333773|NCT04443517|No Intervention|Maintenance-Routine Care / Wake from Volatile|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
16333774|NCT04443504|Experimental|Intervention Group|
16333775|NCT04443504|No Intervention|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
16333776|NCT04443478||Laparoscopic Surgery|Lower Mediastinal Lymphadenectomy should be finished via laparoscopic method.
16333777|NCT04443478||Open Surgery|Lower Mediastinal Lymphadenectomy should be finished via open method.
16333778|NCT04443452||Prevalent Central Sensitisation|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
16333779|NCT04443452||Non-prevalent Central Sensitisation|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
16333780|NCT04443439||No related neurological symptoms and transient ischemic attack|Mild stenosis group: CTA suggested carotid stenosis < 30%; Moderate stenosis group: CTA suggested carotid stenosis of 30-69%; Severe stenosis group: CTA indicated carotid stenosis ≥70%;
16333781|NCT04443426|Experimental|Single dose oral 3-hydroxybutyrate monoester|Cross-over study in 8 patients receiving single-dose oral 3-hydroxybutyrate monoester, 3-OHB salt and placebo.
16333782|NCT04443426|Experimental|Single dose oral 3-hydroxybutyrate Salt|
16333783|NCT04443426|Placebo Comparator|Single dose oral placebo|maltodextrin-based, isocaloric to ketone dosis.
16333784|NCT04443413|Experimental|Arm I (x-ray therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo x-ray therapy over 25 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may then receive a 4-fraction boost of x-ray therapy.
16333785|NCT04443413|Experimental|Arm II (proton beam radiation therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo proton beam radiation therapy over 5 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may receive a concurrent 5-fraction boost of proton beam radiation therapy.
16333786|NCT04443387|Active Comparator|Asthmatic low vitamin D on treatment|asthmatic patient low vitamin D level received treatment for Vitamin D 50000IU weekly
16333787|NCT04443387|Placebo Comparator|Asthmatic low vitamin D on placepo|asthmatic patient low vitamin D level received placepo
16333788|NCT04443348|Experimental|Group A (No RT Boost)|No RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy.There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
16333789|NCT04443348|Experimental|Group B (Low Dose RT Boost)|Low-dose RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
16333790|NCT04443348|Experimental|Group C (High Dose RT Boost)|High-dose RT boost plus pembrolizumab followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
16333791|NCT04443335|Sham Comparator|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
16333792|NCT04443335|Experimental|sequential feeding|This feeding mode utilizes a combination of continuous feeding in the beginning, time-restricted feeding in the second stage and oral feeding in the last stage
16333793|NCT04443322|Experimental|Durvalumab and Lenvatinib|"Participants receive intravenous (IV) durvalumab at 1500mg on Day 1 of each 28-day cycle. Number of cycles: until unacceptable toxicity develops or >42 days before liver transplantation (If patients with locally advanced HCC would undergo liver transplant).
~Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation(If patients with locally advanced HCC would undergo liver transplant)."
16333794|NCT04443309|Experimental|Lenvatinib plus Camrelizumab|"Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
16333795|NCT04443296|Experimental|CCRT+TIL|Cisplatin based concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
16333796|NCT04443283||LTBI Group|IGRA(+)
16333797|NCT04443283||No LTBI Group|IGRA(+)
16333798|NCT04443270|Experimental|Chloroquine phosphate prophylactic group|"Drug: Chloroquine phosphate
~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
16333799|NCT04443270|No Intervention|Control group|Health personnel who want to be included voluntary in the study and meet the inclusion criteria without Chloroquine use.
16333800|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 24Units|Botulinum Toxin Type A (Botulax®) 24Units total dose administered intramuscularly to the bilateral masseter muscles.
16333801|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 48Units|Botulinum Toxin Type A (Botulax®) 48Units total dose administered intramuscularly to the bilateral masseter muscles.
16333803|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 96Units|Botulinum Toxin Type A (Botulax®) 96Units total dose administered intramuscularly to the bilateral masseter muscles.
16333804|NCT04443244|Placebo Comparator|Placebo(Normal Saline)|Placebo(Normal saline) administered intramuscularly to the bilateral masseter muscles.
16333805|NCT04443205||no macrosomy|pregnant women whose child is not macrosomal
16333806|NCT04443205||screened macrosomy|pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
16333807|NCT04443205||no screened macrosomy|pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
16333808|NCT04443192|Active Comparator|Part A Cohort 1 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
16333809|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Single Dose|Single oral dose of placebo by mouth in the fasted state
16333810|NCT04443192|Active Comparator|Part A Cohort 2 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
16333811|NCT04443192|Active Comparator|Part A Cohort 3 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
16333812|NCT04443192|Active Comparator|Part A Cohort 4 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
16333813|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Two Doses|Two doses of placebo (12 h apart) by mouth in the fasted state
16333814|NCT04443192|Active Comparator|Part A Cohort 5 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 5
16333815|NCT04443192|Active Comparator|Part A Cohort 6 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 6
16333816|NCT04443192|Active Comparator|Part A Cohort 7 - ZF874 - Single Dose|Single oral dose of ZF874 by mouth after consuming a high-fat breakfast. Dose Level 3
16333817|NCT04443192|Active Comparator|Part B Cohort 1 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
16333818|NCT04443192|Placebo Comparator|Part B Cohort 1 - Placebo to ZF874|Two doses of placebo (12 h apart) by mouth daily for 28 days.
16333819|NCT04443192|Active Comparator|Part B Cohort 2 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
16333820|NCT04443192|Active Comparator|Part B Cohort 3 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
16333821|NCT04443192|Active Comparator|Part B Cohort 4 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
16333822|NCT04443179||Infants a family history of ASD/ADHD|
16333823|NCT04443179||Infants without a family history of ASD/ADHD|
16333824|NCT04443166|Experimental|Group A|At the beginning of the study (T0), group A will receive one course of PRP+HA program and group B will receive one HA course (a single HA injection (Hyajoint) weekly for 3 weeks). The PRP+HA program includes 3 HA injections and a single PRP injection (Arthrex double syringe system).
16333825|NCT04443166|Active Comparator|Group B|In the 6th month, alternately, group B will receive one PRP+HA program and group A will receive one HA course.
16333826|NCT04443153|Experimental|De-escalation|Subjects randomized to this arm will proceed from DSS to PF to SAP
16333827|NCT04443153|Experimental|Escalation|Subjects randomized to this arm will proceed from SAP to PF to DSS
16333828|NCT04443127|Experimental|Game-Based Rehabilitation|
16333829|NCT04443127|Placebo Comparator|Conventional Rehabilitation|
16333830|NCT04443114|Other|Early Arm|The early arm will receive the experimental organ donation workshop first, followed by the control workshop on end-of-life care.
16333831|NCT04443114|Other|Late Arm|The late arm will receive the control workshop on end-of-life care first, followed by the experimental organ donation workshop.
16333832|NCT04443101||Group（SN6CWS）|Group（SN6CWS）：Implant SN6CWS intraocular lens
16333833|NCT04443101||Group（MI60）|Group（MI60）：Implant MI60 intraocular lens
16333834|NCT04443101||Group（Aspira-aA）|Group（Aspira-aA）：Implant Aspira-aA intraocular lens
16333835|NCT04443088|Other|Dose Escalation|Subjects will receive escalating doses of INV-1120 orally once a day until un-acceptable toxicity or disease progression. Three to six patients will be enrolled per cohort to evaluate the safety and pharmacokinetics for each dose level. After the last patient in each cohort completes Cycle 1 (DLT observation period of 28 days), the Safety Evaluation Team (SET) will evaluate the safety data and pharmacokinetic collected from Cycle 1, and make the decision whether to escalate the dose before opening the second cohort.
16333836|NCT04443075||exposed group|The exposed group consists of the frontline medical workers who take part in the medical team to support Wuhan.
16333837|NCT04443075||non-exposed group|This group includs medical workers who didn't join in the medical team to support Wuhan.
16333840|NCT04443049|Active Comparator|Lenvatinib +Placebo|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
16333841|NCT04443049|Experimental|Lenvatinib and mebendazole|Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
16333842|NCT04443036|Experimental|Albumin-bound Paclitaxel Combined With Toripalimab|"Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W
~Toripalimab：240 mg，IV d1，Q3W
~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months"
16333843|NCT04443023|Active Comparator|Sapien|Patients randomized to treatment
16333844|NCT04443023|Active Comparator|Myval|Patients randomized to treatment
16333845|NCT04443010|Experimental|Phase 1 part: Dose Finding|Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.
16333846|NCT04443010|Experimental|Phase 2 part: Signal Seeking|32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.
16333847|NCT04443010|Active Comparator|Phase 2b part: Activity Evaluation_control arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).
~- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide)."
16333848|NCT04443010|Experimental|Phase IIb part: Activity Evaluation_treatment arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).
~- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF."
16333849|NCT04442984|Active Comparator|FOLFOX6|5FU 400mg/m2 iv bolus d1, 5-FU 2400 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
16333850|NCT04442984|Experimental|mFOLFIRINOX|Irinotecan 180mg/m2 d1, 5FU 250mg/m2 iv bolus d1, 5-FU 2200 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
16333851|NCT04442971|Experimental|Music Stimulation|Patients preferred music is presented via headphones.
16333852|NCT04442971|Active Comparator|Alternative Auditory Stimulation|An audio book is presented via headphones.
16333853|NCT04442971|Sham Comparator|No Auditory Stimulation|Silence is presented via headphones.
16333854|NCT04442958|Experimental|Convalescent Plasma Therapy Group|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
16333855|NCT04442958|No Intervention|Non-Plasma Therapy Group|Standart critical care treatment group
16333856|NCT04442945|Experimental|ANAVEX3-71 Oral|Up to four single ascending doses of ANAVEX3-71 administered orally
16333857|NCT04442945|Placebo Comparator|Placebo arm Oral|Placebo administered orally
16333858|NCT04442932||Interventions|Per test, a minimum of 40 atopic subjects for a given allergy and a total of at least 100 non-atopic subjects. To ensure that sufficient subjects with valid results are enrolled, the atopic enrollment goal per allergy is approximately 50 subjects. For each allergen, approximately 20% of the samples must be in the range of 0.70 to 3.5 IUA/mL and the remainder must cover a measuring range that is representative of the target population. Results from a single positive subject can be used in the analyses of more than one allergen if the subject is sensitized for more than one allergen.
16333859|NCT04442919|Experimental|Ticagrelor followed with methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
16333860|NCT04442919|Active Comparator|Ticagrelor followed with morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
16333861|NCT04442919|Active Comparator|Ticagrelor|patients who received ticagrelor without any analgesia due to unstable angina
16333862|NCT04442906|Active Comparator|group B|IGroup B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline
16333863|NCT04442906|Active Comparator|group BD|. Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
16333864|NCT04442906|Active Comparator|group BF|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).
16333865|NCT04442893|Experimental|Experimental group|The experimental group would be provided with a 6- session RFCBT program for 12 weeks (60-90 mins, once every two weeks).
16333866|NCT04442893|Other|Control group|The control group would receive a 6- session Health Education program for 12 weeks (60-90 mins, once every two weeks)
16333867|NCT04442867|Experimental|Intervention group|Subjects will receive nurse-led case management supported by a social service team.The nurse, functioning as a case manager, is involved in the initial assessment of the participant using the Omaha system. After the initial assessment, the NCM will equip participants with the skills required to perform self-care in health maintenance, including self-monitoring of vital signs, medication adherence, and sources of help if needed.
16333868|NCT04442867|Other|Control group|Participants in the control group will receive a monthly social control call from a trained research assistant
16333869|NCT04442854|Experimental|cognitive behavioral group therapy|A cognitive behavioral group prevention program An 8-session, cognitive behavioral group prevention program, featuring cultural appropriateness. One session per week, 3 hours for each session. The program contents include psychoeducation, cognitive skills training to identify and challenge maladaptive cognitions, and behavioral skills training. Each session contains mood check and homework. Participants' own examples are used in the group to demonstrate the CBT skills.
16333870|NCT04442854|No Intervention|Wait-list control group|No immediate intervention No intervention was provided when the experimental group was receiving services, but the same cognitive behavioral group prevention program was delivered to the wait-list control group after that.
16333871|NCT04442841|Experimental|Single arm (vaccine)|No further description
16333872|NCT04442828||Primary mitral regurgitation|Patients with mitral regurgitation due to mitral valve disease
16333873|NCT04442828||Secondary mitral regurgitation|Patients with mitral regurgitation due to ventricular or atrial disease
16333874|NCT04442802|Experimental|Long time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 6 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
16333875|NCT04442802|Active Comparator|Short time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 3 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
16333876|NCT04442776|Experimental|Intervention group|The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.
16333877|NCT04442776|No Intervention|Control group|The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication
16333878|NCT04442763|Experimental|Densah burs|Osseodensification using Densah burs
16333879|NCT04442763|Active Comparator|Standard drills|conventional drilling using standard drills
16333880|NCT04442750|Experimental|A (0.5%) group|patients will receive a single shot erector spinae block with 30 ml 0.5% bupivacaine followed by general anesthesia
16333882|NCT04442750|Experimental|C (0.25%) group|patients will receive a single shot erector spinae block with 30 ml 0.25% bupivacaine followed by general anesthesia
16333885|NCT04442724|Experimental|Single Arm - Bladder Chemo-Radiotherapy|Fiducial marker placement & cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
16333886|NCT04442711||PFBIO-EXA|All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.
16333887|NCT04442698||Diabetic MGB post op patients|Diabetic MGB post op patients
16333888|NCT04442672|Experimental|compartment syndrome model group(CSM group)|
16333889|NCT04442672|Sham Comparator|sham group|
16333890|NCT04442646|Experimental|ASG|"experimental asthma school group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day"
16333891|NCT04442646|No Intervention|CG|Control group will attend control visits every three months.
16333892|NCT04442633|Active Comparator|conventional therapy|topical corticosteroid plus antifungal
16333893|NCT04442633|Experimental|Glutamine with a topical corticosteroid plus antifungal|Glutamine therapy in combination with a topical corticosteroid plus antifungal
16333894|NCT04442620|Experimental|1st group: Physical Activity and Mediterranean Diet (PA-MD)|"A first group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 35-40% fat, 20% proteins, and 40-45% carbohydrates. Healthy fats (a maximum of 8-10% from saturated fats, >20% from monounsaturated fats, >10% from polyunsaturated fats and <300 mg/day of cholesterol) and low glycaemic index foods rich in fibre (not less than 30-35g /day) are strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Such diet reflects the traditional Mediterranean Diet described in the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet)-Plus study.
~As for physical activity, patients the participants will be recommended a 35 minutes interval training session three times a week. Physical activity sessions of 35 minutes will consist of 5 minutes warm-up, 20 minutes interval training, and 10 minutes breathing and stretching."
16333895|NCT04442620|Experimental|2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)|A second group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30-35% fat, 25% proteins, and 40-45% carbohydrates. Healthy fats and low glycaemic index foods will be strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Participants will be advised to consume 7 meals a day, gradually reducing the caloric content at each main meal, and to walk 10.000 steps a day.
16333896|NCT04442620|Active Comparator|3rd group: Control diet (CD)|A third group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30% fat, 15% proteins, and 55% carbohydrates, and maintain an adequate fibre (25g/day) and cholesterol (<250mg/day) intake. Meal frequency will be of 3-5 meals a day. Moreover, the participants will be advised to walk 10.000 steps a day.
16333897|NCT04442607|Experimental|AI arm|Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
16333898|NCT04442594|Experimental|personalized video|Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
16333899|NCT04442594|Active Comparator|generic vidéo|The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.)
16333900|NCT04442581|Experimental|Treatment (cabozantinib S-malate, pembrolizumab)|Patients receive cabozantinib S-malate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16333901|NCT04442568|Active Comparator|ERAS|all patients in this group will be performed LSG under a specified anesthesia protocol. This protocol includes non-opioid analgesia and sedation. Also short-acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the second hour postoperatively, also will be started oral intake between second and fourth hours.
16333902|NCT04442568|No Intervention|no ERAS|all patients in this group will be performed LSG under a conventional anesthesia protocol which is depended on the anesthesiologist . This protocol includes opioid analgesia and sedation. Also short and long acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the fourth hour postoperatively, also will be started oral intake in the next day morning after surgery.
16333903|NCT04442555|Experimental|3-Hydroxybutyrate treatment|HVMN Ketone Ester 0,5 g / kg
16333904|NCT04442555|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
16333905|NCT04442542|Experimental|Respiratory exercises plus method JaPer|Respiratory exercises plus the new intervention protocol with an inspirometer (JaPer Method)
16333906|NCT04442542|Active Comparator|Protocol of use of inspirometer in a conventional way|Respiratory exercises plus conventional use of the inspirometer.
16333907|NCT04442529|No Intervention|Control|Pregnant women will receive prenatal care as usual.
16333908|NCT04442529|Experimental|Intervention|Pregnant women will receive the 12-session Mothers and Babies intervention
16333909|NCT04442516||Adults receiving Cisplatin as part of their cancer therapy|
16333910|NCT04442516||Children receiving Cisplatin as part of their cancer therapy|
16333913|NCT04442490|Experimental|SAGE-217|Participants will receive SAGE-217 capsules, once daily for 14 days. The dose may be decreased based on safety and tolerability.
16333914|NCT04442490|Placebo Comparator|SAGE-217 Matched Placebo|Participants will receive SAGE-217 matched-placebo capsules, once daily for 14 days.
16333915|NCT04442477||Experimental: Enriched Protein Fractions|This group was given Infant formula with enriched protein fractions
16333916|NCT04442477||Active Comparator: Protein Fractions|This group was given Infant formula with protein fractions
16333917|NCT04442464|Experimental|Study Eye|One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
16333918|NCT04442464|No Intervention|Control Eye|Non-lens wearing eye
16333919|NCT04442451|Experimental|Control Exercise|Low-load knee extension resistance training (20% of 1-RM) without blood flow restriction. A 10-cm wide inflatable cuff will be placed around the upper portion of the thigh but not inflated.
16333920|NCT04442451|Experimental|Blood Flow Restriction Exercise|Low-load knee extension resistance training (20% of 1-RM) with blood flow restriction using a 10-cm wide inflatable cuff placed around the most proximal part of the exercising thigh. Blood flow will be restricted in the BFR leg at above the limb occlusion pressure of the and this will be determined prior to the exercise while the participant is seated in the knee extensor machine. The cuff pressure during the BFR protocol will be 10 mmHg above limb occlusion pressure.
16333921|NCT04442438|Experimental|Intensive care unit 1|Receives of intervention consisting of monthly moral case deliberation (ethical decision-making) meetings, planned and set up by ICU professionals which have received the task of being more attentive to ethical situations during work.
16333922|NCT04442438|Other|Intensive care unit 2|First non-intervention, then flips to experimental arm type after six months.
16333923|NCT04442438|Other|Intensive care unit 3|First non-intervention, then flips to experimental arm type after six months.
16333924|NCT04442438|Other|Intensive care unit 4|First non-intervention, then flips to experimental arm type after twelve months.
16333925|NCT04442438|Other|Intensive care unit 5|First non-intervention, then flips to experimental arm type after twelve months.
16333926|NCT04442438|Other|Intensive care unit 6|First non-intervention, then flips to experimental arm type after Eighteen months.
16333927|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IVVI, Female
16333928|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IVVI, Male
16333929|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
16333930|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
16333931|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IVVI, Female
16333932|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IVVI, Male
16333933|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type IIII, Female
16333934|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type IIII, Male
16333935|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IVVI, Female
16333936|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IVVI, Male
16333937|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type IIII, Female
16333938|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type IIII, Male
16333939|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IVVI, Female
16333940|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IVVI, Male
16333941|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type IIII, Female
16333942|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type IIII, Male
16333943|NCT04442412|Experimental|Arm B (Experimental):|"Patients randomized to Arm B will receive a prephase with oral prednisone and a prephase therapy with VitD according to the below reported schedule followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.
~Schedule for VitD supplementation: 25,000 U/day starting on day -6:
~daily loading dose for 7 days if 25 VitD baseline level 20-40 ng/ml daily loading dose for 14 days if 25 VitD baseline level < 20 ng/ml followed by weekly maintenance supplementation of 25,000 U for the entire duration of immunochemotherapy (6 courses every 21 days - 18 weeks), regardless of the baseline level of 25 VitD."
16333944|NCT04442412|Other|Arm A (Standard arm)|"Patients randomized to Arm A will receive a prephase with oral prednisone followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.
~If patients randomized to arm A are already on VitD, they are allowed to continue receiving VitD supplementation at a dose that can be considered part of the standard of care and does not exceed the maximum standard VitD dose recommended for general adult and elderly population , up to 10,000 U/week VitD"
16333945|NCT04442399|Experimental|Intervention|The intervention was based on the WHO-endorsed manual entitled Positive Connections: Leading Information and Support Groups for Adolescents Living with HIV. For Family Connections, a caregiver companion guide was developed. In brief, adolescent/caregiver pairs attended 10 intervention sessions held every other Saturday at their HIV clinic over a six-month period.
16333946|NCT04442399|No Intervention|Comparison|The comparison arm consisted of standard of care for adolescents as offered at the HIV clinics.
16333947|NCT04442373||Patients undergoing THR with no known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment in THR patients
16333948|NCT04442373||Patients undergoing THR with known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
16333949|NCT04442347|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
16333950|NCT04442347|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
16333951|NCT04442334||The LITMUS Study Cohort|Prospectively recruited NAFLD patients, recruited according to The European NAFLD Registry study protocol.
16333952|NCT04442334||The LITMUS Metacohort|Collated data and biological samples on patients with histologically characterised NAFLD prospectively recruited at contributing academic centres across Europe.
16333953|NCT04442334||EFPIA Clinical Trial Cohort|Collated data and biological samples on patients with histologically characterised NAFLD that have participated in phase 2 and phase 3 trials of IMPs for NAFLD.
16334209|NCT04440631||Control group (healthy volunteers)|
16333954|NCT04442321|Active Comparator|PENS plus exercise group|Experimental: PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently . It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
16333955|NCT04442321|Sham Comparator|Sham PENS plus exercise group|Sham Comparator: Sham PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently. It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
16333956|NCT04442295|Experimental|Single Ascending Doses|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive single doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 10 additional patients.
16333957|NCT04442295|Experimental|Multiple Ascending Doses|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive multiple doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 10 additional patients.
16333958|NCT04442269|Experimental|dupilumab|Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
16333959|NCT04442269|Experimental|Placebo|Matching dupilumab without active substance
16333960|NCT04442256|Other|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a monthly fashion. Observation period will be 30 minutes after injection
16333961|NCT04442230|Experimental|NasoVAX|Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
16333962|NCT04442230|Placebo Comparator|Placebo|Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
16333963|NCT04442191|Experimental|Convalescent plasma|This study will utilize convalescent plasma from donors recovered from infection with SARS-CoV-2 (which causes COVID-19) with neutralizing antibody titers >1:64.
16333964|NCT04442191|Placebo Comparator|Placebo|Placebo utilized in this study will include Fresh Frozen Plasma collected before the COVID-19 pandemic began. As an extra control, some of this plasma will be saved and tested for COVID-19 antibodies to ensure they are not present.
16333965|NCT04442178|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
16333966|NCT04442178|Placebo Comparator|Placebo|Intramuscular (IM) administration of Saline twice a week for 3 weeks
16333967|NCT04442152|Experimental|Intervention|See intervention description
16333968|NCT04442152|No Intervention|Control|Participants who were randomized into the control arm were and will be surveyed at the same time point as intervention participants, but did not receive any intervention.
16333969|NCT04442139||Mini-Gastric Bypass|Patients reported completing survey following Mini-Gastric Bypass
16333970|NCT04442126|Experimental|NM21-1480 Treatment arm|
16333971|NCT04442113|Active Comparator|Control group|Pulmonary vein isolation alone (by catheter ablation)
16333972|NCT04442113|Experimental|STAR guided ablation group|Pulmonary vein isolation plus ablation guided by STAR MappingTM
16333973|NCT04442100|Experimental|bioprosthesis|"prosthetics of heart valves with dentures MedEng-Bio"
16333974|NCT04442074||Stroke Patients|These patients were hospitalized in the neurology / neurovascular department of the Paris Saint-Joseph Hospital Group, for the management of a transient ischemic infarction or accident for which the diagnosis of ipsilateral carotid diaphragm was accepted, between April 2017 and April 2020.
16333975|NCT04442061|Active Comparator|Active transcranial magnetic stimulation|excitatory TMS will be applied to the right posterior STS
16333976|NCT04442061|Sham Comparator|Sham transcranial magnetic stimulation|The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
16333977|NCT04442048|Experimental|IMM-101|The treatment regimen with IMM-101 will be one 1.0 mg (= 0.1 mL) dose given on Day 0, followed by a second dose of 0.5 mg (= 0.05 mL) on Day 14 (-2/+5 days), and a third Dose of 0.5 mg (= 0.05 mL) on Day 45 (+/-14 days)
16333978|NCT04442048|Active Comparator|Observation|
16333979|NCT04442035|Experimental|The teatment group|5-element misic therapy
16333980|NCT04442035|Experimental|The control group|health education
16333981|NCT04442022|Experimental|Phase 2: Selinexor 40 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1, and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
16333982|NCT04442022|Experimental|Phase 2: Selinexor 60 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
16333983|NCT04442022|Active Comparator|Phase 2: R-GDP|Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
16333984|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
16333985|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
16333986|NCT04442022|Placebo Comparator|Phase 3: Placebo + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
16334210|NCT04440605||cI|clincal TNM stage I
16333987|NCT04442009|Active Comparator|Group S = SCPB group|"US-guided SCPB will be performed at the end of the surgery before extubation, with patients in the supine position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the high frequency linear probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath and a 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used.
~Sternocleidomastoid (SCM) muscle will be visualized. The 22 G needle will be inserted between the SCM and the prevertebral fascia by using in plane technique horizontally. The needle tip will be corrected with injecting 2 ml of normal saline. Then a 20 mL dose of 0.25% bupivacaine will be injected here. The same procedure will be performed for the opposite site (totally 40 mL dose of 0.25% bupivacaine)."
16333988|NCT04442009|No Intervention|Group C = Control group|Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16333989|NCT04441996|Experimental|Therapeutic plasma exchange (TPE)|Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
16333990|NCT04441996|Active Comparator|Standard of care|Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
16333991|NCT04441970|Active Comparator|Neutral position|General anesthesia will be induced and nasotracheal tube will be placed through the patient's nose. After 30 seconds, the cuff pressure will be measured using a cuff manometer. Inspiratory tidal volume, expiratory tidal volume, peak inspiratory pressure, and end-tidal carbon dioxide waveform will be recorded three times according to breathing. Whether ventilation is not adequate and air is leaking will be recorded.
16333992|NCT04441970|Experimental|Head extension position|After changing the posture of the head and neck into head extension, cuff pressure will be recorded.
16333993|NCT04441970|Experimental|Head flexion position|After changing the posture of the head and neck into head flexion, cuff pressure will be recorded.
16333994|NCT04441970|Experimental|Head rotation position|After changing the posture of the head and neck into head rotation, cuff pressure will be recorded.
16333995|NCT04441957||Group A, MOCA-group|Procedure/Surgery: MOCA Mechano-Chemical Ablation plus Elastic Compression
16333996|NCT04441957||Group B, Elastic Compression only group|Treatment: Elastic Compression only
16333997|NCT04441944||Telemedicine Cases|Patients presenting to rural emergency departments who had real-time provider-to-provider telemedicine used to supplement their emergency department care.
16333998|NCT04441944||Non-Telemedicine Cases|Patients presenting to rural emergency departments who did not have real-time provider-to-provider telemedicine used to supplement their emergency department care.
16333999|NCT04441931|Experimental|LY3832479|LY3832479 administered intravenously (IV).
16334000|NCT04441931|Placebo Comparator|Placebo|Placebo administered IV.
16334001|NCT04441918|Experimental|Test group|
16334002|NCT04441918|Experimental|Control group|
16334008|NCT04441892|Experimental|QTc Meter|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device
16334009|NCT04441892|Experimental|QTc Meter - Healthy Controls|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.
16334010|NCT04441879|Experimental|Blended Be a Mom|Women will receive a blended intervention (integrating face-to-face and online sessions) for the treatment of postpartum depression.
16334011|NCT04441879|Active Comparator|Control (treatment as usual)|Women will receive intervention provided by primary healthcare units (treatment as usual).
16334012|NCT04441866|Active Comparator|Automated algorithms|Automated 3D techniques in measuring fetal biometry and reconstructing standard anatomical planes
16334013|NCT04441866|Placebo Comparator|Standard technique|Standard 2D assessment
16334014|NCT04441853|Experimental|YouTube video group|The intervention group attended five sessions of weekly-based tutorial, by watching YouTube videos on older people's and their caregivers' lived experience. On each session, they would joined post-video group discussion.
16334015|NCT04441853|Active Comparator|No YouTube video group|The control group were offered for five sessions of tutorial with same content without YouTube or other audio-visual tools. They also needed to join for group discussion in each tutorial.
16334016|NCT04441840|Active Comparator|Active Probiotic Culture|Active culture of Bacillus Coagulans Dose: 1 x 10^9 colony forming units (CFU)
16334017|NCT04441840|Active Comparator|Inactive Probiotic Culture|"Inactive culture of Bacillus Coagulans (GBI-30, 6086) - Marked as StaImune Dose: 1 x 10^9 colony forming units (CFU)"
16334018|NCT04441827|No Intervention|Control|Usual care
16334019|NCT04441827|Experimental|Pranayama|Pranayama breathing exercise
16334020|NCT04441827|Experimental|Deep breathing exercise|Deep breathing exercise
16334021|NCT04441814||Lung cancer screening subjects|Subjects enrolled in SMILE lung cancer screening trial
16334061|NCT04441567|No Intervention|Phase 1|Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2
16334022|NCT04441801|Experimental|15 seconds|Stretching of the hamstring muscles will be performed by the primary researcher. A straight-leg-raising technique will be used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible, each subject's knee will be maintained in extension with the ankle at 90 degrees without medial (internal) or lateral (external) rotation of the lower extremity, and the extremity was raised until the subject reported discomfort. The subject was asked to relax the lower extremity in an effort to prevent contracting muscles from affecting the stretch and to allow for a slow stretch. stretching will continue for 15 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
16334023|NCT04441801|Experimental|30 seconds|the same stretching technique will continue for 30 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
16334024|NCT04441801|Experimental|60 seconds|the same stretching technique will continue for 60 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
16334025|NCT04441801|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end.
16334026|NCT04441788|Experimental|ION-827359|Single-dose of ION-827359 will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks
16334027|NCT04441788|Placebo Comparator|Placebo|Single-dose of placebo will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks
16334029|NCT04441762|Active Comparator|intravenous|30 mg intravenous ketorolac in 10 ml syringe + 1 mL Normal Saline 9% using an intranasal device (0.5 ml in each nostril).
16334030|NCT04441762|Experimental|Intranasal|30 mg intranasal ketorolac in 1 ml intranasal device (0.5 ml in each nostril) + 10 ml Intravenous Normal Saline 9%.
16334031|NCT04441749||nCLE Analysis|Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis
16334032|NCT04441736|Active Comparator|High flow nasal cannula|A device og high flow nasal cannula giving 60 litres / min
16334033|NCT04441736|Placebo Comparator|Conventional oxygen|Nasal cannula giving oxygen up to 10 litres / minute
16334034|NCT04441723|Active Comparator|lag screw with dynamic mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
16334035|NCT04441723|Active Comparator|lag screw with static mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
16334036|NCT04441710||Caregivers|Staff of university hospitals
16334037|NCT04441710||Primary care caregivers|Population of professional caregivers such as general practitioner or freelance nurse.
16334038|NCT04441710||Patients|
16334039|NCT04441697||continuous apomorphine delivery|apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day
16334040|NCT04441697||continous levodopa/carbidopa delivery|levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day
16334041|NCT04441697||deep brain stimulation|bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings
16334042|NCT04441684|Experimental|PCR+ group|This group includes any symptomatic person with a positive COVID result, with a RT-PCR test carried out at least 10 days before inclusion.
16334043|NCT04441684|Experimental|PCR- group|This group includes any symptomatic person with a negative RT-PCR COVID 19 test carried out at least 10 days before inclusion.
16334044|NCT04441684|Experimental|No PCR|This group includes any person, for which no COVID 19 RT- PCR testing was performed.
16334045|NCT04441671|Experimental|Open label|Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00
16334046|NCT04441658|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.
16334047|NCT04441658|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
16334048|NCT04441645|Experimental|the acupoint-on-head group|pressing acupoints only on head
16334049|NCT04441645|Experimental|the acupoint-on-body group|pressing acupoints only on body
16334050|NCT04441645|Experimental|the acupoint-on-head-and-body group|pressing acupoints on head and body
16334051|NCT04441645|No Intervention|the control group|routine care
16334052|NCT04441632|Other|Positive feedback|Participants in the study will provide consistent positive feedback to the colleagues they work with in the medical ICU (MICU) over a 4 week duration.
16334053|NCT04441619|Active Comparator|Repeated exposure|Participants will complete four exercise sessions designed to induce delayed onset muscle soreness in the biceps
16334054|NCT04441619|Active Comparator|Single exposure|Participants will complete one exercise session designed to induce delayed onset muscle soreness
16334055|NCT04441619|No Intervention|Natural history|Participants will complete all sensory testing and imaging but not perform any exercise sessions.
16334056|NCT04441606|Experimental|Different types of cancer|"The study population will include up to 50 patients with disease in whom a diagnostic challenge is met, including but not limited to:
~Inconclusive findings on 18F-FDG PET/CT or other imaging modalities.
~Better delineation of tumor extent prior to therapy
~Malignancies known to show variable avidity to FDG and at times, no uptake at all (e.g. Exocrine Pancreatic cancer, Gastric carcinoma, Mucin-producing or Signet-ring carcinoma).
~Patients unable to optimally comply with the required preparation for FDG imaging.
~The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff."
16334057|NCT04441593|Experimental|Intervention|Videoconferencing Intervention for Heavy Drinking and Chronic Pain
16334058|NCT04441593|Active Comparator|Control|Treatment as Usual
16334059|NCT04441580|Experimental|Artificial intelligence arm|Patients undergoing colonoscopy with artificial intelligence.
16334062|NCT04441567|Experimental|Phase 2|Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.
16334063|NCT04441541|Experimental|Treadmill with auditory feedback group|
16334064|NCT04441541|Experimental|Treadmill with visual feedback group|
16334065|NCT04441541|Experimental|Treadmill with auditory and visual feedback group|
16334066|NCT04441541|Active Comparator|Treadmill training group|
16334067|NCT04441528|Experimental|Lid wipes containing terpinen-4-ol and sodium hyaluronate|The lid wipes will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
16334068|NCT04441528|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
16334069|NCT04441515|Experimental|Music|music supplied by ipod
16334070|NCT04441515|Active Comparator|oral books|Listening to books on ipod
16334071|NCT04441515|Placebo Comparator|usual care|Usual care
16334072|NCT04441476||ICU staff|
16334073|NCT04441463|Experimental|cohort|Mother-child couple
16334074|NCT04441450|Experimental|[14C]ICP-022|Subjects will take a single of 150mg 100μCi of [14C]ICP-022.
16334075|NCT04441437|Experimental|Splint Group|1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
16334076|NCT04441437|Placebo Comparator|No-Splint Group|1-hour task-oriented training without wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
16334077|NCT04441424|Experimental|Convalescent plasma group|21 critically-ill COVID-19 patients were given convalescent plasma: 400 ml of convalescent plasma from COVID-19 recovered subjects. The plasma infusion lasts for one hour.
16334078|NCT04441424|Other|Control group|"This group is 28 critically-ill COVID-19 patients who are at the same disease stage to those of experimental group that were treated with conventional therapy without taking convalescent plasma.
~The conventional therapy: 400 mg once PO Hydroxychloroquine/day with 250mg once PO Azithromycin."
16334079|NCT04441411|Other|NEMOST-AIS|This study is designed as a cohort study.
16334080|NCT04441398|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
16334081|NCT04441398|Placebo Comparator|Placebo|Subjects will receive placebo TID.
16334082|NCT04441385|Experimental|Test arm|100 subjects will be randomly assigned to this arm. Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
16334083|NCT04441385|Other|Control arm|100 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health has issued detailed guidelines for the management of COVID-19. Local Institutional Guidelines and Protocols for supportive management will also be implemented.
16334084|NCT04441359|Experimental|supplemented formula|Standard formula supplemented with prebiotic inulin-type fructans
16334085|NCT04441359|Placebo Comparator|standard formula|Standard Formula not supplemented with prebiotic inulin-type fructans
16334086|NCT04441346||patients with recent hemodialysis(less than 6 month|
16334087|NCT04441346||patients on hemodialysis more than 6 months and l|
16334088|NCT04441346||patients on hemodialysis more than 5 years|
16334089|NCT04441333|Experimental|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.
16334090|NCT04441320|Experimental|CMUS group|Coated metal ureteral stent is indwelled.
16334091|NCT04441320|Other|DJS group|Double-J stent is indwelled
16334092|NCT04441307|Active Comparator|Healthy Foundations|A community-based parenting education program with individual family check ins will be implemented to all participants assigned to this arm.
16334093|NCT04441307|Experimental|Family Foundations|An adapted Family Foundations parenting program for expecting first time parents with individual family check ins will be implemented to all participants assigned to this arm.
16334094|NCT04441294|Experimental|ACE-Plus|"ACE-Plus is a one-on-one dual-session intervention for males aged 16 to 20 within foster care or preventive services settings which promotes condom use and knowledge of dual methods of contraception. The goal of ACE-Plus is to promote correct and consistent condom use of male latex condoms during penile-vaginal sex and to promote male engagement (e.g., discussion, decision-making) with their female partners in the use of female-centered contraception methods.
~Session one focuses on correct and consistent condom use for purposes of HIV/STD prevention including information and activities that address teen pregnancy prevention. Session two, which occurs within 10 to 14 days of the first session, promotes dual-method contraceptive use. Both sessions are one hour."
16334095|NCT04441294|No Intervention|On Track|On Track was the alternative program provided to males randomly assigned to the control group. On Track seeks to assist participants in identifying their aptitudes and preferences regarding their careers and their values associated with employment, and to provide tools to prepare them for the work setting and future job interviews. Participants learn how to identify attitudes, values, preferences, and challenges surrounding a career path, receive an understanding of the documents required for employment, and develop an initial employment strategy and action plan. Trained foster care agency staff deliver the curriculum to participating youth in two one-on-one sessions at agencies. Each session is one hour in length. Session two occurs 10 to 14 days after session one.
16334096|NCT04441281|Active Comparator|Single-tooth tenaculum (Pozzi forceps)|In the control arm, a single-tooth tenaculum, Pozzi forceps, used during routine IUD insertion, is employed to hold and stabilize the cervix.
16334097|NCT04441281|Experimental|AspivixTM cervical vacuum tenaculum|In the experimental arm, the investigational AspivixTM cervical vacuum tenaculum is employed to hold and stabilize the cervix.
16334098|NCT04441255|Experimental|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
16334099|NCT04441255|Experimental|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
16334100|NCT04441242|Placebo Comparator|Retrospective: Low lighting during screening colonoscopy|Screening colonoscopies performed with low lighting conditions.
16334101|NCT04441242|Active Comparator|Prospective: Ambient lighting during screening colonoscopy|Screening colonoscopies performed with ambient lighting conditions.
16334102|NCT04441229|Experimental|Treatment Group|Patients age 12-24 diagnosed with pediatric-onset Multiple Sclerosis
16334103|NCT04441216|No Intervention|Consultation only|Review by Chinese Medicine practitioner only
16334104|NCT04441216|Active Comparator|JinQi JiangTang Fang|JinQi JiangTang Fang (Rhizoma Coptidis, Radix Astragali and Flos Lonicerae)
16334105|NCT04441216|Active Comparator|JM-ELD|JQJT plus extra low dose Ophiopogonis Radix
16334106|NCT04441216|Active Comparator|JM-LD|JQJT plus low doses Ophiopogonis Radix
16334107|NCT04441203|No Intervention|Control|Heart failure clinic follow up
16334108|NCT04441203|Active Comparator|CardioMems|The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.
16334109|NCT04441190|Experimental|Digital Action Observation Therapy (Digital AOT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
16334110|NCT04441190|Experimental|Digital Mirror Therapy (Digital MT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
16334111|NCT04441190|Active Comparator|Conventional Occupational Therapy|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
16334112|NCT04441177|Experimental|Study group|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
16334113|NCT04441177|No Intervention|Control group|Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays.
16334114|NCT04441164|Experimental|Observation of Virtual Actions (steps 1 and 3)|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
16334115|NCT04441164|Placebo Comparator|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
16334116|NCT04441164|Other|Patients|It will be offered to patients hospitalized in these 2 services and presenting post-resuscitation ICU-weakness, especially in the aftermath of COVID infection, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
16334117|NCT04441164|Other|Caregivers|It will be offered to caregivers of the ICU of the Rennes University Hospital, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
16334118|NCT04441164|Experimental|Relaxation (step 3)|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
16334119|NCT04441164|Experimental|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
16334120|NCT04441164|Placebo Comparator|Observation of Virtual Actions|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
16334121|NCT04441164|Experimental|Haptic stimulation|Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
16334122|NCT04441164|Placebo Comparator|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
16334123|NCT04441151|Experimental|Experimental group|Pulmonary rehabilitation therapy
16334124|NCT04441151|No Intervention|Control group|Routine medical treatment
16334125|NCT04441138|Experimental|Concurrent, Split Course Chemoradiation Followed by Durvalumab|Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
16334126|NCT04441125||Experimental|The mothers in the experimental group will receive oxytocin induction before and after delivery(n:35).
16334127|NCT04441125||No Intervention|The mothers in the control group will not receive any oxytocin induction before delivery, and will receive oxytocin induction in the end of delivery(n:35)
16334128|NCT04441112|Experimental|Ketorolac Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with ketorolac.
16334129|NCT04441112|Active Comparator|Triamcinolone Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with triamcinolone.
16334130|NCT04441112|Experimental|Ketorolac Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with ketorolac.
16334131|NCT04441112|Active Comparator|Triamcinolone Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with triamcinolone.
16334132|NCT04441099|Experimental|Dose-escalation Cohort (DEC)|Escalating doses of NBE-002 depending on cohort at enrollment.
16334133|NCT04441099|Experimental|Safety-expansion Cohort (SEC)|Dose to be determined based on DEC.
16334134|NCT04441099|Experimental|Expansion Cohort 1 (EC1)|Dose to be determined based on DEC and SEC.
16334211|NCT04440605||cII|clinical TNM stage II
16334136|NCT04441086|Experimental|eMotion|The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for aging rural adults following a first cardiac event in tandem with usual cardiac rehabilitation. The intervention helps patients recognize their emotions, balance emotional and physical wellbeing, and implement emotion regulation strategies effectively.
16334137|NCT04441086|Active Comparator|Healthy living active control|
16334138|NCT04441086|No Intervention|Usual care|
16334139|NCT04441073|Experimental|Lignocaine|preoperative nebulization of lignocaine
16334140|NCT04441073|Placebo Comparator|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
16334141|NCT04441060|Experimental|distress intervention subject group|Distress intervention program will be developed, and applied to the subject group, and they will be assessed before and after the intervention program with several tools.
16334142|NCT04441060|No Intervention|distress intervention control group|No intervention will be applied to the control group. They will be assessed before and after the intervention program with same tools with subject group.
16334143|NCT04441047|Experimental|Vaccination|ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
16334144|NCT04441034|Experimental|Anti-convulsant medication|The participants will be randomized to receiving an anti-convulsant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
16334145|NCT04441034|Experimental|Anti-depressant medication|The participants will be randomized to receiving an anti-depressant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
16334146|NCT04441021||Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
16334147|NCT04441008|Experimental|aiTBS arm|aiTBS treatment as lead-in phase to ECT standard of care treatment.
16334148|NCT04441008|Active Comparator|ECT arm|ECT as clinically indicated.
16334149|NCT04440995|Experimental|PECS block(P) group|PECS group (P) received general anesthesia and pectoral nerve block(PECS block) with 025% ropivacaine after surgical resection of breast by operator.
16334150|NCT04440995|No Intervention|Control(c) group|only received general anesthesia
16334151|NCT04440982|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015
16334152|NCT04440982|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
16334153|NCT04440969|Experimental|Intervention|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks. (Week 1 - 24)
16334154|NCT04440969|Experimental|Wait-list control|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks after Intervention Group has completed intervention. (Week 25 - 48)
16334155|NCT04440956|Experimental|Intervention|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection."
16334156|NCT04440943|Experimental|CDX-527|"Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.
~Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase."
16334157|NCT04440930|Experimental|White tea|
16334158|NCT04440930|Active Comparator|Salt water with soda|
16334159|NCT04440917|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib
16334160|NCT04440904||Characteristic of aortic length and body surface mark|The diameters and lengths of blood vessels and the distances on the body surface were measured by three-dimensional reconstruction using related Software on CT Workstation
16334161|NCT04440891|Experimental|TMS-Stimulation with X-Torp task|TMS with VR 1 experimental arm
16334162|NCT04440891|Experimental|TMS-Stimulation with MindMotion Go|TMS with VR 2 experimental arm
16334163|NCT04440891|Sham Comparator|TMS-Sham with X-Torp task|TMS sham control with VR 1
16334164|NCT04440891|Sham Comparator|TMS-Sham with MindMotion Go|TMS sham control with sham VR 2
16334165|NCT04440878|Experimental|Static stretching|Static stretching will be administered to the hamstring muscles in the first group.
16334166|NCT04440878|Experimental|Mulligan TSLR technique|The Mulligan TSLR technique will be administered on the same muscle in the second group.
16334167|NCT04440865|Active Comparator|Arm 1- Standard colonoscopy|Standard colonoscopy is performed
16334168|NCT04440865|Active Comparator|Arm 2- Colonoscopy assisted by Genius|Colonoscopy assisted by Genius artificial intelligence system is performed
16334169|NCT04440852|Experimental|TEACCH intervention|TEACCH intervention for ASD
16334170|NCT04440852|No Intervention|conventional rehabilitation group|Other conventional interventions
16334171|NCT04440839|Experimental|Intervention|Telemedicine specialty consultation for patients
16334172|NCT04440839|No Intervention|Standard Care|Standard in person referral to a specialist
16334173|NCT04440826|Active Comparator|Whole Food Meal|Whole foods meal - grilled cheese and drink meal
16334212|NCT04440605||cIII|clinical TNM stage III
16334175|NCT04440826|Experimental|Gluten-Free and Lactose-Free Meal|Gluten-free and lactose-free foods - grilled cheese and drink meal
16334176|NCT04440813|Active Comparator|Clinician Training|Traditional healers randomized to the control arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by trained medical personnel.
16334177|NCT04440813|Experimental|Healer + Clinician Training|Traditional healers randomized to the intervention arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by both healers who already use PPE regularly and trained medical personnel.
16334178|NCT04440800||Study participants|All patients will receive the intervention
16334179|NCT04440787||Three point cuff palpation and Blck mark line technique|"In Three point cuff palpation technique the cuff will be palpated just below the cricothyroid membrane,at the level of suprasternal notch and below the suprasternal notchand the tube is re-positioned in case of any discrepancy between the black mark line technique and three point cuff at three different over the trachea."
16334180|NCT04440774|Experimental|CHIK low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334181|NCT04440774|Experimental|CHIK mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334182|NCT04440774|Experimental|CHIK high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334183|NCT04440774|Experimental|ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334184|NCT04440774|Experimental|ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334185|NCT04440774|Experimental|ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334186|NCT04440774|Experimental|CHIK ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334187|NCT04440774|Experimental|CHIK ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334188|NCT04440774|Experimental|CHIK ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334189|NCT04440774|Placebo Comparator|Placebo|Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
16334190|NCT04440761||Troponin rise/ diagnosis of MINOCA|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease.
16334191|NCT04440748|Experimental|Experimental Group|Participants in the experimental group will perform additional high-intensity therapy on the T-Chair 2.0, which is a newly developed non-CE-marked prototype to train trunk control and sitting balance. This they will do in addition to their normal rehabilitation program.
16334192|NCT04440748|Active Comparator|Control Group|Participants in the control group will execute their normal rehabilitation program.
16334193|NCT04440735|Experimental|DSP107 monotherapy|DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. The study will include up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
16334194|NCT04440735|Experimental|DSP107 in combination with atezolizumab|DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion.
16334195|NCT04440722||Transgender individuals|All transgender individuals referred to center of gender identity Odense
16334196|NCT04440709|Experimental|Brain/neural hand exoskeleton (B/NHE)|
16334197|NCT04440696|Experimental|group 1:dose 1.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
16334198|NCT04440696|Experimental|group 2:dose 3g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
16334199|NCT04440696|Experimental|group 3:dose 4.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
16334200|NCT04440696|Experimental|group 4:dose 6g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
16334201|NCT04440683||Antler plate group|Antler plate group
16334202|NCT04440670|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after birth. Cell dose for all patients was targeted at 5×107 cells per kilogram.
16334203|NCT04440670|Placebo Comparator|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume.
16334204|NCT04440657|Experimental|Immigrant parents|All enrolled parents will be included in the parenting program
16334214|NCT04440592|Placebo Comparator|Placebo|Oral tablet of placebo once a day.
16334215|NCT04440579|Active Comparator|Standard Cystoscopy|Patients will undergo a standard of care cystoscopy
16334216|NCT04440579|Experimental|PTNS and Cystoscopy|Patients will undergo PTNS while undergoing cystoscopy
16334217|NCT04440579|Sham Comparator|Sham PTN and Cystoscopy|Patients will undergo a sham PTNS procedure while undergoing cystoscopy
16334218|NCT04440566|Experimental|Systemic lupus erythematosus (SLE)|
16334219|NCT04440553|Active Comparator|Uniform random|In this arm the types of messages were sent out randomly, i.e. with a uniform random distribution.
16334220|NCT04440553|Experimental|Reinforcement learning|In this arm the types of messages were chosen by a reinforcement learning algorithm. The decision about which message to send was based on several contextual variables, including data for the pedometer app, and consecutive days since messages from different categories were sent.
16334221|NCT04440540|Experimental|lifestyle modification program group|
16334222|NCT04440540|Experimental|usual care group (control)|
16334223|NCT04440527|Experimental|Microshunt|Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).
16334224|NCT04440527|Active Comparator|Trabeculectomy|Patients will be treated with trabeculectomy.
16334225|NCT04440501|No Intervention|Control|Standard education regarding the gluten free diet by the nutritionist will be provided.
16334226|NCT04440501|Experimental|Virtual Reality Program to teach gluten free diet|"Virtual Reality Goggles and education regarding the gluten free diet will be provided.
~This group will receive VIRTUE, and watch a VR educational video, and play Chaos Café, which will be administered by a research team member. This group will be prescribed to take home the VIRTUE headset and play modules for 15 minutes per week until the 6-8 month follow up.
~The VIRTUE technology will track frequency of game playing to control for adherence to the prescription."
16334227|NCT04440488|Experimental|ARALAST NP 120 mg/kg|Participants will receive 120 mg/kg BW of ARALAST NP intravenous (IV) infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
16334228|NCT04440488|Experimental|ARALAST NP 60 mg/kg|Participants will receive 60 mg/kg BW of ARALAST NP IV infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
16334229|NCT04440475|Experimental|Tap Block|"TAP block at the end of the surgery, in addition to conventional postoperative oral medication as needed
~postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours"
16334230|NCT04440475|No Intervention|Conventional postoperative oral medication|postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours
16334231|NCT04440462|Experimental|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
16334232|NCT04440462|Active Comparator|Sterile water|2 ml of sterile water
16334233|NCT04440449|Experimental|Behavioral Lifestyle Intervention|The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
16334234|NCT04440449|Other|Group B control arm|Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.
16334235|NCT04440436|Experimental|IM19 CAR-T cells|IM19 CAR-T cells be administrated in two dose level
16334236|NCT04440423|Experimental|Clotiazepam Test Product|
16334237|NCT04440423|Active Comparator|Clotiazepam Reference Product|
16334238|NCT04440410||Hidradenitis suppurativa|Subjects with active mild, moderate, or severe HS disease using the HS-PGA assessment
16334239|NCT04440410||Atopic Dermatitis|Subjects with active moderate or severe AD disease using the PGA assessment
16334240|NCT04440371|Active Comparator|Tacrolimus|Phototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
16334241|NCT04440371|Active Comparator|calcipotriol / betamethasone|Phototherapy NBUVB will be given 3 times per week and calcipotriol & betamethasone containing cream will be applied once a day
16334242|NCT04440358|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
16334243|NCT04440345|Experimental|IBI362|"Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses.
~Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses.
~Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses.
~Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses.
~Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses."
16334244|NCT04440345|Placebo Comparator|placebo|Participants received matching placebo dose regiments by subcutaneous injection
16334245|NCT04440319|Experimental|Intervention groups (4 PHC/clinics)|Intervention group are individual with T2DM who will receive DM nutrition counseling at selected Public Health Care (PHC). There are 75 subjects in Intervention group at selected 2 districts by randomly and 4 PHC which is selected based on cluster. DM nutrition counseling will be delivered by a selected nutritionist at each PHC. Nutritionist will educate the subjects following DM nutrition education module properly. DM nutrition education will be delivered for 3 months and 30 minutes for each meeting.
16334246|NCT04440319|Experimental|Control groups (4 PHC/clinics)|As the same with intervention group, the control group will have 75 subjects but at the different districts and PHC to avoid contaminant. Control group will follow conventional DM nutrition education. Therefore, there is a selected nutritionists will deliver DM counseling at each PHC.
16334247|NCT04440293|Experimental|Group BBAT / CT|Group BBAT / CT started treatment with BBAT and received 2 days a week for 6 weeks. After the interval of 5-week, group BBAT / CT was treated with CT twice a week for 6 weeks.
16334248|NCT04440293|Experimental|Group CT / BBAT|Group CT / BBAT started treatment with CT and received 2 days a week for 6 weeks. After the interval of 5-week, group CT / BBAT was treated with BBAT twice a week for 6 weeks.
16334283|NCT04440046|Experimental|Real manual therapy|Real manual therapy directed to the thoracic spine and glenohumeral joint added to a therapeutic exercise program
16334249|NCT04440280|Active Comparator|NAC 10% group|Subjects in this group will be treated with eye drops containing a 10% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
16334250|NCT04440280|Active Comparator|NAC 20% group|Subjects in this group will be treated with eye drops containing a 20% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
16334251|NCT04440280|Placebo Comparator|Placebo group|Subjects in this group will be treated with a placebo (Visine Tears Dry Eye Relief artificial tears ophthalmic solution.)
16334252|NCT04440267|Experimental|single arm|Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) in CR. Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors.
16334253|NCT04440254|Other|ONE|One single group of patients
16334254|NCT04440241|Experimental|Test group|submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
16334255|NCT04440241|Experimental|Control group|non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
16334256|NCT04440228|Experimental|Schools implementing TeamSTEPPS|Select schools will take a participatory approach to collaboratively identify solutions to challenges in collocated school-based mental health services based upon the feedback of stakeholders and use TeamSTEPPS to support mental health team-school collaboration.
16334257|NCT04440215|Other|Control|Usual rehabilitation care (no telerehabilitation, interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals)
16334258|NCT04440215|Experimental|Telerehabilitation|A mix of home or rehabilitation center visits, telerehabilitation and interprofessional shared decision making process.
16334259|NCT04440202|Active Comparator|Conventional sea bream group|This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.
16334260|NCT04440202|Experimental|Enriched sea bream group|This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.
16334261|NCT04440189|Placebo Comparator|Placebo|Subjects will receive an injection of Lactated Ringers in their index knee
16334262|NCT04440189|Experimental|Stromal Vascular Fraction (SVF)|Subjects will receive an injection of Stromal Vascular Fraction in their index knee
16334265|NCT04440163|Experimental|1-Immuno Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
16334266|NCT04440163|Experimental|2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
16334267|NCT04440163|Experimental|3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
16334268|NCT04440163|Experimental|4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
16334269|NCT04440163|Experimental|5-Safety Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
16334270|NCT04440163|Experimental|6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
16334271|NCT04440163|Experimental|7-Safety Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
16334272|NCT04440163|Experimental|8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
16334273|NCT04440150|Other|Complicated Acute Appendicitis|The patients were assigned to the complicated acute appendicitis group (Group C) based on the preoperative imaging findings (periappendiceal abscess formation or significant periappendiceal fat tissue contamination in ultrasonography and computed tomography), intraoperative exploration findings (presence of gangrenous appendicitis, perforation or abscess formation), and pathological examination findings (acute phlegmonous appendicitis, acute gangrenous appendicitis or acute perforated appendicitis).
16334274|NCT04440150|Other|Uncomplicated Acute Appendicitis|The patients were assigned to the uncomplicated acute appendicitis group (Group UC) based on the increased diameter and wall thickness of the appendix and detection of minimal contamination in the surrounding fat tissue in the imaging tests; the presence of edema and the absence of gangrene, perforation or abscess in the the exploratory surgery of appendix, and confirmation of the diagnosis of acute appendicitis by the pathological examination findings
16334275|NCT04440137|No Intervention|Control Group|Mother of children will receive a brochure with a standard of care info (with only essential information regarding the harmful effect of bottle feeding) and kid toothbrush and toothpaste (1000ppm of fluoride).
16334276|NCT04440137|Experimental|Intervention group|Mother of the children will be provided with intervention brochure (which include detailed information regarding the harmful effect of bottle feeding), kid toothbrush and toothpaste (1000ppm of fluoride) and a sippy cup.
16334277|NCT04440111|Active Comparator|Control group|One year basic life support training
16334278|NCT04440111|Sham Comparator|Experimental group|Two years basic life support training
16334279|NCT04440098||Isolated Observational group|All participants socially restricted as a result of COVID-19
16334280|NCT04440085|Active Comparator|Intervention group|Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
16334281|NCT04440085|Placebo Comparator|Control group|By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
16334282|NCT04440059|Experimental|ICP-022|Subjects will take ICP-022 150mg once daily (QD).
16334284|NCT04440046|Sham Comparator|Sham thoracic manual therapy|Sham manual therapy directed to the thoracic spine with real manual therapy directed to the glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
16334285|NCT04440046|Sham Comparator|Sham manual therapy|Sham manual therapy directed to the thoracic spine and glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
16334288|NCT04440020|Experimental|Beverage of Olive Oil Leaves|50 patients Beverage of Olive Oil Leaves
16334289|NCT04440020|Active Comparator|Mediterranean dietary protocol Intervention|50 patients Dietary Supplement: Dietary Supplement:Mediterranean Diet
16334290|NCT04440007|Experimental|Abivertinib with Standard of Care|STI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge, in addition to standard of care
16334291|NCT04440007|Active Comparator|Standard of Care|Standard of care treatments for COVID-19 as determined appropriate by the Investigator
16334292|NCT04439994|Active Comparator|Hypertonic saline|Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
16334293|NCT04439994|Placebo Comparator|Isotonic Saline|Each participant will be given i.d. in 0.1 mL volumes of a isotonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
16334294|NCT04439981|Placebo Comparator|Control Group|treated by ice cream without any Curcuma extract supplementation
16334295|NCT04439981|Experimental|Treatment Group|treated by ice cream supplemented by Curcuma extract
16334296|NCT04439968|Active Comparator|Targeted Csats|Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
16334297|NCT04439968|No Intervention|Non-targeted Csats|Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
16334298|NCT04439955|Experimental|CBD|At the end of the one month run-in period, all trial subjects will continue on individual Standard of case plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice a day and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food. If the 300 mg CBD dose level is deemed safe for two weeks patients will continue receiving 300 mg CBD +for an additional follow-up period of three months
16334299|NCT04439929|Experimental|Adalimumab-TUR01|
16334300|NCT04439929|Active Comparator|Adalimumab-EU|
16334301|NCT04439903|Experimental|Web-based Simulation Tool (WST)|
16334302|NCT04439890|Experimental|Anlotinib hydrochloride capsule + chemotherapy|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
16334303|NCT04439890|Placebo Comparator|Placebo + chemotherapy|Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
16334304|NCT04439864|Experimental|MyIDEA|Research Participants interacted with MyIDEA program both in the hospital and in the follow up cardiology appointment.
16334305|NCT04439864|No Intervention|Treatment as normal|The research participants were given the chance to play games on the tablet and received normal clinical education.
16334306|NCT04439838|Experimental|Treatment group|
16334307|NCT04439838|Placebo Comparator|Placebo group|
16334308|NCT04439825|Active Comparator|Botox|
16334309|NCT04439825|Placebo Comparator|Placebo|
16334310|NCT04439812||R=0|Patients without positive margins after gastrectomy for gastric cancer
16334311|NCT04439812||R=1|Patients with positive margins after gastrectomy for gastric cancer
16334312|NCT04439799|Active Comparator|Testosterone Cypionate Group|Participants in this group will receive the intramuscular Testosterone Cypionate intervention for four months
16334313|NCT04439799|Active Comparator|Natesto Group|Participants in this group will receive the intranasal testosterone (Natesto) intervention for four months.
16334314|NCT04439786|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
16334315|NCT04439786|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
16334316|NCT04439773|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
16334317|NCT04439773|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
16334318|NCT04439760|No Intervention|control study.|No intervention
16334319|NCT04439760|Active Comparator|superior cervical block.|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
16334355|NCT04439513|Active Comparator|Radial Artery-Only|time to hemostasis and incidence of radial artery occlusion will be monitored while using the device currently approved by the institution (Hemo-Stop) and following institutional protocols for hemostasis.
16334320|NCT04439747||Control|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, neutrophil- gelatinase assosiated lipocalin-2 (NGAL), adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, antibodies to thyroid peroxidase (Ab-TPO), Ab--R-TSH, Ab-Tg, parathyroid hormone (PTH), vitamin D, osteocalcin, b-cross-laps, prolactin)
16334321|NCT04439747||CKD 1-2|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps, prolactin)
16334322|NCT04439747||CKD 3-5|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps,prolactin)
16334323|NCT04439734|Experimental|Whole-Body Electromyostimulation|WB-EMS once per week for for 16 week (85 Hz, 350 µs, bipolar, duty cycle 4s-4s)
16334324|NCT04439734|No Intervention|Non WB-EMS control|No WB intervention, but maintained physical activity and habitual exercise habits
16334325|NCT04439721|Experimental|γδT|γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.
16334326|NCT04439708||Group 1|Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy
16334327|NCT04439708||Group 2|Control group : patients without choroidal neovascularization
16334328|NCT04439695|Experimental|Low Dose KBP-V001|Subjects in this group will receive the low dose of KBP-V001.
16334329|NCT04439695|Experimental|Intermediate KBP-V001|Subjects in this group will receive the intermediate dose of KBP-V001.
16334330|NCT04439695|Experimental|High Dose KBP-V001|Subjects in this group will receive the high dose of KBP-V001.
16334331|NCT04439695|Placebo Comparator|Placebo|Subjects in this group will receive placebo
16334332|NCT04439682|Experimental|Study group|Aerobic exercise will be performed for a single session
16334333|NCT04439682|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
16334334|NCT04439669|Active Comparator|Starts with active stimulation|"Active nrTMS is given to S2 at the right side (10 sessions in a three week period). Thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to M1 contralateral to the side of pain. After 5 stimulation sessions the response is evaluated. If pain is still ≥510, the investigators change the target to the S2 on the left side for five sessions. If there is response with pain relief, a maintenance therapy with this target is offered for 6 months with gradually reducing stimulation sessions."
16334335|NCT04439669|Placebo Comparator|Starts with sham stimulation|"Sham nrTMS will be targeted to the S2 on the right side, but using a sham box/coil. Stimulation period is similar than for the active comparator. Similarly, thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to S2 at the right side. After 5 stimulation sessions the response is evaluated. If pain is still ≥5/10, the investigators change the target to M1 on the contralateral side of the pain and furthermore to S2 at the left side after 5 stimulation sessions, if pain is still ≥5/10."
16334336|NCT04439656||Absence Seizures|Participants with absence seizures will have their eye movements compared to the EEG recording.
16334337|NCT04439643||Development / training|Selected by stratified partitioning
16334338|NCT04439643||Sequestered / test|Selected by stratified partitioning
16334339|NCT04439630|Sham Comparator|reference|Test product without the active components
16334340|NCT04439630|Experimental|Nopal fraction 1|Fraction one out of two possible
16334341|NCT04439630|Experimental|Nopal fraction 2|Fraction two out of two possible
16334342|NCT04439617||sepsis patient|
16334343|NCT04439617||Sepsis-free patient|
16334344|NCT04439604||patient undergoing surgery under general anaesthesia|
16334345|NCT04439591|Experimental|Intervention group|Intervention group undergoes computerised brain training programme first.
16334346|NCT04439591|Other|Control group|Waitlist control group: control group undergoes programme after intervention group has completed it in a crossover design.
16334348|NCT04439552||CXL group|Patients who are about to undergo a corneal cross-linking (CXL) surgery to treat keratoconus.
16334349|NCT04439552||Control group|Healthy volunteers age and sex matched to the CXL group.
16334350|NCT04439539|Experimental|Cohort 1: Participants Enrolled Prior to Protocol Amendment 5 is in Effect|During the Induction phase, participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (either tenofovir disoproxil or tenofovir alafenamide tablets orally) treatment. At the start of consolidation phase, participants will be randomized to receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 1 and arm 2 (without PegIFN-alpha-2a). According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
16334351|NCT04439539|Experimental|Cohort 2: Participants Enrolled After Protocol Amendment 5 is in Effect|At the start of Induction phase, participants will be randomized to receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (tenofovir disoproxil tablets orally) in arm 3 and will receive JNJ-73763989 subcutaneously along with NA (tenofovir disoproxil tablets orally) treatment in arm 4. At the start of consolidation phase, participants will receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 3 and JNJ-73763989 with NA in arm 4. According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
16334354|NCT04439513|Experimental|Dual Artery Compression|time to hemostasis and incidence of radial artery occlusion will be monitored while using a dual artery compression device (Terry-2-band) to achieve hemostasis.
16334356|NCT04439500|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
16334357|NCT04439500|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
16334358|NCT04439487||Obese patients requiring general anesthesia|Group consists of consecutive, adult, obese patients undergoing elective surgical procedures requiring general anaesthesia, direct laryngoscopy and intubation. All patients undergo general anesthesia according to a standardised protocol. They are preoxygenated with 100% oxygen breathed through a face mask for 3-5 minutes. Induction of general anaesthesia is achieved with propofol 1,5-2 mg·kg-1 (of Ideal Body Weight) and 0,1mg fentanyl or sufentanil 10µg. Muscle relaxation is accomplished with rocuronium 0.6 mg ·kg-1 (of Ideal Body Weight). Depth of muscular blockade is monitored using Train of Four (TOF) method. The first laryngoscopy attempt is performed at TOF 0. The patient is placed in an optimal, sniffing or ramped position as appropriate and a #3 or #4 Macintosh blade is used. Successful intubation is confirmed with bilateral auscultation and capnography.
16334359|NCT04439474|Experimental|Patients with vitamin D deficiency|This group receives 50,000 units of vitamin D3 daily for up to 8 days until the serum level of vitamin D reaches above 30 ng/ml.
16334360|NCT04439474|Active Comparator|Patients without vitamin D deficiency|Participants in this group receive only their usual treatments
16334361|NCT04439448||HIV+ non-obese|HIV+ adults on antiretroviral therapy with a body mass index <30 kg/m2
16334362|NCT04439448||HIV+ obese|HIV+ adults on antiretroviral therapy with a body mass index >=30 kg/m2
16334363|NCT04439448||HIV-negative obese|HIV-negative adults on antiretroviral therapy with a body mass index >=30 kg/m2
16334364|NCT04439422|Experimental|SAINT|
16334365|NCT04439422|Active Comparator|Self-help material|
16334366|NCT04439409||Patients with Cluster Headache (CH)|Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.
16334367|NCT04439396|Placebo Comparator|Control|Saline injection administered during surgical procedure
16334368|NCT04439396|Experimental|Low Dose (15mg) Toradol|15mg ketorolac (toradol) administered during surgery
16334369|NCT04439396|Experimental|High Dose (30mg) Toradol|30mg ketorolac (toradol) administered during surgery
16334370|NCT04439370||Aim 1: Postmenopausal Women|Participants in this group are postmenopausal women.
16334371|NCT04439370||Aim 1: Premenopausal Women|Participants in this group are premenopausal women.
16334372|NCT04439370||Aim 2: Premature/Early Menopause|Participants in this group women who experienced premature or early menopause.
16334373|NCT04439370||Aim 2: Typical-Age Menopause|Participants in this group are women who experienced menopause at a typical age.
16334374|NCT04439357|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334375|NCT04439344|Experimental|Treatment (binimetinib)|Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334376|NCT04439331|Experimental|Treatment (defactinib)|Patients receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334377|NCT04439318|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334378|NCT04439305|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334379|NCT04439292|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334380|NCT04439279|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334383|NCT04439240|Experimental|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334384|NCT04439227|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16334385|NCT04439214|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334386|NCT04439201|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
16334387|NCT04439188|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334388|NCT04439175|Experimental|Treatment (taselisib)|Patients receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334389|NCT04439162|Experimental|group A|antegrade cardioplegia
16334391|NCT04439136|Experimental|Treatment (afatinib dimaleate)|Patients receive afatinib dimaleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334392|NCT04439123|Experimental|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16334426|NCT04438837|Active Comparator|intervention group|participants will recieve hydroxychloroquine in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days.
16334393|NCT04439110|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16334394|NCT04439097|Experimental|Experimental Group|"Patients allocated to the intervention group will perform a MPEP during 6 months, with a frequency of 3 sessions per week, and approximately 45-50 minutes of duration each session. In addition, they will have a Mediterranean Diet.
~The patients in the MPEP will be carried out in small groups of 5-8 people. Structure of sessions: 3 different parts: an initial warm-up, a main part and a final cool-down and relaxation."
16334395|NCT04439097|Active Comparator|Control Group|Participants allocated to the control group will receive usual care and continue with their life normally, without participating in a standardized exercise program. They will be instructed to maintain their current physical activity level.
16334396|NCT04439084||Chronic Liver Disease Group|COVID-19 patients with Chronic Liver Disease.
16334397|NCT04439084||Control Group|COVID-19 patients without Chronic Liver Disease.
16334400|NCT04439058|Active Comparator|Bupivacaine+lignocaine|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with10 ml of bupivacaine 0,25%+ 5ml lignocaine 1%(20 patients).
~Under complete aseptic precautions an ultrasound guided left stellate ganglion block (paratracheal technique ) The patient placed in the supine position with the head in the neutral position and slightly extended.
~The US probe placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia anterior to the C6 vertebral body and deep to the carotid artery. skin infiltration with local anesthetic, the needle inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
16334401|NCT04439058|Other|Normal saline|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with 15 ml of normal saline (20 patients).
~US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland"
16334402|NCT04439045|Experimental|VPM1002|A single dose of 0.1 mL of the reconstituted vaccine containing VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU), administered via intradermal injection.
16334403|NCT04439045|Placebo Comparator|Placebo|A single dose of 0.1 mL of the 0.9% sodium chloride injection, administered via intradermal injection.
16334404|NCT04439032||Spine Fusion using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
16334405|NCT04439019|Experimental|All patients referred to the Alberta Hip and Knee Clinic|All patients who are diagnosed with severe osteoarthritis undergoing total hip/knee replacement surgery and show interest to be part of the study.
16334406|NCT04439006|Experimental|Arm A (ibrutinib)|Patients receive ibrutinib PO QD on days 1-7. Treatment repeats every 7 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who remain hospitalized or are re-admitted after 2 cycles may receive an additional 2 cycles per physician's discretion.
16334407|NCT04439006|Active Comparator|Arm B (usual care)|Patients receive usual care.
16334408|NCT04438980|Experimental|Methylprednisolone Arm|Standard of care plus Methylprednisolone
16334409|NCT04438980|Placebo Comparator|Placebo Arm|Standard of care plus placebo
16334410|NCT04438928|Experimental|Healthy pregnant women - Supplement|"Supplementation with micronutrients plus docosahexaenoic acid (DHA) preparation (Multimicronutrients and docosahexaenoic acid (MMS) soft gel capsules) during 2nd and 3rd trimesters of pregnancy.
~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
16334411|NCT04438928|Other|Healthy pregnant women - Non-Supplement|"Control study group
~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
16334412|NCT04438915|No Intervention|Average weight .control group|Average weight BMI (18.5_25)
16334413|NCT04438915|Active Comparator|Overweight|Overweight BMI ( 25_30 )
16334414|NCT04438915|Active Comparator|Mild obese|Mild obese BMI (30_35 )
16334415|NCT04438902|Experimental|osimertinib combined with anlotinib|
16334416|NCT04438889||AML|Patients with WHO 2016 diagnosis of AML
16334417|NCT04438889||MDS|Patients with WHO 2016 diagnosis of MDS
16334418|NCT04438889||CMML|Patients with WHO 2016 diagnosis of CMML
16334419|NCT04438889||PMF|Patients with WHO 2016 diagnosis of PMF
16334420|NCT04438876|Experimental|Function power training|12-week structured FPT program, conducted by a certified trainer from a community service provider. Sessions were held twice weekly at the respective community senior activity centers, each lasting 60 minutes in duration.
16334421|NCT04438876|Active Comparator|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
16334422|NCT04438850|Experimental|I_600|ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
16334423|NCT04438850|Experimental|I_1200|ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
16334424|NCT04438850|Placebo Comparator|Placebo|placebo
16334425|NCT04438837|No Intervention|control group|no intervention
16334511|NCT04438226|Experimental|Posterolateral|Patients treated with a hemiarthroplasty using the posterolateral approach
16334427|NCT04438824|Experimental|Palbociclib and INCMGA00012|"One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib on Day 1 and INCMGA00012 on day 15 (+/- 7 days) of each cycle at the following dose schedule: (No longer using this) INCMGA00012: 500 mg IV (flat dose) q28 days Palbociclib: 125 mg PO daily for 21 days, followed by 7 days off, q28 days Palbociclib will be taken on Day 1 of each cycle for 21 consecutive days followed by 7 days off (days 22-28 of each Cycle). INCMGA00012 will be administered on Day 15 of (+/- 7 days) each cycle and repeat every 28 days.(No longer using this)
~Part II Arm B, researchers will enroll an additional 30 participants. Participants will receive Palbociclib 125 mg once daily starting on cycle 1 day 1 for 21 days, followed by 7 days off, plus 500 mg of INCMGA00012 on Cycle 1 Day 1 and every 28 days thereafter at the start of each cycle."
16334428|NCT04438811|Other|Consultant Anesthetist|Patients who are randomized to this arm will receive their spinal anesthesia froma consultant anesthetist
16334429|NCT04438811|Other|Medical Officer|Patients randomized to this arm will receive their spinal anesthetic from a medical officer. There will be a consultant anesthetist immediately available if needed but they will not be a direct participant in this arm. Any involvement by the consultant will result in the label of failure for this patient.
16334430|NCT04438798|Placebo Comparator|face mask group|Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
16334431|NCT04438798|Active Comparator|THRIVE group|High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
16334432|NCT04438785|Experimental|INTERVENTION (AirwayGym) GROUP|Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
16334433|NCT04438785|No Intervention|CONTROL GROUP|Patients newly diagnosed with severe OSAHS do no therapy for 90 days.
16334434|NCT04438772|Experimental|LPEC|
16334435|NCT04438772|Sham Comparator|Sham procedure|
16334436|NCT04438759|Experimental|investigational group|Virtual Reality
16334437|NCT04438759|No Intervention|reference group|standard of care
16334438|NCT04438746|Experimental|Group receiving CBAT|
16334439|NCT04438746|Placebo Comparator|Group receiving general emotion training|
16334440|NCT04438733|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
16334441|NCT04438733|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
16334442|NCT04438720|Active Comparator|Extended Release Nifedipine Tablets（Adalat® GITS）|Extended Release Nifedipine reference formulation at a single dose of 30 mg
16334443|NCT04438720|Experimental|Extended Release Nifedipine Tablets|Extended Release Nifedipine test formulation at a single dose of 30 mg
16334444|NCT04438707|Experimental|Experimental group|
16334445|NCT04438707|Active Comparator|Control group|
16334446|NCT04438694|Active Comparator|STANDARD OF COARE|Receiving SOC
16334447|NCT04438694|Experimental|STANDARD CP DOSE Adm (Two infusions)|Two infusions 48 hours apart
16334448|NCT04438668|Active Comparator|Standard Care|Standard care (SC) for screening for FGR is a healthcare provider auscultating the foetal heart rate with a standard stethoscope, palpation of foetal size by hand, and measuring the size of the woman's uterus with a tape measure, and comparing the measurement to the expected measurement for the gestational age of the foetus.
16334449|NCT04438668|Experimental|Standard Care and Centaflow|Centaflow uses sound-derived maternal intra-arterial turbulence as a marker of foetal growth restriction (FGR) and provides information on the foetal heart rate. Indication for use is as a screening device for FGR in women beyond 27 weeks of pregnancy with a singleton pregnancy.
16334450|NCT04438655|Experimental|Oral + Parenteral prophylaxis|"Oral antibiotic drugs:
~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.
~Systemic antibiotic drugs:
~Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.
~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
16334451|NCT04438655|Sham Comparator|Only parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.
~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
16334452|NCT04438642|Other|conventional ceramic onlay with shoulder finishline|tooth that need ceramic onlay restoration, a conventional cavity will be prepared with shoulder finishline.
16334453|NCT04438642|Experimental|conservative ceramic onlay preparation buttjoint with bevel|tooth that need ceramic onlay restoration, a conservative cavity will be prepared with butt joint with bevel finishline.
16334454|NCT04438629||Mild disease|COVID-19 hospitalized patients
16334455|NCT04438629||Severe disease|COVID-19 hospitalized patients in intensive care unit
16334456|NCT04438629||paucisymptomatic syndrome|Mild symptomatic patients in home quarantine
16334457|NCT04438616|Active Comparator|dome magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.
~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor
~We connect magnetic attachment(dome) for each groups on complete denture by pick up procedure at day of implant installation"
16334458|NCT04438616|Active Comparator|flat magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.
~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor
~We connect magnetic attachment(flat) for each groups on complete denture by pick up procedure at day of implant installation"
16334459|NCT04438603||IgAN patients at low risk of disease progression|n = 30, incipient disease
16334460|NCT04438603||IgAN patients at high risk of disease progression|n = 60, incipient disease
16334461|NCT04438603||Long-term stable patients|n = 30, follow-up for at least 15 years
16334462|NCT04438603||Progressive IgAN patients|n = 30
16334463|NCT04438603||Healthy control|n = 30
16334464|NCT04438590|Experimental|Kelulut Honey|"Medical Grade Kelulut Honey which will be in 2 doses.
~The first would be diluted to 800 ml of water, and the second dose in 400ml of water."
16334465|NCT04438590|Active Comparator|Carborie|Carborie Load which will be 100g of carbohydrate in 800 ML of water and 50g of carbohydrate in 400ml of water.
16334466|NCT04438577|Experimental|Efficacy of Lidocaine mucilage-ICG|Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
16334467|NCT04438564|Other|cancer of breast, colorectal, ovarian and endometrial|Patient who diagnostic of Breast cancer, Colorectal cancer, cancer of Ovary, and cancer of Endometrial are can recruit.
16334468|NCT04438551|Active Comparator|Standard dietary counseling|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection.
16334469|NCT04438551|Experimental|Standard dietary counseling plus mobile app|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection. Subjects will use a mobile app to build their shopping lists prior to grocery shopping.
16334470|NCT04438538||Patients with Dizziness|All trial participants are within this group. All trial participants will either have a diagnosis or a suspected diagnosis of Ménière's Disease in order to take part.
16334471|NCT04438525|Active Comparator|early maintenance phase|patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged
16334472|NCT04438525|Active Comparator|maintenance phase|patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged
16334473|NCT04438525|Active Comparator|after stopping VIT|patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged
16334474|NCT04438525|Other|blood donors|patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test)
16334475|NCT04438499|Experimental|Subjects Indicated for a UDS study|The investigational device, i.e. the eSense catheter will be used in all the subjects to assess primary and exploratory objectives. It is a single arm study with no comparative, placebo, sham or control arm.
16334476|NCT04438486|Active Comparator|dietary advice|
16334477|NCT04438486|Experimental|dietary advice+ Barely Green|
16334478|NCT04438473|Experimental|Pectin|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
16334479|NCT04438473|Placebo Comparator|Control|standard formula enteral nutrition feeding without pectin for 7 days
16334480|NCT04438460|Experimental|Patient group|150 children aged 1 month to 12 years with multi-visceral failure syndrome within 48 hours of hospitalization in pediatric resuscitation will be included in this study
16334481|NCT04438460|Other|Control group|60 children aged 1 month to 12 years hospitalized for simple elective surgery will be included in this study
16334482|NCT04438447|Experimental|ERAS plus artificial nutrition|"Patients randomised in the treatment arm will be treated with a full ERAS protocol that establishes oral food at will plus parenteral nutrition (PN) from postoperative day 1. A 3-bag compartment peripheral parenteral solution (mOsm < 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation. In case of the occurrence of any complication impairing the full or partial recovery of oral food, the treatment will be continued until clinically indicated"
16334483|NCT04438447|Active Comparator|Enhanced recovery protocol|"Patients randomised in the control arm will be treated with a full ERAS protocol that establishes oral food at will. In case of the occurrence of any complication impairing the full recovery of oral food within postoperative day 7, patients will receive parenteral nutrition as in the treated arm until clinically indicated"
16334484|NCT04438434|Experimental|Hydrogen Peroxide and Hyaluronic acid mouthwash (BMG0703)|"The enrolled subjects will be examined and treated by specialized medical personnel.
~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.
~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.
~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).
~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
16334485|NCT04438434|Active Comparator|Chlorhexidine 0.2% mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.
~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.
~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.
~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).
~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
16334486|NCT04438434|Placebo Comparator|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.
~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.
~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.
~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).
~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
16334710|NCT04436939|Active Comparator|Ti healing abutment|Healing abutment made of titanium (Ti)
16334487|NCT04438421|Experimental|BMG0703|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
16334488|NCT04438421|Active Comparator|Chlorhexidine 0.2%|Subjects will then be given a 0.2% Chlorhexidine product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
16334489|NCT04438421|Placebo Comparator|Placebo Product|Subjects will then be given a placebo product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
16334490|NCT04438408||severe asthma patient|Adult patients (≥ 18 years) with diagnosis of severe asthma for at least 12 months
16334491|NCT04438395||Enrolled AFL and AF Patients|All subjects that are enrolled are group one, as there is only one group of subjects in this study
16334492|NCT04438382|Experimental|Arm A (infliximab)|Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
16334493|NCT04438382|Experimental|Arm B (intravenous immunoglobulin therapy)|Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
16334494|NCT04438369|Active Comparator|Erector spinae block|"Group ESPB: Multimodal analgesia comprising of preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodon 1 mg/ml.
~Preoperatively positioned bilateral catheters at level T7 injected with ropivacaine 2,5 mg/ml, 30 ml on each side. Postoperative maintenance treatment with injection of 2 mg/ml ropivacaine 30 ml on each side every 6 hours postoperatively. Maximum allowed bolus preoperative ropivacaine dose is 3 mg/kg body weight (BW), while the maximum 24 hour dose postoperatively is 11 mg/kg to avoid local anesthesia systemic toxicity (LAST). The catheter will be discontinued 24 hours after the original procedure. The container with ropivacaine will be masked for blinding of the personnel on the ward."
16334495|NCT04438369|Placebo Comparator|Control|"Control group with standard multimodal analgesia: Preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodone 1 mg/ml.
~Insertion of bilateral catheters preoperatively. Injection of 30 ml saline preoperatively and every 6 hours postoperatively. The catheter will be discontinued 24 hours after the original procedure. The container with saline will be masked for blinding of the personnel on the ward."
16334496|NCT04438356|Experimental|M-health|After the acute myocardial infarction, patients will be randomly assigned to the intervention group. Give the intervention group mobile health care programs and given Garmin monitoring hands ring. In order to give patients clear walking goals and exercise intensity, the intervention group will use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
16334497|NCT04438356|Experimental|wait list control|wait list control for 3 months and then use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
16334498|NCT04438343|Experimental|experimental group|
16334499|NCT04438343|Active Comparator|control group|
16334500|NCT04438330|Experimental|Nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
16334501|NCT04438330|Active Comparator|non-nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
16334502|NCT04438317|Active Comparator|Seldinger Technique|Small bore chest tubes inserted by Seldinger technique. A needle is inserted into the intercostal space, and the aspiration of a fluid allows the confirmation the correct position, possibly after ultrasound tracking. A metal guidewire is inserted through the needle, which is then removed. A dilator is then inserted on the metal guidewire to dilate the skin and the subcutaneous tissues. The chest tube is finally inserted on the guide, which is finally removed, and the chest tube is connected to the aspiration system after fixation to the chest wall.
16334503|NCT04438317|Active Comparator|Surgical-like Technique|Large bore chest tube inserted by surgical-like technique. Progressive chest wall dissection is conducted with appropriate instruments (scissors, scalpel, clamps…) by a non-surgeon physician. Large bore drain with rigid introductor is blindly inserted in the pleural cavity, secured to the chest wall with suture fixation and further connection to the aspiration system.
16334504|NCT04438304|Experimental|Intervention|64Cu-SARTATE will be administered at a fixed administration dose of 200 MBq (5.4 mCi) given as a single bolus intravenous injection.
16334505|NCT04438291|Experimental|Intervention schools|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
16334506|NCT04438291|Other|Control schools|Control and usual care
16334507|NCT04438265|Other|quadratus lumborum|analgesic technique. The evaluation of the patient will consist of 2 stages. The first of these will consist of the evaluation consultation (clinical history, EVN evaluation, WOMAC) and initial treatment (QL2 block). In the second stage, the patient will be followed up with interviews at 3 weeks, 3 and 6 months.
16334508|NCT04438252|Experimental|Cariescan pro|device for early caries detection
16334509|NCT04438252|Experimental|ICDAS II|Index for caries detection
16334510|NCT04438239||Covid-19 discharged|Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
16334512|NCT04438226|Experimental|Direct lateral|Patients treated with a hemiarthroplasty using the direct lateral approach
16334513|NCT04438213|Experimental|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
16334514|NCT04438213|Experimental|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
16334515|NCT04438213|Placebo Comparator|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
16334516|NCT04438200||Adolescents|Individuals aged 10-19 years
16334517|NCT04438200||Young Adults|Individuals aged 20-39 years
16334518|NCT04438200||Elderly Adults|Individuals aged 40+ years
16334519|NCT04438187|Other|Aggressive Arm|If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
16334520|NCT04438187|Other|Conservative Arm|If a patient is suspected of having an ICU-acquired HAP/VAP during the conservative period, quantitative or semi-quantitative endobronchial cultures should be sent. If the patient is in septic shock persistent hypotension requiring vasoactive medications to maintain mean arterial pressure (MAP) ≥65 mm HG or persistent lactic acidosis (>2 mmol/L) despite adequate resuscitation) antimicrobials will be initiated immediately. If the patient has new onset organ dysfunction that is presumed to be due to infection (sepsis) then antimicrobials will be initiated at the discretion of the attending intensivist. In the absence of septic shock or sepsis (intensivist discretion), antimicrobials will not be initiated unless objective evidence of pneumonia is present or another documented source of infection is identified mandating treatment with antimicrobials.
16334521|NCT04438174|Experimental|Amniotic Fluid Injection|Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
16334522|NCT04438174|Active Comparator|Standard of Care Wound Treatment Regimen|Primary dressings are variable and based on the moisture content and microorganism load. In general, wounds respond differently to various topical treatments. Through our clinical practice, we have found that wounds plateau with the same topical for greater than 4 weeks, hence changing antimicrobial topical helps to manage the bacterial overgrowth. We will start with our application of our slurry, a 1:1:1 ratio of Nystatin ointment, Mupirocin Ointment, and Bacitracin Ointment. This slurry will be applied directly to the cleansed wound, followed by silver gauze/foam product to all wounds. Types of silver product- site and comfort predict use of Restore, Mepilex-AG, or Mepitel-AG. If allergies to the above slurry occurs, we will use medical honey with or without bacitracin. If ointment related rash present with transition to silver product only or silver product plus medical honey.
16334523|NCT04438161|Active Comparator|Low Risk|"Low risk natural history study (n=250*)
~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families."
16334524|NCT04438161|Experimental|High Risk|"High risk families in prospective longitudinal study of newborns (n=150*).
~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families.
~Participants in this arm will be randomized to:
~PERCCS (see attached figure and table for details)
~Care as Usual"
16334525|NCT04438135|Active Comparator|active test|
16334526|NCT04438135|Placebo Comparator|placebo test|
16334527|NCT04438122|Active Comparator|Red Wine group|Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.
16334528|NCT04438122|Active Comparator|Ethanol group|Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.
16334529|NCT04438122|No Intervention|Control group|Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks
16334530|NCT04438096|Experimental|100 mg|
16334531|NCT04438096|Experimental|200 mg|
16334532|NCT04438096|Experimental|300 mg|
16334533|NCT04438096|Placebo Comparator|Placebo|
16334534|NCT04438083|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
16334535|NCT04438070|Placebo Comparator|Daily active screening only|
16334536|NCT04438070|Experimental|Daily active screening and self-collected nasal swab|
16334537|NCT04438070|Experimental|Daily active screening and self-collected oral-nasal swab|
16334538|NCT04438070|Experimental|Daily active screening and nurse collected nasopharyngeal swab|
16334539|NCT04438057|No Intervention|Standard of Care|Patient will receive standard of care therapy.
16334540|NCT04438057|Active Comparator|Treatment Arm|Patient will receive convalescent plasma
16334541|NCT04438044|Experimental|ICP-022|150mg,QD
16334542|NCT04438031|Experimental|Navigation Intervention Prenatal|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
16334565|NCT04437914||Group 2 - conventional ECG|The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
16334543|NCT04438031|Experimental|Navigation Intervention 12mo|This program recruits mothers in pediatricians' (12 months old) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
16334544|NCT04438031|Experimental|Navigation Intervention 24mo|This program recruits mothers in pediatricians' (24 months old) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
16334545|NCT04438031|Experimental|Navigation Intervention 36mo|This program recruits mothers in pediatricians' (36 months old) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
16334546|NCT04438031|Other|Control Intervention Prenatal|Brief information will be provided about child development.
16334547|NCT04438031|Other|Control Intervention 12mo|Brief information will be provided about child development.
16334548|NCT04438031|Other|Control Intervention 24mo|Brief information will be provided about child development.
16334549|NCT04438031|Other|Control Intervention 36mo|Brief information will be provided about child development.
16334550|NCT04438031|Experimental|Virtual Navigation Intervention Prenatal|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three virtual Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
16334551|NCT04438031|Other|Virtual Control Intervention Prenatal|Brief information will be provided about child development.
16334552|NCT04438018||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
16334553|NCT04438018||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
16334554|NCT04438018||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
16334555|NCT04438018||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
16334556|NCT04438005|Experimental|ICP-022|
16334557|NCT04437992||Pregnant women|"Pregnant women resident in the Emilia Romagna region who access the combined test at regional counseling centers and hospital prenatal clinics.
~Women able to understand the information, participate in pre-test counseling and provide informed consent."
16334558|NCT04437966|Experimental|Self-management Group|"The intervention consists of three levels - (1) chronic disease self-management workshops, (2) distribution of and teaching on the use of medication pill boxes and (3) use of social media (WhatsApp version 2.0) to encourage medication adherence.
~We combine the Stanford Chronic Disease Self-Management Curriculum, add medication adherence tools and social media use to develop a novel intervention aimed at better blood pressure control. The CDSMP focuses on enhancing skills through problem solving and brainstorming activities. In the workshop we discuss: blood pressure control, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control. Pill boxes will be distributed to all individuals in the intervention group. Post workshop, participants will be sent twice weekly reminders to use their high blood pressure medications via the social media tool WhatsApp. These will be sent for one month."
16334559|NCT04437966|No Intervention|Usual care group|Controls will receive educational material at baseline and one didactic session (on importance of medication adherence to hypertension control) lasting 1 hour delivered by a health care professional.
16334560|NCT04437953|Experimental|Avatrombopag|Patients will receive an initial dose of Avatrombopag 60 mg on Day 1.Starting on Day 2, the dose will be Avatrombopag 20 mg daily.
16334561|NCT04437940||Covid-19 positive women|Women with nasofarangeal Covid-19 PCR test is positive
16334562|NCT04437927||Prospective patients|30 consecutive patients with cardiac FDG PET prescribed
16334563|NCT04437927||Control|30 patients referred for cardiac FDG PET in the nuclear medicine department of the Centre Hospitalier Princesse Grace
16334564|NCT04437914||Group 1 - Smartwatch - single lead (D1)|To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
16334566|NCT04437901||COVID-19 patients|Patients admitted at one of the participating centres with highly suspected/confirmed infection with SARS-CoV-2.
16334567|NCT04437888|Active Comparator|Racemic Ketamine|ketamine 0.5mg/kg bolus on induction of anesthesia and 10mcg/kg/min infusion initiated prior to incision and terminated at the completion of wound closure. Maximum ketamine dose will not exceed 500mg
16334568|NCT04437888|Placebo Comparator|Saline|saline in the same volume as the study drug, administered in the exact same format.
16334569|NCT04437875|Experimental|Component 1|rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene.
16334570|NCT04437875|Experimental|Component 2|rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
16334571|NCT04437875|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
16334572|NCT04437862|Experimental|Q Revascularization System|
16334573|NCT04437849|Experimental|Telemonitoring|
16334574|NCT04437849|No Intervention|Usual Care|
16334575|NCT04437836|Experimental|Control arm|Participants will receive standard treatment of rifampicin
16334576|NCT04437836|Experimental|First High dose|Participants will receive 30mg per kg body weight of rifampicin
16334577|NCT04437836|Experimental|Second high dose|Particpants will receive 40mg per kg body weight of rifampicin
16334578|NCT04437823|Experimental|Group 1 : Treatment|Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).
16334579|NCT04437823|No Intervention|Group 2: standard care|Five (5) subjects will be treated under Standard of Care (SOC) .
16334580|NCT04437810|Experimental|Albumin+ SMT|Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy
16334581|NCT04437810|Placebo Comparator|Placebo+SMT|- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy
16334582|NCT04437797|Experimental|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
16334583|NCT04437797|Active Comparator|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
16334584|NCT04437784|Active Comparator|Laparoscopic Trans-Abdominal Pre-Peritoneal (Lap TAPP group))|Both hernias were treated by laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
16334585|NCT04437784|Active Comparator|Open Pre-Peritoneal Repair ( Open PP group)|Both hernias were treated by open pre-peritoneal single mesh repair with suture fixation
16334586|NCT04437784|Active Comparator|Bilateral Lichtenstein repair (LICHT group)|treated by bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
16334587|NCT04437771||Subjects with Fanconi Anaemia Subtype A (FA-A)|Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
16334588|NCT04437758|Experimental|Hydrolyzed collagen and Vitamin C powder mix|20 g hydrolyzed collagen + 50 mg vitamin C (ascorbic acid) pre-packed powder diluted in 250 ml (8 oz) of water
16334589|NCT04437758|Placebo Comparator|Maltodextrin powder|20 g maltodextrin pre-packed powder diluted in 250 ml (8 oz) of water
16334590|NCT04437745|Experimental|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
16334591|NCT04437745|No Intervention|Control|No Intervention
16334592|NCT04437732|Other|Apioc Lens|All subjects will wear either the Apioc-P or Apioc-PT contact lens design
16334593|NCT04437719|Experimental|Obvio-19 App|"If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations.
~Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention."
16334594|NCT04437706||Participants|Participants completing COVID-19 testing
16334595|NCT04437693|Experimental|Hydroxychloroquine|400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks.
16334596|NCT04437693|Placebo Comparator|Placebo|2 tablets (Placebo White tablets) twice daily on day 1 followed by 2 tablets weekly for 7 weeks
16334597|NCT04437667|Experimental|Intervention Arm|Adolescents participants enrolled in the intervention arm will receive the intervention, Tumaini, loaded on a low-cost Android smartphone, during the long November-December school holidays for the first three years of the study.
16334598|NCT04437667|Active Comparator|Control Arm|Adolescent participants enrolled in the control arm will receive a commercially available age- and language-appropriate educational game or knowledge quiz loaded on a study-provided low-cost Android smartphone.
16334599|NCT04437654|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
16334600|NCT04437654|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
16334601|NCT04437641||Experimental|A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.
16334602|NCT04437602|Experimental|CEM|Patients in experimental arm will go through additional preoperative staging with contrast enhanced mammography
16334603|NCT04437602|No Intervention|No CEM|Patients in No intervention arm will go through no additional preoperative imaging
16334604|NCT04437589||Exposure group|In this group the treatment applied for postoperative pain involves Free-opioid anesthesia (LKDi).
16334605|NCT04437589||Control group|In this group the treatment applied for postoperative pain involves an opioid-based anesthesia.
16334606|NCT04437563|No Intervention|Control|('Standard' care). No intervention offered.
16334607|NCT04437563|Experimental|Intervention|('Standard' care +) The 'Herlev Hospital Empowerment of Relatives through More and Earlier information Supply' (HERMES) intervention.
16334608|NCT04437550|Experimental|high-intensity|
16334609|NCT04437550|Experimental|low-intensity|
16334610|NCT04437537||Pilot Group|Ten subjects with a DFU non-responsive to standard of care for a minimum of treatment period of 28 days.
16334611|NCT04437524|Active Comparator|balance-proprioception exercises group|balance-proprioception exercises group
16334612|NCT04437524|Active Comparator|aerobic exercises group|aerobic exercises group
16334615|NCT04437498|Experimental|nVNS|non invasive vagal nerve stimulation
16334616|NCT04437498|Sham Comparator|sham|sham stimulation
16334617|NCT04437485|Experimental|eIMPACT-DM intervention|eIMPACT-DM is a 6-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for diabetes risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Good Days Ahead, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers (PCPs).
16334618|NCT04437485|Active Comparator|Active Control|Active Control (AC) consists of depression education (study staff), symptom monitoring (study staff), and primary care for depression (clinical staff).
16334619|NCT04437472||CareSignal|-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up.
16334620|NCT04437459|Experimental|Abbreviated Fat Tolerance Test|
16334621|NCT04437459|Active Comparator|Oral Glucose Tolerance Test|
16334622|NCT04437446|Experimental|Case Group|"The Case group corresponds to patients with glaucoma following the clinical criteria for glaucoma:
~papilla excavation> 5/10 with altered ISNT rule, or neuro-retinal rhyme characteristic of glaucoma, or fiber alterations characteristic of glaucoma.
~OCT with typical alterations (loss of the layer of nerve fibers or loss of these ganglion cells), loss of fibers typical of glaucoma.
~Humphrey 24: 2 visual fields produced, reliable and typical of glaucoma.
~The assignment to the Cas group will be carried out by an ophthalmologist specializing in glaucoma according to the following criteria:
~- The intraocular pressure must be increased before the start of treatment (21 mmHg or more), except in cases of normal pressure glaucoma.
~The additional examination corresponds to an OCTA alone leading to an extension of the duration of the consultation by 5 minutes."
16334623|NCT04437446|Experimental|Control Groupe|"The Control group corresponds to patients with no glaucoma, no suspicion or history of glaucoma, ocular hypertension, or alterations detected during the ophthalmological consultation.
~Witnesses will be matched to cases by age (+/- 5 years) and gender.
~For patients in this group, the additional examinations correspond to a visual field, an OCT and an OCTA leading to an extension of the duration of the consultation by 35 minutes."
16334624|NCT04437433|Experimental|Atogepant 60 mg|Taken once daily
16334625|NCT04437420||T-ALL|
16334626|NCT04437420||B-ALL|
16334627|NCT04437407|Other|Control|The first night will be a control night with infrared video recording where only the Ajuvia sleep monitor is worn in passive mode so that each participant can act as her own control for comparison of treatment effect on outcomes.
16334628|NCT04437407|Experimental|PB2-1|During this night, the PB2-1 prototype will be worn with the Ajuvia in passive mode.
16334629|NCT04437407|Experimental|PB2-2|During this night, the PB2-2 prototype will be worn with the Ajuvia in passive mode.
16334630|NCT04437407|Experimental|PB2-3|During this night, the PB2-3 prototype will be worn with the Ajuvia in passive mode.
16334631|NCT04437407|Experimental|PB2-4|During this night, the PB2-4 prototype will be worn with the Ajuvia in passive mode.
16334632|NCT04437407|Experimental|PB2-5|During this night, the PB2-5 prototype will be worn with the Ajuvia in active mode.
16334633|NCT04437394||Study group|Study group was performed on 30 patients who were diagnosed with ankylosing spondylitis using modified New York criterion.
16334634|NCT04437394||Control group|Control group was performed on 30 participants who were healthy.
16334635|NCT04437368|Experimental|GT005 Low Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
16334636|NCT04437368|Experimental|GT005 High Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
16334637|NCT04437368|No Intervention|Untreated control|Approximately 25 subjects are planned, with subjects randomised to untreated control.
16334638|NCT04437355|Active Comparator|Control Group|Young and healthy Group of People (18-50 years) without any pathology of the lower limb
16334639|NCT04437355|Active Comparator|Ankle Fracture Type Weber B|Young and healthy patients with an operative treated fracture of the ankle (type Weber B)
16334640|NCT04437355|Active Comparator|Ankle Fracture Weber C and complex|Young and healthy patients with an operative treated fracture of the ankle (type Weber C or complex fracture)
16334641|NCT04437342||Maternal Group|Pregnant women in labour (vaginal delivery or caesarean section) that are admitted to the hospital. Pre-labour 3 different questionnaires are administered to evaluate depression, general anxiety disorder and the association to the covid-19 pandemic. 40 days post delivery via telephone contact 2 questionnaires are administered, one in order to assess the postpartum disorder the other to assess depression.
16334642|NCT04437329|Experimental|DNF-N|"Induction chemotherapy:
~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks
~Concurrent chemoradiotherapy:
~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy
~Radiotherapy: radical intense modulated radiation therapy"
16334643|NCT04437329|Active Comparator|DPF-P|"Induction chemotherapy:
~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous cisplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks
~Concurrent chemoradiotherapy:
~three cycles of 100 mg/m² cisplatin every 3 weeks, concurrently with intensity-modulated radiotherapy
~Radiotherapy: radical intense modulated radiation therapy"
16334644|NCT04437316|Active Comparator|Low Level Laser|therapeutic laser
16334645|NCT04437316|Placebo Comparator|Placebo Low Level Laser|non-therapeutic laser
16334646|NCT04437303|Active Comparator|Continuation of oral anticoagulants|
16334647|NCT04437303|Active Comparator|Interruption of oral anticoagulants|
16334648|NCT04437290||Alzheimer disease|The group is composed of individuals with a consensus diagnosis of amnestic mild cognitive impairment (MCI) or amnestic multimodal MCI or dementia primarily attributed to Alzheimer's disease (AD), as determined by the UW ADRC Clinical Core. They will have age of presentation > 55 years, sporadic onset, CDR (Clinical Dementia Rating Scale) score 0.5-1.0, and sufficient English competency to complete a standardized cognitive testing battery. All will have no contraindication to MRI and will have had an MRI scan in the UW ADRC Imaging and Biomarker Core. These participants will undergo PET scanning with the investigational tau tracer [18F] MK6240
16334649|NCT04437277|Experimental|Patients consenting|
16334650|NCT04437264|Experimental|Intermittent feed|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
16334651|NCT04437264|Experimental|Continuous feeds|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
16334652|NCT04437251|Experimental|Brain stimulation-induced improvements in leg skill learning|"To examine the degree of stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group. Up to date, most studies have investigated the effects of brain stimulation on hand skill improvements in healthy young adults; little is known about stimulation-induced improvement in the leg skill improvement in stroke survivors as well as in older healthy adults. The investigators will answer the question: Do stroke survivors improve leg skill learning at a comparable rate as healthy young and older adults after brain stimulation transcranial direct current stimulation (tDCS)?"
16334653|NCT04437251|Experimental|Effects of brain stimulation on functional improvements|"To determine the effect of brain stimulation (tDCS) on functional improvements in stroke survivors. Specifically, the investigators will compare stepping reaction time, cortical neuronal activity, peripheral nerve activity, and walking function in the stroke survivors before and after tDCS, and also compared these findings with results from healthy adults. The investigators will answer the question: Do stroke survivors shorten stepping reaction time and improve leg muscle activation and gait performance after tDCS, and these improvements are at a similar rate as compared to data collected from healthy young and older adults?"
16334654|NCT04437251|Sham Comparator|Effects of brain stimulation combined with stepping training|After enrolling to the study, participants with chronic stroke will be randomly assigned to one of two groups: anodal tDCS or sham tDCS groups. All subjects will then undergo a total of twelve training sessions over four weeks in which subjects will learn a novel visuomotor stepping task immediately after visuomotor learning training while 20-minute tDCS (anodal or sham stimulation) is delivered over the leg area of primary motor cortex.The investigators will measure changes in brain neuronal activity, peripheral nerve activity, and walking performance before and after a 12-session training program, and will follow up one week later.
16334655|NCT04437238|Experimental|Intervention - KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
16334656|NCT04437238|Placebo Comparator|Control|Participants allocated to the control condition will receive care as usual but will be asked to complete the health risk questionnaire at baseline, 3- and 6-month follow-up via an online survey to collect outcomes data. The control group will receive full access to KeepWell at the conclusion of the study.
16334657|NCT04437225|Experimental|Constant Infusion of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 5:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 7:30 am for the carbon 13 glycolate infusion which will occur at a constant rate for 10 hours, following a priming dose. From 7:30 am to 5:30 pm, urine collections will occur hourly, and from 8:30 am to 5:30 pm, IV blood collections will occur every half hour. Subjects will receive a meal at 5:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
16334679|NCT04437108|Active Comparator|antimuscarinics|Patients will be treated by solifenacin 10 mg once daily for 6 months.
16334658|NCT04437225|Experimental|Single Intravenous Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for a single dose of carbon-13 glycolate to be administered. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, IV blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
16334659|NCT04437225|Experimental|Single Oral Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. At 8:30 am, subjects will ingest the carbon-13 glycolate, dissolved in to 50 ml (about 1/4 cup) of water. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, intravenous (IV) blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
16334660|NCT04437212|Experimental|Toripalimab Group|All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.
16334661|NCT04437199|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
16334662|NCT04437199|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
16334663|NCT04437186|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
16334664|NCT04437186|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
16334665|NCT04437173|Experimental|Virtual Reality Arm|Patients undergo interventional pain procedure with virtual reality distraction
16334666|NCT04437173|No Intervention|No Intervention Arm|Patients undergo interventional pain procedure without virtual reality distraction
16334667|NCT04437160|Experimental|Adjuvant chemotherapy|"Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
~Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d*4cycles."
16334668|NCT04437160|No Intervention|Observation|No adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
16334669|NCT04437147|Placebo Comparator|Placebo|a) Control placebo (P1) Component Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
16334670|NCT04437147|Active Comparator|3 Billion CFU strains of probiotics|b) 3 Billion CFU (P2) Component Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
16334671|NCT04437147|Active Comparator|8 Billion CFU strains of probiotics|c) 8 Billion UFC (P3) Component Lactobacillus paracasei LPC 00 ID 1076 1 billion CFU;Bifidobacterium longum BL 03 ID 1152 1 billion CFU; Bifidobacterium lactis BS 01 ID 1195 1 billion CFU;Lactobacillus casei LC 03 ID 1872 1 billion CFU; Bifidobacterium animalis LMG 10508 1 billion CFU; Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
16334672|NCT04437134||On-line exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-line. Patients attend both the exercise and educational sessions by logging on to virtual rooms using links sent out by e-mail. The sessions are led and supervised by GLA:D certified physiotherapists.
16334673|NCT04437134||On-site exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
16334674|NCT04437121||Parents of children aged 2-18 years|Parents of children aged 2-18 years during the lockdown due to the COVID-19 pandemic, following their informed consent form prior to their participation to the study.
16334675|NCT04437108|Active Comparator|Li-SWT (suprapubic approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through suprapubic approach.
16334676|NCT04437108|Active Comparator|Li-SWT (perineal approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through perineal approach.
16334677|NCT04437108|Active Comparator|Li-SWT (combined approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through suprapubic and perineal approaches during each session.
16334678|NCT04437108|Sham Comparator|Sham treatment|Patients will be treated by 8 sessions of sham treatment with one week interval, applied through suprapubic and perineal approaches.
16334680|NCT04437095|Experimental|PSBPS Audiorecording|Thirty minute daily administration of audio recording containing messages of psychological support based on positive suggestion delivered via headphones
16334681|NCT04437095|No Intervention|Control|Standard of care
16334682|NCT04437082||Normal|no pre-existing conditions
16334683|NCT04437082||Glaucoma|diagnosis of glaucoma
16334684|NCT04437082||Retina|diagnosis of retina pathology
16334685|NCT04437082||Cornea|diagnosis of corneal condition
16334686|NCT04437069|No Intervention|Standard Care (Control)|Participants will receive standard care and will not view either the Decision Aid or the Values Clarification Exercise
16334687|NCT04437069|Experimental|Decision Aid|Participants view the Decision Aid only
16334688|NCT04437069|Experimental|Decision Aid & Values Clarification Exercise|Participants view both the Decision Aid and the Values Clarification Exercise
16334689|NCT04437056|Other|Stroke patients with upper limb spasticity|Patients with post-stroke upper limb spasticity will be operated for cognitive nerve transfers to spastic muscles to allow for volitional muscle reinnervation and disrupture of spasticity. Adequate healthy nerve donors from the ipsilateral arm will be determined clinically and electrophysiologically.
16334690|NCT04437043|Other|Laparoscopic ventral hernia repair with closure of the defect|In laparoscopic intraperitoneal onlay mesh or IPOM repair, the mesh is inserted intra-abdominally and fixed to the peritoneum / abdominal wall. The general steps include safe entry into the peritoneum, insufflation and placement of the trocars to gain access and visibility (via laparoscope) of the defect. Careful adhesiolysis is performed, which is the removal of scar tissue connecting tissues and organs. The content of the hernia, which may include intestine and fatty tissue, is returned into the abdominal cavity. After closure of the hernia defect, a wide intraperitoneal mesh is fixed over the defect. Desufflation releases the gas from the abdomen. The trocars will be removed and the incisions are closed.
16334691|NCT04437043|Other|Open ventral hernia repair with closure of the defect|An open retromuscular ventral hernia repair involves an incision through the abdominal wall. Adhesiolysis is performed and the content of the hernia is returned into the abdominal cavity. The posterior rectus sheath is separated from the rectus muscle and closed, which closes the abdominal cavity. The mesh is then placed behind the muscle and anterior to the re-approximated posterior rectus sheath. Preperitoneal mesh extension is allowed via transversus abdominis release (TAR). The anterior rectus sheath is closed over the mesh, which closes the hernia.
16334692|NCT04437043|Other|Robotic ventral hernia repair with closure of the defect|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar closure of the hernia defect and similar retromuscular mesh placement as for the open approach. Preperitoneal mesh extension is allowed via TAR. The da Vinci System is a robotic-assisted surgical device that allows the surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of the abdominal cavity. Rather than one long incision with open repair, four to six small incisions are made along the outer part of the abdomen between the rib cage and the hip.
16334693|NCT04437030|Active Comparator|Patient|Patient with Head and neck cancer
16334694|NCT04437030|Other|Healthy subjects|Healty subjects with not history of Tumor disease in the Head and neck region
16334695|NCT04437017|Experimental|Olanzapine+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
16334696|NCT04437017|Active Comparator|Dexamethasone+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists (a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administered, and on day 2-4, the given dose of dexamethasone is 8 mg.
16334697|NCT04436991||Amoxicillin-clavulanate|Administration of amoxicillin-clavulanate as standard care therapy (4x or 6x 1g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
16334698|NCT04436991||Piperacillin-tazobactam|Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
16334699|NCT04436991||Temocillin|Administration of temocillin as standard care therapy (2x or 3x 2g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
16334700|NCT04436978|Active Comparator|First month DAPT|
16334701|NCT04436978|Active Comparator|First month standard therapy|
16334702|NCT04436965|Experimental|Standard nutrition therapy|Dynamic nutrition assessment will be performed to patients. If malnutrion happened, patients would receive oral nutritional supplements (ONS) first, then feeded with nasal feeding tube or PEG when ONS wasn't enough. If all the these enteral nutrition methods couldn't make up for patient's nutritional deficiencies, parenteral nutrition would be considered.
16334703|NCT04436965|Active Comparator|Conventional nutrition therapy|Dynamic nutrition assessment will be performed to patients throughout whole treatment, and symptomatic treatment would be performed if needed.
16334704|NCT04436952|Experimental|H7 coil only|patients undergoing DTMS treatment using the H7 coil
16334705|NCT04436952|Active Comparator|Cool D-B80 coil only|20 patients undergoing rTMS treatment using the cool D-B80 coil
16334706|NCT04436952|Active Comparator|DTMS treatment using the H7 coil + ERP|20 patients undergoing DTMS treatment using the H7 coil + ERP
16334707|NCT04436952|Active Comparator|rTMS treatment using the cool D-B80 coil + ERP|20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP
16334708|NCT04436952|Active Comparator|ERP only|20 patients undergoing ERP only
16334709|NCT04436939|Experimental|PEEK healing abutment|Healing abutment made of polyetheretherketone (PEEK)
16334711|NCT04436926|Experimental|opioid approach bias training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of opioid approach bias modification taking place over two weeks.
16334712|NCT04436926|Sham Comparator|sham training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of sham training taking place over two weeks.
16334713|NCT04436913|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care).
~Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash, 0.12% concentration) for one minute per day; such a regimen will be repeated one week every month.
~Fluoride varnish (5% sodium fluoride) will be applied at baseline visit."
16334714|NCT04436913|Experimental|preventive regimen using Fluoride based toothpaste (Signal).|"Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash, 0.12% concentration) for one minute per day; such a regimen will be repeated one week every month.
~Fluoride varnish (5% sodium fluoride) will be applied at baseline visit."
16334715|NCT04436913|Active Comparator|Fluoride toothpaste and fluoride varnish|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) and fluoride varnish
16334716|NCT04436900|Experimental|Intervention group|20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
16334717|NCT04436887|No Intervention|Primary closure|Primary closure of midline laparotomy
16334718|NCT04436887|Experimental|Mesh closure|Sub-lay permanent mesh supported the closure
16334719|NCT04436874|Experimental|Han ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Han ethnic by endoscopy
16334720|NCT04436874|Experimental|Han ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Han ethnic by endoscopy
16334721|NCT04436874|Experimental|Dai ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Dai ethnic by endoscopy
16334722|NCT04436874|Experimental|Dai ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Dai ethnic by endoscopy
16334723|NCT04436848||PD patients positive for LRRK2 G2385R|
16334724|NCT04436848||PD patients negative for LRRK2 G2385R|
16334725|NCT04436848||Non-PD controls negative for LRRK2 G2385R|
16334726|NCT04436835|Experimental|Supportive care (ART)|Patients undergo ART over 60-90 minutes once a week for up to 5 sessions.
16334727|NCT04436822|Experimental|Subjects with diabetes wearing DS5|Subjects wearing DS5 over 7 days and participating in FSTs.
16334728|NCT04436809|Other|SNB only|"cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have disease-free sentinel nodes (pN0) after primary chemotherapy, are directed to SNB only: i.e. no further treatment to the axilla."
16334729|NCT04436809|Other|SNB + AD|cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have metastatic sentinel nodes (pN1) on sentinel node biopsy (SNB) will undergo axillary dissection (AD) i.e. surgical removal of most axillary lymph nodes.
16334730|NCT04436796|Experimental|Artificial Pancreas|Subjects will be provided the Interoperable Artificial Pancreas System (iAPS) which includes the iAPS phone platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This iAPS is designed to help control blood sugar in people living with type 1 diabetes.
16334731|NCT04436796|Active Comparator|Sensor Augmented Pump/Predictive Low Glucose Suspend|Subjects will continue use of home insulin pump with a study continuous glucose monitor (CGM) and study glucometer. Subject may use home pump in PLGS mode if this is supported and compatible with the study sensor.
16334732|NCT04436783|Experimental|Virtual Reality Epley Maneuver System - VREMS|Patients in the VREMS cohort will be provided with the VREMS device, which will help guide them through the Epley maneuver in a virtual reality environment. All participants will be asked to rate the severity of their symptoms before undergoing the Epley maneuver. Subsequently, patients will be supervised as they perform the Epley maneuver - VREMS assisted. In both groups, once the patient has performed the Epley maneuver (whether with VREMS assistance or with the IH), they will be asked to rate their symptom severity after undergoing the Epley maneuver
16334733|NCT04436783|Active Comparator|Instructional Handout (IH)|Those in the control cohort will be provided an instructional handout (IH) to help them perform the Epley maneuver. They will be given a chance to review the IH, and then they will have a chance to perform the Epley maneuver.
16334734|NCT04436770|Active Comparator|Control Group|Standard physiotherapy and OT
16334735|NCT04436770|Experimental|Experimental|Virtual Reality Therapy and OT
16334736|NCT04436757|Experimental|IPS (Self-image and body-representation program)|"The IPS program (Self-image and body representation) was designed by Dr PLAZAT and coll. for specific use with patients with severe mental disorders suffering of low self- and body-esteem and aiming at  reinsert themselves in the society."
16334737|NCT04436757|Active Comparator|TAU|Treatment As Usual : the usual care proposed by the health service (SUR/CL3R).
16334738|NCT04436744|Experimental|Giredestrant + Palbociclib|
16334739|NCT04436744|Active Comparator|Anastrozole + Palbociclib|
16334740|NCT04436731|Experimental|Hypoxia Exposure|A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
16334741|NCT04436718|Experimental|Daily POCUS|Patients are assessed by facility experts with daily chest ultrasound and findings of interstitial syndrome and IVC measurement are reported to primary care providers.
16334742|NCT04436718|No Intervention|Usual care|Patients are assessed daily by primary care providers per usual care.
16334743|NCT04436705|Experimental|Progressive Muscle Relaxation (PMR) technique|Participants in intervention group continued Progressive Muscle Relaxation (PMR) technique daily for 20 minutes for a total of four weeks addition to usual care. The usual care consists of pharmacological interventions to manage Cancer-related pain.
16334744|NCT04436705|No Intervention|control|control group received only usual care for their pain during the study period. The usual care consists of pharmacological interventions to manage Cancer-related pain.
16334745|NCT04436692|Other|Improve dietary pattern|Nudging approach to test this methodological approach in persons with intellectual disabilitites with goal to improve dietary pattern and loss of weight
16334746|NCT04436666|Experimental|Ice Application|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
16334747|NCT04436666|Experimental|Virtual Reality|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
16334748|NCT04436666|No Intervention|control|No Intervention
16334749|NCT04436653|Experimental|Tricuspid Valve Replacement System|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.
16334750|NCT04436640|Experimental|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
16334751|NCT04436627|Experimental|Mild severity:|Brunnstrom stage of distal part: 5-6
16334752|NCT04436627|Experimental|Moderate severity:|Brunnstrom stage of distal part: 4
16334753|NCT04436627|Experimental|severe severity:|Brunnstrom stage of distal part: 2-3
16334754|NCT04436614|Experimental|Aloe Vera and Crocus|50 patients Aloe Vera and Crocus (saffron) 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle Intervention: Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle 1L, per 15 days.
16334755|NCT04436614|Placebo Comparator|Aloe Vera|50 patients Aloe Vera (simple) in a glass bottle 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera (simple) in a glass bottle Intervention: Dietary Supplement: Aloe Vera (simple) in a glass bottle in a glass bottle 1L, per 15 days.
16334756|NCT04436614|Other|Mediterranean Diet|50 patients Mediterranean dietary protocol Intervention:mediterranean diet
16334757|NCT04436601|Active Comparator|Lactulose|90 ml of Lactulose dissolved in 750 ml of water administered orally by mouth or nasogastric tube (three doses within 24 hrs) continued up to 72 hours or until patient discharge, whichever comes first.
16334758|NCT04436601|Experimental|PEG: Polyethylene Glycol|Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to 72 hours or until patient discharge, whichever comes first
16334759|NCT04436588||DDX3X|DDX3X
16334760|NCT04436562|Experimental|Poziotinib|A single oral dose of 8 mg poziotinib as a capsule formulation (as the hydrochloride salt) containing approximately 100 μCi of [14C]-poziotinib
16334761|NCT04436549||Patients with varicose veins|Patients with varicose veins and eligible to receive open surgery (stab avulsion of varicose veins) as routinely care.
16334762|NCT04436536|Experimental|training with random speed changes|Walking training on treadmill with random speed changes, that is, random sequence of several different walking speeds
16334763|NCT04436536|Active Comparator|training with blocked speed changes|Walking training on treadmill with blocked speed changes, that is a steady progression of faster walking speed.
16334764|NCT04436523|Experimental|Blood flow restriction|The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
16334765|NCT04436523|Sham Comparator|Standard rehabilitation|The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.
16334766|NCT04436510|Experimental|Verdiperstat|Verdiperstat is administered twice daily p.o. for 24 weeks.
16334767|NCT04436510|Placebo Comparator|Matching Placebo|Matching placebo is administered twice daily p.o. for 24 weeks.
16334768|NCT04436497|Experimental|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection
~Dosage: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight"
16334769|NCT04436497|Placebo Comparator|Matching Placebo|"Administration: Subcutaneous injection
~Dosage: Daily subcutaneous injection"
16334770|NCT04436471|Experimental|Component 1|"rAd26 Component, 1 vaccination
~Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene"
16334771|NCT04436471|Experimental|Component 2|"rAd5 Component, 1 vaccination
~Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene."
16334772|NCT04436471|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
16334773|NCT04436458|Experimental|Niclosamide|Continued SOC therapy together with Niclosamide tablets for 14 days
16334774|NCT04436458|Placebo Comparator|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide
16334775|NCT04436445|Active Comparator|dry cupping|Dry cupping is considered to be a noninvasive and inexpensive technique, used worldwide to treating patients with pain syndromes It is in fact a type of physical therapy which is applied by the specialists of acupuncture or other individuals. It improves the subcutaneous blood flow and, as a result, stimulates the autonomic nervous system and reduces the pai
16334776|NCT04436445|Active Comparator|Life style modification|"lifestyle modifications in the form of dietary recommendations, exercises and sleep quality improvement for 8 weeks.The life style modification followed in the treatment: Avoid consumption of all kinds of alcohol beverages. Avoid consumption of spicy foods, pepper, chili and coffee Follow a correct diet assuming each day 50% carbohydrates,30% fats and 20% proteins Increase your intake of fruits, vegetables and foods rich of natural fibers (dark bred, vegetables, spinaches).
~8 hour sleep at night 40 minutes of walking 3time per week."
16334777|NCT04436432||Assessment|Children with ASD ages 3-5 years at baseline
16334778|NCT04436419|Placebo Comparator|Placebo|Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
16334779|NCT04436419|Active Comparator|ALA|Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
16334780|NCT04436406|Other|Arm 1: Non-small cell lung cancer|"Participants with non-small cell lung cancer as per inclusion/exclusion criteria undergo baseline and PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PDL1 single-domain antibody SPECT imaging at 0 and 9 weeks.
~FDG-PET/CT is also performed at baseline (0) and first follow-up (9) weeks scans, in addition to standard CT clinical imaging at 0, 9 and 18 weeks."
16334781|NCT04436406|Other|Arm 2: Melanoma|"Participants with malignant melanoma as per inclusion/exclusion criteria undergo baseline and PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PDL1 single-domain antibody SPECT imaging at 0 and 12 weeks.
~FDG-PET/CT is also performed as standard clinical imaging at baseline (0), first follow-up (12) weeks and 24 weeks."
16334782|NCT04436393||Advanced Breast Cancer|Patients with diagnosis of advanced breast cancer
16334783|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
16334784|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
16334785|NCT04436354|Experimental|vaginoscopic office hysteroscopy in the trendelenburg position|
16334786|NCT04436354|Experimental|vaginoscopic office hysteroscopy in lithotomy position|
16334787|NCT04436341||Patients with Alzheimer's disease|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
16334788|NCT04436341||Patients with Lewy body dementia|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
16334789|NCT04436341||Healthy controls|No treatment interventions. Investigations: physical examination, ear-EEG cranial MR, cognitive tests, blood samples
16334790|NCT04436328|Experimental|Surgical treatment|Surgical treatment of native vertebral osteomyelitis followed by antimicrobial therapy
16334791|NCT04436328|Active Comparator|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only
16334792|NCT04436315|Experimental|Intervention|Exergame intervention
16334793|NCT04436315|Sham Comparator|Control|Active control condition
16334794|NCT04436302|Experimental|Intervention|Dividat senso exergame device
16334795|NCT04436302|Active Comparator|Control|Listening to music
16334796|NCT04436289|No Intervention|Care-as-usual (CAU) study arm|Participants will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
16334797|NCT04436289|Experimental|Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take <30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
16334798|NCT04436276|Experimental|Cohort 1a|Participants (healthy adults aged greater than or equal to (>=)18 to less than or equal to (<=) 55 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study.
16334799|NCT04436276|Experimental|Cohort 1b|Participants (healthy adults aged >=18 to <= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study.
16334800|NCT04436276|Experimental|Cohort 2a|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1, followed by booster vaccination at 6, 12 or 24 months with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination.
16334801|NCT04436276|Experimental|Cohort 2b|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S in the primary regimen or matching Placebo on Day 1 and Day 57, followed by booster vaccination at 8 months, 14 months, and 26 months (that is, 6 months, 12 months, or 24 months after completion of the primary regimen) with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination.
16334802|NCT04436276|Experimental|Cohort 3|Participants (good or stable health adults aged >=65 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study.
16334803|NCT04436263|Experimental|Supplement|Ethanol-water extract of winery by-products
16334804|NCT04436263|Placebo Comparator|Placebo|Maltodextrin-based placebo
16334805|NCT04436250|Active Comparator|Placebo|Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
16334806|NCT04436250|Experimental|S-Ketamine Low dose|S-Ketamine at a dose of 0.2 mg/kg
16334807|NCT04436250|Experimental|S-ketamine High dose|S-ketamine at a dose of 0.4 mg/kg
16334808|NCT04436237|Experimental|Non-visual exproprioception training|The training requires the participant to place the foot at a target without visual cues of the foot in virtual environment.
16334809|NCT04436237|Active Comparator|Visual exproprioception group|The training requires the participant to place the foot at a target with visual cues of the foot in virtual environment.
16334810|NCT04436224|Experimental|hydromorphone|NS 40ML+ hydromorphone(10mg , 2mg:2ml），IV-Pump，maintenance dose 0.50mg/h
16334811|NCT04436224|Active Comparator|fentanyl|NS 40ML+ fentanyl(0.5mg, 0.1mg:2ml），IV-Pump，maintenance dose 0.08-0.2mg/h
16334812|NCT04436224|Active Comparator|Butorphanol|NS 40ML+ butorphanol(10mg, 1mg:1ml），IV-Pump，maintenance dose 0.7-10mg/kg/h
16334813|NCT04436211||TKA (mechanical alignment)|
16334814|NCT04436211||TKA (kinematic alignment)|
16334815|NCT04436198|Experimental|Treatment group: toric IOL plus capsular tension ring|
16334816|NCT04436198|Active Comparator|Control group: toric IOL only|
16334817|NCT04436185|No Intervention|Characteristics of newborns included|Characteristics of newborns included in the randomized controll
16334818|NCT04436185|Experimental|Intraclass Correlation between the NIPS Score of Parent, Nurse|Intraclass Correlation between the NIPS Score of Parent, Nurse
16334819|NCT04436185|Experimental|Comparisons of procedural pain scores among groups|Comparisons of procedural pain scores among groups
16334820|NCT04436172|No Intervention|pre intervention|Before intervention
16334821|NCT04436172|Experimental|post intervention|Received soinal anesthesia
16334822|NCT04436159|Active Comparator|Nissen fundoplication|Addition of 360 fundoplication after crural closure
16334823|NCT04436159|Active Comparator|Toupet fundoplication|Addition of 180 posterior fundoplication after crural closure
16334824|NCT04436146|Other|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
16334825|NCT04436133|Experimental|vaccine group|
16334826|NCT04436133|Active Comparator|Positive control group|
16334827|NCT04436120|Other|Tumor biopsy and blood draw|Tumor biopsy and blood draw
16334828|NCT04436107|Experimental|Part 1 : Zanubrutinib + Lenalidomide|"Zanubrutinib for up to 48 months
~Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months"
16334829|NCT04436107|Experimental|Part 2 : Zanubrutinib+Lenalidomide|"Zanubrutinib for up to 48 months
~Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months"
16334830|NCT04436094|Experimental|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.
~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
16334831|NCT04436094|Active Comparator|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
16334832|NCT04436081|Active Comparator|Hemp-based CBD oil Gelcaps|The intervention consists of 6 weeks oral administration of CBD oil Gelcaps, starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day. At any given dose, if participants develop side effects, the dosage will be reduced to the previous dose.
16334833|NCT04436081|Placebo Comparator|Oral placebo Gelcaps|Participants in the control group will receive oral placebo Gelcaps that are identical in appearance to the CBD oil Gelcaps. Dosing will be identical to the intervention arm.
16334834|NCT04436068|Experimental|Outpatients with known or suspected hydrocephalus|
16334835|NCT04436068|Experimental|Outpatients with other known or suspected neurological condition|
16334836|NCT04436055||All participants|All participants including cannabis users, other drug users, and non-drug users.
16334837|NCT04436042|Experimental|MyHand Treatment|Participants will use the MyHand device during repetitive grasp and release tasks.
16334838|NCT04436029|Experimental|Descartes 11|
16334839|NCT04436016|Experimental|Ivabradine|"Ivabradine will be administered in an individualized regimen adapted to the subject's heart rate at each visit in a dosage ranging from 0-7.5mg twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:
~If heart rate is ≥101 bpm: capsule D (Ivabradine 7.5 mg);
~If heart rate is 86-100 bpm: capsule C (Ivabradine 5 mg);
~If HR is 71-85 bpm: capsule B (Ivabradine 2.5 mg);
~If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (placebo)."
16334840|NCT04436016|Placebo Comparator|Placebo|"Placebo will be administered twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:
~If heart rate is ≥101 bpm: capsule D (Placebo)
~If heart rate is 86-100 bpm: capsule C (Placebo)
~If HR is 71-85 bpm: capsule B (Placebo)
~If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (Placebo)."
16334841|NCT04436003|Experimental|Muscle and Articulation chains GDS method treatment|"Participants in the intervention Group are examined and treated according to the principles of Muscle and Articulation Chains GDS Method. They receive GDS treatment individually, up to 8 sessions of 1 hour."
16334842|NCT04436003|No Intervention|Control (treatment as usual)|The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.
16334843|NCT04435990|Experimental|Experimental:10,000 MM09|10,000 TU/mL of subcutaneous immunotherapy
16334844|NCT04435990|Experimental|Experimental: 30,000 MM09|30,000 TU/mL of subcutaneous immunotherapy
16334845|NCT04435990|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without any active ingredients.
16334846|NCT04435977|Experimental|Cabozantinib|Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
16334847|NCT04435964||Overall series|Patients treated with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule. No limitations to previous lines of treatment. ICI therapy may be either as single agent or in combination. Concomitant chemotherapy (CT) and radiotherapy (RT) is allowed.
16334848|NCT04435951||Group 1 (with TMJD)|Group 1, consists of 60 patients diagnosed with Temporomandibular Joint Dysfunction (TMJD) according to the Research Diagnostic Criteria for Temporomandibular Disorders by a specialist and experienced dentist in TMJD.
16334849|NCT04435951||Group 2 (without TMJD)|Group 2, consists of 60 individuals who did not exhibit TMJD symptoms and have not TMJD diagnosis.
16334850|NCT04435938|Experimental|Stereotactic Body Radiotherapy (SBRT)|The dose prescribed in the study will be 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days. (e.g. treatment given on Monday/Thursday/Mon/Thurs/Mon) (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues.)
16334851|NCT04435925|Active Comparator|Remifentanil|Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.
16334852|NCT04435925|Placebo Comparator|Fentanyl|Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.
16334853|NCT04435912|No Intervention|PS alone group|Patients received only Protamine Sulfate for reversal of Heparin
16334854|NCT04435912|Experimental|PS and HC group|Patients received Hydrocortisone pre-treatment then Protamine Sulfate for the reversal of Heparine
16334855|NCT04435899|Experimental|EFFECTS OF A CHAIR-YOGA EXERCISES ON STRESS HORMONE LEVELS.|assess the changes mediated by exercise on activities of daily life and falls (autonomy), physical fitness, salivary cortisol and alpha amylase in older adults living in social care givers centers. Methods: 35 women (83.81 ± 6.6 years old) were divided into two groups: chair-yoga exercises (CY, n=20) and control group (CG, n=15). All subjects were evaluated before and after 14-weeks of intervention. CY was involved in classes two times per week, while the GC did not participate in any exercise.
16334856|NCT04435899|Experimental|Physical fralty and health outcomes of fitness, sex hormones.|The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
16334857|NCT04435899|Experimental|physical fitness and frailty syndrome institutionalized older|"This study analyzed the relationship between old physical frailty syndrome (PF) and PhFi indicators and assessed how the latter might predict the former. Participants were 119 elderly women (81.96 ±7.89 years) recruited from four social and healthcare centers. PhFi was assessed through muscle strength tests of upper and lower limbs, endurance, agility-dynamic balance, flexibility and body composition.
~The following PF indicators were assessed: weight loss, exhaustion, weakness, slowness and low physical activity level."
16334858|NCT04435899|Experimental|THE RELATIONSHIP BETWEEN FUNCTIONAL DISABILITY OUTCOMES|The associations between functional disability activities of life activities and frailty have already been explored. The contribution of each component of physical frailty and their contribution to understanding the early physical decline of older individuals are poorly explored. The relationships between PF and functional disability and to identify the independent components of frailty that most influence on disability in older women. A cross-sectional study of 119 (81,96±7,89) older women aged 75 and over. Functional disability was assessed through Agility-dynamic and Static balance tests, Activities of daily life and Falls risk screen outcomes.
16334859|NCT04435886|Experimental|Probiotic group|A multi-strain probiotic
16334860|NCT04435886|Placebo Comparator|Placebo group|Identical placebo
16334861|NCT04435873||Mail Survey Participants|Approximately 1200 home patients will receive mail surveys. Of these, one thousand and twenty (1,020) patients will be asked to complete the survey once. One hundred and eighty (180) patients will be asked to complete the survey twice.
16334862|NCT04435873||Telephone Survey Participants|Three hundred (300) home patients will be surveyed by phone. Of those, one hundred and twenty will be asked to complete the survey once. One hundred and eighty patients will be asked to complete the phone surveys on two separate occasions.
16334863|NCT04435860||Ankylosing Spondylitis|Patients with ankylosing spondylitis meeting the inclusion and exclusion criteria
16334864|NCT04435860||Healthy Controls|Healthy individuals meeting the exclusion criteria
16334865|NCT04435847|Experimental|HST 001|HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
16334866|NCT04435847|Placebo Comparator|Placebo - Phosphate Buffered Saline|Phosphate Buffered Saline
16334869|NCT04435821|Experimental|Pediatric Chronic Pain Patients|Individuals 11-18 years old, with chronic pain (lasting at least 2 months).
16334870|NCT04435808|Experimental|Hydroxychloroquine Arm|Group A: up to 275 health care workers who choose to take hydroxychloroquine. Will receive a 600 mg loading dose, followed by 200 mg daily (tablets).
16334871|NCT04435808|No Intervention|No Intervention Arm|Group B: Up to 75 health care workers who choose not to take hydroxychloroquine.
16334872|NCT04435795|Active Comparator|Ciclesonide inhaled and nasal|Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled ciclesonide 600mcg BID x 14 days
16334873|NCT04435795|Placebo Comparator|Placebo|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
16334875|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on warfarin|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.
16334876|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on apixaban|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.
16334877|NCT04435756||Observational (blood collection)|Patients undergo collection of blood every 3-6 months for up to 3 years.
16334878|NCT04435743||DLBCL|Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.
16334879|NCT04435743||FL/MCL/MZL|Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.
16334880|NCT04435743||Maintenance|B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.
16334881|NCT04435730||Group 1|45 patients with cutaneous psoriasis with no musculoskeletal manifestations.
16334882|NCT04435730||Group 2|45 patients with psoriatic arthritis fulfilling CASPAR criteria of PsA
16334883|NCT04435730||Group 3|45 patients with subclinical psoriatic arthritis (patients with cutaneous psoriasis and musculoskeletal manifestations but not fulfilling CASPARcriteria of PsA).
16334884|NCT04435730||Group 4|45 sex and age matched healthy controls
16334885|NCT04435717|Experimental|TCZ 8 mg / kg one dose|TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
16334886|NCT04435717|Experimental|TCZ 8 mg / kg in two|TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
16334887|NCT04435717|No Intervention|standard care treatment|Usual / standard care treatment
16334888|NCT04435704|Experimental|Oxytocin|Oxytocin will be administered at increasing and decreasing rates
16334889|NCT04435691|Experimental|Treatment (azacitidine, venetoclax, magrolimab)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 (may be reduced to days 1-21 for subsequent cycles after principal investigator approval), and magrolimab IV over 2-3 hours on days 1, 4, 8, 11, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycle 2, and days 1 and 15 of cycle 3 and subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16334890|NCT04435678|Other|birch pollen allergy|"106 patients with suspicion of birch pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
16334891|NCT04435678|Other|grass pollen allergy|"106 patients with suspicion of grass pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
16334892|NCT04435678|Other|house dust mite allergy|"148 patients with suspicion of house dust mite allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)"
16334893|NCT04435678|Other|cat allergy|"106 patients with suspicion of cat allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
16334894|NCT04435678|Other|bee venom allergy|"106 patients with suspicion of bee venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
16334895|NCT04435678|Other|vespid venom allergy|"106 patients with suspicion of vespid venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
16334896|NCT04435678|Other|non-allergic individuals|"148 non-allergic individuals will be included in the study. They should have no symptoms that could be related to inhalant allergy or Hymenoptera venom allergy, negative skin test results and undetectable IgE levels.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
16334897|NCT04435665|Experimental|NFX-179 Gel Low|NFX-179 Gel for topical administration, once daily for 28 days
16334898|NCT04435665|Experimental|NFX-179 Gel Mid|NFX-179 Gel for topical administration, once daily for 28 days
16334899|NCT04435665|Experimental|NFX-179 Gel High|NFX-179 Gel for topical administration, once daily for 28 days
16334900|NCT04435665|Placebo Comparator|Vehicle Arm|Vehicle Gel, for topical administration, once daily for 28 days
16335030|NCT04434768|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.
16334901|NCT04435652|Experimental|Experimental: Cohort A|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
16334902|NCT04435652|Experimental|Experimental: Cohort B-arm1|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
16334903|NCT04435652|Experimental|Experimental: Cohort B-arm2|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
16334904|NCT04435639|Experimental|MLD + Adjustable Compression Sleeve.|Manual lymph drainage + Adjustable Compression Sleeve.
16334905|NCT04435639|Active Comparator|MLD + Coban Compression Bandage.|Manual lymphatic drainage + Coban compression bandaging.
16334908|NCT04435613|Other|protective mechanical ventilation|Ten patients with moderate to severe ARDS were subjected to a nearly ultra-protective ventilation strategy generating a reduction in minute ventilation (Tidal volume of 5 ml/kg of predicted body weight together with a 20% reduction in respiratory rate). In addition to end-inspiratory pause, prolongation was set to avoid hypercapnia. Protocol phases: Baseline conditions: Tidal volume of 7 ml/kg. I: Tidal volume of 6 ml/kg. II: Tidal volume of 5 ml/kg. III: Increase end-inspiratory pause until achieving an I:E ratio equal to 1. IV: Respiratory rate reduction until 20% of the basal condition keeping constant I:E ratio equal to 1
16334914|NCT04435587|Experimental|ivermectin|"Combination of
~oral ivermectin 600 mcg/kg/day once daily for 3 days
~Zinc sulfate (100mg/tab) 2 tab every 12 hours for 3 days"
16334915|NCT04435587|Active Comparator|ART/hydroxychloroquine|"Combination of
~Day1 hydroxychloroquine 400mg bid, then 200mg bid on Day 2-5
~Darunavir/ritonavir (400/100mg) every 12 hours for 5 days
~Zinc sulfate (100/tab) 2 tab every 12 hours for 5 days"
16334916|NCT04435574|Experimental|Group A|group A is lactoferrin group, receiving 100mg sachet of lactoferrin once daily.
16334917|NCT04435574|Active Comparator|Group b|group B is the ferrous sulfate group, receiving 6mg/kg/ day single dose of ferrous sulfate.
16334918|NCT04435561|Experimental|Standard physiotherapy rehabilitation and dry needling|"In addition to the usual therapy, the experimental group will receive the application of dry needling technique in the hemiparetic limbs.
~Dry needling intervention will take place over a period of one and a half months (6 weeks), with a total of 6 sessions. Each session will be performed once a week, where a single puncture will be made in each muscle to be treated, using Hong´s technique and lasting 60 seconds per muscle (or until the muscle is release).
~The muscles that will receive dry needling are the following ones:
~Upper limb: infraspinatus, teres minor, pectoralis major, deltoid.
~Lower limb: gastrocnemius, soleus and anterior tibial muscles."
16334919|NCT04435561|Other|Standard physiotherapy rehabilitation|The control group will receive the usual therapy and treatment.
16334920|NCT04435535|Other|Positive expiratory pressure (PEP)|PEP 10 cmH2O 15 min
16334921|NCT04435522|Experimental|Maraviroc Treatment|Maraviroc 300 mg Twice Daily
16334922|NCT04435509|Experimental|Greek Mountain Tea|50 patients Greek Mountain Tea 50 grams one per 30 days. Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams Intervention:Greek Mountain Tea in a plastic bag.
16334923|NCT04435509|Placebo Comparator|Mediterranean Diet|50 patients same dietary habits and a Mediterranean dietary protocol Intervention: Mediterranean diet.
16334924|NCT04435496|Other|GYN-CS insertion|GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.
16334925|NCT04435483|Experimental|Treatment Sequence 1|Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
16334926|NCT04435483|Experimental|Treatment Sequence 2|Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
16334927|NCT04435470||Critical ill children|Critial ill children admited in pediatric intensive care units 1-16 years old
16334928|NCT04435470||Control|Healthy children 1-16 years old
16334959|NCT04435301|Experimental|Beta modulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3). 28Hz acoustic stimuli and 28Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
16334960|NCT04435301|Sham Comparator|Sham modulation group|Sham stimulation was identical to the 40Hz stimulation, except that the acoustic and electric stimulation were ramped down after 0.5 min to remain turned off for the remaining 39.5 min. Sham stimuli are applied for 40min/day, for a total of 5 days.
16334929|NCT04435444|Experimental|Masterful supportive care|This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
16334930|NCT04435444|Active Comparator|Attention control supportive care|This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
16334931|NCT04435431|Experimental|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
16334932|NCT04435431|Experimental|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
16334933|NCT04435431|Experimental|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
16334934|NCT04435431|Placebo Comparator|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
16334935|NCT04435405||Video microanalisys|Video footage analysis of group and individual behavioral processes.
16334936|NCT04435392|Experimental|Part 1: Cohort 1, 0.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 0.5% Cream will be applied topically twice daily.
16334937|NCT04435392|Experimental|Part 1: Cohort 2,1.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 1.5% Cream will be applied topically twice daily.
16334938|NCT04435392|Experimental|Part 1: Cohort 3, 2.5% Jaktinib Qd|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically Once daily.
16334939|NCT04435392|Experimental|Part 1: Cohort 4, 2.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically twice daily.
16334940|NCT04435392|Placebo Comparator|Dose extension: Vehicle Control|the Vehicle Control cream will be applied topically twice daily
16334941|NCT04435392|Experimental|Dose extension: low-dose group, X%|X% based on results of part 1. The Jaktinib Hydrochloride X% Cream will be applied topically twice daily
16334942|NCT04435392|Experimental|Dose extension: high-dose group, Y%|Y% based on results of part 1. The Jaktinib Hydrochloride Y% Cream will be applied topically twice daily
16334945|NCT04435366|Experimental|Zimura Treatment Group|Monthly Zimura 2mg Intravitreal Injections, followed by monthly injections or every other month injections from Month 12 to Month 23
16334946|NCT04435366|Sham Comparator|Sham Treatment Group|Monthly Sham Administration until Month 23
16334947|NCT04435353|Active Comparator|Time-day of respiratory fail|Objective data
16334948|NCT04435353|Active Comparator|Oxygen status|Facultative data
16334949|NCT04435353|Active Comparator|Oxugen support|FiO2
16334950|NCT04435353|Active Comparator|Adverse outcomes|Complication
16334951|NCT04435340|Other|Retrospective|All patients in the retrospective cohort are contacted at least 1 year after surgery and/or 3 years after surgery via phone call or letter, informed about the study and asked to participate. In case of informed consent, they are invited to the study site. They are asked to complete the questionnaires and they undergo a Sonography of the ventral abdomen.
16334952|NCT04435340|Other|Prospective|All patients in the prospective cohort are informed about the study and asked to participate in the outpatient clinic before surgery. In case of informed consent, they are invited to the study site at least one year and three years, respectively, after surgery. They are asked to complete the questionnaires and they undergo an ultrasound of the ventral abdomen.
16334953|NCT04435327||Oxygen therapy|Patients who were hospitalised due to COVID-19 pneumonia and received only oxygen support therapy.
16334954|NCT04435327||Non invasive ventilation (NIV/CPAP)|Patients who were hospitalised due to COVID-19 pneumonia and received non invasive ventilation (NIV/CPAP) as maximum support therapy
16334955|NCT04435327||Invasive ventilation|Patients who were hospitalised due to COVID-19 pneumonia and received invasive mechanical ventilation (IMV)
16334956|NCT04435314|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
16334957|NCT04435314|Placebo Comparator|Placebo|Subjects will receive placebo TID.
16334958|NCT04435301|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator(NeuroConn, Germany). Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3), respectively. 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
16334998|NCT04435041||RECAP early warning score|Development of disease specific early warning score, building on earlier work through literature review and NEWS2 score
16334999|NCT04435041||Implementation/Scale up case studies|Study of implementation and scale up of remote-by-default at four different UK sites
16334961|NCT04435288|Active Comparator|TNFi-induction group|"The patients in the TNFi-induction group will receive golimumab at a standard dose of 50 mg subcutaneously (SC) every 4 weeks (with matching methotrexate (MTX)-placebo). In case of potential intolerance or toxicity to MTX-placebo, the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX-placebo will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
16334962|NCT04435288|Active Comparator|csDMARD-Step-up group|"The patients in the csDMARD-Step-up group will start with oral methotrexate (MTX) at a weekly dose of 15 mg for 4 weeks (with matching TNFi-placebo injections). In case of potential intolerance or toxicity to MTX , the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
16334963|NCT04435275|Active Comparator|Donning PPE using VA then doffing PPE using HC|Study subjects will receive VA guidance for donning first, then guidance from a human coach (HC) for doffing.
16334964|NCT04435275|Active Comparator|Donning PPE using HC then doffing PPE using VA|Study subjects will receive HC guidance for donning first, then VA guidance for doffing.
16334965|NCT04435275|Active Comparator|Intubation using VA then extubation using HC;|Study subjects will receive VA guidance for the intubation first , then HC guidance for extubation procedure
16334966|NCT04435275|Active Comparator|Intubation using HC then extubation using VA|Study subjects will receive HC guidance for the intubation first , then VA guidance for extubation procedure
16334967|NCT04435262||ILR Group followed with RM|Patients with unexplained syncope underwent ILR monitoring and followed with RM
16334968|NCT04435262||ILR Group followed with in-hospital visits|Patients with unexplained syncope underwent ILR monitoring and followed with in-hospital visits
16334970|NCT04435236|Active Comparator|Cervical ESP block group|Cervical ESP block will be performed as described by Elsharkawy at al. (7).
16334971|NCT04435236|Sham Comparator|ISB Block group|ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
16334972|NCT04435223||COVID-19 severe pneumonia|
16334973|NCT04435223||Severe pneumonia due to other pathogene|
16334974|NCT04435210|Experimental|Nifedipine arm|Participants in this arm will be pregnant women with severe hypertension who will receive nifedipine
16334975|NCT04435210|Experimental|Hydralazine|Participants in this arm will be pregnant women with severe hypertension who will receive hydralazine
16334976|NCT04435197|Experimental|Arm A|"Arm 1:
~A: Pembrolizumab 200mg(100mg if weight less than 50kg) IV on days 1 and 22 B: Carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.
~D: Ivor-Lewis or McKeown esophagectomy
~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
16334977|NCT04435184|Experimental|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
16334978|NCT04435184|Active Comparator|Placebo Saline|0.9% saline 100 ml IV once.
16334979|NCT04435171||Open renal transplantation|Patients who were performed open renal transplantation due to end stage renal disease.
16334980|NCT04435171||robot assisted renal transplantation|Patients who were performed robot assisted renal transplantation due to end stage renal disease
16334981|NCT04435158|Experimental|Cohort 1：SHR-1222|Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
16334982|NCT04435158|Experimental|Cohort 2：SHR-1222|Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
16334983|NCT04435158|Experimental|Cohort 3：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
16334984|NCT04435158|Experimental|Cohort 4：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 biomonthly × 6 months
16334985|NCT04435158|Experimental|Cohort 5：placebo|Subcutaneous injection of placebo monthly
16334986|NCT04435145|Experimental|Intervention|Sugar-sweetened beverage warning label
16334987|NCT04435145|No Intervention|Control|No label
16334988|NCT04435132|Experimental|PCNL with the aid of the robotic device|Patients will undergo prone PCNL under fluoroscopic guidance and with the aid of the robotic device.
16334989|NCT04435106||Opaganib + Standard of Care|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
16334990|NCT04435106||Standard of Care|Study participants received Standard of Care
16334991|NCT04435093||MFM completion|
16334992|NCT04435080||Non-rehabilitation|The patients hospitalised in ICU who were provided all the intensive care managements except for rehabilitation interventions (discharged from intensive care unit before April 14, 2020)
16334993|NCT04435080||Rehabilitation|The patients hospitalised in ICU who were provided rehabilitation interventions in addition to all the intensive care managements. (discharged from intensive care unit after April 14, 2020)
16334994|NCT04435067||Cohort A|patients in whom lung metastasis were resected for therapeutic purposes
16334995|NCT04435067||Cohort B|patients in whom lung metastasis were removed for diagnostic purposes only
16334996|NCT04435054|Other|Non invasive tests|
16334997|NCT04435041||Remote assessment tools|Qualitative methods: semi-structured interviews for approx 40 front line clinical practitioners
16335000|NCT04435041||Infrastructure strengthening|Theory and data driven change effort involving policymakers, regulators, professional bodies, industry, patients and citizens with a view to overcoming interacting issues impacting success of digital projects.
16335001|NCT04435028||control group|55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen)
16335002|NCT04435028||ketotifen group|Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment
16335003|NCT04435015|Experimental|Camostat mesylate 200 mg|Participants will be given Camostat mesylate three times daily.
16335004|NCT04435015|Placebo Comparator|Microcrystalline Cellulose|Participants will be given placebo three times daily.
16335005|NCT04435002|Experimental|Intervention Group|For 9 different points acupressure technique applied to this group for 4 weeks
16335006|NCT04435002|No Intervention|Control Group|
16335007|NCT04434989|Experimental|Stereotactic Body Radiation Therapy|SBRT is defined as a special radiotherapy technique. The high dose of radiotherapy is accurately injected into the tumor lesion in one to several times using external irradiation technique. Then the tumor is exposed to high dose and the surrounding normal tissue to low dose.
16335008|NCT04434989|Active Comparator|Radiofrequency Ablation|Percutaneous radiofrequency ablation to the tumor
16335009|NCT04434976||delayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
16335010|NCT04434976||undelayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
16335011|NCT04434950|Experimental|Intervention|Intervention group
16335012|NCT04434937|Experimental|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
16335013|NCT04434898||Ｍild cognitive impairment patients|"The patients with mild cognitive impairment have a Clinical Dementia Rating score of 0.5. First, we will evaluate the correlation between diffusion MRI and the clinical severity and cognitive decline of patients. Second, we will evaluate if diffusion MRI can predict if these patients will develop Alzheimer's Disease and hence be involved in the third year of the study. Patients with mild cognitive impairment should meet the following criteria:
~Between 50-80 years old
~Right-handed
~Clinical Dementia Rating score equal to 0.5
~For patients who have a CDR score of 0.5, should be diagnosed by clinician's judgement of clinical information, daily living activities, and extent of neuropsychological disorders
~Able to understand study requirements and give informed consent"
16335014|NCT04434898||Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
16335015|NCT04434898||Healthy volunteers|"The healthy volunteers should meet the following criteria:
~Between 50-80 years old
~Right-handed
~MMSE score greater than or equal to 26
~Able to understand study requirements and give informed consent"
16335016|NCT04434885||Psoriatic arthritis|Patients diagnosed with PsA and fulfilling the classification criteria for PsA with symptom duration of up to 10 years and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs).
16335017|NCT04434872|Active Comparator|FMT from a healthy donor|"Patients will undergo FMT 4 times during the study:
~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:
~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.
~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
16335018|NCT04434872|Placebo Comparator|FMT from a self donated stool sample|"Patients will undergo FMT 4 times during the study:
~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:
~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.
~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
16335019|NCT04434859||Patients with tinnitus|Patients (over 18 years old) seen at the medical center due to tinnitus, lasting at least 3 months.
16335020|NCT04434846||1|Adults ages 18-55 with ZIKV, DENV, and/or CHIKV seroprevalence.
16335021|NCT04434833||Extra nodal diseases|Patients with both lymph node and extra nodal involvement.
16335022|NCT04434833||Target drugs|Patients enrolled in clinical trials of novel target drugs.
16335023|NCT04434833||Relapse|Patients with high risk of relapse.
16335024|NCT04434820|No Intervention|standard dressing group|patients will receive sterile wound dressing of gauze and tape for 4 days.
16335025|NCT04434820|Active Comparator|External negative pressure dressing system group|patients will receive placement of a sterile dressing of gauze and occlusive adhesive over the closed incision. The dressing's tubing will then be attached to a compact, portable negative-pressure therapy unit (Yuwell 7E-A portable suction unit) that will deliver -80 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
16335028|NCT04434794|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
16335029|NCT04434794|Active Comparator|control|standard treatment according to clinical protocols
16335265|NCT04433078|Experimental|Doxycycline|Participants receive 100 MG BID for 21 days
16335031|NCT04434755||health care professionals in palliative care|health care professionals in palliative care
16335032|NCT04434755||health care professionals in neurorehabiliation|health care professionals in neurorehabiliation
16335033|NCT04434742|Experimental|Intervention group|The subjects in this group receive complex interventions, including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team.
16335034|NCT04434742|Other|Control group|The control group received usual discharge care and community resources that were made available to them as appropriate. A monthly social call was made to each client in the control group in order to exclude social effects. The contents of the social call, such as asking about entertainment and clients' hobbies, were set in the protocol.
16335035|NCT04434729|Experimental|Fetal embolization of vein of Galen malformation|This is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
16335036|NCT04434716|Other|Feasibility of Wearing a Readiband|"Participants will wear the Fatigue Science Readiband for 42 consecutive day. On day one, every seventh day and at the end of the study each participant will complete the Dyspnea-Characteristic scale, BRICS NINR PROMIS Fatigue Short Form6a scale , Modified Pulmonary Functional Status, Dyspnea Questionnaire and the BRICS NINR PROMIS SF v1.0-Sleep Disturbance 6a scale.The Minnesota Living with Heart Failure Questionnaire and Self-Care of Heart Failure Index will be completed on day one and day 60. The purpose of this intervention is to assess the Feasibility of Wearing a Readiband.
~Semi-structured Interview will be conducted at the end of 42 days to assess patient comfort and challenges with wearing the Readiband."
16335037|NCT04434703|Active Comparator|Platelet rich fibrin (PRF)|Platelet rich fibrin is the secoond generation of platelet concentrates which is an autogenous biomaterial that is prepared from the patient's own blood
16335038|NCT04434703|Experimental|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin is the last modification of PRF which is expected to contain a relatively greater number of white blood cellsand growth factors
16335039|NCT04434703|Placebo Comparator|blood clot|normal healing of the wound without adding any biomaterial
16335040|NCT04434690|Experimental|Simultaneous|2 surgeons will perform simultaneous total knee arthroplasty in this group.
16335041|NCT04434690|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
16335042|NCT04434677|Active Comparator|Hypofractionation|Control arm:patients who will receive standard 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
16335043|NCT04434677|Experimental|Ultrahypofractionation|Experimental arm: Patients who will receive 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
16335044|NCT04434664|Active Comparator|Amlodipine besylate|Initial dose 5mg (1 capsule) daily, titrated up to 10mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
16335045|NCT04434664|Active Comparator|Metoprolol succinate|Initial dose 100mg (1 capsule) daily, titrated up to 200mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
16335046|NCT04434651|Experimental|Block group (A)|"26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using 2 % lidocaine before induction of anesthesia.
~The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes."
16335047|NCT04434651|Sham Comparator|control sham group (B)|26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using normal saline.The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes
16335048|NCT04434638|Experimental|Transitions of Care Coordinator Group|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
16335049|NCT04434638|Active Comparator|Usual Care Group|Patients in the usual care group, which served as the control, received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
16335050|NCT04434625|No Intervention|control group|Colonoscopy was performed in the control group directly.
16335051|NCT04434625|Experimental|model-based interference group|Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group colonoscopy directly.
16335052|NCT04434612|Experimental|OXSIGHT smart glasses|Wearing OXSIGHT smart glasses
16335053|NCT04434599|Active Comparator|Fluoroscopically guided ablation|These patients will receive one catheter ablation of typical atrial flutter by fluoroscopically guided radiofrequency ablation catheters
16335054|NCT04434599|Active Comparator|Contact force guided ablation|These patients will receive one catheter ablation of typical atrial flutter by contact force guided radiofrequency ablation catheters using the CARTO 3D electroanatomic mapping system
16335055|NCT04434599|Active Comparator|Local impedance guided ablation|These patients will receive one catheter ablation of typical atrial flutter by local impedence guided radiofrequency ablation catheters using the Rhythmia Ultra-high density 3D electroanatomic mapping system
16335056|NCT04434586|Sham Comparator|angiography 2D|Control group: an arteriography will be performed on the entire treated segment to assess the quality of the result, the application or not an active balloon will be left to the discretion of the operator. In case of application of the active balloon, a new arteriography before decision or not the use of stenting will be practiced. In case of stenting, an arteriographic final is performed.
16335057|NCT04434586|Experimental|angiography 2D with OCT|Experimental group: an arteriography and OCT acquisition on the entire treated segment to ensure the quality of the result, the application or not of an active ball will be left. In case of application of the active balloon, a new arteriography and OCT acquisition before decision or not the use of stenting will be practiced. In case of stenting, a final arteriography and then OCT acquisition are performed.
16335058|NCT04434573||french-speaking digestive surgeons|french-speaking digestive surgeons are visceral and digestive surgeons that have a general surgical activity too. They can have or not an expertise on hernia pathology. They are questioned by survey on decisions about different patient asymptomatic hernia clinical situations.
16335059|NCT04434560|Experimental|Neoadjuvant Immunotherapy|Patients will receive a single dose of neoadjuvant nivolumab and ipilimumab 7 days (± 3 days) prior to surgical resection.
16335060|NCT04434547|Experimental|PRP group|In the PRP group autologous platelets rich plasma was prepared from the blood using the two step centifuge process .Under ultrasound guidance and complete aseptic procedure , 1 ml of PRP was infused inside the uterus while performing the mock embryo transfer
16335061|NCT04434547|No Intervention|Control group|In the control group mock embryo transfer was performed without injecting anything inside the uterus.
16335062|NCT04434534|Experimental|Hipocaloric Diet with Açaí Juçara|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories, including 200g of Açaí Juçara (2 pulps).
16335063|NCT04434534|Active Comparator|Hipocaloric Diet|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories.
16335064|NCT04434508|Active Comparator|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
16335065|NCT04434508|Active Comparator|open right hemicolectomy with CME and central v|open right hemicolectomy with CME and central v
16335066|NCT04434495|Experimental|PRP group|mock embryo transfer and PRP injection
16335067|NCT04434495|No Intervention|control group|only mock embryo transfer
16335068|NCT04434482|Experimental|IMP4297 and temozolomide|"IMP4297 and temozolomide
~The dose levels will be escalated following a modified 3+3 dose escalation scheme."
16335073|NCT04434456||CGuard stenting (interventional)|CGuard implantation in the carotid artery with aneurysm requiring intervention
16335074|NCT04434443|Experimental|trunk exercise on unstable surface|trunk exercise training in supine and sitting positions, with unstable surfaces
16335075|NCT04434443|Sham Comparator|upper limb range of motion exercise|upper limb range of motion exercise in sitting with back fully supported
16335076|NCT04434430|Active Comparator|Gabapentin|Patient will receive preemptive oral gabapentin 600 mg
16335077|NCT04434430|Placebo Comparator|Placebo|Patient will receive oral placebo
16335079|NCT04434404|Placebo Comparator|control group|33, patients in the control group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 without cardioprotective agents
16335080|NCT04434404|Active Comparator|L-carnitine group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine
16335081|NCT04434404|Active Comparator|Silymarin group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin140 mg
16335082|NCT04434391||QF-PCR for GBS screening|QF-PCR for vaginal-rectal samples in pregnant women
16335083|NCT04434378|Placebo Comparator|Placebo|Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
16335084|NCT04434378|Experimental|Interventional|Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.
16335085|NCT04434365|Experimental|Berberine+standard therapy Arm|In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
16335086|NCT04434365|Active Comparator|Standard therapy Arm|In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
16335116|NCT04434144||Group B|Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.
16335150|NCT04433897||Oral estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD
16335151|NCT04433897||Oral estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy.
16335087|NCT04434352|Active Comparator|Baseline Erectile Dysfunction|The first arm of the study will be those men with erectile dysfunction as defined by IIEF score. These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM score and EHS score. Each questionnaire is described in the trial description with a higher score indicating improved function.
16335088|NCT04434352|Active Comparator|Erectile Dysfunction-Penile Rehabilitation|The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.
16335089|NCT04434352|Active Comparator|Erectile Dysfunction Post-Prostate Cancer Treatment|The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.
16335090|NCT04434339|Experimental|group 1|"ESP block group ,Patients received preoperative US guided ESP block on BOTH sides to be operated upon 30 minutes before being transferred to the OR"
16335091|NCT04434339|Experimental|group 2|"TAB group ,Patients received bilateral lower TAB 30 min before being transferred to the OR"
16335092|NCT04434339|No Intervention|group 3|"the control group, Patients will not receive any block."
16335093|NCT04434326|Experimental|[14C]CM082|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]CM082 to healthy Chinese male subjects
16335094|NCT04434313|Experimental|Delivery of iStride™ device gait treatment using telemedicine|"Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.
~Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial."
16335095|NCT04434300|Other|Dapto SC-IV|"First stage :
~Subcutaneous injection of daptomycin 10mg/kg
~Subcutaneous injection of placebo (physiological serum)
~Second stage :
~- Intravenous injection of daptomycin 10mg/kg"
16335096|NCT04434300|Other|Dapto IV-SC|"First stage :
~- Intravenous injection of daptomycin 10mg/kg
~Second stage :
~Subcutaneous injection of daptomycin 10mg/kg
~Subcutaneous injection of placebo (physiological serum)"
16335097|NCT04434274||Group A, MPFF-group|MPFF [Detralex®, Servier, France] 1,000 mg OD for 30 days in the postoperative period.
16335098|NCT04434274||Group B|No venoactive drug prescribed in the postoperative period.
16335099|NCT04434261||Patients tested for SARS-CoV-2|Patients who underwent the preoperative screening program for SARS-CoV-2
16335100|NCT04434248|Experimental|Favipiravir, lower dose (pilot stage)|1600mg BID on the 1st day followed by 600mg BID for 13 days
16335101|NCT04434248|Experimental|Favipiravir, higher dose (pilot stage)|1800mg BID on the 1st day followed by 800mg BID for 13 days
16335102|NCT04434248|Active Comparator|Standard of care (pilot stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
16335103|NCT04434248|Experimental|Favipiravir, selected dose (pivotal stage)|The dose will be selected based on pilot study results.
16335104|NCT04434248|Active Comparator|Standard of care (pivotal stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
16335105|NCT04434235||Dynamic cervical stability|"The participant is asked to move the head in 6 directions in a sitting position and 30° leaning backward sitting position; lateral flexion (left / right), flexion, extension, and rotation (left / right). Results are to be taken for each direction and random at each axial load-level (0 kg, 1kg, 2 kg, and 3 kg). In total 24 measurements.
~The duration of all measurement will be 60 minutes."
16335106|NCT04434235||Cervical Stiffness|The participant is asked to move the head in 4 directions; flexion, extension, and rotation (left / right). Joint-Position Error measurements will be executed in neutral sitting position. Additionally, stiffness will be measured in neutral sitting position and neutral sitting position with 45° cervical flexion. All measurements will be performed with 0 kg and 3 kg axal loading. In total 18 measurements.The duration of all measurement will be 60 minutes.
16335107|NCT04434222|Active Comparator|Compressive stockings group|Group receives postoperatively compressive stockings for a period of 6 weeks.
16335108|NCT04434222|No Intervention|Control group|The control group is treated without compressive stockings.
16335109|NCT04434209|Experimental|NephroCheck-guided interventions|
16335110|NCT04434209|Active Comparator|Standard of Care|Standard of Care assessment and treatment
16335112|NCT04434183|Active Comparator|isokinetic exercise|The group (isokinetic exercise group, n = 25) was given isokinetic exercise.
16335113|NCT04434183|Active Comparator|home exercise|The group(home exercise group, n=25) was given home exercise program.
16335114|NCT04434170||Heart failure|outpatients with heart failure with reduced ejection fraction in treatment with sacubitril/valsartan according to guidelines
16335115|NCT04434144||Group A:|Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days
16335117|NCT04434131|Experimental|Single Arm|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Vitalant from local and national donors following national blood donation guidelines. All subjects receive the convalescent plasma.
16335118|NCT04434118||Rheumatoid Arthritis with COVID-19|
16335119|NCT04434118||Rheumatoid Arthritis without COVID-19|
16335120|NCT04434105|Experimental|PRP group|patients received ultrasound-guided injection of 2 mL PRP into the affected carpal tunnel.patients will be injected twice with 2 weeks intervals
16335121|NCT04434105|Active Comparator|Steroid group|patients received ultrasound-guided injection of 2 mL steroids (40 mg triamcinolone acetonide). into the affected carpal tunnel. patients will be injected twice with 2 weeks intervals
16335122|NCT04434105|Placebo Comparator|Control group|patients received ultrasound-guided injection of 2 mL saline patients will be injected twice with 2 weeks intervals
16335123|NCT04434092|Experimental|Arm A (Crovalimab)|Adult Participants will receive an initial intravenous (IV) loading dose on Week 1 Day 1, followed by 4 weekly crovalimab subcutaneous (SC) doses on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter, for a total of at least 24 weeks of study treatment.
16335124|NCT04434092|Active Comparator|Arm B (Eculizumab)|Adult Participants will receive initial IV weekly doses for 4 weeks which will be followed by Q2W (every 2 weeks) IV administrations starting on Week 5.
16335125|NCT04434092|Experimental|Arm C (Crovalimab) (Exploratory)|Paediatric participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
16335126|NCT04434079||Included individuals|Adult patients consecutively admitted to the ICU from June to October 2018 are eligible if expected length of stay is superior to 24 hours and no oral nutritional has been offered.
16335127|NCT04434066|Experimental|Abdominal Morcellation|Abdominal morcellation will occur following completion of the hysterectomy. Route of incision will be either suprapubic or umbilical incision - based on surgeon preferences. All steps and instruments have been standardized for abdominal morcellation.
16335128|NCT04434066|Experimental|Vaginal Morcellation|Vaginal morcellation will occur following completion of the hysterectomy. All steps and instruments have been standardized for vaginal morcellation.
16335129|NCT04434053|Experimental|MIETHKE M.blue®|
16335130|NCT04434053|Active Comparator|MIETHKE proGAV 2.0® (with SA 2.0®)|
16335132|NCT04434014||males from 20 to above 65 y|will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
16335133|NCT04434014||female from 20 to above 65 y|will be sub divided into 4 groups according to age will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
16335134|NCT04434001|Experimental|ZEPLAST|"In case of bleeding and:
~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;
~MCF FIBTEM < 8 mm : give Fibrinogen Concentrate 30 mg/kg;
~CT EXTEM > 100 s : give Prothrombin Complex Concentrate 20 mg/kg."
16335135|NCT04434001|Active Comparator|Control|"In case of bleeding and:
~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;
~fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg."
16335136|NCT04433988|Placebo Comparator|Control group|100 patients will receive standard treatment plus placebo
16335137|NCT04433988|Experimental|Pentoxifylline group|100 patients will receive standard treatment plus pentoxifylline 1200 mg/day
16335138|NCT04433975|Experimental|Psychosocial Pain Management (PPMI)|Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
16335139|NCT04433975|Active Comparator|Enhanced Usual Care (EUC)|Two individual telephone educational sessions with research study therapist.
16335140|NCT04433962|Active Comparator|conventional rehabilitation group|the conventional rehabilitation group completed hip joint range of motion and muscle strengthening exercises
16335141|NCT04433962|Experimental|conventional rehabilitation + balance training group|The conventional rehabilitation + balance training group completed hip joint range of motion and muscle strengthening exercises and 12 balance exercises.
16335142|NCT04433949|Active Comparator|Arm I (physician choice)|Patients get best supportive care + physician choice of treatment
16335143|NCT04433949|Experimental|Arm II (LDRT)|Patients receive best supportive care + low dose RT (whole lung)
16335144|NCT04433936||Thyroid Gland Dysfunction|Patients with a recent diagnosis of TGD (the study group) were recruited from endocrinology outpatient clinic of Specialized Medical Hospital, Mansoura University. Diagnosis of TGD was based on précised history, clinical examination and laboratory investigations. In order to avoid bias, patients with history of intake of any thyroid-related medications (antithyroid medications or thyroxine replacement), radioactive iodine or thyroidectomy were excluded from the study.
16335145|NCT04433936||Control|fifty age and gender matched healthy subjects without known personal or family history of thyroid disease or any autoimmune diseases were recruited from candidates of refractive surgery referred to the outpatient clinic of Mansoura Ophthalmology Center for pentacam assessment and who were proved to have normal corneal pentacam parameters. They were further examined by the endocrinologist to exclude thyroid dysfunction; this was supported by normal thyroid function profile (serum TSH and free T4) and negative anti-TPO and antithyroglobulin antibodies.
16335146|NCT04433923|Active Comparator|GROUP1|Phototherapy with aluminum foil
16335147|NCT04433923|Placebo Comparator|GROUP2|Phototherapy without aluminum foil
16335148|NCT04433910|Experimental|Convalescent plasma|Convalescent plasma transfusion on day 1, 3 and 5.
16335149|NCT04433910|No Intervention|Best supportive care|Best supportive care, cross over for patients with progressive disease on day 14 with convalescent plasma transfusion on day 15, 17 and 19.
16335152|NCT04433897||Oral estrogen + oral progesterone|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone.
16335153|NCT04433897||Transdermal estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD.
16335154|NCT04433897||Transdermal estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy.
16335155|NCT04433897||Transdermal estrogen + oral progesteron|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron
16335156|NCT04433897||SERM|Women who opt to be treated for their postmenopausal symptoms using SERM's
16335157|NCT04433897||Aromatase inhibitor|Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor.
16335158|NCT04433897||Duavive|Women who opt to be treated for their postmenopausal symptoms using duavive.
16335159|NCT04433897||No treatment|Women who opt not to be treated for their postmenopausal symptoms.
16335160|NCT04433884|Experimental|Conventional MAC Laryngoscope|Patients in this group will undergo intubation using conventional macintosh laryngoscope
16335161|NCT04433884|Experimental|C-MAC Video laryngoscope|Patients in this group will undergo intubation using video C-Mac laryngoscope
16335163|NCT04433845|Experimental|Psilocybin|25mg of Psilocybin
16335164|NCT04433819||Cushing syndrome|Male and female patients diagnosed as Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
16335165|NCT04433819||Controls|Healthy controls matched for age, gender, and body mass index
16335166|NCT04433806|Experimental|Intervention|25 subjects, all referred to community based program for weight loss at ExercisAbilities
16335167|NCT04433793|Experimental|Yoga group|Patients in the yoga group will receive yoga therapy, one hour every week for eight weeks.
16335168|NCT04433793|No Intervention|Waitlist-control group|Patients in the waitlist-control group will receive no intervention at first, but nine weeks after IG, they will get the opportunity to also receive yoga therapy for 8 weeks.
16335169|NCT04433780|Experimental|Delstrigo|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
16335170|NCT04433767|Experimental|Transdermal Nicotine Patch|Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.
16335171|NCT04433754||patients with pancreatic injury|patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
16335172|NCT04433754||patients without pancreatic injury|patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
16335173|NCT04433741|Other|Oxytocin First, then Placebo|Oxytocin administered intravenously for the first half of the study and then will receive intravenous placebo for the second half.
16335174|NCT04433741|Other|Placebo, Then Oxytocin|Placebo administered intravenously for the first half of the study and then will receive intravenous oxytocin for the second half.
16335175|NCT04433728||Adults Phenylketonuric|Adults patients screened in neonatal period for PKU and treated
16335176|NCT04433715||patients with UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
16335177|NCT04433715||patients without UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
16335178|NCT04433702|Experimental|Experimental Eye|10 mmHg of negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that only one goggle receives negative pressure.
16335179|NCT04433702|Placebo Comparator|Control Eye|The opposing eye serves as the intrasubject control for each participant. No negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that the other goggle does not receive negative pressure.
16335180|NCT04433689||Pregnant women|Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.
16335181|NCT04433676||Patients with surgical procedures|Adult patients undergoing surgical procedures under general or regional anesthesia and with an admission to a recovery unit for the initial postoperative care.
16335182|NCT04433663|Experimental|Mentalization-based Intervention|Participants in the intervention group, received mentalization-based psychotherapy with the developed ECOSA axis. Therapist received mentalization-based supervision.
16335183|NCT04433663|Active Comparator|IPT-Inter Personal Therapy|The control group's participants received IPT - interpersonal psychotherapy that focused on resolving interpersonal problems and symptomatic recovery. The control group's therapist received regular supervision - with no emphasis on mentalization or tool's usage.
16335184|NCT04433650|Experimental|Group 1|"The child will firstly undergo phase A without the digital reporting and communication tool.
~The child will secondly undergo phase B with the digital reporting and communication tool (i.e., A, B)."
16335185|NCT04433650|Experimental|Group 2|"The child will firstly undergo phase B with the digital reporting and communication tool.
~The child will secondly undergo phase A without the digital reporting and communication tool (i.e., B, A)."
16335186|NCT04433637|Experimental|Nutrition Group|Pregnant women in the first experimental group were provided to consume cake and fruit juice 30 minutes before the NST procedure.
16335187|NCT04433637|Experimental|Video Group|The video, which contains information about the developments and changes occurring in the mother and the fetus during pregnancy, was watched for 15-20 minutes during the NST procedure, accompanied by music that provided relaxation.
16335188|NCT04433637|No Intervention|Control Group|No intervention was applied to the pregnant women in the control group.
16335189|NCT04433624|Active Comparator|Group (B)|will receive The bilateral ESP blocks before surgery
16335190|NCT04433624|Active Comparator|Group B MG|will receive bilateral ESP blocks performed by each side) before surgery
16335191|NCT04433611|Experimental|'lidocaine flushing' group|intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy
16335192|NCT04433611|Placebo Comparator|Placebo group|intrauterine infusion of 0.9 % normal saline (placebo group) just prior to HyFoSy.
16335266|NCT04433078|Placebo Comparator|Placebo|Participants receive Placebo BID for 21 days
16335193|NCT04433598|Experimental|Nutrition Education Intervention|the participants the intervention group under went to Nutrition Education Intervention program were received the developed educational materials (pamphlets).
16335194|NCT04433598|No Intervention|Treatment as usual|the participants in the control group were received the usual medical care at their respective Center.The developed educational materials (pamphlets) were distributed at the end of the study.
16335199|NCT04433572|Active Comparator|Temsirolimus|Temsirolimus delivered to adventitia and perivascular tissue after primary revascularization
16335200|NCT04433572|Placebo Comparator|Placebo|Saline placebo delivered to adventitia and perivascular tissue after primary revascularization
16335201|NCT04433559|Active Comparator|Group Active Tadalafile|One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
16335202|NCT04433559|Placebo Comparator|Group Placebo|One oral tablet of placebo daily for 14 weeks of treatment.
16335203|NCT04433546|Experimental|High Dose (100 mg) Group|High: Pemziviptadil (PB1046) 100 mg subcutaneous (SC) weekly for 4 weeks or until hospital discharge
16335204|NCT04433546|Experimental|Middle Dose (40 mg) Group|Middle: Pemziviptadil (PB1046) 40 mg SC weekly for 4 weeks or until hospital discharge
16335205|NCT04433546|Placebo Comparator|Low Dose (10 mg) Control Group|Low Control: Pemziviptadil (PB1046) 10 mg SC weekly for 4 weeks or until hospital discharge
16335206|NCT04433533|Active Comparator|Rosuvastatin 20mg (Group 1)|
16335207|NCT04433533|Experimental|Rosuvamibe 10/10mg (Group 2)|
16335208|NCT04433507|Active Comparator|Sleeve Gastrectomy group|This group will receive a Sleeve Gastrectomy only, a mainly restrictive procedure which consists in creating a narrow tube-like stomach based on its lesser curvature.
16335209|NCT04433507|Experimental|Sleeve Gastrectomy + Hiatal Hernia repair group|This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.
16335210|NCT04433494|Experimental|TY-302 ; TY-302 combine with Tamoxifen|"TY-302
~Find the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D) of TY-302, given orally.
~Increased dose cohorts from low dose to MTD, starting at 25mg daily.
~TY-302 combine withTamoxifen in dose-escalation stage
~TY-302: RP2D-1to RP2D daily for 28 days of each 28 day cycle.
~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle.
~TY-302 combine withTamoxifen in dose-expansion stage
~TY-302: RP2D daily for 28 days of each 28 day cycle.
~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle."
16335211|NCT04433481|Experimental|DABIGATRAN|150mg BD for 12 months
16335212|NCT04433481|Placebo Comparator|Placebo|Placebo
16335213|NCT04433468|Active Comparator|RIPC|
16335214|NCT04433468|No Intervention|Control|
16335215|NCT04433442||Participants with Moderate to Severe Plaque Psoriasis|Participants will receive risankizumab (prefilled syringe for injection) as prescribed by the physician in routine clinical practice.
16335216|NCT04433429||RYR plus CoQ|333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
16335217|NCT04433416||hypertension|After admission, two or more of the three blood pressure measurements under the same period of calm state that met hypertension, and the patient reported that he had a history of hypertension and that the blood pressure reached the standard of hypertension in the previous non-medication state was included in the hypertension group
16335218|NCT04433416||non-hypertension|Patients who denied the history of hypertension and were not taking antihypertensive drugs after admission and had normal blood pressure measurements were included in the non-hypertensive group
16335219|NCT04433390|Experimental|Naloxegol group|naloxégol tablet by oral route
16335220|NCT04433390|Placebo Comparator|Placebo group|inert tablet by oral route
16335221|NCT04433377|Experimental|Suprascapular nerve block group|"Suprascapular nerve block will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the suprascapular fossa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 22 gauge 90-mm injector.
~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
16335222|NCT04433377|Experimental|Subacromial injection group|"Subacromial injection will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the subacromial bursa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 21 gauge 38-mm injector.
~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
16335223|NCT04433364||Screening group|"a general population of women giving birth, called screening group included at routine antenatal visits, their partners, and children"
16335224|NCT04433364||COVID-19 group|"group of women testing positive for SARS-CoV-2 or falling ill with COVID-19, called COVID-19 group, their partners, and children"
16335225|NCT04433351|Experimental|SE cohort|Patients in the SE cohort will carry out first the simple rehabilitation protocol (S, 4 weeks) followed by enriched rehabilitation (E, 4 weeks).
16335226|NCT04433351|Experimental|ES cohort|Patients in the ES cohort will carry out first the enriched rehabilitation protocol (E, 4 weeks) followed by simple rehabilitation (S, 4 weeks).
16335227|NCT04433338|Experimental|Intervention group|"Participants in the intervention group will follow a low-calorie diet during 14 days before undergoing surgery. The diet will consist of both meal replacements and regular foods.
~For women, the diet provides ± 900 kcal, 50 grams of carbohydrates, 85 grams of protein, 30 grams of fat and 25 grams of fibres.
~For men, the diet provides ± 1000 kcal, 55 grams of carbohydrates, 100 grams of protein, 30 grams of fat and 30 grams of fibres."
16335264|NCT04433091|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for seven days prior to ablation and 28 days post-ablation
16335228|NCT04433338|No Intervention|Control group|Participants in the control group can eat according to the standard nutritional advices provided by their dietitian. These advices are intended to educate participants on the recommended eating pattern after surgery.
16335229|NCT04433325||Patients transferred|Patients transferred from Paris's Intensive Care Units
16335230|NCT04433325||Patients not transferred|Patients admitted in Intensive Care Units with no transfer from Paris
16335231|NCT04433299||low back pain patients|no intervention
16335232|NCT04433299||controls|no intervention
16335233|NCT04433273|No Intervention|Group A: Healthy control group|Neither placebo nor vestibular stimulation is administered
16335234|NCT04433273|Placebo Comparator|Group B: Placebo control group|Placebo stimulation along with regular treatment
16335235|NCT04433273|Active Comparator|Group C: Intervention group|Electrical vestibular nerve stimulation along with regular treatment
16335236|NCT04433260||Cases|Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19
16335237|NCT04433260||Internal Control|Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19.
16335238|NCT04433260||Population Control|Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected.
16335239|NCT04433260||Follow-up cases|Doctors, nurses and other healthcare workers ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 consenting to receive follow-up surveys (n ~ 400)
16335240|NCT04433260||Follow-up controls|Healthcare Administrative staff who are working in the hospital, not at risk of work-related exposure to patients potentially infected with COVID-19 (n~80)
16335241|NCT04433247|Experimental|Peer Led Group Intervention|In the virtual peer-led group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
16335242|NCT04433247|No Intervention|Wait-List Control|Participants will be placed on a wait list for four weeks, an equal span of time of participants in the peer led group intervention. At four weeks, participants will complete their post-test assessment, then receive the intervention.
16335243|NCT04433234|Experimental|DS-5141b 2.0 mg/kg|Participants who will receive DS-5141b 2.0 mg/kg once weekly.
16335244|NCT04433234|Experimental|DS-5141b 6.0 mg/kg|Participants who will receive DS-5141b 6.0 mg/kg once weekly.
16335245|NCT04433221|Experimental|Multiple sarcoma-specific CAR-T cells|Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers
16335246|NCT04433208|Experimental|Cohort 1 (PPI + probiotic)|Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
16335247|NCT04433208|Experimental|Cohort 2 (Complex oligosaccharide + PPI)|Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
16335248|NCT04433208|Experimental|Cohort 3-6 (Complex oligosaccharide + PPI +probiotic)|Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43
16335249|NCT04433195|Active Comparator|Immediate NAA by clinician|Nucleic acid amplification test requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB
16335250|NCT04433195|Experimental|Immediate NAA as intervention|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, but Xpert MTB/RIF is performed as intervention in this study (intervention group)
16335251|NCT04433195|No Intervention|No immediate NAA|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, and Xpert MTB/RIF is not performed as the initial diagnostic test in this study (control group). Nucleic acid amplification test may be ordered at a later point in time by clinicians as an add-on test after sputum smear microscopy
16335252|NCT04433182|Experimental|Single arm Copa-RB|Induction phase with Copanlisib, Rituximab and Bendamustina. Maintenance phase (for patients who reach at least SD after induction) with Copanlisib in monotherapy.
16335253|NCT04433169|Experimental|Experimental group|ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.
16335254|NCT04433169|Active Comparator|Control group|The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).
16335255|NCT04433156|Experimental|VR-CAP|Rituximab, 375 mg/m2, Intravenous administration on day 0, Bortezomib, 1.3 mg/m2 hypodermic injection on day 1 and 4, combined with regimen: Cyclophosphamide, Epirubicin, and Prednisone: repeated every 3 weeks, up to 6 cycles.
16335256|NCT04433143|Experimental|oral medication|just oral minocycline hydrochloride capsules (100mg/ time, once per day),
16335257|NCT04433143|Experimental|Intense Pulsed Light single filter|Intense pulsed Acne filter
16335258|NCT04433143|Experimental|Intense Pulsed Light two filters|Intense pulsed light Acne filter and another filter (560nm, 590nm or 640nm filter)
16335259|NCT04433117|Other|Control Group|Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
16335260|NCT04433117|Experimental|Test Group|The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
16335261|NCT04433104|Experimental|Treatment (UC-MSC trasnplatation)|1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure
16335262|NCT04433104|Other|control arm|drug therapy according to Vietnamese MOHS procedure
16335263|NCT04433091|Active Comparator|2-HOBA|2-Hydroxybenzylamine(2-HOBA) 250 mg three tabs TID (po) for seven days prior to ablation and 28 days post ablation.
16335268|NCT04433052|Experimental|Personalised prevention program (PPP)|Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.
16335269|NCT04433052|No Intervention|Usual care (UC)|"Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses.
~Randomized UC patients are invited to site visits twice over a three year period."
16335270|NCT04433013|Experimental|Treatment group|
16335271|NCT04433013|Placebo Comparator|Control group|
16335272|NCT04432987|Experimental|Newly Diagnosed Patient Group (n=30)|"I. Dornase Alpha treated group (n=15)
~ii. Control group (n=15)"
16335273|NCT04432987|Experimental|Patient Group Monitored by Mechanical Ventilation (n=30)|"I. Dornase Alpha treated group (n=15)
~ii. Control group (n=15)"
16335274|NCT04432974|Experimental|ACTIVA|ACTIVA closed-loop anesthesia control system
16335275|NCT04432948||Maternal Group|Pregnant women administered into a maternity public hospital in labour (vaginal delivery, caesarean section)
16335276|NCT04432935|Experimental|Bovine Lactoferrin|Intervention group will receive bovine lactoferrin supplementation daily once a day from day 0 of birth to 6 weeks of life.
16335277|NCT04432935|Placebo Comparator|Glucon D|Control group will receive Glucon-D supplementation daily once a day from day 0 of birth to 6 weeks of life.
16335278|NCT04432909||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UroCAD analysis, the result will be compared with cytology and FISH test.
16335279|NCT04432909||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD analysis.
16335280|NCT04432896|Experimental|New dietary protocol|Exclusion of food containing nickel (duration: 4 weeks) + gradual weekly reintroduction of food containing nickel (duration: 4 weeks) under the supervision of a trained dietician who monitors symptoms related to systemic nickel allergy syndrome.
16335281|NCT04432896|Active Comparator|Traditional dietary protocol|Exclusion of foods containing nickel without monitoring for symptoms related to systemic nickel allergy syndrome by a trained dietician.
16335282|NCT04432883|Active Comparator|Experimental: Active cathodal tDCS + Speech-language training|In this arm, 25 patients with stroke induced Aphasia will undergo 15 sessions of active tDCS (x 30 minutes of stimulation) combined with 1 hour simultaneous speech-language training on consecutive weekdays.
16335283|NCT04432883|Sham Comparator|Comparator: Placebo cathodal tDCS + Speech-language training|In this arm, 25 patients with stroke induced Aphasia will undergo 15 sessions of sham tDCS (x 30 minutes sham) combined with 1 hour simultaneous speech-language training on consecutive weekdays..
16335284|NCT04432870||MGH Patients|Patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic at Massachusetts General Hospital
16335285|NCT04432857|Experimental|Ph1a: Urothelial carcinoma of the bladder and NSCLC|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
16335286|NCT04432857|Experimental|Phase 1b: Urothelial carcinoma of the bladder|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
16335287|NCT04432857|Experimental|Phase 1b: Non-Small Cell Lung Cancer (NSCLC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
16335288|NCT04432857|Experimental|Phase 1b: Triple-negative breast cancer (TNBC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
16335289|NCT04432857|Experimental|Phase 1b: Cervical|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
16335290|NCT04432857|Experimental|Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
16335291|NCT04432831|Experimental|Faricimab PTI|
16335292|NCT04432818|Experimental|Pack Health's digital life coaching (DLC)|Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
16335293|NCT04432805|Experimental|Pregnant women|Pregnant women suspected of COVID-19
16335294|NCT04432792||Clinical Records Review|We will receive clinical chart data from the telehealth providers on 3,000 patients (which could include the survey study participants, but we will not know their identities) which will include date of birth, zip code, and dates of service - but will otherwise be de-identified.
16335295|NCT04432792||Study Survey Participants|We aim to enroll at least 3,000 participants to complete the study surveys.
16335296|NCT04432779||Women tested positive to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.
~Follow up end at 1 month post delivery."
16335297|NCT04432779||Women tested negative to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.
~No follow up after delivery."
16335298|NCT04432779||Newborns from women tested positive|"Newborns born to mothers who had a positive nasal swab or a positive serology during pregnancy or at delivery and who consented the follow up study.
~Follow up end at 3 years of age."
16335299|NCT04432779||Newborns from women tested negative|"Newborns born to mothers who had no COVID-19 infection during pregnancy or at delivery and who consented the follow up study. These control children will be matched with children from the other group for gestational age and ethnicity.
~Follow up end at 3 years of age."
16335300|NCT04432766|Experimental|Low dose|
16335301|NCT04432766|Experimental|Medium dose|
16335302|NCT04432766|Experimental|High dose|
16335303|NCT04432753|Experimental|Decision aid with incidental findings information|Participants in this arm will view a video decision aid that include information on incidental findings in lung cancer screening.
16335304|NCT04432753|Active Comparator|Decision aid without incidental findings information|Participants in this arm will view a video decision aid that does not include information on incidental findings in lung cancer screening.
16335305|NCT04432740|Active Comparator|Below Arm Cast Group|All the patients were prepared in the supine position at the emergency department. For analgesia, we used the hematoma block technique with 3 cc of 2% prilocaine hydrochloride®. In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, the standard below arm cast was applied. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
16335306|NCT04432740|Active Comparator|Reverse Sugar Tong Group|In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, sugar tong splint made of 12 layers of plaster was performed by one person. The reverse sugar tong splint succeeds as a classic sugar tong splint by stabilizing the volar and dorsal aspects of the wrist and forearm, maintaining the same degree of immobilization. The splint fold is located distally at the first web space of the hand, which does not immobilize the elbow. In all the groups, the wrist immobilization position was the same; pronated forearm, 15-20° wrist flexion, ulnar deviation, and care was taken not to immobilize the metacarpophalangeal joints. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
16335307|NCT04432727|Experimental|ACTIVE FT-CC|Text message reminders will be sent if subject does not use the device for 2 consecutive days.
16335308|NCT04432727|Experimental|PASSIVE FT-CC|Text message reminders will not be sent to subjects.
16335309|NCT04432714|Experimental|R2-DA-EPOCH|
16335310|NCT04432701|Active Comparator|group A|children were extubated in a light plane of anesthesia, when they are still asleep or have swallowing reflex.
16335311|NCT04432701|No Intervention|group B|Tracheal extubation was performed when the patient regained consciousness, facial grimace, spontaneous eye opening, and purposeful arm movement.
16335312|NCT04432688||Latuda®|Chinese schizophrenia patients who are receiving Latuda® in the real world
16335313|NCT04432675|Experimental|hydroxyethl starch group|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
16335314|NCT04432675|Active Comparator|The control group|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
16335315|NCT04432662|Active Comparator|Erythropoietin|Administration of Erythropoietin (1000 U/kg) IV once a day x 5 doses along with cooling therapy
16335316|NCT04432662|Active Comparator|Darbepoetin Alpha|Administration of Darbepoetin Alpha (10 mcg/kg) IV single dose given less than 24 hours of age along with cooling therapy
16335317|NCT04432662|No Intervention|Standard of care|Standard of care: Cooling only
16335318|NCT04432649|Experimental|Effectiveness of 4SCAR-276 T cells|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
16335319|NCT04432636|Other|Prospective French population based cohort|"Data collection of environmental factors at the recruitment
~Collection of maternal feces
~Collection of infant feces:
~A food questionnaire completed by the mother the week after delivery, a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year and a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
~A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day
~The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up"
16335320|NCT04432623|Experimental|Low dose|A low dose, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
16335321|NCT04432623|Experimental|Middle dose|A middle dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
16335322|NCT04432623|Experimental|High dose|Highest dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
16335323|NCT04432623|Experimental|Expansion group|The highest and well-tolerated dose, once per day on Monday, Wednesday, and Friday, for 12 weeks
16335324|NCT04432610|Experimental|Bisoprolol first, Nebivolol Second|In this arm, patient will first receive bisoprolol, and after 1 week washout period, nebivolol
16335325|NCT04432610|Experimental|Nebivolol first, Bisoprolol second|In this arm, patient will first receive nebivolol, and after 1 week washout period, bisoprolol
16335326|NCT04432597|Experimental|1/Arm 1A|HPV vaccine at 1x10(11) Viral Particles (VP) (DL1) and at 5x10(11) VP (DL2)
16335327|NCT04432597|Experimental|2/Arm 1B|HPV vaccine at RP2D plus M7824 at 1200 mg
16335328|NCT04432597|Experimental|3/Arm 2A|HPV vaccine at RP2D given as neoadjuvant or induction therapy
16335329|NCT04432597|Experimental|4/Arm 2B|HPV vaccine at RP2D plus M7824 at 1200 mg given as neoadjuvant or induction therapy
16335330|NCT04432584|Experimental|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
16335331|NCT04432584|Active Comparator|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
16335332|NCT04432584|Experimental|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
16335333|NCT04432571|Active Comparator|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC)
16335334|NCT04432571|Experimental|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT)
16335335|NCT04432571|Experimental|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV)
16335336|NCT04432571|Experimental|E-NAV/SOC-OIC|Electronic Navigation/SOC-OIC
16335337|NCT04432571|Experimental|E-NAV/CCT|E-Nav/Conditional cash transfer
16335338|NCT04432571|Experimental|E-NAV/IP-NAV|E-Nav/In-Person Peer Navigation
16335339|NCT04432558||Preoperative anxiety level|
16335340|NCT04432558||Postoperative pain and analgesic consumption|
16335341|NCT04432532||Neuroendocrine Tumor|
16335342|NCT04432532||Adrenal Tumor|
16335343|NCT04432519|Experimental|Group CA|Customized healing abutment inserted in immediate implant placement.
16335344|NCT04432519|Active Comparator|Group CM|Resorbable Collagen Membrane for socket closure in immediate implant placement.
16335345|NCT04432506|Experimental|Treatment (cyclophosphamide, fludarabine, axi-cel, anakinra)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
16335346|NCT04432493|Experimental|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
16335347|NCT04432493|Placebo Comparator|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
16335348|NCT04432480||Children|0-15 years old children undergoing surgery under general anesthesia
16335349|NCT04432467|Experimental|mesenchymal stem cells|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells
16335350|NCT04432467|Active Comparator|control|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment
16335351|NCT04432454|Experimental|Treatment|Women who have locally advanced or metastatic ER+/HER2- breast cancer and disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation
16335352|NCT04432441|Active Comparator|Scapular flexion exercise|
16335353|NCT04432441|Active Comparator|Scapular flexion exercise + Electrostimulation|
16335354|NCT04432428|Experimental|sufentanil sublingual tablet|sufentanil sublingual 15µg tablets
16335355|NCT04432415|Experimental|Group Silver Diamine Fluoride|Participants receive Annual applications of 38% SDF solution and semestral applications of artificial saliva and a personalized dental health education program.
16335356|NCT04432415|Experimental|Group Sodium Fluoride Varnish|Participants receive semestral applications of Sodium Varnish Fluoride and a personalized dental health education program.
16335357|NCT04432415|Placebo Comparator|Placebo|Participants receive semestral apllications of artificial saliva and a personalized dental health education program.
16335358|NCT04432402|Experimental|Lenalidomide in Combination With R-GemOx|Lenalidomide 10mg、15mg、20mg、25mg qd PO d1-7 Rituximab 375mg/m2 ivd d0 Gemcitabine 1g/m2 ivd d1 Oxaliplatin 100mg/m2 ivd d1 every14 days as a cycle
16335359|NCT04432389|Experimental|ALLOB|Single injection of ALLOB at fracture site (4 ml)
16335360|NCT04432389|Placebo Comparator|placebo|Single injection of Placebo at fracture site (4 ml)
16335361|NCT04432376|Active Comparator|Active treatment arm|Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
16335362|NCT04432376|Placebo Comparator|Placebo treatment arm|Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days
16335363|NCT04432376|Other|Open-label treatment arm|Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
16335364|NCT04432363|Active Comparator|M1 stimulation|A 20 minutes 1mA direct current stimulation over left M1.
16335365|NCT04432363|Active Comparator|M1+DLPFC stimulation|A 20 minutes 1mA direct current stimulation over left M1 and 1mA direct current stimulation over left DLPFC.
16335366|NCT04432363|Sham Comparator|Sham stimulation|A 20 minutes sham stimulation where the device only is working first 30s and last 30s of the intervention and have a 10 seconds fade out in intensity at each ramp.
16335367|NCT04432350||Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
16335368|NCT04432350||Not Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were not treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
16335369|NCT04432337|Experimental|Type 2 diabetes patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for TD2 patients after cardiac surgery with extracorporeal circulation .
16335370|NCT04432337|Active Comparator|Non-diabetic type 2 patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for non-diabetic type 2 patients after cardiac surgery with extracorporeal circulation
16335371|NCT04432324|Experimental|Intravenous Immune Globulin + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
16335372|NCT04432324|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29
16335373|NCT04432311|Experimental|Binge Focused Therapy (BFT)|Guided self-help - Three online group sessions, homework, and self-guided check-ins to monitor continued progress and/or signs of relapse.
16335374|NCT04432311|Active Comparator|CBT Unguided Self Help (CBT USH)|Pure self-help - The use of the book Overcoming Binge Eating and its associated homework.
16335375|NCT04432298|Experimental|Pamrevlumab|Pamrevlumab: 35 milligrams/kilogram (mg/kg) on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
16335376|NCT04432298|Experimental|Placebo|Pamrevlumab-matching placebo on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
16335377|NCT04432285||Deep Brain Stimulation (GPi-DBS)|Patients with cervical dystonia (CD) who were operated at Oslo University Hospital between June 2004 and December 2017 with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years.
16335378|NCT04432285||Botulinum toxin treatment|CD patients who for a minimum of 3 years have received treatment with botulinum neurotoxin (BoNT) injections at regular intervals (minimum 12 injection cycles) and still are receiving them (Age- and gender matched to the GPi-DBS group)
16335379|NCT04432272|Experimental|Group A|Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain oxygen saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
16335380|NCT04432272|Experimental|Group B|Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
16335381|NCT04432259|Experimental|Arm B: Oral Dexamethasone|Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
16335382|NCT04432259|Placebo Comparator|Arm A: Placebo|Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
16335383|NCT04432246|Experimental|bilateral SMA|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
16335384|NCT04432233|Experimental|Intravenous therapy|Subjected enrolled will receive (a) a 10-day intravenous triple therapy containing esomeprazole 40 mg thrice a day, metronidazole 500 mg twice a day and levofloxacin 500 mg once a day and (b) esomeprazole 20 mg twice a day taken orally for 8 weeks.
16335385|NCT04432220|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
16335386|NCT04432220|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
16335387|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
16335388|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
16335389|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
16335390|NCT04432194|No Intervention|Control group|The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
16335391|NCT04432194|Active Comparator|Pulmonary Rehabilitation Group|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
16335392|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus HMB (4g)|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
16335393|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus citrulline (3g)|Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
16335394|NCT04432181||Group 1, astigmatic patients with amblyopia|astigmatic children with amblyopia
16335395|NCT04432181||Group 2, astigmatic patients without amblyopia|astigmatic children without amblyopia
16335396|NCT04432168|Experimental|Fetoscopic Laser Surgery|fetoscopic laser coagulation of the vascular anastomoses at the placental surface
16335397|NCT04432168|Other|Standard Treatment|Expectant management, IUT (with or without PET), preterm delivery
16335398|NCT04432155|Experimental|NBTX-001|Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
16335399|NCT04432155|Placebo Comparator|Placebo|Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.
16335400|NCT04432142||Proton|Patients receiving proton therapy
16335401|NCT04432142||Photon|Patients receiving photon therapy in 4 fractions or less
16335402|NCT04432129|Experimental|IBBIS II|Integrated Mental Health Care and Vocational Rehabilitation
16335403|NCT04432129|Active Comparator|Service As Usual|Standard vocational rehabilitation and treatment
16335404|NCT04432116|Experimental|virtual reality 1|the subject is in a virtual room and is asked to emit a retrospective time duration judgement at the end of the session
16335405|NCT04432116|Experimental|virtual reality 2|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible while the background of the virtual environment is a starfield with standard speed vs. self-determined speed vs. static stars
16335406|NCT04432116|Experimental|virtual reality 3|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible.Asynchronous distracters vs. synchronous distracters, vs no distracters are displayed while the subjects wait for the target
16335407|NCT04432103|Experimental|Severe COVID-19 pneumonia|Hospitalized patients with SARS-CoV 2 severe infection will receive an anti SARS-CoV 2 Convalescent Plasma
16335408|NCT04432103|Experimental|Critical COVID- 19 pneumonia|Hospitalized patients with SARS-CoV 2 critical infection will receive an anti SARS-CoV 2 Convalescent Plasma
16335409|NCT04432090|Experimental|MBX-2982 first then placebo- Volunteers with Type 1 diabetes|This will be followed by a second study period in which they will be crossed over to the other treatment.
16335410|NCT04432090|Active Comparator|Healthy Volunteers|this group will not receive any medication. It will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
16335411|NCT04432090|Experimental|Placebo first then MBX-2982- Volunteers with Type 1 diabetes|
16335412|NCT04432077|Experimental|Treatment|All participants receive the DINOSAUR intervention
16335413|NCT04432064|Experimental|Phase 3 Active TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation. Participants will receive stimulation for 60 minutes on one day.
16335414|NCT04432064|Sham Comparator|Phase 3 Sham TI-NDBS|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds.
16335415|NCT04432064|Active Comparator|Phase 4 Traditional tDCS|Participants assigned to this condition will receive traditional transcranial direct current stimulation for 60 minutes for 5 days.
16335416|NCT04432064|Experimental|Phase 4 TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation for 60 minutes for 5 days and will be compared to sham stimulation and tDCS.
16335417|NCT04432064|Sham Comparator|Phase 4 Sham stimulation|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds. Participants will be in the scanner for 60 minutes for 5 days. This will be used as the control condition and compared with TI-NDBS and tDCS.
16335418|NCT04432051|Placebo Comparator|GRUP Control|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis.
16335419|NCT04432051|Active Comparator|GRUP Ultrasonography|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis. However, the lung of the patient will be evaluated by ultrasound and the position to use the lung capacity most appropriately will be given.
16335420|NCT04432038||General population of adults from about 30 countries|Data will be collected in general population of adults from about 30 countries. Questionnaires contain also questions about the occurrence of chronic illnesses, being a professional athlete, etc. to control all such aspects.
16335421|NCT04432038||General population of adults from Poland|
16335422|NCT04432038||General population of adults from Germany|
16335423|NCT04432038||General population of adults from China|
16335424|NCT04432038||General population of adults from Vietnam|
16335425|NCT04432038||General population of adults from Spain|
16335426|NCT04432038||General population of adults from Brazil|
16335427|NCT04432038||General population of adults from Croatia|
16335428|NCT04432038||General population of adults from Ethiopia|
16335429|NCT04432038||General population of adults from France|
16335430|NCT04432038||General population of adults from Indonesia|
16335431|NCT04432038||General population of adults from Iran|
16335432|NCT04432038||General population of adults from Sri Lanka|
16335433|NCT04432038||General population of adults from USA|
16335434|NCT04432038||General population of adults from Italy|
16335435|NCT04432038||General population of adults from South Africa|
16335436|NCT04432038||General population of adults from Portugal|
16335437|NCT04432038||General population of adults from Norway|
16335438|NCT04432038||General population of adults from Lithuania|
16335439|NCT04432038||General population of adults from Romania|
16335440|NCT04432038||General population of adults from Pakistan|
16335441|NCT04432038||General population of adults from Ukraine|
16335442|NCT04432038||General population of adults from India|
16335443|NCT04432038||General population of adults from Japan|
16335444|NCT04432038||General population of adults from Russia|
16335445|NCT04432038||General population of adults from Bangladesh|
16335446|NCT04432038||General population of adults from Nigeria|
16335447|NCT04432038||General population of adults from Egypt|
16335448|NCT04432025|Active Comparator|Control|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
16335449|NCT04432025|Experimental|Intervention|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
16335450|NCT04432012|Experimental|arm-A Intra-venous dexamethasone|9 mg of Intra-venous dexamethasone
16335451|NCT04432012|Experimental|arm-B intra-articular dexamethasone|9 mg of intra-articular dexamethasone
16335452|NCT04432012|No Intervention|arm-C routine|No steroid supplementation or other drugs will be added to the routinely performed anaesthesia protocol in the control group
16335453|NCT04431999|Experimental|Whole blood group|Damage control resuscitation for trauma care using whole blood.
16335454|NCT04431999|Active Comparator|Fractionated blood products group|Damage control resuscitation for trauma care using component therapy.
16335455|NCT04431986||NuAge participants|All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes
16335456|NCT04431973|Experimental|Shoulder prothesis|Evaluate the performance of the Medacta Shoulder System total reverse shoulder prothesis
16335457|NCT04431960|Active Comparator|low-BC Group|consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
16335458|NCT04431960|Active Comparator|high-BC Group|consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
16335459|NCT04431960|Placebo Comparator|Control Group|consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
16335460|NCT04431947||Youth|Youth, between the ages of 2 and 17, with type 1 diabetes
16335461|NCT04431947||Parent|Parents of youth with type 1 diabetes
16335462|NCT04431934|No Intervention|CONTROL|No intervention arm
16335463|NCT04431934|Active Comparator|PROBIOTIC|
16335464|NCT04431934|Active Comparator|FMT REGIMEN|
16335465|NCT04431921||Lung cancer patients|Lung cancer survivors who had stable conditions and routine follow-up at Hacettepe University Oncology Hospital
16335466|NCT04431921||Healthy subjects|No health problems related or affect outcome measure parameters examined in this study.
16335467|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
16335468|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
16335469|NCT04431895|Experimental|tofacitinib 5mg twice a day|
16335470|NCT04431882|Experimental|optic nerve sheath fenestration|Leukemic patients mainly those suffering from acute lymphoblastic leukemia.
16335471|NCT04431869||Mothers that contract SARS-CoV-2 during pregnancy|"To evaluate evidence for in-utero vascular accidents that may manifest as intestinal atresias and limb abnormalities in the first 30 days of life as well as rates of preterm labor, fetal growth restriction and spontaneous abortions in pregnant females that contract the SARS-CoV-2 virus during gestation.
~A multidisciplinary approach in conjunction with maternal fetal medicine (MFM), neonatology, and pathology will identify, and recruit infants whom were exposed to COVID-19 while in-utereo. This project will run in parallel with the institution's COVID-19 in Pregnancy Biobank that intends to obtain needed epidemiological and clinical data linked to biosamples to provide insight into SARS-CoV-2 in pregnant women and their infants. This study will request access to enrolled women infected during gestation and their neonates to assess for the conditions suggestive of in-utero vascular accidents such as intestinal atresias or limb anomalies."
16335472|NCT04431869||Infants noted to have intestinal atresias or limb anomalies|"To evaluate children identified in the neonatal intensive care unit (NICU) as having evidence of intestinal atresias or limb anomalies for potential asymptomatic carriers of COVID-19 that could have contracted the disease during the pregnancy.
~Mothers of children identified will undergo SARS-CoV-2 antibody testing to identify the possibility of asymptomatic carriers which may have occurred during the pregnancy."
16335473|NCT04431856|Experimental|Immediate Condition|Participants in the Immediate Condition group will receive a total of 4 sessions of Unified Protocol for COVID-19 Parenting Stress (UP-COVID) intervention
16335474|NCT04431856|Active Comparator|Delayed Condition|Participants in the Delayed Condition group will receive the Self Help Guide (SHG) by the National Child Traumatic Stress Network (NCTSN). They will then receive the UP-COVID intervention following their week 6 assessment
16335475|NCT04431843|Experimental|Spirulina maxima extract|Spirulina maxima extract for 1.5 g/day
16335476|NCT04431843|Placebo Comparator|Placebo|Spirulina maxima extract for 0 g/day
16335477|NCT04431830|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery) for managing pain.
16335478|NCT04431830|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
16335479|NCT04431817||Left transtibial|Left below knee amputation- 25
16335480|NCT04431817||Right transtibial|Right below knee amputation- 25
16335481|NCT04431817||Left transfemoral|Left above knee amputation- 25
16335482|NCT04431817||Right transfemoral|Right above knee amputation- 25
16335483|NCT04431817||Provider|Provider- 15
16335484|NCT04431791||Regorafenib|
16335485|NCT04431791||Fruquintinib|
16335486|NCT04431778|Experimental|Ethosuximide|Patients with chronic peripheral neuropathic pain
16335487|NCT04431778|Placebo Comparator|Placebo|Patients with chronic peripheral neuropathic pain
16335488|NCT04431765|Active Comparator|Patient for Eye Movement desensitization Reprocessing therapy|Patient with post-traumatic Stress Disorder will receive Eye Movement Desensitization reprocessing therapy
16335489|NCT04431765|Placebo Comparator|patients for Trauma-Centred Cognitive and Behavioural Therapy|Patients with post-traumatic Stress Disorder will receive Trauma-Centred Cognitive and Behavioural Therapy
16335490|NCT04431752||Healthy Volunteer|10 healthy volunteers to undergo radiographic examinations of the knee joint.
16335491|NCT04431752||Kellgren-Laurence grading I Osteoarthritis Knee|10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
16335492|NCT04431752||Kellgren-Laurence grading II Osteoarthritis Knee|10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
16335493|NCT04431752||Kellgren-Laurence grading III Osteoarthritis Knee|10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
16335494|NCT04431752||Kellgren-Laurence grading IV Osteoarthritis Knee|10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
16335496|NCT04431713|Experimental|Exenatide|
16335497|NCT04431713|No Intervention|Standard of care|
16335498|NCT04431700|Experimental|Anti-inflammatory whole food|Included food items will include a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., curcumin), fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be permitted or encouraged. Recommended portions of complex carbohydrates (50% - 60%) and lean proteins (20% - 30%) will form the basis of weight-based caloric needs. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Vegetables with high insoluble fiber content will be cooked instead of eaten raw.
16335499|NCT04431700|Active Comparator|Regular Diet|Patients in the control diet arm will be counseled to continue their regular diets and focus on recording all food intake.
16335500|NCT04431687|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.
~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
16335501|NCT04431687|Experimental|Sequence 2|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).
~Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days"
16335502|NCT04431687|Experimental|Sequence 3|"Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).
~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
16335597|NCT04430959|Placebo Comparator|Placebo first then Candesartan|4 weeks of placebo with crossover to the other.
16335503|NCT04431687|Experimental|Sequence 4|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).
~Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets)."
16335504|NCT04431674|Experimental|MRg-FUS MB Treatment|Patients with locally advanced breast cancer (LABC) and chest wall tumours will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
16335505|NCT04431648|Experimental|MRg-FUS MB Treatment|Patients with head and neck cancer will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
16335507|NCT04431622|Experimental|Effects of hearing aid algorithms|Neural processing and cognitive effort will be assessed in individuals who listen to stimuli generated with linear and fast-acting compression hearing aid algorithms and with actual hearing aids.
16335508|NCT04431609||CAROtid WEB associated with cerebral infarction|french multicentric cohort that collects retrospectively and prospectively purely observational data on patients with cerebral infarction associated with a carotid web. Diagnostic, therapeutic or follow-up strategies will be at the discretion of the Stroke Unit taking care of the patient.
16335509|NCT04431596|Active Comparator|Cooling|Participants will be actively cooled during rest breaks.
16335510|NCT04431596|No Intervention|No Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
16335511|NCT04431583||2008-2012 Participants|Participants who underwent bariatric surgery between 2008 and 2012 (inclusive).
16335512|NCT04431583||2013-2016 Participants|Participants who underwent bariatric surgery between 2013 and 2016 (inclusive).
16335513|NCT04431583||2017- 2018 Participants|Participants who underwent bariatric surgery between 2017 and 2018 (inclusive).
16335514|NCT04431570|Experimental|rTMS over M1 region|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is M1 region.
16335515|NCT04431570|Experimental|rTMS over supplementary motor area (SMA)|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is SMA region.
16335516|NCT04431570|Sham Comparator|sham stimulation|
16335517|NCT04431531|Active Comparator|yogatherapy-EMDR|one of the two groups will have yogatherapy treatment and Eye movement desensibilization reprocessing (EMDR)
16335518|NCT04431531|Active Comparator|waiting list and EMDR|The other group will have Eye movement desensibilization reprocessing
16335519|NCT04431518|Experimental|Hemodialysis Group|Receipt of JULUCA one pill per day up to 14 days
16335520|NCT04431518|Active Comparator|Normal Renal Function Group|Receipt of JULUCA one pill per day up to 14 days
16335521|NCT04431492||coronary artery bypass|
16335522|NCT04431492||thoracic surgery|
16335523|NCT04431479||Observational (questionnaire, biospecimen, chart review)|Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.
16335524|NCT04431466|Active Comparator|Standard of care|Standard of care (SOC) treatment
16335525|NCT04431466|Experimental|SOC plus ivermectin 100 mcg/kg|SOC plus ivermectin 100 mcg/kg
16335526|NCT04431466|Experimental|SOC plus ivermectin 200 mcg/kg|SOC plus ivermectin 200 mcg/kg
16335527|NCT04431466|Experimental|SOC plus ivermectin 400 mcg/kg|SOC plus ivermectin 400 mcg/kg
16335529|NCT04431440||Methicillin resistant staphylococcus aureus|
16335530|NCT04431440||vancomycin resistent staphylococcus aureus|
16335531|NCT04431427|Active Comparator|Partially Covered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
16335532|NCT04431427|Active Comparator|Uncovered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
16335533|NCT04431414||Group 1|Persons that are positive for SARS-CoV-2 and are asymptomatic
16335534|NCT04431414||Group 2|Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)
16335535|NCT04431414||Group 3|Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients
16335536|NCT04431401|Experimental|rTMS treatment group|The participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
16335537|NCT04431401|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
16335538|NCT04431388||SIPB (block)|Patients undergone nephectomy and who received SIPB as analgesia
16335539|NCT04431388||QL block|Patients undergone nephectomy and who received QL as analgesia
16335598|NCT04430946|Experimental|Lean patients with type 1 diabetes|Test meal consumed within 10 minutes
16335540|NCT04431375|Experimental|plasma Exchange+Tenofovir+FMT|Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
16335541|NCT04431375|Active Comparator|Tenofovir|TabletTenofovir [antiviral] 300mg per oral once a day
16335542|NCT04431362|No Intervention|Baseline|Participants will not listen to music for 5 to 15 days based on the baseline duration they were assigned.
16335543|NCT04431362|Experimental|Intervention|Participants will listen to music for 3 weeks.
16335544|NCT04431349||ticagrelor|The patient with acute myocardial infarction received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
16335545|NCT04431349||clopidogrel|The patient with acute myocardial infarction received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
16335546|NCT04431336||younger aortic dissection or aneurysm patients|this is an observation cohort study about younger aortic dissection or aneurysm patients without intervention.
16335547|NCT04431323|Experimental|biopsychosocial intervention|"Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters).
~[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group.
~One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.]"
16335548|NCT04431310||Serial seroconversion measurements in hospital employees|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
16335549|NCT04431297|Other|Health Care Workers|Voluntary participation in the virtual presentations
16335550|NCT04431284||Obese patients with binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
16335551|NCT04431284||Obese patients without binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
16335552|NCT04431271||Robot-assisted laparoscopy|Patients who underwent robot-assisted groin hernia repair
16335553|NCT04431271||Conventional laparoscopy|Patients who underwent conventional laparoscopic groin hernia repair
16335554|NCT04431258|Experimental|Arm A) ABTL0812 + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:
~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion, followed by
~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion, followed by
~fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
~ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease."
16335555|NCT04431258|Experimental|Arm B) PLACEBO + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:
~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion, followed by
~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion, followed by
~fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
~Placebo will be administered at the same volume than ABTL0812 in arm A) FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued."
16335556|NCT04431245||Stop antiviral|HBeAg-negative non-cirrhotic CHB patients on long-term NA ≥3 years will be identified. Only those who have undetectable serum HBV DNA by the conventional assay (Cobas Taqman, Roche Diagnostics, Branchburg, NJ) which has a lower limit of detection (LLOD) of 10 IU/mL will be recruited. CHB patients were treated with potent oral NA (i.e. tenofovir or entecavir). All recruited patients will have written informed consent for participation of study. Patients with HCC, cirrhosis, history of liver transplantation, or on immunosuppressants, will be excluded.
16335557|NCT04431232|Experimental|Band Ligation|Band ligation of gastric body for weight loss
16335560|NCT04431206|Experimental|Oxytocin|Oxytocin administered by IV infusion
16335561|NCT04431193|Experimental|Oxytocin 4 picogram/millilitre|Oxytocin infused to maintain serum concentration of 4 picogram/millilitre
16335562|NCT04431193|Experimental|Oxytocin 16 picogram/millilitre|Oxytocin infused to maintain serum concentration of 16 picogram/millilitre
16335563|NCT04431193|Experimental|Oxytocin 64 picogram/millilitre|Oxytocin infused to maintain serum concentration of 64 picogram/millilitre
16335564|NCT04431193|Experimental|Oxytocin 256 picogram/millilitre|Oxytocin infused to maintain serum concentration of 256 picogram/millilitre
16335565|NCT04431180|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors'life saving donation during 2019-nCoV epidemic.
16335566|NCT04431180|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
16335567|NCT04431180|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
16335568|NCT04431180|Placebo Comparator|SMS with blood donor day greeting|SMS content in this group will be about SMS with blood donor day greeting.
16335569|NCT04431167|Experimental|Living well with Lupus Group|A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
16335570|NCT04431167|No Intervention|Usual Care Group|This group will receive all regular medical care and advice healthy
16335571|NCT04431154|No Intervention|Experimental: Usual care|Participants randomized to this arm will receive the standard of care (SOC) following the STAR program protocol in various sites in Johannesburg. This will include provision of an HIV self-screening test kit, the standard linkage officer follow-up call following report of a positive HIVSS test and an invitation to i) participate in study visit 1 to have their positive HIVSS result confirmed and complete blood collection for viral load PCR testing and to ii) participate in study visit 2 at 6 months for Viral Load PCR. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
16335572|NCT04431154|Experimental|Experimental: Incentives and linkage promotion|Participants randomized to this arm will receive the same standard HIV self-screen test kit and linkage officer follow-up call including the invitation to i) participate in study visit 1 and ii) study visit 2. In addition, they will receive a financial incentive if they complete a confirmatory HIV test at visit 1 and if they demonstrate viral suppression at study visit 2, approximately 6 months after positive HIVSS result. They will also receive monthly reminders and incentives to pick up HIV medication. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
16335573|NCT04431141|Experimental|Teneligliptin|
16335574|NCT04431141|Experimental|Empagliflozin|
16335575|NCT04431141|Experimental|Teneligliptin and Empagliflozin|
16335576|NCT04431128||study group|Adenoid hypertrophy
16335577|NCT04431128||Control group|UTI, GE, vomiting, diarrhea
16335578|NCT04431115||Stakeholders|"Academic experts, Politicians and officials of state ministries of health and education and teachers.
~Interviews will be conducted for academic experts, politicians and officials of state ministries of health and education.
~Headteachers and physical education teachers will be administered questionnaires."
16335579|NCT04431115||Parents|Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
16335580|NCT04431115||Primary school children aged 6-12 yrs.|"A cross sectional survey of the biographical data, socio economic status, physical activity level through appropriate questionnaires will be done.
~A pedometer will be attached to the waist of each of the participants for a consecutive 7 days to objectively determine the level of their physical activity."
16335581|NCT04431102|Experimental|PILATES METHOD|"It was intended the Pilates program were low supervision and easily realizable by all patients, which implied flexibility in the schedule. In this sense the sessions of Pilates was adjusted to these assumptions and the Pilates monitor offered several schedules on diferent days of the week.
~The pregnant women assigned to the intervention group were supervised by the midwifery of reference and trained by a Pilates monitor who explained the training program. The women received eight sessions of Pilates, given with a frequency of two classes per week and one hour of duration during a period of four weeks. The exercises for each session were determined beforehand. In addition, the participants maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.
~The therapeutic control were carried out by telephone call and clinical history review between the eighth and tenth day postpartum."
16335582|NCT04431102|No Intervention|MATERNAL EDUCATION|"The control group maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.
~Therapeutic control was carried out by phone call and review of the clinical history between the eighth and tenth day postpartum."
16335583|NCT04431089|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
16335584|NCT04431063|Experimental|Sutured Stump|The group consist of subject with distal stump suturing of perobeus longus agains peroneus brevis in ACL Reconstruction Case
16335585|NCT04431063|No Intervention|Unsutured Stump|The group consist of subject without distal stump suturing of peroneus longus agains peroneus brevis in ACL Reconstruction Case
16335586|NCT04431050||Suspected influenza or other respiratory viral infection.|"Any adult presenting to the Accident & Emergency department with influenza like illness or a febrile illness associated with symptoms such as cough, sore throat or rhinorrhoea, and for whom a respiratory viral screen is clinically indicated.
~For the purposes of this study one nasal swab will be taken from consenting adults."
16335587|NCT04431037|Experimental|Early oral feeding group(A)|Patients admitted in the HDU postoperatively.NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
16335588|NCT04431037|No Intervention|Traditional postoperative care group(B)|Patients in this group were managed traditionally
16335589|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
16335590|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
16335591|NCT04431011||Participants|Healthy right-handed participants aged 18-50
16335592|NCT04430998|Experimental|Zinc L-Carnosine mouth rinse|Using undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 60 seconds, 3 times daily
16335593|NCT04430998|Active Comparator|Chlorhexidine|Using undiluted 10 ml of Chlorhexidine mouth rinse, retain for 60 seconds, 3 times daily
16335594|NCT04430998|Placebo Comparator|Water|Mouth rinsing with 10 ml of water, retain for 60 seconds, 3 times daily
16335596|NCT04430959|Experimental|Candesartan first then Placebo|4 weeks of candesartan with crossover to the other.
16335599|NCT04430946|Experimental|Obese patients with type 1 diabetes|Test meal consumed within 10 minutes
16335600|NCT04430946|Active Comparator|Lean healthy control subjects|Test meal consumed within 10 minutes
16335601|NCT04430946|Active Comparator|Obese healthy control subjects|Test meal consumed within 10 minutes
16335602|NCT04430933|Experimental|NC318 + Pemetrexed/Carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin
16335603|NCT04430933|Experimental|NC318 + Nab-paclitaxel/carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin
16335604|NCT04430933|Experimental|NC318 + Docetaxel|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel
16335605|NCT04430920|Active Comparator|Intensive intraoperative blood pressure management|
16335606|NCT04430920|Placebo Comparator|Conventional intraoperative blood pressure management|
16335607|NCT04430907||Vaccine Accepting|This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
16335608|NCT04430907||Vaccine Rejecting|This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
16335609|NCT04430894|Experimental|Induction|"All participants will receive the same study drugs up to 8 cycles. Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone: Each cycle is 28 days in length.
~Stem cell collection after 4 cycles of therapy. Based on the recommendation participants may or may not proceed to an autologous stem cell transplant (SCT) as part of induction therapy.
~Up Front Autologous Stem Cell Transplant:
~--- 4 cycles of treatment, followed by stem cell collection, high-dose chemotherapy, and autologous SCT followed by 2 additional cycles of therapy (called consolidation) and then maintenance.
~Deferring Stem Cell Transplant:
~Deferring SCT following collection: 4 cycles of treatment, followed by stem cell collection followed by 4 additional cycles of therapy and then maintenance"
16335610|NCT04430894|Experimental|Maintenance-High Risk|"Experimental: Maintenance The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk.
~High Risk: All participants will receive study treatment for up to two years after induction until progressive disease (PD) or unacceptable toxicity
~Lenalidomide
~Carfilzomib
~Isatuximab"
16335611|NCT04430894|Experimental|Maintenance- Standard Risk|"The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk
~Lenalidomide - Standard of care All participants will receive study treatment for up to two years after induction until progressive disease (PD) or unacceptable toxicity"
16335612|NCT04430868|Experimental|LRP group|The participants in LRP group receive lifestyle redesign program plus treatment as usual. The LRP intervention consisted of one 90-minute session each week for 10 weeks
16335613|NCT04430868|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as LRP group.
16335614|NCT04430855|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A for 12 weeks (Period 1) followed by Upadacitinib Dose A for 36 weeks (Period 2).
16335615|NCT04430855|Experimental|Placebo followed by Upadacitinib Dose B|Participants will receive placebo for 12 weeks (Period 1) followed by Upadcitinib Dose B for 36 weeks (Period 2).
16335616|NCT04430842|Experimental|Dose escalation of QBS10072S|Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.
16335617|NCT04430816|Active Comparator|modified chevrel technique|22 participant with large midline incisional hernia underwent repair by double mesh modification of chevrel's technique
16335618|NCT04430816|Active Comparator|ON LAY mesh hernioplasty|21 participant with large midline incisional hernia underwent repair by online mesh hernioplasty
16335619|NCT04430803|Experimental|Hydrogen-rich water|"Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.)
~8 ppm of hydrogen
~Administered one dose two times per day on an empty stomach in the morning and at the evening"
16335620|NCT04430803|Placebo Comparator|Control water|"Tap water
~0 ppm of hydrogen
~Administered one dose two times per day on an empty stomach in the morning and at the evening"
16335621|NCT04430790|Experimental|Doxapram|Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.
16335622|NCT04430790|Placebo Comparator|Placebo|Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.
16335623|NCT04430777|Placebo Comparator|Placebo group|No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
16335624|NCT04430777|Experimental|Intravenous group|A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
16335625|NCT04430777|Experimental|Subcutaneous group|"A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow:
~4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine.
~6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine."
16335626|NCT04430764|Experimental|smoker|
16335627|NCT04430764|Active Comparator|non-smoker|
16335628|NCT04430751|Active Comparator|Immediate start|
16335629|NCT04430751|Active Comparator|wait time control|
16335630|NCT04430738|Experimental|Cohort 1A|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
16335631|NCT04430738|Experimental|Cohort 1B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
16335632|NCT04430738|Experimental|Cohort 1C|Tucatinib + trastuzumab + CAPOX given in 21-day cycles
16335633|NCT04430738|Experimental|Cohort 1D|Tucatinib + trastuzumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles and trastuzumab given every 21 days
16335634|NCT04430738|Experimental|Cohort 1E|Tucatinib + trastuzumab + pembrolizumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles, trastuzumab given in 21-day cycles, and pembrolizumab given in 42-day cycles
16335635|NCT04430738|Experimental|Cohort 1F|Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
16335636|NCT04430738|Experimental|Cohort 1G|Tucatinib + trastuzumab + pembrolizumab. Tucatinib and trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
16335637|NCT04430738|Experimental|Cohort 2A|Tucatinib + trastuzumab + pembrolizumab + (FOLFOX or CAPOX). Either (1) tucatinib and FOLFOX given in 14-day cycles or (2) tucatinib and CAPOX given in 21-day cycles. Trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
16335638|NCT04430738|Experimental|Cohort 2B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles.
16335639|NCT04430725||Observational (microwave ablation, wedge excision, CT)|Patients undergo standard care microwave ablation or wedge resection followed by contrast-enhanced CT imaging at 1, 6, 12, 18 and 24 months. Patients also complete questionnaires over 10-15 minutes at baseline up to 9 months.
16335640|NCT04430699|Experimental|Pembrolizumab, Cisplatin and Radiation Therapy|"Treatment period is 36 weeks with 21 day study cycles.
~Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.
~First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.
~Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks."
16335641|NCT04430673|Experimental|Home-School based VR trial|The VR system will be provided to each participant for a 2-week home- or school- based trial. No additional interventions.
16335642|NCT04430660|Other|Arm 1|Participants will have there glial acetate metabolism assessed via 13C MRS at baseline and then again 14 days later. Participants will wear blinded continuous glucose monitoring devices for ~4 weeks.
16335643|NCT04430647|Experimental|phaco-UCP|Under peribulbar anesthesia, UCP was performed first, followed by phacoemulsification. UCP was performed using the same technique described before [18]. For all treatments, 2nd generation probe was used (EyeOP1, Eye Tech care; France) with the same parameters; Operating frequency was 21 MHz. Number of sectors activated was 6. Acoustic power was 2.45 W; duration of each shot was 8s; and the time between shots was 20s. The probe diameter (11, 12 or 13 mm) was determined according to the eye's biometric readings. The coupling cone was centered on the eye and kept in place with low vacuum suction, followed by introduction of the treatment probe inside the cone, then activation of the transducers by constantly pressing the foot switch. Once UCP treatment was finished, phacoemulsification was commenced
16335644|NCT04430647|Active Comparator|Phaco alone|A standard phacoemulsification was performed with 2.2 mm clear corneal incision, continuous curvilinear capsulorhexis, phacoemulsification and intrabagal implantation of foldable acrylic intraocular lens (AcrySof® IQ SN60WF monofocal; Alcon Laboratories Inc, Fort Worth, TX, USA) for all patients. Irrigation-aspiration was performed for at least 30 seconds to remove any viscoelastic from the anterior chamber. Reformation of the anterior chamber was done with balanced saline solution (BSS), followed by hydration of the corneal wound and side port.
16335645|NCT04430634|Experimental|ABDC|Subjects use MybluTM e-cigarette product variant A (2.4 % nicotine) ad libitum for 2 days, then switch to use variant B (3.6% nicotine) for 2 days, then D (4.0% nicotine) for 2 days and then C (2.5% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
16335646|NCT04430634|Experimental|BCAD|Same as previous arm, but in a different randomization order.
16335647|NCT04430634|Experimental|CDBA|Same as previous arm, but in a different randomization order.
16335648|NCT04430634|Experimental|DACB|Same as previous arm, but in a different randomization order.
16335649|NCT04430634|Experimental|EFHG|Subjects use MybluTM e-cigarette product variant E (3.6 % nicotine) ad libitum for 2 days, then switch to use variant F (2.4% nicotine) for 2 days, then H (3.6% nicotine) for 2 days and then G (4.0% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
16335650|NCT04430634|Experimental|FGEH|Same as previous arm, but in a different randomization order.
16335651|NCT04430634|Experimental|GHFE|Same as previous arm, but in a different randomization order.
16335652|NCT04430634|Experimental|HEGF|Same as previous arm, but in a different randomization order.
16335653|NCT04430621|Experimental|FSH|FSH, 300 IU s.c.
16335654|NCT04430621|Placebo Comparator|Control|Placebo, s.c.
16335655|NCT04430608|Other|Fingerprick glucose|Standard care with fingerprick glucose + blinded CGM stratification on COVID-19 status
16335656|NCT04430608|Experimental|Open continous glucose monitoring (CGM)|Standard care with fingerprick glucose + un-blinded CGM stratification on COVID-19 status
16335657|NCT04430595|Experimental|Multiple 4SCAR T cells to treat breast cancer|Multiple 4SCAR T cells to treat breast cancer
16335658|NCT04430582||Hypoglycemia after upper gastrointestinal (GI) surgery|Participants with hypoglycemia after upper GI surgery, recruited from the Joslin Hypoglycemia Clinic and from other hypoglycemia studies at Joslin.
16335659|NCT04430582||Asymptomatic post-bariatric participants|Participants with a history of bariatric surgery, but without a diagnosis of hypoglycemia, or symptoms of hypoglycemia. They will be recruited by advertisement flyers at postoperative surgical clinics at local hospitals (e.g. Brigham and Women's and Beth Israel Deaconess Hospitals) and from other hypoglycemia studies at Joslin.
16335660|NCT04430582||Hypoglycemia no upper GI surgery & no diabetes (DM) or pre-DM|Participants with hypoglycemia and no history of upper gastrointestinal surgery, and NO current diagnosis of diabetes or pre-diabetes, recruited from the Joslin Hypoglycemia Clinic, or from other hypoglycemia studies at Joslin.
16335661|NCT04430582||Controls, no hypoglycemia or history of upper GI surgery|Participants without hypoglycemia or upper gastrointestinal surgery (controls), recruited by local advertisement. Some participants may be recruited from other hypoglycemia studies at Joslin.
16335662|NCT04430569|Experimental|Alteplase|
16335664|NCT04430556|Other|Volumetric changes in response to sertraline or escitalopram|
16335665|NCT04430543|Experimental|CBM Group|This group will receive Cognitive Bias Modification training
16335666|NCT04430543|Sham Comparator|Control Group|This group will receive Sham (control) training
16335667|NCT04430530|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20 infusion|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
16335669|NCT04430504|Experimental|Telerehabilitation (TR)|Multidisciplinary, weekly video meetings, self-exercises at home, digital diary recordings, follow-up assessments
16335670|NCT04430491||Training dataset|No interventions
16335671|NCT04430491||Validation dataset|No interventions
16335672|NCT04430478|Experimental|Volume flow group|Consecutive patients undergoing sequential volume flow measurements using percutaneous DUS
16335673|NCT04430465|Experimental|High wholegrain then low wholegrain|Starting with high wholegrain intervention followed by low wholegrain intervention
16335674|NCT04430465|Experimental|Low wholegrain then high wholegrain|Starting with low wholegrain intervention followed by high wholegrain intervention
16335675|NCT04430452|Experimental|Arm I (hypofractionated RT, durvalumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16335676|NCT04430452|Experimental|Arm II (hypofractionated RT, durvalumab, tremelimumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
16335677|NCT04430439|Experimental|Psychosocial stress|Participants will complete the Trier Social Stress Test (TSST) immediately following consumption of their assigned meal type (low or high GI).
16335678|NCT04430439|Active Comparator|Control non-stress|Participants will complete a non-stress relaxed task immediately following consumption of their assigned meal type (low or high GI).
16335679|NCT04430426|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days and be administered an intravenous (IV) load of glycolate. Participants will provide urine and blood samples both before the glycolate load to establish baseline levels and after the glycolate load to measure oxalate levels afterwards.
16335680|NCT04430413|No Intervention|Group A|50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
16335681|NCT04430413|Active Comparator|Group B|50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.
16335685|NCT04430361|Experimental|Megestrol|Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.
16335686|NCT04430361|Other|Control|Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day
16335692|NCT04430335|Other|Telephone-Based Cognitive Behavioral Therapy|Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
16335693|NCT04430309|Experimental|Baduanjin exercise group|"The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.
~The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks"
16335694|NCT04430309|Active Comparator|Control group|The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
16335695|NCT04430296|Active Comparator|High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU)|
16335696|NCT04430296|Active Comparator|MicroPulse cyclophotocoagulation (MP-CPC)|
16335697|NCT04430296|Active Comparator|Continuous Wave cyclophotocoagulation (CW-CPC)|
16335738|NCT04429971|Experimental|Immediate PreP initiation|"PreP screening program with immediate PrEP (iPrEP) initiation in the ED using a PrEP starter pack with facilitated linkage to care."
16335701|NCT04430270||Comparison of Perceptions of X-ray, CT and 3D Model|The study group consisted of 11 orthopaedic residents of University Hospital. Selection criteria for the 4 cases was the involved patients who required orthopaedic surgery. 4 cases for orthopaedic procedures were determined with the consensus of experts. As data collection tool was used to evaluate the perceptions of each of these imaging methods in terms of their usefulness in seeing the surgical problem, their efficiency in differential diagnosis and presurgical planning. CT images were converted into in the 3D model was prepared. The survey utilized by our group, addressed the issues in understanding bone anatomy, seeing pathology, and preparation for unexpected events. A multi-item survey was prepared to assess fellow's perception of residency training. Residents who completed their examination in the stations answered the questions on a scale of 10. Descriptive statistics and Friedman test were used for comparison analysis using IBM SPSS Statistics, version 24.
16335702|NCT04430257|Experimental|PrEP for health|Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.
16335703|NCT04430257|Active Comparator|Standard of care|Participants in the standard of care arm will receive PrEP information and referrals.
16335704|NCT04430244|Experimental|DALK using Dehydrated Corneas|Corneal transplantation of anterior lamellar grafts from dehydrated corneas.
16335705|NCT04430244|Active Comparator|DALK using Standard Organ Culture Stored Corneas|Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.
16335706|NCT04430231||Wait list time 0-2 weeks|Wait list time 0-2 weeks
16335707|NCT04430231||Wait list time 2-4 weeks|Wait list time 2-4 weeks
16335708|NCT04430231||Wait list time 4-6 weeks|Wait list time 4-6 weeks
16335709|NCT04430231||Wait list time > 6 weeks|Wait list time > 6 weeks
16335710|NCT04430218|Experimental|iSens|3 months trial with the iSens system
16335711|NCT04430218|No Intervention|State of the Art Prosthesis|3 months trial with their own prosthesis.
16335712|NCT04430192|Experimental|177Lu-PSMA-617 followed by prostatectomy|177Lu-PSMA-617 followed by prostatectomy
16335713|NCT04430179|Active Comparator|Active drug|Dupilumab 300 mg every other week for 24 weeks
16335714|NCT04430179|Placebo Comparator|Placebo|Placebo
16335715|NCT04430166|Experimental|PD-1 monoclonal antibody|
16335716|NCT04430153||Low match|A group with both low observed and perceived upper limb ability.
16335717|NCT04430153||Good match|A group with both good observed and perceived upper limb ability.
16335718|NCT04430153||Mismatch|A group with good observed but low perceived function.
16335719|NCT04430140||1|"CT Scan
~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
16335720|NCT04430127||Colorectal adenocarcinoma|patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging
16335721|NCT04430114|Experimental|TAAA spinal loop graft|
16335722|NCT04430101|Active Comparator|Negative WB radiographs and stress fluoroscopy|"Cohort 1
~Negative weight bearing radiographs:
~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.
~Negative stress fluoroscopy: the midfoot is tested stable"
16335723|NCT04430101|Active Comparator|Negative WB radiographs / positive stress fluoroscopy|"Cohort 2
~Negative weight bearing radiographs:
~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.
~Positive stress fluoroscopy: manual testing reveals midfoot instability"
16335724|NCT04430101|Other|Surgical cohort (Cohort 3)|Patients with positive weightbearing radiographs will be operated on with minimally invasive technique and followed up as an independent cohort.
16335725|NCT04430088|Experimental|VVZ-149 Injections|
16335726|NCT04430088|Placebo Comparator|Placebo|
16335727|NCT04430062||Covid-19 patients operated (February 21st -April 10th)|
16335728|NCT04430049||no visitation group|relatives cannot visit ICU patient during Covid pandemic period in France
16335729|NCT04430049||restrictive visitation group|relatives have restriction to visit ICU patient during Covid pandemic period in France
16335730|NCT04430049||open visitation group|relatives can visit ICU patient during no Covid period in France
16335734|NCT04430010|Experimental|Implementation|Teachers will implement the BEST in CLASS treatment in their classrooms
16335735|NCT04429997|Experimental|Removal of fibrosynovial tissue|Removal of fibrosynovial tissue in patellar non-resurfacing TKA
16335736|NCT04429997|Experimental|Non-removal of fibrosynovial tissue|Non-removal of fibrosynovial tissue in patellar non-resurfacing TKA
16335737|NCT04429984||Velaglucerase alfa (VPRIV)|Participants with Gaucher disease will receive VPRIV therapy according to the investigator's judgment for 12 months.
16335739|NCT04429971|Active Comparator|Out-patient care for PrEP initiation|PrEP screening program with referral to out-patient care for PrEP initiation
16335740|NCT04429971|Experimental|PreP Screening Program|Part 1: Targeted ED-based patients
16335741|NCT04429958||GDM|125 mothers with a history of GDM in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
16335742|NCT04429958||abnormal GCT group|125 mothers with an abnormal glucose challange test (GCT of 130mg/dl or more) in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
16335743|NCT04429958||normal group|125 mothers with both a normal GCT and OGT in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
16335744|NCT04429945|Experimental|Immersive Virtual Reality|A Virtual Reality headset will be used for 30 minutes twice per day outside of usual therapy times while in bed with bedrails raised. Virtual Reality games will be selected that will help with relaxation, pain, and arm and hand recovery after a stroke.
16335745|NCT04429932|Experimental|Product use sequence ABDC|Subjects use MybluTM e-cigarette product variant A (2.4% nicotine) ad libitum for 2 days, then switch to use variant B (2.4% nicotine) for 2 days, then D (2.4% nicotine) for 2 days and then C (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
16335746|NCT04429932|Experimental|Product use sequence BCAD|Same as previous arm, but in a different randomization order.
16335747|NCT04429932|Experimental|Product use sequence CDBA|Same as previous arm, but in a different randomization order.
16335748|NCT04429932|Experimental|Product use sequence DACB|Same as previous arm, but in a different randomization order.
16335749|NCT04429932|Experimental|Product use sequence EFHG|Subjects use MybluTM e-cigarette product variant E (1.2% nicotine) ad libitum for 2 days, then switch to use variant F (1.2% nicotine) for 2 days, then H (2.4% nicotine) for 2 days and then G (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
16335750|NCT04429932|Experimental|Product use sequence FGEH|Same as previous arm, but in a different randomization order.
16335751|NCT04429932|Experimental|Product use sequence GHFE|Same as previous arm, but in a different randomization order.
16335752|NCT04429932|Experimental|Product use sequence HEGF|Same as previous arm, but in a different randomization order.
16335753|NCT04429919|Experimental|AP-325|25 mg capsule for oral use, 4 capsules (100 mg) once daily in the morning before meals
16335754|NCT04429919|Placebo Comparator|Placebo|4 capsules once daily in the morning before meals
16335755|NCT04429906||test group|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
16335756|NCT04429906||control group A|Pulse oximetry monitor/desktop ECG monitor with a medical device registration certificate was selected as reference device A. The mean value of qualified pulse oximetry measured by pulse oximetry monitor/desktop ECG monitor within 2 minutes of each successive measurement of the Huami Smart Wearable Device was used as control group A measurement.
16335757|NCT04429906||control group B|A carbon monoxide blood gas analyzer (CO-oximeter) was selected as reference device B. Arterial blood was sampled and arterial oxygen saturation (SaO2) was obtained from the blood gas analyzer as a control group B measurement.
16335758|NCT04429893|Experimental|Group BM|The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.
16335759|NCT04429893|Active Comparator|Group B|The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml
16335760|NCT04429880|Experimental|Oxytocin|Oxytocin 17 micrograms infusion over 10 minutes
16335761|NCT04429867|Experimental|Hydroxychloroquine|
16335762|NCT04429867|Placebo Comparator|Placebo|
16335765|NCT04429841||D1 Gastrectomy|Patients are managed by radical gastrectomy with D1 lymphadenectomy
16335766|NCT04429841||D2 Gastrectomy|Patients are managed by radical gastrectomy with D2 lymphadenectomy
16335767|NCT04429828|Experimental|e-package: psychological wellbeing for healthcare workers|A COVID-19 educational package on psychological wellbeing for healthcare workers, accessible to all healthcare students.
16335768|NCT04429815||Active smokers.|Active smokers since October 2019.
16335769|NCT04429815||Smokers undergoing smoking cessation|Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.
16335770|NCT04429815||Non-smoking.|Person who's never smoked before.
16335847|NCT04429308|Active Comparator|Chemical Peels|One upper arm will be exposed to Jessner's Solution AND 35% Trichloroacetic acid peel
16335912|NCT04428840|No Intervention|Off-day|No use of the self-measurement kiosk
16335773|NCT04429789|Experimental|Active-Alert Hypnosis|
16335774|NCT04429789|Experimental|Traditional Hypnosis|
16335775|NCT04429789|No Intervention|Wait-List Control|Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
16335776|NCT04429776|Experimental|Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results fed back to recruiting clinical team who can choose to use these to influence their tapering decisions.
16335777|NCT04429776|Active Comparator|No Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results not fed back to recruiting clinical team.
16335778|NCT04429763|Experimental|Experimental|Usual tratment for COVID-19 plus MSC
16335779|NCT04429763|Placebo Comparator|Control|Usual treatment for COVID-19
16335780|NCT04429750|Active Comparator|Immediate umbilical cord clamping|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH management procedure as described in the French national CDH management guidelines (Programme National de Soins).The resuscitation maneuvers are started after the umbilical cord is clamped."
16335781|NCT04429750|Experimental|Intact cord resuscitation|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH resuscitation maneuvers as described in the French national CDH management guidelines (Programme National de Soins) before the umbilical cord is clamped. The resuscitation maneuvers are started at birth while the umbilical cord still bridges mother and child."
16335782|NCT04429737|Experimental|Experimental|The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.
16335783|NCT04429737|Placebo Comparator|placebo|The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.
16335784|NCT04429724|Experimental|health workers at hospital|Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
16335785|NCT04429711|Placebo Comparator|IVERMECTIN|
16335786|NCT04429711|Active Comparator|PLACEBO|
16335787|NCT04429698|Other|POCUS group|Patients in this group underwent POCUS after primary clinical evaluation with the knowledge of their primary physician. This procedure was performed in the first hour after the patients' primary clinical evaluations to evaluate the predetermined parameters in the study form for the heart, lungs, hepatobiliary, aortic and deep veins.
16335788|NCT04429698|No Intervention|Control group|All processes and results were followed without any intervention in the processes related to the patients in this group and the results were recorded in the study form
16335789|NCT04429685|Experimental|Low Dose Ketamine|
16335790|NCT04429685|Placebo Comparator|Saline (placebo)|
16335791|NCT04429672|Experimental|Experimental Group (EG)|"The participants of the Experimental Group receive as treatment the intervention called The Right to your Sexual Health, which is socio-educational and is composed of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Conduct and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of the opening, development and closing phase established in a manual for the facilitator, it should be noted that the intervention is applied by a multidisciplinary team in which the areas of medicine, nursing and psychology participate. In addition, Information and Communication Technologies (ICTs) are used through a Moodle platform that has available to participants digital support material as digital presentations on each of the thematic axes, as well as audiovisual material through the Podcast format of conversations concerning each of the axes."
16335792|NCT04429672|Active Comparator|Control Group (CG)|The participants of the Control Group receive the usual sexual health intervention applied by Secretary of Health consisting of six sessions (one a week) lasting 50 minutes each using illustrative material through rotating official secretary of health folios on reproductive health, sexually transmitted diseases and sexual violence.
16335793|NCT04429659||Group 1, patients with amblyopia and partially refractive ET|children with both amblyopia and partially refractive accommodative esotropia
16335794|NCT04429659||Group 2, patients with refractive ET|children with refractive esotropia
16335795|NCT04429646|Experimental|LAMax left atrial appendage occluder|Intervention device, LAMax left atrial appendage closure system
16335796|NCT04429646|Active Comparator|Watchman (control)|Intervention device, Watchman® LAA Closure Device
16335797|NCT04429633|Active Comparator|Conventional Cardiac intervention|Starting candesartan in patients with left ventricular ejection fraction (LVEF) between 45% and 50% by echocardiogram.
16335798|NCT04429633|Active Comparator|Early Cardiac intervention|Starting candesartan in patients with decreased myocardial strain below 18% regardless of LVEF by echocardiogram.
16335799|NCT04429620||Positive group|Subjects are diagnosed with SARS-CoV2 by qPCR assay.
16335800|NCT04429620||Negative group|Subject were 2 times proved negative SARS-CoV2 by qPCR assay.
16335801|NCT04429607|Active Comparator|Erbium:YAG Laser|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
16335802|NCT04429607|Active Comparator|PDL plus Nd:YAG|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
16335803|NCT04429607|Active Comparator|ED&C treatment|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
16335804|NCT04429594|Other|volonteers|
16335805|NCT04429568|Other|Smoked Cannabis, Vaped Cannabis, or Tobacco Cigarette|"Abstinence from any product night before hospital admission
~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette
~6-hr abstinence and blood draws (PK)
~2 hr Free use session w/ video monitoring
~Free use of assigned product
~12-hr cardiovascular (CV) monitoring
~Circadian blood draws
~12-hr urine collection"
16335806|NCT04429568|Other|Either of the 2 remaining products|"Abstinence from any product night before hospital admission
~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette
~6-hr abstinence and blood draws (PK)
~2 hr Free use session w/ video monitoring
~Free use of assigned product
~12-hr CV monitoring
~Circadian blood draws
~12-hr urine collection"
16335807|NCT04429568|Other|Remaining product|"Abstinence from any product night before hospital admission
~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette
~6-hr abstinence and blood draws (PK)
~2 hr Free use session w/ video monitoring
~Free use of assigned product
~12-hr CV monitoring
~Circadian blood draws
~12-hr urine collection"
16335808|NCT04429555|Experimental|MN-166 (ibudilast)|MN-166 capsules, 50 mg twice daily, for 7 days.
16335809|NCT04429555|Placebo Comparator|Placebo|Placebo capsules, 50 mg twice daily, for 7 days.
16335812|NCT04429529|Experimental|TY027 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
16335813|NCT04429529|Placebo Comparator|Placebo 0.5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16335814|NCT04429529|Experimental|TY027 5mg/kg|Subject will be administered with 5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
16335815|NCT04429529|Placebo Comparator|Placebo 5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16335816|NCT04429529|Experimental|TY027 10 mg/kg|Subject will be administered with 10 mg/kg of TY027 via IV infusion over a period of 30 minutes.
16335817|NCT04429529|Placebo Comparator|Placebo 10 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16335818|NCT04429529|Experimental|TY027 20 mg/kg|Subject will be administered with 20 mg/kg of TY027 via IV infusion over a period of 30 minutes.
16335819|NCT04429529|Placebo Comparator|Placebo 20 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16335820|NCT04429529|Experimental|TY027 30 mg/kg|Subject will be administered with 30 mg/kg of TY027 via IV infusion over a period of 30 minutes.
16335821|NCT04429529|Placebo Comparator|Placebo 30 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16335822|NCT04429516|Experimental|Morphine Sulfate|
16335823|NCT04429516|Placebo Comparator|Placebo|
16335824|NCT04429503|Experimental|aflibercept Q8|Administered every 8 weeks after a loading phase
16335825|NCT04429503|Experimental|High-Dose aflibercept Q12|Administered every 12 weeks after a loading phase
16335826|NCT04429503|Experimental|High-Dose aflibercept Q16|Administered every 16 weeks after a loading phase
16335827|NCT04429490|Experimental|"Group Cases"|patients with pancreatic adenocarcinoma
16335828|NCT04429490|Other|"Group Controls"|patients without pancreatic adenocarcinoma
16335830|NCT04429451|Experimental|4SCAR-PSMA Cell Therapy for PSMA positive tumor|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
16335831|NCT04429438|Experimental|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.
16335832|NCT04429425|Other|EA group|patients with colorectal surgery that willl be performed epidural anesthesia
16335833|NCT04429425|No Intervention|non -EA group|patients with colorectal surgery that willl be performed only general anesthesia
16335834|NCT04429412|Experimental|Metacognitive Training (MCT+)|"MCT+ combines the process-oriented approach of metacognitive group training with elements of individual cognitive-behavioral therapy.
~The metacognitive training program is comprised of 10 modules targeting common cognitive errors in schizophrenia. (Moritz et al, 2013).
~The modules are: 1:Therapeutic alliance, 2: Introducyion to MCT+, 3:Disease model, 4: Attributional style, 5: Decision making, 6: Changing beliefs, 7: Empathizing, 8: Memory, 9: Depression and self-steem, 10: Relapse prevention.
~The treatment consist of 10 weekly sessions of 45-60 minutes."
16335835|NCT04429412|No Intervention|TAU|Treatment as usual.
16335836|NCT04429399|Other|High positive end-expiratory pressure Ventilation|patient ventilated fixing high level of positive end expiratory pressure
16335837|NCT04429399|Other|Low positive end-expiratory pressure Ventilation|patient ventilated fixing low level of positive end expiratory pressure
16335838|NCT04429373|Experimental|Implant installation with PRF|PRF membrane over the buccal aspect of implant site
16335839|NCT04429373|Active Comparator|Implant installation without PRF|Implant installation contralateral to the the experimental implant, without PRF membrane
16335840|NCT04429347|Experimental|Tizanidine 2mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
16335841|NCT04429347|Experimental|Gabapentin 300mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
16335842|NCT04429347|Placebo Comparator|Placebo|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
16335843|NCT04429334|Experimental|nangibotide|
16335844|NCT04429334|Placebo Comparator|placebo|
16335845|NCT04429321|Experimental|Ipilimumab +Nivolumab with Embolization|"Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities.
~Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently."
16335846|NCT04429308|Active Comparator|Photodynamic Therapy|One upper arm will be exposed to blue light therapy
16335848|NCT04429295|Experimental|Group A - Intervention regimen|SHAN6™ + routine pediatric vaccines pneumococcal 13-valent conjugate vaccine [PCV] [Prevnar 13®] and oral rotavirus vaccine [ORV-1] [Rotarix™] at age of 2, 4 months; SHAN6™ + Prevnar 13® at age of 6 months; SHAN6™ administered alone as a booster dose at age of 15-18 months
16335849|NCT04429295|Active Comparator|Group B - Control regimen|SHAN5™ + bivalent oral polio vaccine (bOPV), co-administered with Prevnar 13® and Rotarix™ at 2, 4 months of age and with inactivated polio vaccine [IPV] at 4 months of age; SHAN5™ + bOPV, co-administered with Prevnar 13® at 6 months of age SHAN6™ administered alone as a booster dose at 15-18 months of age
16335850|NCT04429282|Experimental|ibuprofen( 400mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 400 mg .
16335851|NCT04429282|Experimental|ibuprofen( 800mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 800 mg.
16335852|NCT04429282|Placebo Comparator|placebo group|Patients were randomly divided into the group received respectively IV placebo,.
16335853|NCT04429269||mammography and ultrasound|mammography and ultrasound screening
16335854|NCT04429243||GORE® VIABAHN® Stent Graft|Participants will be examined 1, 3, 6, 12 and 24 months following the GORE® VIABAHN® Stent Graft installation.
16335855|NCT04429230|Active Comparator|Real tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
16335856|NCT04429230|Sham Comparator|Sham tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
16335857|NCT04429217|Experimental|Arm-A|experimental post-operative rehabilitation intervention consisting in immediate weight-bearing
16335858|NCT04429217|Active Comparator|Arm-B|control post-operative rehabilitation intervention consisting in delayed weight-bearing
16335859|NCT04429204|Experimental|Basic science (cryoablation, tissue collection)|At the time of standard of care pleural biopsy, patients undergo cryoablation over 30 minutes, then a sample of tissue from the ablated region and a non-ablated (tumor negative control) region are collected.
16335860|NCT04429191|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|"The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
~The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose."
16335861|NCT04429178||women in the 1st trimester of pregnancy.|
16335862|NCT04429178||women in the 2nd trimester of pregnancy.|
16335863|NCT04429178||women in the 3rd trimester of pregnancy.|
16335864|NCT04429178||non-pregnant women|
16335865|NCT04429165||ACL reconstruction|ACL reconstruction using an autologous hamstring tendon
16335866|NCT04429165||control group|knee-healthy, age-matched subjects as a control group
16335867|NCT04429152|Experimental|Doravirine|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
16335868|NCT04429139|Experimental|PDT treatment group|All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
16335869|NCT04429126|Experimental|4-point acupressure group|"The 5-point acupressure group will be instructed on the following acupressure points: sanyinjiao (SP6), Zu San Li (ST36), shenmen (TF4), Yongquan (KI-1), and He Gu (LI4).
~Bilateral 1.5 min for each point, three times daily for 4 weeks."
16335870|NCT04429126|Active Comparator|4 -point acupressure group|"The 2-point acupressure group will be instructed on the following acupressure points: He Gu (LI4) and Tai Chong (LV3).
~Bilateral 1.5 min for each point, three times daily for 4 weeks."
16335871|NCT04429126|No Intervention|Usual care|The usual care group will be required to maintain their daily activities. Weekly telephone follow-up will be conducted by principle investigator.
16335872|NCT04429113||G1 or Early Group|Patients treated before age 7 (Quad Helix on decidual second molars)
16335873|NCT04429113||G2 or Late Group|Patients treated between 7 and 13 years old (Quad Helix on first permanent molars)
16335874|NCT04429100||liver fibrosis stage F0|
16335875|NCT04429100||early-stage liver fibrosis (F1-2)|
16335876|NCT04429100||late-stage liver fibrosis (F3-4)|
16335877|NCT04429087|Experimental|BI 764532|
16335878|NCT04429074||Group 1 (Registrar)|Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon)
16335879|NCT04429074||Group 2 (Consultant)|Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert)
16335880|NCT04429061|No Intervention|SOC Arm|Standard of care (SOC): the sexual reproductive curriculum which is implemented by the schools as part of mandatory SRH education.
16335881|NCT04429061|Active Comparator|Enhanced Arm|The SKILLZ-Girl Curriculum, plus the graduation event (including HIVST + access to family planning) and home based delivery of commodities with subsequent encouragement to be involved with SKILLZ-Clubs at their school
16335882|NCT04429048|Experimental|acupressure group|The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.
16335883|NCT04429048|Sham Comparator|control group|The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.
16335884|NCT04429035|Experimental|Vitamin K2|Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
16335885|NCT04429035|Placebo Comparator|Placebo|Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
16335910|NCT04428853|Experimental|exercise|A schedule has designed by the researcher for group yoga therapy of the participant twice a week, each session lasting for 75- minutes for the duration of 8 weeks
16335886|NCT04429022|Experimental|Prospective cohort|"Pre-Op:
~Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op)
~Acetaminophen 1000mg PO x1 prior to surgery (in pre-op)
~Intra-Op:
~Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL
~Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL
~Will operate at <15mmHg intra-abdominal pressure, with goal of <12mmHg
~At end of procedure during closure of fascia, give 30mg ketorolac IV x 1
~Post-Op:
~Gabapentin 300mg PO BID for 7 days
~Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN
~Celecoxib 200mg PO q 12h x 7d
~Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge"
16335887|NCT04429022|Active Comparator|Historical Control|Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Perocets 12 x 5mg/325 (90MME) upon discharge
16335888|NCT04429009|Experimental|Active Study Group|"Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:
~The Spirobank Smart Spirometer, which is a non-significant risk, FDA-cleared diagnostic spirometer made by Medical International Research (MIR) that connects via bluetooth to an Android tablet.
~A Samsung 10-inch tablet provided by Pad-in-Motion Inc. that will be connected to the hospital GuestWiFi network.
~The ZEPHYRx Respiratory Therapy video game application installed on the tablet. This application consists of seven games that have been created to combine traditional IS techniques with playing a breath controlled video game. The application will record data while playing the video games including date/time of use, game played, inhalation duration, and inhalation volume."
16335889|NCT04429009|Active Comparator|Control Group|Participants in this group will be prescribed to routine respiratory care, Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects to perform a series of at least 10 deep breaths every hour.
16335890|NCT04428996|Experimental|Arm AB|"A means SCIT program, and B means treatment as usual. Arm AB will receive a 60-minutes manual-guide SCIT session each week for 20 times first, then receive treatment as usual.
~Before the SCIT session, after the SCIT session and after 20 weeks treatment as usual, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.
~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
16335891|NCT04428996|Experimental|Arm BA|"A means SCIT program, and B means treatment as usual. Arm BA will first receive treatment as usual, then a 60-minutes manual-guide SCIT session each week for 20 times.
~At the first week, before and after the SCIT session, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.
~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
16335892|NCT04428983|Experimental|Hericium erinaceus mycelium|Hericium erinaceus capsules 1 table tid orally per day for 24 months
16335893|NCT04428983|Placebo Comparator|placebo|placebo capsules 1 table tid orally per day for 24 months
16335894|NCT04428970||TBI patients with ICP monitoring|Patients with severe TBI (GCS<9 on arrival) receiving invasive ICP monitoring
16335895|NCT04428957|Experimental|Telemonitoring group|3 months home-based telemonitoring
16335896|NCT04428957|No Intervention|Control group|3 months standard care
16335897|NCT04428944|Active Comparator|PV antral isolation alone (PVAI)|PV antral isolation alone (PVAI)
16335898|NCT04428944|Active Comparator|PV antral isolation plus ablation of drivers|PV antral isolation plus ablation of drivers (PVAI+drivers)
16335899|NCT04428944|Active Comparator|PV antral isolation plus isolation of posterior wall|PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
16335900|NCT04428931||PD patients|Patients with Asymmetric Parkinson's disease
16335901|NCT04428918||Cohort 1|Allogeneic HCT recipient or patient pending receipt of HCT
16335902|NCT04428905|Experimental|Arm I (personalized care plan, telehealth sessions)|Patients receive a personalized care plan/resource manual. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) about self-management skills building, then 3 maintenance telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) for additional self-management skills building support. A copy of patient's care plan is also sent to their PCP.
16335903|NCT04428905|Active Comparator|Arm II (ASCO care plan, telehealth sessions)|Patients receive an ASCO care plan. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) to answer questions on a handbook about life after cancer treatment, then 3 monthly telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) to answer questions about the handbook. A copy of the ASCO care plan is also sent to their PCP.
16335904|NCT04428892|Experimental|Clinical Simulation|The group denominated SP received a teaching strategy based on a class session with simulated practice for decision-making in clinical skills when caring for a person with LBP. Each session lasted approximately 120 minutes, and the clinical case used for the SP sessions was subjected to face validity with experts in the area of study.
16335905|NCT04428892|Active Comparator|Conventional Pedagogical strategy|"received a class session based on a role playing simulation strategy, structured for the same purpose established in the SP group. This session lasted approximately 120 minutes, and the learning environment was the classroom in which students assumed different roles to act out; some of them acted as people with LBP and others as physiotherapists"
16335906|NCT04428879|Experimental|Phase I single arm trial|
16335907|NCT04428866||Participants with post-bariatric hypoglycemia|Individuals with history of Roux-en-Y gastric bypass surgery, who have a history of hypoglycemia will be recruited from the Joslin Hypoglycemia Clinic.
16335908|NCT04428866||Asymptomatic participants with Roux-en-Y gastric bypass (RYGB)|Individuals with history of RYGB, without a history of or symptoms of hypoglycemia will be recruited from local postoperative surgical clinics and from the community.
16335909|NCT04428866||Control group|Individuals without a history of bariatric surgery will be recruited by local advertisement.
16335911|NCT04428840|Experimental|on-day|Use of the self-measurement kiosk: measurement of vital signs + completion of short questionnaire
16335914|NCT04428827||Medications|Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
16335915|NCT04428814|Experimental|CT-P43 (Part 1)|45mg single dose administration
16335916|NCT04428814|Active Comparator|EU-approved Stelara (Part 1)|45mg single dose administration
16335917|NCT04428814|Experimental|CT-P43 (Part 2)|45mg single dose administration
16335918|NCT04428814|Active Comparator|EU-approved Stelara (Part 2)|45mg single dose administration
16335919|NCT04428814|Active Comparator|US-licensed Stelara (Part 2)|45mg single dose administration
16335920|NCT04428801|Experimental|Phase 2 AdMSC group|"Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days
~Other Names: Celltex-AdMSCs Celltex-AdMSCs"
16335921|NCT04428801|Placebo Comparator|Phase 2 Placebo group|The control group- receive three doses of placebo via intravenously infusion every three days.
16335922|NCT04428788|Experimental|Administration of CC-94676|Escalating doses of CC-94676 administered orally (tablets) once daily.
16335923|NCT04428775|Experimental|Group I (Low Dose)|Group I (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 17.1 mg/twice a day (bid) (total of 34.2 mg/day)
16335924|NCT04428775|Experimental|Group II (High Dose)|Group II (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 34.2 mg/bid (total of 68.4 mg/day)
16335925|NCT04428762|Experimental|I-Port use arm|
16335926|NCT04428762|No Intervention|Regular injection arm|
16335927|NCT04428749||Study group|"Participants are screened using the Yale Swallow Protocol (YSP) 2-4 hours after extubation:
~Ability to swallow is assessed by an ICU nurse using the YSP. If the YSP is negative, the patient may start oral feeding and drinking. In case of a positive YSP, the screening may be repeated within the next 24 hours provided the patient improves clinically. If YSP continues to be positive the patient is referred to assessment by a speech language pathologist (SLP).
~Participants are screened within 24 hours:
~To evaluate YSP against the FEES, the patient undergoes 1) YSP performed by an ICU nurse followed by 2) FEES performed by a SLP (until PAS>6 (aspiration on any food consistency on the Penetration Aspiration Scale (20)). The SLP will be blinded to the assessment made by the ICU nurses. Patients will follow recommendations for oral feeding and drinking as given by the SLP."
16335928|NCT04428723||Hypoglycemia, no upper gastrointestinal (GI) surgery|Males or females with hypoglycemia with neuroglycopenia, but no history of upper GI surgery, diabetes or prediabetes
16335929|NCT04428723||Hypoglycemia, with history of upper GI surgery|Males or females with hypoglycemia with neuroglycopenia, with history of upper GI surgery
16335930|NCT04428723||Controls, without hypoglycemia or upper GI surgery|Males or females with no history of upper gastrointestinal surgery, hypoglycemia, or diabetes.
16335931|NCT04428710||patients admitted to cancer genetic counseling test|Participants were recruited from all consecutive patients referred to the Cancer Genetic Program at the Hospital Universitari i Politècnic la Fe.
16335932|NCT04428697|Experimental|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm. After identifying both the internal and external sphincters completely, under direct vision, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. This section was preserved during the operation in a standard fashion for all patients . Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter bundle was elevated with a right angle clamp, then cut with cautery . The operation was completed with meticulous hemostasis and additional suturing (3/0 absorbable suture) of the proximally dissected mucosal flap underlying the muscularis layer
16335933|NCT04428697|Active Comparator|Closed Lateral Internal Sphincterotomy|The sphincterotomy was performed through a new incision, guided by the surgeon's finger, as described by Boulos et al Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? The British journal of surgery 1984;71:360-2.
16335934|NCT04428684|Experimental|Pepti 3.6 treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
16335935|NCT04428684|Active Comparator|Zoladex 3.6 mg treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
16335936|NCT04428671|Experimental|Treatment (cemiplimab)|"NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~ADJUVANT PHASE: Within 2-6 weeks after standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity."
16335937|NCT04428658|Experimental|Home-based video visits|Participants in the intervention arm will receive home-based video visits with a pediatric endocrinologist every 12 weeks for the duration of 1 year in addition to usual care (which includes initial assistance with setting up secure platforms for diabetes data-sharing and usual quarterly in-person care at the UCD Pediatric Diabetes Clinic).
16335938|NCT04428658|Active Comparator|Standard of Care|The control group will receive usual care, which includes initial assistance with setting up secure platforms for diabetes data-sharing and usual quarterly in-person care at the UCD Pediatric Diabetes Clinic.
16335939|NCT04428645|Experimental|DailyDose Decision Support|Subjects will use DailyDose decision support for 8 weeks at home.
16335940|NCT04428619|Active Comparator|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|The PENFS device has a battery activated generator and wire harness. Four leads are attached to the generator, each with a sterile 2 mm, titanium needle. The patient's ear is trans-illuminated to identify neurovascular bundles that are avoided during needle placement. The generator is attached with adhesive to the skin behind the patient's ear. Needles are inserted into the dorsal and ventral aspects of the ear, within 1-1.5 mm of the vascular branches to create a field effect. The device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The device is worn for 5 days/week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will be asked to wear a SmartWatch during the study to monitor heart rate.
16335941|NCT04428619|Sham Comparator|Sham Device|The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
16335942|NCT04428606|Experimental|Metabolic Rheostat™|Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
16335943|NCT04428606|Experimental|Butyrate Ultra|Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
16335944|NCT04428606|Placebo Comparator|Placebo|Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
16335945|NCT04428593|Experimental|Treamid 5 mg|Cohort 1 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 5 mg (4 subjects) or placebo (1 subject, see placebo arm).
16335946|NCT04428593|Experimental|Treamid 15 mg|Cohort 2 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 15 mg (4 subjects) or placebo (1 subject, see placebo arm).
16335947|NCT04428593|Experimental|Treamid 50 mg|Cohort 3 - 5 subjects were randomized in a 8:2 ratio to be treated either Treamid 50 mg (8 subjects) or placebo (2 subjects, see placebo arm).
16335948|NCT04428593|Placebo Comparator|Placebo|Placebo comparator arm consists of 4 subjects (1 subject from Сohorts 1 and 2, 2 subjects from Cohort 3).
16335949|NCT04428580|Experimental|Online Training|10 lectures that are self-paced with a maximum of three months to complete with each lecture bundle comprising of 5-8 short (about 4 minutes in length), didactic videos that discuss the treatment model and provide mock therapy session video clips (modeling FBT with a typical adolescent AN case), as well as supplementary readings and videotaped role-plays. Enrollees complete each lecture bundle and complete the assignments as they move through the training at their own pace, but to have completed all within the 3-month time frame. When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
16335950|NCT04428580|Active Comparator|Webinar Training|1-hour weekly webinar lectures that essentially is the FBT training that is conducted in person, just recorded. There will be lectures discussing the scientific evidence supporting FBT, how therapists set up treatment for FBT, main interventions used in FBT during each phase, and recorded role-plays illustrating interventions throughout the 3 phases. Enrollees watch each webinar video as it is released weekly over a 12 week (3 month period). When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
16335953|NCT04428554|No Intervention|Control arm|Standard of care
16335954|NCT04428554|Experimental|Experimental arm|
16335955|NCT04428541|Experimental|Questionnaire|Description : 18 items questionnaire, filled by the parents of the child
16335956|NCT04428528||Neoadjuvant Chemotherapy Monitoring|
16335957|NCT04428528||Breast Mass Characterization|
16335958|NCT04428515||Radiotherapy Response Monitoring|
16335959|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
16335960|NCT04428489||Idiopathic cytopenia of undetermined significance (ICUS)|
16335961|NCT04428489||Clonal cytopenia of unknown significance (CCUS)|
16335962|NCT04428476|Other|Open-label arm|Open-label CAP-1002 will be administered to all subjects enrolled in the trial
16335963|NCT04428463|Active Comparator|tympanoplasty using fascia and cartilage|tympanoplasty under general anesthesia using fascia and cartilage witch is the gold standard for treating tympanic membrane perforations.
16335964|NCT04428463|Experimental|Tachosil|repair of tympanic perforations under local anesthesia using Tachosil patch.
16335965|NCT04428450|Experimental|Deprexis (unguided)|web-based self-help program without any support from a therapist during the 10-week treatment period
16335966|NCT04428450|Experimental|Deprexis (guided, with therapist)|web-based self-help program plus scheduled e-mail contact with a therapist during the 10-week treatment period
16335967|NCT04428450|No Intervention|Wait-list|Wait-list group (subjects receive access to Deprexis after 10 weeks)
16335968|NCT04428437||Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by lenvatinib.
16335969|NCT04428437||Non-Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by non-lenvatinib.
16335970|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
16335972|NCT04428398||No renal involvement|Patients with ANCA-vasculitis and no ANCA-associated renal involvement in disease history
16335973|NCT04428398||Renal remission|Patient with ANCA-vasculitis in renal remission
16335974|NCT04428385|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
16335975|NCT04428385|Experimental|Arm 2 (provider-directed intervention)|Providers receive a small payment for each RDT that they perform, RDTs available at study-recommended price
16335976|NCT04428385|Experimental|Arm 3 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
16335977|NCT04428385|Experimental|Arm 4 (consumer-directed and provider-directed in|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
16336474|NCT04424927|Placebo Comparator|Placebo|Placebo, sterile solution for subcutaneous administration
16335978|NCT04428372|Experimental|Mannitol|intravenous 20% mannitol, 0.25g/kg/hour (maximum 25g/hour; maximum 75g per session; maximum volume 375mL/session) as a continuous infusion during dialysis
16335979|NCT04428372|Placebo Comparator|Placebo|0.9% saline at a rate of 1.25mL/kg/hour (maximum volume 375mL) as a continuous infusion during dialysis
16335980|NCT04428359|Experimental|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
16335981|NCT04428359|Experimental|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
16335982|NCT04428346|Active Comparator|Contigency Management (Intervention)|
16335983|NCT04428346|No Intervention|Standard of Care (Control)|
16335984|NCT04428333|Experimental|Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy|
16335985|NCT04428333|Placebo Comparator|Placebo + Pembrolizumab + 5-FU-platinum chemotherapy|
16335986|NCT04428320|Experimental|Bupivicaine pelvic floor muscle injection|Five injections at pre-specified locations at pelvic floor muscle bilaterally after induction of general anesthesia for vaginal pelvic prolapse surgery
16335987|NCT04428320|No Intervention|Standard of care (no injection) preoperatively|No injection - standard analgesia
16335988|NCT04428307|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
16335989|NCT04428307|Experimental|Arm 2 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
16335990|NCT04428307|Experimental|Arm 3 (client-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
16335991|NCT04428281|Experimental|Cohort A1 RO7248824|Participants 5-12 Years
16335992|NCT04428281|Experimental|Cohort A2 RO7248824|Participants 5-12 Years
16335993|NCT04428281|Experimental|Cohort A3 RO7248824|Participants 5-12 Years
16335994|NCT04428281|Experimental|Cohort A4 RO7248824|Participants 5-12 Years
16335995|NCT04428281|Experimental|Cohort A5 RO7248824|Participants 5-12 Years
16335996|NCT04428281|Experimental|Cohort B1 RO7248824|Participants 1-4 Years
16335997|NCT04428281|Experimental|Cohort B2 RO7248824|Participants 1-4 Years
16335998|NCT04428281|Experimental|Cohort B3 RO7248824|Participants 1-4 Years
16335999|NCT04428281|Experimental|Cohort B4 RO7248824|Participants 1-4 Years
16336000|NCT04428281|Experimental|Cohort B5 RO7248824|Participants 1-4 Years
16336001|NCT04428281|Experimental|Cohort B6 RO7248824|Participants 1-4 Years
16336002|NCT04428268|Active Comparator|Chloroquine|Patients will receive chloroquine phosphate 450 mg every 12 hours orally
16336003|NCT04428268|Experimental|Chloroquine plus losartan|Patients will receive Chloroquine phosphate 450mg orally every 12hrs plus Losartan 25mg orally every 12hrs
16336004|NCT04428255|Experimental|HBM9161 Dose A|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
16336005|NCT04428255|Experimental|HBM9161 Dose B|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
16336006|NCT04428255|Placebo Comparator|Placebo|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
16336007|NCT04428242||Group 1|Subjects with normal macular thickness in one or both eyes.
16336008|NCT04428242||Group 2|Subjects with center-involving macular edema due to w/AMD in one or both eyes.
16336009|NCT04428242||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes.
16336010|NCT04428216|Active Comparator|Group RIB = Rhomboid intercostal block group|In group RIB, RIB block will be performed with patients in the lateral decubitus position. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injected into the fascial plane.
16336011|NCT04428216|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16336012|NCT04428203|Experimental|single arm|A Phase I/Ib on the Safety of Epidiolex in Patients with Prostate Cancer with Rising PSA after Localized Therapy with either Surgery or Radiation
16336015|NCT04428177|Experimental|Intrvascular Lithotripsy|Calcified coronary lesions will be treated with intrvascular lithotripsy
16336016|NCT04428177|Active Comparator|Standard therapy|Standard treatment of calcified coronary lesions: cutting, scoring or non-compliant balloon predilatation or rotational atherectomy
16336017|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
16336021|NCT04428138||Patients with Inguinal hernia|Patients presenting with inguinal hernia will undergo vascular in-office visit and echo duplex of aorta, carotid arteries and lower limb arteries in order to detect any abnormalities related to arterial disease (aneurysm, stenosis, flow alteration).
16336022|NCT04428125||Healthy sporty subjects|Healthy sporty subjects that participate in the following sports: baseball, tennis, swimming, rowing, volleyball, rugby football, weightlifting.
16336023|NCT04428125||Healthy non-sporty subjects|Healthy subjects that do not partecipate in sport activities.
16336024|NCT04428112|Experimental|Building Better Caregivers Workshop Group|Building Better Caregivers Workshop is a 6-week online self-management and skills building workshop. Participants receive the online workshop as soon as possible after randomization.
16336025|NCT04428112|Active Comparator|Attention Control Group|Participants will be offered the online workshop after the 12 month trial is completed if they so desire.
16336026|NCT04428099|Experimental|Intervention|Lifestyle change promotion program
16336027|NCT04428099|Active Comparator|Control 1|MBCT program
16336028|NCT04428099|Placebo Comparator|Control 2|Usual care
16336029|NCT04428086|Experimental|Assess PK effects of Apatinib on Rosuvastatin|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.
16336030|NCT04428086|Experimental|Assess PK effects of Apatinib on Metformin|Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.
16336031|NCT04428073|Experimental|Low dose group|Subjects will receive 1.0 mL of low dose vaccine at week 0 and 2.
16336032|NCT04428073|Experimental|High dose group|Subjects will receive 1.0 mL of high dose vaccine at week 0 and 2.
16336033|NCT04428060|Experimental|PERSEUS CPR|Patients will be resuscitated according to the PERSEUS protocol
16336034|NCT04428060|Active Comparator|CONTROL|Patients will be resuscitated according to current Advanced Life Support guidelines
16336035|NCT04428047|Experimental|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
16336036|NCT04428034|Experimental|Learning Skills Together Intervention|Participants in the Learning Skills Together program will begin their participation with a one-on-one phone call with an interventionist, who will ensure the participant is prepared to to attend the group sessions (e.g., familiar with videoconference technology) and will help the participant to set individual goals. The caregiver participant will then attend 4, group-based sessions lasting approximately 1.5 hours each, to learn about common complex care tasks managed by family caregivers to someone with mid-stage Alzheimer's disease, such as managing behavioral symptoms of dementia, incontinence, nutrition, transferring, medication management, and more. Sessions will integrate interactive activities, such as videos, case studies, and discussions. Approximately four weeks later, caregivers will be asked to attend a group reflection session to discuss application of what was learned and progress in meeting individual goals.
16336037|NCT04428021|Active Comparator|Standard therapy protocol (STP)|STP is defined as the best evidence based therapy approved for treatment of COVID-19 patients by Regional Health System emergency committee. STP could be updated during the trial.
16336038|NCT04428021|Experimental|STP + Standard Plasma (SP)|STP + 3 units on day 1-3-5 of Standard Plasma collected in pre-COVID era (January-September 2019)
16336039|NCT04428021|Experimental|STP + COVID-19 Convalescent Plasma (CP)|STP + 3 units on day 1-3-5 of COVID-19 Convalescent Plasma containing neutralizing SARS-Cov-2 antibodies
16336040|NCT04428008|Experimental|Active arm|1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks
16336041|NCT04428008|No Intervention|Control arm|Standard care
16336042|NCT04427995||Oen Angle Glaucoma|• Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.
16336044|NCT04427969||EPP|patients who applied early awake prone position for treatment with conventional oxygen supply
16336045|NCT04427969||non-EPP|patient who only get conventional oxygen therapy as respiratory supply
16336046|NCT04427956|Active Comparator|Isotonic riboflavin|CXL (UVA 9mW/cm2) treatment using isotonic riboflavin
16336047|NCT04427956|Active Comparator|Hypotonic riboflavin|CXL (UVA 9mW/cm2) using hypotonic riboflavin
16336048|NCT04427956|Active Comparator|Iontophoresis|Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).
16336049|NCT04427943||RIKA cohort|patients with periprosthetic knee joint infection scheduled for revision knee arthroplasty surgery
16336050|NCT04427930|Experimental|JOINTSTEM|Long Term Follow-up after Jointstem Transplantation
16336051|NCT04427930|Placebo Comparator|Saline|
16336052|NCT04427917|Experimental|PF-06835919|
16336053|NCT04427917|Placebo Comparator|Placebo|
16336054|NCT04427904|Experimental|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
16336055|NCT04427904|Active Comparator|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
16336056|NCT04427891||Group I|"Patients undergoing emergency surgery due to perforated diverticulitis with peritonitis.
~No intervention, samples from abdominal fluid, blood, tissue, feces"
16336057|NCT04427891||Group II|Patients with colorectal cancer undergoing elective surgery. No intervention. Samples as for Group I
16336058|NCT04427891||Group III|Patients with mild diverticulitis, not undergoing surgery. No intervention. Samples from blood and feces.
16336059|NCT04427878|Experimental|patients with Covid-19|
16336060|NCT04427865|Experimental|Lactoferrin prophylaxis|200 mg oral lactoferrin daily
16336061|NCT04427865|No Intervention|Control group|
16336062|NCT04427852|Experimental|30 day Beef consumption|One serving of beef is consumed each day for 30 days.
16336063|NCT04427852|Placebo Comparator|30 day Veggie Patty consumption|One serving (1 patty) of a vegetable based protein source is consumed each day for 30 days. The weight of the food, total calories, grams of protein, and total fat are the same as the beef serving.
16336064|NCT04427826|Experimental|Patient admitted for acute Exacerbation of Chronic Obstructive|Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and required NIV
16336065|NCT04427800||CKD G4|Chronic kidney disease stage (G4). (eGFR < 30 mL/min/1.73m2)
16336066|NCT04427800||CKD G5|Chronic kidney disease stage (G5). (eGFR < 15 mL/min/1.73m2) with imminent initiation of RRT
16336067|NCT04427800||ESRD on ICHD|End stage renal disease on in centre haemodialysis
16336068|NCT04427800||ESRD on HHD|End stage renal disease on home haemodialysis
16336069|NCT04427800||ESRD on PD|End stage renal disease on peritoneal dialysis
16336070|NCT04427800||Post-transplant|Participants post-transplant
16336071|NCT04427787|Experimental|Cabozantinib+lanreotide|Cabozantinib will be administered orally at a dose of 60 mg/day continuously in combination with Lanreotide 120 mg injection every 28 days. Both treatments will start the same day
16336072|NCT04427774|Experimental|Surufatinib plus Sintilimab|
16336073|NCT04427761||pancreatic cancer health-illness transition|In this prospective longitudinal correlational study, a convenience sample of patients with pancreatic cancer receiving chemotherapy will be asked to report on their health-illness transition experiences and their level of distress.
16336074|NCT04427748||congenital cataract group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and IOL implantation are perfomed ERG
16336075|NCT04427748||age-matched normal children group|age-matched normal children are perfomed ERG
16336076|NCT04427735||before COVID-19|Patients with myocardial infarction from January 24, 2019 to June 24, 2019
16336077|NCT04427735||after COVID-19|Patients with myocardial infarction from January 24, 2020 to June 24, 2020
16336078|NCT04427709|Other|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®) first then placebo injection.
16336079|NCT04427709|Other|Placebo, Then Oxytocin|Subjects in this arm will receive Intramuscular placebo injection first then oxytocin injection
16336080|NCT04427696|Active Comparator|Aerobic walking|The participants in this arm were obligated to carry out one hour aerobic walking (goal setting walking) daily. The goal of aerobic walking: 1. at least 60 steps per minute; 2. continuously walking for 10 minutes.
16336081|NCT04427696|Placebo Comparator|No aerobic walking|The participants in this arm were requested to maintain sedentary life, without joining other physical exercise programmes.
16336082|NCT04427683|Experimental|Brief mindful parenting program|The program will consist of a four-session and last for eight hours integrating mindfulness skills and psychoeducation in managing stress under social unrest and promoting strategies for emotion regulation, conflict management, and self-care.
16336083|NCT04427683|Other|Wait-list control group|A four-minute educational video will be distributed to the participants who accept the randomisation. It includes brief information on mental health. After the participants from experimental group complete the intervention, those in wait-list control group will receive the same intervention.
16336084|NCT04427670|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group.
16336085|NCT04427670|Other|Group intervention|Group intervention will be provided to the experimental group.
16336086|NCT04427657|Active Comparator|Controls|39 patients with knee osteoarthritis undergoing arthroscopic debridement
16336087|NCT04427657|Experimental|Cases|39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
16336088|NCT04427644||Complication positive|Patients with perioeprative complications after laparascopic sleeve gastrectomy before discharge (wound complications, thromboembolic events, staple line leakage, splenic infarction proven by imaging modalities, bleeding detected due to low hemoglobin and hematocrit values during follow-up, acute renal failure due to deterioration in biochemical parameters)
16336089|NCT04427644||Complication negative|Patients without perioeprative complications after laparascopic sleeve gastrectomy before discharge
16336090|NCT04427644||BMI 40 - 45 kg/m2|Operated patients preoperative BMI values between 40 - 45 kg/m2
16336091|NCT04427644||BMI 45 - 50 kg/m2|Operated patients preoperative BMI values between 45 - 50 kg/m2
16336092|NCT04427644||BMI over 50 kg/m2|Operated patients preoperative BMI values 45 - 50 kg/m2
16336093|NCT04427644||Clavien Dindo Major Complications|"Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy This grade also includes wound infections opened at the bedside
~Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included"
16336094|NCT04427644||Clavien Dindo Minor Complciations|3. Requiring surgical, endoscopic or radiological intervention 3a Intervention under regional/local anaesthesia 3b Intervention under general anaesthesia 4. Life-threatening complication requiring intensive care/intensive care unit management 4a Single-organ dysfunction 4b Multi-organ dysfunction 5. Patient demise
16336095|NCT04427631|Experimental|Single arm study|The family will complete questionnaires before and after each childs intervention. Therefore each child will act as their own control.
16336096|NCT04427618|Experimental|Intervention group|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision, and Intravenous oxytocin 5 units post delivery of the baby.
16336097|NCT04427618|Placebo Comparator|Control group|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision, and intravenous oxytocin 5 units post delivery of the baby
16336098|NCT04427605||ketamine group|ketamine intravenous infusion in pediatric patients refractory to conventional analgesic-sedative strategy lasted more than 12 hours (dose range 10-50 mcg/Kg/min)
16336099|NCT04427592|Experimental|pregnant women with placenta accreta spectrum|The participants were subjected to ultrasound to diagnose placenta accreta spectrum followed by new conservative surgical technique.
16336100|NCT04427566|Experimental|Radiation Arm|Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
16336101|NCT04427553|Experimental|Percutaneous Peripheral Nerve Stimulation|"Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve. We will apply a biphasic compensated electrical current at a frequency of 10 Hz, a pulse width of 240 µs and intensity allowed over a pain-free motor threshold (muscle contraction). Each participant will receive 10 repetitions of 10 seconds each one with 10 seconds rest- period between series (total treatment session 1.40 min).
~After that participants will walk during 3 minutes."
16336102|NCT04427553|Placebo Comparator|Control|Participants in the control group will walk during 5 minutes, without receiving any intervention
16336103|NCT04427540|Experimental|Oxytocin|Single IM injection Oxytocin 17 micrograms
16336104|NCT04427527|Experimental|Multi-level Intervention|Receives the project intervention first
16336105|NCT04427527|No Intervention|Delayed Multi-level Intervention|Offered the intervention later in the project
16336106|NCT04427514|Experimental|CAPD group|Standard CAPD therapy wtih telemedicine system
16336107|NCT04427501|Experimental|LY3819253|LY3819253 administered intravenously (IV)
16336108|NCT04427501|Experimental|LY3819253 + LY3832479|LY3819253 + LY3832479 administered IV or subcutaneously (SQ)
16336109|NCT04427501|Placebo Comparator|Placebo|Placebo administered IV
16336112|NCT04427475|Other|pabolizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
16336113|NCT04427475|Other|nafulizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
16336114|NCT04427449|Experimental|Experimental: Single arm 4SCAR-CD44v6 T cells to treat cancer|
16336115|NCT04427436||Patients|Mild Cognitive Impairment (clinical determination)
16336116|NCT04427436||Control|Healthy Elderly
16336117|NCT04427423|Experimental|Positional Distraction plus Stabilization Exercise group|The treatment group will receive positional distraction with stabilization exercises
16336118|NCT04427423|Active Comparator|Stabilization Exercise group|control group will be treated with stabilization exercises only.
16336119|NCT04427410||pregnancy|
16336120|NCT04427410||postpartum|
16336121|NCT04427397|Experimental|Sulcular Bristle Tip Technique (SBTT)|This test group will receive formal instruction on the Sulcular Bristle Tip Technique (SBTT).
16336122|NCT04427397|No Intervention|User manual of the electric toothbrush (DFU)|This control group will be asked to read and use the instructions found in the user manual of the electric toothbrush (DFU). No formal instruction will be provided. The DFU accompany the electric toothbrush regardless of the subject's participation in the research.
16336123|NCT04427384||GammaTile|Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.
16336124|NCT04427371||survivors|Improve or under treatment
16336125|NCT04427371||nonsurvivors|all-cause 28-day mortality
16336126|NCT04427345||Covid19 infection related patients|Patients admitted to COVID wards of the S. Gerardo Hospital of Monza, including Intensive Care wards.
16336127|NCT04427332||Covid19 infection related patients|"All subjects that had access to the nasopharyngeal swabs service of the hospital for the detection of the Sars-CoV-2 virus, both hospitalized and discharged from the hospital and not hospitalized, from mid-May to the end of June 2020, will be consecutively enrolled. It is assumed that 500 people will be recruited."
16336128|NCT04427319|Experimental|Experimental group|Product: β-Alanine Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
16336129|NCT04427319|Placebo Comparator|Placebo group|Product: wheat semolina Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
16336130|NCT04427306|Experimental|Treatment (talimogene laherparepvec)|
16336131|NCT04427293|Experimental|Open Label|All participants will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib 12 mg daily, days 1 through 14, and pembrolizumab 200 mg IV on day 1
16336132|NCT04427267||Health workers|
16336133|NCT04427254|Experimental|Neurological biological samples|
16336134|NCT04427241|Active Comparator|Amantadine plus cerebrolysin|
16336135|NCT04427241|Active Comparator|Amantadine only|
16336136|NCT04427241|Active Comparator|Cerebrolysin only|
16336137|NCT04427228|Experimental|Arm A|
16336138|NCT04427228|Active Comparator|ARM B|
16336139|NCT04427215|Experimental|A - Music Therapy|Two section a week of music therapy
16336140|NCT04427215|Experimental|B - Art Therapy|Two section a week of Art therapy
16336141|NCT04427215|Experimental|C - Dance-Movement Therapy|Two section a week of Dance-Movement Therapy
16336142|NCT04427215|Experimental|D - Bibliotherapy|Two section a week of Bibliotherapy
16336143|NCT04427215|Experimental|E - Physical Activity|Two section a week of systematized physical activity
16336144|NCT04427202|Other|Referral to harm reduction services|Participants will be taken through the study survey and interview, blood and urine toxicology testing and given a referral to a harm reduction organization.
16336145|NCT04427176||Nurses|"Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne will be included.
~They will be wear ARFC mask."
16336146|NCT04427163||Genomic, transcriptomic, proteomic, metabolomic profiles|Determination of genomic, transcriptomic, proteomic, metabolomic profiles in subjects.
16336147|NCT04427150|Experimental|Auditory Training Group|12 hours of psychoacoustic training over 8 weeks
16336148|NCT04427150|Active Comparator|Other Training Group|12 hours of non-psychoacoustic training over 8 weeks
16336149|NCT04427150|No Intervention|TD Group|
16336150|NCT04427137|Experimental|Accelerated LFR|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients that have responded to treatment will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
16336151|NCT04427124||Prospective|Patients admitted into the hospital will receive care based on a multidisciplinary team approach and Institutional critical limb ischemia protocol.
16336152|NCT04427124||Retrospective|A retrospective analysis of all patients with CLI admitted to the hospital from 2017-2019 will serve as a baseline comparator for overall CLI care and long-term mortality out to 2 years will be analyzed in the retrospective cohort using the national death index. Patients will be identified by the following ICD codes: 440.22 (ASVD of extremities with rest pain), 440.23 (ulceration), and 440.24 (gangrene).
16336153|NCT04427111||Mild-moderate OSA patients for MAD treatment|Patients are classified as mild Obstructive Sleep Apnea (OSA) if they have between 5-15 Apnea-Hypopnea Index, moderate if they have between 15-30, and severe if they have >30, as measured by Polysomnography (Epstein LJ, Kristo D, Strollo PJ, et al. 2009). The principal treatment methodology for OSA patients is positive airway pressure. In patients with mild to moderate OSA, oral appliances such as mandibular advancement devices (MAD) is alternately indicated (Ramar K, Dort LC, Katz SG, et al. 2015) The American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al. 2015) recommended titratable-customized MADs for patient comfort and the ability to permit modifications in the amount of mandibular protrusion for treatment efficacy. However, Aarab et al (Aarab G, Lobbezoo F, Hamburger HL, Naeije M. 2010) demonstrated similar therapeutic efficiency of non-titratable-customized MADs in the treatment of OSA
16336154|NCT04427098|Active Comparator|a phase II single-arm interventional prospective study|"Patients included in the interventional study will receive subcutaneous enoxaparin in a single daily dose of:
~60 mg once daily in case of body weight of 45 to 60 kg
~80 mg per day in case of weight from 61 to 100 kg or
~100 mg once daily in case of bodyweight >100 kg
~Enoxaparin will be started on the first day of COVID19 diagnosis and continued for 14 days."
16336155|NCT04427098|Experimental|observational cohort study|Patients included in the observational cohort will will receive standard thrombo-prophylaxis with subcutaneous enoxaparin 40 mg/die
16336156|NCT04427085|Experimental|Obese group|body mass index≥ 30 kg/m2
16336157|NCT04427085|Active Comparator|Non-obese group|BMI < 30 kg/m2
16336158|NCT04427072|Experimental|Capmatinib|400mg of capmatinib tablets, administered orally twice daily
16336159|NCT04427072|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 solution administered by intravenous infusion on Day 1 of every 21-day cycle
16336160|NCT04427059|Experimental|Arm A - laparoscopic assisted TAP block|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (TPA).
16336161|NCT04427059|Active Comparator|Arm B - PSI|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (PSI).
16336162|NCT04427033||CHL & MHL (18 years and older)|CHL= conductive hearing loss MHL= mixed hearing loss
16336163|NCT04427033||CHL & MHL (5 to 17 years)|
16336164|NCT04427033||SSD (5 years and older)|SSD= single sided deaffness
16336165|NCT04427020|Experimental|Milk Protein + Probiotic|25 gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
16336166|NCT04427020|Active Comparator|Milk Protein|25 gram dose of milk protein concentrate
16336167|NCT04427007|Experimental|Experimental Prosthetic Liner|Participants will test the experimental liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
16336168|NCT04427007|Other|Control Prosthetic Liner|Participants will test the control liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
16336169|NCT04426994||Case|Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use
16336170|NCT04426994||Control|Patients on long-term proton pump inhibitor without documented hypomagnesemia
16336171|NCT04426981|Experimental|Intervention arm|Consenting patients will be enrolled into a Behavioral Activation treatment arm. Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities.
16336172|NCT04426968|Experimental|Hepalatide 2.1mg+Pegylated Interferon|
16336173|NCT04426968|Experimental|Hepalatide 4.2mg+Pegylated Interferon|
16336174|NCT04426968|Experimental|Hepalatide 6.3mg+Pegylated Interferon|
16336175|NCT04426968|Active Comparator|placebo+Pegylated Interferon|
16336176|NCT04426955|Experimental|Arm A|Camrelizumb + Paclitaxel + Cisplatin + Radiotherapy.
16336177|NCT04426955|Placebo Comparator|Arm B|Placebo + Paclitaxel + Cisplatin + Radiotherapy.
16336178|NCT04426942||Spontaneous pregnancy|
16336179|NCT04426942||Assisted reproduction pregnancy|
16336183|NCT04426916||normal lumbar spine|Patient without spondylolisthesis or significant spinal anatomic deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
16336184|NCT04426916||spondylolisthesis|Spondylolisthesis patients, with whom the deformity is at just one level. The patients should not have any other significant spinal deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
16336185|NCT04426903|Experimental|LLM Care|LLM Care training Participants use the webFitForAll exergaming computer platform as the physical training component (PT); Participants use the language adapted version of the BrainHQ Program as the cognitive training component (CT)
16336186|NCT04426903|Experimental|Physical Training (PT)|Physical training only. Participants use the webFitForAll exergaming computer platform as the physical training component (PT).
16336187|NCT04426903|Experimental|Cognitive Training (CT)|Cognitive training only. Participants use the language adapted Version of the BrainHQ Program as the cognitive training component (CT).
16336188|NCT04426890|Experimental|Arm 1|300 mg of CT-P39 as SC injections via PFS
16336189|NCT04426890|Active Comparator|Arm 2|300 mg of EU-approved Xolair as SC injections via PFS
16336190|NCT04426890|Experimental|Arm 2-1|300 mg of CT-P39 as SC injections via PFS
16336191|NCT04426890|Active Comparator|Arm 2-2|300 mg of EU-approved Xolair as SC injections via PFS
16336192|NCT04426890|Experimental|Arm 3|"Treatment period 1: 150 mg of CT-P39
~Treatment period 2: 300 mg of CT-P39"
16336193|NCT04426890|Active Comparator|Arm 4|"Treatment period 1: 150 mg of EU-approved Xolair
~Treatment period 2: 300 mg of EU-approved Xolair"
16336194|NCT04426877|Experimental|Experimental group|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
16336195|NCT04426877|Experimental|Control Group|The control group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
16336196|NCT04426864|Active Comparator|Supervised Aerobic Plus Stretching Exercises Group|The participants were instructed to perform the walking exercise at their target HR on a treadmill and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
16336197|NCT04426864|Experimental|Supervised Resistance Plus Stretching Exercises Group|The participants were instructed to perform resistance exercises using weight machines and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
16336198|NCT04426864|Experimental|Home-based Stretching Exercises Group|The participants were instructed to perform the stretching exercises at home.
16336199|NCT04426851|Experimental|Part 2: BI 1358894 (Test 2-Reference 2)|BI 1358894
16336200|NCT04426851|Experimental|Part 2: BI 1358894 (Reference 2-Test 2)|BI 1358894
16336201|NCT04426851|Experimental|Part 1: BI 1358894 (Test 1-Reference 1)|BI 1358894
16336202|NCT04426838|Experimental|PLwD Cognitive Behavioral Therapy for Insomnia (CBTi)|Persons living with dementia in a dyad receiving the CBTi intervention in a videoconferencing format.
16336203|NCT04426838|Experimental|Caregiver Cognitive Behavioral Therapy for Insomnia (CBTi)|Caregivers in a dyad receiving the CBTi intervention in a videoconferencing format.
16336205|NCT04426812||MTurk sample|Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
16336206|NCT04426812||KnowledgePanel|Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
16336207|NCT04426799|No Intervention|Control group|no application
16336208|NCT04426799|Experimental|Experimental group|application is done
16336209|NCT04426786|Active Comparator|Immediate intervention start: active exercise|Immediately starts the six month intervention of active exercise following the baseline scan.
16336210|NCT04426786|Placebo Comparator|Delayed intervention start: passive exercise|Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.
16336211|NCT04426773|Experimental|tDCS treatment|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
16336212|NCT04426760||Women with submucosal leiomyoma(s)|Women with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
16336213|NCT04426760||Women with intramural leiomyomas|Women with intramural leiomyomas undergoing myomectomy
16336214|NCT04426760||Infertility patients|Patients treated at the Department for Reproductive Medicine at the Oslo University hospital failing to conceive after 3 or more embryo transfers with good quality embryos.
16336215|NCT04426760||Fertile women|Healthy, volunteering women with proved fertility with 1 or more deliveries and no history of infertility
16336216|NCT04426734|Experimental|Dextenza|"Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.
~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
16336217|NCT04426734|Active Comparator|Topical Pred Forte 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of
~8x/day week 1 4x/day week 2 2x/day week 3
~1x/day week 4
~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
16336218|NCT04426721|Experimental|Ozone|Participant will receive an intraarticular injection of oxygen-ozone, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
16336219|NCT04426721|Active Comparator|Hyaluronic acid|Participant will receive an intraarticular injection of hyaluronic acid, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
16336220|NCT04426708|Experimental|Mild hepatic impaired subjects (A)|Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
16336221|NCT04426708|Experimental|Moderate hepatic impaired subjects (B)|Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
16336222|NCT04426708|Experimental|Healthy volunteers (C)|Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally
16336223|NCT04426695|Experimental|On Low-Flow Oxygen|Cohort 1 (C1): O2 saturation >93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
16336224|NCT04426695|Experimental|With COVID-19 symptoms but not requiring supplemental O2|Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
16336225|NCT04426695|Experimental|High O2 No Mechanical Ventilation|Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
16336226|NCT04426695|Experimental|On Mechanical Ventilation|Cohort 3 (C3): On mechanical ventilation
16336227|NCT04426682||post-operative urinary incontinents|In patients who have previously had incontinence surgery due to stress incontinence, symptoms may return in the following years, and the patient may reapply with urinary incontinence. The first group will consist of postoperative urinary incontinence recurrent patients. Patients whose urodynamics are reperformed due to recurrence are the study group.
16336228|NCT04426682||without postoperative urinary incontinence|Patients who previously had incontinence surgery due to stress incontinence and who did not have postopertive urinary incontinence but whose urodynamics were repeated during the routine controls will constitute the control group.
16336229|NCT04426669|Experimental|CISH CRISPR TIL / Phase I Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin
16336230|NCT04426669|Experimental|CISH CRISPR TIL / Phase II Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of CISH inactivated TIL
16336231|NCT04426656|No Intervention|Part 2 Standard of Care|Participants will receive written HIV prevention materials including basic facts of PrEP, recommendations for HIV/STIs testing and referrals to local HIV/STIs testing sites and prevention services.
16336232|NCT04426656|Experimental|Part 2 mini-app|In addition to the standard of care, participants in the mini-app arm will have access to the mini-app (i.e. the intervention) during the whole study period.
16336233|NCT04426643|Experimental|mesenchymal stem cells|Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
16336234|NCT04426643|Active Comparator|control|Patients with Urinary incontinence receiving standard treatment
16336235|NCT04426630|Other|mHealth|Heart failure patients enrolled in the mHealth program
16336236|NCT04426617|Experimental|fentanyle|: patients will receive US guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & fentanyl).
16336237|NCT04426617|Experimental|Midazolam|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & midazolam).
16336238|NCT04426617|Placebo Comparator|control|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25%).
16336239|NCT04426604|Experimental|Light induced fluorescence intraoral camera|
16336240|NCT04426604|Experimental|Laser-induced fluorescence device|
16336241|NCT04426604|Active Comparator|Visual-tactile assessment method according to FDI criteria|
16336242|NCT04426591|Experimental|Biotin labeled Red Blood Cells|Participants receiving a transfusion with biotin labeled RBCs. Samples will be taken for 12 weeks after the biotinylated transfusion. During this time participants will continue to receive regular monthly transfusions (non-biotinylated) as part of CTT.
16336243|NCT04426578|Experimental|Perhexiline|
16336244|NCT04426578|Placebo Comparator|Placebo|
16336245|NCT04426565|Other|the motivational enhancement interview|The motivational enhancement interview is a counseling approach developed in part by clinical psychologists William R. Miller and Stephen Rollnick. It is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
16336246|NCT04426565|Other|the individual psychotherapy|The individual psychotherapy is the use of psychological methods, particularly when based on regular personal interaction with adults, to help a person change behavior and overcome problems in desired ways. Psychotherapy aims to improve an individual's well-being and mental health, to resolve or mitigate troublesome behaviors, beliefs, compulsions, thoughts, or emotions, and to improve relationships and social skills.
16336247|NCT04426565|Other|the group psychotherapy|The group psychotherapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including Art therapy, cognitive behavioural therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilised as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.
16336248|NCT04426565|Other|the family therapy|The family therapy is is a branch of psychotherapy that works with families and couples in intimate relationships to nurture change and development. It tends to view change in terms of the systems of interaction between family members.
16336249|NCT04426552|Experimental|Dexmedetomidine|have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
16336250|NCT04426552|Active Comparator|Sevoflurane|(sevoflurane) will be preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
16336251|NCT04426539||Amyloid PET-Positive|Those for whom a beta amyloid PET scan is consistent with underlying AD as causing or contributing to cognitive impairment
16336252|NCT04426539||Amyloid PET-Negative|Those for whom a beta amyloid PET scan has ruled out AD (i.e. not consistent with underlying AD as causing or contributing to cognitive impairment)
16336253|NCT04426526|Experimental|Biceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of biceps brachii.
16336254|NCT04426526|Experimental|Triceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of triceps brachii.
16336255|NCT04426526|Experimental|Lower limb circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of muscles in lower limbs.
16336256|NCT04426526|Experimental|Oblique muscles toning|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of oblique muscles.
16336257|NCT04426513|Active Comparator|Only kinesiotherapy|Patients have only kinesiotherapy of hand without steroid anti-inflammatory drugs and magnetotherapy.
16336258|NCT04426513|Experimental|Kinesiotherapy with bipolar magnetic field|Patients have kinesiotherapy of hand and bipolar magnetic field. All patients without steroid anti-inflammatory drugs.
16336259|NCT04426513|Experimental|Kinesiotherapy with unipolar magnetic field|Patients have kinesiotherapy of hand and unipolar magnetic field. All patients without steroid anti-inflammatory drugs.
16336260|NCT04426500|Placebo Comparator|Placebo/Local Anesthesia|Direct injection of 0.25% bupivacaine into surgical wounds
16336261|NCT04426500|Active Comparator|Ultrasound-guided transversus abdominus plane (UTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
16336262|NCT04426500|Experimental|Laparoscopic-guided transversus abdominus plane (LTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using laparoscopic guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
16336263|NCT04426487|Placebo Comparator|Control|Receiving conventional management for traumatic subarachinoid hemorrhage
16336264|NCT04426487|Active Comparator|progesterone group|Intramusculer progesterone therapy before and after craniotomy
16336265|NCT04426474|Experimental|LY3502970|LY3502970 administered orally.
16336266|NCT04426474|Placebo Comparator|Placebo|Placebo administered orally.
16336270|NCT04426448|Experimental|Intervention group|Participants will receive the BREATHE intervention for three weeks
16336271|NCT04426448|No Intervention|Control group|The participants will receive treatment as usual
16336272|NCT04426435|Experimental|Intervention|Group A: patients receiving HB syrup, 10 cc three times daily
16336273|NCT04426435|Placebo Comparator|Placebo|Group B: patients receiving placebo, 10 cc three times daily
16336274|NCT04426422|Experimental|metformin group|all the patients were treated with metformin 1500-2000mg daily for 3 months.
16336275|NCT04426409|No Intervention|control group|
16336276|NCT04426409|Experimental|ointment group|Ointment group should apply a nasal ointment to both noses using a cotton swab the night before surgery and the morning of surgery.
16336277|NCT04426370||Case|100 rheumatoid arthritis patients (age from 20 to 70 years)
16336278|NCT04426370||Control|95 healthy volunteer
16336279|NCT04426357|Experimental|Group 1 (Participants with Renal impairment): JNJ-64417184|Participants with varying degrees of impaired renal impairment function (moderate renal impairment [optional], severe renal impairment, and end stage renal disease [ESRD] not requiring hemodialysis) will be enrolled and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
16336280|NCT04426357|Active Comparator|Group 2 (Healthy Participants): Control Group|Participants with normal renal function will be enrolled in controlled group and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
16336281|NCT04426344|Experimental|Group A - core warming|Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).
16336282|NCT04426344|No Intervention|Group B - Control Group|Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature < 36°C) or antipyretic therapy for febrile patients, as requested by the treating physician.
16336283|NCT04426331|No Intervention|No Voucher|"Individuals being referred from screening events randomized to no intervention received the standard approach to offering free follow-up examinations (patient education, standard counseling, appointment information packet, reminder phone calls)."
16336284|NCT04426331|Experimental|Voucher Without Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher Without Value Information received a personal voucher."
16336285|NCT04426331|Experimental|Voucher With Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher With Value Information received a personal voucher, which differed from the voucher in the second arm since it included a statement of value."
16336286|NCT04426318|Experimental|Healthy Minds Program Foundations Training|"Healthy Minds Program (HMP) Description:
~The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Richard Davidson, PhD. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose."
16336287|NCT04426318|No Intervention|Wait-list control|Participants assigned to the wait-list control will not receive treatment for the intervention and follow-up period. They will be provided access to the HMP Foundations training after completing follow-up testing.
16336288|NCT04426305|Experimental|Intervention arm|psychosocial support
16336289|NCT04426305|Active Comparator|control arm|care as usual
16336290|NCT04426292|Other|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
16336291|NCT04426279||patient with chronic inflammatory rheumatism|
16336292|NCT04426240|Active Comparator|Cyclosporine|Subject who use cyclosporine and hyaluronate artificial tear 1 month before cataract surgery
16336293|NCT04426240|No Intervention|non-Cyclosporine|Subject who use only hyaluronate eye drop 1 month before cataract surgery
16336363|NCT04425733|Placebo Comparator|Panel B Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
16336294|NCT04426227|Experimental|Group Gaze|The gaze-trained group will be shown a video, derived from the eye tracker, of an expert's visual control whilst performing the ultrasound task. Participants will be made aware of the target-focused gaze strategy (lengthy and stable fixations on the needling target), and the manner in which the gaze shifted from target to tools (hands, needle and transducer) in a fast, smooth fashion. They will then be advised to try to mimic the gaze strategy of the expert while undertaking the needling task as their first training task. After completion of this training task, participants will be shown their own video data, as captured by the eye tracker. Participants will be asked to comment on differences between their own video and the expert video they had previously seen. This feedback process will be replicated a further four training task attempts. Participants in this group will therefore undergo a total of five training attempts of the needling task.
16336295|NCT04426227|Active Comparator|Group Discovery|The discovery learning group will be given no video feedback and will be instructed to perform five training attempts at the needling task without further training or feedback.
16336296|NCT04426214|Experimental|Active tDCS|
16336297|NCT04426214|Placebo Comparator|Sham tDCS|
16336298|NCT04426201|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
16336299|NCT04426201|Placebo Comparator|Saline control|Intramuscular (IM) placebo (normal saline) at the same frequency
16336300|NCT04426188|Sham Comparator|Without mouthguard|Heading series without mouthguard from machine-projected soccer balls at standardized speeds
16336301|NCT04426188|Experimental|With mouthguard|Heading series with mouthguard from machine-projected soccer balls at standardized speeds
16336302|NCT04426175|Experimental|2D LASIK|With the 2D method, the flap resection is created in a planar mode (xy-plane), without vertical cut, at the requested depth.
16336303|NCT04426175|Experimental|3D LASIK|With the 3D method, the flap resection is done in a three-dimensional mode, at the requested depth, with the requested diameter and the desired border (side cut) angle
16336304|NCT04426162|Experimental|Memory Boot Camp Participants|All subjects undergo a 12-week control period, followed by a multi-domain 12-week memory program.
16336305|NCT04426149|Experimental|interventional|supplement: trehalose
16336306|NCT04426136||1. WLE group|patients in this group receiving WLE merely
16336307|NCT04426136||2. other method group|patients in this group receiving any other surgical procedures except WLE
16336308|NCT04426123|Active Comparator|Botulinum toxin|Botulinum toxin type A
16336309|NCT04426123|Placebo Comparator|Saline solution|NaCl
16336312|NCT04426097|Experimental|Cervical Vagal Blockade|
16336313|NCT04426097|Placebo Comparator|Without Blockade|
16336314|NCT04426071||SCI, brain injury, stroke Participants|Those 18 years of age and older, diagnosed with a stroke, spinal cord injury (traumatic and non-traumatic), or acquired brain injury (of all severities, including concussion) living in the community will be included. Additionally, only those the cognitive capacity to understand and complete the measures will be included. Those who consent will complete an online survey on enrollment into the study, and subsequently at 3 and 6 months.
16336315|NCT04426058|Experimental|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
16336316|NCT04426058|Active Comparator|Fascia iliaca|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
16336317|NCT04426045|Experimental|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
16336318|NCT04426045|Active Comparator|Supra-inguinal fascia iliaca compartment block|Participants receiving supra-inguinal fascia iliaca compartment block
16336319|NCT04426032||Patients with RRI between 0.6 and 0.7|Normal renal resistive index
16336320|NCT04426032||Patients with RRI more than 0.7|High renal resistive index
16336321|NCT04426019|Experimental|CLS intervention|
16336322|NCT04426019|Active Comparator|No CLS intervention|
16336323|NCT04426006|Other|PRO-SERO-COV|Blood sample and self-administered questionnaire
16336324|NCT04425993|Experimental|Rectal indomethacin and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.
~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
16336325|NCT04425993|Active Comparator|Rectal indomethacin and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.
~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
16336326|NCT04425993|Active Comparator|Rectal placebo and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.
~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
16336327|NCT04425993|Placebo Comparator|Rectal placebo and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.
~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
16336328|NCT04425980|Experimental|Modified Constraint-Induced Movement Therapy (test treatments)|A list of fine and motor activities consisted of the functional tasks or play activities such as school-education and sports activities, manipulative games, arts, and crafts, etc. to elicit the maximum capacity of the more affected upper limb was created according to the procedure of modified constraint-induced movement therapy (Gordon et al., 2005) and Bimanual training. In addition, specific activities were also chosen in terms of deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request. In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook a role as a dominant hand
16336364|NCT04425733|Experimental|Panel C MK-5475 ≤360 µg|Participants receive ≤360 µg of MK-5475 QD via inhalation from Days 1-7.
16336365|NCT04425733|Placebo Comparator|Panel C Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
16336329|NCT04425980|Active Comparator|Bimanual training|For the Bimanual training, skilled, repetitive, and structured bimanual activities (part or whole task practice) were used to promote bimanual hand use and improve movement deficits determined before the intervention. All targeted deficits of interest were addressed within the context of the selected activity. Specifically, symmetrical bilateral movements were utilized to augment neural input from both sides. Also, meaningful activities such as buttoning and zipping-up trousers, etc. were used to ensure a transition from structured setting to real-life activities
16336330|NCT04425967|Active Comparator|25x2Gy|the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week OTT
16336331|NCT04425967|Experimental|14x3Gy|the study schedule of 14 x 3 Gy, once daily fractionation in a three-week overall treatment time
16336332|NCT04425928|Active Comparator|activity group|Participants received an activity-based home program that was performed for 4 weeks.
16336333|NCT04425928|Experimental|exercise group|Participants received an exercise-based home program was performed that was performed for 4 weeks.
16336334|NCT04425928|No Intervention|control group|No intervention
16336335|NCT04425915|Experimental|Convalescent Plasma with Standard of Care|Two doses of 250 ml Convalescent plasma from recovered COVID-19 patients + Standard of Care will be given to severely sick COVID-19 patients in the treatment arm
16336336|NCT04425915|Active Comparator|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
16336337|NCT04425902|Experimental|Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254|Participants will be administered a single dose of probe substrate drugs: caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg (2.5 milliliter [mL]), digoxin 0.25 mg, and pravastatin 40 mg on Day 1; followed by washout of 10 days. On Days 11 to 20, participants will be administered once daily doses of GSK3640254 200 mg followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.
16336338|NCT04425889||exposed Healthcare workers|Healthcare workers working for 8 weeks in a COVID-19 area
16336339|NCT04425876|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib combined with FOLFIRINOX followed by maintenance Fluzoparib monotherapy
16336340|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
16336341|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
16336342|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
16336343|NCT04425850||IVER+|Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
16336344|NCT04425850||IVER-|Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
16336345|NCT04425837|Active Comparator|Standard care alone|
16336346|NCT04425837|Experimental|SARS-CoV-2 convalescent plasma treatment plus standard care|
16336347|NCT04425824|Experimental|Toripalimab combine with Rituximab|"Experimental: Toripalimab combine with Rituximab
~Induction period:
~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.
~Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.
~Maintenance:
~Toripalimab 240mg administered intravenously (IV) and Rituximab 375mg/m² on Day 1 of each 56-day cycle for 6 cycles."
16336348|NCT04425811|No Intervention|No tape applied|Walking parameters were evaluated without any intervention.
16336349|NCT04425811|Experimental|Kinesiological Tape|Walking parameters were evaluated after kinesiological taping on the tibialis anterior muscle
16336350|NCT04425811|Sham Comparator|Sham taping|Walking parameters were evaluated after sham taping on the tibialis anterior muscle
16336351|NCT04425798||Patients with LEV application|LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
16336352|NCT04425798||Patients without LEV application|LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
16336353|NCT04425785|Experimental|Physical Exercise Group|A structured exercise program for 12 weeks
16336354|NCT04425785|Experimental|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy for 12 weeks
16336355|NCT04425785|No Intervention|Standard Clinical Care|Standard Clinical Care
16336356|NCT04425772|Experimental|Experimental Group|FNC+Standard of Care
16336357|NCT04425772|Placebo Comparator|Control Group|FNC dummy tablet+ Standard of Care
16336358|NCT04425746|Experimental|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
16336359|NCT04425746|Placebo Comparator|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
16336360|NCT04425733|Experimental|Panel A MK-5475 180 µg|Participants receive 180 µg of MK-5475 once daily (QD) via inhalation from Days 1-7.
16336361|NCT04425733|Placebo Comparator|Panel A Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
16336362|NCT04425733|Experimental|Panel B MK-5475 360 µg|Participants receive 360 µg of MK-5475 QD via inhalation from Days 1-7.
16336368|NCT04425707|Experimental|A ivermectin alone|ivermectin will be administarted alone to COVID 19 patients
16336369|NCT04425707|Experimental|B standard care alone|standard care will be administarted alone
16336370|NCT04425707|Active Comparator|C ivermectin added to standard of care|ivermectin will be administarted in adition to standard care
16336371|NCT04425694||F3B ward staff|The e-EWS system will be implemented in a selected surgical ward (F3B ward) in Tuen Mun Hospital. All F3B ward staff will use the system and evaluate its effectiveness.
16336372|NCT04425681|Experimental|Osimertinib With Bevacizumab group|Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
16336373|NCT04425668|Active Comparator|Control Group|
16336374|NCT04425668|Experimental|Academic detailing intervention|
16336375|NCT04425655|Experimental|Fludarabine and CPX351|"Induction 1:
~Fludarabine 30 mg/m2/day IV on days 1-5 for 5 doses Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3, 5 (given 4 hours after fludarabine infusion) for 3 doses
~Induction 2 (residual leukemia after Induction 1):
~Fludarabine 30 mg/m2/day IV on days 1-3 for 3 doses
~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3 (given 4 hours after fludarabine infusion) for 2 doses
~Optional consolidation, up to 2 cycles:
~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 29 mg/m2/day and cytarabine 65 mg/m2/day IV on days 1, 3 for 2 doses"
16336376|NCT04425642|Experimental|Glucose/Amino acids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose and amino acids according age and weight
16336377|NCT04425642|Experimental|Glucose/Amino acids/Lipids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose, amino acids and lipid emulsions according age and weight
16336378|NCT04425629|Experimental|casirivimab+imdevimab low dose|Low dose or body-weight equivalent for those under 18 years of age.
16336379|NCT04425616|Experimental|Universal Interventions|"The delivery of nutrition, exercise and psychological interventions delivered in the following structure:
~Month 1: Up to three times per week
~Months 2-3: Once per week
~Months 4 - 6: One session per month for the last 3 months"
16336380|NCT04425590|Experimental|Experimental Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
16336381|NCT04425590|Active Comparator|Control Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
16336382|NCT04425577|Other|Transabdominal Ultrasound|All patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
16336383|NCT04425564|Active Comparator|Classic (A)|patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)
16336384|NCT04425564|Experimental|metronomic (B)|patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.
16336385|NCT04425551|Active Comparator|Treated|"The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias.
~The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn.
~After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes."
16336386|NCT04425551|No Intervention|Untreated|The lateral eye was observed as control.
16336387|NCT04425538|Experimental|Infliximab|All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
16336388|NCT04425512|Active Comparator|Thyroid Malignancy|Thyroidectomy
16336389|NCT04425512|Sham Comparator|Benign Thyroidal Goitor|Thyroidectomy
16336390|NCT04425512|Other|Control Group|Selective lichtenstein procedure for inguinal hernia
16336391|NCT04425499|Placebo Comparator|Control group|On GEN (Gamified Educational Network), each student will view individually eight videos of an expert performing a running subcuticular suture correctly. The OSATS (Objective Structured Assessment of Technical Skills) Global Rating Scale (GRS) and Subcuticular Suture Checklist will be available beside each video and students will be required to fill them out for each video. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, students will view the same eight videos of an expert performing a running subcuticular suture, however, the videos will be shuffled in a different order. The order of the videos will be the same for all students.
16336392|NCT04425499|Experimental|Self-learning|Each student will view eight videos individually and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. The errors will be technical mistakes in the execution of a running subcuticular suture. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, all students will repeat this activity. However, the same videos will be shuffled in a different order. The order of the videos will be the same for all students.
16336393|NCT04425499|Experimental|Peer-learning|Each student will view eight videos and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. After this initial test, students will interact with other medical students in their group on the GEN platform anonymously for three days. We will display distinct videos on GEN. Comments will be allowed in an interactive way to encourage exchanges. Students will be required to participate in the discussion of at least two videos. Students will not be able to modify their answers on the initial test. On the third day, students in this group will perform a post-test individually with the same eight initial videos but shuffled. The order of the videos will be the same for all students.
16336394|NCT04425499|Experimental|Peer-learning with expert feedback|"Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name expert will be used. The expert will answer any question and comment on the discussion in order to guide the students."
16336395|NCT04425473|Experimental|Esketamine|
16336396|NCT04425473|Placebo Comparator|Placebo|
16336397|NCT04425460|Experimental|Favipiravir|Favipiravir Tablets, 200 mg/tablet Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
16336398|NCT04425460|Placebo Comparator|Placebo|Placebo control group Favipiravir combined with supportive care recommended in the current National/Local guidelines
16336399|NCT04425447|Active Comparator|Group C|30 patients will receive bilateral tumescent local anesthesia as a control group
16336400|NCT04425447|Experimental|Group TPVB|30 patients will receive bilateral US guided thoracic paravertebral block.
16336401|NCT04425447|Experimental|Group TIPB|30 patients will receive bilateral US guided thoracic interfascial plane block
16336402|NCT04425408|Experimental|Positional pillow followed by vibrating belt|26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
16336403|NCT04425408|Experimental|Vibrating belt followed by positional pillow|26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
16336404|NCT04425395|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while producing vocalisations. Produced vocalisations will be audio recorded and physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
16336405|NCT04425382||Darunavir/Cobicistat|Patients received Darunavir/Cobicistat (Rezolsta®) as part of the treatment regimen for COVID-19 pneumonia
16336406|NCT04425382||Lopinavir/Ritonavir|Patient received Lopinavir/Ritonavir (Kaletra®) as part of the treatment regimen for COVID-19 pneumonia
16336407|NCT04425369|No Intervention|inner side approaches for iliac crest bone graft|An anterior approach was used to expose the inner table of the ilium.
16336408|NCT04425369|Experimental|two-sided approaches for iliac crest bone graft|both sides of the ilium were totally exposed of the ilium.
16336409|NCT04425356|Experimental|Intervention Group|This group will receive the LifeXT program
16336410|NCT04425356|No Intervention|Control Group|Wait-list control group that receives the LifeXT program after the conclusion of the study
16336411|NCT04425343|Experimental|Periodontitis, Adult|Plaque samples were taken from subgingival pocket and send to the lab for metagenomic analysis
16336412|NCT04425343|Experimental|Metgenomic analysis|Analysis for whole bacterial count
16336413|NCT04425330|Experimental|physiotherapy exercises + PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.
~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The irradiation will be with LED with a wavelength of 850 nm, energy per point of 25 J, 50 seconds per point and power of 200 mW.
~Treatment will be performed in 24 sessions 2 times a week"
16336414|NCT04425330|Sham Comparator|physiotherapy exercises + SHAM PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.
~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The same LED device will be used in groups. However, in the placebo group (Sham), the device does not emit light.
~Treatment will be performed in 24 sessions 2 times a week"
16336415|NCT04425317|Other|Diagnostic arm|Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
16336416|NCT04425304|Active Comparator|Group counseling|
16336417|NCT04425304|Experimental|Group counseling + persuasive ICT support|
16336418|NCT04425304|Active Comparator|Intensive group counseling|
16336419|NCT04425304|Experimental|Intensive group counseling + persuasive ICT support|
16336420|NCT04425291|Experimental|4-valent HPV Vaccine|Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)
16336421|NCT04425291|Experimental|9-valent HPV Vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
16336422|NCT04425291|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
16336423|NCT04425278|Active Comparator|Real Stimulation|The Real Stimulation of tDCS lasted 20 mins.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
16336424|NCT04425278|Sham Comparator|Sham Stimulation|The Sham Stimulation of tDCS lasted 20 minutes with no current. In particular, the current went up for the first 30 seconds and went down for the last 30 seconds.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
16336425|NCT04425278|No Intervention|Control|Behavior and ERPs dataset should be acquired before and after 14 days.
16336426|NCT04425265|Experimental|Plasma radiofrequency ablation arm|Plasma radiofrequency ablation at low temperature for localized recurrent nasopharyngeal carcinoma
16336427|NCT04425265|Active Comparator|Electrocautery block resection arm|Electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma
16336428|NCT04425252|Other|Standard of Care|Subjects are hospitalized for COVID-19 and will receive all supportive/interventional care per institutional guidelines.
16336429|NCT04425252|Experimental|Brequinar|Subjects will receive standard of care plus brequinar 100 mg daily (Study Days 1-5).
16336430|NCT04425239|Active Comparator|CONTINUOUS ARM:|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal.
16336431|NCT04425239|Experimental|INTERMITTENT ARM:|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
16336432|NCT04425226|Experimental|Pembrolizumab plus Lenvatinib|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle. Number of cycles: until >42 days before liver transplantation or unacceptable toxicity develops. Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation.
16336433|NCT04425226|No Intervention|Comparator|Participants are advised to stay as healthy as possible and wait regularly
16336434|NCT04425213||Normal weight|BMI < 25 kg/m2
16336435|NCT04425213||Overweight|BMI : 25 - 29.9 kg/m2
16336436|NCT04425213||Moderate obesity|BMI : 30 - 39.9 kg/m2
16336437|NCT04425213||Severe obesity|BMI : > or = 40 kg/m2
16336438|NCT04425187|Active Comparator|gefitinib|
16336439|NCT04425187|Experimental|gefitinib&bevacizumab|
16336440|NCT04425174||QL|QL = 30 patients representing the case group receiving QL block.
16336441|NCT04425174||EP|EP = 30 patients representing the control group receiving epidural anesthesia.
16336442|NCT04425161||VO2 ≥15 %|This group is classified based on increased oxygen consumption (VO2) ≥15 % by volume expansion in fluid responders
16336443|NCT04425161||VO2 <15 %|This group is classified based on increased oxygen consumption (VO2) < 15 % by volume expansion in fluid responders
16336444|NCT04425148|Experimental|tACS|40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
16336445|NCT04425148|Sham Comparator|Sham tACS|Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
16336446|NCT04425135|Experimental|Camrelizumab +apatinib mesylate+Pemetrixed + Carboplatin|Camrelizumab combined with apatinib mesylate,Pemetrixed and Carboplatin in the treatment（4-6 cycle）of effective (CR, PR, SD) patients continued to be treated with Camrelizumab combined with apadine mesylate until PD, toxicity intolerance, and other reasons that the researcher thinks need to stop the research treatment.
16336447|NCT04425122||Esophageal cancer|Patients with esophageal cancer (SCC)
16336448|NCT04425122||Non-cancer group|Non-cancer patients scheduled for upper endoscopy
16336449|NCT04425109|Experimental|tempeh steak|The subjects were received the tempeh steak meal with isocal diet containing energy 307.4Kcal
16336450|NCT04425109|Experimental|soybean steak|The subjects were received the soybean steak meal with isocal diet containing energy 307.4Kcal
16336451|NCT04425096|Experimental|Skin to skin contact|The mothers and their babies in the experimental group received a 30-minute skin to skin contact immediately after birth (n:32)
16336452|NCT04425096|No Intervention|Routine care|The babies in the control group received routine care (n:32)
16336453|NCT04425083||Polycystic Ovary Syndrome|Polycystic Ovary Syndrome women
16336454|NCT04425083||control|non- Polycystic Ovary Syndrome women
16336455|NCT04425070|Experimental|ATG-010 + ICE|ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11
16336456|NCT04425070|Experimental|ATG-010 + GEMOX|ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9
16336457|NCT04425057|Experimental|Interval training|Physiotherapy program during two months: Interval training at a high intensity, inlcuding a warm-up and a cool-down. Aerobic exercises, resistance exercises, stretching
16336458|NCT04425057|No Intervention|Control group|No physiotherapy
16336459|NCT04425044||AiM Covid|Self Monitoring of symptoms in AiM Covid App
16336460|NCT04425031|Experimental|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
16336461|NCT04425031|Active Comparator|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
16336462|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Margetuximab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days
~Paclitaxel- via IV, Day 1,8,15 of each cycle
~Margetuximab via IV, Day 1 of each cycle
~Pertuzumab via IV, Day 1 of each cycle"
16336463|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Trastuzumab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days
~Paclitaxel- via IV, Day 1,8,15 of each cycle
~Pertuzumab via IV, Day 1 of each cycle
~Trastuzumab via IV, Day 1 of each cycle"
16336464|NCT04425005|No Intervention|Control group|
16336465|NCT04425005|Experimental|Exercise training group|
16336466|NCT04424992||Covid19 infection related patients|The patients enrolled in the study are all patients with clinical and microbiological diagnosis of COVID-19 infection hospitalized since February 23, 2020 at San Gerardo Hospital (ASST-Monza).
16336467|NCT04424979|Experimental|High power prisms|Various configurations of high power prisms will be developed for each individual and custom fit into spectacles lenses.
16336468|NCT04424966|Experimental|Arm 1|"Phase 0: 125 mg of infigratinib administered orally for 7 days prior to surgical resection.
~Expansion Cohort: 125 mg of infigratinib administered orally for 21 days of a 28-day treatment cycles."
16336469|NCT04424953|Active Comparator|McGrath videolaryngoscope|Anesthetists randomized to this group will intubate patients using the McGrath videolaryngoscope
16336470|NCT04424953|Active Comparator|Direct laryngoscope|Anesthetists randomized to this group will intubate patients using the direct laryngoscope
16336471|NCT04424927|Experimental|PRV-015 Low Dose|PRV-015 Low Dose, sterile solution for subcutaneous administration
16336472|NCT04424927|Experimental|PRV-015 Medium Dose|PRV-015 Medium Dose, sterile solution for subcutaneous administration
16336473|NCT04424927|Experimental|PRV-015 High Dose|PRV-015 High Dose, sterile solution for subcutaneous administration
16336477|NCT04424901|No Intervention|Standard Care|"Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.
~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.
~Data collection ends on day 9."
16336478|NCT04424901|Experimental|Standard Care with Dipyridamole|"For this arm, Dipyridamole 100 mg, tid is given for 7 days. Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.
~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.
~Data collection ends on day 9."
16336479|NCT04424888|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 2 weeks
16336480|NCT04424888|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 2 weeks
16336481|NCT04424875|Experimental|study arm|patients will undergo surgery to remove impacted lower third molar and receive Melatonin (3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%) in the socket following removal of the impacted third molar
16336482|NCT04424875|Placebo Comparator|controlled arm|patients will undergo surgery to remove impacted lower third molar and patients will receive no melatonin (2 ml of hydroxyethyl cellulose gel 2 %).
16336483|NCT04424862|Experimental|Multitarget Therapy|The combined therapy with prednisone, ciclosporin and mycophenolate mofetil.
16336484|NCT04424862|Active Comparator|Control|Ponticelli Regimen
16336485|NCT04424849||COVID-19 patients|Patient tested positive for COVID-19 who had a CT scan
16336486|NCT04424836||H GROUP|patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.
16336487|NCT04424836||C GROUP|patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.
16336488|NCT04424823|Experimental|LED|LED photobiomodulation therapy for the non-specific LBP working nurse
16336489|NCT04424823|Sham Comparator|Sham|Shame group. The all procedure was same as the LED group but the LED ped was upside down without direct treatment.
16336490|NCT04424810|Experimental|Video group|Patients selected to be in the intervention group will be asked to watch a high-quality, physician created video describing their condition and the operative treatment they are about to undergo.
16336491|NCT04424810|Placebo Comparator|Control group|Patients selected to be in the control group will not be asked to watch a video prior to surgery.
16336492|NCT04424797|Experimental|Prone Positioning|Prone positioning
16336493|NCT04424797|Other|Supine Positioning|Supine Positioning
16336494|NCT04424784|No Intervention|20% O2|In the control group, oocyte pickup will be performed in atmospheric oxygen environment (20% oxygen, 89% nitrogen, 6% carbon dioxide).
16336495|NCT04424784|Experimental|5% O2|In the experimental group, oocyte pickup will be performed in a low oxygen tension environment (5% oxygen, 89% nitrogen, 6% carbon dioxide). If time lapse embryo culture system is used, fertilization check and embryo grading will also be conducted under the low oxygen tension environment.
16336496|NCT04424771||Health workers|They include doctors, nurses, techinicians, biologists and other non technical inhospital workers
16336497|NCT04424758|Experimental|Intervention group|Receives information about mammography screening through a video. The video was developed with the goal of informing about mammography screening in a societal perspective using best available evidence.
16336498|NCT04424758|Placebo Comparator|Control group|Receives information about energy systems through a video. The video does not contain any information related to mammography screening.
16336499|NCT04424745|Active Comparator|Attention Bias Modification Training with real tDCS|
16336500|NCT04424745|Placebo Comparator|Attention Bias Modification Training with sham tDCS|
16336501|NCT04424732|Other|Stereotactic Body Radiotherapy for Breast Bony oligometastases|Newly diagnosed bone only oligometastatic breast cancers with 1-3 bone metastases will be enrolled in this protocol. Patients will receive SBRT to all metastatic sites.
16336502|NCT04424719|Other|Patients with uveal melanoma|
16336503|NCT04424706||Normal people|No diabetes and atherosclerosis
16336504|NCT04424706||type 2 diabetes mellitus without atherosclerosis|Newly diagnosed type 2 diabetes without atherosclerosis
16336505|NCT04424706||type 2 diabetes mellitus with atherosclerosis|Newly diagnosed type 2 diabetes with atherosclerosis
16336506|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 28|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 28 will receive a placebo injection at week 36. Subject will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
16336507|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 36|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 36 will receive a placebo injection at week 28. Subjects will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
16336508|NCT04424680|No Intervention|Control|"Patients will be followed in heart failure outpatients units according to the usual established protocol. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.
~Treatment for heart failure will be the same in both groups."
16336509|NCT04424680|Experimental|Intervention|"Patients will participate in the Advanced Care Planning Program. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.
~Treatment for heart failure will be the same in both groups."
16336510|NCT04424667|Active Comparator|Holder pasteurization|Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
16336511|NCT04424667|Experimental|HTST pasteurization|Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
16336512|NCT04424654|Experimental|Bipolar Androgen Therapy (BAT)|Testosterone cypionate 400 mg IM every 28 days for 3 cycles
16336514|NCT04424628|Active Comparator|Radiotherapy 3 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days).
~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again"
16336515|NCT04424628|Active Comparator|Radiotherapy 6 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days).
~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again"
16336516|NCT04424602|Experimental|cyclophosphamide|participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
16336517|NCT04424602|Active Comparator|mycophenolate|participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
16336518|NCT04424589|Experimental|Myofascial release|"Myofascial release or induction (MFR) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. Manual therapists often use their hands using their knuckles, elbows, or other instrumental tools to slowly penetrate the layers of the fascia, using applied pressure with a few kilograms of force that can strain the restricted fascia, this implies a guided gentle stretch.
~The experimental group will receive 1 examination session and 6 myofascial release sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for the spinal at the level of the quadratus lumborum, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks."
16336519|NCT04424589|Sham Comparator|Sham Therapy|The control group will receive 1 examination session and 6 simulated myofascial releasesessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial release, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
16336520|NCT04424576||Regular Menstrual Cycles|22 adolescents with regular menstrual cycles (i.e., once every 4-6 weeks) will be enrolled within 11 months of menarche.
16336521|NCT04424576||Irregular Menstrual Cycles|26 adolescents with irregular menstrual cycles (i.e., < 4 weeks or > 6 weeks between periods) will be enrolled within 11 months of menarche.
16336522|NCT04424563||Group A|Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
16336523|NCT04424563||Group B|While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
16336524|NCT04424537|Placebo Comparator|Control|"A control group will consume 2 meal replacement beverages(MRBs) made with whey protein
~The control diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.
~No overall calorie reduction will be implemented for any group.
~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.
~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
16336525|NCT04424537|Active Comparator|Low protein(LP) diet|"This group will consume 2 meal replacement beverages(MRBs) containing low protein (goal to reduce total protein by 2/3rds).
~LP diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.
~No overall calorie reduction will be implemented for any group.
~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.
~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
16336526|NCT04424537|Experimental|Low branched-chain amino acids (BCAA)|"The group on low-BCAA diet will consume 2 meal replacement beverages (MRBs) per day made with BCAD2 (branched chain amino acid) powder (lacking BCAAs).
~BCAD2 powder(Mead Johnson) is a fortified medical food powder that does not contain the BCAAs isoleucine, leucine, or valine, but provides all other essential and nonessential AAs, carbohydrates, fat, vitamins, and minerals.
~No overall calorie reduction will be implemented for any group.
~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.
~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
16336527|NCT04424511|Placebo Comparator|Control|"Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age:
~Single-dose of 0.5 ml / kg child weight
~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture."
16336592|NCT04424056|Experimental|Anakinra +/- Ruxolitinib|"Anakinra +/- Ruxolitinib
~According to clinical stage (gradual strategy):
~Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib"
16337487|NCT04417829||Only one arm (intervention=TAVI)|There is not control group/arm for comparison.
16336528|NCT04424511|Active Comparator|Azithromycin-biannually (Azi-biannual)|"Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age:
~Single-dose of 0.5 ml / kg child weight
~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug.
~Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg."
16336529|NCT04424511|Active Comparator|Azithromycin-quarterly|"Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age:
~Single-dose of 0.5 ml (20 mg) / kg child weight.
~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin."
16336530|NCT04424485|Active Comparator|Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy|"Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)
~Standard TT+CLND procedure only"
16336531|NCT04424485|Experimental|Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node|"Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).
~TT+CLND with NIR fluorescence ICG"
16336532|NCT04424472|Experimental|Ultrasonography|Patient will be scheduled to undergo an additional US by a blinded sonographer within 4 weeks of their most recent cross-sectional imaging that indicated a recurrence
16336533|NCT04424459||Patients included from 10/01/19 to 12/31/19.|Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.
16336534|NCT04424446||NIH staff|NIH staff undergoing standard NIH COVID-19 screening willing to donate additional research samples.
16336535|NCT04424433|Other|Normoxaemia First|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second.
16336536|NCT04424433|Other|Hyperoxia First|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second.
16336537|NCT04424420|Experimental|Paracetamol|Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.
16336538|NCT04424420|Active Comparator|Ibuprofen|Study phase 1 (single dosing): 800 mg once.
16336539|NCT04424420|Placebo Comparator|Placebo|Study phase 1 (single dosing): Once. Study phase 2 (multiple dosing): Twice daily for a minimum of 12 and a maximum of 14 days.
16336540|NCT04424407|Other|CBT-I|
16336541|NCT04424394|Experimental|DualStim Therapy with Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of umbilical cord-derived Wharton's Jelly formulation.
16336542|NCT04424394|Active Comparator|DualStim Therapy without Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of normal saline.
16336543|NCT04424381|Active Comparator|Rivaroxaban 20 MG Oral Tablet [Xarelto]|rivaroxaban oral tablet [Xarelto] at a single oral dose of 20 mg
16336544|NCT04424381|Experimental|Rivaroxaban 20 MG Oral Tablet|rivaroxaban oral tablet at a single oral dose of 20 mg
16336545|NCT04424368|Experimental|The remote monitoring system|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations and using remote monitoring system.
16336546|NCT04424368|No Intervention|Clinical recommendations|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations.
16336547|NCT04424355||Patients with suspected pneumonia COVID-19|"Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
16336548|NCT04424355||Patients with suspected pneumonia with COVID -19|"Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
16336549|NCT04424329|Experimental|Nutrition intervention|Ingestion of fibers and probiotics daily for 22 days
16336550|NCT04424329|No Intervention|No intervention|No intervention
16336553|NCT04424303||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
16336555|NCT04424264|Experimental|Tenofovir Alafenamide|TAF 25 mg once-daily administered with RIF/INH 600*/300mg
16336556|NCT04424251|Experimental|HSK21542 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg
16336557|NCT04424251|Experimental|HSK21542 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg
16336558|NCT04424251|Experimental|HSK21542 2 μg/kg|Preoperative:2 μg/kg Postoperative:1 μg/kg
16336559|NCT04424251|Experimental|HSK21542|Preoperative:2 μg/kg Postoperative:1 μg/kg
16336560|NCT04424251|Placebo Comparator|Placebo 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg
16336561|NCT04424251|Placebo Comparator|Placebo 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg
16336562|NCT04424251|Placebo Comparator|Placebo 2 μg/kg|Preoperative:2 μg/kg Postoperative:1 μg/kg
16336563|NCT04424251|Placebo Comparator|Placebo|Preoperative:2 μg/kg Postoperative:1 μg/kg
16336593|NCT04424056|Experimental|Tocilizumab +/- Ruxolitinib|"Tocilizumab +/- Ruxolitinib
~According to clinical stage (gradual strategy):
~Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib"
16336594|NCT04424056|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
16336564|NCT04424238|No Intervention|Standard Clinic Prenatal Care (Control Group)|pregnancy's prenatal care appointment would be changed to once every two weeks when diagnosed with GDM. Doctors generally ask GDM women record their daily diet, exercise, weight, BG and blood pressure for at least three days between two visits and give lifestyle guidance according to the records. If they fail to show diaries, doctors would ask them come back with record next week. If BG control is poor, medicine intervention would be considered.
16336565|NCT04424238|Experimental|m-health group (Intervention Group)|participants were managed continuously through WeChat group chat.
16336566|NCT04424225|Experimental|Psilocybin First|Participants in this arm will receive psilocybin first, then niacin
16336567|NCT04424225|Experimental|Niacin First|Participants in this arm will receive niacin first, then psilocybin
16336568|NCT04424212|Experimental|Experimental: Intervention group CoronaCope|ICBT, were participants receive 8 out of 15 possible modules depending on their current problems and needs, 7 week long internet intervention for reducing mental health issues related to the coronavirus pandemic.
16336569|NCT04424212|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
16336576|NCT04424186|Experimental|'Rehabilitation for Life'|Vital sign measurement and rehabilitation
16336577|NCT04424186|Active Comparator|Usual care and rehabilitation|Usual care and rehabilitation provided in primary and secondary sectors
16336578|NCT04424160|Experimental|Endometrial PRP|Patients in whom endometrial PRP was performed
16336579|NCT04424147|Experimental|HVA treatment|All patients with rrAML are treated with HVA regimen
16336580|NCT04424134|Experimental|Bromhexine And Spironolactone|
16336581|NCT04424134|Active Comparator|Base therapy|
16336582|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing|Participants will be approached and randomized to receive standard care plus ECG-stress testing
16336583|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing and CACS|Participants will be approached and randomized to receive standard care plus ECG-stress testing and coronary artery calcium scoring
16336584|NCT04424121|Active Comparator|Standard of care plus CCTA|Participants will be approached and randomized to receive standard care plus ≥ 64 multidetector coronary computed tomography angiography
16336585|NCT04424095||Pediatric patients|Recruited pediatric patients will undergo an in-office vascular visit and an echo duplex scan of lower limbs, in order to detect any symptoms or signs related to chronic venous disease.
16336586|NCT04424082|Other|dead space removal|external dead space will be removed and Vcap parameters (VCO2, PaCO2 and alveolar dead space) recorded before and after.
16336587|NCT04424069|Active Comparator|LASIK group|Patients will do excimer laser LASIK operation for correction of myopia with flap creation by mechanical keratome
16336588|NCT04424069|Active Comparator|SMILE group|Patients will do Femtosecond laser assisted corneal refractive surgery for correction of myopia
16336589|NCT04424069|Active Comparator|Photorefractive keratectomy group|Patients that will undergo photorefractive keratectomy for correction of myopia
16336590|NCT04424069|Active Comparator|Refractive lens exchange|Include eyes that will undergo refractive lens exchange
16336591|NCT04424069|No Intervention|Control group|Myopic control eyes with no surgical intervention
16336669|NCT04423471||Group 2|Psoriasis patients who will receive a biological treatment
16336595|NCT04424043|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
16336596|NCT04424043|Active Comparator|surgery alone|hepatic resection remove the liver tumors
16336597|NCT04424030||Multimodality imaging|Patients who have undergone echocardiography and cardiac MRI as part of their clinical management A research cardiac CT scan will be performed in eligible participants
16336598|NCT04424017||Healthcare workers (HCWs)|
16336599|NCT04424017||Healthy blood donors and healthy subjects in blood bank|
16336600|NCT04424017||Convalescents|
16336601|NCT04424004||MURDOCK Study Participants with valid email address|"Randomized for testing: 1.A randomly selected subset of individuals who consent to participate (N~300-500), will be invited to participate in COVID-19 polymerase chain reaction (PCR) viral testing by at-home collection and return of self-administered nasal swabs. Saliva specimens may replace the nasal swab specimen.
~2. The same randomly selected subset of individuals who collect at-home samples for COVID-19 PCR testing (N~300-500), will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies."
16336602|NCT04423991|Experimental|Exposed group|All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers.
16336603|NCT04423965|Experimental|mFOLFOXIRI|Patients receive 6 cycles of mFOLFOXIRI
16336604|NCT04423965|Experimental|Chemoradiotherapy(CRT)|Patients receive standard chemoradiotherapy
16336605|NCT04423952||Patients with chronic otitis media|Patients aged 7 to 15 years with chronic otitis media.
16336606|NCT04423952||Controls|Minors aged 7 to 15 years, with no and no history of chronic otitis.
16336607|NCT04423939|Experimental|Hematopoietic Stem Cell Transplantation (HCT) Patients|20 HCT patients at Duke
16336608|NCT04423939|Experimental|Caregivers|20 HCT patients caregivers at Duke
16336609|NCT04423926|Experimental|Lenalidomide+CHOP|
16336610|NCT04423913|Experimental|Patients undergoing transarterial embolization of the prostate|Three patients will undergo transarterial embolization of the prostate using unloaded beads.
16336611|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 2.5 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 2.5 mg of doxorubicin.
16336612|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 5.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 5.0 mg of doxorubicin.
16336613|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 10.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 10.0 mg of doxorubicin.
16336614|NCT04423900|Experimental|Plantar Fasciitis App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
16336615|NCT04423900|Experimental|Achilles Tendinopathy App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
16336616|NCT04423900|Experimental|Plantar Fasciitis Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
16336617|NCT04423900|Experimental|Achilles Tendinopathy Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
16336618|NCT04423900|Experimental|Plantar Fasciitis Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
16336619|NCT04423900|Experimental|Achilles Tendinopathy Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
16336620|NCT04423887|Active Comparator|Control|
16336621|NCT04423887|Experimental|Creatine Supplementation|
16336622|NCT04423874|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while listening to vocalisations. Physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
16336623|NCT04423861|Experimental|nitazoxanide BID|Patients will receive nitazoxanide 600 mg BID for 7 days.
16336624|NCT04423861|Placebo Comparator|Placebo|Patients will receive matching placebo BID for 7 days.
16336625|NCT04423848|Experimental|Home Hospital for Lymphoma|The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
16336670|NCT04423471||Group 3|Patients with major depression who will receive an antidepressant treatment
16336626|NCT04423835||lateral closing osteotomy for cubitus varus deformity|The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs.
16336627|NCT04423822||Firefighter|Firefighter with high cardiovascular risk
16336628|NCT04423809||caregivers of adult patients hospitalized in psychiatry|a face-to-face interview with a nurse and self-assessment scales.
16336631|NCT04423783|Experimental|Spider gamification app|Participants play the spider gamification app twice a day for 7 days
16336632|NCT04423783|Experimental|Online exposure + spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play the spider gamification app twice a day for 7 days
16336633|NCT04423783|Active Comparator|Online exposure + non-spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play a non-spider gamification app twice a day for 7 days
16336634|NCT04423770||U.S. dentists|Dentists in the United States
16336635|NCT04423757|Experimental|BI 1358894|
16336636|NCT04423757|Placebo Comparator|Placebo|
16336637|NCT04423744|Experimental|Intervention ABCD|"Intervention A:
~Day 1 and 2: Supra-therapeutic dose of BAY1817080, three times daily (tid) Day 3: Supra-therapeutic dose of BAY1817080 and placebo to moxifloxacin, once
~Intervention B:
~Day 1 and 2: therapeutic dose of BAY1817080 and placebo to BAY1817080, tid Day 3: therapeutic dose of BAY1817080, placebo to BAY1817080 and placebo to moxifloxacin, once
~Intervention C:
~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and moxifloxacin, once
~Intervention D:
~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and placebo to moxifloxacin, once
~Subjects will receive intervention A, B, C and D sequentially. The washing-out period between each intervention is at least 14 days"
16336638|NCT04423744|Experimental|Intervention BCDA|Subjects will receive intervention B, C, D and A sequentially. The washing-out period between each intervention is at least 14 days
16336639|NCT04423744|Experimental|Intervention CDAB|Subjects will receive intervention C, D, A and B sequentially. The washing-out period between each intervention is at least 14 days
16336640|NCT04423744|Experimental|Intervention DABC|"Subjects will receive intervention D, A, B and C sequentially. The washing-out period between each intervention is at least 14 days
~Note: the intervention sequences in this and above arms are examples, the actual order of intervention may differ from these examples"
16336644|NCT04423692||pregnant women with abnormal labs|Mothers who have abnormal labs during pregnancy with abnormal coagulation profile
16336645|NCT04423679||CIN2+|Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
16336646|NCT04423679||< CIN2|Non-cases will include those with <CIN2 on colposcopy/biopsy and women who did not have an indication for colposcopy (because of a negative screening test).
16336647|NCT04423666|Experimental|Intervention|"Will receive:
~education
~a wireless pedometer with set up
~nurse coaching via text message, email or telephone based on participant preference and at frequency determined by the participant"
16336648|NCT04423666|Experimental|Control|"Will receive:
~education
~a wireless pedometer with set up"
16336649|NCT04423653|Experimental|Tele-coaching group|This group will receive exercises videos, 2 sessions a week to be done on participant's own and the 3rd session will be live video conference session for training, supervision, and consultation purposes.
16336650|NCT04423653|Active Comparator|Self-monitored group|This group will receive exercises videos, 3 sessions a week to be done on participant's own with out any supervision.
16336651|NCT04423640||COVID Patients|Diagnosed patients with COVID-19 by PCR
16336652|NCT04423627|Experimental|Clonidine|0.2 mg/day oral
16336653|NCT04423627|Active Comparator|Hydrochlorothiazide|37.5 mg/day oral
16336654|NCT04423627|Placebo Comparator|Placebo|Placebo
16336655|NCT04423614|Experimental|Inspiratory Muscle Training (IMT)|Pre-operative inspiratory muscle training
16336656|NCT04423614|Experimental|Relaxation Breathing (RLX)|Relaxation breathing exercises
16336658|NCT04423588|Other|Dexlansoprazole|The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.
16336659|NCT04423575|Experimental|Outpatients|Health care pathway: patient education, communication to liberal nurses, first-position surgical planning, bariatric surgery (bypass or sleeve) as outpatient procedure, follow-up by home nurse twice-a-day, standardized communication to surgeons, management of possible complications
16336660|NCT04423575|No Intervention|Inpatients|Standard care pathway with bariatric surgery (bypass or sleeve) as inpatient procedure (at least one night in the hospital)
16336661|NCT04423562||Durable LVAD recipient with post implant VO2|
16336662|NCT04423549||tested group|
16336663|NCT04423549||controlled group|
16336664|NCT04423536||tested group|
16336665|NCT04423536||controlled group|
16336666|NCT04423510||Recurrent pilonidal sinus|Postoperative recurrent pilonidal sinus disease
16336668|NCT04423471||Group 1|Psoriasis patients who will receive systemic treatment (mainly methotrexate)
16336671|NCT04423458||Transplanted kidney|No intervention is required. Routine Doppler assessment + 3D scan + Shear wave elastography + Angio-PL.U.S. mood will be immediately recorded afterwards
16336672|NCT04423445|Experimental|Laser acupuncture combined with acupressure (LAA)|A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
16336673|NCT04423445|No Intervention|Control group|Control participants received a similar intervention, but without laser energy output or acupressure.
16336674|NCT04423432|Active Comparator|Control|
16336675|NCT04423432|Experimental|Creatine Supplementation|
16336676|NCT04423432|Experimental|Glucoseamine/ Chondritin Sulfate Supplementation|
16336677|NCT04423419|Other|A|will undergo Peri -articular nerve group block for hip joint under ultrasound guide as analgesia post operative after hip arthroscopy
16336678|NCT04423419|Other|B|will undergo ultrasound guided fascia iliaca block as postoperative analgesia after hip arthroscopy
16336679|NCT04423419|Other|C|will receive ordinary IV analgesia during operation hip arthroscopy
16336680|NCT04423393|Experimental|VIR-3434|
16336681|NCT04423393|Placebo Comparator|Placebo|
16336682|NCT04423380|Experimental|SH3051 capsules treatment|Oral Twice Daily Administration of SH3051
16336683|NCT04423367|Experimental|bortezomib/dexamethasone|Enrolled patients will receive the combination therapy of bortezomib and dexamethasone.
16336684|NCT04423354|Experimental|Research group|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy.
16336685|NCT04423341|Active Comparator|Group A - active medication followed by placebo|
16336686|NCT04423341|Active Comparator|Group B - placebo followed by active medication|
16336687|NCT04423328|Experimental|acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Shenmen→Neiguan→Hegu acupoints.
16336688|NCT04423328|Sham Comparator|sham acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Waiguan→Liangqiu→Tiaokou→ Chengshan acupoints
16336689|NCT04423315||patients with covid-19 pneumonia|patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
16336690|NCT04423302|Experimental|TOTUM-63 3 intakes per day|Experimental active diet supplement TOTUM-63 taken 3 times per day (blinded arm)
16336691|NCT04423302|Placebo Comparator|Placebo 3 intakes per day|Placebo comparator taken 3 times per day (blinded arm)
16336692|NCT04423302|Experimental|TOTUM-63 2 intakes per day|Experimental active diet supplement TOTUM-63 taken 2 times per day (open arm)
16336693|NCT04423289|Experimental|Farmalarm|Farmalarm app for the follow-up
16336694|NCT04423289|No Intervention|Control|Regular primary care follow-up
16336695|NCT04423276|Placebo Comparator|Control|
16336696|NCT04423276|Experimental|Donepezil|
16336697|NCT04423263|Experimental|Intervention|Receives bilateral internal iliac artery occlusion
16336698|NCT04423263|Active Comparator|Control|Does not receive bilateral internal iliac artery occlusion
16336699|NCT04423237||Severe Iron Overload (SIO)|Children affected by Severe Iron Overload who received DEFERASIROX
16336700|NCT04423237||Severe Iron Overload + Ductopenia (SIO+D)|Children affected by Severe Iron Overload + Ductopenia who received DEFERASIROX
16336701|NCT04423224|Active Comparator|Control group|Control group Management of the hemodynamic status in the control group will be performed in the discretion of the attending anesthesiologist, with the aim of keeping mean arterial pressure (MAP) > 65mmHg. The type and amount of delivered fluids, and vasoactive or inotropic drugs will be recorded.
16336702|NCT04423224|Active Comparator|GDFM|Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position & before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.
16336703|NCT04423211|Active Comparator|Arm A (EBRT, goserelin, leuprolide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline.
~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT for 6 months. Patients also receive goserelin acetate SC or leuprolide acetate IM for 6 months starting up to 3 months prior to EBRT but no later than the first fraction of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity."
16336704|NCT04423211|Experimental|Arm B (EBRT, goserelin, leuprolide, apalutamide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline.
~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD for 6 months in the absence of disease progression or unacceptable toxicity."
16336705|NCT04423211|Experimental|Arm C (EBRT, goserelin, leuprolide, apalutamide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arm C undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.
~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD as in Arm B."
16336742|NCT04423029|Experimental|DF6002 in Combination with Opdivo Expansion (Melanoma)|Dose expansion of up to 40 patients with melanoma receiving subcutaneous DF6002 in combination with intravenous Opdivo.
16336706|NCT04423211|Experimental|Arm D (EBRT, goserelin, leuprolide, apalutamide, RT)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arm D undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.
~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo SBRT or 3D CRT, IMRT (including VMAT), and IMPT over 3-5 fractions in the absence of disease progression or unacceptable toxicity."
16336707|NCT04423198||Target Condition|Subjects presenting to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma
16336708|NCT04423198||Trauma Control|Subjects presenting to the ED or UC requiring an Xray but do not have a head trauma
16336709|NCT04423198||Healthy Control|Subjects that are healthy and not taking any prescription medications
16336710|NCT04423185|Experimental|Almonertinib-EGFR mutation|Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
16336711|NCT04423185|Experimental|Dacomitinib-EGFR mutation|Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
16336712|NCT04423185|Experimental|Alectinib-ALK fusion|Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
16336713|NCT04423185|Experimental|Crizotinib-ALK fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
16336714|NCT04423185|Experimental|Vemurafenib-BRAF mutation|Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
16336715|NCT04423185|Experimental|Niraparib-BRCA mutation or HRD|Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
16336716|NCT04423185|Experimental|Pyrotinib-HER-2 overexpression/amplification|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
16336717|NCT04423185|Experimental|Imatinib-CKIT mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
16336718|NCT04423185|Experimental|Palbociclib-CDKN2A mutation|Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
16336719|NCT04423185|Experimental|Crizotinib-ROS-1 fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
16336720|NCT04423185|Experimental|Crizotinib-C-MET amplification|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
16336721|NCT04423185|Experimental|Crizotinib-C-MET mutation|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
16336722|NCT04423185|Experimental|Pyrotinib-HER-2 mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
16336723|NCT04423185|Experimental|Sintilimab-PD-1|Administration: 200mg q21d, to disease progression or intolerable adverse effects.
16336724|NCT04423185|Experimental|Combination ARM-Niraparib & Sintilimab|Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
16336725|NCT04423185|Experimental|Combination ARM-Vemurafenib & Atezolizumab|Vemurafenib (960 mg oral bid) & Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
16336726|NCT04423185|Experimental|Combination ARM-Palbociclib & Atezolizumab|Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
16336727|NCT04423172|Experimental|Using the New Tissue Containment System group|using the new tissue containment system during Laparoscopic Hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
16336728|NCT04423172|No Intervention|Open group|Without using any procteciton system during Laprascopic Hysterectomy.
16336729|NCT04423159|Experimental|OCV vaccine|Shanchol 1.5mL to be administered orally. Each dose contains V.cholerae O1 Inaba El Tor Strain, Inaba classical strain, ogawa classical strain and O139 strain. As well as Thiomersal and a buffer
16336730|NCT04423146||Patients scheduled for elective scoliosis surgery|Patients scheduled for elective scoliosis surgery will be anesthetized in TIVA mode,combining propofol and remifentanil with titration to the target BIS value. Motor evoked potentials will be measured and evaluated by members of operating team perioperatively. The quality of evoked potentials (poor vs good quality) and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
16336731|NCT04423133|Experimental|Online Family Literacy Program|The Ready and Healthy for Kindergarten program is a bilingual family literacy program that uses anticipatory guidance on health routines (e.g., physical activity) to introduce language and literacy skills to children and their families delivered via an online video conference format.
16336732|NCT04423107|Active Comparator|No opioid|Acetaminophen every 6 hours and Ibuprofen every 6 hours
16336733|NCT04423107|Active Comparator|Opioid|Acetaminophen every 6 hours, Ibuprofen every 6 hours, and Oxycodone every 6 hours as needed for breakthrough pain for 10 doses.
16336734|NCT04423068|Experimental|Overall Study|
16336735|NCT04423055|Experimental|COC users or new starts|Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
16336736|NCT04423042|Experimental|Tocilizumab Arm|Tocilizumab 8 mg/kg IV up to a maximum of 800 mg with possible repetition of the same dosage within 28 hours (the optional second dose after 12 hours but before 28 hours following the first dose), based on the clinical judgement of the attending physician in consultation with the COVID-inflammation team.
16336737|NCT04423042|No Intervention|No Intervention Arm|No intervention arm patients will be identified from medical records, as being COVID-19 positive patients with hyperinflammation who did not receive any interleukin antagonist treatment.
16336738|NCT04423029|Experimental|DF6002 Monotherapy Dose Escalation|3+3 dose escalation of subcutaneous DF6002 as monotherapy in patients with solid tumors.
16336739|NCT04423029|Experimental|DF6002 Monotherapy Expansion (Melanoma)|Dose expansion of up to 40 patients with melanoma receiving subcutaneous DF6002 as monotherapy.
16336740|NCT04423029|Experimental|DF6002 Monotherapy Expansion (NSCLC)|Dose expansion of up to 40 patients with non-small cell lung cancer receiving subcutaneous DF6002 as monotherapy.
16336741|NCT04423029|Experimental|DF6002 In Combination with Opdivo Escalation|3+3 dose escalation of subcutaneous DF6002 in combination with intravenous Opdivo.
16336743|NCT04423029|Experimental|DF6002 in Combination with Opdivo Expansion (NSCLC)|Dose expansion of up to 40 patients with non-small cell lung cancer receiving subcutaneous DF6002 in combination with intravenous Opdivo.
16336744|NCT04422990|Experimental|LID018869|Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration.
16336745|NCT04422990|Active Comparator|Biofinity|Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration.
16336746|NCT04422977|Other|CoVID exposure|
16336747|NCT04422964|Experimental|Intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
16336748|NCT04422964|No Intervention|control group|The standard procedure without the 3D obturator.
16336749|NCT04422951|Experimental|Wise interventions plus online behavioral Rx|Wise social psychological interventions (growth mindset and values self-affirmation) plus a usual care online behavioral intervention for weight control.
16336750|NCT04422951|Active Comparator|Online behavioral Rx|Usual care online behavioral intervention for weight control.
16336751|NCT04422938||Manuel compression|Manuel chest compressions will be handled by clinicians
16336752|NCT04422938||Mechanical compression|Mechanical chest compressions will be handled via mechanical chest compression device
16336753|NCT04422912|Experimental|DSG3-CAART|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (4-5 groups) administered as a single cycle.
~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (2 groups) administered as a single cycle.
~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle"
16336754|NCT04422899|Experimental|AIV007 Treatment Dose 1|Intravitreal, Dose 1
16336755|NCT04422899|Experimental|AIV007 Treatment Dose 2|Intravitreal, Dose 2
16336756|NCT04422899|Experimental|AIV007 Treatment Dose 3|Intravitreal, Dose 3
16336757|NCT04422886|Experimental|Physio+tDCS|Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
16336758|NCT04422886|Sham Comparator|Physio+sham|Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
16336759|NCT04422873||in-centre|Currently dialysing in-centre
16336760|NCT04422873||home|Currently dialysing at home
16336761|NCT04422860|Experimental|Gum Arabic varnish|Gum arabic (Acacia senegal) is an exudate obtained from Acacia senegal stems and roots, and other similar African Acacia species. It consists mainly of high molecular weight polysaccharides high concentrations of calcium, magnesium, and potassium salts which can potentially increase tooth remineralization.
16336762|NCT04422860|Active Comparator|Sodium Fluoride varnish|The gold standard remineralizing agent recommended by the guidelines.
16336763|NCT04422860|Active Comparator|10% w/v CPP-ACP, 5% sodium fluoride varnish|CPP-ACP is the most studied non fluoride remineralizing agent.
16336764|NCT04422847|Experimental|intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
16336765|NCT04422847|No Intervention|control group|The standard procedure without the 3D obturator.
16336766|NCT04422834|Experimental|Health Professional Students|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
16336767|NCT04422821|Experimental|FreeStyle Libre™|FreeStyle Libre™ will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will receive subcutaneous sensor for glucose monitoring (FreeStyle Libre™; Abbott Diabetes Care, Alameda, CA) for 4 weeks.
16336768|NCT04422821|Active Comparator|iXell®|iXell® will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will monitor glycemia through use of standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) for 4 weeks.
16336769|NCT04422795|Experimental|External thermomechanical device delivering stimuli|The thermomechanical device is placed on the digit proximally to the injection site with the ice wings frozen and the vibration mechanism switched on.
16336770|NCT04422795|Placebo Comparator|External thermomechanical device without delivering stimuli|The thermomechanical device is placed on the digit proximally to the injection site with the ice wings at room temperature (unfrozen) and the vibration mechanism switched off.
16336771|NCT04422795|Active Comparator|Nail injection with ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection immediately before needle insertion
16336772|NCT04422782|Other|Single Arm|Single Arm
16336773|NCT04422743|Experimental|standard of care + citicoline plus homotaurine (CIT/HOMO)|CIT/HOMO was supplemented for 4 months to the standard of care (SOC, i.e. topical intraocular pressure, IOP, lowering medication)
16336774|NCT04422743|No Intervention|standard of care|only standard of care (SOC, i.e. topical IOP lowering medication) for 4 months
16336775|NCT04422730||pancreatectomy in cancer patients|
16336776|NCT04422730||pancreatectomy in non-cancer patients|
16336777|NCT04422730||mastectomy|
16336778|NCT04422730||Acute leukaemia|
16336779|NCT04422704|Experimental|Retired people|People who are either ordinarily or early retired and who have previously held a paid employment.
16336780|NCT04422691||Covid-19 suspected|Emergency department patients with suspected or diagnosed COVID-19 disease. All patients will be screened at triage and put into isolation if suspected disease. Ultrasound of the patients lungs will be performed after patient consent and findings will be recorded and categorized (Soldati et al., 2020). The use of ultrasound and registration of data will not affect the regular patient evaluation, treatment or logistics.
16336781|NCT04422678|Experimental|Imatinib Standard Dose|"Imatinib 400 mg oral tablet once daily for 21 days
~In addition for the treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
16336782|NCT04422678|Experimental|Imatinib Low Dose|"Imatinib 200 mg oral tablet once daily for 21 days.
~In addition to the treatment for COVID-19 Pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
16336783|NCT04422678|Active Comparator|Control|Treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH).
16336784|NCT04422665|Experimental|Single Exercise|Subjects allocated to this group will perform a single bout of one-legged resistance exercise. This bout will take place 1 day prior to the start of the bed rest. The resistance exercise will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
16336785|NCT04422665|Experimental|Multi Exercise|Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
16336786|NCT04422652|Active Comparator|Strategy 1|Strategy 1: Single-blind Behavioral Activation Therapy plus placebo for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind bupropion (Phase 2) for another 8 weeks.
16336787|NCT04422652|Active Comparator|Strategy 2|Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind BAT (Phase 2) for another 8 weeks.
16336788|NCT04422652|Placebo Comparator|Control|Control: Clinical management attention control plus placebo for 16 weeks
16336789|NCT04422639|Experimental|Arm I (pre-operative SRS/SRT)|Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
16336790|NCT04422639|Active Comparator|Arm II (post-operative SRS/SRT)|Patients undergo surgery within 15 days of randomization followed by standard-of-care SRS or SRT within 30 days of surgery. Patients may undergo additional SRS or SRT if disease returns after treatment.
16336791|NCT04422626||Critically ill COVID-19 patients, who receive CytoSorb therapy|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) CytoSorb therapy on consultant's discretion.
16336792|NCT04422613|Experimental|characterization of pulmonary damage|This clinical trial will be characterized the pulmonary damage after COVID-19 pneumonia
16336793|NCT04422600||Mothers who report use of THC with or without CBD|Mothers who report THC and CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
16336794|NCT04422600||Mothers who report use of CBD only|Mothers who report CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
16336795|NCT04422600||Control Mothers|Recruitment of pregnant women who do not use THC or CBD will be conducted using the Epic MyChart research participant recruitment tool
16336796|NCT04422587||RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
16336797|NCT04422561|Experimental|Ivermectin group|Contacts who will receive prophylactic ivermectin
16336798|NCT04422561|No Intervention|Control group|Contacts who will be only observed without prophylaxis
16336799|NCT04422548|Active Comparator|AI-assisted Group|
16336800|NCT04422548|Active Comparator|Standard|
16336801|NCT04422535||Critical care patients|Patients admitted to critical care units for COVID-19, where ECG records and relevant clinical information are available to assess the impact of the disease and its concomitant treatment on electrocardiographic parameters of ventricular repolarization
16336802|NCT04422509|Experimental|lanadelumab|20 Patients will receive an intravenous dose of 300 mg lanadelumab on day 1, followed by a second dose of lanadelumab 300mg iv on day 4 (if needed).
16336803|NCT04422509|Other|controls|20 patients will received standard of care In additiona, for every index patient we will match one historical controls. Controls will be matched based on age, bodyweight and gender.
16336804|NCT04422496|Experimental|HEC96719 tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B: There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
16336805|NCT04422496|Placebo Comparator|placebo tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B:There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
16336806|NCT04422483||Service Model Level Case Studies|Realist Interviews. MONTHS 9-30 (N=6-8 sites, 12 people per site, 96 interviewees)
16336807|NCT04422483||Individual/family level interviews|Child Interviews. MONTHS 9-30 (N=6-8 sites, 6 people per site, max. 48 interviewees)
16336808|NCT04422483||Individual child/family Level Case Studies:|MONTHS 10-30 (N=6-8 sites, 78 people per model (x4), 312 participants, 156 per NU/SCFT depending on distribution of sites)
16336809|NCT04422483||Focus groups:|MONTHS 9-30 (N=6-8 sites, 6-8 focus groups of up to 8 parents) N= 64
16336810|NCT04422457|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans
16336811|NCT04422431|Experimental|ALXN1840|Participants will receive ALXN1840.
16336813|NCT04422392|Experimental|Neoadjuvant PD-1 antibody puls chemotherapy|"Neoadjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3) Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of combinded adjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will be administered. Thirteen cycles of PD-1 antibody will start within day 21-24 days from day 1 of adjuvant cycle 2."
16336814|NCT04422392|Active Comparator|Neoadjuvant chemotherapy|"Neoadjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3).
~Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of adjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will be administered."
16336815|NCT04422366|Experimental|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
16336816|NCT04422366|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
16336817|NCT04422353|Experimental|video Dance classes|"The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm.
~Classes will be divided into four stages: Joint warm-up and stretching on the chairs; strengthening, balance, and rhythm exercises with the support of the chair; exercises inspired by the samba and forró (Brazilian ballroom dance) basic steps; and Final cool down. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
~The video Dance classes will happen in the period of self-isolation and social distance during the Covid-19 pandemic."
16336818|NCT04422353|Active Comparator|Unsupervised physical activities|The unsupervised physical activity programs will happen in the period of self-isolation and social distance during the Covid-19 pandemic. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
16336819|NCT04422353|No Intervention|control group|The control group will be people with PD, engaged, before the Covid-19 pandemic, in the Dance, the Nordic Walk and the Aquatic Jogging extension projects at Federal University of Rio Grande do Sul but did not do any type of physical activity during the Covid-19 pandemic.
16336820|NCT04422327|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
16336821|NCT04422314||Cohort 1|Lyme disease testing cohort
16336822|NCT04422314||Cohort 2|Endemic, asymptomatic controls
16336823|NCT04422314||Cohort 3|Non-endemic, asymptomatic controls
16336824|NCT04422314||Cohort 4|Potential cross-reactive disease states
16336825|NCT04422314||Cohort 5|Lyme disease testing cohort
16336826|NCT04422301|Experimental|High intensity eccentric training|"High intensity eccentric training high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
~eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction."
16336827|NCT04422301|Experimental|High intensity eccentric training with blood flow restriction|High intensity eccentric training with blood flow restriction high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction
16336828|NCT04422301|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
16336829|NCT04422301|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
16336830|NCT04422275|Active Comparator|Budesonide & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
16336831|NCT04422275|Active Comparator|Placebo & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
16336832|NCT04422275|Active Comparator|Budesonide & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
16336833|NCT04422275|Placebo Comparator|Placebo & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
16336834|NCT04422262||Moli-sani Study sub-cohort|A sample of 2,500 men and women from the Moli-sani Study cohort (2005-2010) who were re-examined in 2017-2020. Participants will be contacted by telephone by researchers of the Moli-sani Study recruitment team in order to collect dietary, lifestyle and psychosocial information and assess potential changes possibly occurred during Phase 1 lockdown.
16336852|NCT04422184|Experimental|REGK GROUP|Dentalclean Daily Regenerator - REFIX technology + potassium citrate
16337488|NCT04417816|Experimental|Exercise training + adipose tissue cavitation|
16336835|NCT04422262||Italian general population|The project will retrospectively collect data through a web-based survey using Google form. The questionnaire consists of the same items used for the Moli-sani sub-cohort. The project aims at including as many subjects' records as possible.
16336836|NCT04422249|Experimental|laparoscopic middle hepatic vein guidance hemihepatectomy|In theory, the advantages of anatomical hemihepatectomy guided by middle hepatic vein are as follows: 1) correctly guiding the transecting plane of the liver parenchyma can reduce the cross-sectional area of the liver and avoid damaging the vascular ducts of the pre-cut liver. so as to reduce the residue of necrotic tissue without blood supply and reduce the occurrence of postoperative complications. 2) active anatomy and exposure of hepatic vein can avoid uncontrollable bleeding after passive injury of hepatic vein, and laparoscopic anatomy has obvious advantage in exposing hepatic vein. 3) it may reduce the early recurrence rate of hepatocellular carcinoma after operation.
16336837|NCT04422249|Active Comparator|laparoscopic traditional anatomic hemihepatectomy|According to textbooks and the views of some scholars at present, traditional anatomical hepatectomy (non-hepatic vein-guided anatomical hepatectomy) has the following advantages: 1) avoiding exposure of hepatic vein can reduce the probability of injury to the trunk of hepatic vein, thus reduce the risk of massive bleeding during operation; 2) the difficulty of operation is relatively low, and a better short-term and long-term effect can be obtained.
16336838|NCT04422236||Obese patients eligible for laparoscopic bariatric surgery|
16336839|NCT04422223||Cohort|Patients newly diagnosed with liver cirrhosis form the Gastro Unit, Amager Hvidovre Hospital, Denmark. All patients with clinically verified diagnosis, irrepsective of disease stage and etiology is included.
16336840|NCT04422210|Experimental|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, will be administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
16336841|NCT04422210|Experimental|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, will be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
16336842|NCT04422210|Experimental|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, will be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
16336843|NCT04422210|Experimental|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
16336844|NCT04422210|Experimental|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
16336845|NCT04422210|Experimental|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
16336846|NCT04422210|Experimental|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
16336847|NCT04422210|Experimental|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort will continue to test venetoclax in both induction and maintenance. Participants will be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction preclude identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax will only be investigated in dose-expansion in the maintenance setting. Participants will be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
16336848|NCT04422197|Active Comparator|Patients with ultrasound-guided botox injection|Effect of Botox injection on lateral abdominal wall muscles after major open abdominal surgery
16336849|NCT04422197|Active Comparator|Patients with no botox injection|Patients with major abdominal surgery without botox injection
16336850|NCT04422184|Experimental|SEN GROUP|Sensodyne Repair and Protect - NOVAMIN technology
16336851|NCT04422184|Experimental|REG GROUP|Dentalclean Daily Regenerator - REFIX technology
16336853|NCT04422158|Experimental|Nuun Single strength|3 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
16336854|NCT04422158|Experimental|Nuun Double strength|6 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
16336855|NCT04422158|Placebo Comparator|Control|Subjects will drink one liter of water over 30 min (250 mL every 7.5 min)
16336856|NCT04422145|Active Comparator|Interventional/intensive|Participants received a structured nurse led education programme surrounding hypoglycaemia. They were encouraged to use self monitoring of blood glucose (SMBG) and had their diabetes medications adjusted according to this. They also received information on how to avoid hypoglycaemia (including the effects of diet, exercise, alcohol and their medications) and how to treat hypoglycaemia should it occur.
16336857|NCT04422145|Placebo Comparator|Standard|Participants returned to their standard diabetes care provider with no intervention.
16336858|NCT04422145|No Intervention|Observational|Participants were happy to have baseline characteristics collected and be followed up using electronic records in a longitudinal fashion but did not wish to be randomized. The observational and standard groups therefore received the same diabetes care.
16336859|NCT04422132|Active Comparator|ARM 1 - 2 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
16336860|NCT04422132|Active Comparator|ARM 2 - 4 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
16336861|NCT04422119|Experimental|Multi-layer foam dressing|Patients in experimental group will receive the application of a multi-layer foam dressing with Safetac in surgical wound
16336862|NCT04422119|Active Comparator|Usual care|Patients in control group will receive standard treatment with povidone-iodine and a gauze dressing with plaster.
16336863|NCT04422080||Keratoconus patient|Patient with keratoconus disease diagnosed on videotopography
16336864|NCT04422080||Healthy patient|Patient consulting for keratoconus screening with no keratoconus on videotopography
16336865|NCT04422067||Case group (Retrognatism)|All pregnant patients with one or more fetuses suffering from a microretrognathia, diagnosed prenatally and integrated into a Pierre Robin Sequence, were included. All cases were confirmed postnatally, either by a pediatric examination or by a fetopathological examination in the case of a medical termination of the pregnancy. We had 21 cases.
16336866|NCT04422067||Control group|47 pregnant patients with fetus without facial abnormalities
16336867|NCT04422054||Open Surgery Repair Group|In the open surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications, in the postoperative period, during follow up.
16336868|NCT04422054||Endovascular Repair Group|In the endovascular surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications in the postoperative period, during follow up.
16336869|NCT04422041|Active Comparator|Early discharge|Discharge between 24 and 48 hours
16336870|NCT04422041|Experimental|Very early discharge|Discharge in less than 24 hours
16336871|NCT04422028|Experimental|Desogestrel Test Product|Participants received two tablets of the test formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
16336872|NCT04422028|Active Comparator|Desogestrel Reference Product|Participants received two tablets of the marketed reference formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
16336873|NCT04422002||Surgical treatment|
16336874|NCT04422002||Palliative treatment|
16336875|NCT04421989|Experimental|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
16336876|NCT04421989|Active Comparator|Support Group|Participants randomized to FBT + Support parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The parent support group facilitates parent discussion and support around a variety of topics central to treatment for pediatric AN including: understanding medical co-morbidities, levels of care for treatment, understanding expected body weight, navigating FMLA, and medications. The facilitator introduces each topic weekly and opens up discussion between parents. The facilitator's role is to ensure the group remains on topic and on time.
16336877|NCT04421976|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
16336878|NCT04421976|Experimental|Driving pressure (DP) guided-PEEP|PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
16336879|NCT04421963|Experimental|Olaparib|Treatment
16336880|NCT04421950|Active Comparator|Wild Blueberry Supplement|30 grams of wild blueberry powder per day in foods items provided to them
16336881|NCT04421950|Placebo Comparator|Placebo supplement|Food items will be provided to them without the wild blueberry power.
16336882|NCT04421937|Experimental|Neuromuscular Electrical Stimulation (NMES) with TDT|
16336883|NCT04421937|Active Comparator|Traditional Dysphagia Therapy (TDT)|
16336884|NCT04421924|Experimental|Thrombelastogram (TEG)|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.
16337489|NCT04417816|Sham Comparator|Exercise training + sham procedure|
16336885|NCT04421924|Experimental|Standard of Care (SOC)|In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
16336886|NCT04421911|Experimental|ketoprofen|
16336887|NCT04421911|Active Comparator|Diclofenac|
16336888|NCT04421898||group 1|group 1 : infants with congenital muscular torticollis
16336889|NCT04421898||group 2|group 2 : healthy , without congenital muscular torticollis
16336890|NCT04421885|Experimental|A: TBPM-PI-HBr (Reference - fasted)|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
16336891|NCT04421885|Experimental|B: TBPM-PI-HBr (Test - fasted)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
16336892|NCT04421885|Experimental|C: TBPM-PI-HBr (Test - fed)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.
16336893|NCT04421872|Experimental|General anesthesia Group|
16336894|NCT04421872|No Intervention|Healthy control group|
16336895|NCT04421859|Experimental|EyeCU App|"Augmented reality mobile application called EyeCU which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes."
16336896|NCT04421846|Other|Group 1 : Status epilepticus|
16336897|NCT04421846|Other|Group 2 : Dysimmune encephalitis|
16336898|NCT04421846|Other|Group 3 : Control patients|
16336899|NCT04421833|Active Comparator|group starting with TOVERTAFEL activities|Participants will benefit from TOVERTAFEL activities for 6 weeks then the usual animation techniques for 6 weeks with a week of wash-out between the two periods.
16336900|NCT04421833|Sham Comparator|group ending with TOVERTAFEL activities|Participants will benefit from the usual animation techniques for 6 weeks then from TOVERTAFEL activities for 6 weeks with a week of wash-out between the two periods.
16336901|NCT04421820|Experimental|Gastric Cancer|
16336902|NCT04421820|Experimental|Pancreatic Cancer|
16336903|NCT04421820|Experimental|Colorectal Cancer|
16336904|NCT04421820|Experimental|Cholangiocarcinoma|
16336905|NCT04421807|Experimental|Exercise+Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
16336906|NCT04421807|Active Comparator|Only Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
16336907|NCT04421794|Experimental|NMES group|For the NMES group one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will deliver NEMS (15 min; 75 EMS contractions completed during the training session; rise time = 0.25 s and descending time = 0.75 s). In order to maximize muscle tension without accompanying detrimental effects on fatigue onset, biphasic symmetric regular-wave pulsed currents (85 Hz) lasting 400 μs will be delivered. Each 4-s steady tetanic stimulation will be followed by pause lasting 8-s, during which subjects will be submaximally stimulated at 4 Hz on the medial arch muscles. According to the recommendations, the two electrodes are placed behind the head of the first metatarsal to stimulate the medial arch intrinsic muscles. The goal is to attain the highest tolerable level of muscle contraction without discomfort during the 15 minutes and to provide a full tetanic contraction of the intrinsic foot muscles during the contraction time.
16336908|NCT04421794|Placebo Comparator|Control group|For the control group the one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will be used to apply a stimulation of 15 minutes considered by TENS at the lowest intensity detectable by the participant in order to not influence the outcomes of interest. Our aim is to strengthen IFM which is not the role of TENS. The two electrodes will be placed on the dominant foot, at the same place than those for the NMES group.
16336909|NCT04421781||Salvage HIFU for local recurrence after prostatectomy and EBRT|Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
16336910|NCT04421768|Experimental|systematic cervical exam training--retrospective measures|Effects of systematic cervical exam training on Labor and Delivery Care The total number of exams per hour of labor or triage stay and exam discrepancy between 2 examiners who performed exams less than 30 minutes apart will be compared between the 6 month time period before the unit wide training and 6 months after completing training
16336911|NCT04421768|Experimental|systematic cervical exam training--prospective measures|Effects of systematic cervical exam training on Labor and Delivery care Patient will be approached to obtain consent for them to have 2 cervical exams performed one after the other when an exam is clinically indicated. The discrepancy between the 2 examiners will be compared between the 6 month time period before the unit wide training and 6 months after completion of the training.
16336912|NCT04421755|Experimental|Produce Only|Receives weekly home delivery of fresh fruits and vegetables
16336913|NCT04421755|Experimental|Produce + Cooking Classes|Receives weekly home delivery of fresh fruits and vegetables plus invitation to participate in a series of three small group culinary medicine cooking classes
16336914|NCT04421755|No Intervention|Control|Control group with no cooking classes or groceries
16336915|NCT04421742||43 COPD|COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks
16336916|NCT04421729|Active Comparator|Savvy Caregiver Program|Savvy Caregiver Program, 6 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
16336917|NCT04421729|Active Comparator|Savvy Express|Savvy Express, 3 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
16336918|NCT04421716|Experimental|Ursolic Acid|Administration of Ursolic Acid twice a day for 2 weeks
16336919|NCT04421716|Experimental|Curcumin|Administration of Curcumin twice a day for 2 weeks
16337490|NCT04417803|Other|diffuse large B-cell lymphoma|
16336920|NCT04421716|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin. If subjects from Cohort 1 or 2 wish to continue in the study, they will undergo a washout period of at least 4 weeks before participating in Cohort 3
16336921|NCT04421703|Experimental|Distance Collaborative|For sites randomized to the distance arm, training will be delivered via web conference, and technical assistance and assessment and feedback will be delivered by phone.
16336922|NCT04421703|Experimental|Blended in-person/distance collaborative|For the QI collaborative arm, training will be delivered in two in-person collaborative meetings; and the remainder of the strategies will be delivered via web-conferencing.
16336923|NCT04421690|Experimental|Cognitive Training|8 week computerized cognitive training
16336924|NCT04421690|Active Comparator|Trivia Training|8 week computerized trivia training
16336925|NCT04421677|Experimental|Phenylbutyrate|Open-label phenylbutyrate
16336926|NCT04421664|Experimental|Treatment|Participants in this arm will receive the study drug, hydroxychloroquine.
16336927|NCT04421664|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
16336928|NCT04421651|Experimental|Treatment group|The participants in the treatment group were offered 20 Dance movement therapy sessions in addition to standard care.
16336929|NCT04421651|No Intervention|Control group|Participants in the control group continued treatment as usual in the health services.
16336930|NCT04421625|Experimental|Diagnostic test for SARS-Cov2 for patients and health staff|"Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens)
~Nasal swab test (only if the patient has symptoms)
~Questionnaires"
16336931|NCT04421612|Experimental|Intensive|This group recieve access to a new module every 3rd day.
16336932|NCT04421612|Experimental|Ordinary|This group recieve access to a new module every 5th day.
16336933|NCT04421599|Experimental|Experimental Group A|Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
16336934|NCT04421599|No Intervention|Control Group|Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
16336935|NCT04421599|Experimental|Experimental Group B|Experimental Group B who were not administered aspiration during IM injection.
16336936|NCT04421586|Experimental|Pregnant women receiving VISTA counseling|Up to 30 pregnant women are screened and counseled for vaccine concerns using VISTA
16336937|NCT04421586|No Intervention|Pregnant women receiving usual care|Up to 30 pregnant women receiving usual care
16336938|NCT04421573|Experimental|BCPHD-D5W with usual care|"Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, 6 and 8 weeks.
~All helpful treatment methods already underway are continued. Other new treatment methods are discouraged."
16336939|NCT04421573|Active Comparator|Waiting period with usual care|All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
16336940|NCT04421560|Experimental|Pembrolizumab + Ibrutinib + Rituximab|"Phase 1b
~Dose escalation will occur using a standard 3+3 dose-escalation approach, beginning at dose level I (560 mg daily) and potentially escalating to dose level 2 (840mg) with rules for escalation and de-escalation.
~Ibrutinib: orally 2x daily
~Pembrolizumab: 200 mg intravenously every 3 weeks
~Rituximab: 375mg/m^2 intravenously once per week for 4 weeks (4 total doses).
~Phase 2
~Participants will receive Pembrolizumab, Rituximab and Ibrutinib at the pre-determined dosage level established in Phase 1b.
~Ibrutinib: orally maximum tolerated dose from phase 1 daily (560 mg or 840mg)
~Pembrolizumab: 200 mg intravenously every 3 weeks
~Rituximab: 375 mg/m^2 intravenously once per week for 4 weeks (4 total doses)."
16336941|NCT04421547|Experimental|Letrozole|Letrozole 1 tablet (2,5 mg) orally once a day
16336942|NCT04421547|Active Comparator|Standard Chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
16336943|NCT04421534|Experimental|Standard of care in addition to 400 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily [two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
16336944|NCT04421534|Experimental|Standard of care in addition to 600 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily [three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
16336945|NCT04421534|Active Comparator|Standard of care only|Standard of care treatment; as per MOHP protocol
16336946|NCT04421521|Experimental|Acupuncture Group|
16336947|NCT04421521|No Intervention|Standard Therapy Group|
16336948|NCT04421508|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 125 mcg/kg IBW/hour
16336949|NCT04421508|Sham Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
16336950|NCT04421495|Experimental|delamanid containing regimen arm|the only one arm to be studied with delamid-containing regimen.
16336951|NCT04421482|Other|Very Low Birth Weight Preterm Infants|Very Low Birth Weight Preterm Infants (birth weight less than 1,500g and less than 32 weeks gestation) admitted to NYU Winthrop NICU. (n=42)
16336952|NCT04421469|Experimental|Comprehensive treatment|Patients with multiple metastatic NPC were given Triprilimab(JS001) and chemotherapy combined with local treatment.
16336953|NCT04421456|Experimental|GWP42003-P 300 mg|GWP42003-P 300 milligrams (mg) per day
16336954|NCT04421456|Placebo Comparator|Placebo|Matching placebo
16336955|NCT04421456|Experimental|GWP42003-P 1000 mg|GWP42003-P 1000 mg per day
16336956|NCT04421443|Active Comparator|3 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 3 days.
16336957|NCT04421443|Active Comparator|5 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 5 days.
16336958|NCT04421443|Active Comparator|8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
16336959|NCT04421430|Experimental|Distraction cards group|Distraction cards was applied to the children in this group during the venipuncture procedure.
16336960|NCT04421430|Experimental|Virtual reality group|Virtual reality intervention was applied to the children in this group during the venipuncture procedure.
16337491|NCT04417803|Other|follicular lymphoma|
16336961|NCT04421430|Experimental|Buzzy® group|Buzzy® was applied to the children in this group during the venipuncture procedure.
16336962|NCT04421430|No Intervention|Control group|The control group received the routine venipuncture procedure and did not receive any other non-pharmacological intervention.
16336963|NCT04421417|Active Comparator|Standard Arthroscopic Rotator Cuff Repair|
16336964|NCT04421417|Experimental|Microfracture and Arthroscopic Rotator Cuff Repair|
16336965|NCT04421404|Experimental|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
16336966|NCT04421404|Placebo Comparator|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
16336967|NCT04421391|Experimental|Treatment Arm|Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
16336968|NCT04421378|Experimental|Phase 1: Arm A: Selinexor+Radiation Therapy|Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
16336969|NCT04421378|Active Comparator|Arm A Control: Temozolomide+Radiation Therapy|Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
16336970|NCT04421378|Experimental|Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.
16336971|NCT04421378|Active Comparator|Arm B Control: Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
16336972|NCT04421378|Experimental|Arm C: Selinexor+Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m^2 of lomustine or 150-200 mg/m^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
16336973|NCT04421378|Active Comparator|Arm C Control: Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 110 mg/m^2 of lomustine or 200 mg/m^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
16336974|NCT04421378|Experimental|Arm D: Selinexor+Bevacizumab|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
16336975|NCT04421378|Active Comparator|Arm D Control: Bevacizumab|Participants with rGBM will receive 10 mg/kg of Bevacizumab IV infusion Q2W in each cycle in a 28 Day cycle for all cycles.
16336976|NCT04421378|Experimental|Arm E: Selinexor+TTField|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
16336977|NCT04421378|Active Comparator|Arm E Control: TTField|Participants with rGBM will receive scalp application of 200 kHz of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
16336978|NCT04421365|Active Comparator|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
16336979|NCT04421365|Sham Comparator|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
16336980|NCT04421352|Experimental|low-dose radiation+CS1001|low-dose radiation+CS1001
16336981|NCT04421339|Experimental|Melatonin|
16336982|NCT04421339|Placebo Comparator|Placebo|
16336983|NCT04421326||Patients with acute ischemic stroke|Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
16336984|NCT04421313|Experimental|Rhumatoid Arthritis|The patients with Rheumatoid arthritis receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
16336985|NCT04421313|Placebo Comparator|Control Subjects|The patients with Control Subjects receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
16336986|NCT04421300|Experimental|smile exercise|smile exercise, 4 times a day，8 weeks
16336987|NCT04421300|Active Comparator|0.1% Sodium Hyaluronate Eye Drops|0.1% sodium hyaluronate, 4 times a day, 8 weeks.
16336988|NCT04421287|Experimental|Zhenyuan capsule|
16336989|NCT04421287|Placebo Comparator|Zhenyuan capsule placebo|
16336990|NCT04421274|Experimental|BM-MSCs group|Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )
16336991|NCT04421274|Sham Comparator|Control group|Receive the best medication, percutaneous coronary intervention
16336992|NCT04421261||Air-Q Self Pressurized Airway Device with Blocker|
16336993|NCT04421261||I-Gel|
16337492|NCT04417803|Other|Hodgkin's lymphoma|
16336994|NCT04421248||Attention Deficit Hyperactivity Disorder (ADHD)|8 to 12 year old children diagnosed with ADHD
16336995|NCT04421248||Typically developing controls (TDC)|Typically developing controls - 8 to 12 year old children
16336996|NCT04421235|Other|Childbirth Support|Women who enroll in the intervention portion of this study will receive the childbirth support elements for which they are eligible in and elect to participate. Possible program elements include prenatal education classes, support group, lactation program, doula support, and parenting classes.
16336997|NCT04421222|Experimental|Cohort 1|200 mg EPI-7386
16336998|NCT04421222|Experimental|Cohort 2|400 mg EPI-7386
16336999|NCT04421222|Experimental|Cohort 3|600 mg EPI-7386
16337000|NCT04421222|Experimental|Cohort 4|800 mg EPI-7386
16337001|NCT04421222|Experimental|Cohort 5|1000 mg EPI-7386
16337002|NCT04421222|Experimental|Cohort 6|800 mg EPI-7386
16337003|NCT04421209|Experimental|Propranolol treatment|"Subjects randomized to the propranolol treatment arm will be administered propranolol 40mg BID for three days prior to surgery, 40mg BID the day of surgery and on post-operative days 1 and 2. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.
~Patients will be evaluated for opioid usend pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.
~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers, and if this correlates to decreased opioid use and pain scores post-operatively.
~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
16337004|NCT04421209|Placebo Comparator|Placebo|"Subjects randomized to the placebo treatment arm will be administered placebo tablets with the same schedule as propranolol in the experimental arm. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.
~Patients will be evaluated for opioid use and pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.
~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers compared to placebo, and if this correlates to decreased opioid use and pain scores post-operatively.
~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
16337005|NCT04421196|No Intervention|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.
~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) & Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
16337006|NCT04421196|Experimental|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.
~The modified multimodal analgesic regimen utilizes the following medications:
~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
16337007|NCT04421183||1|preeclampsia
16337008|NCT04421183||4|normal pregnancy without complication
16337009|NCT04421183||2|hellp
16337010|NCT04421183||3|eclampsia
16337011|NCT04421170|Experimental|Intervention Group|Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
16337012|NCT04421170|No Intervention|Control group|Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
16337013|NCT04421157|Experimental|Schroth group|The Schroth group received Schroth exercises in addition to traditional rehabilitation.
16337014|NCT04421157|Experimental|Stabilization group|The stabilization group received core stabilization in addition to traditional rehabilitation.
16337015|NCT04421144|Experimental|study group|using CAD/CAM surgical cutting guides for maxilla and mandible and customized titanium plates to guide all osteotomies and fixation of both arches.
16337016|NCT04421131|Experimental|mIVAA|Screened for cervical cancer with mIVAA in mobile units
16337017|NCT04421131|No Intervention|Historical controls|Screened for cervical cancer in mobile units using standard of care; Data from medical records of women screened in the year(s) prior to mIVAA implementation
16337018|NCT04421118||standard portal pressure gradient measurement and CT scan|"Procedure/Surgery:
~Portal pressure gradient measurement and CT imaging examination. Three-dimensional models reconstructing and fluid dynamics simulation."
16337019|NCT04421105|Experimental|Group 1 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
16337080|NCT04420728|Active Comparator|Delayed auto mode enabled|Auto mode continuous glucose monitoring enabled 12 weeks post-partum
16337020|NCT04421105|Experimental|Group 2 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
16337021|NCT04421105|Experimental|Group 3 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
16337022|NCT04421105|Placebo Comparator|Group 4 N=12|6 doses 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
16337023|NCT04421092|Experimental|Steroid-Lidocaine Mixture|Will receive numbing injection, which is a mixture of steroid and lidocaine
16337024|NCT04421092|Placebo Comparator|Placebo|Will receive saline injection as a placebo
16337025|NCT04421079|Placebo Comparator|Placebo|Comparable placebos
16337026|NCT04421079|Active Comparator|Low Dose BDPP|8 oz. Concord grape juice + 450 mg Grape seed polyphenol extract + 150 mg Trans-resveratrol
16337027|NCT04421079|Active Comparator|Medium Dose BDPP|16 oz. Concord grape juice + 900 mg Grape seed polyphenol extract + 300 mg Trans-resveratrol
16337028|NCT04421079|Active Comparator|High Dose BDPP|24 oz. Concord grape juice + 1200mg Grape seed polyphenol extract + 450mg Trans-resveratrol
16337029|NCT04421066||Peri-implantitis|Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.
16337030|NCT04421066||Healthy|Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.
16337033|NCT04421027|Experimental|Baricitinib|4 milligrams (mg) of baricitinib given orally with background therapy.
16337034|NCT04421027|Placebo Comparator|Placebo|Placebo given orally with background therapy.
16337035|NCT04421014|Active Comparator|HVMN Ketone Ester/ Arm 1|25 participants
16337036|NCT04421014|Placebo Comparator|Placebo/ Arm 2|25 participants
16337037|NCT04421001|Experimental|I-Port™*(Medtronic) use Arm|Patients will administer insulin via iport system. I-Port™* (Medtronic), infusion set, dedicated for insulin deliery for 72 hours.
16337038|NCT04421001|Active Comparator|Insulin Pen Injections|Patients will administer insulin via injections as usual
16337039|NCT04420975|Experimental|Treatment (BO-112, nivolumab)|Patients receive BO-112 intratumorally on days 1, 8, and 15 and nivolumab IV over 30-60 minutes on days 8 and 22 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
16337040|NCT04420962||Microbial Keratitis|Presence of a bacteria or fungal keratitis with ≥ 2mm stromal infiltrate
16337041|NCT04420962||Viral or Inflammatory Keratitis|Non-infectious inflammatory, Viral, Acanthamoeba, or other forms of keratitis
16337042|NCT04420949|Experimental|Healthy|Healthy adults with visually-induced dizziness with undergo the testing and treatment.
16337043|NCT04420949|Experimental|Vestibular-impaired|Adults with unilateral or bilateral, peripheral vestibular loss who also have visually-induced dizziness with undergo the testing and treatment.
16337044|NCT04420936|Experimental|Lifestyle coaching|
16337045|NCT04420936|Active Comparator|Control tracking|
16337046|NCT04420923|Experimental|Observe-and-Plan|Patients will follow the same protocol as described by dr. Mantel et al. (2014) in the first Observe-and-Plan study conducted in Lausanne.
16337047|NCT04420923|Active Comparator|Treat-and-Extend|Patients will follow the standard treatment protocol for Treat-and-Extend, used for several years in the participating clinics.
16337048|NCT04420910||Parkinson's disease group|being diagnosed with PD by a neurologist, being in Hoehn & Yahr Stage 1-3
16337049|NCT04420910||Healthy group|20 healthy volunteers with matching ages and genders.
16337050|NCT04420897||Normoxy: PaO2 = 80-120 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
16337051|NCT04420897||Moderate hyperoxemia: PaO2 =120-200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
16337081|NCT04420715|Experimental|Less-experienced group|The participant who has completed the number of PCI less than 200 before recruiting
16337082|NCT04420715|Experimental|Experienced group|The participant who has completed the number of PCI more than 200 before recruiting
16337112|NCT04420468||Possible COVID-19 infection and acute myocarditis|"Children presented with an acute myocarditis, fever and shock with a possible COVID-19 infection cared between April 2020 till the end of the main SARS-Cov-2 outbreak in 4 AP-HP Parisian hospitals :
~Necker-Enfants Malades
~Armand Trousseau
~Robert Debré
~Kremlin Bicêtre"
16337052|NCT04420897||Severe hyperoxemia: PaO2 >200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
16337053|NCT04420884|Experimental|Monotherapy Dose Escalation Phase: TAK-676 SA|"Safety Lead-in: TAK-676 0.1 milligram (mg), infusion, intravenously, once weekly, on Days 1, 8 and 15 in 21-day treatment Cycles.
~TAK-676 SA Dose Escalation: TAK-676 SA, infusion, intravenously, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the TAK-676 SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in Phase."
16337054|NCT04420884|Experimental|Combination Dose Escalation Phase: TAK-676 + Pembrolizumab|"TAK-676, infusion, intravenously, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above) plus pembrolizumab 200 mg, infusion, intravenously, once on Day 1 in each 21-day treatment cycles.
~The dosing will be initiated based on the available safety and tolerability data from the initial TAK-676 SA cohorts."
16337055|NCT04420871|Active Comparator|capecitabine reference formulation at a single dose of 150 mg|150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
16337056|NCT04420871|Experimental|capecitabine test formulation at a single dose of 150 mg|The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.
16337057|NCT04420858|Other|Control|The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit.
16337058|NCT04420858|Experimental|Experimental|The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA).
16337059|NCT04420845|Other|Intervention|
16337060|NCT04420832|Active Comparator|Surgical treatment|Patients with a distance of 5 mm or more between tendon ends will be treated surgically and with physiotherapy
16337061|NCT04420832|Other|Non-surgical treatment|Patients with a distance of less than 5 mm between tendon ends will be treated non-surgically and with physiotherapy
16337062|NCT04420819|Experimental|IPC-LOP|this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
16337063|NCT04420819|Experimental|IPC-40%|this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
16337064|NCT04420819|Placebo Comparator|IPC-10mmHg:|this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
16337065|NCT04420819|No Intervention|CONTR|this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
16337066|NCT04420806|Active Comparator|HIT-exercise|13 months of high intensity endurance and resistance exercise - 3 months of exercise break
16337067|NCT04420806|Sham Comparator|control|no exercise intervention that affect the present study outcomes
16337068|NCT04420793||ECT and Voice Recorded Group|This is an add-on study of voice samples to be gathered during ECT clinical treatments. The ONLY research procedures are four tasks on an online form, one text task and three voice recording tasks. These voice recordings will take place in a private room on the 5th floor of the Institute of Psychiatry on the same day of a patient's ECT treatment. The questionnaire will take less than 10 minutes.
16337069|NCT04420780|Experimental|Xyl Group|Children will receive sugar-free gums containing 100% Xylitol as sweetener
16337070|NCT04420780|Active Comparator|Pol Group|Children will receive sugar-free gums containing a polyols mixture plus a low amount of Xylitol (22%).
16337071|NCT04420767|Experimental|tDCS and Go-No Go task|"Certain randomly assigned participants will receive tDCS to the DLPFC for 8 daily 20-minute sessions, with a TDCS amplitude of 2 mAmps.
~During the tDCS session, individuals will perform a 10-min computerized Go-No Go task"
16337072|NCT04420767|Sham Comparator|Sham brain stimulation and Go-No Go task|"Certain randomly assigned participants will receive Sham Stimulation to the DLPFC for 8 daily 20-min sessions. The Sham stimulation is an inactive form of stimulation.
~During the sham brain stimulation session, individuals will perform a 10-min computerized Go-No Go task"
16337073|NCT04420754|Experimental|Cohort -1|AIC100 Cell Dose Level -1 (Flat Dose): 1 x 10e6 CAR T cells
16337074|NCT04420754|Experimental|Cohort 1|AIC100 Cell Dose Level 1 (Flat Dose): 1 x 10e7 CAR T cells
16337075|NCT04420754|Experimental|Cohort 2|AIC100 Cell Dose Level 2 (Flat Dose): 1 x 10e8 CAR T cells
16337076|NCT04420754|Experimental|Cohort 3|AIC100 Cell Dose Level 3 (Flat Dose): 5 x 10e8 CAR Tcells
16337077|NCT04420741|Experimental|Iloprost|Patients randomized to active treatment (n=40 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
16337078|NCT04420741|Placebo Comparator|Isotonic saline|Patients randomized to placebo treatment (n=40 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
16337079|NCT04420728|Experimental|Early auto-mode enabled|Auto mode continuous glucose monitoring enabled 2-10 days post-partum
16338324|NCT04411641|Placebo Comparator|Placebo|Placebo tablet to match SAR442168 once daily
16337083|NCT04420702|Experimental|Early Detection Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy
~Standard of care prostate biopsy will be performed within 12 weeks of MRI
~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
16337084|NCT04420702|Experimental|Active Surveillance Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy
~Standard of care prostate biopsy will be performed within 12 weeks of MRI
~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
16337085|NCT04420689|Experimental|Dose Escalation/De-Escalation Cohorts|This arm of the study will include Dose Escalation/De-Escalation cohorts of ALM-488.
16337086|NCT04420689|Experimental|Dose Timing Cohorts|This arm of the study will include Dose Timing cohorts of ALM-488.
16337087|NCT04420676|Active Comparator|Probiotic|Group 1: receiving a probiotic mixture (Omni-Biotic® 10 AAD) twice a day
16337088|NCT04420676|Placebo Comparator|Placebo|Group 2: receiving a similar looking and tasting placebo without bacteria twice a day
16337089|NCT04420663|Experimental|Manometer Group|"Therapeutic thoracentesis will be performed in a sitting position. wide bore catheter as a pleural catheter will be inserted into the pleural cavity. simple water manometer will be connected to the pleural catheter via 3-way adapter.connected to the infusion lines with one draining into the drainage collection bottle and the other pre-flushed with normal saline hanging down till 40 cm below the puncture site and then rising up (forming a U) with the ascending arm taped to the IV stand. baseline pleural pressure will be registered before the beginning of pleural fluid withdrawal. Pleural pressure curve will subsequently be registered after the withdrawal of each 200 ml of pleural fluid up to a total volume of 1000 ml."
16337090|NCT04420663|No Intervention|Conventional Group|Therapeutic thoracentesis will be performed in a sitting position. The skin will be cleaned with betadine antiseptic solution. Pleural aspiration should take place in a clean area using full aseptic techniques. 5-10 cc Lidocaine 2% will be given as local anesthetic in the site of puncture. the IV cannula is advanced till fluid is aspirated. Then, the needle is withdrawn and the catheter is fixed to two 3-way adapters fixed in series placed in between. connected to the infusion lines with one draining into the drainage collection bottle.
16337091|NCT04420650|Active Comparator|Anodal tDCS|Anodal tDCS of the hypothalamus-cognitive network
16337092|NCT04420650|Active Comparator|Cathodal tDCS|Cathodal tDCS of the hypothalamus-cognitive network
16337093|NCT04420650|Sham Comparator|Sham Stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
16337096|NCT04420598|Experimental|Trastuzumab deruxtecan (DS-8201a)|"Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);
~Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;
~Cohort 3: HER2-positive BC with progressing BMs after local treatment;
~Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;
~Cohort 5: HER2-positive or HER2-low expressing BC with LMC."
16337097|NCT04420585|Experimental|Treatment Group|Desmopressin 0.2mg tablets, dose titrated to effect
16337100|NCT04420559|Experimental|Virtual Reality|
16337101|NCT04420559|Experimental|Distraction Card|
16337102|NCT04420559|No Intervention|Control|
16337103|NCT04420546|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to be more physically active (We want you to plan to increase your level of physical activity). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted not to be physically active and identifying ways to overcome those temptations had been shown to help people change their behaviour.
~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
16337104|NCT04420546|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.
~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
16337105|NCT04420533|Active Comparator|Behavior therapy alone|Behavior therapy alone
16337106|NCT04420533|Experimental|Behavior therapy plus mirabegron 50mg|Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
16337107|NCT04420507||GDM group|pregnant women who are diagnosed after 75g OGTT test between 24~27+6 gestational weeks
16337108|NCT04420507||health group|pregnant women who pass the 75g OGTT test and aren't diagnosed as GDM, and also don't have any other conditions, like hypertensive disorders, IBD, gastrointestinal ulcer, and so on.
16337109|NCT04420494|Experimental|Patients treated with umbilical cord blood|
16337110|NCT04420481|Active Comparator|Growth hormon group|A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.
16337111|NCT04420481|Placebo Comparator|Control group|A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.
16338325|NCT04411628|Experimental|LY3819253|LY3819253 administered intravenously (IV).
16337113|NCT04420455|Experimental|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
16337114|NCT04420442|Active Comparator|Intervention Group|In addition to the comparison between arm 1 and 2, there will be an intraindividual comparison within arm 1.
16337115|NCT04420442|No Intervention|Control Group|No Intervention.
16337116|NCT04420429||Cohort|All patients
16337117|NCT04420403|Experimental|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
16337118|NCT04420403|Active Comparator|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
16337119|NCT04420390|Experimental|Radiotherapy|
16337120|NCT04420377|Placebo Comparator|Placebo Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
16337121|NCT04420377|Experimental|Experimental Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a treatment condition (Carnipure™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
16337122|NCT04420364|Experimental|Maintenance of Immunosuppression|Maintenance of immunosuppression (defined as no change to pre-admission immunosuppression, or reduction in anti-metabolite by up to 50% (to a minimum of MMF 500 mg per day or azathioprine 50 mg per day)
16337123|NCT04420364|Active Comparator|Reduction of Immunosuppression|Reduction of immunosuppression (defined as anti-metabolite withdrawal plus reduction of tacrolimus or cyclosporin, to a minimum target trough concentration of 3 ng/mL for tacrolimus and 50 ng/mL for cyclosporin).
16337124|NCT04420351|Experimental|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
16337125|NCT04420351|Other|Antiplatelet treatment|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
16337126|NCT04420338|Experimental|Chronic hemodialysis patients|
16337127|NCT04420338|Experimental|Caregivers of chronic hemodialysis patients|
16337128|NCT04420312||Group 1|Enrolled the Covid-19 patients with a negative CT Pulmonary Angiogram.
16337129|NCT04420312||Group 2|Enrolled the Covid-19 patients in whom only a CT was performed.
16337130|NCT04420299|Experimental|Experimental - therapeutic bemiparin dose|Sub-cutaneous dose of bemiparin at therapeutic dose for 10 days
16337131|NCT04420299|Experimental|Control - prophylactic bemiparin dose|Sub-cutaneous dose of bemiparin at prophilactic dose for 10 days
16337132|NCT04420286||Hospital having ICU beds|Hospital having ICU beds during COVID-19 outbreak in France
16337133|NCT04420273|Experimental|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
16337134|NCT04420273|Active Comparator|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
16337135|NCT04420273|Experimental|Home sample collection of of concerning moles|The participant will be given directions about taking a picture of the concerning mole. The picture will be reviewed by the physician, who determines if the pigmented lesion is concerning and sends an adhesive patch skin sample collection kit to the participant. The participant will receive directions about obtaining the sample, and returning it to the processing laboratory. The physician will obtain the results of the genomic analysis and provide them to the participant. If the test results indicate that the concerning mole requires a biopsy, then the participant will be advised to seek an appointment within the Northwestern Medicine Healthcare System.
16337136|NCT04420260|Experimental|Treatment oropharyngeal spray + immunostimulant emulsion|Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
16337137|NCT04420260|Placebo Comparator|Placebo|Placebo oropharyngeal spray + Placebo emulsion was taken PO.
16337138|NCT04420247|Experimental|Intervention|"Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital:
~Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days.
~+
~Standard treatment available and recomended by the Brazilian Guidelines for COVID-19."
16337139|NCT04420247|Active Comparator|Control|Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.
16337140|NCT04420234|Experimental|Pharmacokinetics study of single and multiple administration|During the study session, 30 healthy subjects will be administered a single and multiple dose of narfurine hydrochloride orally disintegrating tablets 5 µg (2.5 µg/table) to evaluate the pharmacokinetic parameters and the safety profile.
16337180|NCT04419974||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
16337153|NCT04420195|Experimental|Envarsus XR|Envarsus XR to be initiated once patient is tolerating oral medications
16337154|NCT04420195|Experimental|IR tacrolimus (historical control)|Historical cohort of patients maintained on IR tacrolimus following transplant
16337155|NCT04420182|Other|COVID-19 Virtual Care at Home|"VIRTUES COVID-19 Care at Home Platform
~The components of the platform will include:
~Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data.
~Symptom logs will be entered by the patients.
~Feedback to the patient by the local COVID-19 care team for any action:
~Two-way communication between the patient and the COVID-19 care team
~Ability for team members to see all prior notes in order to have continuity of care
~Reports of these interactions are transmitted to the patient's health record
~Current information on COVID-19 as per the Public Health Agency of Canada"
16337156|NCT04420169||PRE implementation communication protocol|
16337157|NCT04420169||POST implementation communication protocol|
16337158|NCT04420156||i-ROP cohort|Premature infants who are at risk of retinopathy of prematurity(ROP) at participating study sites. As standard of care, babies who are born less than 31 weeks gestational age or less than 1500 grams are routinely screened for ROP. Families are approached to participate in this study where finding from babies' eye exams and associated retinal images along with demographic and other health data are collected and coded with unique identifier. No intervention is administered. The ROP exams and images obtained are done as a standard of care and would be performed even if there is no consent provided.
16337159|NCT04420143||MLX - Medial Lateral Expandable Lumbar Interbody System|Patients who underwent lumbar interbody fusion with the MLX expandable interbody implant will be included in the MLX - Medial Lateral Expandable Lumbar Interbody System cohort.
16337160|NCT04420143||XLX ACR Interbody System|Patients who underwent lumbar interbody fusion with the XLX ACR expandable interbody implant will be included in the XLX ACR Interbody System cohort.
16337161|NCT04420130|Experimental|Camrelizumab combined with ablation and chemotherapy|First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
16337162|NCT04420104|Experimental|esp block group|
16337163|NCT04420104|Active Comparator|control group|
16337164|NCT04420091|Experimental|Cartidyss|
16337165|NCT04420078||CA BrS|Symptomatic BrS patients who underwent catheter ablation of the BrS/VF substrate
16337166|NCT04420065|Active Comparator|Classical biventricular pacing|Commercially available LV-pacing capable CRT devices and quadripolar leads will be implanted. Right ventricular (RV) and right atrial (RA) leads will be placed according to standard practice. The LV lead will also be placed according to standard practice, targeting to a lateral, posterolateral, or anterolateral branch of the coronary sinus (CS). Interventricular delay programmed will be determined based on stroke volume maximization, and will be used as a criterion for BVP optimization. Atrioventricular delay optimization shall be automatically performed by the device.
16337167|NCT04420065|Experimental|Preferential left ventricular pacing|In G2 patients, an algorithm for preferential left ventricular pacing will be activated. Following selection of the dipole maximizing stroke volume during simultaneous LV-RV pacing, subsequent V-V delay optimization shall be delegated to the algorithm. Based on previous studies, a subgroup analysis of G2 will be performed, comparing those receiving ≥50% with those receiving <50% preferential LV pacing evaluated over the total duration of the study (12 months).
16337168|NCT04420052|Experimental|OMT group|
16337169|NCT04420052|Placebo Comparator|Placebo group|
16337170|NCT04420039||1- Single biliary LAMS|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent after failed ERCP cannulation or inaccessible papilla.
16337171|NCT04420039||2- Biliary LAMS plus Doublu-Pigtail plastic Etent|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent (plus double-pigtail plastic stent) after failed ERCP cannulation or inaccessible papilla.
16337172|NCT04420026|Experimental|Experimental Arm|Hepatocellular tumours
16337173|NCT04420013||exposed group|for CRC patients with non-resectable hepatic metastases: surgery for CRC combined with RFA.
16337174|NCT04420013||no-exposed group|for CRC patients with resectable metastases: surgery only without RFA.
16337175|NCT04420000|Experimental|Interventional group|Patients having a Mindfulness program
16337176|NCT04420000|Placebo Comparator|Control group|Patients having a routinary managment
16337177|NCT04419987|Experimental|constitutional platelet patholog|Patient and relatives having a constitutional platelet pathology
16337178|NCT04419974||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
16337179|NCT04419974||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
16337181|NCT04419961|No Intervention|Control|Routine care.
16337182|NCT04419961|Experimental|Intervention|Routine care plus participation in an educational program including a group discussion and a booklet.
16337183|NCT04419948|Experimental|Control|100g white bread plus 40ml butter
16337184|NCT04419948|Experimental|Positive control|100g white bread plus 40ml butter and 400mg ibuprofen
16337185|NCT04419948|Experimental|Refined olive oil|100g white bread plus 40ml refined olive oil
16337186|NCT04419948|Experimental|EVOO with moderate concentration of oleocanthal|100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal
16337187|NCT04419948|Experimental|EVOO with high concentration of oleocanthal|100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal
16337188|NCT04419922||Smartphone Contingency Management Arm|100 participants will be voluntarily recruited at BrightView's Colerain outpatient treatment center to participate in the Smartphone Contingency Management Intervention.
16337189|NCT04419909|Experimental|Retreatment with CTL019/CTL119|All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures.
16337190|NCT04419896||Retrospective|"Inclusion criteria for Retrospective Subjects:
~Men and women 18 years or older;
~Is or was a patient of a Participating Practice and was previously tested with Germline, Genomic, or other Biomarker Tests; and
~For Germline Genetic Test patients, have a diagnosis of cancer or pathogenic or likely pathogenic (P/LP) result."
16337191|NCT04419896||Prospective|"Inclusion criteria for Prospective Subjects:
~Men and women aged 18 years or older;
~Presents consecutively to a Participating Practice and who has previously been screened and tested (i.e., is a new patient scheduled for a visit at a Participating Practice or is an existing patient who returns to a Participating Practice);
~Receives or has received Germline, Genomic, or other Biomarker Testing, either through a prior healthcare provider or a Participating Practice; and
~Consents to be a part of the Registry."
16337192|NCT04419883||Anesthesia Providers|Anesthesia providers from 15 different health care facilities in the United States.
16337193|NCT04419870||Group 1a|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
16337194|NCT04419870||Group 1b|Patients with mitochondrial disease who are NOT ill with acute infection
16337195|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
16337196|NCT04419857|Experimental|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
16337197|NCT04419857|No Intervention|Standard calorie formula|Infant randomly assigned to standard-calorie formula for 14 days
16337198|NCT04419844|Active Comparator|TAR with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect Botox injection .
16337199|NCT04419844|Active Comparator|TAR without Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect without Botox injection .
16337200|NCT04419831|Experimental|Healthy volunteers|
16337201|NCT04419831|Experimental|Binge Heavy drinkers|
16337202|NCT04419831|Experimental|Cannabis Use Disorder|
16337203|NCT04419831|Experimental|Alcohol Use Disorder|
16337204|NCT04419831|Experimental|Individuals with Moderate to Severe Pain|
16337205|NCT04419831|Experimental|Opioid Use Disorder in medication assisted treatment|
16337206|NCT04419818||Left brain damaged patients|"A group of 20 left brain damaged (LBD) patients will perform:
~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);
~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;
~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
16337207|NCT04419818||Right brain damaged patients|"A group of 20 right brain damaged (RBD) patients will perform:
~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);
~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;
~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
16337208|NCT04419818||Healthy controls|"A group of 40 (20 young and 20 elderly) healthy controls (HC) will perform:
~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);
~a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria;
~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
16337209|NCT04419805|Experimental|Single Palatal TAD|Single Palatal TAD for orthodontic molar intrusion
16337210|NCT04419805|Experimental|Two buccal TADs|Two buccal TADs for orthodontic molar intrusion
16337211|NCT04419792||Narcolepsy|
16337212|NCT04419779|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.
16337213|NCT04419779|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.
16337214|NCT04419766|Experimental|intervention|Community of Tambai: Indoors and outdoors spraying with IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester)
16337215|NCT04419766|No Intervention|Control|Community of Micheu 1: Without spraying.
16337216|NCT04419753|Active Comparator|No Attention Focus Walking Group (NAFWG)|In each training session, the NAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway without attention focus instruction (20 minutes) and cool down (5 minutes).
16337217|NCT04419753|Experimental|External Attention Focus Walking Group (EAFWG)|In each training session, the EAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with external attention focus instructions (20 minutes) and cool down (5 minutes).
16337256|NCT04419467|Experimental|CSL346 (low dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
16337257|NCT04419467|Experimental|CSL346 (high dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
16337218|NCT04419753|Experimental|Internal Attention Focus Walking Group (IAFWG)|In each training session, the IAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with internal attention focus instructions (20 minutes) and cool down (5 minutes).
16337219|NCT04419740|Experimental|Mindfulness based psychological intervention|"Patients allocated to the intervention group will receive an email with a link to a video and a pdf document. The video and the pdf document will introduce them to the principles and the practice of mindfulness. They will also receive an access code to an e-tool valid for 1 month. On this e-tool the patient will have access to short guided meditations both general and specific to infertility. They will be instructed to follow the découverte (discovery) program of 8 meditations of 10 minutes and then the program désir de parentalité (wish to become a parent) of 13 minutes 15 meditations of 13 minutes each. Patients will be given access to all other meditations programs of PetitBambou and instructed to meditate with the program for at least 10-15 minutes on a daily basis."
16337220|NCT04419740|No Intervention|Standard care|The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
16337221|NCT04419701|Experimental|periarticular infiltration group|will receive intraoperative periarticular infitration consisting of 89.5 mL of normal saline, 20 mL of 5% bupivacaine and 0.5 mL of adrenaline (4.5 ugm/ml) with a concentration 1:220000 (total volume: 110 mL)
16337222|NCT04419701|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% with adrenaline 2.5 µg/ml with a concentration 1:400000 in the immediate postoperative period.
16337223|NCT04419688|Experimental|STT-5058|
16337224|NCT04419688|Placebo Comparator|Placebo|
16337225|NCT04419662|Experimental|All patients included|
16337226|NCT04419649|Experimental|KER-050 Cohort 1|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
16337227|NCT04419649|Experimental|KER-050 Cohort 2|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
16337228|NCT04419649|Experimental|KER-050 Cohort 3|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
16337229|NCT04419649|Experimental|KER-050 Cohort 4|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
16337230|NCT04419649|Experimental|KER-050 Dose Confirmation Cohort|Participants to receive KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
16337231|NCT04419636|Experimental|Part A Single doses|Lu AG06466 in fast and fed state
16337232|NCT04419636|Experimental|Part B Repeated doses|Lu AG06466 after light meal
16337233|NCT04419623|Experimental|Dose Finding - 200mg BID|200mg TL-895 orally BID taken continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
16337234|NCT04419610|Experimental|Patients with confirmed/suspected C19 given intervention|Intravenous infusion of either placebo or TRV027 at 12mg/hr. Treatment will continue until discharge or for 7 days (whichever is sooner).
16337235|NCT04419610|Placebo Comparator|Patients with confirmed/suspected C19 given no intervention|Saline infusion.
16337236|NCT04419597|Experimental|HEMOPATCH Collagen Patch and PEG Haemostatic Sealant|Two units of the large patch are applied as reinforcement of the primary dural seal (HEMOPATCH 4,5x9cm, 1506253).
16337237|NCT04419597|Active Comparator|Standard of care treatment|Usual clinical practice techniques for reinforcing primary dural closure.
16337238|NCT04419584|Experimental|Modified Qing-Ying Decoction|Herbal granules, twice per day for 12 weeks
16337239|NCT04419584|Placebo Comparator|Identical looking placebo|Placebo granules, twice per day for 12 weeks
16337240|NCT04419571||Suspected or Confirmed COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) with clinically or radiologically suspected COVID-19, or with viral PCR confirmation; diagnosis made 7-days before and 30-days after date of surgery in accordance with the COVIDsurg study criteria (3).
16337241|NCT04419571||Negative or non-suspected COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) without clinically or radiologically suspected COVID-19, or without viral PCR (Polymerase Chain Reaction) confirmation.
16337242|NCT04419558|Experimental|Pamrevlumab|"Treatment phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks, for a total of 17 infusions over 48 weeks.
~Open-label extension phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks for up to 48 weeks"
16337243|NCT04419558|Experimental|Placebo|Pamrevlumab-matching placebo administered by intravenous infusion every 3 weeks for a total of 17 infusions over 48 weeks
16337244|NCT04419545||interstitial pneumonia cases|Chest x-ray diagnosis
16337245|NCT04419545||Negative controls|Chest x-ray Negative for pneumonia
16337246|NCT04419532|Experimental|Dose Escalation (DS-1055a)|Participants will be enrolled into groups with each group receiving an increased dose from the previous group as safety assessments permit in order to determine the optimal dose for safety and tolerability.
16337247|NCT04419519|Experimental|Venetoclax monotherapy|
16337248|NCT04419519|Experimental|Venetoclax with anti-CD20 monoclonal antibody|
16337249|NCT04419506|Experimental|BI 1015550|
16337250|NCT04419506|Placebo Comparator|Placebo|
16337251|NCT04419493|Experimental|Part B: Test treatment (T)|
16337252|NCT04419493|Active Comparator|Part B: Reference treatment (R)|
16337253|NCT04419493|Experimental|Part A: Test|Open-label
16337254|NCT04419480|Experimental|CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge implantation of the CardioMEMS device will receive that device ≤14 days following discharge from the index hospitalization for Cardiogenic Shock, in addition to local standard of care medical therapy.
16337255|NCT04419480|No Intervention|Non-CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge standard of care will be treated according to local standard of care medical therapy following their index hospitalization for Cardiogenic Shock.
16338326|NCT04411628|Placebo Comparator|Placebo|Placebo administered IV.
16337258|NCT04419467|Placebo Comparator|Placebo|Administered as a single IV loading dose followed by SC infusions
16337259|NCT04419441||treated patients|patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
16337260|NCT04419415|Experimental|Skipping breakfast and maintain habitual physical activity|Subject will skip breakfast and maintain habitual physical activity.
16337261|NCT04419415|Experimental|High protein breakfast and maintain habitual physical activity|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and maintain habitual physical activity.
16337262|NCT04419415|Experimental|Skipping breakfast and exercising three times per week|Subject will skip breakfast and participate in organized exercise-training three times per week (and maintain habitual physical activity)
16337263|NCT04419415|Experimental|High protein breakfast and exercising three times per week|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
16337264|NCT04419402|Experimental|Lu-PSMA + Enzalutamide|"Lu-PSMA - 7.5 GBq (± 10%): doses 1 and 2 (Days 15 and 57). Doses 3 and 4 (Days 113 and 169) will be given following result of PSMA PET/CT scans at Day 92.
~Enzalumatide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity."
16337265|NCT04419402|Active Comparator|Enzalutamide|Enzalutamide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity.
16337266|NCT04419389|Experimental|Safety Lead-In Cohort 1|APR-246 + Acalabrutinib in Subjects with R/R CLL.
16337267|NCT04419389|Experimental|Safety Lead-In Cohort 2|APR-246 + Venetoclax + Rituximab in Subjects with R/R CLL.
16337268|NCT04419389|Experimental|Expansion Cohorts|APR-246 + (Acalabrutinib, OR, (Ven+R)) in Subjects with R/R TP53-mutant CLL, and/or MCL, and/or RT
16337269|NCT04419389|Experimental|Safety Lead-In Cohort 3|APR-246 + Venetoclax + Rituximab in Subjects with RT
16337270|NCT04419376||Patients with pARDS|Within 7 days of known clinical insult Respiratory failure not fully explained by cardiac failure or fluid overload chest imaging findings of new infiltrate(s) consistent with acute pulmonary parenchymal disease patients with an oxygenation index (OI) ([FIO2 × mean airway pressure × 100]/PaO2) above 4
16337271|NCT04419376||Patients with non-pARDS|non-pARDS patients who received mechanical ventilation support due to respiratory failure.
16337272|NCT04419363|Experimental|The whole cohort|Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab
16337273|NCT04419350|Experimental|treatment|microneedling.
16337274|NCT04419350|No Intervention|No treatment|No treatment will be done to these hypopigmented lesions
16337275|NCT04419337|Experimental|Active arm|metformin+pioglitazone+an SGLT2 inhibitor
16337276|NCT04419337|Active Comparator|Control arm|metformin with or without combination with following oral antidiabetic drugs: DPP4 inhibitor, sulfonylurea, and acarbose.
16337277|NCT04419324|Other|esophago-gastroscopy endoscopy with narrow band imaging|a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
16337278|NCT04419311|Experimental|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
16337279|NCT04419311|Experimental|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
16337280|NCT04419298||Acute CO poisoning with myocardial injury|"A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers).
~Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival."
16337281|NCT04419285|Experimental|Retinitis Pigmentosa patients|50 patients with very severe Retinitis Pigmentosa
16337282|NCT04419272|Experimental|Methylphenidate|Subjects who will receive methylphenidate in the double-blinded period; when assigned to the active drug, the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 3 weeks.
16337283|NCT04419272|Placebo Comparator|Placebo|Subjects who will receive placebo in the double-blinded period; when assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 4 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
16337284|NCT04419259|Experimental|Erenumab|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
16337285|NCT04419246|Active Comparator|Group I|interscalene block + General anesthesia
16337286|NCT04419246|Active Comparator|Group T|Tranexamic acid +General anesthesia
16337287|NCT04419246|Sham Comparator|Group S|General anesthesia
16337288|NCT04419233||All Participants|Participants with 5q SMA and who were prescribed with nusinersen sodium injection in China according to the local marketing authorization.
16337289|NCT04419220||Observational|Doppler Ultrasound will be performed in all subjects.
16337290|NCT04419207||Patients with Surbery|Patients who with pulmonary nodules in computed tomography and planned to receive thoracic surgery will be included. And those who have other types of cancer, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
16337291|NCT04419207||Healthy Controls|Adult participants (>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
16337292|NCT04419194||Observation|Observation
16337293|NCT04419181|Experimental|Pathologic complete response (pCR)|Participants will receive four cycles of TCHP [docetaxel (Taxotere®), carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who achieve pathologic complete response will receive infusions of trastuzumab every 3 weeks for a total of 12 cycles/infusions.
16337375|NCT04418700|Experimental|Breath Stacking technique|"The intervention group will receive routine physical therapy associated with the Breath Stacking technique in 2 daily sessions of up to 20 minutes.
~The technique consists of an Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes."
16337294|NCT04419181|Experimental|Residual Disease|Participants will receive four cycles of TCHP [docetaxel (Taxotere®, carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who have residual disease may be offered two more cycles of TCHP in the adjuvant settings (optional) per treating oncologist's discretion and then will receive infusion of Trastuzumab Emtansine (TDM1) plus pertuzumab every three weeks for a total of 12 cycles/infusions.
16337295|NCT04419168|Experimental|cCBT|Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
16337296|NCT04419168|Experimental|m-Education|Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
16337297|NCT04419168|No Intervention|Convenience Comparison|Not participating in the intervention. Participants will complete the baseline questionnaire battery only and we will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
16337298|NCT04419142|Experimental|Total infrapatellar fat pad excision group|Infrapatellar fat pad was totally excised during total knee arthroplasty in patients randomized to this group.
16337299|NCT04419142|Experimental|Partial infrapatellar fat pad excision group|Infrapatellar fat pad was partially excised during total knee arthroplasty in patients randomized to this group.
16337300|NCT04419129|Active Comparator|Mobile bearing unicompartmental knee arthroplasty|50 mobile bearing UKA
16337301|NCT04419129|Active Comparator|posterior stabilized fixed bearing total knee arthroplasty|50 posterior stabilized fixed bearing cemented total knee arthroplasty
16337302|NCT04419116|Experimental|tibial preservation bone cut|tibial preservation bone cut following mobile bearing UKA
16337303|NCT04419116|Experimental|tibial conventional bone cut|tibial conventional bone cut following mobilebearing UKA
16337304|NCT04419090|Experimental|Monogenic positive FH, direct contact|
16337305|NCT04419090|No Intervention|Monogenic positive FH, usual care|
16337306|NCT04419090|Experimental|Monogenic negative FH, direct contact|
16337307|NCT04419090|No Intervention|Monogenic negative FH, usual care|
16337308|NCT04419077|Other|Virtual reality exposure|Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
16337309|NCT04419038|Active Comparator|conjunctival autografting with MMC|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
16337310|NCT04419038|Active Comparator|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
16337311|NCT04419025|Active Comparator|NAC|Patients receiving N-acetylcysteine (NAC)
16337312|NCT04419025|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
16337313|NCT04419012||Patients with AF treated with VKA|
16337314|NCT04419012||Patients with AF treated with NOAC|
16337315|NCT04418999|Experimental|Dexamethasone insert|Per participant, one eye will be randomized to receive the intracanalicular dexamethasone insert at the baseline visit (study eye). DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus at the day 1 visit by pulling the lower lid taught and using a forceps to insert the medication into the lower canaliculus through the lower punctum.
16337316|NCT04418999|Active Comparator|Loteprednol etabonate ophthalmic gel 0.38%|Per participant, one eye will be randomized to receive the standard of care topical lotemax etabonate ophthalmic gel 0.38% (control eye). Patients will be prescribed a loteprednol etabonate ophthalmic gel 0.38% and will instill one drop into the eye following a 4x/day,3x/day,2x/day,1/xday weekly taper
16337317|NCT04418986|Sham Comparator|Control (CCI Group)|The Participants will undergo phacoemulsification with on-axis incision
16337318|NCT04418986|Active Comparator|Study (OCCI Group)|The Participants will undergo phacoemulsification with opposite clear corneal incisions
16337319|NCT04418973|Experimental|A - load/apnea|Threshold inspiratory load then apnea
16337320|NCT04418973|Experimental|B- apnea/load|apnea than threshold inspiratory load
16337326|NCT04418934|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext One device.
16337327|NCT04418934|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
16337328|NCT04418921|Experimental|Experimental Group|"Intervention on self-regulation will be carried out through a non-immersive virtual reality platform, SR-Mrehab: Un colegio emocionante in which students must conduct a series of activities designed specifically for this purpose. These activities will be performed by the children using mainly their hands to manage the virtual objects showed in the screen. To do this, our system make use of a Kinect motion sensor connected to the computer to control the body movements of the children. Moreover, our system records some relevant data of the execution of these activities for further analysis of the children's performance.The exercises will be divided into two blocks, emotional regulation (ER) and cognitive regulation (CR), in a total of 10 sessions, once a week, performing an exercise of each block per session. Each session will consists of 60 minutes. ."
16337372|NCT04418726|No Intervention|Traditional Monitoring and Intervention|In this group patient receive traditional AVF monitoring, includes clinical assessment for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V.
16337329|NCT04418921|Active Comparator|Control group|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom (5, 49). Each session will last 50 minutes, just like in the experimental group. The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation. The activities are similar for the experimental group, but the virtual reality system will not be used. It will be held in parallel in another room of the school, on the same day and time, carried out by occupational therapists and students from the students in the last year of occupational therapy degree.
16337330|NCT04418908|Active Comparator|GnRHant + E2|Participants in this arm received GnRHant and a transdermal estradiol patch (0.075 mg/day) for a period of 1 week.
16337331|NCT04418908|Placebo Comparator|GnRHant + PL|Participants in this arm received GnRHant and a placebo patch for a period of 1 week.
16337332|NCT04418895|Experimental|Single Arm: Standard of Care|Investigator's choice of total neoadjuvant therapy (TNT) comprised of neoadjuvant chemotherapy and chemoradiation followed by surgical resection; or neoadjuvant chemoradiation followed by surgical resection and then adjuvant chemotherapy.
16337333|NCT04418882||non septic open fracture|patients having had an open fracture without septic evolution
16337334|NCT04418882||septic open fracture|patients having had an open fracture with septic evolution
16337335|NCT04418869|Experimental|Exercise|All subject will perform three different exercise bouts and one control session.
16337336|NCT04418856|Experimental|Experimental light: Breast cancer surgery and chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
16337337|NCT04418856|Active Comparator|Comparison Light:Breast cancer surgery and chemotherapy|Exposed to comparison systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
16337338|NCT04418856|Experimental|Experimental light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
16337339|NCT04418856|Active Comparator|Comparison light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
16337340|NCT04418843|Experimental|Standard Endoscopic Mucosal Resection|Standard Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
16337341|NCT04418843|Experimental|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
16337342|NCT04418830||Base Interfixated System|
16337343|NCT04418830||Brigade Interfixated System|
16337344|NCT04418830||Coalesce Thoracolumbar Interbody|
16337345|NCT04418830||Cohere XLIF Interbody System|
16337346|NCT04418830||CoRoent Ti PLIF Interbody System|
16337347|NCT04418830||CoRoent Ti TLIF Interbody System|
16337348|NCT04418830||MLX - Medial Lateral Expandable Interbody System|
16337349|NCT04418830||Modulus TLIF Interbody System|
16337350|NCT04418830||Modulus XLIF Interbody System|
16337351|NCT04418830||TLX Interbody System|
16337352|NCT04418830||XLX ACR Interbody System|
16337353|NCT04418830||CoRoent Ti XLIF Interbody System|
16337354|NCT04418830||Cohere TLIF|
16337355|NCT04418830||Modulus ALIF|
16337356|NCT04418817||Modulus XLIF Interbody System|
16337357|NCT04418804|Experimental|Healthy|Participants without an active diagnosis of pleural disease.
16337358|NCT04418804|Experimental|Pneumothorax|Participants diagnosed with pneumothorax during the past 24 hours.
16337359|NCT04418804|Experimental|Pleural effusion|Participants diagnosed with current pleural effusion during the past 48 hours.
16337360|NCT04418791|Experimental|MIF-regular|MIF-regular will start with modified intermittent fasting. After 12 weeks, this arm will return to regular diet with no fasting intervention.
16337361|NCT04418791|Experimental|Regular-MIF|Regular-MIF will start with regular diet with no fasting. After 12 weeks, this arm will start with modified intermittent fasting.
16337362|NCT04418778||BEAR intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma
16337363|NCT04418778||BEAR LifeMoves intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma who are currently living in transitional housing at LifeMoves
16337364|NCT04418778||Control Condition|Treatment as usual group, women participating in individual or group therapy but not taking the BEAR group
16337368|NCT04418752|Other|Psychological therapy|Narrative Exposure Therapy will be delivered to all participants in the study except carer participants recruited to complete informant measures.
16337369|NCT04418739|No Intervention|Control Arm|Standard intraoperative fluid regime
16337370|NCT04418739|Experimental|Treatment Arm|Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
16337371|NCT04418726|Experimental|Intensive Monitoring and Preemptive Intervention|In this group patients receive intensive monitoring and preemptive intervention. AVF surveillance refers to using non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa every month. Clinical assessment refers to monitoring for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V. Preemptive intervention is performed as long as problems are recognized, including health education and timely surgery.
16337373|NCT04418713|Experimental|exercise group with active video-games|exergaming exercise: A combination of traditional exercise and exercise through active video games performed 3 days a week for one hour during 7 months. As well, it will be including some session about nutritional advice.
16337374|NCT04418713|No Intervention|control group|no physical intevention will be provided, but it will be included some sessions on nutritional advice.
16337376|NCT04418700|No Intervention|Routine physical therapy|The control group will receive only routine physical therapy. Routine physiotherapy consists of breathing exercises, using techniques bronchial hygiene and pulmonary reexpansion, and motor physiotherapy through exercise passive, active-assisted or active mobilization, stretching, training activities of daily living, positioning and removal of the bed and guidelines for post-discharge.
16337377|NCT04418687|Active Comparator|Physiotherapy only|Standard treatment post Total Knee Arthroplasty
16337378|NCT04418687|Experimental|Physiotherapy + Orthoglide intervention|Standard treatment post TKA, with additional Orthoglide device provided.
16337379|NCT04418674|Experimental|Ketamine|Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.
16337380|NCT04418674|Active Comparator|Fentanyl|Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.
16337381|NCT04418661|Experimental|SAR442720|"Part 1:
~SAR442720 (also known as RMC-4630) will be administered orally with pembrolizumab which is given by IV once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination.
~Part 2:
~SAR442720 (also known as RMC-4630) will be administered orally with pembrolizumab which is given by IV once every 3 weeks (Q3W) or once every 6 weeks (Q6W). Part 2 will assess the antitumor efficacy and safety of adding SAR442720 to pembrolizumab as 1L NSCLC therapy."
16337382|NCT04418648|Experimental|Toripalimab Consolidation|Patients in experimental group will receive toripalimab consolidation (240 mg) via iv infusion Q3W.
16337383|NCT04418648|No Intervention|Observation|Patients in this group will receive observation.
16337384|NCT04418635|Experimental|Tamsulosin and Prosta-OK® Neo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days
16337385|NCT04418635|Placebo Comparator|Tamsulosin and Prosta-OK® Neo-matched placebo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days
16337386|NCT04418596||Elite Soccer Players|Adolescent male aged 12-16 years old elite athletes that are recruited from special sport school in Leuven-Belgium and play football at a high level.
16337387|NCT04418596||Recreational Soccer players (control)|Adolescent male aged 12-16 years old recruited from ordinary school in Flanders Belgium that play soccer or any other sport recreationally with no high intensity training
16337388|NCT04418583|Experimental|Three-dimensional imaging|Participants receive a three-dimensional image of their chest, just prior to and after application of the Crane technique.
16337389|NCT04418570|Experimental|Cognitive remediation|"Computerized cognitive remediation through Neuropersonal Trainer software, 1.5 h per session twice a week for 12 weeks (36 h of total duration).
~Participants will also attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled."
16337390|NCT04418570|Other|Treatment as usual|Participants will attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled.
16337391|NCT04418557||Pregnant women without COVID-19 Infection|Women who are tested for COVID-19 at the time of admission for labor and delivery and test negative
16337392|NCT04418557||Pregnant women with a history of COVID-19 infection|Women who are tested for COVID-19 at any point during their pregnancy, including at the time of admission for labor and delivery, and test positive
16337393|NCT04418557||Pregnant women vaccinated for COVID-19|Women who are vaccinated against COVID-19 at any point during their pregnancy
16337394|NCT04418544||Control|Do not test positive for COVID
16337395|NCT04418544||COVID-19 Positive|Test positive for Covid using swab test.
16337396|NCT04418531|Experimental|Experimental antibodies (immunoglobulins) infusion|Anti-coronavirus obtained with double-filtration plasmapheresis (DFPP) from convalescent patients
16337397|NCT04418505|No Intervention|Standard of Care|This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.
16337398|NCT04418505|Experimental|Standard of Care + Vielight RX Plus Treatment|The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.
16337399|NCT04418492|Experimental|SAFE intervention|The single group received the SAFE intervention for 10 weeks.
16337400|NCT04418479|Active Comparator|Aspirin monotherapy arm|Patients will receive 100 mg of aspirin once daily.
16337401|NCT04418479|Experimental|Clopidogrel monotherapy arm|Patients will receive 75 mg of clopidogrel once daily.
16337402|NCT04418466|Experimental|DLP-114 alpha-4 (6-months)|2 360mg Risperidone Implants
16337403|NCT04418466|Experimental|DLP-114 alpha-7 (12-months)|2 435mg Risperidone Implants
16337404|NCT04418453||Integration of telemedicine in primary care settings for MOUD|Primary care providers may refer OUD patients to receive telemedicine for MOUD
16337405|NCT04418440|No Intervention|Control|Routine NHS care following traumatic brain injury
16337406|NCT04418440|Experimental|Treatment|Routine NHS care following traumatic brain injury plus daily dose of test compound (oral nutritional supplement)
16337407|NCT04418427|Experimental|1|6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT
16337408|NCT04418427|Experimental|2|2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT
16337409|NCT04418427|Active Comparator|3|Aflibercept 2mg IVT
16337410|NCT04418414|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.
16337411|NCT04418401|Experimental|Experimental group|Treatment with Donafenib 100mg PO BID，and anti-PD-1 antibody 3mg/kg ivgtt Q2W. Treatment will last 6 months, unless the tumor recurrence.
16337412|NCT04418388|Experimental|A|
16337413|NCT04418388|Experimental|B|
16337414|NCT04418388|Experimental|C|
16337415|NCT04418362|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home 4-6 times per week for 8 weeks. Each session consists of 6 blocks of 5 minute training with a one minute rest period between each block.
16337416|NCT04418336|Active Comparator|Endoscopic Pilonidal sinus treatment (EPSIT)|Endoscopic Pilonidal sinus treatment (EPSIT)
16337417|NCT04418336|Active Comparator|Sinus Laser Closure (SiLaC)|Sinus Laser Closure (SiLaC)
16337418|NCT04418336|Active Comparator|lay open technique|lay open technique
16337419|NCT04418323|Active Comparator|Video-assisted anal fistula treatment (VAAFT|Video-assisted anal fistula treatment (VAAFT) in the Management of anal fistula
16337420|NCT04418323|Active Comparator|Fistula-tract Laser Closure (filac)|Fistula-tract Laser Closure (filac)in the Management of anal fistula
16337421|NCT04418323|Active Comparator|Conventional seton|Conventional seton in the Management of anal fistula
16337422|NCT04418310|Active Comparator|Lay open and curettage|Lay open and curettage in Pilonidal sinus
16337423|NCT04418310|Active Comparator|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease
16337424|NCT04418297|Experimental|CT-G20|
16337425|NCT04418297|Placebo Comparator|Placebo|
16337426|NCT04418284||Veterinary Medical students|Veterinary Medical students who are studying anatomy during COVID-19 pandemic lockdown
16337427|NCT04418271|Experimental|Prehabilitation|Prefrail and frail patients receive prehabilitation (new form of care)
16337428|NCT04418271|No Intervention|Standard of Care|Prefrail and frail patients receive no prehabilitation, but receive standard of care
16337429|NCT04418258|Experimental|Capillary Aspiration Endoscopy Catheter group|Small intestine aspirate suction was carried out with a capillary aspiration endoscopy catheter
16337430|NCT04418258|Active Comparator|Aspiration endoscopy catheter group|Small intestine aspirate suction was carried out with an aspiration endoscopy catheter
16337431|NCT04418245||Patients positive for SARS-CoV-2|
16337432|NCT04418232|Experimental|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
16337433|NCT04418219|Experimental|Treatment (SV-BR-1GM, pembrolizumab)|Patients receive cyclophosphamide IV over 1-2 hours on day 1, SV-BR-1-GM ID on day 3, pembrolizumab IV over 30 minutes on day 5, and interferon-alpha-2b ID on days 5 and 7. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16337434|NCT04418206|Other|Samples With DNA|Nasopharyngal swab and blood samples
16337435|NCT04418180|Active Comparator|GROUP1|group receiving single dose fenofibrate
16337436|NCT04418180|Active Comparator|GROUP2|group receiving double dose fenofibrate
16337437|NCT04418180|Placebo Comparator|GROUP3|photo therapy only
16337438|NCT04418167|Experimental|Part A: JSI-1187 Monotherapy Dose Escalation|Locally advanced or metastatic solid tumors with confirmed with MAPK pathway mutation, refractory to or relapsed on prior therapy and received all available therapy known to confer clinical benefit
16337439|NCT04418167|Experimental|Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation|Locally advanced or metastatic solid tumors with confirmed BRAF V600 mutation, refractory to or relapsed on prior therapy and received all available therapy known to confer clinical benefit
16337440|NCT04418167|Experimental|Part C: JSI-1187 Plus Dabrafenib Expansion|"Cohort 1: BRAF V600-mutated metastatic melanoma after two prior therapies for metastatic disease, including anti-PD1 therapy, with or without ipilimumab, and BRAF/MEK inhibitor treatment.
~Cohort 2: BRAF V600-mutated metastatic melanoma after adjuvant therapy for Stage 3 disease followed by one prior therapy for metastatic disease, including anti-PD-1 therapy, with or without ipilimumab, or BRAF/MEK inhibitor treatment.
~Cohort 3: Either BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC), or BRAF V600-muated metastatic solid tumor, after 1 or 2 prior therapies."
16337441|NCT04418154|Experimental|EC-ABX/PD-1|Patients who are treated with epirubicin hydrochloride andcyclophosphamide followed by nanoparticlealbumin-bound paclitaxel and Toripalimab
16337443|NCT04418128|No Intervention|Conventional therapy|The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
16337444|NCT04418128|Experimental|Conventional therapy + Nafamostat mesylate|"The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
~Nafamostat mesylate injection day), taking into account the severity and underlying disease of the clinical trial patient.
~Method of administration: Nafamostat injection is mixed with 1,000 ml of 5% DW infusion, followed by continuous infusion over 24 hours.
~Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient."
16337445|NCT04418115|Experimental|Acupuncture + usual care|Participants randomized to acupuncture treatment will receive 12 acupuncture treatments during 8-12 weeks.
16337446|NCT04418115|No Intervention|Usual care|"Our control group will receive business as usual. Hence, they will continue with their usual care for their CRF. By inclusion in the study and by the end of it, the participants in the control group will fill in the requested and similar instruments as the participants in the acupuncture group. Further, we will document any medical care they have received during the study period. This includes also life styles advice, and to which point they have followed such advices."
16337447|NCT04418102|Experimental|Palmitic acid rich interesterified fat|Snacks (muffins) and spread containing palmitic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
16337448|NCT04418102|Active Comparator|Stearic acid rich interesterified fat|Snacks (muffins) and spread containing stearic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
16337449|NCT04418089|Experimental|Simvastatin|The group received standard treatment with the oral administration of Simvastatin
16337450|NCT04418089|Experimental|Placebo|The group received standard treatment with the oral administration of Placebo
16337451|NCT04418076|Experimental|No feedback|For participants in the control group (Group A), no feedback from the TowerView Health® smart pill box or clinical nurse will be given.
16337452|NCT04418076|Experimental|Automated feedback|For participants in Group B (automated feedback), automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages.
16337453|NCT04418076|Experimental|Automated feedback + Clinician feedback|For participants in Group C, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, clinical nurse will also send personalized feedback and suggestions to the participants in this group.
16337454|NCT04418076|Experimental|Automated feedback + Social Network feedback|For participants in Group D, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, a weekly text reminder will be sent to each participant from a social network designee chosen by the participant.
16337455|NCT04418037|Experimental|Single arm using the Digital Health Feedback System|This protocol is designed to evaluate a novel technology that employs an ingestible sensor to detect medication ingestion for use by persons initiating or restarting antiretroviral (ARV) treatment for HIV infection during a hospital admission.
16337456|NCT04418024|Experimental|AG10 800 mg|TTR stabilizer administered orally twice daily (BID)
16337457|NCT04418024|Placebo Comparator|Placebo|Placebo administered orally twice daily (BID)
16337458|NCT04418011|Active Comparator|Active 10 Hz rTMS|Active treatment will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
16337459|NCT04418011|Active Comparator|Active iTBS|Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
16337460|NCT04418011|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS.
~For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation."
16337461|NCT04417998|Active Comparator|Motion Correction|Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. The purpose of this arm is to evaluate the effectiveness of motion correction software.
16337462|NCT04417998|Active Comparator|Parametric Imaging|Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
16337463|NCT04417985|Experimental|18F-FDG PET/CT with MRI and blood sampling|"The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment.
~The blood sample was collected on the same day of PET/CT scan."
16337464|NCT04417972|Experimental|SHR7280 dose 1|oral administration for 21days,Phase I
16337465|NCT04417972|Experimental|SHR7280 dose 2|oral administration for 21days,Phase I
16337466|NCT04417972|Experimental|SHR7280 dose 3|oral administration for 21days,Phase I
16337467|NCT04417972|Experimental|SHR7280 dose 4|oral administration for 21days,Phase I
16337468|NCT04417972|Active Comparator|SHR7280 low dose|oral administration for 84days,Phase II
16337469|NCT04417972|Active Comparator|SHR7280 high dose|oral administration for 84days, Phase II
16337470|NCT04417972|Placebo Comparator|Placebo|oral administration for 84days, Phase II
16337471|NCT04417959|Other|Phaco-DSAEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's stripping automated endothelial keratoplasty.
16337472|NCT04417959|Other|Phaco-DMEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's membrane endothelial keratoplasty.
16337473|NCT04417946|Experimental|PrEP Messages|The peer leaders and the study staff will post PrEP related health messages
16337474|NCT04417946|Active Comparator|Health messages|The peer leaders and study staff will post general health messages that are not related to sexual health.
16337475|NCT04417933|Experimental|Tumor Electric Fields Treatment System|Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.
16337476|NCT04417920|Active Comparator|group I (Express implant)|conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva
16337477|NCT04417920|Active Comparator|group II (trabeculectomy)|"Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.
~conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of sclerectomy and peripheral iridectomy and closed scleral flab and conjunctiva by nylon 10/0 sutures"
16337482|NCT04417894|Experimental|dupilumab|Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1
16337483|NCT04417894|Experimental|Matching Placebo|Administered SC Q2W, following a loading dose on Day 1
16337484|NCT04417881||patients with acurate heart failure|
16337485|NCT04417855||LDH|Group of symptomatic individuals with LDH confirmed in MRI.
16337486|NCT04417855||Control|Group of asymptomatic individuals with no LDH.
16337493|NCT04417790||Study population|Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.
16337494|NCT04417777||Polynesian patient|Patient with dilatation of idiopathic bronchi
16337495|NCT04417777||Relatives of polynesian patient|Healthy
16337496|NCT04417764|Experimental|TACE combined PD-1 knockout T cell treatment|
16337497|NCT04417751|Experimental|Intervention Group|Intervention group will receive 47 sessions of individual CS and participate in 3 evaluation sessions. The CS program will last 1 year and each individual CS session will last approximately 45 minutes.
16337498|NCT04417751|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
16337499|NCT04417738|Active Comparator|Active|Patients will receive the active treatment.
16337500|NCT04417738|Sham Comparator|Sham|Patients will receive the sham treatment (the identical LED covered by aluminum foil).
16337501|NCT04417725||Chronic kidney disease|
16337502|NCT04417725||Type 2 diabetes mellitus|
16337503|NCT04417725||Comorbid type 2 diabetes mellitus and chronic kidney disease|
16337504|NCT04417712||Patients with ventricular septal defect|"All patients who signed informed consent and are implanted with a KONAR-MF™ VSD Occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post-implant:
~Before discharge 1-3 months after the Procedure 6 months after the procedure 12 months after the procedure"
16337505|NCT04417699|Experimental|TAS102 plus Oxaliplatin|Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID
16337506|NCT04417686|Experimental|patient|
16337509|NCT04417647|Experimental|Group 1|Proximal wound SoC treatment - Distal wound VZ application
16337510|NCT04417647|Experimental|Group 2|Distal wound SoC treatment - Proximal wound VZ application
16337511|NCT04417634|Experimental|RFR: resting full-cycle ratio|RFR will be used to drive PCI
16337512|NCT04417634|Active Comparator|FFR: fractional flow reserve|FFR will be used to drive PCI
16337516|NCT04417595|Experimental|Fish Oil|Participants allocated to n-3 LCPUFA supplementation will be instructed to take four 1000 mg n-3 LCPUFA capsules (Metagenics™) daily. This will provide a total daily dose of 4000 mg n-3 LCPUFAs (2840 EPA and 1160 DHA).
16337517|NCT04417595|Placebo Comparator|Olive Oil|Oleic acid (olive oil) capsules have a similar texture, size, color, and consistency to EPA capsules. Participant will be instructed to take four 100mg olive oil capsules
16337518|NCT04417582||life syte modification only|obese patients followed with life style modification
16337519|NCT04417582||medical teatment with antiobesity drugs|patients prescribed antiobesity drugs
16337520|NCT04417582||bariatric surgery|patients undergone bariatric surgery
16337521|NCT04417569||stimulated cycles|Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection
16337522|NCT04417556|Experimental|Sleep Measurement|Sleep Measurement arm, sleep are simultaneously measured using polosomgraphy, actigraphy and Thai-version Richards Campbell Sleep Questionnaire.
16337523|NCT04417543|Active Comparator|Memantine hydrochloride group|included 50 patients who received memantine
16337524|NCT04417543|Placebo Comparator|Placebo group|included 50 patients who received placebo
16337532|NCT04417517|Experimental|evorpacept (ALX148) + azacitidine|"Phase 1: Participants will receive escalating doses of evorpacept (ALX148) in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle
~Phase 2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle"
16337533|NCT04417517|Active Comparator|azacitidine|Phase 2 only: Participants will receive azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle
16337534|NCT04417504|Experimental|MobFood breakfast kit|
16337535|NCT04417504|Experimental|Control isocaloric breakfast|
16337536|NCT04417491|Experimental|Dry Needling|The intervention group will receive real dry needling (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
16337537|NCT04417491|Sham Comparator|Sham Needling|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
16337538|NCT04417478|Active Comparator|Normal weight|Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2.
16338327|NCT04411615|Experimental|Omega|Omega-3 re-esterified triglyceride form
16337539|NCT04417478|Experimental|class I Obesity|Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2.
16337540|NCT04417478|Experimental|class II Obesity|Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2.
16337541|NCT04417465|Experimental|ABBV-CLS-579 Monotherapy|Participants will receive escalating doses of ABBV-CLS-579
16337542|NCT04417465|Experimental|ABBV-CLS-579 And Programmed Cell Death-1 (PD-1) Inhibitor|Participants will receive escalating doses of ABBV-CLS-579 and PD-1 inhibitor.
16337543|NCT04417452||Mothers / children after diabetes in pregnancy|The study collective is composed of mother-child pairs after gestational diabetes, which were supervised in the Competence Center for Diabetes and Pregnancy at the University Hospital of Jena. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
16337544|NCT04417452||Controls|The control collective is composed of mother-child pairs who were cared for at the same time as the study collective at the University Hospital Jena. This collective is status post singleton pregnancy and term birth. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
16337545|NCT04417439||flame burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
16337546|NCT04417439||scald burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
16337547|NCT04417439||electrical burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
16337548|NCT04417400|Experimental|Intervention|Patients who received MUR at visit 1
16337549|NCT04417400|No Intervention|Control|Patients received standard care and MUR after visit 2 (upon completion of the study)
16337550|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2019|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2019
16337551|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2020|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2020
16337552|NCT04417361|Experimental|Galcanezumab|The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
16337553|NCT04417361|Placebo Comparator|Placebo|The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
16337554|NCT04417348|Active Comparator|Retinoic Acid|patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
16337555|NCT04417348|Placebo Comparator|Sunscreen|patients with melasma treated with UV-Visible light filter alone
16337556|NCT04417335|Experimental|Treatment|BCG vaccine (Danish strain 1331, SSI, Denmark)
16337557|NCT04417335|Placebo Comparator|Placebo|0.9% NaCl
16337558|NCT04417322||Control|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
16337559|NCT04417322||Periodontitis|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
16337560|NCT04417309|Experimental|Moderate Intensity Exercise|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
16337561|NCT04417309|Active Comparator|Control|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
16337562|NCT04417296||nonlaboring term singleton pregnancies|"All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at >37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications"
16337563|NCT04417283||Mother-infant dyads|Mother and/or infant participants will provide a series of biological specimens, including blood, urine, and microbiome samples. Additionally, each participant will wear a silicone wrist band each trimester to capture environmental exposures and will fill out study surveys related to diet, environmental exposures, and social factors.
16337564|NCT04417270|Other|Freestyle Libre 14-day CGM|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
16337565|NCT04417270|Other|Accuchek Inform II meter|ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
16337566|NCT04417257|Experimental|LAU-7b|Active drug as LAU-7b capsules
16337567|NCT04417257|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
16337588|NCT04417101|Experimental|JBT treatment|The participants will be instructed to take their Chinese herbal medicine formula (CHM), which named Juan Bi Tang, and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
16337568|NCT04417231|Experimental|Apheresis group|"10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts at the latest 36 hours after infarction or, in case of an unclear time window, within 36 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is <10 mg/l or if the patient has been discharged from hospital.
~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours."
16337569|NCT04417231|No Intervention|Control group|10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.
16337570|NCT04417218|Experimental|Normal Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the normal lysine diet, participants will be asked to adhere to a specific diet for 1 week. Each study subject will receive 3 meals and 1-2 snacks per day during the study period.
16337571|NCT04417218|Experimental|High Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the high lysine diet, participants will be asked to consume the same foods as in the normal lysine diet, but with the addition of lysine supplements (5g/day).
16337572|NCT04417205|Active Comparator|Carbohydrate rich breakfast|Participants will be provided with 28-days worth of pre-weighed carbohydrate rich breakfast materials to consume before 1000h daily.
16337573|NCT04417205|Experimental|Whey protein enriched breakfast|Participants will be provided with 28-days worth of pre-weighed whey protein enriched rich breakfast materials to consume before 1000h daily.
16337574|NCT04417205|No Intervention|Extended morning fast|Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
16337575|NCT04417192|Experimental|Olaparib or Olaparib Plus Pembrolizumab|Cohort 1 : Olaparib will be administered for 6 weeks before surgery. Cohort 2 : Olaparib and Pembrolizumab will be administered simultaneously for 2 cycles(6 weeks) before surgery.
16337576|NCT04417179|Experimental|TAP block group|"the TAP block will be given by a high frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .
~a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under direct ultrasound visualization, . After confirming the correct placement of the needle and the negative aspiration probe anaesthetic substance will be injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine(10) , and the dissection of the plane was observed. The block will be performed bilaterally."
16337577|NCT04417179|Experimental|ESP group|the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .A blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under strict aseptic precautions until the tip is deep to erector spinae muscle, The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally
16337578|NCT04417166|Experimental|Pembrolizumab and Radiotherapy|"Induction Phase:
~Standard Involved Field Radiation Therapy (IFRT) and pembrolizumab. Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 6 cycles. IFRT will start at first cycle of Pembrolizumab and will be delivered concurrently.
~Patients with complete remission (CR), partial response (PR) and stable disease (SD) after Induction Phase will continue with pembrolizumab maintenance.
~Maintenance Phase:
~Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle up to 34 cycles or until disease progression or unaccepted toxicity"
16337579|NCT04417153||Mindfulness based intervention, Non Emergency (MBI-NE)|"4 week Mindfulness foundation course face to face (MF-NE) or
~8 week Mindfulness Based stress reduction face to face (MBSR-NE)
~The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions. Participants will be provided handouts for the information covered during these talks and discussions.
~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together"
16337580|NCT04417153||Mindfulness based intervention, DORSCON Orange (MBI-Orange))|"4 week Mindfulness foundation course face to face (MF-Orange) or
~8 week Mindfulness Based stress reduction face to face (MBSR-Orange)
~The content of these courses are the same as in the non emergency ones, and consist of four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques. Participants will also be provided with the same handouts for the information covered during these talks and discussions.
~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together."
16337581|NCT04417153||Mindfulness based intervention, Partial lockdown (MBI-Covid)|"4 week Mindfulness foundation course online (MF-Covid) or
~8 week Mindfulness Based stress reduction online, partial lockdown situation (MBSR-Covid)
~The content of these courses are the same as in the non emergency ones. Participants will also be provided with the same handouts for the information covered during these talks and discussions.
~During the partial lockdown, classes can only be held online, using platform as zoom with the teacher and up to around 17 participants together."
16337582|NCT04417140|Experimental|Treatment Arm-dHACM|Patients enrolled in this arm will have a thin sheet of dHACM placed as an overlay over the length of the closed incisions. dHACM is Dehydrated Human Amniotic-Chorion Membrane. It is a FDA registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns.
16337583|NCT04417140|No Intervention|Control Arm|Patients enrolled in this arm will have routine closure.
16337584|NCT04417127|Experimental|Microfinance with Integrated Community-based Care|20 microfinance groups with n=450 participants will be randomized to receive the ICB intervention.
16337585|NCT04417127|Active Comparator|Microfinance with Standard of Care|20 microfinance groups with n=450 participants will be randomized to continue to receive standard of care from an AMPATH-supported rural health facility.
16337586|NCT04417127|No Intervention|Standard of Care without Microfinance|n=300 participants who receive care at an AMPATH health facility and who are not involved in microfinance will serve as matched contemporaneous controls. These participants will be actively followed over the 18-months of the trial.
16337587|NCT04417114|Experimental|Single-Arm Open label|This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
16337669|NCT04416347||Workstream 2|Adult patients admitted to to SGHFT (St. Georges Hospital Foundation Trust) ITU with respiratory failure.
16337589|NCT04417101|No Intervention|No treatment|Participants in the non-treatment period will receive conventional self-care management for myofascial pain syndrome.
16337590|NCT04417088|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to Carboplatin administration.
16337591|NCT04417075|Experimental|Impacto|This is the mobile app to be developed and evaluated in this project.
16337592|NCT04417075|Active Comparator|Dejar de Fumar Asistente|This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto.
16337593|NCT04417062|Experimental|Olaparib-Ceralasertib|"Unresectable disease (can not be surgically removed) will be enrolled into Cohort 1 and Resectable disease (can be surgically removed) which is limited only to the lung parenchyma will be enrolled into Cohort 2.
~Olaparib at a predetermined dose orally 2 times a day on days 1-28
~Ceralasertib will be given at a predetermined dose orally once a day on days 1-7 in 28-day study cycles.
~Patients can remain on treatment for up to 2 years if disease progression has not occurred."
16337594|NCT04417049|Experimental|Pentoxifylline|
16337595|NCT04417036|Experimental|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
16337596|NCT04417036|Experimental|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
16337597|NCT04417036|Placebo Comparator|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
16337598|NCT04417036|Experimental|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
16337599|NCT04417036|Placebo Comparator|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
16337600|NCT04416997||Rheumatoid arthritis patients|Blood and serum samples
16337601|NCT04416984|Experimental|ALLO-501A, ALLO-647|
16337602|NCT04416971||mature AVF|Patients initiate HD with mature AVF.
16337603|NCT04416971||immature AVF|Patients initiate HD with immature AVF.
16337604|NCT04416958||CIED for cardiac resynchronisation|Patients implanted with an CIED for cardiac resynchronisation aiming to avoid pacing induced ventricular dyssynchrony, e.g. His bundle pacing, LBB-area pacing, CRT. These different implanted types of devices may be further analysed as subgroups.
16337605|NCT04416945|Experimental|RACD|Reactive case detection led by VMWs in response to cases in study area HCCA, with follow up testing with HS-RDTs/RDTs in both villages and forest workers; referrals for qualitative G6PD testing for P. vivax cases and 14-day PQ for G6PD non-deficient
16337606|NCT04416945|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMWs; village-based RACD conducted by district staff in some areas
16337607|NCT04416932||Post-operative patients who had total shoulder arthroplasty|Patients who have had a total shoulder replacement will be scheduled for an ultrasound at Duke Radiology. An ultrasound will be completed on the shoulder that has been replaced, which takes no more than an hour. This ends all study involvement.
16337608|NCT04416919|Other|Assembled Mask|Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences. The Fitted Mask will be attached to a bacterial/viral filter for fit testing. After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator. Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes. The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia. At the end, the mask will be removed.
16337609|NCT04416906|Experimental|Biktarvy|This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.
16337610|NCT04416893||Children under 15 years of age in a community|Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.
16337611|NCT04416880|Experimental|Press Tack Needle Acupuncture|Patients in this group were given seirin pyonex press tack needle treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
16337612|NCT04416880|Sham Comparator|Sham Control Press Tack Needle Acupuncture|Patients in this group were given sham treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
16337613|NCT04416867|Active Comparator|group-1 splint and home exercise|Patients in group 1 will be treated with splinting of the affected hand at night and a home exercise program. A wrist orthosis which held the wrist in the neutral position will be used for splinting at night time for a minimum of eight hours. Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
16337614|NCT04416867|Active Comparator|group 2 RESWT|Patients in group 2 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and a total of 3 sessions of RESWT at a frequency of one session per week using the Masterpuls ® mp200 radial shock wave therapy system (Elite-Storz Medical AG, Kreuzlingen, Switzerland). RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
16337615|NCT04416867|Active Comparator|group 3 physical therapy|Patients in group 3 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and two and 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks.
16337616|NCT04416854|Experimental|Chemotherapy plus surgery|Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
16337667|NCT04416360|Experimental|Interview by psychologists|Children and adolescent interview Parents interview Referring caregiver interview
16337617|NCT04416854|Active Comparator|Chemotherapy alone|Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
16337618|NCT04416841|Experimental|Tai Chi Chuan Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour Tai Chi Chuan training per week for 24 weeks and standard diabetic care education.
16337619|NCT04416841|Active Comparator|Fitness Walking Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour fitness walking training per week for 24 weeks and standard diabetic care education
16337620|NCT04416841|Other|Control group|In addition to conventional medical treatment, participants will receive standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
16337621|NCT04416828||Suspected ganglion cyst of the wrist or hand|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging AND cart-based ultrasound imaging before surgery.
16337622|NCT04416815|No Intervention|Usual care|The participants allocated to the control group received no intervention. However, they could, on their own initiative, approach the usual range of community or health services (e.g., home help services, rehabilitation, or medical care).
16337623|NCT04416815|Experimental|eHealth|The intervention will be delivered for 6 months on top of usual care.
16337624|NCT04416802|Experimental|PRP and Li-ESWT treatment|Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
16337625|NCT04416776||Eligible patients for AI test|Device: strabismus diagnostic system.
16337626|NCT04416750|Experimental|Treatment|Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
16337627|NCT04416737|Experimental|Upper Peritoneal, then Lower Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the upper peritoneum then lower peritoneum then subcutaneous space.
16337628|NCT04416737|Experimental|Lower Peritoneal, then Upper Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the lower peritoneum then upper peritoneum then subcutaneous space.
16337629|NCT04416724|Experimental|Phacoemulsification|Main study intervention will be Phacoemulsification
16337630|NCT04416724|Experimental|SLT|Main study intervention will be Selective Laser Trabeculoplasty
16337631|NCT04416711|Active Comparator|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
16337632|NCT04416711|Experimental|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
16337633|NCT04416698||Youth smokers|Participants of Youth Quitline
16337634|NCT04416685|Other|Level 1|Those tumors located superior to the portal confluence were classified as Level I,
16337635|NCT04416685|Other|Level II|those tumors located on the confluence (involving the confluence) located on the portal confluence
16337636|NCT04416685|Other|Level III|those tumors located inferior to the portal confluence
16337637|NCT04416633|Other|Durvalumab|Single arm, Durvalumab , IV
16337638|NCT04416620|Active Comparator|The active group of Syria|"Participants in the active group received the 'pharmacist standard counseling' plus the 'pharmaceutical care service' designed by the research group. Both services were delivered by one female clinical pharmacist who has a Master's degree in pharmaceutical sciences, 5-year work experience in community pharmacies, and comprehensive knowledge of PCOS. The time it took to deliver the counseling and education to each participant in the active group was formally assessed. This time assessment excluded data collection and questionnaire filling time (which was planned to take around 15 min).
~Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise."
16337639|NCT04416620|No Intervention|The control group of Syria|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.
~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
16337640|NCT04416620|Active Comparator|The active group of Jordan|Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise.
16337641|NCT04416620|No Intervention|The control group of Jordan|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.
~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
16337668|NCT04416347||Workstream 1|Adult patients admitted to SGHFT (St. Georges Hospital Foundation Trust) with or without laboratory confirmed SARS- CoV-2.
16337642|NCT04416607|Experimental|corifollitropin alpha|Ovarian stimulation protocol is performed with a single dose of 100 μg (<60 kg) or 150 μg (≥60 kg) of corifollitropin alpha (Elonva, Schering-Plough, Brazil), plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
16337643|NCT04416607|Active Comparator|menotropin|150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3, according to age, AMH level and AFC, plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
16337644|NCT04416594||Factor XIII deficiency|Patients admitted to hospital with FXIII levels below 70% during their hospital stay
16337645|NCT04416581|Experimental|P-CAB 50mg group|"tegoprazan 50 mg + rabeprazole 20mg placebo + tegoprazan 25 mg placebo, once daily.
~Target enrollment: 1250"
16337646|NCT04416581|Active Comparator|PPI group|"rabeprazole 20mg + tegoprazan 50 mg placebo + tegoprazan 25 mg placebo, once daily.
~Target enrollment: 1250"
16337647|NCT04416581|Other|P-CAB 25mg group|"tegoprazan 25 mg + rabeprazole 20mg placebo + tegoprazan 50 mg placebo, once daily.
~Target enrollment: 500"
16337648|NCT04416568|Experimental|Solid Tumor (Stratum 1)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles
~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle
~Patients with INI1-negative relapsed or refractory extracranial solid tumors"
16337649|NCT04416568|Experimental|CNS (Stratum 2)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles
~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle
~Patients with INI1-negative relapsed or refractory CNS tumors"
16337650|NCT04416555|Placebo Comparator|VR googles using exposure sham program|The study groups will receive VR googles and the sham program
16337651|NCT04416555|Active Comparator|VR googles and the real VR program experience.|The study group will receive the VR googles and the real VR program experience.
16337652|NCT04416542|No Intervention|Control|Subjects in this group will be implanted with the Inspire UAS system and will undergo a standard in-lab PSG titration study at approximately 3 months post-activation and a 2-night HST at approximately 6 months post-activation
16337653|NCT04416542|Active Comparator|Home Monitoring|Subjects who have undergone implant of the Inspire UAS System and are randomized to this group will undergo a 2-night HST at 3 months post-activation. Depending on the results of the 2-night HST, the subject will either (a) undergo a PSG titration at 5 months post-activation and a 2-night HST at 6 months post-activation OR (b) undergo only a 2-night HST at approximately 6 months post-activation
16337654|NCT04416529|Experimental|Intervention (tele-MBCT) group|"Tele-MBCT was an 8-week program delivered to participants online via a videoconferencing program called Zoom by a tele-MBCT instructor. Tele-MBCT was delivered in three, 8-week rounds. Each round consisted of 8 weekly, 2-hour group sessions with 4-6 participants on Wednesdays from 2:00 to 4:00 pm. Participants were trained in mindfulness concepts and techniques including mindful eating, body scan, sitting meditation, breathing awareness, mindful walking and mindful movements. Participants were given a mindfulness a book called The Mindful Way Workbook and a practice log. The book was a guide for their daily practice at home and the practice log was a simple log for self-recording daily practices (number of minutes of daily MBCT practice) and a note pad for recording the reasons/obstacles for not practicing."
16337655|NCT04416529|No Intervention|Control Group|Participants in the control group continued their usual caregiving activities.
16337656|NCT04416516|Experimental|Arm 1, Patients with 1 Tumour|"Participants with 1 Target Tumour will receive 3 x ASN-002 1.0x10(11) Injections
~+ VISMODEGIB (150 mg) daily for 4 weeks."
16337657|NCT04416516|Experimental|Arm 2, Patients with 3 or more Tumours|Participants with 3 or more Target Tumours will receive 3 x ASN-002 1.0x10(11) Injections (per tumour) + VISMODEGIB (150 mg) daily for 4 weeks.
16337658|NCT04416503|Experimental|Intervention group|Foot reflexology was performed for 12 week in the intervention group, whereas the control group continued their routine treatment and follow-up.
16337659|NCT04416503|No Intervention|Control group|Usual follow-up was done to the control group.
16337660|NCT04416490||Patients|Patients with high-risk stage II or stage III primary colon cancer who have received curative resection
16337661|NCT04416464||Pneumonia due to SARS-CoV-2 infection|Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
16337662|NCT04416451|Experimental|Rituximab and Venetoclax|Patients will be treated with an Induction phase of rituximab 375 mg/m2 weekly for 4 weeks. Patients will undergo restaging imaging after the last of 4 weekly rituximab doses and before beginning venetoclax. Based on post-rituximab restaging studies, patients will be risk-stratified for risk of Tumor Lysis Syndrome (TLS) and treated in the appropriate setting with TLS prophylaxis per institutional TLS guide lines starting at week 5. Oral venetoclax will follow a ramp-up dosing schedule and will be taken daily after 4 weeks of rituximab therapy. Following the 4-week ramped-up phase of venetoclax, patients will begin their target dose of venetoclax and continue for a maximum of 24 months. In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months. Venetoclax may be continued after this period if patient has not achieved a complete remission
16337663|NCT04416425||Enrolled Cohort|200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.
16337664|NCT04416412||Open Fracture Cohort|"Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion.
~Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.
~Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
~Provision of informed consent."
16337665|NCT04416399|Experimental|Inhaled budesonide|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
16337666|NCT04416399|No Intervention|Standard of care|Standard of care
16337770|NCT04415775|Experimental|Dual-task walking Intervention|
16337670|NCT04416334|Experimental|Colchicine plus symptomatic treatment (paracetamol).|"Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.
~All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice."
16337671|NCT04416334|Active Comparator|Symptomatic treatment|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
16337672|NCT04416321|Other|Device|All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.
16337673|NCT04416308|Other|Seroprevalence survey|NG Test + short self-questionnaire (except validation survey and detailed survey)
16337674|NCT04416308|Other|Validation test of the NG test survey|Blood test + NG test + detailed self-questionnaire
16337675|NCT04416308|Other|Detailed Survey|NG test + self-questionnaire complementary to the short questionnaire
16337676|NCT04416308|Other|Prevalence monitoring (2 population samples)|"Participants having presented a certain or probable COVID: acts of the validation test survey, + follow-up questionnaire,+ blood test + NG test, on D30 and D90
~Others Participants : drawn by lot: acts of the seroprevalence survey, + follow-up questionnaire + NG test, on D90"
16337677|NCT04416295|Active Comparator|Standard COPD care and a digital COPD support system|Device: LifePod The intervention group is testing LifePod on a digital communication platform between patient and healthcare provide
16337678|NCT04416295|Other|Control group Standard COPD Care|
16337679|NCT04416282|Experimental|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
16337680|NCT04416282|Active Comparator|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
16337681|NCT04416269|Experimental|Oral Anti-diabetes Drugs (OADs) alone|OADs will be continued at same outpatient dosage unless contraindicated
16337682|NCT04416269|Active Comparator|Basal bolus insulin|Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.
16337683|NCT04416256||France|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337684|NCT04416256||Spain|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337685|NCT04416256||Portugal|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337686|NCT04416256||Croatia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337687|NCT04416256||Germany|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337688|NCT04416256||Italy|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337689|NCT04416256||Netherlands|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337690|NCT04416256||Austria|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337691|NCT04416256||US|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337692|NCT04416256||Canada|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337693|NCT04416256||Mexico|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337694|NCT04416256||Brazil|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337695|NCT04416256||Uruguay|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337696|NCT04416256||Argentina|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337697|NCT04416256||Chile|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337698|NCT04416256||Australia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337699|NCT04416256||Belgium|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337700|NCT04416256||Finland|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
16337701|NCT04416243|Experimental|Recumbent Stepping, High-Intensity Interval Training|
16337702|NCT04416230|Experimental|Massage|Infants randomized to the massage intervention received a 30 minute massage daily for the 7 day study.
16337703|NCT04416230|Active Comparator|Quiet Time|Infants randomized to the Quiet Time intervention experienced a 30 minute time during which non-essential clinical caregiving tasks were restricted.
16337704|NCT04416217||Topical Steroid Treatment|Pediatric patients with eosinophilic esophagitis scheduled to begin topical steroid treatment for the treatment of their condition. The type of topical steroid is not limited and is at the discretion of the treating physician as are dosing and concomitant treatments.
16337705|NCT04416204|Experimental|Type 2 diabetes|
16337706|NCT04416204|Experimental|Participants without diabetes|
16337707|NCT04416191|Experimental|Limb immobilization|Participants will undergo a 2-week leg immobilization period
16337708|NCT04416178||Parents of children with SCD|Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation
16337709|NCT04416178||Adolescents with SCD|Patient aged 13-18 with HbSS, HbS/ β0thalassemia, or HbSC
16337710|NCT04416165|Experimental|Experimental: 68Ga-DOTA-FAPI-04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
16337711|NCT04416139|Active Comparator|Treated group|Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.
16337712|NCT04416139|No Intervention|Control Group|The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables.
16337713|NCT04416126|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
16337714|NCT04416126|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
16337715|NCT04416113|Active Comparator|photobiomodulation group|"Laser watch Patients will be subjected to low-level laser (diode laser 980nm) for 30 minutes, the recommended dose based on the previous study is 20 J for 3 to 7 days.
~The laser device:
~Laser watched applied at the wrist on the radial artery.
~Laser acupuncture"
16337716|NCT04416113|Active Comparator|photodynamic group|"Methylene blue injection USP 1% will be used as a photosensitizer in PDT.
~0.1 to 0.2 mL of 1% solution per kilogram of body weight Methylene Blue (methylene blue injection) will be injected intravenously very slowly over a period of several minutes to
~After one hour apply Light dose: 100 - 200 J/cm2 50-100 mW/cm2. (50 mW/cm2 increased the phototoxic response as well as the fractionated light application).
~The session will be done twice per week
~Laser watched applied at the wrist on the radial artery."
16337717|NCT04416113|Active Comparator|positive control|This group will include patients who are subjected to conventional treatment
16337718|NCT04416087|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
16337719|NCT04416074|Experimental|Group psychotherapy group|Students will be intervened by an online 5-week professional identity group psychotherapy.
16337720|NCT04416074|Other|Controlled message push group|Students will receive online messages of self-care knowledge forward by researchers.
16337721|NCT04416061||Subjects underwent COVID-19 test|Subjects who underwent COVID-19 test in HKSH during the study period
16337722|NCT04416048|Experimental|Rivaroxaban|Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
16337723|NCT04416048|Other|Standard of Care|Subjects will receive standard of care (SOC) treatment SOC including prophylactic LMWH or UFH, when considered appropriate according to the judgment of the treating physician.
16337724|NCT04416035|Experimental|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle，carboplatin will be administered at an AUC 6 mg/mL/ min by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
16337725|NCT04416035|Active Comparator|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle and carboplatin will be administered at an AUC 6 mg/mL/min (the maximum dose capped at 900 mg) by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
16337726|NCT04416009||mild pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the ward
16337727|NCT04416009||severe pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the intensive care unit
16337728|NCT04415996|Experimental|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.
~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.
~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
16337729|NCT04415996|Sham Comparator|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.
~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
16337730|NCT04415983|Experimental|Nitazoxanide group|Clarithromycin, Nitazoxanide and Proton pump inhibitor
16337731|NCT04415983|Active Comparator|Traditional group|Clarithromycin, Metronidazole and Proton pump inhibitor
16337732|NCT04415970|Experimental|Flotation Therapy|Participants will utilize flotation sensory deprivation tanks.
16337733|NCT04415970|Active Comparator|Sleep Pod|Participants will utilize sleep pods with partial sensory deprivation (no light and silence).
16337734|NCT04415957|Experimental|Elastic Tape Group (ETG)|The ET will be placed in the patient chest wall and abdomen for as long of 2 consecutive weeks.
16337735|NCT04415957|No Intervention|Control Group (CG)|The CG will be an education program in COPD and physical activity recommendations. Besides, after study ends they will be invited to place the ET.
16337736|NCT04415944|Experimental|Second Look Laparoscopy and HIPEC with Carboplatin|Laparoscopic assessment of disease status of the peritoneal cavity with lysis of adhesions as necessary noting either no gross residual disease or minimal residual disease prior to or after resection. This is performed prior to establishment of a peritoneal perfusion circuit and hyperthermic intraperitoneal chemotherapy.
16337737|NCT04415931|Experimental|Local infiltration analgesia group|This group of patients will receive local infiltration analgesia
16337738|NCT04415931|Active Comparator|Interscalene block group|This group of patients will receive interscalene block
16337739|NCT04415918|Experimental|Intervention group|Recruited patient according inclusion/exclusion criteria
16337740|NCT04415918|No Intervention|Historical control|Cohort of historical patients matched to study population to serve as control
16337741|NCT04415905|Experimental|group P|The participants in the group P are anesthetized with propofol.
16337742|NCT04415905|Active Comparator|group S|The participants in the group S are anesthetized with sevoflurane.
16337743|NCT04415892|Other|High-Low-Vehicle|Volunteers in group A will receive a high dose, low dose and vehicle solution of each compound on digit 2, 3 and 4, respectively.
16337744|NCT04415892|Other|Vehicle-High-Low|Volunteers in group B will receive a high dose, low dose and vehicle solution of each compound on digit 3, 4 and 2, respectively.
16337745|NCT04415892|Other|Low-Vehicle-High|Volunteers in group C will receive a high dose, low dose and vehicle solution of each compound on digit 4, 2 and 3, respectively.
16337746|NCT04415892|Other|Paclitaxel Patients|Group of patients after treatment with paclitaxel.
16337747|NCT04415892|Other|Paclitaxel Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Paclitaxel Patients.
16337748|NCT04415892|Other|Oxaliplatin Patients|Group of patients after treatment with oxaliplatin.
16337749|NCT04415892|Other|Oxaliplatin Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Oxaliplatin Patients.
16337750|NCT04415879|Active Comparator|No Mask|Individuals will perform a Modified Balke Treadmill test with no mask and their estimated VO2 peak will be calculated based off of peak workload.
16337751|NCT04415879|Experimental|N-95 Respirator|Individuals will perform a Modified Balke Treadmill test while wearing a N-95 Respirator and their estimated VO2 peak will be calculated based off of peak workload.
16337752|NCT04415879|Experimental|Cloth Mask|Individuals will perform a Modified Balke Treadmill test while wearing a cloth mask and their estimated VO2 peak will be calculated based off of peak workload.
16337753|NCT04415866|Experimental|Effects of PASAT on Sensory Testing|After baseline evaluation of light and pain sensitivity FM subjects and controls will undergo the PASAT task. This task consists of responding to a rapid presentation of numbers by ear phones. Subjects are asked to add each 2 consecutive numbers and provide a response each time the sum is equal to 13. This test will last several minutes and delivered at increasing speed.
16337754|NCT04415853|Experimental|Lerotinib Arm|350 mg,qd, orally about half an hour after a meal, continuous administration, every 21 days for a treatment cycle.
16337755|NCT04415853|Active Comparator|Active Comparator Arm|"Irinotecan: Intravenously administered at a dose of 180 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.
~Tegafur: 40-60mg po bid(d1-d14),every 21 days as a cycle, continuous drug administration from 1 to 14 days of each cycle, and then stopped 7 days."
16337756|NCT04415827|Experimental|Athletes with community-acquired pneumonia|man and women, athletes, age 17-25, patients with community-acquired pneumonia
16337757|NCT04415827|Experimental|Untrained people with community-acquired pneumonia|man and women, untrained people, age 17-25, patients with community-acquired pneumonia
16337758|NCT04415827|Experimental|Athletes with bronchitis|man and women, athletes, age 17-25, patients with bronchitis
16337759|NCT04415827|Experimental|Untrained people with bronchitis|man and women, untrained people, age 17-25, patients with bronchitis
16337760|NCT04415827|Experimental|Athletes with chronic obstructive pulmonary disease|man and women, athletes, age 17-25, patients with with chronic obstructive pulmonary disease
16337761|NCT04415827|Experimental|Untrained people with chronic obstructive pulmonary disease|man and women, untrained people, age 17-25, patients with with chronic obstructive pulmonary disease
16337762|NCT04415827|Experimental|Athletes with acute respiratory infections|man and women, athletes, age 17-25, patients with acute respiratory infections
16337763|NCT04415827|Experimental|Untrained people with acute respiratory infections|man and women, untrained people, age 17-25, patients with acute respiratory infections
16337764|NCT04415814|Experimental|Group 1 (Unilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed unilaterally, which means on one side of the spinous processes. The system will be fixed with standard rod and blockers.
16337765|NCT04415814|Active Comparator|Group 2 (Bilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed bilaterally, which means on the both sides of the spinous processes. The system will be fixed with standard rods and blockers.
16337766|NCT04415801|Experimental|Implant abutments|implant abutments
16337767|NCT04415788|Experimental|Test of Incremental Respiratory Endurance - IMT|Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
16337768|NCT04415788|Experimental|Threshold - IMT|Subjects assigned to the Standard training regimen will receive a commonly used Threshold inspiratory muscle trainer. This device features a one-way spring-loaded valve at one end and a mouthpiece on the other through which subjects will be required to breathe in hard enough to overcome the resistance provided by the spring-loaded valve, allowing correct inspiration to happen. In other words, air flow is blocked until subjects generate sufficient inspiratory pressure to exceed the device pre-set pressure in cmH2O. The resistance will be set using the device's adjustable pressure setting which is fixed at 50% of the subject's MIP at the time of enrollment. The resistance will be readjusted as needed at week 4 to still reflect 50% of their inspiratory muscle strength at that time. Subjects will be coached to perform up to 36 breaths daily using the device. They will be also instructed to complete the training session within a 30-minute period.
16337769|NCT04415788|Sham Comparator|Sham IMT (Low resistence)|The Sham (Low Resistance) training regimen will use the same methods described above for the Standard IMT, except for the amount of resistance applied within the device. Subjects will receive a Threshold which has been set to its minimal resistance, which is 9 cmH2O. Again, subjects will be instructed to perform up to 36 breaths daily using the device within a 30-minute period.
16337773|NCT04415749|Experimental|NasoShield One Dose in Position 1|NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
16337774|NCT04415749|Placebo Comparator|Placebo in Position 1|Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
16337775|NCT04415749|Experimental|NasoShield Two Doses in Position 2|NasoShield on Day 1 and Day 29 in position 2 (Group 2)
16337776|NCT04415749|Placebo Comparator|Placebo in Position 2|Saline placebo on Day 1 and Day 29 in position 2 (Group 2)
16337777|NCT04415749|Experimental|NasoShield Two Doses in Position 3|NasoShield on Day 1 and Day 29 in position 3 (Group 3)
16337778|NCT04415749|Placebo Comparator|Placebo in Position 3|Saline placebo on Day 1 and Day 29 in position 3 (Group 3)
16337779|NCT04415736||Delayed cerebral ischemia|Patients with subarachnoid hemorrhage that develop delayed cerebral ischemia
16337780|NCT04415736||Non delayed cerebral ischemia|Patients with subarachnoid hemorrhage that do not develop subarachnoid hemorrhage
16337781|NCT04415723|Experimental|intervention group|supportive care management programme
16337782|NCT04415723|No Intervention|control group|receive the usual care provided by the health care system of Cyprus
16337783|NCT04415710||Group|Women with diagnosed Sjogren syndrome
16337784|NCT04415697||Responders|Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
16337785|NCT04415697||Not responders|Those who present progression disease according to RECIST 1.1.
16337786|NCT04415684|Experimental|Test Arm|
16337787|NCT04415671|Experimental|Part A- AD-214 SAD in Healthy Volunteers|
16337788|NCT04415671|Placebo Comparator|Part A-Placebo SAD in Healthy Volunteers|
16337789|NCT04415671|Experimental|Part B-AD-214 MAD in Healthy Volunteers|
16337790|NCT04415671|Placebo Comparator|Part B-Placebo MAD in Healthy Volunteers|
16337791|NCT04415658|Experimental|Thyroxine|Intravenous thyroxine infusion
16337792|NCT04415658|Placebo Comparator|Saline Placebo|Intravenous saline infusion
16337793|NCT04415645|Experimental|VVZ-149 Injections|
16337794|NCT04415632|Experimental|LGI Diet|low glycemic index diet
16337795|NCT04415632|Other|HGI Diet|High glycemic index diet
16337796|NCT04415619|Experimental|Intervention group|10 patients will have immediate implant placement with buccal pad of fat free tissue
16337797|NCT04415606|Experimental|QuikClot Control+|QuikClot Control+
16337798|NCT04415606|Placebo Comparator|Standard gauze|Standard gauze per standard of care
16337799|NCT04415593|Experimental|high dose of peanut|20 patients
16337800|NCT04415593|Active Comparator|low dose of peanuts|20 patients
16337801|NCT04415580|Experimental|Vestibular Rehabilitation Group|
16337802|NCT04415580|Active Comparator|Conventional rehabilitation Group|
16337803|NCT04415567||lenvatinib|high-risk patients with HBV-related HCC who took lenvatinib as adjuvant therapy after liver transplantation
16337804|NCT04415567||control|high-risk patients with HBV-related HCC who received routine treatment and follow-up after liver transplantation
16337805|NCT04415554||exposure to aminoglicosides|preterm receiving aminoglycosides
16337806|NCT04415554||non exposure to aminoglycosides|preterm not receiving aminoglycosides
16337809|NCT04415528|Experimental|Intervention group|The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
16337810|NCT04415528|Active Comparator|Wait listed control group|The wait listed control group will be assessed at Time 1, eight weeks before receiving the intervention. This group will receive Time 2 assessments at the beginning of their group delivery. This group will complete Time 3 assessments eight weeks after the completion of group delivery.
16337814|NCT04415502||Measuring of CTHRc1 , its correlation with RAdisease activity|Measuring of CTHRc1 levels and its correlation with RA disease activity
16337815|NCT04415489|Active Comparator|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
16337816|NCT04415489|No Intervention|Saline Infusion Sonography (SIS)|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
16337817|NCT04415476|Other|Sirolimus and Tacrolimus and prednisone|Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
16337818|NCT04415476|Experimental|Standard of Care|"Arm1:) sirolimus and tacrolimus and prednisone group:
~Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml.
~Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if >40 kg / 1 mg/m²/day if <40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effects.
~Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effect"
16337819|NCT04415463|Experimental|FC-SEMS|Placement of multisegmented fully covered self-expandable metal stent
16337820|NCT04415450|Experimental|Nutrition Education Group|The experimental group is the group who received the intervention which is the nutrition education and counseling. Phase I of the data collection from the experimental group which is the pregnant women (baseline assessment) using a questionnaire immediately before receiving nutrition counseling from their ANC providers first took place. Health professionals then started providing nutrition education to pregnant women preselected and assessed before the intervention. Immediate post education evaluation of the pregnant women was done by the same questionnaire used to assess in the pretest. Phase II or post intervention data collection of pregnant women was done after the client was appointed for 6 weeks after the counseling session.
16337821|NCT04415437||healthy|Healthy participants
16337822|NCT04415437||mentally ill|Participants with mental disorders
16337823|NCT04415437||physically ill|Participants with organic disease
16337824|NCT04415437||mentally and physically ill|Participants with mental disorders and organic disease
16337825|NCT04415424|Experimental|Treatment arm A - 4CMenB vaccine|4CMenB vaccine will be administered as an intramuscular injection in 0.5 ml single-dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
16337826|NCT04415424|Placebo Comparator|Treatment arm B - placebo|Placebo will be administered as an intramuscular injection in 0.5 ml single dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
16337827|NCT04415411|No Intervention|Control group|Routine nursing care
16337828|NCT04415411|Experimental|Intervention group|Nursing care based on the Theory of Human Caring
16337829|NCT04415398|Experimental|Delivery of automated external defibrillators using drones|"Three drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating feasibility in:
~Operational feasibility (Legislation, Weather conditions, conflict in airspace)
~Participant feasibility (Failure to respond; Dispatcher, Drone-pilot, Air traffic controller)
~Technological feasibility (Drone technology, software, winch-system , 4G network, radio communication"
16337830|NCT04415385|Experimental|Camrelizumab + Apatinib|Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
16337833|NCT04415346|Experimental|HU-014 Inj(Phase 1|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
16337834|NCT04415333|Experimental|Sodium Butyrate [5 mmol] first, then Sodium Butyrate [80 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-days washout period, they will return to testing office to self-administer the other enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
16337835|NCT04415333|Experimental|Sodium Butyrate [80 mmol] first, then Sodium Butyrate [5 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-day washout period, they will return to the testing office to self-administer the other enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
16337836|NCT04415333|No Intervention|Control|African Americans with normal blood pressure (control group) will not perform self-administration of the enema. They will submit to 1 blood draw and wear the 24-hour ambulatory blood pressure monitor for 1-day.
16337837|NCT04415320|Experimental|X-396(Ensartinib) Capsule|
16337838|NCT04415307|Experimental|Acupuncture|Acupuncture over acupoints.
16337839|NCT04415307|Experimental|Far-Infrared|Far-Infrared heat-patch attachment over acupoints.
16337840|NCT04415307|Experimental|Combination of Acupuncture and Far-Infrared|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
16337841|NCT04415307|Placebo Comparator|Placebo (no Acupuncture nor Far-Infrared)|Far-Infrared heat-patch attachment over acupoints without electric current passing.
16337842|NCT04415281|Experimental|Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
16337843|NCT04415281|Sham Comparator|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
16337844|NCT04415268|Experimental|Multitreatment|"Pharmacological treatment per standard of care (whole study length, starting on week 1).
~Supervised exercise protocol (phase 1, 8 weeks starting on week 9). Unsupervised exercise protocol (phase 2, 8 weeks starting on week 17)."
16337845|NCT04415255|Experimental|EPABI & IABPI|extrapleural autologous blood injection (EPABI) along with intraparenchymal autologous blood patch injection (IABPI)
16337846|NCT04415255|Active Comparator|IABPI-alone|intraparenchymal autologous blood patch injection (IABPI)
16337847|NCT04415242|Active Comparator|suspension group|Arm on the side operated at 90 ° abduction, 90 ° anti-drive, resting on an arm support.
16337848|NCT04415242|Experimental|supported group|Arm on the operated side at 0 ° abduction, 90 ° anti-pulsation, resting on an adjustable support arm support located opposite the patient's head.
16337849|NCT04415216||ISR PCI with thin-DES|
16337850|NCT04415216||ISR PCI with DEB|
16337851|NCT04415203|Experimental|TAES plus usual care|TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); Usual Care: usual medicine treatment for PVCs.
16337886|NCT04414956|Other|Surveillance|All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.
16337852|NCT04415203|Placebo Comparator|Sham-TAES plus usual care|"Sham-TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current.
~Usual Care: usual medicine treatment for PVCs."
16337853|NCT04415190||cholangiocarcinoma with early palliative care|
16337854|NCT04415190||cholangiocarcinoma without early palliative care|
16337855|NCT04415177|Experimental|VR Program A|Software with active intervention
16337856|NCT04415177|Active Comparator|VR Program B|Software without active intervention
16337857|NCT04415164|Experimental|Xueshuantong|Patients will receive intravenously administered Xueshuantong, combined with guidelines-based standard care.
16337858|NCT04415164|Placebo Comparator|Placebo|Patients will receive intravenously administered Xueshuantong placebo, combined with guidelines-based standard care.
16337861|NCT04415138||Robotic-assisted Group|
16337862|NCT04415138||Video-assisted Group|
16337863|NCT04415125|Experimental|elite male ice hockey players|The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
16337864|NCT04415112|Active Comparator|Mediterranean Diet|The MD diet is rich in plant based foods including vegetables, whole cereal and fruit with the main added fat being extra virgin olive oil. In addition, the diet emphasises, while consumption of legumes, nuts and fish is high, consumption of red meat and home-made desserts is low, and consumption of fermented milk and poultry is moderate. The MD diet had a target macronutrient composition of 35-40% fat (with <10% of energy as saturated fat), 40-44% carbohydrate and 20% protein.
16337865|NCT04415112|Active Comparator|Low Fat Diet|The Low Fat diet had a target macronutrient composition of 55% of energy from carbohydrate, 20-25% from fat (with <10% of energy as saturated fat) and 20-25% from protein. Nutrition education focused on choosing foods containing ≤3 grams of fat/serving, limiting added fats, and using low-fat meal preparation strategies. Parents were instructed to offer their children ample amounts of grains, vegetables, fruits, lean meats, low-fat dairy products and limit high-fat foods
16337866|NCT04415099|Experimental|One group|Only one group was assessed before and after performing muscle fatigue protocol.
16337870|NCT04415073|Active Comparator|Axatilimab (SNDX-6352)|Axatilimab on Days 1 and 15, IV + SOC
16337871|NCT04415073|Placebo Comparator|Placebo|Matching placebo on Days 1 and 15 + SOC
16337872|NCT04415060|Experimental|Inhaled - volatile anesthetic|The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
16337873|NCT04415060|No Intervention|Standard Care|The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
16337874|NCT04415060|No Intervention|Non-randomized|In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
16337875|NCT04415047|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System Intervention Device: JenaValve Pericardial TAVR System
16337876|NCT04415034||Pediculosis capitis|Subjects with pediculosis capitis based on the findings of eggs, larva, or an adult parasite on the scalp or in the hair
16337877|NCT04415021|Experimental|Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
16337878|NCT04415021|Sham Comparator|Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
16337879|NCT04415008|Experimental|treatment arm|prospective, open-label, multicenter,single arm
16337880|NCT04414995|Experimental|Paracetamol+Ibuprofen|Patients in Group 1 will receive a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation following by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.
16337881|NCT04414995|Experimental|Paracetamol+normal saline|Patients in Group 2 will receive 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation following by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.
16337882|NCT04414995|Experimental|Ibuprofen+normal saline|Patients in Group 3 will receive 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation following by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours.
16337883|NCT04414982|Experimental|Intervention Values Affirmation|Compare the effects of the values-affirmation exercise with a control exercise in AI/AN patients with hypertension.
16337884|NCT04414982|Active Comparator|Control Values Affirmation|Compare the effects of the values-affirmation exercise in AI/AN patients with its effects in white patients.
16337885|NCT04414969|Experimental|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
16337887|NCT04414943|Experimental|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
16337888|NCT04414943|Placebo Comparator|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
16337889|NCT04414930|Placebo Comparator|TCT + PBO|
16337890|NCT04414930|Active Comparator|TCT + AMPH|
16337891|NCT04414917|Experimental|Twin Block local anesthetic|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s
16337892|NCT04414917|Sham Comparator|Control|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block injection but with no medication administered/dispensed from the syringe, on the side/s of their extraction/s
16337893|NCT04414904||Case group|"Men 18-50 years of age
~Already attending hospital for another reason
~High risk of prior COVID-19 infection:
~EITHER Prior positive COVID-19 PCR test result
~OR history suggestive of COVID-19 illness"
16337894|NCT04414904||Control Group|"Men 18-50 years of age
~Already attending hospital for another reason
~Low risk of prior COVID-19 infection:
~EITHER Negative positive COVID-19 PCR test result within last 4 weeks
~OR no history suggestive of COVID-19 illness"
16337895|NCT04414891|Experimental|NAVA arm|"Delivery of NIV-NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.
~Subjects randomised to this arm will undergo placement of Edi catheter and will be initiated on NIV. Appropriate NAVA level will be selected based on the scalars corresponding to stable ventilation in pressure support mode. During NAVA, the NAVA level would be increased in multiples of 0.2 cm H2O/µV to attain favourable response (tidal volume 6-8mL/kg RR ≤25). Once the patient's clinical condition stabilises, and the Edi maximum starts declining or remains unchanged with stable tidal volumes, NAVA level will be decreased in steps of 0.2 cm H2O/μV every 2 hours. If response to new settings is not favourable earlier settings will be restored. If favourable response is attained the weaning is continued until peak pressure is <12cm H20 and PEEP requirement is <5cm H2O. NIV will be replaced by a venture mask to titrate SpO2 between 88-92%"
16337896|NCT04414891|Active Comparator|ASV arm|Patients randomised to the ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland). The patients will be ventilated with an initial setting of 100%-minute volume (MV%). Increments of 10% will be made every 15 minutes to achieve clinical response (relief of dyspnea, RR<30, and tidal volume 6-8mL/kg). The expiratory trigger sensitivity will be set at 35% and adjusted accordingly. PEEP will be commenced at 3-4 cm H2O and increased by 1 cm of H2O to achieve SpO2 between 89-92% and maximum PEEP of 10 cm of H2O. Weaning would be performed by reducing the MV% gradually in decrements of 10%/hour to a MV% of 60% after the peak inspiratory pressure decreases to <8 cm of H2O, and the respiratory rate is < 28 breaths per minute and patient is able to maintain SpO2 > 90% at FiO2< 30%. Once the patient is comfortable on these settings, NIV will be replaced with oxygen supplementation using a venturi mask to maintain SpO2 between 89 and 92%.
16337897|NCT04414878|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
16337898|NCT04414865||single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
16337899|NCT04414852|Experimental|mild renal impairment|
16337900|NCT04414852|Experimental|moderate remal impairment|
16337901|NCT04414852|Active Comparator|normal renal impairment|
16337902|NCT04414839|Active Comparator|Digital Intubation (Two-finger)|
16337903|NCT04414839|Active Comparator|Video Laryngoscopy|
16337904|NCT04414826|Active Comparator|Mindfulness + Compassion (MC) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching both mindfulness and compassion skills.
16337905|NCT04414826|Active Comparator|Mindfulness Alone (MO) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching mindfulness skills alone.
16337906|NCT04414826|Placebo Comparator|Waitlist Control (WL)|Those in the wait-list control condition will wait one week and complete a one-week follow-up assessment before being randomized to one of the two intervention conditions.
16337907|NCT04414813|Experimental|hAESCs treatment|hAESCs of 50 million transplant to Parkinson's disease participants.
16337908|NCT04414800|Placebo Comparator|Control (Placebo+ Standard of Care))|
16337909|NCT04414800|Active Comparator|Ketamine + Standard of Care|
16337910|NCT04414800|Active Comparator|Fentanyl + Standard of Care|
16337911|NCT04414787|Active Comparator|Intervention|PCplanner intervention during hospitalization
16337912|NCT04414787|No Intervention|Usual care control|Usual care
16337913|NCT04414774|Experimental|using app first|The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
16337914|NCT04414774|Active Comparator|waiting list|During the first 15 days, the control group is inactive (T1). After 15 days (T2) the control group will start using GGSI app for additional 15 days (T3). Participants will fill questionnaires about suicide ideation and related risk factors three time during the study on: T1, T2 and T3.
16337915|NCT04414761|Active Comparator|Antagonist group|Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
16337916|NCT04414761|Experimental|PPOS group|Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger.
16337917|NCT04414748|Active Comparator|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
16337918|NCT04414748|Experimental|PPOS group|Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
16340614|NCT04395339|Placebo Comparator|Control arm|This arm will be treat with blank placebo.
16337919|NCT04414735|No Intervention|1- Control group (Standard immunosuppression)|1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.
16337920|NCT04414735|Experimental|2- Treatment group (ECP+Standard immunosuppression)|2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department
16337921|NCT04414722|Placebo Comparator|Concurrent control yogurt and amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
16337922|NCT04414722|Placebo Comparator|Control yogurt taken 4 hours after amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
16337923|NCT04414722|Active Comparator|Concurrent BB-12 yogurt and amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
16337924|NCT04414722|Active Comparator|BB-12 yogurt taken 4 hours after amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
16337925|NCT04414722|Other|Amoxicillin-clavulanate|Amoxicillin-clavulanate 875 mg-125 mg oral tablet
16337926|NCT04414709|Experimental|Two short implants|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
16337927|NCT04414709|Active Comparator|Single short implant|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
16337928|NCT04414696|Experimental|Intervention|Participants will be asked to use a web-based (eHealth) exercise intervention for 3 months. This eHealth exercise intervention includes over 90, 10-minute exercise videos with options for exercise type, time, and intensity, customized to the weight of the infant. Users can either select up to three 10-minute videos to create a 10 to 30-minute workout or choose a 'Ready Made' workout that is either 10, 20, or 30-minutes long.
16337929|NCT04414696|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard care as suggested by their provider. Participants will complete the same assessments and incentives as the active intervention but will not receive the eHealth exercise intervention.
16337930|NCT04414644|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
16337931|NCT04414644|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
16337932|NCT04414631|Active Comparator|active treatment arm|treatment with conestat alfa in addition to standarf of care
16337933|NCT04414631|No Intervention|Standard of care treatment arm|Standard of care treatment established at the centers
16337934|NCT04414618|Active Comparator|opaganib|Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
16337935|NCT04414618|Placebo Comparator|placebo|Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
16337936|NCT04414605|Experimental|Chinese herbal medicine in combination with secukinumab|Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
16337937|NCT04414592|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc
16337938|NCT04414579|No Intervention|No Intervention: Conventional Insulin Aspart (NovoLog®)|In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
16337939|NCT04414579|Active Comparator|Faster Insulin Aspart (Fiasp®)|In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
16338058|NCT04413591|Experimental|Intervention Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
16337940|NCT04414566|Experimental|IC plus RT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m^2) every three weeks for three cycles during radiotherapy.
16337941|NCT04414566|Active Comparator|IC plus CCRT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.
16337942|NCT04414553|Experimental|Community-AHF|Participants in this arm will receive the 10 month Community Active and Healthy Families Intervention
16337943|NCT04414553|No Intervention|Wait List|Participants in this arm will receive routine primary care follow up for childhood overweight/obesity. After the 10 month experimental period they will be offered the Community Active and Healthy Families Intervention but participation is not required.
16337944|NCT04414540|Experimental|Arm 1: Metformin before Pembrolizumab|Metformin ER 1000mg daily D-14 to D-7. Metformin ER 2000mg daily D-7 to D1. D1 Begin Pembrolizumab 200mg every 3 weeks, while continuing Metformin ER 2000mg daily.
16337945|NCT04414540|Experimental|Arm 2: Metformin after Pembrolizumab|D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
16337946|NCT04414527|Other|Standard counseling|Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines. In the standard health care, pregnant women receive a minimum of four ante-natal care visits at the health centers during which they also receive iron and folic acid supplementation. They participate in monthly forums facilitated by nurses to answer questions and concerns regarding nutritional care.
16337947|NCT04414527|Experimental|Health-Video|Women in the Health-Video group will receive home visits for delivery of healthy nutrition messages using prepared video-based messages every two weeks. They will also participate in monthly forums facilitated by nurses using also videos for demonstration of nutritional care. During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show coordinated by a nurse/ health professional for any questions. During postnatal period, two counseling sessions will be delivered within two weeks of birth, and 12 sessions or twice every month till 6 months.
16337948|NCT04414514|Experimental|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
16337949|NCT04414501|Active Comparator|Tablet study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
16337950|NCT04414501|Active Comparator|VR study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
16337951|NCT04414488||Patient controlled analgesia|General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
16337952|NCT04414488||Thoracic paravertebral block and patient controlled analgesia|Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
16337953|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-40 BIW)|Participants will receive fixed dose of 40 milligram (mg) of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet twice weekly (BIW) on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle.
16337954|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-100 QW)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet followed by 40 mg of low-dose Dexamethasone oral tablet once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone may be given as 20 mg on days 1 and 2 of each week).
16337955|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-80 BIW)|Participants will receive fixed dose of 80 mg of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet BIW on Days 1, 3, 8, 10,15, 17, 22, and 24 of each 28-day cycle.
16337956|NCT04414475|Experimental|Selinexor + Bortezomib + Dexamethasone (SVd)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet on Days 1, 8, 15, 22, and 29 followed by 1.3 milligram per square-meter (mg/m^2) of Bortezomib subcutaneous (SC) injection on Days 1, 8, 15, and 22 and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, 22, and 29 of each 35-day cycle (Dexamethasone dose may be split to 20 mg on days 1 and 2).
16337957|NCT04414462|Experimental|Group I|Group I will receive following exergaming training: heading, tightrope tension,snowboard slalom and table tilt game
16337958|NCT04414462|Active Comparator|Group II|Group II will receive Habituation,wobble board exercises,double leg,single leg and tandem stance training.
16338059|NCT04413591|No Intervention|Control Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
16340861|NCT04393545|Active Comparator|high-voltage galvanic stimulation (EL) group|
16337961|NCT04414436|Experimental|GYNEA- digital coping program|Participants randomized to this arm will receive active treatment after the inclusion
16337962|NCT04414436|No Intervention|Waiting list|6 weeks waiting list before crossing over to GYNEA- digital coping program
16337963|NCT04414423|Experimental|Bone marrow concentrate|Bone marrow concentrate combined with Autogenous bone graft
16337964|NCT04414423|Active Comparator|autogenous bone graft|grafting with autogenous bone graft
16337965|NCT04414397|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM VOLUMA® XC injectable gel in temple. Participants are eligible for touch up treatment.
16337966|NCT04414397|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 3.
16337967|NCT04414384|Experimental|Abdominal Binder|During this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
16337968|NCT04414384|Other|Control|This group of patients will not wear abdominal binders, but during this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
16337969|NCT04414371|Experimental|Group 1 - Yoga Group|Learn online yoga practices and practice daily for 12-weeks
16337970|NCT04414371|Other|Group 2 - Control Group|waist-list control for 4-week, cross-over to yoga practice for 8-week
16337971|NCT04414345|Experimental|CNM-Au8|"Drug: CNM-Au8
~Administration: Oral
~Dosage: 30 mg or 60 mg daily"
16337972|NCT04414345|Placebo Comparator|Matching Placebo|"Administration: Oral
~Dosage: 2 bottles daily"
16337973|NCT04414306|Experimental|Experimental Arm 1|Attendees at in-person events (e.g. health fairs) who meet eligibility criteria will be able to enroll and participate in-person, with some participating in online or telephone survey follow-up.
16337974|NCT04414306|Experimental|Experimental Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up.
16337975|NCT04414306|Experimental|Experimental Arm 3|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up. This arms will serve as an experimental arm for assessing study aim 2 and as a control arm for study aim 1.
16337976|NCT04414306|Experimental|Experimental Arm 4|Patients identified by one or more healthcare systems to be due or overdue for colorectal cancer screening will be informed by their healthcare provider or healthcare system (e.g. via the healthcare system's patient portal) that they are due for screening and will be informed how to schedule an colorectal cancer screening related appointment (e.g. discussion with primary care provider about colorectal cancer screening options) along with the option to receive education about colorectal cancer screening. Patients who are interested in receiving education may view the education with or without participating in the research study. Patients who elect to be study participants will participate in consenting, eligibility screening, pre-test, post-test, and possible three- and six-month using a parallel structure to study arms two and three.
16337977|NCT04414293|Experimental|Treatment|All the patients will be treated with low dose lung radiation
16337978|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 670G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 670G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
16337979|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 780G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 780G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
16337980|NCT04414280||type 1 diabetes patients using Tandem Control-IQ|Patients with type 1 diabetes, aged 6 years or older, who start with the Tandem Control-IQ system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
16337981|NCT04414267|Experimental|BCG vaccine|One intradermal injection of 0.1ml of BCG (BCG vaccine Moscow strain 361-1; Serum Institute of India Pvt. Ltd)
16337982|NCT04414267|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
16337983|NCT04414254|Experimental|conference-Cefprozil for Suspension®|"Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)"
16337984|NCT04414254|Experimental|test-cefprozil granule|cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)
16337987|NCT04414228|Active Comparator|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
16337988|NCT04414228|Active Comparator|ProAQT in guiding goal-directed hemodynamic therapy|Subjects randomized to the GDT group will be managed according to the ERAS algorithm utilizing ProAQT variables (mean arterial pressure, stroke volume variation and cardiac index) If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
16337989|NCT04414215|Experimental|Cognitive training|Emotional working memory training
16337990|NCT04414215|Placebo Comparator|Placebo training|Placebo working memory training
16337991|NCT04414202||1 GROUP|"Patient with an Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery.
~The treatment combines extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor Follow up after this treatment will scheduled 10 years"
16337992|NCT04414189||Arm A|Patients with suspected sepsis at the time of admission to the ICU
16337993|NCT04414189||Arm B|Patients not currently suspected but at high risk for sepsis.
16337994|NCT04414176||Case|Patients with coronary artery stenosis more than 75% (or left-main stenosis more than 50%) are defined as case group
16337995|NCT04414176||Control|Patients with normal angiography are considered as control group.
16337996|NCT04414163|Experimental|IMC-001|Single Dose level (IMC-001 20mg/kg, every 2 weeks)
16337997|NCT04414150|Experimental|SHR-1802|
16337998|NCT04414137||Eosinophilic pneumonia on daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia
16337999|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|
16338000|NCT04414124|Other|Self Supportive Care (SSC) Alone|
16338001|NCT04414111||Kidney transplant recipient|Kidney transplant recipient
16338002|NCT04414072|Active Comparator|laparoscopic sleeve gastrectomy|
16338003|NCT04414072|Active Comparator|mini gastric bypass|
16338004|NCT04414072|Active Comparator|sleeve gastrectomy with loop bipartition|
16338005|NCT04414046|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
16338006|NCT04414033|Experimental|research group|
16338007|NCT04414020|No Intervention|Control|Control group receiving conventional treatment without progesterone
16338008|NCT04414020|Active Comparator|progesterone group|1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
16338009|NCT04414007|Experimental|Internet+ home-based cardiac rehabilitation group|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
16338010|NCT04414007|Active Comparator|conventional care group|The UC-assigned patients will maintain standard of care.The conventional rehabilitation group received routine medical care and traditional home-based cardiac rehabilitation based on the rehabilitation manual and exercise diary, followed up by telephone and outpatient.
16338011|NCT04413994|Active Comparator|Randomized study product group|"receiving study product (human milk fortifier Humavant) until a gestational age of 36 weeks"
16338012|NCT04413994|Active Comparator|Randomized control group|receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation
16338013|NCT04413994|No Intervention|Term control group|Term-born controls as a reference group for outcome parameters
16338014|NCT04413968|Experimental|Interventional|nasopharyngeal and blood sample
16338015|NCT04413942|Active Comparator|FB825|FB825
16338016|NCT04413942|Placebo Comparator|Placebo|Formulation buffer
16338017|NCT04413929||Ergoferon|Oral administration in the therapeutic dosage specified in the instructions for medical use.
16338018|NCT04413903|Active Comparator|Pressure controlled ventilation, Volum controlled ventilation|Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
16338019|NCT04413903|Active Comparator|Optic Nerve Sheath Diameter|In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid. The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel. The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure. After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
16338020|NCT04413890|Active Comparator|Classical administration|One prostaglandin vaginal gel every 24 hours
16338021|NCT04413890|Experimental|Experimental administration|One prostaglandin vaginal gel every 12 hours
16338022|NCT04413877||Descriptive cohort study|"Prospective cohort study of community-dwelling adults ≥65-year-old living at home, with no other exclusion criteria than the inability to use the ICOPE Apps or communicate by telephone/video-call for any reason (cognitive or limited access to technologies like telephone/video-call).
~Cohort study, designed to determine the incidence of frailty in community-dwelling older people during 1-year follow-up, starting the recruitment at a certain point of the COVID-19 pandemic and beyond."
16338023|NCT04413864|Other|SARS-CoV-2 (Covid-19 positive)|Patients hospitalized in intensive care unit (ICU), infected with SARS-CoV-2
16338024|NCT04413851||Dementia|Subjects with a diagnosis of dementia who are experiencing agitation severe enough that it interferes with activities of daily living or social interaction.
16338025|NCT04413838|Experimental|NIVOLUMAB on top of routine standard of care|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND aspartate aminotransferase (AST) > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a NIVOLUMAB treatment and routine standard of care for COVID-19 infection at the time of study inclusion
16338026|NCT04413838|Other|Standard of care for COVID-19 infection|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND AST > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a routine standard of care for COVID-19 infection at the time of study inclusion
16338027|NCT04413812|Experimental|Experimental Group|The experimental group will participate in a 3-months training programme focusing on health competence related outcomes.
16338028|NCT04413812|No Intervention|Control Group|The control group does not participate in the exercise programme but undergoes identical outcome assessments.
16338029|NCT04413799|Active Comparator|lidocaine/ ketamine infusion|Lidocaine/ ketamine infusion will be monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
16338030|NCT04413799|Active Comparator|paravertebral block with ropivacaine|Paravertebral block catheter will be placed by Anesthesiology led Acute Pain Service. Once the catheter is inserted, a ropivacaine bolus and infused with ropivacaine, monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
16338031|NCT04413786|Experimental|oxytocin group|male subjects with oxytocin treatment
16338032|NCT04413786|Placebo Comparator|placebo group|male subjects with placebo treatment
16338033|NCT04413773|Active Comparator|Treatment as usual|Treatment as Usual, Explanation of standard procedures before, during and after surgery by nurse
16338034|NCT04413773|Experimental|Treatment as usual + Video|Treatment as usual and additionally Video
16338035|NCT04413747|Experimental|Yoga-based breathing support|Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
16338036|NCT04413734|Experimental|Triprilumab in combination with chemotherapy of GP|Triprilumab, 240 mg, every 3 weeks (Q3W), Day 1 of each 3 week cycle PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity .
16338037|NCT04413734|Active Comparator|Mono-chemotherapy of GP|Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity.
16338038|NCT04413721|Experimental|Short-term storage RBCs (stored for ≤ 14 days)|patients in this group were transfused with short-term storage RBCs (stored for ≤ 14 days).
16338039|NCT04413721|Active Comparator|Longer-term storage RBCs (stored for ≥21 days)|patients in this group were transfused with longer-term storage RBCs (stored for ≥21 days).
16338040|NCT04413708|Experimental|P3-T PrEP adherence app|"Intended app use includes, at a minimum, participant completion of selected app activities (medication tracking, daily quest, social wall post) each day for the 3 month intervention period.
~Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit."
16338041|NCT04413708|No Intervention|Standard of Care|Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit.
16338042|NCT04413682|Experimental|Supervised Exercise Group|One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
16338043|NCT04413682|Experimental|Telerehabilitation Group|One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
16338044|NCT04413669|Experimental|white light bronchoscopy and autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out for people at high risk for lung cancer with heavy smoking (smoking history> 400 years).Biopsy was taken for abnormal bronchial mucosa.
16338045|NCT04413656|Experimental|ablation group|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
16338046|NCT04413656|Experimental|surgery group|Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
16338047|NCT04413643|Experimental|Noninvasive Ventilation|Subjects will be introduced to NIV and educated on sleep disordered breathing. NIV will be initiated during hospitalization following resolution of acute respiratory failure. NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment. Initial settings will be set with goals of tolerance and acceptance of therapy. Minimum pressure difference between IPAP and EPAP settings will be 5cmH20. Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used. Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device. Data from the device will be reviewed the following day. Tolerance, mask comfort, and acceptance of therapy will be assessed. Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
16338048|NCT04413630|Experimental|Study group|family workshop
16338049|NCT04413617|Experimental|PF-06650833 + tofacitinib|
16338050|NCT04413617|Experimental|PF-06650833 + PF-06651600|
16338051|NCT04413617|Experimental|PF-06650833|
16338052|NCT04413617|Experimental|PF-06651600|
16338053|NCT04413617|Experimental|Tofacitinib|
16338054|NCT04413604|Experimental|YCM Group (1- <3) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
16338055|NCT04413604|No Intervention|Observation Group (1-<3) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
16338056|NCT04413604|Experimental|YCM Group (3-5) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
16338057|NCT04413604|No Intervention|Observation Group (3-5) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
16338060|NCT04413578|Experimental|Dexcom G6 (Intervention Group)|• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
16338061|NCT04413578|Placebo Comparator|Contour NextOne (Standard of Care) Glucometer|• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
16338062|NCT04413565|Experimental|Two surgeon bilateral TKA group|2 surgeons will perform simultaneous total knee arthroplasty in this group.
16338063|NCT04413565|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
16338064|NCT04413552|Experimental|Part I-Active arm|Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort
16338065|NCT04413552|Placebo Comparator|Part II-Placebo arm|Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort
16338066|NCT04413552|Experimental|Part II-Active arm-fed|Study medication will be administered after a high fat meal. Dose to be determine based on a well-tolerated dose studied in Part I.
16338067|NCT04413552|Experimental|Part II-Active arm-fasting|Study medication will be administered under fasted conditions. Dose to be determine based on a well-tolerated dose studied in Part I.
16338068|NCT04413526||radiofrequency-assisted liver resection|radiofrequency-assisted liver resection for intractable liver cancer
16338069|NCT04413526||TACE(transcatheter arterial chemoembolization)|temporary TACE for intractable liver cancer
16338070|NCT04413526||radiofrequency ablation plus TACE|radiofrequency ablation plus TACE for intractable liver cancer
16338071|NCT04413513|Experimental|Integrated Attention Training Program|"The intervention group (I) will receive integrated attention training program (IATP) on a variety of structured attention tasks by an intervention instructor. It is considered to be simple and safe but effective enough for cognitive health promotion."
16338072|NCT04413513|Placebo Comparator|Health Education|The control group (C) will receive health educational sessions on health concerns and physical diseases commonly found in old age during the invention period.
16338073|NCT04413500|Experimental|adaptive intervention|The patients will receive various adaptive digital interventions through mobile app.
16338074|NCT04413474||Study group|Unselected critically ill patients who met the inclusion criteria
16338075|NCT04413461|Experimental|TENS|
16338076|NCT04413461|Placebo Comparator|TENS Sham|
16338077|NCT04413435||Confirmed COVID-19 cases|Patients with PCR test positive were considered as the confirmed COVID-19 cases.
16338078|NCT04413435||Suspected COVID-19 cases|The suspected COVID-19 cases were defined as follows: those who were interpreted in favor of the suspected covid-19 on c-CT by radiologists in addition to the typical symptoms of the novel coronavirus disease such as cough, high fever (>38,5 °C), or dyspnea, and those with a history of contact with another confirmed COVID-19 patient in addition to typical symptoms.
16338079|NCT04413422||propofol|Those patients planned for general surgery, who received propofol as an induction agent for general anesthesia.
16338080|NCT04413422||etomidate|Those patients planned for general surgery, who received etomidate as an induction agent for general anesthesia.
16338081|NCT04413422||thiopental|Those patients planned for general surgery, who received thiopental as an induction agent for general anesthesia.
16338082|NCT04413409|Experimental|surgical group|The metastatic sites are firstly treated by surgery then followed by systemic treatment
16338083|NCT04413409|No Intervention|systemic group|After confirmation of puncture, receive systemic treatment
16338084|NCT04413396||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
16338085|NCT04413383|Active Comparator|Traditional Curved Iris Scissors|The traditional curved Iris scissors are used to during the dermatologic surgery. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
16338086|NCT04413383|Experimental|Modified Curved Iris Scissors|"The Wuennenberg modified curved Iris scissors are used during the dermatologic surgery.
~Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure."
16338087|NCT04413383|Other|Comparative Experience|Both the traditional and modified curved Iris scissors are used and patients are asked which they prefer. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
16338088|NCT04413370||Referral Group (no MGD)|This group of subjects was diagnosed with dry eye (without meibomian gland dysfunction) and need to be a referral to the hospital for further treatments.
16338089|NCT04413370||Referral Group (MGD)|This group of subjects was diagnosed with meibomian gland dysfunction and need to be a referral to the hospital for further treatments.
16338090|NCT04413370||Artificial tears group|This group of subjects was diagnosed with dry eye but can use artificial tears instead of further treatment.
16338091|NCT04413370||Normal control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
16338100|NCT04413305|Experimental|WGS-based screen and control group|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
16338101|NCT04413305|No Intervention|Non-intervention|Non-intervention
16338102|NCT04413292||Group A|21 patients with lung cancer
16338103|NCT04413292||Group B|21 patients with various benign lung diseases
16338104|NCT04413292||Group C|Healthy controls
16338105|NCT04413292||Group D|15 patients with malignant pleural mesothelioma (MPM)
16338106|NCT04413292||Group E|16 patients having various benign pleural diseases
16338107|NCT04413279|Active Comparator|Lipiflow Only Group|Patients with dry eye disease Lipiflow only
16338108|NCT04413279|Experimental|Lipiflow + Dextenza Group|Patients with dry eye disease Lipiflow + Dextenza
16338109|NCT04413266|Active Comparator|Curcumin for CKD|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
16338110|NCT04413266|Placebo Comparator|Placebo for CKD|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
16338111|NCT04413253|Active Comparator|Xiidra Only Group|Patients with dry eye disease Xiidra only
16338112|NCT04413253|Experimental|Xiidra + Dextenza Group|Patients with dry eye disease Xiidra + Dextenza
16338113|NCT04413240|Experimental|Telerehabilitation group|"Patients in this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain telerehabilitation (motor, speech and/or cognitive) with VRRS, K-Wand and Khymu connected to a workstation (Telecockpit)."
16338114|NCT04413240|Active Comparator|Conventional rehabilitation group|"The patients assigned to this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain rehabilitation (motor, speech and/or cognitive). It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated."
16338115|NCT04413227|Experimental|PEG-ENDO+Docetaxel|PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg）+Docetaxel 75 mg/m2，once every 3 weeks at day 1
16338116|NCT04413214|Experimental|Test Group|The 3x3 dose escalation design will be adopted, including 200mg, 400mg and 600mg of Carrimycin; and three subjects at each dose level initially. If there is no DLT in the dose level of 200mg, the dose level of 400mg will be followed; if there is one DLT in the dose level of 200mg, another three patients will be added in the dose level of 200mg; if there is no DLT occurs in the another three patients, the dose level of 400mg will also be followed; if there is one DLT in the another three patients, the trial will be closed. The same condition to the dose level of 400mg and 600mg.
16338117|NCT04413201|Experimental|Afatinib|Afatinib followed by osimertinib or ICT depending on T790M status
16338118|NCT04413201|Active Comparator|Osimertinib|Osimertinib followed by ICT
16338119|NCT04413188|Experimental|A warm foot bath group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
16338120|NCT04413188|No Intervention|Control group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
16338121|NCT04413175|Experimental|a music group|Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
16338122|NCT04413175|No Intervention|control group|control group
16338123|NCT04413162|Other|measurement before and after capsular distention|
16338124|NCT04413136|Experimental|Web-ORLA|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.
~The participant is presented with 3-5 word (level 1) or 8-10 word (level 2) sentences, depending upon the severity of the aphasia. Each sentence is chosen by the software program at random from a group of 150 sentences. The participant is instructed to look, listen, and point to words spoken by the virtual therapist, read highlighted words aloud, and then read the sentence aloud, both chorally with the virtual therapist and independently."
16338125|NCT04413136|Placebo Comparator|Control|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.
~A commercially available game, Bejeweled 2, by PopCap. Participants use loaned 13-in laptop computers to access the Bejeweled interface, which displays an 8 X 8 grid of gems of varying shapes and colors. The objective is to match three gems of the same color and shape to score points and advance to more difficult levels."
16338126|NCT04413123|Experimental|Cabozantinib|"Eligible patients will be enrolled and receive treatment with
~Cycle 1-4 (cycles of 21 days)
~Cabozantinib predetermined protocol dosage po daily
~Nivolumab predetermined protocol dosage via IV every 3 weeks
~Ipilimumab predetermined protocol dosage via IV every 3 weeks
~After the first four cycles of therapy,
~Cabozantinib determined protocol dosage po daily
~Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)"
16338127|NCT04413110||Non-subjective cognitive impaired|Cases of migraine and non-subjective cognitive impaired
16338128|NCT04413110||Subjective cognitive impaired|Cases of migraine and subjective cognitive impaired
16338129|NCT04413110||Control group|Age and sex matched healthy controls
16338173|NCT04412759|Experimental|Microbial cellulose|Novel dressing consisting of a biopolymer spun by the bacteria Acetobacter xylinum (later removed).
16338257|NCT04412109|Active Comparator|injection of low volume of saline|low volume (5 cc) saline injection during thoracic epidural catheterization
16338130|NCT04413097|Active Comparator|DCC and Low Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 .30, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
16338131|NCT04413097|Experimental|DCC and High Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 1.0, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
16338132|NCT04413084|Experimental|Gaze stability exercises|Group I will receive Gaze stability exercises.
16338133|NCT04413084|Experimental|Brandt-Daroff Exercises|Group II will receive Brandt-Daroff Exercises.
16338134|NCT04413071||Health care workers|Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
16338135|NCT04413058||Female healthcare workers|Healthy female healthcare workers at Covid 19 clinic in Istanbul, Turkey
16338136|NCT04413045||C Group|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
16338137|NCT04413032|Experimental|Patients with MS|30 Patients with MS will use the DreaMS App over a study duration of 6 weeks.
16338138|NCT04413032|Experimental|Healthy Volunteers|30 Healthy Volunteers will use the DreaMS App over a study duration of 6 weeks.
16338139|NCT04413019||Group (D): Planned domiciliary care.|Patients within this group will be counseled for home care with self-monitoring for any symptoms suggestive of preterm labor, maternal or fetal distress.
16338140|NCT04413019||Group (H): Planned hospital care.|Patients within this group will be admitted at hospital for close monitoring of maternal & fetal wellbeing & finally the neonatal outcome
16338141|NCT04413006|Experimental|Treatment Arm|Participants who will receive the 6-session Group-Based Virtual Self-Compassion for Chronic Pain treatment
16338142|NCT04412967|Active Comparator|Standard Technique PVC placement|Standard PVC placement technique
16338143|NCT04412967|Experimental|DUST|Dynamic ultrasound-guided short-axis needle tip navigation (DUST)
16338144|NCT04412954|Experimental|Intervention|Health coach with Smartphone application for diet and physical activity
16338145|NCT04412954|No Intervention|Control|No intervention, using a Smartphone application for sleep monitoring
16338146|NCT04412941|Experimental|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
16338147|NCT04412941|Active Comparator|Control group|the rules of sleep hygiene
16338148|NCT04412889|Experimental|CAR-T treatment group|The patients will receive BCMA/CD19 dual-target CAR-T cell treatment. BCMA/CD19 dual-target CAR-T cell dosage ranges from 2×10^5 to 1×10^6 CAR+T/Kg.
16338149|NCT04412876|Experimental|Duloxetine|Receive Duloxetine 30 mg treatment per day
16338150|NCT04412876|Active Comparator|Imipramine|Receive Imipramine 25 mg treatment per day
16338151|NCT04412863|Experimental|Cohort 1d|VIR-2218 given by subcutaneous injection
16338152|NCT04412863|Experimental|Cohort 2d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
16338153|NCT04412863|Experimental|Cohort 3d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
16338154|NCT04412863|Experimental|Cohort 1e|VIR-2218 given by subcutaneous injection
16338155|NCT04412863|Experimental|Cohort 2e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
16338156|NCT04412863|Experimental|Cohort 3e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
16338157|NCT04412863|Experimental|Cohort 1f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
16338158|NCT04412863|Experimental|Cohort 2f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
16338159|NCT04412850|Experimental|Control group|Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
16338160|NCT04412850|Placebo Comparator|placebo group|Normal Saline in equal volume as the control group.
16338161|NCT04412837|Experimental|CBD Patch|Topical CBD patch to be worn for 24 hours and changed daily for the course of 4 weeks.
16338162|NCT04412837|Placebo Comparator|Control Patch|Control placebo patch to be worn for 24 hours and changed daily for the course of 4 weeks.
16338163|NCT04412824|Active Comparator|Alcohol Beverage Cues|Participants will complete an MRI with alcohol beverage visual cues and oral alcohol session.
16338164|NCT04412824|Placebo Comparator|Non-Alcoholic Beverage Cues|Participants will complete an MRI with non-alcoholic beverage cues and oral alcohol session.
16338165|NCT04412811||Patients with hematological disease|Adult and children allogenic Hematopoietic stem cell transplantation recipients
16338166|NCT04412798|Other|group 1|orange juice concentrate
16338167|NCT04412798|Other|Group 2|Sugar-sweetened orange-flavoured beverage
16338168|NCT04412798|Other|Group 3|Whole orange juice with skin removed
16338169|NCT04412785|Experimental|Single Arm|Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
16338170|NCT04412772|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen.
16338171|NCT04412772|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
16338172|NCT04412759|No Intervention|Porcine xenograft|porcine xenograft derived from dermal porcine skin. Standard of care treatement for partila thickness burn at the specfic centre
16338174|NCT04412733|Experimental|Pulsed Ultrasound Group|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2 ) 5-min daily session, 5 days per weeks, for a total of 15 sessions.
16338175|NCT04412733|Sham Comparator|Sham Group|Control group received sham ultrasound with the same protocol.
16338176|NCT04412720|Experimental|Aerobic and Breathing Exercises|The experimental intervention will be aerobic and breathing exercises.
16338177|NCT04412720|Active Comparator|Aerobic and Stretching Exercises|The active comparative intervention will be aerobic and stretching exercises.
16338178|NCT04412707|Active Comparator|Arm A|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a PVC and cycle 2 and onwards melflufen will be administered via a CVC.
16338179|NCT04412707|Active Comparator|Arm B|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a CVC and cycle 2 will be administered via a PVC. From cycle 3 and onwards melflufen will be administered via CVC.
16338180|NCT04412694|Experimental|supplementation group|Patients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
16338181|NCT04412694|Placebo Comparator|placebo group|Patients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
16338182|NCT04412681|Experimental|PE Enhanced Screening|"The PE screening program entails the following for all participants:
~provision of additional demographic and risk factors
~provision of mean arterial pressure
~standard nuchal translucency scan as part of their first trimester screening (FTS) with the addition of the measurement of the uterine artery Doppler by a certified sonographer
~standard blood sample (as part of the FTS)
~results of the PE screening (in the format of a screening report) will be provided to the study team and participant's healthcare provider"
16338183|NCT04412668|Experimental|ATYR1923 1 mg/kg|Single dose of ATYR1923 1 mg/kg
16338184|NCT04412668|Experimental|ATYR1923 3 mg/kg|Single dose of ATYR1923 3 mg/kg
16338185|NCT04412668|Placebo Comparator|Placebo|Single dose of Placebo
16338186|NCT04412655||STEMI patients treated in March April 2019|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
16338187|NCT04412655||STEMI patients treated in March April 2020|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
16338188|NCT04412642|Other|methoxyflurane|methoxyflurane
16338189|NCT04412629|Experimental|Cabozantinib|-Cabozantinib 60 mg by mouth daily on days 1-21
16338190|NCT04412616|Experimental|ZZ06 0.03 mg/kg dose group|ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338191|NCT04412616|Experimental|ZZ06 0.06 mg/kg dose group|ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338192|NCT04412616|Experimental|ZZ06 0.12 mg/kg dose group|ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338193|NCT04412616|Experimental|ZZ06 0.22 mg/kg dose group|ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338194|NCT04412616|Experimental|ZZ06 0.39 mg/kg dose group|ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338195|NCT04412616|Experimental|ZZ06 0.70 mg/kg dose group|ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338196|NCT04412616|Experimental|ZZ06 1.00 mg/kg dose group|ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
16338197|NCT04412603|Experimental|Conventional Mirror Therapy group|"Therapy:
~-With the affected upper limb into the mirror box, perform the exercise with the non-affected extremity which is reflected in the mirror box. -The affected side must perform the corresponding movement within its possibilities, according to the exercise that is being performed with the healthy arm. - It is very important to look at the mirror at all times, which reflects the non-affected side while doing the exercises."
16338258|NCT04412109|Active Comparator|injection of intermediate volume of saline|intermediate volume (10 cc) saline injection during thoracic epidural catheterization
16338451|NCT04410718||The hospitalisation cohort|Patients with diabetes and COVID-19 admitted to the medical ward
16338198|NCT04412603|Experimental|Mirror Therapy Virtual Reality group|"Therapy:
~-Perform the exercises with the non-affected limb, which must be watched constantly with virtual reality glasses, to interpret that this limb corresponds to the affected side. - The affected side accompanies the movement within its possibilities (out of sight of the patient, it can be covered with a handkerchief). - It is very important to look at the non-affected side. The affected side should be out of the visual field to avoid confusion."
16338199|NCT04412590|Experimental|Vermont Family Based Approach|"The VFBA group was offered a variety of supports and services to help them achieve and maintain wellness and address emotional behavioral challenges.
~All families partnered with a Family Wellness Coach (FWC) to design and implement a comprehensive program of family health and wellness with an emphasis on nutrition, exercise, music training, mindfulness, decreasing screen time, and positive parenting.
~Families with a child or parent experiencing significant emotional and behavioral problems were also partnered with Focused Family Coaches (FFCs) and Family Based Psychiatrists (FBPs). FFCs and FBPs respectively provided evidence-based psychotherapy and psychiatric care from the family perspective.
~Families also were also offered health promotion programs, including music lessons for all family members, behavioral parent training, yoga and mindfulness training, and nutrition coaching."
16338200|NCT04412590|Active Comparator|Control|The Control Group received pediatric care as usual.
16338201|NCT04412577|Experimental|TQB3473 tablets|TQB3473 tablets administered once daily in 28-day cycle .
16338202|NCT04412564|Experimental|TQ-B3101 capsules|TQ-B3101 capsules 300mg bid administered orally in 28-day cycle.
16338203|NCT04412538|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
16338204|NCT04412538|Experimental|Low dosage vaccine on a 0- and 14-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
16338205|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
16338206|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 14-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
16338207|NCT04412538|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
16338208|NCT04412538|Experimental|High dosage vaccine on a 0- and 14-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
16338209|NCT04412538|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
16338210|NCT04412538|Placebo Comparator|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0, 14
16338211|NCT04412525|Experimental|27 gauge needle vitrectomy surgery|
16338212|NCT04412525|Experimental|larger than 27 gauge (23G or 25G) needle vitrectomy surgery|
16338213|NCT04412512|Experimental|VATS approach|patients treated by VATS technique.
16338214|NCT04412512|Active Comparator|Thoracotomy approach|patients treated by Thoracotomy technique
16338215|NCT04412499||Methylphenidate + parent-training programm|Methylphenidate and participation in a parent-training programme
16338216|NCT04412499||Methylphenidate alone|Methylphenidate alone
16338217|NCT04412486|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants with serious or life threatening complications from COVID-19 or are at high risk to develop serious complications.
16338218|NCT04412447|Experimental|Subjects|"Phase V1: 1 month of home-based FES-training using isometric contractions of quadriceps and hamstring muscles (3 times a week).
~Phase V2: 2 months of home-based FES-training on an ergo-cycle with arm support (3 times a week)
~Phase V3: 1 month of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting.
~Optional (only for selected pilot):
~Phase V4: 2-4 months of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting. This phase is focussing on optimizing the performance of the pilot and improving the mechanical efficiency of the tricycle.
~Phase V5: Participation on Cybathlon 2020"
16338219|NCT04412434|Other|patients with acute ischemic stroke|This open-label prospective study will be conducted in the single medical center (RAMBAM Medical Center) and will include at least 200 patients with acute ischemic stroke resulted from MCA or ICA occlusion.
16338220|NCT04412408|Experimental|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.
~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
16338221|NCT04412395|Active Comparator|Arm 01 (SOC + Lactoferrin 1200 mg QID)|Patients randomized to this group will receive two 600 mg Lactoferrin tablets QID plus the Standard of Care (SOC) treatment(s).
16338222|NCT04412395|Placebo Comparator|Arm 02 (SOC + Placebo QID)|Patients randomized to this group will receive two placebo tablets QID plus the SOC treatment(s).
16338223|NCT04412382||covid-19|Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
16338224|NCT04412382||control|Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer.
16338225|NCT04412369||Study group|Patients with COVID-19 and cardiac Troponin elevation
16338226|NCT04412356|Experimental|Early tracheotomy|Tracheotomy within 7 days after intubation.
16338227|NCT04412356|Active Comparator|Late tracheotomy|Tracheotomy after at least 10 days after intubation.
16338254|NCT04412122|Experimental|Breathing Exercise|Breathing exercise is accepted as a key to relaxation or cooling down (El-Refayea et al., 2016). It is stated that breathing exercises reduce anxiety by preventing the transmission of pain messages to the spinal cord (Rejeh et al., 2013), reducing the catecholamine response (Rakel & Herr, 2004) and muscle tension by distracting subjects (Kelle, Güzel & Sakallı, 2016).
16338255|NCT04412122|Experimental|Kinesio Taping and Breathing Exercise|According to the application protocols, two applications were made together.
16338256|NCT04412122|Other|Control Group|No intervention was performed to reduce pain in the control group.
16338228|NCT04412343|Experimental|Virtual group exercise|Individuals in the (virtual) group-based exercise program, will have the opportunity to take part in (virtual) group exercise classes, delivered via videoconferencing, by experienced older adult exercise instructors. Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group. Classes will be offered multiple days a week at 9am PST (12 noon EST), and will last approximately 50 minutes. Classes include a warm-up component, moderate intensity exercises as the core component of the class, and a cool-down. At the end of classes participants will have the opportunity to connect in small groups (videoconferencing breakout groups) to socially connect over a beverage (coffee, water) from their own homes. Participants in the group condition will also be sent, by mail, a program t-shirt to foster a sense of distinctiveness.
16338229|NCT04412343|Experimental|Personal exercise|Each of the older adult instructors described above will also contribute to delivering pre-recorded exercise classes (involving the same exercises, intensity, music, and so forth as those described above for the group condition). However, in this instance, instructors will deliver those classes to each participant by referring to themselves as each participant's personal trainer/coach, with language directed to the individual and not the group. That is, no sense of 'groupness' or 'shared social identities/connectivity' will be primed. Also, participants in this condition will not have the opportunity to interact with other older adults after classes have ended and will not receive the same program t-shirts designed to foster a sense of group distinctiveness.
16338230|NCT04412343|No Intervention|Wait-list control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 12-week trial. They will be asked to complete the same questionnaires (and will be remunerated in the same way as those in the other two conditions via $10 per questionnaire completion). At the end of the 12-week trial, participants in this condition will have access to the personal exercise programming.
16338231|NCT04412330|Experimental|ICU followup + physical therapy|Patients surviving ICU admission for Covid-19 will receive ICU follow-up care in an ICU Recovery Clinic plus 8 weeks of physical therapy interventions. ICU Recovery Clinic is standard of care for patients surviving medical ICU admission at University of Kentucky with potential to attend in person or complete through telemedicine up to 5 appointments in the first year after hospital discharge. Physical therapy interventions completed at an outpatient pulmonary rehabilitation center or through telemedicine is not currently standard of care for patients in the short-term recovery phase (1-6 months after hospital discharge) after critical illness.
16338232|NCT04412317||Children < 15 years old|Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic
16338233|NCT04412304||thrombose prophylaxis|The dose used to prevent thromboembolic complication in critically ill
16338234|NCT04412304||double thrombose prophylaxis|Double the dose used to prevent thromboembolic complication in critically ill
16338235|NCT04412304||full dose anticoagulant|Dose used to treat thromboembolic event
16338236|NCT04412291|Active Comparator|Standard-of-care Treatment (SOC)|"SOC according to local recommendations at the Karolinska University Hospital:
~Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep or Klexane or new oral anticoagulants incl. dabigatran, apixaban or rivaroxaban).
~Steroids (Betapred)"
16338237|NCT04412291|Active Comparator|Anakinra + SOC|"Anakinra: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
~SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.."
16338238|NCT04412291|Active Comparator|Tocilizumab + SOC.|Tocilizumab: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.
16338239|NCT04412278||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
16338240|NCT04412265||Covid 19 patients|The study will be conducted on all patients hospitalized affected by pneumonia COVID related.
16338241|NCT04412252|Experimental|Tofacitinib|Participants will receive tofacitinib 10 mg twice per day for 14 days and standard of care therapy.
16338242|NCT04412252|Placebo Comparator|Placebo|Participants will receive tofacitinib-matching placebo twice per day for 14 days and standard of care therapy.
16338243|NCT04412239|Experimental|Telephone Consultation in TB Patients|The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.
16338244|NCT04412213||children of possitive family history of stuttering|
16338245|NCT04412213||children of negative family history of stuttering|
16338246|NCT04412200|Experimental|Hyperbaric oxygen chamber Arm|Patients will be randomized at a ratio of 2:1, to hyperbaric chamber (100% oxygen at 2 ATA)
16338247|NCT04412200|Sham Comparator|Sham hyperbaric chamber Arm|Patients will be randomized at a ratio of 2:1, to Sham chamber (21% oxygen at 1 ATA)
16338248|NCT04412187|Other|TSPO PET imaging|All study participants will receive [18F]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
16338249|NCT04412174|Experimental|GC022F|The patients will receive GC022F CAR-T treatment. GC022F dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.
16338250|NCT04412161||Extra-Malatya|Liver transplant patients with MTD>6 cm of HCC
16338251|NCT04412148|Active Comparator|Intralesional Steroids|
16338252|NCT04412148|Placebo Comparator|Control|
16338253|NCT04412122|Experimental|Kinesio Taping|Kinesio taping is thought to remove the barriers that slow the healing process, activate neurological suppression and reduce pain (El-Refayea, El Nahasa & Ghareebb, 2016; Kamali, Sinaei & Taherkhan, 2018). Kinesio tape stimulates cutaneous mechanoreceptors. Mechanoreceptors decrease sympathetic nervous system activity and increase parasympathetic activity, which can improve intestinal control (Azam, 2017; Szczegielniak, Krajczy, Bogacz, Luniewski & Sliwinski, 2007). Kinesio taping changes skin contours and accelerates blood flow. Increased blood flow brings more oxygen and nutrients to the area. This phenomenon contributes to the natural healing process (Kafa et al., 2015).
16338321|NCT04411667|No Intervention|Group B (SOC)|Standard of Care
16338322|NCT04411654|Experimental|PR001|
16338259|NCT04412109|Active Comparator|injection of high volume of saline|high volume (20 cc) saline injection during thoracic epidural catheterization
16338260|NCT04412096|Experimental|Timolol 0.5%|To compare the variation in response to timolol between individuals
16338261|NCT04412096|Experimental|Latanoprost 0.005%|To compare the variation in response to latanoprost between individuals
16338262|NCT04412083|Other|PPA Tele-Savvy Pilot Intervention|The Tele-Savvy program is comprised of weekly, two-hour interactive classes, over seven consecutive weeks, the same duration as the proposed intervention. Tele-Savvy consists of educational instruction, video and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of contented involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
16338263|NCT04412070||Patient with Non-Muscle invasive Bladder Cancer|Patients in this group will be enrolled before the start of their treatment with BCG. This will start within 4 weeks after the transurethral bladder resection, in accordance with the guidelines
16338264|NCT04412070||Patient with Muscle Invasive Bladder Cancer|Patients in this group will be enrolled in the study before surgical treatment by radical cystectomy
16338265|NCT04412057|Experimental|CERC-002|
16338266|NCT04412057|Placebo Comparator|Placebo|
16338267|NCT04412044|Experimental|Asthmatics|Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment
16338268|NCT04412018|No Intervention|Usual Care|Participants in this arm will continue with usual care
16338269|NCT04412018|Experimental|Icosapent Ethyl|Participants in this arm will take icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
16338270|NCT04412005||Manhiça|Pregnant women attending the Manhiça District Hospital
16338271|NCT04412005||Ilha Josina|Pregnant women attending the Ilha Josina Health Center
16338272|NCT04412005||Magude|Pregnant women attending the Magude Health Center
16338273|NCT04411992|Experimental|Allocated to Vibration intervention (1) A|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
16338274|NCT04411992|No Intervention|Allocated to Control intervention (1) B|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
16338275|NCT04411992|Experimental|Allocated to Vibration intervention (2) B|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
16338276|NCT04411992|No Intervention|Allocated to Control intervention (1) A|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
16338277|NCT04411979|No Intervention|treatment-as-usual|
16338278|NCT04411979|Experimental|treatment-as-usual plus aerobic walking|
16338279|NCT04411966|Experimental|18F-fluorothymidine PET|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
16338280|NCT04411953|Active Comparator|Reference Product (Treatment A)|"Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
16338281|NCT04411953|Experimental|Test Product (Treatment B)|"Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
16338282|NCT04411940|Active Comparator|Reference Product (Treatment A)|Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
16338283|NCT04411940|Experimental|Test Product (Treatment B)|Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
16338284|NCT04411927||control group|this group included 25 typically developed children
16338285|NCT04411927||on-heamodialysis group|this group included children with CKD on-heamodialysis treatment
16338286|NCT04411927||non-dialysis group|this group included children with CKD who don't require dialysis
16338287|NCT04411914|Experimental|Clavulanic Acid|9 Participants will receive 500 mg of CLAV at baseline. Subjects who can tolerate 500 mg/day for 3 days (or matched placebo) will have a dose escalation to 750 mg/day for 3 days. Subjects who can tolerate 750mg/day for three days will have a dose escalation to 1000mg for 4 days.
16338288|NCT04411914|Placebo Comparator|Placebo|"3 participants will receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
16338289|NCT04411901|Experimental|vitamin D 3|oral vitamin D3 drops and tablets
16338290|NCT04411875|Active Comparator|Amlodipine|amlodipine reference formulation at a single dose of 10 mg
16338291|NCT04411875|Experimental|Levamlodipine|levamlodipine test formulation at a single dose of 5 mg
16338323|NCT04411641|Experimental|SAR442168|Dose 1 of oral SAR442168 once daily
16338292|NCT04411862|Experimental|Intervention Group|50 Participants with NAFLD that receive lifestyle modification by Clinical Pharmacist plus Phosphatidylcholine two soft capsules 3 times daily(2.1 g per day) for 6 month
16338293|NCT04411862|Active Comparator|Control Group|50 Participants with NAFLD that receive only lifestyle modification by Clinical Pharmacist
16338294|NCT04411849|Experimental|Group I (early intervention)|During year 2, participants receive the HPV self-testing intervention consisting of mailed HPV self-test devices. Participants also receive an information about cervical cancer. Participants who do not return their self-test within a few weeks receive telephone-based patient navigation. Participants then complete a satisfaction survey and have their medical record reviewed. During years 3-5, this intervention is repeated among women who remain unscreened/underscreened.
16338295|NCT04411849|Active Comparator|Group II (delayed intervention)|During year 2, participants receive usual care consisting of a reminder letter to get a clinic-based cervical cancer screening test and information about cervical cancer. During years 3-5, participants receive the HPV self-testing intervention described for Group I.
16338296|NCT04411836|No Intervention|Control|Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)
16338297|NCT04411836|Experimental|PQ Intervention|Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
16338298|NCT04411836|Experimental|TQ Intervention|Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)
16338299|NCT04411823|Experimental|Intervention arm|Undergo an upper endoscopy with EndoFLIP at baseline before sleeve gastrectomy
16338300|NCT04411810|Experimental|Participants with skin lesions|Participants who have up to 3 concerning skin lesions will be evaluated by both an in-person dermatologist and a team of three teledermatologists(board-certified dermatologists). The teledermatoogy team will deliver a consensus recommendation. If either the in-person dermatologist or teledermatologists are concerned that the skin spot(s) may be a skin cancer, a biopsy will be recommended and can be performed at no charge. Or if both agree that the spot(s) are not concerning for skin cancer, no biopsy will be needed.
16338301|NCT04411784||Main group|Patient with Acute Severe Ulcerative Colitis based on Modified Truelove and Witts Severity Index managed during the study period
16338302|NCT04411784||Control Group|Patients with ASUC managed in the unit from 1st Jan to 31st June 2019
16338303|NCT04411771|Experimental|Extended Assessment - Given shCBT|"The extended assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).
~In the primary analysis, only patients given shCBT are included"
16338304|NCT04411771|Active Comparator|Screening Assessment - Suitable for shCBT but given BI|"The screening assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.
~In the primary anaysis, only patients suited for shCBT are included, as decided from an algorithm based on data from their screening."
16338305|NCT04411771|Experimental|Extended Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomized to Extended Assessment are included, regardless of if they start shCBT or BI"
16338306|NCT04411771|Active Comparator|Screening Assessment - All patients|"Same as the other arm marked as Active comparator, but for the purpose of a secondary analysis all patients randomized to Screening Assessment are included, regardless of if they are suiteble for shCBT or not."
16338307|NCT04411758|Other|Control Group|The control group will not receive any intervention in those first two months, and then the groups will be crossed and will receive the same amount of propolis as the first group.
16338308|NCT04411758|Experimental|Propolis Group|The propolis will be instructed to use 20 drops of standardized green propolis alcohol extract (16% w / v) diluted in 1 glass of water, daily for 2 months before to sleep, and then the groups will be crossed and will not receive any intervention
16338309|NCT04411745||Parturition|Healthy women who are carrying a healthy singleton pregnancy, but have not yet gone to labor at 40 weeks of gestation or who are at term and admitted to hospital for any sign of labor.
16338310|NCT04411732||patients with neuromuscular disorder|cohort of patients with neuromuscular disorder
16338311|NCT04411732||healthy controls|cohort of healthy controls
16338312|NCT04411719|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
16338313|NCT04411719|Experimental|Electric stimulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
16338314|NCT04411719|No Intervention|No treatment group|No electric stimulation is applied.
16338315|NCT04411706|Experimental|Sintilimab+Apatinib+Capecitabine|=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）
16338316|NCT04411693|Active Comparator|Group A: Intravitreal Dexamethasone Implant|Subjects in this arm will be given intravitreal Dexamethasone implant injection at month 0. PRN intravitreal Dexamethasone implant injections will be given for persistent edema, if it has been 10 weeks or more since last implant injection. If it has been less than 10 weeks since last implant injection, subjects will receive PRN intravitreal Aflibercept for persistent edema.
16338317|NCT04411693|Active Comparator|Group B: Intravitreal Aflibercept|Subjects in this arm will be given Intravitreal aflibercept at month 0. PRN intravitreal Aflibercept will be given at months 1-6 for persistent edema.
16338318|NCT04411680|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
16338319|NCT04411680|Active Comparator|Control Arm|Standard of care for COVID-19
16338320|NCT04411667|Experimental|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
16338328|NCT04411602|Experimental|Treatment with Convalescent Plasma|SARS-CoV-2 convalescent plasma from approved donors will be transfused into severely ill patients with confirmed COVID-19 severe respiratory distress. Plasma will be administered on days 0, 2,4, 6 and 8.
16338329|NCT04411589|Experimental|Magnifying endoscopy with optical enhancement system group|Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.
16338330|NCT04411589|Active Comparator|white light endoscopy group|Patients in this group go through gastroscopy under white light endoscopy.
16338331|NCT04411563||Group I-Mild|The patients who have these mild symptoms are low-grade fever (not more than 38 degrees celsius), dry cough, fatigue, sore throat, headache, the new loss of taste, and smell. Patients with normal or mild pneumonia findings of radiological imaging and blood lymphocyte count ≥800 / µl and serum CRP≤40 mg /l, ferritin ≤500ng/ml, D-Dimer ≤1000 ng/ml will be included in group I.
16338332|NCT04411563||Group II-Moderate|The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count <800 / µl or serum CRP> 40 mg / l or ferritin> 500ng / ml or D-Dimer> 1000 ng / ml will be included in group II.
16338333|NCT04411563||Group III-Severe|The patients who have these severe symptoms are all the common symptoms mentioned above along with shortness of breath, chest discomfort, confusion/unresponsiveness, bluish face/lips, possible gastrointestinal issues, like diarrhea or nausea. Patients with ICU (intensive care unit) admission criteria, such as confusion or tachycardia (> 125 / min) or respiratory distress or tachypnea (> 22 / min) or hypotension <90/60 mmHg or SPO2 <93%will be included in group III. Also, patients with the central nervous system and heart involvement will be directly included in the severe case group
16338334|NCT04411550|Experimental|HLX11 group|HLX11 are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
16338335|NCT04411550|Active Comparator|CN-Perjeta group|CN-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
16338336|NCT04411550|Active Comparator|EU-Perjeta group|EU-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
16338337|NCT04411550|Active Comparator|US-Perjeta group|US-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
16338338|NCT04411537|Experimental|Treatment Arm|A total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
16338339|NCT04411524|Experimental|Treatment Arm|A total of 50 MSI-H LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
16338340|NCT04411511||Lean children|Children between 4-18 years, living in the Netherlands.
16338341|NCT04411511||Children with overweight or obesity|Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
16338342|NCT04411498||Group of Systemic Sclerosis|Patients who were followed-up with the diagnosis of diffuse systemic sclerosis in the Hospital of Rheumatology Clinic were evaluated in terms of inclusion criteria. 44 female patients who met the inclusion criteria were included in the study. All patients were evaluated by a rheumatologist with detailed history and physical examination. Scleroderma patient group was evaluated for the presence of other rheumatic diseases that may accompany.
16338343|NCT04411498||Group of control|The healthy control group (96 female ) was evaluated for rheumatic diseases [undiagnosed connective tissue diseases and additional rheumatological diseases] that may accompany secondary FMS exclusion.
16338344|NCT04411485||Group of Ankylosing Spondylitis|Patient with ankylosing spondylitis diagnosed by a rheumatologist
16338345|NCT04411485||Group of control|Healthy volunteers of the same age and gender as patients
16338346|NCT04411472|Experimental|active|recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions
16338347|NCT04411472|Placebo Comparator|placebo|matching placebo
16338348|NCT04411459||COVID-19 pneumonia patients|Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission
16338349|NCT04411446|Experimental|Vitamin D|5 capsules containing 100.000 UI of vitamin D each. The intervention will be 5 capsules given in one-time oral intake.
16338350|NCT04411446|Placebo Comparator|Placebo|5 capsules containing placebo. The intervention will be 5 capsules given in one-time oral intake.
16338351|NCT04411433|Experimental|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).
~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
16338352|NCT04411433|Experimental|Favipiravir (3600 mg + 1600 mg)|"Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).
~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
16338353|NCT04411433|Experimental|Favipiravir combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).
~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
16338354|NCT04411433|Experimental|Favipiravir combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).
~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
16338355|NCT04411433|Active Comparator|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).
~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
16338356|NCT04411433|Active Comparator|Hydroxychloroquine combined with Azithromycin|"Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).
~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).
~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
16338357|NCT04411420|Active Comparator|Integrated Care Pathway|The integrated care pathway provides both on-site physical therapy services and centrally-delivered services via telephone or video from study providers at the Durham VA.
16338358|NCT04411420|Active Comparator|Coordinated Care Management Pathway|The care management pathway involves a referral of patients from a physician to a pain navigator on site at the local VA who is knowledgeable in current recommended treatment guidelines for low back pain.
16338359|NCT04411407|Other|Group WT|PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen
16338360|NCT04411407|Other|Group TW|PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp
16338361|NCT04411394||Healthy Participants|There is no intervention
16338362|NCT04411394||Anxiety Participants|There is no intervention
16338363|NCT04411381|Active Comparator|Telemedicine-based model of care|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
16338364|NCT04411381|No Intervention|Traditional model of care|Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
16338365|NCT04411355|No Intervention|control group patients|non intervention. only rutin care
16338366|NCT04411355|Experimental|intervention group patients|The intervention group was trained and monitored by a professional team in line with the components of the model. Life quality scale, hypertension information questions and chronic care assessment scale were applied to both groups at the beginning and in the sixth month of the study.
16338367|NCT04411342||patients with type 2 diabetes|patients with type 2 diabetes and have normal range of albumine in urine and decline in renal functions
16338368|NCT04411329|Active Comparator|group A|patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery
16338369|NCT04411329|Active Comparator|group B|we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery
16338370|NCT04411329|Active Comparator|group c|we will add 1500 IU hyalurodinase to the mixture given to group A. (20 ml before skin incision and 10 ml at end of surgery
16338371|NCT04411316|Experimental|Pharmacomechanical thrombolysis plus anticoagulation|"This group of patients will receive Pharmacomechanical catheter-directed thrombolysis (PCDT) plus Anticoagulation.
~PCDT will be AngioJet along with alteplase. Anticoagulation will be heparin only"
16338372|NCT04411316|Active Comparator|Anticoagulation|This group of patients will receive standard anticoagulation only. Anticoagulation will be Heparin only
16338373|NCT04411303|Experimental|Reducing interlimb asymmetry with biofeedback post-stroke|We will use a randomized crossover design to determine the performance and retention effects following single-day training sessions with biofeedback of three different gait variables (i.e., step length, propulsive force, and interlimb asymmetry) in 25 individuals with chronic stroke.
16338374|NCT04411303|Experimental|Evaluating capacity for biofeedback use at varied intensities|We will use a within-session randomized crossover design to test the capacity of persons post-stroke (second cohort; n=25) to reduce their interlimb asymmetry using the biofeedback variable found to be the most effective for the group in Aim 1 while walking in three aerobic intensity zones: low, moderate, and vigorous (30-40%, 50-60%, and 70-80% of heart rate reserve, respectively).
16338375|NCT04411290||Total Thyroidectomy (TT)-indicated patients|Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon
16338376|NCT04411277||T2DM Elderly on Insulin CGM|70 patients with type 2 diabetes > 65 years of age taking insulin as treatment. The sample size was calculated to estimate the minimal number of patients necessary to describe the mean TIR (minutes/day).
16338377|NCT04411264|No Intervention|Classic protocol for pain management|classic protocol for pain management during chronic wound dressing
16338378|NCT04411264|Experimental|Virtual reality for pain management|protocol associating virtual reality with the classic protocol for pain management during the treatment of chronic wound dressings
16338379|NCT04411251|Experimental|Outdoor|Nature-centered therapy in a near-natural area
16338380|NCT04411251|Active Comparator|Indoor|Conventional therapy in rooms mainly in a hospital building
16338381|NCT04411238||Patients|
16338382|NCT04411238||Caregivers|
16338383|NCT04411238||Home help|
16338384|NCT04411225|Experimental|Cannabidiol Augmentation|The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
16338385|NCT04411225|Placebo Comparator|Placebo Augmentation|Placebo will appear identical to the cannabidiol solution
16338386|NCT04411212|Active Comparator|Granulocyte colony-stimulating factor and platelet-rich plasma|
16338387|NCT04411212|Other|Control group|
16338388|NCT04411199|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
16338389|NCT04411199|Other|Standard of Care|The SoC for prophylactic antibiotic treatment is based on international guidelines
16338452|NCT04410705|Experimental|Tendinopathy patients|Patients with tendinopathy will be administered ESWT
16338390|NCT04411186|Active Comparator|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Control for this study will be the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
16338391|NCT04411186|Experimental|ERAS and 5 Lung Protective Interventions|"The standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:
~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height)
~Positive end-expiratory pressure (PEEP) 7cm H2O5
~Immediately post intubation recruitment breath (30cm water for 30 seconds)
~Every 1 hour recruitment breath (30cm water for 30 seconds)
~40% FIO2 initially - titrate up as necessary to maintain SPO2 >94%"
16338392|NCT04411173|Active Comparator|Rice Protein|Rice Protein - 24 grams, chocolate, powder
16338393|NCT04411173|Active Comparator|Whey Protein|Whey Protein - 24 grams, chocolate, powder
16338394|NCT04411160||Group A|Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose.
16338395|NCT04411160||Group B|While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
16338396|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
16338397|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
16338398|NCT04411134|Experimental|Arm 1|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
16338399|NCT04411134|Experimental|Arm 2|The MTD from among dose level 1 and dose level 2
16338400|NCT04411108|Active Comparator|Exercise Instruction by PT and written handout|
16338401|NCT04411108|Experimental|Exercise Instruction by Motion Coach Technology|
16338402|NCT04411095|Experimental|Stretching of intrathoracic fascia|A technique will be used to stretch the intrathoracic fascia. The subject lies in his/her back, and a flexion of the upper cervical spine is combined with a retraction movement of the lower cervical and upper thoracic spine, this in combination with inspiration.
16338403|NCT04411095|Placebo Comparator|Test without stretching|A placebo technique is performed by positioning the hands of the therapist on the thorax without pressure or performing a technique. Similar as the stretching technique, a deep inspiration is performed by the patient, for each of the intrathoracic cilinders. This without performing a retraction of the lower cervical and upper thoracic spine.
16338404|NCT04411082|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
16338405|NCT04411082|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
16338406|NCT04411082|Placebo Comparator|Placebo|Oral administration of once daily placebo
16338407|NCT04411069|No Intervention|Patients without previous CINV|Patients who didn't have chemotherapy or that didn´t have any nausea and/or vomiting induced by chemotherapy (CINV) before surgery
16338408|NCT04411069|Other|Patients with previous CINV|Patients who had previous nausea and vomiting induced by chemoterapy.
16338409|NCT04411056|Experimental|Barrier box|Participants will have a barrier box placed during intubation
16338410|NCT04411056|No Intervention|No Barrier box|Participants will have routine intubation with no barrier box
16338411|NCT04411030|Experimental|Part 1|Oral administration of ASTX660 and itraconazole at specific time points.
16338412|NCT04411030|Experimental|Part 2|Oral administration of ASTX660 and midazolam at specific time points.
16338413|NCT04411017|Active Comparator|1L PEG|
16338414|NCT04411017|Active Comparator|2L PEG|
16338415|NCT04411017|Active Comparator|2L sodium picosulfate|
16338416|NCT04411004||Women who underwent shaving for rectal endometriosis|
16338417|NCT04410991|Experimental|SAR442168|Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
16338418|NCT04410991|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
16338419|NCT04410978|Experimental|SAR442168|Dose 1 of oral SAR442168 + placebo to match the teriflunomide tablet once daily
16338420|NCT04410978|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
16338421|NCT04410965|Experimental|teriflunomide|daily oral administration of teriflunomide 14 mg for 24 weeks
16338422|NCT04410952||no EES|Patients with a Type-C pelvic ring fracture who underwent no external emergency stabilization (EES) for the posterior pelvic ring
16338423|NCT04410952||Pelvic binder|Patients with a Type-C pelvic ring fracture who received a pelvic binder for emergency stabilization of the posterior pelvic ring
16338424|NCT04410952||Pelvic C-clamp|Patients with a Type-C pelvic ring fracture who received a pelvic C-clamp for emergency stabilization of the posterior pelvic ring
16338425|NCT04410926|Placebo Comparator|control group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).
~Neuromuscular electrical stimulation The control group received placebo NMES with no current stimulation. In another words, the current intensity was set at 0mA while standing on both feet for 30 minutes."
16338426|NCT04410926|Experimental|intervention group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).
~Neuromuscular electrical stimulation
~The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles. High-voltage pulsed current was set at frequency of 85 Hz with 5 seconds contraction time and 12 seconds rest time while the ramp-up and ramp-down time were 0.3 and 0.7 respectively. The current intensity was adjusted based on the individual tolerance without reporting pain or discomfort while standing on both feet. The stimulation time lasted each session for 30 minutes."
16338453|NCT04410692|No Intervention|Control|Participants' COVID-19 predictions are elicited via a survey
16338427|NCT04410913|Experimental|Visual Healing Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
16338428|NCT04410913|Active Comparator|Standard Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
16338431|NCT04410887|Experimental|PISOXO|"st cycle of PIPAC during 1st laparoscopic exploration Three cycles of SOX
~nd cycle of PIPAC during 2nd laparoscopic exploration Surgery Three cycles of SOX +/-OLAPARIB
~PIPAC Intraperitoneal chemotherapy for PIPAC is Docetaxel Neoadjuvant Chemotherapy Patients will receive three cycles of a standard dose of Tegafur gimeracil oteracil potassium capsule (TGO) plus oxaliplatin (SOX) +Olaparib prior to curative gastrectomy.
~Adjuvant chemotherapy Three cycles of SOX +/- OLAPARIB will be given as postoperative chemotherapy.
~Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg oral twice a day"
16338432|NCT04410874|Experimental|Imvamune|Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study
16338433|NCT04410861|Active Comparator|Minimal Micropulse Arm|"Wavelength 810 577 Power 0.75 W 0.15 W DC 5% 5% Spot size 125um 100um Duration 0.3 sec 0.3 sec Number of spots 100-120 100-120
~."
16338434|NCT04410861|Experimental|Panmacular Micropulse Arm|Wavelength 810 577 Power 1.7 W 0.425 W DC 5% 5% Spot size 500um 500um Duration 0.3 sec 0.3 sec Number of spots 400-450 400-450
16338435|NCT04410848||All patient with suspicion of choledocholithiasis|Patient with the suspect of common biliary duct stone for pain type colic in the right upper quadrant abdomen, the elevation of bilirubin, alkaline phosphatase, pancreatitis, dilated common bile duct and cholangitis. According to the criteria to assign the risk of choledocholithiasis. We are going to validate a scale based on intelligence artificial compared to the clinical predictor.
16338436|NCT04410835||Psychiatric patients|Psychiatric patients with ICD-10 (International Statistical Classification of Diseases and Related Health Problems) F2/F3/F4 diagnosis
16338437|NCT04410835||Healthy Controls|Participants who do not have a psychiatric disorder or a first degree relative with psychiatric disorder.
16338438|NCT04410822||Patients enrolled|an age older than 18 years old and symptoms of FI according to Rome IV criteria.
16338439|NCT04410809|Placebo Comparator|Placebo|The same composition as the active medication but without the active substance TA-46
16338440|NCT04410809|Experimental|TA-46|Decoy protein of the fibroblast growth factor receptor 3
16338443|NCT04410783|Other|Before group|Mechanically ventilated emergency department patients receiving standard post-intubation sedation prior to an educational initiative on the importance of ED-based targeted sedation
16338444|NCT04410783|Other|After group|Mechanically ventilated emergency department patients receiving post-intubation sedation after an educational initiative aimed at improving sedation practices in the ED
16338445|NCT04410770|Active Comparator|Active intervention|Participants assigned to the active treatment arm are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 6 week outcome. The participant is encouraged to continue completing the self-ratings, but does not receive any more support calls. After 6 more weeks, the 12 week outcome is assessed the participant's involvement with the study ends.
16338446|NCT04410770|No Intervention|Wait list|Wait list participants have no study activities for 6 weeks after completing the baseline assessment. After 6 weeks, list participants complete the 6 week assessment. After completing the assessment. wait list participants are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 12 week outcome and the participant's involvement with the study ends.
16338447|NCT04410757||Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply POCUS examinations in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
16338448|NCT04410757||No Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply routine bedside examination techniques in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
16338449|NCT04410731|Experimental|BM-MSC injections for low back pain|Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy
16338450|NCT04410718||The intensive care unit cohort|Patients (with or without diabetes) with COVID-19 admitted to the intensive care unit
16338454|NCT04410692|Experimental|Treatment|Participants' COVID-19 predictions are elicited via a prediction market
16338455|NCT04410679|Experimental|injectabl PRF for treatment of internal root resorption|
16338456|NCT04410666|Experimental|GREEN TEA MOUTH WASH|an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.
16338457|NCT04410666|Placebo Comparator|Placebo|distilled water, in sterile glass containers.
16338458|NCT04410653|Experimental|Arm 1 (KRASwt PDAC)|
16338459|NCT04410653|Experimental|Arm 2 (IMA)|
16338460|NCT04410653|Experimental|Arm 3 (other)|
16338461|NCT04410627|No Intervention|Standard of Care|
16338462|NCT04410627|Experimental|Standard of Care + HoPE|
16338463|NCT04410614|Experimental|Free epithelial graft|Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa
16338464|NCT04410601|Active Comparator|No dysphagia (after total thyroidectomy-TT)|"Patients s/p post-thyroidectomy without complication
~*will NOT be enrolled to standard dysphagia-rehabilitation treatment"
16338465|NCT04410601|Experimental|Dysphagia (with at least one more complication of TT)|"Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.
~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
16338466|NCT04410601|Experimental|Dysphagia (the only complication after TT)|"Patients s/p post-thyroidectomy dysphagia only.
~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
16338467|NCT04410588|No Intervention|saline|saline for pain for nasal packing
16338468|NCT04410588|Active Comparator|levobupivacaine|levobupivacaine for pain of nasal packing
16338469|NCT04410588|Active Comparator|fentanyl +levobupivacaine|fentanyle with levobupivacaine for pain of nasal packing
16338470|NCT04410575|Experimental|Intervention Group (Pharmacist Interventions)|Participants enrolled in the intervention group will receive pharmacist interventions, in addition to standard care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians), at enrollment (month 0) and at months 1, 3, and 6
16338471|NCT04410575|Active Comparator|Control Group (Standard Pharmacist Care)|Patients randomized to the usual care groups will receive standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians) and physician care with no specific interventions for the duration of 6 months
16338472|NCT04410562|Experimental|Hydroxychloroquine|Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
16338473|NCT04410562|Placebo Comparator|Placebo|Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
16338475|NCT04410536|Other|Symptomatic drugs - bridge theray - mindfu|"abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting;
~oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day);
~mindfulness practice daily with standard sessions by smartphone 6 minutes per day."
16338482|NCT04410510|Placebo Comparator|Control group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days Placebo capsule equivalent to 250mg of excipient every 12 hours for 14 days
16338483|NCT04410510|Experimental|Intervention group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days
16338484|NCT04410497|Experimental|Porcine xenograft|Conformité Européenne/European Conformity (CE)-marked dressing product used in clinical practise (Standard of care).
16338485|NCT04410497|Active Comparator|Silver foam|Conformité Européenne/European Conformity (CE)- marked dressing product used in clinical practise
16338486|NCT04410484||1|Admitted patients with IBD (with IBD OR due to COVID) whether tested or not tested for COVID between 1st March and 30th June 2020
16338487|NCT04410484||2|Patients with IBD self-isolating with suggestive COVID19 symptoms (Fever or persistent Cough) or tested positive for COVID19 during same period
16338488|NCT04410484||3|Patients with active IBD identified during the same study period. (definition: increased symptoms suggestive of flare, raised calprotectin, raised CRP, endoscopy or imaging during the previous 6 weeks showing active disease and contacted/reviewed during the study period , admission with IBD ( These will be identified through your helpline/ virtual clinics/Hot clinics/flare lines
16338489|NCT04410484||Control Group|Consecutive patients with active IBD between 1st March 2019-30th June 2019
16338490|NCT04410471||Liver transplant patient after having Covid19|Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
16338491|NCT04410471||No immunosuppressed patient with previous Covid19|Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
16338492|NCT04410458|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic.
16338581|NCT04409821|Experimental|Tele-delivered psychological intervention|Weekly tele-delivered psychological intervention
16338493|NCT04410458|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
16338494|NCT04410458|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
16338495|NCT04410458|Placebo Comparator|SMS with thank-you note|SMS content in this group will be thank-you note for their previous donation(s) .
16338498|NCT04410432||Patient|Patient hospitalized with SARS-Cov2 infection proven by virological sampling.
16338499|NCT04410419|No Intervention|Standard Care|Standard care for patients with diabetes pre-operatively .
16338500|NCT04410419|Experimental|Carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
16338501|NCT04410406|Active Comparator|IA (Ivermectin + Albendazole)|Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
16338502|NCT04410406|Active Comparator|MoxA (Moxidectin + Albendazole)|Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
16338503|NCT04410406|Active Comparator|IDA (Ivermectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
16338504|NCT04410406|Active Comparator|MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
16338505|NCT04410393||sacrocolpopexy patients|Patients who underwent sacrocolpopexy for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
16338506|NCT04410393||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
16338507|NCT04410380|Experimental|Electronic tablet|Spanish-speaking parents receive electronic tablet and teaching about use
16338508|NCT04410367|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
16338509|NCT04410354|Active Comparator|MMPD + remdesivir|Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
16338510|NCT04410354|Placebo Comparator|Placebo + remdesivir|Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
16338511|NCT04410341|Placebo Comparator|Placebo group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet once daily for 12 weeks
16338512|NCT04410341|Experimental|Vildagliptin group|Escitalopram 20 mg tablet once daily for 12 week plus Vildagliptin 50mg tablet once daily for 12 weeks
16338513|NCT04410328|Experimental|Participants receiving Dipyridamole and Aspirin|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally plus standard care. Participants will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily starting on the day of enrollment for a total of 2 weeks.
16338514|NCT04410328|Other|Participants receiving standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
16338515|NCT04410315||Tumorcraniotomy patients|
16338516|NCT04410302||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue samples during standard of care tumor biopsy or surgical resection to establish PDXs. Patients may also undergo collection of blood, saliva, and urine samples to compare DNA abnormalities to noncancer cells in order to determine if they were present before the cancer started or developed with it.
16338517|NCT04410289|Experimental|Intervention Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the intervention group were positioned using props horizontally aligning the external auditory meatus (EAM) with the sternal notch (SN) and the chin with the sinciput. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
16338518|NCT04410289|Active Comparator|Control Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the control group were positioned freely according to the provider's preference. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
16338519|NCT04410276||Patients with enterococcal bloodstream infections|Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
16338520|NCT04410263||COVID-positive ICU patients|The collective of COVID-positive patients on the ICU
16338521|NCT04410250|Active Comparator|Oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 1 will be instructed to clean the child's oral cavity by massaging the gingival rods with gauze and filtered water once a day at night.
~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
16338522|NCT04410250|Experimental|Absence of oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 2 will be advised not to perform any type of oral cavity cleaning of the newborn.
~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
16338582|NCT04409808|Experimental|IRIS vitrectomy device|all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device
16338523|NCT04410237|Experimental|Med-Jet|"The Med-Jet injector is a novel needle-free drug-delivery system, which we believe may be a solution to the impracticalities of ILTA for mild-to-moderate psoriasis. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region.12 The drug-delivery device is highly configurable allowing adjustable depth and volume parameters.12 In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas"
16338524|NCT04410237|Active Comparator|Traditional Syringe|TAC will be injected on a half-plaque while the control half of the plaque will be untreated. A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
16338525|NCT04410224|Experimental|ASN004 ascending doses|Patients will receive escalating doses of ASN004 to identify the best dose for further study.
16338526|NCT04410211|Active Comparator|Group S (inhalational Sevoflurane sedation)|"The inhalational anaesthetic agent and oxygen will be delivered via an anaesthetic circuit with a vaporizer (Sevotec 3, Ohmeda, Streeton UK) with a nasal mask.
~Patients who are allocated for Sevoflurane will be given initial oxygen flow of 8L/min and then Sevoflurane was introduced at a concentration of 0.2% and was increased stepwise by 02% for every 30s up to a maximum of 1.0 minimum alveolar concentration (MAC; 2.05% end tidal). Patient's deepest sedation was recorded and adjusted to achieve optimal Observer's Assessment of Alertness/ Sedation Scale (OAAS) score of 3.
~Inadequate or over sedation was treated by reducing or increasing the Sevoflurane concentration dial by 0.2 - 0.6% until the desired effect is reached.
~Full vital signs monitoring are done for every participant"
16338527|NCT04410211|Active Comparator|Group M (Intravenous Midazolam sedation)|"Patients who are allocated for Midazolam will be given the similar nasal mask delivering 8L/min oxygen. However, Sevoflurane will not be introduced to these patients.
~Midazolam is titrated slowly to achieve OAAS score of 3 but no more than 2.5mg is to be given within 2 minutes period to patients selected to be in Midazolam group.
~Inadequate sedation is treated by giving slow titration of the medication based on the unblinded observer's judgement. Over sedation is treated by withholding the midazolam and continuing oxygen supplementation until the patient returned to the desired sedation level. No other sedative agents are allowed to be given to the patient or else patient will be excluded from this study."
16338528|NCT04410198|Experimental|Roxadustat|
16338529|NCT04410185|Experimental|MEDITATION|Meditation sessions will take place over 12 weekly sessions of 1.5 hours. A retreat (3 hours) will be realized after the 9th session
16338530|NCT04410159|Experimental|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
16338531|NCT04410159|Experimental|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
16338532|NCT04410159|Experimental|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
16338533|NCT04410159|No Intervention|Control|This group will receive the standard treatment protocol without any additional intervention
16338534|NCT04410146|Experimental|Embolization|Middle Meningeal Artery (MMA) embolization
16338535|NCT04410146|Active Comparator|No Embolization|Standard Management
16338536|NCT04410133|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
16338537|NCT04410120||Asthma with recent (<4/52) asthma attack|
16338538|NCT04410107||Severe Pneumonia|"Presence of fever or suspected lower respiratory infection, plus one of the following criteria:
~1) respiratory rate> 30 movements / min; 2) severe respiratory distress 3) Pulse oximetry (SpO2) ≤93% in room air; and/or 3) Pulmonary infiltrates> 50% on chest imaging within 24-48hrs of symptom onset."
16338539|NCT04410107||Acute respiratory distress syndrome (ARDS)|"Onset: acute, i.e. within 1 week of known clinical insult or new or worsening respiratory symptoms; and
~Chest imaging (e.g. X-ray or CT scan): bilateral opacities, not fully explained by effusions, lobar/lung collapse or nodules; and
~Origin of pulmonary edema: respiratory failure not fully explained by cardiac failure or fluid overload; and
~Degree of hypoxemia: arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O."
16338540|NCT04410094|Experimental|Cohort 1: Lazertinib plus Itraconazole|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by itraconazole capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
16338541|NCT04410094|Experimental|Cohort 2: Lazertinib plus Rifampin|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by rifampin capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
16338542|NCT04410081|Experimental|14C-lazertinib|Participants will receive a single oral dose of 14C-lazertinib on Day 1.
16338543|NCT04410068|Experimental|Electrical heating pad|"Electrical heating pad (WARMTAC device). Patients will be randomized to one arm.
~In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down."
16338544|NCT04410068|Experimental|forced-air warming device|Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
16338545|NCT04410055|Active Comparator|Sitting|Three hours of sitting condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
16338546|NCT04410055|Active Comparator|Static standing|Four hours of static standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
16338547|NCT04410055|Active Comparator|Dynamic standing|Four hours of dynamic standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
16338548|NCT04410042|Experimental|Tranexamic Acid|At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
16338583|NCT04409795|Other|HLA+ Group|Participants who are high-risk HLA-DR3 and/or DR4 (+); monogenic variant (+) with rare exome variant ensemble learner (REVEL) score>0.75; and both glutamic acid decarboxylase (GAD65) and islet antigen (IA2) autoantibody (-)
16341071|NCT04391894|Placebo Comparator|ECF843 vehicle BID (Part 1)|ECF843 vehicle BID (Part 1)
16338549|NCT04410042|Placebo Comparator|Placebo|At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
16338550|NCT04410029|Experimental|Intervention|Standard counseling + Healthwise Decision Aid
16338551|NCT04410029|Active Comparator|Control|Standard counseling + a control informational handout.
16338552|NCT04410016|Experimental|Staff Wellbeing Centre|Wellbeing Centres are rooms where staff employed at the hospital trust can go for a break, rest, relaxation, quiet time out, advice support or signposting. They are manned by Wellbeing Buddies who are support workers who offer advice and signposting services. The Centres are accessible to all staff at the Trust.
16338553|NCT04410003|Placebo Comparator|Placebo|Cellulose capsules, cloxacillin, electrolyte purgative (Peglyte)
16338554|NCT04410003|Active Comparator|Active|Capsules of stool from Protected donors, cloxacillin, electrolyte purgative (Peglyte)
16338555|NCT04409990|Other|Shear Wave Elastography|SWE value measurement will be added during the ERUS examination.
16338556|NCT04409977||Patient group|Patients suffering from cluster headache will be included in this group. When analysing the data, the investigators will distinguish those in the in-bout period from those in the out-bout period. People in this group may participate twice: once in the in-bout and once in the out-bout period.
16338557|NCT04409977||Control group|Participants not suffering from cluster headache will be included in this group.
16338558|NCT04409964|Experimental|opioid-free anesthesia|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
16338559|NCT04409964|Active Comparator|opioid anesthesia|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.
16338560|NCT04409938|Experimental|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention.
16338561|NCT04409938|Experimental|Progressive Muscle Relaxation with Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds.
16338562|NCT04409938|No Intervention|Standard Practice|The standard practice of the lab was made.
16338563|NCT04409925|Experimental|rhDNase1 (Pulmozyme, Roche/Genentech)|Single Arm: rhDNase1 (Pulmozyme, Roche/Genentech) 2.5 mg inhaled nebulisations BID, for a maximum of 14 consecutive days.
16338564|NCT04409912|Experimental|Sirolimus coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
16338565|NCT04409912|Placebo Comparator|Plain balloon|The plain balloon or placebo will not be coated. The plain balloon will be inflated at 2 minutes at rated burst pressure (typically 12 to 14 ATM). Plain balloon will be applied to all the narrowed segment of the dialysis circuit
16338566|NCT04409899||Urological surgical patients during COVID-19 pandemic|During the COVID-19 pandemic, the urological patients in the need of a surgical intervention have been screened on the basis of the underline conditions, the priority of surgery, and risk-benefit assessment. A pre-surgical work-out was performed in the selected patients, with some of them being detected of COVID-19 at RT-PCR or suspected for it according to the risk-assessment survey. Enhanced blood tests and X-rays of the thorax were performed as baseline assessments. In case of development of post-surgical unspecific symptoms, clinical and laboratory work-out were performed before to expedite a new RT-PCR, which would have required preventive isolation of a patient in a COVID-19 ward. We evaluated the impact of COVID-19 in this selected cohort and the complications eventually associated with the viral infection.
16338567|NCT04409886|Experimental|HBOT (Hyperbaric Oxygen Therapy)|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
16338568|NCT04409873|Placebo Comparator|Control (Distilled Water)|Over the counter: Distilled water
16338569|NCT04409873|Experimental|Oral-B Mouth Sore (H2O2) mouthwash|Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
16338570|NCT04409873|Experimental|Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash|Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
16338571|NCT04409873|Experimental|CloSYS (ClO2) mouthwash|Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
16338572|NCT04409873|Experimental|Listerine Mouthwash|Over the counter: Listerine Zero (Alcohol-Free)(Johnson and Johnson, USA) (C30H52O3)
16338573|NCT04409860|Active Comparator|control group|In this group, observation is given after CCRT.
16338574|NCT04409860|Experimental|trial group|In this group, adjuvant chemotherapy is given after CCRT.
16338575|NCT04409847||COVID+ PCR|Subjects who are SARS-CoV-2 PCR+ve and/or have diagnostic CXR or CT chest features of COVID -19
16338576|NCT04409847||COVID- PCR|subjects admitted with COVID-19 like symptoms but are SARS-CoV-2 PCR-ve and have CXR or CT chest that show low probability of COVID-19 will form the control group
16338577|NCT04409834|Experimental|Full-dose anticoagulation + antiplatelet therapy|"• Full-dose anticoagulation: Unfractionated heparin IV continuous targeting aPTT of 1.5-2.5X control, or Enoxaparin 1 mg/kg SC Q12h
~• Anti-platelet therapy: Clopidogrel 300 mg PO x1, followed by clopidogrel 75 mg PO QD"
16338578|NCT04409834|Experimental|Full-dose anticoagulation + no antiplatelet therapy|• Full-dose anticoagulation: Unfractionated heparin IV continuous targeting aPTT of 1.5-2.5X control, or Enoxaparin 1 mg/kg SC Q12h
16338579|NCT04409834|Experimental|Prophylactic anticoagulation + antiplatelet therapy|"• Standard prophylactic anticoagulation: Enoxaparin 40 mg SC QD or Unfractionated heparin 5,000 IU SC TID
~• Antiplatelet therapy: Clopidogrel 300 mg PO x1, followed by clopidogrel 75 mg PO QD"
16338580|NCT04409834|Active Comparator|Prophylactic anticoagulation + no antiplatelet therapy|• Standard prophylactic anticoagulation: Enoxaparin 40 mg SC QD or Unfractionated heparin 5,000 IU SC TID
16338584|NCT04409795|Other|HLA- Group|Participants who are high-risk HLA-DR3 and DR4 (-); with known or yet unknown monogenic variants with REVEL score>0.75; and either GAD65 and IA2 autoantibody (-), or autoantibody (+) with titers close to the cutoff
16338585|NCT04409782|Experimental|Arm 1|Registered attendees of a group educational class events will have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
16338586|NCT04409782|Experimental|Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via a geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
16338587|NCT04409769||Description of use of ceftaroline and ceftobiprole|description of patients and their PJI/BJI,conditions of use, adverse event
16338588|NCT04409756|Other|postassessment of the SRQ-T test|the SRQ -T will be obtained to all patients three days after the first assessment
16338589|NCT04409743|Active Comparator|Immediate Treatment|The sleep treatment is Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants randomized to this arm will begin treatment immediately after randomization.
16338590|NCT04409743|Other|Waitlist|The subjects assigned to the Waitlist condition will receive the same CBT-I treatment 7 months after randomization.
16338591|NCT04409730|Experimental|Children with Cerebral Palsy|"Aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of I, II, III according to GMFCS"
16338592|NCT04409717||Patients treated for type II endoleaks|Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
16338593|NCT04409704|Experimental|10 Hz|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 4-6 weeks
16338594|NCT04409691|Active Comparator|prednison group|
16338595|NCT04409691|Experimental|prednison+sirolimus group|
16338596|NCT04409678|Experimental|activity|
16338597|NCT04409678|No Intervention|bed rest|
16338598|NCT04409665|Experimental|Ketamine sedated group|30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
16338599|NCT04409665|Active Comparator|Glucose sedated group|30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
16338603|NCT04409626||Cases|
16338604|NCT04409626||Controls|Matched (5 controls per case) by date of birth +/- 180 days.
16338605|NCT04409613|Active Comparator|Clinical pharmacist-provided services+standard care group|that receive clinical pharmacist-provided services at the Warfarin Counseling Clinic plus standard medical care
16338606|NCT04409613|No Intervention|Standard care group|that will receive standard medical care
16338607|NCT04409600|Active Comparator|Home Based Gait Retraining + Saline Injection|
16338608|NCT04409600|Experimental|Home Based Gait Retraining + Botulinum Toxin Injection|
16338609|NCT04409600|Active Comparator|Supervised Gait Retraining + Saline Injection|
16338610|NCT04409600|Experimental|Supervised Gait Retraining + Botulinum Toxin Injection|
16338611|NCT04409587|No Intervention|NovoLog®-only|In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
16338612|NCT04409587|Active Comparator|Novolog® and Tresiba® Group|This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.
16338613|NCT04409561||Interventions|This patient pool shall be representative of the US population in term of the relative proportion of race/ethnicities. In addition, the population shall be enriched with patients above 60 year old as the target population of the PSP test is mostly the elderly.
16338614|NCT04409548|Active Comparator|Lumbar Disc Hernaition Group|The number of participants in this group is anticipated to be 154. The pain intensity of the patients was recorded by a Visual Analog Scale (VAS) immediately before performing the analysis. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
16338615|NCT04409548|Active Comparator|Healthy Control Group|The number of participants in this group is anticipated to be 54. The participants were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
16338616|NCT04409548|Active Comparator|Preoperative and Postoperative Group|The number of participants in this group is anticipated to be 60. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day, before and 15 days after surgery.
16338617|NCT04409535||Rural Living Community Member|Adult residents of a New Mexico rural county (as federally designated)
16338618|NCT04409535||Urban/Suburban Living Community Member|Comparison group: adult resident of a New Mexico urban/suburban city or town (as federally designated)
16341552|NCT04388527|Experimental|Treatment|Penn COVID-19 convalescent plasma
16338619|NCT04409522|Experimental|Test Group|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
16338620|NCT04409522|Active Comparator|Control Group|Participants in this group will receive the usual treatment of COVID-19
16338621|NCT04409509|Experimental|CSL312|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
16338622|NCT04409509|Placebo Comparator|Placebo|CSL312 diluent administered intravenously
16338623|NCT04409496|Experimental|Intervention group|Chat-based instant messaging support + Self-help booklet
16338624|NCT04409496|Active Comparator|Control group|SMS message support + Self-help booklet
16338625|NCT04409483|Active Comparator|Standard Care|Standard care for COVID-19 according to the national guidelines of Niger
16338626|NCT04409483|Experimental|Standard Care plus lopinavir/ritonavir|Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir
16338627|NCT04409470||Indication for blood gas sampling|To be eligible, patients will need to be classified as critically ill and there has to be a clear clinical indication for an arterial blood gas sampling. Enrollment will be performed in a consecutive manner at all hours.
16338628|NCT04409457|Other|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:
~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.
~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
16338629|NCT04409457|Other|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:
~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.
~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
16338630|NCT04409444||Data (main study)|This study group is for any individual that attends and has a lung health check. The data collected for this study group is to evaluate the uptake and performance of a community-based lung health check / lung screening programme.
16338631|NCT04409444||Biomarker (sub-study)|This sub-study is for participants that are determined to require a CT scan through their lung health check and have also signed up to the data part of the study. This part of the study is to evaluate the potential for biomarkers to improve the early detection of lung cancer.
16338632|NCT04409431|Experimental|Adrenal Artery Ablation|Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol.
16338633|NCT04409431|No Intervention|Spironolactone|Patients in this group will be treated with aldosterone 20-80mg daily according to blood pressure
16338634|NCT04409418|Experimental|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
16338635|NCT04409418|Active Comparator|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
16338636|NCT04409405||Cured population|• Age ≥ 5 year old
16338637|NCT04409405||Contact population|"Age ≥ 5 year old
~Contact of a participant included in cured-population cohort
~Not diagnosed with EVD"
16338638|NCT04409392||Prothestic joint infection due to Staphylococcus lugdunensis|Patients having had a prosthetic joint infection with Staphylococcus lugdunensis
16338639|NCT04409379||acute leukemia group|300 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
16338640|NCT04409366|Active Comparator|Conventional Crown Lengthening; CCL|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days.
16338641|NCT04409366|Experimental|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan
16338642|NCT04409353|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
16338643|NCT04409353|Active Comparator|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
16338644|NCT04409353|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
16338645|NCT04409340||Training cohort|"All patients enrolled will undergo:
~Magnetic Resonance Viscoelastography
~Quantitative ultrasound (QUS)"
16338646|NCT04409340||Validation cohort|"All patients enrolled will undergo:
~• Quantitative ultrasound (QUS)"
16338647|NCT04409327|Experimental|10 mg daily RTB101|TORC1 inhibitor
16338648|NCT04409327|Placebo Comparator|Placebo|Placebo
16338649|NCT04409314||Diagnostic (18F-FAZA PET scan)|Prior to CAR T-cell therapy, patients receive 18F-FAZA IV. Beginning 2 hours after injection, patients undergo PET scan over 30-45 minutes.
16338650|NCT04409301|Experimental|MSAD Intervention|Children receiving cancer treatment in a hospital randomized to the My Special Aflac Duck (MSAD) intervention.
16338687|NCT04408976||Control practices|Patients with urinary tract infection in practices not using the clinical decision support software
16338651|NCT04409301|Active Comparator|Control Group|Children receiving cancer treatment in a hospital randomized to be a control hospital. Children in the control hospitals will receive the My Special Aflac Duck (MSAD) at the end of the intervention period.
16338652|NCT04409288|Experimental|Group A|Apalutamide followed by Enzalutamide Study participants will receive 12 weeks of oral apalutamide (240mg) daily, followed by five weeks of washout period, and then 12 weeks of oral enzalutamide (160mg) daily.
16338653|NCT04409288|Experimental|Group B|Enzalutamide followed by Apalutamide Study participants will receive 12 weeks of oral enzalutamide (160mg) daily, followed by five weeks of washout period, and then 12 weeks of oral apalutamide (240mg) daily.
16338654|NCT04409262|Experimental|Remdesivir + Tocilizumab (RDV+TCZ)|Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
16338655|NCT04409262|Active Comparator|Remdesivir + Placebo (RDV+Placebo)|Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
16338658|NCT04409223|Experimental|Famitinib|
16338659|NCT04409223|Active Comparator|Sunitinib|
16338660|NCT04409210|Experimental|Intervention Group|The intervention group will receive establishment of individual health records, cardiovascular risk assessment, popularization of medical knowledge, personalized reminders and routine treatment.
16338661|NCT04409210|Other|Control Group|The control group just receive routine treatment and routine management.
16338662|NCT04409184||Convalescent subjects|Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection
16338663|NCT04409184||Healthy controls|
16338664|NCT04409171||PD|pancreaticoduodenectomy
16338665|NCT04409171||DP|distal pancreatectomy
16338666|NCT04409145|Experimental|VT30|VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 µL of gel, intended to treat an area of 140 cm2.
16338667|NCT04409132|Experimental|Triferic AVNU infusion pre-dialyzer|Patients will receive one (1) 6.75 mg Fe dose of Triferic AVNU by continuous infusion over 3 hours into the predialyzer blood line.
16338668|NCT04409132|Experimental|Triferic AVNU for injection at T=0 and T= 3 hours|Patients will receive two (2) doses of Triferic AVNU 3.4 mg IV (2.25 mL) at T=0 and T=3 hours of hemodialysis into the venous drip chamber.
16338669|NCT04409132|Experimental|Triferic AVNU for injection at T=0|Patients will receive one (1) dose of Triferic AVNU 0.08 mg/kg IV, up to 6.75 mg Fe, at T=0 of hemodialysis into the venous drip chamber.
16338670|NCT04409132|Experimental|Triferic AVNU for injection at T=0, T=1.5 and T= 3 hours|Patients will receive three (3) doses of Triferic AVNU 2.25 mg Fe (1.5 mL) at T=0, T=1.5 and T=3.0 hours of hemodialysis into the venous drip chamber.
16338671|NCT04409119|Experimental|HIS/LBB pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.
16338672|NCT04409119|Active Comparator|LV pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.
16338673|NCT04409093|Experimental|Nail bed repair with eponychial sent|
16338674|NCT04409093|Active Comparator|Nail bed repair without eponychial stent|
16338676|NCT04409067||TMD-pain group|The TMD-pain group consisted of 30 children aged between 7.1 and 12.3 with a pain-related TMD diagnosis. All the patients in the TMD-pain group had myogenous or arthrogenous TMD according to the RDC/TMD protocol.
16338677|NCT04409067||pain-free TMD group|The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
16338678|NCT04409067||non-TMD group|The non-TMD group comprised 30 children aged between 7.2 and 12.5 without any recognised TMD based on RDC/TMD, Axis I.
16338679|NCT04409054||Patients undergoing the cough and Valsalva protocol|Patients over 18 years old, consulting in neuro urology departement, undergoing ano rectal manometry in order to explore ano rectal disorders
16338680|NCT04409028|Active Comparator|indirect restoration|
16338681|NCT04409028|Active Comparator|direct restoration|
16338683|NCT04408989|Experimental|MB02-SP (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
16338684|NCT04408989|Experimental|MB02-DM (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
16338685|NCT04408989|Active Comparator|US licenced Avastin®|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
16338686|NCT04408976||Software practices|Patients with urinary tract infection in practices using the clinical decision support software
16338690|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
16338691|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
16338692|NCT04408937|Experimental|tropifexor AM 200 micrograms and Placebo (PM)|Tropifexor 200 μg (AM) and Placebo (PM) once daily each
16338693|NCT04408937|Experimental|tropifexor PM 200 micrograms and Placebo (AM)|Tropifexor 200 μg (PM) and Placebo (AM) once daily each
16338695|NCT04408911||Midazolam|Critically ill intensive care unit patients receiving midazolam
16338696|NCT04408911||Lormetazepam|Critically ill intensive care unit patients receiving lormetazepam
16338697|NCT04408898|Experimental|ADP-A2M4 T cells in combination with pembrolizumab|
16338698|NCT04408872|Active Comparator|EGD|SUBJECT WILL UNDERGO ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)
16338699|NCT04408872|Experimental|EUS|SUBJECT WILL UNDERGO ENDOSCOPIC ULTRASOUND (EUS)
16338700|NCT04408859||NACS|The patients with advanced gastric cancer who received neoadjuvant chemotherapy followed by surgery（NACS）.
16338701|NCT04408859||SA|The patients with advanced gastric cancer who received surgery alone.
16338702|NCT04408846|Other|Minimally invasive lumbar fusion|
16338703|NCT04408846|Other|Open posterior lumbar fusion|
16338704|NCT04408820||Roxadustat|Participants will receive oral dose of roxadustat.
16338705|NCT04408807|Experimental|Study Group|ROPEE screening with speculum-free fundoscopy
16338706|NCT04408807|Active Comparator|Control Group|ROPEE screening with speculum fundoscopy
16338707|NCT04408794|Experimental|Vazegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
16338708|NCT04408781|Experimental|Ridge expansion by osseodensifcation|Ridge expansion and osteotomy drilling by osseodensifcation in conjunction with simultaneous implant placement in narrow ridges
16338709|NCT04408781|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
16338710|NCT04408768||Normal RBS|Normal RBS on ICU admission and controlled blood sugar within 24 hours
16338711|NCT04408768||High RBS|High RBS on ICU admission and uncontrolled blood sugar during first 24 hours
16338712|NCT04408755|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
16338713|NCT04408755|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
16338714|NCT04408742||females with Multiple Sclerosis|patients with a confirmed diagnosis of MS according to the McDonald criteria, physician-administered Expanded Disability Status Scale (EDSS) range of 1-3.5, having regular menstrual cycle (between 21-35 days), and cognitive levels to give history and following the instructions
16338715|NCT04408729|Experimental|PrEP My Way intervention|PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.
16338716|NCT04408729|No Intervention|Control|These participants will continue to receive PrEP at the clinic.
16338717|NCT04408716|Experimental|Ablation Index Guided High-Power Short-Duration Group|For patients assigned to undergo AF ablation with ablation index guided high-power short-duration strategy, point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
16338718|NCT04408716|Active Comparator|Standard Radiofrequency Ablation Group|For patients assigned to undergo AF ablation with standard radiofrequency ablation group, point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
16338719|NCT04408703||Ulcerative colitis in clinical remission|Clinical remission with SCCAI <3 at baseline and stable remission for the last 3 months
16338720|NCT04408690|Experimental|Rehabilitation and optional delayed ACL reconstruction|
16338721|NCT04408690|Active Comparator|Immediate ACL reconstruction + rehabilitation|
16338722|NCT04408664|Experimental|Sodium Cromoglycate|Patients will take Sodium Cromoglycate (SCG) (Lomudal®) 4 times daily during 6 months: SCG 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
16338723|NCT04408664|Placebo Comparator|Sodium Chloride 0.9%|Patients will take Sodium Chloride 0.9% 4 times daily during 6 months: Sodium Chloride 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
16338724|NCT04408651|Experimental|Acceptance and Commitment Therapy|
16338725|NCT04408651|Experimental|Compassion-Focused Therapy|
16338728|NCT04408625|Experimental|Low dose|
16338729|NCT04408625|Experimental|Medium dose|
16338730|NCT04408625|Experimental|High dose|
16338731|NCT04408612||Dyspnea in stable coronary artery disease|Stable patients with dyspnea and coronary artery disease
16338732|NCT04408599|Experimental|NC410|NC410 for IV infusion of various dose strengths administered in 14 day dosing cycles
16338733|NCT04408586|Active Comparator|Phentermine - Topiramate Extended Release group|
16338734|NCT04408586|Placebo Comparator|Placebo Group|
16338735|NCT04408573|No Intervention|Regular Continuous High Frequency|Patient remains 2 weeks in the currently chosen stimulation protocol.
16339192|NCT04405193|Placebo Comparator|Placebo|2 capsules of matching placebo administered once daily every morning
16338736|NCT04408573|Experimental|Cycling High Frequency|Patient is stimulated with the same polarity, voltage/current, pulse width and frequency as the currently chosen stimulation protocol, but with cycling stimulation: 40sec On - 02 sec OFF
16338737|NCT04408573|Experimental|Continuous Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
16338738|NCT04408573|Experimental|Cycling Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
16338739|NCT04408560|Active Comparator|Groupe A with homéopathic treatment|Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
16338740|NCT04408560|Sham Comparator|Groupe B without homeopathic treatment|Conventional treatment : paracetamol (drug analgesic class1)
16338741|NCT04408547||soft catheter|Patients who underwent embryo transfer with a soft catheter
16338742|NCT04408547||stiff catheter|Patients who underwent embryo transfer with a stiff catheter because soft couldn't pass
16338743|NCT04408534|Active Comparator|continuous positive airway pressure|Patients receive continuous positive airway pressure as a mode of noninvasive ventilation
16338744|NCT04408534|Experimental|bilevel positive airway pressure|Patients receive bilevel positive airway pressure as a mode of noninvasive ventilation
16338745|NCT04408521|Experimental|NEUROFEEDBACK|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. Self-regulation of alpha rhythm is reflected in the dynamically varying opacity of the video replay window, i.e. the window would turn lighter/darker and reveal/obscure video content during episodes of low/high alpha amplitude, respectively.
16338746|NCT04408521|Placebo Comparator|CONTROL|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. The recording is passive without real-time EEG neurofeedback (i.e. constant brightness and volume).
16338747|NCT04408508|Other|Amoxicillin administration|Oral amoxicillin administered to study patients
16338748|NCT04408495|Experimental|Intervention group_MRA|Recruitment maneuvers and high PEEP
16338749|NCT04408495|Active Comparator|Control group|No recruitment maneuvers and low PEEP
16338750|NCT04408482|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy performed in difficult cannulation
16338751|NCT04408482|Active Comparator|Pancreatic sphincterotomy + pancreatic stent|Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement
16338752|NCT04408469|Experimental|Online EQuIP|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
16338753|NCT04408469|Placebo Comparator|Self-Monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
16338754|NCT04408456|Active Comparator|Post Exposure Prophylaxis (PEP) Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
16338755|NCT04408456|Other|Control Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
16338756|NCT04408443|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
16338757|NCT04408443|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
16338760|NCT04408417|Experimental|Harnessing Sequence A|Participants will harness their child into the 2 different child safety seats in the following order: control, prototype, prototype, control.
16338761|NCT04408417|Experimental|Harnessing Sequence B|Participants will harness their child into the 2 different child safety seats in the following order: prototype, control, control, prototype.
16338762|NCT04408417|Experimental|Harnessing Sequence C|Participants will harness their child into the 2 different child safety seats in the following order: control, control, prototype, prototype.
16338763|NCT04408417|Experimental|Harnessing Sequence D|Participants will harness their child into the 2 different child safety seats in the following order: prototype, prototype, control, control.
16338764|NCT04408404||Type A aortic dissection|Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital
16338765|NCT04408391||COVID-19 patients with anosmia|Patients reporting loss of smell and scoring < 30 on a VAS 0-100 for ability to detect n-Butanol diluted 1/1000
16338766|NCT04408391||COVID-19 patients without anosmia|Patients reporting no loss of smell and scoring > 80 on a VAS 0-100 for ability to detect n-Butanol diluted 1/16000
16338767|NCT04408378||mild pneumonia|The patients who has followed in the ward
16338768|NCT04408378||severe pneumonia|The patiens who has followed in the intensive care unit
16338769|NCT04408378||control group|patients who has not covid 19 pneumonia
16338770|NCT04408365||COVID-19 patients|Adult COVID-19 patients admitted to intensive care units
16338771|NCT04408352|Active Comparator|RF Trigone Ablation Treatment Arm|A compatible standard cystoscopy lens (30°) will be inserted into the Hologic trigone RF Device. The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Ablations at the trigone will be created using the Hologic trigone RF ablation device together with the compatible standard commercially available RF cannula and generator. It is expected that a subject would receive between 4-6 ablations to completely treat the appropriate area of the trigone. At the completion of the procedure, 200 ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge.
16338866|NCT04407689|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
16338772|NCT04408352|Sham Comparator|RF Trigone Ablation Sham Arm|"The sham procedure will mimic the Hologic trigone RF ablation device procedure to maintain subject blinding and provide the most accurate assessment of control data while minimizing risk to the subject.
~The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Suction will be applied to the bladder wall and the cannulas (needles) will be introduced into the bladder wall. Energy will not be delivered to the tissue when each sham ablation is started. In order to maintain blinding of the subject, the typical sounds that Hologic trigone RF ablation device makes during actual ablation/fulguration will be replicated. The simulated ablation procedure will be repeated as many times as necessary to cover the area of the trigone. 4 to 6 sham ablations would be required. At the completion of the procedure, 200ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge."
16338773|NCT04408326||Angiotensin II|Patients with COVID-19 and acute respiratory distress syndrome who received angiotensin II as an add-on vasopressor will be collected
16338774|NCT04408326||Anakinra|Patients with COVID-19 and acute respiratory distress syndrome who received Anakinra (interleukin 1 receptor antagonist) will be collected
16338775|NCT04408326||Angiotensin II control|Patients with COVID-19 and acute respiratory distress syndrome who also received vasopressor support will be matched to angiotensin II group by date of intensive care unit admission, age, history of hypertension, history of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, respiratory support
16338776|NCT04408326||Anakinra control|Patients with COVID-19 and acute respiratory distress syndrome will be matched to Anakinra group by matching age and date of intensive unit care admission
16338777|NCT04408313|Experimental|XR-B|Extended-release buprenorphine
16338778|NCT04408313|Active Comparator|XR-NTX|Extended-release naltrexone
16338779|NCT04408300|Experimental|Ophthalmological exam|
16338780|NCT04408287|Experimental|Intervention|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
16338781|NCT04408274|Experimental|Computerized Tests|
16338782|NCT04408274|Placebo Comparator|Placebo Control|
16338783|NCT04408261|Experimental|Buqitongluo Granule|Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
16338784|NCT04408261|Placebo Comparator|Placebo|Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
16338785|NCT04408248||COVID-19 patients with acute respiratory disease|Adult patients with COVID-19 and moderate or severe respiratory disease
16338786|NCT04408235|Active Comparator|Low-Dose LMWH|Enoxaparin 4000 IU daily
16338787|NCT04408235|Experimental|High-Dose LMWH|Enoxaparin 70 IU/kg twice daily
16338788|NCT04408222||Awake Proning|COVID-19 patients with hypoxemic respiratory failure with awake prone positioning, as tolerated, up to 24 hours daily.
16338789|NCT04408209|Experimental|Convalescent Plasma|Convalescent Plasma - early treatment of patients with severe COVID-19
16338790|NCT04408196||Patients|100 patients admitted to an inpatient rehabilitation facility
16338791|NCT04408196||Caregivers|100 caregivers of patients admitted to an inpatient rehabilitation facility
16338792|NCT04408183|Experimental|GLS-1200|1 mL of GLS-1200 per nostril, TID
16338793|NCT04408183|Placebo Comparator|0.9 %Saline|1 mL of 0.9% Saline per nostril, TID
16338794|NCT04408170||Work Stream A|Patients that are recruited in hospital with either query COVID-19 or who have tested positive for COVID-19.
16338795|NCT04408170||Work Stream B|Known COVID-positive and/or COVID-negative community testing
16338796|NCT04408170||Work Stream C|Undifferentiated community testing
16338797|NCT04408157|Experimental|Self-management booklet|Self-management booklet: developed drawing on existing evidence and work conducted by researchers at the Health Psychology section at KCL, tailored to the current circumstances in response to the COVID-19 pandemic.
16338798|NCT04408157|No Intervention|Education only (waiting-list)|Participants allocated to the waiting-list control arm will receive a link via email to educational materials related to COVID produced by King's College London for an online event and will be provided with the self-management booklet after completing the T2 assessment and qualitative interview. The topics covered in the online event are the same as the ones included in the self-management booklet, without structured guidance and behaviour change techniques to facilitate behaviour change.
16338799|NCT04408144|Experimental|StudyGroup|Patients will receive an addition of dydrogesterone (Duphaston) to the standard treatment for luteal phase support
16338800|NCT04408144|No Intervention|Control Group|Patients will receive the standard treatment for luteal phase support without Dydrogesterone
16338801|NCT04408131|Experimental|Homeless people|Blood sample
16338802|NCT04408118|Experimental|Atezolizumab + Paclitaxel + Bevacizumab (Avastin®)|"All eligible patients will be treated with atezolizumab (840 mg) intravenously on days 1 and 15, Paclitaxel (90 mg/m2) on days 1, 8 and 15 via IV infusion and Bevacizumab (Avastin® 10mg/kg) intravenously on days 1 and 15.
~Treatment cycles and patient visits are organized in scheduled cycles of 28 days."
16338803|NCT04408105||Primary Care Providers|400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
16338896|NCT04407416|Active Comparator|Healthy subjects|The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
16338804|NCT04408105||Gastroenterologists|100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
16338805|NCT04408105||Patients|500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.
16338806|NCT04408092|Experimental|GM-CSF treatment at second-look surgery arm|Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
16338807|NCT04408092|Experimental|GM-CSF treatment at recurrence arm.|"EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients.
~Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician"
16338808|NCT04408079|Experimental|TQB3558 Tablets|TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
16338809|NCT04408066|Experimental|Arm A:Suspected COVID-19 patients|Arm A: Suspected COVID-19 Patients - SARS-CoV-2 viral antigen test swab and blood sample for SARS-CoV-2 IgG/IgM
16338810|NCT04408066|Experimental|Arm B: Previously positive COVID-19 patients|Arm B: Previously Positive COVID-19 patients - SARS-CoV-2 IgG/IgM blood sample. Capillary fingerstick samples will additionally be collected in Stage 2.
16338811|NCT04408053|Experimental|Preventive fixation of the contralateral femoral neck|Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
16338812|NCT04408053|No Intervention|No fixation|
16338813|NCT04408040|Other|Critical Patients|
16338814|NCT04408040|Other|Severe Patients|
16338815|NCT04408040|Other|High Risk|
16338816|NCT04408040|Other|Health Care Providers|
16338817|NCT04408027|Experimental|Virtual-Care Cognitive Behavioural Therapy|
16338818|NCT04408014||HC-USP|Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
16338819|NCT04408014||CORAS|Refugees living in the city of São Paulo
16338820|NCT04408014||Hemocenter|Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
16338821|NCT04408014||CPP - Butantan Penitentiary Progression Center|Participants of the CPP - Butantan Penitentiary Progression Center
16338822|NCT04408014||CHSP - Penitentiary System Hospital Center|Participants of the CHSP - Penitentiary System Hospital Center
16338823|NCT04408014||SABE (Health, Wellness and Aging)|Participants of the SABE Project (Health, Wellness and Aging)
16338824|NCT04408014||ILPI - Long-Term Care Institution for the Elderly|Residents of the Long-Term Care Institution for the Elderly of Botucatu
16338825|NCT04408014||ICR-USP - Children's Institute of HCFMUSP|Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
16338826|NCT04408001||Symptomatic individuals|"Hospital staff identified by the COVID-19 case census cell :
~who have been infected (confirmed by a positive RT-PCR result on a nasopharyngeal swab)
~OR who have displayed clinical signs compatible with COVID-19 despite a negative RT-PCR result."
16338827|NCT04408001||Asymptomatic individuals|Hospital staff who have not been identified by the COVID-19 case census cell.
16338828|NCT04407988|Experimental|Pyrotinib plus Letrozole|
16338829|NCT04407975|Experimental|Betamethasone|Patients will receive 14 mg (2 ml) intramuscular betamethasone
16338830|NCT04407975|Placebo Comparator|Placebo|Patients will receive an equivalent volume of normal saline
16338831|NCT04407962|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
16338832|NCT04407962|No Intervention|Control group|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
16338833|NCT04407949|Other|event detection|
16338834|NCT04407936||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention
16338835|NCT04407910|Experimental|Air-powder polishing device|
16338836|NCT04407910|Experimental|Rubber-cup+paste|
16338837|NCT04407897|Experimental|Radiotherapy|Patients with oligometastatic lesions, fulfilling the inclusion/exclusion criteria's will be assigned to SABR.
16338838|NCT04407884|Experimental|study arm|Subjects will receive an active study device.
16338839|NCT04407871|Experimental|acupuncture and CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after embryo transfer (ET). They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
16338840|NCT04407871|Placebo Comparator|acupuncture and placebo CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
16339217|NCT04405050|Active Comparator|Restrata|Treated with Restrata
16338841|NCT04407871|Placebo Comparator|control acupuncture and CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
16338842|NCT04407871|Placebo Comparator|control acupuncture and placebo CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
16338843|NCT04407832|Active Comparator|low dose PPI|40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
16338844|NCT04407832|Active Comparator|high dose PPI|40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
16338845|NCT04407819||diabetes mellitus type 2|36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
16338846|NCT04407819||CONTROLS|14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
16338847|NCT04407806|Active Comparator|Continuous Pulse Oximetry Monitoring of Oxygen Saturation|Continuous pulse oximetry to measure oxygen saturation
16338848|NCT04407806|Active Comparator|Intermittent Pulse Oximetry Monitoring of Oxygen Saturation|Intermittent pulse oximetry to measure oxygen saturation, measured every 4 hours
16338849|NCT04407793||Diverticulitis Group|Patients with acute diverticulitis episode
16338850|NCT04407793||Diverticulosis group|Patients diagnosed with diverticulosis without any acute diverticulitis episode
16338851|NCT04407793||Non-diverticulosis|Patients without diverticulosis
16338852|NCT04407767|Experimental|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
16338853|NCT04407767|Active Comparator|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
16338854|NCT04407754|Placebo Comparator|Control Arm|This group will receive placebo powder twice daily.
16338855|NCT04407754|Active Comparator|Inositol Arm|This group will receive myo-inositol (2,000mg) plus d-chiro-inositol (50mg) supplement powder twice daily.
16338856|NCT04407741|Experimental|SHR2554+ SHR1701|Drug: SHR2554 recommended dose from phase Ⅰstudy, PO, twice a day, every 3 weeks SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
16338857|NCT04407741|Experimental|SHR1701|Drug: SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
16338858|NCT04407728|Experimental|precocious EchoMorpho-T1|Women whose fetus is at high risk of congenital heart disease after the 1st trimester screening echo (EchoT1), will benefit from an early morphological ultrasound centered on the heart (EchoMorpho-T1) by a sonographer referent between 11 and 14 weeks +/- of an early fetal heart ultrasound (EchoCoeur-T1) between 11 and 15 weeks by a cardio-pediatrician in the event of an abnormality with the EchoMorpho-T1.
16338859|NCT04407715|Placebo Comparator|High Flow Anesthesia, Low Flow Anesthesia|. The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow. Group 1 (n = 40) was operated under high flow anesthesia with 50% O2 - 50% air at 2 L/min and desflurane at 1.1 MAC for the duration of the surgery. For anesthesia maintenance, Group 2 (n=40) was administered 50% oxygen - 50% air at 2 L/min and desflurane for 10-15 minutes. After reaching 1.1 MAC, it was switched to minimal flow with 50-60% oxygen- 40-50% air at 0.5 L/min and desflurane. 10 minutes before the end of the surgery, it was switched to high flow with 50% oxygen -50% air at 2 L/min.
16338860|NCT04407715|Active Comparator|Peroperetive Optic Nerve Sheath Diameter|Optic nerve sheath diameter measurements were performed by an experienced and the same anesthetist. In the measurements, the GE Healthcare Logiq e series USG device and 12-MHz linear probe were used. Longitudinal and transverse axis images were obtained on both eyelids while the patient was in the supine position. Measurements were taken 3 mm behind the optic nerve head
16338861|NCT04407702|Experimental|Control Group|The volunteers in this group will receive the same hygiene instructions as the other groups and will undergo both treatments, except that water will be used instead of the sealant and the laser device will be set to a power of 0 W. In other words, the same irradiation procedure will be performed but without the emission of light.
16338862|NCT04407702|Experimental|Sealant Group|The volunteers in this group will receive treatment with sealant (Permaseal - Ultradent), which is a photopolymerizable methacrylate-based resin.
16338863|NCT04407702|Experimental|Low-Level Laser Group|The volunteers in this group will receive irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation.
16338864|NCT04407702|Experimental|Low Level Laser + Sealant Group|The volunteers in this group will receive the same irradiation administered to Low-level Laser Group. During the last session, these volunteers will also receive the same sealant applied in Sealant Group.
16338865|NCT04407689|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
16338867|NCT04407676|Experimental|Experimental|Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
16338868|NCT04407676|Placebo Comparator|Control|Patients eligible for an investigator initiated trial are given the standard PIS by email and are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They will then be emailed and are also emailed a summary PIS and access to an online set of 10 video educational modules. They will then perform the QuIC-A and QuIC-B again. They will then present for their standard of care consent visit.
16338869|NCT04407663||Bariatric Patient|Inclusion criteria were as follows: obese adults (> 18 years of age, BMI> 40 or > 35 with comorbidities) older than 18 years; patients undergoing bariatric surgery within 6 months; patients who required clinical and instrumental control; presence of a caregiver in case of subject with cognitive impairment; patients with a history of bariatric surgery who requested a first outpatients access or established patients who requested an outpatients' visit for an emerging problem.
16338870|NCT04407650|Active Comparator|Metformin|Oral 1000 mg BD
16338871|NCT04407650|Experimental|Ursodeoxycholic acid|Oral 500 mg BD
16338872|NCT04407637||neck pain patients|Patients with acute non-specific neck pain were consecutively recruited from a private manual physiotherapy center as sample of convenience. Inclusion criteria were acute (<3months) non-specific neck pain with a neck disability index (NDI) > 8% and a Numerical Pain Rating Scale (NPRS) >3 . Patients were excluded if they reported any of the following: a history of neck surgery, dizziness caused by neck or head movements and cervical radiculopathy diagnosed by a physician.
16338873|NCT04407637||healthy|Healthy control participants were included if they reported a NDI < 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
16338874|NCT04407624|Experimental|Intermittent Exercise Group|Warm-up, loading (walking, squat, sitting down on a chair, limb movements with weights, stepping on steps, walking on different floors), cooling and relaxation exercises
16338875|NCT04407624|Active Comparator|Control Group|Warm-up, loading (brisk walking at 60-85% of maximum heart rate), cooling and relaxation exercises
16338876|NCT04407611|No Intervention|Conventional modality|Control arm. Conventional modality entails telephone disclosure of genetic results by a licensed genetic counselor.
16338877|NCT04407611|Experimental|Online modality|Online self-guided modality entails return of genetic results directly to participants, with optional genetic counselor follow-up via telephone.
16338878|NCT04407598||Glenfield Complex COPD Clinic Cohort|Patients previously seen in the complex COPD clinic at the Glenfield Hospital.
16338879|NCT04407585||Covid-19 Symptom Study app-user|UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
16338880|NCT04407559||Groupe 1|Group 1: Rheumatoid arthritis seropositive for RF (+)
16338881|NCT04407559||Groupe 2|Group 2: Rheumatoid arthritis seronegative for RF (-)
16338882|NCT04407546||Families with Children|Families containing an immunocompromised individual that have children in the family setting.
16338883|NCT04407546||Famlies without children|Families containing an immunocompromised individual that do not have children in the family setting.
16338884|NCT04407520||Adult patients with intellectual and/or physical disabilities|Adult patients with intellectual and/or physical disabilities requiring dental treatment under general anesthesia
16338885|NCT04407507|Experimental|Ivermectin|Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
16338886|NCT04407507|Placebo Comparator|Placebo|Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
16338887|NCT04407494||COVID-19|Healthcare workers and adult outpatients attending the COVID-19 screening center of the University Hospital of Montpellier, France.
16338888|NCT04407481||Adults with autosomal dominant polycystic kidney disease|All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
16338889|NCT04407481||Healthy Controls|Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).
16338890|NCT04407468||COVID|Patients with or without prone position
16338891|NCT04407455||Children with cerebral palsy|Children who will be referred to pediatric dentistry above the age of 2 years.
16338892|NCT04407455||Children with typical development|Children who will be referred to pediatric dentistry above the age of 2 years.
16338893|NCT04407442|Experimental|Treatment (azacitidine, dexamethasone, daratumumab)|"PRE-INDUCTION (CYCLE 0): Patients receive azacitidine IV on days -7 to -3 in absence of disease progression or unacceptable toxicity.
~INDUCTION (CYCLES 1-2): Patients receive azacitidine IV on days 22-26, dexamethasone IV or orally (PO), and daratumumab subcutaneously (SC) over 3-5 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity
~CONSOLIDATION (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 5-6, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity
~MAINTENANCE (CYCLES 7+): Patients receive azacitidine IV on days 1-5, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity"
16338894|NCT04407429||Health care workers|Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
16338895|NCT04407429||Patients|Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
16339218|NCT04405050|Active Comparator|NPWT|Treated with NPWT (Negative Pressure Wound Therapy)
16338897|NCT04407416|Active Comparator|Colorectal Cancer patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
16338898|NCT04407416|Active Comparator|Colonic Polyps patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
16338899|NCT04407403|Experimental|Tai Chi tailored for lowering blood pressure (PRESSURE)|During the 12-week Tai Chi intervention, participants in the PRESSURE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the PRESSURE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
16338900|NCT04407403|Experimental|Tai Chi tailored for improving balance (BALANCE)|During the 12-week Tai Chi intervention, participants in the BALANCE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the BALANCE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
16338901|NCT04407403|No Intervention|control group (CONTROL)|During the 12-week Tai Chi intervention, participants in the CONTROL group performed their regular daily activities. In addition, participants in the CONTROL group were instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed. Of note, both PRESSURE and BALANCE were offered to participants assigned in the CONTROL group after data collection was completed.
16338902|NCT04407390|Placebo Comparator|Control|Patients receiving placebo.
16338903|NCT04407390|Experimental|NR|Patients receiving nicotinamide riboside (NR-E)
16338904|NCT04407377|Experimental|Tolperisone 200 mg|Study Drug, Tolperisone 200mg TID
16338905|NCT04407377|Experimental|Tolperisone 400 mg|Study Drug, Tolperisone 400mg TID
16338906|NCT04407377|Active Comparator|Cyclobenzaprine|Active Comparator, Cyclobenzaprine 10mg TID
16338907|NCT04407377|Placebo Comparator|Placebo|Placebo, TID
16338908|NCT04407364||Intervention Cohort|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
16338909|NCT04407364||Historical Cohort|Primary and Revision total hip arthroplasty patients between 18-85 years of age
16338910|NCT04407351|Other|Arm Green LED light - Red LED light|Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks, the rest of the time indoors is not limited by light. Then crossover to red light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks.
16338911|NCT04407351|Other|Arm Red LED light - Green LED light|Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks, and the rest of the time indoors is not restricted by light. Then crossover to green light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks.
16338912|NCT04407338|Experimental|B-DYN Device|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
16338913|NCT04407338|Active Comparator|Conventional bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
16338914|NCT04407325|Experimental|AeoNose|the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
16338915|NCT04407312|Experimental|CILO group|"Intervention:
~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.
~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.
~For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).
~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.
~Drug:
~Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
16338916|NCT04407312|Placebo Comparator|Placebo group|"Intervention:
~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.
~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.
~In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).
~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.
~Drug:
~Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
16338917|NCT04407299||1|180 patients diagnosed with autoimmune rheumatic disease. Patients are RA SLE Rhupus AS Behcet Sjogren Vasculitis FM Polymyalgia APA Sarcoidosis IBD Scleroderma DM PSA Mixed
16338918|NCT04407299||2|control group composed of 180 healthy individuals (matched for age and sex)
16339353|NCT04404062||Trial Participants|Male and female participants aged 5-70 years
16338919|NCT04407286|Experimental|Treatment Group|"This group will receive vitamin D.
~The dosage for the first two weeks will be 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+)
~After two weeks of taking vitamin D, if vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation."
16338920|NCT04407273||with statins|Covid-19 infected patients with statins
16338921|NCT04407273||without statins|Covid-19 infected patients without statins
16338922|NCT04407260||Intervention|Patients on oxygen hoods who have fail conventional high-flow oxygen delivery systems.
16338923|NCT04407260||Control|Patients maintained on conventional high-flow oxygen delivery systems (such as non-rebreather masks, high-flow nasal cannula, BiPAP, CPAP) or who have failed on these conventional symptoms and were subsequently mechanically ventilated.
16338924|NCT04407247|Active Comparator|Arm I (infliximab)|Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
16338925|NCT04407247|Experimental|Arm II (vedolizumab)|Patients receive vedolizumab IV over 1 hour at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
16338926|NCT04407234|Experimental|Tirzepatide + Acetaminophen|Tirzepatide administered subcutaneously (SC) and acetaminophen administered orally.
16338927|NCT04407208|Experimental|Convalescent plasma recipient|Recipients receive 3 times of each 100 ml convalescent plasma on day 0, 3, and 6
16338928|NCT04407195||Healthcare Providers|Healthcare workers (physicians and nurses) who have interacted with patients with known or suspected COVID-19.
16338929|NCT04407182|Experimental|Viusid Plus Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.
~A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.
~Treatment duration: 21 days."
16338930|NCT04407182|No Intervention|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.
~Treatment duration: 21 days."
16338931|NCT04407169||Patients without chronic respiratory disease|All patients hospitalized for severe CoVid-19 without chronic respiratory disease
16338932|NCT04407169||Patients with chronic respiratory diseas|Patients hospitalized for severe CoVid-19 with one chronic respiratory disease
16338933|NCT04407143||lung cancer+COVID-19|Lung cancer patients infected by COVID-19
16338934|NCT04407130|Active Comparator|Tab Ivermectin +Cap Doxycycline|"200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)
~+ Placebo one tablet D2-5"
16338935|NCT04407130|Active Comparator|Tab Ivermectin|"Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5
~+ Placebo two tablets D1 followed by Placebo one tablet D2-5"
16338936|NCT04407130|Placebo Comparator|Placebo|"Drug: Placebo
~3 Placebo tablets D1 followed by 2 tablets D2-5"
16338937|NCT04407091|Experimental|[14C]AZD4831 Oral Solution|One 10 mg dose of [14C]AZD4831 Oral Solution
16338938|NCT04407078|Experimental|Sugammadex group|Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
16338939|NCT04407078|Placebo Comparator|Neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
16338940|NCT04407065|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
16338941|NCT04407065|Active Comparator|HCG|HCG is used to trigger ovulation
16338942|NCT04407052|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
16338943|NCT04407052|Active Comparator|HCG|HCG is used to trigger ovulation
16338944|NCT04407039||Glioma molecular subtype: G-CIMP-low|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338945|NCT04407039||Glioma molecular subtype: G-CIMP-high|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338946|NCT04407039||Glioma molecular subtype: codel|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338947|NCT04407039||Glioma molecular subtype: classic-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338948|NCT04407039||Glioma molecular subtype: mesenchymal-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338949|NCT04407039||Glioma molecular subtype: LGM6-GBM|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338950|NCT04407039||Glioma molecular subtype: PA-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
16338951|NCT04407026||Healthy|Healthy control group (n=25) consisted of the volunteers having clinically healthy gingiva, PD≤3 mm, BOP<10% and no sign of clinical attachment loss and radiographic alveolar bone destruction.
16338952|NCT04407026||Gingivitis|Gingivitis group (n=25) had PD≤3 mm with BOP>50% in the entire mouth, and no clinical attachment loss or alveolar bone loss.
16338953|NCT04407026||Stage 3 periodontitis|Stage 3 periodontitis group included the patients exhibiting PD ≥6 mm and interdental CAL ≥5 mm at %30 or more teeth. They had no more than four teeth loss.
16338954|NCT04407013|Experimental|A|Experimental group with application of the standardized care pathways and symptom management education
16338955|NCT04407013|Other|B|Control group with usual care (symptom monitoring only)
16338956|NCT04407000|Experimental|Test Drug|Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)
16338957|NCT04407000|Active Comparator|Reference drug|Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)
16338958|NCT04406987||decompression|patients treated with decompression for lumbar spinal stenosis
16338959|NCT04406987||fusion|patients treated with decompression with fusion for lumbar spinal stenosis
16338960|NCT04406974||Patients with local recurrence|
16338961|NCT04406974||Patients with advanced colorectal cancer|
16338962|NCT04406961|Active Comparator|Standard sphincterotomy.|"Standard retrograde sphincterotomy is performed on 750 patients using a standard sphincterotome. After deep bile duct cannulation, the standard sphincterotome, the Erlangen pull-type model, retrogradely cuts all layers of the wall of the duodenum and sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve insert standard sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis."
16338963|NCT04406961|Active Comparator|Antegrade sphincterotomy. ASD.|750 patients underwent a new antegrade sphincterotomy using the new sphincterotome design developed by Dr. Dovbenko (ASD). After deep bile duct cannulation, the new design of sphincterotome, antegradely cuts only circular muscle layer of the sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve cannulation new design sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis.
16338964|NCT04406948|Experimental|MGCND00EP1|"Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .
~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).
~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.
~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
16338965|NCT04406948|Placebo Comparator|PLACEBO|"Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).
~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).
~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.
~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
16338966|NCT04406935|Active Comparator|475 KHz|NuEra device treatment using 475 KHz
16338967|NCT04406935|Active Comparator|1 MHz|Arm 2: NuEra device treatment using 1 MHz
16338968|NCT04406935|Active Comparator|2 MHz|NuEra device treatment using 2 MHz
16338969|NCT04406922|Experimental|Intervention group|Cold exposure in the morning and evening.
16338970|NCT04406909|Experimental|Training|Access to training at membership training facility
16338971|NCT04406909|No Intervention|No training|No access to training at membership training facility
16338972|NCT04406896|Experimental|Participants with mild hepatic impairment (Group 1)|Participant with Child-Pugh Grade A Score of 5-6.
16338973|NCT04406896|Experimental|Participants with moderate hepatic impairment (Group 2)|Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.
16338974|NCT04406896|Experimental|Healthy participants (Group 3)|
16338975|NCT04406883|Active Comparator|A (Simavastatin 10 mg with gelatin sponge graft)|A group: After atraumatic extraction, filled the tooth socket with Simvastatin10 mg solution impregnated gelatin sponge.
16338976|NCT04406883|Active Comparator|B(Gelatin sponge graft )|B group: Following atraumatic extraction, put in the tooth socket with gelatin sponge.
16338977|NCT04406870|Experimental|Intervention|patients with propranolol-resistant IHHE are given propranolol combined with sirolimus
16338978|NCT04406857|Experimental|Treatment (ropidoxuridine, capecitabine, radiation therapy)|Patients receive ropidoxuridine PO BID over 7 days per week and capecitabine PO BID over 6 days per week for 6 weeks. Patients also undergo radiation therapy over 1 fraction per day for 5 days per week (Monday-Friday) during weeks 1-5 and for 3 days during week 6 in the absence of disease progression or unacceptable toxicity. Approximately 8-12 weeks after completion of treatment with ropidoxuridine, capecitabine, and radiation therapy, patients undergo standard of care surgery.
16338979|NCT04406831||New Unresectable Pancreatic Cancer|Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
16338980|NCT04406831||Control|Healthy individuals without cancer diagnoses to provide reference microRNA
16338981|NCT04406818|Active Comparator|Healthy Control|
16338982|NCT04406818|Active Comparator|Sickle Cell Anemia|
16338983|NCT04406805||Severe aortic stenosis|Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation
16338987|NCT04406779||Patients with breast cancer|Patients with breast cancer
16338988|NCT04406779||Control|Healthy patients without breast cancer
16338989|NCT04406766|Experimental|Connected nutrition pump system|
16339049|NCT04406285|Active Comparator|Lymphoma Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
16338990|NCT04406753|Experimental|Manual Therapy + Exercise Group|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
16338991|NCT04406753|Active Comparator|Exercise Group|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.
~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
16338992|NCT04406740||All Participants|Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia in the MHealth East Bank operating rooms in which the administration of a nondepolarizing neuromuscular blocking drug (rocuronium or cisatracurium) is anticipated.
16338993|NCT04406727|Experimental|UB-421|"2-arm Comparison Phase: UB-421(25 mg/kg, every 2 weeks) in combination with ARV
~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
16338994|NCT04406727|Active Comparator|Placebo|"2-arm Comparison Phase: Placebo in combination with ARV
~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
16338995|NCT04406714|Experimental|Mailed FIT|Patients randomized to this arm will receive mailed FIT plus up to two reminder letters to complete and return the FIT. Patients with a positive (abnormal) FIT result will be offered patient navigation to facilitate follow-up colonoscopy.
16338996|NCT04406714|No Intervention|Usual Care|Patients randomized to this arm will receive usual care. Current usual care at the participating community health centers consists of a visit-based FIT distribution approach.
16338997|NCT04406675|Other|Patients Amyotrophic Lateral Sclerosis|
16338998|NCT04406675|Other|Control subjects|
16338999|NCT04406649|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
16339000|NCT04406623|Experimental|SL-172154|Intravenous administration
16339001|NCT04406610|Experimental|GD2 CAR-T|Treated by GD2 CAR-T therapy intravenously
16339002|NCT04406610|No Intervention|Control|With no medical intervention
16339003|NCT04406597|Experimental|the New Tissue Containment System group|Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy
16339004|NCT04406597|No Intervention|Open group|Without any protection system during Laparoscopic Ovarian Cystectomy
16339005|NCT04406584|Placebo Comparator|Saline|Injection of 1cc saline into olfactory cleft x4
16339006|NCT04406584|Experimental|Platelet Rich Plasma|Injection of 1cc patient's own platelet rich plasma (PRP) into olfactory cleft x4
16339007|NCT04406571||"pancreatic adenocarcinoma before COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.
16339008|NCT04406571||"pancreatic adenocarcinoma after COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.
16339009|NCT04406545||healthy volunteers|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
16339010|NCT04406545||cardiovascular disease and COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
16339011|NCT04406545||cardiovascular disease without COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
16339012|NCT04406532|Experimental|PT-Pal|Participants randomized to the 14-day intervention arm will receive exercise instructions via PT-Pal. The Pt-Pal is a mobile health technology used to facilitate communication between the Care Team and patients, by allowing the team to send from their web-portal, exercise routines, surveys and educational material to the patient's mobile device. The PT-Pal app then captures the patient activity adherence, and reports those results back to the team including a graphical summary about patients' condition and activity. Clinicians can send/receive HIPAA-secure messages with patients. The app was designed to work with intermittent data connectivity typically found in mobile networks by switching between store-and-forward and real-time mode of connectivity to ensure data delivery.
16339013|NCT04406532|Active Comparator|Self-guided exercises|Participants randomized to the 14-day control arm will be instructed by research staff on how to use the exercise manual provided at the time of their screening.
16339014|NCT04406519||Hemophilia Group|The inclusion criteria in the hemophilia group were as follows; patients aged 6 to 18 years who developed HA in at least one of the lower limb joints due to severe haemophilia (total lower limb HJHS ≥3); to be receiving prophylaxis but have no major bleeding that could affect the musculoskeletal system in the past two weeks; and who did not perform regular physical activity and sports.
16339015|NCT04406519||Control Group|The control group was consisted of healthy peers. The exclusion criteria in the control group were as follows: who had any auditory and visual impairment; who underwent orthopedic injuries including lower limb; and who had any neurological or cognitive impairment that could affect balance.
16339016|NCT04406506||Group A|Group A received nasogastric feeding (NG), insure through ngt pump
16339017|NCT04406506||Group B|"receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.
~Patients were placed in right lateral position"
16339050|NCT04406285|Experimental|Lymphoma Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
16339089|NCT04405934|Other|Genomic-sequence informed IPC measures|Cohort follow baseline (no report receipt), then rapid vs standard sequencing report receipt phase, then return to baseline phase (no report receipt)
16339354|NCT04404049|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
16339018|NCT04406493|Experimental|COVID 19 patients|"COVID 19 patients are admitted to the Infectious Diseases Unit, will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.
~During the hospitalization each patient will undergo this examination twice a day until discharged.
~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need for mechanical ventilation will be measured."
16339019|NCT04406480|Other|90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)|
16339020|NCT04406454||Heathy volunteers|Patients has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, calf and at least a nevus without superficial scales and crusting.
16339024|NCT04406428|Experimental|NKI followed by EBD|
16339025|NCT04406428|No Intervention|Standard EBD|
16339031|NCT04406402|Experimental|Acute glucose tolerance test|A standard oral glucose tolerance test (75 grams of dextrose in 180 cc of water)
16339032|NCT04406402|Experimental|Acute protein load test|A protein-rich, vanilla-flavored powder (Pro-gym, Telpharma, Is
16339033|NCT04406402|Experimental|Acute fat load test|a 100-gram portion of sweet cream containing 300 Kacls, of which 94% of the ingested calories were fat
16339034|NCT04406402|Experimental|Acute alcohol load test|Vodka (100 cc, 40% alcohol)
16339035|NCT04406402|Experimental|Acute exercise|30 minutes of supervised graded walking on a treadmill according to each subject's individual ability. A goal heart rate was calculated as 70% of the age-adjusted maximal allowable heart rate.
16339036|NCT04406402|Experimental|Lifestyle modification program - 12 weeks|12 weeks of weight-loss dietary program constructed according to the guidelines of the American Diabetes Association. Based on weight, gender, and age, daily dietary allowance varied at 1200-1800 Kcal, 50% carbohydrates, 20% protein, and 30% fat. Participants were also asked to engage in moderate physical activity comprised of a 40-minute walk three times a week. A weekly clinic visit alternating with a weekly telephone contact was also required.
16339037|NCT04406389|Active Comparator|Intermediate Dose Prophylaxis|"Subjects will receive one of the following interventions, at their physician's discretion:
~Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min
~Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min
~If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.
~Fondaparinux (if history of heparin-inducted thrombocytopenia [HIT]) 2.5 mg daily subcutaneously"
16339038|NCT04406389|Experimental|Therapeutic Dose Anticoagulation|"Subjects will receive one of the following interventions, at their physician's discretion:
~Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).
~Enoxaparin 1 mg/kg subcutaneously every 12 hours
~Argatroban (if heparin-induced thrombocytopenia [HIT]), dosed according to institutional protocol.
~Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:
~≥100 kg: 10 mg daily
~<100 kg but ≥50 kg: 7.5 mg daily
~<50 kg: 5 mg daily"
16339039|NCT04406376|Active Comparator|Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)
16339040|NCT04406376|Active Comparator|No Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)
16339041|NCT04406350|Experimental|Study group - MRI CO2 and O2 stress test|Pilot Study of Feasibility of tight control of end-tidal respiratory gases during conduct of anesthesia
16339042|NCT04406337|Experimental|Low intensity pulsed ultrasound|Participants in this arm will receive low intensity pulsed ultrasound therapy on the affected knees for 20 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
16339043|NCT04406337|Active Comparator|High intensity continuous ultrasound|Participants in this arm will receive high intensity continuous ultrasound therapy on the affected knees for 10 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
16339044|NCT04406324||SARS-CoV-2 patients|Patients infected by SARS-CoV-2
16339045|NCT04406298|Experimental|Small Quantity Paracentesis|Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
16339046|NCT04406298|Active Comparator|Large Volume Paracentesis|Large Volume Paracentesis > 5 litres
16339047|NCT04406285|Active Comparator|Leukemia Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
16339048|NCT04406285|Experimental|Leukemia Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
16339088|NCT04405947|Other|antero-superior|antero-superior approach
16339051|NCT04406272|Experimental|Before and After Surgery|"VB-111 will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.
~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
16339052|NCT04406272|Experimental|After Surgery|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.
~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
16339053|NCT04406272|Experimental|After Surgery Standard of Care|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.
~Upon recovery from surgery, participants will receive standard of care treatment every 6 weeks until tumor growth is evidenced a two consecutive time points."
16339054|NCT04406259|Other|Verapamil|administration of verapamil to treat cluster headache
16339055|NCT04406246|Experimental|Nitazoxanide early treatment|Health workers with symptoms of COVID-19 not requiring hospitalization will receive an early treatment with nitazoxanide.
16339056|NCT04406220|Active Comparator|Small clog size|
16339057|NCT04406220|Active Comparator|Large clog size|
16339058|NCT04406207||Patients|Patients relapsing or not after hematopoietic stem cell transplantation.
16339059|NCT04406194|Experimental|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
16339060|NCT04406194|Experimental|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
16339061|NCT04406181|Other|operation deferred|Adult patients whose operation date has been deferred due to the pandemic
16339062|NCT04406181|Other|no operation date|Patients who did not have had an operation date and who were told to need cardiac surgery before the pandemic started
16339063|NCT04406181|Other|postoperative consultation deferred|Patients who have been operating on during the month before the pandemic
16339064|NCT04406155||Patients with suspicion of rectosigmoid endometriosis|
16339065|NCT04406142|Experimental|treatment feasibility|feasibility, safety and effectiveness assessment
16339066|NCT04406129|Experimental|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
16339067|NCT04406129|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
16339068|NCT04406116|Experimental|patients receiving microwave therapy using the HS1 Instrument|
16339069|NCT04406103|Experimental|Sleepwell|Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)
16339070|NCT04406103|Active Comparator|Empower|Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)
16339071|NCT04406103|No Intervention|TAU|Treatment-as-usual group: no mailed intervention package.
16339072|NCT04406077|Experimental|Intervention|Patients suffering from hydrocele, underwent treatment using Ligasure device.
16339073|NCT04406064|Experimental|Viral Specific T-cells (VSTs)|
16339074|NCT04406051|Active Comparator|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive colloid preloading (5 mL/kg)
16339075|NCT04406051|Active Comparator|norepinephrine infusion and crystalloid co-loading (NOR-CRYS)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive crystalloid co-loading (10 mL/kg)
16339076|NCT04406038||Healthy adults|Healthy adults randomly sampled from the population of Saint Petersburg
16339077|NCT04406025||participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have attended a Regional Anesthesia Seminar taking place once a year
16339078|NCT04406025||no participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have not attended a Regional Anesthesia Seminar taking place once a year
16339079|NCT04406012|Active Comparator|block group|Paravertebral group at Thoracic 9-10 vertebrae level with an in-plane technique advanced ultrasound guided 10 ml bupivacaine hydrochloride (Marcaine 0.5%, Astra Zeneca) in 20 ml volume was enjected in the paravertebral area with real-time visualisation It was observed that the local anesthetic drug spread on the pleura and the pleura was pushed. All blocks were performed by the same experienced anaesthesiologist.
16339080|NCT04406012|No Intervention|Control group|Conventional analgesia methods were applied to the control group. Control group was relieved by dexketoprofen 50mg intravenously. If the patient was not relieved with dexketoprofen and VAS score >4, tramadol 1 mg kg-1 was administered intravenously.
16339081|NCT04405999|Experimental|Treatment group|medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride
16339082|NCT04405999|No Intervention|Control group|medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride
16339083|NCT04405986|Experimental|Electrophysiological procedure|Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection
16339084|NCT04405973||COVID-19 ARDS, vv-ECMO|All patients in the study centers with diagnosed COVID-19 infection (PCR proven) and treatment with vv-ECMO
16339085|NCT04405960|Experimental|Intervention group|Individuals in intervention group were given oral Vitamin D supplements (Alphacalcidol 1 µg) once daily
16339086|NCT04405960|Placebo Comparator|Control Group|Individuals in control group were given placebo once daily
16339087|NCT04405947|Other|deltopectoral|deltopectoral surgical approach
16339090|NCT04405921|Experimental|Hydroxychloroquine associated to azithromycin|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. Azithromycin: 500 mg at day 1 then 250 mg/day for 4 days. with standard of care in association to treatments.
16339091|NCT04405921|Active Comparator|Hydroxychloroquine with placebo|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. with standard of care in association to treatments.
16339092|NCT04405908|Active Comparator|Adult Group 1|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.
16339093|NCT04405908|Active Comparator|Adult Group 2|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
16339094|NCT04405908|Active Comparator|Adult Group 3|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
16339095|NCT04405908|Active Comparator|Adult Group 4|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .
16339096|NCT04405908|Active Comparator|Adult Group 5|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
16339097|NCT04405908|Active Comparator|Adult Group 6|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
16339098|NCT04405908|Active Comparator|Adult Group 7|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .
16339099|NCT04405908|Active Comparator|Adult Group 8|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
16339100|NCT04405908|Active Comparator|Adult Group 9|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
16339101|NCT04405908|Active Comparator|Elderly Group 10|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
16339102|NCT04405908|Active Comparator|Elderly Group 11|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
16339103|NCT04405908|Active Comparator|Elderly Group 12|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
16339104|NCT04405908|Active Comparator|Elderly Group 13|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
16339105|NCT04405908|Active Comparator|Elderly Group 14|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
16339106|NCT04405908|Active Comparator|Elderly Group 15|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
16339107|NCT04405895|Experimental|Breakfast Diet (3Mdiet)|The Breakfast Diet (3Mdiet) will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
16339108|NCT04405895|Active Comparator|Allday Diet (6Mdiet)|The Allday Diet (6Mdiet) will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% in each of the three snacks.
16339109|NCT04405843|Experimental|Ivermectin|Ivermectin, 300 micrograms / kg, once daily for 5 days
16339110|NCT04405843|Placebo Comparator|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
16339111|NCT04405804|Experimental|Ivabradine|Eligible patients will be given treatment with ivabradine during a titration period which will last from a minimum of 3 days to a maximum of 15 days. This will be followed by a maintenance period of another 14 days. At the end of maintenance period, primary endpoint will be assessed. After maintenance period, the patient will continue ivabradine at the same dosage during a follow-up period that will last 4 months.
16339112|NCT04405791|Experimental|Active stimulation group|"low intensity transcranial focused ultrasound (tFUS) stimulationThe acoustic intensity output of the FUS transducer was validated at the maximum intensity area using a calibrated needle hydrophone (HNR-500, Onda). The incident acoustic intensity and pressure at the FUS focus were 3W/cm2 spatial-peak pulse-average acoustic intensity (Isppa) and a peak negative pressure (Pr) of 300 kPa. The incident acoustic intensity and pressure at the FUS focus were 3W/cm2, and tone burst duration was 1 ms at 50 % duty cycle (thus, pulse repletion frequency was 500 Hz) for the duration of 300 ms, according to the studies in humans. Each sonication was delivered every 6 s for the duration of 20 min (a total FUS stimulation per each session was therefore 200 times). With a derating factor of 55% reduction in pressure transmission by the human skull, estimated in situ Pr was ~135 kPa with an in situ acoustic intensity of 600 mW/cm2 Isppa ."
16339113|NCT04405791|Sham Comparator|Sham stimluation group|"sham stimulation In case of sham stimulation, the same procedure was repeated without providing actual sonication. No subjects in FUS condition hear/feel any tangible somatosensory phenomena; therefore, the sham condition was indistinguishable."
16339114|NCT04405778|Experimental|TAK-102 Cohort 1|TAK-102, 1 × 10^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 30 minutes.
16339115|NCT04405778|Experimental|TAK-102 Cohort 2|TAK-102, 1 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 30 minutes.
16339116|NCT04405778|Experimental|TAK-102 Cohort 3|TAK-102, 1 × 10^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 30 minutes.
16339117|NCT04405765|Active Comparator|Lyopreserved Stravix|Treated with NPWT and lyopreserved Stravix
16339118|NCT04405765|Active Comparator|Cryopreserved Stravix|Treated with NPWT and cryopreserved Stravix
16339119|NCT04405752||12-mm diameter metallic billiary stent|
16339120|NCT04405752||10-mm diameter metallic billiary stent|
16339121|NCT04405739|Experimental|EIDD-2801 twice daily (BID) for 5 days|EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
16339122|NCT04405739|Placebo Comparator|placebo (PBO) twice daily (BID) for 5 days|Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP
16339123|NCT04405713|Active Comparator|from the onset of symptoms within the first 3 days (group 1)|ELC for ACC from the onset of symptoms within the first 3 days (group 1)
16339124|NCT04405713|Active Comparator|from the onset of symptoms within the 4-7 days|ELC for ACC from the onset of symptoms within the4-7 days (group II)
16339125|NCT04405713|Active Comparator|from the onset of symptoms beyond 7 days|ELC for ACC from the onset of symptoms beyond 7 days (group III)
16339126|NCT04405700||Cohort 1 (C1)|Prospective recruitment of pregnant women enrolling in ANC at the site. All HIV+ pregnant women and a 1:1 systematic sample of HIV- pregnant women enrolling in antenatal clinic at the site will be prospectively enrolled in the study. In addition, medical record data for the mother and infant will be collected at the time of delivery for all women who deliver at the site and as such will contribute to a subset of C2 (below). Women enrolled in C1 who do not deliver at the site will be contacted by phone and through field follow-up to ascertain their pregnancy and infant outcomes. Infants born to women enrolled in this component who are suspected of having CAs will be enrolled as outlined in C3 (below) if their mothers deliver at the site. If their mothers do not deliver at the site these infants will be enrolled in the field. Photos/videos of infants with CAs will also be taken for review and classification by a panel of experts (see C3 below).
16339127|NCT04405700||Cohort 2 (C2)|Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
16339128|NCT04405700||Cohort 3 (C3)|Photos/videos of infants with CAs. All newborn infants and stillbirths ≥ 24 weeks gestational age delivered at the site, as well as all infants born to women enrolled in C1, will be assessed by surface exam for the presence of CAs. Video and photographs will be taken of CAs identified on surface exam. These images will be reviewed and classified by panel of experts in genetics, dysmorphology and teratology. Mothers of infants with major CAs will be contacted by phone at 1, 6, and 12 months post-delivery to ascertain their infants' vital status and care engagement status.
16339129|NCT04405687||Severe head and face deformity|
16339130|NCT04405674|Experimental|Tislelizumab plus chemotherapy|Tislelizumab plus Carboplatin/Nab-paclitaxel as induction treatment and followed by Tislelizumab plus pemetrexed as maintenance treatment.
16339131|NCT04405622|Experimental|Toripalimab plus gemcitabin arm|Subjects receive gemcitabine and toripalimab.
16339132|NCT04405609|Experimental|ArmAssist group|"The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage).
~Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months.
~The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians."
16339133|NCT04405596|Experimental|Ambroxol|Participants randomized to the 1350 mg/day group will begin with a dose of 450 mg, increasing bi-weekly to a dose of 1350 mg/day.
16339134|NCT04405596|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
16339135|NCT04405570|Experimental|EIDD-2801 twice daily (BID) for 5 days|Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, Dose H, Dose, I
16339136|NCT04405570|Placebo Comparator|placebo (PBO) twice daily (BID for five days|
16339137|NCT04405544|Other|Main|patients with COVID-19 and Acute Encephalopathy
16339138|NCT04405544|Other|Control|patients with COVID-19 without Acute Encephalopathy
16339139|NCT04405531|Experimental|task-oriented training(TOT)|The first phase of the TOT, functional activity analysis, was performed for the activities, for which performance problem was determined by Canadian Occupational Performance Measure (COPM) and Functional Independence Measure for Children (WeeFIM). In the second phase, the occupational performance, fatigue and functional independence levels that prevent the realization of the activity were determined by functional activity analysis. These designated occupational performance, fatigue and functional independence levels constitute the task of this study, as we aim to improve children's functionality. In the third phase, various functional activities including these tasks were executed. The TOT was practiced by following the above mentioned steps for each performance area. All the activities were designed for the inpatient settings of children.
16339140|NCT04405531|Experimental|conventional occupational therapy (COT)|The treatment efficacy determined by the therapist was provided by considering the functional level in order to achieve the desired goal by the participant. The COT included functional activities based on the client-centered principles of the neuro-developmental approach. All the sessions started with relaxation training combined with breathing exercises. At the end of approximately 10 minutes of application time, individualized functional activities were implemented.
16339141|NCT04405518|Active Comparator|Control group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.
~Formula: 8mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
16339142|NCT04405518|Experimental|intervention group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.
~Formula: 11mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
16339143|NCT04405505|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16339144|NCT04405505|Active Comparator|Paclitaxel for injection (albumin bound)|Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.
16339145|NCT04405492|Experimental|Population 1 : Patients|Hospitalized patients, positive or suspected of SARS-CoV-2 infection
16339146|NCT04405492|Experimental|Population 2 : Hospital caregivers exposed to SARS-CoV-2|Longitudinal study of a hospital caregiver cohort
16339147|NCT04405492|Experimental|Population 3 : Lay users|Suitability of rapid test in view of its intended purpose for self-testing
16339150|NCT04405466||Group 1|Workers working within a production area
16339151|NCT04405466||Group 2|Workers working within a laboratory area
16339152|NCT04405466||Group 3|Workers working within other areas
16341553|NCT04388514|Experimental|Blood ozonization|Blood ozonization plus BAT
16339153|NCT04405453|Active Comparator|Trapezius Muscle İnjection (TMI) group|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
16339154|NCT04405453|Active Comparator|Erector Spina Plane Block (ESPB) group|ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
16339155|NCT04405440||Healthy controls|The healthy control group will perform a well-validated avoidance (behavioral) task and will fill in some questionnaires about eating behaviors, emotions, and feelings.
16339156|NCT04405440||Anorexia Nervosa patients|As the healthy controls, the participants of the anorexia nervosa group will perform the same behavioral task and will fill in the same questionnaires
16339157|NCT04405427|Experimental|head acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the head
16339158|NCT04405427|Active Comparator|body acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the body
16339159|NCT04405401|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
16339160|NCT04405401|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
16339161|NCT04405388|Other|Spermidine first|First treatment period (8 weeks) will be 4 mg spermidine per day orally. Afterwards 4 weeks of wash-out followed by 8 weeks of placebo treatment.
16339162|NCT04405388|Other|Placebo first|First treatment period (8 weeks) will be placebo. Afterwards 4 weeks of wash-out followed by 8 weeks of 4 mg spermidine per day orally.
16339163|NCT04405375|Experimental|treatment arm|gemcitabine 1.25g/㎡ d1, pegaspargase 2500IU/㎡ d1 (max dose =<3750IU) etoposide 75mg/㎡ d1-3 dexamethasone 20mg d1-4 repeated every 21 days, up to 6 cycles.
16339164|NCT04405349|Experimental|Combination Therapy|VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
16339165|NCT04405336|Active Comparator|giving tab block|giving patients tab block
16339166|NCT04405336|Active Comparator|giving PCA|Giving PCA to patients
16339167|NCT04405336|No Intervention|Patients who will not receive PCA or tab block|No tab block or PCA
16339168|NCT04405323|Experimental|Lu AG06466 - Sequence 1|Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.
16339169|NCT04405323|Experimental|Lu AG06466 - Sequence 2|Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.
16339170|NCT04405310|Experimental|EXP-PC-F2|Patients with Pneumonia due to SARS-COV-2 phase 2 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
16339171|NCT04405310|Placebo Comparator|EXP-NONPC-F2|20 Patients with Pneumonia due to SARS-COV-2 phase 2 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
16339172|NCT04405310|Experimental|EXP-PC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
16339173|NCT04405310|Placebo Comparator|EXP-NONPC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
16339179|NCT04405271|Experimental|FTC/TAF|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks.
16339180|NCT04405271|Placebo Comparator|Placebo|Identical tablets to the active experimental tablets with the same characteristics and packaging. A dose of 1 tablet per day will be administered for a total of 12 weeks
16339181|NCT04405258|Active Comparator|PVI alone|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
16339182|NCT04405258|Active Comparator|PVI and PWI|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
16339183|NCT04405245|Experimental|AKB-9778 QD + Latanoprost|• AKB-9778 QD (AM) and placebo for AKB-9778 ophthalmic solution QD (PM) plus latanoprost QD (PM) for 28 days
16339184|NCT04405245|Experimental|AKB-9778 BID + Latanoprost|• AKB-9778 BID (AM & PM) plus latanoprost QD (PM) for 28 days
16339185|NCT04405245|Placebo Comparator|Placebo BID + Latanoprost|• Placebo for AKB-9778 ophthalmic solution BID (AM & PM) plus latanoprost QD (PM) for 28 days
16339186|NCT04405219|Sham Comparator|smokers (S)|
16339187|NCT04405219|Active Comparator|non smokers (NS)|
16339188|NCT04405206||Group A:Clinical complete response (cCR)|Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
16339189|NCT04405206||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
16339190|NCT04405206||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation
16339191|NCT04405193|Experimental|Treatment|2 capsules, each containing 600 mg N-acetylcysteine administered once daily every morning.
16339193|NCT04405180|Experimental|20 mg Sodium Nitrite TID Arm|Subject is to receive active study drug three times per day during treatment (12 weeks +/- 5 days) period and then after the treatment period (up to 16 weeks total).
16339194|NCT04405180|Placebo Comparator|Placebo Control Arm|Subject is to receive placebo three times per day during treatment period (12 weeks +/- 5 days) and then after the treatment testing period (up to 16 weeks total).
16339195|NCT04405167|Experimental|A1: Tasquinimod single agent dose escalation|There are up to 5 planned dose levels, with 3 de-escalation dose levels available in case dose level 1 is determined to exceed the MTD. This arm will enroll 15-30 subjects if all dose levels are explored.
16339196|NCT04405167|Experimental|A2: Tasquinimod single agent expansion|Additional subjects will enroll in arm A2 at the MTD and optimal schedule, so that 12 subjects total who are evaluable for response will have received the MTD/optimal schedule of single agent tasquinimod. Enrollment in arm A2 will not begin until enrollment in arm A1 has been completed and a single agent MTD/optimal schedule has been established.
16339197|NCT04405167|Experimental|B1: Tasquinimod+IRd dose escalation|Dose levels will be defined according to the same tasquinimod doses as in the single agent (Arm A1) dose escalation. Enrollment in arm B1 will not begin until enrollment in arm A1 has been completed and an MTD/optimal schedule has been established for single agent tasquinimod. Initial subjects in arm B1 will be enrolled at the lower of dose level 1 or one dose level below the single agent MTD . If this initial dose level is determined to exceed the combination MTD, further subjects will be enrolled at one dose level lower. Enrollment is not planned in arm B1 at doses higher than the single agent MTD. There are 9-12 planned subjects if all dose levels are explored.
16339198|NCT04405167|Experimental|B2: Tasquinimod+IRd expansion|Additional subjects will enroll in arm B2 at the MTD and optimal schedule, so that 12 subjects total who are both evaluable for response and previously refractory to their most recent Imid/PI combination will have received the MTD/optimal schedule of tasquinimod in combination with ixazomib, lenalidomide, and dexamethasone. Enrollment in arm B2 will not begin until enrollment in arm B1 has been completed and a combination MTD/optimal schedule has been established.
16339199|NCT04405154|Experimental|Investigational Arm|Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
16339200|NCT04405115|No Intervention|No intervention arm|routine care only; will not be scheduled for comprehensive geriatric assessment
16339201|NCT04405115|Active Comparator|Active comparator arm|those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician
16339202|NCT04405102|Experimental|Ozanimod + standard of care|During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).
16339203|NCT04405102|Active Comparator|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
16339204|NCT04405089|Experimental|Active tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over right frontal cortex, cathode over left frontal cortex; 2 mAmps for 26 minutes).
16339205|NCT04405089|Sham Comparator|Sham tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
16339206|NCT04405076|Experimental|mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29.
~Part B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
16339207|NCT04405076|Experimental|mRNA-1273: Dose 50 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29.
~Part B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
16339208|NCT04405076|Experimental|mRNA-1273: Dose 100 ug - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.
~Part B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
16339209|NCT04405076|Experimental|mRNA-1273: Dose 100 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.
~Part B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
16339210|NCT04405076|Placebo Comparator|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.
~Part B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
16339211|NCT04405076|Placebo Comparator|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.
~Part B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
16339212|NCT04405076|Experimental|mRNA 1273.351 20 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.
16339213|NCT04405076|Experimental|mRNA 1273.351 50 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.
16339214|NCT04405076|Experimental|mRNA-1273/mRNA-1273.351 mixture (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.
16339219|NCT04405037|Experimental|Alvimopan Group|"Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.
~All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol."
16339220|NCT04405037|No Intervention|Control Group|Control patients will follow a standard ERAS pathway after surgery, including NPO status, IV fluid rehydration, and nasogastric decompression, early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.
16339221|NCT04405024|Other|Hepatitis C testing|"If the patient is included in the study, HCV serology (2 x 5 ml tubes) will be taken at the time of admission as part of the routine entry assessment.
~These two tubes will be used for HCV screening. The patient is informed of the HCV serology result during hospitalization by an investigator."
16339222|NCT04405011|Experimental|Entecavir 0.5mg daily for 24 weeks|Entecavir will be delivered for 24-week and will be the experimental arm
16339223|NCT04405011|Active Comparator|Entecavir 0.5mg daily for 12 weeks|12-week entecavir will be served as active comparator
16339224|NCT04405011|No Intervention|Control|Control group does not receive prophylactic ETV
16339225|NCT04404998|Experimental|Lower Energy Density & Lower Satiation|Test meal with lower energy density and lower satiation information
16339226|NCT04404998|Experimental|Lower Energy Density & Higher Satiation|Test meal with lower energy density and higher satiation information
16339227|NCT04404998|Experimental|Higher Energy Density & Lower Satiation|Test meal with higher energy density and lower satiation information
16339228|NCT04404998|Experimental|Higher Energy Density & Higher Satiation|Test meal with higher energy density and higher satiation information
16339229|NCT04404985|Active Comparator|Surgical AVFs|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an Surgical AVF intervention group that will undergo a routine surgical AVF creation.
16339230|NCT04404985|Experimental|Endo-vascular AVF|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an endo-vascular AVF intervention group that will undergo a per-cutaneous AVF creation.
16339231|NCT04404959|Active Comparator|fascia iliaca compartment block with ropivacaine|in this arm, the fascia iliaca compartment block will be performed with 40 mL ropivacaine 0.25%
16339232|NCT04404959|Placebo Comparator|fascia iliaca compartment block with placebo|in this arm, the fascia iliaca compartment block will be performed with 40 mL normal saline
16339233|NCT04404946|Active Comparator|phenylephrine infusion|fixed-rate phenylephrine infusion
16339234|NCT04404946|Active Comparator|norepinephrine infusion|fixed-rate norepinephrine infusion
16339235|NCT04404946|Placebo Comparator|placebo infusion|normal saline infusion
16339236|NCT04404907||Males who never deliberately tan|Males responded to an anonymous online survey that they never deliberately tan
16339237|NCT04404907||Males who ever deliberately tan|Males responded to an anonymous online survey that they had ever deliberately tan
16339238|NCT04404894||Prolaris tested patients with Prostate Cancer|Recently diagnosed patients with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites who have undergone Prolaris testing.
16339239|NCT04404881|Experimental|Bevacizumab|"The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. Each period consists of 12 weeks, for a total of 36 weeks.
~Pretreatment Period:Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.
~Induction Period (first 3 months of bevacizumab treatment):
~Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.
~Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.
~Maintenance Period (second 3 months of bevacizumab treatment):
~Hematologic Support: Iron transfusions and red cell transfusions as determined by study doctor.
~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
16339240|NCT04404868||Enrolled patients|"Each patient (whether hospitalized or outpatient) included in the study underwent to a baseline evaluation in which near and remote pathological history were recorded (main concomitant pathologies, drug therapy in progress, previous major surgery) and the following evaluation scales were administered: modified Ashworth scale (MAS), MI (motricity index), FMA (Fughl Meyer assessment) and Modified Rankin' scale (MRS).
~Each patient will subsequently undergo to a follow-up evaluation at 4, 12 and 24 weeks after the date of inoculation through the execution of a specialist visit (physiatric/neurological) and the administration of the following evaluation scales: MAS, MI, FMA and MRS. For the duration of the study, each patient may undergo integrated rehabilitation treatment at the discretion of each of the investigators of each centre involved in the study according to the guidelines and common clinical practice."
16339241|NCT04404855|Other|Intervention Group (NGS + Antibiotic Recommendation)|Next Generation Sequencing results along with Infectious Disease Pharmacist will be shared with clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
16339242|NCT04404855|Other|Control Group|NGS results will not be shared with the clinical provider at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
16339243|NCT04404842||EvidenceQ Cohort|Adult subjects, aged over 18 years, male and female.
16339244|NCT04404829|Experimental|Informational Manual Therapy|It is an integral no orthopedic and very soft manual therapy
16339245|NCT04404816|Experimental|Group 1|premature infants born < 33 G.A. enrolled in the first 72 hours after birth, with respiratory distress syndrome, requiring non-invasive ventilation with FiO2 <0.4
16339246|NCT04404816|Experimental|Group 2|premature infants born < 33 G.A. with respiratory insufficiency requiring mechanical ventilation, after more than 1 failed extubation attempt
16339247|NCT04404790|Experimental|Anfibatide 5 IU/60kg|Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.
16339355|NCT04404049|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
16339248|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
16339249|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
16339250|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
16339251|NCT04404790|Experimental|Anfibatide 7 IU/60kg|Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.
16339252|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
16339253|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
16339254|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
16339255|NCT04404777||Patients with local recurrence|
16339256|NCT04404764||Treated with nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III treated with nusinersen in the Brazilian Unified Public Health System
16339257|NCT04404764||With indication to receive nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III with indication, but not yet receiving nusinersen treatment in the Brazilian Unified Public Health System
16339258|NCT04404751|Active Comparator|Arm 1|
16339259|NCT04404751|Active Comparator|Arm 2|
16339260|NCT04404751|Sham Comparator|Arm 3|
16339261|NCT04404738|Experimental|MicroPort® Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using MicroPort® surgical system
16339262|NCT04404738|Active Comparator|da Vinci Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using da Vinci surgical system
16339263|NCT04404725|Experimental|comfilcon A then samfilcon A|Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study.
16339264|NCT04404725|Active Comparator|samfilcon A then comfilcon A|Subjects were randomized to wear samfilcon A for one month then comfilcon A for one month in this randomized, bilateral cross-over study.
16339265|NCT04404712|Experimental|[11C]MK-3168 PET Scan|
16339266|NCT04404686|Experimental|Indomethacin group|Group of patients receiving Indomethacin for preterm labor treatment.
16339267|NCT04404686|Active Comparator|Nifedipine group|Group of patients receiving Nifedipine for preterm labor treatment.
16339268|NCT04404673||Open rectal resection|
16339269|NCT04404673||Laparoscopic rectal resection|
16339270|NCT04404673||Robotic rectal resection|
16339271|NCT04404673||Trans-anal TME (Ta-TME)|
16339272|NCT04404660|Experimental|AUTO1|
16339273|NCT04404647|Experimental|Intervention|Selected patients who choose to participate will undergo ablation of the target lesion using irreversible electroporation.
16339274|NCT04404621|Experimental|Cross-Over Sequence A|Participants in this arm will be randomized to receive the 18 week program first and be in treatment as usual comparison condition in the following 18 weeks.
16339275|NCT04404621|Experimental|Cross-Over Sequence B|Participants in this arm will be randomized to remain in treatment as usual during the first 18 week period and then receive the 18 week program during the following 18 weeks.
16339276|NCT04404608||Asymptomatic or mild symptoms patients patients|Patients with no or mild symptoms and need no respiratory support.
16339277|NCT04404608||Severe symptoms patients|Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.
16339278|NCT04404608||Critically ill patients|Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients
16339279|NCT04404595|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Phase 1 will include two parts, a dose escalation part to determine the recommended dose for the expansion part. During expansion patients will be treated with the recommended dose determined in the expansion part.
16339280|NCT04404582||Klebsiella pneumoniae|patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients.
16339281|NCT04404569|Experimental|Continued Treatment|"Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study.
~The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose."
16339282|NCT04404556|Experimental|Diabetes Journey|Diabetes Journey is a web-based intervention to address key adherence barriers. Participants randomized to this arm will first receive the mandatory Introduction and Problem-Solving Module. Based on their elevations on the Barriers to Diabetes Adherence measure, participants will receive up to 7 modules in total. Participants will navigate through the web-based theme park map and complete modules independently and then will have accompanying Zoom telehealth sessions with a therapist.
16339283|NCT04404556|Active Comparator|Enhanced Standard of Care|Participants randomized to Enhanced Standard of Care will receive general education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) from each site across 12-weeks. Content to address adherence barriers were modified and or newly developed for the Enhanced Standard of Care group via the T1DToolkit website.
16339356|NCT04404049|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
16339284|NCT04404543|Experimental|Escalation Cohort|"Five dose levels will be tested according to the 3 + 3 dose-escalation design.
~The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1807 to the end of the first cycle (28 days)."
16339285|NCT04404543|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 12~40 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D.
16339286|NCT04404530||Palynziq Therapy for PKU|Participants with PKU who are starting Palynziq therapy.
16339287|NCT04404517|Active Comparator|40mg1w|Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks
16339288|NCT04404517|Active Comparator|80mg2w|Adalimumab at an administration of 80 mg every two weeks
16339289|NCT04404491|Active Comparator|PD-1 and Concurrent chemoradiotherapy|Camrelizumab: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
16339290|NCT04404491|Placebo Comparator|placebo and Concurrent chemoradiotherapy|placebo: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
16339291|NCT04404478|Experimental|B-SWELL|Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
16339292|NCT04404478|Active Comparator|WE|The attention control group (WE), will include education about healthy lifestyle behaviors and peer support. The attention control groups will also have weekly sessions for eight weeks in groups of 11 to 13 midlife Black women. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
16339293|NCT04404465||Control Group|Participants undergoing electrophysiologic (EP) study or ablation for supraventricular tachycardia (SVT) with no history of AF and does not meet criteria of At Risk Group or AF Group
16339294|NCT04404465||At Risk Group|"Participants with no prior diagnosis of AF and have:
~two or more of the following criteria:
~Age >65 years of age
~A diagnosis of hypertension
~A diagnosis of diabetes
~A diagnosis of sleep apnea
~A body mass index (BMI) ≥30
~Stable heart failure (HF) with preserved or reduced ejection fraction (New York Heart Association Class I, II or III)
~Chronic kidney disease (CKD) not requiring dialysis
~AND/ OR
~More than 5% premature atrial complex (PAC) burden on ambulatory ECG monitoring (e.g. holter, ZioPatch, Lifewatch, etc.)"
16339295|NCT04404465||AF Group|Participants who have a history of non-valvular AF or Atrial Flutter (AFL) documented on ECG or ambulatory monitoring within 1 year of enrollment
16339296|NCT04404439|Experimental|Nortriptyline + topiramate|Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
16339297|NCT04404439|Experimental|Verapamil + paroxetine|Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
16339298|NCT04404439|Placebo Comparator|Placebo|Placebo pill.
16339299|NCT04404426|Experimental|L-citrulline|Administration of citrulline enterally for 7 days
16339300|NCT04404426|Placebo Comparator|Placebo|Administration of placeboenterally for 7 days
16339301|NCT04404413|Experimental|PARTICIPANTS|A single-group crossover design was used to compare the effects of 2x8 weeks of high-intensity interval training without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance. There were two weeks in the middle of both phases in which they did not carry out programmed activity, in order not to alter the experimental phase.
16339304|NCT04404387|Experimental|Experimental arm|vitamin C 50 mg/kg every 6 hours for 96 hours.
16339305|NCT04404387|Placebo Comparator|Control arm|Placebo administration
16339306|NCT04404374|Active Comparator|A-PRF|Advanced Platelet-Rich Fibrin
16339307|NCT04404374|Active Comparator|EMD|Enamel Matrix Derivatives
16339308|NCT04404361|Experimental|Pacritinib and SOC|Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC
16339309|NCT04404361|Placebo Comparator|Placebo and SOC|4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC
16339310|NCT04404348|Experimental|Intervention|Three times per week for four weeks, participants will complete a computerized cognitive training session (approximately 30 minutes long).
16339311|NCT04404348|Placebo Comparator|Control|Three times per week for four weeks, participants will complete a computerized session (approximately 30 minutes long) that consists of inert computer games.
16339312|NCT04404335||Healthy (control group)|"This group will include a total of 30 patients free of periodontitis Samples of crevicular fluid to quantity levels of antimicrobial peptide LL-37 will be taken at baseline
~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
16339313|NCT04404335||Periodontitis (test group)|"60 Periodontal patients (subdivided in 2 groups of 30, depending of the severity of their disease):
~30 patients with Stage I-II periodontitis (mild/moderate)
~30 patients with Stage III-IV periodontitis (severe).
~Two sets of samples of crevicular fluid will be obtained before and after receiving a course of routine basic periodontal treatment (root scaling and planing).
~A reevaluation visit to re-assess clinical periodontal parameters will take place at 4-6 weeks after treatment. New samples of crevicular fluid will then be taken at this stage to compare the level of LL-37 before and after the treatment.
~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
16339314|NCT04404322|Experimental|IPT A SCI|The IPT-A SCI follows the intervention protocol, which includes an intensive phase of 5 weekly 50-minute sessions and 3 follow up personal emails.
16339315|NCT04404322|Active Comparator|Treatment as usual|TAU patients receive an integrative combination of psychodynamic, supportive and cognitive behavioural therapy, usually lasting between 10-30 weeks.
16339316|NCT04404322|No Intervention|wait list|WL patients are monitored by a trained clinician during their waiting period and complete the study questionnaire battery at the parallel time intervals.
16339317|NCT04404309||Population 1|Any patient admitted to a psychiatric ward with a clinical diagnosis of (unipolar) major depression
16339318|NCT04404309||Population 2|Any patient with a clinical diagnosis of a moderate or severe unipolar depressive disorder with suicidal tendencies that persist for at least 48 hours after admission
16339319|NCT04404309||Population 3|Patients with moderate or severe unipolar depressive episodes validated by research interviews and suicidal tendencies that persist for at least 48 hours after admission who will be followed up for 6 months
16339320|NCT04404296|Other|25-gauge 20000 PPV|Eyes will undergo pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
16339323|NCT04404257|Experimental|ControlRad System|Participant will undergo Cardiac catheterization or electrophysiology implant procedures with the ControlRad system installed in Cath lab room 5
16339324|NCT04404257|Active Comparator|Without ControlRad System|Participant will undergo the cardiac catheterization or electrophysiology implant procedures per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
16339325|NCT04404231|Sham Comparator|No infrared light therapy|This arm does not receive any phototherapy
16339326|NCT04404231|Active Comparator|810 nm|Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
16339327|NCT04404231|Experimental|945nm|This wavelength has been chosen as a comparison to 810, to see if it works better.
16339328|NCT04404231|Experimental|random frequency|A wavelength between 650-1100nm which is picked at random
16339329|NCT04404218|Experimental|Açaí palm berry extract|Açaí palm berry extract is a powerful antioxidant with no known side-effects and is widely consumed in Brazil. Açaí palm berry chemical composition has been established and includes several antioxidants - gallic acid, catechin, chlorogenic acid, caffeic acid, p-coumaric acid, epicatechin, orientin, cyanidin-3-0-glucoside, luteolin and apigenin. Orientin is the most concentrated compound (7,96mg/g) and this compound is able to modulate the NLRP3 inflammasome.
16339330|NCT04404218|Placebo Comparator|Placebo arm|This study will be double-blinded and placebo-controlled. To ensure double-blinding, placebo and active compound capsules will be over-encapsulated with DBCAPS® capsules, which were developed with a tamper-evident design to address the clinical trial challenges of testing without bias. These capsules are made of gelatin and have no interaction with bioavailability.
16339331|NCT04404205||Adult patient with cochlear implant|Adult patients who had cochlear implant surgery before will be included. We will call patients from our cochlear implant list.
16339334|NCT04404179||CASE|59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
16339335|NCT04404166|Experimental|PINGS 2|
16339336|NCT04404166|No Intervention|Standard of Care|
16339337|NCT04404153|Experimental|Active tDCS|The active tDCS will involve 30-minutes of direct current at intensity of 2 milliamperes (mA).
16339338|NCT04404153|Sham Comparator|Sham tDCS|Sham stimulation consists of the direct current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining application period.
16339339|NCT04404140|Experimental|Ipatasertib + Atezolizumab + Docetaxel|"Part A (Safety Run-In): 12 Participants will be administered Ipatasertib orally once a day [QD] from Day 1 to Day 14 in combination with Atezolizumab administered by intravenous (IV infusion) every 3 weeks (Q3W) on Day 1 of each cycle (a cycle being 21 days) and Docetaxel administered by IV infusion (Q3W) on Day 1 of each cycle. Docetaxel will be administered for a maximum of 10 cycles (approximately 7 months), after which Atezolizumab and Ipatasertib will be administered as a doublet until disease progression. During Part A, a staggered recruitment will be applied to the first and potentially first 6 participants to enrol a participant only once the former one has safely overcome the safety time window (Cycle 1).
~Part B (Expansion): 38 Participants will be administered Ipatasertib, Atezolizumab and Docetaxel as described above, though without a staggered enrolment or safety assessment window."
16339340|NCT04404127|Placebo Comparator|No induction Arm|
16339341|NCT04404127|Active Comparator|Induction with basiliximab|
16339342|NCT04404114||Normal renal function|Normal renal function
16339343|NCT04404114||Acute kidney injury in normal kidney|Acute kidney injury in normal kidney
16339344|NCT04404114||Acute kidney injury in chronic kidney disease|Acute kidney injury in chronic kidney disease
16339345|NCT04404114||Chronic kidney disease|Chronic kidney disease
16339346|NCT04404101|Active Comparator|1). EUS-FNA plus MFB|A 19-G needle plus micro-forceps will be used for FNA plus MFB.
16339347|NCT04404101|Active Comparator|2). EUS-FNA Alone|A 19-G needle will be used for FNA alone.
16339348|NCT04404088|Experimental|Treatment (acalabrutinib, lenalidomide, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21 and rituximab IV on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
16339349|NCT04404075||Group 1 patients|"Age 18 and above
~Eczema Area and Severity Index (EASI) score ≥ 10
~Investigator Global Assessment (IGA) ≥ 3"
16339350|NCT04404075||Group 2 patients|"Age 18 and above
~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10
~Investigator Global Assessment (IGA) 1 or 2"
16339351|NCT04404075||Group 3 patients|"Age 12 to 17
~Eczema Area and Severity Index (EASI) score ≥ 10
~Investigator Global Assessment (IGA) ≥ 3"
16339352|NCT04404075||Group 4 patients|"Age 12 to 17
~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10
~Investigator Global Assessment (IGA) 1 or 2"
16339357|NCT04404036|Experimental|SinuSonic Device|"Aim 1: SinuSonic device used once a day over a 2 day period.
~Aim 2: SinuSonic device used twice daily for 3 minutes in the home setting for 6 weeks.
~Aim 3: SinuSonic device used twice daily for 3 minutes in the home setting for 4 weeks."
16339358|NCT04404023|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
16339359|NCT04404023|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
16339360|NCT04404023|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
16339361|NCT04404023|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
16339362|NCT04404023|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
16339363|NCT04404010|Active Comparator|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
16339364|NCT04404010|Other|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
16339365|NCT04403997|Active Comparator|Chromoendoscopy with methylene blue 0.1%|Once the cecum is reached, a spray catheter is introduced through the working channel and the dye, a 0.1% methylene blue solution, is applied.
16339366|NCT04403997|Experimental|Virtual Chromoendoscopy with NBI with HQ190 endoscopes|Intubation is done with normal white light. Once the cecum is reached, the removal will be done in NBI mode
16339367|NCT04403984||Patients with Luminal A breast cancer|Patients confirmed with Luminal A breast cancer sub type
16339368|NCT04403984||Patients with Luminal B breast cancer|Patients confirmed with Luminal B breast cancer sub type
16339369|NCT04403971|Experimental|0.12% chlorhexidine|Participants will be randomized to Chlorhexidine solution group, applied twice a day by care givers.
16339370|NCT04403971|Sham Comparator|Listerine|Participants will be randomized to Listerine solution group, applied twice a day by care givers.
16339371|NCT04403971|Placebo Comparator|Normal saline|Participants will be randomized to Normal saline group, applied twice a day by care givers.
16339372|NCT04403958|Experimental|PRC|Total wrist arthrodesis with PRC and dorsal plate
16339373|NCT04403958|Active Comparator|TWA|Total wrist arthrodesis with dorsal plate
16339374|NCT04403945||Group 1|healthy volunteers with normal fasting blood glucose and HbA1c, without hypertension, kidney diseases, or taking drugs that affects microcirculation
16339375|NCT04403945||Group 2|type 2 diabetic patients without microvascular complications like Diabetic nephropathy, diabetic retinopathy, diabetic foot or diabetic peripheral neuropathy
16339376|NCT04403945||Group 3|type 2 diabetic patients with diabetic nephropathy diagnosed by clinic or pathology.
16339377|NCT04403919|Active Comparator|Revision total knee arthroplasty: control|
16339378|NCT04403919|Experimental|Revision total knee arthroplasty: active|
16339379|NCT04403919|Active Comparator|Revision Total Hip Arthroplasty: control|
16339380|NCT04403919|Experimental|Revision Total Hip Arthroplasty: active|
16339381|NCT04403906|Experimental|PCL Rapid Antigen Test arm|Single arm trial design. Only patients undergoing standard clinical testing (SARS-CoV-2 PCR test) and consenting for additional testing with the PCL rapid antigen test will be included
16339382|NCT04403880||Group 1|"Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3
~1A: Persons with asymptomatic infection, ages 18 through 55, inclusive
~1B: Persons with asymptomatic infection, age > 55
~1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55
~1D: Persons with symptomatic infection (ie, COVID-19), age > 55"
16339383|NCT04403880||Group 2|"Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3
~2A: Persons 18 through 55 years of age
~2B: Persons > 55 years of age"
16339384|NCT04403880||Group 3|Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
16339385|NCT04403867||Endometrial cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
16339386|NCT04403867||Cervical cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
16339387|NCT04403854||ME/CFS patients|Patients diagnosed according to Canada Criteria 2003
16339388|NCT04403854||Healthy Controls|Age and sex matched healthy controls
16339389|NCT04403841|Other|Intervention|The intervention of group education on type 2 diabetes, including, in addition to usual diabetes care
16339390|NCT04403841|Other|Control|Patients meeting the inclusion criteria assigned to usual diabetes care alone
16339391|NCT04403815||right radial access|"diagnostic coronary angiography and/or PCI performed through right wrist and distal (snuffbox) radial access"
16339392|NCT04403815||left distal radial access|"diagnostic coronary angiography and/or PCI performed through left distal (snuffbox) radial access"
16339393|NCT04403802|Experimental|Arm A: Voxx socks followed by placebo socks|Continuous wear of Voxx Human Performance Technology Socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period)
16339394|NCT04403802|Experimental|Arm B: Placebo socks followed by Voxx socks|Continuous wear of placebo socks for 2 weeks, followed by continuous wear of Voxx Human Performance Technology Socks for 2 weeks (separated by a 2-week washout period)
16339395|NCT04403789|Experimental|Intervention Group|During the intervention period they will receive 2 hours per week of group exercise sessions during working hours for 12 weeks. However, after the intervention period, there will be no change in working hours
16339396|NCT04403789|Active Comparator|Delayed Intervention Group (Control group)|During the intervention period there will be no change in working hours. However, after the intervention period they will receive 2 hours of exercise time during working hours per week for 4 weeks
16339424|NCT04403620|Experimental|Hypofractionated radiotherapy|"Dose and fractionation determined by Phase I:
~Level 1: 44.4 Gy in 12 fractions, 4 fractions/week
~Level 0: 46.5 Gy in 15 fractions, 5 fractions/week
~Level -1: 52 Gy in 20 fractions, 5 fractions/week
~Level -2: 50 Gy in 20 fractions, 5 fractions/week"
16343504|NCT04374708||homosexual cisgender men|fMRI: body morph test and neurocognitive testing
16339397|NCT04403776|Experimental|Treatment A, separated washout phase, followed Treatment B.|"Treatment A:
~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
~washout phase: no later than 72 hours
~Treatment B:
~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
16339398|NCT04403776|Experimental|Treatment B, separated washout phase, followed Treatment A.|"Treatment A:
~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
~Washout phase: no later than 72 hours
~Treatment B:
~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
16339399|NCT04403763|Active Comparator|AGN-190584|Administered as single drop in each eye
16339400|NCT04403763|Experimental|AGN-241622 Dose 3|Administered as single drop in one eye or a single drop in each eye
16339401|NCT04403763|Experimental|AGN-241622 Dose 2|Administered as single drop in one eye or a single drop in each eye
16339402|NCT04403763|Placebo Comparator|Placebo Dose|Administered as single drop in one eye or a single drop in each eye
16339403|NCT04403763|Experimental|AGN-241622 Dose 1|Administered as single drop in one eye or a single drop in each eye
16339404|NCT04403750|Experimental|Combined laser-surgical technology|"Combined laser-surgical technology includes 3 steps:
~Nd-YAG laser excision of the vitreoretinal traction zone
~Pneumatic retinopexy (10% C3F8)
~Barrier laser photocoagulation around retinal break after retinal attachment."
16339405|NCT04403737|No Intervention|Usual Care|Patients in the control arm will have a Rothman Index calculated but this will not be visible to providers.
16339406|NCT04403737|Experimental|Intervention|Patients in the intervention arm will have a Rothman Index calculated and will be visible to providers. Providers will be given a set of clinician-specific recommended-use protocols that they will be encouraged to follow based on the RI thresholds achieved by patients.
16339407|NCT04403724|Active Comparator|premixed injection|will receive an intrathecal injection of 2.4 ml hyperbaric bupivacaine 0.5%, 20 µg fentanyl, and 100 µg preservative-free morphine mixed together.
16339408|NCT04403724|Active Comparator|sequential injections|will receive an intrathecal injection of 2,4 ml hyperbaric bupivacaine 0.5% followed immediately by the opioid mixture by two separate syringes.
16339409|NCT04403711|Active Comparator|local anesthetic and dexmedetomidine|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL dexmedetomidine
16339410|NCT04403711|Placebo Comparator|local anesthetic and placebo|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL normal saline
16339411|NCT04403698|Experimental|24 weeks|Subject receiving alendronate treatment for 24 weeks (n = 20)
16339412|NCT04403698|Experimental|48 weeks|Subject receiving alendronate treatment for 48 weeks (n = 20)
16339413|NCT04403685|Experimental|Tocilizumab|Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
16339414|NCT04403685|No Intervention|Control arm|Best supportive care.
16339415|NCT04403672||COVID-19 positive|ideSHi (CRO) investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
16339416|NCT04403672||COVID-19 Negative|"ideSHi investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
~In addition, 60 fresh specimens which will be tested at IEDCR will also be tested at ideSHi using RealDetect on a real time basis. These samples will also be blinded by IEDCR and sent to the testing laboratory (ideSHi). Of these 60 samples, 30 will be COVID-19 positive and 30 COVID- 19 negative samples. These fresh samples will be provided to ideSHi for testing and analysis for performance evaluation of RealDetect COVID-19 RT-PCR kit."
16339417|NCT04403659|Experimental|Intervention|Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care
16339418|NCT04403659|No Intervention|Control|Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines
16339419|NCT04403646|Experimental|TREATED|"Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.
~Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
16339420|NCT04403646|Placebo Comparator|CONTROL|"Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.
~Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
16339421|NCT04403633|Experimental|Receiving Educational Tool|Patients in this arm will receive the educational tool after the pretest in addition to usual care.
16339422|NCT04403633|No Intervention|Receiving Usual Care|Patients in this arm will receive usual care after the pretest.
16339423|NCT04403620|Active Comparator|Conventionally fractionated radiotherapy|60 Gy in 30 fractions, 5 fractions/week
16339425|NCT04403594||MS with spasticity of one lower extremity|A person diagnosed with Multiple Sclerosis and spasticty of one lower extremity. The person must be able to walk 25 feet and cannot have had Botox in the lower extremity on the last 6 months.
16339426|NCT04403568|Experimental|Ursolic Acid|Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
16339427|NCT04403568|Experimental|Curcumin|Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
16339428|NCT04403568|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
16339429|NCT04403555|Experimental|Ivermectin|Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
16339430|NCT04403555|No Intervention|Standard of care|Standard of care treatment
16339431|NCT04403529|Experimental|Traditional Chinese Medicine|"60 days of oral Traditional Chinese Medicine (prescription for breast cancer Traditional Chinese Medicine formulation)"
16339432|NCT04403529|Placebo Comparator|Placebo|"60 days of oral placebo (placebo contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler)"
16339433|NCT04403516|Experimental|DEXTENZA Group|Patients with Pterygium DEXTENZA Group
16339434|NCT04403516|Experimental|Topical Prednisolone Acetate 1% Group|Patients with Pterygium Topical Prednisolone Acetate 1% Group
16339435|NCT04403503|Active Comparator|Gelatine Sponge|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA)
16339436|NCT04403503|Active Comparator|Gelatine sponge +Cyanoacrylate|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group)
16339437|NCT04403490|Experimental|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
16339438|NCT04403490|Active Comparator|Conventional intervention|Conventional physical and occupational therapy
16339439|NCT04403477|No Intervention|Standard treatment|Standard supportive treatment (Oxygen, Enoxaparine, antibiotic, fluid, immune modulator (Steroid) and or antiviral (favipiravir or ramdesivir or lopinavir + ritonavir)
16339440|NCT04403477|Experimental|Standard treatment + 200 ml plasma|Standard supportive treatment + 200 ml apheretic convalescent plasma single transfusion
16339441|NCT04403477|Experimental|Standard treatment + 400 ml plasma|Standard supportive treatment + 400 ml apheretic convalescent plasma single transfusion
16339442|NCT04403464|Experimental|HABIT-ILE with REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities with an interactive device
16339443|NCT04403464|Active Comparator|HABIT-ILE without REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
16339444|NCT04403451|Experimental|Phase 1/Cohort 1|True North Love Notes, Financial Stability, Jobs
16339445|NCT04403451|Experimental|Phase 2/Cohort 2|True North Love Notes, Financial Stability, Jobs
16339446|NCT04403451|Experimental|Phase 3/Cohort 3|True North Love Notes, Financial Stability, Jobs
16339447|NCT04403438||patients with behçet's or fmf|
16339448|NCT04403425||Emergency laparotomy, obstruction|Patients undergoing emergency laparotomy for intestinal obstruction in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
16339449|NCT04403425||Emergency laparotomy, perforation|Patients undergoing emergency laparotomy for perforated ventricle or intestine in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
16339450|NCT04403412|Experimental|Left atrial appendage closure group|
16339451|NCT04403412|Experimental|Radiofrequency ablation group|
16339452|NCT04403412|Experimental|LAAC combined with radiofrequency ablation group|
16339453|NCT04403399|Experimental|Varenicline then Placebo|Varenicline 0.5 mg BID orally for 3 weeks, followed by a 3-week washout period, then placebo BID orally for 3 weeks
16339454|NCT04403399|Experimental|Placebo then Varenicline|Placebo BID orally for 3 weeks, followed by a 3-week washout period, then Varenicline 0.5 mg BID orally for 3 weeks
16339455|NCT04403386||non-smokers|Participants who have never smoked or do not currently reside with a smoker
16339456|NCT04403386||Smokers|Participants who currently smokes and has smoked for at least 5 years
16339457|NCT04403373|Placebo Comparator|Waitlist control group|Participants in this group receive no intervention during the 12-week period.
16339458|NCT04403373|Experimental|Moderate-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a moderate intensity (~3.5 METs). The training will be conducted outdoors. Each training session lasts for 50 minutes.
16339459|NCT04403373|Experimental|Vigorous-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a vigorous intensity (~7 METs). The training will be conducted outdoors. Each training session lasts for 25 minutes.
16339460|NCT04403360|Experimental|Erector Spinae plane Block (ESPB) group|The ultrasound-guided ESPB was realized at T12 level (levo bupivacaine 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)after the induction of anesthesia but before the start of the surgery.
16339461|NCT04403360|Active Comparator|Local anesthesia infiltration by the surgeon|The surgeon infiltrates the surgical site after skin incision with local anesthetics (Levo Bupivacaïne 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)
16339462|NCT04403347|Experimental|Innovative Dietary Formulation|In addition to regular diets and usual care of hypertension, additional innovative dietary formulation will be orally taken 3 times per day.
16339463|NCT04403347|Active Comparator|Antihypertensive Medication|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
16339464|NCT04403347|No Intervention|Usual Care|Usual Care (Guideline-based patient education and lifestyle recommendations)
16339465|NCT04403334|Experimental|Intracameral levofloxacin|0.5% unpreserved solution
16339466|NCT04403334|Experimental|Intracameral moxifloxacin|0.5% unpreserved solution
16339467|NCT04403321|Placebo Comparator|Eltrombopag|Eltrombopag and the placebo would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day.
16339468|NCT04403321|Experimental|Eltrombopag + Tacrolimus|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. Tacrolimus will be given at 1mg bid with the target concentration to be 5-10 ng/ml throughout the study.
16339469|NCT04403321|Experimental|Eltrombopag + Cyclosporin A|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. Cyclosporin A will be given started with 100mg bid with the target concentration to be 100-150 ng/ml throughout the study.
16339470|NCT04403308|Experimental|ONO-7913 as a Single Agent|
16339471|NCT04403295|Experimental|collaborative specialty care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
16339472|NCT04403295|Active Comparator|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
16339473|NCT04403282|Active Comparator|Paired(right and left neck) comparison group eflornithine|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
16339474|NCT04403282|Placebo Comparator|Paired(right and left neck) comparison group placebo|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
16339475|NCT04403269|Experimental|IgIV|The experimental arm is human immunoglobulins. 2 infusion at D1 and D2. (0.8 g / kg by IV infusion)
16339476|NCT04403243|Experimental|1. Colchicine|30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
16339477|NCT04403243|Experimental|2. Ruxolitinib|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
16339478|NCT04403243|Experimental|3.Secukinumab|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
16339479|NCT04403243|Active Comparator|4.Standard treatment|-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
16339480|NCT04403230|Experimental|Clinical behaviour on teeth prepared without finish line|Evaluate the clinical behavior of restorations placed on teeth prepared without finish line, monitoring periodontal status as well as the prostheses to assess stability and treatment predictability.
16339481|NCT04403217|Experimental|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
16339482|NCT04403204||Established SSI Fracture Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
16339483|NCT04403204||Established SSI Fracture Cohort Subset (DCE-MRI)|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
16339484|NCT04403191||Group A|received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours
16339485|NCT04403191||Group B|received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours
16339486|NCT04403191||Group C|received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours.
16339487|NCT04403178||Children who develops hip displacement|Patient group 1 includes children who developed a Migration Percentage of > 40 % in either hip over a follow-up period of three years.
16339488|NCT04403178||Children who do not develops hip displacement|Patient group 2 includes children who did not develop a Migration Percentage of > 40 % on either hip over a follow-up period of three years
16339489|NCT04403165|Experimental|Cognitively Normal (CN) Older Adults|
16339490|NCT04403152|Experimental|Rehabilitation group|This is the study group in whom post-operative rehabilitation was provided for 5 days.
16339491|NCT04403152|Active Comparator|Mobilization group|This is the control group in whom post-operative mobilization was provided for 5 days.
16339492|NCT04403139|Other|Cohort 1: 30-40 year of age|
16339493|NCT04403139|Other|Cohort 2: 70 years of age or older|
16339494|NCT04403126|Experimental|Forgiveness curriculum for 5th grade|"Classrooms randomly assigned to the experimental group will receive the forgiveness intervention. The forgiveness intervention will follow the curriculum - The Journey Toward Forgiveness -A Guided Curriculum for Children Ages 10-12 (Grade 5 in the US). The Forgiveness Curriculum Guide consists 14 lessons over 12 weeks. Each class meets weekly for 40 to 60 minutes to complete one lesson (in two of the weeks, there will be two lessons)."
16339495|NCT04403126|No Intervention|Regular school instruction|Classrooms randomly assigned to the control group will have instruction as usual.
16339496|NCT04403113|Experimental|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
16339497|NCT04403113|Placebo Comparator|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
16339498|NCT04403100|Active Comparator|Hydroxychloroquine Sulfate|Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
16339499|NCT04403100|Active Comparator|Lopinavir/ Ritonavir|Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
16339500|NCT04403100|Active Comparator|Hydroxychloroquine plus Lopinavir/ Ritonavir|"Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
~Plus
~Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days"
16339501|NCT04403100|Placebo Comparator|Placebo|"Placebo
~Twice a day from day 1 through day 10."
16339502|NCT04403087|Experimental|Trimebutine add group|Addition of Trimebutine on the Bismuth-containing quadruple regimen
16339503|NCT04403087|No Intervention|Control group|Bismuth-containing quadruple regimen
16339504|NCT04403074||Chronic Pancreatitis Patients|Patients that have Chronic Pancreatitis and the current treatment with Celiac Plexus Blocks (CPB) are providing minimal relief of pain (CPB provide less than one month of pain relief). These patient will then receive a Celiac Plexus Neurolysis.
16339505|NCT04403048|Active Comparator|Patients in which standard provisional approach is preformed|Detailed technique is described in the Detailed study description paragraph
16339506|NCT04403048|Experimental|Patients in which provisional DCB approach is preformed|Detailed technique is described in the Detailed study description paragraph
16339507|NCT04403035||ID NOW vs. Acccula arm|Each patient serves as his or her own control. The ID NOW test is the one that is being currently used (i.e. the control) and the Accula test is the newer test being evaluated.
16339509|NCT04403009||the nonsevere Coronavirus Disease 2019 Patients|
16339510|NCT04403009||the severe Coronavirus Disease 2019 Patients|
16339514|NCT04402983|Experimental|Telerehabilitation Group|Physiotherapy will be carried out by conducting online conference method. Program content; Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
16339515|NCT04402983|No Intervention|Control group|Information and exercise brochure will be provided
16339516|NCT04402970|Experimental|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
16339517|NCT04402970|No Intervention|Standard of care|Standard of care provided for ARDS.
16339518|NCT04402957|Placebo Comparator|Placebo|100 mL drug-free IV saline infusion over 2 hours daily
16339519|NCT04402957|Experimental|LSALT|100 mL of 5 mg IV LSALT peptide infusion over 2 hours daily
16339520|NCT04402944|Experimental|Study Drug|Study drug
16339521|NCT04402944|Placebo Comparator|Placebo|Placebo
16339522|NCT04402931|Other|Transcatheter Valve-in-Valve Intervention|Transcatheter Valve-in-Valve Intervention
16339523|NCT04402931|Other|Redo Surgery|Surgical Mitral valve replacement
16339524|NCT04402918|Other|pregnancy patients diagnosed with SARS Cov2 during pregnancy|Delivery day biological samples from the mother and the newborn will be performed
16339525|NCT04402892|Active Comparator|Patients hospitalized for SARS-CoV-2|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
16339526|NCT04402892|Active Comparator|Patients who have recovered from CoV-2-SARS|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
16339527|NCT04402879|Experimental|Prone Positioning (PP)|The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.
16339528|NCT04402879|No Intervention|Control - usual management|The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.
16339529|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose A|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose A
16339530|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose B|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose B
16339531|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose C|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose C
16339532|NCT04402866|Experimental|Part 1: Placebo for MAD|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
16339533|NCT04402866|Experimental|Part 2: TD-0903|99 subjects will be randomized to receive TD-0903
16339534|NCT04402866|Experimental|Part 2: Placebo|99 subjects will be randomized to receive Placebo
16339535|NCT04402853||COVID 19 Patients|hospitalized patients with COVID 19
16339536|NCT04402840|Experimental|Stellate Ganglion Block (SGB)|Clinical Stellate ganglion block
16339595|NCT04402372||Group 2|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F conventional (HLS, Maquet, Germany cannula with downstream line (6F) for femoral artery cannulation
16339539|NCT04402814||Arm A (positive for COVID-19)|"One or two samples of your blood that were previously collected for routine care will be obtained from the hospital laboratory and will be tested for the antibodies against COVID-19 virus.
~First blood sample obtained: 7 to 12 days following onset of symptoms; and/or
~Second blood sample obtained: 12 to 40 days following the onset of symptoms."
16339540|NCT04402814||Arm B (negative for COVID-19)|One sample of blood that was collected for routine care at any point during hospitalization will be obtained from the hospital laboratory and will be tested for the antibodies.
16339541|NCT04402801||Standard of Care Telemedicine Cohort|This cohort will have telemedicine visits in lieu of in-person clinic visits
16339542|NCT04402801||Standard of Care In-Person Cohort|
16339545|NCT04402775|No Intervention|Vascular clamps|Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
16339546|NCT04402775|Experimental|Tourniquet|Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.
16339547|NCT04402762|Experimental|TR treatment sequence|Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma. Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France.
16339548|NCT04402762|Active Comparator|RT treatment sequence|Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France. Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma.
16339549|NCT04402749||Nephrectomy|Patients underwent nephrectomy
16339550|NCT04402736|Experimental|Modified Barthel Index-based rehabilitation nursing program|Patients received the Modified Barthel Index based rehabilitation nursing from qualified nurses.
16339551|NCT04402736|Other|Usual care|Patients received the usual care.
16339552|NCT04402723|Experimental|Donafenib, 0.2g|Donafenib,0.2g,bid,Combination with Cytarabine and Daunorubicin.
16339553|NCT04402723|Experimental|Donafenib,0.3g|Donafenib,0.3g,bid,Combination with Cytarabine and Daunorubicin
16339554|NCT04402710|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Action-Coping Planning and Monitoring Physical Activity Session 4: Goal re-visitation and adjustment and building self-efficacy. Session 5: Physical Activity Enjoyment and Barriers/Solutions. Session 6: Relapse prevention and commitment to exercise. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, antibiotic use, oral health, osteoporosis and vitamin D).
16339555|NCT04402710|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
16339556|NCT04402697|No Intervention|Normal-weight (NW)|Individuals with BMI<25 kg/m2
16339557|NCT04402697|Experimental|Overweight-Obese (OW-OB)|Individuals with BMI>25 kg/m2, submitted to a nutritional intervention (hypocaloric balanced diet) during 6 months and prescription of physical activity to achieve weigh loss
16339558|NCT04402697|Experimental|Metabolically obese normal-weight (MONW)|Individuals with BMI<25 kg/m2, with metabolic alterations related to obesity (hypertriglyceridemia, hypercholesterolemia, hyperglycaemia, hypertension or high waist-hip ratio), submitted to an intervention to improve dietary habits and physical activity in order to achieve a better body composition and metabolic health. Mediterranean diet will be and aerobic and strength exercises will be advised to these individuals.
16339559|NCT04402671|Active Comparator|non-crosslinked collagen membrane group|2 patients (1 male, 1 female)
16339560|NCT04402671|Active Comparator|glutaraldehyde cross-linked collagen membrane|2 patients (2 females)
16339561|NCT04402658|Experimental|Physical performance test|After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of [La-] and [Glucose].
16339562|NCT04402645||Chronic pulmonary hypertension|Diagnosis on echocardiography at 36 weeks CGA using standard criteria (flat interventricular septal motion or right ventricular dilatation)
16339563|NCT04402645||No chronic pulmonary hypertension|Confirmed on echocardiography at 36 weeks CGA
16339564|NCT04402632|Active Comparator|Interventional Cohort: Control Arm|Control
16339565|NCT04402632|Experimental|Interventional Cohort: Treatment Arm|Treatment
16339566|NCT04402632|Active Comparator|Observational Cohort: Control Arm|Control
16339567|NCT04402632|Experimental|Observational Cohort: Treatment Arm|Treatment
16339568|NCT04402619|Experimental|Online CBT|Ten modules with minimum therapist guidance
16339721|NCT04401462|Active Comparator|Non-operative group|conservative treatment
16339569|NCT04402606|Experimental|Evaluation on skin toxicities|This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
16339570|NCT04402593|Experimental|Modified Heidelberg Model of Neuro-Music Therapy (mHNMT)|The mHNMT for Tinnitus program was modified based on participant feedback of the original HNMT. This study will include 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
16339571|NCT04402580|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells)
~How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
~Where: in Hospital
~When and how much: once; diluted in 1000 ml of normal saline."
16339572|NCT04402580|Active Comparator|Mycophenolate Mofetil|"Drug Name: Mycophenolate Mofetil (MMF)
~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis
~Procedures: MMF 1,200 mg/1,73 sqm orally divided in 2 daily doses"
16339573|NCT04402541|Experimental|CB-5339|Orally administered CB-5339
16339574|NCT04402528|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will use the mehealth for ADHD web-based software and have access to a module that allows parents and teachers/childcare providers to develop and implement behavioral interventions such as daily report cards online.
16339575|NCT04402515||Tiotropium plus Olodaterol treatment regimen|
16339576|NCT04402515||Inhaled corticosteroids-containing treatment regimen|
16339577|NCT04402502|Experimental|Healthy Population|Healthy Individuals with no presence of neurological disorders, rheumatoid arthritis or comorbid health conditions, and are not pregnant.
16339581|NCT04402476|Experimental|Device and Control|"Device:
~Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs.
~Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
~Positive Control:
~0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml"
16339582|NCT04402463|Experimental|GPR Group|"Global Postural Reeducation with 2 parts in each session:
~st: 2 postures in lying position - without gravity load (15 minutes each posture): The aim of these postures is to achieve and maintain postural balance and to stretch the posterior muscle chain. In order to achieve this, specific exercises in the lying position are used. That exercises involve a precise use of contractions, stretch reflexes, light and controlled manual tractions and sustained elongations.
~The maintenance of alignment during posture will be achieved by verbal commands and manual contact of the therapist, guaranteeing the active engagement of patient to reach the correct posture.
~st: Standing posture - integration under gravity load (10 minutes): With the participant standing the physiotherapist makes final corrections for postural integration."
16339583|NCT04402463|Experimental|Exercise Group|"Therapeutic exercises. That they will be divided into 3 phases:
~The exercises in these phases will consist in active exercises of the cervical spine and shoulder girdle, motor control exercises, and finally strength and endurance of the cervical flexors and extensors and of the musculature of the shoulder girdle."
16339584|NCT04402450|Active Comparator|suprainguinal fascia iliaca block|Forty mL of levobupivacaine 0.25% with epinephrine 5 ug/mL will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
16339585|NCT04402450|Experimental|Pericapsular nerve group block|Twenty mL of levobupivacaine 0.5% with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle.
16339586|NCT04402437|Active Comparator|Receives LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
16339587|NCT04402437|Active Comparator|Receives QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
16339588|NCT04402424||Two-Week Rule Colorectal Patients|Patients that the GP has referred to two-week rule colorectal clinics at Royal Surrey County Hospital with bowel symptoms or found to be anaemic
16339589|NCT04402411|Active Comparator|Control Group|Patients will receive general anesthesia with intravenous opioid
16339590|NCT04402411|Experimental|Quadratus lumborum|Patients will receive bilateral quadratus lumborum block
16339591|NCT04402411|Experimental|Transversus abdominis plane|Patients will receive bilateral transversus abdominis plane block
16339592|NCT04402385|Experimental|Aspirin|Participants randomized to 81 mg of Aspirin daily
16339593|NCT04402385|Placebo Comparator|Placebo|Participants randomized to placebo daily
16339594|NCT04402372||Group 1|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F bidirectional (BiflowTM, LivaNova, Italy) for femoral artery cannulation
16339596|NCT04402359||Group A|Patients of Group A received meropenem one gram slowly IV infusion every 8 hours for 14 days and gentamicin 7 milligram (mg)/ Kilogram body weight per day slowly IV infusion once daily only for one week after ventilator for 2 weeks
16339597|NCT04402359||Group B|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution). The solution for injection should be administered over 120 minutes.after ventilator for 2 weeks
16339598|NCT04402346|Experimental|Radiofrequency-assisted|
16339599|NCT04402346|Active Comparator|Stapler|
16339600|NCT04402333||Robotic interval debulking surgery|Surgery will commence with an initial assessment with a camera inserted though the belly button. This visual assessment will be used to determine whether it is feasible to proceed with surgery robotically or whether full debulking surgery to zero macroscopic residual disease would be best carried out through an open surgical approach. If an open surgical approach is considered the optimum treatment for the patient and they have consented for this, then this will be done. If there is disease that cannot be removed Robotically after starting by this route, but can be removed via an open incision the surgery will be converted to an open procedure if it is safe to do so. If there are any complications, we may also need to convert to open surgery. The aim of the surgery whether by robotic or open is to remove all visible disease safely.
16339601|NCT04402333||Open interval debulking surgery|Standard Care. Following initial laparoscopic assessment patients not deemed suitable for minimally invasive robotic surgery will proceed with standard open interval debulking surgery through an extended midline incision. These patients will also be followed up to assess recovery, complication rate and quality of life.
16339602|NCT04402320||Control group|extubated and weaning from the ventilator and followed our routine protocol of management post extubation without mechanical ventilation or BIPAP machine
16339603|NCT04402320||Invasive ventilation group|reconnected to mechanical ventilator before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use of NIV.
16339604|NCT04402320||non invasive ventilation group|following the same previous protocol done after extubation with immediate connection to NIV with BIPAP mode for 1 hour and repeated every 12hours for 48 hours, BIPAP adjusted in our study by FIO2 40%, PEEP 8 cmH2O, Pressure support of 15 cmH2O.
16339605|NCT04402307|No Intervention|Usual care|Usual care to patients with dysphagia
16339606|NCT04402307|Experimental|Training|Chin Tuck Against Resistance to patients with dysphagia
16339607|NCT04402281|Placebo Comparator|suPAR algoritm control|Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.
16339608|NCT04402281|Experimental|suPAR algoritm intervention|"Intervention arm (Jorvi Hospital).
~According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question
~Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician.
~If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question
~Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician."
16339609|NCT04402268||Low risk|Low risk of sudden cardiac death according to HCM Risk-SCD Calculator
16339610|NCT04402268||Intermediate risk|Intermediate risk of sudden cardiac death according to HCM Risk-SCD Calculator
16339611|NCT04402268||High risk|High risk of sudden cardiac death according to HCM Risk-SCD Calculator
16339612|NCT04402255|Experimental|behcet group|this group includes 16 patients with behçet
16339613|NCT04402255|Experimental|fmf group|this group includes 16 patients with fmf
16339614|NCT04402255|Active Comparator|healty control|this group includes 16 healthy control
16339615|NCT04402242|Sham Comparator|Standard Care|Control : bispectral index guided anesthesia
16339616|NCT04402242|Experimental|NOL monitoring|Intervention : bispectral index guided anesthesia and NOL index guided anesthesia
16339617|NCT04402216|No Intervention|Current standard of care, no formal preparation|Participants in this group will receive the standard of care with no formal preparation. MRI technologist will meet patient prior to scan introducing role of patient, role of MRI technician, and give verbal discussion of MRI process. MRI technologist will offer opportunity for patient to watch a movie as alternative focus/distraction during MRI scan. The child life specialist will not meet with the caregiver or child during their visit.
16339618|NCT04402216|Experimental|Child Life-led preparation|Participants will meet with a child life specialist who will provide psychological preparation utilizing photos, MRI sounds, verbal discussion of MRI process, and discuss various coping strategies such as deep breathing or stress ball and option to watch a movie for alternative focus/distraction during the scan.
16339619|NCT04402216|Experimental|MRI preparation video|Participants will be shown an MRI preparation video by the research coordinator in the MRI dressing room prior to MRI scan. The MRI preparation video will walk the patient through the MRI experience with a mock patient explaining all the steps of MRI process from check in to discharge. The child life specialist will not meet with the caregiver or child during their visit.
16339620|NCT04402216|Experimental|Child Life preparation with VR|Participants will be provided MRI preparation with a child life specialist using the Kind VR device. The VR (virtual reality) session will consist of an audio and visual MRI experience designed to serve as an opportunity for the patient to practice their scan prior to MRI. The VR session will take place once during the Radiology admission and will be approximately 15 minutes in duration. The VR software was developed by Kind VR and was designed specifically for the purpose of preparation for brain MRI. The interactive VR experience walks patients through each step of an MRI. Patients can practice holding still for the MRI and will get feedback from the VR headset when they are moving their head. Along with VR practice session CCLS will discuss various coping strategies such as deep breathing and/or stress ball and option to watch a movie for alternative focus/distraction during the scan.
16339621|NCT04402203|Experimental|Favipiravir + Standard Treatment|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
16339622|NCT04402203|Placebo Comparator|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
16339623|NCT04402177|Experimental|Hypersensitivity Pneumonitis patients showing lung fibrosis|hypersensitivity Pneumonitis patients that shows lung fibrosis after CT scan ( fibrotic patients ) methyl prednisolone 0.5mg/kg /day orally for 8 weeks
16339624|NCT04402177|Active Comparator|hypersensitivity Pneumonitis patients without lung fibrosis|hypersensitivity Pneumonitis patients that doesn't show lung fibrosis after CT ( non-fibrotic patients ) will be given also methyl prednisolone 0.5mg/kg /day orally for 8 weeks
16339625|NCT04402164|Active Comparator|Dentally anchored Herbst group|Herbst appliance will be anchored on the mandibular dentition
16339626|NCT04402164|Active Comparator|Skeletally anchored Herst group|Herbst appliance will be anchored on mini-plates placed in the para symphesial areas
16339627|NCT04402151|Other|Single Arm|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.
~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.
~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
16339628|NCT04402138|Experimental|Acalabrutinib|Acalabrutinib will be self-administered orally for up to approximately 2 years post-BMT.
16339629|NCT04402125|Experimental|Intervention|Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up
16339630|NCT04402125|Other|Waitlist|Participants randomized to waitlist for 6 months, then offered the intervention for 6 months
16339631|NCT04402086||Biorepository|Participants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
16339632|NCT04402073|Other|standard arms|"Criteria: Adult SHH (p53wt) M0-1, adult WNT M0-1, adult Group 4 M0-1.
~Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
~Criteria: Post pubertal < 18 y SHH (p53wt) M0.
~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy."
16339633|NCT04402073|Experimental|experimental arms|"Radiotherapy Criteria: Adult and post-pubertal SHH (p53wt) M0; adult WNT M0, adult Group 4 M0.
~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy.
~SMO-inhibitor Criteria: Adult and post-pubertal SHH (p53wt) M0.
~Sonidegib 200 mg/day (daily) from first day of radio-chemotherapy until end of maintenance chemotherapy, including 6w chemotherapy break."
16339634|NCT04402060|Experimental|180 mg APL-9 IV plus SOC|
16339635|NCT04402060|Placebo Comparator|Isotonic saline|
16339636|NCT04402047|Experimental|Electroacupuncture group|
16339637|NCT04402047|Active Comparator|Topical DSG group|
16339638|NCT04402034|Experimental|Application of tele-rehabilitation|Individuals that will perform the protocol of virtual reality intervention.
16339639|NCT04402021|Experimental|Aerobic Exercise|Participants randomized to the aerobic exercise group will complete 30 minutes of outdoor walking at a moderate intensity, defined as 50% heart rate reserve from the American College of Sports Medicine (ACSM) exercise prescription recommendations. A 5-minute warm-up and cool-down will occur before and after the 30-minute bout. A Polar H10 heart rate monitor will continuously monitor exercise intensity during the session. Ratings of Perceived Exertion (RPE) will be assessed using the Borg scale (i.e., 6-20 rating system) to indicate perceived exercise effort every 5 minutes during the exercise session. Each session will last approximately 50 minutes.
16339640|NCT04402021|Other|Quiet Rest|Participants randomized to this condition will be instructed to watch a nature documentary void of topics related to sleep or exercise. A Polar H10 heart rate monitor will continuously monitor heart rate during the session to mimic the aerobic exercise condition. Participants will not be permitted to complete homework or work during the allotted time to reduce the chance of unintended stimuli. The quiet rest sessions will be 50 minutes in length.
16339641|NCT04402008|Experimental|Phase 1: Once Daily Dosing|Dose finding at 8 mg, 12 mg, or 16 mg of poziotinib once daily in 28-day treatment cycles.
16339642|NCT04402008|Experimental|Phase 1: Twice Daily Dosing|Dose finding at 4 mg, 6 mg, or 8 mg of poziotinib twice daily in 28-day treatment cycles.
16339643|NCT04402008|Experimental|Phase 2: Once Daily Dosing or Twice Daily Dosing|"Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.
~Cohort 1: EGFR exon 20 insertion mutations
~Cohort 2: HER2 exon 20 insertion mutations"
16339644|NCT04401995|Experimental|Nivolumab and CMP-001 Combination with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2,4,6) for 6 weeks in combination with CMP-001 5mg subcutaneous 1st dose, and the remaining injections, 10mg intra-tumorally will be administered Weeks 2-7. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 5.
~Boost Phase - Nivolumab 480mg IV, every 4 weeks and CMP-001 5mg subcutaneous every 4 weeks up to 48 weeks."
16339645|NCT04401995|Experimental|Nivolumab with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2, 4, 6) for 6 weeks. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 5.
~Boost Phase - Nivolumab 480mg IV, every 4 weeks starting from the time of surgery recovery for up to 48 weeks."
16339646|NCT04401982||Glaucoma Suspect|Individuals with a diagnosis of glaucoma suspect
16339647|NCT04401969||Patients with eumycetoma lesions|Patients with eumycetoma lesions
16339648|NCT04401969||Patients with actinomycetoma lesions|Patients with actinomycetoma lesions
16339649|NCT04401969||Patients with lesions of unknown causality|Patients with lesions of unknown causality
16339656|NCT04401943|Experimental|Fatigue intervention|the Fatigue intervention is a 6 week intervention delivered using video teleconferencing
16339657|NCT04401930||Free-living elderly|"Free-living elderly over the age of 65 living in Metropolitan Area of Milan, in apparent good health conditions.
~Male and Female"
16339658|NCT04401917|Other|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD)|
16339659|NCT04401917|Other|HIV negative (HIV-) subjects with OUD|
16339660|NCT04401917|Other|HIV Positive (HIV+) subjects with OUD negative|HIV+ subjects who may have been opioid-exposed but do not have current or past OUD
16339661|NCT04401917|Other|Healthy volunteer|HIV-, OUD- healthy controls who have been opioid-exposed but do not have current or past OUD
16339662|NCT04401904|Experimental|Dapagliflozin|10 participants with pre-diabetes will be randomized to the experimental group to receive dapagliflozin 10mg by mouth daily for 12 weeks.
16339663|NCT04401904|Other|Nutritional Counseling|10 participants with pre-diabetes will be randomized to receive nutritional counseling weekly for 12 weeks
16339664|NCT04401891|No Intervention|Routine Pre-Operative Education in MD office prior to surgery|
16339665|NCT04401891|Experimental|Formal Pre-operative education/therapy prior to surgery|
16339666|NCT04401878|Experimental|the treatment group (A)|Patients who have PDPH are manged by SPGB, they are assessed by NRS before the block, at 30 mins, 2h, 4h, 6h, 12h, and 24hours after block. The patients are also examined by TCD before and after the block.
16339667|NCT04401878|Experimental|control group (B)|The control group (B) of 60 patients with no PDPH were examined by TCD
16339668|NCT04401865|Experimental|Pulsed, Accelerated|5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
16339669|NCT04401865|Active Comparator|Conventional|4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
16339670|NCT04401852|Active Comparator|MgSO4 group|will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose
16339671|NCT04401852|Placebo Comparator|placebo group|will receive an equal volume of isotonic 0.9% saline over 15-20 minutes
16339672|NCT04401839|Active Comparator|Control group|153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
16339673|NCT04401839|Active Comparator|Study group|156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.
16339674|NCT04401826|Experimental|The conventional approach|Conventionnal ECL using piezosurgery and microsurgical tools
16339675|NCT04401826|Active Comparator|The intervention approach:|Conventionnal ECL with tunneling using piezosurgery and microsurgical tools
16339676|NCT04401813|Experimental|IBI310|An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
16339679|NCT04401787|Active Comparator|laparoscopic anterior resection (LAR)|LAR group included 88 patients, 17 patients converted to open
16339680|NCT04401787|Active Comparator|open anterior resection|Open anterior resection for 56 patients
16339681|NCT04401774|Experimental|Nivolumab Maintenance|All patients will undergo cerebrospinal fluid (CSF) and blood collection as well as MRI imaging as standard of care prior to (- 21 days) first-line treatment initiation, during first-line therapy (before initiation of the 5th methotrexate dose (+/- 7 days)), at completion of first-line chemotherapy therapy (+/- 7 days) as well as 60, 180, and 360 days after enrollment into maintenance or observation (+/- 7 days). Those patients with persistent cfDNA in the CSF after completion of first-line chemotherapy and either complete or partial response on imaging will be enrolled into the nivolumab maintenance treatment arm. All other patients (no persistent cfDNA in the CSF and either complete or partial response on imaging) are followed with observation. Patients who do not respond to first-line therapy are not eligible for nivolumab maintenance and will no longer be followed in the biospecimen and clinical data collection cohort.
16339682|NCT04401761||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are treated with a combination of rivaroxaban and acetylsalicylic acid.
16339683|NCT04401748|Experimental|Arm 1: Venetoclax + Azacitidine (AZA)|Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
16339684|NCT04401748|Active Comparator|Arm 2: Placebo + Azacitidine|Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
16339685|NCT04401735|Experimental|Polydeoxyribonucleotide|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml
16339686|NCT04401735|Experimental|Polydeoxyribonucleotide, Placebo|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)
16339687|NCT04401735|Placebo Comparator|Placebo|Placebo (Normal saline)
16339688|NCT04401722|Active Comparator|PD in normal altitude|PD underwent in the area at the level of the sea, normal altitude region
16339689|NCT04401722|Active Comparator|PD in high altitude region.|PD underwent in high altitude region.
16339690|NCT04401709|Experimental|Gemcitabine/Capecitabine|gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
16339691|NCT04401709|Active Comparator|Capecitabine|capecitabine 2,500 mg/m2 D1-14
16339692|NCT04401696|Experimental|Group A|Use of Bubble CPAP for management of respiratory distress
16339693|NCT04401696|Active Comparator|Group B|Use of Oxygen via nasal cannula for respiratory distress
16339694|NCT04401683|Experimental|Digital Rehabilitation|Standard medical treatment + Fully remote rehabilitation program with a digital therapist
16339695|NCT04401683|Active Comparator|Conventional Rehabilitation|Standard medical treatment + Home-based rehabilitation program
16339696|NCT04401670|Other|Triage with different options|"Self-Collection: hrHPV and Biomarkers Testing (among hrHPV+)
~ThinPrep Specimen: Liquid-Based Cytology (LBC), hrHPV Testing, and Biomarker Testing (among hrHPV+)
~Visual Inspection after Acetic Acid (VIA)"
16339697|NCT04401657|Experimental|FFR Measurement|Myocardia ischemia evaluation during adenosine stress testing
16339698|NCT04401644|Experimental|primary arm|There will only be one set of participants with each participants samples and results as the comparator groups. There will be within group comparison of methods of detection of virus by two test methodologies. Post hoc validation of test performance against reference set.
16339699|NCT04401631||Interventions|"A minimum of 20 subjects with targeted levels of total IgE are needed to participate in the Operator-to-Operator whole blood study.
~A minimum of 20 subjects with targeted levels of allergen-specific and total IgE are needed to participate in the capillary whole blood between-run imprecision study in the POL environment.
~A minimum of 40 subjects with targeted levels of Fel d 1-specific IgE and total IgE are needed to participate in the sample type comparison study. These subjects will be recruited, and their samples analyzed at 1 POL.
~A minimum of 300 subjects (approximately 100 subjects enrolled and evaluated at each of three sites) and with targeted levels of total IgE are needed to participate in the method comparison study."
16339700|NCT04401618||Class V RMGI Restorations|Resin-modified glass ionomer (RMGI - Fuji 2 LC) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
16339701|NCT04401618||Class V Glass ionomer - GIC Restorations|Glass ionomer (GI - Fuji 9) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
16339702|NCT04401605|Experimental|Fermented Food-Supplemented Diet|Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
16339703|NCT04401605|Placebo Comparator|Regular Diet Control Arm|Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.
16339704|NCT04401592||disease and control|
16339705|NCT04401579|Experimental|Remdesivir plus Baricitinib|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
16339706|NCT04401579|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
16339707|NCT04401566|Experimental|Internal Myofascial Release Group|Internal myofascial trigger point release therapy consists of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial release techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point. Releasing pelvic muscle tension includes applying varying amounts of pressure, sometimes gradually stroking and strumming the muscle region while systematically contracting and relaxing the affected muscles to aid in a trigger point release.
16339708|NCT04401566|Experimental|External Myofascial Release Group|Eksternal myofascial trigger point release therapy consists of 30 minutes massage to the abdominal wall, gluteal area and abductors, and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and the lower extremity of the muscle.
16339709|NCT04401566|Other|Control Group|The Control group will have a video about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breathing, pelvic floor muscle stretching, and releasing.
16339710|NCT04401553|Experimental|First Tier Antibiotic|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
16339711|NCT04401553|Active Comparator|Second Tier Antibiotic|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam
16339712|NCT04401527|Active Comparator|Sodium Nitrite|Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.
16339713|NCT04401527|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.
16339714|NCT04401514|Experimental|Experiemntal intervention|The experimental intervention is a 20 min. long rocking chair with music therapy.
16339715|NCT04401514|Active Comparator|Control intervention|Control intervention is also transferred to the rocking chair, but the therapy program will not be turned on.
16339716|NCT04401501|Experimental|Manual Therapy + Exercise Group|Combination of manual therapy and exercises for cervicogenic headache
16339717|NCT04401501|Active Comparator|Exercise Group|Only exercises for cervicogenic headache
16339718|NCT04401475|Experimental|Stage 1|Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.
16339719|NCT04401475|Experimental|Stage 2|Stage 2 (Phase III Study - Canada) For a 1:1 ratio of patients treated with EB05 vs. Placebo, 80% power, and a two-sided alpha of 0.05 (equivalent to one sided test with an alpha of 0.025) to detect an Odds Ratio of 1.50, a total of 884 evaluable patients will be required for Stage 2 (Phase III study). Allowing for 20% attrition, a total of 1,105 patients will be enrolled in this Stage.
16339720|NCT04401462|Active Comparator|Operative group|tension band wiring or plate fixation
16339722|NCT04401449||Acutely illl subjects|COVID-19 subjects treated at the Clinical Center, followed through recovery and into convalescence
16339723|NCT04401449||Recovered subjects|COVID-19 subjects who were treated at other hospitals, followed through recovery and into convalescence
16339725|NCT04401423|Experimental|TXA127|Participants will receive one 3-hour dosage (0.74 mg/kg), intravenously, for 10 days consecutively.
16339726|NCT04401423|Placebo Comparator|Placebo|Participants will receive one 3-hour dosage (0.74 mg/kg), intravenously, for 10 days consecutively.
16339727|NCT04401410|Experimental|Dose Finding Phase|"This phase is designed to evaluate the maximum tolerated dose (MTD) of partially HLA-matched SARS-CoVSTs administered to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.
~The dose finding phase is a standard 3+3 safety study design. The 3 dose levels are:
~DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose)"
16339728|NCT04401410|Experimental|Randomized Pilot - SARS-CoVSTs|Partially HLA-matched Virus Specific T cells (VSTs) will be given by intravenous injection.
16339729|NCT04401410|Active Comparator|Randomized Pilot - Routine Care|Hospitalized patients with COVID-19 will be treated per current institutional guidelines.
16339730|NCT04401397|Experimental|Early mobilization group|Immediately after ICU extubation, enrolled patients will receive an intensive 30-45 minutes, implemented twice a day early mobilization protocol containing psychological empowerment, detailed informative education of patients and close relatives, close monitoring of the recovery course, frequent parameter protocol configuration, high intensity active progressive pulmonary and musculoskeletal exercises and mobility techniques, close monitoring for early identification and measures for prevention and treatment of complications.
16339731|NCT04401397|Active Comparator|Standard care group|Enrolled patients will receive the standard hospital mobilization protocol after their admission to the ward, containing standardized basic pulmonary and mobilization techniques of 15 minutes, once a day.
16339732|NCT04401384|Other|Diclectin plus active acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) , 2-4 tablets/day) + active acupuncture (30 min /every day).
16339733|NCT04401384|Other|Diclectin plus sham acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg), 2-4 tablets/day) + sham acupuncture (30 min /every day).
16339734|NCT04401384|Other|Placebo plus active acupuncture|Diclectin placebo (2-4 tablets/day) + active acupuncture (30 min / every day)
16339735|NCT04401384|Other|Placebo plus sham acupuncture|Diclectin placebo (2-4 tablets/day) + sham acupuncture (30 min /every day)
16339736|NCT04401345|Experimental|Experimental Group (GP)|Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.
16339737|NCT04401345|Placebo Comparator|Placebo Group(NS)|patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min
16339738|NCT04401332|Experimental|Intervention|
16339739|NCT04401332|No Intervention|Usual Care|
16339740|NCT04401319|Sham Comparator|Sham Stimulation Group for Crossover Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the crossover study.
16339741|NCT04401319|Active Comparator|DLPFC Stimulation Group for Crossover Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the crossover study.
16339742|NCT04401319|Active Comparator|AG Stimulation Group for Crossover Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the crossover study.
16339743|NCT04401319|Sham Comparator|Sham Stimulation Group for Parallel Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the parallel study.
16339744|NCT04401319|Active Comparator|DLPFC Stimulation Group for Parallel Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the parallel study.
16339745|NCT04401319|Active Comparator|AG Stimulation Group for Parallel Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the parallel study.
16339746|NCT04401306|Experimental|Self-regulated simulation training|
16339747|NCT04401306|Active Comparator|Instructor-regulated simulation training|
16339748|NCT04401293|Experimental|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.
16339749|NCT04401293|Active Comparator|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
16339753|NCT04401267|Experimental|Intensive Antihypertensive Therapy|Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
16339754|NCT04401267|Active Comparator|Conventional Antihypertensive Therapy|Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
16339755|NCT04401228||covid ICU patients|
16339756|NCT04401228||covid conventionnal ward|
16339757|NCT04401215|Other|Technology Augmented Treatment group|Intervention Group
16339758|NCT04401215|No Intervention|Control group|After the baseline visit the control arm participants will receive no additional follow-up beyond usual care until the 30 days' end. Surveys at the end of 30 days.
16339759|NCT04401202|Experimental|NSO|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
16339760|NCT04401202|No Intervention|Control|Standard of care
16339761|NCT04401189||Breast cancer patients|
16339762|NCT04401189||Healthy controls|
16339763|NCT04401176|Active Comparator|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
16339764|NCT04401176|Active Comparator|Intradetrusor Onabotulinumtoxin A Injection|100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.
16339765|NCT04401150|Experimental|Vitamin C|Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
16339766|NCT04401150|Placebo Comparator|Control|Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
16339767|NCT04401137|Placebo Comparator|Placebo|
16339768|NCT04401137|Experimental|QDX 25|
16339769|NCT04401137|Experimental|QDX 50|
16339770|NCT04401137|Experimental|QDX 100|
16339771|NCT04401137|Experimental|QDX 200|
16339772|NCT04401124||patients treated at surgical emergency rooms|
16339773|NCT04401124||patients receiving surgeries (both elected and emergency)|
16339774|NCT04401111||Survivors of Intensive care unit patients|Survivors of severe COVID-19 pneumonia after intensive care unit
16339775|NCT04401085||Population area cohort - Control Cohort|A population cohort of asymptomatic individuals (only adults). This is a representative sample of the population, which are part of the research project of Institute for Clinical and Experimental Medicine and Czech Academy of Sciences. The second subsample included individuals from the official household survey of Czech Statistical Office. This cohort allowed better comparative analysis of other population cohorts from specific geographical areas.
16339776|NCT04401085||Population cohort from specific geographical areas|"This cohort is based on epidemiologically defined demographic parameters. These are populations from the following geographical areas:
~Brno and the South Moravian Region; Praha; Olomouc; Litoměřice; Litovel and Uničov."
16339777|NCT04401085||Chronically ill patients cohort|A cohort of chronically ill people enrolled by Institute for Clinical and Experimental Medicine with chronic cardiovascular problems, hypertension, or diabetes.
16339778|NCT04401059|Experimental|Elemene plus First-generation EGFR-TKIs|Elemene Injectable Emulsion sequentially with Elemene Oral Emulsion plus First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib).
16339779|NCT04401059|Active Comparator|First-generation EGFR-TKIs only|First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib).
16339780|NCT04401046|Experimental|Post traumatic stress and anxiety evaluation|
16339781|NCT04401033||Endoscopic cohort|Endoscopic examinations: They will be carried out according to the recommendations of the Spanish society for digestive endoscopy (SEED). In summary, the patient will perform a hand wash with hydroalcoholic solution before entering the endoscopy room, and will put on a surgical mask and gloves. Personnel close to the patient will wear an FFP2 mask, exceptionally a surgical mask, a gown (waterproof in high-risk examinations as established in the SEED guidelines), a cap, nitrile gloves and face shield or safety glasses (reusable) and shoe covers. The examinations will be performed by endoscopist-guided sedation in accordance with current clinical guidelines.
16339782|NCT04401033||Ultrasonography cohort|Abdominal ultrasound: They will be carried out according to international clinical guidelines (12). The explorer will wear an FFP2 mask, exceptionally a surgical mask, a gown, a hat, nitrile gloves, and a face shield or safety glasses (reusable) and shoe covers. The gel bottle, transducer, and stretcher will be washed prior to each scan with low-level disinfectant
16339783|NCT04401033||Telephonic cohort|The patient will be telephonically contacted for a medical visit.
16339784|NCT04401020|Experimental|Dose escalation|SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by twice weekly until week 4 (Cycle 1) and twice weekly for each subsequent cycle(s).
16339785|NCT04401007|Experimental|Group 20/30|Two different local anesthetic volumes will be investigated: 20 mL of 1.5% lidocaine (300 mg lidocaine) at one study visit and 30 mL of 1.5% lidocaine (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit
16339786|NCT04401007|Experimental|Group 30/20|(2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. This crossover design allows subjects to serve as their own control.
16339787|NCT04400994|Active Comparator|Rituximab only|"Rituximab infusion 375mg/m2 body surface area (BSA) weekly for 4 weeks from baseline (week 0, 1, 2, 3)
~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 24 (week 24, 25, 26, 27)
~Rituximab infusion 375mg/m2 BSA weekly for 2 weeks at week 52 (week 52, 53)
~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 76 (week 76, 77)
~A total of 12 doses of rituximab will be given in 55 weeks"
16339788|NCT04400994|Experimental|Rituximab and IVIG|"Rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 1, 2, 3);
~Week 4: Rituximab + IVIG 2g per kg
~Week 5, 6, 7: Above treatment repeated for 2nd cycle, infusion of rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 5, 6, 7);
~Week 8: Rituximab + IVIG 2g/kg
~In months 3, 4, 5, 6, patients received a single infusion of rituximab (375 mg/m2 BSA) plus infusion of 2g/kg IVIG
~Thus in 6-month period patients received a total of 12 infusions of rituximab and 7 infusions of IVIG
~If a patient was clinically free of disease at end of 6 months, additional infusions of IVIG will be given at week 30, 38, 48, 60 and 76
~A total of 12 doses of rituximab and 12 cycles of IVIG will be given"
16339789|NCT04400981|Experimental|Intervention arm: RIC plus standard medical therapy|"Remote ischemic conditioning (RIC) will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
~Patients randomized to remote ischemic conditioning will also receive standard medical therapy"
16340638|NCT04395183|Active Comparator|5-HTP + Placebo|5-hydroxytryptophan 100mg PO BID plus placebo matched to creatine monohydrate
16339790|NCT04400981|Active Comparator|Control arm: Standard medical therapy alone|"Standard medical therapy will be administered immediately after randomization in the Emergency Department. Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.
~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
16339791|NCT04400968|Experimental|Auricular therapy group|The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
16339792|NCT04400968|Sham Comparator|Auricular therapy Placebo group|The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.
16339793|NCT04400968|Experimental|Kinesio tape group|The kinesio tape group received an intervention that consisted on the standard application of three elastic bandages. An experienced kinesio tape certified physical therapist applied the taping.
16339794|NCT04400968|Sham Comparator|kinesio tape Placebo group|The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area.
16339795|NCT04400968|No Intervention|Control group|The control group did not receive any treatment. The participants continued with their routine medical treatment. However, the controls completed all the questionnaires to collect the information regarding their symptoms in order to observe their progress with no intervention.
16339796|NCT04400942||Women with uterine myomas undergoing hysteroscopic myomectomy|
16339797|NCT04400929|Experimental|Group A: Treatment Group|Day 1 - 5: Receive study medication Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
16339798|NCT04400929|Placebo Comparator|Group B: Placebo Group|Day 1 - 5: Receive normal saline 0.9% daily (via infusion into the vein) in addition to standard of care treatments
16339799|NCT04400929|Experimental|Group C|Day 6 - 10: Subjects in Group A who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
16339800|NCT04400929|Experimental|Group D|Day 6 - 10: Subjects from Group B to receive study medication (based on the treating physician's assessment), Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
16339801|NCT04400929|Experimental|Group E|Day 11 - 15: Subjects in Group D who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
16339802|NCT04400916|Experimental|Topical tranexamic acid|
16339803|NCT04400916|Placebo Comparator|Topical BSS|
16339804|NCT04400903||Observational (HRV monitoring, questionnaire)|Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.
16339805|NCT04400890|Active Comparator|Resveratrol with Vitamin D3|Resveratrol 1000mg four times per day for 15 days. Vitamin D3 100,000 IU on day 1
16339806|NCT04400890|Placebo Comparator|Placebo with Vitamin D3|Placebo capsules 4 times per day for 15 days. Vitamin D3 100,000 IU on day 1
16339807|NCT04400877||SARS-CoV-2 pos|Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
16339808|NCT04400877||SARS-CoV-2 neg|Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
16339809|NCT04400864|Experimental|Mediterranean Diet|Nutritional guidelines based on the principals of the Mediterranean Diet
16339810|NCT04400864|Experimental|Paleolithic Diet|Nutritional guidelines based on the principals of thePaleolithic Diet
16339811|NCT04400851|Experimental|Sintilimab in advanced childhood cancer patients|
16340639|NCT04395183|Active Comparator|Creatine + Placebo|Creatine 5g PO qday plus placebo matched to 5-HTP
16339841|NCT04400825|Experimental|Dry needling|Dry needling of 3 active MTrPs at most.
16339842|NCT04400825|Active Comparator|Stretching|Stretching of the main hip flexors (rectus femoris, iliopsoas and tensor fasciae latae)
16339843|NCT04400799|Experimental|Test Group|Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.
16339844|NCT04400799|No Intervention|Control Group|No study drug
16339845|NCT04400786|Experimental|On-demand treatment|This group of 98 ankylosing spondylitis patients is prescribed with intermittent Imrecoxib (100mg.prn.po) according to the feeling of pain till 24 weeks. The sulfasalazine (500mg.tid.po) is used.
16339846|NCT04400786|Active Comparator|Continuous treatment|This group of 98 ankylosing spondylitis patients is prescribed with continuous Imrecoxib (100mg.bid.po) for 24 weeks. The sulfasalazine (500mg.tid.po) is used.
16339847|NCT04400773|Experimental|Plyometric Group|This group will receive a 6-week upper body plyometric exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
16339848|NCT04400773|Experimental|Strength Group|This group will receive a 6-week upper body strength exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
16339849|NCT04400760|Other|DAPA Tx|This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
16339850|NCT04400747|Experimental|weekly treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 50,000 IU of vitamin D weekly for 8 weeks.
16339851|NCT04400747|Experimental|daily treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 6,000 IU of vitamin D daily for 8 weeks.
16339852|NCT04400747|No Intervention|control group|20 patients with high calcium (Ca) values in blood tests, patients with kidney and urinary stones, as well as patients who refuse to use vitamin D supplements will be included in the control group
16339853|NCT04400721|No Intervention|PCIA arm|Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)
16339854|NCT04400721|Active Comparator|ESP block arm|ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin [Ropivacaine])
16339855|NCT04400721|Active Comparator|IC block arm|3 ml of 0.5% solution of Naropin [Ropivacaine] per intercostal space, up to a maximum of 30ml
16339856|NCT04400708|Sham Comparator|control group|normal saline injection
16339857|NCT04400708|Experimental|test group|0.5% ropivacaine injection
16339858|NCT04400695|Experimental|RC48-ADC|RC48-ADC common name：Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form：Lyophilized powder injection specification：60 mg / piece Medication plan：Every 2 weeks Expiration date：18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
16339859|NCT04400695|Active Comparator|Physician's Choice|"Physician's Choice:
~HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
~Physician's choice from the following options:
~Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets"
16339860|NCT04400682|Experimental|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
16339861|NCT04400682|Experimental|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
16339894|NCT04400422|Experimental|Lipano MCT formula|Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance
16339862|NCT04400669|Experimental|Mechanical Bowel Preparation|Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
16339863|NCT04400669|Active Comparator|Low fibre diet|Patients will be given detailed instructions about the pre-operative diet (total daily Fibre intake inferior to 10 g) to be used for 3 days prior to surgery.
16339864|NCT04400669|Active Comparator|MBP plus low fibre diet|This group will receive both mechanical bowel preparation and 3-days low fibre diet.
16339865|NCT04400669|No Intervention|Control|Control subjects will receive no instructions about the pre-operative diet (free diet).
16339866|NCT04400630|No Intervention|Control (TAU)|patients without any intervention + treatment as usual (TAU)
16339867|NCT04400630|Experimental|PE intervention+TAU|Physical exercise (PE) intervention + treatment as usual (TAU)
16339868|NCT04400617||Assisted-living residents|The target population will be inactive men and women residents of the Brenda Strafford Foundation (> 50 yrs. old). We expect the participants to be classified as inactivity, which will be defined as an engagement in < 3 sessions/week of 20 min or more of vigorous exercise. Participants should be able to move independently without the assistance of a wheelchair.
16339869|NCT04400617||Control group|Volunteers from the Brain in Motion II (BIM II) study (NCT03035851). The BIM II study aims to examine the mechanisms whereby exercise may improve sleep and cognition in men and women aged 50 to 80 years old. As the baseline measurements of the BIM II study are similar to the assessments proposed in this study, the assisted living residents will be matched with older individuals of the same age and cognitive performance who live independently to answer the last research question.
16339870|NCT04400604||1: Patients with minimal risk of extensive fibrosis|TE < 5.8kPa; rule out cut-off value)
16339871|NCT04400604||2: Patients with intermediate risk of fibrosis|
16339872|NCT04400604||Patients with high risk of extensive fibrosis|
16339873|NCT04400604||Patients with compensated cirrhosis biopsy-proven|
16339874|NCT04400604||Patients with a first decompensation|patients with a first decompensation event of cirrhosis after exclusion of HCC.
16339875|NCT04400578|Experimental|TRICIN|"If a patient is eligible
~local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application
~Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application
~Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application"
16339876|NCT04400565|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
16339877|NCT04400565|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
16339878|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op|Oral nutrition supplementation (ONS) pre-operatively and post-operatively up to being discharged from hospital
16339879|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Oral nutrition supplementation (ONS) pre-operatively, post-operatively up to being discharged from hospital and an extended oral nutrition supplementation post-operatively up to 3 months
16339880|NCT04400552|Active Comparator|Usual intake Pre-op + ONS Post-op|Follow a meal plan of 2000 kcal / day using conventional foods and oral nutrition supplementation (ONS) post-operatively up to being discharged from hospital
16339881|NCT04400539|Experimental|Malignant Pleural Mesothelioma patients|
16339882|NCT04400526|Other|Phase 1: A video competition for anti-drug abuse|Phase 1 aims to increase the public awareness of hazardous effects of drug abuses and existing resources available for drug abusers through a video competition. We will co-organize a video competition for anti-drug abuse with C.H.O.I.C.E. The competition will appeal to the participation of all children (aged 13-18) living in the four targeted districts.
16339883|NCT04400526|Other|Phase 2: Developing a community-based network|Phase 2 aims to develop a community-based network through training anti-drug ambassadors (ADAs). We target to recruit a total of 150 children aged 13 - 18 as ADAs through secondary schools and community centres in the four targeted districts by sending invitation letters. The content of the workshop will be designed by our expert panel. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
16339884|NCT04400526|Other|Phase 3: A mass promotional campaign|Phase 3 aims to engage the public to join the community-based network through anti-drug activities organized by anti-drug ambassadors. They are encouraged to design their own promotional activities for community members in the targeted districts.Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites.
16339885|NCT04400513||Aortic Stenosis|Subjects with echo-confirmed AS graded moderate-to-severe or worse
16339886|NCT04400513||Mitral Regurgitation|Subjects with echo-confirmed MR graded moderate-to-severe or worse
16339887|NCT04400513||Tricuspid Regurgitation|Subjects with echo-confirmed TR graded moderate-to-severe or worse
16339888|NCT04400513||Innocent Murmur|Subjects with echo-confirmed trace/trivial valve disease severity
16339889|NCT04400513||Diastolic Murmur|Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
16339890|NCT04400513||Continuous Murmur|Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
16339891|NCT04400500||Suspected NSTEACS|Patients urgently admitted to the CCU with suspected NSTEACS
16339892|NCT04400487|Experimental|Voxelotor|Participants will receive voxelotor at 1500 mg
16339893|NCT04400474|Experimental|Cabozantinib 40 mg + Atezolizumab 1200 mg|"Cabozantinib 40 mg tablets, oral administration, once daily, continuously.
~Atezolizumab 1200 mg administered intravenously, every three weeks (cycle)."
16339895|NCT04400409|Active Comparator|Intervention A + site 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.
~6-Minute Walk Test (6MWT) will be administered by site staff."
16339896|NCT04400409|Active Comparator|Intervention B + site 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.
~6-Minute Walk Test (6MWT) will be administered by site staff."
16339897|NCT04400409|Active Comparator|Intervention A + CPC EQuIP 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.
~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
16339898|NCT04400409|Active Comparator|Intervention B + CPC EQuIP 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.
~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
16339899|NCT04400396||target HM fortification|Contemporary cohort fed HM with target fortification
16339900|NCT04400396||standard HM fortification|Historical cohort fed HM with standard fortification
16339901|NCT04400383|Experimental|AB011 Injection|AB011 Injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
16339902|NCT04400370||Pediatric patients undergoing lung resection|
16339903|NCT04400357|Experimental|Robotic pancreaticoduodenectomy|Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy.
16339904|NCT04400357|Active Comparator|Open pancreaticoduodenectomy|Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy.
16339905|NCT04400344||Survey Respondents|Respondents are members of the American Association of Diabetes Educators recruited via an introductory email sent out by the AADE on behalf of Podimetrics.
16339906|NCT04400331|Experimental|Valbenazine|Capsule, administered orally once daily.
16339907|NCT04400318|Experimental|Dupilumab|2 x loading dose on Day 1, followed by 1 x maintenance dose every 2 weeks (Q2W) during 24 weeks
16339908|NCT04400318|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 24 weeks
16339911|NCT04400292|Experimental|SLN mapping by NIR with ICG|Patients will undergo ICG injection and NIR imaging for lymphatic mapping. Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy. The SLN biopsy procedure will be performed as described below. Although NIR with ICG is used to assess conduit perfusion in all esophagectomies performed at MSK, its use for lymphatic mapping is considered experimental in esophageal cancer.
16339912|NCT04400279|Experimental|Yoga Exercise group|Using the Down Dog app, this group will be given access to an at-home personalized yoga practice, unique every time the participants complete it. Asked to complete yoga practice 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
16339913|NCT04400279|Experimental|High Intensity Interval Training group|Using the Down Dog app, this group will be given access to at-home bodyweight high intensity interval training (HIIT) workouts. Asked to complete these HIIT workouts 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
16339914|NCT04400279|Experimental|Combination Yoga & HIIT group|Using the Down Dog app, this group will be given access to both the unique yoga practice and bodyweight HIIT workouts. Asked to complete 2 yoga and 2 HIIT workouts per week. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
16339915|NCT04400279|No Intervention|Control group|This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
16339916|NCT04400266|Experimental|Buspirone and Melatonin|Buspirone 15mg and Melatonin 3mg
16339917|NCT04400253|Experimental|Intervention group|The intervention group will receive a 18-week in-person program. The program includes the following components: multi family group counseling, group exercise classes, mother group discussion, daughter group discussion and Fitbit.
16339918|NCT04400253|No Intervention|Control group|The group group will receive print materials about physical activity.
16339919|NCT04400240|Experimental|Intervention|complete questionnaires and phone sessions
16339920|NCT04400240|No Intervention|Control|complete questionnaires only
16339921|NCT04400227|Experimental|Youth-Parent Dyads|Participants will receive the Family Talk intervention and followup.
16340640|NCT04395183|Active Comparator|Creatine + 5-HTP|Creatine 5g PO qday plus 5-hydroxytryptophan 100mg PO BID
16339922|NCT04400214|Experimental|Food Allergy Superheroes Training (FAST) Program|Participants enrolled in this arm of the study will receive 5, 20 minutes skills training sessions designed to promote adherence to food allergy safety guidelines. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
16339923|NCT04400214|Active Comparator|Food Allergy Knowledge (FAK) Intervention|Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
16339924|NCT04400201|Experimental|Remimazolam Tosilate|
16339925|NCT04400201|Active Comparator|Propofol|
16339926|NCT04400188|Experimental|Experimental A (part 1) : Fluzoparib + temozolomide|
16339927|NCT04400188|Experimental|Experimental B (part 2) : Fluzoparib + temozolomide + SHR-1316|
16339928|NCT04400175|Experimental|B-ESP|B-ESP group will be fed with a feeding system with a valved ergonomic teat.
16339929|NCT04400175|Sham Comparator|B-STD|B-STD will be fed with a standard feeding system.
16339930|NCT04400162|Active Comparator|CCT (standard)|This arm consists of the CCT in a standard variant that provides the basic training experience without any added gaming elements.
16339931|NCT04400162|Experimental|CCT (game)|This arm consists of the same CCT as the standard version, however pre-defined gaming elements that are thought to increase usability as well as interest in the intervention have been added.
16339932|NCT04400149||1|amniotic fluid progesterone (this group will be evaluated by the amniotic fluid which was received via amniocentesis). This group consisted of pregnant women who had high risk in the antenal test and give consent to perform amniocentesis. Notwithstanding, amniocentesis detects chromosome abnormalities, neural tube defects, and genetic disorders for the fetuses. İn a routine amniocentesis, 1-2 ml amniotic fluid which was taken in the first place was discarded in order to prevent maternal contamination. Then 15-20 ml amniotic fluid was taken from all of the patients to diagnose genetic disorders of the fetuses. İn this study we evaluate the amniotic fluid progesterone in this 1-2 ml amniotic fluid which was discarded and throw away. Therefore, we are not performing an extra invasive procedure for pregnant women
16339933|NCT04400149||2|serum progesterone (this group consisted of the pregnant women who have amniocentesis procedure and blood samples were taken in the same procedure )
16339934|NCT04400136|No Intervention|GROUP A - no PPI|no PPI treatment (control group)
16339935|NCT04400136|Experimental|GROUP B PPI 1/day for 6 months|(standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
16339936|NCT04400136|Experimental|GROUP C PPI 1/day for 3 months|(standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
16339939|NCT04400110|Experimental|Short treatment group|Amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 5 consecutive days
16339940|NCT04400110|Active Comparator|Standard treatment group|amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 10 consecutive days
16339941|NCT04400097|Experimental|hidden-knot group|
16339942|NCT04400097|Active Comparator|two-knot group|
16339943|NCT04400097|Active Comparator|multi-knot group|
16339944|NCT04400084||Pregnant mothers|Pregnant mothers who have a normal pregnancy
16339945|NCT04400071|Experimental|Active Music Engagement|See intervention description.
16339946|NCT04400071|Active Comparator|Audio Storybooks|See intervention description.
16339949|NCT04400045|Experimental|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0
16339950|NCT04400032|Experimental|Panel 1|25 million cells/unit dose (cumulative dose: 75 million MSCs)
16339951|NCT04400032|Experimental|Panel 2|50 million cells/unit dose (cumulative dose: 150 million MSCs)
16339952|NCT04400032|Experimental|Panel 3|up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)
16339953|NCT04400019|No Intervention|Tracking control|"According to the randomization process described, those nursing homes assigned to the control arm of the trial will receive the same treatment as those assigned to the intervention group, except for the medication, which will be a masked placebo.
~The study is triple blind, so neither the professionals who carry out the follow-up, nor the patients, nor the person in charge of analyzing the data, know to which group each nursing home belongs."
16339954|NCT04400019|Experimental|Intervention|The dose to be used as chemoprophylaxis will be 800mg of Hydroxychloroquine (HCQ) on the first day and 400mg during the subsequent four days. Participating subjects will be followed up at 6, 14 and 28 days.
16339955|NCT04399993|Experimental|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.
~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.
~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
16339956|NCT04399993|Sham Comparator|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.
~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.
~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
16339957|NCT04399980|Active Comparator|Intervention|Treatment infusion
16339958|NCT04399980|Placebo Comparator|Control|Placebo infusion
16339959|NCT04399967|Experimental|Intervention Group|Personalized instant messaging (PIM) + COVID-19 specific advice + AWARD advice + COVID-related health warning leaflet + referral card + COSH booklet
16339960|NCT04399967|Experimental|Control Group|Regular instant messaging (RIM) + AWARD advice + warning leaflet + referral card + COSH booklet
16339961|NCT04399954|Experimental|Ketoflo|Ketoflo to be incorporated into each participant's usual ketogenic diet for 28 days. Amount taken and frequency of intake to be determined by the dietitian.
16339962|NCT04399941|Experimental|IVUS and venography group|Participants in the this group will receive venography/fistulogram, intravascular ultrasound (IVUS), and image processing.
16339963|NCT04399915||Hyperoxalemia/Hyperuricemia Group|
16339964|NCT04399915||Hyperoxalemia/Hyperuricemia-free Group|
16339965|NCT04399915||Healthy Subjects|
16339966|NCT04399902|Experimental|Study blanket|Two standard warmed hospital blankets will be placed on top of the patient and the study blanket on top of the standard warmed blankets, covering as much of the patient as possible, at the discretion of the care team. At all times, clinicians should ensure that the study blanket does not touch the patient's bare skin.The blanket will remain on the patient through their path of care, and removed from the patient at arrival to the ICU/final phase of care, or if the patient temperature exceeds 38˚C at any point.
16339970|NCT04399876|Experimental|Surgery Cohort|"Participant eligibility for intervention and selection of lesion for device placement
~- Surgery Cohort will undergo percutaneous placement of several microdevices in a selected tumor(s) prior to surgery. The microdevice in the surgery cohort will dwell in the tumor tissue for approximately 48 hours to allow time for tissue effects of the drugs in the microdevice reservoirs.
~Placement of at least 1, and up to 6, microdevices depending on the number of lesions, size and accessibility
~Extirpative surgery will proceed according to standard-of-care procedures. The microdevice(s) will be removed surgically along with surrounding tumor tissue.
~Standard of care treatment and follow-up of clinical course"
16339971|NCT04399876|Experimental|Ex-Vivo Cohort|"Each participant will undergo a screening process to determine their eligibility for microdevice placement, consisting of the following items:
~Routine standard of care for radical prostatectomy.
~Placement of implantable microdevice with multiple miniature drug reservoirs but no drug in prostate that have been removed
~Ex vivo image guided removal using retrieval device
~Standard of Care Treatment and follow-up of clinical course"
16339973|NCT04399850|Experimental|Patients who receive hypnosis|Patients who receive hypnosis during procedure by experiment physician
16339974|NCT04399850|No Intervention|Control arm|Patient with conventional pain management
16339979|NCT04399824|Experimental|Arm I (SBRT)|Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
16339980|NCT04399824|Experimental|Arm II (HDR brachytherapy)|Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
16339981|NCT04399798|Experimental|Baricitinib active treatment|Baricitinib 4 mg/day
16339982|NCT04399785|Experimental|Arm 1|
16339983|NCT04399772|Experimental|Cognitive Functional Therapy+ pathway|Treatment is performed by a CFT trained physiotherapists and a psychologist in the Pain Center. Patients receive max 10 consultations over 3 months. The first two sessions is combined with the physiotherapist and psychologist who investigates potential maintaining factors for pain and disability in the patient's everyday life. Remaining sessions are run by the physiotherapist, and the treatment is individually tailored to the needs of the individual patient, aiming to provide the patient with skills in dealing with his / her own situation via information, reflection, change of movement and training of functions and physical level. The psychologist provide extra support for 2-3 sessions to reinforce the physiotherapist work.The ethical committee made blinding conditional on a possibility of usual care after CFT+ if: the patient does not feel ready to stop treatment AND analgesic treatment is inappropriate OR the social situation is problematic OR significant psychological distress.
16339984|NCT04399772|Active Comparator|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.
~Treatment can be diverse, but based on an individual assessment it consists of a combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects) AND (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs. On average patients in the pain center receives 9-10 sessions."
16339985|NCT04399759|Experimental|A-IADL Group|Approach-Instrumental Activities of Daily Living in home
16339986|NCT04399759|Active Comparator|Control group|Home health education
16340641|NCT04395183|Placebo Comparator|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
16339987|NCT04399746|Experimental|Combination|Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).
16339988|NCT04399746|No Intervention|Control|No intervention
16339989|NCT04399733||Ethnicity|Patients will be segmented on a 1:1:1 ratio similar to the EMPOWER-1 study based on ethnicity (White, Black, South Asian).
16339990|NCT04399720||BPS group|patients under Bisphosphonate therapy for at least 24 months
16339991|NCT04399720||healthy patients|healthy patients not assuming with no previous Bisphosphonate assumption
16339992|NCT04399707|Active Comparator|Active TENS Unit|
16339993|NCT04399707|Placebo Comparator|Placebo TENS Unit|
16339994|NCT04399707|No Intervention|No TENS Unit|
16339995|NCT04399681|Other|Suspected COVID-19 Group|Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
16339996|NCT04399642|Active Comparator|Standard|Patients receiving single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision
16339997|NCT04399642|Experimental|Vanco|Patients receiving a single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure
16339998|NCT04399629|Active Comparator|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
16339999|NCT04399629|Experimental|Parenting Wisely|Online parenting training
16340000|NCT04399616|Experimental|Experimental|"The intervention consists of the availability in the patient's medical history of the visual risk map. The patients in the intervention group will have a risk map in their medical history similar to the one presented in image (annex 2), and any care provider will have immediate access to this map which we think will help them to prioritize the implementation of the relevant practices. safe (in relation to the areas that appear in red).
~Areas of risk:
~Other independent variables will be the areas of risk:
~Identification of the patient
~Functional autonomy and quality of life
~Caregiver
~Safe management and use of medicines
~Risk of falls
~Risk of injuries and pressure ulcers
~Symptom control
~Risk of infection associated with health care
~Patient and family values and beliefs
~Social risk
~Unplanned hospital admissions / proactive monitoring
~Continuity of care 7X24 h
~Transfers (between care levels)
~Safety culture
~Nursing work environment"
16340001|NCT04399616|No Intervention|No intervention|The patients in the control group will have in their medical records the usual records of the comprehensive geriatric assessment.
16340002|NCT04399603||COVID critically unwell patients|
16340003|NCT04399603||Non-Covid critically unwell Patietns|
16340004|NCT04399577|Experimental|Wart Patients|Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
16340005|NCT04399564|Active Comparator|temporary hemodialysis catheters|one arm-temporary hemodialysis catheter
16340006|NCT04399564|Experimental|long-term hemodialysis catheters|another arm-long term hemodialysis catheter
16340007|NCT04399551|Experimental|Participants with HIV infection|HIV-infected participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
16340008|NCT04399551|Other|Staff study participants (SSP)|Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
16340014|NCT04399525|Experimental|Sequence 1|Desloratadine 5 mg Levocetirizine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
16340015|NCT04399525|Experimental|Sequence 2|Desloratadine 5 mg Levocetirizine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
16340016|NCT04399525|Experimental|Sequence 3|Levocetirizine 5 mg Desloratadine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
16340017|NCT04399525|Experimental|Sequence 4|Levocetirizine 5 mg Desloratadine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
16340018|NCT04399512|Active Comparator|Patients with liver cirrhosis|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in MELD(model for end stage liver disease) will be checked after treatment.
16340019|NCT04399512|Active Comparator|Normal healthy patients|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis
16340022|NCT04399473||Control group: Usual PT Care|
16340023|NCT04399473||Experimental group: PNE + Usual PT Care|Participants in this arm will receive PNE education in addition to Usual PT Care
16340024|NCT04399460|Experimental|Low Dairy Energy Restrictive Diet|Low-dairy (<1 serving/day) and 500kcal/deficit per day energy restrictive diet
16340025|NCT04399460|Experimental|3 Servings of Full-Fat Dairy with Energy Restrictive diet|Energy-restrictive diet (500 kcal/deficit per day) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
16340026|NCT04399460|Experimental|3 Servings of Full-Fat Dairy but no energy restriction|Normal diet (no energy restriction) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
16340027|NCT04399447||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
16340028|NCT04399447||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
16340029|NCT04399447||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
16340030|NCT04399447||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
16340031|NCT04399447||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
16340032|NCT04399447||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
16340033|NCT04399434||normal pregnancy|pregnancy with a normal fetal size
16340034|NCT04399434||fetal growth restriction|fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
16340035|NCT04399434||fetal macrosomia|fetal birth weight ≥ 4000g
16340036|NCT04399421||Conventional pedicle screw fixation|Patients undergoing conventional pedicle screw fixation without the use of bone cement.
16340037|NCT04399421||Cement-augmented pedicle screw fixation|Patients undergoing pedicle screw fixation augmented with bone cement.
16340038|NCT04399408|Experimental|Study group|Device users
16340039|NCT04399395|Active Comparator|Lifestyle and naltrexone/bupropion|
16340040|NCT04399395|Other|Lifestyle|
16340041|NCT04399382||Non-radiographic group|Participants with non-radiographic axial SpA
16340042|NCT04399382||Radiographic group|Participants with radiographic axial SpA (a.k.a. ankylosing spondylitis)
16340043|NCT04399369|Experimental|SDF|38% silver diamine fluoride solution
16340044|NCT04399369|Active Comparator|NaF|5% sodium fluoride varnish
16340047|NCT04399343|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
16340048|NCT04399343|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
16340049|NCT04399317|Experimental|Group A|This is the treatment group. Patients will be ventilated using the new device (Evone) applying flow controlled ventilation for 48 hours. Ventilation parameters will be assessed every 6-8 hours. All other treatment will be unchanged and according to institutional standards.
16340050|NCT04399317|No Intervention|Group B|These patients will be treated according to institutional standards. Only data will be collected. This is the control group.
16340051|NCT04399304||Simultaneous|One-stage bilateral high tibial osteotomy
16340052|NCT04399304||Staged|Two-stage bilateral high tibial osteotomy
16340053|NCT04399291||Residential care facility residents|Older adults recruited from care homes in Northern Ireland
16340054|NCT04399278|Other|Group A|The EEO test will be applied first over 15 seconds and secondly over 30 seconds (each EEO test separated by 1 minute wash-out period)
16340055|NCT04399278|Other|Group B|The EEO test will be applied first over 30 seconds and secondly over 15 seconds (each EEO test separated by 1 minute wash-out period)
16340056|NCT04399265|Experimental|Trehalose|Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
16340057|NCT04399265|Placebo Comparator|Maltose placebo|Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
16340058|NCT04399252|Experimental|LGG Arm|Participants in this arm will be given LGG for 28 days.
16340059|NCT04399252|Placebo Comparator|Placebo|Participants in this arm will be given a placebo for 28 days.
16340061|NCT04399213|Experimental|Group A|From cubital fossae to wrist: 50 - 15 - 5 µg histamine dihydrochloride
16340062|NCT04399213|Experimental|Group B|From cubital fossae to wrist: 15 - 5 - 50 µg histamine dihydrochloride
16340063|NCT04399213|Experimental|Group C|From cubital fossae to wrist: 5 - 50 - 15 µg histamine dihydrochloride
16340064|NCT04399200||Sleep-disordered breathing group|Sleep-disordered breathing (SDB) patients (AHI>15/h, measured by polysomnography performed 3 months after stroke)
16340065|NCT04399200||Control group|Control patients with no SDB (AHI<15/h, measured by polysomnography performed 3 months after stroke)
16340066|NCT04399187|Experimental|scaling and root planing, Sodium hypochlorite gel application|Periodontal pockets > 5 mm in patients of test group were treated by scaling and root planing and Sodium hypochlorite gel application
16340067|NCT04399187|Placebo Comparator|scaling and root planing alone|scaling and root planing alone was performed
16340068|NCT04399161|Experimental|Child Participants|Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
16340136|NCT04398784|Other|1-Blueberry First/Placebo First|Participants will be randomly assigned into either blueberry-first treatment or placebo-first group.
16340069|NCT04399161|Experimental|Elderly Participants|Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
16340070|NCT04399148|Experimental|Sequence 1|Desloratadine - Aprepitant - Ketotifen
16340071|NCT04399148|Experimental|Sequence 2|Aprepitant - Ketotifen - Desloratadine
16340072|NCT04399148|Experimental|Sequence 3|Ketotifen - Desloratadine - Aprepitant
16340073|NCT04399135|Active Comparator|Normal Patients|All patients admitted to Qassim dental clinics, who need root canal treatment would be screened for possible involvement in this study
16340074|NCT04399135|Active Comparator|Periodontitis Patients|All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. the periodontitis patients would be categorized according to the new periodontitis classification 2017 world workshop.
16340075|NCT04399122|Active Comparator|Acetaminophen with codeine|codeine 30mg/acetaminophen 325mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
16340076|NCT04399122|Active Comparator|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
16340077|NCT04399109|Active Comparator|TCC-COVID mHealth solution|TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms, connected to a back-end clinical database with inbuilt data analytics.
16340078|NCT04399109|No Intervention|Control|Propensity matched and synthetic control groups will be utilised from another local health district not participating in the ReCOVER study. The control group will not be actively recruited at the same time as the intervention. The control group will be matched via data linkage at the completion of the trial. However, it is not a historical control, as the control standard of care treatment will be provided simultaneously as our intervention
16340079|NCT04399096||General population|The general public attending exhibitions of the artworks who wish to complete the on-line questionnaire and feedback
16340080|NCT04399083|Experimental|Single Arm|
16340081|NCT04399070|Placebo Comparator|Propofol group|patients were treated with propofol 1 mg/kg and saline bolus infusion before ECT
16340082|NCT04399070|Active Comparator|Ketamine group|patients were treated with propofol 1 mg/kg and ketamine 0.5 mg/kg bolus infusion before ECT
16340083|NCT04399070|Experimental|S-ketamine group|patients were treated with propofol 1 mg/kg and S-ketamine 0.25 mg/kg bolus infusion before ECT
16340084|NCT04399057||andrological patients|shear wave elastosonography of the corpora cavernosa was performed to all patients who went to our clinic for andrological problems. in addition, the International Index of Erectile Function short form (IIEF5) questionnaire and the Erectile Hardness Score (EHS) questionnaire were administered.
16340085|NCT04399044|No Intervention|Group 1: No flap|Participants will undergo the scheduled vascular surgery procedure without involvement of the plastic surgery team and use of muscle flaps for graft coverage.
16340086|NCT04399044|Experimental|Group 2: Prophylactic muscle flap|Participants will undergo the scheduled vascular surgery procedure and then a muscle flap will be used to cover the vascular graft by a plastic surgeon in the same setting.
16340087|NCT04399031|Experimental|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
16340088|NCT04399031|Experimental|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
16340089|NCT04399031|Experimental|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
16340090|NCT04399031|Experimental|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
16340091|NCT04399031|Experimental|E-cigarette e-liquid 5|Participants will self-administer an e-cigarette e-liquid.
16340092|NCT04399031|Experimental|E-cigarette e-liquid 6|Participants will self-administer an e-cigarette e-liquid.
16340093|NCT04399031|Experimental|E-cigarette e-liquid 7|Participants will self-administer an e-cigarette e-liquid.
16340094|NCT04399031|Experimental|E-cigarette e-liquid 8|Participants will self-administer an e-cigarette e-liquid.
16340095|NCT04399031|Experimental|E-cigarette e-liquid 9|Participants will self-administer an e-cigarette e-liquid.
16340096|NCT04399031|Experimental|E-cigarette e-liquid 10|Participants will self-administer an e-cigarette e-liquid.
16340097|NCT04399031|Experimental|E-cigarette e-liquid 11|Participants will self-administer an e-cigarette e-liquid.
16340098|NCT04399031|Experimental|E-cigarette e-liquid 12|Participants will self-administer an e-cigarette e-liquid.
16340099|NCT04399031|Experimental|E-cigarette e-liquid 13|Participants will self-administer an e-cigarette e-liquid.
16340100|NCT04399031|Experimental|E-cigarette e-liquid 14|Participants will self-administer an e-cigarette e-liquid.
16340101|NCT04399031|Experimental|E-cigarette e-liquid 15|Participants will self-administer an e-cigarette e-liquid.
16340102|NCT04399031|Experimental|E-cigarette e-liquid 16|Participants will self-administer an e-cigarette e-liquid.
16340103|NCT04399031|Experimental|E-cigarette e-liquid 17|Participants will self-administer an e-cigarette e-liquid.
16340104|NCT04399031|Experimental|E-cigarette e-liquid 18|Participants will self-administer an e-cigarette e-liquid.
16340105|NCT04399031|Experimental|E-cigarette e-liquid 19|Participants will self-administer an e-cigarette e-liquid.
16340106|NCT04399031|Experimental|E-cigarette e-liquid 20|Participants will self-administer an e-cigarette e-liquid.
16340107|NCT04399005|Experimental|daily room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
16340137|NCT04398784|Other|2-Crossover|Participants who received blueberry treatment will switch to placebo and vice versa.
16340164|NCT04398641||Nerve and vessel sparing segmental resection (NVSSR)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of nerve and vessel sparing segmental resection (NVSSR)
16340108|NCT04399005|Experimental|after-each-case room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. After-each-case room disinfection was defined as after completing each case.
16340109|NCT04398966|Experimental|PAE Procedure|This will be a single arm, uncontrolled, non-blinded study of PAE using HydroPearl Beads in a small population of 30 subjects with benign prostate hyperplasia (BPH)
16340110|NCT04398953|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
16340111|NCT04398940|Experimental|TQ-B3139 capsules|TQ-B3139 capsules administered orally.
16340112|NCT04398927|Experimental|Folfirinox plus PD1|Patients treated with systemic chemotherapy(regimen: Folfirinox) plus PD1
16340113|NCT04398914|Experimental|Pyrotinib, trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: pyrotinib, trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).
~After surgery：
~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.
~if tpCR: chemotherapy 0-4 cycles according to physician's choice, followed with pertuzumab and trastuzumab up to 1 year total."
16340114|NCT04398914|Active Comparator|Trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).
~After surgery：
~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.
~if tpCR: chemotherapy 0-4 cycles according to physician's choice; followed with pertuzumab and trastuzumab up to 1 year total."
16340115|NCT04398901||Colombia ZIKV-exposed|Seventy children in Colombia were previously enrolled as part of a fetal-neonatal neuroimaging study in 2016-2017 and were from Department of Atlantico, Colombia on the Caribbean coast. Eligible children had prior normal fetal MRI and fetal US, normal birth head circumference, normal clinical exam, no more than mild non-specific postnatal imaging findings, and are thus without findings of CZS.
16340116|NCT04398901||Colombia Non-ZIKV exposed control|The investigators will enroll 70 non-ZIKV exposed children, age 4 to 5 years, in Department of Atlántico, Colombia with birth dates prior to March 31, 2016. Based on the arrival of ZIKV to Colombia in November 2015, this date would ensure a control cohort without congenital ZIKV exposure in the first half of gestation and unlikely during any of the pregnancy.
16340117|NCT04398901||United States ZIKV-exposed|The US cohort either presented during pregnancy or after birth and sought clinical care with the Children's National Congenital Zika Program in Washington, DC and were ZIKV-exposed.
16340118|NCT04398901||United States Non-ZIKV exposed control|The investigators will enroll 32 non-ZIKV exposed children, age 4 years, in Washington, DC.
16340119|NCT04398888|Experimental|BXD|"Participants will be diagnosed and treated by Chinese medicine practitioners (CMPs) with at least 5 years of clinical experience. CMPs will differentiate syndrome and prescript herbs in a semi-standardized protocol, which consists of a base Chinese medicine decoction, BXD, and the additional syndrome-specific herbs.
~The modified decoction will be prepared in a conventional decocting method at the Chinese medicine pharmacy in the clinic (HKBA-HKU CMCTR) and will be packaged into bags by the auto-decocting machines. Participants will take the decoction twice per day, 5 days per week, for 3 weeks."
16340120|NCT04398888|No Intervention|Waitlist|Participants in the waiting list control group will be observed for a three-week waiting period. Rescue medication is not restricted.
16340121|NCT04398875|Experimental|ASC|Traditional manual acupuncture with standard care (ASC) will be provided. Subjects in the ASC group will receive 9 sessions of acupuncture and standard care for 3 weeks. A semi-standardized acupuncture treatment protocol (combined fixed acupoints with additional acupoints by symptom differentiation) will be employed. The fixed acupuncture points including, Guanyuan (CV4), Xuanzhong(GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Zusanli (ST36), Yingtang (EX-HN3), Baihui (GV20), and Qihai (CV6) will be used in every session.
16340122|NCT04398875|Sham Comparator|SSC|Sham acupuncture plus standard care (SSC) will be provided. Subjects in the SSC group will receive 9 sessions of sham acupuncture and standard care for 3 weeks. The Streitberger sham acupuncture will be employed. The selection of acupoints is the same as ASC.
16340123|NCT04398875|Placebo Comparator|SC|Standard care alone (SC) will be provided. Subjects in the SC group will standard care for 3 weeks.
16340124|NCT04398862||Children with Down syndrome and aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
16340125|NCT04398862||Children with Down syndrome without aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
16340126|NCT04398849||14-19 year olds residing in the Northern Territory|All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
16340127|NCT04398836|Active Comparator|Malnourished patients - EEN|patiens will receive EEN for 4 week prior surgery
16340128|NCT04398836|Other|Malnourished patients - enriched diet|patiens will receive an enriched high energy and protein diet.
16340129|NCT04398836|Other|Well nourished patients|Patient will receive a standard nutrition
16340130|NCT04398823|Active Comparator|Foam sclerotherapy,FS|Participants in this arm will receive the enteroscopic treatment with the sclerosing foam of lauromacrogol.
16340131|NCT04398823|Placebo Comparator|Liquid sclerotherapy,Ls|Participants in this arm will receive the enteroscopic treatment with the liquid of lauromacrogol.
16340132|NCT04398810|Experimental|the low-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery
~Cholelithiasis
~Chronic cholecystitis
~Gallbladder polyps
~Gallbladder adenoma
~Porcelain gallbladder
~The experimental group controls the CO2 flow that is injected into the abdominal cavity during surgery and maintains the pressure in the abdominal cavity at a low level of 5 mmHg to perform the surgery."
16340133|NCT04398810|Experimental|the standard-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery
~Cholelithiasis
~Chronic cholecystitis
~Gallbladder polyps
~Gallbladder adenoma
~Porcelain gallbladder
~In the case of the control group, surgery is performed while maintaining the pressure in the abdominal cavity at 12 mmHg as generally performed during surgery."
16340134|NCT04398797|Experimental|Intervention|Use of notification algorithm and nurse follow-up
16340135|NCT04398797|No Intervention|Control|Standard regime (usual care)
16340138|NCT04398771||Treatment|Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)
16340139|NCT04398758|Experimental|Treatment group|"Children of the treatment group receive the cream SanaCutan Basiscreme. The cream's main ingredients are white soft paraffin and liquid paraffin and it is already approved for the treatment of several skin diseases due to its skin care effect."
16340140|NCT04398758|No Intervention|Control group|Children of the control group should avoid regular skincare applications. Skincare is not prohibited, however, it is recommended to use products only in urgent cases.
16340141|NCT04398745|Experimental|Part 1: Participants with normal/mild impaired renal function|Participants with normal or mildly impaired renal function (Normal: estimated glomerular filtration rate [eGFR]: >=90 milliliter per minute per 1.73 meter square [mL/min/1.73 m^2]; Mild impairment: eGFR: 60-89 mL/min/1.73 m^2) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
16340142|NCT04398745|Experimental|Part 1: Participants with severe renal impairment|Participants with severely impaired renal function (eGFR: 15-29 mL/min/1.73 m^2) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
16340143|NCT04398745|Experimental|Part 2: Participants with ESRD (not on dialysis)|"Participants with ESRD (eGFR:
~<15 mL/min/1.73 m^2) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, dose will be decided after evaluation of pharmacokinetic and safety data of Part 1."
16340144|NCT04398745|Experimental|Part 2: Participants with ESRD (on hemodialysis)|Participants with ESRD (eGFR: <15 mL/min/1.73 m^2) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
16340145|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
16340146|NCT04398719|Active Comparator|CBD|
16340147|NCT04398719|Placebo Comparator|Placebo|
16340148|NCT04398706|Experimental|Group 1|One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
16340149|NCT04398706|Experimental|Group 2|One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
16340150|NCT04398706|Experimental|Group 3|One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
16340151|NCT04398706|Active Comparator|Group 4|One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
16340152|NCT04398706|Experimental|Group 5|Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
16340153|NCT04398706|Experimental|Group 6|Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
16340154|NCT04398706|Experimental|Group 7|Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
16340155|NCT04398706|Active Comparator|Group 8|Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
16340156|NCT04398693|No Intervention|Normotensive Patients|40 normotensive patients with systolic BP (SBP) < 140 mmHg and diastolic BP (DBP) < 90 mmHg at the office, without the use of antihypertensive drugs and evaluated through ambulatory blood pressure monitoring (ABPM) to confirm normotension (BP < 130/80 mmHg) and the exclusion of possible masked hypertension.
16340157|NCT04398693|No Intervention|Controlled Hypertensive Patients|40 controlled hypertensive patients using up to three antihypertensive drugs with SBP < 130 mmHg and DBP < 80 mmHg evaluated through 24 hours ambulatory blood pressure monitoring (ABPM).
16340158|NCT04398693|Active Comparator|Resistant Hypertensive Patients|The study will be double-blinded, randomized, placebo-controlled crossover Initially, 20 individuals of the resistant hypertensive group will take prebiotic for 4 weeks, while other 20 individuals this group will use placebo. After a washout period of 4 weeks, the study protocol will be repeated in the other arm.
16340159|NCT04398680|Experimental|Part 1, Group 1: Participants with normal hepatic function|Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase [AST] less than or equal to [<=] Upper limit of normal [ULN]) will be administered with Belantamab mafodotin
16340160|NCT04398680|Experimental|Part 1, Group 2: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Serum bilirubin greater than >1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin
16340161|NCT04398680|Experimental|Part 2,Group 3: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Serum bilirubin >3 times ULN and any AST) will be administered with Belantamab mafodotin
16340162|NCT04398654|No Intervention|Control Group|Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.
16340163|NCT04398654|Active Comparator|Intervention Group|As in control group. In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.
16340165|NCT04398641||Transanal disc excision (TADE)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of transanal disc excision (TADE)
16340166|NCT04398628||Hemophilia|"This cohort includes three Arms:
~PUPs Arm:
~This Arm is for previously untreated patients (PUPs) with congenital hemophilia A or B. This is a longitudinal, observational, prospective and retrospective Arm of PUPs with moderate or severe congenital hemophilia. Participants will be followed to assess inhibitor development within 50 exposure days (ED).
~Hemophilia Natural History Arm:
~This Arm is investigating a natural history of the safety, effectiveness, and practice of treatment for people with hemophilia. It is a longitudinal, observational, prospective Arm for participants with acquired or congenital hemophilia A or B.
~Hemophilia Gene Therapy Outcomes Arm:
~This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. It is a longitudinal, observational cohort Arm following participants prospectively and retrospective for 15 years after vector infusion."
16340167|NCT04398628||Von Willebrand Disease|The Severe VWD Natural History Arm is investigating the natural history of the safety, effectiveness, and practice of treatment for people with severe von Willebrand disease (VWD). It is a longitudinal, observational cohort Arm following participants every 6 months for at least 2 years.
16340168|NCT04398628||Congenital Platelet Disorders|No Arms or Modules at this time.
16340169|NCT04398628||Rare Bleeding Disorders|No Arms or Modules at this time
16340170|NCT04398628||Bleeding NOS|No Arms or Modules at this time
16340171|NCT04398628||Thrombosis/Thrombophilia|No Arms or Modules at this time
16340172|NCT04398628||Non-Neoplastic Hematologic Conditions|No Arms or Modules at this time
16340173|NCT04398615|Experimental|Intervention|Single arm, receiving the experimental device
16340174|NCT04398589|Experimental|SSNB and ANB c DEX|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.
16340175|NCT04398589|Placebo Comparator|SSNB and ANB c saline|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.
16340176|NCT04398576|No Intervention|Support as usual|"There will be no interventions, only support as usual. All GPs receive an information package by post or via e-mail containing:
~Belgian guidelines on the management of hazardous and harmful alcohol use
~A summary card about EIBI for hazardous and harmful alcohol consumption.
~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).
~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider."
16340177|NCT04398576|Active Comparator|Training and support|"All GPs receive an information package by post or via e-mail containing:
~Belgian guidelines on the management of hazardous and harmful alcohol use
~A summary card about EIBI for hazardous and harmful alcohol consumption.
~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).
~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider.
~There shall be tailored training and support for the general practioners. At the start of the study, this group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months."
16340178|NCT04398576|Active Comparator|Training and support and community actions|In this group, GPs receive the same training and support as in the second arm (training and support). There will also be embedded community-based actions within a local strategy.
16340179|NCT04398550|Experimental|Specific Carbohydrate Diet|Exclusive consumption of the specific carbohydrate diet for 6 weeks
16340180|NCT04398550|Experimental|Mediterranean Diet|Exclusive consumption of the Mediterranean diet for 6 weeks
16340181|NCT04398537|Experimental|5mm retraction of clip deployment apparatus|The participants in this group will have clip placement 5mm in front of the biopsy site site.
16340182|NCT04398537|Active Comparator|no retraction of clip deployment apparatus|These participants will the clip delivered at the biopsy site.
16340183|NCT04398524|Experimental|single arm|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
16340184|NCT04398511|Experimental|L brevis|Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
16340185|NCT04398511|Placebo Comparator|Placebo|Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
16340186|NCT04398498||Cohort A: Clinical Practice|Subjects more than 60 days post-transplant
16340187|NCT04398498||Cohort B: Long Term Follow-Up|Subjects who are at least 2 years post transplant up to 5 years post-transplant
16340188|NCT04398485|Experimental|ION251|In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion.
16340189|NCT04398472|Active Comparator|Challenge|"Participants in the challenge will be asked to complete four activities over the next four weeks to address loneliness and social isolation in their communities.
~The activities will involve doing an activity with people in their neighbourhood. These activities have been selected based on being positive, engaging and feasible to the average individuals. An example of the type of activities is having a conversation with a neighbour on the phone or via video chat and safely checking in on someone who is elderly or living alone. All activities will adhere to the relevant country or states health department's safety recommendations and laws during COVID-19.
~Hypothesis 1 (H1). There will be a reduction in the primary outcome, loneliness in participants assigned to the Nextdoor KIND Challenge groups compared to the waitlist control group post the 4-week intervention"
16340190|NCT04398472|No Intervention|Waitlist|
16340191|NCT04398459|Experimental|IBRIAN|
16340642|NCT04395170|Experimental|Convalescent plasma|Plasma from patients recovering from COVID-19.
16340194|NCT04398433|Experimental|INO-3107|Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
16340195|NCT04398420|Active Comparator|TVERP|
16340196|NCT04398420|Active Comparator|TURis|
16340197|NCT04398420|Active Comparator|HoLEP|
16340200|NCT04398394|Experimental|Group 1|Individuals with healthy retina, 18 to 50 years old.
16340201|NCT04398394|Experimental|Group 2|Individuals with healthy retina and presenting with myopia, 18 to 50 years old.
16340202|NCT04398394|Experimental|Group 3|Individuals with healthy retina, over the age of 50.
16340203|NCT04398394|Experimental|Group 4|Patients with early and intermediate AMD, over the age of 50.
16340204|NCT04398394|Experimental|Group 5|Patients with other retinopathies than AMD, over the age of 18.
16340205|NCT04398368|Experimental|Prevention (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.
16340206|NCT04398355|No Intervention|control|basic treatment+Swallowing rehabilitation training
16340207|NCT04398355|Experimental|treatment|basic treatment+Swallowing rehabilitation training+Chinese traditional rehabilitation
16340208|NCT04398342||Children with Cerebral Palsy in Denmark|Children diagnosed with cerebral palsy born 2003 - 2020 and registered in the Danish Cerebral Palsy Follow-up Program.
16340209|NCT04398329|Experimental|Phase 1b (Cohort 1)|Single dose level of HTX-034.
16340210|NCT04398329|Experimental|Phase 1b (Cohort 2)|Individualized doses of HTX-034.
16340211|NCT04398329|Experimental|Phase 2 (Dose C)|Dose of HTX-034 selected from Phase 1b.
16340212|NCT04398329|Experimental|Phase 2 (Dose D)|Dose of HTX-034 selected from Phase 1b.
16340213|NCT04398329|Active Comparator|Phase 1b and Phase 2|Bupivacaine HCl.
16340214|NCT04398316|Experimental|Intravenous Lidocaine|Administered at a dose of 2 mg/kg over 5 minutes
16340215|NCT04398316|Active Comparator|Intravenous Hydromorphone|Administered at a dose of 1 mg over 5 minutes
16340216|NCT04398303|Experimental|ACT-20-MSC in ACT-20-CM|Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
16340217|NCT04398303|Experimental|ACT-20-CM|Conventional treatment plus ACT-20-CM administered intravenously
16340218|NCT04398303|Placebo Comparator|Placebo|Conventional treatment plus placebo (MEM-α) administered intravenously
16340219|NCT04398290|Experimental|iNOpulse Treatment Group|Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days.
16340220|NCT04398290|Active Comparator|Placebo Group|Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days
16340221|NCT04398277|Active Comparator|Initial Low dose|Participants will receive only one daily positive emotion prompt in the first seven days of the toolkit use.
16340222|NCT04398277|Active Comparator|Initial high dose|Participants will receive two daily positive emotion prompts in the first seven days of use.
16340223|NCT04398251|Experimental|Uric acid drug control group|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week
16340224|NCT04398251|Active Comparator|Non-drug control group|They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
16340225|NCT04398238||Pre-PBM|patients screened for surgery before the implementation of PBM program: pre-operative evaluation and treatment according to usual care
16340226|NCT04398238||post-PBM|patients screened for surgery after the implementation of PBM program (3 months allowed for training/optimization): all patients with pre-operative hemoglobin < 13g/dl undergo screening for causes and treatment as needed.
16340227|NCT04398225|Experimental|Cohort 1 (9-12 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
16340228|NCT04398225|Experimental|Cohort 2 (9-12 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
16340229|NCT04398225|Experimental|Cohort 3 (9-12 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
16340230|NCT04398225|Experimental|Cohort 4 (6-8 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
16340231|NCT04398225|Experimental|Cohort 5 (4-5 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
16340232|NCT04398212|Placebo Comparator|Non-complaining group|the students in this group are not complaining of CVS symptoms but will be examined to diagnose CVS or exclude it
16340233|NCT04398212|Experimental|Complaining group|the students in this group are complaining of CVS symptoms but will be examined to document their complains and correlate to clinical findings
16340274|NCT04398108|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
16340234|NCT04398199|Experimental|Hypofractionated Radiation Therapy|Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.
16340235|NCT04398186||Study group 1|Hiperandrogenism + ultrasonographic PCO
16340236|NCT04398186||Study group 2|Menstruel cycle irregular + ultrasonographic PCO
16340237|NCT04398186||Study group 3|Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism
16340238|NCT04398186||Control group|Do not have PCOS
16340239|NCT04398173||Group A (previous negative biopsy)|Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI
16340240|NCT04398173||Group B (biopsy naive)|Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI
16340241|NCT04398160|Experimental|HVLA manipulation|"In the intervention of the experimental group, the investigator will be primarily on the right side of the volunteer and identify C3 through the cervical reference of jaw angle, which is at the disc level between C2/C3 and then contact with the phalanges of third metacarpal in the left transverse of this vertebra.
~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
16340242|NCT04398160|Sham Comparator|Sham technique|"The investigator will be primarily on the right side of the volunteer and identify the C3 vertebra, having as anatomical reference the angle of the jaw, which is at the disc level between C2/C3 and then contact, with the phalanges of the third metacarpal, the left transverse apophysis of this vertebra.
~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
16340243|NCT04398160|No Intervention|No intervention group|The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally.
16340244|NCT04398147|Experimental|phase ⅠLow single dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
16340245|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (18-<55)|6 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
16340246|NCT04398147|Experimental|phase ⅠLow 2 dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
16340247|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (18-<55)|6 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
16340248|NCT04398147|Experimental|phase ⅠLow single dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
16340249|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
16340250|NCT04398147|Experimental|phase ⅠLow 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
16340251|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
16340252|NCT04398147|Experimental|phase ⅠMedium single dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
16340253|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
16340254|NCT04398147|Experimental|phase ⅠMedium 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
16340255|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
16340256|NCT04398147|Experimental|Phase II Low single dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
16340257|NCT04398147|Placebo Comparator|Phase II placebo low single dose (18-<55)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
16340258|NCT04398147|Experimental|Phase II Low 2 dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
16340259|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (18-<55)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
16340260|NCT04398147|Experimental|Phase II Low single dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
16340261|NCT04398147|Placebo Comparator|Phase II placebo low single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
16340262|NCT04398147|Experimental|Phase II Low 2 dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
16340263|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
16340264|NCT04398147|Experimental|Phase II medium single dose (55-<85)|50 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
16340265|NCT04398147|Placebo Comparator|Phase II placebo medium single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
16340266|NCT04398147|Experimental|Phase II medium 2 dose (55-<85)|50 subjects，Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
16340267|NCT04398147|Placebo Comparator|Phase II placebo medium 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
16340268|NCT04398147|Experimental|Phase II Low 1 or 2 dose (18-<55)|100 subjects，Ad5-nCoV containing 5E10 vp, 1or2 dose, Intramuscular administration ，according to the Previous trial results
16340269|NCT04398147|Placebo Comparator|Phase II placebo 1 or 2 dose (18-<55)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
16340270|NCT04398147|Experimental|Phase II Low or medium dosage 1 or 2 dose (55-<85)|100 subjects，Ad5-nCoV containing 5E10 vp or 10E10vp, 1or2 dose, Intramuscular administration，according to the Previous trial results
16340271|NCT04398147|Placebo Comparator|Phase II placebo Low or medium,1 or 2 dose (55-<85)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
16340272|NCT04398134|Experimental|ABI-H2158 plus ETV|ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
16340273|NCT04398134|Placebo Comparator|Placebo plus ETV|Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
16340312|NCT04397666|Experimental|1|
16340275|NCT04398095|Experimental|Radiotherapy with hyperthermia in resectable sarcomas|12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
16340276|NCT04398095|Experimental|Radiotherapy with hyperthermia in non-resectable sarcomas|12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
16340277|NCT04398069|No Intervention|Standard Group|standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.
16340278|NCT04398069|Experimental|personalized hemodynamic goals Group|Personalized hemodynamic goals and catecholamin infusion to achieve normal cerebral perfusion assessed by transcranial doppler: PI < 1,2.
16340279|NCT04398056|Experimental|Chemotherapy plus radiotherapy and Toripalimab|Patients were treated with PF chemotherapy for a maximum of six cycles followed by loco-regional radiotherapy combined with toripalimab.
16340280|NCT04398030|Experimental|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
16340281|NCT04398030|Active Comparator|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
16340282|NCT04398017|Active Comparator|Standard support|
16340283|NCT04398017|Experimental|Hypnosis|
16340284|NCT04398004|Experimental|Clarithromycin arm|Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
16340285|NCT04397991|Experimental|Furosemide|Patients will receive nebulised furosemide
16340286|NCT04397991|Placebo Comparator|Placebo|Patients will receive nebulised 0.9% saline
16340287|NCT04397965|Experimental|Experimental: Continuous Monitoring|Intervention: Device: Cascade Continuous Glucose Monitoring System
16340288|NCT04397939||Patients with Cardiac Injury|Patients with cardiac injury
16340289|NCT04397939||Patients without cardiac injury|Patients without cardiac injury
16340290|NCT04397926|Experimental|neoantigen vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
16340291|NCT04397913||Treatment(paracetamol or ibuprofen)|Paracetamol and ibuprofen are administered at standard dose for children with PDA.
16340292|NCT04397887|Experimental|Men with Azoospermia and varicocele|In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods
16340293|NCT04397822||COVID-19 GROUP Intensive care unit|Patients suffering from COVID-19 hospitalized in intensive care unit
16340294|NCT04397822||COVID-19 GROUP Standard care unit|Patients suffering from COVID-19 hospitalized in standard care unit.
16340295|NCT04397809||Acute Pulmonary Exacerbation (APE)|Those subjects presenting with APE will be treated with at least two pathogen specific I.V. antibiotics, as dictated by their treating physician and compliant with standard guidelines for care of an APE.
16340296|NCT04397809||Baseline Health|Those subjects presenting at baseline health will be identified by their treating physician as such and will not be starting on any treatments for APE.
16340297|NCT04397796|Experimental|BM-Allo.MSC|Subjects in the experimental arm will be administered BM-Allo.MSC
16340298|NCT04397796|Placebo Comparator|Placebo|Subjects in the control arm will be treated with placebo
16340299|NCT04397783|No Intervention|Cruciate incision|the classic cruciate incision in the colostomy construction
16340300|NCT04397783|Experimental|longitudinal incision|longitudinal incision with two proline sutures
16340301|NCT04397770|Experimental|Camre+Apa+TMZ|
16340302|NCT04397757|Experimental|COVID-19 Convalescent plasma|COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
16340303|NCT04397757|No Intervention|Standard care|Standard care alone
16340304|NCT04397744|Experimental|Unidas por Vida y Salud prevention program|Unidas por Vida y Salud (United for Life and Health) prevention program
16340305|NCT04397744|No Intervention|No intervention control|The control arm will not receive the Unidas por Vida y Salud (United for Life and Health) prevention program during the study analysis period (though, the control arm will receive the intervention after study has been completed).
16340306|NCT04397718|Placebo Comparator|Placebo + BSC|No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
16340307|NCT04397718|Experimental|Degarelix + BSC|Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
16340308|NCT04397705|Experimental|Ambulatory monitoring|Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
16340309|NCT04397692|Experimental|Inhaled NO delivered using LungFit™ in addition to SST|Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
16340310|NCT04397692|No Intervention|Standard of care|Control - Standard of care
16340311|NCT04397679|Experimental|Treatment (radiation therapy, temozolomide, chloroquine, TTF)|"Patients undergo 30 fractions of 3D CRT or Intensity-modulated radiation therapy (IMRT) and receive temozolomide by mouth (PO) and chloroquine PO daily from day 1 for the duration of radiation therapy up to day 49. Treatment continues in the absence of disease progression or unacceptable toxicity.
~ADJUVANT TREATMENT: Beginning 4 weeks after the last day of radiation therapy, patients receive temozolomide PO QD on days 1-5 and chloroquine PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients demonstrating continued benefit may continue to receive temozolomide and chloroquine for up to 12 cycles. Patients also undergo TTF therapy over 18 hours or longer per day."
16340313|NCT04397653|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
16340314|NCT04397653|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
16340315|NCT04397640|Other|Sonovue|ICU patients with sepsis and septic shock who are eligible for myocardial contrast echocardiography with sulphur hexafluoride microbubbles contrast Sonovue (Bracco, Milan, Italy) injection.
16340316|NCT04397614|Experimental|No Elevated Risk for COVID-19 Detected|Continue daily mHealth assessments
16340317|NCT04397614|Experimental|Elevated Risk for COVID-19 Detected|Daily mHealth assessments and telemedicine/nurse triage. If non-emergent intervention, enhanced symptom monitoring will occur.
16340318|NCT04397601||A|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
16340319|NCT04397601||B|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
16340320|NCT04397562|Experimental|LVL group|Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy
16340321|NCT04397562|Placebo Comparator|Placebo group|Single subcutaneous administration of placebo in combination with standard therapy
16340322|NCT04397549|Active Comparator|Block group|Cervical Erector Spinae Plane Block administered group
16340323|NCT04397549|Sham Comparator|Control group|Control group
16340324|NCT04397536||Cohort|Patients diagnosed with MDR-TB
16340325|NCT04397523|Other|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
16340326|NCT04397510|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
16340327|NCT04397510|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days
16340328|NCT04397497|Experimental|Mavrilimumab|Single dose of IV Mavrilimumab
16340329|NCT04397497|Placebo Comparator|Placebo|Single dose of matching IV placebo
16340330|NCT04397484|Active Comparator|Levobupivacaine|0.5% levobupivacaine (0.5% Chirocaine) 30ml (150mg) will be injected once for regional anaesthesia before surgery
16340331|NCT04397484|Active Comparator|Xylocaine + adrenaline|2% Xylocaine with adrenaline 1:200,000 30ml (450mg) will be injected once for regional anaesthesia before surgery
16340332|NCT04397471||Healthy Volunteer|A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests.
16340333|NCT04397458|Sham Comparator|Sham Control|20 milliliters (mL) 0.9% saline on each side
16340334|NCT04397458|Experimental|Quadratus Lumborum Block|20 mL solution with 0.25% bupivacaine (50 milligrams (mg)) and 3mg preservative-free dexamethasone on each side
16340335|NCT04397445|Experimental|Ranitidine and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of ranitidine (300 mg) plus low nitrite/NDMA meals (noncured-meats diet)
16340336|NCT04397445|Placebo Comparator|Placebo and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of placebo plus low nitrite/NDMA meals (noncured-meats diet)
16340337|NCT04397445|Experimental|Ranitidine and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of ranitidine (300 mg) plus high nitrite/NDMA meals (cured-meats diet)
16340338|NCT04397445|Placebo Comparator|Placebo and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of placebo plus high nitrite/NDMA meals (cured-meats diet)
16340339|NCT04397432||Elemene plus TKIs|This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
16340340|NCT04397432||TKIs only|This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
16340341|NCT04397419|Experimental|Intervention group|This group is administered a total of 750 ml Red Bull® Energy Drink at defined time-intervals.
16340342|NCT04397419|Placebo Comparator|Placebo group|This group is administered a total of 750 ml still water at defined time-intervals.
16340343|NCT04397406|Active Comparator|Group C (Control group)|pidural analgesia with levobupivacaine alone
16340344|NCT04397406|Experimental|Group D (Dexmedetomidine group)|Epidural analgesia with levobupivacaine and dexmedetomidine
16340345|NCT04397406|Experimental|Group F (Fentanyl group)|Epidural analgesia with levobupivacaine and fentanyl
16340346|NCT04397393||non-camel milk consumption|non-camel milk consumption over life time
16340347|NCT04397393||camel milk consumption|camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).
16340348|NCT04397380||ED Patients|Patients Presenting in Emergency Department
16340349|NCT04397367|Experimental|Ruxolitinib10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
16340350|NCT04397367|Experimental|Ruxolitinib5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
16340351|NCT04397367|Experimental|Ruxolitinib5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
16340352|NCT04397367|Experimental|Ruxolitinib 2.5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
16340353|NCT04397354|Active Comparator|Group 1|intracochlear dexamethasone application during cochlear implantation
16340354|NCT04397354|Active Comparator|Group 2|intratympanic dexamethasone application during cochlear implantation
16340355|NCT04397354|Sham Comparator|Group 3|No drugs during cochlear implantation
16340356|NCT04397341|Experimental|biweekly TPF induction|Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2
16340357|NCT04397328|Experimental|Hydroxychloroquine 200mg|Regular Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg twice a day for 4 consecutive days (5 days in total) Modified Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
16340358|NCT04397328|Placebo Comparator|Placebo Arm|The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
16340359|NCT04397315|Active Comparator|Complete Pulpotomy|In case of complete pulpotomy procedure the exposed pulp tissue will be amputated using sterile bur in high speed hand piece to the level of canal orifices.
16340360|NCT04397315|Active Comparator|Partial Pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece to a depth of 2-3 mm.
16340361|NCT04397289|Experimental|Heparin group|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
16340362|NCT04397289|Experimental|Rivaroxaban group|Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
16340363|NCT04397289|Sham Comparator|Control group|No preventive intervention measures.
16340364|NCT04397276|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
16340365|NCT04397276|Experimental|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
16340367|NCT04397250|Experimental|High-intensity interval training|Participants will be asked to perform four 30 minutes bouts of high-intensity interval exercise per week.
16340368|NCT04397250|No Intervention|Control|Participants will be asked to continue their habitual lifestyle
16340369|NCT04397237||Systemic Lupus Erythematosus|Consecutive Systemic Lupus Erythematosus patients followed-up in each service
16340370|NCT04397237||Sjogren's Syndrome|Consecutive Sjogren's Syndrome patients followed-up in each service
16340371|NCT04397237||Axial Spondyloarthritis|Consecutive Axial Spondyloarthritis patients followed-up in each service
16340372|NCT04397237||Rheumatoid Arthritis|Consecutive Rheumatoid Arthritis patients followed-up in each service
16340373|NCT04397237||Giant Cell Arteritis|Consecutive Giant Cell Arteritis patients followed-up in each service
16340374|NCT04397224||CRT responder|
16340375|NCT04397224||CRT non-responder|
16340376|NCT04397211|Active Comparator|Angiography-derived FFR-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by Angiography-derived FFR-guided strategy
16340377|NCT04397211|Active Comparator|IVUS-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by IVUS-guided strategy
16340378|NCT04397198||HIBRIDH-SG 01|Study subjects with documented ST segment Elevation Myocardial Infarction
16340379|NCT04397185|Experimental|Breast Cancer Locator (BCL)|Subject randomized to BCL surgical guidance to perform partial mastectomy
16340380|NCT04397185|Active Comparator|Wire Localization (WL)|Subject randomized to WL surgical guidance to perform partial mastectomy
16340381|NCT04397159|Experimental|Combination Exercise|Flywheel resistance exercise plus aerobic exercise
16340382|NCT04397159|No Intervention|Standard-of-care|Participants will maintain standard-of-care and current activity levels during the course of the study.
16340383|NCT04397146|Experimental|Single-blind sensory and satiety evaluation|In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
16340384|NCT04397133|Experimental|intervention 1|in this group patients will get 4 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
16340385|NCT04397133|Experimental|intervention 2|in this group patients will get 8 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
16340386|NCT04397133|Sham Comparator|control group|this group will get sham intervention with 0 to 5 cmH2O resistance
16340387|NCT04397107|Experimental|Recombinant Human Interleukin-2|Induced remission period,recombinant human IL-2(500,000 unit per square meter) infusions five days;Maintenance treatment period,recombinant human IL-2 infusions five days then once every two weeks for 6 months.
16340388|NCT04397107|No Intervention|Traditional therapy|Patients were treated with glucocorticoid and/or immunosuppressor.
16340389|NCT04397094|Experimental|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
16340390|NCT04397094|Active Comparator|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
16340391|NCT04397081||Control Group|Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
16340392|NCT04397081||Study group|"Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed atopic disease (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
~Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded."
16340393|NCT04397068|Other|macular pucker wherefore vitrectomy|one eye phaco-vitrectomy and other eye only phaco. No other involvement of drug or device. Standard of care procedure
16340394|NCT04397055|Experimental|Cottonseed Oil|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
16340395|NCT04397055|Active Comparator|Olive Oil|Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
16340396|NCT04397042||recurrent pregnancy loss|Group 1 included thirty women admitted to our clinic for termination of pregnancy due to absence of fetal cardiac activity or absence of fetal pole on ultrasonographic examination. Patients with a history of two or more unexplained first trimester miscarriages and no live births were included in the study
16340397|NCT04397029|Experimental|Subjects without messes|Subjects who are believed to be free of masses.
16340398|NCT04397029|Experimental|Subjects with known masses|Subjects with known masses.
16340399|NCT04397016|No Intervention|Arm 1: Usual Care|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.
~Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure."
16340400|NCT04397016|Experimental|Arm 2: Option Grid|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.
~Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure."
16340401|NCT04397003|Experimental|Neoantigen DNA vaccine+durvalumab|"Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks
~Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks
~Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity
~Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle."
16340402|NCT04396990|Experimental|Group A Dextenza|
16340403|NCT04396990|Active Comparator|Group B Topical Prednisolone|
16340404|NCT04396977|Other|Histamine and placebo skin pricks|Each subject will receive the same histamine (10 mg/ml) and control (saline) skin prick on the right and left forearm on both study visits, to allow an intra-individual comparison
16340405|NCT04396964||surgery|subjects undergoing multilevel lumbar fusion
16340406|NCT04396951|No Intervention|Passive external overheating|"Passive external overheating in the environmental temperature control adjusted to thermal comfort.
~Measure during 6 hours with indirect calorimetry"
16340407|NCT04396951|Active Comparator|Active external overheating with heating plate|Combination of passive and active external heating with heating plate Measure during 6 hours with indirect calorimetry
16340408|NCT04396951|Active Comparator|Active external overheating with air blanket|Combination of passive and active external heating with convective air blanket Measure during 6 hours with indirect calorimetry
16340409|NCT04396938|Experimental|Lamotrigine|Single dose of Lamotrigine (300mg - capsule). In healthy volunteers.
16340410|NCT04396938|Placebo Comparator|Placebo|Placebo capsule: identical appearance to experimental capsule. In healthy volunteers.
16340411|NCT04396912||Control, s/p TT, without complication|Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)
16340412|NCT04396912||Experimental, s/p TT with only VCP|Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)
16340413|NCT04396912||Experimental, s/p TT with only H|Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)
16340414|NCT04396912||Experimental, s/p TT with both VCP+H|"Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);
~Subgroups:
~4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)
~Please answer:
~Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)
~Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?"
16340415|NCT04396899|Other|EHM Implantation|All patients will receive EHM implant
16340416|NCT04396886|Experimental|Bintrafusp Alfa|Single group assignment of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) nonkeratinizing nasopharyngeal carcinoma (NPC)
16340454|NCT04396665|Experimental|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
16340455|NCT04396665|No Intervention|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
16340568|NCT04395703||Maternity staff|Interviews with maternity staff working within a maternity unit including midwifery managers and infant feeding lead staff members.
16340420|NCT04396847|Experimental|Lorcaserin|Lorcaserin (10mg BID)
16340421|NCT04396847|Placebo Comparator|Placebo|Placebo pill (BID)
16340422|NCT04396834|Experimental|Lorcaserin|Lorcaserin (10mg BID)
16340423|NCT04396834|Placebo Comparator|Placebo|Placebo pill (BID)
16340424|NCT04396821|Experimental|Part A Q2W|Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, 5 dose levels will be tested.
16340425|NCT04396821|Experimental|Part A Q3W|Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg,, and 4 dose levels will be tested.
16340426|NCT04396821|Experimental|Part B Cohort 1|Participants with gastric or gastroesophageal junction cancers CLDN18.2 expression, dosed Q2W IV with the Part A Q2W recommended dose.
16340427|NCT04396821|Experimental|Part B Cohort 2|Participants with solid tumors other than gastric or gastroesophageal junction cancers with CLDN18.2 expression dosed Q2W IV with TST001 as above.
16340428|NCT04396821|Experimental|Part B Cohort 3|Participants with any kind of advanced or metastatic solid tumors with CLDN 18.2 expression, dosed Q3W with the Part A Q3W recommended dose of TST001
16340431|NCT04396795|Experimental|PRP group|Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days
16340432|NCT04396795|Placebo Comparator|Placebo group|Participants in this group will receive 2 sessions of placebo injection, each administered 1 month apart ± 7 days.
16340433|NCT04396782|Experimental|physiotherapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
16340434|NCT04396782|Active Comparator|standard physiotherapy rehabilitation|static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.
16340435|NCT04396769|Experimental|FLOW-PA|Participants received the physical activity component of FLOW five days a week during participants' 45-minute long physical education (PE) class period for six months. Intervention activities were designed to promote moderate-vigorous physical activity through circuit-based stations with both aerobic and strength exercises. Trained research staff partnered with PE teachers to facilitate lessons and undergraduate college students were trained to complete activities with participants.
16340436|NCT04396769|Active Comparator|PE class as usual|Participants had PE class as usual 5 days a week for 45 minutes.
16340437|NCT04396756|Experimental|Placebo|Placebo
16340438|NCT04396756|Experimental|PLN-74809 Dose Level 1 (Part A)|PLN-74809 Dose Level 1 (Part A) - 4 weeks
16340439|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part A)|PLN-74809 Dose Level 2 (Part A) - 4 weeks
16340440|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part B)|PLN-74809 Dose Level 2 (Part B) - 12 weeks
16340441|NCT04396756|Experimental|PLN-74809 - Dose Level 3 (Part C)|PLN-74809 Dose Level 3 (Part C) - 12 weeks
16340442|NCT04396756|Experimental|PLN-74809 - Dose Level 4 (Part C)|PLN-74809 Dose Level 4 (Part C) - 12 weeks
16340443|NCT04396743|Active Comparator|Periapical surgery with placement of prf high clots|Patients will undergo periapical surgery and PRF-high clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
16340444|NCT04396743|Active Comparator|Periapical surgery with placement of prf medium clots|Patients will undergo periapical surgery and PRF-medium clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
16340445|NCT04396730|Placebo Comparator|Placebo followed by cannabidiol|Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily for cycle 1. During cycle 3, cannabidiol will be taken once daily along with OCPs.
16340446|NCT04396730|Experimental|Cannabidiol follow Placebo|Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily for cycle 1. During cycle 3. placebo will be taken once daily along with OCPs.
16340447|NCT04396717|Experimental|Pritumumab|"Dose Escalation phase (3+3 patients):
~Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity.
~Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity."
16340448|NCT04396704||Botox|all eligible subjects, in a reverse consecutive order, initiated on onaBoNT-A from 01 March 2015 to 29 May 2017.
16340449|NCT04396704||Dysport|all subjects meeting inclusion/exclusion criteria and initiated on aboBoNT-A from 30 May 2017 to 30 March 2019.
16340450|NCT04396691||Instructors group|Group of flight instructors at the reactor school.
16340451|NCT04396691||Students group|Group of students at the reactor school.
16340452|NCT04396678|No Intervention|PrEP Standard of Care|PrEP standard of care, administered through the Baltimore City Health Department
16340453|NCT04396678|Experimental|PrEP standard of care+behavioral intervention|PrEP standard of care, administered through the Baltimore City Health Department, and the behavioral intervention.
16340456|NCT04396652|Experimental|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
16340457|NCT04396652|Experimental|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.
~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
16340458|NCT04396652|Experimental|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
16340459|NCT04396639|Experimental|Treatment Arm|Fifty eligible male subjects will be enrolled in the treatment arm to receive Moroctocog alfa (AF-CC) until 24 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
16340460|NCT04396626||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
16340461|NCT04396613|Active Comparator|Running Subcuticular Suture|
16340462|NCT04396613|Active Comparator|Interrupted Vertical Mattress Suture|
16340463|NCT04396613|Active Comparator|Staple Closure Techniques|
16340464|NCT04396600||Healthcare Workers Already Starting Peer Support Program|
16340465|NCT04396600||Healthcare Workers Starting Peer Support Program Later|
16340468|NCT04396561|Experimental|Paravertebral group (group P):|After induction of general anesthesia and stabilization of the patients, they were positioned in lateral decubitus position with the side to be blocked uppermost.
16340469|NCT04396561|Experimental|Control group (group C):|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia (IV fentanyl 2 μcg/kg at induction and 1 gm of IV paracetamol).
16340470|NCT04396548|Active Comparator|Group A (midodrine group)|Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
16340471|NCT04396548|Placebo Comparator|Group B (placebo group):|Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
16340474|NCT04396509||women giving birth by normal vaginal delivery|100 women delivered vaginally. . They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
16340475|NCT04396509||women giving birth by c-section|100 delivered with cesarean section. They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
16340476|NCT04396496|Experimental|Daratumumab Injection|"Up to 12 four-week cycles of Daratumumab (DARA), in combination with the immunomodulatory drug (IMiD) lenalidomide.
~DARA is injected. Dosage calculated by weight.On Cycles 1 and 2, DARA is given on Days 1, 8,15 and 22. On Cycles 3-6,DARA is given on Days 1 and 15. On Cycles 7-12, DARA is given on Day 1.
~Lenalidomide is taken by mouth. 15 mg on Days 1-21 of each cycle."
16340477|NCT04396483|Experimental|"Tubal sterilization Pomeroy's method"|
16340478|NCT04396483|Active Comparator|Salpingectomy|
16340479|NCT04396470|Experimental|tVNS treatment|
16340480|NCT04396470|Sham Comparator|tVNS sham treatment|
16340481|NCT04396457|Experimental|Pembrolizumab+Pemetrexed|"200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1.
~500 mg/m^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1.
~*Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed.
~And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met."
16340484|NCT04396431|Other|2|The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy.
16340485|NCT04396418|Experimental|Intervention arm|A 16-week blended learning programme targeting stroke prevention and rhythm control therapy at the healthcare professional level, with controlled assessments, a commitment to change plan, and reinforcement actions
16340486|NCT04396418|Other|Control arm|No added education of healthcare professionals
16340487|NCT04396392|Experimental|VR-based training|receiving only VR intervention
16340488|NCT04396392|Active Comparator|text-based training|receiving only text-based intervention
16340489|NCT04396392|Experimental|VR- and text-based training|receiving both VR intervention and text-based intervention
16340490|NCT04396392|No Intervention|waiting list|waiting list in phase 1 and text-based training after 3 weeks
16340491|NCT04396379|Experimental|Device Implantation|To epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy) using an epicardial implant.
16340492|NCT04396366|Placebo Comparator|placebo|Placebo controlled arm
16340493|NCT04396366|Active Comparator|QBW251|Active comparator drug arm
16340494|NCT04396353||Physically active|Those who receive regular amounts of physical activity. Those who participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen as recommended by the health organizations. Additionally, a person who spend less time sitting (i.e. watching television, surfing the web, playing video games).
16340495|NCT04396353||Sedentary|Those who do not receive regular amounts of physical activity. Where physical inactivity is considered the failure to meet the recommendations of the health organizations, stating that an individual should participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen. Sitting about 70-85% of the time (i.e. watching television, surfing the web, playing video games) is also considered a person living a sedentary lifestyle.
16340496|NCT04396340|Experimental|Dose Escalation|XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.
16340497|NCT04396340|Experimental|Confirmation of Dose|New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose
16340498|NCT04396327|Active Comparator|Active Comparator: 2-Drug Combination|50 mg diphenhydramine and 0.5 mg lorazepam
16340499|NCT04396327|Experimental|Active Treatment: SM-1 3-Drug Combination|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
16340500|NCT04396314|Experimental|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources, is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits. BBAT consists of a broad scope of movements in the following positions: lying, sitting, standing and walking. Relational movements are practiced in therapy with components such as rhythm, form, elasticity, flow, intention and voice
16340501|NCT04396314|Active Comparator|Control|The control group will be treatment for usual for PTSD. Pharmacological treatment is based in fluoxetine, paroxetine, sertraline and venlafaxine. Regarding non-pharmacological treatment the strongly recommendations are cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
16340502|NCT04396301|Active Comparator|Fydrane group|Fydrane is injected intracamerally at the beginning of cataract surgery after the first incision, at a dose of 0.2 ml of solution, in only one injection. Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). No preoperative topical eye drops are used.
16340503|NCT04396301|No Intervention|Reference group:|not injected with intracameral Fydrane. Pupillary dilatation in this group is achieved using preoperative topical eye drops: cyclopentolate hydrochloride 1% and tropicamide 1 % one drop every 15 min for 1 hour preoperatively.
16340504|NCT04396288|Experimental|Healthy volunteers|
16340505|NCT04396275|Experimental|Cooked whole navy beans|A meal consisting of cooked navy beans
16340506|NCT04396275|Experimental|Cooked whole yellow split peas|A meal consisting of cooked yellow peas
16340507|NCT04396275|Experimental|Cooked rice (control)|A meal consisting of cooked rice
16340508|NCT04396262|Experimental|HTD-blueberry beverage with white bread|The beverage prepared using hydro-thermodynamic processing of whole wild blueberries.
16340509|NCT04396262|Experimental|Sweetened water (control) with white bread|The water control of the same volume and with the same amount of available carbohydrate as HTD-blueberry beverage.
16340510|NCT04396249|Experimental|Active tVNS group|The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
16340511|NCT04396249|Sham Comparator|Sham tVNS group|The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
16340516|NCT04396223|Experimental|Avelumab combined with methotrexate and folinic acid|Avelumab administration at 800 mg every 2 weeks and methotrexate administration at 1mg/kg/day during 4 months ½ (median)
16340517|NCT04396197||COVID-19|Observations taken of standard physiotherapy practice. All patients are assessed daily and receive respiratory care and rehabilitation as deemed appropriate by the treating therapist
16340518|NCT04396184|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 288 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once every two weeks for 3 times.
16340519|NCT04396184|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
16340520|NCT04396171||Probable bruxism(+)|
16340521|NCT04396171||Probable bruxism(-)|
16340522|NCT04396158|Experimental|intervention|
16340523|NCT04396145||Surgery group|Subjects who will have chronic otitis media surgery will be included in the study.
16340524|NCT04396132|Experimental|Virtual SVV|The subjects will be tested by virtual SVV. The deviation angle will be measured at 15, 30 and 45-degree head tilt to the left and right side while they are standing
16340525|NCT04396106|Active Comparator|AT-527 + SOC|
16340526|NCT04396106|Placebo Comparator|Placebo + SOC|
16340527|NCT04396080|Experimental|Onlays behaviour depending on materials|Patients who require it as treatment option will be treated with posterior partial restorations, and will have clinical follow-up to obtain a comparison of the behavior of subsequent restorations based on the material.
16340569|NCT04395703||Neonatal unit staff|Staff working within a local maternity unit.
16340528|NCT04396067|Active Comparator|Aerosolized 13 cis retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
16340529|NCT04396067|Active Comparator|All trans retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days
16340530|NCT04396067|Placebo Comparator|Placebo Comparator|4 Placebo tablets twice daily by mouth for 2 weeks
16340531|NCT04396054|Active Comparator|Lag Screws|Group 1: underwent open reduction and internal fixation using two lag screws.
16340532|NCT04396054|Active Comparator|Double Y-shaped plates|Group 2: underwent open reduction and internal fixation using double Y-shaped plates.
16340533|NCT04396041||Patients treated for Pulmonary Arteriovenous Malformation|All participants in the study will be patients who have been treated for Pulmonary Arteriovenous Malformation using Microvascular Plugs, Amplatzer Vascular Plugs or Detachable coils.
16340534|NCT04396015|Placebo Comparator|medium chain triglyceride (MCT) vs placebo|MCT or placebo (olive oil) for 4 months. Crossover at 4 months
16340535|NCT04396015|Other|open label extension|6 months of MCT oil.
16340536|NCT04396002||Primary Open-Angle Glaucoma|Patients diagnosed with primary open-angle glaucoma.
16340537|NCT04396002||Control|Participants with healthy eyes.
16340538|NCT04395989|Experimental|LAR-HER2+|If patients were LAR subtype with HER2 gene activated mutation
16340539|NCT04395989|Experimental|LAR-PAM+|If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
16340540|NCT04395989|Experimental|IM|If patients were IM subtype (CD8 positive T cell more than 20%)
16340541|NCT04395989|Experimental|BLIS|If patients were BLIS subtype or MES subtype and without PI3K/AKT/mTOR pathway activation
16340542|NCT04395989|Experimental|MES-PAM+|If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
16340543|NCT04395976|No Intervention|Control Group|Participants randomised into the control group receive conventional standard care given by recommended guideline.
16340544|NCT04395976|Experimental|Ayurveda|Treatment includes a tailored combination of herbs based on individual constitution (based on Ayurveda) nutritional advice, specific consideration of selected food items, specific lifestyle advice, yoga advice along with standard recommendations.
16340545|NCT04395950|Active Comparator|PF-0522130|PF-05221304 10 mg daily (two 5mg tablets daily in the morning).
16340546|NCT04395950|Placebo Comparator|Placebo|Placebo (two tablets daily in the morning).
16340547|NCT04395937|Active Comparator|respiratory physiotherapy|exercises to improve the way of breathing
16340548|NCT04395937|Experimental|respiratory physiotherapy and physical exercises|intensity determined by the VO2max measured during ergospirometric measure
16340549|NCT04395924||Pregnant women COVID-19 positive by RT-PCR|Pregnant women COVID-19 positive by RT-PCR on nasopharyngeal swabs and/or by serology or with previous history of SARS-Cov-2 positive during the pregnancy coming to the maternity to deliver
16340550|NCT04395911|Other|SCD|Cytopheretic device
16340551|NCT04395885||study group|health care staff, regardless of gender, who is actively working during the outbreak
16340552|NCT04395885||control group|age matched group of non-health worker individuals.
16340553|NCT04395872||COVID-19|Among patients who were confirmed as COVID-19 and admitted to the COVID-19 management ward of Daegu Catholic University Hospital, patients who were consulted by the Department of psychiatry was selected as participants. Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R). were collected from participants. It evaluates whether there is a difference in the psychological scale according to the difference in participants' sociodemographic status and medical severity, and evaluates the effectiveness of psychiatric counseling by comparing clinical psychological measures before and after referral to department of psychiatry.
16340554|NCT04395859||Patients treated with IVT before COVID19 pandemia|Treatment started at least 6 months before the French confinement for COVID19 (15th march 2020)
16340555|NCT04395820||Cystic Fibrosis|
16340556|NCT04395820||Healthy|
16340557|NCT04395807|Active Comparator|Helmet CPAP|Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
16340558|NCT04395807|Active Comparator|HFNC|High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)
16340559|NCT04395794||Medical Employees|Asymptomatic medical employees in high-volume cardiovascular center.
16340560|NCT04395781||Control cases|Children who suspected COVID-19 cases but tested negative for COVID-19
16340561|NCT04395781||Confirmed cases|Children who tested positive for COVID-19
16340562|NCT04395768|Experimental|Vitamin C|"Participants will receive vitamin C in addition to active comparator treatment:
~Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;
~Plus Active Comparator treatment:
~Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days"
16340563|NCT04395768|Active Comparator|Control|Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days
16340564|NCT04395755||Infertile women who had the IVF treatment postponed or delayed|
16340565|NCT04395742||Coffee:1,3,7-trimethylxanthine|
16340566|NCT04395742||Tea and hot chocolate with milk|
16340567|NCT04395716|Experimental|Treatment Group|This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
16340570|NCT04395690|Active Comparator|Inferior Alveolar Block Nerve (IABN)|Inferior Alveolar Block Nerve (IABN) anesthesia technique before posterior mandibular implant placement.
16340571|NCT04395690|Experimental|Infiltration (INF)|Infiltration (INF) anesthesia technique before posterior mandibular implant placement.
16340572|NCT04395677|Experimental|AB-106 （DS-6051b）|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
16340573|NCT04395638|Experimental|Weekly Vitamin D group|
16340574|NCT04395638|Experimental|Daily Vitamin D group|
16340575|NCT04395625|Experimental|Group 1|Patients had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding.
16340576|NCT04395625|Experimental|Group 2|Patients had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
16340577|NCT04395612|Experimental|Treatment arm1|niraparib 200mg/day and brivanib 400mg/day
16340578|NCT04395612|Experimental|Treatment arm2|niraparib 200mg/day and toripalimab 240mg/21 days
16340579|NCT04395599|Experimental|COVID19 patients undergoing visceral surgery|
16340580|NCT04395586||Culture-proven infected patients|
16340581|NCT04395547|Placebo Comparator|Placebo|
16340582|NCT04395547|Experimental|JointAlive™|
16340583|NCT04395521|Experimental|Facebook group arm|Access to a diabetic foot self-management support program via a Facebook group platform for three months plus the standard care.
16340584|NCT04395521|No Intervention|Standard care arm|Carry on with the routine diabetes care offered to the participants in their health facilities.
16340585|NCT04395495||Neurofibromatosis 1 (NF1)|Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.
16340586|NCT04395495||Noonan Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340587|NCT04395495||Noonan Syndrome with Multiple Lentigines|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340588|NCT04395495||Noonan Neurofibromatosis Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340589|NCT04395495||Cardiofaciocutaneous Syndrome|Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340590|NCT04395495||Costello Syndrome|Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340591|NCT04395495||Legius Syndrome|Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340592|NCT04395495||Smith-Kingsmore Syndrome|Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
16340593|NCT04395495||GATOR-1 Mutation|Individuals with a suspected or known mutation of GATOR-1.
16340594|NCT04395495||SYNGAP1-Related Intellectual Disability|Individuals with a suspected or known mutation of SYNGAP1.
16340595|NCT04395495||DLG4 Mutation|Individuals with a suspected or known mutation of DLG4.
16340596|NCT04395495||MAPK1 Gene Mutation|Individuals with a suspected or known mutation of MAPK1.
16340597|NCT04395495||MTOR Gene Mutation|"Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.
~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway."
16340598|NCT04395495||RAS Mutation|"Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.
~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway."
16340599|NCT04395482||covid-19 pneumonia related patients|The study aims to collect the highest number possible of lung CT scan images performed in patients with COVID-19, in order to obtain a large sample size that will allow us to characterize the extent of lung injury, the presence of specific patterns of lung alteration, and their potential association with the outcome of patients - in view of assisting the medical staff in better understanding the grade of the severity impairment in these patients which might be potentially candidates to more intensive therapeutic strategies.
16340600|NCT04395456|Experimental|AMY-101|
16340601|NCT04395456|Placebo Comparator|Placebo|
16340602|NCT04395443|Experimental|patients admitted to emergency department|the intervention is the medication reconciliation
16340603|NCT04395430|Active Comparator|Information Group|Subjects randomized to the Information Group will receive standard care and age appropriate reading books.
16340604|NCT04395430|Experimental|Intervention Group|Subjects randomized to the Intervention Group will receive standard care plus invitation to participate in the online KKH Sports Singapore programme.
16340605|NCT04395417|Experimental|Hyaluronic acid injection group|This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
16340606|NCT04395417|Active Comparator|Prolotherapy injection group|This is the control group in whom prolotherapy injection was given at lateral epicondyle site.
16340607|NCT04395404|Experimental|Single arm|
16340608|NCT04395378||Flying pilots|Flying pilots holding class 1 and class 2 certificates
16340609|NCT04395365|Experimental|Co-trimoxazole|Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months
16340610|NCT04395365|Placebo Comparator|Placebo|Placebo, 960mg capsule oral tablet, to be taken daily for 18 months
16340611|NCT04395352||Pre-ECV|Patients having undergone colonoscopy prior to the introduction of ECV (November 1 2018 to April 30 2019).
16340612|NCT04395352||ECV|Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
16340613|NCT04395339|Experimental|Experimental arm(GM1)|This arm will be treated with GM1.
16340615|NCT04395326||24 months follow-up|"Single-group study Patients have been included for up to 4 weeks after the initiation of Second Generation Antipsychotic (SGA) treatment (baseline)
~Patients under 18 years of age, previously naïve of antipsychotics, starting an SGA or who started an SGA treatment for less than 4 weeks, followed longitudinally at one of the selected recruiting centers, regardless of the diagnosis that motivated the prescription. Comedications and combination of APs are allowed, as this is an observational study.
~The exclusion criteria are the following: participants diagnosed before or at the baseline with diabetes, dyslipidemia, high blood pressure, thyroid dysfunction, hepatic disease, a disorder that can lead to hyperprolactinemia or another disorder that may interfere with the development of the side effects studied in this research, participants taking a drug intended to treat one of the conditions mentioned above before starting the SGA treatment, and pregnancy."
16340616|NCT04395300||Healthcare workers|Physicians, Nurses, Laboratory workers, radiology technicians
16340617|NCT04395287||Preschool children|Attending public preschools in Svendborg, Denmark, at the time of recruitment
16340618|NCT04395274||Current E-Cigarette Users|Monitoring current e-cigarette users
16340619|NCT04395274||Never E-Cigarette / Tobacco Users|Monitoring never users of any tobacco or e-cigarette products.
16340620|NCT04395261||Group 0|Patients were divided into groups according to observation in surgery Empty ear in operation
16340621|NCT04395261||Group 1|Patients were divided into groups according to observation in surgery Serous fluid in operation
16340622|NCT04395261||Group 2|Patients were divided into groups according to observation in surgery Mucoid fluid in operation
16340623|NCT04395261||Group 3|Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation
16340624|NCT04395261||Group 4|Control group. Subjects with no otitis media with effusion
16340625|NCT04395248|Active Comparator|Risk factors of difficult intubation|Appearance anpalpationpalpationpalpationd ultrasound features for predicting difficult laryngoscopy intubation
16340626|NCT04395248|Active Comparator|Radial artery cannulation using ultrasound or blind palpation|In the ultrasound group, a linear vascular probe in the frequencies 5 to 13 MHz (GE 12L-RS, GE Healthcare, Chicago, IL, USA) of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image.
16340627|NCT04395248|Active Comparator|Preoxygenation using high-flow nasal cannula or facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs.
16340628|NCT04395248|Active Comparator|Type of volatile anesthetics and M-Entropy guidance|Patients will be randomized by a computer-generated list into one of the four groups, desflurane with usual care (N=20), desflurane with M-Entropy guidance (N=20), sevoflurane with usual care (N=20), and sevoflurane with M-Entropy guidance (N=20).
16340629|NCT04395235|Experimental|Targeted Surgical Therapy Plan|This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
16340634|NCT04395209|Experimental|stroke individuals|
16340635|NCT04395209|Active Comparator|healthy individuals|
16340636|NCT04395196|Active Comparator|High-dose choline supplementation|2 g choline cation
16340637|NCT04395196|Placebo Comparator|Placebo|Placebo identical to active treatment in appearance, taste, and smell.
16340643|NCT04395170|Experimental|Anti-COVID-19 human immunoglobulin|Anti-COVID-19 human immunoglobulin to be administered intravenously.
16340644|NCT04395170|Active Comparator|Standard (specific) therapy|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.
~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
16340645|NCT04395157||Veterans engaged in VA mental health rehabilitation/recovery|Veterans must be within 6 weeks of discharge from or current receive mental health treatment services in a VA San Diego Healthcare System psychosocial rehabilitation and recovery center (PRRC), mental health residential rehabilitation treatment program (RRTP), general mental health outpatient treatment, or recent acute mental health inpatient hospitalization.
16340646|NCT04395144|Experimental|Awake prone positioning|Prone positioning of patients on nasal high-flow oxygen therapy
16340647|NCT04395144|Active Comparator|Standard care|Standard decubitus positioning of patients on nasal high-flow oxygen therapy
16340648|NCT04395131|Other|Clearum HF Dialysis Subjects|All subjects enrolled in the study and treated with the Clearum HF hemodialyzer
16340649|NCT04395118|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
16340650|NCT04395118|Active Comparator|Mailed Outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
16340651|NCT04395105|Experimental|High dose Dexamethasone|Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
16340652|NCT04395105|No Intervention|Usual care - low dose Dexamethasone|Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial
16340653|NCT04395092|Experimental|K-NK002|
16340654|NCT04395079|Experimental|Arm I (durvalumab, brachytherapy)|Patients receive durvalumab IV on day 1. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
16340655|NCT04395079|Experimental|Arm II (tremelimumab, brachytherapy)|Patients receive tremelimumab IV on day 1. Treatment repeats every 28 days for 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
16340656|NCT04395053|Experimental|Treatment group TR|Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
16340657|NCT04395053|Experimental|Treatment group RT|Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
16340658|NCT04395040||Patients|Elderly patients with digestive cancer or breast cancer.
16340659|NCT04395027|No Intervention|Usual care|These patients will not have their iatrogenic septal defect closed.
16340660|NCT04395027|Experimental|Device|These patients will have their iatrogenic septal defect closed after the mitral intervention is completed.
16340661|NCT04395001|Experimental|behavioral intervention, nurse support plus medication|Subjects randomized to this arm will receive duloxetine, web-based Cognitive Behavioral Therapy (CBT) and nurse support.
16340662|NCT04395001|Experimental|behavioral intervention plus medication|Subjects randomized to this arm will receive duloxetine and web-based Cognitive Behavioral Therapy (CBT).
16340663|NCT04395001|Active Comparator|medication only|Subjects randomized to this arm will receive duloxetine only.
16340664|NCT04394975|Experimental|Test group|Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.
16340665|NCT04394975|Active Comparator|Control group|Sunitinib will be administered 50mg QD orally according to label recommendation (4 consecutive weeks followed by a 2-week off-treatment period,or 2 consecutive weeks followed by a 1-week off-treatment period), until treatment criteria are met.
16340666|NCT04394962|No Intervention|Control group|Patients who will be randomized to the control group will be waiting for the ET procedure without any intervention and without any deviation from the standard of care
16340667|NCT04394962|Experimental|Study group|Exposure to virtual reality environment exposure
16340668|NCT04394949|Active Comparator|Business as Usual Arm|Consumers will usual care
16340669|NCT04394949|Experimental|Experimental Arm|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
16340670|NCT04394936|Experimental|Guselkumab|Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.
16340671|NCT04394936|Placebo Comparator|Placebo|Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.
16340672|NCT04394936|No Intervention|Healthy volunteers|Healthy volunteer cohort (observational)
16340710|NCT04394663|Active Comparator|Standard IV PPI|Pantoprazole 8 mg/hour IV continuous drip for 72 hours
16340711|NCT04394650|Experimental|CC-98633|Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
16340673|NCT04394923|Experimental|"Intervention group or PRINT group"|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print, which is the zone where the atrioesophageal distance is shorter. The maximal distance and the area between the original line and the modified line will be noted. In cases when ablation through the red layer is unavoidable, the delivered energy can be lowered to an ablation index (AI) of 300 regardless of the local wall thickness. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
16340674|NCT04394923|Other|Control group|The ablation line will not be modified from the original one drawn before randomization and RF applications will follow the regular path. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
16340675|NCT04394910|Experimental|Pomegranate Juice|Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
16340676|NCT04394910|Placebo Comparator|Placebo Juice|Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
16340677|NCT04394897||TIVA|TIVA either with remifentanil and propofol infusions separately
16340678|NCT04394897||MIXTIVA 2/1000|MIXTIVA infusion that had remifentanil/propofol proportion 2/1000
16340679|NCT04394897||MIXTIVA 3/1000|MIXTIVA infusion that had remifentanil/propofol proportion 3/1000
16340680|NCT04394884||COVID-19 -|will receive BTK therapy for other reasons
16340681|NCT04394884||COVID-19 + BTK|will receive BTK therapy
16340682|NCT04394884||COVID-19 + No BTK|will not receive BTK therapy
16340683|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
16340684|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2[AOA2]).
16340685|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
16340686|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
16340689|NCT04394845|Experimental|[18F]GTP1|Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).
16340690|NCT04394832|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.
~In the intervention phase the participant was offered around five intervention sessions with a researcher. Each session the participant chose which intrusive memory they would like to focus on and the cognitive task was completed. The intervention included a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants were given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary."
16340691|NCT04394819||experimental and control groups|"Task-oriented EMG-triggered ES treatment will be applied to the experimental group 2 days a week for 5 weeks and will continue with conventional physiotherapy.
~The control group will only continue conventional physiotherapy treatment."
16340692|NCT04394793|Experimental|Study Arm|
16340693|NCT04394780|No Intervention|Peritoneal dialysis at 37 C|Patients underwent peritoneal dialysis with the standard temperature.
16340694|NCT04394780|Active Comparator|Peritoneal dialysis at 32 C|Patients started on continuous ambulatory peritoneal dialysis using a peritoneal dialysate cooled to between 32-33 degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour duration treatment.
16340695|NCT04394754|No Intervention|Control|Patients will receive usual care and no digital health device.
16340696|NCT04394754|Experimental|BodyPort|Patients will receive the BodyPort device.
16340697|NCT04394754|Experimental|Noom|Patients will receive a subscription to the Noom platform.
16340698|NCT04394754|Experimental|Conversa|Patients will receive a subscription to the Conversa platform.
16340699|NCT04394741|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
16340700|NCT04394741|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
16340701|NCT04394715|Experimental|Intervention|Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
16340702|NCT04394715|No Intervention|Control|Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members.
16340703|NCT04394702|Experimental|One Shape Single-file rotary system|
16340704|NCT04394702|Active Comparator|Manual stainless steel K-file|
16340707|NCT04394676|Experimental|Reduction in Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
16340708|NCT04394676|Active Comparator|Standard Amount of Pressure|This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
16340709|NCT04394663|Experimental|High-dose oral PPI|Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours
16340712|NCT04394637||PROSe-ICD|PROSe-ICD [NCT00733590/ Institutional Review Board (IRB) NA_00045142], a large prospective cohort study of patients who received an ICD for primary prevention.
16340713|NCT04394637||Reynolds study|Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.
16340714|NCT04394624|Experimental|Ramucirumab + SAR408701|Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.
16340715|NCT04394611||Fetal Growth Restriction (FGR)|FGR will be defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. Hadlock I formula will be used to calculating estimated fetal weight percentiles
16340716|NCT04394611||Control|healthy pregnancies will be selected for the control group.
16340717|NCT04394598|Experimental|CRT with Dendrobium Huoshanense|"Dendrobium Huoshanense Granules: 3g tid per day for 5weeks
~Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
16340718|NCT04394598|Placebo Comparator|CRT with Placebo|"Placebo: 3g tid per day for 5weeks
~Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
16340719|NCT04394585|Experimental|Smart phone app group|Patients used smart phone app based human coaching program for 3 months postoperatively.
16340720|NCT04394585|Active Comparator|Nutritional consultation group|Patients have two consulting with clinical nutritionist at 1 month and 3 months postoperatively.
16340721|NCT04394572||colorectal cancer|Patients with and without colorectal cancer
16340722|NCT04394559|No Intervention|Usual care|inpatient pharmacists as available; standard discharge orders; standard follow up visit.
16340723|NCT04394559|Experimental|Intervention|Discharge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app.
16340726|NCT04394533|Experimental|Prilocaine (Intervention) Group|Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
16340727|NCT04394533|Active Comparator|Bupivacaine (Control) Group|Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
16340728|NCT04394520|No Intervention|Control|No change will be made to the introduction content or the consent mode (active opt-in and active opt-out) from other related trials
16340729|NCT04394520|Experimental|Modified Intro, Standard Consent|Modified introductory language will be used, but the consent structure (active opt-in and active opt-out) will remain the same.
16340730|NCT04394520|Experimental|Modified Intro, Active Opt-in|Modified introductory language will be used, and the consent mode will be changed to active opt-in only.
16340731|NCT04394520|Experimental|Modified Intro, Active Opt-out|Modified introductory language will be used, and the consent mode will be changed to active opt-out only.
16340732|NCT04394520|Experimental|Modified Intro, Passive Opt-in|Modified introductory language will be used, and the consent mode will be changed to passive opt-in only.
16340733|NCT04394507||Fontan Patients|Fontan patients operated at the two centres between 1991 and 2014.
16340734|NCT04394507||Control Group|Age, gender and weight matched healthy controls.
16340735|NCT04394494|Experimental|Motor Imagery|Patients are instructed in a motor imagery protocol of imaging extension exercises (similar to the CG), without doing the actual extension exercises. Patients will be instructed in visualizing them moving into extension and back as well as common sensations they may experience (as if doing the actual exercise). They will repeat the visualization process 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 visualization exercises.
16340736|NCT04394494|Active Comparator|Control|Patients are instructed in extension exercises and actually, physically doing the actual extension exercises. Patients will physically repeat the extension exercises 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 exercises.
16340737|NCT04394481|Experimental|DMD|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)
16340738|NCT04394481|Active Comparator|Control|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection
16340739|NCT04394468|Other|patient group|Data is collected from women (18-45y) with endometriosis (superficial and / or deep infiltrating endometriosis) where the preferred treatment is a laparoscopic intervention at UZ Gent.
16340740|NCT04394455|Experimental|Brief cognitive behavioral therapy|Medical staff (medical doctors and residents) who will receive brief cognitive behavioral therapy through telepsychiatry.
16340741|NCT04394455|Active Comparator|Crisis intervention therapy|Medical staff (medical doctors and residents) who will receive 3 sessions of crisis intervention therapy through telepsychiatry.
16340742|NCT04394442|Experimental|Hydroxycholoroquine group|
16340743|NCT04394442|No Intervention|Control group|
16340744|NCT04394416|Experimental|Imatinib|Imatinib oral 400 mg daily for 14 days.
16340745|NCT04394416|Active Comparator|Placebo|Placebo oral for 14 days
16340746|NCT04394403|Experimental|immediate guided self-help|In this condition, individuals will be given access to material and exercises based on CBT to reduce their stress
16340747|NCT04394403|No Intervention|waitlist|Individuals in this condition will wait 6 weeks before they are provided access to the guided self-help program
16340773|NCT04394208|Experimental|Group 2|patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses
16340774|NCT04394195||patients with COVID-19 infection|patients with COVID-19 infection
16340748|NCT04394377|Other|Group 1|"The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):
~Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);
~Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation)."
16340749|NCT04394377|Other|Group 2|Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.
16340750|NCT04394364||BIS monitor group|Patients under monitoring of BIS
16340751|NCT04394351|Experimental|Part A - High Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
16340752|NCT04394351|Experimental|Part A - Low Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
16340753|NCT04394351|Experimental|Part B - High Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
16340754|NCT04394351|Experimental|Part B - Low Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
16340755|NCT04394338|Active Comparator|plastic sheath covering|plastic sheath was prepared with the standard 9 cmx15cm self-gripping mesh. Then the meshe were folded and unfolded over or under the plastic sheaths in different directions.
16340756|NCT04394338|No Intervention|mesh placement without plastic sheath|self-gripping mesh were placed without plastic sheath.
16340757|NCT04394325|Experimental|Group A) Intervention group|Group A) an intervention group (n=80) who will receive the standard care and information (oral and written) + the digital information tool.
16340758|NCT04394325|No Intervention|Group B) Control group|Group B) a control group (n=80) who will receive standard care and information (oral and written).
16340759|NCT04394312|Experimental|Intervention|Participants will attended a 75 minute physical literacy workshop (Parent PLAYSHOP). A questionnaire will be completed at the beginning of the workshop and the end of the workshop to measure if there is a difference in parent's knowledge and confidence levels in regard to engaging in meaningful physical activity with their children.
16340760|NCT04394312|No Intervention|Control|Participants will complete the 2 questionnaires online, one week or more apart. Once questionnaires are completed they will be invited to attended the 75 minute physical literacy workshop. The workshop content and delivery will be the same as the intervention group but will not include questionnaires.
16340761|NCT04394286|Experimental|Cohort 1|Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).
16340762|NCT04394286|Experimental|Cohort 2|Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).
16340763|NCT04394286|Experimental|Cohort 3|Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).
16340764|NCT04394273||Long- Term Exercise Group|They will exercise one an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).In this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
16340765|NCT04394273||Short-Term Exercise Group|They will exercise half an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).n this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
16340766|NCT04394273||Home Program|Pregnant women who choose the home program group are told to continue their home program until the 32nd week, which includes posture and body mechanics training, increase their physical activity levels and be as active as possible and take daily walks.
16340767|NCT04394260|Active Comparator|Savvy Caregiver Program (SCP)|The SCP program is comprised of weekly, two-hour interactive classes, over six consecutive weeks, the same duration as the proposed intervention. The SCP consists of educational instruction and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
16340768|NCT04394260|Experimental|Modified LGBT Savvy Group program|LGBT-friendly SCP is designed to assess the stressors and unique needs of LGBT caregivers of PLWD, not reflected in the existing SCP. Modifications to the SCP include themes of physical, interpersonal, financial, social, and environmental stressors specific to LGBT caregivers.
16340769|NCT04394247||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
16340770|NCT04394234||Treatment Group|Participants data who are new users of rivaroxaban, apixaban and dabigatran with prior Non-valvular atrial fibrillation/Venous thromboembolism/Total hip replacement (NVAF/VTE/THR) or Total knee replacement (TKR) in a nationally representative population of insured participants in the United States (US) will be compared pairwise.
16340771|NCT04394234||Comparator Group|Participants data who are new users of warfarin, apixaban, and dabigatran with prior NVAF/VTE/THR or TKR in a nationally representative population of insured participants in the US will be compared pairwise.
16340772|NCT04394208|Placebo Comparator|Group 1|Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo
16340775|NCT04394182|Experimental|An experimental group receiving radiotherapy|an experimental group with a poor or no response to standard medical treatment and without invasive mechanical ventilation (IMV) will receive ultra low-dose lung radiotherapy (0.8 Gy single dose)
16340776|NCT04394169|Experimental|Intervention arm|The intervention is a program that includes early patient care, therapeutic education, and psychological intervention. It will be performed through three medical visits and a psychological intervention that requires seven face-to-face sessions.
16340777|NCT04394169|No Intervention|Standard care arm|Standard medical practice: patient follow-up is carried out by their referring physicians (primary care physicians or specialists) who are outside the study.
16340778|NCT04394156|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.
~In the intervention phase the participant will be offered around five intervention sessions with a researcher. Each session the participant will choose which intrusive memory they would like to focus on and the cognitive task will be completed. The intervention includes a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants will be given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary."
16340779|NCT04394143|Experimental|AD128|The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.
16340780|NCT04394143|Placebo Comparator|placebo|Two placebo capsules (Mannitol) will be administered for the control intervention once daily, just before light outs, for one week.
16340781|NCT04394130|Experimental|CI group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.
~Then a continuous infusion of ropivacaine 0.2% at a flow rate of 6 ml.h-1 will be running for 48h after the bolus administration.
~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
16340782|NCT04394130|No Intervention|SS group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.
~After the injection, the catheter will be removed.
~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
16340785|NCT04394104||COVID-19 Survey Group|Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.
16340786|NCT04394091||PET CT and ultrasensitive PET CT|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .
16340787|NCT04394078||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
16340788|NCT04394065||uEXPLORER total-body PET/CT|Newly diagnosed NPC patients will undergo a one-hour total-body dynamic PET/CT examination and subsequently followed by a conventional PET/CT scan within 30 minutes
16340789|NCT04394052||Soft-tissue tumors|Benign and malignant soft tissue masses
16340790|NCT04394052||Bone tumors|Benign and malignant bone focal bone lesions
16340791|NCT04394039|Experimental|public sp exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
16340792|NCT04394013|Experimental|Mindfulness Arm|The content of the approximately 20 minutes video is recorded in advance of the intervention by a certified teacher with teaching experience. The 20 minutes session consists of a series of body stretching exercises (around 17 different gentle and simple stretches from head to toe) with the incorporation of breathing technique (i.e. when to breathe in and breathe out). The whole body stretching exercise is performed with a sitting position, ideally on an exercise mat. As mentioned above, the participants are required to conduct the stretching exercise by following the guidance video for at least 5 days weekly for at least 2 weeks duration. The video will be uploaded onto a webpage which requires participants to log in and view the video. The webpage and video will be accessible through computers and mobile phones.
16340793|NCT04394013|Active Comparator|Non-mindfulness Arm|In this study, for control group, the participants are instructed with a similar video content as the intervention group, minus the incorporation of breathing technique, as breathing technique is hypothesised to be a key component of mindfulness.
16340794|NCT04394000||Before or control group|All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
16340795|NCT04394000||After or intervention group|On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
16340796|NCT04393987|Experimental|Arms|Treatment Compliance Training The treatment compliance training consists of five sessions in total and was given individually. Each session of the treatment compliance training given once a week took 45 minutes on average.
16340860|NCT04393545|Active Comparator|exercise (EX) group|
16340797|NCT04393987|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
16340798|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
16340799|NCT04393961|Other|Past Positive COVID-19 confirmed|Invited participants who Radish Health has completed a positive COVID-19 test who have recovered from all symptoms for more than 14 days.
16340800|NCT04393961|Other|Physician Diagnosed: Not Tested|Individuals who self report that a medical professional has told them they likely have COVID-19 (and have since recovered), but did not get a confirmatory test.
16340801|NCT04393961|Other|Self-Diagnosed Not Tested|Participant suspects they contracted (and have since recovered) from COVID-19, but they do not have a medical diagnosis or confirmatory test.
16340802|NCT04393961|Other|Likely Exposed, No Symptoms. Not Tested|Participant suspects that they've been exposed to COVID-19, but have not shown symptoms and wonder if they have antibodies so they may return to some normalcy.
16340803|NCT04393948|Experimental|No irradiation|
16340804|NCT04393948|Experimental|100 cGy single lung irradiation|100 cGy single lung radiation
16340805|NCT04393948|Experimental|100 cGy bilateral lung irradiation|100 cGy bilateral lung radiation
16340806|NCT04393935|Experimental|Pharmacy delivered PrEP Intervention|Customers of the study pharmacies who participate in the intervention to receive PrEP through the pharmacy.
16340807|NCT04393922|Experimental|Aim 1|"To accomplish this aim, we will conduct one experiment in two sessions separated by 2- 3 days using a crossover design. Participants will be assigned into one of three groups: spastic SCI, non-spastic SCI, and controls. We expect that people enrolled in Aim 1 will complete 2 visits within 1 week.
~Visit 1 Measurements:
~MVCs
~MEP Recruitment Curves
~iMEPs
~StartReact
~Visit 2 Measurements:
~Participant Reported Spasticity
~MAS
~PSAD
~KINARM
~MRI of brain and spinal cord"
16340808|NCT04393922|Experimental|Aim 2|"To accomplish this aim, we will use a randomized crossover design study with spastic SCI participants receiving a single intervention combining non-invasive acoustic stimuli (Startle) or sham-Startle with motor training to enhance cortico- and reticulo-spinal contribution, separated by ~2 weeks.
~Visit 1 and Visit 2
~Single intervention of:
~Startle + exercise training OR sham-Startle + exercise training
~Pre and post measurements:
~MVCs
~MEP recruitment curves
~iMEPs
~StartReact
~Participant reported spasticity
~MAS
~PSAD
~KINARM
~Neuromechanical hand and/or leg testing
~GRASSP
~TRI-HFT
~10-meter walk test
~Pendulum Test"
16340809|NCT04393909|Active Comparator|Control group|Patients do not have access to the Patient Dx Questionnaire.
16340810|NCT04393909|Active Comparator|Patient Dx Questionnaire User group|Patient enrollees will be randomized to receive the Patient Dx Questionnaire administered by the research staff at the bedside.
16340811|NCT04393896|Experimental|intervention group|Participants in the intervention group will receive the usual financial benefits of the Reward Policy as well as the WIFI program which will include three key components: psycho-education through WOA publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call.
16340812|NCT04393896|No Intervention|control group|Participants in the control group will receive the usual financial benefits of the Reward Policy and receive payment from the Changsha psychiatric hospital. However, they will not have access to the WIFI program since they cannot scan the WeChat barcode for the research.
16340813|NCT04393883|Experimental|Standard maintenance programme group|pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
16340814|NCT04393883|Experimental|Improvement maintenance programme group,|pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
16340815|NCT04393870|Experimental|Maryam's Flower Group|Maryam's flower was placed in a bowl of water and left in the room of the pregnant women who were at 1 cm cervical dilatation and in the first phase of the labor. It was explained to the pregnant women that the leaves of the plant would open up in the water, and they were asked to imagine that the birth canal would simultaneously open up. In effect, they were told to focus on the opening of these leaves during the course of the labor
16340816|NCT04393870|No Intervention|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
16340817|NCT04393857||Oocyte donors|Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory.
16340818|NCT04393844|Placebo Comparator|with obturator|A group using an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
16340819|NCT04393844|Experimental|without obturator|A group that does not use an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
16340820|NCT04393831|Active Comparator|Retzius sparing|Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
16340821|NCT04393831|No Intervention|Conventional (non-Retzius) nerve sparing|A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
16340822|NCT04393818|Experimental|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep), work environment, and social support.
16340823|NCT04393818|Sham Comparator|Control App|Participants allocated to the control App will receive access to a a fully operational mobile phone App with limited contents about management and prevention of mental health problems. Although this group will also receive psychoeducation, the content will be reduced to general, written recommendations.
16340824|NCT04393805||MED-Cohort|Patients hospitalized for SARS-COVID-2 infection in a medical ward
16340825|NCT04393805||ICU-Cohort|Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
16340826|NCT04393792|Active Comparator|Povidone-Iodine|0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
16340827|NCT04393792|Placebo Comparator|Normal Saline|sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
16340828|NCT04393779|Other|HARPOON™ MVRS|Subjects who were treated with the HARPOON MVRS.
16340829|NCT04393766|Experimental|normal saline|
16340830|NCT04393766|Placebo Comparator|non normal saline|
16340832|NCT04393727|Experimental|Intervention|Patients in the intervention group will receive 200 cc of convalescent plasma
16340833|NCT04393727|No Intervention|Control|Patients will continue to receive standard therapy
16340834|NCT04393714|Experimental|autogenous dentin graft treated with nitric acid|
16340835|NCT04393714|Active Comparator|autogenous dentin graft treated with hydrochloric acid|
16340837|NCT04393688|Experimental|Experimental: Tri-wire Peripheral Balloon Dilatation Catheter|Percutaneous transluminal angiography (PTA) will be performed using the Tri-wire Peripheral Balloon Dilatation Catheter. Interventions: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter; Procedure: Percutaneous Transluminal Angiography.
16340838|NCT04393688|Active Comparator|Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.|Percutaneous transluminal angiography (PTA) will be performed using OHICHO Ⅱ PTA Balloon Catheter, a commercially available high-pressure PTA balloon. Multiple balloons, inflations and/or prolonged inflation may be used. Interventions: Device: OHICHO Ⅱ PTA Balloon Catheter. Procedure: Percutaneous Transluminal Angiography.
16340839|NCT04393675|Active Comparator|LT5001|Administered twice daily (maximum 6 g per time, morning and evening respectively)
16340840|NCT04393675|Placebo Comparator|Placebo|Administered twice daily (maximum 6 g per time, morning and evening respectively)
16340841|NCT04393662||Tenodesis group|Tenodesis as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
16340842|NCT04393662||Tenotomy group|Tenotomy as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
16340843|NCT04393649||Older patients / community dwellers|"The inclusion criteria are:
~Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria
~Living and staying at home because of physical and social distancing
~Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)
~Agree to participate in the study
~The exclusion criteria are:
~A concomitant participation to another medical trial
~Living in semi-autonomous residence or CHSLD"
16340844|NCT04393636|No Intervention|Control arm|Participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes.Additional to known risk factors a Covid-19 module will be used as well.
16340845|NCT04393636|Active Comparator|Intervention arm|All participants will receive at the different time intervals through our custom-made Digital Cardiac Counseling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants in the intervention group will receive through the Digital Cardiac Counseling platform different modules with E-counseling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.
16340846|NCT04393623|Experimental|Cognitive Reappraisal Microintervention|"The CR microintervention (session 1) is drawn from Barlow & colleagues empirically supported treatment for emotional disorders (the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders). The microintervention consist of four sections: (1) Introduction to cognitive appraisal; (2) Introducing the idea of thinking traps that prevent reappraisal and maintain negative emotion; (3) Describing cognitive reappraisal as a strategy that can help the participant get out of such thinking traps; (4) Providing an example of this process (situation> negative appraisal > negative emotion > thinking trap > opportunity for cognitive reappraisal) and have participants provide a personalized example."
16340847|NCT04393623|Active Comparator|Psychoeducation (Control)|The manualized psychoeducational control module, serving as an attentional control, is derived from two sources: 1. The first session of the Women's Health Education Manual, which provides psychoeducation about the basic body systems and their function, with focus on components of the immune system and 2. Fact sheets published by the American College of Obstetricians and Gynecologists(ACOG), providing female-specific facts about cancer and heart health. None of this psychoeducation discusses potential relevancy of alcohol use, nor will any behavior changes be suggested during the control microintervention.
16340848|NCT04393610|Active Comparator|Group (L)|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group)
16340849|NCT04393610|Active Comparator|Group M|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
16340850|NCT04393610|Active Comparator|Group F|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
16340851|NCT04393597|Experimental|Group 1|Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.
16340852|NCT04393597|Experimental|Group 2|Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.
16340853|NCT04393584|Experimental|FOLFIRINOX|Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
16340854|NCT04393584|Active Comparator|FLOT|d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
16340855|NCT04393571|Experimental|conventional follow up patients|
16340856|NCT04393571|Experimental|Mobile app follow up patients|
16340857|NCT04393558||COVID-19|Individuals experiencing COVID-19 like symptoms.
16340858|NCT04393558||Healthy Controls|Individuals without any known significant health problems
16340859|NCT04393545|Active Comparator|HV night splint (SP) group|
16340862|NCT04393532|Experimental|Laparoscopic hernia repair using Su2ura Approximation Device|"Surgery will be performed under general anesthesia. Standard antibiotic prophylaxis will be administered at induction of anesthesia. A single surgeon, the PI, will perform the procedure. A surgical assistant will be selected by the PI from the surgical staff of the department.
~The procedure will involve placement of laparoscopic ports, reduction of the hernia sac, closure of the defect with the Su2ura Approximation device and fixation of mesh with tacks over the closed defect.
~Study follow up visits: at post operation discharge, 14 days, 3 months, 6 months."
16340863|NCT04393519||Prospective|Prospective cohort that received TIPS from 05/12/2020 onwards
16340864|NCT04393506|Other|Inductive therapy|Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.
16340865|NCT04393493|Experimental|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:
~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution
~Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution
~Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution
~Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
16340866|NCT04393493|Experimental|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:
~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.
~Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.
~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.
~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
16340867|NCT04393480|Active Comparator|Robotic therapy|Robotic rehabilitation and conventional rehabilitation
16340868|NCT04393480|Sham Comparator|Conventional therapy|Conventional rehabilitation
16340869|NCT04393467|Experimental|real tSMS|tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.
16340870|NCT04393467|Sham Comparator|sham tSMS|A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.
16340871|NCT04393454|Experimental|Sirolimus|Participants will be instructed to take 2 mg every day for 28 days (1 cycle). They will be evaluated in the oncology clinic every 2 weeks to make sure they are tolerating the medication well.
16340872|NCT04393441|Active Comparator|Systane Ultra Multidose|Participants will administer 1 to 2 drops in each eye 3 times daily
16340873|NCT04393441|Experimental|New Artificial Tear Formulation|Participants will administer 1 to 2 drops in each eye 3 times daily
16340874|NCT04393428||COVID-19 patients with urinary samples|COVID-19 patients with urinary samples
16340875|NCT04393415|Active Comparator|patients receiving LGF|
16340876|NCT04393415|No Intervention|patients not receiving LGF nor PRP|
16340877|NCT04393415|Active Comparator|patients receiving Platelet rich plasma|
16340878|NCT04393402||Patients with Covid-19 and admitted in critical care unit|
16340879|NCT04393389||non-CLI group|Rutherford Clinical Category (RCC) 2-3
16340880|NCT04393389||CLI group|critical limb ischemia，Rutherford Clinical Category (RCC) 4-6
16340881|NCT04393350|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16340884|NCT04393324||Transferred patients|A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds
16340885|NCT04393324||Matched Non-transferred patients|A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables
16340886|NCT04393311|Experimental|Ulinastatin|Patients will receive ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
16340887|NCT04393311|Placebo Comparator|Placebo|Patients will receive placebo to match ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
16340888|NCT04393298|Experimental|Part A|Study participants assigned this arm will receive UCB6114 as monotherapy in escalating cohorts at pre-specified dose levels.
16340889|NCT04393298|Experimental|Part B|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with trifluridine/tipiracil (TFD/TPI).
16340890|NCT04393298|Experimental|Part C|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) regimen.
16340891|NCT04393285|Experimental|Abemaciclib and Letrozole|Study treatment will consist of abemaciclib 150mg orally twice a day and letrozole 2.5mg orally once a day.
16340892|NCT04393259||Participants|Women attending an antenatal service using the Rainbow Clinic model of care.
16340893|NCT04393246|Active Comparator|Standard of care|Standard of care
16340894|NCT04393246|Experimental|EDP1815|1.6 x 10^11 cells dosage-in-capsule orally twice per day for up to 7 days (with the option to extend up to 14 days), on top of standard of care
16340895|NCT04393246|Experimental|Dapagliflozin and Ambrisentan|Ambrisentan 5mg tablet orally once per day for up to a maximum of 14 days and Dapagliflozin 10mg tablet orally once per day for up to a maximum of 14 days, on top of standard of care
16340896|NCT04393220|Experimental|Bevacizumab and anti-PD-1 therapy|
16340897|NCT04393220|Active Comparator|Bevacizumab|
16340898|NCT04393220|Active Comparator|anti-PD-1|
16340899|NCT04393207|Sham Comparator|Control group|Patient will receive intrathecal morphine and a Sham TAP block.
16343505|NCT04374708||homosexual cisgender women|fMRI: body morph test and neurocognitive testing
16340900|NCT04393207|Experimental|Liposomal Bupivacaine|Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
16340901|NCT04393207|Active Comparator|Bupivacaine|Patient will receive intrathecal morphine + TAP block with only bupivacaine.
16340902|NCT04393194|Experimental|Vaginal estrogen cream|subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
16340903|NCT04393194|Placebo Comparator|vaginal placebo cream|Subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
16340904|NCT04393181||recipients of hearts with impaired function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with impaired function
16340905|NCT04393181||recipients of hearts with normal function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with normal function
16340906|NCT04393168|Experimental|Patients with unilateral arm or leg lymphedema|
16340907|NCT04393155||COVID-19+|Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
16340908|NCT04393103|Other|Follow up|Follow Up of 30 patients after administration of atropine.
16340909|NCT04393103|Experimental|intralipid 20% adjuvant|30 patients will receive atropine and intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
16340910|NCT04393077|No Intervention|Control|Participants will complete the pre-tests of the introductory features form, SUD, STAI-I, and burnout scales sent via Survey Monkey. The participants (n=40) will be given 15 minutes of free time and asked to be in a position where the individuals were comfortable, in the quietest and most tranquil environment possible. At the end of this period, post-test SUD, STAI-I, and burnout scales will be sent to the participants and they will be asked to fill in the scores.
16340911|NCT04393077|Experimental|Intervention|Firstly, people in the entire group fill out the introductory features form on the online questionnaire form. The time of the meeting will be determined by collaborating with the participants in the experimental group. During the interview, they will be asked to be in a position that was comfortable for the individuals, in the quietest and calm environment possible. At the beginning of the meeting, they will be asked to fill in the pre-test SUD, STAI-I, and burnout scales sent via SurveyMonkey. Then, the EFT session (20 minutes) will be conducted once mutually with the researcher, who is an expert in their field. At the end of the session, they will be filled the post-test SUD, STAI-I and burnout scales
16340912|NCT04393064|Other|full term and preterm|75 preterm and 75 fullterm will be recruited in this study; all will be hemodynamically stable on discharge doing FEES
16340913|NCT04393051|Experimental|BAR group|"Patients who will be assigned (after a computerized randomization) to the BAR group will. receive baricitinib as adjunctive therapy.
~Baricitinib will be administered at 4 mg daily via oral route for 14 days as add-on therapy or 2 mg daily via oral route (eGFR between 30 and 60 ml/min and for patients with age >75 years old) for 14 days as add-on therapy"
16340914|NCT04393051|No Intervention|Control group|Patients in the control group will continue to receive standard therapy.
16340915|NCT04393038|Experimental|ABX464|ABX464 - Capsules + Standard of Care (SOC)
16340916|NCT04393038|Placebo Comparator|Placebo|Placebo - Capsules + Standard of Care (SOC)
16340917|NCT04393025|Other|Intracranial Stenting|25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS
16340918|NCT04393025|Active Comparator|Aspirin+Clopidogrel|25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment
16340919|NCT04393012|Experimental|Noddle Group|Patients who received noddle to allow access to the nurse call system.
16340920|NCT04392999|Experimental|Platelet Rich Plasma|One time injection of 1.5-6cc of platelet rich plasma prepared from a blood sample into cervical facet joints. There is no trade/generic name
16340921|NCT04392999|Active Comparator|Dexamethasone Sodium Phosphate|Corticosteroid: 0.5 cc saline and 0.5cc of 10 mg/mL dexamethasone per facet joint (up to 6 mL total volume for 4 facet injections)
16340922|NCT04392986|No Intervention|Baseline|Baseline measurement
16340923|NCT04392986|Experimental|Intervention|Sunlight intervention
16340924|NCT04392973|Experimental|Intervention|Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
16340925|NCT04392973|No Intervention|Control|Standard of Care Treatment for COVID-19 Infection
16340926|NCT04392960|Experimental|18F-florbetaben PET-CT scans|
16340927|NCT04392947|Active Comparator|combined iTBS/cTBS|"Combined theta burst stimulation (TBS) of the left (intermittent TBS, iTBS) and right (continuous TBS, cTBS) dorsolateral prefrontal cortex (dlPFC; F3 and F4 according to EEG10/20 system). Each stimulation session will comprise 2 trains of 600 stimuli each applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s. In the same session, stimulation with cTBS will be applied continuously for 40 s. Intensity of iTBS/cTBS will be standardized at 80 % of the resting motor threshold (rMT).
~Additionally, patients receive an electrical co-stimulation of the forehead. One electrode is fixed to FZ and the 2nd one is either fixed to the left forehead (iTBS) or the right forehead (cTBS), rectangular aligned to the upper edge of the FZ-electrode with a distance of 0.5 cm. Intensity of the co-stimulation is applied with 50% of TBS-intensity."
16340928|NCT04392947|Sham Comparator|sham stimulation|Setup is identical to combined active iTBS/cTBS but TBS is not actively delivered
16340929|NCT04392934|Experimental|flat shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
16340930|NCT04392934|Experimental|curved shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
16340931|NCT04392934|Experimental|hooked shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
16340932|NCT04392921|Experimental|Intervention Arm|Patients randomized to amiodarone treatment
16340933|NCT04392921|Placebo Comparator|Control Arm|Patients randomized to placebo treatment
16340934|NCT04392908||Patients|Pediatric patients from 12 to 17 with cancer diagnosis only taken by Meyer Children's Hospital prior consent. Knowledge of fluent Italian language is required
16340935|NCT04392908||Parents|Parents of pediatric patients prior consent. Knowledge of fluent Italian language is required
16340936|NCT04392908||Medical Staff|Medical staff including doctor, psychologist and nurse
16340937|NCT04392895||Patients with locally advanced cervical cancer|Patients with locally advanced cervical cancer, who had undergone a PAL
16340938|NCT04392882|Experimental|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day
~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake
~Regular 30-min walk after dinner each day"
16340939|NCT04392882|No Intervention|Usual diet group|"Maintaining usual diet
~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake
~Regular 30-min walk after dinner each day"
16340940|NCT04392869|Experimental|CRAFT group|This arm will instruct the students on an adapted and extended version of the CRAFT program. This is a mindfulness based program which is a systematic combination of practices derived from ancient philosophies, such as yoga and Buddhism, in conjunction with more recent disciplines such as mindfulness, emotional intelligence and positive psychology. The contents are structured along in five consecutive modules aimed at cultivating and enhancing consciousness, relaxation and regulation, attention, bliss and transcendence.
16340941|NCT04392869|Experimental|MBSR group|This arm will instruct the students on an adapted and extended version of the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
16340942|NCT04392869|No Intervention|No intervention group|This group does not receive any instruction. The aim of this arm is to determine if there are any differences in outcomes between the two groups that receive intervention and this one.
16340945|NCT04392843|Other|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
16340946|NCT04392843|Active Comparator|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
16340947|NCT04392830|Experimental|ALZ002 DS|"SAD: 6 cohorts of subjects are planned to be orally dosed, ranging from 15 mg - 800 mg.
~MAD: 3 cohorts of subjects are planned to be orally dosed once or twice daily for 7 consecutive days, ranging from 300 mg - 600 mg."
16340948|NCT04392830|Placebo Comparator|Placebo|Placebo
16340949|NCT04392817|Experimental|the participating group in the intervention|patient complaining of seppch rerrors due t ovelopharyngeal insufficiency and underwent the intervention
16340950|NCT04392804|Experimental|0.1 ml 4% articaine|single dose of 0.1 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
16340951|NCT04392804|Experimental|0.2 ml 4% articaine|single dose of 0.2 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
16340952|NCT04392804|Experimental|0.3 ml 4% articaine|single dose of 0.3 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
16340953|NCT04392791|Active Comparator|Treated group|The participants received thermal water therapy
16340954|NCT04392791|No Intervention|Control group|The participants haven't received thermal water therapy
16340955|NCT04392778|No Intervention|Untreated|Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.
16340956|NCT04392778|Sham Comparator|Saline Control|Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).
16340957|NCT04392778|Experimental|Experimental UC-MSCs|Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)
16340958|NCT04392765|Other|Therapy arm|Six week use of eXciteOSA device. Once daily for 20 minutes.
16340959|NCT04392752|Experimental|Participants|The participants are recruited via the University of Jyväskylä and Finnish Fitness Sports Association web page and social media channels. An online pre-study questionnaire are sent to randomly chosen athletes and control group candidates who claim to fulfill the inclusion criteria and volunteer for the study. The participants selected for the study filled an additional questionnaire which is subsequently reviewed by the physician of the study to confirm that they will meet inclusion criteria relating to health.
16340960|NCT04392752|No Intervention|Control|The target is 15 male ja 15 female participants for both the control and intervention groups. To be included, participants need to be with two or more years of resistance training experience, similar to our previous study in females (Hulmi et al. 2017). If more than 15+15 control participants sign up for the study, the final group will be matched to the intervention group based on age, height, weight, and training experience reported on the pre-study questionnaire. The control group maintain their normal nutrition and training during the study.
16340961|NCT04392739|Other|TPOXX|TPOXX 600 mg BID x 7 days
16340962|NCT04392726||patients with suspected DPLD|
16340963|NCT04392726||patients with known DPLD|
16340964|NCT04392713|Active Comparator|Ivermectin arm|Participants will be administered Ivermectin with standard chloroquine regimen
16340965|NCT04392713|No Intervention|Control arm|This arm will only receive chloroquine as per existing policy of hospital
16340966|NCT04392700|Experimental|group A|drugs：tenofovir disoproxil fumarate, dose：300mg/d
16340967|NCT04392700|Active Comparator|group B|drugs：entecavir dose： 0.5 mg/d
16340968|NCT04392674|Experimental|using the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
16340969|NCT04392661||Laparoscopic Sleeve Gastrectomy (group I)|111 morbid obese females underwent LSG (group I). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
16340970|NCT04392661||Laparoscopic Roux-en-Y Gastric Bypass (group II)|86 morbid obese females underwent LRYGB (group II). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
16340971|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone|TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
16340972|NCT04392648|Experimental|Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone|TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
16340973|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone|TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
16340974|NCT04392648|Experimental|Expansion: TAK-573 + Bortezomib + Dexamethasone|TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
16340975|NCT04392648|Experimental|Expansion: TAK-573 + Pomalidomide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
16340976|NCT04392648|Experimental|Expansion: TAK-573 + Cyclophosphamide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
16340977|NCT04392635|Experimental|Trocar Placement Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery
16340978|NCT04392622|Experimental|d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
16340979|NCT04392622|Experimental|d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
16340980|NCT04392622|Experimental|d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
16340981|NCT04392622|Experimental|d-limonene -8gram|8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation
16340982|NCT04392622|Experimental|de-escalation dose d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
16340983|NCT04392622|Experimental|de-escalation dose d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
16340984|NCT04392622|Experimental|de-escalation dose d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
16340985|NCT04392596|Experimental|patients|40
16340986|NCT04392583||Device: ENTACT Septal Staple|Septoplasty
16340987|NCT04392570||Fasting group|patients with type 2 diabetes who prefer to fast during Ramadan
16340988|NCT04392570||Non-fasting group|patients with type 2 diabetes who are otherwise healthy and have no contraindications for fasting but prefer not to fast
16340989|NCT04392557|Active Comparator|metformin/alogliptin|metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
16340990|NCT04392557|Active Comparator|metformin/pioglitazone|metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
16340991|NCT04392557|Active Comparator|triple therapy|metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
16340992|NCT04392544||Pediatric|Pediatric CF population age 10-18 years.
16340993|NCT04392544||Adult|Adult CF population age ≥ 18 years.
16340994|NCT04392531|Active Comparator|Group A (control)|The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.
16340995|NCT04392531|Experimental|Group B (experimental)|The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.
16340996|NCT04392518|Active Comparator|Hospital based rehabilitation group|This group will perform the exercises in the hospital under the supervision of a physiotherapist
16340997|NCT04392518|Active Comparator|Telerehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection
16340998|NCT04392505|Experimental|The whole study population|All patients will receive durvalumab for up to 1 months after standard treatment With chemoradiotherapy.
16340999|NCT04392492||Patients undergoing transfemoral TAVI with MANTA closure|Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
16343506|NCT04374708||cisgender women|fMRI: body morph test and neurocognitive testing
16341000|NCT04392479|Active Comparator|Aflibercept-FOLFIRI (arm 1)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),
~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),
~Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min (+ 2-minute window),
~5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min (+ 2-minute window),
~5-fluorouracile (D1 to D3): H+3.5: 2400mg/m² IV infusion over 46 hours (+ 1hour window)
~H+49.5: End of treatment administration"
16341001|NCT04392479|Experimental|Aflibercept-mFOLFIRI3 (arm 2)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),
~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),
~Irinotecan (D1 and D3) H+1 and H+49: 75mg/m² IV infusion over 60min (+ 2-minute window) on cycles 1 and 2, then 90mg/m² at cycle 3 and furthers in absence of AEs grade ≥2,
~5-fluorouracile (D1 to D3) H+3: 2400mg/m² IV infusion over 46 hours (+ 1hour window)
~H+50: End of treatment administration"
16341002|NCT04392466||Transtibial amputees|People who use transtibial prosthesis.
16341003|NCT04392466||Transfemoral amputees|People who use transfemoral prosthesis.
16341004|NCT04392466||Healty individuals|Healty individuals
16341005|NCT04392453|Experimental|Robotic therapy|Upper limb robotic rehabilitation by means of the portable robot Icone.
16341006|NCT04392440|Experimental|intervention|
16341007|NCT04392440|Other|control|Usual care
16341008|NCT04392427|Active Comparator|INTERVENTION|"*Intervention:
~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :"
16341009|NCT04392427|No Intervention|CONTROL|"B) Control group: will not receive nothing
~Data collection will include: sociodemographic data, clinical history, results of follow up (daily or according to clinical situation )
~Follow-up: to record any side effects of drugs, swab will be taken for PCR"
16341010|NCT04392414|Experimental|COVID-19 convalescent hyperimmune plasma|Moderately and severely ill COVID-19 patients treated with convalescent hyperimmune plasma. Patients will be infused with two units of 300 ml
16341011|NCT04392414|Placebo Comparator|Non-convalescent fresh frozen plasma (Standard plasma)|Moderately and severely ill COVID-19 patients treated with non-convalescent fresh frozen plasma (standard plasma). Patients will be infused with two units of 300 ml
16341012|NCT04392401||Cohort|Patients over 18 years with a confirmed diagnosis of COVID 19 hospitalized in intensive care unit
16341013|NCT04392388||SAPRIS-SERO|SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
16341014|NCT04392375|Active Comparator|Nifedipine 30MG|Oral administration of 30mg Nifedipine XL q24 hours until delivery
16341015|NCT04392375|Placebo Comparator|Placebo|Matching placebo group q24hrs until delivery
16341016|NCT04392362|Active Comparator|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
16341017|NCT04392362|Active Comparator|Control group|Giving adenosine Ising the recommended AHA two syringe method
16341018|NCT04392349|Other|NORMAL|Normal group includes eyes with healthy cornea.
16341019|NCT04392349|Other|IRREGULAR|Irregular goup includes eyes with irregular astigmatism or corneal scarring.
16341020|NCT04392336|Experimental|Trust/Respect feedback|Clinicians with consumers in this arm receive feedback on trust/respect in addition to symptom feedback.
16341021|NCT04392336|No Intervention|No Trust/Respect feedback|Clinicians with consumers in this arm do not receive feedback on trust/respect and only receive symptom feedback.
16341022|NCT04392323|Experimental|Study Group|Patients will be recruited as an outpatient prior to their surgical procedure or during their hospital admission. If they consent, they will provide signed informed consent and will receive testing with serology and PCR for COVID-19 infection at pre-surgical testing 24-48 hours prior to their scheduled procedure. If they consent while inpatient postoperatively, signed informed consent will be procured after they have completed their pre-operative COVID-19 testing. PCR for COVID entails obtaining a nasopharyngeal swab to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital.
16341023|NCT04392297||Patients with CMV infection|
16341024|NCT04392284|Experimental|Diet Counseling|Delivery of nutrition counseling intervention to improve diet quality.
16341025|NCT04392284|Experimental|Exercise Counseling|Delivery of exercise counseling intervention to increase engagement in physical activity..
16341026|NCT04392271|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.
16341027|NCT04392258||Status post resuscitation|Patients or dataset that underwent resuscitation
16341028|NCT04392232|Experimental|Convalescent Plasma|
16341029|NCT04392219|Experimental|EIDD-2801|EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
16341030|NCT04392219|Placebo Comparator|Placebo|Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
16341031|NCT04392206|Experimental|Adipose Derived Mesenchymal Stem Cells|Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment.
16341032|NCT04392193|Experimental|Proton Particle Therapy for Cardiac Arrhythmia|Subjects who have an ICD with recurrent VT, VF, or VT storm who have failed one prior standard catheter-based ablation after device implantation, will subsequently undergo particle-based extracorporeal ablation.
16341033|NCT04392180||Caregivers|"Caregivers who care for a child that is both under 3 years of age and has experienced acute pain.
~This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child."
16341070|NCT04391894|Experimental|ECF843 0.15 mg/mL BID or vehicle (Part 1)|ECF843 0.15 mg/mL BID or vehicle (Part 1)
16341039|NCT04392141|Experimental|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
16341040|NCT04392141|Experimental|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
16341041|NCT04392128|Experimental|Treatment arm|Patients enrolled in the experimental arm will receive hydroxychloroquine (200mgx3 tablets per day during 10 days) and azithromycine (500 mg at day 1 (2 capsules taken at the same time) then 250mg per day (1 capsule per day) during 4 days).
16341042|NCT04392128|Placebo Comparator|Control arm|Patients enrolled in the control arm will receive a placebo of hydroxychloroquine (3 tablets per day during 10 days) and a placebo of azithromycine (2 capsules taken at the same time at day 1, then 1 capsule per day during 4 days)
16341043|NCT04392115|Experimental|Exercise Group|"The home-based exercise program called the PREPARE program.
~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
16341044|NCT04392115|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
16341045|NCT04392102|Experimental|ZL-2306(Niraparib)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
16341046|NCT04392089||COVID-19|Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation
16341047|NCT04392076||Radiofrequency Ablation (RFA) of RCC|Patients following image guided radiofrequency ablation (RFA) of renal cell carcinoma (RCC)
16341048|NCT04392076||Microwave Ablation (MWA) of RCC|Patients following image guided microwave ablation (MWA) of renal cell carcinoma (RCC)
16341049|NCT04392076||Cryoablation (CRYO) of RCC|Patients following image guided cryoablation (CRYO) of renal cell carcinoma (RCC)
16341050|NCT04392063|Other|Cerebral palsy|Not included
16341051|NCT04392037|Experimental|Iberdomide plus low-dose cyclophosphamide and dexamethasone|"Iberdomide 1.6mg on days 1-21
~Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle
~Dexamethasone 40 mg once weekly (20 mg in patients aged > 75 years)"
16341052|NCT04392024|Other|Triumf|Subjects who have cataract surgery with Triumf IOL
16341053|NCT04392011|Experimental|Arm 1|"Six non-naive* subjects (3 men, 3 women) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.
~*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks."
16341054|NCT04392011|Experimental|Arm 2|"Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 men and 6 women) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.
~For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours."
16341055|NCT04391998|Active Comparator|Anemia without parasitic infection|women with anemia without parasitic infection will receive iron treatment
16341056|NCT04391998|Active Comparator|parasitic infection treated with iron|women with anemia with parasitic infection will receive oral iron treatment
16341057|NCT04391998|Active Comparator|parasitic infection treated with iron and antihelmemsic|women with anemia with parasitic infection will receive oral iron treatment and antihelminsic treatment in the form of metronidazole 500mg tab twice daily for 5 days in cases with Entamoeba or Giardia or albendazol 200mg tab
16341058|NCT04391985|Active Comparator|Cirrhotic Participants|The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
16341059|NCT04391985|Active Comparator|Non-cirrhotic Participants|The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
16341060|NCT04391972|Other|SAV multifocal IOL|Subjects who have cataract surgery with SAV multifocal IOL
16341061|NCT04391959|Experimental|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to twice weekly.
16341062|NCT04391959|Experimental|AZR-MD-001 Active|AZR-MD-001 Active will be dosed up to twice weekly.
16341063|NCT04391933|Other|MRI colon cancer|MRI scan of patients with colon cancer
16341064|NCT04391920||COVID-19 ICU Patients|
16341065|NCT04391907|Active Comparator|IPL group|Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery
16341066|NCT04391907|No Intervention|Non-IPL group|Subject who do not have intense pulsed light (IPL) laser before cataract surgery
16341067|NCT04391894|Experimental|ECF843 0.45 mg/mL TID or vehicle (Part 1)|ECF843 0.45 mg/mL TID or vehicle (Part 1)
16341068|NCT04391894|Experimental|ECF843 0.15 mg/mL TID or vehicle (Part 1)|ECF843 0.15 mg/mL TID or vehicle (Part 1)
16341069|NCT04391894|Placebo Comparator|ECF843 vehicle TID (Part 1)|ECF843 vehicle TID (Part 1)
16341072|NCT04391894|Experimental|ECF843 -Part 2 (concentration/frequency TBD from Part 1)|ECF843 -Part 2 (concentration/frequency TBD from Part 1)
16341073|NCT04391894|Placebo Comparator|ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)|ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)
16341074|NCT04391868|Active Comparator|Viagra tablet|Subjects receive a single dose of 50 mg Viagra tablet followed by plasma sampling for 14 hours.
16341075|NCT04391868|Experimental|Sildenafil citrate ODF without water|Subjects receive a single dose of 50 mg sildenafil ODF without water followed by plasma sampling for 14 hours.
16341076|NCT04391868|Experimental|Sildenafil citrate ODF with water|Subjects receive a single dose of 50 mg sildenafil ODF with water followed by plasma sampling for 14 hours.
16341077|NCT04391855|Experimental|Tramadol with ropivacaine|Tramadol 2mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
16341078|NCT04391855|Experimental|Dexmedetomidine with ropivacaine|Dexmedetomidine 1μg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
16341079|NCT04391855|Experimental|Magnesium with ropivacaine|Magnesium sulfate 10 mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
16341080|NCT04391855|Placebo Comparator|Placebo with ropivacaine|Ropivacaine (10mg/ml) 100mg with 5ml isotonic saline for wound infiltration
16341081|NCT04391842|Experimental|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
16341082|NCT04391829|Experimental|SARS-CoV-2 positive men|Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.
16341083|NCT04391816||Study Participants|Participants that were previously enrolled in the NIAAA Screening Protocol.
16341084|NCT04391803|Experimental|Pipeline™ Flex Embolization Device with Shield Technology™|This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.
16341085|NCT04391790|Active Comparator|Control|Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker
16341086|NCT04391790|Experimental|Intervention|Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit
16341087|NCT04391777|Experimental|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.
~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.
~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
16341088|NCT04391777|Sham Comparator|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.
~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.
~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
16341089|NCT04391764|Experimental|Naltrexone|Naltrexone at a dose of 50 mg per day.
16341090|NCT04391764|Placebo Comparator|Placebo|Placebo tablets will be identical in size, colour, shape, and taste and will be given in a similar manner.
16341091|NCT04391751|Experimental|Single incision|Carpal tunnel release and basal joint arthroplasty through a single radial approach
16341092|NCT04391751|Active Comparator|Double incision|Double approach: carpal tunnel release through palmar approach and basal joint arthroplasty through radial approach
16341093|NCT04391738||BMI SARS-CoV-2|Patients admitted to Intensive Care Unit with SARS-CoV-2
16341094|NCT04391725|Experimental|Periapical surgery with guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and the defect is filled with mixture of iPRF and type 1 collagen granules before flap closure.
16341095|NCT04391725|Active Comparator|Periapical surgery without any guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and flap closure done.
16341096|NCT04391712|Experimental|Experimental|Participants will receive MLS laser treatment along with regular inpatient medical care.
16341097|NCT04391712|Active Comparator|Control Group|Participants will receive regular inpatient medical care.
16341098|NCT04391699|Experimental|CPAP + Heated humidification|CPAP + Heated humidification
16341099|NCT04391699|No Intervention|CPAP alone|CPAP
16341100|NCT04391686||COVID intensive care unit|
16341101|NCT04391686||intensive care unit|
16341102|NCT04391686||obesity|
16341103|NCT04391673||Dizzy group|Patients attending the dizziness and balance exercise programme at Guy's Hospital, London. Patients data will be included if they complete at least 4 sessions.
16341104|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution|
16341105|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution and 70% ethanol|
16341106|NCT04391647||HPV vaccinated group|"Women (18-25 years old) whom are previously fully vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.
~No intervention/drug to be administered."
16341107|NCT04391647||HPV unvaccinated group|"Women (18-25 years old) whom are not previously vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.
~No intervention/drug to be administered."
16341108|NCT04391634|Other|Mechanical ventilation|Preterm infants on mechanical ventilation
16341109|NCT04391621|Experimental|Adipose Derived Stem Cell(ADSC) arm|In this arm, the participant selected keloid will receive a single dose intra-lesional Adipose derived Stem cells infiltration. This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6).
16341110|NCT04391621|Active Comparator|Triamcinolone Acetanoide (TAC) arm|"This arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid.
~This will be a single dose infiltration of 40mg/cubic centimetres."
16341111|NCT04391608|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25 mg/day
16341112|NCT04391608|No Intervention|TDF dose reduction|TDF dose reduction
16343507|NCT04374708||cisgender men|fMRI: body morph test and neurocognitive testing
16341113|NCT04391595|Experimental|Arm 1|400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
16341114|NCT04391582|Experimental|Test - Tilapia Skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage.
16341115|NCT04391582|Active Comparator|Control - Silver sulfadiazine|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and band
16341116|NCT04391569|Placebo Comparator|IV Placebo|Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
16341117|NCT04391569|Experimental|IV ganaxolone active|Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
16341118|NCT04391556|Experimental|Firmagon|120 mg Firmagon subcutaneous injection after a TEP-PSMA
16341119|NCT04391543|Experimental|Experimental Arm|"4 experimental session (baseline, after treatment, 6 month post treatment and 12 months post treatment) with :
~comprehensive interview
~cognitive tests
~anthropometric measures
~postural balance test
~critical force test
~Astrand-Ryhming test
~self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)
~actimetry
~clinical and biological characteristics
~determination of inflammatory markers
~skeletal muscle index"
16341120|NCT04391530|Experimental|emotional freedom technique group|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
16341121|NCT04391530|Experimental|Breathin therapy group|Breathing therapy: the basic recipe After applying pre-test forms to students, the hall will be quiet and dim. In this study, breathing exercise application will be performed in three stages as (1) relax, (2) deep breath and (3) feel yourself.
16341122|NCT04391530|No Intervention|Control group|No intervention was made to the students in the control group.
16341123|NCT04391517|Experimental|Study Population|Included patients will be evaluated by an anaesthesiologist according to national and international guidelines as it is routine at the pre-operative clinic. In addition, all included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
16341124|NCT04391504|Experimental|transesophageal echocardiography guidance|
16341125|NCT04391504|Experimental|intracardiac echocardiography guidance|
16341126|NCT04391491||Heart failure with preserved ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFpEF (Symptoms of HF (NYHA II-IV); LVEF >50%; Elevated levels of natriuretic peptides (NT-pro BNP > 300 pg/ml in sinus rhythm, >600 pg/ml in AF);Relevant structural heart disease (Left ventricle hypertrophy (LVH) and/or Left atrium enlargement (LAE); left atrial volume index (LAVI) >34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females)
16341127|NCT04391491||Microvascular angina|Patients of both sexes and > 18 years with a confirmed diagnosis of MVA (Angina-like chest pain: signs of exercise-induced ischemia (ST-depression on exercise ECG (>1 mm down-sloping or rectilinear ST-segment depression in >2 leads)); No fixed stenosis (>50%) in epicardial coronary arteries or branches at baseline coronary arteriography)
16341128|NCT04391491||Pulmonary hypertension|Patients of both sexes and > 18 years with a confirmed diagnosis of secondary PH due to left heart disease (Left ventricular systolic dysfunction, left ventricular diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow obstruction and congenital cardiomyopathies) or chronic thromboembolic pulmonary hypertension defined by echo when peak tricuspid regurgitation velocity =2.8 m/s and presence of other echo 'PH signs'
16341129|NCT04391491||Heart failure with redused ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFrEF (Symptomatic HF (NYHA class II-IV), left ventricular ejection fraction ≤ 35% (at any time in the past))
16341130|NCT04391478|Active Comparator|milrinone|Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
16341131|NCT04391478|Active Comparator|sildenafil|Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.
16341132|NCT04391465|Experimental|Patients Scheduled for Elective Electrophysiological Study|"High right atrial pacing will occur at the following rates for 60 seconds each, with a rest period of at least 60 seconds between pacing runs:
~600 msec (100 bpm)
~500 msec (120 bpm)
~400 msec (150 bpm)
~350 msec (171 bpm)"
16341133|NCT04391452|Experimental|Dietary supplement group|Group 1:50 stressed subjects who will have a 28-day intake of dietary supplement. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam. Dietary supplement is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg).
16341134|NCT04391452|Placebo Comparator|Placebo group|Group 2 (Placebo comparator (lactose)): 50 stressed subjects who will have a 28-day intake of placebo. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam.
16341135|NCT04391439||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
16341136|NCT04391426||Patients who will undergo ERCP (case group)|
16341137|NCT04391426||Living liver transplantation donors (control group)|
16341168|NCT04391153|Active Comparator|conventional samplig|"Patients with biliary strictures udergo ERCP or EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods.
~Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology."
16341474|NCT04389099||Pathological placenta|Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia without fetal growth restriction ; fetal growth restriction without preeclampsia.
16341138|NCT04391413|Experimental|OCT group|"OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:
~Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.
~Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.
~After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment."
16341139|NCT04391413|No Intervention|Control group|Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.
16341140|NCT04391387|Active Comparator|16-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour after prone position
16341141|NCT04391387|Experimental|24-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour, 24- hour after prone position
16341142|NCT04391374||Conservative treatment|Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.
16341143|NCT04391374||Peripheral artery bypass grafting|Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position
16341144|NCT04391374||Peripheral artery balloon angioplasty and stenting|Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position
16341145|NCT04391361|Experimental|trial group|
16341146|NCT04391361|Placebo Comparator|control group|
16341147|NCT04391348|Experimental|PET-TDM|PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine
16341148|NCT04391335||Group 1|Participants who meet the screening criteria for the development of bronchiolitis obliterans syndrome (BOS) according to the NIH criteria
16341149|NCT04391335||Group 2|Participants who may or may not have abnormal spirometry; however they do not fulfill the NIH criteria for the development of BOS
16341150|NCT04391322||Group 1|Healthy participants without lung disease
16341151|NCT04391322||Group 2|Participants with stable cystic fibrosis
16341152|NCT04391322||Group 3|Participants with cystic fibrosis, anticipated to receive treatment with CFTR-modulator therapy. Please note: treatment is determined by your physician as part of your normal therapy plan.
16341153|NCT04391309|Experimental|anti-CD14 + SOC|"Anti-CD14: 150 participants randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously.
~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
16341154|NCT04391309|Placebo Comparator|Placebo + SOC|"150 participants randomized to Placebo diluent on Days 1-4 intravenously.
~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
16341155|NCT04391296|Experimental|I (Prepectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
16341156|NCT04391296|Active Comparator|II (Subpectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
16341157|NCT04391270|Experimental|web-based intervention group|"Except Library, the participants in this group will also have access to the Intervention sub-section of the website. It will consist of six sessions delivered every two weeks following the same time schedule as the essay delivery in Library."
16341158|NCT04391270|Experimental|blended intervention group|"Except visiting Library and Intervention of the website, the participants in this group will also receive three face-to-face workshops (40 min per session) held at their workplaces."
16341159|NCT04391270|No Intervention|Control group|"The participants in the control group will have access to the Library sub-section of the website. General information of MVPA, health and work productivity will be provided with 18 short essays, which can be downloaded and printed out. The information will be factual and non-personally tailored."
16341160|NCT04391257|Other|Main|gekoTM neuromuscular electrostimulation device (NMES) briefly used on patients with cardiac pacemakers to check if pacemakers detect the gekoTM electrical pulses as interference.
16341161|NCT04391231|Experimental|Pentoxifylline Arm|Pentoxifylline (in suspension with SyrSpend SF)
16341162|NCT04391231|Placebo Comparator|Placebo Arm|Placebo (SyrSpend SF only)
16341163|NCT04391218|Experimental|Multidisciplinary Approach Group|Multidisciplinary medication review and reconciliation during hospitalization involving geriatricians, nurses, pharmacists and supported by a Clinical Decision Support System, followed by an end-user App to support patients/caregivers in the correct drug intake after discharge.
16341164|NCT04391218|No Intervention|Control Group|Medication review and reconciliation will be performed by geriatricians according to Good Clinical Practice and usual habits, that might also include digital and printed supports for medication appropriateness and drug interaction. Drug therapy will be listed and explained to the patient/caregiver at discharge. Patients/caregivers will be allowed to use any tools to support medication adherence, according to their habits and preferences (i.e. calendars, alarms, pill boxes).
16341165|NCT04391192|Experimental|Participants|All participants will be given the phone number and encouraged to call any time they plan to use substances alone
16341166|NCT04391179|Experimental|Dipyridamole 100 Milligram(mg)|100 milligrams (mg) by mouth (PO) four times a day (QID)
16341167|NCT04391179|Placebo Comparator|Placebo|Placebo given by mouth four times a day
16341264|NCT04390477|Experimental|Probiotic|1 pill od containing 1x10E9 cfu of the probiotic
16341265|NCT04390477|No Intervention|Control|No treatment
16341266|NCT04390464|Active Comparator|Standard of care|Standard of care
16341267|NCT04390464|Experimental|Ravulizumab + Standard of care|Ravulizumab IV (adjusted to weight, Day 1 only)
16341169|NCT04391153|Active Comparator|Fluorescence in situ Hybridization (FISH)|Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
16341170|NCT04391140|Experimental|Experimental|Combination of prone position and HFNC
16341171|NCT04391140|No Intervention|Control|Standard care: HFNC set for a SpO2 90-95% if unless indication for intubation is present.
16341172|NCT04391127|Experimental|Hospitalized patients with COVID-19 QTc < 500 mseg|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc < 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
16341173|NCT04391127|Experimental|Hospitalized patients with COVID-19 infection with QTc >500ms|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc > 500 ms could be randomized to ivermectin or placebo.
16341174|NCT04391114|Active Comparator|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to Transurethral Resection of the Prostate (TURP) and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
16341175|NCT04391114|Active Comparator|Top-Down HoLEP|"The Top-Down HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve, with anticipated improved continence [8]. A variation of this method is also being explored in Japan (termed the en-bloc technique with anteroposterior dissection HoLEP) [9]. The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique."
16341176|NCT04391101|Experimental|Intervention group|Administration of two units of fresh frozen plasma (between 400 and 500 ml) obtained from convalescent patients from infection by SARS-CoV-2. Convalescent plasma is defined as the plasma of patients who had PCR confirmed SARS-CoV-2 infection, who have recovered clinically, and who have positive antibodies against SARS-CoV-2.
16341177|NCT04391101|No Intervention|Control group|Subjects assigned to the control group will receive support treatment in the intensive care unit based on institutional management guidelines. The use of antiviral, antimalarial or anti-inflammatory drugs is allowed in both groups according to the ICU protocols.
16341178|NCT04391088||hospitalized people living with diabetes|hospitalized people living with diabetes
16341179|NCT04391075||Exposed|Pudendal nerve block provided
16341180|NCT04391075||Not exposed|Pudendal nerve block is NOT provided
16341181|NCT04391062|Experimental|intraoperative PDT 400J/cm²|
16341182|NCT04391062|Experimental|intraoperative PDT 600J/cm²|
16341183|NCT04391062|Experimental|intraoperative PDT 800J/cm²|
16341184|NCT04391049|Experimental|Treatment (OBP-301, carboplatin, paclitaxel, radiation)|Patients receive OBP-301 by intratumoral injection on days -3, 12, and 26. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
16341185|NCT04391036|Experimental|High Eudragit® Film, then Low Eudragit® Film|High (12.8%) Eudragit® content vaginal film, then low (6.4%) Eudragit® content vaginal film
16341186|NCT04391036|Experimental|Low Eudragit® Film, then High Eudragit® Film|Low (6.4%) Eudragit® content vaginal film, then high (12.8%) Eudragit® content vaginal film
16341187|NCT04391023|Sham Comparator|Sham tDCS|The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
16341188|NCT04391023|Experimental|2 mA tDCS|The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
16341189|NCT04391023|Experimental|4 mA tDCS|The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
16341190|NCT04391010|Other|Health care providers with beard|
16341191|NCT04391010|Other|Health care providers without beard|
16341192|NCT04390997|No Intervention|Periodontally Healthy|20 participants with bleeding on probing less than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
16341193|NCT04390997|No Intervention|Gingivitis|20 participants with bleeding on probing greater than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
16343543|NCT04374422||2|same population during pandemic
16341194|NCT04390997|Other|Periodontitis|20 participants with bleeding on probing greater than or equal to 30%, probing depths greater than or equal to 5mm at least non-adjacent two teeth in each quadrant of the dentition, and clinical attachment loss greater than or equal to 4mm which was measured by six sites per tooth, and radiographic bone loss on the coronal third of root or severe (vertical/ horizontal) bone loss.
16341195|NCT04390984|Experimental|1|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
16341196|NCT04390971|Experimental|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.
16341197|NCT04390958|Experimental|Neoadjuvant chemotherapy group|Total 6 perioperative chemotherapy composed of nab-paclitaxel, cisplatin and capecitabine every 21 days
16341198|NCT04390945|Experimental|Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy|Camrelizumab (200mg Q2W, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons) Simultaneous radiotherapy (50-50.4Gy / 1.8-2Gy / 25-28F) Chemotherapy (Capecitabine, 625mg/m2, bid, oral, d1-5, qw, total 5 weeks).
16341199|NCT04390932|Experimental|Enhanced TA|Therapeutic exercise protocol accompanied by an enhanced TA.
16341200|NCT04390932|Active Comparator|Neutral therapeutic alliance|Therapeutic exercise protocol accompanied by an limited TA
16341201|NCT04390919||high group|high group: monocyte count≥0.445×10*9 cells/L
16341202|NCT04390919||low group|low group: monocyte count<0.445×10*9 cells/L;
16341203|NCT04390906||All participants|Participants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist
16341204|NCT04390893|Experimental|ultrasound positioning group|
16341205|NCT04390893|Active Comparator|leak test positioning group|
16341206|NCT04390880|Experimental|PEt/CT arm|Subjects receive a PET/CT scan.
16341211|NCT04390854|Active Comparator|Induced blood clot scaffold|
16341212|NCT04390854|Experimental|Induced blood clot scaffold combined with Platelet rich fibrin|
16341213|NCT04390841|Experimental|Single Arm ( Qubic Stim Cardiac Stimulator )|There is only one Arm in this trial, the subjects who meet the inclusion and exclusion criteria will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
16341214|NCT04390828|Experimental|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
16341215|NCT04390828|No Intervention|Usual care|usual care
16341216|NCT04390815|Experimental|Intervention|"Before starting the therapeutic procedure, all wounds will be fully washed with normal saline.
~Group A patients will receive 10 units (0.1 mL) of regular insulin (manufactured by novo nordisk) in solution with 1 cc of normal saline 0.9% for each 10 cm of wound. The solution will be sprayed on the wound surface with an insulin syringe needle, once daily.
~The patients in this arm will receive conventional therapy."
16341217|NCT04390815|Placebo Comparator|Control|Before starting the therapeutic procedure, all wounds will be fully washed with normal saline Group B patients will receive conventional topical application without insulin
16341218|NCT04390789|Experimental|single visit retreatment|nonsurgical root canal retreatment will be carried out in single visit.
16341219|NCT04390789|Active Comparator|multi visit retreatment|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
16341220|NCT04390776|Experimental|Treatment Sequence 1|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).
16341221|NCT04390776|Experimental|Treatment Sequence 2|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).
16341222|NCT04390776|Experimental|Treatment Sequence 3|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).
16341223|NCT04390776|Experimental|Treatment Sequence 4|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).
16341224|NCT04390763|Experimental|Safety Run-in|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
16341225|NCT04390763|Experimental|Randomized Arm 1|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
16341226|NCT04390763|Experimental|Randomized Arm 2|Combination of NIS793 + gemcitabine + nab-paclitaxel
16341227|NCT04390763|Active Comparator|Randomized Arm 3|gemcitabine + nab-paclitaxel
16341268|NCT04390464|Experimental|Baricitinib + Standard of care|Baricitinib PO OD (4mg, Days 1-14)
16341269|NCT04390451|Experimental|Whole Health STEPS|Participants will immediately receive Whole Health STEPS.
16341270|NCT04390451|Other|Waitlist|Participants will receive Whole Health STEPS after a defined waiting period.
16341231|NCT04390737|Experimental|HH2853 administered on a BID schedule in continuous 28-day treatment cycles|HH2853 is supplied as tables with dosage strength of 25mg and 200mg. HH2853 is administered orally on a continuous BID schedule in 28-day treatment cycles. Patients in accelerated titration part (ATD) should be administered a single dose on the first day in order to evaluate the PK of a single dose administration. Dosing is twice daily from the second day thereafter.
16341232|NCT04390724||Patient Group 1: Y90 Standard-of-Care|The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
16341233|NCT04390724||Patient Group 2: Y90 Dose determined by results from Group 1|The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1
16341234|NCT04390711||Healthy subjects|We included 40 age- and gender-matched healthy subjects to serve as the control group, who had normal blood pressure, serum fasting glucose, lipid profile, and renal function.
16341235|NCT04390711||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. All patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
16341236|NCT04390711||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association.T2DM without CAD was diagnosed if no luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
16341237|NCT04390698|Experimental|nerve block+opioid-free general anesthesia|Paravertebral block with an ultrasound-guided technique; opioid-free general anesthesia
16341238|NCT04390698|Sham Comparator|sham bock+opioid general anesthesia|Sham block by local infiltration at the same site of paravertebral block; opioid based general aneshesia
16341239|NCT04390685|Experimental|Tacrolimus ointment|Apply whole arm, in a thin layer, once daily for one year
16341240|NCT04390685|No Intervention|Control|
16341241|NCT04390672|Experimental|SUPRAFLEX Cruz|Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
16341242|NCT04390672|Active Comparator|SYNERGY|Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.
16341243|NCT04390646|Active Comparator|Pulsatile GnRH pump treatment|
16341244|NCT04390646|Placebo Comparator|Pulsatile placebo pump treatment|
16341245|NCT04390620||MUCODA|DAFILON - sterile, monofilament, non-absorbable surgical suture material produced from Polyamide
16341246|NCT04390607||Subjects undergoing revision joint surgery|
16341247|NCT04390594|No Intervention|Standard of Care|The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
16341248|NCT04390594|Experimental|Standard of Care + Nafamostat mesilate|"The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
~Nafamostat mesilate"
16341249|NCT04390581|Experimental|Juvéderm® VOLIFT with Lidocaine|All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.
16341250|NCT04390568|Experimental|Dose group 1|
16341251|NCT04390568|Experimental|Dose group 2|
16341252|NCT04390568|Experimental|Dose group 3|
16341253|NCT04390568|Experimental|Dose group 4|
16341254|NCT04390568|Experimental|Dose group 5|
16341255|NCT04390555||CV involvement|Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
16341256|NCT04390555||Control|Patients with COVID-19 without preexisting cardiac involvement.
16341257|NCT04390542|Experimental|Psychoeducation intervention|Psychoeducatoinal intervention
16341258|NCT04390542|No Intervention|Usual care|Information from healthcare providers
16341259|NCT04390516|Other|COViage|Machine learning intervention
16341260|NCT04390503|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Participants randomized to the experimental arm will receive 2 units (approximately 200 to 250 mL per unit, total 400-500mL) of convalescent plasma that was collected from a volunteer who recovered from COVID-19 disease.
16341261|NCT04390503|Active Comparator|Control (albumin 5%)|Participants randomized to the control arm will receive 2 units of 250 mL (500mL total) of albumin (human) 5% infusion. The albumin will be prepared in bags that are identical to the bags used for plasma. The similar appearance of albumin and plasma will facilitate maintaining the blinded status of subjects and most of the study staff.
16341262|NCT04390490|No Intervention|control|Automatic chemiluminescence analyzer will be used for dectecting the concentration of cardiac troponin I as control group.
16341263|NCT04390490|Experimental|Photoelectrochemical immunosensor|Photoelectrochemical immunosensor will be used for dectecting the concentration of cardiac troponin I as test group.
16341271|NCT04390438|Experimental|High-Intensity short time percutaneous electrolysis|Application of a 0,66uA galvanic current in the active TrP through a needle during 10 seconds. During the 20 seconds left necessary to blind the patient and the examiner, the needle was inside but with no electrical current
16341272|NCT04390438|Experimental|Low-Intensity long time percutaneous electrolysis|Application of a 0,22uA galvanic current in the active TrP through a needle during 30 seconds
16341273|NCT04390438|Active Comparator|Dry needling|One acupuncture needle was placed in the active TrP to produce a local twitch response during 30 seconds
16341274|NCT04390425|No Intervention|Control - Standard pneumatic tourniquet pressure|This group receives the standard pneumatic tourniquet pressure during surgery like they would during standard of care.
16341275|NCT04390425|Experimental|Experimental - Limb occlusion pressure|This group receives a slightly lower tourniquet pressure than they would during standard of care. This lowered limb occlusion pressure is determined by the tourniquet device.
16341276|NCT04390412|Experimental|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA fashion
16341283|NCT04390360|Other|Protective ventilation with HME|Protective ventilation + HME
16341284|NCT04390360|Other|Protective ventilation with Heated humidifier|Protective ventilation + HH
16341285|NCT04390360|Other|Implementation of protective ventilation|Protective ventilation implementation
16341286|NCT04390360|Other|Tidal Volume reduction|Tidal volume reduction
16341287|NCT04390347|Experimental|Intervention|The intervention product (Yakult) (supplied as fermented milk) and placebo will be delivered in sealed pots of 65 mL with date stamped expiry. Yakult contains Lactobacillus casei Shirota (a minimum of 6.5 × 109 live cells of Lactobacillus casei Shirota are contained in each pot).
16341288|NCT04390347|Placebo Comparator|Placebo|The placebo will be indistinguishable (identical in taste and colour but will not contain Lactobacillus casei Shirota) to both participants and trial investigators. It will be stored and provided in exactly the same manner as the intervention product.
16341289|NCT04390334|Experimental|Treatment A: Daridorexant|Single dose of 50 mg daridorexant
16341290|NCT04390334|Experimental|Treatment B: Famotidine & daridorexant|Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant
16341291|NCT04390334|Experimental|Treatment C: Efavirenz|600 mg efavirenz once daily in the evening from Day 5 to Day 14
16341292|NCT04390334|Experimental|Treatment D: Daridorexant & efavirenz|Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16
16341293|NCT04390321|Experimental|Down Syndrome LLMcare|Individuals with Down Syndrome which are able to execute the LLMcare physical and cognitive training intervention
16341296|NCT04390295|Experimental|SHR3824+Metformin, Placebo+Metformin|once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks
16341297|NCT04390295|Experimental|SHR3824 5 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
16341298|NCT04390295|Experimental|SHR3824 10 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
16341299|NCT04390282|Experimental|Application-based support system Lifepod®PAD|Patients in the experimental group will be introduced to and use Lifepod®PAD, a web-based application designed to support adherence to lifestyle advice and medication for three months. Lifepod®PAD is built as a two-side system. One side is the patient interface, the web-based application, accessible through a smartphone or tablet. The patients can log information about their lifestyle, symptoms and medication and review their data in relation to recommended targets. They get positive feedback, recommendations about healthy behaviours and receive notifications as short messages depending on their individual health status. The other side is the medical interface managed by the health care professionals. All information the patient is reporting into the app can be accessed by the treating nurse and the system ranks the patients, thus gives high priority to patients who have the greatest needs.
16341300|NCT04390282|No Intervention|Life style advice according to usual practice|Patients in the control group will receive usual care meaning advice about lifestyle changes and medication from the physician at the visit in the vascular open clinic.
16341301|NCT04390269||Infected group|The infected group will be classified according to the severity whether mild ,moderate or severe
16341302|NCT04390269||susceptible (non infected|This group either exposed and not infected .
16341303|NCT04390269||control group|normal control subject
16341304|NCT04390256|Active Comparator|Egg shell powder nanoparticles|
16341305|NCT04390256|Experimental|Clove water extract|
16341306|NCT04390256|Experimental|Carbopol|
16341307|NCT04390256|Experimental|Carboxymethyle cellulose|
16341308|NCT04390243|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16341309|NCT04390230||Patient with peniale implantation|All patients who underwent implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France.
16341443|NCT04389320||Rheumatoid patients receiving hydroxychloroquine|immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics
16341549|NCT04388540||Antigua|School aged children 6 - 12 years living in Antigua
16341310|NCT04390217|Experimental|LB1148|LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
16341311|NCT04390217|Placebo Comparator|Placebo|Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
16341312|NCT04390204|Experimental|Experimental|Motor control exercises are performed on foam mats. The physiotherapist instructs them, and gives a description on paper, as well as a USB key allowing to view the exercises on video. A supervised home self-rehabilitation program on foam mats is implemented.
16341313|NCT04390204|No Intervention|control|According to the recommendations of learned societies, patients are offered voluntary MPP contraction work, in strength and endurance, in increasing complexity, under manual endocavitary control and under biofeedback. A supervised program of self-rehabilitation at home by voluntary contraction of MPP is set up.
16341314|NCT04390191|Experimental|Continuous Positive Airway Pressure (CPAP)|Patients will be given CPAP at fixed pressure of 8-10 cm water pressure for 72 hours continuously
16341315|NCT04390191|No Intervention|Control|Patients in this arm will be not be given any intervention and will be monitored for 72 hours continuously, and then daily for a total of 14 days.
16341316|NCT04390178|Experimental|Convalescent plasma treatment|All participants will receive a bag of convalescent plasma. The bag volume will be 180-200 ml. The first 10 patients will receive 1, 5, 10, 50 and 134 ml of plasma at 30 minute intervals while being closely monitored for adverse events, especially allergic reactions. The remaining twenty patients will receive the convalescent plasma as a slow infusion according to normal routines.
16341317|NCT04390165||Malaysian COVID-19 Cohort|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
16341318|NCT04390152|Experimental|Mesenchymal stem cell|WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
16341319|NCT04390152|Active Comparator|Control group|Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo
16341320|NCT04390139|Experimental|Treatment A|Wharton-Jelly mesenchymal stromal cells on D1 and D3
16341321|NCT04390139|Placebo Comparator|Treatment B|Placebo on D1 and D3
16341322|NCT04390126||Register of haematological malignancies|
16341323|NCT04390126||Idiopathic Pulmonary Fibrosis and PAH Cohort|
16341324|NCT04390126||Giant Cell Arteritis Cohort|
16341325|NCT04390126||AMD and Macular Edema Cohort|
16341326|NCT04390126||Multiple Sclerosis Cohort|
16341327|NCT04390126||Myocardial Infarction Observatory RICO|
16341328|NCT04390126||Heart Failure Cohort|
16341329|NCT04390126||Hemophilia Cohort|
16341330|NCT04390113|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to ALVR105 (Viralym-M)
16341331|NCT04390113|Experimental|ALVR105 (Viralym-M)|Administered as 2-4 milliliter infusion, visually identical to placebo
16341332|NCT04390100|Active Comparator|PRF|PRF membrane is placed in the area where the free gingival graft was taken from the palate
16341333|NCT04390100|Active Comparator|hyaluronic acid|hyaluronic acid gel is placed in the area where the free gingival graft was taken from the palate and the patient is instructed to place the gel 3 times per day
16341334|NCT04390100|Active Comparator|Gel foam|Gel foam is placed in the area where the free gingival graft was taken from the palate
16341335|NCT04390087|Experimental|Exercise|Upper-body rowing performed up to 30 min, 3 times per week with moderate-to-vigorous intensity
16341336|NCT04390087|No Intervention|Control|The participants allocated to the control group will be asked to maintain their normal lifestyle throughout the intervention period
16341337|NCT04390074||COVID-19|Patients with COVID-19 who have received or are receiving Intensive Care in Sweden. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
16341338|NCT04390074||Control|Age- and sex-matched controls are drawn from all residents of Sweden by Statistics Sweden.
16341339|NCT04390061|Experimental|tofacitinib+HYQ|Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days
16341340|NCT04390061|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200mg cp three times a day for 14 days
16341344|NCT04390035|No Intervention|Control|Participants in the control arm will follow the standard-of-care treatment exercises for the 6 months following ACL reconstruction surgery.
16341345|NCT04390035|Experimental|Test (BFRT)|Participants in the test arm will follow the identical physical therapy exercises as the control arm but will perform the exercises with BFRT during the first 16 weeks post-surgery. After reaching the 16-week mark, participants will complete the identical standard-of-care rehabilitation between weeks 16-24.
16341346|NCT04390022|Active Comparator|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
16341347|NCT04390022|Placebo Comparator|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
16341348|NCT04390009|Other|Siemens Biograph Vision PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
16341349|NCT04390009|Other|United Imaging uEXPLORER PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
16341350|NCT04389996||Patients with cancer|Survey
16341444|NCT04389307|Other|Group 1: Bladder Training - Control group|Specific goals are to correct faulty habit patterns of frequent urination, improve control over bladder urgency, prolong voiding intervals, increase bladder capacity, reduce incontinence episodes and restore patient confidence in controlling bladder function
16341351|NCT04389983|Active Comparator|Healthy, under 65 years|Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)
16341352|NCT04389983|Active Comparator|Healthy, over 65 years|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.
~(All MCT doses administered as a single dose at time 0)"
16341353|NCT04389983|Active Comparator|Alzheimer's Disease subjects|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.
~(All MCT doses administered as a single dose at time 0)"
16341354|NCT04389970|Experimental|Time Restricted Feeding|Participants will be asked to follow a time-restricted meal pattern (8:16 protocol)
16341355|NCT04389957||Providers|The quantitative surveys will be delivered to the identified local quality stewards (N=73) and providers (N=657) for each enrolled site via the Research Electronic Data Capture (REDCap) platform at baseline (prior to VA-EQuIP) and 12 months following completion of the VA-EQuIP intervention. We will incorporate established methods of maximizing web survey responses, including multiple, carefully-timed, integrated email contacts.
16341356|NCT04389957||Patients|We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
16341357|NCT04389944|Experimental|convalescent plasma treatment|"After confirmation of negative SARS-CoV-2 polymerase chain reaction (PCR) in two consecutive nasal swabs or 28 days after resolution of symptoms, donor check is performed and plasma donation occurs by apheresis. The plasma is photochemically pathogen reduced using the INTERCEPT Blood System.
~In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up."
16341358|NCT04389931|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
16341359|NCT04389931|Experimental|Periodontal treatment, Omega 3|Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.
16341360|NCT04389918|Experimental|Tality|Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.
16341361|NCT04389905|Experimental|Motivational Interviewing Oral Health Education Group|The intervention group focused on the mothers from before birth until their child reached the age of 3 years. They received repeated questionnaires and repeated oral health education using the Motivational Interviewing (MI) technique.
16341362|NCT04389905|No Intervention|Local Control Group|The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
16341363|NCT04389905|No Intervention|Similar Socio-economics Control Group|This control group is from a Public Dental Clinic with similar socioeconomics (among the families in the catchment area of the clinic) as in the intervention group. This control group included mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
16341364|NCT04389892|Experimental|study participants|After a careful endoscopic ultrasound examination in B mode of the entire pancreas, contrast enhancement was administrated to the participants. The uptake and the wash-out of the agent were followed and then a morphological diagnose was established. EUS-fine needle aspiration of the cyst wall, septa or solid components was guided by the enhancing pattern.
16341365|NCT04389879|Experimental|CAD/CAM|CAD/CAM custom-cut Nickel Titanium (NiTi) FR
16341366|NCT04389879|Active Comparator|Conventional multistranded|Conventional multistranded Stainless Steel (SS) FR
16341367|NCT04389866|Experimental|Both Jawline and Lateral (Zygomatic) Cheek Area Injections|JUVÉDERM VOLUMA™ XC 1-3 syringes (each syringe is 1 cc) will be injected into the lateral cheek (zygomatic) area plus JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation)
16341368|NCT04389866|Experimental|Jawline Injections|JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation)
16341369|NCT04389853|Active Comparator|Flexible ureteroscopy (fURS)|Retrograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
16341473|NCT04389099||Healthy placenta (control)|Pregnant women without preeclampsia and/or fetal growth restriction
16341550|NCT04388540||Dominica|School aged children 6 - 12 years living in Dominica
16341370|NCT04389853|Active Comparator|Mini-percutaneous nephrolithotomy (mini-PCNL)|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs)4
16341371|NCT04389840|Experimental|Dociparstat sodium (DSTAT)|Dociparstat 4 mg/kg IV bolus on Day 1, followed by Dociparstat by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])
16341372|NCT04389840|Placebo Comparator|Placebo|Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])
16341373|NCT04389827||Incident & Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
16341374|NCT04389801|Experimental|Desferal|An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours
16341375|NCT04389801|Placebo Comparator|control group|Will receive glucose 5% over 4 hrs infusion
16341376|NCT04389788|Active Comparator|Rt Eye|The right eye of the patients received carboxy therapy for 6 sessions every 2 weeks. The used device is locally manufactured by a national company for esthetic and dermatological devices. Carbon dioxide gas was subcutaneously injected at the lateral one-third of each eye lid (5 cc gas in each puff according to standardized flowmetry) using insulin syringe. Compression of the injected area will be avoided to prevent rapid leakage of the gas.
16341377|NCT04389788|Active Comparator|Lt Eye|The left eye of the same patients received microneedling with topical glutathione for 6 sessions every 2 weeks. Microneedling was done with Derma pen which is automatic and rechargeable device (vibrating frequency : 6500-10000 r/m , vibration speed level 5 , model :Ultima A6 , company : Dr ,pen and country : Korea). Needle length is adjustable from 0.25 mm to 0,5 mm.Needles number : 36 .Then, Patient was subjected to topical glutathione about 0.25 ml (vial : 600mg/5ml).
16341382|NCT04389762|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
16341383|NCT04389749|Experimental|CPM|The experimental group will have a CPM applied in the PACU immediately post-op and it will be utilized while the patient is awake in bed for 2 hours on and 2 hours off, when not mobilizing with Physical Therapy (PT). The experimental group will also have traditional PT, including sessions 1 to 3 times a week.
16341384|NCT04389749|No Intervention|No CPM|The control group will have typical care, including working with physical therapy 1 to 3 times a week.
16341385|NCT04389736|Experimental|SIT|Sitting
16341386|NCT04389736|Experimental|STAND|Standing
16341387|NCT04389736|Experimental|NMES|Self-selected maximal intensity of neuromuscular electrical stimulation
16341388|NCT04389723|Other|Placebo→ Qualia Mind|Subjects are first administered the placebo then crossover to the investigational product
16341389|NCT04389723|Other|Qualia Mind→ Placebo|Subjects are first administered the investigational product then crossover to the placebo
16341390|NCT04389710|Experimental|Intervention Group|Participants included in the experimental group will receive 200-600 milliliters of convalescent plasma, administered at a rate of 100-250 mL/hr
16341391|NCT04389697|Experimental|Intervention arm|Clear fluids and food up to up to 1 hour before the procedure
16341392|NCT04389697|No Intervention|Control arm|Fasting for solids for up to 6 hours and fluids up to 2 hours before the procedure
16341393|NCT04389671|Experimental|Lyophilized Lucinactant|Lyophilized Lucinactant reconstituted with sterile water for injection
16341394|NCT04389658||Asymptomatic population|Subjects who underwent PCR and ELISA tests for the diagnosis of COVID-19: mainly asymptomatic individuals from three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19 that have performed the PCR and ELISA test for the diagnosis of COVID-19 before initiating the work immediately after Spanish lockdown.
16341395|NCT04389632|Experimental|SGN-B6A|SGN-B6A monotherapy
16341396|NCT04389619|Experimental|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
16341397|NCT04389619|Active Comparator|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
16341398|NCT04389606|Experimental|Study Formula (SF)|New infant formula for term infants
16341399|NCT04389606|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
16341400|NCT04389606|No Intervention|Human Milk Reference Group|Human milk
16341401|NCT04389593||Single arm|This is a single arm study in which all participants have one MRI
16341402|NCT04389580|Active Comparator|13 cis retinoic acid doses orally plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
16341403|NCT04389580|Active Comparator|13 cis retinoic acid doses Aerosolized plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
16341404|NCT04389580|No Intervention|No Intervention:|No study treatment Arm No Isotretinoin or Tamoxofien treatment
16341405|NCT04389567||Patients with COVID-19 taking Famotidine|Use of any dose of oral Famotidine during period of COVID-19
16341406|NCT04389554||Control Group|Healthy pregnant women
16341407|NCT04389554||Study Group|Pregnant women with COVID-19
16341408|NCT04389528|Experimental|tDCS active arm|
16341409|NCT04389528|Placebo Comparator|tDCS placebo|
16341410|NCT04389502|Experimental|CaPtyVa app group|Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
16341411|NCT04389502|Active Comparator|Control group|The ones assigned to the control group will be asked to complete the 10-item clinical vignette quiz according to their current knowledge on local current CRC screening and surveillance guidelines
16341412|NCT04389476||Medical staff in high contact with patients|
16341413|NCT04389476||Other personnel in low contact with patients|
16341414|NCT04389476||Patients|
16341415|NCT04389476||Community residents|
16341416|NCT04389463||Cardiac or thoracic surgery in COVID-19 positive patients|
16341417|NCT04389463||Cardiac/thoracic surgery in COVID-19 negative patients|
16341418|NCT04389450|Experimental|PLX-PAD interval high dose|PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.
16341419|NCT04389450|Experimental|PLX-PAD low dose|PLX-PAD 300, single administration, second administration of placebo after 1 week.
16341420|NCT04389450|Placebo Comparator|Control Group A|Placebo, two administrations, 1 week apart
16341421|NCT04389450|Experimental|PLX-PAD high dose|PLX-PAD, single administration
16341422|NCT04389450|Placebo Comparator|Control Group B|Placebo, single administration
16341423|NCT04389437|Experimental|NCD patients (case)|Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.
16341424|NCT04389437|Other|Control patients with memory complaint|Normal neuropsychological evaluation during assessment
16341425|NCT04389437|Other|Control patients without memory complaint|MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint
16341426|NCT04389424||Anastrozole|Breast cancer women with anastrozole treatment
16341427|NCT04389424||Tamoxifen|Breast cancer women with tamoxifen treatment
16341428|NCT04389424||Exemestane|Breast cancer women with exemestane treatment
16341429|NCT04389424||Basal|Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
16341430|NCT04389424||Recurrence|Breast cancer women luminal type with recurrence of disease during endocrine therapy
16341431|NCT04389411|Experimental|Montelukast|10mg Oral Montelukast once daily for 60 days
16341432|NCT04389411|Placebo Comparator|Placebo|Placebo.
16341433|NCT04389398|Experimental|Pocket compression fixation belt|Pocket compression belt is used to compress the bleeding vessels and reduce bleeding after implantation.
16341434|NCT04389398|Active Comparator|Sand bag compression|Sand bag compression is used to compress the bleeding vessels and reduce bleeding after implantation.
16341435|NCT04389385|Experimental|COVID-19 STCs -Exo therapy|"In addition to the best available treatment, participants will receive inhaler COVID-19 STCs -Exo therapy *.
~Biological: Inhaler CSTH-Exo treatment will be applied daily x 5 times (2.0 x 108 nano vesicle / 3 ml; on day 1 to day 5).
~* If the improvement contribution is observed in the parameters, this application period could be extended"
16341436|NCT04389372|Experimental|Mindfulness by Smartphone|mindfulness therapy by smart phone
16341437|NCT04389359|Experimental|HCQ group (dialysis)|"Dialysis patients will receive Hydroxychloroquine sulfate 200 mg capsules or tablets (oral administration), as 600mg weekly in divided doses, given as 200mg after each dialysis session.
~Non-dialysis patients will receive Hydroxychloroquine sulfate, 400mg twice daily for two days, then 400mg weekly.
~Maximum treatment duration will be 26 weeks (6 months)."
16341438|NCT04389359|No Intervention|Control|Patients will continue with their usual medicines and clinical care without additional HCQ.
16341439|NCT04389346|Active Comparator|Periapical surgery with PRF group|Autologous platelet aggregate (PRF) will be placed over the denuded root surface, following apicoectomy and before flap repositioning.
16341440|NCT04389346|Placebo Comparator|Control group without PRF|Flap will be repositioned following apicoectomy without placement of any autologous platelet aggregate.
16341441|NCT04389333|Experimental|Non-contact MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination. In order to simplify the examination procedure, the data recorder was put on the examination bed. The patient lay down after swallowing the capsule under the remote guidance of the endoscopist.
16341442|NCT04389333|Active Comparator|MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of an endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient was instructed to assume the supine or left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist face to face, the subject turned over on the bed to complete the examination.
16341551|NCT04388540||St. Kitts and Nevis|School aged children 6 - 12 years living in St. Kitts and Nevis
16341445|NCT04389307|Active Comparator|Group 2: Bladder Training+Intra Vaginal Electrical Stimulation|IVES was performed in lithotomy position via Enraf Nonius Myomed 632 device with a vaginal probe. IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24-session treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback
16341446|NCT04389281|Experimental|X-PACT Treatment|Single arm consisting of a six-week treatment period with X-PACT (phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) administered as an intra-tumoral injection. Intra-tumoral injections will be given on D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6. After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart.
16341447|NCT04389268||HCV patients|Patients with uncomplicated newly diagnosed hepatitis C virus
16341448|NCT04389268||Control group|Age and sex matched with patients
16341449|NCT04389255||Healthy people|65 people will be included.
16341450|NCT04389242|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
16341451|NCT04389242|Experimental|app-based cognitive behavioral intervention|"Application-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
16341452|NCT04389242|Other|Wait-list control group|No intervention will be provided when the experimental groups are receiving services, but the access to the App-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
16341453|NCT04389229|Experimental|UTIL-01|Single dose autologous unmodified tumour infiltrating lymphocytes
16341454|NCT04389229|Experimental|CoTIL-01|Single dose autologous gene modified tumour infiltrating lymphocytes
16341455|NCT04389216|Experimental|Radiofrequency|Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.
16341456|NCT04389203|Experimental|Study group|Unilateral tubal disconnection and waiting for pregnancy for 2 years after laparoscopy
16341457|NCT04389203|Experimental|Control group|Unilateral tubal disconnection and ICSI
16341458|NCT04389190|Active Comparator|Standard Protocol|This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
16341459|NCT04389190|Experimental|Low frame rate protocol|This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.
16341460|NCT04389190|Experimental|Customized Protocol|This will have varying settings based on three weight based groups. Small (<60 kg), medium (60-85 kg), large (>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
16341461|NCT04389177|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin|Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks
16341462|NCT04389164|Experimental|Tissue engineering method|The thickness of scar tissue in the middle of the dermis is removed by a roller cutter with a thickness of about 0.01 -- 0.02mm. After cleaning, the dermis can be used for punching and mesh drawing in the dermal rolling machine.Autologous epidermal basal cell suspension was prepared according to the description of autologous epidermal basal cell extraction box.The size of the remaining skin should be the same as the wound surface. After washing with normal saline, the wet yarn should be wrapped for later use.The autogenous scar dermal scaffold was prepared and transplanted onto the wound surface. The autoepidermal basal cells prepared were sprayed or coated between the mesh and the dermal scaffold. Autologous skin slices were transplanted onto the wound surface and fixed with pressure bandaging.
16341463|NCT04389164|Active Comparator|Conventional therapy|Autologous skin was grafted onto the wound surface and fixed with pressure bandage
16341464|NCT04389151|Other|The experimental group|
16341465|NCT04389138|No Intervention|Comparison|In this arm participants will attend 3 study visits to complete study questionnaire and assessments. In between these visits, participants will be asked to wear an activity monitor and record an activity diary for one week. Other than this, participants will continue to receive only standard of care treatment.
16341466|NCT04389138|Experimental|Intervention arm|In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
16341467|NCT04389125|Experimental|Improvement of Blood Flow group|One packet once a day, after breakfast (1.5 g/day, 1.5 g/day as an Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures)
16341468|NCT04389125|Placebo Comparator|Placebo group|One packet once a day, after breakfast (1.5 g/day)
16341469|NCT04389112|Experimental|Patients with actinic keratoses|
16341470|NCT04389112|Experimental|patients with squamous cell carcinoma in situ|
16341471|NCT04389112|Experimental|patients with squamous cell carcinomas|
16341472|NCT04389112|Experimental|patient with invasive metastates|
16341475|NCT04389086|Experimental|Induction chemotherapy + chemoradiotherapy + surgery|Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
16341476|NCT04389086|Active Comparator|Neoadjuvant chemotherapy + surgery|Neoadjuvant chemoradiotherapy followed by surgery
16341477|NCT04389073|Experimental|Arm 1 (PD-1+NVB)|"The treatments received are:
~Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])."
16341478|NCT04389073|Experimental|Arm 2 (PD-1+NVB+Bev)|"The treatments received are:
~Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Bevacizumab (15 mg/kg every 3 weeks, intravenously [IV])."
16341479|NCT04389073|Experimental|Arm 3 (PD-1+NVB+DDP)|"Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Cisplatin (50mg/m2 every 3 weeks, intravenously [IV])."
16341480|NCT04389073|Experimental|Arm 4 (PD-1+VEX)|"Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Cyclophosphamide (50 mg/day, qd, per os)
~Capecitabine (500 mg, tid, per os)"
16341481|NCT04389073|Active Comparator|Arm 5 (NVB)|• Vinorelbine (40 mg/day, tiw, per os)
16341482|NCT04389060|Active Comparator|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing
16341483|NCT04389060|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 2 hours prior to testing
16341484|NCT04389034||Adults|Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy
16341485|NCT04389021|Experimental|VR|The intervention group will receive VR support upon the standard of care during the procedure.
16341486|NCT04389021|No Intervention|Control|The control group will have standard care without the VR support.
16341487|NCT04389008||Postoperative death|
16341488|NCT04389008||Postoperative non-death|
16341489|NCT04388995|Experimental|observed patients|
16341490|NCT04388982|Experimental|MSCs-Exos Dosage 1|MSCs-Exos. low-dose group
16341491|NCT04388982|Experimental|MSCs-Exos Dosage 2|MSCs-Exos mid-dose group
16341492|NCT04388982|Experimental|MSCs-Exos Dosage 3|MSCs-Exos high-dose group
16341493|NCT04388969||Gaucher disease patients|Patients with type 1,2,3 Gaucher disease.
16341494|NCT04388969||GBA carriers with Parkinson disease|Patients with Parkinson disease GBA related (carriers)
16341495|NCT04388943||1|
16341496|NCT04388930||Kidney transplant live-donor|Participants that will be a planned live renal transplant donor
16341497|NCT04388930||Kidney transplant recipient|Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
16341498|NCT04388917||Clip Group|Use of Hemo-lock hemostatic clips during tumor resection to prevent bleeding
16341499|NCT04388917||No Clip group|No Hemo-lock hemostatic clips used during tumor resection
16341500|NCT04388904|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
16341501|NCT04388891|Experimental|Minimally supervised therapy|This group will undergo minimally supervised therapy with the robot ReHapticKnob.
16341502|NCT04388878|Experimental|PF-07054894|Participants will receive single or multiple ascending doses of oral PF-07054894
16341503|NCT04388878|Placebo Comparator|Placebo|Participants will receive matching placebo
16341504|NCT04388865|Experimental|Control|Usual Care
16341505|NCT04388865|Experimental|Clinical Hovering|Remote monitoring with feedback to social support
16341506|NCT04388852|Experimental|Treatment (valemetostat, ipilimumab)|Patients receive valemetostat PO QD on days 1-21 and ipilimumab IV over 90 minutes on day 1 of cycles 1 and 3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16341507|NCT04388839|Experimental|Arm A - First Strike|Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
16341508|NCT04388839|Experimental|Arm B - Second Strike - Maintenance|Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
16341509|NCT04388839|Experimental|Arm C - Adaptive Therapy|Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
16341510|NCT04388839|Active Comparator|Arm - D Conventional Therapy|Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
16341513|NCT04388800|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist."
16341514|NCT04388800|Experimental|app-based cognitive behavioral intervention|"App-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist"
16341515|NCT04388800|No Intervention|Wait-list control group|No intervention will be provided when the experimental group is receiving services, but the access to the app-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
16341516|NCT04388774|Experimental|Ketamine|Total dose administration or 0.5 mg/kg of ketamine
16341517|NCT04388761|Experimental|Intra parenchymal injection|5 subjects will receive AMSCs via direct injection into the kidney parenchyma only
16341518|NCT04388761|Experimental|Intra-arterial infusion|5 subjects will receive AMSCs via intra-arterial infusion only
16341519|NCT04388761|Experimental|Intra parenchymal injection & Intra-arterial infusion|5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion
16341520|NCT04388748|Experimental|SMART-D Intervention Group|Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.
16341521|NCT04388748|No Intervention|Standard of Care Group|Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.
16341522|NCT04388735||Newly Diagnosed MM 1st Line and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.
~Both patients with or without identified caregivers will complete a one time series of questionnaires.
~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete."
16341523|NCT04388735||MM receiving 1-3 prior lines of therapy and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.
~Both patients with or without identified caregivers will complete a one time series of questionnaires.
~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
16341524|NCT04388735||MM patients receiving ≥ 4 lines of therapy and Cargivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.
~Both patients with or without identified caregivers will complete a one time series of questionnaires.
~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
16341525|NCT04388722|No Intervention|Control Arm|
16341526|NCT04388722|Experimental|Investigational Arm|
16341527|NCT04388709|Experimental|Peginterferon lambda-1a|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
16341528|NCT04388709|No Intervention|Best supportive care|Best supportive care
16341529|NCT04388696|Experimental|Sisterhood 2.0|"Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period.
~Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care."
16341530|NCT04388696|Active Comparator|Job Skills Training|The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.
16341531|NCT04388683|Experimental|Intervention|Will receive study drug treatment.
16341532|NCT04388683|No Intervention|Control|Will receive standard of care.
16341533|NCT04388657||Covid Intensive arm|Patients included in intensive care admission by one of the principal investigators from the 3 selectioned centers.
16341534|NCT04388631||Exposed group|Male patient discharged with COVID-19
16341535|NCT04388631||Control group|Healthy male volunteers without COVID-19
16341536|NCT04388618||covid19 positive patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested positive
16341537|NCT04388618||covid19 negative patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested negative
16341538|NCT04388592|Experimental|Nurse practitioner (NP)-led care arm|The patient randomized to the NP intervention arm will be contacted by the NP to be scheduled for an NP appointment within 4 to 6 weeks from the date of the referral. The NP consultation will include patient history, physical examination, symptomatic management strategies as appropriate (eg: bladder and bowel management strategies, fatigue management, depression, anxiety, spasticity etc), discussion of mental and physical health resources for symptomatic treatment, support, physical and mental health resources to optimize functioning (eg: home care, physical/occupational therapy referral) and quality of life. There will be NP followup, in person or by phone or videoconferencing at 3 months, and 6 months. The NP will be using the electronic medical record offered by Alberta Health Services.
16341539|NCT04388592|No Intervention|Usual Care Arm|Those patients randomized to the usual care arm (community neurologist and registered nurses) will be contacted by the NP to be scheduled for an NP appointment in 6 months, so that every participant is given the opportunity to meet with the NP, after their involvement in the study has concluded. During the six-month period, patients randomized to the control group will receive usual care from community neurologists and MS registered nurses or family physicians. The care will be delivered according to standard practices, and follow-up visits will be conducted according to the various neurologists' or family physicians' practices.
16341540|NCT04388553|Experimental|Treatment|lumbar ESP block is performed. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.
16341541|NCT04388553|No Intervention|Control|no regional anaesthesia is performed nor saline is injected into the ESP
16341542|NCT04388540||Jamaica|School aged children 6 - 12 years living in Jamaica
16341543|NCT04388540||Trinidad and Tobago|School aged children 6 - 12 years living in Trinidad and Tobago
16341544|NCT04388540||Belize|School aged children 6 - 12 years living in Belize
16341545|NCT04388540||Barbados|School aged children 6 - 12 years living in Barbados
16341546|NCT04388540||St. Lucia|School aged children 6 - 12 years living in St. Lucia
16341547|NCT04388540||Grenada|School aged children 6 - 12 years living in Grenada
16341548|NCT04388540||St. Vincent & the Grenadines|School aged children 6 - 12 years living in St. Vincent & the Grenadines
16341554|NCT04388514|No Intervention|Standard of Care|"BAT only
~To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days."
16341561|NCT04388488|Experimental|CONNECT TF|Trans-femoral amputees currently using a conventional handmade socket will be fitted with the CONNECT TF adaptable socket system for 6 weeks and their current existing conventional socket for 6 weeks, data collection on both sockets will be performed and outcomes compared.
16341562|NCT04388475|Experimental|All patients|All patients enrolled in this study
16341563|NCT04388462||locked plating with predicted distribution of loc|
16341564|NCT04388462||unlocked plating with predicted distribution of loc|
16341565|NCT04388462||Interlocking nail +/- blocking screws|
16341566|NCT04388423|Experimental|Group S|
16341567|NCT04388423|Experimental|Group C|
16341568|NCT04388410|Experimental|convalescent plasma|Convalescent plasma obtained from volunteers who have recovered from COVID 19. Enclosed with a similar material as the control
16341569|NCT04388410|Placebo Comparator|Normal saline|Normal saline solution in 200 ml plasma bags enclosed with with a similar material as the plasma
16341570|NCT04388397|Experimental|Immediate-access Arteriovenous Grafts|Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
16341571|NCT04388397|Active Comparator|Standard Arteriovenous Grafts|Standard Arteriovenous Grafts as a vascular access for hemodialysis patients
16341572|NCT04388371|Experimental|Prior to subject taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
16341573|NCT04388371|Experimental|subjects taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
16341574|NCT04388358|Other|mixed Chinese herb formula|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
16341575|NCT04388332||Retrospective|20 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
16341576|NCT04388332||Prospective|20 patients who are receiving Tritanium C as standard of care.
16341577|NCT04388319|Experimental|Combination zonisamide and bupropion with e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.
16341578|NCT04388306||Study Group|Thirty-two participants with undergone arthroscopic Rotator Cuff repair
16341579|NCT04388306||Control Group|Thirty-two healthy participants
16341580|NCT04388280|Other|Imaging|Echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries.
16341581|NCT04388280|No Intervention|Observation|No imaging for the estimation of coronary artery disease
16341582|NCT04388267||Septic shock|Patients with septic shock, according to the Sepsis 3 definition, regardless of the origin
16341583|NCT04388267||Major vascular surgery|Patients who underwent elective or emergent major vascular surgery abdominal aortic surgery (open or endovascular surgery)
16341584|NCT04388254|Experimental|Simufilam 100 mg oral tablets throughout|Simufilam 100 mg oral tablets administered twice daily (BID) for the full 24 months (including the randomized period Month 12 to Month 18)
16341585|NCT04388254|Placebo Comparator|Simufilam 100 mg oral tablets / Placebo / Simufilam 100 mg oral tablets|This placebo arm is only for Month 12 to Month 18. Day 1 to Month 12, as well as Month 18 to Month 24 are open-label treatment periods of simufilam 100 mg b.i.d. for all subjects.
16341586|NCT04388241|Experimental|Behavioral Intervention|Children and adolescents with SCD between the ages of 8 and 17 years old (n=20) will be recruited to complete a four-week behavioral intervention designed to reduce pain-related impairment in SCD.
16341587|NCT04388228|Experimental|Extended audit and feedback|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.
~This extended feedback report consists of:
~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.
~A low cognitive load of the feedback where the results will be presented with the help of graphs.
~Action plans to improve the quality of registration
~A push system to minimize the effort the GP must make to consult the feedback."
16341625|NCT04387877|Experimental|Graston Group|Graston technique will be applied on the lateral and posterior myofascial chain area tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
16342180|NCT04383873|Experimental|Intervention|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
16341588|NCT04388228|Active Comparator|Basic feedback|In the past, all GPs received basic feedback on the level of registration in the EHR and this form of feedback will still be provided in the control group. By providing all GPs a basic level of feedback, we do not change the former protocol and all GPs will receive the opportunity to improve their registration performance. Only the way of receiving feedback is more straightforward, the GP needs to login to HealthStat.be.
16341589|NCT04388215|Experimental|Treatment group|"Drug: CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg
~- CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
16341590|NCT04388215|Active Comparator|Comparator group 1|"Drug: CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D013(placebo) 80mg
~- CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D337(placebo) 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
16341591|NCT04388215|Active Comparator|Comparator group 2|"Drug: CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg
~- CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg, orally, 1 tablet once a day for 8 weeks"
16341592|NCT04388202|Experimental|Sertraline|Sertraline 100-200 mg daily for 8 weeks
16341593|NCT04388202|Active Comparator|Escitalopram|Escitalopram 10-20 mg daily for 8 weeks
16341594|NCT04388189|Experimental|Duloxetine|Duloxetine 60 mg daily for 8 weeks
16341595|NCT04388189|Active Comparator|Bupropion|Bupropion 150-450 mg daily for 8 weeks
16341596|NCT04388176|Experimental|C21 followed by placebo|
16341597|NCT04388176|Experimental|Placebo followed by C21|
16341598|NCT04388163|Experimental|Gentian Violet Treatment|A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
16341599|NCT04388137||infants aged 0-3|No intervention.
16341600|NCT04388137||children aged 4-18|No intervention.
16341601|NCT04388124|Placebo Comparator|Placebo|Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
16341602|NCT04388124|Experimental|Bosentan|Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
16341603|NCT04388111|No Intervention|Control Group|Patient receives an intraosseous injection of antibiotics into the tibia as per the standard of care for primary total knee arthroplasty under the study providers.
16341604|NCT04388111|Experimental|Intarosseous Morphine|Patient receives an intraosseous injection of antibiotics + 10mg of morphine into the tibia during their total knee arthroplasty.
16341605|NCT04388098||Asthmatic children|Asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
16341606|NCT04388098||Non-asthmatic children|Non-asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
16341607|NCT04388059||Transection at 2 cm from the pylorus|the effect of transection at 2 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
16341608|NCT04388059||Transection at 5 cm from the pylorus|the effect of transection at 5 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
16341609|NCT04388046|Experimental|skeletal class 2 malocclusion|10 patients treated with type IV Herbst appliance. The appliance was connected directly to the mandible by a bilateral reconstruction bone plates to provide a skeletal anchorage and avoid any mandibular teeth involvement
16341610|NCT04388033|Experimental|Safety Evaluation Group|"Basic treatment phase:
~The patients have surgery followed by concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days).
~Immunotherapy phase:
~Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle. Fusion cells will be suspended in 0.5 mL normal saline and then injected intradermally close to a cervical lymph node. IL-12 will be injected subcutaneously at the same side at dose of 6ug twice for interval of one hour."
16341611|NCT04388020|Experimental|Test Arm|
16341612|NCT04387981|Experimental|[14C]-orvepitant|[14C]-orvepitant administered as 30mg single dose in oral solution
16341613|NCT04387968||agents in contact with the public|patients working with children, policemen, desk office
16341614|NCT04387968||agents with no contact with the public|administrative workers
16341615|NCT04387955|Other|Acrovid|Cohort
16341616|NCT04387942|Experimental|Recombinant Human Interleukin-2|patients were treated with IL-2.
16341617|NCT04387942|No Intervention|Traditional therapy|patients were treated with dipyridamole and/or glucocorticoid，immunosuppressor.
16341618|NCT04387929||IgG negative|No intervantion. Only antibody mesurment from blood sample
16341619|NCT04387929||IgG positive, viral load negative|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
16341620|NCT04387929||IgG positive, viral load positive|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
16341621|NCT04387916|Experimental|KC1036|Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
16341622|NCT04387903||Reoperation group|The group of patients who underwent pancreaticduodenectomy for management of periampullary tumors and required surgical reintervention afterwards for management of procedure-related complications as pancreatic fistula, bleeding, abdominal collection, biliary fistula, gastric fistula.
16341623|NCT04387903||No reoperation group|The group of patients who underwent pancreaticoduodenectomy for management of periampullary tumors and did not require surgical reintervention.
16341624|NCT04387890||Serologic Screening|Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.
16343647|NCT04373694|Experimental|Vaginoscopy|morcellation hysteroscopy with only intravenous sedation
16341626|NCT04387877|Sham Comparator|Sham Group|"Sham graston technique will be applied on lateral and posterior myofascial chain area (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
~(Sham graston technique will be applied to the patient by partially touching the muscle or fascia region via ultrasound gel with the flat part of the Graston tool so as not to provide the activity of the fascia)"
16341627|NCT04387864|Experimental|Whole-body Vibration Exercise Group|"The patients in the WBV exercise group underwent WBV exercise sessions 2 days a week (72 hours in between) for a total of 6 weeks. Each exercise session was performed under the supervision of a physician.
~The patients received support from both hands on the WBV platform and both knees were positioned statically at 40-60 degree flexion (high squat position). All patients stood on the platform with sports socks (without shoes) to avoid the shoes absorbing vibration. Vibration was given by a Power Plate® device where a three-plane oscillation occurs (most vertical, Z axis). In all vibrations, 30 Hz frequency and 2 mm amplitude (low amplitude) were used. The vibration time was set to be 30 seconds in the first two weeks, 45 seconds in the next two weeks and 60 seconds in the last two weeks. The repetition of vibration was increased by 1 repetition every week, starting with 5, and 10 repetitions were given in the last week. A 1-minute rest period was given between each repetition."
16341628|NCT04387864|No Intervention|Home Exercise Group|The home program, which included isometric and isotonic exercises, was followed at home for 6 weeks. Three sets of quadriceps setting as 5 repetitions, 5-second contractions, and three sets of isotonic quadriceps exercise in seating position with weights as 12 repetitions were administered to be performed two days a week. While the patients included in the study group came for TVT exercise two days a week, the patients in the control group performed quadriceps setting exercises also on those days. The patients were invited to the physician follow-up on Wednesday every week for motivation and follow-up. The patients were asked to write their complaints during and after the exercise, if any. In addition, they were asked to note the number of repetitions and sets of their exercises on exercise booklets prepared for the patient.
16341629|NCT04387851||Placebo|Placebo effects are defined as the positive effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive effects.
16341630|NCT04387851||Nocebo|Nocebo effects are defined as the negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have negative effects.
16341631|NCT04387838||Anti-SARS-CoV2 serological status|"At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
~For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60.
~For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped."
16341632|NCT04387825|Experimental|Experimental group|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
16341633|NCT04387825|No Intervention|Control|Evolution and medical therapy effects were observed in the control group.
16341634|NCT04387812|Experimental|Xtrodes home PSG system|Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
16341635|NCT04387799||Negative PCR Covid associated Pneumonia|Patients with pneumonia who test negative to RT-PCR
16341636|NCT04387799||Positive PCR Covid associated Pneumonia|Patients with pneumonia from Covid 19
16341637|NCT04387773|Experimental|GOCOVRI Treatment|All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).
16341641|NCT04387734|Experimental|Ocrevus|
16341642|NCT04387734|Active Comparator|Platform therapies|Platform therapies consist of the following injectable disease modification treatments: IFNb-1a, IFNb-1b, and glatiramer acetate.
16341643|NCT04387721||Trifocal IOL(Finevision IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted First group: FineVision
16341644|NCT04387721||Trifocal toric IOL (Finevision Toric IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted: Second group: FineVisionToric
16341645|NCT04387695|Experimental|SBRT + TACE + Sorafenib|SBRT sequential TACE combined with Sorafenib
16341646|NCT04387695|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
16341647|NCT04387682|Other|OSCC subjects with β-glucan supplement|Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan
16341648|NCT04387682|No Intervention|Healthy donors|healthy donors without pre-surgical administration of whole glucan particle β-glucan
16341649|NCT04387682|No Intervention|OSCC subjects without β-glucan supplement|Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan
16341715|NCT04387149||non CSA-AKI|Patients that did not developed cardiac surgery-associated Acute Kidney Injury
16341716|NCT04387136|Experimental|Sublingual Sufentanil|Participants in this arm will receive the intervention.
16341651|NCT04387630|Experimental|metformin group|"metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.
~Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization."
16341652|NCT04387630|Placebo Comparator|Placebo group|placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.
16341653|NCT04387617|Experimental|CBD Oil Group|
16341654|NCT04387617|Placebo Comparator|Control Group|
16341655|NCT04387604||non vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
16341656|NCT04387604||vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
16341657|NCT04387591|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
16341658|NCT04387591|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
16341659|NCT04387578|Experimental|Group A singlestrand NiTi arch wires|in which 10 patients (5 males and 5 females) were treated with round singlestrand NiTi arch wires in a sequence of 0.012, 0.014, and 0.016 inch.
16341660|NCT04387578|Experimental|Group B Gummetal arch wires|in which 10patients (6 males and 4 females) were treated with niobium-titanium-tantalum-Zirconium arch wires (Gummetal arch wires) in a sequence of 0.014, 0.016, and 0.018 inch.
16341661|NCT04387578|Experimental|Group C multistrand NiTi arch wires|in which 10 patients (4males and 6females) were treated with multistrand NiTi arch wires in a sequence of 0.016, 0.018, and 0.020 inch.
16341662|NCT04387565||Preeclampsia|The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe.
16341663|NCT04387565||control pregnant group|These participants with normal healthy pregnancies at the third trimester (before birth)
16341664|NCT04387565||control non-pregnant group|A volunteer group of healthy women who visited the gynaecology clinic for routine examinations and women who were admitted for pre-pregnancy tests were invited randomly to this research as a control group.
16341665|NCT04387552|Experimental|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
16341666|NCT04387552|Experimental|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
16341667|NCT04387552|Experimental|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
16341668|NCT04387552|Experimental|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
16341669|NCT04387539|Active Comparator|Non-Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks
16341670|NCT04387539|Active Comparator|Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks
16341671|NCT04387526|Active Comparator|SOF/DCV|"Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.
~This arm included non-cirrhotic treatment-naïve patients"
16341672|NCT04387526|Active Comparator|SOF/DCV/RBV + Cirrhosis|This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
16341673|NCT04387526|Active Comparator|SOF/DCV/RBV + Non-Cirrhosis|This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
16341674|NCT04387500|Experimental|Sintilimab injection combined with Inlyta|"Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.
~Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.
~In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs."
16341675|NCT04387487|Experimental|Video Group|"Video Group
~multimedia video information of 4.5 mins regarding procedure, indication and complications related to spinal anesthesia will be shown to patients in intervention group , patient will be allowed to ask questions."
16341676|NCT04387487|No Intervention|non video group|patients in control group will be given verbal information regarding procedure, indication and complication, patient will be allowed to ask questions.
16341677|NCT04387474|Experimental|Experimental group|brain-computer interface rehabilitation training and traditional rehabilitation training.
16341678|NCT04387474|Other|Control group|traditional rehabilitation training.
16341717|NCT04387136|No Intervention|Control|Participants in this arm will not receive an intervention.
16341718|NCT04387123|Active Comparator|Conventional vaginoscopy|Vaginoscopy without vulvar tightness
16341719|NCT04387123|Active Comparator|Tight vaginoscopy|Vaginoscopy via Darwish sheet
16341679|NCT04387461|Experimental|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.
~Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.
~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years."
16341680|NCT04387448|Experimental|GFB-887 multiple ascending dose (MAD) active|GFB-887 active once-daily dosing
16341681|NCT04387448|Placebo Comparator|GFB-887 MAD placebo|GFB-887 placebo once-daily dosing
16341682|NCT04387422|Experimental|150 mg/dL|Hyperglycemia target of 150 mg/dL
16341683|NCT04387422|Experimental|225 mg/dL|Hyperglycemia target of 225 mg/dL
16341684|NCT04387422|Experimental|300 mg/dL|Hyperglycemia target of 300 mg/dL
16341685|NCT04387409|Active Comparator|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.
~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
16341686|NCT04387409|Placebo Comparator|Placebo|Physiological saline 0.1ml
16341687|NCT04387396|Experimental|Physiotherapy|Exercise intervention will be applied to this arm.
16341688|NCT04387396|No Intervention|Control|No intervention will be made to this arm, only evaluations will be made.
16341689|NCT04387383|Experimental|Acupuncture group|Electro-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
16341690|NCT04387383|Placebo Comparator|sham-acupuncture group|Sham-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
16341691|NCT04387357||Control|Neurologically healthy older adults above the age of 50
16341692|NCT04387357||Experimental|Older adults above the age of 50 with Mild Cognitive Impairment or Dementia
16341693|NCT04387318|Experimental|Multimodal training|"IMT + NMES + Pulmonary Rehabilitation
~IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).
~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).
~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
16341694|NCT04387318|Experimental|IMT + Pulmonary Rehabilitation|"IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).
~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
16341695|NCT04387318|Experimental|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).
~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
16341696|NCT04387318|Placebo Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise.
16341697|NCT04387305|Experimental|Tranexamic acid 15 mg/kg bolus|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.
16341698|NCT04387305|Experimental|Tranexamic acid 30 mg/kg bolus|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.
16341699|NCT04387305|Experimental|Tranexamic acid 45 mg/kg bolus|Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.
16341700|NCT04387305|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours
16341701|NCT04387292|Experimental|Ophthalmologic exam|
16341702|NCT04387279||Inflammatory bowel disease|Patients with inflammatory bowel disease who live in COVID-19 hyperemic area
16341703|NCT04387266||Modified reduce-volume target IMRT|Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
16341704|NCT04387240|Experimental|intervention group|this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
16341705|NCT04387240|Placebo Comparator|placibo|this group will receive a placebo of the same shape and picture of the study drug
16341706|NCT04387227|Experimental|Treatment (carboplatin, pembrolizumab)|Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16341707|NCT04387214||Veterinary students and researchers|
16341708|NCT04387201|Experimental|Dulaglutide, then Cyanocobalamin|Dulaglutide is experimental, cyanocobalamin is inactive placebo comparator
16341709|NCT04387201|Experimental|Cyanocobalamin, then Dulaglutide|Cyanocobalamin is inactive placebo comparator, dulaglutide is experimental
16341710|NCT04387175|Experimental|Carriere Motion 3D Class III Appliance|
16341711|NCT04387175|Active Comparator|Facial mask|
16341712|NCT04387162|Experimental|Immediate|Participants will enter treatment after one week baseline
16341713|NCT04387162|Experimental|Delayed|Participants will enter treatment after two week baseline
16341714|NCT04387149||CSA-AKI|Patients that developed cardiac surgery-associated Acute Kidney Injury
16341720|NCT04387110||Ocrelizumab|Women receiving treatment for multiple sclerosis with ocrelizumab infusion between 2 and 36 weeks postpartum.
16341721|NCT04387097||gradual withdrawal following by drip-infusion of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated. Following by drip-infusion of remifentanil for 30 minutes was administered immediately after tracheal extubation.
16341722|NCT04387097||gradual withdrawal of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated.
16341723|NCT04387084|Experimental|Treatment (STF, PD-1/PD-L1 inhibitor)|Patients undergo STF for 47-48 hours prior to immunotherapy and for 24 hours after immunotherapy with standard of care pembrolizumab given IV over 30 minutes, nivolumab IV over 30 minutes, cemiplimab IV over 30 minutes, avelumab IV over 60 minutes, atezolizumab IV over 60 minutes, or durvalumab IV over 60 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16341725|NCT04387058|Other|patients with cirrhosis and and portal hypertension|All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
16341726|NCT04387045|Experimental|Guilty feelings|Write for 20 minutes about a situation that in the participant's past life has caused feelings of guilt.
16341727|NCT04387045|Placebo Comparator|Neutral feelings|Write for 20 minutes about a situation that in the participant's past life has caused neutral feelings.
16341728|NCT04387032|Experimental|Experimental group|Experimental group (students with hypomobile SIJs)
16341729|NCT04387032|Sham Comparator|Control group|control group (students without hypomobile SIJs)
16341730|NCT04387019||I|30 with uncontrolled type 2 DM patients
16341731|NCT04387019||II|30 controlled type 2 DM patients
16341732|NCT04387019||III|30 healthy subjects as a control group
16341733|NCT04387006|Experimental|Osteopatic Manipulative Treatment (OMT)|
16341734|NCT04387006|Placebo Comparator|Manual Placebo (MP)|
16341735|NCT04386993|Experimental|IMRT|-Five 5-Gy fractions of IMRT will be given to the pelvis with elective simultaneous boost to any suspicious lymph node or residual disease to 30 Gy.
16341736|NCT04386980|Experimental|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume administered once intra-articularly
16341737|NCT04386980|Placebo Comparator|Placebo|5 mL of diluent in normal saline administered once intra-articularly
16341738|NCT04386967|Experimental|Dose expansion|Dose expansion trial comprises of 2 cohorts. In cohort 1, OH2 injection will be administered at 1x10e7CCID50/mL . In cohort 2, OH2 injection will be administered at 1x10e7CCID50/mL in combination with Keytruda injection, an anti-PD-1 antibody, and the first doses of the two anti-tumor agents will be administered on the same day.
16341739|NCT04386941|Active Comparator|Greenlight XPS Vaporization|Greenlight 532nm laser photoselective vaporization of the prostate (PVP) is an appealing treatment modality with hemoglobin as tissue target chromophore and relatively short learning curve. The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser. It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibres required in these situations.
16341740|NCT04386941|Active Comparator|Xpeeda Fibre Laser Vaporesection|Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue. Moreover, hemostasis would be improved by the pulse reshaping technology with a wider pulse width, activated by a dedicated footswitch. Therefore, the Lumenis Pulse™ 100W will make prostate vaporesection procedures more precise, faster and efficient, with excellent hemostasis. Consequently, bleeding is minimal, tissue is easier to remove and patients can have their catheter removed faster.
16341741|NCT04386928||Elderly patients with hematological disease|older than 60 years who received hematopoietic stem cell transplantation (HSCT)
16341742|NCT04386915|Experimental|Single-dose experimental group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2 and Day4. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
16341743|NCT04386915|Placebo Comparator|Single-dose control group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
16341744|NCT04386915|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
16341745|NCT04386915|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
16341776|NCT04386655|Active Comparator|In-Person Group|Participants a part of the in-person BICS group will then come to the NRC for the following BICS sessions. This group is the traditional, in-person, BICS group
16342181|NCT04383873|Active Comparator|Control|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
16341746|NCT04386915|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
16341747|NCT04386915|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
16341748|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
16341749|NCT04386889|Other|SLE Vasculitis|20 SLE Female patients will subjected to study of the all vasculitic pattern that may occur.
16341750|NCT04386876|Experimental|Orvical-Kaletra-Orvical-Kaletra|In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. All periods were performed under fasting state.
16341751|NCT04386876|Experimental|Kaletra-Orvical-Kaletra-Orvical|In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.
16341752|NCT04386850|Experimental|Treatment|Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
16341753|NCT04386850|Experimental|Prevention|This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.
16341754|NCT04386837||Aphasics|Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.
16341755|NCT04386824||Behçet's disease|Male patients who arediagnosed as Behçet's disease according to International Study Group Classification Criteria
16341756|NCT04386811|Experimental|Calcitriol|
16341757|NCT04386811|Placebo Comparator|Placebo|
16341758|NCT04386798|Other|survey application to mothers|In the neonatal intensive care, the information form, postpartum specific anxiety scale, and neonatal intensive care unit parent-father stress scale will be filled in for the mothers who have a baby.
16341759|NCT04386772|Experimental|PVE with coils plus TAGM|PVE with coils proximally plus TAGM distally and subsequent major hepatectomy
16341760|NCT04386772|Active Comparator|PVE with multiple coils|PVE with multiple coils and subsequent major hepatectomy
16341761|NCT04386759||Healthcare workers|"Filling when including a first self-survey concerning the period of the last fifteen days. The following questionnaires will be completed online every week until the end of the study.
~For healthcare worker who have already presented a symptomatic infection at the time of inclusion, only the self-survey inclusion will be completed, it will relate to the period of fifteen days preceding the diagnosis."
16341762|NCT04386746|Experimental|Intravesical Gemcitabine/Docetaxel|
16341763|NCT04386733||Cancelled|all adult patients whose surgery was cancelled on the day of the planned procedure
16341764|NCT04386733||Non-cancelled|all adult patients whose surgery was not cancelled on the day of the planned procedure
16341765|NCT04386707|Experimental|Experimental Vaccine-lot 1|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
16341766|NCT04386707|Experimental|Experimental Vaccine-lot 2|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
16341767|NCT04386707|Experimental|Experimental Vaccine-lot 3|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
16341768|NCT04386707|Active Comparator|Control Vaccine|Wild strain IPV (wIPV）manufactured by Sanofi Pasteur S.A.
16341769|NCT04386694|Experimental|PBMT/sMF|"Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.
~PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT."
16341770|NCT04386694|Placebo Comparator|Placebo PBMT/sMF|"Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.
~The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator."
16341771|NCT04386681|Experimental|RCBI|Receiving RCBI intervention, including BICS, ICAN, and RF.
16341772|NCT04386681|No Intervention|Treatment as usual- Control group|Not receiving the RCBI intervention
16341773|NCT04386668|Experimental|LIO-C|Participants receive LIO-C writing intervention
16341774|NCT04386668|Placebo Comparator|Neutral writing control|Participants receive neutral writing control intervention
16341775|NCT04386655|Experimental|Telemedicine Group|BICS-T is the intervention that will take place over telemedicine software on the iPad provided to participants
16341777|NCT04386642|Experimental|Experiment group|Each ampule contains TXA 250 mg. TXA preparation is 2000 mg dilute in normal saline 50 ml to get the concentration of 40 mg/ml. TXA will be administered 20 mg/kg loading over 20 min before skin incision followed by a maintenance infusion of 0.025 ml/kg/h (1 mg/kg/h) until the end of operation.
16341778|NCT04386642|Placebo Comparator|Control group|Normal saline solution 50 ml is prepared in a clear 50 ml syringe similar to the experiment group.
16341779|NCT04386616|Experimental|MSTT1041A|Participants randomized to this arm will receive MSTT1041A. Study treatment will be given in combination with standard of care.
16341780|NCT04386616|Placebo Comparator|MSTT1041A-matched Placebo|Participants randomized to this arm will receive MSTT1041A-matched placebo. Study treatment will be given in combination with standard of care.
16341781|NCT04386616|Experimental|UTTR1147A|Participants randomized to this arm will receive UTTR1147A. Study treatment will be given in combination with standard of care.
16341782|NCT04386616|Placebo Comparator|UTTR1147A-matched Placebo|Participants randomized to this arm will receive UTTR1147A-matched placebo. Study treatment will be given in combination with standard of care.
16341783|NCT04386603||shoulder-tip pain group|The patients in this group have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
16341784|NCT04386603||non-shoulder-tip pain group|The patients in this group don't have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
16341785|NCT04386590|Sham Comparator|'Sham' manual therapy plus Pulmonary Rehabilitation (PR)|Treadmill walking, upper body exercise machine, light weight training and bicycle. These exercises are supervised. In addition to the standard exercise therapy, all participants will undergo a 20-minute session consisting of discussion with the patient and 11 minutes of detuned ultrasound, which has been used in previous studies to account for time and attention for the patient. The detuned ultrasound procedure is to apply the ultrasound gel and turn the machine on, but set the intensity at zero (0) W/cm2
16341786|NCT04386590|Experimental|Manual therapy plus Pulmonary Rehabilitation (CMT+|Manual therapy is made up of gentle Effleurage and cross-fibre friction massage applied to the muscles of the posterior chest wall. Manual Therapy consists of two separate manipulations (Grade V mobilization). Each manipulation involves the delivery of a high-velocity low amplitude (HVLA) posterior to anterior force directed at the inter-vertebral, costo-vertebral and costo-transverse joints. The first manipulation is delivered at the level of the upper/middle thoracic spine while the second is at the level of the middle/lower thoracic spine. In addition to the MT, the participant will also undergo Pulmonary Rehab as previously described.
16341787|NCT04386577|Active Comparator|Vitamin D + fish oil|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Each capsule contains 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA).
16341788|NCT04386577|Active Comparator|Vitamin D + fish oil placebo|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary supplement: Fish oil placebo
16341789|NCT04386577|Active Comparator|Vitamin D placebo + fish oil|Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Dietary supplement: Vitamin D3 placebo
16341790|NCT04386577|Placebo Comparator|Vitamin D placebo + fish oil placebo|Dietary supplement: Vitamin D3 placebo Dietary supplement: Fish oil placebo
16341791|NCT04386564||Mild COVID-19|Pneumonia without respiratory failure
16341792|NCT04386564||Moderate COVID-19 up to 60 years|Respiratory frequency ≥30/minute, blood oxygen saturation≤93%
16341793|NCT04386564||Moderate COVID-19 over 60 years old and severe COVID-19|Pneumonia with respiratory distress syndrome
16341794|NCT04386538|Experimental|Low Starch Diet (LSD)|Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
16341795|NCT04386538|Active Comparator|Control|Participants will receive dietary counselling based on general recommendations for healthy eating.
16341796|NCT04386525|Experimental|Omega-3|Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly
16341797|NCT04386525|No Intervention|Controle|for comparison with interventional arm
16341798|NCT04386499|Experimental|Resveratrol|A nutraceutical formulation (trade mark Genante) composed of resveratrol, REVIFAST, folic acid, Vitamin D
16341799|NCT04386499|Active Comparator|Folic acid|Folic Acid 400 ug
16341800|NCT04386486|Experimental|bathe group|The patients were divided into two equal groups randomly first group is BATHE anamnesis group.
16341801|NCT04386486|Sham Comparator|standart anamnesis group|The patients were divided into two equal groups randomly second group is standart anamnesis group.
16341802|NCT04386473||Left Bundle Branch Pacing|
16341803|NCT04386473||Right Ventricular Outflow Tract Septal Pacing|
16341804|NCT04386447|Experimental|Oxytocin 40 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
16341805|NCT04386447|Experimental|Oxytocin 25 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
16341824|NCT04386343|Placebo Comparator|100% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 100% of the expected dose level in the radiation affected area right after radiation
16341825|NCT04386343|Placebo Comparator|167% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 167% of the expected dose level in the radiation affected area right after radiation
16341826|NCT04386330|Experimental|Narrative Exposure Therapy|Firefighters will receive distance-delivered NET administered by a paraprofessional.
16341827|NCT04386317|Experimental|terazosin therapy|
16342182|NCT04383860|Experimental|5-0 suture|5-0 suture administration during surgery
16341806|NCT04386447|Other|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:
~Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%
~Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.
~Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted
~Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine
~Prophylaxis for deep vein thrombosis
~Steroids are not routinely recommended but may be considered in selected patients."
16341807|NCT04386434|Experimental|Active for Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
16341808|NCT04386421|Experimental|video group|Group A: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed Appliance Treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions. Participants in this group will also receive the same video graphic educational material through their Whats app once weekly for a total duration of 3 months.
16341809|NCT04386421|Experimental|Plaque disclosing tablet|Group B: Plaque-disclosing tablets will be taken by patients on chair-side showing the location of the biofilm. The patients will be given plaque disclosing tablets to be used once weekly for 3 months to evaluate their oral hygiene at home. They will be given written information in the form of leaflets on importance of cooperation and compliance. Participants in this group will receive a reminder log fill, and tablets that are not used will be asked to return to the investigator by the participants to check the compliance.
16341810|NCT04386421|No Intervention|Control. verbal instructions|Control Group C: Controls will be given only routine verbal OHI and will be briefed on the importance of cooperation and compliance at every orthodontic visit for a period of 3 months study. They will receive a reminder log that they will return at the end of the study to check compliance.
16341811|NCT04386408|Experimental|Combination of plant extracts (BSL_EP027)|Volunteers will dissolve in water a sachet per day with the Combination of plant extracts (BSL_EP027), and maltodextrin.
16341812|NCT04386408|Placebo Comparator|Placebo|Volunteers will dissolve in water a sachet per day with maltodextrin.
16341813|NCT04386395||Immuno Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
16341814|NCT04386395||Cortico Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. According to RECOVERY study, early routine administration of dexamethasone 6 mg/day over 10 days. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
16341815|NCT04386382|Experimental|ridge splitting flapless technique using interchangeable guide|"Fabrication of interchangeable surgical guide stent:
~Optical scanning of the dental casts was done using Ceramill map 400
~The treatment plan and the surgical stent were designed using Mimics Innovation Suite 19 ™ software
~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique."
16341816|NCT04386369||Airway Pressure Release Ventilation|Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.
16341817|NCT04386356|No Intervention|Orotracheal intubation with macintosh laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
16341818|NCT04386356|Active Comparator|Orotracheal intubation with Airtraq Video Laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
16341819|NCT04386343|Placebo Comparator|50% dose level arm - Phase I|4 healthy volunteer will use 50% dose level for Phase I in the left hand side and use placebo in the right hand side
16341820|NCT04386343|Placebo Comparator|100% dose level arm - Phase I|4 healthy volunteer will use 100% dose level for Phase I in the left hand side and use placebo in the right hand side
16341821|NCT04386343|Active Comparator|167% dose level arm - Phase I|4 healthy volunteer will use 167% dose level for Phase I in the left hand side and use placebo in the right hand side
16341822|NCT04386343|Placebo Comparator|Placebo arm - Phase II|20 Breast cancer patients will use Placebo in the radiation affected area right after radiation
16341823|NCT04386343|Placebo Comparator|50% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 50% of the expected dose level in the radiation affected area right after radiation
16341828|NCT04386304|Experimental|Dose escalation of (+)-epicatechin|Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.
16341829|NCT04386291|Active Comparator|Anxiety Reduction Training (A.R.T.)|Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
16341830|NCT04386291|Experimental|ART and Kundalini Yoga|This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
16341831|NCT04386291|Experimental|ART and Meditation|This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.
16341832|NCT04386278|Experimental|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
16341833|NCT04386278|Experimental|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
16341834|NCT04386278|Experimental|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
16341835|NCT04386278|Experimental|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
16341836|NCT04386278|Experimental|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
16341837|NCT04386278|Experimental|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
16341838|NCT04386278|Experimental|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
16341839|NCT04386278|Experimental|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
16341840|NCT04386252|Experimental|Phase 1 Antigen Dose Exploration|AV-COVID-19 consisting of autologous DC loaded with 0.1 mcg, 0.33 mcg or 1.0 mcg SARS-CoV-2 spike protein, with or without GM-CSF
16341841|NCT04386252|Experimental|Phase 2|Separate cohorts of patients who have 0 or >1 risk factor related to poor outcome for COVID-19 infection will receive AV-COVID-19 consisting of optimal antigen and GM-CSF formulation.
16341842|NCT04386239|Experimental|Covid-19|Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
16341843|NCT04386226|Experimental|2 grams Ambrotose LIFE|2 grams daily for 8 weeks
16341844|NCT04386226|Experimental|4 grams Ambrotose LIFE|4 grams daily for 8 weeks
16341845|NCT04386226|Active Comparator|2 grams Advanced Ambrotose|2 grams daily for 8 weeks
16341846|NCT04386226|Active Comparator|4 grams Advanced Ambrotose|4 grams daily for 8 weeks
16341847|NCT04386226|Placebo Comparator|Placebo|4 grams Maltodextrin daily for 8 weeks
16341848|NCT04386213|Experimental|Paclitaxel Drug-coated Balloon|
16341849|NCT04386213|Active Comparator|SeQuent® Please Paclitaxel Drug-coated Balloon|
16341850|NCT04386200|Experimental|WEB GROUP|Traditional approach integrated with web-based technologies.
16341851|NCT04386200|Other|TRADITIONAL GROUP|Traditional educational approach
16341852|NCT04386187|Experimental|Arm 1: Experimental Feeding|Small glutathione-rich meals will be prepared and delivered to participants for 12 weeks.
16341853|NCT04386187|Active Comparator|Arm 2: Education Control|Standard of care medical nutrition education for type 2 diabetes will be provided in the form of electronic handouts and web-based resources.
16341854|NCT04386174|Other|Group A|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
16341855|NCT04386174|Other|Group B|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
16341856|NCT04386161|Experimental|Children with dyslexia|Children, aged between 8 and 11 years, with clinical dyslexia diagnosed by a child and adolescent psychiatrist
16341857|NCT04386148||laparoscopic colorectal surgery|Patients undergoing laparoscopic colorectal surgery with use of Obsidian ASG® during primary anastomosis.
16341858|NCT04386122|Experimental|FABALOFEN 60|Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition
16341859|NCT04386122|Active Comparator|JAPROLOX TABLET|Subjects will receive a single dose of 1 JAPROLOX® TABLETS tablet under fed condition
16341860|NCT04386109||Neonates COVID-19 positive|1. Neonatal COVID-19 in babies (<29 days old) in neonatal units, paediatric intensive care units and other in-patient locations.
16341861|NCT04386109||Neonates born to COVID-19 positive mothers|2. Neonates (<29 days old) born to COVID-19 positive mothers requiring neonatal care
16341862|NCT04386096|Experimental|Mehealth for ADHD software with medication continuity tools|
16341863|NCT04386096|Active Comparator|Mehealth for ADHD software with no medication continuity tools|
16341864|NCT04386083||COVID-19 patients with neurologic manifestations|Patients with confirmed COVID-19 disease who presented with neurological symptoms or new-onset neurological disorders/complications
16341865|NCT04386083||COVID-19 patients without neurologic manifestations|Patients with confirmed COVID-19 disease who did not present with neurological symptoms or new-onset neurological disorders/complications
16341866|NCT04386070|No Intervention|Control (normal practice)|Treatment without the trial intervention. Patients will be treated as per hospital routine practice. The control arm may change over the course of the trial and will be monitored by the TMG and DMC
16341867|NCT04386070|Experimental|RESP301|RESP301 is administered quickly (8-10 minutes) via an easy-to-use, vibrating mesh nebuliser. The recommended nebulisers used to administer this intervention are available in all participating countries. The intervention will be administered using a nebuliser according to standard local practice; where permitted for patients to self-administer, a member of the clinical team will ensure that the patient has viewed the intervention administration training video, and will also oversee the patient for the first trial dose to ensure proper administration.
16341910|NCT04385745|Experimental|Biodegradable intramedullary nailing|BIN method will be compared with the ESIN.
16341868|NCT04386057|Experimental|Safety Lead-In Cohort|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis.
~Test the safety of study drugs in combination and define dose levels.
~LY3214996
~HCQ"
16341869|NCT04386057|Experimental|LY3214996 and HCQ Combination|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis. Combined dosage per determined Lead-In Cohort
~LY3214996
~HCQ"
16341870|NCT04386057|Experimental|LY3214996-Monotherapy|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days.Treatment will be administered on an outpatient basis.
~-LY3214996"
16341871|NCT04386057|Experimental|Cross Over Arm|"Participants who are enrolled to Arm 2 who experience radiologic disease progression on monotherapy will have the option to cross-over to receive treatment with the combination. Crossover will occur at the treating investigator's discretion following consultation and approval from the overall principal investigator. Combined dosage per determined Lead-In Cohort
~LY3214996
~HCQ"
16341872|NCT04386044||Hospital in-patients|Cross-sectional study of hospital in-patients admitted with COVID-19 n=200
16341873|NCT04386044||Controls (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
16341874|NCT04386044||Cases (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
16341875|NCT04386031||group with antifungal drug|
16341876|NCT04386031||A control group|A control group will be taken ,patients undergoing thyroidectomy or parotidectomy
16341877|NCT04386005|Experimental|Continuous Glucose Monitoring|All participants will have the continuous glucose monitoring device placed.
16341878|NCT04385992|Experimental|All enrolled patients|Enrolled patients following inclusion criteria
16341879|NCT04385979|Active Comparator|Curcumin|%2 Curcumin gel
16341880|NCT04385979|Active Comparator|Nanocurcumin|%1 NanoCurcumin gel
16341881|NCT04385966|Active Comparator|Standard Volume Dose|24 patients will be included in the Standard Volume Dose arm. 20 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
16341882|NCT04385966|Experimental|Low Volume Dose|24 patients will be included in the Low Volume Dose arm. 10 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
16341883|NCT04385953||Trauma patients|Subject experiencing major trauma
16341884|NCT04385953||Obstetric patients|Obstetric patient with postpartum hemorrhage
16341885|NCT04385940|Experimental|High dose vitamin D|Ddrops® products,Vitamin D3, 50,000 IU, Oral
16341886|NCT04385940|Active Comparator|Low dose vitamin D|Vitamin D3 1000IU
16341887|NCT04385927|Experimental|Immediate e-NET Group|Parents of neurodiverse children with PTSI will receive e-NET immediately after the baseline survey
16341888|NCT04385927|Experimental|Wait List Control Group|Parents of neurodiverse children with PTSI will receive e-NET 3 months after the baseline survey
16341889|NCT04385914||COVID positive patients|
16341890|NCT04385914||COVID negative patients|
16341891|NCT04385901|No Intervention|Standard of Care|These are patients who were diagnosed with COVID19 and recovered with usual care prior to implementation of the rehabilitation program developed by MUHC therapists. These patients will be selected in such a way as to match the approximate demographics that exist within the treatment group. These patients received education and supportive care only.
16341892|NCT04385901|Experimental|Rehabilitation Group|These are patients who were diagnosed with COVID19 and participated in the physical and pulmonary rehabilitation program developed at MU Healthcare as described in the study design.
16341893|NCT04385888|Experimental|Low-calorie sweetener restriction|Participants will be instructed to avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners, and to instead consume unsweetened alternatives, such as plain or sparkling water for 12 weeks.
16341894|NCT04385888|No Intervention|Usual consumption/control|Participants will continue low-calorie sweetener consumption, as usual.
16341897|NCT04385849|Experimental|Experimental Arm|N-803 Recombinant human super agonist interleukin-15 (IL-15) complex
16341898|NCT04385849|Placebo Comparator|Placebo Arm|Sterile saline solution
16341899|NCT04385836|Active Comparator|alpha one antitrypsin group|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) add to 2cm of normal saline solution as nebulizer every 12 hours for 5 days
16341900|NCT04385836|Placebo Comparator|placebo group|we will give 8 ml of normal saline as nebulizer every 12 hours for 5 days
16341901|NCT04385810|Experimental|Ophthalmologic exam|
16341902|NCT04385797||Dyads|Community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers
16341903|NCT04385784|Experimental|Sedentary Intervention Group (SIG)|Group of sedentary older adults who perform the intervention and a home-based exercise program.
16341904|NCT04385784|Experimental|Active Intervention Group (AIG)|Group of active older adults who perform the intervention and a home-based exercise program.
16341905|NCT04385784|Active Comparator|Control Group (CG)|Group of sedentary older adults who perform a home-based exercise program.
16341906|NCT04385771|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
16341907|NCT04385771|Other|vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
16341908|NCT04385758|Experimental|Diabetes-REM Program|
16341909|NCT04385745|Experimental|Elastic Stable Intramedullary Nailing|BIN (biodegradable intramedullary nailing) method will be compared with the ESIN (elastic stable intramedullary nailing)
16341911|NCT04385732|Experimental|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography.
16341912|NCT04385732|No Intervention|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
16341913|NCT04385719|Experimental|Study A Sequence 1|"Single dose remdesivir 150mg IV on Day 1
~Wash out period Day 2-7
~TDF/3TC 300/300mg tablets OD from Day 8-14 single dose remdesivir 150mg IV on Day 14"
16341914|NCT04385719|Experimental|Study A Sequence 2|"TDF/3TC 300/300mg tablets OD from Day 1-7 single dose remdesivir 150mg IV on Day 7
~Wash out period Day 8-14
~Single dose remdesivir 150mg IV on Day 15"
16341915|NCT04385719|Experimental|Study B|TDF/3TC/ATV/r 300/300/300/100mg tablets OD from Day 1-7 single dose remdesivir 150mg IV infusion on Day 7
16341916|NCT04385693|Experimental|Pulpotomy|Group A: The patient will benefit from an experimental treatment: a Pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
16341917|NCT04385693|Active Comparator|Control Group|Group B: Extracted teeth will serve as controls, and information regarding the need or not of space maintenance, and the impact on the occlusion and eruption of the succedaneous permanent tooth will be noted.
16341918|NCT04385680|Experimental|Chlorhexidine vaginal prep.arm|"Women in labor who will receive vaginal cleaning immediately before cesarean section using 50 ml of chlorhexidine gluconate 0.05% solution and standard abdominal scrub with chlorhexidine gluconate 4%. This concentration is indicated within the British National Formulary for swabbing in obstetrics. A swab soaked in the antiseptic will be used to clean the vagina for 30 seconds prior to CS at the time of urinary catheter insertion by long forceps.
~After the CS procedure, the vagina is always cleaned of excess blood as with a dry swab."
16341919|NCT04385680|No Intervention|No vaginal antiseptic arm|Women in labor who will receive abdominal scrub with chlorhexidine gluconate 4% only. Vaginal preparation is not including antiseptic or using normal saline only.
16341920|NCT04385667|Active Comparator|levonorgestrel intrauterine system (LNG-IUD)|"levonorgestrel intrauterine system (LNG-IUD) applied.
~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.
~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.
~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
16341921|NCT04385667|Active Comparator|Megestrol acetate (MA)|"Megesterol arm will receive 160 mg daily
~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.
~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.
~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
16341922|NCT04385654|Experimental|Neoadjuvant toripalimab plus axitinib|Toripalimab (240 mg,ivgtt,q3w) combined with Axitinib (5 mg,po,bid) was treated for 6 weeks and underwent surgery within 2-4 weeks
16341923|NCT04385641|Experimental|Dose-finding (Group A)|"In this study, the dose was explored according to the 3+3 mode, in which group A was divided into three dose groups: 1.5*10＾9 group, 2*10＾9 group and 3*10＾9 group. If DLT occurs in one of the first three subjects in each dose group within four weeks after cell infusion, three subjects will continue to be included. If more than 1/6 cases of DLT appear in 6 subjects with 1.5*10＾9 dose, the dose level and/or cell infusion frequency and method will be reduced after discussion between the investigator, the collaborator and DMC. If DLT did not occur in the first 3 subjects within 4 weeks after receiving 1.5*10＾9 cell infusion，another three subjects were enrolled into the group received 2*10＾9 cell infusion. DLT did not occur within 4 weeks after cell infusion, it will increase to 3*10＾9 dose group. That is to say, the first three subjects were included for observation for 4 weeks in the 3*10＾9 dose group, if DLT did not occur, there will be another 3 cases, reaching to 6 subjects."
16341924|NCT04385641|Experimental|Extended research (Group B)|If DLT≤1/6, the dose will not be increased. This dose will also be used as the treatment dose of group B. If DLT is more than 1/6 in the 3*10＾9 dose group, three subjects will be added in 2*10＾9 dose group. If DLT ≤1/6 in 4-week observation, the 2*10＾9 will be the maximum tolerable dose, and will be used as the treatment dose of group B. The subjects in group A were enrolled first, after at least 4 weeks of observation for all subjects, six subjects will be included in group B.
16341925|NCT04385628||Relatives of patients hospitalized in the intensive care unit|Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
16341926|NCT04385615|Experimental|FMD Group|Participants will be requested to follow a Fasting Mimicking Diet, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
16341927|NCT04385615|No Intervention|Control Group|Participants will be requested to continue with their habitual eating habits, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
16341928|NCT04385602|Placebo Comparator|CON group|placebo
16341929|NCT04385602|Active Comparator|DT group|Intratracheal dexmedetomidine
16341930|NCT04385589|Active Comparator|Dapagliflozin group|50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.
16341931|NCT04385589|Placebo Comparator|Placebo group|50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.
16341932|NCT04385576|Active Comparator|Aerosol Box|Intubation using the Taiwan model Aerosol Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
16341933|NCT04385576|Active Comparator|Intubation Box|Intubation using the UMMC model Intubation Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
16341934|NCT04385563|Experimental|TQ-B211 + docetaxel|Participants will be administered TQ-B211 plus docetaxel once every three weeks(Q3W) in cycles up to cycle 8.
16341935|NCT04385563|Active Comparator|Herceptin®+docetaxel|Participants will be administered Herceptin® plus docetaxel Q3W in cycles up to cycle 8.
16341936|NCT04385550|Experimental|Anlotinib hydrochloride capsule + AK105 injection|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
16341937|NCT04385550|Active Comparator|Standard Second-line Chemotherapy|Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.
16341938|NCT04385537|No Intervention|Control|Participants in this group avoid all nuts for 4-weeks
16341939|NCT04385537|Experimental|PECAN|Participants in this group consume 68 g of pecans/d with no other changes to their habitual diet and avoid all other nuts.
16341940|NCT04385524|Other|Vaccination|"Heplisav B vaccine will be administered to subjects demonstrating completion of two prior series of standard 3-dose Hepatitis B vaccine but still without evidence of seroconversion.
~One dose (20 mcg) of vaccine will be administered intramuscularly followed by Hepatitis B quantitative antibody titer 30-60 days later.
~If still Hepatitis B antibody negative, a second dose (20 mcg) of vaccine will be administered intramuscularly followed by a Hepatitis B quantitative titer 30-60 days later.
~If still no evidence of Hepatitis B immunity (10iU antibody or greater), will be deemed a non-responder to this vaccine"
16341941|NCT04385511|Experimental|supraglottic jet ventilation group|Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
16341942|NCT04385511|No Intervention|mask pressurized ventilation group|"Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will give them 1 min mask pressure respiration, by pressure control V - E technique after muscle relaxant. Check blood gas,stomach-ultrasound after 2 min, then do the tracheal intubation guided by visual laryngoscope."
16341943|NCT04385498|Experimental|BREATHE Intervention|Five session program, with additional sessions provided based on the individual's learning style and needs. Sessions are designed to be 20 to 30 minutes long, to accommodate the needs of the primary health care centers. Sessions will ideally be conducted once per week, but may be conducted as infrequently as once per month.
16341944|NCT04385498|Active Comparator|Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm.
16341945|NCT04385485|Experimental|Active rehabilitation|The patient see an occupational therapist 1-3 days after surgery. A splint is made to immobilise the wrist and work as a extension block for the MCP-joints. This splint has to be worn day and night for 4 weeks. Another splint that immobilise the DIP- and PIP-joints are worn whenever the patient is not exercising. During active exercise the patient follows a strict protocol with both active and passive training and increasing number of repetitions. The rehabilitation is proceeding for 3 months.
16341946|NCT04385485|Active Comparator|Passive rehabilitation|1-3 days after surgery the patient gets a new plaster that immobilise the wrist and work as an extension block for the MCP-joints. The occupational therapist attach rubberbands to the nails of all the fingers and the training is done passively with active hold according to a strict protocol. The training with rubberbands is done during 4 weeks. After that the rehabilitation is active. The rehabilitation is proceeding for 3 months.
16341947|NCT04385459||Patients without coronary artery disease|No prior coronary intervention and no significant stenosis noted during coronary angiography.
16341948|NCT04385459||Patients with coronary artery disease|"Our definition of coronary artery disease is:
~Prior coronary artery bypass grafting or percutaneous coronary intervention
~Significant stenosis or occlusion noted during coronary angiography"
16341949|NCT04385446|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material in the area where the pterygium tissue was removed during the surgery.
16341950|NCT04385446|No Intervention|conjnctival autograft.|Conjunctival autograft was used as a covering material in the area where the pterygium tissue was removed during the surgery.
16341951|NCT04385433|Experimental|EXPERIMENTAL GROUP|RADIOTHERAPY + PRAVASTATIN
16341952|NCT04385433|Placebo Comparator|CONTROL GROUP|RADIOTHERAPY + PLACEBO
16341953|NCT04385420|Experimental|ATR-002 100 mg (SAD)|100 mg ATR-002 once (morning)
16341954|NCT04385420|Experimental|ATR-002 300 mg (SAD)|300 mg ATR-002 once (morning)
16341955|NCT04385420|Experimental|ATR-002 600 mg (SAD)|600 mg ATR-002 once (morning)
16341956|NCT04385420|Experimental|ATR-002 900 mg (SAD)|900 mg ATR-002 once (morning)
16341957|NCT04385420|Placebo Comparator|Placebo (SAD)|Placebo once (morning)
16341958|NCT04385420|Experimental|ATR-002 100 mg (MAD)|100 mg ATR-002 once daily (morning) for 7 days
16341959|NCT04385420|Experimental|ATR-002 300 mg (MAD)|300 mg ATR-002 once daily (morning) for 7 days
16341960|NCT04385420|Experimental|ATR-002 600 mg (MAD)|600 mg ATR-002 once daily (morning) for 7 days
16341961|NCT04385420|Placebo Comparator|Placebo (MAD)|Placebo once daily (morning) for 7 days
16341962|NCT04385407|Active Comparator|SOF + RBV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
16341963|NCT04385407|Active Comparator|SOF + RBV (Experienced)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
16341964|NCT04385407|Active Comparator|SOF + SMV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
16341965|NCT04385407|Active Comparator|SOF + SMV (Expereined)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
16341966|NCT04385381|Experimental|URECA CTO device|investigate the safety and efficacy of the URECA CTO device in facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature.
16341969|NCT04385355|Other|Control Group|Control group will receive an intermediate transmucosal abutment with conventional diameter and 3mm height, once the implants are placed.
16341970|NCT04385355|Experimental|Test Group|Test group will receive an intermediate transmucosal abutment with a TCP design, narrower than the conventional one, of 3mm height, once the implants are placed
16341971|NCT04385342|Active Comparator|FSH then HP-hMG|Women will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering
16341972|NCT04385342|Active Comparator|FSH + HP-hMG|Women will receive 150 IU FSH plus 75IU HP-hMG from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm 150 IU HP-HMG till day of triggering
16341973|NCT04385329|Experimental|Experimental group:shock waves extended to gastrocnemius TrP|Focused shock wave therapy was extended from the plantar fascia to the gastrocnemius-soleus trigger points.
16341974|NCT04385329|Active Comparator|Control group: shock waves not extended to gastrocnemius TrP|A standard focused shock wave therapy exclusively targeted at the plantar fascia
16341975|NCT04385316||Gastric Cancer|
16341976|NCT04385316||Colorectal Cancer|
16341977|NCT04385316||Bladder Cancer|
16341978|NCT04385303|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
16341979|NCT04385303|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
16341980|NCT04385290|Experimental|MODULE trial: dose escalation|Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m^2 i.v. on days 1 to 3).
16341981|NCT04385290|Experimental|MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin|Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
16341982|NCT04385290|Placebo Comparator|MAGNOLIA-trial: conventional chemotherapy+GO and placebo|Phase II (Trial part MAGNOLIA): placebo is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
16341983|NCT04385290|Experimental|MAGMA-trial: conventional chemotherapy+midostaurin and GO|Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML
16341984|NCT04385290|Active Comparator|MAGMA-trial: conventional chemotherapy+midostaurin|Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v plus midostaurin). No additional GO is given.
16341986|NCT04385264|Placebo Comparator|Placebo|Placebo (Mannitol), oral capsules Day 0: 4 capsules PO OD Days 1-5: 2 capsules PO OD
16341987|NCT04385264|Experimental|Hydroxychloroquine|Hydroxychloroquine 200mg (HCQ, Plaquenil), oral capsules Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
16341988|NCT04385251||SARS-CoV-2 infection/COVID-19|Adults who present for SARS-CoV-2 testing will be consented for this study. Participants who are enrolled will be informed that if they have SARS-CoV-2 infection/COVID-19, they will be followed for 28 days in an observational cohort study, and that if they do not have SARS-CoV-2 infection, there will be no further follow-up.
16341989|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
16341990|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
16341991|NCT04385225|Other|Healthy controls|Age-matched controls with normal hearing or mild sensorineural hearing loss: 40 decibel or less in better hearing ear, and normal vestibular function
16341992|NCT04385225|Other|Moderate Sensorineural hearing loss|Moderate Sensorineural hearing loss: 41-60 decibel in the better hearing ear
16341993|NCT04385225|Other|Severe Sensorineural hearing loss|Severe Sensorineural hearing loss: 61-80 decibel in the better hearing ear
16341994|NCT04385225|Other|Bilateral Vestibulopathy|Bilateral vestibulopathy: half with normal hearing, half with severe to profound sensorineural hearing loss
16341995|NCT04385225|Other|Mild Cognitive Impairment|Mild Cognitive Impairment
16341996|NCT04385225|Other|Alzheimer's Disease|Alzheimer's Disease
16341997|NCT04385199|Experimental|Intervention|Convalescent plasma 200mL transfusion
16341998|NCT04385199|No Intervention|Control|Standard therapy for COVID-19 disease as defined by institutional protocols
16341999|NCT04385186|Experimental|Convalescent plasma+Support treatment selected by the hospital|Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.
16342183|NCT04383860|Active Comparator|4-0 suture|4-0 suture administration during surgery
16342000|NCT04385186|Active Comparator|Support treatment selected by the hospital|The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.
16342001|NCT04385173|Experimental|B7-H3 CAR-T|Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval. 3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment. Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
16342002|NCT04385147||ERCP|Patients who will have endoscopic retrograde cholangiopancreatography
16342003|NCT04385147||EUS|Patients who will have endoscopic ultrasound
16342004|NCT04385134||General parturient|Observe the enterovirus infection in general parturients and their neonates.
16342005|NCT04385134||Puerpera with fever|Observe the enterovirus infection in puerpera with fever and their neonates.
16342006|NCT04385134||Febrile newborns|Observe the enterovirus infection in neonates
16342007|NCT04385108|Experimental|hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:
~Patients with severe disease requiring on admission ICU management for ARDS,
~Non-severe hospitalized patients with secondary clinical worsening requiring ICU management,
~Non-severe hospitalized patients without clinical worsening requiring ICU management."
16342008|NCT04385108|Experimental|healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
16342009|NCT04385095|Active Comparator|SNG001|inhalation using the I-neb device.
16342010|NCT04385095|Placebo Comparator|Placebo|inhalation using the I-neb device.
16342011|NCT04385082|Placebo Comparator|Placebo|Smoked Cannabis (~0% THC)
16342012|NCT04385082|Experimental|Low strength cannabis|Smoked Cannabis (~4% THC)
16342013|NCT04385082|Experimental|Higher strength cannabis|Smoked Cannabis (~10% THC)
16342014|NCT04385056|Experimental|Low Dose MSCTC-0010|Participants will receive low-dose cell administration
16342015|NCT04385056|Experimental|Medium Dose MSCTC-0010|Participants will receive medium-dose cell administration
16342016|NCT04385056|Experimental|High Dose MSCTC-0010|Participants will receive high-dose cell administration
16342017|NCT04385043|Experimental|plasma-hyperimmune|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy
16342018|NCT04385043|Active Comparator|standard therapy|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy
16342019|NCT04385030|Active Comparator|ETCC Active associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
16342020|NCT04385030|Sham Comparator|ETCC simulated associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
16342021|NCT04385017|Other|DNA from monocytes|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
16342022|NCT04384991|Experimental|HU007 Eye drop|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.
~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
16342023|NCT04384991|Active Comparator|Restasis Eye drop 0.05% (Cyclosporine)|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.
~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
16342024|NCT04384978|Active Comparator|Control Group|Control Group: Group 2 users will play solitary games (word puzzles) and activities but will have no interaction with Ryan.
16342025|NCT04384978|Experimental|Active Group|Active Group: Group 1 users will play games with and administered by Ryan, 2-3 times a week and 30-minutes per day.
16342026|NCT04384965|Experimental|Accelerated iTBS|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
16342029|NCT04384939|Experimental|Double-J ureteral stent|Pediatric patient with an uropathy or kidney graft need the insertion of Double-J ureteral stent in a routine care
16342030|NCT04384926||Cohort 1|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
16342031|NCT04384926||Cohort 2|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
16342032|NCT04384913||MA (mechanical alignment)|Patients in group MA (mechanical alignment) will be operated according to mechanical implantation technique. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation.
16342053|NCT04384744||GH-POR|Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
16342033|NCT04384913||KA (kinematic alignment)|Patients in group KA (kinematic alignment) will be operated according to kinematic implantation technique. The kinematic cutting blocks will be designed to resurface the femoral and tibial bones to restore each patient´s pre-arthritic anatomy and Joint line. Based on a available CT dat the prearthritic anatomy is reconstructed by compensating bone defects and restoring the physiological cartilage height of 1,7mm. Femoral Flexion is evaluated by the anterior Cortex of the distal femur, tibia slope is defined to 3° due to ACL (Anterior Cruciate Ligament) loss, but cab be adapted during surgery.
16342034|NCT04384900|Experimental|Accelerated prone position|Prone position ventilation initiated as soon as possible following intubation. The patients are maintained in a prone position for 12-16 hrs daily for 5 days, unless one of the following criteria are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption. Following the five day intervention period, prone position ventilation will be continued according to the intervention in the control group
16342035|NCT04384900|Active Comparator|Standard prone position|Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) < 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
16342036|NCT04384874|Active Comparator|Silbernagel combined concentric-eccentric program|A graduated rehabilitation program using exercises with concentric and eccentric contractions and progressing to plyometric training. The exercises are performed daily with progression guided by pain symptoms. There is no specificity in prescribed exercise loading.
16342037|NCT04384874|Experimental|SSC6|A multi-stage rehabilitation program with focus on strength and reactive strength targets, as well as running gait re-training. These exercises will be initially carried out 3 days per week for the first 6 weeks with specific load targets prescribed.
16342038|NCT04384861|Experimental|ACTIVE|The ACTIVE arm of the project received the Mayo Clinic SMART training (1 two-hour in-person workshop) and access to the Mayo Clinic's SMART eLearning Support study modules (4 x 45 minute modules in weeks 1-4; 20 x 10 minute modules weeks 5-24)
16342039|NCT04384861|No Intervention|CONTROL|The CONTROL did not receive any interventions.
16342040|NCT04384848||Chronic myeloid leukemia (CML) patients|CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy
16342041|NCT04384835||Mild to moderate asthma|low or medium dose of inhaled steroids according to GINA guidelines
16342042|NCT04384835||Severe asthma|criteria described by the ATS / ERS guidelines (for the recruitment of severe patients)
16342043|NCT04384822|Experimental|Tai Chi Group|Subjects will participate in a tai chi program conducted in small groups (10 subjects per group) delivered by qualified instructors, who have experience in teaching tai chi to older adults. The tai chi intervention will be prescribed as a 3-month program with two 1-hour sessions weekly. Tai chi forms will be taught for 2 months followed by 1 month of consolidation. The 24-form simplified Yang-style tai chi will be adopted, as it is the most popular form of tai chi and older adults can manage to learn this simplified form of tai chi within 2-3 months. The instructors will introduce the safety issues, proper training principles, and skills to the subjects in their first class to minimize any avoidable adverse events due to improper skill/practice. The appropriate intensity will be individually determined for each subject by the attending instructors to achieve the training principle of progressive adaptation regarding the exercise intensity.
16342044|NCT04384822|Active Comparator|CBT-I Group|Subjects will participate in a conventional CBT-I program conducted in small groups (10 subjects per group) delivered by trained personnel. The CBT-I will be prescribed as a 3-month program with two 1-hour sessions weekly. The CBT-I components will be delivered for 2 months, which is consistent with the duration of the majority of CBT-I treatments, followed by 1 month of consolidation.
16342045|NCT04384809|Experimental|Leukocyte rich platelet rich plasma injection|Patients will be injected with leukocyte rich platelet rich plasma in their common extensor tendon
16342046|NCT04384809|Experimental|Percutaneous tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
16342047|NCT04384783||GH group|GH group: Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
16342048|NCT04384783||NGH group|NGH (non-GH) group: Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
16342051|NCT04384757|Active Comparator|Open distal gastrectomy|An incision of 15~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth II method was used for gastric reconstruction for most cases
16342052|NCT04384757|Experimental|Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.
~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.
~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.
~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.
~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.
~As a general rule, Billroth II method was used for gastric reconstruction for most cases"
16342054|NCT04384744||NGH-POR|Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
16342055|NCT04384744||NGH-NOR|Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
16342056|NCT04384731|Experimental|Surfactant arm|patient receiving the surfactant
16342057|NCT04384731|No Intervention|Control arm|patient not receiving the surfactant
16342058|NCT04384718||Medea Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
16342059|NCT04384718||Asur Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
16342060|NCT04384718||Waiting list Group|Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
16342061|NCT04384705||caregivers|caregivers
16342062|NCT04384692|Experimental|Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)|See detailed description.
16342063|NCT04384679|Experimental|Hydrophilic polymer and potassium ferrate powder|Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
16342064|NCT04384679|No Intervention|Direct pressure with sterile gauze|Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
16342065|NCT04384666|Experimental|LY03003|LY03003 28 mg
16342066|NCT04384666|Active Comparator|Neupro 4Mg/24Hr Transdermal Patch|Neupro 4 mg / 24 Hr. Transdermal Patch
16342067|NCT04384653|Experimental|Treatment A|Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
16342068|NCT04384653|Experimental|Treatment B|IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
16342069|NCT04384640||Patients seated after Intra-Tympanic injection|
16342070|NCT04384627|Active Comparator|Pre-IC GTV|The gross tumor volume (GTV) is delineated according to the pretreatment tumor extension
16342071|NCT04384627|Experimental|Post-IC GTV|The gross tumor volume (GTV) is delineated according to the post-IC tumor extension
16342072|NCT04384614||COVID (+)|Patients COVID19(+) confirmed by PCR
16342073|NCT04384614||COVID (-)|Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
16342074|NCT04384601|Experimental|SOX Chemotherapy|"Three preoperative and three postoperative cycles of SOX chemotherapy
~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)
~Repeated every 21st day"
16342075|NCT04384601|Active Comparator|FLOT Chemotherapy|"Four preoperative and four postoperative cycles of FLOT chemotherapy
~A cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous
~Repeated every 15th day"
16342076|NCT04384588|Experimental|Cancer patients with COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
16342077|NCT04384588|Experimental|Cancer patients with COVID 19 infection and risk factors|All patients will be treated with 1 or more convalescent plasma units
16342078|NCT04384588|Experimental|Non-Cancer patients COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
16342079|NCT04384588|Experimental|Non-cancer patients COVID 19 (+) and risk factors|All patients will be treated with 1 or more convalescent plasma units
16342080|NCT04384562|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 20 mg methylphenidate 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
16342081|NCT04384562|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 4 mg reboxetine 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
16342082|NCT04384562|Experimental|Cholinergic receptor agonist|Participants in the cholinergic receptor agonist group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a gum with 2 mg of nicotine.
16342083|NCT04384562|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
16342084|NCT04384549|Experimental|BCG Arm|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
16342085|NCT04384549|Placebo Comparator|PLACEBO Arm|One intradermal placebo injection.
16342086|NCT04384536|Experimental|Neural therapy group|Neural therapy group underwent local anesthetics injections by the same physician. Local injections, segmental injections and injection of trigger points of the forearm are done. The patients are evaluated at the beginning of the study and after 4 weeks of follow-up. Pre and post-treatment visual analog scale and Duruöz Hand Index scores are obtained.
16342087|NCT04384536|No Intervention|Control group|Control group used thumb spica splint and had rest
16342088|NCT04384523|Experimental|OsrHSA 20 mg/kg IV|
16342089|NCT04384523|Experimental|OsrHSA 40 mg/kg IV|
16342090|NCT04384523|Experimental|OsrHSA 80 mg/kg IV|
16342091|NCT04384523|Experimental|OsrHSA 140 mg/kg IV|
16342092|NCT04384523|Experimental|OsrHSA 200 mg/kg IV|
16342093|NCT04384510||Patients with placenta accreta spectrum (PAS)|This cohort presents patients who were suspected or diagnosed either antenatal or intrapartum with placenta accreta spectrum
16342094|NCT04384497|Experimental|Convalescent plasma treatment|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 7 CP infusions. CP will be given as a slow infusion over 1 hour. Patients will be monitored for adverse events, especially allergic reactions.
16342145|NCT04384107|Experimental|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.
16342098|NCT04384471||People living with Type 1 Diabetes|People from all ages living with type 1 diabetes in the Province of Quebec
16342099|NCT04384458|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with with 20 milligrams twice on day of active zinc for 45 consecutive days
16342100|NCT04384458|Active Comparator|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
16342101|NCT04384445|Experimental|Zofin Plus Standard Care|Participants in this group will receive standard of care plus Zofin on day 0, day 4 and day 8.
16342102|NCT04384445|Placebo Comparator|Placebo Plus Standard Care|Participants in this group will receive standard of care plus placebo (Saline) on day 0, day 4 and day 8.
16342103|NCT04384432|Experimental|Routine Physical Therapy with Thoracic mobility exercise|Combination of Routine Physical Therapy with Thoracic mobility exercise.
16342104|NCT04384432|Active Comparator|Routine Physical Therapy|Routine Physical Therapy exercise
16342105|NCT04384393|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
16342106|NCT04384380|Experimental|HCQ in adult Patients with COVID-19|The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
16342107|NCT04384380|No Intervention|standard of care treatment (SOC)|The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
16342108|NCT04384367|Experimental|Rizatriptan 10mg+ Naproxen 550mg|Rizatriptan 10mg+ Naproxen 550mg
16342109|NCT04384367|Active Comparator|Maxalt 10mg|Rizatriptan10mg
16342110|NCT04384367|Active Comparator|Flanax 550mg|Naproxen 550mg
16342111|NCT04384367|Placebo Comparator|Placebo|Placebo
16342112|NCT04384341|Experimental|Haemophilic patients|Blood sampling Bone Densitometry (BMD)
16342113|NCT04384341|Other|Healthy volunteers|Bone Densitometry (BMD)
16342114|NCT04384328|Experimental|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
16342115|NCT04384328|No Intervention|Standard Care|Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.
16342116|NCT04384315||EVRF|Patients that have undergone Endovenous Radio Frequency® (EVRF®) from F Care Systems (Belgian) for the treatment of primary great and short saphenous vein reflux.
16342117|NCT04384302|Experimental|Visual training|"Pre-specidied visual training methods that use: the Marsden ball, tables that uses green-red visual stimuli, physical reation in response to the visual stimuli that uses the flippers or the preselected distances.
~One set of exercises per week was prepared.
~Each visual training will last for 15 minutes and should be performed by the participant in their home (using the telemedicine devices to control the conduction of each exercise) 3 times a week."
16342118|NCT04384289|No Intervention|''Standard Care''|''Standard Care'' group were given standard care services.
16342119|NCT04384289|Experimental|"Transitional Care Model"|"Transitional Care Model group were given care based on the Transitional Care Model until the post discharge 9th week starting from date of hospitalization."
16342146|NCT04384094||Test subjects|Test subjects according to the inclusion / exclusion criterias.
16342147|NCT04384081|Experimental|Dose group 1|
16342148|NCT04384081|Experimental|Dose group 2|
16342149|NCT04384081|Experimental|Dose group 3|
16342150|NCT04384081|Placebo Comparator|Placebo group|
16342151|NCT04384068||Chinese RA patients|Chinese RA patients who used tocilizumab in real world clinical practice
16344013|NCT04371107|Active Comparator|symptomatic treatment|continuation of symptomatic treatment
16342122|NCT04384263|Experimental|Tai Chi group|"During the 12-week online Tai Chi intervention, participants in the Tai Chi group will attend live online Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 45 minutes/session for 12 weeks. The participants will also practice Tai Chi offline between sessions using instructional videos that will be shared with them at the end of each live online Tai Chi session.
~Participants in the Tai Chi group will be instructed: 1) to maintain their regular level of physical activity outside of the live online Tai Chi exercise sessions and offline Tai Chi exercise, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
16342123|NCT04384263|No Intervention|control|"Participants in the control group will perform only their regular habitual daily activities throughout the 12 weeks of intervention period.
~Participants in the control group will be instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
16342124|NCT04384237|Experimental|Er,Cr:YSGG laser-aided CSF|Experimental: Er, Cr: YSGG laser-aided Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment of the orthodontic treatment by inserting the laser tip at an angle of 10-15º to the radicular surface
16342125|NCT04384237|Active Comparator|Conventional CSF|Fiberotomy comparator: this arm is going to receive a blade conventional Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment by inserting a surgical blade into the gingival sulcus at an angle like that in the laser-aided CSF.
16342126|NCT04384224|Placebo Comparator|sham acupuncture + placebo tablet group|sham acupuncture point + placebo tablet
16342127|NCT04384224|Experimental|true acupuncture + placebo tablet group|true acupuncture point + placebo tablet
16342128|NCT04384224|Experimental|true acupuncture + antihistamine group|true acupuncture point + Dexchlorpheniramine (4 mg)
16342129|NCT04384224|Sham Comparator|sham acupuncture + antihistamine group|sham acupuncture point + Dexchlorpheniramine (4 mg)
16342130|NCT04384211||Radiologists|A computer search of CT scans (2010.01.01-2018.09.30) was performed in Wan Fang Hospital. These CT images were retrospectively reviewed by an experienced radiologist who classified and marked with annotations of vertebral fractures by the Genant's semiquantitative method.
16342131|NCT04384211||Smart Bone|The same CT images were separately reviewed and processed by the artificial intelligence system (Smart Bone) by Quanta for compression fractures. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
16342132|NCT04384198|Experimental|Sonolysis group|Cerebral hemisphere with sonolysis during MitraClip implantation.
16342133|NCT04384198|No Intervention|Control group|Cerebral hemisphere without sonolysis during MitraClip implantation.
16342134|NCT04384185|Experimental|Group A: Exercise therapy|Group A: will perform an exercise protocol to improve the stability of the spine muscle of low-back
16342135|NCT04384185|Experimental|Group B. Manual therapy and exercises|Group B: Will be treated with manual therapy in the diaphragm muscle and the same protocol of therapeutic exercise applied in group A
16342136|NCT04384172|Experimental|Tibial e-stim followed by genital e-stim|Tibial e-stim followed by genital e-stim
16342137|NCT04384172|Experimental|Genital e-stim followed by tibial e-stim|Genital e-stim followed by tibial e-stim
16342138|NCT04384146|Experimental|Quad Shot Radiation|In this trial, patients with centrally located lung tumors will be treated with up to 3 cycles of Quad Shot Radiation. Radiation treatment will be given within 1 week of administration of chemotherapy. Quad Shot radiation will involve: 3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break. The first group of patients will be treated with 2 cycles of quad shot radiation, followed by a 3-month observation period post-RT to allow a complete evaluation of acute toxicity. The next group of patients will be treated with either 1 cycle or 3 cycles of quad shot radiation. The minimum accrual is 4 patients with an expected accrual of 16 patients. Twenty additional patients will be recruited to an expansion cohort.
16342139|NCT04384133|Other|COPD group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. To assess symptom control in patients with COPD, a dyspnea scale of mMRC will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All participants will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD.
16342140|NCT04384133|Other|Healthy control group with a history of smoking|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
16342141|NCT04384133|Other|Healthy control group with no smoking history|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
16342142|NCT04384120|Experimental|Rotator Cuff Rehabilitation Using BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation using blood flow restriction cuffs.
~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy using blood flow restriction cuffs.
~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy using blood flow restriction cuffs."
16342143|NCT04384120|Active Comparator|Rotator Cuff Rehabilitation Without BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation without using blood flow restriction cuffs.
~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy without using blood flow restriction cuffs.
~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy without using blood flow restriction cuffs."
16342144|NCT04384107|Experimental|V114|Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.
16342152|NCT04384055||Covid-19 Positive Patients|This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx
16342153|NCT04384055||Covid-19 Negative Patients|This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx.
16342154|NCT04384042||Malaysian COVID-19 Cohort (Cases)|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
16342155|NCT04384042||Healthy Volunteers (Controls)|A cohort of age and sex-matched healthy volunteers will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
16342156|NCT04384016|Experimental|Evaluating the Safety of Skyvaricella Inj.|"The main target:
~• Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection"
16342157|NCT04384016|Experimental|Evaluating the Immunogenicity of Skyvaricella Inj.|"Secondary target
~• Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
16342158|NCT04384003|Active Comparator|Shear Wave Ultrasound Elastography|Shear Wave Ultrasound Elastography (SWUE, AplioTM 300 Platinum, Toshiba Medical System Corp, Japan, 6I) to examine the morphology and mechanical properties (μ = ρVs2, μ is the shear modulus of the tissue, ρ is the density of muscle (1000 kg m-3), Young's modulus )
16342159|NCT04384003|Active Comparator|The 3-D Motion Analysis|
16342160|NCT04384003|Active Comparator|EMG acquisition system|
16342161|NCT04384003|Active Comparator|Foot intrinsic muscle assessment and training device|"Schematic diagram of the novel modified foot intrinsic muscle (FIM) assessment and training device, which consists of one controller unit (signal generators, amplifier and A/D converter; signal generators provide noise-enhanced vibration to facilitate the muscle activation), 2 voice coil motor & server, 2 optical rulers, 2 rail scale, and 7 load cells.
~The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing and kicking."
16342162|NCT04383990|Active Comparator|Early Glargine|To take insulin Glargine at 6-7 pm
16342163|NCT04383990|Active Comparator|Late Glargine|To take insulin Glargine at 10-12 pm
16342164|NCT04383977|Experimental|Apatinib-Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
16342165|NCT04383977|Active Comparator|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
16342166|NCT04383964|Experimental|Transport distraction osteogenesis|"Locally made and designed submerged monodirectional in the vertical (Y) axis distractor was used.
~A transport disc is created at the remaining stump of the RCU with an L shaped osteotomy.
~The prepared disc is to be wide enough to fit the upper portion of the distrcator.
~The submerged distractor will be placed in a position to guide the transport disc moving up and backwards toward the glenoid fossa.
~The length of the distractor is determined according to the amount of distraction planned to reach the glenoid fossa."
16342167|NCT04383951|Active Comparator|Ketogenic diet|For participants randomized to the ketogenic diet arm, a consultation with the providers of medically supervised weight loss clinic of Indiana University Health will be arranged. Subjects will be educated on the concepts of ketosis, symptoms associated with it, and dietary manipulation to achieve ketosis. Participants in this arm will use the suggested recipes in combination with strict carbohydrate monitoring though checking for urine ketone bodies. These recipes were gathered and vetted by the dietitian at the medically supervised weight loss clinic. We anticipate that this approach will allow for more calorie intake and easier carbohydrate restriction. The follow up visits will be determined by the providers of the medically supervised weight loss clinic based on the symptoms reported and subject's compliance with carbohydrate restriction.
16342168|NCT04383951|Sham Comparator|Standard of Care|For participants randomized to this arm, a consultation with the providers of medically supervised weight loss clinic will be arranged. The discussion will focus on portion control using a balanced diet. A follow up visit will be at 16 weeks. This is the extent of interventions received for participants in this arm.
16342169|NCT04383938|Experimental|Safety Lead In|Patients with advanced solid tumors. Up to 3 dose levels evaluated.
16342170|NCT04383938|Experimental|Expansion 1|Patients with advanced gastric cancer.
16342171|NCT04383938|Experimental|Expansion 2|Patients with advanced urothelial/bladder cancer.
16342172|NCT04383938|Experimental|Expansion 3|Patients with advanced NSCLC.
16342173|NCT04383925|Experimental|BCG-Japan|Infants randomized to receive BCG-Japan at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Japan (Tokyo BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination.
16342174|NCT04383925|Active Comparator|BCG-Russia|Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
16342175|NCT04383912|Experimental|onabotulinum toxin A group (brow)|"Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC
~Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
16342176|NCT04383912|Placebo Comparator|placebo group (brow)|"Product name: normal saline
~Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
16342177|NCT04383899||Case patient|Patients from the cohort with severe coronavirus infection necessitating intensive care (artificial ventilation) with ulterior recovery or fatal outcome.
16342178|NCT04383899||Control patient|All patients from the cohort with non-severe coronavirus infection, who were not admitted to hospital or who were admitted to hospital but without the need for intensive care, and who recovered.
16342179|NCT04383886||Emergency department staff|
16342184|NCT04383847|Experimental|Main study|There is only 1 arm because this is a feasibility and acceptability pilot.
16342185|NCT04383821|Experimental|Double-Trunk Mask|The oxygen delivery system is the DTM
16342186|NCT04383821|Active Comparator|Non-Rebreather Mask|The oxygen delivery system is the NRM
16342187|NCT04383808|Experimental|Arm-1|20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
16342188|NCT04383808|Experimental|Arm-2|20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical. These subjects wont receive an additional injection of radiopharmaceutical.
16342189|NCT04383795||Graves' disease patients|First diagnosed Graves' disease patients volunteered for stool collection
16342190|NCT04383782|Active Comparator|Expectancy Challenge|The expectancy challenge intervention will involve two brief videotaped testimonials in which former smokers discuss their experiences with smoking-related health conditions. Participants will be encouraged to reflect back on the content of each video once per week leading up to the follow-up assessment.
16342191|NCT04383782|Experimental|Expectancy Challenge + Behavioral Activation|In addition to the expectancy challenge intervention (see Expectancy Challenge condition), participants in the Expectancy Challenge + Behavioral Activation group will also receive a novel behavioral activation intervention. Participants will be presented with brief psychoeducation about behavioral activation, several examples of possible functions of cigarette smoking, and several suggestions of behavioral strategies. All participants will receive the same information, but they will be encouraged to apply the information to their personal circumstances and to consider additional examples of rewarding activities they may engage in over the next four weeks. Participants will also be encouraged to engage in at least one behavioral activation activity each week leading up to the follow-up assessment.
16342192|NCT04383782|Placebo Comparator|Neutral Reading|The control group will receive neutral reading materials related to the components and structure of a cigarette. The content will be strictly curated so as to avoid inadvertently encouraging or discouraging smoking among participants.
16342193|NCT04383769||5,000 participants:|"2,500 are PLHIV receiving standard care in the hospital and 2,500 are PLHIV receiving care in DSD-ART model
~Inclusion criteria:
~Thai citizenship
~Age ≥ 18
~HIV positive
~Received ART for at least 6 months at a participating hospital (Except for After hour ART clinic model that will allow participants who receive ART less than 6 months into service)
~One of the following:
~Accept DSD-ART, OR
~Already receiving DSD-ART, OR
~Decline DSD-ART and will continue standard ART service at the hospital."
16342194|NCT04383756|Experimental|Donor Blood|Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants
16342195|NCT04383756|Active Comparator|Banked Blood|Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants
16342196|NCT04383743|Experimental|Treatment (pembrolizumab, aMVAC)|Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.
16342197|NCT04383730||Usual practice of intravenous sedation|The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
16342198|NCT04383730||Usual practice of inhaled sedation|The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
16342199|NCT04383717|Active Comparator|Proposed treatment group|Levamisole and isoprinosine
16342200|NCT04383717|Active Comparator|Control group|hydroxychloroquine and azithromycin
16342201|NCT04383704|Experimental|calorie-restricted modified MIND diet|This arm received instruction in modifying the content of their diet to meet MIND pattern guidelines.
16342202|NCT04383704|Active Comparator|calorie-restricted standard control diet|They instructed to calorie-restricted diet alone.
16342203|NCT04383691|Experimental|Lurasidone|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
16342204|NCT04383691|Placebo Comparator|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
16342205|NCT04383678||COVID-19 positive patients|
16342206|NCT04383665|Sham Comparator|STN DBS off|
16342207|NCT04383665|Experimental|STN DBS 10Hz|
16342208|NCT04383665|Active Comparator|STN DBS 130Hz|
16342209|NCT04383652||Adult cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)
~Age 16 years or older
~Have provided informed consent
~Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
16342210|NCT04383652||Paediatric cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)
~Age less than 16 years
~Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
16342211|NCT04383639|Active Comparator|1|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
16342212|NCT04383639|Experimental|2|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
16342213|NCT04383639|Experimental|3|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
16342214|NCT04383613|Experimental|PRONE POSITIONING|Patients in this arm will be instructed to lie on their stomach while they are in bed for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome.
16342215|NCT04383613|No Intervention|STANDARD OF CARE|Patients in this arm are not specifically instructed to lie on their stomach while they are in bed.
16342216|NCT04383600|No Intervention|Conventional side|Canine retraction was commenced without micro-osteoperforations.
16342217|NCT04383600|Experimental|Mops side|Canine retraction was commenced with micro-osteoperforations.
16342218|NCT04383587|Other|Serologic Arm|Enrolled participants will have COVID19 IgG antibody testing performed.
16342219|NCT04383574|Experimental|Experimental Vaccine-medium dosage|24 participants at medium dosage stage in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants at medium dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
16342220|NCT04383574|Experimental|Experimental Vaccine-high dosage|24 participants at high dosage stage in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants at high dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
16342221|NCT04383574|Placebo Comparator|Placebo|24 participants including 12 at medium dosage stage and 12 at high dosage in phase Ⅰ will receive two doses of placebo according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 50 participants in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
16342222|NCT04383574|Experimental|Experimental Vaccine-low dosage|100 participants at low dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
16342223|NCT04383561|Active Comparator|stage 3 periodontitis|GCF and serum samples were collected before and after treatment from periodontitis patients.
16342224|NCT04383561|Placebo Comparator|Periodontally healthy controls|GCF and serum samples were collected from periodontally healthy controls at baseline for once.
16342225|NCT04383548|Experimental|Hyper immunoglobulins have anti-Corona VS2 immunoglobulin|safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients
16342226|NCT04383535|Experimental|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma, in addition to standard care.
16342227|NCT04383535|Placebo Comparator|Placebo|Single infusion of saline solution, in addition to standard care.
16342228|NCT04383509|Experimental|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
16342229|NCT04383509|Active Comparator|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
16342230|NCT04383496|Experimental|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
16342231|NCT04383483||CoVID patients admitted to ICU|Patients admitted to the intensive care unit with the diagnosis of COVID
16342232|NCT04383470||General population, during COVID pandemic|General population during COVID-19 pandemic. Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
16342233|NCT04383470||General population, 6 months after COVID pandemic|General population, 6 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
16342234|NCT04383470||General population, 12 months after COVID pandemic|General population, 12 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
16342235|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
16342236|NCT04383431|Experimental|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
16342237|NCT04383431|Experimental|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
16342238|NCT04383418|Experimental|High dose group|In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.
16342239|NCT04383418|Experimental|Low dose group|In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.
16342240|NCT04383418|Placebo Comparator|Placebo group|In the placebo group，36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
16342241|NCT04383405|Experimental|Sequential Preparotory Approach|
16342242|NCT04383405|Active Comparator|Conventional|
16342243|NCT04383392|Experimental|Rate adaptive pacing|Turn on Rate adaptive pacing
16342244|NCT04383392|Active Comparator|No Rate adaptive pacing|Turn off Rate adaptive pacing
16342245|NCT04383379|Experimental|Intervention group|6 NICUs in the intervention group . The participating units of the intervention group determine the improvement items (one or more) in each quarter from the list of best practices of breast feeding quality improvement of Jiangsu Province, and report the improvement plan to the supervision unit, and recommend the application of PDSA (plan-do-study-act) for the implementation of quality improvement loop. Report the implementation of quality improvement to the supervision unit on a quarterly basis.
16342246|NCT04383379|No Intervention|control group|Continue current practices
16342247|NCT04383366||Patients with keratoconus|
16342248|NCT04383353||Cancer arm|Participants with new diagnosis of cancer, from whom a blood sample and contemporaneous tissue samples will be collected.
16342249|NCT04383353||Benign disease arm|Participants with benign diseases corresponding to the tumor types in the cancer arm, from whom a blood sample and contemporaneous tissue samples will be collected.
16342250|NCT04383353||Non-tumor arm (Healthy)|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
16342251|NCT04383340|Experimental|Mother-Infant Transaction Program|Four sessions were delivered to the mothers one-on-one based on a manualized protocol while the infants were still in the neonatal intensive care units. These coaching sessions included psychological care for the mother and topics on recognizing premature infant's characteristics, understanding and recognizing signs of infant stress and infant's engagement and disengagement cues, principles of graded stimulation, and how to optimize interactions and avoid over-stimulating the infant.
16342252|NCT04383340|Active Comparator|Treatment as usual|For this group, infants and mothers received standard hospital care following the initial baseline assessment; these mothers were invited to ask questions about recommended ways to take care of their infants, but no specific knowledge or skills targeted by the adapted MITP program were taught
16342253|NCT04383327|Experimental|ParentCorps-Professional Development (PD)|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs
~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
16342254|NCT04383327|Experimental|ParentCorps-Professional Development (PD) + T-Wellness|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs
~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
16342255|NCT04383327|No Intervention|Control|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs
~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
16342256|NCT04383314|Experimental|Exercise Program Group|Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
16342257|NCT04383301|Active Comparator|Intra corneal ring segment|Intra corneal ring segment implantation for moderate keratoconus patients
16342258|NCT04383301|Active Comparator|Corneal Wavefront-guided TPRK and ACXL|Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months
16342259|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Poor response|"If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.
~BEFORE SURGERY TREATMENT:
~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)
~AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)
~All the product are used as commercial formulation
~Other Names:
~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
16342260|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Good response|"If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.
~BEFORE SURGERY TREATMENT:
~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
~AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)
~All the product are used as commercial formulation
~Other Names:
~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
16342261|NCT04383288||No overexpression of ABCB1 / P-glycoprotein|"If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.
~BEFORE SURGERY TREATMENT:
~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
~AFTER SURGERY TREATMENT:
~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
~Total length 34 weeks
~All the product are used as commercial formulation
~Other Names:
~methotrexate cisplatin doxorubicine"
16342262|NCT04383275|Experimental|IRIS-A|
16342263|NCT04383275|Experimental|IRIS-B|
16342264|NCT04383262|Experimental|Lexiva|Lexiva/fosamprenavir at the FDA approved and manufacturers recommended dose (1,400mg twice daily) for 12 weeks
16342265|NCT04383262|Placebo Comparator|Placebo|standard of care
16342266|NCT04383249||Pathology result|Pathology result of the hernia sac
16342267|NCT04383236|Experimental|ChocBalls|(L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
16342268|NCT04383236|Active Comparator|Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt)|"Each 100 g contains:
~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g."
16342269|NCT04383223|No Intervention|YLH Historical Control Group|"Participants in this group will have the following phases:
~Screening
~Single visit assessment"
16342270|NCT04383223|Experimental|YLH iTransition Intervention Group|"Participants in this group will have the following phases:
~Screening
~Baseline Visit
~Follow-Up visits at 6, 12 and 18 month
~Interview visits for selected YLH around 3 and 9 month"
16342271|NCT04383223|Experimental|Provider Group|"Participants in this group will have the following phases:
~Screening
~Baseline Visit
~Follow-Up visits at 6, 12 and 18 month
~Interview visits for selected YLH around 3, 9 and 15 month"
16342272|NCT04383223|Experimental|Transition Champion Group|"Participants in this group will have the following phases:
~Screening
~Baseline Visit and Follow-Up visits at 6, 12 and 18 month
~Interview visits for selected YLH around 3, 9 and 15 month"
16342276|NCT04383197|Experimental|Semaglutide treatment|3 months of therapeutic semaglutide treatment
16342277|NCT04383197|Experimental|Semaglutide and Endurance exercise|12 weeks of endurance exercise concomitant to semaglutide treatment
16342278|NCT04383197|Experimental|Endurance exercise|12 weeks of endurance exercise
16342279|NCT04383184||TRACHEAL FORMING GROUP|Left pulmonary artery transplantation and slide tracheoplasty
16342280|NCT04383184||NON-TRACHEAL FORMING GROUP|only Left pulmonary artery transplantation
16342281|NCT04383158|Active Comparator|PRGF extraction sockets (Test)|Immediately after dental extraction, the socket will be filled with Plasma Rich in Growth Factors (ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16))
16342282|NCT04383158|No Intervention|Unassisted extraction sockets (Control)|Dental extraction sockets to be left to heal spontaneously unassisted.
16342283|NCT04383132|Experimental|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
16342284|NCT04383132|Sham Comparator|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
16342285|NCT04383119|Experimental|Arm A|Trabectedin at the dose of 1.5 mg/m2-1.3 mg/m2 with a top-dose of 2.6 total mg per cycle (according the clinical practice in pretreated patients and in all our ISG studies) will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles
16342286|NCT04383119|Active Comparator|Arm B|Gemcitabine 800-1000 mg/m2 will be administered via a central venous catheter on days 1,8 every 21 days
16342287|NCT04383119|Active Comparator|Observational Cohort|Treatmen according clinical practice (not defined in advance). The patient who will refuse randomization between Arm A and B can choose to participate to the observational cohort to the study, where they will be treated according clinical practice
16342288|NCT04383093||Combination Therapy|"Patients initial assessment included age, waist circumference, blood pressure, clinical laboratory parameters, digital rectal examination. LUTS were evaluated with total IPSS, focusing also on storage, voiding IPSS sub-scores, and IPSS QoL, and Overactive Bladder questionnaire (OAB-q), while ED with IIEF-515. Each patient underwent uroﬂowmetry and postvoid residual volume (PVR) was measured with abdominal ultrasound immediately after voiding. All patients reporting any intake of therapies for LUTS or ED underwent a 4 weeks treatment-free washout period.
~All subjects were treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. The medications were self-administered every day at the same time, before the night rest, without any limitations or variations of sexual activity timing or food intake. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5"
16342289|NCT04383080|Experimental|Low-level laser therapy|Low-level laser irradiation on specific acupuncture points
16342290|NCT04383080|Active Comparator|Acupuncture therapy|Dry needle inserting specific acupuncture points
16342291|NCT04383080|Placebo Comparator|Placebo low level laser therapy|Low-level laser irradiation on specific acupuncture points for placebo control
16342292|NCT04383067|Experimental|Tumor Infiltrating Lymphocytes (TIL)|
16342293|NCT04383054|Experimental|Long PA intervention group|The long PA intervention will be a MI (motivational interview) exploring the participant's knowledge and concerns about PA. An MI involves a semi-structured discussion between an investigator and the participant. The MI initially explores the participant's knowledge of the benefits of PA and their concerns about PA. The MI will then explore the participant's confidence in increasing their PAL, help the participant come up with a plan to increase their PAL and finally the participant will be signposted to further support and local opportunities for PA. The investigator will use a Moving Medicine 'more minutes' conversation tool of a chronic health condition that the patient has to facilitate every MI. Where possible the investigator will discuss the chronic condition that most relates to the participant's current admission to hospital. For patients with no health conditions the primary prevention section will be used.
16342294|NCT04383054|Active Comparator|Short PA intervention group|The short PA intervention will involve a short (1 min) discussion between an investigator and a participant. A Moving Medicine 'one minute' intervention appropriate to the participant's health conditions will be used to guide every short intervention. The short intervention will firstly involve the investigator asking whether the participant knew that doing PA was beneficial for their health. The investigator would then explain to be more PA they could try to build more PA into their daily routine and that this was often enough to meet the current PA recommendations. The investigator will also offer the participant a patient information sheet about PA.
16342295|NCT04383041||Patients with Type 2 Diabetes|Patients with Metformin containing prescription drugs will be eligible for participation and consecutively invited to study participation in their pharmacy.
16342296|NCT04383028|Experimental|MELD-assisted SEEG trajectory planning|Following routine clinical planning, the MELD algorithm will be run on the enrolled patient's scans. Up to 3 extra electrodes may be used to target lesion clusters identified by the algorithm such that the investigators will record from the top 3 clusters, with the aim of improving the rate of identification of a focal seizure onset zone in patients undergoing SEEG.
16342297|NCT04383015|Other|Carbohydrate (CHO)-only|Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
16342298|NCT04383015|Other|50 Percent Basal Rate Reduction (BRR)|A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
16342299|NCT04383015|Other|Combo|The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
16342300|NCT04383002|No Intervention|Standard of Care (control)|Patients will receive standard of care therapy
16342301|NCT04383002|Experimental|Inhaled Nitric Oxide|
16342302|NCT04382989||Mothers of extremely preterm infants|(gestational age < 28 weeks)
16342303|NCT04382989||Mothers of very preterm infants|(gestational age 28 - 31 weeks)
16342304|NCT04382989||Mothers of moderate and late preterm infants|(gestational age 32 - 36 weeks)
16342305|NCT04382989||Mothers of term infants|(gestational age ≥ 37 weeks)
16342306|NCT04382963|Other|High Risk- intense coaching|"age ≥ 55 with MORE than three of the following risk factors:
~History of TIA/Stroke
~History of Coronary Artery disease
~History of Hypertension and/or current elevated blood pressure
~History of Diabetes
~Current smoker
~BMI ≥30"
16342307|NCT04382963|Other|High Risk - standard care|"age ≥ 55 with MORE than three of the following risk factors:
~History of TIA/Stroke
~History of Coronary Artery disease
~History of Hypertension and/or current elevated blood pressure
~History of Diabetes
~Current smoker
~BMI ≥30"
16342308|NCT04382963|Other|Low risk - control|"age ≥ 55 with LESS than three of the following risk factors:
~History of TIA/Stroke
~History of Coronary Artery disease
~History of Hypertension and/or current elevated blood pressure
~History of Diabetes
~Current smoker
~BMI ≥30"
16342309|NCT04382950|Experimental|Experimental: rbACE2 group plus Aerosolized Isotretinoin|rbACE2 0.4 mg/kg IV BID for 7 days (unblinded) plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
16342310|NCT04382950|No Intervention|No Intervention: Control group|Standard of care; no placebo
16342311|NCT04382937|Experimental|P1101 + Ribavirin|P1101 400 µg SC Q2W
16342312|NCT04382937|Active Comparator|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W
16342313|NCT04382924|Experimental|Treatment Arm A|NP-120 (Ifenprodil) 20 mg TID + Standard of Care
16342314|NCT04382924|No Intervention|Control Arm|Standard of Care only
16342315|NCT04382924|Experimental|Treatment Arm B|NP-120 (Ifenprodil) 40 mg TID + Standard of Care
16342316|NCT04382911|Experimental|18F-fluoroestradiol PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
16342323|NCT04382885|Experimental|Cohort 1 (10-17 years)|10 to 12 years: 0.75 mg/day cariprazine oral solution 13 to 17 years: 1.5 mg/day cariprazine oral solution
16342324|NCT04382885|Experimental|Cohort 2 (10-17 years)|10 to 12 years: 1.5 mg/day cariprazine oral solution 13 to 17 years: 3.0 mg/day cariprazine oral solution
16342325|NCT04382885|Experimental|Cohort 3 (5-9 years)|0.5 mg/day cariprazine oral solution
16342326|NCT04382885|Experimental|Cohort 4 (5-9 years)|1.5 mg/day cariprazine oral solution
16342327|NCT04382859|Active Comparator|TAP block with liposomal bupivacaine|Active comparator
16342328|NCT04382859|Other|TAP block with 0.25% bupivacaine|Standard comparator
16342329|NCT04382846|Experimental|Nitazoxanide|Nitazoxanide with standard protocol of treatment
16342330|NCT04382846|No Intervention|Control group|Standard protocol alone
16342331|NCT04382833|Experimental|HOT APPLICATION GROUP|Thermoforming, one of the dry hot application methods, was performed on the sacral (S1-S4) vertebrae region of pregnant women in the hot application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). Thermoforming was applied by wrapping it with a towel to protect pregnant women from the direct effect of its hot surface. The mean water temperature used in thermoforming was 50C. The water temperature was measured using a liquid thermometer. When 50°C water was subjected to hot application, the surface temperature reached around 40°C. The hot application was carried out continuously for 20 min.20 The body temperature of the pregnant women was evaluated before the application.
16342332|NCT04382833|Experimental|MASSAGE GROUP|Massage using effleurage and friction techniques was applied to the 4-5 cm right and left lateral parts of the midline on the sacral (S1-S4) vertebrae region of pregnant women in the massage application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). The massage application was carried out continuously for only 10 min because it was thought to cause irritation to the area where it was practiced.
16342333|NCT04382833|No Intervention|CONTROL GROUP|
16342334|NCT04382820||Families of rare chronically ill children|Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf due to a rare pediatric surgical disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
16342335|NCT04382820||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-21 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
16342336|NCT04382807||Subjective, chronic tinnitus|Tinnitus patients who received internet-based psycho-educational counseling
16342337|NCT04382794||DMT2 COVID19 positive patients treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
16342338|NCT04382794||DMT2 COVID19 positive patients not treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
16342339|NCT04382781||COVID-19 infection|Consecutive patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who showed clinical and analytical data suggestive of macrophage activation syndrome during admission until March 30, 2020 .
16342340|NCT04382768|Experimental|Luarprofen|Inhaled Hypertonic ibuprofen 50 mg tid
16342341|NCT04382755|Active Comparator|Group A (active)|Standard of Care (SoC) + subcutaneous Zilucoplan® + prophylactic antibiotics until 14 days after last Zilucoplan®
16342342|NCT04382755|Placebo Comparator|Group B (control)|Standard of Care (SoC) + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
16342343|NCT04382742|Experimental|Exercise|
16342344|NCT04382729|Experimental|NMES Group|
16342345|NCT04382729|Active Comparator|Control Group|
16342346|NCT04382716||PANS participants|
16342347|NCT04382703|Experimental|Intervention|Given the associated questionnaire which has the embedded self-affirmation exercise.
16342348|NCT04382703|Active Comparator|Control|Given the associated questionnaire without the embedded self-affirmation exercise.
16342349|NCT04382690||India|People residing in India
16342350|NCT04382690||United Kingdom|People residing in the United Kingdom
16342351|NCT04382690||China|People residing in China
16342352|NCT04382690||Australia|People residing in Australia
16342353|NCT04382690||South Africa|People residing in South Africa
16342354|NCT04382690||Indonesia|People residing in Indonesia
16342355|NCT04382690||Saudi Arabia|People residing in Saudi Arabia
16342356|NCT04382677|Experimental|Promoting First Relationships|The PFR program designed for birth families being reunited after foster care placement consists of a manualized 12-session intervention delivered in the home by trained providers.
16342357|NCT04382677|Other|Resource & Referral|The service consists of a needs assessment conducted by phone, followed by a personalized resource packet and referrals, and 3 monthly check-in phone calls.
16342360|NCT04382651|Experimental|MAS825 + SoC|Single dose of MAS825 by i.v. infusion, in addition to Standard of Care (Soc)
16342361|NCT04382651|Placebo Comparator|Matching placebo + SoC|Single dose of Matching Placebo by i.v. infusion, in addition to Standard of Care (Soc)
16342362|NCT04382638|Experimental|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
16342363|NCT04382638|Active Comparator|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
16342364|NCT04382625|Experimental|Hydroxychloroquine (HCQ)|Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
16342365|NCT04382625|No Intervention|Usual Care|The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.
16342366|NCT04382612|Other|HARPOON MVRS|Subjects who were treated with the HARPOON MVRS.
16342367|NCT04382599|Experimental|Added sugar warning message|"Message displayed on warning labels is: WARNING: High in added sugar."
16342368|NCT04382599|Experimental|Weight gain warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to weight gain."
16342369|NCT04382599|Experimental|Type 2 diabetes warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to type 2 diabetes."
16342370|NCT04382599|Experimental|Heart damage warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to heart damage."
16342371|NCT04382599|Active Comparator|Neutral message|"Message displayed on control label is: Please refrain from littering."
16342372|NCT04382586|Experimental|Cohort 1: Zanubrutinib + Supportive Care|Participants not requiring mechanical ventilation (Cohort 1) will receive zanubrutinib plus supportive care
16342373|NCT04382586|Active Comparator|Cohort 1: Placebo + Supportive Care|Participants not requiring mechanical ventilation (Cohort 1) will receive placebo plus supportive care alone
16342374|NCT04382586|Experimental|Cohort 2: Zanubrutinib+Supportive Care|Participants who have been on mechanical ventilation for ≤ 24 hours (Cohort 2) will receive zanubrutinib plus supportive care alone for respiratory distress due to COVID-19 infection for up to 28 days
16342375|NCT04382573||CDK13|CDK13 intragenic pathogenic variant
16342376|NCT04382560|Experimental|Intervention group|The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
16342377|NCT04382560|No Intervention|Wait-list control group|The waiting list group will receive the intervention at the end of the study.
16342378|NCT04382547|Experimental|mesenchymal stem cells|Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
16342379|NCT04382547|Active Comparator|control|Patients with Covid-19 associated pneumonia receiving standard treatment
16342380|NCT04382534||Rehabilitation guidance group|1 to 2 times of rehabilitation instruction according to the rehabilitation instruction program, either online or in person.According to the rehabilitation instruction, the patient performed self-rehabilitation exercises in the isolation point.
16342381|NCT04382534||Systematic rehabilitation treatment|According to the systematic rehabilitation treatment program, the rehabilitation therapist entered the home for one-to-one rehabilitation treatment, once a day, for a total of 10 days.
16342382|NCT04382521|Experimental|Text Message Intervention (TMI)|Participants in the TMI condition will receive daily text messages through an adaptive algorithm plus separate twice-weekly tailored messages focused on a specific health goal.
16342383|NCT04382521|Other|Wait-list Control Group (WLC)|Waitlist Control group participants will begin to receive the full 12-week Text Message Intervention (with all components, e.g., phone check-ins) after completing follow-up assessments at Weeks 12 and 24. Participants in this group will receive no text messages or other study-specific interventions during the first 24 weeks of the study.
16342384|NCT04382456|Experimental|acacia gum|
16342385|NCT04382443|Experimental|Oral Colchicine +BMS implantation|This group will receive after BMS and Colchicine, at the time of PCI, 0,5 mg twice a day during the first three months after stent implantation
16342386|NCT04382443|No Intervention|Second generation Drug eluting stent (DES)|"This group will receive DES at the moment of randomization and will be treated as standard of care.
~All second generation DES should be approved by ANMAT for clinical use."
16342387|NCT04382430|Experimental|US Guided Axillary venous access|Physician/ provider will perform 2 unassisted & 10 solo Ultrasound (US) guided venous access and pocket creation cardiac device implant. First 2 device implant will be done to educate physicians about ultrasound guided venous access. Subsequent subject will be randomized to 2:1 in ultrasound vs. conventional technique.
16342388|NCT04382430|Active Comparator|Conventional technique|Physician/ provider will perform 5 cardiac device implant using conventional technique for venous access and pocket creation.
16342389|NCT04382417||Covid-19|Patients with verified or highly suggestive Covid-19 diagnosis and Intensive Care treatment.
16342390|NCT04382404|Experimental|Sofosbuvir-Velpatasvir|Sofosbuvir-Velpatasvir
16342391|NCT04382391|Experimental|gammaCore Sapphire® (nVNS) plus standard of care|Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
16342392|NCT04382391|Active Comparator|standard of care alone|Will receive standard of care therapies to treat CoViD-19 infection and symptoms
16342393|NCT04382378|No Intervention|control group|Group that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
16342394|NCT04382378|Experimental|50 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
16342395|NCT04382378|Experimental|100 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
16342396|NCT04382365|Other|Internet-Based Insomnia Intervention|"2 weeks of online sleep diaries. Participants will also wear an Actiwatch at night, which records measurements of movements of a limb, providing an estimation of sleep duration, sleep pattern and disturbed sleep.
~9 week interveition period, subjects complete the internet based CBT-I program, consisting of six Cores (Getting Ready, Sleep Scheduling, Sleep Practices, Thinking Differently, Sleep Hygiene, and Moving On).Each Core takes approximately 45-60 minutes to review online, and most participants spend an additional 30-45 minutes per week on recommended exercises.
~Participant will then be instructed to complete a post-Assessment, consisting of one online questionnaire and two weeks of Daily Sleep Diaries. The Actiwatch is worn as before during this two week period."
16342397|NCT04382352|Experimental|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection|Registration number: CTR20181455 Indications: HER2-positive recurrent or metastatic breast cancer Experimental popular topic: Phase Ia clinical study of recombinant anti-HER2 humanized monoclonal antibody composition
16342398|NCT04382339|Active Comparator|Treatment-naive|"Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks
~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
16342399|NCT04382339|Active Comparator|Treatment-experienced|"Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks
~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
16342400|NCT04382326|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
16342401|NCT04382326|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
16342402|NCT04382313|Experimental|the adequate hydration group guided by Vigileo|The rehydration speed is adjusted according to SVV.
16342403|NCT04382313|Active Comparator|the control group|The hydration method is perioperative saline ≤500 ml.
16342404|NCT04382300|Experimental|Treatment arm|pyrotinib 400mg p.o. qd, combined with thalidomide 200mg p.o. qd
16342405|NCT04382287|Experimental|REMIN paste|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
16344053|NCT04370782|Experimental|Experimental Arm 2|"Hydroxychloroquine
~Doxycycline
~Zinc sulfate"
16342406|NCT04382287|Experimental|MI PASTE PLUS|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
16342407|NCT04382287|Active Comparator|COLGATE Total|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
16342408|NCT04382274|Experimental|Quadratus Lumborum Block|the transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized, leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial then placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
16342409|NCT04382274|Experimental|Dual block|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
16342410|NCT04382261|Placebo Comparator|Periodontitis quadrant|Patients undergo non surgical quadrant scaling and root planing
16342411|NCT04382261|Active Comparator|Periodontitis full mouth|Patients undergo non surgical full mouth scaling and root planing
16342412|NCT04382248|Experimental|Interventional Group|An app for tracking medications, receiving personal coaching and educational material
16342413|NCT04382248|Active Comparator|Control Group|An app for tracking medications
16342414|NCT04382235||Covid-19 related Pneumonia patients|The cohort is defined by subjects with a diagnosis of COVID 19-related pneumonia requiring non-invasive ventilatory support.
16342415|NCT04382209|Active Comparator|Erector Spinae plane block group|Erector spinae plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively.
16342416|NCT04382209|Sham Comparator|Control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
16342417|NCT04382196||Health care workers|Health care workers at university hospital
16342418|NCT04382183|Experimental|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
16342419|NCT04382183|Experimental|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the standard Norwegian Health Directorate recommendations for 1 year.
16342420|NCT04382170|Active Comparator|20 mcg|Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
16342421|NCT04382170|Experimental|60 mcg|Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
16342422|NCT04382157|Experimental|Mablet|Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
16342423|NCT04382157|Placebo Comparator|Placebo|Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
16342424|NCT04382144|Active Comparator|Levobupivacaine arm|Patients will receive a single injection of 10 mL of 0.5% (5 mg/mL) levobupivacaine into the common extensor origin.
16342425|NCT04382144|Experimental|Liposomal Bupivacaine arm|Patients will receive a single injection of 10 mL (133mg) of liposomal bupivacaine into the common extensor origin.
16342426|NCT04382131|Experimental|Hypertonic saline nasal irrigation and gargling|Participants in the intervention arm will be asked to perform hypertonic saline nasal irrigation and gargling up to 12 times daily for a maximum of 14 days or until they report that they feel well.
16342427|NCT04382131|No Intervention|Standard Care|Participants in the control arm will be given standard NHS guidance for the management of their symptoms and household hygiene.
16342428|NCT04382118||OWDFO: Open Wedge Distal Femoral Varus osteotomy|
16342429|NCT04382118||CWDFO: Closed Wedge Distal Femoral Varus osteotomy|
16342430|NCT04382105||Control|observation of salivary IL-6 levels
16342431|NCT04382105||Periodontitis|observation of salivary IL-6 levels
16342432|NCT04382092|Experimental|Intervention COVID-19|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
16342433|NCT04382079|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.
~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
16342434|NCT04382079|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).
~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
16342435|NCT04382079|No Intervention|control|Routine care to encourage oral care three times a day.
16342436|NCT04382066|Experimental|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
16342437|NCT04382066|Experimental|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
16342438|NCT04382066|Experimental|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
16342439|NCT04382053|Experimental|DFV890 + SoC|DFV890 will be administered for 14 days in addition to Standard of Care (SoC). SoC will be used as an active comparator.
16342440|NCT04382053|Active Comparator|Standard of Care (SoC)|Standard of Care will be used as a comparator arm.
16342441|NCT04382040|Experimental|ArtemiC|Active study treatment + Standard care
16342442|NCT04382040|Placebo Comparator|PLACEBO|Placebo + Standard care
16342443|NCT04382027|Experimental|Monoacylglycerol|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
16342444|NCT04382027|Active Comparator|Ethyl ester|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in ethyl ester form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
16342445|NCT04382014|Experimental|MAG fish oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
16342446|NCT04382014|Active Comparator|Rice bran oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
16342447|NCT04382014|Active Comparator|Curcumin extract|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
16342450|NCT04381975|Experimental|Move in Mind Program|The Move in Mind Program is a 6-week Rolfing®-based intervention program shortened from ten to six sessions and adapted to a group setting by Rolfing® instructor Monica Canducci.
16342451|NCT04381975|Other|6 Week Waitlist Control|Participants will be crossed over to the Move in Mind program following the 6-week waitlist control. Participants of the waitlist control group will be asked to complete follow-up questionnaires both at the same time as the intervention group (after week six) as well as after their own program.
16342452|NCT04381962|Experimental|Azithromycin|Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
16342453|NCT04381962|No Intervention|Usual standard care|Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
16342454|NCT04381949|No Intervention|Standard extubation Arm|
16342455|NCT04381949|Experimental|Positive pressure extubation arm|
16342522|NCT04381611||Glaucoma Laser|
16342472|NCT04381923|Active Comparator|Helmet Continuous Positive Airway Pressure (CPAP)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC, helmet CPAP will be applied unless a specific contraindication is present.
16342473|NCT04381923|Active Comparator|High Flow Nasal Oxygen (HFNO)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC , HFNO (≥ 40 LPM) will be applied unless a specific contraindication is present
16342474|NCT04381910|Experimental|LY01610|LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
16342475|NCT04381897|Experimental|Group A: NAC 1800mg then Placebo|NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
16342476|NCT04381897|Experimental|Group B: Placebo then NAC 1800mg|NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
16342477|NCT04381884|Experimental|IVERMECTIN (IVER P®)|Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.
16342478|NCT04381884|No Intervention|CONTROL|Patients in this group will receive standard care.
16342479|NCT04381871|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
16342480|NCT04381871|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose
16342481|NCT04381858|Experimental|Severe pneumonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:
~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]
~Requiring invasive mechanical ventilation."
16342482|NCT04381858|Active Comparator|Severe pnemonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:
~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]
~Requiring invasive mechanical ventilation."
16342483|NCT04381845|Other|psychiatric patient|patients who are hospitalized in psychiatric department
16342492|NCT04381806|Experimental|5-ALA|orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)
16342493|NCT04381793|Experimental|Assessing clinical efficacy|Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects
16342494|NCT04381780|Experimental|Assessing clinical outcomes|Nutritional support with Recovery Factors
16342495|NCT04381767||Concussion Evaluation|Adult athletes receiving a clinical evaluation for a suspected concussion after head injury
16342496|NCT04381754||AVG/AVF Treated with Passeo-18 Lux|Patients with failing dialysis access, treated lesions located between the anastomosis to the axillary-subclavian vein junction.
16342497|NCT04381741|Experimental|CD19-7×19 CAR-T plus PD1 monoclonal antibody|
16342498|NCT04381728|Experimental|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.
~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.
~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
16342499|NCT04381715||YY1|YY1 intragenic pathogenic variant
16342500|NCT04381702||Patients with an open approach|Patients requiring pancreatoduodenectomy and operated with an open approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology before the first laparoscopic pancreaticoduodenectomy.
16342501|NCT04381702||Patients with a laparoscopic approach|Patients requiring pancreatoduodenectomy and operated with a laparoscopic approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology operated with a laparoscopic approach.
16342502|NCT04381689|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
16342503|NCT04381689|Active Comparator|GSK PFS|Fluarix Tetra Pre-filled Syringe
16342504|NCT04381676||Flipped Classroom|Residents in the flipped classroom were assigned a pre-class video lecture prior to completing the flipped classroom in-class case-based activity in groups of 2-3 each.
16342505|NCT04381676||Traditional Classroom|Residents in the traditional classroom were assigned a pre-class reading assignment followed by a 44-minute lecture that was delivered in-person using PowerPoint.
16342506|NCT04381663||conservative treatment|In study A this group will be treated conservatively (stenosis). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
16342507|NCT04381663||surgical treatment (stenosis and myelopathy).|In study A this group that will be treated surgically (stenosis and myelopathy). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
16342508|NCT04381650|Experimental|Dose Escalation: TAK-981 + Pembrolizumab (fixed dose)|Escalating doses of TAK-981 with starting dose of 40 mg, intravenous (IV) infusion, on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle and pembrolizumab 200 mg, IV infusion, as a fixed dose every 3 weeks in 21-day Treatment Cycle until RP2D is determined (for a maximum of 24 months).
16342509|NCT04381650|Experimental|Dose Expansion Phase: Cohort A: Non-squamous NSCLC|TAK-981 at RP2D as IV infusion in participants with non-squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342510|NCT04381650|Experimental|Dose Expansion Phase: Cohort B: Cervical Cancer|TAK-981 at RP2D as IV infusion in participants with cervical cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342511|NCT04381650|Experimental|Dose Expansion Phase: Cohort C: MSS-CRC|TAK-981 at RP2D as IV infusion in participants with microsatellite stable colorectal cancer (MSS-CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342512|NCT04381650|Experimental|Dose Expansion Phase: Cohort D: Cutaneous Melanoma|TAK-981 at RP2D as IV infusion in participants with Cutaneous melanoma on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342513|NCT04381650|Experimental|Dose Expansion Phase: Cohort E: Squamous NSCLC|TAK-981 at RP2D as IV infusion in participants with Squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342514|NCT04381650|Experimental|Dose Expansion Phase: Cohort F: Small Cell Lung Cancer|TAK-981 at RP2D as IV infusion in participants with Small cell lung cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342515|NCT04381650|Experimental|Dose Expansion Phase: Cohort G: HNSCC|TAK-981 at RP2D as IV infusion in participants with head and neck squamous cell carcinoma (HNSCC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342516|NCT04381650|Experimental|Dose Expansion Phase: Cohort H: MSI-H/dMMR CRC|TAK-981 at RP2D as IV infusion in participants with microsatellite instability, high levels/ mismatch-repair-deficient colorectal cancer ( MSI-H/dMMR CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
16342517|NCT04381637|Experimental|NIPE|
16342518|NCT04381624|Experimental|Transcutaneous Vagal Stimulation|TVS will be applied through a portable electrostimulation equipment during the whole session in each of the treatment sessions. The electrodes will be placed in the left ear, specifically in the auricular concha. The device will be programmed with a biphasic square current at an intensity that produces a clear tingling sensation that is neither uncomfortable nor painful, with pulses of 300 microseconds, at 25 Hertz, the stimulus will be present for 30 seconds and will be followed by a 30-second rest period repeating this for approximately one hour.
16342519|NCT04381624|Placebo Comparator|Placebo Transcutaneous Vagal Stimulation|In the application of this placebo, the device will be configured with the same parameters and intensity of the real TVS. However the device will be located in the left ear lobe.
16342520|NCT04381611||Primary Glaucoma|
16342521|NCT04381611||Glaucoma Surgery|
16342530|NCT04381598|Experimental|stevia rebaudiana bertoni|Randomly in all subjects one quadrant will be allotted as test site for placing stevia gel in the gingival sulcus having probing depth ≥ 5mm after performing thorough scaling and root planing.
16342531|NCT04381598|Placebo Comparator|placebo|Other quadrant will be allotted as a control site for placing placebo in the gingival sulcus having PD≥ 5mm after performing thorough scaling and root planing.
16342532|NCT04381585|Experimental|Distraction osteogenesis using mini distractor|"A mini distractor will be used to move bone. Distraction osteogenesis originally developed for the severe craniofacial malformations has been adapted to correct vertical defects of the oral bone to improve bone volume for dental procedures.
~However, the design of the distractor
~has not evolved to adapt to a much smaller surgical site such as bone ridge in the oral cavity which necessitates a smaller screw.
~are bulky, cumbersome to place, and cause significant discomfort to the patient.
~has an extraoral component jutting out of the mouth to which a key (blue object) is attached to turn the screw to move bone fragments. Our Solution and the Innovation is to remove the extra-oral component by reducing the size and permitting an atraumatic placement of the screw under the gingiva (gum) thereby lessening irritation for the patient."
16342533|NCT04381572||High fidelity simulation training|Group consisting of medical students scheduled to undergo high fidelity medical simulation as a part of standard scholastic program.
16342534|NCT04381559|Experimental|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
16342535|NCT04381559|Active Comparator|Applied Relaxation|In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
16342536|NCT04381546|Experimental|FES in patients with hemiplegia|Patients will be equipped with 5 inertial measurement units. Two wireless bluetooth pressure insoles will be connected to the Raspberry. Electrical stimulation will be delivered via a wireless stimulator to the quadriceps and hamstrings via surface electrodes. Insoles will be used to online analyze Paretic Foot Support to discriminate between stance and swing phases. Stimulation will also be delivered just before initial contact at the end of swing phase. In stance phase, stimulation will be triggered either to quadriceps or hamstrings, depending on the paretic knee angle estimation relatively to the knee angle setpoint defined by the practitioner as the optimal flexion during stance phase (around 5°).
16342537|NCT04381533|Experimental|I-A-CRA|Internet-delivered Adolescent Community Reinforcement Approach: The treatment program consists of 8 extensive treatment modules delivered over 10 weeks with continuous therapist support and guidance. There are two separate treatments for the young adult and the caregiver/significant other.
16342538|NCT04381533|Active Comparator|Psychoeducation alcohol use|Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
16342539|NCT04381520|Experimental|Heat-sensitive moxibustion plus antihypertensive drugs|
16342540|NCT04381520|Active Comparator|Antihypertensive drugs|
16342541|NCT04381494|Other|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
16342542|NCT04381481|Experimental|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
16342543|NCT04381481|Experimental|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
16342544|NCT04381481|Experimental|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
16342545|NCT04381481|Experimental|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
16342546|NCT04381481|Experimental|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
16342547|NCT04381481|Experimental|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
16342548|NCT04381481|Experimental|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
16342549|NCT04381481|Experimental|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
16342550|NCT04381481|Experimental|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
16342551|NCT04381481|Experimental|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
16342552|NCT04381481|Experimental|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
16342553|NCT04381481|Experimental|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
16342556|NCT04381442|Experimental|Buccal &palatal low level laser therapy|In group I,low level laser therapy was delivered at 10 points; 5 from buccal and 5 from palatal aspects with a total dose of 8 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
16342557|NCT04381442|Active Comparator|Buccal low level laser therapy|In group II, low level laser therapy was delivered at 5 points; from buccal palatal aspects only with a total dose of 4 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
16342558|NCT04381429|Active Comparator|Group 1: A-F-A-F|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.
~All patients will test both insulin treatments (A and F) in alternating periods.
~The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid).
~Each treatment period will last 3 months."
16342559|NCT04381429|Active Comparator|Groupe 2: F-A-F-A|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.
~All patients will test both insulin treatments (A and F) in alternating periods.
~The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP)."
16342560|NCT04381416|Experimental|Cohort I: SEAD treatment|Following the first SEAD™ treatment, women who experience a sub-optimal treatment response (at least 3 months after the first treatment) will be eligible to receive a second SEAD™ treatment (see re-treatment criteria below), which will be performed during the first 1-3 days following the cessation of their menses immediately following decision to retreat.
16342561|NCT04381416|Experimental|Cohort II: Repeted SEAD treatment 1m post op|Following the first SEAD™ treatment, women will undergo a second SEAD™ treatment during the first 1-3 days following the cessation of their next menses.
16342562|NCT04381403|Experimental|Bio-descaling D-Tart toothpaste|Bio-descaling D -Tart is a bio-descaler toothpaste that is manufactured at Du-Var laboratories (1460 Graham Bell, Boucherville, Québec, Canada J4B 6H5)
16342563|NCT04381403|Active Comparator|Crest®|anti-tartar toothpaste, Complete Whitening plus Scope, tartar control produced by Procter & Gamble, Cincinnati, OH),
16342564|NCT04381390|Experimental|Whole egg consumption|This arm involved whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
16342565|NCT04381390|Experimental|Egg whites consumption|This arm involved egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
16342566|NCT04381377|Experimental|Polyoxidonium|Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
16342567|NCT04381377|Placebo Comparator|Placebo|Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
16342568|NCT04381364|Experimental|Medical treatment|Treatment with ciclesonide
16342569|NCT04381364|No Intervention|Standard of Care|Standard Medical Care
16342570|NCT04381338|Experimental|Rehabilitation in COVID-19 patients in ICU|"Every person admitted to ICU for ARDS with a confirmed diagnosis of COVID-19 Motor program
~Intubated patient GCS >8: passive mobilization; postural positioning GCS< 8: passive and active-assist mobilization; postural positioning
~Extubated patient
~If strength < 3 MRC: passive and/or active-assist; functional retraining
~If strength ≥3 MRC: active-assist and active; strength training; functional retraining Pulmonary Rehabilitation
~Intubated patient GCS >8: postural positioning GCS< 8: postural positioning, cautious inspiratory muscle training
~Extubated patient
~If strength < 3 MRC: postural positioning, positive pressure expiration exercise,inspiratory muscle training
~If strength ≥3 MRC: postural positioning, positive pressure expiration exercise, inspiratory muscle training The intensity of exercise will prescribed based on the results of the PFIT. and modified Borg Scale.
~Frequency of sessions: 3×15 min/day"
16342571|NCT04381338|No Intervention|COVID-19 in ICU without Rehabilitation|Standard of care without rehabilitation in ICU
16342589|NCT04381130|Experimental|EF-009|In both the Phase I and Phase IIa portions of the study, subjects will be evaluated for response every 8 weeks after EF-009 wafer implantation for up to 2 years, by CT, PET/CT or MRI (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be assessed based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST v1.1). The total study duration for each subject consists of screening, treatment, and extended follow-up period and survival follow-up period.
16342572|NCT04381325|Experimental|MSB0254 Injection|This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration. An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
16342575|NCT04381260||2016-2019 STEMI Registry|Retrospective data will be collected to develop a well-characterized registry of patients treated from 2016-2019 by any of 14 local rural EMS agencies and transported to a facility capable of performing Percutaneous Coronary Intervention. This registry will be used to determine the time to PCI performance for each of the EMS agencies. Time will be adjusted for patient distance from a PCI center using a linear mixed model with a random effect for center and a fixed effect for distance. This process will allow qualitative methods to identify organizational culture, structure, and clinical processes that impact STEMI care from the two highest and lowest performing rural EMS agencies. (n=750)
16342576|NCT04381260||Key Informant Interviews|After identifying the two highest and lowest performing rural EMS agencies in the 2016-2019 STEMI Registry, key employees from each of those agencies will be recruited to participate in semi-structured key informant interviews. The interviews will assess current clinical care, organizational culture and opportunities for improvement. (n=32)
16342577|NCT04381260||Stakeholder Surveys|Employees at all local EMS agencies will be invited to participate in stakeholder surveys to quantify each agency's use of the care strategies identified during Key Information Interviews. (n=240)
16342578|NCT04381234|Experimental|ATA plus citrate|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan) in combination with citrate (1 mM) containing dialysate
16342579|NCT04381234|Active Comparator|ATA plus predilution hemodiafiltration|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan), in combination with high volume predilution hemodiafiltration
16342580|NCT04381208||Sacroiliac joint pain|Patients diagnosed with sacroiliac joint pain on the basis of history, physical examination and diagnostic sacroiliac joint block
16342581|NCT04381208||Lumbar pain|Patients diagnosed with other chronic lumbar pathologies on the basis of history, physical examination and radiographic studies
16342582|NCT04381195||Aim 1|"Item Drafting and Revising (Aim 1). Together with a stakeholder panel of adults with ASD and parents/caregivers, the study investigators will generate an item pool based on the conceptual model. The measure will utilize the capability scale response options from the PROMIS preferred response sets (4 = without any difficulty, 3 = with a little difficulty, 2 = with some difficulty, 1 = with much difficulty, 0 = unable to do). To increase the reliability of ratings, a visual response scale with objective benchmarks and anchors will be developed for each response option.
~Cognitive Interviews (Aim 1). A battery of assessments will be completed to describe the sample. The investigators will monitor these results to ensure that the sample is representative of the range of functioning in ASD, and will enrich the sample as needed. The assessment battery will be the same as the battery for the calibration sample (see battery in Aim 2)."
16342583|NCT04381195||Aim 2|"Item Calibration (Aim 2). Measures will be completed online. To be conscious of participant burden, the minimum needed measures were selected to describe the sample, enable differential item functioning (DIF) analyses, and support IRT co-calibration.
~The battery will include:
~measures to characterize the sample (demographics, medical/psychiatric history, treatment and education, history, employment, parent- and self-reported IQ/verbal ability, 2) the online version of the Wide Range Achievement Test- Reading;
~measures related to functional outcomes for IRT co-calibration (Vineland Scale of Adaptive Behavior -3; Wisconsin Activities of Daily Living, Specific Levels of Functioning Scale, PROMIS Social Participation, PROMIS Emotional Support, World Health Organization Quality of Life); and
~symptom measures (Emotion Dysregulation Inventory, Adult Behavior Checklist/Adult Self-Report of psychiatric symptoms, and Social Responsiveness Scale - 2 of ASD symptoms)."
16342584|NCT04381182|Other|Biostrap/Apollo Device Use|Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.
16342585|NCT04381169|Experimental|Aggressive fluid resuscitation|"Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h.
~At 12(±4) hours:
~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped
~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours
~Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours"
16342586|NCT04381169|Experimental|Moderate fluid resuscitation|"At recruitment:
~A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h.
~B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus).
~At 12(±4) hours:
~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped
~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours
~Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours"
16342621|NCT04380883|Active Comparator|TRB alone|
16342622|NCT04380870||Chinese Herbal Medicine|Chinese Herbal Medicine for suspected COVID-19 symptoms.
16342623|NCT04380857|Experimental|Dexamethazone ophthalmic insert 0.4 mg|Dexamethazone ophthalmic insert 0.4 mg
16342624|NCT04380857|Experimental|topical prednisolone acetate ophthalmic drops|topical prednisolone acetate ophthalmic drops
16342590|NCT04381117||No Treatment|Subjects who participated in and completed study EN3835-201 and had composite improvement of at least 2-levels on both the Clinician Reported-Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported-Photonumeric Cellulite Severity Scale (PR-PCSS) in EN3835-201 study will be eligible for this study. The study will consist of a single day evaluation approximately 4 years after the first dose of the study drug was received in the EN3835-201 study.
16342591|NCT04381104|Active Comparator|Paracetamol|Capsule Paracetamol 1000 mg 1 hour before the mammography procedure
16342592|NCT04381104|Placebo Comparator|Placebo|The control arm will receive 2 capsules of placebo.
16342593|NCT04381078|Experimental|Intervention|Standardised Verbal Instructions Standardised Written Instructions Audiovisual Guide
16342594|NCT04381078|No Intervention|Control|Standardised Verbal Instructions Standardised Written Instructions
16342595|NCT04381065|Experimental|PKG+ Group|For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is in the target range or out of the target range based on scores provided by the PKG.
16342596|NCT04381065|Placebo Comparator|PKG- Group|For subjects in the PKG- Group, participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
16342597|NCT04381052|Experimental|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
16342598|NCT04381052|Placebo Comparator|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
16342600|NCT04381026|Placebo Comparator|Placebo Group|Pill of 500 mg containing filler agent, two pills daily for eight weeks.
16342601|NCT04381026|Experimental|Treatment Group with botanical extracts|Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.
16342602|NCT04381013|Experimental|Phase 1: Routine surgery|As part of routine cardio-thoracic surgery, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 1 minute.
16342603|NCT04381013|Experimental|Phase 2: ECHO treatment|During care with Extracorporeal Membrane Oxygenation (ECMO) for non-SARS-CoV-2, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 24 hours.
16342604|NCT04381013|Experimental|Phase 3: COVID-19 treatment|Endotracheal tubes split from ventilator delivering oxygen independently to two patients with COVID-19 disease for up to 1 hour.
16342605|NCT04381000|No Intervention|Control Group|The control group will not participate in any exercise program.
16342606|NCT04381000|Experimental|Intervention|The intervention group will participate in an exercise program for 6 weeks/ 2 sessions per week, for a total of 12 sessions of 30-45 minutes each.
16342607|NCT04380987||Predicovid|
16342608|NCT04380974|Experimental|OCTA plus OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization, OCTA and OCT in the extension treatment period.
16342609|NCT04380974|Active Comparator|OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization and OCT in the extension treatment period.
16342610|NCT04380961|Experimental|Sirukumab|Participants will receive single intravenously (IV) dose infusion of sirukumab on Day 1 along with standard of care treatment.
16342611|NCT04380961|Placebo Comparator|Placebo|Participants will receive IV single dose infusion of placebo on Day 1 along with standard of care treatment.
16342612|NCT04380935|Experimental|convalescent plasma and standard of care|
16342613|NCT04380935|Active Comparator|standard of care|
16342614|NCT04380922||Active IBD|"Active Inflammatory Bowel Diseases defined as :
~For Crohn's disease :
~Harvey Bradshaw Index ≥ 4
~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis
~Partial Mayo score ≥ 2
~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months"
16342615|NCT04380922||Non-active IBD|Non-active Inflammatory Bowel Diseases
16342616|NCT04380909|Experimental|Internet-based self-help|The self-help program consists of six text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
16342617|NCT04380909|Other|Waiting control group|Access to internet-based intervention after 3 weeks.
16342618|NCT04380896||SARS-CoV-2 Seropositive Cases|"It will be formed of approximately N= 200 to 350 staff members
~Core Group of PCR Confirmed Cases N ~ 150 to 250:
~A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N ~ 150 to 250 OR
~Other SARS-CoV-2 Sero-positives N ~ 50 to 100:
~B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases"
16342619|NCT04380896||SARS-CoV-2 Seronegative Comparison Group|"It will be formed of approximately N= 800 to 900 staff members
~Core Comparison Group N ~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR
~Other Seronegatives N ~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days"
16342620|NCT04380883|Experimental|InnoSEAL+TRB|InnoSEAL is a hemostatic patch which will be applied along with TRB to control bleeding from access site
16342625|NCT04380844|Active Comparator|Beprevent|10 will become part of the intervention group. Each of the participants in the intervention group is selected. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
16342626|NCT04380844|No Intervention|patients only evaluated|10 will be included in the control group. During the period of the study, we will pass the same questionnaires in the participants assigned to the control group, also leaving a time interval of two weeks, and no device will be installed, nor will any monitoring be carried out in their homes.
16342627|NCT04380831|Experimental|Treatment (TBI using IMRT, cyclophosphamide, HSCT)|Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.
16342628|NCT04380818|Active Comparator|Control group|a control group only receive pharmacological treatment
16342629|NCT04380818|Experimental|Experimental group|an experimental group will receive low-dose lung irradiation
16342630|NCT04380805|Experimental|AK104|AK104 monotherapy
16342631|NCT04380766||Pre-COVID|All patients with pancreatic cancer diagnosis before COVID-19 pandemic
16342632|NCT04380766||COVID|All patients with pancreatic cancer diagnosis during COVID-19 pandemic
16342633|NCT04380753|Experimental|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
16342634|NCT04380740|Placebo Comparator|Standard GVHD Prophylaxis + Abatacept + Placebo|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
16342635|NCT04380740|Experimental|Standard GVHD Prophylaxis + Abatacept Extended dosing|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
16342636|NCT04380727||Almitrine|Administration of 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France), over 30-45 min followed by 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered. Some patients may receive the drug for 36 hours depending on availability..
16342637|NCT04380727||Control|To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were matched to control COVID-19 patients treated without almitrine (time control).
16342638|NCT04380701|Experimental|BNT162a1 (P/B) - Part A 18-55 years of age|Escalating dose levels
16342639|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 18-55 years of age|Escalating dose levels
16342640|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-55 years of age|Escalating dose levels
16342641|NCT04380701|Experimental|BNT162c2 (P/B) - Part A 18-55 years of age|Escalating dose levels
16342642|NCT04380701|Experimental|BNT162c2 (prime only) - Part A 18-55 years of age|Single dose
16342643|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 56-85 years of age|Escalating dose levels
16342644|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 56-85 years of age|Escalating dose levels
16342645|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohorts 11 to 13)|Escalating dose levels
16342646|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohort 14)|Biomarker (B cell and plasma cell immunity)
16342647|NCT04380688|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
16342648|NCT04380688|No Intervention|Arm 2|Best Supportive Care
16342649|NCT04380675|Active Comparator|Music during ESWL|Patients listen to music during ESWL
16342650|NCT04380675|No Intervention|ESWL without music|Patients don't listen to music during ESWL
16342651|NCT04380662||COVID+ patients WITH worsening of the disease|COVID+ patients WITH worsening of the disease (case group)
16342652|NCT04380662||COVID+ patients WITHOUT worsening of the disease|COVID+ patients WITHOUT worsening of the disease (control group)
16342653|NCT04380649|Experimental|ALS people with severe disability|
16342657|NCT04380623|Experimental|Mobile Phone-Based Web-Page: HPV vaccine|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit, tailored education information on the HPV vaccine via a text message with a website link.
16342658|NCT04380623|Active Comparator|Mobile Phone-Based Web-Page: Healthy Lifestyles|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit education information on an unrelated topic (e.g., healthy eating and physical activity) via a text message with a website link.
16342659|NCT04380610||Pediatric SCA|We will develop a novel eGFR equation in 200 pediatric participants
16342660|NCT04380610||Adult SCA|We will develop a novel eGFR equation in 200 adult participants
16342661|NCT04380597||Patients with nail psoriasis|Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
16342662|NCT04380584||I|30 patients with type 2 DM with nephropathy
16342663|NCT04380584||II|30 type 2 DM without nephropathy
16342664|NCT04380584||III|30 non DM as control group
16342727|NCT04380090|Experimental|Drug: Propylene Glycol|One standard dose (17 grams) of propylene glycol by mouth on postoperative day one
16342728|NCT04380077|Experimental|SF6|
16342729|NCT04380077|Active Comparator|Fluid|
16342665|NCT04380571|Experimental|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
16342666|NCT04380571|Experimental|Electrical Stimulation|Bilateral (TPTNS); was applied with an electrode above the medial malleolus A second electrode) was applied just below the same malleolus. Electrical stimulation with a low-frequency current (10 Hz), and adjustable intensity. The procedure was done for 20-30 minutes, three times per week for 3 months together with the conventional maneuvers applied in the control group.
16342667|NCT04380571|Active Comparator|Control group|were managed by conventional methods through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
16342668|NCT04380558||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.
~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
16342669|NCT04380545|Experimental|Treatment (fluorouracil, interferon alpha 2b, nivolumab)|Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16342670|NCT04380532|Experimental|V-SARS recipients|Single arm having at least 20 volunteers administered once-per-day pill of V-SARS
16342671|NCT04380519|Experimental|RPH -104 80 mg|Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
16342672|NCT04380519|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
16342673|NCT04380519|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
16342674|NCT04380506|Experimental|Drain removal|Patients that fulfill criteria for surgical drains removal
16342675|NCT04380480|Experimental|Experiment|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.
~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
16342676|NCT04380467|Experimental|Vitamin D Group|Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.
16342677|NCT04380467|No Intervention|Control|No vitamin D given
16342678|NCT04380454|Experimental|Fast treadmill walking with functional electrical stimulation|Fast treadmill walking with functional electrical stimulation (FastFES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. FES is delivered only to the paretic ankle muscles, enhancing afferent ascending as well as descending corticomotor drive. Increased corticomotor drive in lesioned corticomotor circuits in turn promotes improved timing and intensity of muscle activation in the paretic plantar- and dorsi-flexor muscles, increasing plantarflexor moment and propulsion from the paretic ankle.
16342679|NCT04380454|Active Comparator|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention that provides similar structure, dose, and intensity of stepping practice as FastFES, but does not include FES, and no specific instructions are provided to target practice to the paretic leg or specific ankle deficits
16342680|NCT04380428||Cross section of the student body.|Matriculated students at Portuguese medical and dental faculties.
16342681|NCT04380415|Active Comparator|Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist. ECG will be collected from a single lead ambulatory ECG patch worn on the chest. The data from both the commercial wrist-worn device and the ECG patch are not analyzed real-time.
16342682|NCT04380415|No Intervention|Non Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist.
16342683|NCT04380402|Experimental|Treatment|40 mg
16342684|NCT04380402|No Intervention|Control|Standard care
16342685|NCT04380389|Other|profound hypoxia|
16342686|NCT04380376|Experimental|Melphalan inhalations|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 7-10 consequent days
16342687|NCT04380376|Other|Standard of care group|Patients assigned to the standard of care group will not receive any additional therapy.
16342688|NCT04380363|Experimental|Honda Walk Assist (HWA) Group|Participants utilize HWA device at home for 2 months according to prescribed settings.
16342689|NCT04380363|Active Comparator|Control Group|Participants complete prescribed exercise program at the Shirley Ryan AbilityLab gym for 2 months.
16342690|NCT04380337|Experimental|Radiation/FOLFOXIRI|Treatment will comprise 6 daily fractions of radiotherapy at 5 Gy per fraction followed by 4 months of FOLFOXIRI. Patients who have performance status or conditions that may preclude use of FOLFOXIRI may be treated with FOLFOX or XELOX. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard of care total mesorectal excision (TME).
16342691|NCT04380324|Experimental|LY3471851|Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
16342692|NCT04380324|Placebo Comparator|Placebo|Healthy participants in each cohort will receive the placebo comparator.
16342730|NCT04380064|Experimental|Study Group|Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment
16342693|NCT04380311|Experimental|Precision Tacrolimus|Participants in this arm of the study will have their tacrolimus dose determined using a precision medicine decision support software tool. The participant's transplant physician will consider the recommended dose from the decision support tool in combination with the physician's expertise and experience to determine the proper tacrolimus dose for the participant.
16342694|NCT04380298|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
16342695|NCT04380298|Active Comparator|The control group|In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
16342696|NCT04380285|Active Comparator|Group 1. Custom heel pads and modified soft molded orthotics|Modified soft custom orthotics supported in the medial longitudinal arches and medial shock absorbing heel pads with customized cutout at the point corresponding to the heel pain
16342697|NCT04380285|Active Comparator|Group 2. Custom hard orthotics|Custom hard orthotics made from a positive mold of a foot in neutral position, with arch support and medial heel postings.
16342698|NCT04380272||Brodsky tonsil staging system|An oropharynx examination of all participants will be performed and tonsil size will be evaluated according to the Brodsky staging system. According to this staging system, tonsil sizes will be classified as stage I when the tonsils fill less than 25% of the transverse oropharyngeal space measured between the anterior tonsillar pillars; stage II when they fill between 25% and 50%, stage III when they fill between 50% and 75%, and stage IV when they fill more than 75%.
16342699|NCT04380272||The ultrasonographic data|The submental ultrasonography will be performed on all participants. Ultrasonographic examinations will be performed blinded to the physical examination results. All measurements will be performed by the same radiologist with experience in the field of ultrasonography. A GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) device will be used in the ultrasonography examination. The participants will be viewed using a 2-9 MHz linear probe from the submental region. The examination will be performed while the patient was lying in a supine position with a support placed under the neck.
16342700|NCT04380259|Experimental|MBTR-R (Mindfulness-Based Trauma Recovery for Refugees)|Mindfulness-based group intervention consisting of nine 2.5-hour weekly sessions.
16342701|NCT04380259|No Intervention|Waitlist-Control|Following the 9-week waitlist period and 1-week post-intervention assessment, participants randomized to waitlist-control were offered an equivalent group intervention (i.e., 22.5 total hours, group instructor and cultural mediator, psychoeducation and low-intensity cognitive behavior therapy skill training, relaxation techniques).
16342702|NCT04380246||Clinicians|"Clinicians who care for pediatric patients >50% of their time, who treat pediatric patients who are in acute pain and between 0 and 3 years of age. May include physicians, clinical pharmacists, nurse practitioners, physician assistants, and/or nurses.
~This cohort will complete a qualitative interview about pain and distress in infants and young children."
16342703|NCT04380233|Experimental|Investigational Drug Group|A 8-weeks double-blind treatment period with a Proprietary Chinese Medicine (consists of 4 kinds of Chinese herbs at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
16342704|NCT04380233|Placebo Comparator|Placebo Group|A 8-weeks double-blind treatment period with Placebo Capsules (at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
16342705|NCT04380220||Relapsing MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.
16342706|NCT04380220||Remitting MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.
16342707|NCT04380220||Healthy controls|Age- and sex-matched healthy control subjects.
16342708|NCT04380207|Experimental|QPX7728|antibiotic
16342709|NCT04380207|Placebo Comparator|Placebo|Matched placebo
16342710|NCT04380207|Experimental|QPX2014|antibiotic
16342711|NCT04380194||victims|thirteen patients affected by lightning in collective fulguration
16342712|NCT04380194||healthy witnesses|fourteen healthy witnesses who have never been in contact with lightning, matched on age and sex
16342713|NCT04380181||Dobutamine|Weaning from cardiopulmonary bypass using dobutamine as inotrope.
16342714|NCT04380181||Milrinone-epinephrine|Weaning from cardiopulmonary bypass using milrinone and epinephrine as inotropes.
16342715|NCT04380168|Active Comparator|Modified pec 11 trunk block using ketamine additive|Ultasound guided modified pec 11 trunk block using ketamie hydrochoride 1mg/kg in 2ml volume added to 30ml bupivacaine 0.25% for trunk analgesia
16342716|NCT04380168|Active Comparator|Modified pec 11trunk block using dexmedetomidine additive|Ultasound guided modified pec 11 trunk block using dexmedetomidine 1ug/kg in 2ml volume added to 30ml bupivacaine 0.25%
16342717|NCT04380168|Active Comparator|Modified pec 11trunk block without additive|Ultasound guided modified pec 11 trunk block using bupivacaine 0.25% added to 2ml saline
16342718|NCT04380155|Experimental|Participants|All participants will perform three moderate intensity cycling trials of different duration (30, 60 and 120 min) in an energy replete state.
16342719|NCT04380142|Experimental|ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks
16342720|NCT04380142|Active Comparator|Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951|Participants will receive oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks
16342721|NCT04380129|Experimental|Μusic therapy-conversation sessions|
16342722|NCT04380129|Active Comparator|Discussion sessions|
16342723|NCT04380116|Experimental|Sb+Aware|Patients will access to the Soberlink device and receive treatment with Aware Recovery Care
16342724|NCT04380116|No Intervention|Aware|Patients will only have access to Aware Recovery Care
16342725|NCT04380103|Experimental|XELOXIRI/Bevacizumab|drugs: Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7, administered every 2 week for 12 cycles, after 12 cycles, administer bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy.
16342726|NCT04380090|Active Comparator|Drug: Docusate Sodium|Docusate sodium one pill to be taken twice a day by mouth for 28 days
16342731|NCT04380064|Active Comparator|Control Group|Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
16342732|NCT04380051|Experimental|Arm 1 : skin-to-skin contact associated with a sensory-tonic s|skin-to-skin contact left free for parents associated with a sensory-tonic stimulation five times a week during 15 minutes at each time
16342733|NCT04380051|Active Comparator|Arm 2 : skin-to-skin contact only|skin-to-skin contact left free for parents
16342736|NCT04380025|Experimental|Mirtogenol|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) the experimental group will also take Mirtogenol. Mirtogenol is a dietary supplement composed of bilberry and pycnogenol which are botanical compounds with antioxidant properties. The active components of bilberry are flavonoid anthocyanosides (anthocyanins). Anthocyanosides are the only flavonoids able to reach the eye as a target organ in experimental animals. Unchanged anthocyanosides demonstrated after oral administration that it is absorbed and distributed into ocular tissues, showing its ability to pass through the blood-aqueous and blood retinal barriers.6
16342737|NCT04380025|Placebo Comparator|Lactose based Placebo|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) this control group will also take an identical placebo. This placebo is a inactive lactose based product of the same color and size capsule.
16342738|NCT04380012|Experimental|Single drug group|Pyrotinib: 400 mg, po, qd, 21d for a treatment cycle
16342739|NCT04380012|Experimental|Dual-targeted drug group|Pyrotinib: 400 mg, po, qd, 21d for one treatment cycle; Trastuzumab: first dose 8 mg/kg, then 6 mg/kg, iv, q3w, 21d for one treatment cycle
16342740|NCT04379999|Active Comparator|Atorvastatin|Atorvastatin (LIPITOR) 20 milligram tablet daily for 6 weeks
16342741|NCT04379999|Active Comparator|Atorvastatin and Aspirin|Atorvastatin (LIPITOR) 20 milligram tablet and Aspirin 325 mg tablet daily for 6 weeks
16342744|NCT04379973|Experimental|Tubal flush with Lipiodol Ultra Fluide® after Hyfosy|
16342745|NCT04379973|No Intervention|No tubal flush after Hyfosy|
16342746|NCT04379960||Peptides|PBMCs will be incubated with peptides.
16342747|NCT04379960||W/o peptides|PBMCs will be incubated without peptides.
16342748|NCT04379947||FFR-CABG|Patients with at least one intermediate stenosis that received a preoperative FFR evaluation before being referred for CABG
16342749|NCT04379947||Angio-CABG|Patients with at least one intermediate stenosis that did not received a preoperative FFR evaluation before being referred for CABG
16342750|NCT04379934|Other|Heart failure|Ejection fraction < 45%
16342751|NCT04379934|Other|Non-heart failure|Ejection fraction > 45%
16342752|NCT04379921|No Intervention|Control|Participants will receive standard care.
16342753|NCT04379921|Experimental|Apple Watch and App|Participants will receive standard care, and an Apple Watch to record activity through the App.
16342754|NCT04379895|Active Comparator|Heated RF ablation|Patients with OA that will undergo heated RF of the genicular nerves
16342755|NCT04379895|Active Comparator|Pulsed RF ablation|Patients with OA that will undergo pulsed RF of the genicular nerves
16342756|NCT04379882|Experimental|Digital sedation|30 minutes Silva module
16342757|NCT04379869|Experimental|NNZ-2591 Single dose Cohort 1|Single dose of oral NNZ-2591 in healthy volunteers
16342758|NCT04379869|Experimental|NNZ-2591 Single dose Cohort 2|Single dose of oral NNZ-2591 in healthy volunteers
16342759|NCT04379869|Experimental|NNZ-2591 MAD Cohort 1|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
16342760|NCT04379869|Experimental|NNZ-2591 MAD Cohort 2|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
16342761|NCT04379856|Experimental|Dose 1|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
16342762|NCT04379856|Experimental|Dose 2|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
16342763|NCT04379856|Experimental|Dose 3|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
16342764|NCT04379830|Experimental|Very Low Energy Diet|VLED in its entirety is composed of the following for 3-weeks preoperatively: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
16342804|NCT04379583||Subjects|Female subjects providing DNA saliva sample
16342765|NCT04379804|Active Comparator|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery. The tissue between the carotid artery and the trachea was dissected gently parallel to the direction of the nerve until the nerve is identified visually and,or by hand held stimulation probe. After the identification of RLN, the vessels of inferior thyroid lobe was ligated. The nerve was dissected along its course to the entry point, and then the thyroid lobe was totally dissected from the trachea and the lobectomy was completed. If adverse EMG changes were encountered during lateral approach, traction was released immediately and waited for recovery.
16342766|NCT04379804|Active Comparator|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN nerve was identified at the point of entry both visually and with hand held stimulation probe. The RLN dissection was proceeded craniocaudally by the division of the suspensory ligaments of the berry through the level of inferior thyroid artery. After the identification and visualitzation of the RLN through its whole course, the medial and inferior vessels of the thyroid gland were dissected and ligated. Then, the lobe was dissected from the trachea and lobectomy was completed.
16342767|NCT04379791||case cohort|Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
16342768|NCT04379791||control cohort|Patients without a surgical site infection or a wound complication (normal wound-healing and suture or staple removal) after surgical treatment of an ankle fracture.
16342769|NCT04379778|Experimental|Aerobic exercise|Moderate to high intensity aerobic exercise for 24 weeks.
16342770|NCT04379778|No Intervention|Standard care|Habitual lifestyle including standard care.
16342771|NCT04379765||Grup 1: Exercise and physical therapy programme|30 patients with lumbar spinal stenosis will receive hot pack, transcutaneous electrical nerve stimulation and deep warming as a physical therapy modality , and lumber flexion and strengthening exercises were performed for 7 times/week for 3 weeks.
16342772|NCT04379765||Grup 2: Surgical procedure programme|30 patients with lumbar spinal stenosis underwent decompression operation of the relevant level.
16342773|NCT04379752|Experimental|Cold-atmospeheric pressure plasma activated solution|Treatment arm subjects receive the trial intervention
16342774|NCT04379739|Experimental|camrelizumab + apatinib|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.
~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.
~Adjuvant treatment stage: according to the NCCN guidelines."
16342775|NCT04379739|Experimental|camrelizumab + platinum-based chemotherapy|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.
~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.
~Adjuvant treatment stage: according to the NCCN guidelines."
16342776|NCT04379726||patients with CFRD|Patients with diagnosis of CFRD, after OGTT
16342777|NCT04379726||patients without CFRD|Patients without diagnosis of CFRD, after OGTT
16342778|NCT04379713|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
16342779|NCT04379713|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
16342780|NCT04379700|Experimental|Embolization Group|23 participants who are aged between 30 to 75 years old, with grade 2 or 3 knee OA on the most recent knee radiographs obtained within 6 months of intervention. Each individual participant will be enrolled for approximately 13 months to complete all study visits from the initial screening visit to last follow up at 12-months post intervention.
16342781|NCT04379687|Experimental|Virtual reality|"st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control. 15 minutes
~nd part: Experimental training program for static and dynamic balance in sitting and standing by immersive Virtual Reality. 15 minutes"
16342782|NCT04379687|Active Comparator|Control group|"st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control.15 minutes
~nd part: Training program for static and dynamic balance in sitting and standing, according to Bayouk. 15 minutes"
16342783|NCT04379674|Experimental|Grup 1- Facilitation|It consists of cases that start with the taping of the facilitation.
16342784|NCT04379674|Experimental|Grup 2- İnhibition|It consists of cases that start with the taping of the inhibition.
16342785|NCT04379674|Placebo Comparator|Grup 3- Plasebo|It consists of cases that start with the taping of the placebo.
16342786|NCT04379661|Experimental|Online support group|Online weekly 1-hour moderated support group sessions for 12-weeks; participants complete surveys at baseline and 12-week follow-up
16342787|NCT04379661|No Intervention|Treatment as usual|Inactive control group of participants who complete surveys at baseline and 12-weeks later
16342788|NCT04379648|Other|Posttraumatic stress disorder|cohort of patients with Posttraumatic stress disorder PTSD
16342789|NCT04379635|Experimental|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab|Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium on Day 1 of each cycle for up to a total of 12 cycles
16342790|NCT04379635|Placebo Comparator|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo|Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium on Day 1 of each cycle for up to a total of 12 cycles
16342791|NCT04379609||Employees and students|The control group was selected from among the employees and students of the faculty of dentistry to represent the general population without any temporomandibular disorder (TMD).
16342792|NCT04379609||Patients|Patients who were referred to the Ondokuz Mayıs University Faculty of Dentistry Department of Prosthodontics with a complaint of pain in the chewing muscles were enrolled in this study.
16342805|NCT04379570|Experimental|Arm I (TMR)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
16342806|NCT04379570|Experimental|Arm II (MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
16342807|NCT04379570|Experimental|Arm III (TMR + MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
16342808|NCT04379570|Active Comparator|Arm IV (enhanced usual care)|Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
16342809|NCT04379557|Experimental|High power ablation|Ablation Index guided high power ablation (radio frequency energy: Left atrium anterior segment and roof: 40W, Left atrium inferior/posterior: 30W, near esophagus: 25W)
16342810|NCT04379557|Active Comparator|Conventional ablation|Conventional ablation applying 30-35W strategy for Left atrium anterior segments.
16342811|NCT04379544||COVID-19 Positive Patients Receiving CPUS|Adult patients (18 years) presenting to the ED or ICU with highly suspected diagnosis or confirmed diagnosis of COVID-19 in whom the clinician deems a CPUS (cardiopulmonary ultrasound) is indicated.
16342812|NCT04379531|Active Comparator|Standard Chest CT|
16342813|NCT04379531|Experimental|Low-dose Chest CT|
16342814|NCT04379518|Experimental|Arm I (rintatolimod, recombinant interferon alfa-2b)|Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 (or 4) in the absence of disease progression or unacceptable toxicity.
16342815|NCT04379518|Active Comparator|Arm II/IV (standard of care)|Patients receive standard of care.
16342816|NCT04379518|Experimental|Arm III (rintatolimod)|Patients receive rintatolimod IV over 2.5-3 hours once.
16342817|NCT04379505|Experimental|Quad shot radiation|-Radiotherapy will consist of Quad shot radiation delivered on the Ethos ring gantry kV-CBCT combined with linear accelerator system to a dose of 14 Gy in four, twice-daily fractions of 3.5 Gy delivered at least 6 hours apart over two days for a possible total of 3 cycles delivered in 3 to 4 intervals for a cumulative dose of of 42 Gy in 12 fractions. Cycle 2 and 3 of treatment is not mandated per protocol but may be given at the discretion of the treating physician.
16342818|NCT04379492|Experimental|Arm A - hydroxycholoroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
16342819|NCT04379492|Placebo Comparator|Arm B - placebo|Participants will receive placebo
16342820|NCT04379479|Experimental|Dialyzable Leukocyte Extract|"Oral administration 2 mg/5 mL every 24 hours for 14 days, following by 2 mg/5 mL twice a week for 3 weeks.
~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
16342821|NCT04379479|Placebo Comparator|Placebo|"Oral administration 5 mL every 24 hours for 14 days, following by 5 mL twice a week for 3 weeks.
~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
16342822|NCT04379453|Experimental|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
16342823|NCT04379440||" Acute Ward Patients  care setting cohort"|Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
16342824|NCT04379440||" Nursing Homes (RSA)  care setting cohort"|Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
16342825|NCT04379440||" Home and Outpatients' Care  cohort"|Outpatients at risk of SARS-CoV-2 infection
16342826|NCT04379440||" Dementia Outpatients  cohort"|Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
16342827|NCT04379440||" At home  cohort"|Outpatients at risk of SARS-CoV-2 infection
16342828|NCT04379440||" Outcomes  cohort"|Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
16342829|NCT04379427|Experimental|Optimization and control 1|The first study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
16342830|NCT04379427|Experimental|Optimization and control 2|The second study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
16342831|NCT04379427|Other|Precision and accuracy|During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.
16342832|NCT04379414|Experimental|Newly Diagnosed Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
16342854|NCT04379219|Active Comparator|methotrexate before surgery|"Valid consent
~patient will receive 50 mgm /m2 of methtrexate after full investigation ( CBC, serum creatinie, AlT, AST), 1 week before surgery.
~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )
~Laparotomy transverse incision (pfannenstiel incision)
~Exploration of the abdominal cavity
~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.
~Surgical repair of the uterine incision, and the abdomen"
16342833|NCT04379414|Experimental|Newly Diagnosed Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
16342834|NCT04379414|Experimental|Metastatic Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
16342835|NCT04379414|Experimental|Metastatic Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
16342836|NCT04379401|Other|Biventricular Pacing deactivated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
16342837|NCT04379401|Other|Biventricular Pacing activated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
16342838|NCT04379388|Experimental|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
16342839|NCT04379388|No Intervention|Usual care control|Participants will receive referral to a quit smoking hotline
16342840|NCT04379375|Active Comparator|Inertia|"Participants simply receive and subsequently have default access (i.e., readily and immediately available) to handwashing (HW) materials. This condition will functionally serve as a control comparison. As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment."
16342841|NCT04379375|Experimental|Anchoring|"Involves once again providing default access to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser. The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that overshoots a desired target rate of 10+ daily HWs."
16342842|NCT04379362|Experimental|Low or intermediate grade prostate cancer|
16342843|NCT04379349|Experimental|Active SMS|Weekly interactive SMS text messaging check-ins.
16342844|NCT04379349|Sham Comparator|Sham SMS|Weekly minimally interactive SMS text messages.
16342845|NCT04379336|Experimental|Bacille Calmette-Guérin (BCG)|Participants will receive an intradermal injection of 0.1ml of the suspended BCG vaccine which accounts for 0.075mg of attenuated Mycobacterium bovis. BCG-Vaccin SSI [Statens Serum Institut], Danish strain 1331.
16342846|NCT04379336|Placebo Comparator|Placebo|The placebo used for this study is 0.9% Sodium Chloride (NaCl). Participants that are randomized to the control arm will receive a placebo injection of 0.1ml 0.9% NaCl, which is the same volume and has the same colour as the suspended BCG vaccine.
16342847|NCT04379323|Experimental|YuWell YE900 and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE900 Electronic Sphygmomanometer (YuWell YE900) and with Desk Mercury Sphygmomanometer.
16342848|NCT04379310||covid-19 pneumonia|diagnosed with covid-19 by using PCR and computed tomography scans
16342851|NCT04379271|Experimental|IMU-838|twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
16342852|NCT04379271|Placebo Comparator|Placebo|twice-daily (BID) oral placebo (+ SoC)
16342853|NCT04379219|Active Comparator|surgery|"Valid consent
~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )
~Laparotomy transverse incision (pfannenstiel incision)
~Exploration of the abdominal cavity
~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.
~Surgical repair of the uterine incision, and the abdomen"
16342855|NCT04379206||Men who have sex with men|MSM receiving a self-test kit with optional assistance
16342887|NCT04378933|Experimental|Amber Glasses and Fixed Wake|Participants will wear glasses with amber lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will also be required to wake up at the same time (±30 mins).
16342856|NCT04379193|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
16342857|NCT04379193|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
16342858|NCT04379180||Treatment(bosentan, sildenafil and tadalafil)|
16342859|NCT04379167|Experimental|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma.
16342860|NCT04379154|Experimental|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air in patients hospitalised for COVID-19 infection
16342861|NCT04379141||hypotension|Patients with hypotension after induction of anesthesia
16342862|NCT04379141||non-hypotension|Patients without hypotension after induction of anesthesia
16342863|NCT04379128||patients with epilepsy|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
16342864|NCT04379128||Normal controls|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
16342865|NCT04379115|Active Comparator|Active (tDCS) + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS)
16342866|NCT04379115|Sham Comparator|Sham (tDCS) + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
16342867|NCT04379102||IUD patients|80 patients who matched the inclusion criteria and received IUDs
16342868|NCT04379089||Children <18|"Infants, children, and young adults age < 18 years
~Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)"
16342869|NCT04379076|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
16342870|NCT04379076|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
16342871|NCT04379063||Canadian physicians during COVID-19 pandemic|Any physician who is practicing in Canada during the COVID-19 pandemic, whether they hold a full, provisional, or post-graduate in-training license.
16342872|NCT04379050|Experimental|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for 96 weeks.
16342873|NCT04379037|Experimental|Intervention Arm|Adults over 18 years of age hospitalized because of COVID-19 infection will be treated with transcutaneous auricular vagus nerve stimulation (taVNS).
16342876|NCT04379011|Experimental|Brivaracetam Group|Participants in this arm will receive the investigational drug, Brivaracetam.
16342877|NCT04379011|Placebo Comparator|Control Group|Participants in this arm will receive a placebo.
16342878|NCT04378998|Experimental|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
16342879|NCT04378998|No Intervention|Usual care|
16342880|NCT04378985|Experimental|Wearing a wearable device (the smart watch) for 8 weeks|The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.
16342881|NCT04378972||TREATED GROUP|25 portions of vitreous samples from 25 eyes of patients operated on vitrectomy for complications from diabetic retinopathy, incubated with curcumin, homotaurine and vitamin D3. The substances will be used individually and in triple association, to evaluate a possible synergistic effect on the expression of inflammatory cytokines and endothelial growth factors.
16342882|NCT04378972||CONTROL GROUP|The same fractions of vitreous samples (n = 25) evaluated for the expression of oxidative biomarkers, inflammatory cytokines and metalloproteinases, without prior incubation with the substances of the treated group.
16342883|NCT04378959|Experimental|Lidocaine patch first|This group will receive up to 3 lidocaine patches for 4 weeks, followed by placebo patches after a 1-3 week washout period.
16342884|NCT04378959|Placebo Comparator|Placebo patch first|This group will receive up to 3 placebo patches for 4 weeks, followed by lidocaine patches after a 1-3 week washout period.
16342885|NCT04378946|Experimental|Experimental - Error Augmented feedback (Restricted area)|Error augmented feedback. Random targets always INSIDE of workspace area.
16342886|NCT04378946|Active Comparator|Control - General feedback (Full area)|General feedback about task success. Random target INSIDE or OUTSIDE of workspace area.
16342888|NCT04378933|Active Comparator|Clear glasses and Free Wake|Participants will wear identically appearing glasses with clear lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will not be given instructions regarding sleep schedule.
16342889|NCT04378920|Experimental|4L6715|exploring various doses of LEAF-4L6715
16342890|NCT04378907|Active Comparator|Cigarette Smokers: 0 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
16342891|NCT04378907|Experimental|Cigarette Smokers: 4 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 6 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
16342892|NCT04378907|Experimental|Cigarette Smokers: 15 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
16342893|NCT04378907|Experimental|Cigarette Smokers: 30 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
16342894|NCT04378894|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
16342895|NCT04378894|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Families in the wait-listed control group will participate in a special awareness program but not MOCEP. Although the families in the wait-listed control group will start as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
16342896|NCT04378868|Active Comparator|Surgery within 8 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
16342897|NCT04378868|Experimental|Surgery within 24 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
16342898|NCT04378868|Experimental|Surgery within 8 hours, antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
16342899|NCT04378868|Experimental|Surgery within 24 hours, antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
16342900|NCT04378829||ambulatory follow-up|
16342901|NCT04378829||hospital follow-up|
16342902|NCT04378829||intensive care unit follow-up|
16342903|NCT04378816|Experimental|QPL intervention group|Using shared decision making support tool(Question Prompt List) for intervention
16342904|NCT04378816|No Intervention|Usual care group|No intervention, just continue using usual care
16342905|NCT04378803|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
16342906|NCT04378803|Experimental|Wait-list control (WLC) group|Receives 4 weeks of no-training interval followed by a testing session. Then, 4 weeks of mindfulness training followed by a testing session.
16342909|NCT04378777||Surveillance cohort|Cohort descriptive data will include demographic variables (e.g. age, sex, race, ethnicity), clinical information on enrollment and key aspects of medical history (e.g. concomitant medications, for example). Patients will be longitudinally followed, up to 12 months.
16342912|NCT04378738|Other|Cohort|the healthy people who accepted to participate in the study
16342913|NCT04378725|No Intervention|Control School|"When a student is screened as a smoker. The student will only be receiving Brief Intervention Advice from the dentist.
~Brief Intervention advice: delivered to all schoolchildren regardless of smoking status by the dentist. Brief information of dangers of smoking was embedded in the generic lecture of Dental Health Education given to the whole school in large group."
16342914|NCT04378725|Experimental|Intervention School|The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
16342915|NCT04378712|Experimental|Intervention Group|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
16342916|NCT04378712|Other|Control Group|Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.
16342917|NCT04378699|Experimental|SMR Sensory Motor Rhythm (12-15 Hz)|3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
16342990|NCT04378166|No Intervention|Control|Conventional ultrasound-guided central venous catheterization
16342918|NCT04378699|Experimental|the alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
16342919|NCT04378686||ESKD|Patients with ESKD and on treatment with any form of dialysis
16342920|NCT04378673||parental involvement group|n=46
16342921|NCT04378673||parental presence group|n=42
16342922|NCT04378673||parental absence group|control group, n=32
16342923|NCT04378660|Experimental|Intervention arm|Colonoscopy with AI
16342924|NCT04378647|Active Comparator|Induction ESHAP|3 Cycles ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4]
16342925|NCT04378647|Experimental|Induction BV-ESHAP|3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4] Brentuximab Vedotin [1.8 mg/kg IV, D1]
16342926|NCT04378634|Experimental|ME/CFS Exercise|Patients undergoing the physical stress test (aerobic power index)
16342927|NCT04378634|Experimental|Patients Stress|Patients undergoing the mental stress task (MIST)
16342928|NCT04378634|Active Comparator|Healthy Exercise|Healthy controls undergoing the physical stress test (aerobic power index)
16342929|NCT04378634|Active Comparator|Healthy Stress|Healthy controls undergoing the mental stress task (MIST)
16342930|NCT04378621|Experimental|Pharmacological anti-inflammatory treatment|Use of anti-rheumatic treatment with TNF-α inhibitor (subcutaneous injection given once or twice a week) or JAK inhibitor (per oral tablet once or twice a day)
16342931|NCT04378621|Experimental|Physical hand training|Physical hand training 10 min twice daily while on stable treatment
16342932|NCT04378608|Other|2 DAA (OBV/PTV/r) ± ribavirin (RBV)|Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
16342933|NCT04378595||During Pandemic|During Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. If a positive response is given, the investigators will ask if the food insecurity began or worsened during the pandemic in the past 1 to 2 months.
16342934|NCT04378595||Post-Pandemic|Post-Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. The investigators will assess if food insecurity has stopped or lessened after the pandemic.
16342935|NCT04378582||COVID-19 confirmed|Patients with confirmed COVID-19 by RT-PCR or serological test
16342936|NCT04378582||COVID-19 suspected|Patients suspected COVID-19, as defined by clinical history and course, who have negative RT-PCR or serological test but where treated and cared for as COVID-19 patients
16342937|NCT04378569|Active Comparator|ARQ-252 cream 0.3% QD (once daily)|Active Comparator
16342938|NCT04378569|Active Comparator|ARQ-252 cream 0.3% BID (twice daily)|Active Comparator
16342939|NCT04378569|Active Comparator|ARQ-252 cream 0.1% QD (once daily)|Active Comparator
16342940|NCT04378569|Placebo Comparator|Vehicle cream BID (twice daily)|Placebo Comparator
16342941|NCT04378569|Placebo Comparator|Vehicle cream QD (once daily)|Placebo Comparator
16342942|NCT04378556|Other|Nutrition|All participants received diet coaching, nutrition education and a per-meal protein prescription.
16342943|NCT04378543|Experimental|ART252-L|local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion
16342944|NCT04378530|Experimental|Personalized Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be asked to select a cue to use to remember to meditate.
16342945|NCT04378530|Active Comparator|Study control|Participants in the control group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive non-anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day.
16342946|NCT04378530|Experimental|Fixed Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be given a specific cue (i.e. leaving the bathroom in the morning) to use to remember to meditate.
16342947|NCT04378517|Other|ADHD FAM-SOTC support: A Pilot Study|"Phase-I, a pilot study to evaluate the feasibility of offering a 5-week intervention for families of adolescents diagnosed with ADHD at BUGL. The outcome helps to determining the feasibility of subjecting the intervention to a more rigour and a more expensive and time-consuming RCT.
~Phase-II and III are an RCTs to determine the benefit of a FAM-SOTC intervention: Is there a significant difference in the impact of FAM-SOTC intervention:
~From caregiver's perspective (phase II) on the experience of support for, family functioning, believes, coping patterns, general well-being, parental adaptation and parental assessment of ADHD symptoms and adolescent developmental disruptive behaviour, compared to caregivers receiving delayed treatment?
~From adolescents' perspective (Phase-III) in the assessment of adolescents own self-awareness and self-esteem, after their parents receive FAM-SOTC intervention, compared to a group of adolescents where caregivers receive delayed treatment?"
16342948|NCT04378504||ACS|All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
16342949|NCT04378465||ERP group|A prospective series of consecutive patients undergoing elective colorectal surgery completing a standardized Enhanced Recovery Program (ERP) protocol at the S. Anna University Hospital in Ferrara (Italy) in 2013-2015
16342950|NCT04378465||Non-ERP group|A retrospective series of consecutive patients operated at the same hospital (S. Anna University Hospital in Ferrara), in the same period of time (2013-2015), but with a traditional perioperative care protocol.
16342951|NCT04378452||COM-COVID cohort|Individuals of >16 years old evaluated during the COVID-19 outbreak by an anonymous survey and willing to respond. Expected timeframe for the collection of completed surveys: March 31th, 2020-September 30th, 2020]
16344054|NCT04370769||Women with Kidney Disease|Women with kidney disease
16342954|NCT04378426|Experimental|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50%nitrous oxide and 50% oxygen plus intravenous saline
16342955|NCT04378426|Active Comparator|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
16342956|NCT04378413|Experimental|The Effect of Aquatic Exercises on Pain, quality of life|Water-based exercise program was conducted in the second group of 15 patients in an indoor swimming pool. Temperature of mineral water was 36 °C. The program included warming up by walking forwards, sideways and backwards through the water in the pool; active range of motion of the joints of the lower extremities; stretching lower extremities; strengthening exercises for hips, knees, arms, elbows and wrists; and cooling down (slow walking, squatting and standing).
16342957|NCT04378413|Experimental|The Effect of Land Exercises on Pain, Quality of life|Land-based exercise program included abdominal and back strengthening exercises.
16342958|NCT04378374|Experimental|Baked food made of lentil flour|Food prepared with 100% lentil flour
16342959|NCT04378374|Experimental|Baked food made of lentil flour and wheat flour|Food prepared with a mixture of lentil flour and wheat flour
16342960|NCT04378374|Experimental|Baked food made of wheat flour|Food prepared with 100% wheat flour
16342961|NCT04378374|Experimental|Water|Potable water (energy and carbohydrate-free control)
16342962|NCT04378348|Experimental|Motivational Interview|
16342963|NCT04378348|Experimental|Participatory Group Activity|
16342964|NCT04378348|Placebo Comparator|Control Condition|
16342965|NCT04378335|Experimental|one arm|oral disorder
16342966|NCT04378322|Active Comparator|Nutrition and food purchasing tool + telenutrition|Participants will use an online nutrition and food purchasing tool in addition to telenutrition.
16342967|NCT04378322|Active Comparator|Nutrition and food purchasing tool|Participants will use an online nutrition and food purchasing tool.
16342968|NCT04378322|Active Comparator|Nutrition education tool|Participants will be exposed to an online nutrition education materials.
16342969|NCT04378309|Experimental|ePrep|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
16342970|NCT04378296|Experimental|Teledermatology|The 221 patients who are included in this group will be monitored from the Primary Care centers.
16342971|NCT04378296|No Intervention|Conventional monitoring|The 221 patients included in this group will have to visit the dermatologist at the hospital.
16342972|NCT04378283|Experimental|LET as topical anesthetic for wound repair.|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%) is a topical anesthetic that is routinely used before laceration repair.
16342973|NCT04378283|Active Comparator|EMLA plus infiltration as anesthetic for wound repair.|"EMLA (eutectic mixture of local anesthetics) with subsequent lidocaine infiltration. EMLA is a mixture of lidocaine (2.5%) and prilocaine (2.5%) in a cream base."
16342974|NCT04378270|Experimental|PopSole™ offloading device|This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.
16342975|NCT04378257|Experimental|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform. The sessions will be conducted in the Arabic or English languages.
~Following sessions would focus on psychological first aid based on the following interventional tools:
~Cognitive Behavior Therapy (CBT)
~Acknowledging emotions and normalizing current stress
~Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)
~Behavioral Activation Acceptance and Commitment Therapy (ACT)
~Grounding, Breathing, Acceptance of emotions, and de-fusion"
16342976|NCT04378257|Active Comparator|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice.
16342977|NCT04378244|Experimental|DeltaRex-G|"Escalating doses of DeltaRex-G i.v daily for 7 days as follows:
~Dose Level I: 3-6 patients will receive 1 x 10e11 cfu/dose Dose Level II: 3-6 patients will receive 2 x 10e11 cfu/ dose Dose Level III: 3-6 patients will receive 3 x 10e11 cfu/dose"
16342978|NCT04378231|Experimental|high-dose group|patients take dry suspension of amoxicillin clavulanate potassium 45 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
16342979|NCT04378231|Experimental|standard dose group|patients take dry suspension of amoxicillin clavulanate potassium 30 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
16342980|NCT04378218|Experimental|HIIT Intervention|
16342981|NCT04378205|Experimental|0.014/0.018 NiTi arch wire|0.014-inch NiTi on one side /0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
16342982|NCT04378205|Experimental|0.016/0.018 NiTi arch wire|0.016-inch NiTi on one side / 0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
16342983|NCT04378192|Active Comparator|Face mask ventilation|Use of face mask ventilation technique after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
16342984|NCT04378192|Active Comparator|Laryngeal mask ventilation|Use of laryngeal mask airway LMA for ventilation after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
16342985|NCT04378179||HFpEF|HF patients with preserved ejection fraction (HFpEF)
16342986|NCT04378179||HFrEF|HF patients with reduced ejection fraction (HFrEF)
16342987|NCT04378179||PH|Patients with Pulmonary hypertension (PH)
16342988|NCT04378179||Control|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria.
16342989|NCT04378166|Experimental|Smart glasses|Application of smart glasses for ultrasound-guided central venous catheterization
16342995|NCT04378127|Experimental|educational program + traditional medical care|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
16342996|NCT04378127|No Intervention|traditional medical care|traditional medical care
16342997|NCT04378114|Experimental|Subjects with diabetes wearing Guardian™ Sensor (3). C algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one frequent sample test (FST). C sensor algorithm applied retrospectively to raw sensor data.
16342998|NCT04378114|Experimental|Subjects with diabetes wearing Guardian™ Sensor (3). Zeus algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one FST. Zeus sensor algorithm applied retrospectively to raw sensor data.
16342999|NCT04378101||Anorexia Nervosa Case|Participants in this group have a life-time history of anorexia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
16343000|NCT04378101||Bulimia Nervosa Case|Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
16343001|NCT04378101||Binge-Eating Disorder Case|Participants in this group have a life-time history of binge-eating disorder as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa or bulimia nervosa.
16343002|NCT04378101||Control|Participants in this group have no history of disordered eating behaviors as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
16343003|NCT04378088||Group 1 - experts|"Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).
~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
16343004|NCT04378088||Group 2 - mix experts/trainee|"If intra and interobserver rates in group 1 are >0.7 proceed to group 2 evaluation with the same intervention.
~Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).
~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
16343005|NCT04378075|Experimental|Vatiquinone|15 milligrams/kilogram (mg/kg) if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks
16343006|NCT04378075|Placebo Comparator|Placebo|Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.
16343007|NCT04378062|Active Comparator|Traction Neurectomy|Traction neurectomy - of digital sensory nerves at the time of amputation.
16343008|NCT04378062|Experimental|Targeted Muscle Reinnervation|Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
16343009|NCT04378062|Experimental|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation
16343010|NCT04378049|Active Comparator|Standard total knee arthroplasty|Participants who are randomized to the control group will undergo TKA according to local standard of care. The choice of implant and use of bone cement will be recorded but left to the surgeon's discretion according to their standard practice.
16343011|NCT04378049|Experimental|Robot-assisted partial knee arthroplasty|Participants with isolated medial or isolated lateral compartment OA who are randomized to the intervention group and have one affected knee compartment will receive a robot-assisted unicompartmental knee arthroplasty (UKA). If the patient has medial or lateral OA plus patellofemoral OA they will receive a bicompartmental knee arthroplasty (BiKA) consisting of a two simultaneous UKAs. The partial knee replacement procedures will be performed using the Mako RIO robotic arm (Stryker) according to the manufacturer's instructions. The choice of implant and use of bone cement will be recorded but will be left to the surgeon's discretion. Surgeons will resurface the patella if the patellar cartilage meets Outerbridge grade 3 or 4 criteria
16343012|NCT04378036|Active Comparator|Neurodevelopmental Therapy Group|The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
16343013|NCT04378036|Active Comparator|Hippotherapy Simulator Group|The same participants were taken into a rehabilitation program in which 16 sessions (8 weeks x 2 days a week) the Hippotherapy Simulator device (30 minutes) and Neurodevelopmental Therapy (NDT) (15 minutes) (HS + NDT method) were used together.
16343014|NCT04378023|Other|Study group|Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
16343015|NCT04378010|Experimental|EDP-305 1.5 mg|Once a day orally for 72 weeks
16343016|NCT04378010|Experimental|EDP-305 2 mg|Once a day orally for 72 weeks
16343017|NCT04378010|Placebo Comparator|Placebo|Once a day orally for 72 weeks
16344220|NCT04369482|Active Comparator|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
16343018|NCT04377997|Experimental|Therapeutic Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.
~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.
~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation (LMWH for most subjects but UFH for those with morbid obesity or moderate to severe renal dysfunction as noted below) or standard of care anticoagulation. Those assigned to the therapeutic anticoagulation group will receive a higher dose of heparin."
16343019|NCT04377997|Active Comparator|Standard of Care Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.
~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.
~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation or standard of care anticoagulation. Those assigned to the standard of care anticoagulation group will receive the normal dose of heparin as per the Mass General guidelines."
16343020|NCT04377971|Experimental|Ask-tell-ask method|Study team will provide participant education using the ask-tell-ask method. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
16343021|NCT04377971|Active Comparator|Standard of Care (SOC)|Participants will receive SOC education from the researcher. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
16343022|NCT04377958|Other|Asthmatics|Asthmatic group from which serum samples will be collected for analysis
16343023|NCT04377945|Experimental|Part 1, JM-010 component Group A|Part 1, JM-010 component Group A
16343024|NCT04377945|Experimental|Part 1, JM-010 component Group B|Part 1, JM-010 component Group B
16343025|NCT04377945|Experimental|Part 1, JM-010 component Group C|Part 1, JM-010 component Group C
16343026|NCT04377945|Placebo Comparator|Part 1, Placebo Group|Part 1, Placebo Group
16343027|NCT04377945|Experimental|Part 2, JM-010 combination Group A|Part 2, JM-010 combination Group A
16343028|NCT04377945|Experimental|Part 2, JM-010 combination Group B|Part 2, JM-010 combination Group B
16343029|NCT04377945|Experimental|Part 2, JM-010 component Group C|Part 2, JM-010 component Group C
16343030|NCT04377945|Placebo Comparator|Part 2, Placebo Group|Part 2, Placebo Group
16343032|NCT04377919|Active Comparator|Cranberry|Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks
16343033|NCT04377919|Placebo Comparator|Placebo|Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks
16343034|NCT04377906|Experimental|High Protein-Fiber and Exercise|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day and exercise : aerobic and resistance training for 5x/week, 45 minute each sesion
16343035|NCT04377906|Experimental|High Protein-Fiber|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day
16343036|NCT04377906|Experimental|Exercise|aerobic and resistance training for 5x/week, 45 minute each sesion
16343037|NCT04377906|No Intervention|control|regular diet
16343038|NCT04377893|Experimental|Treatment arm|Participants will receive eye-gaze AT intervention
16343039|NCT04377867||LRBA deficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
16343040|NCT04377867||CTLA4 haploinsufficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
16343041|NCT04377867||Control group|Age matched healthy control group will be used during the study to determine the reference values of the immunological assays.
16343042|NCT04377854||MCS recipients|All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.
16343043|NCT04377854||Recipient of cardiac transplant|All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.
16343044|NCT04377854||Watchful waiting at Rigshospitalet|Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.
16343045|NCT04377841||Facial Demodicosis|"Clinical presentation of facial skin matches any of the followings:
~Pityriasis folliculorum.
~Papulopustular lesion.
~Rosacea.
~Demodex infestation detected by direct microscopic examination ≥ 5 mites/cm2."
16343091|NCT04377503|Experimental|Tocilizumab|Patients will receive Tocilizumab, 8 mg / kg diluted in 100 ml of saline and administered IV for 60 minutes. The dose will be repeated only once 12 hours after the first dose.
16343046|NCT04377841||Ocular Demodicosis|"Clinical presentation of ocular region matches any of the followings:
~Chronic blepharitis.
~Eyelash abnormalities: trichiasis, distichiasis, madarosis.
~Meibomian gland dysfunction.
~Recurrent chalazion.
~Ocular rosacea.
~Demodex infestation detected by cilia epilation test ≥ 1 mite/eyelid."
16343047|NCT04377828|Experimental|Laser intervention|1 to 2 sessions of pigment laser1
16343048|NCT04377815||General Public cohort|General Public
16343049|NCT04377815||Hospital cohort|Medical records of patients hospitalised due to COVID-19
16343050|NCT04377789|No Intervention|non-quercetin group|Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
16343051|NCT04377789|Active Comparator|quercetin prophylaxis group|Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
16343052|NCT04377789|Active Comparator|quercetin treatment group|Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
16343053|NCT04377776||Transplanted patients|Transplanted Kidney, Pancreas or Pancreatic Islet patients at MedicineTransplant Unit - San Raffaele Scientific Istitute
16343054|NCT04377750|Experimental|Tocilizumab treatment group|Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
16343055|NCT04377750|Placebo Comparator|Placebo group|Placebo. intravenous administration of 100 ml of normal saline.
16343056|NCT04377737|Other|RT-PCR Covid-19|
16343057|NCT04377724||ETH cohort|employees or students at ETH Zurich, Switzerland
16343058|NCT04377711|Active Comparator|Group 1|Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI
16343059|NCT04377711|Placebo Comparator|Group 2|Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI
16343060|NCT04377698|Active Comparator|Platelet Rich Fibrin group(PRF)|Following apicoectomy PRF gel was prepared and placed in the osseous defect followed by placement of PRF membrane
16343061|NCT04377698|Active Comparator|Freezed Dried Bone Allograft group(FDBA)|Following apicoectomy FDBA graft were prepared and placed in the osseous defect followed by placement of PRF membrane
16343062|NCT04377685||COVID19 patients|Patient tested positive for SARS-CoV-2 who had a CT scan
16343063|NCT04377672|Experimental|Anti- SARS-CoV-2 Plasma|Human Convalescent Plasma
16343064|NCT04377659|Experimental|Intubation/Mechanical Ventilation|Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
16343065|NCT04377659|Experimental|Respiratory Support|In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)
16343066|NCT04377646|Active Comparator|Hydroxychloroquine & Zinc|"Will receive:
~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.
~Zinc 15 mg at daily dose up to 2 months"
16343067|NCT04377646|Active Comparator|Hydroxychloroquine|"Will receive:
~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.
~Placebo of Zinc"
16343068|NCT04377646|Placebo Comparator|Placebo|Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months
16343069|NCT04377633|Sham Comparator|Pre-intervention|Anesthesia handover during surgery will be performed as usual, i.e., a verbal exchange of pertinent clinical information.
16343070|NCT04377633|Experimental|Post-intervention|Anesthesia handover during surgery will be performed according to a structured checklist.
16343071|NCT04377620|Placebo Comparator|Placebo + Standard of Care (SoC)|Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
16343072|NCT04377620|Experimental|Ruxolitinib 5mg + Standard of Care (SoC)|Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
16343073|NCT04377620|Experimental|Ruxolitininb 15mg + Standard of Care (SoC)|Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
16343074|NCT04377607||Group OP|outpatients with asymptomatic or uncomplicated or mild pneumonia
16343075|NCT04377607||Group H|hospitalized patients
16343076|NCT04377607||Group IC|patients admitted to intensive care unit
16343077|NCT04377594|Experimental|Pulmonary vein isolation plus substrate modification|Pulmonary vein isolation plus ablation of low voltage areas in the left atrium
16343078|NCT04377594|Active Comparator|Pulmonary vein isolation|Pulmonary vein isolation
16343079|NCT04377568|Experimental|Convalescent Plasma + Standard of Care (C19-CP + SoC)|Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
16343080|NCT04377568|No Intervention|Standard of Care (SoC)|Participants will receive standard of care while being hospitalized for COVID-19.
16343081|NCT04377555|Experimental|All Participants|Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.
16343082|NCT04377542|Active Comparator|LIFT|Ligation of intersphincteric fistula tract
16343083|NCT04377542|Active Comparator|Parks|Modified Parks technique
16343084|NCT04377542|Active Comparator|Seton|Two-stage seton placement
16343085|NCT04377529|Experimental|Back Skills Training Champion|In additional to access to the online provider Back Skills Training course, participants in clusters randomised to this arm will receive additional support from a local champion. The local champion will have received additional training and support on the implementation of the Back Skills Training intervention from the study team.
16343086|NCT04377529|Active Comparator|No Champion|Participants in clusters randomised to this arm will not receive any additional training or support beyond access to the online provider Back Skills Training course.
16343087|NCT04377516|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
16343088|NCT04377516|Active Comparator|Exercise group|pelvic floor muscle training
16343089|NCT04377516|Placebo Comparator|Control group|pelvic girdle education
16343090|NCT04377516|Other|Health group|pelvic girdle education
16343092|NCT04377503|Active Comparator|Methylprednisolone|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days in two daily doses. Finally 0.5 mg / kg / day for another 7 days.
16343093|NCT04377477|Experimental|Lung low dose radiotherapy|Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
16343094|NCT04377464||COVID-19 Survivors|Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points.
16343095|NCT04377451|No Intervention|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
16343096|NCT04377451|Experimental|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age <16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
16343097|NCT04377425||Patients with acute neurological symptoms|Consecutive patients with acute neurological disease admitted at the Neurology departments will be tested with a nasopharyngeal swap for SARS-COVID-19 RNA according to standard operating procedures at the department (if estimated hospital stay is >24hours). Medical and clinical characteristics will be collected
16343098|NCT04377425||Stroke patients|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.
~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
16343099|NCT04377425||Seizure/epilepsy|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.
~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
16343100|NCT04377412||Albania|
16343101|NCT04377412||Australia|
16343102|NCT04377412||Czech Republic|
16343103|NCT04377412||France|
16343104|NCT04377412||Germany|
16343105|NCT04377412||Hong Kong|
16343106|NCT04377412||Israel|
16343107|NCT04377412||Italy|
16343108|NCT04377412||Lebanon|
16343109|NCT04377412||Norway|
16343110|NCT04377412||Poland|
16343111|NCT04377412||Russia|
16343112|NCT04377412||Spain|
16343113|NCT04377412||Sweden|
16343114|NCT04377412||Taiwan|
16343115|NCT04377412||Ukraine|
16343116|NCT04377412||United States|
16343117|NCT04377399|Active Comparator|high dose|vitamin D (40,000 IU weekly) for 24 weeks
16343118|NCT04377399|Active Comparator|Low dose|vitamin D (5,000 IU weekly) for 24 weeks
16343119|NCT04377386|Experimental|Intervention group: 1000 IU DV|The 75 participants assigned to the intervention group will take 1 DV capsule of 1000 IU daily for 15 weeks.
16343120|NCT04377386|Placebo Comparator|Control group: 200 IU DV|The 75 participants of the control group will take 1 DV capsule of 200 IU daily for 15 weeks, this dose being the minimum recommended for children. The above, considering that it is ethical for the control group to receive a minimum dose of supplementation.
16343121|NCT04377360|Experimental|Diffusing Alpha-emitter Radiation Therapy (DaRT)|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Tumor response to DaRT will be assessed periodically 3 months after removal.
16343122|NCT04377347||Confirmed spontaneous subarachnoid haemorrhage|"Patients, minimum 18 years of age, identified with the diagnosis in the Danish National Patient Register. The diagnosis is verified by medical record review.
~All patients were initially admitted to a hospital in the Capital Region of Denmark.
~In a national labour marked register and the civil registration register the patients are then followed for four years."
16343123|NCT04377334|Experimental|MSC Treatment|
16343124|NCT04377334|No Intervention|control|
16343125|NCT04377321||group 1 on cochicine|The first group patients received colchicine 0.5 twice daily for 6 months
16343126|NCT04377321||group 2 on glucophage 1 gm twice daily|second group received glucophage 1gm twice daily for 6 months
16343127|NCT04377321||group 3 control|the third group patients were on diet only for 6 months
16343128|NCT04377308|No Intervention|Treatment As Usual|Participants may choose to not take fluoxetine and remain in the study
16343129|NCT04377308|Active Comparator|Fluoxetine|Participants will take fluoxetine 20 mg initially, increasing as tolerated to a maximum of 60 mg until symptoms abate, then will be tapered by 20 mg per week off the fluoxetine Participants will be on fluoxetine for 2 weeks to 2 months depending on symptom duration
16343130|NCT04377282|Experimental|Buckwheat|Cooked buckwheat
16343131|NCT04377282|Experimental|Couscous|Cooked couscous
16343132|NCT04377282|Experimental|Water|Potable water
16343133|NCT04377269|Experimental|Taping Group|33 participants, received ankle taping
16343134|NCT04377269|Experimental|Bandaging|33 participants, received ankle bandaging
16343135|NCT04377269|Placebo Comparator|Placebo Taping (Control) Group|34 participants, received ankle placebo taping
16343136|NCT04377256|Experimental|Radiological assessement|Two CBCTs were recorded and compared, one at the baseline and the other at 4 months post-op. The bone resorption was quantified and analyzed using ITK-SNAP software
16343137|NCT04377256|Experimental|Histomorphometric analysis|During implant placement (4 months after the bone grafting), a bone biopsy is collected and stained with several colorants to analyze the biological bone healing
16343138|NCT04377243|Experimental|V8 850 mg|Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8
16343139|NCT04377243|Placebo Comparator|Placebo 850 mg|Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo
16343140|NCT04377230|Experimental|Biliopancreatic limb 60cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
16343141|NCT04377230|Active Comparator|Biliopancreatic limb 100cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
16344221|NCT04369469|Experimental|Ravulizumab plus Best Supportive Care|
16343142|NCT04377217|Experimental|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months.
16343143|NCT04377204|Active Comparator|Lidocaine Group|Local injection of 1% lidocaine with 1:100,000 epinephrine one time pre-operatively prior to general anesthesia
16343144|NCT04377204|Active Comparator|Lidocaine with Bupivacaine|Local injection of 1% lidocaine with 1:100,000 epinephrine mixed 1:1 with 0.5% marcaine bupivacaine with 1:200,000 epinephrine, one time pre-operatively prior to general anesthesia
16343145|NCT04377191|Experimental|VR 1 Group|In this group, participants received standard exercise and exergame training with Microsoft Xbox 360 Kinect for 2 days per week for 6 weeks.
16343146|NCT04377191|Experimental|VR 2 Group|In this group, participants received standard exercise and exergame training with ALDA balance gear for 2 days per week for 6 weeks.
16343147|NCT04377191|Active Comparator|Control Group|In this group, participants received only standard exercise for 2 days per week for 6 weeks.
16343148|NCT04377178|Experimental|Dentin chips group from automated mill|Dentin particles prepared from dentin grinder will be placed in extraction socket immediately after extraction
16343149|NCT04377178|Active Comparator|Manually milled Dentin chips|Dentin particles prepared from bone mill will be placed in extraction socket immediately after extraction.
16343150|NCT04377165|Active Comparator|Newsfeed|This will provide you with reliable accurate information on the pandemic.
16343151|NCT04377165|Experimental|Gamification|The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.
16343152|NCT04377139||Prophylaxis|Those LTR receiving prophylaxis against CMV
16343153|NCT04377139||Preemptive therapy|Those LTR receiving preemptive therapy against CMV
16343154|NCT04377126|Active Comparator|Unacylated ghrelin|Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).
16343155|NCT04377126|Placebo Comparator|Placebo|Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.
16343156|NCT04377113||RCC patients|"RCC patients (30 pts) will include patients with kidney cancer (renal cell cancer).
~Investigators will collect and analyze:
~blood sample,
~urine sample,
~kidney tissue sample (healthy tissue, carcinomatous tissue and borderline tissue between them)."
16343157|NCT04377113||Healthy patients|"In this group (30 patients) will be recruiting healthy patients (volunteer).
~Investigators will collect and analyze:
~blood sample."
16343159|NCT04377087|Experimental|Olaparib|Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
16343160|NCT04377061||NCWS retrospective and prospective patients|"The clinical charts of NCWS patients, diagnosed by DBPC gluten/wheat challenge, between January 2001 and December 2019, attending the Department of Internal Medicine at the University Hospital of Palermo, the Department of Internal Medicine of the Hospital of Sciacca, and the Department of Medical and Surgical Sciences of the University of Bologna, will be reviewed retrospectively. The investigators prospectively will also survey patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS by DBPC gluten/wheat challenge. The patients will be recruited between January 2019 and January 2022 at the same centers, and at the Internal Medicine Division of the Cervello-Villa Sofia Hospital of Palermo, Palermo."
16343161|NCT04377061||CD retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of a control group of CD patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of CD patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
16343162|NCT04377061||IBS retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of another control group of IBS patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of IBS patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
16343163|NCT04377048|Experimental|Nivolumab/GS|"Part-1: GS Induction
~Patients will receive GS for 1 cycle.
~S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle
~BSA < 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day
~Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle
~After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.
~Part-2: Nivolumab Add-On
~Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle
~S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle
~Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle
~The treatment will be continued until disease progression, intolerance to study treatment or death."
16343164|NCT04377022|No Intervention|Conventional Therapy|In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
16343165|NCT04377022|Experimental|Combined Therapy|In this group, Patients receive Aerobic exercise training in addition to conventional Physical Therapy. Patients undergoes Aerobic exercise training for 25 minutes and 3 days in a week. A total of 15 session of aerobic exercise training session was given to patient.
16343166|NCT04377009|Experimental|Active CBT-I|Internet-guided cognitive behavioral therapy
16343167|NCT04377009|Other|Control|Education control program
16343168|NCT04376996||General cohort|General population cohort aged 0-100 years from Slovenia
16343169|NCT04376983|No Intervention|Control|Patients will get no intervention
16343170|NCT04376983|Experimental|Intervention|Patients will transmit their CRT data every week (first 6 weeks) and then every two week to the Heart Centre Hasselt. The physical activity data will be used to deliver a tailored motivational message to the patient to increase physical activity in this group.
16343171|NCT04376970|Active Comparator|Fluorometholone group|This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
16343172|NCT04376970|Active Comparator|Cyclosporine A group|This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
16343173|NCT04376957|Active Comparator|Counselled with Current Standard Care|Standard of care consists of standard counselling and written materials provided by the oncologist or pharmacy (e.g. instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered).
16343174|NCT04376957|Experimental|Counselled with MASCC Oral agent Teaching Tool (MOATT)|This group will receive counselling using the MASCC Oral Agent Teaching Tool and be compared with the standard of care counselling.
16343175|NCT04376944||Exposed group|Caregivers and agents working directly in COVID units compared to those living.
16343176|NCT04376944||Control group|caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
16343177|NCT04376931|Experimental|Iscador®P as intravenous infusion|"Investigational therapy will be administered in six Dose Groups (DG):
~10 mg, 20 mg, 40 mg, 90 mg, 140 mg and 200 mg Iscador®P. The initial dose group of the study is set to 40 mg Iscador®P. The two lower dose groups (20 or 10 mg) will only be used in case of intolerance at 40 mg Iscador®P. Once per week patients receive intravenous infusions of Iscador®P dissolved in 250 ml of sodium chloride solution (0.9 %). After the 4-week period of the MTD estimation phase each subject will immediately be included into a follow up observation in which he/she receives the last well tolerated dosage they had or the next lower dosage than the currently investigated DG in the running phase Ib study depending on the current estimate of the MTD at that time."
16343178|NCT04376918|Active Comparator|Begin with BVGA|"After initial anesthesia induction, anesthetized volunteers will be ventilated through through the BVGA for 2 minutes and then through the face-mask for 2 minutes. The normal anesthesia procedures will then be resumed.
~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
16343179|NCT04376918|Active Comparator|Begin with Face-mask|"After initial anesthesia induction, anesthetized volunteers will be ventilated through the face mask for 2 minutes and then through the BVGA for 2 minutes. The normal anesthesia procedures will then be resumed
~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
16343180|NCT04376892||Group 1|Exercise capacity under 149 meter
16343181|NCT04376892||Group 2|Exercise capacity between 150 and 249 meter
16343182|NCT04376892||Group 3|Exercise capacity between 250 and 349 meter
16343183|NCT04376892||Group 4|Exercise capacity above 340
16343184|NCT04376879||Step 1: creation of the score|Cohort for the creation of clinical-biological score to predict the risk of intubation in COVID-19
16343185|NCT04376879||Step 2: validation of the score|Cohort for the validation of clinical-biological score to predict the risk of intubation in COVID-19
16343186|NCT04376866|Experimental|Toripalimab+CCRT|"Toripalimab 240mg, and Cisplatin 100mg/m2 (every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT), followed by Toripalimab 240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy.
~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
16343187|NCT04376866|No Intervention|CCRT alone|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT).
~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
16343188|NCT04376853||COVID-19|Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
16343189|NCT04376840|Experimental|adults with severe SARS-CoV2 pneumonia|adult with severe SARS-CoV2 pneumonia
16343192|NCT04376814|Experimental|Test Group|In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.
16343193|NCT04376814|Active Comparator|Control Group|In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.
16343194|NCT04376801||Tension-band Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed tension-band fixation after olecranon osteotomy were classified into Tension-band Fixation Group.
16343195|NCT04376801||Plate Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed plate fixation after olecranon osteotomy were classified into Plate Fixation Group.
16343196|NCT04376788|Experimental|Exchange transfusion|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
16344222|NCT04369469|Other|Best Supportive Care|
16343197|NCT04376788|Experimental|Methylene blue with plasma|Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
16343198|NCT04376788|Experimental|Exchange transfusion and methylene blue with plasma|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
16343199|NCT04376775||Transplant patient|This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.
16343202|NCT04376749||preterm infants received caffeine|preterm infants aged between 28 to 34 weeks gestational age who received caffeine therapy either for prophylaxis or treatment
16343203|NCT04376749||preterm infants received no caffeine|preterm infants aged between 28 to 34 weeks gestational age who received no caffeine therapy
16343204|NCT04376736|No Intervention|Control arm|Patients are reminded about their appointments
16343205|NCT04376736|Experimental|Intervention arm|Patients are offered a one-time home visit by providers in lieu of their upcoming in-person visit
16343206|NCT04376723|Experimental|Assisted self-guidance|Participants will be asked to use the app for five weeks and will be contacted via telephone once a week by a researcher to provide a rationale for using the app, or to offer any information about the app itself. This will not be used to provide therapeutic intervention.
16343207|NCT04376710||Surgeons|
16343208|NCT04376710||Patients|
16343209|NCT04376697|Experimental|Active rTMS|Treatment will be delivered daily (weekdays) rTMS treatments, for up to 10 daily sessions and up to 75 sessions in total.
16343210|NCT04376684|Experimental|Part 1: Participants receiving otilimab|Participants (age >=18 years and <=79 years) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 1.
16343211|NCT04376684|Placebo Comparator|Part 1: Participants receiving placebo 1|Participants (age >=18 years and <=79 years) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 1.
16343212|NCT04376684|Experimental|Part 2: Participants receiving otilimab|Participants (age 70 years or above) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 2.
16343213|NCT04376684|Placebo Comparator|Part 2: Participants receiving placebo 2|Participants (age 70 years or above) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 2.
16343214|NCT04376671||temporal lobe epilepsy|Group of patients with temporal lobe epilepsy
16343215|NCT04376671||Extra-temporal lobe epilepsy|Group of patients with extra-temporal lobe epilepsy
16343216|NCT04376658||Cohort 1|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with up to 4L/minute oxygen supply through nasal catheter.
16343217|NCT04376658||Cohort 2|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection needing oxygen supplementation > 4L/min on nasal catheter or HFNC or NIV or MV or ECMO.
16343218|NCT04376658||Cohort 3|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with moderate or severe ARDS according to the Berlin definition
16343219|NCT04376645|Experimental|Group 1|Group 1: - Class III patients with increased vertical relationship These patients were scheduled for bimaxillary surgical procedures (Maxillary advancement and mandibular setback with posterior maxillary impaction) to correct the antero-posterior and vertical skeletal discrepancies.
16343220|NCT04376645|Experimental|Group 2|Group 2: - Class III subjects with normal vertical relationship These patients were scheduled for mandibular setback surgical procedure (with no posterior maxillary impaction) to correct the antero-posterior skeletal discrepancy.
16343221|NCT04376632|No Intervention|Control|Participants in this group avoid all nuts for 8 weeks.
16343222|NCT04376632|Experimental|Pecan ADD|Participants in this group consume 68 g of pecans/d with no additional dietary instructions and avoid all other nuts.
16343223|NCT04376632|Experimental|Pecan SUB|Participants in this group consume 68 g of pecans/d with instructions to substitute pecans with isocaloric foods in the habitual diet. They are also instructed to avoid all other nuts.
16343226|NCT04376606|Experimental|Left atrial appendage closure group|
16343227|NCT04376606|Experimental|Radiofrequency ablation group|
16343228|NCT04376606|Experimental|LAAC combined with radiofrequency ablation group|
16343229|NCT04376593|Experimental|18F-αvβ6-BP|Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
16343230|NCT04376567|Active Comparator|One stage BBAVF|comparison
16343231|NCT04376567|Active Comparator|Two Stage BBAVF|comparison
16343646|NCT04373694|Active Comparator|Standard hysteroscopy|morcellation hysteroscopy with intravenous sedation and paracervical bloc
16343232|NCT04376554|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
16343233|NCT04376554|Active Comparator|amoxicillin-clavulanate|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or for 10 days.
16343234|NCT04376541||early extubation|the patients extubated in O.R or within 2 hours in the ICU
16343235|NCT04376541||late extubation|the patients extubated after 2 hours from O.R
16343236|NCT04376528|Experimental|Cyclosporin A|
16343237|NCT04376528|Active Comparator|Mycophenolate Mofetil|
16343238|NCT04376515|Experimental|HOPE Intervention|HOPE peer-led intervention
16343239|NCT04376515|No Intervention|Control|Control group- online community without peer leaders
16343240|NCT04376502|Other|radiation therapy (RT)|RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
16343241|NCT04376489|Experimental|Brief cognitive/behavioral strategies|
16343242|NCT04376489|Experimental|Effortful self-regulatory activities|
16343243|NCT04376489|No Intervention|No activities|
16343244|NCT04376476|Experimental|Adult group A1|Adults with confirmed pauci-symptomatic COVID-19 infection recruited through the blood collection centers set up by the occupational health services. Hospital visits (for clinical examination, biology, immunology, virology measurements) are scheduled at day 0, day 3, day 7, day 14, day 21; phone call is scheduled at day 10.
16343245|NCT04376476|Experimental|Adult group A2|Adults with confirmed COVID-19 infection of moderate clinical severity recruited within participating units. Follow-up visits (for clinical examination, biology, immunology, virology measurements) are scheduled at day 0, day 3, day 7, day 14, day 21, and in case of worsening; a day 10 visit will be performed by phone or onsite if the patient is still hospitalized.
16343246|NCT04376476|Experimental|Adult group A3|Adults with confirmed non-COVID-19 viral infection pauci-symptomatic recruited through the blood collection centers set up by the occupational health services. Hospital visits (for clinical examination, biology, immunology, virology measurements) are scheduled at day 0, day 3, day 7, day 14, day 21; phone call is scheduled at day 10.
16343247|NCT04376476|Experimental|Children group E1|Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
16343248|NCT04376476|Experimental|Children group E2|Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
16343249|NCT04376476|Experimental|Children group E3|Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
16343250|NCT04376463|Experimental|Mood state and aminoacids supplementation|The aim of this study was to analyse the isolated and combined effects of BCAA supplementation and exercise on physical frailty status and mood states in pre-frail institutionalized older women.
16343251|NCT04376463|Experimental|Physical Tests|Through the combination of bcaa supplementation and physical exercise is able to improve the functional capacity of the elderly, through the SPPB test battery, short performance physical battery.
16343252|NCT04376463|Experimental|Psychometrics evaluated|Through the combination of bcaa supplementation and physical exercise, it is able to improve moods and cognition of the elderly.
16343253|NCT04376463|Experimental|Fried Scale Phenotype|Primary outcomes include Physical Frailty evaluated according to Fried's Frailty Phenotype2): Shrinking assessed by self-report of unintentional weight loss of four kilograms or more in the last six months; Self-reported exhaustion evaluated by concordance of two questions (7 and 20) of the Center for Epidemiology-Depression (CES-D) scale; Weakness analyzed using the handgrip strength test; Slowness measured by the 4.6 meters walking test; levels of Physical Activity assessed by the (IPAQ).
16343254|NCT04376450|Experimental|Nonincised Papillae Surgical Approach|Nonincised papillae surgical approach is a papillae preservation technique, where an apical approach is carried out, without incisions or disinsertion of tissues at the level of the papillae or marginal tissues.
16343255|NCT04376450|Active Comparator|Entire Papilla Preservation Technique|Entire Papilla preservation technique is a tunnel-like procedure to preserve the defect associated papilla
16343256|NCT04376437|Experimental|medical cannabis|All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
16343259|NCT04376411||patients with Behcet disease|Flow-cytometric assay Detailed 2 Di mention Echocardiographic analysis Two-Dimensional speckle tracking echocardiography
16343260|NCT04376411||Healthy control subjects|Flow-cytometric assay
16343261|NCT04376398||COVID-19|Any pediatric or adult patient with COVID-19 or suspected of COVID-19 scheduled for any intervention
16343265|NCT04376372||TD_lefthanders|Typical developing lefthanded children and adolescents Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
16343266|NCT04376372||F_lefthanders|Forced left handed NBPP children Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
16343267|NCT04376359|Experimental|hyperbaric oxygen therapy|Patients with stroke will receive the hyperbaric oxygen therapy (HBOT) for 40 times, which were completed on 40 business days over a 2-month period and each session lasted 90 minutes at 100% oxygen concentration and 2 atmospheres.
16343268|NCT04376359|No Intervention|Control|Stroke patients were not treated with HBOT except for the same routine treatment as the experimental group.
16343269|NCT04376346|Experimental|Intervention Arm|Participants in the intervention arm will complete the AIY-C curriculum that has been translated for mHealth delivery. This includes completing various activities such as completing their own risk assessment when it comes to AEP and setting goals for themselves.
16343270|NCT04376346|No Intervention|Control Arm|Participants in the control arm will complete activities that are carefully designed under different topics than the intervention arm. In this regard, participants will complete various activities such as quizzes, interactive games and videos. The investigators will ensure that participants in both arms will spend similar time on completing the activities.
16343271|NCT04376333|Active Comparator|STD+CBT|Standard conservative dental orofacial pain care + cognitive-behavioral coping skills treatment
16343272|NCT04376333|Experimental|STD+IATP|Standard conservative dental orofacial pain care + Individualized Assessment and Treatment Program; a highly individualized coping skills training procedure.
16343273|NCT04376320|Active Comparator|Group 1(ceramic membrane)|using customized ceramic membranes for augmentation of vertical mandibular ridge defects in preparation for implant placement
16343274|NCT04376320|Active Comparator|Group 2 (modified sausage technique)|using tenting titanium screws in conjunction with particulate bone graft and collagen membrane (modified sausage technique) for augmentation of vertical mandibular ridge defects in preparation for implant placement
16343275|NCT04376307|Experimental|minimal flow anesthesia|the patiennts who have thoracic sugery with one lung ventilaiton
16343276|NCT04376294|Experimental|Study group|This group received Extracorporeal Shockwave Therapy(ESWT) + conservative Physical Therapy Treatment (eccentric training + stretching exercise)
16343277|NCT04376294|Active Comparator|Control group|This group received conservative physical therapy treatment(eccentric training + stretching exercise) only.
16343278|NCT04376281|Experimental|Noradrenaline group|
16343279|NCT04376268|Active Comparator|Chlorhexidine gluconate|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects.
16343280|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343281|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343282|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343283|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343284|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343285|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343356|NCT04375787|Active Comparator|Statin group|100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention
16343357|NCT04375787|Placebo Comparator|Placebo group|100 patients received placebo
16343286|NCT04376268|Active Comparator|Boric acid mouthwash (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
16343287|NCT04376255|Experimental|Mixed Reality Simulation (Phase 2)|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
16343288|NCT04376255|Active Comparator|Conventional Simulation (Phase 2)|Participants in the control arm will be introduced to workplace training modules using standard in person training.
16343289|NCT04376255|Active Comparator|Remote Mixed Reality Simulation (Phase 1)|During the initial phase of the study, up to 40 participants will enroll in mixed reality simulation remotely for a qualitative assessment of simulation transcripts
16343290|NCT04376242|Experimental|virtual reality then standard technology|patients randomized to this arm will first use virtual reality (VR) during and oral food challenge and then use standard technology during a second oral food challenge
16343291|NCT04376242|Active Comparator|standard technology then virtual reality|patients randomized to this arm will first use standard technology during and oral food challenge and then use virtual reality during a second oral food challenge
16343292|NCT04376229||Cancer patients receiving proton radiation therapy|Registry of cancer patients who receive proton radiation therapy to track disease and toxicity outcomes.
16343293|NCT04376216|No Intervention|Control|No treatment
16343294|NCT04376216|Active Comparator|Prednisone|Oral prednisone. Starting dose of 60 mg with tapering for 2 months
16343295|NCT04376203||Control|any patient with indications for thyroidectomy other than confirmed preoperative cancer
16343296|NCT04376203||Thyroid microcarcinoma|either preoperative detection or random finding after thyroidectomy of another indication.
16343297|NCT04376190|No Intervention|control group|12 patients treated with twin block functional appliance without low-level laser application for 9 month
16343298|NCT04376190|Experimental|laser group|12 patients treated with twin block functional appliance with low-level laser application with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. The laser was applied at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points. Laser application was repeated weekly for three months according to a standard protocol
16343299|NCT04376177||Patients with Thoracic outlet syndrome|Patients referred to the University Hospital of Angers for the diagnostis or follow-up of thoracic outlet syndrome
16343300|NCT04376164|No Intervention|control group|was treated without laser intervention
16343301|NCT04376164|Experimental|laser group|received low level laser therapy
16343302|NCT04376151|Experimental|Intervention|Participants will work through an Acceptance and Commitment Therapy informed self-help bibliotherapy over a period of eight weeks. The bibliotherapy is called 'Get Out of Your Life and Into your Mind' written by Steve. C. Hayes.
16343303|NCT04376138|Experimental|Motor Imagery|A Brain-Computer Interaction (BCI) based intervention while receiving conventional therapy. Use of motor imagery training, allied with brain-computer interaction, as a solution to promote motor and cognitive gains in stroke survivors.
16343304|NCT04376138|Active Comparator|Conventional Therapy|Extra Occupational Therapy sessions while receiving conventional therapy. Use of conventional therapy techniques and tools for motor rehabilitation, following the original therapeutic intervention plan of the participants.
16343305|NCT04376125|Experimental|Suboccipital inhibition in tension headache|"Two groups of patients suffering from tension headache associated with cervicalgia are selected.
~The control group performs conventional therapy. The experimental group performs conventional therapy plus the technique of suboccipital inhibition"
16343306|NCT04376125|Active Comparator|study of results|We compared data from both groups
16343307|NCT04376112|Active Comparator|Standard of Care|
16343308|NCT04376112|Experimental|Pharmacist Intervention|
16343309|NCT04376099||Exercise oximetry|Patients complaining claudication and referred for exercise diagnostic oximetry. Exercise oximetry are performed on treadmill (3.2km/h, 10% slope)
16343310|NCT04376086|Active Comparator|General anesthesia|Patients will receive general anesthesia
16343311|NCT04376086|Experimental|Epidural anesthesia|Patients will receive epidural anesthesia
16343312|NCT04376073|Experimental|Treatment group|"Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh <77 kg) po QD day1~21, Anlotinib 12mg po QD day1~14.
~Starting dose of anlotinib changed to 10mg from 2020-11-13."
16343313|NCT04376060|Experimental|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
16343314|NCT04376047|Experimental|Reverse Trendelenburg position group|Obese critically ill patients who are positioned in reverse Trendelenburg position
16343315|NCT04376047|Active Comparator|Semi-recumbent position group|Obese critically ill patients who are positioned in semi-recumbent position which is the routine ICU position
16343316|NCT04376034|Other|Mild Severity|Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
16343317|NCT04376034|Active Comparator|Moderate Severity|"Adult patients will be treated with 1 unit (200mL) of convalescent plasma
~Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma."
16343318|NCT04376034|Active Comparator|Severe or Critical Severity|"Adult patients will be treated with up to 2 units of convalescent plasma
~Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma."
16343319|NCT04376021|Experimental|Physical Contact|Baby carrier (and education) provided to mother to increase physical contact with baby
16343320|NCT04376021|No Intervention|Control|No intervention
16343321|NCT04376008|Experimental|PI-RADS 1-2|Standard prostate biopsy
16343322|NCT04376008|Experimental|PI-RADS 3-5|Targeted and standard prostate biopsy
16343358|NCT04375774|Other|FFP2|
16343359|NCT04375774|Other|Facial mask|
16343360|NCT04375774|Other|Modified full-face snorkeling|
16343427|NCT04375228|Experimental|Tocilizumab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Tocilizumab.
16343323|NCT04375995|Other|Asthma group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed to all asthmatic patients.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. Asthma control test (ACT) and asthma quality of life scale (AQLQ) will be applied. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma.
16343324|NCT04375995|Other|Healthy control group|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
16343325|NCT04375982|Other|Blood collection|Venepuncture and fingerstick to obtain venous blood and capillary blood respectively
16343326|NCT04375969|Experimental|whole body cryostimulation treatment|WBC will be performed at the Pomeranian Rheumatologic Centre in Sopot. The centre is equipped with an electric cryochamber Zimmer Medicine System, Cryochamber ELECPOL, located in a temperature- and humidity-controlled room. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
16343327|NCT04375969|Experimental|Connection WBC treatment and HIIT training|This group will perform HIIT protocol and WBC sessions . HIIT will be performed after 1h WBC.
16343328|NCT04375969|Active Comparator|Control Group|Control group who will be investigated (meanwhile at baseline and after the interventions)
16343329|NCT04375969|Experimental|HIIT training group|This group will perform only HIIT protocol without cryo-sessions
16343330|NCT04375956|Experimental|Pembrolizumab|Pembrolizumab 200 mg d1 q 21 iv infusion, until disease progression of disease, unacceptable toxicity or patient's refusal. Pembrolizumab will be administered for a maximum of 2 years.
16343331|NCT04375943||diabetic HF-pEF patients|It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (>45%).
16343332|NCT04375943||diabetic HF-rEF patients|It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
16343333|NCT04375930|Experimental|Experimental|The patient will be trained with STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION. The patient will be follow up at 2nd, 6th and 12th weeks.
16343334|NCT04375930|Active Comparator|control|The patient will be trained only skills and discharge education. The patient will be follow up at 2nd, 6th and 12th weeks.
16343335|NCT04375917|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
16343336|NCT04375917|No Intervention|control|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
16343337|NCT04375904|Experimental|Radiation|Treatment will be delivered via image-guided (IG)-SABR in 8 fractions of 7.5Gy. OAR constraints must be respected but minimum dose coverage of 75% to 95% of the PTV will be allowed and minimum dose of 75% to 99% of the GTV will be allowed. The minimums are chosen to represent at least an equivalent BED to the RT standard fractionation of 55 Gy in 20 fractions based on actual treatment dose of 7.5Gy in 8 fractions. In stage 1 there will be 91 evaluable patients. If there are 35 or less ≥G3 TxR-AEs in these 91 evaluable patients, the study will be stopped, and concluded that the regime is not unsafe. If there are 43 or more ≥G3 TxR-AEs in these 91 patients, the study will be stopped, and the conclusion will be made that the regime is not safe. Otherwise, the study will proceed to stage 2 and 87 additional evaluable patients will be accrued (178 evaluable patients total). The conclusion will be made that the regime is not safe if 78 or more TxR-AEs are observed in 178 evaluable patients.
16343338|NCT04375891|Other|Radiotherapy|Radiotherapy alone
16343339|NCT04375891|Other|Radiotherapy plus radiofrequency ablation|Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)
16343340|NCT04375878|Active Comparator|MS1819 2240 mg/day vs PERT arm,|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
16343341|NCT04375878|Active Comparator|MS1819 4480 mg/day vs PERT arm|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
16343342|NCT04375865|Experimental|Treatment A|Period1: Celecoxib 200mg Period2: Tramadol 150mg Period3: Celecoxib 200mg + Tramadol 150mg
16343343|NCT04375865|Experimental|Treatment B|Period1: Celecoxib 200mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Tramadol 150mg
16343344|NCT04375865|Experimental|Treatment C|Period1: Tramadol 150mg Period2: Celecoxib 200mg Period3: Celecoxib 200mg + Tramadol 150mg
16343345|NCT04375865|Experimental|Treatment D|Period1: Tramadol 150mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Celecoxib 200mg
16343346|NCT04375865|Experimental|Treatment E|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Celecoxib 200mg Period3: Tramadol 150mg
16343347|NCT04375865|Active Comparator|Treatment F|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Tramadol 150mg Period3: Celecoxib 200mg
16343348|NCT04375852|Experimental|1|consecutive cases diagnosed with APS-1associated keratitis
16343349|NCT04375839|Experimental|Main treatment group|Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.
16343350|NCT04375839|Active Comparator|Control group|Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.
16343351|NCT04375826|Active Comparator|Epidural analgesia|Only Epidural analgesia is used for this group
16343352|NCT04375826|Active Comparator|Preperitoneal analgesia and IV-PCA|This group is given with both preperitoneal analgesia and Intravenous Patient Controlled Analgesia (IV-PCA)
16343353|NCT04375813|Active Comparator|Active Study Drug Group|Patients will be given 0.5mg eRapa (encapuslated rapamycin) orally each weekday (Monday-Friday) for one year.
16343354|NCT04375813|Placebo Comparator|Placebo Group|Patients will be given a placebo (visually identical to the eRapa (encapsulated rapamycin)) orally each weekday (Monday-Friday) for one year.
16343355|NCT04375800|Experimental|Doravirine + 2 NRTIs|Participants receive DOR (3.2 mg to 40 mg based on weight) in combination with 2 NRTIs (based on local label) for 96 weeks.
16344424|NCT04368000|Experimental|Prone Positioning|
16343361|NCT04375761||SARS-CoV-2 Surveillance: Total Group|"Participants either currently or in the past, enrolled in National Institutes of Health (NIH)-funded cohort studies, and their families (household contacts).
~Active surveillance for detection of SARS-CoV-2 for 6 months, beginning with enrollment. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed at the time that biological samples are collected."
16343362|NCT04375748||Patients treated for symptoms of acute myocarditis.|Patients treated in intensive coronary care unit (ICCU) or intensive care unit (ICU), in one of the participating hospitals, for symptoms of acute myocarditis confirmed by a myocardial MRI and/or a CT scan and/or a myocardial biopsy.
16343363|NCT04375735|Experimental|BLES treatment|For patients randomized to the treatment arm, exogenous BLES will be administered as soon as possible and within 48 hours of intubation. BLES will be administered daily for up to 3 doses, or until the patient is liberated from the ventilator.
16343364|NCT04375735|No Intervention|Control|Patients will receive standard treatment and will not receive surfactant.
16343365|NCT04375722|Experimental|tACS 10 Hz low frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
16343366|NCT04375722|Experimental|tACS 40 Hz high frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
16343367|NCT04375722|Sham Comparator|tACS sham|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.
16343368|NCT04375696|Experimental|Product|60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
16343369|NCT04375696|Placebo Comparator|Placebo|60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
16343370|NCT04375683|Experimental|Ph-positive ALLs|Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen. Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen
16343371|NCT04375657|Experimental|TRIIM Treatment|
16343372|NCT04375657|Active Comparator|Active Control|
16343373|NCT04375631|Experimental|Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)|"Patients receive filgrastim SC daily on days -9 to -4, cladribine IV over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If WBC > 20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients undergo TBI and HCT on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4, cyclosporine IV over 1-2 hours BID on days 5-60, and mycophenolate mofetil IV or PO BID on days 5-28 (transplant with related donors) or TID on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive cyclosporine tapered through day 180 at the discretion of the treating physician in the absence of GVHD."
16343374|NCT04375618|Experimental|EGF impregnated in collagen membrane|EGF impregnated in collagen membrane is placed in gingival recession defects
16343375|NCT04375618|Active Comparator|plain collagen membrane|plain collagen membrane is placed in gingival recession defects
16343376|NCT04375605|Active Comparator|Arm A (control arm)|Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, folinc acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
16343377|NCT04375605|Experimental|Arm B (experimental arm)|Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, folinic acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
16343378|NCT04375566||IT specialist|20 IT Specialist will evaluate the usability and patient-friendliness of the tool
16343379|NCT04375566||Doctors|13 doctors will evaluate the information in the tool
16343380|NCT04375566||Patients|10-20 patients will evaluate the utility and the contribution of the tool in decision making proces.
16343381|NCT04375553|Active Comparator|Exercise group|Intradialytic aerobic exercise, 3 times a week, for 12 weeks.
16343382|NCT04375553|No Intervention|Non-exercise group|Without intradialytic aerobic exercise for 12 weeks.
16343383|NCT04375540|Experimental|Upper first premolars extraction|Included 24 patients (7 males,17 females) with a mean age of 21.56±3.19years who were treated with fixed orthodontic appliance for 2.22±0.31years.
16343384|NCT04375540|Experimental|Upper second premolars extraction|Included 26 patients (8 males,18 females) with a mean age of 22.16±3.59years who were treated with fixed orthodontic appliance for 2.25±0.30 years.
16343385|NCT04375540|No Intervention|No intervention|Included 26 subjects (10 males, 16 females) with a mean age of 20.45±3.29years.This group was included to observe any changes in the vertical gingival display over the 2 years' observation period (1.65±0.17 years).
16343386|NCT04375527|Experimental|Treatment (binimetinib, nivolumab)|Patients receive binimetinib PO BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16343387|NCT04375514|Experimental|ARO-ENaC|ARO-ENaC Inhalation
16343388|NCT04375514|Placebo Comparator|Placebo|Sterile normal saline (0.9% NaCl)
16343389|NCT04375501||COVID-19 positive|All patients admitted with fractured neck of femur during specified time period testing POSITIVE for COVID-19
16343390|NCT04375501||COVID-19 negative|All patients admitted with fractured neck of femur during specified time period testing NEGATIVE for COVID-19
16343391|NCT04375488|Experimental|Resistance Exercise Training Group|Resistance exercise training for 8 major muscle groups and 150 min per week walking suggestions were given
16343392|NCT04375488|Experimental|Inspiratory Muscle Training Group|Resistance exercise training for 8 major muscle groups and inspiratory muscle strength training and 150 min per week walking suggestions were given
16343393|NCT04375488|No Intervention|Control Group|150 min per week walking suggestions were given.
16343394|NCT04375475|Experimental|Bright Changyou probiotic flavored yogurt|Bright Changyou probiotic flavored yogurt contains 5.0×10^8cfu/g of probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum ST-Ⅲ (7mg/kg), and 1.5% of inulin
16343395|NCT04375475|Active Comparator|Bright Changyou lactobacillus flavored yogurt|Bright Changyou flavored yogurt contains probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum ST-Ⅲ (7mg/kg)
16343396|NCT04375475|Active Comparator|Bright flavored yogurt|Bright flavored yogurt contains Lactobacillus bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus casei LC2W (0.1 mg/kg)
16343397|NCT04375462|Experimental|AspireAssist|"Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days, and the AspireAssist group will have a clinic visit at 7 days to have the skin-port placed.
~All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube"
16343398|NCT04375462|Active Comparator|Standard PEG|Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube
16343399|NCT04375449|Active Comparator|Pep2dia- dosage 1|700mg of whey protein hydrolysates single dose
16343400|NCT04375449|Active Comparator|Pep2Dia - dosage 2|1400mg of whey protein hydrolysates single dose
16343401|NCT04375449|Placebo Comparator|Placebo|maltodextrin single dose
16343402|NCT04375436|Active Comparator|NTRX-07-SDD|NTRX-07-SDD at 0.3-8mg/kg; single dose
16343403|NCT04375436|Placebo Comparator|Control|Placebo control
16343404|NCT04375423|Experimental|Intervention|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. In response to the behaviors they report, they receive messages on their smartphones supporting ongoing healthy behaviors or suggesting alternative behaviors to limit risks. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
16343405|NCT04375423|Active Comparator|Control|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
16343406|NCT04375397|Experimental|Ibrutinib|Participants will receive Ibrutinib along with supportive care.
16343407|NCT04375397|Placebo Comparator|Placebo|Participants will receive Placebo along with supportive care.
16343408|NCT04375384|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.
16343409|NCT04375371|Active Comparator|Obese patients who have received a bariatric surgery|Obese patients who have undergone a bariaric surgery as part of routine clinical management within the indication of this intervention.
16343410|NCT04375371|No Intervention|Obese patients without a bariatric surgery|Obese patients who have not undergone bariaric surgery.
16343411|NCT04375332|Experimental|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
16343412|NCT04375319|Experimental|OCT guided 3-month follow-up group|OCT guided the operation, and OCT reexamined 3 months after the operation to evaluate the vascular repair
16343413|NCT04375319|No Intervention|3-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 3 months after operation to evaluate vascular repair
16343414|NCT04375319|No Intervention|6-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 6 months after operation to evaluate vascular repair
16343415|NCT04375306|Active Comparator|angiography guided CABG|angiography guided CABG
16343416|NCT04375306|Experimental|RFR guided CABG|RFR guided CABG
16343417|NCT04375293|Experimental|AERD|Patients suffering from AERD
16343418|NCT04375293|Sham Comparator|Healthy|Healthy Controls
16343419|NCT04375293|Active Comparator|CRSwNP|Patients suffering from CRS with nasal polyps
16343420|NCT04375293|Active Comparator|CRSsNP|Patients suffering from CRS without nasal polyps
16343421|NCT04375280|Experimental|Cohort 1|Participants will be involved in a long-term evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 5 years with evaluations taking place at inclusion, 6 months, at 1, 2 and 5 years
16343422|NCT04375267|Experimental|177Lu-DOTA-TATE and olaparib|
16343423|NCT04375254||Intervention group|Medical students during psychiatry clerkship who received NbN psychopharmacology training
16343424|NCT04375254||Control group|Medical students during psychiatry clerkship who received standard psychopharmacology training
16343425|NCT04375241||Screening with Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
16343426|NCT04375228|Experimental|Rituximab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Rituximab.
16343428|NCT04375215|Active Comparator|Selective caries removal to soft dentin (one step)|In selective caries removal to soft dentine, after caries excavation application of liner will be done on pulpal floor. Teeth will then be filled with composite resin material.
16343429|NCT04375215|Active Comparator|Stepwise caries removal (two step)|The stepwise caries removal is a two step procedure. The first step is similar to selective caries removal to soft dentin group. In the second step, after 6 months lesion will be re-entered to remove remaining carious tissue till firm dentin is encountered. Once all the caries is removed from floor of cavity a liner followed by final restoration with composite will be performed.
16343430|NCT04375202|Experimental|Colchicine plus current care|Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
16343431|NCT04375202|No Intervention|Current care alone|Current care
16343432|NCT04375189|No Intervention|Standard Care|
16343433|NCT04375189|Experimental|Complex Clinic Arm|
16343434|NCT04375176||Tested positive for SARS-CoV-2|"Patients, tested positive for SARS-CoV-2, will be recruited in E.R. of the Ospedale Di Circolo - ASST Settelaghi Teaching Hospital in Varese."
16343435|NCT04375163|Experimental|Massage group (ME)|A sport massage was applied between the sets of an intense isokinetic exercise protocol for knee extensor muscles
16343436|NCT04375163|Active Comparator|Control|the break between the sets of an intense isokinetic exercise protocol for knee extensor muscles was passive
16343437|NCT04375150||Patients with advanced renal cell carcinoma (RCC)|
16343438|NCT04375137||Severe COVID|patients with positive PCR or compatible CT admitted in ICU or intubated
16343439|NCT04375137||Non-severe COVID-19|patients with positive PCR or compatible CT admitted in ward without hypoxia
16343440|NCT04375137||Healthy Controls|Healthy controls with negative IgM/IgG for COVID-19
16343441|NCT04375124|No Intervention|non-peptide group|This group will receive routine treatment and care for COVID-19.
16343442|NCT04375124|Active Comparator|peptide group|This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
16343443|NCT04375111|Active Comparator|SAP block for management of post-mastectomy pain|the patients in this group shall undergo Serraturs anterior plane block for management of post-mastectomy pain.
16343444|NCT04375111|Active Comparator|TTP block combined with SAP block for post-mastectomy pain|the patients in this group shall undergo combined Serraturs anterior plane block, and Transversus thoracic plane block for management of post-mastectomy pain.
16343445|NCT04375098|Experimental|Early COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility
16343446|NCT04375098|Experimental|COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for >7 days after enrolment
16343447|NCT04375085|Other|DESyne X2 Novolimus Eluting Coronary Stent System|
16343448|NCT04375072|Experimental|active tDCS paired with active MBM,|
16343449|NCT04375072|Active Comparator|sham tDCS paired with active MBM|
16343450|NCT04375072|Active Comparator|active tDCS paired with sham MBM|
16343451|NCT04375072|Sham Comparator|sham tDCS paired with sham MBM|
16343452|NCT04375059|Active Comparator|Study group|3 months of interactive attention training programs, 2 times per week, 15 min per session, a total of 24 sessions, with conventional rehabilitation programs
16343453|NCT04375059|No Intervention|Control group|3 months of conventional rehabilitation programs without interactive attention training programs
16343454|NCT04375046|Experimental|Experimental: rbACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
16343455|NCT04375046|No Intervention|No Intervention: Control group|Standard of care; no placebo
16343456|NCT04375033|Experimental|Sublingual Arm|"The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA TIP 40 guidelines 75, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.
~The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-24mg that is standard practice. While the target dose is 16-24mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks until week 48."
16343457|NCT04375033|Experimental|Injectable Arm|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.
16343458|NCT04375020||group1 on GABA|The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
16343459|NCT04375020||group 2 on just insulin|The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.
16343460|NCT04374994|Active Comparator|intervention group|Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks
16343461|NCT04374994|Placebo Comparator|control group|Males with sexual dysfunction who received daily placebo tablets for four weeks
16343462|NCT04374981|Experimental|Celecoxib|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
16343463|NCT04374981|Experimental|Montelukast|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
16343502|NCT04374708||trans men|fMRI: body morph test and neurocognitive testing
16343503|NCT04374708||trans women|fMRI: body morph test and neurocognitive testing
16344425|NCT04368000|Active Comparator|Usual care|
16343464|NCT04374968|Experimental|BFR Treatment|Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.
16343465|NCT04374968|No Intervention|Control|The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.
16343466|NCT04374955|Experimental|İnfantile colic|Mothers of babies diagnosed with infantile colic in the intervention group will receive routine care and start taking probiotic products after the first stool of the babies and blood is taken for intestinal permeability and will continue for 15 days.
16343467|NCT04374955|Other|Control|Mothers of babies diagnosed with infantile colic in the control group will receive routine care for 15 days after blood is taken for the first stool and intestinal permeability of the babies.
16343468|NCT04374942|Experimental|Study drug arm|50% of participants will be randomized to the study drug arm, and will take 400mg hydroxychloroquine orally once a day for three months (Day 1-90).
16343469|NCT04374942|Placebo Comparator|Placebo arm|50% of participants will be randomized to the placebo arm, and will take placebo orally once a day for three months (Day 1-90).
16343470|NCT04374929|Active Comparator|Negative Pressure Wound Therapy|
16343471|NCT04374929|Active Comparator|Anti-Inflammatory Glucocorticoid|
16343472|NCT04374929|Active Comparator|Increased Electrode Spacing|
16343473|NCT04374929|Other|Control|
16343474|NCT04374916|Experimental|Partosure® test + Premaquick® test|All patients will have the same 2 tests.
16343477|NCT04374890|Experimental|Experimental|
16343478|NCT04374877|Experimental|Part A Monotherapy Expansion|The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as monotherapy in up to 42 patients with advanced solid tumors.
16343479|NCT04374877|Experimental|Part B Indication-specific SRF388 Monotherapy Expansion|Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRF388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC (any clear cell component in the histologic definition) and up to 40 patients with HCC.
16343480|NCT04374877|Experimental|Part C SRF388 in Combination with Pembrolizumab|Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in combination with pembrolizumab in patients with advanced RCC or HCC.
16343481|NCT04374864|Experimental|Trilaglibtin 50 mg|Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg trilagliptin. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.
16343482|NCT04374851|Experimental|New Device|The new Hearing aid is essentially the same as the current device (i.e., hardware, use) but with an improved digital signal processing (DSP).
16343483|NCT04374851|Active Comparator|Current Device|The current device is the Hearing aid that is currently sold on the market. It is used as a normal Hearing aid that is worn daily to amplify sounds for Hearing-impaired people.
16343484|NCT04374825|Experimental|Acceptance and Commitment Therapy (ACT)|Weekly video conference groups led by a trained facilitator introducing key concepts of ACT
16343485|NCT04374825|Active Comparator|Cognitive Behavioral Stress Management (CBSM)|Weekly video conference groups led by a trained facilitator introducing key concepts of CBSM
16343486|NCT04374825|No Intervention|Usual care|Patients' usual health care as received over the duration of the pilot trial
16343487|NCT04374799|Active Comparator|Low dose heparin|heparin (25 IU/Kg -maximal dose 3,000 IU)
16343488|NCT04374799|Active Comparator|High dose heparin|heparin 50 IU/kg -maximal dose 5,000 IU
16343489|NCT04374799|Placebo Comparator|Placebo|Normal saline 0.9%.
16343490|NCT04374786|Experimental|Intervention Group|"Will receive a 30-day are trial of the mobile meditation app Calm on study day 0"
16343491|NCT04374773|Experimental|Estradiol|1 week treatment with 0.3 mg/24 hr transdermal estradiol
16343492|NCT04374773|Experimental|Cortisol|1 week treatment with 30 mg hydrocortisone daily, administered in 2 divided doses
16343493|NCT04374760|No Intervention|in-person control|Usual care, initial screening measures conducted in-person in the Emergency Department.
16343494|NCT04374760|No Intervention|Self-Administered Control|Usual care, initial screening measures conducted on their own via an iPad.
16343495|NCT04374760|Experimental|In-person Treatment|Treatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department.
16343496|NCT04374760|Experimental|Self-Administered Treatment|Treatment group (receives text messages), initial screening measures conducted on their own via an iPad.
16343497|NCT04374747|Experimental|Dietary Intervention|Intensive dietary counseling and fruit and vegetable box delivery.
16343498|NCT04374747|No Intervention|Information|Control condition of information on healthy eating during breastfeeding
16343499|NCT04374721|Experimental|Patients with Adrenal Insufficiency|Patients with Adrenal Insufficiency established or newly diagnosed, under glucocorticoid replacement therapy.
16343500|NCT04374721|Experimental|Patients with Cushing's Syndrome|patients with adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent Cushing's Syndrome diagnosis during active disease (new diagnosis or recidivating) at enrollment.
16343501|NCT04374721|Experimental|Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by Adrenal Insufficiency or Cushing's Syndrome.
16343508|NCT04374695||patients with COVID-19|Patients with positive RT-PCR for SARS-CoV-2, and patients with négative RT-PCR for SARS-CoV-2 but clinical presentation highly suggestive of COVID-19, and typical COVID-19 abnormalities on chest CT-Scan.
16343509|NCT04374695||patients without COVID-19|Patients with négative RT-PCR for SARS-CoV-2 and chest CT-Scan or chest X-ray not suggestive of COVID-19
16343510|NCT04374669||patients with lumbar spinal stenosis|Patients with lumbar spinal stenosis will be scheduled for neuroplasty.
16343511|NCT04374643||Confined patients|General population
16343512|NCT04374630|Experimental|Arm 1|Arm 1 is afuresertib 125 mg PO QD + paclitaxel 80 mg/m2 intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 3 week cycle.
16343513|NCT04374630|Active Comparator|Arm 2|Arm 2 is paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15 of a 3 week cycle
16343514|NCT04374617||Venous thromboembolism|Patients at risk of venous thromboembolism (deep venous thrombosis and/or pulmonary embolism)
16343515|NCT04374604||Paturients with preeclampisia|The participants will be pregnant women with late-onset pre-eclampsia
16343516|NCT04374591|Other|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
16343517|NCT04374591|Placebo Comparator|Control|placebo
16343518|NCT04374565|Experimental|Study participants|A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.
16343519|NCT04374552|Experimental|Hydroxychloroquine & Azithromycin|Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days
16343520|NCT04374552|Placebo Comparator|Placebo|Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)
16343521|NCT04374539|Experimental|Plasma exchange|Plasma exchange with human serum albumin + Polyclonal immunoglobulin + standard medical treatment
16343522|NCT04374539|Active Comparator|Standar medical treatment|Standar medical treatment
16343523|NCT04374526|Experimental|Convalescent plasma|Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy
16343524|NCT04374526|No Intervention|Standard therapy|Patients receive standard therapy alone
16343525|NCT04374500|Experimental|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and blood flow was measured. The other forearm was used as the control.
16343526|NCT04374500|Experimental|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
16343527|NCT04374500|Experimental|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse. The other forearm was used as the control.
16343528|NCT04374487|Experimental|Test Arm|50 subjects will be randomized in this arm. Patients in the test group will receive convalescent plasma.
16343529|NCT04374487|Other|Control Arm|50 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.
16343530|NCT04374474|Sham Comparator|Control Group|The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.
16343531|NCT04374474|Experimental|Olfactory Retraining Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.
16343532|NCT04374474|Experimental|Olfactory Retraining_Budesonide Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.
16343533|NCT04374461|Experimental|mechanically ventilated &/or managed in a critical-care|"This arm is closed to accrual as of September 2020. Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.
~Patients will receive treatment for a maximum of 3 weeks or until one of the following:
~Arm A:
~Transfer out of the critical-care unit
~Extubation
~Toxicity
~Death"
16343534|NCT04374461|Experimental|non-mechanically ventilated, non-critical-care|"Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.
~Patients will receive treatment for a maximum of 3 weeks or until one of the following:
~Arm B:
~Discharge from hospital
~Admission to a critical-care unit
~Intubation
~Toxicity
~Death"
16343535|NCT04374448|Other|Sinus Tumor Resection|Those who are undergoing endoscopic sinonasal surgery for benign and malignant tumor removal.
16343536|NCT04374448|Other|Skull Base Surgery|Those who are receiving Endoscopic Skull Base Surgery (ESBS) for minimally-invasive access for removal of skull base tumors, most commonly for ones of pituitary origin.
16343537|NCT04374448|Other|Endoscopic Sinus Surgery|Individuals with chronic rhinosinusitis (CRS) with or without polyposis that are to have endoscopic sinus surgery, a minimally invasive procedure to open the sinuses.
16343538|NCT04374448|Other|Epistaxis Management|Those who have severe nose bleeds and requires going into the operating room for management.
16343539|NCT04374435|Experimental|MKTP with Surgical Blade|The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
16343540|NCT04374435|Experimental|MKTP with Negative Pressure Instrument|Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
16343541|NCT04374435|Experimental|Suction blister grafting without cell dissociation|In this arm, transplanting the blisters without dissociation of the cells will be conducted.
16343542|NCT04374422||1|study group pre-pandemic time interval
16343544|NCT04374409|Experimental|High-flavanol Cocoa powder|Dietary supplement: single serving of a high-flavanol cocoa powder containing 150 mg of (-)-epicatechin and 35.5 mg of (+)-catechin
16343545|NCT04374409|Active Comparator|Low-flavanol Cocoa powder|Dietary supplement: single serving of a low-flavanol cocoa powder intervention containing < 4 mg of (-)-epicatechin and (+)-catechin and matched as best as possible for macronutrients and micronutrients, such as caffeine and theobromine.
16343546|NCT04374396|Sham Comparator|Group 1|patients in this group will receive sham ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery without injection of local anesthetics
16343547|NCT04374396|Experimental|Group 2|patients in this group will receive real ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery with injection of 0.3 ml/kg of 0.25% of plain bupivacaine.
16343548|NCT04374383|Experimental|main treatment group|LASER assisted SRP followed by antimicrobial photodynamic therapy with a novel photosensitizer dye Phthalocyanine
16343549|NCT04374383|Placebo Comparator|control group|LASER assisted SRP
16343550|NCT04374344||Medical professionals|Medical professionals including cardiologists and cardiology residents.
16343551|NCT04374331|Experimental|Video-Assisted Training Group|The patients in the VAT group watch a training video in the patient rooms before RCR in addition to the routine treatment and care in the unit.
16343552|NCT04374331|No Intervention|control group|The control group received the routine treatment and care in the unit. The routine treatment and care of the unit includes verbal briefing by physicians and nurses about the surgical procedure before RCR, cold application and analgesic application for pain control after RCR, using arm sling, verbal discharge training (e.g., drug use, exercises, follow-up time, etc.) and discharge on the first post-operative day in the absence of complications. In addition, patients are invited to weekly controls to explain how to do the exercises and, if necessary, they are referred to physiotherapy.
16343553|NCT04374318|Active Comparator|IT intrathecal|administration of intrathecal dexmedetomidine in addition to bupivacaine for lower limb surgeries
16343554|NCT04374318|Active Comparator|IV intravenous|administration of intravenous dexmedetomidine in addition to spinal anaesthesia for lower limb surgeries
16343555|NCT04374305|Experimental|Brigatinib Sub-Study|Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
16343556|NCT04374292|Experimental|Intervention group|"Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.
~The key message was that healthy dietary habits and health risks are acquired at home and that opportunities for change can be identified in the processes that surround meal times. It begins with selecting and purchasing food, followed by preparation and consumption behaviors. Mothers were encouraged to participate in the sessions which involved the use of food models, videos, slides, and, in some cases, real food. Upon completing each session, mothers were given printed material to add to a home consultation manual.
~Upon concluding consultations and group sessions, mother/child pairs from both groups were asked to return for monthly follow-ups over the next three months."
16343557|NCT04374292|Active Comparator|Control group|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. Similarly, CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
16343558|NCT04374279|Active Comparator|Standard of care and bicalutamide|Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care
16343559|NCT04374279|No Intervention|Standard of care only|Randomized participants receive standard of care only.
16343560|NCT04374253|Experimental|Group 1|Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 104 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
16343561|NCT04374253|Experimental|Group 2|Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
16343562|NCT04374240|Experimental|AdNRGM followed on day 2 by CB1954|The proposed dose levels for AdNRGM are 10^10, 3x10^10, 10^11, 3x10^11, 10^12 vp while the prodrug CB1954 will be given at a standard dose of 24 mg/m^2
16343563|NCT04374227|Experimental|Treatment Group|The treatment group received three osteopathic manipulative treatments once a week for three weeks. The osteopathic manipulative treatment was a full body treatment based upon Dr. Zink's model of a common compensatory pattern.
16343564|NCT04374227|No Intervention|Control Group|This group received an osteopathic structural exam once a week for three weeks without any treatment performed.
16343565|NCT04374214|Active Comparator|Complete Pulpotomy using mineral trioxide aggregate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Mineral Trioxide Aggregate.
16343566|NCT04374214|Active Comparator|Complete Pulpotomy using Simvastatin-alphatricalcium phosphate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Simvastatin -alphatricalcium phospahte.
16343567|NCT04374201||2 zirconia FDPs|11 patients received 2 zirconia fixed dental prostheses
16343568|NCT04374201||1 zirconia FDP|26 patients received 1 zirconia FDP
16343569|NCT04374188|Active Comparator|ciprofloxacin|ciprofloxacin tablets
16343570|NCT04374188|Active Comparator|levofloxacin|levofloxacin tablets
16343571|NCT04374175||Adenocarcinoma group|Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
16343572|NCT04374175||Control group|Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
16343573|NCT04374162|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
16343574|NCT04374162|Experimental|Driving pressure (DP) guided-PEEP|"DP is calculated as plateau pressure - PEEP. 10 min after pneumoperitoneum， PEEP is increased from 5 to 15 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
16343575|NCT04374149|Experimental|1 - TPE Alone|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
16343576|NCT04374149|Experimental|2 - TPE Plus Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
16343577|NCT04374136|Experimental|AL001|AL001 every 4 weeks
16343578|NCT04374136|Placebo Comparator|Placebo|Placebo every 4 weeks
16343579|NCT04374136|Experimental|Open label - AL001|AL001 every 4 weeks
16343580|NCT04374110||Hospitalized patients with COVID-19|Hospitalized patients with COVID-19 will be included in the study in centers around Poland.
16343581|NCT04374110||Infected SARS-CoV-2 patients|patients with SARS-CoV-2 infection not requiring hospitalization
16343582|NCT04374110||Controls|structure-matched and co-existing disease matched control group from the general population.
16343583|NCT04374084|Experimental|Moxibustion plus Cupping|"Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas:
~A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6)."
16343584|NCT04374084|No Intervention|Basic therapy|Basic therapy: rehabilitation direction and basic breathing exercise.
16343585|NCT04374071||Pre-Corticosteroid protocol|Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
16343586|NCT04374071||Corticosteroid Protocol|"As a result of observed poor outcomes, clinical rationale based upon immunology, clinical course of COVID-19, and more recently best available evidence, the HFHS corticosteroid protocol was developed. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the institutional standard on March 20, 2020. Patients with confirmed influenza infection were not recommended to receive corticosteroids.
~Patients with moderate COVID-19 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days."
16343587|NCT04374058||Two Times|The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
16343588|NCT04374058||Three times|Usual thrice-weekly hemodialysis schedule
16343589|NCT04374045||Patients with SARS-CoV-2|patients having a continuous recording of the heart rhythm during their hospitalization
16343590|NCT04374032|Experimental|ENKORTEN|
16343591|NCT04374032|Other|The standard of care treatment|The usual therapeutically established protocol for the treatment of patients with moderate to severe COVID-19 infection
16343592|NCT04374019|Experimental|Arm C: Ivermectin|Ivermectin
16343593|NCT04374019|Experimental|Arm D: Camostat Mesilate|Camostat Mesilate
16343594|NCT04374019|Experimental|Arm E: Artemesia annua|Artemesia annua tea or coffee
16343595|NCT04374019|Experimental|Arm F: Artesunate|Artesunate
16343596|NCT04374006|Experimental|propolis 50|we do sonde everyday to the rat that given treatment of 50mg/kg propolis for 2, 4, and 6 weeks
16343597|NCT04374006|Experimental|propolis 100|we do sonde everyday to the rat that given treatment of 100mg/kg propolis for 2, 4, and 6 weeks
16343598|NCT04374006|Active Comparator|dienogest|we do sonde everyday to the rat that given treatment of 25mg/kg dienogest for 2, 4, and 6 weeks
16343599|NCT04374006|Placebo Comparator|water|we do sonde everyday to the rat that given 0,2 ml water placebo for 2, 4, and 6 weeks
16343600|NCT04374006|Sham Comparator|sham group|after the 2nd laparotomy, we do nothing about sonde, just giving food and drink everyday
16343601|NCT04373993||Nordlandssykehuset HF|
16343602|NCT04373993||Akershus universitetsssykehus|
16343603|NCT04373993||Helgelandssykehuset|
16343604|NCT04373993||Basel University Hospital|
16343605|NCT04373980|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
16343606|NCT04373980|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
16343607|NCT04373980|No Intervention|Control group|
16343608|NCT04373967|Experimental|TQZ2451+metformin hydrochloride|TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
16343609|NCT04373967|Active Comparator|Victoza®+metformin hydrochloride|Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
16343610|NCT04373954|Experimental|Forgiveness Therapy|6-month Forgiveness Therapy; Participants meet once per week, in group setting.
16343611|NCT04373954|Active Comparator|Carey Guides|6-month Carey Guides; Participants meet once per week, in group setting.
16343612|NCT04373941|Experimental|Kasai GCSF|The Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously by day 3 post Kasai surgery
16343613|NCT04373941|No Intervention|Kasai no GCSF|The no GCSF group will not receive GCSF and receives the standard of care
16343614|NCT04373941|Experimental|No Kasai GCSF|The No Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously once the diagnosis of BA is established
16343615|NCT04373941|No Intervention|No Kasai No GCSF|The No Kasai No GCSF group will receive the standard of care and will not receive GCSF
16343616|NCT04373928|Experimental|Drug guided by Mini-PDX/PDX|Procedure: The tumor tissue is used for drug sensitivity test by Mini-PDX, building PC PDX, and acquiring the genetic information by the second genetic sequence or RNA-sequence. PC patients will accept personalized treatment guided by the experimental results of mini-PDX and sequencing.
16343617|NCT04373928|No Intervention|Drug according to guideline|The drugs (gemcitabine, Nab-paclitaxel, S-1) are used ccording to NCCN pancreatic cancer guideline。
16343618|NCT04373915|No Intervention|Standard Bedside Rounding|
16343619|NCT04373915|Experimental|Remote Bedside Rounding|Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.
16343620|NCT04373902|Experimental|Physiological-based cord clamping|In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate >100 bpm and preductal oxygen saturation >85%, while using an fraction of inspired oxygen (FiO2) of <0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.
16343621|NCT04373902|No Intervention|Immediate cord clamping|In the immediate cord clamping group, the cord will be clamped immediately after birth. The infant will then be transferred to the standard neonatal resuscitation table. After cord clamping, all infants will be managed according to the standardised neonatal management protocol for infants with a CDH, which is a consensus of current clinical guidelines by the CDH EURO consortium.
16343622|NCT04373850|Experimental|Home visit group|Will receive a home visit after discharge in addition to the standard discharge planning.
16343623|NCT04373850|No Intervention|Control group|Will receive only the standard discharge planning.
16343626|NCT04373824|Experimental|Group I- Ivermectin|First group with 25 confirmed cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol
16343627|NCT04373824|No Intervention|Group II- standard treatment|The second group with 25 confirmed cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19.
16343628|NCT04373811||Principal cohort|"Quality of life, autonomy and survival will be assessed at one year on 50 patients.
~Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization."
16343629|NCT04373811||Lung cohort|Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.
16343630|NCT04373811||Muscle cohort|Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.
16343631|NCT04373798||Suspected COVID-19|Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
16343632|NCT04373785|Experimental|NG101m and standard treatment|"Concomittant therapy:
~Radiation therapy, oral temozolomide, and oral NG101m
~Adjuvant therapy:
~Oral temozolomide and oral NG101m"
16343633|NCT04373772|Experimental|abdominal massage group|the abdominal massage group received a total of 30 minutes of massage, 15 minutes every morning and evening, until the first defecation.
16343634|NCT04373772|No Intervention|control group|Routine care for the control group
16343635|NCT04373759||Unexpected in-intensive care unit cardiac arrest patients|ICUCA Patients admitted in intensive care unit for a confirmed COVID-19 and presenting an unexpected in-intensive care unit cardiac arrest
16343636|NCT04373759||In-hospital cardiac arrest patients|IHCA Patients admitted in intensive care unit for an in-hospital cardiac arrest with a confirmed Covid-19
16343637|NCT04373759||Out-of-hospital cardiac arrest|OHCA Patients admitted in intensive care unit for an out-hospital cardiac arrest with a confirmed Covid-19
16343638|NCT04373746|Experimental|10-20 kg|Patients undergoing major surgery that weigh between 10-20 kg.
16343639|NCT04373746|Experimental|20-40 kg|Patients undergoing major surgery that weigh between 20-40 kg.
16343640|NCT04373746|Experimental|40-80 kg|Patients undergoing major surgery that weigh between 40-80 kg.
16343641|NCT04373733|Experimental|Favipiravir & Standard of Care|Favipiravir: Day 1 1800mg twice per day, Days 2-10 800mg twice per day
16343642|NCT04373733|Other|Standard of care|No trial intervention
16343643|NCT04373720|Experimental|Diagnostic (MRE, standard of care MRI)|Patients undergo MRE over 10 minutes and then undergo standard of care MRI of the brain with and without contrast at baseline. Within 4 weeks after the initial MRI and MRE scans, patients may undergo standard of care biopsy to check the status of the disease. Within 48 hours after biopsy, patients undergo standard of care MRI to check the status of the disease. Patients who do not undergo biopsy undergo standard of care MRI 4-8 weeks after MRE scan to check the status of the disease.
16343644|NCT04373707|Active Comparator|Low Prophylactic Dose of Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
16343645|NCT04373707|Experimental|Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
16343648|NCT04373668|No Intervention|Control, optimised usual care|Treatment delivered as usual in the care home
16343649|NCT04373668|Experimental|Hypnotic Drug Review|Care homes to receive the Hypnotic Drug Review intervention
16343650|NCT04373668|Experimental|Structured Sleep Hygiene|Care homes to receive the Structured Sleep Hygiene intervention
16343651|NCT04373668|Experimental|Night Time Care Activities Programme (NightCAP)|Care homes to receive the Night Time Care Activities Programme (NightCAP) intervention
16343652|NCT04373668|Experimental|Hypnotic Drug Review and Structured Sleep Hygiene|Care homes to receive the Hypnotic Drug Review and Structured Sleep Hygiene interventions
16343653|NCT04373668|Experimental|Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP|Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions
16343654|NCT04373668|Experimental|Hypnotic Drug Review and NightCAP|Care homes to receive the Hypnotic Drug Review and NightCAP interventions
16343655|NCT04373668|Experimental|Structured Sleep Hygiene and NightCAP|Care home to receive the Structured Sleep Hygiene and NightCAP interventions
16343656|NCT04373642|Experimental|Pembrolizumab + QUADSHOT Radiotherapy|"Combination Treatment
~Pembrolizumab by IV once on day 1 of 21 day cycle, begin 7 days before the first round of QUAD SHOT radiotherapy.
~QUAD SHOT radiotherapy twice a day for two days, begin 7 days after the first dose of pembrolizumab; repeat every 28 days for up to 3 rounds.
~Maintenance Treatment
~Pembrolizumab by IV once on day 1 of 21 day cycle
~On day 21, if the medical oncologist feels that the patient may safely continue treatment, patient will receive a new 21 days cycle of treatment with pebrolizumab."
16343657|NCT04373629|Experimental|attention modulation|
16343658|NCT04373629|Experimental|perceptual modulation|
16343659|NCT04373629|Experimental|naturalistic viewing|
16343662|NCT04373603|Experimental|Intervention: HA plus TXA|HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
16343663|NCT04373603|Placebo Comparator|Control: HA plus Saline|HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
16343664|NCT04373590|Experimental|Decision aid (DA)|a one-page DA for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics.
16343665|NCT04373590|No Intervention|Treatment as usual (TAU)|Treatment as usual without the DA
16343666|NCT04373577|Experimental|ESP group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected beneath the erector spinae muscle sheath at the level of the transverse process of the second lumbar vertebrae
16343667|NCT04373577|Experimental|PENG group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected as the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
16343668|NCT04373564|Experimental|Linear GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan) prior to MRI. Each participant will receive the same GBCA throughout the study.
16343669|NCT04373564|Experimental|Macrocyclic GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI. Each participant will receive the same GBCA throughout the study.
16343670|NCT04373564|Other|No GBCA (Control arm)|Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms. They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g. unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).
16343671|NCT04373551|Experimental|Cultural adaptation of a patient-provider communication tool|Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
16343672|NCT04373538|Experimental|Memory Support Intervention|
16343673|NCT04373512|Experimental|Low Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermitent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
16343674|NCT04373512|Experimental|High Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
16343696|NCT04373356|Experimental|Resin Infiltration|The interproximal surface with initial dental caries that are selected for this group will be treated using the resin infiltration ICON (DMG, Germany) and 5% Sodium Fluoride Varnish
16343697|NCT04373356|Active Comparator|Sodium Fluoride Varnish|The interproximal surface with initial dental caries that are selected for this group will be treated using topical application of 5% Sodium Fluoride Varnish.
16343698|NCT04373343|Other|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
16343675|NCT04373499|Experimental|Virtual Teach-to-Goal (V-TTG)|"The RA will show the patient how to use the tablet to access the education module and be available for questions about the technology / tablet but not about the content. Within the module, the child will:
~answer questions about how to use the inhaler as part of a pre-video assessment.
~watch a video about how to correctly use a Metered Dose Inhaler (MDI) and spacer.
~answer questions on the tablet to assess how well they understand how to use the inhaler.
~If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions."
16343676|NCT04373499|Active Comparator|Brief Intervention (BI)|The RA will give the patient a handout about inhaler technique and read the steps to the child.
16343677|NCT04373473|Experimental|Patients with UC will receive FMT capsules|Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors
16343678|NCT04373473|Placebo Comparator|Patients with UC will receive placebo|Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
16343679|NCT04373460|Experimental|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; ~200-250 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
16343680|NCT04373460|Active Comparator|Standard Control plasma|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
16343681|NCT04373447|Active Comparator|fundus-calot laparoscopic cholecystectomy|use laparoscopic fundus first then calot dissection cholecystectomy
16343682|NCT04373447|Active Comparator|open cholecystectomy|open cholecystectomy
16343683|NCT04373434|Experimental|HH/HF in 2-1-1|"The intervention will be delivered weekly alternating between phone and text/e-mail contact. The Coach will contact participants one week after baseline to review the home environment profile and select the first healthy action. The Coach will review the profile, then present a list of low-cost healthy actions that target possible environmental changes to make in the home. Using a series of open-ended questions, the coach guides participants to select a healthy action to work on. This will be followed at weekly intervals by text/e-mail check-ins to reinforce progress. More healthy actions are added in future calls, for a total of three healthy actions across three months. Participants will document the selected healthy actions on a family contract. The coaching calls, text messages and intervention materials are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention."
16343684|NCT04373434|Active Comparator|Control|Participants in the control condition will receive two mailings on healthy eating. They will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes as HH/HF in 2-1-1, but without the home environment emphasis. Participants will be sent their home environment profile with a list of healthy actions upon completion of the study.
16343685|NCT04373421|Active Comparator|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
16343686|NCT04373421|Active Comparator|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
16343687|NCT04373421|Active Comparator|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
16343688|NCT04373408||ACL rupture without indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL only
16343689|NCT04373408||ACL rupture with indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL and the ALL
16343690|NCT04373395|Experimental|D-CLAG|Administration of D-CLAG regimen (Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor)
16343691|NCT04373382|Experimental|Peer Resilience Champion Support|The clusters that receive this intervention will receive support from a Peer Resilience Champion.
16343692|NCT04373382|No Intervention|No Peer Resilience Champion Support|The clusters in this arm of the study will not receive the Peer Resilience Champion support until they cross-over into the Peer Resilience Champion support arm.
16343693|NCT04373382|Experimental|Enriched Feedback|This arm of the study encompasses individuals who will receive feedback from the survey that will hopefully help provoke self-reflection.
16343694|NCT04373382|No Intervention|Express Feedback|This arm of the study encompasses individuals who will not receive feedback from the survey.
16343695|NCT04373369|Experimental|Vorolanib + Atezolizumab|Consenting and eligible participants who have no evidence of tumor progression after 3 to 4 cycles of standard-of-care induction therapy will receive atezolizumab intravenously (IV) every 3 weeks and vorolanib by mouth daily. Participants can continue to receive treatment up to two years.
16343703|NCT04373304|Experimental|low FODMAP diet|
16343704|NCT04373291|Active Comparator|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.
~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
16343705|NCT04373291|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine.
16343706|NCT04373278||description of infection of free fibula flap reconstruction|
16343707|NCT04373265|Experimental|Relacorilant in Combination with Pembrolizumab|"Patients will treated with a lead-in of 300 mg relacorilant once daily from Day -3 to Cycle 1 Day 1 prior to the first dose of pembrolizumab. From Cycle 1 Day 1 until confirmed p or unacceptable toxicity with relacorilant and pembrolizumab. Pembrolizumab will be administered every 6 weeks (on Day 1 of each 42-day cycle) and relacorilant will be administered daily.
~On Cycle 1 Day 2, the patient's dose increases to 100 mg relacorilant once daily for 2 weeks. The patient's relacorilant doses may then escalate by 100-mg increments every 2 weeks based on tolerability until they reach 400 mg relacorilant once daily.
~For patients who tolerate the 400 mg relacorilant once daily, but their Cushing-syndrome symptoms persist, further dose escalation in 100-mg increments to a maximum of 600 mg relacorilant once daily may be considered after approval of the Medical Monitor and as long as the patient's AUC0-24 at their current dose does not exceed the maximum allowable exposure."
16343708|NCT04373252|Experimental|Fecal Microbiota Transplant|All participants will receive two fecal microbiota transplants one week apart. The transplant will occur via antegrade enema and the enema transplant material will be provided by OpenBiome, the product used is FMT Lower Delivery (FMP 30).
16343709|NCT04373239||Women in BC conceiving by ART|All women in BC registered in the Perinatal Services BC database having undergone Assisted Reproductive Technology. Assisted Reproductive Technology will consist of in vitro fertilization (+/-ICSI). Data from April 1, 2008 to March 31 2018 will be analyzed for live birth rate.
16343710|NCT04373239||Women in BC conceiving spontaneously|he comparison group will be all women in BC registered in the Perinatal Services BC database with spontaneously conceived pregnancies between April 1, 2008 to March 31 2018.
16343711|NCT04373226|Experimental|22q11.2DS|Children aged from 4 to 11 years old with 22q11.2 deletion syndrome
16343712|NCT04373226|Active Comparator|NON22q11.2DS|Children aged from 4 to 11 years old without developmental disease
16343713|NCT04373213||Pleth variability index|Patients undergoing fluid management with Pleth variability index
16343714|NCT04373213||hemodynamic|Patients undergoing fluid management with hemodynamic findings
16343715|NCT04373200|Experimental|COVID-19 patients with associated ARDS|
16343716|NCT04373200|Active Comparator|COVID-19 patients without associated ARDS|
16343717|NCT04373200|Active Comparator|Patients with ARDS from other causes|
16343718|NCT04373187|Experimental|CC-93538, 180mg/mL|26 healthy subjects will receive one injection of 2mL, 180mg/mL CC-93538
16343719|NCT04373187|Experimental|CC-93538, 150mg/mL|26 healthy subjects will receive 2 injections of 1.2mL, 150mg/mL CC-93538
16343720|NCT04373174|Active Comparator|Group E|Thoracic Epidural block + Regional oximetry probe will be placed in the frontal area of the head
16343721|NCT04373174|Sham Comparator|Group P|Regional oximetry probe will be placed in the frontal area of the head
16343722|NCT04373161|Experimental|Suspected COVID-19 patients being discharged to home|Patients will be given a portable, fingertip pulse oximeter to take home. Patients will monitor their resting home oxygen saturation three times per day.
16343723|NCT04373148||COVID-19|Participants diagnosed with COVID-19
16343724|NCT04373148||Controls|Participants not diagnosed with COVID-19
16343725|NCT04373135|Experimental|Experimental|Subjects will be provided a brief educational intervention prior to completing follow up survey about SRA attitudes and knowledge
16343726|NCT04373135|No Intervention|Control|Subjects will not be provided any prior to completing follow up survey about SRA attitudes and knowledge
16343727|NCT04373122|Experimental|REBOA|Insertion of the ER-REBOA Catheter during ongoing CPR
16343783|NCT04372706|Experimental|Part 2: RTX-240 Solid Tumor Expansion|Phase 2: RTX-240 administered intravenously on Day 1 of each cycle.
16343728|NCT04373109||Single-group study|Assessment of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
16343729|NCT04373096|Active Comparator|Group C (Control)|Will use current IPAC-UHN PPE as described under assigned intervention:
16343730|NCT04373096|Experimental|Group H (enhanced PPE group )|Will use modified IPAC-UHN PPE including the prototype hood as described under assigned intervention:
16343731|NCT04373083|Experimental|Concomitant treatment|Treatment Group A
16343732|NCT04373083|Experimental|Sequential treatment|Treatment Group B
16343733|NCT04373070|Experimental|chatbot-based intervention programme (intervention)|"Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the Living well with COPD programme (e.g. educational content, information on exercise training) to the patient."
16343734|NCT04373070|Other|Usual care group (control)|Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity.
16343735|NCT04373057|Experimental|Galacto-oligosaccharide|"Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant.
~Phase II: Subjects will receive GOS, at dose levels 0.25*MTD, 0.5*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant."
16343736|NCT04373057|Placebo Comparator|Maltodextrin|Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
16343737|NCT04373044|Placebo Comparator|Arm II (placebo, antiviral therapy)|Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
16343738|NCT04373044|Experimental|Treatment (baricitinib, antiviral therapy)|Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
16343739|NCT04373031|Experimental|Control|Control Arm: (Pembro + ACT): Pembrolizumab induction (single-dose 200mg IV), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
16343740|NCT04373031|Experimental|Arm A|• Arm A: (Pembro + IRX-2 + ACT): Pembrolizumab (single-dose 200mg IV) + cyclophosphamide (single-dose 300 mg/m2 IV) + IRX-2 induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by IRX-2 re-induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
16343741|NCT04373018|Active Comparator|Sodium hypochlorite|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Sodium hypochlorite during biomechanical preparation.
16343742|NCT04373018|Active Comparator|Chlorhexidine|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Chlorhexidine during biomechanical preparation.
16343743|NCT04373018|Experimental|Chlorhexidine + Hydrogen peroxide|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using a combination of Chlorhexidine + Hydrogen peroxide during biomechanical preparation.
16343744|NCT04373005||Nasopharyngeal (NP) swabs|"NP swabs:
~At the time of consent
~3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment)
~3 months after second swab
~6 months after second swab
~12 months after second swab"
16343745|NCT04372992|Experimental|Early stoma closure|Ileostomy closure between 30 and 40 day after rectal resection
16343746|NCT04372992|Active Comparator|Delayed stoma closure|Ileostomy closure 15 days from the end of adjuvant therapy (up to 60 days)
16343747|NCT04372979|Experimental|SARS-CoV-2 patients treated with convalescent plasma|Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
16343748|NCT04372979|Active Comparator|SARS-CoV-2 patients treated with standard plasma|Subjects will receive an intravenous injection of standard Plasma.
16343749|NCT04372966|Active Comparator|Cemented|This group will receive a cemented Exeter stem and contemporary acetabular component (Stryker).
16343750|NCT04372966|Active Comparator|Uncemented|This group will receive an uncemented Corail stem and uncemented acetabular component (Depuy).
16343751|NCT04372953|Active Comparator|Static PEEP Group|Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.
16343752|NCT04372953|Experimental|Dynamic PEEP Group|"Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm.
~If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O."
16343753|NCT04372940|Experimental|Intervention Side: TXA Irrigation|2.5% tranexamic acid will be applied directly to the wound via bulb irrigation and left in place for 5 minutes in the wound bed
16343754|NCT04372940|Placebo Comparator|Control Side: Saline Irrigation|Contralateral side will serve as a control
16343784|NCT04372706|Experimental|Part 3: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in AML
16344426|NCT04367987||Patients undergoing colorectal surgery|
16343756|NCT04372914|Experimental|BRB Lozenges|Oral lozenges that contain 1 gram of BRB freeze-dried powder
16343757|NCT04372901|Experimental|digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
16343758|NCT04372901|Active Comparator|digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement
16343759|NCT04372888|Other|rare genetic disease|Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)
16343760|NCT04372888|Other|common genetic disease|Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)
16343761|NCT04372875|Experimental|SHS-derived CDS|All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
16343762|NCT04372875|No Intervention|Usual care|All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
16343763|NCT04372862|Active Comparator|Serratus anterior plane block|Serratus anterior plane block was performed in the supine position placing the ipsilateral upper limb in abduction 90 degrees position. Aiming to find the serratus anterior muscle the investigator identified the fifth rib in the mid-axillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) were detected using ultrasound. The investigator penetrated the serratus anterior muscle by a 25 GA, 90 mm spinal needle in-plane concerning the ultrasound probe from superoanterior to posteroinferior to inject deep to it.
16343764|NCT04372862|Active Comparator|Erector spinae plane block|Erector spinae plane block was performed at lateral decubitus with the operation site up, the vertebrae were counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe was placed vertically 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle.
16343765|NCT04372849|Active Comparator|Nasal insulin spray|
16343766|NCT04372849|Placebo Comparator|Placebo spray|
16343767|NCT04372836|No Intervention|Control arm|During laparoscopic enucleation of unilateral endometrial cyst, no intervention is added to subjects allocated to control arm.
16343768|NCT04372836|Experimental|Study arm (with vasopressin injection)|During laparoscopic enucleation of unilateral endometrial cyst, diluted vasopressin is injected into the interface between endometrioma and ovarian parenchyma of patients allocated to study arm.
16343769|NCT04372823||Comparison|Comparison children within family child care homes not exposed to policy/program
16343770|NCT04372823||Intervention|Intervention children within family child care homes exposed to policy/program
16343771|NCT04372810|Experimental|Intervention Group|Intervention group, assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention and again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).
16343772|NCT04372810|Sham Comparator|Sham Group|Sham group, evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up).
16343773|NCT04372797|Experimental|Mild Traumatic Brain Injury Participants|Males and females from 18-50 years of age who present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria: 1) clear mechanism of injury (i.e., direct or indirect impact to head), 2) Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and 3) neurosensory symptoms.
16343774|NCT04372797|Active Comparator|Control Participants|Age- and sex-matched control subjects with minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mild traumatic brain injury will be recruited from the same study sites.
16343775|NCT04372784|Active Comparator|EGD with Balloon Dilatation|Esophagogastroduodenoscopy with balloon dilatation
16343776|NCT04372784|Experimental|EGD with Balloon Dilatation and Cryotherapy|Esophagogastroduodenoscopy with balloon dilatation and cryotherapy
16343777|NCT04372771|No Intervention|Control|No diet or exercise intervention
16343778|NCT04372771|Experimental|Curves Program|The Curves group will follow the high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 7-days at 1,200 kcals/day and then 1,500 kcals/day for the remaining 21-days of the 30-day diet period. The participants will then consume a normal maintenance diet (2,200 kcals/d; 45% carbohydrate, 30% protein, 25% fat) for 30-days. During the maintenance period, participants will diet for 2-days at 1,200 kcals/day if they gain 3 pounds of weight.
16343779|NCT04372771|Experimental|Weight Watchers Momentum Program|"This program is based on the Weight Watchers four pillar approach (food, exercise, behavior and support). The Momentum Program uses POINTS values to help keep track of what you eat. A POINTS budget will be personalized for you at the weekly meetings."
16343780|NCT04372732||Study group|All participants will be detected for antoantibodies and then treated with PD-1 blockade.
16343781|NCT04372719|Experimental|H3N2 10EXP5 TCID50/mL|A/Belgium/4217/2015 (H3N2) (SGS Code: SGS 421-7), Wild-type, influenza A (H3N2) human challenge strain
16343782|NCT04372706|Experimental|Part 1: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors.
16343785|NCT04372706|Experimental|Part 4: RTX-240 Dose Escalation|Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors
16343786|NCT04372693|Experimental|group of students who are learning by Online Distance|"The following principals implemented while online learning will be processing;
~Address and consider the students' differences in online learning application as a new experience.
~Allow for Individual Locus of Control.
~Motivate the student:
~Avoid information overload,
~Create A real-life context,
~Encourage social interaction,
~Provide hands-on activities,
~Encourage student reflection."
16343787|NCT04372693|No Intervention|students who were learned by Traditional Classroom-Based|
16343788|NCT04372680|Experimental|CTUS strategy group|CTUS examination will be performed until the day of patient extubation. CTUS examination will consist on a fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
16343789|NCT04372680|No Intervention|standard strategy group|from the day of patient's inclusion and beyond every day, the clinical team in charge of patients will decide to perform or not an SBT following current recommendations2. These criteria are mainly based on clinical data and do not include any specific ultrasound assessment.
16343790|NCT04372667|Experimental|Post intervention|Community score card approach
16343791|NCT04372654|Experimental|Radial group|Use of Electroducer Sleeve on radial route
16343792|NCT04372654|Experimental|femoral group|Use of Electroducer Sleeve on femoral route
16343793|NCT04372641|Experimental|Treatment (p97 inhibitor CB-5339 tosylate)|Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16343794|NCT04372628|Active Comparator|Group 1 - Lopinavir/Ritonavir|Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
16343795|NCT04372628|Placebo Comparator|Control Group|Placebo unmatched orally twice daily for 14 days
16343796|NCT04372615|Active Comparator|Inebilizumab|"Approximately 58 patients will receive Inebilizumab in addition to first line immunotherapy.
~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).
~All participants will also receive a 3 day course of IVIg."
16343797|NCT04372615|Placebo Comparator|Placebo|"Approximately 58 patients will receive placebo in addition to first line immunotherapy.
~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).
~All participants will also receive a 3 day course of IVIg."
16343798|NCT04372602|Experimental|Duvelisib|-Duvelisib 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.
16343799|NCT04372602|Sham Comparator|Placebo|-Placebo 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.
16343800|NCT04372589|Experimental|Investigational arm|Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.
16343801|NCT04372589|No Intervention|Control arm|Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.
16343802|NCT04372563||healthy|Healthy patients with normal aortic dimensions
16343803|NCT04372563||ascending aortic dilation 45-55, operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves operated on
16343804|NCT04372563||ascending aortic dilation 45-55, non operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves non operated
16343805|NCT04372550|Active Comparator|Standard of Care|"Standard of care treatment:
~- including passive / assisted / active movements, stretching, functional exercise, scar treatment
~Duration: 6-12 weeks"
16343806|NCT04372550|Experimental|Exercise|"Standard of care + added exercises
~Exercise type: resistance and aerobic exercise
~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)
~Duration: 6-12 weeks"
16343807|NCT04372537|Experimental|Hypnosis|"Patients will benefit from formal hypnosis (trance induction, hypno analgesia, comfort suggestions) and/or conversational hypnosis (confusion, distraction, use of chosen words, goodwill using verbal and non verbal languages).
~They will also get to be informed of the proceedings of the performed examination as the standard procedure group."
16343808|NCT04372537|Active Comparator|Standard procedure group.|"Patients will be informed of the proceedings of the performed examination, without using any hypnosis technique.
~This corresponds to the standard clinical procedures used while performing an electroneuromyogram."
16343810|NCT04372511|Experimental|Binaural Beats|Group A : use of stereo headphones that generate sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
16343811|NCT04372511|No Intervention|No sounds|Group B : use of stereo headphones with a white background noise
16343812|NCT04372498|Experimental|Treatment|This is a pivotal trial in members of the same family carrying the V282M nutation in the Gardos channel (KCNN4), which leads to hyperactivation of the channel and red cell dehydration. Up to 6 members of the family are eligible to enroll in this study, which will assess effectiveness based on individual changes of primary endpoints over individually established baselines.
16343813|NCT04372485|Other|mHealth|Adolescents enrolled in this arm will receive treatment-related text messages.
16343814|NCT04372485|No Intervention|Usual care|Adolescents in this arm will receive usual care.
16343815|NCT04372459|Experimental|Online integrated and stepped psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the online integrated and stepped psychosocial care group
16343816|NCT04372459|Experimental|Usual psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the usual psychosocial care group
16343817|NCT04372433|Experimental|Dose Escalation|Dose cohorts treated with intravenous (IV) IO-202 monotherapy, in ascending doses Q2wks.
16343818|NCT04372433|Experimental|Dose Expansion|IV IO-202 monotherapy at the recommended Phase 2 dose and frequency
16343819|NCT04372420|Active Comparator|RhBMP-2|RhBMP-2 belongs to TGF-β super family with osteoinductive property which is capable of promoting bone formation
16343820|NCT04372420|Placebo Comparator|PLATELET RICH FIBRIN|Platelet rich fibrin(PRF) is a healing biomaterial with a great potential for bone and soft tissue regeneration, without any inflammatory reactions
16343821|NCT04372407|Experimental|Treatment Crossover Arm|All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2
16343822|NCT04372394|Experimental|Fed/Fasted|surufatinib with food on Day 1 and surufatinib without food on Day 8
16343823|NCT04372394|Experimental|Fasted/Fed|surufatinib without food on Day 1 and surufatinib with food on Day 8
16343824|NCT04372381|Active Comparator|Supra-Annular transcatheter heart valve|Medtronic Evolut Pro Valve implantation
16343825|NCT04372381|Active Comparator|Annular transcatheter heart valve|Edwards Sapien 3 Ultra implantation
16343826|NCT04372355|Experimental|Chlorite-based drug WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five
16343827|NCT04372342|Experimental|nalbuphine|
16343828|NCT04372342|Placebo Comparator|remifentanil|
16343829|NCT04372329|Experimental|CPAP4HealthySleep: System 1 (ABAB)|Participants in this group will first receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A). Next, they will receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B), re-introduction of type A for another two weeks, followed by re-introduction of type B for two weeks.
16343830|NCT04372329|Experimental|CPAP4HealthySleep: System 2 (BABA)|Participants in this group will first receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B). Next, they will receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A), re-introduction of type B for another two weeks, followed by re-introduction of type A for two weeks.
16343831|NCT04372316|Active Comparator|methylcobalamin injection|
16343832|NCT04372316|Active Comparator|methylcobalamin tablet|
16343833|NCT04372303|Experimental|Short-term Compassion Fatigue Resiliency Program|Experimental I received a short-term program (five hours per day for two days, ten hours in total).
16343834|NCT04372303|Experimental|Long-term Compassion Fatigue Resiliency Program|Experimental II received a long-term program (five weeks, two hours per week, ten hours in total).
16343835|NCT04372303|No Intervention|Control|No intervention was applied to the control group.
16343836|NCT04372290|Experimental|Product usage order ABECD|Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.
16343837|NCT04372290|Experimental|Product usage order BCADE|Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.
16343838|NCT04372290|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.
16343839|NCT04372290|Experimental|Product usage order DECAB|Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.
16343840|NCT04372290|Experimental|Product usage order EADBC|Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.
16343841|NCT04372290|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.
16343842|NCT04372290|Experimental|Product usage order EDACB|Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.
16343843|NCT04372290|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.
16343844|NCT04372290|Experimental|Product usage order BACED|Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.
16343845|NCT04372290|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.
16343846|NCT04372277|Experimental|Enstilar|Enstilar foam
16343847|NCT04372264|Experimental|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
16343848|NCT04372264|Experimental|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
16343849|NCT04372264|Experimental|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
16343850|NCT04372251|Active Comparator|Sinus tarsi approach (STA)|Patients randomized to this arm are operated with plate osteosynthesis via the sinus tarsi approach
16343851|NCT04372251|Active Comparator|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Patients randomized to this arm are operated with percutaneous reduction of the fracture and osteosynthesis with screws, assisted by subtalar arthroscopy
16343852|NCT04372238|Experimental|RAPIDS intervention|Participants randomized to receive the RAPIDS intervention will receive a fentanyl specific behavioral intervention and a brief behavioral intervention to increase willingness to use fentanyl test strips and engage in overdose risk reduction behaviors, in addition to standard OEND.
16343853|NCT04372238|Active Comparator|Standard OEND|In the control arm participants will receive standard overdose education and naloxone distribution (OEND).
16343854|NCT04372225||477 patients|the biological tests of 477 patients undergoing total thyroidectomy were analyzed
16343855|NCT04372212|Active Comparator|Inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.
~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
16343856|NCT04372212|Active Comparator|Inversion and Ligation|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.
~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
16343857|NCT04372186|Placebo Comparator|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
16343858|NCT04372186|Experimental|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
16343859|NCT04372160||Younger school age children|Equal ratio of boys and girls, age range 7-13 years (68 subjects)
16343860|NCT04372160||Older school age children|Equal ratio of boys and girls), age range 14-17 years (68 subjects)
16343861|NCT04372160||Adults|Equal ratio of adult men and women, age range 18-65 years (68 subjects).
16343862|NCT04372147|Experimental|intervention group|MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
16343863|NCT04372147|No Intervention|control group|standard medical care
16343864|NCT04372134|Active Comparator|real rTMS group|motor incomplete traumatic SCI patients receiving real repetitive transcranial magnetic stimulation therapy
16343865|NCT04372134|Sham Comparator|sham r TMS|motor incomplete traumatic SCI patients receiving sham repetitive transcranial magnetic stimulation therapy
16343866|NCT04372121|Experimental|Linzagolix 75 mg|
16343867|NCT04372121|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
16343870|NCT04372095||group 1: Exposed to CPA + Meningioma|"Meningioma diagnosed in women by medical imaging examination and confirmed histologically if surgery is performed.
~Cyproterone acetate taken for at least 6 months."
16343871|NCT04372095||group 2: Exposed to CPA without Meningioma|Women exposed to Cyproterone acetate without developing any meningioma Absence of meningioma assessed by a normal cerebral MRI . Cyproterone acetate taken for at least 5 years.
16343872|NCT04372095||group 3: Not exposed to CPA, Meningioma diagnosed|"Meningioma in women not exposed to cyproterone acetate. Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery was necessary.
~Never exposed to cyproterone acetate."
16343873|NCT04372095||group 4: General population|Subjects (women) never diagnosed with meningioma and not exposed to cyproterone acetate.
16343874|NCT04372082|Placebo Comparator|standard of care (SOC)|
16343875|NCT04372082|Experimental|SOC + Hydroxychloroquine|
16343876|NCT04372082|Experimental|SOC + Diltiazem-Niclosamide|
16343877|NCT04372043||Lebanese population|"The Sleep Hygiene Index with other demographic questions will be applied to the Lebanese population."
16343878|NCT04372030|Other|General population|There is only one arm wishing to participate
16343879|NCT04372017|Experimental|Cohort A: Healthcare worker (hydroxychloroquine)|
16343880|NCT04372017|Placebo Comparator|Cohort A: Healthcare worker (placebo)|
16343881|NCT04372017|Experimental|Cohort B: High-Risk participant (hydroxychloroqine)|
16343882|NCT04372017|Placebo Comparator|Cohort B: High-Risk participant (placebo)|
16343883|NCT04372004|Active Comparator|Viral RNA test using nasopharyngeal swab|
16343884|NCT04372004|Active Comparator|Viral RNA test using sputum|
16343885|NCT04372004|Active Comparator|Serology test using blood|
16343886|NCT04371991||Group 1|Ectopic pregnancy
16343887|NCT04371991||Group 2|Early viable pregnancy
16343888|NCT04371991||Group 3|incomplete miscarriage
16343889|NCT04371991||Group 4|Healthy women
16343890|NCT04371978|Experimental|DPP-4 inhibition|Participants in the Dipeptidyl Peptidase-4 (DPP-4) inhibition group will receive linagliptin in addition to standard of care insulin regimen as per hospital protocol during their entire hospitalization.
16343891|NCT04371978|No Intervention|Control|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during their entire hospitalization.
16343892|NCT04371965|Experimental|Decolonization|1% Povidone iodine mouthwash (95 mL), gargle, and nasal spray (2,5 mL by nostril), and 10% nasal gel (one drop). All four time a day for five days.
16343893|NCT04371965|No Intervention|Control|Absence of local decolonization
16343894|NCT04371952|Experimental|Doxycycline 100mg|Doxycycline capsule containing 2 tablets doxycycline 100mg over-encapsulated. Doxycycline is given at 200 mg once a day and administered per os during 2 weeks
16344010|NCT04371133||Healthy controls|Healthy controls Healthy volunteers n=25
16344011|NCT04371120||Brain Injury Survivors|Traumatic or acquired brain injury survivors, patients of RHI
16343895|NCT04371952|Placebo Comparator|Doxycycline placebo|Doxycycline Placebo capsule 200 mg, containing 1 capsule of a marketed placebo = RODAEL placebo ( lactose, 380 mg / capsule). Doxycycline placebo is given once a day and administered per os during 2 weeks
16343896|NCT04371939|Experimental|I (Romiplostim)|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.
~Patients failing to achieve a complete platelet response cross over to arm II."
16343897|NCT04371939|Experimental|II (Eltrombopag)|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (>6 years) for at least 1 month depending on their response to study drug.
~Patients failing to achieve a complete platelet response switch to arm I."
16343898|NCT04371926|Active Comparator|HCQ arm|"COVID-19 positive cases will receive receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
~Staff randomized to this group will receive HCQ sulfate 400 mg/week for 4 weeks"
16343899|NCT04371926|No Intervention|No-HCQ arm|Will receive standard treatment as needed, but no HCQ
16343900|NCT04371913|Other|Radiation Therapy|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT).
16343901|NCT04371900|Experimental|Experimental Group|Mothers randomized to receive a voucher to be used at Planned Parenthood to cover the cost of contraceptives
16343902|NCT04371900|No Intervention|Control Group|Mothers randomized to NOT receive a voucher. Mothers in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
16343903|NCT04371887|Experimental|Local Tailoring|The intervention arm will consist of six KPSC service areas randomly assigned to the intervention arm. Immediately after primary HPV screening opens at KPSC, the intervention arm will receive the local tailoring interventions. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
16343904|NCT04371887|No Intervention|Hybrid Usual Care|The hybrid-usual care arm will consist of six KPSC service areas randomly assigned to this arm. The hybrid usual care arm will receive regional educational activities for the transition (as will the intervention arm) before the roll out of primary HPV testing. However, they will not receive any research-led intervention or adaptation guidance after primary HPV screening opens at KPSC. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
16343905|NCT04371874|No Intervention|Control|Hypertension of patients in the control group was managed with the original protocol including lifestyle by doctors in village clinic.
16343906|NCT04371874|Experimental|Treatment with Ten Dollars Project (TDP)|"Hypertension of patients in the TDP group were managed with the protocol of Ten Dollars Project (TDP) by doctors in village clinic."
16343908|NCT04371822|Active Comparator|5 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days
16343909|NCT04371822|Active Comparator|7mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days
16343910|NCT04371822|Active Comparator|9 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days
16343911|NCT04371822|Active Comparator|5mg TPPS dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days
16343912|NCT04371822|Placebo Comparator|placebo|No intervention
16343913|NCT04371809||control subjects|
16343914|NCT04371809||subjects with Atrial Fibrillation|
16343915|NCT04371809||subjects with Acute Coronary Syndrome|
16343916|NCT04371809||subjects with Acute Coronary Syndrome and Atrial Fibrillation|
16343917|NCT04371796|Experimental|Sintilimab injection|"Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.
~Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose."
16343918|NCT04371783|Other|Immediate FET group|FET will be performed in the first menstrual cycle following the stimulated IVF cycle
16343919|NCT04371783|Other|Delayed FET group|FET will be performed in the second menstrual cycle following the stimulated IVF cycle
16343920|NCT04371757|Experimental|Aerobic exercise session|The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
16343921|NCT04371757|Experimental|Resistance exercise session|The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
16344012|NCT04371107|Experimental|azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
16343922|NCT04371757|Experimental|Combined exercise session|The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
16343923|NCT04371731|Experimental|Active Arm|Active cohort will use the Care4today platform to help manage their heart failure
16343924|NCT04371731|No Intervention|Control arm|Control arm will contain standard of care heart failure treatment
16343925|NCT04371718|Experimental|JKB-122 Low dose|JKB-122 5 mg daily for 104 weeks
16343926|NCT04371718|Experimental|JKB-122 Medium dose|JKB-122, 15 mg daily for 104 weeks
16343927|NCT04371718|Experimental|JKB-122 High dose|JKB-122 35 mg daily for 104 weeks
16343928|NCT04371718|Placebo Comparator|Placebo|Matched placebo, daily for 104 weeks
16343929|NCT04371705|Experimental|ESPB group|31 patients Will undergo ultrasound guided ESP block with 40 ml bupivacaine 0.25% (20 ml on each side).
16343930|NCT04371705|Placebo Comparator|control group|31 patients anesthetized with the protocol followed by Minia University Hospital
16343931|NCT04371692||High-risk|staff working in a unit specifically for patients infected or suspected of being infected with SARS-Cov2
16343932|NCT04371692||Medium- risk|staff working in a unit that can accommodate patients infected or suspected of being infected with SARS-Cov2, i.e., all care services that do not fall into the high-risk group.
16343933|NCT04371692||Low-risk|off-patient staff
16343934|NCT04371679||Endotracheal intubation and ventilation|Patients admitted at ICU that are intubated and ventilated
16343935|NCT04371679||Non-Invasive Ventilation|Patients admitted at ICU who are non-invasively ventilated
16343938|NCT04371653|Experimental|Active group|Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
16343939|NCT04371653|Placebo Comparator|Placebo group|Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
16343940|NCT04371640|Active Comparator|Sirolimus|Sirolimus + standard medical care Day 1: 10mg Days 2-7: 5mg
16343941|NCT04371640|Placebo Comparator|Placebo|Placebo + standard medical care Day 1: 10mL Days 2-7: 5mL
16343942|NCT04371614|Active Comparator|Prime Time Sister Circle Intervention|The women in this arm participate in a Prime Time Sister Circle (PTSC). The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group. PTSC addresses three key modifiable health risk factors for chronic disease: unmanaged stress, physical inactivity, and unhealthy nutritional choices. It also addresses additional risk factors that contribute to unhealthy lifestyles: lack of knowledge or misinformation about major illnesses-cardiovascular disease (CVD), hypertension, diabetes, cancer, stress and depression-and the failure of African American women to prioritize their health and take proactive steps to manage their health and health outcomes. PTSC gives African American women the information, motivation, tools, skills, and consultative support they need to improve and maintain their health.
16343943|NCT04371614|No Intervention|Usual Care|The women in the arm do not receive the intervention but provide data at baseline, 3 months, 9 months and 15 months.
16343944|NCT04371601|Active Comparator|Control group|conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies
16343945|NCT04371601|Experimental|Experimental group|On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission
16343946|NCT04371588||Deep neuro-muscular blockade|
16343947|NCT04371588||Moderate neuro-muscular blockade|
16343948|NCT04371549|Active Comparator|Glue|Skin closure after cesarean section using glue
16343949|NCT04371549|Active Comparator|Monocryl|Skin closure after cesarean section using running subcuticular sutures using synthetic monofilament
16343950|NCT04371536|Active Comparator|Arm A: Oral iron therapy|Arm A is standard oral iron therapy for 3 months.
16343951|NCT04371536|Experimental|Arm B: Oral iron therapy plus IRONCHILD web-based intervention|Oral iron therapy as per Arm A plus the IRONCHILD web-based intervention aimed at promoting oral iron adherence. This web-based intervention was developed specifically for caregivers of young children with nutritional iron deficiency anemia to promote oral iron adherence.
16343952|NCT04371523|Experimental|Intervention - Hydroxychloroquine|
16343953|NCT04371523|Placebo Comparator|Control|
16343954|NCT04371510|Other|Covid-19 patients with moderate symptoms|Whole blood, culture supernatant, serum
16343955|NCT04371484||children from 0 to 5 years old, hospitalized|
16343956|NCT04371471||Patient with Covid-19|Patient with clinical signs of CoV-2-SARS infection and signs of severity
16343957|NCT04371458|Experimental|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
16343958|NCT04371445|Experimental|Intracanalicular dexamethasone insert group|This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.
16343959|NCT04371445|Active Comparator|Topical steroid drop group|This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.
16343960|NCT04371432||Sample Group 1 (NIHCC)|Existing NIH Clinical Center patients/participants tested positive for SARS-CoV-2 invited to participate by their NIH study team
16343961|NCT04371432||Sample Group 2 (OMS &amp; Field)|Recruited through NIH OMS, referred by collaborators or who self-refer, tested positive for SARS-CoV-2 (and selected relatives of participants irrespective of infection status)
16343962|NCT04371419|Experimental|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
16343963|NCT04371419|Experimental|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
16343964|NCT04371419|Experimental|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
16343965|NCT04371419|Experimental|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
16343966|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
16343967|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
16343968|NCT04371419|Experimental|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
16343969|NCT04371419|Experimental|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
16343970|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messenger
16343971|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messenger
16343972|NCT04371419|Experimental|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
16343973|NCT04371419|Experimental|Control- MGH-MaskS (antiStigma) Discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
16343974|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Concordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
16343975|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Discordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
16343976|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
16343977|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
16343978|NCT04371419|Placebo Comparator|Info later - Pure Control|This group will not receive the videos but will receive information later.
16343979|NCT04371406|Experimental|Experimental Arm|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
16343980|NCT04371406|Sham Comparator|Control Arm|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
16343981|NCT04371393|Experimental|Remestemcel-L Plus Standard of Care|Intravenous infusion of remestemcel-L 2x10^6 MSC/kg of body weight plus standard of care
16343982|NCT04371393|Placebo Comparator|Placebo Plus Standard of Care|Placebo (Plasma-Lyte) plus standard of care
16343983|NCT04371380|Experimental|OLI phase followed by Injection phase|Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.
16343984|NCT04371367|Experimental|avdoralimab|"Biological/Vaccine: avdoralimab intravenous administration of avdoralimab
~Other Names:
~• IPH5401"
16343985|NCT04371367|Placebo Comparator|Placebo|intravenous administration of Placebo
16343986|NCT04371341|Experimental|E1|will receive erector spinae block with 0.25% bupivacaine volume of 2.5 ml/segment
16343987|NCT04371341|Experimental|E2|will receive erector spinae block 0.25% bupivacaine with volume of 3.4ml/segment
16343988|NCT04371341|Experimental|E3|will erector spinae block receive 0.25% bupivacaine with volume of 6.6 ml/segment
16343989|NCT04371341|No Intervention|C|will not receive erector spinae block
16343990|NCT04371315||Positive COVID-19|"Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
~Monthly follow-up until Covid-19 is negative: Respiratory and Whole Blood Samples Collected"
16343991|NCT04371315||Negative COVID-19|Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
16343992|NCT04371302||Intensive Care Unit nurses|Nurses working in the Intensive care Unit of an exclusive Covid-19 hospital in Malaysia, during the Covid-19 pandemic
16343993|NCT04371289||COVID-19 outpatients|Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)
16343994|NCT04371289||COVID-19 inpatients|Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)
16343995|NCT04371250||Youth|Assessed group
16343996|NCT04371237|Experimental|Intermittent pneumatic compression|IPC sleeve device on leg
16343997|NCT04371237|Experimental|Heat therapy|Custom water-circulating garment on leg
16343998|NCT04371224|Experimental|NaliCap|nal-IRI/Capecitabine
16343999|NCT04371224|Active Comparator|NAPOLI|nal-IRI/5-FU/LV
16344000|NCT04371198|Experimental|Organoid|
16344001|NCT04371185|Experimental|BAT2206 injection|45mg; subcutaneous injection
16344002|NCT04371185|Active Comparator|Stelara(US-licensed)|45mg; subcutaneous injection
16344003|NCT04371185|Active Comparator|Stelara(EU-licensed)|45mg; subcutaneous injection
16344004|NCT04371172||Patients with TAVI|cognitive research battery, MRI, laboratory values
16344005|NCT04371159|Experimental|Velieve U.S.|Each participant will test their urine sample using the Velieve U.S. device
16344006|NCT04371146|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 35 mg methylphenidate 1.5 hours before performing the tasks.
16344007|NCT04371146|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 8 mg reboxetine 1.5 hours before performing the tasks.
16344008|NCT04371146|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before performing the tasks.
16344009|NCT04371133||Endometrioma|Endometrioma (n=23)
16344014|NCT04371094|Active Comparator|stylet|The stylet is a device that is put inside the endotracheal tube to facilitate its insertion into the trachea
16344015|NCT04371094|Active Comparator|bougie|The bougie is a device that is inserted into the trachea and an endotracheal tube is loaded over it and is slide into the trachea
16344016|NCT04371081||Amplatzer Piccolo Occluder|Amplatzer Piccolo Occluder device implant
16344017|NCT04371068||Patients suspected of low-grade PJIs|Adult patients suspected of low-grade PJIs, who have a scheduled prosthesis removal or change and who meet the inclusion criteria
16344018|NCT04371055|Experimental|Risk-adapted ECG monitoring for atrial fibrillation|"Intervention Group with high Risk for AF:
~Continuous Rhythm Monitoring using an implantable cardiac Monitor
~Intervention group with low risk for AF:
~7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation"
16344019|NCT04371055|Other|Standard of Care|Standard of care rhythm monitoring
16344020|NCT04371029|Experimental|Experimental|A Polysomnography (PSG) will be performed in all patient the night before extubation, the day prior discharge and 3 month after. Recording will consist in EEG, EOG et EMG of the chin. We will record NIM EMG. We will also performed an actimetry during hospitalization in the post ICU ward. A quality of sleep questionnaire (Pittsburgh questionnaire) will be completed by the patients during the visit at 3 month.
16344021|NCT04371016|Experimental|Verticalization group|"After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed :
~insertion of an esophageal balloon catheter (Nutrivent®, Sidam)
~installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)
~insertion of a Swan-Ganz catheter
~continuous recording of digital and analogic data
~After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected."
16344022|NCT04371003||WNND|40 subject with West-Nile Neuroinvasive Disease will be recruited
16344023|NCT04371003||WNF|40 subject with West-Nile Fever will be recruited
16344024|NCT04371003||controls|20 control will be recruited. These controls will be aged matched to the cases.
16344025|NCT04370990|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
16344026|NCT04370990|No Intervention|controle|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
16344027|NCT04370977|Active Comparator|Artemether-Lumefantrine|4 sites, namely Massinga, Mopeia, Moatize and Montepuez
16344028|NCT04370977|Active Comparator|Amodiaquine-Artesunate|3 sites, namely Massinga, Mopeia and Montepuez
16344029|NCT04370964|Other|Family with young aged people|The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments
16344030|NCT04370951|Active Comparator|Erector Spinae Plane Block|Patients will receive a ESP block with 20mls 0.25% Levobupivicaine bilaterally, pre incision plus standardised multimodal analgesia
16344031|NCT04370951|No Intervention|Control|no ESP block, standardised multimodal analgesia
16344032|NCT04370938|Experimental|Coping strategies video|Individuals will be asked to watch a 1 hour long video that discusses strategies helpful in coping with stress during the COVID-19 pandemic.
16344033|NCT04370938|No Intervention|Control|No additional requests will be made of individuals in the control arm.
16344034|NCT04370925|Active Comparator|Matched control|Patients undergo radical resection of primary colorectal cancer and receive standard adjuvant systemic chemotherapy
16344035|NCT04370925|Experimental|HIPEC|Patients undergo radical resection of colorectal cancer and HIPEC simultaneously or within 2 days after primary tumor resection. Followed by standard adjuvant systemic chemotherapy
16344036|NCT04370899||Familial hypercholesterolaemia children|FH diagnostic criteria were as follows: a positive genetic test or, if no genetic test results were available, LDL-C >160 mg/dL and one parent with a DLCN score >8.
16344037|NCT04370899||Unaffected children|The children evaluated for suspected FH who did not meet the FH criteria were included in the non-FH control group
16344038|NCT04370886|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic
16344039|NCT04370886|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation
16344040|NCT04370886|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation
16344041|NCT04370886|Placebo Comparator|SMS with holiday greeting|SMS content in this group will be about holiday greeting of Labour Day.
16344042|NCT04370873|Experimental|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7
16344043|NCT04370873|Placebo Comparator|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7
16344044|NCT04370873|Experimental|Part 2: MK-5475|Participants receive MK-5475 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28
16344045|NCT04370873|Placebo Comparator|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28
16344046|NCT04370847||Lung Ultrasound (LUS) Examination|Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
16344047|NCT04370834|Experimental|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a >= 1-category worsening on the 7-category ordinal scale from nadir.
16344048|NCT04370808||Mild to severe disease|Mild to severe disease (admission to isolation room)
16344049|NCT04370808||Critical patients|Critical patients (admission to ICU)
16344052|NCT04370782|Experimental|Experimental Arm 1|"Hydroxychloroquine
~Azithromycin
~Zinc sulfate"
16344055|NCT04370756|Active Comparator|Ex only|Participants will perform 8 weeks of supervised exercise training (EX).
16344056|NCT04370756|Placebo Comparator|EX + PL|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of placebo (PL) beetroot juice (deplete of nitrate).
16344057|NCT04370756|Experimental|EX + BR|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of beetroot juice (BR).
16344058|NCT04370743||Group 1|
16344059|NCT04370730|Other|prospective cohort|prospective monitoring of children and adolescents with schizophrenia and related psychotic disorders
16344060|NCT04370704|Experimental|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
16344061|NCT04370704|Experimental|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
16344062|NCT04370704|Experimental|Phase 2|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
16344063|NCT04370691||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
16344064|NCT04370691||Limb Ischemia|Patients presenting with limb ischemia
16344065|NCT04370691||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
16344066|NCT04370691||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than deep vein thrombosis, limb ischemia or thrombosed hemodialysis access for treatment
16344067|NCT04370665|Experimental|Open label single arm|Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.
16344068|NCT04370639|Experimental|AccuFlow Sensor|These 50 patients will wear the AccuFlow sensor device during their surgery, and will complete the post-procedural survey. The data will be reviewed after 25 patients, and the pilot study may be stopped at that point if it is felt that the device feasibility and tolerability have been adequately established.
16344069|NCT04370626|Active Comparator|Screw Fixation|Patients with a clinically diagnosed purely ligamentous perilunate injury requiring an isolated repair to the scapholunate ligament. These subjects will be treated with open reduction and internal fixation using a Kirschner-wire (k-wire).
16344070|NCT04370626|Active Comparator|K-Wire Fixation|Patients with a clinically diagnosed purely ligamentous perilunate injury requiring an isolated repair to the scapholunate ligament. These subjects will be treated with open reduction and internal fixation using a stainless steel smooth shafted headless compression screw.
16344071|NCT04370600|Active Comparator|Group A|These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).
16344072|NCT04370600|Active Comparator|Group B|These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2
16344073|NCT04370587|Experimental|Phase 1|T3011 single agent dose escalation in participants with solid tumors
16344074|NCT04370587|Experimental|Phase 2a Part 1 Arm A|RP2D T3011 single agent in participants with melanoma
16344075|NCT04370587|Experimental|Phase 2a Part 1 Arm B|RP2D T3011 single agent in participants with other solid tumors
16344076|NCT04370587|Experimental|Phase 2a Part 2|RP2D T3011 + pembrolizumab in participants with NSCLC
16344077|NCT04370587|Experimental|Rollover Arm|RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent
16344078|NCT04370561|Active Comparator|1/3 tubular plate|"Standard care according to AO guidelines using the Implant 1/3 tubular plate"
16344079|NCT04370561|Active Comparator|Active ankle plate|"Actual care using the new implant using the Implant Active ankle plate"
16344080|NCT04370548|Experimental|Clindamycin phosphate vaginal gel, 2%|
16344081|NCT04370548|Placebo Comparator|Placebo vaginal gel (Universal HEC Placebo Gel)|
16344082|NCT04370535|Placebo Comparator|Control group + cellulose (Group A)|healthy subjects (control group) receive placebo (cellulose) as powder
16344083|NCT04370535|Active Comparator|Control group + PMA-zeolite(Group B)|healthy subjects (control group) receive PMA-zeolite as powder
16344084|NCT04370535|Placebo Comparator|UCD-group + Cellulose (Group C)|subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder
16344085|NCT04370535|Active Comparator|UCD-group + PMA-zeolite (Group D)|subjects with uncontrolled Crohn disease receive PMA-zeolite as powder
16344086|NCT04370522||Cohort A: hormone-sensitive disease|"Patients who initiate ET in first line of advanced disease, they could be patients de novo with no previous ET or patients who received adjuvant ET and experience disease recurrence more than one year after its completion.
~Patients will be divided in two subgroups according to having or not received previous ET."
16344087|NCT04370522||Cohort B: hormone-resistant disease|"Patients in progression who are starting a first or second line of ET for advanced Breast Cancer (BC) and showing one of following the hormone-resistance criteria to any ET:
~For first line:
~Primary hormone-resistance: disease recurrence occurs within the first two years of adjuvant ET.
~Secondary hormone-resistance: disease recurrence occurs after the first two years of adjuvant ET or during the first year after its completion.
~For second line:
~Primary hormone-resistance: disease progression occurs within the first 6 months of ET for advanced disease.
~Secondary hormone-resistance: disease progression occurs after the first 6 months of ET for advanced disease.
~Patients will be divided in two subgroups according to having primary or secondary hormone-resistance."
16344088|NCT04370509|Experimental|Cohort A (Pembrolizumab monotherapy)|"Preoperative treatment consists of 200mg pembrolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles (9 weeks).
~Within 14-21 days following the end of treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.
~Within 21-42 days after surgery, patients with R0 resection or R1 resection receive 400 mg pembrolizumab every 42 days for up to 9 cycles (1 year) and patients with R2 resection receive pembrolizumab every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
16344089|NCT04370509|Experimental|Cohort B (Pembrolizumab + VEGF-TKI)|"Preoperative treatment consists of 200 mg pembrolizumab IV on day 1 of each cycle, and 5mg axitinib (a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)) PO BID on days 1-42 of each cycle. Axitinib maybe titered in select patients after cycle 1. Treatment repeats every 21 days for up to 3 cycles (9 weeks).
~Within 14-21 days following the end of pre-operative treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.
~Within 21-42 days after surgery, patients with an R0 or R1 resection receive 400 mg pembrolizumab and 1, 3, 5, 7 or 10 mg axitinib PO BID every 42 days for up to 9 cycles (1 year), and patients with an R2 resection receive pembrolizumab IV and axitinib PO BID every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
16344090|NCT04370496|Experimental|SOLUTION group|Patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.
16344091|NCT04370483|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16344092|NCT04370457|Experimental|Experimental arm|Administration of the MyPal ePRO system
16344093|NCT04370457|No Intervention|Standard care arm|No further intervention besides standard palliative care approach if needed
16344094|NCT04370444|Experimental|Experimental (PLR)|Participants will be given the OhNut Phallus Length Reducer (PLR) for use during the study period.
16344095|NCT04370444|Other|Control (Waitlist)|Participants will not have a PLR during the study period. They will be placed on a waitlist to receive the PLR at the end of the study period.
16344096|NCT04370431|Experimental|PartA: TTYP01 single ascending doses|In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.
16344097|NCT04370431|Placebo Comparator|Part A: Placebo|Placebo control for Part A of the study
16344098|NCT04370431|Experimental|Part B: TTYP01 (oral edaravone) first then IV edaravone|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.
16344099|NCT04370431|Experimental|Part B: IV edaravone first then TTYP01 (oral edaravone)|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.
16344100|NCT04370431|Experimental|Part C: TTYP01: fasted dosing first then fed dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.
16344101|NCT04370431|Experimental|Part C: TTYP01: fed dosing first then fasted dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.
16344102|NCT04370418||neoadjuvant chemo-radiation|"Short-course RT: 5 fractions of 5 Gy to a total dose of 25 Gy over 5 consecutive days. IMRT plans are generated with 6 MV photons.
~Dose-escalated concurrent 5-FU: The 3 doses levels of 5-FU are 100, 150, and 200 mg/m2/d. 5-FU will be given by continuous infusion for 20 hours every day starting on the morning of radiation.
~mFOLFOX: will be given 2 weeks after concurrent chemoradiation for a total of 4 cycles, with each cycle being 14 days. Surgery will be omitted in patients with complete pathological response and proceed to adjuvant chemotherapy. If patient develops progressive or metastatic disease, he/she will be omitted from the investigators study.
~The surgery will be considered 4-8 weeks after end of therapy. Adjuvant mFOLFOX6: 6 cycles chemotherapy will begin between 4 weeks and 8 weeks after surgery.
~Toxicities assessment: be using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0."
16344103|NCT04370405|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
16344104|NCT04370392|Active Comparator|control group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
16344105|NCT04370392|Experimental|IV dexmedetomidine group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline containing dexmedetomidine 1 ug/kg over 10 minutes.
16344106|NCT04370392|Experimental|IP dexmedetomidine group|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25% with dexmedetomidine 1 ug/kg) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
16344107|NCT04370379|Experimental|low dose of IBI302|
16344108|NCT04370379|Experimental|high dose of IBI302|
16344109|NCT04370379|Active Comparator|2mg aflibercept|
16344110|NCT04370353|Placebo Comparator|Placebo|Placebo supplement, each capsule containing: 0mg total flavanols, matched for caffeine and theobromine content as experimental supplement (2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM after mixed meal for 7 days.
16344111|NCT04370353|Experimental|Cocoa Flavanols|Experimental supplement, each capsule containing: 316 mg CocoActiv (Naturex, Netherlands: 100mg total cocoa flavanols, 2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM) for 7 days.
16344112|NCT04370340|No Intervention|control|
16344113|NCT04370340|Active Comparator|intervention|
16344114|NCT04370327|Active Comparator|Pain Free Exercise (PF)|Patients will be randomised to twice weekly for 24 weeks of pain free exercise in a supervised exercise programme
16344115|NCT04370327|Active Comparator|Moderate Claudication Pain Exercise (MOD-P)|Patients will be randomised to twice weekly for 24 weeks of moderate claudication pain exercise in a supervised exercise programme
16344147|NCT04370041|Experimental|Dokimos Plus aortic valve implantation|Dokimos Plus aortic valve implantation in all included patients.
16344116|NCT04370327|Active Comparator|Maximal Claudication Pain Exercise (MAX-P)|Patients will be randomised to twice weekly for 24 weeks of maximal claudication pain exercise in a supervised exercise programme
16344117|NCT04370314|Experimental|Zirconia implant-supported crown|Full zirconia implant-supported crown
16344118|NCT04370301|Experimental|Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.
~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1.
~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.
~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is > 1,500/mm^3."
16344119|NCT04370288|No Intervention|Control group|Covid-19 patients treated with standard medical therapy (supportive therapy).
16344120|NCT04370288|Experimental|Intervention group|Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
16344121|NCT04370262|Active Comparator|SOC/Famotidine|Subjects in this study arm will receive a combination of Standard of Care (SOC) treatment and intravenous famotidine. Famotidine Injection, 10mg/mL mixed with Normal Saline is given intravenously at 120mg (30% of 400 mg oral dose). The total daily dose proposed is 360mg/day famotidine IV for a maximum of 14 days, or hospital discharge, whichever comes first. SOC will be administered as per the current clinical protocol for COVID-19.
16344122|NCT04370262|Placebo Comparator|SOC/Placebo|Subjects in this arm will receive the current Standard of Care treatment for COVID-19; plus placebo infusion three times daily.
16344123|NCT04370249||Patient with suspected COVID-19 infection|Patients admitted and managed in an emergency department under suspicion of COVID-19 infection who received a pleuro-pulmonary ultrasound on admission
16344124|NCT04370236|Placebo Comparator|Placebo + Standard of Care|Patients will receive placebo + standard medical care
16344125|NCT04370236|Experimental|INB03 + Standard of Care|Patients will receive INB03 + standard medical care
16344126|NCT04370223|Experimental|Ozone auto-hemotherapy plus standard treatment|Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.
16344127|NCT04370223|No Intervention|Standard treatment alone|Standard treatment will be the one used in each hospital participating in the trial.
16344128|NCT04370210||Child without follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
16344129|NCT04370210||Child with follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
16344130|NCT04370171||Group TC: Diabetic patients followed by Teleconsultation|Teleconsultation group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.
16344131|NCT04370171||Group P: Diabetic patients with conventional follow-up|Conventional group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was differed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients and not available
16344132|NCT04370145|Experimental|moderate cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q12h; Tinidazole injection, iv. drip,20mg/Kg,Qd.
16344133|NCT04370145|Experimental|severe cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q8h; Teicoplanin injection, iv. drip,10mg/Kg,Qd; Tinidazole injection, iv. drip,20mg/Kg,Qd.
16344134|NCT04370145|Active Comparator|control group|Sulperazon, iv.,drip,100mg/Kg,Bid; Tinidazole injection, iv. drip,20mg/Kg,Qd
16344135|NCT04370132||Group of patient with liver venous deprivation|Group of patient with liver venous deprivation
16344136|NCT04370132||Group of patient with portal embolization|Group of patient with portal embolization
16344137|NCT04370119||(1) Healthcare workers|All healthcare workers at University Medicine Greifswald who were enrolled in the study between 04/2020-08/2020
16344138|NCT04370119||(2) Healthcare workers in high-risk areas of the hospital (intensive care, emergency medicine)|Healthcare workers at University Medicine Greifswald who were enrolled in the study between 01/2021-03/2021
16344139|NCT04370119||(3) Healthcare workers after SARS-CoV-2 vaccination|Healthcare workers at University Medicine Greifswald who received a SARS-CoV-2 vaccination within the last 7-21 days
16344140|NCT04370106|No Intervention|Control|Usual care for participants with existing VLU in the CG is defined as visiting the outpatient wound clinic/visits by the community care nurse as prescribed by the physician. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses.
16344141|NCT04370106|Other|Social leg Program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
16344142|NCT04370093|Experimental|Pioglitazone Drug (including Placebo)|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
16344143|NCT04370093|Experimental|Weight Loss, Behavioral|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
16344144|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone 45 mg/day + Weight Loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
16344145|NCT04370080|Experimental|Silver Diamine Fluoride|Topical application of one drop of silver diamine fluoride 38% to active untreated roof surface caries, lesions at the furcation, or lesions at crown margins. Application was repeated once each six months.
16344148|NCT04370028||Divaza|Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
16344149|NCT04370015|Experimental|Treatment group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
16344150|NCT04370015|Placebo Comparator|Control group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
16344151|NCT04370002||No Intervention|This is an observational study. There is no active treatment that is examined.
16344152|NCT04369989||Hydroxychloroquine - NO|Did not receive / are not receiving any Hydroxychloroquine
16344153|NCT04369989||Hydroxychloroquine - YES - started before|Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
16344154|NCT04369989||Hydroxychloroquine - YES - started same|Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
16344155|NCT04369989||Hydroxychloroquine - YES - started after|Hydroxychloroquine date started was after the date recorded for signs of respiratory distress
16344156|NCT04369976|Experimental|SHORT ARM HUMAN CENTRIFUGE|SHORT ARM HUMAN CENTRIFUGE IN COMBINATION WITH EXERCISE INTERMITTENT CENTRIFUGATION TOTAL TIME 30 MINUTES
16344157|NCT04369950|Active Comparator|2 percent Lidocaine with epinephrine and epidural morphine|
16344158|NCT04369950|Experimental|3 percent 2-Chloroprocaine and epidural morphine|
16344159|NCT04369937|Experimental|IMRT + Pembrolizumab + Cisplatin + ISA101b|"IMRT (Intensity Modulated Radiotherapy) of 70 Gy in 35 fractions over 7 weeks (5 fractions per week).
~Pembrolizumab will be administered at 200 mg (fixed dose) IV every 3 weeks (+/- 3 days), beginning beginning one week (week -1) prior to concurrent cisplatin-IMRT.
~Cisplatin will be administered at 100 mg/m2 IV on days 1(Week 0) and 22 (Week 3).
~ISA101b will be administered as three rounds of vaccination 3-4 weeks apart via two SC injections per vaccination round at 100ug/peptide, before pembrolizumab treatment. Vaccination #1 will be administered 1 week before pembrolizumab."
16344160|NCT04369924|Experimental|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
16344161|NCT04369924|Experimental|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
16344162|NCT04369911|Experimental|Low Dose|Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
16344163|NCT04369911|Experimental|High Dose|Acupuncture treatment twice per week for 5 weeks. Ten total acupuncture treatments completed.
16344165|NCT04369872|Experimental|Microwave Ablation|Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
16344166|NCT04369859||pregnant women with COVID-19|Pregnant women who have tested positive for COVID-19
16344167|NCT04369846|Experimental|Test drug group|The arm applies the test drug of GM-XANTHO
16344168|NCT04369846|Placebo Comparator|Placebo group|The arm applies the placebo
16344169|NCT04369833||continuous glucose monitoring group|all participants wearing a continuous glucose monitoring device
16344170|NCT04369820|Experimental|COVID-19 PATIENTS|"Two blood samples (40mL) at 2 different points in time:
~Within the first 72 hours of medical care in resuscitation unit or department.
~Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier."
16344171|NCT04369794|Active Comparator|BCG vaccine|BCG Group (n = 500): 0.1 ml of lyophilized, live and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
16344172|NCT04369794|Placebo Comparator|Placebo|Placebo group (n = 500): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
16344173|NCT04369781||Suspected critical limb ischemia|Patients referred for transcutaneous oxygen pressure measurements due to a clinical suspicion of critical limb ischemia
16344174|NCT04369768|Active Comparator|direct composite restorations|
16344175|NCT04369768|Active Comparator|preformed metal crowns|
16344176|NCT04369755|Other|MRI|A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)
16344177|NCT04369742|Experimental|Hydroxychloroquine|N= 313
16344178|NCT04369742|Placebo Comparator|Placebo|N= 313
16344181|NCT04369716|Active Comparator|Whole fruit 1|Oranges
16344182|NCT04369716|Active Comparator|Whole fruit 2|Apples
16344183|NCT04369716|Experimental|Juice 1 + pomace|Orange Juice + orange pomace
16344184|NCT04369716|Experimental|Juice 2 + pomace|Apple Juice + apple pomace
16344185|NCT04369716|Active Comparator|Juice 1 alone|Orange Juice
16344186|NCT04369716|Active Comparator|Juice 2 alone|Apple Juice
16344187|NCT04369677||First-Episode Psychosis|Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
16344188|NCT04369677||Healthy|Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
16344217|NCT04369495||Cyclophosphamide|Patients with induction therapy for lupus nephritis with cyclophosphamide
16344218|NCT04369495||Mycophenolate|Patients with induction therapy for lupus nephritis with mycophenolate
16344219|NCT04369482|Active Comparator|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
16344189|NCT04369664|Experimental|Type 2 Diabetes group|All participants with type 2 diabetes will be given cholesterol-lowering medicine (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
16344190|NCT04369664|Other|Control group|The participants in the control group are subjects with elevated cholesterol who do not have diabetes. All participants will be given cholesterol-lowering medicines (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
16344191|NCT04369638|Experimental|3D NAM|
16344192|NCT04369638|Active Comparator|Traditional NAM|
16344193|NCT04369625|Experimental|CHIMPS-T|(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents. CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee. The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
16344194|NCT04369625|Experimental|CHIMPS-P-single|"CHIMPS-P-single is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model Let's talk about children (Solantaus), but in a family setting Let's talk WITH children)."
16344195|NCT04369625|Experimental|The CHIMPS-P-group|The CHIMPS-P-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
16344196|NCT04369625|Experimental|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included. Overall, 8 consecutive online modules as well as elective modules will be included. These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents. iCHIMPS will be completed by 2 booster session within a six months follow-up.
16344197|NCT04369625|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
16344198|NCT04369612|Active Comparator|Standard of care|Standard follow-up after kidney transplantation during the first 7-8 post-transplant weeks
16344199|NCT04369612|Experimental|Home-based monitoring|Every second visit will be performed without patients actually visiting the hospital. They take a capillary blood sample themselves, send it to the lab and get a telecom follow-up by treating physician the same day.
16344200|NCT04369599|Experimental|V/Q System|Participants with acute respiratory failure will undergo therapy with the V/Q System.
16344201|NCT04369586|Experimental|meplazumab dose 1|0.06mg/kg for single dose
16344202|NCT04369586|Experimental|meplazumab dose 2|0.12mg/kg for single dose
16344203|NCT04369586|Experimental|meplazumab dose 3|0.2mg/kg for single dose
16344204|NCT04369586|Experimental|meplazumab dose 4|0.3mg/kg for single dose
16344205|NCT04369586|Experimental|meplazumab dose 5|0.42mg/kg for single dose
16344206|NCT04369586|Experimental|meplazumab dose 6|0.56mg/kg for single dose
16344207|NCT04369586|Experimental|meplazumab multiple dose|0.3mg/kg for double doses, 1 dose/week
16344208|NCT04369573|Active Comparator|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
16344209|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20
16344210|NCT04369560|Experimental|Magnetic Resonance Imaging|Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
16344211|NCT04369547|Experimental|Roflumilast|Participants will ingest a capsule containing 250mcg of the phosphodiesterase-4 inhibitor roflumilast. Their baseline TMS evoked potentials (TEP) will be recorded over 100 single TMS pulses prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the left dorsolateral prefrontal cortex (DLPFC). TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
16344212|NCT04369547|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however, this capsule will be contain a placebo. Their baseline TEP will be recorded over 100 single TMS pulses prior to receiving TBS to the left DLPFC. TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
16344213|NCT04369534|Active Comparator|First group|The patients randomized into the first group will be given the newer P2Y12 receptor inhibitor ticagrelor during the 12 months.
16344214|NCT04369534|Active Comparator|Second group|The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
16344215|NCT04369521|Experimental|Intervention|low free sugar diet with nutrition and exercise recommendation
16344216|NCT04369521|No Intervention|control|regular diet with nutrition and exercise recommendation
16344223|NCT04369456|Other|Covid-19 kidney transplant patients with moderate symptoms|
16344224|NCT04369443|No Intervention|MANH|
16344225|NCT04369443|Experimental|LANH|
16344226|NCT04369430|Experimental|AKST4290|Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.
16344227|NCT04369430|Placebo Comparator|Placebo|Subjects will receive placebo, twice daily, for 12 weeks.
16344228|NCT04369417|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
16344229|NCT04369417|Active Comparator|Active Comparator: Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
16344230|NCT04369404|No Intervention|Usual care|In the usual care group, the providers do not have access to the decision aids.
16344231|NCT04369404|Experimental|Patient Decision Aid|Providers have access to patient decision aids to review and discuss during the visit.
16344232|NCT04369391|Experimental|SEP363856 150 mg|SEP363856 tablet 150 mg
16344233|NCT04369391|Placebo Comparator|Placebo|matched placebo
16344234|NCT04369391|Active Comparator|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
16344235|NCT04369378|Experimental|Meditation app group|Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
16344236|NCT04369378|No Intervention|Control group|Participants will be in the no intervention period for 30 days. Two days before the end of the 30 day no intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. After this 30 day no intervention period, participants are invited to use the Insight Timer app if they so choose. Two months after the conclusion of the 30 day no intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
16344237|NCT04369365|Active Comparator|Arm A: Azithromycin|weekly oral azithromycin 1500mg for a maximum of 8 weeks
16344238|NCT04369365|Placebo Comparator|Arm B: Placebo|weekly oral placebo for a maximum of 8 weeks
16344239|NCT04369339|Experimental|Other High Risk HPV Positivity|Colposcopy performed to women with High risk HPV positive ,negative for intraepithelial lesions or malignancy cytology
16344240|NCT04369339|Active Comparator|HPV16/18|Colposcopy performed to women with HPV 16/18 positive ,negative for intraepithelial lesions or malignancy cytology
16344241|NCT04369326|Experimental|Community-Based TPT Initiation|All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children <15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
16344242|NCT04369326|No Intervention|Facility-Based TPT Initiation|Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.
16344243|NCT04369313|Experimental|delayed cord clamping|clamping the cord at least 30s at birth
16344244|NCT04369313|Other|early cord clamping|umbilical cord clamping before 15 seconds
16344245|NCT04369287||IDH1-mutated AML|Patients affected with AML and carryng IDH1 mutations
16344246|NCT04369287||IDH2-mutated AML|Patients affected with AML and carryng IDH2 mutations
16344247|NCT04369287||IDH1/2 unmutated AML|Patients affected with AML without IDH1/2 mutations
16344248|NCT04369274|Experimental|Interventional|All subjects will briefly be placed on the automated BVM compressor device. Measurements obtained while on this device will be compared to those obtained in the same subject prior to mechanical ventilation and while on a conventional ventilator.
16344249|NCT04369248||Control group|30 healthy women with BMI < 30 between 18 and 35 years old
16344250|NCT04369248||Non-obese PCOS|2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score >8 and/ or hyperandrogenemia defining the testosterone level > 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level > 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume >10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI < 30 between age of 18 and 35.
16344251|NCT04369248||Obese PCOS|Obese group are the women with BMI > 30 between age of 18 and 35.
16344252|NCT04369235|Experimental|tCES & upper extremity rehabilitation|The experiment group will receive tCES combined with upper extremity rehabilitation of affected side.
16344253|NCT04369235|Sham Comparator|Sham tCES & upper extremity rehabilitation|The sham control group will receive sham tCES combined with upper extremity rehabilitation of affected side.
16344254|NCT04369222||Controls|Children born from mothers with no consumption of mild analgesics 3 months before or during pregnancy
16344255|NCT04369222||Exposed|Children born from mothers with consumption of mild analgesics 3 months before or during pregnancy
16344256|NCT04369183||Study Group|Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
16344257|NCT04369170|Other|Group A - Control Group|Control group where an intermediate abutment is placed in between the CAD-CAM dental prostheses an the dental implant.
16344258|NCT04369170|Experimental|Group B - Test Group|Test group where the CAD-CAM dental prostheses is connected directly to the dental implant
16344259|NCT04369157||Elective surgery group|Patients undergoing hip/knee replacements or colorectal surgery will be recruited and tested on 3 occasions: pre-op, post-op and at follow-up. POCD status will be determined at post-op and follow up. Cognitive function, zinc status, POCD biomarkers and inflammatory markers will be measured on all 3 occasions.
16344260|NCT04369144|Experimental|Intervention group|The dynamic scapular recognition exercise + rigid taping with 50%-75% tension.
16344261|NCT04369144|Placebo Comparator|Control|The dynamic scapular recognition exercise + placebo taping
16344262|NCT04369131|Experimental|Intervention|All participants will receive intervention in four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominals only FES, and (d) calves, quads, and abdominals FES. Session-by-session alternation among conditions will occur in a unique, predetermined, randomized order for each participant.
16344263|NCT04369118|Experimental|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
16344264|NCT04369118|Active Comparator|conventional postoperative follow-up|Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
16344265|NCT04369092|Other|without swallowing problem|patients without swallowing problem
16344266|NCT04369092|Other|mild swallowing problem|patients with mild swallowing problem
16344267|NCT04369092|Other|severe swallowing problem|patients with severe swallowing problem
16344268|NCT04369079|Experimental|TREATMENT GROUP|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side. The exact sequence and number of procedures differed in each patient according to need as determined by prior functional examination. Before or after every of the treatment procedure treatment group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
16344269|NCT04369079|Other|CONTROL GROUP|Treatment duration was a mean of 4 weeks. Therapy was performed daily excluding weekends and consisted of 45 minutes of individual work with an oncological physiotherapist. The control group underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area. Before or after every of the treatment procedure control group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
16344270|NCT04369066|Other|Subjects who are not showing active SARS-Cov2 infection|
16344271|NCT04369040|Other|High-flow nasal oxygen therapy|Ventilation with High-flow nasal oxygen therapy
16344272|NCT04369040|Experimental|Flow Controlled Ventilation|Ventilation with laryngeal tri-tube with Flow Controlled Ventilation technique
16344273|NCT04369027||preload responders|patients who increase their delta VTI by more than 10% during PLR
16344274|NCT04369027||preload unresponders|patients who do not increase their delta VTI by more than 10% during PLR
16344275|NCT04369014|Experimental|etomidate|
16344276|NCT04369014|Experimental|propofol|
16344277|NCT04369001|Experimental|Intervention Group|(Program ACTIVE n=20) Participants randomized into the Program ACTIVE group will receive a gym membership to a local, Detroit-based community recreation facility where they will complete 150 minutes of exercise per week for 12 weeks and will receive 10 sessions (once weekly) of CBT therapy sessions. Exercise per week will be documented using exercise logs. Exercise logs will be given to research staff at the end of the 12-week timeframe; all exercise logs will be kept organized respective to the participant identification number and related documents (questionnaires and surveys). To ensure treatment fidelity, three CBT and three physical activity sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
16344278|NCT04369001|No Intervention|Enhanced Usual Care|(EUC n=20) Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Participants will not be required to report any use of resources offered or change their course of treatment in any way. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, gym access and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
16344279|NCT04368988|Placebo Comparator|Placebo - Phase 1|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
16344280|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.
16344281|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
16344282|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
16344283|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.
16344284|NCT04368988|Placebo Comparator|Placebo - Phase 2|3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.
16344285|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
16344286|NCT04368988|Experimental|SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
16344287|NCT04368988|Experimental|SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
16344288|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
16344289|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2|3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.
16344290|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
16344291|NCT04368962||MMF group|Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.
16344292|NCT04368949|Experimental|Stepping-Up Group|Participants will attend one 2-hour virtual session (1-hour exercise and 1-hour SM) per week. Each class of 6-8 participants is supervised by a Physiotherapist (PT) and kinesiologist who will individually tailor the exercises for each participant.
16344293|NCT04368949|Active Comparator|TELE Group|The initial telephone session will be 20-30 minutes, with subsequent weekly calls will be approximately 10 minutes.
16344294|NCT04368949|Placebo Comparator|Chair-Based Yoga Group|Participants will attend two 1-hour virtual sessions per week to ensure this group is matched for attention to STEPPING-UP.
16344301|NCT04368923|Experimental|Oxygen Therapy Group|
16344302|NCT04368923|Experimental|Physical Therapy Group|
16344303|NCT04368910|Experimental|Pyronaridine - artesunate|"Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
16344304|NCT04368910|Active Comparator|Chloroquine|"Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
16344305|NCT04368897||COVID-19 Male Patients|Males with laboratory confirmed SARS-CoV-2 infection
16344306|NCT04368884||Healthcare workers|The healthcare workers who are being tested for COVID-19 would be included in this group
16344307|NCT04368884||OPD patients|Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group
16344308|NCT04368884||IPD COVID-19 cases|Admitted positive cases of COVID-19 in the hospital will be included in this group
16344309|NCT04368858|Experimental|Cohort 1 : experimental group|Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
16344310|NCT04368845|Active Comparator|Experimental Intervention Arm: Telerehabilitation|The treatment arm will be given up to 1-hour resistive training exercises, breathing exercises and aerobic exercises administered by an expert physiotherapist via teleconference (telerehabilitation). Every ten days one physiotherapist will record the individualized exercise program, will reevaluate the magnitude of exercise for each patient and reinforce to continue or increase exercise magnitude.
16344311|NCT04368845|No Intervention|No Intervention: Conventional teleconference|The usual care arm will receive standard communication via teleconference every ten days for a six-month period without any specific recommendations and exercise prescription for home training. The control arm will be subject to the same assessments as the experimental arm at the start, and at the 3 and 6 months period.
16344312|NCT04368832||Experimental group|During prenatal monitoring, at least one consultation by remote consultation (phone or teleconsultation)
16344313|NCT04368832||Control group|"Prenatal monitoring by face-to-face consultations adapted to confinement (absence of clinical signs or notion of travel, occupation, contact, clustering (TOCC), no attendant, limited movements inside the hospital and precautions of droplet and contact type)"
16344314|NCT04368819|Active Comparator|Allopurinol|Allopurinol 300mg P.O. once daily for four weeks followed by allopurinol 300mg P.O. twice daily for 12 weeks.
16344315|NCT04368819|Placebo Comparator|Placebo|Placebo pills indistinguishable from the active comparator given P.O. once daily for four weeks, followed by twice daily for 12 weeks.
16344316|NCT04368806|Experimental|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
16344317|NCT04368806|Placebo Comparator|Placebo|Normal Saline with Autologous Serum
16344318|NCT04368793||Discharged COVID-19 patient cohort|All enrolled participants will be given 8 weeks (online 2 weeks + offline 6 weeks) pulmonary rehabilitation intervention, and will be followed up for at least one year, to assess their adherence and efficacy of the rehabilitation program.
16344319|NCT04368780|No Intervention|Control group|Individuals who provide home care to an elderly person who is dependent on the bed
16344320|NCT04368780|Experimental|Experimental group|Individuals who provide home care to an elderly person who is dependent on the bed. It is planned that the exercises will be conducted two days a week with the researcher and on the other days by the caregiver herself for a total of eight weeks.
16344321|NCT04368767|No Intervention|Usual Care: Incubator|The infant will remain in the incubator and stress biomarkers will be collected per protocol
16344322|NCT04368767|Experimental|Intervention: Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, 30 minutes after feeding. SSC will usually occur in the afternoon between 11:30-12:30 pm or 14:30-15:30pm. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. The room will be monitored to maintain a temperature of 72-77 degrees Fahrenheit during SSC. Stress biomarkers will be collected per protocol.
16344323|NCT04368741|Experimental|Experimental group|SANZ®KINGWILL
16344324|NCT04368741|Other|Control group|GLUCERNA SR®
16344345|NCT04368715|Experimental|2780 nm Er:Cr;YSGG laser treated group|Patients treated with Er:Cr;YSGG laser for labial frenectomy
16344346|NCT04368715|Experimental|940 nm Diode laser treated group|Patients treated with 940 nm Diode laser for labial frenectomy
16344347|NCT04368702|Experimental|Phase I - Gastric Cancer|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
16344348|NCT04368702|Experimental|Phase I - Breast Cancer|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
16344349|NCT04368702|Experimental|Phase I - Mantle Cell Lymphoma|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
16344350|NCT04368702|Experimental|Phase I - Larynx|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
16344351|NCT04368702|Experimental|Phase I - Bladder|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
16344352|NCT04368689|Experimental|Floating|Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart.
16344353|NCT04368676|Experimental|Sudarshan Kroya Yoga (SKY)|Sudarshan Kriya Yoga (SKY) will be delivered using the Hospital approved Cisco WebEx platform. The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered.
16344354|NCT04368676|Active Comparator|Health Enhancement Program (HEP)|The Health Enhancement Program (HEP) will be delivered using the Hospital approved Cisco WebEx platform. The online version of HEP for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered. HEP will be taught by Dr. Paris Lai, co-investigator and senior psychiatry resident.
16344355|NCT04368663|Active Comparator|TJ-134 group|The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4 g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) is administered to enrolled patients for 8 weeks.
16344356|NCT04368663|Placebo Comparator|Lactomin group|Lactomin (3g/day) is administered to enrolled patients for 8 weeks.
16344357|NCT04368650|Experimental|Main treatment group|The in situ BMP-2 gel was prepared to a concentration of approximately 0.5 μg/ml and were stored at 4oC. The gel was then dispensed at site of interest in the study.
16344358|NCT04368650|Active Comparator|Control|In patients selected for control group, after degranulation, sticky bone was used to fill the defect. The surgical site was protected and covered using a periodontal dressing.
16344359|NCT04368624||Participants with PKU|"Patients with classical PKU phenotype (serum phenylalanine concentration > 10 mg/dL on a normal diet at diagnosis) # ~25
~Patients with hyperphenylalaninemia (serum phenylalanine concentration < 10 mg/dL on a normal diet at diagnosis) # ~15
~Patients with PKU on therapy with Kuvan # ~10"
16344360|NCT04368624||Non-PKU Control|Study Controls: Up to 50 children and adults without a known metabolic disorder.
16344361|NCT04368611|Active Comparator|fundus first cholecystectomy|start with fundus dissection then complete the dissection
16344362|NCT04368611|Active Comparator|Calot first dissection|start and complete the dissection by dissection of Calot triangle
16344363|NCT04368598|Experimental|High-dose Dexamethasone plus Acetylcysteine|For all patients in this arm, DXM was administered intravenously at 40 mg daily for 4 consecutive days and then stopped. If platelet count remained below 30×10^9/L or there were bleeding symptoms by day 10 to 14, an additional 4-day course of DXM (40 mg daily) was given. Besides, all patients received Acetylcysteine orally at 0.4g three times a day for 4 consecutive weeks in the first month.
16344364|NCT04368585|Experimental|TBPM-PI-HBr Alone (Period 1)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
16344365|NCT04368585|Experimental|TBPM-PI-HBr and Antacid (Period 2)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
16344366|NCT04368585|Experimental|TBPM-PI-HBr and Omeprazole (Period 3)|40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.
16344367|NCT04368572|Experimental|lumbar puncture under hypnosis|Hypnosis is the only act added by protocol to patients receiving a lumbar puncture as part of the etiological assessment of cognitive disorders
16344368|NCT04368572|Active Comparator|lumbar puncture without hypnosis|Lumbar puncture is performed by a physician assisted by a nurse or a psychologist who reassure the patient during the installation and the procedure.
16344369|NCT04368559|Experimental|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-PCP prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo.
16344370|NCT04368559|Active Comparator|Group 2: Oral Antifungal|Subjects in SAR treatment group will receive 400 mg oral fluconazole once daily for 13 weeks. Fluconazole may be switched, due to acute clinically significant GVHD, to 300 mg oral posaconazole twice daily on the first day of the medication switch and 300 mg once daily, thereafter. However, subjects who are switched to posaconazole cannot be switched back to fluconazole. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from daily oral therapy to daily IV therapy at the discretion of the Investigator. In addition, subjects in the SAR group will receive anti-PCP prophylaxis with oral TMP/SMX (80 mg TMP/400 mg SMX) once daily.
16344371|NCT04368546||Patients|Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.
16344372|NCT04368546||Healthy controls|Age-matched subjects without known disease.
16344373|NCT04368533|Experimental|Livionex Dental Gel|Children assigned to this arm will brush/clean teeth with Livionex Dental Gel twice a day for 9 months.They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, and 9 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience at each study visit. A monthly phone call will be made to assess compliance with the study protocol, and to answer any questions or concerns. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
16344374|NCT04368533|Active Comparator|A standard children's toothpaste containing 1500 ppm fluoride|Children assigned to this arm will brush/clean teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for 9 months. They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, and 9 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience at each study visit. A monthly phone call will be made to assess compliance with the study protocol, and to answer any questions or concerns. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
16344375|NCT04368520|Placebo Comparator|Placebo|
16344376|NCT04368520|Experimental|Low dose vitamin D3|
16344377|NCT04368520|Experimental|High dose vitamin D3|
16344378|NCT04368507|Experimental|YYB101+Irinotecan|"b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks
~a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks"
16344379|NCT04368494|No Intervention|Control|Continue with normal activity.
16344380|NCT04368494|Experimental|Exercise|12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week.
16344459|NCT04367727|Experimental|5 minutes before 1|Light emitting diode applied 5 minutes before fatiguing task
16344383|NCT04368429|Experimental|Group 1: MenACYW Conjugate Vaccine|Participants received a single intramuscular (IM) dose of MenACYW Conjugate vaccine on Day 0.
16344384|NCT04368429|Active Comparator|Group 2: Menactra® vaccine|Participants received a single IM dose of Menactra® vaccine on Day 0.
16344385|NCT04368403|Experimental|KHK4827|
16344386|NCT04368377|Experimental|Tirofiban|"Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0.15 microgram/kg/minute for 48 hours.
~Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75 mg daily for 30 days.
~Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75 mg daily for 30 days
~Patents will receive concurrent fondaparinux 2.5 mg s/c per day for the duration of the hospital stay"
16344387|NCT04368364|Active Comparator|Group 1 (Control group)|
16344388|NCT04368364|Experimental|Group 2(Bupivacaine hydrochloride group)|
16344389|NCT04368364|Experimental|Group 3 (ropivacaine hydrochloride group)|
16344390|NCT04368351||Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
16344391|NCT04368351||bacteriotherapy|Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
16344392|NCT04368325||Study group|Total of 46 patients with low serum creatinine levels whose values were obtained from the central laboratory with inclusion criteria (< 40mmol/L)
16344393|NCT04368325||Control group|A total of 61 consecutive patients were obtained who were treated in ICU CHC Osijek, according to the date of admission.
16344394|NCT04368312||Health care providers/hospital staff|The targeted group are doctors and nurses (hospital stuff) of a large university hospital directly confronted with patients with Cov-19
16344395|NCT04368299|Experimental|Telemedicine|Telemedicine group will receive scheduled follow-ups via videoconferencing.
16344396|NCT04368299|Active Comparator|Standard care|Standard care group patients will continue conventional standard in-person outpatient care.
16344397|NCT04368286|Experimental|Rehabilitation group|To conduct a comprehensive pulmonary rehabilitation assessment and treatment
16344398|NCT04368286|No Intervention|Conventional medical group|Conventional medical treatment
16344399|NCT04368273|Experimental|treatment|PD-1 antibody combined CCRT for patients with local advanced cervical cancer.
16344400|NCT04368260|Active Comparator|Control swab|FDA cleared swab
16344401|NCT04368260|Experimental|Prototype swab|Injection molded polypropylene flocked nylon NP swab
16344402|NCT04368247||Nevi undergoing biopsy per SOC|Subjects with Nevi who will as part of their standard of care, will undergo biopsy.
16344403|NCT04368234||COVID-19 Patients|Any Duke patient that is being treated for COVID-19.
16344404|NCT04368195|No Intervention|Control group|This group will not receive any regional block
16344405|NCT04368195|Experimental|Erector spinae block group|This group will receive erector spinae block
16344406|NCT04368182|Experimental|Treatment group|Autologous C-TCR055 administered by intravenous (IV) infusion
16344407|NCT04368169|Experimental|Aromatic Extract|Participants receive the aromatic botanical extract orally every 4-6 waking hours for 3 days.
16344408|NCT04368169|Placebo Comparator|Placebo|Participants receive the placebo matching the botanical extract orally every 4-6 waking hours for 3 days.
16344409|NCT04368156|No Intervention|Control|
16344410|NCT04368156|Experimental|Gammacore treatment|
16344411|NCT04368130|Experimental|SIGNAL|"Program to explore the feasibility and acceptability of a smartphone-based real-time behavioral anomaly detection system (SIGNAL).
~Patients will download the adapted Beiwe app onto their smartphones for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
16344412|NCT04368117|Active Comparator|Standard Therapy (ST)|Patients randomized to the ST group will receive standard of care, routine burn physical therapy.
16344413|NCT04368117|Experimental|Active Therapy (STAT)|Patients randomized to the STAT group will receive an intensive, quantifiable, activity-based physical therapy prescription emphasizing four of the most active components of therapy: mobilization, strength training, aerobic training and functional training.
16344414|NCT04368104||Group A|women using any form of minipills
16344415|NCT04368104||Group B|women subjected to office hysteroscopy for different indications but not using any form of hormones or systemic or local hormonal contraception.
16344416|NCT04368091||All-comers, real-world registry|Subjects requiring infrainguinal revascularization with the Xtreme Touch - Neo (Magic Touch PTA)
16344417|NCT04368078|Experimental|Toripalimab plus Lenvatinib|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
~Toripalimab is a recombinant anti-human PD-1 monoclonal antibody."
16344418|NCT04368052|Other|Observation|preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
16344419|NCT04368039|Experimental|Normobaric Oxygen Therapy (40% FiO2)|4 weeks of nightly normobaric oxygen therapy (40% FiO2)
16344420|NCT04368039|Placebo Comparator|Placebo Condition|4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)
16344421|NCT04368026||Group 1|"Responders currently working in a COVID-19-dedicated hospital, which was transformed by Polish Ministry of Health during SARS-CoV-2 pandemic into institution designated only for SARS-CoV-2 patients, including those developing symptoms and quarantined."
16344422|NCT04368026||Group 2|"Responders currently working in non-COVID-19-dedicated hospital."
16344423|NCT04368013|Experimental|Experimental|The difference from the standard of care is extended sample collection and study related procedures during the study.
16344427|NCT04367974||1|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
16344428|NCT04367974||2|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，and were given once daily in the fourth bag. Total treatment duration was 2 weeks.
16344429|NCT04367948|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
16344430|NCT04367948|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
16344431|NCT04367935|Active Comparator|Intervention|Pentoxifylline tablets 400mg three times daily for 2 months
16344432|NCT04367935|No Intervention|Control|Control Group receiving placebo tablets three times daily for 2 months
16344433|NCT04367922|Experimental|Positive emotion skills invervention|Participants will go through a 6-week positive emotion skills course where 1 new skill opens each week.
16344434|NCT04367909|Experimental|Nimotuzumab plus TC Regimen chemotherapy|Nimotuzumab (200 mg) plus TC Regimen chemotherapy every 3 weeks
16344435|NCT04367909|Active Comparator|TC Regimen chemotherapy|TC Regimen chemotherapy every 3 weeks
16344436|NCT04367883||CST Hospital Incomes|"Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.
~No intervention is performed."
16344437|NCT04367870||Non immune patient|Patients with a negative SARS-CoV-2 immunoassay
16344438|NCT04367870||Immune patient|Patients with a positive SARS-CoV-2 immunoassay
16344439|NCT04367857||Prior Positive polymerase chain reaction (PCR) and Recovered|Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
16344440|NCT04367857||Never tested, history of COVID-19 Symptoms and Recovered|Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
16344441|NCT04367857||Never tested and current COVID-19 Symptoms|Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
16344442|NCT04367857||Never tested and asymptomatic|Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
16344443|NCT04367831|Experimental|Intervention arm: intermediate-dose anticoagulation|"If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily or unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1-0.3 U/mL.
~If eGFR <30 mL/min or acute kidney injury or CRRT: Unfractionated heparin infusion at 10 units/kg/hour (minimum 500 units/hour if CRRT) with goal anti-Xa 0.1-0.3 U/mL"
16344444|NCT04367831|Active Comparator|Control arm: prophylaxis|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):
~If eGFR ≥30 mL/min (stable kidney function):
~BMI < 40 kg/m2: Enoxaparin 40 mg SC daily
~BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h
~BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h
~If eGFR < 30 mL/min or acute kidney injury:
~50-120 kg: Unfractionated heparin 5000 units SC q8h
~>120 kg: Unfractionated heparin 7500 units SC q8h
~If CRRT: Unfractionated heparin infusion pre-filter at 500 units/hour"
16344445|NCT04367818|Active Comparator|Peri-anal local anaesthetic infiltration|Patients in this group will receive the prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline) in a syringe will be connected to 22_ gauge short, beveled needle. The technique of the block will be done guided by Nystrom et al.
16344446|NCT04367818|Active Comparator|caudal anaesthesia|Patients in this group will receive caudal block using 22_gauge short, beveled cannula or needle, The prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline).
16344447|NCT04367792||Patients died with Covid-19 disease|Sample of patients died with Covid-19 disease and pulmonary disease
16344448|NCT04367792||Patients died with Covid-19 and cardiovascular disease|Sample of patients died with Covid-19 disease and pulmonary disease with clear cardiovascular involvement
16344449|NCT04367792||Patient died with myocarditis|Sample of patient died with different types of myocarditis without Covid-19 disease. These samples are used as control and are part of database of previously collected samples of CVPath Institute Inc.
16344450|NCT04367779||A : High Grade Sarcoma|Pediatric and adult patients with High Grade Sarcoma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
16344451|NCT04367779||B : Brain tumors|Pediatric and adult patients with Brain Tumors treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
16344452|NCT04367779||C : Meningioma|Pediatric and adult patients with Meningioma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
16344453|NCT04367766|Active Comparator|Immediate Implant Placement|prosthetically driven immediate implant placement (WinSix, Biosafin) with bone substitute (BioOss Collagen, Geistlich) filling the gap between the buccal socket wall and the implant surface and a collagen matrix (Fibrogide, Geistlich) positioning at the vestibular aspect to increase soft tissue volume, with immediate (non occlusal loading) prosthetic provisionalization.
16344454|NCT04367766|Active Comparator|Alveolar Ridge Preservation (ARP) + Delayed Implant Placement:|ARP performed with bone substitute (BioOss Collagen, Geistlich) and a collagen matrix placed to seal the socket entrance (Mucograft Seal, Geistlich). After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm
16344455|NCT04367766|Active Comparator|Spontaneous Healing + Delayed Implant Placement|extraction socket will be left to heal spontaneously. After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm, and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm .
16344456|NCT04367753||Fulfilled contract|The contract before the epiphysiodesis has been fulfilled with the wanted limb length at the final analysis
16344457|NCT04367753||Failed contract|The contract before the epiphysiodesis hasn't been fulfilled with the wanted limb length at the final analysis
16344458|NCT04367740||Serum Antibodies|Blood samples to be obtained assess for IgG antibodies against SARS-CoV2
16344460|NCT04367727|Placebo Comparator|5 minutes before 2|Light emitting diode applied 5 minutes before fatiguing task
16344461|NCT04367727|Experimental|1 hour before 1|Light emitting diode applied 1 hour before fatiguing task
16344462|NCT04367727|Placebo Comparator|1 hour before 2|Light emitting diode applied 1 hour before fatiguing task
16344463|NCT04367727|Experimental|5 hours before 1|Light emitting diode applied 5 hours before fatiguing task
16344464|NCT04367727|Placebo Comparator|5 hours before 2|Light emitting diode applied 5 hours before fatiguing task
16344465|NCT04367701||Thalassemia group|"16 pediatric patients with thalassemia major undergoing surgery for repair of congenital heart disease.
~Authors measure hemolysis by free plasma hemoglobin concentration."
16344466|NCT04367701||Control group|"25 pediatric patients with demographic data related to those in thalassemia group, undergoing surgery for repair of congenital heart disease.
~Authors measure hemolysis by free plasma hemoglobin concentration"
16344467|NCT04367675|Experimental|INO-5401|Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
16344468|NCT04367675|Experimental|INO-5401 and INO-9012|Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
16344469|NCT04367662|Experimental|Patient with COVID-19 infection|Patient with COVID-19 infection hospitalized in a COVID unit
16344470|NCT04367649|Experimental|Hall technique|
16344471|NCT04367649|Active Comparator|Atraumatic restorative treatment|
16344472|NCT04367649|Sham Comparator|Conventional restorative treatment|
16344473|NCT04367636|Active Comparator|Active Comparator: PSE + OCAT-sham|Psycho-education video + an active placebo training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected scrambled sentences task with online contingent feedback.
16344474|NCT04367636|Experimental|Experimental: PSE + OCAT|Psycho-education video + an attention training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback.
16344475|NCT04367623|Active Comparator|Control|Patients receiving conventional hand therapy, time matched to the duration of total intervention in the Active group
16344476|NCT04367623|Active Comparator|Active|Patients receiving BCI FES prior to the conventional therapy
16344477|NCT04367610||Study Group|Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
16344478|NCT04367597|Experimental|Active NMES|
16344479|NCT04367597|Sham Comparator|Modified NMES sham|
16344480|NCT04367584||Subjects with inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
16344481|NCT04367584||Subjects with non inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
16344482|NCT04367571|Experimental|Osteopathic Manipulative Treatment|
16344483|NCT04367571|Placebo Comparator|Manual Placebo|
16344484|NCT04367558|Experimental|Interventional|Patient suffering from OSA, and found to suffer from obstruction of one or more of the following areas - Lower turbines, Soft Palate, Tonsils, Base-of-tongue.
16344485|NCT04367545|Experimental|Patient with COVID-19 infection suspicion|Patient with COVID-19 infection suspicion are tested using standard diagnosis method
16344486|NCT04367532|Experimental|Foam rolling|Foam rolling of cuff muscles.
16344487|NCT04367532|Experimental|Tissue flossing|Tissue flossing of cuff muscles.
16344488|NCT04367532|No Intervention|Control group|Without any intervention.
16344489|NCT04367506|Experimental|BecomeAnEX|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital.
16344490|NCT04367506|Active Comparator|Usual Care|Brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
16344491|NCT04367493|Experimental|1. Group 55% cocoa intervention|55% cocoa intervention
16344492|NCT04367493|Experimental|2. Group White Chocolate|White chocolate
16344493|NCT04367493|No Intervention|3. Control Group|Control Group
16344494|NCT04367480|Experimental|Group I (TENS)|Patients wear an active wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
16344495|NCT04367480|Placebo Comparator|Group II (placebo TENS)|Patients wear a placebo wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
16344496|NCT04367467||Individuals with solid tumors receiving PARPi|"Kidney function will be assessed by serum creatinine, serum cystatin C, and urine creatinine clearance calculation for patients who opt-in to 24 hour urine collection.
~These laboratory measures will be completed by patients at the following time points:
~Timepoint A: Baseline (prior to PARP inhibitor initiation, at the time of standard of care clinical testing)
~Timepoint B: On-treatment (within 3-9 weeks of PARP inhibitor initiation, at the time of standard of care clinical testing)
~Timepoint C: Post-treatment (within 4 weeks of PARP inhibitor discontinuation, only for those patients with clinically significant changes in GFR based on serum creatinine, cystatin C, or 24 hour urinalysis at Timepoint B"
16344497|NCT04367454|Experimental|Personal Protective Equipment|"Wearing: Tyvek pro-tech® C gear (Bonetti, Milano, Italy), a full visor SGE 400 mask (EN 136:98 CL3) connected to an A2B2E2K2-P3 R filter (Spasciani, Milano, Italy), and well-fitting, non-sterile Mapa Ultranitril 480 gloves (Mapa SAS, Colombes, France)."
16344498|NCT04367454|No Intervention|NO-Personal Protective Equipment|only wearing well-fitting, medical examination nitrile gloves.
16344499|NCT04367441|Experimental|608|8mg, 20mg, 40mg, 80mg, 120mg, 160mg, 200mg
16344500|NCT04367441|Placebo Comparator|Placebo|20mg, 40mg, 80mg, 120mg, 160mg, 200mg
16344548|NCT04367194|Experimental|BPPV Optocinetic|Only Optocinetic training.
16344501|NCT04367428|Experimental|Probiotics|Patients will receive the previously mentioned combination of probiotics pre- and postoperatively
16344502|NCT04367428|No Intervention|No probiotics|Patients will not receive probiotics
16344503|NCT04367415||Normal uterine cavity on office hysteroscopy|If the uterine cavity is normal the patient will be allocated as group A.
16344504|NCT04367415||uterine cavity shown one or more polyps on office hysteroscopy|If there is one or more polyp(s) the patient will be allocated as group B. Localization and size estimation of the polyp(s) is mandatory.
16344505|NCT04367402||Symptomatic Patients|Patients who had symptoms related to COVID-19 infection
16344506|NCT04367402||Health people|Healthy people who never had syntomps related to COVID-19 infection
16344507|NCT04367402||Asyntomatic Individuals|Asyntomatic people to recruit after the restriction have ended
16344508|NCT04367389|Experimental|Intervention|Participants receive a physical activity promotion intervention as well as an individualized exercise plan.
16344509|NCT04367389|No Intervention|Control|
16344510|NCT04367376|Experimental|manual therapy|The control group will receive central postero-anterior grade III mobilization through the pisiform grip method at the level of pain in the lumbar spine.
16344511|NCT04367376|Experimental|instrumental manual therapy|the intervention groub rcieved central postero-anterior mobilization with a force of 20-30 N through physiotherapy instrument mobilization at the level of pain in the lumbar spine.
16344512|NCT04367363||Community sample|We plan to recruit a representative sample of the Singapore population.
16344513|NCT04367337||Poland|Adults, general population, N = 400
16344514|NCT04367337||Australia|Adults, general population, N = 400
16344515|NCT04367337||Canada|Adults, general population, N = 400
16344516|NCT04367337||China|Adults, general population, N = 400
16344517|NCT04367337||France|Adults, general population, N = 400
16344518|NCT04367337||Gambia|Adults, general population, N = 400
16344519|NCT04367337||Germany|Adults, general population, N = 400
16344520|NCT04367337||Israel|Adults, general population, N = 400
16344521|NCT04367337||Italy|Adults, general population, N = 400
16344522|NCT04367337||Malaysia|Adults, general population, N = 400
16344523|NCT04367337||Portugal|Adults, general population, N = 400
16344524|NCT04367337||Romania|Adults, general population, N = 400
16344525|NCT04367337||Singapore|Adults, general population, N = 400
16344526|NCT04367337||Switzerland|Adults, general population, N = 400
16344527|NCT04367324||Low level laser therapy|Applied the low-level laser irradiation
16344528|NCT04367324||Control|No low-level laser application
16344531|NCT04367298||Chronoprevention in hospital falls|Implementation of a hospital preventive measures program: adjusted to the identification of temporal patterns of falls and relative risk factors of falls.
16344532|NCT04367285|Experimental|Sensor-based Training|
16344533|NCT04367285|Active Comparator|Upper limb motor training|
16344534|NCT04367272|Active Comparator|First Knee|The first knee is the knee where the surgery will begin to be applied.
16344535|NCT04367272|Experimental|Second Knee|The second knee is the knee where the surgeon will apply secondly.
16344536|NCT04367259|Active Comparator|Single puncture arthrocentesis (SPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with single puncture arthrocentesis
16344537|NCT04367259|Active Comparator|Double puncture arthrocentesis (DPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with double puncture arthrocentesis
16344538|NCT04367246||Affected Patients|Eligible subjects have a confirmed germline TP53 mutation or variant, OR have a family history of LFS and clinically managed as a LFS patient, OR meet LFS diagnostic criteria including Classic, Chompret, and LFL (Birch and Eeles) criteria. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a blood sample for plasma and a stool sample every six months, as well as access to their residual clinical tissues.
16344539|NCT04367246||Family Members|Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
16344540|NCT04367246||Household Members|Household member of subjects with germline TP53 mutation or variant (LFS), sharing a living space (apartment or free-standing home) for at least 6 months prior to study enrollment. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time stool sample.
16344541|NCT04367233|Active Comparator|Placebo group|General anesthesia with fentanyl, propofol and remifentanyl
16344542|NCT04367233|Experimental|Transverse block group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive transverse plan block, with levobupivacaine 0,25% 0,2 ml/kg.
16344543|NCT04367233|Experimental|Quadratus lumborum group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive quadratus lumborum block with levobupivacaine 0,25% 0,2 ml/kg.
16344544|NCT04367220||Patients with known or suspected cardiovascular disease|All patients with known or suspected cardiovascular disease are studied with a-priori stratification of specific disease-based cohorts.
16344545|NCT04367207||Adult patients with COVID-19 referred to intensive care|Prospective observational cohort study of adult (≥18 years) patients referred to intensive care or high-care units in Africa with suspected or known COVID-19 infection in Africa
16344546|NCT04367194|Experimental|BPPV intervention|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
16344547|NCT04367194|Experimental|BPPV Epley|Only Epley training.
16344549|NCT04367181|Experimental|ELGA group|"*Less than 29 weeks Gestational Age (GA) preemies (100)
~DCS monitoring will be performed for up to 72 hours starting within 2 days after birth. In a subgroup of infants, we will also perform additional measurements with aEEG and FDNIRS. At a second stage we will add Transcranial Doppler Ultrasound (TCD)"
16344550|NCT04367168|Active Comparator|Colchicine|Colchicine PO
16344551|NCT04367168|Placebo Comparator|Placebo|Placebo PO
16344552|NCT04367155|Active Comparator|tranexamic acid local|tranexamic acid inside the irrigation fluid
16344553|NCT04367155|Active Comparator|tranexamic acid IV|tranexamic acid injection
16344554|NCT04367142||positive SARS-Cov2|100 patients with a positive diagnosis of SARS-CoV-2
16344555|NCT04367142||negative SARS-Cov2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
16344556|NCT04367116|Experimental|spinal cord stimulation|the spinal cord stimulation was performed and operated
16344557|NCT04367103|Active Comparator|NEP group|Norepinephrine infusion of 0.025 µg/kg/min and 6 µg bolus will be used if BP is reduced 20 % below baseline.
16344558|NCT04367103|Placebo Comparator|PHE group|Phenylephrine will be started at 25µg/min immediately after the intrathecal local anaesthetic injection and titrated according to blood pressure and pulse rate.
16344559|NCT04367090|Experimental|Pyrotinib and docetaxel plus trastuzumab|
16344560|NCT04367077|Experimental|MultiStem|
16344561|NCT04367077|Placebo Comparator|Placebo|
16344562|NCT04367051|Experimental|Withdrawal group|Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.
16344563|NCT04367051|Active Comparator|Continuation group|Spironolactone will be continued during the study period with other medical therapy in combination.
16344564|NCT04367038|Experimental|Warm Acupressure Procedure Group|"Latent phase Visual Analog Scale and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first warm acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.
~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second warm acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
16344565|NCT04367038|Experimental|Cold Acupressure Procedure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first cold acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.
~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second cold acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
16344566|NCT04367038|Experimental|Conventional Acupressure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase Conventional acupressure was performed for 30 minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated twice more at one-hour intervals.
~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second conventional acupressure procedure was performed twice at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
16344567|NCT04367038|No Intervention|Control Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous sample taken Active phase
~No procedure other than the routine clinical practices were carried out. Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase No procedure other than the normal clinical routines was conducted Visual Analog Scale III and Verbal Category Scale III were performed. Second venous blood sample taken"
16344568|NCT04367025|Active Comparator|SOX|SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 2-4 cycles
16344569|NCT04367025|Experimental|Camrelizumab+ SOX|Camrelizumab:200mg,iv drip for 1h,d1,q3w SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy+ Camrelizumab for 2-4 cycles, adjuvant chemotherapy + Camrelizumab for 2-4 cycles.
16344570|NCT04367012||group 1 NAFLD and group 2 Non NAFLD|study from 20-60 years old.Subjects will be evaluated clinically by abdominal examination for evaluation of fatty liver and grades it into 3 grades .evaluation of fatty pancreas and grade it into 3 grades ,measuring blood pressure and physically by calculating body mass index (BMI) weight/height2
16344571|NCT04367012||Group1 NAFLD & Group 2 Non NAFLD|As the study is randomized cross sectional , all subjects whom have fatty liver by abdominal ultrasound included in group 1 NAFLD , and whom do not have fatty liver by abdominal ultrasound included in group 2.both groups was age and sex matched
16344572|NCT04366999||LSG|In this group, the bariatric procedure is laparoscopic sleeve gastrectomy (LSG), all operations follow the same standard operating procedure.
16344573|NCT04366999||LRYGB|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass (LRYGB), all operations follow the same standard operating procedure.
16344574|NCT04366999||OAGB-MGB|In this group, the bariatric procedure is one anastomosis gastric bypass-mini gastric bypass(OAGB-MGB), all operations follow the same standard operating procedure.
16344575|NCT04366986||Pregnant Women|Women who are currently pregnant
16344576|NCT04366986||Post-partum women|Women who have been pregnant in the past 6 months
16344578|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin o.d.|Effects of 40 mg subcutaneous enoxaparin o.d.
16344579|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin b.i.d|Effects of 40 mg subcutaneous enoxaparin b.i.d
16344580|NCT04366947|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
16344581|NCT04366947|Experimental|Experimental: IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
16344582|NCT04366934||COVID-19 patients|Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection
16344583|NCT04366934||Control subjects|Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia
16344584|NCT04366908|Active Comparator|Control - best available therapy|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
16344585|NCT04366908|Experimental|Treatment|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be
~Start: 2 capsules
~Days 3, 7, 14, 21, 28: 1 capsule"
16344586|NCT04366895|Experimental|control|Participants in control group (Group-A) received conventional manufactured implant overdenture
16344587|NCT04366895|Experimental|intervention|participants in intervention group (Group-B) received CAD-CAM manufactured implant overdenture.
16344588|NCT04366869|Active Comparator|control|traditional approach of removing denture at night
16344589|NCT04366869|Experimental|intervention 1|occlusal splint
16344590|NCT04366869|Experimental|intervention 2|Botox
16344591|NCT04366856|Experimental|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
16344592|NCT04366856|Other|2: No instruction regarding positioning|the control group will get no instruction regarding positioning
16344593|NCT04366843|Experimental|The chair massage group|chair massage 15 min,, 2 x week; measurement before and after each treatment
16344594|NCT04366843|Experimental|The exercise program group|excercises 15 min., 2 x week; measurement before and after each treatment
16344595|NCT04366843|No Intervention|The control group|control 2 measurements, 4 weeks apart
16344596|NCT04366817|Experimental|women in postpartum period|
16344597|NCT04366804||Patients with neuropsychiatric fluctuations|PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)
16344598|NCT04366804||Patients without neuropsychiatric fluctuations|PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)
16344600|NCT04366778||patients hospitalized for Covid-19|Patients with Covid-19 infection hospitalized in Lyon University Hospitals
16344601|NCT04366778||patients hospitalized for Covid-19 who present thrombosis|Patients with Covid-19 infection hospitalized in Lyon University Hospitals who present thrombosis during hospitalization
16344602|NCT04366765||COVID-19 suspects|Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.
16344603|NCT04366739|Experimental|CHLORPROMAZINE (CPZ)|Standard of Care (SOC) plus CHLORPROMAZINE (CPZ)
16344604|NCT04366739|Active Comparator|standard of care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparator arm"
16344605|NCT04366726|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide.
16344607|NCT04366700|Active Comparator|Bone replacement substitute and membrane|periapical surgery will be done and defect will be filled with a mixture of autograft and prf and over the defect and denuded root surface collagen membrane will be placed before closure of flap
16344608|NCT04366700|Active Comparator|membrane|periapical surgery will be done and defect will be filled with blood clot and over the defect and denuded root surface collagen membrane will be placed before closure of flap
16344609|NCT04366687|Active Comparator|PAT-AU|Parents randomized to this arm (i.e., group) receive Parents as Teachers (PAT) services as usual (AU).
16344610|NCT04366687|Experimental|PAT+CSA|Parents randomized to this arm (i.e., group) receive the added CSA-focused session (Smart Parents - Safe and Healthy Kids) added to typical Parents as Teachers (PAT).
16344611|NCT04366674|Active Comparator|Langerbeck's repair|Langerbeck's repair of cleft palate,without specific restoration of levator veli palatini or tensor veli palatini. Incisions along the margins of the cleft at the junction of oral and nasal mucosa. Lateral relaxing incisions were performed and the mucoperiosteal flap of hard palate were elevated on both sides except the ones with only soft palate cleft. The anterior end of the mucoperiosteal flap may be cut off for the purpose of tension relieving and would be resutured to the anterior area during closing. In the soft palate, the division was made between the oral mucous layer and the palatal musculature layer. Hamulus were broken for closing the cleft without tension. Closing was done by two seperated layers, one layer of nasal mucosa-palatal muscle, and one layer of oral mucosa.
16344612|NCT04366674|Active Comparator|restoration of levator veli palatini|The incision was made similar to Langerbeck's repair. During disection, the levator veli palatini was identified after the elevation of flap. The levator veli palatini was separate from the oral and nasal mucosa. During closing, the anterior end of levator veli palatini was rotated towards the midline and the two muscle bundle from the two sides were sutured in the midline. In this process, the tensor veli palatini was not intentionally identified or dissected.
16344641|NCT04366544|Other|Timepoint 3: Immediate Post-Samyama|"Online survey to be completed
~Survey link for participant
~Survey link for spouse
~Blood sample collection: on site at IIIS o Participant only - Not spouse/significant other. EEG and fMRI"
16344613|NCT04366674|Experimental|mordified restoration of tensor veli palatini|Incision was made similar to Langerbeck's repair. During disection, the tensor veli palatini was identified after flap elevation. Its tendinous fibers was released from but still connected to the pterygoid process without breaking the hamulus or cutting off the tendinous fibers. If the tension is too strong during suturing, the tensor tendon could be partly dissected laterally meanwhile be kept continuity medially so that the tensor veli palatini could be rotated more medially. The levator veli palatini, tensor veli palatini, together with the palatine aponeurosis and the nasal mucosa from two sides were sutured in the middle line. The tensor veli palatini may not be jointed to the contralateral one directly.
16344614|NCT04366661|Experimental|screening|Participants undergo low dose CT of the chest
16344615|NCT04366648|Experimental|50mg/m2|Starting dose, administered once only
16344616|NCT04366648|Experimental|75mg/m2|Second dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
16344617|NCT04366648|Experimental|100mg/m2|Third dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
16344618|NCT04366648|Experimental|125mg/m2|Forth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
16344619|NCT04366648|Experimental|150mg/m2|Fifth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
16344620|NCT04366648|Experimental|180mg/m2|Sixth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
16344621|NCT04366648|Active Comparator|175mg/m2|CPT-11, given every 14 days, first 2 cycles of drug delivery will accompanied with PK test,
16344622|NCT04366635|Experimental|Mineralised Plasmatic Matrix Group|Mineralized Plasmatic Matrix (MPM) is a product of mixing of two phases: the mineral phase and the plasma phase. After centrifugation, the white blood cells are recovered and mixed with the mineral phase of bone graft that can be autogenic, allogeneic bone, or a bone substitute like Xenogeneic Bone Synthetic. We will use Beta-tricalcium phosphate as a graft material. The result of this mixture is a homogeneous single component, which is compact and stable, containing the graft, the dense fibrin network, and the promoting healing. And then we are planning to place MPM material to extraction socket of impacted third molar tooth to improve periodontal healing at the distal aspect of second molar tooth. Additional after MPM places to extraction socket, Once the MPM has been placed, it will be covered with a Platelet Rich Fibrin (PRF) membrane and sutured as a primer.
16344623|NCT04366635|Experimental|Beta-tricalcium phosphate Group|Beta-tricalcium phosphate graft will place in the extraction socket and cover with a PRF membrane.
16344624|NCT04366635|Active Comparator|Control Group|In the control group, after removal of impacted third molar tooth no material will be placed on the extraction socket. Only the extraction socket was primarily closed with non-resorbable sutures.
16344625|NCT04366622|Experimental|Riociguat, Child Pugh A|Participants with liver cirrhosis and mild hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344626|NCT04366622|Experimental|Riociguat, Child Pugh B|Participants with liver cirrhosis and moderate hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344627|NCT04366622|Experimental|Riociguat, control A|Healthy age-, weight-, and gender- matched participants to Child Pugh A group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344628|NCT04366622|Experimental|Riociguat, control B|Healthy age-, weight-, and gender- matched participants to Child Pugh B group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344629|NCT04366609||ADHD patients|Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.
16344630|NCT04366596|Experimental|DEB group|angioplasty with paclitaxel eluting balloon
16344631|NCT04366596|Placebo Comparator|POB group|Angioplasty with plain old balloon
16344632|NCT04366583|Experimental|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
16344633|NCT04366583|Active Comparator|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
16344634|NCT04366570||The 1st group|(n=511; 36,45%) included patients with extra-articular injury of the proximal humerus (rotator cuff tear, anatomical and surgical neck fracture)
16344635|NCT04366570||The 2nd group|(n=309; 22,04%) included patients with intra-articular injury of the proximal humerus (contracture of the shoulder joint and shoulder instability, humeral head fracture, including Hill-Sachs lesion)
16344636|NCT04366570||The 3rd group|(n=582; 41,51%) - patients with injury of subacromial (suprahumeral) space (soft tissue injury, acromioclavicular and sternoclavicular joint injury, diaphyseal and distal end clavicle fracture)
16344637|NCT04366557|Experimental|Body posture correction|Subjects from study group had an education about pelvic floor and additional a six week body posture therapy.
16344638|NCT04366557|Other|Without correction of body posture|Subjects form control group had only an education about pelvic floor.
16344639|NCT04366544|Other|Time Point 1: Baseline/Pre-preparatory Samyama|"Survey link for participant
~Survey link for spouse/ control
~Stool collection from home
~Blood sample at home provided by at home phlebotomy services or at Isha Center group meditation by study personnel."
16344640|NCT04366544|Other|Time point 2: Post-Preparatory/Pre-Samyama|"Online Surveys
~Participant
~Spouse
~Stool collection from IIIS/home
~Blood sample collection: on site at IIIS/home EEG and fMRI"
16344751|NCT04365946||Complete type|Patients with complete-type intestinal metaplasia
16344642|NCT04366544|Other|Timepoint 4: 3 months Post Samyama|"Blood draw at home by at home phlebotomist
~Post program online survey follow up to be completed
~Survey link for participant
~Survey link for spouse: https
~Stool collection from home"
16344643|NCT04366531|No Intervention|Monitoring/Treatment as usual|Veterans will not receive any study related interventions.
16344644|NCT04366531|Active Comparator|Reentry Program|Veterans will receive the START-VET reentry program
16344645|NCT04366518|Experimental|Aim 2: Those with psychosis/hallucinations|Participants who have a psychosis spectrum diagnosis and frequent auditory hallucinations will be given physostigmine versus saline.
16344646|NCT04366518|Placebo Comparator|Aim 1: Healthy Controls|Healthy controls will be given scopolamine patches versus placebo patch.
16344647|NCT04366505|Experimental|NFB + (MBRP)|Neurofeedback (NFB) from target region or control region plus Mindfulness-based relapse prevention (for some)
16344648|NCT04366505|Active Comparator|TAU and sham NFB|TAU + Neurofeedback (NFB) from control region
16344649|NCT04366492|Other|persons in prison|
16344650|NCT04366479|Experimental|intervention group|The study lasted for 5 weeks (1 month 7 days). During the research process, we monitor closely, especially the training schedule, implementation, and evaluation, directly and indirectly. Directly assisting participants to do endurance training activities, not directly monitoring via telephone or WhatsApp.
16344651|NCT04366466|Other|suicide attempt patient who will receive sanitory supervision|The control group will establish the health monitoring
16344652|NCT04366466|Experimental|Suicide attempt patient who will participate to PEPS Program|The intervention group will test the program of Promotion of Commitment to Care for the Prevention of Suicidal Recidivism.
16344653|NCT04366453|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations
~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
16344654|NCT04366440|Other|Order set review and modification|The antimicrobial stewardship program will review and change order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
16344655|NCT04366440|Other|Order Set review and Modification plus facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
16344656|NCT04366427|Experimental|Low-pressure hyperbaric oxygenation (L-HBO)|Low-pressure hyperbaric oxygen administration at 1.45 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 sessions (3-4 per week).
16344657|NCT04366427|Experimental|Standard-pressure hyperbaric oxygenation (HBO)|Standard pressure hyperbaric oxygen administration at 2.5 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 non-consecutive sessions (3-4 per week).
16344658|NCT04366427|No Intervention|Control|Control group of athletes, no intervention.
16344659|NCT04366427|Experimental|30% O2|Administration of air mixture with 30% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
16344660|NCT04366427|Experimental|50% O2|Administration of air mixture with 50% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
16344661|NCT04366414|Active Comparator|hook breathing removing nose-clip|"It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
~During that training, only this group will perform an experimental breathing protocol consisted of removing nose-clip previous to surface and then perform hook breathing during 20 seconds. This protocol was applied at the end of each of the 8 submaximes-dynamic apnoeas and after the maximal-dynamic apnoea"
16344662|NCT04366414|Active Comparator|usual breathing (UB)|It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
16344663|NCT04366401|Active Comparator|Conventional Dietary Advice|"The control group will consist of participants diagnosed on the schizophrenic spectrum who will receive conventional dietary counseling (n=25) on an individual basis.
~In the control group, data will be collected on the psychopathological state (PANSS and PSP scales), and blood analysis (hemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
16344664|NCT04366401|Experimental|Prebiotic/Probiotic Dietary Modulation|"In the intervention group (n=25), individual dietary counseling will be established through intensive nutritional counseling to provide a high prebiotic and probiotic food pattern.
~In the experimental group, data will be collected on psychopathological status (Positive and Negative Syndrome Scale -PANSS- and Personal and Social Functioning Scale -PSP-), and blood tests (haemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
16344665|NCT04366388||Frail hospitalized old adults|Over than 65-years of age Admitted into Acute Unit Nonambulatory
16344666|NCT04366375||TLH+BSO|Total Laparoscopic Hysterectomy + Bilateral Salpingo-Oophorectomy N=20
16344667|NCT04366375||TAH + BSO|Total Abdominal Hysterectomy + BSO N=20
16344668|NCT04366362|Active Comparator|Convetional reconstruction group|Patients will undergo ACL reconstruction based on conventional ACL surgery
16344669|NCT04366362|Experimental|Individualised reconstruction group|Patients will undergo ACL reconstruction based on their special anatomical and functional characteristics and with the use of a navigation system
16344670|NCT04366349|Experimental|Participants receiving GSK3772847 70 milligram (mg)|Participants will receive a single dose of GSK3772847 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
16344671|NCT04366349|Experimental|Participants receiving GSK3772847 140 milligram (mg)|Participants will receive a single dose of GSK3772847 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
16344672|NCT04366349|Placebo Comparator|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
16344673|NCT04366336|Experimental|Blood Flow Restriction Training|"Blood flow restriction training (BFRT) uses a specialized tourniquet system to restrict arterial inflow and venous outflow to the limb during low-load resistance exercise.
~BFRT involves placing the pressure cuff before the start of therapeutic exercises.
~Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching"
16344674|NCT04366336|Active Comparator|Standard Physical Therapy|Subjects will receive American College of Sports Medicine guided-strength training Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
16344675|NCT04366323|Experimental|Experimental|
16344676|NCT04366323|No Intervention|Control|
16344677|NCT04366310||capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
16344678|NCT04366297|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
16344679|NCT04366297|Experimental|IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
16344680|NCT04366284|Active Comparator|NOCTEM only (NOCTEM)|No external or internal facilitation
16344681|NCT04366284|Active Comparator|External Facilitation (NOCTEM+EF)|External facilitation only
16344682|NCT04366284|Active Comparator|External and Internal Facilitation (NOCTEM+EF/IF)|External and internal facilitation
16344683|NCT04366271|Experimental|Mesenchymal cells|Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
16344684|NCT04366271|Active Comparator|Standard of care|Standard of care
16344685|NCT04366258|Experimental|t-PBM at High, Middle, Low Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 300 mW/cm2, then 50 mW/cm2, and then 0 mW/cm2.
16344686|NCT04366258|Experimental|t-PBM at High, Middle Irradiance, Sham, Low Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 300 mW/cm2, then 0 mW/cm2, and then 50 mW/cm2.
16344687|NCT04366258|Experimental|t-PBM at High, Low, Middle Irradiance Sham|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 50 mW/cm2, then 300 mW/cm2, and then 0 mW/cm2
16344688|NCT04366258|Experimental|t-PBM at High, Low Irradiance, Sham, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 50 mW/cm2, then 0 mW/cm2 and then 300 mW/cm2
16344689|NCT04366258|Experimental|t-PBM at High Irradiance, Sham, Middle, Low Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 0 mW/cm2, then 300 mW/cm2, and then 50 mW/cm2
16344690|NCT04366258|Experimental|t-PBM at High Irradiance, Sham, Low, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 0 mW/cm2, then 50 mW/cm2, and then 300 mW/cm2
16344691|NCT04366258|Experimental|t-PBM at Middle, High, Low Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 770 mW/cm2, then 50 mW/cm2, and then 0 mW/cm2
16344692|NCT04366258|Experimental|t-PBM at Middle, High Irradiance, Sham, Low Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 770 mW/cm2, then 0 mW/cm2, and then 50 mW/cm2
16344693|NCT04366258|Experimental|t-PBM at Middle, Low, High Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 50 mW/cm2, then 770 mW/cm2, and then 0 mW/cm2
16344694|NCT04366258|Experimental|t-PBM at Middle, Low Irradiance, Sham, High Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 50 mW/cm2, then 0 mW/cm2, and then 770 mW/cm2
16344695|NCT04366258|Experimental|t-PBM at Middle Irradiance Sham High Irradiance Low Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 0 mW/cm2, then 770 mW/cm2, and then 50 mW/cm2
16344696|NCT04366258|Experimental|t-PBM at Middle Irradiance, Sham Low, High Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 0 mW/cm2, then 50 mW/cm2, and then 770 mW/cm2,
16344697|NCT04366258|Experimental|t-PBM at Low High Middle Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 770 mW/cm2, then 300 mW/cm2, and then 0 mW/cm2
16344698|NCT04366258|Experimental|t-PBM at Low, High Irradiance, Sham Middle Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 770 mW/cm2, then 0 mW/cm2, and then 300 mW/cm2
16344699|NCT04366258|Experimental|t-PBM at Low, Middle, High Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 300 mW/cm2, then 770 mW/cm2, and then 0 mW/cm2
16344700|NCT04366258|Experimental|t-PBM at Low, Middle Irradiance, Sham High Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 300 mW/cm2, then 0 mW/cm2, and then 770 mW/cm2
16344701|NCT04366258|Experimental|t-PBM at Low Irradiance, Sham High, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 0 mW/cm2, then 770 mW/cm2, and then 300 mW/cm2
16344702|NCT04366258|Experimental|t-PBM at Low Irradiance, Sham Middle, High Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 0 mW/cm2, then 300 mW/cm2, and then 770 mW/cm2
16344703|NCT04366258|Experimental|t-PBM at Sham, High, Middle, Low Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 770 mW/cm2, then 300 mW/cm2, and then 50 mW/cm2
16344704|NCT04366258|Experimental|t-PBM at Sham, High, Low, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 770 mW/cm2, then 50 mW/cm2, and then 300 mW/cm2
16344705|NCT04366258|Experimental|t-PBM at Sham, Middle, High, Low Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 300 mW/cm2, then 770 mW/cm2, and then 50 mW/cm2
16344706|NCT04366258|Experimental|t-PBM at Sham Middle, Low, High Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 300 mW/cm2, then 50 mW/cm2, and then 770 mW/cm2
16344707|NCT04366258|Experimental|t-PBM at Sham Low, High, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 50 mW/cm2, then 770 mW/cm2, and then 300 mW/cm2
16344708|NCT04366258|Experimental|t-PBM at Sham Low, Middle, High Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 50 mW/cm2, then 300 mW/cm2, and then 770 mW/cm2
16344709|NCT04366245|Experimental|Experimental|
16344710|NCT04366245|Active Comparator|Comparator|
16344711|NCT04366232|Experimental|Anakinra +/- Ruxolitinib|"According to clinical stage (gradual strategy):
~Stage 2b or 3 : Anakinra 300 mg IV
~Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2"
16344712|NCT04366232|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
16344713|NCT04366219||2019|Data collection on patients with Lung cancer diagnosed between March 13, 2019 and August 28, 2019.
16344714|NCT04366219||2020|Data collection on patients with Lung cancer diagnosed between March 13, 2020 and August 28, 2020.
16344715|NCT04366206||Patients exposed to the study variable|Depending on the studied variable (treatment or risk factor)
16344716|NCT04366206||Patients not exposed to the study variable|Depending on the studied variable (treatment or risk factor)
16344717|NCT04366180|Experimental|Probiotic|Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day).
16344718|NCT04366180|Placebo Comparator|Control|Control group who will receive a daily placebo capsule consisting of maltodextrin
16344719|NCT04366167||Cardiac surgery patients|Patients undergoing adult cardiac surgery during the Covid-19 pandemic
16344720|NCT04366154||Patients|
16344721|NCT04366154||Caregivers|
16344722|NCT04366141|Experimental|COVID-19 barrier box intervention group|Attending anesthesiologists will use a COVID-19 barrier box for intubating the patient participants of this group.
16344723|NCT04366141|No Intervention|Control group|Attending anesthesiologists will use standard intubation procedures.
16344724|NCT04366128|Experimental|CAPA indution immunotherapy|CAPA regimen, repeat every 3 week for 4 cycles.
16344725|NCT04366115|Active Comparator|AVM0703 COVID-19 ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
16344726|NCT04366115|Placebo Comparator|Placebo COVID-19 ARDS - placebo|Matching placebo
16344727|NCT04366115|Active Comparator|AVM0703 Influenza ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
16344728|NCT04366115|Placebo Comparator|AVM0703 Influenza ARDS - placebo|Matching placebo
16344731|NCT04366089|Active Comparator|Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
16344732|NCT04366089|Experimental|Oxygen-ozone and probiotic|"Oxygen-ozone therapy, probiotic supplementation plus standard of care
~Oxygen-ozone therapy: systemic autohemotherapy (twice a day).
~Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day)."
16344733|NCT04366076||nonlaboring term singleton pregnancies|A total of 51 nonlaboring term singleton pregnancies were enrolled.
16344734|NCT04366063|Experimental|Two MSC infusion|Intervention Group1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) intravenously plus Conventional treatment.
16344735|NCT04366063|Experimental|Two MSC infusion Plus two EVs infusion|Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), intravenously plus two doses of EVs plus Conventional treatment
16344736|NCT04366063|No Intervention|Control|Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control.
16344737|NCT04366050|Experimental|Ramipril 2.5mg orally daily|"Total 2.5 mg Ramipril per day once a day orally for 14 days
~Intervention: Ramipril"
16344738|NCT04366050|Placebo Comparator|Placebo|Placebo in the form of a capsule, taken orally for 14 days
16344739|NCT04366037|Experimental|Control group|This group performed their routine training
16344740|NCT04366037|Experimental|Experimental 1|This group performed their routine training plus proprioceptive exercises in the warm-up.
16344741|NCT04366037|Experimental|Experimental 2|This group performed their routine training plus proprioceptive exercises in the cool-down
16344742|NCT04366024||Observed group|COVID-19 disease patients who were detected by RT-PCR and CT imaging.
16344743|NCT04366011|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is a twelve-week therapeutic intervention based on the theory that maladaptive thoughts contribute to symptom development and maintenance of PD/A.
16344744|NCT04366011|Experimental|Capnometry Assisted Respiratory Training (CART)|Capnometry-assisted respiratory therapy is a five-week treatment based on the theory that hyperventilation causes or maintains panic disorder.
16344745|NCT04365998|Experimental|BUBOLight® Device|
16344746|NCT04365985|Placebo Comparator|Placebo|Placebo by mouth 1 time per day for patients with stage I or stage 2A COVID-19
16344747|NCT04365985|Experimental|Naltrexone|Naltrexone 4.5 mg by mouth 1 time per day for patients with stage I or stage 2A COVID-19.
16344748|NCT04365985|Experimental|Ketamine|Ketamine IV infusion (0.15 mg/kg based on total body weight for maximum 20 mg every 6 hours) for patients with stage 2B or stage 3 COVID-19; may be increased to 0.3 mg/kg based on total body weight for a maximum of 30 mg every 6 hours if needed. Patients entering this arm from the placebo or naltrexone arms remain on those medications as well.
16344749|NCT04365972|Experimental|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 5 sessions using a variant of the dot-probe task in which the target probe always replaces neutral rather than threat (health-related) stimuli to induce diversion of attention away from threat.
16344750|NCT04365959||covid-19 pneumonia related patients|This study will be conducted on all patients admitted to the Infectious Diseases and UTIR units of the S. Gerardo Hospital in Monza with the diagnosis of related COVID pneumonia requiring oxygen support or CPAP.
16344752|NCT04365946||Incomplete type|Patients with incomplete-type intestinal metaplasia
16344753|NCT04365946||Controls|Healthy subjects
16344754|NCT04365933|Experimental|Arm 1|EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
16344755|NCT04365933|Experimental|Arm 2|EYP001a Dose A QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
16344756|NCT04365920|No Intervention|Re-Entry as Usual|The type and level of services provided to individuals at re-entry will vary across jails and will be carefully documented. For the most part, individuals released to the community will receive a referral to an opioid treatment provider (OTP) for treatment with MOUD, and a subset may potentially be mandated to participate in community based treatment and/or recovery programs such as recovery coaching, and/or sentenced to varying levels of probation.
16344757|NCT04365920|Experimental|Recovery Management Checkups (RMC)|In the RMC condition, participants will have access to services provided as a part of re-entry as usual. In addition, checkups will be provided on a fixed schedule that includes face-to-face monthly checkups for the initial 3 months, and quarterly for the rest of the two years. Participants will have access to referrals and services provided by the jail and linkage to an OTP as part of their usual re-entry procedures. Individuals will meet with a Linkage Manager (LM) upon study enrollment and during each quarterly checkup, during which they will complete a Brief Treatment Needs Assessment, receive motivational interviewing, linkage assistance, or a check-in on continuing care and recovery support. The priority is to engage the individual into treatment with MOUD as soon as possible at the time of release, however, if individuals express a preference for another form of SUD treatment, the LM will work with that individual to link, engage, and retain them in that form of treatment.
16344758|NCT04365920|Experimental|RMC-Adaptive|In the RMC-Adaptive condition, checkups will be provided based on the participant's current need for treatment and will be adapted in three ways. First, the interval between RMC-A check-ups will vary (in 1-month increments) depending upon the individual's assessed need for treatment at the prior check-up. Second, in cases where participants have 3 consecutive checkups in which they need treatment, the LM and treatment provider will discuss how to better meet the participant's needs, e.g., a different treatment provider, different type of MOUD or other types of treatment, and/or additional services. Third, if RMC-A participants are re-incarcerated at the time of their checkup, the LM will meet with the individual while incarcerated to discuss a recovery plan, which may include initiation of treatment with MOUD while incarcerated and re-linkage to an OTP upon release.
16344759|NCT04365907|Experimental|Omarigliptin 12.5 mg|Drug: Omarigliptin 12.5 mg Once weekly new anti-diabetic drug approved only in Japan Other Name: Zafatek tablets
16344760|NCT04365894|No Intervention|Control|The study was applied in 2nd grade nursing students' disability health course. The control group was taught with the traditional method.
16344761|NCT04365894|Experimental|Intervention|The intervention group with learning activities based on the transformative learning theory.
16344762|NCT04365868|Experimental|belapectin 2 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)
~Phase 3: The patient will be switched to the optimal dose"
16344763|NCT04365868|Experimental|belapectin 4 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)
~Phase 3: The patient will be switched to the optimal dose"
16344764|NCT04365868|Placebo Comparator|Placebo|"Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)
~Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)"
16344765|NCT04365855|Other|Subjects at risk for NAFLD|Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
16344766|NCT04365842|Experimental|Digital exercise group|"After the 6-week digital intervention, 1) qualitative interviews have done with 6-15 patients from intervention group to assess the feasibility of digital intervention.
~2) The primary outcomes are hand pain and function and exercise adherence will be evaluated for all participants"
16344767|NCT04365842|Active Comparator|Waiting list conrol|A hand rehabilitation home program will be given to the patients in the group through the telephone messages with brochures.
16344768|NCT04365829|Experimental|Virtual reality|
16344769|NCT04365816||Prospective cohort University Hospital, Grenoble|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344770|NCT04365816||Prospective cohort University Hospital, Toulouse|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344771|NCT04365816||Prospective cohort University Hospital, Nancy|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344772|NCT04365816||Prospective cohort University Hospital, Rennes|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344773|NCT04365816||Prospective cohort Hospices Civils de Lyon|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344774|NCT04365816||Prospective cohort Assistance Publique Hôpitaux de Paris|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344775|NCT04365816||Prospective cohort University Hospital, Rouen|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
16344777|NCT04365790||Patients with triple-negative breast cancer|Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
16344778|NCT04365790||Patients with HER2+ positive breast cancer|Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
16344779|NCT04365777||Awake group|
16344780|NCT04365777||Mild sedation group|
16344781|NCT04365777||Deep sedation group|
16344782|NCT04365764||Exposed to the treatment|Exposure variable will be studied treatment
16344783|NCT04365764||Not exposer to the treatment (control group)|
16344784|NCT04365751|Experimental|Percutaneous microwave ablation group|MWA (Microwave) is an ultrasound-guided, minimally invasive technique that implants ablation electrodes into target tissue to rapidly generate high temperatures and rapidly develop coagulative necrosis in tumor tissue, thereby achieving the goal of local tumor treatment.
16344785|NCT04365751|Other|Laparoscopic hepatectomy|Laparoscopic hepatectomy is a widely used surgical technique in the treatment of benign (malignant) liver diseases
16344786|NCT04365738|Experimental|Pulmonary Rehabilitation|The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day. Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
16344787|NCT04365738|Placebo Comparator|Control|As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
16344788|NCT04365712|Active Comparator|Oscillating saw|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by common oscillating saw
16344789|NCT04365712|Experimental|Piezoelectric tool|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by piezoelectric tool
16344790|NCT04365699|Experimental|Interventional Patients: AT-001|AT-001 1500 mg (3 capsules) were administered by mouth twice daily for up to 14 days
16344791|NCT04365699|No Intervention|Control Match Group 1|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The first matching approach selected all subjects with diabetes mellitus and hypertension, and available data to match participants who received AT-001 for gender, age group (in bins of 5 years), weight, and C-reactive protein (CRP) value at the time of hospital admission.
16344792|NCT04365699|No Intervention|Control Match Group 2|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The second matching approach selected all subjects in the registry with diabetes mellitus and available data to match participants who received AT-001 for gender, age group (in bings of 5 years), and weight (+/- 0.5 kgs).
16344793|NCT04365686|Active Comparator|Group K|Ketofol group
16344794|NCT04365686|Active Comparator|Group P|propofol group
16344795|NCT04365673||Readmitted|Patients that were readmitted within 30 days post hospital discharge
16344796|NCT04365673||Not readmitted|Patients that were not readmitted within 30 days post hospital discharge
16344797|NCT04365660|Experimental|18-F-FTC 146 PET/CT|For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).
16344798|NCT04365647||1|Patient's in whom there is increase in tumor size after craniotomy
16344799|NCT04365647||2|Patient's in whom there was either no increase in tumor size or decrease in tumor size after craniotomy
16344800|NCT04365634||Diabetes|Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
16344801|NCT04365634||Non-diabetes|Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
16344802|NCT04365634||Survivors|COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
16344803|NCT04365634||Non-survivors|COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
16344804|NCT04365621|Other|ultra-high risk of psychosis patient|patient with ultra -high risk of psychosis will be enrolled to the study
16344805|NCT04365608|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy. The standard intubation procedure is to use a styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the guidelines on difficult airway management.
16344806|NCT04365608|Active Comparator|Vie Scope laryngoscopy|Intubation will be done using Vie Scope laryngoscopy
16344807|NCT04365595||SARS-CoV-2 associated respiratory failure|Participants will receive a daily HrQoL questionnaire on their personal smartphone using the docdok health application during 3 months. A selection of participants will furthermore receive a custom-built home disease monitoring device during 1 month. Both procedures start at least 4 weeks after hospital discharge.
16344808|NCT04365582|Experimental|Azithromycin|Azithromycin
16344809|NCT04365582|Experimental|Hydroxychlororquine|Hydroxychlororquine
16344810|NCT04365582|Experimental|Lopinavir/Ritonavir|Lopinavir/Ritonavir
16344811|NCT04365582|No Intervention|standards of care|SoC
16344812|NCT04365569|Experimental|Individualized, nutrition and physical activity intervention|Initial in-person consult with a registered dietitian, with further in-person follow-ups and monthly telephone consults
16344813|NCT04365556|Experimental|TASC Intervention|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
16344814|NCT04365556|No Intervention|Treatment as Usual|Participants will not receive any intervention.
16344815|NCT04365543|Experimental|UP-C/A for Misophonia|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
16344816|NCT04365543|Experimental|Psychoeducation and Relaxation Therapy|Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
16344945|NCT04364646|Active Comparator|Usual Care|Women in the usual care group receive medications and/or talk therapy. Sleep and light levels are monitored at home with wrist actigraphy during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and18 after the baby is born (postpartum weeks 2-6 and 18).
16344817|NCT04365517|Active Comparator|Treatment group|patients will be treated with sitagliptin add on to nutritional therapy with o without insulin treatment. The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
16344818|NCT04365517|No Intervention|Control group|Patients who will be prescribed nutritional therapy with or without insulin treatment
16344819|NCT04365504||Osteoporotic|Post menopausal females with Lumbar T score <-2.5 as determined by dual energy X ray absorbitometry
16344820|NCT04365504||Osteopenic|Post menopausal females with Lumbar T score -1 to -2.5 as determined by dual energy X ray absorbitometry
16344821|NCT04365504||Normal|Post menopausal females with T score >-1 as determined by dual energy X ray absorbitometry
16344822|NCT04365478|Experimental|rSWT group|Radial Extracorporeal Shock Wave Therapy on spastic muscles of upper limb
16344823|NCT04365478|Active Comparator|Control group|conventional physiotherapy
16344824|NCT04365465|Experimental|Active device|Participants in this arm will receive an active NSS-Bridge device placed immediately following their cesarean section.
16344825|NCT04365465|Sham Comparator|Placebo device|Participants in this arm will receive an inactive (sham) NSS-Bridge device placed immediately following their cesarean section.
16344826|NCT04365465|Active Comparator|Active Control|Participants in this arm will receive no device, only the standard postpartum pain control.
16344827|NCT04365452|Experimental|Invia Motion Arm|
16344828|NCT04365439|Experimental|Convalescent plasma|Convalescent plasma from patients after COVID-19
16344829|NCT04365426|Experimental|Oral contraceptive (OC)|Oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
16344830|NCT04365426|Experimental|No oral contraceptive (No OC)|No oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
16344831|NCT04365413|Experimental|Imaging of Tumor or Lymph node|"Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery.
~The temperature of their skin prior to and after MSOT imaging will also be measured."
16344832|NCT04365400|Experimental|DS102 2000mg|Participants in this group will receive 1000mg DS102 capsules twice daily.
16344833|NCT04365400|Experimental|DS102 4000mg|Participants in this group will receive 2000mg DS102 capsules twice daily.
16344834|NCT04365400|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules twice daily.
16344835|NCT04365387|Experimental|Nemolizumab|Participants will receive a loading dose of nemolizumab (60 milligram [mg]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) will then be administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.
16344836|NCT04365387|Placebo Comparator|Placebo|Participants will receive a placebo via 2 SC injections at baseline. Placebo will then be administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
16344837|NCT04365374|Experimental|Surgical Resection and GammaTile Therapy|Surgical Resection and GammaTile Therapy
16344838|NCT04365374|Active Comparator|Surgical Resection and Stereotactic Radiation Therapy|Surgical Resection and Stereotactic Radiation Therapy
16344839|NCT04365322||Severe COVID-19 infection|
16344840|NCT04365322||Light to moderate COVID-19 infection|
16344841|NCT04365322||Cancer patients with COVID-19 infection|
16344842|NCT04365309|No Intervention|the NCP standard treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment).
16344843|NCT04365309|Experimental|the NCP aspirin treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge.
16344844|NCT04365296|Experimental|Aerobic group|This group will include 30 burned patients who will receive aerobic exercises 8 weeks (3times/week) in form of treadmill exercise in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
16344845|NCT04365296|Experimental|Resistance group|This group will include 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
16344846|NCT04365283|Experimental|New Bioactive Restorative Material|ACTIVA Presto restorative material
16344847|NCT04365283|Active Comparator|High Viscosity Glass Hybrid Reinforced Glass Ionomer|EQUIA Forte restorative material
16344848|NCT04365270|Experimental|Chitosan Glass ionomer|"purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.
~will be placed in the prepared cavity over the last layer of caries"
16344849|NCT04365270|Experimental|Chitosan/Titanium dioxide nanoparticles Glass ionomer|"The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.
~The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries"
16344850|NCT04365270|Active Comparator|Chlorhexidine glass ionomer|Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v
16344851|NCT04365270|Placebo Comparator|Glass ionomer|Stock powder and liquid Fuji IX from GC japan
16344974|NCT04364438|Experimental|EMS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Electric Muscle Stimulation (EMS)
16344852|NCT04365257|Experimental|Prazosin|"Prazosin 1mg given to observe if medication is tolerated or if signs or symptoms of hypotension develop (e.g. dizziness, lightheadedness).
~If the patient remains asymptomatic and BP >110/60 mmHg, prazosin is continued at 1mg every 8 hours (q8h).
~Day 3: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 2mg q8h.
~Day 6: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 5mg q8h.
~If the BP is <100/60 mmHg at any time, the next dose should be held, and patient continues with the highest previously tolerated dose 8 hours later.
~If the patient did not tolerate dose escalation to 5mg q8h, one attempt is made to increase dose to 3mg q8h. If this is not tolerated, the patient continues with the highest previously tolerated dose 8 hours later.
~If BP monitoring is not available, repeated occurrences of postural dizziness should trigger drug dose reduction or BP monitoring."
16344853|NCT04365257|Active Comparator|Standard of care|Subjects randomized to this arm will receive standard of care.
16344854|NCT04365231|Experimental|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.
~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
16344855|NCT04365231|Active Comparator|conventional management of patients|Regular management of patients
16344856|NCT04365218|Experimental|Cohort 1 (Dose A)|6 subjects will be randomized to receive MEDI8367 Dose A and 2 subjects will be randomized to receive placebo.
16344857|NCT04365218|Experimental|Cohort 2 (Dose B)|6 subjects will be randomized to receive MEDI8367 Dose B and 2 subjects will be randomized to receive placebo.
16344858|NCT04365218|Experimental|Cohort 3 (Dose C)|6 subjects will be randomized to receive MEDI8367 Dose C and 2 subjects will be randomized to receive placebo.
16344859|NCT04365218|Experimental|Cohort 4 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D and 2 subjects will be randomized to receive placebo.
16344860|NCT04365218|Experimental|Cohort 5 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 2 subjects will be randomized to receive placebo.
16344861|NCT04365218|Experimental|Cohort 6 (Dose D)|15 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 15 subjects will be randomized to receive placebo.
16344862|NCT04365205||severe asthma|"Diagnosis of severe asthma according to the American Thoracic Society / European Respiratory Society task force.
~Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in Forced expiratory volume forced expiratory volume at one second (FEV1) within 12 months before enrollment.
~Documented blood eosinophils ≥ 300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1."
16344863|NCT04365205||non-severe asthma|• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA).
16344864|NCT04365205||non-asthmatic controls|"No prior history of any chronic respiratory disease including asthma.
~No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.
~No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.
~Normal lung function with FEV1 > 90%."
16344865|NCT04365192||I-gel|
16344866|NCT04365192||Self-pressurized air-Q|
16344867|NCT04365179|Experimental|NEROFE|"Dose Level - Nerofe Dose
~-1 - 6mg/m2
~- 12 mg/m2
~- 24 mg/m2
~- 48 mg/m2
~- 96 mg/m2
~- 150mg/m2"
16344868|NCT04365153|Active Comparator|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients </= 40 kg)
16344869|NCT04365153|Active Comparator|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients </= 40 kg)
16344870|NCT04365153|Placebo Comparator|Control|Placebo
16344871|NCT04365140||positive ACD to nickel|Patients with positive epicutaneous patch test to nickel
16344872|NCT04365140||negative ACD to nickel|Patients with negative epicutaneous patch test to nickel
16344873|NCT04365127|Experimental|Progesterone plus SOC|Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
16344874|NCT04365127|No Intervention|SOC only|Subjects will receive institutional standard of care only
16344875|NCT04365114||Single reading|Only one clinician examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
16344876|NCT04365114||Double reading|Two clinicians examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
16344877|NCT04365101|Experimental|Phase I|CYNK-001 infusions on Days 1, 4, and 7
16344878|NCT04365101|Active Comparator|Phase II|Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care
16344879|NCT04365088|Experimental|Deflazacort|Deflazacort is a glucocorticoid used as an anti-inflammatory drug. We used deflazacort 30 mg tablet. Patient took a pill once preoperatively (1 hour ago) in third molar surgery.
16344880|NCT04365088|Placebo Comparator|Sugar pill|Placebo is an inert substance or treatment which is designed to have no therapeutic value. Patients took sugar pill for plasebo once one hour before operation.
16344881|NCT04365075|Experimental|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
16344882|NCT04365075|Active Comparator|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
16344883|NCT04365062|Experimental|Intervention: Excimer laser and drug coated balloon|Intervention: Excimer laser and drug coated balloon group
16344884|NCT04365062|Active Comparator|Excimer laser and plain balloon|Excimer laser and plain balloon group
16344885|NCT04365062|Active Comparator|plain balloon and drug coated balloon|plain balloon and drug coated balloon group
16344886|NCT04365049||Treatment|Patients in treatment group will receive anti-PD-1 antibody intravenously every three weeks and apatinib 250mg per day until disease progression, unacceptable toxicity, death or withdrawal. Concurrent external beam radiation will be initiated after one course of anti-PD-1 treatment. The total radiation dose is over 40Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed.
16344887|NCT04365049||Gemcitabine+cisplatin|Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
16346493|NCT04353778|Other|nVNS|PLWH to undergo non-invasive vagal nerve stimulation
16344888|NCT04365036|Experimental|toripalimab with P-GemOx|Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
16344889|NCT04365036|Active Comparator|P-GemOx|Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
16344890|NCT04365023||1|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy
16344891|NCT04365023||2|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive receiving first line non-platinum chemotherapy
16344892|NCT04365010|Experimental|Sodium Bicarbonate Ringer's Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.
~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
16344893|NCT04365010|Active Comparator|0.9% Sodium Chloride Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.
~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
16344894|NCT04364997|Experimental|Desvenlafaxine Succinate Sustained-Release|
16344895|NCT04364997|Active Comparator|Duloxetine Hydrochloride Enteric-coated|
16344896|NCT04364984||ARB group|Hypertensive patients with COVID-19 who received ARBs
16344897|NCT04364984||ACEi group|Hypertensive patients with COVID-19 who received ACEis
16344898|NCT04364984||DRi|Hypertensive patients with COVID-19 who received DRis
16344899|NCT04364971|Experimental|singleradius|Single Radius(SR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Single Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
16344900|NCT04364971|Experimental|Multiradius|Multi Radius(MR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Multi Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
16344901|NCT04364958|Experimental|Intervention group|Patients who agree participant and will sign the informed consent, will complete the baseline assessment. Then, those allocated to the intervention group will review the web-based PtDA (shown on the computer), with the help of a researcher if necessary, and then will fill the questionnaires assessing the outcome measures in the same web interface.
16344902|NCT04364958|Active Comparator|Control group|Patients allocated to the control group will receive a web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care, and they will also complete the same questionnaires.
16344903|NCT04364945|Placebo Comparator|Control group|General anesthesia is maintained using sevoflurane only. Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
16344904|NCT04364945|Experimental|Dexmedetomidine-remifentanil(DEX-R) group|General anesthesia is maintained using sevoflurane, dexmedetomidine (1 mcg/kg/hr) and remifentanil (0.1-0.2 mcg/kg/min). Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
16344905|NCT04364919|Experimental|aerobic exercise intervention|The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
16344906|NCT04364919|No Intervention|control group|The control group received routine prenatal care only.
16344907|NCT04364906|Active Comparator|Quadratus Lumborum Block 2|Quadratus Lumborum Block 2 (QLB 2) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
16344908|NCT04364906|Active Comparator|Quadratus Lumborum Block 3|Quadratus Lumborum Block 3 (QLB 3) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
16344909|NCT04364893|Other|Group 1|Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
16344910|NCT04364893|Other|Group 2|Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
16344911|NCT04364880|Experimental|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
16344912|NCT04364880|Sham Comparator|Sham controlled intervention|The sham-TBS coil produced a similar sound without a magnetic pulse.
16344913|NCT04364867|Experimental|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
16344914|NCT04364867|Active Comparator|Pain pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
16344915|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 3 weeks|
16344916|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 4.5 weeks|
16344917|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 6 weeks|
16344918|NCT04364854|Other|No Therapy 6 weeks|
16344919|NCT04364828|Other|Host Genome Analysis|For 150 patients from the extreme phenotypes - complementary to Whole Genome Analysis of each patient also Whole Transcriptome will performed Analysis; DNA methylation analysis using EPIC arrays will be performed in the pilot study (phase 1). Identically, in phase 2 starting from month 4, will be generated WGS, Whole transcriptome sequencing (WTS), and methylation data of the 500 patients. Epigenetic changes are likely to occur upon Corona infection. Subsequently, genome and epigenome data with RNA expression pattern will be correlated.
16345029|NCT04364113|Experimental|Study B Very Low Protein Low Pressure|Study B Very Low Protein and Low Pressure
16346494|NCT04353765||cabozantinib arm|
16344920|NCT04364828|Other|Host Response to SARS-CoV-2 Infection|Focus on longitudinal analysis of TCR repertoire of CD4+ and CD8+ T cells from blood samples (PBMCs) from clinically characterized patients (n = 24). The bulk- T-cell receptor (TCR) sequencing will be performed at different time points during the course of disease progression and recovery.
16344921|NCT04364828|Other|Viral Sequence Composition|The Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) viral composition is determined by Next Generation sequencing (different protocols for enrichment are available, and are currently being tested to successfully analyse the virus from different isolates). It is known that SARS-CoV-2 sequence is changing at least one position every second passing from person to person. Numerous variants have been described deriving from 3 different ancestral viruses (named A, B, and C) reflecting different distributions in East Asia, Europeans and Americans. At it is anticipated that other (super)infections may add to the severity of the infection and disease course, the entire metagenome of the throat is being sequenced and analyzed as well.
16344922|NCT04364815|Experimental|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine oral loading dose of 400mg two times per day on Day 1 then 400 mg once a day for Day 2-10 plus standard preventive measures as defined by PGH Hospital Infection Control Unit (HICU)
16344923|NCT04364815|Placebo Comparator|Placebo plus standard preventive measure|Placebo tablet plus standard preventive measures as defined by PGH-HICU
16344924|NCT04364802|No Intervention|Healthcare Workers - Control|Front-line healthcare workers (FLCHW) who are negative for COVID will receive standard PPE and a pre- and post-study test for COVID-19.
16344925|NCT04364802|Experimental|Healthcare Workers - PVP-I|Front-line healthcare workers (FLCHW) who are negative for COVID-19 will receive standard PPE and a pre- and post-study test for COVID-19. Additionally, they will receive PVP-I spray and gargle.
16344926|NCT04364802|No Intervention|Inpatients - Control|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test.
16344927|NCT04364802|Experimental|Inpatients - PVP-I|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays that will be applied shortly after admission or perioperatively.
16344928|NCT04364802|No Intervention|Community - Control|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test.
16344929|NCT04364802|Experimental|Community - PVP-I|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays.
16344930|NCT04364789|Experimental|SAD|"For the SAD part, there will be 5 cohorts (including 1 cohort for food effect assessment).To assess the safety, tolerability, and PK profile. The starting dose will be 50 mg.In each cohort, TT-00920 will be administered to 6 subjects and placebo will be administered to 2 subjects.Safety, tolerability, and PK data for each cohort will be reviewed by the Safety Review Committee (SRC) before the dose escalation in the next cohort.
~One of the 5 cohorts (Cohort X) will be crossed-over to the fed condition to assess the effect of food. Subjects will receive a TT-00920/placebo single oral regimen on Day 1 of each period."
16344931|NCT04364789|Experimental|MAD|MDA will comprise of at least 3 cohorts. The dose in each cohort will be decided by the SRC, based on safety, tolerability, and PK data from Part 1 and/or any preceding dose cohorts from Part 2.Subjects will receive TT-00920 or placebo for 7 consecutive days, once or twice daily based on the PK profile of Part 1.
16344932|NCT04364763|Experimental|RBT-9 (90 mg)|RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.
16344933|NCT04364763|Placebo Comparator|Placebo|0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.
16344934|NCT04364750|Experimental|Group A|"Participants in group A will undergo challenges in the order:
~High-FODMAP beverage + placebo probiotic + L-Histidine
~Low-FODMAP beverage + placebo probiotic + L-Histidine
~High-FODMAP beverage + probiotic + L-Histidine
~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
16344935|NCT04364750|Experimental|Group B|"Participants in group A will undergo challenges in the order:
~Low-FODMAP beverage + placebo probiotic + L-Histidine
~High-FODMAP beverage + probiotic + L-Histidine
~High-FODMAP beverage + placebo probiotic + L-Histidine.
~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
16344936|NCT04364750|Experimental|Group C|"Participants in group A will undergo challenges in the order:
~High-FODMAP beverage + probiotic + L-Histidine
~High-FODMAP beverage + placebo probiotic + L-Histidine
~Low-FODMAP beverage + placebo probiotic + L-Histidine.
~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
16344937|NCT04364737|Active Comparator|Convalescent donor plasma|
16344938|NCT04364737|Placebo Comparator|Lactated ringer's solution or sterile saline solution|
16344939|NCT04364724||Study group|"All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented.
~Eligible consenting patients will sign informed consent."
16344940|NCT04364685|Active Comparator|Normal Walking|The participants performed 30 minutes on levelled surface on the track and field ground. Participants performed moderate intensity walking, self paced.
16344941|NCT04364685|Experimental|Sand Walking|The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
16344942|NCT04364672|Experimental|Women with stage 1-4 newly diagnosed breast cancer|
16344943|NCT04364659|Experimental|Food-specific ICT + TAU|Participants in the Food-specific ICT + TAU group will be encouraged to complete the FoodT phone app (a food-specific go/no-go task) and a food diary daily for four weeks. After four weeks, they will be asked to complete a post-intervention questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
16344944|NCT04364659|No Intervention|TAU|Participants in the TAU group will not receive the Food-specific ICT. After four weeks, they will be asked to complete a 'post-intervention' questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
16346495|NCT04353765||non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm|
16344946|NCT04364646|Experimental|Personalize Integrated Chronotherapy|Women in the integrated chronotherapy group receive usual care (medications and/or talk therapy, as above) and also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor.
16344947|NCT04364633||Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
16344948|NCT04364633||Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
16344949|NCT04364620|Experimental|Arm AB-16B5 and Docetaxel|AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1.
16344950|NCT04364607|Active Comparator|Neostigmine group|After surgery, in the postoperative care unit, participants will receive 0.5 mg IM neostigmine
16344951|NCT04364607|Placebo Comparator|Placebo group|After surgery, in the postoperative care unit, participants will receive IM NaCl 0.9% as a placebo
16344952|NCT04364594|Experimental|affected individual|Patients affected by Coronavirus 19 admitted to the hospital setting
16344953|NCT04364581|Active Comparator|Letrozole group|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
16344954|NCT04364581|Placebo Comparator|Placebo group|Women will be treated with placebo for 10 days before hysteroscopic intervention
16344955|NCT04364568|Experimental|Symptomatic group at three month|"Rivermead Post-Concussion Syndrome >= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview
~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
16344956|NCT04364568|Experimental|Asymptomatic group at three month|"Rivermead Post-Concussion Syndrome < 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview
~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
16344957|NCT04364555|Active Comparator|Active/active|The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.
16344958|NCT04364555|Active Comparator|Placebo/active|The bottle for use in the morning cantains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.
16344959|NCT04364555|Placebo Comparator|Placebo/placebo|Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.
16344960|NCT04364542|Experimental|Suprascapular nerve block (SSNB)|Single shot using the blind block technique with 10 ml 0.75% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
16344961|NCT04364542|Active Comparator|Interscalene Nerve Block (ISB)|Single shot using US-guided interscalene brachial plexus block with 15 ml 0.5% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
16344962|NCT04364529|Experimental|Intervention (pit crew model group)|13 groups being taught the pit crew model
16344963|NCT04364529|No Intervention|control (traditional ALS education)|13 groups being taught along traditional ALS education
16344964|NCT04364490|Experimental|Experimental VF group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.
~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform advanced gait training sessions by the computerized BWS system without visual feedback; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
16344965|NCT04364490|Experimental|Experimental VF+ group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.
~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform the same advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
16344966|NCT04364490|Active Comparator|Control group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.
~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
16344967|NCT04364477|Active Comparator|Tap block Group|Tap Block group :(Group 1) After General anestehesia At the end of the operation, TAP blocks were placed to the 1st group patients.
16344968|NCT04364477|Placebo Comparator|Control Group|No block applied. only General anesthesia was applied.
16344969|NCT04364464|Experimental|Riociguat, healthy participants|Participants with creatinine clearance (CLCR) >80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344970|NCT04364464|Experimental|Riociguat, mild renal impairment|Participants with CLCR 50-80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344971|NCT04364464|Experimental|Riociguat, moderate renal impairment|Participants with CLCR 30-<50 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344972|NCT04364464|Experimental|Riociguat, severe renal impairment|Participants with CLCR <30 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
16344973|NCT04364438|No Intervention|Control Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises
16345359|NCT04361695|Active Comparator|Ketoprophenum|A tablet with 10 mg Ketoprophenum is taken per os 2 hours before surgery
16344975|NCT04364438|Experimental|TENS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Transcutaneous Electric Nerve Stimulation (TENS)
16344976|NCT04364425|Experimental|low dose steroid|patient received ultrasound-guided 40mg triamcinolone + 4cc xylocaine + 12cc NS
16344977|NCT04364425|Active Comparator|high dose steroid|patient received ultrasound-guided 10mg triamcinolone + 4cc xylocaine + 15cc NS
16344978|NCT04364399|Experimental|Experimental group|Mumps vaccine, one dose
16344979|NCT04364399|Active Comparator|Control group|measles, mumps and rubella combined vaccine, live, one dose
16344980|NCT04364386|Experimental|InPress|Treatment with InPress Device for Postpartum Hemorrhage
16344981|NCT04364373|Active Comparator|D2 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed.
~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed.
~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed.
~For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed."
16344982|NCT04364373|Experimental|D3 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed.
~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed.
~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed.
~For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed."
16344983|NCT04364360|Experimental|Sulforaphane supplementation|Daily (2 capsules) consumption of BroccoMax (Jarrow Formulas Los Angeles, CA) for 3-weeks.
16344984|NCT04364334||Knee registry patients|
16344985|NCT04364321|Experimental|Single dose Clonazepam|Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)
16344986|NCT04364321|Active Comparator|Intermittent oral diazepam|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.
16344987|NCT04364295||Implanted with SeaSpine spinal or orthobiologics product|
16344988|NCT04364282||Parent-Child Dyads Taking Part in Weight-Management Programs|Participants in this study will be children and their parents taking part in existing pediatric weight-management programs at participating sites. All participants will be seen at baseline and 6-months for data collection visits.
16344989|NCT04364269|Experimental|VIT-2763 Once a day (QD)|"Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight.
~The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind."
16344990|NCT04364269|Experimental|VIT-2763 Twice a day (BID)|Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
16344991|NCT04364269|Placebo Comparator|Placebo|Participants will be assigned to receive Placebo, Twice a day.
16344992|NCT04364256|Active Comparator|Active NMES|"asymmetric biphasic waveforms at 71 pulses per second frequency (Hz), 400 s pulse duration, 5:10s on:off time (50% duty cycle), and 1.5s ramp-up time. Participants will be in control of the muscle stimulator devices at all times and will be instructed to perform all sessions in the supine position. Bilateral NMES will be delivered via asymmetric, biphasic using four cutaneous parallel channels delivered simultaneously using 2x4 or 3x5 self-adhesive electrodes. For the active NMES group, participants will be encouraged to increase the amplitude to a level of moderate discomfort, such as that experienced during conventional exercise, but not to induce pain. At minimum, the amplitude should induce visible muscle contraction."
16344993|NCT04364256|Sham Comparator|Sham NMES|The amplitude of the muscle stimulators for the Sham group will be capped at 15 milliamperes so patients will only feel cutaneous sensation without achieving muscle contraction.
16344994|NCT04364243|Experimental|Patients exercise|Low back pain patients Next to basic medical physical training therapy group A receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
16344995|NCT04364243|No Intervention|Patients control|Low back pain patients Group B will receive basic medical physical training therapy
16344996|NCT04364243|Experimental|Non-patients exercise|non-patients Groups C will receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
16344997|NCT04364243|No Intervention|Non-patients control|non-patients Group D will receive no intervention
16344998|NCT04364230|Experimental|Arm A|6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 for both arms (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given at the primary site at days 1, 8, 16, 38, 67, and 78 and at the replicate site at day 1. A vaccine that contains all components except for CDX-1140 will be given at the replicate site at days 8 and 16. The vaccine will be given subcutaneously/intradermally.
16344999|NCT04364230|Experimental|Arm B|6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 for both arms (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given at the primary site at days 1, 38, 67, and 78 and at the replicate site at days 1, 8, and 16. A vaccine that contains all components except for CDX-1140 will be given at the primary site at days 8 and 16. The vaccine will be given subcutaneously/intradermally.
16345000|NCT04364217|Other|Treatment|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz
16345001|NCT04364204|Experimental|Kangaroo mother care with bracelet|
16345002|NCT04364204|Active Comparator|Kangaroo mother care|
16345030|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
16345031|NCT04364074|Experimental|GoodBelly Probiotic|Subjects randomized to this arm consume one serving of the Goodbelly lactobacillus plantarum 299v probiotic
16345032|NCT04364074|Placebo Comparator|Placebo|Subjects randomized to this arm consume one serving of the Goodbelly that does not contain lactobacillus plantarum 299v
16345033|NCT04364061|Experimental|Women with overweight or obesity|
16345003|NCT04364191|Experimental|Intervention Arm|Meaningful activity protocol during the day and Assistive Relaxation Therapy (ART) at night; includes 1) Sleep Hygiene Education; 2) Meaningful Activity Modules a) Physical Activity b) Cognitive Activity and c) Social engagement; 3) ART, a breath-based relaxation intervention that is coupled with a physical anchoring task. Participants will complete a daily sleep diary, use the activity modules daily as pre-determined times personalized to the participant, use the ART software when they get in bed to help with insomnia symptoms, and wear an actiwatch for a four-week period. Participants will have biweekly phone consultation with the research nurse.
16345004|NCT04364191|Active Comparator|Control Arm|Study participants in the control group will also receive a tablet and watch, but the meaningful activity modules and ART software will not be accessible to them. The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education. This approach provides staff and technology interaction/attention that is comparable to the intervention arm, and thereby promotes adherence; it has been used as a placebo comparator for many insomnia treatment studies and has low attrition rates. Control subjects will also be asked to complete electronic sleep diaries and wear the actiwatch on the non-dominant wrist to monitor sleep/wake patterns. For both arms, participants will be asked to complete baseline assessments, 1 month (post-intervention) and follow-up (3 month).
16345005|NCT04364178|Experimental|Viral Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
16345006|NCT04364165|Experimental|Standard of care messaging|Participants randomized into this arm will receive standard invitation cards distributed at the Tutu Tester containing basic information encouraging HIV testing. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the standard invitation card and share a brief script including the standard Tutu Tester message that free HIV testing is available at the Tutu Tester, with no further information or motivation to test.
16345007|NCT04364165|Experimental|U=U messaging|Participants randomized into this arm will receive the U=U invitation cards distributed at the Tutu Tester that will seek to assuage the fears of testing HIV positive by conveying the message that HIV treatment makes it possible for HIV positive people to be untransmittable and to live normal lives. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the U=U invitation card and share a brief script asking people if they knew they could control HIV and that pills exist that can keep them healthy and ensure they don't transmit the virus to their sex partners, and that free HIV testing is available at the Tutu Tester.
16345008|NCT04364152|Experimental|PD patients with freezing of gait, internal strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
16345009|NCT04364152|Experimental|PD patients with freezing of gait, external strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
16345010|NCT04364152|Experimental|PD patients without freezing of gait, internal strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
16345011|NCT04364152|Experimental|PD patients without freezing of gait, external strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
16345012|NCT04364152|Experimental|Healthy elders, internal strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
16345013|NCT04364152|Experimental|Healthy elders, external strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
16345014|NCT04364139|Experimental|Lower BP goal and Ramipril|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Ramipril 2.5 to 10 mg/d
16345015|NCT04364139|Experimental|Usual BP goal and Ramipril|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and participants assigned to Receive Ramipril 2.5 to 10 mg/d
16345016|NCT04364139|Experimental|Lower BP goal and Amlodipine|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
16345017|NCT04364139|Experimental|Usual BP goal and Amlodipine|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
16345018|NCT04364139|Experimental|Lower BP goal and Metoprolol|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
16345019|NCT04364139|Experimental|Usual BP goal and Metoprolol|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
16345020|NCT04364126|Active Comparator|Standard of care|Clinical blood pressure measured at regular visits
16345021|NCT04364126|Experimental|Home blood pressure monitoring|Home blood pressure measured daily for 1 week before regular clinical visits
16345022|NCT04364113|Active Comparator|Study A Usual Protein Usual Pressure|Study A Usual Protein and Usual Pressure
16345023|NCT04364113|Experimental|Study A Usual Protein Low Pressure|Study A Usual Protein and Low Pressure
16345024|NCT04364113|Experimental|Study A Low Protein Usual Pressure|Study A Low Protein and Usual Pressure
16345025|NCT04364113|Experimental|Study A Low Protein Low Pressure|Study A Low Protein and Low Pressure
16345026|NCT04364113|Active Comparator|Study B Low Protein Usual Pressure|Study B Low Protein and Usual Pressure
16345027|NCT04364113|Experimental|Study B Low Protein Low Pressure|Study B Low Protein and Low Pressure
16345028|NCT04364113|Experimental|Study B Very Low Protein Usual Pressure|Study B Very Low Protein and Usual Pressure
16345034|NCT04364048|Experimental|Induction durvalumab, chemoradiation, consolidation durvalumab|Induction durvalumab at 1500 mg intravenously (IV) on Day 1 of a four week cycle for 1 cycle, followed by concurrent definitive chemoradiation, followed by consolidation durvalumab at 1500 mg IV Day 1 of every 4 week cycle for up to 12 cycles.
16345035|NCT04364035|Experimental|CCMM+GS-9620|ChAdOx1.HTI 2 doses, MVA.HTI 2 doses, GS-9620 10 doses.
16345036|NCT04364035|Placebo Comparator|PLACEBO|ChAdOx1.HTI placebo 2 doses, MVA.HTI placebo 2 doses, GS-9620, placebo 10 doses.
16345037|NCT04364022|Active Comparator|Lopinavir/Ritonavir|
16345038|NCT04364022|No Intervention|Active surveillance|
16345039|NCT04364009|Active Comparator|Optimized Standard of Care (oSOC)|The control group will receive optimized standard of care alone, including all treatments authorized for COVID-19 by the French Health Ministry and/or the center COVID-19 therapeutic committees at inclusion and during the follow-up.
16345040|NCT04364009|Experimental|Anakinra plus Optimized Standard of Care (oSOC)|The experimental group will receive Anakinra plus optimized Standard of Care. The patients will receive Intravenous injection (IV) of Anakinra 400mg/day (100mg IV every 6 hours) at Day 1, 2 and 3. From Day 4 to Day 10, the patient will receive IV injection of Anakinra 200mg/day (100mg every 12 hours). The total duration of Anakinra is 10 Days
16345041|NCT04363996|Experimental|New Bioactive Restorative Material|Activa Presto Bioactive restorative material
16345042|NCT04363996|Active Comparator|Resin Modified Glass Ionomer|Fuji II
16345043|NCT04363983|Active Comparator|Located/resected colorectal cancer|
16345044|NCT04363983|Active Comparator|Advanced colorectal cancer|
16345045|NCT04363983|Active Comparator|Located/resected pancreatic cancer|
16345046|NCT04363983|Active Comparator|Advanced pancreatic cancer|
16345047|NCT04363983|Active Comparator|Located/resected biliary tract cancer|
16345048|NCT04363983|Active Comparator|Advanced biliary tract cancer|
16345049|NCT04363983|Active Comparator|Located/resected gastroesophageal cancer|
16345050|NCT04363983|Active Comparator|Advanced gastroesophageal cancer|
16345051|NCT04363983|Active Comparator|Located/resected neuroendocrine cancer|
16345052|NCT04363983|Active Comparator|Advanced neuroendocrine cancer|
16345053|NCT04363970||group A- early catheter removal)|in group A, we will remove the catheter after 24 h.
16345054|NCT04363970||Group B- delayed catheter removal|In group B, we will remove the catheter after 48 h.
16345055|NCT04363957|Other|Standard Consent|Patients only receive the standard brachytherapy consent process
16345056|NCT04363957|Experimental|Standard Consent and Video Intervention|Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
16345057|NCT04363944|Experimental|mRehab|Use of mRehab in a home program
16345058|NCT04363931|Experimental|Manual Therapy|Manual Therapy is a widely used physiotherapy modality which is known to be effective in the management of musculoskeletal problems . Manual Therapy is a passive, therapeutic approach used to target a variety of anatomical structures with the intent to create beneficial changes in the amount of pain a patient experiences. Manual Therapy includes joint mobilization, manipulation, or treatment of the soft tissues and is widely used to break fibrous adhesions, restore normal range of motion, reduce local ischemia, stimulate synovial fluid production, and reduce pain .
16345059|NCT04363931|Experimental|Kinesio Taping|Kinesio tape is a type of elastic therapeutic tape that was developed which is used in many different situations with various aims. Advocates of Kinesio Tape state that it may promote different therapeutic objectives such as; improved circulation and lymphatic drainage, pain inhibition, reduction of delayed onset of muscle soreness or improvement in performance and coordination .
16345060|NCT04363918|Active Comparator|intervention (IG1)|
16345061|NCT04363918|Active Comparator|intervention (MyoStim group)|
16345062|NCT04363918|Sham Comparator|control (CG)|
16345063|NCT04363905|Placebo Comparator|Placebo|100 mg lactose capsule
16345064|NCT04363905|Experimental|Ferrous sulfate|20 mg ferrous sulfate and lactose capsule
16345065|NCT04363892|Experimental|Receiving optical and infrared imaging|This is the only arm of the study. All patients will have optical and infrared images acquired of skin on the treated and contralateral sides.
16345066|NCT04363879|Active Comparator|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
16345067|NCT04363879|Experimental|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
16345068|NCT04363866|Experimental|Hydroxychloroquine|400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
16345069|NCT04363866|Placebo Comparator|Placebo|Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
16345070|NCT04363853|Experimental|Tocilizumab tratment|
16345071|NCT04363840|No Intervention|Observation|
16345072|NCT04363840|Experimental|Aspirin 81 mg|
16345073|NCT04363840|Experimental|Aspirin + vitamin D|Offered to COVID-19 patients who are vitamin D deficient AND randomized to aspirin
16345074|NCT04363827|Experimental|Group 1: Hydroxychloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
16345075|NCT04363827|No Intervention|Group 1: Observation|observation only
16345076|NCT04363827|Experimental|Group 2: Hydroxycloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
16345077|NCT04363827|No Intervention|Group 2: Observation|Observation only
16345078|NCT04363814|Experimental|Bactek-R|Subject included in the experimental group will receive Bactek- R.The dose consists on 3 spray puff every 6 hours for 2 weeks.
16345079|NCT04363814|No Intervention|Control|Subject included in the control group will receive standard therapy for COVID-19.
16345118|NCT04363554|Other|Urine dilution test|Urine dilution test
16345119|NCT04363554|Other|Urine concentration test|Urine concentration test
16345080|NCT04363801|Experimental|Part A First Line Treatment|Part A patients will receive IV DKN-01 (300 mg) on Days 1 and 15, IV tislelizumab (200 mg) on Day 1, IV oxaliplatin (130 mg/m2) on Day 1, and oral capecitabine (1000 mg/m2 twice daily [BID]) on Days 1-15 of each 21-day cycle. Part A is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
16345081|NCT04363801|Experimental|Part B1 Second Line Treatment|"Part B patients will receive IV DKN-01 (300 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.
~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
16345082|NCT04363801|Experimental|Part B2 Second Line Treatment|"Part B patients will receive IV DKN-01 (600 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.
~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
16345083|NCT04363788||Cardiopulmonary resuscitation|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
16345084|NCT04363775|Experimental|Regurgitation|intubation in regurgitation condition
16345085|NCT04363775|Experimental|Tongue edema|intubation in Tongue edema condition
16345086|NCT04363762|Experimental|Internet-based multimodal pain program|The iMPP is based on CBT and self-management principles that help patient cope with chronic TMD pain. The iMPP translates a face-to-face therapy to a software platform program.
16345087|NCT04363762|Active Comparator|Occlusal splint|Participants randomized to active control received a hard Michigan-type stabilization splint placed in the upper jaw by one of two calibrated general dentists {Ramfjord, 1994 #276}. The occlusal splint was chosen as the control treatment because it is a conventional and reversible treatment of TMD pain, and it has a known moderate efficacy {Welfare, 2011 #266}.
16345088|NCT04363749|Experimental|15 COVID positive patients|dyspnea rating to various dyspneic stimulus
16345089|NCT04363749|Active Comparator|15 healthy controls|dyspnea rating to various dyspneic stimulus
16345090|NCT04363736|Active Comparator|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
16345091|NCT04363736|Experimental|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
16345092|NCT04363723||patients with an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that developed an acute exacerbation during a pulmonary Rehabilitation program but continued the Rehabilitation program
16345093|NCT04363723||patients without an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that did not develop an acute exacerbation during a pulmonary Rehabilitation program and completed the Rehabilitation program regularly.
16345094|NCT04363710|Experimental|Intervention group|Participants in this arm were advised intervention of Low Calorie Diet (800-1000 Kcal/day) for 8 weeks without any anti diabetic medication
16345095|NCT04363710|No Intervention|Control Group|Participants in this arm were kept on their standard medical treatment
16345096|NCT04363697|Experimental|Dapagliflozin|Dapagliflozin 10 mg administered orally once daily for 2 months
16345097|NCT04363697|Placebo Comparator|Placebo|Matching placebo administered orally once daily for 2 months
16345098|NCT04363684||Longitudinal Arm|Annual clinic visits throughout the length of the study.
16345099|NCT04363684||Biofluid-Focused Arm|Single clinic visit.
16345100|NCT04363645|Experimental|Multicontext approach (Intervention) Arm|Participants received 30-minute sessions of strategy and self-monitoring practice within the context of everyday activities. These sessions were delivered either daily or twice a day. The total number of sessions varied depending on the participant's length of stay in acute rehabilitation.
16345101|NCT04363619|Placebo Comparator|Controls|
16345102|NCT04363619|Experimental|ICH|
16345103|NCT04363619|Experimental|aSAH|
16345104|NCT04363606|Experimental|"Non-fatigued patients who have been in intensive care units"|
16345105|NCT04363606|Experimental|"Fatigued patients who have been in intensive care units"|
16345106|NCT04363606|Experimental|patients who have not been in intensive care units|
16345107|NCT04363593|Other|prospective group COVID|New patients consulting for suspected or diagnosed COVID(+)
16345108|NCT04363593|Other|retrospective group COVID|Patients already diagnosed with COVID(+) or with a suspicion of unconfirmed COVID or at a date before the apparition of the COVID infection (April-March 2019)
16345109|NCT04363593|Other|Hospital staff|All hospital staff including those already diagnosed at COVID(+)
16345110|NCT04363580||Patients|Children consulting for an assessment of central auditory skills
16345111|NCT04363567||CKD 1|"Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.
~20 patients, maximun 4 patients with diabetes."
16345112|NCT04363567||CKD 2|"Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89.
~20 patients, maximun 4 patients with diabetes."
16345113|NCT04363567||CKD 3|"Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59.
~20 patients, maximun 4 patients with diabetes."
16345114|NCT04363567||CKD 4|"Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29.
~20 patients, maximun 4 patients with diabetes."
16345115|NCT04363567||CKD 5|"Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: <15.
~20 patients, maximun 4 patients with diabetes."
16345116|NCT04363567||Dialysis|Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes.
16345117|NCT04363567||Healthy|20 healthy people. Control group
16345120|NCT04363541|Experimental|Thermotherapy|"Electric heat pad applied in the thorax for 90 minutes, twice daily, for 5 days.
~+ Usual in-hospital care"
16345121|NCT04363541|No Intervention|Control|Usual in-hospital care
16345122|NCT04363528|Other|Doppler Echo|patients will have a Doppler Echo when they enter ICU (within 48 hours) and a second Doppler Echo 7 days later
16345123|NCT04363515|No Intervention|Usual Pre-Transplant Counseling Intervention|Subjects in the control arm will undergo usual pre-transplant counseling as per the standard of care.
16345124|NCT04363515|Experimental|Social Support Network Counseling Intervention|Subjects in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks between 2-12 weeks after their initial transplant evaluation and counseling
16345125|NCT04363502|Experimental|clazakizumab at a dose of 25 mg|A first dose of 25 mg of clazakizumab will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25mg clazakizumab (an identical dose to the day 1 dose) will be given no later than day 3
16345126|NCT04363502|Placebo Comparator|placebo|A first dose of placebo will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo (an identical dose to the day 1 dose) will be given no later than day 3
16345127|NCT04363476|Experimental|Intervention|8-week exercise and education intervention. Two 60-minute physiotherapist-lead group exercise classes with education incorporated will be delivered weekly for 8 weeks (16 classes). In addition, participants will complete a 30-minute home exercise session once a week for 8-weeks (8 sessions). After the intervention, the group will enter a 16-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
16345128|NCT04363476|Other|Control|The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
16345129|NCT04363463|No Intervention|Conventional positioning|semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).
16345130|NCT04363463|Experimental|Interventional positioning : prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
16345131|NCT04363450|Experimental|Hydroxychloroquine|Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
16345132|NCT04363450|Placebo Comparator|Placebo|An identical placebo will be administered on an identical dosing interval and frequency.
16345133|NCT04363437|Active Comparator|Colchine|
16345134|NCT04363437|Active Comparator|Usual Care|
16345135|NCT04363424||Validation cohort|Patients with alcoholic cirrhosis with reliable self-reported alcohol use.
16345136|NCT04363424||Clinical application cohort|Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.
16345137|NCT04363411|Experimental|drug use|
16345138|NCT04363398|Experimental|Comprehensive|Coaches from schools randomized to the comprehensive follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a trained research team member will monitor the team weekly for injuries, participation, and adherence, and provide support to the school coaches regarding the warm-up.
16345139|NCT04363398|Active Comparator|Standard|Coaches from schools randomized to the standard follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a research team member will monitor the team weekly for injuries, participation, and adherence, however will not provide support to the school coaches regarding the warm-up.
16345140|NCT04363385|Other|Collection of blood sample|
16345141|NCT04363372|Experimental|MRx-4DP0004|Patients receiving standard of care will add MRx-4DP0004 to their treatment. MRx-4DP0004 is taken as 2 capsules, twice a day for 14 days. Daily dose is 4 x 10^9 to 4 x10^10 colony forming units.
16345142|NCT04363372|Placebo Comparator|Placebo|Patients receiving standard of care will also take 2 placebo capsules, twice a day for 14 days.
16345143|NCT04363359|Experimental|Quadrivalent influenza vaccine HD|Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
16345144|NCT04363359|Experimental|Quadrivalent influenza vaccine LD|Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.
16345145|NCT04363359|Active Comparator|Trivalent influenza vaccine Victoria|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.
16345146|NCT04363359|Active Comparator|Trivalent influenza vaccine Yamagata|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.
16345147|NCT04363346|Experimental|Dose Strategy 1|"Dose Strategy 1:
~Day 1 - FT516 is given at 9x107 cells/dose (low)"
16345148|NCT04363346|Experimental|Dose Strategy 2|"Dose Strategy 2:
~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid)"
16345149|NCT04363346|Experimental|Dose Strategy 3|"Dose Strategy 3:
~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid) + Day 7 - FT516 is given at 9x108 cells/dose (high)"
16345150|NCT04363333||High Probability of OSA|Based on a sleep questionnaire
16345151|NCT04363333||Low Probability of OSA|Based on a sleep questionnaire
16345214|NCT04362813|Experimental|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
16345152|NCT04363320|Experimental|High-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~4-hour onsite visit (NIATx Training)
~11 monthly (one-hour) NIATx coaching calls
~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
16345153|NCT04363320|Experimental|Low-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~One-hour conference call with Executive Sponsor
~Two-hour NIATx webinar training with Change Leader/Team
~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team
~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
16345154|NCT04363320|Experimental|High-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~4-hour onsite visit
~11 monthly (one-hour) NIATx coaching calls"
16345155|NCT04363320|Experimental|Low-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~One-hour conference call with Executive Sponsor
~Two-hour NIATx webinar training with Change Leader/Team
~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team"
16345156|NCT04363307||Adult participants|Adult participants ages 18 and older with AF
16345157|NCT04363294|Other|Participants|Patients who had TAVR and underwent evaluation for ATTR with PYP scan
16345158|NCT04363255|Experimental|Maintenance group|After 4-6 cycles of EP/EC chemotherapy regiment, maintenance therapy with toripalimab and anlotinib was followed and continued until disease progression.
16345159|NCT04363242|Experimental|Part A|Dose escalation of SYN125. Each dose level (low, medium, high) will be tested in a cohort of 3 patients. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
16345160|NCT04363242|Experimental|Part B|Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
16345161|NCT04363216|Experimental|Treatment|Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
16345162|NCT04363216|No Intervention|Routine care|These subject will follow routine care and their clinical courses will be recorded only.
16345163|NCT04363203|Active Comparator|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg capsule in the AM and 200 mg in the PM on Days 2-5
16345164|NCT04363203|Active Comparator|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM followed by 250mg PO every day on days 2-5
16345165|NCT04363203|Placebo Comparator|Placebo|The pills packs for the 3 arms are identical.
16345166|NCT04363190||Cases|
16345167|NCT04363190||Controls|
16345168|NCT04363177|Experimental|Web-based psychosocial peer-to-peer support|"Web-based psychosocial peer-to-peer support, using Thinking Healthy two times during pregnancy"
16345169|NCT04363177|Active Comparator|Standard perinatal care|Perinatal standard care in Hong Kong, Shanghai
16345170|NCT04363164|Experimental|Arm A: Enzalutamide|Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide (160 mg oral daily).
16345171|NCT04363164|Experimental|Arm B: Sequential Testosterone and Enzalutamide|Patients in Arm B will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 (i.e. cycle 1). On Day 1 of cycle 2, patients will stop testosterone and begin enzalutamide 160 mg po q day for 56 days. Each cycle is 56 days. On Day 1 of cycle 3, patient will not take enzalutamide and will again receive injection of testosterone. Patients will continue to alternate one cycle of testosterone (2 injections) with one cycle of 56 days of enzalutamide.
16345172|NCT04363164|Experimental|Arm C: Variable Sequential Testosterone and Enzalutamide|Patients in Arm C will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 injections per cycle. Patients will remain on high dose T for at least one cycle. Each cycle is 56 days. Patients with declining PSA will remain on high dose T for additional cycles of 2 injections until PSA progression occurs based on PCWG3 criteria. Patients with PSA progression (≥25% increase in PSA from baseline) will stop T injection. These patients will then be started on Enzalutamide. Patients on enzalutamide with PSA decline after one 56 day cycle will continue on Enzalutamide until PSA progression occurs. Patients with PSA progression (≥25% increase in PSA from baseline) will stop Enzalutamide and will restart injections of T with 2 injections/cycle. These cycles of switching between T and Enza with onset of PSA progression will continue until clinical and/or radiographic progression occurs.
16345173|NCT04363151||Hydatid cyst patients|patients who underwent surgery for liver hydatid cyst from 2004 to 2018 in two major university-affiliated hospitals in Fars Province, southern Iran
16345174|NCT04363138||bacterial infection|Patients with bacterial infection
16345175|NCT04363138||No bacterial infection|Patients without bacterial infection
16345176|NCT04363112|Other|study with just one arm|"All of participants are in this arm. Mini Kid II and CBCL score are administered between day 3 and 7. Moreover, salivary test will be remove to evaluate cortisol secretion, 4 time per day during 2 consecutive days.
~Psychologic aftercare will be propose if children have psychologic troubles (results of Mini Kid II)"
16345177|NCT04363099||outpatients COVID 19 positive|
16345178|NCT04363086|Experimental|TAU|
16345179|NCT04363086|Experimental|iFD|
16345180|NCT04363086|Experimental|iFD + weekly phone calls|
16345181|NCT04363073|Experimental|Anaabella|Milk will be expressed using Annabella breast pump.
16345182|NCT04363073|Active Comparator|Control pump|Milk will be expressed using a control breast pump.
16345183|NCT04363060|Experimental|Azithromycin with amoxicillin/clavulanate|Combination of azithromycin during 4 days with amoxicillin/clavulanate during 7 days.
16345184|NCT04363060|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/clavulanate every day during 7 days.
16345215|NCT04362813|Placebo Comparator|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
16345216|NCT04362800|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
16345185|NCT04363047||Healthy Volunteers|"These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.
~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.
~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
16345186|NCT04363047||Rheumatoid Arthritis|"These people will have already provided at least one sample as part of the BRAGGSS Study.
~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.
~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
16345187|NCT04363021||cases|Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
16345188|NCT04363021||controls|Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
16345189|NCT04362995||SARS-CoV-2 Infection|St. Jude Children's Research Hospital employees with SARS-CoV-2 infection
16345190|NCT04362995||Controls|St. Jude Children's Research Hospital employees uninfected with SARS-CoV-2 infection
16345191|NCT04362982|Experimental|ADHD|In the first part of the clinical trials, ADHD cohorts are going to undergo a neuropsychological assessement. Moreover, they will interact with the serious game twice (30-45 minutes/each time). In the second part, participants will interact with game two or three times per week (30-45 minutes/each time). Finally, a neuropsychological assessment will be administered following the procedures of the first one.
16345192|NCT04362982|Active Comparator|non-ADHD|Non-ADHD group will follow the same procedures as the experimental one.
16345193|NCT04362943||Complete sample|"Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the Perpetuo Socorro Hospital of Albacete (Spain)"
16345194|NCT04362943||Baricitinib|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.
16345195|NCT04362943||Anakinra|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.
16345196|NCT04362930||Neurological and psychiatric impact of COVID-19|Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
16345197|NCT04362930||Impact of Covid-19 in patients with neurological pathology|patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
16345198|NCT04362917||FDR-|"Adults with a first degree relative with T1D, who have tested negative for islet autoantibodies.
~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
16345199|NCT04362917||FDR+|"Adolescents and adults with a first or second degree relative with T1D, who has tested positive for at least one islet autoantibody.
~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
16345200|NCT04362917||Control|"Adults with no family history of Type 1 Diabetes, who have tested negative for islet autoantibodies
~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
16345201|NCT04362904|Experimental|acupressure|In accordance with the acupressure protocol, each day for four weeks, taking into account the awakening and sleep periods of the individuals, acupressure applied for a total of 3 min to the each acupuncture points (one session 18 minutes) twice a day between 07:00 and 10:00 and 19:00 to 22:00 in the morning patients were asked to perform acupressure by their caregivers or on their own.
16345202|NCT04362904|No Intervention|control|No intervention was applied to the control group.
16345203|NCT04362891|Experimental|Juvéderm®|Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
16345204|NCT04362891|Experimental|Restylane®|Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
16345205|NCT04362891|Experimental|Belotero®|Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
16345206|NCT04362891|Experimental|Stylage®|Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
16345209|NCT04362852||Cancer|No intervention
16345210|NCT04362852||Atopic Dermatitis/Eczema|No intervention
16345211|NCT04362839|Experimental|Treatment (regorafenib, nivolumab, ipilimumab)|Patients receive regorafenib PO QD on days 1-21, nivolumab IV over 30 minutes Q2W, and ipilimumab IV over 30 minutes Q6W. Cycles repeat every 28 day for up to 2 years in the absence of disease progression or unacceptable toxicity.
16345212|NCT04362826|Experimental|Novel probiotic|Investigational novel probiotic plus normal standard of care for breast cancer.
16345213|NCT04362826|Placebo Comparator|Placebo|Placebo plus normal standard of care for breast cancer.
16345217|NCT04362800|Placebo Comparator|Control|10 days of care and classic activities
16345218|NCT04362787||High pressure _ low pressure non-invasive ventilation|"In the high-pressure NIV,52 patients will undergo pressure-limited NPPV at a higher IPAP level. IPAP is initially set at 20 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (up to 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 15 mL/kg of IBW.
~2- EPAP for patients with COPD will be started at EPAP 5 and will be increased till 7 and for the patients with hypoventilation syndrome will be increased up to EPAP 8.
~3-Respiratory rate 10-12 b/min."
16345219|NCT04362761|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
16345220|NCT04362748|Experimental|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
16345221|NCT04362748|Experimental|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
16345222|NCT04362748|Experimental|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
16345223|NCT04362735||Study group|All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)
16345224|NCT04362722|Experimental|Single arm|"40 patients will be enrolled and treated with a mixture of 6.5 Mio IU (~1.08 mg) L19IL2 and 200 µg L19TNF once weekly for 4 consecutive weeks. The dose will be distributed among the lesions via multiple intralesional injections.
~New lesions occurring during the treatment phase will also be treated as described but the treatment period for new lesions will not be extended beyond the previously defined 4 weeks treatment period with clock-start at the time of the first intralesional L19IL2/L19TNF injection.
~After the Tumor Assessment/Safety visit, patients may receive surgery in a curative intention within 6 weeks, in order to assess the pathological response with estimation of percent of residual viable tumor cells."
16345225|NCT04362709||Postoperative complications|
16345226|NCT04362709||No postoperative complications|
16345227|NCT04362696|Experimental|active stimulation|
16345228|NCT04362696|Sham Comparator|sham stimulation|
16345229|NCT04362683||High Power Atrial Fibrillation Ablation|"In our center, routine medical care for atrial fibrillation ablation includes:
~Multidirectional high-density mapping
~High power - short duration settings
~Contact force sensing ablation catheter"
16345230|NCT04362670|Experimental|OTX-CSI-Cohort 1|Formulation 2A-.36 mg
16345231|NCT04362670|Experimental|OTX-CSI-Cohort 2|Formulation 1- .36 mg
16345232|NCT04362670|Placebo Comparator|HV|"Cohort 2:
~Formulation 2B"
16345233|NCT04362670|Experimental|OTX-CSI- Cohort 2|Formulation 2A- .36 mg
16345234|NCT04362670|Placebo Comparator|HV-2|"Cohort 2:
~Formulation 3"
16345235|NCT04362657|Experimental|Computer aided diagnosis|Using CAD to assist in completeness of the examination during OGD
16345236|NCT04362644|Experimental|PET/CT using PET ligands [18F]FDG and [18F]DPA-714|
16345237|NCT04362631||Adults|Adults 18 years or older
16345238|NCT04362618|Experimental|Muscle Strengthening Training (MST)-group|Subjects allocated to the MST group (n=30) will perform a muscle strengthening training program of 12 weeks.
16345239|NCT04362618|Experimental|Behavioral Graded Activity (BGA)-group|Subjects allocated to the BGA group (n=30) will perform a rehabilitation program according to the principles of behavioural graded activity for a period of 12 weeks.
16345240|NCT04362618|No Intervention|Control group|Subjects allocated to the control group (n=30) have to maintain their current life-style and treatment (if any) and to refrain from other new interventions during 24 weeks.
16345241|NCT04362605|Experimental|intervenional group|ENPT
16345242|NCT04362592|Experimental|Percutaneous Technique|The percutaneous technique uses endoscopic scopes through the maternal skin and uterus to perform the surgery.
16345243|NCT04362592|Experimental|Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique consists of performing a laparotomy (incision into the abdominal cavity), exteriorizing the uterus, and using endoscopic scopes through the uterus to perform the correction.
16345244|NCT04362579||Subjects seen in hospital|Subjects will be recruited from Prentice Women's Hospital inpatient antepartum and labor and delivery services, and the outpatient Obstetrics and Gynecology practice, located within Galter tower with the assistance of staff.
16345245|NCT04362579||Home Study subjects|Subjects will be prescreened by an IRB approved staff and recruited from Prentice Women's Hospital's Department of Obstetrics and Gynecology.
16345248|NCT04362553||Adults|Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)
16345249|NCT04362540||Pregnant women with GDM|Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)
16345250|NCT04362527|Experimental|Milrinone|The patients randomized to this arm will have Milrinone (Laboratoires STRAGEN, France)
16345251|NCT04362527|Placebo Comparator|Placebo|The patients randomized to this arm will have Saline solution
16345252|NCT04362514|Experimental|IG|Intervention Group
16345253|NCT04362514|Active Comparator|aCG|Control Group
16345254|NCT04362501|Experimental|dupilumab treatment group|dupilumab treatment group
16345255|NCT04362501|Placebo Comparator|placebo group|placebo group
16345285|NCT04362293|Experimental|Haploidentical (HAPLO)|Patients without an eligible MSD who have a suitable haploidentical (HAPLO) donor available will be enrolled on the HAPLO arm of the study.
16345256|NCT04362488|Experimental|Patients with chronic post-traumatic lateral ankle instability|"The study population consists in patients affected by chronic post-traumatic lateral ankle instability who must undergo surgical intervention of ankle external ligament reconstruction.
~The patients will be analyzed pre and postoperatively using differents tests, questionnaires, instrument and clinical evaluation:
~Delos system (computerized oscillating platform)
~Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires
~modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
16345257|NCT04362475|Active Comparator|Family Youth Intervention (FYI)|The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
16345258|NCT04362475|Active Comparator|ESPI Environment: Social and Physical Intervention (ESPI)|ESPI will enroll 500 community members to examine the effect of blight elimination through lot recovery on primary outcomes of improved social interaction, social cohesion around common neighborhood norms, and collective efficacy to effect change in the neighborhoods . Neighborhood residents will select a cluster of lots (2-3) for lot recovery that are highly visible in the neighborhood (e.g. on a main thoroughfare). The community residents will lead the neighborhood projects. In some cases, neighborhood residents will personally undertake all or part of the greening projects.
16345259|NCT04362475|Other|Wait-List Control|The two communities will get ESPI, upon completion of the study.
16345260|NCT04362475|Active Comparator|FYI and ESPI|Two of the eight neighborhoods will receive both FYI and ESPI intervention.
16345261|NCT04362449|Experimental|Shortened hydration time with dispensary of Akynzeo|ABC-02 regime - gemcitabine and cisplatin with a shortened hydration time and administration of a newer antiemetic
16345262|NCT04362449|Active Comparator|Standard of care|ABC-02 regime - gemcitabine and cisplatin with currently approved hydration time and administration of the current choice of antiemetic
16345263|NCT04362436|Experimental|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
16345264|NCT04362423||propofol+fNIRS|During data collection, only propofol is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
16345265|NCT04362423||sevoflurane+fNIRS|During data collection, only sevoflurane is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
16345266|NCT04362423||neuro-stimulator+fNIRS|During data collection, we use neuro-stimulator to give the stimulation.
16345267|NCT04362410|Experimental|Tezepelumab: Low dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
16345268|NCT04362410|Experimental|Tezepelumab: Medium dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
16345269|NCT04362410|Experimental|Tezepelumab: High dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
16345270|NCT04362410|Placebo Comparator|Placebo|Placebo single dose subcutaneously injection.
16345271|NCT04362397|Experimental|A (first group to receive the intervention)|This arm will receive the attention, care, and self-care training first.
16345272|NCT04362397|Experimental|B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive it after this period.
16345273|NCT04362384|Experimental|Vitamin E ovules|Endoanal Vitamin E ovules will be prescriped during 14 days
16345274|NCT04362384|Active Comparator|Prednisolone ointment|Endoanal Prednisolone ointment will be prescriped during 14 days
16345275|NCT04362371|Experimental|Ainara|"Ainara is a class II medical device, already marketed in several EU countries. The product is a mucoadhesive moisturising gel for vulvovaginal use, indicated for the relief of symptoms of vaginal atrophy and dryness, and related discomfort. In each packaging there is a tube containing the gel (sterile and viscous with about 87% water) and a syringe-like plastic applicator with cannula and plunger.
~Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration)."
16345276|NCT04362358|Experimental|7 sessions of the online CBT programme|
16345277|NCT04362358|Active Comparator|Bibliotherapy|
16345278|NCT04362332|Active Comparator|chloroquine|1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
16345279|NCT04362332|Active Comparator|hydroxychloroquine|2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
16345280|NCT04362332|No Intervention|Supportive care only|3. Supportive care only.
16345281|NCT04362319||Anaesthesiology clinicians|Including Consultants, Specialists and Medical officers serving in the Department of Anaesthesiology and Intensive Care
16345282|NCT04362306|Experimental|Planned Intervention|Patients will be scheduled for CT (computed tomography ) simulation for radiation treatment planning. Prior to simulation, patients will be asked to complete anxiety and patient satisfaction questionnaires. Following completion of the questionnaires, each patient will receive the first intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic. The patient will then be asked to complete a second set of anxiety and patient satisfaction questionnaires and will then undergo the planned simulation.
16345283|NCT04362306|Active Comparator|No Planned Intervention|After patients are enrolled into this study, they will be scheduled for CT simulation for radiation treatment planning. Prior to simulation, patients will receive anxiety and patient satisfaction questionnaires to complete
16345284|NCT04362293|Experimental|Matched Sibling Donor (MSD)|Patients with a suitable HLA matched sibling donor (MSD) will be enrolled on the MSD arm.
16345286|NCT04362280|Experimental|ReCHARGE|intervention intensity is increased through: the creation of family groups, greater involvement of school staff, separate lessons for females, health screeners will be home and families are invited to a nutrition counseling session with a registered dietitian.
16345287|NCT04362280|Active Comparator|Treatment as Usual (TAU)|PE class as usual which consisted of choice time.
16345289|NCT04362241|Experimental|Dextenza|Sustained release Dexamethasone 0.4mg
16345290|NCT04362241|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate Ophthalmic drops
16345291|NCT04362228|Experimental|Whole-body exercise|
16345292|NCT04362215||High AA group|Group 1 consisted of those having an AA level of 3.57-4.16 D (high AA group; those who had near clear vision between 24-28 cm). .
16345293|NCT04362215||Low AA group|Group 2 consisted of those having an AA level of 3.44-3.03 D (low AA group; those who had near clear vision between 29-33 cm)
16345294|NCT04362202|Experimental|experimental|8 individual experimental rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
16345295|NCT04362202|Active Comparator|control|8 individual of standard aquatic rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
16345296|NCT04362189|Experimental|HB-adMSCs|Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.
16345297|NCT04362189|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.
16345298|NCT04362176|Experimental|pathogen reduced SARS-CoV-2 convalescent plasma|Transfusion of convalescent plasma will be administered by clinical or research personnel while the participant is hospitalized on Study Day 0. Plasma will be administered at a rate of 500 mL/hour and will be administered within 12 hours of randomization.
16345299|NCT04362176|Placebo Comparator|Placebo|Participants randomized to the control group will receive 250mL of Lactate Ringers containing multivitamins intravenously on Day 1 as a placebo.
16345300|NCT04362150||COVID-19 positive, recovered|Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
16345301|NCT04362137|Experimental|Ruxolitinib 5 mg|Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
16345302|NCT04362137|Placebo Comparator|Placebo|Matching-image placebo for 14 days with possible extension of treatment to 28 days
16345303|NCT04362124|Experimental|vaccine BCG|"A single dose intradermal application of 0.1 ml of between 1 x 105 to 33 x 105 CFU of BCG, in the deltoid of the non-dominant arm.
~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
16345304|NCT04362124|Placebo Comparator|Placebo|"A single dose intradermal application of 0.1ml of normal saline solution, in the deltoid of the non-dominant arm.
~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
16345305|NCT04362111|Experimental|Anakinra Group|The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to 100 mg twice daily for the remaining 5 days.
16345306|NCT04362111|Placebo Comparator|Control Group|The control group will receive normal saline placebo subcutaneously every 6 hours for period of 10 days. For subjects meeting complete repsonse criteria at 5 days, dosing wll be decreased to twice daily for the remaining 5 days.
16345307|NCT04362098|Experimental|Nurse home visits|Nurse home visits biweekly.
16345308|NCT04362098|No Intervention|Usual care|Usual care.
16345311|NCT04362072|Experimental|Lorlatinib|Participants will take 100 mg (four, 25 mg tablets) once daily.
16345312|NCT04362059|Experimental|Treatment Arm|Patients will be administered surfactant via COVSurf Drug Delivery System
16345313|NCT04362059|Active Comparator|Control Arm|Patients shall receive regular Standard of Care treatment
16345315|NCT04362033|Experimental|PLR group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:
~In PLR arm, patients will be submitted to the PLR maneuver (patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grade) firstly, then PEEP increment maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
16345316|NCT04362033|Experimental|PEEP group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:
~In PEEP arm, patients will be submitted to the PEEP maneuver (consisted in increase the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position) firstly, then PLR maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
16345317|NCT04362020|Experimental|Group-1|No anticoagulation
16345318|NCT04362020|Active Comparator|Group-2|ACT-guided anticoagulation
16345354|NCT04361734||Matching healthy volunteers|Healthy volunteers, matched by age and gender, will be used as a control group
16345355|NCT04361721||Chronic migraine patients|Three monthly administration of erenumab 70 mg subcutaneously.
16345319|NCT04362007|Experimental|Phase 1 dose-escalation part|Subjects with r/r PTCL and r/r CTCL will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RD is determined.
16345320|NCT04362007|Experimental|Phase 1 ATLL expansion part|Subjects with r/r ATLL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
16345321|NCT04362007|Experimental|Phase 2|Subjects with r/r PTCL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
16345322|NCT04361981||Cases|COVID-19 infection patients with a Deep Venous Disease event
16345323|NCT04361968|Experimental|Animal-assisted placebo condition|Participants receive verbal information that they are receiving an analgesic cream. Additionally, and before getting the dog, participants will get a therapeutic rationale for the presence of the dog.
16345324|NCT04361968|Experimental|Placebo condition|Participants receive verbal information that they are receiving an analgesic cream.
16345325|NCT04361968|Experimental|Dog only condition|Before meeting the dog, participants will get a therapeutic rationale for the presence of the dog.
16345326|NCT04361968|Other|Control condition|Participants in this condition will receive no intervention.
16345327|NCT04361955|Other|PD with DBS on|intervention is EEG while at rest and performing tasks, on anti PD medications and off anti PD medications
16345328|NCT04361955|Other|PD with DBS off|intervention is EMG while at rest and performing tasks, on anti PD medications and off anti PD medications
16345329|NCT04361955|Other|ET with DBS on|intervention is EEG while performing tasks and at rest
16345330|NCT04361955|Other|ET with DBS off|intervention is EEG while performing tasks and at rest
16345331|NCT04361942|Experimental|Experimental|Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline
16345332|NCT04361942|Placebo Comparator|Placebo|Intravenous injection of 100 ml of saline containing no cells
16345333|NCT04361916|Experimental|home care with active monitoring|home care with active monitoring conducted by health workers with daily visit to patients.
16345334|NCT04361903||Patients treated with ruxolutinib|SARS-CoV-2 COVID-19 patients with rapid worsening of respiratory parameters in the last 12 hours treated with ruxolutinib, dosage of at least 20 mg x 2 / day in the first 48 hours.
16345335|NCT04361890|Other|Women with predominant SUI|All women with predominant SUI will be referred to a physiotherapist for PFMT as usually. They will have an ultrasound evaluation before and after the session
16345336|NCT04361864||RUTI|patients with at least 3 episodes of UTI during 2019
16345337|NCT04361864||UTI|patients with one or two episodes of UTI during 2019
16345338|NCT04361851|Experimental|Single Arm|Pembrolizumab and Daratumumab
16345339|NCT04361838|Active Comparator|Prayer|Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
16345340|NCT04361838|No Intervention|No Prayer|Patients will receive standard of care treatment while in the ICU.
16345341|NCT04361825|Experimental|Durvalumab(MEDI4736) and AZD6738 combination|
16345342|NCT04361812|Experimental|HS632|HS632 150mg for a single subcutaneous injection
16345343|NCT04361812|Active Comparator|Omalizumab (Xolair®)|Omalizumab 150mg for a single subcutaneous injection
16345344|NCT04361799|Experimental|Closed-loop insulin therapy|
16345345|NCT04361799|Active Comparator|Standard insulin therapy|
16345346|NCT04361773|Active Comparator|Photobiomodulation group|In this group, PBM will be applied daily using LED devices until the lesion presents healthy granulation tissue, absence of necrosis and purulent secretion and, therefore, is suitable for primary closure, closure by flap or graft or for healing by second intention. At this point, the protocol will be finalized.
16345347|NCT04361773|Sham Comparator|Sham group|Sham group participants will receive the application of the disconnected device, for the same period. The characteristic sound of the device will be activated by means of recording.
16345348|NCT04361760|Experimental|Healthy younger participants (20-30y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
16345349|NCT04361760|Experimental|Healthy older participants (65-75y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
16345350|NCT04361747|Experimental|nursing counseling intervention|The nursing counseling intervention was implemented by a maternity nursing instructor. During the 12-week prenatal genetic testing evaluation period, experimental-group participants received three nursing consultation sessions plus regular care, while their control-group peers received regular care only. The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
16345351|NCT04361747|No Intervention|control group|control group participants received regular care only
16345352|NCT04361734||Juvenile onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
16345353|NCT04361734||Adult onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
16345356|NCT04361708|Experimental|High Risk UGT1A1 genotype|
16345360|NCT04361695|Placebo Comparator|Placebo|A tablet containing starch is taken per os 2 hours before surgery
16345361|NCT04361669||Intervention|Patients that receive pharmacist-delivered services in the pilot program
16345362|NCT04361669||Control|Patients that do not receive pharmacist-delivered services in the pilot program
16345363|NCT04361656||Current standard of care preparation|Current Standard of Care for inpatient colonoscopy: The dose of PEG-ELS will be large-volume (4-Liter) administered as either single-dose if colonoscopy is scheduled BEFORE 11 a.m. (250 mL orally every 15 minutes between 6 p.m. and midnight the day prior to procedure), or split-dose if the colonoscopy is scheduled AT or AFTER 11 a.m. (First dose: 2-Liters; 250 mL orally every 15 minutes between 6-8 p.m. the day prior to procedure. Second dose: 2-Liters; 250 mL orally every 15 minutes to be completed 5 hours before the scheduled time of the procedure).
16345364|NCT04361656||Lubiprostone Intervention|"The study entails giving two doses of Lubiprostone in addition to the standard large-volume polythene glycol-electrolytes solution (PEG-ELS) according to the time of the procedure as follow: If the colonoscopy is scheduled BEFORE 11a.m. the patient will receive in addition to the PEG-ELS: Lubiprostone 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy.
~If the colonoscopy is scheduled AT or AFTER 11a.m. the patient will receive in addition to PEG-ELS: Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS"
16345365|NCT04361643|Experimental|Experimental|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
16345366|NCT04361643|Placebo Comparator|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3, and 5.
16345367|NCT04361630|Experimental|Main treatment group|Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.
16345368|NCT04361617|Active Comparator|Epigenetic age knowledge arm|Half of the intervention participants will be randomly selected to be informed of their epigenetic age before the intervention.
16345369|NCT04361617|Active Comparator|No epigenetic age knowledge arm|The other half of intervention participants will not be informed of their epigenetic age before the intervention.
16345370|NCT04361604||250 Patients co infected HIV and SRAS-CoV2|Cohort of Patient co infected HIV AND SRAS-CoV2
16345371|NCT04361604||20 patients infected HIV without COVID-19|Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
16345372|NCT04361591||COVID-19|Liver Transplant recipients
16345373|NCT04361578||Patients|All patients enrolled in the study will be in this group.
16345374|NCT04361565||Individuals diagnosed for COVID-19|
16345375|NCT04361552|Experimental|Arm I (tocilizumab, standard of care)|Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
16345376|NCT04361552|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
16345377|NCT04361539||Elite adolescent badminton players|The population was all the elite adolescent badminton players from a high-level club. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed from September 2018 to May 2019.
16345378|NCT04361526|No Intervention|Control|standard intensive care alone
16345379|NCT04361526|Experimental|Cytokine Adsorption|cytokine adsorption plus standard intensive care
16345380|NCT04361513|Active Comparator|Nerve block group|3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.
16345381|NCT04361513|Other|intra-articular steroid injection|1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.
16345382|NCT04361500||COVID-19 patients with Seraph 100 therapy|
16345383|NCT04361487||Horizontal Cleavage Meniscal Tear|Participants with horizontal cleavage meniscal tears
16345384|NCT04361487||Complex Meniscal Tear|Participants with complex meniscal tears
16345385|NCT04361474|Experimental|Experimental group|Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
16345386|NCT04361474|Placebo Comparator|Control group|Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.
16345387|NCT04361461|Experimental|Group 1|Hydroxychloroquine (400 mg)
16345388|NCT04361461|Experimental|Group 2|Hydroxychloroquine (400 mg) + azithromycin (500 mg)
16345389|NCT04361448|Other|Health Care Workers with Covid-19 symptoms|3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
16345390|NCT04361435|Other|NIOD first|In this arm, we will apply for NIOD first which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses. This arm of patients will receive standard CPT at least 3 hours after the NIOD intervention.
16345391|NCT04361435|Other|CPT first|In this arm, we will apply for CPT first which will be performed by physiotherapists. This arm of patients will receive NIOD procedures which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses at least 3 hours after the CPT intervention.
16345392|NCT04361422|Active Comparator|Isotretinoin|13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
16345393|NCT04361422|Sham Comparator|Standard COVID-19 therapy|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
16345394|NCT04361422|Active Comparator|Standard COVID-19 therapy+ isotretinoin|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.
16345395|NCT04361409|Experimental|Rituximab plus chemotherapy|"Drug:Rituximab
~Drug:Cisplatin
~Drug:Gemcitabine"
16345433|NCT04361123||Clients of Atrium Health|daily syndromic surveillance, monthly serologic IgM/G test
16345396|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy).
16345397|NCT04361383|Placebo Comparator|Control group|patients will be operated under general anesthesia.
16345398|NCT04361383|Active Comparator|QLB group|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
16345399|NCT04361383|Active Comparator|ESPB group|patients will receive ultrasound-guided erector spinae plane block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
16345400|NCT04361370|Experimental|Treatment group|BRCA mutation wild type, non-mucinous , platinum-sensitive recurrent ovarian cancer
16345401|NCT04361357|Experimental|Experimental group|whey protein powder was added on the basis of standardized enteral nutrition preparation.
16345402|NCT04361357|No Intervention|Control group|standardized enteral nutrition preparation only.
16345403|NCT04361331|Other|Toripalimab combined with lenvatinib|"Toripalimab: 240 mg, intravenous infusion, Q3W;
~Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd;"
16345404|NCT04361331|Other|Lenvatinib combined with gemox|"Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd
~Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses"
16345405|NCT04361318|Experimental|Hydroxychloroquine plus Nitazoxanide|200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
16345406|NCT04361318|Active Comparator|Standard care|Standard care delivered in the COVID-19 isolation hospitals.
16345407|NCT04361305|Experimental|tadalafil combined with dapoxetine|
16345408|NCT04361305|Active Comparator|tadalafil mono group|
16345409|NCT04361292|Active Comparator|Group A: one day abstinence period|Patients allocated into group A had an ejaculatory abstinence period of one day
16345410|NCT04361292|Active Comparator|Group B: three days abstinence period|Patients allocated into group B had an ejaculatory abstinence period of three days
16345411|NCT04361279|Experimental|SIBP-02|"Biological: SIBP-02, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.
~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.
~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.
~Treatment cycle: 6 cycles, each cycle is 3 weeks."
16345412|NCT04361279|Active Comparator|Rituximab|"Biological: Rituximab, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.
~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.
~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.
~Treatment cycle: 6 cycles, each cycle is 3 weeks."
16345413|NCT04361266|Experimental|Rotium patch recipient|Subjects with Rotium nano scaffold patch included in rotator cuff repair construct
16345414|NCT04361266|Active Comparator|Control|Subjects undergoing non-patch augmented rotator cuff repair
16345415|NCT04361253|Experimental|Arm A|Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
16345416|NCT04361253|Placebo Comparator|Arm B|Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)
16345417|NCT04361240||Ancillary Cohort|No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
16345418|NCT04361214|Experimental|Leflunomide|"Leflunomide 300 mg once daily administered for three days followed by 30 mg once daily administered for two days or until fevers abate (maximum ten days of treatment allowed).
~If patients report symptoms attributed to the medication, the dose will be administered at 50 mg once daily for the loading dose followed by 20 mg once daily."
16345419|NCT04361201||Ligament plastic surgery ankle|Patient treated priorly by ligament plastic surgery of lateral ankle plane under arthroscopy
16345420|NCT04361201||Control group|Controlateral ankle
16345421|NCT04361188|Experimental|MAC anesthesia group|Parkinson's disease patients receiving deep brain stimulation under MAC anesthesia.
16345422|NCT04361188|Active Comparator|AAA anesthesia group|Parkinson's disease patients receiving deep brain stimulation under AAA anesthesia.
16345423|NCT04361175|Experimental|letrozole group|letrozole group, Patients will receive 5 mg of letrozole oral tablets daily from day 2 of the cycle for 5 days for three successive cycles
16345424|NCT04361175|Experimental|Clomiphene Citrate group|Clomiphene Citrate group, Patients will receive 100 mg : Clomiphene Citrate daily starting on cycle day 2 for 5 days for three successive cycles
16345425|NCT04361162|Experimental|Nivolumab + Ipilimumab + Radiation|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, (Study cycles are 6 weeks.)
~Nivolumab via iv, at predetermined dose every 2 weeks for duration of study.
~Ipilimumab via iv at a predetermined dose on day 1 of 4 study cycles.
~Radiation treatments will be administered every other weekday or 2 days during week 1 of cycle 1."
16345426|NCT04361149|Placebo Comparator|Placebo Topical|The cream was a lipobase cream, applied topically to the participants upper back, on their left side.
16345427|NCT04361149|Active Comparator|Capsaicin Topical|Capsaicin Cream (0.075%), applied topically to the participants upper back, on their left side.
16345428|NCT04361136|Experimental|Delgocitinib cream 1 mg/g|Single topical occlusive administration
16345429|NCT04361136|Experimental|Delgocitinib cream 3 mg/g|Single topical occlusive administration
16345430|NCT04361136|Experimental|Delgocitinib cream 8 mg/g|Single topical occlusive administration
16345431|NCT04361136|Experimental|Delgocitinib cream 20 mg/g|Single topical occlusive administration
16345432|NCT04361136|Placebo Comparator|Delgocitinib cream vehicle|Single topical occlusive administration
16345434|NCT04361123||Health care workers of Atrium Health|daily syndromic surveillance, monthly serologic IgM/G test
16345435|NCT04361110||Acute intestinal ischaemia|Abdominal CT scan within 48 hours preoperative.
16345436|NCT04361110||Controls|Abdominal CT scan within 48 hours preoperative.
16345437|NCT04361097|Experimental|Faecal microbiota transplant|This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
16345438|NCT04361097|Placebo Comparator|Placebo|This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
16345439|NCT04361084|Active Comparator|traditional training|Participants will undertake the Community simulation using traditional methods, physical items to recreate the community environment. Training will be in pairs and will play the role of their own profession when undertaking simulated scenarios. Medium to low fidelity traditional simulation techniques involving scenarios played out using actors as (standardised patients) to participants. Following a briefing, the participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results and are anonymous. They will also complete their pre-questionnaire which will anonymous. Afterwards participants undertake a post-questionnaire and then asked if they wish to take part in a semi-structured interview.
16345440|NCT04361084|Experimental|mixed reality simulation training|Participants will undertake a mixed reality (MR) simulation training session set in two home situations; involving immersive virtual reality equipment. Participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results. The participants will then undertake the simulation watched via live camera by the simulation technician, simulation fellow and a community specialist. Participants will undertake a post simulation questionnaire and then asked if they wish to take part in a semi-structured interview (optional).
16345441|NCT04361071|Active Comparator|Stent|Stent group
16345442|NCT04361071|Active Comparator|Atherectomy|Atherectomy group
16345443|NCT04361058|Experimental|Arm A - HLA-matched unrelated donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with an HLA-matched unrelated donor will be separated into Arm A and treated with Nivolumab post-SCT
16345444|NCT04361058|Experimental|Arm B - HLA-haploidentical donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with a HLA-haploidentical donor will be separated into Arm B and treated with Nivolumab post-SCT
16345445|NCT04361045|Experimental|Intervention Condition|Participants in this condition were delivered 8 weeks of online intervention modules and then were invited to complete a posttest survey.
16345446|NCT04361045|No Intervention|Waitlist Condition|Participants in this condition received no intervention content nor communications for 8 weeks and then were invited to complete a posttest survey.
16345447|NCT04361032|Experimental|Tocilizumab|ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
16345448|NCT04361032|Active Comparator|Deferoxamine|DESFERAL: 500 mg, powder, and solvent for IV solution
16345449|NCT04361006|Active Comparator|Radiofrequency (RF)|Twenty patients will be allocated to this group, which will be treated using radiofrequency (RF) ablation technique.
16345450|NCT04361006|Active Comparator|Cryotherapy (CRYO)|Twenty patients will be allocated to this group, which will be treated using Cryotherapy (CRYO) ablation technique.
16345451|NCT04360993||Patients underwent PET/CT & PET/MRI|Patients with head and neck cancer were underwent PET/CT and PET/MRI for staging, assessment and follow up
16345452|NCT04360980|Active Comparator|Intervention|40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment
16345453|NCT04360980|No Intervention|Standard treatment|40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days
16345454|NCT04360967|Experimental|Randomized Standard Formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
16345455|NCT04360967|Experimental|Randomized Nutrient-enriched formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
16345456|NCT04360967|No Intervention|Non-randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
16345457|NCT04360967|No Intervention|Non-Randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
16345458|NCT04360954||Acute COVID infection|Active infection with positive RT-PCR
16345459|NCT04360954||Convalescent COVID|Recent documented infection. Now asymptomatic and RT-PCR negative.
16345460|NCT04360954||US Controls|Human samples pre-COVID.
16345461|NCT04360954||LMIC Controls|Samples from LMIC pre-COVID.
16345462|NCT04360941|Experimental|Two-part phase 1b trial of induction palbociclib with avelumab|"Recruitment to Part A will be conducted at the Royal Marsden Hospital only. Up to 18 patients will be recruited for dose escalation of palbociclib in combination with fixed dose avelumab.
~Part B will recruit at up to 8 high volume centres. Up to 27 patients will be recruited to treatment with the maximum tolerated dose and schedule established in part A. In Part B of the study, additional selection by triple negative histology and positive androgen receptor status will define the study population."
16345463|NCT04360928|Experimental|Lake Effect Zero Degree Splinting Group|These patients will be randomized to receive the Lake Effect Zero Degree Splint. Patients will follow the same standardized postoperative rehabilitation protocol.
16345464|NCT04360928|Sham Comparator|Standard Hinged Knee Brace|These patients will be randomized to receive a standard hinged knee brace. Patients will follow the same standardized postoperative rehabilitation protocol.
16345465|NCT04360915|Experimental|ASK120067 in fast condition|Take ASK120067 tablets orally once in the first day at 160mg in fast condition.
16345466|NCT04360915|Experimental|ASK120067 in fed condition|Take ASK120067 tablets orally once in the first day at 160mg in fed condition.
16345575|NCT04360161|Experimental|Healthy participants|Swept-source optical coherence tomography A device testing TM/SC and Lens morphology
16345467|NCT04360902|No Intervention|Standard of Care Group|Subjects in the standard of care group will continue to receive anemia management in the same way they normally do as part of their routine dialysis care. For the purposes of this study, this means the use of the clinic's established Mircera® anemia management algorithm. Participation in this study will not affect the anemia management of subjects in the control group.
16345468|NCT04360902|Experimental|Intervention Group|"For subjects randomized into the intervention group, our erythropoiesis model will be used to identify each subject's individual values for several physiological determinants of erythropoiesis based on his/her sex, body height and history of body weights, Hgb concentrations and Mircera® administrations over the preceding 150 to 180 days.
~For subjects in the intervention group, their current method of anemia management will be discontinued. From this point on, Mircera® dose recommendations will be generated by the Anemia Controller software based on our erythropoiesis model and each subject for the duration of their 26-week participation in this study. The Anemia Controller computes the Mircera® doses required to attain the target Hgb level of 10.5 g/dL. Controller-generated Mircera® recommendations will be communicated to the respective clinics' anemia managers on a standardized report."
16345469|NCT04360889|Experimental|Tocopherol|patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
16345470|NCT04360889|Experimental|Micronised purified flavonoid fraction|patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
16345471|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema who will be treated with elastic compression - 90 days
16345472|NCT04360889|No Intervention|Healthy volunteers|healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
16345473|NCT04360876|Experimental|Dexamethasone|Patients assigned to the dexamethasone arm will receive an intravenous dose of 20 mg once daily from day 1 to day 5 which will be reduced to 10mg once daily from day 6 to day 10. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The time from randomization to time for first medication administration will be 4 hours or less. All infusions - dexamethasone and placebo - will be manufactured by the investigational pharmacy at the University of Colorado.
16345474|NCT04360876|Placebo Comparator|Placebo|Participants randomized to the control group will received placebo intravenously for 10 days, one dose per day. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The placebo infusion bags will be as similar as possible to the dexamethasone infusion bags to ensure blinding.
16345475|NCT04360863||Youth smokers|Participants of Youth Quitline
16345476|NCT04360837|Experimental|PEEP incremental-decremental alveolar recruitment|"installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters
~implementation of recruitment:
~increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O
~decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20
~end inspiratory hold manoeuvre at every PEEP level
~recording closing parameters
~Repeating the above detailed intervention once daily as long as the patient is controlled ventilation."
16345477|NCT04360824|Active Comparator|Standard of Care|1) Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30kg/m2).
16345478|NCT04360824|Other|Interventional|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
16345479|NCT04360811|Other|Unexposed group : COVID 19 negatif pregant woman|COVID-19 negative women (not immunize
16345480|NCT04360811|Other|Exposed group : COVID 19 positif pregant woman|Women positive for COVID-19 (symptomatic and asymptomatic) COVID-19 negative women with long-standing immunity
16345481|NCT04360798|Experimental|Unilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will only be applied to the affected lower extremities of the participants.
16345482|NCT04360798|Experimental|Bilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will be applied to the both lower extremities of the participants.
16345483|NCT04360785|Experimental|Methotrexate + Adalimumab|Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
16345484|NCT04360785|No Intervention|Adalimumab|Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
16345485|NCT04360759|Experimental|Arm 1: Chloroquine or hydroxychloroquine|Loading dose of 4 tablets (150 mg chloroquine base per chloroquine salt tablet; 155 mg chloroquine base per hydroxychloroquine tablet) at time 0 and 6 hours, followed by a maintenance dose of 2 tablets at time 12 hours, and then twice daily for a total of 7 days.
16345486|NCT04360759|No Intervention|Arm 2: Standard of care|This does not include specific therapy under current guidelines.
16345487|NCT04360746|Active Comparator|Clinical pharmacist intervention group|"all hip fractured patients admitted to D1 subunit in Beit rivka geriatric rehabilitation center. This group will get a clinical pharmacist review of their medication and a pharmaceutical counseling to the medical staff in the first few days of admission (1-5 days post admission)"
16345488|NCT04360746|Other|control group|"The control group will include all hip fractured patients admitted to D2 subunit in Beit rivka geriatric rehabilitation center. This group will not receive any pharmacist intervention during their rehabilitation."
16345489|NCT04360733||asymptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR but no clinical symptoms
16345490|NCT04360733||symptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR and light clinical symptoms
16345491|NCT04360733||severe Covid-19|Patients with confirmed SARS-CoV2 PCR and severe clinical symptoms with ICU admission
16345492|NCT04360733||healthy controls|Persons with negative SARS-CoV2 PCR
16345651|NCT04359628||SFR|Patients who received treatment in the Swedish Fracture Register
16345493|NCT04360720|No Intervention|Dual Antiplatelet Therapy|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.
~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
16345494|NCT04360720|Experimental|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.
~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone for 12 months.
~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
16345495|NCT04360694|Experimental|Incremental hemodialysis|Procedure: Incremental hemodialysis. It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
16345496|NCT04360694|Active Comparator|Conventional hemodialysis|Procedure: Conventional hemodialysis. It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
16345497|NCT04360681|Experimental|Lofexidine (LFX)|LFX starting dosage is two 0.2 mg LFX tablet taken orally 2 times daily (i.e., 0.8 mg/day). At study visit 2 (Day 3), the dosage is increased to 1.2mg/day (3 tablets, BID). At visit 3 (Day 5), the dose is increased to the target dose of 1.6mg/day (4 tablets, BID). Participants enter the flexible dosing period at visit 4, at which point the LFX dose can be maintained at 1.6 mg/day or decreased to 1.2 mg/day based on symptoms and the clinical judgement of the investigator. The flexible dosing period extends through to visit 6, however, doses will be adjusted during the study as needed.
16345498|NCT04360681|Placebo Comparator|Placebo (PLB)|A placebo drug will be employed as the comparison group to active study drug.
16345499|NCT04360668|Experimental|Muscle Energy Technique combined with Trigger Point Therapy|For this group of participants, combined therapy (Muscle Energy Technique with Trigger Point Therapy) will be used
16345500|NCT04360668|Active Comparator|Muscle Energy Technique|For this group of participants, a single method (Muscle Energy Technique) will be used
16345501|NCT04360668|Active Comparator|Trigger Point Therapy|For this group of participants, a single method (Trigger Point Therapy) will be used
16345502|NCT04360655|Active Comparator|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
16345503|NCT04360655|Experimental|combined with bronchoscopic microwave intervention|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
16345504|NCT04360642|Other|singing arm|"Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.
~Lung function, frailty and health-related quality of life will be assessed by Spirometry, CRQ (chronic respiratory questionnaire), MRC breathlessness scale, Rockwood frailty and Warwick-Edinburgh Mental Well-being Scale (WEMWBS). Participants will be assessed at baseline and then again at completion of the 12-week course.
~Written feedback from participants to capture qualitative experience using narrative and Patient Reported Outcome Measures (PROMs). The attrition and attendance rate will also be recorded for later review."
16345505|NCT04360629|Experimental|high dose TXA|TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol
16345506|NCT04360629|Experimental|low dose TXA|TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol
16345507|NCT04360629|Placebo Comparator|normal saline|saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg
16345508|NCT04360616||MG+|the lesion could detected by mammography
16345509|NCT04360616||US+|the lesion could detected by breast ulrtasound
16345510|NCT04360603|Experimental|27 gauge system|study group, using 27G vitrectomy system
16345511|NCT04360603|Active Comparator|25 gauge system|control group, using 25G vitrectomy system
16345512|NCT04360577|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
16345513|NCT04360577|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
16345514|NCT04360577|No Intervention|Usual care|Chemotherapy without acupuncture
16345515|NCT04360564||Recurrent pregnancy loss|All women with >/=2 pregnancy loss before 20 weeks gestational age
16345516|NCT04360564||Primary recurrent pregnancy loss|Primary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age before the first birth
16345517|NCT04360564||Secondary recurrent pregnancy loss|Secondary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age occurring after the first birth
16345518|NCT04360564||No history of recurrent pregnancy loss|Those with 0 or 1 previous spontaneous pregnancy loss.
16345519|NCT04360551|Experimental|Telmisartan|Telmisartan 40 mg po daily x 21 days
16345520|NCT04360551|Placebo Comparator|Placebo|Placebo
16345521|NCT04360538||COVID19 positive|ICU patients coronavirus positive
16345522|NCT04360538||non-COVID19|ICU patients without coronavirus
16345523|NCT04360525||Elderly patients|Elderly patients (60≤ age) with sigmoid volvulus
16345524|NCT04360525||Young patients|Young patients (<60 age) with sigmoid volvulus
16345525|NCT04360512|Experimental|One session|One session of talus posteriorization
16345526|NCT04360512|Experimental|Two sessions|Two sessions of talus posteriorization
16345527|NCT04360512|Experimental|Three sessions|Three sessions of talus posteriorization
16345528|NCT04360512|Experimental|Four sessions|Four sessions of talus posteriorization
16345529|NCT04360499|Experimental|Low-weight-high-repetitions training|Low-weight-high-repetitions (LWHR) refer to a specific form of resistance exercise which utilizes low weights and very high repetitions. Participants will be exercised 3 times per week for 3 months in small groups.
16345530|NCT04360499|Active Comparator|Pilates Training|Pilates exercises focused on breathing, concentration, control and precision. Participants will be exercised 3 times per week for 3 months in small groups
16345531|NCT04360473|Active Comparator|Placebo group|The patients in this group will receive general balanced anesthesia
16345682|NCT04359472|Other|Treatment Arm|Collection and reapplication of amniotic fluid.
16345532|NCT04360473|Experimental|Ketamine group|The patients in this group will receive 0.3 mg / kg of ketamine in saline (total volume of 100 ml) 15 min before general balanced anesthetic induction
16345533|NCT04360473|Experimental|Magnesium sulfate group|The patients in this group will receive 40 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
16345534|NCT04360473|Experimental|Magnesium / ketamine group|The patients in this group will receive 0.15 mg / kg of ketamine + 20 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
16345535|NCT04360460|Experimental|Experimental|Virtual reality followed by translation into related functional tasks in a real life setting for 2 weeks + conventional therapies
16345536|NCT04360460|Active Comparator|Control|Virtual reality followed by translation into non-related functional tasks in a real life setting for 2 weeks + conventional therapies
16345537|NCT04360447|Experimental|Reformer pilates group|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
16345538|NCT04360447|Active Comparator|Home exercise group|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
16345539|NCT04360434|Experimental|NI006|Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
16345540|NCT04360434|Placebo Comparator|Placebo|"Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.
~In the OLE phase, all subjects will be administered multiple doses of NI006."
16345541|NCT04360421|Experimental|Intraoperative liposomal bupivacaine field block|Patients will receive the maximum dosage of liposomal bupivacaine allowed for their body weight or the full vial, whichever is less. Injected once, along the incision before closure of the skin.
16345542|NCT04360408|Experimental|Intervention|Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.
16345543|NCT04360408|No Intervention|Control|Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers
16345544|NCT04360395|No Intervention|Neurotypical Youth/Young Adults|No intervention administered. The controls will only undergo initial baseline assessments.
16345545|NCT04360395|Experimental|Cerebral Palsy Youth/Young Adults|Baseline and 8 week assessments; 8 week gait therapy
16345546|NCT04360382||Enhanced recovery|"Part I: Preoperative evaluation and preparation:
~Part II: Postoperative daily intervention:
~Part III: Expected daily outcome :
~Phase three: Implementing enhanced recovery program:
~The established pathway will implement on the study group by researcher from admission till discharge as conventional care group assessment in phase one.
~Phase four: Evaluating enhanced recovery program outcomes:
~The efficacy of enhanced recovery program will be determined by comparing outcomes for patients of both control and study groups"
16345547|NCT04360382||Regular care|usual care for all cases of cesarean section at our hospital.
16345548|NCT04360369|Active Comparator|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
16345549|NCT04360369|Active Comparator|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
16345550|NCT04360369|Experimental|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
16345551|NCT04360356|Experimental|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
16345552|NCT04360356|Active Comparator|Standard care|Oxygen via ventilators
16345553|NCT04360343|Experimental|LC51-0255 film-coated tablet|Drug: LC51-0255
16345554|NCT04360343|Active Comparator|LC51-0255 uncoated tablet|Drug: LC51-0255
16345555|NCT04360330|Experimental|Preoperative SABER|"Experimental: Preoperative Stereotactic Ablative Breast Radiotherapy (SABER). Phase I study testing up to 4 dose levels.
~Non-experimental: Participants will undergo standard partial mastectomy and axillary surgery as per discretion of treating physician 4 to 6 weeks (+ at most 1 week delay) after preoperative SABER is completed."
16345556|NCT04360317|Experimental|Experimental group|
16345557|NCT04360304|Experimental|Study group|
16345558|NCT04360291||Healthy volunteers|Healthy volunteers
16345559|NCT04360291||Retinopathy pigment|Patients with retinopathy pigment
16345560|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
16345561|NCT04360265||ABO-102|Participants from prior interventional trials involving the administration of ABO-102.
16345562|NCT04360252|Experimental|Gracie Diet|Patients will have a nutritional consultation and will follow the Gracie diet for a month.
16345563|NCT04360239|Experimental|Fish Oil|Fish-Oil naïve subjects will be started on fish oil 4 weeks prior to surgery and continued until the 6 week follow up. Subjects already taking fish oil will be switched to the study fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
16345564|NCT04360239|No Intervention|Control|No fish oil supplementation
16345565|NCT04360213||Children with Asthma|"Patients ages 1 to 17 years old
~Patients in the Emergency Department or admitted to the hospital for asthma exacerbation."
16345566|NCT04360213||Children with allergy|"Patients ages 1 to 17 years old
~Patients scheduled to do an oral food challenge"
16345567|NCT04360200||Normal Aging|Normal Aging with normal cognitive function
16345568|NCT04360200||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
16345569|NCT04360187|Experimental|Crisaborole ointment|Crisaborole ointment application twice daily for 28 days
16345570|NCT04360187|Placebo Comparator|Crisaborole Placebo Vehicle|Vehicle Ointment application twice daily for 28 days
16345571|NCT04360174|Experimental|OTX-TIC-Cohort 1|15 µg (formulation1) implant
16345572|NCT04360174|Experimental|OTX-TIC-Cohort 2|26 µg (formulation1) implant
16345573|NCT04360174|Experimental|OTX-TIC-Cohort 3|15 µg (formulation 2) implant
16345574|NCT04360174|Experimental|OTX-TIC-Cohort 4|5 µg (formulation 3) implant
16345576|NCT04360148|Experimental|Very-low-calorie-ketogenic-diet|Very-low-calorie-ketogenic-diet (VLCKD) for 12 weeks; hypocaloric-balanced-diet (HBD)
16345577|NCT04360148|Active Comparator|Hypocaloric-balanced-diet|Hypocaloric-balanced-diet (HBD)
16345578|NCT04360135|Experimental|Preemptive acetominophen|Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively
16345579|NCT04360135|Placebo Comparator|Standard of care|Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively
16345580|NCT04360122|Active Comparator|Levamisole|Oral Levamisole 150 mg/day for two days per week for two months
16345581|NCT04360122|Active Comparator|Isoprinosine|Oral Isoprinosine 1 g 3 times per day daily for two months
16345582|NCT04360122|Active Comparator|Levamisole and Isoprinosine|Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months
16345583|NCT04360122|No Intervention|Non-interventional group|No-intervention
16345584|NCT04360096|Experimental|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
16345585|NCT04360096|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
16345586|NCT04360083||Overweight and obese children|Overweight and obese children included in RéPPOP care programs between 2007 and 2010.
16345587|NCT04360070|Experimental|Ketamine Arm|Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
16345588|NCT04360070|No Intervention|Control Arm|Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
16345589|NCT04360057|Other|Hand Hygiene education|
16345590|NCT04360044|Experimental|THC ~5%|4 puffs of cannabis flower containing THC ~5% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
16345591|NCT04360044|Experimental|THC ~5%/CBD ~12%|4 puffs of cannabis flower containing THC ~5% and CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
16345592|NCT04360044|Experimental|CBD ~12%|4 puffs of cannabis flower containing CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
16345593|NCT04360044|Sham Comparator|Sham Cannabis|4 puffs of cannabis flower from which the THC and CBD have been extracted administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
16345594|NCT04360031||Tacrolimus / Mycophenolate Mofetil|All patients receive maintenance immunosuppressive treatment of tacrolimus in combination with Mycophenolate Mofetil.
16345595|NCT04360018|Active Comparator|arm one|participants receive alcohol beverage
16345596|NCT04360018|Placebo Comparator|arm two|Placebo
16345597|NCT04359979|Experimental|tamsulosin treatment|patients will receive 0.4mg/day of Tamsulosin tablet for 3 months
16345598|NCT04359966|Active Comparator|First line therapy for H pylori infection|Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days
16345599|NCT04359966|Experimental|First line therapy for H pylori infection second arm|"Bismuth quadruple first line therapy
~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
16345600|NCT04359966|Active Comparator|Second line therapy for H pylori infection|"Bismuth quadruple second line therapy for those treated with Tripple first line therapy
~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
16345601|NCT04359966|Experimental|Second line therapy for H pylori infection second arm|"Tripple second line therapy
~Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or"
16345602|NCT04359953|Experimental|Hydroxychloroquine|Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
16345603|NCT04359953|Experimental|Azithromycin|Patient will take 250mg of Azithromycin twice a day during 14 days
16345604|NCT04359953|Experimental|Telmisartan|Patient will take 40mg of Telmisartan twice a day during 14 days
16345605|NCT04359953|No Intervention|Usual Care|No intervention
16345606|NCT04359940||Repaired Tetralogy of Fallot|Patients undergoing routine clinical aand CMR surveillance
16345607|NCT04359927||SARS-CoV2/Covid-19 (cases)|Patients with detectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
16345608|NCT04359927||No SARS-CoV2/Covid-19 (controls)|Patients with undetectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
16345609|NCT04359914||NCoV-A-COVID|"adult patients of every age
~admission to hospital with suspected COVID-19 disease
~confirmed SARS-CoV-2 infection within 48 hours after admission"
16345610|NCT04359914||NCoV-A-CONTROL|"adult patients of every age
~admission to hospital with suspected COVID-19 disease
~exclusion of SARS-CoV-2 infection within 48 hours after admission"
16345611|NCT04359914||NCoV-P-COVID|"pediatric patients
~admission to hospital with suspected COVID-19 disease
~confirmed SARS-CoV-2 infection within 48 hours after admission"
16345612|NCT04359914||NCoV-P-CONTROL|"pediatric patient
~admission to hospital with suspected COVID-19 disease
~exclusion of SARS-CoV-2 infection within 48 hours after admission"
16345613|NCT04359901|Active Comparator|Standard of care plus subcutaneous sarilumab|Standard of care as directed by the treating clinicians, plus sarilumab 400 mg subcutaneous injection. Sarilumab is provided in prefilled syringes/pens containing 200 mg each as is used clinically, and both injections will be given as soon as is convenient after the patient has decided to enroll.
16345614|NCT04359901|No Intervention|Standard of care|Standard of care as directed by the treating clinicians.
16345615|NCT04359888||MCET Group|Multi-Component Exercise Training (MCET) Group
16345616|NCT04359888||BRT Group|Balanced Reach Training Group
16345617|NCT04359875|Experimental|Management by a student/general practitioner tandem|Patients will receive a phone call from the medical student who will inquire about their health. The medical student will then transmit this information to the general practitioner who will decide on the most suitable management for the patient.
16345618|NCT04359875|No Intervention|Usual care|"Usual care, i.e. patients will call their general practitioner when needed, up to 1 month, which corresponds to the estimated time for the intervention to be delivered to all patients in the intervention group.
~At the end of the intervention at 1 month, patients in the usual care group will also receive a phone-call from the medical student/general practitioner tandem."
16345619|NCT04359862|Experimental|SEVOFLURANE Group|
16345620|NCT04359862|Active Comparator|PROPOFOL Group|
16345621|NCT04359836||General Population|The general population will have their microbiome sequenced from stool samples provided.
16345622|NCT04359823|Experimental|Statin/Cholesterol Combination Group|This arm will utilize 2% cholesterol and 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
16345623|NCT04359823|Experimental|Statin Alone Group|This arm will utilize 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
16345624|NCT04359810|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent plasma (1 unit; ~200-250 mL) collected from a volunteer who recovered from COVID-19 disease
16345625|NCT04359810|Active Comparator|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (1 unit; ~200-250 mL) of standard plasma collected prior to December 2019
16345626|NCT04359797|Active Comparator|Usual Care|Participants randomized to this arm will remain in their natural choice of position, which is anticipated to favor a supine, semi-recumbent position.
16345627|NCT04359797|Active Comparator|Prone|Participants randomized to this arm will be encouraged to lay in a completely prone position for as much time as is tolerable during hospitalization.
16345628|NCT04359784|Experimental|Prevention (anakinra, axicabtagene ciloleucel)|Patients receive anakinra SC daily on days 0-13 and axicabtagene ciloleucel via infusion on day 0.
16345629|NCT04359771|Active Comparator|Yellow MPL|
16345630|NCT04359771|Active Comparator|Diode MPL|
16345631|NCT04359758|Experimental|Proactive Streamlined Genetic Education and Testing|Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
16345632|NCT04359758|Active Comparator|Usual Care|Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.
16345633|NCT04359732|Other|Hybrid PET/MRI|For the purposes of the study, in addition to standard imaging (EUS and CT scan), a fully integrated hybrid PET/MRI (PET/MRI) study with FDG will replace the Standard PET (pre-surgical evaluation) used for evaluating distant metastases and will be considered as the add-on procedure at three time points. The additional evaluation for patients is that during nCRT treatment.
16345634|NCT04359719||Group mild melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.
~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.
~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
16345635|NCT04359719||Group Moderate-severe melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.
~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.
~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
16345636|NCT04359706||Covid-19 group|Critically ill patients with SARS-CoV-2 infection
16345637|NCT04359706||control group|Historical critically ill patients with no SARS-CoV-2 infection
16345638|NCT04359693||SARS-CoV2 group|Patients receiving invasive mechanical ventilation for more than 48h with SARS-CoV-2 infection
16345639|NCT04359693||Flu group|Patients receiving invasive mechanical ventilation for more than 48h with influenza infection
16345640|NCT04359693||No viral infection group|Patients receiving invasive mechanical ventilation for more than 48h with no viral infection at ICU admission
16345641|NCT04359680|Active Comparator|Nitazoxanide|Two NTZ 300 mg tablets orally twice daily for 6 weeks.
16345642|NCT04359680|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks.
16345643|NCT04359667||tocilizumab|one infusion of TCZ 8 mg/kg i.v., with a maximum dose of 800 mg, and SOC treatment according to local guidelines (hydroxychloroquine or/and lopinavir/ritonavir or/and remdesivir).
16345644|NCT04359654|Experimental|Dornase alfa treatment|Best available care and nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure
16345645|NCT04359654|No Intervention|Best available care|Best available standard of care
16345646|NCT04359641|Experimental|CoMET Display|Display of Continuous Monitoring of Event Trajectories (CoMET) predictive monitoring score, with standard CoMET device training.Risk scores will also be presented daily during rounds to members of the care team.
16345647|NCT04359641|No Intervention|No Display|Standard CoMET device training but no display or presentation of predictive monitoring score.
16345648|NCT04359628||BOA|Patients with osteoarthritis registered in the Better BOA register
16345649|NCT04359628||Swedankle|Patients who underwent ankle replacement, fusion or osteotomies and registered in the Swedish ankle registry
16345650|NCT04359628||xBase|Patients with cruciate ligament injuries who received surgical treatment and were registered in the Anterior Cruciate Ligament Register
16345652|NCT04359628||SHAR|Patients who underwent hip replacement therapy and registered in the Swedish Hip Arthroplasty Register
16345653|NCT04359628||SKAR|Patients with knee osteoarthritis and other diagnoses who underwent knee replacement or osteotomies and were registered in the Swedish Knee Arthroplasty Register
16345654|NCT04359628||Bipolär|Patients with Bipolar disorder receiving treatment and were registered in the Swedish National Register for Bipolar Disorder
16345655|NCT04359628||Swedevox|Patients with respiratory failure receiving technical respiratory assistance and were registered in the Swedish National Registry for Respiratory Failure
16345656|NCT04359628||PsoReg|Patients receiving systemic treatment for psoriasis and were registered in the Swedish Registry for Systematic Psoriasis Treatment
16345657|NCT04359628||SRQ|Patients with rheumatic disease receiving medical treatment and rehabilitation and were registered in the Swedish Rheumatology Quality Register
16345658|NCT04359628||SwedeHF|Patients who received treatments of different types in the Swedish Heart Failure Registry
16345659|NCT04359628||Swespine|Patients with spinal stenosis, disc hernia and related diagnoses receiving surgical spine treatment and were registered in the Swedish Spine Register
16345660|NCT04359628||Population health survey|Data of members of the general population who answered population surveys using the EQ-5D-3L instrument
16345661|NCT04359615|Experimental|Favipiravir|
16345662|NCT04359615|Active Comparator|Control|
16345663|NCT04359589||Acute myocardial infarction (AMI) group|"700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases."
16345664|NCT04359589||Acute ischemic stroke group|"500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
16345665|NCT04359589||Acute lower limb ischemia group|"500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
16345666|NCT04359589||Control group|200 healthy volunteers were included as controls
16345667|NCT04359576||FET|Estrogen/progesterone substituted and natural cycles
16345668|NCT04359563|Experimental|Mindfulness-Based Intervention|The MBI programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on the investigator's ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
16345669|NCT04359550|Experimental|treatment group|ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
16345670|NCT04359550|Placebo Comparator|control group|placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
16345671|NCT04359537|Experimental|Arm 1|Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks
16345672|NCT04359537|Experimental|Arm 2|Hydroxychloroquine Sulphate will be admoinistered at a dose of 400 mg on day 1 followed by 400mg once every 3 weeks for at total of 12 weeks
16345673|NCT04359537|Experimental|Arm 3|Hydroxychloroquine Sulphate will be administered at a dose of 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
16345674|NCT04359537|Placebo Comparator|Arm 4|Control group will recieve Placebo 200mg on day 1 followed by Placebo 200mg every three weeks for 12 weeks
16345675|NCT04359524|Active Comparator|Intervention|Received vitamin D3 capsules (1200 IU/30µg).
16345676|NCT04359524|Placebo Comparator|Control|Received placebo (oil capsules).
16345677|NCT04359511|Experimental|corticosteroid + Optimized Standard of Care|"prednisone 0.7 mg/kg/day for 10 days, administered orally, once a day, or
~hydrocortisone hemisuccinate 3.5 mg/kg/day by continuous infusion for 10 days, administered by IV route if the patient cannot take drugs by oral route,
~standard of care"
16345678|NCT04359511|No Intervention|Optimized Standard of Care|standard of care
16345679|NCT04359498||LAR for rectal cancer|Retrospective chart review for surgical complications related to the LAR surgery, the stoma (diverting loop ileostomy) creation and the stoma reversal procedure after LAR for rectal cancer.
16345680|NCT04359485|Experimental|glycolic acid peel|
16345681|NCT04359485|Placebo Comparator|Saline|
16345683|NCT04359459||Mild COVID-19|Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
16345684|NCT04359459||Severe COVID-19|Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
16345685|NCT04359459||Very Severe COVID-19|Patients with very severe disease admitted to intensive care, who require mechanical ventilation.
16345686|NCT04359446|Other|Stent under-expansion with NC Balloon|
16345687|NCT04359446|Other|Stent under-expansion with Laser Excimer + NC Balloon|
16345688|NCT04359433|No Intervention|Standard group|The participates in this group would provide normal health education of scientific and rational diet.
16345689|NCT04359433|Experimental|Exercise intervention group|Besides normal health education of scientific and rational diet，the participates in this group would be suggested to carry out an anaerobic exercise named Tabata.
16345690|NCT04359420|Experimental|BC-Predict|"Women will be sent an invitation letter one to two days after their breast screening invitation letter, directing prospective participants to the online risk assessment platform. Once participants have consented to the study online, they will be directed to the BC-Predict risk assessment questionnaire. Assessment of the online questionnaire during the pilot phase estimated that most women would be able to complete this within 30 minutes.
~Women who complete the questionnaire will receive 10-year breast cancer risk estimates once they have screened negative for breast cancer, based on the Tyrer-Cuzick model, incorporating mammographic density, and for some women, SNPs (single nucleotide polymorphisms). Women who are identified as being at high (>8%) or moderate (5% and <8%) 10-year risk will be offered a consultation to discuss prevention options including prescription of chemoprevention drugs and/ or more frequent mammography as part of the NHS Breast Screening Programme."
16345691|NCT04359420|Active Comparator|NHS-Breast Screening Programme|Usual care in the NHS Breast Screening Programme, which involves mammography every 3 years for the majority of women
16345692|NCT04359394||PP patients|patients with active PP
16345693|NCT04359381|Experimental|kinesiotaping|by kinesiotaping during menstruation for 3 successive menstruation
16345694|NCT04359381|Experimental|pilate exercises|pilate exercises, 3 sessions per week for 3 months
16345695|NCT04359368||patients with hypersensitivity reactions to NDIPs|Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)
16345696|NCT04359355||Artificial Intelligence|
16345697|NCT04359342|Experimental|HIIT + protein|High-intensity interval training (HIIT) combined with protein supplementation
16345698|NCT04359342|Placebo Comparator|HIIT + placebo|High-intensity interval training (HIIT) combined with placebo
16345699|NCT04359342|Experimental|HIIT and resistance training + protein|High-intensity interval training (HIIT) and resistance training combined with protein supplementation
16345700|NCT04359342|Placebo Comparator|HIIT and resistance training + placebo|High-intensity interval training (HIIT) and resistance training combined with placebo
16345701|NCT04359329|Experimental|Active|Estradiol Patch
16345702|NCT04359329|No Intervention|Control|No intervention
16345703|NCT04359316|Experimental|Azithromycin|
16345704|NCT04359316|Active Comparator|Hydroxychloroquine|
16345705|NCT04359303|No Intervention|CONTROL|Base WHO recommended treatment.
16345706|NCT04359303|Experimental|TREATMENT|Base WHO recommended treatment + Systemic indirect endovenous ozone therapy
16345707|NCT04359290|Experimental|Ruxolitinib treatment|Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days
16345710|NCT04359264|Experimental|Cash transfer|
16345711|NCT04359264|No Intervention|Control|
16345712|NCT04359251|Experimental|Optimizing oxygenation|Best oxygenation during PEEP titration
16345713|NCT04359251|Experimental|Optimizing compliance|Best compliance during PEEP titration
16345714|NCT04359251|Experimental|ARDSnet|PEEP settings according to ARDSnet table
16345715|NCT04359238|Active Comparator|Intervention group with motivation messages|There are 100 patients in the intervention group with automated or observer initiated motivation messages. They receive an individualized training program with regular notifications about their training status via their SmartWatch.
16345716|NCT04359238|Active Comparator|Intervention group without motivation messages|There are 100 patients in the intervention group without automated or observer initiated motivation messages. They receive an individualized training program without regular notifications about their training status via their SmartWatch.
16345717|NCT04359238|No Intervention|Control group|100 patients are in the control group without an individualized training program.
16345718|NCT04359225|Active Comparator|3D telemedicine|3D telemedicine system
16345719|NCT04359225|Placebo Comparator|2D telemedicine|2D telemedicine system (standard care)
16345720|NCT04359212||Medical|subject with a confirmed infection for COVID-19 and needing admission to a medical division for a non-severe clinical disease
16345721|NCT04359212||Intensive|subject with a confirmed infection for COVID-19 and needing admission to an Intensive Cure Unit for a severe to critical disease
16345722|NCT04359199||Radiotherapy with chemotherapy|Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)
16345723|NCT04359199||Radiotherapy with immunotherapy|Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)
16345724|NCT04359186|Experimental|Treatment Interruption Arm|
16345725|NCT04359173||Hypothermic machine perfusion (HMP)|patients who underwent kidney transplantation following HMP
16345726|NCT04359173||Static cold storage (SCS)|patients who underwent kidney transplantation following SCS
16345727|NCT04359160|Experimental|Mobile-app follow-up|The mobile app follow-up group will receive an email, to connect into a secure website. They will answer to periodical questions about their condition. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative. All of this information is submitted via the mobile application (Orthense, Digikare Inc. Blagnac, France).The surgeon will have an access to the answer of the patient in real time, and if the patient didn't answer.
16345795|NCT04358679|Active Comparator|Conventional Treatment|Conventional Treatment: Deep breathing, Assisted coughing, Sustained stretching, Splinting, Bracing and Functional mobility
16345728|NCT04359160|Active Comparator|Conventional follow-up|Patients in the conventional, questionnaire follow-up group will have the same periodical questions but on paper. They will have to stick personally with the schedule without any reminders. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative where they have to bring the questionnaire.
16345729|NCT04359147|Active Comparator|Yohimbine|10 mg
16345730|NCT04359147|Active Comparator|Hydrocortisone|10 mg
16345731|NCT04359147|Active Comparator|Yohimbine + Hydrocortisone|10 mg each
16345732|NCT04359147|Placebo Comparator|Placebo|
16345733|NCT04359121||Physicians|Questionnaires
16345734|NCT04359121||Medical staff|Questionnaires
16345735|NCT04359121||General public|Questionnaires
16345736|NCT04359121||Patients with psychiatric disorders|Questionnaires
16345737|NCT04359108|Experimental|Navigation system for users of a visual prosthesis|This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
16345738|NCT04359095|Active Comparator|I1 Emtricitabine + Tenofovir|Intervention 1: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days
16345739|NCT04359095|Active Comparator|I2 Colchicine + rosuvatatine|Intervention 2: Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
16345740|NCT04359095|Active Comparator|I3 Emtricitabine/ tenofobir + colchicine+ rosuvastatin|Intervention 3: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days + Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
16345741|NCT04359095|Other|I4 Standard Treatment|Intervention 4: Standard treatment. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient, might include Dexamethasone. No viral therapies are included.
16345742|NCT04359082|Placebo Comparator|Placebo|Placebo for 8 straight days
16345743|NCT04359082|Experimental|Bioflavanol|Bioflavanol supplementation for 8 days at 900 mg flavanol per day
16345744|NCT04359069|Experimental|Urinary catheter removal on postoperative day 1|
16345745|NCT04359069|Active Comparator|Urinary catheter removal on postoperative day 3|
16345746|NCT04359056|No Intervention|control|patients for the observational phase. This corresponds to usual cares where no clinical pharmacy activities will be performed
16345747|NCT04359056|Experimental|Interventional|patients for the interventional phase where clinical pharmacy activities will be performed at each step of the care pathway: from hospitalization to home care.
16345748|NCT04359043|Experimental|Mediational Intervention for Sensitizing Caregivers|Half of the child participants and the careworkers in the Community-based Organization taking care of them, received the Mediational Intervention for Sensitizing Caregivers.
16345749|NCT04359043|Other|Treatment as Usual|The other half of child participants and the careworkers in the Community-based Organization taking care of them, received Treatment as Usual which consists of the usual services delivered to children at the CBO: food, help with homework, registrations for birth certificates.
16345750|NCT04359030||Freestyle group|Patients treated with a Freestyle aortic valve bioprosthesis
16345751|NCT04359030||Perimount group|Patients treated with a Perimount aortic valve bioprosthesis
16345752|NCT04359017|Experimental|Lidocaine Hematoma Block|
16345753|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
16345754|NCT04358978|Active Comparator|posterior mesh no attachment|laparoscopic sacral colpopexy with no fixation of posterior mesh
16345755|NCT04358978|Active Comparator|posterior mesh attachment|laparoscopic sacral colpopexy with fixation of posterior mesh by suture
16345756|NCT04358965|Experimental|intravenous tranexamic acid|patients were given a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision plus one vaginal placebo tablet 1 hour before skin incision
16345757|NCT04358965|Active Comparator|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
16345758|NCT04358965|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
16345759|NCT04358952||COVID + patients|Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR
16345760|NCT04358939|Experimental|Prone decubitus group|Prone positioning of patients on nasal high-flow oxygen therapy with usual care
16345761|NCT04358939|No Intervention|Control group|Patients on nasal high-flow oxygen therapy with usual care and positioned in supine
16345762|NCT04358926|Active Comparator|Hyperbaric oxygen therapy|8 sessions in 4 days hyperbaric oxygen therapy
16345763|NCT04358926|No Intervention|Control|Standard of care
16345764|NCT04358913|Experimental|MR Imaging on the Alberta linac-MR P3 system|All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
16345796|NCT04358679|Experimental|Upper Limb ergometer training|Conventional Treatment + Upper Limb (UL) ergo-meter exercise
16345797|NCT04358666|Active Comparator|surgery and focal radiosurgery of the surgical site|
16345798|NCT04358666|Active Comparator|hypofractionned radiosurgery|
16345840|NCT04358419||Healthy controls (pneumocystis pneumonia)|Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.
16345765|NCT04358900||Mood disorder group|Participants must meet criteria for one of the following disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 criteria (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, cyclothymia. Multiple mood disorders are employed, in line with the Research Domain Criteria (RDoC; (53)) framework and the relative imprecision of current symptom diagnostic clusters for tracking treatment responses and course of disease. To ensure adequate representation across diagnostic categories (including controls), the investigators will cap enrollment of major mood disorders (MDD, BD type I/II) to 50%, PDD and cyclothymia to 25% and recruit a healthy comparison group to comprise the remaining 25% of the sample.
16345766|NCT04358900||Control group|Participants who do not meet the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, or cyclothymia.
16345767|NCT04358887|Experimental|periapical surgery with piezo.|After flap reflection bone and root end cutting are done with US6 piezoelectric surgical insert
16345768|NCT04358887|Active Comparator|Periapical surgery with bur.|After flap reflection bone and root end cutting are done with surgical bur.
16345769|NCT04358874|Experimental|Active follow-up|Participants randomized to the active follow-up arm will have follow-up visits in the AKI follow-up clinic every 4 weeks after discharge for a total of 90 days after discharge
16345770|NCT04358874|Active Comparator|Usual follow-up|Participants randomized to the usual follow-up arm will be called at home 4 weeks after the baseline visit to collect information on primary and secondary outcomes.
16345771|NCT04358861|Experimental|Experimental group|Nonsurgical Root canal therapy was performed using dental operating microscope in the experimental group.
16345772|NCT04358861|Active Comparator|Control group|Nonsurgical Root canal therapy was performed without any magnification aid in control group.
16345773|NCT04358835|Experimental|Intubated patients with COVID-19 on a ketogenic diet only|4:1 ketogenic diet formula
16345774|NCT04358822|Active Comparator|30 second cord clamping|Infants in this group will receive delayed cord clamping for 30 seconds.
16345775|NCT04358822|Active Comparator|120 second cord clamping|Infants in this group will receive delayed cord clamping for 120 seconds.
16345776|NCT04358809|Experimental|Suspension of Mw + Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days + Standard therapy of COVID-19
16345777|NCT04358809|Placebo Comparator|Placebo|0.3 ml (0.1ml x 3 Injection) of intradermal Placebo for 3 consecutive days + Standard therapy of COVID-19
16345778|NCT04358796|Experimental|HBOT environment|Cognitive testing in 2ATA, 100% oxygen in breathing-masks
16345779|NCT04358796|Sham Comparator|Control environment|Cognitive testing in 1ATA, air in breathing-masks
16345780|NCT04358783|Experimental|Plasma|Convalescent plasma from cured COVID-19 patients y Supportive management depending on individual needs
16345781|NCT04358783|Experimental|Best Available Therapy|Will receive supportive management depending on individual needs including.
16345782|NCT04358770|Experimental|Test|Clocortolone Pivalate Cream, 0.1%
16345783|NCT04358770|Active Comparator|Reference|Cloderm® (clocortolone pivalate) Cream, 0.1%
16345784|NCT04358757||Cesarean patients|participants undergoing elective cesarean will have measures of recovery assessed (patient-reported outcome measures and activity data from watch)
16345785|NCT04358731|Experimental|NmCV-5|"A total of 1640 subjects 18 to 85 years of age will be accrued contemporaneously across three age groups - 18 to 29 years, 30 to 60 years, and 61 to 85 years.
~Within each age group subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.
~The NmCV-5 subjects in 18-29 year age group will be further randomized 1:1:1 into three different lots (Lot A, B & C) of NmCV-5.
~Total 1230 subjects will be enrolled in NmCV-5 arm."
16345786|NCT04358731|Active Comparator|Menactra|"Subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.
~In Menactra arm, total 410 subjects will be enrolled."
16345787|NCT04358718|Active Comparator|general anesthesia|Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
16345788|NCT04358718|Experimental|general analgesia combined with epidural analgesia|Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
16345789|NCT04358705|Experimental|Young Cigarillo User (YCU) Sample|"Aim 1: Online survey. 392 participants from the full YCU sample
~Supplemental Aim 1: A sample of 196 heterosexual females from the Aim 1 survey will be compared to the SGM females
~Aim 2: Eye tracking activity - A total of 152 participants divided between current/past cigarillo users and non-cigarillo users. These 76 cigarillo users will be accrued from YCU sample participants who participated in Aim 1 and live in the Cleveland, Ohio
~Aim 3: (A total of 162 participants from Aim 1 survey). Consists of the Online Electronic Tobacco Marketplace (ETM) and the aim 3 survey components in the following order:
~Demographic screener questions
~Tobacco product withdrawal scale
~ETM
~Quality Assurance Question
~Tobacco product withdrawal scale
~Survey (nicotine dependence & flavor preferences)
~A sample of 88 heterosexual females from the 162 Aim 3 participants will be compared with 88 SGM participants from supplemental Aim 1"
16345790|NCT04358705|Experimental|Sexual and Gender Minority (SGM) Female Cigarillo Users|"Supplemental Aim 1: An online convenience sample of 196 SGM females will complete the Aim 1 online survey and will be compared to sample of 196 heterosexual females from the YCU sample
~Supplemental Aim 3: (88 SGM females who participated in the Supplemental Aim 1 survey). Consists of the ETM and the aim 3 survey components in the following order:
~Demographic screener questions
~Tobacco product withdrawal scale
~ETM
~Quality Assurance Question
~Tobacco product withdrawal scale
~Survey (nicotine dependence & flavor preferences)"
16345791|NCT04358705|Experimental|Aim 2 - Non-cigarillo users|"Aim 2: (Eye tracking activity)
~A total of 152 participants divided between current/past cigarillo users and non-cigarillo users. These 76 non-cigarillo users will be accrued by means of social media posts and flyers at places that youth most likely frequent"
16345792|NCT04358705|Other|Cognitive interview|Separate population of participants (n=29) who were a mix of cigarillo users, dual e-cigarette and cigarillo users, e-cigarette users, and non-users. The cognitive interviews informed the Aim 1 survey
16345793|NCT04358692|Experimental|Surgical Aortic Valve Replacement|Patients with aortic stenosis
16345794|NCT04358692|Other|Reference|Coronary bypass patients without hypertrophic left ventricular remodeling or sequelae of myocardial infarction
16345799|NCT04358653|Experimental|fall prevention exercise program|The experimental group was designed to undergo supervised exercise 2 days a week for 8 consecutive weeks for 45-50 min/session. The intervention program was implemented at the nursing home facilities.
16345800|NCT04358653|No Intervention|Control Group|The control group did not receive any intervention during that period and were instructed to pursue their habitual daily life activities.
16345801|NCT04358640||Employees of Nîmes University Hospital (France)|Employees of Nîmes University Hospital (France)
16345802|NCT04358627||DEXMEDETOMIDINE|Patients receiving dexmedetomidine continuous infusion since their admittance to ICU. Continuous checking of the primary and secondary outcomes
16345803|NCT04358627||No-DEXMEDETOMIDINE|Historical Control patients matched for ICU admittance diagnosis, age, and concomitant disease and medication state. No Dexmedetomidine. CONtinuous checking of primary outcomes
16345804|NCT04358614|Active Comparator|Case patients|Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
16345805|NCT04358614|Other|Controls|Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.
16345806|NCT04358601|Experimental|All-polyethylene tibial components|Triathlon PS Knee System with all-polyethylene tibial components
16345807|NCT04358601|Active Comparator|Metal-backed modular components|Triathlon PS Knee System with metal-backed modular components
16345808|NCT04358575|Experimental|All-polyethylene tibial components|Triathlon CS Knee System with all-polyethylene tibial components
16345809|NCT04358575|Active Comparator|Metal-backed modular components|Triathlon CS Knee System with metal-backed modular components
16345810|NCT04358562|Experimental|Gefitinib with Anlotinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily and Anlotinib 10mg oral d1-14, every 3 weeks
16345811|NCT04358562|Experimental|Gefitinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily
16345812|NCT04358549|Experimental|Favipiravir Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC
16345813|NCT04358549|Other|Standard of Care Arm|Standard of Care for 14 days
16345814|NCT04358536||COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from COVID-19 patients"
16345815|NCT04358536||Non COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from subsets of non COVID-19 patients"
16345816|NCT04358523|Experimental|ASC18 (D1,D4-13）;RDV + SOF(D27,D30-39)|ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
16345817|NCT04358523|Experimental|RDV + SOF (D1,D4-13）;ASC18(D27,D30-39)|RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 1 and day 4 to 13. ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 27 and day 30 to 39.
16345818|NCT04358510||COViage|Machine learning intervention
16345819|NCT04358497|Experimental|Interventional treatment plus best chronic medical treatment|Sandwich embolization ( 2% polidocanol + Coils) Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
16345820|NCT04358497|Active Comparator|Best chronic medical treatment alone|Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
16345821|NCT04358484|Experimental|Intervention Group|Participants attend The Incredible Years - ASLD parenting intervention and continue to receive usual care at their healthcare center
16345822|NCT04358484|No Intervention|Treatment As Usual (TAU) Group|Participants continue to receive usual care at their Healthcare Center
16345823|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection|Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0
16345824|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection|Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0
16345825|NCT04358471|Sham Comparator|Sham Intravitreal Injection|Intravitreal Sham injection administered once on Day 0
16345826|NCT04358458|Experimental|Treatment Administered|
16345827|NCT04358445|No Intervention|Historical control group|The patients were treated by aneurysm clipping in our hospital in the previous nine months, and normal saline (0.9% Sodium Chloride Injection) had applied as intraoperative perfusion solution in operation of the historical control group. All of the 35 patients selected should meet the inclusion and exclusion criteria of this study.
16345828|NCT04358445|Experimental|MACSF group|Use Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) in the operation, and the remaining treatments should strictly follow the guidelines as same as the historical control group.
16345829|NCT04358432|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
16345830|NCT04358432|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
16345831|NCT04358432|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
16345832|NCT04358432|Experimental|AK102 75 mg|Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
16345833|NCT04358432|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
16345834|NCT04358432|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
16345835|NCT04358419||PA proven/probable/possible|15 patients with proven, probable or possible PA
16345836|NCT04358419||PA suspected, not confirmed|15 patients as the PA patients, but where the diagnosis of PA is rejected.
16345837|NCT04358419||Healthy controls (PA)|15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.
16345838|NCT04358419||Pneumocystis pneumonia positive|Four patients with confirmed pneumocystis pneumonia
16345839|NCT04358419||Pneumocystis pneumonia negative|If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.
16346059|NCT04356716|Active Comparator|Sildenafil|Participants are prescribed sildenafil 40-80 mg daily.
16345841|NCT04358406|Placebo Comparator|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
16345842|NCT04358406|Active Comparator|Rhu-pGSN|Recombinant human plasma gelsolin reconstituted for slow bolus injection.
16345845|NCT04358380||Patients without Liver Injury|Hospitalized patients with COVID-19 disease who did not develop liver injury
16345846|NCT04358380||Patients with Liver Injury|Hospitalized patients with COVID-19 disease who develop liver injury
16345847|NCT04358367|Active Comparator|Dexmedetomidine|spinal anesthesia and intravenous dexmedetomidine(1µg/kg)
16345848|NCT04358367|Placebo Comparator|Saline|spinal anesthesia and placebo (saline).
16345849|NCT04358354|Experimental|FOLFOXiri group|Irinotecan 150 mg/m2 iv drip d1; Oxaliplatin 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
16345850|NCT04358354|Active Comparator|FOLFOX group|Oxaliplatin: 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
16345851|NCT04358341|Active Comparator|Irinotecan alone|150 mg/m2 iv drip d1; Repeat every 14 days.
16345852|NCT04358341|Experimental|Pegliposomal Doxorubicin and 5-FU|Pegliposomal Doxorubicin: 25mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h d1; Repeat every 14 days.
16345853|NCT04358328|Experimental|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
16345854|NCT04358328|Active Comparator|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
16345855|NCT04358315||Observational (smell or puff e-liquids)|Non-user panelists smell and user panelists puff flavored e-liquids and answer questions about the products.
16345856|NCT04358302|Experimental|Device use|"All participants will be provided with the electronic pill bottle cap called Pillsy to use with their regular HCQ prescription bottles at the start of the study."
16345857|NCT04358289|No Intervention|Arm 1: Control group|For commune health center and community
16345858|NCT04358289|Other|Arm 2: Basic antimicrobial stewardship education|For commune health center and community
16345859|NCT04358289|Other|Arm 3: 3. Basic AS education + community education|For commune health center and community
16345860|NCT04358289|Other|Arm 4: Education + participatory action research|For commune health center and community
16345861|NCT04358289|Other|Hospital intervention|For hospital: The hospital interventions will use quality improvement using a participatory action research approach to improve antibiotic stewardship. These activities will be evaluated through a before and after knowledge, attitudes and practice (KAP) survey, to assess whether or not the engagement activities had a measurable impact on knowledge and behaviour. There are not sufficient hospitals in the area to conduct a cluster randomized evaluation, so we will conduct a before and after survey, patient record review, and overall antibiotic use data from the Pharmacy Department
16345862|NCT04358276|Experimental|Group I (PAE)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
16345863|NCT04358276|Experimental|Group II (PAE, physician)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
16345864|NCT04358276|Experimental|Group III (PAE, physician, dermatoscope)|"Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and mimickers common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice."
16345865|NCT04358263|Experimental|rtCGM|Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).
16345866|NCT04358263|Experimental|isCGM|Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
16345867|NCT04358250|Experimental|direct superior approach|Direct superior approach 25 patients
16345868|NCT04358250|Active Comparator|posterolateral approach|posterolateral approach 25 patients
16345869|NCT04358237|Experimental|Experimental: lurbinectedin (PM01183) + pembrolizumab|"During the phase I stage, patients will start receiving pembrolizumab at a fixed dose of 200 mg as a 30-min intravenous (IV) infusion followed by lurbinectedin at a starting dose of 2.4 mg/m2 as a 1-h IV infusion on Day 1, both every 3 weeks (Q3W). Lurbinectedin dose will be escalated from the starting dose in successive cohorts of patients, with a pre-established fixed dose increase (in mg/m2) of approximately 30%.
~During the phase II stage, patients will receive pembrolizumab at a fixed dose of 200 mg as a 30-min IV infusion followed by lurbinectedin as a 1-h IV infusion on Day 1 Q3W at the redommended dose (RD) determined during the phase I stage. A cycle is defined as an interval of 3 weeks. No dose escalation will be allowed during the phase II stage."
16345870|NCT04358224|Other|open-label|open-label
16345871|NCT04358198|Experimental|GIM patient|The patients with GIM will be assessed at both GIM and normal mucosa during endoscopy.
16345872|NCT04358185|Experimental|Itacitinib|Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
16345873|NCT04358172|Experimental|Mobile app|Participants in this group is educated using the mobile application
16345874|NCT04358172|No Intervention|Control|Participants in this group is educated using the conventional method practised in the Faculty of Dentistry, National University of Malaysia (verbal instructions accompanied by demonstrations on dental models)
16345875|NCT04358159|Experimental|Ventralex|Repair with Ventralex patch in sublay position
16345876|NCT04358159|Active Comparator|Progrip|Repair with Progrip in Onlay position
16345877|NCT04358146|Experimental|Test|new thickened infant formula containing fibres
16345878|NCT04358146|Active Comparator|Control|infant formula thickened with locust bean
16345879|NCT04358133|Experimental|Chlorhydrate de morphine|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
16345880|NCT04358133|Placebo Comparator|NaCl 0,9%|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
16345881|NCT04358120|Other|Hyaluronic Acid Combined With Chondroitin Sulfate|The treatment consists of 3 intra articular injections of Hyaluronic Acid With Chondroitin Sulfate administered one per week for 3 consecutive weeks: the 1st at Visit 1 (Week 0), the 2nd at Visit 2 (Week 1) and the 3rd at Visit 3 (Week 2)
16345882|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
16345883|NCT04358094|Experimental|Conversational hypnosis script|Patient who received conversational hypnosis script during peripherical veinous access set up
16345884|NCT04358094|Other|Standard script|Patient who received standard script during peripherical veinous access set up
16345885|NCT04358081|Experimental|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZT) placebo o.d.
16345886|NCT04358081|Experimental|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
16345887|NCT04358081|Placebo Comparator|Arm 3: hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
16345890|NCT04358055|Experimental|WET® gel|"At the screening/baseline visit (Visit 1, Day 1), eligible patients will be assigned to treatment with WET® gel, at the dose of 3-4 nasal applications/day (according to necessity), 1or 2 puff/nostril, for maximum 14 days.
~Treatment will be administered according to patient's need without any relation with the time of the day (i.e. day time or night time administration), however within a maximum of 4 applications/day, which must include one administration in the morning upon awakening and one administration in the evening before retiring to bed."
16345891|NCT04358029||COVID-19 patients|Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital
16345892|NCT04358029||Influenza patients|Patients who have been diagnosed with Influenza infection at Mount Sinai Hospital
16345893|NCT04358029||COVID-19 patients who were hospitalized with abnormal echocardiogram|Patients hospitalized for COVID-19 and who had an abnormal echocardiogram during hospitalization
16345894|NCT04358029||COVID-19 patients who were hospitalize with normal echocardiogram or no echocardiogram done|A matched cohort (for age, gender, troponin level, and days since hospital discharge) who did not have abnormalities on their echocardiograms (or who did not undergo echocardiogram) to ascertain that in this unusual disease, subjects did not develop echo abnormalities following hospital
16345895|NCT04358016|Experimental|terlipression|terlipression 1mg；once every 6 hours；5days
16345896|NCT04358016|Active Comparator|Control|Somatostatin，3mg， once every 12 hours; 5 days
16345897|NCT04358003|Experimental|Plasma Adsorption Cartridge|Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.
16345898|NCT04357990|Experimental|Viruxal Oral and Nasal Spray|The Device will be administered to the oral and nasal passages, three times per day.
16345899|NCT04357990|Placebo Comparator|Placebo|The placebo will be administered to the oral and nasal passages, three times per day.
16345900|NCT04357977||Covid +|Laboratory obtained Covid+ specimen results will be compared to saliva specimen
16345901|NCT04357964||obese and lean individuals|obese and lean individuals
16345904|NCT04357912|Experimental|Experimental group|
16345905|NCT04357912|Active Comparator|Control Group|
16345906|NCT04357873|Experimental|pembrolizumab + vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations
~Vorinostat: 400 mg once daily, until progression"
16345907|NCT04357860|Experimental|Sarilumab 200 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 200 mg single dose.
16346172|NCT04355910|Active Comparator|Continuous calorie restriction (CCR)|A daily 25% energy-restricted Mediterranean-type diet
16345908|NCT04357860|Experimental|Sarilumab 400 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 400 mg single dose.
16345909|NCT04357860|Active Comparator|Control|Subjects treated with the best available treatment up to 14 days.
16345910|NCT04357834||Smartwatch group|
16345911|NCT04357821|Experimental|Combination intervention arm|All volunteers will receive the combination intervention outlined above.
16345912|NCT04357808|Experimental|Sarilumab plus standard of care|Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed
16345913|NCT04357808|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
16345914|NCT04357795|Experimental|CequaTM (Cyclosporine 0.09%) ophthalmic solution|
16345915|NCT04357782|Active Comparator|Mild hypoxemia|S/F ratio >250 prior to Vitamin C infusion
16345916|NCT04357782|Active Comparator|Severe Hypoxemia|S/F ratio ≤250 prior to Vitamin C infusion
16345917|NCT04357769||Patients|Individuals aged 18-70 years with a diagnosis of severe mental disorder (schizophrenia or psychosis spectrum disorder; bipolar disorder; major depressive disorder) who were in a condition of psychopathological compensation, had their last clinical evaluation at the University of Naples Federico II outpatient unit of Psychiatry during January-February 2020, were not positive or suspected positive for COVID-19, and were under strict quarantine
16345918|NCT04357769||Controls (General Population)|Individuals aged 18-70 years who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine (e.g. not getting out for work)
16345919|NCT04357769||First-degree Relatives|Individuals aged 18-70 years who were first-degree relatives and caregivers of an individual included in the Patients group, who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine
16345920|NCT04357756|Experimental|YH001 combined with Toripalimab|All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
16345921|NCT04357743|Experimental|Chin supported Arm ergometry with pursed lip breathing|Chin supported along with Arm ergometry with pursed lip breathing
16345922|NCT04357743|Active Comparator|Arm ergometry with pursed lip breathing|Arm ergometry with pursed lip breathing
16345923|NCT04357730|No Intervention|Control|Patients randomized to Control arm will receive no study medication; the treatment will be standard of care according to the institution's protocol for ARDS.
16345924|NCT04357730|Experimental|Alteplase-50 bolus|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Re-bolusing of Alteplase, at the same dose, is permitted in those patients who show an initial transient response. The repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
16345925|NCT04357730|Experimental|Alteplase-50 bolus plus drip|Patients randomized to Alteplase-50 plus drip group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Immediately following this initial Alteplase infusion, a drip of 2 mg/hr of Alteplase will be initiated over the ensuing 24 hours (total 48 mg infusion).
16345926|NCT04357704|Experimental|bilateral cochlear implant recipients|
16345927|NCT04357704|Active Comparator|normal hearing listners|
16345928|NCT04357691|Other|Healthy individuals (low-high-mod)|Participants will undergo the calibration phase beginning with low intensity training, followed by high, and moderate intensity training. Each training intensity will be performed 3 days a week for 2 weeks
16345929|NCT04357691|Other|Healthy individuals (mod-high-low)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by high, and low intensity training. Each training intensity will be performed 3 days a week for 2 weeks
16345930|NCT04357691|Other|Healthy individuals (mod-low-high)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by low, and high intensity training. Each training intensity will be performed 3 days a week for 2 weeks.
16345931|NCT04357678|Experimental|Qi Gong Programme|Qi Gong Programme
16345932|NCT04357678|Experimental|Short Form Sun Style Tai Chi|Short Form Sun Style Tai Chi
16345933|NCT04357665|Active Comparator|Lap TAPP Group|Patients treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
16345934|NCT04357665|Active Comparator|Open PP Group|Patients treated by open preperitoneal single mesh repair fixated using sutures
16345935|NCT04357665|Active Comparator|Bilateral LICHT Group|Patients treated by standard bilateral Lichtenstein repair using 2 separate meshes fixed by sutures
16345936|NCT04357639||Protease inhibitor exposed|HIV patients treated with antiretroviral drugs including a protease inhibitor
16345937|NCT04357639||Protease inhibitor non exposed|HIV patients treated with antiretroviral drugs without a protease inhibitor
16345938|NCT04357626||Completed discharged hospital rehabilitation electronic record|Completed discharged hospital rehabilitation electronic record of patients who underwent inpatient rehabilitation as part of routine clinical care.
16345939|NCT04357613|Experimental|Expérimental ARM|800mg/d IMATINIB during 14days
16345940|NCT04357613|No Intervention|Comparator ARM|Standard of care
16345941|NCT04357600|Experimental|intravenous injection of UC-MSC|The dosage of the intravenous route is 100 million MSCs for each subject.
16345942|NCT04357587|Experimental|Pembrolizumab|Experimental pembrolizumab and SOC external beam radiation and capecitabine
16345943|NCT04357574||Radiation Oncology Providers|Faculty physicians, residents and advanced practice providers in the Radiation Oncology Department in Duke University Health System (DUHS)
16345944|NCT04357561|Experimental|Exercise group (Schroth best practice)|Exercise program will consists of scoliosis-specific exercises (schroth best practice), which is a pattern specific scoliosis rehabilitation concept and provide three dimensional improvements and include patient education for maintaining corrected posture in daily life. In addition, these exercises provide improvements in neuromuscular control and the endurance of the postural muscles.
16345945|NCT04357561|No Intervention|Control group|Due to there is not a standard preoperative exercise protocol, additional exercise program will not be applied in control group. The patients will wait for the surgery in their routine daily life. Measurements will be performed at the same time frame in experimental group.
16346173|NCT04355910|No Intervention|Control|No advice to restrict energy
16345946|NCT04357548||Feedback system|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
16345947|NCT04357535||Primary Cohort|"Patients enrolled in this study will have data collected from the beginning of their hospital stay until discharge.
~Data collected will include:
~Patient demographics (age, sex, weight, and height)
~Indication for ACE-I, ARB therapy, duration and doses
~Use of any a non ACE-I/ ARB sntihypertensive agents
~Comorbidities, and COVID19 related markers: Including WBC, plateltes, ferritin, CRP, CK, and LD
~CT scan reports
~First positive COVID19 PCR
~Admission to the intensive care unit (ICU) and data relating to ICU stay."
16345948|NCT04357522|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose
16345949|NCT04357522|Active Comparator|Positive control group|Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose
16345950|NCT04357509|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
16345951|NCT04357496||Participants with SARS-COV-2|Participants tested positive for SARS-COV-2 aged 60 years or older
16345952|NCT04357483|Experimental|Collastat|Patients who were applied flowable thrombin containing collagen hemostat matrix after pancreatectomy
16345953|NCT04357483|Active Comparator|Collaseal|Patients who were applied thrombin coated L-dopa contained collagen patch after pancreatectomy
16345954|NCT04357470|Active Comparator|USF Group|DRF with ulnar styloid fracture
16345955|NCT04357470|Active Comparator|NON-USF Group|DRF without ulnar styloid fracture
16345958|NCT04357444|Experimental|1: ILT101|ILT-101 in Subcutaneous route
16345959|NCT04357444|Placebo Comparator|2: Placebo Comparator|Placebo in subcutaneous injections every day during 10 days
16345960|NCT04357431||study group|Health care providers include physicians, nurses, and health officers both medical and nursing subjects.
16345961|NCT04357418||hospital staff|
16345962|NCT04357418||close relatives.|
16345963|NCT04357405||Experimental arm|This group consists of 100 EHPAD which will benefit from ECG teletransmission. all data will be collected
16345964|NCT04357405||Control arm|This arm consists of 50 EHPAD that have not benefited from ECG teletransmission. Only the global death occurrence data will be analyzed, no individual data will be collected.
16345965|NCT04357392|Experimental|Glucocorticoid intervention group|prednisone
16345966|NCT04357392|Placebo Comparator|Placebo control group|placebo
16345968|NCT04357366|Experimental|Anakinra|Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.
16345969|NCT04357353|Sham Comparator|Placebo|All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
16345970|NCT04357353|Experimental|PRP|All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.
16345971|NCT04357340|Experimental|Pulmonary Physiotherapy Techniques group|Pulmonary physiotherapy techniques, 6 sessions during 3 days and incentive spirometer.
16345972|NCT04357340|No Intervention|Control group|Incentive spirometer only
16345973|NCT04357327|Experimental|Symptomatic patients|Patients with symptoms associated with COVID-19, i.e., dyspnea, cough, fever, etc.
16345974|NCT04357327|Active Comparator|Asymptomatic subjects|Asymptomatic patients with low risk phenotype, that means patients with a previous negative swab, no relatives affected by COVID-19 and with reduced social interaction within the last two weeks.
16345975|NCT04357314||Patients with STEMI in 2019|Patient with acute myocardial infarction between March 17, 2019 and April17, 2019
16345976|NCT04357314||Patients with STEMI in 2020|Patient with acute myocardial infarction between March 17, 2020 and April17, 2020.
16345977|NCT04357301|Experimental|Closed-loop|Closed-loop administration of norepinephrine
16345978|NCT04357288|Experimental|Patient Decision Aid|Participants in this arm will use the Patient Decision Aid (PDA), an online education tool about atrial fibrillation designed for patient use, prior to the encounter with their provider.
16345979|NCT04357288|Experimental|Encounter Decision Aid|Participants in this arm will use the Encounter Decision Aid (EDA), an online educational tool about atrial fibrillation designed for patient-provider use, during the encounter with their provider.
16345980|NCT04357288|Experimental|Patient & Encounter Decision Aids|Participants in this arm will use both the PDA & EDA as described above.
16345981|NCT04357288|No Intervention|Standard Care|Participants in this arm will receive standard care, that is they will not use either the PDA or EDA.
16345982|NCT04357275||ICU admissions due to COVID-19|
16345983|NCT04357262|No Intervention|Control|No other non-standard of care activities will be performed
16345984|NCT04357262|Experimental|Intervention|Will be signed up for the automated text messaging program (StreaMD)
16345985|NCT04357236||Experimental Group|The experimental group received 18F-FDG PET examination
16345986|NCT04357236||Control Group|The control group received 18F-FDG PET examination
16345987|NCT04357223|Experimental|Experimental|
16345988|NCT04357223|Placebo Comparator|Placebo|
16345989|NCT04357210||primary sphincteroplasty|end-to-end primary sphincteroplasty with interrupted sutures
16345990|NCT04357210||muco-muscular advancement flap|A U-shaped muco-muscular flap was mobilized and fixed to the anoderm with one-row interrupted absorbable sutures
16346060|NCT04356703||Children submitted to fetoscopic surgery|Children submitted to fetoscopic in utero myelomeningocele repair using the SAFER (Skin-over-biocellulose for Anternatal FEtoscopic Repair) technique will evaluate the neuropsicomotor development at 30 months of chronological age or older
16345991|NCT04357210||full-thickness low rectum posterior semicircular mobilization|Proximal parts of the internal sphincter and the longitudinal muscle were carefully separated from the underlying external sphincter and puborectalis muscle, moving further in the cranial direction, the Waldeyer's fascia was exposed and incised. Full-thickness posterior semicircular flap was fixed to anoderm
16345992|NCT04357197|Experimental|Closed-loop|Closed-loop administration of norepinephrine in critically ill patients
16345993|NCT04357184|Experimental|BFRT with 4 exercises and low resistance loads|Blood flow resistance training will be performed with a standard blood pressure cuff that is placed and inflated by a clinician. The patient will perform 4 exercises with low resistance loads that will produce a muscle burn to enhance promotion of strength. Training will be supervised in the clinic. The cuff is deflated between exercises.
16345994|NCT04357171|Active Comparator|Ileostomy|Loop protective ileostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
16345995|NCT04357171|Active Comparator|Colostomy|Loop protective transverse colostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
16345996|NCT04357158|Other|Patients referred for colonoscopy|
16345997|NCT04357145|Active Comparator|Standard Exercise Group|Exercise training is given to patients in the form of a home exercise program.
16345998|NCT04357145|Experimental|High Dosage Exercise Group|The high dosage exercise training group will implement the recommended exercise program 3 times more than the standard exercise group.
16345999|NCT04357132|Other|VR-Biofeedback|
16346000|NCT04357132|Other|VR-Distraction|
16346001|NCT04357119|Active Comparator|CL measured from Treitz ligament|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 200 cm distal to the ligament of Treitz with the same stapler using a 60 mm blue cartridge
16346002|NCT04357119|Active Comparator|CL measured from ileocecal valve|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 300 cm proximal to the ileocecal valve with the same stapler using a 60 mm blue cartridge
16346003|NCT04357106|Experimental|Convalescent Plasma|200 ml of convalescent plasma, single dose.
16346004|NCT04357093|Experimental|Grape seed extract mouthwash|Grape seed extract mouth wash 15% concentration
16346005|NCT04357093|Active Comparator|Sodium fluoride mouthwash|Sodium fluoride mouthwash 1000 ppm
16346006|NCT04357080||Case|Patients with urethral stricture recurrence
16346007|NCT04357080||Control|Patients with normal, patent urethra
16346008|NCT04357067|Experimental|Lingual brackets|Patients with moderate crowding without extraction treated with Incognito lingual bracket (3M Unitek, Bad Essen, Germany)
16346009|NCT04357067|Experimental|Labial brackets|Patients with moderate crowding without extraction treated with labial bracket (3M Unitek, Ca, USA
16346010|NCT04357054|Active Comparator|Normal uterus|Darwish test
16346011|NCT04357054|Active Comparator|Myomatous uterus|Darwish test
16346012|NCT04357028|Experimental|MMR vaccine|0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm
16346013|NCT04357028|Placebo Comparator|Control|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
16346014|NCT04357015|Experimental|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
16346015|NCT04357015|Active Comparator|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
16346016|NCT04357015|Placebo Comparator|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
16346017|NCT04357002|Experimental|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
16346018|NCT04357002|Active Comparator|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
16346019|NCT04357002|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
16346021|NCT04356976|Experimental|Ventralex|Repair with Ventralex hernia patch in sublay position
16346022|NCT04356976|Active Comparator|Stratafix|Repair with Stratafix suture
16346025|NCT04356937|Experimental|Tocilizumab|"Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.
~Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures."
16346026|NCT04356937|Placebo Comparator|Standard of care plus placebo|Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.
16346027|NCT04356924|Experimental|Psychological treatment|The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
16346136|NCT04356183|Other|Counseling Health As Treatment (CHAT)|CHAT is a control arm designed to reflect traditional clinical counselling.
16346028|NCT04356924|Active Comparator|Cognitive training|Like the experimental group, the active control group also consists of 11 sessions (55 minutes per occasion), once a week. At those occasions, the patient will meet a psychology student under training or a MSc in psychology that coaches the patients during the cognitive training. In between sessions, patients are supposed to take 2 walks (45 minutes per occasion to meaningfully match the home exercises in the experimental group).
16346029|NCT04356924|No Intervention|Treatment as usual|This group receives no intervention. They receive regular health information that is given after the extended cognitive examination at the Cognitive Centers.
16346030|NCT04356911|Placebo Comparator|PLACEBO (Negative Control)|The dental elements of this group had no desensitizing treatment. After whitening therapy, a water-soluble placebo gel (KY®, Johnson & Johnson, SP, Brazil) was applied to dental oral surfaces, then the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of Low Level Laser Therapy (LLLT).
16346031|NCT04356911|Experimental|FBM|The group received the application of a placebo gel associated with LLLT after office bleaching.
16346032|NCT04356911|Experimental|ESTRÔNCIO|After whitening in-office bleaching, the group was treated with desensitization to 10% strontium chloride. Subsequently, a laser tip was positioned at two points (apical and cervical), without emitting light (placebo).
16346033|NCT04356911|Experimental|FBM+ESTRÔNCIO|After whitening in the office, the group received a 10% strontium chloride desensitizer associated with low level light therapy.
16346034|NCT04356898||Diabetes fasting|Diabetes patients who decided to fast during the month of Ramadan
16346035|NCT04356898||Diabetes non-fasting|Diabetes patients who decided to not fast during the month of Ramadan
16346036|NCT04356898||Healthy|Healthy volunteers that decided to fast during the month of Ramadan
16346037|NCT04356872|Experimental|treatment|The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.
16346038|NCT04356859|No Intervention|Crystalloid|Subjects in the crystalloid group will receive fluid resuscitation with Lactated Ringer's titrated each hour to achieve a urine output of 0.5-1mL/kg predicted body weight.
16346039|NCT04356859|Active Comparator|Colloid|Subjects in the colloid group will receive fluid resuscitation with Lactated Ringer's and 5% human albumin solution introduced no earlier than 8 hours post burn and no later than 12 hours post burn in a ratio by volume of 1/3 albumin to 2/3 Lactated Ringer's, and titrated each hour to achieve a urine output of 0.5-1mL/kg (milliliter/kilogram) predicted body weight.
16346040|NCT04356846|Experimental|R/R CLL|Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
16346041|NCT04356846|Experimental|R/R NHL|Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
16346042|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 1|For patients in the rt-PA group, 10 mg of rt-PA dissolved in 5 ml of diluent will be given every 6 hrs for 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). 6 patients will be receiving Invasive mechanical ventilation and another six will be receiving Non Invasive ventilation.
16346043|NCT04356833|No Intervention|Historical matched controls - cohort 1|"Matched historical controls who received standard of care were also recruited at a ratio of 2 controls to every 1 treatment arm patient. Matching will be done according to the following criteria in the order stated:
~Ventilation and oxygen type (IMV and non-invasive oxygen support)
~Severity as determined by PaO2/FiO2 ratio
~Gender
~Age (+/- 2 years, up to a maximum of 10 years)
~Ethnicity"
16346044|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 2|In cohort 2, fewer timepoints will be collected, which will allow for more rapid recruitment while at the same time not compromising safety monitoring. A more flexible dosing regimen for rtPA will be utilised. 30 patients will be recruited in total, with an aim to recruit a minimum of 10 IMV patients and 10 patients on non-invasive oxygen support.
16346045|NCT04356820|Experimental|acupressure|
16346046|NCT04356820|Experimental|music|
16346047|NCT04356820|No Intervention|control|
16346048|NCT04356807|Experimental|Reflex Locomotion Therapy|during 15 minutes once a day five days a week
16346049|NCT04356807|Experimental|Passive Joint Mobilizations|during 15 minutes once a day five days a week
16346050|NCT04356807|Placebo Comparator|Massage|during 15 minutes once a day five days a week
16346051|NCT04356794|Experimental|Medical electroacupuncture(EA)|EA were treated for 4 weeks, 3 times per week.
16346052|NCT04356794|Sham Comparator|Sham electroacupuncture|"Sham acupuncture was performed without stimulation and manipulation to avoid eliciting De Qi sensations.It were treated for 4 weeks, 3 times per week."
16346053|NCT04356755|Experimental|autologous cultured ASC|Subcutaneous injections of autologous cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
16346054|NCT04356755|Placebo Comparator|Placebo|Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
16346055|NCT04356742|Experimental|Dapagliflozin 10mg + Evogliptin 5mg + Metformin|
16346056|NCT04356742|Placebo Comparator|Dapagliflozin Placebo + Evogliptin 5mg + Metformin|
16346057|NCT04356729|Experimental|Atezolizumab and Bevacizumab|"The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.
~Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks
~Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
~Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment"
16346058|NCT04356716|Active Comparator|Standard of Care Sildenafil|Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
16346061|NCT04356690|Experimental|Cohort 1 - Etoposide|"Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4
~If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
16346062|NCT04356690|Experimental|Cohort 2 - Etoposide|"Participants that are NOT on ventilation Etoposide 150 mg/m2 daily days 1 and 4
~Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4. If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
16346063|NCT04356690|No Intervention|Cohort 1 - Control|Standard of care therapy in participants that are on ventilation
16346064|NCT04356690|No Intervention|Cohort 2 - Control|Standard of care therapy in participants that are NOT on ventilation.
16346065|NCT04356677|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
16346066|NCT04356677|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
16346067|NCT04356664|No Intervention|Frozen embryo transfer with Hormonal Replacement Therapy (HRT)|Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
16346068|NCT04356664|Experimental|Frozen embryo transfer with HRT and GnRH agonist|Patient will received 1 or 2 injection of GnRH agonist priori to usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
16346069|NCT04356651|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
16346070|NCT04356651|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
16346071|NCT04356638|Active Comparator|The sedative pre-medication oral Midazolam|
16346072|NCT04356638|Active Comparator|The sedative pre-medication intranasal Dexmedetomidine|
16346073|NCT04356638|Placebo Comparator|Placebo|
16346074|NCT04356638|No Intervention|No Sedative Pre-medication|
16346075|NCT04356625|Other|MEPic|"Ready for extubation (pass SBT)
~Measurement of maximum expiratory pressure during the induced cough (MEPic)"
16346076|NCT04356612||Achilles Tendon Rupture|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
16346077|NCT04356599|Experimental|Intervention Group|All participants will receive study intervention
16346078|NCT04356573|Placebo Comparator|Gold kiwifruit|Subjects ate 2 gold kiwifruit with midday meal for 2 weeks.
16346079|NCT04356573|Active Comparator|Green Hayward kiwifruit|Subjects ate 2 green Hayward kiwifruit with midday meal for 2 weeks.
16346080|NCT04356560||healthcare workers|Actively working at Department of Otorhinolaryngology Head and Neck Surgery & Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark. During 2020 COVID 19 pandemic
16346081|NCT04356560||Patients|Patients presenting with complications to upper respiratory tract infections and patients undergoing surgery involving airway mucosa During 2020 COVID 19 pandemic
16346082|NCT04356547|Active Comparator|Fiberoptic intubation using laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
16346083|NCT04356547|Active Comparator|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
16346086|NCT04356521|Active Comparator|Group LS|Ultrasound-guided infraclavicular block - lateral sagittal approach (20 ml 0.5% bupivacaine)
16346087|NCT04356521|Active Comparator|Group CC|Ultrasound-guided infraclavicular block - costoclavicular approach (20 ml 0.5% bupivacaine)
16346088|NCT04356508|Experimental|Intervention (n=10)|Nivolumab + best supportive care
16346089|NCT04356508|No Intervention|Non-intervention (n=5)|Best supportive care
16346090|NCT04356495|Sham Comparator|Vitamins|"Patients in this arm will receive a vitamin supplement (AZINC forme et vitalité®) during 10 days"
16346091|NCT04356495|Experimental|Telmisartan|Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days
16346092|NCT04356495|Experimental|Ciclesonide|Patients in this arm will receive ciclesonide (Alvesco® 160 µg ) during 10 days
16346093|NCT04356495|Experimental|interferon β-1b|Patients in this arm will receive interferon β-1b (Extavia® 9,6 MUI/300 µg ) during 5 days
16346094|NCT04356482|Experimental|single arm|"Determine the convalescent plasma dose to be administered to two groups: one severely ill (not intubated) and one very severely ill (intubated).
~Second phase: safety and efficacy of the plasma dose found in the same two types of patients."
16346095|NCT04356469|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
16346096|NCT04356456|Experimental|Lumenato Supplement|Lumenato oleoresin
16346097|NCT04356456|Placebo Comparator|Placebo|paraffin oil
16346098|NCT04356430|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
16346099|NCT04356430|Experimental|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
16346100|NCT04356404||Prospective group|Patients will be followed up until development of hepatitis flare or at 2 years after study recruitment. We plan to recruit 150 patients for the prospective cohort.
16346101|NCT04356391|Active Comparator|Connective Tissue Graft harvest from Palate|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Technique. The tooth assigned to the CTG technique will receive the graft harvested from the palate.
16346102|NCT04356391|Experimental|collagen resorbable membrane material|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Surgical Technique (PST). The tooth assigned to the PST technique will receive the collagen resorbable membrane material.
16346103|NCT04356378||"infection with coronavirus SARS-CoV2 group"|"SARS-CoV2 infected patients group: in-patient in the acute phase then requiring rehabilitation."
16346104|NCT04356352|Active Comparator|Lidocaine|1 mg/kg lidocaine to a max of 100 mg
16346105|NCT04356352|Active Comparator|Esmolol|0.5 mg/kg esmolol to a max of 50 mg
16346106|NCT04356352|Placebo Comparator|Placebo|Saline water
16346108|NCT04356326|Experimental|Aspirin 150 mg|Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening
16346109|NCT04356326|Placebo Comparator|Placebo|Placebo taken in the evening
16346110|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & HGB|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and the Hipogastric component (HGB)
16346111|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & VBx|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and Viabahn Balloon Expandable ( VBx)
16346112|NCT04356300|Experimental|The exosome of MSC arm|Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.
16346113|NCT04356300|No Intervention|The control arm|Patients in the control arm will not be given exosome of MSC.
16346114|NCT04356287|Experimental|One infusion of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at months 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.
16346115|NCT04356287|Experimental|Two infusions of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.
16346116|NCT04356287|Placebo Comparator|Placebo infusions|Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.
16346117|NCT04356274|Experimental|Participatory System Dynamics (PSD)|12 clinics assigned to PSD
16346118|NCT04356274|Experimental|Audit and Feedback (AF)|12 clinics assigned to AF
16346119|NCT04356261|Placebo Comparator|Control PNF|Personalized Normative Feedback on non-alcohol/health related topics delivered in all weekly rounds (active control)
16346120|NCT04356261|Active Comparator|Light Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 33% of weekly rounds
16346121|NCT04356261|Active Comparator|Heavy Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 67% of weekly rounds
16346122|NCT04356248|Experimental|High-intensity interval training + energy management education|"High-intensity interval training (HIIT): physiologically defined heart rate-controlled cycling with 80-100 rounds per minute (rpm) at 95-100% of maximum heart rate (HRmax). Participants will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 min with the aim to achieve 60% of HRmax.
~Energy management education (IEME): face-to-face education sessions of 6.5 h in duration over a 3-week period, all conducted by a trained occupational therapist. Participants acquire knowledge and understanding about factors that influence energy and the consequences of fatigue on their habits and lifestyle. Six weeks after returning home, the participants will receive a reinforcement letter in the form of information material to remember the content of the IEME and to reinforce the implementation of the behaviour change in managing energy."
16346123|NCT04356248|Active Comparator|Low-intensity training + progressive muscle relaxation|"Low-intensity training (ST): participants will exercise for 24 min continuously at 65% of participants' HRmax (60-70 rpm).
~Progressive muscle relaxation (PMR): The aim of PMR is to achieve enhanced mental relaxation by reducing muscle tension. Participants will attend six 1-h group sessions over the 3-week intervention period, instructed by a trained physical therapist. Six weeks after returning home, the participants will receive a reinforcement letter with information material for remembering the content of the PMR techniques and to reinforce the implementation of the exercises at home."
16346124|NCT04356235||A:Exp-impl-mastopexy|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
16346125|NCT04356235||B: exp-impl-mastopexy+mesh|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
16346126|NCT04356235||C: exp-impl-mastopexy+implant|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
16346127|NCT04356235||D: exp-impl-mastopexy+implant+mesh|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
16346128|NCT04356235||E: simple masectomy|unilateral simple mastectomy
16346129|NCT04356235||F: bilateral exp-impl|after bilateral SSM, ASM, NSM, expander-implant exchange
16346130|NCT04356222|Experimental|Leptomeningeal Metastasis|Durvalumab + Intrathecal chemotherapy
16346131|NCT04356209|Experimental|EXPERIMENTAL GROUP|ePRO intervention + PRAVASTATINE treatment
16346132|NCT04356209|Other|CONTROL GROUP|PRAVASTATINE treatment ( without ePRO)
16346133|NCT04356196|Experimental|Verapamil group|45 patients will receive 80 mg oral verapamil 3 hours pre-operative
16346134|NCT04356196|Experimental|Bisoprolol group|45 patients will receive Bisoprolol 5mg PO 3 hours preoperative
16346135|NCT04356196|Experimental|placebo group|45 patients will receive placebo tablet PO 3 hours preoperative .
16346137|NCT04356183|Experimental|Supervised Weight loss and Exercise Training (SWET)|SWET includes supervised aerobic (3x/w) and resistance (2x/w) training plus a weekly weight loss session.
16346138|NCT04356170|Active Comparator|TPF (docetaxel, cisplatine, 5-FU)|Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
16346139|NCT04356170|Experimental|TPFm (docetaxel, cisplatine, 5-FU) modifié|Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
16346140|NCT04356157|Other|Special day|The special day takes place with an extraordinary opening of the clinical centre once a month on a pre-festive day (Saturday). During this day, access will be reserved exclusively for men, including those who are not on treatment for HIV. The centre will offer free health promotion services to all participants.
16346141|NCT04356157|Other|Male Champions|"The male champion is a figure present in a few settings which carries out home visits with men and couples and follows up with men who did not accompany their partners to Antenatal Care visits. Usually, this role is covered by the female Expert Clients, namely HIV+ patients working in the organization as volunteers after appropriate training. Some men among patients who are on treatment will be identified and trained to cover this role."
16346142|NCT04356157|Other|Nudge|The intervention based on the use of incentives (nudge) to men who follow the prevention and treatment program aims to evaluate whether this action is effective in guiding behaviour change towards the test, treatment, involvement and adherence to therapy approach.
16346143|NCT04356157|Other|No intervention|No intervention will be carried out in a center.
16346144|NCT04356144||Critical infection|Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU
16346145|NCT04356131|Experimental|experimental group|Students in the experimental group were taught about massage and progressive relaxation exercises (PRE). The phases of the massage and PRE trainings were first explained by being demonstrated by the author on herself. In the meantime, the trainings were video-taped and uploaded to the mobile phones of the students. After the author, each student was made to perform massage and PRE. Both the exercises and massage techniques were daily performed 3 times a day after pain had started and relaxation exercises lasted 30 minutes whereas massage was performed for 15 minutes consecutively
16346146|NCT04356131|No Intervention|control group|The students in the control group continued their routines during the study.
16346147|NCT04356118|Experimental|Endostatin Therapy for NSCLC of LM|"Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer
~Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.
~intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.
~Targeted drugs for non-small cell lung cancer:
~EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs ."
16346148|NCT04356105|Active Comparator|Minimal Stimulation Group|Minimal dose stimulation ovarian induction protocol given to poor responders, involving letrozole, low dose recombinant FSH and GnRH antagonist
16346149|NCT04356105|Active Comparator|Microflare Group|Microflare ovarian induction protocol given to poor responders, involving OCP, GnRH agonist, high dose recombinant FSH
16346150|NCT04356092|Experimental|Perfusion|Consecutive patients scheduled to undergo infrapopliteal angioplasty or stenting, or both, as part of their standard treatment for Rutherford-Becker class 5 and 6 chronic limb-threatening ischemia, were included in the study. All procedures were performed using local anesthesia. An antegrade access was used in all patients followed by the deployment of a 5 or 6 Fr arterial sheaths. A semi-lateral foot projection was preferred and the pre-revascularization DSA of the foot was performed via a 5 Fr angiographic catheter placed at the distal third of the popliteal artery. Following revascularization of one or more tibial arteries, the catheter was placed at the same popliteal segment and post-procedural DSA of the foot was performed following the exact pre-revascularization injection protocol at the same semi-lateral projection. The 2D-perfusion imaging and analysis of the DICOM files was performed after revascularization.
16346151|NCT04356079||Migraine patients|
16346152|NCT04356079||Control|
16346153|NCT04356066|Other|Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise|"History taking: age, sex, disease duration, history of present illness, drug intake, past and family history.
~Physical examination including thorough clinical examination.
~Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018)."
16346154|NCT04356040|Experimental|Main Study|
16346155|NCT04356040|Experimental|HSP Sub-Study|
16346156|NCT04356027|Other|Standard of Care: Angiography, OCT, FFR, and VFR|Patients will have Pre-OCT Angiography, OCT pullbacks, a FFR measurement and a VFR analysis
16346157|NCT04356001|Experimental|Socket preservation group|"Extraction sockets filled with a one-piece dual tissue graft harvested from the tuberosity using an adjusted trephine."
16346158|NCT04355988|Active Comparator|Well controlled diabetics|Nonsurgical root canal treatment
16346159|NCT04355988|Active Comparator|Poorly controlled diabetics|Nonsurgical root canal treatment
16346160|NCT04355988|Active Comparator|Healthy control group|Nonsurgical root canal treatment
16346161|NCT04355975||Medical Therapy / Anticoagulation|
16346162|NCT04355975||Systemic Lysis|
16346163|NCT04355975||Interventional Therapy for PE|
16346164|NCT04355975||Surgical Embolectomy|
16346165|NCT04355962|Experimental|Sevoflurane Sedation|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
16346166|NCT04355962|Active Comparator|Intravenous|No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine
16346167|NCT04355949|Experimental|Patients with premature ejaculation|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
16346168|NCT04355949|Experimental|Normal subjects|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
16346169|NCT04355936|Experimental|TELMISARTAN|Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
16346170|NCT04355936|No Intervention|CONTROL|Patients in this group will receive standard care.
16346171|NCT04355910|Experimental|Intermittent fasting mimic-diet (IFD)|Restrict 75% energy on two non-consecutive days each week.
16346174|NCT04355897|Experimental|Convalescent COVID 19 Plasma|Subjects will receive and intravenous infusion of 500 mls of Convalescent COVID 19 Plasma.
16346184|NCT04355845|Experimental|Sumatriptan and PF-06651600 DDI|In Period 1, participants will receive a single oral 25 mg dose of sumatriptan on Day 1 in the morning. In Period 2 on Day 1, participants will receive a single oral 25 mg dose of sumatriptan and a single 400 mg oral dose of PF-06651600 in the morning. In Period 3 participants will receive a single 400 mg oral dose of PF-06651600 in the evening of Day 1, and then a single oral 25 mg dose of sumatriptan in the morning of Day 2.
16346185|NCT04355832|Placebo Comparator|Placebo 1|The participants will be randomized to placebo infusion.
16346186|NCT04355832|Placebo Comparator|Placebo 2|The participants will be randomized to placebo infusion.
16346187|NCT04355832|Experimental|GLP-1|The participants will be randomized to Glucagon-like peptide-1 infusion.
16346188|NCT04355819|Experimental|Disclosure before|Patients will be told that a hernia was found on CT before the follow-up survey is administered.
16346189|NCT04355819|Experimental|Disclosure after|Patients will be told that a hernia was found on CT after the follow-up survey was administered.
16346190|NCT04355806||Vaccinated NSCLC group|This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
16346191|NCT04355806||Vaccinated Health group|This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
16346192|NCT04355806||Unvaccinated NSCLC group|This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
16346193|NCT04355780||Subgroup 1|Composed of HCT patients with respiratory failure requiring intubation and mechanical ventilation.
16346194|NCT04355780||Subgroup 2|Composed of oncology patients (solid tumor or leukemia patients) who have not undergone HCT and who have respiratory failure requiring intubation and mechanical ventilation.
16346195|NCT04355780||Subgroup 3|Composed of chimeric antigen T-cell receptor infusion recipients who have respiratory failure requiring intubation and mechanical ventilation.
16346198|NCT04355754|Experimental|mechanically ventilated patients|"Adult ICU patients who are mechanically ventilated and who do not require complex modes of ventilation.
~A designated flow divider (Ventil) will be used to divide inspiratory gas flow from ventilator in two separate streams - one to the patient and the second to the artificial lung"
16346199|NCT04355741||Ambulatory|Patients that are self-isolated at home
16346200|NCT04355741||Ward|Patients that are in an isolated room at the hospital
16346201|NCT04355741||ICU|Patients that are in the ICU of the hospital
16346202|NCT04355728|Experimental|UC-MSCs Group|Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
16346203|NCT04355728|Placebo Comparator|Control Group|Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
16346204|NCT04355702||Lupus patients treated by hydroxychloroquine|Lupus patients treated by hydroxychloroquine
16346205|NCT04355702||Lupus patients not treated by hydroxychloroquine|Lupus patients not treated by hydroxychloroquine
16346206|NCT04355689|Experimental|NPI-001|NPI-001 Tablet, 250 mg, BID
16346207|NCT04355689|Placebo Comparator|Placebo|Placebo Tablet, BID
16346208|NCT04355676|Experimental|Selinexor 40mg|Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
16346209|NCT04355676|Experimental|Selinexor 20mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
16346280|NCT04355208|Active Comparator|comparator|Restoration of anterior teeth using polychromatic layering technique using Enamel and Dentin shades (filtek Z350 xt from 3m
16346281|NCT04355195||Cohort before training|500 patients should be asked to participate in the project in the phase of zero value measurement. The documentation of the routine data before the training phase relates to patients aged ≥70 years, male and female, who are undergoing surgery.
16346210|NCT04355663|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
16346211|NCT04355663|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
16346212|NCT04355663|Experimental|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
16346213|NCT04355650|Experimental|Clinical decision tool|Launch of clinical decision support tool at baseline visit with study clinician.
16346214|NCT04355637|No Intervention|Control|patients receiving standard of care to treat their pneumonia
16346215|NCT04355637|Experimental|Intervention|patients receiving standard of care to treat their pneumonia + inhaled budesonide
16346216|NCT04355624||ICU patients|COVID-19 patients admitted in Intensive Care Units
16346217|NCT04355624||Non ICU patients|COVID-19 patients admitted in conventional units
16346218|NCT04355611||Patients with MS or NMO|Cohort study evaluating the epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
16346219|NCT04355598|Experimental|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
16346220|NCT04355598|Active Comparator|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
16346221|NCT04355598|Placebo Comparator|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
16346222|NCT04355585|Experimental|Male|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
16346223|NCT04355585|Experimental|Female|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
16346224|NCT04355572|Experimental|Vitamin D Supplement|Patients will take vitamin D tablet with 4,000IU daily for 6 months.
16346225|NCT04355572|Placebo Comparator|Placebo|Patients will take placebo for 6 months
16346226|NCT04355559||conventional oxygen therapy|Continuous use of current oxygen therapy
16346227|NCT04355559||high flow nasal cannula|change the oxygen therapy to high flow nasal cannula
16346228|NCT04355559||Noninvasive ventilation|change the oxygen therapy to noninvasive ventilation
16346229|NCT04355546||COPD patients|Trimbow 87/5/9 pMDI for COPD prescribed according to licensed indication
16346230|NCT04355533|Experimental|Hospitalized children or consulting at hospital|
16346231|NCT04355533|Experimental|Parents of one included child|
16346232|NCT04355533|Experimental|Children with potential COVID disease during the first wave|
16346233|NCT04355533|Experimental|School children SARS-coV2 positive|
16346234|NCT04355533|Experimental|person living under the same roof as children included in the study|
16346235|NCT04355520|Experimental|TQ-B3525 tablets combined with fulvestrant injection|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
16346236|NCT04355507||Patients with suspicions of COVID-19 pneumonia|Patients with suspicions of COVID-19 pneumonia
16346237|NCT04355468||Control group|General anaesthesia was induced with midazolam 0.1 mgkg-1, propofol 2 mgkg-1 and cisatracurium 0.15 mgkg-1. Anaesthesia was maintained with one minimal alveolar concentration (MAC1) sevoflurane. Patients awoke from anaesthesia in the postanaesthesia care unit (PACU) where extubation was performed by an anaesthetist after administration of incremental doses of atropine and neostigmine, as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia or until side effects occurred. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
16346282|NCT04355195||Cohort after training|From October 1st, 2020, the documentation of the routine data will begin after the training phase: 1,700 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2023.
16346283|NCT04355169|Experimental|Naldemedine 1.25 mg|Participants will receive 1.25 mg naldemedine twice daily (BID) beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
16346284|NCT04355169|Experimental|Naldemedine 2.5 mg|Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
16346285|NCT04355169|Experimental|Naldemedine 5 mg|Participants will receive 5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
16346238|NCT04355468||Opioid Free Aneasthesia group|General anaesthesia was induced with midazolam 0.1 mgkg-1, propofol 2 mgkg-1 and cisatracurium 0.15 mgkg-1. Anaesthesia was maintained with one minimal alveolar concentration (MAC1) sevoflurane. Patients awoke from anaesthesia in the postanaesthesia care unit (PACU) where extubation was performed by an anaesthetist after administration of incremental doses of atropine and neostigmine, as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia or until side effects occurred. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
16346239|NCT04355455|Active Comparator|Citalopram|Administration of citalopram to assess the esophageal sensitivity in HV
16346240|NCT04355455|Placebo Comparator|Placebo|Administration of placebo to assess the esophageal sensitivity in HV
16346241|NCT04355442||contained patients|contained patients
16346242|NCT04355442||Comparative patients|Comparative patients
16346243|NCT04355429|Experimental|CAPTOPROL|Inhalation administration by nebulization
16346244|NCT04355429|No Intervention|STANDARS CARE|According to surviving covid-Campaign guidelines
16346245|NCT04355416|Experimental|curcumin oral gel|
16346246|NCT04355416|Other|subgingival scaling and root planing|
16346247|NCT04355403|Experimental|Hyalo Gyn gel|Vaginal application of Hyalo Gyn gel in prefilled applicators
16346248|NCT04355403|No Intervention|No treatment|No treatment application
16346249|NCT04355377||Patients|
16346250|NCT04355364|Experimental|Experimental group|Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
16346251|NCT04355364|Active Comparator|Control group|Patients will receive the usual care in accordance with good practice.
16346252|NCT04355351|Other|hospital staff exposed to SARS-Cov-2|
16346253|NCT04355351|Other|SARS-Cov-2 infected patient|
16346254|NCT04355338||0-9 years|Participants aging 0-9 years
16346255|NCT04355338||10-19 years|Participants aging 10-19 years
16346256|NCT04355338||20-29 years|Participants aging 20-29 years
16346257|NCT04355338||30-39 years|Participants aging 30-39 years
16346258|NCT04355338||40-49 years|Participants aging 40-49 years
16346259|NCT04355338||50-59 years|Participants aging 50-59 years
16346260|NCT04355338||60-69 years|Participants aging 60-69 years
16346261|NCT04355338||70-79 tears|Participants aging 70-79 years
16346262|NCT04355338||80+ years|Participants aging 80 years or more
16346263|NCT04355325|Active Comparator|Experimental|modified monolithic zirconia crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
16346264|NCT04355325|Placebo Comparator|control|metal ceramic crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
16346265|NCT04355312|Experimental|Kysindo|Group of 45 patients with short-term desire for pregnancy who will undergo laparoscopic ovarian cystectomy with use of indocyanine green. Evaluation of the ovarian reserve preoperatively and longitudinal cohort follow-up after surgery at 6 months and 12 months. Analysis by a new imaging technique.
16346266|NCT04355299|Experimental|Intervention group|a mixed exercise program including aerobic, balance, and resistance exercises that were personally tailored.
16346267|NCT04355299|Other|control group|usual care
16346268|NCT04355286|Experimental|Part 1, one-arm open label pilot study|Part 1 is an open label, 1-arm pilot study to evaluate the systemic absorption and effects of multiple applications of a market-image topical sunscreen formulation containing BEMT (6%) under maximum use conditions in healthy adult subjects.
16346269|NCT04355273|Experimental|Heparin with a concentration of 2 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
16346270|NCT04355273|Experimental|Heparin with a concentration of 4 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
16346271|NCT04355273|Placebo Comparator|normal saline|normal saline is placed in a pressure bag with a pressure of 300 mmHg
16346272|NCT04355260|Experimental|Hypertrophic Obstructive Cardiomyopathy|
16346273|NCT04355247|Experimental|Single Arm|"Patients will be admitted to a regular room in the hospital (not ICU)
~They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.
~Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
16346274|NCT04355234|Experimental|all patients|
16346275|NCT04355234|Experimental|patients who presented a SARS-CoV-2 infection confirmed by PCR|
16346276|NCT04355221|Active Comparator|Group A|using the standard settings of pulsed radiofrequency technique (PRFT). two cycles, each one for 2 minutes at 45 Volts (V) with a pulse width of 10 milliseconds (ms) and a pulse frequency of 4 Hertz (Hz). The cut-off needle tip temperature is set at 420 Celsius (C).
16346277|NCT04355221|Experimental|Group B|using prolonged duration of PRFT. four cycles, each one for 2 minutes at 45V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
16346278|NCT04355221|Experimental|Group C|using higher voltage PRFT.. two cycles, each one for 2 minutes at 60V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
16346279|NCT04355208|Experimental|Intervention|Restoration of anterior teeth using monochromatic layering technique using body shade (filtek universal from 3m
16346453|NCT04353986|Experimental|Beta thalassemia|HCV infected Beta thalassemia major adolescents
16346286|NCT04355169|Placebo Comparator|Placebo|Participants will receive matching placebo BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
16346287|NCT04355156|Experimental|Axitinib|small molecule multi-kinase inhibitor
16346288|NCT04355156|Placebo Comparator|Placebo|
16346289|NCT04355143|Experimental|Colchicine plus current care|Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians
16346290|NCT04355143|Active Comparator|Current care alone|Current care per UCLA physicians alone (control arm)
16346292|NCT04355104|Experimental|Education+standard physical therapy|Consist of 37 patients will take education sessions in addition to standard physical therapy.
16346293|NCT04355104|Active Comparator|Standard physical therapy|Consist of 37 patients take just standard physical therapy.
16346294|NCT04355091|Experimental|Intervention Group|"The pregnant women in this group will be informed about the application of EFT with a written material.
~The pregnant women who have undergone EFT will be interviewed a week or two after the application, and how they feel and whether the problem still disturbs him. If a new issue is reported, similar actions will be repeated for this new issue. The number of EFT sessions was decided based on the condition of the pregnant woman. After all EFT sessions are completed, a re-evaluation (post-test) of Edinburgh Postpartum Depression Scale, Stress Coping Scale and State-Trait Anxiety Inventory will be done.
~The same participants will be asked to apply the other inventories and the postpartum interview form if she had birth three months and six months after the last application (follow-up). In the follow-up study performed three months after the last application, EFT will be applied to the pregnant women in need."
16346295|NCT04355091|No Intervention|control group|"The participants in this group will be talked about the problems they should have in routine midwifery care, the problems they encounter during pregnancy or postpartum period and the subjects they want to receive information.
~If necessary, suggestions will be made for problems related to pregnancy, postpartum period or newborn care. Again, with these participants, after the depression risk determination (pre-test), after the interviews ended (post-test), three months and six months after the last application, Edinburgh Postpar All Depression Scale, Stressful Life Events List, Stress Coping Scale. If the pregnant woman has given birth, State-Trait Anxiety Inventory and postnatal interview form will be performed."
16346296|NCT04355078|Experimental|Neuromuscular Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks. The involved leg is used if nothing else is stated that includes Walking on a treadmill, Squatting exercises, Single leg stance exercise Balance reach leg and arm exercises, Lunge exercises: anterior, lateral and posterior, Step-up and step down exercises, Single leg standing on balance mat, appropriate knee and hip position, Backwards and sideways walking for 5 steps on each side 1, 1 leg and 2 leg Wobble board Exercise and progress after every two weeks
16346297|NCT04355078|Experimental|Strength Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks that includes straight leg raising exercises, Supine position-isometric quadriceps contraction, Supine position-knee flexion and extension ROM exercises, the heel in contact with the bench during the ROM, Prone position-straight leg raising exercises, Prone position-knee flexion & Extension ROM exercises, Stationary biking-before reaching 100 degrees of flexion(Progression: stair climbing and strength exercises), Standing-full weight-bearing, controlled balance double-limb support during parallel and diagonal stance, controlled knee extension, emphasis on full knee extension in weight-bearing position 3 10 reps Standing heel rising exercises both legs and one leg, 1 leg and 2 leg Wobble board Exercise, Step Up and down low height, Squatting exercises without bars/weight, Hamstrings, hip adductor and abductor strengthening exercises and progress after every two weeks
16346298|NCT04355065|Experimental|Cognitive Training with Virtual Reality Videogame|"The Secret trail of mon is a therapeutic video game that has been created for the cognitive training of patients with ADHD.
~Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: attention, memory, reasoning, planning and visuospatial ability.
~Patients have to go to the hospital once a week for training sessions of approximately forty minutes duration during 12 weeks."
16346299|NCT04355065|Experimental|Cognitive Training with Therapeutic chess|"The training in Therapeutic chess consists of four sections:
~Video tutorial: Weekly videos have been recorded in which a chess board and the image of the psychologist explaining the lesson appear. Each week a chess concept will be explained.
~Traditional chess exercises Therapeutic chess exercises: The exercises use the elements of chess but it is not necessary to know how to play chess to perform them. The purpose of the exercise is to work on a specific cognitive area each week.
~Playing online games: The patient must play a minimum of 2 online games on the chess platform chess24.es . The psychologist will follow the progress of each patient.
~At the end of the week, the patient should send an email to the psychologist with the completed exercises and then they will receive a personalised email. This group carries out all the treatment online from their home."
16346300|NCT04355065|Active Comparator|Control Group|This group corresponds to the control group. The control group continues with their prescribed pharmacological treatment without any cognitive intervention. The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects.
16346301|NCT04355052|Active Comparator|A - HCQ + AZT|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
16346302|NCT04355052|Experimental|B - HCQ + CAM|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Camostat mesylat 200 mg TID for 10 days
16346303|NCT04355052|No Intervention|C - NI|No Intervention
16346304|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 50 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
16346305|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 65 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
16346306|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 80 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
16346307|NCT04355026|Experimental|hydroxychloroquine and bromhexine|Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID
16346308|NCT04355026|Active Comparator|hydroxychloroquine alone|hydroxychloroquine 200 mg BID
16346309|NCT04355000|Active Comparator|Hall Technique|In Hall Technique, SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
16346310|NCT04355000|Active Comparator|RMGIC restoration|In RMGIC(Vitremer) filling, carious lesion will be completely removed from primary molars using air rotor and local anaesthesia according to need and filled with vitremer rmgic material.
16346311|NCT04354987|Experimental|Group A|R+R+T+T Period 1 : R Period 2 : R Period 3 : T Period 4 : T
16346312|NCT04354987|Experimental|Group B|R+T+R+T Period 1 : R Period 2 : T Period 3 : R Period 4 : T
16346313|NCT04354987|Experimental|Group C|T+R+T+R Period 1 : T Period 2 : R Period 3 : T Period 4 : R
16346314|NCT04354987|Experimental|Group D|T+T+R+R Period 1 : T Period 2 : T Period 3 : R Period 4 : R
16346315|NCT04354974|Active Comparator|Eco Program (Ecological Cognitive Training for Mood Disorders)|"Duration: four months, 16 sessions
~Frequency: One one-hour session and one hour of personal work per week
~Modalities: Paper and pencil exercises and manipulable tools
~Objective: Learning problem-solving strategies for use in daily life
~Modules: Psychoeducation, Information Processing, Memory, Concept Formation, Functional Disorders"
16346316|NCT04354974|Active Comparator|ThOR Program (Remission Oriented Therapy)|"Duration: four months, 16 sessions
~Frequency: One one-hour session and one hour of personal work per week
~Modalities: Paper tools and verbal exchange with the patient
~Objective: Improvement of the patient's quality of life
~Themes: Mood, social skills, autonomy, motivation, sleep"
16346317|NCT04354961|Experimental|Almonertinib 110mg PO once daily|
16346318|NCT04354961|Active Comparator|Paclitaxel (175mg/m2, iv) and carboplatin (AUC=5, iv)|
16346319|NCT04354948|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 3 min wall squat exercise
16346320|NCT04354948|Placebo Comparator|No pain (Hypotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 3 min wall squat exercise
16346321|NCT04354935|Active Comparator|Méthode 1 ( iTBS)|target region: Dorsolateral Prefrontal left Fréquence : 50 Hz Intensity of the stimulation : 120% SM duration : 3 minutes Number of pulses : 600
16346322|NCT04354935|Active Comparator|Méthode 2 (French touch)|target region : dorsolateral prefrontal cortex right Frequency:1HZ Intensity:120% SM duration : 8 Min 30 Sec Number of plulses : 360
16346323|NCT04354935|Active Comparator|Méthode 3 (FDA)|target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM duration : 37 minutes Number of pulses : 3000
16346324|NCT04354922|Placebo Comparator|Attention control|Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period
16346325|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
16346326|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
16346327|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
16346328|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
16346329|NCT04354909||Biological samples|levels of s-CD95-L (ELISA test)
16346330|NCT04354896|Experimental|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.
16346331|NCT04354896|Placebo Comparator|Placebo|Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
16346332|NCT04354883|Active Comparator|Schmitz-Hinkelbein-Method|
16346333|NCT04354883|Active Comparator|Hinkelbein-Schmitz-Method|
16346334|NCT04354870|Experimental|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
16346335|NCT04354870|No Intervention|Control Group|approximately 50 HCW who choose not to be provided HCQ
16346336|NCT04354857||RT-PCR SARS-CoV-2 positive|
16346337|NCT04354857||RT-PCR SARS-CoV-2 negative|
16346338|NCT04354844||Cyanotic and acyanotic group|questinnaire
16346339|NCT04354831|Experimental|ICU Cohort|Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
16346340|NCT04354831|Experimental|Non-ICU Cohort|Patients who are NOT in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
16346341|NCT04354818||People living with HIV|
16346342|NCT04354818||Recipients of Solid Organ Transplants|
16346343|NCT04354818||People Living with Cancer|
16346344|NCT04354818||People with acquired immunodeficiency|Patients with acquired immunodeficiency associated with other immunosuppressive therapy.
16346345|NCT04354818||People with primary immunodeficiency|
16346346|NCT04354805|Experimental|Group A|The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
16346347|NCT04354805|No Intervention|Group B|A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
16346348|NCT04354779||AUVA HCW|health care workers in Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA)
16346349|NCT04354766||Convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary.
16346350|NCT04354766||Hospitalized convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization.
16346454|NCT04353986|Active Comparator|Control|HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group
16346351|NCT04354740||Group A : Diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
16346352|NCT04354740||Group B: Non diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
16346353|NCT04354727|Experimental|APG-1252|
16346354|NCT04354727|Experimental|APG-1252 + Ruxolitinib|
16346355|NCT04354714|Experimental|Ruxolitinib|-Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.
16346356|NCT04354688|Experimental|T3 Certain Tapered implant with DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
16346357|NCT04354688|Active Comparator|T3 Certain Tapered implant without DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
16346358|NCT04354675|Experimental|Artificial intelligence program|Will complete consult with the use of an artificial intelligence program Chatbot.
16346359|NCT04354675|Active Comparator|in-person genetic counseling|Will complete a traditional in-person genetic counseling. consult by meeting with a Genetics Counselor
16346360|NCT04354662|Experimental|Toripalimab combined with FLOT|In the perioperative period, patients with resectable gastric cancer is treated with flot regimen combined with Toripalimab to observe whether the 3-year disease-free survival (DFS) rate, pathological remission rate, R0 resection rate, D2 radical resection rate, 5-year DFS rate and 5-year OS rate could be improved.
16346363|NCT04354636|Experimental|Silver modified atraumatic restorative treatment|Using silver diamine fluoride incorporated with atraumatic restorative treatment
16346364|NCT04354636|Active Comparator|Atraumatic restorative treatment|Using atraumatic restorative treatment without the application of silver diamine fluoride
16346365|NCT04354623||High Risk Subjects (n=50)|All subjects will be recruited from falls and geriatrics clinics at Vancouver General Hospital. These clinics see about 2500 patients per year and are currently used for research recruitment. Each clinic patient has gait speed measured, which will allow to recruit both high and low risk fallers. This test will allow us to recruit 50 subjects at marked risk for falls, providing us with prospectively gathered dataset of greater than 100 events, five times higher than any other sensor study.
16346366|NCT04354623||Low Risk Subjects (n=50)|We will use newspaper advertisements to recruit and then screen low risk subjects. All subjects will have a gait speed > 0.8 m/s and have had no falls in the last year.
16346367|NCT04354610|Other|Patients hospitalized for Covid-19 infection|"Patients hospitalized for Covid-19 infection will undergo the following evaluations:
~Clinical examination
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
16346370|NCT04354571|Experimental|GROUP (Erector spinae block):|were given general anesthesia plus Erector spinae plane block
16346371|NCT04354571|Active Comparator|GROUP (caudal block):|were given general anesthesia plus caudal block
16346372|NCT04354558||survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
16346373|NCT04354558||non-survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
16346374|NCT04354545||Group 1|Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
16346375|NCT04354532||209 patients were submitted to primary LBSG|All patients submitted to primary Laparoscopic Banded Sleeve Gastrectomy were examined. Collected data included demographic factors, pre-operative weight, pre-operative BMI, operative time, surgical complications, and clinical outcomes in terms of short and mid-term weight loss.
16346376|NCT04354519||Confirmed Cases|"Diagnosed by health professional / Covid-19 test
~Monitored through fortnightly questionnaires"
16346377|NCT04354519||Not Covid-19 cases|"Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.
~non Covid Cases can become COVID cases through self report."
16346378|NCT04354519||Suspected Covid-19 Cases|"Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.
~Fortnighly questionnaire"
16346379|NCT04354493|Experimental|Baseline and Training|This group consists of a baseline and training conditions only.
16346380|NCT04354493|Experimental|Baseline, Training, and Control|This group stops training condition sooner and returns to a control to evaluate carry-over effects.
16346381|NCT04354480|Experimental|RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
16346382|NCT04354480|Placebo Comparator|Placebo|Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
16346383|NCT04354467||Acute Kidney Injury due to Nephrotoxic medication|
16346384|NCT04354467||No Acute Kidney Injury due to Nephrotoxic Medications|
16346385|NCT04354454|Active Comparator|Fitbit|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit only group.
~-- Participants will track their daily steps for 4.5 months with use of a Fitbit
~The study interventions involved in this research are:
~Fitbit (also known as a wearable accelerometer or fitness tracker)
~Way to Health platform
~Surveys/Interviews"
16346490|NCT04353778|No Intervention|Healthy Controls|Healthy controls who do not have HIV
16346386|NCT04354454|Experimental|Fitbit + Game + Support from a Teammate|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit + Game + Support from a Teammate.
~Participants will select a step goal, use a Fitbit to track daily activity, and select a teammate (e.g. family member or friend) who they think will help them achieve their goals.
~Participants will participate a 3-month game designed to increase activity and then followed for another 1.5 months to see if their increased activity can be maintained without the game.
~The study interventions involved in this research are:
~Fitbit (also known as a wearable accelerometer or fitness tracker)
~Help from a Teammate (i.e. friend or family member chosen to help reach goals, if applicable
~Way to Health Platform
~Surveys/Interviews"
16346387|NCT04354441|Experimental|hydroxychloroquine|10-day course of hydroxychloroquine 200 mg tablet twice a day. To be taken orally.
16346388|NCT04354441|Placebo Comparator|Placebo|An identical appearing placebo. To be taken orally twice a day for 10-days.
16346389|NCT04354428|Placebo Comparator|Ascorbic acid and Folic acid|Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
16346390|NCT04354428|Experimental|Hydroxychloroquine and Folic Acid|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5])
16346391|NCT04354428|Experimental|Hydroxychloroquine and Azithromycin|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
16346392|NCT04354428|Experimental|Lopinavir-ritonavir|LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
16346393|NCT04354428|Placebo Comparator|Ascorbic acid|Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days
16346394|NCT04354415|Active Comparator|Tourniquet Group|Tourniquet application during procedures
16346395|NCT04354415|Experimental|Non-Tourniquet group|No application of tourniquet for procedures
16346396|NCT04354389|Experimental|DAS181 b.i.d.+ standard local care for COVID-19|4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19
16346397|NCT04354389|Placebo Comparator|Placebo+ standard local care for COVID-19|nebulized inhalation for 10 consecutive days + standard local care for COVID-19
16346398|NCT04354389|Experimental|DAS181 q.d.+ standard local care for COVID-19|4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19
16346399|NCT04354376||Loop diuretics, thiazides, dihydropyridines|Reference group
16346400|NCT04354376||Telmisartan|Exposure group
16346401|NCT04354363|Active Comparator|PRP|women who will receive PRP before ICSI
16346402|NCT04354363|No Intervention|No PRP|women who willnot receive PRP before ICSI
16346403|NCT04354350||Ramipril|Reference group
16346404|NCT04354350||Telmisartan|Exposure group
16346405|NCT04354337|Experimental|Intervention Group|8-weeks online program with weekly modules for parents to learn about specific sleep topics and implement behavioral changes to improve their child's sleep.
16346406|NCT04354324|Experimental|The test group|Oral administration of 30mci once on an empty stomach.
16346407|NCT04354324|Active Comparator|The control group|Oral administration of 100mci once on an empty stomach.
16346408|NCT04354311|Experimental|Experimental|"Anesthetic induction : total target-controlled intravenous anesthesia d was used with propofol and remifentanil. The effect site was then gradually increased to obtain a satisfaction depth of anesthesia. Assisted ventilation was then started by facemask ventilation (Sat O2>95% and expired CO2 fraction normal, tidal volume of 8 mL/kg, a respiratory rate of 12 cycles per minute, with an FiO2 100% with no positive end expiratory pressure.
~After stabilisation period of 2 minutes and record of the patient's parameters, a standardized nociceptive stimulation was applied at the level of the ulnar nerve (PTC of 50 Hz at 70 mA). The variation of ANI score and hemodynamic parameters were collected during the 2 following minutes.
~After stabilization of ANI, orotracheal intubation was attempted. Maximal variation of heart rate (HR), blood pressure and the occurrence of somatic manifestations (intense cough, movement, tears) were recorded."
16346409|NCT04354298|Experimental|Fall 2019 ID Class|The ID group participated in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2019-December 2019.
16346410|NCT04354298|Experimental|Fall 2020 ID Class|The ID group will participate in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2020-December 2020.
16346411|NCT04354298|No Intervention|Control Group|Participants are pre- and post-tested 12-14 weeks apart after not having changed anything drastic in their daily life.
16346412|NCT04354272||Questionnaire|
16346413|NCT04354259|Experimental|Ambulatory Cohort - Treatment|to receive a single dose of peginterferon lambda 180µg SC at baseline (day 0).
16346414|NCT04354259|Placebo Comparator|Ambulatory Cohort - placebo|Patients in the arm will be given a single injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
16346415|NCT04354259|Experimental|Hospitalized Cohort - Treatment|To receive a dose of peginterferon lambda 180µg SC at baseline and a second dose on day 5.
16346416|NCT04354259|Placebo Comparator|Hospitalized Cohort - placebo|Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 5.
16346417|NCT04354246|Experimental|COM902 monotherapy dose escalation.|Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
16346491|NCT04353778|Active Comparator|Pyridostigmine|PLWH on pyridostigmine 30mg PO TID
16346492|NCT04353778|Placebo Comparator|Placebo|PLWH on placebo
16346418|NCT04354246|Experimental|Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).|COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.
16346419|NCT04354246|Experimental|COM902 monotherapy cohort expansion at RDFE.|COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
16346420|NCT04354246|Experimental|COM902 + COM701 combination cohort expansion both at RDFE.|COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
16346421|NCT04354233|Experimental|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
16346422|NCT04354233|No Intervention|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
16346423|NCT04354220||no shunt, no lung injury|ventilated newborns / infants / children with healthy lungs and without or corrected congenital heart disease and no intra-/extra-cardiac shunt
16346424|NCT04354220||mild lung injury|ventilated newborns / infants / children with mild lung injury (OI between 4 and 8)
16346425|NCT04354220||moderate-severe lung injury|ventilated newborns / infants / children with moderate or severe lung injury (OI above 8)
16346426|NCT04354220||shunt lesion|ventilated newborns / infants / children with cyanotic heart diseases and therefore existing intra-cardiac or extra- cardiac right-left shunt lesions
16346427|NCT04354207||Atopic dermatitis|
16346428|NCT04354207||Asthma|
16346429|NCT04354207||Healthy individuals|
16346430|NCT04354194|Experimental|Conventional Physiotherapy Group|This group will receive 15 sessions of conventional physiotherapy programme 5 times per week.
16346431|NCT04354194|Experimental|Osteopathic Manipulative Treatment Group|This group will receive 9 sessions of Osteopathic Manipulative Treatment programme 3 times per week.
16346432|NCT04354168|Experimental|Nthabi mHealth Application|Twenty women from each of the ten district hospitals will be recruited for a total of 200 participants. Each district hospital will have a separate administrative page on the Nthabi server where women will be enrolled with a unique username and password. Upon enrollment, the women will be asked to engage with Nthabi for two months to discuss the relevant content areas they are interested in learning more about.
16346433|NCT04354155|Experimental|Thromboprophylaxis|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 mg/kg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
16346434|NCT04354142|Experimental|iSpy|In addition to usual care, participants in the intervention group will receive the iSpy intervention.
16346435|NCT04354142|No Intervention|Control|The control group participants will continue to use their usual method of carbohydrate counting for a 3-month period.
16346436|NCT04354129||PID/SID Cutaquig Treated Patients|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
16346437|NCT04354116|Experimental|MARPE|Maxillary expander anchored in mini-implants (MARPE)
16346438|NCT04354116|Active Comparator|Hyrax|Tooth-born anchored maxillary expanders, without mini-implants
16346439|NCT04354090|Experimental|Cohort 0.3-mg|Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort
16346440|NCT04354090|Experimental|Cohort 0.7-mg|Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22
16346441|NCT04354090|Experimental|Cohort 1.5-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22
16346442|NCT04354090|Experimental|Cohort 3.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22
16346443|NCT04354090|Experimental|Cohort 6.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30
16346444|NCT04354077|Experimental|NAc DBS|Subjects will receive bilateral DBS of the NAc
16346445|NCT04354064||Healthy Donor Samples|"Donation of blood and/or urine samples as often as bi-monthly and as many as 24 times in total
~These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise."
16346446|NCT04354064||Samples from Repository and Banking Studies|"Healthy prostate and/or blood and/or urine samples from Genitourinary Repository
~Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies
~Tissue and/or blood samples from Esophageal Repository
~Tissue and/or blood samples from Genitourinary Repository
~Tissue and/or plasma from Sarcoma Tissue Bank
~Tissue and/or plasma from Breast Cancer Bank
~Tissue, plasma, and/or urine from GI Tissue and Blood Bank
~Tissue, blood, and/or urine from Solid Tumor Bank
~Tissue, blood, and/or urine from Lung Cancer Bank
~Tissue and/or blood from Skin Cancer Bank"
16346447|NCT04354051|Experimental|Sodium nitrite|
16346448|NCT04354025|Experimental|Recipient: FLAG + CIML NK Cells + IL-2|-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
16346449|NCT04354025|Other|Donor:|-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
16346450|NCT04354012|Experimental|Treatment|methylene blue, gentian violet, and ovine forestomach wound dressings to HS lesions
16346451|NCT04353999|Experimental|980 nm diode laser photocoagulation|980 nm diode laser was used to coagulate the blood over the bone graft particles and achieve a socket seal after socket grafting
16346452|NCT04353999|Active Comparator|Dense polytetrafluroethylene membrane|dPTFE membrane was used to seal the socket after grafting
16346459|NCT04353960||anticholinergic|Patients who receive anticholinergic medication before strabismus surgery
16346460|NCT04353960||non-anticholinergic|Patients who do not received anticholinergic medication before strabismus surgery
16346461|NCT04353947||Healthy older adults|Healthy older adults with 65 years or older
16346462|NCT04353947||Older adults with Alzheimer's disease|Older adults with Alzheimer's disease with 65 years or older
16346463|NCT04353947||Older adults with Parkinson's disease|Older adults with Alzheimer's disease with 65 years or older
16346464|NCT04353934||Respondents|All adults aged 18 or older who elect to respond to the online survey
16346465|NCT04353921||Single-Dose of Psilocybin|
16346466|NCT04353921||Niacin-Control|
16346467|NCT04353908|Active Comparator|kabat|Rehabilitation will be started in both groups of patients and it will be carried out according to Kabat et al., i.e. a proprioceptive neuromuscular facilitation procedure, twice a week for 8 weeks, by an experienced physioptherapist
16346468|NCT04353908|Experimental|collagen injection|Injections of an equally-balanced solution of MD Neural, MD Matrix and MD Muscle (Guna S.p.a., Milan-Italy), containing collagen of porcine origin, will be administered subcutaneously after applying lidocaine/prilocaine cream on the affected side, by a skilled otonaryngologist in the field of injection treatments, twice a week for 8 weeks
16346469|NCT04353895|Experimental|Robotic group (RG)|Patients in the RG group will be operated using the assistance of the Mazor X Stealth robot
16346470|NCT04353895|Active Comparator|O-arm navigation group (NV)|Patients in the NV group will be operated using the guidance of the Stealth navigation
16346471|NCT04353882||patients with tumor recurrence|
16346472|NCT04353882||patients with-out tumor recurrence|
16346473|NCT04353869||Group 1|"Patients with uncomplicated diabetes and low cardiovascular risk
~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
16346474|NCT04353869||Group 2|"Patients with uncomplicated diabetes and high cardiovascular risk
~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
16346475|NCT04353869||Group 3|"Patients with complicated diabetes
~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
16346476|NCT04353869||Group 4|"Patients without diabetes and with a high cardiovascular risk
~Practical implementation During a scheduled hospitalization or consultation as part of the follow-up of their cardiological problems, additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
16346477|NCT04353869||Group 5|"Patients without diabetes and with a history of cardiovascular event
~Practical implementation During a scheduled hospitalization or consultation as part of the follow-up of their cardiological problems, additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
16346478|NCT04353856||twin pregnancy|Women followed for a twin pregnancy
16346479|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939|Participants will be treated with escalating doses of IBI939 to determine the MTD.
16346480|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab|Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.
16346481|NCT04353830|Experimental|Phase Ib Expansion Stage:IBI939+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.
16346482|NCT04353817|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA in the morning and IVA in the evening.
16346483|NCT04353817|Placebo Comparator|Placebo|Subjects will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
16346486|NCT04353791|Active Comparator|Experimental arm OST-122 low dose|12 subjects will be randomized to receive low dose OST-122 orally daily for 28 days
16346487|NCT04353791|Active Comparator|Experimental arm OST-122 high dose|12 subjects will be randomized to receive high dose OST-122 orally daily for 28 days
16346488|NCT04353791|Placebo Comparator|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
16346489|NCT04353778|No Intervention|PLWH|People living with HIV (HIV)
16346496|NCT04353739|Experimental|Immediate Treatment (IT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
16346497|NCT04353739|Active Comparator|Delay Treatment (DT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
16346498|NCT04353726|Experimental|Intervention group|Eligible participants will be in an intervention group led by a registered dietitian
16346499|NCT04353713|Experimental|Dextrose Gel|"Dextrose 40% gel will be given immediately following stabilization at birth via massage into the buccal membrane. This will be prior to transport from the Delivery Room to the Neonatal Unit.
~A dose of 1 ml of gel (Dextrose) will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.
~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.
~A total dose of 0.5 ml of gel (Dextrose) will be administered to infants born less than or equal to 29+0 weeks gestation.
~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of administering person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
16346500|NCT04353713|Placebo Comparator|Placebo|"2% carboxymethylcellulose gel will be given following stabilization at birth via buccal route. This will be prior to in-house transport from the Delivery Room to the Neonatal Unit.
~A standard total dose of 1 ml of placebo gel will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.
~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.
~A total dose of 0.5 ml of gel (Placebo) will be administered to infants born less than or equal to 29+0 weeks gestation.
~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
16346501|NCT04353700|Active Comparator|Yoga group|A certified yoga instructor led the supervised yoga session. An exercise physiologist taught how to record your Rating of Perceived Exertion to monitor their exercise intensity during the in-home yoga intervention. During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks.
16346502|NCT04353700|No Intervention|Control group|If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
16346503|NCT04353687||Cohort 1 Open Surgeons|Primarily open inguinal hernia surgeon with no or limited previous robotic-assisted experience.
16346504|NCT04353687||Cohort 2 Laparoscopic Surgeons|Primarily laparoscopic inguinal hernia surgeon with no or limited previous robotic-assisted experience.
16346505|NCT04353674|Sham Comparator|Control|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo standard of care
16346506|NCT04353674|Active Comparator|SLEDD with a L-MOD|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
16346507|NCT04353661|Experimental|Arm A Open-label: azithromycin + SOC therapy|Participants will receive azithromycin and SOC theraphy for 52 weeks.
16346508|NCT04353661|Active Comparator|Arm A Open-label: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
16346509|NCT04353661|Active Comparator|Arm B Observational: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
16346511|NCT04353635||Patients with class III dentofacial deformity|No intervention as it will be a retrospective study
16346512|NCT04353622|Active Comparator|Robot-assisted Treatment|Rehabilitation protocol was applied with robotic device (HOUSTONBIONİCS ExoRehab UE1).
16346513|NCT04353622|Active Comparator|Conventional Physiotherapy|Conventional physiotherapy program included neurophysiological approaches.
16346514|NCT04353596|Experimental|Stopping/replacing ACEI/ARB|Chronic treatment with ACEI or ARB will be stopped or replaced.
16346515|NCT04353596|No Intervention|Control|No intervention, which means further treatment with ACEI or ARB.
16346516|NCT04353583||ICU patients|Patients with COVID-19 requiring ICU care
16346517|NCT04353583||Non-ICU patients|In-hospital patients with COVID-19 not requiring ICU care
16346518|NCT04353544|Active Comparator|Immediate cord clamping|Immediate cord clamping was defined as clampingwithin 15 seconds of birth
16346519|NCT04353544|Experimental|delayed cord clamping|when the cord stopped pulsing, or five minutes
16346520|NCT04353518|Experimental|Suspension of Mw|"Intradermal suspension of Mw will be administered in two divided doses:
~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal Mw in two divided dose.
~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal Mw administered."
16346521|NCT04353518|Placebo Comparator|Placebo|"Placebo will be administered in two divided doses:
~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal placebo in two divided dose.
~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal placebo."
16346522|NCT04353505|Experimental|Intra-Arterial Delivery of Ketorolac and Dexamethasone|
16346523|NCT04353492|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections every 4 weeks, following loading of 3 doses in the first 14 days
16346524|NCT04353479|Experimental|Camrelizumab(SHR-1210) Combined With Decitabine|Patients will be administered Camrelizumab(SHR-1210) at D1 and D15 and decitabine at D1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity.
16346525|NCT04353466|Experimental|Trial to asses impact of Elelyso on bone involvement in patien|The infusions will be administered at the selected medical center or in the home care setup. The dose of intravenous (IV) infusions of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months.
16346526|NCT04353427|Experimental|Faith based educational group|"A seven-session faith-based small group educational program using the The Seven Pathways to Healing, Health and Wellness curriculum will be delivered."
16346527|NCT04353414|Active Comparator|Pericapsular Injection (PCI) group|Subjects in PCI group will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
16346528|NCT04353414|Active Comparator|Transmuscular QL Block + Pericapsular Injection (PCI) group|Subjects in the TQLB group will receive the TQLB containing 30mL of 0.5% Bupivacaine Hydrochloride (HCL) plus PCI containing 20 mL of 0.25% of Bupivacaine Hydrochloride (HCL). For PCI, subjects will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
16346529|NCT04353388||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
16346530|NCT04353375|Experimental|HMPL-453|HMPL-453 150mg QD
16346531|NCT04353362|Experimental|Ofloxacin group|
16346532|NCT04353362|Active Comparator|Amoxicillin plus Metronidazole group|
16346533|NCT04353349||Patients operated with an open approach|
16346534|NCT04353349||Patients operated with minimally invasive robotic approach|
16346535|NCT04353349||Patients operated with VATS approach|
16346536|NCT04353336|Experimental|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine with standard of care treatment.
16346537|NCT04353336|No Intervention|No intervention|standard of care treatment alone.
16346538|NCT04353323||Covid area|
16346539|NCT04353323||Non-Covid area|
16346540|NCT04353310|Experimental|Curcumin|
16346541|NCT04353310|Placebo Comparator|Placebo|
16346542|NCT04353297|Experimental|BCI Group|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
16346543|NCT04353297|Active Comparator|Control Group|MI training without BCI support delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
16346544|NCT04353284|Experimental|Camostat mesylate|Camostat mesylate 200mg taken 7 days.
16346545|NCT04353284|Placebo Comparator|Placebo|Placebo taken for 7 days.
16346546|NCT04353271|Experimental|Treatment|Subjects in this arm will receive the study drug
16346547|NCT04353271|Placebo Comparator|Control|Subjects in this arm will take placebo for 6 days
16346548|NCT04353258|Experimental|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
16346549|NCT04353258|Active Comparator|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
16346550|NCT04353245||Arm treatment (HCQ + Azithro)|Participants that used HCQ + Azithro in their treatment for COVID19
16346551|NCT04353245||Arm control (without HCQ + Azithro)|Participants that did not used HCQ + Azithro in their treatment for COVID19
16346552|NCT04353232||DANCAVAS I and II trials|Enrolment started September 2014 and ended in February 2019. Approx. 24 000 were invited, and approx. 15 000 were examined.
16346553|NCT04353232||VIVA screening trial|Enrolment started October 2008 and ended January 2011. In all, 18 749 men were screened.
16346554|NCT04353219|Experimental|research group|training program with compression stocking
16346555|NCT04353219|Active Comparator|control group|training program without compression stocking
16346556|NCT04353206|Experimental|Intubated COVID-19 patients in the ICU|Mechanically ventilated intubated patients with respiratory failure due to COVID-19
16346557|NCT04353193|Experimental|Terlipressin IV bolus|Terlipressin 1mg IV bolus
16346558|NCT04353193|Experimental|Terlipressin IV continuous infusion|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
16346559|NCT04353193|Experimental|Octreotide IV bolus plus continuous infusion|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
16346560|NCT04353180|Active Comparator|13 cis retinoic acid doses orally plus the standard therapy|Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
16346561|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid plus the standard therapy|Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
16346562|NCT04353180|Active Comparator|13 cis retinoic acid doses orally|Infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
16346563|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
16346564|NCT04353180|Sham Comparator|The standard therapy|Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days
16346565|NCT04353141||Pregnant patients with confirmed COVID-19 infection|
16346566|NCT04353141||Pregnant patients symptomatic for COVID-19|Symptomatic patients suspicious for COVID-19 infection (swab is taken on admission)
16346567|NCT04353141||Pregnant patients asymptomatic for COVID19|Patients asymptomatic for COVID19 with other feto-maternal diseases or who come for delivery or caesarean section
16346568|NCT04353128|Experimental|Melatonin|2 mg of melatonin orally before bedtime for 12 weeks
16346569|NCT04353128|Placebo Comparator|Placebo|Identically looking placebo orally before bedtime for 12 weeks
16346570|NCT04353115||Training with Serious Game|Trained group, 5 weeks training with the serious game; patients have a vestibular impairment.
16346571|NCT04353102|Experimental|YH002|All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.
16346572|NCT04353089||Basic Life Support Participants|All persons attending certified Basic Life Support Courses in Denmark from 2016 to 2019
16346573|NCT04353089||OHCA|Out-of-hospital cardiac arrest victims in Denmark from mid 2016 til mid 2019
16346574|NCT04353076|Experimental|Young adults|Young adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
16346575|NCT04353076|Experimental|Older adults (no cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
16346576|NCT04353076|Experimental|Older adults (cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity) with ambient cooling intervention (i.e., exposure to an air-conditioned room) for hours 5-6.
16346577|NCT04353063|No Intervention|control group|"The patients in the control group will not receive any walking exercise education until the 4-week intervention ends. They will then receive the same education material (How walking is beneficial to your health) and will be told about the benefits of walking."
16346578|NCT04353063|Experimental|experimental group|"Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials How walking is beneficial to muscle mass and your health. And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4."
16346579|NCT04353050|No Intervention|Cohort 1 (retrospective)|Only data from medical records and formalin-fixed paraffin-embedded tissue blocks will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
16346580|NCT04353050|No Intervention|Cohort 2 (retrospective)|Only data from medical records, formalin-fixed paraffin-embedded tissue blocks and cytologic slides will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
16346581|NCT04353050|Other|Cohort 3 (prospective)|Patients with pigmented lesions on the skin or mucosa who are referred for excisional biopsy will be offered to apply investigated non-invasive adhesive system on their lesion just before the excisional biopsy. After biopsy cytological slides and FFPE tissue blocks will be prepared. All three types of obtained samples will be investigated separately (adhesive patches, cytologic slides and FFPE tissue blocks) for genetic markers whereas cytologic slides and FFPE tissue blocks will be processed also routinely and regular cytologic and histopathologic report will be generated.
16346584|NCT04353024|Placebo Comparator|Placebo|Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.
16346585|NCT04353024|Experimental|Low dose|Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.
16346586|NCT04353024|Experimental|Low dose with bolus|Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.
16346587|NCT04353024|Experimental|High dose|Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.
16346588|NCT04353024|Experimental|High dose with bolus|Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.
16346589|NCT04353011||patient with chronic painful|
16346590|NCT04352998|Active Comparator|One dose pre-workout supplement condition|One dose/serving of a multi-ingredient pre-workout supplement was administered to the subjects.
16346591|NCT04352998|Active Comparator|Two dose pre-workout supplement condition|Two doses/servings of a multi-ingredient pre-workout supplement was administered to the subjects.
16346592|NCT04352998|Placebo Comparator|Placebo condition|One dose/serving of a placebo was administered to the subjects.
16346593|NCT04352972|Active Comparator|Hospital-based rehabilitation program|
16346594|NCT04352972|Experimental|Tele-monitored home exercise program|
16346595|NCT04352959|Active Comparator|mouth rinse with antiviral|
16346596|NCT04352959|Placebo Comparator|mouth rinse without antiviral|
16346597|NCT04352946|Experimental|Hydrocholoroquine Pre-exposure prophylaxis|HCQ will be administered as 400mg orally once for 60 days.
16346598|NCT04352946|Placebo Comparator|Placebo|Placebo will be administered as 400mg orally once for 60 days.
16346599|NCT04352933|Active Comparator|Hydroxychloroquine - Daily dosing|"Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days.
~Route: Oral. Pharmaceutical form: Tablet"
16346600|NCT04352933|Active Comparator|Hydroxychloroquine - Weekly dosing|"Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days.
~Route: Oral. Pharmaceutical form: Tablet"
16346601|NCT04352933|Placebo Comparator|Placebo|"Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days.
~Route: Oral. Pharmaceutical form: Tablet"
16346602|NCT04352920|Experimental|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
16346603|NCT04352894|Experimental|fluorescence guided peritoneal exploration|Indocyanine green (ICG) intravenous injection and peritoneal exploration with technology able to detect fluorescence generated by ICG
16346604|NCT04352868|Active Comparator|Toric soft contact lens|Toric soft contact lens
16346605|NCT04352868|Experimental|Multifocal toric soft contact lens|A multifocal toric soft contact lens with a +2.00 D add.
16346606|NCT04352855||C/T|C/T cases: individuals fulfilling eligibility criteria and treated with ceftolozane-tazobactam
16346607|NCT04352855||C|C cases: individuals fulfilling eligibility criteria and treated with colomycine
16346608|NCT04352842||Non-survivors|Patients deceased during the study period
16346609|NCT04352842||Survivors|Patients survived during the study period
16346610|NCT04352829|Experimental|EXPERİMENTAL GROUP|1st day, patients were asked to use an MDI sample that didn't contain an active agent. At the same time, they filled the MDI Skill Evaluation Form, obtaining 'the scores of the 1st measurement'. Next, MDI use was explained through the video twice. After each video and explanation, the patients were asked to use the same MDI sample for 10 min. Simultaneously, the skills were marked by the researcher through observation on the form, obtaining 'the scores of the 2nd measurement'. 2nd day, they were again asked to use the MDI. While using the MDI, the form was marked and 'the scores of the 3rd measurement' were found. Later, a video session was held as on the 1st day, the video was watched twice, and after each repetition, were requested to use the MDI again. While they were using the MDI, the skills were simultaneously marked on the form and 'the scores of the 4th measurement were determined. 3rd day, all steps were repeated.
16346611|NCT04352829|No Intervention|CONTROL GROUP|20 patients were recruited to the control group. The controls received a routine training on MDI from their clinic nurses including verbal explanation of MDI use. The controls received training about MDI use in line with ethical principles and watched the video once after the 5th measurement. After the study, participants who wished to watch the training video again were provided internet links.
16346612|NCT04352816|Experimental|Control Group|Participants who do not receive an ICD therapy and have normal Echocardiogram findings and no evidence of arrhythmia will form this group. These participants will receive an MCG scan in addition to their standard care plan We will record the findings of any/all investigations participants receive as per their standard care plan, such as imaging providing left ventricular ejection fraction and usual care blood tests although their research activity/involvement in the trial will cease after the baseline observation. There will be no follow up. We aim to recruit 210 participants to this group to match the anticipated size of the group who receive an ICD but don't receive a shock.
16346613|NCT04352816|Experimental|Observation group|The participants who go on to receive an ICD therapy, as part of standard care, will constitute the 'Observation' group. These participants will undergo an MCG, lying and standing blood pressure and undertake a quality of life questionnaire. Participants in this group will undergo additional blood tests, circulating vascular biomarkers such as (High sensitivity Troponin, Nt pro BNP, CRP, High sensitivity CRP, mRNA, IL-6). All scans and tests that are conducted as part of standard care for evaluation of requirement of ICD implantation will be collected, for example; Echocardiographic, CMRI or MUGA measurements of the heart chambers and function. We will record these findings as this will enable us to substratify patients according to different degrees of cardiac dysfunction
16346614|NCT04352816|Experimental|Device in situ group|"To achieve the secondary objectives of exploring whether features consistent with arrhythmogenesis are extractable from MCG scans on participants with ICDS and pacemakers in situ, the investigators will recruit an additional 30 participants separate from the main trial. Twenty participants will be recruited from the ICD clinic. These participants, who have already had an ICD implanted will be selected with a 50:50 split as to whether they have had previous therapy from the ICD. The presence of an ICD can impact the analysis of MCGs in these patients due to the background signal noise subtraction required to obtain a usable signal. We will use these scans to trial different signal noise reduction strategies. These will be analysed to determine whether the features seen in the main trial can be extracted from this data set.
~10 participants will be recruited who have got an upgrade from a pacemaker to an ICD."
16346615|NCT04352803|Experimental|Autologous Adipose Derived Mesenchymal Cells|Conventional treatment plus MSC's IV
16346616|NCT04352803|No Intervention|Untreated|Conventional treatment only
16346617|NCT04352777|Active Comparator|Cohort 1|Fulvestrant plus abemaciclib
16346618|NCT04352777|Active Comparator|Cohort 2|Aromatase inhibitor plus abemaciclib (with or without ovarian suppression)
16346619|NCT04352751|Experimental|Single Arm|"Intervention: Convalescent plasma (Frozen Solution for infusion) obtained from COVID-19 recovered patients.
~The dosage depends upon the clinical situation and underlying disorder. Children: 15 ml/kg over 4-6 hours once in patients under 35 kg body weight. Adults: maximum 450 - 500 ml over 4-6 hours once in all adults patients."
16346620|NCT04352738||Healthy adults (group I)|
16346621|NCT04352738||Adults with type 1 diabetes (group II)|"T1D for ≥2 years or evidence of undetectable C-peptide (<100pmol/l with concomitant plasma glucose≥4.0mmol/l).
~HbA1c≤8.0mmol/l (64mmol/mol)."
16346622|NCT04352738||Adults after bariatric surgery (group III)|"Female.
~Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) ≥1 year ago.
~Lack of a history of diabetes or pre-diabetes (HbA1c≤5.6% in the absence of anaemia)."
16346623|NCT04352725|Experimental|experimental procedure|"end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat<28cmH2o
~incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
16346624|NCT04352712||Healthy Children|healthy children, untreated, donors of monocytes
16346625|NCT04352712||GHD children|GHD children, untreated, donors of monocytes
16346626|NCT04352699||Naive patients|Group of naive patients who have undergone elective or emergency surgery during the study period
16346627|NCT04352686|Active Comparator|Buspirone|Buspirone 20 mg per oral
16346628|NCT04352686|Placebo Comparator|Placebo|Placebo
16346629|NCT04352673||Healthy individuals|Healthy students 18 years and older
16346630|NCT04352660|Active Comparator|Injection group|MMC delivered by preoperative subconjunctival injection
16346631|NCT04352660|Active Comparator|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
16346632|NCT04352647||female athletes over the age of 18|the presence or absence of urinary incontinence in female athletes is studied. In addition, the quality of life and other aspects are evaluated
16346633|NCT04352634||Healthcare workers|Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)
16346634|NCT04352621|Experimental|Ketamine plus rTMS|Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.
16346635|NCT04352608|Experimental|Emergency schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule
16346636|NCT04352608|Experimental|Emergency schedule & Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule
16346637|NCT04352608|Placebo Comparator|Emergency schedule &Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule
16346638|NCT04352608|Experimental|Routine schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule
16346639|NCT04352608|Experimental|Routine schedule &Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule
16346640|NCT04352608|Placebo Comparator|Routine schedule & Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule
16346641|NCT04352608|Experimental|Emergency schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
16346642|NCT04352608|Experimental|Emergency schedule & Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
16346643|NCT04352608|Placebo Comparator|Emergency schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule
16346644|NCT04352608|Experimental|Routine schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
16346645|NCT04352608|Experimental|Routine schedule &Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
16346646|NCT04352608|Placebo Comparator|Routine schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule
16346647|NCT04352595|Experimental|1% Hemay808|
16346648|NCT04352595|Experimental|3% Hemay808|
16346649|NCT04352595|Experimental|7% Hemay808|
16346650|NCT04352595|Placebo Comparator|vehicle|
16346651|NCT04352582||1|Survey respondants
16346654|NCT04352543|Experimental|Older adults group|Group of older adults >60 years old.
16346655|NCT04352530|Active Comparator|Rewind the Future|Fear appeal, video message to reduce sugar consumption or risk death
16346656|NCT04352530|Experimental|Hear No|"Video of spoken word poem from The Bigger Picture project, Hear No by Joshua Merchant; images of African-American male poet interspersed with images of environment"
16346657|NCT04352530|Experimental|The Longest Mile|"Video of spoken word poem from The Bigger Picture Project, The Longest Mile by Tassiana Willis; images of African-American female poet interspersed with images of environment"
16346658|NCT04352530|Experimental|A Taste of Home|"Video of spoken word poem from The Bigger Picture Project, A Taste of Home by Monica Mendoza; images of Hispanic female poet interspersed with images of environment"
16346659|NCT04352530|Experimental|Lost in Translation|"Video of spoken word poem from The Bigger Picture Project, Lost in Translation by Yosimar Reyes; images of Hispanic male poet interspersed with images of environment"
16346660|NCT04352530|Experimental|Bottled Up|"Video of spoken word poem from The Bigger Picture Project, Bottled Up by Eileen Torrez; images of Hispanic female poet interspersed with images of environment"
16346661|NCT04352530|Experimental|The Corner|"Video of spoken word poem from The Bigger Picture Project, The Corner by Jose Vadi; images of Hispanic male poet interspersed with images of environment"
16346662|NCT04352530|Experimental|Thin Line|"Video of spoken word poem from The Bigger Picture Project, Thin Line by Ivori Holson; images of African-American female poet interspersed with images of environment"
16346663|NCT04352504|Experimental|Almonds|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
16346664|NCT04352504|Active Comparator|Pretzels|Consume 2 oz. serving pretzels (216 calories) daily for 12 weeks
16346665|NCT04352491||Patients with liver disease|All people who have shown at Institute of Liver and Biliary Sciences (1st January 2018 - 31st March 2020), will be sent the SMS for participation.
16346666|NCT04352478||Elder|elderly (≥60 years old).
16346667|NCT04352478||Young|young (<60 years old)
16346668|NCT04352465|Experimental|A|Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
16346669|NCT04352465|Experimental|B|Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
16346670|NCT04352465|Experimental|C|Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
16346671|NCT04352452||RALS|Surgeons perform robot-assisted laparoscopic surgery
16346672|NCT04352452||CLS|Surgeons perform conventional laparoscopic surgery
16346673|NCT04352439|Experimental|Aspirin|Patients with a Khorana risk score of 1 receive 81 mg aspirin daily while receiving neoadjuvant chemotherapy for ovarian cancer.
16346674|NCT04352413|Experimental|Cohort A: PLM60|20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle
16346675|NCT04352413|Experimental|Cohort B: PLM60|15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle
16346676|NCT04352400|Active Comparator|Nafamostat|Nafamostat mesylate on top of best standard of care.
16346677|NCT04352400|Placebo Comparator|Placebo|Placebo on top of best standard of care.
16346678|NCT04352387|Experimental|Montessori Method for Dementia|The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
16346679|NCT04352387|Active Comparator|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
16346680|NCT04352374|Experimental|Aerobic exercise group|"The therapist advised all participants of this group to drink a plenty of water before and after the exercise session to avoid excessive loss of body water during the session. Pregnant women were instructed to have a light meal about one hour before the performance of exercise and to wear comfortable clothes.
~Participants in this group were given a Low-Intensity Aerobic Exercise with Borg scale RPE at 11. Participants were asked to maintain this intensity of rate of perceived exertion throughout the 45 minutes' duration of the aerobic training.
~During the training session, the therapist stood near the patient to observe and detect signs of stopping the exercise. The therapist continuously asked the patient if she felt pain, dizzy or shortens of breath.
~No complications were observed during physical exercise sessions, for example, hypertensive crisis, hypotension, hyperthermia, musculoskeletal lesions, or other complications identified that demanded interruption of the exercise."
16346681|NCT04352374|Active Comparator|Device guided breathing group|"At the beginning the researcher explained the device and study procedures to every participant of this group .The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
~The participant is instructed to alter their breathing rate, aiming for up to 10 breaths per minute, in response to a melody played to them via the asked to use the device for at least 40 min per week, with each session lasting at least 10 min"
16346682|NCT04352361|Experimental|TVB-2640 tablets|
16346683|NCT04352361|Placebo Comparator|placebo|
16346684|NCT04352348|Other|COVID-19 negative|Patients with exclusion diagnosis for COVID-19 infection
16346685|NCT04352348|Other|COVID-19 positive, not severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and not requiring hospitalization
16346686|NCT04352348|Other|COVID-19 positive, severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and requiring hospitalization
16346687|NCT04352348|Other|Follow-up after COVID-19 hospitalization|"Patients previously hospitalized for COVID-19 infection but not recruited for the study can be recruited during a follow-up visit in hospital scheduled in standard care at 3 to 6 months after the hospitalization.
~For this arm, T0 = 3 to 6 months post-COVID-19 follow-up visit"
16346688|NCT04352335||Cohort 1：ICI treatment with immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
16346689|NCT04352335||Cohort 2：ICI treatment without immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs).
16346690|NCT04352322|Experimental|A+HA(tm)|20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
16346691|NCT04352322|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
16346692|NCT04352309||Participants Treated With Glecaprevir/Pibrentasvir (GLE/PIB)|Participants will receive GLE/PIB over 8 weeks of therapy as prescribed by their physicians.
16346693|NCT04352296|Experimental|Experimental group|Individualized BP management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit.
16346694|NCT04352296|Active Comparator|Control group|Standard BP management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure <140 mm Hg, and treatment of hypertension defined by a systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
16346695|NCT04352283|No Intervention|palpation|Usual method to determinate needle puncture site
16346696|NCT04352283|Experimental|Ultrasound|Ultrasound preprocedural exam used to determinate needle puncture site
16346697|NCT04352270|Active Comparator|Group 1- Printed educational materials|Parent-child dyads randomized to this group will receive printed educational materials in English or Spanish about atopic dermatitis.
16346698|NCT04352270|Experimental|Group 2- Educational videos|Parent-child dyads randomized to this group will receive an investigator developed educational video in English or Spanish about atopic dermatitis.
16346699|NCT04352257||ultrasonography|pelvic and transrectal ultrasound
16346700|NCT04352244||Surgical Participants|Individuals undergoing abdominal surgery or radiologically-guided biopsies for clinical indications will be recruited prior to the planned procedures.
16346701|NCT04352231|Experimental|High to Low Fiber Diet Intervention|Participants receive the high fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the low fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
16346702|NCT04352231|Experimental|Low to High Fiber Diet Intervention|Participants receive the low fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the high fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
16346703|NCT04352218|Active Comparator|PTA Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty of internal jugular vein non-thrombotic stenosis in patients with chronic headache
16346704|NCT04352218|Experimental|"PTA + Stenting using Petalo stent"|Percutaneous Transluminal Angioplasty + Stenting of internal jugular vein non-thrombotic stenosis in patients with chronic headache
16346705|NCT04352205|Experimental|Treatment (daratumumab-based treatment)|Patients receive daratumumab IV weekly of cycles 1-3 and on day 1 only of cycle 4, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV or PO on days 1-4 of cycle 1 and on day 1 of cycles 2-4 and PO on days 8 and 15 of all cycles. Beginning cycle 2, patients may also receive lenalidomide PO daily on days 1-14 or thalidomide PO QD on days 1-21. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16346706|NCT04352192|Experimental|Kinesiotaping Group|The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
16346707|NCT04352192|No Intervention|Control Group|The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
16346708|NCT04352179|Experimental|Virtual Education Simulation|All participants will have access to the virtual education simulations.
16346709|NCT04352166|Experimental|extended-release buprenorphine (BXR)|Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
16346710|NCT04352166|Active Comparator|sublingual buprenorphine (BSL)|sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
16346711|NCT04352153|Experimental|Single-use group|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
16346712|NCT04352153|Experimental|Research group|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
16346717|NCT04352114|Experimental|LY3461767 - Subcutaneous (SC)|LY3461767 administered SC.
16346718|NCT04352114|Placebo Comparator|Placebo - SC|Placebo administered SC.
16346719|NCT04352114|Experimental|LY3461767 - Intravenous (IV)|LY3461767 administered IV.
16346720|NCT04352101|Experimental|Bupropion|Participants randomized to take bupropion for 8 weeks.
16346721|NCT04352101|Active Comparator|Escitalopram|Participants randomized to take escitalopram for 8 weeks.
16346722|NCT04352088||Allergic rhinitis patients|
16346723|NCT04352088||Allergic rhinitis and asthma patients|
16346724|NCT04352088||Healthy individuals|
16346725|NCT04352075|Experimental|Microfat + PRP 3M platelets|microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
16346726|NCT04352075|Experimental|Microfat + PRP 1M platelets|microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
16346727|NCT04352075|Experimental|Microfat|microfat (5 ml) and saline solution (5 ml)
16346728|NCT04352062|Experimental|Treatment Group|Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
16346729|NCT04352062|Placebo Comparator|Placebo|1 tablet twice daily (period 6 months)
16346730|NCT04352062|Other|Helicobacter pylori infected group|Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
16346731|NCT04352049|Active Comparator|3TV group|Patients were randomly assigned to receive either three minutes tidal volume (3TV) with a fresh gas flow (FGF 100% O2) via facemask of 5 L/min
16346732|NCT04352049|Active Comparator|8DB group|Or eight vital capacity breaths for 1 minute with FGF of 10 L/min
16346733|NCT04352036||patient|
16346734|NCT04352023|Experimental|A (IV-PCA group)|IV-PCA drug: Fentanyl 3000 mcg and Oxycodone 100 mg were mixed Normal saline 200 ml
16346735|NCT04352023|Experimental|B (PCEA group)|"PCEA drug: Morphine 5 mg and Ropivacaine 750 mg were mixed Normal saline 400 ml
~loading of preadministered Morphine 1 mg and Ropivacaine 11.25 mg"
16346736|NCT04352010|Experimental|"Online-Intervention Res-Up!"|Participants in the Res-Up! group get access to Res-Up! while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
16346737|NCT04352010|Experimental|"Online-Intervention REMOTION"|Participants in the REMOTION group get access to REMOTION while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
16346941|NCT04350684|Active Comparator|Control|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
16346738|NCT04352010|Experimental|Wait-control group|Participants in the wait-control group will not get access to the online-tools while waiting for psychotherapy or while in psychotherapy. Participants will answer questionnaires after inclusion, six weeks later and twelve weeks later.They get access to one of the online-tools after 12 weeks.
16346739|NCT04351997|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
16346740|NCT04351997|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth,
16346741|NCT04351984||Severe Mitral Regurgitation|
16346742|NCT04351971|Experimental|Intervention Group|The dorsal sliding technique C0-C1 will be applied to this group.
16346743|NCT04351971|Sham Comparator|Placebo group|A placebo dorsal mobilization technique will be applied
16346744|NCT04351958|Experimental|"Augmented Reality (No Time Wasted)"|
16346745|NCT04351945||Blood test|Patients will have a blood test to define hormone levels.
16346746|NCT04351932|Active Comparator|bone marrow mesenchymal stem cell|Bone marrow mesenchymal stem cells 10 cc by intra articular injection once
16346747|NCT04351932|Active Comparator|adipose mesenchymal stem cells|Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once
16346748|NCT04351932|Active Comparator|Bone marrow and Adipose mesenchymal stem cells|Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.
16346749|NCT04351919|Experimental|HCQ Arm|
16346750|NCT04351906|Other|ECCO2R|ECCO2R in patients with mild to moderate ARDS with/without AKI requiring dialysis.
16346751|NCT04351880|Active Comparator|Meals - 2 weeks|Receive meal delivery for 2 weeks (1 meal per day for a total of 14 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
16346752|NCT04351880|Active Comparator|Meals - 4 weeks|Receive meal delivery for 4 weeks (1 meal per day for a total of 28 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
16346753|NCT04351867|Experimental|experimental group|docetaxel plus oxaliplatin and capecitabine
16346754|NCT04351867|Active Comparator|control group|oxaliplatin plus capecitabine
16346755|NCT04351854||Patients with SARS-CoV-2-infection|Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED
16346756|NCT04351854||Control group|Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
16346757|NCT04351841|Placebo Comparator|control|15 g maltodextrin per day consumed in the morning
16346758|NCT04351841|Experimental|Active|15 g arabinogalactan per day consumed in the morning
16346759|NCT04351828||Celiac patients compliant to gluten-free diet (GFD)|People with celiac disease who compliant to gluten-free diet (GFD) when they accepted in the study
16346760|NCT04351828||Celiac patients non-compliant to gluten-free diet(NGFD)|People with celiac disease who noncompliant to the gluten-free diet (NGFD) group when they accepted in the study
16346761|NCT04351815|Experimental|Short prehabilitation|This arm will benefit from a 2 weeks prehabilitation program including a personalized dietetic and physical training program as well as psychological support.
16346762|NCT04351815|Other|No prehabilitation|This arm will not benefit from a prehabilitation program before surgery. Patients will be told to maintain a regular physical activity without support.
16346763|NCT04351789|Experimental|Intervention Group|Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. The intervention is based on psychoeducational theory and consists of both written and verbal information. A manual describing the content and procedures of the intervention will be developed to ensure that the intervention is both replicable and transparent. The intervention has a planned duration of 30 minutes and will be conducted by a designated study affiliated researcher, who has a background in healthcare (i.e. nurse or medical doctor).
16346764|NCT04351789|No Intervention|Control Group|Standard of Care at discharge of patients with COVID-19 from hospital is to inform the patients whom to contact in case of worsening of the physical condition, such as increasing e.g. shortness of breath, and of precautions regarding further isolation to avoid infection of household and other contacts, if relevant. Information regarding the patient´s psychological condition is not part of a standard conversation at discharge.
16346765|NCT04351776|Other|VR-Biofeedback|
16346766|NCT04351776|Other|VR-Distraction|
16346767|NCT04351776|Other|360 Video|
16346768|NCT04351763|Experimental|Amiodarone|"Amiodarone - administered intravenously
~Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.
~Oral administration
~200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge."
16346769|NCT04351763|Experimental|Verapamil|"Verapamil - administered intravenously
~Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.
~Oral administration
~120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge."
16346770|NCT04351763|No Intervention|Usual Care|
16346853|NCT04351308|Experimental|MAPI+camrelizumab|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);
~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;
~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);
~camralizumab = 200mg ivgtt. Q2W;"
16346774|NCT04351737|Experimental|Pterygium patients|patients with bilateral pterytium
16346775|NCT04351724|Experimental|(Hydroxy)Chloroquine (STOPPED)|"Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.
~Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available"
16346776|NCT04351724|Experimental|Lopinavir/Ritonavir|Dosage: 200mg/50mg 4-0-4 on day 1 and 3-0-3 thereafter
16346777|NCT04351724|Other|Standard of Care|"patients will be treated with standard of care, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine"
16346778|NCT04351724|Experimental|Rivaroxaban|5mg 1-0-1
16346779|NCT04351724|Active Comparator|Thromboprophylaxis|according to local standard
16346780|NCT04351724|Experimental|RAS Blockade|Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients > 120/80 mmHG are eligible
16346781|NCT04351724|Active Comparator|non-RAS-Blockade|non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment
16346782|NCT04351724|Experimental|Asunercept 25mg|25mg 1x per week, maximum of four doses only patients with oxygen requirement
16346783|NCT04351724|Experimental|Asunercept 100mg|100mg 1x per week, maximum of four doses only patients with oxygen requirement
16346784|NCT04351724|Experimental|Asunercept 400mg|400mg 1x per week, maximum of four doses only patients with oxygen requirement
16346785|NCT04351724|Other|Best Standard of Care - Control Group for Asunercept|only patients with oxygen requirement
16346786|NCT04351724|Experimental|Remdesivir|200mg loading dose on day 1, 100mg for a total treatment duration of 5-10 days
16346787|NCT04351724|Experimental|Pentaglobin|Patients treated at the intensive care unit only, continuous infusion of 7ml/kg/day over 12h for 5 days
16346788|NCT04351724|Other|best standard of care|Patients treated at the intensive care unit only
16346789|NCT04351711||Patients SARS-CoV-2 with respiratory failure|Patients in intensive care
16346790|NCT04351711||Patients SARS-CoV-2 without respiratory failure|Patients hospitalized in normal hospital wards
16346791|NCT04351711||HEALTHY VOLUNTEERS|HEALTHY VOLUNTEERS
16346792|NCT04351711||NON-COVID-19 PATIENTS|Patient hospitalized at the CHU of Nîmes for an infection by a virus other than SARS-CoV-2
16346793|NCT04351711||PAUCISYMPTOMATIC SARS-COV-2+ PATIENTS|Patient positive for SARS-CoV-2 by RT-PCR at the CHU of Nîmes and presenting at most moderate clinical signs without respiratory insufficiency (O2 saturation greater than or equal to 96%) during the confinement period
16346794|NCT04351711||convalescent patients|Additional 1-year follow-up visit
16346795|NCT04351698|Active Comparator|Investigation|Montelukast
16346796|NCT04351698|Placebo Comparator|Match Placebo|Matched Placebo
16346799|NCT04351672|Experimental|Early Time-Restricted Feeding|
16346800|NCT04351672|Experimental|Late Time-Restricted Feeding|
16346801|NCT04351659||Blood donors|Donors who had tested positive for SARS-CoV-2 in the past and have recovered from COVID-19 and are now suitable for blood donation.
16346802|NCT04351646||SARS-CoV-2 negative inpatients|Hospitalised adult patients with SARS-CoV-2 negative tests.
16346803|NCT04351646||SARS-CoV-2 positive inpatients|Hospitalised adult patients with SARS-CoV-2 positive tests.
16346804|NCT04351646||SARS-CoV-2 suspected or confirmed NHS staff|Suspected or proven SARS-CoV-2 positive cases amongst health care professionals and lab staff.
16346805|NCT04351633||osteoporosis patient|
16346806|NCT04351620|Experimental|Hydroxychloroquine|"Hydroxychloroquine 1200 mg daily administered as 600 mg BID for five days or until fevers abate (maximum ten days of treatment allowed).
~If patients report gastrointestinal discomfort, the dose will be administered as 400 mg TID."
16346807|NCT04351607|Experimental|Verum|oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand
16346808|NCT04351607|No Intervention|Control group|no intervention
16346809|NCT04351607|Other|Patient with menstral bleeding - subcollective A|verum or control
16346810|NCT04351607|Other|Patient without menstral bleeding - subcollective B|verum or control
16346811|NCT04351594|Experimental|Topical analgesia (+Menthol)|Biofreeze Topical Gel with active ingredient (Menthol 4%)
16346812|NCT04351594|Placebo Comparator|Topical analgesia (-Menthol)|Biofreeze Topical Gel with no active ingredient (Menthol 0%)
16346813|NCT04351581|Experimental|A: COVID+ Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.
16346814|NCT04351581|Experimental|B: Covid+ Discontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
16346815|NCT04351581|Experimental|C: COVID% Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose.
16346938|NCT04350697||Mini-Sternotomy|Patients underwent aortic surgery by Mini-Sternotomy
16346816|NCT04351581|Experimental|D: COVID% DIscontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during the study period clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during the study period. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
16346817|NCT04351568||medical personel|
16346818|NCT04351568||non medical personel|
16346819|NCT04351555|Placebo Comparator|Arm 1: Placebo with platinum-based chemotherapy|Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
16346820|NCT04351555|Experimental|Arm 2: Osimertinib with platinum-based chemotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
16346821|NCT04351555|Experimental|Arm 3: Osimertinib monotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
16346822|NCT04351542|Experimental|Ayurveda Care Group|Individualised ayurveda treatment was given to participants based on individual constitution.
16346823|NCT04351542|Active Comparator|Usual Care Group|Participants followed the usual care.
16346824|NCT04351516|Experimental|hydroxychloroquine|
16346825|NCT04351516|Placebo Comparator|Placebo|
16346826|NCT04351503||SARSCoV-infected patients (cases)|
16346827|NCT04351503||non-SARS-CoV-2 infected patients (control)|non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
16346828|NCT04351490|Experimental|Group supplementation|
16346829|NCT04351490|No Intervention|Group usual treatment|
16346830|NCT04351477|Experimental|Massage chair group|Use mechanical massage chair for 20 minutes/1 session, 3 sessions/week, for 3 weeks
16346831|NCT04351477|No Intervention|Control|No use of mechanical massage chair for 3 weeks
16346832|NCT04351464|Active Comparator|Physical therapy and Reflexology group|Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
16346833|NCT04351464|Experimental|Just Physical therapy group|The group received a 45-minute physical therapy program involving NDT approaches as the control group. Within the scope of this program, the children were treated with intramuscular stretching and soft tissue mobilization, exercises that improved balance and that supported the development of postural control, position shifts, and stretching and reinforcement exercises in the necessary muscle groups.
16346834|NCT04351438||Centrifuge TPE with citrate|These participants were undergoing centrifuge TPE using citrate anticoagulant
16346835|NCT04351438||Filter TPE with heparin|These participants were undergoing filter TPE using filter-based heparin anticoagulant
16346836|NCT04351438||Filter TPE with citrate|These participants were undergoing filter TPE using filter-based citrate anticoagulant
16346837|NCT04351425|Experimental|study group|study group will be shifted from incubator to an unheated open cot a weight of 1400 grams
16346838|NCT04351425|Active Comparator|control group|control group will be shifted from incubator to an unheated open cot at a weight of 1600 grams
16346839|NCT04351412|Active Comparator|Tactile stimulus|The tactile stimulus was examined using an explorer (# 17/23), passing at a right angle to the bucco-cervical tooth surface of concern. Contributors evaluated participants' pain score on a 10-point visual analogue scale (VAS). The stimulus was used to assess dentine hypersensitivity at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
16346840|NCT04351412|Active Comparator|Air blast stimulus|For air blast stimuli, air was delivered by a three-way syringe from a typical dental unit air syringe at 40 psi (± 10 psi) and 70 °F (± 5 °F). The air flow was aimed at the tooth surface of concern, for 1 second, from a distance of 1 cm. The air blast stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for air blast stimuli at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
16346841|NCT04351412|Active Comparator|Cold stimulus|For cold hypersensitivity assessment, the tooth was isolated using cotton rolls; then, a few drops of extremely cold water were delivered to the tooth from a syringe that had previously been cooled. The cold stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for cold stimulus at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
16346842|NCT04351399||patient with chronic painful inflammatory rheumatism|
16346843|NCT04351386||Atrial Fibrillation (AF)|Patients diagnosed with AF during reference ECG
16346844|NCT04351386||Normal Sinus Rhythm (NSR)|Patients with NSR during reference ECG
16346845|NCT04351386||Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
16346847|NCT04351347|Experimental|Ivermectin|Ivermectin alone in larger doses
16346848|NCT04351347|No Intervention|Standard treatment|Standard of care treatment
16346849|NCT04351334||Patients with ALK-positive NSCLC|
16346850|NCT04351321|Experimental|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.
16346851|NCT04351321|Active Comparator|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.
16346852|NCT04351308|Experimental|API+apatinib|"AP = Doxorubicin (Adriamycin) 20 mg/m2/day * 2 day (total/cycle 40 mg/m²)
~+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);
~I = Ifosfamide 2000 mg/m2/day *5 day (total/cycle 10000 mg/m²);
~apatinib = 500 mg QD;"
16346854|NCT04351308|Active Comparator|MAPI|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);
~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;
~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);"
16346855|NCT04351295|Experimental|Faviprevir|Faviprevir
16346856|NCT04351295|Active Comparator|chloroquine|chloroquine
16346857|NCT04351282|Experimental|SBRT|4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
16346858|NCT04351269||CanGaroo Envelope|Patients who received a CanGaroo envelope with their CIED implantation.
16346859|NCT04351269||Tyrx Envelope|Patients who received a Tyrx envelope with their CIED implantation.
16346860|NCT04351269||No Envelope|Patients who had their CIED implanted with no envelope.
16346861|NCT04351256|Experimental|Arm A (HYPO group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles
~Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)"
16346862|NCT04351256|Active Comparator|Arm B (CON group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles
~Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)"
16346863|NCT04351243|Experimental|Gimsilumab|Gimsilumab high dose on Day 1 Gimsilumab low dose on Day 8
16346864|NCT04351243|Placebo Comparator|Placebo|Normal saline on Day 1 Normal saline on Day 8
16346865|NCT04351230|Active Comparator|Arm A (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16346866|NCT04351230|Experimental|Arm B (trastuzumab emtansine, abemaciclib)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16346867|NCT04351217|Experimental|Music|Music was Indian Classical Flute music, 23 minutes long. It was played on a speaker at equal volume to ensure uniformity.
16346868|NCT04351217|Experimental|Progressive Muscle Relaxation|Progressive Muscle Relaxation was recorded for uniformity of delivery, and was 22 minutes in length. It was played on a speaker at equal volume to ensure uniformity.
16346869|NCT04351204|Other|MRL|radiotherapy on MR linac
16346870|NCT04351191|Active Comparator|HCQ Regular dose|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
16346871|NCT04351191|Experimental|HCQ Loading dose|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
16346872|NCT04351191|Active Comparator|CQ regular dose|Cholorquine 500 mg BID for 5 days plus standard of care
16346873|NCT04351191|Placebo Comparator|Placebo|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
16346874|NCT04351178|Experimental|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0)
16346875|NCT04351178|Active Comparator|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
16346876|NCT04351165|Experimental|Arm 1|"Period 1:
~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);
~Period 2:
~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);
~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
16346877|NCT04351165|Experimental|Arm 2|"Period 1:
~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);
~Period 2:
~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);
~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
16346878|NCT04351152|Experimental|Lenzilumab Arm|Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care
16346879|NCT04351152|Placebo Comparator|Placebo Arm|Participants will receive IV infusion of preservative-free 0.9% sodium chloride solution upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care
16346880|NCT04351139||gynecological cancer|Patients over 18 with gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned during the period of COVID-19 pandemic during 2020
16346881|NCT04351139||control group|Patients over 18 with gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned outside the period of COVID-19 pandemic, on the end of the year 2019
16346882|NCT04351126|Other|Control group|patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
16346883|NCT04351126|Experimental|treatment group|patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
16346884|NCT04351126|Experimental|prevention group|patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis
16346885|NCT04351113|Experimental|MITO-AO|Healthy older adult subjects ages 65-75 will take the supplement MITO-AO during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (31P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
16346886|NCT04351113|Experimental|PB-125|Healthy older adult subjects ages 65-75 will take the supplement PB-125 during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
16346939|NCT04350697||Mini-Thoracotomy|Patients underwent aortic surgery by Mini-Thoracotomy
16346887|NCT04351113|Placebo Comparator|Placebo|Healthy older adult subjects ages 65-75 will take placebo during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
16346888|NCT04351100||Diacerein group|Osteoarthritis and dry eye patients treated with Diacerein
16346889|NCT04351087|Active Comparator|Platelet Rich Plasma|157cc of whole blood will be harvested via standard venipuncture from the antecubital fossa and mixed with 24cc ACD-A (manufacturer recommends 8cc ACD-A per 52cc of whole blood). 156ml of whole blood will be processed in the FDA Cleared Angel cPRP system at 2% hematocrit. 1ml of whole blood and the resultant PRP will be analyzed in the Sysmex XN-350 for complete analysis (platelet, leukocyte, red blood cell counts). The remaining PRP will be injected under sterile technique using ultrasound-guidance through a superolateral approach. For patient comfort, 2cc of 1% lidocaine can be administered using a 26-gauge needle (into soft tissues only). PRP will then be injected using a 25-guage needle. A maximum of 6ml of PRP will be injected. Injection site will be cleaned and bandaged and patient will be dismissed with post-injection precautions and 1 month follow-up scheduled.
16346890|NCT04351087|Active Comparator|Microfragmented adipose tissue|Adipose is aspirated from the subcutaneous tissue of the buttock or abdomen. Aspiration site is injected with 10ml 1% lidocaine with epinephrine. A small poke incision is made with an 11-blade scalpel. Then 120ml of Klein solution is injected into the adipose tissue. Solution sits for 15 minutes to allow for adequate anesthesia. Aspiration cannula is inserted and moved in a back and forth motion for 2 minutes to allow for adipose aspiration. 30ml fat will be aspirated. Aspiration site is cleaned and bandaged. The aspirated fat is processed using the Lipogems system. 30ml of adipose is transferred to the device, saline is run through the device to remove oils and then approximately 5-7ml of adipose tissue is removed and ready for injection. The Microfragmented adipose tissue are then injected in identical fashion to the PRP above.
16346891|NCT04351074|Active Comparator|group A , LIFT|39 patients underwnt ligation of the intersphincteric track( LIFT) for treatment of transsphincteric fistula
16346892|NCT04351074|Active Comparator|group B fistulectomy|39 patients under went fistulectomy for treatment of transsphincteric fistula
16346893|NCT04351061|Experimental|Acetazolamide Arm|Participants in this arm will receive the Acetazolamide intervention for 7 consecutive days post standard of care endoscopic skull base surgery.
16346894|NCT04351048|Experimental|SW|stepwise excavation
16346895|NCT04351048|Experimental|OneS|one step excavation
16346896|NCT04351035||Children with CNS tumours|Patients newly diagnosed with CNS tumours in children younger than 18 y/o, who were under in-patient treatment, were labeled as candidate cases in the CNOG-MC001 cohort for reviewing.
16346897|NCT04351022|Experimental|CD38 positive relapsed or refractory acute myeloid leukemia|
16346898|NCT04351009|Experimental|Indocyanine green sentinel lymph node mapping|Indocyanine green dye is injected in the submucosa around the tumor to identify sentinel lymph nodes intra-operatively with near infrared fluorescence imaging.
16346899|NCT04350996||Continuous alcohol monitoring|Wearable BACtrack Skyn device
16346900|NCT04350970|Active Comparator|Control|The cardiopulmonary exercise test was performed with patient breathing room air.
16346901|NCT04350970|Active Comparator|NIV|The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
16346902|NCT04350970|Active Comparator|HFNT|The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
16346903|NCT04350957|Experimental|Low-dose Imaging|Enrolled patients will undergo two separate dynamic contrast-enhanced MRI's, one with 25% of the contrast dose and one with 100% of the contrast dose recommended by weight. During the first visit, the subject will receive 25% of the standard dose of contrast media 0.1 mM/kg will be administered at 2 mls/second followed by the acquisition of a series of DCE images. On the second visit, the subject will receive 100% of the contrast media followed by the same imaging protocol as the one subsequent to the first contrast administration.
16346904|NCT04350931|Active Comparator|BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds (In Egypt, the available BCG vaccine is the Copenhagen BCG vaccine - The Danish Strain 1331 of Mycobacterium Bovis). Each 0.10 mL vaccine contains 200000-800000 colony forming units.
16346905|NCT04350931|Placebo Comparator|intradermal normal saline|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds.
16346906|NCT04350918|Experimental|Muscle Energy Technique (MET)|MET Group received 12 treatment sessions of MET (Nagrale et al, 2010) two times a week in addition to conventional physiotherapy. The procedures employ voluntary muscle contractions by the patient in a precisely controlled direction and intensity against a counterforce applied by the Physiotherapist. The technique requires the therapist to provide stabilization to the segment on which the distal aspect of the muscle attaches. A command for anisometric contraction of the muscle is given that causes accessory movement of the joint. Several specific muscle energy techniques are described for the subcranial region of the cervical spine.
16346907|NCT04350918|Experimental|Static stretching (SS)|"Subjects in SS Group received 12 treatment sessions of static stretching (Dutton et al, 2008) two times a week in addition to conventional physiotherapy.
~Stretching involves the application of manual or mechanical force to elongate structures that have adaptively shortened and are hypo-mobile (Sullivan, 2007) Static stretching involves stretching a muscle to a point of discomfort and holding the stretch for a length of time, followed by a return to normal resting muscle length (Andrews et al, 2004). Muscles of the neck were stretched in especially in side flexion, extension, flexion and side rotation for 10 seconds and was repeated 10 times for a session."
16346908|NCT04350905|Experimental|Mosquito Feeding|Each participant will receive one mosquito feeding with 5 starved female Aedes aegypti mosquitoes.
16346909|NCT04350892|Active Comparator|Roux-en-Y Gastric Bypass Surgery|
16346910|NCT04350892|Active Comparator|Sleeve Gastrectomy Surgery|
16346911|NCT04350892|Active Comparator|Very Low Calorie Diet|
16346912|NCT04350879||Diabetic patients|Women between 18 and 40 years old with type 1 and type 2 diabetes
16346940|NCT04350684|Experimental|Umifenovir|Umifenovir + Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
16346913|NCT04350866||Pre-Implementation (0-, 6-, 12-, or 18-months)|Following training in BBTI, all sites (except site 1) will enter the pre-implementation phase for 6-, 12-, or 18-months. During this phase, sites will not receive any access to or support for the implementation strategies. They will deliver and implement BBTI as they see fit. Qualitative interviews will be conducted at the end of this phase.
16346914|NCT04350866||Implementation (12-months)|After the pre-implementation phase, all sites will enter a 12-month implementation phase (except site 1, which will begin implementation following BBTI training). During this phase, sites will receive access to and support for the bundle of implementation strategies, both from the hub site and their local champion/internal facilitator. During this phase, PCMHI clinicians trained in BBTI will receive feedback as necessary regarding their BBTI skills from their local champion/internal facilitator. During this phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
16346915|NCT04350866||Post-Implementation (6-months)|Following the 12-month implementation phase, each site will have access to and support for the implementation strategies removed and similar to the pre-implementation phase, will deliver and implement BBTI as they see fit. During this 6-month phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
16346916|NCT04350853|Experimental|Surgical extrusion group|Surgical extrusion is performed in each patient of this group
16346917|NCT04350840|Experimental|Feedback|Participating endoscopists will make high confidence diagnosis according to their judgment time
16346918|NCT04350827|Active Comparator|Platelet Rich Plasma|Procedure will be carried out with excellent sterile technique. 54ml of whole blood will be drawn. 54ml will be processed by centrifugation using the GPS III system (Zimmer Biomet, Warsaw, IN) and 1 ml will undergo a complete blood count (for a baseline comparison to determine the fold increase in platelets). The resultant PRP (5ml) will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) into the patellar tendon using ultrasound guidance to accurately direct the injection to the site of the tendon abnormality. The patient will rest after the injection for 15 minutes and then be dismissed.
16346919|NCT04350827|Active Comparator|Platelet Rich Plasma plus IGF|The PRP preparation and blood draw will be identical to the above. 55ml of whole blood will be drawn (1ml will undergo a CBC and the remaining 54ml will be used to make PRP). In addition to preparing the PRP, the resultant PPP (instead of discarding it) will be placed into the Plasmax device (Zimmer Biomet, Warsaw, IN) and concentrated via a second centrifugation cycle. The plasmax concentrate (concentrated IGF) will be added to the PRP (3ml of PRP + 2ml of plasmax concentrate for a total of 5ml) and then will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) under ultrasound guidance followed by the same rest period.
16346920|NCT04350814|Experimental|Self-Compassion Intervention Arm|Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.
16346921|NCT04350814|Active Comparator|Self-Reflection|Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.
16346922|NCT04350801||high risk MCI|MCI patients with amyloid beta positive (based on peripheral blood level)
16346923|NCT04350801||low risk MCI|MCI patients with amyloid beta negative (based on peripheral blood level)
16346924|NCT04350788|Placebo Comparator|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
16346925|NCT04350788|Experimental|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
16346926|NCT04350775|Experimental|RE-IADL group|Reablement
16346927|NCT04350775|Placebo Comparator|Control group|General community rehabilitation
16346928|NCT04350762|Experimental|Supplement + Fish Oil|"Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.
~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA)."
16346929|NCT04350762|No Intervention|Control|No dietary supplements. Participants will continue current intake.
16346930|NCT04350749|Experimental|Test group (PRF group)|PRF membrane is added to the bone block to evaluate if any effect on bone healing, soft healing, post-operativ pain
16346931|NCT04350749|Active Comparator|Control group (Standard operation)|A standard bone augmentation procedure, which is weel-described is performed to compare the outcome of the test group
16346932|NCT04350736|Experimental|TD-0903 for SAD (Part A)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
16346933|NCT04350736|Experimental|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
16346934|NCT04350736|Experimental|TD-0903 for MAD (Part B)|8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
16346935|NCT04350736|Experimental|Placebo for MAD (Part B)|2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
16346936|NCT04350723|Experimental|Intervention - Awake Proning|"The oxygen mask or NIPPV or HFNC will be initiated at the treating team's discretion. The patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating oxygen mask or NIPPV or HFNC treatment.
~Once the patient achieves the above parameters within 15 minutes of initiating oxygen therapy through any modality, the healthcare team will start awake proning."
16346937|NCT04350723|No Intervention|Control - Standard of Care|"The patient will receive usual care without proning at the discretion of the treating team.
~The oxygen mask or NIPPV or HFNC will be initiated, the choice of starting oxygen mask versus NIPPV versus HFNC will be up to the treating team, the patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating NIPPV or HFNC treatment."
16346942|NCT04350671|Experimental|Interferon-β 1a|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
16346943|NCT04350671|Active Comparator|Control|Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
16346944|NCT04350658||TAVR|all comers study including all transfemoral or transcarotid TAVR procédures. direct implantation is the default strategy usually used in our enter as in may centers
16346945|NCT04350645|Active Comparator|Tranexamic acid group|Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)
16346946|NCT04350645|Placebo Comparator|Control group|The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)
16346947|NCT04350619||Genetic study in retrospective and prospective groups|Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention
16346948|NCT04350606|Experimental|PF-006462700 group|All enrolled participants will be administrated PF-006462700.
16346949|NCT04350593|Active Comparator|Dapagliflozin 10mg|Dapagliflozin 10 mg daily
16346950|NCT04350593|Placebo Comparator|Placebo|Dapagliflozin matching placebo 10 mg daily
16346951|NCT04350580|Experimental|Intervention - IGIV|Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started before the 96th hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.
16346952|NCT04350580|Placebo Comparator|Placebo|Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.
16346953|NCT04350567|Experimental|Intervention|
16346954|NCT04350554||Retrospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 and who became pregnant during this period.
16346955|NCT04350554||Prospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 who will become pregnant during the year 2020 and who agree to participate in a telephone survey.
16346956|NCT04350541|Experimental|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
16346957|NCT04350541|Active Comparator|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
16346958|NCT04350528||Chlorpromazine|
16346959|NCT04350528||Pentobarbital|
16346960|NCT04350515|Experimental|Cyberball: Other Exclusion|Cyberball Paradigm - the avatar will be excluded by the player
16346961|NCT04350515|Experimental|Cyberball: Player Exclusion|Cyberball Paradigm - the player will be excluded by the other players
16346962|NCT04350502|Experimental|complicated pleural infection patients|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
16346963|NCT04350489||Control|Periodontally healthy group
16346964|NCT04350489||Periodontitis|Patients with periodontitis
16346965|NCT04350476|Other|Vital Connect Patch Arm|"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system:
~VitalConnect Vital Sign Patch (FDA approved for this indication)"
16346966|NCT04350463|Experimental|Arm A: SCLC in ICI naïve subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.
~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
16346967|NCT04350463|Experimental|Cohort B: SCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.
~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
16346968|NCT04350463|Experimental|Cohort C: sqNSCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.
~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
16346969|NCT04350450|Experimental|Treatment Group|Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
16346970|NCT04350450|No Intervention|Control Group|Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms
16346971|NCT04350437|Other|induction of labor monitoring|meticulous data collection from patients and plotting that data in a machine learning model
16346972|NCT04350424||Propofol Arm|Outpatients receiving anesthesiologist-administered propofol for elective outpatient endoscopic procedures
16346973|NCT04350424||Opioid / Benzodiazepine Arm|Outpatients receiving endoscopist-administered opioid / benzodiazepine for elective outpatient endoscopic procedures
16346974|NCT04350411|Experimental|Conventional diathermy|DIEP/ MS-TRAM breast reconstruction free flap raise performed with conventional diathermy
16346975|NCT04350411|Experimental|PEAK PlasmaBlade™|DIEP/ MS-TRAM breast reconstruction free flap raise performed with PEAK PlasmaBlade™
16346976|NCT04350398|Experimental|Hippotherapy treated group|"During the initial week of intervention, sessions will be mainly carried on horseback. We will use the movement of the horse: (i) to allow patient re-appropriating her body and find harmony; (ii) to initiate rehabilitation of movements (shoulder, neck, upper extremity, whole body), gesture and femininity. The goal is to reconstruct a harmonic body image both in the private and public sphere, through different techniques. A few walking sessions may be needed to reinforce some landmarks.
~During the short stages the work will be mainly done by walking alongside the horse. These reinforcement periods act like a trampoline, necessary to have a new momentum providing the opportunity to take a step back from the everyday, to regenerate somehow. The reaction time is generally optimized considering the imprint done during the initial long stage. One of the main themes that come up during this period is fear (relapse, the future, not achieving the goals, pain, relationship issues, etc.)."
16346977|NCT04350398|Placebo Comparator|Conventional therapy treated group|Patients in the control group are followed by dedicated personnel of the Montpellier Institut du Sein. This personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
16346978|NCT04350385|Experimental|Group 1|Agility Training
16346979|NCT04350385|Active Comparator|Group 2|.Conventional intervention
16346980|NCT04350372|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NT System
16346981|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 5 x week|"TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
~All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci."
16346982|NCT04350359|Active Comparator|Fixed-dose TTNS protocol|"Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes.
~Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week."
16346983|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
16346984|NCT04350346|Active Comparator|The patient group who taken Motilitone|
16346985|NCT04350346|Active Comparator|The patient group who taken Gasmotin|
16346986|NCT04350333|Experimental|CBT-I group|Five sessions composed of: psychoeducation on sleep change during pregnancy and postpartum; sleep hygiene principles; stimulus control technique, sleep restriction technique (f this technique will be too difficult for the participants to be apply, a replacement and less disabling technique will be applied: sleep compression); psychoeducation on the child's sleep at birth and on the change in the sleep-wake cycle in the early stages of the child's life; cognitive control technique; cognitive reconstruction technique and de-catastrophization; relapses prevention.
16346987|NCT04350333|Active Comparator|Assertive communication training|Five sessions composed of: psychoeducation and explanation of the importance of emotional and cognitive factors for good sleep. Psychoeducation about the concept of assertiveness, explanation of the passive, aggressive and assertive style; explanation and exercises regarding self-esteem and positive self-image; explanation of the development of sleep of the child in the first years of life; explanation and exercises on the phase of the management of feedback and requests; conflict management; relapses prevention.
16346988|NCT04350320|Experimental|COLCHICINE|"The colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 28 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.
~+ standard therapy for COVID-19 according to the stablished hospital protocols."
16346989|NCT04350320|Placebo Comparator|control group|Standard therapy for COVID-19 according to the stablished hospital protocols.
16346990|NCT04350307|Active Comparator|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
16346991|NCT04350307|Active Comparator|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
16346992|NCT04350294||Serious Mental Illness *RECRUITMENT IN THIS GROUP IS CLOSED|"Mothers with a serious mental illness*
~*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
16346993|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since February 2021
16346994|NCT04350281|Active Comparator|Treatment group|Subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3 and hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care
16346995|NCT04350281|Active Comparator|Control group|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care alone.
16346996|NCT04350255|Active Comparator|Trident II Hemispherical cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup
16346997|NCT04350255|Active Comparator|Trident II Tritanium cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup
16346998|NCT04350229|Experimental|EXPERIMENTAL GROUP|"In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
~Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg."
16346999|NCT04350229|Active Comparator|CONTROL GROUP|Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg and dexamethasone 10mg.
16347000|NCT04350216|Experimental|Sarilumab therapy|Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
16347001|NCT04350203||Intracorporeal Anatomosis (IA)|Laparoscopic Right colectomy with intracorporeal (IA) side-to-side isoperistaltic anastomosis
16347002|NCT04350203||Extracorporeal Anastomosis (EA)|Patients submitted to a Laparoscopic Right Colectomy with extracorporeal anastomosis (EA)
16347281|NCT04348201|Active Comparator|dietary modification|diet must be rich in vitamins.
16347003|NCT04350190|Experimental|Apatinib combined with PD-1|Eligible patients begin to use apatinib mesylate tablets and PD-1, apatinib mesylate tablets at the recommended dose of 250mg,oral, QD, continuous administration, 4 weeks (28 days) as an observation cycle. Until the disease progressed or unbearable adverse reactions appeared. If missed medication occurs during the medication period, it is confirmed that the next medication time is less than 12 hours, then there will be no replenishment. The recommended dose of PD-1 is 200mg/time, Q2W, intravenous injection, 4 weeks (28 days) as an observation cycle, until disease progression or intolerable toxicity.
16347006|NCT04350164||treatment|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
16347009|NCT04350125|Experimental|Platelet Rich Plasma Treatment|Male subjects diagnosed with Erectile Dysfunction (ED) will receive platelet rich plasma injections.
16347010|NCT04350086|Experimental|Experimental arm|
16347013|NCT04350060|Experimental|Intervention Group|Subjects with dementia will be living in a retro-fitted room with technological enhancements for a 12 month period.
16347014|NCT04350060|No Intervention|Standard of Care Group|
16347015|NCT04350047||Transabdominal inferior vena cava thrombectomy|Patients undergoing radical nephrectomy and inferior vena cava thrombectomy transabdominal without thoracotomy
16347016|NCT04350034|Experimental|Xbox training group|The study group received Xbox training plus routine physical therapy protocol treatment. The dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system (Xbox 360 Kinect console; Microsoft Inc., Redmond, Washington, USA).
16347017|NCT04350034|Placebo Comparator|Control group|patients participated in a routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
16347018|NCT04349995||Amplatzer PFO Occluder|Percutaneous PFO Closure using Amplatzer PFO occluder
16347019|NCT04349982||No cardiovascular risk|If no patients with no cardiovascular risk can be included in the study, we will divide the cohorts into different categories (e.g. low, medium and high cardiovascular risk).
16347020|NCT04349982||low cardiovascular risk|
16347021|NCT04349982||high cardiovascular risk|
16347022|NCT04349969|Experimental|Treatment|AK117 monotherapy
16347023|NCT04349956||Patients from a randomized placebo-controlled study of UBX0101|Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
16347024|NCT04349943|Experimental|inflammatory bowel disease|According to the patient's disease condition, tube feeding time, internal and surgical diagnosis and treatment plan, standard step-based nutrition treatment was carried out for the patients with adaptive signs of nutrition treatment, and dynamic nutrition evaluation and efficacy evaluation were carried out.
16347025|NCT04349930|Experimental|Cannabidiol|CBD vaginal suppository
16347026|NCT04349930|Placebo Comparator|Placebo|Placebo vaginal suppository
16347027|NCT04349917|Placebo Comparator|Placebo, then Methylphenidate|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
16347028|NCT04349917|Experimental|Methylphenidate, then Placebo|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
16347029|NCT04349891|Experimental|TEA at ST36 and PC6 first and then sham TEA|Patients in this group will be treated with TEA at ST36 and PC6 for 4 weeks, followed with a 2-week washout period and another 4-week period with sham TEA.
16347030|NCT04349891|Experimental|Sham-TEA and then TEA ST36 and PC6|Patients in this group will be treated with sham-TEA for 4 weeks, followed with a 2-week washout period and another 4-week period with TEA at ST36 and PC6.
16347031|NCT04349878|Placebo Comparator|Control|scaling and root planing alone
16347032|NCT04349878|Active Comparator|phytotherapeutic|scaling and root planing plus phytotherapeutic agent
16347033|NCT04349865||Idiopathic PD|PD patients without the LRRK2 G2385R mutation
16347034|NCT04349865||LRRK2 G2385R PD|PD patients with the LRRK2 G2385R mutation
16347035|NCT04349865||LRRK2 G2385R carriers|Subjects without PD who screen positive for the LRRK2 G2385R mutation
16347036|NCT04349865||Controls|Subjects without PD who screen negative for the LRRK2 G2385R mutation
16347037|NCT04349852|Experimental|BrainHQ Cognitive Training Arm|Participants will randomized into the BrainHQ Cognitive Training modules which are 45 minutes training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, noise cancelling head phones will also be provided to the participants. Participants will complete the training protocols in the lab under the study team's supervision to ensure the participants are engaged and are completing the tasks.
16347038|NCT04349852|Other|BrainHQ People Skills Arm|Participants will randomized into the BrainHQ People Skills Modules which are 45 minutes training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, noise cancelling head phones will also be provided to the participants. Participants will complete the training protocols in the lab under the study team's supervision to ensure the participants are engaged and are completing the tasks.
16347039|NCT04349839||ACRODAT study arm|No intervention
16347040|NCT04349839||Standard Practice Arm|No intervention
16347041|NCT04349826|Active Comparator|Azithromycin+Cefixime|Azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) AND Cefixime 20-30mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days.
16347042|NCT04349826|Placebo Comparator|Azithromycin+placebo|Azithromycin 20mg/kg/day oral dose once daily (Max 1gm/day) for 7 days AND Cefixime-matched placebo for 7 days.
16347043|NCT04349800|Experimental|Single Ascending Dose - 5 mg|
16347044|NCT04349800|Experimental|Single Ascending Dose - 10 mg|
16347045|NCT04349800|Experimental|Single Ascending Dose - 20 mg|
16347046|NCT04349800|Experimental|Single Ascending Dose - 40 mg|
16347047|NCT04349800|Experimental|Single Ascending Dose - 80 mg|
16347048|NCT04349800|Experimental|Single Ascending Dose - 160 mg|
16347049|NCT04349800|Experimental|Single Ascending Dose - 300 mg|
16347050|NCT04349800|Experimental|Single Ascending Dose - 600 mg|
16347051|NCT04349800|Experimental|Formulation Screen|
16347052|NCT04349800|Experimental|Food Effect|
16347053|NCT04349787||Colorectal polyp patients|Patients who have a colonoscopy in regular care as part of the Dutch colorectal screening program, in the context of complaints or in the context of the follow-up of previously diagnosed bowel diseases. And who have at least one colorectal polyp found and resected during the examination.
16347054|NCT04349774|Active Comparator|Control Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml 0.375% Bupivacaine
16347055|NCT04349774|Active Comparator|Treatment Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml Normal Saline.
16347056|NCT04349761|Experimental|Cohort 1 - 5mg MyMD1|8 subjects randomized to receive either 5mg MyMD1 (6 subjects) or Placebo (2 subjects)
16347057|NCT04349761|Experimental|Cohort 2 - 10mg MyMD1|8 subjects randomized to receive either 10mg MyMD1 (6 subjects) or Placebo (2 subjects)
16347058|NCT04349761|Experimental|Cohort 3 - 15mg MyMD1|8 subjects randomized to receive either 15mg MyMD1 (6 subjects) or Placebo (2 subjects)
16347059|NCT04349761|Experimental|Cohort 4 - 20mg MyMD1|8 subjects randomized to receive either 20mg MyMD1 (6 subjects) or Placebo (2 subjects)
16347060|NCT04349761|Experimental|Cohort 5 - 25mg MyMD1 or Placebo|8 subjects randomized to receive either 25mg MyMD1 (6 subjects) or Placebo (2 subjects)
16347061|NCT04349748|Experimental|Group 1|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the second observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
16347062|NCT04349748|Experimental|Group 2|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the third observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
16347063|NCT04349748|Experimental|Group 3|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fourth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
16347064|NCT04349748|Experimental|Group 4|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fifth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
16347065|NCT04349735|Experimental|Adults with asthma or COPD|Assessment of inhalation technique by three methods in all patients
16347066|NCT04349722|Active Comparator|Hyoscine|Participants receive intravenous bolus of 1ml (20 mg) Hyoscine
16347067|NCT04349722|Placebo Comparator|Placebo|Participants receive intravenous bolus of 1ml normal saline
16347068|NCT04349709|Experimental|Brief school-based DBT-A|The students of classes randomized to experimental group receive the brief school-based DBT-A..
16347069|NCT04349709|No Intervention|control group|The students of classes randomized to control group continue their school activity as routine.
16347070|NCT04349696|Active Comparator|T2DM with Child-Pugh A|"All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg.
~Intervention: Drug: Mitiglinide Tablets 10 mg"
16347071|NCT04349696|Experimental|T2DM with Child-Pugh B|"All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg.
~Intervention:Drug: Mitiglinide Tablets 10 mg"
16347072|NCT04349683|Experimental|Experimental group|basic treatment combined with Jinshuibao
16347073|NCT04349683|Placebo Comparator|Control group|basic treatment and placebo
16347074|NCT04349657|Experimental|Supera Peripheral Stent System treatment group|These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
16347075|NCT04349657|Active Comparator|Endarterectomy treatment group|These patients will be treated surgically with endarterectomy
16347076|NCT04349644|Experimental|SENSE Theatre|A peer-mediated, theatre-based intervention designed to improve social cognition and behavior.
16347077|NCT04349644|No Intervention|Waitlist Control Group|This group will not receive the intervention during the testing phase of the intervention but will eventually receive the theatre intervention.
16347078|NCT04349631|Experimental|HB-adMSCs|Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2,6,10, 14, 18, 22, 26.
16347079|NCT04349618|Active Comparator|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight
16347080|NCT04349618|Experimental|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20
16347081|NCT04349605|Experimental|Meditation|This is a daily 15 minute meditation with guided breathing. Accessible through an app.
16347320|NCT04347941|Experimental|Prone Positioning|Intervention patients will remain up to 16 hours per day in Prone Positioning with 45 minutes breaks for meals
16347082|NCT04349605|Experimental|Kundalini Yoga|This is a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
16347083|NCT04349605|No Intervention|Treatment as Usual|This group will serve as the comparison to assess the efficacy of the active treatments in that no study treatment will be provided. The participants will be asked to not start new treatments during the 8 weeks of the study.
16347084|NCT04349592|Experimental|Combination therapy group|hydroxychloroquine 200mg TID for 7 days plus Azithromycin 500mg OD 1st day and 250 from day 2 to 5
16347085|NCT04349592|Active Comparator|Monotherapy therapy group|hydroxychloroquine 200mg TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
16347086|NCT04349592|Placebo Comparator|Control group|Placebo Cap TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
16347087|NCT04349579|Experimental|Rifamycine|Rifamycine is a broad spectrum semi-synthetic antibiotic that acts on gram-positive and gram-negative microorganisms. As a local application, it has areas of use in dentistry such as washing fistula mouths, maxillary sinus and abscess wounds and treating osteomyelitis.
16347088|NCT04349579|Active Comparator|Saline|Saline, also known as saline solution, is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds. It is also used to dilute other drugs to be injected and to wash the operation site in dental surgery operations. It is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.
16347089|NCT04349553|Experimental|ZH9PA 1x10^9 CFU|1mL ZH9PA 1x10^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
16347090|NCT04349553|Experimental|ZH9PA 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
16347091|NCT04349553|Experimental|ZH9PA 1x10^10 CFU plus ZH9 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline and 1mL ZH9 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
16347092|NCT04349553|Placebo Comparator|Placebo|1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
16347093|NCT04349527||RB Group|In this Group Patients receive round-block oncoplastic breast coserving surgery
16347094|NCT04349527||RG Group|In this Group Patients receive retrogladular oncoplastic breast coserving surgery
16347095|NCT04349514||Friedreich ataxia|Individuals with a diagnosis of Friedreich ataxia.
16347096|NCT04349514||Control|Individuals without a diagnosis of Friedreich ataxia.
16347097|NCT04349501|Experimental|RSI-MRI|Participants will undergo RSI-MRI at three time points: before androgen deprivation therapy (ADT); after neoadjuvant ADT but before radiation therapy (RT); and after RT.
16347098|NCT04349488|Active Comparator|Treatment|Anode placed over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16347099|NCT04349488|Placebo Comparator|Placebo|Anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16347100|NCT04349475|Experimental|Omega 3 Supplementation|Supplementation of 4g of DHA/EPA daily
16347101|NCT04349475|Placebo Comparator|Safflower Oil Supplement|Supplementation of Safflower Oil daily
16347102|NCT04349462|Other|VFSS and Water Sip Test|Enrolled patients will undergo a water sip test and Videofluroscopy Swallow Test (VFSS)
16347103|NCT04349449||Vedolizumab Participants|Participants diagnosed with moderate to severe CD from approximately 20 investigational sites will be observed over a period of 12 months after initiation of treatment with vedolizumab, intravenous infusion under standard clinical care.
16347104|NCT04349436|Experimental|RP1, intra-tumoral injection, oncolytic virus|RP1 administered as an intra-tumoral injection every 2 weeks.
16347105|NCT04349423|Experimental|No Social Media Use|Participants will be asked to refrain from using all social media
16347106|NCT04349423|Experimental|Maximum 30 minutes of use|Participants will be asked to only use social media at most 30 minutes a day.
16347107|NCT04349423|Experimental|Maximum 1 hour of use|Participants will be asked to only use social media at most 60 minutes a day.
16347108|NCT04349423|Experimental|Maximum 2 hour of use|Participants will be asked to only use social media at most 120 minutes a day.
16347109|NCT04349423|Experimental|Maximum 3 hour of use|Participants will be asked to only use social media at most 180 minutes a day.
16347110|NCT04349410|Experimental|Treatment 1|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Azithromycin 500 mg IV on day 1, followed by 250 mg IV on days 2-5 (to prevent bacterial superinfection ).
16347111|NCT04349410|Experimental|Treatment 2|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Doxycycline 100mg IV q 12 hrs with each dose given over 1 to 4-hours (to prevent bacterial superinfection ).
16347112|NCT04349410|Experimental|Treatment 3|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
16347113|NCT04349410|Experimental|Treatment 4|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
16347114|NCT04349410|Experimental|Treatment 5|Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
16347115|NCT04349410|Experimental|Treatment 6|Remdesivir 200 mg IV on day 1, followed by 100 mg IV qD for a total of 10-days.
16347321|NCT04347941|Active Comparator|Standard Care|Control patients will receive full standard care. Prone Positioning as a rescue intervention is permitted and is recorded.
16347116|NCT04349410|Experimental|Treatment 7|"Tocilizumab 8mg/kg IV (not to exceed 800 mg) over 60-minutes. If clinical improvement is not noted, three additional doses may be administered at q 8-hour intervals from the initial infusion for a total of 4-doses maximum.
~ANY PATIENT DEMONSTRATING CYTOKINE RELEASE SYNDROME WILL HAVE THIS TREATMENT ARM AUTOMATICALLY ADDED."
16347117|NCT04349410|Experimental|Treatment 8|Methylprednisolone 125 mg IV every 6-hours for 3 days; then 125 mg IV every 12-hours for 2 days; then 125 mg IV daily for 2 days; then 60 mg IV daily for 2 days [with each infusion given over 30-minutes]; then Solumedrol dose pack to taper off steroids.
16347118|NCT04349410|Experimental|Treatment 9|Interferon alpha-2b 5 million units per nebulizer BID.
16347119|NCT04349410|Experimental|Treatment 10|Losartan 25 mg po qD. IRB held due to questions about benefit.
16347120|NCT04349410|Experimental|Treatment 11|Convalescent Plasma 2-units ABO-compatible with antibody titer of 1:320 dilution. Each unit intravenously infused over 4-hours.
16347121|NCT04349397||Pediatric tonsillectomy patients|All patients enrolled into study prior to undergoing tonsillectomy or adenotonsillectomy
16347122|NCT04349384||Colon adenocarcinoma|Patient who underwent surgical resection for colon adenocarcinoma
16347123|NCT04349384||Rectal adenocarcinoma|Patient who underwent surgical resection for rectal adenocarcinoma
16347124|NCT04349371|Experimental|CQ group|Participants will receive CQ supply for 3 months. Patients will receive a supply of 36 -- 250 mg tabs or placebo that will last 3 months (enough for taking two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
16347125|NCT04349371|Placebo Comparator|Placebo group|Participants will receive placebo supply for 3 months. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
16347126|NCT04349358|Other|FDG and FCH PET/CT|
16347127|NCT04349345||sperm count over time|observation
16347128|NCT04349332|Active Comparator|Helmet non invasive ventilation (NIV)|Patients randomized to the intervention group will be extubated to helmet NIV.
16347129|NCT04349332|No Intervention|Control invasive mechanical ventilation|Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
16347130|NCT04349319|Other|Digital preoperative planning|To use digital preoperative planning software
16347131|NCT04349306|Experimental|rasburicase|rasburicase 0.20 mg/kg/day by intravenous (IV) over 30 minutes for 1 to 5 days according to the level of plasma uric acid or Investigator's clinical judgement
16347132|NCT04349293|Experimental|Patients with cancer|
16347133|NCT04349280|Experimental|Participants receiving bintrafusp alfa|Participants will receive bintrafusp alfa 1200 milligram (mg), intravenous (IV) infusion, once every 2 weeks (Q2W) until progressive disease (PD), death, unacceptable toxicity, study withdrawal or up to 2 years.
16347134|NCT04349267|Experimental|BMS-986315|
16347135|NCT04349267|Experimental|BMS-986315 + nivolumab|
16347136|NCT04349267|Experimental|BMS-986315 + cetuximab|
16347137|NCT04349241|Experimental|favipiravir|favipiravir in a regimen of 3200 mg (1600 mg 12 hourly) loading dose on day-1 followed by 1200 mg maintenance dose (600 mg 12 hourly daily) on day-2 to day-10
16347138|NCT04349241|Active Comparator|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10.
16347139|NCT04349228|Experimental|Hydroxychloroquine (HCQ)|Exposed health care professionals working in the intensive care unit
16347140|NCT04349228|Placebo Comparator|Placebo|Exposed health care professionals working in the intensive care unit
16347141|NCT04349202||Beaumont employees|Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies, their immediate family members, and members of other high-risk groups.
16347146|NCT04349176|Experimental|Group A 100U|
16347147|NCT04349176|Experimental|Group A 155U|
16347148|NCT04349176|Experimental|Group B 100U|
16347149|NCT04349176|Experimental|Group B 155|
16347150|NCT04349163||Caregivers|Physicians and nurses working at the Emergency Department, Intensive care Unit, infectious disease Department, Anaesthesiology.
16347151|NCT04349150|Experimental|Virtual reality|Participants on this arm will have their colonoscopy initiated under virtual reality instead of standard sedatives and narcotics
16347152|NCT04349137|Experimental|In-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a synchronized (in-phase) manner at a frequency of 6Hz
16347153|NCT04349137|Active Comparator|Anti-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a desynchronized (anti-phase, i.e. with a difference of 180deg) manner at a frequency of 6Hz
16347154|NCT04349137|Sham Comparator|Sham tACS|A sham transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC at a frequency of 6Hz using physical vibrations instead of electrical current
16347322|NCT04347915|Experimental|Clevudine|Clevudine 120mg (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
16347155|NCT04349124|Other|Treatment Group|The treatment group will provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
16347156|NCT04349124|Placebo Comparator|Control Group|The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the sever range (>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
16347157|NCT04349111|Other|Experimental: Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
16347158|NCT04349098|Experimental|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
16347159|NCT04349098|Placebo Comparator|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
16347160|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
16347161|NCT04349085|Experimental|Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
16347162|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
16347163|NCT04349085|Placebo Comparator|Placebo PBMT/sMF before WOD and Placebo PBMT/sMF after WOD.|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
16347164|NCT04349072|Experimental|Drug: Mavacamten|"Mavacamten Capsules
~Other names:
~MYK-461"
16347165|NCT04349072|Placebo Comparator|Drug: Placebo|Matching Placebo Capsules
16347166|NCT04349059|Active Comparator|Plant-based arm|Sequence one as outlined in the Study Description section consists of 7 visits to the doctors office, following a plant based diet and using the The Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
16347167|NCT04349059|Active Comparator|Animal-based arm|Sequence two as outlined in Study Description section consists of 7 visits to the doctors office, following a animal based diet and using the The Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
16347168|NCT04349046||Patient who received the Exception stem|Patient who received the Exception stem between January 2008 and September 2012 and consented to the original data collection.
16347169|NCT04349033|Experimental|Emotional Disclosure and Brain Education|Patients are interviewed about stress and other emotional issues and are educated about how emotions and the brain influence pain.
16347170|NCT04349033|Active Comparator|Emotional Disclosure only|Patients are interviewed about stress and other emotional issues only.
16347171|NCT04349033|Placebo Comparator|Pain Information Control|Patients are interviewed about their pain history and experience.
16347172|NCT04349007|Active Comparator|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in
16347173|NCT04349007|Experimental|School food ready-to-use|peanut-based school food ready-to-use
16347174|NCT04349007|Experimental|School food ready-to-use plus Milk|peanut-based school food ready-to-use with milk
16347175|NCT04348994|Experimental|Laser therapy|Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
16347176|NCT04348981|Experimental|Wearable|All patients eligible to enroll in the Enhanced Recovery after Cardiac Surgery pathway will be offered a wearable fitness tracking device.
16347177|NCT04348968||Patient who received a Maxera Cup of large diameter|Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.
16347178|NCT04348955||women with adjuvant breast cancer|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
16347179|NCT04348929|Experimental|Confinement group|Delivery during covid-19 confinement period
16347180|NCT04348929|Other|Control group|Delivery after the withdrawal of all sanitary measures (mask, social distancing, limited visits during post-partum immediate)
16347181|NCT04348929|Other|Epidemic group|Delivery after confinement period and before the withdrawal of sanitary measures implemented (mask, social distancing, limited visits during post-partum immediate)
16347182|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with surface lesions|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
16347183|NCT04348916|Experimental|Dose expansion of ONCR-177 in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
16347184|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
16347185|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory solid tumor cancer with liver metastases
16347186|NCT04348916|Experimental|Dose expansion of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory solid tumor cancer with liver metastases
16347187|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory solid tumor cancer with liver metastases
16347188|NCT04348903|Experimental|Virtual Reality Distraction|Virtual reality refers to a human-computer interface that completely immerse the child in a simulated environment. It integrates multiple perceptual senses including; the visual, auditory and kinaesthetic stimulation modalities. Virtual reality diverts children's attention away from the negative feelings associated with unpleasant experience.
16347189|NCT04348903|Experimental|Positive Pre-Visit Imagery Intervention|Positive pre-visit imagery is one of the superior cognitive- behavioral interventions. It is kind of psychological preparation that is designed to provide children with a step-by-step explanation of the dental local anaesthesia injection in an attractive approach
16347190|NCT04348890|Experimental|Treatment Arm|
16347191|NCT04348877|Other|Antibody-Rich Plasma|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
16347194|NCT04348851|Experimental|4-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
16347195|NCT04348851|Experimental|8-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
16347196|NCT04348851|Active Comparator|8-Week Attention Control|The Registered Nurses (RNs) will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare provider.
16347197|NCT04348851|No Intervention|Standard Care|Caregivers receiving standard of care
16347198|NCT04348825||Patients, depression|Patients who receive ECT as part of clinical care
16347199|NCT04348825||Healthy|Healthy controls who do not receive ECT but otherwise the same assessments.
16347200|NCT04348825||Patients, atrial fibrilation|Patients who receive Electro Cardio Version (ECV) due to Atrial Fibrilation
16347201|NCT04348812|Experimental|tDCS Active|Transcranial direct current stimulation with ABMT
16347202|NCT04348812|Sham Comparator|tDCS sham|Transcranial direct current sham stimulation with ABMT
16347203|NCT04348799||BPD group|premature infants diagnosed with BPD after postnatal day 28
16347204|NCT04348799||control group|premature infants without BPD after postnatal day 28
16347205|NCT04348786|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate
16347206|NCT04348786|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole
16347207|NCT04348773|Experimental|Dehydration|
16347208|NCT04348773|Experimental|Rehydration|
16347209|NCT04348760|Experimental|Intervention|Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week
16347210|NCT04348747|Experimental|Treatment (anti-HER2/3 dendritic cell vaccine)|"TREATMENT PHASE: Patients receive anti-HER2/HER3 dendritic cell vaccine ID on days 1, 15, and 29. Patients also receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 15-17 and 29-31.
~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive a booster dose of anti-HER2/3 dendritic cell vaccine ID, celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV every 3 months in the opinion of principal investigator."
16347211|NCT04348708||Dose Level Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
16347212|NCT04348708||Dose Level Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
16347213|NCT04348708||Dose Level Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
16347214|NCT04348695|Experimental|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.
~Simvastatin 40 mg orally every 24 hours for 14 days."
16347215|NCT04348695|Other|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
16347216|NCT04348669|Experimental|Tele-yoga|This is a single group study with all subjects included in this single arm. All subjects will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
16347217|NCT04348656|Experimental|Convalescent plasma|~500 mL ABO compatible convalescent apheresis plasma
16347218|NCT04348656|No Intervention|Standard of care|Treated as per institutional standard of care.
16347219|NCT04348643|Experimental|CEA+ CAR-T|CAR-T cell reinfusion is carried out in 1~3 times
16347220|NCT04348630|Experimental|HOT condition|Participants are exposed to 36°C and 45% relative humidity for 8 hours. These conditions were chosen to represent an extreme heat condition (i.e., heatwave) and are similar to peak domicile conditions measured in low-income high-rise apartment complexes during heatwaves.
16347221|NCT04348630|Experimental|WARM Condition|Participants are exposed to 31°C and 45% relative humidity for 8 hours. These conditions are similar to mean domicile conditions measured in a variety of domicile types during heat waves complexes during heatwaves and are consistent with the World Heath Organization recommendation for maximal indoor temperatures.
16347222|NCT04348630|Experimental|TEMPERATE Condition|Participants are exposed to 26°C and 45% relative humidity for 8 hours. These conditions are consistent with Toronto Public Health recommendation for maximal indoor temperatures, which are based on the increase in mortality associated with increases in outdoor temperature above these limits.
16347223|NCT04348630|Experimental|COOL Condition|Participants are exposed to 22°C and 45% relative humidity for 8 hours. These conditions are consistent with actively cooled (air-conditioned) domicile.
16347224|NCT04348617|Experimental|Exercise-Rest|This group will perform the exercise condition at least 1 week after the preliminary visit and will perform the resting condition a minimum of 15 days and a maximum of 2 months after the exercise condition.
16347225|NCT04348617|Experimental|Rest-Exercise|This group will perform the resting condition at least 1 week after the preliminary visit and will perform the exercise condition a minimum of 15 days and a maximum of 2 months after the resting condition.
16347226|NCT04348604|Experimental|Customized Adherence Enhancement for AYA|This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
16347227|NCT04348604|Active Comparator|Enhanced Treatment as Usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
16347228|NCT04348591|Experimental|Misophonia Group|Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
16347229|NCT04348591|Active Comparator|Emotional Dysregulation Clinical Group|Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
16347230|NCT04348578|No Intervention|control group|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL NaOCl and 5mL sterile saline in the control group.The root canals were dried with sterile paper points and were filled with gutta-percha and AH Plus sealer with the cold lateral condensation method and the entry cavity was restored with composite. All treatments were performed following a standardized procedure by one operator. After completion of the root canal treatment, periapical radiographs were taken using the paralleling technique. All the patients were called for follow-up examination at 12 months, and were examined radiographically.
16347231|NCT04348578|Experimental|QMix 2in1|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL Mix 2in1 and 5mL sterile saline in the experimental group.
16347232|NCT04348565|Experimental|Diabetes Care Programme|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
16347233|NCT04348565|No Intervention|Standard Usual Care|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
16347234|NCT04348539|Experimental|Balance training|The balance training consists of 3 moments: warm up, main and stretch. Warm-up with mobility exercises for major joints and large muscle groups. The main part will have eight exercise stations divided into: a) five balance exercises (dynamic and static with or without object balance) on a varied floor, b) three agility exercises, and a stretching of the worked muscle groups and a final relaxation.
16347235|NCT04348539|Experimental|Strength training|Muscle strength training will consist of 3 moments: warm up, main and stretch. Warm up with mobility exercises for the main joints and large muscle groups. The main part will include strength exercises with lower and upper limbs with two sets of 6-12 repetitions according to periodization, and a stretching of the muscle groups worked
16347236|NCT04348539|Experimental|Cardiorespiratory endurance training|The older people walking training consists of 3 moments: warm up, main and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed, then walk according to the training cycle, and then a stretching of the main muscle groups. Will be held, twice a week for 45 minutes each session. The training intensity will follow 60-110% of the volume of the 6-minute Test (6MWT) and the Borg Scale at moderate to difficult intervals. the training
16347237|NCT04348539|No Intervention|Control group|control group: who will receive educational lectures on health, walking and aging.
16347238|NCT04348526|Experimental|Corticision|Patients will undergo a corticision procedure in order to accelerate tooth movement
16347239|NCT04348526|Active Comparator|Traditional treatment|Patients will undergo traditional orthodontic treatment without any surgical intervention.
16347240|NCT04348513|Experimental|T3 solution for injection|T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
16347241|NCT04348513|Placebo Comparator|Placebo|Composition identical apart from the active substance. Same dosage.
16347242|NCT04348500|Active Comparator|Clazakizumab|25 mg in 50 cc NS given by IV infusion x 1 dose
16347243|NCT04348500|Placebo Comparator|Placebo|50 cc NS given by IV infusion x 1 dose
16347323|NCT04347915|Placebo Comparator|Placebo|Matching Placebo (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
16347244|NCT04348487|Other|Standard procedure|For the conventional TIVAPS with cephalic vein approach, incision was made either in the midline of infraclivular or supraclavicular. Cathether was introduced to the central and then connected to the laterally implanted port in the deltopectoral region. The experience in the local center experienced several pitfalls with this method such as pneumothorax, pinch-off syndrome, compression of the catheter by the clavicle, kinking of the catheter, and loss of patencty.
16347245|NCT04348474|Experimental|HCQ + AZT|All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (00 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care.
16347246|NCT04348461|No Intervention|Control|Patients receiving regular respiratory distress treatment
16347247|NCT04348461|Experimental|Treatment|Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
16347248|NCT04348435|Experimental|Allogeneic HB-adMSCs 200MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
16347249|NCT04348435|Experimental|Allogeneic HB-adMSCs 100MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
16347250|NCT04348435|Experimental|Allogeneic HB-adMSCs 50MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
16347251|NCT04348435|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14.
16347252|NCT04348422||Symptomatic|COVID-19 RT-PCR positive patients with reported symptoms
16347253|NCT04348422||Asymptomatic|COVID-19 RT-PCR positive patients without presenting any symptoms
16347254|NCT04348409|Experimental|nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
16347255|NCT04348409|Placebo Comparator|Placebo|Patients will receive placebo BID for 7 days
16347256|NCT04348396||Elderly patients affected by COVID-19|The group taken into consideration consists of elderly patients hospitalized with diagnosed COVID-19.
16347257|NCT04348383|Experimental|Defibrotide + standard therapy|Defibrotide + standard therapy
16347258|NCT04348383|Placebo Comparator|Placebo|Placebo + standard therapy
16347259|NCT04348370|Experimental|BCG Group|FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area.
16347260|NCT04348370|Placebo Comparator|Placebo Group|A single dose will consist of 0.1 mL saline
16347261|NCT04348357|Active Comparator|Traditional Visit|Patients come to the office for a traditional postoperative visit
16347262|NCT04348357|Experimental|Tele-medicine|Patients receive postoperative care via telemedicine
16347263|NCT04348344|Experimental|intervention group|"health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise，strength training and breath training.
~Patients in stable stages using the home-based rehabilitation exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training."
16347264|NCT04348344|No Intervention|control group|health education of pulmonary rehabilitation
16347265|NCT04348305|Experimental|Hydrocortisone|"Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.
~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours)."
16347266|NCT04348305|Placebo Comparator|Isotonic Saline|"Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).
~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours)."
16347267|NCT04348292|Experimental|Treatment (sirolimus, durvalumab)|Patients receive sirolimus PO QD on days 1-21 in the absence of disease progression or unacceptable toxicity. Starting on day 22, patients receive durvalumab IV over 1 hour. Treatment with durvalumab repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within a 2-3 week period after the second dose of durvalumab, but not earlier than two weeks after the administration of durvalumab, patients undergo standard of care surgery.
16347268|NCT04348279|Active Comparator|custom made acrylic stent|the donor sites of the participants were covered with custom made acrylic stent
16347269|NCT04348279|Experimental|propylene mesh|in the test group, the donor sites received propylene mesh.
16347270|NCT04348266|Experimental|RFA|The assigned location will be treated with RFA at all lesion.
16347271|NCT04348266|No Intervention|Control|No treatment will not be performed at this location. However, if endoscopist detects any suspicious lesion during the scheduled endoscopy, the biopsy will be done and standard treatment will be performed accordingly.
16347272|NCT04348253|Active Comparator|Berger|Bergers capsulodesis
16347273|NCT04348253|Active Comparator|3LT|Three ligament tenodesis
16347274|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
16347275|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
16347276|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
16347277|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
16347278|NCT04348227||Before pandemic is declared|Positive endotracheal aspirates addressed from January 1st 2019 to January 1st 2020
16347279|NCT04348227||After pandemic is declared|Positive endotracheal aspirates addressed from February1st 2020 to February 1st 2021
16347280|NCT04348201|Active Comparator|foot reflexology|foot reflexology session which takes about 20 minutes.
16347282|NCT04348188|Experimental|Supervised exercise group|Supervised intervention group: 3 weekly sessions of 1 hour during 6 weeks of therapeutic exercise in which aerobic physical activity will be combined with exercise strength of different muscle groups plus stretches on a supervised basis and strengthening of self-care.
16347283|NCT04348188|Active Comparator|Not supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
16347284|NCT04348175|Experimental|Mild impairment|
16347285|NCT04348175|Experimental|Moderate impairment|
16347286|NCT04348175|Experimental|Severe impairment|
16347287|NCT04348175|Experimental|Normal (control)|
16347288|NCT04348162|Active Comparator|Cocoa Flavanols|Cocoa is taken every day for 10-12 weeks.
16347289|NCT04348162|Active Comparator|Berries anthocyanins|Red-berries are taken every day for 10-12 weeks.
16347290|NCT04348162|Active Comparator|Cocoa flavanols plus berries anthocyanins|Cooa and red-berries are taken every day for 10-12 weeks.
16347291|NCT04348162|No Intervention|Control|Normal diet for 10-12 weeks
16347292|NCT04348149|Experimental|Intervention group|
16347293|NCT04348149|No Intervention|Wait-list|
16347294|NCT04348136|Experimental|JR-141|
16347295|NCT04348123|Experimental|Outreach educational program|"Participants will be given a survey to elucidate beliefs and barriers around breast health and mammography.
~A brief, culturally-appropriate educational session about breast health and mammography will follow and will be delivered by a female public health educator.
~After education, eligible women will be offered a free on-site mammogram"
16347296|NCT04348110|Placebo Comparator|Placebo tablets|
16347297|NCT04348110|Experimental|Blueberry Chewable Tablets|
16347298|NCT04348097|Experimental|activator trigger point therapy|"The Activator adjusting instrument used had force settings ranging from 1 to 6
~. For this study a force setting of 3 was used."
16347299|NCT04348097|Active Comparator|Trigger point dry needling|First, a tight band was held between the index finger and the thumb of the non-dominant hand and the needle (0.25-40 mm - Shen Long) was perpendicularly inserted into the muscle with the dominant hand.
16347300|NCT04348084||who developed POPF|Patients undergone curative distal pancreatectomy for PDAC who developed POPF
16347301|NCT04348084||who did not develop POPF|Patients undergone curative distal pancreatectomy for PDAC who did not develop POPF
16347302|NCT04348071|Experimental|Ruxolitinib|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
16347303|NCT04348058|No Intervention|Control group|Invitation letter and reminder letter to screening colonoscopy
16347304|NCT04348058|Experimental|Call Center|Telephone recruitment by motivational conversation and colonoscopy appointment
16347305|NCT04348058|Experimental|Combined|Non responders to invitation and reminder letter will be recruited by telephone conversation
16347306|NCT04348045|Experimental|ARM A - olaparib|Olaparib tablets at 300 mg orally twice daily until PD (RECIST 1.1) or unacceptable toxicity.
16347307|NCT04348045|Experimental|ARM B - durvalumab plus selumetinib|"Durvalumab plus selumetinib until PD (RECIST 1.1 and/or iRECIST), unacceptable toxicity, withdrawal of consent, or death.
~Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle,
~Selumetinib administered as 75 mg twice daily dose for 21 days on and 7 days off (a 28-day cycle)."
16347308|NCT04348045|Active Comparator|ARM C - FOLFIRI|FOLFIRI FOLFIRI (irinotecan 180 mg/m2 IV on day 1, folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2 every 2 weeks) until PD (RECIST 1.1) unacceptable toxicity, withdrawal of consent, or death.
16347309|NCT04348032|Active Comparator|PLD|PLD 40 mg/m2 D1 ivgtt q4w
16347310|NCT04348032|Experimental|PLD + Apatinib|PLD 40 mg/m2 D1 ivgtt q4w + Apatinib 250mg po qd
16347311|NCT04348019|Experimental|Time restricted feeding|Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours. Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
16347312|NCT04348019|Placebo Comparator|Control|Participants in the control arm of the study will fast each night for 8 hours.
16347313|NCT04348006|Experimental|Induction Therapy|Bortezomib will be administered as part of VCD or VRD protocols
16347314|NCT04347980|Experimental|Dexamethasone and Hydroxychloroquine (HCQ/DXM)|"Patients included in the HCQ / DXM group will benefit from standardized ventilatory management and administration of HCQ in the same manner as the HCQ group. They will receive in addition to DXM at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of DXM before."
16347315|NCT04347980|Active Comparator|Hydroxychloroquine (HCQ)|"Patients included in the HCQ  group will benefit from standardized ventilatory management. Patients included in the HCQ group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before."
16347316|NCT04347967|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
16347324|NCT04347902|Experimental|PN with SMOFLipid|Parenteral nutrition with MCT/LCT/olive oil/fish oil (SMOFLipid, Fresenius Kabi, Germany, SMOF group)
16347325|NCT04347902|Active Comparator|PN with Olive oil|Parenteral nutrition with Olive oil/LCT 80:20 (ClinOleic, Baxter Healthcare, USA, OO group)
16347326|NCT04347902|Active Comparator|PN with MCT/LCT|Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)
16347327|NCT04347889|Experimental|Hydroxychloroquine|Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months
16347328|NCT04347889|Active Comparator|Vitamin C|Oral Vitamin C 1,000 mg daily for three months
16347329|NCT04347876||Group A|COVID-19 positive with positive tuberculin test
16347330|NCT04347876||Group B|COVID-19 positive with negative tuberculin test
16347331|NCT04347863|Experimental|Experimental group|Group swallowing disorder diet preparation program
16347332|NCT04347863|No Intervention|Control group|No Intervention
16347333|NCT04347850||Patient with Covid-19 confirmed (middle form)|Covid-19 confirmed: middle form
16347334|NCT04347850||Patient with Covid-19 confirmed (severe form)|Covid-19 confirmed : severe form
16347335|NCT04347850||Patient with Covid-19 not confirmed|Covid-19 not confirmed
16347336|NCT04347837|Experimental|Investigational device|The investigational device will be used for all participants
16347337|NCT04347824||low risk|"This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2* or more of the following findings:
~urine osmolarity below normal values
~leukozyturia
~hematuria
~albuminuria/ proteinuria * if urine is positive for nitrite or bacteria, abnormal urine status is defined as 3 or more of the findings."
16347338|NCT04347824||intermediate risk|This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.
16347339|NCT04347824||high risk|This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.
16347340|NCT04347811|Experimental|Death Cafe Arm|Participants undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
16347341|NCT04347811|No Intervention|Control Arm|Participants do not undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
16347342|NCT04347798||Inflammatory arthritis patients on biologic + anti-malarial|Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
16347343|NCT04347798||Inflammatory arthritis patients on biologic + NO anti-malarial|Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
16347344|NCT04347785||Neurologic deficit|All consecutive patients from a tertiary referral center who underwent CEA for carotid artery stenosis who presented alterations in the neurologic examination after ICA clamping during CEA area selected
16347345|NCT04347785||control|The control patients are submitted to the same procedure but with no neurologic alterations, are consecutively selected. a 1 to 1 ratio is used
16347346|NCT04347772|Experimental|Supplements Group - SS|"The SS will be received tailored and more intensive and ongoing nutrition support and lifestyle advice as compared with the NN and will be supplemented with ONS, available in 400g/can, providing 226 kcal/serving and 9.6 g protein/serving. Participants will be encouraged to consume the ONS in small, frequent, in between meals.
~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
16347347|NCT04347772|No Intervention|Control Group - NN|"While participants in NN which referred as control group will received the standard care of the clinic without supplemented with ONS. Nutritional advice will be based on a guideline specifically focused on treatment of symptoms such as nausea, vomiting, loss of appetite and diarrhoea, and how to deal with the symptoms through nutritional approaches. Basically, the advice will be given by the oncologist or nurses in the clinic.
~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
16347348|NCT04347759|Other|System with coaching messages|A telephone-computer interface IVR system to report symtopms and to receive coaching messages based on symptom severity.
16347349|NCT04347746|Active Comparator|Clinical group|Individuals with bilateral idiopathic CTS with clinical criteria and mild to moderate ENMG severity and symptom evolution time above six months.
16347350|NCT04347746|Active Comparator|Surgical group|Individuals with bilateral idiopathic CTS with clinical criteria and severe ENMG in at least one hand and symptom evolution time above six months. These will be submitted to surgery on the severe hand and if equal severity on both hands, the dominant hand will be operated, with the patient's consent.
16347351|NCT04347733|Experimental|Group A|Intra-articular injection, 20 mg (0.5 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.5 mL of normal saline
16347352|NCT04347733|Experimental|Group B|40 mg (1 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.0 mL of normal saline
16347353|NCT04347733|Active Comparator|Group C|20 mg (0.5 mL) of triamcinolone acetonide and 1 mL of hyaluronidase mixed with 2 mL of 2% lidocaine and 6.5 mL of normal saline
16347354|NCT04347720||Indomethacin Arm|Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.
16347355|NCT04347720||Standard dose ibuprofen Arm|Standard dose ibuprofen [Oral/intravenous] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.
16347378|NCT04347590|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
16347356|NCT04347720||Adjustable dose ibuprofen Arm|Adjustable dose ibuprofen [Oral/intravenous] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy
16347357|NCT04347720||Acetaminophen Arm|Acetaminophen [Oral/intravenous] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.
16347358|NCT04347720||Control group|Infants <29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy
16347359|NCT04347720||Reference group|Infants <29 weeks GA who were never diagnosed with PDA
16347360|NCT04347707|Experimental|BRIDGE Clinical Group|This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
16347361|NCT04347707|No Intervention|Baseline Comparison Group|This group of mother-child dyads will not meet diagnostic criteria for depression and will serve as a comparison group for baseline measures. Dyads will be matched to the BRIDGE clinical group based on household income and child age.
16347362|NCT04347681|Experimental|Treatment Group|We are aiming to include 40 patients (recipients) who have COVID 19 but have not recovered yet as per the inclusion criteria.
16347363|NCT04347681|No Intervention|control group|Patients who only consent for sharing their clinical and laboratory data will serve as a control group to compare the efficacy of the convulsant plasma. Age and sex matched historical control could be used if need.
16347364|NCT04347668|Active Comparator|Usual Care|All residents are seen by a RN, with care by Registered Practical Nurse (RPN) and Personal Support Worker (PSW) staff 24/7. Residents supported by behavior support Ontario staff; include Behavior responsive team. Residents prior to admission have been assessed by the Geriatric program. Residents may receive psychotropic or cognitive enhancement medications. The residents are seen routinely seen once a week by the physician. Their Dementia is monitored weekly but the physician as well as daily by the registered staff. Quarterly or more frequently cognitive assessments are completed and referrals made to appropriate specialists. A day would include meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
16347365|NCT04347668|Experimental|Virtual Reality|"Virtual Reality (VR) is a scenario that simulates experiences. The immersive environment is similar to the real world, creating an experience. A person using virtual reality equipment is able to look around the artificial world, move around in it, and interact with virtual features or items. VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds that simulate a user's physical presence in a virtual or imaginary environment. A library has been developed, set to music, as well, we will use library items already part of the BroomX. We will attempt to use BroomX in their own room or in a suitable room within the LTC home. The participants still get the immersive experience, and the projection device has automatic controls that conform the visuals to a 360 experience no matter what size the room is, or what chairs, window blinds, are in the room."
16347366|NCT04347655|Experimental|HFrEF|patients with heart failure with reduced ejection fraction
16347367|NCT04347655|Experimental|HFpEF|heart failure with preserved ejection fraction
16347368|NCT04347655|Active Comparator|Control|healthy (no heart failure) control participants
16347369|NCT04347642|Active Comparator|Umbilical port|A Hasson port will be inserted at the level of the umbilicus,in the midline, traversing only aponeurotic layers.
16347370|NCT04347642|Experimental|Paraumbilical port|A bladeless 12mm port will be inserted lateral to the midline, traversing aponeurotic layers and rectus abdominis muscle.
16347371|NCT04347629|No Intervention|Usual Care|Usual clinical care
16347372|NCT04347629|Experimental|Video Decision Aid|The video intervention consists of a video decision aid along with a video declaration (ViDec), which is recorded by the patient. The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
16347373|NCT04347616|Experimental|NK cells without IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. NK cells administration will not be followed by sc IL-2. N=3.
16347374|NCT04347616|Active Comparator|NK cells with low dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 3.0 x 10^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total. N=3
16347375|NCT04347616|Active Comparator|NK cells with higher dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 6.0 x 10^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total.
16347376|NCT04347603|Experimental|General Anesthesia|- General anesthesia : After pre-anesthetic preparation (25-50 mg Hydroxizine orally), the anesthesia induction will be performed by IV perfusion of Propofol 1 to 2 mg/kg, Sufentanyl for analgesia 0,2 to 0,4 µg/kg, curarisation with Atracurium 0,15 mg/kg. The anaethesia depth will be monitored by the bispectral index (BIS). Orotracheal intubation will be performed, the patient will be ventilated to controlled volume with 6-8 mL/kg of current volume based on expected body weight (PBW). The respiratory rate will be adjusted to have an ETCO2 between 35 and 45 mmHg. The anesthesia will be maintained through the Sevorane at 0.7-1 MAC, the average blood pressure will be controlled through a pressure cuff with a target between 60 and 80 mmHg. The Fio2 will be adapted to obtain saturation > 94% with 5 cmH2O PEEP.
16347377|NCT04347603|Active Comparator|Local Anesthesia|Local anesthesia at the device introduction site will be obtained by infiltration of Naropein.
16347379|NCT04347590|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to at least 2 capillary glycemic tests per day.
16347380|NCT04347551|Experimental|Eye movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
16347381|NCT04347551|Active Comparator|Head movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
16347385|NCT04347525|Experimental|Intervention|This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
16347386|NCT04347525|No Intervention|Control|This group will receive treatment as usual
16347387|NCT04347512|Experimental|Hydroxychloroquine|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).
~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc)"
16347388|NCT04347512|Active Comparator|Control|The patient is given antibiotics only. Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc).
16347389|NCT04347512|Experimental|Hydroxychloroquine and Azithromycin|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).
~Azithromycin is given for 5 days, with a loading dose of 500 mg at D1, and 250 mg for the next 4 days.
~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc) In case of moderate renal failure (glomerular filtration rate between 30 and 60 mL/min/m²), hydroxychloroquine dosage are lowered by half."
16347390|NCT04347499|Experimental|Intervention|This group will receive CaCBT based guided selfhelp using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
16347391|NCT04347499|No Intervention|Control|This group will receive treatment as usual
16347392|NCT04347486|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
16347393|NCT04347486|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
16347394|NCT04347486|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
16347395|NCT04347486|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation
16347396|NCT04347473|Experimental|Ilumya|Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
16347397|NCT04347460||COVID 19|Patients requiring ICU treatment due to severe COVID 19 interstitial pneumonia or otherwise COVID-19 related disease
16347398|NCT04347447|Experimental|normal protein diet|The normal protein diet (Control) will contain the RDA for protein of (0.8 g/kg/d), with the protein provided from a variety of animal and plant-based sources, including lean beef (one 3-oz portion per week), chicken, eggs, dairy, beans, grains, nuts, seeds.
16347399|NCT04347447|Experimental|a beef protein-rich diet|High protein diet predominantly provided from lean beef (one 3-oz portion per day; total beef intake 24 oz/week). The energy content of the additional protein foods will be isocalorically offset by substitution for low-protein foods.
16347400|NCT04347447|Experimental|a protein-rich diet non-red meat|High-protein group from a variety of animal and plant-based sources (excluding additional red meats).
16347401|NCT04347434|Experimental|Atorvastatin 80 mg|"Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.
~If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day."
16347402|NCT04347434|Active Comparator|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C of ≤1.4 mmol / L and a decrease in the indicator by ≥50% after 5-6 weeks from the onset of AMI, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
16347403|NCT04347421|Experimental|Krill oil group|This group takes Krill oil for 12 weeks
16347404|NCT04347421|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
16347405|NCT04347408||Healthy Children|Healthy children of healthcare workers between 2 and 15 years of age
16347406|NCT04347395|No Intervention|Group 1: Control Group|Current best practice for prevention of HAP
16347407|NCT04347395|Experimental|Group 2: Intervention|Respiratory Bundle Intervention
16347408|NCT04347382|Experimental|Nigella Sativa & Honey Group|"Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)
~along with standard medical care"
16347409|NCT04347382|Placebo Comparator|Standard Medical Care|Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)
16347410|NCT04347369||Observed group|The patients who were detected COVID-19 disease by RT-PCR and CT imaging.
16347411|NCT04347343|Experimental|COMBO|Neuromuscular Electrical Stimulation and Blood Flow Restriction (COMBO) in addition to standard postoperative rehabilitation.
16347412|NCT04347330|Experimental|Intensive BP Control|Participants randomized into the Intensive BP Control arm will have a goal of home SBP <120mmHg. For most participants in the Intensive Group, a two- or three-drug regimen should be initiated at randomization. Following the randomization visit, addition of another drug or medication dose titration is indicated if home SBP is ≥120 mmHg. Monthly visits will continue in the Intensive Group until home SBP <120 mmHg or no more titration planned. If the home SBP is not <120 mmHg at the every 6-month visit, then an antihypertensive drug from a class different from what is being taken should be added, rather than up-titration the dosage of previous drugs, unless there are compelling reasons against this practice.
16347477|NCT04346940|Experimental|Study Group|The group to which the exercise protocol consisting of chair-based exercises will be applied.
16347478|NCT04346940|Active Comparator|Control Group|Group to be given an exercise brochure
16347479|NCT04346927|Experimental|Study Group|The group to which the exercise protocol consisting of breathing exercises, posture exercises, peripheral muscle training and light aerobic exercises will be applied.
16347413|NCT04347330|Active Comparator|Standard BP Control|Participants randomized into the Standard BP Control arm will have a goal of home SBP <135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is <125 mmHg.
16347414|NCT04347317|Active Comparator|Low Intensity IMT|
16347415|NCT04347317|Experimental|High Intensity IMT|
16347416|NCT04347304|Experimental|cocoa polyphenols|21 grams of dark chocolate (289 mg polyphenols)
16347417|NCT04347304|Placebo Comparator|polyphenols free|21 grams of white chocolate (0 mg polyphenols)
16347418|NCT04347291|Experimental|FAMS 2.0|"Patient participants will receive FAMS 2.0 components (monthly phone coaching and text message support for goals and medication adherence) for nine months. Linked support persons will receive text message support tailored to the goal set by the patient participant.
~All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes."
16347419|NCT04347291|Placebo Comparator|Print Materials|All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes.
16347420|NCT04347278||Patients receiving treatment for COVID19|
16347421|NCT04347265|Experimental|NMP in level 1|Participants in this group received NMP of the sciatic nerve in the gluteus region
16347422|NCT04347265|Experimental|NMP in level 2|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
16347423|NCT04347265|Experimental|NMP in level 3|Participants in this group received NMP of the sciatic nerve before popliteus region
16347424|NCT04347252|Experimental|Glucagon at basal glycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
16347425|NCT04347252|Experimental|Glucagon at hyperglycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
16347426|NCT04347252|Experimental|Glucagon at hyperglycemia with GLP-1R blockade|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study; concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
16347427|NCT04347239|Placebo Comparator|Placebo|
16347428|NCT04347239|Experimental|700mg Leronlimab|
16347429|NCT04347226|Experimental|BMS-986253|BMS-986253 2400mg IV
16347430|NCT04347226|No Intervention|Standard of Care treatment|Usual treatment of COVID-19 per study physician discretion
16347431|NCT04347213||omnivors|Participants who habitually consume all food groups in their diet.
16347432|NCT04347213||vegetarian|Participants who habitually avoid meat in their diet.
16347433|NCT04347213||vegan|Participants who habitually avoid all animal source food in their diet.
16347434|NCT04347213||low-carbohydrate high-fat diet|Participants who habitually avoid carbohydrate in their diet.
16347435|NCT04347174|Experimental|Suspension of Mw + Standard therapy of COVID-19|"0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days
~+ Standard therapy of COVID-19"
16347436|NCT04347174|Placebo Comparator|Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of Placebo intra-dermal for 3 consecutive days
16347437|NCT04347161|Experimental|Intervention Arm|Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
16347438|NCT04347161|Active Comparator|Control Arm|Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
16347439|NCT04347148|Experimental|SNAGs treatment|cervicogenic patients will undergo SNAGs treatment. Based on personal history, the offending active cervical movement (i.e. the movement predominantly causing dizziness) will be identified and treatment direction will be determined. As suggested, the active movement to most likely cause dizziness is cervical extension, though also rotation or flexion will be shown to provoke it. With the participant in an upright sitting position, a skilled physiotherapist (blinded to the allocation) will apply a sustained passive accessory movement (glide) while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing their symptoms. This procedure will be repeated six times.
16347480|NCT04346927|Active Comparator|Control Group|group to be given an exercise brochure
16347481|NCT04346914|Experimental|Combined treatment group|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
16347482|NCT04346901|Other|Single Intervention|Before-and-After type of research
16347440|NCT04347148|Placebo Comparator|Detuned Laser|cervicogenic patients will receive a sham treatment, carried out by the another skilled therapist (blinded to the allocation) and consisting in exposition to a detuned laser. A laser - deactivated by the manufacturer in order to produce no effective emission - will appear to operate normally, emitting a light signal and a beeping sound. Such procedure - which was shown to not activate somatosensory receptors and to have a very strong placebo effect - will be used for six applications, lasting 20 seconds, on various sites on the upper cervical spine, at a distance of 0.5-1cm from the skin.
16347441|NCT04347135|Experimental|F-18 FES PET/MRI|16α-(18)F-fluoro-17β-estradiol ([F-18] FES)
16347442|NCT04347122|Active Comparator|Bony tumor treated with Tranexamic acid (TXA)|This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
16347443|NCT04347122|No Intervention|Bony tumor treated without TXA|This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
16347444|NCT04347122|Active Comparator|Soft tissue sarcoma treated with Tranexamic Acid (TXA)|This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA
16347445|NCT04347122|No Intervention|Soft tissue sarcoma treated without TXA|This group of participants will undergo soft tissue sarcoma resection of the lower extremity.
16347446|NCT04347109||Biventricular Pacing|Patients implanted with a device enabling cardiac resynchronization therapy.
16347447|NCT04347109||Right Ventricular Pacing|Patients implanted with a right ventricular pacing device.
16347448|NCT04347096|Experimental|mHealth Intervention|The mHealth intervention group will have access to the Internet for using a newly developed Simple health web app and receive an activity tracker. The web app users are required to: (1) wear an activity tracker every day; (2) set goals of daily stand-up, physical activity, and healthy eating bi-weekly; (3) record stand-up, physical activity, and healthy eating behaviors daily; (4) set reminders to stand-up and record health behaviors; and (5) read educational and motivational tools. After completing the behavioral record, the personal advice will automatically provide to encourage, motivate and support the user. Moreover, the user will be able to look at his/her personal and team health ranking.
16347449|NCT04347096|Other|Control Intervention|The control intervention group will only receive educational tools (usual care).
16347450|NCT04347083|Experimental|Experiment|Reflex latency will be measured in this arm
16347451|NCT04347070||Patients accepted in ICU diagnosed with COVID-19|Patients accepted in ICU diagnosed with COVID-19
16347452|NCT04347057|Experimental|Arm 1|"Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period.
~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
16347453|NCT04347057|Experimental|Arm 2|"Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period.
~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
16347454|NCT04347044|Experimental|Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up plus Pulmonary rehabiltation
16347455|NCT04347044|Active Comparator|Non-Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up
16347456|NCT04347031|Experimental|group 1 cohort 1|"80 patients who receive Mefloquine prescribed according to the following scheme:
~1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.
~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.
~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
16347457|NCT04347031|Experimental|group 1 cohort 2|"80 patients who receive Hydroxychloroquine prescribed according to the following scheme:
~• 1st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day; 2nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
16347458|NCT04347031|Experimental|group 2 cohort 1|A concomitant therapy consisting of Mefloquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Mefloquine is same as for group 1 cohort 1.
16347459|NCT04347031|Experimental|group 2 cohort 2|A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
16347460|NCT04347018|Experimental|BRIUS|BRIUS orthodontic appliance (wire) will be used to treat the patients. BRIUS appliance will be engaged to regular orthodontic brackets intra-orally to initiate orthodontic treatment at the University at Buffalo Orthodontic Clinic.
16347461|NCT04347018|Active Comparator|Preadjusted edgewise full fixed appliance|regular full fixed orthodontic appliance (FFA) appliances will be used to treat patients. These are regular orthodontic brackets with standard orthodontic wires used to treat patients at the University at Buffalo Department of Orthodontics
16347462|NCT04347005|Experimental|AR882 (Dose A)|
16347463|NCT04347005|Experimental|AR882 (Dose B)|
16347464|NCT04347005|Experimental|AR882 (Dose C)|
16347465|NCT04347005|Experimental|AR882 (Dose D)|
16347466|NCT04347005|Experimental|AR882 (Dose E)|
16347467|NCT04347005|Experimental|AR882 (Dose B) Solid Oral Formulation|
16347468|NCT04347005|Placebo Comparator|Placebo|
16347469|NCT04347005|Active Comparator|Allopurinol|
16347470|NCT04347005|Active Comparator|Febuxostat|
16347471|NCT04346979|Experimental|Study Group|Telerehabilitation based yoga and mindfulness training will be given to the study group.
16347472|NCT04346979|Experimental|Control Group|Yoga and mindfulness training will be provided by sending a video recording to the control group.
16347473|NCT04346966|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
16347474|NCT04346966|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
16347475|NCT04346953|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
16347476|NCT04346953|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
16347483|NCT04346888|Experimental|HBM9161 (680mg and 340 mg)|Subcutaneous injection; Blinded: HBM9161 680mg; Open-label: HBM9161 340mg;
16347484|NCT04346888|Experimental|HBM9161 (340 mg)|Subcutaneous injection; Blinded: HBM9161 340mg; Open-label: HBM9161 340mg;
16347485|NCT04346888|Placebo Comparator|Placebo, HBM9161 (340 mg)|Subcutaneous injection; Blinded: Placebo; Open-label: HBM9161 340mg;
16347486|NCT04346875|Experimental|Regularly changing group|Participants will undergo dressing every 3 days by the senior wound care nurse
16347487|NCT04346875|Active Comparator|Non-changing group|Participants will not be subject to dressing change.
16347488|NCT04346862|Experimental|Acetyl-L-carnitine hydrochloride|
16347489|NCT04346862|Placebo Comparator|Placebo|
16347490|NCT04346849|Experimental|MTA pulpotomy|Teeth receiving pulpotomy using MTA
16347491|NCT04346849|Experimental|Biodentine pulpotomy|Teeth receiving pulpotomy using Biodentine
16347492|NCT04346849|Experimental|Bioceramic pulpotomy|Teeth receiving pulpotomy using Bioceramic
16347493|NCT04346836|Experimental|Metabolic Syndrome|"Elderly women with Metabolic Syndrome
~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
16347494|NCT04346836|Experimental|Non-Metabolic Syndrome|"Elderly women without Metabolic Syndrome.
~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
16347495|NCT04346823|Experimental|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3 minutes. Then, parturients breath 1% of sevoflurane in mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min. Values of inspired (FI) and end-tidal (FET) concentrations of sevoflurane, oxygen and respiratory rate (RR) measured by end-tidal carbon dioxide (EtC02) were monitored continuously and recorded at 30 seconds intervals by a gas analyzer.
~30 seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure. HR, FI and FET concentration of sevoflurane, Sp02 and EtC02 will be recorded at 30-s interval during ECV. Non-invasive BP will be recorded every one minute. Duration of ECV in addition to level of difficulty estimated by obstetrician will be recorded.
~ECV considered successful when a cephalic presentation, confirmed by ultrasound scan, achieved."
16347496|NCT04346823|No Intervention|No sevoflurane|If the parturient is assigned to the control (nonintervention) group, the participants will not receive any medications neither tocolytics nor analgesics as the routine care in our hospital. However, the participants will be monitored throughout the procedure for vital signs and for pain scores as in the intervention group.
16347497|NCT04346810||Recovery room caregivers|Caregivers working at a recovery room shifted into an intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
16347498|NCT04346810||Intensive care unit caregivers|Caregivers working at a conventional intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
16347499|NCT04346797|Experimental|Eculizumab|Eculizumab
16347500|NCT04346797|No Intervention|Standard of Care|Best standard of care
16347501|NCT04346784|Experimental|maintaining positive working memory training|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
16347502|NCT04346784|Experimental|repressing negative working memory training|Repressing negative working memory training is a dual n-back task containing visual and auditory stimulus.Both two types of stimulus are negative.In this training, subjects are required to identify whether the location of picture presented on the screen or the word appeared in the headphone is the same as the picture or the word presented n before, then react with typing correspondingly.Each training session contains 16 blocks which are consisted with 20+n trails.
16347503|NCT04346784|Experimental|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
16347504|NCT04346784|Placebo Comparator|Positive placebo ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
16347505|NCT04346771|Experimental|Maintaining Positive Working memory|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
16347506|NCT04346771|Placebo Comparator|Positive Attention Bias Modification|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
16347507|NCT04346758|Other|Modified Shamrock approach|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
16347508|NCT04346745|Experimental|Treatment group|The treatment group will receive intervention of a peer mentoring program plus usual services they could receive from community agencies.
16347509|NCT04346745|No Intervention|Control group|The control group will receive usual services they could receive from community agencies.
16347510|NCT04346732|Experimental|Vapocoolant spray|Vapocoolant spray was applied to the donors in the vapocoolant spray group.
16348652|NCT04338516|Experimental|Ossix™ Bone|subjects treated with Ossix™ Bone (Datum Dental Ltd)
16347511|NCT04346732|No Intervention|Control|The donors in the control group were not given any intervention during the blood collection process.
16347512|NCT04346719|Experimental|10 kHz stimulation|"Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16347513|NCT04346719|Experimental|20 kHz stimulation|"Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16347514|NCT04346719|Sham Comparator|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
16347515|NCT04346706|Experimental|Immediate implantation|Tooth extraction, immediate insertion of an implant with immediate temporization
16347516|NCT04346706|Experimental|Delayed implantation|Implant inserted in a healed socket with immediate temporization
16347517|NCT04346693|Active Comparator|group 1|80 patients with moderate and critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). Standard therapy is prescribed recommended by the Ministry of Health of the Russian Federation.
16347518|NCT04346693|Experimental|group 2|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days).
16347519|NCT04346693|Experimental|group 3|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
16347520|NCT04346693|Experimental|group 4|80 patients with moderate to critical severity of the disease with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular administration of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days) in conjunction with inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
16347521|NCT04346680|Experimental|Experimental group|
16347522|NCT04346667|Active Comparator|Arm 1|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
16347523|NCT04346667|Experimental|Arm 2|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
16347524|NCT04346667|Active Comparator|Arm 3|Chloroquine 500 mg BID for 5 days plus standard of care
16347525|NCT04346667|Placebo Comparator|Arm 4|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
16347526|NCT04346654|Experimental|Eltrombopag + Dexamethasone|Patients will be treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg QD from day 1-4) to induce sustained response off treatment.
16347527|NCT04346654|Active Comparator|Dexamethasone|Patients will be treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 every 14-28 days) to induce sustained response off treatment
16347528|NCT04346628|Experimental|Favipiravir|In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.
16347529|NCT04346628|Active Comparator|Placebo|In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.
16347530|NCT04346615|Experimental|Zavegepant|Zavegepant (BHV-3500) 10 mg intranasal (IN) Q8h for 14 days
16347531|NCT04346615|Placebo Comparator|Placebo|Placebo Q8h for 14 days
16347532|NCT04346602||patients with COVID-2019|Patients with COVID-2019 would be observed.
16347533|NCT04346589|Experimental|Antibodies (immunoglobulins) infusion|Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
16347534|NCT04346576|Experimental|Probiotics (LcS per 65 mL) prevent health problems in children|Probiotic test product was fermented milk containing 6.5 billion of LcS per 65 mL (108 CFU/mL), manufactured by Yakult Vietnam, Co., Ltd. The nutritional composition of the test product is 0.8 g of protein, <0.1 g of fat, 12.4 g of carbohydrates, and the total energy is 52.7 kcal per bottle. Subjects were asked to drink one bottle of the test product per day after lunch for 12 weeks on consecutive days. The test products were stored in a refrigerator (< 10°C), protected from direct sunlight, and used before their expiration date. Adherence to the intervention protocol was confirmed as follows; teachers at kindergartens or parents at home provided the probiotic drinks (1 bottle/day x 7 days/week) after lunch.
16347535|NCT04346563|Experimental|Kinesio tape, functional correction applying|The experimental group, trained by Certified Kinesio tape researcher will attache the kinesio tape. Attaching the kinesio tape by using functional correction techniques, apply tape from the front of the acromion process to the spinous process T10 on both sides, providing 50% of the tape's tension (Kase, 2003, Han JT et al) to create a scapular retraction.
16347536|NCT04346563|Placebo Comparator|Placebo Kinesio taping apply|Apply kinesio tape without tension.
16347537|NCT04346550|Active Comparator|Drain Group|Suction drain was placed in sub hepatic region through 5 mm lateral trocar site.
16347538|NCT04346550|No Intervention|Without Drain Group|No drain was placed
16347539|NCT04346524||microbiome sampling|pregnant women with type 1 diabetes
16347540|NCT04346511|Experimental|Acupuncture|In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.
16347652|NCT04345731|Experimental|Condition 3 - FOP warning label|This condition will involve presenting critical drug/drug, and drug/diagnosis information in a novel Front-of-Pack (FOP) warning label.
16347541|NCT04346511|Sham Comparator|Sham Acupuncture|Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site.
16347542|NCT04346498|Experimental|CB-SSC|The participant received CB-SSC for 2 hours per day for three consecutive days
16347543|NCT04346498|Placebo Comparator|CC-SSC|Following a 30 minute washout time, the same participant would continue to receive chest-to-chest (CC) SSC for 2 hours. This was also conducted for three consecutive days
16347544|NCT04346485|Experimental|SP TFL RIRS with 145 mcm fiber|Superpulse thulium fiber laser RIRS with 145 mcm laser fiber
16347545|NCT04346485|Experimental|SP TFL RIRS with 200 mcm fiber|Superpulse thulium fiber laser RIRS with 200 mcm laser fiber
16347546|NCT04346485|Active Comparator|Ho:YAG RIRS with 200 mcm fiber|Ho:YAG laser RIRS with 200 mcm laser fiber
16347547|NCT04346472||Gliomes de grade II initial|Gliomes de grade II initial
16347548|NCT04346459|Active Comparator|Group A- Fastrach (control group)|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using intubating laryngeal mask airway Fastrach following blind intubating method through Fastrach"
16347549|NCT04346459|Active Comparator|Group B- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using I-gel supraglottic airway device as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
16347550|NCT04346459|Active Comparator|Group C- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using the Protector laryngeal mask airway as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
16347551|NCT04346446|Experimental|Convalescent Plasma+Supportive Care|Convalescent Plasma+Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients
16347552|NCT04346446|Active Comparator|Random Donor Plasma+Supportive Care|Random Donor Plasma+Supportive Care
16347553|NCT04346433|Experimental|Adolescents with Normal Weight|This group will be comprised of 30 adolescents with normal weight (BMI equal to or greater than the 5th percentile but less than the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
16347554|NCT04346433|Experimental|Adolescents with Overweight or Obesity|This group will be comprised of 30 adolescents with overweight or obesity (BMI equal to or above the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
16347555|NCT04346420|Experimental|O2 DTM+|The standard nasal cannula interface is accompanied with the DTM
16347556|NCT04346420|Active Comparator|O2 DTM-|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient, without the DTM
16347557|NCT04346407|Experimental|Dronabinol|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
16347558|NCT04346407|Placebo Comparator|Placebo|Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery
16347559|NCT04346394|Experimental|Yohimbine|The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.
16347560|NCT04346381|Experimental|camrelizumab combined with famitinib|Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
16347561|NCT04346368|Experimental|Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)|Conventional treatment plus BM-MSCs
16347562|NCT04346368|Placebo Comparator|Placebo|Conventional treatment plus placebo
16347563|NCT04346355|Experimental|Experimental Arm|Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
16347564|NCT04346355|Other|Control Arm|Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
16347565|NCT04346342||Mechanical ventilation|COVID patients receiving invasive mechanical ventilation
16347566|NCT04346329|Placebo Comparator|Control|Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
16347567|NCT04346329|Experimental|treated|hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
16347568|NCT04346316|Active Comparator|SHR0302 Dose#1|
16347569|NCT04346316|Active Comparator|SHR0302 Dose#2|
16347570|NCT04346316|Active Comparator|SHR0302 Dose#3|
16347571|NCT04346316|Placebo Comparator|Placebo|
16347572|NCT04346303|Other|Short-term Interactive Video Games|Short-term video games will be applied to patients with mental illness who are staying in communities. Games will be applied in a group-activity format with 8 to 12 patients in each session. The interventions will be conducted at a two sessions per week for a 3-week long period. There are 3 time points for data collection, including 2-weeks before the intervention, the week before the intervention, and the week after the intervention. Each patient will be his/her own controlled comparison.
16347573|NCT04346290|No Intervention|Control|Standard anesthesia care for kidney donor
16347574|NCT04346290|Experimental|Dexmedetomidine|Standard anesthesia care and perioperative infusion of dexmedetomidine for kidney donor
16347575|NCT04346264||General Cohort|Population general cohort from the Austrian LEAD Study
16347576|NCT04346238||Patients with Friedriech Ataxia genetically confirmed|Patients with Friedriech Ataxia genetically confirmed
16347577|NCT04346225|Experimental|Cohort A: Hyperpolarized C13 MRI at a single time point|Participants will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at a single time point and will receive up to two 13C pyruvate (C-1 and C-2 labeled 13C pyruvate) investigational medicinal product (IMP) injections on the day of imaging (2nd injection is optional), as well as optional MR- or CT- guided tumor biopsies at baseline and at the time of disease progression following completion of HP C-13 MRI at the corresponding time point
16347686|NCT04345458|Experimental|group II|once weekly 50 mg prefilled liquid etanercept
16347578|NCT04346225|Experimental|Cohort B: Hyperpolarized C13 MRI at multiple time points|Participants will undergo hyperpolarized (HP) C13 MRI at baseline and 12 weeks (+/- 8 weeks). Participants in Cohort B may undergo additional optional MR imaging at the time of disease progression. the same sequence of injections (C-1 labeled pyruvate first, C-2 labeled pyruvate second) will be used for subsequent scan time points as well.
16347579|NCT04346212||Patients infected by SARS-CoV-2|Patients infected by SARS-CoV-2 at the Hospital de Mataró, Hospital de St. Jaume i Sta. Magdalena and other medicalized facilities in Mataró.
16347580|NCT04346199|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
16347581|NCT04346199|No Intervention|Arm 2|Best Supportive Care
16347582|NCT04346186||Hospital Staff in the Capital Region of Denmark|
16347583|NCT04346186||Healthy volunteer blood donors|
16347584|NCT04346173|Experimental|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
16347585|NCT04346160||Patients with bilateral conjunctivitis|Hospitalized patient affected by COVID-19 disease with bilateral conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
16347586|NCT04346160||Patients without conjunctivitis|Hospitalized patient affected by COVID-19 disease without any signs of conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
16347587|NCT04346160||Healthy control group|group of healthy patients considered as controls
16347588|NCT04346147|Experimental|Imatinib 400 mg|Imatinib 400 mg 1 tablet 24 hours
16347589|NCT04346147|Experimental|Baricitinib 4 mg|Baricitinib 4 mg 1 tablet 24 hours
16347590|NCT04346147|Experimental|Supportive treatment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
16347591|NCT04346134|Experimental|mini-PNL group|In which percutaneous nephrolithotomy will be performed using miniature nephroscope.
16347592|NCT04346134|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
16347593|NCT04346108|Experimental|Epoch 1: Immune Globulin Intravenous (IGIV)|Participants will receive approximately 200 to 600 milligrams per kilogram (mg/kg) of Immunoglobulin Globulin Intravenous (IGIV) infusion for every 3 or 4 weeks for a total of 13 weeks.
16347594|NCT04346108|Experimental|Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive approximately 50 to 200 mg/kg of IGSC infusion, 20 percent (%) once a week for a total of 24 weeks.
16347595|NCT04346108|Experimental|Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive approximately 100 to 400 mg/kg of IGSC infusion, 20% once every two weeks in a sub-set of 7 participants for a total of 12 weeks.
16347596|NCT04346095|Experimental|Oral Sedative|"Participants will receive oral triazolam 30 minutes prior to surgery.
~Dose for BMI less than 35: 0.125 mg
~Dose for BMI greater than or equal to 35: 0.25 mg
~Followed by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.
~Vitals will monitored by the operating room nurses."
16347597|NCT04346095|Active Comparator|Intravenous Sedative|"This group will receive an intravenous sedative. The sedative is limited to midazolam, fentanyl, propofol.
~Follow by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.
~IV and monitoring will be performed by anesthesiologist or CRNA."
16347598|NCT04346082|Experimental|online mindfulness group|
16347599|NCT04346069|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group
16347600|NCT04346069|Other|Parent-child interaction therapy|Parent child interaction therapy will be provided to the experimental group
16347601|NCT04346030|Experimental|steroid and hydrodissection|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
16347602|NCT04346030|Active Comparator|steroid only|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)
16347603|NCT04346017|Experimental|Ventilation support|The experimental group will include Covid-19 infected patients with non-invasive or invasive ventilation support (BCRSS score ≥3).
16347604|NCT04346017|Other|Control group|The control group will include Covid-19 infected patients who don't have respiratory problems justifying a transfer to intensive care.
16347605|NCT04346004|Placebo Comparator|Control group|Participants in this group are administered N/S.
16347606|NCT04346004|Experimental|Iron isomaltoside group|Participants in this group are administered Iron isomaltoside & Vitamin B12.
16347609|NCT04345978|Placebo Comparator|Normal Fasting|The patient starts fasting 8 hours before the operation,and does not take any solid or liquid foods and nutrients during the fasting process.The fasting period does not strictly limit the consumption of pure water,After surgery 8 hours,the patients was allowed to feeding.
16347610|NCT04345978|Experimental|Prolong Fasting|The patient starts fasting 24 hours before the operation, and does not take any solid or liquid foods and nutrients during the fasting process. The fasting period does not strictly limit the consumption of pure water.After surgery 24 hours,the patients was allowed to feeding.
16347611|NCT04345965||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
16347612|NCT04345952|Experimental|Calm Meditation|Participants in the Calm group will be asked to use the Calm app ad libitum during their time spent receiving chemotherapy at the Mays Cancer Center (~2 hours) and while at home between treatment cycles ad libitum. Participation will be measured during the entire intervention using internal tracking systems within the app (i.e., # of times logged in, type of meditation accessed, time spent meditating, date and time of meditation accessed). This data will be provided to us through data coordinator of the app.
16347687|NCT04345458|Active Comparator|group III|25 mg twice weekly lyophilized etanercept powder
16347688|NCT04345445|Experimental|Tocilizumab|Tocilizumab is given at 8 mg/kg (body weight) once and administered as an intravenous infusion within no less than 60 minutes.
16347613|NCT04345952|No Intervention|Usual Care|The usual care control group will not be offered anything to listen to during their chemotherapy treatment cycles or when they are between chemotherapy treatment cycles. They will receive their treatment as intended without any additional intervention.
16347614|NCT04345939||GenSeizer|Sputum and lavage fluids are tested for pathogens using GenSeizer
16347615|NCT04345939||PCR reverse hybridization|Sputum and lavage fluids are tested for pathogens using PCR reverse hybridization
16347616|NCT04345939||Target sequencing after incubation|Sputum and lavage fluids are tested for pathogens using Target sequencing after incubation
16347617|NCT04345926|Experimental|Dose-response|"- Concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL) (LOS time).
~- Patients will be intubated and remifentanil will be decreased to 4 ng/mL.
~- Concentration of propofol that caused the LOS will be maintained for 20 minutes (Baseline time).
~- Propofol will be increased in steps of 0.3 mcg/mL for 7 minutes until an episode of burst suppression will be observed (Burst suppression time).
~EEG activity will be acquired using a SedLine® monitor during the complete protocol."
16347618|NCT04345913|Active Comparator|Group I (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16347619|NCT04345913|Experimental|Group II (eribulin, copanlisib)|Patients receive copanlisib IV over 60 minutes and eribulin IV over 2-5 minutes on days 1 and 8 or days 1 and 15. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
16347620|NCT04345900|Experimental|20 mg/m^2 Plinabulin|Docetaxel + 20 mg/m^2 Plinabulin
16347621|NCT04345900|Experimental|10 mg/m^2 Plinabulin|Docetaxel + 10 mg/m^2 Plinabulin
16347622|NCT04345900|Experimental|5 mg/m^2 Plinabulin|Docetaxel + 5 mg/m^2 Plinabulin
16347623|NCT04345900|Active Comparator|6 mg Pegfilgrastim|Docetaxel + 6 mg Pegfilgrastim
16347626|NCT04345874|Experimental|Nutrition technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
16347627|NCT04345874|Experimental|Children's environmental health technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
16347628|NCT04345861|Active Comparator|monotherapy hydroxychloroquine|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) + placebo from Day 1 to Day 5
16347629|NCT04345861|Experimental|combination hydroxychloroquine + azithromycin|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) and azithromycin 500mg (Day 1 ), 250 mg (from day 2 to Day 5)
16347630|NCT04345848|Experimental|Therapeutic anticoagulation|Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
16347631|NCT04345848|Active Comparator|Prophylactic anticoagulation|Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.
16347632|NCT04345835|Active Comparator|prone flexed|prone flexed PCNL position
16347633|NCT04345835|Active Comparator|prone|prone position PCNL
16347634|NCT04345822||normotension|patients without diagnosis or treatment for hypertension
16347635|NCT04345822||hypertension|patients with diagnosis or treatment for hypertension
16347636|NCT04345809||GROUP A. MESH WITH OMEGA-3|Group A - 6.4-cm diameter circular prosthesis C-QUR V-Patch with an omega-3 coating
16347637|NCT04345809||GROUP B. MESH WITHOUT OMEGA-3|Group B - 6.4-cm diameter circular prosthesis BARD Hernia Patch , without omega-3 in its composition
16347638|NCT04345796|Active Comparator|carvedilol+empagliflozin|Patients will receive carvedilol SR 16mg and empagliflozin 10mg qd.
16347639|NCT04345796|Active Comparator|carvedilol alone|Patients will receive carvedilol SR 16mg alone.
16347640|NCT04345796|Active Comparator|empagliflozin alone|Patients will receive empagliflozin 10mg and matching placebo of carvedilol.
16347641|NCT04345796|Placebo Comparator|placebo|Patients will receive matching placebo of carvedilol.
16347642|NCT04345783|Experimental|Camrelizumab+Apatinib Mesylate+Tegio|
16347643|NCT04345770|Sham Comparator|Without HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
16347644|NCT04345770|Experimental|With HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
16347645|NCT04345757|No Intervention|Standard instructions|Standard instructions: activity restrictions, including no strenuous exercise, sexual intercourse, or lifting objects greater than 25 pounds for 6 weeks or until evaluation at the 6 week postpartum visit
16347646|NCT04345757|Experimental|Study Group|Study group: Structured 10 week exercise protocol
16347647|NCT04345744|Experimental|Test group 1|administration of a hyaluronic and 0.2% chlorhexidine mouth rinse
16347648|NCT04345744|Experimental|Test group 2|administration of chlorhexidine 0.2% mouth rinse
16347649|NCT04345744|Active Comparator|Control Group|No administration of mouth rinses after surgery
16347650|NCT04345731|No Intervention|Condition 1 - Control|"We note that our within subjects experimental design, in which each subject receives all treatments, is not well suited to this system of reporting. Thus we are defining arms as the label treatments we are evaluating. This label is the control label treatment which represents the current, legally required over-the-counter labeling standard."
16347651|NCT04345731|Experimental|Condition 2 - Highlighted|This condition will involve a novel method of presenting critical active ingredient, drug/drug, and drug/diagnosis information with highlighting.
16347802|NCT04344782|No Intervention|Standard of Care|
16347653|NCT04345731|Experimental|Condition 4- FOP+Highlighting label|This condition will combine both the highlighting and FOP labeling interventions from conditions 2 and 3. Note: Across the four arms we are essentially doing a 2 (highlighting/no highlighting) by 2 (front of pack warning/ no front of pack warning) within subjects design.
16347654|NCT04345718|Experimental|Interventional|Single subcutaneous injection of a 28-day formulation of extended-release buprenorphine within 72 hours of anticipated hospital discharge.
16347655|NCT04345718|Active Comparator|Treatment as Usual|Community standard of care that includes initiation of either methadone, sublingual (SL) buprenorphine, or naltrexone prior to hospital discharge.
16347656|NCT04345692|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
16347657|NCT04345692|No Intervention|Usual Care|usual care for hospitalized patients diagnosed with COVID-19
16347658|NCT04345679|Experimental|Hospitalized patients with SARS CoV-2 infection|
16347659|NCT04345666|Experimental|Testosterone group|20 patients will receive a 200 mg testosterone cyprionate intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
16347660|NCT04345666|Placebo Comparator|Placebo group|20 patients will receive a sterile saline intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
16347661|NCT04345653|Experimental|Study arm - Hydroxychloroquine Sulfate (HCQ)|HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
16347662|NCT04345640||Covid-19 with liver disease|Covid-19 with liver disease
16347663|NCT04345640||Covid-19 without liver disease|Covid-19 without liver disease
16347664|NCT04345614|Experimental|Auxora|Patients will be randomized 1:1 to receive either Auxora or placebo
16347665|NCT04345614|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive either Auxora or placebo
16347666|NCT04345601|Experimental|Mesenchymal stromal cells|Patients will receive up to 2 infusions of mesenchymal stem cells.
16347667|NCT04345601|Other|Control Group|Patients will receive supportive care or treatment designated by their treating doctor.
16347668|NCT04345588|Active Comparator|group received dexamethasone perineural|injection dexamethasone 0.05 mg/kg perineural.
16347669|NCT04345588|Active Comparator|group received dexamethasone intravenous|injection dexamethasone 0.05 mg/kg intravenously.
16347670|NCT04345575|Experimental|VR Group|VR group participants were mailed an Oculus Go Virtual Reality headset preloaded with VR software developed by AppliedVR. Treatment content consisted of a variety of 21 sessions to support participants in learning cognitive and behavioral self-management skills based on evidence-based CBT principles and skills, biofeedback and mindfulness strategies used in pain management. The program was designed to improve self-regulation of cognitive, emotion, and physiological response to stress and pain.
16347671|NCT04345575|Active Comparator|Audio Group|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the Audio program included didactic and experiential content that was not identifical but was closely matched to the VR content (sans references to visual imagery that would be confusing in the absence of visual content). Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
16347672|NCT04345562|Active Comparator|Back and forth pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin prep over the suspected skin incision site for 30 sec - the first applicator will then be used in a back and forth pattern work up towards the upper edge of the surgical field. The first applicator will then be discarded. The second applicator will then again start at the expected site of the incision and again working inferiority until the lower edge of the surgical field is reached.
16347673|NCT04345562|Active Comparator|Circular pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin over the suspected skin incision site for 30 sec - the applicator will then be moved in a circular pattern moving outwards form the incision site until approximately half of thee surgical field is cleaned. The second applicator will then be used to complete the surgical prep until the entire surgical field is prepped in accordance with the package instructions.
16347674|NCT04345549|Experimental|Ayurveda|All the participants were advised to self-isolate for 7-days and maintain hygiene and self-care as per recommended guidelines. Along with that, participants were advised to constitution based Ayurveda treatment using herbs, life style and yoga.
16347675|NCT04345536||Patients hospitalized with confirmed Covid-19|All patients hospitalized with confirmed Covid-19
16347676|NCT04345523|Experimental|Treatment Arm|Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.
16347677|NCT04345523|Active Comparator|Control Arm|Standard of Care (SOC) for COVID-19
16347678|NCT04345497|Experimental|Diabetes-Specific Formula|Diabetes-specific formula 1-2 servings a day and Standard of Care
16347679|NCT04345497|Other|Standard of Care|Standard of Care
16347680|NCT04345484|Experimental|GMT Intervention + Health Lifestyle Program|The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
16347681|NCT04345484|Active Comparator|Health Lifestyle Program|The control group enters directly into the HLP without any other study visits. The HLP includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
16347682|NCT04345471|Experimental|MD-120 100 mg|
16347683|NCT04345471|Experimental|MD-120 50 mg|
16347684|NCT04345471|Placebo Comparator|Placebo|
16347685|NCT04345458|Experimental|group I|twice weekly 25 mg prefilled liquid etanercept
16347689|NCT04345445|Active Comparator|Methylprednisolone|Reconstituted methylprednisolone is infused over 30 minutes and administered at a dose of 120mg/day for 3 days
16347690|NCT04345432|Experimental|Gabapentin|"The experiment will be divided into the following phases:
~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above
~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.
~7 day drug washout phase - no medication will be taken
~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.
~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
16347691|NCT04345432|Placebo Comparator|Placebo|"The experiment will be divided into the following phases:
~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above
~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.
~7 day drug washout phase - no medication will be taken
~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.
~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
16347692|NCT04345419|Experimental|Remdesivir|Remdesivir with standard of care treatment standard of care treatment
16347693|NCT04345419|Placebo Comparator|Standard of care|Standard of care treatment alone.
16347694|NCT04345406|Experimental|ACEIs|ACEIs with conventional treatment for COVID19
16347695|NCT04345406|Experimental|Conventional treatment of COVID19|Conventional treatment of COVID19
16347696|NCT04345393|Experimental|Digital Transformation Network (DTN) Program|IBD patients at the 3 sites will be sent a message to their Smartphone
16347697|NCT04345393|Active Comparator|Control Arm|Patients will enter the control group once they initially complete the ePRO and online assessment tools. They will remain in the control group, and then at set intervals each site will transition these patients into the DTN intervention arm.
16347698|NCT04345380|Active Comparator|Acrysof Rotation|Implantation of the Acrysof SN60WF Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
16347699|NCT04345380|Active Comparator|Tecnis Rotation|Implantation of the Tecnis ZCB00 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
16347700|NCT04345380|Active Comparator|Envista Rotation|Implantation of the Envista MX60 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
16347701|NCT04345367|Experimental|Abrocitinib 200 mg plus placebo injection|Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
16347702|NCT04345367|Active Comparator|Dupilumab 300 mg plus placebo tablets|Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
16347703|NCT04345354||Patient with continuous positive airway pressure treatment|
16347704|NCT04345354||without continuous positive airway pressure treatment|
16347705|NCT04345341|Active Comparator|Laparoscopic assisted TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
16347706|NCT04345341|No Intervention|no TAP block|no TAP block would be done
16347707|NCT04345328||Roux-en-Y gastric bypass|Patients who were planned for surgery with Roux-en-Y gastric bypass and were operated
16347708|NCT04345328||Sleeve Gastrectomy|Patients who were planned for surgery with Sleeve Gastrectomy and were operated
16347709|NCT04345328||Control group|Obese patients involved in a weight loss program that focuses on diet and lifestyle changes
16347710|NCT04345315||asymptomatic population at high risk of infection|healthy individuals at high risk of infection, including individuals who have had contact with a patient tested positive for COVID-19, voluntary health workers and oncological patients candidate to immunosuppressive therapy
16347711|NCT04345315||COVID-19 patients|patients with confirmed diagnosis of COVID-19
16347712|NCT04345302|Experimental|Brief motivational treatment|"Participants in the intervention group will receive the Brief Motivational Treatment, which is a primary care-adaptation of the Motivational Enhancement Therapy as manualized in the Project MATCH [19]. This treatment consists of four 45-minute sessions, provided by a psychologist at weeks one, two, six, and twelve. The first three sessions, occurring during the first six weeks, are more active regarding the behavioural change, while the last session functions as closure and review of the process. If a participant asks for more support, they will be able to attend up to two extra sessions before the last one.
~The main adaptations are:
~The translation into Chilean Spanish.
~Update of Motivational Interview concepts.
~Companion training material that includes a demonstrative video and practical exercises.
~An adapted personalized feedback procedure.
~Information on additional resources available in the primary care centre and the community."
16347713|NCT04345302|Active Comparator|Enhanced usual care|"All participants will receive an educational brochure on alcohol use disorder, with self-help materials and guides on how to get additional support.
~The physicians within the PC centre will also receive information on how to diagnose alcohol use disorders, prescription guides for the medications that are available for treating these disorders in the PC centre (mainly Disulfiram and any other if available), and directions on when and where to refer clients for treatment."
16347714|NCT04345289|Active Comparator|Convalescent plasma|Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
16347715|NCT04345289|Placebo Comparator|Infusion placebo|Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.
16347716|NCT04345276|Experimental|Danoprevir+Ritonavir group|
16347717|NCT04345263|Active Comparator|MTA pulpotomy|Tooth will receive MTA & resin composite restoration
16347718|NCT04345263|Active Comparator|Biodentine pulpotomy|Tooth will receive Biodentine & resin composite restoration
16347719|NCT04345263|Active Comparator|Bioceramic pulpotomy|Tooth will receive Bioceramic & resin composite restoration
16347932|NCT04343859|Experimental|IMMH-010-240mg|Part A Dose escalation study: 240mg, QD, Cycle0Day1, Cycle1Day1- CycleN
16347720|NCT04345250|Experimental|Participants|"For a period of 6 days between the exercise trials (i.e., following visit 3), each participant will be put on a restricted energy restricted diet consisting of a 25% reduction in their habitual total daily calorie intake. To keep the diet consistent and standardized, participants will record their typical food intake during a control week using the Eat This Much app, which will then provide an overall portion plan and the 25% caloric restriction measure for the intervention week. Thus, the intervention diet will mirror the control diet in terms of types of food consumed, with the difference being in the amount consumed. There will be no restriction regarding water, but drinks will be restricted according to the overall calorie intake plan."
16347721|NCT04345237|Experimental|Experimental group 1 (TS + placebo)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.
~Daily consumption for 3 months of placebo milk."
16347722|NCT04345237|Experimental|Experimental group 2 (TS + leucine)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.
~Daily consumption for 3 months of milk enriched with leucine."
16347723|NCT04345237|Experimental|Experimental group 3 (HRC + placebo)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.
~Daily consumption for 3 months of placebo milk."
16347724|NCT04345237|Experimental|Experimental group 4 (HRC + leucine)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.
~Daily consumption for 3 months of milk enriched with leucine."
16347725|NCT04345237|Experimental|Experimental group 5 (no physical exercise + leucine)|"The subjects will not carry out any type of physical activity.
~Daily consumption for 3 months of milk enriched with leucine."
16347726|NCT04345237|No Intervention|Control (no physical exercise + placebo)|"The subjects will not carry out any type of physical activity.
~Daily consumption for 3 months of placebo milk."
16347727|NCT04345224|Experimental|Dynamic tape|The gluteal muscle group will be covered with a dynamic tape.
16347728|NCT04345224|Experimental|Rigid tape|The gluteal muscle group will be covered with a rigid tape.
16347729|NCT04345224|Sham Comparator|Sham tape|The gluteal muscle group will be covered with a paper tape - a sham application.
16347730|NCT04345211|Active Comparator|Group1 (G1): walking group|"All walks will be done immediately after the MT and TB intervention, as this has been shown to improve the synergistic effect of combining the two interventions. The walking sessions will be organized twice a week. The walking sessions will begin with a 10-minute warm-up. After warming up, you will take a continuous walk for 10-20 min, at a target intensity of 13 (somewhat difficult) on the Borg scale. Using the Borg scale, which ranges from 6 to 20, participants will be asked to walk at an intensity of 13 (perception of somewhat difficult activity). Each session will be completed with a 10 minute cool down period. The objectives of Walinking will be individualized according to the level of physical condition of each participant. The walking group will include a weekly walking goal of 75 minutes."
16347731|NCT04345211|Active Comparator|Group 2 (G2): walking plus manual therapy|"Walking as previously described plus a self-administered manual chest therapy:
~- Neurolymphatic points pressure: Participants will be placed in a neutral position and their arms next to their bodies. They are asked to take a conscious breath. The physical therapist will apply firm, direct rotary pressure through the thumb or fingertip for 1 minute from the T1 transverse processes to the T12 transverse processes. Suboccipital decompression / mobilization, slippage of the cervical vertebral joints (anterior / posterior), myofascial release of sternocleidomastoid and trapezius, slippage of the sternoclavicular joint (anterior / posterior direction), myofascial release of intercostal muscles and paravertebral muscles (anterior rib mobilization, posterior, lateral), mobilization of the scapulothoracic joint, diaphragmatic release."
16347732|NCT04345211|Active Comparator|Group 3 (G3): walking plus thorax exercises with Theraband.|Walking as previously described plus a self-administered exercises with elastic-band. The exercises will include chest and arms exercises in sitting position.
16347733|NCT04345211|No Intervention|Group 4 (G4): control group|Control group will do usual life and assessments as the rest of the groups.
16347734|NCT04345198|Experimental|Intervension|Adrenal artery ablation is performed in PA patients with resistant hypertension.
16347735|NCT04345185||Project Viva|Project Viva (1999-present) enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age.
16347736|NCT04345185||Infant Feeding Practices Study II|The Infant Feeding Practices Study II (IFPS II, 2005-2007) enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years.
16347737|NCT04345172|Active Comparator|a lacrimal dilator group (Group LD)|The patients allocated to receive STB performed with a lacrimal dilator
16347738|NCT04345172|Active Comparator|a Wescott scissors (Group WS)|The patients allocated to receive STB performed with a Wescott scissors
16347739|NCT04345159||Patient with autoimmune disease|Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.
16347740|NCT04345146|Experimental|FSRT & Bevacizumab|Patients will receive Bevacizumab before and after FSRT: daily FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases with Bevacizumab(7.5mg/kg, q3w, IV)
16347741|NCT04345133|Active Comparator|Undersized Drilling Group|Exposed patients to the reduction of the final drill dimensions at the insertion implants protocol sequence
16347742|NCT04345133|Other|Conventional Drilling Group|Group with the conventional protocol recommended by the manufacturer
16347743|NCT04345120|Experimental|SY-008-6mg/d|2mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，12mg/d.
16347744|NCT04345120|Experimental|SY-008-12mg/d|4mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，18mg/d.
16347803|NCT04344769||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
16347745|NCT04345120|Experimental|SY-008-18mg/d|6mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
16347746|NCT04345120|Placebo Comparator|SY-008 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
16347747|NCT04345107|Experimental|SY-009-1mg/d-1|0.5mg BID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-1mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
16347748|NCT04345107|Experimental|SY-009-1mg/d-2|1mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8.Start at the same time as the SY-009-1mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
16347749|NCT04345107|Experimental|SY-009-2mg/d-1|1mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
16347750|NCT04345107|Experimental|SY-009-2mg/d-2|2mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
16347751|NCT04345107|Experimental|SY-009-4mg/d|2mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. If the test and safety assessment of 4mg daily dose group (2mg bid) are completed and the dose termination standard is not met, the test will be terminated; if the safety assessment during or after the test reaches the dose termination standard, the study of 3mg daily dose group (1.5mg bid) will be carried out, and then the test will be terminated.
16347752|NCT04345107|Experimental|SY-009-3mg/d|1.5mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
16347753|NCT04345107|Placebo Comparator|SY-009 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
16347754|NCT04345094|Experimental|Comparator|Emulsion containing 1% Hexylresourcinol
16347755|NCT04345094|Active Comparator|Intervention|Emulsion containing 2% Hydroquinone
16347756|NCT04345081||SRNSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.
~This Group receive Skin Reducing Nipple Sparing Mastectomy"
16347757|NCT04345081||SSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.
~This Group receive Skin Sparing Mastectomy"
16347758|NCT04345068|Experimental|Calm Meditation|"The intervention will be 8-weeks in duration and will consist of a series of pre-approved meditation classes. Patients will be asked to participate in at least 10 min/day of meditation (i.e., ~70 min/week). Week 1-4 will consist of the 7 Days of Calm followed by the 21 Days of Calm, which are introductory courses offered by Calm and provide basic, introductory meditation classes for beginners. Weeks 5-8 will consist of patients participating in the Daily Calm that Calm provides, consisting of 10-12 min meditation classes that have a unique focus each day. Patients will be instructed to participate in at least 10 min/day of meditation, but will be encouraged to do more if they can."
16347759|NCT04345068|Active Comparator|Health Education Podcast|The control group will serve as an active control group and will be matched for time and attention to the intervention group. Participants assigned to the control group will be asked to listen to/view 10-min/day (i.e., ~70 min/week) of health education podcasts via a smartphone app. Topics covered in the health education control vary and will be aimed at providing useful and informative health-related information pertinent to cancer patients. The podcast app was developed by an independent app developer, and it was designed to mirror the type of functionality that the Calm app offers its users.
16347760|NCT04345055|Experimental|Fascial treatment|Treatment the lumbar fasciae
16347761|NCT04345055|Placebo Comparator|Placebo group|Introduce in a machine off
16347762|NCT04345042|No Intervention|First Group|In the first group; the investigators applied the TP such as hot pack, ultrasound, exercise and TENS.
16347763|NCT04345042|Experimental|Second Group|In the second group; the investigators applied the classic massage (Swedish Technique) together with TP.
16347764|NCT04345029|Experimental|Experimental group (Lippia citriodora + sabdariffa)|"Consumption for 60 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.
~Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days."
16347765|NCT04345029|Placebo Comparator|control group Placebo (sucrose)|Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days.
16347766|NCT04345016|Experimental|All Participants|Eligible participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) during the intervention/treatment phase. Each was followed for one year or until study disenrollment, health plan disenrollment, death, or end of the study and follow-up period. Outcomes data from eligible participants from the two years prior to the intervention/treatment phase and the period of time after the intervention ended through the analysis date (2020-01-01) were evaluated. For this period, these participants received standard medical and diabetic foot care.
16347804|NCT04344769||Healthy individuals as controls|Age and gender-matched healthy controls
16347805|NCT04344756|Experimental|Active Coagulation|
16347958|NCT04343651|Experimental|700mg Leronlimab|
16347767|NCT04345003|Experimental|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.
~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
16347768|NCT04344990|Active Comparator|Group E- Epidural analgesia|Continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure. The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The epidural catheter is placed preoperatively.
16347769|NCT04344990|Active Comparator|Group F- Femoral blockade|Continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The femoral catheter is placed preoperatively.
16347770|NCT04344990|Active Comparator|Group I- Intraarticular infusion|Continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The intraarticular catheter is placed before the closure of the incision.
16347771|NCT04344977||Convalescent survivors of COVID-19|Convalescent survivors of COVID-19: history of COVID-19 like illness or positive test for SARS-CoV-2 and has the protocol-specified minimum anti-SARS-CoV-2 neutralizing antibody titer
16347772|NCT04344964||Phone consult group|Information collected prospectively on FTA patients and questionnaire (satisfaction)
16347773|NCT04344964||Face-to-face consult group|Information collected retrospectively on FTA patients
16347774|NCT04344951|Experimental|UNIKINON (Chloroquine phosphate)|Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.
16347775|NCT04344938||medical personel|
16347776|NCT04344938||non medical personel|
16347777|NCT04344925||Aerosol-reducing Mask|The participant will be placed on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
16347778|NCT04344925||Standard Mask|The patient will be placed on BIPAP using the standard mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
16347779|NCT04344912||COVID19- Population|Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan
16347780|NCT04344912||COVID19+ Population|Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan
16347781|NCT04344899||Historical|Retrospective Review
16347782|NCT04344899||ERAS Patients|Prospective Review
16347783|NCT04344886|Experimental|Conventional (dual-phase) SPECT/CT|Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
16347784|NCT04344886|Experimental|Multi-phase SPECT/CT|Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
16347785|NCT04344873|Experimental|Older Adult participants|Older adult participants (ages 55-75) will be assessed for arterial function using FMD analysis, PWV calculations, T Cell phenotyping, and proportion of inflammatory biomarkers after injections of placebo and abatacept.
16347786|NCT04344860|Active Comparator|rVWF plus TA|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia) plus Tranexamic Acid 1 gm IV within 3 hours of delivery; and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
16347787|NCT04344860|Active Comparator|rVWF alone|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia); and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
16347788|NCT04344847|Other|coincidental GIST during LSG patients|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.
16347789|NCT04344834||Health care workers|Egyptian health care workers
16347790|NCT04344834||General population|Any Egyptian personnel
16347791|NCT04344834||Recovered fromCOVID-19|Patients recovered from COVID-19
16347792|NCT04344821|Placebo Comparator|Control|No diet or exercise intervention
16347793|NCT04344821|Experimental|No Diet plus Exercise|No diet, exercise only intervention
16347794|NCT04344821|Experimental|High Protein Diet plus Exercise|High protein diet and exercise intervention
16347795|NCT04344821|Experimental|High Carbohydrate Diet plus Exercise|High carbohydrate diet and exercise intervention
16347796|NCT04344808|Experimental|Navigation group|Dental implants will be placed using a dynamic computer assisted surgery system
16347797|NCT04344808|Active Comparator|Freehand group|Dental implants will be place without any guidance. Only virtually planning the ideal position on a 3D image (Cone beam computed tomography)
16347801|NCT04344782|Experimental|Bevacizumab|
16347806|NCT04344756|No Intervention|Standard of Care|Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance < 30mL/min.
16347807|NCT04344743|Experimental|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
16347808|NCT04344730|Placebo Comparator|Standard oxygen 1|Standard oxygen and placebo of Dexamethasone
16347809|NCT04344730|Experimental|Standard oxygen 2|Standard oxygen and Dexamethasone
16347810|NCT04344730|Experimental|CPAP 1|CPAP and placebo of Dexamethasone
16347811|NCT04344730|Experimental|CPAP 2|CPAP and Dexamethasone
16347812|NCT04344730|Experimental|HFNO 1|HFNO and placebo of Dexamethasone
16347813|NCT04344730|Experimental|HFNO 2|HFNO and Dexamethasone
16347814|NCT04344730|Placebo Comparator|mechanically ventilated 1|placebo
16347815|NCT04344730|Experimental|mechanically ventilated 2|Dexamethasone
16347816|NCT04344717|Experimental|Short bowel syndrome|Single dose administration of 2.5 mg and 5 mg (1 week wash out between 2 doses) apixaban to patients with short bowel syndrome requiring long term parenteral nutrition
16347817|NCT04344717|Other|Normal gastrointestinal tract|Single dose administration of 2.5 mg or 5 mg apixaban to patients with a normal gastrointestinal tract with an indication for anticoagulation with apixaban (atrial fibrillation).
16347818|NCT04344704||DX devices with SMART headset detection enabled|The SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
16347819|NCT04344704||DX device programmed in single chamber mode|"with the activation of one of the available discrimination criteria:
~Onset: distinguishes slow onset or onset tachycardias from sudden onset
~Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring.
~Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width"
16347820|NCT04344691|No Intervention|Control|5 minutes waiting time
16347821|NCT04344691|Experimental|Stretching|Rectus femoris static stretching during 90' (with three hold-relax progressions until final ROM)
16347822|NCT04344678|Placebo Comparator|Control group|Escitalopram 20 mg tablet plus one placebo tablet
16347823|NCT04344678|Experimental|Sildenafil group|Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
16347824|NCT04344665|Experimental|Virtual Care and Remote Automated Monitoring|
16347825|NCT04344665|No Intervention|Standard Care|
16347826|NCT04344652|Experimental|Photoscreening|Photoscreening of patients 0 to 10 years of age
16347827|NCT04344626|Experimental|Brain tonometry|Participants undergoing intra-operative brain tissue stiffness measurements using a digital tonometer. Evaluated brain tissue is both presumed normal and abnormal based on results of pre-operative evaluations.
16347828|NCT04344613|Experimental|Blood samples|
16347829|NCT04344600|Experimental|Peginterferon lambda alfa-1a|peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
16347830|NCT04344600|Placebo Comparator|Placebo|Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2
16347831|NCT04344587|Experimental|Intervention group|Participants in the intervention arm will receive a text message on their smartphones linking to the Qualtrics intervention website
16347832|NCT04344587|Active Comparator|Usual care group|Participants in the usual care arm will receive a text message on their smartphone linking to the Qualtrics usual care website
16347833|NCT04344561|Experimental|Postural Positioning|Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
16347834|NCT04344561|No Intervention|Standard Care|Participants in this group will have beds managed per standard nursing protocol.
16347835|NCT04344548|Experimental|Treatment group|Adult patients with COVID-19 infection with NEWS 2 score >4
16347836|NCT04344535|Active Comparator|Convalescent Donor Plasma|
16347837|NCT04344535|Placebo Comparator|Standard Donor Plasma|
16347838|NCT04344522|Experimental|sequential 2 stage procedure|In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later
16347839|NCT04344522|Experimental|combined single stage procedure|In this arm, both IOL exchange and DMEK will be performed in the same setting
16347840|NCT04344509||COVID19-positive patients|
16347841|NCT04344509||COVID19-negative patients|
16347842|NCT04344483|Active Comparator|Group A ( Lidocaine + Adrenaline)|Group A patients will receive 2% Lidocaine and 1:100,000 adrenaline soaked gauze over skin graft donor site of thigh per operatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site.
16347843|NCT04344483|Placebo Comparator|Group B ( Normal Saline)|Group B patients will receive normal saline soaked gauze over skin graft donor site of thigh intraoperatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site
16347844|NCT04344470|Experimental|Healthy Volunteers|Healthy Volunteers
16347845|NCT04344444|No Intervention|Arm A|Supportive Care only
16347846|NCT04344444|Experimental|Arm B|Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
16347847|NCT04344444|Experimental|Arm C|Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5
16347848|NCT04344431|Experimental|HBO group|
16347849|NCT04344431|No Intervention|Non-HBO group|
16347850|NCT04344418|Active Comparator|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at the Kenyatta National Hospital (KNH) and Aga Khan University Hospital Nairobi (AKUHN). A diagnosis will be selected based on the same pre-defined checklist and the time the diagnosis is made recorded.
16347890|NCT04344067|No Intervention|Control Group|
16347851|NCT04344418|Experimental|Nurse-performed focused cardiac ultrasound (FoCUS)|The experimental arm will consist of nurse-performed FoCUS for patients with cardiorespiratory failure. A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
16347852|NCT04344405|Experimental|Vit D|
16347853|NCT04344405|Active Comparator|control|
16347854|NCT04344392|Other|Dysphagic hemiplegic patients|Dysphagic patients with hemiplegia as assessed by clinical examination
16347855|NCT04344392|Other|Control|Volunteers which do not have an active swallowing dysfunction.
16347856|NCT04344379|Active Comparator|Arm Title : hydroxychloroquine|
16347857|NCT04344379|Placebo Comparator|Placebo of hydroxychloroquine|
16347858|NCT04344379|Active Comparator|azythromycin|
16347859|NCT04344366||group A|children with low birth weight
16347860|NCT04344366||group B|children with normal birth weight
16347861|NCT04344327||Patients with COVID-19|Patients hospitalized in conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)
16347862|NCT04344314|Other|Small gauge arm|2 PIVCs of same gauge and different lengths
16347863|NCT04344314|Other|Large gauge arm|2 PIVCs of same gauge and different lengths
16347864|NCT04344301|Experimental|AUDIO|"Participant clinic visits will be audio recorded locally on a secure, HIPAA-compliant server. Patient access to recordings will be performed via a secure web-based platform.
~Additionally, participants will be offered the After Visit Summary (AVS) prior to clinic departure, per Usual Care (UC)"
16347865|NCT04344301|No Intervention|Usual Care|During the trial, patients will be offered to receive the AVS prior to clinic departure as is the current standard at each site.
16347866|NCT04344288|Experimental|Prednisone group|Prednisone during 10 days after randomization
16347867|NCT04344288|Other|Control group|
16347868|NCT04344275|Experimental|Kinesio-taping (KT)|The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
16347869|NCT04344275|Placebo Comparator|Placebo Kinesio-taping (KT)|Kinesio-tape was applied with no tension and technique on the middle trapezius.
16347870|NCT04344262|Active Comparator|control (C) group|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg
~Maintenance doses of muscle relaxant will be given throughout the intraoperative period
~to maintain the Train-of-four values continuously less than 2"
16347871|NCT04344262|Experimental|minimal dose (M) group|"Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected
~boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal."
16347872|NCT04344236|No Intervention|Control|
16347873|NCT04344236|Experimental|Saline oral/nasal rinse|
16347874|NCT04344236|Experimental|0.5% Povidone/Iodine oral/nasal rinse|
16347875|NCT04344236|Experimental|0.12% Chlorhexidine oral/nasal rinse|
16347876|NCT04344223|Experimental|Experimental balance shoes|Tests and familiarization phases with experimental balance shoes (Axis Comfort Development®)
16347877|NCT04344223|Active Comparator|Personal shoes|"Same tasks than the condition Experimental balance shoes but realized with personal shoes (own personal shoes of subjects)"
16347878|NCT04344210|Experimental|Tele-Intervention|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
16347879|NCT04344210|No Intervention|Usual Care|Participants will receive the usual care
16347880|NCT04344184|Active Comparator|Infusion|L-Ascorbic Acid (Vitamin C), intravenous infusion
16347881|NCT04344184|Placebo Comparator|Standard of care|Dextrose 5% Water
16347882|NCT04344158|Experimental|AK105 combined with Anlotinib|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16347883|NCT04344158|Active Comparator|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
16347884|NCT04344145||Target Group|This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
16347885|NCT04344145||Control group|"This group includes healthcare workers who are actively involved in usual medical care units, referred in this study as non-Covid-19 units. They will fill same self-reported questionnaires and scales than those filled in the Target group, also upon their inclusion.This group will be the comparator of the Target Group to assess the frontline Covid-19 condition."
16347886|NCT04344106|Experimental|Prone positioning|"Participants are all turned to prone position for an optimal minimum duration of 3 hours .
~Tolerance, oxygen saturation, heart rate and position are monitoring during all procedure. Arterial blood gases are realized before, 1 to 2 hours after the beginning of the prone position, and 6 to 12 hours after resupination."
16347887|NCT04344093|Experimental|Connected patch validation|
16347888|NCT04344080|Active Comparator|CytoSorb-Therapy|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
16347889|NCT04344080|No Intervention|Standard of care|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care
16347891|NCT04344067|Experimental|Far Infrared Therapy Group|In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.
16347892|NCT04344054|Experimental|Arm 1|RV3-BB/TV P2-VP8 boost
16347893|NCT04344054|Experimental|Arm 2|RV3-BB/TV P2-VP8 co-administered
16347894|NCT04344054|Experimental|Arm 3|RV3-BB primed TV P2-VP8
16347895|NCT04344054|Experimental|Arm 4|Rotarix®/TV P2-VP8 Boost
16347896|NCT04344054|Experimental|Arm 5|Rotarix®/TV P2-VP8 co-administered
16347897|NCT04344054|Experimental|Arm 6|TV P2-VP8 alone
16347898|NCT04344041|Experimental|Intervention group|High dose of vitamin D3
16347899|NCT04344041|Active Comparator|Comparator group|Standard dose of vitamin D3
16347900|NCT04344028|Experimental|True Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program improves performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
16347901|NCT04344028|Active Comparator|True Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
16347902|NCT04344028|Placebo Comparator|Control Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program increases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
16347903|NCT04344028|Sham Comparator|Control Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
16347904|NCT04344015|Other|Convalescent Plasma Donation|The goal of this study is to identify individuals who have previously been infected with COVID-19 and collect plasma from those who meet inclusion criteria for convalescent plasma donation. This protocol will allow for the collection, manufacturing, and storage of convalescent plasma that may be administered to patients with COVID-19 in the near future. In addition, it allows for testing of SARS-COV-2 antibody titers in the plasma that has been collected to inform studies assessing outcomes for patients currently infected with COVID-19 who have received convalescent plasma infusions.
16347905|NCT04344002||lung cancer+COVID-19|lung cancer patients diagnosed with COVID-19
16347906|NCT04343989|Experimental|Clazakizumab 25 mg|
16347907|NCT04343989|Experimental|Clazakizumab 12.5 mg|
16347908|NCT04343989|Placebo Comparator|Placebo|
16347909|NCT04343976|Experimental|Lambda Treatment|Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda
16347910|NCT04343976|Placebo Comparator|Saline Placebo|Subcutaneous injection of saline placebo
16347911|NCT04343963|Active Comparator|Pyridostigmine|Pyridostigmine bromide tablet (60mg P.O. once per day for 14 days)
16347912|NCT04343963|Placebo Comparator|Placebo|Placebo tablet (60mg P.O. once per day for 14 days)
16347913|NCT04343950|Experimental|Intervention 1: SMS reminders in colorectal cancer screening|SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
16347914|NCT04343950|Active Comparator|Usual Care 1: Reminder letter in colorectal cancer screening|Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
16347915|NCT04343950|Experimental|Intervention 2: SMS reminders to return the screening test|SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
16347916|NCT04343950|Active Comparator|Usual Care 2: No intervention|No reminders will be sent.
16347917|NCT04343950|Experimental|Intervention 3: SMS invitation among prior participants|Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
16347918|NCT04343950|Active Comparator|Usual Care 3: Invitation letter|Letter invitations will be sent.
16347919|NCT04343937||Retrolaminar block|Retrolaminar block for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
16347920|NCT04343937||İntravenous analgesia|İntravenous analgesia for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
16347921|NCT04343924|Experimental|Diving Group|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
16347922|NCT04343924|Active Comparator|Virtual reality Group|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates.
16347923|NCT04343924|No Intervention|Control Group|The subjects of this group will be monitored and treated for PTSD and will not attend the dive discovery course or virtual reality sessions.
16347924|NCT04343911|No Intervention|conventional positioning|positioning with shoulder braces
16347925|NCT04343911|Active Comparator|positioning on Pink Pad ®|
16347926|NCT04343885|Experimental|177Lu-PSMA+ Docetaxel|7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
16347927|NCT04343885|Other|Docetaxel (Control)|Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
16347928|NCT04343872|Active Comparator|Receive lifestyle modification alone (DPP)|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services
16347929|NCT04343872|Experimental|Receive lifestyle modification with metformin therapy|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services plus metformin recommendation
16347930|NCT04343859|Experimental|IMMH-010-60mg|Part A Dose escalation study: 60mg, QD, Cycle0Day1, Cycle1Day1-CycleN
16347931|NCT04343859|Experimental|IMMH-010-120mg|Part A Dose escalation study:120mg, QD, Cycle0Day1, Cycle1Day1- CycleN
16348786|NCT04337450|Active Comparator|SOC|Standard-of-care (SOC)
16347933|NCT04343859|Experimental|IMMH-010-360mg|Part A Dose escalation study:360mg, QD, Cycle0Day1, Cycle1Day1- CycleN
16347934|NCT04343846||group A|low birth weight children
16347935|NCT04343846||group B|normal birth weight children
16347936|NCT04343833|Active Comparator|Control with Standard dental implant|Patients were treated with implants Inhex Ticare Standard (Mozo Grau, Ticare, Valladolid, Spain). The implants presented a surface treated with Reabsorbable Blast Media (RBM), conical macro-design with non-aggressive threads, internal connection, and platform switching. On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
16347937|NCT04343833|Experimental|Test with the new implant design|Patients were treated with Implants Inhex Quattro Ticare (Mozo Grau, Ticare, Valladolid, Spain). The implants also presented a surface treated with RBM, conical macro-design with expanded micro threads, internal connection, and platform switching.On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
16347938|NCT04343820||Breast reconstruction|Women who have had a mastectomy and want a secondary breast reconstruction by implant.
16347939|NCT04343807|Active Comparator|PECS block|For patients in PECS group (PG), after induction of general anesthesia, the nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
16347940|NCT04343807|Active Comparator|Control Group|For patients in control group, after induction of general anesthesia, no nerve block will be performed and only intravenous nalbuphine will be given.
16347941|NCT04343794|Experimental|Biovitals|Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
16347942|NCT04343794|No Intervention|Control|Usual standard care
16347943|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a|
16347944|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b|
16347945|NCT04343768|Active Comparator|Control group: hydroxychloroquine + Lopinavir / Ritonavir|
16347946|NCT04343755|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
16347947|NCT04343742||chlorine dioxide 3000 ppm. Bottle x 150 cc.|"Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.
~7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).
~Both the original dioxide bottle and the preparation for the day should be kept refrigerated."
16347948|NCT04343729|Active Comparator|Methylprednisolone|0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.
16347949|NCT04343729|Placebo Comparator|Placebo|Saline solution, twice daily, for 5 days. Injectable.
16347950|NCT04343716|Experimental|White women|White women aged 65-75 with knee OA
16347951|NCT04343716|Experimental|Black women|Black women aged 65-75 with knee OA
16347952|NCT04343703|Experimental|Telephone-based management|Telephone-based management will consist of a three-phase intervention: 1) An initial 15-20 min call at 1 week of enrollment in which the cases manager introduces him/herself, and does a short assessment of the current suicide risk, 2) A 5-10 min telephone follow-up at 1, 3, 6, 9 and 12 months, 3) If suicide risk is detected, a 15-45 min crisis intervention call will be done, tailored to the participant's characteristics and context. If deemed necessary, an emergency face-to-face appointment will be scheduled. At each phone call information regarding the current treatment, adherence to mental health services, and current life stressors will be collected.
16347953|NCT04343703|Experimental|iFightDepression for Suicide|The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked. The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
16347954|NCT04343703|Active Comparator|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual. TaU will consist of any routine procedures applied at each participating site.
16347955|NCT04343703|Experimental|Self Awareness of Mental Health|The Self Awareness of Mental Health (SAM) is an adaptation of the Youth Awareness of Mental Health program, originally developed for the Saving and Empowering Young Lives in Europe (SEYLE) study. The SAM aims to raise mental health awareness about risk and protective factors associated with suicide, provide knowledge about depression and anxiety, and enhance the skills needed to cope with adverse life events and suicidal behavior. The intervention is delivered by trained clinical psychologists in five, 45-60 minutes, face-to-face sessions.
16347956|NCT04343690|Experimental|Health Care Workers|Faculty, staff, and trainees dealing with COVID-19 pandemic
16347957|NCT04343651|Placebo Comparator|Placebo|
16347959|NCT04343638|Active Comparator|conventional nociception control arm|Intraoperative opioid will be administered by conventional clinical practice. ANI monitor readings will not be visible to the anesthesiologist.
16347960|NCT04343638|Experimental|ANI-monitor guided nociception control arm|Intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50.
16347961|NCT04343625|Experimental|Modified sitting, gentle yoga class|Participants attended a modified sitting gentle yoga class,10 weekly classes, each 60 minutes in duration.
16347962|NCT04343612|Experimental|Anodal|Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation
16347963|NCT04343612|Experimental|Bilateral|Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation
16347964|NCT04343612|Experimental|Cathodal|Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation
16347965|NCT04343612|Placebo Comparator|Placebo|anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation
16347966|NCT04343599|Experimental|Hypopressive exercises|Patients completed 10 weeks of abdominal hypopressive exercises with two sessions of 30 minutes per week.
16347967|NCT04343599|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
16347968|NCT04343586|Experimental|Adult treatment arm|Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
16347972|NCT04343560||patients with MACS|Patients with adrenal adenoma and dexamethasone suppression test >1.8 mcg/dl
16347973|NCT04343560||healthy controls|no history of adrenal and pituitary disease, no exogenous steroids
16347974|NCT04343547|Experimental|1|
16347975|NCT04343547|Experimental|2|
16347976|NCT04343547|Experimental|Experimental 3|
16347977|NCT04343534||Original Shared Decision Making Process scale|Patients receive the original version of the Shared Decision Making Process scale.
16347978|NCT04343534||Revised Shared Decision Making Process scale|This group completes a new version of the scale with different wording for several items.
16347979|NCT04343521|Experimental|Targeted Indoor Residual Spraying (TIRS)|All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster
16347980|NCT04343521|No Intervention|Control|Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)
16347981|NCT04343508|Experimental|Fortified rice|fortified rice for daily lunch and dinner each day of the week (i.e. 14 meals/week) for six months
16347982|NCT04343469|Active Comparator|Bariatric surgery|The effect of bariatric surgery (RYGB or LSG) on central inflammation
16347983|NCT04343469|No Intervention|No intervention|Healthy lean volunteers
16347984|NCT04343443|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination centered on congestion
~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
16347985|NCT04343430|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination centered on congestion
~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
16347986|NCT04343417||Biorepository|Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
16347987|NCT04343391|Experimental|Brief Individual Psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
16347988|NCT04343391|Experimental|Brief Group Psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
16347989|NCT04343391|Active Comparator|Treatment as usual|Medication provided by a general practitioner.
16347990|NCT04343365||Participants Reviewed by ETB|Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
16348020|NCT04343131|Active Comparator|Low-carb/high protein diet|Low-carb/high protein diet for 7 days
16348021|NCT04343131|Active Comparator|Reference diet|Reference diet for 7 days
16348022|NCT04343118||Group Removal|All patient receiving surgical removal of plate osteosynthesis
16348023|NCT04343105|Sham Comparator|sham group|will receive sham bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position
16348024|NCT04343105|Experimental|real group|will receive real bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position with 10 ml bupivacaine 0.5% + 10 ml lidocaine 2% in total volume 20 ml for each side.
16347991|NCT04343352|Experimental|In application group; Mobile Epilepsy Training Program Impleme|"Mobile epilepsy training program will be introduced to the parents in the application group and pre-tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale).
~The participants will only use the mobile epilepsy training program application.
~Parents in the application group will be monitored for 3 months using the mobile epilepsy training program. The researcher will follow the participants' use of the mobile application with the interface of the mobile epilepsy training program.
~During the monitoring phase, the Epilepsy Information Questions screen will be given once every 15 days, and the training module will be reopened automatically on missing or incorrect answers and the parent's information on this subject will be renewed.
~- At the end of the 3rd month, posttests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale) will be applied face-to-face."
16347992|NCT04343352|No Intervention|In the control group|"- The purpose of the project will be shared with the parents in the control group, and the pre-tests Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied.
~There is no structured training program in the outpatient functioning. Routine practice of the hospital; is the education and information provided by the physician to the family during the outpatient clinic.
~At the end of the 3rd month, the final tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied face to face.
~After the work is completed, the mobile application will be installed on the phones of the control group, the application will be taught and applied."
16347993|NCT04343326|Active Comparator|accelerated corneal cross linking+ delivery of systemic oxygen|corneal cross linking is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
16347994|NCT04343326|Active Comparator|accelerated corneal collagen cross-linking|corneal cross linking with the same accelerated protocol without additional oxygen therapy.
16347995|NCT04343326|Active Comparator|conventional corneal collagen cross-linking|Conventional corneal cross linking using 30 mW/CM2 UV-A ablation for 30 minutes
16347996|NCT04343313|Experimental|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
16347997|NCT04343300|Other|Control group|Control group without Pilates exercise during 12 weeks Participants were advised to keep their routine Falls diary calendar
16347998|NCT04343300|Experimental|Pilates group|Pilates classes were held twice weekly for one hour. The classes were divided into a warm-up, mat Pilates with accessories and a cool-down. Participants used small items of equipment such as bands, circles or rings, blocks, spyke balls and foam rollers. The intervention lasted 12 weeks; the classes were supervised twice a week. The supervised exercises were evaluated every four weeks (frequency and intensity) focused on the lower limb (muscles related to gait), core and trunk (muscles related to posture). The participants were asked to perform supplementary at-home workouts three times a week using a booklet and video that was provided to the participants. The video and booklet to introduce the six principles of Pilates, warm-up exercises, exercises on the chair, mat Pilates exercises and cool-down exercises. Participants were advised to perform these exercises three times a week for 30 minutes at home.
16348001|NCT04343261|Experimental|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
16348002|NCT04343248|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks
16348003|NCT04343248|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks
16348004|NCT04343235|Experimental|labetalol + furosemide|labetalol + furosemide
16348005|NCT04343235|Active Comparator|labetalol only|labetalol only
16348006|NCT04343222|Experimental|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
16348007|NCT04343222|Experimental|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
16348008|NCT04343222|Placebo Comparator|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
16348009|NCT04343209||Individuals with confirmed or suspected cardiovascular disease|Individuals in this group will undergo myocardial perfusion imaging, utilizing Ammonia N-13 PET imaging agent. Each individual will receive two intravenous injections of Ammonia N-13 in accordance with site imaging protocol.
16348010|NCT04343196|Experimental|Group A: Low-dose DVA group|Image acquisition at a reduced X-ray dose, 0.36 µGy/frame (70% reduction) image processing by DVA
16348011|NCT04343196|Active Comparator|Group B: Normal-dose DSA group|Image acquisition at a normal dose (1.2 µGy/frame) image processing by DSA
16348012|NCT04343183|Active Comparator|HBOT treatment group|Patients will receive hyperbaric oxygen therapy
16348013|NCT04343183|No Intervention|Standard of Care group|Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol
16348014|NCT04343170|Placebo Comparator|control group|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
16348015|NCT04343170|Experimental|ultra-short-term treatment|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
16348016|NCT04343157|Experimental|Image-guided cognitive sparing brain SRS|This is a single arm phase II study where enrolled subjects will receive intracranial SRS will performed identically to standard of care, except for implementing additional imaging techniques and software for additional regional avoidance for cognitive sparing (specifically sparing white matter and the bilateral hippocampus)
16348017|NCT04343144|Experimental|Nivolumab|
16348018|NCT04343144|No Intervention|Standard of Card|
16348019|NCT04343131|Active Comparator|Mediterranean diet|Mediterranean diet for 7 days
16348025|NCT04343092|Experimental|Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)|Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily
16348026|NCT04343079|Experimental|braeast cancer|breast cancer patients
16348027|NCT04343066|Experimental|External hex implant|External hexagone implant connection
16348028|NCT04343066|Experimental|Internal hex implant|Internal implant connection
16348029|NCT04343053|Other|SARS-Cov-2 infection|Single study group of patients with respiratory failure due to SARS-Cov-2 infection. Three blood samples will be collected at different stages of disease: early, defined as first 96 hours, mid, defined as time from 96 hours and 14 days, late. defined as >14 days
16348030|NCT04343040|Experimental|perioperative glucose intake|glucose intolerant patients with perioperative glucose (carbohydrate supplement (Preload™) intake before Gastric By-Pass or Sleeve Gastrectomy.
16348031|NCT04343040|Sham Comparator|6 hours of preoperative fasting|glucose intolerant patients receiving 6 hours of preoperative fasting before Gastric By-Pass or Sleeve Gastrectomy.
16348032|NCT04343027|No Intervention|Standard of care group|Participants who did not have their physicians review their patient-reported outcome measurements with them during the office visit.
16348033|NCT04343027|Experimental|Consultation group|Participants who had their physicians review their patient-reported outcome measurements reviewed with them during the office visit.
16348034|NCT04343014|Experimental|Tongue Root Retractor|Patients in this arm will receive fibroscopic endotracheal intubation with tongue root retractors.
16348035|NCT04343014|Active Comparator|Conventional Fibroscope|Patients in this arm will receive fibroscopic endotracheal intubation without any other devices.
16348036|NCT04343001|No Intervention|Standard care|Usual standard of care at the study hospital
16348037|NCT04343001|Experimental|Aspirin|Aspirin 150mg once daily
16348038|NCT04343001|Experimental|Losartan|Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
16348039|NCT04343001|Experimental|Simvastatin|Simvastatin 80mg once daily
16348040|NCT04343001|Experimental|Aspirin and Losartan|Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
16348041|NCT04343001|Experimental|Aspirin and Simvastatin|Aspirin 150mg once daily and Simvastatin 80mg once daily
16348042|NCT04343001|Experimental|Losartan and Simvastatin|Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
16348043|NCT04343001|Experimental|Aspirin, Losartan and Simvastatin|Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
16348044|NCT04342988|Other|Cequa Treatment In Cataract Patients with Dry Eye Disease|Duration of Study Treatment - 4 weeks All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose. Dosing will be BID, both eyes, assuming both eyes will eventually undergo cataract surgery. Otherwise, single eye treatment in the operative eye will be permitted.
16348045|NCT04342975|Active Comparator|Basis|The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.
16348046|NCT04342975|Placebo Comparator|Placebo|Correspondent placebo, a capsule not containing the active component.
16348047|NCT04342962|Experimental|Experimental arm|"12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days.
~Patients will receive the study drug until disease progression or in case of toxicity."
16348048|NCT04342936|Experimental|Camrelizumab for Injection|Participants receive Camrelizumab 200mg intravenously (IV) on Day 1 of each 2-week cycle
16348049|NCT04342936|Active Comparator|Chemotherapy|Participants receive investigator's choice of chemotherapy (Gemox, IGEV or DHAP) for up to 6 cycles.
16348050|NCT04342923||Complete cohort|All patients undergoing PD during study period in all participating center/units in Spain.
16348051|NCT04342910|Experimental|camrelizumab (SHR-1210) combined with apatinib|Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.
16348052|NCT04342910|Active Comparator|Paclitaxel or Irinotecan|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.
16348053|NCT04342897|Experimental|LY3127804|Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
16348054|NCT04342897|Placebo Comparator|Placebo|Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.
16348055|NCT04342884||Clients of Wake Forest Baptist Health (WFBH)|
16348056|NCT04342884||Health care workers of Wake Forest Baptist Health (WFBH)|
16348057|NCT04342871|Experimental|Fam-CT|Patients will receive access to intervention materials.
16348058|NCT04342858|Other|Standard of care|Control will receive standard oral hygiene instructions (OHI every three months)
16348059|NCT04342858|Active Comparator|Standard of care + Fluoride varnish|Intervention 1 will receive standard OHI and application of topical fluoride varnish containing 5% NaF (Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK) every three months
16348060|NCT04342858|Experimental|Standard of care + Fluoride varnish with Tricalcium phosphate|Intervention 2 will receive standard OHI and application of topical fluoride varnish containing 5% NaF + TCP (Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA) every three months
16348098|NCT04342559|Experimental|Group I|"Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07
~Participants will be instructed on how to use it as follows:
~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.
~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
16348492|NCT04339699|Active Comparator|Amplatzer PFO Occluder|Participants treated with the Amplatzer PFO Occluder device
16348493|NCT04339686||Suspicion of COVID 19|
16348061|NCT04342845|Experimental|Motivational interviewing|The intervention group received an education program in small groups that included no more than ten members. The content was designed based on MI theory and the theory of patient empowerment. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise. Each module started with a brief introduction to relevant background knowledge, which was followed by small-group discussions about personal barriers and techniques for overcoming challenges. During the small group discussions, educators acted as MI facilitators, using group MI techniques to strengthen participants' motivation.
16348062|NCT04342845|Placebo Comparator|Traditional lectures|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI.
16348063|NCT04342832|Active Comparator|Early invasive treatment (cryoballoon ablation)|
16348064|NCT04342832|No Intervention|Standard medical care|
16348065|NCT04342819|Experimental|SGLT2i|Empagliflozin 25 mg per oral once daily
16348067|NCT04342793|Placebo Comparator|Placebo|Placebo
16348068|NCT04342793|Experimental|ALS-L1023 1,200mg|ALS-L1023 600mg twice a day
16348069|NCT04342793|Experimental|ALS-L1023 1,800mg|ALS-L1023 900mg twice a day
16348070|NCT04342754|Experimental|Deep Brain Stimulation ON (DBS ON)|The device will be turned ON
16348071|NCT04342754|Sham Comparator|Deep Brain Stimulation OFF (DBS OFF)|The device will be turned OFF
16348072|NCT04342741|Active Comparator|Foley catheter inpatient|Participants had intracervical ripening with foley catheter after admission into the ward.
16348073|NCT04342741|Active Comparator|Foley catheter outpatient|Participants had intracervical ripening with foley catheter and allowed home.
16348074|NCT04342728|Active Comparator|Ascorbic Acid|8000 mg of ascorbic acid divided into 2-3 doses/day with food.
16348075|NCT04342728|Active Comparator|Zinc Gluconate|50 mg of zinc gluconate to be taken daily at bedtime
16348076|NCT04342728|Active Comparator|Ascorbic Acid and Zinc Gluconate|8000 mg of ascorbic acid divided into 2-3 doses/day with food and 50 mg of zinc gluconate to be taken daily at bedtime.
16348077|NCT04342728|Other|Standard of Care|Standard of care medications only as prescribed by patient's physician.
16348078|NCT04342715||Patients|Patients who have a diagnosis of visceral leishmaniasis and will be treated with SSG/PM
16348079|NCT04342715||Control|Healthy volunteers
16348080|NCT04342689|Experimental|Intervention|Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
16348081|NCT04342689|Placebo Comparator|Control|Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.
16348082|NCT04342676|Experimental|patients|LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
16348083|NCT04342663|Experimental|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
16348084|NCT04342663|Placebo Comparator|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
16348085|NCT04342650|Active Comparator|Intervention|CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.
16348086|NCT04342650|Placebo Comparator|Placebo|Placebo tables of equal characteristics and duration of treatment.
16348087|NCT04342637||Practicing gastroenterologists|Practicing physicians performing gastrointestinal endoscpy
16348088|NCT04342624|Experimental|Cinnamon|Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.
16348089|NCT04342624|Placebo Comparator|Placebo|Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.
16348090|NCT04342611|Experimental|Patients under the care of TA Oncologist|These patients will be under the care of an oncologist who will be randomized to training in the TA intervention.
16348091|NCT04342611|No Intervention|Patients under the care of Usual Care Oncologist|These patients will be under the care an oncologist who will be randomized to usual care.
16348092|NCT04342598||Adult outpatient pulmonary MDR-TB patients|
16348093|NCT04342598||Household contact controls|
16348094|NCT04342598||Non-household contact controls|
16348095|NCT04342585|Active Comparator|Vaginal progestogen|200mg of vaginal progestogen will be inserted before bedtime every day from time of recruitment until 34 weeks gestation.
16348096|NCT04342585|Active Comparator|Vaginal pessary|Vaginal pessary with an internal diameter size of 32 or 35 mm will be inserted at the time of recruitment and kept until 34 weeks gestation.
16348097|NCT04342572|Experimental|Intra-arterial injections of melphalan|-Participants will receive intra-arterial injections of melphalan Q4W for 3 cycles.
16348196|NCT04341727|Active Comparator|Hydroxychloroquine alone|Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
16348099|NCT04342559|Experimental|Group II|"Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08
~Participants will be instructed on how to use it as follows:
~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.
~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
16348100|NCT04342546|Experimental|Toxicity test|"For all patients, the NovaGray RILA Breast® test will be performed within 15 days of surgery , 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, within 15 days of starting chemotherapy.
~The test consists of a blood sample of 2x4 mL"
16348101|NCT04342533|Experimental|ThuFLEP|Patients who underwent thulium fiber enucleation of the prostate
16348102|NCT04342533|Active Comparator|HoLEP|Patients who underwent holmium laser enucleation of the prostate
16348103|NCT04342507|Other|Group A: conservative|conservative treatment with lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
16348104|NCT04342507|Experimental|Group B: probiotics|in addition to the conservative treatment they receive probiotics mixture (Streptococcus thermophilus, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus) once a day up to 3 months.
16348105|NCT04342494|Experimental|Enhanced Feedback + Standard Feedback|Participants will receive enhanced feedback from the MyDataHelps study app in addition to standard feedback from the activity tracker.
16348106|NCT04342494|Experimental|Headspace app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
16348107|NCT04342494|Experimental|Headspace app + Enhanced Feedback + Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback activity tracker.
16348108|NCT04342494|Experimental|SilverCloud app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
16348109|NCT04342494|Experimental|SilverCloud app +Enhanced Feedback +Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback from the activity tracker.
16348110|NCT04342455|No Intervention|traditional scanning protocol group|In coronary CTA examination,each subject will be injected 50 ml contrast agent (Iodixanol 320) with the flow rate of 5 ml/s in tube voltage of 120 kVp.
16348111|NCT04342455|Experimental|double-low scanning protocol group|In coronary CTA examination,the tube voltage(70，80,100kVp),contrast agent(Iodixanol 320) volume and flow rate of each subject are adapted to his or her cardiac ejection fraction(EF) and body mass index(BMI).
16348112|NCT04342442||Steroid-refractory a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-refractory a GvHD
16348113|NCT04342442||Steroid-responsive a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-responsive a GvHD
16348114|NCT04342429|Experimental|Prospective Study of Intensity-Modulated Proton Therapy (IMPT)|This is the first prospective study to investigate the safety and efficacy of IMPT for the treatment of SCLC. We will utilize adaptive planning throughout the radiation course. In addition, we will study the dosimetric parameters of IMPT and their correlation with treatment-related toxicities, particularly cardiac events.
16348115|NCT04342416|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):
~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
~Experimental: Intervention phase ('B'):
~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
~Intervention: Behavioral: Brief cognitive intervention"
16348116|NCT04342403||Sarcoidosis|Patients with sarcoidosis willing to participate
16348117|NCT04342390|Experimental|Exercise Group|Study participants in this group will be asked to complete 4 weeks of high-intensity interval training (HIIT).
16348118|NCT04342390|No Intervention|Control Group|Study participants in this group will not undergo HIIT exercise training during this study.
16348119|NCT04342377|Experimental|Selective Targeted Sampling|"During patients' Endobronchial Ultrasound (EBUS) procedure, they will first undergo:
~Selective Targeted Sampling - endosonographic assessment of at least 3 mediastinal lymph node stations (4R, 4L, and 7) using the four criteria of the Canada Lymph Node Score (predictor of nodal disease during Endobronchial Ultrasound). Each lymph node will be assigned a CLNS ranging from 0 to 4. Triple Normal lymph nodes will be defined as those that appear normal on CT (diameter < 1 cm), AND normal on PET (SUV < 2.5), AND normal on EBUS (CLNS < 2). Lymph nodes that are found to be Triple Normal will be marked as Not for Biopsy, whereas all other lymph nodes will be biopsied."
16348120|NCT04342377|Active Comparator|Systematic Sampling|"Upon completion of Systematic Targeted Sampling, all patients will crossover and receive the standard of care:
~Systematic Sampling - all lymph nodes previously marked as Not for Biopsy will be biopsied.
~At the conclusion of the EBUS procedure, all nodal stations would have been sampled as is mandated by current guidelines."
16348121|NCT04342364|Active Comparator|Slush nitrogen|oocytes are randomized to undergo vitrification utilizing slush nitrogen
16348122|NCT04342364|Active Comparator|Liquid Nitrogen|oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care
16348123|NCT04342351|Experimental|Experimental: sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months
16348124|NCT04342351|Active Comparator|Active Comparator: perindopril|perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months
16348125|NCT04342325|Experimental|ADR-001|Intravenous infusion of ADR-001 (Mesenchymal stem cell)
16348126|NCT04342299||Responders|"Responders are participants who show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.
~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
16348127|NCT04342299||Non-responders|"Non-responders are participants who do not show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.
~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
16348128|NCT04342273|Experimental|KW-6356 therapeutic dose|Oral administration
16348129|NCT04342273|Experimental|KW-6356 supratherapeutic dose|Oral administration
16348130|NCT04342273|Placebo Comparator|Placebo|Oral administration
16348131|NCT04342273|Active Comparator|Moxifloxacin|Oral administration
16348132|NCT04342260|Experimental|Active Monitoring|Clinicians will receive symptom alerts if the survey suggests increased or worsening symptoms.
16348133|NCT04342260|Active Comparator|Passive Monitoring|Clinicians will not receive any symptom alerts.
16348134|NCT04342247||androgen deficient|
16348135|NCT04342247||healthy|
16348136|NCT04342221|Experimental|Hydroxychloroquine Sulfate|First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
16348137|NCT04342221|Placebo Comparator|Placebo|Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)
16348138|NCT04342182|Experimental|Convalescent plasma|Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
16348139|NCT04342182|No Intervention|Standard of care|standard of care (supportive care, oxygen, antibiotics)
16348140|NCT04342169|Experimental|HCQ|Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
16348141|NCT04342169|Placebo Comparator|Placebo|Those randomized to placebo will receive a placebo to be taken on the same schedule.
16348142|NCT04342156|Experimental|Intervention|"Treatment arm will be given Hydroxychloroquine sulfate. Dose: 800 milligrams (mg) (4 pills of 200mg) in two divided doses on day 1 followed by 400mg (2 pills of 200mg) in two divided doses on day 2, 3,4, 5.
~Mode of administration: Oral pills of 200mg of HCQ; Supply: The total supply of all the pills (12 pills of 200mg per subject in the study group) will be given to the recruited subject from day 1."
16348143|NCT04342156|Other|Standard Preventive Measures|No intervention. Standard recommended preventive measures by the ministry of health.
16348144|NCT04342143||Stroke|Patients who have a diagnosis of stroke by a stroke consultant from UK National Health Service Trust within 3 months to 5 years of study start date.
16348145|NCT04342130|Experimental|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
16348146|NCT04342117||Duvelisib|Patients who take duvelisib.
16348147|NCT04342117||Other PI3K-inhibitors|Patients who take a PI3K-inhibitor other than duvelisib
16348148|NCT04342104||NIV|Patients on Bilevel NIV
16348149|NCT04342104||CPAP|Patients on CPAP
16348150|NCT04342091|Experimental|Microneedling|Participants with fibrosing alopecia will receive microneedling with a tattoo machine.
16348151|NCT04342078||Preterm Child group|Preterm children at the age of 5 years; Born before 34 gestation weeks in 2014-2017; Cared in Oulu University Hospital
16348152|NCT04342078||Preterm Adult group|Preterm born adults at the age of 24-25 years; Born before 34 gestation weeks in 1994-1997; Cared in Oulu University Hospital
16348153|NCT04342078||Adult Control group|Age and gender matched term born controls for comparison of the entry assessments in the Preterm Adult group
16348154|NCT04342065|Active Comparator|Group (G)|received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.
16348155|NCT04342065|Active Comparator|Group (C)|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
16348156|NCT04342039|Placebo Comparator|Placebo|Participants will use a placebo nasal spray before being exposed to a series of allergen and pollution challenges.
16348157|NCT04342039|Active Comparator|Budesonide nasal|Participants will use budesonide nasal spray before being exposed to a series of allergen and pollution challenges.
16348158|NCT04342026||Parent of patient with cryptorchidism|parent exposition of endocrine disruptors
16348159|NCT04342026||Parent of patient without cryptorchidism|Parent exposition of endocrine disruptors
16348160|NCT04342013|Experimental|Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations with use of the clinical decision support application in the perioperative setting.
16348161|NCT04342013|No Intervention|No Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations without use of the clinical decision support application in the perioperative setting.
16348162|NCT04342000|Experimental|Intervention Group|Movement Education Workshop
16348163|NCT04342000|Sham Comparator|Control Group|Sham Education Workshop
16348164|NCT04341987|Experimental|brief Imagery Rehearsal Therapy|"The brief two-session, behaviorally-based imagery rehearsal intervention is based on components from previous group and individual formats that have been published, but will be presented in an abbreviated manner. In the first session, Veterans will be presented with psychoeducation about dreaming, basics of sleep hygiene and stimulus control techniques, how to change negative dreams from a learned habit perspective, re-scripting, and how to rehearse new dream imagery. They will then be asked to complete in-session practice of imagery rehearsal with the new imagery developed. Veteran will be instructed in practice post-session."
16348165|NCT04341987|Other|Treatment As Usual|Patients in this condition are free to receive treatment as usual for nightmares, which may be a medication, supportive counseling or no treatment.
16348166|NCT04341974||surgical patients|Adult patients undergoing major elective general abdominal surgery for ontological disease
16348197|NCT04341727|Active Comparator|Hydroxychloroquine plus azithromycin|"Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets."
16348167|NCT04341961|Experimental|Pom Juice|The study participants will all be asked to drink pomegranate juice for 2 weeks, and 4 weeks of continued usual diet and avoid pomegranate juice (other than what is given to you), berries (strawberries, blackberries, raspberries (red, black, yellow), cranberries), walnuts, pecans, hazelnuts, pecans, chestnuts, red and white guava, pomegranates, flaxseeds, dark chocolate and cocoa, coffee, tea, rose hip, olives, artichoke, dried herbs and beefsteak tongue mushrooms).
16348168|NCT04341948|Active Comparator|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
16348169|NCT04341948|Sham Comparator|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
16348170|NCT04341935|Experimental|DPP4 group|Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
16348171|NCT04341935|Active Comparator|Control group|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
16348172|NCT04341922|Experimental|Intervention: Online Cognitive-Behavioral intervention|The three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
16348173|NCT04341922|No Intervention|Wait-list|The wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).
16348174|NCT04341909||Trainee Group|Patients who undergo ERCPs with trainee involvement
16348175|NCT04341909||control group|Patients who undergo ERCPs without any trainee involvement
16348176|NCT04341896||Caregivers|Prior obese living kidney donors who served as the primary caregiver for their recipient
16348177|NCT04341896||Non-caregivers|Prior obese living kidney donors who were not the primary caregiver for their recipient
16348178|NCT04341883|Experimental|anti-PD-1|PD-1+albumin-bound paclitaxel
16348179|NCT04341870|Experimental|Sarilumab + Azithromycin + Hydroxychloroquine|Sarilumab combined with Azithromycin and Hydroxychloroquine
16348180|NCT04341870|Active Comparator|Sarilumab|Sarilumab only
16348181|NCT04341857|Experimental|Sintilimab combined with FLOT regimen|Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
16348182|NCT04341844|Experimental|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
16348183|NCT04341844|Placebo Comparator|Control|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
16348184|NCT04341831|Experimental|Group 1|We will be added 200mg teicoplanin powder around instrument for each level.
16348185|NCT04341831|No Intervention|Group 2|We will not used any antibiotic powder in this group.
16348186|NCT04341818|Experimental|Strength Training and Vitamin D monthly|Four weeks of Vitamin D (50.000 IU once per month) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
16348187|NCT04341818|Experimental|Strength Training and Vitamin D daily|Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
16348188|NCT04341818|Experimental|Strength Training and no Vitamin D|Four weeks of no vitamin D administration followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
16348189|NCT04341805|Active Comparator|Group A. Physiological saline.|The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
16348190|NCT04341805|Experimental|Group B. Solution hyperoxygenated fatty acids|The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
16348191|NCT04341779|Experimental|Intervention arm|Point-of-care adherence testing and Point-of-care viral load testing
16348192|NCT04341779|No Intervention|Standard-of-care arm|No adherence testing and lab-based viral load testing
16348193|NCT04341766||Patient hospitalised with COVID-19 infection|Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
16348194|NCT04341753|Experimental|Pulmonary rehabilitation|"In addition to the usual evaluation, other tests will be carried out in addition and specifically for this study:
~the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);
~2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
16348195|NCT04341740|Experimental|Renal Cell Carcinoma or Urothelial Carcinoma Patients|Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.
16348259|NCT04341389|Active Comparator|Arm 2|5×10^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
16348198|NCT04341727|Active Comparator|Chloroquine alone|Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
16348199|NCT04341727|Active Comparator|Chloroquine plus azithromycin|"Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets."
16348200|NCT04341714||patients enrolled|Patients with telephone consultation on neurourology department, age > 18
16348201|NCT04341701|Other|COPD|COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist
16348202|NCT04341701|Other|Asthma|asthma according to GINA 2019 but without any smoking restriction
16348203|NCT04341688|Experimental|Povidone-Iodine 0.2% (BETADINE®)|0.2% Povidone-Iodine (BETADINE®) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
16348204|NCT04341688|Experimental|Hydrogen peroxide 1% (ActiveOxy)|ActiveOxy (1% Hydrogen peroxide) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
16348205|NCT04341688|Active Comparator|Neem extract (Azadirachta indicia)|Neem extract (Azadirachta indicia) gargle will be prepared by chemistry laboratory. patients will do 10ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
16348206|NCT04341688|Active Comparator|Hypertonic saline (2%NaCl)|10 ml gargle and nasal lavage using Hypertonic saline for 20-30 seconds, thrice daily for 6 days.
16348207|NCT04341688|Placebo Comparator|Positive controls|10 ml gargle and nasal lavage using distilled water for 20-30 seconds, thrice daily for 6 days.
16348208|NCT04341675|Active Comparator|Sirolimus|Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
16348209|NCT04341675|Placebo Comparator|Placebo|Matching placebo
16348210|NCT04341662|Experimental|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination & Escalation; and 3) an implementation strategy, focusing on simulation-based training, peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with action line, and MOTIVE emergency kits."
16348211|NCT04341662|Active Comparator|Usual care|Usual care with dissemination of the current guidelines
16348212|NCT04341649|Active Comparator|Head massage by therapist|Head massage therapist will practice massage covering the scalp, front head, occipital area and neck.
16348213|NCT04341649|Active Comparator|Helmet massage BREO|Breo helmet will be installed for massaging the head at different defined places.
16348214|NCT04341649|Active Comparator|Low Laser Therapy|Laser light can penetrate the skin and stimulate the nervous connections. The investigators will use a laser pen (Min Sheng).
16348215|NCT04341649|Active Comparator|Sham Low Laser Therapy|The investigators will use the same laser pen, but without laser beam.
16348216|NCT04341649|Active Comparator|TENS ear stimulation|The investigators will use the (Hwato) device that provides electrical pulse at various frequency and intensity. This TENS device is a prototype modified for ear stimulation.
16348217|NCT04341649|Active Comparator|Deep and Slow breathing|This intervention is guided by an app that leads to a full respiratory.
16348218|NCT04341649|Sham Comparator|Relaxed Reading time|Participants will read the newspaper in a quiet environment.
16348219|NCT04341636|Experimental|vertical bitewing|All of the bitewing radiographs will be evaluated by two experienced restorative dentists for caries. All observers will be instructed on the definition of the rating scale before the examination sessions. The observers will be using the following a 5-point confidence scale as follows: 1=caries definitely absent; 2=caries probably absent; 3=equal chance of caries being present or absent; 4=caries probably present; 5=caries definitely present. If caries was detected a second 5-point confidence scale as follows: 1=caries mostly absent (< 25%); 2=caries slightly presence( 25%-50%) ; 3=about half of the border are presence; 4=caries probably clear ( most boarders are presence); 5=caries definitely clear ( all borders are presence ).
16348220|NCT04341636|Active Comparator|horizontal bitewing|All of the bitewing radiographs will be evaluated by two experienced periodontist for bone loss measurements. The steel wire will be used to determine the magnification factor as explained by G Li et al. 8 The steel wire and cemento enamel junction (CEJ) - if not obscure by caries - will be used as reference points for bone loss measurements. Each tooth will be measured mesially and distally twice and all these measurements will be adjusted using the steel measurement.9 All the measurements will be conducted using IC measure INK software.
16348221|NCT04341623|Other|Control Group|All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis
16348222|NCT04341623|Other|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence.
16348223|NCT04341623|Other|GPSkin group|The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily.
16348224|NCT04341610|Active Comparator|ASC|100 million allogeneic adipose-derived mesenchymal stromal cell
16348225|NCT04341610|Placebo Comparator|Placebo|Saline
16348226|NCT04341597|Experimental|transperineal sonographic cervix assessment|
16348227|NCT04341597|Active Comparator|endovaginal sonographic cervix assessment|
16348228|NCT04341584|Experimental|ANAKINRA|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).
~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
16348229|NCT04341584|No Intervention|Standard of care|
16348260|NCT04341389|Placebo Comparator|Arm 3|Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
16348230|NCT04341571|Experimental|Probiotics|15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
16348231|NCT04341571|Experimental|Metformin|15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
16348232|NCT04341558|No Intervention|Baseline|During this baseline period, postoperative monitoring will be continued as normal by nursing and medical staff without intervention. No training of family members will take place
16348233|NCT04341558|Active Comparator|Intervention|Family carers will be trained to perform and document basic vital signs whilst they provide personal care to their relatives after surgery in order to supplement patient monitoring conducted by nursing staff.
16348234|NCT04341545|Experimental|Letrozole|Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
16348235|NCT04341545|Placebo Comparator|Placebo|Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
16348236|NCT04341519||Family members|"Age>18y
~Non-opposition to participate to the telephone interviews
~One family member per patient: the family member the most implicated in the patient's care
~3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited."
16348237|NCT04341519||Patients|"Patients:
~Age>18y
~Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic
~Having received invasive or noninvasive mechanical ventilation
~Non-opposition to participate to the telephone interviews.
~3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.
~COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)
~Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia
~Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs."
16348238|NCT04341519||healthcare providers|Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
16348239|NCT04341506||Participant ECG|The study has one arm, I.e., we will collect daily ECGs in 100 participants and track their ECG over three months. We will then compare ECGs pre and post COVID-19 diagnosis in any participant diagnosed with COVID-19 to assess for any early ECG changes that may aid with diagnosing.
16348240|NCT04341493|Experimental|Nitazoxanide + hydroxychloroquine|Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
16348241|NCT04341493|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg PO every 12 hours for 7 days
16348242|NCT04341480||Chemotherapy group|Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
16348243|NCT04341480||Control group|No treatment, based on patient's choice. Total observation duration is 6 weeks.
16348246|NCT04341454|Experimental|DWP14012 X mg QD|"Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo
~Evening: 1 tablet of DWP14012 Y mg placebo"
16348247|NCT04341454|Experimental|DWP14012 Y mg BID|"Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg
~Evening: 1 tablet of DWP14012 Y mg"
16348248|NCT04341454|Placebo Comparator|placebo|"Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo
~Evening: 1 tablet of DWP14012 Y mg placebo"
16348249|NCT04341441|Active Comparator|Study Drug - Daily Dose|The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
16348250|NCT04341441|Active Comparator|Study Drug - Weekly Dose|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
16348251|NCT04341441|Active Comparator|Placebo|All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
16348252|NCT04341441|Active Comparator|Non-Randomized Active Comparator|A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.
16348253|NCT04341428|Experimental|DWP14012 20mg|Orally, once daily
16348254|NCT04341428|Active Comparator|Lansoprazole 15mg|Orally, once daily
16348255|NCT04341415|Experimental|Auricular neuromodulation|
16348256|NCT04341415|Sham Comparator|Control|
16348257|NCT04341402|Experimental|Experimental|miconazole 3% & diclofenac sodium 1% & urea 40% in topical gel daily for 6 months.
16348258|NCT04341389|Active Comparator|Arm 1|1×10^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
16348787|NCT04337450|Experimental|DTG/3TC|Dolutegravir (DTG) and lamivudine (3TC) (known as DTG/3TC)
16348261|NCT04341376|Experimental|Enhanced First Connections|Enhanced First Connections is a short-term risk assessment and response home visiting referral program. The goal of Enhanced First Connections is to identify family needs and link families to community resources, including evidence based home visiting models. Enhanced First Connections includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation. Women who enroll in Enhanced First Connections are expected to receive between four and eight home visits before being referred to other community resources.
16348262|NCT04341376|No Intervention|Treatment as Usual|Women who receive Treatment as Usual will follow the usual course of clinical care throughout their pregnancy and into the postpartum period, and will be eligible for the typical array of community services that may be offered to them.
16348263|NCT04341363|Experimental|Microneedling|Participants with androgenic alopecia will receive microneedling with a tattoo machine.
16348264|NCT04341350|Active Comparator|Usual sedation|Sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug.
16348265|NCT04341350|Experimental|Inhaled sedation|Sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of an analgesic drug.
16348266|NCT04341337||expert|interviews of expert of pipac about ethical issues
16348267|NCT04341324||Active arm: Subjects received hormonal therapy|"Study subject inclusion criteria
~Male patients 18 years or older
~Adenocarcinoma of the prostate either histologically or cytologically confirmed
~Decided to be put on ADT -bilateral orchidectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist, with or without additional antiandrogen
~After ADT performed, serum testosterone level should reach castrated level, i.e. < 50 ng/dL after 6 weeks of treatment
~Able to consent for the participate in the study"
16348268|NCT04341324||Control arm: Subjects do not plan to receive hormonal therapy|"Control subject:
~Male patients 18 years or older
~Adenocarcinoma of the prostate either histologically or cytologically confirmed
~Able to consent for the participate in the study"
16348269|NCT04341311|Experimental|Marizomib|"All patients will initially receive marizomib (MRZ) alone (Course A1) The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design
~-Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses."
16348270|NCT04341311|Experimental|Marizomib + Panobinostat|"If tolerated,combination of Marizomib: and panobinostat on subsequent cycles. The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design.
~Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses.
~Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course"
16348271|NCT04341298|Experimental|Avulux® device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
16348272|NCT04341298|Sham Comparator|Control/sham device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
16348273|NCT04341285|Active Comparator|Early ECMO|Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
16348274|NCT04341285|Active Comparator|Late ECMO|Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.
16348275|NCT04341272|Active Comparator|Upper Extremity Compression Device|Patients randomized to have pneumatic compression device placed on upper extremity following surgery
16348276|NCT04341272|Other|Control|Patients randomized to have pneumatic compression device placed on lower extremity following surgery
16348277|NCT04341259|Experimental|Ipatasertib as a Single Agent|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD). This study has three study periods: a screening period (up to 14 days in length), followed by a treatment period of up to approximately 2 years (Cycle 1 will be 35 days in length, all subsequent cycles will be 28 days in length) and a 28-day follow-up period after the treatment discontinuation or study completion.
16348278|NCT04341246||Cases|Cases are defined as those patients who have undergone liver biopsy and have confirmed NASH and fibrosis
16348279|NCT04341246||Controls|Controls are patients have undergone a liver biopsy with neither significant NASH nor significant fibrosis
16348280|NCT04341220|Experimental|Anodal tDCS + Exercise|Anodal tDCS applied over primary motor cortex (M1) - Dose: 1mA, 20 minutes + ( concomitantly) protocol of specific exercises for balance
16348281|NCT04341220|Sham Comparator|Sham tDCS + Exercise|Sham tDCS applied over primary motor cortex (M1) - Dose: 1mA, 30 seconds ON, + (concomitantly) protocol of specific exercises for balance
16348282|NCT04341207|Experimental|Cohort 1|Advanced Cancer Patients with SARS-CoV-2 positive test & Covid19 symptoms
16348283|NCT04341207|No Intervention|Cohort 2|Advanced Cancer Patients with SARS-CoV-2 negative test & Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.
16348284|NCT04341207|No Intervention|Cohort 3|Advanced Cancer Patients with SARS-CoV-2 positive or negative test & no Covid19 symptoms
16348285|NCT04341207|Experimental|Cohort 4|Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease & no Covid19 symptoms & Pretreated or with frail conditions following the HCSP definition
16348286|NCT04341194|No Intervention|Standard care with glucose|Control Group with standard care comprises facilitated tucking done by a nurse or the parent, oral glucose (300 mg/ml) and the opportunity to suck on a pacifier or on a parent's or a nurse's plastic gloved finger. The infant is placed on an examination table for the venipuncture.
16348287|NCT04341194|Experimental|Skin-to-skin contact|Skin-to-skin contact is a method widely used in neonatal care globally. The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
16348409|NCT04340427|Experimental|TQB3455 Tablets|TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
16348288|NCT04341194|Experimental|Skin-to-skin contact/breastfeeding/parental singing|Parent-driven interventions are skin-to-skin care, breastfeeding and multi-sensory stimulation like vocalisation. They are all a combination of multiple sensory inputs comprising auditory, tactile and olfactory recognition. Research has started to investigate breastfeeding in combination with Kangaroo-mother- care for example, which has shown to be an effective mix. A multimodal approach that includes a combination of non-pharmacological approaches is considered more effective during venipuncture than single strategies and provides greater pain relief.
16348289|NCT04341181|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
16348290|NCT04341181|Experimental|Atezolizumab|Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab.
16348291|NCT04341181|Experimental|Avelumab|Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab.
16348292|NCT04341181|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
16348293|NCT04341181|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib.
16348294|NCT04341181|Experimental|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib.
16348295|NCT04341181|Experimental|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab.
16348296|NCT04341181|Experimental|Trastuzumab emtansin|Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin.
16348297|NCT04341181|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib.
16348298|NCT04341181|Experimental|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib.
16348299|NCT04341168||Children and Adolescents with COVID-19|age range: newborn - 18 years old, subgroups will be established
16348300|NCT04341168||Adults with COVID-19|age range: from 18 years old, subgroups will be established
16348301|NCT04341168||Control group|all ages, any respiratory tract infection, subgroups will be established
16348302|NCT04341155|Active Comparator|Dexamethasone|"Sixty nine patients will be administered randomly dexamethasone 20 mg IV for 7 days.
~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
16348303|NCT04341155|Placebo Comparator|Placebo|"Sixty nine patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days.
~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
16348304|NCT04341142|Experimental|Serological tests will be applied on patients blood sampling|Serological tests will be applied on patients blood sampling
16348305|NCT04341129|Experimental|Abbreviated MRI using Dotarem|Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. The shorter imaging times achieved with the abbreviated DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol using Dotarem® (Gadoterate Meglumine) by comparing the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol.
16348306|NCT04341116|Experimental|TJ003234 6 mg/kg|
16348307|NCT04341116|Experimental|TJ003234 3 mg/kg|Part 1 only
16348308|NCT04341116|Placebo Comparator|Placebo|
16348315|NCT04341077|Experimental|SHR3162|A single dose of fluzoparib was administered orally
16348316|NCT04341064|Experimental|SHINE|Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
16348317|NCT04341064|No Intervention|Standard Education|Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.
16348318|NCT04341051||Case|we will observe the regional saturation of O2 through NIRS at the following time: T0(before peripheral anesthesia); T1 (5 minutes from the block); T2 (15 minutes from the block); T3 (30 minutes from the block); T4 (after revascularization); At each interval PA, SpO2 and NIRS were also recorded in the contralateral limb as control data.
16348319|NCT04341038|Experimental|Intervention|"Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.
~In addition, these patients can receive all the treatments considered necessary for their clinical management."
16348320|NCT04341038|No Intervention|Usual care|These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.
16348321|NCT04341012||Normal|No known medical conditions
16348322|NCT04341012||Liver Cirrhosis|Clinically diagnosed with cirrhosis
16348323|NCT04341012||COVID-19 tested|Persons with known test results for COVID-19 RNA
16348324|NCT04341012||Other|Persons with other medical diagnosis, no known liver disease, negative for COVID-19
16348325|NCT04340999||Manifested Group|Manifested Group , enrolled patients who had any of the following manifestations(Fatigue,muscle cramps or numbness)
16348326|NCT04340999||Non-Manifested Group|Non-manifested group in which enrolled patients didn't report any of the following manifestations
16348327|NCT04340986||patients with Hepatocellular carcinoma|
16348328|NCT04340986||patients with Cholangiocarcinoma|
16348329|NCT04340973|Active Comparator|Anodal|Anodal tDCS: Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16348330|NCT04340973|Active Comparator|Bilateral|Bilateral : Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16348331|NCT04340973|Active Comparator|Cathodal|Cathodal : Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16348332|NCT04340973|Active Comparator|Extracephalic|Extracephalic : Anode placer over the affected primary motor cortex, cathode over right shoulder. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16348333|NCT04340973|Placebo Comparator|Placebo|Placebo : anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
16348334|NCT04340960|No Intervention|Control Group|"The control group will not be monitored with continuity of care. After this period 30 day emergency department visits will be measured and compared between the two groups, along with 30 day readmission rates, in-hospital length of stay, mortality, quality of recovery 40 item scale (QoR-40), European Quality of LIfe 5 Dimensions (EQ5D), patient satisfaction score, and societal and hospital cost.
~No intervention will be administered."
16348335|NCT04340960|Experimental|Home Monitoring Group|At the time of hospital discharge, the control group will be discharged without receipt of home monitoring and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and ECG (electrocardiogram)) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for 4 weeks and have their ECG, NIBP, HR (heart rate), SPO2 and pain scores evaluated 4 times a day for 2 weeks.
16348336|NCT04340947|Other|Menthol very low nicotine cigarette|Participants will smoke menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one menthol flavored very low nicotine cigarette in the laboratory.
16348337|NCT04340947|Other|Non-menthol very low nicotine cigarette|Participants will smoke non-menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one non-menthol flavored very low nicotine cigarette in the laboratory.
16348338|NCT04340934|Experimental|Use of REZUM system|Surgery of benign prostatic hyperplasia by REZUM system
16348339|NCT04340921||1. COVID-19+ (n=120)|"COVID-19 positive without evidence of myocardial injury (n=120). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection.
~Exclusion criteria: No biochemical evidence of acute myocardial injury (serum troponin>99th centile within previous 48-hour period)."
16348340|NCT04340921||2. COVID-19+ Myocardial injury+ (n=20)|"COVID-19 positive with myocarditis (n=20). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection and clinically suspected or confirmed myocarditis including evidence of acute myocardial injury (troponin >99th centile within the previous 48-hour period) at the time of recruitment.
~Exclusion criteria: significant chronic kidney disease (eGFR ≤30 or dialysis-dependent) or septic shock at the time of initial assessment. We will also exclude patients with a diagnosis of chronic heart muscle disease and those with known significant chronic or acute obstructive coronary disease."
16348341|NCT04340921||3. COVID-19+ Complication+ (estimated 10-25%)|Inclusion criteria: Participants form Groups 1 and 2 in whom a prespecified complication ocurs will be included in a derived Group3.
16348342|NCT04340908|Experimental|Treatment|Dapagliflozin 10 mg tablet
16348343|NCT04340908|Placebo Comparator|Control|matching placebo tablet
16348346|NCT04340882|Experimental|Treatment (docetaxel, ramucirumab, pembrolizumab)|Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16348347|NCT04340869|Experimental|Theobromine|Natural extract from Cocoa
16348348|NCT04340869|Active Comparator|Remin Pro|Fluoride , Hydroxyapatite , and Xylitol
16348349|NCT04340869|Experimental|Combination|Remin Pro and Theobromine
16348410|NCT04340414|Experimental|NCP patient with severe ARDS and/or high ventilator supported|The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment
16348494|NCT04339673|Active Comparator|MNB- masseteric nerve block|masseteric nerve block with local anesthesia lidocaine single app.
16348350|NCT04340843|Experimental|Treatment (belinostat, guadecitabine, ASTX727)|Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline (within 21 days of the first cycle) and during cycle 2 (on day 3, 4, or 5). In addition, patients undergo MRI or CT scans every 2 cycles (8 weeks) while receiving guadecitabine or ASTX727 and belinostat.
16348351|NCT04340830|Experimental|smoker|Those consuming at least 10 cigarette a day for ten years were included in smoker group.
16348352|NCT04340830|Active Comparator|non-smoker|Patients who never smoke were included in non-smoker group. Patients who quit smoking were not included in this group.
16348353|NCT04340804|Experimental|Kcal labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal counter synchronised with the food amount changes (i.e., increasing/decreasing).
16348354|NCT04340804|Experimental|PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes (i.e., increasing/decreasing) with 4 min being equivalent to 20 kcal.
16348355|NCT04340804|Experimental|Kcal and PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal and PACE counters synchronised to the food amount changes (i.e., increasing/decreasing).
16348356|NCT04340804|No Intervention|No labelling|Participants allocated to this group will only see on the screen the amount of food increasing or decreasing based how many times they tap on the corresponding keys.
16348357|NCT04340791|No Intervention|Default proportion & no labelling|"No intervention:
~Default proportion condition (33% lower energy density items - 67% higher energy density items). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
~No labelling."
16348358|NCT04340791|Experimental|Default proportion & labelling|"When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
16348359|NCT04340791|Experimental|Increased proportion & no labelling|The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
16348360|NCT04340791|Experimental|Increased proportion & labelling|"The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
~When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
16348361|NCT04340778|Experimental|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion.
16348362|NCT04340778|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
16348363|NCT04340778|Placebo Comparator|placebo|inert placebo Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
16348364|NCT04340765|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
16348365|NCT04340752|Experimental|Group 1:ICG 7.5 mg|Subjects in this group are randomized to receive 7.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
16348366|NCT04340752|Experimental|Group 2:ICG 12.5 mg|Subjects in this group are randomized to receive 12.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
16348367|NCT04340752|Experimental|Group 3: ICG 25 mg|Subjects in this group are randomized to receive 25 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
16348368|NCT04340739||Cohort 1 (8 Patients)|A wireframe mock-up of the GEMINI platform will be usability tested by 8 chronic pain patients from whom feedback will be collected by completing a virtual semi-structured interview. Outcomes: Quantitative Testing Data from Usability Testing Prompt. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
16348369|NCT04340739||Cohort 2 (16 Patients)|"A live version of GEMINI will be beta-tested by 16 chronic pain patients through completing a faux medical group visit (MGV). This will include things like exploring the education topics available, interacting with the other participating patients, and interacting with a medical provider posing as the faux group's health care provider, all in order to robustly test the system in a live environment. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide."
16348430|NCT04340206|Experimental|face-to-face support and Chatbot online support group|Experimental, Intervention Group A: face-to-face support and Chatbot online support group: 5-week intervention according to ACT principles with the web- and mobile-based Youth Compass plus program, face-to-face support (2 meetings) and weekly online support and feedback from the Chabot eCoach built within the program (one third of the participants is randomly assigned to this group)
16348370|NCT04340739||Cohort A (8 Healthcare Providers)|Eight healthcare providers will be divided into pairs, and these pairs will each conduct a faux medical group visit (MGV) with faux patients (staff will pose as patients). They will be asked to complete the faux session as if it were actual patients of theirs, conduct pre- and post-session tasks, and provide usability feedback on the platform. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
16348371|NCT04340713|Experimental|Information support group|The experimental group was given information support program intervention on the basis of routine information communication.
16348372|NCT04340713|No Intervention|Routine care group|The control group was given routine information communication.
16348373|NCT04340700|Experimental|THC|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
16348374|NCT04340700|Placebo Comparator|Placebo|Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
16348375|NCT04340687||IP group|All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.
16348376|NCT04340687||IN group|All patients received one single dose of 100mg rectal indomethacin after ERCP.
16348377|NCT04340674|Experimental|Telerehabilitation based on aerobic exercise|Aerobic low-impact exercise guided by audiovisual material. The intensity of exercise is adapted to each participant and is established according to the perceived effort after each session, according to the modified Borg perceived effort scale.
16348378|NCT04340674|No Intervention|Control group|Group that maintain the same medical treatment and not receive additional intervention.
16348379|NCT04340661|Experimental|Bionocol arm|
16348380|NCT04340661|Placebo Comparator|Placebo arm|
16348381|NCT04340635||Multi-center data collection|Without intervention
16348382|NCT04340622|Active Comparator|Reduction in opioid cravings and use|These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.
16348383|NCT04340622|Placebo Comparator|Small reduction in opioid cravings and use|Sham condition.
16348384|NCT04340609|Experimental|Intravenous Group|Dosage of intravenous route is 2 million MSCs/kg for each subject.
16348385|NCT04340609|Experimental|Intracoronary Group|Dosage of intracoronary route is ±50 million MSCs for each subject.
16348386|NCT04340609|No Intervention|Control Group|Standard treatment of acute myocardia infarction
16348389|NCT04340570|Experimental|Intervention|Receives pharmacist home televisit for medication management
16348390|NCT04340570|No Intervention|Usual Care|Usual care for outpatient medication management
16348391|NCT04340557|Experimental|Group A (Study drug+SOC)|Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
16348392|NCT04340557|No Intervention|Group B (SOC)|Standard of Care
16348393|NCT04340544|Experimental|Hydroxychloroquine|Hydroxychloroquine 600mg daily for 7 days
16348394|NCT04340544|Placebo Comparator|Placebo|Equivalent number of placebo capsules
16348395|NCT04340531|Experimental|Arm I (early arm)|Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
16348396|NCT04340531|Active Comparator|Arm II (delayed arm)|Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
16348397|NCT04340518|Experimental|Post-scleral lens wear|Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
16348398|NCT04340505||Active uveitis patients.|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist and requires an injectable fluocinolone acetonide implant to treat their inflammation.
16348399|NCT04340492|Experimental|Adapted Physical Activity group|
16348400|NCT04340492|Sham Comparator|control group|
16348401|NCT04340479||Absent lung ultrasound findings of active COVID infection|Absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
16348402|NCT04340479||Present lung ultrasound findings of active COVID infection|Presence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
16348403|NCT04340466||Suspected or proven COVID-19 critically ill patients|
16348404|NCT04340466||Control|
16348405|NCT04340453|Active Comparator|Group 1 (Hip and Knee Exercise Program)|Standard exercise physiotherapy treatment of a Hip and Knee Exercise Program plus stretching.
16348406|NCT04340453|Experimental|Group 2 (BFR-training hip and knee exercise group)|BFR-training hip and knee exercise group plus stretching.
16348407|NCT04340440|Active Comparator|D1 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy
16348408|NCT04340440|Active Comparator|D2 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy
16348411|NCT04340401|Experimental|TNT+SHR1210|"Patients with high-risk locally advanced rectal cancer will receive chemotherapy and SHR-1210 before chemoradiaton, after chemoradiaton, patient will receive consolidation chemotherapy. This arm is called Total Neoadjuvant Treatment (TNT) plus SHR-1210. The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX ( Capecitabine + Oxaliplatin ) plus SHR-1210 over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.
~Finally, patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs."
16348412|NCT04340388|Active Comparator|Switch from a non-integrase based regimen to dolutegravir|Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
16348413|NCT04340388|Active Comparator|Continue on non-integrase inhibitor based regimen|Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
16348414|NCT04340375|Experimental|AP green tea extracts|8 weeks
16348415|NCT04340362|Experimental|VX-147|Subjects will receive VX-147 orally at Dose 1 for 2 weeks and at Dose 2 for 11 weeks.
16348416|NCT04340349|Experimental|Experimental: Hydroxychloroquine plus Bromhexine|200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
16348417|NCT04340349|Placebo Comparator|Hydroxychloroquine plus Bromhexine|200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
16348418|NCT04340323|Experimental|Group A-intensive exercise group|"Dosage of intensive exercise group - 12 weeks, five times a week for 30 minutes per day; five times with education by a physiotherapist, followed by continuation at home.
~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.
~Educating probands about anatomy, physiology and pelvic floor muscle function.
~Training of pelvic floor muscles in different positions.
~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
16348419|NCT04340323|Active Comparator|Group B-low-intensity exercise group|"Dosage of low-intensity exercise group - 12 weeks, twice a week for 15 minutes per day; five times with physiotherapist education, followed by continuation at home.
~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.
~Educating probands about anatomy, physiology and pelvic floor muscle function.
~Training of pelvic floor muscles in different positions.
~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
16348420|NCT04340310||Home respiratory poligraphy|Group A: Children between 4 and 14 years-old with initial OSA suspicion there will be allocated to Home Respiratory Polygraphy (HRP)
16348421|NCT04340310||Polysomnography|Group B: Children between 4 and 14 years-old with initial OSA suspicion and concommitant diseases and false negative suspicion from HRP there will allocated to Hospital Nocturnal Polysomnography
16348422|NCT04340297|Experimental|Experimental group|Tongjiang granules are taken orally in liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally in spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally in cold-heat complicated syndrome, one bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
16348423|NCT04340297|Placebo Comparator|Control group|Tongjiang placebo granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua placebo granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei placebo granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
16348424|NCT04340284|Experimental|Patients with nonunion of long bones|A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation
16348425|NCT04340271|Experimental|Extracorporeal shock wave therapy group|Patients in the ESWT group were explained to select the most hypertrophic and retracting area for the treatment on dominant hand. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
16348426|NCT04340271|Sham Comparator|sham stimulation group|The same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy
16348427|NCT04340258|Experimental|Pembrolizumab & Cesium-131|200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
16348428|NCT04340232|Experimental|Baricitinib Arm|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of baricitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 2 mg baricitinib once daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving baricitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
16348429|NCT04340219||Cancer patients|Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (CPDI, DASS-21, and WHOQOL-BREF).
16348491|NCT04339699|Active Comparator|NobleStitch EL|Participants treated with the NobleStitch EL device
16349976|NCT04328857|Experimental|Treatment|Upper limb rehabilitation with pseudoelastic orthosis
16348431|NCT04340206|Experimental|only chat-robot online support group|Experimental, Intervention Group B: only chat-robot online support group: 5-week intervention according to ACT principles with the web-and mobile-based Youth Compass plus program, no face-to-face support, and weekly online support and feedback from the chatbot eCoach built within the program (one third of the participants is randomly assigned to this group)
16348432|NCT04340206|Experimental|Experimental Control|"Experimental Control:
~Control group, no intervention (one third of the participants is randomly assigned to this group)"
16348436|NCT04340180|Experimental|Subjects with enhancing breast lesions|
16348437|NCT04340167|Experimental|Autologous humanized anti-CD22 CAR-T treatment|
16348438|NCT04340154|Experimental|chimeric antigen receptor T cell treatment|
16348439|NCT04340141|Experimental|Arm I (perioperative chemotherapy, surgery)|Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Within 2-8 weeks of completing neoadjuvant chemotherapy, patients undergo surgical resection. Patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16348440|NCT04340141|Active Comparator|Arm II (surgery, adjuvant chemotherapy)|Patients undergo surgical resection. Beginning 3-12 weeks after surgery, patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
16348441|NCT04340128|Active Comparator|1|Intra-lesional injection of Glucantime once a week
16348442|NCT04340128|Experimental|2|Intra-lesional injection twice a week, 0.1/cm2
16348444|NCT04340102|Experimental|BecomeAnEx|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital program.
16348445|NCT04340089||observation group|the patients can go to squatting on the toilet at any time as they want to after taking the capsule
16348446|NCT04340089||control group|The patients can move freely
16348447|NCT04340076|Experimental|Dose reduction|Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.
16348448|NCT04340076|Active Comparator|Normal dose|Patients will continue treatment with the normal/maintenance dose of the biologicals.
16348449|NCT04340063|Active Comparator|Treadmill group|Participants randomized to the Treadmill group will complete high intensity gait training on a treadmill.
16348450|NCT04340063|Experimental|Movement Amplification group|The locomotor training protocol described for the Treadmill group will be used for the Movement Amplification group with one exception. The Movement Amplification group will perform all gait training within the movement amplification environment.
16348451|NCT04340050|Experimental|Treatment with anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours
16348452|NCT04340037||proximal ureteral stone patient|Patients underwent percutaneous nephrolithotomy treating unilateral, solitary and proximal ureteral stones.
16348453|NCT04339998||Patients with Suspected or Confirmed COVID-19|Patients 18 years of age and older under investigation for COVID-19 and those patients that are positive for COVID-19 at University of Minnesota Medical Center and Bethesda Hospital. Informed consent will be obtained from the patient or decision maker prior to study inclusion
16348454|NCT04339985|Experimental|ATx201 OINTMENT 4%|ATx201 OINTMENT 4%
16348455|NCT04339985|Experimental|ATx201 OINTMENT 7%|ATx201 OINTMENT 7%
16348456|NCT04339985|Experimental|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
16348457|NCT04339972|Experimental|Active LIFUP then Sham LIFUP|Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2
16348458|NCT04339972|Sham Comparator|Sham LIFUP then Active LIFUP|Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2
16348459|NCT04339959||Phase I|First, we will test proof-of-concept that participants will be able to follow the testing protocol and use the tablet computer to communicate with the investigator (10-12 participants). The test protocol will be refined based on what is learned after a minimum of 10 participants. We anticipate no more than 12 participants needed for this phase.
16348460|NCT04339959||Phase II|Next, 10-20 new participants will be enrolled to evaluate the validity of videoconference vs. face-to-face assessment (i.e., direct observation) of physical performance. Communication will occur between the remote assessor and the participant. The direct observer will not communicate directly to the participant, unless there is a safety issue. After completing 10 participants without a major change in the test protocol, we will proceed to the next phase.
16348461|NCT04339959||Phase III|This phase involves participants repeating the test protocol, but without the face-to-face assessment (i.e., direct observation). This will test the ability of the participant to receive the box of test instructions and materials in the mail, unpack the box, communicate with the remote assessor via videoconferencing, pack up the box, and return it (postage paid) to the study team. This step will involve 5-10 participants from Phases 1 and 2, who have provided approval for future contact (see approved Future Contact form). Once 5 participants have successfully and safely completed the test protocol, we will proceed to Phase 4.
16348462|NCT04339959||Phase IV|This phase is the same as Phase 3, except it includes newly enrolled participants, i.e., representing the first-time participants have enrolled/participated in this study. This will eliminate the practice effect that will occur in phase 3. This step will enroll 5-10 participants.
16348463|NCT04339946||Patients with suspicious of rectosigmoid endometriosis|
16348464|NCT04339933||BC|Patients who were diagnosed with bladder cancer
16348465|NCT04339920||Chinese patients with clinical suspicious of prostate cancer|Chinese patients with clinical suspicious of prostate cancer, due to elevated serum PSA or abnormal digital rectal examination, will be recruited for the study from the Prince of Wales Hospital and North District Hospital.
16348466|NCT04339907|Sham Comparator|Cataract surgery only|Participants needing cataract surgery, without glaucoma or any other corneal diseases.
16348467|NCT04339907|Sham Comparator|Glaucoma surgery only|Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
16348468|NCT04339907|Experimental|Corneal transplantation|"Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.
~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure."
16348469|NCT04339907|Experimental|Intraocular surgery following corneal transplantation|"Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).
~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation."
16348470|NCT04339907|Experimental|Glaucoma surgery following corneal transplantation|"Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).
~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation."
16348471|NCT04339868|Active Comparator|Terlipressin group|Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease terlipressin until stop
16348472|NCT04339868|Placebo Comparator|Placebo group|Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease placebo until stop
16348473|NCT04339842||Adults in quarantine due to the virus outbreak|Individuals over the age of 18 who spend most of their time at home in social isolation because of the Coronavirus to prevent the risk of contracting the virus
16348474|NCT04339829|Other|Dacomitinib 45mg PO ,QD|Single arm
16348475|NCT04339816|Experimental|HC-A group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and 500 mg of Azithromycin once in 24 hours (with the first dose of hydrochloroquine)
~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval 250 mg of Azithromycin once in 24 hours (with the first daily dose of hydrochloroquine)"
16348476|NCT04339816|Active Comparator|HC group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)
~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)"
16348477|NCT04339816|Placebo Comparator|C group|• Day 1-5: Patients receive two doses of placebo in 12 hours interval and 1 extra dose of placebo once in 24 hours
16348478|NCT04339803|Experimental|mirror therapy|lower limb mirror therapy using ankle exercise
16348479|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
16348480|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
16348481|NCT04339777|Active Comparator|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
16348482|NCT04339777|Active Comparator|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
16348483|NCT04339764|Experimental|Experimental|Five participants will undergo RPE transplantation in one eye. Eligible eyes will have GA, best-corrected visual acuity (BCVA) between 20/100 and 20/500, and a fellow eye that has same or better BCVA. If the National Eye Institute (NEI) Data and Safety Monitoring Committee (DSMC) gives clearance to proceed based on review of data from the first cohort, a second cohort of up to seven additional participants with GA, BCVA between 20/80 and 20/500 in the eye being considered for RPE transplantation, and same or better visual acuity in the other eye may undergo the procedure to gather additional safety and potential efficacy data useful for planning future studies. Up to 20 participants may be enrolled to allow for screening failures or for participants withdrawing from the study prior to RPE transplantation.
16348488|NCT04339725||Fecal DNA|Extraction fecal DNA and compare disease group to normal group
16348489|NCT04339712|Experimental|anakinra|In case of diagnosis of MAS, IV anakinra 200mg three times daily (every eight hours) for 7 days. Patients who will receive anakinra treatment and who suffer from kidney dysfunction will receive 50% of the dose i.e. 100mg anakinra three times daily for 15 days
16348490|NCT04339712|Experimental|tocilizumab|"In case of diagnosis of immune dysregulation IV tocilizumab 8mg/kg body weight once up to a maximum of 800mg. These patients will receive anakinra at the above dose in case they meet one of the following contra-indications for tocilizumab:
~absolute neutrophil count less than 2,500/mm3;
~absolute platelet count less than 100,000/mm3; and
~AST or ALT more than 1.5 x the upper normal limit"
16348495|NCT04339673|Active Comparator|LA -trigger point injection with local anesthetic|local anesthetic injections on trigger points in masseter
16348496|NCT04339673|Placebo Comparator|DN-dry needling|dren needling to masseter
16348497|NCT04339660|Experimental|UC-MSCs treatment group|Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.
16348498|NCT04339660|Placebo Comparator|Control group|Participants will receive conventional treatment and Placebo intravenously.
16348499|NCT04339647|Experimental|The SIMS Programme|The SIMS programme is a community-based intervention which improvised the usual care (defined as the existing preschool oral health programme) offered by the Ministry of Health. The target group is 5-6-year-old preschool children and their parents. Apart from the usual care, the 5-6-year-old children receive interventions carried out by teacher in school and home tooth brushing supervision by parents. In addition, parents/guardians will receive OHE from the DT team, free toothbrush and toothpaste (1000ppm F) for child home tooth brushing and supervised child home tooth brushing for 6 months.
16348500|NCT04339647|No Intervention|Control|The control group receives the usual care from the preschool oral health programme. The usual care is described as a DT team visiting the school to do an oral examination, provides OHE to the children, and applies fluoride varnish (20,000 ppmF) twice/year.
16348501|NCT04339634||Program of All-Inclusive Care for the Elderly|The Program of All-Inclusive Care for the Elderly (PACE) provides comprehensive medical and supportive services for community-dwelling persons, mostly older adults (>55 years), as an alternative to institutionalization. Medical services are provided by an interdisciplinary team of healthcare professionals, Tabula Rasa HealthCare being the pharmacy care provider for several PACE organizations.
16348502|NCT04339621||Treatment Naive|20 patients with AIH will be recruited that will be treatment naive at the time of recruitment.
16348503|NCT04339621||Treatment cessation review|77 AIH patients will be recruited who will have been on treatment for the past 18-24 months and will be coming in to meet their physician to review treatment cessation options
16348504|NCT04339595|Experimental|Tildrakizumab|
16348505|NCT04339569||History of patellar tendinopathy|
16348506|NCT04339569||Healthy controls|
16348507|NCT04339543|Other|Longitudinal assessment|
16348508|NCT04339504|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
16348509|NCT04339504|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
16348510|NCT04339504|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
16348511|NCT04339478||Autofluorescence|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:
~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
16348512|NCT04339478||Control|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection without autofluorescence device. The following intraoperative variables will be recorded for all patients:
~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands"
16348513|NCT04339465|Experimental|CARE-FAM|The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
16348514|NCT04339465|Experimental|WEP-CARE|The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 10 standardized writing tasks on a secured internet platform. The 10 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.
16348515|NCT04339465|Experimental|CARE-FAM + WEP-CARE|The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.
16348516|NCT04339465|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
16348517|NCT04339439|No Intervention|Closure without vessel loop|These patients will receive standard of care closure of the carpal tunnel release incision.
16348518|NCT04339439|Experimental|Closure with vessel loop|These patients will receive closure of the carpal tunnel release incision with a vessel loop placed under the sutures.
16348519|NCT04339426|Experimental|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
16348520|NCT04339413|Experimental|Gantenerumab|Participants will continue receiving open-label gantenerumab by subcutaneous (SC) injection every four weeks (Q4W) at the same dose as administered in the parent studies.
16348521|NCT04339400|Experimental|TQ05105 Tablet|TQ05105 tablet 5mg administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
16348550|NCT04339166|No Intervention|Group B|Single thawed blastocyst transfer with blastocyst selection according to morphologic score.
16348522|NCT04339387||Coronavirus Disease 2019 positive, suitable for discharge|Patients with Coronavirus Disease 2019 who do not require supplemental oxygen, do not require intensive care unit-level care, and do not die.
16348523|NCT04339387||Coronavirus Disease 2019 positive, not suitable for discharge|Patients with Coronavirus Disease 2019 who do require supplemental oxygen, do require intensive care unit-level care, or do die.
16348524|NCT04339374||Ex vivo imaging|"Patients with known adenomatous polyps or malignancies in the colon or rectum undergoing resection will be considered for enrollment
~Participation will include imaging of both normal and known pathologic portions of the specimen ex vivo immediately following resection. The specimen will then undergo fixation and standard pathologic evaluation, with subsequent correlation between imaging and pathologic findings.
~This data will also be used to develop a convolutional neural network (CNN) to assist in interpreting photoacoustic imaging data."
16348525|NCT04339374||In vivo imaging|"Patients with distal rectal lesions (benign or malignant tumors within 15cm of the anal verge) will be enrolled for the in vivo imaging portion of the study
~Participation will include an intraoperative, in vivo evaluation of the tumor with a novel endorectal photoacoustic ultrasound probe as well as ex vivo imaging post-resection as described above. Following the induction of anesthesia, patients will undergo a 20 minute endorectal imaging evaluation performed by their colorectal surgeon. After imaging, the patient will then undergo standard-of-care surgical resection of the rectum. The resection specimen will then be imaged ex vivo as performed in the ex vivo cohort of this study.
~For this portion of the pilot, enrollment will be limited to 40 participants"
16348526|NCT04339361|Experimental|lidocaine spray|four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion
16348527|NCT04339361|Active Comparator|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
16348528|NCT04339361|Placebo Comparator|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
16348529|NCT04339348|Experimental|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus vaginal inert placebo cream at the time of IUD insertion
16348530|NCT04339348|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine anesthetic cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo will be given 3 hours before LNG-IUD insertion
16348531|NCT04339348|Placebo Comparator|placebo|inert vaginal placebo cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours before LNG-IUD insertion
16348532|NCT04339322||Patients with Covid-19|Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health
16348533|NCT04339309|Active Comparator|Kiel Center|Non-surgical periodontal treatment with interdental hygiene devices in periodontitis patients.
16348534|NCT04339309|Active Comparator|Cairo Center|Non-surgical periodontal treatment without interdental hygiene devices in periodontitis patients.
16348535|NCT04339296|Experimental|Intervention group|Intervention group included medication management with Spencer.
16348536|NCT04339296|No Intervention|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
16348537|NCT04339283|Experimental|Standardized Hibiscus sabdariffa tea Arm|300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days
16348538|NCT04339283|No Intervention|Water Arm|300 mL of distilled water is administered to the participants daily for 28 days.
16348539|NCT04339270|Active Comparator|Azithromycin according to symptoms|Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.
16348540|NCT04339270|Experimental|Azithromycin according to rheology|Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.
16348541|NCT04339244|Active Comparator|ONSD measurement under lower blood pressure|ONSD measurement under mean blood pressure of 60~70 mmHg
16348542|NCT04339244|Active Comparator|ONSD measurement under highly normal blood pressure|ONSD measurement under mean blood pressure of 90~100 mmHg
16348543|NCT04339231|Active Comparator|Ropivacaine group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
16348544|NCT04339231|Placebo Comparator|Saline 0,9% group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with saline solution, in a concentration of 0.9%, advancing it through the nasal cavities towards the posterior wall of the nasopharynx. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that the solution is absorbed by the mucosa up to the sphenopalatine ganglion, which, in general, is anatomically three millimeters deep from the surface. After the established time, the cotton buds are removed.
16348545|NCT04339218|Experimental|Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin|Cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
16348546|NCT04339218|Active Comparator|Arm pembrolizumab-pemetrexed-carboplatin|Combination of Pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
16348547|NCT04339192|Experimental|Surgery group|receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.
16348548|NCT04339192|No Intervention|Medical group|receiving medical treatment only
16348549|NCT04339166|Experimental|Group A|Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.
16348551|NCT04339153|Experimental|Parent Training (PT)|The goal of intervention plan is to teach the basic applied behaviour analysis techniques to find out the antecedent of the problem behaviour, enhance adaptive skills and reduce noncompliance. Sessions will be interactive, and action-oriented through the provision of workbooks, modelling, videos, rehearsal (with child when present), homework tasks, and feedback (Bearss et al., 2015). The parents will be trained on the protocol and delivered 60 to 90 minutes preferably individual sessions over 24 weeks.
16348552|NCT04339153|No Intervention|Parent Education (PE)|"The Parent education group will serve as an attention-placebo condition to control for general effects of the intervention.
~There will be 12 core sessions and 1 home visit regarding knowledge of autism, learning about the principles of managing behavior, teaching new skills; improving social interaction and communication. Each session will last for 60 to 90 minutes over 24 weeks."
16348553|NCT04339140|Experimental|Zafirlukast|Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
16348554|NCT04339127||Cohort NMDARE-HSE|Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
16348555|NCT04339114|Sham Comparator|Control meal|Pancake
16348556|NCT04339114|Active Comparator|Control meal + Cinnamon|Pancake seasoned with cinnamon
16348557|NCT04339114|Active Comparator|Control meal + Italian herb mix|Pancake seasoned with Italian herb mix
16348558|NCT04339114|Active Comparator|Control meal + Active-Herbs/Spice mix|Pancake seasoned with pumpkin spice
16348559|NCT04339101|Experimental|Treatment (itacitinib adipate, tacrolimus, sirolimus)|"RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
~ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity."
16348560|NCT04339088||HIFU|Patients that have undergone high focused ultrasound treatment for varicose veins
16348561|NCT04339075||Venablock|Patients that have undergone Venablock treatment
16348562|NCT04339062|Experimental|Cohort 1 Cemiplimab|"Participants who received allogeneic hematopoietic stem cell transplant
~-- Cemiplimab: via IV, flat predetermined dosage every 21 days"
16348563|NCT04339062|Experimental|Cohort 2 Cemiplimab + Everolimus/Sirolimus + Prednisone|"Participants who received a kidney transplant will receive
~Cemiplimab via IV, flat predetermined dosage every 21 days
~Everolimus or Sirolimus-least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
~Prednisone 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapering doses while receiving Cemiplimab"
16348564|NCT04339049|Experimental|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
16348565|NCT04339049|Active Comparator|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
16348566|NCT04339049|Placebo Comparator|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
16348567|NCT04339036|Experimental|Oral CapTem + Y90 Radioembolization|"Capecitabine 750 mg/m2 twice daily orally for 14 days and temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities.
~Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4."
16348570|NCT04339010|Experimental|Hypopressive|"st session: the meetings were provided by a physiotherapist, who also discussed the location and function of the pelvic organs, PFM, and the transversus abdominis (TrA) muscles. The participants learned how to activate TrA muscles. The training was performed during full expiration, the physiotherapist check and coordinate the group to maintain the Tra contraction. The women were also trained to inhale through the nose and exhale through the mouth maintaining an apical breathing pattern.
~nd session: The contractions were executed during six different positions the ones which they will keep following through the whole treatment.
~rd session: The patients were exposed to all the six positions (supplementary material) and their three variations (positions 1, 3, 5 and 6 ). Every meeting obeyed the same schedule through the five weeks of treatment and was accompanied by two physiotherapists."
16348571|NCT04339010|Active Comparator|Hypopressive + PFMC|This group receives the same protocol than the Hypopressive group, but with a verbal command to realize the PFM contraction during the activation of the deep abdominal muscle.
16348572|NCT04338997|Experimental|IZD174|Intra subject dose escalation of IZD174
16348573|NCT04338984|Active Comparator|General anesthesia alone (AG)|"Opioid based analgesia:
~Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).
~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
16348574|NCT04338984|Experimental|Erector Spinae Plane Block and General Anaesthesia (ESPAG)|"Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision.
~Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).
~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
16348575|NCT04338958|Experimental|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days
16348576|NCT04338945||Residents in surgical areas|
16348608|NCT04338763|Experimental|Arm B: RP72 in combination with Gemcitabine|
16348577|NCT04338919|Experimental|O-APT group|Ticagrelor 90 mg twice daily plus aspirin 100mg once daily in the first month, Ticagrelor 90mg bid between the second and the sixth months Ticagrelor 45mg bid between the seventh and the twelfth months
16348578|NCT04338919|Active Comparator|S-APT group|ticagrelor 90 mg twice daily plus aspirin 100mg once daily for 12 months
16348579|NCT04338906|Experimental|Camostat + Hydroxychloroquine|Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
16348580|NCT04338906|Active Comparator|Placebo + Hydroxychloroquine|Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
16348581|NCT04338893|Active Comparator|ROSA Total Knee Robotic Instrumentation|Total knee arthroplasty performed with ROSA Total Knee Robotic instrumentation
16348582|NCT04338893|Active Comparator|Conventional TKA Instrumentation|Total knee arthroplasty performed with conventional instrumentation
16348583|NCT04338867|Active Comparator|Therapeutic arm|Patients who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN) with the release of 10 mg in 24 hours, for 24 hours with a 12-hour rest interval (to avoid saturation of receptors)
16348584|NCT04338867|Active Comparator|Control arm|Patients who received whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions, in 10 days of treatment)
16348585|NCT04338854|Experimental|Root canal treatment|It's one of the restorative groups with LA (Local Anesthesia). An aerator and micromotor were used as cavity preparation in this group. Only conventional root canal treatment and extirpation were planned for the children included in the root canal treatment group in the measurement session.
16348586|NCT04338854|Experimental|Pulpotomy treatment|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. it was noted that at least one of the approximal surfaces of the teeth had decay and iron sulfate (ViscoStat®, UltraDent, South Jordan, USA) was used as pulpotomy material
16348587|NCT04338854|Experimental|two-surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
16348588|NCT04338854|Experimental|one surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group.
16348589|NCT04338854|Experimental|two-surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
16348590|NCT04338854|Experimental|one surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group.
16348591|NCT04338854|Experimental|fluoride application by disposable arch tray|It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
16348592|NCT04338854|Experimental|fluoride application by cotton roll|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
16348593|NCT04338854|Experimental|Fissure Sealant group|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups.
16348594|NCT04338841|No Intervention|Phase1: Before HOME-CoV rule implementation|"Observational assessment of current practices: no recommendation is performed.
~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion.
~Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.
~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
16348595|NCT04338841|Experimental|Phase 2: After HOME-CoV rule implementation|"Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision.
~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.
~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
16348596|NCT04338828|Experimental|Treatment Group|Inhaled nitric oxide
16348597|NCT04338828|Placebo Comparator|Control Group|Inhaled supplemental oxygen
16348598|NCT04338815|Experimental|Determine optimal assistance pattern|
16348599|NCT04338815|Experimental|Determine effects on endurance|
16348600|NCT04338802|Placebo Comparator|Placebo group|Empty capsules with the same appearance and ingredients as Nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
16348601|NCT04338802|Experimental|Nintedanib group|Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
16348602|NCT04338789|Experimental|Group 1|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed immediately before molar protraction on the left or right side of the patient.
16348603|NCT04338789|Experimental|Group 2|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed 3 months after molar protraction with no piezocision on the left or right side of the patient.
16348604|NCT04338789|No Intervention|Group 3|It consisted of 20 subjects (40 molars) where molar protraction was performed with no piezocesion.
16348605|NCT04338776|Experimental|UroLift|Patient randomized to the UroLift arm will receive the FDA-approved UroLift procedure.
16348606|NCT04338776|Experimental|Rezūm|Patient randomized to the Rezūm arm will receive the FDA-approved Rezūm procedure.
16348607|NCT04338763|Experimental|Arm A: RP72 monotherapy|
16348609|NCT04338750|Experimental|TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACTICs)
16348610|NCT04338750|Active Comparator|mEUC|minimally-Enhanced Usual Care (mEUC)
16348611|NCT04338737|Active Comparator|fluid and soft food|It consists of 100 patients that will be allocated for early post-operative oral feeding receiving water and clear fluid approximately 2 hours after surgery, followed by soft food and regular diet 4 hours later irrespective to intestinal sounds, flatus or stool.
16348612|NCT04338737|Active Comparator|fluid only|It consists of 100 patients that will be allocated for early Postoperative oral feeding receiving water and clear fluid approximately 2 hours after surgery till the return of intestinal sounds, then soft food and regular diet later on.
16348613|NCT04338737|Active Comparator|Npo|It consists of 100 patients that will receive no oral feeding till passage of flatus instead 2 to 3 Litres of intravenous fluid will be used for feeding. Water and fluid will be then offered, followed by soft foods and then a regular diet.
16348614|NCT04338724|Experimental|CS1002|
16348615|NCT04338711|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR E1 administered in the fasted state.
16348616|NCT04338711|Experimental|Treatment B|Single oral 10 mg dose of tofacitinib MR E2 administered in the fasted state.
16348617|NCT04338711|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR E3 administered in the fasted state.
16348618|NCT04338711|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR E1 administered in the fed state.
16348619|NCT04338711|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR E3 administered in the fed state.
16348620|NCT04338711|Active Comparator|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state.
16348621|NCT04338698|Active Comparator|Control Intervention|Hydroxychloroquine
16348622|NCT04338698|Experimental|Comparator 1|Azithromycin
16348623|NCT04338698|Experimental|Comparator 2|Oseltamivir
16348624|NCT04338698|Experimental|Comparator 3|Hydroxychloroquine + Azithromycin
16348625|NCT04338698|Experimental|Comparator 4|Hydroxychloroquine + Oseltamivir
16348626|NCT04338698|Experimental|Comparator 5|Oseltamivir + Azithromycin
16348627|NCT04338698|Experimental|Comparator 6|Hydroxyquinine + Oseltamivir + Azithromycin
16348628|NCT04338698|No Intervention|Observational Cohort|Non-consenting to randomization
16348629|NCT04338685|Experimental|RO7119929|Participants will receive RO7119929 every week in 3-week cycles. In Part A (dose-escalation on a weekly schedule) maximum tolerated dose (MTD) and/or recommended dose for expansion cohorts (RDE) will be determined. Following determination of MTD and/or RDE, treatment will commence at up to three different doses in specific expansion cohorts of participants for extended PD analysis (Part B).
16348630|NCT04338672||Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in 2020.
16348631|NCT04338672||Pre Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in the following years: 2017, 2018, 2019,
16348632|NCT04338659|Other|IBI322|
16348633|NCT04338646||Patients enrolled|Patient with multiple sclerosis and lower urinary tract symptoms, age >18 Expanded Disability Status Scale score between 1 and 6.5
16348634|NCT04338633|Active Comparator|Conventional calcium hydroxide paste|Application of Conventional calcium hydroxide paste
16348635|NCT04338633|Experimental|Calcium hydroxide nanoparticle|Application of Calcium hydroxide nanoparticle
16348636|NCT04338633|Experimental|Combined Calcium hydroxide with silver nanoparticle|Application of Combined Calcium hydroxide with silver nanoparticle
16348637|NCT04338620|Experimental|A: Experimental Group|Participants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and cisplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
16348638|NCT04338620|Experimental|B: Control group|Participants receive totally 3 cycles of albumin-bound paclitaxel combined with cisplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
16348639|NCT04338607||All study patients|All study patients will be in one group.
16348640|NCT04338581|Experimental|AMG 714|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
16348641|NCT04338581|Placebo Comparator|Placebo|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
16348642|NCT04338568|Active Comparator|LUS observer 1|The subject will undergo a Lung Ultrasound by observer nr 1
16348643|NCT04338568|Active Comparator|LUS observer 2|The subject will undergo a Lung Ultrasound by observer nr 2
16348646|NCT04338542||neoadjuvant chemotherapy plus bevacizumab|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy plus bevacizumab and, finally, the surgical resection of liver metastasis.
16348647|NCT04338542||neoadjuvant chemotherapy|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy and, finally, the surgical resection of liver metastasis.
16348648|NCT04338542||control group|Patients presenting with synchronous primary tumour and metastasis resected without any preoperative systemic therapy.
16348651|NCT04338516|Active Comparator|Bio-Oss® Collagen,|subjects treated with Bio-Oss® Collagen, (Geistlich, Inc.)
16348653|NCT04338503||HF patients|Decompensated heart failure patients undergoing right heart catheterization.
16348654|NCT04338490|Experimental|Intervention|
16348655|NCT04338490|No Intervention|Control|
16348656|NCT04338477|Experimental|Nephrosolid|Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal
16348657|NCT04338464|Experimental|Treatment Group|
16348658|NCT04338451|Active Comparator|Music during the first part of ESWL|Patients listen to music during the first part of ESWL treatment (first 1800 SW).
16348659|NCT04338451|Active Comparator|Music during the second part of ESWL|Patients listen to music during the second part of ESWL treatment.
16348660|NCT04338438|Experimental|Apatinib Mesylate tablets combined with S-1 capsules|single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
16348661|NCT04338425|No Intervention|No Communication group|Participants will not communicate with their surgeons until the post operative office visit.
16348662|NCT04338425|Active Comparator|Voice call group|Participants will receive voice call from the surgeon after being discharged and before their post operative office visit.
16348663|NCT04338425|Active Comparator|Video call group|Participants will receive video call from surgeon after being discharged and before their post operative office visit
16348664|NCT04338412|Active Comparator|Group U|Performers' umbilicus
16348665|NCT04338412|Active Comparator|Group R|Performers' lowest rib margin
16348666|NCT04338412|Active Comparator|Group X|Performers' xiphoid process
16348669|NCT04338373|Experimental|experimental|"0.01% Atropine Sulfate solution in Comfort Drops, nightly instillations to both eyes"
16348670|NCT04338334|Active Comparator|CONTROL GROUP|Control group includes physical therapy protocol composed of manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active arm therapeutic exercises.
16348671|NCT04338334|Experimental|COHESIVE BANDAGE GROUP|Cohesive bandage is a self-adherent lightweight bandage, made of a porous nonwoven polyester material. A single self-adherent inelastic bandage will be directly applied at full stretch on cleaned and dried skin (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States) in a spiral method around the limb, starting at the hand and a layer overlap of 50%, so that the greatest compression was located at the distal points, gradually decreasing toward the proximal shoulder part. Cohesive latex-free bandages will be available for those allergic women. Women will do progressive active arm therapeutic exercises with bandaging.
16348674|NCT04338308||SVG PCI|
16348675|NCT04338295|Experimental|Microneedling|Participants with Alopecia Areata will receive microneedling with a tattoo machine.
16348676|NCT04338282|Experimental|treatment arm|anti-PD-1 antibody (toripalimab) 240mg/d, every 3 weeks, for up to one year or until disease progression.
16348679|NCT04338256||Students enrolled in the Wellness Course|Students in this group are enrolled in the Wellness Course for the Spring 2020 or Fall 2020 semesters
16348680|NCT04338256||Controls|Students in this group are enrolled at study sites during the Spring 2020 or Fall 2020 semesters, but are not enrolled in the Wellness Course
16348681|NCT04338243|Experimental|Glumetinib+Osimertinib|The investigational product Glumetinib will be orally administrated when fasting at dose level of 300mg QD and Osimertinib will be orally administrated when fasting at dose level of 80mg QD
16348682|NCT04338230|Experimental|Experimental: Experimental group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
16348683|NCT04338230|No Intervention|No Intervention: Control group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points).
16348684|NCT04338217|Experimental|Bionator|The modified Bionator was used to correct the open bite malocclusion. Patients were asked to wear the appliance every day.
16348685|NCT04338217|Active Comparator|Removable Appliance with Posterior Bite Planes|A removable appliance with poster bite planes was used to correct the open bite malocclusion. Patients were asked to wear this appliance full time expect eating times.
16348686|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
16348687|NCT04338191|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy
16348688|NCT04338191|Active Comparator|mFOLFOX6 adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy
16348689|NCT04338178|Experimental|Experimental intervention|Standard outpatient program, with additional group sessions integrating the experimental intervention : Cognitive Remediation Therapy (CRT), Emotional Skills Training (EST), and Cognitive Behavioral Therapy focused on craving and food addiction (CBT), delivered once a week during 10 weeks.
16348690|NCT04338178|Active Comparator|Standard intervention|Standard outpatient program, with additional group sessions integrating control intervention : multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches, delivered once a week during 10 weeks.
16348691|NCT04338165|Experimental|Evolocumab, 420 milligrams|Single injection of 420 milligrams of evolocumab (REPATHA®) one month before coronary angiography and coronary microcirculation (IMR) measurement.
16348692|NCT04338165|No Intervention|Control arm|Measurement of coronary microcirculation (IMR) during coronary angiography, without prior evolocumab injection.
16348693|NCT04338152|Experimental|FFT-CHR|Family-Focused Therapy for Clinical High-Risk Individuals
16348694|NCT04338152|Active Comparator|Enhanced Care|Enhanced Care Psychoeducation for Clinical High-Risk Individuals
16348695|NCT04338139|Experimental|Bio-oss Collagen|90% xengeneic bovine bone partciles + 10% collagen type I
16348696|NCT04338126|Experimental|Tranexamic Acid Treatment|Oral dosing of tranexamic acid at dose of 1300 mg p.o. three times per day x 5 days; alternative dosing intravenously with loading dose of 10 mg/kg followed by 1 mg/kg/hr infusion x 5 days
16348697|NCT04338126|Placebo Comparator|Placebo Treatment|2 tablets of placebo three times per day x 5 days; alternative dosing intravenous normal saline at volumes similar to those use for experimental arm
16348698|NCT04338100||Chest Ultrasound|Only one arm, all included patients having chest ultrasonography.
16348699|NCT04338087||Fertility treatments|Men participating in fertility treatments.
16348700|NCT04338087||Spontaneous pregnancy|Men whose wives conceived spontaneously.
16348701|NCT04338074|Experimental|Tranexamic Acid Treatment|
16348702|NCT04338074|Placebo Comparator|Placebo Treatment|
16348706|NCT04338035||Patients with rectosigmoid endometriosis|
16348710|NCT04338009|Experimental|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
16348711|NCT04338009|Experimental|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
16348712|NCT04337996|Experimental|experimental arm|These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
16348713|NCT04337970|Experimental|Phase Ib, Dose Level 1|3-6 participants
16348714|NCT04337970|Experimental|Phase Ib, Dose Level 2|3-6 participants
16348715|NCT04337970|Experimental|Phase Ib, Dose Level 3|3-6 participants
16348716|NCT04337970|Experimental|Phase II, Dose Expansion|Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)
16348717|NCT04337944|Experimental|Patients with KPro, PPV, and endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
16348718|NCT04337918|No Intervention|Prevention - Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
16348719|NCT04337918|Experimental|Prevention - NORS + Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
16348720|NCT04337918|Other|Treatment Sub-Study|"Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.
~Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
16348721|NCT04337905|Experimental|Children with ADHD|Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders
16348722|NCT04337905|Active Comparator|Children without ADHD|Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders
16348723|NCT04337879|Experimental|AL2846 + mFOLFOX6|AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.
16348724|NCT04337879|Experimental|AL2846 + FOLFIRI|AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
16348725|NCT04337853|Experimental|Intervention group|N=6
16348726|NCT04337853|Active Comparator|Control group|N=7
16348727|NCT04337827|Experimental|Rituximab and Acalabrutinib|Participants will receive treatment of Rituximab weekly for 4 weeks, and Acalabrutinib twice daily for 4 weeks. Response assessment via diagnostic CT scans will dictate further treatment decisions.
16348728|NCT04337814|Experimental|COTA Arm|Patients getting combined (C) oral (O) and topical (T) analgesics (A)
16348729|NCT04337814|Experimental|OA Arm|Patients getting oral (O) analgesics (A) and topical placebo
16348730|NCT04337814|Placebo Comparator|Placebo Arm|Patients getting oral placebo and topical placebo
16348731|NCT04337801|Experimental|Acupressure|The acupressure was carried out as two sessions, postpartum second (the first session of intervention) and fourth hours (the second session of intervention). The intervention was applied bilaterally and clockwise (left Pericardium 6, left Large Intestine 4, right Large Intestine 4 and right Pericardium 6) in this study. The acupressure was applied for three minutes in average, one minute for massage and two minutes for pressure per point; with an average of 12 minutes for the whole application. In addition, the pain score of the women was assessed by themselves through the VAS before the intervention (Time 1) and 15 minutes (Time 2) after the intervention at postpartum second hour. Also, it was assessed before the intervention (Time 3) and 15 minutes (Time 4) after the intervention at postpartum forth hour. Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
16348732|NCT04337801|Placebo Comparator|Placebo|The Pericardium 6 and Large Intestine 4 points were slightly touched without pressure to women in the placebo group. Touches were applied to each acupressure point for three minutes similar to the acupressure group, each session of placebo lasted approximately 15 minutes. Similar to the acupressure group, In parallel with the acupressure, the pain score of the women was recorded at the postpartum second hour (Time 1) before intervention and 15 minutes later after intervention (Time 2), and at the fourth hour (Time 3) before intervention and 15 minutes later after intervention (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the researcher.
16348733|NCT04337801|No Intervention|Control Group|No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
16348734|NCT04337788|Experimental|gerontological telemonitoring action|"Nurses answer a daily resident-reported questionnaire (e.g. temperature, dyspnea, pain), edited by French health authorities. From D0 to D20, data are transmitted to the NHSP. Warning algorithms specially developed for older persons identify signs that are monitored by the NHSP geriatrician coordinator. A feedback is provided to the general physician for specific actions required and appropriate support.
~A last questionnaire is completed at D30 by the nurse in order to stop monitoring and know event occurred between D20 to D30."
16348735|NCT04337788|No Intervention|routine care without gerontological telemonitoring|routine care
16348736|NCT04337762||Healthy|Healthy adult individuals residing in the United States with no history of COVID-19
16348737|NCT04337762||COVID-19 Confirmed|United States adults that have tested positive for SARS-CoV-2 virus which causes the human disease COVID-19 (IE novel coronavirus) or those that have been exposed to a confirmed case and are awaiting testing
16348738|NCT04337749|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to participants for 2 weeks
16348739|NCT04337749|Active Comparator|ZnO-NPs socks|ZnO-NPs socks were given to participants for 2 weeks
16348740|NCT04337749|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks were given to participants for 2 weeks
16348741|NCT04337749|Placebo Comparator|Placebo|Placebo socks were given to participants for 2 weeks
16348742|NCT04337736|Active Comparator|Aerobic training|12-weeks, 3-days-a week, supervised aerobic (Nordic walking or Walking) physical exercise (PhE) protocol; duration of each PhE session: 70 minutes; rate of perceived exertion (RPE): 10-11 (1st-4th week); 12-13 (5th-8th week); 13-14 (9th-12th week).
16348743|NCT04337736|Active Comparator|Resistance training|12-weeks, 2.3-days-a week (total of 28 lessons), supervised resistance physical exercise (PhE) protocol; duration of each PhE session: 50 minutes.
16348744|NCT04337723|Experimental|Intervention|Clinic participants will be taught how to do ABI testing and WIfI scoring to identify patients with PAD/DM disease for early vascular referral.
16348745|NCT04337710|Experimental|Exclusive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
16348746|NCT04337710|Active Comparator|Progressive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
16348747|NCT04337684||Historical Control|
16348748|NCT04337684||Treated with Copper Histidinate|
16348749|NCT04337671|Experimental|Training group (A)|The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
16348750|NCT04337671|No Intervention|control group (B)|Control group not receiving any training . They are taking their prescribed medications only.
16348751|NCT04337658|Experimental|Trastuzumab± Pertuzumab+ Fulvestrant|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.
~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
~Fulvestrant(Faslodex): 500mg intramuscular injections at day 1, 15, 28 and every 4 weeks thereafter"
16348752|NCT04337658|Active Comparator|Trastuzumab± Pertuzumab+ Capecitabine|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.
~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
~Capecitabine: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
16348753|NCT04337645|Experimental|Test group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline) combined with implantoplasty
16348754|NCT04337645|Active Comparator|Control group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline)
16348755|NCT04337632|Experimental|PP|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.
16348756|NCT04337632|Active Comparator|TP|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
16348757|NCT04337619|Experimental|Standard Behavioral Weight Loss Treatment|
16348758|NCT04337619|Experimental|Behavioral + Mindful Acceptance|
16348759|NCT04337619|Experimental|Behavioral + Values|
16348760|NCT04337619|Experimental|Behavioral + Mindful Awareness|
16348761|NCT04337619|Experimental|Behavioral + Acceptance + Values|
16348762|NCT04337619|Experimental|Behavioral + Acceptance + Awareness|
16348763|NCT04337619|Experimental|Behavioral + Values + Awareness|
16348764|NCT04337619|Experimental|Behavioral + Acceptance + Values + Awareness|
16348765|NCT04337606|Experimental|chidamide in combination with decitabine|chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks
16348766|NCT04337606|Experimental|decitabine in combination with Camrelizumab|decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6
16348767|NCT04337593|Experimental|treatment arm|2500 IU/m2 pegaspargase given on day 1, 20 mg basiliximab given on day 1 and 8, repeated every 3 weeks
16348768|NCT04337580|Experimental|Omeprazole Plus Standard of Care for Prostate Cancer Regimen|This intervention will be given on an outpatient basis. Omeprazole, 80 mg twice daily.
16348769|NCT04337567|Active Comparator|Patients over 75 years_RF ablation|Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
16348770|NCT04337567|Active Comparator|Patients over 75 years_ballon cryoablation|Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
16348771|NCT04337554||Older healthy|Individuals over 40 years of age
16348772|NCT04337554||Peripheral artery disease|Individuals over 40 years of age with peripheral artery disease.
16348773|NCT04337541|No Intervention|Normal recommendations, no mask|Normal behavior according to the authority's recommendations or
16348774|NCT04337541|Experimental|Normal recommendations AND mask|Normal behavior according to the authority's recommendations AND use of facial masks
16348775|NCT04337528|Experimental|Thrust Group|Participant will receive the thrust technique manipulation of the affected sacroiliac joint.
16348776|NCT04337528|Active Comparator|Muscle-energy group|Participant will receive the muscle-energy technique manipulation of the affected sacroiliac joint.
16348777|NCT04337528|Placebo Comparator|Placebo Group|Participant will receive a placebo manipulation of the affected sacroiliac joint.
16348778|NCT04337515|Experimental|Patients receiving allogeneic hematopoietic cell transplant|"The test product is a stem cell product which has been alpha-beta T- cell depleted using the CliniMACS system. Alpha-beta T-cell depleted cells are given intravenously over a period of time as dictated by the final volume of the infused product (5 ml/kg/hour).
~The target dose of CD34+ cells is ≥20x10^6/kg, but a minimum of
~≥2.5x10^6/kg is required. The target dose of T-cell receptor (TCR) alpha-beta CD3+ cells is ≤1x10^5/kg."
16348779|NCT04337502||severe group|The severe group was designated when the patients had one of the following criteria during hospitalization issued by the Chinese National Health Committee (Version 3-5). 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse Oximeter Oxygen Saturation ≤ 93% at rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO2/FiO2) ≤ 300 mmHg; 4) One of the conditions as following: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.
16348780|NCT04337502||non-severe group|The non-severe group was designated when the patients did not occur in the mentioned severe criteria until discharged from the hospital.
16348781|NCT04337476|Experimental|mother's song|At the suggestion of the music therapist, the mothers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
16348782|NCT04337476|Experimental|father's song|At the suggestion of the music therapist, the fathers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
16348783|NCT04337476|Experimental|singing of the music therapist|Music therapist will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
16348784|NCT04337476|No Intervention|No singing|Control group (not subjected to musical stimulation- no singing). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
16348785|NCT04337463|Experimental|ATG-008 and Toripalimab|Toripalimab will be combined with ATG-008.
16348788|NCT04337437|Experimental|Genakumab injection：5 groups|150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,
16348789|NCT04337437|Placebo Comparator|Placebo for this trial : 5 groups|"The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
~Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,"
16348790|NCT04337424||Participants with active infection test to SARS-COV2|Sampling of saliva (1 to 2 ml)
16348791|NCT04337424||Convalescent participants for SARS-COV2|Sampling of saliva (1 to 2 ml)
16348792|NCT04337424||Participants cured to SARS-COV2|Sampling of saliva (1 to 2 ml)
16348793|NCT04337424||Participants with negative test to SARS-COV2|Sampling of saliva (1 to 2 ml)
16348794|NCT04337411||Cohort 1|Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
16348795|NCT04337411||Cohort 2|Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
16348796|NCT04337398|Experimental|Wearables|Adults with several mental illness
16348797|NCT04337398|Experimental|Wearables and exergames|Adults with several mental illness
16348798|NCT04337385|Experimental|3 hours of Prolonged Sitting|Participants will sit continuously for three hours before receiving a mixed meal challenge.
16348799|NCT04337385|Experimental|3 hours of interrupted sitting with hourly HIIE|Participants will have their three hour sitting period interrupted with high intensity interval cycling exercise (HIIE) at 30, 90 and 150 minutes into the intervention. In each exercise bout, they will cycle at 90% peak power for 3 x 60 second periods with 75 seconds of recovery in-between.
16348800|NCT04337372|Experimental|Effects of shared book reading|There will be one arm since all participants will undergo the same intervention.
16348801|NCT04337333|Other|Two-in-one stent|Endoscopic placement of a Two-in-one stent into the extrahepatic bile duct, considering the longitudinal location of the stricture segment and predicted safety margin
16348802|NCT04337307||standard decontamination|incubators decontaminated with antiseptic molecules, healthcare workers involved in this decontamination, patients housed in these incubators
16348803|NCT04337307||steam pulverization|incubators decontaminated with steam pulverization, healthcare workers involved in this decontamination, patients housed in these incubators
16348804|NCT04337268|Active Comparator|human glucagon-like peptide-1|"Intervention:
~Drug: human glucagon-like peptide-1 Other names: GLP-1"
16348805|NCT04337268|Placebo Comparator|Placebo|"Intervention:
~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1"
16348806|NCT04337255|Active Comparator|MIND DIET intervention|Allocation and blinding 3 year intervention of MIND Diet + counseling
16348807|NCT04337255|Placebo Comparator|Usual care diet intervention|3 year Intervention of usual care diet + counseling
16348808|NCT04337242|Experimental|Blended Dynamic Interpersonal Therapy (B-DIT)|B-DIT is based on the same treatment principles as face-to-face Dynamic Interpersonal Therapy (DIT) and has the same structure of treatment consisting of three phases: (a) an exploration and engagement phase, (b) a middle or working through phase, and (c) an ending phase. B-DIT consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
16348809|NCT04337242|Experimental|Blended Cognitive Behavioral Therapy (B-CBT)|B-CBT is based on the same treatment principles as face-to-face Cognitive Behavioral Therapy (CBT). These include (a) psycho-education about depression, (b) cognitive restructuring (i.e., identifying and challenging maladaptive thoughts and beliefs, fostering problem solving capacities), (c) mindfulness and acceptance based approaches, and (d) relapse prevention. B-CBT in this trial consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
16348810|NCT04337242|Active Comparator|Dynamic Interpersonal Therapy (DIT)|DIT is a short-term, integrative psychodynamic, 16 weekly sessions individual therapy for depression. DIT formulates the presenting symptoms of depression as responses to interpersonal difficulties or perceived threats to attachments (loss/separation) and hence also as threats to the self.
16348811|NCT04337242|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a brief talking therapy that consists of a maximum of 16 sessions, offered over 4 to 6 months. CBT is based on the assumption that depression is directly related to patterns of thinking. Specifically, dysfunctional and often automatic patterns of thinking are assumed to be related to the onset and maintenance of depression.
16348812|NCT04337229|Experimental|artificial intelligence techniques|Facial and body movements of newborns will be recorded by camera, and images will be processed in computer environment by using artificial intelligence techniques. As a result, it is planned to create a technology that determines the comfort level of the newborn quickly and simply and can be used by the mobile device.
16348813|NCT04337203|Experimental|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
16348814|NCT04337177|Experimental|90 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 90 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
16348815|NCT04337177|Experimental|110 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 110 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
16348816|NCT04337177|Experimental|75 mg/m2/day VAL-413 (Orotecan®)|In the event the 90 mg/m2/day starting dose is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented. Orotecan® at 75 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
16348817|NCT04337125|Other|ADHD group|ADHD children with their parents
16348818|NCT04337125|Other|Control group|Children with typical development and their parents
16348819|NCT04337086|Experimental|T4k|
16348820|NCT04337086|Active Comparator|Twin block|
16348821|NCT04337073|Placebo Comparator|normal saline (N) group|Before anesthesia induction, N group received corresponding intravenous normal saline of the same volume.
16348822|NCT04337073|Active Comparator|propofol (P) group|Before anesthesia induction, P group received intravenous injection of 0.3mg/kg propofol
16348823|NCT04337060|Active Comparator|Group LB|Ultrasound-guided bilateral erector spinae plane block (10 ml 1% lidocaine + 10 ml 0.5% bupivacaine) + intravenous morphine patient-controlled analgesia.
16348824|NCT04337060|Sham Comparator|Group S|Ultrasound-guided bilateral erector spinae plane block. block (20 ml Normal Saline) + intravenous morphine patient-controlled analgesia.
16348825|NCT04337047||Vik sein|Vik sein users
16348826|NCT04337047||Vik asthme|Vik asthme users
16348827|NCT04337047||Vik migraine|Vik migraine users
16348828|NCT04337047||Vik depression|Vik depression users
16348829|NCT04337034|Experimental|mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0)
16348830|NCT04337034|Active Comparator|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured
16348831|NCT04337021|Active Comparator|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving-related stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
16348832|NCT04337021|No Intervention|Usual Care|CGs in this arm will be contacted telephonically once by a CM. After a brief needs assessment, the CM will provide contact information for appropriate VA (e.g., local CSP clinicians) and non-VA community resources/services. CGs will be sent brochures for the national VA CSP. Information on both the program's website (which includes links to training, education, resources, and outreach programs for CGs) and the national CG hotline number will be included in the mailed packet. After this initial contact, CGs in this group will only be contacted again 4 and 9 months after baseline for administration of follow-up research assessments. CGs will be encouraged to seek medical, psychological, social support, and social services that are available to them through VAMCs or any other non-VA/community source. CGs in the SOS group will be offered similar information.
16348833|NCT04337008|Active Comparator|Positive COVID 19 patient with no respiratory distress|
16348834|NCT04337008|Experimental|Positive COVID 19 patient with respiratory distress|
16348835|NCT04336995|Other|Exercise|Everyone is in this arm
16348838|NCT04336969|Other|T1D Patients|Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
16348839|NCT04336956||hospitalized children with Covid19|- Children < 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
16348840|NCT04336943|Experimental|Treatment (durvalumab, olaparib)|All patients receive durvalumab IV over 1 hour on day 1 of each cycle. Patients with CDK12 mutation and MMRd/MSI-high also receive olaparib PO BID on days 1- 28 of cycles 3-6. Patients with homologous recombination mutation also receive olaparib PO BID on days 1-28 of cycles 1-6. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
16348841|NCT04336930||Cardiac Arrest group|Patients remaining comatose after a cardiac arrest
16348842|NCT04336917|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve Rhomboid Intercostal and Subserratus Plane Block under ultrasound guidence at the end of the surgery.
16348843|NCT04336917|No Intervention|Control Group|Routine standard perioperative and postoperative analgesic protocol will be given.
16348844|NCT04336904|Experimental|Favipiravir|"Experimental: Favipiravir Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction."
16348845|NCT04336904|Placebo Comparator|Placebo|"Comparator: Placebo Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
16348846|NCT04336891||Hypoactive Sexual Desire Disorder|Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
16348847|NCT04336891||Moderate to severe VVA|Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
16348848|NCT04336891||Mild to moderate VVA|Women with dyspareunia due to mild to moderate VVA (n=37)
16348849|NCT04336891||HSDD + VVA|Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).
16348918|NCT04336267|Sham Comparator|Sham group|7-day detoxification protocol + 5 consecutive days of sham treatment over the primary motor cortex.
16348850|NCT04336878|Experimental|Healthy Habits in Pregnancy and Beyond intervention|Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice & purchasing, portion size, eating behaviour & keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
16348851|NCT04336878|No Intervention|Control group|The control group will receive 'usual' antenatal care which does not involve routinely delivered specific or standardised dietary advice.
16348852|NCT04336852|Experimental|Arm 1|
16348853|NCT04336826|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 24 weeks.
16348854|NCT04336813|Experimental|Group A|Receive ARS in lecture 1 and act as controller in lecture 2
16348855|NCT04336813|Active Comparator|Group b|Receive ARS in lecture 2 and act as controller in lecture 1
16348856|NCT04336774|Experimental|Echocardiogram patients|Patients scheduled to have an echocardiogram (echo) and who are also being evaluated for, or are positive for COVID-19.
16348857|NCT04336761||Child suspected of infection with COVID-19.|Child included with positive included
16348858|NCT04336748|Active Comparator|Hydroxychloroquine|200mg once daily
16348859|NCT04336748|Placebo Comparator|Placebo|
16348860|NCT04336735|Experimental|Immunization Tool Users|Users will trial a novel transplant-specific immunization tool (app)
16348863|NCT04336709|Active Comparator|Calcipex II|Calcipex group Manufactures Nishika, Yamaguchi, Japan Color- White Formulation- Water based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Water-based calcium hydroxide paste without radio contrast agent (Barium Sulfate) Packaging- (1 syringe of Calcipex Plain II (1.8g), 2 needles of Nishika Spin with 2 needle caps) Storage requirement- Room temperature (1-30℃).
16348864|NCT04336709|Active Comparator|Metapex|Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
16348865|NCT04336696|Active Comparator|Comparison between the studied groups regarding management.|The postoperative RAI scan after 1 month, showed a positive residual tumour in lateral LN in 70 patients in the controlled group and 13 patients in Group II, 8 patients in group III. In group I, Patients with residuals were submitted to RAI ablation.
16348866|NCT04336696|Other|Recurrence free survival|patients with total thyroidectomy only had shorter recurrence free survival
16348867|NCT04336683|Other|Patient|Patients undergoing gynecological brachytherapy, will be imaged with a 3D ultrasound medical device for the purpose of efficacy testing.
16348868|NCT04336670|Experimental|Virtual Reality group|Immersive Virtual Reality exercise program.
16348869|NCT04336670|Active Comparator|Usual activities group|Usual center therapies
16348870|NCT04336644|Experimental|Continuous patch monitoring system|"Participants will receive standard of care treatment with either arsenic trioxide or capecitabine. They will have continuous patch monitor system (BodyGuardian Heart) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.
~Twelve-lead ECGs are routinely performed in patients receiving arsenic trioxide at baseline and twice weekly during the first 4 weeks of therapy. These ECGs (total of up to 9) will be accessed for the purposes of this study. Patients who receive capecitabine do not routinely have ECGs performed after baseline, but for the purposes of this study, two serial ECGs will be conducted on Day 14 and Day 28 of Cycle 1 of treatment (total of 5 including baseline)."
16348871|NCT04336631|Other|Routine Medical Follow Up, Counseling & Usual Care|Behavioral counseling was provided to the patients on each consecutive follow up after enrolling in this study. They were adequately followed on physical exercise, reduced salt intake, lifestyle modifications, and smoking cessation. All measurements of blood pressure and weight were maintained and recorded.
16348872|NCT04336631|No Intervention|Routine Medical Follow Up & Usual Care|Usual routine medical care was provided to the study participants only.
16348873|NCT04336605||Young-HUNT|The young-HUNT study is a renowned, representative, population-based study where all adolescents living in the Nord-Trøndelag county have been invited to participate in four subsequent waves, from 1995 to 2019. Information about the study can be found here: https://www.ntnu.edu/hunt/young-hunt. In this study data from the Young-HUNT1-4 studies (1995-2019) will be linked to longitudinal, individual data from the Norwegian prescription Database (NorPD) (2004-2020), providing a unique, longitudinal dataset in which research questions will be explored. To obtain good, reliable follow-up data and outcome measures for the young-HUNT3 participants (2006-2008) the investigators will additionally include longitudinal data from the HUNT4 study of young adults (2017-2019); applicable for those participating in both the YoungHUNT3 and the YoungHUNT4.
16348874|NCT04336592||Patients|Patients scheduled to receive a surgical spine procedure at Mayo Clinic
16348875|NCT04336592||Clinicians|Surgeons, Physician pain specialists and allied health caring for participating patients
16348876|NCT04336579||Control|Retrospective review of patients (participants) with standard analgesia post total knee arthroplasty
16348877|NCT04336579||Diaphragmatic Breathing|Intervention: Participants will perform diaphragmatic breathing exercises postoperatively as part of their multi-modal pain regimen.
16348878|NCT04336566|Active Comparator|Melatonin|5mg dose of melatonin manufactured by Good Neighbor Pharmacy
16348879|NCT04336566|Placebo Comparator|Placebo|Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient
16348919|NCT04336254|Experimental|hDPSCs group|Routine treatment + Intravenous injection of human dental pulp stem cells
16348920|NCT04336254|Placebo Comparator|Control group|Routine treatment + Intravenous saline injection (Placebo)
16348880|NCT04336553|Experimental|Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS). SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
16348881|NCT04336540|Experimental|Energy labelling|Energy labelling provided on restaurant menus
16348882|NCT04336540|No Intervention|No energy labelling|No energy labelling provided on restaurant menus
16348883|NCT04336540|Experimental|Increased availability of lower energy meals|Higher proportion of meals are 600kcals or less
16348884|NCT04336540|No Intervention|Baseline availability of lower energy meals|Proportion of meals that are 600kcals or less at baseline level
16348885|NCT04336527|Experimental|Home Treatment with Peer Support|Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.
16348886|NCT04336527|Active Comparator|Home Treatment without Peer Support|Patients receive conventional home treatment by a homehome treatment/crisis resolution team without contacts to a peer support worker.
16348887|NCT04336514|Experimental|Experimental Arm|
16348888|NCT04336501|Experimental|IM19 CAR-T group|Subject will be treated with IM19 car-t cells
16348889|NCT04336488|Experimental|Orochem (Test)|fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
16348890|NCT04336488|Active Comparator|Conventional (Control)|fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
16348891|NCT04336475|Experimental|Group 1|exercise regimen and oral hygiene care advices
16348892|NCT04336475|Active Comparator|Group 2|oral hygiene care advices
16348893|NCT04336462|Experimental|oxyhydrogen|conventional treatment + hydrogen/ oxygen inhaled
16348894|NCT04336462|Experimental|oxygen|conventional treatment + oxygen inhaled
16348895|NCT04336449|Experimental|Cohort 1 100 mg eptinezumab|
16348896|NCT04336449|Experimental|Cohort 2 300 mg eptinezumab|
16348897|NCT04336449|Placebo Comparator|Placebo|
16348898|NCT04336436|Experimental|Mindfulness Training and Nutrition Counseling|"Baseline and 3-6 month follow up visits will be arranged for all participants.
~Visits will be conducted at baseline prior to initiation of mindfulness training and nutrition counseling, and at the 3-6 month follow up. Clinical and laboratory assessments will be obtained at each visit."
16348899|NCT04336423||Healthy smoker|Healthy smokers with smoking history at least 10 pack-years and normal spirometry value
16348900|NCT04336423||COPD patient|Patients with smoking history at least 10 pack-years and persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
16348901|NCT04336410|Experimental|Group 1: INO-4800|Participants will receive one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
16348902|NCT04336410|Experimental|Group 2: INO-4800|Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
16348903|NCT04336410|Experimental|Group 3: INO-4800|Participants will receive one ID injection of 0.5 mg of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
16348904|NCT04336397|Active Comparator|High Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
16348905|NCT04336397|Active Comparator|Medium Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
16348906|NCT04336397|No Intervention|Usual Care|usual care (i.e., opportunistic screening recommendation at a clinic visit)
16348908|NCT04336358|No Intervention|Standard Early medical abortion care|Counseling, history, instruction, family planning with clinic nurse. Ultrasound to assess gestational age.
16348909|NCT04336358|Experimental|Telemedicine|Online consultation questionnaire and counseling, family planning information. Instruction for the abortion received to the participants Facebook Messenger. Gestational age <9 weeks assessed by bimanual palpation, ultrasound only in case of uncertainty.
16348910|NCT04336332|Experimental|Arm 1: Hydroxychloroquine Sulfate + Azithromycin|"Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
~Azithromycin 500 mg taken by mouth on Day 1, followed by
~Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days."
16348911|NCT04336332|Experimental|Arm 2: Hydroxychloroquine Sulfate alone|• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
16348912|NCT04336332|No Intervention|Arm 3: Placebo|"Placebo pills Days 1-6.
~If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days"
16348913|NCT04336319|Experimental|Patients with a confirmed diagnosis of UC who underwent IPAA|Patients who meet inclusion criteria will be enrolled and will sign an informed consent form. The study includes six visits to the IBD clinic and phone calls between visits.
16348914|NCT04336306|Experimental|Evaluation of chronic hemodynamic and autonomic repercussions|Participants in a cardiovascular rehabilitation program will be randomly allocated to CR + VRBT interventions. This group will hold 3 weekly sessions (one for VRBT and two for CR) for 12 weeks. In the first, sixth and last week, chronic hemodynamic data and autonomic data will be evaluated.Furthermore,at the end of 12 weeks, a focus group with therapists and a focus group with patients will be held to identify qualitative aspects in relation to the insertion of VRBT. And in all eligible patients of CR wiil be applied the Questionnaire of barriers identification in frequenters of Cardiovascular Rehabilitation.
16348915|NCT04336293|Experimental|active|active sTMS
16348916|NCT04336293|Sham Comparator|sham|sham sTMS
16348917|NCT04336267|Experimental|Transcranial direct current stimulation (tDCS) group|7-day detoxification protocol + 5 consecutive days of anodal tDCS treatment over the primary motor cortex.
16348921|NCT04336241|Experimental|Dose escalation of RP2 - superficial tumors|Dose escalation of RP2 alone in 3 cohorts with IT injections in superficial tumors.
16348922|NCT04336241|Experimental|Dose escalation of RP2 - deep/visceral tumors|Dose escalation of RP2 alone in 3 cohorts with imaging guided IT injections in deep/visceral tumors.
16348923|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - superficial tumors|Doses of RP2 (IT) in superficial tumors with nivolumab (IV).
16348924|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - deep/visceral tumors|Imaging guided doses of RP2 (IT) in deep/visceral tumors.
16348925|NCT04336241|Experimental|Seronegative cohort|Doses of RP2 (IT) in HSV seronegative participants.
16348926|NCT04336228|Placebo Comparator|Healthy Control Group|The healthy placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
16348927|NCT04336228|Placebo Comparator|Obsessive-Compulsive Disorder Control Group|The OCD placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
16348928|NCT04336228|Experimental|Healthy Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
16348929|NCT04336228|Experimental|Obsessive-Compulsive Disorder Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
16348930|NCT04336215||Healthcare Workers|500 HCW with high intensity direct patient care from two RBHS-affiliated academic hospitals: Robert Wood Johnson University Hospital (New Brunswick, NJ) and University Hospital (Newark, NJ) and Rutgers School of Dental Medicine (Newark, NJ) . Since rates of asymptomatic carriage, clinical infection, and morbidity likely vary by age and sex, the aim is to recruit 125 HCW in each of the following 4 groups: males ages 20-59; males ages ≥60; females ages 20-59; and females ages ≥60.
16348931|NCT04336215||Non-Healthcare Workers|250 non-healthcare workers (NHCW) from Rutgers faculty, postdoctoral students, students, other trainees, administrators, and staff who do not have patient contact. The aim is to recruit even numbers of NHCW from each of these 4 groups: males ages 20-59; males ages ≥60; females ages 20-59; females ages ≥60.
16348932|NCT04336215||Household Members|Complementing the HCW cohort study, approximately 540 household members in a subset of the participants who test positive and negative for SARS-CoV-2 will be invited to be followed prospectively to assess patterns of viral transmission. The target population will be multigenerational households (e.g., with children and/or parents) from up to 6 infected HCW, 6 infected NHCW, 4 uninfected HCW, and 4 uninfected NHCW at each timepoint. The participant will ask household members to contact research staff if they wish to volunteer for the study. Research coordinators will individually consent adult members of the household for questionnaire and serial samples collection. When children are in the home, parental permission as well as assent for children ages 7 and older (written at ages 12 and older) will be the course of action. The estimated 540 participants assumes 20 houses per timepoint, 9 timepoints, and an average of 3 participants per house.
16348933|NCT04336202|Other|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
16348934|NCT04336189|Active Comparator|SP + DP placebo every 4 weeks|
16348935|NCT04336189|Active Comparator|DP + SP placebo every 4 weeks|
16348936|NCT04336189|Active Comparator|SP + DP given every 4 weeks|
16348937|NCT04336176|Active Comparator|PulseFlow DF boot|PulseFlow DF boot
16348938|NCT04336176|Active Comparator|Usual Care|Measurements will be taken from patients wearing usual standard of care
16348939|NCT04336176|Sham Comparator|Sham|Sham shoe (closest to barefoot or baseline pressures)
16348940|NCT04336163|Experimental|Prospective Study Group|For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
16348941|NCT04336163|Other|Prospective Control Group|For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.
16348942|NCT04336150|Experimental|Hypopressive exercisesE|"Hypopressive exercises described according to Dr. Caufriez
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive exercises according to the original method described by Dr. Caufriez, which is based on performing the hypopressive maneuver in 33 postures that he described (1,2)."
16348943|NCT04336150|Experimental|Hypopressive exercises&PFM contraction|"Hypopressive exercises + active pelvic floor muscle contraction:
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive exercises according to the original method described by Dr.Caufriez, which is based on performing the hypopressive maneuver in 33 postures he described, plus the active contraction of the pelvic floor muscles (PFM) during the hypopressive maneuver."
16348944|NCT04336150|Experimental|Hypopressive maneuver|"Hypopressive maneuver:
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive maneuver with transabdominal ultrasound biofeedback."
16348945|NCT04336150|Experimental|Hypopressive maneuver&PFM contraction|"Hypopressive maneuver + pelvic floor muscles contraction:
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive maneuver plus active contraction of the pelvic floor muscles with transabdominal ultrasound biofeedback."
16348946|NCT04336124|Experimental|CVM-1118 ER|Dose escalation (escalation from 400, 600, 800 to 1200 mg of CVM-1118 ER Capsule)
16348947|NCT04336111|No Intervention|control group|will receive sham bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position.
16348948|NCT04336111|Experimental|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
16349099|NCT04335045|Placebo Comparator|Control for 100mg Dose|1 placebo capsule (n=2)
16348949|NCT04336098|Experimental|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
16348950|NCT04336098|Experimental|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
16348951|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel in patients with locally advanced or metastatic solid tumors. Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with advanced pancreatic ductal adenocarcinoma (PDAC) to further evaluate safety with SRF617 and gemcitabine + albumin-bound paclitaxel combination therapy.
16348952|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with pembrolizumab (Keytruda®) in patients with locally advanced or metastatic solid tumors. Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma to further evaluate safety with SRF617 and pembrolizumab combination therapy.
16348953|NCT04336085|Experimental|caudal group|Caudal block using ultrasound guidance. the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine and the depth and gain will be adjusted for optimal visual quality.the needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
16348954|NCT04336085|Experimental|PENG group|The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. the needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.
16348955|NCT04336072|Experimental|Reminder Focused Positive Psychiatry (RFPP)|RFPP aims to enhance contextual discrimination and emotional regulation, and promote the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
16348956|NCT04336072|Active Comparator|Trauma Focused Cognitive Behavioral Therapy (TFCBT)|TFCBT is inclusive of the trauma narrative (TN) & processing components facilitated the child talking about memories individually and in groups, the last sessions focused on grief-specific elements.
16348957|NCT04336059|Other|group 1|will receive sham PENG block with normal saline in total volume of 20 ml.
16348958|NCT04336059|Experimental|group 2|will receive real PENG block with bupivacaine (0.25%) in total volume of 20 ml.
16348959|NCT04336046|Sham Comparator|control group|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
16348960|NCT04336046|Experimental|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
16348961|NCT04336033|Experimental|Counseling + Renal Diet App|Subjects in the intervention group will receive an individualized dietetic counseling from the researcher aided with the newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients
16348962|NCT04336033|Placebo Comparator|Counseling + Printed Nutrition Pamphlet|Individualized dietetic counseling aided with printed nutrition pamphlet prepared by Ministry of Health, Malaysia
16348963|NCT04336007|Experimental|Radio-frequency group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode on.
16348964|NCT04336007|Placebo Comparator|Placebo group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode off.
16348965|NCT04336007|Sham Comparator|Control Group|NO INTERVENTION athlete's usual pre-competition warming-up
16348966|NCT04335994|Active Comparator|Standard of Care|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
16348967|NCT04335994|Experimental|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
16348968|NCT04335981|Experimental|FT-CC and Swallow Exercises|
16348969|NCT04335981|Active Comparator|Swallow Exercises|
16348970|NCT04335968|Experimental|Experimental group|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery
16348971|NCT04335968|Placebo Comparator|Control group|placebo of this drug with the same schedule, during the same period of time.
16348972|NCT04335942|Other|AFNOR 3.6 alerts|"Alert called AFNOR 3.6 in connection with the dispersion index described by Drummond et al 1985 and validated by Sprigle et al 2003. This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),"
16348973|NCT04335942|Other|AFNOR 3.6 alerts and Guidelines|"AFNOR 3.6 alerts and Guidelines alerts. By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009)."
16348974|NCT04335929|Experimental|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
16348975|NCT04335890|Experimental|DC IKKb|Vaccination with IKKb matured RNA loaded Dendritic Cells
16348976|NCT04335877|Experimental|Private sector component + modified BCC|Private sector component + modified BCC + current standard of care
16348977|NCT04335877|No Intervention|Control|Current standard of care + standard BCC
16348978|NCT04335864|Active Comparator|Group A|39 patients with hydrosalpinx will have laparoscopic salpingectomy
16348979|NCT04335864|Active Comparator|Group B|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
16348980|NCT04335851|Experimental|Physical Activity Group|"Individuals in this group will be given walk at home exercise video made by American Hearth Association. Videos for each week will be chosen by therapist. They will be asked to do exercise 3 days a week for 4 weeks by following the videos. The intensity and duration of the exercises will be gradually increased by therapists each week. Exercise follow-ups will be done over the phone and by asking individuals to keep an exercise diary."
16348981|NCT04335851|No Intervention|Control Group|Physically inactive individuals will be included to study as control. Individuals will be asked to continue their daily routines.
16348982|NCT04335838||Polytrauma Patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
16348983|NCT04335825|Active Comparator|phacotrabeculectomy|patients undergoing phacotrabeculectomy
16348984|NCT04335825|Active Comparator|ExPress device implantation|patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification
16348985|NCT04335812|Experimental|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
16348986|NCT04335812|Active Comparator|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
16348989|NCT04335786|Experimental|Active treatment arm|Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
16348990|NCT04335786|Placebo Comparator|Placebo arm|Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
16348991|NCT04335773||Sars-CoV-2 positive|Children positive for SARS-CoV-2
16348992|NCT04335773||SARS-CoV-2 negative|Children negative SARS-CoV-2
16348993|NCT04335760||Patients with Coronary Artery Disease|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.
~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.
~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
16348994|NCT04335760||healthy subjects|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.
~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.
~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
16348995|NCT04335747||Group 1|Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
16348996|NCT04335747||Group 2|Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
16348997|NCT04335747||Group 3|Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
16348998|NCT04335747||Group 4|Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection
16348999|NCT04335734|Active Comparator|Nissen fundoplication with fixation of the wrap|In this arm, which included 87 patients we performed the following manipulations: NF was supplemented with suturing wrap to the diaphragmatic crura (52 patients) on each side using two non-absorbable stitches. In case of weak conditions of crura or short esophagus (35 patients) fundoplication wrap was sutured to the body of stomach using two non-absorbable stitches on each side. .
16349000|NCT04335734|Active Comparator|Nissen fundoplication without fixation of the wrap|Arm included 51 patients, who underwent classic Nissen fundoplication without wrap fixation.
16349001|NCT04335721|Experimental|Voxelot|Voxelotor 1500mg once a day
16349002|NCT04335721|Other|Standard of Care (SOC)|Observational while receiving SOC
16349003|NCT04335708|Experimental|Intervention|Daily consumption of 5 mL of edible gel with intracellular content of Lactobacillus casei CRL-431 during 30-d
16349004|NCT04335708|Placebo Comparator|Placebo|Daily consumption of 5 mL of edible gel without intracellular content of Lactobacillus casei CRL-431 during 30-d
16349005|NCT04335695|Other|Vascular Rehabilitation and Follow Up|All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.
16349006|NCT04335682|Active Comparator|Darolutamide (DARO)|Patients will take DARO at a dose of 600 mg (300 mg ×2 tablets) by mouth twice daily beginning on Day 1, of Week 1. Patients will take DARO throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
16349100|NCT04335045|Active Comparator|200mg Dose|1 x 200 mg PH100 capsule (n=6)
16349007|NCT04335682|Active Comparator|Enzalutamide (ENZ)|Patients will take ENZ at a dose of 160 mg PO once daily (QD), beginning on Day 1, of Week 1. Patients will take ENZ throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
16349008|NCT04335669|Active Comparator|Arm A (Platinum-based dose dense EC):|Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
16349009|NCT04335669|Experimental|Arm B (Platinum-based with capecitabine):|Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
16349010|NCT04335656|Experimental|Treatment Group|Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.
16349011|NCT04335656|Placebo Comparator|Placebo Group|Subjects will be randomized to the treatment or placebo group. The placebo is a capsule taken by mouth once a day for 6 months.
16349012|NCT04335643|Experimental|TEACH|Participants will undergo CBT and continue medical TAU.
16349013|NCT04335643|No Intervention|Control|Participants will only continue medical TAU.
16349014|NCT04335630||Cases|Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR.
16349015|NCT04335630||Controls|Age- and gender-matched subjects admitted to the hospital with similar symptoms but negative PCR testing for SARS-CoV-2 (one negative PCR test for patients of low clinical suspicion and two negative tests, 24 hours apart from each other, for patients of high clinical suspicion).
16349016|NCT04335617|Experimental|Investigational|Patients receive MMPF 500mg for one year
16349017|NCT04335617|Placebo Comparator|Placebo|Patients receive Placebo for one year
16349018|NCT04335604|Experimental|JPI-547|
16349019|NCT04335591|Experimental|Linzagolix 75 mg|
16349020|NCT04335591|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
16349021|NCT04335578|Experimental|Zampilimab Cohorts|Participants will be randomized to receive zampilimab (UCB7858).
16349022|NCT04335578|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo.
16349023|NCT04335565|No Intervention|Water|250 ml of water mixed with 1g of citric acid.
16349024|NCT04335565|Active Comparator|Sugar|65g of sugar dissolved in 250ml of water
16349025|NCT04335565|Experimental|Stevia|5g of stevia dissolved in 250ml of water
16349026|NCT04335552|Active Comparator|Standard of care|
16349027|NCT04335552|Experimental|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
16349028|NCT04335552|Experimental|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
16349029|NCT04335552|Experimental|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
16349030|NCT04335539|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously on Day 1, in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
16349031|NCT04335539|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered intravenously every 8 hours for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
16349032|NCT04335526|No Intervention|Metformin alone|
16349033|NCT04335526|Other|Metformin with cholestyramine|
16349034|NCT04335513|Experimental|Intervention|Early diabetes management and education including focused education based on pathophysiology of type 1 diabetes, factors which impact blood glucose, and effects of insulin using data from continuous glucose monitoring device (CGM) worn unblinded at least 20 days per month with interpretation and education on results. Early initiation of insulin therapy, when warranted based on a pattern of prolonged or repeated high blood glucose values.
16349035|NCT04335513|Active Comparator|Control|Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK (ongoing studies at BDC). This includes: blood glucose checks 2-3 times per month, participant-led contact with study personnel when abnormalities are noted and transition to clinical care when criteria for clinical type 1 diabetes are met.
16349036|NCT04335487|Experimental|ICBT for PTSD Tailored for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy for PTSD tailored specifically for Canadian public safety personnel.
16349037|NCT04335487|Experimental|Transdiagnostic ICBT Tailored for PSP|Therapist-guided, transdiagnostic Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
16349038|NCT04335474||Surgical drainage|Cases that have surgical management
16349039|NCT04335474||Percutaneous drainage|Cases that have the nonoperative management by percutaneous drainage
16349040|NCT04335461|Placebo Comparator|Placebo|Placebo group, with no regional nerve blockade administered.
16349041|NCT04335461|Experimental|Fracture block|Patients will have an intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine
16349042|NCT04335461|Experimental|Fascia iliaca block|Fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine
16349043|NCT04335448||Arterial Switch Operation - Transposition of Great Arteries|Patients with previous arterial switch operation for the treatment of a transposition of great arteries will constitute the sole group of the cohort.
16349044|NCT04335435|Experimental|Oat Bran Consumption|Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.
16349101|NCT04335045|Placebo Comparator|Control for 200mg Dose|1 placebo capsule (n=2)
16349102|NCT04335045|Active Comparator|400mg Dose|2 x 200 mg PH100 capsules (n=6)
16349103|NCT04335045|Placebo Comparator|Control for 400mg Dose|2 placebo capsules (n=2)
16349104|NCT04335045|Active Comparator|800mg Dose|4 x 200 mg PH100 capsules (n=6)
16349105|NCT04335045|Placebo Comparator|Control for 800mg Dose|4 placebo capsules (n=2)
16349045|NCT04335422|Experimental|Robotic group|Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).
16349046|NCT04335422|Active Comparator|Control group|Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).
16349047|NCT04335409|Experimental|Participants irradiated for lung cancer|Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis. Risk factors include mean dose to the ipsilateral lung >13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung >20 Gy without other factors.
16349048|NCT04335396||adult patients with diabetes mellitus|Subgroup 1 - consecutive patients with diabetes mellitus with scleredema skin disorder Subgroup 2 - consecutive patients with diabetes mellitus without scleredema Subgroup 3 - patients with diabetes and scleredema - already cared in the tertiary center of the Rheumatology Department of the University of Pécs, in Hungary.
16349049|NCT04335370||Patients with CF lung disease receiving Polymyxin B (PMB)|Participants receiving polymyxcin B as part of standard of care treatment for CF exacerbation will have blood drawn measure blood concentrations of PMB
16349050|NCT04335357|Placebo Comparator|placebo|The appearance and fill of placebo syringes will be identical to the active comparator.
16349051|NCT04335357|Active Comparator|TBR-760|TBR-760 is supplied as a ready-to-use solution in pre-filled syringes at a concentration of 5 mg/ml.
16349052|NCT04335344||Control|Healthy patients
16349053|NCT04335344||Periodontitis|Patients with periodontitis
16349054|NCT04335344||Cardiovascular disease|Patients with cardiovascular disease
16349055|NCT04335344||Periodontitis + cardiovascular disease|Patients with Periodontitis + cardiovascular disease
16349056|NCT04335331|Experimental|PreDM CDS|The PreDM CDS arm engages patients, clinicians, and health educators in the following 3 intervention components, followed by audit and feedback for clinicians: 1) Evidence-based information about T2D prevention 2) Tailored referral to local ILI programs through a novel platform integrated into the CDS; and 3) Prompt to consider metformin prescription using the routine EHR medication order function embedded in the CDS.
16349057|NCT04335331|Placebo Comparator|Standard Care|Standard care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
16349058|NCT04335318|Experimental|Colonoscopy with AI-assistance group|Colonoscopies were performed with AI-assistance.
16349059|NCT04335318|No Intervention|Standard Colonoscopy group|Standard clinical procedure
16349060|NCT04335305|Experimental|Tocilizumab plus Pembrolizumab (MK-3475)|"Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.
~Patients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 ≤ 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."
16349061|NCT04335305|No Intervention|Continued Standard of Care|Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine.
16349062|NCT04335292|Experimental|Treatment Arm|"First-line treatment = osimertinib, 80 mg, oral, daily; Second-line treatment = platinum (carboplatin or cisplatin) + pemetrexed chemotherapy, prescribed as per institutional standards; Third-line treatment = osimertinib rechallenge, 80 mg, oral, daily.
~Patients may enter the study at first-line treatment, second-line treatment, or third-line treatment. This is dependent on meeting the eligibility criteria."
16349063|NCT04335279|Experimental|SPIN-CHAT: Videoconference Intervention|Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
16349064|NCT04335279|No Intervention|Wait-list Control|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.
16349065|NCT04335266|Experimental|Treatment group A|Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
16349066|NCT04335266|Experimental|Treatment group B|Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
16349067|NCT04335253|Experimental|Multiple Ascending Dose|Dose escalation according to cohort allocation
16349106|NCT04335045|Active Comparator|1200mg Dose|6 x 200 mg PH100 capsules (n=6)
16349107|NCT04335045|Placebo Comparator|Control for 1200mg Dose|6 placebo capsules (n=2)
16349108|NCT04335045|Active Comparator|1600mg Dose|8 x 200 mg PH100 capsules (n=6)
16349109|NCT04335045|Placebo Comparator|Control for 1600mg Dose|8 placebo capsules (n=2)
16349201|NCT04334408|Active Comparator|Subjects with CADASIL treatment intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with Fremanezumab injections.
16349068|NCT04335240|Experimental|Music Therapy Intervention|"This protocol is a Family Centered Care Music Therapy Intervention. The methodologies will provide early intervention from the first days of hospitalization in NICU and consist of music therapy sessions both active (parental chant, live music and lullaby) and receptive (listening to recorded tracks). The music therapy accompanies the newborn and the parents during the hospitalization and focuses its attention on the emotional-relational care, according to the different needs that they will develop over time.Therapy sessions will be performed starting from three times per week, on three different days of the week, during the entire hospitalization of the enrolled infants. After discharge music therapy treatment will be performed once a week until twelve months of corrected age.
~Stress level of infants and parents and neurobehavioral and neurological development of children will be assessed."
16349069|NCT04335240|No Intervention|No music therapy intervention|Music therapy is not administered in this group. Control group (no music therapy). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
16349070|NCT04335227|Experimental|Yoga therapy group|Structured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
16349071|NCT04335227|Experimental|Aerobic exercise group|Aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
16349072|NCT04335227|Experimental|Combined yoga therapy and aerobic exercise group|Combined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
16349073|NCT04335227|Active Comparator|Control group|Nutritional management uniquely prepared by dietitian
16349075|NCT04335201|Experimental|Arm Label|with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
16349076|NCT04335188||In-patients with SARS-CoV-2 infection|"In-patients fulfilling the following criteria:
~SARS-CoV-2 infection In-patient treatment Written informed consent for participation in observational study No explicit medical exclusion criteria are stated to avoid selection bias."
16349077|NCT04335175||Tourette Syndrome|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
16349078|NCT04335175||Obsessive Compulsive Disorder|Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
16349079|NCT04335175||Healthy Controls|Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
16349080|NCT04335162||Patients with cardiovascular complications|Patients presenting with cardiomyopathies or venous thromboembolism
16349081|NCT04335162||Patients without cardiovascular complications|Patients without cardiomyopathies or venous thromboembolism
16349082|NCT04335162||Intensive Care Unit patients|Patients admitted in intensive care unit
16349083|NCT04335162||Hospital Ward patients|Patients admitted in hospital ward
16349084|NCT04335149||COREVALVE|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a COREVALVE
16349085|NCT04335149||EDWARDS|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a EDWARDS
16349086|NCT04335136|Active Comparator|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
16349087|NCT04335136|Placebo Comparator|Group B (placebo control)|
16349088|NCT04335123|Experimental|Open Label Losartan|50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy.
16349089|NCT04335110|Other|Intervention|Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
16349090|NCT04335097|Active Comparator|Control|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
16349091|NCT04335097|Active Comparator|Intervention|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
16349094|NCT04335071|Experimental|Actemra|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
16349095|NCT04335071|Placebo Comparator|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
16349096|NCT04335058|Experimental|Group A: Lactoferrin plus oral iron|Treated for 2 months regularly with oral administration of 100 mg Lactoferrin tablet twice a day before meals with oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
16349097|NCT04335058|Active Comparator|Oral iron alone|Oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
16349098|NCT04335045|Active Comparator|100mg Dose|1 x 100 mg PH100 capsule (n=6)
16349110|NCT04335032|Experimental|Eicosapentaenoic acid gastro-resistant capsules|"Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg gastro-resistant capsules 2g daily (two capsules twice daily).
~One capsule of EPA-FFA gastro-resistant capsules contains 500mg EPA-FFA in a capsule containing gelatin, glycerol, sorbitol, titanium dioxide, FD&C blue No. 1, hypromellose phthalate, dibutyl sebacate."
16349111|NCT04335032|Placebo Comparator|Placebo|Placebo capsules that cannot be visually differentiated from the active treatment
16349112|NCT04335006|Experimental|Experimental A|Subjects receive Carelizumab in combination with Nab-paclitaxel plus Apatinib,each 4-week cycle
16349113|NCT04335006|Experimental|Experimental B|Subjects receive Carelizumab in combination with Nab-paclitaxel,each 4-week cycle
16349114|NCT04335006|Active Comparator|Comparator C|Subjects receive nab-paclitaxel intravenously each 4-week cycle.
16349115|NCT04334993|Experimental|Blinatumomab pre-transplant to high risk Ph-negative ALL pts.|Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
16349116|NCT04334980|Experimental|bacTRL-Spike|"Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);
~Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;
~Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;
~Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.
~Group 5 (n=12): DSMB-defined prime and boost doses of bacTRL-Spike delivered with a 28-day intervening interval."
16349117|NCT04334967|Experimental|Treatment Arm|Patients in the treatment arm will receive 200 mg oral hydroxychloroquine. Day 1: 400 mg doses twice (800 mg total). Days 2-5: 200 mg dose twice (400 mg total daily).
16349118|NCT04334967|Active Comparator|Control Arm|Patients in the control arm will receive 500 mg oral Vitamin C. Day 1: 1000 mg dose twice (2000 mg total) Days 2-5: 500 mg dose twice (1000 mg total daily).
16349119|NCT04334954||Healthy Volunteers|Healthy Volunteers
16349122|NCT04334928|Experimental|Emtricitabine/Tenofovir|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg
~Strength: 200 mg/245 mg tablets
~Dose: one tablet once a day (both at dinner)"
16349123|NCT04334928|Experimental|Hydroxychloroquine|"Hydroxychloroquine 200 mg + Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg
~Strength: 200 mg tablets
~Dose: one tablet once a day (both at dinner)"
16349124|NCT04334928|Experimental|Emtricitabine/Tenofovir+Hydroxychloroquine|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Hydroxychloroquine 200 mg
~Strength FTC/TDF:200 mg/245 mg tablets
~Strength HC: 200 mg tablets
~Dose: one tablet FTC/TDF plus one tablet HC once a day (at dinner)"
16349125|NCT04334928|Placebo Comparator|Placebo|"Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg
~Placebo tablets with similar appearance to study drugs.
~Dose: one tablet once a day (both at dinner)"
16349126|NCT04334915|Experimental|Arm A: Cenicriviroc Mesylate (CVC)|"Cenicriviroc mesylate (CVC) 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing antiretroviral (ARV) regimens.
~For participants who are on an efavirenz (EFV)-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
16349127|NCT04334915|Placebo Comparator|Arm B: Placebo for CVC|"Placebo for CVC 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing ARV regimens.
~For participants who are on an EFV-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
16349128|NCT04334902||Abnormal|The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism
16349129|NCT04334902||Normal|The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism
16349130|NCT04334889||Chronic low back pain (CLBP)|All CLBP patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months.
16349131|NCT04334889||Asymptomatic controls|Asymptomatic participants should have had no history of LBP requiring medical attention during the last two years and no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics.
16349132|NCT04334876|Other|High Risk Healthcare Workers|At home, finger prick, antibody test.
16349133|NCT04334863|Experimental|WP1066|There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8 and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
16349134|NCT04334850|Experimental|Targeted antibiotic treatment according to the results of mPCR|a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
16349135|NCT04334850|Other|Control arm|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
16349136|NCT04334824||Hydrochlorothiazide|Patients who received a new prescription for hydrochlorothiazide (alone or in combination with non-ACE inhibitor antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
16349137|NCT04334824||Angiotensin-converting enzyme (ACE) inhibitors|Patients who received a new prescription for an ACE inhibitor (alone or in combination with non-hydrochlorothiazide antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
16349138|NCT04334811|Other|Arm|No arm
16349139|NCT04334798|Experimental|PFM&electro&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).
16349140|NCT04334798|Experimental|PFM&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).
16349141|NCT04334798|Experimental|PFM&electro&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).
16349142|NCT04334798|Experimental|PFM&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).
16349143|NCT04334785|Experimental|cryo-ablation group|In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
16349144|NCT04334772|Experimental|Muscle belly Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at hamstring muscular belly. The acupuncture needle will correspond to the negative electrode or cathode.
~The group will also receive a passive stretching exercise treatment by a physical therapist."
16349145|NCT04334772|Experimental|Tendon Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at the hamstring tendon. The acupuncture needle will correspond to the negative electrode or cathode.
~The group will also receive a passive stretching exercise treatment by a physical therapist."
16349146|NCT04334772|Active Comparator|Control|Group to receive treatment by assisted passive stretching performed by a physical therapist on tightness hamstrings.
16349149|NCT04334733|Experimental|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography.
16349150|NCT04334733|Experimental|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
16349151|NCT04334733|Experimental|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography and the children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
16349152|NCT04334733|Experimental|Control group|No intervention was made to children in the control group
16349153|NCT04334720||Observation group of positive F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
16349154|NCT04334720||Observation group of no abnormal changes in F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
16349155|NCT04334720||The control group|Corresponding to the observation group, the time, sequence and protocol were consistent
16349156|NCT04334707||Acute Kidney Injury Cohort|The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.
16349157|NCT04334707||Chronic Kidney Diseases Cohort|High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.
16349158|NCT04334694|Other|Atrial flow regulator|In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).
16349159|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
16349160|NCT04334681||LF Group|Patients who have been operated with the modified Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
16349161|NCT04334668|Active Comparator|Oral Sodium Chloride|Subject will be given 2 grams of oral sodium chloride three times daily with meals for approximately 4 days
16349162|NCT04334668|Placebo Comparator|Placebo|Subject will be given a placebo orally three times daily with meals for approximately 4 days
16349163|NCT04334655||Clinic 1|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
16349164|NCT04334655||Clinic 2|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
16349165|NCT04334655||Clinic 3|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
16349166|NCT04334655||Clinic 4|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
16349167|NCT04334642|Experimental|Athletes from the Paralympic Boccia Brazilian Team|The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
16349168|NCT04334629|No Intervention|Standard of care|
16349169|NCT04334629|Experimental|Standard of care plus lipid ibuprofen|
16349170|NCT04334616|Active Comparator|Conventional Laryngocope|Patients in this arm will be intubated with conventional Macintosh laryngoscope
16349171|NCT04334616|Active Comparator|Video Laryngocope|Patient in this arm will be intubated with Karl Storz Video Laryngoscope
16349172|NCT04334603|Experimental|Home-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home
16349173|NCT04334603|Active Comparator|Clinical-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital
16349174|NCT04334590||Cleft Lip/Nose Repair without PSIO|Participants who will undergo cleft lip/nose repair prior to addition of PSIO as part of standard of care in Hopkins.
16349175|NCT04334590||Presurgical Infant Orthopedic Therapy|Participants who will undergo cleft lip/nose repair after addition of PSIO as part of standard of care in Hopkins.
16349176|NCT04334577|Experimental|Attenuated Zoster Vaccine, Live|One shot of the vaccine (with live viruses titer >=4.3 LgPFU per dose)
16349177|NCT04334577|Placebo Comparator|Placebo|one shot of placebo with no live virus
16349178|NCT04334564|Active Comparator|Test team|Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
16349179|NCT04334564|Placebo Comparator|Control group|Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
16349180|NCT04334551|Experimental|switch from etravirine to doravirine|switches to doravirine,
16349181|NCT04334538|Active Comparator|S-RUTF|Children will receive approximately 150 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
16349182|NCT04334538|Experimental|oat-RUTF|Children will receive approximately 150 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
16349183|NCT04334525|No Intervention|Generic placemats and frequent diner cards|Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
16349184|NCT04334525|Experimental|Placemats and frequent diner cards promoting healthier meals|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
16349185|NCT04334512|Experimental|Quintuple Therapy|Patients will be treated with quintuple therapy for 10 days.
16349186|NCT04334512|Placebo Comparator|Placebo|Patients will be treated with placebo.
16349187|NCT04334499||Age Related Macular Degeneration|Subjects with Age Related Macular Degeneration upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
16349188|NCT04334499||Glaucoma|Subjects with Glaucoma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
16349189|NCT04334499||Diabetic Retinopathy|Subjects with Diabetic Retinopathy upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
16349190|NCT04334499||Ocular Trauma|Subjects with Ocular Trauma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
16349191|NCT04334499||Control|Subjects with no ocular disease or trauma comorbidities upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
16349192|NCT04334486|Experimental|Video Game Trained|Subjects will participate in video gaming for 10 minutes prior to Eyesi simulator test of surgical skills.
16349193|NCT04334486|No Intervention|No Video Game Training|No video gaming will occur for warm up to Eyesi simulator test of surgical skills
16349194|NCT04334473|Other|cataract patients|Patients having cataract candidates for phacoemulsification with or without glaucoma are prepared to do cataract surgery with preoperative and postoperative assessment of intraocular pressure and ocular bio-metrics using UBM.
16349195|NCT04334460|Active Comparator|Active Group|
16349196|NCT04334460|Placebo Comparator|Placebo Group|
16349197|NCT04334447|Experimental|Intervention Group Patients|All HF patients that experience a HF education session
16349198|NCT04334434|Experimental|Study Group|The group to which the exercise protocol consisting of aerobic and strengthening exercises will be applied.
16349199|NCT04334434|No Intervention|Control Group|Control group where evaluations will be made.
16349200|NCT04334421||Mesh group|After resection, pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) and covered with subcutaneous flap.
16349237|NCT04334161||non-PHH non-surgical controls|Absence of any conditions or previous surgery known to affect gastro-intestinal integrity and food absorption.
16349202|NCT04334408|Placebo Comparator|Subjects with CADASIL placebo intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with placebo injections.
16349203|NCT04334382|Experimental|Hydroxychloroquine|
16349204|NCT04334382|Active Comparator|Azithromycin|
16349205|NCT04334369|Sham Comparator|Single Vision Contact Lenses|
16349206|NCT04334369|Experimental|Multifocal Contact Lenses|
16349207|NCT04334356|Experimental|App Intervention|All participants will receive the web app for prevention of posttraumatic stress.
16349208|NCT04334343|Active Comparator|Athletic group|
16349209|NCT04334343|Active Comparator|Sedentary exercise group|
16349210|NCT04334343|Active Comparator|Sedentary no-exercise group|
16349211|NCT04334330|Experimental|Treatment group|
16349212|NCT04334317|Experimental|Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants)|A single dose of TAK-071 7.5 milligrams (mg), tablet, orally, on Day 1.
16349213|NCT04334317|Experimental|Sentinel Cohort: Placebo (Healthy Participants)|A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1.
16349214|NCT04334317|Experimental|TAK-071 + Placebo (PD Participants)|TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by >=3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2. Dosage for the remaining participants will be determined depending on pharmacokinetic (PK) results, safety and physiologically based PK modelling data from the sentinel cohort.
16349215|NCT04334317|Experimental|Placebo + TAK-071 (PD Participants)|TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by >=3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2. Dosage for the remaining participants will be determined depending on PK results, safety and physiologically based PK modelling data from the sentinel cohort.
16349216|NCT04334304|Active Comparator|Posterior Stabilized TKA without robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA without robot-assistance
16349217|NCT04334304|Experimental|Posterior Stabilized with robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA with robot-assistance
16349218|NCT04334304|Experimental|Bicruciate retaining TKA without robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA without robot-assistance
16349219|NCT04334304|Experimental|Bicruciate retaining TKA with robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA with robot-assistance
16349220|NCT04334278|Experimental|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
16349221|NCT04334278|Active Comparator|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth. To control for in between session practice, participants will receive an mp3 recording and informational handout to complete after each session.
16349222|NCT04334265|Experimental|Anluohuaxian combined with regular treatment group|Anluohuaxian: 6g each time, twice a day
16349223|NCT04334265|No Intervention|regular treatment group|
16349224|NCT04334239||Intervention|Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.
16349225|NCT04334239||Control|Cancer patients who have not undergone inpatient treatment in a certified cancer centre.
16349226|NCT04334226||Patient and Caregiver Dyad|Individuals who participated in the Stoma Boot Camp study and their caregiver will form a dyad
16349227|NCT04334213|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.
~Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets)."
16349228|NCT04334213|Experimental|Sequence 2|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days
16349229|NCT04334213|Experimental|Sequence 3|Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
16349230|NCT04334213|Experimental|Sequence 4|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).
16349231|NCT04334200|Experimental|Cultivate yourself: support for caregivers of dementia persons|There will be six sessions (1 or 2 session per week). The duration of each session will be 1.5-2 hours per session. The contents include: introduction on dementia, caregivers' role, how to communicate with dementia persons, tips on caregiving, stress and emotional management. The training content has been verified by one social worker, family caregivers of individuals living with dementia and a teacher who teach Chinese, Chinese history and culture in the secondary school in Hong Kong. No adverse comments are received from them.
16349232|NCT04334187|Experimental|Smoke Cessation Group|Mindfulness-based smoking cessation sessions will follow the mindfulness based addiction treatment (MBAT) intervention for smoking cessation. Sessions are in group format for two hours, weekly. Two groups of sessions with about 10 participants per group will be organized.
16349233|NCT04334174|Experimental|Single Arm|Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
16349234|NCT04334161||PHH patients|Patients with Roux-en-Y gastric bypass ≥1 year ago and confirmed postprandial hyperglycaemic hypoglycaemia (PHH). PHH is defined as postprandial plasma or sensor glucose<3.0mmol/l according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
16349235|NCT04334161||non-PHH gastric bypass patients|Patients with Roux-en-Y gastric bypass ≥1 year ago without evidence of PHH.
16349236|NCT04334161||non-PHH sleeve gastrectomy patients|Patients with sleeve gastrectomy ≥1 year ago without evidence PHH.
16349977|NCT04328857|No Intervention|Control|Upper limb rehabilitation without pseudoelastic orthosis
16349238|NCT04334148|Active Comparator|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
16349239|NCT04334148|Placebo Comparator|Placebo|Matching placebo tablets
16349240|NCT04334135|Experimental|MitoQ|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after acute MitoQ supplementation (80 - 160mg).
16349241|NCT04334135|Placebo Comparator|Placebo|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a placebo matched in appearance to the MitoQ.
16349242|NCT04334122|Experimental|Control group|"All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
~As a traditional treatment, patients received hot packs, conventional transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound and exercise.
~Hot packs used as superficial heat were wrapped in a towel and applied to the waist area for 20 minutes.
~Conventional TENS used as analgesic current were applied to the waist region for 20 minutes with 4 electrodes with 2 outputs, with a current time of 180 ms at a frequency of 80 Hz.
~It was applied with a dose of 1Mhz for 5 minutes with ultrasan (Chattanooga Intelect Mobile Combo model device) used to heat deep tissues.
~Waist exercises were asked to be done during the treatment, with 10 repetitions, each exercise twice a day (morning and evening)."
16349243|NCT04334122|Experimental|Experiment group|"In addition to the traditional physiotherapy program, tool-assisted soft tissue mobilization was performed 3 times a week (12 sessions with 1 day interval) in the experimental group.
~Instrument Assisted Soft Tissue Mobilization (IASTM) treatment was applied to ilicostalis lumborum, priformism, gluteus medius, erector spinas, quadratus lumborum muscles, superficial and deep fascia. Before applying the application, petroleum jelly was applied to the area and the tool was slipped.
~IASTM treatment was applied to the treated muscle fibers for 6 minutes, each technique (SWEEP-FAN-BRUSH-SWEEP techniques) with 8-10 repetitions.
~Sweep: Applied in all directions at 30 or 60 degree angle. Fan: It was applied by moving one side fixed arm at 30 degree angle. Brush: It was applied in straight steps at 30 degrees angle. Each stage of IASTM treatment was done by the physiotherapist."
16349244|NCT04334109|Experimental|Family-DSME|"Approach
~Family motivational interviewing techniques
~Family goal setting
~Understanding supportive and nonsupportive family behaviors
~Family behavioral changes Mode of Delivery
~Group sessions delivered by a certified diabetes educator (CDE) to patients and their family members Dosage
~10 hours delivered in one-hour sessions over 10 weeks Participants
~300 patients with T2D and 300 family members (family members will take part in educational sessions and data collection)"
16349245|NCT04334109|Active Comparator|Standard-DSME|"Approach
~Individual motivational interviewing techniques
~Individual goal setting
~Individual behavioral changes Mode of Delivery
~Group sessions delivered by a CDE to patients Dosage
~10 hours delivered in one-hour sessions over 10 weeks Participants
~300 patients with T2D (family members will take part in data collection but not educational sessions)"
16349246|NCT04334096|Experimental|QoL diagnosis and therapy|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
16349247|NCT04334083|Experimental|Emergency physicians|actors during the work
16349248|NCT04334083|Experimental|medical externship student|spectator during the emergency physician work
16349249|NCT04334083|Experimental|psychology student|spectator during the emergency physician work
16349251|NCT04334044|Experimental|Ruxolitinib|Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan
16349252|NCT04334031|Experimental|IMMINeNT cohort|
16349253|NCT04334018|Placebo Comparator|conventional CRT|
16349254|NCT04334018|Experimental|MPP CRT|
16349255|NCT04334005|Active Comparator|Usual care|Prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations.
16349256|NCT04334005|Experimental|Intervention group|25000 UI of vitamin D supplement in addition to the above-mentioned drug recommendations.
16349257|NCT04333992|Active Comparator|propofol-remifentanil group|"Anesthetic induction was achieved with an initial target concentration of propofol 4 ㎍/mL and remifentanil 3-4 ng/mL.
~Anesthesia was maintained with a fixed target concentration of propofol 2-4 ㎍/mL and remifentanil 2-3 ng/mL"
16349258|NCT04333992|Active Comparator|sevoflurane-remifentanil group|"Anesthetic induction was achieved with thiopental 5 mg/kg and initial target concentration of remifentanil 3-4 ng/mL.
~Anesthesia was maintained with 1.5-2.5% end-tidal concentration sevoflurane in 50% oxygen with air and remifentanil 2-3 ng/mL"
16349259|NCT04333979|Experimental|Drain replacement|Effects of drainage
16349260|NCT04333979|No Intervention|Drain not placed|Effects of not using drain
16349261|NCT04333966|Experimental|Interactive PBI|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
16349262|NCT04333966|Active Comparator|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call toAction: A Guide for Families.
16349263|NCT04333940|Experimental|1. 3D CBCT GROUP|Preoperative 3-dimensional CBCT will be taken.
16349264|NCT04333940|Active Comparator|2D PR GROUP|Preoperative 2-dimensional periapical radiographs will be taken using paralleling technique with customized Jig
16349308|NCT04333628|Other|Standard of care|The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
16349265|NCT04333927|Experimental|Treatment|Patients in treatment group will receive camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. After 1 or 2 courses of camrelizumab, patients went on to receive capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week) concurrent with radiotherapy (45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed).
16349266|NCT04333927|Placebo Comparator|Observation|Patients in observation group will not receive any anti-cancer therapy.
16349267|NCT04333914|Experimental|Autophagy inhibitor (GNS651)|
16349268|NCT04333914|Other|Standard of care|
16349269|NCT04333914|Experimental|anti-NKG2A (Monalizumab)|
16349270|NCT04333914|Experimental|anti-C5aR (Avdoralimab)|
16349271|NCT04333888|Experimental|Treatment|
16349272|NCT04333888|No Intervention|Control|
16349273|NCT04333875||TAVR/SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to transcatheter aortic valve replacement or surgical aortic valve replacement.
16349274|NCT04333875||Deferred Intervention|Patients with severe but not critical aortic Stenosis will undergo deferred intervention.
16349275|NCT04333862||Healthcare workers providing healthcare|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
16349276|NCT04333862||Healthcare workers staying at home|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
16349277|NCT04333862||Hospitalized patients|To compare the infection rate of hospitalized patients versus healthcare workers
16349278|NCT04333836|Experimental|Aligners group|Receiving full set of aligners ( Clear Removable Orthodontic appliance) until complete canine retraction
16349279|NCT04333836|Active Comparator|Conventional Brackets group|leveling and alignment of lower followed by complete canine retraction
16349280|NCT04333823|Experimental|Intervention (Dapagliflozin)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
16349281|NCT04333823|Placebo Comparator|Control (Placebo)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
16349282|NCT04333810||Active IBD patients|Patients with active IBD, based on colonoscopic evaluation and biopsy results.
16349283|NCT04333810||IBD patients in remission|IBD patients in remission, with no recently colonoscopic evidence of disease, and only on maintenance therapy.
16349284|NCT04333797|Other|Transitional age youth|Assessed group.
16349285|NCT04333784||exercise with BFR|Patients with rotator cuff tendinopathy will perform the exercises with a pneumatic cuff and blood flow restricted.
16349286|NCT04333784||Control|Patients with rotator cuff tendinopathy will perform the exercises without a pneumatic cuff.
16349287|NCT04333771|Placebo Comparator|Placebo|
16349288|NCT04333771|Experimental|SHR0302 dose1|
16349289|NCT04333771|Experimental|SHR0302 dose2|
16349290|NCT04333758|Experimental|Jintronix Intervention|"2 consecutive phases of intervention for all participants using Jintronix virtual reality telerehabilitation software.
~Phase 1 consisted of 9 (3/week for 3 weeks) 45-min/session clinic-based sessions conducted by study team therapist, with concurrent caregiver training.
~Phase 2 consisted of 20 (5/week for 4 weeks) 45min/session home-based sessions supervised by trained caregiver, with telemonitoring by study team therapist."
16349291|NCT04333745|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.
16349292|NCT04333732|Experimental|M-M-R II ®|Education and surveillance plus M-M-R II ®
16349293|NCT04333732|Placebo Comparator|Placebo|Education and surveillance plus placebo
16349294|NCT04333719||terminally ill patients in specialized palliative|terminally ill patients in specialized palliative care facilities
16349298|NCT04333693||Cases|Adults (age>18years) undergoing any type of vascular surgery (open surgery, endovascular surgery or hybrid procedure) in an operating theatre and either before or after surgery: lab test confirmed COVID-19 or clinical diagnosis of COVI-19 infection (no test performed)
16349299|NCT04333680|Active Comparator|Phased Array|Operators who will be using a phased array-type transducer to perform the FAST exam on a healthy normal volunteer.
16349300|NCT04333680|Active Comparator|Curvilinear|Operators who will be using a curvilinear array-type transducer to perform the FAST exam on a healthy normal volunteer.
16349301|NCT04333667|Experimental|Intervention group|The intervention group will get an 8-week mindfulness-based internet intervention.
16349302|NCT04333667|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
16349303|NCT04333654|Experimental|Hydroxychloroquine|Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days
16349304|NCT04333654|Placebo Comparator|Placebo|Matching placebo
16349305|NCT04333641||small AAA patients|all patients with small AAA
16349306|NCT04333628|Experimental|low dose chloroquine|oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
16349307|NCT04333628|Experimental|Regular dose chloroquine|oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
16349978|NCT04328844|Experimental|Single arm with IOA-244|
16349979|NCT04328831|Other|IBI322|Single arm
16349309|NCT04333615|Sham Comparator|Control Session|The control session will consist of resting on the treadmill for 30 min. It will be recommended that the patient do cycles in which he / she stands for 3 to 5 minutes and sits for 2 to 3 minutes in between, aiming to minimize the effect of body positioning on cardiovascular responses.
16349310|NCT04333615|Experimental|Self-selected Session|In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
16349311|NCT04333615|Active Comparator|Walking with pain|In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
16349312|NCT04333602|Experimental|Screening and Treatment of Asymptomatic Bacteriruria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. If we detect asymptomatic bacteriuria specific treatment will be instituted.
16349313|NCT04333602|No Intervention|Screening and NO treatment of Asymptomatic Bacteriuria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. No treatment will be instituted.
16349314|NCT04333589|Experimental|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
16349315|NCT04333589|No Intervention|Regular treatment group|Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.
16349319|NCT04333563|Active Comparator|CPAP|respiratory stressed infants getting Continuous positive airway pressure (CPAP)
16349320|NCT04333563|Experimental|respiratory stressed infants getting NIV NAVA|respiratory stressed infants getting Non-invasive neurally adjusted ventilatory assist (NIV NAVA)
16349321|NCT04333550|Experimental|Experimental: Desferal addition to standard treatment|
16349322|NCT04333550|Experimental|Experimental: standard treatment|
16349323|NCT04333537|Experimental|Sentinel Lymph Node (SLN) Biopsy|Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy.
16349324|NCT04333537|Active Comparator|Elective Neck Dissection (END)|Patients undergo standard END.
16349325|NCT04333524||Group A|Staging
16349326|NCT04333524||Group B|Criteria for response assessment
16349327|NCT04333511|Experimental|Sequence 1|TPS first with crossover to Sham-TPS
16349328|NCT04333511|Experimental|Sequence 2|Sham-TPS first with crossover to TPS
16349329|NCT04333498|Experimental|Receiving Feedback From DBS|This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.
16349330|NCT04333485|Active Comparator|House Hold Active Case Finding (HHACF)|Existing health workers at the RNTCP TB Units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer standardized World Health Organization (WHO)-recommended TB symptom screen questionnaire (amended to include cough of any duration) to treated TB cases and their HH contacts. All those with any TB symptom will have a spot sputum taken at the home.
16349331|NCT04333485|Experimental|Telephonic Active case finding (TACF)|Standardised WHO-recommended TB symptom screen questionnaire will be administered to TB patients by existing health workers at the RNTCP via telephone calls at 6 and 12 months post-treatment completion. The TB patient (index case) will also be asked about any TB symptoms among household (HH) contacts. All HHs with suspected TB among the index TB case or a HH contact will be visited by RNTCP health workers to collect spot sputum specimens at their home.
16349332|NCT04333472|Experimental|Piclidenoson|Piclidenoson 2 mg every 12 hours orally added to standard of care
16349333|NCT04333472|Placebo Comparator|Placebo|Placebo every 12 hours orally added to standard of care
16349334|NCT04333459|Active Comparator|Group 1 - Full Dose Hataan|"Group 1 will be vaccinated with the Full Dose of HTNV DNA vaccine, 2 mg of pWRG/HTN-M(co) with 0.5 mg/each deltoid."
16349335|NCT04333459|Active Comparator|Group 2 - Half Dose Hataan|"Group 2 will be vaccinated with the Half Dose of HTNV DNA vaccine, 1 mg of pWRG/HTN-M(co) with 1.0 mg/each deltoid."
16349336|NCT04333459|Active Comparator|Group 3 - Full Dose Puumala|"Group 3 will be vaccinated with the Full Dose of PUUV DNA vaccine, 2 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
16349337|NCT04333459|Active Comparator|Group 4 - Half Dose Puumala|"Group 4 will be vaccinated with the Half Dose of PUUV DNA vaccine, 1 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
16349338|NCT04333433||MicroShunt treatment group|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device
16349339|NCT04333433||Trabeculectomy control arm|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure
16349340|NCT04333420|Experimental|Arm A: SOC + IFX-1|
16349341|NCT04333420|Experimental|Arm B : SOC + Placebo|
16349342|NCT04333407|Experimental|Active Arm|
16349343|NCT04333407|No Intervention|Control Arm|
16349380|NCT04333134|Experimental|Dose level 1|Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
16349344|NCT04333394|Active Comparator|Probiotic|The probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei PXN 37, Lactobacillus rhamnosus PXN 54, Streptococcus thermophilus PXN 66, Bifidobacterium breve PXN 25, Lactobacillus acidophilus PXN 35, Bifidobacterium longum PXN 30, Lactobacillus bulgaricus PXN 39)
16349345|NCT04333394|Placebo Comparator|Placebo|Placebo capsules have an identical appearance to probiotic capsules and contain microcrystal cellulose.
16349346|NCT04333381|Active Comparator|Common Practice|Patients included in the phase I will receive common practice.
16349347|NCT04333381|Experimental|Educational and organizational measures|Patients included in the phase II will be attended by emergency nurses that received the educational and organizational intervention.
16349348|NCT04333368|Experimental|MSC|
16349349|NCT04333368|Placebo Comparator|NaCl|
16349350|NCT04333355|Experimental|COVID-19 patients receiving Convalescent Plasma|Convalescent Plasma from patients who recently recover from COVID-19
16349351|NCT04333342|Experimental|Wearable device group|Participants use wearable device and their heart rate and activity are monitored. If their resting heart rate (rHR) increase beyond the set range or they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If their rHR stay within set range and they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
16349352|NCT04333342|No Intervention|Control group 1|articipants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
16349353|NCT04333342|No Intervention|Control group 2|Participants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6 months after discontinuing anti-thyroid drugs.
16349354|NCT04333329|Experimental|AD Patients|"All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))
~- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mm²"
16349355|NCT04333316|Other|large head group|study the postoperative patient's satisfaction
16349356|NCT04333316|Other|dual mobility group|study the postoperative patient's satisfaction
16349357|NCT04333303|Experimental|Advance Care Planning Program|Implementation of a complex regional Advance Care Planning program.
16349358|NCT04333303|No Intervention|Care as usual|
16349359|NCT04333290|Experimental|Single Arm: Healthy subjects|The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
16349360|NCT04333277|Experimental|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
16349361|NCT04333277|Placebo Comparator|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
16349362|NCT04333264|Active Comparator|suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
16349363|NCT04333264|Active Comparator|no suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
16349364|NCT04333251|Experimental|convalescent plasma|This arm will receive convalescent plasma
16349365|NCT04333251|Placebo Comparator|best supportive care|Oxygen therapy
16349366|NCT04333238|Active Comparator|Standard template|Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format
16349367|NCT04333238|Experimental|New template|The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized
16349368|NCT04333225|Experimental|Hydroxychloroquine|Subjects who chose to enter the HCQ arm received a loading dose of 800 mg HCQ on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks
16349369|NCT04333225|No Intervention|Control|Subjects who declined taking HCQ were considered as controls
16349370|NCT04333212|Other|study arm|We projected a total of 1,100 study cases, which encompassed 100 cases of women with no intraepithelial lesion or malignancy (NILM) cytology, 300 cases of ASCUS, 300 cases of low grade squamous intraepithelial lesion (LSIL) and 400 cases high grade squamous intraepithelial lesion (HSIL) in cervical cytology.
16349371|NCT04333199|No Intervention|Control|Patients do not receive an email
16349372|NCT04333199|Experimental|Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
16349373|NCT04333199|Experimental|Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
16349374|NCT04333173||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
16349375|NCT04333160|Experimental|JTA-004|single knee intra-articular injection of JTA-004 solution (2ml)
16349376|NCT04333160|Placebo Comparator|placebo|single knee intra-articular injection of saline solution (2ml)
16349377|NCT04333160|Active Comparator|Hylan G-F 20|single knee intra-articular injection of Hylan G-F 20 (6ml)
16349378|NCT04333147|Experimental|Participants receiving GSK3196165 in qualifying study|Participants receiving GSK3196165 in their qualifying study will continue to receive GSK3196165 at the same dose level (90 mg or 150 mg weekly) in this study.
16349379|NCT04333147|Experimental|Participants receiving comparator in qualifying study|Participants receiving a comparator (e.g. tofacitinib or sarilumab) in their qualifying study will be re-randomized to receive either GSK3196165 90 mg or 150 mg weekly in this study.
16349416|NCT04332835|Active Comparator|Control Group|Participants included in the control group will receive standard therapy defined by institutional protocol.
16349381|NCT04333108|Experimental|Masitinib & BSC|"Experimental Arm:
~Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC).
~Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control."
16349382|NCT04333108|Placebo Comparator|Placebo & BSC|"Placebo Comparator:
~Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)"
16349383|NCT04333095|Active Comparator|Liposomal Bupivacaine Block|Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
16349384|NCT04333095|Placebo Comparator|Saline Block|Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
16349385|NCT04333069|Other|Uncorrected and best corrected visual acuity|Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery
16349386|NCT04333043||Hearing Aids|Hearing Aids use
16349387|NCT04333030||Psychiatry|patients who come for psychiatric consultation
16349388|NCT04333030||addictology (other than tabacco)|patients who come for addictology consultation
16349389|NCT04333030||endocrinology|patients who come for endocrinology consultation
16349390|NCT04333017|Experimental|treated patient|Percutaneous radiofrequency ablation of parietal endometriosis
16349391|NCT04333004|Experimental|Pembrolizumab Combined With Chemotherapy|
16349392|NCT04332991|Active Comparator|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
16349393|NCT04332991|Placebo Comparator|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
16349394|NCT04332978|Experimental|Group I|"Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.
~Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging"
16349395|NCT04332978|Active Comparator|Group II|"Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.
~GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging"
16349396|NCT04332965|Experimental|Patients with chronic periodontitis|Patients with CP (n=30) had teeth with 30% periodontal bone loss and ≥ 2 non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and bleeding on probing.
16349397|NCT04332965|Experimental|Patients with gingivitis|Participants with G (n=30) had gingival index ≥ 2 and other inflammation signs.
16349398|NCT04332965|No Intervention|Participants with periodontal healthy|The H group (n=30) consisted of individuals with no attachment loss, no history of periodontal disease, PD ≤3 mm, and whole-mouth bleeding scores <10%.
16349399|NCT04332939|Experimental|Exercise + real tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.
~For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min)."
16349400|NCT04332939|Sham Comparator|Exercise + Sham tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.
~For the first week, participants will receive 5 daily sessions of sham tDCS."
16349401|NCT04332926|Active Comparator|Own Brand Cigarette|
16349402|NCT04332926|Experimental|ECIG 30 Watts, 0 mg/ml nicotine|
16349403|NCT04332926|Experimental|ECIG 30 Watts, 8 mg/ml nicotine|
16349404|NCT04332926|Experimental|ECIG 30 Watts, 15 mg/ml nicotine|
16349405|NCT04332926|Experimental|ECIG 30 Watts, 30 mg/ml nicotine|
16349406|NCT04332900|No Intervention|Control condition|In this condition there will not be any application of therapeutic approach.
16349407|NCT04332900|Experimental|Intervention proximal condition|The proximal therapeutic approach will be the SERF strap (S.E.R.F. strap; DonJoy Orthopedics, Inc., vista, CA).
16349408|NCT04332900|Experimental|Intervention distal condition|The distal therapeutic approach will be a pair of foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each (Propulsão Produtos Biomecânicos, Minas Gerais, Brazil).
16349409|NCT04332887|Experimental|Multidimensional Exercise Program|Patients in this group will receive a 12 week exercise program including: (1) one 20-30 minute individual exercise consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) telephone follow-up once per week for 12 weeks.
16349410|NCT04332887|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
16349411|NCT04332874|Experimental|Participants with Sarcoma|Advanced/metastatic extremity sarcoma eligible for pembrolizumab and isolated limb infusion (ILI)
16349412|NCT04332861||Prospective observational cohort|"For data analysis, the cohort will be subdivided as follows:
~Identification and Validation cohorts
~Patients with and without complicating factors
~Patients with and without measured inflammatory marker levels"
16349413|NCT04332848|Experimental|(B) Empirical therapy|choose antibiotics according to drug history
16349414|NCT04332848|Active Comparator|(A) Susceptibility testing guided therapy|choose antibiotics according to susceptibility testing
16349415|NCT04332835|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.
16349514|NCT04332198|Experimental|ALS patients|
16349417|NCT04332822|Active Comparator|Arm A - R-mini-CHOP|"Cycles 1-6, duration 21 days
~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6
~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
16349418|NCT04332822|Experimental|Arm B - R-pola-mini-CHP|"Cycles 1-6, duration 21 days
~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
~Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6"
16349419|NCT04332809|Active Comparator|Saline-gentamicin irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline-gentamicin solution
16349420|NCT04332809|Active Comparator|Saline irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline solution
16349421|NCT04332809|No Intervention|No irrigation|ayer-by-layer irrigation of the appendectomy wound will not be performed
16349422|NCT04332796|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
16349423|NCT04332796|Active Comparator|ZnO-NPs socks|ZnO-NPs socks to patients for 2 weeks
16349424|NCT04332796|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks to patients for 2 weeks
16349425|NCT04332783||Healthy Typical Adults|Observers including radiologists and non-radiologists will be asked to participate in computer based tasks in which they visually search for, detect, localize, and categorize tumors in x-ray images.
16349426|NCT04332770||Hypothyroid group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to withdraw their levothyroxine for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
16349427|NCT04332770||Control group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to get rhTSH (not to withdraw their levothyroxine) for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
16349428|NCT04332757|Experimental|Training Intervention|18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation.
16349429|NCT04332757|No Intervention|Usual care control|Usual care acting as a control group.
16349430|NCT04332744|Active Comparator|Control Arm (Arm A)|Patients will receive enzalutamide capsules orally once daily continuously (160 mg) in addition to standard ADT (unless surgical castration).
16349431|NCT04332744|Experimental|Interventional Arm (Arm B)|Patients will receive enzalutamide capsules 160 mg in combination with talazoparib (PF-06944076) capsules 0.5 mg, both orally daily and continuously in 28-day cycle, in addition to standard ADT (unless surgical castration).
16349432|NCT04332731|Experimental|Renal angiography and Renal denervation|"Symplicity Spyral™ multi electrode renal denervation system
~After renal angiography, participants in the experimental group will be immediately treated with renal denervation procedure using standard techniques. The participants will remain blinded throughout the procedure."
16349433|NCT04332731|Sham Comparator|Renal angiography|In the control group, the sham procedure will consist of only a renal angiogram. Participants will undergo diagnostic renal angiogram but will not receive any therapeutic endovascular treatment. Participants will remain on the procedure table for at least 20 min after the angiogram to prevent possible unblinding of randomization allocation.
16349434|NCT04332718|No Intervention|24 Hour Holter|Patients who are randomised to the 24 Hour Holter monitoring will be contacted within one month from randomisation. The repeat 24 Hour Holter result will be explained to the patient at the end of 30-day follow-up.
16349435|NCT04332718|Active Comparator|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
16349436|NCT04332705||Patients with colon cancer|Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
16349437|NCT04332705||Patients without colon cancer|Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
16349438|NCT04332692|Experimental|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination focusing on congestion
~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds
~Blood sample retrieved for biological assessment and biobanking
~Telephone follow-up"
16349439|NCT04332679|Active Comparator|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
16349440|NCT04332679|Experimental|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
16349441|NCT04332666|Placebo Comparator|Placebo|Standard of care treatment
16349442|NCT04332666|Experimental|Study drug|Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
16349443|NCT04332653|Experimental|Phase 1b: NT-I7 Dose Escalation|"NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16349444|NCT04332653|Experimental|Phase 2a: CPI Treated Triple Negative Breast Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16349445|NCT04332653|Experimental|Phase 2a: CPI Treated Non-small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16350085|NCT04328077|Placebo Comparator|Placebo|Orally administered.
16349446|NCT04332653|Experimental|Phase 2a: CPI Treated Small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16349447|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16349448|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16349449|NCT04332653|Experimental|Biomarker Cohort: CPI Naïve Ovarian Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory ovarian cancer (OC). Participants will receive a starting dose of 960 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
16349450|NCT04332640|Experimental|Next Generation Phaco System|VERITAS Vision System
16349451|NCT04332627|Active Comparator|sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
16349452|NCT04332627|Placebo Comparator|neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
16349453|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
16349454|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
16349455|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
16349456|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
16349457|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
16349458|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.
~Endowment: Give patients the impression they already have the account, so they value it more.
~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
16349459|NCT04332601|Experimental|ENERGY intervention|"ENERGY Intervention:
~14 sessions of 1h CBT intervention (standardized fatigue treatment comprising six modules over 14 individual therapy sessions)
~1 session per week
~With a psychologist (different to the psychologist who will perform the assessments)
~Individual sessions
~and Treatment as usual"
16349460|NCT04332601|Other|Treatment as usual (TAU)|"Comparison group
~TAU defined by antipsychotic medication coupled with day hospital care"
16349461|NCT04332588|Experimental|Herceptin monotherapy cohort|Herceptin monotherapy cohort. Locally advanced HER2+ breast cancer patients receiving neoadjuvant Herceptin monotherapy prior to combination therapy will undergo three contrast-enhanced [18F]FMISO PET/MRI scans. Each imaging session will be identical. Imaging session one will be after diagnosis and before beginning monotherapy. Imaging session two will be within 10 days prior to beginning combination therapy with targeted HER2 agents. Imaging session three will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
16349462|NCT04332588|Experimental|Combination therapy cohort|Locally advanced HER2+ breast cancer patients that receiving neoadjuvant combination therapy including Herceptin will undergo two contrast-enhanced [18F]FMISO PET/MRI imaging. Imaging session one will be after diagnosis and before beginning combination therapy. Imaging session two will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
16349463|NCT04332562|No Intervention|normotensive control group|Normotensive volunteer
16349464|NCT04332562|No Intervention|hypertensive control group|Hypertensive patients with no restriction on their salt intake
16349465|NCT04332562|Experimental|hypertensive interventional group|intervention is going to be salt restriction
16349466|NCT04332549|Active Comparator|Reconstitution Method 1|
16349467|NCT04332549|Active Comparator|Reconstitution Method 2|
16349468|NCT04332536|Experimental|Chronic Heart Failure|
16349469|NCT04332536|Active Comparator|Age-matched healthy controls|
16349470|NCT04332523|Experimental|Group 1: Participants with Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
16349471|NCT04332523|Experimental|Group 2: Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
16349472|NCT04332523|Experimental|Group 3: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
16349473|NCT04332523|Experimental|Group 4: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of JNJ-53718678 suspension on Day 1.
16349474|NCT04332510|Experimental|Infant milk 1|
16349475|NCT04332510|Experimental|Infant milk 2|
16349476|NCT04332510|Experimental|Infant milk 3|
16349477|NCT04332510|Experimental|Infant milk 4|
16349478|NCT04332497|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
16349479|NCT04332497|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16349480|NCT04332497|Active Comparator|Group ISCB = ISCB group|In group ISCB, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
16349481|NCT04332484||Acute on Chronic Liver Failure|All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
16349482|NCT04332484||Cirrhosis of Liver|All patients with cirrhosis of liver with age more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
16349483|NCT04332471|Active Comparator|Control|Patients in the control group will be treated using the home therapy protocol only.
16349484|NCT04332471|Active Comparator|Radial shockwave therapy|Patients will receive 4 sessions of radial shockwave therapy.
16349485|NCT04332471|Active Comparator|Focused shockwave therapy|Patients will receive 4 sessions of focused shockwave therapy.
16349486|NCT04332458|Other|Patients with stroke without exercise experience|Patients who are discharged from the hospital within one month after a minor stroke or TIA and are not offered physical rehabilitation afterwards
16349487|NCT04332458|Other|Patients with stroke with exercise experience|Patients with a minor stroke who have participated in an exercise study (HITPALS)
16349488|NCT04332445|Experimental|Experimental|subjects, 18-70 y, healthy
16349489|NCT04332432|Experimental|belapectin|"Single dose of 4 mg/kg of lean body mass (LBM) belapectin solution for injection administered intravenously (infused over approximately 60 minutes).
~Group 1: 16 matched healthy subjects with normal hepatic function
~Group 2: 8 subjects with mild hepatic impairment (Child-Pugh Class A [4 x subjects with a score of 5 and 4 x subjects with a score of 6])
~Group 3: 8 subjects with moderate hepatic impairment (Child-Pugh Class B [score of 7 to 9])
~Group 4: 8 subjects with severe hepatic impairment (Child-Pugh Class C [score of 10 to 14])."
16349490|NCT04332419|Experimental|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
16349491|NCT04332393|Experimental|metformin group|
16349492|NCT04332393|No Intervention|No treatment group|
16349493|NCT04332380|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
16349494|NCT04332367|Experimental|Carboplatin, Taxane And Ramucirumab|Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
16349495|NCT04332354||T2D diabetes obese subjects|Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
16349496|NCT04332341|Experimental|Nicotinamide riboside (NR)|
16349497|NCT04332328||Ulcerative patients|
16349498|NCT04332328||Non ulcerative patients|
16349499|NCT04332315|Active Comparator|VALS|Vaginally asissted laparoscopic sacrocolpopexy
16349500|NCT04332315|Active Comparator|AS|Abdominal Sacrocolpopexy
16349501|NCT04332302|Experimental|Power training group|Participants will be enrolled in a resistance training program.
16349502|NCT04332302|No Intervention|Control group|Participants will be doing their normal life.
16349503|NCT04332289||PHH patients|Patients following Roux-en-Y gastric bypass surgery (≥1 year ago) with confirmed post-prandial hyperinsulinemic hypoglycemia
16349504|NCT04332289||Healthy controls|Non-PHH, non-surgical healthy individuals
16349505|NCT04332276|Experimental|Cerebroventricular administration of A- dopamine|Cerebroventricular administration of dopamine prepared and stored in anaerobia
16349506|NCT04332276|Active Comparator|Optimized oral dopaminergic treatment|Optimized oral dopaminergic treatment with L-dopa (at least 5 doses a day) with dopaminergic agonist, monoamine B inhibitor and catechol-o-methyl inhibitor (if tolerated) (A-dopamine replaced by saline un the pump during optimized oral dopaminergic treatment)
16349507|NCT04332263|Experimental|Neuromuscular Electrical Stimulation - NMES|NMES will be applied bilaterally on the quadriceps femoris muscle of ICU patients. An electrical stimulation system and an ICU-designed dynamometer will be used with the patients lying in bed, with the hips and the knees flexed at 60 and 90 degrees, respectively. Supramaximal single-pulse's peak force will be used to determine the NMES intervention level. NMES (alternating biphasic current, stimulation frequency = 80 Hz, 1 ms pulse duration) will be used to evoke tetanic forces (EF) at 50% of the supra-maximal single-pulse EF (i.e., 10-12% of a maximal voluntary isometric contraction). NMES protocol will be performed five times a week, lasting 20 min. Muscle fatigue will be evaluated every 5 min of the intervention, and will be determined as a 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol. If and when a 10% reduction of the single-pulse EF is achieved, the intervention protocol will be terminated before the 20 min.
16349508|NCT04332263|No Intervention|Control Group - CG|The control group (CG) will only perform conventional physiotherapy and will not receive any NMES training, but will be evaluated through the same evaluations and in the same moments of the two above mentioned intervention groups. Conventional physiotherapy will be given to all three groups.
16349509|NCT04332237||Hypothermia group|Hypothermic trauma patients or hypothermic patients with traumatic brain injury specifically.
16349510|NCT04332237||Normothermia group|Normothermic trauma patients or normothermic patients with traumatic brain injury specifically.
16349511|NCT04332224|Experimental|Non-shivering cooling group|Cooling devices
16349512|NCT04332211|Experimental|Pseudoephedrine Group|Patients randomized to pseudoephedrine prior to hyperbaric therapy
16349513|NCT04332211|Placebo Comparator|Placebo Group|Patients randomized to placebo prior to hyperbaric therapy
16349515|NCT04332185|Experimental|Vestibulart socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
16349516|NCT04332172|Placebo Comparator|General information|Control
16349517|NCT04332172|Experimental|General information + SMS|SMS refers to tailored text messaging.
16349518|NCT04332172|Experimental|Baseline brief intervention|Brief technology-delivered intervention for alcohol use during pregnancy
16349519|NCT04332172|Experimental|Baseline brief intervention + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
16349520|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device.
16349521|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
16349522|NCT04332159|Experimental|Intervention group|Inhalation of Methoxyflurane through a Penthrox inhaler
16349523|NCT04332159|Placebo Comparator|Control group|Inhalation of placebo (0.9% salin solution) through a Penthrox inhaler
16349524|NCT04332146|Experimental|Mindfulness-based intervention|
16349525|NCT04332146|Active Comparator|Booklet-based psychoeducation group|
16349526|NCT04332133|Active Comparator|group 1|group 1 of DME which treated by SML
16349527|NCT04332133|Active Comparator|group 2|Group 2 of DME which treated by intravitreal injection of Ranibizumab
16349528|NCT04332133|No Intervention|group 3|control group of diabetic patients received no treatment
16349529|NCT04332120|Active Comparator|Mini Laparotomic|In patients undergoing spinal anesthesia, a suprapubic 3-5 centimeter incision was entered into the abdomen. After both tubes were isolated, bilateral tube ligation was performed by Pomeroy method. After bleeding control was achieved, it was repaired in accordance with the anatomy of the abdomen.
16349530|NCT04332120|Active Comparator|Laparoscopic|In patients undergoing general anesthesia, Verres was inserted into the abdomen through the umbilicus. Pneumo peritoneum was created with carbon dioxide (CO2). Optical imaging was placed into the abdomen from the umbilicus with 10-trochar. Auxiliary trochars from 3 centimeter supero-medial of both spina iliaca anterior superior were placed in the abdomen. bilateral tubas were isolated. Bilateral tubal ligation was performed with the help of bipolar cautery. bleeding control was achieved. trochars were taken out of the abdomen. the skin was closed.
16349531|NCT04332120|Active Comparator|posterior colpotomy|The patient underwent spinal anesthesia and was placed in a high lithotomy position. cervical uteri was observed with the help of speculum. A 3 centimeter vertical incision was opened 2 centimeter below the cervix uteri. Peritoneal cavity was entered from this area. bilateral tubas were isolated. Bilateral tubal ligation was performed using the pomeroy method. bleeding control was achieved. peritoneal and posterior cervical incision line was repaired.
16349532|NCT04332107|Experimental|Azithromycin|1.2g of oral azithromycin
16349533|NCT04332107|Placebo Comparator|Placebo|Matching placebo
16349534|NCT04332094|Experimental|Intervention|Early administration of tocilizumab associated with hydroxychloroquine and azithromycin.
16349535|NCT04332094|Active Comparator|Control|Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin.
16349536|NCT04332081|Experimental|Hyperbaric oxygen therapy (HBOT)|
16349537|NCT04332081|No Intervention|Standard of Care|
16349538|NCT04332068|Active Comparator|Arm 1|Permethrin cream plus placebo tablets
16349539|NCT04332068|Experimental|Arm 2|Ivermectin (200 µg/kg) plus placebo cream
16349540|NCT04332068|Experimental|Arm 3|Ivermectin (400 µg/kg) plus placebo cream
16349541|NCT04332068|Experimental|Arm 4|Ivermectin (800 µg/kg) plus placebo cream (except the Bangladesh site)
16349542|NCT04332055|Experimental|ERVIN PLUS|The doctor and the patient will have access to the ERVIN generated data
16349543|NCT04332055|No Intervention|ERVIN MINUS|The doctor and the patient will not have access to the ERVIN generated data
16349544|NCT04332042|Experimental|tofacitinib|Tofacitinib cp 5mg: 2pills twice a day for 14 days
16349545|NCT04332029|Experimental|CBT + WGP + CM|The experimental intervention includes three components: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation; 2) Weight Gain Prevention module (WGP) and; 3) Contingency Management (CM) procedure reinforcing tobacco abstinence.
16349546|NCT04332029|Active Comparator|CBT + WGP|The active comparator will include only the first two components of the experimental intervention: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation and 2) Weight Gain Prevention module (WGP).
16349547|NCT04332016||COVID-19 infected patients|
16349548|NCT04332003|Active Comparator|RIC Treatment|Participants will receive active RIC treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
16349549|NCT04332003|No Intervention|SHAM Comparator|Participants will receive sham treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
16349550|NCT04331990|Active Comparator|Standard Physical Therapy|Control group for the study. Intervention in the form of warm-up and strengthening, stretching and neuromuscular control exercises.
16349551|NCT04331990|Experimental|Intermittent Mechanical Traction|Standard care in addition to intermittent mechanical distraction of the knee joint.
16349552|NCT04331990|Experimental|Continuous Mechanical Traction|Standard care in addition to continuous mechanical distraction of the knee joint
16349553|NCT04331977|Experimental|Quadhelix Group|
16349554|NCT04331977|Active Comparator|Hyrax Group|
16349555|NCT04331964|Active Comparator|Mineral Trioxide Aggregate (MTA)|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The exposed pulp tissues will be directly capped with a 3mm of MTA (Pro Root MTA) layer.
16349556|NCT04331964|Experimental|MTA with platelet rich fibrin (PRF).|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The PRF membrane obtained after centrifugation of the patient's own blood is going to be placed over the exposed pulp. Then, a 3mm of MTA (Pro Root MTA) will be placed over the PRF membrane.
16349557|NCT04331951|Experimental|Targeted biopsy within Sydney Protocol|"The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.
~All tissues will be sent to immunohistochemistry as a gold standard.
~Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated."
16349558|NCT04331938|Experimental|Open Label Arm|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion. This will be performed on both sides. Patients will be asked to rate their pain pre- and 30 minutes post-procedure on a scale of 0-10. Patients will also be asked to rate their nausea and photophobia on a similar scale. Patients will be reevaluated at 24 hours and 48 hours post procedure.
16349559|NCT04331925|Other|Anxiety and depression screening|Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the start of the study. After two weeks or at the time of discharge, participants will complete the HADS questionnaire again
16349560|NCT04331925|Experimental|Anxiety and depression screening with journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period. They will also complete the HADS questionnaire before and after the intervention period of two weeks. At the end of the intervention period, these parents will also complete a survey regarding their experience with journaling
16349561|NCT04331899|Experimental|Study drug Peginterferon Lambda-1a|Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
16349562|NCT04331899|Placebo Comparator|Placebo injection|Study participants will receive a placebo along with the standard of care treatment.
16349563|NCT04331873|Experimental|Ultrasound|An ultrasound will be obtained to evaluate placement of the gastrostomy tube prior to obtaining the standard contrast injection
16349564|NCT04331847||Quantitative observational descriptive study|among women presenting for abortion-related complications
16349565|NCT04331847||Qualitative study|among women with a near-miss or a potentially life-threatening complication
16349566|NCT04331847||Rapid health facility assessment with the health professional|in charge of Post-Abortion Care
16349567|NCT04331847||Knowledge Attitudes, Practice and Behavior quantitative survey|among health care providers involved in the management of abortion-related complications
16349568|NCT04331834|Experimental|Pre-exposure prophylaxis of SARS-CoV-2|Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
16349569|NCT04331834|Placebo Comparator|Control group with placebo|Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
16349570|NCT04331808|Experimental|TOCILIZUMAB|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
16349571|NCT04331808|No Intervention|Standard of care|
16349572|NCT04331795|Experimental|Group A|Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
16349573|NCT04331795|Experimental|Group B|Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
16349578|NCT04331743|Experimental|PLM60|"Three dose levels will be tested according to the 3 + 3 dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days)."
16349579|NCT04331730|Experimental|AKST4290 (800 mg) + Aflibercept|Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
16349580|NCT04331730|Experimental|AKST4290 (1600 mg) + Aflibercept|Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
16349581|NCT04331730|Placebo Comparator|Placebo + Aflibercept|Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment
16349582|NCT04331717|Experimental|Diet and exercise with BAE|After enrollment in the clinical trial, all men will be enrolled in diet and exercise counseling through the weight management program for a total of 4 weeks. If participants lose >5 pounds of total body weight from weight management alone in the first 4 weeks, these participants will be excluded from study and will not undergo BAE but will be encouraged to continue with weight management. Those still enrolled will undergo BAE. Within 7 days of BAE, men will be given ADT (lupron subcutaneous injection).
16349583|NCT04331704|Experimental|Personalized Information|Participants randomized to this condition will complete a web-based questionnaire and then receive personalized information regarding their alcohol use and sexual health behavior. They will complete daily, phone-based IVR monitoring for assessment purposes and receive further personalized information based on their responses.
16349584|NCT04331704|Active Comparator|Educational Information|Participants randomized to this condition will complete a web-based questionnaire and then receive educational material regarding their alcohol use and sexual health behavior. They will complete daily phone-based IVR monitoring for assessment purposes.
16349585|NCT04331691|Active Comparator|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
16349586|NCT04331691|Experimental|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
16349587|NCT04331678|No Intervention|Usual Care|Participants will be complete survey at enrollment and then again in 3 months.
16349588|NCT04331678|Active Comparator|Active|"Participants in the App group will receive usual care and complete survey at enrollment and then again in 3 months.
~In addition, they will be asked to download the study app to their mobile device and use it at least once per week during the 3-month study period."
16349589|NCT04331665|Experimental|Ruxolitinib to prevent COVID-19 pneumonia|All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.
16349590|NCT04331652|Experimental|Polypectomy without anesthesia or analgo-sedation|Patient will undergo polypectomy without anesthesia.
16349591|NCT04331626|Experimental|Low-dose Gemcitabine Combined With nivolumab|Bristol-myers squibb (BMS) company's nivolumab injection liquid (trade name: odiwal). Recommended dosage: 3mg/kg, intravenously injected once every 2 weeks for 60 minutes. As long as clinical benefit is observed, continue treatment with this product for up to 6 courses. Gemcitabine hydrochloride injection from eli lilly. Use 50% of the recommended dose, i.e. 500mg/m2, intravenously for 30 minutes. Day 1 and day 8 administration. Depending on the patient's tolerance to gemcitabine, a reduced dose may be considered for each treatment cycle or one treatment cycle. Use for 1 year. If a Ⅲ magnitude of adverse reactions, it is necessary to permanently discontinued.
16349592|NCT04331613|Experimental|CAStem|A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
16349593|NCT04331600|Experimental|CHLOROQUINE|Standard of care + chloroquine phosphate + telemedical approach.
16349594|NCT04331600|Other|CONTROL GROUP|Standard of care + telemedical approach.
16349595|NCT04331587|Experimental|Bronchoscopy|"Following airway inspection, the radial endobronchial ultrasound probe will be inserted through the working channel of the 4mm bronchoscope and will be advanced into the targeted bronchial segment towards the targeted lesion. Bronchoscopy will be performed using monoplanar fluoroscopic guidance until the peripheral lesion is located and confirmed using radial probe EBUS.
~a. If a concentric view is obtained, biopsy will proceed using conventional instruments (TBNA) through the 4mm bronchoscope.
~b. If an eccentric view is obtained, the 4mm bronchoscope will be withdrawn and the 3mm bronchoscope with the radial ultrasound probe will be advanced to the target lesion. Attempts will be made using the 3mm bronchoscope to obtain concentric views and ability to do so will be recorded. Biopsies will be obtained using conventional instruments (TBNA)through the 3mm bronchoscope regardless of the final ultrasound image (concentric or eccentric)."
16349596|NCT04331574||covid-19 patients|Patients with certified diagnosis of COVID-19 recruited in Italian hospitals
16349597|NCT04331561|Experimental|Sensory Re-weighting|Adults with self-reported visually-induced dizziness will be recruited to help establish the feasibility and tolerability of the testing and training methods, as well as observe for any effects of the sensory re-weighting intervention. Tests involve assessing motion sickness, vision, somatosensation, balance, and perception of verticality. The treatment provided is designed to facilitate re-weighting of sensory feedback for orientation and balance. Participants will serve as their own controls.
16349598|NCT04331535|Experimental|Polygenic risk score (PRS) - high risk stratum|Patient-participants in the PRS-high arm and their providers will receive their high-PRS results at baseline, along with educational resources about the results.
16349599|NCT04331535|Active Comparator|Usual care (UC) - high risk stratum|Patient-participants in the UC-high arm and their providers will receive their high-PRS results after a 24-month observation period, along with educational resources about the results.
16349600|NCT04331535|Experimental|Polygenic risk score (PRS) - average risk stratum|Patient-participants in the PRS-average arm and their providers will receive their average-PRS results at baseline, along with educational resources about the results.
16349601|NCT04331535|Active Comparator|Usual care (UC) - average risk stratum|Patient-participants in the UC-average arm and their providers will receive their average-PRS results after a 24-month observation period, along with educational resources about the results..
16349602|NCT04331522||Antibiotics|Children aged 0-18 years investigated for allergy to antibiotics
16349603|NCT04331522||Milk|Children aged 0-18 years investigated for allergy to milk
16349604|NCT04331522||Egg|Children aged 0-18 years investigated for allergy to egg
16349605|NCT04331522||Peanut|Children aged 0-18 years investigated for allergy to peanut
16349606|NCT04331522||Hazelnut|Children aged 0-18 years investigated for allergy to hazelnut
16349607|NCT04331522||Sesame|Children aged 0-18 years investigated for allergy to sesame
16349608|NCT04331522||Wheat|Children aged 0-18 years investigated for allergy to wheat
16349609|NCT04331522||walnut|Children aged 0-18 years investigated for allergy to walnut
16349610|NCT04331522||cashew|Children aged 0-18 years investigated for allergy to cashew
16349611|NCT04331522||Pistachio|Children aged 0-18 years investigated for allergy to pistachio
16349612|NCT04331522||Almond|Children aged 0-18 years investigated for allergy to almond
16349613|NCT04331522||Soy|Children aged 0-18 years investigated for allergy to soy
16349614|NCT04331522||Fish|Children aged 0-18 years investigated for allergy to fish
16349615|NCT04331522||Shellfish|Children aged 0-18 years investigated for allergy to shellfish
16349616|NCT04331522||Poppy seed|Children aged 0-18 years investigated for allergy to poppy seed
16349617|NCT04331509||Symptom tracker users|No Intervention
16349618|NCT04331496|Experimental|Hypertonic solution|Hypertonic solution 4 ml 3% , for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
16349619|NCT04331496|Active Comparator|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
16349703|NCT04330833|Experimental|Novel Communication Intervention|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the novel communication intervention group.
16349620|NCT04331483|Experimental|Physical activity intervention|"The intervention consists of an adapted physical activity (APA) program defined at baseline, incorporating supervised sessions with an APA teacher, as well as autonomous sessions. The program is individualized according to age, aerobic capacity, and PA preferences.
~The total duration of the intervention is a maximum of 3 months (during the period of hospitalization in a sterile room)."
16349621|NCT04331470|Experimental|Levamisole Pill + Budesonide+Formoterol inhaler+Standard care|This group will take Levamisole + Budesonide/Formoterol along side with standard treatment regime.
16349622|NCT04331470|Active Comparator|Standard care|This group will take standard treatment regime introduced by Ministry of health.
16349623|NCT04331444|Experimental|Group A, CGM|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin.
~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group A (intervention) will, in similarity to the HCPs, receive a CGM-education and training session led by the study investigator and will be interactive and hands-on, using case studies. The training session will include spoken and written instructions on how to insert and wear the CGM device and how to interpret the CGM information to better understand the relation between participants blood glucose and their diabetes self-management."
16349624|NCT04331444|Experimental|Group B, CGM + peer-support|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin plus 3 sessions of peer-support in groups of 6 participants.
~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group B (intervention incl. peer-support) will, in similarity to group A, receive a CGM-education and training session. The training and CGM-course for participants in group B are similar to the course for group A with the addition of three peer-support sessions. The approach will be participatory and adaptable to allow flexibility in the content of the peer-support sessions and involving customized use of participatory methods i.e. dialogue tools and exercises."
16349625|NCT04331444|Active Comparator|Group C, SMBG|"Standard self-monitoring of blood glucose according to standard guidelines, in 12 months.
~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly."
16349626|NCT04331431|Other|spinal cord tumors|
16349627|NCT04331418|No Intervention|control group|"On arrival to operating room, Noninvasive monitors, such as electrocardiography, noninvasive blood pressure (NIBP), oxygen saturation (SpO2), will be attached and baseline parameters such as heart rate, mean arterial pressure, and peripheral oxygen saturation will be recorded .
~General anesthesia will be induced with O2/sevo (FiO2 = 1 /sevoflurane 8% MAC), cis-atracurium 0.1 mg/kg iv, +/- fentanyl 1 mcg/kg iv. Trachea will be intubated with an appropriate sized, endotracheal tube and maintenance of anesthesia by O2/Air (FiO2 = 0.4), sevoflurane 2% MAC.
~Dexamethasone 0.15 mg/kg iv will be given as PONV prophylaxis. Increments of fentanyl 0.5 mcg/kg iv and cis-atracurium 0.03 mg/kg iv will be given according to hemodynamics and capnography."
16349628|NCT04331418|Experimental|caudal group|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
16349629|NCT04331418|Experimental|dexmetomidine group|Children in this group will be received (1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr) with a suggested maximum dose of 2 mcg/kg.of dexmedetomidine is available in a 100 mcg/mL concentration in a 2 mL preservative-free vial. It may be prepared as a 2 to 4 mcg/mL solution using normal saline
16349630|NCT04331405|Experimental|Pilot group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received hUCBMC infusions weekly (4 infusions overall) in addition to standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
16349631|NCT04331405|No Intervention|Control group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
16349632|NCT04331392|Experimental|Spatial navigation intervention|
16349633|NCT04331392|Active Comparator|Educational Videos|
16349634|NCT04331379|Experimental|Nasal Elevator|
16349635|NCT04331379|Active Comparator|Taping Alone|
16349636|NCT04331366|Experimental|Treatment with GO2 PEEP MOUTHPIECE|Participants receiving treatment with the GO2 PEEP MOUTHPIECE
16349637|NCT04331353|Active Comparator|Comparator 1 (tailored approach)|Multi-component intervention tailored to the participant's allergic profile.
16349638|NCT04331353|Active Comparator|Comparator 2 (insecticidal bait)|Insecticidal bait for cockroach reduction.
16349639|NCT04331340|Experimental|Pharmacist Intervention|Pharmacist assessment of LUTS, with recommendations and education regarding lifestyle, behaviour, and/or medications related to bladder health. Follow-up at 3 and 6 weeks.
16349640|NCT04331340|Active Comparator|Control|Pharmacist questions regarding presence of LUTS, with provision of healthy aging literature. Follow-up at 6 weeks.
16349641|NCT04331327|Active Comparator|Allogenic lyophilized growth factors|Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
16349642|NCT04331327|No Intervention|Standard of care|The patients were kept on their traditional medications without any intervention
16349643|NCT04331314|Experimental|SYMBIOS®|Sinus augmentation with SYMBIOS® Biphasic Bone Graft Material
16349644|NCT04331314|Active Comparator|Algipore®|Sinus augmentation with Algipore® Bone Substitution Material
16349645|NCT04331301|Active Comparator|vapoenucleation group|Group A
16349646|NCT04331301|Active Comparator|needlescopic enucleation|group B
16349701|NCT04330846|Experimental|SEMS group|"Post-procedural admission in the Short Stay Unit (SSU).
~Superficial sedation by endoscopist or anesthesiologist depending on the center.
~Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist
~Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion.
~Removal time of the prosthesis 4 weeks."
16349647|NCT04331288|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.
16349648|NCT04331275|Experimental|Viral Specific T-cells (VSTs)|
16349649|NCT04331236|Experimental|Patient and Caregiver Intervention|Patient and Caregivers receive both cognitive behavioral intervention and yoga interventions each week, for 7 weeks.
16349650|NCT04331210|Active Comparator|Group 1|Using diclofenac sodium suppository 50 mg immediately after suturing and then every 8 hours
16349651|NCT04331210|Active Comparator|Group 2|Using diclofenac sodium tablets 50 mg every 8 hours after birth
16349652|NCT04331197|Active Comparator|Clomiphene Citrate-High BMI women|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
16349653|NCT04331197|Active Comparator|Letrozole-High BMI women|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
16349654|NCT04331184|Experimental|RFA using combined bipolar and monopolar energy delivery|Control group: The historic cohort is used to compare the results of the conventional alternating unipolar radiofrequency energy transfer mode with RFA.
16349655|NCT04331171||Web-application users|questionnaire of comorbidity and symptomes completed by the user on his smartphone
16349656|NCT04331158|Experimental|Dry cupping group|The dry cupping will be applied with a force of two suctions generating a negative pressure on the skin during the time of 15 minutes.
16349657|NCT04331158|Placebo Comparator|Dry cupping sham group|The dry cupping sham group will receive the same procedures as the dry cup group, with the difference that the negative pressure imposed after application will be released in a few seconds.
16349658|NCT04331145|No Intervention|Clopidogrel 75 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:
~Normal basal platelet reactivity (PRU < 160 assessed with VerifyNow P2Y12 assay): Patients will continue with clopidogrel 75 mg/day until TAVI and during the following three months. All patients will be assessed by clinical follow up and platelet reactivity according to the protocol. Prescription of aspirin 100mg/day will be encourage as per guidelines recommendations."
16349659|NCT04331145|Active Comparator|Ticagrelor 60 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hrs before the index-TAVI procedure, patients with:
~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24 hours before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
16349660|NCT04331132|Placebo Comparator|Conventional diuretic group|The conventional furosemide treatment will follow the modified 2019 Position Statement from the ESC Heart Failure Association
16349661|NCT04331132|Active Comparator|Vasopressin-2 antagonist group|Tolvaptan 15mg once daily for 2 days will be added-on the furosemide strategy based on the modified 2019 Position Statement from the ESC Heart Failure Association
16349662|NCT04331119|Experimental|Duvelisib Maintenance|"Patients who received the standard BEAM regimen with autologous hematopoietic stem cells transplant will begin duvelisib maintenance at 25 mg PO BID after count recovery (approximately 30 days after transplant) for one year. If the patient is in a complete remission at day +100, with no evidence of disease on PET/CT, then the dosing schedule of duvelisib may be changed to 25 mg BID for 14 days, then 14 days off in 28 day cycles (at the treating physician's discretion). If the patient has residual disease, duvelisib will continue at 25 mg BID until they have a negative PET CT. PET CTs will be completed every 3 months for patients with residual disease. Duvelisib maintenance will be continued for one year post-transplant.
~Starting on 06/10/2021, all new participants will be enrolled to take 25 mg BID of duvelisib on days 1-14 of a 28 day cycle."
16349663|NCT04331106||Population in Germany|Reasonably large and representative sample of the general population in Germany
16349664|NCT04331093|Experimental|resectable stage III-IV Acral melanoma|
16349668|NCT04331067|Active Comparator|Arm A: Neoadjuvant chemo + nivolumab|-Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
16349702|NCT04330833|Active Comparator|Enhanced Usual Care Parent Education|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the enhanced usual care parent education group.
16349803|NCT04330196|Experimental|Glucose condition|In the experimental condition patients ingest 200ml of water containing 75g of glucose
16349669|NCT04331067|Experimental|Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab|"Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
~Cabiralizumab will be given IV at a dose of 4 mg/kg every 2 weeks for 12 weeks."
16349670|NCT04331054|Active Comparator|1: Usual practice|arm will be follow during 30 days
16349671|NCT04331054|Experimental|2: Usual practice + SYMBICORT RAPIHALER|Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)
16349672|NCT04331041|Experimental|MR-guided SBRT + Defactinib|"Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation).
~Participants who are candidates for surgical resection will undergo standard of care surgery at 2 weeks post-end of SBRT (+/- 1 weeks) or 12 weeks post-end of SBRT (+/- 1 week). These participants will discontinue defactinib the day prior to the operation and will resume taking it for the remainder of the 17 cycles 4 to 6 weeks after surgery. Participants who are not candidates for surgical resection will continue to receive defactinib uninterrupted. All participants should receive 17 cycles of defactinib unless they experience disease progression or intolerable toxicity."
16349673|NCT04331041|Active Comparator|MR-guided SBRT|-Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT)
16349674|NCT04331028|Experimental|Shockwave therapy|After dental extraction, a shockwave therapy will be applied to the area.
16349675|NCT04331028|No Intervention|Control|After dental extraction, no treatment will be applied
16349676|NCT04331002|Experimental|Experimental|The experimental group will receive a single 32 mg Zilretta injection approximately 4 weeks after meniscus surgery.
16349677|NCT04331002|Placebo Comparator|Placebo|The placebo group will receive a single 5 mL injection of normal saline approximately 4 weeks after meniscus surgery.
16349678|NCT04330989|Experimental|Group 1a: iNSC and Adherence supporter training|HIV-positive women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for ART.
16349679|NCT04330989|No Intervention|Group 1b: Standard of Care|HIV-positive participants randomly assigned to the control arm will antiretroviral educational material about HIV prevention and treatment (as appropriate to this arm).
16349680|NCT04330989|Experimental|Group 2a: iNSC and Adherence supporter training|HIV-negative women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for PrEP.
16349681|NCT04330989|No Intervention|Group 2b: Standard of Care|HIV-negative participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
16349682|NCT04330976|Experimental|Nutrition and physical activity intervention|
16349683|NCT04330976|Other|Control|
16349684|NCT04330963||Hypersomnolence group|All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)
16349685|NCT04330963||Healthy controls|
16349686|NCT04330963||SDB controls|Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.
16349687|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
16349688|NCT04330937|Experimental|experimental group|volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).
16349689|NCT04330937|Placebo Comparator|control group Placebo (sucrose)|volunteers consume 1 capsule per day for 3 months. (saccharose).
16349690|NCT04330924|Experimental|Virtual Reality|3D avatar in a virtual simulation environment
16349691|NCT04330924|No Intervention|Live Simulation|Live-based simulation in a simulation ward
16349692|NCT04330911|Experimental|The HIIT Group (High Intensity Interval Training Group)|
16349693|NCT04330911|Experimental|The MICT Group (Moderate Intensity Continous Training Group)|
16349694|NCT04330885|Experimental|Prehab group|"The patients in the PREHAB group will meet with a PT for 6 weeks pre surgery. The PT will coach the patient in 1:1 visits with a graded activity program with the purpose to affect fear of movement and raising level of self-efficacy with physical activity. The intervention comprises; cycling on a stationary cycle. Instructions of exercises that strengthen the deep and the superficial abdominal muscles and the back muscles. Information to contract the abdominal muscles in posturally loaded position to support their back. Information on flexion exercises of their lumbar spine and to keep the back in a flexed position when standing and walking (as opposed to extension). Recommendation to use Nordic walk (stavar) for outdoor walking"
16349695|NCT04330885|No Intervention|Care as usual|Control group will be treated with care as usual meaning information from a PT two weeks prior to the surgery with information on the surgery and to stay active. Both groups will be given information on to stay active and home exercises following the surgery.
16349696|NCT04330872|Active Comparator|Enteric coated Aspirin|"EC aspirin loading dose 300mg followed by 100 mg (2 days).
~The study's total duration is 3 days."
16349697|NCT04330872|Placebo Comparator|Plain Aspirin|"Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)
~The study's total duration is 3 days."
16349698|NCT04330859|Experimental|Intervention|Parent-driven intervention bundle of 6 evidence-based elements: vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy
16349699|NCT04330859|Placebo Comparator|Routine care|Routine care per unit guidelines
16349700|NCT04330846|Experimental|EBD group|"Post-procedural admission in the Short Stay Unit (SSU).
~Superficial sedation by endoscopist or anesthesiologist depending on the center.
~Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion.
~A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation.
~Dilation failure will be considered if > 2 dilations are required."
16349804|NCT04330196|Placebo Comparator|Control condition|In the control condition patients ingest 200ml of water sweetened with 700mg of aspartame
16349704|NCT04330820|Experimental|Venetoclax+Cytarabin+ Mitoxantron|The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
16349705|NCT04330807|Other|Patient with chronic kidney disease|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
16349706|NCT04330807|Other|CONTROL GROUP|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
16349707|NCT04330794|Experimental|NMFACT|record the caries index using the NMFACT chart
16349708|NCT04330794|Active Comparator|DMF index|record the caries index using the DMF chart
16349709|NCT04330781|Experimental|Intervention group|N=123
16349710|NCT04330781|Active Comparator|Control group|N=31
16349711|NCT04330768|Experimental|PRF|
16349712|NCT04330768|Active Comparator|MTA|
16349713|NCT04330755|Placebo Comparator|Group C|Control group will received saline
16349714|NCT04330755|Active Comparator|Group L|Levosimendan group will received levosimendan infusion
16349715|NCT04330755|Active Comparator|Group M|Levosimendan and Magnesium sulphate group will received both drugs
16349716|NCT04330742||0 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 0, at which time 0 mL of fluids will have been administered.
16349717|NCT04330742||250 mL crystalloid.|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 1, after the spinal has been placed and approximately 250 mL fluids has been administered.
16349718|NCT04330742||500 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 2, at which time 500 mL of fluids will have been administered.
16349719|NCT04330742||1000 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 3, at which time 1000 mL of fluids will have been administered.
16349720|NCT04330729|Experimental|Dialysis patients|Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.
16349721|NCT04330716|Active Comparator|Group A: Standard genetic counseling|Will receive standard genetic counseling prior to genetic testing.
16349722|NCT04330716|Experimental|Group B: Educational video|Will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing.
16349723|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
16349724|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
16349725|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
16349726|NCT04330690|No Intervention|Control|This arm will receive standard supportive care guidelines for COVID-19. This is expected the vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
16349727|NCT04330690|Experimental|Remdesivir plus standard supportive care|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
16349728|NCT04330690|Experimental|Interferon plus standard supportive care|Interferon-beta-1a, 22 or 44 micrograms subcutaneously on days 1, 3 and 6, plus optimized supportive care
16349729|NCT04330677|Experimental|1. Oxytocin spray, 2. Estrogen gel|
16349730|NCT04330677|Experimental|1. Oxytocin spray, 2. Placebo gel|
16349731|NCT04330677|Experimental|1. Placebo spray, 2. Estrogen gel|
16349732|NCT04330677|Placebo Comparator|1. Placebo spray, 2. Placebo gel|
16349733|NCT04330664|Experimental|Phase 1 Dose Exploration|Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849
16349734|NCT04330664|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens
16349735|NCT04330664|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination
16349736|NCT04330638|Placebo Comparator|Usual Care|
16349737|NCT04330638|Active Comparator|Anakinra|
16349738|NCT04330638|Active Comparator|Siltuximab|
16349739|NCT04330638|Active Comparator|Anakinra + Siltuximab|
16349740|NCT04330638|Active Comparator|Tocilizumab|
16349741|NCT04330638|Active Comparator|Anakinra + Tocilizumab|
16349742|NCT04330625|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for four weekly doses
16349743|NCT04330612|No Intervention|Control|In the control pathway, the surgeons communicated with the family only once near the completion of the procedure.
16349744|NCT04330612|Experimental|Intervention|In the intervention group, the families received additional standardized electronic updates via pagers.
16349745|NCT04330586|Experimental|Ciclesonide|Ciclesonide 320ug oral inhalation q12h for 14 days
16349746|NCT04330586|No Intervention|Control|Standard care without ciclesonide
16349747|NCT04330573||Chronic Non-Specific Neck Pain|Patients with chronic non-specific neck pain. No interventions
16349748|NCT04330573||Control/Healthy Group|Volunteers without pain. No interventions.
16349749|NCT04330560|Experimental|Electronic Activity Tracking system (EATs)|Receive the mHealth intervention by wearing activity tracker link with to the healthcare system with standard care
16349750|NCT04330560|Active Comparator|Fitness Tracker (FT)|Receive the mHealth intervention by wearing activity tracker without the link to the healthcare system
16349751|NCT04330560|Placebo Comparator|Control (C)|Standard care only
16349805|NCT04330183|Placebo Comparator|Normal Saline|Patients here will be administered 3cc of normal saline as placebo
16349806|NCT04330183|Experimental|Ketamine Interventions|Patients will be administered weight based 0.3mg/kg of ketamine
16349807|NCT04330144|Experimental|administration of hydroxychloroquine as PEP|
16349808|NCT04330144|Active Comparator|control with no PEP|
16349752|NCT04330547|Active Comparator|Analgesic administration|"The analgesic treatment will be tailored to the patient's medication and will be based on 3 levels (based on Ventafridda et al., 1985):
~Level 1 : Non-opioid analgesics
~Level 2 : Weak opioids analgesics
~Level 3 : Strong opioids analgesics
~If the patient is already on pain medications, we will add the lowest effective dose of the level above the level of the regular pain medications of the patient. (e.g. if the patient has no analgesic treatment, he will be given a non-opioid analgesic (level 1). If he already has a level 1 treatment, we will go for level 2 medication. If he has level 2 treatment, we will go for level 3. And if the patient is already at level 3, we will increase the dosage by steps (reference: 5mg oxycodone as first choice for level 3 drugs)). Preferably, the medication will be administered by oral intake or gastrostomy feeding tube. If it is not possible, other routes of administration are allowed."
16349753|NCT04330547|Placebo Comparator|Placebo administration|Folavit capsules will be used as a placebo
16349754|NCT04330534|Experimental|BCX9930|Parts 1, 2 and 3
16349755|NCT04330534|Placebo Comparator|Placebo|Parts 1 and 2 only
16349756|NCT04330508||Group A|Chronic hepatitis C without Cirrhosis
16349757|NCT04330508||Chronic hepatitis C with Cirrhosis|
16349758|NCT04330508||Healthy Volunteers|
16349759|NCT04330495|Experimental|Testing and prophylaxis of SARS-CoV-2|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
16349760|NCT04330495|Active Comparator|placebo|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
16349761|NCT04330482|Other|Internet Links|A tablet pre-loaded with a list of internet links relating to dementia caregiving that participants will be instructed to use at least 4 times weekly for 3 months.
16349762|NCT04330482|Experimental|CARE-Well App|A tablet pre-loaded with the CARE-Well app that participants will be instructed to use at least 4 times weekly for 3 months.
16349763|NCT04330469|Experimental|Periodontal therapy|Patients offered periodontal therapy in 2-4 sittings (n=40), Dental hygiene advised
16349764|NCT04330469|Sham Comparator|Control|Patients given standard medical treatment (n=40), Dental hygiene advised
16349765|NCT04330456|Experimental|SaE treatment|"This group will receive combined treatment of soft tissue sarcoma that include 3 steps:
~step - preoperative stereotactic radiation therapy in hypofractionation mode (5 fractions 5 Gy each)
~step - operation
~step - postoperative conformal radiation therapy in normofractionation mode (25 fractions 2 Gy each)"
16349766|NCT04330443|Experimental|Ultrasound group|The neonatologist-researcher (NR) performed the lung ultrasound at admission during the first hour of life. The neonatologist-assistant (NA) of the baby was not blinded to the result of the lung ultrasound. If the patient had a lung ultrasound score higher than >8 or when FiO2 exceeded 30% patient received surfactant therapy during in the first 72 hours of life
16349767|NCT04330443|No Intervention|Chest X Ray|The NR performed the LUS at admission/suspicion during the first hour of life. The NA was not blinded to the result of the LUS. Patient received surfactant therapy only when FiO2 exceeded 30% during the first 72 hours of life
16349768|NCT04330430|Experimental|T-VEC + Nivolumab|Patients will receive pre-surgically 4 courses T-VEC (up to 4ml; first dose 10^6 PFU per mL, subsequent doses at 10^8 PFU per mL). Patients will also receive a flatdose of 240mg Nivolumab every 2 weeks after the first T-VEC injections (starting at 2nd T-VEC course at week 3, followed by the next doses at week 5 and 7).
16349769|NCT04330417|Experimental|EMG Glove Group|A total of 12 sessions of robot-assisted hand training for 6 consecutive weeks.
16349770|NCT04330417|Active Comparator|Control Group|A total of 12 session of standard hand therapy sessions in 6 consecutive weeks.
16349771|NCT04330404|Experimental|Cognitive strategy training|The experimental group will receive the Cognitive strategy training (CST), which includes awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments.
16349772|NCT04330404|Active Comparator|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
16349773|NCT04330391|No Intervention|Usual Care|Individuals randomized to the usual care group will receive standard care. This may include a physical therapist and/or nutritionist referral. Brigham and Women's Hospital offers several programs for patients interested in losing weight, including the Nutrition Wellness Service (NWS) and Program for Weight Management (PWM). Insurance coverage for these programs varies by patient insurance.
16349774|NCT04330391|Experimental|Intervention|Intervention subjects will use the Nutrimedy mobile app and be connected at enrollment with a registered dietitian who will contact intervention participants weekly or bi-weekly via video calls and unlimited in-app text messaging for up to three months. The first week will include either one 55-minute video session or two 25-minute sessions. Weeks 2-4 will have weekly 25-minute video calls, and weeks 5-12 will have biweekly 25-minute sessions for a total of 8-9 sessions over 12 weeks. Together, participants and dietitians will come up with goals for the 12 weeks, and dietitians will check on progress toward these goals using in-app tools such as food logs and messaging between video calls. All patients will be encouraged to lose at least 20 pounds with a goal BMI<40 kg/m2 after 12 weeks. The intervention group will also receive all aspects of the usual care arm including the opportunity to have a physical therapist and/or nutritionist referral.
16349775|NCT04330378||Hospital-at-home|All patients who are enrolled into the NUHS@Home Programme will be recruited into this arm. Patients will be sent home via ambulance, where they will be reviewed by a NUHS@Home nurse. Intravenous therapies, pillboxes for medication, remote monitoring software, and telecommunication tools will be set up as indicated. NUHS@Home doctors will visit at least once daily, and nurses at least twice daily as required. Therapists will conduct home visits as necessary. The NUHS@Home team is available 24/7. When conventional discharge criteria are met, the patient will be discharged. The NUHS@Home clinical team will be under clinical governance of Division of Advanced Internal Medicine at NUH and patients will be considered 'inpatients' throughout the treatment period.
16349776|NCT04330378||Usual in-hospital care|Patients who would otherwise be eligible for NUHS@Home but are not able to be enrolled due to capacity will be recruited into this arm. They will receive usual care in the wards that they are already in until they are discharged.
16349777|NCT04330378||Rejected cohort|Patients who were offered but declined enrolments inot the NUHS@Home programme will be approached for consent to be in the rejected cohort. There will be no change to the patient's clinical management.
16349778|NCT04330365|Active Comparator|Whole Health Team (WHT) Intervention Arm|The WHT intervention arm includes four core elements: 1) An interdisciplinary WHT collaborating with primary care; 2) Personalized Health Planning with prioritization of multi-modal non-pharmacological and CIH pain management approaches; 3) Whole Health Coaching sessions to assist patients in developing and implementing a Personalized Health Plan for chronic pain care; and 4) the web/mobile Whole Health Resource Directory provided to patient participants (in addition to their providers) to support non-pharmacologic/CIH chronic pain care.
16349779|NCT04330365|Active Comparator|Primary Care Group Education (PC-GE) Intervention Arm|Primary Care Group Education (PC-GE) iss the comparator arm, which is an abbreviated form of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) adapted for group use in primary care.
16349780|NCT04330365|Placebo Comparator|Usual Primary Care (UPC) Arm|In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
16349781|NCT04330352|Experimental|"Mindfulness-based STOP touching your face intervention"|"Eligibility participants who are allocated to the intervention group will be required to find a time to monitor and record their behavior of hand-to-face contacts, including the frequency and length (in second) of face-touching in any of the mucosal area (eyes, nose, mouth) and nonmucosal area (ears, cheeks, chin, neck, forehead, hair) during a 60-minute period. Then, they will receive the online mindfulness-based STOP touching your face program. Each participant will be required to practice this technique until they feel confident and natural. The systematic review showed the efficacy of single session of brief MBIs, the average length was 15 minutes, ranged from less than 5 to 25 min. Thus, the requirement practice time will be at least 15 minutes (excluding the time of reading the text and the first time of listening to the audio). Later (at least 1-hour interval), they will be asked to self-monitor and report their one-hour face-touching behavior again."
16349782|NCT04330352|No Intervention|Contron information intervention|"Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive STOP touching your face program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval."
16349783|NCT04330339|Experimental|Fasting|"Eligible participants will undergo baseline assessments prior to starting the intervention.
~Baseline assessments include measurements of weight, height, quality of life, fatigue, mood, levels of physical activity, and blood markers.
~Participants will fast for 13 hours nightly for 12 weeks.
~Assessments will be repeated at the completion of the 12-week intervention."
16349784|NCT04330326|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
16349785|NCT04330326|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
16349786|NCT04330313|Experimental|Traction and stretching|This grup received stretching exercises after traction therapy for 18 sessions, 3 times per week.
16349787|NCT04330313|Experimental|Laser therapy and stretching|This grup received stretching exercises after laser therapy for 18 sessions, 3 times per week.
16349788|NCT04330313|Experimental|Hot pack and stretching|This grup received stretching exercises after hotpack therapy for 18 sessions, 3 times per week.
16349789|NCT04330313|Experimental|Stretching only|This grup received only stretching exercises for 18 sessions, 3 times per week.
16349790|NCT04330300|Experimental|Alternative anti-hypertensive medication|Switch to an alternative BP medication (specifically a Calcium channel blocker [CCB] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.
16349791|NCT04330300|Active Comparator|Continue ACEi/ARB antihypertensive|Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.
16349792|NCT04330274||Group 1|Unilateral transtibial amputee
16349793|NCT04330274||Group 2|Unilateral transfemoral amputee
16349794|NCT04330261||SARS-CoV-2 Positive Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
16349795|NCT04330261||SARS-CoV-2 Negative Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-negative for SARS-CoV-2 will be considered the unexposed (control) group in this study. These children will have exactly the same prospective follow-up as the other group.
16349796|NCT04330248|Experimental|Erdafitinib and Rifampin|Participants will receive single oral dose of erdafitinib dose 1 on Day 1 after an overnight fast of at least 10 hours in Period 1 followed by repeated doses of rifampin orally (once daily Days 15 to 28) after an overnight fast of at least 10 hours in Period 2. After 6 Days of rifampin treatment, on Day 21, participants will receive a single oral dose of erdafitinib dose 1 with that day's rifampin dose.
16349797|NCT04330235||Intervention Group|Children 2-10 years of age dining at fast-food restaurants in New York City and Philadelphia, where a healthy default beverage policy will be enacted.
16349798|NCT04330235||Control Group|Children 2-10 years of age dining at fast-food restaurants in northern New Jersey, where a healthy default beverage policy will not be enacted.
16349799|NCT04330222||Patients with lacunar stroke due to SVD|
16349800|NCT04330222||Healthy stroke free volunteers|
16349801|NCT04330209||LowGI/nutrigenetic|"114 overweight (n=1) and obese (n=113) subjects (M = 55, F = 59, age 24-56y, all of Romanian heritage and similar socio-economic status), who were patients at a weight management clinic (Bucharest, Romania), gave written informed consent for their weight loss data to be prospectively analysed for this study.
~Upon enrolment at the weight management clinic, the subjects self-selected either a ketogenic diet or a low-GI nutrigenetic diet. 61 subjects (34 female; age 42.0 ± 6.7y) selected the low-GI nutrigenetic diet plan."
16349802|NCT04330209||Ketogenic|As above + Fifty-three subjects (25 female; age 43.0 ± 7.2y) selected the ketogenic diet plan
16349809|NCT04330131|Experimental|Treated families|The treated families will complete up to 3 interventions: 3Ts - Newborn, 3Ts - Well Baby, and 3Ts - Let's Talk! The ideal progression is that treated families will complete all three interventions. Before completing their first intervention, participants will complete set of baseline surveys measuring their knowledge and beliefs about child development. They will repeat these measures when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
16349810|NCT04330131|No Intervention|Comparison Families|Comparison families will not receive any of the 3Ts interventions but will complete the same surveys as the treatment group at study enrollment and again when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
16349811|NCT04330118||20 patients with DRESS syndrome|
16349812|NCT04330118||20 patients with drug induced MPE with eosinophilia|patients with drug induced maculopapular exanthema (MPE) with eosinophilia
16349813|NCT04330118||20 patients with drug induced MPE without eosinophilia|
16349814|NCT04330118||20 Healthy subjects|
16349815|NCT04330079|Experimental|Dapagliflozin|
16349816|NCT04330079|Other|Lifestyle modification|
16349817|NCT04330066||Exogenous hormone replacement thaw cycle|Participants in this group will follow Boston IVF's standard exogenous hormone replacement protocol. Participants will take Estrace 3mg twice daily by mouth for endometrial preparation. After 16-18 days of Estrace, endometrial thickness will be measured by transvaginal ultrasound but medication and ultrasounds will be continued until the endometrial lining is ≥ 7 mm. Once the final endometrial lining is ≥ 7 mm (T1), the doctor of record will start the participant the following day with intramuscular progesterone daily or intramuscular progesterone every 3 days with daily vaginal progesterone. Frozen embryo transfers would occur on the sixth day of progesterone.
16349818|NCT04330066||Natural thaw cycle|Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone < 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.
16349819|NCT04330053|Experimental|Experimental|Information - Education about falls and Exercise for Fall Prevention
16349820|NCT04330053|Active Comparator|Control|Information - Education about falls without Exercise for Fall Prevention
16349822|NCT04330027|Experimental|Growth factors|Patients in this group will receive one lyophilized Growth Factors injection supplied as a powder in a tightly sealed container.
16349823|NCT04330027|Placebo Comparator|Saline|Patients in this group will receive an injection with equal volume of saline; i.e 2ml of 0.9% sodium chloride.
16349824|NCT04329988||Primary care patients aged 18 or more|All patients consulting in a general practitioner office, aged 18 or more, who completed the questionnaire
16349825|NCT04329975||Participants with Nocturia|Participants with nocturia due to nocturnal polyuria treated with MINIRINMELT OD Tablet 25μg or 50μg as per daily clinical practice.
16349826|NCT04329962|Experimental|Group I (blueberry extract, blueberry powder)|Participants undergo a washout on days -7 to -1 and then consume blueberry extract confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry powder confection on day 8.
16349827|NCT04329962|Experimental|Group II (blueberry powder, blueberry extract)|Participants undergo a washout on days -7 to -1 and then consume blueberry powder confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry extract confection on day 8.
16349828|NCT04329949|Experimental|Relacorilant with nab-paclitaxel|Patients will be treated with relacorilant, administered orally, once daily in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
16349829|NCT04329923|Active Comparator|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
16349830|NCT04329923|Placebo Comparator|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
16349831|NCT04329923|Experimental|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
16349832|NCT04329923|Active Comparator|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
16349833|NCT04329923|Experimental|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
16349834|NCT04329923|Placebo Comparator|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
16349835|NCT04329910||Lean|BMI < 25
16349836|NCT04329910||overweight|BMI 25 - 29.9
16349837|NCT04329910||class i obesity|BMI 30 -34.9
16349838|NCT04329910||class ii obesity|BMI 35 - 39.9
16349839|NCT04329910||class iii obesity|BMI >= 40
16349840|NCT04329897|Experimental|Software Messaging|Acceptance and Commitment Therapy Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy
16349841|NCT04329897|No Intervention|Control|Subjects randomizing into this arm did not receive the text message study intervention.
16349842|NCT04329884|Active Comparator|Intra-articular corticosteroid injections|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. Radiology guidance will be used to guide needle placement within the affected hip to administer lidocaine and a corticosteroid intra-articularly.
16349883|NCT04329598|Experimental|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
16349843|NCT04329884|Active Comparator|Cooled radiofrequency ablation|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. The HALYARD* COOLIEF* SINERGY* Cooled Radiofrequency Probe (sterile, single use) is inserted through a COOLIEF* SINERGY* Introducer used with fluoroscopy guidance in the AP view to visualize the hip joint and sensory nerve areas over the acetabulum (femoral) and ischium (obturator) where the cooled radiofrequency ablation will be applied to create a focal thermal lesion to encompass and denervate the targeted nerves.
16349844|NCT04329858|Active Comparator|conventional glass ionomer|
16349845|NCT04329858|Experimental|zinc modified glass ionomer|
16349846|NCT04329858|Experimental|silver modified glass ionomer|
16349847|NCT04329845|Active Comparator|open splenectomy for splenic injury in trauma|open splenectomy as a technique for removal of the spleen in case of injury to spleen
16349848|NCT04329845|Active Comparator|laparoscopic splenectomy for splenic injury in trauma|laparoscopic splenectomy as a technique for removal of the spleen in case of injury to spleen
16349849|NCT04329832|Experimental|Hydroxychloroquine|
16349850|NCT04329832|Active Comparator|Azithromycin|
16349851|NCT04329806|Experimental|Moxonidine|Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
16349852|NCT04329806|Active Comparator|Amlodipine|Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
16349853|NCT04329793|Experimental|Intervention arm|Assisted gait training with Walkbot System and their usual Physical Therapy.
16349854|NCT04329793|Active Comparator|Control arm|Their usual Physical Therapy.
16349855|NCT04329767||IRIS Arm|Utilize the CT scan along with the IRIS 3D model preoperatively and intraoperatively
16349856|NCT04329767||CT Arm|Utilize only the standard 2D CT scan preoperatively and intraoperatively
16349857|NCT04329754|Other|iPure|"IPure IOL (PhysIOL, Belgium): a new single-piece hydrophobic acrylic IOL. The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration.
~Patient were allocated into two groups. The study group received the iPure lens (Physiol, Liege) while the control group received Tecnis ZCB00 (Johnson&Johnson). Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
16349858|NCT04329754|Other|ZCB00|"ZCB00 IOL (Johnson&Johnson, United States): a standard IOL.The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design.
~Patient were allocated into two groups. The study group received the iPure lens (Physiol, Liege) while the control group received Tecnis ZCB00 (Johnson&Johnson). Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
16349859|NCT04329741|Experimental|Intervention|6-week basic dog obedience training course
16349860|NCT04329741|No Intervention|Control|Waitlist control
16349861|NCT04329728|Experimental|DLBCL and high-grade B-cell lymphoma|Diffuse Large Cell B-Lymphoma High-grade B-cell Lymphoma
16349862|NCT04329728|Experimental|MCL (Chronic Lymphoid Leukemia)|Chronic Lymphoid Leukemia
16349863|NCT04329728|Experimental|Primary Mediastinal Large B-cell lymphoma|Primary mediastinal large B-cell lymphoma
16349864|NCT04329728|Experimental|Burkitt or Burkitt-like lymphoma/leukemia|Burkitt or Burkitt-like lymphoma/leukemia
16349865|NCT04329728|Experimental|CLL/SLL|Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
16349866|NCT04329728|Experimental|B- or T-ALL|B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma
16349867|NCT04329715|Experimental|Expedited instructions|
16349868|NCT04329715|Active Comparator|Restricted instructions|
16349872|NCT04329689|Experimental|septal myectomy alone versus septal myectomy|"The aims of the present study is to:
~Compare the results of adequate septal myectomy alone versus septal myectomy + mitral repair in patients with HOCM.
~Effect of mitral repair on outcome of patients with systolic anterior motion that accompanies HOCM."
16349873|NCT04329676|Experimental|Deep Brain Stimulation|Patients will undergo bilateral implant of directSTIM system in the STN.
16349874|NCT04329663|Experimental|training group|Ten children with ADHD who got the 20 sessions training of the Indonesian computer-based game prototype. They we were assessed by CATPRS, BRIEF and fMRI BOLD
16349875|NCT04329650|Experimental|Siltuximab 11mg/Kg|
16349876|NCT04329650|Active Comparator|Methylprednisolone 250mg/24h|
16349877|NCT04329637|Active Comparator|IHC (intergrative health care) arm|Meditation and care coordination in addition to usual care
16349878|NCT04329637|No Intervention|usual care|usual care
16349879|NCT04329624|Active Comparator|Levosimendan|Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
16349880|NCT04329624|Placebo Comparator|Placebo|Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
16349881|NCT04329611|Active Comparator|hydroxychloroquine|hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days
16349882|NCT04329611|Placebo Comparator|Placebo|Matching Placebo
16350086|NCT04328064|Active Comparator|Rosuvastatin Drug|Active drug-rosuvastatin 40 mg
16349884|NCT04329598|Experimental|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
16349885|NCT04329585|Experimental|GABA antagonist|In the end of the experiment, 0.2mg of flumazenil(GABA antagonist) is given to the participant.
16349886|NCT04329585|Placebo Comparator|Placebo|In the end of the experiment, the same volume of normal saline is given to the participant.
16349887|NCT04329572|Experimental|HCQ + AZT|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) and AZT (500 mg/ 5 days) on top of standard care.
16349888|NCT04329546||Cases|Cases are patients with COVID-19.
16349889|NCT04329546||Contacts|Contacts are household contacts of an index (case) patient.
16349890|NCT04329533|Experimental|Intervention Group - access to meditation app|"Will receive a 30-day free trial of the mobile meditation app Calm on study day 0"
16349891|NCT04329533|No Intervention|Control Group - no access to meditation app|"Will not have the intervention until after the 30 day study period and then will receive a 30-day free trial of the mobile meditation app Calm on study day 30"
16349892|NCT04329494|Experimental|Arm I (PIPAC, cisplatin, doxorubicin)|Patients with ovarian, uterine, appendiceal, or gastric cancer, undergo PIPAC with cisplatin, followed by doxorubicin. Treatment repeats every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16349893|NCT04329494|Experimental|Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)|Patients with colorectal cancer undergo PIPAC with oxaliplatin. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16349894|NCT04329481|Active Comparator|mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder. These include Shiitake, Maitake, Trametes Coriolus Versicolor, Agaricus.
~Compliance to treatment will be considered as taking 80% of supplement/placebo treatment, and will be monitored by telephone calls and emails to patients during the study phase, and by counting the pills which were not taken at the end of the trial.
~Treatment with Mycodigest supplement will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
16349895|NCT04329481|Placebo Comparator|placebo|"will be be identical in size, shape and color to Mycodigest Treatment with Mycodigest placebo will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
16349896|NCT04329468|Experimental|DS-MCE examination|Subjects with or without digestive symptoms will be enrolled to take DS-MCE and conventional esophagogastroduodenoscopy (EGD) within 48h successively.
16349897|NCT04329455||Intervention group|
16349898|NCT04329442|Experimental|PrEP Received|Participants will be provided with a free 30-day supply of PrEP.
16349899|NCT04329429|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.5 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
16349900|NCT04329416|Other|Predicted depth of insertion|The predicted insertion depth of the DLT was calculated using the formula [0.249 x (BH) 0.916] before induction of anesthesia using an application on the smartphone
16349901|NCT04329403|Experimental|Test Group|Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks
16349902|NCT04329403|Active Comparator|Reference Group|Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks
16349903|NCT04329403|Placebo Comparator|Placebo Group|Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks
16349904|NCT04329390||anticoagulant|Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.
16349905|NCT04329377||platelet count in iiron overload|
16349906|NCT04329364|Experimental|Laser Haemorrhoidoplasty (LAH)|treatment that we would like to study
16349907|NCT04329364|Active Comparator|Conventional Open Haemorrhoidectomy (COH)|gold standard treatment as comparator
16349908|NCT04329351|Experimental|Guided bone regeneration Group|After extraction, Guided bone regeneration was conducted using the PTFE-d membrane (CytoplastTM Ti-250 Titanium-Reinforced, Anterior Narrow 12 mm x 24 mm, Osteogenics, Lubbock, TX, USA) was customized with scissors and adjusted over the socket, exceeding three millimeters from its margins. Then, the membrane was inserted subperiostally under the buccal and palatal flaps with the help of the Molt detacher. Minimal flap reflection was performed to stabilize the membrane, which was maintained intentionally exposed to the oral environment. Before suturing, the passive stability of the membrane over the alveolus was confirmed, as well as the absence of folds or wrinkles in the membrane. The flaps were then be approached in the pre-extraction position and sutured with crossed sutures, aiming to increase the stability of the membrane, with PTFE 4-0 thread (Cytoplast PTFE, CS0618PREM, Osteogenics, Lubbock, TX, USA).
16349909|NCT04329351|Placebo Comparator|Non-Guided bone regeneration group|After extraction, no further treatment (No addition of Guided bone regeneration) was performed. The flaps were then repositioned and sutured with 5.0 nylon thread (Ethicon, Jonhson's Jonhson, São José dos Campos).
16349910|NCT04329338|No Intervention|Gut and vaginal sample collection|Gut and vaginal samples were collected for Nugent score, and 16S rRNA metagenomics communities.
16349911|NCT04329338|Experimental|Gut and Vaginal sample after Lactobacillus|Seven women diagnosed with BV by Nugent score (7-10) provided vaginal and gut sample after 14 days oral intake of 3 grams (2.5X108 cfu/g) of Lactobacillus pentosus KCA1
16349942|NCT04329104|Experimental|Dose-escalation study: Arm 3: 40 mg/kg of CIS43LS|Participants will receive 40 mg/kg of CIS43LS on Day 0. After the last participant in Arm 3 reaches Day 7 safety follow-up, an interim safety evaluation will be performed before enrollment begins for the Efficacy study.
16349943|NCT04329104|Experimental|Efficacy study: Arm 1: 10 mg/kg of CIS43LS|Participants will receive 10 mg/kg of CIS43LS on Day 0
16349944|NCT04329104|Experimental|Efficacy study: Arm 2: 40 mg/kg of CIS43LS|Participants will receive 40 mg/kg of CIS43LS on Day 0.
16349945|NCT04329104|Placebo Comparator|Efficacy study: Arm 3: Placebo|Participants will receive placebo on Day 0.
16349912|NCT04329325|Experimental|Blinatumomab & Concurrent Oral Tyrosine Kinase Inhibitor (TKI)|Patients may receive steroids and hydroxyurea pre-study entry and receive a 7-day steroid prephase before starting TKI therapy. Planned initial TKI is dasatinib 140 mg daily; dasatinib dose may be reduced or TKI may be changed to a different agent under certain conditions. Induction consists of continuous TKI + 24 days of dexamethasone, followed by taper of dexamethasone, with bone marrow aspirate/biopsy (BMA) and CNS prophylaxis at days 22 and 43. Patients achieving morphologic complete response post-induction proceed to consolidation with up to 3 cycles of blinatumomab (28-day cycles, 14 days between cycles) + TKI, with BMA and CNS prophylaxis between cycles. Patients achieving complete molecular response may proceed to maintenance with up to 4 more cycles of blinatumomab (28-day cycles with 28 days between cycles) + TKI, with CNS prophylaxis between cycles and BMA after cycles 5 and 7. Patients can come off study to undergo allogeneic hematopoietic cell transplantation at any time.
16349913|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349914|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349915|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349916|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349917|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349918|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349919|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
16349920|NCT04329299||Blood Biomarkers Analyses|15 ml of blood sample will be obtained from each study participant, for blood-based biomarkers analyses.
16349921|NCT04329273|Experimental|Training group|"For the balance exercise the participants will perform one-legged stance of certain duration, on a stable surface.
~For the sliding leg curl exercise the participants lay supine on a mat, wearing only socks in order to create a slippery surface between their heels and the gym floor. The player begins by extending the hip and having the working leg on knee flexion. The contralateral limb is on hip flexion and knee flexion. The base of support is the shoulder blades, the elbows and the heel of the working leg. After assuming this position, the player begins to extend the knee, as slowly as possible, resisting the low friction properties of the ground.
~The core stability program consists of front plank, side planks, supine bridge, leg lowering and superman exercise. These exercises will be performed at the end of the training session, in contrast to the balance and hamstring exercises which will be executed before the training session."
16349922|NCT04329273|No Intervention|Control group|The participants in this group will follow only the usual training program
16349923|NCT04329260||Pediatric population|"Children between 3 to 18 years old with severe (BMI> IOTF-30) and early (before the age of 6) obesity.
~A Saliva sample for screening of the deletion Δ6-8 of LEPR gene will be performed for each child."
16349924|NCT04329260||Adult member family|The screening of the same deletion according the same procedure will be proposed to the adult family member if the child presents the deletion Δ6-8 of LEPR gene.
16349925|NCT04329247|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 6 weeks.
16349926|NCT04329247|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 6 weeks. After this period of time, participants will begin the best treatment available.
16349927|NCT04329234||acute heart failure|Patients with acute heart failure
16349928|NCT04329221|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
16349929|NCT04329221|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
16349930|NCT04329208||Cerebral vasospasm|13 patients developed symptomatic cerebral vasospasm detected by CT angiography and TCD
16349931|NCT04329208||Non Vasospasm|27 patients without cerebral vasospasm
16349932|NCT04329195|Experimental|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
16349933|NCT04329195|Active Comparator|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
16349934|NCT04329169|Experimental|Virtual Implant Planning|
16349935|NCT04329156|Experimental|Digitally Flip Technique|
16349936|NCT04329156|Active Comparator|Stock Healing Abutment|
16349937|NCT04329143|Active Comparator|open completion cholecystectomy|open completion cholecystectomy for cystic duct stump stone
16349938|NCT04329143|Active Comparator|laparoscopic completion cholecystectomy|lap completion cholecystectomy for cystic duct stump stone
16349939|NCT04329130|Experimental|Chidamide combined Lenalidomide|"Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days.
~one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator."
16349940|NCT04329104|Experimental|Dose-escalation study: Arm 1: 5 mg/kg of CIS43LS|Participants will receive 5 mg/kg of CIS43LS on Day 0. Once all participants in Arm 1 reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin for Arm 2.
16349941|NCT04329104|Experimental|Dose-escalation study: Arm 2: 10 mg/kg of CIS43LS|Participants will receive 10 mg/kg of CIS43LS on Day 0. Once all participants in Arm 2 reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin for Arm 3.
16349946|NCT04329091|Experimental|Dexmedetomidine Arm|Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.
16349947|NCT04329065|Experimental|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16349948|NCT04329052|Experimental|Experimental group|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
16349949|NCT04329052|No Intervention|Control group|Participants would have their usual activity without any intervention.
16349950|NCT04329039|Active Comparator|Group 1|Active somatostatin analogue combined with perioperative antibiotics
16349951|NCT04329039|Placebo Comparator|Group 2|Placebo combined with perioperative antibiotics
16349952|NCT04329026|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
16349953|NCT04329026|Placebo Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
16349954|NCT04329013|Active Comparator|Left lateral position|The patient will be in left lateral position during EGD
16349955|NCT04329013|Experimental|Prone position|The patient will be in prone position during EGD
16349956|NCT04329000|Experimental|On-demand PPI therapy|The patients in this group were advised to take PPI for 8 weeks continuously, followed by on-demand PPI therapy for the following 40 weeks.
16349957|NCT04329000|Active Comparator|Continuous PPI therapy|The patients in this group were advised to take PPI QD continuously for 48 weeks.
16349958|NCT04328987||Clopidogrel user|"* Uninterrupted (continuous) use of clopidogrel: cessation of clopidogrel less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of clopidogrel is sum of before and after the CSP
~patient who stopped clopidogrel only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 1 day.
~patient who stopped clopidogrel from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of clopidogrel -> excluded from study.
~patient who stopped clopidogrel from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of clopidogrel was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of clopidogrel -> excluded from study."
16349959|NCT04328987||Aspirin user|"* Uninterrupted (continuous) use of aspirin: cessation of aspirin less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of aspirin is sum of before and after the CSP
~patient who stopped aspirin only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 1 day.
~patient who stopped aspirin from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of aspirin -> excluded from study.
~patient who stopped aspirin from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of aspirin was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of aspirin -> excluded from study."
16349960|NCT04328974||the lumbar CSF drainage group|We named the patients treated with the protocol and the lumbar CSF drainage as the lumbar CSF drainage group.
16349961|NCT04328961|Placebo Comparator|Ascorbic Acid|Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days
16349962|NCT04328961|Experimental|Hydroxychloroquine|Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days
16349963|NCT04328948|Experimental|Chemoradiation therapy with elective nodal irradiation|Chemoradiotherapy consists of 5-FU (1,000 mg / m2, day1-4, day29-32), CDDP (75 mg /m2, day1, 29) and radiotherapy (50.4 Gy/28Fr)
16349964|NCT04328948|Active Comparator|Chemoradiation therapy with involved field irradiation|Chemoradiotherapy consists of 5-FU (700 mg /m2, day1-4, day29-32), CDDP (70 mg /m2, day1,29) and radiotherapy (60 Gy/30Fr)
16349965|NCT04328935|Experimental|written exposure therapy|The treatment consists of written exposure therapy (WET), which is manualized trauma-focused CBT in five sessions over 5 weeks.
16349966|NCT04328922|Active Comparator|Fecal microbial transplantation|FMT capsules fecal capsules on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will be matched to donors according to their CMV status (past exposure - CMV positive donors will be used for CMV positive patients, and CMV negative donors will be used for CMV negative patients).
16349967|NCT04328922|Placebo Comparator|Placebo|Placebo capsules placebo capsules- on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will receive placebo capsules.
16349968|NCT04328909|Experimental|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
16349969|NCT04328909|Active Comparator|Control Group|Usual care - No E-Care app will be provided
16349970|NCT04328896|Experimental|Intervention|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
16349971|NCT04328883|Active Comparator|162 mg Non-Enteric-Coated Chewable aspirin|Non-enteric coated aspirin (162mg, single dose)
16349972|NCT04328883|Experimental|50 mg ASA inhalation powder|Dry powder inhaled aspirin (50mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
16349973|NCT04328883|Experimental|100 mg ASA inhalation powder|Dry powder inhaled aspirin (100mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
16349974|NCT04328870|Active Comparator|oxytocin and spinal anesthesia|spinal anesthesia combined with intravenous oxytocin infusion
16349975|NCT04328870|Active Comparator|general anesthsia|general anesthesia alone
16349980|NCT04328805|Experimental|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
16349981|NCT04328805|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
16349982|NCT04328792||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
16349983|NCT04328779|Experimental|multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks.
16349984|NCT04328779|Active Comparator|multi-task treadmill walking|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill.
16349985|NCT04328779|Active Comparator|traditional rehabilitation|Traditional rehabilitation group will train strength, balance, and gait.
16349986|NCT04328766|Experimental|DWP14012 Cohort A|
16349987|NCT04328766|Experimental|DWP14012 Cohort B|
16349988|NCT04328766|Experimental|DWP14012 Cohort C|
16349989|NCT04328753|Experimental|super oxidized water group|
16349990|NCT04328753|Active Comparator|chlorhexidene group|
16349991|NCT04328753|Placebo Comparator|distilled water|
16349992|NCT04328740|Experimental|Monotherapy|TP-1454
16349993|NCT04328740|Experimental|Combination Therapy|TP-1454, ipilimumab and nivolumab
16349994|NCT04328727|Experimental|eltrombopag|Participants will receive eltrombopag in combination with r-ATG and CsA.
16349995|NCT04328714|Experimental|Adult Population|Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
16349996|NCT04328714|Experimental|Pediatric Population|Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
16349997|NCT04328701|Experimental|Mindfulness-based CBT|All participants will receive four individual mindfulness-based CBT sessions.
16349998|NCT04328701|No Intervention|Treatment as Usual|All participants will undergo surgery as usual, with no additional intervention.
16349999|NCT04328662||Cohort 1: Participants with RRMM|Participants diagnosed with relapsed or refractory multiple myeloma (RRMM) who have received at least one dose of ixazomib plus lenalidomide - low dose dexamethasone (IRd) treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
16350000|NCT04328662||Cohort 2: Participants with NDMM, RRMM, and Non-myeloma|Participants with NDMM, RRMM, and Non-myeloma Participants diagnosed with newly diagnosed multiple myeloma (NDMM) who have received at least one dose of ixazomib-based regimen treatment and diagnosed with RRMM who have received at least one dose non-IRd ixazomib-based regimens treatment, and diagnosed with non-myeloma who have received at least one dose of ixazomib-based regimens treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
16350001|NCT04328636|Experimental|NebMag|Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
16350002|NCT04328636|Active Comparator|IVMag|Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo
16350003|NCT04328623|Active Comparator|Infiltration|Ultrasound-guided hand infiltration
16350004|NCT04328623|Experimental|Hypnosis|Hypnosis before Ultrasound-guided hand infiltration
16350005|NCT04328610|Experimental|LYMPHA technique group|LVA at the time of Axillary Dissection
16350006|NCT04328610|No Intervention|Non-LYMPHA technique group|No preventive surgical approach
16350007|NCT04328597||Chronic postoperative pain|Patients scoring 3 or more on the EuraHS Quality of Life assessment after elective inguinal hernia repair
16350008|NCT04328597||Non chronic postoperative pain|Patients scoring less than 3 on the EuraHS Quality of Life assessment after elective inguinal hernia repair
16350009|NCT04328584|Experimental|SNS|Intraoperative imaging/surgical navigation system (SNS)
16350010|NCT04328571|Experimental|OLE enzymatically treated|Participants will receive 1 capsule of OLE enzymatically treated + 1 stick of maltodextrin each day in the morning for 21 days
16350011|NCT04328571|Experimental|OLE + probiotic|Participants will receive 1 capsule of OLE + 1 stick of probiotic each day in the morning for 21 days
16350012|NCT04328571|Active Comparator|OLE|Participants will receive 1 capsule of OLE + 1 stick of maltodextrin each day in the morning for 21 days
16350013|NCT04328558|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
16350014|NCT04328558|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16350015|NCT04328545|Experimental|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
16350016|NCT04328545|Active Comparator|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
16350087|NCT04328064|Placebo Comparator|Placebo drug|Placebo oral tablet
16350017|NCT04328545|Sham Comparator|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
16350018|NCT04328532|Experimental|Pregnancy with suspicion of PAA|
16350019|NCT04328532|Other|Pregnancy without suspicion of PAA|
16350020|NCT04328519||patient(hospitalized)|patients who are admitted to the emergency department and hospitalized.
16350021|NCT04328519||control(not hospitalized)|patients who are admitted to the emergency department and not hospitalized.
16350022|NCT04328506|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (test product) under fasted state, after a wash period of 5 days, the subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state.
16350023|NCT04328506|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (test product) under fasted state.
16350024|NCT04328506|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of CM082 tablet (test product) after meal, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (reference product) after meal.
16350025|NCT04328506|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of CM082 tablet (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of CM082 tablet (test product) after meal
16350026|NCT04328493|No Intervention|Control arm|Patients randomized to the control arm will receive a standard of care therapy (a supportive care/treatment according to VN MoH's guideline).
16350027|NCT04328493|Experimental|Intervention arm|"In addition to standard of care therapy, patients randomized to the intervention arm receive chloroquine phosphate as below.
~For adult ≥ 53kg: 1000mg (4 tablets) at initial dose (T=0), followed by 500mg (2 tablets) at 6 hours later (T=6), and 500mg (2 tablets) once daily for 9 days.
~For adult from 45 - 52kg: 875mg (3.5 tablets) at T=0, followed by 500mg (2 tablets) at T=6 and 500mg (2 tablets) once daily thereafter.
~For adult weighted 38 -<45 kg: 750mg (3 tablets) at T=0, followed by 375mg (1.5 tablets) at T = 6 and 375mg (1.5 tablets) once daily thereafter.
~For adult weighted <38 kg: 625mg (2.5 tablets) at T=0, followed by 375mg (1.5 tablets) at T=6 and 375mg (1.5 tablets) once daily thereafter.
~The total duration of treatment with chloroquine will be 10 days."
16350028|NCT04328480|Active Comparator|Local standard of care plus colchicine|Local standard of care plus colchicine (specific dosage schedule)
16350029|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate / high-risk patients
16350030|NCT04328467|Experimental|Intervention Once Weekly|400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks
16350031|NCT04328467|Experimental|Intervention Twice Weekly|400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks
16350032|NCT04328467|Placebo Comparator|Control Group|Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks
16350033|NCT04328454||COVID-19 patients|Hospitalized patients with COVID-19
16350034|NCT04328441|Experimental|BCG vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
16350035|NCT04328441|Placebo Comparator|Placebo|Intracutaneously 0.1ml of 0.9% NaCl solution
16350036|NCT04328428|Experimental|(A)modified BL40 acupuncture|modified BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain.
16350037|NCT04328428|Active Comparator|(B)EM32 acupuncture|EM32 acupuncture Participants receive EM32 acupuncture once on the opposite site.
16350038|NCT04328428|Active Comparator|(C)BL40 acupuncture|BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain
16350039|NCT04328415|Experimental|healthy volunteers|
16350040|NCT04328415|Experimental|patients with Chronic Kidney Disease|
16350041|NCT04328402||Children and adolescents submitted to PSG in sleep laboratory|Children (1 to 11 years) and adolescents (12 to 18 years), who were referred to a sleep laboratory and submitted to full-night polysomnography due to suspicious of sleep disorders.
16350042|NCT04328389|Placebo Comparator|Placebo Comparator: electric toothbrush|Participats will be instructed to used electric toothbrush for home supragingival plaque removal
16350043|NCT04328389|Experimental|Professional oral hygiene|Full-Mouth professional oral hygiene consisting in scaling and root planing, four quadrants in one session.
16350044|NCT04328376|Experimental|Prospective FEMQT Group|Propositus patients with genetically proven LQTS and their relatives
16350045|NCT04328363|Experimental|Intervention|The intervention will be carried out by primary care nurses over eight visits: baseline visit and follow-up visits which take place 15 days, 1, 2, 4, 6, 9, and 12 months after baseline with a final visit evaluation at 18 months. The intervention will be based on the social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles in people with prediabetes. The content of the intervention proposed is based on the NHS and it will be carried out at three levels (individual, group and community) to facilitate the patient empowerment and promotion of healthy lifestyles with a positive orientation using the community resources.
16350046|NCT04328363|No Intervention|Control|The Control group will receive routine standard care.
16350047|NCT04328350||AYA who are on treatment 2-12 months post -diagnosis|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.
~Participants (30 on-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
16350048|NCT04328350||AYA who are off -therapy 1 to 4 years|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.
~Participants (20 off-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
16350049|NCT04328337|Experimental|Non-diabetic, normal weight individuals receiving Intralipid|Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)
16350050|NCT04328337|Placebo Comparator|Non-diabetic, normal weight individuals receiving saline|Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2
16350051|NCT04328311|Experimental|Active|Watermelon juice
16350052|NCT04328311|Other|Control|Low nitrate water.
16350053|NCT04328285|Experimental|Hydroxychloroquine (HCQ) vs Placebo|"Group 1.1: HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards
~Group 1.2: Placebo of HCQ, 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards."
16350054|NCT04328285|Experimental|Lopinavir/ritonavir (LPV/r) vs Placebo|"Group 2.1: LPV/r 200/50 mg, 2 tablets twice daily
~Group 2.2: Placebo of LPV/r, 2 tablets twice daily"
16350055|NCT04328272|Experimental|Hydroxychloroquine|tablet hydroxychloroquine (HCQ). Day-1 (initial) 1st dose, 3 tablets (200 mg per tablet), 2nd dose after 6 hours, 3 tablets (200 mg per tablet) per oral. From day 2 to 7 (maintenance dose), 2 tablets twice a day.
16350056|NCT04328272|Active Comparator|Azithromycin|Tablet azithromycin (AZC) 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 7.
16350057|NCT04328272|Placebo Comparator|Suger Tablets|Placebo (sugar tablet) twice daily for 7 days
16350058|NCT04328246|Experimental|IES Device + Standard of Care|Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
16350059|NCT04328246|Active Comparator|Standard of Care|Standard of care treatment for pressure injuries is turning the patient every two hours.
16350060|NCT04328233|Experimental|Time-Restricted Eating|
16350061|NCT04328207|Other|No financial incentive|This group will receive standard of care eye health education alone and no financial incentive for completing a referral visit.
16350062|NCT04328207|Experimental|Financial incentive|This group will receive a financial incentive once the referral visit is completed (if one was required) as well as eye health education.
16350063|NCT04328194|Experimental|Study Group|80 patients with breast cancer
16350064|NCT04328194|Placebo Comparator|Control Group|20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
16350065|NCT04328181|Experimental|SPCCT and standard DECT|Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
16350066|NCT04328168|Active Comparator|Group1|Conventional Physiotherapy
16350067|NCT04328168|Active Comparator|Group2|robot-assisted gait training
16350068|NCT04328155|Experimental|Hotpack Group|Group I (15 subjects) received 18 sessions hotpack to hamstring muscles and self stretching exercise3 times per week.
16350069|NCT04328155|Experimental|Infrared Group|Group II (15 subjects) received 18 sessions infrared to hamstring muscles and self stretching exercise3 times per week.
16350070|NCT04328155|Experimental|Ultrasound Group|Group III (15 subjects) received 18 sessions ultrasound to hamstring muscles and self stretching exercise 3 times per week.
16350071|NCT04328155|Active Comparator|Control|Group IV (15 subjects) received 18 sessions self stretching exercise 3 times per week.
16350072|NCT04328142|Experimental|Qigong|The Qigong experimental group performed the 20 figures to improve health and longevity described by the master of Qigong 'Wang Ziping'. These are based on therapeutic exercises of Traditional Chinese Medicine. They work on breathing, flexibility and balance. Each figure was repeated 6 times. The sessions were administered twice a week during 45 minutes and were guided by a Doctor in Western Medicine who is also qualified as a Doctor of Traditional Chinese Medicine and Qigong teacher.
16350073|NCT04328142|Experimental|Physiotherapy|The physiotherapy experimental group completed an active exercises program guided by a qualified physiotherapist. The exercise programme was based on active shoulder, hips and spine kinesiotherapy. It included a warm up of 3-5 minutes walking, followed by 6 repetitions of shoulder and hip exercises in standing, cervical spine exercises in sitting or standing, according to the comfort of the patient, thoracic and lumbar spine exercises performed in supine on a mat and balance exercises in standing. Stretching exercises were also performed at the end of the session. The exercises were accompanied by gentle breathing coordinated with the movements. The sessions were administered twice a week during 45 minutes.
16350074|NCT04328142|No Intervention|Control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
16350075|NCT04328129|Experimental|Primary case|Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)
16350076|NCT04328129|Experimental|Family contact|Subject who lived in the household of the primary case while the primary case was symptomatic
16350077|NCT04328116||Study Group|Neodent GM Zygomatic Dental Implants will be placed. Multiple implants may be placed in a single subject.
16350078|NCT04328103|Active Comparator|Cognitive Behavior Therapy (CBT)|Following established procedures at the Depression Evaluation Service (DES) at New York State Psychiatri Institute (NYSPI), 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
16350079|NCT04328103|Placebo Comparator|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
16350080|NCT04328090|Experimental|CDSS-Antimicrobial stewardship|Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm.
16350081|NCT04328090|No Intervention|Standard of care|Teams in the control arm will continue with usual standard clinical care.
16350082|NCT04328077|Experimental|TERN-101 dose level 1|Orally administered.
16350083|NCT04328077|Experimental|TERN-101 dose level 2|Orally administered.
16350084|NCT04328077|Experimental|TERN-101 dose level 3|Orally administered.
16350088|NCT04328051|Active Comparator|Ocean E.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and external hexagon connection.
16350089|NCT04328051|Active Comparator|Ocean I.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and internal hexagon connection.
16350090|NCT04328051|Active Comparator|Ocean C.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and conical connection.
16350091|NCT04328038||USA|Cohort from the USA
16350092|NCT04328038||Germany|Cohort from Germany
16350093|NCT04328025|Active Comparator|Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP|"For TGW in the intervention arm, peers will deliver HIVST and PrEP medications monthly in between quarterly clinic visits. Quarterly clinic-based testing will confirm accuracy of self-tests and identify inaccurate test results. Additionally, peers will remind TGW to self-test before opening a new PrEP bottle. They will also distribute STI self-sampling kits to TGW for own use, and with regular partners as needed. They will present smart phone instructional videos showing trans women how to self-collect pharyngeal, rectal and urine specimens for Neisseria gonorrhoeae and Chlamydia trachomatis testing.
~Peers will: a) motivate ongoing adherence; b) promote repeat HIV testing; and c) support PrEP use as problems arise. Self-sampling for STIs will be performed monthly by participants (with questions answered by the peer or other study staff as needed)."
16350094|NCT04328025|No Intervention|Facility-Delivered Care|Participants will receive facility-based HIV counseling, PrEP prescriptions condoms, risk reduction counseling, and management of sexually transmitted infections as standard of care.
16350095|NCT04328012|Experimental|Losartan|losartan 25 mg po QD X 14 days
16350096|NCT04328012|Placebo Comparator|Placebo|placebo QD X 14 days
16350097|NCT04327999|Experimental|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
16350098|NCT04327986|Experimental|1/Arm 1A|De-escalating doses of M9241 in combination with M7824
16350099|NCT04327986|Experimental|2/Arm 1B|De-escalating doses of M9241 in combination with M7824 and SBRT
16350100|NCT04327986|Experimental|3/Arm 2|RP2D of M7824 and M9241 in combination with SBRT
16350101|NCT04327947|Experimental|women, 18-39 y|Health volunteers, 18-39 y, with vaginal dryness
16350102|NCT04327947|Experimental|premenopause women|Health volunteers, 40 years to premenopause, with vaginal dryness
16350103|NCT04327947|Active Comparator|climacteric women|Health volunteers, climacteric, with vaginal dryness
16350104|NCT04327934|Active Comparator|Healthy Control|Healthy control participants.
16350105|NCT04327934|Experimental|AE-PCOS|Participants with AE-PCOS.
16350106|NCT04327921|Experimental|peer navigation social support for smoking cessation|36 HIV-positive smokers will have a 30-minute session with the study nurse to discuss smoking cessation. They will also discuss the importance of social support for quitting and the role of a Peer Navigator. Those participants who set a quit date will choose medication/s in collaboration with the nurse and/or physician. The Peer Navigator will be introduced and will reinforce adherence to medication. The Peer Navigator will ensure that the patient picks up the medication, and will help to manage side effects via physician/nurse consultation. The Peer Navigator will provide social support for quitting via weekly phone calls for 12 weeks.
16350107|NCT04327921|Active Comparator|Standard Condition|36 HIV-positive smokers will receive standard care. Participants will meet for a 30-minute session with a study nurse. They will receive counseling based on the 5A's. The nurse will ask about current smoking habits, advise the participant to quit, assess readiness to quit, and assist by providing resources (community programs, Quit line phone number). The nurse will calculate Lung Age which will serve as a motivation tool to encourage smokers to quit. Those willing to set a quit date will be instructed to call their physician for cessation medication and will provided with the National Cancer Institute self-help pamphlet. Those participants not willing to set a quit date will be instructed to contact their physician when they are ready.
16350108|NCT04327869||Abdominal symptoms group|The investigators selected 10 subjects (male: female = 1: 1) from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel
16350109|NCT04327869||Healthy control group|The investigators selected another 10 subjects (male: female = 1: 1) from healthy volunteers.
16350110|NCT04327856||Cataract surgery group|Patients which were administrated to the Ophthalmology Clinic Medical University of Bialystok due to scheduled cataract removal surgery
16350111|NCT04327843|Experimental|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
16350112|NCT04327830||Older adults and their caregivers|Older adults who have received or are receiving home care services and their caregivers
16350113|NCT04327830||Interdisciplinary health and social care providers|Interdisciplinary health and social care providers who provide home care services to older adults
16350114|NCT04327817|Other|Multifidus ReActiv8 stimulator|The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an implantable pulse generator, implantable leads, programmer, activator and magnet.
16350115|NCT04327804||Odd numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an odd numbered year will first have their left nostril swabbed by the foam swab followed by their right nostril being swabbed by the two polyester swabs.
16350309|NCT04326296|Experimental|Experimental Group|PD-L1 Monoclonal Antibody Combined With Lenalidomide
16350116|NCT04327804||Even numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an even numbered year will first have their left nostril swabbed by the two polyester swabs followed by their right nostril being swabbed by a foam swab.
16350117|NCT04327791|Experimental|baloxavir|Baloxavir: 40 mg po once for wt < 80 kg OR 80 mg po once for wt >/= 80 kg
16350118|NCT04327791|Placebo Comparator|placebo|placebo po once
16350119|NCT04327778|Experimental|Music therapy|Patients will be exposed every two weeks
16350120|NCT04327765|Experimental|Cohort 1|Single orally-inhaled dose
16350121|NCT04327765|Experimental|Cohort 2|Single orally-inhaled dose
16350122|NCT04327765|Experimental|Cohort 3|Single orally-inhaled dose
16350123|NCT04327739|Experimental|Intervention 1 Exercise|Participants allocated to this group received a 10 weeks exercise programme for neck and upper limbs muscles
16350124|NCT04327739|Experimental|Intervention 2 Exercise and INIT|Participants allocated to this group received the same exercise programme as group 1 in combination with the integrated neuromuscular inhibition technique (INIT)
16350125|NCT04327739|Experimental|Intervention 3 Exercise and SMT|Participants allocated to this group received the same exercise programme as group 1 in combination with cervical manipulation
16350126|NCT04327739|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home based general exercise sheet
16350127|NCT04327726|Placebo Comparator|Control group|received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
16350128|NCT04327726|Active Comparator|Dexmedetomidine group|received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score <2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.
16350129|NCT04327713||fish oil supplementation|"fish oil supplementation, usually capsules with a defined content of EPA and DHA
~dosage and duration of intervention differ between the included studies of our meta-analysis"
16350130|NCT04327713||placebo supplementation|"placebo supplementation, usually capsules with a defined content of non-fish oil or other components
~content, dosage and duration of intervention differ between the included studies of our meta-analysis"
16350131|NCT04327700|Experimental|Regorafenib and TheraBionic|"TheraBionic is a device that consists of battery-driven radiofrequency electromagnetic field generator. The metal mouth spoon antenna is placed on the anterior part of the tongue during treatment.
~Regorafenib is a 40 mg tablet administered orally."
16350132|NCT04327687|Experimental|remote ischemic conditioning|remote ischemic conditioning is a physical strategy performed by an electric auto-control device with cuffs placed on bilateral arms: five cycles of 5-min inflation and 5-min deflation one or two times per day. The duration of the treatment is six months.
16350133|NCT04327687|Active Comparator|conventional therapy|conventional therapy
16350134|NCT04327661|Experimental|Tradipitant High Dose|
16350135|NCT04327661|Experimental|Tradipitant Low Dose|
16350136|NCT04327661|Placebo Comparator|Placebo|
16350137|NCT04327648|Active Comparator|Social interaction treatment|During the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. ASD children are followed up closely.
16350138|NCT04327648|Sham Comparator|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
16350139|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment. ASD children are followed up closely.
16350140|NCT04327635|Experimental|PEP in Acute Myocardial Infarction|Patients with an acute myocardial infarction who undergo cardiac catheterization at least four hours after onset of symptoms will receive a one-time intracoronary infusion of PEP within 20 minutes after stent placement or post-dilation.
16350141|NCT04327609|Experimental|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
16350142|NCT04327609|Active Comparator|Control Treatment|POBA
16350143|NCT04327596|No Intervention|Conventional Treatment|Subjects will receive management of AF consisting of either rate or rhythm control.
16350144|NCT04327596|Active Comparator|AF Ablation|Subjects will undergo early RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
16350145|NCT04327583|Experimental|Coordinated pharmaceutical path|Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
16350146|NCT04327583|No Intervention|Standard of care|Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
16350147|NCT04327570||ICU-hospitalised COVID-19 patients|COVID-19 positive patients hospitalised in intensive care ('severe disease').
16350148|NCT04327570||ward-hospitalised COVID-19 patients|COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe').
16350149|NCT04327557|Experimental|MBCP Childbirth Education Course|This arm will undergo the 9-week MBCP course.
16350150|NCT04327557|Active Comparator|Non-MBCP Childbirth Education Course|This arm will undergo the TAU (treatment as usual) childbirth education course (one that does not have a huge mindfulness component).
16350151|NCT04327544|Experimental|Frailty Intervention group|A multi-domain intervention program that includes nutrition education and low to moderate multi-component exercise intervention.
16350152|NCT04327544|No Intervention|Control group|Respondents in the control group will not receive any nutritional education or exercise intervention activities.
16350153|NCT04327518|Experimental|TECNIS® Toric II|Subjects will be implanted in one or both eyes with the study lens
16350154|NCT04327505|Experimental|Hyperbaric oxygen|Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice
16350155|NCT04327505|No Intervention|Control|Best practice
16350310|NCT04326283|Experimental|Trametinib (0.5 mg)|One tablet of trametinib 0.5 mg per day
16350156|NCT04327492||Carotid endarterectomy|"This study is a non-interventional prospective cohort study. The population corresponds to patients submitted to CEA under regional anesthesia. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) will be prospectively recruited. The expected patient follow-up will be of 5 years.
~The demographics will be recorded in a prospective, protected database. Blood samples will be collected in clot activator serum tubes at three timepoints: timepoint 1 - before surgery (until 15 days before surgery); timepoint 2 up to 48h postoperatively; timepoint"
16350157|NCT04327466|Experimental|Osciflow|Crossover sequence of experimental treatment and active comparator.
16350158|NCT04327466|Active Comparator|Highflow|Crossover sequence of experimental treatment and active comparator.
16350159|NCT04327453|Experimental|XP-endo Finisher file|removal of double antibiotic paste intracanal medication with XP-endo Finisher file
16350160|NCT04327453|Experimental|Irrisafe Ultrasonic tip|removal of double antibiotic paste intracanal medication with passive ultrasonic irrigation
16350161|NCT04327453|Active Comparator|side vented needle|removal of double antibiotic paste intracanal medication with conventional syringe irrigation
16350162|NCT04327440||Nyambi, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
16350163|NCT04327440||Nyambi, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
16350164|NCT04327440||Kalembo, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
16350165|NCT04327440||Kalembo, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
16350166|NCT04327414|Experimental|Intervention group|Implementation of standing desks in classroom. To ensure that adolescents will spend sufficient time at the standing desks, 1/3 to half of the classroom will be provided with standing desks. The school will be asked to actually replace some traditional desks with these standing desks, instead of just adding standing desks to the classroom set-up to ensure as much as possible that the desks are being continuously used throughout the intervention period.
16350167|NCT04327414|No Intervention|Control group|No implementation of standing desks in classroom.
16350168|NCT04327401|Experimental|Intervention group|Dexamethasone. After randomization, dexamethasone [20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
16350169|NCT04327401|No Intervention|Control|Standard treatment (according to the treatment protocol for 2019-nCoV infection).
16350170|NCT04327388|Experimental|Sarilumab 200 mg|"Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):
~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and
~Increase/recurrence of fever or
~Increase/no change in fraction of inspired oxygen (FiO2) requirement or
~Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction."
16350171|NCT04327388|Experimental|Sarilumab 400 mg|"Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):
~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and
~Increase/recurrence of fever or
~Increase/no change in FiO2 requirement or
~Required vasopressors, ECMO or development of multi-organ dysfunction."
16350172|NCT04327388|Placebo Comparator|Placebo|"Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):
~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and
~Increase/recurrence of fever or
~Increase/no change in FiO2 requirement or
~Required vasopressors, ECMO or development of multi-organ dysfunction."
16350173|NCT04327375||observational|observational
16350174|NCT04327362|Experimental|Cluster 1: Sham to active tDCS crossover at PE Session 4.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-3, and 20 min. of active tDCS prior to PE sessions 4-10.
16350175|NCT04327362|Active Comparator|Cluster 2: Sham to active tDCS crossover at PE Session 5.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-4, and 20 min. of active tDCS prior to PE sessions 5-10.
16350176|NCT04327362|Active Comparator|Cluster 3: Sham to active tDCS crossover at PE Session 6|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-5, and 20 min. of active tDCS prior to PE sessions 6-10.
16350177|NCT04327362|Active Comparator|Cluster 4: Sham to active tDCS crossover at PE Session 7.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-6, and 20 min. of active tDCS prior to PE sessions 7-10.
16350178|NCT04327362|Active Comparator|Cluster 5: Sham to active tDCS crossover at PE Session 8.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-7, and 20 min. of active tDCS prior to PE sessions 8-10.
16350179|NCT04327349|Other|COVID-19 Patients|
16350180|NCT04327336|Active Comparator|Manual|In this group non invasive mechanical ventilation will be manually titrated during a polysomnography. The Philips A40 ventilator will be used in Spontaneous-Timed (ST) mode.
16350181|NCT04327336|Active Comparator|Automatic|In this group the ventilator will run in an automatic mode (AVAPS) with the same Phillips A40 ventilator.
16350182|NCT04327310|Experimental|Meplazumab|The vial of meplazumab will be reconstituted with 1 mL of water for injection. The required amount of drug solution will be withdrawn and added to 100 mL sterile normal saline (0.9%) for IV infusion. A single dose of meplazumab will be infused over 60 minutes at a constant rate using an infusion pump.
16350183|NCT04327310|Placebo Comparator|Placebo|100ml placebo will be infused over 60 minutes at a constant rate using an infusion pump, single time.
16350242|NCT04326881|Experimental|SHR-1314 A|single dosing SHR-1314 A
16350186|NCT04327271|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
16350187|NCT04327271|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
16350188|NCT04327258||All patients|Patients undergoing elective surgery with anesthesia
16350189|NCT04327245|Experimental|Intervention ingest a 5000 mg of D-tagatose|Intervention: Women with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.e.
16350190|NCT04327245|No Intervention|No Intervention: Intervention ingest a water (control group)|Woman with resistance insulin who ingest a water (control group)
16350191|NCT04327245|Experimental|Intervention ingest a 15,3 mg of stevia|"Intervention: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
16350192|NCT04327232|Experimental|Active|"For patients randomized to active experimental arm: Spironolactone
~Patient will receive study drug for 18 months. Study drug dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day, with 1 tablet being 25mg spironolactone. Study drugs are titrated every 3 months based on patients' potassium and eGFR blood tests results."
16350193|NCT04327232|Placebo Comparator|Control|"For patients randomized to control arm: Placebo
~Patient will receive placebo for 18 months. Placebo dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day. Placebo are titrated every 3 months based on patients' potassium and eGFR blood tests results."
16350194|NCT04327219|Experimental|CDED diet|The CDED will be divided into 3 stages: 0-6 weeks- induction phase (phase 1), weeks 7-12 step-down phase (phase 2), week 13 -24 maintenance phase (phase 3). During these weeks the diet is structured and contains a list of allowed/disallowed foods, and mandatory foods with specific daily/weekly amounts. Patients will be asked to progress with the diet if they respond to the diet clinically. Patients who do not improve, but show a clinicaly significant trend in symptoms, may be asked to prolong a dietary phase until reaching clinical reaction.
16350195|NCT04327219|No Intervention|standard diet|The control standard diet will be personally tailored for nutritional needs according to patient's daily recommended intake (DRI) for calories and protein intake (25kcal/kg and 0.8-1gr/kg per day respectivlly), and will follow the clinical guidelines for dietary therapy of patients with IBD.
16350196|NCT04327206|Experimental|BCG vaccine|Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
16350197|NCT04327206|Placebo Comparator|0.9% Saline|Participants will receive a single 0.1 mL dose of 0.9%NaCl injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
16350198|NCT04327193|Experimental|Driving pressure|The selected PEEP which makes the driving pressure lowest is applied during the operation.
16350199|NCT04327193|Active Comparator|Conventional|Conventional PEEP (5cmH2O) is applied.
16350200|NCT04327180||patients suspected of infection with COVID-19.|Patients included with positive PCR and patients with negative PCR included
16350201|NCT04327167|Other|Digital intervention|
16350202|NCT04327154|Experimental|Digital nerve repair|There is no comparator for this study. All patients are in the treatment allocated group for digital nerve repair with the TISSIUM™ Nerve Coaptation Device.
16350203|NCT04327141|Experimental|Protein pacing and intermittent fasting|During the 8-week weight loss (WL) phase, participants assigned to the PP-IF will consist of PP days, whereby female participants will consume four and male participants will consume five meals/snacks total, two of which (breakfast and lunch) will include a protein powder meal replacement mixed with water (240-400 kcals per meal) along with an evening dinner meal (~500 kcals), an afternoon snack (men only), and an evening snack (250 kcals). Subjects will be calorie restricted to ~1500 and ~1800 calories per day, women and men, respectively during PP days. For each IF day, subjects will be provided a variety of supplements/snacks made by Isagenix International LLC. The PP-IF group will be further divided into two subgroups for weeks 1-4. One subgroup will consist of five days of PP and two days of IF, and the second subgroup will consist of six days of PP and one day of IF. For weeks 5-8 both subgroups will follow 6 days of a PP diet and 1 day IF.
16350204|NCT04327141|Experimental|Heart Healthy|The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming <35% of kcal as fat; 50%-60% of kcal as carbohydrates; <200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
16350205|NCT04327128|Active Comparator|Intervention group|Standard heart failure care and a digital heart failure support system
16350206|NCT04327128|Other|Control group|Standard heart failure care
16350207|NCT04327115|Other|Arm 1|"(C-I-I-I) : the centers apply the Control strategy in Period 1 and then apply the Intervention strategy in Periods 2 to 4."
16350208|NCT04327115|Other|Arm 2|"(C-C-I-I) : the centers apply the Control strategy in periods 1 and 2 and then apply the Intervention strategy in periods 3 and 4."
16350209|NCT04327115|Other|Arm 3|"(C-C-C-I) : the centers apply the Control strategy in periods 1, 2 and 3 and then apply the Intervention strategy for period 4."
16350243|NCT04326881|Experimental|SHR-1314 B|single dosing SHR-1314 B
16350244|NCT04326881|Experimental|SHR-1314 C|single dosing SHR-1314 C
16350245|NCT04326868|Active Comparator|Albendazole|ABZ (400mg)
16350246|NCT04326868|Experimental|Albendazole and Mebendazole|ABZ 400mg + 1 tablet of MBZ (500mg)
16350247|NCT04326868|Experimental|Albendazole and Pyrantel|ABZ (400mg) + Pyr (125 mg)
16350306|NCT04326322|Experimental|Methionine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
16350307|NCT04326309||Cohort 1|Individual Application Downloaders
16350210|NCT04327102|Experimental|Experimental : intervention group|Combination of health education tools and health literacy intervention: on the basis of the control group, the hypertension health education tools are used as the education media to encourage patients to find out the elements of the tool chart, use the picture content to guide the topic development, encourage patients to discuss with each other, realize heuristic questions, rather than a single indoctrination, so as to deepen the understanding and memory of patients. At the end of the course, patients are encouraged to set short-term goals to encourage behaviors that continue to achieve larger goals. At the same time, health literacy lectures were organized during the hospitalization. Health literacy lecture is mainly to learn the information that hypertension needs to pay attention to in order to improve the health literacy of hypertension patients and other indicators.
16350211|NCT04327102|No Intervention|No intervention:The control group|No intervention except conventional care were performed for the control group
16350212|NCT04327089|Experimental|Part 1- Cohort 1|Single oral dose of 400 mg Setanaxib administered as 1x400 mg tablet in fasting conditions.
16350213|NCT04327089|Experimental|Part 1- Cohort 2|Single oral dose of 800 mg Setanaxib administered as 2x400 mg tablet in fasting conditions.
16350214|NCT04327089|Experimental|Part 1- Cohort 3|Single oral dose of 1200 mg Setanaxib administered as 3x400 mg tablet in fasting conditions.
16350215|NCT04327089|Experimental|Part 1- Cohort 4|Single oral dose of 1600 mg Setanaxib administered as 4x400 mg tablet in fasting conditions.
16350216|NCT04327089|Experimental|Part 2- Cohort 5|Repeated 10-Day dosing of 1200mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 1x400mg tablet in the evening in fedding conditions.
16350217|NCT04327089|Experimental|Part 2- Cohort 6|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions.
16350218|NCT04327089|Experimental|Cohort 7|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions. Additionnaly, this cohort includes the evaluation of potential Drug-Drug interactions with CYPs and transporters.
16350219|NCT04327076|Experimental|Robot system intervention|"Evaluate the patient and sign the informed consent
~The patient was given general anesthesia
~Use magnetically guided tracheal intubation and airway cleaning robot system"
16350220|NCT04327063|Placebo Comparator|Placebo|Saline (30 mL maximum)
16350221|NCT04327063|Experimental|Ropivacaïne|Ropivacaïne 5 mg/mL (not to exceed 3 mg/kg and 30 ml of maximal volume)
16350222|NCT04327050|Experimental|Magnetic-ESD|Patients in MAG arm will be treated using magnetic anchored guided endoscopic submucosal dissection.
16350223|NCT04327037|Experimental|NK cells + IL-2|After cycle of chemotherapy patient receive one intravenous infusion of expanded haploidentical NK cells on day 0. On alternate days, 6 doses of subcutaneous IL-2 is administered with start on day -1.
16350224|NCT04327024|Experimental|Verinurad 24 + allopurinol|"Dose [mg] verinurad/allopurinol:
~Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 24/300"
16350225|NCT04327024|Experimental|Verinurad 12 + allopurinol|"Dose [mg] verinurad/allopurinol:
~Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 12/300"
16350226|NCT04327024|Experimental|Allopurinol alone|"Dose [mg] verinurad/allopurinol:
~Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose 0/300"
16350227|NCT04327024|Placebo Comparator|Placebo|Placebo [mg] in 3 steps 0/0
16350228|NCT04327011|Experimental|Experimental|Single arm Toca 511 vector/5-FC prodrug
16350229|NCT04326998|Active Comparator|non-solvent|mechanical or heat treatment
16350230|NCT04326998|Experimental|solvent|GuttaClear
16350231|NCT04326985|Experimental|Autologous Mesenchymal Stem Cells Treatment (MSCs)|"The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
~The treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.
~T0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
16350232|NCT04326985|Active Comparator|Hyaluronic acid (HA)|"The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.
~T0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
16350233|NCT04326959|Experimental|UC-MSCs + CM|A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
16350234|NCT04326959|Experimental|CM + CM|A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
16350235|NCT04326959|Experimental|Triamcinolon acetonide|A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.
16350236|NCT04326920|Active Comparator|Active sargramostim treatment group|Inhaled sargramostim 125mcg twice daily for 5 days on top of standard of care. Upon progression to ARDS and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125mcg/m2 body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment
16350237|NCT04326920|Placebo Comparator|Control group|standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards, will have the option (clinician's decision) to initiate IV sargramostim 125mcg/m2 body surface area once daily for 5 days
16350238|NCT04326907|Experimental|CAT injection group|After fistulectomy for complex anal fistula, CAT (harvested from abdominal subcutaneous adipose tissue by Coleman's procedure) was injected into the tissue surrounding the internal opening, and inside the perianal wound obtained after fistulectomy.
16350239|NCT04326907|No Intervention|No CAT injection group|Patients of this group were treated with anal fistulectomy without CAT injection.
16350240|NCT04326894|Experimental|Methotrexate|25mg oral MTX tablets
16350241|NCT04326894|Placebo Comparator|Placebo|25 mg/week placebo tablets
16350248|NCT04326855|Experimental|20 patients with advanced COPD|This will be a cross sectional observational study. COPD patients will be recruited from those referred to the Pulmonary Rehabilitation programme at RVI Hospital in Newcastle upon Tyne. Potentially eligible patients will be identified by the physiotherapy team within the Trust, who will provide initial information about the study. Delegated investigators will confirm eligibility and discuss full details of the trial. Patients will be given time to consider participation in the trial before written informed consent is obtained.
16350249|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
16350250|NCT04326842||Control|Patients without carotid artery stenosis
16350251|NCT04326829|Experimental|QL1604 Injection|
16350252|NCT04326816|Active Comparator|Direct Composite Restorations (DCR)|"All teeth were reconstructed with directly applied composite restorations. No preparation of teeth was performed except in cases of sharp occlusal edges.
~Rubberdam or cotton rolls and suction devices were used for moisture control. For bonding, a 3-step etch-and-rinse adhesive was applied according to manufacturer's instructions, using 37% phosphoric acid (DMG, Hamburg, Germany), Clearfil SA Primer, and Clearfil Photobond (Kuraray, Osaka, Japan). A micro-hybrid composite (Clearfil AP-X, Kuraray) was used for posterior restorations and palatal veneer restorations. Restorations were placed according to the DSO-technique (Direct Shaping by Occlusion). In front teeth, both a palatal and buccal veneer restoration was placed.
~Experimental restorations were all restorations on first molars and all palatal veneer restorations on maxillary anterior teeth."
16350253|NCT04326816|Experimental|Indirect Composite Restorations (ICR)|"Indirect 'tabletop' restorations were placed on all first molars (n=4) and palatal veneers ('backings') (n=6) on maxillary anterior teeth. Remaining teeth received directly applied restorations. Preparation of teeth for indirect restorations was limited to removal of sharp edges.
~All indirect restorations were laboratory manufactured using a micro-hybrid composite (Clearfil Estenia C&B, Kuraray, Osaka, Japan). Adhesive surfaces of the restorations were air-abraded with aluminum-oxide powder (<50 µm). Rubberdam or cotton rolls were used for moisture control during cementation. Seating of indirect restorations was checked intraorally, followed by cleaning of its adhesive surface with phosphoric acid 37% and application of silane (Clearfil Ceramic Primer, Kuraray, Osaka Japan).The adhesive surface of the abutment tooth was etched with phosphoric acid and ED-primer II (Kuraray) was applied. Finally, restorations were cemented, using Panavia F (Kuraray)."
16350254|NCT04326803|Experimental|Vaccine group|Administration of 3 doses hepatitis B vaccine (recombinant hepatitis B vaccine, injectable suspension for intramuscular use) at month 0, 1 and 2.
16350255|NCT04326790|Experimental|Intervention|Colchicine, on top of standard treatment
16350256|NCT04326790|Active Comparator|Control|Standard treatment, including all medications recommedned by the National Public Health Organization
16350257|NCT04326777|Other|Ballon pulmonary angioplasty|Ballon pulmonary angioplasty(BPA) is a stepwise procedure requiring several separate sessions. The interval of a series of BPA is one month. In a series of BPA, there are 2 sessions, which are repeated at a 2-week interval. BPA is performed primarily on one side of the lung in the first session, then after 2 weeks, performed on the other side of the lung. In each session, the fluoroscopy time or the amount contrast are less than 60min and 200ml, respectively.
16350258|NCT04326764|Experimental|Panobinostat|Panobinostat 20 mg oral three times weekly every second week
16350259|NCT04326764|No Intervention|Standard of Care|Treatment according to local standards
16350260|NCT04326738|Placebo Comparator|normal saline (N) group|N group received corresponding intravenous normal saline of 1ml·kg-1.
16350261|NCT04326738|Active Comparator|midazolam (M) group|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam.
16350262|NCT04326725||Hydroxychloroquine|Subjects with prophylaxis
16350263|NCT04326712||Group 1|Unilateral transtibial amputees using conventinional manufactured socket
16350264|NCT04326712||Group 2|Unilateral transtibial amputees using 3D manufactured socket
16350265|NCT04326699|Active Comparator|Sacroiliac joint injection group|The active group will receive bilateral sacroiliac joint injection of 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) under ultrasound guidance.
16350266|NCT04326699|No Intervention|control group|The other group will not receive the sacroiliac joint injection
16350267|NCT04326686|Other|N-of-1 study|For 24 weeks, each participant will measure their blood pressure and respond to questionnaires daily, and visit the institute to provide a blood sample every 4 weeks. The study is split into three 8-week phases, the first of which will start when each participant is enrolled. For the first 8-week observation phase (A1) the participant is instructed to continue with their usual diet and exercise habits. For the second 8-week intervention phase (B), the participant will be provided with wholegrains and nuts and recommended to substitute these in place of refined grains and other snacks, respectively. They will also receive dietary advice for following the Dietary Approaches to Stop Hypertension (DASH) diet. For the final 8 week follow-up period (A2), provision of wholegrains and nuts will cease but the participant will continue with measurements at the same frequency as previously.
16350268|NCT04326673||diurnal variation assessment|Assessment of diurnal variation in salivary testosterone adjusted for prandial state
16350269|NCT04326673||Glucose load measurements|Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load
16350270|NCT04326660|No Intervention|Control|Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.
16350301|NCT04326374|Experimental|TransCon hGH|"TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight.
~The treatment will continue 52 weeks."
16350302|NCT04326374|Active Comparator|Daily hGH|"Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight.
~The treatment will continue 52 weeks."
16350303|NCT04326348|Experimental|TQ05105 Tablet|TQ05105 tablet administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
16350304|NCT04326335|Active Comparator|Felt-tip marking|
16350305|NCT04326335|Experimental|Felt-tip marking + 3D printed ostomy button|
16350271|NCT04326660|Experimental|SCOPE-Chinese Women Intervention|"SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention.
~Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant.
~Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total.
~Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences."
16350272|NCT04326647|Experimental|Kinesiotaping Group|We used kinesiotaping (gastrocnemius and lumbar back) plus exercise
16350273|NCT04326647|Active Comparator|Exercise Group|We used only exercise
16350274|NCT04326634|Experimental|Controlled exercises Group|
16350275|NCT04326634|Experimental|Non controlled exercises Group|
16350276|NCT04326621|Experimental|PRT group|pressure Release Technique and exercises
16350277|NCT04326621|Active Comparator|Exercises group|Only exercises
16350278|NCT04326595|Active Comparator|surgical termination|
16350279|NCT04326595|Active Comparator|medical termination|
16350280|NCT04326569|Experimental|adults with trans-sphenoidal endoscopic pituitary surgery|adult with trans-sphenoidal endoscopic pituitary surgery for tumour of the sellar region
16350281|NCT04326556|Experimental|Prospective cohort for etiological and prognostic purposes|
16350282|NCT04326543||ADHD and typically developing controls|120 subject: 53 with an ADHD clinical diagnosis and 57 typically developing controls aged between 3 and 16 years old.
16350283|NCT04326530||Persistent asthmatic children|"150 steroid-naive, persistent asthmatic children enrolled during their first consultation at the IRIB-CNR outpatient clinic.
~They will underwent three visits:
~screening visit (-2 days);
~baseline visit (day 0);
~last visit (+90 days).
~They will be treated with controller medications according to GINA recommendations (http://ginasthma.org)."
16350284|NCT04326517||Emphysematous pyelonephritis|This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.
16350285|NCT04326504||Patients starting DTG-based regimens|ART-naïve patients, starting cART regimens based on DTG
16350286|NCT04326504||Switch cohort|Patients on stable ART regimens switching to DTG (any reason)
16350287|NCT04326504||Therapy failure|ART-experienced patients switching to DTG-containing regimens due to virological failure
16350288|NCT04326504||Non-DTG group|Patients who started a non-DTG containing regimen
16350289|NCT04326491||HCC|Participants are diagnosed with HCC on top of cirrhosis
16350290|NCT04326491||Cirrhosis with no HCC|Participants are diagnosed with cirrhosis but have no HCC
16350291|NCT04326478|Experimental|Azithromycin Group|Enrolled children in a household randomized to the experimental group will receive a single weight-based dose of azithromycin administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera. They will then complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
16350292|NCT04326478|Placebo Comparator|Non-antibiotic Placebo Group|Enrolled children in a household randomized to the placebo arm will receive a single dose of non-antibiotic placebo during their first study visit, which will occur within 12 hours of a member of their household testing positive for cholera. Like the participants in the intervention arm, they will complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
16350293|NCT04326465|Experimental|Fractional CO2 Laser Therapy at 10-15% Laser Density Coverage|Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10-15% laser density. The patient will receive three laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
16350294|NCT04326452|Experimental|Enrolled Subjects|The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support of any Person Under Investigation for infection by the COVID-19 virus.
16350295|NCT04326439|Experimental|Aflac-AML Regimen for Low Risk AML Patients|"Participants in this arm will receive the standard Aflac-AML Regimen with the following chemotherapy:
~Induction-1: patients on Induction-I will receive gemtuzumab + ADE therapy based on genotyping. Lasts a total of 28 days.
~Induction II - MA
~Intensification I - AE
~Intensification II - HD ARAC/LASP
~Patients with low risk status who had low risk markers and were MRD positive at the end of Induction I and continue to be MRD positive after Induction II will come off protocol."
16350296|NCT04326439|Experimental|Aflac-AML Regimen for High Risk AML Patients|"Participants in this arm will receive standard Aflac-AML Regimen with the following chemotherapy:
~Induction-1: patients will receive gemtuzumab in addition to ADE therapy based on genotyping. Induction I lasts a total of 28 days.
~Induction 1 for FLT3-ITD patients - ADE (10+3+5) with GO with Sorafenib
~Induction II - MA
~Induction II for FLT3-ITD patients - MA with Sorafenib
~Intensification I - AE
~Intensification I for FLT3-ITD patients - AE with sorafenib
~Intensification II - HD ARAC/LASP
~Intensification II for FLT3-ITD patients - HD ARAC/LASP with sorafenib
~Hematopoietic stem cell transplantation (HSCT)
~If a patient is classified as High risk after Induction I, they may proceed to best allogenic donor SCT following Induction II. These patients may receive a third course of chemotherapy prior to HSCT. In cases where HSCT is not an option, patients can receive 4 cycles of chemotherapy. Only patients with FLT3-ITD mutation will receive sorafenib."
16350297|NCT04326426|Experimental|Tradipitant|Tradipitant 85 mg PO BID
16350298|NCT04326426|Placebo Comparator|Placebo|2 capsules of matching placebo
16350299|NCT04326400||Hospital de la Princesa employees|
16350300|NCT04326387||Research Participants (Patients)|"Inpatients symptomatic of suspected COVID-19 Baseline swab of nose/throat, nasopharyx, or endotracheal tube aspirate. SAMBA II point of care test on this swab.
~Standard of care bloods taken for PHE and additional confirmatory diagnostic PCR assessment.
~Serum antibody tests on any excess blood tests during inpatient stay for immune response monitoring.
~Outcome assessment at 1 month"
16350308|NCT04326309||Cohort 2|Public Space and Vehicle Data Capture
16350311|NCT04326283|Experimental|Trametinib (1 mg)|Two tablets of trametinib 0.5 mg per day
16350312|NCT04326283|Experimental|Trametinib (2 mg)|One tablet of trametinib 2 mg per day
16350313|NCT04326283|Active Comparator|Riluzole (100 mg)|One tablet of riluzole 50 mg taken twice per day
16350314|NCT04326270|Active Comparator|nCPAP prongs|
16350315|NCT04326270|Active Comparator|Infant cannula|
16350316|NCT04326257|Experimental|Nivolumab+Relatlimab|"Nivolumab will be dosed 480mg IV q 4 weeks and Relatlimab 160mg IV q 4 weeks
~One cycle is defined as 4 weeks of treatment and both drugs are given on the same day.
~Patients will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
16350317|NCT04326257|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be dosed at 3mg/kg IV q 2 weeks and Ipilimumab 1mg/kg IV q 6 weeks.
~Patients will receive four doses of Ipilimumab and the last dosage of Nivolumab 3mg/kg IV q 2 weeks will be given at the time of the 4th dose of Ipilimumab, followed 2 weeks later by Nivolumab 480 mg IV q 4 weeks. A cycle of therapy will be defined as 4 weeks of treatment. The patient will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
16350318|NCT04326244||Snoring obesity patient|Constitution in Chinese Medicine Questionnaire, physical examination, blood test and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled
16350319|NCT04326231|Experimental|Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
16350320|NCT04326218|Other|Cohort|All patients included will have to be taken blood samples
16350321|NCT04326205|Experimental|Dual-aided|active tDCS to the ipsilesional primary motor cortex (M1lesioned) followed by FES to the paretic hand during MT
16350322|NCT04326205|Active Comparator|FES-alone|sham tDCS to the M1lesioned followed by FES to the paretic hand during MT
16350323|NCT04326205|Active Comparator|tDCS-alone|active tDCS to the M1lesioned followed by sham FES to the paretic hand during MT
16350324|NCT04326205|Placebo Comparator|Dual-sham|sham tDCS to the M1lesioned followed by sham FES to the paretic hand during M
16350325|NCT04326192|Experimental|All subjects|All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.
16350326|NCT04326179||Age 0 to 4 at day of visit|This study is entirely based on surveys and chart reviews. Data collected as part of this study will not directly inform the care of participating patients and families.
16350327|NCT04326166||Group A|Patients who receive Double therapy or Insulin
16350328|NCT04326166||Group B|Patients who receive DPP-4 inhibitor
16350329|NCT04326166||Group C|Drug-naïve patients
16350330|NCT04326153|Experimental|experimental arm|Sintilimab+Albumin paclitaxel:+Carboplatin:
16350331|NCT04326140|Experimental|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
16350332|NCT04326140|Sham Comparator|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
16350333|NCT04326127||Control|Healthy volunteers
16350334|NCT04326127||Case|Volunteers with diagnosed sleep apnea
16350335|NCT04326114|Experimental|Inspiratory training|
16350336|NCT04326114|Experimental|Expiratory training|
16350337|NCT04326114|No Intervention|Control|
16350338|NCT04326088||head and neck cancer with free flap reconstruction|patients with head and neck cancer who underwent tumor wide excision and primary free flap reconstruction or secondary free flap reconstruction between March 2008 and February 2017
16350339|NCT04326075|Experimental|Early CPAP treatment|Early treatment with CPAP in addition to current clinical practice
16350340|NCT04326075|No Intervention|Control|Current clinical practice, which currently does not involve the use of CPAP.
16350341|NCT04326062|Experimental|Main Study|A pharmacist will join the practice team for six months.
16350342|NCT04326062|Experimental|PROM Study|A nested Patient Reported Outcome Measure (PROM) study will be undertaken during month four and five of the six-month intervention period to explore the impact of the intervention in older adults (aged ≥65 years).
16350343|NCT04326049|Experimental|LLETZ with videocolposcopy|The LLETZ procedure will be performed using a videocolposcopy
16350344|NCT04326049|Active Comparator|LLETZ with binocular colposcopy|The LLETZ procedure will be performed using a binocular colposcope
16350345|NCT04326036|Experimental|Lipoaspiration|Closed sterile, disposable microcannula of small volume adipose tissue, including the stromal vascular fraction (SVF) (cells and stromal tissue
16350346|NCT04326036|Experimental|Isolation & Concentration of cSVF|Isolation & Concentration of cellular stromal vascular fraction (cSVF) using Healeon Centricyte 1000 Centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
16350347|NCT04326036|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 250 cc of sterile Normal Saline IV solution and deployed though 150 micron in-line filtration and intravenous route over 30-60 minute timeframe
16350348|NCT04326036|Other|Liberase TM|Use of sterile Liberase TM enzyme to allow cSVF separation and isolation
16350349|NCT04326036|Other|Sterile Normal Saline|250 cc of sterile Normal Saline for Intravenous with sterile 150 micron in-line filtration for suspension of the concentrated cSVF and deployment IV
16350350|NCT04325997|Experimental|an ordinary laryngos with mouth opener|
16350351|NCT04325997|No Intervention|Video laryngoscopy intubation|
16350353|NCT04325984||Dexamethasone group|Group of patients receiving dexamethasone 8 mg as part of the multimodal analgesia.
16350354|NCT04325984||Control group|Group of patients receiving multimodal analgesia, not comprising dexamethasone; moreover, ondansetron 4 mg is administered for the control of PONV.
16350355|NCT04325971|Experimental|Healthy Subjects|All healthy subject are gathered in one arm
16350356|NCT04325958|Placebo Comparator|Placebo cannabis|Participants will drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC)
16350357|NCT04325958|Experimental|Active cannabis|Participants will drive the simulator before and after smoking an active cannabis cigarette (12.5% THC)
16350358|NCT04325945|Experimental|Laser acupuncture|808nm low level laser therapy
16350359|NCT04325945|Sham Comparator|Sham laser acupuncture|no low level laser output but same device
16350360|NCT04325932|Experimental|Urinary Kallikrein group|Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
16350361|NCT04325932|No Intervention|control group|with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
16350362|NCT04325906|Active Comparator|high flow nasal cannula only|Receive high flow nasal cannula only
16350363|NCT04325906|Experimental|HFNC plus prone positioning|Receive high flow nasal cannula plus prone positioning
16350364|NCT04325893|Active Comparator|Hydroxychloroquine|
16350365|NCT04325893|Placebo Comparator|Placebo|
16350366|NCT04325880|Placebo Comparator|Placebo arm|Patients in this arm will receive a placebo formula
16350367|NCT04325880|Active Comparator|Mirabegron arm|Patients in this arm will receive Mirabegrone 50 mg once daily
16350368|NCT04325880|Active Comparator|Tamsulosin arm|Patients in this arm will receive tamsulosin o.4 mg once daily
16350369|NCT04325880|Active Comparator|Solifenacin arm|Patients in this arm will receive solifenacin 10 mg once daily
16350370|NCT04325867|Experimental|All patients with known cardiovascular disease|"All these patients will be provided an electronic account on a dedicated platform were they can be supervised and can call for advice / help.
~This kind of tele-medical project aims to keep these patients in a so-called proximity, monitoring their vital parameters, checking their medication and providing dedicated advices according to their complaints.
~Moreover, all these patients will receive digital watches with ecg-recording capabilities, thus a dedicated physician could correlate their symptoms with few clear paraclinical variables.
~All of these patients' complaints will be stratified according to elaborated protocols based on the European Cardiovascular Guidelines.
~Moreover, a psychologist and a chaplain will deal with their (new) problems due to social isolation."
16350371|NCT04325854||Ectopic pregnancy population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all ART procedures (both I and II level) performed between 2009 and 2018.
16350372|NCT04325841|Experimental|Autologous Murine Anti-CD19 CAR-T treatment|
16350373|NCT04325828|Experimental|Apalutamide plus GnRH Agonist|Participants will receive apalutamide 240 milligram (mg) in combination with a gonadotropin-releasing hormone (GnRH) agonist until disease progression, unacceptable toxicity, death, or the end of the study and each treatment cycle will be of 28 days.
16350374|NCT04325815||CADDIE|The endoscopist will be assisted with CADDIE system to detect polyps. The endoscopist will perform optical diagnosis of polyps with the assistance of the CADDIE's polyp characterisation function.
16350375|NCT04325815||Standard Procedure|In addition to routine colonoscopy the endoscopist will perform optical diagnosis of detected polyps without the assistance of the CADDIE.
16350376|NCT04325802|Experimental|Cohort 1: Placebo, then Intervention|Patients will start with placebo in week 1 and cross over to Naltrexone in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
16350377|NCT04325802|Active Comparator|Cohort 2: Intevention, then Placebo|Patients will start with Naltrexone in week 1 and cross over to the palcebo treatment in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
16350378|NCT04325802|No Intervention|Circadian Rhythm of Itch|Patients in this arm will receive no intervention, only data collection.
16350381|NCT04325776|Experimental|AL2846+An analog of zoledronic acid injection|AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
16350382|NCT04325776|Active Comparator|An analog of AL2846+ zoledronic acid injection|An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
16350383|NCT04325763|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16350384|NCT04325763|Experimental|TQB2450+Anlotinib(blank)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16350458|NCT04325243|Placebo Comparator|placebo group|placebo tablets of the same shape, color and size of sildenafil citrate tablets
16350507|NCT04324892||Treat to target|The study has only 1 cohort with treat-to-target strategy
16350385|NCT04325763|Placebo Comparator|TQB2450(blank)+Anlotinib(blank)|TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16350386|NCT04325750|Placebo Comparator|Control|The simulated mode technique is applied (machine off)
16350387|NCT04325750|Experimental|TECAR THERAPY|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
16350388|NCT04325737|Experimental|SEP-363856|
16350389|NCT04325737|Placebo Comparator|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
16350390|NCT04325724|Other|Beginner psoriatic arthritis patients|Every patients consulting in dermatologic or rheumatologic department for a skin psoriasis with clinical symptoms which may lead to the suspicion of psoriatic arthritis
16350391|NCT04325724|Other|Confirmed psoriatic arthritis patients|Every patients with psoriatic arthritis followed in rheumatologic department
16350392|NCT04325724|Other|Rheumatoid arthritis or Digital osteoarthritis patients|Followed in rheumatologic department
16350393|NCT04325724|Other|Skin psoriasis patients without any articular symptoms|
16350394|NCT04325711|Experimental|CSPCH131 dose Escalation and expansion|"In the dose escalation part of Stage I, five dose levels will be tested according to the 3 + 3 dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131."
16350395|NCT04325698|Experimental|Arm A|PF-06439535 (CN) + paclitaxel + carboplatin
16350396|NCT04325698|Active Comparator|Arm B|Bevacizumab-EU + paclitaxel + carboplatin
16350397|NCT04325685|Placebo Comparator|Control group|
16350398|NCT04325685|Active Comparator|Antiseptic (Octenisept) group|
16350399|NCT04325685|Experimental|Bacteriophage (Sextaphag) group|
16350400|NCT04325672|Experimental|Convalescent Plasma Group|Subjects will receive 1-2 units (300-600 mL) of plasma with an anti-SARS-CoV-2 titer of >1:64.
16350401|NCT04325659|Active Comparator|Lofexidine/Sham Bridge Device|Lofexidine (Lucemyra) encapsulated
16350402|NCT04325659|Placebo Comparator|Sham Bridge Device /Placebo Study Drug|Inactive Bridge Device and placebo study drug
16350403|NCT04325659|Experimental|Active Bridge Device/ Placebo Study Drug|Active Bridge Device and placebo study drug
16350404|NCT04325646||CORSER-1a|Subjects who had been to China in the weeks before the outbreak began
16350405|NCT04325646||CORSER-1b|Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
16350406|NCT04325646||CORSER-2a|Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
16350407|NCT04325646||CORSER-2b|Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
16350408|NCT04325646||CORSER-2c|"Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.
~study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise
~study among pupils from 5 to 12 and their parents in elementary schools located in Oise
~study among choir members"
16350409|NCT04325646||CORSER-2d|Staff of health care institutions
16350410|NCT04325646||CORSER-2e|Subjects in care, hospitalized or residing in health care facilities
16350411|NCT04325646||CORSER-3|Subjects returning from a humanitarian mission that started before 31/01/2020
16350412|NCT04325646||CORSER-2f|Subjects with two symptomatic episodes of SARS-CoV-2 infection
16350413|NCT04325646||CORSER-4|Subjects being vaccinated against COVID-19
16350414|NCT04325633|Experimental|1: Naproxen|Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
16350415|NCT04325633|Placebo Comparator|2: Standard of care|Standard of care
16350416|NCT04325620|Experimental|HIP1601 Amg|The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.
16350417|NCT04325620|Placebo Comparator|HGP1805|The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.
16350418|NCT04325607|Experimental|Negative Pressure Wound Therapy with instillation|Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
16350419|NCT04325607|Active Comparator|Negative Pressure Wound Therapy|Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
16350420|NCT04325594|Experimental|Main Group|Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1×10 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy
16350421|NCT04325594|Active Comparator|Control Group|Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy
16350422|NCT04325581|Experimental|Post LSG with Liraglutude|Liraglutide in incremental dose upto maximum of 1.8 mg per day subcutaneously once a day.
16350423|NCT04325581|Placebo Comparator|Post LSG without Liraglutide|Normal Saline in equivalent per day subcutaneously once a day
16350424|NCT04325568|Other|Clinician Manual|"Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability.
~Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'."
16350459|NCT04325230|Experimental|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
16350460|NCT04325217||Patients newly initiating Ofev®/Nintedanib Capsules|
16350425|NCT04325568|Other|AutoTutor (PsyGist)|"AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing.
~PsyGist will guide participants through its three components."
16350426|NCT04325555||Respondents on PrEP|"On PrEP status will be operationalized in multiple ways, and sensitivity analyses will be conducted using multiple definitions as a result of the self-reported nature of the study.
~Respondents on PrEP are respondents who reported that they are currently on PrEP
~Respondents on PrEP are respondents who reported to have ever been on PrEP
~When respondents are used as their own controls, years on PrEP will be those in which they reported to have been on PrEP for at lest 6 months, and PrEP initiation will be the first such year
~A comparison group will be constructed by matching on a variety of characteristics, when this method is applied. Most importantly, age, and STD testing frequency among others, which influence the likelihood of being on PrEP and via that avenue sexual practices, as well as the likelihood of detecting STDs (i.e., ascertainment bias). In other models adjustments will be made for these factors."
16350427|NCT04325542|Other|HBSAG positive with rapid test|Newborns from woman who are positive with HBSAG rapid test got WHO recommended HBV vaccination at birth to avoid HBV transmission
16350428|NCT04325529||remitted MDD|Unmedicated Remitted Participants with Past History of MDD
16350429|NCT04325529||Control subjects|healthy control subjects
16350430|NCT04325516|Experimental|People with a lower limb amputation|"Participants will perform four tasks in a randomized order:
~sit to stand
~dorsi flexion of the foot
~knee extension
~hip extension"
16350431|NCT04325516|Experimental|Able bodied individuals|"Participants will perform four tasks in a randomized order:
~sit to stand
~dorsi flexion of the foot
~knee extension
~hip extension"
16350432|NCT04325503|Experimental|Treatment|carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
16350433|NCT04325490|Experimental|Liquid powder|Liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin on the selected intertrigo area.
16350434|NCT04325490|Active Comparator|Hydrocortisone|1% hydrocortisone cream
16350435|NCT04325477|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
16350436|NCT04325464|Experimental|PEAR-003A|Digital Therapeutic
16350437|NCT04325438|Experimental|Pharmaceutical Care|Groups with usual care by health professionals and additional health interventions provided by pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
16350438|NCT04325438|No Intervention|Non-Pharmaceutical Care|Groups with usual care from health providers other than pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
16350439|NCT04325425|Experimental|mFOLFIRINOX|mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
16350440|NCT04325425|Active Comparator|platinum - etoposide|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
16350441|NCT04325399|Experimental|Planning|"The volitional help sheet (VHS) comprises of a list of challenges to being physically active (e.g. If I'm tempted not to go to the gym because it's cold outside) and a list of possible ways to overcome thes (e.g. then I will make myself go to the gym anyway because I know I will feel better afterward). In the experimental VHS link group, participants are asked to form if-then plans by drawing a line between challenges and solutions to link them together."
16350442|NCT04325399|No Intervention|No planning|Participants in the VHS tick group are presented with the exact same volitional help sheet as the experimental group, the only difference being that participants in this group are not asked to make if-then plans. Rather, participants in the control group are asked to tick challenges and solutions that they feel are relevant to them.
16350443|NCT04325386|Experimental|Education sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
16350444|NCT04325386|Placebo Comparator|No education sessions|
16350445|NCT04325360|Experimental|Cathodal Transcranial Direct Current Stimulation (c-tDCS)|Participants in this arm of the study will receive cathode transcranial direct current stimulation.
16350446|NCT04325360|Sham Comparator|Sham-tDCS|Participants in this arm of the study will receive sham transcranial direct current stimulation.
16350447|NCT04325347|Experimental|Virtual reality|Virtual Reality will be provided to all participants, just before sleeping.
16350448|NCT04325347|No Intervention|Control|No specific intervention will be provided.
16350449|NCT04325334|Experimental|Running volume increase|Participants will be be given a running program based on their running mileage on inclusion and supported by regular contacts with the study trainer.
16350450|NCT04325321|Other|Stress reactivity|Stress reactivity test
16350451|NCT04325308|Experimental|Protein-enriched human milk diet|Infants in this group will receive protein-enriched expressed human milk or donor human milk during the first 2 weeks after birth.
16350452|NCT04325308|Active Comparator|Usual human milk diet|Infants in this group will receive either expressed human milk or donor human milk during the first 2 weeks after birth.
16350453|NCT04325295|Active Comparator|Surgical treatment strategy:|
16350454|NCT04325295|Active Comparator|Gonadotrophins treatment strategy|
16350455|NCT04325282|Experimental|Children with BECTS|Children will receive sham and active rTMS on 2 separate study visits separated by at least 1 week.
16350456|NCT04325256||study group|All pregnant women who will attend the labor unit for induction of labour due to different indications during the study period will be invited to participate in the study.
16350457|NCT04325243|Experimental|study group|50 mg oral sildenafil citrate tablet
16350461|NCT04325204|Experimental|Caregivers|Caregivers of a person living with dementia will participate in the Faith-HAT intervention for 12 weeks.
16350462|NCT04325204|Experimental|Persons living with dementia|Persons living with dementia will participate in the Faith-HAT intervention for 12 weeks.
16350463|NCT04325191|Experimental|High Salt and Melatonin|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.
16350464|NCT04325191|Placebo Comparator|High Salt and Placebo|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.
16350465|NCT04325178|Experimental|Animal|Participants receive the majority of their protein from animal-derived protein sources (1.8g.kg.day).
16350466|NCT04325178|Experimental|Non-animal|Participants receive all their protein from non-animal-derived protein sources (1.8g.kg.day).
16350467|NCT04325165|Experimental|1: Chronic SCI subjects|"These subjects will undergo:
~Bilateral implantation of PPN DBS electrodes;
~Electrical stimulation of the DBS electrodes and
~Intensive locomotor training"
16350468|NCT04325152|Experimental|FCSEMS+Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. One to two centimeters of distal end of FCSEMS was left outside of the papilla and the stent was released. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
16350469|NCT04325152|Sham Comparator|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
16350470|NCT04325126||RBP4 in diabetes|RBP4 in diagnosed diabetes.
16350471|NCT04325126||RBP4 in pre-diabetes (pre-DM)|RBP4 in pre-diabetes (pre-DM).
16350472|NCT04325126||RBP4 in DM-CVD|RBP4 in diabetic cardiovascular disease.
16350473|NCT04325126||RBP4 in CVD|RBP4 in single coronary artery disease.
16350474|NCT04325126||RBP4 in NC|RBP4 in healthy controls.
16350475|NCT04325113|Placebo Comparator|NaCl 0,9%|patients receive 5ml of NaCl 0,9% at the level of the tonsils lodge
16350476|NCT04325113|Active Comparator|Xylocaine 2%|patients receive 5ml of Xylocaïne 2% at the level of the tonsils lodge
16350477|NCT04325113|Active Comparator|Levobupivacaine 0,5%|patients receive 5ml of Levobupivacaine 0,5% at the level of the tonsils lodge
16350478|NCT04325100|Experimental|Switch - i|Individual sessions
16350479|NCT04325100|Experimental|Switch - g|Group programme
16350480|NCT04325087|Experimental|Active iTBS|Active stimulation of the dlPFC directly after trauma exposure and on the following two days
16350481|NCT04325087|Placebo Comparator|Placebo iTBS|Same procedure as in the active stimulation group but with a placebo stimulation imitating the sensation of a real iTBS protocol.
16350482|NCT04325074|Experimental|Mental practice|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice group was n=12.
16350483|NCT04325074|Experimental|Mental practice + skill training|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice + skills training group was n=13.
16350484|NCT04325074|Active Comparator|Control group|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of control group was n=10.
16350485|NCT04325061|No Intervention|Control group|Patients will be treated with standard intensive care
16350486|NCT04325061|Active Comparator|Dexamethasone|Standard intensive care plus dexamethasone
16350487|NCT04325035|Experimental|Istaroxime|Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
16350488|NCT04325035|Placebo Comparator|Placebo|Placebo (lactose lyophilized powder) IV infusion for 24 hours
16350489|NCT04325022||Primary Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in primary THA
16350490|NCT04325022||Revision Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in revision THA
16350491|NCT04325009|Experimental|RTRT|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
16350492|NCT04325009|Experimental|TRTR|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
16350493|NCT04324996|Experimental|NK cells|The NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
16350494|NCT04324996|Experimental|IL15-NK cells|The NK cells secreting super IL15 superagonist are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
16350495|NCT04324996|Experimental|NKG2D CAR-NK cells|The NKG2D CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
16350496|NCT04324996|Experimental|ACE2 CAR-NK cells|The ACE2 CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
16350497|NCT04324996|Experimental|NKG2D-ACE2 CAR-NK cells|The NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
16350498|NCT04324983|Other|Biomarker|This single-arm study is a Phase I study to exploratively identify potential biomarkers in patients with early prostate cancer relapse and limited metastases in PSMA-PET, who need further assistance in treatment decisions (for or against local treatment options).
16350499|NCT04324970|Experimental|Tookie vest|Participant issued with Tookie vest
16350500|NCT04324944|Experimental|Collaborative Decision Skills Training|Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
16350501|NCT04324944|Active Comparator|Money Management|Money Management is the active control arm.
16350502|NCT04324931|Experimental|Biomechanical corrections|In this group, biomechanical correction will be perform with the help of mobilization with movement to correct biomechanical misalignment and along with this conventional treatment, in which Hydrocollatoral packs for 20 minutes, Interferential Therapy for 15 minutes with beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program for 3 sessions of 20 minutes on alternative days for 3 weeks. Which will be given for three days a week for three weeks.
16350503|NCT04324918|Experimental|HCP1102|
16350504|NCT04324918|Active Comparator|HGP1408|
16350505|NCT04324905|Experimental|Sequence 1|
16350506|NCT04324905|Experimental|Sequence 2|
16350508|NCT04324879|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
16350509|NCT04324866||Group 1|Patients with chronic plaque psoriasis on immunosuppressant therapy
16350510|NCT04324866||Group 2|Psoriatic patients' partners
16350511|NCT04324866||Group 3|Patients with atopic dermatitis treated with dupilumab
16350512|NCT04324853||S. haematobium positive|Preganant women infected with Schistosomia hematobium alone
16350513|NCT04324853||geohelminths positive|pregnant women infected with geohlminths alone
16350514|NCT04324853||Helminth negative|Pregnant women free of anyn helminths infection
16350515|NCT04324840|Experimental|Adjuvant Treatment|CC-90010-with standard dose TMZ
16350516|NCT04324840|Experimental|Concomitant treatment.|CC-90010 combined with standard dose TMZ and RT
16350517|NCT04324827|Experimental|Graston Technique® Group|The application was applied by a GT® certified therapist with 12 years of experience in orthopedic rehabilitation and soft tissue treatments. Hamstring, gastrosoleus and plantar fascia were scanned with GT® instruments and the treated soft tissue was treated. The instruments used differ according to the application protocol and regions are determined with reference to the GT® manual. The treatment lasted 8 minutes for each leg and was applied to both legs equally and by the same person for a total of 16 minutes.
16350518|NCT04324827|Experimental|Foam Roller Group|FR was applied to gastrosoleus and hamstring muscle groups and plantar fascia. TriggerPoint Grid X Foam Roller and Nano Foot X Roller were used in the application. Hamstring, gastrosoleus and plantar fascia for 3 minutes were performed for a single leg. The treatment lasted 8 minutes on one leg and was applied equally to both legs for a total of 16 minutes. Before the application, the participants were informed with verbal and visual warnings about how to do the applications. During the application, the participant was instructed about the time with a stopwatch. The patient himself regulated the pressure applied to the FR; however, the participant was instructed to apply FR as much body weight as possible. The frequency of application was about 0.5 Hz (ie, each rolling cycle lasted for about 2 seconds).
16350519|NCT04324827|Experimental|Dynamic Stretch|DS protocol was prepared with reference to the work of Faigenbaum et al 2005. The protocol consists of 10 dynamic exercises of 10 minutes of medium and high intensity. Each dynamic stretching exercise was performed at a distance of 13 meters. The participants were given a 10-second rest period between each exercise. The participants were given verbal feedback about their postures during the exercises and the video of the exercises was shown to the participant.
16350524|NCT04324801|Experimental|Single arm|This is a within-subject repeated-measures design.
16350525|NCT04324788||Group 1|"Transtibial amputation
~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
16350526|NCT04324788||Group 2|"Transfemoral amputation
~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
16350527|NCT04324775||Group 1|Exercise+Manual Lymphatic Drainage
16350528|NCT04324775||Group 2|Exercise+Swedish Massage
16350529|NCT04324749|Experimental|Group A (roasted peanuts)|Group A: Habitual diet + 25 g/day of whole skin roasted peanuts (RP)
16350530|NCT04324749|Experimental|Group B (peanut butter)|Group B: Habitual diet+ 2 tbsp/day (32 g/day) of peanut butter (PB)
16350531|NCT04324749|Experimental|Group C (control)|Group C: Habitual diet + 2 tbsp/day (32 g/day) of control supplement
16350532|NCT04324736||Patients with diabetes|
16350533|NCT04324736||Patients without diabetes|
16350534|NCT04324723|Experimental|Intervention|Participants in this group received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
16350535|NCT04324723|No Intervention|Control|Participants in this group did not received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
16350536|NCT04324684||Covid19 pneumonia with comorbidities|"Patients with pneumonia from Covid 19 with at least one of the following comorbidities:
~Hypertension
~Obesity and/or type 2 diabetes
~Cardiovascular disease
~Chronic obstructive lung disease"
16350537|NCT04324684||Covid2 pneumonia without comorbidities|Without any of the following comorbidities
16350538|NCT04324645||Active Symptom Monitoring via Noona|Participants will undergo a single training session on how to use the Noona software no more than 4-12 weeks before starting therapy. They can start using the software immediately after the training session. Patients will be invited to complete either the Chest Radiotherapy (if radiotherapy alone), Chemotherapy-18 (if chemoradiation therapy), or Bone Radiotherapy (if other) module at baseline, every other week throughout therapy, and during follow up for 90-days. Patients will be encouraged by the treatment team to complete the baseline symptom report prior to starting any therapy and to complete the reports during therapy and in follow up. Patients will also complete the EORTC QLQ-C30 and the NCCN Distress Thermometer at baseline (no more than 12 weeks before starting therapy), within 1 week of completing therapy, and at 90-days follow up. Patients will be encouraged to use Noona's other features beyond invited modules and PRO inventories, such as the diary during the study
16350539|NCT04324619|Experimental|Immediate|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning immediately.
16350540|NCT04324619|Experimental|3 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 3 months.
16350541|NCT04324619|Experimental|6 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 6 months.
16350542|NCT04324619|Experimental|12 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 12 months.
16350543|NCT04324606|Experimental|Group 1a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
16350544|NCT04324606|Active Comparator|Group 1b|Volunteers will receive a standard single dose of MenACWY vaccine
16350545|NCT04324606|Experimental|Group 1c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 5x10^10vp ChAdOx1 nCoV-19 9 months later
16350546|NCT04324606|Experimental|Group 1d|Volunteers will receive a standard single dose of MenACWY vaccine. 9 moths later they will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 4-12 weeks apart
16350547|NCT04324606|Experimental|Group 2a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
16350548|NCT04324606|Active Comparator|Group 2b|Volunteers will receive a standard single dose of MenACWY vaccine
16350549|NCT04324606|Experimental|Group 2c|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and week 8
16350550|NCT04324606|Experimental|Group 2d|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 2.5x10^10vp ChAdOx1 nCoV-19 at week 8
16350551|NCT04324606|Active Comparator|Group 2e|Volunteers will receive two standard single doses of MenACWY vaccine at week 0 and week 8
16350552|NCT04324606|Experimental|Group 2f|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
16350553|NCT04324606|Active Comparator|Group 2g|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
16350554|NCT04324606|Experimental|Group 3a|Volunteers will receive one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 4
16350555|NCT04324606|Experimental|Group 3b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0, a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
16350556|NCT04324606|Experimental|Group 4a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
16350557|NCT04324606|Active Comparator|Group 4b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
16350558|NCT04324606|Experimental|Group 4c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
16350559|NCT04324606|Active Comparator|Group 4d|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
16350560|NCT04324606|Experimental|Group 5a|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 ≤ 16 weeks apart, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
16350561|NCT04324606|Experimental|Group 5b|Volunteers will receive two standard single doses of MenACWY vaccine ≤ 16 weeks apart, a dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months then a second dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) 4-12 weeks later
16350562|NCT04324593|Experimental|IV line with an attached Deltran BP transducer|After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
16350563|NCT04324580|Active Comparator|Delayed mobilization/Formal physical therapy group|Participants will be placed into a volar-based plaster splint post-operatively. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. After that, participants will be placed into a custom thermoplastic splint by a therapist. This will be worn for 5 weeks. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks. The splint will be removed only for formal and home physical therapy and hygiene.
16350564|NCT04324580|Active Comparator|Immediate mobilization/self guided physical therapy group|Participants will be placed into a soft dressing after surgery. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. This group will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
16350565|NCT04324567||APR-open|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparotomy.
16350566|NCT04324567||APR-robot|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparoscopic robot assisted technique.
16350567|NCT04324554||MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
16350568|NCT04324541||Mexican American Adults|No intervention
16350569|NCT04324528|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
16350570|NCT04324528|Other|control-arm: vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
16350571|NCT04324515|Other|Study Arm without cholecystectomy|Study Arm: Patients with gastric bypass without concomitant cholecystectomy
16350572|NCT04324515|Other|Control Arm with cholecystectomy|Control Arm: Patients with gastric bypass with concomitant cholecystectomy
16350573|NCT04324502||Neuroendocrine neoplasms (tumours)|Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization/ ablative therapies or surgery.
16350574|NCT04324489|Experimental|DAS181 Treatment|Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
16350609|NCT04324268|Experimental|SC 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.
16350610|NCT04324268|Experimental|SC 5 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.
16350575|NCT04324476|Experimental|Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI|"Induction chemotherapy:
~Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI:
~Bevacizumab: 5mg/kg, iv, 30min, d1, 2w; Oxaliplatin: 85mg/㎡, iv, 120min, d1, 4w; Irinotecan: 150mg/㎡, iv, 90min, d15, 4w; Capecitabine: 1000mg/㎡, bid, d2-8, 2w.
~Maintenance chemotherapy:
~Bevacizumab: 7.5mg/kg, iv, 30min, d1, q3w; Capecitabine: 1000mg/㎡, bid, d2-15, 2w."
16350576|NCT04324463|Experimental|Colchicine|"Outpatients:
~0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).
~Inpatients:
~1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.
~(*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days [total 28 days]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days)."
16350577|NCT04324463|Experimental|Interferon Beta [This arm is now closed to recruitment]|"Inpatients Only:
~0.25 mg by subcutaneous injection on days 1, 3, 5 & 7"
16350578|NCT04324463|Experimental|Aspirin (ASA)|"Outpatients:
~75 to 100 mg once daily for 28 days.
~Inpatients:
~75 to 100 mg once daily for 28 days"
16350579|NCT04324463|Experimental|Rivaroxaban|"Inpatients Only:
~2.5 mg twice daily for 28 days."
16350580|NCT04324463|No Intervention|Usual Care (Control)|Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.
16350581|NCT04324450|Experimental|Patients radiotherapy +|Patients cured of a brain tumour and who have received radiotherapy in childhood
16350582|NCT04324450|Experimental|Patients radiotherapy -|Patients cured of a brain tumour and who have received surgery and/or chemotherapy but were not irradiated
16350583|NCT04324450|Experimental|Healthy volunteers|"Healthy volunteers (control group) matched in age, manual laterality, gender and parental education to Patients radiotherapy +"
16350584|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|Two groups of patients with differing internet access: access from home or access in clinic only
16350585|NCT04324424|Experimental|Undialyzed ESRD subjects (P1)|"Part 1: Undialyzed end stage renal disease (ESRD) patients to receive a single dose of HMS5552 ( 25mg ) tablets orally
~."
16350586|NCT04324424|Experimental|Healthy volunteers (H)|"Part 1: Matched healthy volunteers to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~H group and P1 group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
16350587|NCT04324424|Experimental|Severe renal impaired subjects (P2)|"Part 2：Severe renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~P2 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
16350588|NCT04324424|Experimental|Moderate renal impaired subjects (P3)|"Part 2：Moderate renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~P3 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
16350589|NCT04324424|Experimental|Mild renal impaired subjects (P4)|"Part 2：Mild renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~P4 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
16350590|NCT04324411|Experimental|treatment group|combined sirolimus(serum concentration to be 4-10ng/ml) and ATRA (20mg bid) for at least 6 months
16350591|NCT04324398|No Intervention|group I (control )|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping, between each file and till the final rinse
16350592|NCT04324398|Experimental|Group II|irrigation with 5% cold sodium hypochlorite (2-5°C) from the beginning of cleaning and shaping and between each file. Final rinse was done by 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
16350593|NCT04324398|Experimental|Group III|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
16350594|NCT04324398|Experimental|Group IV|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of cold saline (2-5°C) for 5 minutes
16350595|NCT04324372|Experimental|HEC68498|HEC68498 will be administered daily
16350598|NCT04324346|Experimental|PICC-Line|Women allocated to PICC-line when receiving chemotherapy
16350599|NCT04324346|Experimental|Subcutaneous Venous Access Port (SVAP)|Women allocated to SVAP when receiving chemotherapy
16350600|NCT04324333|Experimental|Using Digital wearable system for fall detection|Digital wearable system (Owlytics Healthcare's app) enables a 24/7 health-tracking service, collecting personal health data from wearable wristbands and insoles. The data is analyzed by machine-learning algorithms that can detect abnormal physiological patterns. This allows the prediction and prevention of potentially harmful health events (such as falls).
16350601|NCT04324320||outpatients (oncological rehabilitation)|the population studied in this cross-sectional study includes patients with malignant tumour diseases and benign CNS tumours who present to the Outpatient Clinic for Oncological Rehabilitation at the Department of Physical Medicine and Rehabilitation of the Medical University of Vienna
16350602|NCT04324307|Experimental|PD-L1/CTLA4 BsAb|For 2nd line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W
16350603|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + GP|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Gemcitabine 1000 mg/m2 and Nab-paclitaxel 125 mg/m2 , 28days/cycle
16350604|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + FOLFIRINOX|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Oxaliplatin 68 or 85 mg/m2, Irinotecan 135 or 150 or 180 mg/m2, Calcium Folate 400 mg/m2, Fluorouracil 2400mg/m2, 14 days/cycle
16350605|NCT04324294|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
16350606|NCT04324268|Placebo Comparator|Placebo|Placebo
16350607|NCT04324268|Experimental|SC 0.3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.
16350608|NCT04324268|Experimental|SC 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.
16350611|NCT04324268|Experimental|IV 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.
16350612|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.
16350613|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002) (Priming)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.
16350614|NCT04324268|Experimental|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 300 mg of lirentelimab (AK002) administered subcutaneously.
16350615|NCT04324268|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive a total of 450 mg of lirentelimab (AK002), administered as two separate subcutaneous injections.
16350616|NCT04324255||Low ratio|Liver recipient with low preoperative von Willbrand factor-to-protein C ratio
16350617|NCT04324255||High ratio|Liver recipient with high preoperative von Willbrand factor-to-protein C ratio
16350618|NCT04324242||Group1|visual feedback
16350619|NCT04324242||Group2|traditional feedback
16350620|NCT04324229|Active Comparator|liraglutide|
16350621|NCT04324229|Placebo Comparator|placebo|
16350622|NCT04324216|Experimental|Experimental group|3D virtual reality and hands-on aromatherapy
16350623|NCT04324216|No Intervention|Control group|No intervention
16350624|NCT04324203|Experimental|Experimental group|Three-dimensional Virtual Reality and Horticultural Therapy
16350625|NCT04324203|No Intervention|Control group|No intervention
16350626|NCT04324190|Experimental|Online support program|Guided online support program, consisting of modules (structured in chapters) aiming at reduce stress related to the COVID-19 pandemic.
16350627|NCT04324190|Active Comparator|Waiting period (WHO recommendation)|"Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations Coping with stress during the 2019 nCoV outbreak. Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'."
16350628|NCT04324190|No Intervention|No intervention (natural course)|"This non-randomised arm (recruited separately; anticipated sample size of 500 subjects, not counted in the overall anticipated sample size) consists of subjects not intending to participate in the Selfapy online support program. Assessment points in this arm are comparable to those in the arm Online support program (in the 'No intervention (natural course)' arm, T1 refers to time of study inclusion)."
16350629|NCT04324138|Experimental|Experimental group|Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
16350630|NCT04324138|Sham Comparator|Control group|Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
16350631|NCT04324112|Experimental|Arm 1/Experimental therapy|Treatment with encorafenib and binimetinib
16350632|NCT04324099||Conduct disorder|children and adolescents with CD
16350633|NCT04324099||Autism-Spectrum disorder|children and adolescents with ASD
16350634|NCT04324099||typically developing adolescents|typically developing adolescents
16350635|NCT04324086|Experimental|XP-endo Finisher file|removal of calcium hydroxide intracanal medication with XP-endo Finisher file
16350636|NCT04324086|Experimental|Irrisafe Ultrasonic tip|removal of calcium hydroxide intracanal medication with passive ultrasonic irrigation
16350637|NCT04324086|Active Comparator|side vented needle|removal of calcium hydroxide intracanal medication with conventional syringe irrigation
16350638|NCT04324073|Experimental|SARILUMAB|Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1).
16350639|NCT04324073|No Intervention|Standard of care|best standard of care
16350640|NCT04324060|Active Comparator|TPO treatment group|Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months
16350641|NCT04324060|Placebo Comparator|control|Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months
16350642|NCT04324034|Experimental|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
16350643|NCT04324034|Active Comparator|laparoscopy|conventional laparoscopy
16350644|NCT04324021|Active Comparator|Emapalumab|Emapalumab i.v infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
16350645|NCT04324021|Active Comparator|Anakinra|Anakinra i.v infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
16350646|NCT04324021|No Intervention|Standard of care|Standard of care according to local practice
16350647|NCT04324008|Experimental|Constic|Constic (DMG, Hamburg, Germany)
16350648|NCT04324008|Experimental|G-ænial Universal Flo|G-ænial Universal Flo (GC Corporation, Tokyo, Japan) in combination with G-Premio Bond (self-etch mode)
16350649|NCT04324008|Experimental|Tetric N-Flow (self-etch)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (self-etch mode)
16350650|NCT04324008|Experimental|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (etch&rinse mode)
16350651|NCT04323982|Experimental|New Cataract Surgery|Traditional surgery combined triamcinolone staining of the anterior vitreous (TA)
16350652|NCT04323982|Active Comparator|Traditional Cataract Surgery|For patients younger than 2 years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + A-vit) For patients older than 2years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + primary intraocular lens implantation + anterior vitrectomy (ACCC+ I/A + PCCC + IOL + A-vit)
16350653|NCT04323969|Experimental|Specific Modification Target|A 15 degree relative increase to foot progression angle
16350654|NCT04323969|Experimental|Self-directed Modification|"A self-directed increase to foot progression angle that is as much as is comfortable."
16351155|NCT04320550||abdominal pain|one group of children complaining of recurrent abdominal pain
16350655|NCT04323956|Experimental|Treatment (parsaclisib, R-CHOP)|Patients receive parsaclisib PO QD on days 1-10 or 1-14, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16350656|NCT04323943|Experimental|Carbon-AFO (C-AFO)|Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
16350657|NCT04323943|Active Comparator|Custom-made thermo-plastic orthosis (CM-AFO)|Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
16350658|NCT04323943|No Intervention|Without orthosis (NO)|No orthosis - patient will wear only their shoes
16350659|NCT04323930|Experimental|eyeWatch|
16350660|NCT04323930|Experimental|Trabeculectomy|
16350661|NCT04323917||Cases|Subjects affected by Pancreatic carcinoma (PC) confirmed by tissue biopsy
16350662|NCT04323917||Controls|Healthy Subject enrolled following colon cancer screening via colonoscopy
16350663|NCT04323904||Hantavirus Group|Patients with cultural, serological, molecular evidence of hantavirus infection
16350664|NCT04323904||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
16350665|NCT04323891||Higher Trainee/Service Doctor|
16350666|NCT04323865||Study 2. Repeatability of FHRV|
16350669|NCT04323839||Pregnant Women|Women who are currently pregnant and are suspected or diagnosed COVID-19 positive.
16350670|NCT04323839||Post-partum women|Women who have been pregnant in the past 6 weeks and are suspected or diagnosed COVID-19 positive.
16350671|NCT04323826|Experimental|salads with olive oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water mixture will be provided to consume.
16350672|NCT04323826|Experimental|salads with olive oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
16350673|NCT04323826|Experimental|salads with coconut oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
16350674|NCT04323826|Experimental|salads with coconut oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water mixture will be provided to consume.
16350675|NCT04323813||Cases|CRC patients: primary, Stage I-IV (localized, node negative or node positive) colon carcinoma confirmed by tissue biopsy, and patients with advanced adenoma (including high-grade dysplasia, HGD).
16350676|NCT04323813||Controls|Controls subjects as well as healthy clean colonoscopy subjects or with hyperplastic polyps, and healthy subjects with diminutive adenoma-low grade dysplasia (LGD) and with inflammatory bowel disease (IBD).
16350677|NCT04323800|Experimental|High titer anti-SARS-CoV-2 plasma|Participants with High titer anti-SARS-CoV-2 plasma.
16350678|NCT04323800|Active Comparator|SARS-CoV-2 non-immune plasma|Participants with SARS-CoV-2 non-immune plasma.
16350679|NCT04323787||COVID19 test positive/pending or high clinical suspicion|COVID19 test positive/pending/high clinical suspicion- patient admitted to hospital
16350680|NCT04323774|No Intervention|Aim 1-Part 1 Stakeholder Interview|"This arm will focus on finding the best format for the study intervention (called AYA-RISE) whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.
~The research study procedures include:
~Using and reviewing AYA-RISE
~Participating in audio-recorded, 30-minute interviews"
16350681|NCT04323774|Experimental|Aim 1-Part 2|"This arm is a pilot study of the study intervention (called AYA-RISE).
~The activities involved in this part of the study are:
~Baseline Questionnaire
~Using and reviewing AYA-RISE
~Follow-up Questionnaire
~Brief interviews to get feedback on AYA-RISE"
16350682|NCT04323774|Active Comparator|Aim 2-Genetic Counseling|"The names of the study activities involved in this study are:
~Baseline Questionnaire
~Follow-up Questionnaire
~Medical record review
~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
16350683|NCT04323774|Experimental|Aim 2- Genetic Counseling with AYA-RISE|"The names of the study activities involved in this study are:
~Baseline Questionnaire
~Follow-up Questionnaire
~Medical record review
~Using the study intervention, AYA-RISE
~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
16350684|NCT04323774|No Intervention|Aim 3 Semi-structured interviews|Each site will conduct 30-minute interviews with patients, caregivers, and providers, and site principal investigators.
16350685|NCT04323748|Experimental|rituximab|All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
16350686|NCT04323735|Active Comparator|Low Dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 ]LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
16351187|NCT04320264||Low oxidizers/high lactate|Individuals with low aerobic oxidation
16350687|NCT04323735|Active Comparator|High dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
16350688|NCT04323722|Experimental|Empty bladder|Planning CT scan and CBCTs with empty bladder after standard Planning CT scan and CBCTs with filling bladder
16350689|NCT04323709||levosimendan group|All patients undergoing VA-ECMO from January 2012 to December 2018 and treated with levosimendan were eligible.
16350690|NCT04323709||group control|All patients undergoing VA-ECMO from January 2012 to December 2018 but not treated with levosimendan were eligible.
16350691|NCT04323696|Other|Over-sewing|Patients under over-sewing arm are subjected to staple line reinforcement using over-sewing method
16350692|NCT04323696|Other|Plication|Patients under over-sewing arm are subjected to staple line reinforcement using plication method
16350693|NCT04323683||Low progesterone|Women with progesterone level below 15 ng/ml
16350694|NCT04323683||Normal progesterone|Women with progesterone level above 15 ng/ml
16350695|NCT04323670|Other|Selectra 3D|Guiding catheter to position the brady lead into a untypical heart position
16350696|NCT04323657|Experimental|Phase 1|The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort.
16350697|NCT04323657|Experimental|Phase 2|The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen.
16350698|NCT04323644||Cohort 1|Patients with COVID-19 infection undergoing surgery
16350699|NCT04323631|Experimental|The intervention group|The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).
16350700|NCT04323631|Other|The control group|The control group will not receive hydroxychloroquine.
16350701|NCT04323618|Other|Free breathing or Breathe Well|Free breathing or Breathe Well
16350702|NCT04323605|Experimental|outpatient assistance program|
16350703|NCT04323592||Exposed to Methylprednisolone|Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
16350704|NCT04323592||Non-exposed to Methylprednisolone|Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.
16350705|NCT04323579||prospective cohort of stage I-II lung cancer patients|A prospective cohort of stage I-II lung cancer patients (N=80) candidates to surgery at Humanitas, and 40 controls with benign nodules.
16350706|NCT04323579||retrospective screening cohort of 50 patients|A retrospective screening cohort of 50 patients with screened lung cancer at MUG.
16350707|NCT04323579||prospective screening cohort of 30 patients|A prospective screening cohort of 30 patients with screened lung cancer and 100 matched negative controls enrolled at Humanitas cohort of 1000 participants (expected annual rate 1.5%).
16350708|NCT04323579||retrospective screening cohort from the NELSON study|A retrospective screening cohort from the NELSON study.
16350709|NCT04323579||Prospective cohort of stage IV lung cancer patients|A Prospective cohort of stage IV lung cancer patients (N=30) candidate to systemic therapy.
16350710|NCT04323566|Experimental|Treatment-first arm|Participants receive i.v. infusions with 500 mg Rituximab at 0 and 4 months, followed by placebo infusions (NaCl) at 8 and at 12 months, Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
16350711|NCT04323566|Experimental|Placebo-first arm|Participants receive placebo (NaCl) i.v. infusions at 0 and 4 months, followed by 500-mg-Rituximab infusions at 8 and 12 months. Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
16350712|NCT04323553||ESBL E.coli strains from 24 contact-index patients|48 ESBL-E. coli strains from 24 contact-index patients
16350713|NCT04323540|Active Comparator|Xenograft+collagen membrane|Reconstructive approach (Xenograft+collegen membrane)
16350714|NCT04323540|Experimental|Xenograft+collagen membrane+autologous soft tissue graft|Reconstructive approach (Xenograft+collegen membrane) plus soft tissue graft (autologous, harvested as FGG)
16350715|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1|Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
16350716|NCT04323527|Active Comparator|High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1|High dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
16350717|NCT04323527|Placebo Comparator|Placebo (5 days) (Study stage 2) - Clorocovid 3|Placebo group consists of 3 placebo tablets bid (day 1), and 3 placebo tablets once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
16350718|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3|Low dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
16350719|NCT04323514|Experimental|Patients with COVID-19 pneumonia|Consecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
16350720|NCT04323501|Experimental|Experimental treatment group|"This group will undergo an intensive-rehabilitation treatment of post-stroke sensorimotor disability based on a guided self-rehabilitation contract. This approach is based on the fact that the patient must complete a diary of his self-rehabilitation activity in order to verify its correct and full execution. The treatment protocol will be defined on the basis of the clinical picture (patterns) manifested by the patient (the intensity and frequency of the exercises will be adapted according to the characteristics of each patient). The duration of treatment will be the same for all patients. The exercises will be performed every day throughout the study period (12 months).
~Before undertaking the intensive self-management treatment, each patient will undergo 10 sessions of neurorehabilitation treatment at the UOC Neurorehabilitation of the Integrated University Hospital according to normal clinical practice, during which the patient will be provided with infographic support material."
16350721|NCT04323501|Active Comparator|Control group|The patients allocated to the control group, during the study period they will undergo conventional outpatient rehabilitation treatment (usual care) at the Neurorehabilitation Unit of the AOUI according to the clinical practice through the procedures provided for by the Health System National.
16350722|NCT04323488|Experimental|Lindamood-Bell Seeing Stars|Subjects receive reading instruction focusing on the building blocks of reading
16350723|NCT04323488|No Intervention|Control|Subjects are followed longitudinally but do not receive intervention
16350724|NCT04323475|Active Comparator|Standard of Care|Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
16350725|NCT04323475|Experimental|Cocktail-SPK and standard of care|The experimental drug consists of Cocktail-SPK used as an adjunct to the standard of care. Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
16350726|NCT04323462|Experimental|Intensive Glucose Control|"Intensive Glucose control Insulin ≥3 times per day; Goals: prePBG 80-130 & post PBG <180 (60% of all readings); HbA1c <8% at 3 months SMBG at least 14 readings/week (3-5 FBG, rest PPBG) and/or CGMS readings Reexamined weekly for 1 month; then fortnightly for 3 months and then monthly till 6 months
~Intensive subgroup will receive a standard glucometer with strips as one-week supply or CGMS for glycemic monitoring. They will receive a diabetic monitoring log/chart for home use. The chart and glucometer will have to be shown at each week of follow up. Number of hypoglycemic events in past week will be checked for each patient. This sub group will receive instructions to use 3 times bolus (regular/analogue) and single time basal insulin (glargine). Treatment goals will be conveyed at first contact and reinforced at each visit. Insulin dose modulation will be done telephonically. Patients will be reviewed weekly for 1 month and then fortnightly."
16350727|NCT04323462|Active Comparator|Conventional Glucose control|Fixed dosage of oral anti-diabetic drugs/insulin per week as patient is receiving prior; Insulin <3 times per day SMBG <3 times per day
16350728|NCT04323449|Experimental|Vision-guided control|New custom control method
16350729|NCT04323449|Experimental|Default control|Default control method (joystick or switch)
16350730|NCT04323436|Experimental|Run-in part|capmatinib in combination with spartalizumab
16350731|NCT04323436|Experimental|Randomized part - Arm 1 spartalizumab|capmatinib in combination with spartalizumab
16350732|NCT04323436|Experimental|Randomized part - Arm 2 placebo|capmatinib in combination with placebo
16350733|NCT04323423|No Intervention|Control (CON)|1) Condition A (CON): This will be the control condition. It will consist of uninterrupted sitting from 8 am until 7 pm, only rising from the chair to void.
16350734|NCT04323423|Experimental|one 10 minute bout - (LONG)|will consist of completing one 10-minute bout of light intensity walking (RPE 6-9) 30 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform this bout. The participant will repeat this after lunch and dinner, for an accumulated total of 30 minutes of light walking.
16350735|NCT04323423|Experimental|four 2.5 minute bouts SHORT|will consist of interrupting sitting with four 2.5-minute bouts of light walking at 30 minutes, 60 minutes, 90 minutes and 120 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform these bouts. The participant will repeat this after breakfast, lunch and dinner for an accumulated total of 30 minutes of light walking.
16350736|NCT04323410|Experimental|Cast immobilization|"In the casting group, padded synthetic dorsal above elbow and volar below elbow splints are applied in ED without local or general anesthesia. Dorsal displacement and shortening of the radius are not corrected, but the forearm is attempted to be manipulated straight during application of the splints. The casted forearm is then supported by a collar and cuff sling. Splints are removed in an outpatient clinic at 4 weeks.
~Cast immobilization is discontinued after 4 weeks and when the fracture site is nontender. If palpated tenderness is still present, the patient is given a dorsal forearm splint which can be removed (maximum of 2 weeks usage)."
16350737|NCT04323410|Active Comparator|Percutaneus pinning|In the surgery group, a padded dorsal above elbow splint is applied in ED. Reduction and percutaneous pinning are performed under anesthesia in operating room by an experienced attending pediatric orthopedic surgeon within 7 days from the injury. Pin fixation is performed with two 1.6 mm pins. Padded dorsal above elbow and volar below elbow splints are applied. Splints and pins are removed at the outpatient clinic at 4 weeks after surgery.
16350738|NCT04323397|Experimental|nasal high frequency oscillatory ventilation|"nHFO: flow 8-10 L/minute, frequency 10 Hz, MAP = MAP (before extubation) + 2 or 8 (preterm), 10 (term) cmH2O, dP = 2-3 times of MAP with visible chest oscillations or 25-35 cmH2O, I:E = 1:1, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%"
16350739|NCT04323397|Experimental|nasal synchronized intermittent positive pressure ventilation|"nSIPPV: flow 8-10 L/minute, rate 60/minute, PIP = PIP (before extubation) + 2-5 or 20 (preterm), 25 (term) cmH2O, PEEP = 5 cmH2O, IT = 0.5 s, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%. The highest trigger sensitivity avoiding auto triggering was selected."
16350769|NCT04323241|Experimental|Study Group|In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.
16351188|NCT04320264||High oxidizers/low lactate|Individuals with high aerobic oxidation
16350740|NCT04323384|Experimental|Biotene® followed by Sham|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into either Protocol A or Protocol B. In their first session, participants in Protocol A will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the experimental condition. For the experimental condition, participants will be instructed to apply Biotene® Oralbalance Moisturizing Gel according to package directions. Testing will then be repeated. In the second session, after baseline testing, participants will receive the sham condition (instead of the experimental condition). For the sham condition, participants will be instructed to rinse their mouth with room temperature distilled water. Testing will then be repeated.
16350741|NCT04323384|Experimental|Sham followed by Biotene®|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into two protocols: 1) Protocol A and 2) Protocol B. In their first session, participants in Protocol B will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the sham condition. Testing will then be repeated. In the second session, after baseline testing, participants will receive the experimental condition (instead of the sham condition). Testing will then be repeated.
16350742|NCT04323371||Acute decompensated heart failure|patients admitted with Acute decompensated heart failure Complicated by cardiogenic shock
16350743|NCT04323358|Active Comparator|IOL Master® 700|Biometry will be performed three times consecutively.
16350744|NCT04323358|Active Comparator|Pentacam®|Keratometry will be performed three times consecutively.
16350745|NCT04323358|Active Comparator|Casia II®|Keratometry will be performed three times consecutively.
16350746|NCT04323358|Active Comparator|Spectralis Anterion®|Biometry will be performed three times consecutively.
16350747|NCT04323345|Experimental|Natural Honey Group|"Natural Honey
~1gm/kg/day divided into 2 to 3 doses for 14 days in addition to standard care"
16350748|NCT04323345|Active Comparator|Standard Care|Current standard care including supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
16350749|NCT04323332|Experimental|Traditional Chinese Medicine|TCM prescription and conventional treatments
16350750|NCT04323332|No Intervention|Control|conventional treatments
16350751|NCT04323319|Experimental|ESWT Group|Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
16350752|NCT04323319|Experimental|Graston Technique® Group|The application was carried out by Graston Technique® (GT®) certified, a therapist with orthopedic rehabilitation and soft tissue treatments for over 12 years. GT® instruments were used to diagnose and treat the damaged soft tissue of gastrocnemius and plantar fascia. The application protocol and the instruments used according to the regions were determined with reference to the GT® manual. GT® treatment can be given to the same region twice a week. A minimum of 2 days break was given between the applications. Gastrocnemius and plantar fascia application completed in 5 minutes in one leg. GT2, GT4 and GT6 instruments used for application.The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
16350753|NCT04323319|Experimental|Control Group|Stretching group was accepted as the control group. the patient monitored once a week at the hospital and continue home stretching program at home. These patients will be given information about plantar fasciitis as well as other groups. Plantar fascia and gastrosoleus self-stretching exercises will be required to be performed twice a day for thirty seconds and three repetitions for 4 weeks. The patients will be followed with an exercise follow-up form.
16350754|NCT04323306|Active Comparator|Cohort 1 SAD|5 mg MMV533 with single ascending dose
16350755|NCT04323306|Active Comparator|Cohort 2 SAD|Single ascending dose to be determined after SRC review of previous cohort.
16350756|NCT04323306|Active Comparator|Cohort 3 SAD|Single ascending dose to be determined after SRC review of previous cohort.
16350757|NCT04323306|Active Comparator|Cohort 4 SAD|Single ascending dose to be determined after SRC review of previous cohort.
16350758|NCT04323306|Active Comparator|Cohort 5 SAD|Single ascending dose to be determined after SRC review of previous cohort.
16350759|NCT04323306|Active Comparator|Cohort 6 SAD|Single ascending dose to be determined after SRC review of previous cohort.
16350760|NCT04323306|Active Comparator|Cohort 7 SAD|Single ascending dose to be determined determine after SRT review of previous cohort. Dose will not exceed 400 mg.
16350761|NCT04323306|Active Comparator|Part 2: Food Effect|Open label, 2-period cross-over, randomized, pilot food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV533 determined to be safe in Part 1.
16350762|NCT04323293|Experimental|CPM - Cold Water Bath|
16350763|NCT04323293|Sham Comparator|CPM - SHAM|
16350764|NCT04323280|Active Comparator|Conventional Therapy|Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg) for 3 months
16350765|NCT04323280|Experimental|Dexamethasone therapy|Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg)
16350766|NCT04323267|Experimental|Digital Home Exercise Program|Limber Digital Application Device (3 x a week for 8 weeks)
16350767|NCT04323267|Active Comparator|Physical therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
16350768|NCT04323241|No Intervention|control group|In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.
16350884|NCT04322422|Active Comparator|ICS/LABA only|
16351189|NCT04320264||Obese|Severely obese scheduled for surgery
16350770|NCT04323228|Experimental|Intervention|the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.
16350771|NCT04323228|Placebo Comparator|Placebo|Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.
16350772|NCT04323215||Support system users|Usual care (behavioral treatment) plus the support system for self-monitoring of weight and communication with the clinic during one year of treatment.
16350773|NCT04323215||Control group|Children treated with usual care according to regular treatment routines registred in BORIS the Swedish childhood obesity treatment register
16350774|NCT04323202|Experimental|Permbrolizumab|Participants will undergo fine cut CT imaging (head and neck) followed by at least 4 doses of pembrolizumab q 3 weeks. After the 4th dose of pembrolizumab as appropriate, patients will undergo standard surgical resection, with all non-marginal tissue as well as the pre-op biopsy to be stored for collateral research. 2 weeks after initial flap or graft insert (which would be equivalent to stage 1 of a forehead flap) patients would continue for a total of approximately 1 year of pembrolizumab q 3 weeks (another 13 doses, thus 17 doses total).
16350775|NCT04323189|Other|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
16350776|NCT04323189|Other|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
16350777|NCT04323176|Experimental|Village Model|Participate as a member of the Village using a website for 12 months.
16350778|NCT04323163|Experimental|Yoga Group|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet three times a week for 60 minutes over the 6 month study duration. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
16350779|NCT04323163|Experimental|Aerobic Group|Trained exercise instructors will lead participants through an aerobic group exercise class. Sessions will begin with a 15-20 minute aerobics class and increase in duration over the 6 months capping off at 40-minutes per session. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program.
16350780|NCT04323163|Active Comparator|Stretching Toning Group|Participants randomized to this group will meet three times a week for an hour-long structured group exercise session. This group will perform stretching and toning exercises using resistance bands, balance disks, and exercise mats.
16350781|NCT04323150|Experimental|Closed suction systems|
16350782|NCT04323150|Other|Open (conventional) suction|control group
16350783|NCT04323137|No Intervention|Control|This group receives no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
16350784|NCT04323137|Experimental|High risk only|This group receives messages telling them they have been identified to be at high risk for flu complications without specifying how or why the health system believes this to be the case.
16350785|NCT04323137|Experimental|High risk based on medical records|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records.
16350786|NCT04323137|Experimental|High risk based on algorithm|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by an AI/ML system.
16350787|NCT04323124|Experimental|Treatment|PF-07059013 assignment
16350788|NCT04323124|Placebo Comparator|Placebo|Placebo assignment
16350789|NCT04323098|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg with prophylactic corticosteroids
16350790|NCT04323085|Active Comparator|Speech-in-Noise Treatment Program|A behavioural speech therapy program involving 12, one-hour treatment sessions over a 4-week period
16350791|NCT04323085|Active Comparator|Speech-to-Noise Feedback Device Program|A speech treatment program involving the use of a speech-to-noise feedback device during 12, one-hour treatment sessions over a 4-week period
16350792|NCT04323085|No Intervention|Delayed Treatment|Assessments but no intervention for a period of 13 weeks.
16350793|NCT04323072|Experimental|Group A|Resection of antrum proximally 2 cm to the pylorus
16350794|NCT04323072|Active Comparator|Group B|Resection of antrum proximally 6 cm to the pylorus
16350795|NCT04323059|Experimental|Standardized milk-based formulation|Formulation of maize with milk that is rich in methionine
16350796|NCT04323059|Experimental|Standardized non-milk based formulation|Formulation of maize with soybeans that is rich in methionine and lysine
16350797|NCT04323059|Active Comparator|Hospital-based formulation|Formulation of maize, milk and soybeans
16351190|NCT04320251|Experimental|1|The single observational cohort
16350801|NCT04323033|Experimental|PERS stent|20 Patients will receive PERS stent
16350802|NCT04323033|Active Comparator|NEPTUN C stent|20 Patients will receive NEPTUN C stent
16350803|NCT04323020|Experimental|Comatose cardiac arrest patients|Comatose cardiac arrest patients will be undergoing CT perfusion test
16350804|NCT04323007|Other|Nephrotic syndrome patients|This study is to evaluate Thyroid Hormone profile in patients with Nephrotic syndrome to identify clinical predictor of Thyroid dysfunction in patients with Nephrotic syndrome
16350805|NCT04322994|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
16350806|NCT04322994|Experimental|Intervention|"Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
~Intervention: Device: High-flow nasal cannula"
16350807|NCT04322981|Experimental|Community Pharmacist-Led|Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.
16350808|NCT04322981|Active Comparator|Academic hepatology|Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.
16350809|NCT04322968|Experimental|Chronic pain with PTSD+IV ketamine infusion|
16350810|NCT04322968|Active Comparator|Chronic pain with PTSD+IV ketorolac infusion|
16350811|NCT04322968|Experimental|Chronic pain without PTSD+IV ketamine infusion|
16350812|NCT04322968|Active Comparator|Chronic pain without PTSD+IV ketorolac infusion|
16350813|NCT04322955|Experimental|Treatment with cabozantinib and nivolumab with nephrectomy|All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. The first three to six subjects (group 1) will have the cabozantinib held for three weeks prior to removal of the kidney. If there are no unexpected side effects from the surgery, then future subjects (group 2) will have the cabozantinib stopped for two weeks prior to the nephrectomy.
16350814|NCT04322942||Non-infection|
16350815|NCT04322942||Infection without sepsis|
16350816|NCT04322942||Sepsis-2|
16350817|NCT04322942||Sepsis-3|
16350818|NCT04322929|Experimental|Oral roflumilast|Oral roflumilast 250 microgram daily will be started at the baseline visit for 4 weeks. For those who can tolerate the initial 4-week treatment, roflumilast will be increased to 500 microgram daily, allowing subsequent dose reduction back to 250 microgram daily in case of CTCAE grade 3 or 4 toxicities.
16350819|NCT04322916||RM Pressfit vitamys|Participants treated with a RM Pressfit vitamys hip cup in combination with a Mathys hip stem
16350820|NCT04322903|Experimental|Trauma-informed mindfulness-based stress reduction program|The program includes three 2-hr sessions to promote physical and emotional wellbeing through mindfulness techniques and health promotion activities; two home visits to provide individualized sessions with a nurse and a community health navigator; and a follow-up session 4 weeks after intervention to discuss perception of the intervention.
16350821|NCT04322877|Experimental|Body surface mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and non-invasive body surface mapping.
16350822|NCT04322877|Experimental|Catheter-based mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and invasive catheter-based mapping.
16350823|NCT04322864|Active Comparator|In-person supervised intervention|
16350824|NCT04322864|Experimental|Web-based instrument intervention|
16350825|NCT04322851||B-line positive|
16350826|NCT04322851||B-line negative|
16350827|NCT04322838||Patients|30 patients with self-reported seasonal allergic airway symptoms in the period from 1st of August to 15.th of october
16350828|NCT04322838||Controls|15 non-allergic individuals
16350829|NCT04322825|Experimental|intervention|24 weeks of TENS
16350830|NCT04322812|Active Comparator|Active PBMT|Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
16350831|NCT04322812|Placebo Comparator|Placebo PBMT|Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
16350832|NCT04322799|Experimental|Acetabular cup HXLPE (Intervention)|Randomization to HXLPE acetabular component.
16350833|NCT04322799|Experimental|Acetabular cup Conventional PE (control)|Randomization to Coventional PE as control group
16350834|NCT04322786||ACEI user|Individuals with an ACEI prescription in the study population.
16350835|NCT04322786||Matched controls|Individuals without an ACEI prescription, and matched to the users by sex and 10-year age categories.
16350836|NCT04322773|Experimental|Roactemra iv|Single dose treatment with 400 mg tocilizumab intravensously
16350837|NCT04322773|Experimental|Roactemra sc|Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
16350838|NCT04322773|Experimental|Kevzara sc|Single dose treatment with 1 x 200 mg sarilumab subcutaneously
16350839|NCT04322773|Active Comparator|Standard care|Management as usual
16350840|NCT04322760|Active Comparator|Group A (control group)|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly without lidocaine patch
16350841|NCT04322760|Experimental|Group B|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly with a patch of lidocaine 5% was applied to the skin
16350842|NCT04322747||Participants scheduled to undergo skull-based surgery|Participants scheduled to undergo skull-based or mastoid surgery as part of their standard care will receive Audiometry for extended high frequencies, DPOAE, ECochG before and after the procedure in the non operated ear.
16350843|NCT04322734||ASD (General)|150 children with ASD and unknown MD status
16350844|NCT04322734||ASD (With MD)|50 children with ASD and confirmed MD
16350845|NCT04322734||ASD (No MD)|50 children with ASD and ruled out MD
16350846|NCT04322734||Epilepsy|50 children with epilepsy (primary) and no ASD
16350847|NCT04322734||Brain Tumor|50 children with brain tumor (primary) and no ASD
16350848|NCT04322734||Psychiatric Disorder|50 children with psychiatric disorder (primary) and no ASD, using lithium treatments
16350849|NCT04322734||MD (No ASD)|50 children with MD (primary) and no ASD
16350850|NCT04322734||TD (With ASD Sibling)|50 TD children with a sibling with ASD/neurodevelopmental delay
16350851|NCT04322734||TD (No ASD Sibling)|50 TD children with no siblings with ASD/neurodevelopmental delay
16350852|NCT04322708|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo.
16350853|NCT04322708|Experimental|1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).
16350854|NCT04322708|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.
16350855|NCT04322695|Experimental|Rehabilitation Education Care Program (RECP)|Cancer rehabilitation program and patients education can improve disability and promote return to work.
16350856|NCT04322695|Other|Usual care|Usual care
16350857|NCT04322682|Active Comparator|Colchicine|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
16350858|NCT04322682|Placebo Comparator|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
16350859|NCT04322669|Experimental|Pidotimod|
16350860|NCT04322669|Placebo Comparator|Placebo|
16350861|NCT04322656|Active Comparator|Effect of Lipiflow treatment on biometrical outcomes|One eye of each patient will be treated with Lipiflow
16350862|NCT04322656|No Intervention|Control eye|The contralateral eye will serve as control eye
16350863|NCT04322643|Experimental|CPI therapy|Patients will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy.
16350864|NCT04322630||Pediatric Cardiac Bypass Patients|Blood samples obtained from patients ages from birth-19 years-old as well as cyanotic and acyanotic cardiac lesions who underwent cardiac bypass.
16350865|NCT04322604|Placebo Comparator|Placebo|Placebo
16350866|NCT04322604|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): a first dose of 1 mg/kg followed by 5 monthly doses of 3 mg/kg.
16350867|NCT04322565|Experimental|Colchicine|Administration of Colchicine 1mg (or 0.5 mg in CKD)/day + standard of care for COVID-19 pneumonia
16350868|NCT04322565|No Intervention|Standard of care|Standard of care for COVID-19 pneumonia
16350869|NCT04322552|Experimental|Treament|In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；
16350870|NCT04322539|Experimental|fruquintinib plus best supportive care|In this arm, subjects will receive active study drug plus best supportive care
16350871|NCT04322539|Placebo Comparator|placebo plus best supportive care|In this arm, subjects will receive placebo plus best supportive care
16350872|NCT04322526|Experimental|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
16350873|NCT04322526|Placebo Comparator|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
16350876|NCT04322500|Other|Group A: conservative|conservative treatment
16350877|NCT04322500|Experimental|Group B: probiotics|in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)
16350878|NCT04322461|Experimental|Parkinson disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
16350879|NCT04322461|Experimental|Alzheimer's disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
16350880|NCT04322448||Cubital Tunnel Syndrome Patients|Cubital Tunnel Syndrome patients. Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
16350881|NCT04322448||Peroneal Nerve Decompression Patients|Patients with compressive peroneal nerve neuropathy and will undergo a Peroneal Nerve Decompression (PND). Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
16350882|NCT04322435|Other|Adrenal insufficiency|Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.
16350883|NCT04322422|Experimental|ICS/LABA plus Montelukast|
16350885|NCT04322409|Experimental|NMES|The experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus.
16350886|NCT04322409|Placebo Comparator|TENS|The placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus
16350887|NCT04322396|Placebo Comparator|Control|"This arm will receive standard care and placebo in 15 days.
~Azithromycin placebo:
~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1
~Hydroxychloroquine placebo:
~Day 1-15: 200 mg x 2"
16350888|NCT04322396|Active Comparator|Intervention|"This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.
~Azithromycin:
~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1
~Hydroxychloroquine:
~Day 1-15: 200 mg x 2"
16350889|NCT04322383|Experimental|Arm 1/Experimental therapy|Treatment with binimetinib
16350890|NCT04322370|Active Comparator|Group A|VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap
16350891|NCT04322370|Active Comparator|Group B|Standard of Care Treatment Arm- Zone 2 flexor tendon repair
16350892|NCT04322357|No Intervention|Daily Glucocorticoid (GC)|Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.
16350893|NCT04322357|Active Comparator|WeekEnd Glucocorticoid with No Exercise|Participants with DMD will be given a low dose, weekend regimen of prednisone over the course of 1 year.
16350894|NCT04322357|Active Comparator|WeekEnd Glucocorticoid with Exercise|Participants with DMD will be given a low dose, weekend regimen of prednisone over the course of 1 year, in combination with a 6-month in-home exercise training program.
16350895|NCT04322344|Experimental|oral escin group|Standard therapy+Escin tablet 40mg*3, os for 12 days
16350896|NCT04322344|Sham Comparator|control group|standard therapy
16350897|NCT04322344|Experimental|parenteral escin group|standard treatment + sodium Escinate 20mg iv/day for 12 days
16350898|NCT04322331||T1N+|T1 tumor with positive lymph node,N1/N2/N3
16350899|NCT04322331||T2/T3N0|T2/T3 tumor with negative lymph node
16350900|NCT04322318|Experimental|Arm I (Regimen UH-3)|See outline in detailed description section.
16350901|NCT04322318|Experimental|Arm II (Regimen ICE/Cyclo/Topo)|"CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment repeats every 21 days during cycles 1, 2, 4, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
~CYCLES 3, 6, 8, AND 10: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days during cycles 3, 6, 8, and 10 in the absence of disease progression or unacceptable toxicity."
16350902|NCT04322305|Experimental|Pregabalin|Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
16350903|NCT04322305|Placebo Comparator|Placebo|Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
16350904|NCT04322292|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.
16350905|NCT04322266|Experimental|Sequence 1 (Reference-Test)|Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
16350906|NCT04322266|Experimental|Sequence 2 (Test-Reference)|Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608
16350907|NCT04322253|Experimental|Neladenoson bialanate, mild hepatic impairment|Subjects with Child Pugh score 5 or 6 received a single immediate-release (IR) tablet dose of 10 mg neladenoson bialanate in the fasted state
16350908|NCT04322253|Experimental|Neladenoson bialanate, moderate hepatic impairment|Subjects with Child Pugh score 7-9 received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
16350909|NCT04322253|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
16350910|NCT04322240|Experimental|type 2 DM with peripheral neuropathy|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication, antidiabetic drugs, or medications used for managing arterial hypertension or dyslipidaemia during the study.
16350911|NCT04322227|Experimental|Healthy|
16350912|NCT04322227|Experimental|PD|
16350913|NCT04322214|Experimental|COBI period (5 days) + Placebo period (5 days)|volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB
16350914|NCT04322214|Experimental|Placebo period (5 days) + COBI period (5 days)|volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB.
16350915|NCT04322201|Experimental|Intervention group - Continuous passive paracentesis|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care.
16350916|NCT04322201|Active Comparator|Control group - Large volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter performed and repeated during ICU stay according to standard-of-care clinical practice.
16350917|NCT04322188||group 1|Patients in Cohort A were treated with siltuximab after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation
16350918|NCT04322188||Group 2|The control cohort will include all the patients with pneumonia/ARDS in need of non-invasive ventilation (CPAP or NIV) or intubation and not receiving experimental treatments in the ReCOVID-19-2020
16350919|NCT04322175|Experimental|Single dose pharmacokinetic test|The 72 healthy subjects enrolled were admitted to the trial ward the day before the trial. On the day of dosing, the subjects were given 0.1% meloxicam eye drops once, 1 drop / time.
16350920|NCT04322175|Experimental|Multiple dose tolerance test|Eight healthy subjects were enrolled in the trial ward the day before the trial. 0.1% meloxicam eye drops were administered 4 times, 1 drop / time, and were administered at 8:00, 12:00, 16:00 and 20:00 daily for 3 consecutive days.
16350949|NCT04321941|Experimental|CTE (Computerised Tomography Enterography)|CTE examination performed with experimental contrast agent, Lumentin.
16350921|NCT04322162|Experimental|Active implementation - Wave 1 (First and Second Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 1 corresponds to Wave 1."
16350922|NCT04322162|Experimental|Active implementation - Wave 2 (Third and Fourth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 2 corresponds to Wave 2."
16350923|NCT04322162|Experimental|Active implementation - Wave 3 (Fifth and Sixth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 3 corresponds to Wave 3."
16350924|NCT04322149|Experimental|AT-1501|4 sequential dose cohorts
16350925|NCT04322136|Other|IPC (with talc pleurodesis if suitable)|"The patients will undertake daily drainage to day 14 post insertion. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter.
~Participants will be taught how to perform pleural drainage by the main study doctor at the hospital or a specialist nurse. They will drain their own IPCs at home with the either the help of a family member or friend or have access to community nursing support systems."
16350926|NCT04322136|Other|Pleurodesis via VATS|Participants will undergo VATS within two weeks of randomisation. VATS is usually performed in an operating theatre, using either general anaesthesia or local anaesthesia with sedation. The pleural fluid will be removed and adhesions can be divided (adhesiolysis). Assessment of lung re-expansion will be performed intra-operatively. If lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed to induce a pleurodesis, including, but not limited to, talc poudrage and mechanical abrasion. Decortication may be performed if deemed appropriate and feasible by the operating surgeon. A chest drain will be left in situ after the surgery. Post-operative care will be administered as per local practice.
16350927|NCT04322123|Experimental|Hydroxychloroquine|Hydroxychloroquine after randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 07 days.
16350928|NCT04322123|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 07 days.
16350929|NCT04322123|No Intervention|Control|standard treatment protocol for 2019-nCoV infection.
16350930|NCT04322110|Experimental|VLCK diet group|Subjects undergoing treatment with weight loss program PronoKal Method
16350931|NCT04322110|Active Comparator|Control group|Subjects undergoing treatment with low calorie diet
16350932|NCT04322097|Other|DISE patients|DISE
16350934|NCT04322071||Lower risk of long term complications|Young people with diabetes who have HbA1c <58mmols/mol, and family members.
16350935|NCT04322071||Higher risk of long term complications|Young people with diabetes who have HbA1c ≥75mmols/mol and <100mmols/mol, and family members.
16350936|NCT04322058||Fathers or paternal caregivers to a child 0-18 years of age|Parenting and Healthy Relationship Education (10 Core 24/7 workshops covering- 15 hours of education), financial and economic mobility programming, comprehensive case management, and supplemental workshops utilizing the Within My Reach curriculum.
16350937|NCT04322045|Experimental|participants|All tested serum PSA. Some conducted mpMRI with/without prostate biopsy under instruction.
16350938|NCT04322032|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug"
16350939|NCT04322032|Experimental|Group 2|"Period 1: Test drug
~Period 2: Reference drug"
16350940|NCT04322019||"Amikacin treatment group"|Intensive care patients on renal replacement therapy with Amikacin treatment
16350941|NCT04322006|Experimental|TJ004309 Injection|2mg/kg~20mg/kg TJ004309 Injection is administered once a week for a treatment cycle every 28 days
16350942|NCT04321993|Experimental|Baricitinib|
16350943|NCT04321993|No Intervention|Clinical standard of care|
16350944|NCT04321980|Experimental|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.
16350945|NCT04321980|Experimental|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
16350946|NCT04321967|Experimental|Nitroglycerine paste|The randomized breast will receive Nitroglycerine paste and Dermabond.
16350947|NCT04321967|Placebo Comparator|Dermabond|The control breast will receive Dermabond only
16350948|NCT04321954|Experimental|LENVATINIB|"Study procedures include screening for eligibility and study treatment, evaluations, and follow up visits
~Lenvatinib will be administered orally daily at a predetermined dose for 2 or 4 cycles, dependent on response. 1 cycle is 28 days.
~Surgery per standard of care will follow lenvatinib treatment."
16350950|NCT04321941|Active Comparator|MRE (Magnetic Resonance Enterography)|Comparative diagnostic method performed with the contrast agent Movprep®
16350951|NCT04321928|Other|Group A|General health education arm.
16350952|NCT04321928|Other|Group B|Personalized health education arm.
16350954|NCT04321902|Experimental|The experimental group in acute cholecystitis|"inclusion criteria
~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
~Gallbladder with surrounding organs due to gallbladder inflammation
~Patients over 19 years of age
~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used as before and during surgery."
16350955|NCT04321902|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
~Gallbladder with surrounding organs due to gallbladder inflammation
~Patients over 19 years of age
~Sencond-generation cephalosporin (Shincef inj., 750mg, Cefuroxime sodium, Shin-poong pharm.co.) was used as before and during surgery."
16350956|NCT04321889|Experimental|BEO|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
16350957|NCT04321889|Placebo Comparator|Placebo|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
16350958|NCT04321876||NMG IM 211 E Chicago Ave|
16350959|NCT04321876||NMG IM ARKES|
16350960|NCT04321876||NMG IM 1460 N Halsted St|
16350961|NCT04321876||NMG IM 201 E Huron St|
16350962|NCT04321876||NMG Integrative Medicine 150 E Huron St|
16350963|NCT04321876||NMG IM 1776 N Milwaukee Ave|
16350964|NCT04321876||NMG IM 20 S Clark St|
16350965|NCT04321876||NMG IM FM 1704 Maple Ave|
16350966|NCT04321876||NMG IM 259 E Erie St|
16350967|NCT04321876||NMG IM 1135 S Delano Ct|
16350968|NCT04321876||NMG IM 1333 W Belmont Ave|
16350969|NCT04321863||Adults with Crohn's disease in remission|All patients recruited will submit two samples to facilitate faecal zinc and qFIT in addition to FC which is standard of care. All patients recruited will have an additional tube of blood taken to measure serum zinc at the same time as they have their routine (standard of care) monitoring bloods taken - no additional venepuncture will be required.
16350970|NCT04321850|Placebo Comparator|Group1|Control
16350971|NCT04321850|Experimental|Group 2|Intervention (Zinc)
16350972|NCT04321837|Active Comparator|Coral calcium complex and ibandronate|
16350973|NCT04321837|Active Comparator|Ibandronate and vitamin D|
16350974|NCT04321837|Active Comparator|Coral calcium complex|
16350975|NCT04321824||the innovative programm (PASS de ville)|specific care for precarious people
16350976|NCT04321824||the standard of care|
16350977|NCT04321811||Participants|"Adult men and women currently in the United States and willing to provide written informed consent and:
~who are feeling sick but have not tested positive for COVID-19
~who are feeling sick and have tested positive for COVID-19
~People who are not feeling sick but want to participate"
16350978|NCT04321798|Experimental|Physical Activity|Promoting Engagement in Physical Activity
16350979|NCT04321785|Placebo Comparator|Placebo|
16350980|NCT04321785|Experimental|Caffeine|
16350981|NCT04321772|Experimental|High Intensity Interval Resistance Training (HIIRT)|"HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30 rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets."
16350982|NCT04321772|Active Comparator|Traditional Resistance Training (TRT)|"TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75 of rest between sets."
16350983|NCT04321759|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
16350984|NCT04321759|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health..
16350985|NCT04321746|Active Comparator|Ketamine|
16350986|NCT04321746|Placebo Comparator|Control|
16350987|NCT04321720|Experimental|3-g footbath|Footbath with 3g mustard flour per liter of water
16350988|NCT04321720|Experimental|6-g footbath|Footbath with 6g mustard flour per liter of water
16350989|NCT04321720|Experimental|12-g footbath|Footbath with 12g mustard flour per liter of water
16350990|NCT04321720|Placebo Comparator|Warm water footbath|Footbath with warm water only
16350991|NCT04321707|Experimental|15O-H2O PET/MR|All included patients will have two 15O-H2O PET/MR scan performed.
16350992|NCT04321668|Other|Injection of SYNVISC-ONE|Patients suffering from symptomatic knee osteoarthritis (OA), receiving intra-articular (IA) injection of SYNVISC-ONE® (Hylan G-F 20; 10 mL single-injection viscosupplement)
16350993|NCT04321655|Experimental|High Intensity LASER Therapy group (HILT)|Forty patients with chronic KOA in HILT group will received Class IV LASER therapy. A Class IV LASER emits power more than 500 milliwatt (mW) .
16350994|NCT04321655|Experimental|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in ibuprofen gel phonophoresis (IGP) group will administered with continuous ultrasound set at a frequency of 1 megahertz (MHz) and an intensity of 1 W/cm2 was applied on a circular basis.
16350995|NCT04321655|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with chronic KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
16350996|NCT04321655|Active Comparator|Conventional physiotherapy group (CPT)|Individual with chronic KOA will be educated on how to do the set of exercises correctly at their home during the first session. All the groups will receive the same, standardized exercise protocol for KOA which consisted of nine exercises including muscle strengthening and flexibility training.
16350997|NCT04321642|Experimental|Entonox|Inhalation Entonox in active phase of labor ( cervical dilatation more than 5 cm ) Inhaled Entonox before true uterine contraction in 30 sec , inhaled in 4-5 times for 1 contraction
16350998|NCT04321642|Active Comparator|Not receive Entonox|Not receive any gas when archive in active phase of labor( cervical dilatation more than 5 cm )
16350999|NCT04321629|Experimental|Autologous Fat Tissue Group|Group of patients treated with intra-articular injections of autologous adipose tissue.
16351000|NCT04321629|Active Comparator|PRP Group|Group of patients treated with intra-articular injections of platelet-rich-plasma.
16351001|NCT04321616|Active Comparator|Hydroxychloroquine|
16351002|NCT04321616|Active Comparator|Remdesivir|
16351003|NCT04321616|Active Comparator|Control group - SoC|
16351004|NCT04321603|Other|People living with HIV|Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
16351005|NCT04321590|Experimental|3 g 35% beta-glucan|Supplement containing 3 g of 35% oat beta-glucan
16351006|NCT04321590|Experimental|5 g 35% beta-glucan|Supplement containing 5 g of 35% oat beta-glucan
16351007|NCT04321590|Experimental|3 g 70% beta-glucan|Supplement containing 3 g of 70% oat beta-glucan
16351008|NCT04321590|Experimental|5 g 70% beta-glucan|Supplement containing 5 g of 70% oat beta-glucan
16351009|NCT04321577||Residual disease|Participants with incidental gallbladder cancer with presence of residual disease in the re-resection specimen or in intra-operative findings.
16351010|NCT04321577||No residual disease|Participants with incidental gallbladder cancer with absence of residual disease in the re-resection specimen or in intra-operative findings.
16351011|NCT04321564||Nullipar pregnant women|
16351012|NCT04321564||multipar pregnant women|
16351013|NCT04321551|Experimental|Provocative Hormonal Testing|"Recombinant follicle stimulating hormone (r-FSH) will be administered intravenously one time at a dose of 150 IU during the early follicular phase of the first menstrual cycle after enrollment (Menstrual Cycle I).
~Subjects will receive no intervention during Menstrual Cycle II (washout cycle).
~During the early follicular phase of Menstrual Cycle III, subjects will receive an intramuscular (i.m.) injection of estradiol valerate 5 mg on study day 1, followed by an i.m. injection of progesterone in oil 50 mg on study day 2."
16351014|NCT04321538||Failed Vision Screen Cohort|This cohort represents the entire group of study participants- children who were referred to Yale New Haven Hospital and Yale Medicine for a failed vision screen by either their primary care provider or their school.
16351015|NCT04321525|Active Comparator|Cognitive-behavioral therapy (CBT)|Individual Cognitive Behavioral Therapy
16351016|NCT04321525|Experimental|Personal construct therapy (PCT)|Individual Personal Construct Therapy
16351017|NCT04321525|Experimental|Personal construct therapy with virtual reality (PCT-VR)|Individual Personal Construct Therapy with an immersive virtual reality app
16351018|NCT04321499||lung cancer|stage IA-IIIA lung cancer
16351019|NCT04321499||benign nodules|ruled out lung cancer via Operation or CT-scan follow-up
16351020|NCT04321460|Experimental|LRG-002|LRG-002 once daily for 14 days
16351021|NCT04321460|Placebo Comparator|Placebo|Placebo once daily for 14 days
16351022|NCT04321447|Experimental|Clinical practice guideline (CPG) group|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme
16351023|NCT04321447|No Intervention|Usual care group|Usual care
16351024|NCT04321434|Experimental|Hyperoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests
~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
16351025|NCT04321434|Placebo Comparator|Normoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests
~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
16351026|NCT04321421|Experimental|treated|treated with hyperimmune plasma
16351027|NCT04321395|Experimental|Vigabatrin|
16351028|NCT04321395|Placebo Comparator|Placebo|
16351029|NCT04321356||Stryker Triathlon PCR TKA|Subjects implanted with a Stryker Triathlon PCR TKA
16351030|NCT04321356||Stryker Triathlon PS TKA|Subjects implanted with a Stryker Triathlon PS TKA
16351031|NCT04321356||Zimmer Persona PCR TKA|Subjects implanted with a Zimmer Persona PCR TKA
16351032|NCT04321356||Zimmer Persona PS TKA|Subjects implanted with a Zimmer Persona PS TKA
16351033|NCT04321343|Experimental|Group 1|PXL065 Dose 1
16351034|NCT04321343|Experimental|Group 2|PXL065 Dose 2
16351035|NCT04321343|Experimental|Group 3|PXL065 Dose 3
16351036|NCT04321343|Placebo Comparator|Group 4|Placebo oral tablet
16351037|NCT04321330|Experimental|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
16351038|NCT04321317|Other|Undernourished Patients|All patients included will be included in the unique arm of the study
16351039|NCT04321304|Sham Comparator|Sham|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial, but stays at 0 mA in the intervening time.
16351040|NCT04321304|Experimental|2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
16351041|NCT04321304|Experimental|4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16351042|NCT04321291|Experimental|Nurse information|The patient will receive a generic information leaflet plus an Individual information by nurse on biosimilars
16351043|NCT04321291|Other|Information Leaflet|The patient will receive a generic information leaflet only
16351044|NCT04321278|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]
16351045|NCT04321278|Active Comparator|Hydroxychloroquine|Hydroxychloroquine [400mg 2x/day, 12/12h]
16351046|NCT04321252|Experimental|KAE609|Experimental study drug
16351047|NCT04321252|Placebo Comparator|Placebo|Matching Placebo
16351048|NCT04321239|Experimental|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
16351049|NCT04321239|No Intervention|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
16351050|NCT04321226|Experimental|Femtosecond Laser guided Arcuate Keratotomy|Arcuate keratotomy will be performed together with Laser cataract surgery
16351051|NCT04321213||Healthcare professionals in the Region of Västmanland|Healthcare professionals of all professions working in-hospital with patient contact at two hospitals in the Region of Västmanland, Sweden. Data is collected by questionnaires.
16351052|NCT04321213||Healthcare professionals in the Region of Dalarna|Healthcare professionals of all professions working in-hospital with patient contact at three hospitals in the Region of Dalarna, Sweden. Data is collected by questionnaires.
16351053|NCT04321200||Cross-sectional-150 infants (atypical vs typical)|Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
16351054|NCT04321200||Longitudinal cohort - 50 infants (atypical vs typical)|Arm (Study) 2: To discover the features related to long-term motor development. Here we will convert data collected longitudinally from 50 infants, using both instrumented gym and video recordings, into estimates standard clinical tests change over time and track features over developmental timescales.
16351055|NCT04321200||Cross-sectional-1500 infants (atypical vs typical)|Arm (Study) 3: To develop a computer vision-based algorithm to quantify infant motor performance from a single-camera video. Here using video data from 1200 infants, plus those gathered from Arm 1 and Arm 2, we will extract pose data from single-camera video recordings and convert these into kinematic features and relevant scores needed to classify infant movement.
16351056|NCT04321174|Experimental|Lopinavir/ritonavir|This arm will receive oral lopinavir/ritonavir 400/100 mg (or equivalent weight-based dosing) twice daily for 14 days.
16351057|NCT04321174|No Intervention|Control|This arm will receive no intervention.
16351058|NCT04321161|Experimental|AML relapse under DLI and Bicanorm treatment|Analysis of T cell metabolism, immune phenotype and serum pH before and after Bicanorm (Sodium bicarbonate) treatment.
16351059|NCT04321148|Other|standard of care PCI|
16351060|NCT04321148|Experimental|Impella-protected PCI|
16351061|NCT04321135|Experimental|Guided Lifestyle Program|The Intervention will be conducted in a cohort of 20 (anticipated) and is designed to increase self-efficacy, social support and perceived access to healthy eating and exercise resources and promote weight loss. Participants assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies. The second hour will be supervised exercise including aerobics and resistance training. The second weekly session will be a one-hour supervised exercise session. Participants will also receive 2-3 text messages weekly.They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.The Guided Lifestyle program is four months long (16 weeks). Please note, the Guided Lifestyle program participants will be offered a booster session off-study.
16351062|NCT04321135|Active Comparator|Self-Guided Lifestyle Program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
16351063|NCT04321122|Experimental|Ultrasound cyclo plasty(UCP)|Ultrasound cyclo plasty treatment for primary open-angle glaucoma patients.
16351064|NCT04321109|Experimental|Collagen cone|Collagen matrix
16351065|NCT04321109|Active Comparator|Allograft|mineralized corticocancellous allograft
16351066|NCT04321096|Placebo Comparator|Placebo|2 pills 3 times daily for 5 days
16351067|NCT04321096|Experimental|Camostat Mesilate|2x100 mg pills 3 times daily for 5 days
16351068|NCT04321083|Experimental|O2 brain (central) measurement|INVOS will be applied simultaneously for monitoring along with the regular polysomnography (sleep lab) workup
16351069|NCT04321070|Experimental|Clindamycin Phosphate|Topical, once daily, for 84 days.
16351070|NCT04321070|Active Comparator|Clindamycin Phosphate RLD|Topical, once daily, for 84 days
16351071|NCT04321070|Placebo Comparator|Vehicle of the test product|Topical, once daily, for 84 days
16351072|NCT04321057||Group questionnaire|Patient's height and weight are asked by questionnaire in this group. It includes patients at the cardiological department of Saarland University.
16351073|NCT04321057||Group male doctor|Patient's height and weight are asked by a male doctor in this group. It includes patients at the cardiological department of Saarland University.
16351074|NCT04321057||Group female doctor|Patient's height and weight are asked by a female doctor in this group. It includes patients at the cardiological department of Saarland University.
16351075|NCT04321057||Group male nurse|Patient's height and weight are asked by a male nurse in this group. It includes patients at the cardiological department of Saarland University.
16351076|NCT04321057||Group female nurse|Patient's height and weight are asked by a female nurse in this group. It includes patients at the cardiological department of Saarland University.
16351077|NCT04321057||Group family doctor|Patient's height and weight are asked by questionnaire in this group. This is the control group,including patients at a family doctor.
16351078|NCT04321044|Other|Renal Denervation|We attempt to identify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch
16351088|NCT04321018|Experimental|Meal with medium chain triglycerdies first|Arm 1: participants randomized to receive the mixed meal with medium chain triglycerides first.
16351089|NCT04321018|Active Comparator|Meal with medium chain triglycerdies second|Arm 2: participants randomized to receive the mixed meal without medium chain triglycerides first.te
16351090|NCT04320992||tested group|
16351091|NCT04320992||controlled group|
16351092|NCT04320979|Experimental|internal mammary nodal irradiation|chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation
16351093|NCT04320979|Active Comparator|no-internal mammary nodal irradiation|ipsilateral chest wall and supraclavicular +-axillary nodal irradiation
16351094|NCT04320966||Acquired Anemia|Otherwise healthy individuals with hemoglobin below 10.5 g/dl or hematocrit below 32
16351095|NCT04320966||Control|Age and sex matched individuals with hemoglobin in the upper quartile of normal
16351096|NCT04320953|Experimental|Non-contact MCE examination|Study subject in this arm receives non-contact MCE examination.
16351097|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 20mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
16351098|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 40mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
16351099|NCT04320914|Experimental|High Intensity LASER Therapy group (HILT)|Fourty patients with chronic KOA in HILT group will receive Class IV LASER therapy. A Class IV LASER emits power more than 500 mW .
16351100|NCT04320914|Active Comparator|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in IGP group will administered with continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis
16351101|NCT04320901|Experimental|Harmonic|Endoscopic procedure will be done by Harmonic ACE7+
16351102|NCT04320901|Experimental|Ligasure|Endoscopic procedure will be done by Ligasure
16351104|NCT04320875|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
16351105|NCT04320875|Active Comparator|Conventional Physiotherapy (CPT) group|Individual with KOA will be educated on how to do the set of exercises correctly at their home during the first session. Consisted of nine exercises including muscle strengthening and flexibility training.
16351106|NCT04320862||Duke Health region and beyond|Individuals in the Duke Health region as well as individuals beyond the Duke Health region who have flu-like symptoms, a viral test order for COVID-19, confirmed COVID-19, or concern for exposure to COVID-19.
16351107|NCT04320849||Patients with Biotronik Leads|"Patients with these models: LSiello S, Solia S
~Description: Active Fixation Leads"
16351108|NCT04320849||Patients with Boston Scientific Leads|"Patients with these models: 4452, 4453, 4456, 4457
~Description: FINELINE II/FINELINE II Sterox Passive Fixation (polyurethane)
~Boston Scientific 4463, 4464, 4465, 4469, 4470, 4471 FINELINE II/FINELINE II Sterox EZ Positive Fixation (polyurethane)"
16351109|NCT04320849||Patients with Abbott Leads|"Patients with these models: LDA 210Q
~Description: Optisure Single Coil Defibrillation Lead"
16351110|NCT04320849||Patients with Medtronic Leads|"Patients with these model: 6935M
~Description:Quattro Secure Single Coil Defibrillation Lead"
16351111|NCT04320836||Cervical epidural steroid injection|This group will receive an interlaminar cervical ESI at C6-7 or C7-T1 with 1 mL steroid (depo-methylprednisolone 40 mg at Johns Hopkins and the DC VA Hospital or dexamethasone 10 mg at Seoul National University) and 2 mL normal saline.
16351112|NCT04320823|Experimental|Experimental Group|Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.
16351113|NCT04320823|Active Comparator|Control Group|Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.
16351114|NCT04320810||mNGS diagnosis|Using mNGS to diagnosis infectious disease of this group
16351115|NCT04320797||Active lupus nephritis|Patients with proliferative lupus nephritis (Class III and IV)
16351116|NCT04320797||Control|Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI
16351117|NCT04320784|Experimental|Time restricted eating (TRE)|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
16351118|NCT04320784|Active Comparator|Control (CTRL)|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
16351154|NCT04320563|Placebo Comparator|Comparative Power 1|These group of participants will receive the comparative power 1 treatment
16351119|NCT04320771|Experimental|Neladenoson bialanate, mild renal impairment|Subjects with eGFR ≥60 - <90 mL/min/1.73 received a single immediate-release (IR) tablet dose of 10 mg of neladenoson bialanate in the fasted state
16351120|NCT04320771|Experimental|Neladenoson bialanate, moderate renal impairment|Subjects with eGFR ≥30 - <60 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
16351121|NCT04320771|Experimental|Neladenoson bialanate, severe renal impairment|Subjects with eGFR <30 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
16351122|NCT04320771|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
16351123|NCT04320758|Experimental|single crown in dental aesthetic zone|teeth in dental aesthetic zone
16351124|NCT04320758|Experimental|teeth need single crown in dental aesthetic zone|teeth in dental aesthetic zone
16351125|NCT04320745|Experimental|Androderm®|All participants to receive standard dose of Androderm of 4 mg/day applied nightly on Visit 1. At Visit 2 testosterone concentration will be measured.
16351126|NCT04320732||Individuals with COVID-19 infection|"Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included.
~Only subjects >18 years old will be included in the study."
16351127|NCT04320732||Individuals tested for COVID-19 infection with negative test|Confirmed by routine laboratory diagnosis
16351128|NCT04320732||Healthy individuals|Recruitet from the general population
16351129|NCT04320732||Risk groups for COVID-19 exposure|Including, but not limited to healthcare workers.
16351130|NCT04320732||Patients admitted to hospital|Without COVID-19 infection.
16351131|NCT04320706|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
16351132|NCT04320706|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
16351133|NCT04320680|Other|lupus cohort follow up|it is a descrption lupus patients study
16351134|NCT04320667||Active ANCA glomerulonephritis|Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement
16351135|NCT04320667||Control|Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission
16351136|NCT04320654|Experimental|advice of staying active|The patients will be advised to stay as physically active as possible and continue their everyday activities as normally as possible.
16351137|NCT04320654|Experimental|walking program|Patients will be encouraged to go about their normal daily activities. At week one, patients will be asked to familiarize themselves with wearing the pedometer and recording their daily steps in a walking diary for the subsequent 7 days. The patients will return to see the physiotherapist at the end of week one to discuss any issues with the program, pedometer or recording of desired information. A step target for week two will be agreed between the physiotherapist and the patient by referring to the mean daily step count recorded at baseline, and the average step count calculated from the walking diary
16351138|NCT04320654|Experimental|Backward walking|All patients will be instructed to walk at their desired pace 3 days per week with a steady rhythm. The duration of each training session will initially be 15 minutes and will gradually increase, and finally reach 25 minutes, for every session (Hao Chen, 2011). There will be no constraint or indication about head and trunk position during backward training
16351139|NCT04320654|Experimental|Targeted home-based hip exercise|Patients who will be assigned in this group will perform a hip exercise program for six weeks, three times / week to ensure an adequate recovery between exercise sessions (appendix V). The strengthening exercises will focus on strengthening the gluteus maximus (GMax), gluteus medius (GMed), gluteus minimus (GMin) and short hip external rotator muscles (Distefano et al., 2009).
16351140|NCT04320654|No Intervention|control group|The patients will not be given any intervention and will be asked to come after 6 weeks for re-assessment
16351141|NCT04320641|Experimental|acupressure|
16351142|NCT04320641|Experimental|music|
16351143|NCT04320641|No Intervention|control|
16351144|NCT04320628|Experimental|Experimental|Target ulcer cleansed with NaOCl. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NaOCl.
16351145|NCT04320628|Placebo Comparator|Control|Target ulcer cleansed with NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NSS.
16351146|NCT04320615|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
16351147|NCT04320615|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
16351148|NCT04320602|Experimental|Ravulizumab|Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
16351149|NCT04320589|Active Comparator|General Anesthesia|Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
16351150|NCT04320589|Active Comparator|Dexmedetomidine|Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
16351151|NCT04320576|Experimental|Bulk-fill resin composite|Bulk-fill resin composite will be places with bulk technique.
16351152|NCT04320576|Active Comparator|Nano-fill resin composite|Nano-fill resin composite will be placed with 2 mm thickness layering technique.
16351153|NCT04320563|Active Comparator|Full power treatment 4|These group of participants will receive the full power treatment 4
16351156|NCT04320537||MJ user|non-treatment-seeking chronic heavy marijuana (MJ) users of both sexes and all ethnicities between the ages of 21-40 years who are willing to follow the study protocol and abstinence from marijuana for three weeks
16351157|NCT04320537||Control|age- and sex-matched healthy control participants who are willing to follow the study protocol and remain in the study for three weeks
16351158|NCT04320524|Experimental|All subjects|
16351159|NCT04320511||Patients with SARS-COV 2|Patients with SARS-COV 2 undergoing CT-V
16351160|NCT04320498|Active Comparator|control group|The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)
16351161|NCT04320498|Experimental|PRP group|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
16351162|NCT04320472||Follow up|Follow up of all included patients up to 3 months after enrollement
16351163|NCT04320459||ankylosing spondylitis|55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic
16351164|NCT04320459||healthy control|age and sex matched healthy controls
16351165|NCT04320446|Experimental|Caffeine|A dose of 3 mg/kg of caffeine (i.e. a vegetable extraction from green coffee beans, Harrison Sport Nutrition®, Spain) was ingested before the beginning of each test.
16351166|NCT04320446|Placebo Comparator|Placebo|A dose of 3 mg/kg of placebo (i.e. 100% purity microcrystalline cellulose, Acofarma, Spain) was ingested before the beginning of each test.
16351167|NCT04320433|Experimental|Experimental|Participants will undergo two trials visit (with a week of separation). During the visits they will ingest an oral glucose load solution (oral glucose tolerance test) and gas exchange will be measured over the following 3-hours. The glucose levels will be monitored through a Glucose meter in different time frames.
16351168|NCT04320420|Experimental|Experimental arm|"The APA program is defined in 3 stages:
~STEP 1: during the initial chemotherapy over 3 months
~3 supervised APA sessions/week on site:
~two muscle strengthening sessions, stretching, flexibility in the gym
~a cardio session (Nordic Walking: outdoors)
~at home: exercise book if the patient wishes
~STEP 2: during hospitalization for the autograft, over 1 month:
~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work
~If the patient wishes, he can continue the exercises carried out with the APA engineer independently
~STEP 3: after the transplant
~the first 3 months:
~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),
~1-hour cardio session/week independently
~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
16351170|NCT04320394|Other|Septic shock patients|Patients with septic shock will be taken from an additional tube to analyze their immune response
16351171|NCT04320381||Group A|subjects in the hypertonic saline study randomized to discontinue or maintain therapy
16351172|NCT04320381||Group B|subjects in the dornase alfa study randomized to discontinue or maintain therapy
16351173|NCT04320381||Group C|subjects who were randomized but withdrew early from the SIMPLIFY Study.
16351174|NCT04320381||Group D|subjects in the hypertonic saline study randomized to discontinue or maintain therapy with FEV1% predicted between 40 and <60%
16351175|NCT04320381||Group E|caregiver participants (parents and legal guardians of eligible patient participants less than 18 years of age who were randomized in the SIMPLIFY study)
16351176|NCT04320368||Alzheimer's disease cohort|"40-100 years old (≥ 40 years old, ≤ 100 years old)
~cognitive impairment: Alzheimer's questionnaire >4 and MMSE<22
~informed consent is signed by the patient or his family members"
16351177|NCT04320368||Vascular cognitive impairment cohort|"40-100 years old (≥ 40 years old, ≤ 100 years old)
~acute cerebral infarction is first diagnosed according to WHO criteria 1
~the time from onset to hospital ≤7 days
~informed consent is signed by the patient or his family members"
16351178|NCT04320368||A cohort of people with normal cognitive function|"40-100 years old (≥ 40 years old, ≤ 100 years old), without cognitive impairment, Alzheimer's questionnaire ≤4 and MMSE≥22
~informed consent is signed by the patient"
16351179|NCT04320355|Experimental|Soft tissue manual therapy|The researcher student will place the gloves with the force sensor on the thumb of her right and left hand. She will evaluate the Caesarean section scar and identify the most rigid scar areas when compression is applied. On these identified areas, the researcher student will apply the manual therapy procedure described in the independent variable (compression + shear) section. This procedure will be applied to all identified rigid areas of the Caesarean section scar.This procedure will last 10 minutes (approximately 2 minutes per rigid area). After this time, the researcher-student will remove the force sensor and leave the room.
16351182|NCT04320316|Experimental|Crysvita (burosumab-twza) Treatment|"The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.
~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.
~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension."
16351183|NCT04320303|Experimental|adaptive NK cells infusion post transplantation|Adaptive donors expanded NK cells infusion at day 20±3d and 27±3d post transplantation
16351184|NCT04320290|Experimental|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet
16351185|NCT04320277|Experimental|Patients|All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.
16351186|NCT04320277|Active Comparator|Controls|All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.
16351191|NCT04320238|Experimental|low-risk group|medical staff work in non-isolated general wards or laboratories, not directly contact with COVID-19 patients.
16351192|NCT04320238|Experimental|high-risk group|doctors and nurses work in isolated ward, directly contact with COVID-19 patients.
16351193|NCT04320225||Lower vitamin D level group|The vitamin D level is lower than 20 nmol/L.
16351194|NCT04320225||Higher vitamin D level group|The vitamin D level is higher than 20 nmol/L.
16351195|NCT04320212|Active Comparator|lumber epidural analgesia|: the patient will be placed in the lateral position, Lidocaine will be given using 5 ml syringe and a 18 G Tuohy needle will be introduced in the epidural space, using the ultrasound, under strict aseptic precautions. The ultrasound probe will be placed 90 degrees into transverse orientation and slided cephalad or caudad to obtain the transverse interspinous view (TI view) 2 levels above the operation level. patient will receive 20 ml of 0.25% plain bupivacaine after negative aspiration for blood or cerebrospinal fluid. Then, the patient will be placed in prone position to start the surgical procedure
16351196|NCT04320212|Active Comparator|erector spinae analgesia|the patient will be placed in the prone position. Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer. The Erector Spinae muscle and transverse process will be then identified, and a 18 G Tuohy needle will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side)
16351197|NCT04320199|Experimental|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
16351198|NCT04320199|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
16351199|NCT04320186|Active Comparator|Treatment|Participants viewed informational video content plus entertainment content
16351200|NCT04320186|Placebo Comparator|Control|Participants viewed entertainment content only
16351201|NCT04320173|Experimental|Lidocaine Patch (Sequence ABC)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied in Period 1, and 3 lidocaine 5% patches were applied in Period 2, and 3 lidocaine 5% medicated plasters were applied in Period 3.
16351202|NCT04320173|Experimental|Lidocaine Patch (Sequence CAB)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 2, 3 lidocaine 5% medicated plasters were applied in Period 1, and 3 lidocaine 1.8% patches were applied in Period 2, and 3 lidocaine 5% patches were applied in Period 3.
16351203|NCT04320173|Experimental|Lidocaine Patch (Sequences BCA)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 3, 3 lidocaine 5% patches were applied in Period 1, and 3 lidocaine 5% medicated plasters were applied in Period 2, and 3 lidocaine 1.8% patches were applied in Period 3.
16351204|NCT04320160|No Intervention|Positive control group|Include the thirty patients before any treatment
16351205|NCT04320160|Active Comparator|PRP group|Include fifteen patients that will recieve PRP sessions .Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
16351206|NCT04320160|Active Comparator|Fractional CO2 group|Include fifteen patients that will recieve FR: CO2 laser sessions.Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
16351207|NCT04320147|Experimental|MRI tartget biopsy|"MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
~Next conventional ultrasound-guided 12-core systematic biopsy would be performed by urologist. This portion will be performed without information of the MRI report."
16351208|NCT04320121|Experimental|Nelutri™ group|This group takes Nelutri™ for 12 weeks
16351209|NCT04320121|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
16351210|NCT04320108|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
16351211|NCT04320108|Sham Comparator|Control group|Sham therapy
16351212|NCT04320095|Experimental|Bizact device for one tonsil|Bizact tonsillecotmy device which is an advanced bipolar device using radiofrequency and pressure to ligate the encountered vessels during tonsillectomy.
16351213|NCT04320095|Active Comparator|Electrocautery for second tonsil|Electrocautery is the standard technique used at our institution.
16351214|NCT04320095|Experimental|Bizact device for both tonsils|Consecutive cases of tonsillectomy will be done using Bizact device and compare the operative time collectively for those cases and compare it to same number of cases done using the standard procedure ( Electrocautery)
16351215|NCT04320095|Active Comparator|Electrocautery for both tonsils|As explained on the above arm description
16351216|NCT04320082||Elderly cohort|Patients >70 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
16351217|NCT04320082||Young cohort|Patients between 18 and 30 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
16351218|NCT04320069|Experimental|Single|All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days.
16351219|NCT04320056|Active Comparator|Control group|"Usual care will be provide to patients concerning their medical management.
~In the Control Group usual, oxygen will be delivered as per usual local practices"
16351220|NCT04320056|Experimental|Intervention group|"Usual care will be provide to patients concerning their medical management.
~In the Intervention group, automated oxygen administration will be delivered with FreeO2"
16351221|NCT04320043||Anterior cervical decompression surgery|Adult patients who underwent anterior cervical decompression surgery for radiculopathy and/or myelopathy due to cervical degenerative disc disease. Patients underwent one of the following interventions: ACD, ACDF, ACDF with plating or corpectomy.
16351223|NCT04320017||COVID-19 patients|Patients diagnosed with COVID-19 by PCR done on nasal sample.
16351273|NCT04319692|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
16351224|NCT04320004|No Intervention|Baseline|"Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a silent best practice alert (BPA) in these clinics. This Silent BPA is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list."
16351225|NCT04320004|Active Comparator|Education Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.
16351226|NCT04320004|Active Comparator|Education Intervention with Reminder|This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
16351227|NCT04320004|Active Comparator|Education + Disposal Bag Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.
16351228|NCT04320004|Active Comparator|Education + Disposal Bag Intervention with Reminder|This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
16351229|NCT04319991|Placebo Comparator|Placebo|
16351230|NCT04319991|Experimental|Probiotics product|
16351231|NCT04319978|Active Comparator|Group A|Group A will receive single dose of dexamethasone IM 8mg 1 hour pre-operatively.
16351232|NCT04319978|Active Comparator|Group B|Group B will receive a single dose of dexamethasone IM 8mg immediately after surgery.
16351233|NCT04319939||Participants receiving mechanical ventilation|
16351234|NCT04319926|Experimental|Lidocaine Patch (Sequence T1T2)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
16351235|NCT04319926|Experimental|Lidocaine Patch (Sequence T2T1)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.
16351236|NCT04319913|Experimental|ANI-guided|ANI-guided narcotics use to maintain ANI value between 50 to 70
16351237|NCT04319913|No Intervention|Control|narcotics use guided by clinical experience, ANI is still recorded but would be covered up intraoperatively
16351238|NCT04319900|Experimental|favipiravir tablets+chloroquine phosphatetablets tablets group|favipiravir tablets+chloroquine phosphatetablets tablets
16351239|NCT04319900|Experimental|favipiravir tablets group|favipiravir tablets
16351240|NCT04319900|Placebo Comparator|placebo treatment group|placebo
16351241|NCT04319874|Sham Comparator|sham group|Treated with conventional chemotherapy drugs
16351242|NCT04319874|Placebo Comparator|NC group|Treated with conventional chemotherapy drugs and Placebo
16351243|NCT04319874|Experimental|experimental group|Treated with conventional chemotherapy drugs and Ganoderma lucidum
16351244|NCT04319861|Experimental|Anal fistula plug|The anal fistula plug procedure was performed as followings. A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
16351245|NCT04319848|Experimental|TE-EK treatment group|The TE-EK surgery will be performed by the Principle Investigator with a standard DSAEK technique. The PI has performed over 300, EK surgeries and we have previously shown that the corneal endothelial loss rates from the PI are 16% at 1 year with a primary graft failure rates of <1.5%. A patient's participation in the study or not will not change the treatment strategy in any manner.
16351246|NCT04319835|Experimental|Microdialysis catheter|Surface Microdialysis catheter will be placed onto the surgical reconstruction after esophagectomy and will be evaluated for clinical safety and performance. The metabolic profile as measured by Microdialysis will be correlated to the clinical outcome. No interventions based on the results will be performed.
16351274|NCT04319679|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
16351247|NCT04319822|Experimental|blood samples, muscular biopsy, and quality of life|quality of life, blood samples, quadriceps biopsy in intensive care unit (before and after the ICU hospitalization and one at M6
16351248|NCT04319809|Experimental|Device feasibility|To investigate the utility of a device adaptation allowing Argus II users to detect the presence and location of desired objects. Performance of the unaided Argus II system will be compared with performance using the system augmented with object recognition.
16351249|NCT04319796||Ataxia & HSP|Patients suffering of Ataxia or HSP or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these Rare Neurological Disease (RND).
16351250|NCT04319796||Leukodystrophies|Patients suffering of Leukodystrophies or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
16351251|NCT04319796||Frontotemporal Dementia|Patients suffering of Frontotemporal Dementia or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
16351252|NCT04319796||Dystonia, Paroxysmal Disorders and Neurodegeneration with|Patients suffering of Dystonia, Paroxysmal Disorders and Neurodegeneration with Brain Iron Accumulation (NBIA) or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
16351253|NCT04319796||Atypical Parkinsonism|Patients suffering of Atypical Parkinsonism or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
16351254|NCT04319796||Huntington's Disease & Choreas|Patients suffering of Huntington's Disease or Choreas or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
16351255|NCT04319783|Experimental|Darolutamide|Darolutimide 600mg BD
16351256|NCT04319783|Experimental|Local consolidation Radiotherapy + Darolutamide|Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease
16351257|NCT04319770|Active Comparator|periodontal regenerative surgery + EMD (control)|periodontal regenerative surgery with enamel matrix derivative
16351258|NCT04319770|Experimental|periodontal regenerative surgery + HA (test)|periodontal regenerative surgery with hyaluronic acid
16351259|NCT04319757|Experimental|ACE1702 Dose Level 1|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.
~Dose Level: 1 Planned number of subjects: 1 to 6"
16351260|NCT04319757|Experimental|ACE1702 Dose Level 2|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 2 Planned number of subjects: 1 to 6"
16351261|NCT04319757|Experimental|ACE1702 Dose Level 3|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 3 Planned number of subjects: 3 to 6"
16351262|NCT04319757|Experimental|ACE1702 Dose Level 4|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 4 Planned number of subjects: 3 to 6"
16351263|NCT04319757|Experimental|ACE1702 Dose Level 5|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 5 Planned number of subjects: 3 to 6"
16351264|NCT04319757|Experimental|ACE1702 Dose 6|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 6 Planned number of subjects: 3 to 6"
16351265|NCT04319744||Assistants who have a habit of playing video|"Group I:Anesthesia assistants who have a habit of playing video games before Video game will be played for 5 days a day with 0.5 hours mobile phone (Pubg mobile) for those who have previous game experience.
~Intubation training will be provided with video style.Within the scope of this training, 1-All participants will watch videos about Video style application.
~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first
~4-Responsible investigators will practice and show on the real patient.
~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.
~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
16351266|NCT04319744||Assistants who do not have the habit of playing video|"Group II:Anesthesia assistants who do not have the habit of playing video games No video game will be played before intubation with video style for this group.
~Intubation training will be provided with video style. Within the scope of this training, 1-All participants will watch videos about Video style application.
~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first
~4-Responsible investigators will practice and show on the real patient.
~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.
~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
16351267|NCT04319731|Experimental|Treatment|"Treatment groups:
~1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)"
16351270|NCT04319705|Experimental|Azithromycin|Azithromycin, 500mg capsule, 3 times per week, during a 12-week period, administered orally
16351271|NCT04319705|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP, capsule, 3 times per week, during a 12-week period, administered orally
16351272|NCT04319692|Experimental|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks.
16351278|NCT04319640|Experimental|CBTI|N= 80 participants are offered Cognitive behaviour therapy for insomnia (CBT-I)
16351279|NCT04319640|Active Comparator|psychoeducation|N= 80 participants are offered psychoeducation about information on ASD
16351280|NCT04319627|Experimental|Rosuvastatin|Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.
16351281|NCT04319627|Placebo Comparator|Placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
16351282|NCT04319614|Experimental|Tranexamic acid|
16351283|NCT04319614|Placebo Comparator|Saline|
16351284|NCT04319601|Experimental|rituximab combined with chidamde and lenalidomide|rituximab and chidamide, lenalidomide
16351285|NCT04319588|Experimental|Parasternal Group|"The parasternal group of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia."
16351286|NCT04319588|Active Comparator|Case control group|"The case control group will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids."
16351287|NCT04319575|Experimental|Chitosan calcium hyroxide paste|after the access preparation and cleaning and shaping, chitosan calcium hydroxide paste will be placed in the canal and kept for 4 weeks.
16351288|NCT04319575|Active Comparator|triple antibiotic paste|after the access preparation and cleaning and shaping, ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.
16351289|NCT04319562|Experimental|needle-embedding therapy|The participants in this group will be treated with intradermal thumbtack needle.
16351290|NCT04319562|Sham Comparator|shame needle-embedding therapy|The participants in this group will be treated with shame intradermal thumbtack needle.
16351291|NCT04319549|Experimental|group 1 ketorolac tromethamine irrigant|group 1 patients with acute irreversible pulpitis with apical periodontitis
16351292|NCT04319549|Active Comparator|group 2 sodium hypochlorite irrigant|group 2 patients with acute irreversible pulpitis with apical periodontitis
16351293|NCT04319536||Healthy individuals|
16351294|NCT04319523||COPD patients|
16351295|NCT04319523||Healthy subjects|
16351296|NCT04319510|Experimental|Craniosacral therapy|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
16351297|NCT04319510|Experimental|Craniosacral self-help group training|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
16351298|NCT04319510|Other|Treatment as usual / wait list control|Waiting period of six months.
16351299|NCT04319497|Other|Refraction reproducibility and agreement|Subjective and objective refraction will be performed in all patients
16351300|NCT04319484|Experimental|lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
16351301|NCT04319484|Placebo Comparator|Placebo|The placebo pills are made identical to the investigating lenvatinib in appearance
16351302|NCT04319471|Experimental|Sufficient Chemotherapy Combine With Maintenance Chemotherapy|Patients with oligometastatic Nasopharyngeal Carcinoma was given S-1 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving sufficient chemotherapy and consolidative local therapy
16351303|NCT04319458|Experimental|Fotonovela|Fotonovela mental health literacy intervention: Secret Feelings/Sentimientos Secretos
16351304|NCT04319458|Active Comparator|Control|Control mental health literacy intervention: NIH publication - Depression: What You Need to Know
16351305|NCT04319445|Experimental|Migraine Patients/Providers/Faculty/Staff/Other|
16351306|NCT04319432|Experimental|3 days voice rest|
16351307|NCT04319432|Experimental|7 days voice rest|
16351308|NCT04319419|Experimental|Supplement with micronutrients|Nutrition education with a supplement
16351309|NCT04319419|Experimental|Nutrition education|Group received only nutrition education
16351310|NCT04319406|Experimental|PROLOTHERAPY|Prolotherapy will be performed with 12.5 % Dextrose into superior joint space of involved TMJ
16351311|NCT04319406|Active Comparator|DRY NEEDLING|Dry needling will be performed into superior joint space of involved TMJ
16351312|NCT04319393|Experimental|CBT Nurses|Interventional group
16351313|NCT04319393|No Intervention|Consultation Nurses|Control Group
16351314|NCT04319380|Active Comparator|SMC with SP+AQ|Administration of tetanus/diphtheria toxoids vaccine followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
16351315|NCT04319380|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1 and 2.
16351316|NCT04319380|Active Comparator|RTS,S/AS01 plus SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
16351317|NCT04319367|Active Comparator|Arm A|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion followed by intensively monitored Antiretroviral Treatment Interruption (ATI)
16351318|NCT04319367|Placebo Comparator|Arm B|ART plus placebo infusion followed by an ATI (control arm). On re-starting ART, participants will receive immediate dual LS bNAbs and then a second ATI 24 weeks after bNAb infusion.
16351319|NCT04319354|Experimental|pCR|
16351320|NCT04319354|Experimental|Partial responders|
16351321|NCT04319354|Active Comparator|Non-responders|
16351322|NCT04319328||Cefazolin|n = 20
16351323|NCT04319328||Ceftazidime|n = 20
16351324|NCT04319328||Ciprofloxacin|n = 20
16351325|NCT04319302||Paediatric biliary obstruction|This was a retrospective review of all paediatric patients who had undergone an IVGT graft procedure for biliary tract anatomical obstruction in the past five years. We looked at the indications for surgery, the demographic profile of the patients, outcomes following surgery and outlined the surgical technique used.
16351349|NCT04319107||Control patients|Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.
16351326|NCT04319289|Experimental|Group (A)|"Included 15 patients who are participating in an aerobic interval training exercise program with vitamin D supplementation (cholecalciferol 400 IU/day).
~The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks."
16351327|NCT04319289|Experimental|Group (B)|Included 15 patients who are receiving vitamin D supplementation only . One capsule containing (cholecalciferol 400 IU) was taken every day for 12 weeks
16351328|NCT04319289|Experimental|Group (c)|Included 15 patients who are participating in an aerobic interval training exercise program only. The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks.
16351333|NCT04319263|Experimental|intermediate and high risk non muscle invasive bladder cancer|
16351334|NCT04319250|Active Comparator|Group 1|Ischemic compression and rehabilitation program applied to the group 1
16351335|NCT04319250|Active Comparator|Group 2|IASTM and rehabilitation program applied to the group 2
16351336|NCT04319237||All Participants|
16351337|NCT04319224|Experimental|Vopratelimab|Participants will continue to receive vopratelimab monotherapy per parent protocol.
16351338|NCT04319224|Experimental|Vopratelimab with ipilimumab|Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
16351339|NCT04319224|Experimental|Vopratelimab with nivolumab|Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.
16351340|NCT04319211||People who isolate at home with the danger of coronavirus|Demographic data of the individuals participating in the study will be recorded. International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
16351342|NCT04319185|Experimental|Intervention|All patients who qualify for the study will receive the intervention
16351343|NCT04319159|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).
~One single Photodynamic therapy (PDT)."
16351344|NCT04319146|Other|robot-assisted radical prostatectomy|patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis
16351345|NCT04319133|Experimental|intervention|Participants will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
16351346|NCT04319133|No Intervention|control|Participants will not doing fasting or intake restriction within 8 weeks
16351347|NCT04319120||questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed.
16351348|NCT04319107||Marfan Syndrome (MFS) patients|Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.
16351350|NCT04319094|Experimental|PEERS|Peer mentors who have experience of depression are trained and supervised to deliver depression care. Peers will meet with depressed older adults for 8 weekly meeting lasting approximately 45 minutes. Peer mentors will provide social support defined as emotional, informational and appraisal support that includes coping strategies. Peers will be supervised by a mental health professional.
16351351|NCT04319094|Active Comparator|Social interaction|A study staff member will provide eight weekly social interaction visits and phone calls to the depressed older adult.
16351352|NCT04319081||Uncontrolled patients with hypercholesterolemia|Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab
16351353|NCT04319068||Healthy|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years.
16351354|NCT04319068||Hypertensive|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years
16351355|NCT04319042|Active Comparator|Immediate Loading|Group A. The implant receives an artificial tooth the same day as it is placed.
16351356|NCT04319042|Active Comparator|Early Loading|Group B. The implant receives an artificial tooth 4 weeks after placement.
16351357|NCT04319029|No Intervention|Non-intervention|Patients received a conventional pharmaceutical care plan, the patients offered optimal pharmacological therapy wit statin.
16351358|NCT04319029|Active Comparator|Intervention|The Patients offered to predesign pharmaceutical care plans aimed to improved patient's knowledge, adherence, satisfaction, and quality of life. The patients offered optimal pharmacological therapy wit statin.
16351359|NCT04319003|No Intervention|Control School|This school did not receive intervention (until after the study was completed)
16351360|NCT04319003|Experimental|Intervention School|This school received a one-week sugar-reduction intervention
16351361|NCT04318990|Experimental|Distal radial artery access|Wrist rests on a comfortable underground which brings the wrist in passive ulnar flexion. Patient is asked to bring the thumb under the other four fingers. After disinfection, patient is covered with a sterile drape. Brachial drape is applied to the hand exposing the anatomical snuff box and the proximal radial. Under ultrasound guidance, local anesthesia applied by SC injection of 5cc of lidocaine filling the radial fossa. Puncture performed at the point of maximal pulsation proximal in the anatomical snuffbox. If fails, a puncture more distal, can be attempted. After successful anterior wall puncture a radial sheath wire is advanced. Proper position verified by fluoroscopy or by ultrasound to ensure the wire didn't traverse the palmar arch, followed by introduction of a hydrophilic sheath. After administration of a spasmolytic cocktail containing 200-400 mcg of nitroglycerin and 5 mg of verapamil, the operator can take up a position at the level of the patient's knees.
16351362|NCT04318990|Active Comparator|Proximal radial artery access|Half of the patients enrolled in the study undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized proximal radial access for cardiac catheterization.
16351363|NCT04318977|Experimental|high-frequency repetitive transcranial magnetic stimulation|repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex using 3000 pulses applied with 10Hz and 120% resting motor threshold
16351364|NCT04318977|Experimental|theta burst stimulation|intermittent theta burst stimulation over left dorsolateral prefrontal cortex using 600 pulses applied in trains of 10 triplets/bursts (50Hz) with 8s intertrain-interval and 120% resting motor threshold
16351365|NCT04318977|Placebo Comparator|sham rTMS|half of the patients with high-frequency repetitive transcranial magnetic stimulation and half of the patients with theta burst Stimulation with angled coil (45 degree) or sham coil
16351366|NCT04318964|Experimental|TAEST16001 cells treat tumor antigen NY-ESO-1|"The dose escalation was carried out according to the principle of 3 + 3 increase. Four dose levels (calculated by the number of tcr-t positive cells) were set up: the dose level was 1: 5 × 108 ± 30%; the dose level was 2: 2 × 109 ± 30%; the dose level was 3: 5 × 109 ± 30%; the dose level was 4: 1.2 × 1010 ± 30%. Three patients in the first group, if there is no DLT, they will be enrolled in the next higher dose group; if one of the three patients in a certain dose group has DLT, three patients in the group will be supplemented with the same dose and method. If DLT occurred in 1 or more of the 3 cases, the dose increase was stopped. The former dose was defined as MTD; if DLT did not occur in 3 cases, the dose increased to the next group. Dose escalation is not allowed for the same patient."
16351367|NCT04318951|Experimental|Intensive communicative-pragmatic social interaction.|Intensive Language-Action Therapy (ILAT).
16351368|NCT04318951|Other|Standard care.|All participants will receive standard care.
16351369|NCT04318938|Active Comparator|Standard Arm with any available ALK TKI|"st line: Any approved 2nd-generation TKI according to investigator's choice
~nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)"
16351370|NCT04318938|Experimental|Experimental Arm with Brigatinib|"st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8
~nd line: Any available ALK TKI according to investigator's choice"
16351372|NCT04318912||COPD patients|Adults age 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) having been prescribed any COPD treatment (initial or subsequent) outside of a clinical trial.
16351373|NCT04318899|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.
16351374|NCT04318886|No Intervention|Usual Care|
16351375|NCT04318886|Experimental|Project ENABLE Cornerstone|
16351376|NCT04318873|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
16351377|NCT04318873|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
16351379|NCT04318847|No Intervention|Habitual Clinical Practice|Habitual Clinical Practice
16351380|NCT04318834|Experimental|Individuals with advanced biliary tract cancer|Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
16351381|NCT04318821|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), PC6 (Neiguan, B3), ST25 (Tianshu, B3), ST36 (Zusanli, B2), CV4 (Guanyuan), CV12 (Zhongwan, B3).
16351382|NCT04318821|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
16351383|NCT04318808|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi, B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3) , SP9 (Yinlingquan, B2).
16351384|NCT04318808|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
16351385|NCT04318795|Experimental|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
16351386|NCT04318795|Experimental|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
16351387|NCT04318782|Experimental|Thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
16351388|NCT04318769|Experimental|AFFIRM|AFFIRM is an 8-session psychoeducational weekly group intervention
16351389|NCT04318769|No Intervention|Waitlisted control|Waitlisted control
16351390|NCT04318756||Italian patients suffering from mucinous neoplasms|Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
16351391|NCT04318756||Italian patients with familiarity/genetic predisposition|Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
16351392|NCT04318743|Experimental|autoinjector - vial/syringe - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
16351393|NCT04318743|Experimental|vial/syringe - autoinjector - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
16351394|NCT04318743|Experimental|vial/syringe - vial/syringe - autoinjector|Single dose of Glepaglutide 10 mg for each treatment sequence
16351395|NCT04318730|Experimental|Arm 1|
16351396|NCT04318717|Experimental|Pembrolizumab + Hypofractionated radiation therapy|"Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).
~Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy."
16351398|NCT04318691||acute respiratory failure group|60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure
16351399|NCT04318691||vascular surgery control group|10 control patients admitted to the ICU after a planned vascular surgery
16351400|NCT04318691||Healthy volunteers group|10 healthy subjects.
16351401|NCT04318678|Other|CD123-CAR T cell therapy|CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.
16351402|NCT04318665|Experimental|CT Perfusion|Severe TBI patients will be undergoing CT perfusion test
16351403|NCT04318652|Other|Methylprednisolone eye drops|Preservative free steroids methylprednisolone 5% eye drops (prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company) was prepared and given for all enrolled cases by the following regimen 5 times/day for 5 days with gradual decrease every third day over the following 2 weeks
16351404|NCT04318652|Placebo Comparator|distilled water eyedrops|Distilled water eyedrops instilled 3 times per day for two weeks
16351405|NCT04318639|Experimental|Donepazil+CRT|Donepazil+CRT
16351406|NCT04318626|Other|PMPBB3|"Name: [18F] PMPBB3，[18F]1-Fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)ben
~Dosage form: intravenous injection
~Dose(s): 7mCi
~Dosing schedule: Visit 2
~Mechanism of action (if known): high affinity radiotracer for the tau protein
~Pharmacological category：Radio pharmaceutical"
16351407|NCT04318626|Other|THK|"Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline
~Dosage form: intravenous injection
~Dose(s): 10mCi
~Dosing schedule: Visit 2
~Mechanism of action (if known): high affinity radiotracer for the tau protein
~Pharmacological category：Radio pharmaceutical"
16351408|NCT04318600|Experimental|human amniotic mesenchymal stem cell treatment group|
16351409|NCT04318600|No Intervention|blank control group|
16351410|NCT04318587|Experimental|Allosure Arm|All subjects will be in arm one and will have AlloSure blood draws at multiple time points.
16351411|NCT04318574|Experimental|Interventional|Balance, Agility, Strengthening Exercise (BASE) class intervention - a 6-week exercise class to determine the change in balance performance, fear of falling and self-efficacy
16351412|NCT04318561|Experimental|Gallium-68 NODAGA-LM3 group|Patients will undergo a Gallium-68 NODAGA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
16351413|NCT04318561|Experimental|Gallium-68 DOTA-LM3 group|Patients will undergo a Gallium-68 DOTA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
16351417|NCT04318535|Experimental|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
16351418|NCT04318535|Experimental|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
16351419|NCT04318535|Experimental|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
16351420|NCT04318522|Experimental|Stimulation Group|
16351421|NCT04318522|Sham Comparator|Control Group|
16351422|NCT04318509|Experimental|PKU GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
16351423|NCT04318496|Experimental|Acupuncture with press tack needle group (Acu)|the press tack needles (PYONEX Φ0.20×0.6 mm made by Seirin Corporation) has a diameter of 0.2 mm and length of 0.6 mm will be used on the following bilateral points; GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack needles retention time will be 4 days.
16351424|NCT04318496|Placebo Comparator|Placebo group (Con)|The pess tack placebo is PYONEX sticker and pack that is identical to the press needle, except that the needle part was removed. The acupuncturist will apply the stickers on the following bilateral acupoints: GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack stickers retention time will be 4 days.
16351425|NCT04318483||Angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
16351426|NCT04318483||Without angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
16351427|NCT04318470||PPROM|Preterm premature rupture of membranes between 16 0/7 and 33 6/7 weeks gestation
16351428|NCT04318470||Healthy controls|Gestational-age-matched controls without preterm premature rupture of membranes or other pregnancy complications
16351429|NCT04318457||Brochoscopy|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during bronchoscopy will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
16351430|NCT04318457||ERCP|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during ERCP will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
16351431|NCT04318444|Experimental|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
16351432|NCT04318444|Placebo Comparator|Placebo|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
16351433|NCT04318431|Other|Data collection and rhinopharyngeal swab|"After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.
~During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR."
16351434|NCT04318418||Cases|Patients who developed severe COVID-19 disease (including fatal events)
16351435|NCT04318418||Controls|Infected patients who did not develop severe COVID-19 respiratory disease (including individuals who recovered from the infection)
16351436|NCT04318392||Patients with suspected sarcoidosis|Patients presenting with suspected sarcoidosis.
16351437|NCT04318392||Healthy controls|Healthy controls matched for age and gender. Recruitment of spouses and partners will also take place where possible.
16351438|NCT04318379|Experimental|Low dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
16351439|NCT04318379|Experimental|High dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
16351440|NCT04318366||COVID-19 patients|
16351441|NCT04318353||early enteral feeding|start enteral feeding within 2 days postoperative
16351442|NCT04318353||control|start enteral feeding after 2 days postoperative according to clinician discretion based on clinical progress(ranging from 1-5 days after passage of flatus or stool.
16351443|NCT04318340|Active Comparator|Standard Applicators|All patients will be fitted with the 2.6 cm applicator and sized up to the 3.0 cm applicator if tolerable.
16351444|NCT04318340|Experimental|Tapered Applicator|All patients will be fitted with the novel tapered 3.0 cm applicator. Patients have the option of having magnetic resonance imaging with the tapered applicator in place.
16351446|NCT04318314||Healthy and asymptomatic healthcare workers|Healthy and asymptomatic healthcare workers
16351447|NCT04318301||ACEI/ARB|COVID-19 patients with hypertension who had previously taken ACEI/ARB for antihypertensive treatment
16351448|NCT04318301||non ACEI/ARB|COVID-19 patients with hypertension who had not previously taken ACEI/ARB for antihypertensive treatment
16351449|NCT04318262||Patient with Staphylococcus lugdunensis infection|All consecutive patients with S. lugdunensis infection (microbiological and clinical data)
16351450|NCT04318262||Patient with Staphylococcus aureus infection|Patients with S. aureus infection (microbiological and clinical data), matched to the hospital sector for S. lugdunensis infections
16351451|NCT04318262||Patient with other coagulase negative Staphylococcus infection|Patients with CoNS infection (microbiological and clinical data),matched to the hospital sector for S. lugdunensis infections
16351452|NCT04318249|Experimental|Assisted Relaxation Therapy|This group will be receiving an assisted relaxation therapy intervention
16351453|NCT04318249|Experimental|Modified Assisted Relaxation Therapy|This group will be receiving a modified version of an assisted relaxation therapy intervention
16351454|NCT04318236|Experimental|Online-Program + factors 1,2,3,4|"In this arm all four factors are set to active (i.e. yes):
~diagnostic interview
~motivational module
~guidance
~e-mail reminders"
16351455|NCT04318236|Experimental|Online-Program + factors 1,2,3|"In this arm three factors are set to active (i.e. yes):
~diagnostic interview
~motivational module
~guidance"
16351456|NCT04318236|Experimental|Online-Program + factors 1,2,4|"In this arm three factors are set to active (i.e. yes):
~diagnostic interview
~motivational module
~e-mail reminders"
16351457|NCT04318236|Experimental|Online-Program + factors 1,2|"In this arm two factors are set to active (i.e. yes):
~diagnostic interview
~motivational module"
16351458|NCT04318236|Experimental|Online-Program + factors 1,3,4|"In this arm three factors are set to active (i.e. yes):
~diagnostic interview
~guidance
~e-mail reminders"
16351459|NCT04318236|Experimental|Online-Program + factors 1,3|"In this arm two factors are set to active (i.e. yes):
~diagnostic interview
~guidance"
16351460|NCT04318236|Experimental|Online-Program + factors 1,4|"In this arm two factors are set to active (i.e. yes):
~diagnostic interview
~e-mail reminders"
16351461|NCT04318236|Experimental|Online-Program + factor 1|"In this arm one factor is set to active (i.e. yes):
~- diagnostic interview"
16351462|NCT04318236|Experimental|Online-Program + factors 2,3,4|"In this arm three factors are set to active (i.e. yes):
~motivational module
~guidance
~e-mail reminders"
16351463|NCT04318236|Experimental|Online-Program + factors 2,3|"In this arm two factors are set to active (i.e. yes):
~motivational module
~guidance"
16351464|NCT04318236|Experimental|Online-Program + factors 2,4|"In this arm two factors are set to active (i.e. yes):
~motivational module
~e-mail reminders"
16351465|NCT04318236|Experimental|Online-Program + factor 2|"In this arm one factor is set to active (i.e. yes):
~- motivational module"
16351466|NCT04318236|Experimental|Online-Program + factors 3,4|"In this arm two factors are set to active (i.e. yes):
~guidance
~e-mail reminders"
16351467|NCT04318236|Experimental|Online-Program + factor 3|"In this arm one factor is set to active (i.e. yes):
~- guidance"
16351468|NCT04318236|Experimental|Online-Program + factor 4|"In this arm one factor is set to active (i.e. yes):
~- e-mail reminders"
16351469|NCT04318236|Experimental|Online-Program + no factor|"In this arm no factor is set to active (i.e. yes):"
16351470|NCT04318223|Experimental|single-arm study following a Simon's two-stage optimal design|Single-arm study with the primary objective of assessing the efficacy and safety of palbociclib in combination with fulvestrant (Faslodex) in women with HR+, HER2-negative metastatic breast cancer, regardless of their menopausal status, whose disease has progressed after prior treatment with AI plus a CDK4/6 inhibitor.
16351471|NCT04318210|Experimental|TDF-FTC as PrEP|Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
16351472|NCT04318197|Active Comparator|Global rehabilitation|2 hours of daily rehabilitation, 3 days per week during 4 weeks
16351473|NCT04318197|Experimental|Personalized rehabilitation|2 hours of daily rehabilitation including at least 2 times 20 minutes of electrostimulation on atrophied muscles, 3 days per week during 4 weeks
16351474|NCT04318197|No Intervention|Classic rehabilitation|40 minutes of rehabilitation, once a week during 4 weeks.
16351475|NCT04318184|Experimental|Exercise|Submaximal aerobic exercise protocol
16351476|NCT04318171||Carotid arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
16351477|NCT04318171||Peripheral arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
16351478|NCT04318171||AVF.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
16351479|NCT04318171||Vein mapping|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
16351480|NCT04318158|Experimental|Group(B)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% on each side.
16351481|NCT04318158|Active Comparator|Group(BD)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
16351482|NCT04318158|Active Comparator|Group(BF)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
16351483|NCT04318145|Experimental|Part A: PL-3994 Dose Ascension|Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.
16351484|NCT04318145|Experimental|Part B: PL-3994 Single Dose|Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.
16351485|NCT04318106|Experimental|'Experimental' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be the optimum chromaticity to alleviate visual stress symptoms. To be worn for a minimum of 10 weeks for concentrated tasks.
16351486|NCT04318106|Placebo Comparator|'Control' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
16351487|NCT04318093|Experimental|BMS-986259|
16351489|NCT04318080|Experimental|Cohort 1|Participants with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after autologous hematopoietic stem cell transplantation (HSCT) and failed to achieve a response or progressed after brentuximab vedotin
16351490|NCT04318080|Experimental|Cohort 2|Participants with relapsed or refractory cHL who have received at least 2 prior systemic chemotherapy regimens and failed to achieve a response or progressed after brentuximab vedotin, and are not candidates for autologous or allogeneic HSCT
16351491|NCT04318067|Experimental|Sleep problems i Attention Deficit Hyperactivity Disorder|Children age 6 to 12 years having ADHD and Sleeping problem will be treated with Melatonin 3 mg one a day (before bedtime)
16351492|NCT04318054|Experimental|Immediate intervention group|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, in the 2 months following the randomization, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
16351493|NCT04318054|Other|Deferred intervention group|Deferred intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, one year after the inclusion, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
16351494|NCT04318041|Experimental|diacerein (Artrodar)|
16351495|NCT04318041|Placebo Comparator|placebo|
16351496|NCT04318028|Experimental|Diagnostic (7 Tesla MRI)|Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and 6-9 months.
16351497|NCT04318015|Experimental|High-risk Treatment|Hydroxychloroquine 200mg per day for 60 days.
16351498|NCT04318015|Placebo Comparator|High-risk Placebo|Placebo tablet per day for 60 days.
16351499|NCT04318015|Experimental|Low-risk Treatment|Hydroxychloroquine 200mg per day for 60 days
16351500|NCT04318015|Placebo Comparator|Low-risk Placebo|Placebo tablet per day for 60 days.
16351501|NCT04318002|Experimental|Group 1A|Volunteers (aged 18-45 years) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2
16351502|NCT04318002|Experimental|Group 1B|Volunteers (aged 18-45 years) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
16351503|NCT04318002|Experimental|Group 2A|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2.
16351504|NCT04318002|Experimental|Group 2B|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 6.
16351505|NCT04318002|Experimental|Group 2C|Volunteers (aged 5-17 months) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
16351506|NCT04318002|Experimental|Group 2D|Volunteers (aged 5-17 months) of high malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
16351507|NCT04317989|Experimental|Practice Facilitation (top 50th percentile)|Practices with performance in the upper 50th percentile will receive practice facilitation for the duration of the intervention period.
16351508|NCT04317989|Experimental|Practice Facilitation + Embedded Teleheath|The lower 50th percentile of practices (based on performance after 6 months of practice facilitation) will be randomized to 2 arms. Of those practices randomized, this arm will receive continued practice facilitation plus embedded telehealth services related to interventions for unhealthy alcohol use.
16351509|NCT04317989|Experimental|Practice Facilitation (bottom 50th percentile)|The lower 50th percentile of practices (based on uptake of services after 6 months of practice facilitation) will be randomized to 2 arms. Of those practices randomized, this arm will receive ongoing practice facilitation for the duration of the intervention period (but will not receive embedded telehealth services).
16351510|NCT04317976|Active Comparator|Centrally located oesophagus post GA|Oesophagus remained central after general anaesthesia, cricoid pressure applied by fingertips under ultrasound guidance
16351511|NCT04317976|Experimental|Eccentric located oesophagus post GA|Oesophagus eccentric located after general anaesthesia, paralaryngeal pressure and cricoid pressure applied by fingertips under ultrasound guidance
16351512|NCT04317963||Cases|Patients who have received bezlotoxumab 10 mg/kg intravenously in addition to standard CDI treatment.
16351513|NCT04317963||Controls|Patients who have received only standard CDI treatment.
16351514|NCT04317950|Other|Vojta group|All participants were properly instructed and signed an informed consent previous to the interventions. They were comfortably laid down on their back with eyes open, wearing the EEG cap and electromyography electrodes during the intervention. They were asked to remain relaxed and still during the whole process. After a first minute of resting, the experimental group received a continuous reflex locomotion stimulus during the next 8 minutes.
16351515|NCT04317950|Sham Comparator|Control group|On the contrary, the control group received a continuous sham stimulus during the next 8 minutes.
16351518|NCT04317924|Experimental|Reinforcement of air leak|Participants in this arm will receive reinforcement with the NEOVEIL (polyglycolic acid felt) which will be impregnated with human fibrinogen and thrombin.
16351519|NCT04317924|Active Comparator|No reinforcement of air leak|Participants in this arm will receive standard of care for air leak post lung resection.
16351520|NCT04317898|Active Comparator|serratus plane block|20 ml of Bupivacine 0.25% +80mg triamcinlone will be injected in serratus plane under ultrasound.
16351521|NCT04317898|Active Comparator|paravertebral block|10 ml of bubivacine 0.25% +80 mg triamcinlone will be injected at T2 level (paravertebral) under ultrasound.
16351522|NCT04317885|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
16351523|NCT04317872|Experimental|Current protocol|"Current protocol: patients will receive a single shot of 25mg of aacidexam iv (5cc) at induction. After 12 hours these patients will another shot of 10mg of aacidexam iv (2cc) on the ward."
16351524|NCT04317872|Active Comparator|Old protocol|"Old protocol: patients will receive a single shot of 5mg of aacidexam iv at induction (5cc). After arrival 12 hours these patients will receive a placebo, i.e. a shot of 2 cc of NaCl 0.9% iv (Mini-Plasco van B. Braun)."
16351525|NCT04317859|Experimental|Behavioural Activation (Intervention)|Originally a component of Cognitive Therapy, Behavioural Activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to modify one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations and mood symptoms.
16351526|NCT04317859|No Intervention|Waitlist (Control)|The Control group (waitlist) will receive treatment as usual while waiting to receive BA intervention (at the end of intervention group therapy time, which will consist of 18 sessions over an 14 week period). This group will be assessed by clinical staff that offer treatment as usual for mood symptoms and quality of life measures during the waiting time.
16351527|NCT04317846|Active Comparator|Intra-radial group|intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
16351528|NCT04317846|Experimental|Intravenous-post group|intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
16351529|NCT04317846|Experimental|Intravenous-pre group|intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
16351530|NCT04317833|Experimental|Dose Escalation SSS17|Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)
16351531|NCT04317833|Placebo Comparator|Escalation matching Placebo|Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)
16351532|NCT04317820|Experimental|DBR Condition|Involves 8 weekly sessions of DBR treatment.
16351533|NCT04317820|No Intervention|Wait-list Condition|No intervention for approximately 8 weeks.
16351534|NCT04317807|Active Comparator|Study Drug group|Participants in this group will receive 500 mg of levetiracetam twice daily for 12 weeks. After 12 weeks, levetiracetam will be gradually decreased and stopped over the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
16351535|NCT04317807|Placebo Comparator|Placebo Group|Participants in this group will receive a placebo that looks like the levetiracetam pill twice daily for 12 weeks. After 12 weeks, the levetiracetam dose will be tapered for the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
16351536|NCT04317794||All Participants|Participants who were prescribed with nusinersen sodium injection in Korea according to local marketing authorization.
16351537|NCT04317781|Experimental|Treatment (tagraxofusp-erzs)|Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16351538|NCT04317768|Experimental|Study group|They will be educated and motivated by an intensive program consisting of verbal instructions, Power Point lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
16351539|NCT04317768|Other|Control group|They will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
16351540|NCT04317755|Experimental|Intervention|Comics-based body image programme
16351541|NCT04317755|No Intervention|Control|Schools lessons as usual
16351542|NCT04317742|Active Comparator|Sleep Healthy Using the Internet (SHUTi) Intervention Group|Participants will receive a direct link to access the SHUTi program (per randomization) from the study team.
16351543|NCT04317742|Active Comparator|Online Patient Education (PE) Control Group|Participants will receive a direct link to access online patient education (per randomization) from the study team.
16351544|NCT04317729|Experimental|Diagnostic|Collection of whole blood via fingerstick and venipuncture
16351545|NCT04317716|Experimental|Intervention|Fall prevention program and brochure about falls and fall risk factors
16351546|NCT04317716|Other|Control|Bbrochure about falls and fall risk factors
16351547|NCT04317703|Experimental|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
16351548|NCT04317703|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
16351549|NCT04317690||High Cholesterol|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
16351550|NCT04317690||High Blood Pressure|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
16351551|NCT04317690||Colorectal Cancer Screening|People between the ages of 50-75 with no previous diagnosis of colon cancer, who have been screened for colon cancer (or discussed screening for colon cancer) in the past 2 years, or who had first colon cancer screening in past 2 years. These people will see items only pertaining to colon cancer screening.
16351552|NCT04317690||Breast Cancer Screening|Females between the ages of 40-50 with no previous diagnosis of breast cancer who have had mammogram (or discussed having a mammogram) in the past 2 years, or had first mammogram in past 2 years. These people will see items only pertaining to breast cancer screening.
16351553|NCT04317690||Prostate Cancer Screening|Men between the ages of 45-69 with no previous diagnosis of prostate cancer who have been screened for prostate cancer (or discussed screening for prostate cancer) in the past 2 years or had first prostate cancer screening in the past 2 years. These people will see items only pertaining to prostate cancer screening.
16351554|NCT04317677|Other|Babies hospitalized in the pediatric sleep unit|
16351555|NCT04317664|No Intervention|Control Group|The Control Group will have the in-vehicle device installed in the teen's car, but all feedback features will be disabled.
16351556|NCT04317664|Experimental|Feedback Only Group|The Feedback Only Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens can review their driving data. Teens will also receive biweekly cumulative driving reports.
16351557|NCT04317664|Experimental|Feedback and Parent Communication Group|The Feedback and Parent Communication Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens and parents can review their driving data. The parent will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a motivational interviewing professional. A second booster session will also occur two months after the initial training. Both teens and parents will receive a biweekly cumulative driving report.
16351558|NCT04317638||breastfed group|Infants on exclusive breast feeding for the first 6 months of life and their mothers
16351559|NCT04317638||formula fed group|Infants on exclusive formula feeding for the first 6 months of life
16351560|NCT04317638||mixed fed group|Infants on mixed feeding (formula & breast feeding) and their mothers
16351561|NCT04317625|Experimental|participants|All of the participants tested serum PSA, some of them conducted mpMRI with/without prostate biopsy under instruction.
16351562|NCT04317612|Active Comparator|Active berry product|Once daily consumption over the period of the study
16351563|NCT04317612|Placebo Comparator|Reference product|Once daily consumption over the period of the study
16351564|NCT04317599||Non interventional|All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
16351566|NCT04317573|Active Comparator|Personalised card|The personalised card was printed by the attending ophthalmologist for the patient via a web accessible software we have developed. The software allowed the reviewing physician to select the medications the patient was prescribed and auto-generate a personalised card that will be sent to the network printer. The card illustrated the patient's eye drop regime in a simple pictorial format using coloured pictures of the eye drop bottles and universally recognised symbols. It can be folded to a compact size of 11cm x 7.5cm to allow patients to carry around in their wallets. This card will be given to patients at the end of their consult and explanation will be provided by the attending physician who will manually tick in the corresponding boxes depending on the frequency of administration
16351567|NCT04317573|Active Comparator|Personalised card and telereminder|Patients who were recruited into the group receiving tele-monitoring were contacted via text messages daily by a programmed software at the scheduled time of eye drop administration. They were required to acknowledge the reminder by replying a 'Yes' if they had administered the eyedrop and 'No' if they had not. A nil reply was taken as a 'No'.
16351568|NCT04317573|No Intervention|No intervention|No intervention
16351569|NCT04317560|Active Comparator|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
16351570|NCT04317560|Experimental|Arthrocentesis plus i-PRF injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. Only the second needle was removed without removing the first needle inserted. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
16351571|NCT04317547|No Intervention|Control Group|The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
16351572|NCT04317547|Experimental|Intervention Group|Parents will receive STS, which will include 1) Individualized virtual communication training and a booster session delivered by a traffic safety communication specialist; and 2) An online parent-teen safe driving communication guide. In addition, the Azūga™ in-vehicle device and app will be installed as described above and all feedback features will be enabled. Three types of feedback will be provided to teens: 1) Direct audio feedback; 2) Detailed cumulative driving data; and 3) A customized weekly driving summary report. Parents in this group will receive access to the teen's cumulative driving data and a weekly driving summary report. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
16351575|NCT04317508|Active Comparator|Intervention group|Topicale® topical anesthetic gel patch (Benzocaine 18%)
16351576|NCT04317508|Placebo Comparator|control group|Opahl® topical anesthetic gel (Benzocaine 20%)
16351577|NCT04317495|Experimental|Computerized Cognitive Training (CCT)|The patients will receive CCT during their standard rTMS treatments (after having 5 days of treatment until the pre-taper treatment).
16351578|NCT04317482|Other|Standard social stress task|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three standard scenarios presented in counterbalanced order. This will involve approximately 30 minutes of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
16351579|NCT04317482|Other|Stressful experience in the ED|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three experiences surrounding their most stressful ED visit. These experiences are presented in counterbalanced order. This will involve approximately 30 of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
16351580|NCT04317469||ARDS group ,|
16351581|NCT04317469||non ARDS group|
16351582|NCT04317443||Super-Mini Percutaneous Nephrolithotomy|Patients undergo SMP
16351583|NCT04317443||Extracorporeal Shock Wave Lithotripsy|Patients undergo ESWL
16351584|NCT04317430|Active Comparator|Treatment group|Niclosamide tablets 1 gram once daily
16351585|NCT04317430|Placebo Comparator|Control group|Lactose tablets
16351618|NCT04317404||Diabetic with Knee Osteoarthritis|HbA1c between 6.5% - 12.0% in the 3 months prior to Visit 1
16351619|NCT04317404||Pre-diabetic with Knee Osteoarthritis|HbA1c between 5.6% - 6.4% in the 3 months prior to Visit 1
16351620|NCT04317404||Non-diabetic with Knee Osteoarthritis|HbA1c < 5.6% in the 3 months prior to Visit 1
16351621|NCT04317391|Experimental|Pain management program|All enrolled patients participate in a 20 hour pain management program over a period of 8 weeks. The program is based on Mindfulness Based Stress Reduction with modifications to fulfill needs of the Taiwanese chronic pain population.
16351622|NCT04317365|Active Comparator|patients receiving remembering|
16351623|NCT04317365|No Intervention|patients not receiving extra remembering|
16351624|NCT04317352||Multivisceral resection (MRV)|MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
16351625|NCT04317339|Experimental|Zhigancao Tang granule group|Participants in experimental group will receive Zhigancao Tang granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters, diuretics as needed.
16351626|NCT04317339|Placebo Comparator|Zhigancao Tang placebo group|Participants in experimental group will receive Zhigancao Tang placebo granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
16351627|NCT04317326|Experimental|Life style modification|"Lifestyle modifications group (Control) will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 <55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88)"
16351628|NCT04317326|Active Comparator|Life style modificacion and automatic NIV(AVAPS-AE)|Automatic NIV: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 20 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight. These parameters may be modified according to patient tolerance or non-compensated leak.
16351629|NCT04317326|Experimental|Life style modification and titrated NIV(S/T mode)|In-laboratory polysomnographic NIV titration will be performed according to published guidelines (Berry R et al JCSM 2010). In addition to lifestyle modification and oxygen (if required), home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel PAP with backup respiratory rate (BIPAP S/T mode). The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG.
16351630|NCT04317326|Active Comparator|Life style modification and titrated CPAP|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines (SEPAR guideline or AASM guideline). In addition to lifestyle modification and oxygen (if required), home CPAP therapy at a fixed pressure will be initiated.
16351631|NCT04317300|Experimental|E-cigarette users|Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.
16351632|NCT04317287|Experimental|Cardio formulation|Tomato-based formulation with dietary supplement
16351633|NCT04317287|Placebo Comparator|Placebo|Placebo softgels
16351634|NCT04317274|Experimental|High Cholesterol Good Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
16351635|NCT04317274|Experimental|Colorectal Cancer Good Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
16351636|NCT04317274|Experimental|High Cholesterol Poor Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
16351637|NCT04317274|Experimental|Colorectal Cancer Poor Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.
16351638|NCT04317261|Experimental|Hematuria patients|
16351639|NCT04317248|Experimental|MSDCV immune therapy combined with radical surgery therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time before the first time of MSDCV immune therapy
16351640|NCT04317248|No Intervention|Radical surgery therapy|Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time
16351641|NCT04317248|Experimental|MSDCV immune therapy combined with TACE therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: the first time of TACE therapy must perform before the first time of MSDCV immune therapy， then perform when necessary according to subjects condition
16351642|NCT04317248|No Intervention|TACE therapy|Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: perform when necessary according to Subjects condition
16351643|NCT04317248|Experimental|MSDCV immune therapy combined with targeted agents therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
16351644|NCT04317248|No Intervention|Targeted agents therapy|Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
16351645|NCT04317235|Active Comparator|3 ml ropivacaine|interscalene block using 3 ml under ultrasound put medication on each nerve
16351646|NCT04317235|Active Comparator|5 ml ropivacaine|interscalene block using 5 ml under ultrasound put medication on each nerve
16351647|NCT04317222|Experimental|eCRRT group|Initiated CRRT within the first 24 post-transplant hours.
16351648|NCT04317222|No Intervention|Control group|Standard treatment.
16351649|NCT04317209|Experimental|SHR0410 low dosage|
16351650|NCT04317209|Experimental|SHR0410 medium dosage|
16351651|NCT04317209|Experimental|SHR0410 high dosage|
16351652|NCT04317209|Placebo Comparator|Placebo|
16351653|NCT04317183|Experimental|Chamomile topical gel|"Topical oral chamomile gel three times daily for three weeks.
~Topical oral chamomile gel is prepared with the aid of Pharmacognosy and pharmaceutics departments, faculty of pharmacy, Alexandria University and mucoadhesive hydrogels (Carbopol® 970)."
16351654|NCT04317183|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:
~Miconaz oral gel BBC oral spray Oracure gel
~Dose: Three times a day for three weeks"
16351655|NCT04317183|Experimental|combination therapy|"Topical oral chamomile gel three times daily for three weeks in combination with the symptomatic treatment
~Symptomatic treatment which included:
~Miconaz oral gel BBC oral spray Oracure gel
~Symptomatic treatment dose: Three times a day for three weeks"
16351656|NCT04317170|Experimental|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia.
16351657|NCT04317170|No Intervention|No Music|Patients will undergo their routine procedure without being played music.
16351658|NCT04317157|Experimental|Caffeine Clinical Trial|Participants will ingest 6 mg.kg-1 of caffeine ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
16351659|NCT04317157|Placebo Comparator|Placebo Clinical Trial|Participants will ingest placebo ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
16351660|NCT04317157|Experimental|Placebo-deceived Caffeine|Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
16351661|NCT04317157|Placebo Comparator|Placebo-deceived Placebo|Participants will be informed they are ingesting placebo ~45 minutes before the trial.
16351662|NCT04317157|Active Comparator|Control-Caffeine|Participants will be informed they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
16351663|NCT04317157|No Intervention|Control|Participants will perform a baseline trial with no intervention.
16351664|NCT04317144|Active Comparator|Web-based follow-up programme|Participant randomized to the Web-based follow-up programme receive access to web-portal called www.1177.se
16351665|NCT04317144|Active Comparator|No follow-up.|Participants does not receive the web-based follow-up programme. e-questionnaires are sent out.
16351669|NCT04317092|Experimental|tocilizumab treatment|All the patients enrolled are treated with tocilizumab.
16351670|NCT04317079|Active Comparator|15mg of hydroxytyrosol|15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
16351671|NCT04317079|Active Comparator|5mg of hydroxytyrosol|5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
16351672|NCT04317079|Placebo Comparator|placebo|2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
16351673|NCT04317066|Experimental|Pembrolizumab in Participants with rrPMBCL|Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months.
16351674|NCT04317053|No Intervention|Site-Directed Care (SDC)|Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.
16351675|NCT04317053|Experimental|Relay program (peer navigation)|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
16351676|NCT04317040|Experimental|CD24Fc|Participants receive single dose of 480 mg CD24Fc, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
16351677|NCT04317040|Placebo Comparator|Placebo|Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.
16351678|NCT04317027|Experimental|All subjects|All subjects in this trial will receive the new fighting clothing while performing the study protocol
16351679|NCT04317014||cases|early puberty girls of Han Chinese
16351680|NCT04317014||controls|normal development girls of Han Chinese
16351681|NCT04317001|Active Comparator|Active treatment with modafinil|active intervention
16351682|NCT04317001|Placebo Comparator|Placebo|placebo intervention
16351683|NCT04316988||Ultrasonography|Ultrasonography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by ultrasound machine over the trachea.
16351684|NCT04316988||Capnography|Capnography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by capnograph, evaluationg the graph character and end tidal CO2 value.
16351685|NCT04316975|Other|Biopsy: Barrett's Esophagus, Intramucosal adenocarcinoma|"Subjects will undergo standard of care (SOC) standard esophagogastroduodenoscopy (EGD) for the treatment of their condition (BE or IMC). Four (4) research biopsies will be taken from the midpoint of current disease. In cases where EMR (Endoscopic Mucosal Resection) is performed clinically, no research biopsies will be taken. Following CEIM, four (4) additional research biopsies will be collected, from the midpoint of previous BE site.
~Laboratory Biomarker Analysis: Correlative studies
~Esophagogastroduodenoscopy: Standard of care, research biopsies will be collected if clinical biopsies are taken"
16351686|NCT04316962|Experimental|Complex rehabilitation|See intervention described elsewhere.
16351687|NCT04316949||Derivation cohort|"Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020.
~."
16351688|NCT04316949||Validation cohort|Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
16351689|NCT04316936|Experimental|Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg|Omidria (= ketorolac + phenylephrine) and intracanalicular dexamethasone insert (punctal plug)
16351690|NCT04316936|Experimental|Omidria + Dexycu|Omidria (= ketorolac + phenylephrine) and intraocular dexamethasone suspension
16351691|NCT04316936|Active Comparator|Omidria + Prednisolone Acetate 1%|Omidria (= ketorolac + phenylephrine) and topical prednisolone acetate ophthalmic drops
16351692|NCT04316923||Children with cardiomyopathies|Children aged 0-18 years that have been diagnosed with DCM, HCM or LVNC on the basis of a two-dimensional echocardiography with color Doppler.
16351693|NCT04316923||Healthy children|The control group will be composed of healthy children, in whom heart disease will be excluded using echocardiography.
16351694|NCT04316910||Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
16351695|NCT04316910||Non-Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
16351701|NCT04316858|Active Comparator|Water|Water will be used as solvent for sodium phosphate
16351702|NCT04316858|Active Comparator|Zero calorie carbonated drink|Zero calorie carbonated drink will be used as solvent for sodium phosphate
16351703|NCT04316845|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
16351704|NCT04316832|Experimental|Intervention/treatment|The mindfulness based cognitive training will be delivered in one session and will include short mindfulness exercises.
16351705|NCT04316832|Placebo Comparator|No intervention|Control exercise, participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
16351706|NCT04316819|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
16351707|NCT04316819|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
16351708|NCT04316806|Experimental|Probiotic|Treatment with probiotic formula
16351709|NCT04316806|Other|Antibiotic|Treatment with antibiotic rifaximin
16351710|NCT04316793|Experimental|Dry needling (DN)|Intramuscular insertion
16351711|NCT04316793|Sham Comparator|Sham needling (SN)|Intradermal insertion
16351712|NCT04316780||Nintedanib until 0 day - 2 days before transplant|Nintedanib taken until 0 - 2 days before receiving transplant
16351713|NCT04316780||Nintedanib until 3 days - 28 days before transplant|Nintedanib taken until 3-28 days before receiving transplant
16351714|NCT04316780||Nintedanib until > 28 days before transplant|Nintedanib taken until more than 28 days before receiving transplant
16351715|NCT04316780||Pirfenidone until 0 day - 1 day before transplant|Pirfenidone taken until 0 - 1 day before receiving transplant
16351716|NCT04316780||Pirfenidone until 2 days - 28 days before transplant|Pirfenidone taken until 2-28 day before receiving transplant
16351717|NCT04316780||Pirfenidone until > 28 days before transplant|Pirfenidone taken more than 28 days before receiving transplant
16351718|NCT04316767|Experimental|App Intervention|Participants will download a mobile self-care app on their smartphones. The app guides users through exercises based on cognitive behavioral therapy principles. Participants will be able to use the app as frequently as desired throughout the course of the study.
16351719|NCT04316767|No Intervention|Control|Participants will receive usual supportive care provided to family members of ICU patients.
16351720|NCT04316754|No Intervention|Control group|No music will be played to the control group.
16351721|NCT04316754|Active Comparator|Intervention 1|During angiography, the Intervention-1 group will listen to the music that the child wants to listen.
16351722|NCT04316754|Active Comparator|Intervention-2|"The Intervention-2 group will listen to the music which determined by the researchers. The music which determined by the researchers is The art of fugue by Johann Sebastian Bach. The music to be played has been decided by examining the literature. (DOI: 10.4274/jpr.24892)"
16351723|NCT04316741|Experimental|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
16351724|NCT04316741|No Intervention|Control|Enhanced usual care brochure plus attention control with social media messaging
16351725|NCT04316728|Other|negative Patients|Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility
16351726|NCT04316715|Experimental|Life-Steps for PreP|Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.
16351727|NCT04316715|No Intervention|Standard of Care|Participants in this group will not receive an intervention outside the standard of care.
16351728|NCT04316702|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
16351729|NCT04316702|Active Comparator|Pharmacotherapy|Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 2 weeks, patients will be evaluated and dose will be adjusted as necessary and tolerated, up to the maximum dosage recommended for FM. Patients may also be switched from one medication to the other according to clinical judgment of the physician.
16351730|NCT04316689|Experimental|S-588210 (S-488210 + S-488211)|Participants will receive subcutaneous injections once a week for 4 weeks and then a biweekly extension treatment for 8 weeks. Each treatment will consist of 1 subcutaneous injection of 1 mL of S- 488210 and 1 subcutaneous injection of 1 mL of S-488211 containing 1 mg each of the 5 peptides.
16351731|NCT04316676|Other|Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR|Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
16351732|NCT04316663|Experimental|Well-Being and Sleep Hygiene|Participants in the experimental group will receive an intervention focused on both principles of psychological well-being and sleep hygiene education.
16351733|NCT04316663|Active Comparator|Sleep Hygiene (Control)|Participants in the control group will receive sleep hygiene education alone.
16351734|NCT04316650|Other|SSRI Group|Treated by ISRS at inclusion
16351735|NCT04316650|Other|Anti-androgen Group|Treated by anti-androgen at inclusion
16351736|NCT04316650|Other|No SSRIs or antiandrogen treatment at inclusion|no treatment
16351737|NCT04316624|Experimental|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
16351738|NCT04316611|Experimental|Potassium chloride|Potassium chloride
16351739|NCT04316598|Experimental|Cannabis (B)|"Subjects will be admitted in the center to receive 4 doses of inhaled cannabis in 3 days.
~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every cannabis administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
16351740|NCT04316598|Placebo Comparator|Cannabis placebo (B)|"Subjects will be admitted in the center to receive 4 doses of an inhaled treatment based on placebo-THC in 3 days.
~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
16351741|NCT04316585|Experimental|Participants receiving GSK2982772 960 mg|Participants will receive GSK2982772 960 mg oral tablets once daily for 12 weeks.
16351742|NCT04316585|Placebo Comparator|Participants receiving placebo|Participants will receive GSK2982772 matching placebo oral tablets once daily for 12 weeks.
16351743|NCT04316572|Experimental|mental health specialist video consultation|"The intervention group will receive five video consultations with psychotherapists directly in the GP's practice.
~The consultations will be carried out via the web portal of a certified video service provider (arztkonsultation ak GmbH). The patient will be located in the GP's practice and the psychotherapist in his practice or another suitable room. Patients are scheduled for five sessions of 50 minutes."
16351744|NCT04316572|No Intervention|treatment as usual by the GP|Routine treatment by the GP, which may or may not include conversations about psychosocial problems and/or referral to specialised services (e.g., inpatient therapy, counseling, self-help).
16351748|NCT04316520|Experimental|Ketogenic diet|Ketogenic diet + standard of care
16351749|NCT04316507|Experimental|Oncologist led genetic counselling and testing|All subjects receive Oncologist Led Genetic Counselling and Testing
16351750|NCT04316494|Experimental|Hydroxychloroquine|"Patients will be receive 400mg of Hydroxychloroquine (2 x 200mg) to take daily for 52 weeks. Hydroxychloroquine will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.
~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
16351751|NCT04316494|Placebo Comparator|Placebo|"Patients will be receive 400mg of Placebo (2 x 200mg) to take daily for 52 weeks. Placebo will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.
~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
16351752|NCT04316481|Other|AngelMed Guardian System|All eligible subjects will have the AngelMed Guardian System implanted with alerting features turned ON; receive an external device which provides additional alerting; and receive training on system use.
16351753|NCT04316455|Experimental|Integrative Yoga Therapy|Participants engaging in a 6-week chronic pain self-management program. Intervention: Integrative Yoga Therapy
16351754|NCT04316442|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
16351795|NCT04316130|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
16351755|NCT04316429|Active Comparator|Egg phase:|Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets.
16351756|NCT04316429|Placebo Comparator|Control phase:|The participants will consume a vegan diet for 6 weeks.
16351757|NCT04316416|Active Comparator|T7 Bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
16351758|NCT04316416|Active Comparator|T9 bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging transverse process T9 (9th thoracal vertebrae) by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
16351759|NCT04316416|Placebo Comparator|Control group|Postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard pain follow-up and monitorization will be performed. No block will be performed in this group.
16351760|NCT04316403|Experimental|Laser-assisted corticotomy|Er:YAG laser beam was used to perform several perforations to the alveolar bone around the canine in one side of the mouth hoping that would accelerate canine retraction
16351761|NCT04316403|No Intervention|Traditional treatment|Canines in this group were retracted by the conventional manner.
16351762|NCT04316390|Experimental|Hesperidin (A)|study drink without hesperidin and without vitamin C compared to study drink with hesperidin
16351763|NCT04316390|Experimental|Hesperidin + Vitamin C (B)|study drink with vitamin C compared to study drink with hesperidin and vitamin C
16351764|NCT04316377|Active Comparator|Treatment|Chloroquine therapy in addition to standard of care
16351765|NCT04316377|No Intervention|No Treatment|Standard of care
16351766|NCT04316364|Experimental|Treatment group A|"Neoadjuvant setting: SHR-316 and carboplatin and Paclitaxel (Albumin Bound) 3 cycles;
~Adjuvant setting: SHR-1316 up to 16 cycles"
16351767|NCT04316364|Placebo Comparator|Treatment group B|Neoadjuvant setting: Placebo and carboplatin and Paclitaxel (Albumin Bound) 3 cycles;
16351768|NCT04316351|Experimental|Toripalimab + Pemetrexed + Anlotinib|
16351769|NCT04316338|Experimental|Active intermittent theta-burst stimulation (iTBS)|6 weeks of iTBS delivered at 80% resting motor threshold will be delivered to personalized regions in the prefrontal cortex based on each individual's functional connectivity.
16351770|NCT04316325||Women and girls seeking abortion.|
16351771|NCT04316312|Experimental|Inspiratory muscle training group|
16351772|NCT04316299||AKI|COVID-19 patients with acute kidney injury
16351773|NCT04316299||non-AKI|COVID-19 patients without acute kidney injury
16351774|NCT04316286|Experimental|Tele-multidisciplinary participants|Patients undergoing televisit
16351775|NCT04316286|Other|In-office standard participants|Patients undergoing in-office visits
16351776|NCT04316260|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
16351777|NCT04316260|Active Comparator|Treatment As Usual|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
16351778|NCT04316234|No Intervention|A. Clean Air|Clean air - no vaping was done.
16351779|NCT04316234|Experimental|B. Passive vaping|E-cigarette users were present in an adjacent chamber during both exposures, but only in situation B they were vaping and the vape-polluted air was passed on to the exposure chamber.
16351780|NCT04316221|Active Comparator|Control|The standard of nutrition care in Guatemala includes the following clinical care, as determined to be necessary by the MHA medical and nutrition teams: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
16351781|NCT04316221|Experimental|Intervention|The intervention group will receive an intervention to promote daily egg consumption for a six month period, in addition to the local standard of nutrition care. Specifically, intervention group participants will be provided with enough eggs for the infant to consume one egg, daily, for six months, and also with education on preparation and consumption of eggs.
16351782|NCT04316208|Experimental|Supratentorial tumor surgery|Patients undergoing elective supratentorial tumor surgery under general anesthesia will be ventilated with positive end-expiratory pressures of 0, 5 and 10 cmH2O after craniotomy.
16351783|NCT04316195||Patient admitted for an acute traumatic spinal cord injury|
16351784|NCT04316182|Experimental|Cabozantinib|Cabozantinib at 60 mg/day in monotherapy until symptomatic tumor progression, unacceptable adverse events, patient decision or death
16351789|NCT04316156|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
16351790|NCT04316156|Active Comparator|Exercise using brochure|brochure
16351791|NCT04316143|Experimental|50 mg zamicastat|50 mg zamicastat once daily (half a tablet of 100 mg)
16351792|NCT04316143|Experimental|100 mg zamicastat once daily|100 mg zamicastat once daily (one tablet of 100 mg)
16351793|NCT04316143|Experimental|150 mg zamicastat once daily|150 mg zamicastat once daily (one and a half tablet of 100 mg)
16351794|NCT04316143|Experimental|200 mg zamicastat once daily|200 mg zamicastat once daily (two tablets of 100 mg)
16351798|NCT04316104|Experimental|CuidTXT|This intervention, CuidaTXT [Spanish for self-care and texting], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
16351799|NCT04316091|Experimental|Experimental group|neoadjuvant chemotherapy+SPIONs/SMF
16351800|NCT04316091|Sham Comparator|Control group|neoadjuvant chemotherapy
16351801|NCT04316078|Experimental|personalized engagement platform|Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.
16351802|NCT04316078|No Intervention|control group|The control group will not be registered to the PEP nor receive any PEVs.
16351803|NCT04316065|Other|Group 1|15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8
16351804|NCT04316065|Other|Group 2|15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8
16351805|NCT04316052|Experimental|aerobic training group|At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine.
16351806|NCT04316052|Experimental|strength training group|Strength training prescriptions will be in accordance with recommendations of the American College of Sports Medicine.
16351807|NCT04316039|Experimental|RT+TMZ|
16351808|NCT04316039|Active Comparator|RT|
16351809|NCT04316026|Experimental|interventional group|group receiving shock wave therapy
16351810|NCT04316026|Sham Comparator|control group|sham shock wave therapy
16351811|NCT04316013|Active Comparator|A|Sevoflurane + intravenous lidocaine
16351812|NCT04316013|Active Comparator|B|Sevoflurane + placebo
16351813|NCT04316013|Active Comparator|C|Propofol TIVA + intravenous lidocaine
16351814|NCT04316013|Active Comparator|D|Propofol TIVA + placebo
16351815|NCT04316000||A - Removal of the Subepithelial Tumour|The subephitelial tumour is successfully removed by endoscopic band ligation without resection.
16351816|NCT04316000||B - Non Removal of the Subepithelial Tumour|The subephitelial tumour is not successfully removed due to various reasons (size >15-mm, not technical success,...).
16351817|NCT04316000||C - Not Observed or Benign Subepithelial Tumour|The subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients.
16351818|NCT04315987|Experimental|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
16351819|NCT04315987|Placebo Comparator|Placebo|Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
16351820|NCT04315974||Nonvalvular atrial fibrillation patients (NVAF)|Eligible patients comprise men and women aged 18 years or older with nonvalvular atrial fibrillation diagnosis undergoing ablation procedure.
16351821|NCT04315961|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
16351822|NCT04315948|Experimental|Remdesivir|"Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.
~n=475"
16351823|NCT04315948|Experimental|Lopinavir/ritonavir (stopped on June 29, 2020)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.
~n=620"
16351824|NCT04315948|Experimental|Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.
~Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).
~n=620"
16351825|NCT04315948|Experimental|Hydroxychloroquine (stopped on May 24, 2020)|Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620
16351826|NCT04315948|Active Comparator|Standard of care alone|Standard of care alone before March, 2021.
16351827|NCT04315948|Experimental|AZD7442|"Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.
~n=620"
16351828|NCT04315948|Active Comparator|Standard of care with placebo|Standard of care with placebo since April, 2021 n=620
16351829|NCT04315935|Experimental|butorphanol group|Butorphanol (10-20 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
16351830|NCT04315935|Active Comparator|fentanyl group|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
16351831|NCT04315922||Severe Ischemic Stroke|Severe Stroke as defined by inclusion criteria
16351832|NCT04315922||Mild Ischemic Stroke|Mild Stroke as defined by inclusion criteria
16351833|NCT04315922||Transient Ischemic Attack|Transient Ischemic Attack as defined by inclusion criteria
16351834|NCT04315909|Experimental|Intervention group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus vitamin supplements (E (200 IU/ 2day) and C (250 mg/ 2day) ) for 8 weeks.
16351835|NCT04315909|Experimental|Control group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus placebo for 8 weeks.
16351836|NCT04315896|Active Comparator|treatment|Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
16351837|NCT04315896|Placebo Comparator|placebo|identical placebo, one tablet every 12 hours for 10 days
16351838|NCT04315883||Standard Treatment|"Evaluation of change of HRQOL survey responses will be performed:
~at baseline (time of treatment) and
~1 month post treatment
~6 months post treatment
~12 months post treatment
~5 years post-treatment
~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
16351839|NCT04315857||diabetics|diabetics receiving chemotherapy for cancer
16351840|NCT04315844|Experimental|balloon|To evaluate the efficacy and security of Ewata combined with a stent device in the treatment of acute ischemic stroke within 8 hours To prove whether the clinical efficacy and safety of Ewata r is not inferior to other guidings.
16351841|NCT04315818||study group|expermintal
16351842|NCT04315818||control group|placebo
16351843|NCT04315805|Experimental|Integrative Yoga Therapy|Integrative Yoga Therapy will be provided by yoga therapist once a week and participants will be encouraged to practice at home once or twice a day.
16351844|NCT04315805|No Intervention|Wait-list Control|Participants in waiting list will serve as control group for the intervention period. After the ftherapy group has received treatment, the same program will be offered to participants in the wait-list control group.
16351845|NCT04315792|Experimental|Endoxifen Arm|Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks
16351846|NCT04315792|Placebo Comparator|Placebo Arm|Placebo tablets of endoxifen. Patients will continue administration with their initial randomized medication for 3 weeks
16351847|NCT04315779|Active Comparator|Conventional laparoscopy|In this arm, patients will be treated via conventional laparoscopy
16351848|NCT04315779|Active Comparator|Transvaginal natural orifice transluminal endoscopic surgery|In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery
16351849|NCT04315753||cancer patients (clinical stage I and II) +controls|70 lung cancer patients (clinical stage I and II) diagnosed outside screening and candidates to surgical resection at Humanitas Hospital, and 70 controls with benign nodules. Cancer patients will undergo blood collection before and at 4 months after surgical resection. Blood will be used for CTC analysis, exosome antigens and circulating free DNA (cfDNA) mutational analysis.
16351850|NCT04315753||prospective screening cohort of high risk individuals|a prospective screening cohort of high risk individuals enrolled at Humanitas Hospital (1000) will allow to recruit 50 patients with screening detected lung cancer and a large number of negative controls. Analysis of CTC, exosome antigens and cfDNA mutation profile will be performed.
16351851|NCT04315740|Sham Comparator|Clean Air|Just clean air - no exposure
16351852|NCT04315740|Experimental|Cooking|Four ovens were frying pork - one at a time. When the first oven finished, the next oven started and so forth for approx. 7 hours.
16351853|NCT04315740|Experimental|Candles|10 lit candles were placed at a table. Burning for approx. 7 hours with light ventilation.
16351854|NCT04315727|Other|Study population|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies.
~Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation)."
16351855|NCT04315714|Experimental|IBS Yoga Intervention (delivered online/virtually via Zoom)|Ten participants with IBS will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
16351856|NCT04315714|Experimental|IBS Waitlist Control Condition|Ten participants with IBS will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
16351857|NCT04315714|Experimental|HC Yoga Intervention (delivered online/virtually via Zoom)|Ten participants serving as HC will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
16351858|NCT04315714|Experimental|HC Waitlist Control Condition|Ten participants serving as HC will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
16351860|NCT04315688||Tresiba®|Patients with type 2 diabetes
16351861|NCT04315675|Experimental|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs The Guided Imagery Programs include: 1.) Relaxation and Wellness; 2.) Immune System Imagery; and 3.) Healing Trauma.
16351862|NCT04315675|Experimental|Cognitive Power Intervention|The participant who is randomly assigned to this group completes The Power as Knowing Participation in Change Version II (PKPCT) to determine 1.) Freedom to Act Intentionally, 2.) Involvement in Creating Change, 3.) Freedom to Act Intentionally and 4.) My Involvement in Creating Change.
16351863|NCT04315675|Experimental|Cognitive Power Intervention and Guided Imagery|The participant is randomly assigned to this group completes both the Guided Imagery Intervention and the Cognitive Power Intervention.
16351864|NCT04315675|No Intervention|Control Group|The participant is randomized to the control group and completes all study measures twenty-one days after the baseline data are competed. .
16351894|NCT04315441||Soldiers|any soldier who attended the Military Medical Center of Sector N°5 for the annual re-engagement medical visit during the period from January 1, 2017 to November 13, 2018.
16352092|NCT04314011|Experimental|HUC-MSCs Group|Human umbilical cord mesenchymal stem cells (80 Million cells/200ml): delivered via peripheral intravenous infusion.
16351865|NCT04315662|Experimental|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
16351866|NCT04315662|Active Comparator|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
16351867|NCT04315649|Experimental|3D movie|3D movie viewing
16351868|NCT04315636|Experimental|Surfactant nebulisation|The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.
16351869|NCT04315636|No Intervention|Standard care|The control group will receive standard care (PEEP, +/- noninvasive positive pressure ventilation, without surfactant nebulisation).
16351870|NCT04315623|Experimental|Reginal citrate anticoagulation|Patients accepted regional citrate anticoagulation for CRRT. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L. Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+. Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.
16351871|NCT04315623|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
16351872|NCT04315610|Experimental|Access to mobile application|This application will help parents to recognize symptoms of reduced health status in their infant, provide decision-making support, increase their communication skills with health professionals, and provide easier access to quality assured information. At first login, the diagnosis, treatment, and contacts in the health service are registered to provide parents with personalized information that is adapted to their infant's needs. Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application.
16351873|NCT04315610|Active Comparator|Treatment as usual|This group receives traditional oral and written information about their child's heart defect and further follow-up.
16351874|NCT04315597|Experimental|Hypericum extract STW 3-VI (Laif® 900, BAY98-7108)|
16351875|NCT04315597|Placebo Comparator|Placebo|
16351876|NCT04315584|Experimental|Diagnostic|Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
16351877|NCT04315571|Active Comparator|Group A|Routine Large Volume Paracentesis (LVP) with albumin infusion
16351878|NCT04315571|Active Comparator|Group B|Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
16351879|NCT04315558|Experimental|Revefenacin|Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.
16351880|NCT04315558|Active Comparator|Ipratropium|Nebulized ipratropium will be delivered via nebulizer Q6 hours.
16351881|NCT04315545||Healthy women pregnant of singleton with a BMI ≥25 kg/m2|Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.
16351882|NCT04315532|Active Comparator|Pregnancy Group|"GCF and saliva samples were taken from pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from pregnant periodontal healty individuals baseline and after 8 weeks.
~Intervention: Non-surgical periodontal treatment was performed for pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
16351883|NCT04315532|Active Comparator|Non-Pregnancy Group|"GCF and saliva samples were taken from non-pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from periodontal healty individuals baseline and after 8 weeks.
~Intervention: Non-surgical periodontal treatment was performed for non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
16351884|NCT04315519|Experimental|Blood Flow Restricted Aerobic (BFRA)|Low intensity Aerobic exercise with Blood Flow Restriction
16351885|NCT04315519|Experimental|Moderate Aerobic Exercise (MAE)|moderate intensity aerobic exercise
16351886|NCT04315506|Experimental|SGR|Scheduled gradual reduction. Participants are asked to gradually reduce smokeless tobacco usage.
16351887|NCT04315506|Active Comparator|Control group|Participants in this arm will be given the Enuff Snuff cessation manual.
16351888|NCT04315493|Experimental|A|
16351889|NCT04315493|Experimental|B|
16351890|NCT04315480|Experimental|tocilizumab|
16351891|NCT04315467|Experimental|SGM-101|SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.
16351892|NCT04315454|Placebo Comparator|Group A|patients will receive 20 ml of normal saline into interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
16351893|NCT04315454|Experimental|Group B|Patients will receive 20 mg 0.25% Levobupivacaine into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
16351895|NCT04315441||Civilians|The civilian populations were recruited from two free cardiovascular risk factors screening campaigns carried out from January 04, 2017 to January 10, 2017 and from November 12, 2018 to November 18, 2018
16351896|NCT04315428||premature swaddled|the childs in this group will be wrap in a lange (swaddled)
16351897|NCT04315428||premature no swaddled|the childs in this group will be not swaddled
16351898|NCT04315415|Other|6 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
16351899|NCT04315415|Other|12 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
16351900|NCT04315415|Other|24 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 24 months.
16351901|NCT04315402||Group 1 (provider-patient concordant)|
16351902|NCT04315402||Group 2 (provider-patient discordant)|
16351903|NCT04315389||EXPERIMENTAL|OPEN LABEL USING HEALTHCARE ROBOTS IN PARALLEL (non comparison) EXPOSURE: 90 MINUTES 3 TIMES PER DAY FOR 3 DAYS, NON CONSECUTIVE
16351904|NCT04315376|Experimental|Exercise-Diet Group|The participants receive a personal exercise program according to Astrand-rhyming test baseline results, and a hypo-caloric diet intervention
16351905|NCT04315376|Active Comparator|Diet Group|The participants no receive a personal exercise program, only the hypo-caloric diet
16351906|NCT04315363|Experimental|Intervention|Brain MRI and Motivational Behavioral Intervention
16351907|NCT04315363|Active Comparator|Active control|Brain MRI and Control Behavioral Intervention
16351908|NCT04315350|Experimental|Curcumin|Participant receives both curcumin and prednisolone. Curcumin for 11 days, prednisolone for 10 days. Curcumin: 2 tablets (each contains 100 mg curcumin) twice daily. Prednisolon: 50 mg (capsule) every morning
16351909|NCT04315350|Other|Prednisolon|Participant receives prednisolone and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon: 50 mg (capsule) every morning
16351910|NCT04315350|Placebo Comparator|Placebo|Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.
16351911|NCT04315337|Experimental|Virtual Training Arm|This is a within-participant study with one arm. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task and a control task.
16351912|NCT04315324|Experimental|Treatment (AKR1C3-activated prodrug OBI-3424)|Patients receive AKR1C3-activated prodrug OBI-3424 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
16351913|NCT04315311|Experimental|CREON|Participants will receive daily dose of CREON.
16351914|NCT04315298|Experimental|Sarilumab 200mg IV (P2)|Phase 2
16351915|NCT04315298|Experimental|Sarilumab 200mg IV (P3:C1)|Phase 3: Cohort 1
16351916|NCT04315298|Experimental|Sarilumab 400mg IV (P2)|Phase 2
16351917|NCT04315298|Experimental|Sarilumab 400mg IV (P3:C1)|Phase 3: Cohort 1
16351918|NCT04315298|Experimental|Sarilumab 800mg IV (P3:C2)|Phase 3: Cohort 2
16351919|NCT04315298|Experimental|Sarilumab 800mg IV (P3: C3)|Phase 3: Cohort 3
16351920|NCT04315285|Active Comparator|Control group|12 sessions of treadmill training with instruction of 'swing your arms'
16351921|NCT04315285|Experimental|Heel-strike group|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
16351922|NCT04315285|Experimental|Big step group|12 sessions of treadmill training with instruction of 'lift your foot up high'
16351923|NCT04315285|Experimental|Internal focus heel-strike|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
16351924|NCT04315285|Experimental|External focus shoe-strike|12 sessions of treadmill training with instruction of 'strike the ground with your shoe-heel'
16351925|NCT04315272|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
16351926|NCT04315272|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
16351927|NCT04315259|Experimental|Laser activated irrigation|conventional root canal treatment was done , 2.5% sodium hypochlorite was used and was activated by 980 nm with a repeated pulse mode using a pulse duration of 5 s and a pulse interval of 0.2 ms. The laser irradiation will be delivered for 1 minute into the canal up to 1 mm short of the working length, with circling movements from the apical part moving towards the coronal part (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100)
16351928|NCT04315259|Experimental|Soft tissue laser application|"Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices.
~Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product"
16351929|NCT04315259|No Intervention|conventional root canal|conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with no laser intervention
16351932|NCT04315220|Experimental|Experimental group (Core stability training (CST))|"Core stability training (CST) consists of two levels: level 1- Mat exercises (includes abdominal muscle contraction, bridging,cat stretch,single leg circle and superman) and level 2- Swiss ball exercises (includes abdominal muscle contraction, bridging and squatting by using therapy ball).
~There will be three sets of 15 repetitions of each exercises. The first set will consist of 10 seconds hold period, follow by 12 seconds hold in second set and 15 seconds hold in third set respectively. The entire session will last for approximately 30 minutes."
16351933|NCT04315220|Active Comparator|Control group|Will not receive any kind of training.
16351934|NCT04315207|Active Comparator|In-person visit|"In-person meeting with the patient in the out-patient department. The patient is free to bring up to four* relatives or other persons of their own choice to the in-person meeting.
~(* Restriction due to space limitation)."
16351935|NCT04315207|Experimental|Telephone call|Telephone call with the patient. The patient is free to turn on loudspeaker to include relatives or other persons in the telephone conversation, alternatively to ask the physician to call and inform one relative or other person after the patient-doctor telephone call
16351936|NCT04315194||clarithromycin-naproxen-oseltamivir|Efficacy of clarithromycin-naproxen-oseltamivir combination therapy vs. oseltamivir alone for hospitalised paediatric influenza patients
16351937|NCT04315181|Experimental|Oral opioid agonist|Participants will receive non-therapeutic experimental doses of active or placebo oral opioid agonist. Active opioid agonist/placebo will be administered once per session and will be administered orally.
16351938|NCT04315181|Experimental|Oral sedative|Participants will receive non-therapeutic experimental doses of active or placebo oral sedative. Active sedative/placebo will be administered once per session and will be administered orally.
16351939|NCT04315181|Experimental|Opioid agonist/sedative|Participants will receive non-therapeutic, experimental doses of active opioid agonist/placebo in combination with non-therapeutic, experimental doses of active sedative/placebo. Opioid/placebo and sedative/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid and sedative doses will be administered orally.
16351940|NCT04315155|Experimental|Double Regimen|belinostat in combination with nivolumab
16351941|NCT04315155|Experimental|Triplet Regimen|belinostat in combination with nivolumab and ipilimumab
16351942|NCT04315142|Experimental|Transcutaneous tibial nerve stimulation (TTNS)|
16351943|NCT04315142|Sham Comparator|TTNS sham stimulation|
16351944|NCT04315129|Other|Single arm|A single arm will have biosensor (experimental) diagnoses compared to clinical (control, current standard of care). All participants in this group willl have a biosensor, with the data masked to patients, providers and clinical researchers
16351945|NCT04315116|Experimental|Treament|Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
16351946|NCT04315103|Experimental|the combined-injection group|patients received a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
16351947|NCT04315103|Active Comparator|the one-injection group|patients received a single injection of 3 ml PRP
16351948|NCT04315077|Experimental|Experimental Group|Subjects will consume one serving per day (25mg) of the treatment condition (Oceanix ®) for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
16351949|NCT04315077|Placebo Comparator|Placebo Group|Subjects will consume one serving per day (25mg) of the microcrystalline cellulose-based placebo condition for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
16351950|NCT04315064|Experimental|Treatment with MTX110|
16351951|NCT04315051|Placebo Comparator|Placebo Gel|Placebo gel daily application for 4 weeks
16351952|NCT04315051|Active Comparator|Cohort 1|DBI-001 Gel daily application for 4 weeks
16351953|NCT04315038||All patients|Spinal anesthesia
16351954|NCT04315025|Active Comparator|Conditioned Medium (CM)|a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar
16351955|NCT04315025|Active Comparator|UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar
16351956|NCT04315025|Active Comparator|UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar
16351957|NCT04315012|Experimental|Receiving mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
16351958|NCT04315012|No Intervention|Standart|not to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
16351959|NCT04314999||Patients diagnosed with a chronic spontaneous urticaria|Patients with a chronic spontaneous urticaria who were being treated at the allergology of the university hospital Basel between the 1st of June and the 30th of September
16351960|NCT04314986|Experimental|AR882 (Dose A)|
16351961|NCT04314986|Experimental|AR882 (Dose B)|
16351962|NCT04314986|Experimental|AR882 (Dose C)|
16351963|NCT04314986|Experimental|AR882 (Dose D)|
16351964|NCT04314986|Placebo Comparator|Placebo|
16351965|NCT04314973|Active Comparator|Control phase|Patients will follow walking exercises sessions, without wearing the robotic device, for 30 sessions of 45 min.
16351966|NCT04314973|Experimental|Intervention phase|Patients will walk with the robotic device, for 30 sessions of 45 min.
16351967|NCT04314960|Experimental|CAI subjects|Subjects in this group will receive eight 20-minutes gait training sessions with functional electrical stimulation.
16351968|NCT04314934|Experimental|Active|ANAVEX2-73
16352004|NCT04314674|Active Comparator|%3 HS infusion 20 ml/h|After the head fixation 3% hypertonic saline at 20 ml/h infusion rate will be administered during the operation
16352005|NCT04314674|Active Comparator|%20 mannitol 0,6 gr.kg-1|After the head fixation %20 mannitol 0,6 gr.kg-1 will be administered over the 20 min intravenously.
16352255|NCT04312724|Experimental|No clincal need|Participants enrolled that do not require a new socket
16351969|NCT04314921|Experimental|10-week Yoga|Eighteen healthy elderly people, who were classified into two age groups, participated in this study. All participants had not practiced yoga before and were asked not to perform any sports activities while the research was ongoing. In the experimental group, participants (n = 18) had to participate in 10 weeks of yoga classes. In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life. All experimental group subjects participated in Himalayan yoga classes, which lasted 10 weeks: 2 times per week, 90 min per session. Yoga classes were conducted by 16-year-old qualified yoga instructor from Yoga Academy, Kaunas.
16351970|NCT04314921|No Intervention|Control|In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life.
16351971|NCT04314908|Experimental|Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0."
16351972|NCT04314908|Experimental|Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0 and sonic activation assisted irrigation will be applied."
16351973|NCT04314908|Experimental|Non Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point."
16351974|NCT04314908|Experimental|Non Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point and sonic activation assisted irrigation will be applied."
16351975|NCT04314895|Experimental|NanoPac|Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
16351976|NCT04314869|Experimental|Recipient|Patient with absolut uterine factor will undergo uterus transplantation.
16351977|NCT04314856|Experimental|Fragile X Syndrome|"Adult males aged 18-30 years diagnosed with FXS will undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.
~These participants will only be administered once with 18F-FTC-146."
16351978|NCT04314856|Experimental|Healthy Volunteers (Control)|"Adults aged 18-65 years undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.
~Test-retest studies will be performed where these individuals will each be injected twice with 18F-FTC-146."
16351979|NCT04314843|Experimental|Lenzilumab and Axicabtagene Ciloleucel|"Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab.
~Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0."
16351980|NCT04314830|Active Comparator|Gait training without perturbation|Walking on a treadmill with the same duration as a participants of the experimental arm matched for initial gait speed. Treadmill speed did not change along the training program
16351981|NCT04314830|Experimental|Gait training with perturbations|Walking on a treadmill with perturbations produced by changes in the speed of one of the belt of the split-belt treadmill during one gait cycle. Changes in treadmill speed were applied on the paretic or non-paretic side, with and increase or a decrease of the speed of the belt in various magnitude. Perturbations were either repeated with the same characteristics or with different characteristics. Outside of perturbations, treadmill speed did not change along the training program.
16351982|NCT04314817||Patients treated for Covid-19|
16351983|NCT04314804|Experimental|Smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
16351984|NCT04314804|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
16351985|NCT04314791||US scan with calculation of the PAI|
16351986|NCT04314778|Experimental|Intervention|Participants in the intervention arm will have a postoperative daily step goal that increases from baseline by 500 steps each day.
16351987|NCT04314778|No Intervention|Control|Participants in the control group will have data collected passively via Fitbit.
16351988|NCT04314765|Experimental|bayonet flap|Bayonet flap is performed to extract the the lower third molar
16351989|NCT04314765|Experimental|envelope flap|Envelope flap is performed to extract the the lower third molar
16351990|NCT04314739|Active Comparator|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
16351991|NCT04314739|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
16351992|NCT04314726|Active Comparator|amelogenins group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. Amelogenins effect was evaluated by applying them only in the test site and comparing healing results with those obtained on the contra-lateral site
16351993|NCT04314726|Placebo Comparator|placebo group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. In this group (control site) the conventional treatment was performed, and healing was ensured only by the simple blood clot
16351994|NCT04314713|Placebo Comparator|Scopolamine HBT 0.005 mg/kg|Dose of Scopolamine 0.005mg/kg verses Placebo
16351995|NCT04314713|Placebo Comparator|Scopolamine HBT 0.007 mg/kg|Dose of Scopolamine 0.007mg/kg verses Placebo
16351996|NCT04314713|Placebo Comparator|Scopolamine HBT 0.011 mg/kg|Dose of Scopolamine 0.011mg/kg verses Placebo
16351997|NCT04314713|Placebo Comparator|Scopolamine HBT 0.014 mg/kg|Dose of Scopolamine 0.014mg/kg verses Placebo
16351998|NCT04314713|Placebo Comparator|Scopolamine HBT 0.021 mg/kg|Dose of Scopolamine 0.021mg/kg verses Placebo
16351999|NCT04314713|No Intervention|Placebo|Placebo controlled
16352000|NCT04314687|Experimental|UCMSCs + CM|UCMSCs + CM is administered via intrathecal injection
16352001|NCT04314687|Experimental|UCMSCs|UCMSCs is administered via intrathecal injection
16352002|NCT04314687|Active Comparator|Standard Therapy|Physiotherapy
16352003|NCT04314674|Active Comparator|%3 HS bolus 3 mL.kg-1|After the head fixation 3 mL.kg-1 %3 hypertonic saline will be administered over the 20 min intravenously.
16352006|NCT04314661|Experimental|Arthoscopy + UC-MSCs + CM + CM|After arthroscopy patient will be given UC-MSCs 5 million cells, after 2 weeks patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
16352007|NCT04314661|Experimental|Non Arthoscopy + UC-MSCs + CM + CM|Patient will be given UC-MSCs 5 million cells, after 2 weeks patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
16352008|NCT04314661|Experimental|Non Arthoscopy + CM + CM|Patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
16352009|NCT04314648|Active Comparator|START|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.
~The components of the START intervention are as follows:
~Triage
~Engage, Assess, and Plan
~Treat
~Communicate and Coordinate
~Follow up
~Monitor"
16352010|NCT04314648|No Intervention|Usual Care|Usual care for people with alcohol or opioid use disorder.
16352011|NCT04314635|Active Comparator|TAU comparison group|TAU includes standard care modules (psychoeducation, coping, safety planning, problem solving, healthy lifestyle) administered to the teen while they are hospitalized on the inpatient unit. All teens, as part of TAU, also receive skills groups, individual treatment, and family planning meetings. All TAU families will receive a referral to an outpatient provider (standard care procedure) plus referral to specialized CHR case management services.
16352012|NCT04314635|Experimental|Brief intervention group|TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (~45-60 minutes per session).
16352013|NCT04314622|Experimental|Supaglutide (Part A)|Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.
16352014|NCT04314622|Placebo Comparator|Placebo(Part A)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
16352015|NCT04314622|Experimental|Supaglutide (Part B)|Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.
16352016|NCT04314622|Placebo Comparator|Placebo (Part B)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
16352017|NCT04314609|Experimental|Ultrasound , fluroscope|After injection of corticosteroids with 1 ml contrast in sacroiliac joint using ultrasound and withdrawal of the needle, an antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular.
16352018|NCT04314596|Placebo Comparator|Placebo Group|Participants will engage in a one day, whole-body, cross-training course while consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
16352019|NCT04314596|Experimental|Experimental Group|Participants will engage in a one day, whole-body, cross-training course while consuming the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
16352020|NCT04314583|Active Comparator|Attention Control Group|Adult patients attending cardiovascular rehabilitation.
16352021|NCT04314583|Experimental|Gratitude Journaling Group|Adult patients attending cardiovascular rehabilitation.
16352022|NCT04314570|Experimental|Ropivacaine Treatment|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Ropivacaine through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
16352023|NCT04314570|Placebo Comparator|Saline Control|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
16352024|NCT04314544|Experimental|Arm A|
16352025|NCT04314544|Placebo Comparator|Arm B|
16352026|NCT04314531|Experimental|Arm A|
16352027|NCT04314531|Placebo Comparator|Arm B|
16352028|NCT04314505|Experimental|Opioid Sparing Protocol|Preemptive(before incision): Parecoxib sodium 40 mg Postoperative: Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses.
16352029|NCT04314505|Active Comparator|Opioid Based Patient Controlled Analgesia|Preemptive(before incision) and Postoperative: the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours; adjusted by the PCA staff
16352030|NCT04314492|Experimental|Intracapsular tonsillectomy with coblation|(Total) Intracapsular tonsillectomy (ICTE) with coblation
16352031|NCT04314479|Experimental|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes
16352032|NCT04314479|Other|Symptom Assessment Only|For participants randomized to the control condition weekly symptom assessment telephone calls will be completed by staff at the University of Arizona Cancer Center Behavioral Measurements Interventions Shared Resource (BMISR). At week 13 an exit interview will be completed by the study coordinator to record participants feedback regarding study intervention, length, coaches, etc… In addition, staff from BMISR will call to repeat all baseline measures with the exception of the demographic questionnaires. Symptom assessment calls will take approximately 15 minutes.
16352033|NCT04314453||T group|The degenerative lumbar spinal stenosis patients accepted the PELD with TESSYS procedure.
16352034|NCT04314453||U group|The degenerative lumbar spinal stenosis patients accepted the PELD with U route procedure.
16352035|NCT04314440|Experimental|Music therapy|After the initial warm up session music therapy will be delivered three times a week for 15-20 minutes. All babies in the experimental group will be exposed to three weeks of music therapy sessions that is a total of 9 music therapy session prior to discharge from the hospital. The baby will be placed at the bassinet 15 minutes before music therapy begins. The baby will be in the bassinet during music therapy and 15 minutes post music therapy to allow measurement of physiological indicators. If parents are present during music therapy they will not engage in kangaroo care during the music therapy session or when physiological measurements are being taken pre and post music therapy, but can do so at other times.
16352036|NCT04314440|No Intervention|Control|Infants in this group will not receive any music therapy but will receive all other standard care provided to infants at the Regina General Hospital (RGH). All measurements will be carried out for all the infants in this group at the time when observations are carried out for infants in the music therapy group.
16352037|NCT04314427||Gastric by-pass|Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
16352038|NCT04314427||Sleeve gastrectomy|Sleeve gastrectomy reduces the stomach size by vertical stapling
16352040|NCT04314401||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 10 years.
16352041|NCT04314388|Experimental|Intervention: Outdoor walking Rehabilitation Programme|Participants in the intervention will be provided with an exercise diary. This will include walking routes for the instructor led 3-month outdoor-walking rehabilitation programme. The exercise diary will also include home exercises for the participants to complete twice-per-week that will be explained in detail, using coaching points and images to support. As these exercises will be completed at home. Each exercise has four progressions ranging from easy to hard.
16352042|NCT04314388|Other|Control: The light Stretches Programme|The control group intervention will be a non-exercise intervention to avoid training effects. The control group will be asked to keep to their normal activities of daily living and given ten targeted active stretches for the upper and lower body three times per week at home. Participants in the control group will each be provided a booklet for the given stretches.
16352043|NCT04314375|Experimental|Low Dose Budesonide|
16352044|NCT04314375|Experimental|High Dose Budesonide|
16352045|NCT04314375|Placebo Comparator|Placebo|
16352046|NCT04314362|Experimental|AZR-MD-001 Active|AZR-MD-001 ointment/semi-solid drug (1.0%)
16352047|NCT04314362|Experimental|AZR-MD-001 Active + Conventional Treatment|AZR-MD-001 ointment/semi-solid drug (1.0%) plus Hylo-Forte®
16352048|NCT04314362|Experimental|AZR-MD-001 vehicle|AZR-MD-001 vehicle control
16352049|NCT04314310|Active Comparator|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
16352050|NCT04314310|Placebo Comparator|placebo|equal volume of normal saline
16352051|NCT04314297|Experimental|Anlotinib In Combination With Durvalumab|
16352052|NCT04314284|Other|Historical Control Survey|-The investigators will conduct a historic control survey of 80-100 recently diagnosed gynecologic, colorectal, and lung cancer patients. They can complete the survey in-person, over the phone, or online. The survey will take approximately 15 minutes to complete. It will ask about their knowledge of health insurance and confidence communicating about care costs.
16352053|NCT04314284|Other|Oncology Providers|-The investigators will train 15 gynecologic, colorectal, and lung cancer care providers in using I Can PIC and discussing costs with patients in a brief 15 minute presentation that can be delivered in-person or virtually. Providers will complete a survey before and after their brief training at the start of the study. These surveys will take approximately 5-10 mins to complete in total. During the study, at 3- and 6- months, the investigators will give real-time feedback to providers on the percent of time that they screened for financial distress and referred patients to I Can PIC. At the end of the study, the investigators will examine adoption, implementation, and maintenance measures.
16352054|NCT04314284|Experimental|I Can PIC|-Approximately 80-100 participants will use I Can PIC. This will take approximately 10-15 minutes. After their next appointment with their provider, they will complete a brief survey about their knowledge of health insurance and confidence communicating about care costs. This will take about 10 mins. Patient participants who choose to complete the study in person may view I Can PIC on a tablet provided in the clinic or at the office. Then after their appointment, they can complete the survey on a tablet provided in the clinic or at the office. If they choose to complete it over the phone, the investigators will email them the link to I Can PIC and then call them when it is time to complete the survey. If they wish to complete it online, the investigators will email them the link to I Can PIC, and then the survey after their appointment. After 3-6 months, participants will receive a 5-10 minute follow-up survey which they can complete in-person, online, or over the phone.
16352055|NCT04314258|Experimental|Drinking Moringa oleifera tea|The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
16352056|NCT04314258|No Intervention|Drinking plain water|The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.
16352057|NCT04314245||Urothelial carcinoma group|Subjects who diagnosed with incident or recurrent urothelial carcinoma (including bladder/ureter/renal pelvis) by surgical pathology.
16352058|NCT04314245||interference group|Subjects who diagnosed with incident or recurrent bladder cancer other than urothelial carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer) by surgical pathology.
16352059|NCT04314245||Control group|Subjects who clinically diagnosed with benign disease of the urinary system, such as Urinary calculi, urinary tract infection (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.
16352060|NCT04314245||Healthy volunteers group|Volunteers who have a normal routine urine test / ultrasound examination of the urinary system and do not carry suspected tumors of other organs.
16352061|NCT04314219|Experimental|Arm 1: Intervention|
16352062|NCT04314219|Active Comparator|Arm 2: Standard of Care|
16352063|NCT04314206|Experimental|VNRX-5024|Capsule formulation
16352064|NCT04314206|Placebo Comparator|Placebo|Placebo for VNRX-5024
16352065|NCT04314193|Experimental|methotrexate|
16352066|NCT04314193|Active Comparator|prednisolone|
16352067|NCT04314180||Slit-lamp image quality assessment|Device: an artificial intelligence system for quality assessment of slit-lamp images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center
16352068|NCT04314167|Experimental|LDL lowering therapy|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
16352069|NCT04314154||Study group|Group of all patients hospitalized in the SMHC and due participate in rehabilitative procedures
16352070|NCT04314141||Transgender patients|Transgender patients who carry out sex reassignment surgery.
16352071|NCT04314141||Cismale patients|Cismale patients who carry out surgery to correct a congenital or acquired lack of penis.
16352072|NCT04314128|Other|Patients suspected of IIH at baseline|"Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.
~Healthy controls will be recruited to match the patients."
16352073|NCT04314115|Active Comparator|Mindfulness|A brief intervention in mindfulness will be administered
16352074|NCT04314115|Active Comparator|Systemic therapy|A brief systemic therapy intervention will be administered
16352075|NCT04314115|Active Comparator|Cognitive behavioral therapy and positive psychology|A brief intervention of traditional cognitive behavioral therapy with positive psychology elements will be administered
16352076|NCT04314115|No Intervention|Waiting list|Waiting list, as a control group
16352077|NCT04314102||1|"Individuals will be evaluated before knee arthroplasty surgery. They will come for control in the 1st and 3rd months after surgery.
~No intervention will be made."
16352078|NCT04314089|Experimental|GT103|Participants will receive GT103 every 3 weeks. GT103 will be escalated from .3mg/kg up 10 to mg/kg or until MTD is found
16352079|NCT04314076|Active Comparator|Gait Training (GT) with Rythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS
16352080|NCT04314076|Other|Gait training (GT) without Rythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS
16352081|NCT04314050|Active Comparator|tramadol|1,5 mg /kg tramadol will perform intraoperatively in 100 ml saline within 15 minutes at 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
16352082|NCT04314050|Active Comparator|dexmedetomidine|1 mcg/kg dexmedetomidine bolus will perform after anesthesia induction and followed by infusion of 0.5 mcg/kg/h until 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
16352083|NCT04314050|Placebo Comparator|control|1 gr paracetamol will perform intraoperatively
16352084|NCT04314037|Experimental|Sequence 1 (T1-R1-T2-R2)|Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
16352085|NCT04314037|Experimental|Sequence 2 (R1-T1-R2-T2)|Participants will receive first dose of Biltricide on Day 1 in treatment period 1 followed by first dose of Cesol on Day 8 in treatment period 2 followed by second dose of Biltricide on Day 15 in treatment period 3 followed by second dose of Cesol on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
16352086|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 1: A-B-C|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
16352087|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 2: A-C-B|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
16352088|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 3: B-A-C|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
16352089|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 4: B-C-A|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
16352090|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 5: C-A-B|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
16352091|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 6: C-B-A|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
16352093|NCT04314011|Placebo Comparator|Control Group|Placebo:normal saline(200ml) delivered via peripheral intravenous infusion.
16352094|NCT04313985|Active Comparator|Electrical Stimulation|"Treat the patient's wound area:
~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.
~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.
~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
16352095|NCT04313985|Sham Comparator|Sham Electrical Stimulation|"Treat the patient's wound area:
~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.
~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.
~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
16352096|NCT04313972|Experimental|Low-dose naltrexone|2mg low-dose naltrexone capsules
16352097|NCT04313972|Placebo Comparator|Placebo|Placebo capsules
16352098|NCT04313959|Active Comparator|Local anesthetic|Patients assigned for local anesthetic group will receive a single-shot ultrasound-guided erector spine plane block with 25 mL of 0.2% of ropivacaine
16352099|NCT04313959|Active Comparator|Local anesthetic + steroid|Patients assigned for local anesthetic + steroid group will receive a single-shot ultrasound-guided erector spine block plane with 25 mL of 0.2% of ropivacaine with 4 mg dexamethasone
16352100|NCT04313946||Symptomatic Patients|Our goal is to identify an artificial intelligence algorithm that can be run on lung radiographs in patients with influenza / respiratory viral symptoms who come to the emergency department / triage. This algorithm aims to identify the radiographs of patients with COVID-19 and those with influenza pneumonitis, with accuracy verified by COVID-19 tests.
16352101|NCT04313920|Experimental|Nutritional Supplement|Ready to drink liquid
16352102|NCT04313907|Experimental|Acitve laser+topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus topical clonazepam 1 mg, 3 times at day, same 14 days both
16352103|NCT04313907|Sham Comparator|Sham laser+topical clonazepam|Using sham laser (six sesions) plus topical clonazepam 1 mg, 3 times at day, same 14 days both
16352104|NCT04313907|Placebo Comparator|Active laser+placebo of topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus placebo of topical clonazepam (lactose), 3 times at day, same 14 days both
16352105|NCT04313894|Experimental|Stem Cell Therapia Group|A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
16352108|NCT04313868|Experimental|Phase 1A.1: Peripheral IV|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
16352109|NCT04313868|Experimental|Phase IA.2: Hepatic Artery Infusion|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
16352110|NCT04313868|Experimental|Phase IA.3: Intratumoral Injection|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
16352111|NCT04313855|Experimental|Chronic post-operative pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.
~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
16352112|NCT04313829|Active Comparator|Intervention group|The intervention group received Pharmacist counseling for 15 minutes include giving standard medicine information service and explaining the validated pharmacist counseling module which contained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed dose.
16352113|NCT04313829|No Intervention|Control group|The control group received standard medicine information services by Pharmacists.
16352114|NCT04313816||unique group|patients visiting their family physician
16352115|NCT04313803||American Fork|CGM usage months 1 and 3
16352116|NCT04313803||Central Orem|CGM usage for month 1
16352117|NCT04313803||North Canyon, Saratoga Springs, and Lehi|CGM usage for 1-3 months
16352118|NCT04313790|Experimental|Heparin Infusion|heparin infusion 500unit \hour
16352119|NCT04313790|Other|Subcutaneus Heparin|subcutaneous heparin 5000unit \ 8 hours
16352120|NCT04313777|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
16352121|NCT04313777|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
16352122|NCT04313764|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
16352123|NCT04313764|Active Comparator|Group Infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
16352124|NCT04313751|Experimental|Education, Physical Activity, and Stress Management Program|Classes for the intervention group will be run by a bilingual interventionist and will last 120 minutes weekly for 12 weeks and then monthly for 3 months.
16352125|NCT04313751|Active Comparator|Wait-list Control|Data in the wait-list control group will be collected at the same time intervals as the intervention group. After Time 3 data collection, they will be offered the Phase I intervention (12 weekly sessions).
16352126|NCT04313738|Experimental|Intervention group|Experimental: Intervention group Intervention group: Home visit, health education, telephone counseling At the intervention group; the researcher firstly made spirometry meausurement in hospital. After, the researcher made pretest (baseline measurement) before nursing interventions at the first home visit. At the first home visit, the researcher was offered education and guide smoking cessation. Second, Third and fourth home visit were made 15 days later, one and six months after visit first visit. During the second, third and fourth home visits, firstly the patient's stage of change was determined and then appropriate nursing intervention was performed in accordance with the guidelines.Between the third and fourth home visits, the participants were contacted through telephone calls once a month. At fourth home visit, the researcher made posttest. After the patient was invited to the hospital and spirometry measurements were repeated.
16352127|NCT04313738|No Intervention|Control Group|At the control group; No home visits were paid to the control group. The researcher made measurements twice at in the first and sixth months in the hospital. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
16352128|NCT04313725|Experimental|Boost|Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.
16352129|NCT04313725|Placebo Comparator|Placebo|Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.
16352131|NCT04313686|Experimental|Mindfulness-based therapy|The mindfulness training program included mindfulness meditation practices, self-enquiries, mindful movement as well as understanding of stress physiology and cognitive awareness in the Breathworks/ Paradigm system of mindfulness-based approaches. Participants were enrolled in 5-10-person groups that met weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
16352132|NCT04313686|Active Comparator|No-Intervention|The control group would attend their routine follow-up visits at the neurology outpatient clinic.
16352133|NCT04313673||randomized|Patients who were followed up in our clinic with a diagnosis of preterm labor that spontaneously took action and were born before 37 weeks of gestation will form a group.
16352134|NCT04313660|Experimental|Anlotinib In Combination With PD-1/L1 Inhibitor|
16352135|NCT04313647|Experimental|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
16352136|NCT04313647|Experimental|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
16352137|NCT04313647|Experimental|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
16352138|NCT04313647|Experimental|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
16352139|NCT04313647|Experimental|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
16352140|NCT04313634|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
16352141|NCT04313634|Experimental|Fisetin Treatment Group|Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
16352142|NCT04313634|No Intervention|Untreated Control Group|Subjects will not receive any intervention
16352631|NCT04310046|Other|PCI before TAVI|PCI is performed within 1-45 days before TAVI.
16352145|NCT04313595|Experimental|Breathing frequency monitoring|
16352146|NCT04313582|Experimental|SmartPrompt|
16352147|NCT04313569|No Intervention|Conservative treatment|Use of medications, like analgesic, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAID) and local painkillers, depending on the patient condition, and physiotherapy, lifestyle and daily activity modification, patient education about positioning of the knee
16352148|NCT04313569|Other|Arthroscopic menisctomy|
16352149|NCT04313556|Other|Lateral patellar release|Arthroscopic lateral patellar retinacular release
16352150|NCT04313543|Experimental|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. There is 3 days for wash out period. These tests will be repeated for 3 times for baseline glucose calculation. After that, volunteers take 50 g of longan syrup in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. Glycemic index of longan syrup is calculated from area under the curved of blood glucose after longan syrup taking divided to mean of area under the curved of blood glucose after glucose taking
16352151|NCT04313530|Experimental|fatigue in MSA Arm one|This arm will receive a total 10 sessions of TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
16352152|NCT04313530|Sham Comparator|fatigue in MSA Arm two|This arm will receive a total 10 sessions of sham-TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
16352153|NCT04313517|Experimental|Yoga@Work|Yoga session were developed to practice at work anytime feasible.
16352154|NCT04313517|No Intervention|Wait list Control group|Control group with no intervention. After Intervention period, group was offered same sessions.
16352155|NCT04313504|Experimental|Niraparib & Dostarlimab|"Niraparib starting on Day 0. Niraparib will be administered as continuous daily dose, orally 200 or 300 mg.
~Dostarlimab IV administered via a 30-minute infusion on Day 1 of every 21 day cycle. 500mg for first 4 doses followed by 1000 mg every 6 weeks."
16352156|NCT04313491|Experimental|Yoga@Work|
16352157|NCT04313478||Preterm Infants|They were as follows: being at 3 to 9 months' corrected age, gestational age of less than 36 weeks + 6 days, birth weight of 2000 g or less. Infants with any genetic, metabolic, orthopedic congenital abnormalities or chronic diseases and parents' rejection to participate in the study were excluded.
16352158|NCT04313478||Term Infants|They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
16352159|NCT04313465|No Intervention|Control (Routine Care)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a cardiac troponin blood test upon admission to the Emergency Department. Participants will then have a repeat cardiac troponin blood test in 3 hours.
16352160|NCT04313465|Experimental|Intervention (Immediate Discharge)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a troponin blood test upon admission to the Emergency Department. Participants will then be discharged.
16352161|NCT04313452|Placebo Comparator|regular diet|50% of energy from carbohydrates, 30% fat and 20% from protein
16352162|NCT04313452|Active Comparator|Mediterranean diet|60% of energy from carbohydrates, 25% fat and 15% from protein
16352163|NCT04313439|Experimental|Treatment|Online Cognitive Therapy (I-CT)
16352164|NCT04313426|Experimental|Integrative Yoga Therapy|Self managed Yoga based practices were included in one to one sessions for 6-sessions.
16352165|NCT04313413|Experimental|Yoga@Work|Yoga sessions specifically designed for office workers were provided in work settings. participants were given handouts and encouraged to practice in their own time and space during work days.
16352166|NCT04313400|Experimental|Part 1 Dose Escalation: 3% to 70% of the BSA|Open-label AMTX-100 CF 1.1% w/w, topically applied twice a day for 7 consecutive days to all treatable AD affected areas from 3% to 70% of the Body Surface Area (BSA) (3% BSA ≤ AD Affected Area ≤ 70% BSA)
16352167|NCT04313400|Experimental|Part 2 Group A: Low dose concentration (0.11% w/w)|AMTX-100 CF Low dose concentration (0.11% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
16352168|NCT04313400|Experimental|Part 2 Group B: Medium dose concentration (0.33% w/w)|AMTX-100 CF Medium dose concentration (0.33% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
16352169|NCT04313400|Experimental|Part 2 Group C: High dose concentration (1.1% w/w)|AMTX-100 CF High dose concentration (1.1% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
16352170|NCT04313400|Placebo Comparator|Part 2 Group D: Placebo|Placebo (Vehicle) (0% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
16352171|NCT04313387||Control group - Normal eyes (CG)|"• Control group - Normal eyes (CG): 351 eyes without KC of 351 patients who underwent LASIK or photorefractive keratectomy (PRK), stable after at least 18 months of follow-up, without any changes in the posterior elevation at the 18-month Pentacam in relation to the preoperative exam (surgeries performed in 2012-2018). Our objective topographic criteria were: both eyes with a KISA% index of less than 60%, Kmax of 47.2 D or less, and I-S difference of less than 1.45 D. Because no truly established tomographic parameter(s)/cut-off(s) for differentiating normal from keratoconus suspect eyes exist, we adapted our classification for normal eyes to the recent publication by Ambrósio et al. by adding the criterion of overall subjective normal topography and tomography examinations based on the evaluation of experienced refractive surgeon (GCAJ). Only one eye was randomly selected for further statistical analysis."
16352196|NCT04313205|Active Comparator|Capsule|JKB-122 capsule on period 1 followed by JKB-122 Tablet on period 2
16352197|NCT04313205|Active Comparator|Tablet|JKB-122 tablet on period 1 followed by JKB-122 capsule on period 2
16352198|NCT04313192|Experimental|Pulse rate 2Hz (hertz)|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
16352199|NCT04313192|Experimental|Pulse rate 10Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
16352172|NCT04313387||Very assimetric ectasia with normal topography|• Very assimetric ectasia with normal topography group (VAE-NT G): 88 eyes of 88 patients with very asymmetric ectasia with normal topography (VAE-NT) in one eye and frank ectasia (VAE-E) in the fellow eye. The inclusion criteria followed previous studies (28, 32, 33) Eyes in this group with insufficient topographic findings to meet diagnostic criteria for keratoconus, and following features normal-appearing cornea on slit-lamp biomicroscopy, keratometry, retinoscopy. These cases were the less affected eye (fellow eye) of a keratoconic patient was included if the following criteria were met: KISA% index of less than 60%, I-S difference of less than 1.45 D, and Kmax of 47.2 D or less (ie, same topographic criteria as in normal eyes, except than in normal eyes, both eyes of the patient met the criteria). These patients can be considered with corneas highly susceptible to ectasia.
16352173|NCT04313387||Keratoconus group (KCG)|• Keratoconus group (KCG): 148 patients (one eye each) with bilateral clinical KC. The KCG included one eye randomly selected from 148 patients with keratoconus; one eye was randomly included per patient to avoid selection bias related to the use of both eyes from the same patient. The inclusion criteria were the same as for VAE-E, except that both eyes of the patient met the ectasia criteria.
16352174|NCT04313374|Active Comparator|Morphine PCA 1 mg|The patient controlled analgesia device give 1mg morphine for each demand of the patient.
16352175|NCT04313374|Active Comparator|Morphine PCA 0,5 mg|The patient controlled analgesia device give 0,5 mg morphine for each demand of the patient.
16352176|NCT04313374|Placebo Comparator|Placebo|The patient controlled analgesia device give 2 mL serum physiologic for each demand of the patient.The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.
16352178|NCT04313348|Active Comparator|Control Arm|Study participants in this arm will receive no SMS reminders nor social supporter notifications.
16352179|NCT04313348|Experimental|Intervention Arm 1|"Participants will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery at their preferred time and day of the week will be sent to study participants. The content of the SMS reminders will be customized and determined by each individual at enrollment. If the participant has no preference, we will suggest This is your ANC visit reminder, encouraging you to attend. This technology is already integrated and running in Uganda via the Yo! Uganda Gateway."
16352180|NCT04313348|Experimental|Intervention Arm 2|"Participants will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information and SMS reminders same as those of scheduled SMS arm above + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for the study participant they are supporting for all the study follow-up period (also called the social support engagement arm). Social supporters will be able to personalize the SMS content at enrollment. They will be advised to assist study participants with any problems that may affect ANC attendance or facility delivery, but will not be given specific instructions on what to do."
16352181|NCT04313335|Experimental|Duloxetine|Apart from the standard treatment, participants in the Duloxetine Arm will be administered with oral duloxetine (up to 60 mg per day) in the acute herpes zoster period.
16352182|NCT04313335|No Intervention|Control|Participants will be given the standard treatment during the acute herpes zoster period.
16352183|NCT04313322|Experimental|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
16352184|NCT04313309|Experimental|Support Group|This is the only group in the study consisting of patients with chronic musculoskeletal pain who are receiving the Integrative Yoga Therapy Program
16352185|NCT04313296|Experimental|Patients identified at PBMC with a documented diagnosis of AF|Patients identified at PBMC with a documented diagnosis of AF (at any point in time) and who have undergone any cardioversion.
16352186|NCT04313283|Experimental|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders for 12 weeks.
16352187|NCT04313270||Patients with FH starting a treatment with Evolocumab®|
16352188|NCT04313257|Active Comparator|Passive Occlusion|This arm will include those participants who will follow a daily occlusive treatment of 2 hours.
16352189|NCT04313257|Experimental|Active Occlusion|This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.
16352190|NCT04313244|Experimental|Group 1|0.5 mL Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) will be co-administered with 0.5 mL Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
16352191|NCT04313244|Experimental|Group 2|0.5 mL 9vHPV vaccine IM will be administered once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
16352192|NCT04313231||MDS|"Female and male patients aged 18 years and older
~MDS, MDS/MPN diagnosis based on current WHO classification. CCUS and CHIP defined by Valent (Valent, Oncotarget, 2018) and by Stauder (Stauder, Blood, 2018)"
16352193|NCT04313231||control|age-matched healthy persons
16352194|NCT04313218||A|recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
16352195|NCT04313218||B|women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
16352200|NCT04313192|Experimental|Pulse rate 150Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
16352201|NCT04313179|Experimental|Music group|"Deep Sleep music track from Bedtime Mozart: Classical Lullabies for Babies, played through smart phone speakers, at maximum sound up to 45 dB, starting 20 minutes before the heel prick procedure, continuing through the procedure and for 5 minutes after the procedure. Also given 0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure for baseline pain relief."
16352202|NCT04313179|Placebo Comparator|Placebo group|0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure. No music played.
16352203|NCT04313166|Experimental|Cu(II)ATSM|copper-containing synthetic small molecule
16352204|NCT04313153|Experimental|Vadadustat once daily|
16352205|NCT04313153|Experimental|Vadadustat three times weekly|
16352206|NCT04313153|Active Comparator|Darbepoetin alfa|
16352207|NCT04313127|Experimental|Low-dose Group|Subjects received one dose of 5E10 vp Ad5-nCoV at 18 to 60 years old
16352208|NCT04313127|Experimental|Middle-dose Group|Subjects received one dose of 1E11 vp Ad5-nCoV at 18 to 60 years old
16352209|NCT04313127|Experimental|High-dose Group|Subjects received one dose of 1.5E11vp Ad5-nCoV at 18 to 60 years old
16352210|NCT04313114|Active Comparator|PRIME CRC|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will also receive automated reminder calls and texts for both screening options to encourage screening.
16352211|NCT04313114|Active Comparator|Enhanced Usual Care|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will receive no reminder calls.
16352212|NCT04313101||Cases (ICUAW)|57 critically ill patients developing ICUAW during their stay in the intensive care unit will be included in the study as cases.
16352213|NCT04313101||Controls|A total of 57 Critically ill patients in the same period who did not develop ICU acquired weakness during their ICU stay will be included as controls.
16352214|NCT04313088|Other|Experimental Group A|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group A will take eluxadoline 100mg by mouth twice for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take matching placebo by mouth twice daily. Each participant in Group A will take 42 days of eluxadoline 100mg twice daily followed by 42 days of placebo over the course the study.
16352215|NCT04313088|Other|Experimental Group B|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group B will take placebo by mouth twice daily for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take eluxadoline 100mg by mouth twice daily. Each participant in Group B will take 42 days of placebo followed by 42 days of eluxadoline 100mg twice daily over the course the study.
16352216|NCT04313062|Experimental|Intervention|"The intervention group will receive the PM ACTIVAS' intervention model. This intervention will be done by a member of the technical staff (previously trained) at the patient's home (house call). In the house call, the trainee will perform a multidimensional assessment of the patient's falling risks factor (internal and external), deliver a  Falling Prevention Kit  and lastly establish together (with the patient and their family) a plan to change the hazards in their home. The patients will receive a telephone follow-up by the same technical staff member until the final house call, which will be 12 months after the recruiting. Finally, 12 months after recruitment, they will receive a last house call where the trainee will assess with the patient and the family the plan, ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period), and conduct the final survey."
16352217|NCT04313062|No Intervention|Standard care|"The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the  Falling Prevention Kit ."
16352218|NCT04313049|Active Comparator|Motor control|
16352219|NCT04313049|Experimental|Vocal control|
16352220|NCT04313036|Experimental|Defibrotide|5 day course of defibrotide at standard dosing 25 mg/kg/day in 4 divided doses of 6.25 mg/kg. If not in CR by day 5, will be given for >/= 21 days or per discretion of enrolling physician.
16352221|NCT04313023|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3, 6, and 10
16352222|NCT04313023|Placebo Comparator|Sterile saline for inhalation|Sterile saline for inhalation given by nebulization on Study Days 1, 3, 6, and 10
16352223|NCT04313010|Experimental|Regenerative endodontics therapy with PRF|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. Only the apex 1/3 of the root canal need to be filled with blood. PRF was injected into the root canal to a level below the CEJ, then wait for 10-15min to coagulate.
16352224|NCT04313010|Active Comparator|Regenerative endodontics therapy with BC|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. The adequate blood need to be full with canal space and below the CEJ, then wait for 10-15min to coagulate.
16352225|NCT04312997|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3 and 6
16352226|NCT04312997|Placebo Comparator|Sterile saline for inhalation|Sterile saline for Inhalation given by nebulization on Study Days 1, 3 and 6
16352227|NCT04312971|Placebo Comparator|Placebo|Infusion of normal Saline 0.9%will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
16352228|NCT04312971|Active Comparator|Norepinephrine|Infusion of norepinephrine (40 µg/ml) will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
16352229|NCT04312958||Trauma patients|Trauma patients experiencing traumatic injuries requiring a full trauma team response.
16352230|NCT04312958||Liver transplant patients|Patients undergoing liver transplant surgery.
16352231|NCT04312945|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16352232|NCT04312945|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16352233|NCT04312945|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16352234|NCT04312945|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16352235|NCT04312932|Experimental|Long chain polyunsaturated fatty acid (LCPUFA) Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days
16352236|NCT04312932|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
16352237|NCT04312919|Experimental|Intervention Group|3 in-person visit group
16352238|NCT04312919|Active Comparator|Control/Crossover Group|5 in-person visit group
16352239|NCT04312893|Experimental|Acupuncture group (ACU)|Patients in acupuncture group will receive traditional Chinese acupuncture combined with Tung's style acupuncture using Press Tack Needle (PYONEX Φ0.20×0.6 mm made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles. The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment will use bilateral acupuncture (if patient's condition does not allow it, unilateral acupuncture will be done). The patient will lie in a supine position during the treatment. Acupuncturist will disinfect the acupoint location with an alcohol pad (70% alcohol), then the acupuncturist will press the needles sticker to the mentioned above acupoints. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
16352240|NCT04312893|Placebo Comparator|Control group (CON)|Patients randomized to the control group will receive press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment methods and patients position will be identical to acupuncture group. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
16352241|NCT04312880|No Intervention|Control|Patient will receive no transexemic acid of any kind
16352242|NCT04312880|Experimental|IV-transexemic acid|weight adjusted standard dose of TXA will be administered to these subset of patients prior to incision in IV-form
16352243|NCT04312880|Experimental|Topical-transexemic acid|the wound site after the surgery is completed will be bathed in TXA for a standardized period of time prior to skin closure
16352244|NCT04312867|Experimental|Project STRONG|Project STRONG is an active skill-based intervention designed to prevent adolescent dating violence among middle school boys. Boys and a parent will complete the web-based program together focusing on improving communication and emotion regulation.
16352245|NCT04312867|Active Comparator|Health Promotion|Health Promotion is an information-based program designed to mimic content areas provided during middle-school health education. The content is provided via a web-based interface to mirror the content delivery in the active intervention (Project STRONG).
16352246|NCT04312841|Experimental|Treatment (letermovir)|Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
16352247|NCT04312815|Experimental|SM03 600 mg|"SM03: 600 mg intravenous (IV) Randomizd period:on week 0,2,4 and 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.
~Open-lable treatment on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
16352248|NCT04312815|Placebo Comparator|Placebo|"placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.
~SM03: 600 mg intravenous (IV) on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
16352249|NCT04312802||Observational|Single arm observational study
16352250|NCT04312789|Experimental|Treatment (avatrombopag)|Patients receive avatrombopag PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity. Avatrombopag will be titrated weekly until platelet count of greater than or equal to 60,000/uL is achieved and persists for 7 consecutive days, and the patient remains free from platelet transfusion.
16352251|NCT04312776||Patients infected with CA-MRSA|It is an observational study, no interventions to any of the two study arms.
16352252|NCT04312776||Healthy people without any infection|It is an observational study, no interventions to any of the two study arms.
16352253|NCT04312750|Experimental|Lidocaine Patch|All subjects received one lidocaine topical system, which was applied to a predetermined fixed area on subject's left side of the back or right side of the back (lower/mid back) according to randomization schedule and worn for 12 hours.
16352254|NCT04312724|Active Comparator|Clinical need|Participants enrolled that require a new socket.
16352256|NCT04312711|Experimental|intervention|All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
16352257|NCT04312698|Experimental|Experimental Group 1|
16352258|NCT04312698|Placebo Comparator|Comparator Group 1|
16352259|NCT04312698|Placebo Comparator|Comparator Group 2|
16352260|NCT04312685|Active Comparator|Prometra Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refills 1-3) and will be compared to 3 months retrospectively collected pain scores (VAS, ODI and Global Pain Scale Assessments) and drug doses prior to peristaltic pump explant.
16352261|NCT04312685|No Intervention|Retrospective records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
16352264|NCT04312646||patients with thyroid nodules|
16352265|NCT04312607||Philadelphia chromosome positive|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
16352266|NCT04312607||Philadelphia chromosome negative|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
16352267|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 50mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
16352268|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 75mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
16352269|NCT04312594|Placebo Comparator|Placebo and Basic treatment|Mimic tablets of Jaktinib Dihydrochloride Monohydrate 50mg BID and 75mg BIDand basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
16352270|NCT04312581|Experimental|First group (shock wave)|Extracorporeal shock wave therapy
16352271|NCT04312581|Active Comparator|Second group (conventional rehabilitation)|conventional rehabilitation
16352272|NCT04312568|Experimental|Fadanafil|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
16352273|NCT04312568|Placebo Comparator|Placebo|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
16352274|NCT04312542||SRP with minocycline HCl microspheres|Participants in this cohort received the intervention of minocycline HCl microspheres, 1 mg in the interventional phase of the trial.
16352275|NCT04312542||SRP without minocycline HCl microspheres|Participants in this cohort did not have minocycline HCl microspheres, 1 mg administered during the interventional phase of the trial.
16352276|NCT04312529|Experimental|Overhead athletes|
16352277|NCT04312516||Controls|Healthy volunteers without neurocognitive impairment
16352278|NCT04312516||Patients|Patients undergoing surgical procedure with at least mild cognitive impairment preoperatively
16352279|NCT04312503||COHORT A: Lurasidone|Patients treated with Lurasidone
16352280|NCT04312503||COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)|Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
16352281|NCT04312490|Experimental|patients|all patients with myocarditis
16352282|NCT04312477|Experimental|Experimental group|Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
16352283|NCT04312477|Active Comparator|Control group|Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
16352284|NCT04312464||Discharged group|The individual which is defined as patient discharged from hospital
16352285|NCT04312464||Dead group|The individual which is defined as patient with all-cause death
16352286|NCT04312438|Experimental|13 mo to 15 yo children diagnosed with Cow's Milk Allergy|oral food challenge with cow's milk proteins
16352287|NCT04312425||Group C|General anesthesia was induced with classic rapid sequence induction protocol.
16352288|NCT04312425||Group M|General anesthesia was induced with modified rapid sequence induction protocol.
16352289|NCT04312399|Other|oral hormonal therapy|Postmenopausal women who start with oral hormonal therapy (Progesteron + uterogestan) according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352290|NCT04312399|Other|transdermal hormonal therapy|Postmenopausal women who start with transdermal hormonal (Oestrogel + uterogestan) therapy according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352291|NCT04312399|Other|oral hormonal therapy + hysterectomy|Postmenopausal women who start with oral hormonal therapy (progesteron) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352309|NCT04312334|Other|Control 1|Control 1: Hand washing with bar soap and water for 15 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 15 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
16352377|NCT04311970|Other|EoE patients|Patients will all be administered the EsoCheck device as a diagnostic test
16352292|NCT04312399|Other|transdermal hormonal therapy + hysterectomy|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352293|NCT04312399|Other|oral hormonal therapy + IUD|Postmenopausal women who start with oral hormonal therapy (Progynova) according to standard of care practice and have already an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352294|NCT04312399|Other|transdermal hormonal therapy + IUD|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and have an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352295|NCT04312399|Other|selective oestrogenreceptor modulators|Postmenopausal women who start with hormonal therapy according to standard of care practice and take selective oestrogenreceptor modulators (Nolvadex) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352296|NCT04312399|Other|aromatase inhibitors|Postmenopausal women who start with hormonal therapy according to standard of care practice and who taken aromatase inhibitors (Femara) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352297|NCT04312399|Other|Duavive|Postmenopausal women who start with hormonal therapy according to standard of care practice and who take duavive because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352298|NCT04312399|Other|Control|Postmenopausal women who don't start with hormonal therapy according to standard of care practice. At the first study visit blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
16352299|NCT04312386|Experimental|A new 4-week lunch menu|Optimized lunch menu with 30% lower greenhouse gas emissions, nutritionally adequate
16352300|NCT04312360|Experimental|intervention track 1|"14 patient with right-sided colon cancer receive intervention before the hemicolectomi.
~both arms of this study use the same intervention."
16352301|NCT04312360|Experimental|intervention track 2a|"14 patient with right-sided colon adenoma receive intervention before the endoscopic mucosa resection.
~both arms of this study use the same intervention."
16352302|NCT04312347|Experimental|Personalized dosing of tamoxifen|Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.
16352303|NCT04312334|Experimental|Treatment 1|Treatment 1: Hand cleaning with the Supertowel for 15 seconds. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recorded by means of weighing the towel before and after soaking. The volunteers will use the soaked Supertowel for 15 seconds to clean their pre-contaminated hands.
16352304|NCT04312334|Experimental|Treatment 2|Treatment 2: Hand cleaning with a Supertowel that is damp for 60 seconds The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The water on the Supertowel will then be squeezed out so that it is not dripping. The Supertowel will be weighed before soaking and after squeezing. Volunteers will clean their pre-contaminated hands with the damp Supertowel for 60 seconds.
16352305|NCT04312334|Experimental|Treatment 3|"Treatment 3: Hand cleaning for 60 seconds with a Supertowel that has been soaked in contaminated water.
~A Supertowel will be soaked in water which has artificially contaminated with non-pathogenic E.coli. The water will be designed to mimic highly contaminated grey water so it will be contaminated at 2,000 cfu/100 ml which is double the acceptable level of contamination for handwashing. Volunteers will clean their pre-contaminated hands with the contaminated Supertowel for 60 seconds."
16352306|NCT04312334|Experimental|Treatment 4|"Treatment 4: Hand cleaning for 60 seconds with a Supertowel that is visibly dirty and oily.
~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water .The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 60 seconds."
16352307|NCT04312334|Experimental|Treatment 5|"Treatment 5: Hand cleaning for 30 seconds with a Supertowel that is visibly dirty and oily and it is soaked in whater which has artificially contaminated with non-pathogenic E.coli.
~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water (which will be contaminated with E.coli).The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 30 seconds."
16352308|NCT04312334|Experimental|Treatment 6|Treatment 6: Hand cleaning with the Supertowel which is fully dry for 60 seconds.
16352310|NCT04312334|Other|Control 2|"Control 2: Handwashing with bar soap and water for 60 seconds The control group will wash their pre-contaminated hands with normal bar soap and water for 60 seconds by following the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps was given to them, appendix). After handwashing, hands will be allowed to dry for 3 minutes"
16352311|NCT04312334|Other|Control 3|"Control 3: Handwashing with bar soap and contaminated water for 60 seconds. Water which is contaminated with non-pathogenic E.coli. at 2,000 cfu/100ml will be stored in a bucket which has a tap at the base. The control group volunteers will wash their hands with the contaminated water and bar soap for 60 seconds. They will follow the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps will be given to them). After handwashing, hands will be allowed to dry for 3 minutes."
16352312|NCT04312334|Other|Control 4|Control 4: Hand cleaning for 60 seconds with a clean Supertowel. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recordedby means of weighing the Supertowel before and after soaking. The control group will clean their pre-contaminated hands of with thesoaked Supertowel for 60 seconds.
16352313|NCT04312334|Other|Control 5|Hand washing with bar soap and water for 30 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 30 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
16352314|NCT04312321|No Intervention|CONTROL|CONTROL group: low urgency cases with routine operation of paramedic crew with optional consultation with a doctor over the phone.
16352315|NCT04312321|Experimental|PHONE|In the PHONE group, there will be a mandatory consultation of a doctor over the phone in all low urgency cases.
16352316|NCT04312321|Experimental|VIDEO|In the VIDEO group, there will be a mandatory consultation of a doctor over the audiovisual consultation in low urgency cases
16352317|NCT04312308||Non-Small Cell Lung Cancer Treated with Atezolizumab|Patients with Non-Small Cell Lung Cancer Treated with Atezolizumab
16352318|NCT04312295|Experimental|ACP-SCT program|The ACP simulation-based communication training (ACP-SCT)program was designed 12 hours (4hours/week) workshop for nephrology nurses.
16352319|NCT04312295|No Intervention|Without ACP-SCT program|The control group only gives the ACP simulation-based communication training program handbook.
16352320|NCT04312282|Experimental|Cohort 1, Sequence 1A: Fed then fasted|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fed conditions
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions"
16352321|NCT04312282|Experimental|Cohort 1, Sequence 1B: Fasted then fed|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fed conditions"
16352322|NCT04312282|Experimental|Cohort 2: Tesetaxel plus itraconazole|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and itraconazole on Day -3 through Day 14 of a 21-day cycle"
16352323|NCT04312282|Experimental|Cohort 3: Tesetaxel plus rifampin|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and rifampin on Day -6 through Day 14 of a 21-day cycle"
16352324|NCT04312269|Experimental|All phase TMR|TMR during every stage of sleep
16352325|NCT04312269|Experimental|Slow-wave sleep (SWS) only TMR|TMR during slow-wave sleep only
16352326|NCT04312269|Experimental|Reduced frequency TMR|TMR during only subset of sessions
16352327|NCT04312269|Sham Comparator|Sham TMR|Patients receive no TMR
16352330|NCT04312243|Experimental|Treatment Group|Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
16352331|NCT04312243|No Intervention|Control Group|Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
16352332|NCT04312217|Active Comparator|Medical clowning|Preoperative medical clown exposure
16352333|NCT04312217|No Intervention|Control|Normal preop care
16352334|NCT04312204|Experimental|Sintilimab+Gemcitabine+Carboplatin|
16352335|NCT04312191|No Intervention|Control Group|The Control Group participants (Group A) will be initiating radiation therapy and receiving only standard of care therapy per their Radiation Oncologist.
16352336|NCT04312191|Experimental|Test Group|The Test Group participants (Group B) will be initiating radiation therapy and receiving standard of care therapy per their Radiation Oncologist. This group will also be taught mantra-based meditation to use during each radiation treatment session and encouraged to practice MM ad libitum outside of the treatment setting.
16352337|NCT04312178|Other|return vaginal self-swab by mail|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail
16352338|NCT04312178|Other|financial incentive mail-back vaginal self-swab|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail to obtain a cash incentive
16352339|NCT04312178|Other|handing over the vaginal swab to a professional|Socially disadvantaged women who have received a vaginal self-swab and need to report it to a health professional
16352340|NCT04312178|Other|financial incentive the vaginal self-swab to a pro|Socially disadvantaged women who have received a vaginal self-swab and have to report it to a health professional to obtain a cash incentive
16352341|NCT04312165|Experimental|Duramesh Laparotomy Closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
16352342|NCT04312165|Active Comparator|Control group-Conventional suture closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
16352374|NCT04311996|Experimental|Alone|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
16352375|NCT04311983|Active Comparator|Tobacco Quitline only|Smokers in this study group will be offered their state Tobacco Quitline programs
16352343|NCT04312152|Active Comparator|PMS Placebo|"If body weight is up to 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
16352344|NCT04312152|Active Comparator|ASD Placebo|"If body weight is up to 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
16352345|NCT04312152|Experimental|PMS Active compound|"If body weight is up to 20 kg:
~Q10 ubiquinol, 50 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Q10 ubiquinol, 100 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
16352346|NCT04312152|Experimental|ASD Active compound|"If body weight is up to 20 kg:
~Q10 ubiquinol, 50 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Q10 ubiquinol, 100 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
16352347|NCT04312139||Fast progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated fast progression from moderate to severe aortic valve stenosis: echocardiographic dVmax>0.25 m/sec/year (difference in transaortic Vmax).
16352348|NCT04312139||Slow progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated slow progression from moderate to severe aortic valve stenosis: echocardiographic dVmax<0.15 m/sec/year (difference in transaortic Vmax).
16352349|NCT04312139||Prospective Moderate Aortic Valve Stenosis|100 consecutive prospectively enrolled patients with moderate aortic valve stenosis. Plus 20 patients accounting for 20% drop-out rate, total prospective cohort = 120 patients.
16352350|NCT04312139||Negative calcium score group|50 patients at intermediate to high risk for Cardiovascular Disease (CVD) and negative aortic valve and coronary calcium score at CT scan, prospectively followed-up. Plus 10 patients accounting for 20% drop-out rate, total control cohort = 60 patients.
16352351|NCT04312126||Arm 1|46 healthy young (18-35) volunteers
16352352|NCT04312126||Arm 2|46 healthy older (50-80) volunteers
16352353|NCT04312126||Arm 3|46 chronic (>6 months post-stroke) stroke patients
16352354|NCT04312113|Experimental|Autologous mesenchymal stem cells|Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis.
16352355|NCT04312100||Mild cases with conventional oxygen therapy|COVID-19 patients who were considered mild cases will receive conventional oxygen therapy in addition to standard treatment
16352356|NCT04312100||Moderate/Severe cases with nasal high flow oxygen inhalation|COVID-19 patients who were considered Moderate/Severe cases will receive nasal high flow oxygen inhalation in addition to standard treatment
16352357|NCT04312100||Moderate/Severe cases with non-invasive ventilation|COVID-19 patients who were considered Moderate/Severe cases will receive non-invasive positive pressure ventilation in addition to standard treatment
16352358|NCT04312087|Experimental|MLND|Modified lateral neck dissection (compartment II-V) is performed in all patients.
16352359|NCT04312087|Experimental|SLNB|Sentinel lymph node biopsy in the lateral neck is performed. The decision of neck dissection is based on the result of sentinel lymph node biopsy.
16352360|NCT04312061|Experimental|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
16352361|NCT04312061|Placebo Comparator|placebo|oral placebo tablet given 1 hour before LNG-IUD insertion
16352362|NCT04312048|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
16352363|NCT04312048|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
16352364|NCT04312035|Experimental|End-range mobilization|End-range mobilization performed in end-position of the knee joint
16352365|NCT04312035|Experimental|Non end-range mobilization|Non end-range mobilization performed in loose-packed position of the knee joint
16352366|NCT04312035|Placebo Comparator|Control|Sham technique performed in loose-packed position of the knee joint
16352367|NCT04312022|Experimental|Berry extract intake|Intake of a berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain)
16352368|NCT04312022|Placebo Comparator|Placebo intake|Intake of a placebo (flour capsule)
16352369|NCT04312009|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
16352370|NCT04312009|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
16352371|NCT04311996|Experimental|Friend and Target Both|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
16352372|NCT04311996|Experimental|Friend Provides Support|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
16352373|NCT04311996|Experimental|Unfamiliar Peer and Target|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
16352376|NCT04311983|Experimental|Tobacco Quitline plus Smoke Free Homes|Smokers in this study group will be offered their state Tobacco Quitline programs, but if they decline, they will be offered a Smoke Free Homes intervention
16352378|NCT04311957|Active Comparator|Boosted PI Group|"Continuation of the same second-line regimen taken prior to entry:
~This includes either Lopinavir/ritonavir (LPVr) 400 mg/100 mg BID or Atazanavir/ritonavir (ATV/r) 300 mg/100 mg QD
~plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)."
16352379|NCT04311957|Experimental|B/F/TAF Group|Combination tablet of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
16352380|NCT04311944|Experimental|Early Fast-Track Care|Participants will be eligible for fast-track care after 8 to 12 weeks, if viral load is suppressed (<200 copies/mL)
16352381|NCT04311944|Active Comparator|Standard (Deferred Fast-track) Care|Participants will be eligible for fast-track care after 24 weeks, if viral load is suppressed (<200 weeks)
16352382|NCT04311931|Experimental|Experimental Creative Dance group|The experimental group intervention will attend the creative dance program. The program integrates 3 sessions / week of 60 minutes on alternated days.
16352383|NCT04311931|No Intervention|Control group|"The control group will maintain the usually daily activities, not attending any exercise program.
~After study end, the control group will have the opportunity to participate on an exercise program."
16352384|NCT04311905|Experimental|Laser activated irrigation LAI|Diode Laser activated irrigation
16352385|NCT04311905|Placebo Comparator|conventional root canal treatment|mock LAI , conventional root canal treatment 2.5% sodium hypochlorite
16352386|NCT04311879|Experimental|Soft tissue laser Diode laser application|Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices. Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product
16352387|NCT04311879|Placebo Comparator|conventional root canal treatment|Placebo : conventional root canal conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with mock laser intervention
16352388|NCT04311866|Active Comparator|Spica cast|Standard practice for the management of the femoral shaft fractures.
16352389|NCT04311866|Experimental|Synthetic fabric|Offer resistance, durability and low weight to treatment of femoral shaft fractures
16352390|NCT04311853||practitioner interviews|phone interviews conducted
16352391|NCT04311840||SAH patients with nimodipine|Patients with SAH receiving nimodipine as prevention of vasospasms and as a nootropic drug.
16352392|NCT04311840||SAH patients without nimodipine|Patients with SAH not receiving nimodipine as prevention of vasospasms and as a nootropic drug or in whom the drug has been temporarily discontinued.
16352393|NCT04311827||Serratus anterior plane block and traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
16352394|NCT04311827||Traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
16352395|NCT04311814|Other|v-MUCP value|All patients referred for urodynamics explorations will have a measure of the MUCP during a Valsalva manoeuver
16352396|NCT04311801|Experimental|OCT Arm|Each patient underwent OCT examinations.
16352397|NCT04311788|Experimental|Intervention group|Prophylactic self gripping mesh (Program, Medtronic) will be placed in rectorectus space to prevent incisional hernia.
16352398|NCT04311788|Active Comparator|Control group|Abdomen of the patients in the control group will be closed by using small stitch closure with suture to wound length of 4:1 and slowly absorbable monofilament suture.
16352399|NCT04311775||video laryngoscopy|video laryngoscope is a camera laryngoscope system used to see the larynx with camera
16352400|NCT04311775||laryngoscopy|laryngoscopy is a method used to see the larynx.
16352401|NCT04311749||Fetal growth restriction|
16352402|NCT04311749||Severe preeclampsia|
16352403|NCT04311749||Low PAPP-A|
16352404|NCT04311749||Healthy control|
16352405|NCT04311736|Active Comparator|Exergame|Moderate intensity cycling only 3 times per week for 12 weeks + concurrent virtual reality cognitive training, supervised by an exercise specialist
16352406|NCT04311736|Active Comparator|Cycling|Moderate intensity cycling only 3 times per week for 12 weeks, supervised by an exercise specialist
16352407|NCT04311736|Sham Comparator|Stretching|Stretching 3 times per week for 12 weeks, supervised by a therapist
16352408|NCT04311723|Active Comparator|Group I (conventional mechanical ventilation)|Patients receive anesthesia using a standard short breathing tube called LMA and then undergo standard of care bronchoscopy.
16352409|NCT04311723|Experimental|Group II (VESPA)|Patients receive anesthesia using a longer breathing tube called an endotracheal tube and then undergo standard of care bronchoscopy.
16352410|NCT04311710|Experimental|Part 1 Arm A: mM, mUC, HCC|metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)
16352411|NCT04311710|Experimental|Part 1: Arm B: mM|metastatic Melanoma (mM)
16352412|NCT04311710|Experimental|Part 2: Arm A: NSCLC|metastatic non small cell lung cancer (NSCLC)
16352413|NCT04311710|Experimental|Part 2: Arm B: RCC|advanced or metastatic renal cell carcinoma (RCC)
16352414|NCT04311697|Experimental|Aviptadil IV in escalating doses + standard of care|Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr
16352415|NCT04311697|Experimental|Placebo + standard of care|Patients will first be treated with placebo infusion + maximal intensive care
16352416|NCT04311684||Patients with proteinuria|Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements
16352417|NCT04311684||Healthy volunteers|Healthy men/women between age group 18-65 years will be included for urine protein measurements
16352418|NCT04311671|Experimental|Moxidectin|Moxidectin 8 mg per oral on Day 0
16352419|NCT04311671|Active Comparator|Ivermectin|Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
16352420|NCT04311658|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG-IUD insertion
16352421|NCT04311658|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to LNG- IUD insertion
16352422|NCT04311645|Other|1st group|Oral activated charcoal in a dose of 30 gm/day
16352423|NCT04311645|Other|2nd group|Dry seeds in a dose of 1 gm/ day
16352424|NCT04311645|No Intervention|3rd group|control group
16352425|NCT04311632|Experimental|Arm 1|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
16352426|NCT04311632|Experimental|Arm 2|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
16352427|NCT04311632|Active Comparator|Arm 3|ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
16352428|NCT04311619|Experimental|Major Depression Disorder Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer before and after Repetitive Transcranial Magnetic Stimulation (rTMS) treatment
16352429|NCT04311606|Experimental|Saline and aflibercept|Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept
16352430|NCT04311606|Experimental|Hyaluronidase and aflibercept|Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept
16352431|NCT04311606|Placebo Comparator|Hyaluronidase alone|Group 3: Sub-tenon injection of HA injection alone
16352432|NCT04311593||group 1|control group with normal platelet count
16352433|NCT04311593||group 2|patients with acute ITP
16352434|NCT04311593||group 3|patients with chronic ITP
16352435|NCT04311580|Experimental|urothelial high risk non-muscle invasive bladder cancer|patients with urothelial high risk non-muscle invasive bladder cancer after failed intravesical bacillus Calmette-Guérin treatment.
16352436|NCT04311567|Experimental|Tofacitinib|Oral tablet tofacitinib 5 mg BID for 48 weeks
16352437|NCT04311567|Active Comparator|Methotrexate|Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
16352438|NCT04311541||Dexlansoprazole|Participants diagnosed with GERD and initiated treatment with dexlansoprazole MR therapy will be observed prospectively at 150 sites in Russian federation for a period of 2 months.
16352439|NCT04311515|Active Comparator|30 mg PU AD|75 subjects will be treated with active PU-AD on a 1:1 ratio qd
16352440|NCT04311515|Placebo Comparator|30 mg Placebo|75 subjects will be treated with placebo SyrSpend on a 1:1 ratio qd
16352441|NCT04311502|Experimental|Arm 1: Experimental 3-month, with CFZ loading dose|Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
16352442|NCT04311502|Active Comparator|Arm 2: Standard of care for drug-susceptible (DS) TB|Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
16352443|NCT04311502|Experimental|Arm C: PK only subgroup|Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
16352444|NCT04311489|Experimental|Ularitide|Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
16352445|NCT04311489|Placebo Comparator|Placebo|Matching placebo. Continuous IV infusion for 48 hours.
16352446|NCT04311476|Placebo Comparator|Placebo|0.9% sodium chloride infusion within 24 hours after birth
16352447|NCT04311476|Experimental|ACBMNC|Autologous Umbilical Cord Blood Mononuclear Cells intravenously within 24 hours after birth,dose is 5×107cells/kg ,
16352448|NCT04311463|Experimental|Paroxetine hydrochloride followed by PAXIL|
16352449|NCT04311463|Experimental|PAXIL followed by paroxetine hydrochloride|
16352450|NCT04311450|Experimental|Behavioral Weight Loss|Behavioral: Participants randomized assigned to this arm will received 12 weeks of Behavioral Weight Loss (BWL) counseling.
16352451|NCT04311450|No Intervention|Waitlist Control|Waitlist Control: Participants assigned to this arm will attend follow-up visits to control for the effect of time. Following completion of post-treatment assessment participants in the waitlist control group will be offered an abbreviated BWL treatment.
16352452|NCT04311437|Experimental|Self-acupressure group|The subjects in experimental group will undergo additional self-acupressure therapy in addition to Valsalva and Toynbee maneuvers before the first HBOT. The acupoints used are TE17 (Yifeng, 翳風), TE21 (Ermen, 耳門), SI19 (Tinggong, 聽宮), GB2 (Tinghui, 聽會).
16352453|NCT04311437|Placebo Comparator|Control group|The subjects in control group will receive Valsalva and Toynbee maneuvers alone.
16352454|NCT04311424|Experimental|14C Tirzepatide|A single dose of [14C]-tirzepatide administered subcutaneously (SC).
16352455|NCT04311411|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
16352456|NCT04311411|Placebo Comparator|Placebo|Placebo administered SC.
16352457|NCT04311411|Active Comparator|Liraglutide|Liraglutide administered SC.
16352458|NCT04311398||Respiratory infection group|Patients went to fever clinic with respiratory infectious symptoms in Huashan Hospital affiliated to Fudan University
16352459|NCT04311385||Diverticulitis|"Patients admitted as an emergency with acute diverticulitis diagnosed by CT scan.
~Inclusion criteria
~Patients over 18 years old
~Informed consent form signed
~Diagnosed of acute diverticulitis
~CT scan reported as 1-2 pericolic bubbles with or without free fluid
~Exclusion criteria
~o CT scan showing free distant bubbles in the abdomen"
16352460|NCT04311372|Experimental|Educational session+Material+Videos (Group 1)|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
16352461|NCT04311372|Active Comparator|Educational session+Material ONLY (Group 2)|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
16352462|NCT04311359||Group/Cohort|Brain Oedema induced by drugs reported to the FAERS database from inception till first quarter of 2019
16352463|NCT04311346||Cardiac transplant|Patients exposed to cardiac transplantation
16352464|NCT04311333|Experimental|All patients|"All patients undergo endostomal three-dimensional ultrasonography, computerized tomography, clinical examination and laparotomy/laparoscopy.
~At all the respective examinations, the presence of a parastomal hernia as well as hernia location and size is evaluated."
16352465|NCT04311320|Experimental|Low-Resource Oxygen Blender|This is a single-arm study. All participants will receive respiratory support using the investigational device.
16352466|NCT04311307|Experimental|Patients|GSDIa patients
16352467|NCT04311307|Active Comparator|Controls|Healthy volunteers
16352468|NCT04311294|Active Comparator|ANS-6637 Low Dose|200mg ANS-6637 (2 tablets)
16352469|NCT04311294|Active Comparator|ANS-6637 High Dose|600mg ANS-6637 (2 tablets)
16352470|NCT04311294|Placebo Comparator|Placebo|0mg matched placebo (2 tablets)
16352471|NCT04311281||Suspected AD|"Participants with suspected AD enrolling in the trial must meet all of the following criteria:
~Cognitive deficits do not occur exclusively in the context of a delirium.
~Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).
~There is insidious onset and gradual progression of impairment in one or more cognitive domains.
~The participant has documented memory problems in one or more other cognitive domains, such as language, visual-spatial functioning, executive functioning, etc. (Busse et al., 2006)."
16352472|NCT04311281||Suspected CTE / TES|"Required Features:
~Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure; progressive course; and at least 1 supportive feature
~History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma
~Head trauma exposure is repetitive in nature
~Demonstrated progressive course
~Delayed symptom onset
~Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (executive, visuospatial, memory, and language).
~Supportive Features (only 1 required):
~Emotional dysregulation
~Behavioral change
~Motor disturbance"
16352473|NCT04311268|Experimental|Observational|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
16352474|NCT04311255|Active Comparator|intercostal group|group of patient receiving inrercostal nerve block as analgesia
16352475|NCT04311255|Active Comparator|pecs group|group of patient receiving pectoralis nerve block as analgesia
16352476|NCT04311229|Experimental|Negative-Pressure Wound Therapy group|NPWT was applied three times for Class III and pressure ulcers. An initial pre-treatment measurement was used as a baseline, followed by three post-treatment measurements after each round to evaluate wound healing. A total of four measurements were performed for each subject. Wound healing was measured using the PUSH Tool and the 3DWM device in both groups.
16352477|NCT04311229|Other|CONTROL GROUP|wet to dry dressing group
16352478|NCT04311216||Shoulder instability participants|Participants with previous a previous episode(s) of shoulder instability
16352479|NCT04311216||Age matched controls (no instability)|Participants with no previous a previous episode(s) of shoulder instability
16352480|NCT04311203|Experimental|Mental Health First Aid Intervention|Two-day MHFA training provided by MHFA England. Organisations will raise awareness of the presence of MHFA in the workplace, with delivery of MHFA by trained members to participants in the workplace.
16352481|NCT04311203|No Intervention|Control|A brief consultation from MHFAE on the promotion of mental health and well-being in the workplace.
16352482|NCT04311190|Experimental|ICU A|Family members' involvement in the care of their beloved one
16352483|NCT04311190|No Intervention|ICU B|Standard care
16352484|NCT04311177|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
16352485|NCT04311177|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
16352486|NCT04311164||Steno Tech Survey Respondents|A cohort of individuals with type 1 diabetes treated with CSII at either SDCC or NOH participating in the Steno Tech Survey.
16352487|NCT04311164||General Type 1 Diabetes Population|A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca. 25.000 individuals).
16352488|NCT04311151|Experimental|self seizures visualization group|Visualization of the own epileptic seizures occured during hospital admission.
16352489|NCT04311151|No Intervention|usual management|Usual way management
16352490|NCT04311138|Experimental|Experimental group|Experimental group receive a 10-wk diversified community-based reablement service.
16352491|NCT04311138|Active Comparator|Control group|Control group receive a 10-wk multicomponent training.
16352492|NCT04311125|Active Comparator|total hip arthroplasty via the mini posterior approach|total hip arthroplasty via the mini posterior approach. This approach was first described by Kocher and Langenbeck and later modified by Gibson in 1950. There is a convex incision centered on the posterior rim of the major trochanter. The incision follows the curve of the buttock and at the height of the posterior lip of the major trochanter, it is peripherally oriented along the posterior outer surface of the femur. The major gluteus is divided along the muscle fibers. Guiding sutures are inserted into the tendon mass of the hip rotor muscles just prior to their origin on the major trochanter and dissected to expose and subsequently retract the posterior hip capsule.
16352493|NCT04311125|Active Comparator|THR via the anterior approach without traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
16352494|NCT04311125|Active Comparator|THR via the anterior approach with a traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
16352495|NCT04311112|Placebo Comparator|ZA placebo|
16352496|NCT04311112|Active Comparator|ZA low dose|
16352497|NCT04311112|Active Comparator|ZA high dose|
16352632|NCT04310046|Experimental|PCI after TAVI|PCI is performed within 1-45 days after TAVI.
16352498|NCT04311099|Experimental|Ultrasound-guided TAP|Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
16352499|NCT04311099|Experimental|Laparoscopic assisted TAP|Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
16352500|NCT04311099|Placebo Comparator|Placebo|Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
16352501|NCT04311086|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
16352502|NCT04311073|Experimental|Tranexamic Acid|Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time
16352503|NCT04311073|Placebo Comparator|Placebo|Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision
16352504|NCT04311047|Experimental|USPIO-enhanced MRI|Ferumoxtran-10 contrast will be intravenously administered 24-36 before performing an MRI scan. The MRI scan will be discussed with the surgeon prior to resection. Findings on MRI will be compared to pathology.
16352505|NCT04311034|Experimental|RC48|
16352506|NCT04311021||Diabetes type 1|
16352507|NCT04310995|Experimental|Nicorandil|oral Nicorandil 5mg (Tablets) three times daily for 168 days
16352508|NCT04310995|Active Comparator|Diltiazem Hydrochloride|oral Diltiazem 180mg (Sustained-release Tablets) once daily for 168 days
16352509|NCT04310995|Active Comparator|Isosorbide Mononitrate|oral Isosorbide Mononitrate 50mg (Sustained-release Capsules) once daily for 168 days
16352510|NCT04310982||Health Adults|Forty-nine healthy participants (30 females, 19 males) completed the test-retest protocol with 7 days between tests. Participants were; 23,58±2,65 years of age, 62,9±10,08 kg of weight and 168,76±8,31 cm of height. Participants included in the study did not have any musculoskeletal, neurological or other pathology potentially affecting their gait and jump performance.
16352511|NCT04310969|Experimental|treatment group|Patients are treated every two weeks for a total of three times. Forceful expression of the meibomian glands is followed after each therapy.
16352512|NCT04310969|Sham Comparator|control group|Forceful expression of the meibomian glands only for patients.
16352513|NCT04310969|Active Comparator|active control group|LipiFlow® treatment is used as an active comparator.
16352514|NCT04310956|Experimental|Y-Knot group|Patients use Y-Knot all-suture anchor
16352515|NCT04310956|Active Comparator|Biocomposite suture anchor|Patients use Biocomposite suture anchor
16352516|NCT04310943|Experimental|Arm 1|Tislelizumab (200mg,Q3W )+Bevacizumab(15 mg/kg,Q3W)+Albumin paclitaxel(100mg/m2,d1,8,15) for 4 cycles, and if there is no disease progression, patients will receive Tislelizumab(200mg,Q3W) until progression or death.
16352517|NCT04310930|Active Comparator|Intensive Therapy A|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin AND clofazimine.
16352518|NCT04310930|Experimental|Intensive Therapy B|Following Randomisation 1, Participants will receive inhaled amikacin (IA), IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin AND clofazimine.
16352519|NCT04310930|Experimental|Intensive Therapy C|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin.
16352520|NCT04310930|Active Comparator|Consolidation A|Oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
16352521|NCT04310930|Experimental|Consolidation B|Inhaled amikacin (IA), oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
16352522|NCT04310917|Other|Lipoprotein a level|blood lipoprotein (a) test
16352523|NCT04310904||ICU cardiac output (CO) assessment patients|all ICU patients intubated/ventilated with a central line and an arterial catheter who need trans esophageal echocardiography examination with a saline contrast test.
16352524|NCT04310891||Markerless|Markerless Tumour Tracking will be used to observe the radiation beam is accurately targeting the tumour.
16352525|NCT04310865|Experimental|Yinhu Qingwen Granula Group|Based on the standard medical treatment, the patients will be given Yinhu Qingwen Granula for 10 days.
16352526|NCT04310865|Placebo Comparator|Yinhu Qingwen Granula Low-dose Group|Based on the standard medical treatment, the patients will be given 10% dose of Yinhu Qingwen Granula for 10 days.
16352527|NCT04310839||outpatient left laparoscopic colectomy|Left laparoscopic laparoscopic colectomy patient managed on an outpatient basis
16352528|NCT04310826|Experimental|Prevention (dietary intervention)|Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
16352529|NCT04310813||Endoscopic urologic patients|Patients with bladder cancer or benign prostate hyperplasia undergoing urologic endoscopic procedures.
16352530|NCT04310800|Experimental|LIFT-plug|The LIFT-plug procedure was performed as followings. A portion of the fistula tract was excised from ei¬ther end within the intersphincteric space. One porcine small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures.
16352560|NCT04310540|Active Comparator|Surgical resection / Liver transplant|30 undergoing resection or transplant will under go a 68 Ga labeled PSMA 11 (or PSMA - HBED _ CC) PET/MRI or PET/CT scan
16352561|NCT04310540|Active Comparator|Locoregional therapy|30 undergoing locoregional therapy will under go a maximum of two 68 Ga labeled PSMA 11 (or PSMA - HBED _ CC) PET/MRI or PET/CT scan with possible biopsy after the first PET Scan
16352531|NCT04310800|Experimental|LIFT|The LIFT procedure was performe as followings. The curvilinear incision and dissection of the intersphincteric tract were made as in the LIFT-plug technique. After the tract was isolated, the tract was doubly-ligated and suture-ligated with absorbable sutures as close as possible to the lateral margin of the internal anal sphincter and the medial margin of the external anal sphincter. The tract was then divided between the two sutures. A portion of the fistula tract was excised after ligation of ei¬ther end within the intersphincteric space. The medial ligature was very close to the internal opening, and nearly obliterated the internal opening. The external opening was then enlarged to allow adequate drainage. The internal and external sphincters were then re-approximated, and the skin was closed loosely with interrupted 3/0 absorbable suture.
16352532|NCT04310787||HBV-ACLF|To investigate the clinical events and prognosis of patients with hepatitis b associated acute on-chronic liver failure
16352533|NCT04310774|Experimental|Consolidation therapy|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
16352534|NCT04310761||pregnancy population after one single blastocyst transfer|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from a period between 2014 and 2018.
16352535|NCT04310748|Active Comparator|Total Intravenous Anesthesia(TIVA)|Anesthesia is maintaining with TIVA (Group 1)
16352536|NCT04310748|Active Comparator|Inhalation Anesthesia|Anesthesia is maintaining with inhalation anesthesia (Group 2)
16352537|NCT04310735|Experimental|Experimental: Expect-Yes|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will perceive an opportunity to smoke during the experimental session.
16352538|NCT04310735|Experimental|Experimental: Expect-No|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will not perceive an opportunity to smoke during the experimental session.
16352539|NCT04310722||Gram-negative bacilli and MRSA infections in ICU|Carbapenem-resistant Gram-negative bacilli [Carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Klebsiella pneumoniae (CRKP), and Carbapenem-resistant Pseudomonas aeruginosa (CRPsA) ] and methicillin-resistant Staphylococcus aureus (MRSA) is prevalent around the world, and the isolation rate and resistance rate has increasing in China, especially in ICU. So, investigators aim to study transmission mechanism, resistance mechanism and horizontal transfer mechanism of these pathogens.
16352540|NCT04310709|Experimental|REGONIVO|"Nivolumab - 480 mg IV on Day 1, every 4 weeks
~Regorafenib
~- 80 mg per oral once daily for 21 consecutive days starting on Day 1, every 4 weeks."
16352541|NCT04310696|Experimental|Buteyko group|Buteyko breathing exercises
16352542|NCT04310696|Active Comparator|Pursed lip breathing|Pursed lip breathing exercises
16352543|NCT04310683|Other|natural cycle for endometrium preparation|patients will have ovulation before embryo transfer
16352544|NCT04310683|Experimental|hormone replaced cycle for endometrium preparation|patients will do not have ovulation before embryo transfer
16352545|NCT04310670|Experimental|Patients with FND|Diagnosis of Functional Neurological Disorder of movement clinically established according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria
16352546|NCT04310657|Experimental|Precision therapy|
16352547|NCT04310657|No Intervention|control|
16352548|NCT04310644||Postural Orthostatic Tachycardia Syndrome|Patients with orthostatic intolerance because of Postural orthostatic tachycardia syndrome diagnosed in our outpatient clinic by tilt table examination.
16352549|NCT04310644||Ehlers Danlos Syndrome|Patients with hypermobile or classical EDS who are already diagnosed including genetical testing for classical or vascular EDS and Marfan Syndromes
16352550|NCT04310644||Autoimmune autonomic neuropathy/Pure autonomic failure|Patients who have an autoimmune autonomic neuropathy based on clinical diagnosis and antibody testing in our outpatient clinic. Cardial MIBG Scintigraphy should have been performed.
16352551|NCT04310644||Healthy controls|Healthy controls with no documented cardiovascular or neurological disorders and no symtoms of autonomic failure/dizziness/fainting
16352552|NCT04310618||Adults with bronchiectasis|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase
16352553|NCT04310605||Step 1 only|Participants in the study who only receive Step 1 of specialised CBT
16352554|NCT04310605||Step 1 and 2|Participants who receive both Step 1 and Step 2 of speciliased CBT for tinnitus.
16352556|NCT04310579|No Intervention|Lead-In|Read Rebreathing Reproducibility Assessment
16352557|NCT04310579|Active Comparator|Part 1 Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) tablets and intravenous (IV) placebo 1x per day.
~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.
~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.
~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.
~Note: Initial doses of oxycodone will be 10 mg, but may be increased to 15 mg if necessary based on criteria specified in protocol. Initial doses of midazolam will be 0.0375 mg/kg but may be increased to 0.075 mg/kg based on criteria specified in protocol."
16352558|NCT04310579|Active Comparator|Part 2 Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.
~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.
~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
16352559|NCT04310553|Experimental|Arm 1|This project plans to enroll 40 patients receiving nanoknife treatment, our center enrolls 20 patients, and the other two centers will enroll 10 patients each. The number of patients expected to participate in the study is 240.
16352562|NCT04310527|Experimental|Treatment A: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib reference formulation will be given under fasted condition.
16352563|NCT04310527|Experimental|Treatment B: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib test formulation will be given under fasted condition.
16352564|NCT04310527|Experimental|Treatment C: Administration of ensidenib fed|A single oral 100 mg dose of enasidenib test formulation will be given under fed condition.
16352565|NCT04310514|Active Comparator|Experimental: glucose - fructose - xylitol - saccharose|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
16352566|NCT04310514|Active Comparator|Experimental: fructose - glucose - saccharose - xylitol|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
16352567|NCT04310514|Active Comparator|Experimental: xylitol - saccharose - glucose - fructose|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
16352568|NCT04310514|Active Comparator|Experimental: saccharose - xylitol - fructose - glucose|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
16352569|NCT04310501||CKD Patients|"Patients (n=150) with CKD (Stages 1-5 pre-dialysis, undergoing dialysis, kidney transplantation) who fulfil the inclusion criteria from the Nephrology Dept and Renal Transplant Unit of the University Hospital of Ioannina.
~Sixty patients will be selected for the pilot study which will include blood and urine tests and specific polymorphism analysis (pharmacogenetic tests)"
16352570|NCT04310475|Experimental|Active Treatment|This is a case series
16352571|NCT04310462|Experimental|New eRX Interface|Providers assigned to the intervention arm will be presented with a new eRX interface upon writing new prescriptions for hydroxychloroquine in the EHR.
16352572|NCT04310462|No Intervention|Standard Interface|Providers assigned to the no intervention arm will be presented with the usual ordering interface when prescribing new prescriptions for hydroxychloroquine in the EHR.
16352573|NCT04310449|Experimental|Connective tissue graft and customized healing abutment|Immediate implant placement with CTG and customized healing abutment.
16352574|NCT04310449|Experimental|Bone graft and customized healing abutment|Immediate implant placement with bone graft till the crest of the bone and customized healing abutment
16352575|NCT04310449|Experimental|Bone graft and ovate pontic|bone grafts in the socket and ovate Pontic
16352576|NCT04310449|Active Comparator|Bone graft in dual zone and customized healing abutment|immediate implant placement with bone grafts in the dual zone and customized healing abutment
16352577|NCT04310436|Experimental|Looking down to naval.|Modifying Saccade origin by looking down to naval.
16352578|NCT04310436|Placebo Comparator|Looking up in the air.|Modifying Saccade origin by looking up in the air.
16352581|NCT04310410|Experimental|Combined Focused Ultrasound and Radiotherapy|Combination of focused ultrasound and external beam radiotherapy
16352582|NCT04310397|Experimental|Treatment (dabrafenib, trametinib, surgery, spartalizumab)|"NEOADJUVANT TREATMENT: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo surgical resection of melanoma.
~ADJUVANT TREATMENT OF pCR PATIENTS: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity.
~ADJUVANT TREATMENT OF NON pCR PATIENTS: Patients receive spartalizumab IV over 30 minutes on day 1, dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity."
16352583|NCT04310384|Active Comparator|Endotracheal Intubation, gold standart|Standart of Care with Macintosh laryngoscope
16352584|NCT04310384|Active Comparator|Alternative|Endotracheal Intubation with novel device
16352585|NCT04310371|Experimental|Obese adolescents|BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention
16352586|NCT04310371|No Intervention|Control group|to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
16352587|NCT04310358|Experimental|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
16352588|NCT04310358|Experimental|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
16352589|NCT04310345|Experimental|Animal-Assisted Interaction|Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
16352590|NCT04310332||1L-PEG|Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.
16352591|NCT04310332||4L-PEG|Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.
16352592|NCT04310319|Other|Normal salt, low protein treatment period|6 grams of sodium chloride daily / Placebo
16352593|NCT04310319|Other|Normal salt, normal protein treatment period|6 grams of sodium chloride daily / 40 grams of protein daily
16352594|NCT04310319|Other|Low salt, low protein treatment period|Double placebo
16352595|NCT04310319|Other|Low salt, normal protein treatment period|Placebo / 40 grams of protein daily
16352596|NCT04310306||Rescue stenting group|
16352597|NCT04310293|Other|POOR RESPONDERS|poor responders low AMH LOW AFC
16352598|NCT04310280|Experimental|Topical insulin glargine|The wound surface is treated locally with glargine insulin injected sub-dermal in a daily matter for 7 days. Allocation is randomized.
16352599|NCT04310280|Placebo Comparator|0.9% saline solution|The wound surface is treated with conventional wound care in a daily matter for 7 days. Allocation is randomized.
16352600|NCT04310267|Active Comparator|classic occlusal level, low point of force application|the point of force application for maxillary protraction is at the level of the occlusal plane.
16352630|NCT04310059|Active Comparator|Materna|
16352601|NCT04310267|Active Comparator|Nasal level, Medium point of force application|the point of force application for maxillary protraction is at 20 mm from the occlusal plane (Nasal floor).
16352602|NCT04310267|Active Comparator|Infrorbital level, High level|the point of force application for maxillary protraction is at the level of the infraorbital foramen
16352603|NCT04310254|Active Comparator|EDTA and CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA and CHX solution.
16352604|NCT04310254|Active Comparator|EDTA solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA solution.
16352605|NCT04310254|Active Comparator|CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for CHX solution.
16352606|NCT04310241||Control subjects|Subjects who state they have no eye or neurologic problems or disease other than perhaps wearing glasses or contact lenses and upon review of medical history.
16352607|NCT04310241||Amblyopia|Clinical diagnosis of amblyopia
16352608|NCT04310228|Experimental|Favipiravir Combined With Tocilizumab group|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
~Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
16352609|NCT04310228|Active Comparator|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
16352610|NCT04310228|Active Comparator|Tocilizumab group|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
16352611|NCT04310215|Experimental|Microfracture + CARTISTEM®|CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.
16352612|NCT04310215|Active Comparator|Microfracture|Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.
16352613|NCT04310202||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and additional follow-up visits after surgery.
16352614|NCT04310176|Active Comparator|Standard|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab for 12 cycles (24 weeks)
~Maintenance treatment (Standard): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab until disease progression or unacceptable toxicity"
16352615|NCT04310176|Experimental|Experimental|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab + Valproic Acid administered oral daily from day -14 increasing doses and an intra-patient titration for a target serum level of 50-100µg/ml for 12 cycles (24 weeks)
~Maintenance treatment (Experimental): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab + Valproic Acid until disease progression or unacceptable toxicity"
16352616|NCT04310150|Experimental|Treatment arm label- Collastat®|
16352617|NCT04310150|Active Comparator|Control arm label- Floseal®|an marketed product is Floseal
16352620|NCT04310111|Experimental|EUS-RFA|Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.
16352621|NCT04310098||CADASIL patients|
16352622|NCT04310098||Asymptomatic carriers of CADASIL|
16352623|NCT04310098||Relatives of CADASIL patients and carriers|
16352624|NCT04310098||Unrelated healthy controls|
16352625|NCT04310085|Experimental|PfSPZ-DVI challenge and artemether lumefantrine|"16 healthy, malaria-naïve males and females, aged 18-55 years, were enrolled in 2 cohorts (8 participants/cohort; a participant may be enrolled in one cohort only). There were two target levels of parasitaemia previously achieved in healthy participants in malaria VIS at other study sites, i.e., 5000 parasites/mL blood in Cohort 1 and 10000 parasites/mL blood in Cohort 2. (Based on observed levels of parasitaemia in Cohort 1, the target threshold for treatment in Cohort 2 was maintained at 5,000 p/mL).
~qPCR was performed, malaria clinical score assessed twice daily and participants were administered registered antimalarial therapy, i.e., Riamet®, when the following criteria were met:
~Cohort 1: ≥5000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion.
~Cohort 2: ≥10000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion."
16352626|NCT04310072|Experimental|neuromuscular electrical stimulation group|"For patients who underwent NMES therapy, four electrodes (two 50/100 mm and two 50/50 mm, Compex Performance) were placed on the skin above the quadriceps muscle approximately 5 cm below the inguinal fold and 3 cm above the upper patella border.
~The electrical stimulation protocol consisted of electrical current at frequency of 10 Hz, 20 seconds stimulation time (time on) and 20 seconds resting time (time off) with variable intensity (until visible muscular contraction) for one hour per day until discharge (Compex).The NMES therapy was on top of conventional rehabilitation described below."
16352627|NCT04310072|No Intervention|Control group|"The control group consisted of patients who performed daily active upper and lower limbs exercise in bed and in a stand position (3x10 repetitions, somewhat hard on the Borg scale)."
16352628|NCT04310059|Active Comparator|Folic acid 5mg|
16352629|NCT04310059|Active Comparator|Folic acid 0.5mg|
16352633|NCT04310033||Cases|"> 18 years old
~Non-opposition of the patient or relatives
~Lung, head and neck or colorectal cancer
~Non scheduled ICU admission
~At least 24 hours of ICU stay
~Alive at ICU discharge
~Able to answer by phone to quality of life questionary"
16352634|NCT04310033||Controls|"Cancer patients not admitted in ICU, matched with the cases according to
~the type of primary cancer
~the presence or absence of oncogenic addiction
~the setting of anticancer treatment (curative/palliative)
~the line of anticancer treatment (none/L1/L2-L3/>L3)."
16352639|NCT04309994||Experimental|bypass surgery with blood cardioplegia by means of MPS
16352640|NCT04309994||Active Comparator|bypass surgery with blood cardioplegia by means of Cardioplexol ®
16352641|NCT04309981|Experimental|ARI0002h|Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized
16352642|NCT04309968|Experimental|solid tumors|Experimental: Solid tumors Part 1 - Dose-escalation of SYHA1801 in patients with advanced solid tumors.Daily dosing of SYHA1801 on Days 1 and 4-31 of 28-day cycle. Escalating dose cohorts.
16352643|NCT04309968|Experimental|advanced cancers|Part 2 - Dose-expansion of SYHA1801 in patients with advanced cancers potentially sensitive to BRD4 inhibitor.The dose level and schedule of SYHA1801 of 28-day cycle at the MTD determined in Part 1.
16352644|NCT04309955|Experimental|modified thoracic drainage group|After surgery, both a chest tube and a pigtail catheter are inserted into the middle and posterior axillary lines of the 7th intercostal space, respectively.
16352645|NCT04309955|No Intervention|traditional thoracic drainage group|After surgery, only a chest tube is inserted into the midaxillary line of the 7th intercostal space, traditionally.
16352646|NCT04309942|Experimental|Guided Clinical Pharmacy Consultation group|Patients following either Revlimid - Velcade - Dexamethasone or Revlimid - Dexamethasone protocols with the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
16352647|NCT04309942|No Intervention|Standard group|Patients following either Revlimid - Velcade - Dexamethazone or Revlimid - Dexamethazone protocols but without the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
16352648|NCT04309929||Women with breast cancer|Female patients (age> 18yrs) in ASA class <4; candidate for a planned surgery for simple mastectomy, simple mastectomy with immediate reconstruction, mastectomy with sentinel node biopsy, modified radical mastectomy (unilateral or bilateral)
16352649|NCT04309916|Experimental|Tegoprazan 50mg|Tegoprazan 50mg tablet, once daily, oral administration
16352650|NCT04309916|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg tablet, once daily, oral administration
16352651|NCT04309903|Experimental|Manual Therapy|The experienced physiotherapist has applied manual therapy (MT) to the arthropathic joints. MT was started with myofascial release techniques (MRT), then continued with mobilization techniques using Kalternborn. Superficial MRT consisted of 3 strokes, via manual movement on the tissue, encourage release of the superficial fascia. In the Kalternborn mobilization technique, Grade I-II mobilization was applied with traction without using a strap. The same exercises given to the home exercise group were given to the patients in this group as well.
16352652|NCT04309903|Active Comparator|Home Exercise|The home exercises (HE) consisted of active ROM exercises, passive stretching exercises, progressive resistive exercises, weigh-bearing and stance exercises were performed by the patient for 30 minutes at home.
16352653|NCT04309890||Study group|
16352654|NCT04309877|Experimental|PO theophylline & IV LPS|Oral (PO) theophylline 400 mg/day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
16352655|NCT04309877|Experimental|PO placebo & IV LPS|PO methylcellulose (placebo) daily for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
16352656|NCT04309877|Experimental|PO theophylline & IV placebo|PO theophylline 400 mg/day for 2 weeks followed by a single IV bolus of 0.9% saline
16352657|NCT04309877|Placebo Comparator|PO placebo & IV placebo|PO methylcellulose (placebo) daily for 2 weeks followed by a single IV bolus of 0.9% saline
16352658|NCT04309864|No Intervention|Focus group-Veteran|Veterans will inform study staff regarding desired device design refinements
16352659|NCT04309864|No Intervention|Focus group-Clinicians|Clinicians will inform study staff regarding desired app design changes
16352660|NCT04309864|Other|Usability-inpatients|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
16352661|NCT04309864|Other|Usability-in-home|The Veteran will use the CMAP system at home for two weeks to use in their daily routines, along with wearing the acti-graph one week prior, two weeks during and one week after CMAP usage.
16352662|NCT04309825|Experimental|G-tube endoscopies patients|patients who will undergo an endoscopy through g-tube port
16352663|NCT04309812|Active Comparator|Short Stimulation|1 minute duration of stimulation per day for 30 days
16352664|NCT04309812|Experimental|Long Stimulation|30 minutes duration of stimulation per day for 30 days
16352665|NCT04309799|Other|Single 10 minute session|Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
16352666|NCT04309799|Other|Optional Extension|Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
16352667|NCT04309773|Experimental|Bezafibrate in addition to standard UDCA therapy|"Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (experimental arm)"
16352668|NCT04309773|Placebo Comparator|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy
16352669|NCT04309760|Active Comparator|gender dysphoria subjects|Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy
16352670|NCT04309760|Other|control subjects|Control group inclusions, of open-label patients without gender dysphoria.
16352671|NCT04309747|Experimental|nanosecond knife group|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
16352672|NCT04309734|Experimental|Part A - 60 mg AT-777 single dose|
16352673|NCT04309734|Experimental|Part A - 120 mg AT-777 single dose|
16352674|NCT04309734|Placebo Comparator|Part A - Placebo single dose|
16352675|NCT04309734|Experimental|Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks|
16352676|NCT04309721|Experimental|Perampanel|immediate enteral administration of Perampanel, 12 mg
16352677|NCT04309721|Placebo Comparator|Placebo|immediate enteral administration of placebo
16352678|NCT04309708|Experimental|Original Perfusor Line(Art.No.8723017)|
16352679|NCT04309708|Active Comparator|Original Perfusor Line(Art.No.8723010)|
16352680|NCT04309695|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
16352681|NCT04309682|Experimental|crestal sinus approach technique|Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
16352682|NCT04309682|Active Comparator|lateral sinus elevation technique|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take plac
16352683|NCT04309669|Experimental|Tot'hema|three ampoules per day during 12 weeks daily dose: 150mg of iron per day.
16352684|NCT04309656|Experimental|Panel 1: Pretomanid after meal|Each participant will receive four single-dose treatments. Panel 1 will receive a meal before dosing.
16352685|NCT04309656|Experimental|Panel 2: Pretomanid after fast|Each participant will receive four single-dose treatments. Panel 2 will fast before dosing.
16352686|NCT04309643|Experimental|CTP-543|In Period 1, participants will receive a single oral dose of the combination oral contraceptive (OC) on Day 1. There will be a washout period of 7 days between dosing in Period 1 and the first dose in Period 2. In Period 2, participants will receive twice daily oral doses of CTP-543 for 8 consecutive days with a single dose of the combination OC co-administered on Day 4.
16352687|NCT04309630|Active Comparator|intercostal block|patients received intercostal block will be evaluated by visual analog score for pain assesment
16352688|NCT04309630|Experimental|erector spina plane block|patients received erector spina plane block will be evaluated by visual analog score for pain assesment
16352689|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
16352690|NCT04309578|Experimental|treatment arm|Single arm
16352691|NCT04309565|Active Comparator|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
16352692|NCT04309565|Experimental|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
16352693|NCT04309552|Experimental|High Grade Glioma (HGG)|Thirty newly diagnosed treatment-naïve subjects with suspected HGG based on clinical presentation and MRI findings and undergoing surgical planning will be accrued in this study.
16352694|NCT04309539|Active Comparator|Fascia iliaca block|Patients will receive Fascia iliaca block
16352695|NCT04309539|Active Comparator|combined LFCN block with PENG block|Patients will receive a combined lateral femoral cutaneous nerve block with pericapsular nerve group block
16352696|NCT04309526|Experimental|NCO-48 Fumarate|NCO-48 Fumarate
16352697|NCT04309526|Placebo Comparator|Placebo|Placebo Comparator
16352698|NCT04309513|Active Comparator|Step Counter to motivate physical activity|Participants will be encouraged to work up to achieving at least 10,000 steps a day, higher if possible and reasonable, as measured by a wearable device.
16352699|NCT04309513|Experimental|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device.
16352700|NCT04309500|Experimental|African-American Participant-Co-Participant Dyads|5 Non-Hispanic African-American participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT).
16352701|NCT04309500|Experimental|White Participant-Co-Participant Dyads|5 Non-Hispanic White participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT)
16352702|NCT04309487||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
16352705|NCT04309461|Active Comparator|Stress Management Group|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
16352706|NCT04309461|Experimental|Adapted MBC2 Group|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
16352707|NCT04309448|Experimental|Perturbation-based balance training with FES|
16352708|NCT04309435|Experimental|Self-esteem intervention|"The self-esteem intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:
~Engagement and listening
~Positive regard and empathy
~Collaboration
~Development of a shared understanding of low self-esteem (a 'psychological formulation')
~Provision of written or audio-visual information relating to low self-esteem
~Between-session activity for participant
~Provision of structured self-help material relating to low self-esteem
~Testing of beliefs related to low self-esteem
~Practicing new strategies related to low self-esteem
~Development of a shared plan to maintain gains in self-esteem"
16352709|NCT04309435|Placebo Comparator|Self-esteem control group|'Assessment and support' for participants with low self-esteem will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
16352710|NCT04309435|Experimental|Self-stigma intervention|"The self-stigma intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:
~Engagement and listening
~Positive regard and empathy
~Collaboration
~Development of a shared understanding of high self-stigma (a 'psychological formulation')
~Provision of written or audio-visual information relating to self-stigma
~Between-session activity for participant
~Provision of structured self-help material relating to self-stigma
~Testing of beliefs related to self-stigma
~Practicing new strategies related to self-stigma
~Development of a shared plan to maintain reductions in self-stigma"
16352711|NCT04309435|Placebo Comparator|Self-stigma control group|'Assessment and support' for participants with high self-stigma will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
16352712|NCT04309435|Experimental|Jumping to conclusions intervention group|"The 'jumping-to conclusions' (JTC) intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:
~Engagement and listening
~Positive regard and empathy
~Collaboration
~Development of a shared understanding of role of JTC (a 'psychological formulation')
~Provision of written or audio-visual information relating to JTC
~Between-session activity for participant
~Provision of structured self-help material relating to JTC
~Testing of beliefs related to JTC
~Practicing new strategies related to reducing JTC
~Development of a shared plan to maintain reductions in JTC"
16352743|NCT04309214|Experimental|MCT fats|MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption.
16352744|NCT04309188|Experimental|Stroboscopic Training Group|Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
16353276|NCT04305509||LDH patients|Patients with lumbar disc herniation which was treated with manual therapy
16352713|NCT04309435|Placebo Comparator|Jumping to conclusions control group|'Assessment and support' for participants who demonstrate the JTC bias will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
16352714|NCT04309422||Overexpression of PDL1|Overexpression of PDL1
16352715|NCT04309422||Absence of overexpression of PDL1|Absence of overexpression of PDL1
16352716|NCT04309409|Experimental|Nivolumab (Arm A)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):
~Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines."
16352717|NCT04309409|No Intervention|Observation, High Risk (Arm B)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):
~Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines."
16352718|NCT04309409|No Intervention|Observation, Low Risk (Arm C)|"Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization:
~These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients."
16352719|NCT04309396|Experimental|Breath analyzer|Candidates who, after the screening period are eligible to receive the AIRE device.
16352720|NCT04309383||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
16352721|NCT04309370|Experimental|20 Hz rTMS targeting the LDLPFC|
16352722|NCT04309370|Experimental|20 Hz rTMS targeting the LSPC|
16352723|NCT04309344|Experimental|RF|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage
16352724|NCT04309344|Active Comparator|Control|The mechanical shaver is used to remove superficial fibrillations.
16352725|NCT04309331|Experimental|PKU Motion|amino acid based protein substitute
16352726|NCT04309318||Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
16352727|NCT04309318||High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
16352731|NCT04309292|Experimental|Treatment Arm|protein supplementation plus prebiotic supplementation
16352732|NCT04309292|Placebo Comparator|Placebo Arm|Protein supplementation plus placebo
16352733|NCT04309279|Experimental|Zentangle group|
16352734|NCT04309279|No Intervention|Wait-list Control Group|
16352735|NCT04309266|Experimental|Robot Assisted Therapy with Metacognitive Skills Training|All participants will be enrolled in the single arm of this study, where they will receive robot assisted therapy combined with metacognitive skills training.
16352736|NCT04309253|Other|PMPBB3|"Primary endpoint(s):
~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.
~Secondary endpoints:
~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
16352737|NCT04309253|Other|AV45|"Primary endpoint(s):
~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.
~Secondary endpoints:
~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
16352738|NCT04309240|Experimental|rivaroxaban|oral Rivaroxaban 10mg per day for 90days
16352739|NCT04309240|No Intervention|blank control|mechanical prophylaxis
16352740|NCT04309227|Experimental|Traditional High-Intensity Training|Participants will perform their training at ~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
16352741|NCT04309227|Experimental|Low Intensity plus Blood Flow Restriction Training|Participants will perform their training at ~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
16352742|NCT04309227|No Intervention|Control|Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.
16352745|NCT04309188|Active Comparator|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
16352748|NCT04309162|Experimental|soft tissue therapy|Soft tissue therapy includes various techniques which is usually done by manipulating the soft tissues. The techques like stroking, petrissage, percussing maniulations are proved helpful in managing various painful conditions. The main effect of the soft tissue therapy is enhanced blood circulation to the area. When the techniques of soft tissue therapy are applied they will results in stretching and rubbing the muscular tissue which results in increased venous flow to heart and removal of the lactic acid accumulation occurs as the fresh supply of blood to the area will increased. Endorphins the natural pain relievers are released as there is improved oxygenation and perfusion of oxygen in tissues.
16352749|NCT04309149|Experimental|MCT fats|Kanso MCT oils and margarine will be consumed daily for 7 days each to assess tolerability and compliance
16352750|NCT04309136|Experimental|Neoadjuvant Anlotinib|
16352751|NCT04309123|Experimental|Treatment|TransAeris stimulation therapy adjunctive to continued mechanical ventilation will begin 24 hours after leaving the operating room, if subject remains on mechanical ventilation. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.
16352752|NCT04309110|No Intervention|Standard care with geko™ T3 device|Current geko™ device incorporating hydrogel adhesive designated KM10T
16352753|NCT04309110|Active Comparator|geko™ X-T3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
16352754|NCT04309097|Experimental|Digital intervention|Participants will have access to a live-streaming App that offers Recess and Exercise Advocate Program (REAP).
16352755|NCT04309097|Active Comparator|Information-only intervention|Participants will have access to health information only.
16352756|NCT04309084|Experimental|Phase I|Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
16352757|NCT04309071|Experimental|Salivary insulin responses to mixed meal tolerance test|Saliva samples and finger prick glucose will be collected after at least 4 hours of fasting and then at 60 and 90 minutes following ingestion of a standardized meal tolerance test.
16352758|NCT04309058|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
16352759|NCT04309058|No Intervention|Control|The other group do not interfere.
16352760|NCT04309045|Experimental|DBT|Standard DBT treatment
16352761|NCT04309045|Active Comparator|DDP|dynamic deconstructive psychotherapy (DDP) treatment, is part of a trend of dynamic therapies to treat borderline personality disorder. DDP is a treatment specifically developed for a population with more severe symptoms those dealing with borderline personality disorder.
16352762|NCT04309045|Placebo Comparator|control group|patients on the waiting list for treatment, or patients in the hospital under routine care. Which will form the control group.
16352763|NCT04309032|Experimental|Bladder fill|Retrograde bladder filling of 250cc of 0.9% normal saline for irrigation prior to removal of foley catheter
16352764|NCT04309032|No Intervention|No bladder Fill|no filling prior to removal of foley catheter
16352765|NCT04309006|Experimental|CTG and customized healing abutment|Customized healing abutment used with connective tissue graft
16352766|NCT04309006|Experimental|CTG and conventional healing abutment|Conventional healing abutment (same diameter of the implant) used with connective tissue graft
16352767|NCT04309006|Active Comparator|customized healing abutment|Customized healing abutment used without connective tissue graft
16352768|NCT04309006|Active Comparator|conventional healing abutment|Conventional healing abutment (same diameter of the implant) without connective tissue graft
16352769|NCT04308980|Experimental|Active treatment|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use specialized medical nutrition product together with diet based on the measured individual requirements in energy and protein intake.
16352770|NCT04308980|Placebo Comparator|Control group|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use masked placebo together with diet based on the measured individual requirements in energy and protein intake.
16352771|NCT04308967|Experimental|Balance exercises and information|Balance exercises six weeks and three days in a week and information about central sensitisation.
16352772|NCT04308967|No Intervention|Information|Information about central sensitisation.
16352773|NCT04308954|Experimental|Fragile X Syndrome|Adult males aged 18-30 years diagnosed with FXS will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
16352774|NCT04308954|Experimental|Idiopathic Intellectual Developmental Disorder|Adult males aged 18-30 years diagnosed with idiopathic intellectual developmental disorder will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
16352775|NCT04308941|Active Comparator|Scleral Tonopen|The first 10 subjects will be randomly chosen for the first cohort (scleral TonoPen)
16352776|NCT04308941|Active Comparator|Scleral Pneumatonometer|The second 10 subjects will be randomly chosen for the second cohort (scleral pneumatonometry)
16352777|NCT04308941|Active Comparator|Diaton|The third 10 subjects will be randomly chosen for the third cohort (Diaton).
16352778|NCT04308928||Children with suspected meningitis|Patients must have a clinical diagnosis of meningitis including one or more of the following symptoms: headache, irritability, vomiting, fever and neck stiffness (Table 1). The diagnosis of probable or possible TBM is based on 1) clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside the central nervous system and 5) additional laboratory criteria. A scoring system then determines whether a patient falls in the probable or possible TBM category. Points are allocated for a positive finding in each of the categories, with a maximum score for each category. A total score of at least 10 is compatible with probable TBM, while a total score of at least 6 equates with a possible TBM diagnosis.
16352779|NCT04308928||Children with definite tuberculous meningitis|Definite TBM requires demonstration of acid- fast bacilli in the CSF, Mycobacterium tuberculosis culture from CSF, a positive nucleic acid amplification test (PCR) of CSF or histopathological evidence of Mycobacterium tuberculosis from a central nervous system site.
16352780|NCT04308915|Experimental|Game-based training|Participants play games for cognitive training
16352781|NCT04308902||Children previously enrolled in the OptiMoM Fortifier Study|This is an observational study of children who were previously enrolled in a trial (Bovine vs. Human Milk-Based Fortifier Study) between 2014 and 2016 during which time they were randomized to have their feeds (mother's own milk or pasteurized donor breastmilk) nutrient enriched with a human milk-based fortifier or a bovine protein-based fortifier.
16352782|NCT04308902||Term-born Comparison|This is an observational study of children born at full term (>= 37 weeks gestation) and weighing more than 2500g. These children will be recruited from the communities in which the OptiMoM participants live.
16352783|NCT04308889|Active Comparator|Without Supplementation|No planned dietary supplementation
16352784|NCT04308889|Experimental|With Supplementation|The subject will take 4 capsules (1gram each) of Lovaza daily at 8pm, starting the evening before blister induction and continuing until the second blister fluid has been removed.
16352785|NCT04308876|Experimental|Manual therapy and strengthening exercises|Manual therapy and strengthening exercises were applied totally 15 sessions for 5 weeks 3 times a week in hospital by physiotherapist.
16352786|NCT04308876|Active Comparator|Strengthening exercises|Patients in this group performed the strengthening exercises given to the experimental group on their own at home with experimental group at the same time, frequency and dose.
16352787|NCT04308863|Experimental|Chitosan scaffold/ MTA pulp dressing material|
16352788|NCT04308863|Active Comparator|MTA pulp dressing material|
16352789|NCT04308850|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
16352790|NCT04308850|No Intervention|Control|The other group do not interfere.
16352791|NCT04308837|Experimental|Patients With Local Regional Advanced Gastric Cancer|Patients with local regional advanced gastric cancer after at least 4 weeks post diagnostic laparoscopy and HIPEC, will receive all of the treatments described in the study protocol.
16352792|NCT04308824|Active Comparator|Clipping|Prophylactic endoscopic clip will be placed after polypectomy
16352793|NCT04308824|Experimental|Cyanoacrilate|A solution of Cyanoacrilate will be nebulized after the placement of prophylactic clip
16352794|NCT04308811|Other|platelet rich plasma group|intrauterine platelet rich plasma injection and intrauterine balloon insertion after hysteroscopic lysis of intrauterine adhesions
16352795|NCT04308811|Other|amniotic membrane graft group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon covered by freeze-dried amniotic membranes.
16352796|NCT04308811|Other|intrauterine balloon group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon
16352797|NCT04308798|Experimental|Control group|No surgical glove changing during total knee arthroplasty procedure
16352798|NCT04308798|Experimental|Treatment 1 group|Changing surgical glove after draping and before cementation during total knee arthroplasty procedure
16352799|NCT04308798|Experimental|Treatment 2 group|Changing surgical glove before cementation during total knee arthroplasty procedure
16352802|NCT04308772|No Intervention|Usual Care|Those randomised to the usual care arm will receive a leaflet which contains a standard programme of exercises Participants will be asked to complete their exercise programme as prescribed (at least once per day).
16352803|NCT04308772|Experimental|Web-based physiotherapy|Participants will receive a six week exercise programme, based on those in the usual care exercise sheet delivered via the web-based physio website (www.giraffehealth.com).
16352804|NCT04308759|Experimental|Group I (Quitbot)|Participants participate in the Quitbot program which involves prompted, focused conversations for 42 days. Therapy description withheld to protect the integrity of the study.
16352805|NCT04308759|Active Comparator|Group II (Texting)|Participants participate in texting program over 42 days where they receive messages to support quitting smoking. Therapy description withheld to protect the integrity of the study.
16352806|NCT04308746|Experimental|Individualistic|Participants write 3 statements to 3 questions relating to his/her differences from his/her immediate community
16352807|NCT04308746|Experimental|Collectivistic|Participants write 3 statements to 3 questions relating to his/her similarities with his/her immediate community
16352808|NCT04308733|Active Comparator|real tDCS|30 patients will be treated with real anodal tDCS over the contralateral pharyngeal motor cortex
16352809|NCT04308733|Sham Comparator|sham tDCS|30 patients will be treated with sham tDCS over the contralateral pharyngeal motor cortex
16352810|NCT04308707||Surgical specialties|
16352811|NCT04308707||Anesthesiology|
16352812|NCT04308694|Experimental|Pharmacy-based methadone treatment|Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.
16352813|NCT04308681|Experimental|IPF Dose 1 + Post Treatment Follow-up or OTE|IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
16352814|NCT04308681|Experimental|IPF Dose 2 + Post Treatment Follow-up or OTE|
16352815|NCT04308681|Placebo Comparator|IPF Placebo + Post Treatment Follow-up or OTE|
16352816|NCT04308681|Experimental|PF-ILD Dose 1 + Post Treatment Follow-up or OTE|PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
16352817|NCT04308681|Experimental|PF-ILD Dose 2 + Post Treatment Follow-up or OTE|
16352818|NCT04308681|Placebo Comparator|PF-ILD Placebo + Post Treatment Follow-up or OTE|
16352819|NCT04308668|Experimental|Treatment|Participants in this arm will receive the study drug.
16352820|NCT04308668|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
16352821|NCT04308655||Patient participants|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until five days postpartum.
16352822|NCT04308655||Provider participants|This cohort will include clinicians who provide care for pregnant patients with OUD. Providers will be interviewed and will complete one survey cross-sectionally.
16352823|NCT04308629|Experimental|tDCS over PMAs|One session of transcranial direct current stimulation (tDCS) over premotor areas (PMAs)
16352824|NCT04308629|Active Comparator|tDCS over M1|One session of transcranial direct current stimulation (tDCS) over primary motor area (M1)
16352825|NCT04308616||Psoriasis|Patients with psoriasis
16352826|NCT04308603|Experimental|pregnant patient whose fetuses have an antenatal NIH|All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
16352827|NCT04308590|Experimental|Relacorilant|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
16352828|NCT04308590|Placebo Comparator|Placebo|Placebo matched to study drug
16352829|NCT04308577|Experimental|Ketogenic diet with MCT|Ketogenic Diet supplemented with MCT everyday for 6 weeks.
16352830|NCT04308551|Experimental|Indobufen|200 mg Indobufen, bid po, 90 days
16352831|NCT04308551|Active Comparator|Aspirin|100 mg Aspirin, qd po, 90 days
16352832|NCT04308538|Active Comparator|Standard Recession|Bilateral lateral rectus muscle recession using standard tables stated by Parks.
16352833|NCT04308538|Experimental|Reduced Recession|Bilateral lateral rectus muscle recession using reduced numbers by one millimeter than the standard tables.
16352834|NCT04308525||ERAS Group|Prospectively included patients after introduction of an ERAS programme
16352835|NCT04308525||Control group|We retrospectively evaluated our procedures for the period 2014-2016
16352836|NCT04308512|Experimental|Intervention Group (IG): Care coordination with Care4AD system|All participants will receive Care4AD device.All reminders will be activated in the intervention group (IG). Essential activity daily living (ADL) tasks will be pre-programmed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
16352837|NCT04308512|No Intervention|Control Group (CG): Standard of care|Participants in control group (CG) will also receive Care4AD device. However, all reminders and programming of activity daily living (ADL) tasks will be de-activated in the CG.
16352838|NCT04308499|Experimental|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions
16352839|NCT04308499|Active Comparator|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions
16352840|NCT04308473|Experimental|Arm 1: Ultra-processed Meal + Antibiotics to supress gut flora|Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
16352841|NCT04308473|Experimental|Arm 2: Ultra-processed Meal + No Antibiotics|Subjects in Arm 2 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of ultra-processed foods.
16352842|NCT04308473|Experimental|Arm 3: Whole Food Meal + Antibiotics to supress gut flora|Subjects in Arm 3 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of whole, unprocessed foods.
16352843|NCT04308473|Experimental|Arm 4: Whole Food Meal + No Antibiotics|Subjects in Arm 4 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of whole, unprocessed foods.
16352844|NCT04308460|Active Comparator|arthrocentesis group|the group of internal derangement patients which was treated with arthrocentesis procedure
16352845|NCT04308460|Active Comparator|operative arthroscopy group|the group of internal derangement patients which was treated with operative arthroscopy procedure
16352846|NCT04308447|Experimental|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
16352847|NCT04308434|Experimental|CSD190601-11|Subjects will self-assign to flavor variant CSD190601-11 of 1.5% ENDS products based on their preferred flavor.
16352848|NCT04308434|Experimental|CSD190601-12|Subjects will self-assign to flavor variant CSD190601-12 of 1.5% ENDS products based on their preferred flavor.
16352849|NCT04308434|Experimental|CSD190601-13|Subjects will self-assign to flavor variant CSD190601-13 of 1.5% ENDS products based on their preferred flavor.
16352850|NCT04308434|Experimental|CSD190601-14|Subjects will self-assign to flavor variant CSD190601-14 of 1.5% ENDS products based on their preferred flavor.
16352851|NCT04308434|Experimental|CSD190601-15|Subjects will self-assign to flavor variant CSD190601-15 of 1.5% ENDS products based on their preferred flavor.
16352852|NCT04308434|Experimental|CSD190601-16|Subjects will self-assign to flavor variant CSD190601-16 of 1.5% ENDS products based on their preferred flavor.
16352853|NCT04308434|Experimental|CSD190601-17|Subjects will self-assign to flavor variant CSD190601-17 of 1.5% ENDS products based on their preferred flavor.
16352854|NCT04308434|Experimental|CSD190601-21|Subjects will self-assign to flavor variant CSD190601-21 of 3.0% ENDS products based on their preferred flavor.
16352855|NCT04308434|Experimental|CSD190601-22|Subjects will self-assign to flavor variant CSD190601-22 of 3.0% ENDS products based on their preferred flavor.
16352856|NCT04308434|Experimental|CSD190601-23|Subjects will self-assign to flavor variant CSD190601-23 of 3.0% ENDS products based on their preferred flavor.
16352857|NCT04308434|Experimental|CSD190601-24|Subjects will self-assign to flavor variant CSD190601-24 of 3.0% ENDS products based on their preferred flavor.,
16352858|NCT04308434|Experimental|CSD190601-25|Subjects will self-assign to flavor variant CSD190601-25 of 3.0% ENDS products based on their preferred flavor.
16352859|NCT04308434|Experimental|CSD190601-26|Subjects will self-assign to flavor variant CSD190601-26 of 3.0% ENDS products based on their preferred flavor.
16352860|NCT04308434|Experimental|CSD190601-27|Subjects will self-assign to flavor variant CSD190601-27 of 3.0% ENDS products based on their preferred flavor.
16352861|NCT04308421|Experimental|Low level red light/laser|Patients will be treated twice a week for 12 weeks with low irradiation 650 nm +/- 5 nm red light on one randomly allocated side of the face or body
16352862|NCT04308421|No Intervention|Control side|An affected area on the contralateral side of the face or body or within a single patch will not be treated
16352863|NCT04308408|Active Comparator|Mexican Guideline Daily Allowance (GDA)|Guideline Daily Amounts (GDA) is a purely numerical and reductive labeling system, indicates the grams and percentages (according to the guideline-based daily intakes) per portion of kilocalories, saturated fats, other fats, sugars, and sodium, with no specific judgement, opinion or recommendation.
16352864|NCT04308408|Experimental|Ecuador's Multiple Traffic Light (MTL)|Multiple traffic light labels, an interpretive nutrient-specific FOP label, use the typical traffic light colors (green, yellow/amber, red) and text descriptors to indicate the high, medium, or low content of total fat, sugar and salt.
16352865|NCT04308408|Experimental|Chilean Warning Labels in Red|Warning Labels (WL), another nutrient-specific interpretive FOP labelling scheme, include 'high in' symbols for products that exceed limits of energy, sodium, sugar and saturated fat.
16352866|NCT04308395|Experimental|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
16352867|NCT04308369|Other|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
16352868|NCT04308343|Active Comparator|Methotrexate group|
16352869|NCT04308343|Active Comparator|Letrozole group|
16352870|NCT04308343|Active Comparator|Gonadotropins releasing hormone antagonist group|
16352871|NCT04308330|Experimental|Vorinostat|"The first cycle of chemotherapy will not include the experimental agent vorinostat. This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT.
~Cycle 1
~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.
~Temozolomide: 125 mg/m2/day PO Days 1-5.
~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.
~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.
~Cycles 2-12
~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.
~Temozolomide: 125 mg/m2/day PO Days 1-5.
~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.
~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.
~Vorinostat: Dose per escalation schema daily Days 1-5.
~Vorinostat will not be administered during Cycle 1."
16352872|NCT04308317|Experimental|Tetrandrine Cohort|"After the subjects were enrolled, they were given Tetrandrine 60mg QD for a course of 1 week(Take 6 days, stop using for 1 day)"
16352873|NCT04308317|No Intervention|Control Cohort|Treatment according to standard protocols without intervention
16352876|NCT04308291||MiniMed™ 780G System|Subject will use the MiniMed™ 780G System as per standard of care.
16352877|NCT04308278|Experimental|2LEBV® / 2LXFS®|6 months of treatment
16352878|NCT04308278|Placebo Comparator|Placebo|6 months of treatment
16352879|NCT04308252||Pharmaco-resistant epilepsy (PRE)|Pharmaco resistant patients are defined by seizures despite adequate dosing of ≥2 anticonvulsant drugs.
16352880|NCT04308252||Pharmaco-sensitive epilepsy (PSE)|Pharmaco-sensitive patients are defined by no seizures for 6 months.
16352881|NCT04308252||Sibling control|Sibling of the of the PRE study participants.
16352882|NCT04308239|Experimental|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.
~Reactive balance training involved both slip and trip training.
~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.
~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
16352883|NCT04308239|Active Comparator|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.
~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
16352884|NCT04308226|No Intervention|Usual care without patient navigation|Participants assigned to this arm will be given basic educational materials on general lung health and referred back to their primary care provider (PCP) for management as per usual practice.
16352885|NCT04308226|Experimental|Usual care with patient navigation|Participants assigned to this arm will be informed about lung cancer screening (LCS), provided educational materials on LCS and patient navigation, and offered access to an LCS navigator who will partner with participants and primary care providers (PCPs) to facilitate low-dose computed tomography (LDCT) completion and follow-up.
16352886|NCT04308213|Experimental|Bone Marrow aspirate|All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit.
16352887|NCT04308200|Other|CO-OP+NDT group|The CO-OP+NDT group received twelve sessions of CO-OP approach, with the baseline and end of treatment assessments, each lasting approximately one hour. Parents and / or caregivers were advised to observe sessions as often as possible to encourage adaptation and transfer to life. Furthermore, CO-OP+NDT group received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist.
16352888|NCT04308200|Other|NDT group|NDT group received just NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity and postural reactions.
16352889|NCT04308174|Experimental|Durvalumab + Gem/Cis|"<Investigational arm: preoperative phase (up to 4 cycles)> Durvalumab 1,500 mg IV on Day 1, every 3 weeks (preop period) 1,500 mg IV Day 1, every 4 weeks (postop period) Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks
~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
16352890|NCT04308174|Active Comparator|Gem/Cis|"<Control arm: preoperative phase (up to 4 cycles)> Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks
~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
16352891|NCT04308161|Experimental|vitamin D oral gel|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks.
~Topical oral Vitamin D gel is prepared with the aid of pharmaceutics department, faculty of pharmacy, Alexandria University. It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation."
16352892|NCT04308161|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Dose: Three times a day for six weeks"
16352893|NCT04308161|Experimental|combination therapy|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks in combination with the symptomatic treatment
~Symptomatic treatment which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Symptomatic treatment dose: Three times a day for six weeks"
16352894|NCT04308135||vascular parkinsonism|the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
16352895|NCT04308135||Parkinson's disease|50 patients diagnosed as Parkinson Disease
16352896|NCT04308135||Controls|30 healthy controls.
16352897|NCT04308122|Active Comparator|Cervical Orthosis (CO)|Cervical orthosis will be worn at all times for 6 weeks according the standard of care after posterior cervical fusion
16352898|NCT04308122|Experimental|No Orthosis (NO)|No cervical orthosis will be worn after posterior cervical fusion
16352899|NCT04308109|No Intervention|Control|No intervention, the same as the current state of education. Caregivers will still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
16352900|NCT04308109|Experimental|Active study|In addition to the current state of education, the active study group will undergo highly realistic simulation. This involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers will complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
16352901|NCT04308109|Active Comparator|Active control|In addition to the current state of education, the active control will undergo low-fidelity simulation that approximates the highly realistic clinical scenarios except with the use of a low-fidelity doll equipped with a tracheostomy and without the audiovisual inputs. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
16352902|NCT04308096|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks (adult) 2 weeks (pediatric)
16352903|NCT04308083|Active Comparator|convergent neck|Group A Sweden & Martina Prama (P). Transgingival tapering machined collar, 2.8 mm in height.
16352904|NCT04308083|Sham Comparator|divergent neck|Group B Straumann Tissue Level (TL). Transgingival widening polished collar, 1.8 mm in height.
16352905|NCT04308070|Experimental|Catheter without Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter without hemostatic agent
16352906|NCT04308070|Experimental|Catheter with Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter with hemostatic agent
16352907|NCT04308057||Aquatic Exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in swimming or other aquatic, primarily aerobic-based, training regimes for more than 2 times a week, for more than 6 months, at the time of the assessments.
16352908|NCT04308057||Land-based exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in land-based, primarily aerobic training regimes (e.g. aerobic exercise) for more than 2 times a week, for a period longer than 6 months, at the time of the assessments.
16352909|NCT04308057||Mixed exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in both land-based and aquatic, primarily aerobic, exercise regimes on an equal basis, for more than 6 months.
16352910|NCT04308057||Sedentary.|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants who are sedentary (e.g., defined as undertaking less than 60 min of structured/planned physical activity per week), for a period longer than 6 months.
16352911|NCT04308044||Chronic MSK Pain|Participants who have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), and psychological state via the completion of questionnaires by the patient.
16352912|NCT04308044||Healthy Control|Participants who do not have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), insole assessment (40 healthy control participants), and psychological state via the completion of questionnaires by the patient.
16352913|NCT04308031|Experimental|Ivabradine|Subject will be randomly assigned to either Ivabradine or Digoxin group. Ivabradine starting dose is 2.5 mg twice daily(BID). ECG will be performed at each visit during the treatment phase and dose will be adjusted based on the heart rate result from the ECG. Total treatment phase is 16 weeks ( 4 months).
16353037|NCT04307212|Active Comparator|Trained|Participants who have been CrossFit training at least 3 times per week for the previous 3 months. These individuals will be invited in person to participate in the study.
16352914|NCT04308031|Active Comparator|Digoxin|Subject will be randomly assigned to either Ivabradine or Digoxin group. Digoxin starting dose is 0.125mg once daily(QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60. Dose adjustment will be based on heart rate result from ECG performed at each treatment visit and Digoxin level from blood sample collected from each visit during treatment phase. Total treatment phase is 16 weeks ( 4 months).
16352915|NCT04308018|Active Comparator|S1|Caudal end of the instrumentation at S1
16352916|NCT04308018|Active Comparator|S2alar-iliac|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
16352917|NCT04307992|Experimental|Intervention|Device: ANEUFIX
16352918|NCT04307979|Experimental|Bulletproof Coffee|A black coffee (bullet proof coffee keurig pod) with 29 grams of added fat (1 tablespoon bullet proof brain octane medium chain triglyceride oil, and 1 tablespoon bullet proof grass fed ghee) blended for 20 seconds with butter scent that is added to the lid.
16352919|NCT04307979|Placebo Comparator|Black Coffee|Black coffee that is blended for 20 seconds with butter scent added to the top of the lid.
16352920|NCT04307966||Intervention|537 pre-adolescent grade 6 learners and their parent (n=537) were invited to participate. Trained educators delivered lessons about HIV and obesity to all Grade 6 students at 5 government-run schools. The classroom curriculum for students required delivery of a five-hour face-to-face intervention delivered weekly through 10 30-minute lessons. Students were asked to communicate their learnings to their parents at home. Parents were requested to read through the lesson in a workbook and to sign acknowledgement that they had read the content. The workbook contained shared student-parent homework activities that took approximately 30 minutes per week. Data was only collected from Learners (n=425) and parents (n= 427)who had consented to the study. A pretest was conducted. The intervention was then implemented. A posttest was conducted afterwards. Both parents and learners answered self-reported questionnaires.
16352921|NCT04307953|Experimental|AZD0530|
16352922|NCT04307953|Experimental|Placebo/AZD0530|
16352923|NCT04307940|Experimental|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
16352924|NCT04307940|Active Comparator|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
16352925|NCT04307940|Placebo Comparator|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
16352926|NCT04307914|Active Comparator|External Beam Radiotherapy|In the control arm, patients will undergo standard radiotherapy for painful bone metastases.The radiation schedule is at the discretion of the treating radiation oncologist.
16352927|NCT04307914|Experimental|MR-HIFU|In the intervention arm, patients will be offered MR-HIFU treatment instead of standard radiotherapy. Treatment will be given following the international guidelines for MR-HIFU.
16352928|NCT04307914|Experimental|Combination EBRT + MR-HIFU|In the combination arm, patients will undergo standard radiotherapy followed by MR-HIFU in a short timeframe.
16352929|NCT04307901||Incomplete colonoscopy|Individuals referred to colon capsule endoscopy due to incomplete colonoscopy investigation.
16352930|NCT04307901||Colonoscopy general anesthesia|Individuals referred to colon capsule endoscopy as alternative to colonoscopy under general anesthesia.
16352931|NCT04307901||Colonoscopy declined|Individuals referred to colon capsule endoscopy after completion of bowel preparation for colonoscopy, but who have declined colonoscopy to be carried out.
16352932|NCT04307888||Study group|Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.
16352933|NCT04307875||Rohingya refugee camp population|A sample of 1500 randomly selected individuals aged 18 years and above living in the Rohingya refugee camp 1E.
16352934|NCT04307875||Shamlapur refugee hosting community population|A sample of 1500 randomly selected individuals aged 18 years and above living in the refugee hosting community Shamlapur neighbouring the Rohingya refugee camps.
16352935|NCT04307862|Experimental|ZEP-3Na 0.1%|The ZEP-3Na 0.1% cream will be applied topically twice daily
16352936|NCT04307862|Experimental|ZEP-3Na 1%|The ZEP-3Na 1% cream will be applied topically twice daily
16352937|NCT04307862|Placebo Comparator|Vehicle Control|The Vehicle Control cream will be applied topically twice daily
16352940|NCT04307836|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
16352941|NCT04307836|No Intervention|Control group|Subjects are not treated with the renal denervation, not sham, after randomization and maintained baseline anti-hypertensive medications
16352942|NCT04307823|Active Comparator|Treadmill training group|Treadmill training according to American College of Sports Medicine's guidelines
16352943|NCT04307823|Experimental|Treadmill protocol and respiratory training group|Treadmill training, slow breathing training and incentive spirometry
16352944|NCT04307784|Experimental|Vitamin D3 alone Group|Treated with VD3 (50.000 IU/week)
16352945|NCT04307784|Experimental|Omaga-3 alone Group|Treated with (1000 mg) wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
16352946|NCT04307784|Experimental|Vitamin D3 and Omega-3 Combination, Group|Treated with 50.000 IU VD3 per week and 1000 mg wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
16352947|NCT04307784|Experimental|Control Group|No intervention was given.
16352948|NCT04307771|Experimental|m-health application|a mobile app designed to send reminders for brushing and give information on maintaining oral health
16352949|NCT04307771|Other|Leaflet|This is the control arm. An educational leaflet for maintaining oral hygiene will be given to participants in this arm
16353109|NCT04306679|Other|Control|Children underwent the routine pre-operative preparations, which included a section on pain assessment.
16353110|NCT04306666||Walant group|Walant group
16352950|NCT04307758||Healthy Adults|Healthy subjects aged 18-35 years were enrolled in this study. The muscle strength assessment of the foot intrinsic muscles was assessed with the make test and the break test. The tests were performed with the hip and knee semiflexed in prone position with a hand-held dynamometer. The experimental protocols and methods were explained in detail to all subjects. All participants provided written informed consent in keeping with the ethical principles of the Declaration of Helsinki.
16352951|NCT04307745||Physiotherapist|
16352952|NCT04307745||Doctor|
16352953|NCT04307745||Physical trainer|
16352954|NCT04307745||Trainer|
16352955|NCT04307719||Mexican Jewish Community|Sample of Patients from the Mexican Jewish Community to be subjected to genetic testing
16352956|NCT04307706|Experimental|Intervention group|''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group
16352957|NCT04307706|No Intervention|Control group|Only data collection was carried out. No attempt was made by the researcher during the study.
16352958|NCT04307693|Experimental|Lopinavir/ritonavir|Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
16352959|NCT04307693|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
16352960|NCT04307693|No Intervention|Control|No lopinavir/ritonavir and hydroxychloroquine
16352961|NCT04307680|Active Comparator|Kegel exercise|Using high-intensity Kegel exercise regimen for 8 weeks (5 times a week; 3 times a day involved; 3 sets of 10-12 contractions)
16352962|NCT04307680|Active Comparator|Magnetic stimulation|Using 16 extracorporeal magnetic innervation treatments during 8 weeks (2 times a week).
16352963|NCT04307641|Experimental|Intervention|Pharmacists who received in the intervention.
16352964|NCT04307641|No Intervention|Control|Pharmacists who did not received in the intervention.
16352965|NCT04307628|Active Comparator|Walnut|Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
16352966|NCT04307628|Placebo Comparator|Nut-Free|Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
16352967|NCT04307615|Experimental|Oxygen + CPAP-treatment|
16352968|NCT04307615|Active Comparator|Oxygen-treatment|
16352969|NCT04307602|Experimental|Children with cerebral palsy GMFCS IV-V|Exercise intervention in the waling aide Innowalk
16352970|NCT04307602|Active Comparator|Children with cerebral palsy GMFCS I-II|Exercise intervention on spinning bikes
16352971|NCT04307602|Active Comparator|Children without disabilities|Exercise intervention on spinning bikes
16352972|NCT04307589||Caregiving grandparents|
16352973|NCT04307589||Non-caregiving grandparents|
16352974|NCT04307589||Middle-aged and older adults not being a grandparent|
16352975|NCT04307576|No Intervention|R1 - SR standard arm|Standard risk arm receiving standard treatment (Delayed Intensification including Doxorubicin).
16352976|NCT04307576|Experimental|R1 - SR experimental arm|Standard risk arm, receiving Delayed Intensification without Doxorubicin IV 3 x 30 mg/m2/dose.
16352977|NCT04307576|No Intervention|R2 - IR-low standard arm|Standard treatment with Delayed Intensification including Doxorubicin and Maintenance including Vincristine+Dexamethasone pulses.
16352978|NCT04307576|Experimental|R2 - IR-low experimental arm A|Standard treatment with omission of Doxorubicin IV 3 x 30 mg/m2/dose in the Delayed Intensification phase.
16352979|NCT04307576|No Intervention|R3 - IR-high standard arm|Intermediate risk high arm receiving Standard Maintenance Therapy.
16352980|NCT04307576|Experimental|R3-InO - IR-high experimental arm|Inotuzumab IV 0,5 mg/m2, given on days 253, 260, 267 and on days 274, 281, 288 before start of Standard Maintenance Therapy.
16352981|NCT04307576|Experimental|ABL-class fusions intervention|Imatinib p.o. 340 mg/m2 given daily from day 15 or 30 (depending on age) to the end of therapy (week 106) in addition to Standard IR-high chemotherapy.
16352982|NCT04307576|Experimental|R3-TEAM - IR-high experimental arm|6-tioguanine p.o, 2,5-12,5 mg/m2, given daily in addition to Standard Maintenance Therapy.
16352983|NCT04307576|Experimental|ALLTogether1 DS Blinatumomab intervention|Blinatumomab IV, 5 mcg/m2/day up to 28 mcg/day (detailed dosing in protocol) continous infusion. Two 28 day courses with a two week treatment free interval in between. Blinatumomab courses replace Consolidation 1 and Consolidation 2 in the standard protocol adapted for Down syndrome patients.
16352984|NCT04307576|Experimental|R2 - IR-low experimental arm B|Standard treatment with omission of monthly pulses of Vincristine IV 1,5 mg/m2/dose and 5 days of Dexamethasone p.o. 6 mg/m2/day in the Maintenance Phase.
16352985|NCT04307563|Other|Mindfulness group|Participants will attend 6 weekly educational and mindfulness sessions.
16352986|NCT04307550|Experimental|Isopropyl Alcohol|10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
16352987|NCT04307550|Placebo Comparator|Sterile Saline|10 inhalations of a sterile saline pad held within 2cm from the nares
16352988|NCT04307537|Experimental|pcRUG|Peri-catheter retrograde urethrography
16352989|NCT04307537|Active Comparator|VCUG|Voiding cysto-urethrography
16352990|NCT04307524|Experimental|laparoscopic repair|suture repair of cesarean scar niche using laparoscopy
16352991|NCT04307524|Active Comparator|medical treatment|conservative management
16352992|NCT04307511|Experimental|low dose DAPT therapy|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment
16352993|NCT04307511|Active Comparator|standard dose DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
16352994|NCT04307498|Other|Intensive Outpatient Program - Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks plus seven augmentations designed to maximize treatment outcomes. If necessary, the treatment window may be extended for another week.
16352995|NCT04307485|Active Comparator|standard dose ticargrelor based DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
16352996|NCT04307485|Experimental|low dose ticargrelor based DAPT|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment
16352997|NCT04307472|No Intervention|Control|Control arm will receive no intervention.
16353111|NCT04306666||Axillary Brachial Plexus Block|Axillary Brachial Plexus Block
16352998|NCT04307472|Experimental|Clinician nudge|"The clinician nudge using an active choice intervention in the electronic health record will be delivered to the clinician during the patient's visit. This will be through a Best Practice Advisory that describes the guideline criteria for which the patient is eligible for statin therapy, provides pre-selected options for a statin with alternative options.
~The clinician nudge using monthly peer comparison messages will be sent as an inbox message through the electronic health record. Clinicians will be told what percent of their eligible patients have been prescribed a statin and how that compares to peer clinicians at Penn Medicine."
16352999|NCT04307472|Experimental|Patient nudge|The patient nudge will be a text message. Patients with a visit scheduled with their primary care clinician will be identified and sent this text 72 hours before their scheduled visit. The text will remind them of the visit, inform them of their eligibility for a statin, describe the benefits and risks of statin therapy, and ask the patient to discuss statin therapy with their primary care clinician during the visit.
16353000|NCT04307472|Experimental|Clinician Nudge and Patient Nudge|The clinician nudge and patient nudge will be implemented.
16353001|NCT04307459||Coronavirus Infection|All patients admitted to the Respiratory Unit with SARS-CoV-2 infection and respiratory failure
16353002|NCT04307446|Experimental|10 Minutes|Subject takes part in 10 minute VR experience
16353003|NCT04307446|Experimental|20 Minutes|Subject takes part in 20 minute VR experience
16353004|NCT04307433|Experimental|Arm 1|ST Narrative + mHealth: Storytelling narrative video on tablets
16353005|NCT04307433|Active Comparator|Arm 2|mHealth: a video with a voice over presenting didactic materials on tablets
16353006|NCT04307433|Placebo Comparator|Arm 3|Control: non-narrative educational materials will be read
16353007|NCT04307420|Experimental|Sonic Fill Restoration|Using sonic activation system turns the highly filled sonic fill composite into a flowable which enables the material to rapidly fill the cavity effortlessly- greatly reducing procedure time.
16353008|NCT04307420|Active Comparator|Composite Resin Restoration|Direct composite restorations are the most requested and performed dental procedures. The incremental placement technique is the gold standard for posterior universal composite placement.
16353009|NCT04307407|Experimental|Aerobic Exercise|The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.
16353010|NCT04307407|No Intervention|Standard care|Participants in this arm will not receive any follow-up on exercise during the intervention period.
16353011|NCT04307407|Other|Reference Group|Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm
16353012|NCT04307394|Experimental|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
16353013|NCT04307381|Experimental|IONIS-PKK-LRx|Participants will be administered IONIS-PKK-LRx SC for up to 52 weeks
16353014|NCT04307368|Experimental|FODMAP diet|Patients with IBS. Interventions: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
16353015|NCT04307368|Experimental|Elimination-rotational diet|Patients with IBS. Interventions: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
16353016|NCT04307368|Experimental|Classic diet|Patients with IBS. Interventions: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
16353017|NCT04307355|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
16353018|NCT04307355|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
16353019|NCT04307342||Posterior MIPO|Patients treated with posterior MIPO for Humerus Diaphyseal Fractures With Extra-articular Distal Humeral Anatomical Plate
16353020|NCT04307329|Experimental|Monalizumab + trastuzumab - low TILs (<5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
16353021|NCT04307329|Experimental|Monalizumab + trastuzumab - high TILs (>=5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
16353022|NCT04307316|Experimental|ACBT group|Active cycle breathing technique
16353023|NCT04307316|Active Comparator|Conventional treatment group|Conventional treatment group
16353024|NCT04307303|Experimental|Abdominal functional electrical stimulation|
16353025|NCT04307303|Sham Comparator|Low dose abdominal functional electrical stimulation arm|
16353026|NCT04307290|Experimental|DEX group|received intravenous dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery
16353027|NCT04307290|Placebo Comparator|CON group|received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.
16353028|NCT04307277|Other|Control arm|
16353029|NCT04307277|Experimental|Experimental arm|
16353030|NCT04307264||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, liver stiffness measurement and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, Prothrombin time, albumin).
16353031|NCT04307251|Experimental|Navio™ Robotics-assisted Surgical System|
16353032|NCT04307251|Experimental|Conventional, non-robotics-assisted total knee surgical system|
16353033|NCT04307238|Other|Propofol group|General anesthesia will be maintained by continually intravenous administered propofol.
16353034|NCT04307238|Other|Sevoflurane Group|General anesthesia will be maintained by inhalative administered sevoflurane.
16353035|NCT04307225||CABG|Patients whom has undergone CABG surgery for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
16353036|NCT04307225||PCI|Patients whom has undergone PCI for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
16353038|NCT04307212|Active Comparator|Untrained|Nonactive/non--exercise trained participants who have participated in any type of exercise no more than 2 times per week for the past 3 months. These individuals will be recruited from the general public.
16353039|NCT04307199|Experimental|Group A|Membrane sweep @ 39 weeks' gestation only
16353040|NCT04307199|Experimental|Group B|Membrane sweep @ 40 weeks' gestation only
16353041|NCT04307199|Experimental|Group C|Membrane sweep @ 39, 40 and 41 weeks' gestation or until onset of labour
16353042|NCT04307199|Experimental|Group D|Membrane sweep @ 40 and 41 weeks' gestation or until onset of labour
16353043|NCT04307199|No Intervention|Control Group|Women in the control arm will not receive a membrane sweep and will receive usual care (as defined by local hospital protocols and vaginal examination to determine Bishop score only).
16353045|NCT04307173|Experimental|Cohort 1|9 subjects for MAD 1 cohort. 6 subjects on KBL693, 3 subjects on placebo.
16353046|NCT04307173|Experimental|Cohort 2|9 subjects for MAD 2 cohort. 6 subjects on KBL693, 3 subjects on placebo.
16353047|NCT04307160||Group I|Patients ≤ 5 years of age
16353048|NCT04307160||Group II|Patients ≥ 7 years of age
16353049|NCT04307147|Experimental|NX (vinorelbine and capecitabine )|Standard therapy plus NX chemotherapy for 4 cycles, (vinorelbine 25 mg/m² d1,8 and capecitabine 1250 mg/m² d1-14, every 3 weeks)
16353050|NCT04307147|No Intervention|Control group|Standard therapy
16353051|NCT04307134||R/R ALL|Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia (ALL)
16353052|NCT04307082|Experimental|Ibrexafungerp|Oral [14C]-Ibrexafungerp Single Dose
16353053|NCT04307069|Experimental|Immediate oxytocin infusion|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, she will receive oxytocin for augmentation of labor.
16353054|NCT04307069|Experimental|Expectant management for 24 hours|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, we will wait for spontaneous delivery to occur. After 24 hours of rupture of membranes, the woman will receive oxytocin for augmentation of labor.
16353055|NCT04307056|Experimental|HIFU|Patients Treated with high intensity focused ultrasound (HIFU)
16353056|NCT04307056|Active Comparator|Prostatectomy|Patients Treated by Radical Prostatectomy
16353057|NCT04307043||postnatal age|
16353058|NCT04307043||General information and echocardiographic data|General information:(1)Record the gestational age, birth weight, length, delivery way, Apgar score, maternal pregnancy status, prenatal bleeding or not after admission.(2)PS use, ventilator mode, other illness and complications should be recorded during hospitalization. (3) Record the baby's heart rate, respiratory rate, blood pressure, body surface area on every check.
16353059|NCT04307030||0 ~ 18 years old children|Children During Outpatient or Hospitalization
16353060|NCT04307004|Other|Unattended vs Attended Blood Pressure|Participants blood pressure will be measured three times attended and three times unattended. Whether investigators measure blood pressure attended first and then unattended or unattended first and then attended will be assigned using a random number generator. At visit 2, clinic blood pressure will be measured three times attended and three times unattended, as at visit 1, but in the reverse order.
16353061|NCT04307004|Other|ABPM vs HBPM|Participants will be fitted with either the Microlife WatchBP O3 ambulatory blood pressure monitoring device or instructed on how to use the Microlife WatchBP Home N home blood pressure device, depending on which they are assigned to complete first. The order in which participants undergo ambulatory or home blood pressure monitoring will be assigned through a random number generator.
16353062|NCT04306991|Experimental|Fever|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
16353063|NCT04306991|Experimental|Apyrexia|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
16353064|NCT04306978|Active Comparator|CareLink Express RM system|Patients in the remote monitoring (RM) group will undergo the implantation of Ensura DR MRI SureScan pacing system. Patients in the RM group should visit the main follow-up clinic 12 weeks after discharge, and then the device data will be remotely transmitted to the CareLink Express Network at least once in 3 months. Research personnel will contact patients by telephone once in 6 months. If participants indicate they have experienced a study outcome event (corresponding to the study endpoints), the event will be recorded. If remote transmission or telephone call data require to make clinical decision an in-hospital visit will be induced.
16353065|NCT04306978|Active Comparator|Standard follow-up|Patients in the control group will receive Adapta DR pacing system without remote monitoring using. All patients from the control group should have the first in-hospital visit 12 weeks after pacemaker implantation. Then, the follow-up will be provided according to the standard guidelines
16353066|NCT04306965|Experimental|Apremilast|Apremilast will be administered to patients as 30 mg oral tablets taken twice daily for 24 weeks. An initial 5-day titration will be implemented to improve tolerability.
16353067|NCT04306952|Experimental|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
16353068|NCT04306952|Experimental|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
16353069|NCT04306952|Experimental|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional office hoursin between the bi-weekly group sessions and one all day meditation retreat."
16353070|NCT04306939||Case/Chronic complex disorders|Chronic complex disorders are composed of multiple population sub classifications - many of which have not been fully defined. Thus, all eligible patients should be included to maximize study power. Sufficient numbers of controls, those individuals in the general population, who may or may not have complex disorders are needed to match future comparison studies for a subset of questions, and so should also be included.
16353112|NCT04306653|Experimental|ACTH|patients with acute gout treated with ACTH
16353113|NCT04306653|Active Comparator|Betamethasone|patients with acute gout treated with betamethasone
16353114|NCT04306640|Experimental|intervention group|the intervention group will receive the denneroll cervical traction orthotic in an attempt to improve the altered sagittal cervical spine alignment (AHT and ARA C2-C7).
16353071|NCT04306939||Control|The number of controls that are anticipated for this study is less than patient numbers since they will not be needed for calculating the minor allele frequency of the majority of genetic polymorphism of interest in genetic association studies. This data is already available in public and research databases. Controls will be useful for evaluating case report form questions, providing assessment of the local genetic pool, and for possibly participating in future studies as provided by the consent.
16353072|NCT04306926|Experimental|TQB2450+SBRT|SBRT three days before TQB2450.
16353073|NCT04306913|Active Comparator|Control|
16353074|NCT04306913|Experimental|Esmolol|
16353075|NCT04306900|Experimental|Combo 1|TTX-030 plus budigalimab plus mFOLFOX6
16353076|NCT04306900|Experimental|Combo 2|TTX-030 plus budigalimab plus docetaxel
16353077|NCT04306900|Experimental|Combo 3|TTX-030 plus mFOLFOX6
16353078|NCT04306900|Experimental|Combo 4|TTX-030 plus pembrolizumab
16353079|NCT04306900|Experimental|Combo 5|TTX-030 plus budigalimab (selected tumors evaluated in expansion)
16353080|NCT04306900|Experimental|Combo 6|TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine
16353081|NCT04306900|Experimental|Combo 7|TTX-030 plus nab-paclitaxel + gemcitabine
16353082|NCT04306900|Experimental|Combo 8|Budigalimab plus mFOLFOX6
16353083|NCT04306887|Experimental|TQ-B3101|TQ-B3101 capsule administered orally.
16353084|NCT04306874|Experimental|High Protein Supplement|60 g total protein per day, administered via twice daily ensure max protein shakes
16353085|NCT04306874|No Intervention|Control|No intervention on diet; routine dietary practice
16353086|NCT04306861||Treatment Naïve PDAC Patients|Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
16353087|NCT04306848|Experimental|Pilot|Eligible subjects who have consented to the study, and have had the baseline data gathered as part of their participation in the Lifestyle Medicine Clinic, an intensive therapeutic lifestyle medicine program, will be given a CGMs device and supplies, and instructed in how to utilize these. They will set up the app on their smart phone to provide them with feedback on their glucose level to correlate with their lifestyle activities.
16353088|NCT04306835|Active Comparator|CPAP + CBT-i|Patients treated simultaneously with CPAP for their OSAS and cognitive behavioral therapy for their insomnia.
16353089|NCT04306835|No Intervention|CPAP only|Patients suffering from OSAS and insomnia, but only treated with CPAP.
16353090|NCT04306809|Experimental|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
16353091|NCT04306796|Experimental|intervention group|Patients receiving 3D-printed made to measure splints for postoperative or post-traumatic treatment in hand surgical patients
16353092|NCT04306796|Active Comparator|control group|Patients receiving thermoplastic splints individually adjusted by occupational therapists
16353093|NCT04306783|Experimental|Arm A: In-Home Sensor Monitoring|Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor. Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities. There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed. Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
16353094|NCT04306783|No Intervention|Arm B: Survey Only|Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
16353095|NCT04306770|Active Comparator|Intervention|OPTIMUM Programme
16353096|NCT04306770|No Intervention|Control|Treatment as usual
16353097|NCT04306757|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during cardiac surgery until admission to postoperative ICU. Individualisation will be established by compliance guided end-expiratory and peak pressure setting, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
16353098|NCT04306757|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during cardiac surgery until admission to postoperative ICU. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
16353099|NCT04306731|Experimental|Interventional (Group M)|The group of patients given nanotechnology structured water magnalife
16353100|NCT04306731|Active Comparator|Control (Group T)|The group of patients given Trimethoprim
16353101|NCT04306731|Placebo Comparator|Placebo (Group O)|The group of patients given ordinary bottled drinking water
16353102|NCT04306718|Experimental|studyarm|Hyalocytes from ERM and ILM are cultured in alphaMEM to examine their proliferation habits
16353103|NCT04306705||Tocilizumab|Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes. Tocilizumab was administered according to the local label.
16353104|NCT04306705||Continuous Renal Replacement Therapy|Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive 3 times or more.
16353105|NCT04306705||Standard care|Standard of care therapy per local written policies or guidelines.
16353106|NCT04306692|Experimental|Inositol group|Myo-inositol 4000 mg Dosing: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged) during 3 consecutive treatment cycles.
16353107|NCT04306692|Active Comparator|Clomiphene citrate group|Each tablet contains 50 mg of clomiphene citrate Dosing: 1 tablet per day, per os, from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days during 3 consecutive treatment cycles.
16353108|NCT04306679|Experimental|Interventional arm|The intervention, which was aimed to educate children on how to use pain scales and provide reliable pain assessments was based on a two short animation clips, lasting approximately 5 min each, and a short (5 min) guided interaction between the study nurse and the participants, in between the two clips.
16353115|NCT04306640|Active Comparator|Control group|Both the intervention group and the control group will complete a multimodal program of 10 weeks consisting of myofascial release, thoracic spine mobilization and manipulations, and physical pain relief methods.
16353116|NCT04306627|Active Comparator|Perindopril/Amlodipine arm|"Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.
~Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia."
16353117|NCT04306627|Active Comparator|Perindopril/Amlodipine/Atorvastatin arm|Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.
16353118|NCT04306614|Experimental|Capillary technique|
16353119|NCT04306614|Placebo Comparator|Suction technique|
16353120|NCT04306601|Experimental|Low-Intensity focused ultrasound brain stimulation|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
16353121|NCT04306588|Experimental|Tele-rehabilitation exercise Group|Participants who are suffering from a chronic illness such as COPD or CHF and are referred for tele-rehabilitation intervention at the VA-Houston will be qualified for the purpose of this study.
16353122|NCT04306562|Experimental|Intervention group|Patients in an intervention group will be ask about a history of food consumption in the past seven days to analyze a nutritive value of food consumption with a program (INMUCAL-Nutrients V.4.0, Institute of Nutrition, Mahidol University) and estimate an enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day with nutritional counseling by researchers. Special enteral formula will be selected if patients have specific conditions including renal failure, hyperglycemia/diabetes and liver failure, acute and chronic pulmonary disease and immunocompromised states. Otherwise, standard formula will be provided. Duration of enteral protein supplementation is at least 14 days from a preanesthetic clinic visit to a day of surgery.
16353123|NCT04306562|No Intervention|Control group|Patients in a control group will be sent to assess and improve nutritional status by primary doctor as a conventional care pathway.
16353124|NCT04306549|Experimental|Bulk-fill resin composite-sonic activated|5 mm bulk-filling without capping lightcured 40s
16353125|NCT04306549|Experimental|Bulk-fill resin composite|4 mm bulk-filling without capping lightcured 10s
16353126|NCT04306549|Experimental|Microhybrid resin composite|2 mm layers, lightcured 20s
16353127|NCT04306536|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
16353128|NCT04306536|No Intervention|Control group|Best local diet
16353129|NCT04306523||Observational Cohort|One group of 100 sets of twin infants, observed from 4 months of age until 2years of age.
16353130|NCT04306510|Other|Group 1|TEGSEDI
16353131|NCT04306497||Cohort of western medicine|"Routine treatment：
~① support treatment:maintain water and electrolyte balance .
~②oxygen therapy: give nasal catheters to inhale oxygen.
~③ basic treatment of traditional Chinese and western medicine: antiviral drugs and proprietary Chinese medicines with similar composition or function to the observed scheme of differentiation and treatment of traditional Chinese medicine are not included in the scope of such drugs.
~Antiviral drugs ：Clinicians can judge according to the patient's condition according to the latest version of the diagnosis and treatment plan for COvID-19 issued by the General Office of the National Health Commission / the Office of the State Administration of traditional Chinese Medicine (currently the latest version is the sixth trial edition). Select any of the recommended antiviral drugs(for example:IFN-α、lopinavir-ritonavir、Ribavirin、Chloroquine Phosphate、Arbidol)or a combination of two antiviral drugs."
16353132|NCT04306497||Cohort of integrated TCM and western medicine|"routine treatment + Antiviral drugs + the following TCM regimens. 1.TCM regimens:① Early stage: Dampness trapped in exterior and interior. Recommended prescription: Huoxiang 15g, Suye15g, Cangzhu15g, Houpo10g, Qianhu15g, Chaihu15g, Huangqin10g, Qinghao20g, Xingren10g, JInyinhua15g, Lianqiao15g.
~Take decocted or granule, one dose a day.
~② Middle stage: Dampness-toxicity blocking lung Recommended prescription: Zhimahuang9g, Xingren10g, Sangbaipi30g, Tinglizi20g, Dongguazi20g, Fabanxia10g, Houpo10g, Suzi15g, Baijiezi10g, Gualoupi15g, Xuanfuhua9g, Xiangfu10g, Yujin10g, Taoren10g, Huangqi20g.
~Take decocted or granule, one dose a day."
16353133|NCT04306484||patients with tumoral brain lesion|The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.
16353134|NCT04306484||patients with non-tumoral brain lesion|The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).
16353135|NCT04306471|Experimental|Treatment arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition the study intervention involving a monthly subcutaneous injection of evolocumab 420 mg for 12 months
16353136|NCT04306471|Placebo Comparator|Control arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition a Placebo subcutaneous injection for 12 months.
16353137|NCT04306458|Experimental|Robot assisted minimally invasive esophagectomy|Robot assisted minimally invasive esophagectomy
16353138|NCT04306458|Active Comparator|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
16353169|NCT04306198|Active Comparator|Lag Screw|Device: Trochanteric Fixation Nail (TFN) whit lag screw Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
16353273|NCT04305522|Experimental|Probiotic 1 group|A commercially-available multi-strain probiotic with added magnesium and vitamin B6
16353139|NCT04306445|Active Comparator|GF-IGB: Obalon Balloon|Obalon balloons are gas-filled balloons used for weight loss by taking up more space in the stomach. There are three separate balloons that are placed. They are inflated once the capsules containing the balloons are swallowed. The second balloon is swallowed two weeks after the first balloon, and the third balloon is swallowed four to eight weeks after the second balloon. All three balloons are removed six months after the first balloon is placed.
16353140|NCT04306445|Active Comparator|Medically Supervised Meal Replacement Program: My New Weigh|Meal Replacements are used for weight loss in order to achieve a very low-calorie diet that is nutritionally balanced. Four to five meal replacements are consumed per day. If only four meal replacements are consumed per day, three servings of vegetables and two servings of fruit are consumed as well. This program lasts for about five months or twenty weeks.
16353141|NCT04306406|Other|Raspberry Smoothies|Single serving smoothies drink made with red raspberries to be consumed daily for two weeks
16353142|NCT04306393|Experimental|Treatment Group|Inhaled Nitric Oxide until PaO2/FiO2 >/= 300 mmHg
16353143|NCT04306393|No Intervention|Control Group|
16353144|NCT04306367|Experimental|Experimental|"Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)
~Olaparib bid, Oral tablet continuously"
16353145|NCT04306354|Experimental|Conventional oxytocin treatment (T + OC)|32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
16353146|NCT04306354|Placebo Comparator|Conventional treatment with placebo administration (T + PBO)|32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
16353147|NCT04306354|No Intervention|Conventional treatment (T)|32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.
16353148|NCT04306341|Experimental|Experimental|Neurofeedback in conjunction with Dialectical Behavior Therapy
16353149|NCT04306341|No Intervention|Control|Dialectical Behavior Therapy (treatment as usual)
16353150|NCT04306328|Experimental|Neurostimulation|
16353151|NCT04306315|Experimental|Brodalumab 210 mg + brodalumab 70 mg add-on*|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any visit with efficacy assessments after Week 16 will receive a dose adjustment to 280 mg brodalumab every 2 weeks.
16353152|NCT04306315|Placebo Comparator|Brodalumab 210 mg + placebo add-on*|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any time visit with efficacy assessments Week 16 will receive a dose adjustment to 210 mg brodalumab + placebo every 2 weeks.
16353153|NCT04306302|Experimental|Medium-dose ExPEC10V or Placebo: Group 1|Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
16353154|NCT04306302|Experimental|High-dose ExPEC10V or Placebo: Group 2|Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.
16353155|NCT04306289|Active Comparator|Real tDCS|The participant will receive anodal tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
16353156|NCT04306289|Sham Comparator|Sham tDCS|Identical to the real tDCS, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
16353157|NCT04306276||Patients undergoing direct IVF|Patients directly undergo IVF without receiving previous hormonal treatment
16353158|NCT04306276||Patients pretreated with DNG|Patients having received a three-month treatment with DNG before undergoing IVF
16353159|NCT04306263|Experimental|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics (Human milk oligosaccharide, Glucooligosaccharides) and probiotics.
16353160|NCT04306263|Active Comparator|Standard formula|Infants receiving a standard infant formula.
16353161|NCT04306263|Active Comparator|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
16353162|NCT04306250|Experimental|anterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the anterior access, ie dissection through the anterior vaginal wall.
16353163|NCT04306250|Active Comparator|posterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the posterior access, ie fixation through the vaginal posterior wall.
16353164|NCT04306237|Experimental|IMB-1018972|Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks
16353165|NCT04306237|Placebo Comparator|Placebo|Participants will receive matching placebo tablets twice daily for 16 weeks
16353166|NCT04306224|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
16353167|NCT04306211|Active Comparator|Facial mask|facial mask for oxygen delivery
16353168|NCT04306211|Experimental|SuperNO2VA|SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask
16353170|NCT04306198|Active Comparator|Helical Blade|Device: Trochanteric Fixation Nail (TFN) whit helical blade Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
16353171|NCT04306185|Experimental|OVARIAN FRAGMENTATION|Ovarian fragmentation through laparoscopy in patients who meet criteria ( Poor ovarian responders and poor ovarian reserve).
16353172|NCT04306172||Readmitted inpatients/Cases|"Outcome 1: Patients who were readmitted within 18 days of index hospitalization discharge date to the same hospital, with a diagnosis leading to the same Major Diagnostic Group as the index stay (definition according to Swiss Diagnosis Related Groups system, case merger)
~Outcome 2: Patients with an unplanned readmission within 30 days of index hospitalization discharge date to the same hospital. An unplanned readmission was defined as a readmission through the emergency department."
16353173|NCT04306172||Non-Readmitted inpatients/Controls|Outcome 1 & 2: Patients who were not readmitted within 30 days of index hospitalization discharge date.
16353174|NCT04306159|Sham Comparator|General anesthesia|Basal blood pressure and heart rate were recorded after midazolam administration of 0.02 mg/kg. Anesthesia was induced with sufentanil 0.4 μg/kg and propofol 2-2.5 mg/kg, IV route. An IV bolus of cisatracurium 0.1 mg/kg IV was given to facilitate tracheal intubation. Anesthesia was maintained with propofol 4-6 mg/kg/h combined dexmedetomidine 0.2 μg/kg/h(after 0.2 μg/kg/h loading dose within 15min)by bispectral index (BIS) 40-60 and additional bolus doses of remifentanil 0.2-0.5 μg/kg/min to keep arterial pressure values around 20% below baseline values. Sufentanil 0.1-0.2 μg/kg and flurbiprofen 100mg was administrated once the abdomen was closed, then a patient controlled analgesia pump was used. No RSB was performed.
16353175|NCT04306159|Experimental|Subcostal TAP combined with General anesthesia|After induction, TAP was performed. The transversus abdominis plane is imaged with the ultrasound probe obliquely on the upper abdominal wall, along the subcostal margin near the midline.The needle tip was advanced to the desired position where 20 mL 0.375%ropivacaine(Dexamethasone 5mg was added)were injected.The technique is repeated on the opposite side. Anesthesia method and management was same as general anesthesia group.
16353176|NCT04306159|Experimental|Modified RSB combined with General anesthesia|After induction, Modified RSB was performed based on midline incision-guided. The rectus muscle is imaged with the ultrasound probe in a transverse orientation below the xiphisternum and above the umbilicus.The needle tip was advanced to the two desired position where 10 mL ropivacaine 0.375% were injected causing hydrodissection of the rectus muscle away from the posterior rectus sheath.The technique is repeated on the opposite side.Anesthesia method and management was same as general anesthesia group.
16353177|NCT04306146|Experimental|CAD-9303|Capsules of CAD-9303 will be administered as a single or multiple dose(s). The initial dose will be 3 mg up to 1000 mg total daily dose.
16353178|NCT04306146|Placebo Comparator|Placebo|Matching placebo will be provided in capsules and administered as a single or multiple dose(s).
16353179|NCT04306133|Experimental|PENG BLOCK AND WOUND INFILTRATION|Participants receiving PENG block combined to wound infiltration
16353180|NCT04306133|Active Comparator|WOUND INFILTRATION|Participants receiving wound infiltration alone
16353181|NCT04306120|Active Comparator|noxious cold group|The group received noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
16353182|NCT04306120|Active Comparator|noxious heat group|The group received noxious heat (46 - 47°C) stimuli on the affected leg for 30 minutes.
16353183|NCT04306120|Active Comparator|alternative thermal stimulation group|The group received alternative noxious heat (46 - 47°C) and noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
16353184|NCT04306107|Experimental|NIV with prone position|Use of prone position during NIV
16353185|NCT04306107|Placebo Comparator|NIV (conventional)|NIV on conventional position
16353186|NCT04306107|Experimental|HFNC on prone position|Prone position during HFNC
16353187|NCT04306107|Placebo Comparator|HFNC (conventional)|HFNC on conventional position
16353188|NCT04306081|Experimental|Treatment Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of evolocumab 420 mg via subcutaneous injections for 6 months.
16353189|NCT04306081|Placebo Comparator|Control Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of placebo via subcutaneous injections for 6 months.
16353190|NCT04306068|Experimental|Experimental group|Athletes included in the experimental group will perform a plyometric exercise protocol. Each session will consist of a 4-station circuit with 1 minute rest between each station and 30 seconds between sets
16353191|NCT04306068|No Intervention|Control group|Athletes included in the control group will follow their usual warm-up routine.
16353192|NCT04306055|Experimental|Questionnaire with precaution information|Questionnaire in this group includes information about precaution of blood donation during epidemic of COVID-19.
16353193|NCT04306055|Experimental|Questionnaire without precaution information|Questionnaire in this group dose not include information about precaution of blood donation during epidemic of COVID-19.
16353194|NCT04306055|No Intervention|No questionnaire group|Ever donors in this group would not receive the questionnaire.
16353195|NCT04306042||Treatment|Patients diagnosed with primary stage IIIB-IV squamous cell lung cancer and treated in 92 medical centers between 01 September 2019 and 30 June 2020 will be targeted for study inclusion.
16353196|NCT04306029|No Intervention|Pre-Intervention|
16353197|NCT04306029|Experimental|Post-Intervention|"Postpartum staff has received the Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
16353198|NCT04306016|Experimental|Sensory stimulation|Participants allocated to the intervention group will receive a model-based sensory stimulation intervention, which is aimed at providing visual and auditory stimulation to ICU patients with additional support from family caregivers.
16353199|NCT04306016|No Intervention|Usual care|Participants in the control group will receive usual care routine that they are receiving or planning to receive. The registered ICU nurses will provide the same nursing care as previously, including but not limiting to the use of sedation, analgesia, spontaneous breathing trial, indwelling catheter, feeding, and bowel care.
16353239|NCT04305782|Experimental|Release/Relock Socket - In Lab|The test socket will be operated by the participant in lab, following a structured protocol. This arm focuses on the order effects on the re-lock panel and pin mechanisms on limb volume.
16353200|NCT04306003|Experimental|Enhanced Recovery After Surgery (ERAS) pathway|"Preop
~Diet: Solids until midnight before surgery with a carbohydrate rich drink before midnight and 3-hours prior to surgery.
~Analgesia: Acetaminophen 975mg & Celecoxib 400mg administered PO 1-hour before surgery.
~Intraop
~Hypothermia prevention: Forced-air warming units and core temperature monitoring.
~Fluid management: Euvolemic fluid management with balanced crystalloid solution.
~Analgesia: 0.25% bupivacaine block of intercostal nerves and rectus sheath by the surgical team. Additional IV analgesia by anesthesiologist with the goal to minimize opioids.
~PONV prophylaxis: Ondansetron 4-8mg IV during emergence.
~Postop
~Diet: Clear fluids immediately post-op. Saline lock and advance to DAT on POD#1.
~Analgesia: Routine administration of Acetaminophen 975mg PO q6h & Celecoxib 200mg PO q12h. Opioids used as breakthrough analgesia only. No PCA.
~Early mobilization: Mobilization within the first 24 hours after surgery with assistance."
16353201|NCT04306003|Active Comparator|Standard Perioperative Care|Patients in the control arm received routine perioperative care as determined by respective surgeons participating in the study.
16353202|NCT04305990|Experimental|Demand-driven delivery followed by free-flow delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a demand-driven delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
16353203|NCT04305990|Experimental|Free-flow delivery followed by demand-driven delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
16353204|NCT04305977|Other|WAVE-TW Arm|All participants will receive the WAVE-TW intervention.
16353205|NCT04305964|Experimental|Nastent® users|Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) < 20/ hour sleep who receive Nastent® as treatment modality
16353206|NCT04305951|No Intervention|Routine care group|Subjects assigned to this group will continue their routine care without receiving any acupuncture and acupressure treatment during the study period. The routine care may include physiotherapy and intellectual activities. Post-trial treatment of either CAT, CAE, or CAT+CAE will be offered to serve as a compensation for their participation.
16353207|NCT04305951|Active Comparator|CAT group|Subjects assigned to comprehensive acupuncture therapy (CAT) group will receive CAT treatment in addition to routine care.
16353208|NCT04305951|Active Comparator|CAE group|Subjects assigned to 'Comfy Acupressure for the Elderly (CAE)' group will receive CAE in addition to routine care.
16353209|NCT04305951|Active Comparator|CAT + CAE group|Subjects assigned to CAT+CAE group will receive CAT+CAE in addition to routine care.
16353210|NCT04305925|Experimental|Focal Laser Ablation|The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
16353211|NCT04305912|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to verofilcon A daily disposable lenses for one week.
16353212|NCT04305912|Active Comparator|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
16353213|NCT04305899|Experimental|Treatment Group 1|
16353214|NCT04305899|Experimental|Treatment Group 2|
16353215|NCT04305899|Experimental|Treatment Group 3|
16353216|NCT04305899|Experimental|Treatment Group 4|
16353217|NCT04305899|Experimental|Treatment Group 5|
16353218|NCT04305899|Experimental|Treatment Group 6|
16353219|NCT04305899|Experimental|Treatment Group 7|
16353220|NCT04305899|Experimental|Treatment Group 8|
16353221|NCT04305899|Experimental|Treatment Group 9|
16353222|NCT04305899|Experimental|Treatment Group 10|
16353223|NCT04305886|Experimental|Intervention|Providers were placed in small groups and given the intervention of a discussion guide to facilitate discussion.
16353224|NCT04305886|No Intervention|Control|Providers were placed in small groups and not given a discussion guide to facilitate discussion.
16353225|NCT04305873||EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test <93%
16353226|NCT04305873||Non-EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test >95%
16353227|NCT04305873||Intermediate EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test of 93-95%
16353228|NCT04305860|Active Comparator|Modified starch without flavoring|Patients thicken water with modified starch during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
16353229|NCT04305860|Active Comparator|Modified starch with flavoring|"Patients thicken water with modified starch adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
16353230|NCT04305860|Active Comparator|Xanthan gum without flavoring|Patients thicken water with xanthan gum during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
16353231|NCT04305860|Active Comparator|Xanthan gum with flavoring|"Patients thicken water with xanthan gum adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization.They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
16353232|NCT04305847||Qual'AXI group|patients for whom distal arm surgery was performed under Axillary Brachial Plexus Block
16353233|NCT04305834|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16353234|NCT04305808||Recurrent Urinary tract infection|Menopausal women, with two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year
16353235|NCT04305808||Healthy controls|Menopausal women, without prior history of UTIs or other urologic abnormalities.
16353240|NCT04305782|Experimental|Release/Relock Socket - Out of Lab|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the effects of the re-lock panel and pin mechanisms on participant comfort.
16353241|NCT04305782|Experimental|Release/Relock Socket & Control|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the comparing participant experience using the novel mechanism versus traditional socket mechanisms.
16353242|NCT04305769|Placebo Comparator|Alanyl-glutamine 0g|
16353243|NCT04305769|Experimental|Alanyl-glutamine 4g|
16353244|NCT04305769|Experimental|Alanyl-glutamine 24g|
16353245|NCT04305769|Experimental|Alanyl-glutamine 44g|
16353246|NCT04305756|Experimental|Weight-based LMWH|"Participants will receive a weight-based dose of prophylactic enoxaparin.
~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours"
16353247|NCT04305756|Active Comparator|Fixed LMWH|"Participants will receive a fixed dose of prophylactic enoxaparin.
~For BMI <40: 40mg injected subcutaneously every 24 hours
~For BMI > or = to 40: 40mg injected subcutaneously every 12 hours"
16353248|NCT04305743|Experimental|5 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 5 injections of 2 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
16353249|NCT04305743|Active Comparator|20 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 20 injections of 0.5 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
16353250|NCT04305730|Experimental|Pedometer Group|This group will be given a pedometer following radical cystectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 1,000/day. POD 3-6: 2,000/day. POD 7-9: 3,000/day. POD 10-14: 4,000/day. POD 14-21: 5,000
16353251|NCT04305730|Active Comparator|Control group|This is the control group. Following radical cystectomy subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
16353252|NCT04305717|Experimental|ReDS-guided strategy|For patients in this arm, daily measurements from the device will be revealed to the treating physician. Discharge can be planned when the clinical stability is achieved and the ReDS value is ≤35%. In case of a ReDS value >35%, treating physicians will follow a predefined algorithm before discharge to improve the results of ReDS test.
16353253|NCT04305717|No Intervention|Standard of care strategy|The drugs dosage, especially diuretics, will be selected according to the presence of symptoms and signs of systemic congestion and according to current recommendations. All the daily ReDS measurements will be blinded to the treating physician.
16353254|NCT04305691|Experimental|Treatment (ixazomib)|Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
16353255|NCT04305678|Experimental|Single Arm|Patients with a biopsy proven diagnosis of eosinophilic fasciitis
16353256|NCT04305665||HIV-1 positive persons|
16353257|NCT04305652|No Intervention|Control group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below )
16353258|NCT04305652|Experimental|Experimental group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below) The caregivers of Alzheimer's patients will be trained for 3 months according to the Progressively Lowered Stress Threshold Model with a home visit.
16353259|NCT04305613||Cohort|Patients with locally advanced non-small cell lung cancer
16353262|NCT04305587|Experimental|Active Obesity|Part B
16353263|NCT04305587|Placebo Comparator|Placebo Obesity|Part B
16353264|NCT04305587|Experimental|Active T2DM|Parts A and C
16353265|NCT04305587|Placebo Comparator|Placebo T2DM|Parts A and C
16353266|NCT04305574||Community sample|We plan to recruit a representative sample of the Singapore population.
16353267|NCT04305561|Other|Ultrasound + Contrast-enhanced ultrasound|"Patients are offered a contrast-enhanced ultrasound (CEUS) examination in addition to conventional imaging. All included patients undergo both CEUS and conventional imaging, enabling them to act as their own controls.
~Pilot study: 60 patients Main study: 112 patients"
16353268|NCT04305561|No Intervention|Conventional imaging|"Dual-tracer 99mTechnetium-pertechnetate/ 99mTechnetium-sestamibi subtraction scintigraphy with single-photon emission computerised tomographic/CT fusion imaging (SPECT/CT) combined with conventional ultrasound.
~Pilot study: 60 patients Main study: 112 patients"
16353269|NCT04305548|Experimental|Trabectedin|Trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
16353270|NCT04305535|Active Comparator|Peptidic+Probiotic|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and mix of probiotics during 6 months
16353271|NCT04305535|Active Comparator|Peptidic+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
16353272|NCT04305535|Placebo Comparator|Polymeric+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
16353277|NCT04305496|Experimental|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
16353278|NCT04305496|Placebo Comparator|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
16353279|NCT04305483|Active Comparator|Laser Bleaching|35% Hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative containing bleaching agent activated with diode laser
16353280|NCT04305483|Active Comparator|Chemical Bleaching|35% Hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water containing chemical bleaching agent used for control group without a laser activation
16353282|NCT04305457|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
16353283|NCT04305457|No Intervention|Control|Patients assigned to the control group will not receive any gas therapy.
16353284|NCT04305457|Experimental|Nitric Oxide Inhalation (Non-Randomized)|All subjects part of this arm will receive nitric oxide gas either as an inpatient or outpatient. Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system. Patients in this arm will not be randomized, so that all patients receive the study medication.
16353285|NCT04305444|Experimental|Disease-specific cohorts|Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days
16353287|NCT04305418|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
16353288|NCT04305418|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
16353289|NCT04305405|Experimental|Dose 1|Below 35 kilos
16353290|NCT04305405|Experimental|Dose 2|Greater than/equal to 35 kilos
16353291|NCT04305392|Experimental|Normal liver function|Patients will receive single dose of SHR4640
16353292|NCT04305392|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR4640
16353293|NCT04305392|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR4640
16353294|NCT04305379|Experimental|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction (Sling + Intussusception)
16353295|NCT04305379|Active Comparator|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction (Intussusception Only)
16353296|NCT04305366||Head and Neck Cancers|This study will target patients with a diagnosis squamous cell carcinoma in the head and neck. In addition, this study will also target patients undergoing tonsillectomy or sleep surgery as the control group. This study will aim to enroll an equal number of patients into both the study group and control group. However, this will be dependent on patient encounters within the adult ENT clinic.
16353297|NCT04305353|Experimental|ICU Diary Group|Patients randomized to this group receive the ICU diary, along with PTSD education
16353298|NCT04305353|Other|PTSD Education-only Group|Control Group: patients randomized to this group only receive PTSD education
16353299|NCT04305340|Experimental|SKIIN Textile Device in children with healthy hearts|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down.
16353300|NCT04305340|Experimental|SKIIN Textile Device in children with heart failure|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down
16353301|NCT04305327|Experimental|Brodalumab|Brodalumab for 52 weeks. The dose will be determined by the participant's body weight.
16353302|NCT04305327|Active Comparator|Ustekinumab|Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
16353303|NCT04305327|Placebo Comparator|Placebo/brodalumab|Placebo for the first 12 weeks and brodalumab for the following 40 weeks. The dose will be determined by the participant's body weight.
16353304|NCT04305327|Placebo Comparator|Placebo/ustekinumab|Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.
16353305|NCT04305314||Group 1: PRI > 70%|Compliance with the Enhanced Revovery protocol higher than 70%
16353306|NCT04305314||Group 2: PRI < 70%|Compliance with the Enhanced Revovery protocol lower than 70%
16353307|NCT04305288||Gemox|The patients received conventional chemotherapy Gemox
16353308|NCT04305288||mFOLFIRINOX|The patients received chemotherapy modified FOLFIRINOX
16353309|NCT04305275|Experimental|SAGE-324 60 mg|Participants will receive SAGE-324 60 mg dose (tablets) orally in the morning for 28 days.
16353310|NCT04305275|Placebo Comparator|SAGE-324 Matched Placebo|Participants will receive SAGE-324 matched placebo, oral tablets for 28 days.
16353311|NCT04305249|Experimental|ATG-017|ATG-017 will be administered orally on an empty stomach QD in the first cohort of solid tumors group and BID 12 hours apart (no food or drink other than water for 2 hours prior to, and for 1 hour after study treatment administration) in other cohorts. All doses of ATG-017 should be taken at approximately the same time each day. Patients will receive study treatment in 21-day cycles.
16353312|NCT04305236|Experimental|Abemaciclib and Fulvestrant|Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
16353705|NCT04302584|Active Comparator|NE|patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
16353313|NCT04305223|Experimental|Dry needling and upper extremity stretching program Arm|"Participants will receive a combination of dry needling and upper extremity stretching.
~Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin America, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
~A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter."
16353314|NCT04305223|Active Comparator|Dry Needling Arm|Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin American, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
16353315|NCT04305210|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
16353316|NCT04305210|Experimental|18F-florbetapir|18F-florbetapir (AV45) imaging
16353317|NCT04305197|Experimental|Lower Dose|
16353318|NCT04305197|Experimental|Medium Dose|
16353319|NCT04305197|Experimental|Higher Dose|
16353320|NCT04305197|Placebo Comparator|Placebo|
16353329|NCT04305171||coronary heart disease patients with periodontitis|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.
~Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth."
16353330|NCT04305171||coronary heart disease patients without periodontitisHD|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.
~Non-periodontitis classified as having PD ≤ 3 mm."
16353331|NCT04305171||non-coronary heart disease patients with periodontitis|Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth.
16353332|NCT04305171||non-coronary heart disease patients without periodontitis|Non-periodontitis classified as having PD ≤ 3 mm.
16353333|NCT04305158|Experimental|Nitrous Oxide|Patient receiving Nitrous Oxide are evaluated for success of the procedure
16353334|NCT04305158|Active Comparator|IV Sedation group|In this group a combination of Midazolam and Fentanyl is used per endoscopic discretion
16353338|NCT04305132||Depression|Subjects with depression treated with electroconvulsive therapy
16353339|NCT04305132||Healthy|Healthy subjects
16353340|NCT04305106|Experimental|Bevacizumab Group|
16353341|NCT04305106|No Intervention|Control Group|
16353342|NCT04305093||Precision Analytical patients|Individuals who had laboratory work completed at Precision Analytical and completed the associated questionnaire on symptoms and comorbidities.
16353343|NCT04305080|Experimental|Anodic Oxidation of implant abutment|
16353344|NCT04305080|Sham Comparator|Untreated implant abutment|
16353408|NCT04304677||Pre PCI state|The current study will analyze the pre-PCI pullback recording and amount of FFR step-up. The association of the amount of FFR step-up with post-PCI percent FFR increase, post-PCI FFR, and clinical outcome at 2 years will be analyzed
16353345|NCT04305067|Experimental|Supervised aerobic and resistance exercise|16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
16353352|NCT04305028||Experimental: Rivaroxaban [2.5 mg] + Aspirin|Drug: Rivaroxaban 2.5 mg twice daily, tablet Drug: Aspirin 75-100 mg once daily, tablet
16353353|NCT04305028||Active Comparator: Aspirin|Drug: Aspirin 75-100 mg once daily, tablet
16353354|NCT04305015|Active Comparator|Routine opioid management|Clinicians will be blinded to NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when
16353355|NCT04305015|Experimental|NOL-guided opioid administration|Clinicians will titrate fentanyl to keep NOL under 25 - always using good clinical judgement for individual patients
16353356|NCT04305002|Experimental|Exenatide|
16353357|NCT04305002|Placebo Comparator|Placebo|
16353358|NCT04304989|Experimental|Intervention|This group of participants will receive a video-based mHealth program which includes two main elements: 1) nurse case management supported by a social service team, 2) individual-specific video messages covering self-care topics delivered via smartphone
16353359|NCT04304989|Other|Control|The participants in this group will receive usual care
16353360|NCT04304976|Experimental|Training with ROBERT® Passive|Training performed with ROBERT® in passive mode, resulting in active assistive training.
16353361|NCT04304976|Experimental|Training with ROBERT® Active|Traning performed with ROBERT® in Active mode, resulting in active resistive training.
16353362|NCT04304963||T1DM and intact awareness of hypoglycaemia|200 participants with T1DM and intact awareness of hypoglycaemia
16353363|NCT04304963||T1Dm and impaired awareness of hypoglycaemia|50 participants with T1Dm and impaired awareness of hypoglycaemia
16353364|NCT04304963||insulin treated T2DM|350 participants with insulin treated T2DM ( > 1 injections / day)
16353365|NCT04304950|Experimental|Ulcerative Colitis: Azathioprine|Participants with Ulcerative Colitis taking Azathioprine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
16353366|NCT04304950|Experimental|Ulcerative Colitis: 6-Mercaptopurine|Participants with Ulcerative Colitis taking 6-Mercatopurine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
16353367|NCT04304950|Experimental|Crohn's Disease: Azathiopurine|Participants with Crohn's Disease taking Azathioprine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
16353368|NCT04304950|Experimental|Crohn's Disease: 6-Mercaptopurine|Participants with Crohn's Disease taking 6-Mercaptopurine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
16353369|NCT04304937||Cohort 1|test-retest at baseline and 7 days later
16353370|NCT04304937||Cohort 2|test at baseline and 8 weeks post treatment
16353371|NCT04304924|Experimental|Personalised telephone-based health education|"The personalized telephone based intervention:
~Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);
~Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
16353372|NCT04304924|No Intervention|Standard health educational program|
16353373|NCT04304911|Experimental|UP in blended format|Clinicians will follow the UP therapist manual, 2nd edition, recently translated by Osma and Crespo (13,14). The same contents through a digital material (video and audio) will be integrated in the UP-APP. The program can be developed in a range of 12 to 16 sessions. The UP includes 8 modules
16353374|NCT04304911|Active Comparator|Treatment as usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
16353375|NCT04304898||Single Group Assignment|Intervention group without a control group
16353376|NCT04304885||Sonication method|The treatment strategies of all patients will be based on the cultural results to be made by the sonication method.
16353406|NCT04304703||Internal Medicine resident subjects|Subjects who are categorical Internal Medicine residents at Penn State Hershey Medical Center (PGY1-PGY3), and meet inclusion/exclusion criteria, will be enrolled in this study and wear the WHOOP strap 3.0 for real-time measurement of physiologic metrics.
16353407|NCT04304690|Other|caregiver|caregivers from emergency, ICU, virology and infectious disease services
16353377|NCT04304872|Experimental|Gamification Intervention|"Participants sign a pledge agreeing to try their best to meet their goals.
~Participants are entered into a game. Each week they receive 70 points. Each day, they are told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.
~Participants choose a support partner who receives a weekly email with the participant's progress. The study group will hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, the study group will have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
16353378|NCT04304872|Experimental|Loss-Framed Financial Incentive Intervention|Participants are informed that each week that $14 is placed in a virtual account for them. Each day, the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
16353379|NCT04304872|Experimental|Gamification and Loss-Framed Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
16353380|NCT04304859||Cases referred from GP|BASIC (Brief Assessment of Impaired Cognition) MMSE (Mini Mental State Examination) Extensive diagnostic work-up including clinical interview, neurological and physical examination, laboratory screening tests, structural neuroimaging
16353381|NCT04304859||Healthy controls|"Test performed:
~BASIC MMSE GDS-15 (Geriatric Depression Scale)"
16353382|NCT04304846||AMPLIFy group|Mother, premature child and teacher will complete questionnaires and interviews on attachment, maternal stress and child behavior
16353383|NCT04304833|Active Comparator|Provider-Based Care Model Arm|Non-connected home vital sign equipment will be given to patients in this group. The patients in the group will be instructed to record their daily readings on a paper log provided by the research team. These monitoring devices will not transmit readings to a centralized location and no one will be alerted to out-of-range readings or compliance with taking daily vital sign measures. At the front page of the log, normal ranges will be described with brief instructions about what participants/caregivers should do if their readings are out-of-range. Logs will be collected at baseline, 3-months and 6-months.
16353384|NCT04304833|Experimental|mHealth Model Arm|Connected home vital sign equipment (mHealth) will be given to patients in this group. The patients will be instructed to take their daily readings, which will automatically be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse (RN) Call Center will be automatically alerted and the event will be triaged. Daily measures and medical follow-up from the measures will be counted and collected at baseline, 3-months, and 6-months.
16353386|NCT04304807|Experimental|Group I|Forty five preterm infants with signs of feeding intolerance who received 20 mg of melatonin treatment in addition to traditional antibiotic treatment.
16353387|NCT04304807|Sham Comparator|Group II|Forty five preterm infants with signs of feeding intolerance who received traditional antibiotic treatment only.
16353388|NCT04304794||Group with prophylaxis|Group of 13 patients with euthyroid goiter who received prophylactic treatment before and after iodinated contrast medium (ICM) injection. 6 patients received thiamazole with sodium perchlorate, one day prior to ICM and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily). 7 patients received only thiamazole as prophylactic treatment due to lack of sodium perchlorate at the time.
16353389|NCT04304794||Group without prophylaxis|Group of 23 patients with euthyroid goiter who received no prophylactic treatment before iodinated contrast medium injection.
16353390|NCT04304781|Experimental|Dimer Application with SFE imaging|Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.
16353391|NCT04304768|Experimental|HIV positive opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
16353392|NCT04304768|Experimental|HIV positive non-opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
16353393|NCT04304768|Experimental|HIV negative opioid users|Participants will receive flu vaccination as part of the study
16353394|NCT04304768|Experimental|HIV negative non-opioid users|Participants will receive flu vaccination as part of the study
16353395|NCT04304755|Experimental|Investigational Medical Product : Zoledronic acid|Zoledronic acid 5 mg IV at baseline and after 26 weeks.
16353396|NCT04304755|Placebo Comparator|Placebo: NaCl 0,9%|100 ml 0.9% NaCl IV at baseline and after 26 weeks.
16353397|NCT04304742||Suspicion of hip fracture|Suspicion of hip fracture
16353398|NCT04304729||Diabetics|Girls and boys aged 14-18 years old, living with Type 1 Diabetes.
16353399|NCT04304729||Control|Age and sex matched adolescents without any type of diabetes
16353400|NCT04304716|Active Comparator|Fibular free flap-Block performed|For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
16353401|NCT04304716|Active Comparator|Anterolateral thigh free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
16353402|NCT04304716|Active Comparator|Radial forearm free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
16353403|NCT04304716|No Intervention|Fibular free flap -Control|No additional procedures beyond the normal standard of care will be performed
16353404|NCT04304716|No Intervention|Anterolateral thigh free flap-Control|No additional procedures beyond the normal standard of care will be performed
16353405|NCT04304716|No Intervention|Radial forearm free flap-Control|No additional procedures beyond the normal standard of care will be performed
16353501|NCT04304001|Active Comparator|Usual care|Control group participants will receive a FIT kit, a mailed targeted CRC brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
16353409|NCT04304664|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
16353410|NCT04304664|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
16353411|NCT04304651|Active Comparator|Limited cancer screening|Limited screening alone.
16353412|NCT04304651|Experimental|Limited cancer screening + FDG PET/CT|Limited screening + FDG PET/CT
16353413|NCT04304638||Radiation(Chemo-radiation)|Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.
16353414|NCT04304638||radiation+EGFR-TKI|Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.
16353415|NCT04304638||EGFR-TKI|Patients in this group had been treated with EGFR-TKI without any other treatment until progression.
16353416|NCT04304625|Experimental|Tranexamic acid|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
16353417|NCT04304625|Placebo Comparator|Placebo|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
16353418|NCT04304599|Experimental|LoFric Elle|New hydrophilic female urinary catheter for single use. Ready-to-Use.
16353419|NCT04304573||Patients with hypocalcemia symptoms and low serum calcium|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
16353420|NCT04304573||Patients with hypocalcemia symptoms and normal serum calcium|Patients with hypocalcemia symptoms but without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
16353421|NCT04304560|Placebo Comparator|Control Group|Control group will receive the standard therapy for DM & HFrEF and placebo.
16353422|NCT04304560|Experimental|Dapagliflozin|Intervention group will receive 10mg of Dapagliflozin (Forxiga) ® tablet and standard therapy for HFrEF.
16353423|NCT04304547|Active Comparator|Sequence A|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
16353424|NCT04304547|Active Comparator|Sequence B|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
16353425|NCT04304547|Active Comparator|Sequence C|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
16353430|NCT04304521||Intensive care|Patients admitted in the intensive care unit of the University Hospital of Saint-Etienne, France between December 2018 and July 2019
16353431|NCT04304508|Experimental|BAY2433334 high dose|
16353432|NCT04304508|Experimental|BAY2433334 medium dose|
16353433|NCT04304508|Experimental|BAY2433334 low dose|
16353434|NCT04304508|Placebo Comparator|BAY2433334 matching placebo|
16353435|NCT04304495|Experimental|Intervention|"In addition to the usual care arm, the Intervention arm will receive a physical therapy and pharmacy consultation in the ED. PTs will perform a fall risk assessment and provide recommendations on the safety of discharge. Pharmacists will perform medication review, recommend cessation or tapering of medication that increase fall risk using motivational interviewing (MTM) techniques.
~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
16353436|NCT04304495|No Intervention|Usual care arm|"The ED clinician will perform a standard medical evaluation, including a focused history and exam to identify injuries, laboratory tests and radiologic imaging. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics).
~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
16353437|NCT04304482|Experimental|ANAVEX2-73 Active|ANAVEX2-73 liquid oral solution
16353438|NCT04304482|Placebo Comparator|ANAVEX2-73 Placebo|Placebo liquid oral solution
16353439|NCT04304469||women|women consulting for domestic violence
16353440|NCT04304456||HA-BSI|Patients with HA-BSI treated in an ICU
16353441|NCT04304430||Dapagliflozin|Patients who initiated a new therapy with dapagliflozin
16353442|NCT04304430||DPP-4i|Patients who initiated a new therapy with a DPP-4i
16353443|NCT04304404|Experimental|Intervention group (BrCaRRP)|Individual interventions based on the Health Belief Model and the The Health Promotion Model involving education, guidance, counseling, case management and surveillance for women with high breast cancer risk
16353444|NCT04304404|No Intervention|Control Group|An information note will be given to the control group. The post-tests will be collected at the end of 12 weeks
16353445|NCT04304391|Experimental|Group A|Conventional Gingivectomy:Technique is performed with conventional surgical instruments.
16353446|NCT04304391|Experimental|Group B|Diode Laser Assisted Gingivectomy: Technique is performed with using diode laser.
16353447|NCT04304391|Experimental|Group C|Er:YAG Laser Assisted Gingivectomy: Technique is performed with using Er:YAG laser.
16353448|NCT04304391|No Intervention|Group D|Negative Control Group
16353449|NCT04304378|Active Comparator|Stabilization Techniques (ST)|"Participants randomized into ST will receive 6 weekly 1-hour sessions of Stabilization Techniques from a Khmer-speaking mental health professional. Sessions provide an opportunity to improve emotion regulation and provide coping skills for managing symptoms of PTSD.
~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
16353450|NCT04304378|Experimental|Stabilization Techniques with Behavioral Activation (ST+BA)|"Participants randomized into ST+BA will receive 3 weekly 1-hour sessions of ST and 3 weekly 1-hour sessions of BA from a Khmer-speaking mental health professional. Sessions include stabilization techniques and behavioral skills that aim to establish and maintain routines, reduce avoidance, and manage negative emotions.
~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
16353451|NCT04304365|Active Comparator|Clinic follow-up group|All participants in this group will receive the standard of care at BMC which includes receiving a follow-up visit date and time before leaving the initial visit, when they receive the medications for abortion. Patients then return to clinic 1-2 weeks later to be seen by a provider with an ultrasound for confirmation of abortion completion. Participants who do not come for a return visit receive one phone call to reschedule their appointment.
16353452|NCT04304365|Experimental|Home follow-up group|Participants enrolled in the home follow-up group will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. At enrollment, they will receive instruction for timing of contact, how to use the LSPT, as well as the test itself. The participant will take the pregnancy test at home in 14 days and answer completion questions by text message for follow-up. Patients that screen positive will be asked to return to clinic for a visit with a provider.
16353453|NCT04304352|Experimental|Metronomic VEX|Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
16353454|NCT04304326|Experimental|Intervational|"FT: Functional training with elastic band Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.
~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group.
~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
16353455|NCT04304326|Experimental|Arms and Interventions|"Resistance exercise with weight training machines. Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.
~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).
~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
16353456|NCT04304313|Experimental|Sildenafil citrate tablets|
16353457|NCT04304300||Study group|Glioma, IDH mutated, grade 2 and 3
16353458|NCT04304287|Experimental|Experimental|Preoperative blood donations 14 day before total hip replacement procedure Donation of one dose of autologous blood 14 day before total hip replacement procedure
16353459|NCT04304287|Active Comparator|Active comparator|Preoperative blood donation 72 hours before total hip replacement procedure Donation of one dose of autologous blood 72 hours before total hip replacement procedure
16353460|NCT04304287|Other|Other|Without preoperative blood donation
16353461|NCT04304274|Experimental|PTPVB-ropivacaine|Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
16353462|NCT04304274|Placebo Comparator|PTPVB-saline|Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine
16353463|NCT04304261|Experimental|Dapagliflozin|12 weeks of Dapagliflozin(10mg/day) treatment, randomly
16353464|NCT04304261|Experimental|Metformin|12 weeks of Metformin (1500-2000mg/day) treatment, randomly
16353465|NCT04304248|Experimental|Neoadjuvant chemo-immunotherapy|"Neoadjuvant treatment (Albumin-bound paclitaxel + carboplatin + toripalimab) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.
~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment."
16353466|NCT04304235|Active Comparator|Control|Hospital nurses will triage participants using the Emergency Triage and Treatment (ETAT) guidelines, the triage policy that is currently in place at the study hospital sites.
16353467|NCT04304235|Experimental|Intervention|Hospital nurses will triage participants using the digital triage tool (mhealth intervention).
16353468|NCT04304222|Other|Sequence A|To receive the conventionally made denture framework then the 3D printed denture framework.
16353469|NCT04304222|Other|Sequence B|To receive the 3D printed denture framework then the conventionally made denture framework.
16353470|NCT04304209|Experimental|Cohort A|Four cycles of neoadjuvant PD1 antibody Sintilimab, followed by curative surgery or watch and wait, then four cycles of adjuvant PD1 antibody Sintilimab ± Capeox according to pathologic response
16353547|NCT04303585||SAP block|This group includes patients who receive preoperative Serratus Anterior Plane block
16353471|NCT04304209|Experimental|Cohort B-arm 1|Four cycles of neoadjuvant PD1 antibody Sintilimab, Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy
16353472|NCT04304209|Active Comparator|Cohort B-arm 2|Four cycles of neoadjuvant Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy
16353473|NCT04304196|Experimental|TEMPO|These patients and caregivers will be able to access the TEMPO modules and will receive technical support to use it effectively. Patients will receive usual care throughout the study.
16353474|NCT04304196|Active Comparator|Control|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
16353475|NCT04304183||slow transit constipation|patients diagnosed with slow transit constipation had undergone surgery.
16353476|NCT04304170|Experimental|Verum group|The dietary supplement under study was composed of fructo-oligosaccharides - FOS: 4.95 gr / sachet and Bifidobacterium animalis lactis: VES002 (LMG P-28149): 5 billion / sachet. They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
16353477|NCT04304170|Placebo Comparator|Placebo group|The comparative product was a placebo that looked strictly identical to the verum and contained only excipients (60% maltodextrin / 40% sucrose).They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
16353478|NCT04304157|Experimental|satisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
16353479|NCT04304157|Experimental|unsatisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
16353480|NCT04304144|Experimental|Part A: CAEL-101 combined with SoC CyBorD|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The initial cohort dose assignments of CAEL-101 will be: Cohort 1 - 500 mg/m^2 Cohort 2 - 750 mg/m^2 Cohort 3 - 1000 mg/m^2. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
16353481|NCT04304144|Experimental|Part B: CAEL-101 combined with SoC CyBorD and daratumumab|CAEL-101 is administered as an intravenous (IV) infusion at the RP3D dose level. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
16353482|NCT04304131|Experimental|Colorectal cancer|Confirmed colorectal cancer under colonoscopy
16353483|NCT04304131|Experimental|Colon polyp|Confirmed colorectal polyp under colonoscopy
16353484|NCT04304131|Active Comparator|Healthy|Confirmed no cancer nor polyp under colonoscopy
16353485|NCT04304092|Experimental|Low amount, low intensity|
16353486|NCT04304092|Experimental|Low amount, high intensity|
16353487|NCT04304092|Experimental|High Amount, low intensity|
16353488|NCT04304092|Experimental|High Amount, high intensity|
16353489|NCT04304092|No Intervention|Control|
16353490|NCT04304079|Experimental|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
16353491|NCT04304066|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
16353492|NCT04304053|Active Comparator|No Intervention- SARS-CoV-2 surveillance|"Study 1- Contacts will complete a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and day 14.
~Study 2- Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3 and 7.
~Isolation of patient and contact tracing as per national guidelines."
16353493|NCT04304053|Experimental|Testing, treatment and prophylaxis of SARS-CoV-2|"Study 1- Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14.
~Study 2- Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7.
~Isolation of patient and contact tracing as per national guidelines."
16353494|NCT04304040|Experimental|Single Arm|
16353495|NCT04304027|Experimental|Tailored exercise intervention|8 weeks of aerobic interval training at moderate intensity which is modified according to the levels of self-reported fatigue
16353496|NCT04304027|Active Comparator|Standard exercise intervention|8 weeks of aerobic interval training at a moderate intensity
16353497|NCT04304027|No Intervention|Usual care control|Participants in the usual care control group will continue to receive their standard care independent of this study
16353498|NCT04304014|Experimental|L. reuteri|"Group that will receive L. reuteri one dose per day in an oral suspension
~Intervention: Dietary Supplement: L. reuteri"
16353499|NCT04304014|Experimental|B. longum and P. Pentosaceus|"Group that will receive B. longum and P. Pentosaceus one dose per day in an oral suspension.
~Intervention: Dietary Supplement: B. longum and P. Pentosaceus"
16353500|NCT04304001|Experimental|Community Health Advisor|Intervention arm participants will be scheduled to receive the CHA intervention within 4 to 6 weeks after enrollment, a FIT kit, a mailed targeted CRC brochure, and a follow-up telephone survey at 3- and 12-months post-intervention
16353548|NCT04303585||ESP block|This group includes patients who receive preoperative Erector Spinae Plane block
16353502|NCT04303988|Experimental|Cohort HR+/HER2+|Hormone receptor negative, HER2 positive participants will receive Pyrotinib in combination with Temozolomide until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16353503|NCT04303988|Experimental|Cohort HR-/HER2-|Hormone receptor negative, HER2 negative participants will receive SHR1316 in combination with bevacizumab plus cisplatin or carboplatin until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16353504|NCT04303975||Group 1: Patients with neoadjuvant chemotherapy|"The patients of group1 will receive one of the following treatments:
~neoadjuvant chemotherapy & concurrent chemoradiotherapy
~neoadjuvant chemotherapy & radiotherapy
~neoadjuvant chemotherapy & radiotherapy & adjuvant chemotherapy"
16353505|NCT04303975||Group 2: Patients without neoadjuvant chemotherapy|"The patients of group2 will receive one of the following treatments:
~concurrent chemoradiotherapy
~concurrent chemoradiotherapy & adjuvant chemoradiotherapy
~radiotherapy & adjuvant chemotherapy"
16353506|NCT04303949|Experimental|Experimental|e-book for termination
16353507|NCT04303949|Other|Control|routine care Written form health education
16353508|NCT04303936|Other|Patients with severe HA under FVIII concentrates prophylaxis|
16353509|NCT04303923||Male group|Male patients who performed transthoracic echocardiography with arterial ultrasonography
16353510|NCT04303923||Female group|Female patients who performed transthoracic echocardiography with arterial ultrasonography
16353511|NCT04303897||XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
16353512|NCT04303884|Experimental|Experimental: Pembrolizumab|Chemo-resistant gestational trophoblastic neoplasias treated with pembrolizumab
16353513|NCT04303871|Active Comparator|patients|pregnant female with hypertension admitted in ICUfor control of BP invasive assessment of BP by radial cannulation was compared against non-invasive assessment of BP by an automated oscillometric BP device (Mobil-O-Graph )
16353514|NCT04303871|Placebo Comparator|control|matched control females of the same age but not pregnant invasive compared to non-invasive measurement of BP by same technique
16353515|NCT04303858|Experimental|RO7284755 as a Single Agent|Part 1: Dose-escalation of RO7284755 as a single agent. RO7284755 will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
16353516|NCT04303858|Experimental|RO7284755 in Combination with Atezolizumab|Part 2: Dose-escalation of RO7284755 in combination with atezolizumab.
16353517|NCT04303858|Experimental|RO7284755 as a Single Agent and/or with Atezolizumab|Part 3: Extension of RO7284755 as a single agent and/or in combination with atezolizumab.
16353518|NCT04303845|Experimental|Treatment with Erenumab|Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
16353519|NCT04303832|Experimental|eye exercise group|This group made different types of eye exercises beside the traditional treatment of strabismus which is eye glasses
16353520|NCT04303832|Sham Comparator|control group|This group had traditional treatment of strabismus which is eye glasses
16353521|NCT04303819||newly diagnosed T2DM participants|newly diagnosed T2DM participants without anti-diabetic drugs intake
16353522|NCT04303806|Experimental|Group 1|40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.
16353523|NCT04303806|Experimental|Group 2|40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily.
16353524|NCT04303780|Experimental|AMG 510|
16353525|NCT04303780|Active Comparator|Docetaxel|
16353526|NCT04303767|Experimental|Test (ART + CPP-ACP)|In this group, teeth selected will receive intervention with CPP-ACP and restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
16353527|NCT04303767|Active Comparator|Control (ART)|in this group, teeth selected will receive restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
16353528|NCT04303754|Experimental|Diabetes-Specific Formula|Diabetes-Specific Formula
16353529|NCT04303754|Experimental|Bread and Spread|White bread with spread
16353530|NCT04303754|Experimental|Rice Porridge|Rice Porridge
16353531|NCT04303741|Experimental|Camrelizumab +Apatinib+Eribulin|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv Q3W combination with Apatinib 250mg, po, daily (d1-d21)and Eribulin1.4mg/m2 iv d1, d8 Q3W
16353532|NCT04303728|Experimental|Muscle ultrasound|Muscle ultrasound will be performed for the patient on admission and at 1-2 months from inpatient rehabilitation.
16353533|NCT04303715|Experimental|No SLNB group|The study arm - BCS without SLNB
16353534|NCT04303715|Other|SLNB group|The Control Arm - BCS with SLNB(+/-ALND)
16353535|NCT04303702|Placebo Comparator|Control|
16353536|NCT04303702|Active Comparator|Oxytocin|
16353539|NCT04303676|Active Comparator|Virtual Practice Facilitation with e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions utilizing alcohol use e-learning modules to guide and focus the process and content
16353540|NCT04303676|Active Comparator|Virtual Practice Facilitation without e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions without utilizing alcohol use e-learning modules
16353541|NCT04303663|Active Comparator|Fibular Plate|Open reduction and internal fixation of the fibular fracture Fixation of the fibular will be performed with a fibular plate +/- lag screws as judged intraoperatively
16353542|NCT04303663|Experimental|Fibular Nail|Percutaneous or mini-open reduction of the fibular fracture and fixation with a fibular nail.
16353543|NCT04303637||High school student|13-18 year old students enrolled in schools within Singapore.
16353544|NCT04303624||Community sample|Representative sample of the Singapore population
16353545|NCT04303598|Experimental|FNC Treatment Group|FNC 3mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;3TC placebo 1 tablet;daily oral before bedtime
16353546|NCT04303598|Active Comparator|3TC control group|3TC 300mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;FNC placebo 1 tablet;daily oral before bedtime
16353549|NCT04303572|Experimental|Eloctate ITI plus Emicizumab|Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
16353550|NCT04303572|Active Comparator|Eloctate ITI|Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
16353551|NCT04303559|Active Comparator|Eloctate|Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
16353552|NCT04303559|Experimental|Emicizumab|Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.
16353553|NCT04303546||< 30 years|
16353554|NCT04303546||30-60 years|
16353555|NCT04303546||> 60 years|
16353556|NCT04303533|Experimental|EFP-NF|
16353557|NCT04303520|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients
16353558|NCT04303507|Experimental|Chloroquine or Hydroxychloroquine|"In Asia, the participant will receive chloroquine.
~In Europe, the participant will receive hydroxychloroquine
~Specific drug allocation will be determined by country prior to activation based upon factors such as inventory availability and importation requirements"
16353559|NCT04303507|Placebo Comparator|Placebo|
16353560|NCT04303494||Experimental1|preterm infants will be routinely immunised during primary hospitalisation
16353561|NCT04303494||Experimental2|preterm infants discharged and readmitted for immunisation during the 3-year period
16353562|NCT04303494||Control|healthy control infants
16353563|NCT04303481|Other|normal diet|
16353564|NCT04303481|Experimental|weight loss program kit|
16353565|NCT04303481|Experimental|weight loss program kit with A. muciniphila prebiotics|
16353566|NCT04303468|Experimental|GABA|GABA is a nutrient commonly present in our diet in for example tomatoes and potatoes. It is also commercially sold as dietary supplement. A dose of 500 mg, 3 times daily is used
16353567|NCT04303468|Placebo Comparator|Placebo|The placebo consists of capsules containing powdered cellulose.
16353568|NCT04303455||Study group|"The study will evaluate a cohort of participants meeting the following inclusion criteria:
~Admission to ICU after elective and emergency cardiac surgery following cardiopulmonary bypass
~Age 18 years and above
~Arterial, central venous and pulmonary arterial catheters have been inserted as part of routine care
~Data collection, serum renin among routine blood collection on admission, 6 and 24 hours after admission to ICU"
16353569|NCT04303442||Patients undergoing TEP|Patients diagnosed with unilateral or bilateral primary and/or recurrence inguinal hernia undergoing Total Extraperitoneal laparoscopic hernia repair.
16353570|NCT04303429|No Intervention|observation group|Patients enrolled in the observation group will not receive any chemotherapy drugs
16353571|NCT04303429|Experimental|adjuvant chemotherapy group|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
16353572|NCT04303416|Experimental|Patients|Patients before and after the treatment
16353573|NCT04303403|Experimental|Dose Escalation and Expansion|"Dose Escalation:
~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses.
~Dose Expansion:
~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase.
~A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment."
16353574|NCT04303390|Active Comparator|24 hour Cefuroxime arm|25% of the entire study participants are assigned to 24 hours and second generation cephalosporin
16353575|NCT04303390|Active Comparator|24 hour Cefazolin arm|25% of the entire study participants are assigned to 24 hours and first generation cephalosporin
16353576|NCT04303390|Active Comparator|48 hour Cefuroxime arm|25% of the entire study participants are assigned to 48 hours and second generation cephalosporin
16353577|NCT04303390|Active Comparator|48 hour Cefazolin arm|25% of the entire study participants are assigned to 48 hours and first generation cephalosporin
16353578|NCT04303377|Experimental|Evolocumab|Evolocumab administration in the acute phase of ST elevation myocardial infarction
16353579|NCT04303377|No Intervention|Standard of care|
16353580|NCT04303364||Subjects without T2DM and without HF|
16353581|NCT04303364||Patients without T2DM and with HFpEF|
16353582|NCT04303364||Patients with T2DM and without HFpEF|
16353583|NCT04303364||Patients with T2DM and HFpEF|
16353584|NCT04303364||Patients without T2DM and with hypertrophic cardiomyopathy|
16353585|NCT04303364||Patients with T2DM and with hypertrophic cardiomyopathy|
16353586|NCT04303351||0-9 missing teeth|participants with 0-9 missing teeth
16353587|NCT04303351||10-19 missing teeth|participants with 10-19 missing teeth
16353588|NCT04303351||23-31 missing teeth|participants with 23-31 missing teeth
16353589|NCT04303351||Edentulous|participants with no teeth
16353590|NCT04303338|Experimental|Masotherapy with neural tension|The investigators are going to massage the patient´s upper limb applying a radial nerve neural tension. In order to the upper limb should be positioned lowering the scapula, elbow extended, internal rotation glenohumeral, forearm pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and finally glenohumeral abduction.
16353591|NCT04303338|Active Comparator|Masotherapy with non-neural tension|The investigators are going to practice a conventional upper limb massage
16353592|NCT04303325|Placebo Comparator|Control|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
16353593|NCT04303325|Active Comparator|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine.
16353701|NCT04302610|Sham Comparator|SHAM mask|a sham mask (SHAM) which was the same HME mask with holes cut across the entire ventilator cup and the ventilator removed
16353594|NCT04303312|Active Comparator|Benzydamine Hydrochloride|"Control Group:Benzydamine Hydrochloride spray by mouth three times daily for 20 days.
~Follow up: The patients will be recalled at one week interval for 20 days."
16353595|NCT04303312|Experimental|90%solcoseryl and 10% pumpkin seed oil|Intervention group: 90% solcoseryl and 10% pumpkin seed oil spray by mouth three times daily for 20 days
16353596|NCT04303299|Experimental|Oseltamivir plus Chloroquine in Mild COVID19|Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19
16353597|NCT04303299|Experimental|Darunavir and Ritonavir plus oseltamivir|Darunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19
16353598|NCT04303299|Experimental|Lopinavir and Ritonavir plus Oseltamivir in mild COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19
16353599|NCT04303299|Experimental|Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19
16353600|NCT04303299|Experimental|Favipiravir lopinavir /Ritonavir for mod. To severe|Lopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19
16353601|NCT04303299|Experimental|Darunavir /ritonavir oseltamivir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
16353602|NCT04303299|Experimental|Darunavir /ritonavir favipiravir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
16353603|NCT04303299|No Intervention|Conventional Qurantine|Patient who unwilling to treatment and willing to quarantine in mild COVID19
16353604|NCT04303286||Recovery Group|The liver function of HCC patients on the fifth day after the operation is recovered.
16353605|NCT04303286||Recovery Delay Group|The liver function of HCC patients on the fifth day after the operation is delayed recovered.
16353606|NCT04303286||Control Group|The patients on benign disease of the liver
16353607|NCT04303260|Active Comparator|Interventional arm|"Patients in the interventional arm will be asked to complete 3 different videos repeatedly, as many days a week as possible. This repetition is to be maintained even if a patient missed one day of training.
~The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation."
16353608|NCT04303260|Placebo Comparator|controled arm|"Patients in the controled arm will also be asked to practice generally recommended exercises in 3 different videos repeatedly, as many sets as possible..
~The control arm will practice generally recommended exercises, without particular attention to the abdomen."
16353609|NCT04303247|Experimental|CD19+CD22 targeted CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.
~dosage: the number of anti CD19+CD22 CAR T cells
~-1(if needed) 1×10^5/KG
~3×10^5 /KG
~6×10^5 /KG
~1×10^6/KG
~Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion."
16353610|NCT04303234|Active Comparator|Artinibsa|"Powerful local anesthetic with short time for patients who can not tolerate normal doses of vasoconstrictor latency.
~High lipid solubility gives a better diffusion through the soft tissue and bone being very effective in infiltrative techniques.
~Duration:
~Latency time: 2 minutes
~Each mL contains:
~4%Articaine 1:100000. Hydrochloride 40.00 mg, Epinephrine (D.C.I) 0.005 mg tartrate"
16353611|NCT04303234|Experimental|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
16353612|NCT04303221|Experimental|GAJL - Young adult with lymphedema|Women age 35 to 59 years (young adult) with lymphedema - exercise group
16353613|NCT04303221|Experimental|GAJ - Young adult without lymphedema|Women age 35 to 59 years (young adult) without lymphedema - exercise group
16353614|NCT04303221|Experimental|GIL - Elderly with lymphedema|Women aged 60 to 80 years (elderly) with lymphedema - exercise group
16353615|NCT04303221|Experimental|GI - Elderly without lymphedema|Women aged 60 to 80 years (elderly) without lymphedema - exercise group
16353616|NCT04303208|Other|study group|2 ml of whole blood sample will be collected on EDTA tube for detection of Plasmacytoid dendritic cells and Toll like receptor 8 by flow cytometry
16353617|NCT04303208|Other|control group|2 ml of whole blood sample will be collected on EDTA tube for detection of Plasmacytoid dendritic cells and Toll like receptor 8 by flow cytometry
16353618|NCT04303195|Experimental|NG101 - 5 mg|NG101 5 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
16353619|NCT04303195|Experimental|NG101 - 10 mg|NG101 10 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
16353620|NCT04303195|Experimental|NG101 - 20 mg|NG101 20 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
16353621|NCT04303195|Placebo Comparator|Placebo|Placebo-matching, capsules, orally, QID (4 times a day) for up to 12 weeks
16353622|NCT04303182|Active Comparator|Standard 3 port TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
16353623|NCT04303182|Active Comparator|LESS TEP|Group B will undergo laparoscopic TEP inguinal hernia repair with a single skin incision 2-3cm.
16353702|NCT04302610|No Intervention|Control|No mask (CONT) wearing only the balaclava to which the HME and SHAM mask were attached. Mouth and face not covered.
16353628|NCT04303143||Primary|Primary
16353629|NCT04303130|Experimental|Camrelizumab (SHR-1210) Combined With Endostar|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.
~The combination regimen is a medication cycle every three weeks (21 days)."
16353630|NCT04303117|Experimental|Arm 1/Monotherapy|Treatment with NHS-IL12 at de-escalating doses if necessary
16353631|NCT04303117|Experimental|Arm 2/Combination therapy|Treatment with NHS-IL12 at MTD and M7824 at a fixed dose
16353632|NCT04303104|Active Comparator|Mobile ACF|Xpert Edge performed at point-of-care employing a low-cost panel van that is staffed by three health care workers. Patients identified with active TB will be initiated on TB treatment on the same day at the nearest clinic. On site HIV testing will also be offered. Thus, the interventional package is one of ACF + POC TB testing (TB testing by Xpert will occur on site at the van).
16353633|NCT04303104|Placebo Comparator|Centralised ACF|Similar to active arm but Xpert Ultra will be performed at a centralized laboratory (samples will be transported to the laboratory with results being available in a few days). Thus, the standard of care package is ACF + distant TB testing (TB testing by Xpert will occur at a distant laboratory site).
16353634|NCT04303091|Experimental|Exercise group|Single-arm study. Participants enrolled engaged in a 12-week exercise program.
16353635|NCT04303078|Experimental|Children with Cerebral Palsy (Cases)|
16353636|NCT04303078|Other|Typically Developing Children (Controls)|
16353637|NCT04303065|Experimental|Dexamethasone|"Dexamethasone will be a short and descending course: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
~Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain). The Son Espases Pharmacy Department will be in charge of developing and conditioning the 4mg, 2mg and 1mg dexamethasone / placebo capsules needed for 12 days of treatment, keeping the researchers blind"
16353638|NCT04303065|Placebo Comparator|Control|"The preparation and conditioning of the capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
~The Son Espases Pharmacy Department will be responsible for identifying the containers and sending them by courier to the participating hospitals. A record of the dispensing of test samples will be kept and will be sent in acknowledgment of receipt for control"
16353639|NCT04303052|Active Comparator|over-the-wire technique with 145 cm guidewire|Catheter tip placement using Seldinger over-the-wire technique with 145 cm guidewire
16353640|NCT04303052|Active Comparator|modified technique with 70 cm guidewire|Catheter tip placement using Seldinger modified technique with 70 cm guidewire
16353641|NCT04303039|Experimental|Treatment A|Single 1.0 mg dose of ABP-671 in the fasted state.
16353642|NCT04303039|Experimental|Treatment B|Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast.
16353643|NCT04303026|Active Comparator|Treatment Group|Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline
16353644|NCT04303026|Placebo Comparator|Placebo Group|Participants receiving Placebo with two infusions of 100 ml 0.9% saline with 3 months interval.
16353645|NCT04303013|Active Comparator|Standard of Care|
16353646|NCT04303013|Experimental|Meditation|
16353647|NCT04303000|Experimental|Opioid Overdose Education and Naloxone Distribution|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will be provided with a naloxone nasal spray kit (4mg).
16353648|NCT04303000|Active Comparator|Opioid Overdose Education|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will receive information about pharmacies in their area where they can purchase a naloxone kit.
16353649|NCT04302974||Sub-study 1: Trajectory study|All HA primary care patients aged 18 years or above with doctor-documented HT and/or DM receiving care in HA General Out-patient Clinics or Family Medicine Clinics (FMC) identified from the HA CMS database between 2006 and 2019, to explore the trajectory patterns for clinical, treatment and complication profiles and investigate the impact of multi-morbidity, continuity-of-care, different service delivery models and management strategies (including investigation frequency and specific drug regimens) on outcomes and health service utilization.
16353650|NCT04302974||Sub-study 2: RAMP-DM|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who attended the first RAMP-DM assessment between August 2009 to September 2010
16353651|NCT04302974||Sub-study 2: usual care only|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who have never attended any RAMP-DM assessment between August, 2009 to December, 2019
16353652|NCT04302974||Sub-study 3: RAMP-HT|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who attended the first RAMP-HT assessment between October 2011 to March 2013
16353653|NCT04302974||Sub-study 3: usual care only|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who have never attended any RAMP-HT assessment between October 2011 to December 2021
16353654|NCT04302974||Sub-study 4: PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have received the first PSCC call between September, 2012 to August, 2016 after the first RAMP-DM assessment
16353655|NCT04302974||Sub-study 4: without PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have never received any PSCC services between September 2012 to December 2021
16353658|NCT04302948|No Intervention|Treatment as usual|TaU includes screening for anti-HCV using a rapid point-of-care (PoC) test to screen for exposure to HCV followed by counseling, brief education and referral to provider for further evaluation for HCV treatment.
16353659|NCT04302948|Experimental|Rapid PoC RNA testing|Intervention arm includes Tau ( screening for anti-HCV using a rapid point-of-care (PoC) test, and a rapid PoC screening test for HCV RNA, counseling plus, brief education and referral to a provider for further evaluation for HCV treatment. Rapid HCV RNA testing will be conducted using Cepheid Xpert (r) system.
16353660|NCT04302935||chronic pain patients|
16353661|NCT04302909|Active Comparator|Active Comparator|fESWT
16353662|NCT04302909|Sham Comparator|Sham Comparator|Sham fESWT
16353663|NCT04302896|Experimental|dolutegravir + emtricitabine/tenofovir alafenamide|Tivicay® (dolutegravir 50 mg tablet) + Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg combination tablet), one tablet of each taken by mouth once daily for 15 days
16353664|NCT04302896|Experimental|dolutegravir + tenofovir disoproxil fumarate + lamivudine|Tivicay® (dolutegravir 50 mg tablet) + Viread® (tenofovir disoproxil fumarate 300 mg tablet) + lamivudine 300 mg tablet, one tablet of each taken by mouth once daily for 15 days
16353665|NCT04302883|Experimental|Intervention group|TEE FEES
16353666|NCT04302883|Active Comparator|Control group|FEES
16353667|NCT04302870|Experimental|Memantine|
16353668|NCT04302870|Experimental|Trazodone|
16353669|NCT04302870|Placebo Comparator|Placebo|
16353670|NCT04302844|Active Comparator|Imago Relationship Therapy (IRT)|Couples will receive 12 to 16 Imago relationship therapy sessions (90 minutes each; one session per week) with an experienced and certified Imago Relationship therapist.
16353671|NCT04302844|Active Comparator|Waitlist with Bibliotherapy followed by Workshop|Couples will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read during that time. After 12 weeks and the 12-week assessment has been completed, couples will receive a Getting the Love You Want workshop.
16353672|NCT04302831|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
16353673|NCT04302831|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
16353674|NCT04302818|Experimental|Social skills group training SKOLKONTAKT|Manualised social skills group training.
16353675|NCT04302818|Active Comparator|Active control comparison group|Social activities in a group setting.
16353676|NCT04302805|Placebo Comparator|PE/rATG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg).
16353677|NCT04302805|Active Comparator|PE/rATG/IVIG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg) and IVIG 0.5g/kg intravenous infusions, on 1st, 3rd and 5th postoperative day. This is a center standard of care regimen.
16353678|NCT04302792|No Intervention|Stage 1: Interviews and focus group sessions|"Group A: Cancer patients (requiring or have required texture-modified foods and/or experiencing or have experienced taste&smell alterations in the last 12 months) will be required to attend a one-hour online interview.
~Group B: Relatives of cancer patients (requiring texture-modified foods and/or experiencing taste&smell alterations) will be required to attend a 2-hour online focus group session.
~Group C: Healthcare professionals with a minimum of a year's experience with oncological patients that require texture-modified foods and/or have taste & smell alteration will be required to attend a 2-hour online focus group session.
~A food diary will be given to Group A and B to complete for 7-days prior to their session. Topics to be discussed during the interview and the focus group sessions will include the food requirements of cancer patients, the barriers of the current food products, possible solutions to these requirements if any and their expectations towards new food solutions."
16353703|NCT04302597|Active Comparator|Staples|Women who underwent repeated cesarean section with skin closure using staples.
16353704|NCT04302597|Experimental|Tissue adhesive|Women who underwent repeated cesarean section with skin closure using 2-octylcyanoacrylate tissue adhesive.
16353679|NCT04302792|Experimental|Stage 2: Texture-modified foods for cancer patients|The study will involve conducting a tasting trial over a 2-weeks period where participants will be required to consume a maximum of three 3D printed texture-modified food based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
16353680|NCT04302792|Experimental|Stage 3: Taste-optimised foods for cancer patients|The study will involve conducting a home test over a one-month period where participants will be required to consume taste-optimised products based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
16353681|NCT04302779|Experimental|Solid Model|Whey Permeate Lemon Cupcake and Protein Fortified Lemon Cupcake
16353682|NCT04302779|Experimental|Liquid Model|Whey Protein Beverage
16353683|NCT04302740|Active Comparator|LEAP|Housing First plus LEAP
16353684|NCT04302740|No Intervention|Service-As-Usual|Housing First
16353685|NCT04302727|Experimental|Med-South Weight Loss Intervention|The intervention will be delivered in 3 phases over 24 months: Phase I (4 months) provides a foundation for adopting and maintaining a healthful dietary pattern (Med-style, tailored for the southeastern United States); Phase II (8 months) focuses on weight loss; and Phase III (12 months) on maintenance of or continued weight loss, as appropriate.
16353686|NCT04302727|Active Comparator|Augmented Usual Care (WW)|The intervention that will be offered to control group participants is WW™ (formerly known as Weight Watchers). The study will provide access to the 'Workshop + Digital' option of WW™ during the 2 year intervention.
16353687|NCT04302714|Active Comparator|cervical injection|Fluorescent SLN Imaging With Indocyanine Green (ICG), using near-infrared fluorescence imaging, will be used as a dye for SLN mapping. Injections will be performed intraoperative. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room, and 4 mL is injected directly into the cervix. This solution was injected intracervically at 3 and 9 o'clock positions, both submucosally and deep into the cervical stroma. A spinal needle 18-gauce is used to inject the ICG. The 4 mL can be divided into 4 separate injections (1 mL each). The ICG should be injected slowly, at a rate of 5 to 10 seconds per quadrant.
16353688|NCT04302714|Experimental|hysteroscopic injection|hysteroscopy is performed using an operative hysteroscope. Uterine distension is obtained by means of saline solution. Usually, the fluid bag is placed 50 cm above the patient's plane so that the intracavitary pressure does not exceed 40 mm Hg. After visualization of uterine cavity a 22-gauce, 40-mm needle was introduced into the operative port and IGC is injected peritumorally. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room. The injection is performed subendometrially around the lesion, or, if the uterine cavity was totally involved by disease, at 3, 6, 9, and 12 o'clock . The depth of needle placement is modulated by visualizing endometrial elevation during injection.
16353689|NCT04302701|Experimental|Dichoptic arm|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
16353690|NCT04302701|Active Comparator|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near. Adherence to the treatment protocol will be assessed by having the parent call / send a message to an investigator at the start and end of the occlusion sessions completed each day, thus making the most as accurate as possible assessment of the patient's adherence to the prescribed treatment
16353691|NCT04302688||modeling cohort|The 445 patients were grouped in chronological order.
16353692|NCT04302688||validating colort|The remaining 224 patients.
16353693|NCT04302675|Experimental|Prevention, Maternal Immunization|
16353694|NCT04302649|Experimental|Intervention group|Patients received Peritoneal Equilibration Test (PET). In the intervention group, dialysate was warmed in a specific microwave oven calibrated to 37°C and infusion temperature was confirmed to be 37°C before infusion
16353695|NCT04302649|No Intervention|Control group|Patients received Peritoneal Equilibration Test (PET). In the control group, current practice was used (batch warming with a pad calibrated to 37°C) and dialysate temperature was measured just before infusion.
16353696|NCT04302636|Experimental|The hypoglycemic index diet group|"Patients in the experimental group ate two portions of food each day.This diet will last for 12 weeks.
~Food provided by the canteen: one egg for breakfast;Lunch and dinner are 50g of rice with all the dishes.
~Dietary nutrition and supplementary food: according to the weight and height of the patient, the daily energy required was calculated, which was divided into six levels: 1400kcal, 1600kcal, 1800kcal, 2000kcal, 2200kcal and 2400kcal.The six corresponding nutritional auxiliary food powders are: 20g-30g-40g-50g-60g-70 g.The suspension was prepared in the proportion of 160ml warm water poured into 55 grams and given to the patient."
16353697|NCT04302636|No Intervention|General diet group|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
16353698|NCT04302623|Experimental|Online yoga program|An 8-week online live facilitator-led yoga program.
16353699|NCT04302623|Experimental|Control|Advice only group.
16353700|NCT04302610|Experimental|HME MASK|During the Exercise, participants wore either an HME mask (MASK) (ColdAvenger® expedition balaclava, USA, www.coldavenger.com)
16353706|NCT04302584|Active Comparator|NE/VP|patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
16353707|NCT04302571|No Intervention|Healthy control|Voluntary subjects without peripheral arterial disease
16353708|NCT04302571|Sham Comparator|IC patients, no exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, given advices to perform regular aerobic activity
16353709|NCT04302571|Active Comparator|IC patients, exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, home-based combined physical exercise
16353710|NCT04302558|Experimental|Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while the blood flow to the leg is reduced by a blood flow restriction cuff.
16353711|NCT04302558|Sham Comparator|SHAM Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while a blood flow restriction cuff is applied but inflation pressure will be limited
16353712|NCT04302545|Experimental|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
16353713|NCT04302545|No Intervention|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
16353714|NCT04302532|Active Comparator|Clomiphene|clomiphene citrate 150 mg once a day for 5 days
16353715|NCT04302532|Experimental|clomiphene and coenzyme q10|clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day
16353716|NCT04302519|Experimental|Pulp mesenchymal stem cells|1. 3, 7 days to increase the injection of mesenchymal stem cells
16353717|NCT04302506||Patients with drug-induced liver injury|Patients who underwent liver biopsy and were diagnosed with drug-induced liver injury were diagnosed as DILI.
16353718|NCT04302493|Experimental|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course.
16353719|NCT04302493|Active Comparator|Stroke Support Group (SSG)|As a control group, participants will participate in 8 weeks of weekly Stroke Support Group.
16353720|NCT04302480|Experimental|Alternative smoking products (ASP)|
16353721|NCT04302480|Active Comparator|Sugar-sweetened beverages (SSB)|
16353722|NCT04302467|Experimental|GDFT group|Fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, when SVV>13%, 4 mL/kg bolus of hydroxyethyl starch will be infused within 5 min. If SVV falls below 13%, the bolus will be suspended. If SVV is still more than 13%, 100 μg of phenylephrine will be administered when CI is more than 2.5 L/min/m2, 1 mg of dopamine will be administered when CI is less than 2.5 L/min/m2. When SVV<13%, but mean arterial pressure (MAP)<65 mmHg, 8 μg of norepinephrine will be administered. The hemodynamic status will be repeatedly measured every 10 min.
16353723|NCT04302467|Experimental|restrictive fluid therapy group|fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, hydroxyethyl starch will be infused to supply blood loss, the ratio of hydroxyethyl starch to blood loss is 1:1. 0.01-0.1 μg/kg/min of norepinephrine will be administered to maintain MAP>65 mmHg.
16353724|NCT04302454|Active Comparator|Radiotherapy without hormonal therapy|Metastase-directed radiotherapy without the addition of hormonal therapy
16353725|NCT04302454|Experimental|Radiotherapy combined with hormonal therapy|Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
16353726|NCT04302441|Experimental|NXH group|Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
16353727|NCT04302441|No Intervention|H group|Patients should receive trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year.
16353728|NCT04302428||Pediatric CF Patients|Pediatric patients ages 3 months to 3 years with CF identified via newborn screening.
16353729|NCT04302415||only liver metastasis|There is no other intervention, only clinical treatment.
16353730|NCT04302415||only lung metastasis|There is no other intervention, only clinical treatment.
16353731|NCT04302415||only brain|There is no other intervention, only clinical treatment.
16353732|NCT04302415||No distant metastasis|There is no other intervention, only clinical treatment.
16353733|NCT04302415||More than two organs metastasis|There is no other intervention, only clinical treatment.
16353734|NCT04302402|Active Comparator|Rifaximin|Rifaximin 550mg thrice daily for 14 days Other Name: Normix
16353735|NCT04302402|Placebo Comparator|Placebo|Placebo thrice daily for 14 days
16353736|NCT04302389|Experimental|Lifestyle Modification Program|This 6-month intervention includes the use of three components: WW's mobile app, virtual workshops, and a private online community. The WW Program involves: self-monitoring of weight, dietary intake, and physical activity; making dietary changes; increasing physical activity; shifting to a more helpful mindset; and learning behavioral strategies to manage these goals. Each week, participants will set goals and weigh-in with a coach via virtual workshop. Participants will be encouraged to use the app and private online community daily and attend weekly virtual workshops. The weekly virtual workshop led by a trained WW Coach features a behavior change technique and enables the participant to practice it to support their goals. These are actionable techniques and strategies that are grounded in scientific research.
16353737|NCT04302376||Catheter-related thrombosis|The presence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
16353738|NCT04302376||No catheter-related thrombosis|The absence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
16353739|NCT04302363||Control Group|Healthy controls must be 18-75 years old with no tumors and no history of cancer.
16353740|NCT04302363||Test Group|Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.
16353981|NCT04300595|Active Comparator|general anesthesia (Group G)|Patients receive general anesthesia with intravenous opioids and local infiltration of saline (Group G)
16353741|NCT04302350|Active Comparator|group A 100% O2|After the targeted segment bronchus, artery, and intrasegmental vein were identified and dissected by ligation or stapler cutting, the sputum suction operation was performed on the healthy and surgical lungs,by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate of the ventilator (group A is 100% O2 ), adjust the APL valve to 20cmHg, so that the storage gas bag is filled with test gas, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg, after the lungs where the target segment is completely expanded, perform pure oxygen mechanical single lung ventilation, waiting for clear presentation of the plane between segments.
16353742|NCT04302350|Experimental|group B 75% N2O|After the surgeon has finely dissected the target artery, vein, and bronchi, accurately judged and processed it,and the patient with the end-of-breath carbon dioxide sampling tube on the monitor was terminated to a portable TD600-SH-N2O detection end of the nitrous oxide concentration detector to measure the test gas concentration (express in vol%), by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate to 1 and N2O flow rate of the ventilator to 3( group B 75% N2O), adjust the APL valve to 20cmHg, making the N2O concentration detector reach the predetermined gas concentration, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg.
16353743|NCT04302350|Experimental|Group C 50% N2O|After the surgeon has finely dissected the target artery, vein, and bronchi, accurately judged and processed it, and the patient with the end-of-breath carbon dioxide sampling tube on the monitor was terminated to a portable TD600-SH-N2O detection end of the nitrous oxide concentration detector to measure the test gas concentration (express in vol%), by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate to 1 and N2O flow rate of the ventilator to 1( group C 50% N2O), adjust the APL valve to 20cmHg, making the N2O concentration detector reach the predetermined gas concentration, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg.
16353744|NCT04302337|Active Comparator|Conventional Curettage Adenoidectomy|Adenoidectomy with Beckmann Adenoid Curette
16353745|NCT04302337|Experimental|Curettage Adenoidectomy With Transoral Endoscopic Ablation|Transoral endoscopic adenoidectomy with Coblator 2 system
16353746|NCT04302324|Experimental|daratumumab/clarithromycin/pomalidomide/dexamethasone|"Induction Phase: 8 cycles (each cycle is 28 days)
~Daratumumab:
~1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8
~Clarithromycin
~500mg PO BID until VGPR or 8 cycles, whichever occurs first
~Pomalidomide 4mg PO on Days 1-21
~Dexamethasone 20mg IV as pre-medication on Day 1, 8, 15, 22 20mg PO on the day after daratumumab for Cycle 1-2 40mg PO pre-daratumumab on Day 1 and 15 for Cycle 3-6 40mg PO on non-daratumumab on Day 8 and 22 for Cycle 3-6 20mg PO pre-daratumumab on Day 1 for Cycle 7-8
~Maintenance Phase: up to 24 months (each cycle is 28 days)
~Daratumumab 1800 mg SC on Day 1
~Pomalidomide 4mg PO on Day 1-21
~Dexamethasone 20mg IV pre-daratumumab on Day 1"
16353747|NCT04302311|Active Comparator|Standard of Care|Holter monitoring
16353748|NCT04302311|Active Comparator|Enhanced Monitoring|Kardia/AliveCor monitoring with additional Holter monitoring as needed
16353749|NCT04302298|Experimental|Virtual Reality Group|This group will go through the virtual reality simulation of a procedure prior to doing it on a plastic SawBone.
16353750|NCT04302298|No Intervention|Technique Guide Group|This group will go be able to read through a technique guide on the procedure prior to doing it on a plastic SawBone. This is the current method of learning in surgical residencies.
16353751|NCT04302285|Experimental|Exercise trial|In this trial, participants were asked to exercise for one hour under controlled laboratory conditions. Participants were exercising on the treadmill at speed and grade corresponding to 60% of their V̇O2max. Participants were wearing a HR monitor and a face mask while exercising, connected to indirect calorimetry equipment. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
16353752|NCT04302285|Experimental|Control trial|In this trial, participants were asked to rest for one hour. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
16353753|NCT04302259|Experimental|SCI Patient|Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
16353754|NCT04302233|Experimental|New pharmaceutical support (NPS)|"An NPS is an interview comprising the following elements:
~The delivery of the identification sheet of their implants with:
~a quiz to focus the patient's attention
~a description of the characteristics of their prosthesis using a specific photo of their implant
~a presentation of the medical device vigilance.
~an explanation of the value of the identification sheet for their implant, An in-depth presentation of an information booklet on living at home with their prosthesis and on medical and paramedical monitoring.
~For patients in orthopedic surgery: a booklet specific to their prosthesis and the surgical approach For plastic surgery patients, the information sheets published by the French Society of Plastic Reconstructive and Aesthetic Surgery (SOF.CPRE).
~A time to answer any questions the patient may have"
16353755|NCT04302233|No Intervention|Usual pharmaceutical support (UPS)|"An UPS is an interview comprising the following elements:
~The delivery of the same patient-implant sheet as in arm 1, but without additional oral information.
~The delivery and oral presentation of the same booklet as practiced in the arm 1 (NPS).
~And a time to answer any questions from the patient months"
16353756|NCT04302220||high myopia|Population who have high myopia.
16354322|NCT04298151|Active Comparator|ketac molar aplicap|conventional viscous glass ionomer restoration
16353757|NCT04302207|Experimental|High intervention hospital (Nationwide Childrens Hospital)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; provider surveys measuring the acceptability, appropriateness, feasibility, and perceived burden of piloted strategies; review of patient data extracted from electronic health record 1-year pilot, 10 months post-pilot data
16353758|NCT04302207|No Intervention|Low intervention hospital (Childrens Hospital Colorado)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; review of patient data extracted from electronic health record 1-year pilot, 10 months post-pilot data
16353759|NCT04302194||Patients with Phenylketonuria|
16353760|NCT04302194||normal healthy children|
16353761|NCT04302181|Experimental|Stellate Ganglion Block|One time administration of a stellate ganglion block
16353762|NCT04302168|Active Comparator|Choline Supplement Group|Choline Supplement 470 mg twice daily for total of 8 weeks.
16353763|NCT04302168|Placebo Comparator|Placebo Group|Placebo pill twice daily for total of 8 weeks.
16353764|NCT04302155|Experimental|Nintendo Wii|Balance-specific exer-games focusing on dynamic aspects of center of pressure (COP) on Wii fit system.
16353765|NCT04302155|Experimental|Traditional|Mini trampoline two balance exercises of 6 minutes on mini trampoline for a total duration of 3 min on each leg Inflatable discs 4 balance exercises of 12 minutes on BOSU ball 6 minutes on rounded side and 6 minutes on rigid side.
16353766|NCT04302142|Experimental|Intervention group|
16353767|NCT04302142|Placebo Comparator|Control Group|
16353768|NCT04302129|Experimental|ultrasound guided erector spinae block and general anaesthesia|Ultrasound guided erector spine plane block is done after general anaesthesia and prone positioning
16353769|NCT04302129|Active Comparator|Multimodal analgesia with general anaesthesia|Multimodal analgesia given with general anaesthesia in form of ketorolac and paracetamol
16353770|NCT04302116|Experimental|Combination therapy with vigabatrin and prednisolone|"Vigabatrin (tablet of 500 mg) dose based on weight divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment. Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks.
~Prednisolone (tablet of 5 mg), 40 mg of prednisolone (10 mg oral 4 times a day) for 14 days. Prednisolone will be increased to 60 mg/day (20 mg oral 3 times a day) if seizures still occur at Day 7 or recur within Day 8 - 14. Then, prednisolone will be reduced every 5 day until completely off within 1 month. Total prednisolone duration is 1 month."
16353771|NCT04302116|Active Comparator|Vigabatrin alone|"Vigabatrin (500 mg/tab) dose will be calculated on weight basis divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment.
~Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks."
16353772|NCT04302103|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
16353773|NCT04302103|Experimental|RC18 240 mg|Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
16353774|NCT04302090|Experimental|pain level changes according to the use of the Winner flow|"each included patient will experience :
~a period of consecutive spontaneous uterine contractions without using the regulated expiration mouthpiece
~a period of consecutive uterine contractions managed by the regulated expiration method using the Winner flow"
16353775|NCT04302077|Active Comparator|Telemedicine Post Op|Patients with an even-ending medical record number (0,2,4,6,8) will be randomized to virtual visit/telemedicine. This will be done by using Epic and MyChart-integrated telemedicine functionality for video visits with the Principal Investigator's patients. This is considered standard of care.
16353776|NCT04302077|Active Comparator|In-Office Post Op|Patients with an odd-ending medical record number (1,3,5,7,9) will be randomized to the office visit.
16353777|NCT04302064|Experimental|AKCEA-TTR-LRx|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of AKCEA-TTR-LRx administered SC.
16353778|NCT04302064|Placebo Comparator|Placebo|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of AKCEA-TTR-LRx-matching placebo administered SC.
16353779|NCT04302051||Study Group|The hepatic fat estimation will be performed on the same subjects with the use of the thermo-acoustic device and by MRI-PDFF. The data obtained from the two estimations will be compared.
16353780|NCT04302038|Experimental|Potato protein|Participants will be provided with 25 g of potato protein twice per day in addition to a diet set at the recommended daily allowance. Total protein intake for this group will be 1.6 g/kg/day
16353781|NCT04302038|Placebo Comparator|Control group|This group will consume protein from food sources set at 0.8 /kg/day including 2 pudding placebo cups per day.
16353787|NCT04301999|Active Comparator|PDT group|Patients in PDT group underwnt PDT
16353788|NCT04301999|Experimental|RFA group|Patients in RFA group underwent RFA
16353789|NCT04301986|Experimental|TNE Followed by EGD|Subjects will undergo administration of a transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
16353790|NCT04301986|Experimental|Cytosponge, then TNE, followed by EGD|Subjects will undergo administration of Cytosponge and transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
16353791|NCT04301973|Other|Healthy people|
16353792|NCT04301960|Experimental|Single task group|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
16353793|NCT04301960|Experimental|Dual-task|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
16353794|NCT04301947|Active Comparator|Standard warm-up protocol|The standard warm-up protocol consists of 5 (five) minutes of stationary cycling, followed by calf, hamstring and quadriceps stretching. For all stretching positions 30 (thirty) seconds will be set. For calf stretching, the participant places his hands on the waist and projects his dominant limb behind of the center of mass line, the contralateral limb will be placed forward until the stretch sensation on the dominant limb start. For hamstring stretching, the participant will be instructed to bend over the hip, reaching the foot of the dominant limb in dorsiflexion. Emphasis will be placed on maintaining the heel of the dominant limb on the floor and maintaining posture. Finally, for quadriceps stretching, the participant will perform a knee flexion and will hold the dominant lower limb foot close to the gluteus with the ipsilateral upper limb hand. Emphasis will be placed on maintaining trunk posture.
16353795|NCT04301947|Experimental|Gluteal activation warm-up|"The gluteal activation warm-up protocol consists of performing a standard warm-up protocol with additional shell exercise. The shell exercise will be performed with the participant side-lying with hip and knee flexed, an elastic band (PREFORM BETTER Inc. Rhode Island, USA) will be placed around the distal thigh to promote resistance and the participants will be instructed to perform hip abduction movements. The exercise will be performed in multiple sets (3 sets) of 12 repetitions, with 30 seconds interval between exercises in order to minimize the fatigue effect. Medium and heavy elastic bands tensions will be used and adjusted according to the effort perception parameter from the OMNI scale for effort perception for resistance training."
16353796|NCT04301934|Active Comparator|Vaginal Estrogen Therapy Group|Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
16353797|NCT04301934|Experimental|Laser Therapy Group|Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.
16353798|NCT04301921|Other|Group 1|Traditional puncture site + no anticoagulation
16353799|NCT04301921|Other|Group 2|Traditional puncture site + ACT-guided anticoagulation
16353800|NCT04301908||antiviral therapy group|Patients with chronic hepatitis B and cirrhosis were treated with antiviral drugs
16353801|NCT04301895|Other|Interactive|Subject will be asked to continually interactive with the investigators, answering a series of standard questions during the remifentanil infusion and recovery periods.
16353802|NCT04301895|Other|Non-interactive|All verbal interaction will be avoided and extraneous sounds will be eliminated from the environment during the remifentanil infusion and recovery periods.
16353803|NCT04301882||interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
16353804|NCT04301882||direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
16353805|NCT04301869|Active Comparator|Intravenous therapy|Intravenous antibiotics administered for pleural space infection
16353806|NCT04301869|Active Comparator|Oral therapy|Oral antibiotics administered for pleural space infection
16353807|NCT04301856||CF children treated with CFTR modul|Cystic fibrosis patients under 18 years treated with CFTR modulators according to french health recommendations observational cohort study
16353808|NCT04301843|Experimental|Eflornithine (DFMO)|"In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.
~Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.
~DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study."
16353809|NCT04301830||Spinal anesthesia|Patients undergoing cesarean section under spinal anesthesia
16353810|NCT04301817||Prone position|Patients undergoing surgery in prone position
16353811|NCT04301804|Experimental|Dose level 1|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 1
16353812|NCT04301804|Experimental|Dose level 2|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 2
16353813|NCT04301804|Experimental|Dose level 3|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 3
16353814|NCT04301778|Experimental|Durvalumab and SNDX-6352|Participants will receive Durvalumab and SNDX-6352.
16353815|NCT04301765|Experimental|testosterone 1.62% gel|Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
16353816|NCT04301765|Placebo Comparator|placebo gel|The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
16353817|NCT04301752||Neurobrucellosis|Brucellosis associated with neuropsychiatric manifestations
16353818|NCT04301752||Non-neurobrucellosis|Brucellosis not associated with neuropsychiatric manifestations
16353819|NCT04301739|Experimental|HLX10 + chemotherapy→ HLX10|HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles)
16353820|NCT04301739|Placebo Comparator|Placebo + chemotherapy→ Placebo|Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → Placebo (9 cycles)
16353821|NCT04301726|Experimental|Deutetrabenazine|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
16353822|NCT04301726|Placebo Comparator|Placebo|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
16353823|NCT04301700|Experimental|relaxation|The progressive muscle relaxation intervention, designed by Jacobson (1987), will be consist of sessions involving straining and relaxing all muscle groups from head to foot with deep breathing and last for 20 min. The patients will be asked to tense a very muscle group for 5 s and relax after counting up to 10 s while breathing out. In this way, facial, head, neck, shoulders, arms, chest, abdomen, legs, hips, feet and fingers muscles are stretched and relaxed on purpose for relaxing in patients with COPD.
16353824|NCT04301700|Experimental|mindfulness meditation|The research team closely will be following the mindfulness meditation intervention, developed by Kabat-Zinn, Lipworth, and Burney (1985), which is a part of the mindfulness-based stress reduction program. Mindfulness meditation is including interventions such as yoga, body scan, walking meditation, and sitting meditations. In the present study, the researchers will prefer sitting meditation. In this context, the second co-author will want patients to sit up in the chair in an upright and comfortable position. The patients will focus on deep breathing and felled the breath flowing throughout their body during the interventions that will last for 20 min in each session.
16353825|NCT04301700|No Intervention|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
16353828|NCT04301674||Occupational Asthma|Patients refered for assesment of occupational asthma
16353829|NCT04301674||Respiratory Healthy Control|Employees at Oslo University Hospital
16353830|NCT04301661||ABC/3TC Cohort|"Persons on abacavir/lamivudine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.
~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
16353831|NCT04301661||TAF/FTC Cohort|"Persons on tenofovir alafenamide/emtricitabine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.
~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
16353832|NCT04301661||Switch Cohort|"Persons switching from abacavir/lamivudine-containing therapy as part of their standard HIV care will change to their newly prescribed regimen.
~Participants will be on study for 3 weeks, and will have blood drawn at Days 0, 1, 3, 7, 10, 14, 18, and 21 following their switch."
16353833|NCT04301648|Active Comparator|Common Practice|Patients included in the phase before will receive common practice.
16353834|NCT04301648|Experimental|STAR Nurse|Patients included in the phase after will receive care by a STAR Nurse.
16353835|NCT04301635||Preoperative (Pre-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, preoperative
16353836|NCT04301635||Postoperative (Post-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, postoperative
16353837|NCT04301609|Active Comparator|ImmunoVita®|250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)
16353838|NCT04301609|Placebo Comparator|Placebo|473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye
16353839|NCT04301596||SSc patients|
16353840|NCT04301583|Active Comparator|Procyanidin B2 enriched cocoa|Participants receiving cocoa capsules
16353841|NCT04301583|Placebo Comparator|Placebo group|Participants maltodextrin capsules
16353842|NCT04301570|Other|Ultrasound|The intervention measurement is the determination of bone age using the ultrasound device.
16353843|NCT04301570|Other|XR|The control measurement is the determination of the bone age by the imaging method using X-rays.
16353844|NCT04301557|Experimental|PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC|Induction regimen: Capeox+PD1 antibody for 1 cycle, Concurrent chemoradiotherapy regimen: Capeox+PD1 antibody for 2 cycles and concurrent , Interval regimen: Capeox+PD1 antibody for 1 cycle, TME surgery or watch and wait for cCR patients Adjuvant regimen: Capeox+PD1 antibody for 2 cycles, Capecitabine+PD1 antibody for 2 cycles
16353845|NCT04301544|Experimental|INDAK & Standardized Vascular Care Group|The experimental arm will receive training on the ballroom dance modules called INDAK (Improving Neurocognition through Dance and Kinesthetics), nutrition counseling and vascular risk management
16353846|NCT04301544|Active Comparator|Standardized Vascular Care Group|The control group will receive nutrition counseling and vascular risk management
16353847|NCT04301531|Experimental|Arm 1 (intervention arm)|Arm 1 or the intervention arm will involve seven communities: 4-monthly mass screening, and treatment of those who test positive by CHWs will be conducted. Febrile cases will be tested and treated by CHWs any time
16353848|NCT04301531|Other|Arm 2 (control arm)|Arm 2 or the Control arm will involve 2 communities: mass screening and treatment only done at baseline and at evaluation. Febrile cases will be tested and treated by CHWs any time.
16353849|NCT04301518|Experimental|PTB Prevention|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
16353850|NCT04301518|No Intervention|Control|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the Control arm will not receive the PreTRM® test results. Control arm subjects will continue on with standard of care.
16353851|NCT04301505|No Intervention|control|Usual care.
16353852|NCT04301505|Other|Intervention 1|COPD management checklist will be delivered at the beginning of the study.
16353853|NCT04301505|Other|Intervention 2|COPD management checklist will be delivered at the beginning of the study and repeated after 6 months.
16353854|NCT04301492|Experimental|Vortioxetine|first visit medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit (Week 1 - Visit 2) to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day (Visit 3- Phone contact). At Week 4-8-12 (Visits 4-5-6) patients will return to the site to perform all clinical evaluations required and to receive study drug. Visit 7 subjects will return to the site to perform all the assessment required by protocol.
16353855|NCT04301479|Active Comparator|Steroid|Patients assigned for steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
16353856|NCT04301479|Placebo Comparator|Control|Patients assigned for control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
16353857|NCT04301466|Experimental|Qi Zhi Tong Luo group|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. Each capsule was weighted 0.5g. Qi Zhi Tong Luo capsule (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
16353858|NCT04301466|Placebo Comparator|Placebo group|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
16353859|NCT04301453|Experimental|Maternal Scent Group|Infants in this group will be exposed to a breast pad worn by their mothers to extract maternal scent. This exposure will last 24 hours.
16353860|NCT04301453|No Intervention|Control Group|Infants in this group will receive standard of care.
16353861|NCT04301440|Active Comparator|patients with anxious and / or depressive characteristics : treated group|patients with anxious and / or depressive characteristics, The device with the electromagnetic wave will be connected
16353862|NCT04301440|Placebo Comparator|patients with anxious and / or depressive characteristics : placebo group|The device with the electromagnetic wave will not be connected
16353863|NCT04301427|Other|Obese patient|
16353867|NCT04301401|Experimental|Patients being evaluated for changes in microbiota|Patients being evaluated for changes in vaginal microbiota following transvaginal surgery.
16353868|NCT04301388|Experimental|TVCL-based|Monitor progression of labor by shortening of cervix examined by transvaginal cervical length
16353869|NCT04301388|Active Comparator|Conventional-based|Monitor progression of labor by per vaginal exam to detect cervical change
16353870|NCT04301375|Experimental|Study treatment|
16353871|NCT04301349|Experimental|vaginal dinoprostone|vaginal dinoprostone 6 mg (two tablets) 3 hours prior to IUD insertion
16353872|NCT04301349|Active Comparator|vaginal misoprostol|vaginal misoprostol 400 mcg (two tablets) 3 hours prior to IUD insertion
16353873|NCT04301349|Placebo Comparator|placebo|two tablets of placebo similar in shape ,color, odor to the study drugs
16353874|NCT04301336|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
16353875|NCT04301336|Experimental|Vit-D experimental group|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
16353876|NCT04301336|Experimental|Zinc supplements experimental group|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
16353877|NCT04301336|Experimental|Statin experimental group|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
16353982|NCT04300595|Active Comparator|Local anesthesia (Group L)|Patients receive general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).
16353878|NCT04301336|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
~in addition, Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response in addition, Morphine medication as a pain killer is administered, if Patient weight <50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
~This group received regular blood transfusion session."
16353879|NCT04301323|Experimental|BHVI1|BHVI1 eye drops
16353880|NCT04301323|Experimental|BHVI2|BHVI2 eye drops
16353881|NCT04301323|Experimental|BHVI3|Combination of BHVI1 and BHVI2 eye drops
16353882|NCT04301323|No Intervention|Non-randomized control group|a separate control group including 105 children enrolled and followed with only single-vision spectacles.
16353883|NCT04301310|Experimental|Treatment Group|
16353884|NCT04301284|Experimental|CAD-1883|"Capsules of 150 mg of CAD-1883 will be administered orally, twice daily (BID). The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
~The initial dose regimen evaluated will be 150 mg BID. Additional dose regimens up to 600 mg BID will be determined based on forthcoming clinical data."
16353885|NCT04301284|Placebo Comparator|Placebo|Matching placebo will be provided in capsules, to be administered orally, twice daily. The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
16353886|NCT04301271|Experimental|Simvastatin|Simvastatin and Escitalopram
16353887|NCT04301271|Placebo Comparator|Placebo|Placebo and Escitalopram
16353888|NCT04301258||Articular Cartilage Defect of the Knee|Patients, who undergo an articular cartilage repair of the knee using ProChondrix CR.
16353889|NCT04301258||Articular Cartilage Defect of the Ankle|Patients, who undergo an articular cartilage repair of the ankle using ProChondrix CR.
16353890|NCT04301258||Articular Cartilage Defect of the Foot|Patients, who undergo an articular cartilage repair of the foot using ProChondrix CR.
16353891|NCT04301258||Articular Cartilage Defect of the Hip|Patients, who undergo an articular cartilage repair of the hip using ProChondrix CR.
16353892|NCT04301245||ETEP group|Exercise Training and Educational Program (ETEP) group. Patients who accepted the educational program in addition to the exercise training.
16353893|NCT04301245||ET group|Exercise Training (ET) group. Patients who refused the educational program and did only the exercise training.
16353894|NCT04301232||Fast-Track Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Patients who fulfilled criteria of all scoring systems were defined as eligible for PACU by-pass (fast-tracking) and transferred into phase II recovery area in the ward without observation in PACU (Group FT = Fast Track;)
16353895|NCT04301232||PACU Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Ineligible patients were taken into PACU where their treatments were continued until discharge criteria were achieved (Group PACU)
16353896|NCT04301206|Experimental|Intervention: Receiving video material|The parents who accepts to participate and receives videos and action cards by sms
16353897|NCT04301206|No Intervention|Control group|The parents who accepts to participate, but proceed to 1813 and do not receive videos and action cards
16353898|NCT04301193|Other|Pregnant Women|All subjects will have the same intervention. Samples will be taken and manipulated in the laboratory for use of the Hemosonic Qauntra Analyzer
16353899|NCT04301180|Experimental|Experimental|"The experimental group conducted 10 weekly sessions, with an approximate duration of 45 minutes per session, which consisted of the presentation of food education content while conducting an orchard with seasonal vegetables. Simple recipes were also described in which these vegetables were included to be made at home, along with information on children's books that dealt with the topic of food and were available in the public library.
~All children in the experimental groups were given written instructions so that they could perform at their home, together with their parents, the manipulative activities suggested each week. All these contents were common for all the participants in the study. Session material was renewed weekly."
16353900|NCT04301180|No Intervention|Control|"The control group received the usual training corresponding to the contents of the human body module that is currently taught in each center."
16353901|NCT04301167|Experimental|Single group|An AB single-case experimental design will be used. An RCT would be inappropriate since the befriending intervention is known to improve wellbeing. As such participants will have data collected in a pre- and post-intervention phase, for a maximum of 13 time points. This approach has been identified by What Works Clearinghouse as an acceptable empirical design to include in evidence based practice reviews (Kratchowill et al., 2010).
16353902|NCT04301154|Experimental|Group A|25 study participants aged ≥ 9 years will be enrolled and randomized into arms 1, 2 and 3. They will be from 3 different study sites (Stellenbosch University, Cape Town, South Africa; Chulalongkorn University, Bangkok, Thailand; Children's Hospital Bambino Gesù, Rome, Italy). The rationale for including aged 9 and above is because Cervarix is licensed for age ≥ 9 years.
16353903|NCT04301154|Experimental|Group B|20 participants will be enrolled to investigate the effects of vaccination with HIVIS DNA ± Cervarix and MVA-CMDR in youth previously enrolled in the PEDVAC study in which 10 had received HIVIS DNA and 10 did not receive vaccine in 2009-2012. They are perinatally HIV-infected and currently being followed at the Children's Hospital Bambino Gesù in Rome. Their median (range) ages are 21 (15 to 25) years old.
16353904|NCT04301141|Experimental|Virtual Reality Assisted Cognitive Behavioural Therapy|Between 8 to 20 individual in-person sessions of VR-assisted CBT will be delivered on a weekly basis by NHS therapists who are trained in delivering CBT to this patient group.
16353905|NCT04301128|Experimental|EXPERIMENTAL GROUP|Patients in the experimental group were able to install and set up mobile application on android phones via Bluetooth and were informed about the sick android application. Patients were reminded and guided by subcutaneous anti-TNF drug treatments from mobile application. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales.
16353983|NCT04300582|Active Comparator|Standard pharmaco-invasive strategy|Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.
16353906|NCT04301128|Active Comparator|CONTROL GROUP|An anti-TNF drug administration training booklet were given to patients in the control group and were required to take advantage of the booklet on subcutaneous anti-TNF drug production. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales. At the end of the study (twenty forth week) was applied to all patients.
16353907|NCT04301115|Active Comparator|conventional group|conventional partial denture
16353908|NCT04301115|Experimental|attachment group|unlateral attachment retained partial denture
16353909|NCT04301115|Experimental|tooth implant supporeted prosthesis|tooth implant supported bridge
16353910|NCT04301102|Experimental|Experimental|"Hemodynamic management will be based on the functional hemodynamic parameters provided by Hemosphere platform with the Acumen IQ sensor, including cardiac output, stroke volume, SVV and Acumen IQ specific parameters: maximal arterial pressure rise (dP/dtmax), dynamic arterial elastance (Eadyn) and HPI
~As a pattern replacement of interstitial space, we will use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.
~The protocol of action on the intravascular space will be based on the maintenance of systolic volume with colloids (hydroxyethyl starch - Voluvén®)."
16353911|NCT04301102|Other|Control|"Hemodynamic management will be based on the functional hemodynamic parameters provided by the HemoSphere platform® with the FloTrac® sensor, including cardiac output (CO), stroke volume (SV), and stroke volume variation (SVV)
~As a pattern replacement of interstitial space, we use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.
~The protocol action for the intravascular space will be based on a recently published hemodynamic optimization algorithm (Heming N, Moine P, Coscas R, Annane D. Perioperative fluid management for major elective surgery. British Journal of Surgery. 2020;107:e56-62). The fluid used will be hydroxyethyl starch (Voluven®)."
16353912|NCT04301089|Experimental|Experimental intervention|Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
16353913|NCT04301076|Experimental|Treatment (lenalidomide, EPOCH)|"INDUCTION THERAPY: Patients receive lenalidomide PO QD on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients also receive doxorubicin hydrochloride IV continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients with CR, PR, or SD may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity."
16353914|NCT04301063||RV3278A arm|"study product RV3278A is applied twice a day on the face during the whole study.
~In case of reaction resulting from the use of the product, the subject will inform the investigator who will explain to him/her what to do : application reduction or stop applications for a while"
16353915|NCT04301050|Experimental|Yoga Intervention|Participants will complete 8-week course (75-minute, weekly yoga classes) delivered online via videoconferencing software. Participants will complete patient-reported outcomes at baseline (prior to class 1) and post-intervention (after class 8), as well as post-intervention measures of feasibility/acceptability.
16353916|NCT04301037|Active Comparator|Tension band wiring|This group was treated by k-wires fixation and tension band wiring
16353917|NCT04301037|Active Comparator|Cannulated screws|This group was treated by 2 cannulated screws
16353918|NCT04301024||nitrous oxide misusers|nitrous oxide misusers among the teenagers consulting in an addictology center dedicated to young drug users in Montpellier
16353919|NCT04301011|Experimental|Arm A: TBio-6517 alone|Dose escalation of TBio-6517 alone administered by direct injection into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months.
16353920|NCT04301011|Experimental|Arm B: TBio-6517 and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. TBio-6517 will be directly injected into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 8 via intravenous (IV) infusion every 3 weeks for up to 24 months.
16353921|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in MSS-CRC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with microsatellite stable colorectal carcinoma (MSS-CRC). Booster injections of TBio-6517 are permitted for up to 24 months.
16353922|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in TNBC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with triple negative breast cancer (TNBC). Booster injections of TBio-6517 are permitted for up to 24 months.
16353923|NCT04300998||older lymphoma patients|This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
16353924|NCT04300998||older patients with lymphoma and other lymphoid malignancies|This is a prospective observational cohort where 100 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
16353925|NCT04300998||older patients with myeloma and other plasma cell disorders|This is a prospective observational cohort where 60 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo
16353926|NCT04300985|Sham Comparator|Placebo group|Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
16353927|NCT04300985|Active Comparator|Dexmedetomidine group|Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
16353984|NCT04300582|Experimental|Fast pharmaco-invasive strategy|Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.
16353928|NCT04300985|Active Comparator|Magnesium sulfate group|Thirty patients in this group will receive infusion of magnesium sulfate (20 mg/kg/h). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
16353929|NCT04300972|Other|fixed dose|
16353930|NCT04300972|Experimental|weight and body type adapted dose|
16353931|NCT04300959|Experimental|Experimental group|Anlotinib in combination with Sintilimab with Gemcitabine plus(+)Cisplatin
16353932|NCT04300959|Active Comparator|Control group|Standard platinum-based chemotherapy
16353933|NCT04300946||TMS on the cerebellum followed by placebo TMS|TMS preceding the time prediction and language tests
16353934|NCT04300946||Placebo TMS followed by TMS on the cerebellum|TMS preceding the time prediction and language tests
16353935|NCT04300946||TMS on the cerebellum set in time on waiting periods|
16353936|NCT04300946||TMS on the cerebellum not set in time on waiting periods|
16353937|NCT04300933|Experimental|Neurofeedback therapy|Fifty participants conduct neurofeedback daily for 5 days.
16353938|NCT04300920|Experimental|N-acetylcysteine|600 mg oral N-acetylcysteine (NAC) three times daily for 24 months.
16353939|NCT04300920|Placebo Comparator|Placebo|Placebo tablet three times daily for 24 months.
16353940|NCT04300907|Experimental|Provant Infinity Therapy|Open-label treatment with Provant Infinity Therapy
16353941|NCT04300894|No Intervention|Usual care group|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
16353942|NCT04300894|Experimental|Mamma Mia group|"Usual prenatal/postpartum care plus use of the Mamma Mia program"
16353943|NCT04300894|Experimental|Mamma Mia Plus group|"Usual prenatal/postpartum care plus use of the Mamma Mia program plus occasional contacts from study staff"
16353944|NCT04300881|Experimental|Treatment|Eplerenone
16353945|NCT04300881|No Intervention|Control|
16353946|NCT04300855|Experimental|Sunphenon® 90D|Participants will be administered a standardized formulation of whole Green Tea Catechin for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
16353947|NCT04300855|Placebo Comparator|Placebo|Participants will be administered a placebo for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
16353948|NCT04300842||Cancer patient|This project expects to enroll 60 cancer patients and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
16353949|NCT04300842||Healthy population|This project expects to enroll 60 healthy population and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
16353950|NCT04300829|Experimental|Simple hygiene rules of the site + Cicaderma ointment|Hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and Cicaderma ointment application)
16353951|NCT04300829|Active Comparator|Preventive standard cares|Preventive standard cares of the site including hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and a maximum of one topical treatment
16353952|NCT04300816|Experimental|CBT-UT|Seven telephone-based sessions of cognitive behavioral therapy for uncertainty tolerance (CBT-UT) delivered over seven weeks.
16353953|NCT04300816|Active Comparator|tCBT|Seven telephone-based sessions of traditional cognitive behavioral therapy (tCBT) delivered over seven weeks.
16353954|NCT04300816|No Intervention|TAU|Participant continues with their lives as they normally would.
16353955|NCT04300790|Experimental|CohortA: Normal fasting glycemia|"Alpelisib plus metformin and fulvestrant: During the first cycle, patients will receive fulvestrant and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (one tablet of 200mg and two tablets of 50mg once a day) on a continuous dosing schedule starting on Cycle 1• Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.
~Fulvestrant: 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles)."
16353956|NCT04300790|Experimental|CohortB: Fasting glycemia|"Alpelisib plus metformin and fulvestrant: During the first cycle, patients will receive fulvestrant and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (one tablet of 200mg and two tablets of 50mg once a day) on a continuous dosing schedule starting on Cycle 1• Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.
~Fulvestrant: 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles)."
16353957|NCT04300777||Treated with Non-Cervical Pedicle Screw Systems|
16353958|NCT04300764|No Intervention|Control|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Control participants' steps will be passively monitored. Data will continue to be collected for 30 days after discharge.
16353959|NCT04300764|Experimental|Gamification Intervention|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Intervention patients will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Data will continue to be collected for 30 days after discharge.
16353960|NCT04300751|Experimental|Alcohol|Participants will receive experimental doses of active or placebo alcohol, p.o. Alcohol/placebo will be administered once per session.
16354097|NCT04299854||Single Balloon Foley Catheter|Induction of labor by single balloon Foley catheter
16353961|NCT04300751|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered orally
16353962|NCT04300751|Experimental|Opioid Agonist/Alcohol Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with experimental doses of active alcohol placebo. Opioid/placebo and alcohol/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Both opioid and alcohol doses will be administered orally.
16353963|NCT04300738|Other|Patients undergoing CT scann for CCS determination|
16353964|NCT04300725|No Intervention|Verbal Counseling|Patients in one study arm receive only verbal counseling prior to their induction of labor.
16353965|NCT04300725|Experimental|Video Counseling|Patients in other study arm will receive verbal + video counseling prior to their induction of labor.
16353966|NCT04300712|Other|Tracking of the children with difficulties|All parents and teachers will respond to the questionnaires and the beginning and end of school year which is not done in the routine for tracking the children in difficulty.
16353967|NCT04300699|Other|Ovarian cancer patients over 70 years receiving chemotherapy|Patients with ovarian cancer receiving chemotherapy as either first line treatment (i.e. newly diagnosed advanced stage III/IV cancer) or at first relapse. Patients to receive a Geriatric Assessment including interventions for functional or other identified deficits and appropriate specialist algorithm-determined interventions.
16353968|NCT04300686|Active Comparator|Tocilizumab|This group of 20 TAK cases are prescribed with tocilizumab (Dose: 8mg/kg. qm. ivgtt.) for 24 weeks.
16353969|NCT04300686|Experimental|Adalimumab|This group of 20 TAK cases are prescribed with adalimumab (Dose: 40mg.bim.IH.) for 24 weeks.
16353970|NCT04300673|Experimental|All patients|Intervention: radio guided surgery
16353971|NCT04300647|Experimental|Tiragolumab plus Atezolizumab|Participants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16353972|NCT04300647|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16353973|NCT04300634||Children whose parents are physiotherapists|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
16353974|NCT04300634||Children whose parents are athletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
16353975|NCT04300634||Parents of children who are atletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
16353976|NCT04300634||Parents of children who are physiotherapist|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
16353977|NCT04300621|Experimental|Treatment Sequence 1: OTF 1, 4, 2, 3|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 1 in period 1; followed by OTF 4 in period 2; followed by OTF 2 in period 3; followed by OTF 3 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
16353978|NCT04300621|Experimental|Treatment Sequence 2: OTF 2, 1, 3, 4|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
16353979|NCT04300621|Experimental|Treatment Sequence 3: OTF 3, 2, 4, 1|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 3 in period 1; followed by OTF 2 in period 2; followed by OTF 4 in period 3; followed by OTF 1 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
16353980|NCT04300621|Experimental|Treatment Sequence 4: OTF 4, 3, 1, 2|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 4 in period 1; followed by OTF 3 in period 2; followed by OTF 1 in period 3; followed by OTF 2 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
16353985|NCT04300569||Patients and Caregivers: Overall Population|"Overall population of this study will include both patients with ISWRD associated with AD-D, AD-D with CVD, and/or VaD, and care givers of patients. Patients and caregivers will undergo all study procedures. Caregivers may care either for a patients who undergo all study procedure (including interview) as well for patients who do not undergo any study procedures but give consent or assent for the use of their medical records in the study (non-interviewed patient)."
16353987|NCT04300543||Group 1 MS patients|patients with multiple sclerosis
16353988|NCT04300543||Group 2 patients with other neurological disorders|patients with inflammatory or non inflammatory neurological diseases other than multiple sclerosis
16353989|NCT04300543||Group 3 healthy control|No neurological or immunological disease
16353990|NCT04300517|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
16353991|NCT04300517|Placebo Comparator|maltodextrin|Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.
16353996|NCT04300491||Beneficiaries of suspension walking|
16353997|NCT04300491||Non-Beneficiaries of suspension walking|
16353998|NCT04300478|Other|Sedentary Control/REx|Subjects will complete the Sedentary control testing sessions, have a 7-14 day washout period, and then complete the REx
16353999|NCT04300478|Other|REx/Sedentary Control|Subjects will complete the REx testing sessions, have a 7-14 day washout period, and then complete the Sedentary control
16354000|NCT04300465|Experimental|Rheumatoid arthritis - With Partner Group|In this group patients with stable rheumatoid arthritis and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
16354001|NCT04300465|Active Comparator|Rheumatoid arthritis - Without Partner Group|"In this group patients with stable rheumatoid arthritis undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.
~For the patients with rheumatoid arthritis, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
16354002|NCT04300465|Experimental|Chronic Kidney Disease - With Partner Group|In this group patients with stable stage 3 or 4 chronic kidney disease and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
16354003|NCT04300465|Active Comparator|Chronic Kidney Disease - Without Partner Group|"In this group patients with stable stage 3 or 4 chronic kidney disease undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.
~For the patients with chronic kidney disease, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
16354004|NCT04300452|Active Comparator|Carbetocin group|In the carbetocin group will be administered 100 mcg of carbetocin diluted in 100 cc of N/S 0.9% in a continuous rapid-flow intravenous infusion.
16354005|NCT04300452|Active Comparator|Ergometrin group|In the ergometrine maleate group will be administered intravenously 0.2 mg of the substance slowly in a bolus administration.
16354006|NCT04300439|Active Comparator|Arm A: metallic reusable ancillary.|This control group will be constituted of patients who will have the GMK® prosthesis with metallic reusable ancillary.
16354007|NCT04300439|Experimental|Arm B: Efficiency single use ancillary.|This group will be constituted of patients who will have the GMK® prosthesis with Efficiency single use ancillary.
16354008|NCT04300426|Experimental|ACHIM by gastroduodenoscopy|"Intestinal microbiota (acronym ACHIM - anaerobically cultured human intestinal microbiota) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml, containing approximately 10^9 bacteria / ml.
~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
16354009|NCT04300426|Placebo Comparator|Placebo by gastroduodenoscopy|"ACHIM culture media (no bacteria) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml.
~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
16354010|NCT04300413|Experimental|High-Intensity Rehabilitation plus Mobility (HeRo)|The HeRo group will receive a behavior-change intervention based in the principals of behavioral economics to improve mobility. Physical and occupational therapists have been trained to deliver a high-intensity, functional intervention as the standard of care in this skilled nursing facility.
16354011|NCT04300400||Delphi panel|Urologists of the Belgian Working group of Functional Urology willing to participate on the Delphi project.
16354012|NCT04300387|No Intervention|customary care|customary care for CKD
16354013|NCT04300387|Active Comparator|multidisciplinary care|multidisciplinary team care for CKD
16354014|NCT04300374||Sevoflurane only|inhalation of sevoflurane during general anesthesia
16354015|NCT04300374||Remifentanil and Sevoflurane|remifentanil infusion and inhalation of sevoflurane during general anesthesia
16354016|NCT04300361||Non-Western patients|Patients of non-Western descent with an indication for treatment with fluoropyrimidine-based chemotherapy. A patient is classified as non-Western if a one (1) of the parents or more than two (>2) of the grand parents are of non-Western descent.
16354017|NCT04300348|Active Comparator|Heel2Toe Group|The Heel2Toe group will have 5 therapy sessions to learn to trigger the sensor with a strong heel strike and how to use device for home practice for 3 months. During the home practice, participants will be instructed to walk with the device for a minimum of 10 minutes per day in feedback mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
16354018|NCT04300348|Other|No-feedback Control Group (Control group)|The Control group will do the same 5 sessions of training and 3 months of practice but without the Heel2Toe device in feedback mode, just in data acquisition mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
16354019|NCT04300335|Experimental|High Risk - Individual Exercise|Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.
16354020|NCT04300335|Experimental|Low Risk - Group Exercise|Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.
16354021|NCT04300322|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
16354022|NCT04300322|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
16354023|NCT04300309|Experimental|artemether lumefantrine (2.5 mg:30 mg)|artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
16354030|NCT04300283|Experimental|Pre-operative hypnosis|
16354031|NCT04300270||Validation cohort|Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
16354032|NCT04300270||Clinical implementation cohort|Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
16354035|NCT04300231|Active Comparator|Thoracic epidural|1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
16354036|NCT04300231|Active Comparator|Rectus Sheath Block|2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
16354037|NCT04300231|Active Comparator|Surgeon Infiltration with Liposomal Bupivacaine (LB)|3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.
16354038|NCT04300231|Active Comparator|Surgeon Infiltration|4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
16354039|NCT04300218|Experimental|iCBT-I + CAU|Participants of this arm will get access to the course of the online cognitive-behavioral therapy for insomnia (iCBT-I) for 2 months along with the treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment
16354040|NCT04300218|Active Comparator|CAU|Participants of this arm will get a treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment. Then provided completion of all the assessments and satisfying eligibility criteria participants of this arm will get tha access to the 2-month iCBT-I course followed by the post-treatment assessment
16354041|NCT04300205|Experimental|High intensity LED light treatment|Participants treated with high intensity LED phototherapy
16354042|NCT04300205|Experimental|Sham high intensity LED light treatment|Participants set up to be treated with light device but after being masked, the device is moved off the wound
16354043|NCT04300192|Experimental|Group 1: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of whole-cell pertussis (wP) vaccine during the first 2 years of life
16354044|NCT04300192|Experimental|Group 2: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 3 doses of wP followed by 1 dose of acellular pertussis (aP) vaccine during the first 2 years of life
16354045|NCT04300192|Experimental|Group 3: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 2 doses of wP vaccine followed by 2 doses of aP vaccine during the first 2 years of life
16354046|NCT04300192|Experimental|Group 4: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 1 dose of wP vaccine followed by 3 doses of aP vaccine during the first 2 years of life
16354047|NCT04300192|Experimental|Group 5: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of aP vaccine during the first 2 years of life
16354048|NCT04300192|Experimental|Group 6: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of wP vaccine during the first 2 years of life
16354049|NCT04300192|Experimental|Group 7: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of aP vaccine during the first 2 years of life
16354050|NCT04300166|Active Comparator|Telemedicine & Humidification Intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse/sleep technologist is checking the downloaded data three times per week. The contacts will be due to:
~CPAP usage <4h/ night for 3 consecutive night
~the median leakage was above 0.4 L/sec on 3 consecutive nights The nurse/sleep technologist informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits) will be discussed. The patient is encouraged to use CPAP every night. In the case of adherence >4h/night and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail."
16354051|NCT04300166|No Intervention|Control without Telemedicine & humidification|In the control arm, no wireless telemedicine and humidifier will be used with CPAP but data stored in the CPAP machine are collected at the follow-up visit after 1 month
16354052|NCT04300153|Experimental|ESP Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml 0.25% bupivacaine at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
16354053|NCT04300153|Sham Comparator|Control Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml normal saline at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
16354054|NCT04300140|Experimental|Phase 1b: AVB-S6-500+Cabo|
16354055|NCT04300140|Experimental|Phase 2: AVB-S6-500+Cabo|
16354056|NCT04300140|Experimental|Phase 2: Cabo alone|
16354057|NCT04300127|Experimental|Pioglitazone|Candidates who after the screening period are eligible to receive Pioglitazone
16354058|NCT04300114|Experimental|Maintenance Fluzoparib monotherapy|
16354059|NCT04300114|Placebo Comparator|Maintenance placebo monotherapy|
16354060|NCT04300101||DLBCL patients|All patients with diagnosis of DLBCL
16354061|NCT04300088||Patients with advanced solid cancer treated with anti-PD(L)1|Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
16354062|NCT04300075||CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
16354063|NCT04300062|Experimental|Rebiopsy|
16354064|NCT04300049|Experimental|Change in Glycerol Ra|The difference in rate of lipolysis (glycerol Ra) during the basal state (-120 -0 minute) between subjects receiving glucagon and saline represents the change in whole body lipolysis caused by glucagon.
16354065|NCT04300036|Experimental|longan syrup|Take 15 ml of longan syrup once a day for 3 months
16354066|NCT04300036|Placebo Comparator|Placebo syrup|Take 15 ml of placebo syrup once a day for 3 months
16354067|NCT04300023|No Intervention|Study 1: Normal Care Control Group|Study 1: Normal Care Control Group [will crossover and complete the cycling intervention following the initial 6-months]
16354068|NCT04300023|Experimental|Study 1: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
16354069|NCT04300023|Experimental|Study 2: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
16354070|NCT04300023|Experimental|Study 2: Solo Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to cycling without a partner for a target duration and intensity.
16354071|NCT04300010|Active Comparator|Blue Light Therapy|FDA cleared blue light product, Omniluxblue (Globalmed Technologies, Glen Elen, CA), which emits a 415 nm blue light irradiance of 40mW/cm2. Following the application of blue light protective eyewear, the blue light therapy device will be centered over the deltopectoral interval according to device standardized use instructions and a 23-minute treatment will be administered to dry skin. As was done in the topical BPO group, following treatment, a skin swab culture of the treatment shoulder will be taken, then both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder. Participants and research personnel conducting the blue light treatments will be wearing medical grade blue light protective glasses for safety.
16354098|NCT04299815|Active Comparator|Oral lactate|Sodium D/L lactate solution, 25g/L in 300mL water
16354099|NCT04299815|Placebo Comparator|Iso-lactic intravenous lactate infusion|iv sodium D/L lactate to elevate [lactate] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
16354100|NCT04299802|Active Comparator|Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)|LR-PRP will be administered via usual protocol with venous blood draw and concentration via centrifugation. The LR-PRP will be injected under ultrasound guidance into the gluteus minimus and gluteus medius tendons, enthesis and surrounding bursae.
16354072|NCT04300010|Active Comparator|5% Topical Benzoyl Peroxide Gel|A pea-sized amount, ~0.5 grams, will be applied to a 10cm strip over the deltopectoral interval beginning the morning 48 hours prior to schedule research visit to obtain cultures. The benzoyl peroxide will be applied on dry skin after a shower. The gel will be applied once in the morning and once in the evening for two consecutive days as well as the morning of the scheduled research visit. Following treatment, a skin swab culture of the treatment shoulder will be taken, both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder.
16354073|NCT04300010|Active Comparator|Light and Gel|Prior to treatment, a skin swab culture will be taken, 5% topical benzoyl peroxide treatment will be performed on dry skin immediately after a shower as described in the above paragraph. Again, five total treatments will be performed prior to research visit. On the day of the research visit, the blue light therapy protocol described above will be performed exactly the same followed by culture obtainment.
16354074|NCT04299997||163 mpMRIs corresponding to consecutive patients who underwent|The mpMRIs were performed on a 1.5T GE MR units or on 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
16354075|NCT04299984||Open Conversions|Patients undergoing total or partial endograft explantation for any EVAR complication.
16354076|NCT04299984||SemiConversions|Patients undergoing open or laparoscopic surgery for any EVAR complication (mostly endoleak correction) with complete endograft preservation.
16354077|NCT04299971|Active Comparator|methotrexate|This group of 38 TAK cases are prescribed with methotrexate tablets (Dose: 15.0 mg. qw. p.o.) for 24 weeks.
16354078|NCT04299971|Experimental|Tofacitinib|This group of 38 TAK cases are prescribed with tofacitinib tablets (Dose: 5.0 mg. bid. p.o.) for 24 weeks.
16354079|NCT04299945|Experimental|Dietary nitrate supplementation|The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)
16354080|NCT04299945|Placebo Comparator|Placebo|The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)
16354081|NCT04299932|Experimental|Electroacupuncture(EA) group|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 [Zhongliao], BL35 [Huiyang] and Spleen Meridian (SP) 6 [Sanyinjiao]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
16354082|NCT04299932|Sham Comparator|Sham Electroacupuncture (SA) group|Participants in SA group will receive treatment at bilateral sham BL33 [Zhongliao], sham BL35 [Huiyang] and sham SP6 [Sanyinjiao]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
16354083|NCT04299932|No Intervention|Waiting List (WL) group|Participants in WL group will be followed up for 20 weeks. Participants only receive healthcare education and advice on lifestyle modification, which will be received by all the participants in the three groups.
16354084|NCT04299919||Recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
16354085|NCT04299919||Non-recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
16354086|NCT04299906|Experimental|Solaris Vascular Stent Graft|Implant of Solaris Vascular Stent Graft in aorto-iliac lesions
16354087|NCT04299893|Experimental|Ozone Group|"Drug: Ozone Ozone Group: Usual treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
~Other Names: O3"
16354088|NCT04299893|Placebo Comparator|Control Group|"Drug: Oxygen Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
~Other Names: O2"
16354089|NCT04299880|Other|Napabucasin monotherapy|Patients in this arm will receive napabucasin administered orally, twice daily
16354090|NCT04299880|Other|Napabucasin in combination with Gemcitabine and Nab-paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously once weekly, on 3 of every 4 weeks.
16354091|NCT04299880|Other|Napabucasin in combination with Nivolumab|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly nivolumab 3mg/kg administered intravenously over 60 minutes.
16354092|NCT04299880|Other|Napabucasin in combination with paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly paclitaxel administered intravenously once weekly, on 3 of every 4 weeks.
16354093|NCT04299880|Other|Napabucasin in combination with FOLFIRI|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly FOLFIRI. Addition of bevacizumab, per Investigator choice, will be permissible.
16354094|NCT04299867||< 34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.
~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
16354095|NCT04299867||34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.
~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
16354096|NCT04299854||Vaginal Dinoprostone|Induction of labor by 10mg of vaginal dinoprostone
16354101|NCT04299802|Active Comparator|Percutaneous Ultrasonic Tenotomy|Percutaneous Ultrasonic Tenotomy will be administered via usual protocol within an outpatient surgical setting or in-office procedure. Patient will be anesthetized with local anesthetic and a <5mm incision will be made along the lateral hip with an #11 scalpel. A 14-G angiocath will be introduced through the defective area of the tendon down to the enthesis. Multiple passes will be made and then the percutaneous ultrasonic tenotomy device will be introduced to the defective area. No more than 5 minutes of energy cutting time will be used to address the defective area down to the enthesis, which will debride abnormal tissue but leave normal healthy tissue intact.
16354102|NCT04299789||Probable Civilian|This cohort represents those in which the Military Service Identification Tool has determined are a civilian and have not served in the Armed Forces.
16354103|NCT04299789||Probable Veteran|This cohort represents those in which the Military Service Identification Tool has determined are a military veteran and have served in the Armed Forces.
16354104|NCT04299776|Experimental|IPR therapy|Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position
16354105|NCT04299776|Active Comparator|Standard airway|Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position
16354106|NCT04299763|Experimental|Beta-Glucan (BETA)|experimental group, received a supplement of oats beta-glucan (5 g) for 12 weeks.
16354107|NCT04299763|Placebo Comparator|Control (CN)|placebo group, received a supplement of cellulose microcrystalline (5g) for 12 weeks.
16354108|NCT04299750|Experimental|Alveolar Ridge Preservation|Patients in this arm will undergo atraumatic extraction of an hopeless tooth and a socket preservation procedure. Alveolar ridge preservation will be performed using a slow-resorption bone substitute and a collagen membrane that covers the graft.
16354109|NCT04299750|Active Comparator|Natural healing|Patients in this arm will undergo atraumatic extraction of an hopeless tooth. The socket will follow natural healing.
16354110|NCT04299737||First patient in the case pair|This patient will receive the treatment bundle. S. aureus transmission surveillance will be conducted.
16354111|NCT04299737||Second patient in the case pair|This patient will receive usual care. S. aureus transmission surveillance will be conducted.
16354112|NCT04299724|Experimental|Injection of Covid-19/aAPC vaccine|
16354113|NCT04299711||Baseline|This study intends to recruit 3,428 Chinese adolescent students exposed to the novel coronavirus disease 2019 in the baseline survey
16354114|NCT04299711||6-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 6 follow-up study.
16354115|NCT04299711||12-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 12 follow-up study.
16354116|NCT04299711||18-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 18 follow-up study.
16354117|NCT04299698||Carbohydrate reduction group|Participants chose to control their body fat mass by reducing their carbohydrate intake through observation study periods.
16354118|NCT04299698||Fat reduction group|Participants chose to control their body fat mass by reducing their fat intake through observation study periods.
16354119|NCT04299698||Intense exercise group|Participants chose to control their body fat mass by vigorously increasing the time and intensity of exercise through observation study periods.
16354120|NCT04299698||Moderate exercise group|Participants chose to control their body fat mass by moderately increasing the time and intensity of exercise through observation study periods.
16354121|NCT04299672|Experimental|Postural reconstruction|"Maximum external rotation of the hip in lower limb elevation and the dorsal flexion of the ankle with flexion of the toes, performed in both lower limbs alternately and independent.
~Participant must control breathing. The detail phases of a general intervention are:
~PASSIVE displacement of the segment until reaching CRITICAL AMPLITUDE, which corresponds to the light myofascial stress or to the appearance of evoked responses.
~ACTIVE MAINTENANCE of the critical amplitude.
~WORK BREATHING.
~INDUCTIVE ACTIVE APPLICATIONS with movements of great relative amplitude.
~FINISHING CRITERIA: reduction or extinction of evoked responses, patient fatigue or execution of the technique for 15 minutes without any of the above premises having been reached."
16354122|NCT04299646|Experimental|Steretactic radiotherapy plus systemic treatment|
16354123|NCT04299646|Active Comparator|Systemic treatment|
16354124|NCT04299633|Experimental|Part 1: vadadustat plus sevelamer carbonate|Participants will receive vadadustat 300 milligrams (mg) once on Days 1, 3, 5, and 7. Participants will receive sevelamer carbonate 1600 mg once on Days 3, 5, and 7.
16354125|NCT04299633|Experimental|Part 2: vadadustat plus calcium acetate|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive calcium acetate 1334 mg once on Days 3, 5, and 7.
16354126|NCT04299633|Experimental|Part 3: vadadustat plus Auryxia®|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive Auryxia® 2 grams once on Days 3, 5, and 7.
16354128|NCT04299607||AFI patients|"Blood will be collected from patients presenting with an undifferentiated fever.
~Samples will be tested with:
~the Malaria Ag Pf/Pan test SD Bioline
~the SD Bioline Dengue Duo IgM/IgG/NS1
~the DPP Zika Chikungunya Dengue test from Chembio
~the DPP Fever Panel II assay
~the Leptospira IgM ELISA test from Serion
~an in-house ELISA tests for scrub and murine typhus IgM
~blood culture for detection of Burkholderia pseudomallei"
16354129|NCT04299594||sickle cell disease patients|120 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study
16354130|NCT04299581|Experimental|Cryoablation in combination with Camrelizumab|Cryoablation treatment starts at day 1. Camrelizumab will be initiated on day 14 after Cryoablation. Camrelizumab will be administered every three weeks (3mg/Kg, IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16354131|NCT04299568|Experimental|Anti gravity treadmill training|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization followed by Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes.
16354132|NCT04299568|Active Comparator|Control|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization only
16354133|NCT04299542|Active Comparator|conventional Multi-detector CT (MDCT)|Percutaneous lung biopsy using MDCT
16354134|NCT04299542|Active Comparator|cone-beam CT (CBCT)|Percutaneous lung biopsy using CBCT
16354135|NCT04299529|Experimental|HTM plus UPP|Urinary proteomic profiling administered on top of home blood pressure telemonitoring and guideline-endorsed non-pharmacological and pharmacological management of risk factors
16354136|NCT04299529|Other|HTM alone|Home blood pressure telemonitoring administered on top of non-pharmacological and pharmacological management of risk factors
16354137|NCT04299516|Experimental|Two-team SBA|Two-team simultaneous bilateral total knee arthroplasty
16354138|NCT04299516|Active Comparator|Single-team SBA|Single-team simultaneous bilateral total knee arthroplasty
16354139|NCT04299503|Active Comparator|Crisaborole|ointment applied topically in the morning and in the evening
16354140|NCT04299503|Placebo Comparator|Placebo|ointment applied topically in the morning and in the evening
16354141|NCT04299490|Experimental|Sleep Continuity Disruption|The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.
16354142|NCT04299490|Experimental|Sleep Fragmentation|The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.
16354143|NCT04299490|Active Comparator|Undisturbed Sleep|An 8-hour period of undisturbed sleep is permitted on each night.
16354144|NCT04299477|Experimental|Patients with periodontitis and osteoporosis|Group 1 : Patients who have periodontitis and osteoporosis prescribed with bisphosphonates
16354145|NCT04299477|Experimental|Systemically healthy patients with periodontitis|Group 2: Patients who have no systemic diseases but diagnosed as periodontitis
16354146|NCT04299477|No Intervention|Systemically and periodontally healthy individuals|Group 3: Healthy controls
16354147|NCT04299464|Placebo Comparator|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
16354148|NCT04299464|Experimental|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
16354149|NCT04299464|Experimental|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
16354150|NCT04299451|Experimental|Open dialogue about CAM (ODC-COC)|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.
~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
16354151|NCT04299451|No Intervention|Standard care|Standard care including referral to a homepage about complementary alternative medicine
16354152|NCT04299438|Active Comparator|Propranolol|IV Propranolol - 2mg; one possible repeat dose ≥2 hours later
16354153|NCT04299438|Placebo Comparator|Placebo|Normal saline placebo- 2 mL; one possible repeat dose ≥2 hours later
16354154|NCT04299425|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).
16354155|NCT04299425|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).
16354156|NCT04299412||Melioidosis cases|serum samples collected from patients with B. pseudomallei positive cultures
16354157|NCT04299412||Non-melioidosis cases|serum samples collected from patients with B. pseudomallei negative cultures
16354158|NCT04299399||nomal|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of biomechanics with other groups will be performed.
16354159|NCT04299399||seasonal allergic conjunctivitis(SAC)|Eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of corneal biomechanics with other groups and correlation analysis of corneal biomechanical parameters and other measurement indicators will be performed.
16354160|NCT04299399||vernal keratoconjunctivitis (VKC)|At first visit, eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured. All patients will adopt a unified medication regimen:0.1% tacrolimus eye drops four times daily; 0.1% flumirone eye drops twice daily; azelastine hydrochloride eye drops four times daily; hyaluronic acid sodium eye drops four times daily. After 1M, 0.1% flumilone eye drops will be replaced with 0.02% flumirone eye drops twice daily, and rest of the medication will remain unchanged. The same ophthalmological examinations will be performed again after 3 month medication.
16354161|NCT04299399||keratoconus|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of these parameters with other groups will be performed.
16354162|NCT04299373|Experimental|Alcohol: Oral administration|Participants in this arm will consume a measured dose of alcohol orally, with the goal of achieving a target peak breath alcohol concentration of .065% within 20 minutes.
16354163|NCT04299373|Experimental|Alcohol: Intravenous administration|Participants in this arm will be infused intravenously with a dose of alcohol sufficient to raise their breath alcohol concentration to .065% within 20 minutes.
16354187|NCT04299113|Experimental|Treatment (vinorelbine, mocetinostat)|Participants receive mocetinostat in combination with vinorelbine
16354188|NCT04299100|No Intervention|Control Group|Participants randomized to the Control Group will receive usual care from their pain physician.
16354447|NCT04297189|Experimental|Coaching Intervention|Single arm pilot study of coaching intervention
16354164|NCT04299360||standard BIV|the following group describes the effects of the left ventricular stimulation involving a dipole of two electrodes located inside a suitable vessel branch of the coronary sinus (CS). Standard BIV pacing modality can be achieved by either a quadripolar electrode implanted in the CS, of which only two poles will be used for cardiac resynchronization therapy, or by a bipolar electrode equipped with just two electrodes. The latter describes the old technology, requiring a change into typology of generator which has to display an IS-1 connection (due to different distal terminal of the electrode itself), instead of the new one IS-4 connection that has been developed for quadripolar electrodes.
16354165|NCT04299360||MPP BIV|Such modality of left ventricular stimulation requires a dynamic use of the four electrodes located in the proximal segment of the electrocatheter that allows the recruitment of a vast area of the left ventricle. It is limited by the presence of scars on left ventricle surface, or phrenic nerve inadvertent stimulation.
16354166|NCT04299308|Experimental|Moderate Intensity Aerobic Exercise|45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR
16354167|NCT04299308|Experimental|High Intensity Aerobic Exercise|65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR
16354168|NCT04299295|Experimental|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
16354169|NCT04299295|Active Comparator|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
16354170|NCT04299282|Active Comparator|CanGaroo|The treatment group will receive a CanGaroo envelope with implantation of a CIED
16354171|NCT04299282|No Intervention|No CanGaroo|The control group will not receive a CanGaroo envelope with implantation of a CIED
16354172|NCT04299256|Experimental|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
16354173|NCT04299256|No Intervention|Control|Like the intervention group, the control group session (attention-matched education) which composed of 10-12 participants were performed with a booklet containing hemodialysis and its use in a silent room located in the hemodialysis units. The patient information provided in-person training on hemodialysis and its use for 20 min in a group session at the hemodialysis unit, on the first day of the study. During the study period, the participants in the control group were not subjected to any additional intervention.
16354174|NCT04299243|Experimental|Spherical Lens|Randomized to Spherical Lens worn in a daily disposable mode
16354175|NCT04299243|Active Comparator|SiHy Daily|Randomized to SiHy Daily worn in a daily disposable mode
16354176|NCT04299217|Active Comparator|Mango Leaf Extract|300 mg Mangifera indica (mango) leaf extract standardized to ≥ 60% mangiferin (Zynamite®), plus carrier
16354177|NCT04299217|Placebo Comparator|Placebo|Carrier (placebo)
16354178|NCT04299204|Experimental|Years 1997-2007|Group-1, PCNL was performed in the first 10 years period (Years 1997-2007);
16354179|NCT04299204|Experimental|2008- to the present|The PCNL was performed in the second ten years period from 2008 to the present.
16354180|NCT04299191|Experimental|Dose Escalation|"The dose level corresponds to 80% of the maximum tolerated dose of 2-OHOA in adult patients when adjusted for body surface area. The escalation will be to the 100%, and 120% of the maximum tolerated dose of 2-OHOA in adult patients when adjusted for body surface area. Dose escalation decisions will be made by all active Investigators in collaboration with the Medical Monitor when at least three patients have completed the DLT observation period (Cycle 1) at each dose level. When the third patient at any given dose level has received 14 days of therapy, an escalation teleconference will be scheduled after that patient has completed the DLT observation period (Cycle 1). The decision to progress to the next dose level will be made on the basis of review of all significant 2-OHOA-related toxicities."
16354181|NCT04299165|Experimental|Device: KAIA COPD-App (Medical Mobile Application).|The study intervention is an exercise training program that requires only a chair or water bottles, consisting of training elements with progressive levels of intensity, individually adaptable to the participant's exercise level. This training program is delivered to the participants with the help of KAIA COPD-App. Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
16354182|NCT04299165|Active Comparator|Usual Care|"The Training of the control-group is performed by regular recommendations/ Standard of care. Standard of care in this context means to hand out the brochure  Besser Leben mit COPD  including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database."
16354183|NCT04299152|Experimental|Stem Cell Educator therapy treat patients with SARS-CoV-2|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
16354184|NCT04299152|No Intervention|Conventional treatment of patients with SARS-CoV-2|Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.
16354185|NCT04299126|Experimental|high absorption pad for blood and pus|High absorption pad for blood and pus with natural antimicrobial agent composes of sericin and chitosan. It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
16354186|NCT04299126|Active Comparator|commercial wound dressing|Commercial wound dressing is gauze dressing impregnated with paraffin, containing 0.5% chlorhexidine acetate (Bactigras). It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
16354319|NCT04298164|Experimental|Intervention group|Group that receives the intervention
16354189|NCT04299100|Experimental|Sleep Health Program - Suspected No/mild sleep apnea|Participants randomized to the Sleep Health Program with no/mild sleep apnea.
16354190|NCT04299100|Experimental|Sleep Health Program - Suspected Moderate/severe sleep apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea.
16354191|NCT04299087|Experimental|Dystonia and/or tremor|Adults with a diagnosis of dystonia and/or tremor
16354192|NCT04299087|Experimental|Control|Healthy adults without a history of any neurological disorder, with a similar age distribution and sex ratio as the dystonia and/or tremor group
16354193|NCT04299074|Other|Addiction|problematic addiction
16354194|NCT04299061|Experimental|Study Group|
16354195|NCT04299048|Experimental|PF-06946860|subcutaneous injection
16354196|NCT04299035|Experimental|Thoracic surgery + ESPblock|Thoracic surgery + ESPblock + standard pain management
16354197|NCT04299035|Experimental|Abdominal surgery + ESPblock|Abdominal surgery + ESPblock + standard pain management
16354198|NCT04299035|Experimental|Spinal surgery + ESPblock|Spinal surgery + ESPblock + standard pain management
16354199|NCT04299035|No Intervention|Thoracic surgery|Thoracic surgery + standard pain management
16354200|NCT04299035|No Intervention|Abdominal surgery|Abdominal surgery + standard pain management
16354201|NCT04299035|No Intervention|Spinal surgery|Spinal surgery + standard pain management
16354202|NCT04299022||Prospective Registry|Treatment for diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with Vivigen Cellular Bone Matrix
16354203|NCT04299022||Retrospective Data Collection|Treatment of diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with adjunct bone graft utilized in the acute, delayed, non-union and fusion settings.
16354204|NCT04299009|Experimental|Retimer bright light therapy glasses|active bright light therapy in the green/blue spectrum range
16354205|NCT04299009|Sham Comparator|sham-Retimer bright light therapy glasses|bright light therapy with light in the red spectrum (not active)
16354206|NCT04298996||study group (passive smoking children)|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
16354207|NCT04298996||control group|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
16354208|NCT04298983|Experimental|Abemaciclib + ADT+ RT|Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
16354209|NCT04298970|Active Comparator|Intervention|Consuming a product containing 35-40 gram of freeze dried kale a day.
16354210|NCT04298970|Placebo Comparator|Placebo|Consuming a placebo product.
16354211|NCT04298957|Other|See and treat|Cone biopsi is offered to women age ≥ 45 years referred to Department of Obstetrics and Gynecology due to a positive cervical screening test and partly or invisible transformation zone.
16354212|NCT04298944||BeHealthY Cohort|Children from BeHealthY cohort who are obese/overweight but do not have mood disorders are eligible for this study. The children will be given additional questionnaires to assess emotional/behavioral well being.
16354213|NCT04298944||CHAMPION trial Cohort|"Children who are overweight/obese and have severe mental illness, and who have agreed to be contacted for future research.
~Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments."
16354214|NCT04298944||Pediatric Medical Psychiatric (PMP) Clinic Cohort|Children from the PMP Clinic who have severe mental illness but healthy weight. Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments.
16354215|NCT04298931||Patients undergoing open abdominal surgery|
16354216|NCT04298918|Experimental|Dose Escalation Phase|Participants will receive venetoclax in combination with a fixed dose of trastuzumab emtansine.
16354217|NCT04298918|Experimental|Dose Expansion Phase|Participants will receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
16354218|NCT04298918|Experimental|Randomized Phase II Arm 1|Participants will receive trastuzumab emtansine + placebo.
16354219|NCT04298918|Experimental|Randomized Phase II Arm 2|Participants will receive trastuzumab emtansine + venetoclax.
16354220|NCT04298905|No Intervention|Standard of Care|Individuals randomized to standard of care will receive a standardized adherence education session and provided with a paper-based diary to track appointments and adherence. Instructions will be provided on the importance of daily adherence in the primary health care facility closest to patients' residence, as per standard of care. Directly observed therapy (DOT) is recommended for all patients at patients' nearest clinic. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
16354221|NCT04298905|Active Comparator|mHealth intervention|Individuals randomized to the intervention arm will receive the same standardized adherence education, followed by an orientation session to the study intervention. This orientation will include education on basic smartphone operations and use. The CHW will set up appointment reminders for clinic visits as well as daily adherence reminders for submission of the video DOT sessions and symptom reports. A smartphone capable of downloading apps, receiving short message service (SMS) and access wifi and cellular connectivity will be provided to intervention patients. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
16354222|NCT04298892||hematologic disorder or malignancy|
16354223|NCT04298879|Experimental|IBI376|IBI376 will be administered orally at a dose of 20 mg once daily for 8 weeks followed by 2.5 mg once daily.
16354224|NCT04298866|Other|Experimental arm|
16354225|NCT04298853|Active Comparator|Standard|Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
16354320|NCT04298164|Active Comparator|Control group|Group that receives treatment as usual
16354226|NCT04298853|Experimental|Study|Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
16354227|NCT04298840|Experimental|Creatine Monohydrate|
16354228|NCT04298840|Placebo Comparator|Placebo|
16354229|NCT04298827|Active Comparator|Unimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment.
16354230|NCT04298827|Active Comparator|Trimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation, nutritional counseling and group therapy, prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment. Patient nutritional assessments will be obtained with Patient Generated Subjective Global Assessment questionnaires as well as targeted questioning by the dietician.
16354231|NCT04298801|Experimental|Nurse-driven HIV screening for key populations+UD|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
16354232|NCT04298801|Active Comparator|Physician-directed diagnostic testing alone|
16354233|NCT04298788|Placebo Comparator|White dishware|standard white dishware used in the home
16354234|NCT04298788|Experimental|blue dishware|specially designed blue dishware, plates and bowls
16354235|NCT04298775|Active Comparator|spinal anesthesia with morphine|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine + 200 mcg of Morphine
16354236|NCT04298775|Active Comparator|spinal anesthesia without morphine + peripheral nerve block|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine and peripheral nerve block with 0.2 to 0.375% Ropivacaine, in a volume of 20 to 30 mL.
16354237|NCT04298762|Placebo Comparator|Comparison Group|Physicians in the control group did not receive peer comparison emails.
16354238|NCT04298762|Experimental|Intervention Group|Physicians in the intervention group received peer comparison emails.
16354239|NCT04298749|Experimental|GX-P1 dose level 1|GX-P1 dose level 1
16354240|NCT04298749|Experimental|GX-P1 dose level 2|GX-P1 dose level 2
16354241|NCT04298749|Experimental|GX-P1 dose level 3|GX-P1 dose level 3
16354242|NCT04298736|Experimental|Bariatric Surgery|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy
16354243|NCT04298736|Active Comparator|Lifestyle Modification|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.
16354244|NCT04298723|Experimental|Left Atrial Appendage Occlusion|Percutaneous closure of the LAA by use of CE-mark approved LAA occlusion device Watchman / Watchman FLX
16354245|NCT04298723|No Intervention|Best medical therapy for anticoagulation|Standard of care (according to current guidelines)
16354246|NCT04298710|Experimental|Arm Cycling|Arm cycling on an arm crank ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
16354247|NCT04298710|Experimental|Leg Cycling|Leg cycling on a leg cycling ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
16354248|NCT04298710|Placebo Comparator|Sitting|Participants will remain seated after carbohydrates consumption.
16354249|NCT04298697|Experimental|TDF/FTC for one week|The first 10 participants (Arm A) will take TDF/FTC for three consecutive days of one week and will have biologic specimens collected at 8 study time points.
16354250|NCT04298697|Experimental|TDF/FTC for four weeks|The second 10 participants (Arm B) will take TDF/FTC for three consecutive days for four weeks and will have biologic specimens collected at 20 study time points.
16354251|NCT04298684|Experimental|Metformin|In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control.
16354252|NCT04298684|Placebo Comparator|Sitagliptin|In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months.
16354253|NCT04298671|Experimental|Yoga-Pilates Group|The 30-minute web-based video exercise program will combine the best yoga-Pilates exercises focused on the pelvic floor, based on prior research and expert opinion, in collaboration with yoga-Pilates instructors that participants will complete 4 times per week for 8 weeks.
16354254|NCT04298658||HIV and Insomnia|Participants will test positive for HIV and Insomnia.
16354255|NCT04298658||HIV Without Insomnia|Participants will test positive for HIV and test negative for Insomnia.
16354256|NCT04298658||Non HIV with Insomnia|Participants will test negative for HIV and test positive for Insomnia.
16354257|NCT04298658||Non HIV Without Insomnia|Participants will test negative for HIV and test negative for Insomnia.
16354258|NCT04298645|Experimental|High GI carbs breakfast / dinner|Participants will receive a meal rich in high GI carbohydrates for breakfast (day 5) first. After the wash-out day (day 6), the identical meal will be provided for dinner (day 7).
16354259|NCT04298645|Experimental|High GI carbs dinner / breakfast|Participants will receive a meal rich in high GI carbohydrates for dinner (day 5) first. After the wash-out day (day 6), the same meal will be provided for breakfast (day 7).
16354260|NCT04298632|Experimental|Youth-only|Only the youth receives the education program
16354261|NCT04298632|Experimental|Family enhanced|A parent and the youth both receive the education program
16354262|NCT04298632|No Intervention|Control|neither parent, nor youth receives the education program
16354263|NCT04298619||Standard cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
~symptom assessment
~blood tests
~physical examination"
16354264|NCT04298619||Imaging cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
~symptom assessment
~blood tests
~physical examination
~Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes"
16354265|NCT04298606|Experimental|Prevention (recombinant human EGF-rP64K/montanide ISA 51)|"LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity."
16354266|NCT04298593|Other|ECG monitoring|All patient will be under telemetry
16354267|NCT04298580|Active Comparator|PVB before surgery|
16354268|NCT04298580|Active Comparator|PVB after surgery|
16354269|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg [BID] plus ASA 75mg [OD] has been made by the investigator.
16354270|NCT04298554|Experimental|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily
16354271|NCT04298554|Placebo Comparator|Placebo (hemp oil)|CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily
16354272|NCT04298541|Experimental|Patients with Meningioma|Subjects with suspected meningioma planned for surgery who meet the inclusion and exclusion criteria.
16354273|NCT04298528|Experimental|dronabinol|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
16354274|NCT04298528|Placebo Comparator|placebo|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
16354275|NCT04298515|Other|Type 2 Diabetes group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
16354276|NCT04298515|Other|Insulin resistance group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
16354277|NCT04298515|Other|Obesity group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
16354278|NCT04298489|Experimental|stage III/IV gastrointestinal cancer patients|The study group (Personalized drug sensitivity test) was treated according to the physician's opinion. Tumor tissues are obtained during the surgery or via biopsy with informed consent, for the purpose of ex vivo assay.
16354279|NCT04298476|Placebo Comparator|A|Saline will be placed in syringe instead of ropivicaine 0.2% and the nerve block will be placed in the adductor canal at the desired location by the anesthesiologist
16354280|NCT04298476|Active Comparator|B|An adductor canal block will be placed with local anesthetic in the proximal 1/3 of the operative leg
16354281|NCT04298476|Active Comparator|C|An adductor canal block will be placed with local anesthetic in the middle 1/3 of the operative leg
16354282|NCT04298476|Active Comparator|D|An adductor canal block will be placed with local anesthetic in the distal 1/3 of the operative leg
16354283|NCT04298463||COHORT A: dalbavancin|Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.
16354284|NCT04298463||COHORT B: lipo and glyco-peptid drugs|Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.
16354285|NCT04298450|Experimental|Active SMS Intervention|Participants assigned to the experimental arm will receive the active SMS intervention. Participants in the active intervention group who consent to participate will be asked to complete a web-based survey. Based on survey findings, purposive sampling will be used to select a subsample of 12 to 20 participants for qualitative interviews.
16354286|NCT04298450|Sham Comparator|Sham SMS|Participants assigned to the sham comparator will receive the sham SMS intervention. They will not be re-contacted.
16354287|NCT04298437|Experimental|Parent Group Treatment|Families who meet inclusion criteria will participate in the Parent Group Treatment (ADAPT Program).
16354288|NCT04298437|No Intervention|No Treatment|Families who do not meet inclusion criteria will not be invited to participate in the ADAPT Program.
16354289|NCT04298424|Experimental|Peer-led|The experimental group will conduct a 4-week peer self-management program and receive the original outpatient routine care.
16354290|NCT04298424|No Intervention|No Peer-led|The control group will only issue a self-management manual and receive the original outpatient routine care.
16354291|NCT04298411|Experimental|Experimental Arm|Participants will take part in 12 one-hour rehabilitation sessions over 12 weeks in the clinic at Holland Bloorview Kids Rehabilitation Hospital and Institut de réadaptation en déficience physique de Québec, during which they will play games developed for the Novint Falcon.
16354292|NCT04298398|Experimental|Mindfulness (MBCT)|Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).
16354293|NCT04298398|Experimental|Emotion Focused Therapy (EFT-CR)|Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).
16354294|NCT04298398|Other|Control Group|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
16354295|NCT04298385||Individuals with oblique proximal phalanx fractures of finger|Traction orthosis and exercise
16354296|NCT04298346||Case|
16354297|NCT04298346||Control|
16354298|NCT04298333|Experimental|BP-C1|BP-C1 will be used as supportive care
16354299|NCT04298320|Experimental|SHR-1210 + AIN457|SHR-1210 was administered 200mg iv every 2 weeks in combination with AIN457 150mg or 300mg ih every 2 weeks
16354300|NCT04298307||Patients with calcified coronary artery disease|Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.
16354301|NCT04298294|Experimental|injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with i-PRF& bone graft
16354302|NCT04298294|No Intervention|no injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with bone graft
16354303|NCT04298281||Parents of patients who have a family care conference criteria|These will be parents of patient who have one of our defined family care conference criteria
16354321|NCT04298151|Experimental|zirconomer improved|zirconia reinforced glass ionomer restoration
16354304|NCT04298281||Parents of patients who do not have a family care conference criteria|These will be parents of patients who do not have one our defined family care conference criteria
16354305|NCT04298255|Experimental|ROSI only|Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner
16354306|NCT04298255|Experimental|Half ROSI-half Sperm Donor Fertilization|Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm
16354307|NCT04298242|Experimental|MRgFUS Treatment|The pancreatic tumor will be ablated with magnetic resonance guided focused ultrasound (MRgFUS).
16354308|NCT04298229|Active Comparator|Protocolized diuretic therapy|"The patient will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.
~The initial loop diuretic regimen after enrollment:
~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.
~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol."
16354309|NCT04298229|Experimental|Protocolized diuretic therapy plus SGLT2 inhibitor therapy|"The patient will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.
~The initial loop diuretic regimen after enrollment:
~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.
~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.
~The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge."
16354310|NCT04298216|Active Comparator|Assessment of Inferior Vena Cavae with Subcostal View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the subcostal region.
16354311|NCT04298216|Experimental|Assessment of Inferior Vena Cavae with Transhepatic View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the transhepatic region.
16354315|NCT04298190|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
16354316|NCT04298190|Active Comparator|Enhanced Usual Care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
16354317|NCT04298177|Experimental|QDOT-LAWT|"A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used.
~The primary ablation mode for PVI will depend on the calculated LAWT at each atrial point, as follows:
~**< 3.5-mm LAWT (red, and yellow colors): vHPSD ablation will be performed. If <1-mm LAWT (red color): Power 90 W; the duration of RF applications will be reduced to 2 seconds. If 1-3.5 mm LAWT (yellow color): Power 90 W; the duration of RF applications will be 4 seconds, according to the QDOT-FAST protocol.
~**> 3.5-mm LAWT (green color): QMODE ablation will be performed. 50 W with AI target = 500"
16354318|NCT04298177|Active Comparator|CLOSE|"In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. A ThermoCool® SmartTouch® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) will be used. The ablation will be performed using a proprietary RF generator (SMARTABLATE®; Biosense Webster, Diamond Bar, CA, USA).
~Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of ≥ 400 at the posterior wall/roof and ≥ 550 at the anterior wall are reached."
16354323|NCT04298138|Experimental|Low dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
16354324|NCT04298138|Experimental|Medium dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
16354325|NCT04298138|Experimental|High dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
16354326|NCT04298125|Experimental|Exercise in Pregnancy in Community|The Expecting intervention at the ACNC includes three 30-45 minute, in-person exercise sessions per week. The sessions are gradually increased in length over the first weeks of participation, and are comprised of 15-30 minutes of moderate aerobic activity (recumbent bike, walking on a treadmill or on an elliptical machine) as well as 5-10 minutes of resistance training using hydraulic exercise equipment. The sessions conclude with stretching exercises. Throughout the session, a personal trainer assesses the rating of perceived exertion using the 6 to 20 point Borg scale of exhaustion.41 Between sessions, participants are asked to monitor their daily step count with a target of 10,000 steps per day using a pedometer provided to the participant. This number is reported to or downloaded by the personal trainer at each in-person session. These elements will be adapted to provide a similar exercise experience that is accessible to women in their local community.
16354327|NCT04298125|No Intervention|Standard Care|Participants will receive guidance on exercise from their physician as usual.
16354328|NCT04298112||relapse after radical treatment for prostate cancer|prostate cancer patients with biochemical relapse following radical treatment, or patients with persistently elevated PSA levels after radical prostatectomy, that have been (or will be) referred to PSMA PET/CT and PSMA PET/MRI at one of the participating hospitals.
16354329|NCT04298099|Active Comparator|Ropivacaine 0.2% at 0.3ml/kg|Ropivacaine 0.2% at 0.3ml/kg
16354330|NCT04298099|Active Comparator|Ropivacaine 0.5% at 0.3ml/kg|Ropivacaine 0.5% at 0.3ml/kg
16354331|NCT04298086|Experimental|Exercise Treatment and Plant-Based Diet|Will consist of structured exercise treatment plus a calorie-restricted plant-based diet. Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed at MSK or on a treadmill under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service. Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
16354332|NCT04298086|Active Comparator|Physical activity and nutrition counseling|Will consist of a general physical activity recommendations and nutrition education by exercise physiologists and registered dietitians. Treadmills will be provided to patients in the counseling arm.
16354333|NCT04298060|Experimental|DAS181 SD group Cohort 1, Stage 1|DAS181 SD group 4.5mg/day for 7 or 10 days
16354334|NCT04298060|Experimental|DAS181 HD group Cohort 1, Stage 1|DAS181 HD group 9mg/day for 7 or 10 days.
16354335|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 1|Placebo 0mg/day for 7 or 10 days
16354336|NCT04298060|Experimental|DAS181 group, Cohort 1, Stage 2|DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.
16354337|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 2|Placebo 0mg/day for 7 or 10 days
16354338|NCT04298060|Experimental|DAS181 group, Cohort 2, Stage1 and 2|DAS181 4.5mg/day or 9mg/day for 7 or 10 days
16354339|NCT04298047|Experimental|Intervention group|The participants in the Intervention group will be participants of the MMFA participatory art-based activity.
16354340|NCT04298047|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the MMFA participatory art-based activity.
16354341|NCT04298034|Experimental|Treatment|The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.
16354342|NCT04298034|No Intervention|No-treatment|
16354343|NCT04298021|Experimental|AZD6738 + Durvalumab|"Durvalumab 1500 mg iv on D1
~AZD6738 240 mg bid on D15-D28 Every 4 weeks C1D1 dose of durvalumab will be delivered, and AZD6738 of 240 mg bid will be dosed at D15-D28. Every cycle consists of 4 weeks."
16354344|NCT04298021|Experimental|AZD6738 + Olaparib|"AZD6738 160 mg qd on D1-D7
~Olaparib 300 mg bid on D1-D28 Every 4 weeks Every cycle consists of 4 weeks. AZD6738 of 160 mg qd will be administered on D1-D7. Olaparib will be delivered as 300 mg bid dose on D1-D28."
16354345|NCT04298008|Experimental|AZD6738 + Durvalumab Cohort|This is a study enrolling advanced BTC patients who have been previously treated with immunotherapy, to explore the combination of AZD6738+durvalumab
16354346|NCT04297995|Experimental|HLX10 Plus HLX07 (stage 1L)|3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly
16354347|NCT04297995|Experimental|HLX10 Plus HLX07 (Stage 1H)|3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly
16354348|NCT04297982|Experimental|Intervention group (Mandala activity)|Scales were applied to the experimental group in the first encounter with the adolescent (pre-test). Then, a total of two sessions of individual mandala activities were performed at least 48 hours apart. Each adolescent freely drawn and painted the unstructured mandala on white paper, starting from the center and expanding. The same scales were reapplied last (post-test).
16354349|NCT04297982|Other|Control group|Scales were applied to the control group with an interval of 5 days and received routine nursing care (pre-test, post-test).
16354350|NCT04297969||GCK Glow fixation|Patients screened with GoCheck Kids flash concentrated iPhone 7+
16354351|NCT04297943|Active Comparator|3D Orthosis|See summary
16354352|NCT04297943|Active Comparator|Custom Thermoplastic Orthosis|See summary
16354353|NCT04297930||Paul Glaucoma Implant Surgery|Patients who had surgery with the Paul Glaucoma Implant
16354360|NCT04297891||ARSACS|Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.
16354361|NCT04297891||SPG7|Participants with genetically confirmed SPG7 (ORPHA:99013) will be recruited. Target sample size for the SPG7 cohort is 72.
16354362|NCT04297891||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as the ARSACS and SPG7 cohort. Target sample size for the control cohort is 50.
16354363|NCT04297878|Experimental|Group A|Taking two SsK12 lozenges at night on days 1, 7 and 14.
16354364|NCT04297878|Active Comparator|Group B|One SsK12 daily at night for 14 days.
16354365|NCT04297865|Experimental|A dose as CJ-15314 or placebo|Oral administration of A as CJ-15314 or placebo once a day
16354366|NCT04297865|Experimental|B dose as CJ-15314 or placebo|Oral administration of B as CJ-15314 or placebo once a day
16354367|NCT04297865|Experimental|C dose as CJ-15314 or placebo|Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days
16354368|NCT04297865|Experimental|D dose as CJ-15314 or placebo|Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days
16354369|NCT04297865|Experimental|E dose as CJ-15314 or placebo|Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days
16354370|NCT04297865|Experimental|F dose as CJ-15314 or placebo|Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days
16354371|NCT04297852|Active Comparator|Vegan drink|Treatment group
16354372|NCT04297852|Placebo Comparator|Control|Placebo group
16354373|NCT04297839|Active Comparator|Control Group|"Patients in this group will receive heparin during hemodialysis sessions, at a dose of 1.000 units at the beginning and 500 units per hour in a syringe infusion pump.
~If the patient has a contraindication for the heparin use, it will receive saline continuous administration.
~This is the actual standard of care performed in extended hemodialysis sessions."
16354374|NCT04297839|Experimental|Citrate Group|Patients in this group will receive regional citrate anticoagulation, with acid-citrate-dextrose 2.2% (ACD). Dose of 3 mmol per liter of filtered blood. The systemic calcium levels are measured every two hours and a solution of calcium chloride is infused in a peripheral venous access, accordingly to citrate infusion rate and the systemic calcium values.
16354375|NCT04297826|Experimental|Harvest for Health|The study is a gardening intervention among 150 older cancer survivors and individuals living with chronic disease (cardiovascular disease and diabetes) in the states of Alabama and Mississippi. This program focuses on 15 counties where a Community Health Advisor training program is in place (Bullock, Calhoun, Dallas Madison, Marengo, Monroe, Sumter, Talladega, Walker Counties in Alabama and Boliver, Granada, Humphrey, Panola, Sunflower, and Yazoo Counties in Mississippi). Participants are paired with Cooperative Extension certified Master Gardeners to plant a vegetable garden at their place of residence (the intervention). Baseline, midpoint, and 1 year follow up will occur. Previous pilot work provides an established relationship with the Cooperative Extension as well as training mechanisms for the Master Gardeners.
16354376|NCT04297813|Active Comparator|Control|The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
16354377|NCT04297813|Experimental|Test|Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
16354378|NCT04297787|Other|Treatment|The treatment protocol the study team will be following is as follows for all enrolled patients. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
16354379|NCT04297774|Experimental|virtual reality group|18 sessions of standard treatment plus virtual reality treatment.
16354380|NCT04297774|Active Comparator|standard treatment group|18 sessions of standard treatment plus balance training.
16354381|NCT04297761|Placebo Comparator|Filtered air|Subjects will be exposed once to filtered air for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
16354382|NCT04297761|Experimental|Wood Smoke|Subjects will be exposed to air containing wood smoke for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
16354383|NCT04297748|Experimental|Cohort A|Patients (pts) will receive an initial trace (100 mg, IV) dose of zirconium-89 (1.8-2.5 mCi) labelled M7824 (89Zr-M7824) on day 1, sequential PET imaging over 1 week will be performed to determine the biodistribution 89Zr-M7824 into the tumour and normal tissues. All patients who remain on study after Day 14 will have a 1200 mg dose of M7824 q2w beginning on Cycle 1 Day 15. Pts will then receive a 2nd infusion of 100 mg of 89Zr-M7824 with cold M7824 making a total dose of 1200mg on Day 29. All patients will then receive a dose of cold 1200mg M7824 on Cycle 1 Day 43. Patients will continue to receive a therapeutic dose of 1200 mg q2w of M7824 until disease progression or unacceptable toxicity. Patients who do not achieve a CR after 3 doses of M7824 in Cycle 1, may then commence treatment with concurrent chemotherapy with carboplatin and pemetrexed at conventional doses.
16354384|NCT04297748|Experimental|Cohort B|Cohort A will determine whether or not high PD-L1 positive disease is required at study entry to Cohort B. All other assessments within cohort A will be undertaken.
16354385|NCT04297735|Active Comparator|Standard of care group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
16354386|NCT04297735|Experimental|Telemedicine group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
16354387|NCT04297696|Experimental|exercise group|therapeutic exercises
16354388|NCT04297696|No Intervention|control group|
16354393|NCT04297670||Unvaccinated against HPV boys|Sexually active unvaccinated against HPV 16-20 years old boys.
16354394|NCT04297657|Experimental|intervention group|
16354395|NCT04297657|No Intervention|control group|
16354396|NCT04297631|Experimental|Vancomycin Powder|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
16354397|NCT04297631|Experimental|Tobramycin Powder|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
16354398|NCT04297618|Experimental|Xiidra treatment|Each participant will use the same study drops, Xiidra, over the course of the 12-week study.
16354399|NCT04297605|Experimental|Experimental 1: pembrolizumab and Pemetrexed|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days
~Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)"
16354400|NCT04297605|Experimental|Experimental 2: pembrolizumab and Nab-paclitaxel|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days
~Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles followed by pembrolizumab alone"
16354401|NCT04297592|Active Comparator|Group A - antibiotic group|Patients will be given 7-days of an oral antibiotic (either cephalexin or doxycycline) to be started after completion of standard perioperative intravenous antibiotics following primary hip or knee arthroplasty
16354402|NCT04297592|No Intervention|Group B - no additional antibiotic|No antibiotics will be prescribed following standard perioperative IV antibiotics following primary hip or knee arthroplasty.
16354403|NCT04297566||Crohn disease's patients|Crohn's disease patients seen in gastroenterology consultation or coming in day hospital for treatment
16354404|NCT04297553|Active Comparator|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
16354405|NCT04297553|Active Comparator|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
16354406|NCT04297540|Experimental|Active-tDCS group|8 sessions (in two weeks) of active tDCS combined with a virtual reality training
16354407|NCT04297540|Sham Comparator|Sham-tDCS group|8 sessions (in two weeks) of sham tDCS combined with a virtual reality training
16354408|NCT04297527|Experimental|Conventional Physiotherapy Group|Group I (18 subjects) received 15 sessions of Conventional Physiotherapy program (CPP) 5 times per week.
16354409|NCT04297527|Experimental|Mulligan Mobilization Group|Mulligan Mobilization was administered 9 sessions (3 days a week, for 3 weeks). .
16354410|NCT04297527|Experimental|Conventional Physiotherapy plus Mulligan Mobilization Group|Conventional Physiotherapy (15 session) plus Mulligan Mobilization Programme (9 session) were applied in this group. CP were applied 5 days a week and CP+MM 3 days a week for 3 weeks.
16354411|NCT04297501||All participants|All enrolled participants in this study
16354412|NCT04297488|Experimental|INR|Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.
16354413|NCT04297475||rheumatoid arthritis|The patients are diagnosed with RA according to the American College of Rheumatology (ACR) criteria, and the current clinical state was in-active or relapse. The patients receive final diagnosis and disease evaluation by two experienced rheumatologists
16354414|NCT04297462|Experimental|3-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during three consecutive days after the contact with influenza
16354415|NCT04297462|Active Comparator|7-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during seven consecutive days after the contact with influenza
16354416|NCT04297436|Other|Bexsero|Each participant is compared to baseline (before vaccination)
16354417|NCT04297423|Experimental|Plenvu|Plenvu split dose
16354418|NCT04297423|Active Comparator|Citrafleet|citrafleet in split dose
16354419|NCT04297410|Experimental|Neoadjuvant LuPSMA|
16354420|NCT04297384|Active Comparator|Group I (standard educational materials, surveys)|Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
16354421|NCT04297384|Experimental|Group II (personalized information, surveys)|Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
16354422|NCT04297371||CTD with RVH|The diagnosis of CTD was made based on the clinical classification criteria. The RVH patient was diagnosed by an echocardiography demonstration (later confirmed by CMR) of a hypertrophic RV (maximal end-diastole RV wall thickness >4 mm) due to CTD.
16354423|NCT04297371||CTD without RVH|The diagnosis of CTD was made based on the clinical classification criteria.The subjects were enrolled as having non-RVH if their RV wall thickness was ≤ 4 mm (later confirmed by CMR).
16354424|NCT04297371||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
16354448|NCT04297176|Experimental|Traditional monitoring method|Patients are dosed using two timed vancomycin serum concentrations
16354425|NCT04297358|Experimental|Stroke patients|40 consecutive sessions of hyperbaric oxygen will be administered at a pressure of 2 absolute atmosphere (ATA) to 10 patients. If there are drop outs, recruitment will be continued until a total of 10 patients with at least 30 sessions.
16354426|NCT04297345|Experimental|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.
~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
16354427|NCT04297345|No Intervention|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
16354428|NCT04297332|Experimental|Arm I (active EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
16354429|NCT04297332|Experimental|Arm II (active EFT, control FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
16354430|NCT04297332|Experimental|Arm III (control EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
16354431|NCT04297332|Active Comparator|Arm IV (control EFT, control TFP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.
16354432|NCT04297319|Experimental|1 - Laser intervention|Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks
16354433|NCT04297319|Placebo Comparator|2 - Laser placebo|Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks
16354434|NCT04297306|Active Comparator|Exercise prescription|"This group will be provided with a prescript exercise program, taken from UK National Guidance.
~The advice will be directed to be undertaken for 6 weeks immediately prior to surgery."
16354435|NCT04297306|Experimental|Exercise prescription and Virtual Reality Exercise Gaming|"This group will be provided with a prescript exercise program as in Arm 1. However, this group of patients will also be presented with a Virtual Reality Headset, pre-programmed with Exercise promoted games which will be provided to support and encourage their exercise regimen.
~Again this advice and support will be directed to be undertaken for 6 weeks immediately prior to surgery."
16354436|NCT04297293|Experimental|Ramosetron-ODT|
16354437|NCT04297293|No Intervention|Control|
16354438|NCT04297280|Experimental|TACE in combination with sintilimab|TACE treatment starts at day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator decision. Sintilimab will be initiated on day 14 after the first TACE session. Sintilimab will be administered every three weeks (200mg fixed dose IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16354439|NCT04297267|Experimental|GP group|Patients should receive four cycles of GP regimen (cisplatin at 75 mg/m2 iv infusion on day 1 plus gemcitabine at 1250 mg/m2 iv infusion over 30 min on day 1 and 8 every 3 weeks).
16354440|NCT04297254|Experimental|Lenvatinib 12 mg or 8 mg|Participants with body weight (BW) greater than or equal to (>=) 60 kilogram (kg), will receive lenvatinib 12 milligram (mg) (03 capsules), and participants with BW less than (<) 60 kg, will receive lenvatinib 8 mg, (02 capsules), orally, once daily with or without food in 28-day cycles for a maximum 6 cycles of 4 weeks each for a total of 24 weeks or until disease progression, death, intolerable or unacceptable toxicity, or withdrawal of consent, whichever occurs earlier.
16354441|NCT04297241|Experimental|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
16354442|NCT04297228|Experimental|Step by Step Program|"Thirteen 1.5 hour weekday educational sessions, five 1-hour weekday fitness classes and seventeen 1 hour weekend walks/farmer's market trips were scheduled over 22 weeks. The planned total contact time was 41.5 hours, above the minimum effective amount and recommended by the USPSTF. Children participated in all activities. Weekly text messages with motivational messages and reminders were planned.
~Educational Topics included:
~Intro and Goal Setting How to Read Nutrition Labels How to Build a Healthy Meal Choose My Plate/Walking for Fitness Healthy Fast Food Add More Fruits/Vegetables to Meals Add More Physical Activity Each Day Healthy Snacks and Drinks Healthy Desserts Circuit Training at Home Favorite Recipe Makeover Step by Step Jeopardy Celebration of Completion"
16354443|NCT04297215|Placebo Comparator|Control group|This group will receive therapeutic clothing without antimicrobial agents
16354444|NCT04297215|Active Comparator|Chitosan group|This group will receive antimicrobial therapeutic clothing based on chitosan
16354445|NCT04297215|Active Comparator|Silver group|This group will receive antimicrobial clothing based on silver.
16354446|NCT04297202|Experimental|Apatinib Combined With SHR-1210 Injection|"SHR-1210 Injection: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle; Apatinib : D1-D21 : 250 mg, orally, qd; Before surgery, the patient's surgical pathology samples still need to be collected.
~D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation;
~After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. The cycle of a three-week plan will be performed with a total of 8 cycles with the treatment of Apatinib combination with SHR-1210 Injection."
16354554|NCT04296526|Experimental|Contemplation|
16354449|NCT04297176|Active Comparator|One concentration method|Patients are dosed based on one timed vancomycin serum level
16354450|NCT04297163|Active Comparator|Hospital management|Patient's receive no intervention, the follow up is the usual for a patient following CPAP therapy.
16354451|NCT04297163|Experimental|Telemedicine management|CPAP remote monitoring of patients, including a mobile application and a voicemail.
16354452|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
16354453|NCT04297137|Experimental|Mycoprotein|Ingestion of 30 g mycoprotein drink
16354454|NCT04297137|Experimental|Spirulina|Ingestion of 30 g spirulina protein drink
16354455|NCT04297137|Experimental|Chlorella|Ingestion of 30 g chlorella protein drink
16354456|NCT04297137|Experimental|Pea|Ingestion of 30 g pea protein drink
16354457|NCT04297137|Experimental|Lupin|Ingestion of 30 g lupin protein drink
16354458|NCT04297137|Active Comparator|Milk|Ingestion of 30 g milk protein
16354459|NCT04297124|Experimental|[14C]-CC-90009|A single IV dose of 0.6 mg [14C]-CC-90009 containing approximately 2 µCi of radioactivity will be administered on Day 1 under fasted conditions.
16354460|NCT04297111|Placebo Comparator|Placebo|Maltodextrin containing capsule
16354461|NCT04297111|Experimental|Probiotic|Probiotic containing capsule
16354462|NCT04297098||Asthmatic patients|
16354463|NCT04297098||Allergic patients|
16354464|NCT04297098||Control group|
16354465|NCT04297085|Experimental|Cases|
16354466|NCT04297072||Rivaroxaban|Participants in this group administered oral anticoagulant Rivaroxaban
16354467|NCT04297072||Vitamin-K antagonists (VKAs)|Participants in this group administered oral anticoagulants VKAs
16354468|NCT04297059|Experimental|Intervention group|Implementation of Ajyal Salima intervention to promote healthy eating and encourage physical activity in Lebanese school-children.
16354469|NCT04297059|No Intervention|Control group|Group of students not receiving any intervention
16354470|NCT04297046|Active Comparator|QLB for total abdominal hysterectomy|Quadratus lumborum block (QLB) was performed bilaterally with 0,3 ml/kg 0.25% bupivacaine (maximum dose 3 ml/kg) solution injection on each side.Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
16354471|NCT04297046|Active Comparator|TAPB for total abdominal hysterect0my|The transversus abdominis plane block (TAPB)was performed bilaterally with 0.3 ml/kg of 0.25% bupivacaine (maximum dose 3 ml/kg) solution . Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
16354472|NCT04297033|Experimental|Lovastatin intervention|combination of 40mg/d 12m lovastatin and symptomatic treatment drugs as a treatment strategy for BAVM .
16354473|NCT04297033|Placebo Comparator|placebo|combination of placebo and symptomatic treatment drugs as a treatment strategy for BAVM
16354474|NCT04297020||Pre-menopausal BCS + ET|Pre-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
16354475|NCT04297020||Post-menopausal BCS + ET|Post-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
16354476|NCT04297020||Pre-menopausal Healthy Control|Pre-menopausal healthy control group
16354477|NCT04297020||Post-menopausal Healthy Control|Post-menopausal healthy control group
16354478|NCT04297007|Active Comparator|Group P = PECS-II group|In group P, PECS will be performed with patients in the supine position at the end of the surgery before extubation by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions the high frequency linear probe (11-12 MHz) will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. US probe will be placed on the 4th rib. The muscles PMm, Pmm and Sam will be visualized. At the anterior axillary level or mid-axillary level, via the in-plane technique, Pecs II will be applied by injecting 20 mL of 0.25% bupivacaine in a cephalad to caudad direction to the fascia on Sam.
16354479|NCT04297007|Active Comparator|Group R = RIB group|In group R, RIB block will be performed with patients in the lateral decubitus position at the end of the surgery before extubation. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injectted into the fascial plane.
16354480|NCT04297007|No Intervention|Group C = Control group|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16354481|NCT04296994|Experimental|Open-label Dose Escalation and Expansion Study of QL1706|"Part 1 (Dose escalation): QL1706 will be administered in sequential cohorts each receiving 1 of 4 doses of QL1706 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.
~Part 2 (Dose Expansion): The PK parameters of QL1706 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
16354482|NCT04296981|Experimental|video-based patient information|Viewing an explanatory video (8 minutes) to improve communication and understanding of stroke issues and stages of the continuum of care
16354483|NCT04296968|Experimental|Expectation and experimental pain in humans|
16354484|NCT04296955|Experimental|Health communication intervention|Motivational interview as a new health communication intervention (one arm)
16354485|NCT04296955|No Intervention|Standard care|Standard care
16354555|NCT04296526|Experimental|Preparation|
16354489|NCT04296929|Experimental|Affected arm in lymphedema patients|Complex decongestive physiotherapy treatment will be applied to the arm (affected arm) that develops lymphedema after unilateral breast cancer treatment.
16354490|NCT04296929|No Intervention|Unaffected arm in lymphedema patients|After unilateral breast cancer treatments, the non-lymphedema side in the upper extremities, is the unaffected arm. No treatments will be applied to the unaffected side.
16354491|NCT04296916|Experimental|Intervention arm|medical reduction of IOP by eyedrops
16354492|NCT04296916|No Intervention|control arm|follow up without medication
16354493|NCT04296903|Experimental|MID-C treatment|
16354494|NCT04296890|Experimental|Treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
16354495|NCT04296877|Active Comparator|Habitual Contact Lens|All subjects are re-fit into habitual Acuvue® Oasys® contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days.
16354496|NCT04296877|Active Comparator|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for two weeks, for a minimum of at least 6 hours per day for 10 days.
16354497|NCT04296864|Placebo Comparator|Placebo|Placebo of Dupilumab
16354498|NCT04296864|Experimental|Dupilumab|one loading dose of Dupilumab 600 mg followed by Dupilumab 300 mg weekly for a total of 16 weeks
16354499|NCT04296851|Experimental|niclosamide|650mg daily
16354500|NCT04296851|Placebo Comparator|placebo|identical- appearing placebo
16354501|NCT04296838|Experimental|refractory UME patients treated with Conbercept|patients in this arm should meet the inclusion criteria and the definition of refractory UME
16354502|NCT04296825|Placebo Comparator|P|Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).
16354503|NCT04296825|Active Comparator|CA|Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
16354504|NCT04296825|Experimental|C|Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).
16354505|NCT04296825|Experimental|A|Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
16354506|NCT04296812|Experimental|Injeti Self-Love Model|"Psychoeducational intervention focusing improving self-esteem and increasing self-awareness.
~The session will start with discussion on healthy relationships, self-esteem.
~A white board will be used in group format and regular 8.5 by 11 paper during individual session to illustrate the Self-Love model and the characteristics and traits that are effected by self-love and lack of self-love.
~At the end of illustration and discussion there will be handout of the self-love intervention.
~The session will end by answering questions and emphasizing the importance of having self-awareness of traits that promote low-self-esteem, and finally, strategies to promote and maintain self-esteem."
16354507|NCT04296799|Experimental|Single Ascending Dose|The study will consist of 6 cohorts (1 cohort per dose level) of 8 subjects (6 subjects receiving the study drug and 2 receiving matching placebo), for a total of 48 subjects.
16354508|NCT04296799|Experimental|Multiple Ascending Dose|The study will consist of 3 cohorts (1 cohort per dose level) of 8 subjects. Six subjects will receive study drug and 2 subjects will receive matching placebo, daily for 14 consecutive days, for a total of 24 subjects (18 study drug; 6 placebo).
16354509|NCT04296786|Experimental|Chidamide plus Sintilimab|Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.
16354510|NCT04296760||Women with suspicious of deep posterior pelvic endometriosis|
16354511|NCT04296747|Experimental|Induction therapy|patients would accept toripalimab combined with chemotherapy as induction therapy, then radical treatment(surgery or chemoradiotherapy) according to whether the tumor could be resectable or the evaluation result according to RECIST1.1. Ones with PD after induction therapy will enter survival follow-up directly
16354512|NCT04296721|Experimental|Intensive weight-loss program|The life style change program will consist of two stages. The first will consist of a 3-month period of intensive diet and progressive exercise with biweekly consultations with a nutritionist (in groups or individually). The second stage will last for 9 months, until completion, with a diet that is progressively higher in calories, with more intense exercise, under the supervision of a community nurse and an individual nutritional consultation at 9 months.
16354513|NCT04296721|Active Comparator|Standard dietary recommendations|Patients will be followed according to the usual recommendations: A written diet (designed by a hospital nutritionist) and an exercise plan, depending on the patient's age and activity level, without any other type of evaluation or visit Visits in the Sleep Disorders Unit will be scheduled at 3 and 12 months
16354514|NCT04296708|Experimental|ExerCube group|The ExerCube is an immersive fitness game setting that combines innovative soft- and hardware designs with state of-the-art training concepts. The ExerCube has three walls which serve as virtual reality projection screens and haptic interfaces. The ExerCube is a playful physical-cognitive exergame training. The user navigates a virtual environment/reality via whole body exercise. The video game navigates the user and triggers various cognitive functions. The used physical exercises are functionally and elicit the improvement of endurance and strength components. Via different monitoring systems (points and heart rate), the game adapts to the individual abilities and training level to tailor workout intensity. The ExerCube training consists of two sessions a week each session will last about 30 minutes of which 25 minutes will be pure playtime
16354515|NCT04296708|No Intervention|Control group|The control group does not have any additional ExerCube training.
16354516|NCT04296695|Experimental|B/F/TAF|50mg/600mg/300mg
16354517|NCT04296695|Active Comparator|TDF/3TC/EFV|300mg/300mg/400mg
16354518|NCT04296682|No Intervention|Atraumatic Extraction Without Gingival Graft|Alveolar closure with elevation of total flaps and simple suture (Silk thread 4.0, Ethicon, Johnson & Johnson, SJC).
16354519|NCT04296682|Experimental|Atraumatic Extraction With Gingival Graft|Closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual palate.
16354520|NCT04296669|Experimental|Full desk allocation|All children within this classroom received a sit-stand stand
16354521|NCT04296669|Experimental|Partial desk allocation|six sit-stand desks were provided in this classroom. Children were rotated between these desks and traditional desks
16354522|NCT04296669|No Intervention|Control|Traditional classroom furniture was used
16354523|NCT04296656|Active Comparator|Intervention group|"Mothers in the intervention group were taught the infant calming technique 5 S's, a part of The Happiest Baby (THB) method. THB is based on the theory that infants have an innate calming reflex that can soothe infant fussing, excessive crying and prolong sleep. This reflex is triggered by five activities that mimic the sensory milieu of the womb. The 5 S's include swaddling, side position, sound (white noise), swing and suck.
~The intervention consisted of a 20-minute face-to-face guidance session with the researcher, executed individually in the mother's hospital room. Each mother was given a leaflet to take home that explained the 5 steps in short. Safety issues, such as safest sleep position (supine), allowing hips to flex and how to avoid overheating when swaddled, were addressed. The same researcher executed each guidance session to maintain standardization."
16354524|NCT04296656|No Intervention|Control group|Standard care on postpartum ward (breastfeeding and infant care guidance and support in recovering from childbirth and transitioning into parenthood).
16354525|NCT04296643|Experimental|Medical Mask|Medical Mask worn when providing care to patient with febrile respiratory illness
16354526|NCT04296643|Active Comparator|N95 respirator|N95 respirator worn when providing care to patient with febrile respiratory illness
16354527|NCT04296630|Active Comparator|Message #1|This arm will receive one of three social media messages that is preferred by our target population through focus groups that are being conducted as part of a previous study.
16354528|NCT04296630|Active Comparator|Message #2|This arm will receive the second social media message that is preferred by our target population as identified from our previous focus group study.
16354529|NCT04296630|Active Comparator|Message #3|This arm will receive the third social media message that is preferred by our target population as identified from our previous focus group study.
16354530|NCT04296630|Active Comparator|Tailored Arm|This arm will receive social media messages that will be tailored by one of the following variables: gender (men/women), age (younger/older), location (urban/rural), or social economic status (level of education). Testing to be conducted in a previous study will identify the variable that messages are tailored by.
16354531|NCT04296617||Observational (medical chart review)|Patients' medical charts are reviewed.
16354532|NCT04296604|Experimental|Traumatic Brain Injury|This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354533|NCT04296604|Experimental|Major Depressive Disorder|This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354534|NCT04296604|Experimental|Bipolar Disorder|This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354535|NCT04296604|Experimental|Schizophrenia|This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354536|NCT04296604|Experimental|Attention Deficit Hyperactivity Disorder|This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354537|NCT04296604|Experimental|Borderline Personality Disorder|This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354538|NCT04296604|Experimental|Substance Use Disorder|This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354539|NCT04296604|Active Comparator|Healthy Controls|This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
16354540|NCT04296591||study group|The study group consisted of late preterm cases(34-37 weeks of gestation) and
16354541|NCT04296591||control group|the control group consisted of term cases (<37 weeks of gestation).
16354542|NCT04296578|Experimental|Cohort 1: 5.5 mg selenite|Given orally, 5.5 mg selenite with food (within 30 mins of eating), for 5 weeks and monthly there after
16354543|NCT04296578|Experimental|Cohort 2: 11 mg selenite|Given orally, 11 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
16354544|NCT04296578|Experimental|Cohort 3: 16.5 mg selenite|Given orally, 16.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
16354545|NCT04296578|Experimental|Cohort 4: 22 mg selenite|Given orally, 22 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
16354546|NCT04296578|Experimental|Cohort 5: 27.5 mg selenite|Given orally, 27.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
16354547|NCT04296578|Experimental|Cohort 6: 33 mg selenite|Given orally, 33 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
16354548|NCT04296565|Other|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
16354549|NCT04296565|Experimental|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
16354550|NCT04296552|Experimental|12 week lowFODMAP dietary intervention|Patients with IBS-D are enrolled in a 12 week strict lowFODMAP dietary intervention study.
16354551|NCT04296539||Sedentary|Involving little exercise or physical activity
16354552|NCT04296539||Exercise|Subjects who were performing regularly pilates exercises for at least six months
16354553|NCT04296526|Experimental|Precontemplation|
16354556|NCT04296513||High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white-light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.
16354557|NCT04296513||High-definition magnification with digital chromoendoscopy.|The subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
16354558|NCT04296500||Decision tree algorithm training/testing|The investigators divided data of 67 patients into 5 groups to do 5 fold cross validation. Four groups were used to train decision tree algorithm and one group was used to test it.
16354559|NCT04296487|Experimental|Autologous Chondrocyte Injection|Autologous chondrocytes were isolated and expanded in laboratory, then injected at 2x10^6 of cells per cm^2 of the cartilage defect.
16354560|NCT04296474|Active Comparator|Active ILIT treated|Patients that have received ILIT with birch and grass allergen 5-6 years previously
16354561|NCT04296474|Placebo Comparator|Non- AIT treated|Patients that have received placebo ILIT 5-6 years previously and patients with birch and grass pollen induced allergic rhinitis that have not previously been treated with allergen immunotherapy (AIT).
16354562|NCT04296461|Experimental|Welgenaleucel (UWC19)|Part I The safety and efficacy of Welgenaleucel (UWC19) will be evaluated in a standard 3+3 dose escalation approach.The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10^6 CAR-T cells/kg administered intravenously once.
16354563|NCT04296448|No Intervention|Traditional Otoscope|Pediatric trainees use a traditional otoscope to evaluate pediatric patient ears. Trainees' supervisors will also evaluate patients with the traditional otoscope. The study evaluates concordance of the exams.
16354564|NCT04296448|Experimental|Cellscope|Pediatric trainees use a cellphone otoscope (Cellscope) to evaluate pediatric patient ears. Trainees' supervisors will evaluate patients remotely with the video on the cellphone otoscope. The study evaluates concordance of the exams.
16354565|NCT04296422|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
16354566|NCT04296422|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
16354567|NCT04296422|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
16354568|NCT04296409||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Deglutition Handicap Index, and Turkish version of the Eating Assessment Tool.
16354569|NCT04296396|Experimental|Individualized Opioid Prescription|Individualized opioid prescription protocol and shared decision making
16354570|NCT04296396|Other|Fixed Opioid Prescription|fixed opioid prescription of 20 tablets of oxycodone 5mg
16354571|NCT04296383|Experimental|Azithromycin plus Xiyanping injection group|
16354572|NCT04296383|Active Comparator|Azithromycin group|
16354573|NCT04296370|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
16354574|NCT04296370|Experimental|Single Arm|Fluzoparib
16354575|NCT04296370|Active Comparator|Physician's choice chemotherapy|Capecitabine or Vinorelbine
16354576|NCT04296357||IVF children|Children born from in-vitro fertilization
16354577|NCT04296357||IVM children|Children born from in-vitro maturation
16354578|NCT04296344|Experimental|Treatment|Participants with chronic pain to receive acupuncture therapy treatments and yoga therapy sessions.
16354579|NCT04296331||POC only|Participants who enter the DC Department of Corrections within the first 2 months of the study will be offered opt-out Point-of-Care (POC) rapid testing
16354580|NCT04296331||POC + Ag/Ab|Participants who enter the DC Department of Corrections within the third and fourth months of the study will be offered opt-out POC and 4th generation laboratory-based antigen/antibody testing (Ag/Ab)
16354581|NCT04296331||Ag/Ab only|Participants who enter the DC Department of Corrections within the fifth and sixth months of the study will be offered Ag/Ab testing.
16354582|NCT04296305|Experimental|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.
~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
16354583|NCT04296305|Experimental|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.
~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
16354584|NCT04296292||AMBITION Trial Participants|Individuals who have been enrolled into the AMBITION trial
16354585|NCT04296292||The next-of-kin of AMBITION Trial Participants|Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline
16354586|NCT04296292||AMBITION Researchers|Individuals working on the AMBITION trial
16354587|NCT04296279|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP014 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
16354588|NCT04296279|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,2 month."
16354589|NCT04296279|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 4,5,6 month."
16354590|NCT04296279|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
16354591|NCT04296279|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
16354592|NCT04296279|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
16354593|NCT04296266|Experimental|Alda-341 treatment|Alda-341 treatment at 2 g/day for 14 days up until the day before regular medical care surgery.
16354594|NCT04296240|Experimental|Neoadjuvant chemotherapy|Oxaliplatin 130mg/m2 d1 and Capecitabine 1250mg/m2 bid1-14 or other fluorouracils, every 21 or 14 days for 2 to 4 cycles, and efficacy evaluation every 2 cycles;
16354595|NCT04296227|Experimental|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
16354596|NCT04296214||A|Azacitidine 50 mg/m2 for 10 days each 28 days
16354597|NCT04296214||B|Azacitidine 75 mg/m2 for 7 days each 28 days
16354598|NCT04296201|Experimental|Treatment in the face area|5 female subjects will receive treatment in the face area
16354599|NCT04296201|Experimental|Treatment in the buttocks area|5 female subjects will receive treatment in the buttocks area
16354600|NCT04296201|Experimental|Treatment in the abdominal region|5 male subjects will receive treatment in the abdominal region
16354601|NCT04296188|Active Comparator|serratus anterior plane block|The serratus anterior plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via patient controlled analgesia (PCA) device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
16354602|NCT04296188|Active Comparator|erector spina plane block|The erector spina plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via PCA device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
16354603|NCT04296175|Active Comparator|conventional group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 or 3 weeks followed by paclitaxel 80mg/m2 d1,d8,d15, every 3 weeks.
16354604|NCT04296175|Experimental|carboplatin group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 weeks followed by paclitaxel 80mg/m2 and carboplatin AUC=2 d1,d8,d15, every 4 weeks.
16354605|NCT04296162|Experimental|Single arm|6 cycle of oral vinorelbine or capecitabine combined with trastuzumab (21 days per cycle), followed by sequential single trastuzumab to 1 year
16354606|NCT04296149|Experimental|Y-90-DOTATOC|Patients affected by Small Intestine neuroendocrine tumors
16354610|NCT04296123|Experimental|Intervention|
16354611|NCT04296123|No Intervention|Control|
16354612|NCT04296110|Active Comparator|Control|Participants will receive music relaxation therapy. They will be asked to listen to designated music daily for 12 weeks.
16354613|NCT04296110|Experimental|Biofeedback|Participants will receive a biofeedback intervention. They will be asked to practice breathing at their designated resonance frequency using provided biofeedback device daily for 12 weeks.
16354614|NCT04296097|Experimental|Deep Brain Stimulation (DBS) activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON
16354615|NCT04296097|Other|Deep Brain Stimulation (DBS) non-activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF
16354616|NCT04296084||healthy individuals|Volunteer healthy individuals who are between the ages of 20-40 and who do not have any medical condition to affect gait or arm swing.
16354617|NCT04296071||Group 1|patients who tend to have longer CPB
16354618|NCT04296071||Group 2|Patients who have shorter CPB
16354619|NCT04296058||SOX4 high|Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group
16354620|NCT04296058||SOX4 low|Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group
16354621|NCT04296045|Placebo Comparator|Glucose|
16354622|NCT04296045|Experimental|MCE|
16354623|NCT04296045|Experimental|MCE + Glucose|
16354624|NCT04296032|Experimental|virtual reality group|Standard treatment 30 minutes plus virtual reality game 30 minutes, twice a week for 9 weeks.
16354625|NCT04296032|Active Comparator|standard treatment group|Standard treatment 60 minutes, twice a week for 9 weeks.
16354626|NCT04296019|Experimental|Fruquintinib|Patients who achieved stable disease (SD) or partial response (PR) or complete response (CR) following palliative first-line treatment will receive maintenance therapy with fruquintinib.
16354627|NCT04296019|No Intervention|Observation|Patients who achieved SD or PR or CR following palliative first-line treatment will receive treatment-free observation.
16354628|NCT04296006|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
16354629|NCT04296006|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
16354630|NCT04295993|Experimental|methylene blue group|The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
16354631|NCT04295993|Active Comparator|Norepinephrine group|The patients in this group will receive norepinephrine infusion.
16354632|NCT04295980||Geschwind's area BAVMs|
16354633|NCT04295980||Healthy controls|
16354634|NCT04295967||1|presence of recurrence of urothelial carcinoma
16354635|NCT04295967||2|absence of recurrence of urothelial carcinoma
16354660|NCT04295798|Experimental|Personalized tDCS|Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average nE over the dlPFC of the same size as the one delivered by a traditional montage using sponges in an average subject at 1.5 mA of current. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
16354763|NCT04295044|Active Comparator|Normal protein diet|received normal protein diet, prescribed by dietitian
16354636|NCT04295954|Experimental|Yoga Intervention|"This group will receive the Yoga Intervention for dysmenorrhea that will consist of 3 yoga sessions a week of 30 minutes each, for 12 weeks. The first 4 weeks 1 of the sessions will be face to face and the other 2 home sessions guided by a vieo and a brochure, and tutored from the virtual platform by the yoga teacher and researchers. This space will also serve for participants to share experiences.
~After the first 4 weeks, participants will continue with the virtually tutored home yoga program, consisting of 3 weekly sessions of 30 minutes until completing the 12 weeks. They will be protected in all cases by the teacher and researchers.
~All intervention group participants will be invited to participate in online focus groups during week 12 to explore their experiences and satisfaction with the progress of the study and to implement adaptations, if necessary.
~They will be evaluated before the start of the yoga program per month, 3 months, 6 months and a year after the intervention."
16354637|NCT04295954|No Intervention|Control group without intervention|Participants in the comparison group without intervention will not receive yoga intervention, will follow their conventional treatment and their usual daily activities. They will be told not to do yoga. They will be evaluated in advance, per a month, 3 months, 6 months and a year after the intervention.
16354639|NCT04295928|Experimental|Intervention|Implementation of a personalized pharmaceutical plan with a view to increasing the patient's therapeutic education in the hospital and in the community (entrance and discharge reconciliation, 3 pharmaceutical interviews in the hospital, strengthening of the community-hospital link , 3 outpatient pharmaceutical consultations)
16354640|NCT04295928|No Intervention|Usual care period|No changes to usual center practices
16354641|NCT04295915||Specimens that meet inclusion criteria|
16354644|NCT04295889|Active Comparator|Group A|"Group A will receive an invitation for home based albuminuria screening using a more conventional urine collection device (known as Peespot Test)."
16354645|NCT04295889|Active Comparator|Group B|"Group B will receive an invitation for home based albuminuria screening using an app (internet application) and an ACR dipstick test (known as ACR| EU Test)."
16354646|NCT04295876|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-PN supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment.
16354647|NCT04295876|Experimental|BRIDGES Arm|Women assigned to The BRIDGES Project intervention arm will be connected with and receive Ryan White HIV/AIDS Program services (see above as described under Control Arm), as well as receive Peer Navigation support via one-on-one sessions, phone/text-based check-ins, and 6 unique syndemic-responsive 120 -minute group sessions designed to build coping skills (3 sessions) and assertive communication and behavior (3 sessions).
16354648|NCT04295863|Experimental|standard interval dosing|
16354649|NCT04295863|Experimental|extended interval dosing|
16354650|NCT04295850||Low Dose Aspirin|Pregnant singletons with at least one high risk factor for preeclampsia (prior preeclampsia, chronic hypertension, pregestational diabetes, lupus, antiphospholipid antibody syndrome, or chronic kidney disease) who are planning to, but have not yet started, aspirin therapy <16 weeks' gestation. Patients will take 81mg aspirin as prescribed.
16354651|NCT04295837|Experimental|ABLE - A Better everday LifE|A home-based occupational therapy intervention addressing ADL task performance issues among persons living with chronic conditions. The ABLE intervention is occupation-focused and -based, and follows a structured process of assessment, goalsetting, intervention and evaluation.
16354652|NCT04295837|Active Comparator|Usual care|Community-based occupational therapy addressing ADL task performance issues among persons living with chronic conditions
16354653|NCT04295824||Mild AD|"20 subjects with mild local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally mild)."
16354654|NCT04295824||Moderate AD|"20 subjects with moderate local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally moderate)."
16354655|NCT04295824||Severe AD|"20 subjects with severe local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally severe)."
16354656|NCT04295824||Healthy|20 healthy volunteers
16354657|NCT04295811|Experimental|EsoCheck and EsoGuard vs. EGD with or without biopsies|All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
16354658|NCT04295798|Experimental|Traditional tDCS|At the beginning of stimulation, the current will be increased manually from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. Participants will be instructed to notify study personnel if and when they feel any uncomfortable sensation. The ramp-up will be stopped at this point and for the remainder of the session tDCS will be delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
16354659|NCT04295798|Sham Comparator|Traditional Sham|A traditional sham will be used to maximize blinding of traditional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration as described with the Traditional tDCS will be used; however, current will automatically be ramped down 60 seconds after ramp-up.
16354727|NCT04295330|Placebo Comparator|placebo group|the same volume of normal saline will be administered during anesthesia.
16354764|NCT04295031||DM2 without renal disease|patients with type 2 diabetes with normal renal function
16354661|NCT04295798|Sham Comparator|Personalized Sham|An active sham will be used in which very low-level currents (0.5mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
16354662|NCT04295785||autoimmune necrotizing myopathy beginning before 18|
16354663|NCT04295772|Experimental|DOR/ISL|Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
16354664|NCT04295759|Experimental|Dose-finding|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
16354665|NCT04295746|Experimental|Serious Game ShopAut|Each participant played 10 game sessions, one per week, for no more than 30 minutes.
16354666|NCT04295733||Cohort 1|Hematopoietic Stem Celi Transplant (HSCT) patients
16354667|NCT04295733||Cohort 2|HIV infected subjects
16354668|NCT04295733||Cohort 3|Patients candidates for / in treatment with biological drugs such as monoclonal antibodies anti CD-20 (rituximab or ocrelizumab)
16354669|NCT04295720|Experimental|Transcranial magnetic stimulation (TMS)|We propose to test the efficacy of rTMS for the treatment of PCCI. Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
16354670|NCT04295707|Experimental|Monthly replacement orthokeratology without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
16354671|NCT04295707|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
16354672|NCT04295707|Active Comparator|Yearly replacement lenses with weekly protein removal|Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
16354673|NCT04295681|Experimental|MMH-MAP|Oral administration. 2 tablets twice daily (approximately at the same time). The drug is taken outside a meal (between the meals or 15 min prior to meal or fluid intake). Tablets should be held in the mouth until completely dissolved. The overall duration of treatment is 90 months.
16354674|NCT04295681|Placebo Comparator|Placebo|Oral administration. For 90 days according to MMH-MAP dosing regimen.
16354675|NCT04295668||Usual care|A contemporaneous control group of patients was build using propensity score matching (PSM) methodologies taking into account the following matching variables: type of surgery, age, sex, American Society of Anesthesiologists Index (ASA) and adjusted morbidity groups (GMA) grading.
16354676|NCT04295668||Prehabilitation|"Prospective sample of risk patients who are candidates for major surgery attended in the outpatient offices of the Hospital Clínic de Barcelona.
~Inclusion criteria: i) American Society of Anesthesiologists Index (ASA) 3-4; and / or, ii) age ≥ 75 years; and / or iii) major aggressive surgery; and, iv) solid organ transplant candidate.
~Exclusion criteria: i) Non-elective surgery; ii) Known metastatic disease before surgery; iii) Unstable respiratory or heart disease; or, iv) Locomotive or cognitive limitations that prevent adherence to the program."
16354677|NCT04295655|Experimental|Global Exercise Group|all patients received the Control Group treatment added to global exercise treatment. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises. The number of repetitions was adapted to the subject's response taken into account the perceived dyspnea and fatigue during the exercise performance.
16354678|NCT04295655|Experimental|Functional Electrostimulation Group|"all patients received the Control Group treatment plus neuromuscular stimulation therapy (SEFAR Rehab X2, DJO France S.A.S., France) on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).
~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
16354679|NCT04295655|Active Comparator|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy.
16354680|NCT04295642|Placebo Comparator|Part 1|Will include 4 subjects (3 active + 1 placebo) that will receive a single 15mg dose with approximately 48 hours of confinement and a follow-up after 7 days.
16354681|NCT04295642|Experimental|Part 2|"2A: will include 14 subjects to complete 12 with 28 days of dosing with 7 days (+/-2) of follow-up, with at least 14 days of confinement.
~-or- 2B: will include 20 subjects to complete 12 with 2 dosing days and 5 days of washout with 7 days (+/-2) of follow-up, with 4 days of confinement (may be increased up to 12 days at the investigators discretion)."
16354682|NCT04295629|Active Comparator|VAS (Visüel Analog Score)|VAS : 0-10 points 0 means: no pain 10 means: incredible pain
16354683|NCT04295629|Active Comparator|LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)|LANSS 0-24 points >12 points : has chronic neuropathic pain <12 points: no chronic neuropathic pain
16354684|NCT04295616|Experimental|IPV & active breathing training|"Intrapulmonary Percussive Ventilation (IPV) and active breathing exercises, provided by trained speech and language therapists.
~This training will be performed in combination with a multidisciplinary rehabilitation programme."
16354685|NCT04295616|Active Comparator|Active breathing training only|Active breathing training provided by trained speech therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.
16354686|NCT04295603|Experimental|Toucher Massage intervention|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes on the foot area .
16354761|NCT04295070|Experimental|High dose cohort|CodaVax-RSV delivered intranasally via dropper
16354762|NCT04295044|Experimental|High protein diet|received high protein diet, prescribed by dietitian
16354687|NCT04295603|Experimental|Homedics Machine intervention|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes."
16354688|NCT04295590|Experimental|Frequency then Intensity|Training period 1: Frequency comparison Training period 2: Intensity comparison
16354689|NCT04295590|Experimental|Intensity then Frequency|Training period 1: Intensity comparison Training period 2: Frequency comparison
16354690|NCT04295577||Cohort 1: Retrospective Cohort|"This cohort will include:
~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib but in whom quality of life data are not available.
~Patients who have previously commenced Niraparib prior to the MONITOR Study opening at the site but are now deceased but will be eligible for retrospective data collection without the need for informed consent.
~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site but have discontinued treatment.
~Data in respect of AEs, SAEs, ADRs and AESIs will be recorded in Case Report Forms and be identified via the patient's medical records. There is no requirement to complete trial specific SAE reporting forms in this cohort."
16354691|NCT04295577||Cohort 2: Prospective Cohort|"This cohort will include:
~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib and in whom quality of life data is available.
~Patients who are due to commence maintenance Niraparib treatment."
16354692|NCT04295564|Experimental|eCPAP|Participants will remain on CPAP for 2 additional weeks once CPAP stability criteria is met.
16354693|NCT04295564|No Intervention|dCPAP|Participants will discontinue CPAP as per usual care once CPAP stability criteria is met.
16354694|NCT04295551|Experimental|Experimental group of ordinary COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
16354695|NCT04295551|Active Comparator|Control group of ordinary COVID-19|ritonavir/ritonavir treatment
16354696|NCT04295551|Experimental|Experimental group of severe COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
16354699|NCT04295525|Placebo Comparator|Controls subjects placebo|Placebo mucoadhesive oral tablet
16354700|NCT04295525|Experimental|Controls subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
16354701|NCT04295525|Placebo Comparator|Diseased subjects placebo|Placebo mucoadhesive oral tablet
16354702|NCT04295525|Experimental|Diseased subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
16354703|NCT04295512|No Intervention|Usual Care|Community therapists delivering routine care to participant children with no training in UOT
16354704|NCT04295512|Experimental|UOT Training|Therapists enrolled in UOT Training
16354705|NCT04295486|Experimental|Treatment Once Daily|Participant receives 81 mg aspirin taken once daily beginning the night before surgery and up to 28 days post surgery.
16354706|NCT04295486|Active Comparator|Treatment Twice Daily|Participant receives 81 mg aspirin taken twice daily (one in the morning and one at night) beginning at the night before surgery and up to 28 days post surgery.
16354707|NCT04295473|Experimental|Reduced port laparoscopic gastrectomy|The definition of reduced port laparoscopic gastrectomy was 1-3 ports used in laparoscopic gastrectomy for gastric cancer.
16354708|NCT04295473|No Intervention|Standard laparoscopic gastrectomy|5 ports were used in standard laparoscopic gastrectomy
16354709|NCT04295460|Experimental|Dual Therapy|Dolutegravir plus lamivudine
16354710|NCT04295460|Active Comparator|Triple Therapy|Dolutegravir plus TAF/FTC
16354711|NCT04295447|Other|Standard of care|"Observation only or
~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
16354712|NCT04295447|Experimental|Apalutamide|30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care
16354713|NCT04295421|Active Comparator|Canal adductor block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
16354714|NCT04295421|Experimental|IPACK block|"IPACK was realized after spinal anesthesia. Patient was placed in a supine position and knee placed in position of 90° flexion. A low-frequency ultrasound probe was positioned in the popliteal crease, and the needle was inserted from medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle was placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.2% ropivacaine was injected for each side.
~A ACB was done postoperatively with 20 ml ropivacaine 0.2% and a catheter was kept for 48H with 4 ml/h saline"
16354715|NCT04295408|Placebo Comparator|PLACEBO|Pericapsular Nerve Group block with 40 ml saline
16354716|NCT04295408|Experimental|Pericapsular nerve group block|Pericapsular Nerve Group block with 2 mg.kg-1Ropivacaine in 40 ml of saline
16354717|NCT04295395||group1|preterm infant with closed ductus arteriosus, <32 weeks birth weight < 1500g, and > 72 hours of age
16354718|NCT04295395||group2|preterm infant with PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
16354719|NCT04295395||group3|preterm infant with hemodynamically significant PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
16354720|NCT04295382|Experimental|Software Application|
16354721|NCT04295369|Experimental|Lifestyle Medicine Group|
16354722|NCT04295369|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment.
16354723|NCT04295356|Active Comparator|Auto injector|a single dose (40 mg) of CT-P17 via AI
16354724|NCT04295356|Active Comparator|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
16354725|NCT04295343||Patients with suspicious of rectosigmoid endometriosis|
16354726|NCT04295330|Experimental|Lidocaine group|at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery.
16354728|NCT04295317|Experimental|Combined the therapy using Capecitabine and PD-1|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
16354729|NCT04295304|Experimental|NR600 device implantation|Retinal surgery and implantation of epi-retinal prosthesis
16354730|NCT04295278||Systemic inflammatory response syndrome|Systemic inflammatory response syndrome in patients in the pediatric intensive care unit.
16354731|NCT04295265|Experimental|Smartphone|Receive daily whatsapp/ SMS message remind the drug intake.
16354732|NCT04295265|No Intervention|Control|receive instruction to take the medication at recruitment
16354733|NCT04295252||cardiogenic shock patients|All-comers cardiogenic shock patients Admitted to the Intensive Coronary Care Units
16354734|NCT04295239|Experimental|MRI|Pre-operative AND post-operative MRI
16354735|NCT04295226||Participants in Structured post-stroke follow-up in Malmö|"Consecutive patients with acute ischemic stroke or intracerebral hemorrhage, treated in-hospital at Skåne University Hospital in Malmö and discharged straight to own home.
~The intervention consists of a structured follow-up visit, managed by a stroke nurse, 3 months after stroke followed by a multidisciplinary team rounds resulting in an individual treatment plan for stroke-related health problems, and a final follow-up at 12 months"
16354736|NCT04295213|Experimental|oligosaccharide group|intervention with oligosaccharides, total duration of study is 13 weeks
16354737|NCT04295213|Placebo Comparator|placebo group|Placebo comparator, total duration of study is 13 weeks
16354738|NCT04295200|Experimental|Dry needling with electrical stimulation|Use of dry needles (this is the generic name for sterile, solid filament needles) are inserted into the lumbar multifidi. Intramuscular electrical stimulation will then be applied by attaching a six-lead electrical stimulation unit to the needles. Electrical stimulation will be applied through the needles at the participant's desired frequency (between 4-6 Hz) and for up to 10 minutes total.
16354739|NCT04295187||Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
16354740|NCT04295187||Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
16354741|NCT04295161|Active Comparator|Reference|
16354742|NCT04295161|Experimental|Prototype 1|
16354743|NCT04295161|Experimental|Prototype 2|
16354744|NCT04295161|Experimental|Prototype 3|
16354745|NCT04295161|Experimental|Prototype 4 fasted|administered in fasted state
16354746|NCT04295161|Experimental|Prototype 4 fed|Administered in fed state
16354747|NCT04295148|Active Comparator|Semitendinosus graft|Participants receive the Semitendinosus Graft technique during ACL reconstruction.
16354748|NCT04295148|Active Comparator|Quadriceps tendon-bone graft|Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.
16354749|NCT04295135|Experimental|OneSheet access|Clinics or providers who receive access to, and training in the Chronic Pain OneSheet, and use it while caring for patients with chronic pain.
16354750|NCT04295135|No Intervention|Normal practice|Clinics or providers who do not receive access to, or training in the Chronic Pain OneSheet, and care for patients with chronic pain as they would normally.
16354751|NCT04295122|Active Comparator|Phacoemulsification + ECP laser|"Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. The viscoelastic will be washed-out of the capsular bag after IOL insertion. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment.
~Intracameral cefuroxime and dexamethasone will be injected into the anterior chamber and sutures used to close the incisions as required."
16354752|NCT04295122|Active Comparator|Phacoemulsification alone|Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. For this study, monofocal IOLs are required.
16354753|NCT04295109|Active Comparator|Fentanyl group(group F)|Fentanyl citrate injection, specification: 10mL: 0.5mg / piece (production unit: niching chang rendu Pharmaceutical Co., Ltd., valid period: 48 months) For group F patients,0.5mg fentanyl was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
16354754|NCT04295109|Experimental|Oxycodone group(group O)|Oxycodone hydrochloride injection, specification: 1mL: 10mg / branch (production unit: HAMOL LIMITED, valid period: 60 months) For group O patients,30mg oxycodone was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
16354755|NCT04295109|Experimental|Butorphanol group(group B)|Butorphanol tartrate injection, specification: 1 mL: 1 mg / branch (production unit: Jiangsu henryi Pharmaceutical Co., Ltd., valid period: 24 months); For group B patients,10mg butorphanol was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
16354756|NCT04295096|Other|Experimental|Healthy donor
16354757|NCT04295083|Experimental|Experimental group|The experimental group will be six 1,5 h weekly of clay based group study and interviewed face-to-face twice by the researchers.
16354758|NCT04295083|No Intervention|Control group|The control group will interviewed face-to-face twice
16354759|NCT04295070|Placebo Comparator|Placebo|Saline (0.9%) delivered intranasally via dropper
16354760|NCT04295070|Experimental|Low dose cohort|CodaVax-RSV delivered intranasally via dropper
16354765|NCT04295031||DM2 with renal impairment|patients with type 2 diabetes with impaired renal function
16354766|NCT04295018|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
16354767|NCT04295005||All patients who started an Empagliflozin therapy|
16354768|NCT04295005||All patients who started a DPP-4 inhibitor therapy|
16354769|NCT04295005||All patients who started a Sitagliptin therapy|
16354770|NCT04295005||All patients who started a GLP-1 receptor agonist therapy|
16354771|NCT04294992|Experimental|Granisteron group|
16354772|NCT04294992|Active Comparator|Ondansetron group|
16354773|NCT04294979|Experimental|Rehabilitation|Conventional Physical Therapy
16354774|NCT04294966|Placebo Comparator|Placebo|
16354775|NCT04294966|Active Comparator|7.5 mg THC|
16354776|NCT04294966|Active Comparator|15 mg THC|
16354777|NCT04294953|Active Comparator|Group (I) (D) : (Duloxetine group)|
16354778|NCT04294953|Placebo Comparator|Group (II) (P): (placebo group)|
16354779|NCT04294940|Other|Group A: standard of care|The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
16354780|NCT04294940|Other|Group B: standard of care + mobile application CardiCare™|The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
16354781|NCT04294927|Experimental|Risk-reducing salpingectomy with delayed oophorectomy|Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.
16354782|NCT04294927|Active Comparator|Risk-reducing salpingo-oophorectomy|Risk-reducing salpingo-oophorectomy.
16354783|NCT04294914|Active Comparator|Fibromyalgia|Individuals with fibromyalgia.
16354784|NCT04294914|Experimental|Healthy controls|Healthy, pain-free individuals
16354785|NCT04294901|Experimental|Gabapentin (Gaba)|Patients prescribed gabapentin with a total daily dose >1800mg without exclusion criteria who have a primary care appointment with a provider in the Gaba cohort
16354786|NCT04294901|Experimental|Diabetes (DM)|Patients prescribed either insulin or a sulfonylurea meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the DM cohort
16354787|NCT04294901|Experimental|Proton Pump Inhibitor (PPI)|Patients prescribed a PPI meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the PPI cohort
16354788|NCT04294888|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80% of a patient's active motor threshold. rTMS will be administered in an excitatory iTBS pattern. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
16354789|NCT04294888|Sham Comparator|Sham stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80% of a patient's active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory performance, or whether practice effects or other non-specific effects are responsible for any changes in memory which may be observed.
16354790|NCT04294875|Other|MPT0B640|There is Single Arm in this Clinical Trials.
16354791|NCT04294862|Experimental|TNP-2092 300mg IV|TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
16354792|NCT04294849|Experimental|Venous Thromboembolism Arm|This will be a cohort of patients age 8- ≤ 21 years old with objectively diagnosed DVT and/or PE.
16354793|NCT04294836|Experimental|Curcumin|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)
16354794|NCT04294836|Placebo Comparator|Placebo|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)
16354795|NCT04294823||FRANCE - CHU creteil|An internal physical examination including vital signs measurements and a 13C-UBT with the standard test meal (Helicobacter Test INFAI) will be performed. Patients with a positive UBT will undergo upper endoscopy. All biopsy samples will be analysed in the local laboratory of the centre. Patients with a negative UBT will undergo also upper endoscopy. Endoscopic procedures and subsequent investigations will be identical in patients with a positive and with a negative UBT. H. pylori positive and negative patients will perform the 13 C-UBT breath tests with new test meal on Day 30. The study will be conducted in outpatients. Starting on Day 1, H. pylori positive and negative patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast. Patients will return to the hospital/medical practice for UBT breath tests with new test meal on Day 30. Patients will be followed-up for 7 days after discontinuation of PPI treatment.
16354796|NCT04294810|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
16354797|NCT04294810|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
16354798|NCT04294784|Experimental|Nab-P/PD-1|Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.
16354799|NCT04294784|Active Comparator|Nab-P|Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.
16354800|NCT04294771||Myocarditis and other cardiovascular toxicities ICI-related|Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
16354801|NCT04294771||Non case|Non-case will be patients exposed to ICI without cardiovascular toxicities
16354802|NCT04294745|Experimental|Group A|Buccal infiltration of 4% Articaine
16354803|NCT04294745|Active Comparator|Group B|Inferior alveolar nerve block of 4% Articaine
16354804|NCT04294732|Placebo Comparator|Only spinal anesthesia|Only spinal anesthesia without peripheral nerve block
16354805|NCT04294732|Active Comparator|high concentration|8 ml saline with 8 ml bupivacaine
16354806|NCT04294732|Experimental|low concentration|8 ml bupivacaine with 16 ml of saline
16354807|NCT04294719||Inpatient Clients|Have a chart diagnosis of a schizophrenia spectrum illness, capacity to consent or availability of a substitute decision-maker to consent with the assent of the participant and is residing on a CAMH inpatient forensic unit (general security)
16354808|NCT04294706|Experimental|Hemp arm|Randomly assignment to Hemp arm (60 mg/day of hemp oil extract x 6 weeks)
16354809|NCT04294706|Placebo Comparator|Placebo arm|Randomly assigned to Placebo arm (60 mg/day of cellulose x 6 weeks)
16354810|NCT04294693||Pediatric Population|The investigator intends to collect information on all total joint arthroplasty patients identified within the surgical practice of Dr. Nathan Donaldson for non-tumor related diagnoses at Children's Hospital Colorado.
16354813|NCT04294667|Experimental|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol througout the Treatment Period.
16354814|NCT04294667|Placebo Comparator|Placebo|Subjects will receive placebo througout the Treatment Period.
16354816|NCT04294641|Experimental|Intervention|Determine response rate via continuous daily dose by mouth to determine efficacy
16354817|NCT04294628|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16354818|NCT04294615|Experimental|FMT through a naso-jejunal tube|The purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
16354819|NCT04294615|Active Comparator|FMT through TET|The purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
16354820|NCT04294602|Experimental|Exercise Program|This group received therapeutic exercises and patient education. For patients to encounter fewer problems and to reduce their problems, some recommendations were made that should be taken into consideration in daily life. These suggestions were given in writing. The exercise program included muscle stretching, massage of painful muscles, guided opening and closing movements, gentle isometric tension exercises against resistance, correction of body posture and relaxation techniques. All exercises were done in 6 repetitions a set, 3 sets a day, 3 days a week, treatment program lasted 4 weeks.
16354821|NCT04294602|Experimental|Low Level Laser Therapy Program|This group received LLLT, therapeutic exercises and patient education in the therapy programs. LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points. The application was applied to MTrP or sensitive points in the mastication and cervical muscles.LLLT program was done in 3 days a week, the treatment program lasted 4 weeks.
16354822|NCT04294602|Experimental|Manual Pressure Release Program|ThisThis group received manual pressure release (MPR), therapeutic exercises and patient education in the therapy programs. MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, MTrPs in the mastication and neck muscle. Applied pressure gradually with finger over the MTrPs until the subject reported a 'moderate but easily tolerable' pain value of 7 out of 10. When the pain value decreased to at least 3 or 4 therapist increased pressure again until discomfort and/or pain appeared again. This process was repeated until there was no MTrP tension/tenderness or 60 s had elapsed. MPR program was done in 3 days a week, the treatment program lasted 4 weeks.
16354823|NCT04294576|Experimental|Arm 1; BJ-001|Phase 1a Part 1 and Part 2: dose escalation for BJ-001 as single agent
16354824|NCT04294576|Experimental|Arm 2; BJ-001 and PD-1 or PD-L1 inhibitor|Phase 1a Part 3: dose escalation for BJ-001 in combination with an PD-1 or PD-L1 inhibitor. Approximately Phase 1b: expansion cohorts for the combination of BJ-001 and an PD-1 or PD-L1 inhibitor.
16354825|NCT04294563|Experimental|Immediate Intervention Group|Participants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
16354826|NCT04294563|Active Comparator|Wait-llist Control Group|Participants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.
16354827|NCT04294537|Experimental|TAP block|Bilateral ultrasound-guided single-shot TAP block with 0,15% levobupivacaine 0,75 mg/kg per side.
16354828|NCT04294537|Active Comparator|LIA - local wound infiltration|Wound infiltration with 0,5% levobupivacaine 1.5 mg/kg
16354829|NCT04294511|Experimental|Experimental|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
16354830|NCT04294498|Experimental|Durvalumab|Durvalumab
16354831|NCT04294485|Experimental|Experimental group|Physical therapy intervention Efficacy of electrostimulation intervention combined with lower limbs exercise.
16354832|NCT04294485|No Intervention|Control group|Participants will no receive physical therapy intervention
16354833|NCT04294472|Experimental|Cohort 1|Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses
16355555|NCT04289272|No Intervention|Control|Students receive lessons-as-usual.
16354834|NCT04294472|Experimental|Cohort 2|Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses
16354835|NCT04294472|Experimental|Cohort 3|Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses
16354836|NCT04294472|Placebo Comparator|Placebo Cohort 1, 2, 3|5% dextrose in water [D5W] IV delivered every 28 days for a total of 4 doses
16354837|NCT04294459|Experimental|Phase 1|Isatuximab dose level 1 or dose level minus 1 depending on predefined unacceptable toxicities observed.
16354838|NCT04294459|Experimental|Phase 2: Cohort A|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with living donor.
16354839|NCT04294459|Experimental|Phase 2: Cohort B|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with no living donor cleared for donation.
16354840|NCT04294433|Active Comparator|Infanrix-hexa+Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa
16354841|NCT04294433|Experimental|Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa
16354842|NCT04294433|Experimental|Infanrix-hexa+Twinrix|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively
16354843|NCT04294420|Experimental|Patient education program|Patient education program
16354844|NCT04294407||Stroke group|20 to 65 years old patients, with the clinical diagnosis of stroke (Mini-mental state examination (MMSE) score of ≥25)
16354845|NCT04294407||Healthy group|20 to 65 years old healthy subjects, without the clinical diagnosis of stroke
16354846|NCT04294394||rhomboid block|With a 6-13 Mhz linear USG probe, at the thoracal level of 6-7 vertebra in the sagittal position, in the cranio-caudal direction with a 22 G and 100 mm block needle in the medial of the scapula, after entering the facial plane between the rhomboid muscle and the intercostal muscle, 0.25% bupivacaine 20 ml of the local anesthetic solution will be given.
16354847|NCT04294394||erector spinae group|After the patient is taken in the lateral position, the probe T5 is 3 cm lateral to the spinous process, 22 G and 100 mm block needle with 6-13 Mhz linear ultrasonography and the facial plane between the transverse proces and the erector spina muscle is entered, and 20 ml of a local anesthetic solution consisting of 0.25% bupivacaine will be given.
16354848|NCT04294394||control group|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
16354849|NCT04294381|Experimental|pilot of SMART-goal-setting health behavior decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
16354850|NCT04294368|Other|Control|Standard fortification of breast milk
16354851|NCT04294368|Experimental|Experimental|Targeted fortification of breast milk
16354852|NCT04294355|Experimental|Artificial intelligence-Assisted colonoscopy|Tandem colonoscopy of proximal colon assisted with artificial intelligence followed by conventional colonoscopy
16354853|NCT04294355|Active Comparator|Conventional colonoscopy|Tandem conventional colonoscopy of proximal colon followed by usual conventional colonoscopy
16354854|NCT04294342|Active Comparator|Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program which consists of three blocks. All sessions include: Balance, Strength, power and break fall exercises. The intervention group i tested before and after the 10 week exercise.
16354855|NCT04294342|No Intervention|Control Group|The subjects in the control group go about their normal life for 10 weeks without any intervention. The control group is tested before and after the 10 week period.
16354856|NCT04294329|Experimental|Group Quadratus lumborum block with bupivacaine|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine where a solution of 0.25% bupivacaine 0.2 ml /kg (lean body weight) is used on each side with care not to exceed the toxic dose.
16354857|NCT04294329|Placebo Comparator|Group Quadratus lumborum block with saline|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine.A volume of 0.2ml/kg normal saline will given for each side.
16354858|NCT04294316|Other|Sonovue group|ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest who are eligible for enhanced-contrast brain ultrasound, extracranial echo-color duplex, and ocular ultrasound.
16354859|NCT04294303|Experimental|Telemonitoring|Subjects were assigned to web based telemonitoring system.
16354860|NCT04294303|Other|Control|Subjects were assigned to conventional monitoring.
16354861|NCT04294290|Experimental|hCT-MSC infusion|
16354862|NCT04294277|Experimental|Treatment arm|Treatment with Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule until 12 months.
16354863|NCT04294264|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16354864|NCT04294251|Experimental|DWP450|
16354865|NCT04294251|Placebo Comparator|Placebo|
16354866|NCT04294238|Experimental|Post-exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage of peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
16354867|NCT04294225|Experimental|Treatment (anastrozole, letrozole)|Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 >= 1.3 pg/ml and E2 >= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
16354868|NCT04294199|Active Comparator|Immobilization|Patients in this group will be given a knee immobilizer to wear for 2 weeks and then receive outpatient physical therapy evaluation and treatment
16354869|NCT04294199|Experimental|Early range of motion|Patients in this group will be allowed to move the knee and start outpatient physical therapy and treatment immediately.
16354939|NCT04293731|Active Comparator|Symbiter-Smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
16356341|NCT04283695|Experimental|Part 3|IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
16354870|NCT04294173|Experimental|video group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the experimental group in the classroom setting. Video presentation including powerpoint presentation and tracheostomy care skill application will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained by the researchers to the video group students in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be watched by the video-assisted teaching method, and the video of tracheostomy care The videos will be sent to students via e-mail. A two-day warning message will be sent to the students from the WhatsApp group to watch the video by the researchers. A week later, students will be invited to the basic skills laboratory for tracheostomy care.
16354871|NCT04294173|No Intervention|demonstration group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the control group in the classroom setting. Powerpoint presentation will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained to the control group students by the researchers in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be taken to the basic skills laboratory and tracheostomy care will be performed on the dummy by the researchers using the demonstration method. Then, students will be given the output of the powerpoint presentation and asked to study the lecture notes for a week. A two-day warning message will be sent by the researchers to students from the WhatsApp group to study. A week later, students will be invited to the basic skills laboratory to practice tracheostomy care.
16354872|NCT04294160|Experimental|Dabrafenib + LTT462 backbone arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
16354873|NCT04294160|Experimental|Dabrafenib + LTT462 + trametinib triplet arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
16354874|NCT04294160|Experimental|Dabrafenib + LTT462 + LXH254 triplet arm 2|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
16354875|NCT04294160|Experimental|Dabrafenib + LTT462 + TNO155 triplet arm 3|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
16354876|NCT04294160|Experimental|Dabrafenib + LTT462 + spartalizumab triplet arm 4|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
16354877|NCT04294160|Experimental|Dabrafenib + trametinib + TNO155 triplet arm 5|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
16354878|NCT04294147|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC)
16354879|NCT04294147|Active Comparator|Erenumab|Erenumab administered SC
16354880|NCT04294134|Experimental|MIO-CPP|The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO. The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added.
16354881|NCT04294134|Active Comparator|CPP-only|"CPP (control) is typically offered through weekly sessions with the mother-child dyad that last 1 to 1.5 hours. The CPP control intervention will last 9 months. CPP is offered by mental health Child-Parent Specialist, who receive ongoing consultation and supervision in addition to initial training. This is the model that will be followed for the control group.
~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008)"
16354882|NCT04294121|Experimental|Children|"Children aged 5-13 years, all genders, will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Children will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Children will also be asked to rank the cereals in order of their preference (i.e., Most (1) to Least (6)). Children will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
16354883|NCT04294121|Experimental|Parents|"Parents or guardians of the children in the study will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Parents will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Parents will also be asked to rank the cereals in order of which they would be most likely to purchase for a child (i.e., Most (1) to Least (6)). Parents will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
16354884|NCT04294108||Patients underwent VATS lobectomy|All consecutive patients scheduled for video-assisted thoracoscopic surgery lobectomy.
16354885|NCT04294095|Experimental|Intervention|During the first four weeks of the MBMM+ program, participants will receive electronic informational handouts covering topics on weight management as well as the benefits and safety concerns related to prenatal physical activity. Starting week 5 of the 12-week intervention, participants will attend two in-person, group physical activity sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics. Sessions will be held on weekday evenings and weekend mornings as these times were preferred by pregnant women. Each session will include both didactic and experiential components to increase knowledge and skill building.
16354940|NCT04293731|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
16354977|NCT04293510||group study 2|age and sex matched healthy children free from any infection with no family history of immunological diseases
16354886|NCT04294095|Active Comparator|Control|Electronic materials related to various prenatal topics including preparation for birth, birthing options, and responsive parenting will be distributed twice a week for the first 4-weeks of the program. Starting week 5 of the 12-week intervention, participants will attend two in-person, group sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics.
16354887|NCT04294082||Mindfulness based intervention|A shortened version of a mindfulness-based intervention originally developed by Jon Kabat-Zinn for management of chronic pain.
16354888|NCT04294069|Active Comparator|Azithromycin 500mg|500mg azithromycin PO daily for seven days
16354889|NCT04294069|Active Comparator|Azithromycin 1000mg|1000mg azithromycin PO once at admission
16354890|NCT04294056|Experimental|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
16354891|NCT04294056|Active Comparator|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
16354892|NCT04294043|Experimental|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
16354893|NCT04294030||Sexually active persons who self-select for HSV-2 testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
16354894|NCT04294030||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
16354895|NCT04294030||Low prevalence population|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
16354896|NCT04294030||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior; 1/2 low risk sexual behavior
16354897|NCT04294017||patients|participants undergoing a diagnostic laparoscopy and have a histologically confirmed Endometriosis
16354898|NCT04294017||controls|participants undergoing a diagnostic laparoscopy where no evidence of Endometriosis could be found
16354899|NCT04294004|Experimental|KUR-113, Stage 1|During stage 1, subjects randomized to this arm will receive TGplPTH1-34 in fibrin (0.4mg/ml) that will be applied within and around a polyetheretherketone (PEEK) intervertebral cage. The maximum dose that will be applied is 4 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
16354900|NCT04294004|Active Comparator|Autologous Bone Graft|During stage 1 of the study, subjects randomized to this arm will receive local autologous bone graft. In the event of insufficient local autograft, Iliac crest bone graft may be used to supplement.
16354901|NCT04294004|Experimental|KUR-113, Stage 2|During stage 2, subjects will receive TGplPTH1-34 in fibrin that will be applied within and around a PEEK intervertebral cage at a concentration of either 0.2mg/ml or 0.7mg/ml. The concentration received will be selected by the DSMB based on the results of stage 1. The maximum dose that will be applied is either 2 mg or 7 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
16354902|NCT04293991|Active Comparator|High flow nasal cannula (HFNC) group|HFNC group will receive immediate connection to HFNC with a flow of 60L/min, and FIO2 adjusted to have SpO2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. In case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. Patients will be encouraged to have their mouth closed during HFNC to augment positive end expiratory pressure (PEEP) created by high flow.
16354903|NCT04293991|Active Comparator|Non invasive ventilation (NIV) group|NIV group, patients will be connected to ICU ventilatoron NIV mode for at least 4 hours, through a NIV continuous positive airway pressure (CPAP)mask with ventilator settings; pressure support (PS) level of 8 cmH2O and PEEP level of 5 cmH2O,which can be increased to 10 cmH2O to maintain tidal volume between 6-8 ml/Kg and FiO2 adjusted to keep SpO2 equal or more than 92%.At least patient will be on NIV for 12 hours during the day, alternating with Venturi mask 10-15 L/min to keep FiO2 equal or more than 92%.
16354904|NCT04293978|Experimental|Virtual Reality relaxation|Participants may request to use the application at any time during their stay at the ward, as many times as they wish. Participants sign in using an anonymous study ID and sessions (and outcomes) are automatically logged by the device to this ID.
16354905|NCT04293965|Experimental|Single Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in a single dose to assess the safety, tolerability, PK and PD profile of X842.
16354906|NCT04293965|Experimental|Multiple Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in multiple doses to assess the safety, tolerability, PK and PD profile of X842. The dose ascending at this stage will be based on the results of the single dose tolerability study.
16354907|NCT04293965|Experimental|Food Effect Study|A randomized, open label, single-dose, self-controlled, double-cycle, two-way crossover clinical trial.
16354908|NCT04293952|Experimental|BRACE group|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
16354909|NCT04293952|Active Comparator|BRE group|this group include Balance Resistance Exercises Stretching Range Of Motion exercises Ankle flexion Ankle extension Knee flexion Knee extension Hip flexion Hip extension Hip adduction Hip abduction
16354910|NCT04293939||Preterm children|Children born before the 37th week of gestation: clinical sample
16354911|NCT04293939||Full-term children|Children born after the 37th week of gestation: control sample
16354912|NCT04293926|No Intervention|Control|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises.
16354913|NCT04293926|Experimental|Exercise|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.
16354975|NCT04293523||Hemophilia A patients|All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.
16354914|NCT04293913|Experimental|intervention group|In the intervention group, communication was established with the illustrated communication material. The pain, anxiety scores, and hemodynamic data of the patients were recorded by the intensive care nurse in three consecutive measurements starting with the first communication (0th minute) and at 30th and 60th minutes. On the first postoperative day, the satisfaction of the communication established with them, as well as their evaluations regarding the adequacy of this communication and their comfort levels were determined during the time they received mechanical ventilation therapy.
16354915|NCT04293913|No Intervention|control group|no intervention
16354916|NCT04293900||Study cohort|24-hour dietary recall, hand grip strength, accelerometer, International Physical Activity Questionnaire (IPAQ), Patient-reported outcomes survey (NCI-PRO-CTCAE), Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Treatment - Lymphoma (FACT-lym), urine sample (optional), fecal sample (optional)
16354917|NCT04293887|Experimental|Standard therapy + interferon therapy|Standard treatment + recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days.
16354918|NCT04293887|No Intervention|Standard therapy + blank therapy|Standard therapy
16354919|NCT04293874|Experimental|Low Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 6 oz. wild salmon (1 steak, 6oz /steak)or 14.3 oz. (5.5 packs, 2.6 oz/pack) of chunk light tuna (1020 mg Omega-3LC/week) for 6 weeks.
16354920|NCT04293874|Experimental|High Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 12 oz. wild salmon (2 steak,12 oz /steak)or 28.6 oz. (11 packs, 2.6 oz/pack) of chunk light tuna (2040 mg Omega-3LC/week) for 6 weeks.
16354921|NCT04293861|Experimental|HYMOVIS Arm|A treatment cycle consists of two injections administered at one week interval. For the purpose of this study, two treatment cycles of two injections of HYMOVIS® at baseline and 6 months will be performed per patient at V1 (Day 0), V2 (Day 7), V5 (Day 180) and V6 (Day 187).
16354922|NCT04293848|Experimental|music with low-sinusoidal sound (vibrations)|Participants will listen to music and low-sinusoidal sound (vibroacoustic therapy).
16354923|NCT04293848|Placebo Comparator|Control Group|Participants will listen to music alone.
16354924|NCT04293835||Cancer group|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.
16354925|NCT04293835||Normal group|200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
16354926|NCT04293822|Experimental|Study group|Group of 30 patients randomly selected will use topical Cetirizine 1% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
16354927|NCT04293822|Active Comparator|Control group|Group of 30 patients randomly selected will use topical Minoxil 5% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
16354928|NCT04293809|Experimental|Cohort 1 - EXPAREL|A total of 15 subjects will be enrolled in this cohort. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of saline
16354929|NCT04293809|Experimental|Cohort 2 - EXPAREL|A total of 15 subjects will be enrolled. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of 0.5% bupivacaine HCl (150mg)
16354930|NCT04293796|Experimental|TNBC group|A group with TNBC in neoadjuvant therapy will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then 12 cycles of neoadjuvant polychemotherapy according to the paclitaxel 60-100 mg / m² scheme in 1 day + carboplatin AUC 2 1 p in 7 days. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
16354931|NCT04293796|Experimental|HER2-positive breast cancer group|ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
16354932|NCT04293783|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 two tablet by mouth 1 time per day
16354933|NCT04293783|Placebo Comparator|Placebo|Placebo two tablet by mouth 1 times per day
16354934|NCT04293770|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.
~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
16354935|NCT04293757|Experimental|Rotational angio|Patients that will undergo 3D rotational angiography before cryoballoon ablation
16354936|NCT04293757|No Intervention|No rotational angio|Patients that will receive no preprocedural imaging before cryoballoon ablation
16354937|NCT04293744|Experimental|Colloid priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL PrimECC.
16354938|NCT04293744|Active Comparator|Standard priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
16354941|NCT04293718||Acute erosive gingivitis|Patients presenting acute erosive gingivitis, isolated or predominant compared to other oral lesions, which required at least one papillary gingival biopsy for diagnostic purposes. Patients were included in the study regardless of age and general health.
16354942|NCT04293705|Experimental|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions. In addition, biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim to monitor patients' activities on problem-solving related to the TOPS program contents and the problem solving process in real life. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
16354943|NCT04293705|Active Comparator|modified TOPS group|Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
16354944|NCT04293692|Experimental|UC-MSCs treatment group|Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).
16354945|NCT04293692|Placebo Comparator|Control group|Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7.
16354946|NCT04293679|Experimental|Cohort A: STP705 10 μg dose|Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks
16354947|NCT04293679|Experimental|Cohort B: STP705 20 μg dose|Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks
16354948|NCT04293679|Experimental|Cohort C: STP705 30 μg dose|Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks
16354949|NCT04293679|Experimental|Cohort D: STP705 60 μg dose|Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks
16354950|NCT04293679|Experimental|Cohort E: STP705 120 μg dose|Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks
16354951|NCT04293666|Experimental|Kefir drink|(2) The first phase of Kefir, the second phase of the placebo group (hereinafter referred to as group B
16354952|NCT04293666|Placebo Comparator|placebo|(1) first-stage placebo and second-stage Kefir group (hereinafter referred to as group A).
16354953|NCT04293653|Experimental|Care bundle|Patients above 75 years where emergency surgery is indicated and with a Clinical Frailty Scale Score of 1-6 will be included in a perioperative care-bundle. While waiting for surgery patients will be monitored and optimized if deteriorating. Antibiotics will be administered if indicated. Surgery is delivered within 2, 6 or 24 h depending on suspected abdominal pathology and clinical condition.
16354954|NCT04293601|Experimental|Experimental group|"All enrolled neonates will receive interventions that will be performed with different frequency and method according to newborns' risk factors, as well as the following standard interventions received by control group's newborns:
~appropriate use of hydrocolloid, headbands, masks and prongs
~frequently assess skin integrity
~humidity and heat gases"
16354955|NCT04293601|Other|Standard care|"Newborns have received the interventions according to local protocol (standard nursing care) in 2018, as detailed in the assigned intervention"
16354956|NCT04293575||In list group|patients on active heart transplantation (HTx) list with a low likelihood to receive a donation shortly (e.g. for body weight or blood group)
16354957|NCT04293575||"Bridge to decision BTD group"|patients suitable for HTx, but that were still waiting for clinical decision
16354958|NCT04293575||"(Bridge to candidacy BTC group)"|patients who could not be yet in list for HTx because of concomitant, potentially reversible, contraindications such as severe pulmonary hypertension, elevated pulmonary-vascular-resistance, unsatisfactory response to vasodilator challenge or other causes resulting in a prohibitive peri-procedural risk (as pre-transplant body mass index [BMI] >35 kg/m2, severe renal dysfunction with creatinine clearance <30 mL/min) and other reasons (current alcohol, tobacco or drug abuse, poor social support, non-residents)
16354973|NCT04293549||rhNGF group|Therapeutic contact lens use was discontinued during the duration of the study. Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment. Changes in the corneal epithelium and stroma were evaluated by slit lamp biomicroscopy and photo documentation of the cornea after fluorescein staining.
16354974|NCT04293549||control comparator group|control comparator group was matched for age and gender and underwent assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline.
16354976|NCT04293510||group study 1|children and adolescents who diagnosed as lupus patients
16354978|NCT04293497|Experimental|Pancreatic Cancer|This arm includes patients with pancreatic cancer. Cytology specimens will be obtained with endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer. Cytology staining will be performed in the cytology specimens.
16354979|NCT04293484|Experimental|Real tDCS - Real tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
16354980|NCT04293484|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
16354981|NCT04293458|Experimental|EsoCheck vs. EGD with or without biopsies|All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
16354982|NCT04293432||Group/Cohort|Torsade de Pointes induced by drugs reported to the FAERS database from inception till first quarter of 2019 (1990-2019)
16354983|NCT04293406||Established Prostate Cancer Group|Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
16354984|NCT04293406||At Risk of Prostate Cancer Group|"At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.
~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study)."
16354985|NCT04293393|Active Comparator|Arm A: Doxorubicin plus cyclophosphamide and taxane|"Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
~Approximately duration of 24 weeks (6 months)."
16354986|NCT04293393|Experimental|Arm B: Letrozole plus abemaciclib +/- LHRH|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- luteinizing hormone-releasing hormone (LHRH) analogs in premenopausal women, up to 12 months, in 28-day cycles.
16354987|NCT04293380|Other|normal karyotype|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
16354988|NCT04293380|Other|down syndrome|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
16354989|NCT04293367|Experimental|Exercise|14 African American Women with obesity will be randomly assigned to the 14-week high intensity interval training program
16354990|NCT04293367|No Intervention|Control|14 African American Women with obesity will be randomly assigned to serve as a reference group, i.e. follow the same protocol as the experimental group, however, they will not undergo exercise training
16354991|NCT04293354|Active Comparator|Serratus Plane Block|The Serratus plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
16354992|NCT04293354|Sham Comparator|Control|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
16354993|NCT04293341|Experimental|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
16354994|NCT04293341|Active Comparator|Disorder Specific Therapies|To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
16354995|NCT04293328|Experimental|Monthly replacement lenses without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
16354996|NCT04293328|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
16354997|NCT04293315|No Intervention|Control|This is the usual care arm. Healthcare workers will provide people with the Fecal Occult Blood Test (FOBT) and information about risk to develop CRC and the importance of early detection.
16354998|NCT04293315|Experimental|Intervention|The same as the Control Arm plus the primary care team of the PCCs will be trained and participate in 8 improvement cycles.
16354999|NCT04293302||Brain abnormality|Newborn who had any gestational brain sonographic abnormality
16355000|NCT04293302||No brain abnormality|Newborn who did not have any gestational brain sonographic abnormality
16355001|NCT04293289|Other|Treatment|"BNCT(Boron Neutron Capture Therapy)
~SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr."
16355002|NCT04293276|Experimental|Treatment group|Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16356342|NCT04283682|No Intervention|standard group|Feeding procedures follow clinical nursing practices
16355003|NCT04293263|Experimental|MCI patients hospitalised in the research departments|each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.
16355004|NCT04293263|Active Comparator|MCI patients hospitalized in the research departments|each of the elderly in the control group will Listen to random music twice a week for about 40 minutes each time, on personal headphones.
16355005|NCT04293250|Experimental|Physical activity group|"Investigators employ the recommendations of the American College of Sport Medicine and the World Health Organization for adults to divide our enrolled patients having moderate-intensity as 30-60 min∙d-1 (≥150 min∙wk-1 ) or vigorous-intensity as 20-60 min∙d-1 (≥75 min∙wk-1) for 6-8 weeks preoperatively.
~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.
~The operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
16355006|NCT04293250|Experimental|non-physical activity group|"No any moderate-intensity or vigorous-intensity physical activity for our enrolled patients preoperatively.
~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.
~Various types of operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
16355007|NCT04293224|Experimental|DGA Mediterranean diet pattern, energy balance|Diet plan focused on energy balance (meets calorie needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
16355008|NCT04293224|Experimental|DGA Mediterranean diet pattern, negative energy balance|Negative energy balance (~25% calorie reduction compared to needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
16355009|NCT04293224|Experimental|TAD diet pattern|Typical American Diet (TAD) with negative energy balance (~25% calorie reduction compared to needs) which mimics intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium based on data from What We Eat in America (WWEIA).
16355010|NCT04293211||Control|Upon completion of B-Con presentation, this group will be tested regarding tourniquet placement using the rubric. A tourniquet is regarded as appropriately placed if it is 2 inches above the wound, not located on a joint, appropriate tightness (meaning a finger cannot be placed under it and it is indenting the mannequin). This is as per prior studies. Feedback will be given at the end of this session.
16355011|NCT04293211||Simulation|This group will have to interact with a panicked actor/actress as well as the SIM MAN 3G who will have two wounds under his clothes. One that will be actively pumping a large amount of arterial blood that will require tourniquet placement and the other wound with trace venous bleeding that will require simple pressure with a clean cloth. Participants will be given feedback on items that they missed. The observer will fill out the rubric and give feedback to the group.
16355012|NCT04293185|Experimental|bb1111|"Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene.
~Plerixafor mobilization and apheresis will also be used for collection of rescue cells."
16355013|NCT04293172|Experimental|Ticagrelor|The double-blinded study drug dose will be weight dependent.
16355014|NCT04293172|Placebo Comparator|Placebo|The double-blinded study drug dose will be weight dependent
16355015|NCT04293159|Experimental|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
16355016|NCT04293146|Active Comparator|pre-pectoral IBBR|
16355017|NCT04293146|Active Comparator|sub-pectoral IBBR|
16355018|NCT04293120|Experimental|Training|Training 4 sessions over a one week time period of 180 catches/stops with a medicine ball.
16355019|NCT04293107||Phase 1: Content Validity Testing|Cohort of 6 parents/carers of children with cerebral palsy and GORD, who will be interviewed regarding the content validity of the PGSQ when used to assess symptoms of GORD in children with cerebral palsy.
16355020|NCT04293107||Phase 2: Reliability (test-retest) Testing|Cohort of 20 parents/carers of children with cerebral palsy and GORD, who will review and complete the adapted version of the PGSQ (post Phase 1) at two time points, two weeks apart.
16355021|NCT04293094|Experimental|Dose Exploration Phase|Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
16355022|NCT04293094|Experimental|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
16355023|NCT04293094|Experimental|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
16355024|NCT04293081|Active Comparator|chlorpheniramine maleate group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to chlorepheniramine maleate group (A)
16355025|NCT04293081|Placebo Comparator|placebo group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to placebo group (A)
16355026|NCT04293068||Control group|Related tests were normal, because the male factor alone required the first IVF/ICSI cycle; Follow-up of included patients was conducted to determine whether embryo transplantation was performed, and the score of transferred embryos was recorded, and the final control group would be confirmed after achieving clinical pregnancy
16355027|NCT04293068||Recurrent implantation failure|Previous ≥3 consecutive embryo transfer failures
16355028|NCT04293068||Recurrent spontaneous abortion(miscarriage)|≥2 consecutive spontaneous abortions or embryo damage
16355407|NCT04290260|Experimental|Use of breast bra|Patients allocated on this group wear a breast bra from admission to hospital discharge.
16355029|NCT04293055|Experimental|Maintenance program+possibility of phone coaching|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. Some participants randomized to this condition will also receive 4 consecutive weeks of phone coaching at some point over the 1-year intervention period (this is determined by a weight-based algorithm).
16355030|NCT04293055|Active Comparator|Maintenance program only|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. No participants in this condition will receive phone coaching.
16355031|NCT04293042|Experimental|BK cystitis and/or nephropathy|All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency, dysuria, hematuria, elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter), performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory
16355032|NCT04293029|Experimental|Normal liver function|Patients will receive single dose of SHR0302
16355033|NCT04293029|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR0302
16355034|NCT04293029|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR0302
16355035|NCT04293016|Active Comparator|Support as usual|
16355036|NCT04293016|Experimental|Problem Solving therapy|
16355037|NCT04293016|Experimental|ICU diary|
16355038|NCT04293003|Experimental|Fasting|6-hour morning fasting
16355039|NCT04293003|Experimental|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
16355040|NCT04293003|Experimental|Mediterranean|Consumption of a Mediterranean breakfast
16355041|NCT04292990|Experimental|Fentanyl|Intervention: Drug: Fentanyl Transdermal Patch
16355042|NCT04292990|Active Comparator|Morphine|Intervention: Drug: Morphine Controlled-Release Tablets
16355043|NCT04292951|Experimental|GDT group|Intraoperative fluid and inotropic/vasoactive drugs management based on information from FloTrac/EV1000
16355044|NCT04292951|Active Comparator|Control group|Intraoperative fluid and inotropic/vasoactive drugs management based on CVP, blood pressure, heart rate, and clinical signs at the discretion of attending anesthesiologists
16355045|NCT04292938|Active Comparator|Ketogenic diet|patients will follow a low carbohydrate high lipid personalized diet causing blood BOHB level to be between 1.5-4 mmol/l for six months
16355046|NCT04292938|No Intervention|control group|Patients will be asked to maintain their usual dietary regimen
16355047|NCT04292925|Experimental|Experimental Group|Intervention with the new treatment protocol will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
16355048|NCT04292925|Active Comparator|Control group|Intervention with conventional therapy will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
16355049|NCT04292912|Experimental|Participants receiving GSK2798745|
16355050|NCT04292899|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
16355051|NCT04292899|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
16355052|NCT04292899|Experimental|Part B: Remdesivir, 10 Days (Extension)|Part B (Extension) will enroll participants after enrollment to Part A is complete. Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10.
16355053|NCT04292899|Experimental|Part B: Remdesivir 10 days (Mechanically Ventilated)|Participants on mechanical ventilation will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10
16355054|NCT04292886|Active Comparator|thin endometrium ,treatment,Tamoxifen|From the 2nd day of the menstrual cycle, the patient took tamoxifen and femoston
16355055|NCT04292886|Placebo Comparator|thin endometrium ,treatment,Vitamin C|From the 2nd day of the menstrual cycle, the patient took Vitamin C and femoston
16355056|NCT04292873|No Intervention|Control|
16355057|NCT04292873|Experimental|Vitamin D|Enteral supplement of 569,600 IU vitamin D
16355058|NCT04292860||Breast Cancer Pts|Post-operative (lumpectomy or mastectomy) female breast cancer patients who will receive radiation to the whole breast or chest wall and the regional nodes.
16355059|NCT04292847|Experimental|Geriatric Assessment|Participants fill out the geriatric assessment during a clinic visit and receive recommendations based on results
16355060|NCT04292821||Patients consulting for breast lesion Bi Rads 4 or 5|Patients consulting for breast lesion Bi Rads 4 or 5
16355061|NCT04292808|Other|Penthrox|Low Dose Methoxyflurane
16355062|NCT04292795|Experimental|Group A|Intervention: Shortwave Diathermy Frequency: 27.12 MHz Time Duration: 10min Duration of Treatment: 4 weeks. Sessions per Week: 2 sessions per week
16355063|NCT04292795|Experimental|Group B|Intervention: Therapeutic Ultrasound Frequency: 1-3MHz Intensity: 0.2-1W/cm2 Time Duration: 10mins Duration of Treatment: 4 weeks Sessions per Week: 2 sessions per week
16355064|NCT04292782|Active Comparator|CAUDAL BLOCK|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and needle of diameter and length respectively between 22G and 25G, 35mm and 40mm according to the child's size (Braun).The patient is positioned laterally with their hips flexed to 90°. The sacral hiatus is forming with the two posterior superior iliac spines an equilateral triangle. The puncture is performed between the two sacral cornuae. The sacrococcygeal ligament gives a perceptible 'pop' when crossed. After crossing the sacro-coccygeal ligament, the needle is redirected 30° to the skin surface, and then advanced a few millimeters into sacral canal. After verifying absence of spontaneous reflux of blood or cerebrospinal fluid, slowly injection of Ropivacaine 0.25% 1ml/ kg
16355102|NCT04292509|Experimental|SAP with predictive stop before low|Sensor-augmented pump therapy with the use of the predictive stop before low mode of action
16355103|NCT04292509|Active Comparator|SAP with stop on low|Sensor-augmented pump therapy with the use of the predictive stop on low mode of action
16355065|NCT04292782|Experimental|anterior Quadratus lumborum block|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and a 22G, 50-mm, insulated facet type needle (BBraun Stimuplex Ultra 360°). Patients were placed in the lateral position, a probe was placed transversely to the abdominal flank. The needle was inserted using an in-plane technique and was preceded further into the fascia between the QLM and PM. Following confirmation of the correct space with the administration of 0.5-1 ml local anesthetic, block was induced with 1 ml/kg, 0.25% Ropivacaine,
16355066|NCT04292769|Experimental|Decitabine combined with DC-CIK|Test group: decitabine combined with autologous DC-CIK cells infusion: decitabine 10mg / d, intravenous administration of d-5 to d-1, autologous DC-CIK cells infusion: first course: d1-d3 The second course: d14-d16; the total number of cells is about 5-10 × 109; IL-2: 200,000 IU / d subcutaneous injection, the first course: d0-d4, the second course: d13-d17, every 2 weeks 1 course of treatment, 2 courses in total.
16355067|NCT04292769|Active Comparator|DC-CIK|Control group: autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109; One course: d0-d4, the second course: d13-d17, 1 course every 2 weeks, a total of 2 courses.
16355068|NCT04292756|Active Comparator|Triamcinolone Acetonide 40 mg|Arm 1
16355069|NCT04292756|Active Comparator|Triamcinolone Acetonide 4 mg|Arm 2
16355070|NCT04292743|Experimental|Eryaspase plus FOLFIRINOX|"Eryaspase will be administered on day 1 and 15 of a 4 week cycle (intravenous infusion) in dose escalating/reduction depending on the cohort the patient is assigned to
~mFOLFIRINOX dosing will include 5-fluorouracil 2400 mg/m² over 46 hours, oxaliplatin 85 mg/m², Irinotecan 150 mg/m² (intravenous infusion) on Day 1 and 15 of the 4 weeks cycle for a maximum of 12 cycles."
16355071|NCT04292730|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
16355072|NCT04292730|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
16355073|NCT04292730|Active Comparator|Part A: SOC Therapy|Participants will receive continued standard of care therapy.
16355074|NCT04292730|Experimental|Part B: Extension Treatment, Remdesivir 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
16355075|NCT04292717|Active Comparator|Deficit-oriented training group|
16355076|NCT04292717|Active Comparator|Non-specific, standardised walking training group|
16355077|NCT04292704|Experimental|Laser group|Fractional CO2 laser therapy in consolidation treatment once a month for 3 months and treatment was prohibited during menstrual period.
16355078|NCT04292704|Other|Clotrimazole group|Clotrimazole tablets 500mg PV biw q3d in consolidation treatment once a month for 6 months and treatment was prohibited during the menstrual period.
16355079|NCT04292691|Experimental|Ropivacaine|A cumulative amount of approx. 40ml ropivacaine 0.5% (≙400mg (2x200mg) ropivacaine) is applied immediately before surgery. They are applied in a ring wall 10 cm cranially of the tip of the medial and lateral malleolus (N. peroneus superficialis (N. cutaneus dorsalis medius et intermedius, N. saphenus, N. suralis), as well as sonographically controlled (N. peroneus profundus and N. suralis)
16355080|NCT04292691|Placebo Comparator|Ringer's Lactate|Analog to the Experimental Arm, but the same amount of Ringer (40ml) will be plicated instead Ropivacaine
16355081|NCT04292678|Experimental|Relaxation|Caregivers of patients with advanced cancer will apply 20 minutes of progressive muscle relaxation exercise twice a week, for 8 weeks with a group session.
16355082|NCT04292678|Active Comparator|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
16355083|NCT04292665|Experimental|Classical Massage|Patients will receive a total of fourteen individual applied classical massage sessions, twice daily for seven days, each session lasting 30 minutes.
16355084|NCT04292665|Experimental|Relaxation|Patients will receive a total of fourteen individual counseling sessions, in a quiet room, twice daily for seven days, each session lasting 20 minutes.
16355085|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
16355086|NCT04292652||EVAR group|Individuals undergoing endovascular aortic repair. n=40
16355087|NCT04292652||OR group|Individuals undergoing open repair. n=40
16355088|NCT04292639|Experimental|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
16355089|NCT04292626|Experimental|Lymphoma|At least five (5) evaluable subjects with Hodgkin Lymphoma or Non Hodgkin Lymphoma. The tested injected dose of 500 MBq.
16355090|NCT04292600||UMMC|Cohort recruited at University of Mississippi Medical Center
16355091|NCT04292600||UAB|Cohort recruited at University of Alabama in Birmingham
16355092|NCT04292600||BRH|Cohort recruited at Brandon Regional Hospital by Bay Area Consulting Telemedicine
16355093|NCT04292587||Women with hirsutism|Women between the ages of 18-45 with hirsutism
16355094|NCT04292587||Women without hirsutism|Women between the ages of 18-45 without hirsutism
16355095|NCT04292574||Participants with Spinal Muscular Atrophy|
16355096|NCT04292561|Experimental|light general anesthesia|During anesthesia maintenance, patients were received with low concentration sevoflurane to maintain a target of 0.8 MAC.
16355097|NCT04292561|Experimental|deep general anesthesia|During anesthesia maintenance, patients were received with high concentration sevoflurane to maintain a target of 1.0 MAC.
16355098|NCT04292548||study group (passive smoking children)|
16355099|NCT04292548||control group|
16355100|NCT04292535|Active Comparator|Passive Control|20 minute sedentary control period during which participants watched an emotionally neutral video.
16355101|NCT04292535|Experimental|Acute Exercise|20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.
16355104|NCT04292496|Experimental|Intraperative leak testing group|i) the integrity of the anastomosis can be directly observed under gastroscopy. ii) the distal of Roux limb was temporarily blocked, then the bowel of anastomosis was inflated by air, following 60 milliliter methylene blue.
16355105|NCT04292496|No Intervention|Non-intraoperative leak testing group|Non intraoperative leak testing was performed intraoperatively.
16355106|NCT04292470|Experimental|Amitriptyline|Amitriptyline 10 mg daily
16355107|NCT04292457|Experimental|Propofol|Anesthesia is maintained with Propofol
16355108|NCT04292457|Experimental|Sevoflurane|Anesthesia is maintained with Sevoflurane
16355109|NCT04292444|Experimental|RAGE polymorphism (TT)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TT) will be selected and scanned twice.
16355110|NCT04292444|Experimental|RAGE polymorphism (TA/AA)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TA/AA) will be selected and scanned twice.
16355111|NCT04292418||study group 1|(rejector group )include Paediatric living donor kidney transplant recipients (aged 4-18 years) at least 35 child recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the study group 1 measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test
16355112|NCT04292418||study group 2|the second group (non rejector group ) include Paediatric living donor kidney transplant recipients (aged 4-18 years) recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the studied group at least 35 child measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test in the study group 2
16355114|NCT04292392|Experimental|A - ACB + Periarticular Block|Group A: patient will receive a preop ACB, followed by Intra-articular block during TKA surgery
16355115|NCT04292392|Experimental|B - ACB + IPACK Block|Group B: patient will receive a preop ACB+IPACK block before TKA surgery only
16355116|NCT04292392|Experimental|C - ACB + IPACK + Periarticular Block|Group C: patient will receive a preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
16355117|NCT04292366|Experimental|Intervention arm I|pre-notification approximately ten days prior to intervention, invitation and one reminder (three-staged intervention)
16355118|NCT04292366|Experimental|Intervention arm II|invitation, one reminder after 45 days and a second reminder three months after invitation (three-staged invitation procedure)
16355119|NCT04292366|Experimental|Intervention arm III|pre-notification, invitation, reminder after 45 days and reminder after three months (four-staged invitation procedure)
16355120|NCT04292366|Active Comparator|Control group|invitation and one reminder after 45 days (usual care)
16355121|NCT04292327||The ordinary COVID-19|Consistent with the diagnosis of ordinary COVID-19.
16355122|NCT04292327||The heavy COVID-19.|Consistent with the diagnosis of heavy COVID-19.
16355123|NCT04292327||The critical COVID-19|Consistent with the diagnosis of critical COVID-19
16355124|NCT04292314|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.
~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
16355125|NCT04292314|Experimental|Nigella sativa experimental group|"50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.
~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
16355126|NCT04292314|Experimental|Hydroxyurea experimental group|"50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
16355127|NCT04292314|Experimental|Natural honey experimental group|"50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
16355128|NCT04292314|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
~in addition to iron chelator agent, this group receive regular blood transfusion session."
16355129|NCT04292301|Experimental|STrategically Acquired Gradient Echo (STAGE)|STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging. All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
16355130|NCT04292288||Foreign body granuloma|men injecting paraffin oil
16355133|NCT04292262||AKI|
16355134|NCT04292262||Non AKI|
16355135|NCT04292249||Elective on-pump cardiac surgery patients|Adult patients (≥18 years) undergoing elective on-pump cardiac surgery (isolated coronary artery bypass graft (CABG), single and multiple valvular procedures, combined CABG and valvular surgery, and others).
16355136|NCT04292236|Placebo Comparator|Placebo|Administered at time 0 min and 300 min. Cellulose was used as the placebo.
16355137|NCT04292236|Active Comparator|Dietary Supplement|Administered at 0 min and 300 min. Combination of lauric acid, perilla oil and diindolylmethane was used as the dietary supplement.
16355138|NCT04292223|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg administered orally
16355139|NCT04292210|Experimental|CAPD handling|"A connecting device simplifying the steps during a cycle of Peritoneal dialysis. Instead of directly doing a manual connection and manually breaking a frangible, the device assist in connecting and breaking the frangible.
~This study was done demonstrating a continuous ambulatory peritoneal dialysis (CAPD)"
16355140|NCT04292197|Experimental|18-MC SAD Study|In Part 1, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice in 1 day.
16355141|NCT04292197|Experimental|18-MC MAD Study|In Part 2, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice a day for 7 consecutive days.
16355142|NCT04292184|Active Comparator|UW (perfusion solution) + sodium thiosulfate (STS)|We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
16355143|NCT04292184|No Intervention|UW (perfusion solution)|Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.
16355144|NCT04292171|Active Comparator|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
16355145|NCT04292171|Placebo Comparator|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
16355146|NCT04292158||Main Group|Hospitalized for at least 1 day clinic stay at the participating hospitals
16355147|NCT04292145|Experimental|Relaxation Application|Participants will follow the relaxation application.
16355148|NCT04292145|Active Comparator|Relaxation Only|Participants will use any relaxation technique they normally use to relax.
16355149|NCT04292132|Active Comparator|Conventional loading|Loading of 4 interforaminal implants three months after surgery.
16355150|NCT04292132|Experimental|Immediate Loading|Loading of 4 interforaminal implants immediately after surgery.
16355151|NCT04292119|Experimental|Lorlatinib and Crizotinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.
~Phase 1 (the dose-finding portion of the study) will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.
~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days
~Crizotinib will be administered orally twice daily at a predetermined dose for 28 days
~Phase II patients will be treated with Lorlatinib and Crizotinib at a dose recommended based on the phase I study."
16355152|NCT04292119|Experimental|Lorlatinib and Binimetinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.
~The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.
~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days
~Binimetinib will be administered orally twice daily at a predetermined dose for 28 days.
~Phase II patients will be treated with Lorlatinib + Binimetinib at a dose recommended based on the phase I study."
16355153|NCT04292119|Experimental|Lorlatinib and TNO155|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.
~The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.
~Lorlatinib will be administered orally once daily at a predetermined dose for 21 days
~TNO155 will be administered orally once daily at a predetermined dose for 14 out of 21 days.
~Phase II patients will be treated with Lorlatinib + TNO155 at a dose recommended based on the phase I study."
16355154|NCT04292106|Placebo Comparator|Placebo|
16355155|NCT04292106|Experimental|Red Spinach Extract (RSE)|
16355156|NCT04292093|Experimental|Home rehabilitation training|Home rehabilitation training
16355157|NCT04292093|Active Comparator|Home control activity|Home control activity
16355158|NCT04292080|Experimental|Group TECFIDERA™|30 patients will receive oral administration of Dimethyl Fumarate (Tecfidera™) 120 mg twice a day for the first week and then 240 mg of Tecfidera twice a day for 51 weeks following approved standard treatment scheme.
16355159|NCT04292080|Other|No comparator|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
16355160|NCT04292067||patients with SPA|100 SPA patients
16355161|NCT04292067||Healthy subjets|200 healthy subjets in control group
16355162|NCT04292067||patients with RA|100 RA patients
16355163|NCT04292054|Active Comparator|active group|"The antibiotic prophylaxis will be cefazolin 2 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump, in case of absence of colonization to Pseudomonas aeruginosa prior to the surgical procedure.
~The dose administer is 2g.
~Antibiotic prophylaxis will be piperacilline-tazobactam 4 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe driver in patients with burn wound colonized to Pseudomonas aeruginosa.
~The dose administer is 4g."
16355164|NCT04292054|Placebo Comparator|Placebo group|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
16355165|NCT04292028|Experimental|pilates group|The Pilates group participated in an 8-week clinical Pilates training program
16355166|NCT04292028|Active Comparator|Control group|Control group were given a home-based exercise program
16355167|NCT04292015|Experimental|Standard then Intervention|Infant will undergo standard method of examination with binocular indirect opthalmoscope (BIO) followed by retinal imaging with Optos ultra-wide field retinal imaging device.
16355168|NCT04292015|Experimental|Intervention then Standard|Infant will undergo retinal imaging with Optos ultra-wide field retinal imaging device followed by standard method of examination with binocular indirect opthalmoscope (BIO).
16355169|NCT04292002|Experimental|Health Checks|Workplace health checks - in this intervention employees can select from a range of optional health checks/tests and receive tailored health advice and a health resource pack.
16355170|NCT04291989|Experimental|Earlobe and Finger Prick versus venous blood lactate sampling|Compare blood Lactate levels between ear lobe and finger against venous forearm blood sample using the electronic hand held lactate device in hip fracture patients with good cognitive function (AMT >/= 7)
16355171|NCT04291976|Experimental|back-to-back HDWLE|Similar to single-pass HDWLE, with a second segmental inspection after the first examination in the same session. Equipment is similar to 1.
16355172|NCT04291976|Active Comparator|single-pass HDWLE|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
16355173|NCT04291976|Active Comparator|Chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or 0.3% indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two arms.
16355174|NCT04291963|Active Comparator|DGG + TUN|The multiple adjacent gingival recession sites were treated with DGG in conjunction with TUN technique.
16355175|NCT04291963|Active Comparator|SCTG + TUN|The multiple adjacent gingival recession sites were treated with SCTG in conjunction with TUN technique.
16355176|NCT04291950||Control group|Hispanic and NHW women undergoing either a benign breast surgery or prophylactic mastectomy.
16355177|NCT04291950||Newly diagnosed TNBC|Hispanic and NHW with newly diagnosed TNBC. Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy).
16355178|NCT04291924||Ablebodied individuals|
16355179|NCT04291924||Spinal Cord Injured Individuals|
16355180|NCT04291911||INTENSIVE CARE UNITS|
16355181|NCT04291898|Active Comparator|Device: ASO|Participants implanted with the AMPLATZER™ Septal Occluder (ASO)
16355182|NCT04291898|Active Comparator|Device: FSO|Participants implanted with the Occlutech Figulla Flex II® (FSO).
16355183|NCT04291898|Active Comparator|Device: GSO/GAO|Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)
16355184|NCT04291885|Experimental|Avelumab|6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
16355185|NCT04291885|Placebo Comparator|Placebo|6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
16355186|NCT04291872|Experimental|Non-Heated Arm|Proximal cavities were restored with Equia Forte (GC Corporation, Europe) according to manufacturer's orders.
16355187|NCT04291872|Experimental|Heated Arm|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
16355188|NCT04291859|Experimental|Lu AF28996|Participants will receive ascending oral doses of Lu AF28996 once daily for 14 days (Day 1 to Day 14) in all cohorts. On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement.
16355189|NCT04291846|Experimental|A|
16355190|NCT04291846|Experimental|B|
16355191|NCT04291833|Active Comparator|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
16355192|NCT04291833|Active Comparator|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
16355193|NCT04291833|Placebo Comparator|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
16355194|NCT04291820|Experimental|Intravenous induction with desflurane maintenance|The EMLA patch will be removed, and intravenous induction with propofol + opioid will be performed. The anaesthesia will be maintained with desflurane according to the levels of Bispectral index (BIS). Neuromuscular blockade is optional based on operator decision.
16355195|NCT04291820|Active Comparator|Inhalation induction with sevoflurane,sevoflurane maintenance|The EMLA patch will be removed, and inhalation induction with the sevoflurane will be performed. After peripheral vein cannulation, the opioid will be administered. The neuromuscular blockade is optional based on operator decision. Anaesthesia will be maintained with sevoflurane according to the set BIS levels.
16355196|NCT04291807|Experimental|Video education|A video of ERCP procedure has been viewed to the patients who will undergo ERCP and questions about the procedure had been answered by the primary investigator (experienced endoscopy nurse)
16355197|NCT04291807|No Intervention|Direct ERCP|Patients arranged ERCP for any reason underwent directly to the ERCP without any video education.
16355198|NCT04291794|Active Comparator|Conventional bolus induction|Hypnotic component of general anesthesia induction will be a single bolus of propofol 2mg/kg followed by turning on sevoflurane 2% at a fresh gas flow of 2L/min.
16355199|NCT04291794|Experimental|Target-controlled induction|Hypnotic component of general anesthesia induction will be target-controlled propofol infusion tritiated to loss of consciousness. Propofol target-controlled infusion will be maintained.
16355200|NCT04291781|Experimental|RC18 160mg|RC18 160mg SC once weekly ,and total of 24 doses
16355201|NCT04291781|Experimental|RC18 240mg|RC18 240mg SC once weekly ,and total of 24 doses
16355202|NCT04291781|Placebo Comparator|Placebo|Placebo SC once weekly ,and total of 24 doses
16355203|NCT04291768|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
16355204|NCT04291768|Active Comparator|Control group|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician
16355205|NCT04291755||Checkpoint inhibitor therapy|Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
16355206|NCT04291742|Experimental|0: cognitive|target prostate biopsies by cognitive fusion
16355207|NCT04291742|Experimental|1: software|target prostate biopsies by software
16355208|NCT04291729|Experimental|Ganovo+ritonavir with or without interferon nebulization|
16355209|NCT04291716|Other|Single Arm|This is a single-arm study. All subjects enrolled in the study will wear the device during stay in the EMU.
16355210|NCT04291703|Experimental|Antithymocyte globulin (ATG)|Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods. The first infusion is given at baseline visit (day 1), the second is given the next day at baseline visit (day 2). Body weight at baseline (Day 0- admission for the ATG/placebo infusion) will be used in calculating the doses for all infusions. The first dose (0.5mg/kg) will be infused over a minimum of 4 hours, and the second dose (2mg/kg) over a minimum of 4 hours with a maximum infusion time for each infusion of 10 hours. The second dose should be given no less than 12 and no more than 24 hours after completion of the previous dose. The final prepared product is to be labeled to protect the blind. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion.
16355311|NCT04291014|Experimental|BWLT once daily|Participants in this arm will receive bright white light therapy daily once a day (in the evening)
16355211|NCT04291703|Placebo Comparator|Placebo|"0.9% Sodium Chloride Injection USP (Normal saline) is to be dispensed as the placebo for this study. The placebo is to be prepared dispensing an infusion bag of 0.9% Sodium Chloride Injection USP (Normal saline) with no additives (no ATG, no premedications) and label the product to protect the blind. The placebo will also be administered over a minimum of 4 hours for the first and second doses with a maximum infusion time of 10 hours. The second dose of the placebo arm should be given no less than 12 and no more than 24 hours after completion of the previous dose. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion."
16355212|NCT04291690|No Intervention|Control Group|Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.
16355213|NCT04291690|Experimental|Intervention Group|Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.
16355214|NCT04291677|Experimental|Intervention group in which musical intervention|Group A: Experimental group in which musical intervention will be applied between the first and the third day of mechanical ventilation.
16355215|NCT04291677|Other|Control group|Group B: Control group with standard treatment without musical intervention.
16355216|NCT04291664|Experimental|Prostate Cancer|
16355217|NCT04291651||Retrospective|The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts.
16355218|NCT04291651||Prospective|The prospectively enrolled patients in this study are the primary population of interest.
16355219|NCT04291638|Experimental|Remote Caregiver Training|The Remote Caregiver Training arm consists of participation in a 5-hour, videoconferencing-based caregiver training program.
16355220|NCT04291638|Experimental|Remote Caregiver Training + Intensive Treatment|The Remote Caregiver Training + Intensive Treatment arm consists of participation in a 5-hour, videoconferencing-based caregiving training program, followed by participation in the videoconferencing-based intensive group behavioral treatment program.
16355221|NCT04291625|Other|congenital ptosis|children who had congenital ptosis with levator function of 4mm or better, underwent levator muscle resection guided by intraoperative lagophthalmos formula.
16355222|NCT04291612||Part 1|Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.
16355223|NCT04291612||Part 2|Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)
16355224|NCT04291599|Experimental|Experimental Arm - Ketorolac (Opioid-Sparing)|Patients assigned to this arm of the study will follow the standardized step-up approach to pain management per the hospital Evidenced Based Guideline (EBG). If analgesia is not obtained with first-line medications such as acetaminophen, the patient will be given the NSAID ketorolac intravenously every 6 hours at the standard weight-based dose throughout hospitalization. If the patient experiences continued pain, they (or their guardian/ caregiver) may request a rescue medication in the form of low-dose morphine (or an alternative opioid if allergic to morphine) at 0.025 mg/kg/dose every 4 hours.
16355225|NCT04291599|Active Comparator|Control Arm - Conventional Treatment/Standard of Hospital Care|Patients assigned to this arm of the study will be treated per institutional policy and procedural care as dictated by established hospital order sets and at the discretion of the provider. This may involve the step-up approach per the hospital EBG utilizing acetaminophen or ibuprofen as first-line agents; however, it remains at the discretion of the treating provider. The current standard of care for children presenting to the ED is based on prescribing order sets within the electronic medical record (EMR). Physicians in the BCH emergency department choose in an intermittently-prescribed manner, standard doses of analgesia including acetaminophen (Tylenol) or ibuprofen per the hospital EBG, as well as opioids (morphine, hydromorphone).
16355226|NCT04291586|Experimental|Virtual Reality|The Virtual Reality group will perform personalized activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
16355227|NCT04291586|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalized to their deficits and generated automatically through a Task Generator.
16355228|NCT04291573|Active Comparator|HD-tDCS and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with real stimulation (30min) over 13 consecutive training days (3 weeks)
16355229|NCT04291573|Sham Comparator|Sham stimulation and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with Sham stimulation (30min) over 13 consecutive training days (3 weeks)
16355230|NCT04291560|Experimental|Prenatal Heart Smart Intervention|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, the group will complete a sequential static stretching exercise 5 days per week for 10 weeks. The stretching exercise consists of 20 seconds of stretching, for 3 repetitions per muscle group.
16355231|NCT04291560|No Intervention|Usual Care (Control)|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, this group will complete moderate-intensity walking 5 days per week for 10 weeks in accordance to usual care.
16355232|NCT04291547|Experimental|Computerised Behavioural Activation Programme|All recruited young people will be given the BALM (Behavioural Activation for Low Mood) programme to work through
16355233|NCT04291521||Adult trauma patients requiring RSI|Patients who received an induction medication for intubation.
16355234|NCT04291508|Active Comparator|IV Acetaminophen-Active|Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).
16355235|NCT04291508|Active Comparator|IV Vitamin C-Active|Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses)
16355236|NCT04291508|Placebo Comparator|Acetaminophen-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
16355237|NCT04291508|Placebo Comparator|Vitamin C-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
16355238|NCT04291495|Experimental|ANDROSITOL®TEST|At least 45 patients (13 for each category: low, medium, and high responders, + 15% of hypothetical drop-outs)
16355239|NCT04291482|Experimental|Intervention arm|The intervention group participants will be assessed with EMA and they will provide daily data regarding their predictors of weight loss outcomes and their adherence to the personal weight loss plan (phase I, month 0-3). Then participants will receive tailored information regarding the most predictive factors relevant to their weight loss trajectories (phase II, month 3-6). The information will be tailored and delivered through emails and text messages.
16355240|NCT04291482|Other|Control arm|Control group participants will receive basic educational weight loss information in a form of educational factual emails and text messages.
16355241|NCT04291469|Placebo Comparator|Control group|Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks
16355242|NCT04291469|Experimental|Probiotics group|Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0*10^9 colony forming units, oral, daily for 14 weeks
16355243|NCT04291469|Experimental|Prebiotics group|Combined inulin+maltodextrin tables, oral, daily for 14 weeks
16355244|NCT04291456|Experimental|Minocycline|Minocycline 100 mg oral twice daily for up to 24 month
16355245|NCT04291443|Experimental|Upper First Premolar One Side|Heavy force (225 g)
16355246|NCT04291443|Experimental|Upper First Premolar Other Side|Light Force (25 g)
16355247|NCT04291417||CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis. Results will not be used to manage patients.
16355248|NCT04291404|No Intervention|Standard of Care (Control) Arm|Standard of care treatment, which may include a combination of the following, at the discretion of the treating team and family: parent/ caregiver support, child life services, healthcare provider support, etc.
16355249|NCT04291404|Experimental|Intervention Arm|Addition of distraction via an immersive, interactive VR experience to Standard of Care
16355250|NCT04291391|Experimental|Lean-normoglycemic (control)|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
16355251|NCT04291391|Experimental|Obese - normoglycemic|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
16355252|NCT04291391|Experimental|obese-glucose intolerant|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
16355253|NCT04291391|Experimental|obese with type 2 diabetes|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
16355254|NCT04291378|Active Comparator|Photon radiation therapy|The patient is treated with standard radiation therapy based on photons
16355255|NCT04291378|Experimental|Proton radiation therapy|The patient is treated with experimental radiation therapy based on protons
16355256|NCT04291365|Other|Normal weight|
16355257|NCT04291365|Other|Obesity Class 1|
16355258|NCT04291365|Other|Obesity Class 2|
16355259|NCT04291365|Other|Obesity Class 3|
16355260|NCT04291352|Experimental|Taurine|675mg taurine four times daily
16355261|NCT04291352|Placebo Comparator|Placebo|placebo four times daily
16355262|NCT04291339|Experimental|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
16355263|NCT04291339|Active Comparator|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
16355264|NCT04291313|Placebo Comparator|Current recommended dose of vitamin D|Women in this study arm receive 10 µg of vitamin D3 per day, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
16355265|NCT04291313|Experimental|Higher dose of vitamin D|Women in this arm receive 90µg of vitamin D3 per day: 10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3.
16355266|NCT04291300|Experimental|Lutetium treatment|Drug: Lutetium-177-PSMA-I&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
16355267|NCT04291287||Triple antithrombotic therapy|patients taking Triple antithrombotic therapy (aspirin and a P2Y12 inhibitor, in addition to either a DOACs or warfarin/acenocumarol)
16355268|NCT04291287||Dual antithrombotic therapy|patients taking Dual antithrombotic therapy (aspirin or P2Y12 inhibitor in addition to either a DOACs or warfarin/acenocumarol)
16355269|NCT04291274||inhalation anesthesia group|Unilateral and Bilateral cochlear implantation,which used inhalation anesthesia
16355270|NCT04291274||intravenous anesthesia group|Unilateral and Bilateral cochlear implantation, which used intravenous anesthesia
16355271|NCT04291261|Other|Extracorporeal photopheresis (ECP) with Uvadex|Patients in this single Arm study all receive the intervention consisting of ECP with Uvadex plus the standard of care treatment which consists of systemic corticosteroids 2mg/kg. Response to treatment will be evaluated on day 28. Patients will receive study treatment till day 56 and thereafter be followed until 1 year.
16355405|NCT04290273|Experimental|Morning exposure in week 1|Participants will have their first week of testing starting in the morning
16355272|NCT04291248|Experimental|Anlotinib+AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16355273|NCT04291248|Experimental|AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
16355274|NCT04291235|Active Comparator|Airway Management Pathway|An airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients can breathe on their own and appear able to protect their airway
16355275|NCT04291235|Active Comparator|Usual Care|The usual clinical practice is often to keep the patient on artificial respiration for longer in the hope that the patient will wake up before removing the tube, or performing a tracheostomy if the patient doesn't wake up
16355276|NCT04291222|Experimental|IBS implantation|Implantation of IBS in PDA in duct-dependent cyanotic CHD
16355277|NCT04291209|Active Comparator|Experimental arm with Intratympanic NAC injection|One ear will be randomly chosen for the experimental treatment and receive intratympanic NAC injections 60 minutes prior to their scheduled chemotherapy sessions
16355278|NCT04291209|No Intervention|Control arm with No injection|The control ear will not receive any injections
16355279|NCT04291196|Experimental|Immersive Virtual Reality|Patients will be immersed in the ECT experience using VR-ECT 360o video (VR-ECT).
16355280|NCT04291196|Other|Standard Treatment|Patients will receive standard preparation for their ECT session.
16355281|NCT04291183|Experimental|elderly people to undergo hortic culture therapy|Horticultural Therapy will be applied to the elderly in the experimental group in the form of two days a week visit for eight weeks. Flower and vegetable seedlings suitable for the season will be planted in the garden with the elderly. The elderly will be asked to take care of the plants they planted every day (irrigation and collecting extra herbs) and the elderly people will be observed by doing these processes twice a week
16355282|NCT04291183|No Intervention|elderly people who will not receive horticultural therapy|pre-test data forms will be applied to the control group. Post-test data forms will be reapplied after 8 weeks
16355283|NCT04291170|Experimental|QDASH|Completing the tasks on the QuickDASH
16355284|NCT04291170|Active Comparator|KOOSJR|Completing the tasks on the KOOSJR
16355285|NCT04291157|Experimental|Proactive CVD prevention|Proactive invitation to total CVD risk estimation incorporating the PRS and provision of guideline based preventive interventions.
16355286|NCT04291157|Active Comparator|Usual care|Usual GP care (opportunistic CVD risk estimation and prevention upon usual GP contacts).
16355287|NCT04291144||Patients|Inclusion criteria are mild to moderate DLB, age above 50, ability to give informed consent.
16355288|NCT04291144||Healthy controls|Age above 50.
16355289|NCT04291131||Veterans with COPD|Veterans with COPD who will participate in a physical activity intervention or exercise program
16355290|NCT04291118|Other|Medical Management and Sinus Surgery in private system|These patients will first receive medical management for their symptoms and then will undergo sinus surgery much earlier than the other group as they will include patients being operated in the private system.
16355291|NCT04291118|Other|Medical Management and Sinus Surgery in public system|These patients will first receive medical management for their symptoms, and then will undergo sinus surgery after a waiting period of at least 1 year since they are on the public wait-list.
16355292|NCT04291118|Other|Medical Management Only|These patients will only receive medical management for their symptoms as they will not require sinus surgery.
16355293|NCT04291105|Experimental|Melanoma intratumoral|Melanoma, IV & IT VV1 + cemiplimab Patients will receive both intravenous (IV) VV1 and intratumoral (IT) VV1 on Day 1. Will also receveive an infusion of cemiplimab on Day 1.
16355294|NCT04291105|Experimental|Melanoma|Melanoma, IV + cemiplimab Patients will receive both IV VV1 and cemiplimab on Day 1.
16355295|NCT04291105|Experimental|Hepatocellular carcinoma|Hepatocellular carcinoma Patients will receive both IV VV1 and cemiplimab on Day 1.
16355296|NCT04291105|Experimental|Non-small cell lung cancer|Non-small cell lung cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
16355297|NCT04291105|Experimental|Endometrial cancer|Endometrial cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
16355298|NCT04291092|Experimental|single-arm|single-arm
16355299|NCT04291079|Experimental|Part A1: Dose Escalation|Part A1 will determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of SRK-181 as a single agent and will determine the recommended Phase 2 dose (RP2D) of SRK-181 as a single-agent.
16355300|NCT04291079|Experimental|Part A2: Dose Escalation|Part A2 will determine the MTD or MAD of SRK-181 in combination with anti-PD-(L)1 antibody therapy and will determine the RP2D of SRK-181 in combination with anti-PD-(L)1 antibody therapy for use in Part B.
16355301|NCT04291079|Experimental|Part B: Dose Expansion|In Part B, parallel cohorts of patients with Non-small cell lung cancer (NSCLC), Urothelial Carcinoma (UC), Cutaneous melanoma (MEL), or other advanced or metastatic solid tumor type that is not NSCLC, UC, or MEL, will be enrolled to confirm the tolerability of the RP2D of SRK-181 (determined in Part A2) and to evaluate the anti-tumor activity of SRK-181 in combination with an anti-PD-(L)1 antibody therapy.
16355302|NCT04291079|Experimental|Long Term Extension Phase (LTEP)|"Patients may continue treatment in a LTEP:
~Part A1: Patients may continue treatment with SRK-181 as a single agent at the RP2D in the LTEP following 3 cycles of treatment with SRK-181 as a single agent in Part A1.
~Part A2: Patients may continue treatment with SRK-181 at the RP2D in combination with anti-PD-(L)1 antibody therapy in the LTEP following 3 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part A2.
~Part B: Patients may continue treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy following 9 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part B"
16355303|NCT04291066|Experimental|Treatment|oral N-acetyl cysteine and oral multivitamin tablets
16355304|NCT04291066|No Intervention|Non-Treatment|Routine Care
16355305|NCT04291053|Experimental|experimental group|Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)
16355306|NCT04291053|No Intervention|control group|standard therapy
16355307|NCT04291040|Experimental|Decision Aid|
16355308|NCT04291040|Active Comparator|Routine Care|
16355309|NCT04291027|Experimental|Aquatic Group Exercise|
16355310|NCT04291027|Active Comparator|Land Based Group Exercise|
16355312|NCT04291014|Experimental|BWLT twice daily|Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
16355313|NCT04291014|Experimental|BWLT weekly|Participants in this arm will receive bright white light therapy once weekly (in the evening).
16355314|NCT04291014|Experimental|DRLT twice daily|Participants in this arm will receive dim red light twice daily (morning and evening).
16355315|NCT04291001|Active Comparator|ENG Implant alone|Women will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
16355316|NCT04291001|Active Comparator|ENG Implant plus oral UPA|Women will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
16355317|NCT04290988|Experimental|Active EEG Neurofeedback|15 sessions of active EEG neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
16355318|NCT04290988|Sham Comparator|Sham Feedback|15 sessions of sham neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
16355319|NCT04290975|Experimental|Task-shifted arm|In the task-shifted arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a CHW, with a physician consult available to the CHW as needed.
16355320|NCT04290975|Active Comparator|Enhanced usual care arm|In the enhanced usual care arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a physician, with a CHW collecting standardized data to mirror that of the intervention arm.
16355321|NCT04290962|Experimental|Supportive Care (web-based lifestyle intervention)|Participants complete the 12-month Precision Nutrition Coaching Program web-based lifestyle intervention consisting of physical activity at home or a local gym, nutritional/lifestyle habit with a new focus biweekly, and educational lessons about health, nutrition, fitness, or behavior change.
16355322|NCT04290936|Experimental|Arm 1|NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.
16355323|NCT04290936|Placebo Comparator|Arm 2|NUC-naïve patients will be randomization into placebo arm.
16355324|NCT04290936|Active Comparator|Arm 3|NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.
16355325|NCT04290910|Experimental|Weight Loss Program|Single arm, all participants receive the weight loss program
16355326|NCT04290897|Experimental|Supportive care (anhydrous enol-oxaloacetate)|Patients receive anhydrous enol-oxaloacetate PO BID for 8 weeks in the absence of worsening symptoms or unacceptable toxicity.
16355327|NCT04290884|Experimental|Local administration of tranexamic acid|"All patients hip fracture will be treated according to the hospital standard procedure
~Check complete blood count on admission and Day 3 post-operation.
~10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control
~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.
~Transfusion when clinically indicated or Hb < 8g/dL
~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)
~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.
~After discharge, patients will be seen in 6 weeks and 3 months"
16355328|NCT04290884|No Intervention|Control group|"All patients hip fracture will be treated according to the hospital standard procedure
~Check complete blood count on admission and Day 3 post-operation.
~10ml normal saline injected under the deep fascia around the fracture site under x-ray control
~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.
~Transfusion when clinically indicated or Hb < 8g/dL
~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)
~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.
~After discharge, patients will be seen in 6 weeks and 3 months"
16355329|NCT04290871|Experimental|Treatment Group|Nitric Oxide gas will be administered in the ventilatory circuit.
16355330|NCT04290871|Sham Comparator|Control Group|The delivery system will be set up anyway without study gas administration
16355331|NCT04290858|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
16355332|NCT04290858|No Intervention|Control|The control group will receive the standard of treatment without any active, placebo or sham Comparator.
16355333|NCT04290845|Experimental|Relief-Hybrid|Relief-Hybrid relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
16355334|NCT04290845|No Intervention|Referral to Mental Health/Usual Care|Continuation of medical attention and treatment provided by physicians and other medical professionals at the primary care practice. Referral for mental health based on clinical indication. Participants receive an educational booklet on pain.
16355335|NCT04290832|Experimental|CO intervention|"South Africa: All health facility staff working in facilities assigned to the intervention arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers) plus the CO intervention.
~Mexico: Doctors/anyone eligible to be an abortion provider working in facilities assigned to the intervention arm receive the CO intervention."
16355336|NCT04290832|No Intervention|Control|"South Africa: All health facility staff working in facilities assigned to the control arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers).
~Mexico: No intervention"
16355337|NCT04290819|Experimental|Resistance Training with Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
16355338|NCT04290819|Experimental|Resistance Training with Caffeine|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
16355339|NCT04290819|Experimental|Resistance Training with Caffeine and Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
16355340|NCT04290819|Placebo Comparator|Resistance Training with Placebo|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
16355341|NCT04290806||ESCC|250 patients with esophageal squamous cell carcinoma
16355342|NCT04290806||GAC|250 patients with gastric adenocarcinoma
16355343|NCT04290806||GEJAC|250 patients with gastroesophageal junction adenocarcinoma
16355344|NCT04290793|Experimental|Experimental group|Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
16355345|NCT04290793|Active Comparator|Control group|Patients will only receive Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
16355346|NCT04290767|Other|Sonovue|ICU patients with acute shock status (septic or non-septic) who are eligible for enhanced-contrast brain ultrasound with sulphur hexafluoride microbubbles contrast (Sonovue, BRACCO, Milan, Italy) examination.
16355347|NCT04290754|Experimental|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
16355348|NCT04290754|Active Comparator|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive-behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
16355349|NCT04290741|Experimental|Auricular (Battlefield) Acupuncture|Auricular acupuncture involves placement of needles based on battlefield acupuncture protocol which involves the placement of needles in up to 5 sites on each ear to treat pain.
16355350|NCT04290741|Experimental|Peripheral Acupuncture|Peripheral acupuncture involves placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
16355351|NCT04290741|No Intervention|Control|Standard of care without acupuncture
16355352|NCT04290728|Experimental|High flow|Apply high-flow nasal oxygenation during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
16355353|NCT04290728|Active Comparator|Control|Apply nothing during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
16355354|NCT04290715||group A|
16355355|NCT04290715||group I|
16355356|NCT04290702|Active Comparator|epidural|
16355357|NCT04290702|Active Comparator|combined|
16355358|NCT04290702|Active Comparator|dural puncture epidural|
16355359|NCT04290689||Botulinum Toxin-A injection treatment|Toe walking Cerebral Palsy subject who are subject to Botulinum toxin-A injection treatment. The dosage will be determined by the Orthopaedic Consultant
16355360|NCT04290689||Serial casting stretching treatment|Toe walking Cerebral Palsy subject who are subject to serial casting stretching treatment.
16355361|NCT04290676||DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
16355362|NCT04290663|Active Comparator|RAI group|
16355363|NCT04290663|Experimental|GUIDED FOLLOW-UP group|
16355364|NCT04290650|Other|Modified CBT for insomnia|All patients admitted to one of the psychosis ward will be offered the same customized treatment focusing on sleep in addition to treatment as usual.
16355365|NCT04290650|Other|Treatment as usual|All patients admitted to the other two psychosis wards will only receive treatment as usual.
16355366|NCT04290637|Experimental|No sea swimming|Stop sea swimming for 4-6 weeks
16355367|NCT04290637|Active Comparator|Sea swimming|Continue sea swimming for 4-6 weeks
16355368|NCT04290624|Experimental|Intervention Group|Participants will be instructed to use a dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride, COREGA denture foaming cleanser and mouth rinse containing 90 parts per million (ppm) sodium fluoride. Participants will brush with a strip of the dentifrice (full brush head) applied to the full length of the toothbrush head for 2 minutes followed by 2 pumps of denture cleanser foam brushed onto removable partial denture (RPD) for 90 seconds and 10 milliliter (ml) of mouth rinse for swished around the mouth for 1 minute. Participants will apply all these products twice daily (morning and evening) for 12 weeks.
16355369|NCT04290624|No Intervention|Reference Group|Participants will not be supplied any products and will continue with their existing dental/denture hygiene practices and should not make changes to either their established habits nor to the products they use following screening.
16355370|NCT04290611||Enzalutamide drug-induced toxicity|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by enzalutamide, with a chronology compatible with the drug toxicity
16355371|NCT04290585|Experimental|Health Services Research (text message reminder)|Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.
16355372|NCT04290572|Experimental|Isotretinoin 10 mg/day|One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.
16355373|NCT04290572|Experimental|Isotretinoin 20 mg/day|One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.
16355374|NCT04290572|Active Comparator|Isotretinoin 30 mg/day|One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.
16355406|NCT04290273|Experimental|Afternoon exposure in week 1|Participants will have their first week of testing starting in the afternoon
16356792|NCT04280718|Experimental|efgartigimod PH20 SC|Patients treated with efgartigimod PH20 SC
16355375|NCT04290546|Experimental|Cohort I without Ipilimumab Lead in|"Haploidentical donor derived CIML NK cell infusion with subcutaneous N-803 for eligible patients with platinum-refractory and immune checkpoint blockade-refractory, advanced head and neck squamous cell carcinoma (Cohort 1)
~CIML NK cell infusion (Dose 0 or -1) infused on Day 0.
~Interleukin-15 Superagonist dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles)."
16355376|NCT04290546|Experimental|Cohort 2 with Ipilimumab Lead In|"Cohort 2 treated with an ipilimumab lead-in prior to CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone.
~Participants in the ipilimumab subgroup (Cohort 2) will receive a single dose of lead-in ipilimumab via iv per protocol determined dose followed by lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.
~CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0
~Interleukin-15 Superagonist (N-803) Administration
~-- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).
~Cohort 2 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
16355377|NCT04290533|Experimental|Active HD-tDCS|
16355378|NCT04290533|Sham Comparator|Sham HD-tDCS|
16355379|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:
~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)
~Thereof: IVT eligible patients:
~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment
~Thereof: IV rtPA treated patients:
~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
16355380|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:
~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)
~Thereof: IVT eligible patients:
~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment
~Thereof: IV rtPA treated patients:
~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
16355381|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:
~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)
~Thereof: IVT eligible patients:
~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment
~Thereof: IV rtPA treated patients:
~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
16355382|NCT04290455|Experimental|treatment arm|using the microblepharoexfoliative procedure
16355383|NCT04290455|Active Comparator|control arm|using eyelid wipe (Optase)
16355384|NCT04290442|Active Comparator|Adductor canal block (ACB)|
16355385|NCT04290442|Experimental|Adductor canal block plus SPANK block|
16355386|NCT04290429|Experimental|SR-GI-GVHD|Analysis of patient's stool frequency, albumin serum levels and quantification of Paneth cell numbers in GI biopsies before and during teduglutide treatment.
16355387|NCT04290416|Experimental|Microwire electrodes|Activity of individual neurons will be recorded via microwire contacts. These microwire electrodes do not interfere with the macrowire clinical recordings.
16355388|NCT04290403|Experimental|Pull ups|Pull-up continence products
16355389|NCT04290403|Experimental|Styled briefs with tapes|Styled briefs with tapes
16355390|NCT04290390|Active Comparator|Annovera (alone)|Annovera taken alone (without itraconazole or rifampin)
16355391|NCT04290390|Active Comparator|Annovera with itraconazole use|Subjects will dose with 200 mg/day of itraconazole for five days before Annovera insertion and through Days 1 to 8 of Annovera use
16355392|NCT04290390|Active Comparator|Annovera with rifampin use|Subjects will dose with 600 mg/day rifampin for 8 days, between Days 4 to 11 of Annovera use during their respective treatment cycles
16355393|NCT04290377|Active Comparator|Conventional OT + Motor Imagery OT|Conventional OT (30 minutes/day) plus Motor Imagery OT (30 minutes/day) for 10 days.
16355394|NCT04290377|Experimental|Conventional OT + BMI-assisted Motor Imagery OT|Conventional OT (30 minutes/day) plus BMI-assisted motor imagery OT (30 minutes/day) for 10 days.
16355395|NCT04290364||Prospective cohort|Patients newly diagnosed with pancreatic cancer included in the prospective part of the study
16355396|NCT04290364||Retrospective cohort|Patients diagnosed with pancreatic cancer before early palliative care was introduced (historical control patients)
16355397|NCT04290351||Band ligation and phlebotonic group|"Patients with rubber band ligation and the prescribed anti hemorrhoidal drug will be examined in this group.
~(Note: The researcher has no contribution or intervention to the treatment method.)"
16355398|NCT04290351||Only phlebotonic group|"Patients who are prescribed the only 450mg of diosmin + 50mg of hesperidin as a treatment for bleeding internal hemorrhoids will be examined in this group.
~(Note: The researcher has no contribution or intervention to the treatment method.)"
16355399|NCT04290338|Experimental|PIOMI Group|Patients in this group will receive the intraoral and extraoral stimulations provided by the PIOMI protocol. These stimulations will last 5 minutes and will be performed once a day for 7 consecutive days for each patient.
16355400|NCT04290338|No Intervention|Control Group|Patients in this group will receive classic care.
16355401|NCT04290325|Experimental|HMPL-453|HMPL-453
16355402|NCT04290312|Other|Mastiha oil|As a control to the experimental design, timepoint 0 was considered.
16355403|NCT04290286|Experimental|intervention group|Trans persons (n = 105) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)
16355404|NCT04290286|No Intervention|waiting group|Trans persons (n = 105) wait 4 months until they are offered online intervention according to the i2TransHealth model of care (waiting group)
16356987|NCT04279249|Sham Comparator|Sham HEPA Filtration|
16355408|NCT04290260|Active Comparator|Usual care|Usual care: participants will not wear a breast bra until discharge from the hospital
16355409|NCT04290247|Experimental|Ultrasound + X-ray|Ultrasound first then x-ray examination
16355410|NCT04290234||Non-medicated healthy adults with childhood maltreatment|The 25-item retrospective Childhood Trauma Questionnaire (CTQ) will be administered to assess history of abuse and neglect. The CTQ measures five types of maltreatment: emotional, physical, and sexual abuse and emotional and physical neglect.
16355411|NCT04290221|Experimental|Percutaneous electrolysis in the lumbar nerv|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
16355412|NCT04290221|Active Comparator|Percutaneous electrolysis in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 3 weeks).
16355413|NCT04290208|Active Comparator|Intravenous Administration of Acetaminophen|A single peri-operative dose of acetaminophen 1000 mg IV over 15 minutes after skin is closed.
16355414|NCT04290208|Active Comparator|Per Oral Administration of Acetaminophen|A pre-operative liquid dose of acetaminophen 1000mg orally in the on-call to Operative Room.
16355415|NCT04290195|Experimental|ziv aflibercept patients|20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO
16355416|NCT04290182|Experimental|Single arm: MSC administration to vocal fold scar|1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)
16355417|NCT04290169|Other|Adults with hemiplegic spastic cerebral palsy|Adults (> 18 years old) with hemiplegic spastic cerebral palsy, with reduced hand function and spasticity as prevalent finding under clinical examination. Also these patients can walk but have problems with balance. Participants' cognitive function does not limit them to perform video game training.
16355418|NCT04290156|Experimental|Joint visits|Subjects in the intervention arm attend a total of four joint transition visits performed with the participation of both the adult and the pediatric gastroenterologist.
16355419|NCT04290156|No Intervention|Usual care|Adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists with respect the patient's treatment plan.
16355420|NCT04290143|Active Comparator|Colored healing water|Colored medical water in a bath tub. A single 20 minutes-long treatment will be performed.
16355421|NCT04290143|Placebo Comparator|Placebo - Colored tap water|Colored tap water. The temperature and the pH of the tap water will be adjusted to the temperature pH of the healing water. A single 20 minutes-long treatment will be performed.
16355422|NCT04290117|Experimental|ACT-Chrono|First Acceptance and Commitment (ACT) training, followed by chronobiological training
16355423|NCT04290117|Experimental|Chrono-ACT|First chronobiological training, followed by ACT training
16355424|NCT04290117|Other|Chrono|First no training, followed by chronobiological training
16355425|NCT04290117|Other|ACT|First no training, followed by ACT training
16355426|NCT04290104|Experimental|1gr oral ampicillin/sulbactam group|The group to be prescribed 1 g oral ampicillin/sulbactam twice a day while discharged after laparoscopic cholecystectomy due to ACC.
16355427|NCT04290104|No Intervention|Antibiotic not prescribed group|Antibiotics not prescribed when discharged after laparoscopic cholecystectomy due to ACC.
16355428|NCT04290091||Patients with CAD|Patients who have hemodynamically significant CAD.
16355429|NCT04290091||Patients without CAD|Patients who don't have hemodynamically significant CAD.
16355430|NCT04290078|Experimental|Kaia Back Pain Study Intervention|"The study intervention consists of training sessions conducted daily by the participant via Kaia back pain program. This content combines several approaches that may be effective when used together such as physical exercises, relaxation practices and learning modules. Additionally, there is availability of an electronic motion coach on a set of exercises.
~Users also receive behavioural health coaching provided by Kaia's coaching staff based on a coaching curriculum."
16355431|NCT04290078|Active Comparator|Control Group|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth.
16355432|NCT04290065|Experimental|Experimental group|The intervention will take place over a period of 4 weeks, with 2 weekly sessions, with an estimated execution time of 1.50 to 3 minutes each. A manual therapy technique of inhibition of the suboccipital musculature and an axial traction of the upper hemiarchy will be performed
16355433|NCT04290065|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
16355434|NCT04290039|Active Comparator|Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.
~Each bottle will only be used to administer a single dose, to a single subject."
16355435|NCT04290039|Active Comparator|High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.
~Each bottle will only be used to administer a single dose, to a single subject."
16355436|NCT04290039|Active Comparator|Intravenous (IV)|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.
~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.
~Each vial will only be used to administer a single dose, to a single subject."
16355437|NCT04290026|Active Comparator|metoclopramide versus granisetron|Ultrasound assessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section: A randomized, double-blind, placebo-controlled study
16355438|NCT04290013|Experimental|norethisterone -women with Dysfunctional uterine bleeding|
16355439|NCT04290013|Experimental|tranexemic acid-women with Dysfunctional uterine bleeding|
16355440|NCT04290000||hematological malignancies|hematological malignancies treated with CAR-T Cells
16355441|NCT04289987|Experimental|CVI-HBV-002|"CVI-HBV-002 1.0mL(20ug/dose)
~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
16355442|NCT04289987|Placebo Comparator|Normal Saline|"Normal Saline Choonwae Inj. 1.0 mL
~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
16355443|NCT04289974||Palbociclib+fulvestrant|"100 cases of patients with ER+, HER2- breast cancer, experienced resistance after first line endocrinotherapy, will be assigned participants into treatment regimen, including palbociclib combined with fulvestrant.
~FFPE blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals on the points before administration and since resistance appearance. The tissue will be sequenced by a pan-cancer DNA panel (500+ genes) and whole transcriptome sequencing (WTS).
~5-10 ml peripheral blood will be collected from each patient on the points before administration, 1 month after treatment, every subsequent visit and resistance appearance. The liquid biopsy will be sequenced by a pan-cancer ctDNA panel (300+ genes).
~The genomic characteristics of patients received resistance will be analyzed. The relevant pathway mechanisms will be identified."
16355444|NCT04289961|Other|Single Arm|Observational study of CTC microemboli in portal vein blood samples.
16355445|NCT04289948|Experimental|Phage|
16355446|NCT04289948|Placebo Comparator|Placebo|
16355447|NCT04289935|Experimental|single arm|"Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy
~rCR / near-rCR in MRI
~Registration
~US-guided VAB
~Breast conserving surgery / mastectomy
~Pathology examination 1. Preoperative VAB, 2. Surgical specimen"
16355448|NCT04289909|Other|MS patients|RRMS Patients with optic neuritis, RRMS patients without optic neuritis or Progressive MS patients
16355449|NCT04289909|Other|Control group|Healthy volunteers
16355450|NCT04289896|Experimental|Experimental group|Each session will last 20 minutes, taking place 2 days a week, for a period of 4 weeks. Prior to the completion of the routine training of each team, the plyometric exercise program will be carried out in the experimental group. When the intervention ends, the members of the experimental group will perform the usual training
16355451|NCT04289896|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
16355452|NCT04289883|Experimental|High molecular weight whey protein-alginate/Calcium alginate|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
16355453|NCT04289883|Experimental|Nano-particulated whey protein/Non-particulated whey protein|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
16355454|NCT04289870|Experimental|Innoventric Trillium™ Stent Graft Single Arm|Single-arm, open label, multi-center study
16355455|NCT04289857|Experimental|Experimental group|Each session will last a maximum of 5 minutes, taking place for 3 days a week, over a period of 4 weeks. The intervention will be performed at the start of training (before warm-up).
16355456|NCT04289857|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
16355457|NCT04289844|Experimental|Experimental group|Each session of the intervention will have a duration of 15 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength and resistance strength
16355458|NCT04289844|Active Comparator|Control group|Each session of the intervention will have a duration of 10 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength
16355459|NCT04289831|Active Comparator|Direct Surgery (DS) group|patients subjected to direct surgery (DS) within 1 week after randomization
16357371|NCT04276740|Active Comparator|MitoQ|Participants will take oral MitoQ 40 mg daily
16355460|NCT04289831|Active Comparator|Preoperative Biliary Drainage (PBD) group|patients managed by Preoperative Biliary Drainage followed by surgery after 4-6 weeks.
16355461|NCT04289818|No Intervention|Control|Conventional Education Class
16355462|NCT04289818|Experimental|Coaching|Health Coaching
16355463|NCT04289805|Active Comparator|standard-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the French participating centres.
16355464|NCT04289805|Experimental|letrozole-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the Belgian participating centres.
16355465|NCT04289805|No Intervention|non-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and who have access to the Fertility Clinics in all the participating centres but are not willing to preserve their fertility by undergoing oocyte/embryo cryopreservation.
16355466|NCT04289792|Experimental|SBRT with concurrent chemotherapy|SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy
16355468|NCT04289766|Active Comparator|Conventional Treatment|Conventional Treatment includes exercises limbs
16355469|NCT04289766|Experimental|Focal Muscle Vibration (120Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.
~Conventional Treatment"
16355470|NCT04289766|Experimental|Focal Muscle Vibration (60Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.
~Conventional Treatment"
16355471|NCT04289753|Active Comparator|Brief clinician education|Clinicians attributed to clinics in the brief clinician education arm will receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
16355472|NCT04289753|Experimental|Clinical decision support nudges and brief clinician education|Clinicians attributed to clinics randomized to the clinical decision support nudges and brief clinician decision support arm will receive clinical decision support within the EHR when conditions meet alert triggering criteria. These clinicians will also receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
16355473|NCT04289740|Experimental|cognitive-bahavioral therapy|Trasdiagnotic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period.
16355474|NCT04289740|Active Comparator|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
16355475|NCT04289727||Group 1|Those with Type 1 Diabetes.
16355476|NCT04289727||Group 2|Those without Type 1 Diabetes.
16355477|NCT04289714|Experimental|R-DOT|Remote Directly Observed Therapy
16355478|NCT04289714|Experimental|Haillie|Smartinhaler Haillie
16355479|NCT04289714|Experimental|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
16355480|NCT04289701||Hypertension Cohort|"Hypertension patients recruited in the Hypertension Prevention and Control Initiative in China project."
16355481|NCT04289675||Interferon-Beta|Patients with first treatment : interferon beta (1a subcutaneous 22 or 44 µg thrice a week OR 1a intramuscular 30 µg once a week OR 1b subcutaneous 250 µg every other day OR 1a PEGylated subcutaneous 125 µg every two weeks)
16355482|NCT04289675||Dimethyl fumarate|Patients with first treatment : dimethyl fumarate (oral, 240 mg twice a day)
16355483|NCT04289675||Teriflunomide|Patients with first treatment : teriflunomide (oral, 14 mg once a day)
16355484|NCT04289662|Experimental|K-924 LD|K-924 LD once daily
16355485|NCT04289662|Experimental|K-924 HD|K-924 HD once daily
16355486|NCT04289649|Experimental|K-924 LD|K-924 LD tablet once daily
16355487|NCT04289649|Experimental|K-924 HD|K-924 HD tablet once daily
16355488|NCT04289649|Active Comparator|Pitavastatin 2 mg|K-924 LD Placebo tablet once daily
16355489|NCT04289649|Active Comparator|Pitavastatin 4 mg|K-924 HD Placebo tablet once daily
16355490|NCT04289636|Experimental|Weight loss and self-compassion|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week mindfulness-based self-compassion program which combines the skills of mindfulness and self-compassion as a means for improving emotional resilience, well-being, and weight control.
16355491|NCT04289636|Active Comparator|Weight loss and nutrition/cooking education|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week nutrition and cooking education program which will provide basic nutrition knowledge and cooking skills for healthy eating.
16355492|NCT04289623||Standard email|This email mentions the cost-saving benefits of enrollment by participants who met their 2018 goals. It also includes the message that registration can be completed quickly (in less than five minutes). Finally, it also includes reward incentive information, wherein registering by a March deadline provides qualified recipients with the potential to win prizes. This information is contained in all other emails.
16355518|NCT04289480||ENTERPRISE 2 group|"The study population enrolled for this clinical study is aneurysm patients who need stent-assisted coiling treatment, using ENTERPRISE 2 device."
16355519|NCT04289467|Experimental|Fenfluramine treatment|Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.
16355554|NCT04289272|Experimental|Dove Confident Me|Dove Confident Me body image intervention to be delivered to students 1 lesson per week for 5 weeks (5 x 45 minute lessons).
16355493|NCT04289623||Loss frame email|"In addition to the content of the generic email, the subject line and content of the loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. This email further frames the reward as something recipients will miss out on if they do not sign up.
~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
16355494|NCT04289623||Testimonial (medical expert) email|"In addition to the content of the generic email, the testimonial (medical expert) email includes a testimonial from a doctor, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.
~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a presumed authority figure. Recipients may be more likely to enroll for this program if they see a physician - who would be seen as an authority on health and wellness - talking about the medical benefits of the program. It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
16355495|NCT04289623||Testimonial (rank-and-file) email|"In addition to the content of the generic email, the testimonial (rank-and-file) email includes a testimonial from a customer care specialist, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.
~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a peer (relative to most Geisinger employees). Recipients may be more likely to enroll for this program if they see a rank-and-file employee talking about the program as this person would be more relatable (relative to a doctor). It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
16355496|NCT04289623||Social norms (percentage) email|"In addition to the content of the generic email, the social norms (percentage) email will include communication about the percentage of benefit-eligible employees who had already registered for myHealth Rewards.
~This message sets up a descriptive norm, showing that a majority of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. The use of percentages makes it clear that this behavior is indeed being done by most people in the group. It is unclear in the current context and population if a message using percentages or numbers would be more effective."
16355497|NCT04289623||Social norms (number) email|"In addition to the content of the generic email, the social norms (number) email will include communication about the number of benefit-eligible employees who had already registered for myHealth Rewards.
~This message sets up a descriptive norm, showing that a large number of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. While the use of numbers does not indicate that this behavior is being done by a majority, using a large number can be more convincing just in showing sheer quantity."
16355498|NCT04289610|Sham Comparator|Control Group|In this group a pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). The device is not going to be activated in the control group. The device will be set at 0 V. TCPRF treatment is going to be applied for one session.
16355499|NCT04289610|Active Comparator|Study Group|A pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). It will be activated in the study group. In the study group device will be set at 80 V, every pulse will continue for 10 milliseconds and 5 pulses per second. TCPRF treatment is going to be applied for one session in both groups.
16355500|NCT04289597||Obese patients|Obese patients with BMI>30
16355501|NCT04289584|Experimental|Experimental group|Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session. Prior to training, strength and proprioception exercises will be performed.
16355502|NCT04289584|No Intervention|Control group|The players included in the control group will follow their usual routine prior to their Taekwondo training.
16355504|NCT04289558|Experimental|Sodium Nitrite|Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)
16355505|NCT04289545|Placebo Comparator|Control Bread|no added guar gum
16355506|NCT04289545|Active Comparator|Functional Bread 1|10% guar gum, low molecular weight
16355507|NCT04289545|Active Comparator|functional Bread 2|10% guar gum, high molecular weight
16355508|NCT04289545|Active Comparator|Functional Bread 3|15% guar gum, low molecular weight
16355509|NCT04289545|Active Comparator|Functional Bread 4|15% guar gum, high molecular weight
16355510|NCT04289532|Experimental|99mTc-RWY SPECT/CT|Volunteers and patients were injected intravenously with 11.1 MBq/kg of 99mTc-RWY in one dose and underwent SPECT/CT scan 30-60 min later.
16355511|NCT04289506||Community-acquired pneumonia (Sepsis)|Community-acquired pneumonia with organ dysfunction
16355512|NCT04289506||Abdominal sepsis|Abdominal infection due to peritoneal soiling, biliary infection, urinary tract infection leading to organ dysfunction
16355513|NCT04289506||Infection of unknown origin (Sepsis)|Infection of unknown origin of less than 72 hours duration, including bacteraemia with organ dysfunction
16355514|NCT04289506||Organ dysfunction related to non-infectious cause (SIRS)|Patients admitted to the ICU following out-of hospital cardiac arrest OR Patients admitted to the ICU following major trauma (ISS>12) OR Patients admitted to the ICU following pancreatitis with organ dysfunction
16355515|NCT04289506||Healthy volunteers|Healthy volunteers
16355516|NCT04289493|Experimental|Group 1: first to receive therapy|27 patients that will receive study specific speech therapy in the first 3 months since study inclusion. From months 3-6 they will be group 2 controls.
16355517|NCT04289493|Experimental|Group 2: second to receive therapy|27 patients that will receive study specific speech therapy during months 3-6 since study inclusion. During the first 3 months of the study period, they will be group 1 controls.
16355553|NCT04289285|Placebo Comparator|Placebo SC Q8W|
16355520|NCT04289454|Other|Effect of flavor modifiers|Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.
16355521|NCT04289441|Active Comparator|probiotic treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day
~Lactobacillus salivarius LS01 (DSM 22775): 10^9 CFU Bifidobacterium breve B632 (DSM 24706): 10^9 CFU Maltodextrin and silicon dioxide"
16355522|NCT04289441|Placebo Comparator|Placebo treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day
~Maltodextrin and silicon dioxide"
16355523|NCT04289428||A|Not currently on antiviral therapy for HBV and HBV DNA detectable
16355524|NCT04289428||B|Stable on HBV antiviral therapy for at least 3 months with HBV DNA < 20 IU/ml
16355525|NCT04289415|Experimental|Individual Placement and Support|"The intervention used in this study will be a time-limited version of IPS. The employment specialist offers up until nine months job-search support and four months in-work support, giving a total of 13 months job-related support. If a participant succeeds in obtaining work before nine months has passed the remaining job-search support months may be transferred to in-work support time.
~In the follow-up time while seeking employment, the employment specialists will work with the participants to identify skills and aspirations, establish contact with potential employers and ensure economic advice and help with benefits planning. The in-work support involves individual and regular contact with the participant and the employer.
~All participants who receive this intervention will do so in addition to their clinical treatment. The treatment provider and the employment specialist should cooperate and clarify roles together with the patient."
16355526|NCT04289415|Active Comparator|Selv help kit and work shop|The participants in the control intervention will be offered a self-help tool kit and a following introduction course to help participants see what their opportunities are, and specific tips on how to get further help. The course will last three hours a session over four days, with the offer of an individual one hour follow up session with the course leader when the course is over. The goal of the control group intervention is to enable the participants to make use of the services offered at the ordinary labor and welfare service.
16355527|NCT04289402|Experimental|Personalized tDCS|Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minutes session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
16355528|NCT04289402|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
16355529|NCT04289389||HUNT4 70+|All inhabitants in Nord-Trøndelag 70 years of age and older were invited.
16355530|NCT04289389||HUNT4 Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age and older were invited.
16355531|NCT04289376|Other|Gaze tracking|No intervention. Monitor gaze as subjects watch a video
16355532|NCT04289363||ED patients|Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.
16355533|NCT04289363||Stakeholders and community leaders|Stakeholders within and outside the hospital, including ED providers, hospital leadership, ED patients, ED staff, and community opinion leaders will be recruited to participate in the IF booster and qualitative focus groups and interviews.
16355534|NCT04289363||ED-initiated BUP patients|ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits and data matching.
16355535|NCT04289363||ED-initiated BUP patients - 2|ED patients who are eligible to receive ED-initiated BUP but unable or unwilling to participate will provide authorization for health services review and data matching with available registry, claims or administrative data.
16355536|NCT04289363||Data-matching ED patients|All ED patients screening positive for non-medical opioid use
16355537|NCT04289337|Experimental|Combined probiotics (1)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
16355538|NCT04289337|Experimental|Combined probiotics (2)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.
16355539|NCT04289337|Experimental|Combined heat-killed probiotics (1)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
16355540|NCT04289337|Experimental|Combined heat-killed probiotics (2)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.
16355541|NCT04289337|Experimental|Probiotic metabolites|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.
16355542|NCT04289337|Placebo Comparator|Placebo|Does not contain probiotics, heat-killed probiotics and related metabolites.
16355543|NCT04289324|Experimental|Intervention|lung recruitment maneuvers performed every twelve hours during HFOV
16355544|NCT04289324|No Intervention|Control|no regular lung recruitment maneuvers during HFOV
16355545|NCT04289311|Experimental|Intervention arm|Single group study; all participants are in the intervention arm and receive the intervention
16355548|NCT04289285|Experimental|IBI306 450mg SC Q4W|
16355549|NCT04289285|Placebo Comparator|Placebo SC Q4W|
16355550|NCT04289285|Experimental|IBI306 600mg SC Q6W|
16355551|NCT04289285|Placebo Comparator|Placebo SC Q6W|
16355552|NCT04289285|Experimental|IBI306 600mg SC Q8W|
16355556|NCT04289259||Biopsy sample|Tumor mutational burden (TMB) will be assessed on a sample of the biopsy done during standard care of patients.
16355557|NCT04289259||Surgical sample|TMB will be assessed on a sample of the tumor surgical specimen resected during standard care of patients.
16355558|NCT04289259||Biopsy sample + surgical sample|TMB will be assessed both on a sample of the biopsy and a sample of the tumor surgical specimen resected during standard care of patients.
16355559|NCT04289246|Experimental|Treatment Group (TG)|On the first day of the intervention phase, research assistants visited TG's participants to introduce the MAD in the presence of caregivers. After the training session, which lasted 40 min approximately, the MAD was personalized according to the participant's prescriptions and through discussions with them on an appropriate schedule for presenting the reminders. Research assistants used the MAD administrator sub-system to enter the medication names, health problems to address, timetables, and the frequency at which medications should be taken. Then, they attached and configured NFC tags to each of the pill containers, which included selecting the images that best represented the pills and their containers to be used to form the visual reminders. Afterward, the MAD was placed in the homes' area where participants reported taking medications. MAD was used for 5 weeks during which data on medication adherence and system adoption was collected from the TG.
16355560|NCT04289246|No Intervention|Control Group (CG)|Participants in the CG followed their medication routine as usual. During 5 weeks data on medication adherence was collected.
16355561|NCT04289220|Experimental|Anti-CD19 CAR-T Cells Injection|Anti-CD19 CAR-T Cells Injection, Dosage form：injection Dosage:1-2.5x10^6/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
16355562|NCT04289207|Experimental|Romiplostim and danazol|Treatment group (romiplostim and danazol)
16355563|NCT04289194|Experimental|HCR040 (Phase 1)|Participants with moderate to severe acute respiratory distress syndrome (6 patients)
16355564|NCT04289194|Placebo Comparator|Control group (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
16355565|NCT04289194|Experimental|HCR040 (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
16355566|NCT04289181|Experimental|Medically Tailored Meals (MTM)|Participants randomized to the MTM arm will receive MTM for 4 weeks. Meals will be prepared and delivered by Meals on Wheels, a non-profit organization that has been delivering meals to seniors nationwide for decades. Meals on Wheels will deliver 21 complete meals to the patient's home each week. They can accommodate a wide range of patient needs and preferences (e.g., low sodium, gluten-free, no pork products, cultural preferences). Meals on Wheels will contact the patient directly to set up an initial assessment phone call to collect relevant data (e.g., specific patient goals for their HF) and to set up a delivery schedule. Nearing the 4-week mark when meal delivery ends, investigators will check-in with each participant to track progress, assess treatment fidelity and answer any questions. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
16355567|NCT04289181|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with HF. This includes regular visits with a HF provider (primary care or cardiology), standard nutrition teaching, medication optimization and post discharge support. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and HF self-management. These services follow guideline directed medical therapy. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
16355568|NCT04289168|Experimental|Music Class|Music Class attendance
16355569|NCT04289168|No Intervention|Play Class|Play date class attendance
16355570|NCT04289142|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1.2 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.2 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
16355571|NCT04289142|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
16355572|NCT04289129|Experimental|men|
16355573|NCT04289129|Experimental|women|
16355574|NCT04289116|Experimental|We Test|Each participant or couple will receive MI-CST + observation of ACT videos + CHTC. Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
16355575|NCT04289116|Active Comparator|Individual HIV Testing and Counseling|Individual HIV Testing and Counseling (IHTC). Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
16355576|NCT04289103|Experimental|Inolimomab/Leukotac|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.
~Treatment phase - Leukotac will be given up to D28
~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion"
16355577|NCT04289090|Experimental|Group A|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only.
16355578|NCT04289090|Experimental|Group B|Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.
16355579|NCT04289077||Patients with histopathological proven DTF|
16355580|NCT04289064||Fundus image quality assessment|Device: an artificial intelligence system for quality assessment of fundus images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center.
16355581|NCT04289051|Experimental|HYDRAL Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
16355582|NCT04289051|Active Comparator|BIOTENE® Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
16355583|NCT04289051|Placebo Comparator|Placebo Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
16355609|NCT04288817|Active Comparator|Cryotherapy and intralesional tuberculin PPD|Efficacy of cryotherapy combined with intralesional tuberculin purified protein in treatment of multiple common warts
16355584|NCT04289038|Experimental|training and relaxation|"Training: Following the patient assessment, on the second and third days of the weekly hemodialysis session, patients will be provided with training based on the need to manage the itching symptom.
~Autogenic Relaxation: It is an exercise program consisting of standard sentences that describe the body's absolute comfort and calm features."
16355585|NCT04289038|Experimental|training and virtual reality|"Training: Following the patient assessment, on the second and third days of the weekly hemodialysis session, patients will be provided with training based on the need to manage the itching symptom.
~Virtual reality: Playing games via smart phone with virtual reality glasses and headset"
16355586|NCT04289025|Active Comparator|Exercise|Personalised exercise programme is provided to the exercise group.
16355587|NCT04289025|No Intervention|No Intervention|This group of patients will receive no intervention.
16355588|NCT04289012|Experimental|Helicobacter Screening|All patients with confirmed MI (both STEMI and NSTEMI) will be tested for Hp infection with bedside UBT.
16355589|NCT04288999|Experimental|Arm A|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy
~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)
~Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)
~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
16355590|NCT04288999|Active Comparator|Arm B|"Surgery plus Adjuvant chemotherapy
~Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV
~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
16355591|NCT04288986|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 8-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 8-weeks. The activity sessions will include semi-structured free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
16355592|NCT04288973||Typical development children|Control sample
16355593|NCT04288973||Children with developmental disability|Clinical sample
16355594|NCT04288960||Chronic Stroke|Twenty chronic stroke patients (>3months post-stroke) will complete a one off session in a biomechanics lab. This session will include the Fugl Meyer Questionnaire and several walking trials along a flat, level 10m walkway. During this participants will wear a belt mounted accelerometer and small reflective markers on joints.
16355595|NCT04288947|Other|Usual Care|Training of midwives on 4 respectful maternal care modules.
16355596|NCT04288934|Active Comparator|patients with complete transection of the spinal cord|This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.
16355597|NCT04288934|Active Comparator|patients with SCI without total transaction.|This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla.
16355598|NCT04288921|Experimental|Nasal swab|Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
16355599|NCT04288921|Experimental|Nasopharyngeal swab|Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
16355600|NCT04288908|Experimental|Social exclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives fewer passes than the other two participants (i.e., 10 out of 60).
16355601|NCT04288908|Active Comparator|Social inclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives a comparable number of passes than the other two participants (i.e., 20 out of 60).
16355602|NCT04288895|Experimental|Vortioxetine|flexible-dose
16355603|NCT04288869||Interventional radiology or surgery under general anesthesia|Monitoring of patients (mean arterial blood pressure, Transcranial Doppler , bispectral index, near infrared spectroscopy) who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anaesthesia during the interventional neuroradiology or orthopedic surgery in adults .
16355604|NCT04288856|Experimental|Cohort A: BIIB078 First Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
16355605|NCT04288856|Experimental|Cohort B: BIIB078 Second Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
16355606|NCT04288856|Experimental|Cohort C: BIIB078 Third Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
16355607|NCT04288830|Experimental|TCMMMRT First|Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
16355608|NCT04288830|Active Comparator|Aerobic Exercise First|Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
16355991|NCT04286061|No Intervention|Control group|Players included in the control group will follow their usual training routine.
16355610|NCT04288817|Active Comparator|Intralesional tuberculin PPD|Efficacy of Intralesional tuberculin purified protein deravative monotherapy in the treatment of multiple common warts
16355611|NCT04288804||Control (healthy, non-PD participants)|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
16355612|NCT04288804||PD|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
16355613|NCT04288791|Experimental|Equia Forte Fil|
16355614|NCT04288791|Experimental|Zirconomer Improved|
16355616|NCT04288765|Experimental|Group A - Non transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone
16355617|NCT04288765|Active Comparator|Group B - transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone Autologous stem cell transplantation (ASCT)
16355618|NCT04288752|Experimental|VR101 Lubricating Intravaginal Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
16355619|NCT04288752|Sham Comparator|Sham Ring|"Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
~Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added."
16355620|NCT04288739||Acute Myeloid Leukemia (AML) group|"patients who are diagnosed as Acute Myeloid Leukemia (AML) based on peripheral blood, bone marrow, immunophenotyping and who fulfill the WHO 2016 criteria.
~Complete blood count (CBC), bone marrow aspirate, flow cytometric immunophenotyping, cytogenetic analysis and fluorescence in situ hybridization (FISH) for XIST gene will be performed for all AML patients in the study."
16355621|NCT04288726|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.
~Dose Level 1: 4 × 107 CD30.CAR-EBVST cells
~Dose Level 2: 1 × 108 CD30.CAR-EBVST cells
~Dose Level 3: 4 × 108 CD30.CAR-EBVST cells"
16355622|NCT04288700|Active Comparator|Group A|
16355623|NCT04288700|Active Comparator|Group B|
16355624|NCT04288700|Active Comparator|Group C|
16355625|NCT04288700|Active Comparator|Group D|
16355626|NCT04288687|Other|Niraparib Arm (only arm)|Niraparib 200 mg by mouth daily (2 x 100 mg pills) on a 28 day cycle
16355627|NCT04288674||Leptospirosis group|Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.
16355628|NCT04288674||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
16355629|NCT04288661|No Intervention|Drain|The patients of this arm undergo perianastomotic drain placement, as per standard of care institutional practice
16355630|NCT04288661|Experimental|No drain|The patients of this arm do not undergo perianastomotic drain placement.
16355631|NCT04288648||SUI group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
16355632|NCT04288648||control group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
16355633|NCT04288635||Septic shock admitted in Angers' ICU|Patients aged more than 18, admitted in University Hospital of Angers, who meet the full criteria of septic shock
16355634|NCT04288622|Experimental|ESM-derived personalised feedback (ESM-F) group|Participants will be required to participate in an ESM data collection procedure. Participants will be required to complete a beep-questionnaire 3 days a week, over a 6-week period. The mobile app will be programmed to emit a beep 10 times per day at random intervals between 7.30 and 22.30. At each beep, participants will use the app to digitally complete a brief beep-questionnaire, which covers current affect, current context and activities. Moreover, participants will receive weekly standardized feedback on personalized patterns of positive affect.
16355635|NCT04288622|No Intervention|ESM group|Participant will be required to participate in the same ESM data collection procedure as the ESM-F group. The personalised feedback report will be given to the participant after the whole study period (32 weeks) instead of weekly during data collection process.
16355636|NCT04288622|No Intervention|Control (CON) group|Participants will not be required to participate in the 6-week ESM data collection procedure. They will also receive the personalised feedback report based on the ESM data collected at baseline and week 7.
16355637|NCT04288609|Experimental|Intendu FBT inpatient|Motion Based Cognitive Video Games Software
16355638|NCT04288609|Active Comparator|paper and pencil tasks|paper and pencil tasks
16355639|NCT04288596||Eligible for Registry|All consecutive patients who undergo any of the five ACHDi interventions (complex catheterization, ASD closure, PFO closure, CoA stenting, and PPVI) at the time of Registry launch, who have also consented to participate.
16355640|NCT04288570|Active Comparator|Bone socket formation with a punch|suture anchor socket creation with punch
16355641|NCT04288570|Active Comparator|Bone socket formation with a drill|suture anchor socket creation with drill
16355642|NCT04288557||Sleep clinic patients|All adult patients, from 18 years and up to and including 65 years of age, on the waiting list for overnight polysomnography (PSG) recording at Leicester General Hospital.
16355643|NCT04288557||Healthy volunteers|All adults, from 18 and up to and including 65 years of age without a known sleep disorder.
16355644|NCT04288544|Active Comparator|Experimental: Intervention group|The patients get 1x 5,3g per day the microalgae Phaeodactylum tricornutumover for two weeks.
16355645|NCT04288544|Active Comparator|Omega-3 capsules|The patients get one capsule per day of the Omega-3-fatty acid capsules for 2 weeks.
16355646|NCT04288544|Experimental|sea fish (facultative)|as positive control, one portion of fish is eaten per week for 2 weeks after the Intervention of 8 weeks and 2 wash out (omega 3 must not be eaten).
16355647|NCT04288531||Pregnant and pregnant to be on iodine supplementation|Women in preconception, pregnant and lactating, receiving iodine supplementation
16355648|NCT04288531||Pregnant and pregnant to be not on iodine supplementation|Women in preconception, pregnant or lactating, not receiving iodine supplementation
16355649|NCT04288531||Women of childbearing age|Women of childbearing age not planning to become pregnant.
16355650|NCT04288518|Experimental|Primary Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.
~At least five (5) evaluable subjects with primary brain tumor. The tested injected dose 500 MBq."
16355651|NCT04288518|Experimental|Recurrence of Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.
~At least five (5) evaluable subjects with recurrence of brain tumor. The tested injected dose 500 MBq"
16355652|NCT04288505|Experimental|single arm|
16355653|NCT04288492|Experimental|biofeedback|Respiratory exercise using biofeedback device(ResCalm) 2-3 times / day for 3 minutes until discharge from hospital, once in recovery room before surgery
16355654|NCT04288492|No Intervention|general|General surgical schedule without control exercise
16355655|NCT04288479|Experimental|Doing a single HIT session in gestational week 22-36|
16355656|NCT04288466|Active Comparator|Adults|Adults < 60 years-old maltodextrin solution 450ml
16355657|NCT04288466|Active Comparator|Elders|Elders 65 or more years-old maltodextrin solution 450ml
16355658|NCT04288453|Experimental|Community-based activity program|Engagement in 8-week community-based activity program
16355659|NCT04288440|Active Comparator|Silicone filled eyes|Eyes filled with silicone oil
16355660|NCT04288440|Active Comparator|Idiopathic ERM|Eyes not filled with silicone oil
16355661|NCT04288427|Experimental|Finasteride Treatment|Patients who are eligible will be given 5ARI therapy, Finasteride, for medical management of Benign Prostatic Hyperplasia (BPH) symptoms. Only patients with lower urinary tract symptoms (LUTS) as assessed by AUA urinary symptom score > than 8, (suggestive of moderate LUTS) prostate size > 40cc, no prostate nodule/tenderness/firmness and increased PSA between 4-10ng/ml requiring prostate biopsy will be enrolled. Then, they will have prostate MRIs/needle biopsies and blood/urine collection followed by treatment with Finasteride (standard of care). They will be followed in urology clinic for assessment of LUTS every 6 months and Finasteride responsiveness at the 12-month time point. Prostate biopsy samples will be evaluated for SRD5A2 gene expression/methylation, hormonal androgen/estrogen levels (which will be repeated in blood samples). Prostate MRIs will assess size/inflammatory changes at the start and 3-year time points.
16355662|NCT04288414||fNIRS applied|All of the participants' brain activity was evaluated with fNIRS.
16355663|NCT04288388|Experimental|massage group|Immediately before the episiotomy repair was started (after exit of placenta and applying local anesthetic agent), women assigned to the study (massage) group were asked to place plastic gloves filled with ice pieces in the LI4 point on hand. This application was made for 5 minutes to the right hand and for 5 minutes to the left hand. The episiotomy was opened by the same midwife as all the women to the right mediolateral and repaired by the same midwife with the same technique and material.The ice massage was repeated until the episiotomy repair was over; total massage time and episiotomy repair time were recorded. Women were asked to mark the perceived pain level before the application and at the end of the application using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair).
16355664|NCT04288388|No Intervention|Control group|I the control group women were not excluded from routine practice; women were asked to mark the perceived pain level before episiotomy repair begin and at the end the repair using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair) like the study (massage) group.
16355665|NCT04288375|Experimental|extremity soft tissue sarcoma (STS)|Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
16355666|NCT04288362|Experimental|Intervention Group|
16355667|NCT04288362|Active Comparator|Control Group|
16355668|NCT04288349|Active Comparator|epinephrine + ropivacaine +saline|1% epinephrine solution + 30 ml of 1% ropivacaine solution diluted with 20 ml of 0.9% saline for achievement a 0.75% anesthetic solution in a ratio of 1: 200 000
16355669|NCT04288349|Placebo Comparator|epinephrine + saline|1% epinephrine solution + 50 ml of 0.9% saline in a ratio of 1: 200 000.
16355670|NCT04288336|Experimental|Prevention (intermittent fasting)|Beginning when patients' PSA is detectable up to 24 months after surgery, patients follow a daily intermittent fasting routine consisting of restricting the daily eating period to 8 hours (e.g. between 1PM-9PM) followed by 16 hours of prolonged nightly fasting for up to 1 year or until secondary therapy commences.
16355671|NCT04288323|Experimental|Single arm|This is a single arm study in which all participants have one ultrasound and one abbreviated MR exam
16355672|NCT04288297||distal minimally invasive distal chevron|The investigators compare the results of a consecutive cohort of patients treated with the above mentioned technique in comparison to the results of patients treated with the minimally invasive Reverdin-Isham technique, presented in literature
16355673|NCT04288284||Emergency group|Patients presented to emergency by complicated colorectal cancer ( Obstruction, bleeding or perforation)
16355674|NCT04288284||Elective group|Patients presented with uncomplicated colorectal cancer for resection treatment
16355701|NCT04288063||Early onset T1D children|25 young, prepubertal and very early pubertal (Tanner stages 1 and 2) children (13 females and 12 males) with early onset T1D
16355702|NCT04288050||Diabetic subjects under dialysis|Diabetic subjects under dialysis
16355703|NCT04288024|Experimental|Postural|During training, participants in this group are instructed to focus on their posture during weight-shifting.
16355704|NCT04288024|Experimental|Suprapostural|During training, participants in this group are instructed to focus on their suprapostural task during weight-shifting.
16355675|NCT04288271|Experimental|Adherence Intervention|"The objective of the intervention is to improve medication adherence. Patient-participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Patient will form an Adherence Support Team (AST) including the participant, a parent (or other) and the Coach (study coordinator). The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete if-then plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 6-week and 10-week check-ins.
~HCP-participants at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. They will also be alerted by study staff to critical non-adherence events."
16355676|NCT04288271|Other|Healthy Living Education Intervention|"Patient-participants will receive a healthy living education intervention with the use of an e-pillbox. Contacts with the coach will occur at the same intervals as at adherence intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The coach will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the coach will either continue the conversation on the topic selected at the outset or provide education on another topic. The coach will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
~At the end of the healthy living intervention at 14W, patient-participants at will be offered extended use of the e-pillbox, with dose reminders enabled and access for themselves and enrolled HCPs to the adherence-tracking website for an additional 8 weeks. They will not receive coaching during this period."
16355677|NCT04288258|Experimental|Treatment|Health and Wellness Program
16355678|NCT04288245|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
16355679|NCT04288245|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
16355680|NCT04288232|Experimental|Intravitreal aflibercept|Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
16355681|NCT04288219|Active Comparator|Standard of Care Treatment|Continuous supplemental oxygen and nifedipine 30mg will be administered to patients.
16355682|NCT04288219|Experimental|Non-Invasive Positive Pressure Ventilation Management|CPAP at 10mmHg with supplemental oxygen, as well as nifedipine 30mg will be administered to patients.
16355683|NCT04288206|Placebo Comparator|Placebo control|Patient will receive 'study drug' which is comprised of 300 mL of normal saline without any medication/antibiotic, which will be delivered by intravenous means at the time of surgery.
16355684|NCT04288206|Active Comparator|Cefazolin prophylaxis|Patient will receive 'study drug' which is comprised of weight-based dose of cefazolin mixed in 300 mL of normal saline, which will be delivered by intravenous means at the time of surgery.
16355685|NCT04288193||Trinity Health LIFE New Jersey PACE|Participants enrolled in Trinity Health LIFE New Jersey PACE facility who received an antipsychotic medication for the treatment of BPSD or insomnia
16355686|NCT04288180||Social Anxiety Disorder|A group of adults with social anxiety disorder will be recruited for a psychological/behavioral research study.
16355687|NCT04288167|Experimental|Patients with suspected brain injury|This arm will consist of up to 30 pediatric patients who entered the Emergency Room and who are suspected of having mild traumatic brain injury. Two sample sets will be collected within the first 10 hours from the injury.
16355688|NCT04288167|Active Comparator|Healthy controls|This arm will consist of up to 30 healthy control subjects, the samples of whom will be compared to the samples of brain injury patients (Arm 1). One sample set will be collected from healthy children without any known brain injury.
16355689|NCT04288154|Experimental|EMS Group - Experimental|EMS device will be turned on during exercise for this group.
16355690|NCT04288154|Placebo Comparator|EMS Group - Control|EMS device will be turned off during exercise for this group.
16355691|NCT04288141||Group 1: Early HER2 positive breast cancer|Study participants in Group 1 will include patients prescribed neoadjuvant systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive early breast cancer.
16355692|NCT04288141||Group 2: Metastatic HER2 positive breast cancer|Study participants in Group 2 will include patients prescribed systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive metastatic breast cancer.
16355693|NCT04288128||SCA early-manifest and premanifest patients|This cohort is defined by individuals with a SARA score between 0 and 15 (both values included).
16355694|NCT04288128||Control participants|This cohort is defined by individuals with a SARA score less than 5 and no significant neurological symptoms.
16355695|NCT04288115|Active Comparator|"Levothyroxine group (sham discontinuation)"|Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
16355696|NCT04288115|Placebo Comparator|"Placebo group (real discontinuation)"|Stop the current dose of levothyroxine and take study placebo
16355697|NCT04288102|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|Participants will receive standard of care plus 3 does of UC-MSCs
16355698|NCT04288102|Placebo Comparator|Placebo|Participants will receive standard of care plus 3 does of placebo
16355699|NCT04288089|Experimental|Palbociclib + H3B-6545 (Escalation and Expansion)|
16355700|NCT04288076|Experimental|PEEP Titration Arm|
16355705|NCT04288011||Clinical EDSS|The Kurtzke EDSS, is a clinical rating scale for multiple sclerosis having scores between 0 to 10 that are assigned by a trained clinician. Smaller impairments are assessed at lower scores and disability is assessed at higher scores. It is important to note, however, that despite being denoted on an ordinal scale, each level on the scale is not indicative of an equal change in disability.
16355706|NCT04288011||MLA EDSS|The Kurtzke EDSS, is a clinical rating scale or multiple sclerosis having scores between 0 to 10 that are assigned by a technique based upon several different Machine Learning Algorithms that are combined to produce a single score
16355707|NCT04287998||1|PE group
16355708|NCT04287998||2|Control group
16355709|NCT04287985|Placebo Comparator|Placebo|Placebo (0.9% NaCl) will be administered IV
16355710|NCT04287985|Experimental|Low Dose - VIS649|Low dose of VIS649 administered IV
16355711|NCT04287985|Experimental|Medium Dose - VIS649|Medium dose of VIS649 administered IV
16355712|NCT04287985|Experimental|High Dose - VIS649|High dose of VIS649 administered IV
16355713|NCT04287972|Experimental|LSG-DPC|Laparoscopic Sleeve Gastrectomy and Diaphragmatic Pillar Closure.
16355714|NCT04287972|Active Comparator|LSG|Laparoscopic Sleeve Gastrectomy
16355715|NCT04287959|Active Comparator|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
16355716|NCT04287959|Active Comparator|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
16355717|NCT04287946|Experimental|Ablation|
16355718|NCT04287933|Active Comparator|Drain|
16355719|NCT04287933|No Intervention|No drain|
16355720|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA less than 20|The first 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score less than 20.
16355721|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA more than 20|The second 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score more than 20.
16355722|NCT04287907|Experimental|Monitor|Qualitative End Tidal Co2 detector will be attached to the face mask used to provide mask ventilation to the preterm baby before connected to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
16355723|NCT04287907|No Intervention|Control|face mask used to provide mask ventilation to the preterm baby will be connected directly to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
16355724|NCT04287894|Experimental|Cohort 1A (firste cohort)|1 course Durvalumab (1500mg) + Tremelimumab (75mg) + 1 course of Durvalumab (1500mg) followed by CRT
16355725|NCT04287894|Experimental|Cohort 2A|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
16355726|NCT04287894|Active Comparator|Cohort 2B|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
16355727|NCT04287881|Other|Adult patients who have epileptic seizures|Patients with adult-onset epileptic seizures and diagnosed ischemic stroke.
16355730|NCT04287855|Experimental|Intervention|Isatuximab, Carfilzomib, Pomalidomide and Dexamethasone
16355731|NCT04287842|No Intervention|control|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. This provides complete suppression of animal responses to pain, fixation, tracheal intubation. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed.
16355732|NCT04287842|Experimental|training ischemia|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. Comparison of a total GSK-3 and phosphorytated (Ser9) GSK-3beta (pGSK3b) in brain tissuesupracardiac bundle of vessels by means of a special hook after cardiac arrest and absence of ventilation lasts 10 min.
16355733|NCT04287842|Active Comparator|desflurane|Intervention. Drug: Desflurane. Desflurane 8 vol% anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Surgery: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
16355734|NCT04287842|Active Comparator|sevoflurane|Sevoflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
16355735|NCT04287829|Experimental|pembrolizumab and lenvatinib|"Patients will receive pembrolizumab 200mg/iv (fixed dose) every 3 weeks and lenvatinib 20mg QD in a three weekly cycle.
~Treatment continues until disease progression by modified (i)RECIST for MPM, severe toxicity, serious intercurrent illness, patient request for discontinuation, need or use for any other anti-cancer agent other than protocol treatment, except for palliative radiotherapy, for a maximum period of 35 cycles"
16355736|NCT04287816|Experimental|Zero hard-boiled egg at 0 h|No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
16355737|NCT04287816|Experimental|One hard-boiled egg at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.
16355738|NCT04287816|Experimental|Two hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
16355739|NCT04287816|Experimental|Three hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
16355740|NCT04287816|Experimental|One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.
16355741|NCT04287816|Experimental|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.
16355742|NCT04287803|Experimental|intervention Arm|Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)
16355743|NCT04287790||Health professionals after intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (July 2020)
16355744|NCT04287790||Hospitalized patient before intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 18 months before the start (January 1st 2020) of the implementation intervention
16355745|NCT04287790||Health professionals before intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (December 2019)
16355746|NCT04287790||Hospitalized patient after intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 12 months after the start (January 1st 2020) of the implementation intervention
16355747|NCT04287777|Experimental|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
16355748|NCT04287777|Active Comparator|Mupirocin ointment|Topical administration of Mupirocin ointment 20mg/g TID for 7 days.
16355749|NCT04287777|Placebo Comparator|Placebo|Topical administration of Placebo (ointment) TID for 7 days
16355750|NCT04287751|Other|Overnight Oximetry|Participants record simultaneously overnight oximetry on night 1 and continue with prolonged recordings alone for a total of 4 nights
16355751|NCT04287738|Experimental|Navigated Care|Telephone-based collaborative dementia care navigation
16355752|NCT04287738|No Intervention|Survey of Care|Control group that will receive usual care and undergo the same regular assessments as patients enrolled in Navigated Care
16355753|NCT04287725|Experimental|exercise + active Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.
~Photobiomodulation therapy: will be performed using the active super pulsed laser (904nm)."
16355754|NCT04287725|Placebo Comparator|exercise + placebo Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.
~Photobiomodulation therapy: will be performed using the placebo super pulsed laser (904nm)."
16355755|NCT04287712||Participants received surgery|Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.
16355756|NCT04287699|Experimental|labor dance group|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment.The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
16355757|NCT04287699|No Intervention|Control group|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
16355758|NCT04287686|Experimental|rhACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
16355759|NCT04287686|No Intervention|Control group|Standard of care; no placebo
16355760|NCT04287673|Experimental|RIST-UR|"Group having performed the rehabilitation involving strongly the trunk for the first 3 months and then having performed its usual rehabilitation for the last 3 months.
~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
16355761|NCT04287673|Experimental|UR-RIST|"Group having performed its usual rehabilitation for the first 3 months and then having performed the rehabilitation involving strongly the trunk for the last 3 months.
~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
16355762|NCT04287673|No Intervention|Typically Developing children|Typically developing children who served as a control group in the first assessment (Trunk Control Measurement Scale, dynamic posturography on an unstable sitting device, clinical gait analysis)
16355764|NCT04287647|Active Comparator|Transpyloric stent|In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
16355803|NCT04287426|Active Comparator|Group receiving remifentanil at induction|Remifentanil 2 μg/kg at induction
16355765|NCT04287647|Sham Comparator|Sham|In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
16355766|NCT04287634|Experimental|Segmental Mobilization|Hot Fermentation Soft tissue mobilization + Targeted Segmental Mobilization Home plan exercise= cervical muscles stretching, postural care
16355767|NCT04287634|Experimental|Entire Spine Mobilization|Hot fermentation Soft tissue mobilization + Entire spine mobilization Home plan exercises=cervical muscles stretches, postural care
16355768|NCT04287608||Patients with qualifying conjunctivitis events|
16355769|NCT04287608||Patients with no clinical signs of eye inflammation|
16355770|NCT04287595|Experimental|intervention group|inhalation aromatherapy with orange essential oil
16355771|NCT04287595|No Intervention|control group|routine care
16355772|NCT04287582||Level 1 DMD|According to Brooke Lower Extremity Functional Classification Level 1
16355773|NCT04287582||Level 2-3 DMD|According to Brooke Lower Extremity Functional Classification Level 2 or 3
16355774|NCT04287582||Healthy Group|healthy children with similar demographic characteristics with children with DMD
16355775|NCT04287569|Experimental|video recording of endoscopy|Record of sequences of video-endoscopy and the reflectance of light through fibroscopy
16355776|NCT04287556||Population in risk of MH|Patient with hypermetabolic response of skeletal musculature by causes related with Malignant Hyperthermia in the literature.
16355777|NCT04287543|Experimental|Melatonin group|Patients with PD who will receive 25 mg of melatonin gel at 12 hours a day and half an hour before sleeping for 12 months
16355778|NCT04287543|Placebo Comparator|Placebo group|Patients with PD who will receive 25 mg of placebo gel at 12 hours a day and half an hour before sleeping for 12 months
16355779|NCT04287530|Experimental|Tachidino + PUFA supplementation|Group 1 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform). The program will be delivered during four weeks, starting two months after the pre-testing session. Additionally, the children will receive daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
16355780|NCT04287530|Active Comparator|Tachidino + Placebo|Group 2 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session, exactly as Group 1. Additionally, the children will receive daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
16355781|NCT04287530|Experimental|PUFA supplementation|Groups 3 will receive only daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
16355782|NCT04287530|Placebo Comparator|Placebo|Groups 4 will receive only daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
16355783|NCT04287530|No Intervention|Control group|Typically Developing participants, as a comparison group for experimental tasks and for PUFA levels in the blood
16355784|NCT04287517|Active Comparator|Capacitive-Resistive Therapy Group|This group was treated with capacitive resistive diathermy and exercise
16355785|NCT04287517|Sham Comparator|Sham Group|This group was treated with sham capacitive-resistive diathermy and exercise
16355786|NCT04287504||Yeast, control|Women negative for vulvovaginal candidosis on Gram stain smear.
16355787|NCT04287504||Yeast, study group|Women positive for vulvovaginal candidosis on Gram stain smear.
16355788|NCT04287504||Bacterial vaginosis, control|Women negative for bacterial vaginosis on Gram stain smear.
16355789|NCT04287504||Bacterial vaginosis, study group|Women positive for bacterial vaginosis on Gram stain smear.
16355790|NCT04287491|Experimental|Virtual Reality Group|This group will receive the virtual reality intervention during out-patient bedside procedures.
16355791|NCT04287478|Experimental|Intravenous (IV)|Phage administered via the intravenous route.
16355792|NCT04287478|Experimental|Intravesical (IVS)|Phage administered via the intravesical route.
16355793|NCT04287478|Experimental|Subcohort A|Selected phage for E. coli administered via selected route based on previous Arms.
16355794|NCT04287478|Experimental|Subcohort B|Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
16355795|NCT04287478|Experimental|Subcohort C|Selected phage for E. coli administered via selected route based on previous Arms.
16355796|NCT04287478|Experimental|Subcohort D|Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
16355797|NCT04287452|Placebo Comparator|Control|Emergency department patients enrolled in the control arm will receive usual care. Emergency department providers enrolled in the control arm will work their shift as usual.
16355798|NCT04287452|Active Comparator|Intervention|Emergency department patients and providers in the intervention arm will be exposed to and/or interact with a certified therapy dog and handler
16355799|NCT04287439|Experimental|Relaxation|"Patients will receive a training session for progressive muscle relaxation exercise.
~They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence."
16355800|NCT04287439|Experimental|Meditation|Patients will receive a training session for minfullness meditation They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
16355801|NCT04287439|Active Comparator|Attention matched control group|Patients will receive a training session focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods.
16355802|NCT04287426|Active Comparator|Group receiving rocuronium at induction|Rocuronium 0,6 mg/kg at induction
16355804|NCT04287413|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
16355805|NCT04287413|Active Comparator|Usual care|The physician-led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, order diagnostic imaging, prescribe medications and/or refer based on their assessment findings and patient preferences.
16355806|NCT04287387|Experimental|Glucophage group|
16355807|NCT04287387|Experimental|Acarbose group|
16355808|NCT04287387|Experimental|Sitagliptin group|
16355809|NCT04287387|Experimental|Dapagliflozin group|
16355810|NCT04287387|Experimental|Pioglitazone group|
16355811|NCT04287387|Experimental|Glimepiride group|
16355812|NCT04287374|Experimental|Multi-component Well-being Intervention|Reading and writing activities based on cognitive restructuring (rephrasing automatic negative thoughts), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities)
16355813|NCT04287374|Sham Comparator|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
16355814|NCT04287361||Loading dose < 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam < 0.03 mg / kg
16355815|NCT04287361||Loading dose ≥ 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam ≥ 0.03 mg / kg
16355816|NCT04287348|Other|Beovu (Brolucizumab)|Prospective, one-treatment-arm, monocentre study
16355817|NCT04287335||High risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer
16355818|NCT04287335||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
16355819|NCT04287322|Experimental|Tactile-kinesthetic stimulation|Received tactile-kinesthetic stimulation three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
16355820|NCT04287322|Experimental|Recorded maternal voice|Listened to recorded maternal voice stimulation, three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
16355821|NCT04287322|No Intervention|Control|Received only standard nursery care
16355822|NCT04287296|Experimental|App users|The app users who are at least 18 years old.
16355823|NCT04287283||HBOT|Patients with chronic brain injury or cognitive complaints that have been treated with Hyperbaric oxygen therapy and underwent computerized cognitive tests before and after the treatment
16355824|NCT04287270|Other|Assesment of MSA patients and healthy controls|Demographic information (sex, age, occupation, height, bodyweight ...), clinical and medical status, diagnosis date and Mini-Mental Status Scale data of all participants will be recorded at the first visit. Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure and maximal inspiratory mouth pressure, expiratory muscle strength will be evaluated with expiratory mouth pressure. Also, the pulmonary function test will be applied.
16355825|NCT04287257|Active Comparator|Standard treatment + Active FHP|The PEMF device - FHP (supplied by commercial support) will be placed under the cast in the ER after diagnosing the fracture and will be applied for 24 hours a day continuously for 30-40 days.
16355826|NCT04287257|Sham Comparator|Standard treatment + Sham FHP|Half of the PEMF devices will be not activated at random before the application to the patients. Two types of activators will be provided by the company: active and sham. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device. The company supplying the PEMF-devices will have no knowledge of patient outcome.
16355827|NCT04287244|Experimental|Active tSDCS|Anodal tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (designed by Sooma). The anode will be positioned over the spinal cord area at the level of the spinous processes of 10th-11th thoracic vertebra.
16355828|NCT04287244|Sham Comparator|Sham tSDCS|Sham stimulation will be delivered to the same spinal cord area using a sham tSDCS device that delivers a direct current for 10 seconds at the beginning and end of tSDCS to provide sensory experiences similar to active stimulation.
16355829|NCT04287231|Experimental|Dual-tDCS & PT|Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about 1 hours). Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program for lower limb performence.
16355830|NCT04287231|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performence.
16355831|NCT04287218|Experimental|TG-iConquerFear|The participant is guided through the web-based sessions by minimum weekly contact with an experienced therapist (estimated ½ hour/week for 10 weeks). The therapist will motivate, answer questions and give feedback on written material and exercises.
16355832|NCT04287218|Active Comparator|Augmented treatment as usual|"The control group is described as augmented treatment as usual (aTAU), since the diagnostic telephone interview exceeds standard treatment. Further more, the participants will be referred to a website with a non-guided, publicly available E-learning program in cancer rehabilitation hosted by the Region of Central Jutland (livogkraeft.rm.dk). In addition to written material the website includes self-help instructions for meditation."
16355834|NCT04287192|No Intervention|Control|Control: Control participants will complete surveys at 4 time points (baseline, 1-2 weeks, 1 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, and assess their quality of life. Aside from completion of these surveys, no changes to their usual care will occur.
16355835|NCT04287192|Experimental|(Digital Bridge intervention)|"Experimental (Digital Bridge intervention) participants will complete surveys at 4 time points (baseline, 1-2 weeks, 1 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, assess their quality of life, and goal attainment.
~One to two days before discharge, patients will work with their team to develop the PODS in Care Connector. Once the PODS is created, the patient and hospital provider will be prompted to set transition goals using the ePRO tool."
16355836|NCT04287179|Experimental|Semaglutide 0.50 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.
16355837|NCT04287179|Active Comparator|Semaglutide 0.25 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.
16355838|NCT04287153|Experimental|Croytherapy on abdomen and saddlebags|Six (6) to 10 applicators (application area of 17 cm X 6 cm) are applied on the dorsal side (back, waist, saddlebags) for 45 minutes and then on the ventral side (belly) for 45 minutes, with adjustments according to the size of the participant. The temperature applied with the device is variable (-10°c to -7°C).
16355839|NCT04287140|Experimental|Saline|1000 ml of 0.9% normal saline bolus over one hour.
16355840|NCT04287140|No Intervention|No Saline|10 ml of 0.9% normal saline over one hour.
16355841|NCT04287114|Experimental|Healthy young men and women|Single group consisting of 10 men and 10 women
16355842|NCT04287101|Experimental|home PAC|A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
16355843|NCT04287101|Active Comparator|hospital PAC|A rehabilitation PAC team will care for patients in the hospital within 3 weeks after acute hospitalization. The patient will have 1 to 2 session(s) of PT or OT on weekdays, and a daily physician visit and nurse care.
16355844|NCT04287101|No Intervention|conventional care group|usual care
16355845|NCT04287088|No Intervention|Control|After IMPROD bpMRI all men undergo prostate biopsies. In men with Likert scores of 1-2, TRUS guided systematic biopsies are performed. In men with Likert 3-5 score, in addition to systematic biopsies, two targeted biopsies are taken from each lesion (up to two lesions).
16355846|NCT04287088|Experimental|Intervention|After IMPROD bpMRI prostate biopsies are performed according to shared decision-making by the treating urologist and the patient. If biopsies are to be performed, in men with IMPROD bpMRI likert scores of 1-2, 12-core systematic TRUS guided biopsies are performed and in men with Likert 3-5 score lesions systematic biopsies are performed and two targeted biopsies are taken from each lesion (up to two lesions). If biopsies are not performed, men are referred for a PSA follow-up.
16355847|NCT04287075||Surgery|Participants who elect to undergo surgery for the treatment of their chronic, neuropathic pain
16355848|NCT04287075||Non-surgery|Participants who elect to not have surgery for the treatment of their chronic, neuropathic pain
16355849|NCT04287062|Placebo Comparator|Placebo|Placebo sleep medication (2 placebo oral capsules)
16355850|NCT04287062|Active Comparator|Suvorexant|Sleep medication (20mg suvorexant; 2 10mg capsules; patients can self-titrate to 1 10mg capsule)
16355851|NCT04287049|Experimental|14 Day Azithromycin Monotherapy|For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
16355852|NCT04287036|Experimental|Test/Control|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Test/Control
16355853|NCT04287036|Experimental|Control/Test|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Control/Test.
16355854|NCT04287023|Experimental|Group Physical therapy|1 physical therapists and groups of 10 patients during the sessions
16355855|NCT04287023|Active Comparator|Individual physical therapy|1 physical therapist and 1 patient during the sessions
16355856|NCT04286997|Experimental|GRAIL population|patients are treated with 20 sessions of GRAIL rehabilitation, associated to 20 traditional physiotherapy sessions (1+1 a day, during a period of 30 days)
16355857|NCT04286997|Active Comparator|traditional population|subjects are treated with 40 sessions of traditional physiotherapy (2 a day, during a period of 30 days)
16355858|NCT04286984||Pre-upPBM|Patients with a diagnosis of gastric cancer before the upPBM implementation in their attending center
16355859|NCT04286984||Post-upPBM|Patients with a diagnosis of gastric cancer after the upPBM implementation in their attending center
16355860|NCT04286958|Experimental|Camrelizumab|All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
16355861|NCT04286945|Other|SENSORY EXOTROPIA PATIENTS WITH LARGE ANGLES .|Patients with monocular low vision or loss of vision due to congenital or acquired cause with exodeviation of the poorly seeing eye ≥ 50PD, were included in the study.
16355862|NCT04286932||5-12y|
16355863|NCT04286919|Active Comparator|ExRx#1: Physical Activity Guidelines|ExRx#1 uses the Frequency, Intensity, Time, and Type or FITT principle of exercise prescription to prescribe the Physical Activity Guidelines for Americans which is a weekly goal of 150-minutes of moderate intensity aerobic physical activity plus 2 days of muscle strengthening physical activity. ExRx#1 communicates the ultimate goal of the physical activity guidelines for Americans using an image adopted from the physical activity guidelines website that depicts the weekly goal. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the physical activity guidelines ultimate weekly goal by providing a weekly prescription of Frequency, Intensity, Time, and Type of physical activity that accomplishes meeting the physical activity guidelines weekly goal.
16355902|NCT04286581|Active Comparator|Ambu Auragain Laryngeal mask airway|Group 2 will receive the Ambu Auragain Laryngeal Mask Airway for airway maintenance during general anesthesia
16356047|NCT04285645|No Intervention|Control group|Athletes included in the control group will continue with their usual training routine.
16355864|NCT04286919|Experimental|ExRx#2: Heat Map|ExRx#2 uses the heat map image published in the 2018 Physical Activity Guidelines Advisory Committee Scientific Report that communicates the dose-response relationship between increased physical activity and improved health to prescribe the message that all physical activity across all Frequencies, Intensities, Time bouts and Types (FITT) counts towards health. ExRx#2 is founded in the Integrated Behavior Change Theory and emphasizes that all physical activity matters regardless of FITT as depicted by the heat map image. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the ExRx#2 heat map ultimate weekly goal of moving more throughout the day across all intensities in order to achieve optimal health as represented by the deep green color on the bottom right of the heat map image.
16355865|NCT04286906||One group (cohort)|Asthmatic patients
16355866|NCT04286893||TAVI group|Consecutive patients undergoing TAVI
16355867|NCT04286880|Experimental|TEST GROUP|Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle.
16355868|NCT04286880|Active Comparator|CONTROL GROUP|In control group, dry needling will be performed.
16355869|NCT04286867|Experimental|Alcohol Moderation Group 1|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
16355870|NCT04286867|Active Comparator|Alcohol Moderation Group 2|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
16355871|NCT04286841||Neoadjuvant immunotherapy|
16355872|NCT04286828||Females with Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
16355873|NCT04286828||Healthy Females|20 healthy volunteers with matching ages and genders.
16355874|NCT04286815|Experimental|Experimental Group|a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency）.
16355875|NCT04286802|Experimental|Salt-meter|Patients received salt-meter in conjunction with dietary education by trained dietician to help monitoring the salt content in food, as well as usual care by their primary physicians.
16355876|NCT04286802|Active Comparator|Control|Patients received dietary education by trained dietician and usual care by their primary physicians.
16355881|NCT04286776|Experimental|Direct Electrical Stimulation|Stimulation will be applied concurrently with the task, if applicable, and stimulation trials will be interleaved with sham trials, where no stimulation is delivered.
16355882|NCT04286763||Hilar stricture|Bile duct Stricture (corresponding to E3, E4 and E5 from of Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
16355883|NCT04286763||Low level Stricture|Bile duct Stricture (corresponding to E1 and E2 from Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
16355884|NCT04286750|Experimental|ACT-1004-1239 Dose level 1 (30 mg) to 5|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
16355885|NCT04286750|Placebo Comparator|Placebo|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
16355886|NCT04286737|Experimental|Intervention Group|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
16355887|NCT04286737|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
16355888|NCT04286724|Experimental|Intervention|
16355889|NCT04286711|Experimental|Albumin-paclitaxel Combined With Apatinib and Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day; Repeat the therapeutic schedule every 3 weeks
16355890|NCT04286698|Active Comparator|Complex decongestive physiotherapy program group|Manuel lymph drainage, compression mask, exercises and skin care
16355891|NCT04286698|Active Comparator|Home program group|Self-manuel lymph drainage and home exercises
16355892|NCT04286698|No Intervention|Control group|No intervention
16355893|NCT04286672||Group 1:|• 35 bladder cancer patients diagnosed by biopsy before treatment.
16355894|NCT04286672||Group 2:|35 apparently healthy individuals who were matched by age and sex .
16355895|NCT04286659||Control Group|90 Apparently healthy individuals
16355896|NCT04286659||IBD group|90 Previously or Newly Diagnosed Ulcerative Colitis and Crohn's disease
16355897|NCT04286646||Pupil diameter before/after cataract|The investigators measure the pupil diameter before and after (3 months) cataract. Mesopic and photopic conditions
16355898|NCT04286607|Experimental|ARQ-151 Cream 0.3%|
16355899|NCT04286594|Experimental|CBD|0.5ml of sublingual CBD solution (30mg/ml) administered twice daily for six weeks.
16355900|NCT04286594|Placebo Comparator|Placebo|Matched placebo solution administered twice daily for six weeks.
16355901|NCT04286581|Experimental|Igel Larnygeal Mask Airway|Group 1 will receive the I-Gel Laryngeal Mask Airway for airway maintenance during general anesthesia
16355903|NCT04286568|Experimental|WOW Intervention|"Participants will receive blood pressure monitor and health passport to record blood pressure readings for 3 months.
~Participants will receive daily text message reminders to take and record blood pressure readings.
~Participants will receive health education and health care navigation. Participants will be assessed for social determinants of health. Participants will take surveys 3 times over 3 months. Participants will receive home visits or phone calls to collect data and receive health coaching."
16355904|NCT04286555|Active Comparator|DASH4D diet with lower sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 1500 mg/day
16355905|NCT04286555|Active Comparator|DASH4D diet with higher sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 3700 mg/day
16355906|NCT04286555|Active Comparator|Comparison diet with lower sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 1500 mg/day
16355907|NCT04286555|Other|Comparison diet with higher sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 3700 mg/day
16355908|NCT04286542|Experimental|Provocation with cold air|Participants will be exposed to cold dry air for 15 minutes
16355913|NCT04286516|Experimental|Reaching with TMS|All participants enrolled in this group will receive TMS while performing reaching movements in a robotic system.
16355914|NCT04286503|Experimental|Carrimycin|basic treatment + Carrimycin
16355915|NCT04286503|Active Comparator|lopinavir/ritonavir or Arbidol or chloroquine phosphate|any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
16355916|NCT04286490|Experimental|Prone position|
16355917|NCT04286477||15 conventional hemodialysis patients|15 patients undergoing hemodialysis with high-flux dialyzer
16355918|NCT04286477||15 patients undergoing online-hemodiafiltration|15 patients undergoing conventional hemodialysis with high-flux dialyzer will be allocated to online-hemodiafiltration with the same dialyzer
16355919|NCT04286477||15 patients undergoing expanded hemodialysis with MCO dialyzer|15 hemodialysis patients undergoing hemodialysis with a high-flux dialyzer will be allocated to HDx with an MCO dialyzers (THERANOVA dialyzer, Baxter International Inc. (NYSE: BAX))
16355920|NCT04286477||15 patients undergoing peritoneal dialysis|15 patients undergoing peritoneal dialysis
16355921|NCT04286464||Term born group (H)|Healthy, white and term Born infants and Children Born 38-42 weeks postconceptional
16355922|NCT04286464||Preterm group (P)|Healthy, white preterm Born infants and Children Born <37 weeks postconceptional Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD)
16355923|NCT04286464||Risk pregnancy group (RP)|White preterm Born infants and Children, including Twins Born <37 weeks postconceptional With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE) With gestational Diabetes (GDM) With IVF or Amnion dysfunction
16355924|NCT04286451|Experimental|Sleep Restriction|Women will undergo 4 nights of sleep restriction treatment.
16355925|NCT04286451|Experimental|Habitual Sleep|Women will undergo 4 nights of habitual sleep treatment.
16355926|NCT04286438|Experimental|Bentracimab (PB2452) Infusion - Open Label Active Drug|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. Patients with uncontrolled major or life-threatening bleeding.
~Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients in need of urgent surgery or invasive procedure."
16355927|NCT04286425|Placebo Comparator|Placebo|"500 µl of saline solution applied in the vaginal volt twice :
~one month before the IVF procedure during the ovulation period
~Same month of the IVF procedure after ovum pick up"
16355928|NCT04286425|Active Comparator|seminal plasma|"500 µl of seminal plasma applied in the vaginal volt twice :
~one month before the IVF procedure during the ovulation period
~Same month of the IVF procedure after ovum pick up"
16355929|NCT04286412|Experimental|Treatment Arm|At least twenty five eligible male subjects will be enrolled in the treatment arm to receive Nonacog alfa until 16 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
16355930|NCT04286399|Other|Intensive Treatment Group|High dose of RAASi and beta-blockers (unless contraindicated) as well as preferential use of SGLT2i as per local drug label guidelines on top of standard therapy.
16355931|NCT04286399|No Intervention|Control Group|Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.
16355932|NCT04286386||Arm Ia (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy.
16355933|NCT04286386||Arm Ib (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy and at a second time 3-4 weeks after.
16355934|NCT04286386||Arm II (MRSI, surgery)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy, followed by standard of care surgery within 6 months after.
16355935|NCT04286373|Experimental|Active stimulation then placebo stimulation|"VNS active for 12 weeks, then VNS placebo for 12 weeks.
~The VNS placebo stimulation period being the control one."
16355936|NCT04286373|Experimental|Placebo stimulation then active stimulation|"VNS placebo for 12 weeks, then VNS active for 12 weeks.
~The VNS placebo stimulation period being the control one."
16355965|NCT04286217||Pre-existing HTN; de novo HDP, PE type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
16356119|NCT04285008|Other|Pure-Vu System|Intervention - Colonoscopy procedure using Pure-Vu System
16355937|NCT04286347|Experimental|HCV, HBV, HIV testing|All patient ≥ 18 years-old with a next planned surgery in Lariboisiere Hospital, Paris, France, able to give written informed consent for testing will be proposed to be tested for HIV and HCV if no previous testing found in the medical record and will be proposed to be tested for HBV if the patient belong to a high-risk group: high prevalence area (Asia, sub-Saharan Africa, French Indies, East and South Europe, North-Africa, Middle-East, India, Pakistan, South-America), IVDU, prisoners, unprotected sexual intercourses.
16355938|NCT04286334|Active Comparator|Group A - control Group|Customized titanium mesh without collagen membrane 15 patients will undergo bone regeneration with custom-made mesh without a collagen membrane. (Meshes - 3D-mesh BTK, Biotec, Vicenza, Italy.) Digitally designed by an operator before the surgery (digital technique).
16355939|NCT04286334|Experimental|Group B - Test Group|Customized titanium mesh with collagen membrane 15 patients will undergo bone regeneration with a custom-made titanium mesh (BTK, Biotec- Vicenza, Italy). Digitally designed by an operator before the surgery (digital technique), covered by collagen membrane (Cytoplast RTM, Osteogenics, deore materials, Verona, Italy).
16355940|NCT04286321|Experimental|Zero hard-boiled egg|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
16355941|NCT04286321|Experimental|Two egg whites|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two egg whites (0 g fat) prior to the 72-h pharmacokinetics trial.
16355942|NCT04286321|Experimental|Two hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.
16355943|NCT04286321|Experimental|Vegetable oil|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with vegetable oil (9.6 g fat) prior to the 72-h pharmacokinetics trial.
16355944|NCT04286308|Experimental|Brain signal data collection|Brain signal data collection at the time of deep brain stimulation (DBS) surgery.
16355945|NCT04286295|Experimental|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
16355946|NCT04286295|Active Comparator|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
16355947|NCT04286282|Active Comparator|Standard of Care|The first 100 participants with HIV and depression will receive standard of care including SSRI therapy.
16355948|NCT04286282|Experimental|Standard of Care + Group Support Psychotherapy|The second 100 participants with HIV and depression will receive standard of care, including SSRI therapy, and group support psychotherapy.
16355949|NCT04286282|Active Comparator|Standard of Care (Non-Depressed)|100 participants with HIV and without depression will receive standard of care therapy for HIV and no depression treatment.
16355950|NCT04286269|Experimental|Intervention|Participants in this group will be randomized to receive the intervention.
16355951|NCT04286269|Sham Comparator|Placebo|Participants in this group will be randomized to receive a sham treatment.
16355952|NCT04286256|Experimental|Treatment Group|The treatment group received motivational interviewing.
16355953|NCT04286256|No Intervention|Control Group|The control group received standard information only.
16355954|NCT04286243|Active Comparator|Model 1 - Clinic Based Screening|Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
16355955|NCT04286243|Experimental|Model 2 - Community Based Screening|Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
16355956|NCT04286217||No prior hypertension (HTN); no HDP in pregnancy|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
16355957|NCT04286217||No prior HTN; de novo HDP, GH type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
16355958|NCT04286217||No prior HTN; de novo HDP, GH type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
16355959|NCT04286217||No prior HTN; de novo HDP, PE type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
16355960|NCT04286217||No prior HTN; de novo HDP, PE type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
16355961|NCT04286217||No prior HTN; no HDP in pregnancy; postpartum HDP|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
16355962|NCT04286217||Pre-existing HTN; no HDP in pregnancy|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
16355963|NCT04286217||Pre-existing HTN; de novo HDP, GH type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
16355964|NCT04286217||Pre-existing HTN; de novo HDP, GH type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
16355966|NCT04286217||Pre-existing HTN; de novo HDP, PE type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
16355967|NCT04286217||Pre-existing HTN; no HDP in pregnancy; postpartum HDP|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia,with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
16355968|NCT04286217||Other causes of macular injury leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury leading to HDP, either gestational hypertension or preeclampsia
16355969|NCT04286217||Other causes of macular injury not leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury not leading to HDP
16355970|NCT04286204|Experimental|Basic Life Support Training based on ICTs|It will be conformed with students from one highschool random selected. They will receive a basic life support training based on Information and communication technologies.
16355971|NCT04286204|Active Comparator|Classic Basic Life Support Training|It will be conformed with students from another highschool random selected. They will receive a full and conventional basic life support training based on American and Hear Association recommendations.
16355974|NCT04286178|Experimental|Treatment|patients in this arm will be treated with creatine and coenzyme Q10 supplements
16355975|NCT04286178|Placebo Comparator|Placebo|patients in this arm will be given placebo supplements that look and taste identical to the active supplements
16355976|NCT04286165|Active Comparator|BPS webSTAIR 6 Levels with Per Support|Participants in BPS webSTAIR will complete a baseline, posttreatment and 2-month follow-up assessment. In the BPS webSTAIR condition, participants will first complete a welcome module to orient them to the program. After randomization, participants will have 10 weeks to complete the 6 modules. Every time the Veteran logs on they will have the opportunity to engage with a Veteran peer for support through the web program. Contacts can last for up to an hour. Veterans will receive a series of automated reminders and engagement emails that the Vets Prevail program sends at various points in the program.
16355977|NCT04286165|No Intervention|Wait List|In Wait list, they will be asked to go about your life as usual. They will be asked not to participate in any other programs for PTSD or depression symptoms for 10 weeks. After the 10 weeks you can begin any other program for PTSD or depression. They will also be given the option of participating in BPS webSTAIR or be provided with information about other web-based programs that might be of interest or relevant to them.Participants in the WL condition will complete a baseline, a second assessment at the 10th week, conclude their involvement in the study and be offered the Vets Prevail coping program. During their time in the study wait list participants are asked to not seek any treatment from VetsPrevail or other entities for a period of 10 weeks. They are instructed to simply go about their lives as normal.
16355978|NCT04286152|Experimental|Mirabegron and narcotic analgesia|Drug: Mirabegron 50mg tablet, oral, daily from stent insertion until removal - 7days Drug: Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
16355979|NCT04286152|Placebo Comparator|Placebo|Drug: Placebo for Mirabegron, 1 tablet, oral, daily from stent insertion until removal - 7days Drug:Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
16355982|NCT04286126|Active Comparator|bilateral DMPFC|This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.
16355983|NCT04286126|Active Comparator|right OFC|This arm will receive continuous theta-burst stimulation to the right OFC site.
16355984|NCT04286113|Active Comparator|Control group|Participants will receive non-personalized information (one-size-fits-all) diet, sleep and physical activity recommendations via messaging delivered by app.
16355985|NCT04286113|Experimental|Intervention Group|Participants will receive personalized messages about achieving healthy diet, physical activity and sleep as well as summary of their performance for the week and month. They will also receive personalized content about research volunteerism and altruistic activities.
16355986|NCT04286087|Experimental|Investigational Arm|
16355987|NCT04286087|Active Comparator|Control Group|
16355988|NCT04286074|Experimental|Experimental group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.
~Prior to training, the muscle training technique will be performed against a resistance of 50% of the maximum inspiratory pressure of each athlete"
16355989|NCT04286074|Active Comparator|Control group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.
~Prior to training, the muscle training technique will be performed against a resistance of 10% of the maximum inspiratory pressure of each athlete"
16355990|NCT04286061|Experimental|Experimental group|Each session will last 1 or 2 minutes, with one intervention being carried out a week, over a period of 4 weeks. Prior to the start of training, the instrument-assisted soft tissue mobilization technique will be performed
16356120|NCT04284995|Experimental|Cohort 1|Cohort 1: 0.075 mg/kg RUC-4. 8 STEMI Patients will be enrolled.
16355992|NCT04286048|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session.
~Prior to training, each pitcher will perform his normal warm-up routine, notifying the investigator when he feels ready to perform the training. The intervention through weight implements will consist in the application of the protocol described by Fleising et al. The objective of the application of the technique is to produce an increase in the speed of the throws."
16355993|NCT04286048|No Intervention|Control group|Athletes included in the control group will conduct their training and activities on a daily basis
16355994|NCT04286035|Active Comparator|Femoral group|
16355995|NCT04286035|Active Comparator|Adductor group|
16355996|NCT04286022|Experimental|Speed Loss 20% Group|The SL20% group will carry out a program based on the limitation of the speed loss, allowing to perform the exercise only until a speed loss of 20% is achieved, following a similar methodology previously published (Pareja-Blanco et al., 2017). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 6-series routine with an open number of repetitions will be carried out twice, allowing as many repetitions as possible to perform until a 20% loss of execution speed is reached. The intensity of work will be 70% 1RM, resting 4 minutes between sets. As an only exercise, an elbow flexion (bicep curl) with dumbbell will be performed.
16355997|NCT04286022|Experimental|Reduced Rest Time Group|The RRT group will carry out a program based on the reduction of rest time between series, following a previously published methodology (Stragier et al., 2019). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 5 series routine with progressive repetition volume (3 to 7) at 70% 1RM will be performed twice, resting 15 seconds between sets and 150 seconds between each of the 2 blocks. The exercise to be performed will be an elbow flexion (bicep curl) with dumbbell.
16355998|NCT04285996|Other|All patients|Pilot study: All registered patients will undergo a PET scan using [18F]-FBA-A20FMDV2.
16356000|NCT04285970||Medullary injured|Injured Medullary users of manually driven wheelchairs for daily locomotion
16356001|NCT04285970||Healthy volunteers|Healthy volunteer with at least 2 hours' experience using a manual wheelchair
16356002|NCT04285957||pre-test Group|"Consecutive recruitment of 10 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.
~Inclusion criteria: age 18-90, stroke occurred within 3 months from enrollment; clinical stability (SIC = 0). The exclusion criteria are: stroke recurrence; visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the the patients' understanding of and the reliable answering to the two assessment tools"
16356003|NCT04285957||Validation Group|Recruitment of 60 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.Inclusion criteria: age 18-90, stroke occurred within 8 months from enrollment; clinical stability (SIC = 0). If the following criteria are present: visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the patients' understanding of and the reliable answering to the two assessment tools, the interview shall be carried out with a proxy
16356004|NCT04285944|Active Comparator|Study|
16356005|NCT04285944|No Intervention|Control|
16356006|NCT04285918||Cohort A|Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature)
16356007|NCT04285918||Cohort B|Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO
16356008|NCT04285905|Active Comparator|Enhanced standard of care|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner"
16356009|NCT04285905|Active Comparator|Group 2|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners"
16356010|NCT04285905|Active Comparator|Group 3|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners
~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
16356011|NCT04285905|Active Comparator|Group 4|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners
~Female partner delivered oral HIV self-testing kits for primary male partner"
16356012|NCT04285905|Active Comparator|Group 5|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners
~Female partner delivered oral HIV self-testing kits for primary male partner
~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
16356013|NCT04285892|Experimental|CAPA IVM|CAPA IVM is a 2-step In vitro Maturation system in which an additional culture step, in which the oocytes are kept in meiotic arrest by the presence of the C-type Natriuretic peptide (CNP) for 22-24 hours, is preceding the in vitro maturation step in which maturation medium is supplemented with amphiregulin (AREG). The 'IVM System' of Medicult-Origio is used as a base medium.
16356014|NCT04285892|No Intervention|Standard IVM|The IVM is performed as a single step protocol in which oocytes are immediately exposed to in vitro maturation medium for 30 hours. This is the current standard procedure in the clinical practice using the commercially available 'IVM System' of Medicult-Origio. Standard IVM medium: 10% HSA + 75mIU/ml FSH + 100mIU/ml hCG
16356015|NCT04285879|Experimental|BFR Exercise Group|"In addition to the standard ACL protocol, patients in this study will utilize the Owen Recovery Science exercise protocol for BFR [18]. The following guidelines will be followed concerning exercise progression, occlusion pressure and difficulties with volume achievement.
~A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study."
16356016|NCT04285879|No Intervention|Non-BFR exercise group|As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine
16356017|NCT04285866||Durvalumab Group|Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
16356018|NCT04285853|Experimental|Oxycodone Arm|"Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 rescue medications, in the Oxycodone arm will be placebo rescue medications.
~All participants will also receive the following as part of standard of care:
~Oral non-opioid (1000 mg acetaminophen), every 8 hours.
~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.
~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.
~Intraoperative education on post-surgical pain management."
16356019|NCT04285853|Placebo Comparator|Placebo Arm|"Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 rescue medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone rescue tablets.
~All participants will also receive the following as part of standard of care:
~Oral non-opioid (1000 mg acetaminophen), every 8 hours.
~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.
~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.
~Intraoperative education on post-surgical pain management."
16356020|NCT04285840|Other|Single arm study|To establish a standardized procedure for venous ACT sampling during atrial fibrillation ablation. Analyses will examine the relationship and agreement between venous and arterial ACTs.
16356021|NCT04285827|Experimental|CSL889 Cohort 1 (Dose 1)|CSL889 administered as a single IV infusion
16356022|NCT04285827|Experimental|CSL889 Cohort 2 (Dose 2)|CSL889 administered as a single IV infusion
16356023|NCT04285827|Experimental|CSL889 Cohort 3 (Dose 3)|CSL889 administered as a single IV infusion
16356024|NCT04285827|Experimental|CSL889 Cohort 4 (Dose 4)|CSL889 administered as a single IV infusion
16356025|NCT04285827|Experimental|CSL889 Cohort 5 (Dose 5)|CSL889 administered as a single IV infusion
16356026|NCT04285827|Experimental|CSL889 Cohort 6 (Dose 6)|CSL889 administered as a single IV infusion
16356027|NCT04285814||Normal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with normal results.
16356028|NCT04285814||Abnormal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with abnormal results.
16356029|NCT04285801||COVID-19 infection|critically ill patients with COVID-19 infection
16356030|NCT04285775||Insertion of Dialysis Catheter|Hospital inpatients planned for dialysis catheter insertion, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
16356031|NCT04285775||Removal of Dialysis Catheter|Hospital inpatients planned for dialysis catheter removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
16356032|NCT04285762||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA by a single surgeon from March 2016 to October 2018.
16356033|NCT04285749|Experimental|Fluvastatin|"Participants will receive Fluvastatin for 2 weeks.
~RNA-sequencing and gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision."
16356034|NCT04285736|Experimental|Group A Ivabradine Group|
16356035|NCT04285736|Active Comparator|Group B Control Group|
16356036|NCT04285723||alpelisib|Patients treated with alpelisib
16356037|NCT04285710|Other|Control|Subjects enrolled in the subject group will receive standard care treatment for infected diabetic wounds, including debridement surgery and wound dressings. However, in order to maintain consistency with the phototherapy arm, subjects within the control group will visit the clinic twice a week, with the first visit being for the debridement surgery, and the second visit being for clinical wound dressing redressing.
16356038|NCT04285710|Experimental|Phototherapy|For this intervention therapy, subjects enrolled in the experimental group will still receive standard care treatment for infected diabetic wounds. However, experiment group subjects will receive phototherapy treatments alongside standard care. A mobile pulsed laser device will be utilized to apply nanosecond pulsed 410 nm light onto both the cellulitis afflicted regions and open wound portions of a patient's infected diabetic ulcer wound twice a week over the course of the 3 month study. The device will be designed and produced by the Ji Xin Cheng Lab located at the Boston University Charles River Campus. Phototherapy sessions will occur twice a week, with the first session occurring after debridement surgery, and the second session occurring later in the week during clinical wound dressing redressing.
16356039|NCT04285697|Experimental|group 1|During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
16356040|NCT04285697|No Intervention|group 2 control|The pre-operative service sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form.
16356041|NCT04285684|Other|Ketamine, lactation|Lactating women--4 subjects, 2 dosage format: ketamine 0;5mg/kg and 1.0mg/kg IM at least 5 days apart.
16356042|NCT04285671|Experimental|Treatment (necitumumab, trastuzumab, osimertinib)|Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16356043|NCT04285658||Ureteroscopy|
16356044|NCT04285658||Percutaneous Nephrolithotomy|
16356045|NCT04285658||Shock Wave Lithotripsy|
16356046|NCT04285645|Experimental|Experimental group|Each session will last 15 minutes, taking place 2 days a week, over a period of 4 weeks. Prior to training, the exercise protocol will be carried out. Prior to the start of the intervention, the exercises to be performed will be explained to the participants and it will be verified that they are capable of performing them correctly.
16356048|NCT04285632|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of each training session.
~Prior to training, the Counter Movement Jump and Drop Jump exercises will be performed"
16356049|NCT04285632|No Intervention|Control group|Athletes included in the control group will continue with their usual warm-up routine.
16356050|NCT04285619|Experimental|Experimental group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
16356051|NCT04285619|Active Comparator|Control group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
16356052|NCT04285606|Experimental|Patient-led rehab group|Immobilization in arm sling for a short period time followed by patient-led shoulder exercises for rehab following reverse shoulder arthroplasty
16356053|NCT04285606|No Intervention|Supervised rehab group|Prolonged immobilization in arm sling followed by supervised physical therapy by therapists for rehab following reverse shoulder arthroplasty
16356054|NCT04285593|Experimental|Experimental group|"Each session will last 10 minutes, taking place two days a week, over a period of four weeks. The intervention will take place at the beginning of the training session.
~The players included in the experimental group will perform an exercise protocol with Bulgarian squats."
16356055|NCT04285593|No Intervention|Control group|The players included in the control group will continue with their usual warm-up routine.
16356056|NCT04285580|Experimental|Bimatoprost SR 10 μg|Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
16356057|NCT04285580|Other|LUMIGAN 0.01%|Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
16356058|NCT04285567|Experimental|VEN + G|Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
16356059|NCT04285567|Active Comparator|FCR/BR|Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
16356060|NCT04285554|Experimental|Hepatic Denervation|
16356061|NCT04285528|Experimental|General Anesthesia|The first group which will undergo general anesthesia, will be anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway will be inserted afterwards.
16356062|NCT04285528|Experimental|PFK group|The second group will undergo intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine will be added, this aims to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water for injection will be added to the mixture.
16356063|NCT04285515|Experimental|Lumateperone 42mg|Lumateperone 42mg administered once daily in the evening
16356064|NCT04285515|Placebo Comparator|Placebo|Matching placebo administered once daily in the evening
16356065|NCT04285502|No Intervention|CONTROL GROUP|patients without a drain
16356066|NCT04285502|Experimental|CASE GROUP|Patients a drain inserted
16356067|NCT04285476|Experimental|Signature of 10 microRNA|Signature of 10 miRNA in patients with Thyroid Cytologies of undetermined type and with a Bethesda classification 3, 4 or 5
16356068|NCT04285450|Experimental|Vitamin K 1mg|
16356069|NCT04285450|Placebo Comparator|Control|
16356070|NCT04285437|Experimental|massage|neonates are massaged by their mother during the first 2 months after birth.
16356071|NCT04285437|No Intervention|control|neonates are not massaged.
16356072|NCT04285424|Experimental|HSCT patients with acute steroid-resistant GI-related GVHD|Patients will receive 500ml fecal microbiota which were sprayed evenly on the entire colon through colonscopy or duodenal nutrition tube injection which collected from one unrelated healthy donors. Patients receiving FMT treatment will be followed for at least 1,3,5,7 days.Stool, blood and colonic mucosa samples will be serially collected and tested (before pre-treatment, 1,3,5,7 days after FMT).
16356073|NCT04285411|Experimental|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
16356074|NCT04285398|Other|Study Group 1|Four years follow up of patients with ophthalmic examination.
16356075|NCT04285398|Other|Study Group 2|Four years follow-up of patients with ophthalmic examination and mobility testing.
16356076|NCT04285385|Experimental|Aromatherapy|0.10 ml of lavender essential oil 30 minutes prior surgery
16356077|NCT04285385|Sham Comparator|Sham Aromatherapy|0.10 ml mineral oil 30 minutes prior surgery
16356078|NCT04285372|Experimental|Test group|No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
16356079|NCT04285372|Active Comparator|Control group|Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
16356080|NCT04285346|Other|Open-label|ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension
16356081|NCT04285333|Active Comparator|fascial iliaca|: A linear high frequency ultrasound probe (10-15MHz) was placed in a transverse direction over the anterior thigh below the inguinal ligament. We identified the femoral artery and the iliacus muscle lateral to it, covered by the fascia iliaca. The needle was inserted in plane and a 22 gauge, 50 mm needle was advanced until the tips placed underneath the fascia iliaca. Following negative aspiration, the local anesthetic solution was injected in 5mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine
16356082|NCT04285333|Experimental|Percapsular nerve group block|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine.
16356083|NCT04285320|Active Comparator|Intravesical antibiotic instillation|
16356084|NCT04285320|Active Comparator|Oral antibiotic suppressive therapy|
16356085|NCT04285307|Experimental|Study group|Study group
16356086|NCT04285294||RDEB patients with a cSCC|
16356087|NCT04285294||Non-RDEB patients with a SCC induced by ultraviolet radiation|
16356088|NCT04285294||Healthy donors without RDEB nor SCC|
16356089|NCT04285281|Experimental|Gabapentin|Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
16356090|NCT04285281|No Intervention|Control group|Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
16356091|NCT04285268|Experimental|Treatment (rituximab, venetoclax, bortezomib)|Patients receive rituximab IV on day -1 of cycle 1, then on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-14 and bortezomib IV or SC on day -1 of cycle 1, then on days 1, 8, and 15 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for rituximab and up to 26 cycles for venetoclax and bortezomib in the absence of disease progression or unacceptable toxicity.
16356092|NCT04285255|Active Comparator|Opioids anesthesia|received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
16356093|NCT04285255|Active Comparator|OFA|received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
16356094|NCT04285242||Participants with Cancer|Assessments and observations for up to 40 days with one overnight hospital stay.
16356095|NCT04285242||Healthy Volunteers - Group A|Assessments and observations for up to 2 days with one overnight hospital stay.
16356096|NCT04285242||Healthy Volunteers - Group B|Assessments and observations for up to 2 days.
16356097|NCT04285229|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind and extended treatment periods.
16356098|NCT04285229|Placebo Comparator|Placebo|Placebo given SC during the double-blind period and then ixekizumab will be given SC during the extended treatment periods.
16356099|NCT04285216|Experimental|Dry needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
16356100|NCT04285216|Active Comparator|Strain counter strain|Hot pack 10 minutes, stretching,Neck isometrics, Strain counter strain (S C S)
16356101|NCT04285203|Experimental|Educational Video|Participants were exposed to 2 educational videos in addition to standard of care education.
16356102|NCT04285203|No Intervention|Standard of Care|Participants received standard of care education.
16356103|NCT04285190|Experimental|The T89 treatment group|Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID(every morning and evening), for 10 days (Depending on clinical need and practicability, the use can be extended for up to 14 days).
16356104|NCT04285190|No Intervention|The blank control group|All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
16356105|NCT04285177||Horizontal muscle surgery|Patients suffering from esotropia or exotropia, will have medial/lateral rectus recession/resection
16356106|NCT04285177||Patients with Inferior Oblique Overaction|Will undergo inferior Oblique Myectomy
16356107|NCT04285177||Patients with combined horizontal and oblique muscle surgery|Having combined surgery
16356108|NCT04285138|Experimental|Phantom limb exercises|Participants in this group will be treated with routine physical therapy, mirror therapy and Phantom limb exercises. Treatment time: 1 hour
16356109|NCT04285138|Active Comparator|conventional treatment|In this group, participants will be treated by routine physical therapy and mirror therapy protocol. Treatment time: 35 minutes
16356110|NCT04285099|Experimental|PD patients with FOG after STN-DBS[A]|Initially started by A setting
16356111|NCT04285099|Experimental|PD patients with FOG after STN-DBS[B]|Initially started by B setting
16356112|NCT04285086|Experimental|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
16356113|NCT04285086|Active Comparator|Anagrelide|Capsules, Daily, p.o.
16356114|NCT04285073|Experimental|Paclitaxel-eluting graft|Single-arm
16356115|NCT04285060|Experimental|Training Group|All participants are assigned to the training group with the Samsung GEMS-H.
16356116|NCT04285034||Ribavirin only|"Patients will receive ribavirin in accordance with Nigerian treatment guidelines. Patients will either receive the McCormick regimen or the Irrua regimen.
~PK blood tests will be done on Day 1,2,5,6,10,11,12,13, discharge; Paxgene RNA blood test on day 1, 3, 5, discharge Haematocrit finger prick test on day 1,2, 5, 6, 10, discharge"
16356117|NCT04285034||Cardiocascular study only|Cardiac tests (NICAS (daily), ECG (Day 1, 5, 10, discharge), Echocardiogram (Day 1, 5, discharge), Ultrasound (Day 1, 3, 5, 7, 10), Endopat (Day 1 and discharge)) will be done throughout; Haematocrit finger prick test daily PAXgene RNA blood test on day 1, 5, discharge
16356118|NCT04285008|No Intervention|standard Colonoscopy|"Control arm
~Colonoscopy procedure using standard flushing and suctioning - standard of care"
16356121|NCT04284995|Experimental|Cohort 2|Cohort 2: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
16356122|NCT04284995|Experimental|Cohort 3|Cohort 3: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
16356123|NCT04284982|Experimental|Heavy resistance training program|
16356124|NCT04284969|No Intervention|Control arm|Patients treated according current practice of the inclusion center. If interventions are implemented locally (geriatric assessment, nutrition, physical activity) they may be proposed to the patient.
16356125|NCT04284969|Experimental|Intervention arm : PROADAPT program|Patients benefiting from the PROADAPT (interventional arm) program.
16356126|NCT04284956|Experimental|Proximal group|Proximal segment of saphenous veins are harvested from the thigh by No-Touch technique and randomized to bypass the left or right territory of coronary system
16356127|NCT04284956|Active Comparator|Distal group|Distal segment of saphenous veins are harvested from the shank of the ipsilateral leg by No-Touch technique and used to bypass the right or left territory of coronary system (depending on the randomizing result of the proximal segments)
16356128|NCT04284943|Active Comparator|Long limb Roux-en-Y reconstruction|Long limb Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
16356129|NCT04284943|Active Comparator|Conventional Roux-en-Y reconstruction|Conventional Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
16356130|NCT04284943|Active Comparator|Billroth II reconstruction|Billroth II reconstruction method follows subtotal gastrectomy for gastric cancer
16356131|NCT04284930|Experimental|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
16356132|NCT04284930|Active Comparator|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
16356133|NCT04284930|Active Comparator|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
16356134|NCT04284917|Experimental|Receive Carglumic Acid|Experimental Case_ Carglumic Acid
16356135|NCT04284904||matched sibling hematopoietic stem cell transplantation|aGVHD biomarker in matched sibling donor hematopoietic stem cell transplantation
16356136|NCT04284904||unrelated allogeneic hematopoietic stem cell transplantation|aGVHD biomarker in unrelated donor hematopoietic stem cell transplantation
16356137|NCT04284904||haploidentical hematopoietic stem cell transplantation|aGVHD biomarker in haploidentical donor hematopoietic stem cell transplantation
16356138|NCT04284878||A|patients with inflammatory bowel disease
16356139|NCT04284878||B|healthy subjects
16356140|NCT04284865|Experimental|Intervention group|The web platform includes three respiratory exercises: diaphragmatic breathing, thoracic expansion exercise and thoracic expansion exercise assisted upper limbs. It is suggested to do each of the three exercises once a day (AM and PM), four repetitions each. An electronic logbook is also available on the platform to record the duration and the type of others cardiorespiratory exercise of their choice (cycling, walking, using stairs, etc.) as well as strengthening (upper and lower body).
16356141|NCT04284852|Experimental|Experimental arm|Niraparib 200 or 300mg daily orally for 18 cycles unless disease progression or intolerable side effects (whichever occurs first)
16356142|NCT04284839|Active Comparator|Direct Oral Anticoagulation (DOAC)|Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
16356143|NCT04284839|Placebo Comparator|Vitamin K Antagonist|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
16356144|NCT04284826|Experimental|mitomycin C injection group|A submucosal needle injection of 4mL of a MMC preparation (0.5mg/mL) into the tearing esophageal wall after esophageal bougie dilation on refractory benign esophageal stricture
16356145|NCT04284813|Experimental|Telemedicine|Community Reinforcement and Family Training for first episode psychosis delivered via telemedicine (CRAFT-FT) with 6-8 weekly sessions of 60-minute therapy.
16356146|NCT04284787|Active Comparator|Arm I (AZA, VEN)|"INDUCTION THERAPY PHASE: Patients receive azacitadine IV over 10-40 minutes or SC on days 1-7 and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY PHASE: Patients receive azacitadine IV over 10-40 minutes or SC on days 1-7 and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment per physician discretion."
16356147|NCT04284787|Experimental|Arm II (AZA, VEN, pembrolizumab)|"INDUCTION THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitadine IV over 10-40 minutes or SC on days 1-7, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitadine IV over 10-40 minutes or SC on days 1-7, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment with azacitadine and venetoclax per physician discretion."
16356149|NCT04284761|Experimental|Biolen|Biolen bicalutamide implant. Single implantation. In situ until prostatectomy
16356150|NCT04284748|Experimental|Plyometric training with blood flow restriction|Routine physiotherapy program + Plyometric training with blood flow restriction, 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
16356188|NCT04284553|Experimental|Open Encounter + Sign-off alert|
16356189|NCT04284553|Experimental|Order Entry + Pre-commitment|
16356151|NCT04284748|Active Comparator|Plyometric training|Routine physiotherapy program + Plyometric training 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
16356152|NCT04284735|Other|Controls|Patients with RA and without ILD
16356153|NCT04284735|Other|Cases|Patients with RA and ILD
16356154|NCT04284722|Active Comparator|Metformin +|The study intervention involves the self-administration of metformin in the same dosage as the patient's regular dosage according to regular dosing schedule and randomization.
16356155|NCT04284722|No Intervention|Metformin -|The control group involves no intervention, which means cessation of oral metformin therapy 24 hours prior to surgery according to the local guidelines of the anesthesia department and the national anesthesiology guidelines.
16356156|NCT04284709|Experimental|exercise group|exergames with simultaneous cognitive-physical training
16356157|NCT04284709|Active Comparator|control group|multicomponent exercise intervention focused on physical and cognitive training
16356158|NCT04284696|Active Comparator|Verum|"patients with emesis gravidarum who take a chewing gum with vitamin C (verum) ad libitum several times daily for 2 weeks"
16356159|NCT04284696|Placebo Comparator|Placebo|"patients with emesis gravidarum who take chewing gum without vitamin C (placebo) ad libitum several times daily for 2 weeks"
16356160|NCT04284696|No Intervention|Nihil|patients with emesis gravidarum who do not use chewing gum during the study phase
16356161|NCT04284683|Experimental|Normal and overweight participants|"Healthy males and female, age 6 to 30. BMI range for participants age 6 to 18 is between 5th percentile to 85th percentile, overweight BMI between the 85 and 95th percentile, and obese, above the 95th percentile.
~BMI range for participants age 18 to 30 is between 18.5 to 24.9 for normal weight, 25-30 for overweight and above 30 for obese."
16356162|NCT04284670|Experimental|Eccentric treadmill training|The intervention group will perform an 8 week program, 2 sessions a week for a total of 16 sessions. training will be done on a designated negative gradient treadmill. first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
16356163|NCT04284670|Experimental|Control group|The control group will receive the same amount of training under neutral gradient surface(0%).The program will be 8 weeks while in each week there will be two exercise sessions and a total of 16 sessions. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. Training intensity will be 70%-80% out of maximal heart-rate.
16356164|NCT04284657|No Intervention|ARM I: Control group|Standard therapy alone
16356165|NCT04284657|Active Comparator|ARM II: PRAVASTATIN|Standard therapy and PRAVASTATIN 40 mg QD
16356166|NCT04284657|Active Comparator|ARM III: PRAV + Sodium Citrate|Standard therapy and PRAVASTATIN 40 mg QD and Sodium Citrate (up to 30 mL TID)
16356167|NCT04284644|Experimental|Group P|Patient received a dose of 1.5 mg/kg of Propofol slowly over 2 minutes for induction.
16356168|NCT04284644|Experimental|Group S|Patient received 8% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen.
16356169|NCT04284644|Experimental|Group C|Patient received 4% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
16356170|NCT04284618||assessment of radiographic angles on standardized films|On Standing standardized radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
16356171|NCT04284618||assessment of radiographic angles on off axis view films|On off axis view radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
16356174|NCT04284592|No Intervention|Control group|Patients do not receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
16356175|NCT04284592|Experimental|RIP group|Patients receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
16356176|NCT04284579|Experimental|time for cannulation|intravenous cannulation after sevoflurane induction
16356177|NCT04284566|Experimental|TAU + multicomponent treatment FIBROWALK|FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
16356178|NCT04284566|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option. Patients were offered the opportunity to participate in the next wave of group intervention at the end of the study (3 months).
16356179|NCT04284553|Experimental|Base Order Entry Alert|
16356180|NCT04284553|Experimental|Base Open Encounter Alert|
16356181|NCT04284553|Experimental|Order Entry + Follow-up booster Alert|
16356182|NCT04284553|Experimental|Open Encounter + Follow-up booster Alert|
16356183|NCT04284553|Experimental|Order Entry + Cold State outreach|
16356184|NCT04284553|Experimental|Open Encounter + Cold State outreach|
16356185|NCT04284553|Experimental|Order Entry + Simplified|
16356186|NCT04284553|Experimental|Open Encounter + Simplified|
16356187|NCT04284553|Experimental|Order Entry + Sign-off alert|
16356195|NCT04284540|Experimental|Adjuvant Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have undergone surgery
16356196|NCT04284540|Experimental|Definitive Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have not had surgery
16356197|NCT04284514|Experimental|AKB-9778 Ophthalmic Solution|Up to 4 daily dose levels of AKB-9778 Ophthalmic Solution will be evaluated. Doses will be administered in both eyes daily for 7 days.
16356198|NCT04284514|Placebo Comparator|Vehicle Control Ophthalmic Solution|Matched vehicle-control ophthalmic solution will be administered in both eyes daily for 7 days.
16356199|NCT04284501||Study|children with Migraine headache
16356200|NCT04284501||Control|Healthy children
16356201|NCT04284488|Experimental|APG-1387 in combination with Toripalimab|
16356202|NCT04284462|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
16356203|NCT04284462|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
16356204|NCT04284462|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
16356205|NCT04284462|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
16356206|NCT04284462|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
16356207|NCT04284462|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
16356208|NCT04284449||Enrolled Participants|This is a whole-practice precision medicine model in which a participant-specific Naturopathic treatment program is developed and implemented for older adults with cognitive complaints.
16356209|NCT04284436|Experimental|High Intensity Exercise|Treadmill exercise 4x per week at 80-85% HRmax.
16356210|NCT04284436|Active Comparator|Moderate Intensity Exercise|Treadmill exercise 4x per week at 60-65% HRmax.
16356211|NCT04284410|Experimental|CLASP-PE arm|
16356212|NCT04284397|Experimental|Critical Temperature 10 Torr (Lighter)|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356213|NCT04284397|Experimental|Critical Temperature 14 Torr (Lighter)|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356214|NCT04284397|Experimental|Critical Temperature 18 Torr (Lighter)|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356215|NCT04284397|Experimental|Critical Temperature 10 Torr (Light)|Subjects will perform exercise at ~300W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356216|NCT04284397|Experimental|Critical Temperature 14 Torr (Light)|Subjects will perform exercise at ~300W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356217|NCT04284397|Experimental|Critical Temperature 18 Torr (Light)|Subjects will perform exercise at ~300W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356218|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Lighter)|Subjects will perform exercise at ~200W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356219|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Lighter)|Subjects will perform exercise at ~200W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356220|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Lighter)|Subjects will perform exercise at ~200W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356221|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Light)|Subjects will perform exercise at ~300W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356222|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Light)|Subjects will perform exercise at ~300W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356223|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Light)|Subjects will perform exercise at ~300W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356224|NCT04284397|Experimental|Critical Temperature 10 Torr (Lighter) w/ Aspirin|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356225|NCT04284397|Experimental|Critical Temperature 14 Torr (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356226|NCT04284397|Experimental|Critical Temperature 18 Torr (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356227|NCT04284397|Experimental|Critical Temperature 10 Torr (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356228|NCT04284397|Experimental|Critical Temperature 14 Torr (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356229|NCT04284397|Experimental|Critical Temperature 18 Torr (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
16356230|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356231|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356232|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356233|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356234|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356235|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
16356236|NCT04284384||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years of age or older were invited to participate in HUNT4 70+.
16356237|NCT04284384||HUNT Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age or older were invited to participate in HUNT4 70+.
16356238|NCT04284358|No Intervention|Standard Instruction workshop|Standard instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and then attempt it themselves.
16356239|NCT04284358|Experimental|Technology Integrated Instruction workshop|Technology integrated instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application.
16356240|NCT04284345|Experimental|Saline Pd/Pa|Eligible subjects will undergo invasive coronary physiology measurements including whole cycle resting Pd/Pa, iFR, RFR, cFFR, Saline Pd/Pa and FFR
16356241|NCT04284319|Experimental|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
16356242|NCT04284293|Experimental|Group 1A|"Visual acuity of 20/200 or worse
~Single, unilateral, subretinal injection of 300,000 CNS10-NPC (n=3)"
16356243|NCT04284293|Experimental|Group 1B|"Visual acuity of 20/200 or worse
~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=3)"
16356244|NCT04284293|Experimental|Group 2|"Visual acuity between 20/80 and 20/200
~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=10)"
16356245|NCT04284280|Experimental|Early Routine Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) when feeds of 150 ml/kg/day are reached (120Kcal/kg/day)
16356246|NCT04284280|Active Comparator|Selective Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) only for weight gain less than 15g/kg/day after full feeds of 180 ml/kg/day are achieved (120 Kcal/kg/day). If milk of any infant in the selective fortification group gets fortified the volume will be decreased to 150 ml/kg/day to keep the total caloric intake equal.
16356247|NCT04284267|No Intervention|Healthy Control|This group consists of individuals with no psychiatric diagnosis.
16356248|NCT04284267|Experimental|Bipolar Group: Low-Dose TMS|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive low-dose TMS (i.e., 600 pulses).
16356249|NCT04284267|Experimental|Bipolar Group: High-Dose TMS|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive high-dose TMS (i.e., 1800 pulses).
16356250|NCT04284267|Sham Comparator|Bipolar Group: Sham TMS|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive sham TMS (i.e., not actual stimulation is applied though the sensations of actual stimulation are mimicked).
16356251|NCT04284254|Experimental|Phase 1: Dose Escalation|
16356252|NCT04284254|Experimental|Phase 2 - Expansion at MTD|
16356253|NCT04284241|Experimental|Intervention group|"Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. Parents also undergo and active health education by the investigator with the  Parents' Health-Education Handbook, and Handbook will be given to them. Handbook includes the knowledge of symptoms, hazards, epidemiology, risk factors, therapy, and prevention of pediatric urolithiasis, and also baby's right feeding methods. Follow up is made every year in the first three years, and the program is done as the baseline."
16356254|NCT04284241|No Intervention|Control group|Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Newborns' parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. But parents do not undergo active health education. And Handbook will not be given to them. However, a poster which has the same content as the Handbook is normally displayed in the maternity ward. Parents have the opportunity to see the poster, but without any special remind. Follow up is made every year in the first three years, and the program is done as the baseline.
16356255|NCT04284228|Experimental|Safety Evaluation Phase|Treatment with NEXI-001 T cells, derived from PBMCs of original HLA- matched HCT donor.
16356256|NCT04284228|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI-001 T cell product at the dose established from the Safety Evaluation Phase.
16356257|NCT04284215|Experimental|Albumin paclitaxel|"Albumin paclitaxel 40mg/m2/week was injected into normal saline at the same time as radiotherapy, once a week. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)] Repeat every cycle (21-28 days/cycle, minimum 2 cycles).
~Three-dimensional radiotherapy:
~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
16356258|NCT04284215|Active Comparator|Paclitaxel|"Paclitaxel 175 mg/m2 was injected into saline solution on the first day. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and on the second day. (Because toxicity and heart problems can replace DDP)]Repeated every cycle (21-28 days/cycle, minimum 2 cycles).
~Three-dimensional radiotherapy:
~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
16356259|NCT04284202|Experimental|PD-1 plus Dasatinib|
16356260|NCT04284176|Experimental|Mirrow therapy and action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. The first 15 minutes will include myrror therapy 6 activities and the remaing 45 minutes both unimanual and bimanual action-observation therapy activities.
16356261|NCT04284176|Experimental|Action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. There protocol includes both unimanual and bimanual action-observation therapy activities.
16356262|NCT04284163|Experimental|Gamification group|Problem solving based methodology
16356263|NCT04284163|Active Comparator|Traditional teaching group|Master lesson methodology
16356264|NCT04284150|Experimental|dexmedetomidine or Midazola treat supraventricular tachycardia|Comparison of efficacy of dexmedetomidine and Midazolam in the treatment of SVT
16356265|NCT04284137|Experimental|Modified FE-SaLiR|FE-SaLiR is based on modified Ba Duan Jin and Wu Qin Xi exercises that include low to moderate intensity age-tailored activities targeting different parts of the body, integrating breathing and mindfulness. A trained Community Health Worker will serve as the class instructor.
16356266|NCT04284137|Experimental|Unmodified Chinese Medicine Exercise|The Ba Duan Jin and Wu Qin Xi low- to moderate- intensity exercises published by the General Administration of Sport of China. A trained Community Health Worker will serve as the class instructor.
16356267|NCT04284137|Active Comparator|Active Control|The active control program is a health education program for attention control. The participants will learn knowledge and skills about healthy aging and nutrition in a group with hands-on activities.
16356268|NCT04284124|Active Comparator|Erector Spinae block|Done unilaterally with the patient in the prone position about 20 min before induction of general anesthesia. Skin is prepared by 10% povidone iodine. An ultrasound machine with a large bandwidth, multifrequency convex probe (1-8 MHz) will be used for block performance. A 22G, 50-mm, at the T4 level of the spine using an in-plane approach. Probe is placed 2-3 cm laterally to the spine using a sagittal approach. Once the erector spinae muscle and the transverse processes is identified, the needle will be inserted deep into the muscle. The needle will be directed from a cranial to a caudal direction. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of local anesthetic, 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic will be observed in both cranial and caudal directions.
16356269|NCT04284124|Active Comparator|PECS type II block|Done unilaterally, patient is put in the supine position with ipsilateral arm abducted and externally rotated with elbow flexed 90 degrees. High frequency probe is put in the ipsilateral clavipectoral triangle between the clavicle medially and above and the shoulder joint laterally. The pectoralis major and minor and the plane between them are identified guided by pulsating thoracoacromial artery or its pectoral branch. Needle is advanced in plane targeting the space where the artery is located, 2ml of normal saline is injected to confirm the location. Then, 10 ml of bupivacaine 0.25% is injected. Probe is moved laterally and caudally towards the anterior axillary fold parallel to the deltopectoral groove till the serratus muscle slips appear underneath the pec minor attached to the underlying ribs. Targeting the plane between pec minor and serratus at the level of the third rib, 2 ml of normal saline is injected for confirmation of the needle tip then 20 ml of bupivacaine 0.25%.
16356270|NCT04284111||Children with myopia|"A total of 1,000 children from 8 hospitals in China is required to undergo ophthalmic examinations and complete questionnaires at baseline and
~1yr after wearing ortho-k lenses."
16356271|NCT04284098|Placebo Comparator|GA group|Group I (GA group): Standard general anesthesia (GA) .
16356272|NCT04284098|Active Comparator|Bupivacaine group|Group II (B group): ultrasound-guided PECS block using bupivacaine 0.25% + standard GA.
16356273|NCT04284098|Active Comparator|Dexmedetomidine&bupivacaine group|Group III (D group): ultrasound-guided PECS block using bupivacaine 0.25% and Dexmedetomidine 1µg/kg+standard GA.
16356274|NCT04284085|Experimental|Intervention group|There will be psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
16357372|NCT04276740|Placebo Comparator|Placebo|Participants will take an oral matched placebo daily
16356275|NCT04284085|No Intervention|Control group|They will receive a fact sheet on suicide and also tips on how to increase suicidal ideation.
16356276|NCT04284072|Experimental|All subjects|Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.
16356277|NCT04284059|Active Comparator|vitamin AD group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin A 6000 IU/day and vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks.
16356278|NCT04284059|Experimental|vitamin D group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks. After the study, vitamin D group will be administrated with vitamin A on the basis of serum retinol concentration after the study.
16356279|NCT04284059|Placebo Comparator|placebo group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive placebo once a day in addition to methylphenidate for 8 weeks. After the study, the placebo group will be prescribed with vitamin A and vitamin D supplementation on the grounds of retinol and 25 (OH)D concentration.
16356280|NCT04284046||High CT score|
16356281|NCT04284046||Low CTscore|
16356282|NCT04284033|Experimental|Standard then Extended Infusion Set|Participants will start with wearing the standard infusion set for up to 7 days, then switch to the Extended Wear infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
16356283|NCT04284033|Experimental|Extended then Standard Infusion Set|Participants will start with wearing the Extended Wear infusion set for up to 7 days, then switch to the standard infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
16356284|NCT04284020|Experimental|Educational program & pelvic floor muscle training|"The educational strategy will consist of explaining a healthy lifestyle guide with videos, mobile apps and activities about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, high impact sports, constipation, smoking, or drinking too much caffeine and alcohol. They will also instruct in toilet habits.
~The pelvic floor muscle training (PFMT) protocol will be applied. Participants will perform exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.
~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
16356285|NCT04284020|Active Comparator|PFMT group|"They will receive a basic behavioral educational strategy in the first session including pelvic anatomy and physiology, recommendations to avoid risk factors and toilet habits.
~The PFMT protocol will be applied. Participants will perform PFMT exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.
~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
16356286|NCT04284007|Active Comparator|Perineural levobupivacaine with intravenous saline|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous saline.
16356287|NCT04284007|Experimental|Perineural dexamethasone in addition to levobupivacaine|Patients will receive levobupivacaine-dexamethasone in interscalene brachial plexus block plus intravenous saline.
16356288|NCT04284007|Experimental|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous dexamethasone.
16356289|NCT04283994|Experimental|Survey-based Patient/Clinician Jumpstart|The Survey-based Patient/Clinician Jumpstart Guide will be developed with two types of data: 1) EHR data; and 2) Survey data. Using automated methods and NLP/ML algorithms, the presence/absence of POLST, advance directives and DPOA documentation will be identified from both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. The survey data will be completed by patients or their surrogate/family at enrollment and will provide assessments of the following: a) preferences for discussions about goals of care; b) most important barrier and facilitator for having such discussions; and c) current goals of care. These elements are contained within the Jumpstart guides and the information is tailored to each recipient (i.e., patient, surrogate/family, or clinician).
16356290|NCT04283994|Active Comparator|EHR-based Clinician Jumpstart|The EHR-based Clinician Jumpstart Guide will be developed by using automated methods and NLP/ML algorithms to both inpatient and outpatient EHR notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation. It will not include survey-based information.
16356291|NCT04283994|No Intervention|Usual care|Patients in this arm receive usual care; neither subjects nor providers will receive either version of the Jumpstart Guide.
16356292|NCT04283981|Active Comparator|Control Group|
16356293|NCT04283981|Experimental|Treatment Group|
16356294|NCT04283968|Experimental|Treatment arm|All patients will receive 4 fecal microbial transplantations from healthy donors each 2 weeks apart
16356295|NCT04283968|Placebo Comparator|Placebo followed by treatment arm|All patients will receive 4 placebo fecal transplantations followed by 4 fecal microbial transplantations from healthy donors each 2 weeks apart
16356296|NCT04283942|Experimental|Intermittent Calorie Restriction (ICR)|Eat only instant nutrition bar in two consecutive days each week, 4 sticks / day, 1 for breakfast, 2 for lunch, 1 for dinner. And the total caloric intake is 497.2kcal/day. In the rest 5 days each week, subjects are allowed ad libitum to their usual food.
16356297|NCT04283942|Other|Control|Followed by NAFLD guidelines' recommendation of 25 kcal / kg / day, we only ask them to adjust their daily diet. No experimental foods or drugs are supplied.
16356298|NCT04283929|Experimental|Intervention 1 (Int1)|Facilities assigned to the enhanced package for Int1 will receive alerts and reminders to promote linkage of HIV positives from diagnosis to care.
16356299|NCT04283929|No Intervention|Control 1 (Ctrl1)|Facilities assigned to the Ctrl1 will not receive any additional equipment, software tools, training or other forms of support.
16356300|NCT04283929|Experimental|Intervention 2 (Int2)|Randomise the Intervention 1 group into two additional arms: Intervention 2 (Int2) and Control (Ctrl2). Facilities assigned to Int2 will also receive alerts and reminders to improve lab reporting as part of their enhanced package.
16356301|NCT04283929|No Intervention|Control 2 (Ctrl2)|Facilities assigned to the Ctrl2 will not receive any additional equipment, software tools, training or other forms of support to improve lab reporting as part of their enhanced EMR.
16356302|NCT04283929|Experimental|Intervention 3 (Int3)|Randomise the Intervention 2 group into two additional arms: Intervention 3 (Int3) or Control (Ctrl3). Facilities assigned to Int3 will receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
16356303|NCT04283929|No Intervention|Control (Ctrl3)|Facilities assigned to Ctrl3 will not receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
16356304|NCT04283916||Botox injection|30 consecutive patients will have 300 IU of botulinum toxin injected to six spots in abdominal wall to gain abdominal wall musculature relaxation.
16356305|NCT04283890|Experimental|Phase Ib|
16356306|NCT04283890|Active Comparator|Phase II - Combination treatment|
16356307|NCT04283890|Active Comparator|Phase II - PHP|
16356308|NCT04283877|Experimental|Methylphenidate|30 mg methylphenidate, 60 minutes before testing
16356309|NCT04283877|Placebo Comparator|Control|30 mg of lactose pill, 60 minutes before testing
16356310|NCT04283864||Group A|
16356311|NCT04283864||Group B|
16356312|NCT04283864||Group C|
16356313|NCT04283838|Experimental|Humanistic care|Psychological and physical rehabilitation based humanistic care regimen was used to prevent depression and PTSD in healthcare workers who participated in the treatment of COVID-19.
16356314|NCT04283825|Experimental|Humanistic care|In addition to routine therapy, the combinations of different psychological and physical rehabilitation activities will be applied to the patients.
16356315|NCT04283825|No Intervention|Non-humanistic care|Patients only receive routine therapy.
16356316|NCT04283812|Experimental|D1 Stereotactic System Assessment|Participants in the clinical study will consist of subjects approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic. Subjects will have a Key secured to their skull for attachment of an MRI-compatible localizer box or D1 stereotactic frame. 3D Euclidian distance error(s), trajectory accuracy(s), operating room time, and comfort level of the system will be assessed.
16356317|NCT04283799|Experimental|The new HMF group|Very preterm infants tolerating 80mL/kg/day of enteral feeding for >24 hours are started to receive the new human milk fortifier. Study procedure is from the first day of full-strength fortification feeding to the 21th days of that.
16356318|NCT04283799|No Intervention|Other HMF group|This group is a historical control group using the other HMF. Infants with similar gestational age, birth weight, feeding start time and length of hospitalization are enrolled into the control group.
16356319|NCT04283786||General Practitioner|General Practitioners working within primary care in the UK
16356320|NCT04283786||Primary Care Patients|Patients cared for in primary care who started on oral bisphosphonates within the last 24 months for prevention of fragility fractures
16356321|NCT04283786||Secondary Care Clinicians|Clinicians working in secondary care as specialists (e.g. nurses, consultants) involved in the treatment of osteoporosis
16356322|NCT04283786||Secondary Care Patients|Patients cared for in secondary care receiving hospital based (intravenous) bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months
16356323|NCT04283786||Clinical Academics|Clinical academics involved in osteoporosis research
16356324|NCT04283786||Secondary Care Clinicians - Novel Care|Clinicians working in secondary care as specialists (e.g. nurses, consultants) from the osteoporosis service in Nottingham and Sheffield with insight into alternate bisphosphonate treatments
16356325|NCT04283786||Secondary Care Patients - Novel Care|Patients cared for in secondary care receiving alternative bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months at the osteoporosis service in Nottingham or Sheffield
16356326|NCT04283786||Commissioners|Commissioners involved in osteoporosis services
16356327|NCT04283773||Malignant ovarian germ cell tumors ( MOGCTs).|22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
16356328|NCT04283773||Mature cystic teratomas.|20 cases of mature teratomas will be treated by anti P16 antibody .
16356329|NCT04283773||Normally apparent ovaries.|20 cases of normally apparent ovaries will be treated by anti P16 antibody .
16356330|NCT04283760||Healthy Group|"Demographic Information
~Mental Chronometry Test
~Movement Imagination Questionnaire- Revised Second
~Beck Depression Inventory"
16356331|NCT04283760||Acute Stroke Patients|"Demographic Information
~Mental Chronometry Test
~Movement Imagination Questionnaire- Revised Second
~Beck Depression Inventory
~Trail Making Test
~Barthel Index
~Motor Assessment Scale
~Trunk Impairment Scale
~Mini Mental Test
~Glaskow Coma Scale"
16356332|NCT04283734|Experimental|Intervention group|Long/diffuse coronary lesion should be evaluated and guided by iFR pullback with Syncvision software to achieve a final iFR of 0.90
16356333|NCT04283734|No Intervention|Control group|Long/diffuse coronary lesion should be treated guided by angiography
16356334|NCT04283721|No Intervention|No Video|These patients will not see the educational video on epidural/spinal analgesia and will receive the usual Irish standard of care.
16356335|NCT04283721|Experimental|Antenatal Video|These patients will see the educational video on epidural/spinal analgesia only at the antenatal classes.
16356336|NCT04283721|Experimental|Labour Video|These patients will see the educational video on epidural/spinal analgesia only at the beginning of labour.
16356337|NCT04283721|Experimental|Video Twice|These patients will see the educational video on epidural/spinal analgesia twice (during antenatal classes and at the beginning of labour).
16356338|NCT04283708|Experimental|Skeletal chin deficiency|Advancement genioplasty with submental liposuction
16356339|NCT04283695|Experimental|Part 1|IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
16356343|NCT04283682|Experimental|intervention group|At appropriate time to invite mothers of premature infants into the NICU for skin-to-skin and breastfeeding
16356344|NCT04283669|Other|Open Label Continuous Treatment|Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as >20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.
16356345|NCT04283656|Other|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
16356346|NCT04283656|Other|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
16356347|NCT04283656|Other|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
16356348|NCT04283643|Experimental|Healthy Human Subjects|Healthy human subjects will complete study procedures in the research lab at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation.
16356349|NCT04283643|Experimental|Acute Pain Patients|Acute Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
16356350|NCT04283643|Experimental|Chronic Pain Patients|Chronic Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
16356351|NCT04283630|Active Comparator|Randomization and Dietary supplement Interventions|The dietary nitrate supplement was provided in the form of commercial beetroot juice (Sport Beet IT shot, Heartbeet Ltd) for all participants, whereas vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the concentrated beetroot juice with breakfast meals, and then the vitamin C supplement (1000 mg)or placebo at the same time one-hour post beetroot juice supplementation
16356352|NCT04283630|Placebo Comparator|Placebo|Vitamin C placebo was matched with the active vitamin c capsules in shape, color, and size.
16356353|NCT04283617|Experimental|Diabetic with short duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes < 5 years
16356354|NCT04283617|Experimental|Diabetic with long duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes > 5 years
16356355|NCT04283604|Experimental|ADHD with MPH|ADHD participants, taking MPH before the second session
16356356|NCT04283604|No Intervention|ADHD no MPH|ADHD participants will perform motor tests in both session, without any intervention, for evaluation of learning effect among ADHD participants.
16356357|NCT04283604|No Intervention|Healthy participants|Non-ADHD participants will serve as a control group for learning effect on motor tests
16356358|NCT04283591|Experimental|Experimental Intervention|Acupuncture Treatment Group: will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week. They also will continue to receive the conventional rehabilitation programme.
16356359|NCT04283591|Other|No Intervention|Control Group: will be included in the conventional rehabilitation programme and no interventional procedures will be made.
16356360|NCT04283578|Experimental|Oxytocin|intranasal administration of OT
16356361|NCT04283578|Placebo Comparator|Placebo|intranasal administration of placebo
16356362|NCT04283565|No Intervention|Strategy 1: Usual practice|No systematic screening of asymptomatic AOMI and routine management of FRCV.
16356363|NCT04283565|Experimental|Strategy 2: Motivationnal interviewing|No systematic screening of asymptomatic AOMI and management of CVRF by a motivationnal interviewing.
16356364|NCT04283565|Experimental|Strategy 3: Systematic screening of AOMI by BPI measurement|Systematic screening of AOMI by BPI measurement and routine management of FRCV.
16356365|NCT04283565|Experimental|Strategy 4: Both strategies|Systematic screening of AOMI by BPI measurement and management of CVRF by a motivationnal interviewing.
16356366|NCT04283552|Experimental|Main Cohort: Dynamic PET Imaging|-Dynamic PET/CT imaging will begin at approximately the same time as the clinically prescribed radiotracer injection and will continue until approximately the start of the clinical scan
16356367|NCT04283552|Experimental|Repeatability Cohort: Dynamic PET Imaging|"Dynamic PET/CT imaging will begin at approximately the same time as the FDG or DOTATATE injection and will continue until approximately the start of the clinical scan
~A subset of patients (up to 30 scheduled to undergo FDG or DOTATATE PET/CT imaging) will be asked to return within 7 days for a repeat imaging study."
16356368|NCT04283539||CPI with ircAE|Participants on check point inhibitors with immune related cutaneous adverse event
16356369|NCT04283539||no ircAE|Participants who do not have a cutaneous adverse event
16356370|NCT04283526|Experimental|NIS793 + MBG453|treatment with NIS793 + MBG453
16356371|NCT04283526|Experimental|NIS793 + MBG453 + Spartalizumab|Treatment with NIS793 + MBG453 + Spartalizumab
16356372|NCT04283526|Experimental|NIS793 + MBG453 + Decitabine|treatment with NIS793 + MBG453 + Decitabine
16356373|NCT04283526|Experimental|NIS793|treatment with NIS793
16356374|NCT04283526|Experimental|MBG453|treatment with MBG453
16356436|NCT04283214|Experimental|Bariatric manikin with athletic equipment|CPR performed on a bariatric manikin wearing athletic equipment
16356437|NCT04283201|Experimental|Diet|
16356375|NCT04283513|Experimental|Efficacy of IV Ribavirin|The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
16356376|NCT04283500|Experimental|BUP treatment arm|Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.
16356377|NCT04283487|Experimental|Fructans solution|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody.The fructans solution used in this study is 500 ml water containing 40g fructans
16356378|NCT04283487|Active Comparator|Glucose solution|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a positive control in this study. The glucose solution used in this study is 500 ml water containing 40g glucose.
16356379|NCT04283487|Placebo Comparator|Saline solution|The saline solution does't contain any sugar and used in this study is 500ml 0.9% normal saline.
16356380|NCT04283474|Experimental|XG005-03|XG005-03 in 3 dose levels
16356381|NCT04283474|Placebo Comparator|Placebo|Placebo in all cohort
16356382|NCT04283461|Experimental|Arm 1|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)
16356383|NCT04283461|Experimental|Arm 10|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
16356384|NCT04283461|Experimental|Arm 11|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
16356385|NCT04283461|Experimental|Arm 12|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
16356386|NCT04283461|Experimental|Arm 13|10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
16356387|NCT04283461|Experimental|Arm 14|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle after Day 209 in participants from Arm 1,4,7,10, 11, and 12 from 18 years of age or older. N=70.
16356388|NCT04283461|Experimental|Arm 15|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle no later than Day 394 in participants from Arm 2,3,5 and 8 from 18 years of age or older. N=50.
16356389|NCT04283461|Experimental|Arm 2|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
16356390|NCT04283461|Experimental|Arm 3|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
16356391|NCT04283461|Experimental|Arm 4|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
16356392|NCT04283461|Experimental|Arm 5|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
16356393|NCT04283461|Experimental|Arm 6|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
16356394|NCT04283461|Experimental|Arm 7|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
16356395|NCT04283461|Experimental|Arm 8|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
16356396|NCT04283461|Experimental|Arm 9|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
16356397|NCT04283448|Experimental|Lentil|0.66 cups lentils
16356398|NCT04283448|Sham Comparator|Control|0.0 cups lentils
16356399|NCT04283435|Placebo Comparator|estradiol valerate + placebo|preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova) .from the first day of the cycle till 12th day and we add placebo from the first day of the cycle till the day of start progesterone (we stop 3 days before embryo transfer).
16356400|NCT04283435|Experimental|estradiol valerate + Sildenafil citrate|We add Sildenfil citrate 50 mg daily from the first day of the period till the day of starting the progesterone. and stop 3 days before the embryo transfer.
16356401|NCT04283422||patintes on mechanical ventilation|
16356402|NCT04283422||patintes not on mechanical ventilation|
16356403|NCT04283409|Experimental|Motor Control Exercise|The primary goal of motor control exercises is to retrain optimal control and coordination of the spine. It uses principles of motor learning such as segmentation, simplification and task-specific practice to retrain control of trunk muscles activation, alignment and movement. The first stage of the treatment involves assessment of the postures, movement patterns and muscle activation associated with symptoms and a retraining program designed to improve activity of muscles assessed to have poor control (usually the deep trunk muscles). Participants are taught how to contract these muscles independently. During this stage additional exercises for breathing control, posture of spine and movement are performed. The second stage of the treatment involves the progression of the exercises towards functional activities, firstly using static then dynamic tasks. Education is also included.
16356432|NCT04283227|Experimental|OTL-200 Gene Therapy|OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
16356433|NCT04283214|Active Comparator|Traditional manikin|CPR performed on a traditional manikin
16356434|NCT04283214|Experimental|Traditional manikin with athletic equipment|CPR performed on a traditional manikin wearing athletic equipment
16356404|NCT04283409|Experimental|Graded Activity|The primary goal of graded activity is to address individual modifiable contextual factors associated with the pain experience such as self-efficacy, pain-related fear, kinesiophobia and unhelpful beliefs/behaviors about back pain while at the same time addressing physical impairments such as endurance, muscle strength and balance. A primary goal of the program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. Activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Cognitive-behavioral principles are used to help patients overcome the natural anxiety associated with pain and activities.
16356405|NCT04283383|Experimental|Intervention training|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out, and the improvement of knowledge and skills will be evaluated, as well as the improvement of quality of care based on clinical indicators.
16356406|NCT04283383|No Intervention|control|
16356407|NCT04283370|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
16356408|NCT04283370|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
16356409|NCT04283357|Active Comparator|Exercise Group|One group only treated with short foot exercises.
16356410|NCT04283357|Active Comparator|Virtual Reality Group|The second group treated with virtual reality
16356411|NCT04283344|Experimental|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula: (1) a fixed deduction, depending on county of residence, for transportation costs for six round trips to the grocery store per month; and (2) an earnings deduction equal to 10 percent of earned income for households with at least one employed household member.
16356412|NCT04283344|No Intervention|Control Group|Households in the control group continued to receive their regular monthly SNAP benefit amounts.
16356413|NCT04283331|Experimental|Bandage Contact Lens + Proparacaine|The eye that receives a bandage contact lens soaked in proparacaine.
16356414|NCT04283331|No Intervention|Bandage Contact Lens WITHOUT Proparacaine|The eye that receives a bandage contact lens (standard of care).
16356415|NCT04283318|Other|Healthy|Age >18 years; BMI 20-27 kg/m2; Fasting plasma Glucose <110 mg/dL
16356416|NCT04283318|Other|Obese people|Age >18 years; BMI >30 kg/m2; Fasting Plasma Glucose <110 mg/dL
16356417|NCT04283318|Other|Type 2 Diabetes|Age >18 years; Diagnosed Type 2 Diabetes mellitus (diet or a monotherapy or combination of metformin, DPP-4-inhibitors or sulfonylurea)
16356418|NCT04283318|Other|Type 1 Diabetes|Age >18 years; Diagnosed Type 1 Diabetes mellitus >12 months; Treated with multiple daily Insulin injections (MDII) or continuous subcutaneous Insulin Infusion (CSII); Stable Insulin therapy as clinically assessed by the study physician C-Peptide negative defined as 0.3 nmol/L; No diabetic ketoacidosis within the last 12 months; No severe hypoglycaemia requiring external assistance within the last 12 months; Running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring
16356419|NCT04283305|Experimental|Virtual reality approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training in the virtual reality. Alcoholic beverages are pushed away with a controller and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
16356420|NCT04283305|Active Comparator|Computer-based approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training on the computer. Alcoholic beverages are pushed away with a joystick and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
16356421|NCT04283305|No Intervention|Treatment as usual|Participants will receive treatment as usual on the wards. For ethical reasons, participants in this condition will get the offer to undertake the already scientifically validated computer-based approach avoidance training after their completion of the study.
16356422|NCT04283292|Experimental|Capsaicin|capsaicin 0.075% cream applied once topically
16356423|NCT04283292|Active Comparator|Placebo|placebo cream applied once topically
16356424|NCT04283279|Experimental|Virtual reality exercise|20 participants will be randomised to this arm
16356425|NCT04283279|Experimental|Vestibular rehabilitation exercise|20 participants will be randomised to this arm
16356426|NCT04283279|Other|Control|20 participants will be randomised to this arm
16356427|NCT04283266|Active Comparator|Synbiotic group|The synbiotic was composed of fructo-oligosaccharides (FOS): 4.95 g/ sachet and Bifidobacterium animalis lactis: 5 billion / sachet (n=13)
16356428|NCT04283266|Placebo Comparator|Placebo group|A placebo was composed of maltodextrin (60%) and sucrose (40%) : 5 g /sachet (n =14)
16356429|NCT04283253|Experimental|Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
16356430|NCT04283240|Active Comparator|Sildenafil|50 mg sildenafil oral. One dose
16356431|NCT04283240|Placebo Comparator|Placebo|Placebo pill. One dose
16356435|NCT04283214|Experimental|Bariatric manikin|CPR performed on a bariatric manikin
16356439|NCT04283188|Experimental|Adolescents with bipolar disorder|25 adolescents aged 14 to 21 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
16356440|NCT04283175|Other|Neuromuscular disease (MNM) subjects|
16356441|NCT04283175|Other|Hemiparetic subjects|
16356442|NCT04283175|Other|Healthy subjects|
16356443|NCT04283162|Experimental|conventional treatment plus calcium dobesilate|maintain lifestyle habits and the usual treatment, plus the use of calcium dobesilate (500 mg, orally, 3 times per day) for 12 months
16356444|NCT04283162|Active Comparator|conventional treatment group|maintain lifestyle habits and the usual treatment for 12 months
16356445|NCT04283149|Experimental|EVO ICL Surgery for Myopia|Enrolled subjects with myopia will undergo ICL surgery in one or both eyes with EVO MICL model.
16356446|NCT04283149|Experimental|EVO+ ICL Surgery for Myopia|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ MICL model.
16356447|NCT04283149|Experimental|EVO TICL Surgery for Myopia with Astigmatism|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO TICL.
16356448|NCT04283149|Experimental|EVO+ TICL Surgery for Myopia with Astigmatism|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ TICL.
16356449|NCT04283136|Active Comparator|Type 1 tablet - part 1|Subjects will receive a single dose of padsevonil Type 1 tablet in the period defined by the pre-specified sequence they were randomized on to.
16356450|NCT04283136|Experimental|Type 2 tablet - part 1|Subjects will receive a single dose of padsevonil Type 2 tablet in the period defined by the pre-specified sequence they were randomized on to.
16356451|NCT04283136|Experimental|Type 3 tablet - part 1|Subjects will receive a single dose of padsevonil Type 3 tablet in the period defined by the pre-specified sequence they were randomized on to.
16356452|NCT04283136|Experimental|Type 4 tablet - part 1|Subjects will receive a single dose of padsevonil Type 4 tablet in the period defined by the pre-specified sequence they were randomized on to.
16356453|NCT04283136|Experimental|Type 5 tablet - part 1|Subjects will receive a single dose of padsevonil Type 5 tablet in the period defined by the pre-specified sequence they were randomized on to.
16356454|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fasted)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
16356455|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fed)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
16356456|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fasted)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
16356457|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fed)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
16356458|NCT04283123|Experimental|Treatment|Participants assigned to this group will receive an automated bidet (TOTO Washlet S300e with remote control) and an occupational therapy intervention over 3-4 in-home visits.
16356459|NCT04283123|Active Comparator|Waitlist Control|Caregivers will wait for 30 days and then will be offered the intervention.
16356460|NCT04283110|Active Comparator|Midazolam group|Midazolam group will receive 1 mg intrathecal midazolam once during induction for anethesia
16356461|NCT04283110|No Intervention|control group|control group will receive placebo ( 0.5cm of sterile saline
16356462|NCT04283097|Experimental|KPG-818|KPG-818 dose escalation
16356463|NCT04283084|Experimental|Study group|Number of participants in this group is anticipated to be 25. Participants in this group will be receiving 10 minutes of exercise with the virtual reality based balance and coordination training system (MARBES). In the MARBES system two exercises (1. Balance exercise, 2. Coordination exercise) will be played for 5 minutes each.
16356464|NCT04283045|Active Comparator|JASPER (6 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 6 weeks. If child is an early responder, he/she will do JASPER for 30 minutes with TA and 30 minutes of JasPEER (JASPER with two TAs and two students) daily, 5 times a week, for the remaining 18 weeks of the study.
~If child is a slow responder, he/she can get randomized to receive 30 minutes of Structured Teaching and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 18 weeks of the study.
~Or
~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 18 weeks of the study."
16356465|NCT04283045|Active Comparator|JASPER (12 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 12 weeks. If child is an early responder, he/she will do JASPER for 30 minutes with TA and 30 minutes of JasPEER (JASPER with two TAs and two students) daily, 5 times a week, for the remaining 12 weeks of the study.
~If child is a slow responder, he/she can get randomized to receive 30 minutes of Structured Teaching and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 12 weeks of the study.
~Or
~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 12 weeks of the study."
16356466|NCT04283032||Multiparametric magnetic resonance + transrectal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)
16356467|NCT04283032||Multiparametric magnetic resonance + transperineal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)
16356468|NCT04283032||Transrectal biopsy|The patient underwent a transrectal biopsy (BPTE)
16356469|NCT04283032||Transperineal biopsy|The patient underwent a transperineal biopsy (BPTP)
16356470|NCT04283019|Experimental|CBD without THC|oral formulation containing 100mg CBD and 0mg THC
16356471|NCT04283019|Experimental|CBD with 3.7 mg THC|oral formulation containing 100mg CBD and 3.7mg THC
16356472|NCT04283019|Experimental|CBD with 2.8 mg THC|oral formulation containing 100mg CBD and 2.8 mg THC
16356473|NCT04283006|Experimental|Administration of CD20/CD22 dual Targeted CAR T-cells|A dose levels of 3-5*10E6/kg are administrated for each subject.
16357375|NCT04276714|Experimental|Adjustable socket|First week of the study is with adjustable socket
16356474|NCT04282993|Experimental|Wearable Devices Monitoring|Patients will be provided with wearable devices for at-home monitoring heart rhythm and rate, blood pressure, pulse oximetry, quality and quantity of sleep, and pace counting.
16356475|NCT04282993|Active Comparator|Standard of Care Monitoring|Patients will be evaluated by periodical clinical visits.
16356476|NCT04282980|Experimental|DCC-2618|DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.
16356477|NCT04282967|Experimental|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
16356478|NCT04282954|Experimental|Group 1|JP-1366 A mg
16356479|NCT04282954|Experimental|Group 2|JP-1366 B mg
16356480|NCT04282954|Experimental|Group 3|JP-1366 C mg
16356481|NCT04282954|Active Comparator|Goup 4|Esomeprazole 40 mg
16356482|NCT04282941|Experimental|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
16356483|NCT04282941|Experimental|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
16356484|NCT04282928|Active Comparator|Routine treatment group|"Participants will receive the treatment according to the treatment principle of severe and critical cases in Influenza diagnosis and treatment plan (2019 version)"
16356485|NCT04282928|Experimental|HUC-MSCs adjuvant Group|Participants will receive intravenous infusion of definitive HUC-MSCs (1×10^6 cells/Kg × body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment.
16356486|NCT04282915|Active Comparator|Implementation as Usual|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme adapted by the Nepal Ministry of Health.
16356487|NCT04282915|Experimental|RESHAPE|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme, plus they will have co-facilitation by mental health service users providing recovery testimonials as well as aspirational figures presenting testimonies and conducting myth-busting sessions.
16356488|NCT04282902|Experimental|Pirfenidone group|This study was designed to randomize approximately 147 adult subjects.The patients were stratified according to whether the onset time was less than 14 days, and randomly divided into groups at a ratio of 1:1. The group received pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer.
16356489|NCT04282902|No Intervention|Standard treatment group|This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤ 14 days and randomly divided into groups of 1: 1. This group only receives standard treatment
16356490|NCT04282889||Liver transplantation group|"The study population will include 20 adults (age range of 18 - 75 years) who are undergoing liver transplantation. Inclusion criteria are patients undergoing liver transplantation with English as their native language.
~Exclusion criteria include patient's refusal, or on medical anticoagulation therapy. Informed consents will be obtained from the patients who agree to participate in this clinical study."
16356491|NCT04282889||Healthy volunteer|The control population will include 20 adult volunteers (age 18-65 years) who meet the in the American Society of Anesthesiologists (ASA) Physical Status (PS) Classes 1 criteria. Exclusion criteria will be refusal, volunteers on any medication or significant history of bleeding.
16356492|NCT04282876||Degarelix|Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
16356493|NCT04282876||Control|Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
16356494|NCT04282863|Active Comparator|robotic-assisted laparoscopic myomectomy (RM)|After randomization, participants who are assigned to the robotic-assisted laparoscopic myomectomy (RM) agree to receive RM.
16356495|NCT04282863|Placebo Comparator|Conventional laparoscopic myomectomy (LM)|After randomization, participants who are assigned to the Conventional laparoscopic myomectomy (LM) agree to receive LM.
16356496|NCT04282850|Experimental|Pulmonary Vein Isolation (PVI) Group|Subjects randomized to this treatment arm will undergo atrial fibrillation ablation, and undergo routine post-procedural follow-up.
16356497|NCT04282850|No Intervention|Medical Management|Subjects randomized to this treatment arm will undergo medical management of the arrhythmia, but will not undergo invasive electrophysiologic procedures to address subject's AF.
16356498|NCT04282837||NW|normal weight control
16356499|NCT04282837||MHO|metabolic healthy obesity
16356500|NCT04282837||LMO|hypometabolic obesity
16356501|NCT04282837||HMO-U|hypermetabolic obesity with hyperuricemia
16356502|NCT04282837||HMO-I|hypermetabolic obesity with hyperinsulinemia
16356503|NCT04282824|Experimental|Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
16356504|NCT04282824|Experimental|Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
16356505|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
16356506|NCT04282798|Experimental|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
16356507|NCT04282785||Cohort of patients with severe infections|Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim
16356508|NCT04282772||Ectopic Eruption|The ectopic eruption of PFMs were classified in two ways: impacted and self-corrected.
16356509|NCT04282746|Experimental|JNJ-54135419|Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions.
16356510|NCT04282733|Experimental|Mindfulness Rounds|Participants will be exposed to thrice weekly Mindfulness Rounds education on the Unit; participation in the actual sessions is voluntary.
16356511|NCT04282733|No Intervention|Control|No intervention will take place on this Unit
16356512|NCT04282720|Other|SurgiMend Mesh|"SurgiMend Mesh - FDA approved noncross-linked bovine dermis biologic mesh. SurgiMend Mesh will be used according to FDA approved recommendations for the use of abdominal wall hernia reinforcement.
~SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend is specifically indicated for:
~Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias."
16356513|NCT04282707|Experimental|Endoscopic closure|Prospectively collected patients for gastric ESD and would undergo closure of defect
16356514|NCT04282707|Other|Historical control|Historical control of patients who underwent gastric ESD
16356515|NCT04282694||High risk (former) smokers|"Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
~Inclusion criteria
~Age between 50 and 75 years
~Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
~Status of current smoker or ex-smoker for <10 years.
~Exclusion criteria
~• Personal history of cancer within the prior 5 years"
16356516|NCT04282668|Experimental|TAS1440|TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
16356517|NCT04282668|Experimental|TAS1440 + ATRA|TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
16356518|NCT04282655|Active Comparator|Control|Standard method of warming breast milk in a hot water bath prior to feeding.
16356519|NCT04282655|Experimental|Treatment Guardian Milk Warmer (Medela TM)|External continuous milk warmer that heats milk within the tubing just posterior to the feeding tube to provide milk at body temperature for feeding infusion.
16356520|NCT04282642|Experimental|Cognitive Training|Computerized Cognitive Training
16356521|NCT04282642|Experimental|WLC|Waitlist Control
16356522|NCT04282629|Experimental|Milrinone|"milrinone group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely."
16356523|NCT04282629|Placebo Comparator|Standard Care|The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.
16356524|NCT04282616|Experimental|Home-based unstructured physical activity program|According to each patient's baseline physical activity level, the facilitator will advise patients to start or to increase their spontaneous activity by giving counselling on total exercise time, mode, intensity and frequency as suggested by the American College of Sport Medicine guidelines. Every patient will be provided with a log-book and a wearable physical activity monitor, which has to be returned in the subsequent controls, to favor adherence and objectively measure the exercise activities
16356525|NCT04282616|Experimental|Home-based structured low-intensity physical activity program|According to each patient's baseline physical activity level, a semi-personalized walking program, will be provided. This program, derived from previous experience on renal patients, includes a 10-min session/day of intermittent walking (1- or 2-min work and 1-min seated rest) to be performed at home at prescribed speed. The speed, converted into walking cadence and followed by a metronome, is weekly increased. Patients will be provided with a daily log containing the detailed exercise prescription and spaces to give a feedback on training execution and related symptoms.
16356561|NCT04282343|Other|Arm II - DISCO app|Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans.
16356597|NCT04282070|Experimental|SHR-1701 (Arm A)|SHR-1701 for R/M NPC failure after platinum-based chemotherapy
16356526|NCT04282616|Experimental|In-hospital structured supervised physical activity program|"Patients will join the room properly equipped for the exercise program in groups of maximum four subjects for a 2-time/week thirty minutes training sessions, to be performed for dialysis patients immediately before or after the dialysis treatment, or in non-dialysis according to their preferences.
~Each sessions will include low-intensity walking exercises (similar to the structured home-based training), resistance and power exercises with elastic bands and light weights. Each sessions will begin and end with a warm-up and cool-down period of stretching. The total duration of the session will be about 30 minutes. Rate of perceived exertion will be collected and the training intensity will be set according to the patient's baseline capacity and weekly increased."
16356527|NCT04282616|No Intervention|No-training|Patients choosing this option will not start any physical activity program, but they will perform the outcome measures, acting as a control group.
16356528|NCT04282603|Experimental|Experimental Meal Replacement|Participants randomized to this arm will consume 5 servings/day of experimental meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of experimental meal replacement for 12 weeks during the weight maintenance portion of the trial.
16356529|NCT04282603|Active Comparator|Bariatrics Advantage Meal Replacement|Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.
16356530|NCT04282590|Experimental|Treatment Period 1: TRK-750, Treatment Period 2: placebo|
16356531|NCT04282590|Experimental|Treatment Period 1: placebo, Treatment Period 2: TRK-750|
16356532|NCT04282577||patients with chron's disease|
16356533|NCT04282577||patients with ulcerative cholitis|
16356534|NCT04282564|Experimental|CO-OP Arm (early phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 3 weeks.
16356535|NCT04282564|Experimental|CO-OP Arm (mid phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2.5 weeks.
16356536|NCT04282564|Experimental|CO-OP Arm (late phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2 weeks.
16356537|NCT04282551|Experimental|oligosaccharide group 1|
16356538|NCT04282551|Experimental|oligosaccharide group 2|
16356539|NCT04282551|Placebo Comparator|placebo group|
16356540|NCT04282538|Active Comparator|Group A - Active|Active rTMS for Gait Dysfunction of Hemiplegia
16356541|NCT04282538|Sham Comparator|Group A - Sham|Sham rTMS for Gait Dysfunction of Hemiplegia
16356542|NCT04282538|Active Comparator|Group B - Active|Active tDCS for Frontal Gait Dysfunction
16356543|NCT04282538|Sham Comparator|Group B - Sham|Sham tDCS for Frontal Gait Dysfunction
16356544|NCT04282512|Experimental|Group A : sodium bicarbonate-rich mineral water and tap water|"First 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
~15-days washout period Last 15-days period with daily intake of 1.5l of tap water."
16356545|NCT04282512|Experimental|Group B : tap water and sodium bicarbonate-rich mineral water|First 15-days period with daily intake of 1.5l of tap water. 15-days washout period Last 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
16356546|NCT04282499|Experimental|combined exercise|combined exercise (aerobic+resistance training)
16356547|NCT04282499|Active Comparator|aerobic exercise|aerobic exercise only
16356550|NCT04282460|Experimental|Baduanjin practice|Baduanjin practice group will be asked to use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
16356551|NCT04282460|Active Comparator|Regular physical exercise|The regular physical exercise group will be asked to take physical exercise for at least half an hour every day in addition to regular physical activities at school.
16356552|NCT04282408|Experimental|Treatment|Group treated with 3D printed brace
16356553|NCT04282395|Experimental|Resilience-Based Diabetes Self-Management Education|The RB-DSME structure involves 8 weekly classes, 8 bimonthly support group sessions, and 2 booster sessions. The RB-DSME builds on foundational resilience resources (e.g., self-efficacy, social support), infusing novel resilience resources (e.g., adaptation to stress, finding positive meaning, spiritual coping) into the RB-DSME curriculum.
16356554|NCT04282395|Active Comparator|Standard Diabetes Self-Management Education|The scope and sequence of the standard diabetes self-management education (DSME) curriculum are aligned with national standards of the American Diabetes Association. DSME groups receive a 10-month intervention: 8 weekly educational sessions, followed by 8 bimonthly support group sessions, followed by 2 booster sessions.
16356555|NCT04282369|Active Comparator|HHFNC|In this group patients will receive respiratory support by high flow nasal cannula.
16356556|NCT04282369|Active Comparator|nCPAP|In this group patients will receive respiratory support by nasal CPAP.
16356557|NCT04282369|Active Comparator|nIPPV|In this group patients will receive respiratory support by nasal IPPV.
16356558|NCT04282369|Active Comparator|nHFO|In this group patients will receive respiratory support by nasal high frequency oscillatory. ventilation.
16356559|NCT04282356|Experimental|Intraperitoneal chemotherapy|Cisplatin 100mg/m2 during surgery IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8 after surgery with at least 3 courses performed (up to 4-6 allowed)
16356560|NCT04282343|Other|Arm I- Usual care|Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plans.
16356593|NCT04282109|Active Comparator|Arm 2|ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)
16356562|NCT04282330|Other|CEST imaging performed|CEST imaging will be performed (15 min): Axial 3D volume acquisition at 3.5 mm isotropic voxel size, 20-30 offset frequencies, plus Axial 3D T1w and T2w map at same resolution for use in CEST quantification. A routine stroke MRI protocol will also be performed (10 min): Axial T2w; Axial DWI and ADC (apparent diffusion coefficient) using accelerated multi-band sequence; Axial T2w* or SWI (susceptibility weighted imaging); and dynamic susceptibility contrast-enhanced (DSC) perfusion imaging following contrast agent administration (5 min, provided Radiology Department protocols allow DSC (e.g. no renal impairment)).
16356563|NCT04282317|Other|Healthy Volunteer|This arm will enroll healthy volunteers as controls
16356564|NCT04282317|Other|Gastroparesis Subjects|This arm will enroll a) patients with gastroparesis from type 1 diabetes and b) patients with gastroparesis from vagus nerve trauma
16356565|NCT04282304|Other|Usual Care|The patients in this arm will have usual care during preoperative period, bariatric surgery and follow-up.
16356566|NCT04282304|Experimental|UGECAM|During the preoperative period, the patients in this arm will have usual care and a 4 weeks intensive, comprehensive behavioral lifestyle intervention. They will then have usual bariatric surgery and follow-up.
16356567|NCT04282291||SIPB (block)|patients who underwent a modified BRILMA (intercostal rami block, middle axilary line) ultrasound-guided block with portable device with lineal probe and needle 80 mm. With the patient lying supine, the probe was placed in the sagittal plane of the middle axillary line to identify the aim thoracic structures. Under aseptic conditions, the needle was inserted in plane, caudo-craneal, to reach the fascial plane between the serratus anterior muscle and the external intercostal muscle at the eighth rib. A bolus dose of levobupivacaine 0.25% was administered, 3 ml of local anesthetic for each segment we want to block
16356568|NCT04282291||control (morphine)|PCA (patient controlled analgesia) morphine was initiated immediately postoperatively using CADD Smith Medical pumps. All patients received PCA-morphine with the initial dose being 0.5-1 mg. The bolus dose was 0.01mg/kg mg morphine, with lockout time interval of 15 - 30 min, limiting of 8mg/hour, as the default program. The continuous (basal) dose was increased after 12-24 hours if using frequent demand doses or if pain not controlled and decreasing if no bolus was taken.
16356569|NCT04282278|Experimental|Group A|
16356570|NCT04282278|Experimental|Group B|
16356571|NCT04282278|Experimental|Group C|
16356572|NCT04282265|Placebo Comparator|Placebo|
16356573|NCT04282265|Experimental|Red Spinach Extract|
16356574|NCT04282252|Experimental|IV fluid restriction group|"No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:
~In case of severe hypoperfusion or severe circulatory impairment defined by:
~Lactate 4 mmol/L or above or mean arterial blood pressure below 50 mm Hg or mottling beyond the kneecap or urinary output less than 0.1 mL/kg bodyweight/h, but only in the first 2 hours after randomisation. A bolus of 250-500 mL of IV crystalloid solution may be given.
~In case of overt fluid losses (eg, vomiting, large aspirates, diarrhoea, drain losses, bleeding or ascites tap) IV fluid may be given to correct for the loss.
~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to correct dehydration or electrolyte imbalances and/or to ensure a total fluid input of 1 L per 24 hours."
16356575|NCT04282252|Active Comparator|Standard care group|There will be no upper limit for the use of IV or oral/enteral fluids. In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
16356576|NCT04282239|Experimental|Pectoral nerves block type 2 (PECS2)|The intervention is the PECS2 block, a previously developed modality for preventing pain in the anterior chest. The medication used in the block is Ropivicaine 0.5%, Lidocaine 1% + 1:100,000 epinephrine, and 40 μg dexmedetomidine. Patients will receive a standard post-operative pain regimen per institutional protocol.
16356577|NCT04282239|No Intervention|Control Group: standard post-operative pain regimen|Patients will receive a standard post-operative pain regimen per institutional protocol.
16356578|NCT04282226|Active Comparator|active tVNS|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical
16356579|NCT04282226|Placebo Comparator|sham tVNS|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
16356580|NCT04282213||Control samples|For each case, neuromuscular measurements gathered with GE CARESCAPE B450 monitor (E-NMT module).
16356581|NCT04282213||Case samples|For each case, neuromuscular measurements gathered with TOFCuff monitor.
16356582|NCT04282200|No Intervention|Standard of Care|Patients receiving standard of care pain management including opioids.
16356583|NCT04282200|Active Comparator|Ketorolac|Patients will receive standard of care pain management plus intravenous ketorolac.
16356584|NCT04282187|Experimental|Treatment (decitabine, ruxolitinib, fedratinib)|Patients receive decitabine IV QD over 1 hour on days 1-10, and either ruxolitinib PO BID or fedratinib PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16356585|NCT04282174|Experimental|Regimen A|Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
16356586|NCT04282174|Experimental|Regimen B|Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.
16356587|NCT04282161|Experimental|Axys EX device|
16356588|NCT04282148|Experimental|ABT NG DES 48 EECSS|Participants will receive ABT NG DES 48 EECSS device
16356589|NCT04282135||Infected|patients with detected Influenza RNA in nasopharyngeal swabs
16356590|NCT04282135||not infected|patients without detected Influenza RNA in nasopharyngeal swabs
16356591|NCT04282135||SARS CoV2|patients with SARS-Cov-2 infection
16356592|NCT04282109|Experimental|Arm 1|NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)
16356598|NCT04282070|Experimental|SHR-1701 (Arm B)|SHR-1701 for R/M NPC failure after anti PD-1/PD-L1 antibody therapy
16356599|NCT04282070|Experimental|SHR-1701 plus Gemcitabine and Cisplatin (Arm C)|SHR-1701+Gemcitabine+Cisplatin for first line treatment of R/M NPC
16356600|NCT04282070|Experimental|SHR-1701 plus Albumin Paclitaxel (Arm D)|SHR-1701+Albumin Paclitaxel for R/M NPC failure after first line anti PD-1/PD-L1 antibody therapy
16356601|NCT04282057|Experimental|shockwave therapy group|This group performed aerobic exercise just after shock wave therapy in the abdominal region.
16356602|NCT04282057|Experimental|radiofrequency group|This group performed aerobic exercise just after radiofrequency in the abdominal region.
16356603|NCT04282057|Active Comparator|control group|This group only performed aerobic exercise.
16356604|NCT04282044|Experimental|Dose Escalation|Dose escalation cohort for treatment of solid tumors that are relapsed, refractory or intolerant to standard care, or refusing standard therapies.
16356605|NCT04282031|Experimental|phase 1 (dose escalation)|Participants will first receive single dose BPI-1178 orally at dose levels of 25mg, 75mg, 150mg, 250mg and 400mg followed by a 7-day washout period , and then start receiving the 28 days/cycle continuous treatment until disease progression or unacceptable toxicity.
16356606|NCT04282031|Experimental|phase 2a cohort A|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with fulvestrant for 3 weeks followed by 1 week off as a treatment cycle, until disease progression or unacceptable toxicity.
16356607|NCT04282031|Experimental|phase 2a cohort B|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with letrozole for 3 weeks followed by 1 week off as a treatment cycle, until disease progression or unacceptable toxicity.
16356608|NCT04282018|Experimental|Part A: BGB-10188 Monotherapy Dose Escalation|BGB-10188 capsules administered orally once daily (QD) in 5 cohorts of escalating doses
16356609|NCT04282018|Experimental|Part B: BGB-10188 + Zanubrutinib Dose Escalation|BGB-10188 capsules administered orally QD at a dose level less than RP2D and RP2D in combination with zanubrutinib 160mg (2*80mg capsules) administered orally twice daily (BID)
16356610|NCT04282018|Experimental|Part C: BGB-10188 + Zanubrutinib Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part B in combination with zanbrutinib 160mg (2*80mg capsules) administered orally BID
16356611|NCT04282018|Experimental|Part D: BGB-10188 + Tislelizumab Infusion Dose Escalation|BGB-10188 capsules administered orally QD in upto 4 cohorts of escalating doses in combination with tislelizumab 200mg IV infusion administered every 3 weeks (Q3W)
16356612|NCT04282018|Experimental|Part E: BGB-10188 + Tislelizumab Infusion Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part D in combination with tislelizumab 200mg IV infusion administered Q3W
16356613|NCT04282005|Experimental|surgery group|Fourteen patients who meet study criteria will be assigned to the study group and will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
16356614|NCT04282005|Active Comparator|lifestyle and diet|Fourteen patients matched to the surgery group for age, gender, BMI, diabetes status, and NALFD score will undergo additional lifestyle interventions, dietary counselling and or meal replacement by a dietician aimed at inducing at least a 5-7% weight reduction, prior to their surgery (while on the waiting list for surgery).
16356615|NCT04281992|Experimental|AUP1602-C|AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.
16356616|NCT04281979|Experimental|Study Agent|
16356617|NCT04281979|Placebo Comparator|Placebo|
16356618|NCT04281966|Experimental|Experiment|For young people from schools randomly assigned to the experimental ASEP condition will participate in the ASEP intervention. The ASEP intervention is a Third-Party Policing partnership that involves a partnership between police and school, an ASEP conference and follow up which is organized and led by a conference facilitator with the young person, their parent (or guardian), a school representative (e.g., teacher), and a uniformed school-based police officer. The police and school representatives will be trained by the facilitator to utilize procedurally just dialogue during the entirety of the conference. The ASEP conference script will utilize a procedurally just dialogue to increase both the young person and their parents' perceptions and knowledge of the legitimacy of the truancy laws, police, and schools in order to gain willing compliance to follow the rules.
16356619|NCT04281966|No Intervention|Control|"Participants allocated to the control condition will be given the business-as-usual' approach to handling school non-attendance. The control participants will be sanctioned in the usual manner for engaging in truancy through the requirements denoted in the Queensland Education (General Provisions) Act (2006)."
16356620|NCT04281953||People with ototoxicity|People living with and beyond who experience ototoxicity as a result of chemotherapy
16356621|NCT04281927||Atrial fibrillation|Patients with presumed atrial fibrillation will undergo monitoring with the device and Holter ECG.
16356622|NCT04281927||Sinus rhythm|Patients with presumed sinus rhythm will undergo monitoring with the device and Holter ECG.
16356623|NCT04281927||Sinus rhythm and frequent extrasystoles|Patients with presumed sinus rhythm and frequent extrasystoles will undergo monitoring with the device and Holter ECG.
16356624|NCT04281901|Experimental|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
16356625|NCT04281901|Active Comparator|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
16356626|NCT04281875|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
16356627|NCT04281875|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
16356628|NCT04281862|Experimental|Group A|Dextenza
16356629|NCT04281862|Active Comparator|Group B|Topical Prednisolone
16356630|NCT04281849|No Intervention|Usual care|Patients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
16356632|NCT04281836|Experimental|Breathing awareness through use of virtual reality breathing|Healthy participants were recruited in this group.
16356633|NCT04281836|Active Comparator|Traditional breathing awareness|Healthy participants were recruited in this group.
16356634|NCT04281823||Cardiovascular Magnetic Resonance|All patients who present to the Houston Methodist CMR Laboratory
16356635|NCT04281810|Experimental|TEDS|Subjects received transcutaneous electrical diaphragm stimulation (TEDS) for 30min/ day till the end of the weaning trial
16356636|NCT04281810|No Intervention|Control|Subjects received similar medical treatment except for the TEDS program.
16356637|NCT04281797||Kidney transplant recipients|Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
16356638|NCT04281797||HSCT-recipients|Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
16356639|NCT04281797||MSCT-recipients|Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
16356640|NCT04281797||Liver transplant recipients|Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
16356641|NCT04281784|Experimental|EHR-based Clinician Jumpstart|The EHR-based Jumpstart Guide will be developed by extracting data from the EHR using automated methods with both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation and patients' code status.
16356642|NCT04281784|No Intervention|Usual Care|The clinicians (hospital teams) for patients in the control group will not receive Jumpstart guides. These subjects will receive usual care.
16356643|NCT04281771|Experimental|Patients who undergo cardiac MRI|Patients undergo cardiac within 30 days after TAVI to assess the amount of paravalvular leakage.
16356644|NCT04281758|Active Comparator|Caffeine beverage (control)|Flavored still beverage with caffeine 100 mg
16356645|NCT04281758|Experimental|Caffeine beverage plus bioactive 1|Flavored still beverage with caffeine 100 mg + quercetin 250 mg
16356646|NCT04281758|Experimental|Caffeine beverage plus bioactive 2|Flavored still beverage with caffeine 100 mg + curcumin 80 mg
16356647|NCT04281758|Experimental|Caffeine beverage plus bioactive 3|Flavored still beverage with caffeine 100 mg + methylliberine 75 mg
16356648|NCT04281745|Experimental|Coretox®|Botulinum toxin type A to be intramuscularly injected at 4 sites of corrugator muscle and at 1 site of procerus muscle with 0.1 mL (4U) at each site, for a total of 0.5 mL (20U). The administration of the investigational product was performed once at the start of each cycle
16356649|NCT04281719|Experimental|Mobile App|Youth will be assigned to interact with a novel mobile application during a course of outpatient psychotherapy for substance use disorder(s) and co-occurring mental health disorder(s).
16356650|NCT04281706||Etomidate-Time-Frame|Patients that underwent cardiac surgery between October 1st, 2012 and September 30th, 2013
16356651|NCT04281706||Propofol-Time-Frame|Patients that underwent cardiac surgery between February 1st, 2014 and January 31st, 2015
16356652|NCT04281693|Experimental|Screening participants|
16356653|NCT04281680||Pasireotide|Patients who received pasireotide perioperatively
16356654|NCT04281680||Octreotide|Patients who received perioperative octreotide
16356655|NCT04281680||Control|Patients who received no additional medication in the timely cohort
16356656|NCT04281667|Experimental|Mechanical Bowel Preparation and Oral Antibiotics|Mechanical Bowel Preparation and Oral Antibiotics
16356657|NCT04281667|Active Comparator|Mechanical Bowel Preparation Only|Mechanical Bowel Preparation Only
16356658|NCT04281654|Experimental|Ballroom Dance|The Dance group participants will take part in ballroom dance lessons twice/week for 45-minutes/session for 10 weeks
16356659|NCT04281654|Experimental|Ukulele|The Music group participants will take part in ukulele lessons twice/week for 45-minutes/session for 10 weeks
16356660|NCT04281654|Active Comparator|Control|The Control group participants will meet 2 times per week for 45-minutes/session for 10 weeks to participate in a social conversational group for 10 weeks
16356661|NCT04281641|Experimental|TCHP|"Neoadjuvant Therapy (Cycles 1-7):
~Cycle 1: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) Cycle 2-7: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) + followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).
~Adjuvant Therapy:patients would complete 1 year of PH-based regimen in the adjuvant setting.
~Patients are assessed by [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 68Ga-Affibody HER-2 Imaging PET. Besides, the changes of biomarkers would be examined by gene sequencing and organoid drug sensitivity test."
16356662|NCT04281628|Placebo Comparator|Control group|control group: where normal saline will be administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
16356663|NCT04281628|Active Comparator|ketamine group|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
16356664|NCT04281615|Experimental|Intervention (Generic Message)|Receives promotional materials that feature a generic messaging approach.
16356665|NCT04281615|No Intervention|Control (Threshold Message)|Receives promotional materials that use traditional, threshold messages.
16356666|NCT04281602||Rheumatoid arthritis patients|Adult patients suffering from rheumatoid arthritis, diagnosed according to American College of Rheumatology/European League Against Rheumatism 2010 criteria and requiring a anti-IL-6 treatment
16356667|NCT04281602||Healthy controls|Healthy controls not suffering from acute or chronic inflammatory disease at inclusion.
16356668|NCT04281589|Experimental|Group 1|tidal volüm is 4 ml/kg
16356669|NCT04281589|Experimental|Group 2|tidal volüm is 6 ml/kg
16356670|NCT04281589|Experimental|Group 3|tidal volüm is 8 ml/kg
16356671|NCT04281589|Experimental|Group 4|tidal volüm is 10 ml/kg
16356672|NCT04281576|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with XELOX. For HER-2 positive patients, Trastuzumab is given together with XELOX.
16356673|NCT04281563|Experimental|the MCT oil massage|The neonates received massage with MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
16356674|NCT04281563|Placebo Comparator|massage alone|The neonates received massage without MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
16356675|NCT04281563|No Intervention|no massage groups|no intervention
16356676|NCT04281550|Experimental|Think drink intervention|The Think Drink multicomponent hydration intervention was introduced into the intervention group care homes through a staff workshop.
16356677|NCT04281537||Patient with Fabry Disease on ERT (agalsidase alfa)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa)
16356678|NCT04281537||Patient with Fabry Disease on ERT (agalsidase beta)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase beta)
16356679|NCT04281537||Caregiver|Caregiver of patient with Fabry Disease on ERT
16356680|NCT04281524|Experimental|CSL312 Cohort 1 (Dose 1)|CSL312 administered as IV infusion
16356681|NCT04281524|Experimental|CSL312 Cohort 2 (Dose 2)|CSL312 administered as IV infusion
16356682|NCT04281524|Experimental|CSL312 Cohort 3 (Dose 3)|CSL312 administered as IV infusion
16356683|NCT04281524|Experimental|CSL312 Cohort 4 (Dose 4)|CSL312 administered as IV infusion
16356684|NCT04281524|Placebo Comparator|Placebo|Placebo administered as IV infusion
16356685|NCT04281498|Experimental|Patients with MPN|Ruxolitinib and Enasidenib combination therapy
16356688|NCT04281472|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC in both stage A as stage B
16356689|NCT04281472|Placebo Comparator|Placebo|patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B
16356690|NCT04281459|Experimental|SCT 4/7|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with short cycle scheme of 4 consecutive days on and 3 days off treatment
16356691|NCT04281459|Active Comparator|Control|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with standard scheme of 7 days per week of treatment
16356692|NCT04281446|Experimental|G-FBM-CEN|Photobiomodulation application in women of endogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
16356693|NCT04281446|Sham Comparator|G - Sham - CEN|"Sham Photobiomodulation (disabled) application in women of endogenous cycle.
~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:
~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
16356694|NCT04281433|Experimental|unilateral|
16356695|NCT04281433|Experimental|bilateral|
16356696|NCT04281420|Experimental|ATG-019 Alone|A starting does of 30 mg QoD×3 ATG-019
16356697|NCT04281420|Experimental|ATG-019 + Niacin ER|A starting dose of 60 mg ATG-019 and 500 mg niacin ER
16356698|NCT04281407|Experimental|Probiotics treatment on midazolam and acetaminophen metabolism|"Experimental:
~Day 1: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV) Days 1-28: Visbiome (2 capsules) administered BID Day 11: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV)"
16356699|NCT04281394|Experimental|Robot assisted gait training|Robot assisted gait training(RAGT) group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks. SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements.
16356700|NCT04281394|Active Comparator|conventional physical training group|The conventional group underwent conventional physical therapy( even level gait training and range of motion exercises) twice a day, 5 times a week in 12 weeks.
16356701|NCT04281381||Desmoid Fibromatosis|Participants will have a clinical diagnosis of desmoid fibromatosis, either new or newly recurrent
16356702|NCT04281355|Experimental|Randomisation A - Intervention|In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.
16356703|NCT04281355|Experimental|Randomisation B - Intervention|In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.
16356704|NCT04281342|Experimental|Aprocitentan 25 mg|Therapeutic dose level
16356705|NCT04281342|Experimental|Aprocitentan 100 mg|Supratherapeutic dose level
16356706|NCT04281342|Placebo Comparator|Matching placebo|
16356707|NCT04281342|Other|Moxifloxacin|
16356708|NCT04281316|Active Comparator|Non Invasive Ventilation device group|The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
16356709|NCT04281316|Experimental|Nasal High Flow (MyAirvo) device group|The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.
16356710|NCT04281303||Endoscopic vertical gastroplasty|Proof-of-concept study that will prospectively include a number of patients undergoing endoscopic vertical gastroplasty + lifestyle modifications to evaluate the effect of this technique in an adult population with obesity and NASH cirrhosis
16356711|NCT04281290|Experimental|Experimental group|Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
16357376|NCT04276714|Experimental|Classical socket|First week of the study is with classical socket
16356712|NCT04281277|Active Comparator|low target group|"target of mean arterial pressure(MAP) at 65-70 mmHg.
~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
16356713|NCT04281277|Experimental|high target group|"target of mean arterial pressure (MAP) at 80-85 mmHg.
~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
16356714|NCT04281264|No Intervention|NorCON|Normoxia Control Group
16356715|NCT04281264|Active Comparator|HypCON|Hypoxia Control Group
16356716|NCT04281264|Placebo Comparator|NorCIR|Normoxia Circuit Training with Elastic Bands Group
16356717|NCT04281264|Experimental|HypCIR|Hypoxia Circuit Training with Elastic Bands Group
16356718|NCT04281264|Placebo Comparator|NorVIB|Normoxia Whole-body Vibration Training Group
16356719|NCT04281264|Experimental|HypVIB|Hypoxia Whole-body Vibration Training Group
16356720|NCT04281251|Experimental|ERAT arm|This is the treatment arm where endoscopic therapy of acute appendicitis would be performed
16356721|NCT04281238|Experimental|yoga group|Participants in this group will be given yoga training 3 days a week for 8 weeks. In addition, patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
16356722|NCT04281238|Other|Control group|Patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
16356723|NCT04281225|Placebo Comparator|Placebo only condition|Participants in this condition will be told at the time of the initial assessments (T1) that the device they will be testing will improve their hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked if they perceive their hearing to be changed by the device in addition to qualitative descriptions of the audio. This group will allow researchers to investigate the main effect of the placebo hearing aid - without calling participant's attention to variability in their symptoms.
16356724|NCT04281225|Experimental|Placebo and ATV condition|Participants in this condition at the time of the initial assessments (T1) will be told that the device they will be testing will improve their hearing. They will then be told that in-order to receive the maximum benefit from the hearing device, they should focus on instances in which they can hear better and worse. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will asked 1) if they perceive their hearing to be changed by the device; 2) to note any changes in what they heard in the audio focusing on the story in the ballad; and 3) whether their hearing is possibly impacted by activities and behavior and what they were doing.This condition will enable researchers to test the effects of the interaction between attention to variability and the placebo effect.
16356725|NCT04281225|Experimental|ATV only condition|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
16356726|NCT04281225|No Intervention|Control condition- no ATV or Placebo effect.|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for ergonomic purposes. They will listen to the audio and record volume levels at the start and at the end of the audio and provide feedback on the design. They will be told that each day they will listen to a brief audio (ballad of under 3 minutes) and will be asked a few similar questions twice daily for 6 days. After the 2nd audio of the day, they will be asked for feedback on the hearing device design. They will also be asked about their general health and wellness, as compared to the last time they were contacted.This group will allow researchers to test for the effects of having any device at all.
16356727|NCT04281212||CTO|Period of 1 month in the participating centers, during which all the patients with CTO and responding to all selection criteria may be included in the study, in order to describe which therapeutic choices have been chosen for this type of patient.
16356728|NCT04281212||CTO with attempted angioplasty|Period of 2 months in the participating centers, during which all the patients for whom an angioplasty has been attempted after a CTO, and responding to all selection criteria, may be included in the study, in order to evaluate the success of the procedure
16356729|NCT04281199|Experimental|Treatment (TBI, IMRT)|Patients undergo TBI using IMRT with VMAT or tomotherapy BID on days -7 to -4 then undergo stem cell transplantation on day 0.
16356730|NCT04281186||Cross-sectional cohort|720 type 2 diabetic patients (>5 years duration), older than 65 years of age
16356731|NCT04281186||Prospective study-MCI|168 Patients from the cross-sectional cohort diagnosed with mild cognitive impairment during the cross-sectional evaluation
16356732|NCT04281186||Prospective study normocognitive|63 Patients from the cross-sectional cohort without mild cognitive impairment evaluated during the cross-sectional evaluation
16356733|NCT04281160||Clinical Metric|Patients and healthy controls were evaluated by expert raters with standard clinical metrics of neurologic function.
16356734|NCT04281160||Mobile Activity Metric|Patient performed mobile activity
16356735|NCT04281147||No Ra-223 received|Patients did not receive Ra-223
16356736|NCT04281147||Early Ra-223 (2nd line)|Patients received Ra-223 in 2nd line
16356737|NCT04281147||Late Ra-223 (3rd or later lines)|Patients received Ra-223 in 3rd or later lines
16356738|NCT04281134|Experimental|Summit RC+S DBS Implant for OCD|all subjects will receive surgical implantation of DBS system
16356765|NCT04280926||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
16356739|NCT04281134|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
16356740|NCT04281121|Active Comparator|supplemented|Life style modification, diet regimen and Omega-3 fatty acids supplementation
16356741|NCT04281121|Active Comparator|non supplemented|Life style modification and diet regimen
16356744|NCT04281095|Experimental|Botulinum toxin type A(ATGC-110)|
16356745|NCT04281095|Active Comparator|Botulinum toxin type A|
16356746|NCT04281082||ICP|To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives
16356747|NCT04281069||"patients visiting the centre de santé"|Women visiting to the selected health centres in the Oujda province will be invited to participate
16356748|NCT04281056|No Intervention|Control|
16356749|NCT04281056|Experimental|Tooth removal|Tooth removal and their replacement by means of a denture Teeth have been removed and replaced by means of dentures for at least one year
16356750|NCT04281030|Active Comparator|Active Comparator: Progressive Muscle Relaxation (PMR) Therapy|After the PMR APP is loaded onto the subject's smartphone, the subject will perform PMR in the ED and discuss the optimal time and place to practice PMR at home. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
16356751|NCT04281030|Active Comparator|Active Comparator: Monitored Usual Care (MUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
16356752|NCT04281017|Experimental|TIVA anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
16356753|NCT04281017|Active Comparator|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
16356754|NCT04281004|Active Comparator|Amniotic Fluid (AFED)|
16356755|NCT04281004|Placebo Comparator|Saline Solution|
16356756|NCT04280991|Experimental|Moderate intensity exercise under mild normobaric hypoxia|The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation.
16356757|NCT04280991|Placebo Comparator|Moderate intensity exercise under normoxia|The participants will perform moderate intensity exercise at 50% WMAX (determined during maximal workload test) under normoxia (FiO2: 21%) two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge test will be performed at day 5 to determine fasting/postprandial substrate oxidation.
16356758|NCT04280978||Aquired Brain Injury|Suitable potential participants would be children with ABI, at least 6 months post onset, from 6 to 11 years old, without diagnosis of aphasia, dysarthria, apraxia, and/or sensorial difficulties (visual and hearing), with Italian as a first language.
16356759|NCT04280965|Experimental|Quetiapine|Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed
16356760|NCT04280965|Active Comparator|Treatment As Usual (TAU)|Standard of care medications
16356761|NCT04280952|Experimental|CONVIVO|tumor tissue identification with the CONVIVO system
16356762|NCT04280939|Active Comparator|spinal anesthetic without intrathecal narcotic|spinal anesthetic with standard painkillers without intrathecal narcotics
16356763|NCT04280939|Experimental|spinal anesthetic with morphine|spinal anesthetic with 100 micrograms of intrathecal morphine
16356764|NCT04280939|Experimental|spinal anesthetic with hydromorphone|spinal anesthetic with 20 micrograms of intrathecal hydromorphone
16356766|NCT04280913||COVID-19 patients|Hospitalized patients with COVID-19
16356767|NCT04280900|Experimental|cybertherapy|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
16356768|NCT04280900|Other|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
16356769|NCT04280887|Experimental|Intervention|Participants will wear the device for the specified test period (3 months)
16356770|NCT04280874|Active Comparator|GROUP A|106 randomly selected pregnant women
16356771|NCT04280874|Active Comparator|GROUP B|106 randomly selected pregnant women
16356772|NCT04280861|Experimental|Intervention Group|The intervention group will participate in multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
16356773|NCT04280861|No Intervention|Control Group|Usual clinical care,
16356774|NCT04280848|Experimental|UCPVax vaccine|UCPVax is a therapeutic vaccine derived from telomerase combined with Montanide ISA51 VG as adjuvant.
16356775|NCT04280835|Experimental|Group Psychoeducation that Focused on Social Skill Development|The Psychoeducation program that focused on social skill development, consists of 8 sessions, one day a week, each lasting an average of 60 Minutes. Psychoeducation was conducted in three groups and each of them consisted of eight patients.
16356776|NCT04280835|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
16356777|NCT04280822|Experimental|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles
~Surgery:
~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).
~After surgery/ maintain period:
~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)"
16356778|NCT04280822|Active Comparator|Neoadjuvant chemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
~Surgery:
~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
16356779|NCT04280809|Experimental|Laser|Subsequently to the suture, laser was applied in the right or left side randomly on each patient, according to a sheet of randomization. GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2.
16356780|NCT04280809|No Intervention|Non-laser|Every patient, on the control side, the same handpiece was applied intraorally, but laser was not activated
16356781|NCT04280796|Experimental|Substudy 1|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 1 an operant learning paradigm will be implemented to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement and vice versa.
~Primary objectives:
~To develop psychophysical methods that allow the independent assessment of sensory-discriminative and emotional-motivational pain responses and
~to show that emotional-motivational and sensory-discriminative pain components can be dissociated
~Secondary objective:
~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in how strongly sensory-discriminative and emotional-motivational pain responses can be dissociated"
16356782|NCT04280796|Experimental|Substudy 2|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.
~Primary objective:
~To demonstrate that in chronic pain patients, emotional-motivational pain responses are increased relative to sensory-discriminative pain responses
~Secondary objective:
~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in the present dissociation of sensory-discriminative and emotional-motivational pain responses in chronic pain patients"
16356783|NCT04280783|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
16356784|NCT04280783|Other|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
16356785|NCT04280770|Sham Comparator|Non retinal detachment group|35 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
16356786|NCT04280770|Active Comparator|retinal detachment group|15 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
16356787|NCT04280757||Arm 1|Biopsied ICSI embryos
16356788|NCT04280757||Arm 2|Non biopsied ICSI embryos
16356789|NCT04280757||Arm 3|Natural pregnancy embryos
16356790|NCT04280744|Experimental|Music therapy|Music listening intervention provided by a board certified music therapist.
16356791|NCT04280731|Experimental|Fermented drink|
16356793|NCT04280705|Placebo Comparator|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
16356794|NCT04280705|Experimental|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
16356798|NCT04280679|Other|Arm of patient treated by HIFU|Compression bandages
16356799|NCT04280653|Experimental|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
16356803|NCT04280601|Other|Low vitamin level at baseline|At specific time points we will measure vitamin D status (baseline and 12-months) and re-enforcing vitamin D supplementation in those with insufficient or deficient vitamin D levels. More specifically, we will ask patients with insufficient or deficient vitamin D levels at enrollment to increase vitamin D intake by 1,000 IU units (to a maximum of 2,000 IU if the patient is already on vitamin D supplementation) for the 12 month period.
16356804|NCT04280588|Experimental|Treatment group|
16356805|NCT04280588|No Intervention|Control group|
16356806|NCT04280562|Experimental|"Real SPR"|"Participants will receive the device which will run the real Sana Pain Reliever (SPR) protocol and a tablet with a mobile application to record pain levels and other questionnaires"
16356807|NCT04280562|Sham Comparator|Sham SPR|Participants will receive the device which will run a sham SPR protocol and a tablet with a mobile application to record pain levels and other questionnaires
16356808|NCT04280549||Healthy Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
16356809|NCT04280549||Type 2 Diabetic Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
16356810|NCT04280536|Experimental|Cohort A|Patients with prior exposure to fluoropyrimidines
16356811|NCT04280536|Experimental|Cohort B|Patients without prior exposure to fluoropyrimidines
16356812|NCT04280523|Experimental|ESR-specific PET Scan|"Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes.
~Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)"
16356813|NCT04280510||Active coeliac patients|Patients with active coeliac disease
16356814|NCT04280510||Treated coeliac patients|Patients with coeliac disease on gluten free diet
16356815|NCT04280510||Sprue type I|Patients with refractory coeliac disease of type I
16356816|NCT04280510||Sprue type II|Patients with refractory coeliac disease of type II
16356817|NCT04280510||Intestinal Lymphoproliferations|Patients with intestinal lymphoproliferations
16356818|NCT04280510||Non coeliac enteropathies|Patients with non coeliac immune-mediated enteropathy
16356819|NCT04280510||Patients without neoplastic or inflammatory intestinal disease|Patients without neoplastic or inflammatory intestinal disease
16356820|NCT04280497|Experimental|Biomarker CIRCI neg: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
16356821|NCT04280497|Placebo Comparator|Biomarker CIRCI neg: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
16356822|NCT04280497|Experimental|Biomarker endocan: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
16356823|NCT04280497|Placebo Comparator|Biomarker endocan: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
16356824|NCT04280497|Experimental|Biomarker GILZ: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
16356825|NCT04280497|Placebo Comparator|Biomarker GILZ: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
16356826|NCT04280497|Experimental|Biomarker CPD: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
16356827|NCT04280497|Placebo Comparator|Biomarker CPD: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
16356828|NCT04280497|Experimental|Biomarker Transcriptomic SRS: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
16357377|NCT04276701|Experimental|Systemic lupus erythematosus (SLE)|
16356829|NCT04280497|Placebo Comparator|Biomarker Transcriptomic SRS: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
16356830|NCT04280497|Experimental|Biomarker Endotype B: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
16356831|NCT04280497|Placebo Comparator|Biomarker Endotype B: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
16356832|NCT04280484|Experimental|Acute Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts
16356833|NCT04280484|Sham Comparator|Sham Acute Intermittent Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts.
16356834|NCT04280471|Experimental|Treatment (OpenBiome FMT capsule DE)|Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
16356835|NCT04280458|Experimental|Intervention group|patients will receive intensive care of rehabilitation of psychomotor
16356836|NCT04280458|Active Comparator|Control group|patients will receive standard care
16356837|NCT04280445|Experimental|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
16356838|NCT04280432||Cesarean|Women hospitalized for cesarean section
16356839|NCT04280419||Healty Subjects|Healthy Subjects Twenty-five healthy individuals will be included in the study. Physical properties of cases will be recorded. Respiratory functions and respiratory muscle strength will be evaluated. Physical activity will be assessed using the International Physical Activity Survey (IPAQ). Respiratory muscle endurance will be evaluated using an incremental workload test and fixed threshold load test. Tests will be repeated three times as motivational music, slow-paced music, and music. Heart rate, respiratory frequency, perceived exertion will be evaluated before and after the test.
16356840|NCT04280406|Active Comparator|Test|- 500mg of azithromycin one hour before implant placement
16356841|NCT04280406|Placebo Comparator|control|- identical placebo one hour before implant placement
16356842|NCT04280393|Experimental|Endocuff|Colonoscopy procedure with the use of endocuff
16356843|NCT04280393|Active Comparator|Control|Standard Colonoscopy procedure
16356844|NCT04280380||Mechanical ventilated patients without cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.
~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.
~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
16356845|NCT04280380||Mechanical ventilated patients with cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.
~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.
~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
16356846|NCT04280367||Comparator group|Specific learning disorders group
16356847|NCT04280367||neuro-developmental complexed group|Group of neuro-developmental complexe of learning
16356848|NCT04280367||Complexed with anxiety|Disorders in learning with anxiety
16356849|NCT04280354||patients with severe community acquired pneumonia (cases)|Cases: Patients with severe community acquired pneumonia with required ICU admission.
16356850|NCT04280354||patients without pneumonia or sepsis (controls)|Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever >38°C, C reactive Protein (CRP) >100mg/L, no infection focus expected in ≥ 24h.
16356851|NCT04280341|Experimental|RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody|RC48-ADC(Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate) JS001(Recombinant Humanized Anti-PD1 Monoclonal Antibody)
16356852|NCT04280328|Experimental|Ciforadenant in combination with daratumumab|Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.
16356853|NCT04280315||Cases|"Cases are patients with type 1 diabetes in three age strata:
~20 participants in the age of 2-10 years
~20 participants in the age of 11-20 years
~10 participants with more than 30 years of diabetes duration"
16356854|NCT04280315||Controls|Controls are age and sexmatched with the cases and are recruited from the neuropediatric clinic at Herlev Hospital as well as relatives and parents of patients in the whole Pediatric Department
16356855|NCT04280302|Experimental|Virtual reality based therapy|
16356856|NCT04280302|Active Comparator|Conventional Therapy|
16356857|NCT04280289|Experimental|Cannabidiol extract|"10 healthy subjects (5 female, 5 male), will be enrolled into the study. Each subject will receive a single CBDE dose delivering 2.5 mg/kg CBD, after consumption of a standardized meal.
~Nine (9mL) of blood for PK analysis, at each of the following timepoints: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the study drug administration.
~Urine will be collected at the following timepoints: Predose, 0-4 hrs, 4-8 hrs, 8-12 hrs, 12-24 hrs, 24-36 hrs, 36-48 hrs, and 48-72 hrs for PK analysis"
16356858|NCT04280276|Active Comparator|Group 1 - Patients with high IPV (designated as ≥ 30%).|Patients with high IPV (designated as ≥ 30%).
16356988|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
16356859|NCT04280276|Active Comparator|Group 2 - patients with normal IPV (< 30%).|Patients with normal IPV (< 30%). Will assess risk of subclinical acute rejection in patients with high IPV compared to normal IPV. All tacrolimus 12 h trough levels in patients with stable allograft function at least 3 months post-transplant.
16356860|NCT04280263|Active Comparator|Caffiene|This group will receive 150mg caffeine tablets to be taken twice per day
16356861|NCT04280263|Placebo Comparator|placebo|
16356862|NCT04280250|Active Comparator|Group 1|Active control arm: Volitional help-sheet with instruction: We want you to plan to increase your level of physical activity. Research shows that if people can identify situations in which they are likely to be tempted not to be physically active and ways to overcome temptation they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page are a series of common situations in which people feel tempted not to be physically active; please tick all those that apply to you personally. On the right hand side of the page are a series of possible solutions; please tick all those that apply to you personally. Tick as many or as few situations and solutions as you like.
16356863|NCT04280250|Experimental|Group 2|"Experimental arm: Volitional help-sheet with instruction:
~We want you to plan to increase your level of physical activity. Research shows that if people link being tempted not to be physically active with a way to overcome that temptation, they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page below is the temptation not to be physically active; on the right hand side of the page are a series of possible solutions. Please draw lines linking being tempted not to be physically active (left hand side) to solutions (right hand side) that you think might work for you personally. Please make as many situation-solution links as you like."
16356864|NCT04280237||Cefazolin in liver transplantation|Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin
16356865|NCT04280224|Experimental|NK Cells Treatment Group|Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2*10E7 NK cells/kg body weight).
16356866|NCT04280224|No Intervention|Conventional Control Group|Participants will only receive conventional treatment.
16356867|NCT04280211||COPD Group|Patients who are over 40 years old, diagnosed with COPD
16356868|NCT04280211||Control Group|Healthy adults over 40 years old
16356869|NCT04280198|No Intervention|No Intervention: Group 1 - Control|Participants will attend three laboratory visits: baseline 1, baseline 2, and post-test. At baseline 2 and post-test, the primary outcome of child RRV of food vs. parent child interaction is measured. Other measures include child height and weight, child self-regulation, and parenting in the context of a parent-child interaction task. Participants in the control group will not be assigned to complete any intervention activities during the 4-week intervention phase (which takes place between baseline 2 and post-test visits); however, they will receive contacts from a member of the lab each week in the form of electronic reminders (i.e. texts) to remind them of their upcoming post-test laboratory appointment and will receive some intervention materials after the post-test assessment.
16356870|NCT04280198|Experimental|Experimental: Group 2 - Intervention|Participants will attend the same three laboratory visits as the control group. The intervention group will also participate in a 4-week intervention, which consists of the parent watching brief weekly parenting videos from the online Triple P Parenting Program and completing interactive parent-child activities from activity boxes created by our laboratory (~60 min of interactive activities/week). Participants will use their activity boxes to practice specific parenting skills from the week's parenting video. Throughout the intervention phase, participants will receive regular text messages to remind them of the week's activities and ask several questions about engagement in study activities over the past 24 hours. The intervention group will also complete an exit interview about the intervention following the post-test assessment to provide insights on fidelity and acceptability.
16356871|NCT04280185|Experimental|Hyperthermic Intraperitoneal chemotherapy|Hyperthermic Intraperitoneal chemotherapy was started immediately after CRS, or the first HIPEC was completed within 48 hours after surgery: temperature 43℃, duration 60 minutes, Paclitaxel (60mg/m2) was selected. The second HIEPC was completed 7 days after the first HIPEC: temperature 43℃, duration 60min, carboplatin AUC (5-6) was selected. 30 minutes before using Paclitaxel, 10ML saline + 10mg dexamethasone intravenous infusion, 20mg diphenhyramine intramuscular injection, and 100ML saline + 0.3g cimetidine intravenous infusion. On the eighth day, intravenous chemotherapy with Paclitaxel (135mg/m2) was finally completed. 5 courses of TC intravenous chemotherapy were performed after 3 weeks
16356872|NCT04280185|No Intervention|intravenous chemotherapy|intravenous chemotherapy were performed 6 Cycles after CRS. Paclitaxel: 175mg/m2, iv infusion, no less than 3h per infusion, followed by carboplatin: AUC 5-6, iv infusion, no less than 1h per infusion, 1 dose on the first day of a week, 1 cycle every 3 weeks, a total of 6 cycles. Paclitaxel should be pretreated to prevent severe allergic reactions.
16356873|NCT04280172|Experimental|Cultural Competence Education|Participants in the intervention group will attend cultural competence education
16356874|NCT04280172|Active Comparator|Standard Mentoring Education|Participants in the control group will complete standard mentoring education that does not include a cultural competence component
16356875|NCT04280146|Active Comparator|Degree of food processing|unprocessed vs ultra-processed foods according to NOVA table.
16356876|NCT04280146|Active Comparator|eating rate|slow vs fast eating rate (kcal/min), manipulated by food form
16356877|NCT04280133|Experimental|Educational Video Tool|Patients randomized to the intervention arm will watch a 3-minute video educational tool about CAR-T cell therapy prior to admission for CAR-T cell therapy.
16356878|NCT04280133|No Intervention|Standard Care|Patients randomized to the control arm will receive usual care per the treating team. Any questions regarding CAR-T cell therapy will be directed to the patient's medical team
16356879|NCT04280120|Experimental|Neural Mobilisation Group|"Massage therapy.
~Faradic electrical stimulation.
~Exercises in front of the mirror.
~Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest."
16357378|NCT04276688|Active Comparator|Study group|triple combination
16357379|NCT04276688|Active Comparator|Control group|single
16356880|NCT04280120|Active Comparator|Conservative group|"Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
~Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
~Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes."
16356881|NCT04280107||Temporomandibular Dysfunction|For this study, 154 patient files who were admitted to the radiology department of the faculty of dentistry between 2013 and 2019 with complaints such as TMJ pain, mouth opening restriction, joint sound, joint function disorder were scanned retrospectively. Inclusion criteria: TMD patients with MR and CBCT images recorded in the digital archive. Exclusion criteria: Patients who have been operated or treated from TMJ, patients with head and neck trauma, patients with orthodontic treatment.
16356882|NCT04280081|Experimental|Selpercatinib|Selpercatinib given orally.
16356883|NCT04280068|Active Comparator|Clinician Guide|Clinician Guide is an evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
16356884|NCT04280068|Active Comparator|Clinician Guide plus HealthCall|Clinician Guide plus the use of HealthCall, a smartphone application to monitor daily alcohol use, ART adherence and other health behaviors.
16356885|NCT04280055|Experimental|Psilocybin|
16356886|NCT04280042||Thoracoscopic surgical ablation|Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
16356887|NCT04280042||Cather ablation|Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
16356888|NCT04280029|Experimental|SELUTION SLR™ DEB|
16356889|NCT04280029|Active Comparator|Control Treatment|"For subjects randomized to the control group (SOC) the treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. The decision should be based on the treating physicians' assessment of the best treatment option for the individual patient. However, it is expected that patients with one prior stent will receive DES and patients with two prior stents will receive POBA. Treating physicians may deviate from this if it is determined to be in the best interest of the patient, but the justification for the treatment decision must be recorded in eCRF.
~Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices."
16356891|NCT04280003|Experimental|Treatment group|15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.
16356892|NCT04280003|Placebo Comparator|Placebo group|15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group.
16356893|NCT04279990||Functional dyspepsia patients with JHS|Patients with functional dyspepsia as defined by the Rome III criteria and joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
16356894|NCT04279990||Functional dyspepsia patients without JHS|Patients with functional dyspepsia as defined by the Rome III criteria and WITHOUT joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
16356895|NCT04279990||Healthy subjects|Healthy subjects with no gastrointestinal diseases including no functional dyspepsia
16356896|NCT04279977||Inpatient Rehabilitation Facility|Individuals post-stroke who are discharged to an inpatient rehabilitation facility.
16356897|NCT04279977||Skilled Nursing Facility|Individuals post-stroke who are discharged to a skilled nursing facility.
16356898|NCT04279964|Experimental|Boot Camp Translation|Intervention practices will undergo the Boot Camp Translation process.
16356899|NCT04279964|Active Comparator|Control|Control practice will behave as usual.
16356900|NCT04279951|Experimental|Omega 3|"Intake of 1 gram omega-3 (capsules) per day for 20 weeks
~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
16356901|NCT04279951|Placebo Comparator|Placebo|"Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks
~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
16356902|NCT04279951|No Intervention|Control|No intervention
16356903|NCT04279938|Other|Safety Run in & Main Efficacy Part|"Part 1 (safety run-in) aims to evaluate the maximum tolerated dose (MTD) of tinostamustinein combination with pembrolizumab (200mg Q3W) and rituximab (375mg/m2 Q3W). The dose of tinostamustineestablished to be safe and tolerable in this combination will be used in part 2 of the trial (main efficacy part).
~The aim of part 2 is to detect signals of anti-tumour activity and to further assess the safety of this combination treatment in r/r DLBCL. The study has a strong focus on correlative research in order to identify mechanisms of response and resistance to pembrolizumab and the pembrolizumab/R-tinostamustinecombination."
16356904|NCT04279925|Experimental|Locally-made Miniplate and screw|"The investigators define Biomet® miniplate 1.5 as miniplate produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate that is using in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog.
~The investigators define Biomet® screw 1.5 as screw produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws."
16356989|NCT04279223|Active Comparator|5 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
16357421|NCT04276402|No Intervention|Left side of the maxilla|
16356905|NCT04279925|Active Comparator|Imported Miniplate and screw|"The investigators define locally-made miniplate as plate produced by the Faculty of Technique Universitas Indonesia, The particular plate that is using in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
~The investigators define locally-made screw as screw produced by the Faculty of Technique Universitas Indonesia, with dimensions of 4.57 mm long and 1.5mm diameter."
16356906|NCT04279912|Experimental|Patients with Multiple Sclerosis and Tremor|Participants will undergo MRgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
16356907|NCT04279886|Other|Three-dimensional scan arm|
16356908|NCT04279873||Adults with nosocomial pneumonia|Diagnostic procedures on pulmonary secretion collected by tracheal suctioning and bronchoalveolar lavage.
16356909|NCT04279847|Experimental|INCB057643 Monotherapy|INCB057643 dose escalation (Part 1) and dose expansion (Part 2: treatment group A).
16356910|NCT04279847|Experimental|INCB057643 Combination with Ruxolitinib|Combination arm in dose escalation (Part 1) and dose expansion (Part 2: Treatment Group B)
16356911|NCT04279834|Active Comparator|PAP Treatment|Participants will receive a PAP device and will attend four weekly sessions to receive education about this treatment.
16356912|NCT04279834|Active Comparator|Sleep Education I|Participants will attend four weekly sessions to receive education about strategies to improve sleep.
16356913|NCT04279834|Active Comparator|Sleep Education II|Participants will attend four weekly sessions to receive education about sleep health.
16356914|NCT04279821||Colonic diverticulosis and macroscopic signs of inflammation|No interventional study
16356915|NCT04279808|Experimental|measured distance|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will measure the distance between the skin puncture site and the outside of anterior wall of the jugular vein. Next, we will insert the dilator on the guidewire by the measured length."
16356916|NCT04279808|No Intervention|conventional method|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will insert the dilator on the guidewire as commonly used method of the practitioners."
16356917|NCT04279782||Exclusion group|Patients with two consecutive negative results of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swabs
16356918|NCT04279782||Confirmed group|Patients with positive result of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swab
16356919|NCT04279769|Experimental|Cohort 1|CB-280 twice daily at 50 mg for 14 days
16356920|NCT04279769|Experimental|Cohort 2|CB-280 twice daily at 100 mg for 14 days
16356921|NCT04279769|Experimental|Cohort 3|CB-280 twice daily at 200 mg for 14 days
16356922|NCT04279769|Experimental|Cohort 4|CB-280 twice daily at 400 mg for 14 days
16356923|NCT04279769|Placebo Comparator|Placebo|Placebo twice daily for 14 days
16356924|NCT04279756|Active Comparator|Mildly Impaired Group|This group is with participants with mildly impaired hip internal range of motion, from 25-30 degrees.
16356925|NCT04279756|Active Comparator|Moderately Impaired Group|This group is with participants with moderately impaired hip internal range of motion, from 20-24 degrees.
16356926|NCT04279756|Active Comparator|Severely Impaired Group|This group is with participants with severely impaired hip internal range of motion, less than 20 degrees.
16356927|NCT04279743|Experimental|ApoE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
16356928|NCT04279743|Experimental|ApoE4 non carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
16356929|NCT04279730||Inpatient pulmonary rehabilitation|Multidisciplinary inpatient pulmonary rehabilitation program lasting 4 weeks (40 sessions, 2 sessions per day, 5 days per week).
16356930|NCT04279717||Subjects with von Willbrand Disease Acquired|
16356931|NCT04279717||Subjects with von Willbrand Disease Congenital|
16356932|NCT04279691||periodontitis and rheumatoid arthritis|group 1: patiernts with periodontitis and rheumatoid arthritis. only
16356933|NCT04279691||periodontitis|group 2: patiernts with periodontitis
16356934|NCT04279678||patients undergone mitral repair|includes all patients undergone repair of mitral valve with CABG
16356935|NCT04279678||patients with no mitral repair|includes all patients where no repair done for mitral valve , only CABG
16356936|NCT04279665|Experimental|Subjects undergoing electrophysiology procedure|Subjects will wear a virtual reality (VR) headset for a total of 40 minutes separated over 2 sessions during an electrophysiology procedure they are already scheduled to undergo.
16356937|NCT04279652|Experimental|Supervised exercise group|The treatment program was determined as 3 sessions per week for 8 weeks and 60 minutes per session. The treatment program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
16356938|NCT04279652|Active Comparator|Home exercise group|The exercise program, which is prepared for the individual, will be applied to the home exercise group with 60 minutes of 3 times a week.
16356939|NCT04279652|No Intervention|Control group|Children will not be included in any treatment program. The assessments will be done again 8 weeks later.
16356940|NCT04279639||qigong practice|Patients in this arm participated in qigong as part of their treatment at the Pain Management Unit
16356941|NCT04279639||control|Patients attend the pain management unit but do not undertake qigong practice.
16356942|NCT04279626||LETS-M|Women who were older than 20 years old and had not reached menopause, with symptomatic uterine myomas, such as hypermenorrhea, infertility, a mass effect-related urinary frequency, and constipation, received LETS-M.
16356943|NCT04279613|Experimental|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site
16356944|NCT04279613|Placebo Comparator|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
16356945|NCT04279600|Experimental|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
16357422|NCT04276389|Active Comparator|OCT-guided arm|
16356946|NCT04279600|Active Comparator|Taurine supplementation associated to exercise training|"Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
16356947|NCT04279600|Placebo Comparator|Placebo supplementation associated to exercise training|"Placebo supplementation composed of capsules of starch powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
16356948|NCT04279587|Experimental|Residential camp participant|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at a regional camp.
16356949|NCT04279574|Other|CAD/CAM Onlays|Lithium disilicate chairside CAD/CAM onlays (IPS emaxCAD/Ivoclar) will be adhesively bonded using a selective enamel etch technique with an adhesive (3M) and cement (3M).
16356950|NCT04279574|Other|CAD/CAM Crowns|Full contour zirconia crowns (3M Chairside Zirconia/3M) will be cemented using a self-adhesive cement (3M).
16356951|NCT04279561|Experimental|Diagnostic (68GA-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
16356952|NCT04279548|Active Comparator|On DBS|Patients in the on mode DBS
16356953|NCT04279548|Sham Comparator|Off DBS|Patients in the off mode DBS
16356954|NCT04279535|Experimental|Treatment group|Participants applied topical solution of ascorbic acid twice daily for 8 weeks
16356957|NCT04279509|Experimental|Cancer patient|Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
16356958|NCT04279483|Experimental|7-11 Group|Participants visit 7-11 every weekday during the 4-week (20 store visits total) intervention period
16356959|NCT04279483|Experimental|CVS Group|Participants visit CVS every weekday during the 4-week (20 store visits total) intervention period
16356960|NCT04279483|No Intervention|Control|Participants are not asked to alter their behavior during the 4-week (0 store visits) intervention period
16356961|NCT04279470||Adverse Events with cellular therapies|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Chimeric Antigen Receptor T-cell and Cellular Therapies, with a chronology compatible with the drug toxicity
16356962|NCT04279457|Active Comparator|Standardized Hydration protocol|These cases will follow Charleston Area Medical Centers standard Hydration protocol
16356963|NCT04279457|Active Comparator|Hydration + Device|These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
16356964|NCT04279444|Experimental|Active BKR-017|Open label study. All patients will receive 28 days of active treatment.
16356967|NCT04279418|Experimental|Mixed functional foods group with SCD|Thirty participants in this group will take mixed functional foods for three months.
16356968|NCT04279418|Placebo Comparator|Placebo group with SCD|Thirty participants in this group will take placebo for three months.
16356969|NCT04279405|Experimental|YY-20394|treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity.
16356970|NCT04279392|Active Comparator|Active Infusion|At 6 weeks post surgery, 5 mg of zoledronic acid in 100 ml of saline will be infused intravenously over a 15 minute time period.
16356971|NCT04279392|Placebo Comparator|Non-active Infusion|At 6 weeks post surgery, 100 ml of saline will be infused intravenously over a 15 minute time period.
16356972|NCT04279379|Experimental|treatment arm|Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.
16356973|NCT04279366||Winter course|The recruited particpants attending the winter course
16356974|NCT04279366||Fall course|The recruited particpants attending the winter course
16356975|NCT04279353|Experimental|Mindfulness Based Intervention|Participants was asked to answer PSS-10 questionnaire to measure their stress level, then they received Mindfulness Based Intervention program for 4 weeks and did the PSS-10 test again after 4 weeks.
16356976|NCT04279327||cases|cytology positive for malignancy
16356977|NCT04279327||controls|cytology negative for malignancy
16356978|NCT04279314|Experimental|Trofinetide|
16356979|NCT04279288|Experimental|participants enrolled with epistaxis and/or nasal fractures|
16356980|NCT04279275||Survey|Knowledge survey
16356981|NCT04279262||Anonymised records from 6 ambulance services|The total available sample for analysis for this cohort is estimated to be at least 50,000 incidents across 6 ambulance trusts. The investigators will describe the epidemiology of CFR provision to rural health areas using an anonymised dataset.
16356982|NCT04279262||Interviews with patients (and/or relatives)|The investigators will interview about 15-20 patients (and/or relatives) who have been attended by CFRs.
16356983|NCT04279262||Interviews with CFRs|The investigators will interview about 15-20 CFRs/ CFR scheme leaders.
16356984|NCT04279262||Interviews with Ambulance staff|The investigators will interview about 15-20 ambulance staff who have experience of working with CFRs.
16356985|NCT04279262||Interviews with GPs and commisioners|The investigators will interview about 10-15 GPs and ambulance service commissioners.
16356986|NCT04279249|Active Comparator|HEPA Filtration|
16356990|NCT04279223|Sham Comparator|10 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
16356991|NCT04279210|Experimental|PRP Treatment|Women with SUI received PRP injection into anterior vaginal wall (near external urethral sphincter) once per month for three times.
16356992|NCT04279197|Experimental|Basic Treatment+Fuzheng Huayu Tablet|"basic treatment (respiratory function rehabilitation training + Vitamin C tablets)
~FZHY"
16356993|NCT04279197|Placebo Comparator|Basic Treatment+Placebo|"basic treatment (respiratory function rehabilitation training + Vitamin C tablets)
~placebo"
16356994|NCT04279158|Experimental|patients with optic ataxia (OA)|
16356995|NCT04279158|Experimental|patients with hemispatial neglect|
16356996|NCT04279158|Experimental|patients with attention-deficit hyperactivity disorder|
16356997|NCT04279158|Active Comparator|Healthy volunteers|
16356998|NCT04279145|Experimental|pulmonary hypertension group 1|each patient will be submitted to : swan-ganze catheterization detailed echocardiography blood sample for biomarkers (troponin, uric acid and micro RNA)
16356999|NCT04279132||TOTAL INTRAVENOUS ANESTHESIA|
16357000|NCT04279132||INHALATION ANESTHESIA|
16357001|NCT04279119|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
16357002|NCT04279106|Experimental|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16357003|NCT04279106|Active Comparator|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16357004|NCT04279106|Active Comparator|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16357005|NCT04279106|Placebo Comparator|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16357006|NCT04279093||Pregnant/postpartum women and their partners|"The investigators aim to recruit 20 women in late pregnancy from the Antenatal Assessment Unit and the Antenatal Clinic at St Mary's Hospital. Their partners will be invited to participate where applicable.
~Inclusion and exclusion criteria for pregnant women are as follows:
~Inclusion: after 36 weeks gestation, aged over 18 years and fluent in English, under the care of Manchester University NHS Foundation Trust
~Exclusion: current stillbirth (women experiencing a stillbirth during the study will be withdrawn from the study), fetal abnormality, or multiple pregnancy
~Inclusion criteria for partners: male or female partners of a mum participating in the study, aged over 18 and fluent in English."
16357007|NCT04279080||1|rectal cancer patients
16357008|NCT04279080||2|ovarian cancer patients
16357009|NCT04279067|Experimental|BCI-FES dorsiflexion therapy with physiotherapy|"Subjects will undergo placement of an EEG cap using standard technique connected to our custom BCI system. Subjects will provide 5 min of training EEG data as they engage in alternating epochs of idling and attempted foot dorsiflexion (of the paretic side). In the online phase, the subjects will perform 20-25 BCI-FES runs. A total of 12 sessions will be performed at a rate of 3x/week (over 4 weeks). Each BCI-FES therapy session will be followed by 1 hour of conventional physiotherapy.
~Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises."
16357010|NCT04279067|Experimental|Dose-and intensity-matched physiotherapy|"Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
~In the dose-matched control group (Group 2), it will be 2 hours/session."
16357011|NCT04279054|Active Comparator|Group A: 150 mcg morphine|Patients in this group will receive 150mcg of morphine in their neuraxial block
16357012|NCT04279054|Experimental|Group B: 50 mcg morphine|Patients in this group will receive 50mcg of morphine in their neuraxial block
16357013|NCT04279041|Experimental|Fanta and Zunba rotatory files|Fanta and Zunba rotatory files
16357014|NCT04279041|Active Comparator|manual K-files|manual K-files
16357015|NCT04279028|Active Comparator|Standard CBT|
16357016|NCT04279028|Experimental|Adapted CBT|
16357017|NCT04279015|Active Comparator|Conventional rehabilitation treatment|Conventional physiotherapy program, consisting of standardised active (exercise) and passive (hotpack, ultrasound, conventional TENS) physical therapy methods, was applied by the same physiotherapist.
16357018|NCT04279015|Active Comparator|Kinesio tape procedure|In addition to the conventional physiotherapy program Kinesio tape was performed every day of conventional treatment immediately after the session ended by the same physiotherapist.
16357019|NCT04279002||Respiratory rehabilitation course|Patients who has completed at least one respiratory rehabilitation course at the Espace du Souffle (Tours France) within the 5 years prior to inclusion
16357020|NCT04278989|Active Comparator|Anti-tumor B|1,200 mg three times a day.
16357021|NCT04278989|Placebo Comparator|Placebo|Placebo taken three times a day.
16357022|NCT04278976|Experimental|CoBaTriCE|Implementation of CoBaTrICE. The implementation of CoBaTrICE is based on: 1. Training the trainers; 2. Multiple Workplace-based assessment exercices; 3. The use of an electronic portfolio.
16357023|NCT04278976|No Intervention|Control|The participants of the control group will follow the current official model of training in ICM in Spain, which is based on exposure to experiences through time-based clinical rotations; a generic report, non-based on formal assessment, about knowledge, technical and nontechnical skills is performed after every clinical rotation, and yearly by the tutor.
16357024|NCT04278963|Experimental|Yin Hu Qing Wen Decoction Group|Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
16357025|NCT04278963|Placebo Comparator|Yinhu Qingwen Decoction low-dose group|Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
16357026|NCT04278963|Active Comparator|Integrated Chinese and Western Medicine group|Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml). The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
16357027|NCT04278950|Active Comparator|Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with 0.10% PVP-I (0.01% available iodine). Patients will be instructed to dilute 2.5mL of the betadine (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
16357028|NCT04278950|Placebo Comparator|Placebo Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with a placebo PVP-I solution. Patients will be instructed to dilute 2.5mL of the placebo PVP-I (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
16357029|NCT04278937|Active Comparator|Azithromycin group|women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
16357030|NCT04278937|No Intervention|Control group|women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
16357031|NCT04278924|Placebo Comparator|Part A: Double Blind, Placebo|TAK-079 placebo-matching injection subcutaneously (SC) once weekly (QW) for 8 weeks.
16357032|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 1|TAK-079 Dose 1, SC injection QW for 8 weeks.
16357033|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 2|TAK-079 Dose 2, SC injection QW for 8 weeks.
16357034|NCT04278924|Experimental|Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1|Participants who received placebo in double-blind Part A and opt to receive further treatment who have been randomized to receive TAK-079 Dose 1, SC injection QW for 8 weeks in OLE phase of Part A.
16357035|NCT04278924|Experimental|Part A: OLE Phase, TAK-079 Dose 2|Participants who received placebo in double-blind Part A and opt to receive further treatment who have been randomized to receive TAK-079 Dose 2, SC injection QW for 8 weeks in OLE phase of Part A.
16357036|NCT04278924|Placebo Comparator|Part B: Double Blind, Placebo|TAK-079 placebo-matching injection SC, QW for 8 weeks.
16357037|NCT04278924|Experimental|Part B: Double Blind, TAK-079 Dose 3|TAK-079 Dose 3, SC injection QW for 8 weeks.
16357038|NCT04278924|Experimental|Part B: OLE Phase, TAK-079 Dose 3|Participants who received placebo in double-blind Part B and opt to receive further treatment will receive TAK-079 Dose 3, SC injection QW for 8 weeks in OLE phase of Part B.
16357039|NCT04278911||Participates|This is an observational study
16357040|NCT04278898|Experimental|N-acetylcysteine then Placebo|
16357041|NCT04278898|Experimental|Placebo then N-acetylcysteine|
16357042|NCT04278885|Experimental|Lanadelumab|
16357043|NCT04278872|Experimental|SJX-653|Participants will receive SJX-653
16357044|NCT04278872|Placebo Comparator|Placebo|Participants will receive placebo
16357045|NCT04278859|Experimental|0.3mg/kg repeat dose every 21 days up to 2 years|
16357046|NCT04278859|Experimental|1 mg/kg repeat dose every 21 days up to 2 years;|
16357047|NCT04278859|Experimental|3 mg/kg repeat dose every 21 days up to 2 years;|
16357048|NCT04278859|Experimental|10 mg/kg repeat dose every 21 days up to 2 years;|
16357049|NCT04278846|Experimental|DepoFoam bupivacaine|local anesthetic
16357050|NCT04278846|Active Comparator|bupivacaine HCl|local anesthetic
16357051|NCT04278833|Other|Particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 10-80mg of triamcinolone or 3-9mg of betamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
16357052|NCT04278833|Other|Non-particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 4-10mg of dexamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
16357053|NCT04278820|Experimental|Climbing group|
16357054|NCT04278820|Experimental|Titration group|
16357055|NCT04278820|Experimental|Extension group|
16357056|NCT04278807|Experimental|PENG-group|Ultrasound-guided PENG-block - 30 patients
16357057|NCT04278807|Experimental|FIB-group|Ultrasound-guided Fascia Iliaca block - 30 patients
16357058|NCT04278794|Experimental|Transitional Care Stroke Intervention (TCSI)|Participants randomly assigned to the intervention group will be offered the intervention in addition to usual care provided by in-patient and outpatient stroke rehabilitation services. The TCSI is a 6-month stroke transitional care intervention, provided in addition to usual stroke care, that includes four core components: comprehensive hospital discharge plan, structured home visits and telephone support, monthly intraprofessional case conferences, and linkages to primary care and other healthcare and community services. The TCSI will be delivered by an interprofessional team of care providers at the study site, including an occupational therapist, registered nurse, speech language pathologist, physical therapist, and social worker from a hospital-based outpatient stroke rehabilitation setting.
16357059|NCT04278794|No Intervention|Control|Usual care provided by in-patient and out-patient stroke rehabilitation services.
16357060|NCT04278781|Experimental|Chondrosarcoma|Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma
16357061|NCT04278768|Experimental|CA-4948 dose escalation|Patients receive CA-4948 monotherapy PO BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16357062|NCT04278768|Experimental|CA-4948 dose escalation + Azacitidine|The starting dose level for CA-4948 will be 200 mg BID for 21 days (Days 1-21) of a 28-day Cycle. Anticipated CA-4948 doses will be 200, 300, 400 mg BID. Azacitidine 75 mg/m2 intravenous (IV) or subcutaneously (SC) will be administered as 7 doses on a 28-day Cycle (e.g., 7 consecutive doses or split doses with weekend break 5-2, starting at Day 1)
16357063|NCT04278768|Experimental|CA-4948 dose escalation + Venetoclax|The starting dose level for CA-4948 will be 200 mg BID for 21days of a 28-day Cycle. Anticipated CA-4948 doses will 200, 300, 400 mg BID. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
16357423|NCT04276389|Placebo Comparator|Angiography-guided arm|
16357064|NCT04278768|Experimental|CA-4948 monotherapy dose expansion|The Expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 4 Cohorts and patients will be assigned to each Cohort based on baseline disease.
16357065|NCT04278755|Experimental|Continuous OC|Continuous daily oral drospirenone + ethinyl estradiol for 84 days (i.e., 12-weeks).
16357066|NCT04278742|Experimental|Interventional - collaborative education|Collaborative style of communication whereby the clinician and patient co-creates the treatment plan
16357067|NCT04278742|No Intervention|Control group|Traditional directive and didactic style of patient information will be provided
16357068|NCT04278729|Experimental|Nephrotic Syndrome Arm|Patients diagnosed with Nephrotic syndrome will be in this arm.
16357069|NCT04278729|Experimental|Healthy Arm|Healthy volunteers will be in this arm.
16357070|NCT04278716||Utilization of a safe return to play checklist|Athletes who were treated for a capsulolabral tear who have undergone arthroscopic capsulolabral repair surgery will be evaluated using an objective checklist prior to being allowed to return to their sport. The utilization and outcome of using this checklist will be evaluated
16357071|NCT04278703|Active Comparator|15 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
16357072|NCT04278703|Active Comparator|25 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
16357073|NCT04278703|Active Comparator|35 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
16357074|NCT04278690|No Intervention|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
16357075|NCT04278690|Experimental|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
16357076|NCT04278690|Experimental|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
16357077|NCT04278677|Active Comparator|Melatonin supplementation|5mg melatonin tablets to be taken for 6 weeks
16357078|NCT04278677|No Intervention|No supplementation|
16357079|NCT04278651|Active Comparator|Oral Iron|325mg oral iron (ferrous sulfate) twice daily
16357080|NCT04278651|Experimental|Intravenous Iron|510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.
16357081|NCT04278638|Experimental|with IORT|
16357082|NCT04278638|Active Comparator|without IORT|
16357083|NCT04278625||Cyanotic CHD|Cyanotic congenital heart disease (CHD) patients presenting for Fontan palliation.
16357084|NCT04278625||Acyanotic CHD|Acyanotic congenital heart disease (CHD) patients presenting for repair via median sternotomy.
16357085|NCT04278612|Experimental|Intervention|"Provision of comprehensive care including the following:
~Baby:
~Measure weight and length Plot on appropriate growth charts in Road to Health Card (RTHC) Discuss with mother about the growth of the baby Identification of malnutrition and appropriate management Age-appropriate nutrition counselling Immunisation Developmental screening Vitamin A supplementation Deworming HIV Care: If mother is HIV positive -
~Polymerase chain reaction (PCR) test for the baby repeated at 10 weeks
~Nevirapine for the baby for six weeks
~Mother:
~Cervical cancer screening Provide family planning Screening tuberculosis (TB) and sexually transmitted infections (STIs)
~HIV Care:
~HIV positive mothers - provide ART for the mother and adherence support
~HIV negative mothers- HIV test every three months while breastfeeding"
16357086|NCT04278612|Active Comparator|Control|Routine maternal and child care service delivery
16357087|NCT04278599|Experimental|Test group|The patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
16357088|NCT04278599|Placebo Comparator|Control group|The patients will be administered Placebo tablets for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
16357089|NCT04278586|Experimental|Live-Online Mindful Recovery OUD Care Continuum|Live-Online Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed for patients with OUD prescribed buprenorphine to be delivered in a live-online environment. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. The live-online M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then a mindfulness maintenance check-in support group.
16357090|NCT04278586|Active Comparator|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
16357091|NCT04278573|Experimental|Vitamin D3 Treatment Group|Subjects will receive a Vitamin D3 injection into their wart
16357092|NCT04278573|Placebo Comparator|Placebo Group|Subjects will receive a placebo injection into their wart
16357093|NCT04278560|Experimental|Behavioral intervention plus tDCS|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
16357094|NCT04278560|Active Comparator|Behavioral intervention plus sham stimulation|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.
16357095|NCT04278547|Experimental|Experimental group|Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis;
16357096|NCT04278547|No Intervention|Control group|Standard of care, universal prophylaxis with valgancyclovir for 3 months).
16357097|NCT04278534|Experimental|Arm I (VERT)|Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
16357098|NCT04278534|Active Comparator|Arm II Control Group I (usual education materials)|Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
16357099|NCT04278534|Active Comparator|Arm II Control Group II (face-to-face education module)|Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
16357100|NCT04278534|Active Comparator|Observational Cohort (usual education materials)|Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
16357101|NCT04278521|Other|Unipolar Depression|Patients diagnosed with unipolar depression.
16357102|NCT04278508|Active Comparator|Group A|P < 10.0 ng/ml with increasing P dosage from 800 mg to 1200 mg daily from the FET day.
16357103|NCT04278508|Active Comparator|Group B|P < 10.0 ng/ml without change in drug regimen.
16357104|NCT04278508|Active Comparator|Group C|P ≥ 10.0 ng/ml without change in drug regimen.
16357105|NCT04278495|Active Comparator|Losartan|"to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp & Dohme-UK),"
16357106|NCT04278495|Placebo Comparator|Placebo|to receive either placebo
16357107|NCT04278482|Active Comparator|DHA supplement|Supplement rich in DHA form algae source
16357108|NCT04278482|Placebo Comparator|Placebo|Placebo supplement
16357109|NCT04278469|Active Comparator|Patients with chemotherapy|
16357110|NCT04278469|No Intervention|Patients without chemotherapy|
16357111|NCT04278456||general anesthesia|c-section with general anesthesia
16357112|NCT04278456||spinal anesthesia|c-section with spinal anesthesia
16357113|NCT04278456||epidural anesthesia|c-section with epidural anesthesia
16357114|NCT04278443||Low dose rate brachytherapy|20 patients receiving low dose rate brachytherapy
16357115|NCT04278443||High dose rate brachytherapy|20 patients receiving high dose rate brachytherapy.
16357116|NCT04278430|Experimental|Real tDCS group|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 1.5 mA intensity
16357117|NCT04278430|Sham Comparator|Sham tDCS|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 0 mA intensity.
16357118|NCT04278430|Active Comparator|Control|The normal heathy children age matched undergo the same activity and brain stimulation as the real tDCS group.
16357121|NCT04278404||Children and young adults who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
16357122|NCT04278391|Experimental|A (RT)|Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
16357123|NCT04278391|Experimental|B (TR)|Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)
16357124|NCT04278378|Active Comparator|Riboflavin|1.6 mg riboflavin / day for 24 weeks
16357125|NCT04278378|Experimental|Folic Acid|0.4 mg folic acid/ day for 24 weeks
16357126|NCT04278378|Experimental|Riboflavin + Folic Acid|1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
16357127|NCT04278378|Placebo Comparator|Placebo|
16357128|NCT04278365|Experimental|AMP-A|Participants will complete 11, 90-minute sessions of positive affect training. The positive affect training will be conducted in an individual setting. Positive affect training directly targets reward and positive valence processing and has been shown by previous research to enhance positive affect (and decrease negative affect).
16357129|NCT04278352|Experimental|Mindfulness Based Relapse Prevention|MBRP is a group aftercare program that integrates mindfulness skills training with cognitive-behavioral relapse prevention strategies. The intervention consists of eight weekly two-hour group therapy sessions, delivered by two facilitators with 6-12 people. The experimental group will complete the intervention in weeks 1-8. They will continue treatment as usual for weeks 9-16.
16357130|NCT04278352|No Intervention|Control|The waitlist control group will not receive the MBRP program during weeks 1-8 and will continue treatment as usual. During weeks 9-16, the control group will receive MBRP.
16357131|NCT04278339|Experimental|CONTROLLED SUBJECTS|In this arm, only controlled subjects (pathological-free) will be investigated.
16357132|NCT04278339|Experimental|PATIENTS|In this arm, only patients with scyzophrenic syndrome will be investigated.
16357133|NCT04278326|Experimental|Experimental|"Patients infected by oncogenic HPV and presented a high grade cervical dysplasia or a cervical cancer
~Patients with cervical or vaginal cancer
~All patients"
16357134|NCT04278313|Experimental|PRP group|Platelet RICH Plasma prepared using RegenLab FDA approved device.
16357135|NCT04278313|Placebo Comparator|PPP group|Platelet POOR Plasma prepared using RegenLab FDA approved device.
16357136|NCT04278300||case|patient with age-related exudative macular degeneration
16357137|NCT04278300||control|Patient with no macular disorder and in need of cataract surgery
16357138|NCT04278287|Experimental|Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy|Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).
16357167|NCT04278040|Experimental|Non-cystic fibrosis bronchiectasis (NCFB) patients|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 5 consequent days
16357168|NCT04278027|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy. CRT will be based on CIRCuiTS, a computerized program.
16357169|NCT04278027|No Intervention|Treatment as usual|Treatment as usual
16357879|NCT04273061|Experimental|Breast Cohort|Cohort of participants whose primary tumour type is breast.
16357139|NCT04278274||patients will be evaluated by artificial intelligence system and expert radiologist|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment, and not yet receive total mesorectum excision (TME) surgery will be enrolled. The post-neoadjuvant treatment MRI images features of each enrolled patients will be captured by the artificial intelligence system, and evaluated by experienced radiologists as well. Blind to the pathologic report of TME specimen, both approaches further respectively yield a predicted pathologic response to neoadjuvant treatment for each enrolled patient, shown as pCR or non-pCR.
16357140|NCT04278261|Experimental|Focal therapy|Using focal therapy(Irreversible electroporation) to treat patients with localized Prostate cancer
16357141|NCT04278261|Active Comparator|Radical prostatectomy|Using radical prostatectomy to treat patients with localized Prostate cancer
16357142|NCT04278248|Experimental|experimental group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose
16357143|NCT04278248|Active Comparator|Positive control group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose
16357144|NCT04278222|Experimental|Anlotinib Plus Toripalimab|the combination of Anlotinib Plus Toripalimab as first-line treatment
16357145|NCT04278209|Experimental|Breakfast 1 - Breakfast 2|Participants will receive Breakfast 1 then Breakfast 2.
16357146|NCT04278209|Experimental|Breakfast 1 - water|Participants will receive Breakfast 1, then water.
16357147|NCT04278209|Experimental|Breakfast 2 - water|Participants will receive Breakfast 2, then water.
16357148|NCT04278209|Experimental|Breakfast 2 - Breakfast 1|Participants will receive 2 servings, then 1 serving of the study product.
16357149|NCT04278209|Experimental|Water - Breakfast 1|Participants will receive water, then Breakfast 1.
16357150|NCT04278209|Experimental|Water - Breakfast 2|Participants will receive water, then Breakfast 2.
16357151|NCT04278170||Case group|Rheumatoid arthritis patients who met the American College of Rheumatology (ACR) 2010 RA classification
16357152|NCT04278157|Experimental|SCBT-SB|A culturally centered CBT treatment protocol called Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
16357153|NCT04278157|Active Comparator|Treatment as Usual|Treatment as usual is base on the standard care for teens and their parents under a community mental health center.
16357154|NCT04278144|Experimental|Single agent BDC-1001|Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies
16357155|NCT04278144|Experimental|Combination BDC-1001 plus pembrolizumab|Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies
16357156|NCT04278131|Experimental|Cohort 1|BSO1 Cohort 1 dose
16357157|NCT04278131|Experimental|Cohort 2|BS01 Cohort 2 dose
16357158|NCT04278131|Experimental|Cohort 3|BS01 Cohort 3 dose
16357159|NCT04278118|Experimental|Cohort I (hypofractionated radiation therapy)|Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
16357160|NCT04278118|Experimental|Cohort II (hypofractionated radiation therapy)|Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
16357161|NCT04278105|Experimental|HD-tCES & upper extremity rehabilitation|The experiment group will receive HD-tCES combined with upper extremity rehabilitation of affected side.
16357162|NCT04278105|Sham Comparator|Sham HD-tCES & upper extremity rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
16357163|NCT04278092|Experimental|Paclitaxel plus Cetuximab|Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
16357164|NCT04278053|Experimental|Nitrosigine supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Nitrosigine (1.5 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
16357165|NCT04278053|Experimental|Citrulline-Malate supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Citrulline-Malate (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
16357166|NCT04278053|Placebo Comparator|Placebo|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, dextrose (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
16357234|NCT04277559|Active Comparator|Patient preferential music|The preference of the patients will be listened to preoperatively through the headphones.
16357170|NCT04278001|Other|Ambulatory blood pressure measurement|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
16357171|NCT04277988||Crossed leg position|Patients in this group will be randomly allocated to sit in crossed leg position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
16357172|NCT04277988||Standard Sitting position|Patients in this group will be randomly allocated to sit in standard position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
16357175|NCT04277962|Experimental|Patients having vaginal delivery|EBL will be estimated visually vs quantitatively at time of vaginal delivery.
16357176|NCT04277949|Experimental|Erbium laser|All participants will receive Erbium laser treatment on their right post-auricular region
16357177|NCT04277949|Experimental|DNA repair enzyme|All participants will apply topical DNA repair enzymes on their left post-auricular region
16357178|NCT04277936|Experimental|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
16357179|NCT04277923|Experimental|SMOF lipid emulsion|the SMOF lipid emulsion is SMOFlipid.
16357180|NCT04277923|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin.
16357181|NCT04277910|Active Comparator|MT2004|MT2004 oral capsules treated group
16357182|NCT04277910|Placebo Comparator|Placebo|Placebo oral capsules treated group
16357183|NCT04277897|Experimental|Drug SAD Cohorts|Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.
16357184|NCT04277897|Placebo Comparator|Placebo SAD Cohorts|Matching placebo, orally, once daily in one single administration.
16357185|NCT04277897|Experimental|Drug MAD Group|Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.
16357186|NCT04277897|Placebo Comparator|Placebo MAD Group|Matching placebo, orally, once daily for 7 days.
16357187|NCT04277897|Experimental|Food-influnced Group|Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.
16357188|NCT04277884|Experimental|Firibastat|Capsules
16357189|NCT04277884|Placebo Comparator|Placebo|Matching capsules
16357190|NCT04277871|Experimental|The intervention group|The intervention group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The intervention group attended on-site group practice sections and performed individual home-based practice.
16357191|NCT04277871|Active Comparator|The comparison group|The comparison group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The comparison group performed individual home-based practice only.
16357192|NCT04277858|Experimental|Neoadjuvant chemotherapy and surgery|"Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.
~Carboplatin may be used instead of Cisplatin."
16357193|NCT04277845|Experimental|Group 1|"Bortezomib 1.3mg/m2 SC D1, 8, 15
~- Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15
~Lenalidomide 25mg/d D1-21
~Dexamethasone 40mg D1, 8, 15
~Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.
~If a patient is frail, the starting dosage will be as follows.
~Bortezomib 1.0mg/m2 SC D1, 8, 15
~- Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15
~Lenalidomide 15mg/d D1-21
~Dexamethasone 40mg D1, 8, 15
~Dose adjustment for more than 75: 20mg"
16357194|NCT04277845|Active Comparator|Group 2|"Lenalidomide 25mg/d D1-21
~Dexamethasone 40mg D1, 8, 15, 22
~Dose adjustment for more than 75: 20mg
~If a patient is frail in both study group, the starting dosage will be as follows.
~Lenalidomide 15mg/d D1-21
~Dexamethasone 40mg D1, 8, 15
~Dose adjustment for more than 75: 20mg ."
16357195|NCT04277832||single arm|Group of psoriasis patients will select randomly. All selected psoriasis patients will be consulted to a physician experienced in rheumatology and all of patients will fill TUPAST and TOPAS 2 forms.
16357196|NCT04277819||Patients with cystic fibrosis related liver disease|Patients with cystic fibrosis, who meet the criteria for diagnosis of liver disease according to the European Cystic Fibrosis Society best practice guidelines
16357197|NCT04277819||Patients without cystic fibrosis related liver disease|
16357198|NCT04277806|No Intervention|Standard group|No interventions would be conducted in this group and the preterm infants would be fed in the normal way.
16357199|NCT04277806|Experimental|Intervention group|The preterm infants in this group would be fed according to the new process.
16357200|NCT04277793|Experimental|Monitored self-guided problem solving intervention|Monitored self-guided problem solving intervention
16357201|NCT04277780|Experimental|CGM Sensor|Subjects will receive the Libre Pro Freestyle continuous glucose monitor (CGM) sensor that will be applied to their upper arm at the time of hospital discharge. They will be asked to peel off the sensor after 14 days and mail it to the endocrinology clinic in a stamped envelope that will be provided. They will also be provided the conventional diabetes management which will include instructions on fingerstick blood glucose monitoring and logging which they will start after the CGM sensor is removed. The sensor data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time the sensor is placed for further management of their diabetes.
16357202|NCT04277780|Active Comparator|Conventional Diabetes Care|Subjects will receive only the conventional diabetes management at the time of hospital discharge which includes instruction on fingerstick blood glucose monitoring and logging onto a blood glucose log sheet for 14 days. They will then be asked to fax/mail/call-in the blood glucose log. The log data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time of hospital discharge for further management of their diabetes.
16357203|NCT04277767||mild cognitive impairment (MCI)|observational
16357204|NCT04277767||Patients with mild to moderate AD|observational
16357205|NCT04277767||Normal controls|observational
16357206|NCT04277754||two-year-old children with typical development|
16357207|NCT04277741|Experimental|Resistant starch bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
16357208|NCT04277741|Active Comparator|Native wheat bar|The control group will consume one native wheat starch bar per day.
16357209|NCT04277715|Experimental|Parent training|Parents of participating children with chronic symptoms will receive the intervention in a virtual group format. Groups will last 90-minutes and run for 6-8 weeks. Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
16357210|NCT04277702|Experimental|Montelukast + standard treatment|
16357211|NCT04277702|Placebo Comparator|Placebo+ standard treatment|
16357212|NCT04277689|Experimental|Brain signal data collection|Collection of brain data during deep brain stimulation
16357213|NCT04277663|Experimental|IBI310 + IBI308|Participants will be treated with IBI310 in combination with IBI308
16357214|NCT04277663|Experimental|IBI308|Participants will be treated with IBI308
16357215|NCT04277663|Active Comparator|high-dose recombinant interferon a-2B|Participants will be treated with recombinant interferon a-2B
16357216|NCT04277650|Active Comparator|Once weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided once weekly clinical evaluations
16357217|NCT04277650|Experimental|Twice weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided twice weekly clinical evaluations
16357218|NCT04277637|Experimental|BGB-11417 Monotherapy Dose Finding: Part 1|Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined
16357219|NCT04277637|Experimental|BGB-11417 Monotherapy Expansion Cohorts: Part 2|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile
16357220|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until RP2D can be determined in combination with zanubrutinib
16357221|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile in combination with zanubrutinib
16357222|NCT04277624|Experimental|Fezolinetant: Test Formulation then Reference Formulation|Participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 2.
16357223|NCT04277624|Experimental|Fezolinetant: Reference Formulation then Test Formulation|Participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 2.
16357224|NCT04277611|Active Comparator|QLB|The patient is in the prone position. A low-frequency convex probe is placed in a transverse, oblique, and paramedian orientation approximately lateral to the posterior axillary line. The needle is then inserted in-plane from the medial side of the transducer and advanced laterally to enter the interfascial plane between the Quadratus Lumborum muscle and the kidney. We confirmed that the local anesthetic appeared to press down the kidney in the ultrasound image
16357225|NCT04277611|Active Comparator|ESPB|Using aseptic technique, a high frequency linear array transducer was placed at the T9 vertebral level. After identifying the ribs and sliding towards the midline in a longitudinal parasagittal orientation, the overlying Erector Spinae is identified by visualization of the transition between the rib and transverse apophysis a block needle is inserted in plane with ultrasound beam and is advanced in a cephalo-caudal direction until the tip contacted the transverse process.
16357226|NCT04277598|Experimental|Lead In Phase: APO-2: 25U/ml|Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;
16357227|NCT04277598|Placebo Comparator|Lead In Phase: Placebo|Topical administration of placebo; 0.5 ml per square cm wound;
16357228|NCT04277598|Experimental|Main Phase: APO-2: 12.5 U/ml|Topical administration of APO-2, 12.5 U/ml; 0.5 ml per square cm wound;
16357229|NCT04277598|Experimental|Main Phase: APO-2: 25 U/ml|Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;
16357230|NCT04277598|Experimental|Main Phase: APO-2: 50 U/ml|Topical administration of APO-2, 50 U/ml; 0.5 ml per square cm wound;
16357231|NCT04277598|Placebo Comparator|Main Phase: Placebo|Topical administration of placebo; 0.5 ml per square cm wound;
16357232|NCT04277585|Experimental|OASIS Clients|Clients of the OASIS Program who live at least 45 minutes away from an Early Psychosis Coordinated Specialty Care Program and are willing to engage in some of their services through telehealth.
16357233|NCT04277572||Aortic valve replacement|using different ways of aortic valve replacement either by prosthetic valves or by ozaki technique
16357235|NCT04277559|Active Comparator|Classical music|Classical music (Four Seasons from Vivaldi) will be listened to preoperatively through the headphones.
16357236|NCT04277559|Placebo Comparator|No music|the patients will not listen.
16357237|NCT04277546|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
16357238|NCT04277546|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
16357239|NCT04277533||Patient group|NEC preterm neonates with gestational ages are between 28-36 weeks regardless of birth weight. NEC diagnosis and staging will be according to Bell's staging criteria .
16357240|NCT04277533||Control group|Stable preterm neonate with matched gestational and postnatal ages without infectious diseases.
16357241|NCT04277520|Active Comparator|Continous rotation|instrumentation was done in continuous rotation motion
16357242|NCT04277520|Active Comparator|Reciprocation|instrumentation was done in reciprocation motion
16357243|NCT04277520|Active Comparator|Adaptive motion|instrumentation was done in adaptive motion
16357244|NCT04277507|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
16357245|NCT04277494|Experimental|Clorethyl cold spray® (Vapocoolant spray)|"23 volunteer athletes who are studying at the Faculty of Health Sciences of Acıbadem University, between the ages of 18-23, with a subcutaneous fold thickness of the quadriceps muscle between 5 mm and 15 mm (Shadgan et al., 2015).
~From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application."
16357246|NCT04277481||Group 1 (10 minute cold pack)|10 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
16357247|NCT04277481||Group 2 (12 minute cold pack)|12 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
16357248|NCT04277481||Group 3 (15 minute cold pack)|15 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
16357249|NCT04277481||Group 4 (20 minute cold pack)|20 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
16357250|NCT04277442|Experimental|Treatment (nivolumab, decitabine, venetoclax)|"INDUCTION: Patients receive nivolumab IV over 30 minutes on day 15 of cycle 1 and days 1 and 15 of subsequent cycles, decitabine IV over 60 minutes on days 1-10 of induction cycle 1 (and cycles 2 and 3 if needed), and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients who achieve a CR or CRi receive nivolumab IV over 30 minutes on days 1 and 15, decitabine IV over 60 minutes on days 1-5, and venetoclax PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16357251|NCT04277429||Normal cardiac function|Normal cardiac function
16357252|NCT04277429||Heart failure with reduced ejection fraction|Heart failure with reduced ejection fraction
16357253|NCT04277429||Heart failure with preserved ejection fraction|Heart failure with preserved ejection fraction
16357254|NCT04277416||Entrada Hip System|All orthopaedic patients that are scheduled to undergo primary total hip arthroplasty using the Entrada™ Hip System within 12 weeks will be screened for the following eligibility criteria.
16357255|NCT04277403|Experimental|HA-WBRT+SIB|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
16357256|NCT04277403|Active Comparator|SRS|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
16357257|NCT04277390||Controls|145 systemically and periodontally healthy pregnant women Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
16357258|NCT04277390||Group A|"Group A-100 Systemically healthy pregnant women with chronic periodontitis.
~Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155."
16357259|NCT04277390||Group B|Group B- 100 Preeclamptic pregnant women with chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
16357260|NCT04277390||Group C|Group C-100 Preeclamptic pregnant women without chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
16357261|NCT04277377||DSA in patients with kidney failure|Patients on kidney transplantation waiting list with DSA detected by Luminex (and mean fluorescence intensity (MFI) > 1000) in their blood.
16357262|NCT04277364|Active Comparator|High dose phosphatidic acid|750mg of phosphatidic acid per day for 8 weeks
16357263|NCT04277364|Active Comparator|Low dose phosphatidic acid|375mg of phosphatidic acid per day for 8 weeks
16357264|NCT04277364|Placebo Comparator|Placebo|750mg of corn starch per day for 8 weeks
16357265|NCT04277351|Experimental|tACS in individuals with and without dyslexia|Each participant in both the group of normo-readers and individuals with dyslexia receive all tACS stimulation conditions (fixed frequencies and sham) over different experimental days.
16357266|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.
~Subjects withdrawn from the study for any reason will be replaced."
16357267|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 2000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.
~Subjects withdrawn from the study for any reason will be replaced."
16357373|NCT04276727|Active Comparator|Menthol|Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
16357268|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.
~Subjects withdrawn from the study for any reason will be replaced."
16357269|NCT04277325|Experimental|Intervention|Couples will receive 19-21 free sessions of Emotionally-Focused Therapy.
16357270|NCT04277325|No Intervention|Waitlist|Couples will receive no intervention during the trial. After the trial is ended, they will be invited to participate in a weekend intervention meeting.
16357271|NCT04277312|Experimental|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
16357272|NCT04277312|Experimental|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
16357273|NCT04277312|Experimental|Nourish and Engage|This arm of the intervention delivered both the Nourish and Engage interventions as detailed above.
16357274|NCT04277312|No Intervention|Delayed|The delayed arm of the intervention was the control arm. Schools randomised to this arm of the study were offered the Engage intervention resources after endpoint data collection.
16357275|NCT04277299|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Solution which is the surgical pathway currently practiced in the study hospital. The ICory-Solution has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
16357276|NCT04277299|No Intervention|Control group|Children in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care. Parents in this group will receive BuddyCare mobile app which is supposed to be as a normal routine in this hospital.
16357277|NCT04277286||Experimental group|Patients transferred to adult service according to the Transend transition program (between September 2016 and January 2018)
16357278|NCT04277286||Control group|Patients transferred to adult service without a transition program, in the same center, before the implementation of Transend (between January 2015 and September 2016)
16357279|NCT04277273|Other|Patients treated in the MaxilloFacial Prosthesis consultation|Patients treated in the MaxilloFacial Prosthesis consultation (Dental Department, Pitié-Salpêtrière Hospital Group)
16357280|NCT04277260||Full term delivery|In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
16357281|NCT04277260||Preterm delivery(35-37 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
16357282|NCT04277260||Preterm delivery(32-35 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
16357283|NCT04277260||Preterm delivery(28-32 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
16357284|NCT04277247|Experimental|Botulinum Toxin Type A Treatment|Injections
16357285|NCT04277247|Placebo Comparator|Placebo|Injections
16357286|NCT04277221|Experimental|Standard therapy with ADCTA vaccine (study group)|"- ADCTA vaccine as study treatment
~Dose(s): Ten doses, including 2~4×10^7 cells for the 1st dose (double doses), and 1~2×10^7cells for the 2nd to 10th doses.
~Administrative route: The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic.
~Frequency: The primary immunization inoculation is followed by 3 vaccines bi-weekly and then 6 vaccines monthly inoculation, for a total of 10 doses.
~- Bevacizumab as standard therapy"
16357287|NCT04277221|Active Comparator|Standard therapy (control group)|"No study treatment
~Bevacizumab as standard therapy"
16357288|NCT04277208||Arthroscopic Rotator Cuff Repair|
16357289|NCT04277195||NUH Adjuvant Breast Cancer Cohort: Historical|This is a series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (1986-1999; n=1650). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
16357290|NCT04277195||NUH Adjuvant Breast Cancer Cohort: New|A series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (2000-2006; n=2000). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
16357374|NCT04276727|Placebo Comparator|Placebo|Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
16357291|NCT04277195||NUH Neoadjuvant Breast Cancer Cohort|For many years clinical data on this cohort of breast cancer patients has been collected in a master clinical database by the clinical team supporting Dr Chan (1996-2021; n=900 patients). This has been used for internal audits and reviews of clinical practice. The study research team will work with a pseudo-anonymised copy of this dataset.
16357292|NCT04277195||NUH Oncotype DX tested Adjuvant Breast Cancer Cohort|A list of patients tested with Oncotype DX as part of their standard treatment pathway (2015-2021; n=200) will be collected and will form the basis of a master clinical database for this cohort. The database will be managed and populated by the clinical team supporting Dr Chan. The study research team will work with a pseudo-anonymised copy of this dataset.
16357293|NCT04277182|Placebo Comparator|Control group|It will be accepted as the control group and 4 experimental burn wounds will be created on the back of the rats in the group and no treatment will be given.
16357294|NCT04277182|Active Comparator|1% Silver Sulfadiazine|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 1% Silver Sulfadiazine will be done on the back of the rats every day for 21 days.
16357295|NCT04277182|Active Comparator|%0.2 Nitrafurozon|4 experimental burn wounds will be created on the back of the rats in the group and dressing with %0.2 Nitrafurozon will be done on the back of the rats every day for 21 days.
16357296|NCT04277182|Experimental|10% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 10% Propolis will be done on the back of the rats every day for 21 days.
16357297|NCT04277182|Experimental|15% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 15% Propolis will be done on the back of the rats every day for 21 days.
16357298|NCT04277182|Active Comparator|Propolis vehicle|4 experimental burn wounds will be created on the back of the rats in the group and dressing with Propolis vehicle will be done on the back of the rats every day for 21 days.
16357299|NCT04277156|Experimental|Flostrum Baby|"The test product will be Flostrum Baby, which is a food supplement consisting of two bacterial strains: Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063, 5x10^9 CFU and 1x10^8 CFU, respectively, per seven drops.
~Flostrum Baby - in children below 12 years of age, 7 drops, twice daily; in children older than 12 years, 14 drops, twice daily."
16357300|NCT04277156|Active Comparator|Dicoflor|"The control product will be Dicoflor, which is a food supplement containing L rhamnosus ATCC 53103, 5x10^9 CFU, per five drops.
~Dicoflor - the manufacturer recommends 5-10 drops daily, with no age specification. For the purposes of this study, 5 drops, twice daily, in children below 12 years of age; 10 drops, twice daily, in children older than 12 years."
16357301|NCT04277143||critical ill patient with bloodstream infections|Severe patients with bloodstream infections often have sepsis / septic shock, acute kidney injury (AKI), hypoproteinemia, and renal replacement treatment.
16357302|NCT04277130|Experimental|Intervention group|Intervention with active video games
16357303|NCT04277130|No Intervention|Control group|No intervention
16357304|NCT04277117|Experimental|Medically Tailored Meal Delivery|1 ready-to-eat and 1 frozen medically tailored meal delivered by Meals on Wheels volunteers/drivers Monday through Friday.
16357305|NCT04277117|Other|Remain on interest list|participants randomized to remain on the Meals on Wheels interest list will receive regular Meals on Wheels services when they reach the top of the list (typically 4-6 months from placement on the list).
16357306|NCT04277104|Experimental|Healthy intervention|Acoustic stimulation
16357307|NCT04277104|Sham Comparator|Healthy sham|No stimulation
16357308|NCT04277104|Experimental|At risk intervention|Acoustic stimulation
16357309|NCT04277104|Sham Comparator|At risk sham|No stimulation
16357310|NCT04277104|Experimental|MCI (mild cognitive impairment) intervention|Acoustic stimulation
16357311|NCT04277104|Sham Comparator|MCI (mild cognitive impairment) sham|No stimulation
16357312|NCT04277091|No Intervention|Control|No exercise
16357313|NCT04277091|Experimental|High-intensity interval exercise|10 x 60 s intervals at 80% peak power output (interspersed with 60 s recovery intervals at 10% peak power output)
16357314|NCT04277091|Experimental|Moderate-intensity continous exercise|50% peak power output (duration determined to elicit same energy expenditure as high-intensity interval exercise condition)
16357315|NCT04277078||Intubated asthma attack|Patients who had been hospitalised with asthma attack, then intubated during hospitalisation.
16357316|NCT04277078||Non-Intubated asthma attack|Patients who had been hospitalised with asthma attack without intubation during hospitalisation.
16357317|NCT04277065|Experimental|Bulldog tourniquet in laparoscopic Hepatectomy|The bulldog tourniquet , a reusable vessel occlusion instrument forblocking the liver inflow-blood in laparoscopic liver resection, was uniformly employed in all patients randomized to Bulldog laparoscopic hepatectom group in the present study.
16357318|NCT04277065|Active Comparator|cotton tourniquet in laparoscopic Hepatectomy|The cotton tourniquet ,a reusable vessel occlusion instrument for blocking the liver inflow-blood in laparoscopic liver resection
16357319|NCT04277052|Experimental|Group 1|Muscle disorders
16357320|NCT04277052|Experimental|Group 2|Disc displacements
16357321|NCT04277052|Experimental|Group 3|Other common joint disorders
16357322|NCT04277052|Experimental|Group 4|Mix type
16357323|NCT04277052|Experimental|Group 5|Healthy individuals
16357324|NCT04277039|Experimental|OMT+CT|It consists of 8 sessions of osteopathic treatment and two 20-min sessions of cognitive training per week per 2 months
16357325|NCT04277039|Active Comparator|osteopathic treatment|It consists of 8 sessions of osteopathic treatment throughout the 2-month study period
16357326|NCT04277039|Other|usual care|patients will continue the routine care as established by international guidelines
16357327|NCT04277026|Experimental|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals. The intervention will take place two times per week for four weeks (Weeks 1-4). During weeks 5-8 the experimental group will continue treatment as usual and will not be receiving the mindful walking intervention.
16357370|NCT04276753|Placebo Comparator|Placebo|"The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.
~Placebo emulsion will be applied topically on full face twice a day for 8 weeks."
16357328|NCT04277026|No Intervention|Control|Participants will engage in treatment as usual during the first four weeks and will not be receiving the experimental intervention (mindful walking) during weeks 1-4. After the experimental group completes the mindful walking intervention, the control group will complete the mindful walking intervention (weeks 5-8).
16357329|NCT04276987|Experimental|MSCs-derived Exosomes Treatment Group|Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
16357330|NCT04276974|Experimental|Organic first then non-organic|Organic diet then non-organic diet, each for 4 consecutive days
16357331|NCT04276974|Experimental|Non-organic first then organic|Non-organic diet then organic diet, each for 4 consecutive days
16357332|NCT04276961|Experimental|Acupuncture plus usual care|Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
16357333|NCT04276961|Sham Comparator|Sham acupuncture plus usual care|Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
16357334|NCT04276948|Experimental|Active1|312 mg dose of active
16357335|NCT04276948|Experimental|Active2|812 mg dose of active
16357336|NCT04276948|Placebo Comparator|Placebo|placebo
16357337|NCT04276935||Health Services Research (cognitive interviews)|Participants take part in cognitive interviews in Spanish over 45-60 minutes.
16357338|NCT04276922|Experimental|Visual Arts Group|Visual Arts group - sketch journals
16357339|NCT04276922|Experimental|Music Group|Music group involves music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making.
16357340|NCT04276922|Experimental|Dance/Movement Group|Dance/Movement group - movement check-in, gentle physical warm-up, and then either a structured or improvisational movement process.
16357341|NCT04276922|Experimental|Writing/Poetry Group|Writing/Poetry group uses writing workshops using integral elements of good writing.
16357342|NCT04276922|Experimental|Control Group|Surveys at baseline and 12 weeks later.
16357343|NCT04276909|Experimental|Lum Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection at the beginning of the surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
16357344|NCT04276896|Experimental|pathogen-specific DC and CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
16357345|NCT04276883|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
16357346|NCT04276883|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
16357347|NCT04276883|Placebo Comparator|Placebo|Sublingual placebo film
16357348|NCT04276870|Experimental|Subjects with hypodiploid B-ALL|
16357349|NCT04276870|Experimental|Subjects with t(17;19) B-ALL|
16357350|NCT04276870|Experimental|Infant subjects with very high risk KMT2A B-ALL|
16357351|NCT04276870|Experimental|Subjects with central nervous system (CNS) relapse who did not|
16357352|NCT04276857|Other|Single arm study|All eligible patients will receive combination chemotherapy and if there i s a positive response they will undergo IRE.
16357353|NCT04276844||Non diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test ≥ 16 mm for women and ≥ 18 mm for men
16357354|NCT04276844||Persistent diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test < 16 mm for women and < 18 mm for men
16357355|NCT04276831|Active Comparator|Laryngoscope McCoy|Patients will be intubated using laryngoscope McCoy
16357356|NCT04276831|Active Comparator|Laryngoscope Macintosh|Patients will be intubated using laryngoscope Macintosh
16357357|NCT04276818|Active Comparator|PRP group|Second-degree superficial burn group treated with PRP
16357358|NCT04276818|Active Comparator|conventional treatment group|second-degree superficial burn group treated with cream containing silver sulfadiazine
16357359|NCT04276805|Active Comparator|tVNS group|Participants will undergo cognitive training with tVNS
16357360|NCT04276805|Sham Comparator|Sham group|Participants will undergo cognitive training with earlobe sham
16357361|NCT04276792|Experimental|Horizontal implementation approach|The Horizontal implementation approach of the O-TLM intervention is accompanied by facilitated collaboration between Criminal Justice and Community Behavioral Health systems. Direct involvement of stakeholders with differing perspectives and buy-in from agency leadership and policymakers are key elements. The Horizontal approach involves first developing a prototype (including how to modify existing practices, overcome implementation barriers, and manage roles and responsibilities) that are tested and refined before being rolled out systematically to other units within an agency.
16357362|NCT04276792|Active Comparator|Vertical implementation approach|The Vertical implementation approach of the O-TLM intervention relies on the traditional criminal justice system's typical use of a hierarchical structure and the use of a top-down implementation approach (i.e., administrative orders) for directing change. Top-down regulatory and policy changes are viewed as vital levers for driving system change.
16357363|NCT04276779|Experimental|Alcohol and Negative Mood|
16357364|NCT04276779|Placebo Comparator|Placebo and Negative Mood|
16357365|NCT04276779|Active Comparator|Alcohol and Positive Mood|
16357366|NCT04276779|Placebo Comparator|Placebo and Positive Mood|
16357367|NCT04276766|Experimental|Beetroot|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the beetroot group were asked to consume 140ml beetroot juice (James White Drinks Company, Suffolk, UK). The 140 ml of beetroot juice equate to approximately 8.4 mmol of NO3- ."
16357368|NCT04276766|Placebo Comparator|Placebo|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the placebo group were asked to consume 140 ml nitrate-depleted beetroot juice (James White Drinks Company, Suffolk, UK)."
16357369|NCT04276753|Experimental|Terminalia Chebula fruit extract|"The test product is an emulsion. It contains Terminalia Chebula fruit extract.
~Test product will be applied topically on full face twice a day for 8 weeks."
16357380|NCT04276662|Experimental|Cohort 1: Mild hepatic impairment|Participants who have mild hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
16357381|NCT04276662|Experimental|Cohort 2: Moderate hepatic impairment|Participants who have moderate hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
16357382|NCT04276662|Experimental|Cohort 3: Healthy participants|Healthy participants who have normal hepatic function with sex, age (±10 years [y]), and weight (±20%) matching with the mild and moderate hepatic impairment cohorts.
16357383|NCT04276649||Caltrate+Mesalazine|Patients in this group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months.
16357384|NCT04276649||Mesalazine|Patients in this group were received with Mesalazine 4g/d orally at least 12 months.
16357385|NCT04276636|Experimental|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
16357386|NCT04276636|No Intervention|Control|The other group do not interfere.
16357387|NCT04276610|No Intervention|Healthy Control Participants|Older adults (65+) without impairments in vision or hearing. This groups will simply be followed for the study period (1 year), measured at 6 months intervals, to provide control comparison data for all outcome measures
16357388|NCT04276610|Experimental|Low Vision Participants|Older adults (65+) with impairments in vision but without hearing impairment. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
16357389|NCT04276610|Experimental|Dual Sensory Impairment Participants|Older adults (65+) with impairments in both vision hearing hearing. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
16357390|NCT04276597|Experimental|Lu177 DOTATOC treatment|4 doses of 200mCi 177Lu- DOTATOC PRRT
16357391|NCT04276584|Active Comparator|Positive airway pressure (PEP)|Deep inspiration followed by expiration to a resistance of 10-15 cm H2O. Done three times, each time with 10 inspiration/expiration cycles
16357392|NCT04276584|Experimental|Speaking loudly|Speaking loudly during 3 minutes.
16357393|NCT04276584|Experimental|Singing|Singing a Swedish song. The study will end with this song.
16357394|NCT04276571|Experimental|GRAIL|
16357395|NCT04276571|No Intervention|No treatment|
16357400|NCT04276545|Experimental|IV administration of dexmedetomidine|IV administration of a single loading dose DEX (0.5μg/kg)
16357401|NCT04276545|Active Comparator|IV administration of midazolam|IV administration of midazolam (0.05mg/kg)
16357402|NCT04276532|Experimental|Sentinel lymph node sampling|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN)
16357403|NCT04276532|Active Comparator|Pelvic lymphadenectomy|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
16357404|NCT04276519|Experimental|Experimental|Physiotherapeutic non-invasive position-induced opening of the intervertebral foramen and pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
16357405|NCT04276519|Active Comparator|Control group|Pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
16357406|NCT04276506|Experimental|information booklet group|information session before the coronary angiography
16357407|NCT04276506|Experimental|music group|music session before the coronary angiography
16357408|NCT04276506|No Intervention|control group|No information or music session before the coronary angiography
16357409|NCT04276493|Experimental|Cohort 1- ZW25 + Docetaxel|ZW25 intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer
16357410|NCT04276493|Experimental|Cohort 2- ZW25 + Tiselizumab + Chemotherapy|ZW25 intravenous (IV) infusion followed by tiselizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma
16357411|NCT04276480|Experimental|Intervention|The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
16357412|NCT04276454|Experimental|Single arm|
16357415|NCT04276428|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
16357416|NCT04276428|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
16357420|NCT04276402|Experimental|Right side of the maxilla|
16357424|NCT04276376|Experimental|Cohort 1A-D|"Molecularly selected cohorts that harbor DNA repair deficiency, defined as bi-allelic loss-of-function alteration (mutation and/or deletion) in at least one of the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, PALB2, RAD51C, RAD51D, FANCA, NBN, RAD51, RAD54L.
~1.A - Non-Small Cell Lung Cancer
~1.B - Urothelial Bladder Cancer
~1.C - metastatic Castration Resistant Prostate Cancer
~1.D - others: any histology, excepted breast cancer or serous ovarian cancer"
16357425|NCT04276376|Experimental|Cohort 2A-C|Platinum-sensitive disease 2.A - Non-Small Cell Lung Cancer 2.B - Urothelial Bladder Cancer 2.C - Gastric or gastro-esophageal junction adenocarcinoma
16357426|NCT04276376|Experimental|Cohort 3|Metastatic Castration Resistant Prostate Cancer (mCRPC)
16357427|NCT04276376|Experimental|Cohort 4|Clear Cell Renal Cell Carcinoma
16357428|NCT04276363|Experimental|Thrive Professional Learning plus ParentCorps|1) Professional Development, Program Training and Coaching; 2) Program for Parents of Pre-K Students; and 3) Program for Pre-K Students. The three intervention components are expected to strengthen relationships and communication between parents and teachers and promote safe, nurturing and predictable environments, which contribute to child mental health and achievement.
16357429|NCT04276363|Experimental|Thrive Professional Learning only|Best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders.
16357430|NCT04276363|Experimental|Inspire Professional Learning|Led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
16357431|NCT04276350|Experimental|Acupuncture|"Acupuncture Regime:
~2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions"
16357432|NCT04276350|Active Comparator|Best medical therapy|"Best Medical Therapy Regime:
~3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily"
16357433|NCT04276324|Active Comparator|Control Group|Only testing sessions
16357434|NCT04276324|Experimental|Resistance training group|Ten weeks of resistance training
16357435|NCT04276311|Experimental|symptomatic patients with complex de novo FP arterial lesions|in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo FP arterial lesions (TASC C).
16357436|NCT04276298|Active Comparator|Metronidazole|Group A receiving 10% metronidazole cream
16357437|NCT04276298|Active Comparator|Metronidazole + Diltiazem|Metronidazole 10% + Diltiazem 2%
16357438|NCT04276298|Active Comparator|Metronidazole + Lignocaine|Metronidazole 10% + Lignocaine 4%
16357439|NCT04276298|Active Comparator|Metronidazole + Diltiazem + Lignocaine|Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
16357440|NCT04276285|Active Comparator|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
16357441|NCT04276285|Active Comparator|US TAP|Subcostal TAP block will be performed after surgery under ultrasound guidance
16357442|NCT04276285|No Intervention|No TAP|No TAP block will be performed
16357443|NCT04276259|Experimental|Buprenorphine Injection + Oral Placebo Pill|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
16357444|NCT04276259|Experimental|Naltrexone Oral Tablet + Intramuscular Saline Injection|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
16357445|NCT04276259|Experimental|Oral Placebo Pill + Intramuscular Saline Injection|Inert pill and saline injection that have no inherent power to produce an effect. In the inert pill condition, participants will receive one IM arm injection of saline (1ML) and an oral placebo tablet.
16357446|NCT04276246|Experimental|Experimental|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to retentive components (Group A, Test) which are connected to the implants to retain the RPD
16357447|NCT04276246|Experimental|Control|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to supportive components (Group B, Control), which are connected to the implants to support the RPD
16357449|NCT04276220|Other|Tenosynovial Biopsy|
16357450|NCT04276207|Experimental|100 U/mL LY900014|100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
16357451|NCT04276207|Active Comparator|100 U/mL Insulin Lispro (Humalog)|100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.
16357452|NCT04276194|Experimental|Treatment (intensity modulated proton therapy)|Patients undergo intensity modulated proton therapy once daily over 30 fractions and also undergo MRI over 20 minutes during fractions 7, 13, 20, and 30 of radiation in the absence of disease progression or unacceptable toxicity.
16357453|NCT04276181||CNaTT|The surgical procedures are described in the section Detailed description
16357454|NCT04276155|Experimental|Device|Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation
16357455|NCT04276155|No Intervention|Control|Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.
16357456|NCT04276142|Experimental|Tension-Type Headache - ceprica|online program: ceprica, additional to care as usual
16357457|NCT04276142|Active Comparator|Tension-Type Headache - Placebo|Other: online evidence-based information regarding headache, additional to care as usual
16357458|NCT04276142|Experimental|Migraine - ceprica|online program: ceprica, additional to care as usual
16357459|NCT04276142|Active Comparator|Migraine - Placebo|Other: online evidence-based information regarding headache, additional to care as usual
16357460|NCT04276129|Experimental|post-surgical CHX mouth-rinses (treatment group - CHX)|periodontal surgery + post-surgical CHX mouth-rinses + buccal attached gingival (G) biopsies 24 hr after surgical procedure
16357461|NCT04276129|Other|NO post-surgical mouth-rinses treatment (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
16357462|NCT04276116|No Intervention|Usual Care|
16357463|NCT04276116|Experimental|Usual care + communication of pulmonary age|
16357464|NCT04276090|Experimental|Colorectal liver metastases|Patients with unresectable colorectal liver metastases will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (FOLFOX, FOLRIRI, or oxaliplatin/irinotecan, or panitumumab if KRAS/NRAS wild type)
16357465|NCT04276090|Experimental|Intrahepatic cholangiocarcinoma|Patients with unresectable intrahepatic cholangiocarcinoma will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (gemcitabine/oxaliplatin or gemcitabine alone)
16357466|NCT04276077|Experimental|High-frequency electrical muscle stimulation|
16357467|NCT04276077|Experimental|Low-frequency electrical muscle stimulation|
16357468|NCT04276077|No Intervention|Control|
16357469|NCT04276064|Experimental|Patients with insomnia|Patients with insomnia disorder according to DSM-5 criteria
16357470|NCT04276064|Experimental|Healthy controls|Healthy controls
16357471|NCT04276051|Experimental|Cryoablation of the Vagus Nerve|"The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40oC) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
~Participants will also receive standardized dietary and exercise counseling from a registered dietitian and exercise physiologist."
16357472|NCT04276051|Active Comparator|Lifestyle intervention only|Participants will receive standardized dietary and exercise counseling from a registered dietitian and exercise physiologist.
16357473|NCT04276038|Active Comparator|Active LLLT|"Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped.
~Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution."
16357474|NCT04276038|Sham Comparator|Sham LLLT|Half of the LLT devices will be not activated at random before the application to the patients. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device.
16357475|NCT04276025||German cohort Bayreuth|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
16357476|NCT04276025||German cohort Hof|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
16357477|NCT04276025||Chinese cohort Beijing|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
16357478|NCT04276012|Experimental|Intervention group|The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
16357479|NCT04276012|No Intervention|Control group|Usual clinical care
16357483|NCT04275986|Experimental|Experimental arm|Endoscopic resection+ concurrent chemoradiotherapy
16357484|NCT04275973|Other|Healthy controls|The Control participants are for methods development and do not constitute a formal study group
16357566|NCT04275414|Experimental|bevacizumab plus standard care|Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.
16357485|NCT04275973|Experimental|Prosthesis user with transtibial amputation|Experiments will use standard commercially available prostheses for participants with lower-limb amputation. Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA).
16357486|NCT04275973|Experimental|Orthoses user with drop-foot|"This arm will consists of participants with unilateral drop-foot. A subset of the drop-foot population will be persons with Multiple Sclerosis and currently unilateral drop-foot.
~For participants in this arm, standard commercially-available orthoses or standard-of-care custom orthoses will be used, as well as standard commercially-available electrical stimulation neuro-orthoses."
16357487|NCT04275960|Experimental|Arm_25 + 75 mg (Fasted)|Healthy male participants receive a single dose of 25 mg selitrectinib (Period 1) and 75 mg selitrectinib (Period 2) in fasted state.
16357488|NCT04275960|Experimental|Arm_50 + 50 mg (Fasted/Fed)|Healthy male participants receive a single dose of 50 mg selitrectinib in fasted state (Period 1) and 50 mg selitrectinib in fed state (Period 2).
16357489|NCT04275960|Experimental|Arm_100 + 150 mg (Fasted)|Healthy male participants receive a single dose of 100 mg selitrectinib (Period 1) and 150 mg selitrectinib (Period 2) in fasted state.
16357490|NCT04275947||Training|
16357491|NCT04275947||Validation|
16357492|NCT04275934||Cohort|This project will evaluate the impact of self-insured employers implementing an innovative care model utilizing pharmacist-delivered MTM services for health plan beneficiaries with high blood pressure.
16357493|NCT04275921|Experimental|Study participants cohort I|3 stage III NSCLC patients receiving radiotherapy will be imaged, each for a single MRI session using TWIST and HASTE sequences.
16357494|NCT04275921|Experimental|Study participants cohort II|12 patients will be imaged, each for two MRI sessions taking place during the radiotherapy schedule and separated by at least a week.
16357495|NCT04275895|Experimental|Prematurely born Children|"Evaluation of different attention or/and postural activities :
~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).
~Child perception of the vertical compared to the real vertical
~Evaluation of the posture of the child during different visual conditions
~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
16357496|NCT04275895|Active Comparator|Term born Children|"Evaluation of different attention or/and postural activities
~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).
~Child perception of the vertical compared to the real vertical
~Evaluation of the posture of the child during different visual conditions
~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
16357497|NCT04275869|Experimental|Experimental Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
16357498|NCT04275869|No Intervention|Control Group|Control group will receive the standard treatment which consists of regular gynaecological visits; the Reproduction Service gynaecologists will recommend healthy lifestyle habits and give the patients a document detailing a specific diet they should follow for weight loss.
16357499|NCT04275843|Active Comparator|Traditional Diet|Unprocessed/minimally processed whole foods.
16357500|NCT04275843|Active Comparator|Modern Diet|Multi-ingredient, ultra-processed formulations of the traditional diet.
16357501|NCT04275830|Experimental|Baseline and HRVB+DS group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to HRVB+DS arm. This group will receive a standardized HeartMath© Inner balance device and HRV biofeedback training session at the start of the two-week intervention period. They will be asked to attend either a group or one-on-one 30-minute HRVB training session and asked to practice their HRV biofeedback skills at home for 10 minutes each day for a two-week period. Participants will also be asked to watch four digital stories of other HCT patients (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
16357502|NCT04275830|Other|Baseline and HRVB waitlist +DS control group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to HRVB waitlist +DS control arm. After the baseline data collection, during two weeks, they will be provided four digital stories of other HCT patients sharing their experiences (challenges, feelings, strategies, coping, each 2-3 minutes long). At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
16357503|NCT04275817||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking: unintentional weight loss of ≥ 5% between two assessments, 2) Weakness: a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy: answer of no to the question Do you feel full of energy? from the 15-item Geriatric Depression Scale; 4) Slowness: average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level: PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
16357504|NCT04275817||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).
~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.
~In this study, an individual will be considered a CHI if they meet the following criteria: no history of dementia, no use of anti-dementia drugs, normal cognitive performance on cognitive tests and normal scores of ADL and IADL scales. Different participant subgroups will be identified: 1) Individuals will be classified as MCI if they meet the following criteria: Objective cognitive impairment (i.e., performance between 1.5 and 1.9 SDs below the age-appropriate mean) in one or two cognitive domains (i.e., episodic memory and/or executive function) and normal scores of ADL and IADL scales; 2) Individuals will be considered older adults with mild-stage major neurocognitive disorders"
16357567|NCT04275401||patients|patients with clinical presentions of change in muscle tone
16357568|NCT04275401||volunteers|healthy volunteers with normal muscle tone
16357505|NCT04275817||Individuals with MCR|"The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
~Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?)."
16357506|NCT04275804|Active Comparator|Control group: conventional dressing|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Dressing by a specialized wound-nurse is the current gold-stand of treatment for diabetic ulcers.
16357507|NCT04275804|Experimental|Vibration group: conventional dressing and LMHFV|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Alternate dat 20-week course of whole-body vibration therapy Alternate day 20min sessions on a self-designed vibration platform with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm). Since the participants will return for dressing change on alternate days, the vibration group will also undergo the LMHFV on the same attendance.
16357508|NCT04275791|Experimental|hierarchized|Structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
16357509|NCT04275791|No Intervention|all-or-nothing|Structured regional health organization, composed of non-hierarchical trauma centers at different levels according to their capacity to receive severe trauma victims (all-or-nothing type).
16357510|NCT04275778|Active Comparator|Hydroxychloroquine|"Hydroxychloroquine will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.
~Treatment will be continueted during the pregnancy and will be stopped at delivery."
16357511|NCT04275778|Placebo Comparator|Placebo group|"Placebo will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.
~Treatment will be continueted during the pregnancy and will be stopped at delivery."
16357512|NCT04275765|No Intervention|Arm 1: Routine Care|Participants will undergo routine care but take part in assessments.
16357513|NCT04275765|Active Comparator|Arm 2:Behavioral Intervention with nudges & Facebook|Participants will receive nudges and be enrolled in social media platform.
16357514|NCT04275765|Active Comparator|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
16357515|NCT04275752|No Intervention|Usual Care Group|Subjects will receive no formal exercise recommendations
16357516|NCT04275752|Experimental|Exercise Intervention Group|Subjects will complete an exercise program
16357517|NCT04275739|Experimental|Experimental: Episodic Future Thinking|
16357518|NCT04275739|Active Comparator|Control: Vivid Memory Task|
16357519|NCT04275726|Experimental|Myval THV Series|"Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site.
~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
16357520|NCT04275726|Active Comparator|Contemporary Valves|"Stratification and equal allocation will be done for each valve within contemporary valves, i.e., 50% Sapien THV Series and 50% Evolut THV Series.
~Sapien THV Series will consist of Sapien 3/Sapien 3 Ultra THVs or any subsequent advanced version commercially available at the study site.
~Evolut THV Series will include Evolut R/Evolut PRO THVs or any subsequent advanced version commercially available at the study site.
~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
16357521|NCT04275713|Experimental|Standard Chemoradiotherapy +/- metformin|Metformin will be given orally at doses of 850 mg twice a day. Metformin will be started one week prior to the start of standard cisplatin-based chemoradiotherapy, and will be continued throughout the entire radiation treatment
16357522|NCT04275713|Active Comparator|Standard chemoradiotherapy|"Standard chemoradiotherapy is given as a combination of EBRT and IGT:
~45 Gy in 1.8 Gy/fraction to the pelvis/abdomen, 5 fractions/week
~55-57.5 Gy in 2.2-2.3 Gy/fraction to pathological lymph nodes as a simultaneously integrated boost (SIB)
~4 fractions of brachytherapy, 7.8 Gy/fraction, to the cervix
~Concomitant Cisplatin weekly during the external beam radiotherapy (EBRT)"
16357523|NCT04275700|Experimental|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma.
16357524|NCT04275687|Experimental|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.
~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin."
16357525|NCT04275661|Placebo Comparator|Group (C) (control group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7.
16357526|NCT04275661|Experimental|Group (K) (Ketamine group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg ketamine at each level with total dose 2mg/kg
16357527|NCT04275661|Experimental|Group (M) (magnesium sulphate group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg MgSo4 at each level with total dose 2mg/kg
16357528|NCT04275648|Experimental|Asthmatuner field tests vs laboratory tests|Each participant will perform two standardized field tests either before or after Eucapnic Voluntary Hyperpnea or Methacholine bronchial provocation test. In addition, unstandardized field tests will be performed in case of exercise induced respiratory symptoms.
16357880|NCT04273061|Experimental|Lung Cohort|Cohort of participants whose primary tumour type is lung.
16357529|NCT04275635||Children with myopia|A total of 3,000 children from Zhongshan Ophthalmic Center is required to undergo ophthalmic examinations and complete questionnaires at baseline and 1yr after wearing Ortho-K.
16357530|NCT04275622|Experimental|Intervention|Intervention group receives lifestyle intervention for hypertriglyceridemia.
16357531|NCT04275622|No Intervention|Control|Control group receives regular surveillance.
16357532|NCT04275609|Experimental|Artificial Intelligence generating endoscopic report|In this group, the endoscopic report was generated by artificial intelligence (AI) based on the structured diagnostic report generation system.
16357533|NCT04275609|Active Comparator|Physicians writing endoscopic report|In this group, the endoscopic report was writing by physicians.
16357534|NCT04275596|Active Comparator|2QR complex|Patients who undergo anal surgery will apply 2QR complex topical agent on the wound until healing
16357535|NCT04275596|Active Comparator|Placebo|Patients who undergo anal surgery will apply placebo cream on the wound until healing
16357536|NCT04275583|Experimental|TQB3602 capsule|TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.
16357537|NCT04275570|Active Comparator|Motivational Interview.|Repeated motivational interview during prenatal care visits
16357538|NCT04275570|No Intervention|Usual intervention|Usual intervention
16357539|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
16357540|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
16357541|NCT04275544||Patients with PCs|"HOCM Patients developing postoperative complications (PCs) following septal myectomy.
~PCs include all-cause mortality, heart failure, low cardiac output syndrome, stroke, spinal cord injury, acute respiratory distress syndrome, reintubation, reoperation, permanent implantable cardioverter defibrillator, kidney injury, renal failure, liver injury, and liver failure."
16357542|NCT04275544||Patients without PCs|HOCM Patients do not develope postoperative complications following septal myectomy.
16357547|NCT04275518|Experimental|APG-115/APG-115+Cytarabine in Relapse/Refractory AML|
16357548|NCT04275518|Experimental|APG-115/APG-115+Aza in relapsed/progressed high risk MDS|
16357549|NCT04275505|Active Comparator|treatment group|the participants were given 10 sessions of shortwave diathermy treatment and elbow splint and told to avoid symptom provoking activities
16357550|NCT04275505|Placebo Comparator|control group|the participants were given 10 sessions of placebo shortwave diathermy treatment (the device was not turned on), elbow splint and told to avoid symtpom provoking activities
16357551|NCT04275492|Experimental|Fasting group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects were given 1 tablet of test preparation (T) orally and 240mL warm water on an empty stomach, and the other 15 subjects were given 1 tablet of reference preparation (R, Siforl®) orally and 240mL warm water on an empty stomach.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
16357552|NCT04275492|Experimental|Feeding group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects took 1 tablet of the test preparation (T) orally and 240mL warm water about 30min after the high-fat meal, and another 15 subjects took 1 tablet of the reference preparation (R, Siforl®) orally and 240mL warm water about 30min after the high-fat meal.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
16357553|NCT04275479||SDS - without Diabetes diagnosis|SDS - without Diabetes diagnosis
16357554|NCT04275479||SDS with Diabetes Diagnosis|SDS with Diabetes Diagnosis
16357555|NCT04275479||Cystic Fibrosis (CF) patients data & lab results|De-identified data from age matched population norms, CF patients associated pancreatic insufficiency known or treated diabetes
16357556|NCT04275466|Experimental|necrotic cavity lavage|This arm was performed necrotic cavity lavage after debridement
16357557|NCT04275466|No Intervention|non-necrotic cavity lavage|This arm was not performed necrotic cavity lavage after debridement
16357558|NCT04275453|Experimental|Ketogenic diet - 24 hours|Subjects will undergo FDG PET/CT after 1 day of dietary modification (ketogenic diet for at least 3 meals) and 12 hours of fasting prior to FDG injection.
16357559|NCT04275453|Experimental|Ketogenic diet - 72 hours|Subjects will then undergo FDG PET/CT after 3 day of dietary modification (ketogenic diet for at least 9 meals) and 12 hours of fasting prior to FDG injection.
16357560|NCT04275453|Experimental|Exogenous ketone ester|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants. The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of ~3 mmol/L are reached within 60 minutes . By way of comparison, website marketing of the commercial drink recommends ingestion 30 minutes prior to athletic performance. We will also perform echocardiography immediately before and 30 minutes after the drink.
16357561|NCT04275440|Experimental|Exercise group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
16357562|NCT04275440|Experimental|Caloric restriction group|The caloric restriction plan will be designed based on individual basal metabolic rate.
16357563|NCT04275440|Experimental|Combined intervention group|Participants will receive both exercise and caloric restriction intervention at the same time.
16357564|NCT04275427|Experimental|study laser group|laser therapy on knee for 2 weeks
16357565|NCT04275427|No Intervention|control group|no intervention
16357666|NCT04274660|Experimental|DWELL Intervention|People with type 2 diabetes participating in the 12-week DWELL (Diabetes and WELLbeing) Programme
16357569|NCT04275388||Xiyanping injection +other drugs|Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
16357570|NCT04275388||other drugs|Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
16357571|NCT04275375||hyperbaric bupivacaine|The dosage of hyperbaric bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
16357572|NCT04275375||plain bupivacaine|The dosage of plain bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
16357573|NCT04275375||bupivacaine with intrathecal fentanyl|The dosage of bupivacaine with intrathecal fentanyl decided by the clinical anesthesiologist. This study is an observational study.
16357574|NCT04275362||DJO subjects for surgical technique|Subjects who meet the inclusion criteria and receive a DJO Empowr total knee replacement but will not participate in motion data collection
16357575|NCT04275362||DJO subjects for data collection|Subjects who meet the inclusion criteria and consent to be in the study will receive a DJO Empowr total knee replacement and participate in motion data collections at pre-op, and 6 and 12 months post-op. Subjects will also participate in pre-op, 6 month, 1 year, 2 year, 5 year, and 10 year post-op clinical data collections
16357576|NCT04275362||Prospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
16357577|NCT04275362||Stryker TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Stryker Triathlon total knee replacement and participated in motion analysis pre-surgery and 6 and 12 months post-surgery.
16357578|NCT04275362||Biomet TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Biomet Vanguard total knee replacement and participated in motion analysis pre-surgery and 12 months post-surgery.
16357579|NCT04275362||Retrospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
16357580|NCT04275349||Exposure group(continuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
16357581|NCT04275349||Exposure group(uncontinuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
16357582|NCT04275349||Completely unexposed group|xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
16357583|NCT04275349||Incompletely unexposed group|xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
16357584|NCT04275336|Experimental|EMLA group|The specialist nurse who is to perform IV cannulation determine the puncture site. A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse performed IV cannulation for them.
16357585|NCT04275336|Experimental|Distraction group|The multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They are also taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
16357586|NCT04275336|Experimental|Combined group|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
16357587|NCT04275323|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
16357588|NCT04275323|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
16357589|NCT04275310|Experimental|Microeconomic intervention|
16357590|NCT04275310|No Intervention|Waitlisted control|
16357591|NCT04275297|Experimental|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
16357592|NCT04275297|Placebo Comparator|Attention Control|The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
16357593|NCT04275284||PCV10 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks and 9 months of age.
16357594|NCT04275284||PCV13 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks and 9 months of age.
16357595|NCT04275284||PCV10 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 14 weeks and 9 months of age.
16357596|NCT04275284||PCV13 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 14 weeks and 9 months of age.
16357597|NCT04275284||PCV10 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
16357598|NCT04275284||PCV13 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
16357703|NCT04274400||Patients referred for polysomnography|Patients referred for polysomnography will be classified according to the presence of OSA, insomnia or both.
16357704|NCT04274387|Experimental|MBSR group|participants who receiving 8-week MBSR between the pretest and posttest
16357599|NCT04275271|Experimental|Intervention group|Intervention group will be received sexuality teaching skills for promotion of professional competence based on information, motivation and behavioral skills model for adolescent sexuality after signing informed consent form and being informed about the goals and details of intervention for 6 sessions (one two hour session per week).
16357600|NCT04275271|No Intervention|Control group|The control group will not receive any intervention until the end of the research.
16357601|NCT04275258|Experimental|Intervention group|"Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge. In addition, subjects will receive:
~A face-to-face meeting prior to discharge where the PA will discuss with the subject their individualized pain management plan and individualized opioid taper plan.
~PA will contact subject on the phone within the first week after hospital discharge to ensure subject plans to follow up with PCP and to troubleshoot any subject concerns related to pain management."
16357602|NCT04275258|No Intervention|Control group|Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
16357603|NCT04275245|Experimental|Meplazumab|10mg Meplazumab by intravenous infusion, every day for 2 days
16357604|NCT04275232|Experimental|Allogenic Plasma Aliquots|Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
16357605|NCT04275219|Experimental|Tong-Fu-Xing-Shen herbal formula|Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
16357606|NCT04275219|Placebo Comparator|The Placebo of Tong-Fu-Xing-Shen herbal formula|The Placebo of Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.
16357607|NCT04275206|Experimental|Medicinal water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in tap water.)
16357608|NCT04275206|Placebo Comparator|Tap water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in medicinal water.)
16357609|NCT04275193|Experimental|Zishenqing|The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
16357610|NCT04275193|Placebo Comparator|Placebo|The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
16357611|NCT04275180|No Intervention|control|Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
16357612|NCT04275180|Experimental|Argatroban group|Argatraban is used on the basis of standard medical treatment.
16357613|NCT04275167|Experimental|Feasibility of TCE and TNE|Feasibility is measured by the number of participants that we have successfully deployed the Trans-nasal imaging device/Tethered capsule device in.
16357614|NCT04275154||CAR-T patients|Relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) with intent to undergo commercially available CAR-T cell therapy
16357615|NCT04275141|Other|Mauriac syndrome|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 45-min cycling exercise at time 300 min.
16357616|NCT04275141|Other|Type 1 diabetes mellitus|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 45-min cycling exercise at time 300 min.
16357617|NCT04275128||Conventional Genicular Ablation|This group is scheduled to receive conventional genicular ablation to treat their chronic knee pain.
16357618|NCT04275128||Cooled radiofrequency Ablation|This group is scheduled to receive cooled radiofrequency ablation to treat their chronic knee pain.
16357619|NCT04275115|Experimental|Foliglurax|Foliglurax, iv midazolam and cocktail of CYP450 probe substrates
16357620|NCT04275102|Experimental|Three times weekly symptom screening|Three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks
16357621|NCT04275089|Experimental|Reia Vaginal Pessary|
16357622|NCT04275076|Experimental|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate
16357623|NCT04275076|Experimental|bipolar transurethral enucleation of the prostate|bipolar transurethral enucleation of the prostate
16357624|NCT04275050|Experimental|TQB3303 Tablet|TQB3303 Tablet administered orally once. Then TQB3303 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
16357625|NCT04275037|Experimental|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
16357626|NCT04275037|Active Comparator|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
16357627|NCT04275037|No Intervention|Control Group|The control group will receive usual medical care
16357628|NCT04275024|Experimental|Experimental group|"AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.
~The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
16357629|NCT04275011|Active Comparator|Static Posture and Balance Exercise|Participants in the control group will receive equal attention through a static posture and balance exercise class two times per week, in a small group setting.
16357630|NCT04275011|Experimental|Progressive Resistance and Impact Exercise|The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
16357631|NCT04274998|Experimental|patient with Alzheimer disease|Patient is diagnosed with Mild Cognitive Impairment or Alzheimer's disease.
16357632|NCT04274998|Experimental|Healthy volunteer|Subject must be a Healthy.
16357633|NCT04274985||1|Patients with temporomandibular disorders
16357667|NCT04274660|No Intervention|DWELL non-intervention/Control|People with type 2 diabetes who are receiving routine care from their GP and healthcare team. People with type 2 diabetes will continue to receive routine standard care. Routine care in this respect constitutes usual health and social care or any other nationally or locally commissioned education programmes
16357634|NCT04274972||Pancreaticoduodenectomy patients|All patients, affected by a resectable PDAC of the head of the pancreas, visited at the Department of Pancreatic Surgery of Verona, will be enrolled. All the patients must be scheduled for an elective PD. The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated.
16357635|NCT04274959|Active Comparator|ceramic onlay with shoulder preparation design.|posterior ceramic onlay restoration with shoulder design with 1 mm shoulder thickness
16357636|NCT04274959|Experimental|ceramic onlay with butt joint preparation design|posterior ceramic onlay with butt joint preparation design with flat occlusal reduction with inclined surface
16357637|NCT04274946|Active Comparator|RAI+PB+US|Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
16357638|NCT04274946|Experimental|RAI+ICG+US|Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
16357639|NCT04274946|Experimental|RAI+PB+ICG+US|Sentinel lymph node mapping with triple tracer (radioisotope,ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
16357640|NCT04274946|Experimental|PB+ICG+US|Sentinel lymph node mapping with triple tracer (ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
16357641|NCT04274933|Experimental|Dose Escalation: Venetoclax and Capecitabine|Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
16357642|NCT04274933|Experimental|Dose Expansion: Venetoclax and Capecitabine|Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
16357643|NCT04274920|Experimental|Bioactive Glass|18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
16357644|NCT04274920|Active Comparator|Light cured calcium hydroxide|18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
16357645|NCT04274907|Experimental|Dose Escalation Phase: Venetoclax + Pembrolizumab|Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.
16357646|NCT04274907|Experimental|Randomization Phase: Venetoclax + Pembrolizumab|Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.
16357647|NCT04274907|Active Comparator|Randomization Phase: Pembrolizumab Monotherapy|Participants will receive pembrolizumab Dose A
16357648|NCT04274894|Experimental|AndroGel|Participants will receive AndroGel 1.62% once daily
16357649|NCT04274868||Children and adolescents with liver tumor|Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
16357650|NCT04274842|Other|D-OCT image observational|Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
16357651|NCT04274829||PTMC|Patients with papillary microcarcinoma of the thyroid
16357652|NCT04274816|Experimental|Tremelimumab|Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
16357653|NCT04274803|Experimental|Intralipid group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
16357654|NCT04274803|Active Comparator|Standard care group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
16357655|NCT04274790||Metastatic colon cancer|Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.
16357656|NCT04274764|Experimental|Personalized eHealth Education & Motivational Interviewing|Personalized eHealth Glaucoma Education & Motivational Interviewing
16357657|NCT04274764|No Intervention|Standard Education|Participant will receive standard glaucoma education.
16357660|NCT04274738|Experimental|Mavorixafor and Ibrutinib|Each participants will initially receive mavorixafor at Dose Level 1 (200 mg QD) in combination with ibrutinib 420 mg. Cohort A will comprise the first 6 participants enrolled in the study that complete at least their first cycle at Dose Level 2 (400 mg QD). Cohort A participants will start at Dose Level 1 and be allowed to dose escalate after the first cycle to Dose Level 2, if no DLTs are observed during the first cycle of each participant. Cohort B will comprise the next 6 participants enrolled into the study that complete at least their 1st cycle at Dose Level 3 (600 mg QD). Cohort B participants will start at Dose Level 1 and be allowed to dose escalate up to Dose Levels 2 and 3. Cohort C will comprise the remainder of participants enrolled up to the total of 18. Cohort C participants will start at Dose Level 1 and be allowed to escalate to 400 and 600 mg after each dose level has been deemed safe by participants from Cohort A and B.
16357661|NCT04274686|Experimental|Tegaderm application|Patients will receive bag-mask ventilation with Tegaderm placement.
16357662|NCT04274686|Active Comparator|No Tegaderm|Patients will receive bag-mask ventilation without Tegaderm placement.
16357663|NCT04274673|Other|low (less 10ng/dl)|Patients who have low cotinine levels (less 10ng/dl)
16357664|NCT04274673|Other|medium (10-500ng/dl)|Patients who have medium cotinine levels (less 10-500ng/dl)
16357665|NCT04274673|Other|high (more 500ng/dl)|Patients who have high cotinine levels (less 10-500ng/dl)
16357989|NCT04272359||Group 3|GLP1-RA + Long-Acting Insulin +/- Metformin
16357668|NCT04274647|Experimental|Device and Control|"NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose. 0.2ml"
16357669|NCT04274634||Conditions with predisposition to lens oscillations|Marfan Syndrome and Pseudoexfoliation
16357670|NCT04274634||Age-matched with normal axial lengths|
16357671|NCT04274634||Age-matched with extreme axial lengths|
16357672|NCT04274634||Intraocular lens|
16357673|NCT04274634||Pre- and post- cataract surgery|
16357674|NCT04274634||Normals|
16357675|NCT04274621||Patients, family members of patient, medical staff|
16357676|NCT04274608|Experimental|Intervention Arm|"Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above
~Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox."
16357677|NCT04274608|Active Comparator|Control Arm|Patients will undergo a 12-week weight management program.
16357678|NCT04274595|Experimental|Psoriasis patients|
16357679|NCT04274582|Experimental|Chokeberry extract consumption|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
16357680|NCT04274569|Active Comparator|Sodium fluoride (NaF)|Group 1: Quarterly application of a 5% NaF varnish (Duraphat® Varnish, Colgate-Palmolive Ltd, (UK) Ltd., Guildford, Surrey, UK)
16357681|NCT04274569|Experimental|NaF plus tricalcium phosphate (TCP )|Group 2: Quarterly application of 5% NaF-TCP (ClinproTM White Varnish; 3M ESPE, St Paul, MN, USA)
16357682|NCT04274569|Experimental|NaF plus CPP-ACP|Group 3: Quarterly application of a 5% NaF plus casein phosphopeptide-stabilized amorphous calcium phosphate complexes (CPP-ACP) (MI Varnish TM; GC corporation, Itabashi-Ku, Tokyo, Japan)
16357683|NCT04274543|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
16357684|NCT04274543|Active Comparator|Saline|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
16357685|NCT04274530|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy (CBT). Participants will complete a series of online modules via a mobile application in addition to standard of care for their fracture injury. Participants will be assigned a dedicated CBT therapist, and receive feedback and support from their therapist via in-app messaging. The CBT program will last approximately 6-8 weeks.
16357686|NCT04274530|No Intervention|Control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
16357687|NCT04274517|Experimental|Sterile Water|
16357688|NCT04274517|Experimental|3.5% betadine|
16357689|NCT04274517|Experimental|0.05% chlorhexidine gluconate|
16357690|NCT04274504||patients|metatstatic breast
16357691|NCT04274491||Pelvic Organ Prolapse Surgery Patients|Participants with greater than or equal to stage II pelvic organ prolapse who are scheduled for reconstructive surgery will be recruited. Participants will be asked to complete a preoperative online survey regarding their health, recovery expectancy, and different roles. Additional online surveys will be send on postoperative days 14 and 42 to measure postdischarge surgical recovery
16357692|NCT04274478|Other|Single group|
16357696|NCT04274452|Experimental|efgartigimod|Patients receiving an intravenous infusion of efgartigimod
16357697|NCT04274452|Placebo Comparator|placebo|Patients receiving an intravenous infusion of placebo
16357698|NCT04274439|Experimental|Internet-Based Pain Education and Exercise|"Patients allocated to the intervention group will receive a login and password for individual access to the website designed for the study. The content of this intervention will include videos and animations based on pain education, physical activity promotion and general exercises. The pain education component will be based on the E-pain intervention developed by Reis et al (2017), which includes nine main features: (1) acceptance, (2 and 3) education about pain, (4) sleep hygiene, (5) recognizing stress and negative emotions, (6) increasing positive coping in lifestyle, (7) exercises, (8) communication and (9) relapse prevention. The exercise component will include general exercises aiming to improve strength, flexibility, control and coordination.
~Patients in this group will also receive weekly text messages and a health coaching over the telephone. The text messages will include information on the benefits of exercises, motivation, and positive messages about dealing with pain."
16357699|NCT04274439|Active Comparator|Online Booklet|The patients allocated to the control group will have access to an online booklet containing general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. They will also receive one phone call at week 4 and text messages once a week during the study period.
16357700|NCT04274426|Active Comparator|Control arm with Platinum-based chemotherapy|"Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d
~Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 & d8) q21d
~Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d"
16357701|NCT04274426|Experimental|Carboplatin + Mirvetuximab soravtansine (IMGN853)|Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
16357702|NCT04274413|Experimental|Interventional Arm|All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
16357990|NCT04272359||Group 4|SGLT2 inibitori + DPP4 inibitori +/- Metformin
16357705|NCT04274387|No Intervention|passive control group|participants who not undergoing any interventions for 8 weeks between the pretest and posttest
16357706|NCT04274374|Experimental|experimental arm|In the experimental arm will receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day
16357707|NCT04274374|Active Comparator|control arm|the control arm will received 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
16357708|NCT04274361|Experimental|Ketamine arm|Early ketamine infusion therapy at a rate of 3 mcg/kg/min. All ketamine infusions will be calculated based on ideal body weight (IBW), unless actual body weight is less than ideal. Ketamine infusion therapy will be continued for 48 hours. At 2-4 hours post-infusion the patient's pain will be reassessed. If the NPS is more than 5 the infusion will be increased to 5mcg/kg/min. Following each change in the infusion rate the patient's pain will be reassessed at 2-4 hours and adjustments made accordingly. Maximum infusion rate will be set at 9mcg/kg/min. Conversely, The RAAPS team should be notified if neurologic symptoms (hallucinations, delusions, disturbing dreams, vertigo) are developing and, at the discretion of the RAAPS service, a single dose of lorazepam or midazolam may be utilized. The infusion can be decreased from in 2 mcg/kg/min increments if there are symptoms believed to be related to the infusion that do not respond to benzodiazepines.
16357709|NCT04274361|Placebo Comparator|Placebo arm|The 65 patients randomized to the control arm will receive placebo saline solution at a rate equivalent.
16357710|NCT04274348|Other|Skin biopsies and blood samples|
16357711|NCT04274335|Experimental|Intravenous tranexamic acid|
16357712|NCT04274335|Experimental|Intramuscular tranexamic acid|
16357713|NCT04274335|Experimental|Oral liquid tranexamic acid|
16357714|NCT04274335|No Intervention|No tranexamic acid|
16357715|NCT04274322||Cohort 1|High NUTRIC score
16357716|NCT04274322||Cohort 2|low NUTRIC score
16357717|NCT04274309||Patient's tissues exposed|Tonsil of each patient will be imaged using the medical device
16357718|NCT04274309||Patient's tissues not exposed|Tonsil of each patient will not be imaged using the medical device
16357719|NCT04274296||Control|Control-cohort in which no change in care is needed
16357720|NCT04274296||Advisory|Cohort in which advisory is activated
16357721|NCT04274270|Experimental|experimental group|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
16357722|NCT04274257|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
16357723|NCT04274257|Experimental|Double-Blind Rituximab|Participants will receive double-blind rituximab from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
16357724|NCT04274244|Experimental|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"The study participants will first undergo SCALE AND ROOT PLANING. This procedure is the same as that used in the active comparator group and the control group.
~Eight weeks following the initial therapy, reevaluation of the intrabony defects in the interproximal sites with a clinical probing depth >5 mm will be performed by radiographs as well as by using William's graduated periodontal probe to confirm the indication for periodontal surgery. Pairs of premolar and molar teeth in the maxilla or the mandible will be randomized to receive the test treatment (REGENERATIVE PERIODONTAL SURGERY with adjunctive hyaluronic acid gel application) or to serve as active comparators (regenerative periodontal surgery with adjunctive enamel matrix derivative application)."
16357725|NCT04274244|Active Comparator|Enamel Matrix Proteins|"SCALE AND ROOT PLANING
~REGENERATIVE PERIODONTAL SURGERY: Application of enamel matrix derivative."
16357726|NCT04274244|No Intervention|Scale and root planning|Control group: Just SCALE AND ROOT PLANING is performed
16357727|NCT04274231||TKI best effect group|TKI best effect was defined achieve complete cytogenetic response (CCyR)after 3 months of treatment and the level of BCR/ABL<10% after 3 months of treatment,the level of BCR/ABL<1% .
16357728|NCT04274231||TKI resistance group|TKI resistance was defined as the lack of a complete hematologic response (CHR) after 3 months of TKI treatment, the lack of any cytogenetic response after 6 months of treatment, the lack of major cytogenetic response (MCyR) (Ph-positive cells > 35%) after 12 months of treatment, an increase of white blood cell (WBC) count in at least two consecutive samplings (with a doubling of the count from the nadir to ≥ 20×109/L or an absolute increase of ≥ 50×109/L), or a relapse after a CHR or MCyR.
16357729|NCT04274231||TKI intolerance group|TKI intolerance was defined as at least grade 3 nonhematologic toxicity or grade 4 hematologic toxicity persisting for more than 7 days, related to TKIs at any dose.
16357730|NCT04274218|Experimental|Walking perturbation - Free|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with both arms free and individuals with amputation will walk with their prosthesis.
16357731|NCT04274218|Experimental|Walking perturbation - Limited|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with one arm bound to their side with straps and individuals with amputation will walk without their prosthesis.
16357732|NCT04274205|Active Comparator|Influence on brief supportive psychotherapy|Intervention group
16357733|NCT04274205|Active Comparator|Influence of brief supportive psychotherapy|Control group
16357734|NCT04274192|Experimental|Synchronized HFNC|This will be the experimental arm in which subjects will receive HFNC synchronized to his/her own efforts via NAVA
16357735|NCT04274192|Other|Continuous HFNC|This arm will be considered the control arm in which subjects will receive continuous HFNC.
16357736|NCT04274179|Experimental|Diet therapy|Modified Atkins Diet - high fat, low carbohydrate, outpatient initiated approach. Parents will check urine ketones twice weekly and follow by email, phone and clinic. Labs at baseline and 3 months. Dietitian support.
16357766|NCT04273984|Placebo Comparator|3- Group 3 (placebo group)|Group 3 ): will take2 placebo tablets
16357767|NCT04273971|Experimental|Plyometric exercise|
16357737|NCT04274179|Active Comparator|Drug therapy|Families will have the usual care for absence epilepsy at the discretion of the family's neurologist and the family choice. Typically ethosuximide bis in die (BID), however, if convulsions have occurred or other factors are involved, the child may be started on valproate or lamotrigine. The child will continue medications with dose adjustment and antiseizure drug levels checked as usual.
16357738|NCT04274166|Experimental|Experimental|2 s.c. secukinumab 150 mg injections
16357739|NCT04274153|Experimental|Gardasil9|Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
16357740|NCT04274140||Obese Pregnant Women|obese, BMI 30-50
16357741|NCT04274140||Normal weight pregnant women|normal weight, BMI 18.5-25
16357742|NCT04274127|Other|children aged 16 to 24|estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
16357743|NCT04274114|Experimental|Experimental group|Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.
16357744|NCT04274114|Placebo Comparator|Placebo group|Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.
16357745|NCT04274101||Nifurtimox|Patients treated with Nifurtimox from 1984 to 2017
16357746|NCT04274101||Benznidazole|Patients treated with Benznidazole from 1984 to 2017
16357747|NCT04274088||Tecnis;|Patients who received the Tecnis multifocal IOL.
16357748|NCT04274088||Diffractiva|Patients who received the Diffractiva multifocal IOL.
16357749|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
16357750|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
16357751|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
16357752|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
16357753|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
16357754|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
16357755|NCT04274062||peri partum integrated nursing care of placenta previa|"Part (1) personal data:
~Part (2) baseline and characteristics of the patients participants:
~Tool II- An observation checklist: This tool is develop by researcher according to guideline of Royal College of Obstetricians and Gynaecologists, 2018), and divide into three main parts: preoperative, intraoperative and postoperative.
~Part (1) pre-operative: includes assessment of :
~patients general condition
~investigation
~reserved blood
~Hemoglobin level
~Impact of hysterectomy option. -9-
~Part (2) Intra-operative:
~Includes assessment of :-
~Investigation
~Vital signs
~Hypothermia
~Blood loss
~I.V fluid
~Blood gases
~Fetal condition and APGAR score.
~Part (3) Post-operative: Includes:
~maternal complication
~fetal complication
~psychological satisfaction"
16357756|NCT04274062||peri partum regular care of placenta previa|Routine nursing care of all cases of placenta previa (preoperative, intraoperative and postoperative)..
16357757|NCT04274049|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
16357758|NCT04274049|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
16357759|NCT04274036||Fibromyalgia Patients|Fibromyalgia patients diagnosed according to the 2016 American College of Rheumatology criteria.
16357760|NCT04274036||Healthy-Controls|Healthy controls without pain or chronic illness
16357761|NCT04274023|Experimental|TSR-042 arm|TSR-042 at a dose of 500 mg in IV infusion (given over t30-minutes) every 21 days for the first 4 doses, followed by 1.000 mg on day 1 of every 42 day.
16357762|NCT04273997|Active Comparator|Metronidazole Ointment|"Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
~One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound"
16357763|NCT04273997|Placebo Comparator|Placebo Ointment|"Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
~One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound."
16357764|NCT04273984|Active Comparator|1- Group 1 (misoprostol 200 mcg|"Group 1 :will take 1 tablet (200 mcg) of misoprostol and 1 placebo tablet,
~.,"
16357765|NCT04273984|Active Comparator|2- Group 2 (misoprostol 100 mcg)|Group 2: will take1 tablet (100 mcg) of misoprostol and 1 placebo tablet,
16357768|NCT04273958|Experimental|Virtual reality|The intervention will consist of the use of a virtual reality helmet during the painful medical procedure. The content has been developed by a private company with the goal of providing a relaxing and soothing exploration of a virtual world.
16357769|NCT04273958|Active Comparator|Computer screen|The comparator will consist in the screening of the same virtual world on the computer screen.
16357772|NCT04273932|Experimental|Lithium aspartate 15mg a day|15mg of elemental lithium administered every morning by mouth.
16357773|NCT04273932|Experimental|Lithium aspartate 45mg a day|20mg every morning and 25mg every evening of elemental lithium administered by mouth.
16357774|NCT04273932|Experimental|Lithium carbonate|The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.
16357775|NCT04273932|No Intervention|No lithium treatment|Control arm
16357776|NCT04273919|Sham Comparator|Mindfulness Mediation|Subjects will undergo virtual reality in a non-embodied (no first person bodily experience) program called Lumen, which was developed by Stanford University's Virtual Human Interaction Lab.
16357777|NCT04273919|Experimental|Graded Motor Imagery|The subjects will engage in 2 therapeutic modules intended to help them practice increasing range of motion safely, and using small movements of the lower back.
16357778|NCT04273906|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
16357779|NCT04273906|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
16357780|NCT04273893|Experimental|SBRT Additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
16357781|NCT04273893|Active Comparator|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
16357782|NCT04273880|Experimental|10 mg Psychostimulant|Drug: Methylphenidate (MPH) Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 10mg of MPH an hour and a half before the testing session is set to begin, to account for the time taken for the effects of the drug to start.
16357783|NCT04273880|Placebo Comparator|90 mg Vitamin C|Placebo: Vitamin C Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 90mg of Vitamin an hour and a half before the testing session is set to begin, to follow the exact protocol that is used for MPH.
16357784|NCT04273867||Chronic Hypersensitivity Pneumonitis Patients|
16357787|NCT04273841|Active Comparator|Caffeine Group|This group will receive caffeine gum.
16357788|NCT04273841|Placebo Comparator|Placebo|This group will receive gum without caffeine.
16357789|NCT04273815|Experimental|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.
16357790|NCT04273815|Experimental|TQ-A3334 tablets + anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16357791|NCT04273802|Experimental|Cohort A - First line treatment|Untreated patients
16357792|NCT04273802|Experimental|Cohort B - Hypomethylating failure|Patients in absence of response after hypomethylating agents treatment
16357793|NCT04273789|Experimental|far infrared reflecting sleepwear|Sleepwear (shorts + tshirt) with far infrared reflecting ceramic print produced by Dagsmejan AG (Zurich, Switzerland)
16357794|NCT04273789|Placebo Comparator|Placebo sleepwear|Sleepwear (shorts + tshirt)
16357795|NCT04273776|Active Comparator|Suvorexant Arm|10 mg of Suvorexant
16357796|NCT04273776|Active Comparator|Zolpidem Arm|5 mg of Zolpidem
16357797|NCT04273776|Placebo Comparator|Placebo|10mg of Avicel
16357798|NCT04273763|Experimental|Group A|Treatment group
16357799|NCT04273763|Active Comparator|Group B|Control group
16357800|NCT04273737|Experimental|Amantadine|Daily regimen of amantadine hydrochloride tablets for 6 weeks: dosing of 5mg/kg divided by two daily doses (max daily dose of 300 mg)
16357802|NCT04273711||Obese patients|
16357803|NCT04273711||Non-obese patients|
16357878|NCT04273074|Other|preoperative sonographic assessment group|preoperative sonographic assessment to airway
16357804|NCT04273698|Experimental|Clinical intervention|The project involved recruiting families, with children under the age of five years old, who were experiencing one or more difficulties, and these families were offered five therapeutic sessions, based on a psychodynamic parent-infant psychotherapy approach.
16357805|NCT04273685|Experimental|Intervention Condition|Cognitive remediation training, cognitive behavioural therapy, social recovery therapy
16357806|NCT04273685|Active Comparator|Control Condition|Treatment as usual (TAU),non-directive counselling
16357807|NCT04273672||Parkinson's Disease|Subjects with Parkinson's Disease
16357808|NCT04273672||Control|Subjects without Parkinson's Disease
16357809|NCT04273659|Experimental|Pulses and Cereal 1|Pulses and cereal 1 containing study product is served. Dietary intervention.
16357810|NCT04273659|Experimental|Pulses and Cereal 2|Pulses and cereal 2 containing study product is served. Dietary intervention.
16357811|NCT04273646|Experimental|UC-MSCs Treatment Group|"Conventional treatment plus UC-MSCs:
~Participants will receive conventional treatment plus 4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1，Day 3，Day 5，Day7)."
16357812|NCT04273646|Placebo Comparator|Conventional Control Group|"Conventional treatment plus Placebo:
~Without UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1，Day 3，Day 5，Day7)."
16357813|NCT04273633|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant shoulder
16357814|NCT04273633|Placebo Comparator|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant shoulder
16357815|NCT04273620|Experimental|Intervention-Control (IC)|In the Intervention-Control (IC) arm, patients will first receive the intervention (OKS-READ) containing 15 individual therapy sessions within a maximum time period of 28 days. Afterwards they will receive the control therapy (again 15 sessions within max. 28 days).
16357816|NCT04273620|Active Comparator|Control-Intervention (CI)|In the Control-Intervention (CI) arm, patients will first receive the control therapy (15 sessions within max. 28 days), followed by the intervention phase (15 therapy sessions OKS-READ within a maximum time period of 28 days).
16357817|NCT04273607|Experimental|No anticoagulation|Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin
16357818|NCT04273607|No Intervention|Anticoagulation, ECMO standard of care|Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.
16357819|NCT04273594|Experimental|FemBloc|Investigational device and procedure
16357820|NCT04273581|Placebo Comparator|Control group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. placebo：100mg/d，qn，for 14 days.
16357821|NCT04273581|Experimental|Thalidomide group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. thalidomide：100mg/d，qn，for 14 days.
16357822|NCT04273568|Experimental|Group1 (PNF group)|Scapular PNF and exercise program was applied to the PNF group.
16357823|NCT04273568|Active Comparator|Group 2 (Exercise group)|Exercise program was applied to the exercise group
16357824|NCT04273555|Experimental|[18F]-Fluorodeoxyglucose (FDG) PET/ MRI|
16357825|NCT04273542|Other|Control cohort|"In this cohort, women recruited participated to organised breast cancer screening. They must not have breast cancer.
~They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening)."
16357826|NCT04273542|Other|Patient cohort|"In this cohort, women for who a breast cancer has been diagnose will be included.
~Only one liquid biopsy will be collected before any treatment."
16357827|NCT04273542|Other|Exploratory cohort|"In this cohort, women with high risk of BRCA1/2 mutation but without breast cancer.
~6 liquid biopsies will be collected : each year after inclusion during 5 years."
16357828|NCT04273529|Placebo Comparator|Control group|placebo
16357829|NCT04273529|Experimental|Thalidomide group|thalidomide
16357830|NCT04273516|Experimental|Intervention|Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily
16357831|NCT04273516|Placebo Comparator|Comparator|Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily
16357832|NCT04273503|Experimental|Intervention|All participants will receive education on maintaining a healthy diet and improving physical activity.
16357833|NCT04273490||Hereditary hypophosphatemia|Adult persons with genetically or biochemically verified hereditary hypophosphatemia.
16357834|NCT04273490||Control|Adult control persons without disturbances in calcium, vitamin D or phosphate homeostasis matched on age, gender and menopausal status.
16357835|NCT04273464|Experimental|Brava-group|External tissue expanders will be used 3 weeks prior to operation and 2 weeks postoperatively in order to enhance the volume and survival of fat cells. We expect that each patient in the fat transplantation group will need 4-6 transplantation sessions of about 1.5 to 2 hours each to achieve satisfactory volume and shape of the breast.30 participants.
16357836|NCT04273464|Active Comparator|DIEP-group|30 participants. We expect 1-2 operative sessions of respectively 5-7 and 2-3 hours duration in the DIEP group. The risk of reoperation (second operation during the first postoperative week) in the DIEP group is 5-10 %
16357837|NCT04273425||Study cohort (Confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.
~Those who receive a positive diagnosis will be followed up upon completion of first-line treatment, and questionnaire data and blood samples collected again."
16357838|NCT04273425||Control cohort (non-confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.
~Samples from patients who receive a negative myeloma diagnosis will be used as negative controls."
16357839|NCT04273412|Experimental|lifestyle intervention (LI)|moderate-intensity lifestyle intervention (Individualised counseling on diet, physical activity, and target weight gain) by license dietitian
16357840|NCT04273412|No Intervention|usual standard care group (UC)|standard antenatal care as per usual clinic protocol
16357841|NCT04273399|Experimental|Crohn's Disease|Twelve week jumping based exercise intervention
16357842|NCT04273399|Active Comparator|Controls|Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups
16357844|NCT04273373|Active Comparator|Standard dose albumin+SOC|20% albumin1.5 g/kg at diagnosis and 1 g. SOC (Standard of Care)
16357845|NCT04273373|Experimental|Low dose albumin+SOC|20% albumin.5 g/kg at diagnosis and 0.5 g/kg. SOC (Standard of Care)
16357846|NCT04273360|Active Comparator|Systematic use group|
16357847|NCT04273360|Experimental|Restrictive use group|
16357848|NCT04273347||patient with brain trauma|all patient with brain trauma in intensive care unit
16357849|NCT04273347||patient with spinal cord injury|all patient with spinal cord injury in intensive care unit
16357850|NCT04273334|Experimental|68Ga-NEB injection and PET/CT scan|Patients for lymphatic disorders imaging: The patients were subcutaneously injected with 68Ga-NEB and underwent PET/CT scan 20~40min after the injection.
16357851|NCT04273321|Experimental|MP group|
16357852|NCT04273321|No Intervention|Con group|
16357853|NCT04273308|Experimental|whole-body vibration training|a 12-week whole-body vibration training that conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time.
16357854|NCT04273295|No Intervention|the control group|This group receives senna-based laxatives.
16357855|NCT04273295|Experimental|the study group|This group managed by abdominal massage with senna-based laxatives.
16357856|NCT04273282|Active Comparator|Dexycu Group|A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.
16357857|NCT04273282|Active Comparator|Control Group|A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
16357858|NCT04273269|Experimental|8x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 8x10^12 vg/Kg LYS-GM101
16357859|NCT04273256|Experimental|Myo-inositol arm|Patients will be supplemented with 2 grams of Myo-inositol + at least 400 μg of folic acid (received from routinely prescribed multivitamins) every day for 3 months before the IVF cycle.
16357860|NCT04273256|No Intervention|Control arm|Patients will receive at least 400 μg of folic acid from routinely prescribed multivitamins every day for 3 months before the IVF cycle.
16357861|NCT04273243||Subjects who received AT-GTX-501 gene transfer|Subjects with CLN6 Batten disease who previously received AT-GTX-501 in the preceding study (Study AT-GTX-501-01).
16357862|NCT04273217|Experimental|AV-1|Single dose
16357863|NCT04273217|Placebo Comparator|Placebo|Single dose
16357864|NCT04273204|Experimental|UCP Group|
16357865|NCT04273204|Other|Control Group|
16357866|NCT04273191|Experimental|Brexanolone|Participants will receive a single dose of commercial brexanolone as part of standard of care.
16357867|NCT04273178|Experimental|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
16357868|NCT04273165|Active Comparator|Etravirine Dose 1|Etravirine dose 200 mg per diem(100+100)
16357869|NCT04273165|Active Comparator|Etravirine Dose 2|Etravirine dose 400 mg per diem (200+200)
16357870|NCT04273152||children with allergy|children with allergies
16357871|NCT04273152||healthy control|healthy control (non allergic children)
16357872|NCT04273139|Experimental|Ibrutinib and Venetoclax (3 dose ramp up)|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~First 12 participants
~Ibrutinib will be administered at a predetermined dose, once daily for 28 days
~TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)
~Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2."
16357873|NCT04273139|Experimental|Ibrutinib and Venetoclax (2 dose ramp up)|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Ibrutinib will be administered at a predetermined dose, once daily for 28 days
~TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)
~Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up schedule during cycle 2."
16357874|NCT04273126|Experimental|Intervention|This arm consists of approximately 8-10 modules lasting approximately one hour and consisting of psychoeducation and core components including communication, problem solving, goal setting, and dealing with stress, tailored to families with experiences of homelessness and parental substance use.
16357875|NCT04273126|No Intervention|Treatment as usual|Families in the standard care condition will receive treatment as usual at their facility, which may include case management at the facility, and mental health services and supportive services from organizations affiliated with the sites.
16357876|NCT04273113|Experimental|Heart Rate Variance (HRV) biofeedback training|Patients to participate in 15 biofeedback sessions, 3 times a week (5 weeks in total).
16357877|NCT04273100|Experimental|Treatment group|The participants will receive the combined treatment of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE, lobaplatin and epirubicin and anti-angiogenic therapy (lenvatinib)
16357881|NCT04273061|Experimental|GI Cohort|Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
16357882|NCT04273061|Experimental|GU Cohort|Cohort of participants whose primary tumour type is genitourinary.
16357883|NCT04273061|Experimental|Gyne Cohort|Cohort of participants whose primary tumour type is gynecological.
16357884|NCT04273061|Experimental|Sarcoma Cohort|Cohort of participants whose primary tumour type is sarcoma.
16357885|NCT04273061|Experimental|Primary Unknown Cohort|Cohort of participants whose primary tumour type is unknown.
16357886|NCT04273061|Experimental|Other Cohort|Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with cancers from the head and neck, skin, or rare cancers.
16357887|NCT04273048|Active Comparator|Diet and Exercise|Group 1 = Diet Intervention group: They will be asked to follow a personalized diet during study period and record what they eat. The meal plan for this study is Mediterranean style and nutritionally complete for 8 to 12 weeks or until oocyte retrieval procedure. Exercise Intervention: Exercise 3 times/week at a gym of their choice or at home for 8 to 12 weeks or until oocyte retrieval procedure. Exercises will be light intensity and short duration at first and will gradually increase to moderate intensity and longer duration during the first 3 weeks. They will also be encouraged to walk an average 10,000 steps per day and wear a pedometer to monitor progress.
16357888|NCT04273048|No Intervention|Standard Care|Group 2 = Standard: They will receive standard care from the Little Rock Fertility Center.
16357889|NCT04273035|Active Comparator|Midazolam Group|"Midazolam(Buccolam 5mg/ml)
~0.5mg/kg oral, max 12mg
~one time
~given 30 min prior to going to holding"
16357890|NCT04273035|Active Comparator|IPAD group|"No premedication
~IPAD when arriving at the holding
~any games, movies, clips, puzzles"
16357891|NCT04273022|Experimental|SCT Group|Fifteen SCT subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
16357892|NCT04273022|Active Comparator|Control Group|Five healthy subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
16357893|NCT04273009|Active Comparator|Renew Anal Insert|The device is intended for self-insertion through the anal canal aided by a fingertip applicator.
16357894|NCT04273009|Active Comparator|Percutaneous tibial nerve stimulation|A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.
16357895|NCT04272996|Other|surgery alone|craniotomy for SDH evacuation
16357896|NCT04272996|Active Comparator|Surgery plus embolization|surgery for evacuation of SDH followed by embolization of middle meningeal vessel
16357897|NCT04272970|Active Comparator|New gene / protein variant functional study|Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional familial thrombocytopenia.
16357898|NCT04272970|Sham Comparator|Normal gene / protein variant functional study|"Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to provide control observations / analyses / measures for the Active Comparator arm"
16357899|NCT04272957|Experimental|HMPL-306|HMPL-306 administered continuously as a single agent orally every day in a 28-day cycle.
16357900|NCT04272944|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 3 mg/kg to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
16357901|NCT04272931|Experimental|Portal and Hepatic Vein Embolization|3 patients per center over one year approximately 90 patients in total. Patients will undergo portal vein and hepatic vein embolization instead of only portal vein embolization.
16357902|NCT04272918|Experimental|CSM condition|Social Worker 1 of CSM conditions will work with caregivers according to the guidelines and template of the Care Support Model, including the formulation of the intervention plan based on CNA scores of different need domains, the use of the caregiver intervention plan template, service matching drawing reference from caregiver resource database, service formulation based on CNA scores of different strength domains, the use of the case monitoring template and guideline.
16357903|NCT04272918|No Intervention|Non-CSM condition|Social Worker 2 of the Control Group will not be notified of the CNA scores of his/her caregivers. The intervention plan, services assignment and case management of participants of the control group will be based on Social Worker 2's own judgement using the information shared by the caregivers, and the social worker's own observation.
16357904|NCT04272918|Experimental|PP-E condition|Experimental Group will be led a consultant who is an expert, with the help of a degree-holder social worker to facilitate capacity building, empowerment and long-term well-being. Measurement of outcome variables will be conducted before the start of the program, at the end of the program, and 3 months after the program ended.
16357905|NCT04272918|No Intervention|Non PP-E condition|Measurement of outcome variables will be conducted at the same point of time as PP-E condition. There will be no treatment or intervention for the control group.
16357906|NCT04272905||Maternity patients|"> 18 years
~Post-natal following any form of delivery
~Between 4 and 48 hours after delivery
~Able to understand English adequately to give consent and complete the questionnaire"
16357907|NCT04272905||Maternity Unit Staff|"Doctors, midwives and other staff
~Work on labour ward"
16357908|NCT04272892|Experimental|Digital CBT-I|6 weeks digital (online) cognitive behavioural therapy for insomnia
16357909|NCT04272892|Active Comparator|Sleep hygiene information|Leaflet of sleep hygiene information
16357910|NCT04272866|Active Comparator|Group 1|Teeth in this group will be sealed with clinpro sealant
16357911|NCT04272866|Experimental|Group2|Teeth in this group will be sealed with embrace wetbond sealant
16357912|NCT04272866|Experimental|Group3|Teeth in this group will be sealed with triage sealant
16357913|NCT04272853||Athletes|440 subjects will be recruited (see calculation of the sample size for details): all subjects will be athletes, professional or non-professional, belonging to any sporting discipline, members of one of the sports federations of the Lombardy region, officially recognized by CONI (National Committee of Italian Olympic Team).
16357914|NCT04272840|No Intervention|Standard Care|Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record).
16357915|NCT04272840|Experimental|Low Glycemic Index|Standard care + Glycemic Index. Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record). Diabetes Canada and Dietitian's Canada resources on glycemic index will also be reviewed: the Glycemic Index Food Guide, Flip Cards, and Recipes.
16357916|NCT04272827|Active Comparator|Intervention group|In the intervention group, patients will receive liposuction treatment (number of surgeries at the discretion of the attending study physician: a maximum of 4 surgical procedures, with a minimum of 5 and a maximum of 7 weeks between each surgery) with concomitant complex decongestive therapy (CDT), if necessary, to maintain surgical outcomes as required by the patient.
16357917|NCT04272827|Other|Control group|"After randomisation, the control group will be treated for 12 months with complex decongestive therapy (CDT) alone.
~After these 12 months, patients can opt for liposuction treatment if they continue to meet the inclusion and exclusion criteria."
16357918|NCT04272814|Experimental|Compression therapy|compression therapy
16357919|NCT04272814|Active Comparator|Standard treatment|standard treatment
16357920|NCT04272801|Experimental|Neoadjuvant endocrine therapy|All participants enrolled to the study will receive 3 months of neoadjuvant endocrine therapy (e.g. tamoxifen or aromatase inhibitors (AIs) such as letrozole, anastrozole, or exemestane). The choice and dose of endocrine therapy will be at the discretion of the treating medical oncologist.
16357921|NCT04272788||CD patients|CD patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.CD patients are followed for 14 weeks after the first administration of infliximab. At week 14 of Infliximab treatment, CD patients are classified as remission group (CDAI<150 and endoscopic mucosal healing, R group) and non-remission group (CDAI≥150 and/or mucosal non-healing group, N group).
16357922|NCT04272788||Healthy controls|Healthy controls without Crohn's Disease.
16357923|NCT04272775|Experimental|Cohort 1: Ixazomib 4.0 mg|Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
16357924|NCT04272775|Experimental|Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone|Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
16357925|NCT04272775|Experimental|Cohort 3: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
16357926|NCT04272775|Experimental|Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
16357927|NCT04272762|Active Comparator|Ablation|pulmonary vein isolation
16357928|NCT04272762|Placebo Comparator|Placebo|placebo procedure
16357929|NCT04272749|Experimental|Dairy and non-dairy milks|Questionnaires and consumption behaviors of dairy and non-dairy milks
16357930|NCT04272736|Experimental|Low calorie protein substitute|Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.
16357931|NCT04272723||VMP members of the SFMV|VMP (vascular medicine physicians) members of the SFMV (French Society of Vascular Medicine )
16357932|NCT04272723||VMP registered as willing to do medical research|VMP (vascular medicine physicians) registered as willing to do medical research
16357933|NCT04272710||ACEI treatment|hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
16357934|NCT04272710||Control|hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
16357935|NCT04272697||Heterozygous Familial Hypercholesterolaemia|Adults and children with Heterozygous Familial Hypercholesterolaemia.
16357936|NCT04272697||Homozygous Familial Hypercholesterolaemia|Adults and children with Homozygous Familial Hypercholesterolaemia
16357937|NCT04272697||Unaffected (non-FH) relatives of FH individuals|Adults and children with unaffected (non-FH) relatives of FH individuals
16357938|NCT04272684|Experimental|Interventional|Driving Assessment
16357939|NCT04272671|Experimental|Educational Intervention Arm|The intervention arm will receive educational material that enhances the standard of care for deprescribing opioids and BZDs.
16357940|NCT04272671|No Intervention|Ususal Care (Control Arm)|Control group will receive standard of care
16357941|NCT04272658||value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma"
16357942|NCT04272645|Experimental|Arm A - Abemaciclib 200 mg|Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
16357943|NCT04272645|Experimental|Arm B - Abemaciclib 150 mg + atezolizumab|Atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily.
16357944|NCT04272645|Experimental|Experimental: Arm C - Patients with CDK12 loss|"Group 1 - Atezolizumab: Patients with CDK12 loss will receive atezolizumab monotherapy on the first day of each 21-day cycle
~Group 2 - Abemaciclib 150 mg + atezolizumab: Patients with CDK12 loss will receive atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily."
16357945|NCT04272632|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
16357946|NCT04272632|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
16357947|NCT04272632|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
16357948|NCT04272619|Experimental|Liver Cancer Education|
16357949|NCT04272606|Active Comparator|Treatment|1:1 randomization, given tranexamic acid during surgery, visual acuity exam
16357950|NCT04272606|Placebo Comparator|Placebo|1:1 randomization, given standard of care treatment during surgery, visual acuity exam
16357951|NCT04272593|Experimental|Simultaneous Control|Simultaneous pattern recognition style of control allows prosthetic users to actuate more than one hand/arm function on their device at the same time.
16357952|NCT04272593|Active Comparator|Conventional Control|Conventional, seamless sequential pattern recognition style of control allows prosthetic users to actuate a single hand or arm functions on their device at a time.
16357953|NCT04272580|Sham Comparator|Control group|No preload was given before spinal anesthesia
16357954|NCT04272580|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia
16357955|NCT04272580|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
16357956|NCT04272580|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
16357957|NCT04272567|Sham Comparator|Control group|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
16357958|NCT04272567|Experimental|0.025 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).
16357959|NCT04272567|Experimental|0.05 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).
16357960|NCT04272567|Experimental|0.075 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).
16357961|NCT04272567|Experimental|0.1 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).
16357962|NCT04272541|Active Comparator|Psychoeducation program|The intervention program consists of psychopharmacology (standard intervention in mental health services) + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program is implemented for three months, allocated in several sessions.
16357963|NCT04272541|Active Comparator|Habitual intervention|Intervention program consists of psychopharmacology (standard intervention in mental health services). This program is implemented for three months.
16357964|NCT04272528|Experimental|experimental group|Nurses provide uniform care to patients according to the quality standards.
16357965|NCT04272528|Placebo Comparator|control group|Nurses provide the routine care to patients.
16357966|NCT04272515|Experimental|BA patients and their parents|"Collection of blood samples from BA patients and their parents
~Collection of explanted liver tissue and skin biopsy of BA patients"
16357967|NCT04272502|Experimental|Sequence A|CKD-828, D326, D337, CKD-F1, CKD-F2
16357968|NCT04272502|Experimental|Sequence B|CKD-828, D326, D337, CKD-F1, CKD-F2
16357969|NCT04272502|Experimental|Sequence C|CKD-828, D326, D337, CKD-F1, CKD-F2
16357970|NCT04272489|Experimental|Adaptive Control|The adaptive control system updates the pattern recognition control algorithm by incorporating new EMG data each instance the prosthetic user recalibrates their device.
16357971|NCT04272489|Active Comparator|Non-Adaptive Control|The conventional, non-adaptive control systems resets the pattern recognition control algorithm by deleting old EMG data each instance the prosthetic user recalibrate their device.
16357972|NCT04272476|Experimental|Acupuncture and moxibustion|Acupuncture points: Baihui(GV 20), Mingmen(GV 4), Bilateral Neiguan(PC 6), Bilateral Shenmen(HT 7), Bilateral Hegu(LI 4), Bilateral Zusanli(ST 36), Bilateral Taichong(LR 3). Each treatment takes about thirty minutes,3 times a week(treatment on Monday, Wednesday and Friday) for 8 weeks.
16357973|NCT04272476|Active Comparator|Western medicine|Fluoxetine 20 mg capsule by mouth every day for 8 weeks.
16357974|NCT04272437|Experimental|TRA group|"Tokoro Combination and Rehmannia and Akebia Formula (TRA) in each one batch number were manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous manufacturer of concentrated herbal extract granules in agreement with the standards of good manufacturing practices (GMP) in Kaohsiung City, Taiwan.
~TRA contains Tokoro Combination and Rehmannia and Akebia Formula Tokoro Combination and Rehmannia and Akebia Formula consists of Dioscorea Hypoglaucae Rhizoma, Acori Graminei Rhizoma, Linderae Radix, Alpiniae Oxyphyllae Fructus, Poria, Rehmanniae Radix, Akebiae Caulis, Lophatheri Hebra, and Glycyrrhizae Radix at a 2:2:2:2:1:1.3:1.3:1.3:2.5 ratio."
16357975|NCT04272437|Placebo Comparator|placebo group|The placebo was also prepared as granules by Chung Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA.
16357976|NCT04272424|Active Comparator|group A|laparoscopic hernioplasty with no fixation
16357977|NCT04272424|Active Comparator|group B|laparoscopic hernioplasty with tacker fixation
16357978|NCT04272424|Active Comparator|group C|laparoscopic hernioplasty with histoacryl fixation
16357979|NCT04272411|Sham Comparator|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device
16357980|NCT04272411|Active Comparator|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device
16357981|NCT04272411|Active Comparator|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device
16357982|NCT04272398|Active Comparator|Treatment|Used dynamic elastomeric fabric orthoses with physiotherapy and rehabilitation program
16357983|NCT04272398|Experimental|Control|Only physiotherapy and rehabilitation program
16357984|NCT04272372||Group 1|Complete Decongestive Therapy
16357985|NCT04272372||Group 2|Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
16357986|NCT04272372||Group 3|Complete Decongestive Therapy + Local Ketoprofen gel
16357987|NCT04272359||Group 1|SGLT2 inibitori +/- Metformin
16357988|NCT04272359||Group 2|DPP4 inibitori +/- Metformin
16357991|NCT04272346|Experimental|Peer helping condition|Participants in the peer helping condition will be asked to write about their cancer experience with an emphasis on using the experience to benefit a newly-diagnosed AYA cancer patient.
16357992|NCT04272346|Experimental|Processing + peer helping condition|Participants in the processing + peer helping condition will be asked to first write about their deepest thoughts and feelings about their cancer experience (3 writings), then share advice to a newly-diagnosed AYA cancer patient (final writing).
16357993|NCT04272346|Placebo Comparator|Facts-only writing condition|Participants in the facts-only writing condition will be asked to write about their cancer experience. Unlike the previous conditions, they will not be instructed to write for the benefit of a newly-diagnosed AYA cancer patient.
16357994|NCT04272333|Experimental|CIVO Microdose Injection of Motolimod and Nivolumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of motolimod, nivolumab, or motolimod combined with nivolumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
16357995|NCT04272320|No Intervention|Group C|
16357996|NCT04272320|Active Comparator|Group TFP|Transversalis fascia plane block, before the surgical procedure.
16357997|NCT04272307||Acute Severe Ulcerative Colitis group|
16357998|NCT04272307||Non-severe Ulcerative Colitis group|
16357999|NCT04272294|Experimental|Use of Optical Spectroscopy|Optical spectroscopy used to characterize treatment response
16358000|NCT04272281|Experimental|Share making tool decision|Patient recruited from general practitioner in this group will use a share making tool decision to adapt antibiotherapy
16358001|NCT04272281|Active Comparator|Standard recommandation|Patients recruited from general practitioner will receive the standard medical care
16358002|NCT04272268||Nasal High flow Oxygen|Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
16358003|NCT04272255|Active Comparator|DPI-386 nasal gel|"DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as 0.2 mg / 0.1 g"
16358004|NCT04272255|Placebo Comparator|placebo nasal gel|Placebo nasal gel product is the same but does not contain scopolamine HBr
16358005|NCT04272255|Experimental|Transderm Scop®|TDS patch delivers 1.5 mg of scopolamine over a 72-hour period. TDS arm will apply two TDS patches over the six treatment days.
16358006|NCT04272242|Experimental|Arm 1: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally twice daily (~12 hours apart). Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.
~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.
~Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses."
16358007|NCT04272242|Experimental|Arm 2: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally each morning. Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.
~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.
~Participants will remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. DTG will be from non-study ARV supply.
~NOTE: Arm 2 will only open based on assessment of DTG pharmacokinetics (PK) data from participants in Arm 1."
16358008|NCT04272229|Active Comparator|Control Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
16358009|NCT04272229|Experimental|Migrain Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
16358010|NCT04272216||Treatment with HydroPearl via radial access|all patients will be in the same group/cohort in this open-label, single-arm, observational registry.
16358011|NCT04272203|Experimental|Dose Escalation: Participants With AML|Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184
16358012|NCT04272203|Experimental|Dose Escalation: Participants With NSCLC|Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184
16358013|NCT04272203|Experimental|Dose Expansion: Participants With AML|Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML
16358014|NCT04272203|Experimental|Dose Expansion: Participants With NSCLC|Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC
16358015|NCT04272177|Experimental|SDM group|Shared decision making using PDAs. PDAs is used as a tool explain the advantages and disadvantages of the traditional reversal drugs and sugammadex. And by following SDM principles, the patients are guided to consider their individual values and preferences and helped to make a choice that best meet their needs.
16358016|NCT04272177|No Intervention|Control group|Current approach to explain details of anesthesia using a single introductory sheet made by the two hospitals or provided by the pharmaceutical companies is used.
16358017|NCT04272164|Active Comparator|technical taekwondo training|Light jogging,running, Stretching exercises,Pushups and sit ups, Punches,Kicks
16358018|NCT04272164|Experimental|weighted rope taekwondo training|weighted rope jump training along with tachnical taekwando training
16358019|NCT04272151|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
16358020|NCT04272138|Experimental|Calm Meditation|Participants in the intervention group will be exposed to 10 minutes per day of meditation via a smartphone application for 4 weeks. Participants will log their meditation participation in an online weekly log.
16358199|NCT04270903||Phototype I - II|EPR measurement at the surface of the skin (arm)
16358021|NCT04272138|Active Comparator|Educational Podcast Control|Participants in the control group will be exposed to 10 minutes per day of health education podcasts via a smartphone application for 4 weeks. Participants will log their podcast participation in an online weekly log.
16358022|NCT04272125|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
16358023|NCT04272112|Active Comparator|Glass-ceramic|30 dental crowns of lithium-disilicate glass-ceramic
16358024|NCT04272112|Active Comparator|Zirconia|30 dental crowns of high translucent zirconia
16358025|NCT04272112|Active Comparator|Zirconia with mini-veneer|30 dental crowns of high translucent zirconia with a mini-veneer of porcelain
16358026|NCT04272099||PG1 (patients with diabetes 0-25 years of age)|Patients 0 to 25 years of age, with a diagnosis of diabetes that are either followed at Kay Mackenson Pediatric Clinic, Haiti, or who are of Haitian ancestry, defined as both maternal and paternal grandparents being born in Haiti, and attend one of the three diabetes clinics in Montreal.
16358027|NCT04272099||PG2 (patient's principal caregiver)|The patient's principal caregiver (a parent of legal guardian).
16358028|NCT04272086|Placebo Comparator|Bupivacaine TAP|TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
16358029|NCT04272086|Experimental|Liposomal bupivacaine TAP|TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side
16358030|NCT04272073|Active Comparator|Standard Care|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.
~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
16358031|NCT04272073|Experimental|High-Protein Mediterranean Diet|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.
~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet
~eating more fruit and vegetables,
~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),
~replacing butter and margarine by olive oil as the main culinary fat,
~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 high-protein yoghurts to eat each day)."
16358032|NCT04272073|Experimental|Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.
~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
16358033|NCT04272073|Experimental|High-Protein mediterranean Diet and Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.
~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet
~eating more fruit and vegetables,
~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),
~replacing butter and margarine by olive oil as the main culinary fat,
~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 high-protein yoghurts to eat each day)."
16358034|NCT04272060|Experimental|CT Angiography|Research CT angiography.
16358035|NCT04272060|Active Comparator|Conventional Angiography|Standard medical care which includes cardiac catheterization and invasive coronary angiography.
16358036|NCT04272047|Experimental|Knee Control+|Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
16358037|NCT04272047|Experimental|Adductor strengthening program|The Adductor strengthening program consists of a single exercise with three levels of difficulty. The exercise is based on the Copenhagen Adduction exercise. Teams are to carry out the Adductor strengthening program as part of their regular warm-up 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
16358038|NCT04272047|Active Comparator|Knee Control|Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
16358039|NCT04272034|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
16358040|NCT04272034|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
16358041|NCT04272034|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
16358042|NCT04272021|Experimental|ADHD sample|Children with a diagnosis of ADHD
16358045|NCT04271982||Cohort A|Cohort A includes patients (N=20 000) screened for nutritional risk at Haukeland University Hospital (HUS) during point prevalence surveys between 2008 and 2018. The point prevalence surveys included all adult patients in somatic departments, and were performed 2-4 times per year since 2008. We expect the sample in the study to include approx. 9000 patients ≥ 65 years.
16358046|NCT04271982||Cohort B|"Cohort B includes older service users (≥65 years) with information on nutrition variables from the KPR-registry in the period 2016 to 2018 (n=approx. 270 560). All Norwegian municipalities report data on nutritional risk screening and nutrition plan for individual service users in Kommunalt pasientregister (KPR). These nutritional data will be linked to registry data on health care services use and patient outcome variables from the The Norwegian Patient Registry (NPR)"
16358047|NCT04271956|Experimental|Tislelizumab + Zanubrutinib|"Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
~Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
~Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation"
16358048|NCT04271943|Active Comparator|COMPUTER BASED EXERCISES|
16358049|NCT04271943|Active Comparator|AEROBIC EXERCISES|
16358050|NCT04271930|Experimental|Mindfulness Awareness Practices for Insomnia|Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with 5 minutes and increasing to 20 minutes over the course of the 6-week intervention - as is standard with the Mindfulness Awareness Practices (MAPs) course - with practice prior to bedtime. An intervention training manual is the cornerstone of standardized delivery of MAP-I. Participants are also provided with a book on mindfulness (Fully Present: The Science, Art, and Practice of Mindfulness, authored by the Mindfulness Awareness Research Center (MARC) leader and MAP-I instructor Diana Winston) as well as access to the University of California Los Angeles (UCLA) Mindful App courtesy of the MARC at UCLA (via personal iPhone or study-administered tablets per patient preference), which contains pre-recorded guided meditations for use in daily practice.
16358051|NCT04271930|Active Comparator|Sleep Health Education|Six individual 1-hour videos will be shown to participants at the same time points as, and with equal duration to, the MAP-I intervention. These videos will be recorded presentations that have been modified for HCT recipients based upon similar SHE interventions delivered in prior studies. Similar to the intervention group, patients in the SHE group will also participate in group Zoom chat sessions with equal frequency and duration lead by a study research coordinator. These sessions will allow for general patient interaction to discuss sleep and any questions or comments they may have, as lead by the group facilitator.
16358052|NCT04271917|Active Comparator|Treatment As Usual (TAU)|"Participants will receive a 5-day supply of acetaminophen 500mg and ibuprofen 200mg.
~Instructions for use: Take one tablet of each medication at the same time every 4-6 hours as needed for pain."
16358053|NCT04271917|Placebo Comparator|Placebo|"Participants will receive a 5-day supply (15mL) of inactive placebo in a dropper vial.
~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
16358054|NCT04271917|Experimental|CBD 17mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 17mg/mL.
~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
16358055|NCT04271917|Experimental|CBD 37 mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 37mg/mL.
~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
16358056|NCT04271904|Experimental|Anti-inflammatory Diet|Those on the anti-inflammatory diet will be given a meal plan and recipes to be followed at home after consultation with the study dietitian. In brief, this meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, refined sugars and wheat, etc.). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, etc.). Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes.
16358057|NCT04271904|Placebo Comparator|Placebo Diet|Participants on the placebo diet will be given a meal plan and recipes by the study dietitian. The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). There are many counter-intuitive restrictions in the anti-inflammatory diet that we will be using (banned foods include white beans, soy, eggplant, oats, raspberries, strawberries, prunes, walnuts, cashews, soy milk. Allowed foods include maple syrup, honey, lean beef, lamb, brown rice, feta cheese, butter). Therefore, even fairly astute and educated participants may have trouble discerning which diet they are consuming (anti-inflammatory or placebo).
16358058|NCT04271904|No Intervention|Non-dieting Control|Those in the non-dieting control condition will not be asked to alter their diet in any way.
16358059|NCT04271891|Experimental|With WBPC|Intensive rehabilitation programs :The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks additional WBPC: The duration will be 30 minutes a time
16358060|NCT04271891|Placebo Comparator|Control|Intensive rehabilitation programs: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks without WBPC.
16358061|NCT04271878|Other|All participants|All participants will receive the same interventions
16358062|NCT04271865|Other|therapy induced anemia for HCV treated patients|"Four types of interventions:
~Educational to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
~Provision of Dates : Dates fruit intake for all the anaemic patients
~Recipe book
~Model kitchen for all patients having Hemoglobin lower than normal hemoglobin levels; less than 13.2 grams (g) of hemoglobin per deciliter (dL) of blood for men and less than 11.6 for women."
16358063|NCT04271852|Experimental|UUI patients|50 UUI patients will have biofeedback treatment once a week.
16358064|NCT04271852|No Intervention|Control|
16358065|NCT04271839|Experimental|Fluticasone/formoterol k-haler (medium strength)|In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength)
16358066|NCT04271839|Active Comparator|Standard of Care (SoC)|In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength)
16358067|NCT04271826|Experimental|cases with normal CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
16358200|NCT04270903||Phototype III - IV|EPR measurement at the surface of the skin (arm)
16358068|NCT04271826|Experimental|cases with proven appendicitis on CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
16358069|NCT04271813|Experimental|Anlotinib and Sintilimab|the combination of Anlotinib with Sintilimab as first-line treatment
16358070|NCT04271800|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
16358071|NCT04271787||strongly dissatisfied|
16358072|NCT04271787||dissatisfied|
16358073|NCT04271787||neutral|
16358074|NCT04271787||satisfied|
16358075|NCT04271787||strongly satisfied|
16358076|NCT04271787||don't know|
16358077|NCT04271774||Infants with ASD-affected sibling|Infants, enrolled at 0-6 months of age, who have a sibling diagnosed with ASD.
16358078|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
16358079|NCT04271748|Experimental|Time Restricted Feeding|Subjects will be required to fast for 16 consecutive hours daily for 4 weeks. The registered dietitian will provide subjects counseling on the intermittent fasting regimen.
16358082|NCT04271722|Experimental|Mifepristone|Mifepristone 200mg 24hours before the induction day
16358083|NCT04271722|Active Comparator|Balloon catheter|Balloon catheter with 40ml placed 24hours before the induction day
16358084|NCT04271709|Active Comparator|Enhanced Intervention|Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
16358085|NCT04271709|Placebo Comparator|Usual Care|Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
16358088|NCT04271670|Experimental|Warm water footbath with ginger powder|Footbath with ginger powder with a maximum duration of 20 minutes.
16358089|NCT04271670|Experimental|Warm water footbath with mustard powder|Footbath with mustard powder with a maximum duration of 20 minutes.
16358090|NCT04271670|Active Comparator|Warm water only footbath|Warm water only footbath with a maximum duration of 20 minutes.
16358091|NCT04271644|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
16358092|NCT04271631|No Intervention|Control|Received conventional education group
16358093|NCT04271631|Experimental|Intervention 1|Received conventional education group and Mobile Application-Based Diabetes Education
16358094|NCT04271631|Experimental|Intervention 2|Received Mobile Application-Based Diabetes Education and Health Coaching
16358095|NCT04271618|Active Comparator|Traditional Treatment Arm|Participants in this group will receive conventional rehabilitation program for postural correction 2 hours/3 sessions' weekly/3 successive months.
16358096|NCT04271618|Experimental|TheraTogs Undergarment Arm|Participants in this group will receive the same conventional rehabilitation program as in traditional group in addition to wearing of TheraTogs soft orthotic undergarment with strapping system.
16358097|NCT04271605|Experimental|behavior intervention and pharmacological therapy|"For participants with abnormal biochemical markers, pharmacological therapy and diet modification are applied.
~Dietary education on phosphorus additives is applied specifically for retention of phosphorus or high serum phosphorus level.
~Exercise for bone and cardiovascular health.
~Osteoporosis medications are initiated according to the reimbursed criteria of National Health Insurance, otherwise medications are used with non-insurance payment."
16358098|NCT04271592|Experimental|Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form|A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
16358099|NCT04271592|Placebo Comparator|Part 1: SAD Cohorts 1-7 Placebo Liquid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
16358100|NCT04271592|Experimental|Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form|Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
16358101|NCT04271592|Placebo Comparator|Part 1: MAD Cohorts 8-10 Placebo Liquid Form|Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
16358201|NCT04270903||Phototype V - VI|EPR measurement at the surface of the skin (arm)
16358514|NCT04268537|Experimental|thymosin group|Thymosin, 1.6 mg sc qd, last for 5 days
16358102|NCT04271592|Experimental|Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
16358103|NCT04271592|Placebo Comparator|Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
16358104|NCT04271592|Experimental|Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
16358105|NCT04271592|Placebo Comparator|Part 2: Single Dose Fed Cohort 12 Placebo Solid Form|A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
16358106|NCT04271579|Active Comparator|Unilateral lymphnode dissection|Salvage lymphnode dissection is performed on the PSMA PET positive side, according to template (obturator, iliac external, iliac internal, iliac commun) and possibly including other anatomical pelvic regions
16358107|NCT04271579|Active Comparator|bilateral Lymphnode dissection|In addition, a salvage lymphnode dissection is performed on the opposite side with resection of the corresponding fields, which were taken on the PSMA-PET positive side
16358108|NCT04271566|Experimental|Experimental|Patients receiving an education program along with usual medical care
16358109|NCT04271566|No Intervention|Non Experimental|Patients receiving usual medical care
16358110|NCT04271553|No Intervention|Control|Patient will undergo standard workflow for elective surgical admissions.
16358111|NCT04271553|Experimental|Video|In addition to standard workflow, will also receive the intervention bundle which consists of a cartoon video and sets of activity sheets
16358112|NCT04271540|Experimental|Subjects treated with Tildrakizumab|Informed consent will be obtained from study participants willing to participate in MiNIMA. Study participants will then undergo the baseline rest/stress cardiac PET scan along with echocardiography. The final PET scan and echocardiogram will occur at 6 months after the intervention.
16358113|NCT04271527|Experimental|cognitive targeted biopsy|a novel three-dimensional matrix positioning based cognitive fusion targeted biopsy combined with a standard 20-region template guided biopsy
16358114|NCT04271527|Active Comparator|software targeted biopsy|software-based fusion targeted biopsy combined with a standard 20-region template guided biopsy
16358115|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active|Increasing doses of RPT193 will be administered to healthy volunteers
16358116|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo|Matching placebo will be administered to healthy volunteers
16358117|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active|Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
16358118|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo|Matching placebo will be administered once/day for 7 days to healthy volunteers
16358119|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Expansion Part C - active|RPT193 will be administered daily for 28 days to patients with atopic dermatitis
16358120|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Expansion Part C - placebo|Matching placebo will be administered daily for 28 days to patients with atopic dermatitis
16358121|NCT04271501|No Intervention|Control|Area without surgical intervention
16358122|NCT04271501|Active Comparator|Melanocyte-Keratinocyte Transplantation|Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation
16358123|NCT04271501|Experimental|RECELL 1:5|Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation
16358124|NCT04271501|Experimental|RECELL 1:10|Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation
16358125|NCT04271501|Experimental|RECELL 1:20|Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation
16358126|NCT04271488|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 35 milligram (mg) tablet of E7090 in the morning with 150 milliliters (mL) of water following an overnight fast of at least 10 hours.
16358127|NCT04271488|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive 10 mg dose of E7090 as capsule (2 capsules each of 5 mg) in the morning with 150 mL of water following an overnight fast of at least 10 hours.
16358128|NCT04271488|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, race, gender and body weight) will receive a single 35 mg tablet of E7090 in the morning with 150 mL of water following an overnight fast of at least 10 hours.
16358131|NCT04271462||Study group|Patients undergoing surgery (>120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).
16358515|NCT04268537|Placebo Comparator|control group|stand treatment
16358132|NCT04271449|Experimental|Cerebellum tDCS|Cerebellum tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
16358133|NCT04271449|Experimental|Primary motor cortex|Primary motor cortex tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
16358134|NCT04271449|Sham Comparator|Sham tDCS|Sham tDCS arm will serve as a sham comparator for other experimental conditions. This arm will be subdivided into two groups depending on the localisation of the electrodes (cerebellum placement vs primary motor cortex placement).These two subgroups will be divided again in two subgroups depending on the task exposed (pointing vs throwing).
16358135|NCT04271436|Experimental|PET/CT + PET/MR|-Eligible patients will have imaging assessments (as part of the study) performed at three time-points: pre-treatment, following cycle 1 of treatment, and following cycle 2 of treatment. Baseline FDG PET/CT will be a standard-of-care procedure. If possible, PET/CT imaging will be performed, followed immediately by PET/MR imaging during each imaging session. At minimum, PET/MR should be obtained at least once during each time-point (i.e. either during the FDG or FLT procedure). FDG imaging and FLT imaging should be performed at least 24 hours apart and no more than 7 days apart.
16358136|NCT04271423|Active Comparator|Control|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
16358137|NCT04271423|Experimental|Test|The test will be a flapless technique, no flap will be reflected.
16358138|NCT04271410|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
16358139|NCT04271397|Other|Active tuberculosis|
16358140|NCT04271397|Other|Latent tuberculosis infection|
16358141|NCT04271384|Experimental|SABR + Nivolumab|"Pre-operative treatment with standard SABR (3 x 18 Gy or 5 x 10 Gy or 8 x 7.5 Gy) concomitant with nivolumab at 360 mg every 21 days x3 doses.
~Standard-of-care surgery to be performed after 12 weeks from D1 of treatment."
16358142|NCT04271371||Prototype intervention|To be developed through Phase 1 and 2
16358143|NCT04271358|Experimental|Peer Coaching|Participant receive a 6 month peer health coaching intervention.
16358144|NCT04271358|No Intervention|Education only|Participants receive education-only material (newsletter) biweekly for 6 months
16358145|NCT04271332|Experimental|Arbaclofen|Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
16358146|NCT04271332|Placebo Comparator|Placebo|The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
16358147|NCT04271319|Experimental|BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.
16358148|NCT04271319|Sham Comparator|Electrical Stimulation - Sham Comparator|Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.
16358149|NCT04271306|Experimental|Groups 1A & 1B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
16358150|NCT04271306|Experimental|Groups 2A & 2B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
16358151|NCT04271306|Experimental|Groups 3A & 3B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
16358152|NCT04271306|Experimental|Group 3C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
16358153|NCT04271306|Experimental|Groups 4A & 4B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
16358154|NCT04271306|Experimental|Group 4C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0 and 1 and a dose of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at month 6.5
16358155|NCT04271293||Patients with PEG and oral anticoagulan treatment|Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.
16358156|NCT04271280||High Risk and Very High Risk Dyslipidemic Participants|Participants are stratified as High and Very High Risk (as assessed by the Framingham risk score for High Risk participants and the SMART score for Very High Risk participants and ) as well as if previously or newly diagnosed.
16358157|NCT04271267||Acute Rejection Cohort|The subset of samples corresponding to biopsy-proven acute rejection
16358158|NCT04271267||Rejection-free Cohort|The subset of samples corresponding to a transbronchial biopsy free of acute cellular rejection.
16358160|NCT04271241|No Intervention|Control (Ctrl)|Ctrl group di not undergo any training
16358161|NCT04271241|Experimental|PS bilateral limbs (PSBil)|PSBil underwent 12 weeks of passive stretching on both the lower limbs
16358162|NCT04271241|Experimental|PS monolateral limb, stretched limb (PSMonoSL)|PSMonoSL underwent 12 weeks of passive stretching on just one lower limb (SL). Outcomes form this group were obtained from the stretched
16358163|NCT04271241|Experimental|PS monolateral limb, contralateral limb PSMonoCL|PSMonoCL involved the same participants as in PSMonoSL. Outcomes form this group were obtained from the contralateral not stretched limb (CL). Data from this limb helped in identify possible PS-induced crossover effects in the vasomotor response.
16358164|NCT04271228|Experimental|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
16358230|NCT04270721|Experimental|Before and after intervention (sequence 2)|For the 'Before and after intervention' group, data are collected both before and after the training.
16358231|NCT04270721|No Intervention|Before intervention (sequence 3)|"The 'before intervention' group collects data only before the training.
~*This arm will receive the educational intervention after data collection is completed."
16358232|NCT04270708|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 3mcg/kg
16358543|NCT04268381||Periodontitis (n=40)|
16358165|NCT04271215||Overweight/Obesity|BMI at diagnosis will be used. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
16358166|NCT04271202|Other|Treatment|Effects of galacenezumab (emgality) treatment (injectable 240 mg initial dose followed by 120 mg treatments 1 and 2 month later) on brain functioning.
16358167|NCT04271189|Experimental|POLYCHEM|Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
16358168|NCT04271189|Active Comparator|STANDARD CARE|Standard of care according to the local health service.
16358169|NCT04271150|Experimental|Self-etch|Self-etch mode of the universal adhesive will be used
16358170|NCT04271150|Active Comparator|Total-etch|Total etch mode of the universal adhesive will be used
16358171|NCT04271137|Other|Orbital fractues|Orbital fractures
16358172|NCT04271124|Active Comparator|PR|
16358173|NCT04271124|Experimental|PR+ET|
16358174|NCT04271111|Experimental|Active treatment|Computerized intervention aimed at reducing perceived hostility.
16358175|NCT04271111|Active Comparator|Control condition|Computerized intervention aimed at increasing overall physical health.
16358176|NCT04271098||Open-heart surgery|Patients undergoing open-heart surgery with cardiopulmonary bypass
16358177|NCT04271085||Patients in the last phase of life|Patients in the last phase of life and their families
16358178|NCT04271072||Study|"Parturients that underwent cesarean delivery and is POSITIVE for the composite outcome of either:
~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), and/or
~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
16358179|NCT04271072||Control|"Parturients that underwent cesarean delivery and is NEGATIVE for the composite outcome of both:
~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), AND
~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
16358183|NCT04271046|Experimental|Experimental Group- STAR-C-VTF|"This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:
~self-directed learning in which the caregiver will receive training materials delivered electronically through a web-based learning portal;
~one orientation phone visit with a coach;
~ongoing support from the coach via telephone and secure messaging in the web-portal.
~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
16358184|NCT04271046|Active Comparator|Control|"One orientation phone visit with a coach. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages.
~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
16358185|NCT04271033|Experimental|Carotid Artery Stenting|Consecutive male and female patients older than 18 year with symptomatic and increased-stroke-risk asymptomatic carotid lesions that require revascularization by Neurovascular Team decision.
16358186|NCT04271020|Experimental|UroLift|
16358187|NCT04271007|Active Comparator|Group I|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi, Medley on the opposite side
16358188|NCT04271007|Active Comparator|Group II|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Aché on the opposite side
16358189|NCT04270994|Experimental|Misoprostol|
16358190|NCT04270981|Experimental|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250|single administration of 960 mg (4 × 240 mg capsules) acoziborole in oral and fasted condition
16358191|NCT04270968|Experimental|ESWT Group|received ESWT once a week for 4 weeks (0.25 ml/mm2, 1000 shocks) plus topical none steroidal anti-inflammatory drug (NSAID; 3 times /day for 4 weeks).
16358192|NCT04270968|Experimental|control group|received only topical NSAID.
16358193|NCT04270955|Active Comparator|Symptomatic, standard of care|Patients in this group will be offered all procedures and care deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
16358194|NCT04270955|Experimental|Symptomatic, MMA embolization + standard of care|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Symptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
16358195|NCT04270955|Active Comparator|Asymptomatic, standard of care|Patients in this group will be offered all procedures deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
16358196|NCT04270955|Experimental|Asymptomatic, standard of care + MMA embolization|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Asymptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
16358197|NCT04270942|Experimental|Teplizumab treated|Administration of teplizumab by intravenous infusion
16358198|NCT04270929|Experimental|Oxaliplatin PEDD-PRVI|Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
16358202|NCT04270890|Experimental|Study participants|Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
16358203|NCT04270877|Experimental|Naltrexone|"Low Dose Naltrexone (LDN) is administered for 12 weeks, including a titration phase of 4 weeks.
~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.
~The medicine is taken orally as tablets once daily in the evening."
16358204|NCT04270877|Placebo Comparator|Placebo|"LDN-placebo is administered for 12 weeks, including a titration phase of 4 weeks.
~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.
~The medicine is taken orally as tablets (similar in size, shape and taste to the active medication), once daily in the evening."
16358205|NCT04270864|Experimental|Regimen A1|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod Q3W
16358206|NCT04270864|Experimental|Regimen A2|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod QW
16358207|NCT04270851||Borderline Resectability|Patients with colorectal liver metastases where the decision-making on technical resectability is difficult, i.e. 'borderline resectable,' where a group of liver surgeons might reasonably be expected to find the decision whether to operate to be challenging. A group of up to 20 such patients will undergo pre-operative LiMAx test and HepaT1ca pre-operative scanning. Recruited participants' data will be used to create anonymised online case scenarios to be used in a survey, assessing whether liver surgeons find these pre-operative assessments helpful in their decision-making on technical resectability.
16358208|NCT04270838|Experimental|Group 1|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
16358209|NCT04270838|Experimental|Group 2a|Volunteers aged 2-6 years. Volunteers will receive a standalone dose of 1×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
16358210|NCT04270838|Experimental|Group 2b|Volunteers aged 2-6 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
16358211|NCT04270838|Experimental|Group 2c|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
16358212|NCT04270825|Experimental|CBT with IPT|Group CBT with IPT will consist of 20 weekly two-hour sessions and has been developed for the proposed study based on the protocols for group CBT for HD and group IPT. Treatment includes strategies from CBT, including cognitive restructuring, behavioral exposures, and organizational strategies, as well as strategies from IPT, including role-play, interpersonal skills building, communication analysis, and decision analysis.
16358213|NCT04270812|Experimental|Sleep Treatment|This arm consists of the sleep treatment that will be administered to all participants in the single-arm open trial.
16358214|NCT04270799||Lung Nodules|"A cohort of 1000 patients with incidental lung nodules will be identified using clinical records at participating NHS sites.
~Link-anonymised CT scan images and data will be stored using a central database for radiomics and artificial intelligence research, to predict the risk of malignancy."
16358215|NCT04270786|Experimental|Early de-escalation|In the experiment arm, empirical antibiotics will be stopped and levofloxacin prophylaxis will be resumed in case of afebrile after 72 hours.
16358216|NCT04270786|Other|Standard|In the control group, empirical antibiotics will be continue until recovery of neutropenia or at least 7 days as standard clinical practice.
16358217|NCT04270773|Other|Only arm|Single arm, Receiving treatment
16358218|NCT04270760|Active Comparator|Arm 1 Olpasiran Dose 1|
16358219|NCT04270760|Active Comparator|Arm 2 Olpasiran Dose 2|
16358220|NCT04270760|Active Comparator|Arm 3 Olpasiran Dose 3|
16358221|NCT04270760|Active Comparator|Arm 4 Olpasiran Dose 4|
16358222|NCT04270760|Placebo Comparator|Arm 5 Placebo Dose 5|
16358223|NCT04270747|Experimental|ABP 938-Treatment Group A|Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.
16358224|NCT04270747|Active Comparator|Aflibercept-Treatment Group B|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8).
16358225|NCT04270747|Active Comparator|Aflibercept-Treatment Group B1|Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48
16358226|NCT04270747|Experimental|ABP 938-Treatment group B2|Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
16358227|NCT04270734|Active Comparator|normal 25-36 gestational week preterm infant|
16358228|NCT04270734|Experimental|25-36 gestational week preterm infant with IVH|25-36 gestational week preterm infant with Intraventricular haemorrhages (IVH)
16358229|NCT04270721|Experimental|After intervention (sequence 1)|'After intervention' group receives the training immediately and data are only collected after the intervention.
16358233|NCT04270708|Active Comparator|Triclofos|Oral Triclofos Sodium 50mg/kg
16358234|NCT04270695||blood flow restriction|An inflatable cuff (14 cm in width * 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver both condition of BFR and BFR-free twice a week, for six weeks.
16358235|NCT04270682|Experimental|Adult Cohort|Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
16358236|NCT04270682|Experimental|Pediatric Cohort|Pediatric cohort patients (≥1 month and <16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.
16358237|NCT04270669|Experimental|RC28-E 0.5mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 0.5mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
16358238|NCT04270669|Experimental|RC28-E 1.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
16358239|NCT04270669|Experimental|RC28-E 2.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
16358240|NCT04270656|Experimental|Insulin pump therapy|
16358241|NCT04270656|Active Comparator|Multi-injection treatment ( MDI ).|
16358242|NCT04270643|Experimental|Vitamin D|Two oral doses of 5 mg (200,000 international units) vitamin D3 in 1 ml ethyl oleate, given at baseline and two weeks thereafter
16358243|NCT04270643|Placebo Comparator|Placebo|Two oral doses of 1 ml ethyl oleate
16358244|NCT04270630|No Intervention|Standard of care|Patients in the control arm of the study will undergo standard of care treatment, discussing catheterization with their treating physicians.
16358245|NCT04270630|Experimental|Shared decision aid|Patients in the interventional arm of the study will discuss catheterization with their treating physicians, in addition to having access to the shared decision aid tool and a shared decision conversation with a co-investigator clinician.
16358246|NCT04270617|No Intervention|Control arm|The control arm will involve usual care - 6 weeks of physical therapy, NSAIDs, and epidural steroid injections
16358247|NCT04270617|Experimental|Yoga Arm|The study arm will involve a yoga protocol devised by Eddie Stern - a renowned Ashtanga yoga practitioner, and can include NSAIDs.
16358248|NCT04270591|Other|SCC244 300mg|Phase Ib: SCC244 300mg, QD Phase II: SCC244 300mg, QD
16358249|NCT04270578||Women with GDM|
16358250|NCT04270578||Women without GDM|
16358251|NCT04270565|Experimental|Intervention Group|The intervention group will receive real-time gait-training interventions along with a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and wear a Garmin watch to get information from the sensors to the watch for feedback. They will also do home exercises during the study, and to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises and get instructions on feedback for the next week.
16358252|NCT04270565|Active Comparator|Control Group|The control group will receive only a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and do home exercises during the study. Participants will be asked to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises.
16358253|NCT04270552|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
16358254|NCT04270552|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
16358255|NCT04270539|Experimental|Experimental Group (nap)|The experimental group will be allowed to take a brief nap daily on school days during the study period.
16358256|NCT04270539|No Intervention|Control Group (no nap)|The control group will not be allowed to take daily nap on school days during the study period.
16358257|NCT04270526|Active Comparator|Active treatment|50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
16358258|NCT04270526|Placebo Comparator|Placebo treatment|50 mL 1% lidocaine + 50ml of 0.9% normal saline
16358259|NCT04270513||EVT by Flying Intervention Team in primary stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, for whom a Flying Intervention Team is flown to the primary stroke center in order to perform endovascular treatment.
16358260|NCT04270513||EVT after secondary transfer to comprehensive stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, who are transferred to a comprehensive stroke center for endovascular treatment.
16358261|NCT04270500|Active Comparator|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
16358262|NCT04270500|No Intervention|Standard of care (SOC)|Common to both groups as part of the enhanced recovery after surgery (ERAS) protocol as the standard of care in our institution.
16358263|NCT04270487|Experimental|IBS diet|The simple IBS diet is a diet based on the Low FODMAPs diet and the NICE (National Institute of Health and Care Excellence) IBS diet. Patients will be aid to follow the diet with a mobile app.
16358264|NCT04270487|Active Comparator|Otilonium bromide|Otilonium bromide is a a frequently used musculotropic spasmolytic. The dosis used will be 40 mg t.i.d.
16358265|NCT04270474|Experimental|Active Intervention (ACT)|Pharmacist-based Deprescribing
16358266|NCT04270474|Sham Comparator|Usual Care (UC)|Usual Care
16358594|NCT04268069|Placebo Comparator|Placebo Ophthalmic Solution (vehicle)|vehicle
16358267|NCT04270461|Experimental|Arms|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
16358268|NCT04270448|Active Comparator|Control|Practice of a joystick based motor sequence task. Participants receive feedback that they have completed the practice trials in that block of practice.
16358269|NCT04270448|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
16358270|NCT04270448|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
16358273|NCT04270409|Experimental|Isatuximab, lenalidomide, and dexamethasone (ILd)|Isatuximab intravenous (IV) administration on Days 1, 8, 15, and 22 during Cycle 1 (28 days per cycle), and Days 1 and 15 during Cycles 2-12, and Day 1 during subsequent cycles; lenalidomide per os (PO) administration on Days 1 to 21; and dexamethasone IV administration only on Day 1 during Cycle 1 and PO on Days 8, 15 and 22 of Cycle 1 and Days 1, 8, 15, and 22 of subsequent cycles
16358274|NCT04270409|Active Comparator|Lenalidomide and dexamethasone (Ld)|Lenalidomide PO administration on Days 1 to 21 and dexamethasone PO administration on Days 1, 8, 15, and 22 of every 28-day cycle
16358275|NCT04270383||2019-nCoV infection group|Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019-nCoV infection group.
16358276|NCT04270383||Control group|Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019-nCoV infection group are classified as the control group.
16358277|NCT04270370|Experimental|LY3478045 (Part A)|LY3478045 administered orally.
16358278|NCT04270370|Placebo Comparator|Placebo (Part A)|Placebo administered orally
16358279|NCT04270370|Experimental|LY3478045 (Part B)|LY3478045 administered orally.
16358280|NCT04270370|Placebo Comparator|Placebo (Part B)|Placebo administered orally
16358281|NCT04270370|Experimental|LY3478045 + Atorvastatin (Part B)|LY3478045 co-administered with atorvastatin orally.
16358282|NCT04270370|Placebo Comparator|Placebo + Atorvastatin|Placebo co-administered with atorvastatin orally.
16358283|NCT04270331|No Intervention|A Before group|No protocol assigned
16358284|NCT04270331|Experimental|An After group|PADS (pain, agitation, delirium, sleep deprivation assessment and management) protocol assigned
16358285|NCT04270318|Active Comparator|CH pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
16358286|NCT04270318|Experimental|CH pulpotomy-NaOCl|After hemorrhage control,pulp chamber was cleansed with 5% NaOCl for 30 s prior the CH pulpotomy. Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
16358287|NCT04270318|Active Comparator|MTA pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
16358288|NCT04270318|Experimental|MTA pulpotomy-NaOCl|"After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. MTA NaOCl (n = 31 teeth): Pulp chamber was cleansed with 5% NaOCl for 30 s prior the MTA pulpotomy.
~Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs."
16358289|NCT04270305|Experimental|orientation|Orientation training with GRAIL
16358290|NCT04270305|Active Comparator|walking|Walking training with GRAIL
16358291|NCT04270279|Experimental|Xueshuanxinmaining Tablet|"Patients were given Xueshuanxinmaining tablet orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
16358292|NCT04270279|Placebo Comparator|Placebo|"Patients were given Xueshuanxinmaining tablet simulation orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
16358293|NCT04270266|Experimental|Group I (meditation)|Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.
16358294|NCT04270266|Active Comparator|Group II (educational)|Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.
16358295|NCT04270253|Experimental|End-range mobilization|End-range mobilization applied 6 times for 2*2 min in end-range of flexion and extension end-range of the tibiofemoral and patellofemoral joint beside the same conservative therapy, as used for the Control
16358296|NCT04270253|Active Comparator|Control|Conservative therapy including aquatic exercises (5-times), land-based exercises (3-times), balneotherapy (5-times) and TENS therapy (3-times)
16358297|NCT04270214|Other|Dysport|Single arm study, all participants will receive Dysport injections
16358298|NCT04270201||Case group|OSCC patients (n = 60)
16358299|NCT04270201||Control group|Healthy volunteers (n = 240)
16358300|NCT04270188||anterior sacrospinofixation with autologous tissue|patients with middle and / or anterior prolapse ≥ II in the POP-Q classification and for whom an intervention by anterior sacrospinofixation by autologous tissues is planned.
16358301|NCT04270175|Experimental|daratumumab/pomalidomide/dexamethasone|"Pomalidomide:
~(4mg orally) on days 1-21 of a 28-day cycle
~Dexamethasone:
~20mg IV as premedication on days 1, 8, 15, and 22
~20mg orally the day after daratumumab dosing for cycles 1-2 of induction
~40mg IV as premedication on days 1 and 15 on daratumumab treatment days
~40mg orally on non-daratumumab days (8 and 15) for cycles 3-6
~20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)
~If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.
~Daratumumab:
~1800mg sub-cutaneously weekly x8 weeks
~1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)
~1800mg sub-cutaneously every 4 weeks cycles 7 and beyond"
16358302|NCT04270162|Experimental|New intervention protocol with inspirometer|Respiratory exercises without use of inspirometerwill be taken out 50% and 80% to have it as muscle strength training values for the respiratory muscles based on the contra-relax technique)
16358303|NCT04270162|Active Comparator|Protocol of use of inspirometer in a conventional way|This gonna be a experimental group 2 with conventional use of the conventional way.
16358304|NCT04270162|Active Comparator|Respiratory exercises without use of inspirometer|This group gonna be a control group with breathing exercises without the use of inspirometer.
16358305|NCT04270149|Experimental|ESR1 peptide vaccine|200 mcg ESR1 peptides plus 1ml Montanide and 100 mcg GM-CSF administered subcutaneously weeks 0, 1, 2, 4, 5, 6 for a total of 6 injections.
16358306|NCT04270136|Experimental|breast cancer mastectomy|
16358307|NCT04270123||Group 1|Group 1 consists of breast cancer patients with local or locally advanced disease. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. A subgroup of participants within this group (those who have changed disease or treatment status) will be asked to complete the above questionnaires again, three months later (+-1 week). They will also complete an anchor question. Completing twice is for the responsiveness to change analysis.
16358308|NCT04270123||Group 2|Group 2 consists of metastatic breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires at one time point only.
16358309|NCT04270123||Group 3 - follow up|Group 3 consists of follow up breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. One-to two weeks later, a subgroup of participants in this group (with no evidence of disease and /or change in health status) will complete the above questionnaires, as well as an anchor question. Completing twice is for the test-retest analysis.
16358310|NCT04270110||Case|Patients with subclinical hypothyroidism
16358311|NCT04270110||Control|Patients with Normal thyroid function
16358312|NCT04270097||Emirati Genetic T2D cohort|
16358313|NCT04270084|Other|Treatment|Participants will be asked use a mobile health (m-health) app for 2 months. The app is designed to provide weekly education and motivation about healthful diet and physical activity behaviors in adolescents and their parent/adult caretaker. Both adolescent and parent/adult caretaker participants will use the app to enter weekly self-report data, set healthy eating and exercise goals, and receive educational and motivational content. Participants will conduct a weekly self-assessment of waist circumference, diet, and physical activity during the 2 month trial.
16358314|NCT04270071|Experimental|Yangxin Shengmai Granules|"Patients were given Yangxin Shengmai granules orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
16358315|NCT04270071|Placebo Comparator|Placebo|"Patients were given Yangxin Shengmai granules simulation orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
16358316|NCT04270058||Cohort 1|Cohort 1 will be pregnant patients who have been exposed to at least 1 dose of TEGSEDI within 25 weeks prior to conception or during pregnancy.
16358317|NCT04270058||Cohort 2|Cohort 2 will be pregnant patients who have hATTR-PN, who were not exposed to TEGSEDI or have not received TEGSEDI within the previous 25 weeks prior to conception.
16358318|NCT04270045||Single|Non-invasive forced airway oscillometry
16358319|NCT04270032||malignant group|women with malignant lesions confirmed by pathology
16358320|NCT04270032||benign group|women with benign lesions confirmed by pathology or stable in follow-up > 2 years
16358321|NCT04270032||normal group|women have normal images with follow up > 2 years
16358322|NCT04270019|Experimental|Experimental|This group will receive polyethylene glycol (50% weight/volume) applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
16358323|NCT04270019|Placebo Comparator|Control|This group will receive normal saline applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
16358324|NCT04270006|Experimental|Exosomes|
16358325|NCT04269993|Placebo Comparator|Vaporized cannabis: placebo|Vaporized cannabis: placebo dose
16358326|NCT04269993|Experimental|Vaporized cannabis: medium THC/medium CBD|Vaporized cannabis: medium THC/medium CBD dose
16358327|NCT04269980|Active Comparator|Group (PHN)|Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure
16358328|NCT04269980|Active Comparator|Group MG|Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
16358329|NCT04269967||Tele-rehabilitation|Patients who choose tele-rehabilitation
16358330|NCT04269967||Usual care|Patients who choose usual (rehabilitation) care
16358331|NCT04269954|Experimental|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin.
16358332|NCT04269954|Other|Low-molecular-weight heparin therapy|Low-molecular-weight heparin combined with routine drug therapy.
16358333|NCT04269941||prognostic factors of gastrointestinal stromal tumors|for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.
16358334|NCT04269928|Experimental|Adrenal Artery Ablation|Patients in the intervention group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
16358335|NCT04269928|No Intervention|Adrenalectomy|Patients in this group will be treated with unilateral laparoscopic adrenalectomy
16358336|NCT04269915|Experimental|Intervention|Volunteers will be exposed to escalating doses of female Schistosoma mansoni cercariae
16358340|NCT04269876|Experimental|Marine Lipid Oil concentrate|Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
16358341|NCT04269876|Placebo Comparator|Placebo|Placebo softgels with Placebo capsules
16358342|NCT04269863|Experimental|Control Group|This group of 75 patients is the control group that will be receiving the standard lowest dosage of 81mg aspirin.
16358343|NCT04269863|Experimental|Treatment Group|This group of 75 participants is the treatment group that will be receiving personalized aspirin dosage between 81mg-325mg (within standard clinical recommendations), which will be determined based on platelet analysis via PFA-200.
16358344|NCT04269850|Experimental|FMT+ruxolitinib+steroids|ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid
16358345|NCT04269837|Experimental|Supportive Care (sexual health counseling)|Patients receive sexual health counseling prior to starting and at the completion of radiation.
16358346|NCT04269824|Experimental|Intervention Group|Residents of the peri-urban ward randomized to this group will receive the norm and network-centric intervention package that includes individual, household, group and community-level interventions. No hardware will be provided. Behavior change components will focus on shifting empirical expectations of improved sanitation behaviors in their wards as well as building capacity to achieve toilet construction and behavioral goals.
16358347|NCT04269824|No Intervention|Control Group|Residents of these wards will not receive any intervention. They may be exposed to other WASH interventions promoted by the government and/or other parties independent of this study.
16358348|NCT04269811|Experimental|Flu-Bu-Mel|Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2
16358349|NCT04269798|Active Comparator|Traditional Treatment Arm|Will receive conventional rehabilitation program for the lower limbs, balance and gait training. Two hours of conventional physical therapy program /session - 3 sessions/week/ three successive months.
16358350|NCT04269798|Experimental|Functional Electrical Stimulation Group|Will receive 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
16358351|NCT04269785|Active Comparator|Radiofrequency ablation|These patients will receive ablation by radiofrequency catheter, guided by of 3-dimensional electro-anatomic mapping technology
16358352|NCT04269785|Active Comparator|Cryoballoon ablation|These patients will receive ablation by cryoballoon catheter, guided by X-ray fluoroscopy
16358353|NCT04269772|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.
~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
16358354|NCT04269772|Other|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided by prison and community providers, as part of routine care in the criminal justice re-entry context. Study staff will provide no additional treatment in this arm.
16358355|NCT04269759||Pregnancy women|
16358356|NCT04269746||Control group|The control population comprised normal healthy individuals.
16358357|NCT04269746||Precancerous group|patients with precancerous colorectal diseases
16358358|NCT04269746||CRC group|patients with colorectal cancer
16358359|NCT04269733||Subjects with a DDD-pacemaker due to high-degree AV block|
16358360|NCT04269720|No Intervention|Control|Participants will not receive biofeedback intervention.
16358361|NCT04269720|Experimental|Biofeedback|Participants will receive a biofeedback intervention daily for 8 weeks. Each biofeedback session lasts approximately 10 minutes.
16358362|NCT04269707|Other|IV Iron|The primary objective in this study is to allow participants who were randomized to receive oral iron in the 1VIT17044 trial and who had an unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in IBD treatment) to receive one course of FCM. This course of FCM will consist of two doses of FCM at 15 mg/kg (maximum single dose of 750 mg), separated by seven days.
16358363|NCT04269694|No Intervention|Control|No dressing applied in the donor site after harvesting the graft
16358364|NCT04269694|Experimental|Test|An antibacterial honey dressing material (Medihoney, http://www.medihoney.com) will be applied to donor site.
16358365|NCT04269681|Experimental|High Flow Nasal Cannula Arm|Participants will receive HFNC if they have no delirium and signs of ARF. The device is supposed to be used continuously in the nose with some changes in flow and/or temperature according to tolerance. There is no crossover to the standar of care arm.
16358366|NCT04269681|Active Comparator|Standard respiratory support|Participants will receive standard of care with low flow oxygen catheter or mask initially. If there is any sign of clinical deterioration NIV can be offered if tolerated by the patient. There will be no cross over with HFNC arm.
16358367|NCT04269668|Active Comparator|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
16358368|NCT04269668|Experimental|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
16358369|NCT04269655|Experimental|Intervention CB CGM|On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
16358370|NCT04269655|No Intervention|Usual Care|For UC, CGM data will be blinded to the care team and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours for patients who are not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring: UC (and intervention) participants' glucose levels will be managed using the glucose management protocol and the Diabetes APN will assess UC participants' POC data documented in the EMR from the previous 24-48 hours and make recommendations for changes to the basal/bolus regimen to improve glucose management.
16358371|NCT04269642|Placebo Comparator|PT320 2.0mg Placebo|will be injected subcutaneously once a week for 48 weeks
16358372|NCT04269642|Experimental|PT320 2.0mg treatment 1|will be injected subcutaneously once a week for 48 weeks
16358373|NCT04269642|Experimental|PT320 2.5mg treatment2|will be injected subcutaneously every two weeks for 48 weeks. (Actually, patients will be injected PT320 2.5 mg and placebo alternately once a week.)
16358374|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
16358375|NCT04269616|Experimental|Numerical survival, followed by disability information|Participants in this arm were presented with a pictograph displaying numerical survival information, followed by a pictograph displaying disability information.
16358376|NCT04269616|Experimental|Survival with description, followed by disability information|Participants in this arm were presented with a pictograph displaying survival information including the average course of stay in the NICU, followed by a pictograph displaying disability information.
16358377|NCT04269616|Experimental|Disability information, followed by numerical survival|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying numerical survival.
16358378|NCT04269616|Experimental|Disability information, followed by survival with description|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying survival information including the average course of stay in the NICU.
16358379|NCT04269603|Other|30 healthy adult volunteers|Healthy adult volunteers without hemorrhagic diathesis.
16358380|NCT04269590|Experimental|Dual Task (DT) training - PD|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of patients with Parkinson's disease (PD)
16358381|NCT04269590|Active Comparator|Single Task (ST) training - PD|Practice of the Swipe Slide Pattern task alone for a group of patients with Parkinson's disease (PD)
16358382|NCT04269590|Experimental|Dual Task (DT) training - HC|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of healthy age-matched controls.
16358383|NCT04269590|Active Comparator|Single Task (ST) training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls
16358384|NCT04269577|Experimental|SSP training - early PD|Practice of the Swipe Slide Pattern task alone for a group of patients with early Parkinson's disease (PD)
16358385|NCT04269577|Experimental|SSP training - mid PD|Practice of the Swipe Slide Pattern task alone for a group of patients with mid-stage Parkinson's disease (PD)
16358386|NCT04269577|Experimental|SSP training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls (HC)
16358387|NCT04269564|No Intervention|group A|Group A patients received the standard ventilation protocol as follows: volume-controlled ventilation mode, with VT 6 ml/kg of ideal body weight, inspiratory : expiratory ratio 1 : 2, a PEEP of 4 cmH2O, and respiratory rate 10-12 breaths/min that will be adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mmHg and inspired oxygen fraction of 0.5.
16358388|NCT04269564|Active Comparator|group B|Patients in group B received the standard ventilation protocol with stepwise peep until end of surgery and extubation.
16358389|NCT04269551|Experimental|BIVV020 IV|Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.
16358390|NCT04269538|Experimental|SAD Cohorts 1-2 Experimental Arm|Experimental Arm Active drug 150 mg and 450 mg SC dosing
16358391|NCT04269538|Placebo Comparator|SAD Cohorts 1-2 Placebo Arm|Placebo Arm
16358425|NCT04269239|Other|Sleep Habits|This group will meet with a study therapist to discuss strategies to implement healthy sleep habits that may enhance recovery from knee or hip surgery.
16358426|NCT04269226|Experimental|Recruitment maneuver|Recruitment maneuver
16358427|NCT04269226|Active Comparator|No recruitment maneuver|No recruitment maneuver
16358392|NCT04269525|Experimental|pneumonia|According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 * 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored.
16358395|NCT04269499|Other|Study patients|All patients receive holmium radioembolization as per usual
16358396|NCT04269486||Inpatient participant|Inpatients who signed the informed consent form that she will be observed during the hospitalization period
16358397|NCT04269473|Experimental|Experimental Group|Participants in the experimental group will receive a telehealth gait retraining intervention in addition to standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
16358398|NCT04269473|Active Comparator|Control Group|Participants in the control group will receive standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
16358399|NCT04269460|Active Comparator|subcostal transversus abdominis plane block (sTAP)|patients will be in the supine position; after preparing the skin with with povidone iodine, a high frequency (5-10 MHz) ultrasound probe will be used tp identify the rectus abdominis muscle, then 1 mL/Kg of bupivacaine 0.25% will be injected in the plane between rectus abdominis and transversus abdominis muscles.The patient will then be positioned for the procedure if other than supine position is chosen.
16358400|NCT04269460|Active Comparator|quadratus lumborum block (QLB)|patients will be positioned in the lateral decubitus position so that the blocked side will be the uppermost one. After skin sterilization with povidone iodine the ultrasound probe will be positioned to identify the quadratus lumborum muscle. then 1 mL/Kg of bupivacaine 0.25% will be injected behind the QL muscle on the lateral border of the erector spinae muscle.The patient will then be positioned for the procedure if other than lateral decubitus position is chosen.
16358401|NCT04269434|No Intervention|Screening|In the screening arm, Ng/Ct results will be sent by the STI Laboratory to the study physicians and these participants will be treated and partner contact tracing will be done.
16358402|NCT04269434|Other|No screening|In the no screening arm, the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
16358403|NCT04269408|Experimental|NicaPlant®|"10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.
~In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines."
16358404|NCT04269408|Other|Control|Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
16358405|NCT04269395|Active Comparator|MAL Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit of the active cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
16358406|NCT04269395|Placebo Comparator|Vehicle Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit in the vehicle cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
16358407|NCT04269382|Other|Combined non-invasive and invasive BP measurements|Patients will all undergo measurement of BP through 3 different techniques over a 30-min period: continuous noninvasive BP measurement (with the finger cuff and Clearsight™ device), repeated intermittent oscillometric NIBP measurements with a cuff placed around a calf or an arm, and continuous invasive BP measurement (through an indwelling arterial catheter).
16358408|NCT04269369|Experimental|Group A|Dosage according to French guidelines
16358409|NCT04269369|Experimental|Group B|Dosage according to literature
16358410|NCT04269356|Experimental|BMS-986256|
16358411|NCT04269330|Sham Comparator|1-Normal size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
16358412|NCT04269330|Active Comparator|2- small size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
16358413|NCT04269317|Experimental|Tixel C|Tixel Treatment, between 3-5 treatment session according to investigator's review of subject response follow by 3 Follow up sessions, 1,3 and 6 month after last treatment visit. Subject would be questioned about pain levvel, subjective dountime assessment and subjective response assessment. Images would be taken before treatment visit and in Follow-Up.
16358414|NCT04269304||Observational|Intermediate Age-Related Macular Degeneration Patients
16358415|NCT04269278||0 ng/ml|Blood specimen which was added 0 ul of dexmedetomidine
16358416|NCT04269278||0.5 ng/ml|Blood specimen which was added 0.25 ul of dexmedetomidine
16358417|NCT04269278||1.0 ng/ml|Blood specimen which was added 0.5 ul of dexmedetomidine
16358418|NCT04269278||1.5 ng/ml|Blood specimen which was added 0.75 ul of dexmedetomidine
16358419|NCT04269265|Experimental|All Participants|In this single-arm study, all participants will receive the intervention
16358420|NCT04269252|Placebo Comparator|CHI-804 at 6 mL|Standard 6 mL dose of placebo oil.
16358421|NCT04269252|Active Comparator|CHI-907 at 1.5 mL|Subjects are assigned to receive one dose of CHI-907.
16358422|NCT04269252|Active Comparator|CHI-907 at 3 mL|Subjects are assigned to receive one dose of CHI-907.
16358423|NCT04269252|Active Comparator|CHI-907 at 6 mL|Subjects are assigned to receive one dose of CHI-907.
16358424|NCT04269239|Other|Healthy Habits|This group will meet with a study therapist to discuss strategies to implement healthy habits that may enhance recovery from knee or hip surgery.
16358429|NCT04269200|Active Comparator|Arm A (control)|Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
16358430|NCT04269200|Experimental|Arm B (durvalumab+placebo)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
16358431|NCT04269200|Experimental|Arm C (durvalumab+olaparib)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
16358432|NCT04269187|Experimental|With theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU and before administration of theophylline; 200 mg/d orally for 12 days then reassessment of diaphragm by ultrasound.
16358433|NCT04269187|No Intervention|No theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU then reassessment of diaphragm by ultrasound before discharge
16358436|NCT04269148||Head and Neck Cancer patients|Turkish patients diagnosed with head and neck cancer
16358437|NCT04269122||Part 1|30 eligible subjects will be asked to participate in 3 inpatient visits, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
16358438|NCT04269122||Part 2|90 eligible subjects will be asked to participate in 1 inpatient visit, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
16358439|NCT04269109||Control Cohort|A control cohort from September 1, 2018 - October 31, 2018
16358440|NCT04269109||Intervention Cohort|An intervention cohort from March 1, 2019 - April 30, 2019
16358441|NCT04269083|Experimental|experimental arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
16358442|NCT04269083|Active Comparator|control arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
16358443|NCT04269070|Active Comparator|Move, Stand|Usual behavior condition, followed by the standing condition, followed by the LPA condition.
16358444|NCT04269070|Active Comparator|Stand, Move|Usual behavior condition, followed by the LPA condition, followed by the standing condition.
16358445|NCT04269057||HFpEF|heart failure patients with preserved ejection fraction who using ARNI
16358446|NCT04269057||HFrEF|heart failure patients with reduced ejection fraction who using ARNI
16358447|NCT04269031|Experimental|Cohort 1|On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
16358448|NCT04269031|Experimental|Cohort 2|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
16358449|NCT04269031|Experimental|Cohort 3|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
16358450|NCT04269031|Experimental|Cohort 4|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
16358451|NCT04269031|Experimental|Cohort 5|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
16358452|NCT04269031|Experimental|Cohort 6|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).
16358453|NCT04269018|Experimental|Cancer specific Mobile text message|This arm will receive daily mobile text message related with cancer risks and prevention
16358454|NCT04269018|Active Comparator|general health messages|This arm will receive general health message once a week
16358455|NCT04269005|No Intervention|Treatment as usual|"phase 0: Treatment as usual in combination with baseline and follow-up Survey but without any screening procedures (facilitating the study as a run-in phase to establish study procedures).
~phase 1: randomized and main control condition with TAU + collection of information on psychosocial distress in the baseline
~Intervention effects will be estimated, using the distressed focus sample, contrasting Phase 2 vs. Phase 1.
~We intend to conduct additional statistical analyses to compare data from phases 2 and 1 vs. phase 0 to estimate potential effects of introducing parts of the screening 1 without consequences."
16358511|NCT04268563|Experimental|sitagliptin/metformin|Intervention group3: received Sitagliptin/metformin (Janumet, Merck,West Drayton, UK. 50/500 mg), two times daily
16358593|NCT04268082|Active Comparator|Control Group|The Control Group followed verbal instructions of physiotherapist during training.
16358456|NCT04269005|Experimental|Intervention condition|"phase 2: implementation of the SCCM
~The intervention (SSCM) will be implemented step-wise in predefined sections at all three sites using a stepped-wedge cluster randomized trial design. Clusters will be randomized to different sequences that dictate the timing at which each cluster will switch from the control to the intervention condition."
16358457|NCT04268992|Experimental|Long-term exercise|Supervised exercise training three times a week for three months.
16358458|NCT04268992|No Intervention|Usual care|Patients are not offered supervised exercise.
16358459|NCT04268979|Experimental|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
16358460|NCT04268979|No Intervention|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
16358461|NCT04268966|Experimental|CMX001|Initial dose of 200mg followed by 4 doses of 100mg
16358462|NCT04268953|Experimental|AC-SD-03|Study drug administered concurrently with a standard meal
16358463|NCT04268927|Experimental|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .
~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
16358464|NCT04268927|Active Comparator|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
16358465|NCT04268914|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for IV placement and induction of anesthesia. Current standard of care practices at CHLA for outpatient surgery induction will include the following steps. Children may receive midazolam, parental presence during induction and any other intervention or medication chosen by the HCP. The research team will have no input to the decision regarding the use of any therapy.
16358466|NCT04268914|Experimental|VR Randomization|When a child is assigned to the VR condition s/he will have the added component of VR distraction during pre-surgical preparation. Children in the VR condition will interact with an immersive 3D virtual environment presented via a HMD (head-mounted display), a helmet with computer screens for each eye. This study will use two HMDs at two possible time points: (1) Prior to and during IV placement, participants will play using the Oculus Go; (2) Prior to and during anesthesia induction, participants will play using the Mira Prism.
16358467|NCT04268901|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for the medical procedure.
16358468|NCT04268901|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction.
16358469|NCT04268888|Active Comparator|TACE/TAE Alone|Transarterial Chemoembolisation (TACE) and/or Transarterial Embolisation (TAE) Alone.
16358470|NCT04268888|Experimental|TACE/TAE and Nivolumab|As above for TACE/TAE. Nivolumab adminstered as a flat dose of 480mg IV.
16358471|NCT04268875|Experimental|OCT|"Patient witch coronary artery disease who has been stented and is hospitalised for stable angina or acute coronary syndrome requiring a further coronary angiogram (regardless of time since implantation or type of the initial stent.
~- Identification of intrastent restenosis during coronary angiography and realisation of an immediate or deferred OCT."
16358472|NCT04268849|Active Comparator|Oral Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
16358473|NCT04268849|Active Comparator|IV Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
16358474|NCT04268836|Experimental|Treatment arm|Patients will be treated by the Optimal Acuity Clear-K Low Vision Aid System.
16358477|NCT04268810|Experimental|Chondroitin sulphate 2%|chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
16358478|NCT04268810|Active Comparator|DMSO 50%|DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks
16358479|NCT04268797|Experimental|HR rTMS H7-coil intervention group|
16358480|NCT04268797|Sham Comparator|sham control group|
16358481|NCT04268784|Experimental|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
16358482|NCT04268784|Placebo Comparator|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
16358483|NCT04268771|Experimental|Arm A: DRL_RI|Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with Rituximab, will be enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infusions on Day 1 and Day 15
16358512|NCT04268550|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib orally PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16358513|NCT04268537|Experimental|PD-1 group|Anti-PD-1 antibody, 200mg, IV, one time
16358484|NCT04268771|Active Comparator|Arm B: US-Rituximab or EU-Rituximab|"Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with rituximab, will be enrolled.
~Patients enrolled in Arm -B will continue to receive US-rituximab or EU-rituximab. The rituximab reference product used (US-licensed rituximab [Rituxan] or EU-approved rituximab [MabThera]) should be the same in the prior and the randomized treatment course, respectively."
16358485|NCT04268745|Experimental|Virtual Reality|Progressive immersive training with the virtual reality app Scenes: start from most salient to the patient, eventually do all Duration: start at 60 seconds, increase over time up to 3 minutes per scene Complexity: start minimal, gradually increase up to most complex Tasks: standing with diverse base of support (BOS), head turns (progress with speed, planes); stepping, turning 8 weeks, 1 visit per week, 30 minutes long In home: Gait and balance exercises, No exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long
16358486|NCT04268745|Active Comparator|Traditional Vestibular Rehabilitation|"Progressive gait, gaze stability and balance exercises Gait: walking with head turns, progress with range, speed and planes of head movement; change of walking BOS: wide, normal, tandem Gaze: focus on a target while moving head side to side / up down. Progress with speed, duration, busier background, standing to walking.
~Balance: standing balance tasks, progress with BOS (wide to narrow to tandem), support surface, eyes closed, duration, head turns.
~8 weeks, 1 visit per week, 30 minutes long In home: Gait, gaze stability and balance exercises, including exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long"
16358487|NCT04268719||Gastro-Esophageal Reflux Disease|Patients defined as having GERD as per Lyon Consensus
16358488|NCT04268719||Non-acid Reflux|Patient excluded for GERD as per Lyon Consensus
16358489|NCT04268706|Experimental|CD30 positive r/r classical Hodgkin Lymphoma|"Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.
~Patients will be treated with autologous CD30.CAR-T cells."
16358491|NCT04268667|Experimental|Upper cervical spine manipulation group|Spinal thrust joint manipulation on the atlantoaxial joint
16358492|NCT04268667|Active Comparator|Cervicothoracic spine manipulations group|Different spinal thrust joint manipulations on the thoracic spine (T6), mid-cervical spine (C3-C4) and cervicothoracic junction (C7-T1).
16358493|NCT04268654|Experimental|Ischemic Conditioning|"Preoperative artery embolization prior to esophagectomy
~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
16358494|NCT04268654|No Intervention|Control|"Surgery without previous ischemic conditioning of the gastric conduit
~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
16358495|NCT04268641|Experimental|Use of positioning equipment order 1|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
16358496|NCT04268641|Experimental|Use of positioning equipment order 2|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
16358497|NCT04268641|Experimental|Use of positioning equipment order 3|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
16358498|NCT04268641|Experimental|Use of positioning equipment order 4|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
16358499|NCT04268641|Experimental|Use of positioning equipment order 5|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
16358500|NCT04268641|Experimental|Use of positioning equipment order 6|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
16358501|NCT04268628||Participants with mCRPC|Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen [PSA] response).
16358502|NCT04268615|Experimental|Patients|Patients suffering from chronic bilateral vestibular hypofunction
16358503|NCT04268615|Active Comparator|healthy subject group|
16358504|NCT04268602|Experimental|Intervention Group|intradermal 1% lidocain injection 4 cc+ exercise and transcutaneous electrical nerve stimulation
16358505|NCT04268602|No Intervention|Control Group|exercise and transcutaneous electrical nerve stimulation
16358506|NCT04268589|No Intervention|control group|routine study
16358507|NCT04268589|Experimental|virtual reality group|Three days a week, 2 times a day, 15 minutes in the morning and in the evening for 9 days in total
16358508|NCT04268563|Placebo Comparator|Placebo|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
16358509|NCT04268563|Experimental|Metformin|Intervention group 1: received Metformin (Glucophage, Merck, West Drayton, UK; 500 mg ,two times daily
16358510|NCT04268563|Experimental|Sitagliptin|Intervention group2: received Sitagliptin (Januvia, Merck,West Drayton, UK. 50 mg, two times daily
16358516|NCT04268524|Experimental|monotherapy miltefosine|Miltefosine capsules (Impavido®) 2.5 mg/kg daily PO for 28 days <30 kg BW allometric miltefosine dose based on fat-free mass. (approx. 2.5 mg/kg); >30 - ≤44kg BW: 100 mg/day BID; ≥45kg BW 150mg TDS
16358517|NCT04268524|Experimental|Thermotherapy|Thermotherapy (ThermoMed 1.8 ®) 50°C for 30 seconds, 1 session
16358518|NCT04268524|Experimental|Combination miltefosine and thermotherapy|Miltefosine capsules 2.5 mg/kg daily PO for 21days, and thermotherapy 50°C for 30 seconds, one session on day 1 of the miltefosine.
16358519|NCT04268524|Active Comparator|° Meglumine antimoniate (Glucantime®) intralesional|Meglumine antimoniate (Glucantime®) intralesional injections 0.5-3ml, 8 sessions, bi-weekly
16358520|NCT04268511||Caudal epidural block group|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
16358521|NCT04268511||Pudendal nerve block group|The long axis of the ultrasound probe was positioned on a horizontal line connecting the ischial tuberosity that had been previously located by palpation to the anus. The ischial tuberosity could be easily identified as a hypoechoic area that is bounded superiorly by a hyperechoic line. The probe was then moved medially on the same axis until the rectum appeared as another hypoechoic area.
16358522|NCT04268498|Experimental|Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)|Participants in this group will receive Bortezomib, Lenalidomide and Dexamethasone on a 21 day treatment cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
16358523|NCT04268498|Experimental|Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)|Participants in this group will receive Carfilzomib, Lenalidomide and Dexamethasone on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
16358524|NCT04268498|Experimental|Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)|Participants in this group will receive Carfilzomib, Lenalidomide, Dexamethasone with Daratumumab, Acetaminophen, Diphenhydramine and Montelukast on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
16358525|NCT04268485||IPF patients|Patients with an MDT diagnosis of idiopathic pulmonary fibrosis. Patients will be observed over a 12 month period and have serial serum samples taken for KL-6 level.
16358526|NCT04268472|Experimental|TR Sequence|In first Intervention period subjects was administered test medecine (GP30101) and in seconde Intervention period subjects was administered reference medecine (Prezista)
16358527|NCT04268472|Experimental|RT Sequence|In first Intervention period subjects was administered reference medecine (Prezista) and in seconde Intervention period subjects was administered test medecine (GP30101)
16358528|NCT04268459|Active Comparator|Regular exchange|Patients will be appointed each 3 months for regular exchange of voice prosthesis.
16358529|NCT04268459|Active Comparator|Leakage exchange|Patients will have voice prosthesis exchange when leakage occurs.
16358530|NCT04268420|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP013 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
16358531|NCT04268420|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,2 month."
16358532|NCT04268420|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 4,5,6 month."
16358533|NCT04268420|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
16358534|NCT04268420|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
16358535|NCT04268420|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
16358536|NCT04268407|Experimental|2-day prophylactic antibiotics|use prophylactic antibiotic for 2 days after transoral thyroidectomy
16358537|NCT04268407|Other|7-day prophylactic antibiotic|use prophylactic antibiotic for 7 days after transoral thyroidectomy
16358538|NCT04268394|Experimental|Part 1: CC-99677 with Methotrexate and Sulfasalazine|Fixed-sequence involving CC-99677 + Methotrexate 7.5 mg and sulfasalazine 1000 mg
16358539|NCT04268394|Experimental|Part 2: CC-99677 with Itraconazole and Rifampin|Fixed-sequence involving CC-99677 + Rifampin 600 mg and Itraconazole 200 mg
16358540|NCT04268394|Experimental|Part 3: CC-99677, Midazolam, Digoxin, Metformin, Rosuvastatin|Fixed-sequence involving CC-99677 + Midazolam 2 mg, Digoxin 0.25 mg, Metformin 500 mg, and Rosuvastatin 10 mg.
16358541|NCT04268381||Healthy (n=23)|
16358542|NCT04268381||Gingivitis (n=20)|
16358544|NCT04268355|Experimental|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers
16358545|NCT04268342|No Intervention|Standard care|When clinical services are in the standard case phase of the study, all cases of gonorrhoea infection diagnosed at those services will be managed according to current standard of care management guidelines i.e. all cases of gonorrhoea infection will be treated with ceftriaxone by injection plus oral azithromycin tablets as first line therapy, regardless of whether the treatment is given at the initial clinic or the return clinic visit.
16358546|NCT04268342|Active Comparator|Implementation|When clinical services are assigned to the implementation phase, first line treatment for gonorrhoea infection for patients treated at their first clinic visit will remain the same as it is currently: ceftriaxone by injection plus oral azithromycin tablets. However, patients who are not treated presumptively will be treated at their return visit on the basis of the drug resistance test results. Patients with gonorrhoea infection that is shown to be susceptible to ciprofloxacin will be treated with oral ciprofloxacin therapy when they return for review at clinical services in the implementation phase. Patients with gonorrhoea infection that is not susceptible to ciprofloxacin or with an indeterminate ciprofloxacin result will be treated with ceftriaxone by injection.
16358547|NCT04268329|Other|Educational website: Patient|Patients with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. Patients will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. Patients will be asked to review the material on the website between their initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. Patients will be asked to record the number of times they visit the website and the time spent during each visit. Patients will be given a log sheet to document their use/time on the website. During the 2nd clinic visit patients will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, the patient's participation in the study will be completed.
16358548|NCT04268329|Other|Educational website: Family member|A family member of a patient with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. They will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. They will be asked to review the material on the website between their relatives initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. The family member will be asked to record the number of times they visit the website and the time spent during each visit. They will be given a log sheet to document their use/time on the website. During the 2nd clinic visit the family member will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, their participation in the study will be completed.
16358549|NCT04268316|Experimental|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
16358550|NCT04268316|Active Comparator|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
16358551|NCT04268316|No Intervention|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week for three weeks (4 sessions) to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
16358552|NCT04268303|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms dexmedetomidine
16358553|NCT04268303|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms dexmedetomidine
16358554|NCT04268303|Placebo Comparator|Placebo|Sublingual placebo film
16358555|NCT04268290|Experimental|SILS plus one assistant ERAS|"Preoperative:
~preadmission information, education, counseling, optimization ( breathing training), shortening fasting time and carbohydrate load
~Intraoperative:
~The intravenous fluid therapy is restricted. All patients undergo single incision plus one port laparoscopic surgery(SILS plus one).
~A suitable warming device (such as forced-air heating blankets) and warmed intravenous fluids are been adopted routinely to keep body temperature
~Postoperative:
~multimodal analgesia (surgical site infiltration, a nonsteroidal anti-inflammatory drug, epidural analgesia) early oral intake and move. nasogastric tubes should not be used routinely. Nasogastric tubes inserted during surgery are been removed before reversal of an aesthesia."
16358556|NCT04268277|Experimental|Rituximab & Pembrolizumab|"Cycle 1 (21 days cycle):
~Rituximab: 375 mg/m2 day 1, 8, 15 Pembrolizumab: 200 mg IV fixed dose day 2
~Cycle 2-18 (21 days cycle) or until progression or non-tolerable toxicity:
~Rituximab: 375 mg/m2 day 1 every second cycle Pembrolizumab: 200 mg IV fixed dose day 1"
16358557|NCT04268264|Experimental|Treatment arm|Will receive trial intervention, Incremental haemodialysis (n=40)
16358558|NCT04268264|Other|Control arm|Historical controls. Matched controls from database of historical patients receiving conventional, three times weekly haemodialysis treatment (n=40)
16358559|NCT04268251|Experimental|Deep learning based denoising MR|1 mm slice thickness coronal contrast-enhanced T1 weighted imaging with deep learning based denoising vs. 3 mm slice thickness coronal contrast-enhanced T1 weighted imaging
16358560|NCT04268238|Experimental|Control group|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate). Afterwards, this group will receive no treatment. Instead of the sealant, water will be used and the laser will remain with power 0W, that is, there will be no light emission, giving the group the characteristic of the control group, no treatment.
16358561|NCT04268238|Experimental|Sealant group|In this group, besides the instructions described in the control group, the teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal (sealant) for 5 seconds to the tooth surface and light curing for 20 seconds.
16358562|NCT04268238|Experimental|Low Level Laser Group|In this group, besides the instructions described in the control group, volunteers will receive irradiation with AsGaAl laser, wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, energy density of 35 J/cm2 (considering a spot size of 0.028 cm2 of this equipment), the dose will be 1 J per point. The irradiation will be performed at a cervical, an apical point and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
16358563|NCT04268238|Experimental|Low Level Laser + Sealant Group|In this group, patients will receive the treatments described in Control group, Sealant group and Low Level Laser Group.
16358564|NCT04268225|Experimental|Ultrasound Guided Dynamic Needle Tip Positioning Technique|In this arm the US transducer, protected with a sterile cover and sterile gel will be placed in the short axis above the distal end of the selected vein, moving the probe to place the vein in the center of the ultrasound screen under the middle mark of the image. The catheter needle will be inserted close to the transducer. The needle tip will be visualized as a white dot on the ultrasound screen. Then, the transducer will be shifted slightly proximally until the white dot disappears from the screen. The needle and the transducer will be moved alternately toward the patient several times to visualize the needle tip in real time. After penetrating the anterior wall of the vein, these steps will be repeated a few more times with a smaller insertion angle to visualize the white dot in the vein. Finally, the outer catheter will be fully advanced and the needle core will be extracted.
16358565|NCT04268225|Active Comparator|Traditional insertion group|For traditional insertion technique insertion attempt will be blind or tactile. Otherwise, the same protocol and measurements as elaborated for the US guided group will be applied.
16358566|NCT04268212|Experimental|Bitter Melon|The participants were asked to consume 100 ml of bitter melon juice 15 minutes prior to the 75-g oral glucose intake. Participants drank the juice within 5 minutes. Participants remained seated throughout the following 2 hours.
16358567|NCT04268212|Experimental|Exercise|Participants performed 30 minutes of treadmill walking at 65% of the age-predicted maximum heart rate. The exercise started 15 minutes after the 75-g oral glucose intake.
16358568|NCT04268199|Other|Self Injection of Bortezomib|Subcutaneous self administration of bortezomib
16358569|NCT04268186|Experimental|Direct tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target mid-cingulate cortex directly.
16358570|NCT04268186|Experimental|Indirect tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target the middle frontal gyrus, a brain area connected to mid-cingulate cortex.
16358571|NCT04268186|Experimental|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be individually optimized to simultaneously stimulate key nodes connected to mid-cingulate cortex, including anterior insula, MFG and supramarginal gyrus.
16358572|NCT04268186|Sham Comparator|Sham tDCS|Placebo transcranial direct current stimulation (tDCS) will be applied.
16358573|NCT04268173|Experimental|Immediate Intervention|Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention.
16358574|NCT04268173|Experimental|Delayed Intervention|"Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention after being put on a wait-list for three months.
~Per the protocol amendment approved on 9/3/2021, no additional participants will be recruited into the delayed intervention arm."
16358575|NCT04268173|No Intervention|Nonintervention|Participants enrolled in this arm will receive services as usual from Vivent Health and will not engage in the intervention.
16358576|NCT04268160||Patients with severe aortic stenosis undergoing TAVR|GPx activity levels will be measured on the day of TAVR procedure, the day of discharge, 1 month, and 6 months after the procedure
16358577|NCT04268160||Patients without aortic stenosis|GPx activity levels will be measured on day of recruitment
16358578|NCT04268147||Spinocerebellar Ataxia-1|individuals with a genetically confirmed diagnosis of SCA-1
16358579|NCT04268147||Spinocerebellar Ataxia-2|individuals with a genetically confirmed diagnosis of SCA-2
16358580|NCT04268147||Spinocerebellar Ataxia-3|individuals with a genetically confirmed diagnosis of SCA-3
16358581|NCT04268147||Spinocerebellar Ataxia-6|individuals with a genetically confirmed diagnosis of SCA-6
16358582|NCT04268147||Freidreich's Ataxia|individuals with a genetically confirmed diagnosis of FA
16358583|NCT04268147||FA Controls|Healthy, age-matched controls
16358584|NCT04268147||SCA Controls|Healthy, age-matched controls
16358585|NCT04268134|Experimental|Omega 3 fatty acid supplement|Omega-3 ethyl esters orally daily (containing 465 mg eicosapentaenoic acid [EPA] and 375 mg docosahexaenoic acid [DHA] per capsule,supplied as 4 x 1gm capsule)
16358586|NCT04268121|Experimental|Phase II|Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas
16358587|NCT04268121|Active Comparator|Prospective cohort|Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy
16358588|NCT04268108||group 1|"arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy.
~arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes"
16358589|NCT04268095|Experimental|No dressing change|Patients do not change dressing from procedure to first clinic followup after 14 days.
16358590|NCT04268095|Experimental|Ambulatory dressing change|Patients change dressing by an ambulatory nurse (not associated with the study) 2 times a week from surgery to first clinic followup after 14 days
16358591|NCT04268095|Experimental|No dressing|Patients take off dressing at post operative day 1 and clean it 3 times per day as instructed.
16358592|NCT04268082|Experimental|Experimental Group|The Experimental Group followed the training wearing sensorized insoles that provided plantar pressures and shift of foot center of pressure images reported on monitors.
16358595|NCT04268069|Active Comparator|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution
16358596|NCT04268056||RT patients|100 patients with breast cancer undergoing radiation therapy
16358597|NCT04268043|Experimental|flexible laryngeal airway|
16358598|NCT04268043|Experimental|proseal laryngeal mask airway|
16358599|NCT04268030||GBA mutation carriers with PD undergoing STN-DBS|
16358600|NCT04268017|Experimental|Healthy volunteer|
16358601|NCT04268004|No Intervention|Standard of Care (Control)|Participants will receive a standard of care fertility consult.
16358602|NCT04268004|Experimental|FP Decision Tool and Discussion (Treatment)|Participants will receive a standard of care fertility consult and will participate in a family-centered psychoeducational intervention consisting of completing a FP Decision Tool and participating in a guided discussion about responses and discrepancies identified in the FP Decision Tool.
16358603|NCT04267991||Tacrolimus|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
16358604|NCT04267991||Phototherapeutic Keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
16358605|NCT04267991||Control|patients received only artificial tears eyedrop
16358606|NCT04267978|Experimental|glioblastoma|
16358607|NCT04267978|Experimental|lower-grade glioma|
16358608|NCT04267965||Group A|Patients who have been successfully operated on with total parathyroidectomy for symptomatic secondary hyperparathyroidism and their PTH levels are below 72 pg/dL within one week after surgery.
16358609|NCT04267965||Group B|Patients who have had regular dialysis and their iPTH levels are around 500 pg/dL
16358610|NCT04267952|Experimental|first group|Hand hygiene intervention program prepared by using planned behavior theory will be applied to the students in this group.
16358611|NCT04267952|Active Comparator|second group|Students in this group will be given classic hand hygiene training
16358615|NCT04267926|Placebo Comparator|Placebo|Placebo
16358616|NCT04267926|Active Comparator|20mg of MitoQ|20mg of oral mitoquinol
16358617|NCT04267926|Active Comparator|40mg of MitoQ|40mg of Oral Mitoquinol
16358618|NCT04267913|Experimental|Arm A (docetaxel, dexamethasone, sapanisertib)|Patients receive docetaxel IV and dexamethasone IV over 30 minutes on days 1 and 8 and sapanisertib PO QD on days 2-4, 9-11, and 16-18. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel is discontinued, patients receive sapanisertib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16358619|NCT04267913|Active Comparator|Arm B (standard of care treatment)|Patients receive standard of care treatment comprising either docetaxel IV and dexamethasone IV over 30 minutes on day 1 or docetaxel IV, dexamethasone IV over 30 minutes, and ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16358620|NCT04267900|Experimental|99mTc-HPArk2 SPECT/CT|The patients were injected with 11.1 (MBq) per kilogram body weight of 99mTc-HPArk2 in one dose intravenously and underwent SPECT/CT scan 30-60 min later.
16358621|NCT04267887|Experimental|Treatment (apalutamide, abiraterone acetate, prednisone, ADT)|Patients receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of care.
16358622|NCT04267874|Experimental|Arm I (BRB nectar, placebo, biospecimen collection)|Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
16358623|NCT04267874|Experimental|Arm II (placebo, BRB nectar, biospecimen collection)|Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
16358624|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
16358628|NCT04267835||MICS (Minimal invasive coronary surgery)|Patients undergoing MIDCAB surgery.
16358629|NCT04267835||OPCABG (thoracotomy off-pump CABG)|Patients undergoing thoracotomy OPCABG surgery
16358630|NCT04267822|Experimental|RV521 Capsules|RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
16358631|NCT04267822|Placebo Comparator|RV521 Placebo Capsules|RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.
16358632|NCT04267809|Experimental|Metformin 850mg once daily|Metformin 850mg tablet will be administered orally once daily for 10 consecutive days.
16358633|NCT04267809|Experimental|Metformin 850mg twice daily|Metformin 850mg tablet will be administered orally twice daily for 10 consecutive days.
16358634|NCT04267809|Experimental|Metformin 1000mg once daily|Metformin 1000mg tablets will be administered orally once daily for 10 consecutive days.
16358635|NCT04267809|Experimental|Metformin 1000mg twice daily|Metformin 1000mg tablets will be administered orally twice daily for 10 consecutive days.
16358636|NCT04267796|Experimental|Group I (lifestyle intervention)|Participants complete lifestyle intervention consisting of 1-3 sets of high-resistance circuit training sessions per week, up to 150 minutes of aerobic training per week, and diet recommendations from a health coach or registered dietitian twice per week for 16 weeks.
16358637|NCT04267796|Active Comparator|Group II (wait-list, lifestyle intervention)|Participants are placed on a wait-list and then complete lifestyle intervention after 4 months.
16358638|NCT04267770|Experimental|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
16358639|NCT04267770|Active Comparator|flat rates|flat basal rate
16358640|NCT04267757|Experimental|group 1|RVF with Martius flap
16358641|NCT04267757|Experimental|group 2|RVF without Martius flap
16358642|NCT04267744|Other|Remote patient monitoring|"After consenting to the study, the Myia in-home suite of devices, and mobile phone application if the patient owns a smart phone, will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.
~Patients enrolled will transmit daily vital sign data to the Myia Health remote patient monitoring platforms for clinical review.
~Enrolled patients will complete medication change/compliance survey monthly to assess for medication changes.
~Enrolled patients will complete symptomatic assessments (KCCQ-12) at 0, 3, and 6 months.
~Enrolled patients will complete a Check-In survey to assess utility and usability of the intervention at the 2, 4, and 6 month timepoints"
16358643|NCT04267731|Placebo Comparator|Placebo|Cellulose 0.75g per day
16358644|NCT04267731|Experimental|Low dose|0.25g VMK223 per day
16358645|NCT04267731|Experimental|Middle dose|0.5g VMK223 per day
16358646|NCT04267731|Experimental|High dose|0.75g VMK223 per day
16358647|NCT04267718|Experimental|Patients with the Padua and IMPROVE Bleeding scores|A number of centres will be randomized to systematically evaluate all eligible patients with the Padua and IMPROVE Bleeding scores within 48 h after hospitalization.
16358648|NCT04267718|No Intervention|Patients will be evaluated according to clinical judgment only|A number of centres will be randomized to the Control arm of the study, in which patients will be evaluated for their thrombotic and hemorrhagic risk according to clinical judgment only.
16358649|NCT04267705|Active Comparator|Black bean|A cup of black bean 7 days/week over a 12-week period
16358650|NCT04267705|Active Comparator|Chickpea|A cup of chickpea 7 days/week over a 12-week period
16358651|NCT04267705|Placebo Comparator|Control|A cup of white rice 7 days/week over a 12-week period
16358652|NCT04267692|Experimental|Harm Reduction Treatment Circles (HaRTC)|Participants will attend 8, weekly Harm Reduction Treatment Circles. We will not limit participants' access to other treatment or services.
16358653|NCT04267692|No Intervention|No-Treatment control|We will not limit participants' access to other treatment or services.
16358654|NCT04267679|Experimental|Cannabidiol|Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.
16358655|NCT04267666|Experimental|Inspiratory Muscle Strength Training|in the form of: Inspiratory threshold muscle trainer in addition to traditional chest physical therapy intervention (Deep breath, cough training)
16358656|NCT04267666|Experimental|Incentive Spirometer|incentive spirometer, three sessions per week for six weeks
16358657|NCT04267653|Active Comparator|lactoferrin|Oral bovine lactoferrin (bfl) 100 mg once daily on empty stomach
16358658|NCT04267653|Active Comparator|ferrous sulfate|Oral ferrous sulfate 3-6 mg/kg of elemental iron/day in divided doses
16358659|NCT04267653|Active Comparator|combined|combined therapy (both lactoferrin and ferrous sulfate)
16358660|NCT04267640|Experimental|AMG0001 4mg|AMG0001 4mg + standard wound care
16358661|NCT04267640|Experimental|AMG0001 8mg|AMG0001 8mg + standard wound care
16358662|NCT04267640|Placebo Comparator|Placebo|Placebo + standard wound care
16358663|NCT04267627|No Intervention|Usual Care|No intervention.
16358664|NCT04267627|Experimental|CARING with telemedicine|Patients will receive the nurse-led supportive care intervention over telemedicine videoconferencing from home or from a satellite telemedicine site in Virginia.
16358665|NCT04267627|Experimental|CARING face-to-face|Patients will receive the nurse-led supportive care intervention in person.
16358666|NCT04267614||Patients with Rheumatoid Arthritis (RA)|Patients receiving etanercept from Baghdad teaching hospital registry(Rheumatology center) from 2012 till 2017. Patients were identified as receiving early versus delayed etanercept treatment.
16358667|NCT04267588||Navio App|The investigators propose to collect self-report and passively collected biological data and evaluate participants' relation to clinical and laboratory pain as well as patients' willingness to use and level of comfort with the mobile pain management digital platform and wearable biosensors. Eligible participants will be consented, given two biosensors (i.e., Apple Watch Series 1 with KardiaBand; Spire), a sleep monitoring device (actigraph watch), and a mobile app enabled smartphone, then trained on how to use the app (and device if appropriate) and biosensors. Participants will keep medications constant and not have any new pain treatment procedures over the course of the study period and 2 weeks prior to starting the study.
16358668|NCT04267575|Experimental|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
16358707|NCT04267315|Sham Comparator|Placebo|3 weekly sessions of subcutaneous saline injections. Participants will undergo 0.2mL subcutaneous saline injections superficial to the trigger points identified at initial assessment. The same superficial sites will be injected in all procedures.
16358670|NCT04267549|Experimental|treatment|eligible patients will be given sintilimab (200mg, iv, q3w,)， apatinib (250mg/d， QD)，S1 （50mg PO，b.i.d d1-14 ）and nab-paclitaxel (260mg, iv, 3h, d1,q3w) for 3-6 cycles. If patients converted to surgery, then administer treatment post surgery upto 3cycles. Then give sintilimab and apatinib each 3 weeks for maintenance .
16358673|NCT04267523|Experimental|Web-based parenting intervention|Families randomized to this intervention group will receive a self-administered web-based parenting intervention. Parents have access to a weekly 6-modules parenting intervention.
16358674|NCT04267523|Active Comparator|Face-to-face parenting intervention|Families randomized to this intervention group will receive a face-to-face group parenting intervention. Groups will meet weekly for 120 minutes for 4 weeks.
16358675|NCT04267497|Experimental|Nebulized Amphotericin B|Amphotericin B.
16358676|NCT04267497|Placebo Comparator|Nebulized Placebo|Sterile water for injection.
16358677|NCT04267484||Older adults with mild cognitive impairment|"WP1, older adults with cognitive impairment will use a GPS tracker for 2 weeks, during which they are asked 1) to keep a daily diary about their activity (travel diary), 2) take the researcher on a walk that they often do (walking interview), and 3) participate in an in-depth interview after 2 weeks, in which their experience with the GPS ans the travel diary data are discussed.
~WP2, older adults with mild cognitive impairment, caregivers, health professionals and technology developers will collaborate during group discussion meeting to co-design the e-decision support platform to be adapted.
~WP3, older adults with mild cognitive impairment, caregivers and health professionals will then be asked to use the adapted e-decision support platform and fill a survey."
16358678|NCT04267471|Experimental|Tai Chi|3 sessions of Tai Chi per week for 12 weeks
16358679|NCT04267471|Active Comparator|Walking|3 sessions of walking per week for 12 weeks
16358680|NCT04267471|No Intervention|Waiting-list|
16358681|NCT04267458|Other|HCV infected patients with non-elevated sCr than basal levels|a group of egyption patients with HCV infection with non-elevated sCr than basal levels and treated with sofuspovir as an direct acting antiviral drug
16358682|NCT04267445||Embolization patients|"Single center, open label, pilot study. Eligible patients will undergo transarterial embolization of the prostatic vasculature. Each patient will undergo a single embolization procedure.
~After completion of treatment in the first 2 patients and a review of follow-up assessments after 7 days, subsequent patients will be enrolled if no safety concerns have arisen in the first 2 patients.
~Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
~Magnetic resonance imaging (MRI) and CEUS is used to assess changes in prostate volume and in central gland enhancement characteristics using 3D volume assessment software."
16358683|NCT04267432|Placebo Comparator|Placebo|Placebo
16358684|NCT04267432|Experimental|TCI633|Testing product
16358685|NCT04267432|Active Comparator|Type 2 collagen|Known drug for OA
16358686|NCT04267419||healthy Control|MDA and NO in saliva
16358687|NCT04267419||keratosis|MDA and NO in saliva
16358688|NCT04267419||leukoplakia|MDA and NO in saliva
16358689|NCT04267419||Oral lichen Planus|MDA and NO in saliva
16358690|NCT04267419||oral Squamous cell carcinoma|MDA and NO in saliva
16358691|NCT04267406||Cirrhosis|Patients who diagnosed as cirrhosis. 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
16358692|NCT04267406||Non-cirrhotic portal hypertension|Patients who diagnosed as extrahepatic portal hypertension (due to portal vein thrombosis). 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
16358693|NCT04267406||Control|Healthy volunteers, who admitted to our hospital for any complaints, but was not determined any organic disease. 2 ml EDTA blood sample was taken from healthy volunteers, during their hospital admition. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
16358697|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
16358698|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
16358699|NCT04267367|Experimental|Intervention|The intervention will include a dietitian-led nutrition education, counseling session and individual basis diet plan emphasis on glycemic control diet targeted to T2DM patients attending during the OPD visits in hospital.
16358700|NCT04267367|No Intervention|Usual care|The usual care arm will be only provided general education.
16358701|NCT04267354|Experimental|Arm cycling|Participants will perform arm cycling using a table-top arm cycler. Cadence and resistance of the exercise will be determined as per each individual's tolerance. All exercise will be supervised by the neuromuscular specialist physio, to ensure it is completed safely. Participants will be able to have plenty of breaks during the assessments.
16358702|NCT04267341||Mild Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 1-2
16358703|NCT04267341||Moderate Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 2.5-3
16358704|NCT04267341||Healthy Control|Healthy People
16358705|NCT04267328||Patients having surgery|Older adults undergoing elective orthopedic surgery.
16358706|NCT04267315|Active Comparator|Active|3 weekly sessions of TPI. Participants will undergo 1mL injections of 1% lidocaine in the muscles identified with either active or latent trigger points at the initial assessment. The same muscles will be injected at all procedures.
16358708|NCT04267302|Other|Baby Bouncer Group|Participants in the group will be receiving a baby bouncer for use from infant's birth up to 8 months after birth.
16358709|NCT04267302|Other|Baby Bouncer Group with Infant T-Shirt with LENA|A subsample of the participants in the baby bouncer group will also receive infant t-shirts with wearable audio recorders.
16358710|NCT04267302|Other|Baby Carrier Group|Participants in the group will be receiving a baby carrier for use from infant's birth up to 8 months after birth.
16358711|NCT04267302|Other|Baby Carrier Group with Infant T-Shirt with LENA|A subsample of the participants in the baby carrier group will also receive infant t-shirts with wearable audio recorders.
16358712|NCT04267289|Experimental|iCBT treatment group|Subjects were given license to use Beating the Blues, a commercially available iCBT program. Subjects were given 3 months to use the program.
16358713|NCT04267276|Experimental|Part 1: BI 1265162 - intravenous|
16358714|NCT04267276|Experimental|Part 2: BI 1265162 - oral|
16358715|NCT04267263|No Intervention|Delayed Treatment Control group|Participants will receive the treatment after completion of the 3-month follow-up assessment
16358716|NCT04267263|Experimental|Lifestyle group|Participants will receive the treatment immediately
16358717|NCT04267250|Experimental|Sequence 1|In sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into period 2 where they will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10.
16358718|NCT04267250|Experimental|Sequence 2|In sequence 2, period 1, participants will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10. After a wash-out period of at least 10 days, participants will continue into period 2 where they will receive an additional single dose of OC.
16358719|NCT04267237|Experimental|Atezolizumab|Participants will receive atezolizumab on Day 1 of each 28-day cycle (Q4W) for 12 cycles.
16358720|NCT04267237|Experimental|Atezolizumab + RO7198457|Participants will receive atezolizumab Q4W along with RO7198457 for 12 cycles.
16358721|NCT04267224||Early group|Patients receiving the loading dose of Ticagrelol 90 mg more than 60 minutes before PCI.
16358722|NCT04267224||Late group|Patients receiving the loading dose of Ticagrelol 90 mg less than 60 minutes before PCI.
16358723|NCT04267211|Experimental|Illustrated Consult|
16358724|NCT04267211|Experimental|Standard Consult|
16358725|NCT04267198|Active Comparator|Massed Intention Treatment (massed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 3 weeks.
16358726|NCT04267198|Active Comparator|Distributed Intention Treatment (distributed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 12 weeks.
16358727|NCT04267185|Experimental|Immediate Intervention|PwMS-CG dyads will receive six group telerehabilitation sessions (~60 min each) every other week for a period of 12 weeks. This will be interspersed with brief one-on-one support telephone calls in the weeks that group sessions do not occur. All participants will be taught techniques for monitoring PA behaviour, setting personalized goals to increase PA and reduce sedentary time, and strategies for overcoming challenges to PA participation. Make-up sessions will be offered to those who miss group sessions. The one-on-one support telephone calls will serve to reinforce the information provided during the group sessions, monitor safety and troubleshoot any issues with intervention content.
16358728|NCT04267185|No Intervention|Delayed Control|The delayed control group will not receive the intervention during the study period. Participants assigned to the control group will be offered the intervention once the study is completed.
16358729|NCT04267172|Experimental|Surgical Residents with additional simulation training|Surgeon participant Group 1a: Interventional group ('StR's'): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving additional simulation training.
16358730|NCT04267172|Active Comparator|Surgical Residents with routine training|Surgeon participant Group 1b: control group (StR's): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving routine and normal training.
16358731|NCT04267172|Active Comparator|Orthopaedic Surgeon 'Experts & Fellows'|Consultant Orthopaedic Surgeons (n=5), and nationally appointed Arthroplasty Fellows (n=8). Surgeon participants within this group will not undergo any interventions.
16358732|NCT04267159|Active Comparator|Conventional treatment by acute cardioversion|Participants in the conventional treatment arm will be returned to sinus rhythm in the emergency department within 48 hours of symptom onset unless they convert to sinus rhythm spontaneously.
16358733|NCT04267159|Experimental|Elective treatment by delayed cardioversion|Participants in the elective treatment arm will be returned to sinus rhythm in an out-patient clinic approximately one week after randomizatio unless they convert to sinus rhythm spontaneously.
16358734|NCT04267146|Experimental|newly diagnosed high-grade glioma|"Phase I : Open label, non-randomized, safety run study in nine patients. In case of safety issue a -1 dose level will be tested.
~Phase II : Open label, non randomized, efficacy study of nivolumab in addition to radiotherapy and temozolomide. This phase will start when the RP2D has been defined after the last patients evaluable for DLT achieved the first 6 weeks of treatment (the radio-chemotherapy period) with a DLT rate below 30% during the the phase I study."
16358735|NCT04267133|Experimental|All Participants|
16358736|NCT04267120|Experimental|Lenvatinib + Pembrolizumab|-Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.
16358737|NCT04267107|Experimental|Managing Fatigue:The Individual Program|"Participants in the experimental group will receive the 6-week MFIP. Individuals in experimental group :
~will participate in six one-to-one sessions (each takes 60 to 90 minutes)
~will complete the Feasibility Questionnaire #1, after each session (10 questions) (Appendix 6)
~will complete Feasibility Questionnaire #2 after completing all six-sessions (12 questions) (Appendix 7)
~will complete the post-test measurement after completion of the program (approximately 60 minutes to complete)
~will complete the follow-up measurement, three months after the completion of the program (approximately 60 minutes to complete)
~will be advised to continue with their current healthcare services.
~may participate in one focus group (one-hour session)"
16358763|NCT04266886|Experimental|Arm II (usual care, self-hypnosis guided relaxation)|Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.
16358764|NCT04266873|Experimental|AffloVest HFCWO intervention|Use of the AffloVest for 30 mins, twice a day for 6 weeks
16358765|NCT04266860|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
16358738|NCT04267107|No Intervention|Control Group|"Participants in the control group will not receive the IMFP and they will be advised to continue with their current healthcare services.
~Participants in the control group:
~will complete post-test measurements after 6 weeks (approximately 60 minutes),
~will complete the follow-up measurements three months later after completing the program (approximately 60 minutes).
~will be advised to continue with their current healthcare services.
~Following the study, participants in the control group will be offered the manual of the program and a three-hour training workshop after (three months after the baseline testing). In this workshop, they will learn about the about the program, including the pre-session activities, in-session activities, and homework. This workshop will be conducted by occupational therapists."
16358739|NCT04267081|Experimental|Arm 1 (de novo AML)|"This arm will recruit the patients with de novo AML unfit for conventional chemotherapy. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.
~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
16358740|NCT04267081|Experimental|Arm 2 (relapsed, refractory or secondary AML)|"This arm will recruit the patients with relapsed, refractory or secondary AML. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.
~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
16358741|NCT04267068|Experimental|Intervention|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
16358742|NCT04267068|Active Comparator|Control|Online daily activity scheduling interactive article (control)
16358743|NCT04267042|Active Comparator|Budesonide via Mucosal Atomization Device (MAD)|"Patients in this arm will administer budesonide using a mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) once a day at least 5 times a week for 6 months postoperatively. The MAD atomizes the medication into particles from 30-100 um in size thus increasing the surface area for drug absorption.
~Budesonide is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the MAD syringe."
16358744|NCT04267042|Active Comparator|Budesonide via nasal saline irrigation (INSI)|"Patients in this arm will administer impregnated budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed Pharmaceuticals, Santa Rosa, California) once a day at least 5 times a week for 6 months postoperatively.
~Budesonide is provided in nebules (1mg/2cc).Patients will place two nebules of budesonide into the 240mls of saline."
16358745|NCT04267029||Cases: CRTR (cardiorespiratory transfusion reaction)|Respiratory/cardiovascular disturbances after transfusion (>/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever
16358746|NCT04267029||Controls: HRFTR (high risk febrile transfusion reactions)|Post-transfusion fevers requiring laboratory investigation (Tmax>/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)
16358747|NCT04267016||All Subjects Enrolled|Renal transplant recipients who are undergoing routine management
16358748|NCT04267003|Experimental|DLPFC Stimulation + Task|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during cognitive task completion.
16358749|NCT04267003|Experimental|DLPFC Stimulation + Rest|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during rest.
16358750|NCT04267003|Sham Comparator|Sham Stimulation + Task|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during cognitive task completion.
16358751|NCT04267003|Sham Comparator|Sham Stimulation + Rest|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
16358752|NCT04266990|Experimental|Epilepsy patients|Epilepsy patients admitted for clinical purposes in the EEG monitoring units at the UZ
16358753|NCT04266990|Active Comparator|Healthy volunteers|Healthy volunteers recruited from among colleagues from the department and hospital staff
16358754|NCT04266977|Experimental|Treatment Dexamethasone|"The restrictive DEX regimen is applied from referral to the neurosurgical center until discharge. All administered steroids will be stopped immediately after study inclusion.
~If one or more of the previously defined failure criteria occurs, patients will be treated with DEX."
16358755|NCT04266938|Active Comparator|Prospective RAPID|The prospective RAPID arm will include all patients who meet inclusion criteria and who start BIC/F/TAF within 7 days of HIV diagnos
16358756|NCT04266938|Active Comparator|Prospective Non- RAPID|The prospective non-RAPID arm will include all patients identified as having new HIV diagnosis per health department records, but who failed to establish care at the 550 Clinic and begin BIC/F/TAF within one week of diagnosis
16358757|NCT04266938|Active Comparator|Retrospective Non- RAPID|The retrospective Non-RAPID arm will include historic controls who enrolled in the treatment program from 2012, when universal ART guidelines were implemented, until prior to the implementation of RAPID start of ART.
16358758|NCT04266925|Experimental|3 referees|Three referees were present on the field during these youth soccer matches.
16358759|NCT04266925|Active Comparator|1 referee|One referee was present on the field during these youth soccer matches.
16358760|NCT04266912|Experimental|Treatment (avelumab, M6620)|Patients receive avelumab IV over 60 minutes on days 1 and 15, and M6620 IV over 60 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16358761|NCT04266899|Experimental|FDS+Treadmill gait training|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Treadmill gait training during two weeks.
16358762|NCT04266886|Active Comparator|Arm I (usual care)|Patients receive usual care including receipt of multi-modal analgesia and the injection of a local analgesic at the time of surgery on the ERAS pathway.
16358766|NCT04266860|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
16358767|NCT04266847|Experimental|unilateral mild cataract patients|The patients who underwent monocular IOL implantation before and then present mild cataract in the fellow eye.
16358768|NCT04266834|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
16358769|NCT04266834|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
16358770|NCT04266821|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
16358771|NCT04266821|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
16358772|NCT04266808|Experimental|An interactive telehealth monitoring and biofeedback system|Participants in this group will receive feedback of pressure relief maneuvers and wheelchair propulsion activity. Feedback for pressure relief will include information during the activity to identify adequate duration and magnitude of pressure relief activity, reminders of when the next pressure relief is due, and daily aggregate information regarding the number of successful pressure relief maneuvers performed.
16358773|NCT04266808|Sham Comparator|Education Control|Participants will receive education on the importance and recommended frequency of pressure relief maneuver for prevention of pressure ulcer/injury and on the importance and recommended amounts of physical activity for health.
16358774|NCT04266795|Experimental|Arm A: Pevonedistat + Venetoclax + Azacitidine|Pevonedistat 20 mg/m^2 as a 60-minute intravenous (IV) infusion on Days 1, 3, and 5 in each 28-day cycle plus venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. If remission is confirmed in Cycle 1 or thereafter, venetoclax 400 mg can be administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m^2 IV or subcutaneous (SC) dosing on Day 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle.
16358775|NCT04266795|Active Comparator|Arm B: Venetoclax + Azacitidine|Venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. If remission is confirmed in Cycle 1 or thereafter, venetoclax 400 mg can be administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m^2 IV or SC dosing on Days 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle.
16358776|NCT04266782|Experimental|Physical exercise program and Long-walking|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.
~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
16358777|NCT04266782|No Intervention|Usual care|The subjects will be followed according to current standard.
16358778|NCT04266782|Active Comparator|Control group-intervention|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.
~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
16358779|NCT04266769|Experimental|Patients with Malocclusion|
16358780|NCT04266756|Experimental|Cohort 1: Selexipag Matrix Tablets|Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
16358781|NCT04266756|Experimental|Cohort 2: Selexipag Encapsulated Pellets|Participants will receive oral doses of selexipag encapsulated) pellets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
16358782|NCT04266743|Experimental|Hemiparetic patient|patients who had a stroke at least 6 months before inclusion
16358783|NCT04266730|Experimental|PANDA-VAC combined with pembrolizumab|The final primary therapeutic neoantigen vaccine product will comprise 6 peptides at a dose of 300 μg per peptide and Poly-ICLC at a dose of 500 μg formulated in an aqueous solution containing <5% DMSO in isotonic dextrose for a total volume of 750 μL. The vaccine will be administered subcutaneously via 3 equal volume (250 μL) injections, one in an arm and one in each leg. The product will be administered on the following schedule: Days 1 and 4 of Week 1, Day 1 of Week 2, Day 1 of Week 3, Day 1 of Week 4, Day 1 of Week 11, and Day 1 of Week 21.
16358784|NCT04266717|Experimental|Baby Play Parent Education Group|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
16358785|NCT04266717|Active Comparator|Milestone Education Group|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
16358842|NCT04266288|Placebo Comparator|Placebo|0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose
16361200|NCT04250103||caregiver|caregivers who take care of patients with home health care
16358786|NCT04266704|Experimental|Intervention|Along with providing education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence, the intervention arm is designed to promote information sharing and stimulate broad cortical neural networks, the default mode (DMN), which focuses on emotion-management and self-awareness.
16358787|NCT04266704|Active Comparator|Control|education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence
16358788|NCT04266691||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
16358789|NCT04266691||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
16358790|NCT04266678|Experimental|Elastic band resistance training|Resistance training with elastic resistance bands two days per week for 6-weeks.
16358791|NCT04266678|Active Comparator|Dumbbell resistance training|Resistance training with dumbbell weights two days per week for 6-weeks.
16358792|NCT04266678|No Intervention|Non-exercise Control|Education and guidance for exercise recommendations in older adults but no active training sessions.
16358793|NCT04266665|Active Comparator|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
16358794|NCT04266665|Placebo Comparator|Normal saline|Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.
16358795|NCT04266652|Experimental|Autogenous bone block|the monocortical block grafts were harvested from the retromolar region (i.e. linea oblique) by using of rotating (i.e. carbide burs)
16358796|NCT04266652|Experimental|Tooth block|In the first group, a second mucoperiosteal flap was elevated to surgically remove the respective wisdom tooth. After its removal and during the same surgery, the crown was decapitated at the cemento -enamel junction using a rotating carbide bur under gentle sterile saline cooling and the exposed pulp was preserved. The separated tooth root was adapted to match the size and shape of the defect area. To improve ankylosis between the graft and the defect site, the layer of cementum at the respective downward aspects of the root was carefully removed using a diamond bur until the underlying dentin was entirely exposed
16358797|NCT04266639|Active Comparator|Remote Ischemic Conditioning|"Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.
~Initial Remote Ischemic Conditioning: < 2 hours from inclusion
~Remote Ischemic Postconditioning: twice daily for 7 days
~Usual care with or without acute reperfusion therapy"
16358798|NCT04266639|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.
~Initial Sham Remote Ischemic Conditioning: < 2 hours from inclusion
~Sham Remote ischemic Postconditioning: twice daily for 7 days
~Usual care with or without acute reperfusion therapy."
16358799|NCT04266639|No Intervention|Controls|The control group will not receive treatment with Remote Ischemic Conditioning.
16358800|NCT04266626|Experimental|Group A kinesiotaping therapy|"Protocols mentioned in kinesiological taping i.e. 45 minutes will be pursued as with longer sessions children may tire out easily. Taping Technique for lip muscles would be used by cutting 2 I tapes according to the structure of lip muscles.The tape will be fixed in the center of the mouth on the upper lip, will be placed on an open mouth and a 10% tension will be given to the paper. The tape will then end at the corner of the upper lip. Kinesiotape wouldn't be placed on the lips. The second tape piece will be fixed to the center of the lower lip.The edges of the tape should overlap slightly.
~The other piece of tape will be placed under chin (base of tongue) on sub mandibular triangle, inside the jaw line on the base of the tongue. A strip 1-1 ½ inch long will be cut, and then will further be cut in half such that the stretch is horizontal. It will be anchored in the middle on sub mandibular triangle. Paper off the tension to both sides."
16358801|NCT04266626|Active Comparator|Group B Oral Motor Manipulation therapy|"For the oral motor manipulation technique CP chair will be required to maintain the good sitting posture of children. Trunk will be in upright position with cut out lap board of the CP chair. Hips, knees and ankles would be flexed to 90 degrees. Shoulders and arms will be rested in symmetrical manner by keeping them rested in lap board and foot rest will be used to rest the feet tightly to control movement and maintain good posture. Each child would be taken for 12 weeks of therapy with three sessions per day of 15 minutes each. Oral motor manipulation like tapping protocols would be used for 45 minutes; slow, even rhythmic pressure will be applied around lip muscle and base of tongue muscle, keeping in view the comfort level of patient.
~Training to do manipulation exercises will be given to the parents of children with CP at ."
16358802|NCT04266613||All Subjects Enrolled|High immune risk transplant recipients who are undergoing routine management under current standard of care
16358803|NCT04266600|Experimental|Prospective arm (extended mesenteric resection)|"Surgery can be performed either laparoscopically or open depending on surgeon preference and the circumstances of the surgery. Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis. The entire mesentery related to the specimen will be removed.
~Outcomes in the prospective arm will be compared to historical controls."
16358804|NCT04266600|No Intervention|Retrospective arm|Retrospective patient data will be obtained by querying the Opera operating room database of both study institutions. Electronic records will be analyzed for all patients undergoing a first-time ileocolic resection for Crohn's Disease between January 1, 2009 - December 31, 2018.
16358805|NCT04266587|Experimental|Healthy volunteers|blood sampling is done on healthy volunteers
16358806|NCT04266574|Experimental|Near Infrared Spectroscopy (NIRS)|
16358807|NCT04266574|Active Comparator|Standard Care|
16358808|NCT04266561|Other|lap. recurent inguinal hernia repair|After induction of general anesthesia, the patient was placed supine in Trendelenburg's position. Insertion of the main umbilical port. Laparoscopic hernia repair was done by intracorporeal insertion of purse string technique with some modifications
16358809|NCT04266548|Experimental|super-selective hepatic artery ICG injection group|single arm for feasibility study of intra-hepatic artery base fluorescent segmental demarcation
16358810|NCT04266535||TCI|Patients receiving Target Controlled Infusion (TCI) Anesthesia
16358811|NCT04266535||MCI|Patients receiving Manually Controlled Infusion (MCI) Anesthesia
16358812|NCT04266522|Active Comparator|Arm I (printed materials)|Patients receive printed materials describing the technical aspects of their treatment.
16358813|NCT04266522|Experimental|Arm II (printed materials, physicist interaction)|Patients receive printed materials as in Arm I. Patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.
16358814|NCT04266509|Experimental|Rifampin and PF-06651600 DDI|In Period 1, participants will receive a single oral 50 mg dose of PF-06651600. In Period 2, participants will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, in the morning of Day 8 participants will be administered with rifampin 600 mg 2 hour prior to administration of a single 50 mg oral dose of PF-06651600.
16358815|NCT04266496|Other|<2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention
~Complete a 3 day Frequency Volume chart
~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
16358816|NCT04266496|Other|=> 2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention
~Complete a 3 day Frequency Volume chart and collection of the urine of the last day and night to complete osmolality and sodium testing.
~Measuring the circumference off the lower limbs just after awakining and before falling asleep
~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
16358817|NCT04266470|Experimental|Lara Device Scan|This imaging study will be obtained strictly for the research purposes of mid-treatment assessment of blood flow and uptake kinetics analysis
16358818|NCT04266444|Active Comparator|Level 4|10Cubes game in virtual reality using very small bouncing blocks
16358819|NCT04266444|Active Comparator|Level 3|10Cubes game in virtual reality using very small non-bouncing blocks
16358820|NCT04266444|Active Comparator|Level 2|10Cubes game in virtual reality using large bouncing blocks
16358821|NCT04266444|Active Comparator|Level 1|10Cubes game in virtual reality using large non-bouncing blocks
16358822|NCT04266431|Experimental|EMPOWER|EMPOWER is a multichannel, behavioral lifestyle intervention delivered remotely. The goals of EMPOWER are to induce a loss of 5% or more of initial weight within 6 months and to maintain these improvements at 12 and 24 months, by meeting dietary and physical activity goals. Coach-participant contacts will occur by phone and email, without in-person visits. Coaching contacts will be weekly for the first 12 weeks and then monthly thereafter. Men will have access to a web-based system that (1) provides support for behavioral methods of weight management and (2) allows coaches to review participant self-monitoring data and monitor participant progress towards goals. Men will record diet, exercise, and weight on the web or on a smart phone application.
16358823|NCT04266431|No Intervention|Standard of Care|Men randomized to the standard of care group will continue to receive treatment from the mens' medical oncologist. These men will also be provided with a one page informative brochure on lifestyle recommendations adapted from the American Cancer Society Prostate Cancer Survivorship Care Guidelines, at the time of randomization. At the end of the trial, men in this arm will be offered a one-time counseling session with an intervention coach on healthy lifestyle.
16358826|NCT04266405|Placebo Comparator|Placebo drink|
16358827|NCT04266405|Experimental|Collagen and Zhuyin Drinks|
16358828|NCT04266392|Experimental|1|
16358829|NCT04266379|Experimental|Closed-Loop Control (CLC)|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
16358830|NCT04266379|Active Comparator|Sensor Augmented Pump (SAP)|Closed-loop subcutaneous insulin infusion and continuous glucose monitoring manage by patient
16358831|NCT04266366|Active Comparator|Face-to Face rehabilitation program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience. This program will be developed in the rehabilitation service of the study health centers. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
16358832|NCT04266366|Experimental|Telemedicine Program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 8 weeks, with a total of 24 sessions
16358833|NCT04266353|Experimental|Single arm|Participants with receive resveratrol at 150 mg daily for 6 weeks
16358834|NCT04266340|Placebo Comparator|placebo|no premedication
16358835|NCT04266340|Experimental|oralmidazolam|0.5 mg/kg oral midazolam group
16358836|NCT04266340|Experimental|intravenous midazolam|0.05 mg/kg intravenous injection midazolam group
16358837|NCT04266340|Experimental|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
16358838|NCT04266327|Experimental|I-125 Seed Implantation|All the enrolled patients were treated with ct-guided radioactive i-125 seed implantation assisted by 3D printing template.Prescription dose 110-130gy.
16358839|NCT04266301|Experimental|MBG453 + Azacitidine|Participants will receive MBG453 plus Azacitidine
16358840|NCT04266301|Placebo Comparator|Placebo + Azacitidine|Participants will receive Placebo plus Azacitidine
16358841|NCT04266288|Experimental|Ketamine|Ketamine 0.5 mg/kg in 0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose.
16358843|NCT04266275|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 20 weeks
16358844|NCT04266275|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of intravaginal placebo once a week for 20 weeks
16358845|NCT04266262|Experimental|High-Intensity interval training (HIIT)|
16358846|NCT04266262|Experimental|High-intensity resistance training (HIRT)|
16358847|NCT04266262|No Intervention|Usual care (UC)|Provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
16358850|NCT04266236|Active Comparator|L3 LPB technique (P group)|ultrasound-guided shamrock approach L3 lumbar plexus block with single-needle technique
16358851|NCT04266236|Active Comparator|T12 combined with L3 and L4 LPB technique (TP group)|ultrasound-guided posterior approach thoracic 12 combined with L3 and L4 lumbar plexus block with mulitple-needle technique
16358852|NCT04266236|Experimental|L3 LPB combined with QLB (LPQLB-SNT, PQ group)|ultrasound-guided shamrock approach L3 lumbar plexus block combined with quadratus lumborum block with single-needle technique
16358853|NCT04266223|Experimental|Mask-free surface monitoring|Lay in treatment position for 20 minutes with surface monitoring technology activated
16358854|NCT04266210|Experimental|Fuji Bulk|Glass ionomer (Fuji Bulk, GC, Tokyo Japan)
16358855|NCT04266210|Experimental|G-ænial Posterior|Posterior composite resin(G-ænial Posterior, GC, Tokyo Japan)
16358856|NCT04266197|Experimental|RT234-vardenafil inhalation powder|RT234 at capsule dose strength of 0.5 mg. RT234 will be administered using a variant of the RS01 Monodose Dry Powder Inhaler named Axially Oscillating Sphere dry powder inhaler (AOS DPI) device (RPC Plastiape, Osnago, Italy).
16358857|NCT04266184|Experimental|Kinesio tape (KT)|Abdominal and symphisis pubis supported lumbopelvic KT will be applied. This group will also receive the same educational program with the control group.
16358858|NCT04266184|Active Comparator|Pelvic belt (PB)|A narrow and flexible adjustable pelvic belt will be used in high position (just under the spina iliaca anterior superior). This group will also receive the same educational program with the control group.
16358859|NCT04266184|Other|Control group|This group will receive a 1-hour educational program composed of neuroscience education and ergonomic training.
16358860|NCT04266171|Experimental|CGMS Diet Education|
16358861|NCT04266171|Active Comparator|Conventional Diet Education|
16358862|NCT04266158|Active Comparator|MyoPro 2 Motion-G-orthosis-None|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
16358863|NCT04266158|Active Comparator|Comfy Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
16358864|NCT04266158|Active Comparator|No Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
16358865|NCT04266145|Active Comparator|intravenous dexmedetomidine|20 mL 0.25% levobupivacaine plus 1 mL normal saline will be administrated for adductor-canal-blockade while for intravenous solution; 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline will be prepared
16358866|NCT04266145|Active Comparator|adductor-canal-blockade dexmedetomidine|20 mL 0.25% levobupivacaine containing 1 mL of 0.5 mcg.kg-1 dexmedetomidine will be used for adductor-canal-blockade whereas, 20 mL 0.9% saline will be prepared for intravenous infusion
16358867|NCT04266132|Active Comparator|Retrolamianar block (RLB)|General anaesthesia will be induced.Ultrasound-guided RLB will be performed under strict aseptic precautions with patient in the lateral position.The anesthetic solution will be injected.
16358868|NCT04266132|Active Comparator|Ilioinguinal nerve block (INB)|General anaesthesia will be induced. Ultrasound-guided INB will be performed under strict aseptic precautions with patient in the supine position.The anesthetic solution will be injected.
16358979|NCT04265469|Experimental|Patients with diabetics get mobile education|Patients with diabetics get mobile education
16358980|NCT04265469|No Intervention|Patients with diabetics|Patients with diabetics
16358869|NCT04266119|Experimental|Intervention|"The HOPE intervention can be accessed through web. It consists of two sessions per week, with a total of four sessions. In this study, participants will be sent weekly weblinks for access to each session. Each session take about ten minutes to complete. Each session consist of pre-post multiple-choice and/or open-end question, video(s) and mental health information. The first session is about depression. The second session is about positive psychology and consists of relevant exercises such as gratitude, affect-based and strength-based exercises. The third session describes anxiety disorder. The last session describes relaxation techniques and self-management of unhelpful thoughts.
~Each session consists of quizzes, video(s), and graphical / written information"
16358870|NCT04266119|Active Comparator|Control|The group will receive a control website intervention that consists of several graphical inspirational quotes. Examples of the quotes are, 'Today is full of possible' and 'You can do anything'.
16358871|NCT04266106|Placebo Comparator|Placebo Comparator|
16358872|NCT04266106|Experimental|probiotic|
16358873|NCT04266093||Cohort 1|Subjects who have received treatment on an NCI GMB or GMB gene therapy protocol.
16358874|NCT04266080|Experimental|childhood cancer survivors & and one parent/legal guardian|The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).
16358875|NCT04266067|Active Comparator|PNF exercise|In the PNF exercise group; exercises were performed in company with a physiotherapist 5 days a week (30 minutes ) for 4 weeks. Five specific techniques were applied to the patients: dynamic stabilization, rhythmic stabilization, combined isotonic contractions, and hold-relax active motion
16358876|NCT04266067|Active Comparator|Frenkel exercise|In the Frenkel exercise group, Frenkel coordination exercises were given in home exercise program 5 days a week for 4 weeks.The physiotherapist demonstrated Frenkel exercises to them once.
16358877|NCT04266054|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care
16358878|NCT04266054|No Intervention|Control|The comparison group will receive usual clinical care.
16358879|NCT04266041|Experimental|High-density EEG localization in epilepsy|High-density EEG will be used for brain localization in epilepsy patients
16358880|NCT04266041|Active Comparator|High-density EEG localization in healthy controls|High-density EEG will be used for brain localization in healthy controls
16358881|NCT04266041|Experimental|High-density EEG localization in tumor patients|High-density EEG will be used for brain localization in tumor patients
16358882|NCT04266041|Experimental|High-density EEG localization in peripheral nerve patients|High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
16358883|NCT04266041|Experimental|High-density EEG localization in stroke patients|High-density EEG will be used for brain localization in patients who have recently experienced a stroke
16358884|NCT04266028|Experimental|Cohort 1|Cohort 1 randomized in 2:1 will receive a single s.c. dose of DM-101 or matching placebo
16358885|NCT04266028|Experimental|Cohort 2|Cohort 2 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
16358886|NCT04266028|Experimental|Cohort 3|Cohort 3 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
16358887|NCT04266028|Experimental|Cohort 4|Group 4 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
16358888|NCT04266015|No Intervention|Control group|Patients assigned to control group will not receive feeding via the nasogastric tube during operation
16358889|NCT04266015|Experimental|Intraoperative feeding group|Patients assigned to intraoperative feeding group will receive enteral nutrition formula via the nasogastric tube during operation
16358890|NCT04266002|Other|HIV-1 infected adult associated neurocognitiv|HIV-1 infected adult subjects with HIV-associated neurocognitive disorders despite effective antiretroviral therapy in plasma for more than one year, analyzing the evolution of cognitive disorders with Global Deficit Score and HAND classification, and markers of macrophagic inflammation in blood and cerebrospinal fluid, after a change in HIV treatment with an increased of the new scale CHARTER score ≥ 3 (total treatment score to be ≥ 9)
16358891|NCT04265989|Experimental|coronary artery aneurysm with branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, accompany with branches origin from the aneurysm
16358892|NCT04265989|Experimental|coronary artery aneurysm without branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, without any branch origin from the aneurysm
16358893|NCT04265989|Experimental|Coronary artery aneurysm with localized stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. localized stenosis defined as lesion to more than 70% stenosis and length less than 20 mm
16358894|NCT04265989|Experimental|Coronary artery aneurysm with diffuse stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. Diffuse stenosis defined as lesion to more than 70% and length more than 20 mm
16358895|NCT04265963|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
16359046|NCT04264988||Patients who had pelvic hemorrhage|Patients who had pelvic hemorrhage during complex abdomino-pelvic surgery
16358900|NCT04265924|Active Comparator|>0.85 FIO2 group|This group receives FIO2 >0.85 during the surgery.
16358901|NCT04265924|Active Comparator|<0.7 FIO2 group|This group receives FIO2 <0.7 during the surgery.
16358908|NCT04265898||Test Group|Reported mild cognitive deficits
16358909|NCT04265898||Control Group|No cognitive deficits
16358910|NCT04265872|Experimental|Bortezomib followed by pembro/cis|There is only one arm.
16358911|NCT04265859|Experimental|Depressed|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
16358912|NCT04265859|Other|Healthy Control|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
16358913|NCT04265846|Experimental|bifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.
16358914|NCT04265846|Experimental|mix bifocal IOL group|The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally
16358915|NCT04265846|Experimental|trifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.
16358916|NCT04265846|Experimental|EDOF IOL group|The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.
16358917|NCT04265846|Experimental|blend vision group|The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.
16358918|NCT04265846|Experimental|monovision designed group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
16358919|NCT04265846|Active Comparator|monofocal IOL group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
16358920|NCT04265833|Active Comparator|calcium hydroxide|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with calcium hydroxide. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed to prevent pulp exposure. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity.The residual demineralized dentin was covered with a thin layer of Ca(OH)2 (approximately 1 mm2) in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
16358921|NCT04265833|Experimental|Biodentine|Thirty seven primary molar teeth were selected to apply indirect pulp therapy with Biodentine. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide-bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. A thin layer of tricalcium silicate-containing pulp-capping material (Biodentine) (approximately 1 mm2) consisting of powder and liquid was applied to the demineralized dentin tissue and a 12-min setting time was allowed for hardening, in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
16358922|NCT04265833|Experimental|TheraCal LC|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with TheraCal LC. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. Flowable form of resin-reinforced tricalcium silicate-containing material (TheraCal LC) was applied directly onto the demineralized dentin at a maximum thickness of 1 mm and was polymerized for 20 sec (Valo LED), in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
16358923|NCT04265820|Experimental|Group 1|The unilateral cataract patients in the Group 1 will undergo phacoemulsification and unilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
16358924|NCT04265820|Active Comparator|Group 2|The bilateral cataract patients in the Group 2 will undergo phacoemulsification and bilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
16358981|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg IV Pregabalin|The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).
16358982|NCT04265456|No Intervention|Placebo|Saline solution
16358925|NCT04265807|Active Comparator|Intervention Group|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on an upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
16358926|NCT04265807|Sham Comparator|Control Group|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
16358927|NCT04265794|Experimental|Intervention|6-week community-based behavioral program consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. The intervention targets knowledge, attitudes, and skills related to sugar-sweetened beverage consumption and water consumption, with reduction in sugar-sweetened beverage consumption and increase in water consumption being the primary behavioral targets.
16358928|NCT04265794|No Intervention|Comparison|Parent-child pairs in comparison sites will receive usual care (standard Boys and Girls Club programming) during the study and the intervention upon study completion.
16358929|NCT04265781|Experimental|Dose escalation BAY1817080|Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.
16358930|NCT04265781|Experimental|Dose expansion BAY1817080|Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.
16358931|NCT04265781|Placebo Comparator|Dose escalation Placebo|Participants receive placebo tablets orally as a single dose on Day 1.
16358932|NCT04265781|Placebo Comparator|Dose expansion Placebo|Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.
16358933|NCT04265768|Placebo Comparator|No Soft tissue augmentation surgery|No soft tissue augmentation concomitant to implant placement. Negative control group.
16358934|NCT04265768|Experimental|Soft tissue augmentation surgery with Fibro-Gide|"Soft tissue augmentation concomitant to implant placement with a porcine, volume-stable cross-linked collagen matrix (Fibro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland).
~Test group."
16358935|NCT04265768|Active Comparator|Soft tissue augmentation surgery with patient's CTG|"Soft tissue augmentation concomitant to implant placement with a connective tissue graft (CTG) taken from the patient's palate or retromolar area.
~Positive control group."
16358936|NCT04265755|Experimental|Single arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
16358937|NCT04265742|Experimental|Group A. Normal BMD, no fracture|Post-menopausal women with normal bone density (BMD t-score >-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
16358938|NCT04265742|Experimental|Group B. Normal BMD, with fracture|Post-menopausal women with normal bone density (BMD T-score >-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
16358939|NCT04265742|Experimental|Group C. osteoporotic, no fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
16358940|NCT04265742|Experimental|Group D. osteoporotic, with fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
16358941|NCT04265729|Other|single test product arm|use of Neocate Infant and Junior marketed products (product type depending on subject's age and condition)
16358942|NCT04265716|Active Comparator|L. reuteri|Topical administration of ointment with L. reuteri DSM17938, rubbed into skin twice per day
16358943|NCT04265716|Placebo Comparator|Placebo|Rubbed into skin twice per day
16358944|NCT04265703|Active Comparator|Internal jugular vein site|Ultrasound-guided central venous catheterization at internal jugular vein site
16358945|NCT04265703|Active Comparator|Subclavian vein site|Ultrasound-guided central venous catheterization at subclavian vein site
16358946|NCT04265703|Active Comparator|Innominate vein site|Ultrasound-guided central venous catheterization at innominate vein site
16358947|NCT04265690|Experimental|Teen and Tot Centering subjects|The cooking classes and text messages will supplement the subject's standard of care by incorporating text messages and a cooking class.
16358948|NCT04265677|Experimental|Telemedicine FCR|These patients will be eligible to use telemedicine for Family Centered Rounds
16358949|NCT04265677|Placebo Comparator|Control|These patients will not be eligible to use telemedicine for Family Centered Rounds (standard of care)
16358950|NCT04265664|Experimental|Telerehabilitation|Receives the telerehabilitation protocol
16358951|NCT04265651|Experimental|Infigratinib 0.016 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
16358952|NCT04265651|Experimental|Infigratinib 0.032 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
16358953|NCT04265651|Experimental|Infigratinib 0.064 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
16358983|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg +/- 25 IV Pregabalin|Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.
16358954|NCT04265651|Experimental|Infigratinib 0.128 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
~Dose Expansion:
~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
16358955|NCT04265638|Experimental|Exercise|
16358956|NCT04265638|No Intervention|Usual Care|
16358957|NCT04265625|No Intervention|blind tracheotomy|no endoscopic guidance tracheotomy
16358958|NCT04265625|Experimental|endoscopic guidance tracheotomy|With endoscopic guidance tracheotomy
16358959|NCT04265612|Experimental|Negative Pressure dressing|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
16358960|NCT04265612|Active Comparator|Aquacel hydrogel dressing|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
16358961|NCT04265586|No Intervention|No insomnia|This group contains participants who report only mild symptoms of insomnia (Insomnia Severity Index, ISI<15).
16358962|NCT04265586|Experimental|Digital Cognitive Behavioural Therapy (iCBT)|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Intervention is iCBT for participants with insomnia (7-16 weeks).
16358963|NCT04265586|Experimental|Sleep hygiene education|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Sleep hygiene education (approximately 1 hour)
16358964|NCT04265573||Children under-five|Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
16358965|NCT04265573||Individuals five years of age and above|Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
16358966|NCT04265573||Pregnant women|Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
16358967|NCT04265560|Experimental|Progressive Resistance Training|"The intervention group will receive 8 weeks of Progressive Resistance Training (PRT), twice a week, in addition to usual care. An upper limb functional goal will be identified through discussion with the researcher and the participant. PRT will be individually tailored to target two muscle groups and will be chosen in order to develop strength to progress towards the participants functional goal.
~The chronic spinal cord injury exercise guideline parameters will be applied (3 sets of 8-10 repetitions, 1-2 mins rest between sets). Participants will be inducted to their PRT programme and will then independently complete the 8 week programme. During each of the following sessions, assistance for set up of equipment and/or limb position will be given by the researcher and/or the participants family, friend or carer, once they have been trained. PRT sessions will be recorded in a diary to monitor sets and repetitions completed, and intensity (visual analogue scale (VAS))."
16358968|NCT04265560|No Intervention|Usual care only|Participants will continue with their usual care, consistent with standard National Health Service (NHS) care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting up to 90 minutes. Physiotherapists provide a combination of group exercise and one to one function-orientated physiotherapy sessions to improve balance, general muscle strength, wheelchair and/or transfer skills.
16358969|NCT04265547|Experimental|Intervention Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Participants in the intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion.
16358970|NCT04265547|No Intervention|Control Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion. Control arm participants will be offered the chemical-free products, cleaning supplies, and air filter at this time.
16358971|NCT04265534|Experimental|Telaglenastat with Pembrolizumab and Chemotherapy|The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.
16358972|NCT04265534|Placebo Comparator|Placebo with Pembrolizumab and Chemotherapy|Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.
16358973|NCT04265521|Experimental|Biocool Footcare|"Treatment regime:
~During week 1: Once daily for 7 days (7 doses) During week 2 and 3: Once every second day for 14 days (7 doses)"
16358974|NCT04265508||Low MELD score|MELD score of 6 - 11
16358975|NCT04265508||High MELD score|MELD score of ≥ 17
16358976|NCT04265495||DUAL TRIGGERING|PATIENTS WILL RECEIVE DUAL TRIGGERING
16358977|NCT04265495||URINARY HCG|PATIENTS WILL RECEIVE URINARY HCG
16358978|NCT04265495||RECOMBINANT HCG|PATIENTS WILL RECEIVE RECOMBINANT HCG
16358984|NCT04265443||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI
16358985|NCT04265430|Experimental|MRI after radiation therapy (Cohort I)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy, and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.
16358986|NCT04265430|Experimental|MRI after surgery (Cohort II)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.
16358987|NCT04265417||RARC group|Participants in this group underwent robotic assisted rectal cancer resection
16358988|NCT04265417||NOSE group|Participants in this group underwent robotic rectal cancer resection assisted rectal with natural orifice extraction
16358989|NCT04265391|Experimental|Snakehead fish cookies|Subjects who were given intervention of snakehead fish cookies during the study period
16358990|NCT04265391|Placebo Comparator|Standard cookies|Subjects who were in control group and received standard cookies
16358991|NCT04265378|Experimental|Stimulation group|Anodal tDCS + intensive cognitive training
16358992|NCT04265378|Sham Comparator|Sham group|Sham tDCS + intensive cognitive training
16358993|NCT04265365|Experimental|rTMS+rPMS_iTBS_R|In this group, they received intermittent theta burst stimulation(iTBS) on affected hemisphere after following iTBS at radial nerve on affected hand.
16358994|NCT04265365|Experimental|rTMS+rPMS_cTBS_R|In this group, they received intermittent theta burst stimulation on affected hemisphere after following continuous theta burst stimulation(cTBS) at radial nerve on affected hand.
16358995|NCT04265365|Sham Comparator|rTMS +sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at radial nerve on affected hand.
16358996|NCT04265365|Experimental|rTMS+rPMS_iTBS_M/U|In this group, they received iTBS on affected hemisphere after following iTBS at median/ulnar nerve on affected hand.
16358997|NCT04265365|Experimental|rTMS+rPMS_cTBS_M/U|In this group, they received iTBS on affected hemisphere after following cTBS at median/ulnar nerve on affected hand.
16358998|NCT04265365|Sham Comparator|sham-rTMS+sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median/ulnar nerve on affected hand.
16358999|NCT04265365|Experimental|rTMS + optimal-rPMS|In this group, patient received iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation(rPMS) on affected hand.
16359000|NCT04265365|Experimental|rTMS+ sham-rPMS|In this group, patient received iTBS on affected hemisphere after following sham repetitive peripheral magnetic stimulation on affected hand.
16359001|NCT04265365|Sham Comparator|sham-rTMS+optimal-rPMS|In this group, patient received sham iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation on affected hand.
16359002|NCT04265352||Prenetal cardiac echogenic focus|Newborn infants who had prenatal cardiac echogenic focus
16359003|NCT04265339|No Intervention|None smokers|50 participants who are non-smokers
16359004|NCT04265339|Experimental|Smoking Cessation|50 smokers who quit smoking
16359005|NCT04265339|No Intervention|Active smokers|50 smokers who continue smoking
16359006|NCT04265326||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
16359007|NCT04265313||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
16359008|NCT04265300|No Intervention|Control|No intervention provided
16359009|NCT04265300|Experimental|Creative Roots|The intervention group will receive Creative Roots beverages and be instructed to have at least one drink (251mL) available at each meal (i.e. breakfast, lunch, and dinner) and drink as much as they would like throughout the day (i.e. ad libitum) of either Creative Roots or any other beverage they would normally consume. Subjects will be asked the keep their empty Creative Roots bottles to return them to the lab. Subjects will be instructed to refrigerate the beverages for better taste, and to refrigerate the beverages after opening.
16359010|NCT04265287||Pediatric patients with severe pneumonia|Pediatric patients admitted to PICU due to severe pneumonia
16359011|NCT04265274|Experimental|Disulfiram, vinorelbin, cisplatin, copper|Vinorelbine 25mg/m2 day 1 and 8, Cisplatin 75mg/m2 day 1, every 3 weeks, Disulifiram um 400mg daily and 2 mg of elementary Copper daily, continuously.
16359015|NCT04265248|Experimental|Virtual Reality|"The subjects will use Fulldive VR as the first degree of difficulty where only tilt movements are necessary, for the second degree of difficulty the game VR Ocean Aquarium 3D will be used, where bending, extension and rotation movements will be integrated, also introducing a sensory element to integrate the sound of the sea.
~For these patients to perform the same work as group 2, the physiotherapist will have to count and control in each exercise the number of movements that the patient performs so as not to exceed the proposed dose in the active comparator group (3 sets of 10 repetitions of each exercise)."
16359016|NCT04265248|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
16359017|NCT04265235|Experimental|Home-based Exercise Program|12-weeks, remotely monitored home-based exercise program consisting or aerobic and resistance exercise
16359018|NCT04265222|Other|Conventional Fluoroscopy|Participants undergoing femoroplasty with conventional treatment
16359019|NCT04265222|Experimental|HipCheck|Participants undergoing femoroplasty with Stryker HipCheck System
16359020|NCT04265209|Other|SPECT and PET|[123I]-FP-CIT SPECT imaging procedure first, then [18F] LBT-999 PET Imaging procedure
16359021|NCT04265209|Other|PET and SPECT|[18F] LBT-999 PET imaging procedure first, then [123I]-FP-CIT SPECT imaging procedure
16359022|NCT04265196|Experimental|cognitive behavioral group therapy|A Cognitive Behavioral Therapy intervention is based on a unique protocol built in the light of previous research in the field and includes a 10-week treatment focused on coping with pain and stress.
16359023|NCT04265196|Experimental|Mindfulness-based group therapy|A mindfulness-based group therapy intervention was built inspired by a mindfulness protocol that is effective in treating pain, and includes adjustments to the physical distress of fibromyalgia patients as well as an emphasis on coping with stress and pain.
16359024|NCT04265196|No Intervention|control group|A control group will wait for 3 months, during which the subjects will complete the questionnaires and only after the end of the period will they participate in the treatment so that it will serve as a control group without intervention.
16359025|NCT04265183|Experimental|patients treated with preformed metal crowns|All patients included received a preformed metal crown on their HSPM affected teeth.
16359026|NCT04265170|Experimental|Single-arm|Eligible patients are treated with BlastX and VAC. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks and 8 weeks for larger wounds (2 subjects only). Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.
16359027|NCT04265157||Early occlusion of hepatoduodenal ligament|Early occlusion of hepatoduodenal ligament during mobilization of the liver of the recipient by using portal vein clamp or occlusive temporary bands.
16359028|NCT04265157||classical occlusion of hepatoduodenal ligament|classical occlusion of hepatoduodenal ligament after mobilization of the liver of the recipient immediately before explantation by suing of portal vein clamp
16359029|NCT04265144|Experimental|subjects SSc diagnosed|Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria
16359030|NCT04265131|Experimental|Experimental group|art therapy is delivered on top of treatment as usual (TAU). TAU means that individual verbal therapy takes place on a regular basis, whereby the frequency varies depending on the severity of the eating disorder and the patient's request for help. Cognitive-behavioral therapy is provided with elements of dialectical behavioral therapy, and there is also the possibility of family or couple counseling by a family-based therapist.
16359031|NCT04265118|Experimental|Sideward Tilt of Bed|During sleep, while lying in supine position, the participant will be tilted sidewards by the bed. In practice, the experimenter activates the bed at timepoints during the night where the participant is lying in supine position. Activating the bed results in one half of the bed lifting 10 to 40 Degrees sidewards.
16359032|NCT04265105|Active Comparator|standard of care|Short acting beta agonist or inhaled corticosteroids
16359033|NCT04265105|Experimental|fluticasone-vilanterol|LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
16359034|NCT04265079|Experimental|Added weight to hand|
16359035|NCT04265066||Measurement of sublingual microcirculation|
16359036|NCT04265053|Experimental|Male NOS|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
16359037|NCT04265053|Experimental|Male COX|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
16359038|NCT04265053|Experimental|Female NOS|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
16359039|NCT04265053|Experimental|Female COX|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
16359040|NCT04265027|Experimental|Group 1 (50 mg Dose)|"Test IMP: 50 mg BIA 9 1067 and Reference IMP: 50 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.
~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
16359041|NCT04265027|Experimental|Group 2 (25 mg Dose)|"Test IMP: 25 mg BIA9 1067 and Reference IMP: 25 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.
~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
16359042|NCT04265014|Active Comparator|Goal-directed fluid treatment|"Fluid management will be performed according to SVV and CI monitoring. When patients have SVV>10%, 250 cc crystalloid will be administered and when SVV fell below 10% during 30-minute monitoring standard (5 mL/kg/hr) crystalloid infusion continues. If SVV continues above 10%, a second fluid bolus of 250 cc colloid (minifluid challenge) will be administered.
~If the desired SVV level can not be reached, the Hct values will be examined. Blood replacement will be performed when Hct<30% in patients with coronary artery disease (CAD) and when Hct<25% for other patient groups. If the desired SVV level can not be reached in spite of blood replacement products, if CI will be below 2.5 L/min/m2 vasopressor will begun. If SVV will be at normal values with CI below 2.5 L/min/m2, inotrop will begun."
16359043|NCT04265014|Active Comparator|liberal fluid treatment|"Fluid management will be performed according to MAP, HR and urine output.
~If peroperative urine amounts will be <0.5 mL/kg/hr during two-hour monitoring, with MAP<65 mmHg, HR>100/min for at least 30 minutes and CVP falls 20% compared to basal values, the same anesthesiologist will begin additional fluid replacement of 5 mL/kg/hr based on clinical experience.
~Blood product replacement will be provided at Hct<30% for those with coronary artery disease and at Hct<25% for other patients."
16359044|NCT04265001|Active Comparator|Control group|Topical cholrhexidine hydrochloride 125 mg/100 ml available commercially (Hexitol; Arab Drug Company for Pharmaceutical and Chemical Industries, Cairo, Egypt) mouthwash. Topical cholrhexidine hydrochloride mouthwash treatment has been repeated three times per day for one week.
16359045|NCT04265001|Experimental|Hyaluronic acid group (HA group)|Topical hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash (Aftamed; Bioplaxpharma, UK).Topical hyaluronic acid mouthwash treatment has been repeated three times per day for one week.
16361296|NCT04249440||PST|patient accepts preoperative systemic treatment as upfront strategy
16359047|NCT04264975|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation in patients who have advanced solid cancer with primary (group 1) or secondary resistance (group 2) to immuno-oncology
16359048|NCT04264962|Experimental|Yang Yin Fu Zheng Jie Du therapy|
16359049|NCT04264962|Placebo Comparator|Routine medical care|
16359050|NCT04264949|Experimental|group application (GA)|"benefit from conventional care in a rehabilitation center, therapeutic education program and education in the use of the smartphone application mon coach dos"
16359051|NCT04264949|Active Comparator|Groupe conventional care (GCC)|benefit from conventional care in a rehabilitation center and therapeutic education program
16359052|NCT04264936|Experimental|RC48-ADC and JS001|
16359053|NCT04264923|Experimental|All patients enrolled|All patients enrolled with receive the HyGIeaCare Prep with a new lab sampling technique to be used on all patients enrolled in the study.
16359054|NCT04264910|Experimental|Calm Meditation|Participants (n=49) will be provided free access to and asked to register for the consumer-based mobile meditation app on their phone. Participants (n=49) will then receive an email containing 28 weeks of free access to Calm. Participants (n=49) will be asked to use Calm at least 10 minutes per day and encouraged to use it as much as they would like during the intervention. This prescription mimics how a new, paying member would use the app (full exposure with autonomy).
16359055|NCT04264910|No Intervention|Control|The control group will be asked to maintain normal activity and refrain from using Calm meditation app.
16359056|NCT04264897|Experimental|Metformin|"The investigators use a ramp up dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
16359057|NCT04264897|Placebo Comparator|Placebo|"Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate).
~The same dosing schedule will be followed as for metformin. The investigators use a ramp up dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
16359058|NCT04264858|Experimental|Treatment group|Immunoglobulin of cured patients
16359059|NCT04264858|Placebo Comparator|Control group|γ-Globulin
16359060|NCT04264845||Provider Focus Group|All heart failure providers at the participating centers will be screened as potential participants.
16359061|NCT04264845||Patient Interview Group|Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
16359062|NCT04264845||PROs/Clinical Data Integration Group|"Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
~This group includes a sub-study of patients providing blood samples."
16359063|NCT04264832||observation group|Participants were eligible if they met the Rotterdam diagnostic criteria of polycystic ovary syndrome (PCOS) and meet the inclusion and exclusion criteria , and all study participants received questionnaires and underwent the physical, transvaginal ultrasound and body composition examination. Blood samples were collected for analysis of metabolic markers, metabonomics and hormones.
16359064|NCT04264832||control group|The control group participants are normal women and had no history of any type of diabetes, cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization), stage 2 hypertension , malignant disease or severe renal or hepatic disease. They accepted the same examinations as the observation group.
16359066|NCT04264806|Experimental|Azacitidine: Participants with MDS or CMML|Participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) will receive azacitidine 75 milligram per meter square (mg/m^2) body surface area (BSA) subcutaneously or Intravenously per local label on Days 1 through Day 7 of each 28-day cycle. Participants will be treated until disease progression; relapse from complete remission (CR), partial remission (PR), or marrow complete remission (mCR); transformation to acute myeloid leukemia (AML); death; or unacceptable toxicity.
16359067|NCT04264806|Experimental|Azacitidine and Cusatuzumab: Participants with MDS or CMML|Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.
16359068|NCT04264793|Experimental|Intervention|Behavioral Lifestyle Intervention (3 health centers): In addition to usual care in the health center, the intervention included individual counseling and group education on nutrition and physical activity.
16359121|NCT04264494|Placebo Comparator|placebo group|Fifty RA patients were injected intra-articularly with 3 doses of saline in their joints.
16359069|NCT04264793|Active Comparator|Control|Control (4 health centers): Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
16359070|NCT04264780||Younger than 50 years of age|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently less than 50 years of age
16359071|NCT04264780||50 years of age or older|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently 50 years of age or more
16359072|NCT04264767||Cases Group|Peripheral blood collection via routine venipuncture
16359073|NCT04264767||Control Group|Peripheral blood collection via routine venipuncture
16359074|NCT04264754||Cases Group|Subjects who have already been diagnosed with liver cancer, however did not yet undergo any surgery, ablation, embolization or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
16359075|NCT04264754||Control Group|"Cancer free subjects with high risk to development HCC. High risk subjects include the following:
~Subjects with HCV (hepatitis C virus) and cirrhosis
~Subjects with HBV (hepatitis B virus) and cirrhosis
~Non-cirrhotic chronic HBV subjects at intermediate or high risk of HCC, according to EASL (European Association for the Study of the Liver) Clinical Practice Guidelines for the management of hepatocellular carcinoma
~Subjects with NAFLD (Non-Alcoholic Fatty Liver Disease) with cirrhosis
~Cirrhotic patients due to any other reasons, including alcohol disease"
16359076|NCT04264741|Experimental|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 4 weeks.
16359077|NCT04264741|Sham Comparator|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday. Treatment will lasted for 4 weeks.
16359078|NCT04264715|Experimental|405nm light room|In this room, surgeries will be performed under ambient light including the wavelength 405nm
16359079|NCT04264715|No Intervention|Control room|In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies
16359080|NCT04264702||Prospective arm|Patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
16359081|NCT04264702||Control Arm|The control arm will consist of matched Stage I to Stage IV CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
16359082|NCT04264689|Active Comparator|thoracic epidural|thoracic epidural will be done before induction of general anesthesia
16359083|NCT04264689|Experimental|serratus anterior block|ultrasound guided serratus anterior block will be done after induction of general anesthesia
16359084|NCT04264689|Experimental|erector spinae block|ultrasound guided erector spinae block will be done after induction of general anesthesia
16359085|NCT04264676|Active Comparator|Metronidazole|supplement of metronidazole 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6(6 treatments totally),and every 6 weeks for CapeOX (4 treatments totally).
16359086|NCT04264676|Placebo Comparator|Placebo|supplement of identical-appearing placebo 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6 (6 treatments totally),and every 6 weeks for CapeOX 4 treatments totally).
16359087|NCT04264663|Experimental|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and furazolidone 100mg po bid for 14d
16359088|NCT04264663|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
16359089|NCT04264650|No Intervention|Control group|Standard care
16359090|NCT04264650|Experimental|One active intervention group|provided with COOL Passport, a mobile healthcare application
16359091|NCT04264650|Experimental|The other active intervention group|provided with access to the Health Promotion Cloud system and use of game-based interactive platforms along with COOL Passport
16359092|NCT04264637|Experimental|Azelastine hydrochloride 0.15% + Placebo|Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively.
16359093|NCT04264637|Experimental|Placebo + Azelastine hydrochloride 0.15%|Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively.
16359094|NCT04264624|Experimental|Guided Biofilm Therapy with Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the adjunctive treatment, he/she will also receive subgingival biofilm removal with Perioflow combined with Erythritol powder at sites with PD≥ 5 mm, including the experimental sites, prior to subgingival biofilm removal with USD.
16359095|NCT04264624|Active Comparator|Guided Biofilm Therapy without Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the control treatment, all teeth present will receive the application of disclosing agent, full-mouth supragingival and intra-sulcular biofilm removal with Airflow at sites with PD up to 4 mm, full mouth supra gingival calculus removal with USD, and subgingival biofilm removal with USD at sites with PD> 4 mm, including the experimental sites, as required.
16359096|NCT04264611|Experimental|Short Foot Exercise Group|The group that received the short foot exercise
16359097|NCT04264611|Experimental|Towel Curl Exercise Group|The group that received the towel curl exercise
16359098|NCT04264611|No Intervention|Control Group|The group that received no exercise
16359099|NCT04264598|Experimental|Experimental Adult Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
16359100|NCT04264598|Experimental|Experimental Children Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
16359101|NCT04264598|Experimental|Experimental Infant Group - Medium dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV Intervention: Biological: Three-dose regimen of medium dosage investigational sIPV
16359102|NCT04264598|Active Comparator|Control Infant Group - commercialized sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV Intervention: Biological: Three-dose regimen of commercialized sIPV
16359103|NCT04264598|Active Comparator|Control Infant Group - commercialized IPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV Intervention: Biological: Three-dose regimen of commercialized IPV
16359104|NCT04264585|Experimental|Standard ICBT|Clients assigned to the Standard ICBT condition will receive the standard version of the ICBT course, which consists of four lessons spread across the span of five weeks. Clients will receive five weeks of therapist support.
16359105|NCT04264585|Experimental|ICBT with Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive the Planning for Change lesson before Lesson 1 of the UniWellbeing Course.
16359106|NCT04264585|Experimental|ICBT with Booster|Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course.
16359107|NCT04264585|Experimental|ICBT with Motivational Interviewing and Booster|Clients assigned to the ICBT with Motivational Interviewing and Booster condition will receive access to both the Motivational Interviewing content (before Lesson 1 of the UniWellbeing Course) and the booster session (one month after ICBT course).
16359108|NCT04264572|Experimental|Medically Tailored Meals (MTM)|Participants in this arm will receive MTM for 12 weeks. Meals will be prepared and delivered by MANNA, a non-profit organization that has provided MTM for patients with chronic illnesses in Philadelphia and Southern New Jersey since 1990. MANNA will deliver 21 complete meals to the patient's home each week, providing 45-60 grams of carbohydrates per meal for optimal glucose control based on ADA guidelines and 100% of overall nutritional requirements based on USDA guidelines. In addition, children and any senior dependents for whom the participant is the primary caregiver will receive meals for the entire 12 weeks for no additional cost, as this is standard of care of MANNA services. MANNA registered dieticians will cater the program to meet the specific needs (e.g., dietary restrictions, cultural preferences). Investigators will provide information on community resources in the area, including food resources, for all patients.
16359109|NCT04264572|Experimental|MTM + tele-Medical Nutrition Therapy (MNT)|Patients in this arm will receive MTM services as well as tele-MNT over 12 months. The tele-MNT intervention will be delivered by a registered dietician within the Jefferson endocrine clinic, with assistance by other endocrine dieticians and fellows. In the first months, video visits focus on supporting individuals who are not selecting, preparing or purchasing their own meals. As the end of MTM services approaches, the intervention shifts to focus on the transition from MTM to self-directed eating. Based on Academy of Nutrition and Dietetics recommendations, each participant's MNT will include the following core features: nutrition assessment, intervention, care coordination, monitoring and evaluation. The following will also be addressed: nutrition prescriptions, nutrient intake, energy intake, glycemic index and load, alcohol consumption and physical activity. The schedule includes individual visits in the first 6 months and monthly group session in months 7-12.
16359110|NCT04264572|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with DM, which includes regular visits with a diabetes provider (primary care or endocrine), standard ADA information pamphlets and referral to 1) diabetes education classes and 2) nutrition counseling by dieticians and nurse practitioners. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and diabetes self-management (e.g., diabetes.org). The standard of care at Jefferson for patients with DM is to begin with a single group MNT visit lasting from 60-90 minutes. Each participant's need for additional sessions and general time-frame for follow-up is individually determined following the group session, based on patient preference. Historically, only about 2% of the Jefferson population engages in these services, thus minimizing dilution of the effect of the tele-MNT.
16359111|NCT04264559|Other|Healthy control group|This group will include 40 healthy adults.
16359112|NCT04264559|Other|CSAP group|This study will include 40 patients with chronic stable angina pectoris (CSAP).
16359113|NCT04264559|Experimental|Healthy intervention group|This group will include 40 healthy adults. They will receive moxibustion intervention.
16359114|NCT04264546|Experimental|Experimental Adult Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
16359115|NCT04264546|Experimental|Experimental Children Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
16359116|NCT04264546|Experimental|Experimental Infant Group - High dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
16359117|NCT04264533|Experimental|VC|12g Vitamin C+sterile water for injection; total volume: 50ml. 12ml/h; infusion pump；q12h.
16359118|NCT04264533|Placebo Comparator|Sterile water for injection|50ml water for injection. 12ml/h; infusion pump; q12h.
16359119|NCT04264520|Experimental|PTSD Psychoeducation + Skills Intervention|
16359120|NCT04264494|Experimental|PRP group|Fifty RA patients were injected intra-articularly with 3 doses of PRP in their joints
16361441|NCT04248478||Healthy Volunteers|Healthy volunteers are planned to be included in this arm.
16359122|NCT04264481|Experimental|Adductor Canal Block|Adductor Canal Block (Saphaenous Nerve Block) done under Ultrasonographic guidance with 5cc of Bupivacaine, 5cc of lidocaine diluted with 10 cc of Normal Saline
16359123|NCT04264481|Active Comparator|Intra-articular Steroid and Lignocaine|Intra-articular knee joint injection of 40mg triamcinolone and 1-2cc of lidocaine
16359124|NCT04264468||response group and the non-response group|Received neoadjuvant chemotherapy according to the routine clinical diagnosis and treatment, and evaluated the clinical efficacy once every two cycles of chemotherapy. According to the clinical efficacy, the patients were divided into the neoadjuvant chemotherapy response group and the non-response group (evaluation standard RECIST1.1).
16359125|NCT04264455||Biomonitor only|Patients receive a Biomonitor only
16359126|NCT04264455||Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor|Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
16359127|NCT04264455||ICD Implantation|Patients receive an ICD only
16359128|NCT04264442|Experimental|Losmapimod|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until study drug approval or until the study is discontinued by the Sponsor.
16359129|NCT04264429|Experimental|Infrapatellar strap|This group will perform the functional tests with the infrapatellar strap positioned on the painful knee.
16359130|NCT04264429|Experimental|Elastic Band|This group will perform the functional tests with the elastic band positioned on the painful knee.
16359131|NCT04264429|No Intervention|Control|This group will perform the functional tests without elastic band or infrapatellar strap positioned on the painful knee.
16359132|NCT04264416|Experimental|Whole-Body Electromyostimulation|16 weeks of dynamic WB-EMS: one supervised session per week, 20 min session; impulse-frequency: 85 Hz; impulse breadth 350 µs; intermittent 4-6 s; of impulse - 4 s of impulse break; impulse intensity RPE 7 (hard+ to very hard) on Borg CR 10 Scale.
16359133|NCT04264416|No Intervention|Non exercising control|...maintained physical activity and exercise habits during the study period.
16359134|NCT04264403|Active Comparator|Renal Denervation|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. If randomized to the Renal Denervation Group RDN procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
16359135|NCT04264403|No Intervention|Sham Procedere|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. In these patients no RDN will be performed.
16359138|NCT04264377||Healthy|26 healthy subjects
16359139|NCT04264377||Asthma|26 subjects with asthma
16359140|NCT04264364||laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy
16359141|NCT04264364||endoscopic sleeve gastroplasty|Patients who underwent endoscopic sleeve gastroplasty
16359142|NCT04264325||Malignant pleural effusions : diaphragmatic ultrasound measure|
16359143|NCT04264299|Active Comparator|T tube drainage|Closure of common bile duct after choledocholithotomy over T tube
16359144|NCT04264299|Experimental|Primary closure|Primary closure of the common bile duct after choledocholithotomy
16359145|NCT04264299|Experimental|Antegrade stenting|Closure of common bile duct over antegrade biliary plastic stent
16359146|NCT04264286|Active Comparator|Esmolol group|Patients will receive intravenous esmolol after the end of the surgical procedure.
16359147|NCT04264286|Placebo Comparator|Placebo group|Patients will receive intravenous saline after the end of the surgical procedure.
16359148|NCT04264273||Participants with Parkinson´s disease.|Participants who fulfilled the diagnostic criteria of Parkinson´s disease.
16359149|NCT04264273||Participants without a neurological disease|25 neurologically healthy patients of the local otolaryngological clinic, in whom submandibular gland needle biopsy was performed due to a clinical indication.
16359150|NCT04264260|Experimental|colchicine group|The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
16359151|NCT04264234|Experimental|Placenta Previa|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
16359152|NCT04264221|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.
~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
16359153|NCT04264221|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
16359187|NCT04263922|Active Comparator|Valsartan Group|Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
16361520|NCT04247932||Register|Matched sample from register data, no intervention provided
16359154|NCT04264208|Experimental|68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI|Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
16359155|NCT04264208|Experimental|68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI|Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
16359156|NCT04264195|Experimental|Constraint-induced movement therapy|Constraint-induced movement therapy (PEPS-MIT)
16359157|NCT04264195|Active Comparator|Bimanual manipulation|Bimanual manipulation (PEPS-Bimanual)
16359158|NCT04264182|Experimental|Ultra-conservative ICD programming|Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
16359159|NCT04264182|No Intervention|Standard programming (physician discretion)|Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD
16359160|NCT04264169||• Study group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will be complicated by placenta accreta spectrum
16359161|NCT04264169||• Control group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will not be complicated by placenta accreta spectrum
16359162|NCT04264156|Experimental|160 mg/kg|Lucinactant for inhalation, 160 mg total phospholipids (TPL)/kg Delivered as an aerosol once, with up to 3 repeats of 80 mg/kg allowed within 36 hours of birth
16359163|NCT04264156|Sham Comparator|nCPAP Only|nCPAP Only as sham comparator. Bubble nCPAP is standard of care. Treatment time behind barrier to match active treatment delivery time
16359164|NCT04264143|Experimental|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
16359165|NCT04264130|Active Comparator|artemisinin-based combination therapies|subjects given Artemisinin-based combined therapies according to the study instruction
16359166|NCT04264130|Sham Comparator|non-artemisinin drugs|subjects given non artemisinin based combined therapies like describe in the study protocol
16359167|NCT04264117|Active Comparator|FlexAbility (Mesh-like irrigated tip catheter) group|
16359168|NCT04264117|Experimental|TactiCath (Contract force monitoring catheter) group|
16359169|NCT04264104|Experimental|Low dose neural mobilization|Four series of 10 repetitions of neural mobilization targeting the tibial nerve.
16359170|NCT04264104|Active Comparator|High dose neural mobilization|Eight series of 10 repetitions of neural mobilization targeting the tibial nerve.
16359171|NCT04264078|Experimental|anti-CD7 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
16359172|NCT04264052||CBE & MRIE|Forty healthy volunteers split in different age ranges (20-30 years n=10, 30-40 years n=10, 40-50 years n=10 and 50-60 years n=10) will undergo two airway assessments at rest and during exercise. The exercise assessments will be a continuous bronchoscopy during exercise (CBE-1st visit) and magnetic resonance imaging during exercise (MRIE-2nd visit) separated by at least three days to ensure for a sufficient cardiorespiratory and musculoskeletal recovery.
16359173|NCT04264039|Experimental|anti-CD19 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD19 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
16359174|NCT04264026|Experimental|Open Label|Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 40 mg MDMA.
16359175|NCT04264013|Placebo Comparator|Exercise|Exercise
16359176|NCT04264013|Active Comparator|Exercise + Diet|Exercise + eggs
16359177|NCT04264000|Experimental|platelet-rich plasma|The perineural injection with PRP is a potential treatment for peripheral entrapment neuropathy
16359178|NCT04264000|Active Comparator|5% dextrose|The perineural injection of 5% dextrose is a novel management for peripheral entrapment neuropathy
16359179|NCT04263987|Active Comparator|Holmium Laser Enucleation of Prostate|Traditional holmium laser enucleation of the prostate as currently performed
16359180|NCT04263987|Experimental|Moses Holmium Laser Enucleation of Prostate|holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.
16359181|NCT04263974|Experimental|Smartphone Application|"A protocol of exercises and general recommendations based on the current scientific evidence will be provided through a smartphone application. A follow-up of the use of the application will be carried out. The treatment protocol will last 6 months, during which a minimum of 4 weekly sessions of exercises will be carried out at home.
~Each pathology will have an unique program of exercises and recommendations."
16359182|NCT04263974|Active Comparator|Conventional Treatment|Those in this group will received the conventional treatment protocol provided within the Andalusian Public Health System. This will consist on the delivery of an exercise program and recommendations using a sheet of paper. Participants will be told to perform the exercises during 6 months, with minimum of 4 weekly sessions of exercise that will be carried out at home.
16359183|NCT04263961||COPD GOLD I - II|"Inclusion for mild-moderate COPD patients (n = 100):
~Age between 45-65 years.
~GOLD classification I or II according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].
~Cessation of smoking for ≥6 months.
~≥5 packyears of smoking.
~Absence of asthma.
~Written informed consent."
16359184|NCT04263961||Controls|"Inclusion for healthy controls (n = 100):
~Age between 45-65 years.
~Absence of COPD according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].
~Cessation of smoking for ≥6 months.
~≥5 packyears of smoking.
~Absence of asthma.
~Written informed consent."
16359185|NCT04263948|Experimental|Picado Arm|Patient Under Picado Monitoring plateform
16359186|NCT04263922|Experimental|Huaiqihuang group|Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
16359188|NCT04263909|Experimental|sufentanil SL arm|Each patient will receive 30mcg of sufentanil SL prior to extubation in the operating room, and then as needed in the recovery room, guided by pain scores.
16359191|NCT04263883|Active Comparator|Conventional treatment|Usual Care Group: Conventional treatment: moist hot pack. manual therapy, Therapeutic Exercise.Home program routine.
16359192|NCT04263883|Experimental|Study or Experimental Group|"moist hot pack.
~manual therapy.
~Therapeutic Exercise.
~Home program routine. 5.3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill. For 10 weeks(3Times/week for 20 minutes)."
16359193|NCT04263870|Experimental|Sintilimab plus capecitabine and oxaliplatin|Subjects enrolled are treated with oral capecitabine 1000mg per m2 bid for two weeks（every 3 weeks）and intravenous oxaliplatin 130mg per m2（every 3 weeks）in combination with sintilimab 200mg (every 3 weeks)
16359194|NCT04263844|Active Comparator|Dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine 1 mcg/kgBB thirty minutes before induction
16359195|NCT04263844|Active Comparator|Midazolam|subject will receive premedication with intranasal midazolam 0,1 mg/kgBB thirty minutes before induction
16359196|NCT04263831|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).
~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be two dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.
~The dose levels will be as follows:
~Cohort 1: 1.0x10^6 IU/m^2/day. Cohort 2: 1.25x10^6 IU/m^2/day."
16359197|NCT04263818|Experimental|Motions during colonoscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
16359198|NCT04263805|Experimental|Vignette with research climate|Participants in this arm will receive vignettes describing a dilemma situation in research (e.g adding honorary author) with additional sentence describing research climate (i.e. an environment where their peer had detrimental practice in a similar situation)
16359199|NCT04263805|Active Comparator|Vignette without research climate|Participants in this arm will receive vignettes describing a dilemma situation in research without the additional sentence describing research climate
16359200|NCT04263792|Other|Biodistribution cohort|The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [18F]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
16359201|NCT04263792|Other|The Dynamic cohort|The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of [18F]fluoropropyl-trimethoprim.
16359202|NCT04263779|No Intervention|Default List (case manager level)|In this condition, all SNF options will be presented to case managers in Repisodic in rank order according to Repisodic's algorithm that weights dimensions such as Centers for Medicare & Medicaid Services (CMS) quality metric ratings, distance, and the match between SNF features and specific patient need. The list only includes SNFs that accept the patient's insurance.
16359203|NCT04263779|Experimental|P-SNF Top-Sorted List (case manager level)|"This condition is the same as the Default List, except that relevant providers (i.e., those meeting patient needs and located within a threshold distance to be determined per hospital) who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
~Situations in which there are no relevant P-SNFs will be flagged yet still assigned to this condition, in an intent-to-treat analysis; the default algorithm-based rank-ordered approach will be applied to all non-preferred providers."
16359204|NCT04263779|No Intervention|Full List/Full Map/Default Video (patient level)|All SNF options, both P-SNFs and NP-SNFs (up to a maximum of 10 by default) that case managers preselected for patients will be presented to patients in rank order (according to Repisodic's algorithm, as described above). Patients will also have the option of viewing the default Repisodic map, which will show the SNFs on the list, and patients will be provided the link to an introductory video presenting the SNF selection and discharge process. When only a paper printout is available, the same SNF sorting order will be presented on paper.
16359205|NCT04263779|Experimental|P-SNF List/P-SNF Map/P-SNF Video (patient level)|This is the same as the Full List condition, except that both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. Moreover, the link to viewing the optional introductory video will be highlighted, and the video will include sections describing the advantage of P-SNFs for care coordination. When only a paper printout is available, the same SNF sorting order will be presented on paper, with only the P-SNFs presented on the first page.
16359206|NCT04263766|Experimental|Healthy Adult Volunteers|The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.
16359207|NCT04263753|Experimental|conservative surgery for bladder in placenta accretta|
16359208|NCT04263740|Experimental|Kinesio Taping plus Traditional Physical Therapy|Kinesio Taping plus Traditional physical therapy
16359209|NCT04263740|Other|Traditional Physical Therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises.
16359210|NCT04263727||Asthma|Non-Interventional. Patients with asthma will be screened and enrolled into the active Asthma disease-specific cohort.
16359211|NCT04263727||Chronic Obstructive Pulmonary Disease (COPD)|Non-Interventional. Patients with COPD will be screened into the inactive COPD disease-specific cohort.
16359212|NCT04263727||Idiopathic Pulmonary Fibrosis (IPF)|Non-Interventional. Patients with IPF will be screened into the inactive IPF disease-specific cohort.
16359213|NCT04263714|Experimental|Exercise|All subjects will perform both aerobic and resistance exercise
16359214|NCT04263701|Active Comparator|Conventional Physiotherapy Group|45 minutes, 2 days in a week for 8 weeks
16359215|NCT04263701|Experimental|Dual Task Training Group|45 minutes, 2 days in a week for 8 weeks
16359216|NCT04263688||Immunotherapy effective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
16359217|NCT04263688||Immunotherapy Ineffective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
16359218|NCT04263675||GDM+|Women with history of gestational diabetes
16359219|NCT04263675||GDM-|Women without history of gestational diabetes
16359220|NCT04263662||Pre-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours prior to implementation of an analgesia-sedation algorithm.
16359221|NCT04263662||Post-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours after implementation of an analgesia-sedation algorithm.
16359222|NCT04263649||All subjects|patients who require a PICC
16359223|NCT04263636||Study group|Patients that underwent uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs (PanOptix or PanOptix toric, Alcon Laboratories, Inc., Fort Worth, TX, USA)
16359224|NCT04263636||Control group|Patients of similar age without cataract that their crystalline lens has not been replaced.
16359225|NCT04263623|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
16359226|NCT04263623|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
16359227|NCT04263623|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
16359228|NCT04263610|Experimental|Non-Germany: Dimethyl fumarate standard scheme|"Part 1: Participants will receive Dimethyl fumarate (DMF) standard scheme from baseline to Week 16.
~Part 2: Participants achieving a Psoriasis Area and Severity Index (PASI) 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
16359229|NCT04263610|Experimental|Germany: Dimethyl fumarate standard scheme|Part 1: Participants will receive DMF standard scheme from Baseline to Week 16. Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40.
16359230|NCT04263610|Experimental|Germany: Dimethyl fumarate simplified scheme|"Part 1: Participants will receive DMF simplified scheme from Baseline to Week 16.
~Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
16359231|NCT04263597|Experimental|2'-fucosyllactose|"Patients will be randomized 1:1 to either receive 2FL at dose level 0 (starting dose) or placebo (2g oral glucose).
~Starting Dose for ages 0-5 years: 2.5 g/day; Ages 5.1-10 years: 5 g/day; Ages >10 years: 10 g/day
~After 20 patients are enrolled at the first dose level for an arm, enrollment of that arm will be paused. Randomization for the 20 patients will be unblinded and the safety and tolerability of 2FL doses will be compared to placebo for that arm. If 6/10 patients can take 80% of their planned doses, that dose level will be determined as tolerable and a dose escalation will be performed. If 5/10 patients are unable to take at least 80% of planned doses the dose will be determined to not be well tolerated and a dose de-escalation will be done.
~Dose escalation for ages 0-5 years: 5 g/day; Ages 5.1-10 years: 7.5 g/day; Ages >10 years: 15 g/day
~Dose de-escalation for ages 0-5 years: 1.25 g/day; Ages 5.1-10 years: 2.5 g/day; Ages >10 years: 5 g/day"
16359232|NCT04263597|Placebo Comparator|Placebo (2g oral glucose)|Patients will be randomized 1:1 to either receive 2FL at dose level 0 (starting dose) or placebo (2 g oral glucose).
16359233|NCT04263597|Experimental|Initial enrollment to establish safety|The investigators will enroll 5 patients of ages ≥10 years undergoing allogeneic HSCT. 2'-FL will be administered to these patients from day-7 until day+30 after HSCT at the starting dose. Once safety is determined the investigators will then enroll an additional 5 patients of ages 5-10 years and administer 2'FL to these patients at the proposed dose for this age group from day-7 to day+30 after HSCT. Once safety is determined, the investigators will enroll 5 patients of ages 0-5 years and administer 2'FL at starting doses to children from day-7 to day+30 after HSCT. Once safety is established in these patients we will proceed with the randomized portion of the study.
16359235|NCT04263558|Active Comparator|LHF|Long intervention (16 sessions) High parental involvement (5 sessions) Feedback
16359236|NCT04263558|Active Comparator|LHN|Long intervention (16 sessions) High parental involvement (5 sessions)
16359237|NCT04263558|Active Comparator|LLF|Long intervention (16 sessions) Low parental involvement (Brochure) Feedback
16359238|NCT04263558|Active Comparator|LLN|Long intervention (16 sessions) Low parental involvement (Brochure)
16359239|NCT04263558|Active Comparator|SHF|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions) Feedback
16359240|NCT04263558|Active Comparator|SHN|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions)
16359241|NCT04263558|Active Comparator|SLF|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure) Feedback
16361827|NCT04245722|Experimental|FT596 Monotherapy, CLL|FT596 monotherapy in adult subjects with r/r CLL
16359242|NCT04263558|Active Comparator|SLN|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure)
16359243|NCT04263545|Active Comparator|Intervention|
16359244|NCT04263545|Placebo Comparator|Standard Care|
16359245|NCT04263519|Active Comparator|Low Serum Level|Stable Blood Tacrolimus of 2-5 ng/ml.
16359246|NCT04263519|Active Comparator|High Serum Level|Stable Blood Tacrolimus of 5.1-10 ng/ml.
16359247|NCT04263506|Experimental|Vignette with supervisor's opinion|Participants in this arm will receive vignettes with an additional sentence describing supervisor's opinion (i.e. supervisor does not oppose to detrimental research practice)
16359248|NCT04263506|Active Comparator|Vignette without supervisor's opinion|Participants in this arm will receive vignettes without an additional sentence describing supervisor's opinion.
16359249|NCT04263493|Active Comparator|Early mobilization (loading)|"This constitutes the currently accepted regime and is therefore considered the control group.
~Cast/orthopedic boot for 6 weeks No weight bearing: week 0-2 Partiel weightbearing from week 3 Full weightbearing from week 7 ROM exercises 5 times a day from week 3"
16359250|NCT04263493|Experimental|Delayed mobilization (loading)|Loading of the Achilles tendon is delayed for 6 weeks. Cast/orthopedic boot for 12 weeks No weight bearing: week 0-6 Partiel weightbearing from week 7 Full weightbearing from week 13 ROM exercises 5 times a day from week 3
16359251|NCT04263480|Experimental|Arm A: Carfilzomib + Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated. Patients will receive in addition Carfilzomib for two years.
16359252|NCT04263480|Active Comparator|Arm B: Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated.
16359253|NCT04263467|Experimental|Intervention group|Participants in the intervention group will receive a 6-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
16359254|NCT04263467|Experimental|Control group|Participants in the control group will receive standard oncological treatments; immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
16359255|NCT04263454|Other|Healthy Control|All healthy control participants will undergo the same screening and experimental procedures. Healthy controls must report no other medical conditions ( including fibromyalgia) to be considered for inclusion. All healthy controls will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
16359256|NCT04263454|Experimental|Fibromyalgia|All fibromyalgia participants will undergo the same screening and experimental procedures. However, fibromyalgia participants will need to meet 2010 American College of Rheumatology diagnostic criteria for fibromyalgia. All fibromyalgia participants will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
16359257|NCT04263441|Experimental|NICE Intervention|The proposed intervention will engage clients in the health care enrollment and navigation process in-person, at the time of the HIV testing event. Subjects will be asked to share thoughts on the satisfaction survey.
16359258|NCT04263441|No Intervention|Control Intervention|Subjects will be offered a handout on how to enroll in healthcare coverage This group will be provided with the site's standard healthcare enrollment and linkage to care, which is specific to the health care clinic they are visiting. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review. Subjects will be asked to share thoughts on the satisfaction survey.
16359259|NCT04263428|Experimental|Irregular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights, including an adaptation night and a baseline night of 7.5 h time in bed (0:00-7:30). Afterwards, they are instructed to sleep in bed on a schedule alternated between 6 h, i.e. 1:30-7:30, and 9 h, i.e. 22:30-7:30).
16359260|NCT04263428|No Intervention|Regular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights of 7.5 h time in bed (0:00-7:30).
16359261|NCT04263415|Placebo Comparator|group P|once-weekly injection with placebo pen.
16359262|NCT04263415|Experimental|group S|Once-weekly application of semaglutide
16359263|NCT04263402|Experimental|Methylprednisolone(<40mg/d)|
16359264|NCT04263402|Experimental|Methylprednisolone(40~80mg/d)|
16359265|NCT04263389||control group|control group is a normal matched group.
16359266|NCT04263389||study group|study group is a group of chronic mechanical cervical pain
16359267|NCT04263363|Experimental|CDS pathway|When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP
16359268|NCT04263350|Experimental|Treatment A|Fixed-dose combination mini-tablet
16359269|NCT04263350|Experimental|Treatment B|Separate products taken at the same time
16359270|NCT04263337||Low Cognitive Functioning/Low Concussion History|Former NFL players with low cognitive function and low concussion history will be included in this group.
16359271|NCT04263337||High Cognitive Functioning/ High Concussion History|Former NFL players with high cognitive function and high concussion history will be included in this group.
16359272|NCT04263337||Low Cognitive Functioning/High Concussion History|Former NFL players with low cognitive function and high concussion history will be included in this group.
16359273|NCT04263337||High Cognitive Functioning/Low Concussion History|Former NFL players with high cognitive function and low concussion history will be included in this group.
16359274|NCT04263337||Healthy Male Controls|Healthy male demographically matched controls will be included in this group.
16359334|NCT04262999||drug sodium valproate|individuals on antiepileptic drug sodium valproate for at least 1 year at the time of participation of the study.
16359275|NCT04263337||Low Cognitive Functioning/Medium Concussion History|Former NFL players with low cognitive function and medium concussion history will be included in this group.
16359276|NCT04263337||Medium Cognitive Functioning/Low Concussion History|Former NFL Players with medium cognitive functioning and low concussion history with be included in this group.
16359277|NCT04263337||Medium Cognitive Functioning/Medium Concussion History|Former NFL Players with medium cognitive functioning and medium concussion history with be included in this group.
16359278|NCT04263337||Medium Cognitive Functioning/High Concussion History|Former NFL Players with medium cognitive functioning and high concussion history with be included in this group.
16359279|NCT04263337||High Cognitive Functioning/Medium Concussion History|Former NFL Players with high cognitive functioning and high concussion history with be included in this group.
16359280|NCT04263324|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
16359281|NCT04263324|No Intervention|Control group|No intervention
16359282|NCT04263311|Experimental|Community Health Workers (CHW) treatment group|There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
16359283|NCT04263311|No Intervention|Control group|There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes
16359284|NCT04263298|Experimental|Fulvestrant Group|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
16359285|NCT04263298|Active Comparator|Capecitabine Group|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
16359286|NCT04263285|Experimental|rTMS (Repetitive Transcranial Magnetic Stimulation)|
16359287|NCT04263272|Experimental|Upper Body Exercise|Seated upper body circuit training program for 16-weeks. Frequency - 1 to 3 one-hour sessions per week.
16359288|NCT04263259|Experimental|Attentional Bias Modification|Participants complete attentional bias modification using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
16359289|NCT04263259|No Intervention|Attentional Bias Control|Participants complete attentional bias assessment-only using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
16359290|NCT04263246|Experimental|PhytoDyNAmic|Six capsules per day b.i.d.
16359291|NCT04263246|Placebo Comparator|Inulin|Six capsules per day b.i.d.
16359292|NCT04263233||Other|This program, which is provided for all patients new to dialysis at the participating units, will be evaluated by assessing patient clinical outcomes and the results of surveys measuring patient-reported symptoms, quality of life, knowledge and activation. In addition, satisfaction with the program will be assessed.
16359293|NCT04263220|Experimental|Prototype exoskeleon 1|The experimental trial will be performed with the prototype exoskeleton
16359294|NCT04263220|Experimental|Prototype exoskeleon 2|The experimental trial will be performed with the prototype exoskeleton
16359295|NCT04263220|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
16359296|NCT04263207||anti-Tat Ab positive subjects|
16359297|NCT04263207||anti-Tat Ab negative subjects|
16359298|NCT04263194|Experimental|Default Mode Network (DMN)|The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).
16359299|NCT04263194|Experimental|Central Executive Network (CEN)|The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).
16359300|NCT04263194|Placebo Comparator|Placebo|The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.
16359301|NCT04263181||Cohort 0|"-A technical run-in of 5 patients with any of the following:
~Standard cytarabine/idarubicin induction, includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) & idarubicin 12 mg/m2 per day for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed
~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle.
~Azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle
~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter.
~Azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
16359302|NCT04263181||Cohort 1|"Patients treated with cytarabine/idarubicin induction therapy
~Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed (e.g. cytarabine/daunorubicin or Vyxeos)."
16359303|NCT04263181||Cohort 2|"Patients treated with decitabine
~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle."
16359304|NCT04263181||Cohort 3|"Patients treated with azacitidine
~Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle"
16359333|NCT04263012||Patients with an implanted LVAD|Patients which received an implantation of a left ventricular assist device (LVAD) at the University Hospital Basel since 2014
16359370|NCT04262739|Experimental|NYH817G and NYH100P|
16359305|NCT04263181||Cohort 4|"Patients treated with decitabine + venetoclax
~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
16359306|NCT04263181||Cohort 5|"Patients treated with azacitidine + venetoclax
~Patients will receive azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
16359307|NCT04263168|Experimental|Bariatric Surgery Candidates|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
16359308|NCT04263168|Sham Comparator|Laparoscopy Cholecystectomy|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
16359309|NCT04263155|Experimental|Experimental: The Body Project for high school young women|The 4-hour Body Project workshop delivered by trained peer leaders
16359310|NCT04263155|No Intervention|Control|The business-as-usual comparison group does not participate in the Body Project but may engage in any other programs or services they normally would
16359311|NCT04263142|Experimental|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16359312|NCT04263142|Experimental|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16359313|NCT04263142|Experimental|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16359314|NCT04263142|Experimental|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16359315|NCT04263142|Experimental|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16359316|NCT04263116|Experimental|BAM group|Balloon assisted maturation
16359317|NCT04263116|Experimental|NO BAM|NO Balloon assisted maturation
16359318|NCT04263103|Experimental|Experimental group with SJ-RS-WL2015|Item code: SJ-RS-WL2015, a visual training software program, 15 minutes of one section, twice a day, and for 1 year
16359319|NCT04263103|No Intervention|control group|No special treatment, but observation
16359320|NCT04263090|Experimental|Rigosertib + Nivolumab|Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
16359321|NCT04263077|Placebo Comparator|PLACEBO|IN THE PLACEBO GROUP, THE ENDS OF THE TAPES WILL BE APPLIED NO TENSION WITHOUT OVERLAPPING EACH OTHER.
16359322|NCT04263077|Other|50% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 50% TENSION.
16359323|NCT04263077|Other|75% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 75% TENSION.
16359324|NCT04263077|Other|100% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 100% TENSION.
16359325|NCT04263064|Active Comparator|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine).
16359326|NCT04263064|Experimental|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
16359327|NCT04263051|Experimental|UCPVax + Nivolumab|"UCPVax vaccine (0,5 mg)
~Nivolumab (480 mg)"
16359328|NCT04263051|Other|Standard second line chemotherapy|"Standard second line chemotherapy at the choice of the investigator.
~This arm will permit to assess the good calibration of the hypothesis on the experimental arm."
16359329|NCT04263038|Active Comparator|Anticoagulation|Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.
16359330|NCT04263038|Placebo Comparator|No anticoagulation|Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.
16359331|NCT04263025|Experimental|CLARIX CORD 1K|They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).
16359332|NCT04263025|Active Comparator|Controls|They will undergo RARP without adjunctive CLARIX® CORD 1K.
16359335|NCT04262999||drug levetiracetam|individuals on antiepileptic drug levetiracetam monotherapy for at least 1 year at the time of participation of the study.
16359336|NCT04262999||drug sodium valproate + levetiracetam|individuals on antiepileptic drug sodium valproate + levetiracetam combination therapy for at least 1 year at the time of participation of the study.
16359337|NCT04262999||control group|systemically healthy individuals
16359338|NCT04262973|Experimental|experimental group|The experimental group will not only receive six-hour dementia care course, but also a half-day interprofessional education workshop, maintain a six-month interprofessional practice model, and join interprofessional practice experience-sharing conferences.
16359339|NCT04262973|Active Comparator|control group|The control group will only receive six-hour dementia care course.
16359340|NCT04262960|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
16359341|NCT04262960|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
16359342|NCT04262947|Active Comparator|Conventional Method|Placement of peripheral venous catheter using conventional methods
16359343|NCT04262947|Experimental|VeinViewer Visualization Only|Use of a VeinViewer to visualize the most suitable target. Once the target has been identified and marked, the device will be placed aside and the peripheral venous catheter will be placed using conventional methods
16359344|NCT04262947|Experimental|Constant Imaging with VeinViewer|Identification of the most suitable target and placement of a peripheral venous catheter under constant imaging with a VeinViewer
16359345|NCT04262934|Experimental|Cholecalciferol treatment|Arm A : Cholecalciferol 100.000 UI - oral - every month
16359346|NCT04262934|Active Comparator|No treatment|Arm B : No vitamin D administration
16359347|NCT04262908||Patients implanted with hip or knee prostheses|Patients who had hip or knee arthroplasty will be followed and asked at 3-months visit if they resumed their job or not. In both cases, further informations will be gathered
16359351|NCT04262882|Experimental|Multilevel Family Planning Intervention|A multi-level, community-based intervention delivered in groups of couples to increase contraceptive uptake, reduce discontinuation, and reduce the incidence of unintended pregnancy, and improve intermediate outcomes (knowledge, attitudes, norms, communication, equity).
16359352|NCT04262882|Active Comparator|Time and attention-matched control|A community sanitation intervention delivered in groups of couples to increase at-home and community hygiene practices.
16359355|NCT04262856|Experimental|Arm 1 (zimberelimab monotherapy)|Participants will receive zimberelimab monotherapy by IV infusion.
16359356|NCT04262856|Experimental|Arm 2 (domvanalimab and zimberelimab combination therapy)|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.
16359357|NCT04262856|Experimental|Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)|Participants will receive oral etrumadenant in combination with zimberelimab and domvanalimab by IV infusion
16359358|NCT04262843|Experimental|Treatment (fludarabine, TMLI, HCT, cyclophosphamide)|"CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard."
16359359|NCT04262830||All Study Participants|This is an observational study where all study participants are within a single group.
16359360|NCT04262817|Experimental|E-cigarette flavor|In this arm, participants will receive two experimental e-cigarette flavors
16359361|NCT04262817|Experimental|E-cigarette nicotine form|In this arm, participants will receive two forms of nicotine in an e-cigarette
16359362|NCT04262804|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
16359363|NCT04262804|Active Comparator|Trastuzumab & Chosen Chemotherapy|The dosage and administering of Trastuzumab is 8 mg/kg loading dose then 6 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
16359366|NCT04262765|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:
~Age: 18-49 years
~Weight: 55-105 kg
~Height: 163-188 cm
~BMI 18.5-29.9 kg/m²"
16359367|NCT04262752|Experimental|chronically constipated people|Adults with chronic constipation due to either neurogenic bowel dysfunction (NBD) as consequence of a neurogenic condition such as Multiple sclerosis or Parkinson Disease, or to unkwon origin (Idiopathic No-NBD)
16359368|NCT04262739|Experimental|NYH817G|
16359369|NCT04262739|Experimental|NYH100P|
16359371|NCT04262726|Experimental|REMOTION + TAU|Participants in the REMOTION group receive REMOTION in addition to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
16359372|NCT04262726|Active Comparator|TAU|Participants in TAU receive psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
16359373|NCT04262713|Other|Patients implanted with Meije duo stem size 1 or 2|"Among this arm, patients that meet criteria ( weight>
~60kg and / or a long neck / varus and / or a DEVANE score ≥ 4 ) will perform hip X ray"
16359374|NCT04262700|Experimental|Intervention 01|Subjects use new LifeScan provided BGMS for 12 weeks.
16359375|NCT04262687|Experimental|Immunotherapy + chemotherapy|Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.
16359376|NCT04262674|Experimental|Cognitive-motor training|Simultaneous cognitive-motor training (i.e. exergame) and strength training
16359377|NCT04262674|No Intervention|Control|Passive control group
16359378|NCT04262661|Experimental|NNC0472-0147 Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147.
16359379|NCT04262661|Placebo Comparator|Placebo Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo.
16359380|NCT04262661|Experimental|NNC0472-0147 Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days
16359381|NCT04262661|Active Comparator|Insulin glargine Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days.
16359382|NCT04262648|Experimental|Treatment|
16359383|NCT04262648|Placebo Comparator|Control|
16359384|NCT04262635|Experimental|ArmA Cetuximab plus Capecitabine|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
16359385|NCT04262635|Active Comparator|ArmB Cetuximab|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
16359386|NCT04262622|Active Comparator|Group TEA|
16359387|NCT04262622|Active Comparator|Group RSB|
16359388|NCT04262596|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
16359389|NCT04262596|Active Comparator|Traditional decision aid booklet|A traditional patient decision aid bookelet that includes provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
16359390|NCT04262570|Experimental|SMA patients (therapy arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~Magnetic Resonance Imaging (MRI) of lower leg
~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
16359391|NCT04262570|Active Comparator|SMA patients (control arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~Magnetic Resonance Imaging (MRI) of lower leg
~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
16359392|NCT04262557|Experimental|Sunrise+PSG|PSG and Sunrise® will be set at the patient's home by IC@dom. The first night, the patient will be equipped by both PSG and Sunrise® and only by the Sunrise® for the two following nights.
16359393|NCT04262544|Experimental|mHealth|Intervention group
16359394|NCT04262544|Active Comparator|Usual Care|Control group
16359395|NCT04262518|Other|Outcomes4Me App Users|This cohort will download and use the Outcomes4Me mobile app for breast cancer.
16359396|NCT04262505|Experimental|Mediterranean Diet Group (Group A)|The intervention is based on components of the traditional Mediterranean diet which is primarily a plant based diet and emphasises intakes of vegetables, whole grains and fruit with the main added fat being extra virgin olive oil.The diet will be modified and tailored to cultured preferences by the registered dietitian. Participants will be informed of their diet allocation group during the baseline teleconsultation and will commence the diet the following day or as soon as is feasible for 12 weeks. Participants will be provided with resources specifically designed to explain the components of the Mediterranean diet and how it will be followed.
16359397|NCT04262505|Experimental|Healthy Eating Group (Group B)|Participants assigned to the Healthy Eating group will be advised to adhere to the current healthy eating guidelines and will be provided with resources to inform them of these guidelines and sample meal plans that are readily available on the Healthy Ireland website.
16359399|NCT04262466|Experimental|IMC-F106C - Arm A - Phase 1|Dose Escalation
16359400|NCT04262466|Experimental|IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1|Dose Escalation
16359401|NCT04262466|Experimental|IMC-F106C - Phase 2|Monotherapy dose expansion
16359402|NCT04262427|Experimental|Single Group Assignment|Cyclophosphamide 50mg PO OD for 3 weeks as monotherapy followed by cyclophosphamide 50mg PO OD with pembrolizumab 200mg IV every 3 weeks
16359403|NCT04262401|Active Comparator|Standard health coaching|Standard health coaching to increase health behaviors
16359404|NCT04262401|Experimental|Habit-focused health coaching|Health coaching enhanced with a focus on habit formation using a mobile application called Habit Design
16359766|NCT04259827|No Intervention|No online cognitive training|normal clinical follow-up without cognitive training or gaming
16359405|NCT04262388|Experimental|Window|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with locally advanced disease (window) and treated with durvalumab 1500 mg given by IV x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to definitive therapy (e.g. surgery)."
16359406|NCT04262388|Experimental|Metastatic|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with recurrent/metastatic (metastatic) disease and treated with durvalumab 1500 mg given by IV every 4 weeks and oleclumab 3000 mg given by IV every 2 weeks x 4 doses then IV every 4 weeks till disease progression, toxicity, withdrawal of subject consent, or another discontinuation reason."
16359407|NCT04262375|Experimental|Durvalumab and Oleclumab|A single dose level for oleclumab and durvalumab will be used, comprising of Oleclumab 3000 mg IV Q2W for 4 doses, then Q4W AND Durvalumab 1500 mg IV Q4W
16359408|NCT04262349|Experimental|intervention|"Every week because of differences in the number of pregnant women who attended the school participating women were divided into two groups using a random number table created in the program via the computer itself. The purpose of the study was explained to pregnant women, informed consent form and data collection tools of the study were collected by face to face interview technique. In the first interview to all pregnant women; Personal Information Form, Course Information Form, Pittshburg Sleep Quality Index (PUKI) and General Self-Efficacy Scale were applied. Pregnant women in the intervention group were given a two-session training program to improve sleep quality and Sleep Guide and Safe Baby Sleep Conditions Brochure."
16359409|NCT04262349|No Intervention|control|"Pregnant women in the control group were subjected to routine practice without any training given by the researcher. Four weeks after the completion of the sleep training, all pregnant women were contacted by telephone and the data collection tools were applied for the second time and the final test applications were completed. After completion of the data collection process made a new plan for training to improve the quality of sleep to pregnant women in the control group and the Sleep Guide and Safe Baby Sleep Conditions Brochure is given."
16359410|NCT04262336|Active Comparator|DB-020 for Injection, 12%/placebo|dosage
16359411|NCT04262336|Active Comparator|DB-020 for Injection, 25%/placebo|dosage
16359412|NCT04262310||Study Aims|To obtain normative data (median, 10th and 90th percentile) as well as inter-individual coefficient of variation (COV, assessed by [SD/mean]) with approximately 15 participants in each age group: 18-30, 31-45, 46-60, and 60-70 years old. To assess intra-individual COV [assessed by [SD/mean]. To assess effect of standard diets containing 16.25 or 32.5 g fiber/day during the two 24 hour periods before and during the measurement of permeability
16359413|NCT04262297||Prosthesis users|Prosthesis users with transtibial amputation
16359414|NCT04262297||Able-bodied Controls|Prosthesis users' age-, sex- and dominancy-matched healthy controls
16359415|NCT04262258|Experimental|Blueberry Enriched Diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
16359416|NCT04262245|Other|irrigation activation method|Irrigation activation is a crucial stage of root canal treatment. Therefore, the effect of activation methods on post treatment is an important fact for the comfort of patients.
16359417|NCT04262232|Experimental|Ca-HELP|This intervention arm will consist of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
16359418|NCT04262219|Experimental|iShare|Participants will be asked to listen to a podcast intervention.
16359419|NCT04262206|Experimental|atorvastatin 40mg|40mg atorvastatin po qd from consent to study end
16359420|NCT04262206|Placebo Comparator|Placebo|matching placebo po qd from consent to study end
16359421|NCT04262193|Placebo Comparator|Suvorexant placebo|Placebo (inert) tablet
16359422|NCT04262193|Experimental|Suvorexant 10mg|Suvorexant 10mg tablet
16359423|NCT04262193|Experimental|Suvorexant 20mg|Suvorexant 20mg tablet
16359424|NCT04262180|Experimental|Base intervention- Fitbit with EHR integration|All participants will receive a first-line intervention (i.e., Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal) and will be evaluated for response/non-response every 4 weeks until week 20.
16359425|NCT04262180|Experimental|Nonresponders -Stepped up to Online gym|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Online gym."
16359426|NCT04262180|Experimental|Nonresponders -Stepped up to Coaching calls|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Coaching calls."
16359427|NCT04262167|Experimental|Low Dose LSCs (cohort 1) n = 4 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 100 million Lung Spheroid Stem Cell (LSC) infusion.
16359428|NCT04262167|No Intervention|Usual Care (Cohort 1) n = 2 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
16359429|NCT04262167|Experimental|High Dose LSCs (Cohort 2) n = 12 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 200 million LSC infusion.
16359430|NCT04262167|No Intervention|Usual Care (Cohort 2) n = 6 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
16359491|NCT04261738|No Intervention|Control|The first 2-hour session will be a control where participants will sit quietly (as they would in the hyperbaric chamber) and will not be allowed to consume carbohydrates unless directed to by the hyperbaric department hypoglycemia protocol.
16359431|NCT04262154|Experimental|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
16359432|NCT04262141|Experimental|IMG-7289 in ET and PV Patients|"Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered:
~The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity.
~The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity."
16359433|NCT04262128||Type 2 Diabetes Mellitus|women age 60-75 years with uncomplicated type 2 diabetes mellitus
16359434|NCT04262128||Healthy Controls|healthy women age 60-75 years
16359435|NCT04262115|Experimental|AM-EX|Participants in this group will be prescribed morning aerobic exercise.
16359436|NCT04262115|Experimental|PM-EX|Participants in this group will be prescribed evening aerobic exercise.
16359437|NCT04262102|Active Comparator|Group 1 (SD_SF)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
16359438|NCT04262102|Experimental|Group 2 (SD_BLW)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
16359439|NCT04262102|Experimental|Group 3 (HFV_SF)|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
16359440|NCT04262102|Experimental|Group 4 (HFV_BLW)|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
16359441|NCT04262089|Experimental|primary dMMR uterine cancer patients|primary dMMR uterine cancer patients
16359442|NCT04262089|Experimental|primary POLE-EDM uterine cancer patients|primary POLE-EDM uterine cancer patients
16359443|NCT04262076|Experimental|Combination of pulpine with Polyamidoamine Dendrimer|Removal of Caries infected dentin from the walls and floor of the cavity and then apply polyamidoamine Denrimer for 30 secs ,then washed out of the cavity followed by placement of Pulpine over affected Dentin.
16359444|NCT04262076|Active Comparator|Pulpine|Removal of Caries infected dentin from the walls and the floor of the cavity followed by application of Pulpine over affected Dentin.
16359445|NCT04262063|Experimental|tell play do technique|Tell play do technique with a dental imitation toy and using euphemisms instead of demonstrating on a model or observing one. Tell play do technique provides a better explanatory concept of the dental procedure and can lead to more cooperation of the children patients which can influence the dental treatment in a good and positive way.
16359446|NCT04262063|Active Comparator|tell show do technique|Tell show do is the gold standard of the non-pharmacological behavior management techniques. It is based on the principle of learning theory and it is performed by the dentists themselves . It is the most important behavior modification technique practiced by dentists and it is commonly used for management of children anxiety in the first dental visit .
16359447|NCT04262050|Experimental|TMS + tDCS group|
16359448|NCT04262050|Experimental|sham TMS + tDCS group|
16359449|NCT04262050|Experimental|tDCS group|
16359450|NCT04262050|Experimental|TMS group|
16359451|NCT04262037|Experimental|HPPV|will receive high frequency positive pressure ventilation during cardiopulmonary bypass at tidal volume 2 ml/kg and respiratory rate 80. Lung ultrasound will be done at the beginning and end of surgery
16359452|NCT04262037|Experimental|CPPV|will receive continuous positive airway pressure of 10 cmH2o during the bypass. Lung ultrasound will be done at the beginning and end of surgery
16359453|NCT04262037|No Intervention|Control|will be disconnected from the ventilation (passive deflation). Lung ultrasound will be done at the beginning and end of surgery.Lung ultrasound will be done at the beginning and end of surgery
16359454|NCT04262024|Active Comparator|Cabergoline with health education by a nurse|Women with hyperprolactiemia scheduled for cabergoline therapy 0.5 mg twice weekly for one month plus health education by a nurse.
16359455|NCT04262024|Active Comparator|cabergoline without health education by a nurse|Women with hyperprolactiemia scheduled for cabergoline therapy 0.5 mg twice weekly for one month without health education by a nurse.
16359456|NCT04262011|Other|immediate treatment|After randomization, patients who are allocated to the immediate treatment group will receive treatment.
16359457|NCT04262011|Other|postponed treatment|After randomized patients will be allocated to this group, they will wait for the follow-up of the study to receive delayed treatment.
16359458|NCT04261998|Experimental|Service-learning group|Intervention group will perform a service-learning program with real patients with heart transplantation and coronary syndrome, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
16359459|NCT04261998|No Intervention|Control group|Control group will perform a physical therapy program for heart transplantation and coronary syndrome, but without meeting real patients. One meeting will be performed in order to establish groups and search information based on evidence in scientific databases.
16359492|NCT04261738|Experimental|Hyperbaric Oxygen|"The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute [ATA]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an air break. They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours."
16359493|NCT04261725||Squamous Cell Lung Cancer|Genetic analysis for searching EGFR mutation
16359494|NCT04261712|Experimental|Paltusotine|
16359460|NCT04261985|Active Comparator|Mobile Phone Obesity Intervention|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the intervention arm. Every week for 4 weeks, caregivers will receive 4 interactive multi-media phone prompts to support the intervention's targeted topics. Each mobile phone prompt starts with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share their goal/s, perceived barriers, questions, tips and strategies that may be helpful to other participants. Each week, caregivers will also receive strategies, and individual and group feedback on changing unhealthy behaviors. The content shared by caregivers are summarized by a team research assistant and sent back to participants at the end of every week.
16359461|NCT04261985|No Intervention|Control|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the control (no intervention) arm. Every week for 4 weeks, these caregivers will receive 4 interactive multi-media phone prompts around managing common illness in young children (i.e. fever, vomiting, constipation, etc.) Each mobile phone prompt will start with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share questions and strategies that may be helpful to other participants. Each week, caregivers will also receive tips and group feedback based on group questions. The content shared by caregivers will be summarized by a team research assistant and sent back to participants at the end of every week.
16359462|NCT04261972||CHARM|Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
16359463|NCT04261959||myoActivation only|Participants who receive one or more sessions of myoActivation. They may receive 1:1 counselling also, but will not receive physiotherapy or group counselling
16359464|NCT04261959||Physiotherapy only|Participants who receive one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive myoActivation or group counselling
16359465|NCT04261959||myoActivation and Physiotherapy|Participants who receive one or more sessions of myoActivation AND one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive group counselling
16359466|NCT04261933||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
16359467|NCT04261920|Experimental|Single decoction group: Huangqi Guizhi Wuwu decoction|The dosage of granules: Sheng huangqi granule 5.5g/bag, Guizhi granule 0.9g/bag, Baishao granule 1.6g/bag, Ganjiang granule 1.7g/bag, Dazao granule 7g/bag. Take twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
16359468|NCT04261920|Placebo Comparator|Simulator group: Huangqi Guizhi Wuwu decoction Placebo|The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
16359469|NCT04261907|Experimental|ASC09/ritonavir group|ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
16359470|NCT04261907|Active Comparator|lopinavir/ritonavir group|Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
16359471|NCT04261894|Experimental|OPTIMIZE|This arm includes implementation of the OPTIMIZE perinatal care checklist with patient navigation support.
16359472|NCT04261894|No Intervention|Standard Care|This arm includes provision of standard perinatal care.
16359473|NCT04261881|Active Comparator|Nutraceutical intervention, 5 capsules twice daily.|Participants will consume the nutraceutical blend ATP-Fuel at 5 capsules twice daily.
16359474|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules once daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules once daily.
16359475|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules twice daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules twice daily.
16359476|NCT04261868|Experimental|Virtual Reality|Dichoptic playing games with fine stimulation will present to the amblyopic eye.
16359477|NCT04261868|Active Comparator|Patching|Non- amblyopic eye will be recommended to patch.
16359478|NCT04261855|Experimental|Arm A|Avelumab plus External Beam Radiation Therapy (EBRT)
16359479|NCT04261855|Experimental|Arm B|Avelumab plus External Beam Radiation Therapy (EBRT)
16359480|NCT04261855|Experimental|Arm C|Avelumab plus Lutetium-177 (177Lu)-DOTATATE
16359481|NCT04261829||Autologous Fat Transfer|
16359482|NCT04261816||Operating room extubation group|extubation in the operating room immediately following liver transplantation
16359483|NCT04261816||ICU extubation group|extubation in the ICU following liver transplantation
16359484|NCT04261803||Familial Hypercholesterolemia children|
16359485|NCT04261803||Control children|
16359486|NCT04261790|Other|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
16359487|NCT04261777|Experimental|SPL-01-001|
16359488|NCT04261764|Experimental|TCM-FMD|"Fasting-Mimicking Diet Combined With a Dispelling Dampness Meal Replacement Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
16359489|NCT04261764|Placebo Comparator|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
16359490|NCT04261751||Clinicians|Physicians, Nurses, or Respiratory Therapists will be taking the Clinician Questionnaire electronically.
16359495|NCT04261686|Other|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
16359496|NCT04261673|Experimental|Decompressive Craniectomy|After the evacuation of epidural hematoma, the bone flap should not be replaced at the end of the operation.
16359497|NCT04261673|Experimental|Craniotomy|After the evacuation of epidural hematoma, the bone flap must be replaced and fixed with an appropriate fixation system.
16359498|NCT04261660||fresh|NO INTERVENTION
16359499|NCT04261660||Frozen embro transfer natural|NO INTERVENTION
16359500|NCT04261660||Frozen embro transfer hormonal|NO INTERVENTION
16359501|NCT04261647|Experimental|Experimental group 1|kinesio- taping technique plus traditional physical therapy program.
16359502|NCT04261647|Experimental|Experimental group 2|Pelvic floor exercise plus traditional physical therapy program.
16359503|NCT04261647|Active Comparator|Control group|traditional physical therapy program in the form of stretching of piriformis, stretching of iliopsoas and clam shell exercise, seat cushioning and seat kitz.
16359504|NCT04261634|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
16359505|NCT04261634|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
16359506|NCT04261595|Active Comparator|Dates group 1|For the group of the date 1, Diagnosed autistic patients will be given three pieces of Dates will be given on daily basis for 12 weeks as follow: Three pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
16359507|NCT04261595|Active Comparator|Dates group 2|For the group of the date 2, Diagnosed autistic patients matched for age and sex will be given five pieces of Dates will be given on daily basis for 12 weeks as follow: five pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
16359508|NCT04261595|Active Comparator|Group 3|Group 3 (no- Dates fruit group): Diagnosed autistic patients matched for age and sex will not receive any dates
16359509|NCT04261582||AERD participants|Participants with aspirin exacerbated respiratory disease. Adults with aspirin allergy, nasal polyps and adult-onset severe asthma.
16359510|NCT04261582||Healthy controls|Healthy participants that do not have asthma.
16359511|NCT04261582||Non-aspirin sensitive asthma participants|Participants with asthma, but that do not have a sensitivity to aspirin.
16359512|NCT04261569|Experimental|Illuminated arm|patients with intraventricular near-infrared light illumination
16359513|NCT04261569|No Intervention|control arm|patients without any medical device
16359514|NCT04261556|Experimental|Real HD-tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal high definition transcranial direct current stimulation (HD-tDCS).
~In the first 20 min of the 40 min-intervention, HD-tDCS and CCT will be provided simultaneously."
16359515|NCT04261556|Sham Comparator|Sham HD-tDCS + CCT|40 min/day of CCT + 20 min/day of apparent (sham) HD-tDCS. In the first 20 min of the 40 min-intervention, HD-tDCS and CCT will be provided simultaneously.
16359516|NCT04261543|Experimental|High Protein and Early Exercise|High protein is defined as a protein prescription of ≥2.2 gram/kg body weight; Early exercise is defined as exercise by using cycle ergometry for 45 minutes per day within 24 hours of randomization
16359517|NCT04261543|Active Comparator|Usual Care|Usual care has a protein prescription of ≤1.2 gram/kg body weight and exercise prescription as per the discretion of attending clinicians
16359518|NCT04261530|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
16359519|NCT04261530|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
16359520|NCT04261530|Experimental|Self-care|It is a 7-months 2 hours-session (1 session per month) of self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
16359521|NCT04261530|Experimental|Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
16359522|NCT04261517|Experimental|Hydroxychloroquine and conventional treatments|After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.
16359523|NCT04261517|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without hydroxychloroquine.
16359524|NCT04261504|Experimental|Integrative Body Mind Training (IBMT)|mindfulness
16359525|NCT04261504|Active Comparator|Relaxation Training (RT)|relaxation
16359526|NCT04261491|Experimental|postmenopausal women with low BMD and chronic periodontitis|postmenopausal women with low BMD and chronic periodontitis will be evaluated after SRP for serum bone resorption markers- CTX and inflammatory markers TNF-α, IL-6
16359527|NCT04261478|Active Comparator|Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be revascularized with a stent during the acute thrombectomy procedure.
16359528|NCT04261478|No Intervention|No Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be not revascularized with a stent during the acute thrombectomy procedure.
16362048|NCT04243980||Group 1|Patients after total hip arthroplasty with short femoral stem
16359529|NCT04261465|Experimental|Paclitaxel Carboplatin Olaparib|"Subjects will receive weekly therapy with paclitaxel 60 mg/m2 IV and carboplatin AUC 2 IV for 3 weeks out of 4, and olaparib tablets at the dose of 150 mg bid administered orally for 3 consecutive days (D1-D3), every week for each cycle.
~After 3 cycles patients will be evaluated for interval debulking surgery. After surgery they will receive consolidation treatment with paclitaxel and carboplatin according to Investigator's choice"
16359530|NCT04261452|Other|COPD|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
16359531|NCT04261452|Other|Overlap|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
16359532|NCT04261439|Experimental|Arm 1|Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)
16359533|NCT04261439|Experimental|Arm 2|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1
16359534|NCT04261426|Experimental|IVIG therapy+ standard care|
16359535|NCT04261426|Placebo Comparator|Standard care|
16359536|NCT04261413|Experimental|RS-0139|There will be only RS-0139 arm in the study.
16359537|NCT04261400|Experimental|MAMAACT|Post graduate training of midwives in intercultural communication and health education materials for the pregnant women.
16359538|NCT04261400|No Intervention|Control|Care as usual
16359539|NCT04261387|Experimental|LUT014 Gel|LUT014 Gel topical application to the dermatitis area qd for 28 days
16359540|NCT04261387|Placebo Comparator|Placebo for LUT014 Gel|
16359541|NCT04261374||Measurement of sublingual microcirculation|
16359542|NCT04261361|Experimental|CBT-AD intervention|"Adherence counseling
~Psycho-education package
~The intervention program consists of three components: 1) eight weekly sessions of face-to-face interventions, 2) four weekly consolidation individual telephone calls and 3) three monthly individual follow-up phone calls."
16359543|NCT04261361|Active Comparator|enhanced treatments usual (ETAU)|"Adherence counseling;
~Psycho-education package;
~To maintain some control over the contact time, we will give them 4 bi-weekly individual phone calls of about 10 minutes each while the CBT-AD intervention group is having their 8 weeks of face-to-face group sessions."
16359544|NCT04261335|Experimental|CL2020 cells|Intravenous injection of CL2020 cells
16359545|NCT04261322|Experimental|rabies patient 1|not received immunoglobulins and symptomatic
16359546|NCT04261322|Experimental|rabies patient 2|received immunoglobulins and symptomatic
16359547|NCT04261322|Experimental|rabies patient 3|not received immunoglobulins and not yet symptomatic
16359548|NCT04261322|Experimental|rabies patient 4|received immunoglobulins and not symptomatic
16359549|NCT04261309||Elderly with back pain in primary healthcare|Consecutive women and men 55 years of age or older who seek primary care (GP, physiotherapist or chiropractor) with a new episode of back pain (preceded by 6 months without visiting a primary care provider for similar complaints)
16359550|NCT04261296|Experimental|Dry needling|Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
16359551|NCT04261296|Experimental|balneotherapy|Arm 2: Balneotherapy A total of 15 sessions, 20 minutes a day, 5 days a week for 3 weeks, will be held in the spa, which operates within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.
16359552|NCT04261296|Experimental|Dry needling + balneotherapy|Arm3: dry needling + balneotherapy Both of these methods will be applied to patients in the third group.
16359553|NCT04261283|Experimental|Circuit Training|Specific exercise are designed in circuit training
16359554|NCT04261283|Active Comparator|Control Group|Conventional treatment
16359555|NCT04261270|Experimental|ASC09F+Oseltamivir|
16359556|NCT04261270|Experimental|Ritonavir+Oseltamivir|
16359557|NCT04261270|Experimental|Oseltamivir|
16359558|NCT04261257|Experimental|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a serum pregnancy test for women of childbearing age, a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of your care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks (CT scan of the cerebral arteries), a transcranial Doppler, a biological assessment, a 24-hour holter or long-term holter.
~Within 24 hours after admission: The cerebral artery scan, (usual care), is carried out and is supplemented by the additional examination of this research corresponding to a cardiac scanner (not requiring additional injection of contrast medium).
~The following examinations of usual care are carried out within 3 days of inclusion: a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care."
16359559|NCT04261244|Experimental|Experimental Arm|preoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
16359560|NCT04261244|Active Comparator|Standard treatment|standard treatment (postoperative radiotherapy) in breast cancer after neoadjuvant chemotherapy
16359635|NCT04260711|No Intervention|Continuation of DMT|Continuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
16359821|NCT04259411|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
16359561|NCT04261218|Experimental|Group 1 - Dose Finding|The first 3 patients enrolled in Group 1 will receive tomivosertib at a dose of 100 mg orally twice daily (BID), under fasting conditions, and will be assessed for dose limiting toxicities (DLTs) during this 'run-in' period. They will also receive the first cycle of tomivosertib IN COMBINATION with weekly paclitaxel in the 'post run-in' period. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2 (detailed in the arm below).
16359562|NCT04261218|Experimental|Group 2 - Dose Expansion|It is anticipated that Group 2 patients will receive tomivosertib at a dose of 100 mg orally twice daily (BID) during the 'run-in' period, which is taken in combination with weekly paclitaxel (according to market label) during the 'post run-in' period.
16359563|NCT04261179|Other|Lymphoseek + Nanocoll|Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
16359564|NCT04261166|Experimental|BOL-PK-ST-02F|Sublingual tablets
16359565|NCT04261166|Experimental|BOL-PK-ST-02E|Sublingual tablets
16359566|NCT04261166|Experimental|B3 is BOL-PK-ST-02D|Sublingual tablets
16359567|NCT04261166|Experimental|BOL-PK-ST-02A|Drops
16359568|NCT04261166|Experimental|BOL-PK-ST-02C|Drops
16359569|NCT04261166|Experimental|BOL-PK-ST-02B|Drops
16359570|NCT04261153|Other|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
16359571|NCT04261140|Experimental|High-viscosity glass ionomer|
16359572|NCT04261140|Experimental|flowable composite|
16359573|NCT04261140|Experimental|bulkfill composite|
16359574|NCT04261140|Experimental|nanohybrid composite|
16359575|NCT04261127|Experimental|experimental arm|"The analysis of phenotypic data in RADIAL and the analysis of DNA (analysis of the Friedreich gene ± PMDA panel) will be performed for all patients in order to meet the main objective and the secondary objectives.
~Specifically for the secondary objectives (N ° 3, 4 and 5), randomization via eCRF (electronic case report form) will be performed for the interpretation of genetic analyzes (PMDA panel) without inducing any change for the patients. This randomization, by block and by center, will allow the attribution of one of the following two groups:
~Control group: interpretation of genetic analyzes without the use of RADIAL;
~Experimental group: interpretation of genetic analyzes using RADIAL. Exome analysis (secondary objective n ° 6) will be carried out for all the patients who remained without diagnosis at the end of the first part, and for whom the DNA of relatives is available."
16359576|NCT04261101|Experimental|Block A|Test intervention with questions regarding diabetes and adrenal
16359577|NCT04261101|Active Comparator|Block B|Test intervention with questions regarding thyroid and hypophysis
16359579|NCT04261075|Experimental|IPH5201 monotherapy dose escalation|IPH5201 monotherapy
16359580|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab|IPH5201 plus durvalumab
16359581|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab + oleclumab|IPH5201 plus durvalumab and oleclumab
16359582|NCT04261062||Subject|Patients in surgical intensive unit
16359583|NCT04261049|Experimental|ZILRETTA Injection|All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.
16359584|NCT04261036|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1g of vitamin C for 14 days.
16359585|NCT04261036|Placebo Comparator|Women on a placebo regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take placebo for 14 days
16359586|NCT04261023|Experimental|Abatacept|Treatment arm - 125mg sub-cutaneous injection at week 0 and once weekly thereafter for a maximum of 48 weeks
16359587|NCT04261023|No Intervention|Control arm - CCP Next Generation|Observational study cohort - usual care
16359588|NCT04261010|Experimental|Ustekinumab|Group 1 (n=12): ustekinumab 45 mg (or 90 mg for patients > 100 kg) subcutaneously at baseline (W0), 4 weeks later (W4), and every 12 weeks until week 24 (i.e. W0, W4, and W16).
16359589|NCT04261010|Experimental|Guselkumab|Group 2 (n=12): guselkumab 100 mg subcutaneously (regardless of the weight of the patient) at weeks 0 and 4, followed by a maintenance dose every 8 weeks through week 24 (i.e. W0, W4, W12 and W20).
16359590|NCT04261010|Active Comparator|ADALIMUMAB|Group 3 (n=12): adalimumab 40 mg (regardless of the weight of the patient), subcutaneously every other week, starting from the baseline until week 24 (i.e.W0, W2, W4, W6, W8, W10, W12, W14, W16, W18, W20 and W22).
16359591|NCT04260997|Experimental|Oral Probiotic Product|
16359592|NCT04260997|Placebo Comparator|Placebo product|
16359593|NCT04260984|Active Comparator|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
16359594|NCT04260984|Active Comparator|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
16359595|NCT04260971|Experimental|Cyclical Stimulation|This group will undergo cyclical stimulation mode of stimulation
16359596|NCT04260971|Active Comparator|Continuous Stimulation|This group will undergo the standard continuous mode of stimulation
16359636|NCT04260698|Experimental|omidubicel|"Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:
~Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))
~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.
~Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation."
16359597|NCT04260958|Experimental|Intervention center|Patients at intervention centers will be offered remote video exCR (first-hand option) or usual care centre-based exCR. The exercise program (remote/centre-based) will be standardized and performed for totally 60 minutes, 2 times a week for 3 months. Exercise will be individually prescribed and progressed by physiotherapists in accordance with guidelines. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
16359598|NCT04260958|No Intervention|Control|At control centers, patients will be offered usual care centre-based exCR only.
16359599|NCT04260945|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
16359600|NCT04260932|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
16359601|NCT04260919|No Intervention|Control|The participants just received standard medical treatment
16359602|NCT04260919|Experimental|Intervention|The participants received medical treatment and chest physiotherapy sessions
16359603|NCT04260906|Active Comparator|Vagus nerve stimulation|Patients were admitted to the treatment as day visitors. Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears . The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
16359604|NCT04260906|Active Comparator|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
16359605|NCT04260893|Experimental|Tixel Treatment|3 Tixel treatment sessions, 2 weeks apart follow by 3 Follow up sessions
16359606|NCT04260880||Test group 1|individuals with mild depression
16359607|NCT04260880||Test group 2|individuals with moderate depression
16359608|NCT04260880||control group|systemically healthy individuals
16359609|NCT04260867|Experimental|Aromatherapy|
16359610|NCT04260867|Sham Comparator|Sham|
16359611|NCT04260854|Active Comparator|Bupivacaine HCl|Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.
16359612|NCT04260854|Placebo Comparator|Saline|Immediately prior to surgical wound closure, participants randomized to saline, will receive saline injections along the closure site.
16359613|NCT04260828|Active Comparator|Aspirin|
16359614|NCT04260828|Placebo Comparator|Placebo (sugar pill)|
16359615|NCT04260815|Experimental|anodal tDCS on the left inferior frontal gyrus (IFG)|
16359616|NCT04260815|Experimental|anodal tDCS on the right IFG|
16359617|NCT04260815|Sham Comparator|sham tDCS|
16359618|NCT04260802|Experimental|Drug: Dose Escalation|Escalating doses of OC-001 administered intravenously (IV)
16359619|NCT04260802|Experimental|Drug: Combination: Tumor Type 1|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
16359620|NCT04260802|Experimental|Drug: Combination: Tumor Type 2|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
16359621|NCT04260789|Other|Treatment|Treatment with Seraph Filter
16359622|NCT04260789|No Intervention|Control|
16359623|NCT04260776|Experimental|Phase 1|Participants will be randomly assigned to one of the two text message programs that correspond with the web-based intervention (MyWebQuit): 1) standard, 1-way text messages, or 2) interactive, 2-way text messages
16359624|NCT04260776|Experimental|Phase 2|"For the first 5 weeks after randomization, engagement with the website will be monitored. Participants who continue to engage with the website will continue with the same Phase 1 treatment components until the 3-month follow-up.
~Participants who disengage with the website will be randomly assigned to receive one of three re-engagement strategies: 1) interactive, re-engagement text messages, 2) re-engagement email, or 3) no re-engagement strategy"
16359625|NCT04260763|Experimental|Social Cognition Group|Social Cognition Group
16359626|NCT04260750|Experimental|Expert-chosen content, regular guidance|Content chosen by the therapist, weekly guidance by a therapist.
16359627|NCT04260750|Experimental|Expert-chosen content, on-demand guidance|Content chosen by the therapist, guidance upon request from the health care team.
16359628|NCT04260750|Experimental|Participant-chosen content, regular guidance|Content chosen by participants themselves, weekly guidance by a therapist.
16359629|NCT04260750|Experimental|Participant-chosen content, on-demand guidance|Content chosen by participants themselves, guidance upon request from the health care team.
16359630|NCT04260737|No Intervention|Standard Care|The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.
16359631|NCT04260737|Experimental|Decision Aid + Standard Care|"The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:
~An overview about prostate cancer;
~An overview of different treatment options (e.g. surgery and active surveillance)
~The pros and cons of different treatment options (e.g., physical, emotional, social).
~A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option."
16359632|NCT04260724|Active Comparator|TMS group|Transcranial magnetic stimulation for four weeks
16359633|NCT04260724|Sham Comparator|Sham group|sham coil stimulation for four weeks (Although the sound of sham coil is the same to that of real TMS during intervension, no stimulation is applied. )
16359634|NCT04260711|Experimental|Discontinuation of DMT|Discontinuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
16359637|NCT04260685|Active Comparator|lidocaine|the Patient will receive IV bolus of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h
16359638|NCT04260685|Active Comparator|esmolol|the Patient will receive IV bolus of esmolol 0.5 mg/kg over ten minutes followed by continuous infusion of 100-300 ug/kg/min
16359639|NCT04260672|Experimental|Child-Centred Health Dialogue (CCHD)|The intervention CCHD consists of two parts 1) a universal Child Centred Health Dialog by the CHS-nurse directed in the first place to all 4-year-olds and their families (10 minutes) and 2) a targeted Family Guidance by the CHS-nurse to families where a child is identified with overweight at the age of 4 (60 minutes). All children invites to their regular 5-yrs health visit.
16359640|NCT04260672|No Intervention|usual care|Usual care for preschool children identified with overweight and obesity Usual care is performed according to national guidelines that invites all 4-year-olds to a '4-years health visit' including a health conversation. A survey on usual care in the case of identified overweight initial to this study among almost all nurses working at the participating CHCs showed that two thirds of questioned CHS-nurses used to invite families in which the child is identified with overweight for 1 or 2 extra visits outside the usual program. The majority o referred children to a dietician, or to another caregiver. All children invites to their regular 5-yrs health visit.
16359641|NCT04260659|Active Comparator|Opioid liberal group|
16359642|NCT04260659|Experimental|Opioid free group|
16359643|NCT04260646|Active Comparator|Standard Urotherapy without enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch.
16359644|NCT04260646|Experimental|Standard Urotherapy with enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch. In addition an enuresis alarm will be provided and worn by the participants during the night.
16359645|NCT04260633|No Intervention|Group 1|22-hour tray wear time, DM assisted aligner change frequency
16359646|NCT04260633|Active Comparator|Group 2|22-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
16359647|NCT04260633|Sham Comparator|Group 3|22-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
16359648|NCT04260633|Active Comparator|Group 4|12-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
16359649|NCT04260633|Sham Comparator|Group 5|12-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
16359650|NCT04260607|Experimental|Experimental-Ketamine|single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes
16359651|NCT04260607|Placebo Comparator|Placebo-Saline|100ml Normal Saline infused over 40 minutes
16359652|NCT04260594|Experimental|Arbidol tablets + basic treatment|
16359653|NCT04260594|Sham Comparator|basic treatment|
16359654|NCT04260581|Experimental|PD patients who have taken amantadine|
16359655|NCT04260568||Persistent Postural Perceptual Dizziness|Semi-structured interviews
16359656|NCT04260555|Experimental|TEST|tid PO, DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml
16359657|NCT04260555|Active Comparator|Reference 1|tid PO, Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml
16359658|NCT04260555|Active Comparator|Reference 2|tid PO, Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml
16359659|NCT04260542|Active Comparator|FAST Lean|Short-term fasting (FAST), comparator group of lean subjects
16359660|NCT04260542|Experimental|FAST Obese|Short-term fasting (FAST), experimental group of obese subjects
16359661|NCT04260542|Experimental|KETO Obese|Medium-term ketogenic diet intervention (KETO), experimental group of obese subjects
16359662|NCT04260529|Experimental|Arm A|"Phase I of the trial, dose escalation, safety and tolerability will be documented and the MTD/RP2D will be determined. Cohorts of 3 subjects (in total 12 subjects) will receive IT injections with CyPep-1 by intratumoral injection at Day 1 of weeks 1, 3 and 5.
~In Phase IIa of the trial, dose expansion, the safety and tolerability will be further evaluated in an expanded cohort of 9 subjects at the RP2D of CyPep-1, determined in Phase I. CyPep-1 administration is planned as Q2W injections"
16359663|NCT04260529|Experimental|Arm B|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 15 subjects in total, using a staggered approach. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
16359664|NCT04260529|Experimental|Arm C|The safety and tolerability of at least two dose levels of CyPep-1, the RP2D and the dose immediately below that, are planned to be evaluated when CyPep-1 is administered intratumorally to a metastatic lesion in the liver. CyPep-1 administration is planned as Q2W injections.
16359665|NCT04260516|Active Comparator|N-acetylcysteine group|Patients received oral n-acetylcysteine syrup on dose of 10 mg/kg/day as single dose for 3 months
16359666|NCT04260516|No Intervention|Non n-acetylcysteine group|Thalassemia major patients on regular chelation therapy who didn't receive n-acetylcysteine and served as controls
16359667|NCT04260503||Biliary Atresia|Disease group
16359668|NCT04260503||Choledochal cyst|Disease control
16359669|NCT04260503||Neonatal hepatitis|Disease control
16359670|NCT04260503||Healthy baby|Healthy control
16359671|NCT04260490||Cases|"Cases will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected.
~Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
16359672|NCT04260490||Controls|"Controls selected after stratification on department of residence, sex and age of the cases and who give a written informed consent to participate.
~Controls will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses in both cases and controls. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
16359673|NCT04260477|Experimental|6EH³R3Z|(Rifampicin (R)/ Isoniazid (H) / Pyrazinamide (Z)/Ethambutol (E)) 6-month high-dose treatment; New high-dose isoniazid / high-dose rifampicin retreatment regimen (6EH³R3Z) - that includes triple-dose rifampicin (R3; 30 mg/kg), and triple-dose isoniazid (H3; 15 mg/kg), complemented with pyrazinamide (Z) and ethambutol (E).
16359674|NCT04260477|Active Comparator|6EHRZ|Standard of care: 6-month 6RHZE regimen with dose combination tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E)
16359675|NCT04260464|Experimental|PF-06700841 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
16359676|NCT04260464|Experimental|PF-06700841 Normal Renal Function|This arm includes participants with normal renal function who will receive a single oral dose of 30 mg PF-06700841 on Day 1
16359677|NCT04260464|Experimental|PF-06700841 Moderate Renal Impairment|This arm includes participants with moderate renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
16359678|NCT04260464|Experimental|PF-06700841 Mild Renal Impairment|This arm includes participants with mild renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
16359679|NCT04260451|Experimental|Driving pressure group|Positive end expiratory pressure is adjusted to tidal volume of 5 mL/kg of ideal body weight, inspiratory:expiratory=1:2, and minimize driving pressure (plateau pressure minus end expiratory pressure) during one-lung ventilation. Other procedures are same with the control arm.
16359680|NCT04260451|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 5mL/kg of ideal body weight and positive end expiratory pressure of 5cmH2O during one-lung ventilation
16359681|NCT04260438|Experimental|Group 1|"Period 1: Treatment A
~Period 2: Treatment B
~Period 3: Treatment C"
16359682|NCT04260438|Experimental|Group 2|"Period 1: Treatment A
~Period 2: Treatment C
~Period 3: Treatment B"
16359683|NCT04260438|Experimental|Group 3|"Period 1: Treatment B
~Period 2: Treatment A
~Period 3: Treatment C"
16359684|NCT04260438|Experimental|Group 4|"Period 1: Treatment B
~Period 2: Treatment C
~Period 3: Treatment A"
16359685|NCT04260438|Experimental|Group 5|"Period 1: Treatment C
~Period 2: Treatment A
~Period 3: Treatment B"
16359686|NCT04260438|Experimental|Group 6|"Period 1: Treatment C
~Period 2: Treatment B
~Period 3: Treatment A"
16359687|NCT04260425|Experimental|High then low avenanthramides content oats|This arm will receive the high avenanthramides content oatmeal at the first session and the low avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
16359688|NCT04260425|Experimental|Low then high avenanthramides content oats|This arm will receive the low avenanthramides content oatmeal at the first session and the high avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
16359689|NCT04260412|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO membrane, then dialysis for 4 weeks with MCO membrane and increased fiber intake
16359690|NCT04260412|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
16359691|NCT04260399|Experimental|Lavender Aromatherapy|Passive exposure via an ambient essential oil diffuser to lavender aromatherapy
16359692|NCT04260399|Placebo Comparator|Placebo Aromatherapy|Passive exposure via an ambient essential oil diffuser to saline water aromatherapy
16359693|NCT04260386||Staff receiving the MOMS training|Delegates taking part in the routine Multidisciplinary Obstetric and Midwifery Simulation (MOMS) training course at the Chelsea and Westminster Hospital.
16359694|NCT04260373|Experimental|[14C]SHR4640|Patients will receive single dose of [14C]SHR4640 (Suspension, 10mg/80μCi).
16359695|NCT04260360|Experimental|NanoDoce|Intratumoral injection of NanoDoce (2.0 to 6.0 mg/mL) at a volume not to exceed 5.0 mL. NanoDoce will be administered on up to two occasions with at least 4 weeks between doses.
16359696|NCT04260347||Patients >80 years after approval|
16359697|NCT04260347||Patients >80 years before approval|
16359698|NCT04260334|Experimental|Intervention Group|
16359699|NCT04260334|No Intervention|Control Group|
16359700|NCT04260321||AI|Artificial intelligence colonoscopy
16359701|NCT04260321||Control|White light colonoscopy
16359702|NCT04260308||residents|"Voluntary residents
~Can use mobile phone or computer"
16359703|NCT04260308||medical staff|"Voluntary residents
~Can use mobile phone or computer"
16359704|NCT04260282||Neutrophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils <300/mm3 in blood and <3% in induced sputum
16359705|NCT04260282||Eosinophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils >300/mm3 in blood and/or >3% in induced sputum
16359706|NCT04260243|Sham Comparator|Sham Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + sham Myofascial Release
16359707|NCT04260243|Experimental|Experimental-Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + Myofascial Release
16359708|NCT04260230|Experimental|Lifetemp/Lifetouch sensors|Participants will be asked to wear the sensors for six weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care in any way.
16359709|NCT04260217|Experimental|APG2575 400 mg|APG2575 400mg ramp up arm
16359710|NCT04260217|Experimental|APG2575 600 mg|APG2575 600 mg ramp up arm
16359711|NCT04260217|Experimental|APG2575 800 mg arm|APG2575 800 mg arm ramp up
16359712|NCT04260204|Active Comparator|Retrograde priming|retrograde autologous Blood Priming of Cardiopulmonary Bypass (RAP) in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
16359713|NCT04260204|Active Comparator|conventional priming|conventional cardiopulmonary priming in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
16359742|NCT04260009|Experimental|Ph 2:Brigatinib (Unresectable/Recurrent ALK+ IMT) Participants|Brigatinib recommended phase 2 dose (RP2D) determined during phase 1, tablet or AAF orally QD in participants with Unresectable/ Recurrent ALK+ IMT for up to 2 years in dose expansion phase.
16359716|NCT04260178|Experimental|Experimental groups|For the experimental group, EBIP was implemented in three stages:(1) hospital training;(2) home visits + training, which includes motivational interventions that facilitate chronic disease self-care and symptom management with nurse-patient cooperation; and (3) telephone follow-ups and assistance. A handbook was developed in line with the relevant literature and input from two specialist physicians (1,17-20). The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior. The trainings sessions were conducted in a hospital seminar room using PowerPoint presentations. Afterward, patients were asked to demonstrate what they learned, and the parts that were not clear were explained again. The training was concluded after deciding for the first home visit appointment. For patients that could not effectively use the handbook, a close relative was included to all steps of the study.
16359717|NCT04260178|Other|Control groups|Control groups were evaluated with an introductory survey form, PFT, BDI, BMI and SCMP-G scales before and after the study. There were no additional interventions to the control group.
16359718|NCT04260165|Experimental|Proximal Row Carpectomy|
16359719|NCT04260165|Active Comparator|Four-corner fusion|
16359720|NCT04260152|Active Comparator|Control: CAF + CTG|Following root preparation and conditioning, the CTG is obtained from the palate according to the randomization scheme and shaped to the recipient site and may be sutured to the papilla region and the coronally advanced flap (CAF) is sutured into place.
16359721|NCT04260152|Experimental|Test: CAF + Geistlich Fibro-Gide® (test)|Following root preparation and conditioning, Geistlich Fibro-Gide® is cut to size and shaped to the recipient and may be sutured and the coronally advanced flap (CAF) is sutured into place.
16359723|NCT04260113|Experimental|Apatinib Arm|
16359724|NCT04260100|Experimental|Intervention Group|
16359725|NCT04260100|No Intervention|Control Group|Routine care group
16359726|NCT04260087||New Daily Persistent Headache|"This cohort will consist of participants diagnosed with New Daily Persistent Headache (NDPH). New daily persistent headache (NDPH) is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. The headache is daily and unremitting from very soon after onset (within 3 days at most), usually in a person who does not have a history of a primary headache disorder.
~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
16359727|NCT04260087||Chronic Migraine|"This cohort will consist of participants diagnosed with chronic migraine. Chronic migraine is defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache. Chronic migraine occurs in approximately 1% of the population. Studies estimate that about 2.5% of people with episodic migraine will transition to chronic migraine each year.
~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
16359728|NCT04260087||Healthy Volunteers|"This cohort will consist of healthy volunteers who have not been diagnosed with either NDPH or chronic migraine.
~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
16359729|NCT04260074||Oral Cancer group|20 consecutive patients with oral squamous cell carcinoma referred to the Department of Otolaryngology - Head and Neck Surgery
16359730|NCT04260074||Healthy oral mucosa group|20 controls with normal buccal mucosa upon examination.
16359731|NCT04260061|Experimental|exoskeleton group|The Hand of Hope therapy device will be used in this group. The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
16359732|NCT04260061|Experimental|end effector group|The Amadeo Hand-Therapy-System will be used in this group. The Amadeo is a mechatronic rehabilitation device that allows each individual finger to move independently and separately. The main target group are patients suffering from functional motor disabilities of the distal upper extremity. The Amadeo consists of the electrically driven moment mechanism, a supportive framework which is adjustable in height and includes a hand-arm support, and a control and operating unit (all-in-one PC). The finger slides can produce flexion/extension movement of the fingers and the thumb. The fingers and the thumb of the affected hand are attached to the slides and then passive, assistive, active or interactive therapy regime can be started. The integrated sensors for force and position measurement enable quantitative recording and evaluation of the finger range of movement and force.
16359733|NCT04260048||Normal weight|Group defined based on BMI percentile for age and sex.
16359734|NCT04260048||Overweight|Group defined based on BMI percentile for age and sex.
16359735|NCT04260048||With obesity|Group defined based on BMI percentile for age and sex.
16359736|NCT04260035|Active Comparator|Vasoactive Intestinal Polypeptide (VIP)|"Intravenous infusion of 8 pmol/Kg/min of Vasoactive Intestinal Polypeptide (VIP).
~The infusion is administered at constant speed by an automatic pump, lasting 120 minutes."
16359737|NCT04260035|Placebo Comparator|Sterile, isotonic, non-active saline (Placebo)|Intravenous infusion of sterile, isotonic, non-active saline 9 mg/ml (placebo). The infusion is administered at constant speed by an automatic pump, lasting 120 minutes.
16359741|NCT04260009|Experimental|Phase 1: Brigatinib|Brigatinib tablet or age-appropriate formulation (AAF), orally once daily in 28-day Cycles with reference to adult dose of 90 mg in Week 1 and 180 mg starting in Week 2 based on participant's weight as dose level 1. Participants could receive dose level 2 based on safety and tolerability of dose level 1 in dose escalation phase (Ph).
16359743|NCT04260009|Experimental|Ph 2 :Brigatinib (Relapsed/Refractory ALK+ ALCL) Participants|Brigatinib RP2D determined during phase 1, tablet or AAF orally QD in participants with Relapsed/ Refractory ALK+ ALCL for up to 2 years in dose expansion phase.
16359744|NCT04259996||MODIFIED NATURAL CYCLE|"The term 'modified natural cycle' refers to a natural cycle in which ovulation is triggered by exogenous hCG administration in order to provide optimal timing scheduling embryo transfer. In contrast to the natural cycle, the applied hCG may lead to a different luteal phase profile. Luteal phase support is common clinical practice in those cycles.
~On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.
~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
16359745|NCT04259996||STIMULATED CYCLE|"On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.
~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
16359746|NCT04259983||Patients with CF with normal obstruction severity|In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
16359747|NCT04259983||Patients with CF with mild obstruction severity|In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
16359748|NCT04259983||Patients with CF with moderate obstruction severity|In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
16359749|NCT04259970|Experimental|Phase 1|Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).
16359750|NCT04259970|Experimental|Initiation of CFTR Modulator|Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.
16359751|NCT04259957||Clinician using Virtual Reality in Pain Management Program|Clinicians who have used immersive virtual reality as part of Pain Management program group.
16359752|NCT04259944|Experimental|Liquid Biopsy-Guided Adjuvant Treatment|"A post-surgical LB executed 2-4 weeks after surgery will guide a Molecular Adjuvant treatment:
~ctDNA+ patients: CAPOX for 3 months
~ctDNA- patients: capecitabine (CAPE) for 6 months. LB after 1 cycle and if found ctDNA+ will be switched to CAPOX.
~A post-Molecular Adjuvant treatment LB will be performed and instruct subsequent treatment:
~ctDNA+/+ patients: up-scale to a Molecular Metastatic treatment with FOLFIRI for 6 months or until radiological progression or toxicity;
~ctDNA-/+ patients: up-scale to a Molecular Metastatic treatment with CAPOX for 6 months or until radiological progression or toxicity. LB after 3 months at the end of treatment and in case of positivity switch to FOLFIRI.
~ctDNA+/- patients: de-escalate treatment to CAPE for 3 months. 3 LB performed within 3 months and in case of positivity switch to FOLFIRI.
~ctDNA-/- patients: interventional follow-up comprising 2 further LB and in case of positivity switch to CAPOX treatment."
16359753|NCT04259931||No relapses|Patients with clostridium difficile infections without relapses
16359754|NCT04259931||Relapsing patiens|Patients with clostridium difficile infections with relapses
16359755|NCT04259918|Experimental|Control|no applying alveolar recuritment maneuver
16359756|NCT04259918|Active Comparator|Low ARM|Applying 30 cmH2O of alveolar recruitment maneuver 5 times every 5sec
16359757|NCT04259918|Active Comparator|High ARM|Applying 60 cmH2O of alveolar recruitment maneuver 5 times every 5sec
16359760|NCT04259879|Experimental|Fasting|The participants will follow a short-term fasting period for 36 hours
16359761|NCT04259853|Experimental|QFR-guided PCI group|QFR-guided revascularization on non-culprit vessels in patients with STEMI
16359762|NCT04259853|Active Comparator|CAG-guided PCI group|CAG-guided revascularization on non-culprit vessels in patients with STEMI
16359763|NCT04259840||Peri-implantitis|Patients who underwent resective surgical treatment for peri-implantitis at the University of Michigan Graduate Periodontics clinic from January 1, 1990 through July 1, 2018
16359764|NCT04259827|Experimental|Online cognitive training|6-week online personalized cognitive training using Neuronation platform 4 training session three times a week. Each session is composed of 5 exercises from one out of 4 cognitive domains: Memory, Attention, Speed and Reasoning
16359765|NCT04259827|Active Comparator|Aspecific online games|online application not created with a cognitive training purpose, for the same amount of time and frequence as the experimental group
16359767|NCT04259814|Experimental|Speech-Language Treatment plus mCIMT|"4 participants
~Baseline phase: Speech-language treatment (SLT), 1 hour a day, 3 days a week. The length of the baseline phase will be staggered across subjects.
~Treatment phase: SLT combined with modified constraint-induced movement therapy(mCIMT) 1 hour a day, 3 days a week.
~Total of baseline and treatment sessions will be 20 to 30 sessions."
16359768|NCT04259801|Experimental|NNC0480-0389 and semaglutide|"Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
~Part 2: 12 subjects will receive 4 doses of s.c. NNC0480-0389 co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c semaglutide."
16359769|NCT04259801|Experimental|NNC0480-0389 and placebo (semaglutide)|"Part 1: 4 subjects will receive a single dose of s.c. NNC0480-0389 co-administered with semaglutide placebo.
~Part 2: 4 subjects will receive 4 doses of s.c. NNC0480-0389, co-administered with semaglutide placebo after 8 weeks of dosing with semaglutide placebo."
16359770|NCT04259801|Active Comparator|Placebo (NNC0480-0389) with semaglutide|"Part 1: 2 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with s.c. semaglutide.
~Part 2: 4 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c. semaglutide"
16359771|NCT04259801|Placebo Comparator|Placebo (NNC0480-0389) with placebo (semaglutide)|"Part 1: 3 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with semaglutide placebo.
~Part 2: 2 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with semaglutide placebo, after 8 weeks of dosing with semaglutide placebo."
16359772|NCT04259788|Experimental|Intervention|The intervention group will receive in-person dietary counseling from a registered dietitian to help participants consume a diet that is consistent the AHEI dietary guidelines. Participants in this arm will be asked to consume this diet for a 12-week period and discontinue any vitamin or supplement intake during this time. During the first 4 weeks 2 meals and 1 snack/day will be shipped to the participant. During the last 8 weeks of the intervention, the study will provide the participants with a 14-day meal plan (3 meals and 2 snacks) that adheres to the AHEI maximum score criteria to help facilitate adherence to the diet.
16359773|NCT04259788|No Intervention|Control|Participants in this arm will not receive the dietary intervention.
16359774|NCT04259775|Active Comparator|Automated Insulin Dose Adjustment (AIDA)|Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
16359775|NCT04259775|Active Comparator|Control|Standard Care - change in therapy settings effected a regularly scheduled patients visits
16359776|NCT04259762|Experimental|Breast, Colorectal, and Cervical Cancer Screening|The investigators will train Community Health Representatives (CHRs) in interactive group discussions techniques. CHRs will administer 1 session/week, lasting approximately 2 hours, and conducted among 12 men or women ages 21-75 per cluster. The CHRs will distribute the cancer-specific (i.e., breast, colorectal, and cervical) small media during the first session and refer to it during the course of the 4 sessions. During the sessions, the CHRs will function as a facilitator linking information with practical skills. At the end of the 4-week INT, participants will receive a voucher to present to a designated point-person at the health center who would schedule the screening for the age- and gender-specific cancers.
16359777|NCT04259762|No Intervention|Control|Historical control
16359778|NCT04259749|Active Comparator|Status Quo|The StoreLab power wall will display all tobacco products.
16359779|NCT04259749|Experimental|Flavors Banned|The StoreLab will display tobacco products without characterizing flavors, but will allow mint and menthol products to be displayed.
16359780|NCT04259749|Experimental|Flavors and Menthol Banned|The StoreLab will display only tobacco products without characterizing flavors; mint and menthol will not be displayed.
16359781|NCT04259723|Experimental|Intervention|
16359782|NCT04259723|No Intervention|Control|
16359783|NCT04259710|Placebo Comparator|Pedometer only|participants will be given a pedometer and instructed how to use it, but will not participate in the goal setting intervention.
16359784|NCT04259710|Active Comparator|Pedometer and intervention|participants will be given a pedometer and participate in a weekly goal setting meeting with the investigator and will receive weekly tips.
16359785|NCT04259710|Experimental|Pedometer, intervention and implementation intentions|participants will be given a pedometer and participate in the weekly goal setting as above. In addition, 3 times during the intervention they will fill out a form that encourages performance of implementation intentions.
16359786|NCT04259697|Experimental|Clinical pilates|Exercises will be performed two times per week for twelve weeks.
16359787|NCT04259697|Experimental|Whole body vibration|Exercises will be performed two times per week for twelve weeks.
16359788|NCT04259684|Experimental|gNO Group|Participants in the treatment group will receive gNO added to the oxygenator gas flow at 20 ppm throughout the duration of cardiopulmonary bypass.
16359789|NCT04259684|No Intervention|Control Group|Participants in the control group will receive standard conduction of cardiopulmonary bypass.
16359790|NCT04259671|Experimental|Intervention- My Autism Passport App|"Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. The contact information for a member of the research team who will be able to provide technical support will be available on the consent form. Families will use the mobile application for a total of 18 months.
~Given that this is a pragmatic trial of a tool that tracks services, it also may be used to communicate service access to other providers."
16359791|NCT04259671|No Intervention|Control-Standard of care|Families in the control group will continue with standard of clinical care, and receive any of the usual supports their clinic and region provides, including access to physicians, service navigators, social workers, nurses, etc.
16359792|NCT04259658|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for cutaneous metastases.
16359793|NCT04259645|Active Comparator|Low Volume group|30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each block of 0.375% Bupivacaine x 20 ml
16359794|NCT04259645|Experimental|High Volume group|30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each block of 0.375% Bupivacaine x 20 mL + Normal Saline Solution 20 mL
16359822|NCT04259398|Experimental|TIVA|propofol infusion targeting bispectral index 40-60
16359823|NCT04259398|Active Comparator|inhalation (Sevoflurane)|sevoflurane targeting bispectral index 40-60
16359795|NCT04259632|Experimental|Time Restricted Eating (TRE)|For the TRE group, we will restrict the eating window to 8 hours, where they will eat ad libitum. This is the same interval established by Dr. Panda and by our preliminary data. This interval will be entered into the mCC app and participants will be asked to adhere to this eating window during the intervention. All eating occasions will be logged using the mCC app. Only water and medications will be allowed outside of the eating window.
16359796|NCT04259632|Active Comparator|Caloric Restriction (CR)|Participants randomized to CR will meet with the study dietitian prior to the intervention and be counseled on options to reduce their caloric intake by 15%, while maintaining their eating window. The 15% reduction was selected as our preliminary data and recent literature suggest that TRE with ad libitum intake reduces caloric intake by ~270 to 300 cal/day. The 15% CR is similar to the 11.9% CR achieved by the CALERIE-2 study, which is a 2 year study of CR.26 All eating occasions will be logged using the mCC app. The weekly dietitian review of the mCC information will include maintenance of the eating window and examination of dietary intake to determine compliance with the 15% CR.
16359797|NCT04259632|No Intervention|Unrestricted Eating (non-TRE)|For the unrestricted eating (non-TRE) group, participants will eat ad libitum per their usual habits. They will receive initial counseling about mCC logging. All eating occasions will be logged using the mCC app.
16359798|NCT04259619|Experimental|Low-Level Laser Therapy|During 2-3 days this group receives three low-level laser therapy (LLLT) treatments with the Soft Power Laser carried out by a specially trained breastfeeding consultant.
16359799|NCT04259619|Placebo Comparator|Placebo Therapy|During 2-3 days this group receives three placebo treatments with an identically looking laser, which in contrast submits only red colored light. The therapy is also carried out by a specially trained breastfeeding consultant.
16359800|NCT04259606|Active Comparator|Cassia Cinnamon|Cassia cinnamon, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
16359801|NCT04259606|Placebo Comparator|Calcined Magnesia|Placebo consists in calcined magnesia, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
16359802|NCT04259593|Experimental|Exercise Training Group|Exercise training group performed three weekly sessions for 16 weeks. This program consisted of moderate intensity aerobic, resistance, balance, and stretching exercises. The duration of every exercise session was 35 minutes during the first week and 65 minutes from the second week onward.
16359803|NCT04259593|No Intervention|Control Group|The control group received usual lymphoma care
16359804|NCT04259567|Active Comparator|Filter|Patients with CytoSorb absorber
16359805|NCT04259567|No Intervention|Control|Patients without CytoSorb absorber
16359806|NCT04259554|Experimental|OFC rTMS|repetitive transcranial magnetic stimulation
16359807|NCT04259528|Experimental|Patients with esophageal stricture following surgical repair|Patients with esophageal atresia following surgical repair who developed an esophageal stricture
16359808|NCT04259515|Active Comparator|Bukcberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
16359809|NCT04259515|Experimental|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
16359810|NCT04259502|Experimental|RIB Group|A single injection Rhomboid intercostal block will be performed under ultrasound guidance
16359811|NCT04259502|Active Comparator|ESP Group|A single injection Erector spinae plane block will be performed under ultrasound guidance
16359812|NCT04259489|No Intervention|Traditional therapy group|All patients in the control group will receive routine diabetes management, including lifestyle education, health guidance, blood glucose monitoring and medicine adjustment and other treatments which conducted by the endocrinology medical team. After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
16359813|NCT04259489|Active Comparator|Shared Care group|The Patients download the Shared Care mobile application and connect with the smart-glucometer BG1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
16359814|NCT04259476|Active Comparator|group A|WIll be given low dose perioperative ketamine infusion, as well as a ketamine bolus at start of surgery.
16359815|NCT04259476|Placebo Comparator|group B|will be given normal saline infusion and bolus at start of surgery.
16359816|NCT04259463||Concious sedation|Patients undergoing third molars extraction under concious sedation. The patient is fully familiarized with the sedation procedure. The anesthesiologist suppresses the patient's consciousness with the help of intravenous medication;
16359817|NCT04259463||Full anesthesia|Patients undergoing third molars extraction under full anesthesia. . The patient is fully acquainted with the procedure of general anesthesia. It is a controlled state of unconsciousness when protective reflexes disappear, the patient cannot breathe and does not respond to verbal commands. A special intubation tube is introduced into the airways.
16359818|NCT04259450|Experimental|AFM24|"Phase 1: Treatment of escalating doses of AFM24.
~Phase 2a: Treatment of AFM24 at maximum tolerated dose/recommended phase 2 dose, stratified into cohorts by tumor type."
16359819|NCT04259437|Experimental|High Protein, Energy Dense Nutritional Supplement|2 servings per day
16359820|NCT04259424|Experimental|Aerobic Exercise + Upper Extremity Rehabilitation|Subjects will receive a total of 18 intervention sessions. In each intervention session, subjects will perform 15 minutes of aerobic exercise on a stationary cycle followed by 200 repetitions of an upper extremity rehabilitation program.
16359894|NCT04258904|Experimental|Intervention|Skin Care Program
16359824|NCT04259385|Active Comparator|Calorie/Control Label Condition|Beverages at the concession stand and in the parent survey in this arm will display solely a calorie label.
16359825|NCT04259385|Experimental|Text Warning Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display both a text warning and a calorie label.
16359826|NCT04259385|Experimental|Sugar Graphic Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display a sugar graphic warning label depicting the amount of sugar in the product, the same text warning, and a calorie label.
16359827|NCT04259372||Primary Diagnosis|Analysis of patient blood at primary diagnosis of AML
16359828|NCT04259372||Relapse|Analysis of patient blood at time point of relapse after allo-HCT
16359829|NCT04259372||Remission|Analysis of patient blood during remission after allo-HCT
16359830|NCT04259359||patients who will be treated with bee venom immunotherapy|
16359831|NCT04259346|Experimental|Ixekizumab (Reference)|Approved formulation of ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
16359832|NCT04259346|Experimental|Ixekizumab (Test)|Test formulation of ixekizumab administered as a SC injection via AI.
16359833|NCT04259333|Experimental|Test Arm|celecoxib 200 mg tablet by mouth every 12 hours for 7 days postoperatively prn pain
16359834|NCT04259333|Active Comparator|Control Arm|codeine 30mg-acetaminophen 300mg-caffeine 15 mg tabelt by mouth every 4 hours for 7 days postoperatively prn pain
16359838|NCT04259307|Experimental|Intensive nutrition group|Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks
16359839|NCT04259307|No Intervention|Control group|Standard nutritional support only per day for 3 weeks
16359840|NCT04259294|Experimental|Telerehabilitation group via mobile apps|The experimental group will receive home-based treatment program through mobile apps
16359841|NCT04259294|Active Comparator|Control group via paper and pencil instructions|The control group will receive treatment via written home program sheets
16359845|NCT04259268||Web based questionnaire|Information registered by patient in the web based questionnaire
16359846|NCT04259268||Outpatient assessment|"Information registered by the anesthesiologist and based on the web based questionnaire, the electronic records of patient and the face to face interview"
16359847|NCT04259268||Virtual assessment|Information registered by the anesthesiologist and based on the web based questionnaire and the electronic records of patient
16359848|NCT04259255||Edaravone|During an estimated 12-month period, eligible participants who are prescribed Edaravone within the approved indication will be invited to participate in the study.
16359849|NCT04259242|Experimental|premenopausal women with low BMD and periodontitis|Experimental: postmenopausal women with low BMD and chronic periodontitis postmenopausal women with low BMD and chronic periodontitis will be evaluated after SRP for serum bone resorption markers - CTX and inflammatory markers TNF-α, IL-6
16359850|NCT04259229|Experimental|Mushroom intervention|Subjects will be randomized and assigned to consume the Mediterranean Diet with mushrooms for eight weeks.
16359851|NCT04259229|Active Comparator|Control|Subjects will be randomized and assigned to consume the Mediterranean Diet without mushrooms for eight weeks.
16359852|NCT04259216|Experimental|IMPACT Intervention|"Remote brief video session, introducing basic principles of cognitive behavioral theory and the structure of the mobile application message portion of the intervention.
~Eight-weeks longitudinal tailored Cognitive Behavioral Therapy (CBT)-based messaging program"
16359853|NCT04259216|Active Comparator|Control Enhanced Online Resources (EOR)|1. We will provide a link to an online resource packet with information on bullying and mental health resources.
16359854|NCT04259203|Experimental|Erickson hypnosis|5 sessions of Erickson hypnosis (1 session per week), associated with autohypnosis at home in-between sessions.
16359855|NCT04259203|No Intervention|Usual care|Usual management of pain symptoms
16359856|NCT04259190|Experimental|Values rationale|Interoceptive exposure exercises will be introduced as a way to help participants engage in more that they value.
16359857|NCT04259190|Active Comparator|Standard rationale|Interoceptive exposure exercises will be introduced as a way to help participants experience less discomfort.
16359858|NCT04259164|Active Comparator|QMF149|Mometasone furoaat / Indacaterol
16359859|NCT04259164|Experimental|QVM149|Mometasone furoaat / Indacaterol / Glycopyrronium
16359860|NCT04259151|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
16359861|NCT04259151|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
16359862|NCT04259138|Other|Symptomatic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission.
16359863|NCT04259138|Other|Symptomatic and endoscopic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.
16359895|NCT04258904|No Intervention|Control|Usual Treatment
16362049|NCT04243967|Experimental|MUSIC THERAPY|
16359864|NCT04259138|Other|Symptomatic, endoscopic and histological remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.
16359865|NCT04259125||Acute symptomatic seizures|This is a cohort of 72 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after being diagnosed with seizures. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after seizures are diagnosed, to participate in an optional blood draw at 2-4 months of age, and to complete surveys at 12 & 24 months of age.
16359866|NCT04259125||Control|This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after birth.
16359867|NCT04259112|Experimental|high pressure + deep block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards post-tetanic count (PTC) 1-2.
16359868|NCT04259112|Experimental|high pressure + moderate block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards train-of-four (TOF) twitch 1-2.
16359869|NCT04259112|Experimental|low pressure + deep block|Intra-abdominal pressure will be set to 7-10 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
16359870|NCT04259112|Experimental|low pressure + moderate block|Intra-abdominal pressure will be set to 7-10 mmHg. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards TOF twitch 1-2.
16359871|NCT04259099||QUALITY OF LIFE QUESTIONNAIRES|The group is anticipated to consist of 150 female and male with osteoporosis, osteopenia or normal bone mineral density.
16359872|NCT04259086|Experimental|DAXI|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL) & Lateral Canthal Lines (LCL)
16359873|NCT04259073|Placebo Comparator|Group C|two capsules filled with sugar
16359874|NCT04259073|Active Comparator|Group P150|two capsules; one of them containing sugar (like the placebo one), the other is the active drug (pregabalin 150 mg)
16359875|NCT04259073|Active Comparator|Group P300|two capsules of pregabalin (150 mg)
16359876|NCT04259060|Active Comparator|Hydroxocobalamin with Butyrate|
16359877|NCT04259060|Placebo Comparator|Placebo with Butyrate|
16359878|NCT04259047|Experimental|Diabetes Regulation for Eyesight and Memory (DREAM)|DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
16359879|NCT04259047|Active Comparator|Enhanced Usual Care (EUC)|EUC consists of home visits by a CHW in which general DM education is provided.
16359880|NCT04259034||systemically healthy individuals with oral lichen planus|systemically healthy individuals diagnosed with oral lichen planus on clinical and histopathological basis.
16359881|NCT04259034||systemically healthy individuals without oral lichen planus|systemically healthy individuals without any clinical feature of oral lichen planus.
16359882|NCT04259008|Active Comparator|Standard neonatal trace elements|"Parenteral nutrition containing 5 mCg/kg/day manganese from Multitrace-4 Neonatal."
16359883|NCT04259008|Experimental|Manganese-free neonatal trace elements|"Parenteral nutrition containing the same trace element doses as Multitrace-4 Neonatal minus manganese."
16359884|NCT04258995|Experimental|GBS6 no aluminum phosphate (GBS6 no AlPO4)|
16359885|NCT04258995|Experimental|GBS6 with aluminum phosphate (GBS6 with AlPO4)|
16359886|NCT04258982||AECOPD group|The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.
16359887|NCT04258969|Experimental|Pedaling Group|During the first 2 hours of their chemotherapy infusions, participants will pedaling for 30 minutes using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. Additionally, subjects will complete both a physical activity questionnaire (International Physical Activity Questionnaire) and a quality of life questionnaire (European Organization for Research and Treatment of Cancer QLQ - CR 29) at baseline and following their last chemotherapy treatment. A questionnaire on chemotherapy side effects (Memorial Symptom Assessment Scale) will be gathered at baseline, during chemotherapy cycles 3, 6, and/or 12, and following completion of chemotherapy treatment. Lastly, muscular strength and physical performance will be measured via grip strength tests and TGUG tests within 2-4 weeks of the post-surgery and chemotherapy completion CT scans.
16359888|NCT04258943|Experimental|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
16359889|NCT04258930|Active Comparator|Group A: Aluminum sulphate and calcium acetate drying soaks|Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.
16359890|NCT04258930|Experimental|Group B: Topical sterile silicone gel for wounds|Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.
16359891|NCT04258930|Experimental|Group C: Hydrocolloid dressing|Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.
16359892|NCT04258917|Experimental|Total Knee Arthroplasty|
16359893|NCT04258917|Experimental|Anterior Cruciate Ligament Reconstruction|
16359896|NCT04258865|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
16359897|NCT04258865|Experimental|Sequence 2|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
16359898|NCT04258865|Experimental|Sequence 3|"Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
16359899|NCT04258865|Experimental|Sequence 4|Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
16359900|NCT04258865|Experimental|Sequence 5|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
16359901|NCT04258865|Experimental|Sequence 6|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
~Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions"
16359902|NCT04258852|Experimental|Low Strength, High Strength|
16359903|NCT04258852|Experimental|High Strength, Low Strength|
16359904|NCT04258839|Experimental|Arm 1|Brexpiprazole
16359905|NCT04258826|Experimental|LY3154207|LY3154207 administered orally in one of two study periods.
16359906|NCT04258826|Placebo Comparator|Placebo|Placebo administered orally in one of two study periods.
16359907|NCT04258813|Experimental|Control|40 PCP clinics; 400 patients
16359908|NCT04258813|Experimental|iGuide Intervention|40 PCP clinics; 400 patients
16359909|NCT04258800|Experimental|With music|Colonoscopy performed with music
16359910|NCT04258800|No Intervention|Without music|Colonoscopy performed without music
16359911|NCT04258787||Group A: No Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy but do not require surgery per standard-of-care guidelines.
16359912|NCT04258787||Group B: Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy, who require Descemet's Stripping Endothelial Keratoplasty (DSAEK), Descemet's Membrane Endothelial Keratoplasty (DMEK), or Descemet's Stripping Only (DSO) surgery. All treatment decisions will be made by the attending physician based on standard-of-care guidelines. (The study does not designate a treatment modality or pay for the treatment.)
16359913|NCT04258774|Active Comparator|Healthy Adults|
16359914|NCT04258774|Active Comparator|Adults diagnosed with vascular pathology of the brain|
16359915|NCT04258761|Experimental|10XB-101 Solution for Injection 1.25% and 2.0%|Participants receive 10XB-101 Solution for Injection, 1.25% or 2.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
16359916|NCT04258748|Experimental|Motivational Interviewing (MI)|
16359917|NCT04258748|Experimental|Gaming and MI|
16359918|NCT04258748|Active Comparator|Conventional dental health education|
16359919|NCT04258735|Other|Metastatic breast cancer cohort|Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
16359920|NCT04258722|Experimental|Trainee + Teleneonatologist|Trainee, teleneonatologist, nurse, and respiratory therapist will perform resuscitation
16359921|NCT04258722|Active Comparator|Trainee|Trainee, nurse, and respiratory therapist will perform resuscitation.
16359922|NCT04258709|Experimental|Antenatal Milk Expression (AME) Intervention Group|Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
16359923|NCT04258709|Active Comparator|Video-based Infant Care Education Control Group|Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).
16359924|NCT04258696|Active Comparator|Gingival retraction by ultrapak retraction cord|
16359925|NCT04258696|Experimental|Gingival retraction by diode laser|
16359926|NCT04258683|Experimental|Pembrolizumab with CyBorD|This will be a single arm study of pembrolizumab with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
16359927|NCT04258670||Cross-reactive loiasis|This cohort will prospectively enroll 50 adults (age 18+) with cross-reactive antigenemia based on a positive filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
16359928|NCT04258670||non-cross-reactive loiasis|This cohort will prospectively enroll 10 adults (age 18+) with a negative filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
16359929|NCT04258657|Experimental|Paclitaxel-albumin and S-1|
16359930|NCT04258644|Experimental|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&D8, 100～120 mg/m2 S-1：D1~14, 60mg bid
16359931|NCT04258631|Active Comparator|Arm I (laparotomy, liposomal bupivacaine)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine.
16359932|NCT04258631|Experimental|Arm II (laparotomy, liposomal bupivacaine, hydromorphone)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine and hydromorphone IT.
16359933|NCT04258618|Active Comparator|CBT-I (Cognitive Behavioral Therapy for Insomnia) with TMS|
16359934|NCT04258618|Other|rTMS (repetitive Transcranial Magnetic Stimulation)|Subjects will be getting Transcranial Magnetic Stimulation as part of their standard of care.
16359935|NCT04258605||ASHCOM Shoulder System subjects|Subjects implanted with the ASHCOM Shoulder System
16359936|NCT04258592|Experimental|Patients|A single dose of 18F-MFBG will be intravenously injected in 10 patients with neural crest tumors or neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and efficacy assessment.
16359937|NCT04258579|Experimental|Video PROTECT|Participants will receive PROTECT therapy once a week for 9 weeks.
16359939|NCT04258553||Cervix cancer|Cervix cancer n=62
16359940|NCT04258553||Healthy controls|Healthy volunteers n=61
16359941|NCT04258540|Experimental|Intervention group|The intervention group received a yoga course for 12 weeks, two times a week. Each yoga class was 1.25 hr in duration.
16359942|NCT04258540|Active Comparator|Control group waitlist|The control group were on a waitlist during the period of measurements, and received the same yoga course after all measurements had been completed.
16359943|NCT04258527|Experimental|Patients with advanced malignancies with FGF/FGFR alterations|
16359944|NCT04258514|Experimental|Virtual Reality Vasectomy|This group of men will undergo vasectomy while wearing VR goggles.
16359945|NCT04258514|Experimental|Standard Vasectomy|This group of men will undergo a standard vasectomy without using VR goggles.
16359946|NCT04258501|Experimental|Mulberry fruit extract|1.5 g of mulberry fruit powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
16359947|NCT04258501|Experimental|Mulberry leaf extract|1.0 g of mulberry leaf powdered extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
16359948|NCT04258501|Experimental|White bean extract|3 g of white bean powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
16359949|NCT04258501|Experimental|Apple extract|2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
16359950|NCT04258501|Experimental|Elderberry extract|2 g of elderberry powder extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
16359951|NCT04258501|Experimental|Turmeric extract|0.18 g of curcumin powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
16359952|NCT04258501|Experimental|Turmeric extract + Apple extract|0.18 g of curcumin powdered extract + 2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
16359953|NCT04258501|Experimental|Turmeric extract + Elderberry extract|0.18 g of curcumin powdered extract + 2 g of elderberry powder extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
16359954|NCT04258501|Placebo Comparator|Rice porridge control|Bowl containing 60 g of extruded rice + 300 ml of boiling water
16359955|NCT04258488|Experimental|Oral Factor Xa inhibitor|
16359956|NCT04258488|Active Comparator|Vitamin K antagonist|
16359957|NCT04258475|Experimental|Raltegravir-Calcium PK measure|"Patients will have a total of 8 visits during the study after initial screening visit to gauge patient eligibility:
~Day 1 visit: Oral administration of Raltegravir. Day 7 visit: Oral administration of Raltegravir and Calcium 500 mg in the morning. Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 8).
~Day 8 visit: day 7's 24 hour phlebotomy visit. Day 14 visit: Oral administration of Raltegravir and Calcium 1000 mg in the morning. Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 15).
~Day 15 visit: Day 14's 24 hour phlebotomy visit. Day 21 visit: Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 22).
~Day 22 visit: Day 21's 24 hour phlebotomy visit. Day 51: Final safety visit. Follow-up for patient safety and data collection from diary."
16359958|NCT04258462|Experimental|Diagnostic (HP 13C pyruvate MRI)|Patients receive HP 13C pyruvate IV and then undergo 13C MRI scan 1-2 minutes post HP 13C pyruvate injection. Patients may receive an optional second HP 13C pyruvate injection and undergo 13C pyruvate MRI scan 15 to 60 minutes following completion of the first scan.
16359960|NCT04258436|Active Comparator|Group 1-Block Arm|Group1 will receive an ultra-sound guided serratus anterior block after induction of general anesthesia
16359961|NCT04258436|No Intervention|Group 2-No Block Arm|Group 2 will not receive a serratus block after induction of general anesthesia
16359962|NCT04258423|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
16359963|NCT04258423|Experimental|Study Arm|Everolimus as maintenance immunosuppression
16359964|NCT04258410|Placebo Comparator|Placebo|Blinded subjects in this arm will receive 2 placebo (blank) soft chews, twice daily, orally for 20 weeks.
16359965|NCT04258410|Experimental|Active Drug|Blinded subjects in this arm will receive 1 g/day of Quercetin delivered in 2 soft chews (250 mg/chew), twice daily, orally, for 20 weeks.
16359966|NCT04258397|Active Comparator|Experimental, pirfenidone|"Pirfenidone 267 mg capsules
~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
16359967|NCT04258397|Placebo Comparator|Placebo, pirfenidone|"Pirfenidone placebo capsules
~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
16359968|NCT04258384||Patient|The study included individuals whose native language is Turkish, who are literate, over the age of 18, diagnosed with rheumatoid arthritis, without cognitive impairment and communication problems, and who want to participate in the study.
16359969|NCT04258371|Experimental|Dapagliflozin Treatment Arm|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
16359970|NCT04258371|Placebo Comparator|Placebo Arm|Placebo Matching Dapagliflozin Tablet for 12 weeks
16359971|NCT04258358|Experimental|People living with dementia intervention group|"Long term care and support are provided in a dementia care friendly environment with emphasis on 'the person's home'. Each resident's home carries a registered address to symbolise the person's home. Based on needs and strengths, people living with dementia and their families are supported to choose the technology to enable the person's independence plus developing new and maintaining existing skills. Examples of supportive and assistive technology include mobile devices, memory clocks, gas and flood detectors, sensor mats and global positioning system trackers or safe return ornaments. Routine care follows a holistic integrated health and social care plan tailored to the needs of the person living with dementia.
~Respite care provided in guesthouse facilities embody a similar approach only for a shorter period of time without assigning registered home addresses."
16362050|NCT04243967|Experimental|CONTROL|
16359972|NCT04258358|No Intervention|People living with dementia control group|"People living with dementia in need of long-term rehabilitation or recovery for at least eight months; and people living with dementia in need of respite care for up to 14 days
~People living with dementia will continue to use standard care. Standard care in this respect constitutes usual health and social care or any other nationally acceptable form of therapy that people living with dementia would seek to use."
16359973|NCT04258345|Other|Active Feeding Arm|This is a feeding study.
16359974|NCT04258332|Other|High Salt Diet then Low Salt Diet|"The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.
~The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg)."
16359975|NCT04258332|Other|Low Salt Diet then High Salt Diet|"The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).
~The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure."
16359976|NCT04258319|Experimental|Affected (Lymphedema)|Subjects affected lymphedema extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
16359977|NCT04258319|Active Comparator|Unaffected (Control)|Subjects unaffected extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
16359978|NCT04258306|Active Comparator|Resveratrol|180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
16359979|NCT04258306|Experimental|REVIFAST|180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold & Zucc. Root supported on Magnesium hydroxide).
16359980|NCT04258293||Patients|Patients on prolonged corticosteroid therapy (more than three months)
16359981|NCT04258280|Active Comparator|Usual Care|
16359982|NCT04258280|Experimental|Enhanced Care|
16359983|NCT04258267|Experimental|Early mobilization|Patients will be allowed to use their shoulder earlier. The immobilization period is shorter.
16359984|NCT04258267|Experimental|Delayed mobilization|The immobilization period is longer.
16359985|NCT04258254|Experimental|Multimodal|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in tasks requiring interpersonal synchrony, multilimb coordination (asymmetrical and ipsi/contralateral motions), and balance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
16359986|NCT04258254|Active Comparator|General Movement|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in structured physical activity focused on flexibility, strength, and endurance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
16359987|NCT04258254|Active Comparator|Standard of Care|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in seated play focused on reading, building, and art-craft activities. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
16359988|NCT04258241|Active Comparator|Local infiltration analgesia with local anesthetic (LIA+)|Local infiltration analgesia will be performed at the end of the surgery by injection of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
16359989|NCT04258241|Placebo Comparator|Local infiltration analgesia without local anesthetic (LIA-)|Local infiltration analgesia will be performed at the end of the surgery by injection of 0.3 mg of epinephrine and 120 ml of normal saline.
16359990|NCT04258215|Experimental|Positive pressure achieved with PSA|Maximum airway inflation pressure achievable before a significant leak occurs.
16359991|NCT04258202|Experimental|positive end expiratory pressure group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. PEEP increased in a stepwise manner from 5 to 20 cmH2O, until plateau pressure 30 cmH2, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with positive end expiratory pressure (PEEP) 5cmH2O.
16359992|NCT04258202|Experimental|tidal volume group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. Tidal volume increased in steps of 4mL/kg of ideal body weight until plateau pressure 30 cmH2O, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with PEEP 5 cmH2O.
16359993|NCT04258189|Experimental|Panel 1: Treatment Sequence ABDC|Participants will receive Treatment A (a single dose of JNJ-64417184 [oral solution with preservatives] in fasted condition) in treatment Period 1; followed by Treatment B (a single dose of JNJ-64417184 [oral solution with preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment D (a single dose of JNJ-64417184 [oral solution without preservatives] in fed [high-fat meal] condition) in treatment Period 3, followed by Treatment C (a single dose of JNJ-64417184 [oral solution without preservatives] in fasted condition) in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16359994|NCT04258189|Experimental|Panel 1: Treatment Sequence BCAD|Participants will receive Treatment B in treatment Period 1; followed by Treatment C in treatment Period 2; followed by Treatment A in treatment Period 3, followed by Treatment D in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16359995|NCT04258189|Experimental|Panel 1: Treatment Sequence CDBA|Participants will receive Treatment C in treatment Period 1; followed by Treatment D in treatment Period 2; followed by Treatment B in treatment Period 3, followed by Treatment A in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16359996|NCT04258189|Experimental|Panel 1: Treatment Sequence DACB|Participants will receive Treatment D in treatment Period 1; followed by Treatment A in treatment Period 2; followed by Treatment C in treatment Period 3, followed by Treatment B in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16359997|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EFG|Participants will receive Treatment E (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fasted condition) in treatment Period 1; followed by Treatment F (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment G (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16359998|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16359999|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16360000|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16360001|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16360002|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
16360003|NCT04258176||Intervention group|Patients seen in the multidisciplinary pathway
16360004|NCT04258176||Comparison group|Multimorbid patients seen several outpatient clinics who did not undergo the trajectory
16360005|NCT04258163||MCT Group|People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
16360006|NCT04258163||MET Group|People who received endocrine therapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
16360007|NCT04258163||Observation Group|People who didn't receive any maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks.
16360008|NCT04258150|Experimental|Experimental|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 6 mg/kg (up to 480 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 (± 3 days) twice in total every 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Tocilizumab 8 mg/kg is given IV on day 1 (± 3 days) over 1-hour, repeated every 4 weeks. Tocilizumab infusion over 30 minutes is allowed after 5. infusion in the absence of infusion related events.
16360009|NCT04258137|Experimental|Experimental procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
16360010|NCT04258137|No Intervention|Standard procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
16360011|NCT04258137|Experimental|Experimental procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
16360012|NCT04258137|No Intervention|Standard procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
16360013|NCT04258124|Experimental|Experimental group|"Each session will last 10 minutes, taking place 3 days a week, over a period of 6 weeks. The intervention will take place at the beginning of the training session. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
~Exercise 1. In quadruped position, keeping the back flat, making an isometric contraction of the transverse muscle, and raising one arm and one leg contralaterally.
~Exercise 2. Training of the deep cervical flexor muscles, supine. Players will move their heads slowly towards craniocervical flexion.
~Exercise 3. In standing position, an ocular-cervical coordination exercise by means of a cranio-cervical flexion, adding a rotation, guided by an eye feedback provided by the physiotherapist by means of a laser projected on a wall."
16362792|NCT04238611|Experimental|Lactate microneedle|Measurement of lactate through microneedle
16360014|NCT04258124|No Intervention|Control group|Athletes in the control group will be asked to follow their usual warm-up routine.
16360015|NCT04258111|Experimental|IBI310 + Sintilimab|
16360016|NCT04258098||OA+MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
16360017|NCT04258098||MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. No oral antibiotics was administered to the patients.
16360018|NCT04258085||Screening plus EMR|Individuals in this group are those residing in districts where health facilities have implemented a breast cancer screening program integrated with cervical cancer screening.
16360019|NCT04258085||Early diagnosis plus EMR|Individuals in this group are those residing in districts where health facilities will implement a breast cancer early diagnosis program focused on expediting evaluation for women with breast symptoms.
16360020|NCT04258072|Experimental|open label,single arm|Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
16360021|NCT04258059|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
16360022|NCT04258059|Sham Comparator|Inactive UV Device|A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
16360023|NCT04258046|Experimental|Oral Trametinib|Patients will receive oral trametinib once daily
16360024|NCT04258033|Experimental|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
16360025|NCT04258020|Experimental|Experimental: alternating BiPAP and HFNC|Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
16360026|NCT04258020|No Intervention|Historical Control: standard of care|A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
16360027|NCT04258007|Placebo Comparator|Reversal Neostigmine|Patients undergoing cardiac catheterization will receive a combination of 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
16360028|NCT04258007|Active Comparator|Reversal Sugammadex|Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
16360029|NCT04257994||patients with arrhythmic disorders|Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust as well as family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis.
16360030|NCT04257981|Experimental|Experimental group|"Transcranial direct stimulation + virtual related group:
~Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp Virtual reality (KVR) is the use of a computer interface involving upper limb activity in pediatric rehabilitation. VR creates an artificial environment, presented to the user through appropriate sensory stimulations."
16360031|NCT04257981|Sham Comparator|Control group|Sham Transcranial direct stimulation Group + virtual related group; The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies.
16360032|NCT04257968|Experimental|Diagnostic intervention|Complete diagnostic intervention
16360033|NCT04257955||Pancreatic cancer|"Outpatients seen at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele, Milan (Italy) will be considered includable if:
~Adult patients (≥18 years);
~Of Italian mother tongue;
~Have a histologic diagnosis of PDAC obtained during the 4 weeks before the visit
~The visit is the first visit after completion of diagnostic procedures and is set to communicate the diagnosis and treatment strategies
~Give full, written informed consent
~The following exclusion criteria will be applied:
~PDAC recurrence after previous diagnosis and treatment
~poor performance status (ECOG ≥ 3);"
16360069|NCT04257682|Active Comparator|Bupivacaine|The participant will receive Bupivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
16360037|NCT04257916|Experimental|Experimental group|"The intervention by kinesiotape will be done with the player in supine position with the foot in dorsal flexion, anchoring the strip below the sole of the foot without tension, adding 50-70% tension until internal and external malleolus, and ending without tension. Another strip will be placed under the external malleolus, anchoring the bandage and following the talus (50-70% tension), leaving the scaphoid bulge free, surrounding the plant without tension and leaving the 5th metatarsal free. The bandage continues on the peroneal-astragalin ligament and the external malleolus (50-70% tension), until the tendon without tension. In the end we will surround the internal malleolus to the Achilles tendon without tension, ending with the same tension in the external malleolus and the neck of the talus.
~The myofascial technique and strength training will be the same in both groups."
16360038|NCT04257916|Active Comparator|Control group|"The myofascial technique will be carried out by positioning the caudal hand of the physiotherapist in the astragalin and heel region, and the cranial hand in the middle foot. With a tibiotarsal traction, the foot will be everted, performing a shear in the astragalin zone, using a combined and slow technique.
~All players will warm up for 10 minutes on tape, at a speed of 7 km / h without inclination. The strength work was carried out with an isoinertial machine (Space Whell) with intervalic methodology: 20 -10, with 4 series and doing three exercises: Squat, Lunges and Deadlift. One minute breaks will be made between sets."
16360039|NCT04257903||Occlusal Splint Therapy|The data of patients who previously received occlusal splint therapy were evaluated. Participants in the study received occlusal splint therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received occlusal splint therapy as part of routine medical care, and a researcher studied the effect of occlusal splint therapy.
16360040|NCT04257903||Low-Level Laser Therapy|The data of patients who previously received Low-Level Laser Therapy were evaluated. Participants in the study received Low-Level Laser Therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received Low-Level Laser Therapy as part of routine medical care, and a researcher studied the effect of Low-Level Laser Therapy.
16360041|NCT04257890|Experimental|CBT intervention group|In addition to the information about IGD of the control group, the intervention group will receive eight weekly group-based 90-minute CBT sessions.
16360042|NCT04257890|Active Comparator|Wait-list control group|Members will receive printed education material about IGD but not CBT during the treatment period.
16360043|NCT04257877||Diabetes type 1|Patients= diabetes type1
16360044|NCT04257877||Healthy participants|Healthy participants = Control group
16360045|NCT04257864||Erlotinib followed by docetaxel|Erlotinib given for twelve consecutive days before docetaxel
16360046|NCT04257864||Docetaxel followed by erlotinib|Erlotinib given for twelve consecutive days after docetaxel
16360047|NCT04257864||Bevacizumab treated|Bevacizumab treated patients
16360048|NCT04257851|Active Comparator|Group T (n=30)|Theophylline group
16360049|NCT04257851|Active Comparator|Group S (n=30)|Sumatriptan group
16360050|NCT04257838||Piperacillin-Tazobactam or Meropenem Cohort|Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.
16360051|NCT04257825|Other|Initial Off|Individuals were asked to not use their device on weeks 1 and 3 of the study. They were asked to use their device on weeks 2 and 4.
16360052|NCT04257825|Other|Initial On|Individuals were asked to not use their device on weeks 2 and 4 of the study. They were asked to use their device on weeks 1 and 3.
16360053|NCT04257812||Ceftolozane-Tazobactam cohort|Patients older than 18 years old that are hospitalised in the Virgen Macarena University Hospital that are being treated with Ceftolozane-Tazobactam in empiric or targeted treatment.
16360054|NCT04257799||Women with breast cancer diagnosis|Women with diagnosis of invasive breast cancer based on pre-surgical biopsy, and scheduled for breast-conserving surgery in the Dartmouth-Hitchcock (DH) Outpatient Surgical Center.
16360055|NCT04257786|Active Comparator|Group 1|1ry surgery
16360056|NCT04257786|Active Comparator|Group 2|Neoadjuvant Chemotherapy followed by surgery
16360057|NCT04257773|Experimental|Immediate Treatment|Participants in this group will receive treatment/intervention immediately.
16360058|NCT04257773|Experimental|Delayed Treatment|Participant in this group will receive treatment/intervention 2-week later.
16360059|NCT04257760|No Intervention|Standard care|These ALS patients and their caregivers will receive standard care.
16360060|NCT04257760|Experimental|Early palliative care|These patients will receive a palliative care consultation that would not be requested by their care team as standard of care.
16360061|NCT04257747|Sham Comparator|Healthy volunteers|
16360062|NCT04257747|Active Comparator|patients requiring radial forearm flap reconstruction|
16360063|NCT04257747|Experimental|patients having received hand allotransplantation|
16360064|NCT04257734||optic neuritis|Aquaporin 4 antibody seropositive optic neuritis patients, Myelin oligodendrocyte glycoprotein antibody seropositive optic neuritis patients, and double antibodies seronegative optic neuritis patients
16360065|NCT04257708||normal uterine cavity|
16360066|NCT04257708||abnormal uterine cavity|
16360067|NCT04257695|Experimental|TapPro|Biweekly telephone and in-person visits with a clinician over six months. At each visit, a protocol adapted from the Prescription Opioid Taper Study will be provided to participants, who will learn about pain coping, distraction techniques, diaphragmatic breathing, sleep techniques, and progressive muscle relaxation techniques. All are specifically designed for patients with chronic pain on chronic opioid therapy. During visits, taper parameters will be discussed and the provider will work through a dose reduction schedule, if participants are in agreement. Additionally, urine drug screens will be obtained.
16360068|NCT04257695|No Intervention|Usual Care|Participants randomized to the usual care arm will continue seeing their primary care providers as indicated.
16360070|NCT04257682|Active Comparator|Ropivacaine|The participant will receive Ropivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
16360071|NCT04257682|Active Comparator|Mepivacaine|The participant will receive Mepivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
16360072|NCT04257669||Iron sufficient|Haemoglobin ≥120g/L Serum ferritin > 20μg/L
16360073|NCT04257669||Non-anaemic iron deficient|Haemoglobin ≥120g/L Serum ferritin ≤ 20μg/L
16360074|NCT04257669||Iron deficient anaemic|Haemoglobin <120g/L Serum ferritin ≤ 20μg/L
16360075|NCT04257669||Anaemic without iron deficiency|Haemoglobin <120g/L Serum ferritin > 20μg/L
16360076|NCT04257656|Experimental|Remdesivir group|active remdesivir
16360077|NCT04257656|Placebo Comparator|Control group|Placebos matched remdesivir
16360078|NCT04257643|Experimental|Experimental group|water-based exercise was conducted at a hydrotherapy pool for the Eden Heelth Care,Cairo The pool measures 8 × 15 m and ranges from 1 to 1.8 m in depth with access via steps. Interventions were conducted predominately in the deeper section of the pool so participants immerse their neck in water. Thermo neutral water temperature, 30-32 °C at room temperature. Females were instructed to adjust water depth completely covering clavicles from standing position. Diaphragmatic breathing during exercise routine to assist with lymph fluid clearance. Exercise continuously for 40 to 45 min Full-body warm-up exercise for 10 min and cooling down for 10 minutes. Plus land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.
16360079|NCT04257643|Active Comparator|Control group|Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles
16360080|NCT04257617|Experimental|Single arm, ZL-1201|Single arm, ZL-1201
16360081|NCT04257604||Perampanel|Participants with partial-onset seizures, with or without secondary generalization will receive perampanel tablets as add-on therapy according to the approved summary of product characteristics (SmPC) after the baseline visit as part of the clinical practice and will be observed after 3 months (visit 1), 6 months (visit 2), and 12 months (final visit).
16360082|NCT04257591|Experimental|hamstring strengthening|8-week protocol (3 days per week) based on isometric, concentric and excentric exercisesof hamstrings
16360083|NCT04257591|No Intervention|Control|No intervention added to regular training.
16360084|NCT04257578|Experimental|Treatment (acalabrutinib, axicabtagene ciloleucel)|Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive acalabrutinib PO every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel IV at 36-96 hours after completion of lymphodepleting chemotherapy.
16360085|NCT04257565|Active Comparator|Control group|The Control Group will receive usual and customary care from their vascular specialist.
16360086|NCT04257565|Experimental|Intervention Group|The Intervention Group will receive usual and customary care from their vascular specialist and they will be provided and trained to use the wheeled knee walker.
16360087|NCT04257552|Active Comparator|Attention Control Group|If randomized to the attention control arm participants will receive discharge instruction from the postpartum nurses per usual care. Study investigators will ask them to provide us with an SMS number. This will enable collection of self-reported breast feeding duration as well as texts on general infant care. The infant care texts are educational in nature and no data will be collected. Participants will receive a total of two texts on general infant care in the first month postpartum. This increased attention to the control arm mirrors the attention received by the Healthy Beyond Pregnancy arms and seeks to isolate the effect of the intervention from a general increased level of contact with providers. Participants that answer 80% of the infant feeding questions will receive a financial compensation.
16360088|NCT04257552|Active Comparator|Pre-Scheduled Postpartum Visit:|If randomized the the usual care with pre-scheduled visit arm, participants will schedule their postpartum visit with the study coordinator and receive discharge information per usual care. Participants that answer 80% of the infant feeding questions (collected via text messaging) will receive a financial compensation.
16360089|NCT04257552|Experimental|Healthy Beyond Pregnancy|Healthy Beyond Pregnancy is a web platform with an electronic survey that assesses a participant's self-identified postpartum concerns. Participants are then presented with 3 educational videos that reflect their self-identified needs from the survey. The Healthy Beyond Pregnancy generates an individualized passport for postpartum care. This passport for care lists the women's self-identified postpartum needs as well as issues that should be prioritized based on her health history.The individualized passport for postpartum care will be printed out and given to participants. After the participant schedules her postpartum visit, she will receive a print out that includes the date and time of her appointment, a copy of the commitment statement as well as a reminder of the monetary incentive she will receive if she fulfills her commitment and attends her postpartum visit.
16360090|NCT04257539|Experimental|Intervention Group|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior. This will include an initial, in-person behavioral intervention with a health coach trained and a 4 week phone call. Participants will receive a wrist-worn activity prompter to aid in sedentary behavior reduction.
16360091|NCT04257539|No Intervention|Wait-list Control Group|Chronic low back pain participants in this group will not receive the intervention until completion of the study. Over the 8 week intervention period, participants will be asked to maintain currently levels of physical activity, sedentary behaviors, and treatment for low back pain.
16360092|NCT04257539|No Intervention|Pain-free Control Group|These subjects will be healthy, pain-free adults and receive no intervention. Over the 8 week intervention period, participants in this group will be asked to maintain currently levels of physical activity, sedentary behaviors, and medication regimen.
16360093|NCT04257526|Active Comparator|Intervention|Colorectal cancer free participants receive evidence-based diet and lifestyle advice in addition to the 'usual care' following a positive FIT test and diagnostic colonoscopy
16360094|NCT04257526|No Intervention|Control|Colorectal cancer free participants receive the 'usual care' following a positive FIT test and diagnostic colonoscopy
16363174|NCT04236063||Haematological malignancy|Patients with haematological malignancy
16360095|NCT04257513||Healthy controls subjects|Subjects without known family history of HD, or tested negative for the HD expansion mutation.
16360096|NCT04257513||Symptomatic HD subjects|Subjects HD gene expansion carriers who have clinical diagnostic motor symptoms of defined HD, and disease stage I to III.
16360097|NCT04257513||Presymptomatic HD subjects:|Subjects HD gene expansion carriers who not have clinical diagnostic motor features of HD.
16360098|NCT04257500|Experimental|Contraceptive Ring|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), which releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily.
16360099|NCT04257487|Active Comparator|Treatment A|Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
16360100|NCT04257487|Active Comparator|Treatment B|Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
16360101|NCT04257487|Placebo Comparator|Treatment C|2 indistinguishable placebo capsules BID, for 12 months
16360102|NCT04257474||Assessing Health Services Utilization Model (HSUM)|150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.
16360103|NCT04257474||Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI
16360104|NCT04257461|No Intervention|Group1 Arm A|Observation only
16360105|NCT04257461|Other|Group 1 Arm B|Mono- or bichemotherapy: fluoropyrimidine with or without Oxaliplatin (choice by physician/patient or by randomisation)
16360106|NCT04257461|Other|Group 2 Arm C|Monochemotherapy: fluoropyrimidine
16360107|NCT04257461|Other|Group 2 ARM D|Bichemotherapy: fluoropyrimidine with oxaliplatin
16360108|NCT04257448|Experimental|Romidepsin/nab-Paclitaxel/Gemcitabine (Arm A)|Part 1a: Romidepsin (2 mg/m² or 3.3 mg/m² or 7 mg/m²) will be administered in combination with nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
16360109|NCT04257448|Experimental|Azacitidine/nab-Paclitaxel/Gemcitabine (Arm B)|Part 1a: Azacitidine (20 mg/m² or 30 mg/m² or 40 mg/m²) will be administered on Days -7 to Day -3 of each treatment cycle. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
16360110|NCT04257448|Experimental|Romidepin/Azacitidine/nab-Paclitaxel/Gemcitabine (Arm C)|Part 1a: The intervention to be administered depends on the determined dose in Arm A and Arm B. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
16360111|NCT04257448|Active Comparator|nab-Paclitaxel/Gemcitabine (Standard Arm)|nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be administered on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle.
16360112|NCT04257448|Experimental|Arm C or B or A|In Part 1b (expansion part) of the study, one of the treatment arms (Arm C over Arm B over Arm A) will be continued. Treatment will only be performed with the study drug that were tolerable in Part 1a (dose escalation).
16360113|NCT04257448|Experimental|Durvalumab/Lenalidomide|Part 2: All patients from Part 1 who have not progressed after three cycles receive standard fixed dose Durvalumab (1500 mg) on Day 1 of each 28-day treatment cycle by IV infusion in combination with orally administered low-dose Lenalidomide (10 mg) on Days 1 to 21 until documented disease progression. Study treatment is given for a maximum of 13 cycles.
16360114|NCT04257435|Active Comparator|Traditional Behavioral Health Treatment|
16360115|NCT04257435|Experimental|Positive Psychological Group Treatment|
16360116|NCT04257422|Experimental|Intentional Rounding|In the centers randomized to Intentional Rounding the ward nurses will have to adopt a new proactive care method towards hospitalized patients
16360117|NCT04257422|No Intervention|Control|In randomized controlled centers, nurses guarantee the standard care provided by the ward
16360118|NCT04257409|Experimental|DF patient active|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
16360119|NCT04257409|Active Comparator|DF patient control|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
16360120|NCT04257409|Experimental|Diabetic patient with mild neuropathy|Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
16360121|NCT04257409|Experimental|Diabetic patient with severe neuropathy|Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
16360122|NCT04257396|Experimental|Arm 1 CARA Positioning|Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
16360123|NCT04257396|No Intervention|Arm 2 Standard of Care|Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.
16360124|NCT04257383|Experimental|Treatment|Families in the treatment cells will receive the Sugira Muryango treatment immediately after household identification and enrollment.
16360125|NCT04257383|Experimental|Waitlist Control|Families in the control cells will receive the Sugira Muryango treatment following the completion of the 12-month follow up on the original treatment group.
16360126|NCT04257370|Experimental|Kerecis™ Omega3 Wound|
16360127|NCT04257370|Active Comparator|Standard of care|
16360224|NCT04256707|Experimental|Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)|Selinexor 80 mg oral does QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer [CRC] Patients).
16360128|NCT04257357|Experimental|Exercise group|Eight-week supervised exercise program: Patients in the intervention group receive the same usual care as the patients in the control group. In addition, the patients participate in an eight-week supervised interval training program. Briefly put, the patients are required to participate in at least 16 out of 20 possible training passes over the period of eight weeks. The training consists of a brief warm up followed by 35-50 minutes of interval training on a bicycle. The intensity and duration will increase over time
16360129|NCT04257357|Active Comparator|Control group|"Patients in the control group receive usual care as a minimum. This includes three-five days of hospitalization where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
~It is considered an active comparator as all patients in the control group perform a watt-max cycle ergometer test with VO2 measurement 3 times, and this in it-self can influence patients' activity level."
16360130|NCT04257331|Experimental|SREIA group|Participants in this arm will be families who attend the first wave of the two rounds of delivery. They will be the intervention group.
16360131|NCT04257331|No Intervention|Waitlist Control|Participants in this arm will be families who attend the second wave of the two rounds of delivery. They will be the control group.
16360132|NCT04257318|Experimental|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregn
16360134|NCT04257266|Experimental|Cryo Cooling Pack|Cryo cooling pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
16360135|NCT04257266|Active Comparator|Commerical Ice Pack|The commercial ice pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
16360136|NCT04257253|Experimental|Targeted exercise program|Targeted motor control and isolated lumbar extensor strengthening exercises. Supervised 12-week program, 2 times a week.
16360137|NCT04257253|Active Comparator|General exercise program|General exercise program including upper body and lower body strengthening and flexibility exercises. Supervised 12-week program, 2 times a week.
16360138|NCT04257240||study group|patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver
16360139|NCT04257240||control group|patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
16360140|NCT04257227|Experimental|rTMS Intervention Group|
16360141|NCT04257214|No Intervention|Treatment as usual|Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.
16360142|NCT04257214|Active Comparator|Office based CBT|Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.
16360143|NCT04257214|Active Comparator|CRS/CPS|Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.
16360144|NCT04257214|Active Comparator|CBT+CRS/CPS|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
16360150|NCT04257175|Experimental|Cyclophosphamide, Flodarabine,CAR-T cells|"The appropriate participants will undergo lymhopheresis to collect lymphocytes from PBMC peripheral blood. CAR T CD19 cells will be produced. The participants will receive cyclophosphamide 300 mg / m² and flodarabine 30 mg / m² lymphodeplition intravenously daily for 3 days.
~The CAR-T CD19 cells will be given on the 5 to 7 day post lymphodeplition ."
16360151|NCT04257162|Other|Experimental Arm|Patients treated with Trastuzumab Deruxtecan (T-DXd; DS-8201a)
16360152|NCT04257149|Experimental|Hemorrhagic stroke group (group A)|Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
16360153|NCT04257149|Experimental|Ischemic stroke group (group B)|Patient group B is defined as patients that are diagnosed with ischemic stroke.
16360154|NCT04257149|Experimental|Stroke mimic group (group C)|Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
16360155|NCT04257136|Experimental|Treatment|Treatment with VBI-S
16360156|NCT04257123|Experimental|Controlled-Feeding|For two weeks (separated by a wash-out week), participants will consume all meals in the Nutrition Science facility.
16360157|NCT04257123|Experimental|Free-Feeding|For two weeks (separated by a wash-out week), participants will receive no dietary guidance and will be allowed to consume whatever they desire.
16360158|NCT04257110|Experimental|Part 1: Dose-escalation|Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle.
16360159|NCT04257110|Experimental|Part 2: Cohort 1|Subjects will be administered BB-1701 at one or two dose levels (e.g. MTD and the dose below MTD)
16360160|NCT04257110|Experimental|Part 2: Cohort 2|Subjects will be administered BB-1701 at one or two dose levels (e.g. MTD and the dose below MTD)
16360363|NCT04255888|Active Comparator|Thin periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
16360161|NCT04257097|Active Comparator|Group A - control group|25 patients will undergo bone regeneration with a titanium reinforced PTFE Mesh (RPM - Osteogenics Lubbock Texas USA), manually shaped and modeled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption (Vitala - Osteogenics Lubbock Texas USA)
16360162|NCT04257097|Experimental|Group B - Test group|25 patients undergo bone regeneration with a custom-made titanium mesh (Yxoss CBR - Reoss Filderstadt Germany), digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption (Bio-Gide - Geistlich Baden Baden Germany)
16360163|NCT04257084|Active Comparator|CE-NBI|High definition chromoendoscopy with target biopsy, at 1st surveillance colonoscopy during the trial High definition NBI with target biopsy, at 2nd surveillance colonoscopy during the trial
16360164|NCT04257084|Active Comparator|NBI-CE|High definition NBI with target biopsy, at 1st surveillance colonoscopy during the trial High definition chromoendoscopy with target biopsy, at 2nd surveillance colonoscopy during the trial
16360165|NCT04257071|Active Comparator|Usual Care|Participants randomized to the usual care study arm will receive the usual care for their MS.
16360166|NCT04257071|Experimental|OOP Cost Communication and Optimization|Participants in this study arm in addition to usual care, will receive a personalized discussion of their OOP cost estimates for treatment obtained through an online price transparency tool, personalized analysis of expenses by financial counselor, and enrollment in any cost optimization opportunities for which they are eligible using a comprehensive financial navigation program.
16360167|NCT04257058|Experimental|Electronic educational material|Participants will complete an online pre-test survey via REDCap. One week after the pre-test survey is completed, AYAs will be sent electronic media via email to review on their own. Study staff will confirm receipt and review of material and schedule a post-test survey to be completed in REDCap two weeks after material is reviewed.
16360168|NCT04257045||Observational (interview, survey)|"STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.
~STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes."
16360169|NCT04257032|Experimental|Reference 1 (R1)|
16360170|NCT04257032|Experimental|Test 1 (T1)|
16360171|NCT04257032|Experimental|Reference 2 (R2)|
16360172|NCT04257032|Experimental|Test 2 (T2)|
16360173|NCT04257019|Experimental|Lavender|Lavender mask before and during procedure
16360174|NCT04257019|Active Comparator|Almond|Almond oil mask before and during procedure
16360175|NCT04257019|Sham Comparator|Water|Water mask before and during procedure
16360176|NCT04257006|Experimental|patients undergoing CRRT with oXiris membrane|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.
~Indications for CRRT (SCUF) with oXiris after ICU admission:
~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.
~Or high risk of pulmonary edema after cardiac surgery:
~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)
~CVP (central venous pressure) ˃ 12 mm H2O.
~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.
~In this arm the treatment of fluid overload will be provided via SCUF with oxiris membrane"
16360177|NCT04257006|No Intervention|standard protocol|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.
~Indications for CRRT (SCUF) with oXiris after ICU admission:
~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.
~Or high risk of pulmonary edema after cardiac surgery:
~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)
~CVP (central venous pressure) ˃ 12 mm H2O.
~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.
~In this arm the management of fluid overload will be provided via diuretics or IHD (in condition diuretics treatment resistance)"
16360178|NCT04256993||Ra-223 initiators|"Patients diagnosed with mCRPC (Metastatic Castration-Resistant Prostate Cancer) who start treatment with Ra-223. Patients will be identified from the Patient-overview Prostate Cancer (PPC), a sub-registry of the Prostate Cancer data Base Sweden (PCBaSe) data set."
16360179|NCT04256993||Initiators of other standard of care|The comparator cohort will be patients using standard of care other than Ra-223.
16360180|NCT04256980|Experimental|Pemigatinib in patients with advanced/metastatic or surgically|Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma
16360181|NCT04256967||Sport sciences|Bachelor and master students who study sport science or physical activity and health science
16360182|NCT04256967||Controls|Bachelor and master students who study other fields not related to sport or physical activity and health sciences.
16360183|NCT04256954|Experimental|Peer navigation|Those who are assigned to the intervention arm will receive peer navigation service by a trained peer navigator who will link them with mental health, medical and substance use services in the community.
16360184|NCT04256954|No Intervention|Standard of Care|SOC consists of TAU + monitoring and emergency referral, as is required to fulfil ethical obligations to trial participants. To determine the naturalistic effects and costs of adding peer navigation intervention, participants in both conditions can receive any other treatment available to them and we will not exclude participants receiving other treatment. We will carefully characterize TAU for each condition as part of our service utilization assessment.
16360185|NCT04256941|Experimental|Arm I (ribociclib, palbociclib, abemaciclib, fulvestrant)|Patients receive ribociclib PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive fulvestrant IM for 2 injections over 1-2 minutes each on days 1 and 15 of cycle 1 and day 2 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16360186|NCT04256941|Active Comparator|Arm II (ribociclib, palbociclib, abemaciclib, letrozole)|Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16360187|NCT04256928|Experimental|Intervention group|"This group of participants will have any body hair in the operative field clipped with an electrical clipper by hospital personnel, during preparation for planned surgery.
~4 microbiological samples will be taken from all participants in this group."
16360188|NCT04256928|No Intervention|Control group|"This group of participants serve as the control group. Any body hair in the operative field is left intact.
~4 microbiological samples will be taken from all participants in this group."
16360189|NCT04256915|Experimental|CBT-I + Bright Light|n = 50
16360190|NCT04256915|Active Comparator|CBT-I + Placebo Light|n = 50
16360191|NCT04256915|No Intervention|Wait-list Control|n = 50
16360192|NCT04256889|Experimental|nfant(R) feeding system|Addition of nfant(R) technology, along with visual assessments and cue-based feeding practices, to facilitate an infant's progression to full oral feeding and potentially improve developmentally supportive feeding practices.
16360193|NCT04256876|Active Comparator|Active TTNS|Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
16360194|NCT04256876|Sham Comparator|TTNS sham intervention|"Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.
~Home therapy: Daily stimulation during 60 minutes."
16360195|NCT04256863|Experimental|Breakfast / Lunch (BFL)|This group will complete a 16-week standard behavioral weight control intervention in which they will be asked to consume >50% of their daily energy goal before 3PM. To do so, they will complete weekly experiential learning sessions in conjunction with the SBT lessons.
16360196|NCT04256863|Active Comparator|Dinner (DIN)|This group will complete a 16-week standard behavioral weight control intervention. They will not be given any recommendations regarding the timing of their energy consumption, but instead encouraged to follow the same energy goals at the BFL group.
16360197|NCT04256850|Experimental|Acceptance and Commitment Therapy (ACT)|Focuses on addressing cognitive and emotional barriers to successful weight loss maintenance.
16360198|NCT04256850|Experimental|Self-Regulation (SR)|Focuses on using self-monitoring and self-reinforcement techniques to improve weight loss maintenance.
16360199|NCT04256837|Experimental|VNS - Live donor kidney recipients.|Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
16360200|NCT04256837|Sham Comparator|sham VNS - Live donor kidney recipients.|Live donor kidney recipients. As above, but without applying any VNS
16360201|NCT04256837|Experimental|VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
16360202|NCT04256837|Sham Comparator|sham VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. As above, but without applying any VNS
16360203|NCT04256824|Experimental|Coated Polyglactin 910 with Triclosan|Coated vicryl plus
16360204|NCT04256824|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated vicryl
16360205|NCT04256798|Experimental|Mouthwash and liberal oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.
16360206|NCT04256798|Active Comparator|No mouthwash and liberal oxygen during surgery|No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.
16360207|NCT04256798|Experimental|Mouthwash and restrictive oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.
16360208|NCT04256798|Active Comparator|No mouthwash and restrictive oxygen during surgery|No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.
16360209|NCT04256785|Experimental|VSL#3|probiotic VSL#3, 2 sachets b.i.d for 3 months
16360210|NCT04256785|Placebo Comparator|placebo|matched placebo, 2 sachets b.i.d for 3 months
16360211|NCT04256759|Experimental|Dupilumab|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
16360212|NCT04256746|Placebo Comparator|Boiled Rice|63 g of raw rice was cooked.
16360213|NCT04256746|Experimental|Boiled Rice+0.37 gr extract|63 g of raw rice was cooked and 0.37 gr mulberry fruit powdered extract added and mixed
16360214|NCT04256746|Experimental|Boiled Rice+0.75 gr extract|63 g of raw rice was cooked and 0.75 gr mulberry fruit powdered extract added and mixed
16360215|NCT04256746|Experimental|Boiled Rice+1.12 gr extract|63 g of raw rice was cooked and 1.12 gr mulberry fruit powdered extract added and mixed
16360216|NCT04256746|Experimental|Boiled Rice+1.50 gr extract|63 g of raw rice was cooked and 1.50 gr mulberry fruit powdered extract added and mixed
16360217|NCT04256746|Placebo Comparator|Rice porridge|60 g of rice porridge was rehydrated with 300 ml boiling hot water
16360218|NCT04256746|Active Comparator|Rice porridge+1.50 gr extract|60 g of rice porridge was rehydrated with 300 ml boiling hot water and 1.50 gr mulberry fruit powdered extract added and mixed
16360219|NCT04256733|Experimental|Supra-threshold capsaicin|Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
16360220|NCT04256733|Placebo Comparator|Sub-threshold capsaicin|Participants will be exposed repeatedly to a single sub-threshold dose of aerosolized capsaicin through a nebulizer during treatment. This sub-threshold dose will elicit minimal or no urge-to-cough.
16360221|NCT04256707|Experimental|Monotherapy: Normal Hepatic Function (Selinexor)|"Cohort 1:
~Week 1: selinexor 5 x 20-mg tablet daily;
~Week 2: selinexor 1 x 100-mg tablet daily
~Cohort 2:
~Week 1: selinexor 1 x 100-mg tablet daily;
~Week 2: selinexor 5 x 20-mg tablet daily."
16360222|NCT04256707|Experimental|Monotherapy: Impaired Hepatic Function (Selinexor)|"Cohort 3:
~Patients with Moderate Hepatic Impairment with any Solid Tumors; - Selinexor 2 x 20-mg tablet once weekly (QW);
~Cohort 4:
~Patients with Severe Hepatic Impairment with any Solid Tumors;
~- Selinexor 2 x 20-mg tablet QW."
16360223|NCT04256707|Experimental|Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)|Selinexor 60 mg oral dose QW and docetaxel 75 mg/m^2 intravenously (IV) once every 3 weeks (Non-small cell lung cancer [NSCLC] patients).
16360225|NCT04256707|Experimental|Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)|"Cohort 1:
~Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5- fluorouracil (5-FU) 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).
~Cohort 2:
~Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5-FU 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients)."
16360226|NCT04256694||Healthy Adult Subjects|
16360227|NCT04256681|Experimental|patients affected by hereditary spastic paraplegia|40 subjects affected by genetically determined hereditary spastic paraparesis or subjects without defined genetics but who unequivocally show a dominant or recessive familiarity with exclusive involvement of the pyramidal system.
16360228|NCT04256681|Active Comparator|healthy subjects|40 healthy subjects will also be recruited to whom the questionnaire will be submitted to assess the variability of the score within a healthy population.
16360229|NCT04256668|Active Comparator|good embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with normal embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal fertilization rate >50% and normal blastocyst development rate >50%).
16360230|NCT04256668|Active Comparator|poor embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with poor embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal or slightly reduced fertilization rate <50% and low or absent blastocyst development (0 or only 1 blastocyst).
16360231|NCT04256668|Placebo Comparator|natural conception|20 previously infertile men, normal history, normal genital status, normal sperm count, DNA fragmentation rate <20% (as given by TUNEL) and achieving pregnancy naturally (without medical intervention).
16360232|NCT04256655|Experimental|Cohort 1 0.225 g|Randomized to treatment with either CDX-6114 0.225g or matching Placebo
16360233|NCT04256655|Experimental|Cohort 2 0.75g|Randomized to treatment with either CDX-6114 0.75g or matching Placebo
16360234|NCT04256655|Experimental|Cohort 3 2.25g|Randomized to treatment with either CDX-6114 2.25 g or matching Placebo
16360235|NCT04256642|Active Comparator|Intrathecal morphine|
16360236|NCT04256642|Experimental|Erector Spinae Plane Block|
16360237|NCT04256629|Experimental|Treatment ABC|Subjects will receive a single dose of all 3 treatments (A, B, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
16360238|NCT04256629|Experimental|Treatment BCA|Subjects will receive a single dose of all 3 treatments (B, C, and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
16360239|NCT04256629|Experimental|Treatment CAB|Subjects will receive a single dose of all 3 treatments (C, A, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
16360240|NCT04256629|Experimental|Treatment ACB|Subjects will receive a single dose of all 3 treatments (A, C, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
16360241|NCT04256629|Experimental|Treatment BAC|Subjects will receive a single dose of all 3 treatments (B, A, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
16360242|NCT04256629|Experimental|Treatment CBA|Subjects will receive a single dose of all 3 treatments (C, B and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
16360243|NCT04256616||Bladder cancer patients|80 patients with carcinoma of the bladder; divided in 20 patients Ta (low grade), 20 patients Ta/T1 (high grade) and 20 patients T2. Only for liquid samples collection we will include 20 CIS (carcinoma in situ) patients
16360244|NCT04256616||Controls- Healthy subjects|30 age and sex-matched subjects not suffering from carcinoma of the bladder, already hospitalized in ICH; we expect to enroll 24 males and 6 females of which 10 of 40- 60 years old, 10 of 60-70 years old, 10 of >70 years old.
16360245|NCT04256603|Other|1|Gabapentin prior to admission
16360246|NCT04256603|Other|2|Gabapentin during admission
16360247|NCT04256603|Other|3|No gabapentin
16360248|NCT04256590||Study|Patients aged 16 years or younger who were to undergo adenoidectomy surgery were eligible for inclusion in this group. Tongue surface areas were measured twice by submental USG.The first measurements (TSA2) were done immediately after endotracheal intubation but before insertion and placement of the tongue depressor. The second measurements (TSA1) were done after adenoidectomy surgery and after removal of the tongue depressor but just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue swelling.
16360249|NCT04256590||Control|This group included patients aged 16 years or younger who did not need adenoidectomy surgery and any head and neck procedures. Tongue surface areas of the patients were measured twice by submental USG as in the study group. TSA1s were done immediately after endotracheal intubation, and TSA2s were done at the end of the surgical procedure just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue edema.
16360250|NCT04256577||patients proven having (SLE)|20 patients proven to have systemic lupus Erthematosus without renal impairment (eGFR) ≥ 80 ml/min/1.73 m2 and albumin / creatinine ≤ 30 mg/g)
16360251|NCT04256577||patients proven to have (LN) by renal biopsy|Group (2) 25 patients proven to have LN by renal biopsy before starting treatment and after 3 cycle of treatment (eGFR < 80 ml/min/1.73 m2 and albumin/creatinine ratio > 30 mg/g)
16360252|NCT04256577||healthy control|(20) patients healthy control matched in age and sex
16360253|NCT04256564|Experimental|Oblique visualization linear probe|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein
16360254|NCT04256564|Experimental|Y-shape visualization micro-convex probe|A micro-convex endocavity ultrasound probe will be utilized to place the central catheter into the brachiocephalic vein
16360255|NCT04256551|Experimental|Machine Learning App + Registered Dietitian facilitator|The ML-RD group will be provided access to the Heali mobile application as well as a personal RD to provide nutrition support and answer any questions through a real-time messaging system within the mobile app. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
16360256|NCT04256551|Active Comparator|Machine Learning App|The ML-APP group receives access to the Heali mobile dietary application. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
16360257|NCT04256551|Placebo Comparator|Standard Dietary Education|Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
16360258|NCT04256538||Crohn's Disease Group|Patients are diagnosed as Crohn's disease and have no history of colectomy.
16360259|NCT04256538||Ulcerative Colitis Group|Patients are diagnosed as ulcerative colitis and have no history of colectomy.
16360260|NCT04256538||Healthy Control Group|Individuals that have no past medical history.
16360261|NCT04256525|Experimental|Aspirin 100mg|
16360262|NCT04256525|Experimental|rivaroxaban 10mg|
16360263|NCT04256525|Experimental|low molecule heparin|
16360264|NCT04256525|No Intervention|Reference|mechanical prophylaxis
16360265|NCT04256512|Experimental|Cryotherapy|Subjects diagnosed with breast cancer undergoing 3 months of taxane based chemotherapy will be provided Elasto Gel® Therapy Mittens and Foot Wraps to be worn on both hands and feet at each chemotherapy infusion during their three months of treatment. Subjects will start wearing the mittens and foot wraps 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion. We will assess for peripheral neuropathy, physical functioning, and quality of life prior to initiation of taxane based therapy, immediately after completion of taxane based chemotherapy, and again at 3 months following completion of therapy.
16360266|NCT04256499||Water load test|Patients experiencing a syndrome of inappropriate antidiuresis who had an acute water load test
16360267|NCT04256499||Control group|Patients who had an acute water load test and who did not experience any water homeostasis anomalies
16360268|NCT04256486|Experimental|Family DSMES|
16360269|NCT04256486|Experimental|Wait List|
16360270|NCT04256473|Experimental|Intervention|"Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.
~Depending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes)."
16360271|NCT04256473|Active Comparator|Control|Usual care with alteplase 0.9 mg/kg in 60 minutes
16360272|NCT04256460|Experimental|Intervention arm|Behavior intervention including health education on diet, exercises and self management support through peer support, and also receive regular care and follow up in community health centers
16360273|NCT04256460|No Intervention|Control arm|Receiving regular care and follow up in Community health centers
16360274|NCT04256447||Sixty-eight children and adolescents with type 1 diabetes|Sixty-eight children and adolescents aged between 4 and 18 years with type 1 diabetes. Patients with celiac disease, thyroid disease, other autoimmune diseases, concurrent illness, patients with diabetic nephropathy, other renal disease and in therapy with natriuretic drugs were excluded.
16360275|NCT04256434|Experimental|Dinabuphine sebacate|Each subject in cohort 1 will receive 150 mg Dinalbuphine sebacate (75 mg/mL x 2 mL) intramuscularly.
16360276|NCT04256434|Active Comparator|Nalbuphine HCl|Each subject in cohort 2 will receive 20 mg Nalbuphine (20 mg x 1 mL) intramuscularly.
16360277|NCT04256421|Experimental|Tiragolumab + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
16360278|NCT04256421|Active Comparator|Placebo + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
16360279|NCT04256408|Experimental|Treatment group|Treatment group
16360280|NCT04256382|Experimental|experimental group|The experimental group took two-hour online course about dementia pain care in two weeks.
16360281|NCT04256382|Active Comparator|comparison group|The comparison group took two-hour online course about dementia care in two weeks.
16360283|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at double dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 4,6 g per 100g of powder (group fed with double dosage of fermented matrix compare trial FERCT15)
16360284|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at triple dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 6,9 g per 100g of powder (group fed with triple double dosage of fermented matrix compare trial FERCT15)
16360285|NCT04256356|Placebo Comparator|Infants born by CS-fed standard formula|Infants born by CS-fed formula milk without fermented matrix
16360286|NCT04256356|Other|Infants born by CS-breastfed|Infants born by cesarean section fed with mother milk during were the reference group
16360287|NCT04256343|Experimental|D2O Dose 1|Lower dose of D2O for MPS
16360288|NCT04256343|Experimental|D2O Dose 2|Moderate dose of D2O MPS
16360289|NCT04256343|Experimental|D2O Dose 3|Higher dose of D2O for MPS
16360290|NCT04256330||Lean and metabolically healthy|
16360291|NCT04256330||Lean and metabolically unhealthy|
16360292|NCT04256330||Overweight and metabolically healthy|
16360293|NCT04256330||Overweight and metabolically unhealthy|
16360294|NCT04256330||Obese and metabolically healthy|
16360295|NCT04256330||Obese and metabolically unhealthy|
16360296|NCT04256317|Experimental|Phase 1, Stage A (Dose Escalation)|In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered, followed by subcutaneous (SC) azacitidine, ASTX030 and oral cedazuridine on a specific dosing schedule; in Cycle 2, oral ASTX030 (cedazuridine + azacitidine) will be administered
16360297|NCT04256317|Experimental|Phase 1, Stage B (Dose Expansion)|Oral cedazuridine + azacitidine will be administered at the recommended dose for expansion (RDE) as individual separate tablets
16360298|NCT04256317|Experimental|Phase 2, Sequence A|Oral ASTX030 (cedazuridine + azacitidine) will be administered in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
16360299|NCT04256317|Experimental|Phase 2, Sequence B|SC azacitidine will be administered in Cycle 1, followed by oral cedazuridine + azacitidine tablets in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
16360300|NCT04256317|Experimental|Phase 3, Sequence A|Participants will receive ASTX030 tablets in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
16360301|NCT04256317|Experimental|Phase 3, Sequence B|Participants will receive SC azacitidine in Cycle 1 followed by ASTX030 tablets in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
16360302|NCT04256304|Experimental|Intervention group|"Personalized Health Engagement Plan group
~First face-to-face session (Motivational interviewing) + Pre-tests
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus
~Phone call coaching
~A set of personalized home-based exercises
~Second face-to-face session (Motivational interviewing) + Post-tests
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
16360303|NCT04256304|No Intervention|Control group|"First meeting (Pre-tests)
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus
~Second meeting (Post-tests)
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
16360304|NCT04256278|Experimental|Intervention Group|
16360305|NCT04256278|Placebo Comparator|Control Group|
16360306|NCT04256252|Experimental|Rituximab|Intravenous rituximab was administered at a fixed dose of 100 mg once weekly for 3 weeks, followed by maintenance treatment with 100 mg rituximab every 6 months.
16360307|NCT04256239|Experimental|Dignity Therapy Group|"Dignity Therapy is a short-term psychotherapy aimed at improving patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress. Therapy sessions, lasting between 20 and 60 minutes, were offered at the patients' bedside and audiotaped, and were conducted by a trained psyco-oncologist. After each therapy session, the audiotaped interview data were transcribed verbatim by a different psycho-oncologist and edited and reshaped into a written narrative by an expert in DT over the course of the next two to three days. Once the editing process was completed, another session was held to allow the therapist to read the generativity document to the patient and to make any editorial changes the patient deemed necessary. The final version of the generativity document was given to the patient to bequeath it to individuals of their choosing"
16360308|NCT04256239|No Intervention|Control Group (Standard Palliative Care)|Standard Palliative Care was performed by a multidisciplinary care team composed of a palliative doctor, a psycho-oncologist, a nurse, a physiotherapist, a healthcare assistant, a social assistant, a volunteer and a spiritual assistant, tailoring care to the needs of patients and their families.
16360309|NCT04256213|Experimental|Nivolumab + Ipilimumab|
16360310|NCT04256200|Active Comparator|Dienogest|Deinogest (Visanne) 2mg/day orally for 24 weeks
16360311|NCT04256200|Active Comparator|Oral Contraceptive Pills|Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks
16360312|NCT04256187||Healthy group|Caregivers of children who treated with botulinum toxin.
16360313|NCT04256174|Experimental|Part 1:15mg cohort|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
16360314|NCT04256174|Experimental|Part 1: 50mg cohort|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
16360315|NCT04256174|Experimental|Part 1: 150mg cohort|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
16360316|NCT04256174|Experimental|Part 1: 300 mg cohort|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
16360317|NCT04256174|Experimental|Part 1: 600 mg cohort|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
16360318|NCT04256174|Experimental|Part 2: low dose cohort|Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
16360319|NCT04256174|Experimental|Part 2: medium dose cohort|Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
16360320|NCT04256174|Experimental|Part 2: high dose cohort|Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
16360321|NCT04256148|Experimental|ALXN1830 Dosing Regimen 1|
16360322|NCT04256148|Experimental|ALXN1830 Dosing Regimen 2|
16360323|NCT04256148|Experimental|ALXN1830 Dosing Regimen 3|
16360324|NCT04256148|Active Comparator|Placebo|
16360325|NCT04256135|Experimental|Experimental mobilization: Mulligan|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
16360326|NCT04256135|Active Comparator|Control mobilization: AP Maitland|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
16360327|NCT04256122||Responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.
~Patient treated with adjuvant MMC or BCG that did not experience recurrence for at least 42 months after TURBT
~Patients are tumor-free at the moment of the analysis"
16360328|NCT04256122||Non responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.
~o Patient treated with adjuvant MMC or BCG that experienced recurrence in the first 24 months after TURBT."
16360329|NCT04256096|Experimental|thrombectomy|mechanical thrombectomy with stent-retriever and/or thromboaspiration
16360330|NCT04256096|Active Comparator|Clinical treatment|Best Medical treatment
16360331|NCT04256083||AFE (amniotic fluid embolism)|Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.
16360332|NCT04256083||Control 1|Women admitted for prophylactic elective cesarean section.
16360333|NCT04256083||Control 2|Women with acute collapse in the peripartum period (with systolic blood pressure <80 mmHg twice and for> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).
16360334|NCT04256070|Experimental|Education, tele-consultation and training booklet|"Informed Consent Form will be taken in written from those who agree to participate in the research.
~In the first intervention, Information Form Based on Watson's Human Care Theory, Chronic Obstructive Pulmonary Disease Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected. Subsequently, education, counseling nursing care and education booklet based on Watson's Human Care Theory will be given.
~Teleconsultation based on Watson's Human Care Theory will be given during the intervention at weeks 2, 4, 6, 8 and 10.
~24-hour tele-consultancy will be given on subjects determined for the management of COPD in case of necessity at the request of the individual.
~In the last intervention in the 12th week, face to face with the individual, Consultancy based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form, Telephone Interview Evaluation Form will be applied."
16360335|NCT04256070|No Intervention|Standart care, no intervention|"Informed Consent Form will be taken in writing from those who agree to participate in the research.
~At the first meeting, Information Form Based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected.
~Interventions will not be applied to individuals in this group and routine treatment and follow-up will continue.
~- COPD Self-efficacy Scale, face-to-face meeting at the end of the 12th week. George Quality of Life Scale, Respiratory Function Test Form will be repeated.
~A training booklet for COPD management will be provided."
16360336|NCT04256057|Other|magnesium sulphate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
16360337|NCT04256044||Observational|Observational
16360338|NCT04256031||Excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are higher than 30
16360339|NCT04256031||Non-excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are 30 or less
16360340|NCT04256018|Experimental|LD TSEBT|"Mogamulizumab with low dose total skin electron beam therapy. •
~LD (12 Gy) TSEBT will be initiated on Cycle 1 Day 2 (± 2 days) of mogamulizumab over 2 to 3 week period per standard of care (SOC), as tolerated. Mogamulizumab (1 mg/kg) will be administered over 60 minutes as follows (per SOC and FDA approved use in MF and SS):
~Cycle 1 only: Days1; 8; 15; and 22 (± 2 days)
~Cycle 2 and beyond: Day 1 and Day 15 (± 3 days)"
16360341|NCT04256005|No Intervention|Control|Participants will attend the laboratory and complete no exercise. The participants will remain seated for the 29 minutes of the session.
16360342|NCT04256005|Experimental|105% VO2Peak|Participants will complete ten intervals at a work rate which equates to 105% VO2peak with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
16360343|NCT04256005|Experimental|50% ∆ Gas Exchange Threshold|Participants will complete ten intervals at a work rate which equates to 50% ∆ GET with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
16360344|NCT04255992|Active Comparator|Calcium arm|1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
16360345|NCT04255992|Active Comparator|Vitamin D/Calcium|1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
16360346|NCT04255979|Experimental|Cohort 1|Single dose of HY209 0.1 mg/kg or placebo.
16360347|NCT04255979|Experimental|Cohort 2|Single dose of HY209 0.2 mg/kg or placebo.
16360348|NCT04255979|Experimental|Cohort 3|Single dose of HY209 0.4 mg/kg or placebo.
16360349|NCT04255979|Experimental|Cohort 4|Single dose of HY209 0.8 mg/kg or placebo.
16360350|NCT04255979|Experimental|Cohort 5|Single dose of HY209 1.6 mg/kg or placebo.
16360351|NCT04255979|Experimental|Cohort 6|Single dose of HY209 3.2 mg/kg or placebo.
16360352|NCT04255966||Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
16360353|NCT04255953|Active Comparator|Treatment as Usual|Following baseline assessment, patients randomized to the TAU arm will receive monthly dietary pamphlets and web-based obesity prevention educational materials from the U.S. Office of Disease Prevention and Health Promotion (https://healthfinder.gov/HealthTopics/). After the 6-month assessment, TAU patients will begin the weight loss intervention arm.
16360354|NCT04255953|Experimental|Group Telehealth Obesity|Participants will receive 24 weekly group phone counseling sessions and monthly individual sessions that encourage healthy eating and exercise. The planned intervention is guided by a social-cognitive framework and includes self-monitoring, goal setting, stimulus control, social support, cognitive reframing of unrealistic and negative thoughts, and developing positive expectancies for long-term weight control. The primary objective is to decrease caloric intake and increase physical activity to produce weight loss of approximately .4 to.9 kg per week, with the study goal of 10% reduction from baseline.
16360355|NCT04255940||After outbreak|
16360356|NCT04255940||Past 3 months|
16360357|NCT04255940||Last year|
16360358|NCT04255927|Experimental|Coated Polyglactin 910 with Triclosan|Coated Polyglactin 910 with Triclosan
16360359|NCT04255927|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated Polyglactin 910 without Triclosan
16360360|NCT04255914|Experimental|Root coverage procedure along with orthodontic treatment|subepithelial connective tissue graft and orthodontic levelling and alignment
16360361|NCT04255914|Active Comparator|Root coverage procedure only|sub epithelial connective tissue graft procedure for recession coverage
16360362|NCT04255888|Active Comparator|Thick periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
16360364|NCT04255875|Experimental|Treatment Healthy Participants|Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326
16360365|NCT04255875|Placebo Comparator|Placebo Healthy Participants|Participants will receive matching placebo
16360366|NCT04255875|Experimental|Treatment for SCD|Participants will receive a multiple dose of subcutaneous PF-07209326
16360367|NCT04255862|Experimental|Test 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).
16360368|NCT04255862|Other|Reference 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).
16360369|NCT04255862|Experimental|Test 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).
16360370|NCT04255862|Other|Reference 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
16360371|NCT04255849|Experimental|9-valent HPV vaccine|Participants receive 9-valent HPV vaccine 0.5mL at entry, Month 2 and Month 6
16360372|NCT04255849|Placebo Comparator|Saline Placebo|Participants receive 0.9% NaCl 0.5 mL at entry, Month 2 and Month 6
16360373|NCT04255836|Experimental|Durvalumab therapy|Chemo+Durvalumab (PD-L1 monoclonal antibody)1500 mg every 3 weeks [q3w] intravenously [iv] for 4 cycles, then SBRT 50-60 Gy/≤10f + Durvalumab 1500 mg q4w, then Durvalumab 1500 mg q4w for up to 24 months or until progression or other discontinuation criteria are met.
16360374|NCT04255823|Experimental|Multi-faceted intervention|"A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (>300DDD/patient/year).
~Their general practitioner (GP) will receive a dear doctor letter with an algorithm related to PPI deprescribing."
16360375|NCT04255823|Experimental|"Dear doctor letter of the GP"|"Only the GP will receive the dear doctor letter with the algorithm.
~Their patients will not receive any patient education material."
16360376|NCT04255823|No Intervention|Control|Neither the patients nor their GP will receive information.
16360377|NCT04255810||Women with breast implants and self-reported symptoms of BII|Women undergoing elective breast implant removal without replacement who self-report systemic symptons associated with BII
16360378|NCT04255810||Women with breast implants and no self-reported BII|Women undergoing elective breast implant exchange or removal without self-reported symptoms of BII
16360379|NCT04255810||Women undergoing elective mastopexy (breast lift)|Women undergoing an elective mastopexy (breast lift) without breast implants or soft tissue support
16360380|NCT04255797|Experimental|experimental group|The experimental group will perform massage in an incubator. The researchers provide a natural plant-based massage oil for the parents.
16360381|NCT04255784|Experimental|Active iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days. Each session will deliver 1800 pulses of active iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
16360382|NCT04255784|Sham Comparator|Sham iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 1800 pulses of sham iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
16360383|NCT04255771|Experimental|Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI|This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.
16360384|NCT04255771|Placebo Comparator|Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion|As a control, this clinical trial also set up a placebo control group. The effect of adjuvant chemotherapy was obtained by random grouping and comparing the effects of patients in the experimental group and the control group.
16360385|NCT04255758|Experimental|Vigorous-intensity Aerobic Exercise|Vigorous-intensity aerobic exercise, single intervention
16360386|NCT04255745|No Intervention|Assessment-only control|30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
16360387|NCT04255745|Experimental|Intervention|60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
16360388|NCT04255732|Other|Extent of retinal periphery area viewing|For the 30 patients fundus photography will be performed using two ultra-wide-field imaging systems.
16360389|NCT04255719|Experimental|Unilateral DBS of the subthalamic nucleus (STN)|To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS. The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits. Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state. 45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
16360390|NCT04255719|Experimental|Unilateral DBS of the globus pallidus interna (GPi)|To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS. The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
16360391|NCT04255706|Other|Biometric measurement repeatability|Biometric measurements will be performed in all patients
16360523|NCT04254887|Active Comparator|EST|Large incision of the duodenal nipple
16360392|NCT04255693|Experimental|Change in disease manifestations|The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.
16360393|NCT04255693|Active Comparator|No change in disease flow|"To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the experimental groups factors will be analysed to establish the difference."
16360394|NCT04255680||FRDA Subjects|Male and female subjects with FRDA confirmed by genetic testing (aim for a 50:50 distribution of males to females)
16360395|NCT04255680||Controlled Subjects|Male and female control subjects (matched by age [+/- 2 years] and sex)
16360396|NCT04255667||Study group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing with hemostat at start of surgery
16360397|NCT04255667||Control group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing without hemostat
16360398|NCT04255654|Experimental|Brief Intervention|There is only 1 intervention for this study. They will have the brief intervention completed on them. There is no control group.
16360399|NCT04255641||frozen embryos|
16360400|NCT04255628||with cancer pain|head and neck and esophageal cancer patients. with cancer pain
16360401|NCT04255628||without cancer pain|head and neck and esophageal cancer patients. without cancer pain=30
16360402|NCT04255615|Other|3D Ultrasound with AI|AI tool to assess antral follicle count using 3 D Ultrasound
16360403|NCT04255602|Experimental|low dose ticagrelor|After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation
16360404|NCT04255602|Active Comparator|standard dose ticagrelor|subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation
16360405|NCT04255589|Experimental|Experimental Group|Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)
16360406|NCT04255589|Active Comparator|Active comparator Group|Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)
16360407|NCT04255576|Experimental|Experimental: JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg SC Q4W with a loading dose of 2 mg/kg SC on study days 8 and 15.
16360408|NCT04255563||DCB treatment|DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
16360409|NCT04255537||Patients with STEACS intended for urgent angio/reperfusion.|This population mostly includes STEACS patients for whom primary PCI is intended. A minority of this population includes patients with STEACS intended for urgent angiography for persistent ST elevation and/or symptoms but with symptoms onset > 12 hours (secondary PCI), urgent angiography after failed fibrinolysis (rescue PCI), or patients receiving fibrinolysis.
16360410|NCT04255537||Patients with STEACS NOT intended for urgent angio/reperfusion|This population mostly includes STEACS patients not receiving reperfusion for late presentation (i.e. > 12 hours) or patient preference. Note that patient in this category may receive diagnostic angiography for better diagnostic assessment and/or risk stratification but NOT on an urgent basis.
16360411|NCT04255537||Patients with NSTEACS intended for invasive management|This population includes patients with NSTEACS managed invasively with coronary angiography within 72 hours. Most patients are a high-risk feature (i.e. positive troponin, GRACE risk score > 140, hemodynamic/electrical instability) for whom angiography is intended.
16360412|NCT04255537||Patients with NSTEACS NOT intended for invasive management|This population includes patients who are candidate for an initially conservative strategy. Note that this category may include patients who are subsequently managed with coronary angiography, including recurring symptoms of myocardial ischemia, or hemodynamic/ electrical instability.
16360413|NCT04255524|Experimental|Group 1/Control|Spherical equivalent: -2.00～+2.00 D
16360414|NCT04255524|Experimental|Group 1/Myopia|Spherical equivalent: -3.00～-6.00 D
16360415|NCT04255524|Experimental|Group 3/High|Spherical equivalent: -6.00～-10.00 D
16360416|NCT04255524|Experimental|Group 4/Super High|Spherical equivalent: <-10.00
16360417|NCT04255511|Experimental|Twin block|Removable Functional appliance
16360418|NCT04255511|Active Comparator|Fixed appliance|Preadjusted fixed appliance
16360419|NCT04255498|Experimental|Etanercept|50 MG/ML Prefilled Syringe (once a week for 4 weeks)
16360420|NCT04255498|Experimental|Mifepristone|(300 mg once a day for 7 days) will follow the etanercept.
16360421|NCT04255485||Short time anesthesia group|Unilateral cochlear implantation,which time of anesthesia is less than 3 hours
16360422|NCT04255485||Long time anesthesia group|Bilateral cochlear implantation, which time of anesthesia is more than 3 hours
16360423|NCT04255472|Experimental|WHO caregiver skills training program|Strategies to support children's communication skills by learning to engage in play activities and daily home routines activities with their caregivers.
16360424|NCT04255472|Experimental|Treatment as usual (TAU)|TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets.
16360425|NCT04255459|Other|Moist Snuff users|Subjects for whom moist snuff is their usual brand of tobacco product.
16360426|NCT04255459|Other|Camel Snus users|Subjects for whom Camel Snus is their usual brand of tobacco product.
16360427|NCT04255459|Other|Dual users of Camel Snus and cigarette|Subjects who use both Camel Snus and cigarettes as their usual brands of tobacco products.
16360428|NCT04255459|Other|Dual users of moist snuff and cigarettes|Subjects who use both moist snuff and cigarettes as their usual brands of tobacco products.
16360429|NCT04255459|Other|Cigarette smokers|Subjects for whom cigarettes is their usual brand of tobacco product.
16360430|NCT04255459|Other|Non-tobacco users|Subjects who do not use tobacco products.
16360431|NCT04255446||Dysfunctional Breathing|Patients with Dysfunctional breathing age between 16 to 75 will be included.
16360432|NCT04255446||Healthy Volunteers|Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.
16360435|NCT04255420|Experimental|SPG Block|Sphenopalatine ganglion block using cotton-tipped applicators soaked in 1% lidocaine will be performed.
16360436|NCT04255420|Active Comparator|Standard Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg.
16360437|NCT04255407|Experimental|I-ONE® group|"I-ONE® therapy will be initiated in the 15 days preceding the ACL reconstruction surgery and in the first 60 days following the surgery.
~Paracetamol 1000 mg will be supplied to both groups, to be taken for pain control as per normal clinical practice."
16360438|NCT04255407|Placebo Comparator|Control group|Patients will not be treated with I-ONE®. Pain will be treated with common NSAID and Paracetamol.
16360439|NCT04255381|Experimental|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Use Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system
16360440|NCT04255368|Experimental|Water-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
16360441|NCT04255368|Experimental|Fat-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
16360442|NCT04255368|Active Comparator|No choline|A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.
16360443|NCT04255355|Active Comparator|Pelvic alignment and forceful expiration exercise|
16360444|NCT04255355|Experimental|Pelvic repositioning exercise|
16360445|NCT04255355|Experimental|Diaphragmatic breathing exercise|
16360446|NCT04255342|Active Comparator|Group 1|Group 1: 3 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
16360447|NCT04255342|Active Comparator|Group 2|Group 2: at 6 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed.
16360448|NCT04255342|Active Comparator|Group 3|Group 3: 9 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
16360449|NCT04255329|Other|Usual reading group|The leader of the activity reads aloud a text to four participants seated around the table. The readen text is a normal, currently used in a everyday life support such as a journal article. Consequently it is not previously adaptated to people with cognitive impairements. After the reading phase, the leader asks the participants the questions about the content.
16360450|NCT04255329|Other|Montessori reading roundtable group|The group counts four participants and one activity leader. Each person have the same Montessori reading roundtable book.
16360451|NCT04255316|Experimental|Modified eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a modified eversion carotid endarterectomy
16360452|NCT04255316|Active Comparator|Standard eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a standard eversion carotid endarterectomy
16360453|NCT04255303|Experimental|Usability testing|"A near-live clinical laboratory for refining iCPR workflows with a high likelihood of adoption. Using think-aloud and thematic protocol analysis procedures, written simulations of sore throat and cough patient encounters with 6-8 RNs will be observed and analyzed. RNs will be instructed to follow think-aloud protocols throughout, which call for them to verbalize all thoughts as they interact with the system. Subsequent cohorts of 6-8 RNs will participate in rapid-cycle, low-cost, near-live usability sessions where they interact with a simulated patient rather than a written scenario. Simulations will be conducted in-situ at a representative practice location. All will be audio-taped and screen-capture software will be used to record all human-EHR interactions."
16360454|NCT04255303|Experimental|live-usability testing|"This pre-clinical testing serves as a near-live clinical laboratory for refining iCPR workflows with a high likelihood of adoption. Using think-aloud and thematic protocol analysis procedures, written simulations of sore throat and cough patient encounters with 6-8 RNs will be observed and analyzed. RNs will be instructed to follow think-aloud protocols throughout, which call for them to verbalize all thoughts as they interact with the system. Subsequent cohorts of 6-8 RNs will participate in rapid-cycle, low-cost, near-live usability sessions where they interact with a simulated patient rather than a written scenario. Simulations will be conducted in-situ at a representative practice location. Additional cycles of near-live usability testing will be conducted if required to model the impact of proposed changes to the iCPR tools or workflows. All sessions will be audio-taped and screen-capture software will be used to record all human-EHR interactions."
16360455|NCT04255303|No Intervention|Control No intervention group|standard care will continue as usual.
16360456|NCT04255290|Experimental|Experimental group|Leg Squat Lounge: The player will be placed in squat position and her partner will be placed behind, suspending the most posterior leg in the air. With the leg that is supported, you will perform a monopodal jump with controlled fall, supporting the foot from tip to heel. It will be done with both lower limbs performing 1 series of 5 repetitions with 30 seconds of rest between sets. 180 jump: The footballer will start in bipodal support, with the trunk erect and hands on the hips. Perform a bipodal jump with a 180º turn during this, keeping the fall for 2 seconds. Each repetition, the turn will be done in a different sense. It will carry out 2 series of 20 sec of execution with 20 sec of rest between series. Brad jump stick landing: The player will stand in hands-free standing. Perform a bipodal jump as far as possible. The knees will not exceed the tip of the foot and the fall will be with a trunk position as straight as possible. He will make 5 jumps the first two weeks.
16363272|NCT04235322|Experimental|2LHERP® arm|2LHERP® treatment (6 months of treatment)
16360457|NCT04255290|Active Comparator|Control group|"Nordic Funds: One player will stand on her knees, while the other, behind, fixes her legs. The kneeling footballer must drop forward in a controlled manner until she touches the ground and returns to the starting position. The Diver: Player in monopodal support on the lower limb to work, performing hip flexion with the arms forward and the opposite lower limb back, looking for a horizontality in the pelvis (with 10º-20º knee flexion) It will be done with both lower limbs.
~The Glider: With the footballer standing in front of her partner, holding both of them by the shoulders, she lets one leg slide back while the other stays fixed. To return to the starting position, it will be helped by the other player, while the knee will not exceed 10 degrees of flexion. The distribution of all the exercises will be: 2 sets of 5 repetitions with 20 sec rest between sets"
16360467|NCT04255264||Study patients|Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status.
16360468|NCT04255251|Experimental|Intervention group|Subjects in this group will receive Silver Diamine Fluoride around their crown margins every six month for the next 3 years.
16360469|NCT04255251|Active Comparator|Fluoride varnish group|Subjects in this group will receive fluoride varnish around their crown margins every six month for the next 3 years.
16360470|NCT04255238|Experimental|Gemigliptin 50 mg and Dapagliflozin 10 mg|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin 10 mg per day
~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
16360471|NCT04255238|Active Comparator|Gemigliptin 50 mg and Dapagliflozin placebo|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin placebo per day
~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
16360472|NCT04255238|Active Comparator|Gemigliptin placebo and Dapagliflozin 10mg|"Subject shoud took 1 tablet of Gemigliptin placebo and 1 tablet of Dapagliflozin 10 mg per day
~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
16360473|NCT04255225|Experimental|10-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
16360474|NCT04255225|Experimental|20-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
16360475|NCT04255225|Experimental|30-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
16360476|NCT04255212|Experimental|Soft tissue treatment|Participants will be treated with 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms.
16360477|NCT04255212|Placebo Comparator|Mechaninsms explanation|Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
16360478|NCT04255212|Sham Comparator|Anatomy and human upper limb functions|Participants will be instructed with a 10 minute lesson on the anatomy of the upper limb and on upper limb functions in human evolution. It will be explained that human upper limb has the unique ability to throw objects stronger and faster than any other animal on the planet and also that compared to the monkeys is not properly developed for climbing. Human world records of single finger pull and double hands pull will be presented.
16360479|NCT04255199|Experimental|Intervention|Primary care and urgent care clinicians randomized to the intervention arm will receive two to three visits with a standardized patient instructor who will physicians how to facilitate patient acceptance of a watchful waiting strategy with regard to spinal imaging in the context of acute low back pain.
16360480|NCT04255199|Placebo Comparator|Control|Primary care and urgent care clinicians randomized to the control arm will receive a single visit with a standardized patient who simulates a visit with patient with acute low back pain but will deliver no instruction on patient communication or other content.
16360481|NCT04255186|Experimental|Thermal CRMRF|"9 sessions in 3 week of Thermal CRMRF: The power of the RFCR equipment in this intervention will be 35 VA in capacitive method (10% of the maximum power of the equipment) and 30 W in the resistive method (15% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
~In Thermal CRMRF it will be necessary to adapt to the patient's thermal sensitivity"
16360482|NCT04255186|Experimental|Subthermal CRMRF|9 sessions in 3 week of Subthermal CRMRF: The power of the RFCR equipment in this intervention will be 7 VA in capacitive method (2% of the maximum power of the equipment) and 4 W in the resistive method (2% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessions a week).
16360483|NCT04255186|Sham Comparator|Sham CRMRF|9 sessions in 3 week of sham stimulation: The application will be carried out in the same way as in the experimental groups, but in this case the manufacturer will introduce a simulated stimulation protocol so that the device does not emit current + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
16360484|NCT04255173|Experimental|Geriatric osteoporotic patients|We measured different anthropometric and body composition measurements as body weight, BMI, percentage body fat, skeletal muscle index (SMI), ABSI, waist (WC) and hip circumference (HC) in geriatric population to investigate the relation to osteoporosis.
16360485|NCT04255160|Experimental|Estradiol|Transdermal estradiol (0.1mg/day patch)
16360486|NCT04255160|Placebo Comparator|Placebo|Placebo
16360487|NCT04255147|Experimental|Mesenchymal Stromal Cell Therapy|Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee.
16360488|NCT04255134|Experimental|Abatacept|Drug administered to participants with active rheumatoid arthritis
16360489|NCT04255134|Active Comparator|Adalimumab|Comparator drug administered to participants with active rheumatoid arthritis
16360490|NCT04255121|Experimental|alkalinization of adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
16360491|NCT04255121|Active Comparator|adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using a adrenaline lidocaine solution
16360492|NCT04255108||Men/Women who meet the inclusion/exclusion criteria|
16360493|NCT04255095|Active Comparator|Nasobiliary drainage|
16360494|NCT04255095|Experimental|Naso-pancreatic drainage(negative pressure)|
16360495|NCT04255069|Placebo Comparator|Placebo|Placebo, oral, daily
16360496|NCT04255069|Experimental|Dose 1|JKB-122, Dose 1, oral, daily
16360497|NCT04255069|Experimental|Dose 2|JKB-122, Dose 2, oral, daily
16360498|NCT04255056|Experimental|Pyrotinib|"Eligible patients will receive four cycles of epirubicin and cyclophosphamide combined with pyrotinib.
~Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.
~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
16360499|NCT04255043|Experimental|IVUS-guided DCB|In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.
16360500|NCT04255043|Active Comparator|Angiography-guided DCB|In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.
16360501|NCT04255030|Experimental|First stage: Self-directed Coping Together|
16360502|NCT04255030|Experimental|First stage: Minimally guided telephone support (lay coaching)|
16360503|NCT04255030|Experimental|Second stage: High intensity Motivational Interviewing (MI)|
16360504|NCT04255017|No Intervention|Symptomatic supportive treatment|Symptomatic supportive treatment
16360505|NCT04255017|Experimental|Abidol hydrochloride was added on the basis of group I.|Abidol hydrochloride 0.2g once,3 times a day,2 weeks
16360506|NCT04255017|Experimental|Oseltamivir was added on the basis of group I.|Oseltamivir 75mg once,twice a day,2 weeks
16360507|NCT04255017|Experimental|Lopinavir/ritonavir was added on the basis of group I.|Lopinavir/ritonavir 500mg once,twice a day,2 weeks
16360508|NCT04255004|Active Comparator|A-PBMNC therapy|Patients in A-PBMNC therapy are treated with wound bed multiple perilesional and intramuscular injections of PBMNC cells suspension (0.2-0.3cc in boluses). This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
16360509|NCT04255004|No Intervention|No A-PBMNC therapy|Patients in No A-PBMNC therapy receive only supportive treatment including wound care and pain killer drug.
16360510|NCT04254991||Infectious disease group|
16360511|NCT04254991||Non-infectious disease group|
16360512|NCT04254978|Experimental|IMG-7289|IMG-7289 administered daily for 169 consecutive days
16360513|NCT04254965|Experimental|Group 1|Participants of integrated music therapy (integration of active and passive music therapy) includes instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. The four stages of activities are warm-up, main activities, secondary activities, and the ending section.
16360514|NCT04254965|Active Comparator|Group 2|Participants of the music listening group will receive background music listening, music selection based on the musical preference and background of subjects, for relax or boost the spirit of the subjects.
16360515|NCT04254965|Sham Comparator|Group 3|Participants in the control group receive their regular occupational therapy during the experimental period.
16360516|NCT04254939|Experimental|CS3007(BLU-285)|
16360517|NCT04254926|Experimental|Revie ⊕ intervention early|participants randomized into (i) the intervention group (IG) receive the Revie ⊕ intervention early on.
16360518|NCT04254926|Experimental|Revie ⊕ intervention later|The control group (CG) receives the same intervention Revie ⊕ but later on (i.e., after eight weeks).
16360519|NCT04254913|Experimental|MT-1186|Patients receive the edaravone oral suspension.
16360520|NCT04254900||Male wheelchair athletes|Other
16360521|NCT04254900||Female wheelchair athletes|Other
16360522|NCT04254887|Experimental|EPBD|Small incision of the duodenal nipple + EPBD
16360524|NCT04254874|Experimental|Abidol hydrochloride|Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day).
16360525|NCT04254874|Experimental|Abidol Hydrochloride combined with Interferon atomization|Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I.
16360526|NCT04254861|Experimental|Simplified Papilla Preservation Flap (SPPF) and PRGF|
16360527|NCT04254861|Active Comparator|Simplified Papilla Preservation Flap (SPPF) and GTR|
16360528|NCT04254848|Experimental|completely edentulous patients with maxillary tori|20 completely edentulous patients with maxillary tori will be recruited for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
16360529|NCT04254848|Active Comparator|completely edentulous patients without maxillary tori|20 completely edentulous patients without maxillary tori will serve as control group for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
16360530|NCT04254835|Experimental|intervention group|Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
16360531|NCT04254835|Active Comparator|control group|"Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study.
~Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks."
16360532|NCT04254822|Experimental|HVPG-guided therapy|HVPG will be determined before randomization. In this arm, patients with an adequate reduction in HVPG (responders) receive carvedilol whereas nonresponders receive TIPS.
16360533|NCT04254822|Active Comparator|Standard therapy|In this group, both responders and nonresponders will receive combination therapy of carvedilol and endoscopic variceal ligation as first-line therapy. If first-line therapy fails, TIPS will considered.
16360534|NCT04254809|Experimental|Re-Evaluating Suicidal Thoughts|Participants in this condition will complete the experimental intervention at the baseline appointment.
16360535|NCT04254809|Sham Comparator|Healthy Social Living|Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.
16360536|NCT04254796|Experimental|TARA Training|
16360537|NCT04254796|No Intervention|Control|
16360538|NCT04254783|Experimental|Cytochrome P450 (CYP) + Risankizumab|In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
16360539|NCT04254770|Active Comparator|ADA (American Dental Association) approved Manual Toothbrush|
16360540|NCT04254770|Experimental|Marketed Power Toothbrush|
16360541|NCT04254757|Other|Percutaneous endoscopic surgery group|
16360542|NCT04254757|Other|Open decompression and fusion surgery group|
16360543|NCT04254744||Acyanotic children|Acyanotic children undergoing cardiac surgery due to congenital heart disease
16360544|NCT04254744||Cyanotic children|Cyanotic children undergoing cardiac surgery due to congenital heart disease
16360546|NCT04254718|Experimental|Digital Storytelling|Legacy intervention via digital story for NICU parents
16360547|NCT04254705|Other|Subjects with CF and R334W mutation|Subjects with CF and R334W mutation
16360548|NCT04254692|Active Comparator|Liposomal Bupivacaine|Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
16360549|NCT04254692|Other|Bupivacaine|Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
16360550|NCT04254679|Experimental|Opioid analgesia|
16360551|NCT04254679|Active Comparator|Opioid-free analgesia|
16360552|NCT04254666|Other|Physical Literacy & Food Literacy Intervention|This is a pilot project to assess the feasibility of a physical literacy and food literacy intervention for adolescents with ID ages 12-16 years.
16360553|NCT04254653|Experimental|Immediate Intervention|Participants receive diabetes nutrition education classes immediately.
16360554|NCT04254653|Experimental|Wait list intervention|Participants wait listed (control) for 3 months and then receive the diabetes nutrition education classes.
16360555|NCT04254640|Experimental|C-CAG|cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.
16360558|NCT04254614|Experimental|Personalised mobile application for IBD patients|This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.
16360559|NCT04254601|Experimental|Experimental group 1|Patients in group (A) consisted of 15 participants, received a program of NBUB, DIXWELL EMLY 98 -ABRP 64 ,made in France (wavelength 311 to 313nm) , in addition to topical aknemycin medications (topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period after 8 weeks).
16360585|NCT04254380|Active Comparator|Active Comparator: Humalog|EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled). Subjects randomized to the Humalog group will participate in the study for 26 weeks.
16363273|NCT04235322|Placebo Comparator|Placebo arm|Placebo treatment (6 months of treatment)
16360560|NCT04254601|Experimental|Experimental group 2|Participants in-group (B) consisted of 15 participants, received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks Plus topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
16360561|NCT04254601|Active Comparator|Control group|Patients in the group C, consisted of 15 participants, were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
16360562|NCT04254588||Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED.
16360563|NCT04254575||body dysmorphic disorder (BDD)|Adults with a current primary diagnosis of body dysmorphic disorder (BDD)
16360564|NCT04254562|Experimental|Experimental Group: HYPE Services|The experimental arm will be receiving the HYPE intervention for 12 months and followed for an additional 24 months.
16360565|NCT04254562|Active Comparator|Control Group: Enhanced Academic Services|"The control arm will receive a special personalized packet of resources available on campus as enhanced academic services as usual."
16360566|NCT04254549|Experimental|Intervention Treatment|Subjects diagnosed with gastroparesis will receive Rifaximin
16360567|NCT04254549|Placebo Comparator|Placebo Group|Subjects diagnosed with gastroparesis will receive a placebo
16360568|NCT04254523|Experimental|Programmed intermittent epidural bolus (PIEB)|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour.
16360569|NCT04254523|Experimental|Continuous epidural infusion (CEI)|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate in milliliters per hour.
16360570|NCT04254510|Experimental|Study Group|Myofascial relaxation technique
16360571|NCT04254510|No Intervention|Control group|
16360572|NCT04254484|Experimental|SIESTA Rehab|"Stroke floor on which nurses will be receiving training (SIESTA Rehab Education) on how to minimize nighttime disruptions and batching overnight tasks to preserve sleep for patients hospitalized on that floor. Stroke patients admitted to the SIESTA Rehab Unit will be screening for sleep disordered breathing using ApneaLink.
~Patients hospitalized on this unit will be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
16360573|NCT04254484|No Intervention|Control Unit|"Patients on this unit will receive usual care for stroke patients as outlined by SRALab. including routine nursing care without any intervention to promote sleep like SIESTA and routing sleep disorders screenings based on clinician judgement.
~Patients hospitalized on this unit will also be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
16360574|NCT04254471|Experimental|Dose escalation (AL3810 + carboplatin + etoposide)|Phase II:Participants will receive AL3810 orally in combination with carboplatin and etoposide during the Cycles 1-4 . AL3810 dose escalated form 5mg to 10mg step-up to determine the recommended dose of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
16360575|NCT04254471|Experimental|AL3810+ carboplatin + etoposide|Phase III:Participants will receive AL3810(recommended dose will be determined by safety monitoring committee (SMC) in Phase II) orally in combination with carboplatin and etoposide during the Cycles 1-4. Thereafter, participants will receive maintenance AL3810 until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
16360576|NCT04254471|Placebo Comparator|Placebo+ carboplatin + etoposide|Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
16360577|NCT04254458||PACG group|Cases who had first acute attack of primary angle closure glaucoma
16360578|NCT04254445|Experimental|Training video arm|Patients will watch a personalized custom training video, in addition to the standard explanation provided by the medical staff
16360579|NCT04254445|No Intervention|Verbal explanation arm|Patients will standard explanation about the procedure, provided by the medical staff
16360580|NCT04254432|Experimental|remote ischemic conditioning arm|Device: remote ischemic conditioningRIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 30+/-2days. Other Names:• RICDevice: ambulatory blood pressure monitoring diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment
16360581|NCT04254419|Experimental|NK cell infusion|"For source PBMCs from the patient, up to 3ml/kg (maximum 150ml) of heparinized peripheral blood will be drawn. NK cell product will be manufactured by a GMP facility. Once the NK cell goes through the appropriate procedures, it will undergo a lot release testing and cryopreservation by day 14 for infusion.
~If NK cells fail to meet release criteria or are insufficient in number for the dose level assigned, collection of PBMCs may be repeated up to 2 additional times.
~Duration of study therapy is up to 12 weeks and nine doses of NK cells."
16360582|NCT04254393|Experimental|Early Adolescent Skills for Emotions (EASE) Program|Early Adolescent Skills for Emotions (EASE) is a new, brief, targeted, group psychological intervention program (Dawson et al., 2019) based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (WHO, 2016).
16360583|NCT04254393|Placebo Comparator|Treatment as Usual (TAU)|Participants in control arm will be able to avail the routine services available in school settings.
16360584|NCT04254380|Experimental|Experimental: Gan & Lee Insulin Lispro Injection|Gan & Lee Insulin Lispro Injection for subcutaneous injection, 100 U/mL, in a disposable multidose pen injector with a pre-filled 3-mL type I glass cartridge. Subjects randomized to the Gan & Lee Insulin Lispro Injection group will participate in the study for 26 weeks.
16360614|NCT04254185|Active Comparator|Subcutaneous anterior transposition|Anterior transposition repositions the ulnar nerve, providing decompression and lengthening by moving the nerve anterior to the axis of elbow rotation
16360586|NCT04254367|Experimental|Intervention group - experimental TAU + intervention|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
16360587|NCT04254367|No Intervention|TAU - no intervention|Treatment as usual following local routines on each primary care center
16360588|NCT04254354||transgender men|no intervention
16360589|NCT04254341||patients with OSA|Subjects that underwent regular sleep studies (PSG) and found to have moderate/severe obstructive sleep apnea
16360590|NCT04254341||subjects without OSA|Subjects that underwent regular PSG and found not to have sleep apnea
16360591|NCT04254328|Experimental|Nintendo Wii Fit|Nintendo Wii Fit group work program; 13 exercises in 5 groups including 3 yoga exercises, 3 balance exercises, 2 aerobic, 2 training plus exercises and 3 muscle-workout will be done respectively. Patients in this group will exercise for 8 weeks, 3 days in a week and 40-50 minutes of exercise within resting interval.
16360592|NCT04254328|Experimental|Respiratory|Respiratory training group participants' will do deep breathing exercise against resistance of 30% of intraoral pressure. This exercise will be applied for 8 weeks, each day of the week, twice in a day for 15 minutes and 4-5 normal breaths after 4-5 deep breaths. Each week, intraoral pressure will be measured and new training intensity values will be determined.
16360593|NCT04254328|No Intervention|Control|Patients in the control group will not be included in any exercise program, but all groups will be advised of walking in order to increase physical activity level.
16360594|NCT04254315|Experimental|Cardiac rehabilitation+cognitive therapy|"The intervention group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively.
~In addition, the intervention group follows a standardized group based cognitive therapy program with participation of maximum four patients, consisting of 5 sessions (each 2 hours) performed by a trained cardiac rehabilitation nurse."
16360595|NCT04254315|No Intervention|Cardiac rehabilitation|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
16360596|NCT04254315|No Intervention|Control group without psychological distress|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
16360597|NCT04254302|No Intervention|Control|Participants randomized into the control arm will receive usual care as per the service delivery models and pathways planned in their region. As a pragmatic trial, no attempt will be made to standardize practices which may vary across professionals. Usual practices may be categorised as either reference to online websites deemed appropriate by their healthcare professional, general recommendations, referral for services, or none of the above.
16360598|NCT04254302|Experimental|Experimental|WECARE intervention include: 1) 30-minute appointments with an occupational therapist or a physiotherapist, as part of a multidisciplinary team, to problem-solve the child's motor performance issues, provide recommendations to stimulate the child's motor development, and intervene online directly with the child, if needed; offered bimonthly during the first three months, then on a patient-identified needs-basis. 2) A chat function where participants can privately contact the therapist; flexible access as per participant needs. 3) A forum open to all intervention group participants where they can communicate with each other or with the therapist, who will also act as a forum moderator; flexible access as per participant needs. 4) Access to static online information via relevant websites and resources on child development; flexible access based on participant needs.
16360599|NCT04254289|Active Comparator|Usual Care|Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
16360600|NCT04254289|Experimental|Home-based exercise program|Home-based individualized exercise program based on heart rate reserve (HRR).
16360601|NCT04254276||Symptomatic group|Office workers with neck and shoulder area musculoskeletal pain
16360602|NCT04254276||Asymptomatic group|Office workers without neck and shoulder area musculoskeletal pain
16360603|NCT04254263|Experimental|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
16360604|NCT04254263|No Intervention|No Pyrotinib|Observation follow-up
16360605|NCT04254250||High risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
16360606|NCT04254250||Low risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
16360607|NCT04254237|Active Comparator|Intervention group|Infraumbilical Hasson trocar incision.
16360608|NCT04254237|Sham Comparator|Control group|Supraumbilical Hasson trocar incision.
16360609|NCT04254224||Diverticulitis Hinchey I-IV|Patients with complicated diverticulitis (Hinchey I-IV) treated conservatively (iv antibiotics with or without percutaneous, transrectal or transvaginal drainage) or surgically.
16360610|NCT04254211||EVAR|Patinets with AAA, treated electively by EVAR. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively. Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause
16360611|NCT04254198|Placebo Comparator|Control|Modified Attention Placebo Control
16360612|NCT04254198|Experimental|TERTULIAS structured dialogue peer support groups|Structured Dialogue peer support group
16360613|NCT04254185|Active Comparator|Simple decompression|In-situ decompression releases only the compressive ligamentous structures overlying the ulnar nerve.
16360615|NCT04254172||Single cohort|There is no randomization or stratification in this study. All subjects will complete the same study assessments.
16360616|NCT04254159|Experimental|Neuromuscular Electrical Stimulation Group|Asthma Education Aerobic Exercise Quadriceps Strengthening by superimposed NMES
16360617|NCT04254159|Active Comparator|Control Group|Asthma Education Aerobic Exercise Quadriceps Strengthening
16360618|NCT04254146|Experimental|Study group|Aerobic exercise will be performed for a single session
16360619|NCT04254146|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
16360620|NCT04254133||Case Ascertainment|Men with metastatic prostate cancer
16360621|NCT04254133||Family Recruitment|Male relatives of men with metastatic prostate cancer found to have a germline DNA Repair Gene mutation
16360622|NCT04254120|Active Comparator|Cognitive-behavioral therapy (CBT)|
16360623|NCT04254120|Experimental|Integrated motivational interviewing and CBT|
16360626|NCT04254094||Early onset dementias (EOD)|Prospective multicenter cohort of EOD patients with a three-year follow-up in tertiary Reference Memory centers
16360627|NCT04254081|Experimental|Buprenorphine 0.15mg + 1% lidocaine paracervical block|Paracervical block with 18mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate plus 0.15mg of buprenorphine
16360628|NCT04254081|Placebo Comparator|1% lidocaine paracervical block|Paracervical block with 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate
16360629|NCT04254068|Experimental|Parent based prevention|Parent-Based Prevention (PBP; Sadeh-Sharvit & Lock, 2018) is a manualized preventive intervention, focused on increasing parental awareness and competence to facilitate healthy eating habits, body image, and self-regulation in children whose parent has an eating disorder history. PBP is comprised of three phases that focus on unique goals. The strategies in each session include psycho-education, behavioral experiment planning, and skill practicing to augment parents' insight into how the context of the parental cognitions and behaviors may impact child outcomes, with the goal of creating a longstanding effect.
16360630|NCT04254068|No Intervention|Usual care|Families randomized to usual care will be permitted to utilize any medical, psychological, or nutritional services they desire for the waitlist period of 16 weeks.
16360631|NCT04254055|Experimental|Experimental group|"Exercise 1 with medicine ball. Standing player with 90º shoulder abduction and elbow flexion. He will receive the ball with an external rotation returning it with internal rotation. Exercise 2 with elastic band. From standing, he will fix the elastic band with his foot and perform a shoulder flexion with his contralateral limb. Exercise 3 of iron with support of the hands on the floor and shoulder, elbow and wrist aligned. You should perform a scapula approach and separation without altering its initial position. Exercise 4 BodyBlade ©. From standing with 90º of 90 ° shoulder abduction and elbow flexion. It will perform an anteroposterior thrust, causing a wave effect to stabilize the shoulder joint for 30 seconds.
~Athletes will do 15 repetitions of each exercise."
16360632|NCT04254055|No Intervention|Control group|Players included in the control group will not receive any intervention.
16360633|NCT04254042|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
16360634|NCT04254042|Active Comparator|Zofenopril Arm|30 mg Zofenopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
16360635|NCT04254029|Experimental|Non-randomized single-arm of MOROLSTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.
~The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days."
16360636|NCT04254016|Experimental|Non-randomized single-arm of HIBISTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.
~The intervention consisted on the administration of Hibiscus-Stevia drink at a dose of 4 mg / kg / day / for Stevia and 4 g / day for Hibiscus for a period of 8 weeks and after meals."
16360637|NCT04254003|Other|Test, then Control|DT1 Toric contact lenses worn first, followed by AO1DfA contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
16360638|NCT04254003|Other|Control, then Test|AO1DfA contact lenses worn first, followed by DT1 Toric contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
16360639|NCT04253990|Experimental|Precut-EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.
~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
16360640|NCT04253990|Active Comparator|Conventional EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.
~Conventional EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current"
16360641|NCT04253977|Experimental|HEALTH-P2|Along with PAT National Center, parent educators affiliated with PAT sites in HEALTH-P2; with be trained to use the HEALTH-P2 training curriculum (implementation strategy).
16360642|NCT04253977|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual.
16360662|NCT04253847|Active Comparator|SRPS group|"Standard retrograde pancreatosplenectomy(SRPS) includes several key points. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
16360643|NCT04253964|Experimental|Performance Status 0-1 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.
~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.
~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:
~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
~PLUS
~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:
~Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS
~Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR
~Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
16360644|NCT04253964|Experimental|Performance Status 2 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.
~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.
~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:
~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
~PLUS
~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:
~Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS
~Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR
~Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
16360645|NCT04253951|Experimental|LUS-monitored management (LUS-m)|In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.
16360646|NCT04253951|Sham Comparator|Standard care management (SC-m)|Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.
16360647|NCT04253938|Other|Education|"Visit 1 - Parent/Caregiver will complete a questionnaire about breastfeeding/formula feeding practices and food insecurity. The questionnaire includes a nutrition history, asking how much formula is consumed, number of times they are breastfed per day, what types and amounts of solid foods are consumed, and if vitamins and/or iron drops are given (including frequency and amount). After the questionnaire, the participant will be asked to demonstrate how they typically prepare infant formula. Finally, the PI or designee will provide a brief education about appropriate feeding practices as recommended by the AAP. This will include appropriate formula preparation methods, use of juice, introduction of cow's milk and solids, as well as basic nutrition information.
~Visit 2 - If the family returns for a clinic visit again before the child turns 1 year of age, the same procedures as Visit 1 will be performed, including reinforcement of education."
16360648|NCT04253925|Experimental|global postural correction exercises|global postural correction exercises in addition to Kegel exercises
16360649|NCT04253925|Active Comparator|Kegel exercises|only Kegel exercises
16360650|NCT04253912|Experimental|VBP-245|Topical 2% Povidone-Iodine Gel
16360651|NCT04253912|Placebo Comparator|Control|Placebo Gel (no Povidone-Iodine)
16360652|NCT04253899|Active Comparator|Standard pediatric group:|patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)
16360653|NCT04253899|Experimental|Experimental pediatric group:|patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)
16360654|NCT04253899|Active Comparator|Standard adult group:|patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)
16360655|NCT04253899|Experimental|Experimental adult group:|Patients ≥18 yo with acute perforated appendicitis and observation (n=25)
16360656|NCT04253886|Active Comparator|Group A|The Ovassapian Fibreoptic Intubating Airway has a flat lingual surface that widens distally. This provides better retraction of the tongue to prevent it and the soft tissues of the anterior pharyngeal wall from herniating around the side of the airway. The airway has a pair of vertical sidewalls and two pairs of curved guide walls at its proximal section. These walls are separated by a gap which allows removal of the airway after intubation has been completed
16360657|NCT04253886|Active Comparator|Group B|"Fekry airway:
~● It has two parts are: Airway body& Special connector
~Airway body consists of:
~Flange → it is the buccal end it is 7 cm wide to prevent it from
~moving deeper into mouth & may also serve to fix airway in place.
~Bite Portion → it is straight & fits between teeth &oral cavity.
~Oral straight part → open anterior lingual part; it varies in length according to size
~Pharyngeal curved part → extends backwards to correspond the shape oropharynx and ends below laryngeal inlet.
~The connector: it is a special type (two sizes: adult and pediatric) can attach to all ventilating machines& it has a teeth rest act as a bite block."
16360658|NCT04253873|Experimental|Apatinib mesylate + temozolomide|Apatinib mesylate tablets (0-14 days, 500 mg, qd), one week apart, then temozolomide (150mg/m2, 5 days);Every 28 days is a cycle, the drug until the disease progress, the toxicity of intolerable.
16360659|NCT04253860|Experimental|TENS|Transcutaneous electrical neurostimulation will be applied for 30 minutes three times a week during 90 days
16360660|NCT04253860|Sham Comparator|Sham|A sham comparator will be applied for 30 minutes three times a week during 90 days. The device does not emit electrical impulses
16360661|NCT04253847|Experimental|RAMPS group|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
16360663|NCT04253834|Active Comparator|Control Arm|Participants will be assigned to the Incentive spirometer after surgery
16360664|NCT04253834|Experimental|GO2 Mouthpiece|Participants will be assigned to the Bidirectional Oxygenation Valve (GO2 Mouthpiece) after surgery
16360665|NCT04253821|Active Comparator|Forward head posture|
16360666|NCT04253821|Active Comparator|Non-Forward head posture|
16360667|NCT04253808|Experimental|Experimental arm|The experimental arm (N=15) will be given a CRHF diet for 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for ~6.5 weeks. The CRHF diet will be composed of 45% unsaturated fats, 25% proteins, and 30% carbohydrates.
16360668|NCT04253808|Active Comparator|Control arm|The control arm (N=15) will receive standard of care including a well-balanced diet, prescribed with enough calories/proteins to maintain body weight for approximately 2 weeks (during radiotherapy preparation) followed by standard treatment for ~6.5 weeks.
16360669|NCT04253795|Active Comparator|Laryngeal mask group (Group 1)|Laryngeal mask will be placed in the airway by the anesthesiologist. Lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing
16360670|NCT04253795|Active Comparator|Double lumen tube Group (Group 2)|After the correct position of double lumen tube will be determined, one lung ventilation will be started. Lung isolation will be achieved by deflation of the nondependent lung.
16360671|NCT04253782|Experimental|Team Intervention Arm|Recovery coaches and trained health educators will team together and meet with participants (remotely/electronically and/or by phone or in person, when appropriate) at least twice and for a maximum of 7 times. This includes access to mediation-assisted therapy, trained mental healthcare providers, and educational resources.
16360672|NCT04253756|No Intervention|18-gauge autogard catheter|Standard of care
16360673|NCT04253756|Experimental|20-gauge BD Nexiva Diffusics|Intervention
16360674|NCT04253743|Experimental|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households were randomly assigned to receive either: (1) $40 extra in SNAP benefits per eligible child (<5 years) per month (n=1,919); (2) $40 extra in SNAP benefits per eligible child per month plus case management and nutrition education (n=1,919); or (3) only regular monthly SNAP benefit (n=7,467). The first two groups were the treatment arms and the third was the control group.
16360675|NCT04253743|No Intervention|Control Group|The control group received regularly allotted SNAP benefits.
16360676|NCT04253730|No Intervention|Control Condition|Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
16360677|NCT04253730|Experimental|Cold Condition|Subjects will be cooled for 60-90 min at ~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at ~ 41°C using the liquid perfused suit.
16360678|NCT04253717|Experimental|Motor control exercise program|Participants will be physically trained during pregnancy and will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
16360679|NCT04253717|No Intervention|Control|Participants will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
16360680|NCT04253704|Experimental|2% IDL lotion|The left arm of each subject was used for the test material hydrating lotion (IDL).
16360681|NCT04253704|Placebo Comparator|Control lotion|The right arm of each subject was used for control lotion lacking the IDL component.
16360682|NCT04253691|Experimental|Virtual Reality Based Relaxation Therapy|This is a pilot trial with one treatment condition (VR mediation).
16360683|NCT04253678||Study group|"Study participants will be started on a flexible-dose of vortioxetine (5-20 mg) followed by a baseline assessment of primary outcomes using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Perceived Deficit Questionnaire - 5 items (PDQ-5), and secondary outcomes using the EORTC Quality of life Questionnaire (QLQ-C30) and Clinical Global Impression (CGI). The assessment timelines will be at week 2, week 4, week 8, and week 12.
~Side effects, if any, will be recorded using the Antidepressant Side-effect Checklist (ASEC)."
16360684|NCT04253665|No Intervention|Usual care|Discharge teaching is usually not delivered in a systematic or consistenly way, nor by relying on a particular intervention model.
16360685|NCT04253665|Experimental|Discharge teaching|Receiving tailored discharge teaching by nurses during hospital stay.
16360686|NCT04253652||Oral iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
16360687|NCT04253652||Intravenous iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed intravenous iron as part of their treatment from their doctor. Participants will receive an infusion of either 1000mg or 1500mg
16360688|NCT04253639||Chronic pain patients|
16360689|NCT04253626|Experimental|Intravenous iron|Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
16360690|NCT04253626|Active Comparator|Oral iron|Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin < 9.
16360691|NCT04253613||periodontal therapy|Systemically healthy subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
16360692|NCT04253613||periodontal+laser therapy|Systemically healthy subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment(NSPT) split-mouth designed study
16360693|NCT04253613||diabetic periodontal therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
16360694|NCT04253613||diabetic periodontal+laser therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment (NSPT) split-mouth designed study
16360695|NCT04253600|Other|MRI Acquisition|This does not refer to any group intervention. At-risk and control children will take part in a natural-sleep MRI protocol.
16361201|NCT04250090||Long-term type ureteral stent set|Patients with Long-term type ureteral stent set due to ureteral stricture.
16360696|NCT04253587|Experimental|LabyrinthVR Trackers|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
16360697|NCT04253587|Experimental|LabyrinthVR Scoot|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
16360698|NCT04253587|Placebo Comparator|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
16360699|NCT04253587|Active Comparator|Coherence|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
16360700|NCT04253574||Patients with malignant melanoma|258 patients (w: 112, m: 146 age: 61±16 years) met the primary inclusion criteria. They were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)).
16360701|NCT04253561|Experimental|Ipatasertib + Trastuzumab + Pertuzumab|"Ipatasertib will be given from Day 1 to Day 21 in every 28-day cycles. The starting dose is 400 mg orally (PO) QD and may be decreased to 300 mg QD and further to 200 mg QD (dose levels 1, - 1 and -2, respectively).
~Pertuzumab will be given IV every 21 days at the dose of 420 mg.
~Trastuzumab will be given SC every 21 days at the dose of 600mg. Intravenous (IV) Trastuzumab"
16360702|NCT04253548|Experimental|iPeer2Peer Program|
16360703|NCT04253548|Other|Standard of Care|Waitlist Control Group
16360704|NCT04253522|Experimental|Arm 1 (early phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 3 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 5 weeks
16360705|NCT04253522|Experimental|Arm 2 (mid phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 4 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 4 weeks
16360706|NCT04253522|Experimental|Arm 3 (late phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 5 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 3 weeks
16360707|NCT04253509||Lung cancer|
16360708|NCT04253509||Benign pulmonary disease|
16360709|NCT04253496||Prospective|
16360710|NCT04253496||Retrospective|
16360711|NCT04253483|Experimental|Arm I (HDR)|Patients undergo HDR.
16360712|NCT04253483|Experimental|Arm II (SABR)|Patients undergo SABR every other day for 5 treatments.
16360713|NCT04253470||cleavage stage embryo|embryo which is on day 2 or 3
16360714|NCT04253470||blastocyst embryo|embryo which is on day 5
16360715|NCT04253457|Experimental|Corticosteroid injection|Single injection of 1ml of triamcinolone (40mg/1ml)
16360716|NCT04253457|Active Comparator|Corticosteroid and local anaesthetic injection|Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine
16360717|NCT04253444|Active Comparator|slow deep breathing|Patients are instructed to do deep breathing at full inspiratory capacity for 4 seconds followed by forced expiration in 6 seconds (forced vital capacity) for 10 minutes.
16360718|NCT04253444|Sham Comparator|sham breathing|Patients are instructed to count 10 breaths and tick a box every time they count ten breaths. The counting distracts the patient reducing the effect of focussing of breathing on their autonomic nervous system.
16360719|NCT04253431|Experimental|L01|Finger pricking using lancing device with personal lancets
16360720|NCT04253431|Experimental|L02|Finger pricking using lancing device with personal lancets
16360721|NCT04253431|Experimental|L03|Finger pricking using lancing device with personal lancets
16360722|NCT04253431|Experimental|L04|Finger pricking using lancing device with personal lancets
16360723|NCT04253431|Experimental|L05|Finger pricking using lancing device with personal lancets
16360724|NCT04253431|Experimental|L06|Finger pricking using lancing device with personal lancets
16360725|NCT04253431|Experimental|L07|Finger pricking using lancing device with personal lancets
16360726|NCT04253431|Experimental|L08|Finger pricking using lancing device with personal lancets
16360727|NCT04253431|Experimental|L09|Finger pricking using lancing device with personal lancets
16360728|NCT04253431|Experimental|L10|Finger pricking using lancing device with personal lancets
16360729|NCT04253418|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of target lesion.
16360730|NCT04253405|Active Comparator|High Flow Nasal Cannula (HFNC)|The HFNC (Airvo2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
16360731|NCT04253405|Active Comparator|Non-invasive positive pressure ventilation (NIPPV)|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.
16360732|NCT04253379|Experimental|pediatric epilepsy children|
16360733|NCT04253379|Active Comparator|healthy children|
16360734|NCT04253366|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
16360735|NCT04253353|Experimental|rosuvastatin and tafamidis fixed sequence|"Period 1: rosuvastatin 10 mg (single oral administration)
~Washout
~Period 2: tafamidis 61 mg capsule(multiple doses, twice a day) + rosuvastatin 10 mg (single oral administration)"
16360736|NCT04253340|Experimental|Bone mineral analyser|"Diagnostic Test: Bone mineral analyser
~high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12"
16360740|NCT04253301|Experimental|Treatment|Subjects will have the InnoVein Valve implanted
16360741|NCT04253288|Other|Patients with severe radiation toxicity|Patients who received radiotherapy and developed abnormal radiation-induced toxicity
16360742|NCT04253275|Other|Ischemic stroke patients|Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging
16360743|NCT04253275|Other|hemorragic stroke patients|Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging
16360744|NCT04253275|Other|healthy controls|Stroke-free
16360745|NCT04253262|Experimental|Dose Level -2|300 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
16360746|NCT04253262|Experimental|Dose Level -1|400 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
16360747|NCT04253262|Experimental|Dose Level 1|400 mg Rucaparib, 45 mg Copanlisib
16360748|NCT04253262|Experimental|Dose Level 2|500 mg Rucaparib, 45 mg Copanlisib
16360749|NCT04253262|Experimental|Dose Level 3|600 mg Rucaparib, 45 mg Copanlisib
16360750|NCT04253262|Experimental|Dose Level 4|600 mg Rucaparib, 60 mg Copanlisib
16360751|NCT04253236|Experimental|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
16360752|NCT04253236|Experimental|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
16360753|NCT04253223|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses
16360754|NCT04253210|Experimental|Sexualized images / High photo modification|
16360755|NCT04253210|Experimental|Sexualized images / Low photo modification|
16360756|NCT04253210|Experimental|Nonsexualized images / High photo modification|
16360757|NCT04253210|Experimental|Nonsexualized images / Low photo modification|
16360758|NCT04253210|Experimental|Control images|
16360759|NCT04253197|Other|Morbidly adherent placenta|This arm was given stage according to ultrasound features.
16360760|NCT04253171|Active Comparator|Lithoplasty lesion preparation|Balloon lithoplasty will be used as lesion preparation.
16360761|NCT04253171|Active Comparator|Conventional lesion preparation|Conventional and modified balloons will be used as lesion preparation.
16360762|NCT04253158|Experimental|Educational standard|The aim of this arm is to increase knowledge about alcohol and other drug use.
16360763|NCT04253158|Experimental|Educational standard and Harm prevention|The aim of this arm is to increase knowledge about alcohol and other drug use and increase intentions for the use of harm prevention strategies.
16360764|NCT04253158|Experimental|Educational standard and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use and shift alcohol-related expectancies.
16360765|NCT04253158|Experimental|Expectancies and Harm prevention|The aim of this arm is shift alcohol-related expectancies and increase intentions to use harm prevention strategies.
16360766|NCT04253158|Experimental|Educational standard and Normative perceptions|The aim of this arm is to increase knowledge about alcohol and other drug use and correct erroneous alcohol-related normative perceptions.
16360767|NCT04253158|Experimental|Normative perceptions and Harm prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions and increase intentions to use harm prevention strategies.
16360768|NCT04253158|Experimental|Educational standard, Normative Perceptions, and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use, correct erroneous alcohol-related normative perceptions, and shift alcohol-related expectancies.
16360769|NCT04253158|Experimental|Normative perceptions, Expectancies, and Harm Prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions, shift alcohol-related expectancies, and increase intentions to use harm prevention strategies.
16360770|NCT04253145|Experimental|PM01183 w/ Atezolizumab|Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). Following analysis of cohorts, dose levels can be escalated from 2.5mg to 3.2, to a maximum dose of 3.5 mg of PM01183
16360771|NCT04253132|Active Comparator|50 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
16360772|NCT04253132|Active Comparator|300 mg daily oral dose|300 mg daily, oral dose of tolfenamic acid
16360773|NCT04253132|Active Comparator|600 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
16360774|NCT04253132|Placebo Comparator|Placebo control - 50 mg daily oral dose|50 mg daily oral placebo control
16360775|NCT04253132|Placebo Comparator|Placebo control - 300 mg daily oral dose|300 mg daily oral placebo control
16360776|NCT04253132|Placebo Comparator|Placebo control - 600 mg daily oral dose|600 mg daily oral placebo control
16360777|NCT04253106|Experimental|Unaffected carriers of constitutional mutations|Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
16360778|NCT04253106|Active Comparator|All patients with FOGD|without observation of macroscopic lesions paired with cases (age and sex)
16360779|NCT04253080|No Intervention|patients with primary thin melanoma < 1mm|patients with primary thin melanoma (Breslow thickness less than 1 mm)
16360780|NCT04253080|No Intervention|patients with primary thick melanoma > 3 mm|patients with primary thick melanoma (Breslow greater than 3 mm)
16360781|NCT04253080|Other|patient with melanoma who received first line treatment|patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies
16360782|NCT04253067|Active Comparator|Active fCO2 laser treatment|Laser probe will be inserted into the vagina. The laser treatment is delivered at 6 points to the vaginal wall. Delivery begins at the most proximal and the wand is retracted by 1 cm and another row of laser treatment is delivered. The number of levels is determined by vaginal length.
16360783|NCT04253067|Sham Comparator|Sham fCO2 laser treatment|Laser probe will be inserted into the vagina. To prevent the delivery of laser energy, the laser will remain in standby mode during the visit. Keeping the laser in standby mode prevents laser exposure. The treatment will appear to be the same as the active treatment. The machine maintains a low humming noise while in standby mode.
16360942|NCT04251910|Active Comparator|Cohort 2- 60 Micrograms|"Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.
~Additional 20 subjects receive 60 Micrograms or placebo."
16360784|NCT04253041|Experimental|Control|The control group will be exposed to 15 different appearance-neutral images of interior design, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was most prevalent in the previous image?) regarding characteristics of the last image they were exposed to.
16360785|NCT04253041|Experimental|Fitspiration|Participants assigned to the Fitspiration condition (n=30) will be exposed to 15 different fitspiration images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
16360786|NCT04253041|Experimental|Body Positive|Participants assigned to the Body Positive condition (n=30) will be exposed to 15 different body positive images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
16360787|NCT04253028|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after bariatric surgery (this includes: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Gastric Plication and Duodenal Switch).
16360788|NCT04253002|Experimental|Robinson's Culturally Adapted Coping with Stress Course|
16360789|NCT04253002|Active Comparator|Standard Care Control Condition|
16360790|NCT04252989||Children with active myopia treated with ATROPINE eye drops|
16360791|NCT04252976|Experimental|Mantra Meditation|8 weeks of mantra meditation with weekly group sessions.
16360792|NCT04252976|Experimental|Mantra Meditation plus Ethical Practice|8 weeks of mantra meditation plus ethical practice with weekly group sessions.
16360793|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises|8 weeks of mantra meditation plus Yoga Exercises with weekly group sessions.
16360794|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises plus Ethical Practice|8 weeks of mantra meditation plus Yoga Exercises plus ethical practice with weekly group sessions.
16360795|NCT04252963|Experimental|Mucolase|
16360796|NCT04252963|Placebo Comparator|Placebo|
16360797|NCT04252950|Experimental|CB-SET Treatment|Participants randomized to this group will receive a community-based structured exercise therapy (CB-SET) along with the standard of care (revascularization)
16360798|NCT04252950|Active Comparator|Control|Participants randomized to this group will receive standard of care (revascularization)
16360799|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 0.5 mg/kg|HAM8101 (Adrecizumab) : 0.5 mg/kg
16360800|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 2 mg/kg|HAM8101 (Adrecizumab) : 2 mg/kg
16360801|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 8 mg/kg|HAM8101 (Adrecizumab) : 8 mg/kg
16360802|NCT04252924||students|medical student, dental medicine student, pharmacy student, nursing student, physiotherapy student, dietetics student, kinesiology student, biomedical laboratory techniques student, biomolecular science student, psychology student, economy student, student of maritime sciences
16360803|NCT04252911||Anaesthetised patients|50 patients undergoing robotic surgeries under general anesthesia
16360804|NCT04252898|Experimental|Intervention arm|In this arm (site n°1), participants will purchase their products in the restaurant first in a control phase and then in an interventional phase with the Nutri-Score affixed on food products.
16360805|NCT04252898|No Intervention|Control arm|In this arm (site n°2), participants will purchase their products in the restaurant during the whole study without any label affixed on food products.
16360806|NCT04252885|Experimental|Group A-Standard treatment+lopinavir/ritonavir|In group A, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days).
16360807|NCT04252885|Active Comparator|Group B-Standard treatment+arbidol|In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).
16360808|NCT04252885|No Intervention|Group C-Standard treatment|In group C, 25 cases are only given ordinary treatment.
16360809|NCT04252872|Experimental|Sequence A|"Period 1 : HCP0605+HGP1405
~Period 2 : HCP1401"
16360810|NCT04252872|Experimental|Sequence B|"Period 1 : HCP1401
~Period 2 : HCP0605+HGP1405"
16360811|NCT04252859|Experimental|All Participants|One session of [18F]FES PET/CT Imaging
16360812|NCT04252846||Perampanel|Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.
16360813|NCT04252833|Experimental|CT-044 600 mg|The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.
16360814|NCT04252820|No Intervention|Control|No prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer and zero-heat-flux temperature sensor will be used to measure the temperature throughout the perioperative period.
16360815|NCT04252820|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
16360816|NCT04252820|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
16360817|NCT04252820|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
16360840|NCT04252638|Active Comparator|Cognitive Behavioral Therapy including Sleep Restriction|The control intervention is Cognitive Behavioral Therapy for insomnia (CBT-I). This is the first line treatment for adults with chronic insomnia. The therapy consists of education, relaxation, and behavioral therapy, including sleep restriction. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
16360943|NCT04251910|Active Comparator|Cohort 3- 90 Micrograms|Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
16360818|NCT04252807|Experimental|Intervention arm|"Distressed mothers randomized to intervention arm will receive a common elements based integrated intervention that combines evidence based elements from packages of care addressing early stimulation, responsive feeding and perinatal depression. The integrated intervention is expected to a) improve mother psychological distress, b) improve family support, c) improve child development and d) promote mother-infant interaction.
~The participants will receive 15 monthly sessions at home by lay health workers. First three sessions will be delivered to the participants in the third trimester of pregnancy, followed by 12 monthly sessions afterwards."
16360819|NCT04252807|Active Comparator|Treatment as Usual (TAU)|The participants in the control arm will receive the routine monthly visits by the trained Lady Health Workers (LHWs) of their respective areas.
16360820|NCT04252794|Experimental|Patients who undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will undergo splenic artery ligation (graft inflow modulation)
16360821|NCT04252794|Active Comparator|No splenic artery ligation|If inclusion criteria are met, after randomisation, these group of patients will not undergo splenic artery ligation (graft inflow modulation)
16360822|NCT04252781|Other|Exhaustive exploration|Exhaustive exploration of newly diagnosed COPD patients (pulmonary pathology and associated comorbidities)
16360823|NCT04252768|Experimental|Eftilagimod alpha + Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15 and 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
16360824|NCT04252755|Other|EEG Neurofeedback|Within-subjects sessions of EEG neurofeedback
16360825|NCT04252742|Experimental|Erenumab|"The 4-month DBTP has 2 phases:
~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.
~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptans as well as non-ictal burden."
16360826|NCT04252742|Experimental|Placebo|"The 4-month DBTP has 2 phases:
~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.
~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptans as well as non-ictal burden."
16360827|NCT04252729|Experimental|Psychotherapy|Psychotherapy sessions based on the theoretical line of Psychoanalytic Psychosomatics for 1 year, every 10 days.
16360828|NCT04252729|No Intervention|No psychotherapy|Follow-up according to institutional routine, without psychotherapy sessions.
16360829|NCT04252716||VISTHESIA 1.5|Ophtalmologic surgery supported by Visthesia OVD
16360830|NCT04252716||ProVisc|Ophtalmologic surgery supported by Provisc OVD
16360831|NCT04252703|Active Comparator|Minimalist|The 'Minimalist' strategy is PCI treatment of the culprit lesion only. Other coronary stenoses are to be managed medically. It is recognized that there may be multiple culprit lesions in such patients, though there are no data on how frequently this might be expected. Operators may elect to treat multiple putative culprit lesions in this case.
16360832|NCT04252703|Experimental|More complete|The 'More complete' strategy is PCI of the culprit lesion and fractional flow reserve (FFR)- or instantaneous wave-free ratio (iFR)-guided treatment of other angiographically significant (> 50% diameter) stenoses amenable to coronary stenting in vessels with reference diameters ≥2.5mm. Physiological assessment is strongly encouraged but not mandatory for lesions of ≥90% angiographic stenosis. PCI of chronic total occlusions will not be attempted as part of the study.
16360833|NCT04252690|Experimental|Mobiderm|MOBIDERM® autofit : auto-adjustable compression stocking
16360834|NCT04252677|Active Comparator|Obesity Prevention Only|"Three topics to improve adolescents' obesogenic behaviors will be addressed in the intervention:
~Health information:
~• Factual information about healthy eating and activity (PA) including diet and PA recommendations, physical and health effects of prevention behaviors, risk perception for obesity-related chronic illnesses, compensatory beliefs about obesogenic behaviors
~Motivation:
~Personal: Create positive attitudes toward engagement in healthy eating and PA
~Social: Enlisting social support to increase healthy eating and PA
~Social: Identification of community resources that promote and support healthy eating and PA
~Behavioral Skills
~Tips for engaging in prevention behaviors and avoiding risk behaviors in the context of existing barriers
~Skills for social situations around behaviors
~Skills for making behavior part of routine
~Build autonomy, self-efficacy and model good health decision-making for health behaviors"
16360835|NCT04252677|Experimental|Health Literacy and Obesity Prevention|"Obesity prevention and health literacy (HL).
~Health Literacy
~Functional HL: skills for reading/understanding nutrition labels and medication instructions.
~Interactive HL: verbal skills for interacting with others on health issues.
~Critical HL: connections between advocacy and health
~Media HL: skills for accessing and identifying reliable source of media.
~Health information:
~• Factual information about healthy eating and activity (PA)
~Motivation:
~Create positive attitudes toward engagement in healthy eating and PA
~Enlisting social support to increase healthy eating and PA
~Identification of community resources that promote and support healthy eating and PA
~Behavioral Skills
~Tips for engaging in prevention behaviors and avoiding risk behaviors
~Skills for social situations around behaviors
~Skills for making behavior part of routine
~Build autonomy, self-efficacy and good health decision-making for health behaviors"
16360836|NCT04252664|Experimental|Remdesivir group|active remdesivir
16360837|NCT04252664|Placebo Comparator|Control group|Placebos matched remdesivir
16360838|NCT04252651||Blood Draw|This study will involve blood draws to test for specific cytokines
16360839|NCT04252638|Experimental|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment therapy is a well-established treatment for other disorders including depression, anxiety and chronic pain, but has not been thoroughly investigated for insomnia. The therapy consists of mindfulness, acceptance, identification of personal life values and committed action. In addition, patients in this group will receive sleep restriction, a behavioral therapy component of cognitive behavioral therapy for insomnia. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
16360940|NCT04251923|No Intervention|vaginal prolapse surgery not accompanied with sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need.
16360841|NCT04252625|Active Comparator|Arm 1: Q-Urol|"Patients will be randomized in a 1:1 ratio to receive Q-Urol, two capsules, twice daily for 6 weeks after brachytherapy placement.
~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
16360842|NCT04252625|Placebo Comparator|Arm 2: Placebo|"Patients will be randomized in a 1:1 ratio to receive Placebo, two capsules, twice daily for 6 weeks after brachytherapy placement.
~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
16360843|NCT04252612|Experimental|Cohort 1: Pramlintide 60 mcg twice daily|Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
16360844|NCT04252612|Experimental|Cohort 2: Pramlintide 60 mcg three times daily|Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
16360845|NCT04252612|Experimental|Cohort 3: Pramlintide 120 mcg three times daily|Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
16360846|NCT04252599||Control group|
16360847|NCT04252599||Multiple sclerosis group|
16360848|NCT04252599||Multiple sclerosis trunk impairment|
16360849|NCT04252586|Experimental|GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
16360850|NCT04252573|Experimental|ChEVAS System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
16360851|NCT04252560||Colorectal|30 patients operated for colorectal cancer
16360852|NCT04252560||HIPEC|15 patients operated with CRS+HIPEC for peritoneal carcinomatosis
16360853|NCT04252547|Experimental|Grup 1|"-During the Procedure Group 1 The preprocedural measurements(weight, heart rate and oxygen saturation ) will be applied to the infants in Group 1 before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother.
~During the second feeding hour, his/her heart rate and oxygen saturation will begin to be recorded ten minutes before the feeding hour. The data will be recorded for ten minutes and then the infant will be taken out of the incubator and weight is measured only in his/her clean diaper. He/she will be handed over to the mother to breastfeed."
16360854|NCT04252547|Experimental|Grup 2|"- During the Procedure Group 2 The preprocedural measurements will be applied to the infants in Group 2 before the first feeding hour when they are included in the study and then they will be breastfed by their mothers.
~The preprocedural measurements (weight, heart rate and oxygen saturation) will be applied to the infant during the second feeding hour and then he/she will be held on his/her mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother."
16360855|NCT04252534|Active Comparator|Repetitive electromagnetic stimulation|Group 1 consists of 20 RP patients (40 eyes) who received combined rEMS with PRP. In this group, patients received rEMS for 30 minutes before subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
16360856|NCT04252534|Active Comparator|Platelet rich plasma|Group 2 consists of 20 RP patients (40 eyes). In this group, patients received only subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
16360857|NCT04252534|No Intervention|Natural course|Group 3 consists of 20 RP patients (40 eyes). Patients in this group did not accept any interventional application and were only followed up. The
16360858|NCT04252521|Active Comparator|metoclopramide+ dexketoprofen trometamol|10 mg metoclopramide+ 50 mg dexketoprofen trometamol
16360859|NCT04252521|Experimental|metoclopramide|10 mg metoclopramide
16360860|NCT04252521|Experimental|dexketoprofen trometamol|50 mg dexketoprofen trometamol
16360861|NCT04252508|Experimental|With animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
16360862|NCT04252508|No Intervention|Standard route|"The information about the surgery will be given by the surgeon during the consultation.
~Those about anaesthesia will be delivered by anaesthesiologist during the anaesthetic consultation."
16360863|NCT04252495|Experimental|Subjects with moderate hepatic impairment (Group 1)|
16360864|NCT04252495|Experimental|Healthy subjects (Group 2)|
16360865|NCT04252482|Experimental|cpap|usage cpap 3month
16360866|NCT04252482|No Intervention|Usual care|Usual care 3month
16360867|NCT04252469|Experimental|intervention|receiving oral care with 20mL of 0.12% CHX by medicine cup, gargling 30 seconds.
16360868|NCT04252469|No Intervention|Control|Standardized care
16360869|NCT04252456|Other|standard chemotherapy for advanced colorectal cancer|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.
16360870|NCT04252443|Other|Nurse|The research population consisted of 190 nurses working in a university hospital. Because all of the nurses in the research population could not be reached, a sample was selected using a simple random sampling method. One hundred twenty-seven nurses were interviewed in the research population, with a 95% confidence interval and a 5% sampling error.
16360871|NCT04252430|Active Comparator|Patients with renal impaired function|6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe ranal impaired function
16360872|NCT04252430|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired renal function patients
16360873|NCT04252417|Active Comparator|Patients with hepatic impaired function|8 patients with hepatic impairment of moderate Child Pugh category
16360874|NCT04252417|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired hepatic function patients
16360941|NCT04251910|Active Comparator|Cohort 1- 30 Micrograms|Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
16360944|NCT04251910|Active Comparator|Part B Cohort|Part B cohort consists 46 subjects receiving 40 Micrograms or placebo
16360875|NCT04252391|Active Comparator|Standard care|Standard care will consist of standard physical therapy care which may include the following: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, dry needling with or without electrical trigger point dry needling, soft tissue release and prescribed therapeutic exercises .
16360876|NCT04252391|Active Comparator|standard care with perineural electrical dry needling.|This arm will consist of standard care with perineural electrical dry needling, using a high frequency stimulation placed near the nerve, differing from addressing muscular trigger points. For example, a dry needle placed in the semispinalis capitus muscle along the greater occipital nerve pathway, stimulated at 80 Hz.
16360877|NCT04252378|Experimental|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and external intercostal muscle near 5th rib.
16360878|NCT04252378|Active Comparator|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
16360879|NCT04252365|Experimental|arm 1|"Patients with PD-L1 high expression (TPS≥50%) receive Sintilimab injection 200mg i.v. on day 1 every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
~Patients with PD-L1 low or negative expression (TPS<50%) receive Sintilimab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Sintilimab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
16360880|NCT04252365|Active Comparator|arm 2|"Patients with PD-L1 high expression (TPS≥50%) receive Pembrolizumab injection 200mg i.v. on day 1once every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
~Patients with PD-L1 low or negative expression (TPS<50%) receive Pembrolizumab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Pembrolizumab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
16360881|NCT04252352|Active Comparator|Ablative fractional CO2 laser resurfacing|One fractional CO2 laser treatment are performed of acne scars on one side of the face
16360882|NCT04252352|Active Comparator|Radio-frequency microneedling|One radio-frequency microneedling treatment are performed of acne scars on one side of the face
16360883|NCT04252339|Experimental|RLY-1971 - Dose Escalation/Expansion|"Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified
~Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified."
16360884|NCT04252326|Active Comparator|Doctor|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
16360885|NCT04252326|Active Comparator|Nurse|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
16360886|NCT04252326|Active Comparator|Dentist|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
16360887|NCT04252313|No Intervention|Group A|This arm represents the control group. They will be undergoing the circumcision without any music, with the established standard for analgesia [EMLA+Sucrose+Ring Block]
16360888|NCT04252313|Experimental|Group B: Music|"In addition to the standard analgesia as explained for group A, Music will be played from the Baby Go to Sleep playlist which includes nursery rhymes and lullabies metonymized to an actual human heartbeat (Houser, 1994). Music will start after the baby settles on the board and before the surgeon starts the procedure."
16360889|NCT04252300|Experimental|Healthy subjects_Period 1|Healthy adults from USA receive a single dose of rosuvastatin (interaction drug) in Period 1.
16360890|NCT04252300|Experimental|Healthy subjects_Period 2|The healthy adults from Period 1 receive both rosuvastatin + BAY1817080 in Period 2.
16360893|NCT04252274|Experimental|Darunavir, Cobicistat and conventional treatments|After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments.
16360894|NCT04252274|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without darunavir and cobicistat.
16360895|NCT04252261|Experimental|sulforaphane|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
16360896|NCT04252261|Placebo Comparator|placebo|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
16360897|NCT04252248|Experimental|Stratum 1|Patients having received standard, definitive chemoradiotherapy according to current, national guidelines with curative intent and being at high risk for disease recurrence (patients are considered at high risk if they display a positive nodal status of their cancer (anogenital HPV-induced tumor) or if the tumor is locally advanced and/or if they display a positive nodal status with extracapsular extension (head and neck HPV-induced tumor). Study therapy (as additional therapy to standard chemoradiation) will start after a time interval of 6-8 weeks after finishing chemoradiotherapy
16360898|NCT04252248|Experimental|Stratum 2|"Patients with non-curative and progressive disease having received all standard, national approved systemic therapies (according to current, national guidelines with regard to the specific tumor entity), and/or presently not eligible for a respective therapy, and/or refused respective therapy. Study treatment thereby represents a potential palliative, last-line systemic therapy option (late salvage)."
16360899|NCT04252235|Sham Comparator|Sham air purifier|Participants will receive a sham air purifier that will be installed in the bedroom and living room. These purifiers will make a noise, but will not filter the air.
16360900|NCT04252235|Experimental|True air purifier|Participants will receive a HEPA air purifier in the bedroom and living room.
16360901|NCT04252222|Experimental|VL3|Tracheal intubation with VL3 videolaryngoscope
16361289|NCT04249492|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens.
16360902|NCT04252209|Experimental|patients with sjogren's received natural mixture|"The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.
~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
16360903|NCT04252209|Active Comparator|patients with sjogren's recievrd CMC|"the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.
~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
16360904|NCT04252196|Experimental|Device Usability Study|Usability evaluators of medical device (Healthy volunteers).
16360905|NCT04252170|Experimental|Feasibility study, Stroke Survivors|BAC feasibility study at PowerBack, Piscataway NJ, with stroke patients.
16360906|NCT04252157|Experimental|kinesiotaping|Kinesotape will be apply with suitable tension and necessery region.
16360907|NCT04252157|Placebo Comparator|plesebo taping|Tape will be appy with randomly region without tension.
16360908|NCT04252157|Other|control|Nothing will be applied
16360909|NCT04252144|Experimental|GERD|Patients with verified gastroesophageal reflux disease
16360910|NCT04252144|Other|Contol|Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
16360911|NCT04252131|Experimental|Cassia seed|oral administration of Cassia seed (3.0g), once/day for 12 weeks
16360912|NCT04252131|Placebo Comparator|Cassia seed placebo|oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks
16360913|NCT04252118|Experimental|MSCs Treatment Group|Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
16360914|NCT04252118|No Intervention|Conventional Control Group|Without MSCs Therapy but conventional treatment should be received.
16360915|NCT04252105|Experimental|Antioxidant rich diet|
16360916|NCT04252105|No Intervention|Regular diet|
16360917|NCT04252092|Experimental|Sensory Group|15 patients who will be applied 15 sessions of sensory training
16360918|NCT04252092|Experimental|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
16360919|NCT04252079|Other|We compare different endovascular techniques as an alternative|We compare different endovascular techniques as an alternative to surgical reconstruction to repair JAAS regarding ; success rates, 30-day mortality, endoleak events secondary intervention rates
16360920|NCT04252066||Cohort 1|Cohort 1 will be pregnant and/or breastfeeding patients who have Fabry Disease, and have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
16360921|NCT04252066||Cohort 2|Cohort 2 will be pregnant and/or breastfeeding patients who have Fabry Disease, who were not exposed to migalastat during pregnancy and/or breastfeeding.
16360922|NCT04252053|Experimental|Supervised Pilates-Based Core Stability Training Group|In order to detect the effects of pilates-based core stabilization training (PBCST) on isokinetic knee strength and postural sways, individuals with MS will receive pilates-based core stabilization training for 8 weeks and 2 days a week. One educational session will perform to teach basic principles of pilates based training. Individuals in this group will receive treatment at the clinic by physiotherapist supervision. All sessions will be individualized (not group training).
16360923|NCT04252053|Active Comparator|Home exercise group|The home exercise group will perform the same PBCST exercises at home during the same period (8 weeks, 2 days a week) as the brochures prepared for them. Individuals in this group will receive one educational session which includes basic principles of pilates and one session which includes two-week exercise program. Participants will be invited to the clinic every two weeks to ensure the progression of the exercises and the exercise program will be updated.
16360925|NCT04252014|No Intervention|Non-Tobacco Messages|Participants in the control group will receive messages about health topics unrelated to tobacco use (e.g., sun safety). Messages will be delivered online through 4 brief study communications.
16360926|NCT04252014|Experimental|Hookah Tobacco Messages|Participants in the hookah tobacco messaging group will receive hookah tobacco public education messages delivered online through 4 brief study communications. Messages will communicate about the risks of hookah tobacco use in the following theme areas: 1) Health Harms; 2) Addictiveness; 3) Social Use; 4) Flavorings. The order of message themes delivered in each study communication will be randomized.
16360927|NCT04252001|Experimental|Group YT|Group receives YESS! game and transition-toolkit
16360928|NCT04252001|Experimental|Group GT|Group receives control game and transition-toolkit
16360929|NCT04252001|Experimental|Group T|Group receives transition-toolkit
16360930|NCT04252001|No Intervention|Group O|Group receives usual transition care
16360931|NCT04251988|No Intervention|Standard of Care (No VR) Randomization|Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
16360932|NCT04251988|Experimental|VR Randomization|Patients will receive virtual reality in addition to standard of care.
16360933|NCT04251975|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
16360934|NCT04251975|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
16360935|NCT04251962|Experimental|Bupivacaine|Epidural solution containing 0.1% bupivaacaine in normal saline
16360936|NCT04251962|Experimental|Bupivacaine + Fentanyl|Epidural solution containing 0.1% bupivacaine and 3 mcg/ml of fentanyl in normal saline
16360937|NCT04251936|Experimental|Exercise training plus smoking cessation group program|
16360938|NCT04251936|Active Comparator|Smoking cessation group program|
16360939|NCT04251923|Experimental|vagianl prolapse surgery accompanied with TVT sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need. Patient who falls in Group will undergo mid urethral sling with tension free vaginal tape (TVT) using TVT mid urethral sling.
16360945|NCT04251897|Active Comparator|Standard care mattress|Patient will have 2 days to familiarize with the novel support surface. Patient will be on standard care mattress. They will be turned over every 2 hours for 3 days.
16360946|NCT04251897|Experimental|Novel support surface|"After the standard care mattress, the same patient will be placed on novel support surface. They will be turned over every 2 hours for 3 days.
~Patient will then continue with the novel support surface and turned every 3 hours for 3 days.
~They will then continue with the novel support surface and turned every 4 hours for 3 days."
16360947|NCT04251884|Experimental|Receiving the pudendal nerve block|
16360948|NCT04251884|Active Comparator|Not receiving the pudendal nerve block|
16360949|NCT04251871|Experimental|Conventional medicines and TCMs granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
~Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days."
16360950|NCT04251871|Active Comparator|Conventional medicines|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
16360951|NCT04251858|Experimental|Athletes with oral problems|Athletes with periodontal diseases or gingivitis
16360952|NCT04251858|No Intervention|Athletes without oral problems|Athletes diagnosed without oral problems
16360953|NCT04251845|Active Comparator|Trial group|Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily
16360954|NCT04251845|Placebo Comparator|Control Group|Intervention : Placebo once daily
16360955|NCT04251832|Experimental|Ultrasound guided percutaneous lavage with STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using sodium thiosulfate 25 %: a volume of 1 mL of sodium thiosulfate will be prepared in a syringe and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. At the end of the procedure 1 mL (250 mg) of thiosulfate will be injected inside the calcific deposit. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.
~Only a single procedure will be performed and the outcomes measured after 1 week, 1 month and 3 months."
16360956|NCT04251832|Active Comparator|Ultrasound guided percutaneous lavage without STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using of saline solution and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.
~Only a single procedure will be performed and the outcomes measured after 1week, 1month and 3months"
16360957|NCT04251819|Placebo Comparator|Placebo|Participants randomized to this arm will receive Placebo.
16360958|NCT04251819|Experimental|Baclofen 5mg|Participants randomized to this arm will receive 5 mg of Baclofen.
16360959|NCT04251819|Experimental|Baclofen 10mg|Participants randomized to this arm will receive 10 mg of Baclofen.
16360960|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
16360961|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
16360962|NCT04251793||Er:YAG laser-assisted debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with the aid of the laser treatment two years ago at the Graduate Periodontics Clinic at University of Michigan.
16360963|NCT04251793||Standard mechanical debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with dental scalers two years ago at the Graduate Periodontics Clinic at University of Michigan.
16360964|NCT04251780|Experimental|Hyperaldosteronism treatment|Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinol Metab, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.
16360965|NCT04251767|Experimental|Observational group|5u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
16360966|NCT04251767|Placebo Comparator|Control group|5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
16360967|NCT04251741|Active Comparator|Usual care group|Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
16360968|NCT04251741|Experimental|'Drug concentration guided' group|Patients with a concentration <1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
16360969|NCT04251728|Experimental|Exercise plus AMPS group (AMPS-G)|Physical exercise and automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold, performed two times a week for 12 weeks.
16360970|NCT04251728|Sham Comparator|Exercise plus SHAM group (Exercise-G)|Physical exercise and simulated automated mechanical peripheral stimulation (AMPS) with intensity at the sensory threshold performed two times a week for 12 weeks.
16360971|NCT04251715|Experimental|mFOLFIRINOX, Floxuridine-DEX, mFOLFIRI|"Treatment Period 1 - mFOLFIRINOX for 4 cycles (cycle = 14 days) Cycle 1
~Oxaliplatin 85 mg/m2 intravenously (iv) over 2 hours
~Folinic acid 400 mg/m2 iv over 2 hours
~Irinotecan 165 mg/m2 iv over 90 minutes
~Fluorouracil 400 mg/m2 iv bolus after folinic acid
~Fluorouracil 2,400 mg/m2 continuous infusion over 46 hours
~Dosages on Cycle 2, 3, and 4 will be reduced by 25% Treatment Period 2 - HAI delivery of floxuridine + mFOLFIRI for 2 cycles (cycle = 28 days)
~Floxuridine-DEX (with heparin and saline) - 0.12 mg/kg/day; via HAI pump, adjusted for weight and flow rate
~mFOLFIRI on Day 15
~Irinotecan 180 mg/m2 iv over 30 minutes to 1 hour
~Folinic acid 400mg/m2 iv over 30 minutes to 1 hour
~5-FU 1000 mg/m2 continuous infusion over 46 hours"
16360972|NCT04251702||Healthy Low-Risk Nulliparous Women in Spontaneous Labor|Healthy Nulliparous women with a Singleton Term fetus in the Vertex position in spontaneous labor.
16360973|NCT04251689|Experimental|intervention|mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
16360974|NCT04251689|Placebo Comparator|placebo|0.9% normal saline 100 ml one hour after cisplatin
16360975|NCT04251663||HS subjects|Subjects with active HS disease, among which at least 5 will be treatment-naïve
16360976|NCT04251663||Healthy Controls|Healthy subjects
16360977|NCT04251650||low severity|patient with periodontitis stage I and II
16360978|NCT04251650||high severity|patient with periodontitis stage III and IV
16360979|NCT04251637||adult patients scheduled for thoracic pulmonary|"Adult patients scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.
~- Having stated their non opposition to be part of this protocol"
16360980|NCT04251624|Experimental|Goal Management Therapy|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length. Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.
16360981|NCT04251624|Active Comparator|Psychosocial Education|Psychosocial education will provide educational materials (e.g., brain function, neuroplasticity) and lifestyle interventions (e.g., sleep hygiene, stress, exercise). They will be matched for length and for amount of facilitator contact with the Goal Management Therapy sessions. Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length. Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.
16360982|NCT04251611|No Intervention|Control group|The usual care in patients with myocardial ischemia without other cardiovascular risk factors (CVFR) will be to attend one visit per year with doctor and nurse of the local health center. In this visit, it will be done a blood test and an electrocardiogram. Blood pressure, weight, body mass index, abdominal circumference will be measured and, in case of detecting enolic habit, smoking or sedentary lifestyle, generic advice will be done. If the patient, apart from myocardial ischemia, presents diabetes mellitus type 2, 3-4 follow-up visits per year will be recommended and will be increased according to specific needs. In case of presenting hypertension, will be recommended 2 visits with the nurse and one visit with the doctor per year and will be increased according to specific needs. In addition, in this case the blood pressure is checked every 6 months. During all visits, professionals will reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
16360983|NCT04251611|Experimental|Intervention group|"Patient will go to health center to visit the cardiac rehabilitation (CR) reference team, which is composed for a doctor and a nurse. This team will establish the guideline of action in the maintenance and/or increase in the physical exercise practice, in function of the resources of each zone and the preferences and motivations of the patient. They also reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
~At the end of the visit, control visit will be given with the CR reference team at 3, 6 and 12 months after completing the supervised physical exercise program of phase II of the CRP. In case of detecting specific needs for the patient and/or relapses, the team will consult with the appropriate professional (cardiologist, cardiology nurse, physiotherapist, rehabilitator, nutritionist and/or psychologist). At the same time, the patient will be informed of the possibility of re-evaluating the CR reference team."
16360984|NCT04251598|Experimental|Education group|"Only I am Protecting my Child From the Sun program was given."
16360985|NCT04251598|Experimental|Education + SMS group|"The I am Protecting my Child From the Sun program was given. After the program, an SMS message was sent on Wednesday and Saturday for 12 weeks. A total of 25 SMS messages were sent to remind the subject and applications."
16360986|NCT04251598|No Intervention|Control group|"No attempt was made by the researcher during the study. Only data collection was carried out. At the end of the research, the I am Protecting my Child From the Sun program was given.."
16360987|NCT04251585|Experimental|Low Insulin|Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.
16360988|NCT04251585|Experimental|Medium Insulin|Regular insulin (Novolin-R) 40 international units (10 units) in each nostril twice daily for 21 days, 100 µl volume.
16360989|NCT04251585|Experimental|High Insulin|Regular insulin (Novolin-R) 80 international units (10 units) in each nostril twice daily for 21 days, 200 µl volume.
16360990|NCT04251585|Placebo Comparator|Placebo|0.9% sodium chloride in each nostril twice daily for 21 days, 100 µl volume.
16360991|NCT04251572|Experimental|HCV reinfection after DAA therapy in PWID|Hepatitis C virus reinfection after directly acting antiviral treatment in persons who inject drugs. DAA therapy is an inclusion criteria, not an intervention.
16360992|NCT04251559|Active Comparator|patients with gestational diabetes mellitus|study group
16360993|NCT04251559|Placebo Comparator|healthy participants|control group
16360997|NCT04251520|No Intervention|Control Group|Standard care by Palliative Medicine physician
16360998|NCT04251520|Experimental|Intervention Group A|Standard care by Palliative medicine physician plus pharmacist review of medications
16360999|NCT04251520|Experimental|Intervention Group B|Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
16361000|NCT04251507|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
16361001|NCT04251507|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
16361002|NCT04251494||Phenylketonuria (PKU) participants|"During their outpatient clinic appointment, participants will:
~Undergo routine height and weight measurements and blood tests. A full patient history will be taken, including a record of cardiovascular disease within the family. Blood samples will be collected, including phenylalanine, lipids, vitamin B12 and related biomarkers.
~Complete a 14-item diet history questionnaire, and fill in a 3 day diet diary before they arrive at their outpatient clinic appointment, which will be collected after the participant signs the informed written consent form.
~Undergo assessment of carotid Intima-media thickness (CIMT), pulse wave velocity (PWV), ankle brachial pressure index (ABPI) and systolic and diastolic blood pressure."
16361003|NCT04251494||Age and gender matched reference controls|Only Phenylketonuria (PKU) patients will be studied. Controls are generated from the literature. Reference CIMT values exist for a healthy population based on age and gender (Engelen et al., 2013), eliminating the need to assess age- and gender-matched controls. The study would otherwise require performing blood tests and vascular assessments on healthy individuals, generating a risk of harm and a possible incidental finding. It would be inconvenient for controls because they would need to travel to hospital and undergo invasive venepuncture.
16361004|NCT04251481|Experimental|Optimization of Techniques|To optimize the diffusion MRI methods for assessment of cell viability, metabolism and perfusion in head and neck cancer. There will be 24 subjects enrolled for 2 year duration. Treatment-naïve patients with cervical metastatic lymph nodes (diameter > 10 mm) of HNSCC will be recruited to have one research PET/MR scan (including dMRI) and one dMRI-only scan within three days prior to treatment. These data will be used to optimize the dMRI method and assess the repeatability.
16361005|NCT04251481|Experimental|: Longitudinal Monitoring|To assess the feasibility of using diffusion MRI metrics at early stages of treatment for prediction of treatment response in head and neck cancer patients undergoing standard-of-care chemoradiation therapy. There will be 36 subjects enrolled for 3 year duration. The study will do bi-weekly measurement to monitor tumor response longitudinally. This study will be restricted to treatment-naïve patients who present pathologically confirmed HNSCC with metastatic lymph nodes and who are scheduled to receive standard care of radiation therapy with concurrent chemotherapy. The patients enrolled in this arm of the study will have 4 dMRI scans. The imaging data for each patient will be the proposed dMRI measures at the baseline and their changes at each follow-up time period. DCE-MRI will be included in the baseline scan for tumor delination as in standard-of-care cancer imaging and to compare with the proposed dMRI method.
16361006|NCT04251468|Other|GEPII|All patients who completed the study.
16361007|NCT04251455||TMJ disease/disorder characterisation|Patients with the diagnosis disc displacement without reduction (DDwoR), or disc displacement with reduction (DDwR), or osteoarthritis (OA), or chronic inflammatory arthritis (CIA) were designated to TMJ surgery. According to the Swedish national guidelines on TMJ surgery DDwoR, OA, and CIA patients had arthroscopy and DDwR had discectomy.
16361008|NCT04251442|Experimental|Study Group|The study group will have soft tissue balance performed with the use of IOS.
16361009|NCT04251442|No Intervention|Control Group|Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values.
16361010|NCT04251429|Experimental|Immediate Intervention Group|SHIFT study team provides coaching to Health and Safety Committee to implement a participatory program for increasing committee effectiveness.
16361011|NCT04251429|Other|Delayed Intervention Group|Active Comparator for 2 years: status quo program remains in place with new ongoing data collection. Then experimental intervention as above.
16361012|NCT04251416|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
16361013|NCT04251403|Experimental|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
16361014|NCT04251390||trexo Home intervention|Participants family is renting a trexo Home from trexo. The decision to use the device was separate from this research, and the decision to do research on its use was secondary. The proposed procedures may be modified to adapt to the child and family's interest and needs. Participant will use the trexo Home in their home, school, and community.
16361015|NCT04251377|Experimental|Single-stage surgery + DAC® + topical antibiotics|Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
16361016|NCT04251377|No Intervention|control group : two-stage surgery|Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
16361017|NCT04251364|Experimental|Acetazolamide|Oral acetazolamide (250 mg/day) intake for 9 months
16361018|NCT04251364|Experimental|Atorvastatin|Oral atorvastatin (40 mg/day) intake for 9 months
16361019|NCT04251364|Placebo Comparator|Placebo|Oral placebo pill (daily) intake for 9 months
16361020|NCT04251351|Experimental|Arm 1|Paracetamol 15 mg/kg/dose 6 hourly for 72 hours
16361021|NCT04251351|Sham Comparator|Arm 2|Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.
16361022|NCT04251338||delayed visual maturation|children with delayed visual maturation
16361023|NCT04251325||Basic Life Support Course Participants|The study population includes all Danish citizens who attended a BLS training course certificate from 2016-2018 above the age of 15.
16361024|NCT04251325||Background population|The entire danish population above 15 years whom have not attended a BLS training course certificate from 2016-2018.
16361112|NCT04250675|Sham Comparator|Sham|Participants will apply Intermittent Pneumatic Compression (IPC) using a customized version of the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The sham device applies a compression sequence of 30 mmHg to the foot, ankle and calf with inflatable cuffs.
16361290|NCT04249479|Experimental|CM temperature 20° C|CM is administered to the patient at a temperature of 20° C.
16361025|NCT04251312|Experimental|Preoperative dental hygiene education|Patients who are scheduled for elective esophageal or lung resections who consent to participate will undergo oral hygiene education and be given an oral hygiene packet. An oral hygiene assessment using the Plaque Assessment tool will be conducted in the clinic. A Dysphagia Screening Tool questionnaire will also be administered. Patients who screen positive for dysphagia will be referred to Speech Pathology for evaluation but for the study purposes, the only data collected from the evaluation will be whether or not the participant received this intervention. A repeat dental exam will occur on the day of surgery. Patients will be followed for 30 days post operatively.
16361026|NCT04251299|Experimental|Single Arm|All participants will receive the 10-month mentored, vegetable gardening intervention
16361027|NCT04251273|Experimental|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.
~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
16361028|NCT04251273|Other|Assessment only Control|After an initial enrollment message, participants will be contacted periodically to assess e-cigarette use. At the end of the intervention period, they will receive information on how to sign up for This is Quitting if they are interested in the program
16361029|NCT04251260|Experimental|Positioning in flexion|Intervention: Positioning of body in flexion and aligment towards midline with Snuggle up (Philips, USA)
16361030|NCT04251260|No Intervention|Control group|No intervention
16361031|NCT04251247||Acute aortic dissection|Patients with a diagnosis of acute aortic dissection.
16361032|NCT04251247||Acute pulmonary embolism|Patients with a diagnosis of acute pulmonary embolism
16361033|NCT04251247||Non-cardiac chest pain|Patients with non-cardiac chest pain
16361034|NCT04251234|Experimental|Healthy controls|"No co-morbid medical or psychiatry diagnoses
~No family history of mental illness
~No current medication use
~Non-smoking"
16361035|NCT04251234|Experimental|Bipolar I disorder|"Clinical diagnosis of Bipolar I disorder
~Can be (not required, not exclusionary) taking lithium and/or sodium valproate and/or antidepressants
~Can be (not required, not exclusionary) light smokers"
16361036|NCT04251221|Experimental|Social Drinkers|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08.
16361037|NCT04251208||Integrated Care|This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
16361038|NCT04251208||Referral-Based Care|This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
16361039|NCT04251195|Experimental|Cognitive Intervention|
16361040|NCT04251195|Active Comparator|Active Control Intervention|
16361041|NCT04251182|Placebo Comparator|Placebo|Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
16361042|NCT04251182|Experimental|15mg T3D-959|T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.
16361043|NCT04251182|Experimental|30mg T3D-959|T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.
16361044|NCT04251182|Experimental|45mg T3D-959|T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.
16361045|NCT04251169|Experimental|Pembrolizumab + Paclitaxel|Pembrolizumab 200 mg every 3 weeks (on D1 of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m2 administered at days 1, 8, 15 of each 21-day cycle beginning at cycle 2.
16361046|NCT04251156|Experimental|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
16361047|NCT04251156|Placebo Comparator|Placebo (semaglutide)|Once-weekly injections of gradually increased doses of semaglutide placebo
16361048|NCT04251143||Ectasia|Keratoconus, Keratoconus suspects
16361049|NCT04251130||Cognitively Normal Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
16361050|NCT04251130||Mild Cognitively Impaired Older Adults or Older Adults with Alzheimer's Disease|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
16361051|NCT04251117|Experimental|GNOS-PV02 + INO-9012 + Pembrolizumab|"First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured.
~GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI."
16361113|NCT04250675|Active Comparator|Active Comparator - Intermittent Pneumatic Compression|Participants will apply Intermittent Pneumatic Compression (IPC) using the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The Arterial Assist Device® applies a compression sequence of 120 mmHg to the foot, ankle and calf with inflatable cuffs.
16361291|NCT04249479|Active Comparator|CM temperature 37° C|CM is administered to the patient at a temperature of 37° C.
16361052|NCT04251104|Experimental|Level of personal relevance of images|This is an exploratory randomized controlled study to compare the effectiveness of three types of autobiographical stimuli, classified according to their level of personal relevance (high, medium and low), in the induction of positive emotions resulting from the retrieval of specific positive autobiographical memories. To this end, the investigators will use three types of images, classified according to their personal relevance: a) personal autobiographical photographs (high personal relevance); b) images of locations related to the participants' lives (medium personal relevance); and c) images from the Internation Affective Picture System (IAPS; low personal relevance).
16361053|NCT04251104|Other|Age (young and older adults comparison)|To analyse any age-related differences in the effectiveness of the use of the three types of images to regulate emotion, the investigators will compare the efficacy of the three categories of pictures (high, medium and low relevance) in inducing positive mood states in a group of young adults (age range: 18-35 years) and a group of older adults (65 years or over).
16361054|NCT04251091|Experimental|ReWalk Soft Exosuit|During this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out an 18 session training protocol.
16361055|NCT04251078||Myelodysplastic Syndromes - Progression cohort|According to the literature (Greenberg et al, Blood. 2012), around 5-15% are expected to progress to high/very high-risk MDS subtype or to acute myeloid leukemia (AML). According to the total cohort of patients, it is expected that 20 of them would comprise this group and will be studied by targeted deep sequencing.
16361056|NCT04251078||Myelodysplastic Syndromes - Non Progression cohort|20 patients without progression will be analyzed by targeted deep sequencing in order to find out if there are any differences in the mutational spectrum compared with those disease progression cases.
16361057|NCT04251065|Experimental|Daratumumab-GDP|"This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell origin and a central evaluation of immunohistochemical positivity of CD38 on bioptic material used to perform local diagnosis of relapsed disease, or that used for the more recent biopsy in the case of refractory patients. A core needle biopsy is considered sufficient for review and CD38 evaluation. Evaluation at central laboratory can be performed in bone marrow sections in those patients with only bone marrow lymphoma infiltration.
~Only patients with confirmed eligible diagnosis and a percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for study treatment.
~The treatment consists of an induction phase and a maintenance phase."
16361058|NCT04251052|Experimental|Group I (bilateral salpingectomy)|Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery.
16361059|NCT04251052|Active Comparator|Group II (bilateral salpingo-oophorectomy)|Patients undergo bilateral salpingo-oophorectomy.
16361060|NCT04251039||PCI with pre-treatment with P2Y12 inhibitors|"SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo:
~Assessment of platelet reactivity (Time 0, T0) (VFN)
~PCI (start = T1; end= T2)"
16361061|NCT04251039||PCI with treatment with P2Y12 inhibitors only after procedure.|"SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo:
~Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0)
~Assessment of platelet reactivity (Time 0, T0) (VFN)
~PCI (start of PCI= T1; end of infusion of Cangrelor= T2)"
16361062|NCT04251026|Experimental|Cohort A|Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II
16361063|NCT04251026|Experimental|Cohort B|A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants.
16361064|NCT04251026|Experimental|Cohort C|A consistent dose level in participants with neuronopathic MPS II
16361065|NCT04251013|Active Comparator|Group A: RX Cytology brush, Boston Scientific FIRST|A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy
16361066|NCT04251013|Active Comparator|Group B: Infinity®, US Endoscopy FIRST|A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific
16361067|NCT04251000|Experimental|Joovv Pilot Experimenta Arm|Individuals will receive 90 day access to the Joovv infrared mini light device.
16361068|NCT04250987|Experimental|IC connected to a sensor|Single use of a IC connected to a sensor
16361069|NCT04250974|Experimental|electroacupuncture|electroacupuncture at points after surgery
16361070|NCT04250974|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
16361071|NCT04250974|No Intervention|Control group|only oral or injection painkiller were used after surgery
16361072|NCT04250961|Experimental|Shower Group|Patients who had a shower in 48-72 hours after Median Sternotomy
16361073|NCT04250961|Active Comparator|Control Group|Patients whose sternal incision site was not connected water until remove sutures
16361074|NCT04250948|Active Comparator|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1
~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
~S-1:40~60mg Bid, d1~14, q3w;
~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;
~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
16361075|NCT04250948|Experimental|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1
~JS001: 240mg, ivdrip, d1, q3w;
~S-1:40~60mg Bid, d1~14, q3w;
~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;
~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
16361292|NCT04249466||Patient with cystic fibrosis|
16361293|NCT04249453||Chronic low back pain with high disability|Veterans with chronic, non-specific LBP and a Roland-Morris Disability Questionnaire (RMDQ) score of >12 (gender-balanced, n1=18)
16361076|NCT04250922|Placebo Comparator|Arm A: SoC + placebo for 2-OHOA|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm A will receive placebo every day from Day 1 of week 3 to the end of this Phase.
~The start of the first cycle during the Maintenance (Adjuvant) Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.
~Subjects in Arm A will receive placebo every day during the first 3 weeks of each 28-day cycle and until progression. Patients will continue with Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
16361077|NCT04250922|Experimental|Arm B: SoC + 12 g/day of 2-OHOA|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm B will receive 2-OHOA every day from Day 1 of week 3 to the end of this Phase.
~The start of the first cycle during the Maintenance Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.
~Subjects in Arm B will receive 2-OHOA during the Maintenance Phase. Patients will continue to be administered with 2-OHOA after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
16361078|NCT04250909||Passeo 18 PTA|Previous treatment with uncoated Passeo 18 PTA balloon catheter
16361079|NCT04250909||Passeo-18 Lux DCB|Previous teatment with Passeo-18 Lux DCB
16361080|NCT04250896|Other|Control|Control group will receive standard child care in health units plus exposure to EsIAN (Strategy of Integral Attention to Nutrition)
16361081|NCT04250896|Experimental|Intervention|Intervention group will receive SMS messages sent through a cell pone in addition to the control group receive (standard child care in health units plus exposure to EsIAN)
16361082|NCT04250883|Experimental|A. Experimental group 1|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement
16361083|NCT04250883|Experimental|B. Experimental group 2|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 14 mmHg IAP after trocar introduction for perfusion measurement
16361084|NCT04250883|Active Comparator|C. Control group 1|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement
16361085|NCT04250883|No Intervention|D. Control group 2|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)); 14 mmHg IAP after trocar introduction for perfusion measurement
16361086|NCT04250870|Active Comparator|Nursing Home Residents|Nursing home residents (n=59) were evaluated in five different nursing homes.
16361087|NCT04250870|Active Comparator|Community-Dwelling Elderly|The community-dwelling elderly people (n=59) were selected from two different municipalities of the city.
16361088|NCT04250857||Suspected Sudden Cardiac Arrest|All subject with suspected of a circulatory arrest for any cause.
16361089|NCT04250844||Botulinum|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functional luminal imaging probe (EndoFLIP). The dosage will be determined by the patient's physician.
16361090|NCT04250844||Control|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections.
16361091|NCT04250831|Experimental|Glucomannan, oligofructose and chromium mixture|Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie
16361092|NCT04250818||Control Group|Patients with mTNBC who receive chemotherapy only
16361093|NCT04250818||Experimental Group|patients with mTNBC who receive a combination of chemotherapy and Immunotherapy
16361094|NCT04250805|Active Comparator|Lidocaine|Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
16361095|NCT04250805|Experimental|Lidocaine and Ropivacaine|Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance
16361096|NCT04250792|Experimental|single arm|Low dose naltrexone was prescribed to the patients affected with psoriasis.
16361097|NCT04250779|Placebo Comparator|Control Group|In this arm, patients are provided with standard-of-care instructions on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned off.
16361098|NCT04250779|Active Comparator|Treatment Group|In this arm, patients are provided with active guidance from CapMedic device on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned on.
16361099|NCT04250766|Other|Single arm echo-guided uterine biopsy|
16361100|NCT04250753||Patients with lumbar spinal stenosis|
16361101|NCT04250740|Experimental|Coffee A|
16361102|NCT04250740|Experimental|Coffee B|
16361103|NCT04250740|Experimental|Coffee C|
16361104|NCT04250727|Experimental|3mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 3mg nicotine concentration.
16361105|NCT04250727|Experimental|6mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 6mg nicotine concentration.
16361106|NCT04250714||Treatment patients|Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use
16361107|NCT04250701||Dyslexia (D)|
16361108|NCT04250701||Intellectual Disability (ID)|
16361109|NCT04250701||Control (C)|
16361110|NCT04250688|Experimental|Esko Bionics Suit + Functional Electrical Stimulation|
16361111|NCT04250688|No Intervention|Control|
16361157|NCT04250402||Arm 4|Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
16361118|NCT04250649|Active Comparator|Intervention|Betadine solution disinfection of the subcutaneous tissue during primary shoulder surgery
16361119|NCT04250649|No Intervention|Controle|Control group with surgery without disinfection of the subcutaneous tissue but dissection with an electric cautery during primary shoulder surgery
16361120|NCT04250636|Experimental|Study Participants|HIV-infected individuals, off ART, and with plasma HIV-1 RNA levels between 500 and 100,000 copies/ml by standard assays. Study participants will receive a single intravenous infusion of 3BNC117-LS and a single infusion of 10-1074-LS. The antibodies will be administered sequentially and dosed at 30 mg/kg.
16361121|NCT04250623|Experimental|subjects, 18-70 y, healthy|subjects, 18-70 y, healthy
16361122|NCT04250597|Experimental|1.0 mg/kg|
16361123|NCT04250597|Experimental|3.0 mg/kg|
16361124|NCT04250597|Experimental|10 mg/kg|
16361125|NCT04250597|Experimental|30 mg/kg|
16361126|NCT04250597|Experimental|60 mg/kg|
16361127|NCT04250584|Experimental|Test Device|Novel Mandibular Advancement Device
16361128|NCT04250584|Active Comparator|Predicate Device|Predicate Mandibular Advancement Device
16361129|NCT04250571|Experimental|No treatment group|Participants will receive no pills and will be told that they are in the no treatment group
16361130|NCT04250571|Experimental|Imaginary pill (IP) group|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence)
16361131|NCT04250571|Experimental|Open label placebo group|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo)"
16361132|NCT04250545|Experimental|Treatment (CB-839 HCl, sapanisertib)|Patients receive glutaminase inhibitor CB-839 hydrochloride PO BID and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16361133|NCT04250532||Lifeguard|Lifeguards who work on the Atlantic coast of Gironde France.
16361134|NCT04250519|Experimental|1% sodium hypochlorite & dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
16361135|NCT04250519|Active Comparator|1% sodium hypochlorite as irrigant &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
16361136|NCT04250519|Experimental|5.25% sodium hypochlorite and dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
16361137|NCT04250519|Active Comparator|5.25% sodium hypochlorite &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
16361138|NCT04250506|Experimental|Treatment A: Daridorexant 50 mg|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
16361139|NCT04250506|Experimental|Treatment B: Daridorexant 200 mg|Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.
16361140|NCT04250506|Placebo Comparator|Treatment C: Placebo|Placebo administered as tablets (4 x 50 mg) for oral use.
16361141|NCT04250506|Active Comparator|Treatment D: Moxifloxacin 400 mg|Moxifloxacin administered as film-coated tablets for oral use.
16361142|NCT04250493|Experimental|MSA patient|Patients will be recruited at the French Reference Center for MSA.
16361143|NCT04250493|Other|Control|Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
16361144|NCT04250480|Experimental|Beta-alanine|4 g by mouth, 3 times per day with regular meals for 14 days.
16361145|NCT04250480|Placebo Comparator|Placebo|4 g by mouth, 3 times per day with regular meals for 14 days.
16361146|NCT04250454|No Intervention|Control|Elsass Standard Care
16361147|NCT04250454|Active Comparator|Intervention|Enriched eviroment, Feed back training, Electrical stimulation, nutrition
16361148|NCT04250441|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
16361149|NCT04250428|No Intervention|Control|Women in the control arm will have (standard) access to antenatal care.
16361150|NCT04250428|Experimental|Demand intervention|Women in this arm will receive a home visit by a study nurse at the beginning of their pregnancy that will inform them regarding the importance of iron and folic acid supplementation as well as malaria prophylaxis.
16361151|NCT04250428|Experimental|Supply intervention|Women in this arm will get a monthly visit by study nurses. Women who did not obtain supplements or malaria prophyllaxis through routine antenatal care services will be directly provided with the supplements and malaria drugs by the study nurse.
16361152|NCT04250415||Operative Arm|
16361153|NCT04250415||Non-operative Arm|
16361154|NCT04250402||Arm 1|"Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
~Other Name: ESD"
16361155|NCT04250402||Arm 2|"Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally."
16361156|NCT04250402||Arm 3|Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
16361158|NCT04250389||Patients with VS receiving methylene blue infusion|The studied population will be all patients receiving methylene blue for refractory vasoplegic shock (VS) after Cardiopulmonary Bypass (CPB). Refractory VS is defined as follow: a dose of norepinephrine > 0.5µg/kg/min to obtain a mean arterial pressure of 65-75 mmHg with a normal or increase cardiac (> 2 L.min-1.m-2). Patients will be included in the investigator's 20-bed adult cardiothoracic intensive care unit (ICU) in a tertiary teaching hospital (Hopital Cardiologique Louis Pradel, Hospices Civils de Lyon).
16361159|NCT04250376|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
16361160|NCT04250363|Experimental|M5717|Participants will receive single ascending oral dose of M5717 powder in capsule after DVI of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
16361161|NCT04250363|Placebo Comparator|Placebo|Participants will receive placebo matched to M5717 after DIV of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
16361162|NCT04250350|Experimental|Lebrikizumab|every 2 weeks (Q2W)
16361165|NCT04250324|Experimental|BZ019|The subjects are enrolled into 2 dose-escalation cohorts, include 3x10^6/kg、6x10^6/kg, and dose-expansion cohorts, maybe 8x10^6/kg、10x10^6/kg.
16361166|NCT04250311|Experimental|MMH-407|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
16361167|NCT04250311|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
16361168|NCT04250298|Other|Iron deficient blood donors|Daily intake of 30 mg of sucrosomal iron during 90-120 days (male and female whole blood donors)
16361169|NCT04250272|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
16361170|NCT04250272|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
16361171|NCT04250259|Placebo Comparator|Placebo|Alcoholic Cirrhosis on placebo
16361172|NCT04250259|Experimental|1,200 mg SAMe|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
16361173|NCT04250259|No Intervention|Non-drinking Controls|Non-drinking healthy controls
16361174|NCT04250246|Experimental|Ipilimuamb plus nivoluamb plus guadecitabine|ipilimumab plus nivolumab combined with guadecitabine
16361175|NCT04250246|Active Comparator|Ipilimumab plus nivolumab|Ipilimumab plus nivolumab
16361178|NCT04250220|Experimental|intervention group|e-health-based strategy
16361179|NCT04250220|No Intervention|control group|symptom based AF-screening
16361180|NCT04250207|Experimental|K-321 QID|K-321 Ophthalmic Solution Dose A
16361181|NCT04250207|Experimental|K-321 BID|K-321 Ophthalmic Solution Dose B
16361182|NCT04250207|Placebo Comparator|Placebo|Vehicle Solution Dose
16361183|NCT04250194|Experimental|Navigation Bronchoscopy (NB) with F-Nav|
16361184|NCT04250194|Experimental|CT-guided Biopsy|
16361185|NCT04250181||Standard RF|ablation with RF power of 30 Watts (30W) and with 25 Watts (25W) on posterior wall
16361186|NCT04250181||High RF 40W (40 Watts)|ablation with RF power of 40 watts (40W)
16361187|NCT04250181||High RF 50W (50 Watts)|ablation with RF power of 50 watts (50W)
16361188|NCT04250155|Experimental|Phase 1a Dose Escalation|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
16361189|NCT04250155|Experimental|Phase 1a Dose Expansion|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
16361190|NCT04250155|Experimental|Phase 1b Dose Escalation|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
16361191|NCT04250155|Experimental|Phase 1b Dose Expansion|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
16361192|NCT04250142|Active Comparator|Conventional Glass Ionomer|Selective removal of carious tissue to soft dentin. Deep carious dentin will be lined by a conventional glass ionomer, followed by a composite resin restoration.
16361193|NCT04250142|Experimental|Self-etching Adhesive|Selective removal of carious tissue to soft dentin. Deep carious dentin will not be lined and a self-etching adhesive will cover the tissue, followed by a composite resin restoration.
16361194|NCT04250129||SLNB (-)&level 1-3 RT|SLNB (-)&level 1-3 RT
16361195|NCT04250129||SLNB (+)&level 1-3 RT|SLNB (+)&level 1-3 RT
16361196|NCT04250129||SLNB(+)&ALND&level 3 RT (+/-level 1-2)|SLNB(+)&ALND&level 3 RT (+/-level 1-2)
16361197|NCT04250116|Experimental|Anticoagulation mono therapy|
16361198|NCT04250116|Active Comparator|Dual antithrombotic therapy|
16361202|NCT04250077|Experimental|CRAFT-A|"Participants assigned to the CRAFT-A will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1)Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.
~CRAFT-A participants also attend a weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations."
16361203|NCT04250077|Experimental|CRAFT-C|"Participants assigned to the CRAFT-C groups will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.
~CRAFT-C participants attend a weekly 60-minute individualized on-on-one coaching session with a CRAFT certified coach. During weekly individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations. One-on-one sessions involve roleplays that are tailored to the participants' specific circumstances"
16361204|NCT04250077|Active Comparator|PEER|"Participants assigned to the PEER group will participate in an online peer support forum with other CSOs.
~Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully. This individual also will report any adverse or severe adverse events that members mention online."
16361205|NCT04250064|Experimental|Concurrent low-dose Bevacizumab|Low-dose concurrent Bevacizumab with standard radiotherapy
16361206|NCT04250064|Experimental|Ultra-low-dose RT|Ultra-low-dose RT
16361207|NCT04250051|Experimental|Treatment (combination chemotherapy, ivosidenib)|"INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
16361208|NCT04250025|Experimental|EXPERIMENTAL GROUPE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
16361209|NCT04250025|No Intervention|CONTRO GROUPE|60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.
16361210|NCT04250012|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 10-week internet-based acceptance and commitment therapy intervention with three remote meetings with a psychologist"
16361211|NCT04250012|Active Comparator|Psychoeducation|"Group Psychoeducation will receive a self-help booklet and a link to mobile wellness training program"
16361212|NCT04249999|Experimental|Intervention|Access to online physical activity platform (www.activonline.com.au) in addition to usual care.
16361213|NCT04249999|No Intervention|Control|No access to online physical activity platform. Continue with usual care.
16361214|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 17 and 19 lb BPW|Participants will be randomized to both 17 and 19 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
16361215|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 19 and 17 lb BPW|Participants will be randomized to both 19 or 17 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
16361216|NCT04249973||IgE-mediated cow's milk allergy|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
16361217|NCT04249973||Suspected of cow's milk allergy, but with negative diagnosis|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
16361218|NCT04249973||IgE-mediated food allergy, other than cow's milk|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
16361294|NCT04249453||Chronic low back pain with low disability|Veterans with chronic, non-specific LBP and a RMDQ score of 12 (gender-balanced, n2=18)
16361219|NCT04249973||Healthy brothers and sisters|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
16361220|NCT04249960|No Intervention|Transition as usual|Young people in this group will receive usual care and transition as usual, they will be our control group.
16361221|NCT04249960|Experimental|Managed transition|Young people in this group will do the managed transition, they will be our experimental group.
16361222|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1a)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
16361223|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)|Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
16361224|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1c)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
16361225|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)|Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
16361226|NCT04249934|Experimental|Caffeinated Coffee|
16361227|NCT04249934|Active Comparator|Decaffeinated Coffee|
16361228|NCT04249921||Experimental|"Use acupuncture to treat the patients who received the surgery of CPA tumor. Acupoints of reference: Yifeng(TE17),Tinggong(SI19),Xiaguan(ST07),Wind Pool(GB20),Outer Pass(SJ5),Union Valley(LI4),Yang Mound Spring(GB34),Leg Three Li(ST36).
~Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS)."
16361229|NCT04249921||Control|1.Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).
16361230|NCT04249908|Active Comparator|Healthy Subjects|
16361231|NCT04249908|Experimental|Mild Renal Impairment (RI)|
16361232|NCT04249908|Experimental|Moderate RI|
16361233|NCT04249908|Experimental|Severe RI|
16361234|NCT04249895||Main Cohort|All patients are undergoing radiotherapy in Tata Medical Center
16361235|NCT04249882|Placebo Comparator|Placebo|Matched to active medications
16361236|NCT04249882|Active Comparator|Varenicline|1 mg twice a day
16361237|NCT04249882|Active Comparator|Naltrexone|50 mg once a day
16361238|NCT04249869|Experimental|Group A|Group A will receive VGH-AD1 two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 8 weeks. Post-follow up will be 4 weeks later.
16361239|NCT04249869|Placebo Comparator|Group B|Group B will receive placebo two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the VGH-AD1 for another 8 weeks. Post-follow up will be 4 weeks later.
16361240|NCT04249856||Women examined by colposcopy|Women referred to colposcopy at our facilities who met inclusion criteria
16361241|NCT04249843|Experimental|Phase 1a: Dose Escalation|BGB-3245 administered orally (PO) as a continuous daily administration, in 28 day and 30 day cycles
16361242|NCT04249843|Experimental|Phase 1b, Group 1: Dose Expansion, non-V600 B-RAF mutations|BGB-3245 administered orally (PO) as a continuous daily administration, in 28 day and 30 day cycles in participants with non-V600 B-RAF mutations including RAF fusions
16361243|NCT04249843|Experimental|hase 1b, Group 2: Dose Expansion, B-RAF V600 mutations|BGB-3245 administered orally (PO) as a continuous daily administration, in 28 day and 30 day cycles in participants with B-RAF V600 mutated melanoma or NSCLC B-RAF and/or MEK inhibitor resistant tumors (i.e. have progressed on a B-RAF-inhibitor and/or MEK-inhibitor)
16361244|NCT04249830|Experimental|Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
16361245|NCT04249817|Experimental|Video conferencing with extended role practitioner|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
16361246|NCT04249817|No Intervention|Usual care|Participant goes to their rheumatologist's clinic for follow-up, including physical assessment by their rheumatologist, as they would normally.
16361247|NCT04249804|Experimental|Intrathecal Mg group|45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine
16361248|NCT04249804|Experimental|IV Mg infusion group|45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia
16361249|NCT04249804|No Intervention|control|0.5% heavy bupivacaine in the spinal with no additives
16361250|NCT04249791|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from live donor.
16361251|NCT04249778|Experimental|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
16361252|NCT04249778|Placebo Comparator|Placebo|Participants will receive placebo once daily
16361253|NCT04249765|Experimental|Hand strength|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer
~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned.
~The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer."
16361254|NCT04249752||Group 1 with GBS patients|GBS patients
16361255|NCT04249752||Group 2 with CIDP patients|with CIDP patients
16361295|NCT04249453||Controls|Asymptomatic veterans with no recent history of LBP (gender-balanced, n3=18)
16361256|NCT04249739|Experimental|CapeOx+Pembrolizumab|"Run in exploratory Biomarker group (N=10)
~Cycle 1 Only CapeOX monotherapy
~Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy
~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy CapeOx+Pembrolizumab therapy (N=68)
~Cycle 1 up to Cycle 8 CapeOX + pembrolizumab therapy
~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy : CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal."
16361257|NCT04249726|Experimental|Direct composite resin restoration|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations
16361258|NCT04249726|Active Comparator|Full coverage metal-ceramic crown|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations followed by full coverage metal-ceramic crown
16361259|NCT04249713|Experimental|Brodalumab|Brodalumab 210mg subcutaneously every week for 24 weeks
16361260|NCT04249700|Experimental|Whole-body Hyperthermia (WBH)|All participants receive WBH for 80-110 minutes in the Curve Sauna Dome infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
16361261|NCT04249687|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection
16361262|NCT04249687|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
16361263|NCT04249674||Patient under a CYP2D6 inhibitor and under Tramadol|
16361264|NCT04249674||Patient not under a CYP2D6 inhibitor but under Tramadol|
16361265|NCT04249648||Patients with new diagnosis of heart failure with reduced ejection fraction|Patients with new diagnosis of heart failure with reduced ejection fraction who will be started on renin-angiotensin-aldosterone system inhibitors or in whom there is a plan to increase renin-angiotensin-aldosterone system inhibitors (if already taking prior to diagnosis of heart failure).
16361266|NCT04249648||Patients with hyperkalaemia|Hospitalised patients and patients attending emergency department who have at least 1 blood test with a potassium level of ≥5.5 mmol/l.
16361267|NCT04249648||Healthcare professionals managing patients with hyperkalaemia|Healthcare professionals (doctors, pharmacists, non-medical prescribers) who manage patients with hyperkalaemia and/or heart failure and hyperkalaemia.
16361268|NCT04249635||Reference Group|Healthy term (> 37 weeks of gestation) newborns of women with pregestational body mass index (BMI) ≥18,5 and <24,9 in the first prenatal visit.
16361269|NCT04249635||Maternal obesity (MO) Group|Newborns of women with pregestational BMI ≥30 that received 200 mg/dayDHA supplementation.
16361270|NCT04249635||MO+DHA Group|Newborns from women with pregestational BMI ≥30 that received 800 mg/day DHA supplementation.
16361271|NCT04249622|Experimental|Arm I (rifaximin, pertuzumab-based chemotherapy)|Patients that experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy receive rifaximin PO BID on days 1-5 and standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
16361272|NCT04249622|Active Comparator|Arm II (pertuzumab-based chemotherapy)|Patients that do not experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy continue receiving standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
16361273|NCT04249609|Experimental|High Carbohydrate Meals Around Exercise|On day 1, high CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will consist of pasta, meat ball and orange juice. On the day 2, participants will exercise for 60 minutes and then in 60 minutes will consume morning meal, providing 30% of their total daily energy requirements. Morning meal will consist of oats, skimmed-milk, banana and seedless raisins.
16361274|NCT04249609|Experimental|Low Carbohydrate Meals Around Exercise|On day 1, low CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will based on burger, cheese, mushroom, nuts, and butter.On the day 2, participants will exercise fro 60 minutes and then in 60 will consume morning meal, providing 30% of their total daily energy requirements. Meal will consist of white bread, egg, cheese, olive oil, nuts, and olives.
16361276|NCT04249583|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
16361277|NCT04249583|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
16361278|NCT04249570|Experimental|Iodine|gastrostomy feeding tube is coated with a layer of Betadine by aseptic gauze before PEG technique
16361279|NCT04249570|No Intervention|No iodine|gastrostomy feeding tube is not coated with a layer of Betadine by aseptic gauze before PEG technique
16361280|NCT04249557|Experimental|EIM group|This contains: A 12-week Exercise is medicine teaching class containing 6-18 patients per group (class size may be limited by social distancing policy in Hong Kong), homework are prescribed to participants to encourage regular exercise. The exercise level will be recorded by a tracker and provides feedback to the participants and physical trainer. The physical parameters such as fat percentage and blood pressure level will be feedback to the patients to encourage exercise. (If sports center are closed by the Government, the classes will be conducted online)
16361281|NCT04249544|Experimental|Impulsive group, placebo then pramipexole|half of the impulsive group will first get the placebo on the first day and pramipexole on the second day
16361282|NCT04249544|Experimental|Impulsive group, pramipexole then placebo|half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day
16361283|NCT04249544|Experimental|Non-impulsive group, placebo then pramipexole|half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day
16361284|NCT04249544|Experimental|Non-impulsive, pramipexole then placebo|half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day
16361285|NCT04249531|Experimental|Amikacin|Patients will receive once amikacin i.v. 7,5 mg/kg in the first week
16361286|NCT04249518|No Intervention|nurse instruction of CPAP|Normal extradition. 45 minutes face to face with a nurse.
16361287|NCT04249518|Experimental|Video extradition|Access to 7 min video - explaining how to start CPAP and how to adjust the mask.
16361288|NCT04249492|Experimental|IOL implantation experimental|Experimental arm: Enhanced depth of focus (EDOF) intraocular lens.
16361297|NCT04249440||upfront surgery|patient accepts upfront surgery and run postoperative systemic treatment
16361298|NCT04249427|Active Comparator|Erenumab|140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
16361299|NCT04249427|Placebo Comparator|Placebo|Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
16361302|NCT04249388||Decliners of Pulmonary Rehabilitation|No intervention, just observation
16361303|NCT04249362|Experimental|Cohort A|Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.
16361304|NCT04249362|Experimental|Cohort B|Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.
16361305|NCT04249349|Experimental|Robot-assisted Gait|Participants will receive assisted gait with a motorized ankle foot orthosis. Patient´s gait will be analyzed by a photogrammetry system during device assistance. Session will involve 1 hour of supervised training.
16361306|NCT04249336|Experimental|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
16361307|NCT04249336|Active Comparator|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
16361308|NCT04249336|Active Comparator|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
16361309|NCT04249336|Placebo Comparator|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
16361310|NCT04249323|Experimental|Part 1: SAD Cohorts A through H CORT113176|Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.
16361311|NCT04249323|Placebo Comparator|Part 1: SAD Cohorts A through H Placebo|Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.
16361312|NCT04249323|Experimental|Part 2: MAD Cohorts A through D CORT113176|Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
16361313|NCT04249323|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.
16361314|NCT04249323|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.
16361315|NCT04249310||Tiotropium/Olodaterol|Combination of Tiotropium and Olodaterol
16361316|NCT04249310||Tiotropium|
16361317|NCT04249297||IVF/Dydrogesteron|Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology
16361318|NCT04249284|Experimental|Treatment A : BMS-986165|
16361319|NCT04249284|Experimental|Treatment B: BMS-986165 prototype 1|
16361320|NCT04249284|Experimental|Treatment C: BMS-986165 prototype 2|
16361321|NCT04249284|Experimental|Treatment D: BMS-986165 prototype 2|
16361322|NCT04249271||euthyroid, no antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
16361323|NCT04249271||borderline euthyroid, no antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling
16361324|NCT04249271||hypothyroidism, no antibodies|TSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
16361325|NCT04249271||euthyroid, with antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
16361326|NCT04249271||borderline euthyroid, with antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling
16361327|NCT04249271||hypothyroidism, with antibodiesal|TSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
16361328|NCT04249258|Experimental|Dobutamine|Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
16361329|NCT04249245||Parkinson Patients|"These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).
~They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015."
16361330|NCT04249245||Control Subjects|"They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned.
~If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group."
16361331|NCT04249232|Active Comparator|abaloparatide prefilled syringe|Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.
16361332|NCT04249232|Placebo Comparator|Placebo prefilled syringe|For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.
16361333|NCT04249219|Experimental|E-Cigarette Ads|All individuals in the study will see the same e-cigarette advertisements presented in a random order.
16361334|NCT04249206|Experimental|Hydraulic Sealer Group|"The single-cone obturation technique is based on a master cone of gutta-percha in conjunction with a hydraulic sealer.
~Hydraulic endodontic cements exhibit excellent hydraulic properties, biocompatibility and bioactivity."
16361335|NCT04249206|Active Comparator|Zinc oxide-eugenol Sealer Group|The continuous wave of condensation of gutta-percha and a zinc oxide-eugenol (ZOE) sealer is a gold standard in endodontic obturation.
16361336|NCT04249193||Transfusion|
16361337|NCT04249167|Experimental|Treatment (cryoablation, atezolizumab, nab-paclitaxel)|Patients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab IV on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16361338|NCT04249154|Other|Post-op IMRT & hormonal therapy|The protocol is designed to recruit patients who have undergone prostatectomy and high risk features of the disease were found post-operatively or for patients that, after prostatectomy, a PSA rise has been documented will be enrolled in the Phase II trial. Patients will receive Eligard injection 8-12 weeks before starting radiation. The second injection is given 12 weeks after the first one concomitant with radiation therapy.
16361339|NCT04249141||ICU providers|Surveys and a concept mapping exercise will be administered to ICU providers who participated in the ICU Liberation Collaborative
16361340|NCT04249141||Secondary Data Analysis|Secondary data analysis will used information on patients and providers who participated in the ICU Liberation Collaborative
16361341|NCT04249128|Experimental|Veg Collagen & Keratin Free (Hair Skin Nails)|Participants will receive a free 3 month supply of Collagen & Keratin for Hair, Skin & Nail Health
16361342|NCT04249128|Experimental|Veg Collagen Extended with Powder Free (Hair Skin Nails)|Participants will receive a free 3- month supply of Collagen & Keratin for Hair, Skin & Nail Health extended with a pro-berry powder
16361343|NCT04249128|Experimental|Veg Collagen & Keratin $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin for Hair, Skin & Nail Health
16361344|NCT04249128|Experimental|Veg Collagen Extended with Powder $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin extended with pro-berry powder for Hair, Skin & Nail Health
16361345|NCT04249128|Experimental|Ceramides and Astaxanthin Free (Skin)|Participants will receive a free 3-month supply of ceramides and Astaxanthin for Hair, Skin & Nail Health
16361346|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder Free (Skin)|Participants will receive a free 3-month supply of Ceramides and Astaxanthin for Hair, Skin & Nail Health
16361347|NCT04249128|Experimental|Ceramides and Astaxanthin $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
16361348|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
16361349|NCT04249115|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of targeted lesion.
16361350|NCT04249102|Experimental|CGM Group|The study group will be provided with a Continuous Glucose Monitoring system (Guardian Connect from Medtronic).
16361351|NCT04249102|Active Comparator|FGM Group|The control group will be provided with a Flash Glucose Monitoring system (Abbott Diabetes Care).
16361352|NCT04249089|Active Comparator|Relaxation Group|
16361353|NCT04249089|No Intervention|Control group|
16361356|NCT04249063|Experimental|Treatment Group|NovaSure EA with an injection of local anaesthetic into the fundus. Paracervical block and procedural sedation as per usual.
16361357|NCT04249063|Placebo Comparator|Control Group|NovaSure EA with an injection of normal saline into the fundus. Paracervical block and procedural sedation as per usual.
16361358|NCT04249050|Experimental|Intervention group|The intervention group is receiving a nutritional drink containing potential immune stimulating ingredients (fish oil, arginine, nucleotides)
16361359|NCT04249050|No Intervention|Control group|The Control group is receiving the hospital´s Standard Of Care.
16361360|NCT04249037|Active Comparator|Arm A: Rapid Start Group|Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
16361361|NCT04249037|Placebo Comparator|Arm B: Standard Group|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
16361362|NCT04249024|Experimental|Laser treatment|
16361363|NCT04249024|Active Comparator|Mucosal flap surgery|
16361442|NCT04248465|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
16361577|NCT04247464|No Intervention|Standard diet|The participants will follow an standard diet during the chemotherapy treatment
16361364|NCT04248998|Experimental|Chemotherapy plus Fasting-Mimicking Diet (FMD)|"Experimental Arm A will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD.
~Chemotherapy will consist of:
~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by
~twelve consecutive cycles of weekly paclitaxel 80 mg/mq
~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles."
16361365|NCT04248998|Experimental|Fasting-mimicking diet plus metformin plus chemotherapy|"Experimental Arm B will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD and daily metformin
~Chemotherapy will consist of:
~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by
~twelve consecutive cycles of weekly paclitaxel 80 mg/mq
~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles.
~Metformin will be administered at an initial dosage of 850 mg/dya, and then escalated to the maximum dosage of 1700/day (two 850 mg tablets) if well tolerated. Metformin will be interrupted 7 days before surgery."
16361366|NCT04248985||Pre-Intervention|Baseline measurement of timing and behavior in OOH cardiac arrest patients presenting with ongoing CPR.
16361367|NCT04248985||Post-Intervention|Timing and behavior in OOH cardiac arrest patents presenting with ongoing CPR
16361368|NCT04248972|Experimental|Intervention|A treatment with whole body red light therapy (NovoTHOR®) will be carried out
16361369|NCT04248972|Placebo Comparator|PLACEBO INTERVENTION|A placebo whole body red light will be carried out
16361370|NCT04248959|Experimental|PREHAB|Facility and home-based multimodal prehabilitation (aerobic exercise training, resistance exercise training, mindfulness)
16361371|NCT04248959|No Intervention|USUAL CARE|Self-directed physical activity and provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
16361372|NCT04248946|Experimental|MRI stream|"In this stream all patients receive 2 experimental interventions (anodal tDCS and cathodal tDCS) and a sham intervention (sham tDCS). These are delivered in randomised order, ensuring a balanced distribution of participants across possible orders. They will receive 5 sessions per condition (on consecutive days), for a total of 15 sessions.
~I. Anodal, cathodal, sham II. Anodal, sham, cathodal III. Cathodal, anodal, sham IV. Cathodal, sham, anodal V. Sham, anodal, cathodal VI. Sham, cathodal, anodal"
16361373|NCT04248946|Experimental|Bedside stream|"In this stream all patients receive 1 experimental interventions (either anodal tDCS or cathodal tDCS) and 1 sham intervention (sham tDCS). These include only 1 session per condition and are delivered in randomised order, resulting in the following possible combinations:
~I. Anodal, sham II. Cathodal, sham III. Sham, anodal IV. Sham, cathodal
~Participants will be randomly assigned to the above groups ensuring a balanced distribution of participants across them."
16361374|NCT04248933|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRC-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
16361375|NCT04248920|Experimental|Intervention Group|Intervention Group. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO). As part of the C2C program, participants will be contacted 6 months later for a supplementary consultation over the telephone and to answer any questions. Epilepsy is unique among chronic, episodic disorders in that PWE lose their ability to make choices during a seizure and depend to a greater degree on the decisions of others including family, friends and colleagues. For this reason, we encourage the PWE to invite their support network to attend the patient education sessions.
16361376|NCT04248920|Other|Waitlist Control Group|Waitlist Control Group. The control group continues TAU and will be followed up 12 months after randomization. The control group will receive C2C after the 12-month follow-up.
16361377|NCT04248907|Experimental|Socket A|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
16361378|NCT04248907|Active Comparator|Socket B|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
16361379|NCT04248907|Active Comparator|Socket C|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
16361380|NCT04248894|Experimental|High-intensity interval training (HIIT)|High-intensity interval training (HIIT) = the exercise of high intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the HIIT session was established based on the HR and workload levels corresponding to 5% above the respiratory compensation point.
16361545|NCT04247724|Experimental|Active group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of men playing recreational handball"
16361381|NCT04248894|Experimental|Moderate-intensity continuous training (MICT)|Moderate-intensity continuous training (MICT) = the exercise of moderate intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the MICT session was established based on the HR and workload levels corresponding to anaerobic threshold and respiratory compensation point
16361382|NCT04248894|Sham Comparator|No training|The patients are instructed to avoid any regular exercise program or any non-supervised exercise protocol during the study.
16361383|NCT04248881|Active Comparator|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
16361384|NCT04248881|No Intervention|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2020 (first timers) and have not yet received health education information."
16361385|NCT04248868|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
16361386|NCT04248855|Experimental|SAD Cohort 1|All enrolled patients will receive one dose of KAN-101 Dose A
16361387|NCT04248855|Experimental|SAD Cohort 2|All enrolled patients will receive one dose of KAN-101 Dose B
16361388|NCT04248855|Experimental|SAD Cohort 3|All enrolled patients will receive one dose of KAN-101 Dose C
16361389|NCT04248855|Experimental|SAD Cohort 4|All enrolled patients will receive one dose of KAN-101 Dose D
16361390|NCT04248855|Experimental|MAD Cohort 5|All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
16361391|NCT04248855|Experimental|MAD Cohort 6|All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
16361392|NCT04248855|Experimental|MAD Cohort 7|All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo
16361395|NCT04248816|Experimental|Usual Care|Standard of care
16361396|NCT04248816|Experimental|Opt-out|Facilitated outreach and opt-out framing
16361397|NCT04248816|Experimental|Opt-out + Incentive|Facilitated outreach and opt-out framing plus a financial incentive
16361398|NCT04248803|No Intervention|Total etch control group|No gluma desensitizer application
16361399|NCT04248803|Experimental|TE - GLUMA application prior to acid etching|TE- Total Etch GLUMA - Desensitizing agent
16361400|NCT04248803|Experimental|TE - GLUMA application after acid etching|TE- Total Etch GLUMA - Desensitizing agent
16361401|NCT04248803|No Intervention|Self etch control group|No gluma desensitizer application
16361402|NCT04248803|Experimental|SE - GLUMA application prior to acid etching|SE - Self Etch GLUMA - Desensitizing agent
16361403|NCT04248803|Experimental|SE - GLUMA application after acid etching|SE - Self Etch GLUMA - Desensitizing agent
16361404|NCT04248790|Experimental|Experimental: the mobile App|Participants in the intervention arm will receive access to all the app capabilities. The app features include information on HIV testing locations, sex and PrEP diary and reminder of taking PrEP.
16361405|NCT04248777|Other|left main PCI guided by OCT|The LM PCI strategy is guided by 3 OCT runs, according to a pre-defined standardized protocol.
16361406|NCT04248764|Experimental|Foam roller group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, foam roler will be applied to the participants' quadriceps femoris muscles in a prone position for five minutes.
16361407|NCT04248764|Experimental|Massage group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
16361408|NCT04248764|No Intervention|Control group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, the participants will rest in the long sitting position for 5 minutes.
16361409|NCT04248751|Experimental|Graft-Augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin. Then, the graft will be delivered to the subacromial space and positioned over the bursal surface of the suprasinatus tendon, ensuring that the lateral edge of the implant will overlap with the head of the humerus. The graft will be fixed with tendon and bone staples.
16361410|NCT04248751|Active Comparator|Non-augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin.
16361411|NCT04248738|Experimental|SocNSuppR|Inpatient teams systematically provided with information about patients' social needs and supportive resources.
16361438|NCT04248491|Active Comparator|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
16361443|NCT04248465|Placebo Comparator|Placebo|Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
16361412|NCT04248725|Experimental|E-TIPS|The E-TIPS intervention is based upon a cognitive-behavioral intervention for pain that was developed for and shown to be effective in people with chronic pain and a physical disability such as the conditions of interest in this study. Eight, 45-minute telephone sessions will be delivered by a clinician. A patient workbook will be used to facilitate skill acquisition and rehearsal in and outside of sessions. The intervention includes education about the role of unhelpful thoughts, particularly pain catastrophizing, and unhelpful pain coping behaviors; instruction in how to identify and change unhelpful or negative thinking about pain; utilization of helpful coping strategies; relaxation techniques; behavioral activation including setting goals for physical activation, activity pacing and scheduling; and coping with pain flare-ups. Each session includes a brief relaxation exercise. Participants receive digital audio recordings of relaxation exercises to practice at home.
16361413|NCT04248725|No Intervention|Usual care|Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
16361414|NCT04248712|Experimental|Treatment Group|Participants receive Famotidine 40 mg tab twice daily by mouth and Loratadine 10 mg tab once daily by mouth for 12 weeks.
16361415|NCT04248712|Placebo Comparator|Placebo Group|Participants receive Famotidine placebo tablet matching Famotidine orally twice daily for 12 weeks, and Loratadine placebo tablet matching Loratadine orally daily for 12 weeks.
16361416|NCT04248699|Experimental|Lumenato Supplement|tomato oleoresin
16361417|NCT04248686|No Intervention|Control|Referral to standard care - student health center on campus.
16361418|NCT04248686|Active Comparator|Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity.
16361421|NCT04248660||Uterine artery doppler measurements|"Uterine artery doppler measurements will be made in the same patients at 11-14 weeks and 20-22 weeks of pregnancy.
~Doppler results will be classified according to pregnancy results and primary results will be doppler findings."
16361422|NCT04248647|Experimental|Intervention Group|4-week multimodal preoperative intervention (i.e., Prehabilitation) consisting of an aerobic and strength training program, nutritional counselling and psychological support to help improve physical and psychological health prior to surgical resection of colorectal cancer.
16361423|NCT04248621|Experimental|Intermittent Androgen Deprivation|ADT including luteinizing hormone-releasing hormone (LHRH) agonist and antagonist, antiandrogen, or maximum androgen blockade (MAB) should be withdrawn after 6 months of ADT, if the prostate-specific antigen (PSA) reaches its nadir (< 4 ng/dL) and serum testosterone reaches castration level (< 50 ng/dL).
16361424|NCT04248621|Active Comparator|Continuous Androgen Deprivation|ADT including LHRH agonist and antagonist, antiandrogen, or MAB without any discontinuation during study period.
16361425|NCT04248608|Experimental|erector spinae block|Ultrasound guided erector spinae block with will be done after induction of intravenous anesthesia. After identification of trapezius, rhomboid major, and erector spinae muscles. The needle will be inserted in a cephalad-to-caudal direction until the tip contact transverse process and the needle tip is visualized in the plane deep to the erector spinae muscle. The needle tip position is confirmed by visualizing linear spread of test dose between the muscles after injection. A total dose of 25 mL of 0.25% bupivacaine will be injected.
16361426|NCT04248608|Experimental|serratus anterior block|Ultrasound guided serratus anterior block will be done after induction of intravenous anesthesia. The serratus anterior, latissimus dorsi, and the intercostal muscles will be identified in the fourth and fifth intercostal level, an 18 G Tuohy needle will be advanced in the plane between the serratus anterior muscle and the intercostal muscles. A total dose of bupivacaine 25ml in a concentration of 0.25% will be administered under the serratus muscle after a test dose using an in-plane technique.
16361427|NCT04248608|Active Comparator|intravenous morphine|intravenous morphine will be administrated in a dose of 0.1 mg per kg after induction of general anesthesia
16361428|NCT04248595|Experimental|Azacitidine plus HAG|"Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of 12cycles.
~AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF"
16361429|NCT04248595|Experimental|Azacitidine plus HIA|"Patients of denovo or relapsed AML(age<60y) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.
~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin"
16361430|NCT04248595|Experimental|Azacitidine plus HDA|"Patients of denovo or relapsed AML(age<60y) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.
~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Daunorubicin"
16361431|NCT04248582|Experimental|Cryotherapy|Patients will receive neoadjuvant cryotherapy at specified dose frequency interval
16361432|NCT04248569|Experimental|DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab|
16361433|NCT04248556|Experimental|subjects, 18-59 y, healthy|patch test with investigation product
16361434|NCT04248543|Experimental|quantitative MRI at 4 weeks|
16361435|NCT04248530|Experimental|Renal denervation therapy group|The subject treated by renal denervation by using DENEX system.
16361436|NCT04248517|Experimental|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
16361437|NCT04248517|No Intervention|Treatment as Usual group|participants will undergo their routine treatment.
16361439|NCT04248491|Sham Comparator|Emsella Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (<10% power).
16361440|NCT04248478||Fibromiyalgia Patients|Patients diagnosed with fibromyalgia according to 2013 American College of Rheumatology criteria are planned to be included in this arm.
16361444|NCT04248452|Experimental|Arm A (FOLXFOX)|Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16361445|NCT04248452|Experimental|Arm B (CAPOX)|Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16361446|NCT04248452|Experimental|Arm C (radiation therapy, FOLFOX)|One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
16361447|NCT04248452|Active Comparator|Arm D (FOLFOX)|Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
16361448|NCT04248452|Experimental|Arm E (radiation therapy, CAPOX)|One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
16361449|NCT04248452|Active Comparator|Arm F (CAPOX)|Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
16361450|NCT04248439|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
16361451|NCT04248426|Experimental|ATI-2173|
16361452|NCT04248426|Placebo Comparator|ATI-2173 Placebo|
16361453|NCT04248413|Other|Standard rehabilitation protocol|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution.
16361454|NCT04248413|Experimental|Standard rehabilitation plus Blood Flow Restriction Therapy|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution in addition to the BFR therapy. Per recommendations of Owens Recovery Science, the organization responsible for certifying physical therapists in BFR therapy, the therapy will take place concurrently throughout the duration of the rehabilitation.
16361455|NCT04248400|No Intervention|Control|No intervention
16361456|NCT04248400|Active Comparator|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
16361457|NCT04248400|Experimental|Tai Chi|A 24 weeks Tai Chi training with three 1-hour section per week
16361458|NCT04248387|Experimental|Toripalimab group|The subjects in this group receive intravenous drip infusion of Toripalimab at a dose of 3 mg / kg once every 2 weeks for a total of two cycles
16361459|NCT04248374|No Intervention|Fatty Acid Taste|Fatty acid taste without sour adaptation
16361460|NCT04248374|Experimental|Fatty Acid Taste after sour adaptation|Fatty Acid Taste after sour adaptation
16361461|NCT04248361|Experimental|TEM-PCR Diagnosis|The TEM-PCR diagnostic technology will be used to assess for a source pathogen involved in the subject's acute respiratory illness. Results of the TEM-PCR URI Panel will be used by the physician to guide treatment decisions. If indicated, the investigator may also utilize rapid strep testing and rapid influenza testing for diagnosis. In the event a lower respiratory infection is suspected a chest x-ray or complete blood count (CBC) with differential may also be performed.
16361462|NCT04248361|Active Comparator|SOC/Empiric Diagnosis|The Standard of Care for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
16361463|NCT04248335|Experimental|In Weight Management Program|Evaluate the effect of liver fat on pharmacology of PPI's, and if applicable midazolam
16361464|NCT04248335|Experimental|Not in Weight Management Program|Evaluate the effect of liver fat on drug metabolism of PPI's, and if applicable midazolam
16361465|NCT04248322||Subjects who used a Connected Catheter|Subjects will have Neurogenic Lower Urinary Tract Dysfunction and will have participated in a study with a Connected Catheter. These characteristics will create a 2 (bladder management) x ~5 (etiology) = 10 cell matrix for recruiting for participant interviews.
16361466|NCT04248322||Caregiver of Subject who used a Connected Catheter|Caregiver (n=20) interviews will be done for those who care for individuals with similar bladder managements and etiologies.
16361467|NCT04248309|Experimental|A1|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
16361468|NCT04248309|No Intervention|A2|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A2：without additional treatment
16361469|NCT04248309|No Intervention|B|Group B：serum progesterone ≥7.24ug/L， without additional treatment
16361470|NCT04248283|Experimental|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
16361471|NCT04248270|Other|The relationship between image and AD disease|To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.
16361472|NCT04248257|Experimental|PeACE peer coaching arm|Behavioral, PeACE, PeACE consists of 3 streamlined 30-minute psychosocial telephone counseling sessions delivered by a well-trained peer coach. Coaches are lay YARs from HBOC families demonstrating good knowledge, communication skills, and protocol mastery.
16361473|NCT04248257|Active Comparator|Community peer coaching arm|Behavioral, usual care, Participants in the usual care arm will receive navigation to peer support with a range of community groups who provide these services.
16361474|NCT04248244|Experimental|Early Palliative Care Integration|12 months of PC with concurrent standard treatment for MM, QOL assessments
16361477|NCT04248205|Active Comparator|Intraoperative ketamine infusion|Subjects in this group will receive standard anesthesia during surgery and a dose of ketamine at 0.3 mg/kg IV bolus prior to surgical incision. If the procedure lasts more than 1 hour, an additional bolus dose will be given.
16361478|NCT04248205|No Intervention|Control group|This group will only receive the standard anesthesia during surgery with no ketamine.
16361479|NCT04248192|Experimental|Donor Derived HIV-Specific T-cells (DD HST-NEETs)|Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
16361480|NCT04248179|Active Comparator|Active|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Ropivacaine 5mg/ml corresponding to 3 * 10ml * 5mg/ml Ropivacaine = 150mg Ropivacaine.
16361481|NCT04248179|Placebo Comparator|Placebo|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Sodium chloride 9mg/ml corresponding to 3 * 10ml * 9mg/ml Sodium chloride = 189mg Sodium chloride.
16361482|NCT04248153|Experimental|Group A|BR55 will be performed in the early follicular phase first and in the late follicular phase thereafter.
16361483|NCT04248153|Experimental|Group B|BR55 will be performed in the late follicular phase first and in the early follicular phase thereafter.
16361484|NCT04248140|Experimental|WiFi - Sham|first Intervention WiFi, second intervention sham
16361485|NCT04248140|Experimental|Sham - WiFi|first intervention sham, second intervention WiFi
16361486|NCT04248127|Experimental|Honey sweetened yogurt|1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.
16361487|NCT04248127|Placebo Comparator|Sugar sweetened yogurt|Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.
16361488|NCT04248101|Active Comparator|Group 1|88 cases of umbilical granulomas who were treated with double ligation
16361489|NCT04248101|Active Comparator|Group 2|88 cases of umbilical granulomas who were treated with topical silver nitrate
16361490|NCT04248088|No Intervention|Educational Control Group|Education provided for optional use
16361491|NCT04248088|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly for 6 months
16361492|NCT04248075||Control|Patients who do not want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
16361493|NCT04248075||Dexmedetomidine|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
~After the induction of spinal anestheisa, dexmedetomidine is administered for sedation during surgery."
16361494|NCT04248075||Propofol|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
~After the induction of spinal anestheisa, propofol is administered for sedation during surgery."
16361495|NCT04248075||Midazolam|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
~After the induction of spinal anestheisa, midazolam is administered for sedation during surgery."
16361496|NCT04248062||IEM experts|Heterogeneous group of health professionals (physicians, psychologists, nutritionists) working in the field of Inborn Errors of Metabolism (IEM)
16361497|NCT04248062||Paediatric IEM patients|IEM patients between 10 and 18 years
16361498|NCT04248062||Parents of paediatric IEM patients and patient representatives|"Parents of IEM patients (between 0 and 18 years)
~Patient representatives"
16361499|NCT04248049|Experimental|Experimental side|Roots covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
16361500|NCT04248049|Active Comparator|Control side|Roots covered with coronally advanced flap (CAR)
16361501|NCT04248036|Other|Circle Of Security Parenting, COS-P|Pilot study, assessing eligibility, outcome measures and compliance to Group intervention
16361502|NCT04248023|Experimental|Intervention Practices|Intervention practices will work with a practice facilitator to make practice specific changes to address unhealthy alcohol use.
16361503|NCT04248023|No Intervention|Control Practices|Control practices will continue to screening and address unhealthy alcohol use based on their existing practice patterns.
16361504|NCT04248010|Active Comparator|standard tDCS|20 min of standard 2-electrode transcranial direct current stimulation (2 mA) at a previously reported scalp location.
16361505|NCT04248010|Active Comparator|HD-tDCS - anterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to anterior language areas of the brain.
16361506|NCT04248010|Active Comparator|HD-tDCS - posterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to posterior language areas of the brain.
16361507|NCT04248010|Sham Comparator|sham tDCS|sham transcranial direct current stimulation using a brief pulse at the beginning and end of the 20 min intervention.
16361508|NCT04247997|Experimental|Group D|disconnect pulmonary vague nerve branches
16361509|NCT04247997|No Intervention|Group P|preserve the pulmonary vague nerve branches
16361510|NCT04247984|Experimental|mXELIRI+ Bevacizumab|
16361511|NCT04247984|Active Comparator|FOLFIRI + Bevacizumab|
16361512|NCT04247971||Obese, early-onset asthmatics|Obese adults (BMI>or= 30) between the ages of 21-60 with an initial asthma diagnosis at <12 years of age
16361513|NCT04247971||Obese, late-onset asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with an initial asthma diagnosis at >12 years of age
16361514|NCT04247971||Obese non-asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with no asthma diagnosis
16361515|NCT04247958||Robotic-assisted colorectal resection|Subjects with either a suspected or confirmed benign or malignant disease of the colon and rectum who are scheduled to undergo a robotic-assisted resection of the colon or rectum.
16361516|NCT04247945|No Intervention|HSC|
16361517|NCT04247945|Experimental|MSC+HSC|
16361518|NCT04247932||Municipal|Individual participants receiving active labor market intervention from municipal providers
16361519|NCT04247932||Non-profit|Individual participants receiving active labor market intervention from non-profit providers
16363806|NCT04231812|Other|open lable|Prospective, open-label
16361521|NCT04247893|Active Comparator|Exercises with blood flow restriction|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Device: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.
16361522|NCT04247893|Experimental|Exercises with blood flow restriction + photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.Photobiomodulation a mesh composed of multiple diodes containing 50 Infrared LEDs.
16361523|NCT04247893|Placebo Comparator|Blood flow restriction exercises + placebo photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted. Photobiomodulation turned off with a mesh composed of multiple diodes containing 50 Infrared LEDs.
16361524|NCT04247880|Experimental|Mentees|This arm consists of apprentice-level, female-identifying construction workers who will receive active mentorship (the intervention) for two years from trained journey-level mentors.
16361525|NCT04247880|No Intervention|Control Apprentices|This arm consists of apprentice-level, female-identifying construction workers who will not receive mentorship.
16361526|NCT04247867|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO (Theranova) membrane then dialysis for 4 weeks with MCO membrane and increased fiber intake
16361527|NCT04247867|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
16361528|NCT04247854|Active Comparator|Probiotic|
16361529|NCT04247854|Placebo Comparator|No intervention|
16361530|NCT04247841|No Intervention|Phase I: Current Practice|This represents the first phase of the study in which a prospective cohort of patients will complete the survey to define baseline rates of recall of perioperative risk and level of patient satisfaction with risk discussion
16361531|NCT04247841|Experimental|Phase II Visual Aid & Scripted Risk Discussion|This will involve a group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
16361532|NCT04247841|Active Comparator|Phase II Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
16361533|NCT04247828|Experimental|Adaptive and individualized AAC|Adaptive and individualized AAC for subjects with SPI
16361534|NCT04247815|Experimental|ATI-450 plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
16361535|NCT04247815|Placebo Comparator|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
16361536|NCT04247802|Experimental|Backwards Walking (BW) programme|This group will undertake a routine course of one to one out-patient physiotherapy which will include a BW programme. The BW programme will be prescribed by a physiotherapist and the participant will carry it out, along with other prescribed exercises, in their own home. Each participant will initially be prescribed a 5 minute BW programme to be completed once a day. The length of the BW programme and intensity will be progressed or regressed as deemed appropriate by the treating clinician with the aim for patients to achieve at least 10 minutes of BW every day of the week.
16361537|NCT04247802|Active Comparator|Usual Care|This group will undertake a routine course of one to one out-patient physiotherapy over 12 weeks. To allow comparison between the two groups the control group will also have up to four review appointments where their home exercise programme can be progressed or regressed. The physiotherapy treatments will be not be restricted (apart from no BW programme) to allow for a pragmatic approach based on the treating clinician's clinical judgement, however their content will be recorded on treatment logs.
16361538|NCT04247789||Total sample|This group consists of older adults living in a rest home, who are proper for inclusion criteria
16361539|NCT04247776|Experimental|Prehab|General nutrition, relaxation, and exercise instructions. Home-based functional exercises, Fitbit goals, and nutrition supplements.
16361540|NCT04247776|Active Comparator|ERAS|Enhanced Recovery After Surgery standard of care plus Fitbit.
16361541|NCT04247763|Experimental|Arm 1 (Saturated Fat Meal, Oleic Sunflower Oil Meal)|
16361542|NCT04247763|Active Comparator|Arm 2 (Oleic Sunflower Oil Meal, Saturated Fat Meal)|
16361543|NCT04247750|Experimental|Open label trial|Sirolimus 0.5 mg tablets
16361544|NCT04247737|Experimental|gluten free diet|six week gluten free diet
16361546|NCT04247724|Experimental|Active group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of women playing recreational handball"
16361547|NCT04247724|Experimental|Inactive group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of men continuing their normal lifestyle patterns"
16361548|NCT04247724|Experimental|Inactive group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of women continuing their normal lifestyle patterns"
16361549|NCT04247711|Experimental|OTCH|OTCH is based on OTNY, a Coordinated Specialty Care program for people with first-episode psychosis. The program is implemented by a multidisciplinary team, who provide coordinated, evidence-based services based on the interests, needs, and preferences of each participant.
16361550|NCT04247711|Placebo Comparator|Usual FEP services|This is generally provided in mental health outpatient clinics which serve a population enrolled in the public health care system.
16361551|NCT04247685|Experimental|12-Lead ECG|The study group patients will have MRI with 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical
16361552|NCT04247685|Active Comparator|3-lead ECG gating system|the control group will have MRI with 3-lead ECG gating which is standard of care.
16361553|NCT04247659|Experimental|Experimental group|In the experimental group, sodium aescinate is added on the basis of conventional treatment(such as anti-platelet and improve circulation).The treatment course of sodium aescinate is 10 days,20mg/day.
16361554|NCT04247659|No Intervention|Control group|The control group will receive conventional treatment(anti-platelet and improve circulation) without sodium aescinate.
16361555|NCT04247646|Active Comparator|Melatonin|Melatonin 5 mg sublingual nightly x 29 nights, starting on post-operative day 0.
16361556|NCT04247646|Placebo Comparator|Placebo|Placebo troche, sublingual nightly x 29 nights, starting on post-operative day 0.
16361557|NCT04247633|Experimental|palbociclib plus endocrine therapy treatement|"Patients with Clinical high risk/Genomic High risk (in BCT score)-high and ER positive/HER2 negative EBC after Curative Surgery
~Palbociclib at a dose of 125mg, orally once daily on Day 1 to Day 21 followed by 7 days off in a 28-day cycle for a total duration of 2 years
~Standard adjuvant endocrine therapy for a duration of at least 5 years from the start of the treatment."
16361558|NCT04247620|Experimental|DiaBetter Together Intervention|Young Adult participants with type 1 diabetes (ages 17-25) who are approaching transfer from pediatric to adult care will be randomized to either the DiaBetter Together Intervention group or the Usual Care group. After randomization to the intervention group, young adults will be assigned a Peer Mentor. Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
16361559|NCT04247620|Other|Peer Mentors|Peer Mentors will deliver the DiaBetter Together intervention and will also be enrolled as study participants to permit assessment of their own outcomes from delivering this peer support intervention to younger people with diabetes. Peer Mentors will be experienced young adults with T1D who have transferred to adult diabetes care.
16361560|NCT04247620|No Intervention|Usual Care|Participants randomized to the comparison condition will receive usual diabetes care only, without additional intervention through the study. They will participate in all study activities related to data collection, but will not receive the Peer Mentor intervention. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
16361561|NCT04247594|Experimental|Cohort A open label|Participants will receive progressively higher doses of voxelotor administration starting from 1500 mg
16361562|NCT04247594|Experimental|Cohort B open label|Participants will receive doses higher than 1500 mg administered without up-titration
16361563|NCT04247581|Other|Cohort 1|This will include subjects with no known history of AF and are in normal sinus rhythm at time of screening
16361564|NCT04247581|Other|Cohort 2|This will include subjects with known persistent or permanent AF who are in AF at the time of screening
16361565|NCT04247568|Experimental|Hypnosis|
16361566|NCT04247568|Placebo Comparator|Control|
16361567|NCT04247542|Experimental|Ibezapolstat|Active investigational antibacterial agent: ibezapolstat 450 mg po Q12H x 10 days
16361568|NCT04247542|Active Comparator|Vancomycin|Standard of care: Vancomycin 125 mg po Q6H x 10 days
16361569|NCT04247529|Placebo Comparator|No exposure to conflict|
16361570|NCT04247529|Experimental|Exposure to conflict|
16361571|NCT04247516|No Intervention|Standard Control Group|The standard control group (CG) will not have access to the self-regulatory (SR) intervention program.
16361572|NCT04247516|Experimental|Online-intervention group I (IGI)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:
~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration."
16361573|NCT04247516|Experimental|Online-intervention group II (IGII)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:
~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration; iii) the program includes gamification strategies with the purpose of promoting engagement in participants."
16361574|NCT04247490||Pediatric AIH|Patients diagnosed with hepatitis type 1 and type 2 formulated between the ages of 0 and 18.
16361575|NCT04247477|Experimental|A-B-A-C|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B) - Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C)
16361576|NCT04247477|Experimental|A-C-A-B|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C) - Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B)
16364098|NCT04229615|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
16361578|NCT04247464|Experimental|Fasting|The participants will follow a short-term fasting period for 44-48 hours, starting 24 hours before chemotherapy treatment
16361579|NCT04247451|Experimental|Interventional group|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.
~Metabolic data: body composition using BIA (Nutrilab Akern) and REE using indirect calorimetry (Cosmed Q NRG) will be analyzed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
16361580|NCT04247438|Other|Biofilm formation|Biofilm formation after 12 and 36 h on PMMA (polymethyl methacrylate) dentures and the number of brushing cycles needed to remove it.
16361581|NCT04247425|Experimental|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
16361582|NCT04247399|Experimental|Simulation-based learning + clinical training|
16361583|NCT04247399|No Intervention|Clinical training|
16361584|NCT04247386|Experimental|PEG-Mizone prep|"The evening before the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 60g Polyethylene Glycol (PEG-4000) with 0.6L Mizone+0.4L water at a rate of 250 ml every 15 min.
~On the day of the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 120g Polyethylene Glycol (PEG-4000) with 1.2L Mizone+0.8L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
16361585|NCT04247386|Active Comparator|PEG-ELS prep|"The evening before the colonoscopy: In the PEG-ELS prep group, all the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min.
~On the day of the colonoscopy: all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
16361586|NCT04247373|Experimental|laparoscopic gastrectomy with pneumoperitoneum|
16361587|NCT04247360|Other|cuff pressure with 20cmH2O|continuous monitoring and maintaining cuff pressure with 20 cmH2O during surgery
16361588|NCT04247360|Other|cuff pressure with 30cmH2O|continuous monitoring and maintaining cuff pressure with 30 cmH2O during surgery
16361589|NCT04247347|Experimental|Self-Management|
16361590|NCT04247347|Active Comparator|Usual Care|
16361591|NCT04247334|No Intervention|Cautious Participants|Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
16361592|NCT04247334|Experimental|Impulsive Participants- Active Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
16361593|NCT04247334|Sham Comparator|Impulsive Participants- Sham Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
16361594|NCT04247321|Experimental|Subjects with acute brain injury|Subjects requiring placement of a Licox Brain Tissue Oxygen device for their clinical care will also have Near-infrared spectroscopy (NIRS) monitoring system placed
16361595|NCT04247308|Experimental|experimental group|"Sensory stimulations (ATVV) will be consisting of Soft lullaby between of 30-40 dB for Auditory, Gentle stroking massage in supine position(upper and lower limb)for Tactile, Visual Stimulations with Black and white card (distance of 8-10 in), gentle rocking (vertical and horizontal direction) for the stimulation of vestibular system and oral stimulation including stocking cheeks, lips, jaw and tongue, rubbing gum.Each stimulation will be given for 3 minutes.
~Movement therapy will include: Guided range of motion: flexion-extension movements of lower limb (bicycle riding pattern). Hand should be placed around knee joint. Care must be taken as PI consist the cartilaginous joints at wrist and ankle. Anti gravity movements in prone (neck and spinal extension), Anti gravity movements in sitting (supported) and Upright positioning for 3min each"
16361596|NCT04247308|Active Comparator|control group|receives routine care from the nursing team as well as daily maternal care, such as being held in the mother's arms
16361597|NCT04247295|Experimental|Wood cast|Participants will be trialling the woodcast plaster method
16361598|NCT04247295|Placebo Comparator|Traditional Cast|Traditional cast used to be compared to.
16361599|NCT04247282|Experimental|A/arm A|M7824 (Days 1, 15)
16361600|NCT04247282|Experimental|B/arm B|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (Day 1)
16361601|NCT04247282|Experimental|C/arm C|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
16361602|NCT04247269||Enteral formula standard|Children fed an intact protein formula
16361603|NCT04247269||Enteral formula semi-elemental|Children fed a semi-elemental protein formula
16361604|NCT04247256|Experimental|Treatment arm|SCO-101 in combination with FOLFIRI
16361605|NCT04247243|Experimental|Rapid testing|Abbott ID NOW Strep A testing.
16361606|NCT04247243|Active Comparator|Reference testing|Culture-based testing.
16361607|NCT04247230|Experimental|PET500 (0.1%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:
~PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg"
16361608|NCT04247230|Experimental|PET500 (0.25%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:
~PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg"
16361609|NCT04247230|Experimental|PET500 (0.5%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:
~PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg"
16361610|NCT04247230|Experimental|PET500 placebo comparator|Each actuation of the pump spray dispenses 130µl PET500 [vehicle only]. Two pumps will dispense 260µl
16361611|NCT04247230|Active Comparator|STUD100 (9.6%)|Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R
16361612|NCT04247204|Experimental|Platelet-rich plasma (PRP) intrauterine infusion|
16361613|NCT04247191|Experimental|P-Chat|The P-Chat is a brief individually delivered intervention
16361614|NCT04247191|Experimental|PBI|The PBI is a handbook developed by the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
16361615|NCT04247191|Experimental|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above.
16361616|NCT04247191|No Intervention|Control|This group will only complete assessments and will not receive any intervention.
16361617|NCT04247178||Patients undergoing elective orthopaedic surgery|
16361618|NCT04247178||Healthy Volunteers|
16361619|NCT04247165|Experimental|Experimental|"Nivolumab 3 mg/kg will be given on day 1 (± 2 days) of each 28-day treatment cycle until the progression of disease, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given once only on day 1 cycle 1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Pre-medication for chemotherapy (based on standard-of-care and local institutional standards) and chemotherapy will then be administered after a further 30 minutes rest period.
~The recommended dose of nab-paclitaxel is 100 mg/m2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle. Gemcitabine 800 mg/m2 will be administered over 30 to 40 minutes immediately after nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle."
16361620|NCT04247152|Other|Intraoperative Aberrometry vs Preoperative Biometry|Retrospective view of existing chart data.
16361621|NCT04247139|Experimental|Commercial Kefir|Commercially produced kefir
16361622|NCT04247139|Experimental|Traditional Kefir|Traditionally grown kefir
16361623|NCT04247126|Experimental|Single Agent Dose Escalation|Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.
16361624|NCT04247126|Experimental|SY-5609 + Fulvestrant|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.
16361625|NCT04247113|Experimental|PBP-B|Parent-based Prevention following a Bariatric Surgery (PBP-B) is a 6-session parent-based program designed to guide parents who have undergone a weight loss surgery and their partners in developing healthy eating habits in their children
16361626|NCT04247100|Experimental|Active Stimulation (8)|"Participants will receive active auricular microstimulation via TENS unit for 8 weeks.
~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks."
16361627|NCT04247100|Sham Comparator|Sham Stimulation (4), Active (4)|"Participants will receive sham therapy via inactive TENS unit for 4 weeks, followed by active auricular microstimulation via TENS for 4 weeks.
~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks (4 weeks of therapy with inactive TENS, 4 weeks with active TENS)."
16361628|NCT04247087|Experimental|Intervention group|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
16361629|NCT04247087|Placebo Comparator|Control group|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
16361630|NCT04247074|Experimental|QM1114-DP in the LCL + Placebo in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
16361631|NCT04247074|Placebo Comparator|Placebo in the LCL and GL|"A buffered solution; Mode of administration:
~intramuscular injection"
16361632|NCT04247074|Experimental|Placebo in the LCL + QM1114-DP in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
16361633|NCT04247074|Experimental|QM1114-DP in the LCL + GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
16361634|NCT04247061|Experimental|Smoking Cessation intervention|At a dental cleaning visit, participants will watch a brief educational video that provides guidance and advice on smoking cessation. Participants will then interact with a text program for a month to motivate them to use smoking cessation resources. Participants will also be required to make contact with the resources in order to demonstrate feasibility of study flow.
16361635|NCT04247048|Experimental|Control group|Patients with no major LDL cholesterol abnormalities (patients eligible for LDL-apheresis, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / LDL-C) dl in primary prevention)) and a level of Lp (a) <50 mg / dl
16361636|NCT04247048|Experimental|High-dose group|Patients with no major LDL-cholesterol abnormalities (LDL-apheresis eligible patients, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / dl in primary prevention)) and a level of Lp (a)> 80 mg / dl
16361637|NCT04247022|Experimental|female subjects, 18-59 y, healthy|74 female subjects, 18 to 59 years of age, healthy with complaints of vaginal dryness that will receive the heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days.
16361638|NCT04247009|Active Comparator|Meat|Patients with RA served a meal of meat
16361639|NCT04247009|Active Comparator|Fish|Patients with RA served a meal of fish
16361640|NCT04247009|Active Comparator|Vegan|Patients with RA served a vegan meal
16361641|NCT04247009|Active Comparator|Meat controls|Matched controls served a meal of meat
16361642|NCT04246996|Active Comparator|Gentamicin Arm|At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
16361643|NCT04246996|Sham Comparator|Control Arm|If the patient is randomized to no instillation, at the end of the surgery but prior to awakening from anesthesia, the surgeon will clamp the catheter and label the catheter with the clamping time. The purpose of clamping the catheter for subjects receiving usual care will be to ensure patients are masked to study arm assignment if they wake up and notice their catheter. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
16361644|NCT04246983|Experimental|Patients with HIV undergoing point of care ultrasound|
16361645|NCT04246970|No Intervention|Control group|Conventional medical care
16361646|NCT04246970|Experimental|Prehabilitation group|Conventional medical care and 8 weeks of a Prehabilitation supervised program
16361647|NCT04246970|Experimental|Prehabilitation and posttransplant training group|Conventional medical care, 8 weeks of a Prehabilitation supervised program and a posttransplant training program.
16361648|NCT04246931||Pulmonologists|Interviews with pulmonologists
16361649|NCT04246931||General practitioners|Interviews with general practitioners
16361650|NCT04246931||Patients|Survey with COPD patients
16361651|NCT04246918|Placebo Comparator|Standard Treatment Group|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
16361652|NCT04246918|Active Comparator|Intervention Arm|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
16361653|NCT04246905|Active Comparator|sulforaphane|sulforaphane treatment arm
16361654|NCT04246905|Placebo Comparator|placebo|placebo arm
16361655|NCT04246892||group before alarm withdrawal|
16361656|NCT04246892||groupe after alarm withdrawal|
16361657|NCT04246879|Experimental|MRI|
16361658|NCT04246866|Experimental|Dose 1|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the lowest dose of GEM103
16361659|NCT04246866|Experimental|Dose 2|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the medium dose of GEM103
16361660|NCT04246866|Experimental|Dose 3|A single dose of GEM103 will be administered via intravitreal injection. This arm will be a higher dose of GEM103
16361661|NCT04246866|Experimental|Dose 4|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the highest (extension) dose of GEM103
16361662|NCT04246853|Active Comparator|Active tDCS of the resting state motor network|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
16361663|NCT04246853|Sham Comparator|Sham tDCS of the resting state motor network|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
16361664|NCT04246840||Study group|15 adult patients who underwent allogenic hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficieny 15 to 45 years ago
16361665|NCT04246840||Control group|15 age-matched healthy individuals
16361666|NCT04246827|Experimental|Enhanced Lifestyle Weight Management Condition|The Enhanced Lifestyle Weight Management condition participants participated in a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors was integrated into a lifestyle behavioral weight loss intervention.
16361667|NCT04246827|No Intervention|Standard Care Control|Participants received standard care of rheumatoid arthritis.
16361668|NCT04246814|Placebo Comparator|CC + dressing|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
16361669|NCT04246814|Active Comparator|LG1 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
16361670|NCT04246814|Active Comparator|LG2 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
16361671|NCT04246814|Active Comparator|LG3 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
16361674|NCT04246788|Experimental|Cohort 1 : experimental group|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
16361675|NCT04246788|Active Comparator|Cohort 2 : controle group|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
16361676|NCT04246775|Other|Treatment|Peristeen given
16361677|NCT04246762|Experimental|Olokizumab 128 mg +Cocktail drugs|"All subjects will receive the following treatment:
~Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) administered on Day 1, single subcutaneous injection of OKZ 128 mg administered on Day 8 and second dose of Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) administered on Day 22"
16361678|NCT04246749|Experimental|Part A: [14C]-CRN00808 Oral Solution|Single oral dose of CRN00808 containing [14C]-CRN00808
16361679|NCT04246749|Experimental|Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer|Single oral dose of CRN00808 followed by [14C]-CRN00808 IV microtracer injection
16361680|NCT04246736|Experimental|Intervention group|"The intervention group received a Recovery programme including three group sessions."
16361681|NCT04246736|No Intervention|Control group|The control group was on a waiting list to receive the intervention after the last follow-up measure (six months after the intervention group's last group session).
16364099|NCT04229615|Experimental|Single Arm|Fluzoparib
16361682|NCT04246723|Experimental|Cohort A (Narlaprevir + Ritonavir + Sofosbuvir for 12 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg Once a day (QD)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 12 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.
~Sofosbuvir can be taken with or without meals."
16361683|NCT04246723|Experimental|Cohort B (Narlaprevir + Ritonavir + Sofosbuvir for 8 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg QD (once daily)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 8 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.
~Sofosbuvir can be taken with or without meals."
16361684|NCT04246697|Active Comparator|Standard of Care A|"Randomized controlled prospective trial to compare two standards of care for head and neck surgery pain management. Arm A, will include:
~Scheduled Tylenol 1000 mg IV one time dose intra-operatively, then 650 mg via PEG tube or PO Q4H to a max dose of 4gm/24 hrs
~Opioids prn based on Numeric Pain Scale (0-10, with 0 indicating no pain and 10 indicating worst pain ever):
~0-3: no prn meds, reassurance, listen to music, watch TV.
~4-7: Oxycodone 5 mg q4h prn via PEG tube or PO with a maximum of 30 mg/24 hours.
~8-10 Morphine 2 mg IV q2h prn breakthrough pain."
16361685|NCT04246697|Experimental|Standard of Care B|"Arm B, will include:
~Arm A description with addition..
~Scheduled Ketorolac starting post-op day #1, 15 mg q6h (max 120 mg/day), for a total of 5 days
~Scheduled Gabapentin starting 7 days preoperatively to continue postoperatively
~Regional block per anesthesia protocol - Initial block: 0.5% bupivacaine, 20 ml Continuous infusion: 0.125% bupivacaine at 6 ml/hr with a 5 ml bolus available every 30 mins"
16361686|NCT04246684|Active Comparator|Control arm|In the control arm patients receive 5x5 Gy followed by 9 cycles of consolidation chemotherapy mFOLFOX6 or alternatively 6 cycles of CAPOX, followed by re-staging at week 22-24 as established as new preferred neoadjuvant regimen by the RAPIDO trial.
16361687|NCT04246684|Experimental|Experimental arm|The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
16361688|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^7 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^7 Inf.U.
16361689|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^8 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^8 Inf.U.
16361690|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^9 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^9 Inf.U.
16361691|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^10 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^10 Inf.U.
16361692|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (Trastuzumab + TVH)|TAEK-VAC-HerBy will be administered to patients who are on stable dose of Trastuzumab. TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total.
16361693|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (T-DM1 + TVH)|TAEK-VAC-HerBy will be administered to patients who are on stable dose of T-DM1. TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total.
16361694|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (Trastuzumab + Pertuzumab + TVH)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of Trastuzumab and Pertuzumab. TAEK-VAC-HerBy will be administered every three weeks with three administrations in total.
16361695|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (Her2 + TVH + PD1/PD-L1)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total in combination with a HER2 antibody and a PD-1/PD-L1 Antibody.
16361696|NCT04246658|Experimental|Treatment group|gait training on platform swing walkway for 30 minute.
16361697|NCT04246658|Experimental|control group|conventional physical therapy program
16361698|NCT04246645|No Intervention|CONTROL GROUP|received the selective physiotherapy exercises
16361699|NCT04246645|Experimental|STUDY GROUP|received the same selective physiotherapy exercises program in addition to core stability exercises three times/week for 60 min for 12 weeks
16361700|NCT04246632|Experimental|Open label|Single arm study, all subjects receive device
16361701|NCT04246619|Experimental|Pregabalin Krka Arm|"ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN.
~Investigator can choose on V2:
~Total Pregabalin Krka daily dose: 25 mg/day
~Total Pregabalin Krka daily dose: 50 mg/day
~Total Pregabalin Krka daily dose: 75 mg/day
~Total Pregabalin Krka daily dose: 150 mg/day
~Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on)
~V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day
~V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day"
16361702|NCT04246619|Experimental|Dulsevia® Arm|"• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:
~Investigator can choose on V2:
~Total Dulsevia® daily dose: 30 mg/day
~Total Dulsevia® daily dose: 60 mg/day
~V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.
~V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day."
16361703|NCT04246606||ER+/HER2- infiltrating early breast cancer|Patients with ER+/HER2- infiltrating early breast cancer for which EndoPredict molecular signature was performed.
16361704|NCT04246593|Experimental|Intervention - Market|"Partner sites that are randomized to the Intervention - Market will plan and start (or expand) a Mobile Market and run the Market weekly for at least 10 months (non necessarily nonconsecutive). The Mobile Market will follow the Veggie Van Model which includes a share model, price reductions (incentives), and an educational component."
16361735|NCT04246424|Active Comparator|Fitbit + Coaching|Fitbit + coaching will receive both the fitbit and coaching interventions.
16364100|NCT04229615|Placebo Comparator|Placebo|Placebo
16361705|NCT04246593|No Intervention|Control - Planning|At Control - Planning (comparison) sites, engagement will focus on involving community members in food access program planning and research. It is anticipated that each organization will create one or more community advisory committees to oversee their food access work. At comparison sites, engagement efforts will be more generally centered on food access and understanding what types of programs would be most acceptable. Examples of community engagement activities include community forums and listening sessions, informational tables at community events, and establishment of text, e-mail or social media sites for ongoing communication and feedback around food access issues. As part of this community engagement work, partners will collect contact information from community members that will assist in the data collection process.
16361706|NCT04246580||Indocyanine green|Women with endometrial and cervical cancer undergoing indocyanine green-guided systematic pelvic lymphadenectomy by laparoscopy or robotic surgery
16361707|NCT04246580||Control|Women with endometrial and cervical cancer undergoing systematic pelvic lymphadenectomy by laparoscopy or robotic surgery without the use of indocyanine green tracer injection.
16361708|NCT04246567|Active Comparator|Total intravenous anesthesia technique for group 1 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 6-10 mg / kg / h propofol and 0.0,4mcg / kg remifentanyl infusion / min. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.
~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.
~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
16361709|NCT04246567|Active Comparator|Inhalation anesthesia technique for group 2 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 40% Oxygen 60% N2O2 and Sevoflurane at a concentration of 1.5-3.5% with 2 L / minTGA to provide a value of BIS between 40-60. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.
~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.
~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
16361710|NCT04246554|Experimental|Control|Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
16361711|NCT04246554|Experimental|Ketorolac|Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control
16361712|NCT04246541|Experimental|Control|Patients will receive standard of care Percocet for post-operative pain control following meniscus debridement surgery
16361713|NCT04246541|Experimental|Ketorolac|Patients will receive IV ketorolac during surgery. They will then receive 3 days of oral ketorolac every 6 hours for pain control following surgery.
16361716|NCT04246515|Experimental|Blood Flow Restriction Training|As from week 2 in the rehabilitation proces, this experimental group will receive exercises in combination with blood flow restriction. While occluding the vascular flow of the limb (startpoint = above the injury site), participants will perform 3 exercises: wall squat, leg press and bridge (3 sets of 30 repetitions). These blood flow restricted exercises are always on top of the classic rehabilitation.
16361717|NCT04246515|Sham Comparator|Sham Blood Flow Restriction Training|The same description as the experimental arm is applicable here. However, The Blood Flow restriction material will be attached to the injured limb without occluding the vascular blood flow.
16361718|NCT04246515|Active Comparator|Classic rehabilitation|This group will undergo the classic rehabilitation program.
16361719|NCT04246502|Experimental|A|
16361720|NCT04246502|Active Comparator|B|
16361721|NCT04246489|Experimental|Bintrafusp alfa|
16361722|NCT04246476||Parkinson disease|People living with Parkinson disease.
16361723|NCT04246476||Controls|Age-matched controls.
16361724|NCT04246463||Thoracic - TEVAR|
16361725|NCT04246463||Abdominal - EVAR|
16361726|NCT04246463||Custom Device|
16361727|NCT04246463||Other indications|Isolated Iliac Artery Aneurysm (IIAA)
16361728|NCT04246450|No Intervention|LVEF between 35%-50%, no noninvasive risk factors (NIRFs)|Follow up, no further intervention
16361729|NCT04246450|No Intervention|LVEF between 35%-50%, NIRFs present, noninducible|Follow up, no further intervention
16361730|NCT04246450|Active Comparator|LVEF between 35%-50%, NIRFs present, inducible|All patients in this group will receive an ICD
16361731|NCT04246450|Sham Comparator|LVEF <35%, no NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
16361732|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
16361733|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, inducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
16361734|NCT04246437|Experimental|[18F]F-DOPA|All patients will receive [18F]F-DOPA for PET imaging to measure pre-synaptic dopamine in the brain.
16361736|NCT04246424|Active Comparator|Coaching|Coaching group will receive weekly remote coaching lessons by phone email or text for 1-6 weeks. They will also receive a weekly email lesson for 1-6 weeks on things such as basics of sleep, enhancing sleep environment and managing stress.
16361737|NCT04246424|Active Comparator|Fitbit|Fitbit group will receive a Fitbit and are asked to monitor their sleep over the smartphone application for 1-6 weeks.
16361738|NCT04246424|No Intervention|Self-management|Self-management participants will be given some information of improving sleep but asked to keep their same schedule. Once their participation concludes, they will be given the opportunity to receive a fitbit and coaching if they so choose.
16361739|NCT04246411|Active Comparator|Ultrasound|Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field
16361740|NCT04246411|Placebo Comparator|Auscultation|Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field
16361741|NCT04246398|Experimental|Fecal microbiota transplant (FMT)|"10 capsules per dose for 6 consecutive weeks, twice a week, for a total of 120 capsules.
~Each inoculum will be prepared from the feces of 1 donor and a dose of 10 capsules contains sieved, concentrated material derived from a mean of 10 grams of fecal matter. Donors are healthy, nonpregnant adults aged 18 to 50 years, taking no medications, and with a normal body mass index (18.5-25 [calculated as weight in kilograms divided by height in meters squared])."
16361742|NCT04246398|Placebo Comparator|placebo|Placebo capsules will consist of a combination of saline/glycerol (same vehicle as FMT capsules). The inner capsules is dark (green colored), so the general appearance of the capsules is the same to the people who do not prepare them.
16361743|NCT04246385|Experimental|Allocated to intervention|Participants will participate in a one on one session to complete their COPM and set their goal for the group. Participants will participate in 6 group sessions focusing on the CO-OP approach.
16361744|NCT04246385|No Intervention|Allocated to control|"The control group will receive usual care occupational therapy including a mix of individual sessions and occupational therapy groups that do not include the CO-OP group."
16361745|NCT04246372|Experimental|On Treatment|Tofacitinib 5mg oral tablets twice daily for 16 weeks
16361746|NCT04246359|Experimental|RP induction and maintenance|"1. Induction phase:
~Rituximab: 375mg / m2, ivd, d1;
~Pegylated interferon α-2b: 135 μg (500,000 U), H, d1, 8 Repeated every 21 days, Maximum 6 cycles 2. Maintenance phase:
~1) Rituximab: 375mg / m2, ivd, d1; 2) Pegylated interferon α-2b: 135 μg (500,000 U), H, d1,30 Repeated every 2 months, Maximum 12 cycles"
16361747|NCT04246346|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
16361748|NCT04246333|No Intervention|Gastric Feeds|Patients in this arm will receive feeds via the standard route which is gastric feeds.
16361749|NCT04246333|Experimental|Duodenal Feeds|Patients in this arm will receive feeds via the experimental route which is duodenal feeds.
16361750|NCT04246320|Experimental|Intervention|Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
16361751|NCT04246294||Sleep apnea patients|"This group of patients will have been monitored over night with cardiorespiratory monitoring (CRM). CRM enables the physician to establish an Apnea-Hypopnea Index (AHI) which will be used for diagnosis. An AHI > 15 is considered moderate-to-severe sleep apnea, and this is the focus group of patients in the current project.
~These patients will be followed for 12 months during continuous positive airway pressure (CPAP) treatment. Adherence to the CPAP treatment will be closely monitored."
16361752|NCT04246281|Active Comparator|Group 1: Peripheral Nerve Stimulation (PNS)|Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
16361753|NCT04246281|Active Comparator|Group 2: Standard Interventional Management (Standard of Care)|Subjects in Group 2 will receive the standard of care. Group 2 subjects may be able to crossover to receive PNS after 12 months from start of treatment (Visit 16).
16361754|NCT04246268|Experimental|Treatment Group|"Device: INVOcell Intravaginal Culture System
~Intervention: During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5-days vaginal incubation."
16361755|NCT04246255|Placebo Comparator|Group C|Serum Physiologic %0,9 ampules ; 0,3ml {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
16361756|NCT04246255|Experimental|Group L|xylocaine %10 pump spray ; 30mg lidocaine {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
16361757|NCT04246229|Experimental|transcutaneous bilirubinometry|in this arm the bilirubin level to monitor the effect of phototherapy will be measured through transcutaneous mbiirubinometry
16361758|NCT04246229|Active Comparator|serum bilirubin|In this arm the bilirubin level to monitor the effect of phototherapy wil be measured through measurements of serum bilirubin obtained through blood draws
16361759|NCT04246216|Experimental|Percutaneous Electrical Nerve Stimulation|The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
16361760|NCT04246216|Active Comparator|Surgery|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
16361761|NCT04246203||Group A|Patients are allocated to group A according to preoperative presence of detectable ctDNA.
16361762|NCT04246203||Group B|Patients are allocated to group B according to preoperative absence of detectable ctDNA.
16361763|NCT04246190|Experimental|Group 1|"Period 1: CKD-501 and D759
~Period 2: CKD-396"
16361764|NCT04246190|Experimental|Group 2|"Period 1: CKD-396
~Period 2: CKD-501 and D759"
16361910|NCT04245020|Active Comparator|In person|Patients will be followed in person in the Outpatient department at 6-8 weeks
16361767|NCT04246164|Active Comparator|HD-tDCS combined with CT|HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
16361768|NCT04246164|Sham Comparator|sham HD-tDCS combined with CT|sham HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
16361769|NCT04246151|Experimental|Vancomycin & probiotic placebo|Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
16361770|NCT04246151|Experimental|Probiotic & vancomycin placebo|Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
16361771|NCT04246151|Placebo Comparator|Probiotic placebo & vancomycin placebo|Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
16361772|NCT04246138|Active Comparator|kinematically alignment|
16361773|NCT04246138|Active Comparator|mechanical alignment|
16361774|NCT04246125||Therapeutic interventional radiology|Patients undergoing an interventional radiology procedure, at risk for developing radiation-induced skin lesions, including acts of therapeutic interventional neuroradiology (angioplasties, embolization of aneurysms, embolization of arteriovenous malformations , etc…), embolizations and ablations of thoracic tumors, therapeutic cardiac acts (transluminal angioplasties and chronic coronary occlusions) and abdominal embolizations.
16361775|NCT04246112|Experimental|Treatment group|Participants are diagnosed with tic disorder and/or Tourette syndrome. They will undergo treatment to improve overall handwriting skills.
16361776|NCT04246099||Group opioid free anesthesia|Patient benefit of the opioid free anesthesia protocol
16361777|NCT04246099||Group opioid based anesthesia|Patient don't benefit of the opioid free anesthesia protocol
16361783|NCT04246060||Cohort 1|Patients on extended release cysteamine treatment at study enrollment
16361784|NCT04246060||Cohort 2|Patients switching from immediate release cysteamine to extended release cysteamine during the study
16361785|NCT04246060||Cohort 3|Patients remaining on immediate release cysteamine treatment
16361786|NCT04246047|Experimental|Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)|
16361787|NCT04246047|Active Comparator|Daratumumab and Bortezomib plus Dexamethasone (Arm B)|
16361788|NCT04246034|Experimental|Cases|As described by Saaristo et al. in 2012, the surgical technique starts with wide axillary scar removal, followed by elevation of contralateral dual flap which includes DIEP/MS-TRAM with attached groin lymph nodes and fat, then the anastomosis is preferably done to internal mammary vessels.
16361789|NCT04246021|Experimental|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.
~Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion
~If the needed Ferric carboxymaltose dose is > 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
16361790|NCT04246008|Experimental|Neuromuscular training group|This group will receive a 60-min neuromuscular training sessions twice a week, for 10 weeks until the completion of twenty sessions
16361791|NCT04246008|Active Comparator|Conventional training group|This group will receive a 60-min convencional cardiac rehabiliation session twice a week, for 10 weeks until the completion of twenty sessions
16361792|NCT04245982||group (C)|healthy controls group
16361793|NCT04245982||group (P)|periodontitis group
16361794|NCT04245982||group (DP)|diabetes and periodontitis group
16361795|NCT04245969|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the shoulder
16361796|NCT04245969|Experimental|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the affected shoulder
16361826|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, Lymphoma|FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma
16361797|NCT04245969|Experimental|No intervention group|To evaluate at the same time than the others groups but without being treated with 448 kilohertz Capacitive Resistive Monopolar Radiofrequency.
16361798|NCT04245956|Experimental|Transcatheter Mitral Valve Repair arm|Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
16361799|NCT04245943|Experimental|Exercise|18 weeks supervised strength and aerobic exercise training
16361800|NCT04245930|Active Comparator|Bovine Pericardial Patch|Immediate implant breast reconstruction using bovine pericardial patch. n=88
16361801|NCT04245930|Experimental|TiLOOP® Bra Mesh|Immediate implant breast reconstruction using TiLOOP® Bra Mesh. n=88
16361802|NCT04245917||MNGIE Patients|Patients with mitochondrial neurogastrointestinal encephalomyopathy
16361803|NCT04245904||proffesional basketball player|
16361804|NCT04245904||sedentary control|
16361805|NCT04245891||Control group|boli of ephedrine phenylephrine (45μg/mL-3mg/mL) if the variation of MAP < 20% of baseline (MAP before spinal anaesthesia).
16361806|NCT04245891||Protocol group|continuous infusion of norepinepineprhine at 20 μg/mL, started at 0.05 μg/kg/min. The dosage of norepinephrine was then adjusted to maintain a variation in MAP < 20% of baseline. In case of failure, the use of a control group boli injection was possible.
16361807|NCT04245878||intensive care unit inpatient|Inpatient intubated resuscitation patient with a scheduled extubation
16361808|NCT04245865|Experimental|Arm A, standard treatment + tocotrienol|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + tocotrienol OR capecitabine + bevacizumab + tocotrienol
16361809|NCT04245865|Placebo Comparator|Arm B, standard treatment + placebo|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + placebo OR capecitabine + bevacizumab + placebo
16361810|NCT04245852|Experimental|Experimental group|Experimental group will receive standard physical therapy care in addition to being provided a strength education video.
16361811|NCT04245852|Active Comparator|Control Group|The control group will receive standard physical therapy care at the University of Illinois at Chicago Faculty Practice.
16361812|NCT04245839|Experimental|Administration of JCAR017|"Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents.
~JCAR017 will be infused on Day 1 at a dose of 100 × 10^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells."
16361813|NCT04245826||Low-calorie Sweetened Beverages (LCSBs)|Beverages exclusively using zero-energy (e.g., acesulfame-potassium, aspartame, cyclamate, saccharin, sucralose, advantame, neotame), and /or reduced-energy food additives (e.g., stevia, monk fruit).
16361814|NCT04245813|Experimental|Intervention|"Consists of 3 interdisciplinary educational sessions and Face-to-face with a fortnightly telephone follow-up and text messages. Each session will be directed by medical staff (cardiologist and / or physiatrist) and supported by other health professionals (physical therapist, occupational therapist, nutritionist and psychologist). The educational sessions, include the topics knowledge of the disease, recognition of alarm signs, pharmacological treatment, healthy lifestyle habits, mental health and regular aerobic exercise; The entire educational component will be based on the Colombian clinical practice guide for the prevention, diagnosis, treatment and rehabilitation of heart failure."
16361815|NCT04245813|No Intervention|Control|Once the patient ends phase II of the cardiac rehabilitation program, he/she will receive the usual care, which consists of a 5-minute educational intervention by a physiatrist at the end of the functional test, where recommendations are given on healthy lifestyle habits, adherence to pharmacological treatment and regular aerobic exercise. This educational intervention will be performed after each of the functional tests (at the end of phase II of the program and during the follow-up of patients at months 1, 3, 6 and 12 during Phase III of the program) performing 5 educational interventions in total .
16361816|NCT04245800||Observational|All participants will be part of the prospective observational cohort. If participants develop flu-like symptoms, they will be prompted to complete the flu@home self-test kit. Analysis will be conducted for various subgroups (e.g. age, vaccination status)
16361817|NCT04245787|Experimental|Self assembling peptide with fluoride|
16361818|NCT04245787|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|
16361819|NCT04245774|Experimental|Group L (Hyperbaric Levobupivacaine)|"7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
~In order to obtain hyperbaric levobupivacaine, 1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water."
16361820|NCT04245774|Active Comparator|Group B (Hyperbaric Bupivacaine)|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (Marcaine® Spinal Heavy, 0.5%, 4 mL ampoule, AstraZeneca/England, Eczacıbaşı/Turkey, dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
16361821|NCT04245761|Experimental|Sonidor®|Application: following the summary of product characteristics (l tablet per day) At the 7-day phone call the Investigator can increase the dosage to 2 tablets per day only in non-responding subjects.
16361822|NCT04245748|Active Comparator|Escitalopram|Adaptively randomized, double-blind treatment with escitalopram for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with escitalopram or citalopram for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
16361823|NCT04245748|Active Comparator|Duloxetine|Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
16361824|NCT04245722|Experimental|FT596 Monotherapy, Lymphoma|FT596 monotherapy in adult subjects with r/r B-cell Lymphoma
16361825|NCT04245722|Experimental|FT596 in Combination with Rituximab, Lymphoma|FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma
16361828|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, CLL|FT596 in combination with Obinutuzumab in adult subjects with r/r CLL
16361829|NCT04245709|Experimental|Open label Arm|This is an open label pilot trial in which 25 people with ALS will take clenbuterol orally at 40-80 micrograms twice daily for 24 weeks.
16361830|NCT04245696|Experimental|Single Group|Single Arm: All subjects will undergo treatment for skin laxity in the submentum with a Dermal and SubQ handpiece
16361831|NCT04245683||Operative Group|Patients who select operative treatment and follow up after successful neoadjuvant treatment.
16361832|NCT04245683||Non-operative Group|Patients who select non-operative follow up after successful neoadjuvant treatment
16361833|NCT04245670|Experimental|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
16361834|NCT04245657||Breast Cancer Survivors|Female breast cancer survivors who underwent unilateral breast cancer surgery ( total or conservative) and completed their adjuvant therapies such as chemotherapy and radiotherapy prior to participation in this study.
16361835|NCT04245631||RAA assay for 2019-nCoV|a simple, fast and portable recombinase aided amplification (RAA) assay for 2019-nCoV
16361836|NCT04245605||Early angiography|Patients admitted to hospital with acute heart failure undergoing coronary angiography within 14 days of hospital admission
16361837|NCT04245605||Control|Patients admitted to hospital with acute heart failure not undergoing coronary angiography within 14 days
16361838|NCT04245592|Experimental|Extra Virgin Olive Oil|Women with fibromyalgia will consume Extra Virgin Olive Oil.
16361839|NCT04245592|Experimental|Refined Olive Oil|Women with fibromyalgia will consume Refined Olive Oil.
16361840|NCT04245579|Experimental|Experimental Group|"The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures.
~In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.)."
16361841|NCT04245579|No Intervention|Control Group|The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
16361842|NCT04245566|Experimental|Prostatic Artery Embolization (PAE)|PAE will be performed as an inpatient or outpatient procedure by interventional radiologists who are familiar with the procedure and according to established techniques. A unilateral femoral sheath is placed in the right common femoral artery under local anaesthesia. The prostatic arterial supply is identified by selective internal iliac arteriography. Prostatic arteries are selectively catheterised and embolised by use of 250-600 μm microspheres . PAE is performed bilaterally if possible and considered successful in the absence of the normal blush of the prostate and stasis of flow in the prostate arteries on angiography after embolisation.
16361843|NCT04245566|Placebo Comparator|Pharmocotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations. Thus, patients with a prostate size smaller than 40mL will be treated with 0.4 mg tamsulosin once daily, while patients with larger prostates will be treated with 0.4 mg tamsulosin plus 0.5 mg dutasteride once daily during the complete study follow-up.
16361844|NCT04245553|Experimental|All Participants|
16361845|NCT04245540|Experimental|Active|1,050 mg per day of encapsulated Pau d' Arco taken orally for 2 months.
16361846|NCT04245527|Experimental|Study Arm|20 minutes Joovv Solo every day for 8 weeks.
16361847|NCT04245514|Experimental|Durvalumab with 3 RT cohorts|Patients will be allocated in a 1:1:1 ratio to the three radiotherapy regimens (Arm A: 20 x 2 Gy weekdaily, Arm B: 5 x 5 Gy weekdaily, and Arm C: 3 x 8 Gy q2d) using the minimization method with a random component (80% allocation probability) to reduce predictability of allocation according to the following stratification factor: T classification (T1-2 vs T3-4).
16361848|NCT04245501|Experimental|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized 16-session intervention aimed at reducing interpretation bias. In this study, CBM-I is personalized to youth anxiety symptoms. During CBM-I sessions, youth indicate whether word-sentence pairs are related, and are provided with feedback aimed to reduce bias.
16361849|NCT04245501|Placebo Comparator|Interpretation Control Condition (ICC)|"Computerized 16-session intervention that is not believed to significantly modify bias. In this study, youth see stimuli personalized to their anxiety symptoms. During ICC sessions, youth see word-sentence pairs and are required to indicate whether word and sentence are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
16361850|NCT04245488|Other|taste testing|Participants will first taste 5 sour solution containing acetic acid for sour compounds, sucrose esters, and xanthan gum to help them stay dissolved). Then rate them for their taste intensities. Next, participants will taste 5 butyric acid solutions, 5 hexenoic acid solutions, 5 caprylic acid solutions, 5 lauric acid solutions, 5 palmitic acid solutions, 5 oleic acid solutions, and 5 linoleic acid solutions (all will also contain the sucrose esters and xanthan gums.) and rate them for their taste intensities. This should take no longer than 1 hour. Participants will spit all samples into a cup after tasting them. They will not swallow any samples.
16361854|NCT04245462||Participants|Older aged (>60 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco, Mexico).
16364682|NCT04225468|No Intervention|Treatment As Usual (TAU)|No intervention will be administered.
16361855|NCT04245449|Experimental|e learning+therapy (TEAACH)|TEAACH-Training to Empower Activity-dependent plasticity-based Arm-use habits in the Community and at Home
16361856|NCT04245436|Active Comparator|Duloxetine|Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.
16361857|NCT04245436|Active Comparator|Escitalopram|Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
16361858|NCT04245423|Active Comparator|Augmented Usual Care (AUC)|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. Almost all practices have hired mental health clinicians, equivalent to the care managers in the investigators' collaborative care model, to treat mild and moderate depression and anxiety. These clinicians typically are licensed clinical social workers; a few are nurses or psychologists. No care managers have received systematic training in treating patients with OUD. The clinicians will retain their role and continue to treat and monitor patients with mental health conditions in these practices. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD. Patients are informed that the primary care practice provides both OUD and mental health treatment and are referred back to their provider for referral or to schedule care. A list of available community resources are available to the patient.
16361859|NCT04245423|Experimental|Collaborative Care (CC)|"CC condition includes the following elements:
~Personnel trained to assist with scheduling, reminders and referrals;
~PCP trained and waivered to provide evidence-based pharmacotherapy for OUD;
~Addictions psychiatrist with collaborative care expertise to provide treatment consultation and supervision in both OUD and mental health issues;
~A care manager trained in evidence-based interventions for individuals with OUD and psychiatric disorders, who provides care in the primary care practice as part of the collaborative care team;
~Measurement-guided care and treat-to-target practices, using validated measures of substance use, depression, anxiety as well as measures of adherence and side effects;
~Electronic and in-person systematic communication regarding patient care among team members, facilitated by the electronic health record; and
~Shared patient-provider decision making."
16361860|NCT04245423|Experimental|Collaborative Care + Certified Recovery Specialist (CC+)|In addition to the collaborative care model described above, patients in the CC+ condition will have access to a Certified Recovery Specialist (CRS) to assist with treatment engagement and retention. A CRS is a person in the community who is in recovery and may share similar experiences and barriers that participants have faced. They will work with participants as a peer to help them coordinate information and needs with their providers. The CRS will take participants to their PCP appointments and any other appointments that they may have to help them engage and stay in care to remain healthy. They will also provide education and help participants work on their recovery goals. They will identify and support linkages to community resources and help participants identify barriers to full participation in their recovery and develop strategies to overcome those barriers.
16361861|NCT04245410||Patients surgically treated of pancreatic metastases from RCC|Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.
16361862|NCT04245397|Experimental|Oral Dose of S-682|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
16361863|NCT04245384|Experimental|Internet-based treatment|Internet-based dietetic treatment with video calls, no physical meetings
16361864|NCT04245384|Active Comparator|Standard treatment|Dietetic treatment with physical meetings
16361865|NCT04245371|Active Comparator|Active|Lidocaine Patch 1.8% applied to affected hand at night for 2 weeks following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle.
16361866|NCT04245371|Placebo Comparator|Placebo|Placebo Patch applied to affected hand at night for 2 weeks for 12 hours during each 24-hour daily cycle.
16361867|NCT04245358|Other|Ainara|Ainara is a class II medical device, already marketed in several EU countries. Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
16361869|NCT04245332|Experimental|Fish Oil|This group will receive fish oil (4g/d).
16361870|NCT04245332|Placebo Comparator|Placebo|This group will receive coconut oil (4g/d) as an iso-energetic, iso-lipidic placebo comparator to the fish oil arm.
16361871|NCT04245319|Other|NbUVB|Group A: patients will receive three NB-UVB sessions per week for 48 sessions.
16361872|NCT04245319|Experimental|Combined nbUVB and Acitretin|Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3mg/kg/day daily.
16361873|NCT04245306|Experimental|Children with Autism Spectrum Disorders|A group of 25 children with autism spectrum disorders (ASD)
16361874|NCT04245306|Active Comparator|Typically Developing children|A larger group of 150 typically developing children (TD)
16361875|NCT04245306|Experimental|Children with Developmental Language Disorders|A group of 25 children with developmental language disorders (DLD)
16361876|NCT04245293|Experimental|Ainara|Experimental: Ainara Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
16361877|NCT04245293|Active Comparator|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.
~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
16361911|NCT04245007|Experimental|Intervention|Subject will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
16361878|NCT04245280|Active Comparator|PENG and LFCN blocks with ropivacaine|For the PENG block, and after negative aspiration, 20 ml of a solution of ropivacaine 0.5% with epinephrine 2.5 mcg/ml will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same solution will be injected with the same needle.
16361879|NCT04245280|Placebo Comparator|PENG and LFCN blocks with saline solution|For the PENG block, and after negative aspiration, 20 ml of a saline solution will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same saline solution will be injected with the same needle.
16361880|NCT04245267|No Intervention|Control|Patients in the wait-list being attended with the standard model of care for diabetes in primary care units.
16361881|NCT04245267|Experimental|DIABEMPIC program|Intervention comprised by an interdisciplinary team care, patient-centered care approach, structured diabetes education program, promotion of self-management, audit, and guaranteed supply of anti-diabetic medication.
16361882|NCT04245254|Experimental|Intervention Arm|Single arm study. Receives collagen protein powder.
16361885|NCT04245215|Placebo Comparator|1. Subcutaneous ustekinumab every 8 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
16361886|NCT04245215|Active Comparator|2. Subcutaneous ustekinumab every 4 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
16361887|NCT04245202|Active Comparator|Active Comparator: HFNCOT|Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation >92%.
16361888|NCT04245202|Active Comparator|Active Comparator: St-FMOT|To obtain oxygen saturation >92%
16361889|NCT04245176|Experimental|Quantitative Genetic Counseling|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:
~-- Quantitative genetic counseling: Discussion is guided by tables and graphs."
16361890|NCT04245176|Active Comparator|STANDARD GENETIC COUNSELING|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:
~-- Standard genetic counseling: Standard of care discussion"
16361891|NCT04245163|Experimental|Intervention Group|Participants in the intervention group will be invited for the training program.
16361892|NCT04245163|No Intervention|Control Group|Participants who will be randomized in control group will receive normal care (the care that each clinic provides to the patients) and will be given an educational material (without telling them that they are in the control group). They will receive, however, the education class later (at the end of the study).
16361894|NCT04245124|Experimental|SMART INTERVENTION|N= 81 20 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
16361895|NCT04245124|Experimental|TCR|N= 81 60 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
16361896|NCT04245111||Open Fracture Cohort|Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent.
16361897|NCT04245111||Complication Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
16361898|NCT04245111||Closed Fracture Cohort|"Patients 18 years of age or older Closed extremity fracture Planned definitive fracture management with external fixation, internal fixation, or joint fusion.
~Provision of informed consent"
16361899|NCT04245098|Experimental|Amyloid|Biopsy
16361900|NCT04245085|Active Comparator|Arm A|"Atezolizumab (1200 mg) Q3W, until PD
~Bevacizumab (15 mg/kg), Q3W, until PD
~Carboplatin (AUC5) Q3W, 4-6 cycles
~Paclitaxel (175-200 mg/m2), Q3W, 4-6 cycles"
16361901|NCT04245085|Active Comparator|Arm B|"Atezolizumab (1200 mg), Q3W, until PD
~Bevacizumab (15 mg/kg), Q3W, until PD
~Pemetrexed (500 mg/m2), Q3W, until PD"
16361902|NCT04245072|Active Comparator|Ranibizumab|Arm 1
16361903|NCT04245072|Active Comparator|Aflibercept|Arm 2
16361904|NCT04245059|Experimental|Transcranial Direct Current Stimulation|Each subject will receive transcranial electrical stimulation at primary motor cortex in both hemispheres. The pilot program will include 12 sessions with a frequency of 3 times per week during 4 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 milliamp using 6x4 cm electrodes. The participants will also complete a set of manual dexterity, grip and pinch tests bilaterally at baseline and post-intervention to determine if the subject responds to tDCS. Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin disorders and other possible side effects of tDCS.
16361905|NCT04245046|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:
~Age: 18-49 years
~Weight: 55-105 kg
~Height: 163-188 cm
~BMI 18.5-29.9 kg/m²"
16361906|NCT04245033|Experimental|IPTsc arm|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) will be given in all wards in the IPTsc arm at an interval of four months, three times a year.
16361907|NCT04245033|No Intervention|Control|No intervention will be given to wards randomised in this arm
16361908|NCT04245020|Active Comparator|Text Message|Patients will be followed up with a series of text messages at 6-8 weeks
16361909|NCT04245020|Active Comparator|Telephone|Patients will be followed with a telephone conversation at 6-8 weeks
16361912|NCT04245007|No Intervention|Control|Subject will prohibited from doing fasting or intake restriction within 8 weeks
16361913|NCT04244994|Other|Intervention and Control|Self-taken penile meatal swabs versus first-catch urine for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
16361914|NCT04244981|Experimental|PCC group|When APTT is prolonged (>1.5 times normal), patients will be given a 4-factor PCC based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR>6, PCC 50 IU/kg).
16361915|NCT04244981|Active Comparator|FFP group|When APTT is prolonged (>1.5 times normal), patients will be given a dose of 10-15 ml/kg FFP.
16361916|NCT04244929|Experimental|PCL removal|Patients will undergo surgery by sacrificing the PCL
16361917|NCT04244929|Active Comparator|PCL preservation|Patients will undergo surgery with retaining the PCL
16361918|NCT04244890||Uninterrupted CPAP|Newborn infants in need of respiratory support directly after birth
16361919|NCT04244877|Experimental|Rifaximin|Rifaximin 550 mg by mouth twice daily for eight weeks.
16361920|NCT04244864|Active Comparator|Treatment as usual (TAU)|8-12 months of treatment
16361921|NCT04244864|Experimental|Cross-sectoral social intervention|8-12 months of treatment
16361922|NCT04244851||Malnourished patients|Malnourished patients
16361923|NCT04244838|Experimental|MP-TKA group|20 patients candidates for cemented TKA with MP design for tri-compartment gonarthrosis will be recruited on indications of the surgeon and according to normal clinical practice at the Orthopedic and Traumatological Clinic 2nd of the Rizzoli Orthopedic Institute.
16361924|NCT04244825|Experimental|Cohort 1a BLD-2660|900 mg (6 x 150 mg capsules) BID
16361925|NCT04244825|Experimental|Cohort 1b BLD-2660|900 mg (6 x 150 mg capsules) BID (Optional)
16361926|NCT04244825|Experimental|Cohort 2 BLD-2660|600 mg (4 x 150 mg capsules) BID
16361927|NCT04244825|Experimental|Cohort 3 BLD-2660|300 mg (2 x 150 mg capsules) BID
16361928|NCT04244825|Placebo Comparator|Cohort 1a Placebo|900 mg (6 x 150 mg capsules) BID
16361929|NCT04244825|Placebo Comparator|Cohort 1b Placebo|900 mg (6 x 150 mg capsules) BID (Optional)
16361930|NCT04244825|Placebo Comparator|Cohort 2 Placebo|600 mg (4 x 150 mg capsules) BID
16361931|NCT04244825|Placebo Comparator|Cohort 3 Placebo|300 mg (2 x 150 mg capsules) BID
16361932|NCT04244812|Other|CSAP group|"Participants in the CSAP group will receive examination of laser doppler flowmetry(LDF).
~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian"
16361933|NCT04244812|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
16361934|NCT04244812|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
16361935|NCT04244799|Experimental|Behavioral nudges|Schools randomized to this arm will receive the behavioral nudges intervention and the Philippines Department of Education national WASH in Schools (WinS) policy.
16361936|NCT04244799|Active Comparator|Control group|Schools in the control group will not receive handwashing nudges but will receive DepEd's national WASH in Schools (WinS) policy.
16361937|NCT04244786|Active Comparator|active anodal tDCS to ventrolateral prefrontal cortex (VLPFC)|1.5 milliamp (mA) anodal tDCS over right ventrolateral prefrontal cortex; 20-minutes, 6-sessions
16361938|NCT04244786|Sham Comparator|sham anodal tDCS to VLPFC|Identical electrode montage, sham tDCS over 6 sessions.
16361939|NCT04244773|Experimental|Intervention group: ENDS and smoking cessation|
16361940|NCT04244773|Active Comparator|Control group: Smoking cessation counseling|
16361941|NCT04244760|Active Comparator|Verbal Patients|
16361942|NCT04244760|Active Comparator|Non-verbal Patients|
16361943|NCT04244747|Active Comparator|induction of labour by breast stimulation|women at term with previous cesarean section and an indication to induce labor. In order to induce labour by breast stimulation, an electrical pump was used. The cup was alternated between the nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes, with a total induction time of 6 hours.
16361944|NCT04244747|Active Comparator|induction of labour by catheter balloon|women at term with previous cesarean section and an indication to induce labor. In the catheter balloon group, a 16-F Foley catheter was inserted into the cervical canal and inflated with 60 cc sterile saline solution and was kept in place for 12 hours.
16361945|NCT04244747|No Intervention|spontaneous labour|women in latent phase of spontaneous labour .
16361946|NCT04244734|Active Comparator|Group 1|The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load (initially at 40% load from results in MIP).
16361947|NCT04244734|Experimental|Group 2|The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load (initially at 60% load from results in MIP).
16361948|NCT04244721|Sham Comparator|a group of children receiving the usual therapy (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
16361949|NCT04244721|Experimental|a group of children receiving TAU plus the PACT intervention.|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
16361950|NCT04244708|Experimental|Radiotherapy plus temozolomide|Undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day), followed by six cycles of adjuvant temozolomide.
16361951|NCT04244708|Placebo Comparator|Radiotherapy plus placebo|Radiotherapy treatment alone undergoing fractionated radiotherapy, total 54 Gy, 2GyX27, received placebo.
16361952|NCT04244695|Experimental|Dexamethasone 16 mg|Dexamethasone (4mg) 4 tab oral once daily in the morning
16361953|NCT04244695|Active Comparator|Dexamethasone 8 mg|Dexamethasone (4mg) 2 tab and placebo 2 tab oral once daily in the morning
16361954|NCT04244695|Placebo Comparator|Placebo|Placebo 4 tab oral once daily in the morning
16361955|NCT04244682|Other|Healthy participants receiving rTMS|Participation will require up to three visits. One visit will take up to an hour, and the other visits will each take up to three hours each. During the first visit, participants will be consented, and their brains will be scanned using magnetic resonance imaging. Participants will receive rTMS during two study visits.
16361956|NCT04244669|Experimental|SCS with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% of pain in that area.
16361957|NCT04244669|Experimental|SCS with SCS DTM Stimulation|IIn this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms.
16361958|NCT04244656|Experimental|CTX120|Administered by IV infusion following lymphodepleting chemotherapy.
16361959|NCT04244643||Patients with soft contact lenses|
16361960|NCT04244630|Other|Antioxidants|Eligible patients will receive over-the-counter anti-oxidants, namley CoQ10, vitamin E, NAc cysteine, and L-cystine at defined doses.
16361961|NCT04244617|Experimental|iCBT with addition of peer-support (iCBT-PS)|Participants in the iCBT-PS, are guided by both a psychologist and a peer-support in the iCBT-program used in the study.
16361962|NCT04244604|Experimental|High Sodium Meal (2500 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a high sodium meal (2500 mg sodium).
16361963|NCT04244604|Placebo Comparator|Low Sodium Meal (140 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a low sodium meal (140 mg sodium) which will serve as the control condition to demonstrate whether or not observed changes are due to high sodium or occur irrespective of sodium in the postprandial state.
16361964|NCT04244591|Placebo Comparator|standard care|standard care
16361965|NCT04244591|Experimental|standard care + methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
16361966|NCT04244578|Experimental|Active-Sham tDCS|Each tDCS sessions will be delivered for 5 days for a total of non consecutive two weeks. The first session will be active tDCS and two months after, a sham tDCS will follow.
16361967|NCT04244578|Active Comparator|Sham-Active tDCS|"Each tDCS sessions (sham tDCS and active tDCS) will be delivered for 5 days for a total of non consecutive two weeks.
~The first session will be sham tDCS and two months after, an active tDCS will follow."
16361968|NCT04244565||Self-directed clinical learning|examining the effect of Self-directed clinical learning model as compared to the traditional models to improve nurses' Airway management competencies and minimize airway related incidents.
16361972|NCT04244539|Experimental|Experimental group|a received routine physical therapy program, in addition to HILT. Patients in the study group received pulsed Nd: YAG laser treatment, produced by a HIRO 3 device (ASA Laser, Arcugnano, Italy). The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2),
16361973|NCT04244539|Active Comparator|Control group|The control group received traditional physical therapy program in the form of strengthening exercise, stretching , and range of motion exercise.for the affected digits and wrists. for one hour, three sessions per week for 8 weeks.
16361974|NCT04244526||Group1|Group 1:pregnant women with cystitis
16361975|NCT04244526||Group2|Group 2: pregnant women with Pyelonephritis
16361976|NCT04244526||Group3|Group 3: pregnant women with asymptomatic bacteriuria
16361977|NCT04244513|Experimental|HD-DBS|This group will be routinely activated after surgery and then stimulated for 6 months.
16361978|NCT04244513|Sham Comparator|HD-sham-DBS|This group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months
16361979|NCT04244500||Influenza|Influenza testing
16361980|NCT04244487|Experimental|intraoperative endoscopic variceal ligation group|intraoperative endoscopic variceal ligation group Every patient of vagus nerve-preserving group will receive the synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation procedure
16361981|NCT04244487|No Intervention|Non-intraoperative endoscopic variceal ligation group|Every patient of conventional group will receive single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation procedure
16361982|NCT04244474|Experimental|vitamin D3 supplementation|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) . Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
16361983|NCT04244474|Placebo Comparator|Placebo|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
16361984|NCT04244461|Experimental|Personalized normative feedback|Personalized feedback about drinking behavior compared to peers
16361985|NCT04244461|No Intervention|Control|Control participants will receive content similar in length but different in content from the PNF (i.e., non-drinking focused). These participants will receive information based on their actual and perceived behavior of playing video games, a strategy used in prior PNF work to balance attention to non-targeted behaviors.
16361986|NCT04244448|Other|BIKTARVY® ADMINISTRATION DISSOLVED IN WATER|BIKTARVY® route in healthy volunteers: dissolved in water in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of dissolved in water versus crushed and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
16361987|NCT04244448|Other|BIKTARVY® ADMINISTRATION CRUSHED|BIKTARVY® route in healthy volunteers: crushed in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of crushed versus dissolved in water and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
16361988|NCT04244448|Other|BIKTARVY® ADMINISTRATION SOLID|BIKTARVY® route in healthy volunteers: solid tablet in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of solid form of BIKTARVY® versus dissolved in water and crushed in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
16361989|NCT04244435|Experimental|Thoracic epidural analgesia|CABG and thoracic epidural analgesia will be used for perioperative analgesia postoperative period
16361990|NCT04244435|Active Comparator|Opioids|CABG and opioids will be used for perioperative analgesia
16361991|NCT04244435|Active Comparator|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
16361992|NCT04244422|Active Comparator|cyst enucleation using piezosurgery|SATLEC ACTEON peizotome 2 was used for bone cutting and separating the cystic lining from the surrounding bone.After complete removal of the cyst, the bony window was replaced back in place and the flap was sutured.
16361993|NCT04244422|Active Comparator|cyst enucleation using conventional surgery|A carbide bur was used to remove the bone to uncover the cyst. A periosteal elevator and a curette were used to aid in the removal of the cystic lesion.
16361994|NCT04244396||Drug refractory, symptomatic persistent atrial fibrillation|Asian population
16361995|NCT04244383|Experimental|chronic hepatitis C virus patients|50 chronic hepatitis C virus patients taking will be trated with direct acting antiviral treatment with three months regimen (Sofosbuvir + Daclatasvir).
16361996|NCT04244383|Experimental|treated chronic hepatitis C virus patients|the selected 50 chronic hepatitis C virus patients received direct acting antivirals: Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virological response at 12 weeks following the end of treatment (SVR12).
16361997|NCT04244370|Experimental|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
16361998|NCT04244344|Experimental|interventional|"all High fall risk subjects who meet the criteria by STRATIFY Tool"
16361999|NCT04244318|Experimental|Video Feedback ODISEA 2.0.|Once a week, the 5 session intervention of Video-feedback ODISEA 2.0 will be done with the family. In the first session, a play interaction between the child and the caregiver will be recorded for 10 minutes. The second session will be done between the therapist and caregivers, where they will watch different selected parts of the video, and will provide feedback through a mentalization constructed framework. Then, in the third session another play interaction video will be recorded, that will be discussed on the fourth session with the caregiver. Finally, in the fifth session a final interaction video will be recorded.
16362000|NCT04244318|No Intervention|Control Group.|Patients in control group will be placed as a non intervention group. After collecting the post-test data, they will be offered the same intervention than the experimental group.
16362001|NCT04244305|Experimental|Treadmill Training|"Participants in the treadmill training group will perform endurance training during the post-operative period using a treadmill (Salter Housewares, UK) for a minimum of 20 sessions. Intensity of training will be set according to 80% of the mean speed achieved during the 6MWT for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week.
~After the endurance training, participants will perform resistance training for 20 - 30 minutes for conditioning of the main muscles in the upper and lower limbs using elastic bands, dumbbells and body-weight exercises. Intensity will progressively increase up to 70% of the maximum isometric strength measured with a hand-held dynamometer. Volume of training will also increase from 1 to 3 sets of 12 repetitions each. When needed patients will also be taught breathing exercises and airway clearance techniques."
16362002|NCT04244305|Active Comparator|Cyclo-ergometry Training|Participants in this group will perfom endurance training during the post-operative period using a cycle ergometer (Monark 828e, Monark AB, Sweeden) for a minimum of 20 sessions. Intensity of training will be set according to the results of a symptom-limited incremental cycle-ergometry test performed on the first day to achieve 80% of the maximal workload obtained for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week. Participants in this group will also perfom resistance training and breathing exercises as in the treadmill training group.
16362003|NCT04244292|Other|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
16362004|NCT04244279|Experimental|Intervention group|The intervention group will participate in a workshop regarding ergonomic principles in baby care. Finally, a brochure will be distributed summarizing the main contents of the workshop. One month and two months after the intervention, the intervention group will receive a videotaped reminder of the principles presented at the workshop via an email or WhatsApp message.
16362005|NCT04244279|No Intervention|Control group|The control group will not receive any intervention during the data collection period. The intervention will be given three months after the beginning of the research, in the format of the brochure and videos sent via email or WhatsApp.
16362006|NCT04244266||Ideal Body Weight|groups of patients divided according to neostigmine dose weight, ideal body weight (IBW)
16362007|NCT04244266||Total Body Weight|groups of patients divided according to neostigmine dose weight, total body weight (TBW),
16362008|NCT04244266||Adjusted Body Weight|groups of patients divided according to neostigmine dose weight, , adjusted body weight (ABW)
16362009|NCT04244253|Experimental|OPC-64005 20 mg|
16362012|NCT04244240||Sickle cell disease patient|Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.
16362013|NCT04244227|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
16362014|NCT04244227|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
16362015|NCT04244214||More Stamina users|This group of patients will use the app for 60 days and all information about utilization will be recorded
16362016|NCT04244201|Experimental|VHT treatment|Patients will be treated with VHT for 1 hour four times per week
16362017|NCT04244188||Patients treated for aortic arch aneurysms|Patients treated for aortic arch aneurysms by double branched endovascular repair (Bolton Medical) will be included.
16362018|NCT04244175|Experimental|High Dose: CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.
16362019|NCT04244175|Experimental|Low Dose: CVL-865 7.5 mg|Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.
16362020|NCT04244175|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.
16362021|NCT04244162||Study Group|brain scans, cognitive tests, blood biomarkers
16362022|NCT04244149|Experimental|Intervention group|Participants will exert an exercise prolonged session
16362023|NCT04244123||growth hormone deficiency|growth hormone deficiency, requiring growth hormone treatment
16362024|NCT04244123||small for gestational age|small for gestational age and failure of post natal catch up height gain, requiring growth hormone treatment
16362025|NCT04244123||Turner syndrome|short stature due to Turner syndrome, on growth hormone treatment
16362026|NCT04244123||chronic renal failure|short stature due to chronic renal failure, treated with growth hormone treatment
16362027|NCT04244123||Prader Willi syndrome|short stature due to Prader Willi syndrome, treated with growth hormone treatment
16362028|NCT04244097|Experimental|B group|-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.
16362029|NCT04244097|Active Comparator|BN group|Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.
16362030|NCT04244084|Experimental|MMH-407|Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.
16362031|NCT04244084|Placebo Comparator|Placebo|According to the scheme of receiving MMN-407 until the end of the study.
16362032|NCT04244071|Active Comparator|Group C|"Usual care (Group C): The patients in this group received routine hospital care.
~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
16362033|NCT04244071|Experimental|Group A|"The patients in Group A were warmed up using a gown blowing warm air starting at least 30 min prior to the surgery until they were anesthetized.
~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
16362034|NCT04244071|Experimental|Group B|"Routine care was provided for the patients in Group B in the preoperative and intraoperative periods. In the postoperative period, patients were warmed up using a gown blowing warm air after they were transferred to the post-anesthesia care unit, and continued to be warmed up on the basis of the temperature set by themselves until they wore their own clothes in the ward.
~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
16362035|NCT04244058|Active Comparator|NMDA blocker|Comprehensive functional analyses of dynamic [18F]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second [18F]FPEB-PET will be acquired.
16362036|NCT04244058|Experimental|NMDA blocker + L-DOPA|All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of [18F]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each [18F]FPEB-PET acquisitions.
16362037|NCT04244045|Experimental|Experimental group 1|suboccipital muscle inhibition plus passive stretch of hamstring muscle.
16362038|NCT04244045|Experimental|Experimental group 2|Neural slump strtch position plus passive stretch of hamstring muscle.
16362039|NCT04244045|Active Comparator|Control group|passive stretch of hamstring muscle
16362040|NCT04244032|Experimental|Working Memory Training (WM)|Participants complete training in a working memory task designed to utilize individually-adapted difficulty levels.
16362041|NCT04244032|Experimental|Inhibitory Control Training (IC)|Participants complete training in an inhibitory control task designed to utilize individually-adapted difficulty levels.
16362042|NCT04244032|Active Comparator|Bias Modification Training (BM)|Participants complete training in an active comparator task designed to weaken approach responses to alcohol-associated cues.
16362043|NCT04244032|No Intervention|Non-Trained control (NTC)|No active intervention is delivered beyond typical care.
16362044|NCT04244006|Experimental|Dupilumab|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).
16362045|NCT04244006|Placebo Comparator|Placebo|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of placebo (syringe of 2 mL for subcutaneous administration)..
16362046|NCT04243993|Other|Bio-MA|Calcium silicate cement containing calcium chloride accelerator
16362047|NCT04243993|Other|ProRoot MTA|Calcium silicate cement without calcium chloride accelerator
16362051|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose = 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.
~The PCA setting:
~1) Continuous dose = 0; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
16362052|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose ≠ 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.
~The PCA setting:
~1) Continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
16362053|NCT04243954|Active Comparator|Oral Morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.
~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
16362054|NCT04243941|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
16362055|NCT04243928|Active Comparator|control group|15 diplegic children received regular exercise program including balance exercise
16362056|NCT04243928|Experimental|study group|15 diplegic children recieved regular exercise program plus putting kinesiotape
16362057|NCT04243915|Experimental|PNMES plus exercise|6-week intervention program with 3 treatment sessions of PNMES and motor control exercise program.
16362058|NCT04243915|Sham Comparator|Sham PNMES (introducing the needle) plus exercise|Sham PNMES (introducing the needle) plus motor control exercise program
16362059|NCT04243915|Active Comparator|TENS plus exercise|6-week intervention program with 3 treatment sessions of TENS plus motor control exercise program.
16362060|NCT04243915|Placebo Comparator|Placebo PNMES (without inserting the needle) plus exercise|6-week intervention program with 3 treatment sessions of placebo PNMES (without inserting the needle) and exercise
16362061|NCT04243902|Experimental|1 - standard manual valve (without leg-bag)|"The valve will initially be tested in 8 participants who currently use a standard manual valve (without leg-bag).
~This first group will include a safety cohort of participants (n=4). All safety data will be reviewed from the initial 4 participants before further participants can undergo the study investigation."
16362062|NCT04243902|Experimental|2 - drainage bag with free drainage|The valve will then be tested with participants (n=8) who currently use a drainage bag with free drainage.
16362063|NCT04243889|Experimental|NEOX Cord 1K applied fetoscopically|
16362064|NCT04243876||paraoxanase|Enzyme level
16362065|NCT04243876||Myocardial infarction|RESULTS OF ANGIOGRAPHY
16362066|NCT04243863|Experimental|VNRX-7145|Oral dosing
16362067|NCT04243863|Placebo Comparator|Placebo|Oral dosing
16362068|NCT04243850|Experimental|Empagliflozin|Empagliflozine 7 days
16362069|NCT04243850|Placebo Comparator|Placebo|Placebo 7 days
16362070|NCT04243837|Experimental|LYT-100 in healthy volunteers with Food|LYT-100, multiple ascending
16362071|NCT04243837|Placebo Comparator|Placebo in healthy volunteers with Food|Placebo, multiple administrations
16362072|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fasted|LYT-100, Dose below MTD for 1 dose
16362073|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fasted|Placebo, for 1 administration
16362074|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fed|LYT-100, Dose below MTD for 1 dose
16362075|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fed|Placebo, for 1 administration
16362076|NCT04243837|Experimental|LYT-100 in patients with BCRL|LYT-100 BID for 6 months
16362077|NCT04243837|Placebo Comparator|Placebo in patients with BCRL|Placebo BID for 6 months
16362078|NCT04243824|Experimental|All participants|All enrolled study participants will receive Ga-68MAA and PET/MRI scan.
16362079|NCT04243811|Experimental|laser group|local anesthesia applyed with 940 nm diode laser
16362080|NCT04243811|Active Comparator|conventional group|local anesthesia applyed with topical anesthesia
16362081|NCT04243798|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
16362082|NCT04243798|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
16362083|NCT04243785|Experimental|Phase 1a (Dose Escalation Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 20 mg (60 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
16362084|NCT04243785|Experimental|Phase 1b (Cohort Expansion Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). Phase 1b will continue at the MTD or the highest dose achieved in Phase 1a.
16362085|NCT04243785|Experimental|Continued Treatment Phase|Participants who complete one cycle of BTX-A51 treatment in either Phase 1a or Phase 1b will be offered continued access to treatment for up to eight 28-day cycles if the Investigator determines that the benefit outweighs the risk. Dosing will continue at the assigned dose or may be increased (not to exceed a level already tolerated by at least one participant if Phase 1a is ongoing or the MTD/recommended Phase 2 dose if already established).
16362086|NCT04243772||Lithiasic patients|Lithiasic patients of the CHU Brugmann Hospital
16362087|NCT04243759|Experimental|Control App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
16362088|NCT04243759|Experimental|Standard App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
16362089|NCT04243759|Experimental|Experimental, Feedback App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
16362090|NCT04243746|Experimental|Time Restricted Feeding +Standard Malaysian Healthy Plate(QQH)|Subjects practise time restricted feeding (TRF) in addition to the Standard Malaysian Healthy Plate (QQH).
16362091|NCT04243746|Active Comparator|Standard Malaysian Healthy Plate (QQH)|Subjects practise the QQH dietary plan.
16362092|NCT04243733|Other|calcium enriched mixture material (CEM)|Using CEM as a pulpotomy agent against MTA pulpotomy agent.
16362093|NCT04243733|Experimental|Mineral trioxide aggregate material (MTA)|Using MTA as a pulpotomy agent against CEM pulpotomy agent.
16362094|NCT04243720||IRIS|Patients with a histological or cytological diagnosis of solid malignancies. Patients must have progressed on immunotherapy as their most recent line of therapy.
16362095|NCT04243694|Experimental|Intervention group|mindfulness intervention administered
16362096|NCT04243694|No Intervention|Control group|no intervention administered
16362097|NCT04243681|Experimental|Combination MSC and HSC|Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance
16362098|NCT04243681|Active Comparator|Standard of care for Cirrhosis management|Diuretics, Hepatoprotective agents and Lactulose
16362099|NCT04243668|Experimental|ANTI REFLUX MUCOSAL ABLATION THERAPHY|In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.
16362100|NCT04243655|Experimental|Hemoperfusion treatment with HA 330-II|Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with SMT as per patients requirement.
16362101|NCT04243655|Active Comparator|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
16362102|NCT04243629|Experimental|Rapid Insulin-Plus-Pramlintide|Rapid insulin and pramlintide infusion in two insulin pumps
16362103|NCT04243629|Placebo Comparator|Rapid Insulin-Plus-Placebo|Rapid insulin and placebo (saline) infusion in two insulin pumps
16362104|NCT04243616|Experimental|Drug Treatment|Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
16362105|NCT04243603|Experimental|Internet-based ERITA-DK|ERITA is a youth-adapted version of Emotion Regulation Group Therapy (ERGT), based on cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and Acceptance and Commitment Therapy (ACT), which encounters emotional recognition and regulation, crisis strategies and skills training. The ERITA intervention is provided as add-on to TAU and consists of 12 weeks, manualized, therapist guided internet-based therapy. The intervention also provides six modules for the parents focusing on NSSI and other risk-taking behaviors, emotional awareness, and validation skills. The participants must complete one module every week while the parents must complete a module every second week. A mobile app is available to complement the online treatment. The app includes reminders of homework and skills and allows to report on both self-destructive behaviors and impulses daily.
16362106|NCT04243603|Active Comparator|Treatment as Usual (TAU)|Child and Adolescent Mental Health Services (CAMHS) offer specialized treatment for children and adolescents. TAU encounters a variety of clinical treatment and assessment offers, representing a highly inhomogeneous group of treatments, for instance: Pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy, supportive counselling and psychoeducation. Throughout the trial course the treatment responsibility is handled by clinicians providing TAU.
16362107|NCT04243590||Neonatal brachial plexus palsy|"25 patients will be included. The level of the brachial plexus lesion will be recorded. Parents of all patients were asked to fill in the Turkish version of the Hand-at-Home Questionnaire and in addition, the upper extremity section of the Pediatric Outcomes Data Collection Instrument (PODCI) in patients with OBP."
16362108|NCT04243590||Unilateral cerebral palsy|"25 patients will be included. The level of Manual Ability Classification System (MACS) will be recorded. Parents of all patients were asked to fill out the Turkish version of the Hand-at-Home Questionnaire at Home, as well as the Children's Hand-Use Experience Questionnaire (CHEQ) in patients with CP."
16362109|NCT04243577|Experimental|Experimental Sensors|This arm will include the use of the experimental wearable sensors we are developing.
16362110|NCT04243577|Active Comparator|Conventional Sensors|This arm will include the use of the conventional sensors: regular snap on sEMG electrodes and IOPI device bulb.
16362111|NCT04243564|Active Comparator|PLMA|The PLMA, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
16362112|NCT04243564|Active Comparator|I-gel|The I-gel, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
16362113|NCT04243551|Active Comparator|Latiglutenase|IMGX003
16362114|NCT04243551|Placebo Comparator|Placebo|Placebo
16362115|NCT04243538|No Intervention|Control arm|Standard of care.
16362116|NCT04243538|Experimental|I-HoME intervention|
16362117|NCT04243512|Experimental|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
16362118|NCT04243499|Experimental|IV ICT01 Monotherapy|Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
16362119|NCT04243499|Experimental|IV ICT01 + IV Pembrolizumab|A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion
16362120|NCT04243486|Experimental|UHE-105 Shampoo|UHE-105 Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
16362121|NCT04243486|Placebo Comparator|Vehicle Shampoo|Vehicle Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
16362122|NCT04243473||Prostate Biopsy, Urine sample and Blood sample|For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
16362123|NCT04243460|Experimental|CTG connective tissue graft augmentation|CTG connective tissue graft (CTG) was used for soft tissue augmentation. I
16362124|NCT04243460|Active Comparator|XCM Xenogeneic collagen matrix (XCM)graft augmentation|Xenogeneic collagen matrix (XCM) was used for soft tissue augmentation.
16362125|NCT04243434|Experimental|Cohort A|Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
16362126|NCT04243434|Experimental|Cohort B|VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
16362127|NCT04243421|Experimental|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).
~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.
~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
16362128|NCT04243408|Experimental|group 1|
16362129|NCT04243408|Placebo Comparator|group 2|
16362130|NCT04243395|Experimental|Pork|1 ounce lean pork
16362131|NCT04243395|Experimental|Egg|1 large whole egg
16362132|NCT04243395|Experimental|Black beans|0.5 cups of cooked black beans
16362133|NCT04243395|Experimental|Almonds|0.5 ounce of whole almonds
16362134|NCT04243382|Experimental|group 1|Autologous umbilical cord blood transfusion Single dose of an Autologous umbilical cord blood transfusion
16362135|NCT04243382|Experimental|group 2|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml,
16362136|NCT04243369|Other|Experimental - Collaboration Live software|
16362137|NCT04243356|Experimental|Nurse Encounter Group|Nurses that are assigned to this group will be asked to take surveys before and immediately following the post-ICU clinic encounter with a patient that they had cared for in the ICU during a follow-up care visit with the former ICU - patient.
16362138|NCT04243356|Other|Nurse Control Group|Nurses assigned to this group will only complete surveys and will not see a former patient in a post-ICU visit.
16362139|NCT04243343|Experimental|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program.
16362140|NCT04243343|Active Comparator|Standard of care|Standard of care prescribed home exercise program.
16362144|NCT04243317|Active Comparator|Control|The control group will adhere to a 1200 kcal restriction daily for 12 weeks.
16362145|NCT04243317|Experimental|Experimental|The experimental group will adhere to a 1200 kcal restriction daily for 12 weeks and will maintain sleep improvement
16362146|NCT04243304|Experimental|PD patients|At baseline and 2-year follow-up
16362147|NCT04243304|Active Comparator|Healthy controls|At baseline and 2-year follow-up
16362148|NCT04243278|Experimental|PO LD-ASA|Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
16362149|NCT04243278|Placebo Comparator|PO Placebo|A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.
16362150|NCT04243265|Experimental|Patients treated with MPFL reconstruction|"Patients underwent MPFL reconstruction using a minimally invasive technique using a fascia lata allograft performed at the Rizzoli Orthopedic Institute between 2011 and 2015 by the team of Prof. Marcacci.
~Clinical and radiographic evaluation will be performed during outpatients visits."
16362151|NCT04243252|Experimental|Intervention Food Pantries|Food pantries will complete online training to help them rank foods by nutritional value and promote those foods to pantry clients; the effect on pantries and their clients will be measured.
16365470|NCT04219826|Placebo Comparator|Placebo - Cohort 1|Subjects will receive placebo for up to 10 weeks
16362152|NCT04243252|Active Comparator|Control Food Pantries|Food pantries will continue to operate as usual during the study period; the effect on pantries and their clients will be measured.
16362153|NCT04243226|Experimental|this study is to develop exercise prescription of TBI patients|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve cognitive performance, depression relief and quality of life with improvement of CBF. This will be a three-year study, with the first two year using a mixed method to explore the feasibility of such a safety exercise prescription. In the second to third year, a randomized clinical control trial will be applied in TBI patients to evaluate the effectiveness of programmed aerobic exercise to promote cognitive status, 6 minutes walk test, depression relief and quality of life.
16362154|NCT04243226|No Intervention|No exercise prescription in TBI patients|Routine Care of TBI Patients
16362155|NCT04243213|Experimental|Vibration Group|Intervention group I receives a unit of 10 minutes daily on the vibrating plate with an upright posture of 15 ° postoperatively from the 2nd to the 7th day
16362156|NCT04243213|Experimental|15° Tilt Group|Intervention group II is positioned postoperatively from day 2 to day 7 for 15 minutes at 15 degrees, but without vibration
16362157|NCT04243213|Placebo Comparator|Control Group|The control group only receives standard physiotherapy and no further treatments
16362158|NCT04243200||Analyses of repeat ambulance calls and costs|For our analyses of repeat ambulance calls and costs we will use routine anonymised data from routine call-and-dispatch and clinical records data from EMAS for 12 months before the intervention was first introduced (September 2017) to at least 6 months after the final step of the introduction in April 2019, i.e. October 2019. This is likely to involve the analysis of an estimated 11916 cases so that we can implement a stepped wedge (non-randomised control)design .
16362159|NCT04243200||Survey of patients receiving intervention|We will survey about 447 patients who received the intervention in order to obtain data from a sample of n=96
16362160|NCT04243200||Survey of ambulance staff|We will send out surveys/questionnaires to all front-line ambulance staff (n=approximately 600)
16362161|NCT04243200||Qualitative interviews of staff|We will sample 10-15 staff for qualitative interviews.
16362162|NCT04243200||Qualitative interviews of patients|We will sample 10-15 patients for qualitative interviews
16362163|NCT04243187|Experimental|Clinical Study|"9 visits, once a week, for bean intake (80 grams of dried beans, soaked for 12 hours, cooked in new water for 1.5 - 2 hours. This is approximately 160 grams of cooked beans).
~Four varieties of beans (3 native and 1 commercial) will be analyzed, which will be consumed in duplicate by participants (8 visits).
~A ninth visit will be made to perform a exhaled hydrogen test with raffinose (5 grams), as a positive control."
16362164|NCT04243174|Other|SMS Messages|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
16362165|NCT04243161|Experimental|Group 1|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.
16362166|NCT04243161|Active Comparator|Group 2|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.
16362167|NCT04243148|Experimental|Multifactorial intervention|Frail and pre-frail patients will receive multifactorial intervention consisting of home exercise, BCAA supplements and a multispecies probiotic for 12 months.
16362168|NCT04243148|Experimental|Control group|Frail and pre-frail patients will be followed but will not receive any specific intervention.
16362169|NCT04243135|Active Comparator|ESWT group|All patients in both groups were applied with a hot pack for 40-minutes, transcutaneous electrical nerve stimulation for 30-minutes (100 Hz frequency and 60 milliseconds pulse duration), and a home-based exercise program around the knee for 30-minutes per day for three weeks. Also, each patient in group 1 received shockwaves of continuous frequency and intensity (2000 shocks, 10 Hz, 2.0 to 3.0 bar), while the second group of patients received sham-ESWT. In group 1, for a total of 3 weeks, r-ESWT was undertaken with 2000 pulse each time at a week interval totaling 6000 pulse by using a radial shock wave therapy system (vibrolith ortho tip ESWT (ELMED Turkey)).
16362170|NCT04243135|Sham Comparator|Sham-ESWT group|The other group received sham-ESWT at 0.1 bar in the same area. The patients were placed supine with the affected knee at 90 degrees flexion at each treatment session. The shock wave probe was held stationary on painful points around the knee or at the patellofemoral and tibiofemoral borders of the target knee.
16362173|NCT04243109|Experimental|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:
~Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started.
~Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.
~Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles.
~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
16362174|NCT04243096|Experimental|Exercise-based Physical Therapy|12 week in-person exercise-based physical therapy
16362175|NCT04243083|Experimental|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
16362176|NCT04243083|Experimental|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
16362206|NCT04242888|Experimental|Posterior Capsular Stertch|Posterior capsule is stretched through a novel maneuver
16362177|NCT04243083|Experimental|Food Effect Panel|Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.
16362178|NCT04243070|Other|3-channel Holter ECG recording for EPS patient|Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
16362179|NCT04243070|Other|12-channel Holter ECG recording for non-EPS patients|Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period
16362180|NCT04243044|Experimental|Intensity 1 (0.8x resting threshold, 30 minute duration)|Transcutaneous spinal stimulation will be applied continually at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
16362181|NCT04243044|Experimental|Intensity 2 (0.8x resting threshold, dual-site, 30 minute duration)|Transcutaneous spinal stimulation will be applied continually at 0.8x resting threshold at two sites as determined from baseline testing of posterior root muscle reflexes.
16362182|NCT04243044|Experimental|Intensity 3 (burst 0.8x rest threshold, 30 minute duration)|Transcutaneous spinal stimulation will be applied in bursts at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
16362183|NCT04243044|Experimental|Frequency 1 (30 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 30 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
16362184|NCT04243044|Experimental|Frequency 2 (50 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 50 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
16362185|NCT04243044|Experimental|Frequency 3 (80 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 80 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
16362186|NCT04243031||All subjects|Those with TB and those without TB.
16362187|NCT04243018|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Intervention to improve well-being and reduce the negative effects of shame and self-stigma in a population of adults experiencing homelessness.This will involve participating in two sessions, lasting two and a half hours each, over a period of two weeks. Well-being will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition participants will be provided with an acceptance and commitment training workbook. The workbook will foster core processes of the ACT model through psycho-education, daily exercises, tips and tools.
16362188|NCT04243018|Active Comparator|Peer Support Group|This peer support group will involve discussing themes around experiencing homelessness, shame and stigma and will be facilitated by an experienced peer support group leader.This will involve participating in two sessions, lasting two hours each, over a period of two weeks.
16362193|NCT04242979|Other|Human albumin use in liver cirrhosis|"Each participant involved in the study will be assessed for his or her knowledge using (tool I).
~5-Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.
~6-Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).
~7-Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians."
16362194|NCT04242966|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
16362195|NCT04242966|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
16362196|NCT04242953|Experimental|SCO-120|
16362197|NCT04242953|Placebo Comparator|Matching Placebo|
16362198|NCT04242940|Experimental|Ponto 4 sound processor|All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
16362199|NCT04242927|Experimental|Nicotinic acid + Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
16362200|NCT04242927|Active Comparator|Routine care|Routinely apply urea ointment and provide best supportive care.
16362201|NCT04242914|Experimental|Research: Ketamine + Midazolam|Research group will receive ketamine and midazolam.
16362202|NCT04242914|Experimental|Control: Midazolam|Control group will receive midazolam.
16362203|NCT04242901||Colorectal cancer|Patients recently diagnosed colorectal cancer
16362204|NCT04242888|Experimental|Rotator Cuff Facilitation|The function of Rotator cuff muscles is passively augmented in one of the 5 trials
16362205|NCT04242888|Experimental|Serratus Anterior Stretch|Seratus anterior muscles is stretched through a novel technique
16362207|NCT04242888|Experimental|Acromioclavicular Joint Mobilization|Acromio clavicular joint is mobilized posterio-anterior
16362208|NCT04242888|Experimental|Pragmatic Interventions|"The pragmatic interventions is a set of interventions which include
~Rotator cuff facilitation
~Posterior capsular stretch
~Serratus anterior muscle stretch
~Acromioclaicualr joint mobilization
~Thoracic spine manipulation and
~Stretch to the subclavious muscles"
16362209|NCT04242875||PanOptix|Participants will receive the PanOptix intraocular lens.
16362210|NCT04242849||IDH1/2 mutated patients|Patients harboring mutations in IDH1 or IDH2 genes
16362211|NCT04242849||Patients without IDH1/2 mutations|Patients that don´t present any mutation in IDH1/2 genes
16362212|NCT04242836||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language
~30 patients with low vision (LVG) with adequate literacy of written Greek language
~These patients are tested on the printed Greek MNREAD"
16362213|NCT04242836||Study group|The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
16362214|NCT04242823|Other|Baseline screening cohort|This group undergoes hrHPV self-swab and triage if positive. Triage evaluation occurs in all women and includes visual inspection with acetic acid, colposcopy and image capture for automated visual evaluation
16362215|NCT04242810|Active Comparator|Active rTMS|rTMS applied over memory task-based brain target
16362216|NCT04242810|Placebo Comparator|Sham rTMS|Sham rTMS applied over memory task-based brain target
16362217|NCT04242797|Active Comparator|Calmare|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
16362218|NCT04242797|Active Comparator|Traditional TENS|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
16362219|NCT04242784||Spoke Hospital|Patients that undergo the Code Stroke process at Spoke Hospitals
16362220|NCT04242784||Hub Hospital|Patients that undergo the Code Stroke process at Hub Hospitals
16362221|NCT04242784||Transfer|Patients that undergo the Code Stroke process at a Spoke Hospital and transfer to the Hub Hospital
16362222|NCT04242771|Experimental|Experimental group|Participants will utilize a daily sleep program available within a widely used smartphone app, which includes seven soundtracks (10-15min each) for guided mindfulness practice at bedtime. Techniques include breathing exercises, mental imagery, awareness of body and mind, and muscle and body relaxation.
16362223|NCT04242771|No Intervention|Control group|Participants randomized to the waitlist control group will be asked to maintain their usual care during the one month after baseline assessment. They will be asked not to start any new treatments for their insomnia. At the end of the one-month study, they will be given access to the mobile app.
16362224|NCT04242758|Experimental|Dapaglifozin|People undergoing SGLT2i (Dapaglifozin) therapy
16362225|NCT04242758|Experimental|Hydrochlorothiazide|People undergoing thiazide (Hydrochlorothiazide) therapy
16362226|NCT04242745|Experimental|Intervention group|Procedure/Surgery:The intervention group was given education and a wristwatch which gave an audible alarm to remind them to drink liquid.
16362227|NCT04242745|No Intervention|Control group|The control group was given only education.
16362228|NCT04242732|Experimental|MPFL reconstructed|20 patients with previous recurrent patella dislocation who underwent MPFL reconstruction surgery with fascia lata allograft between 2012 and 2013
16362229|NCT04242719|Active Comparator|Only electromagnetic stimulation|Only rEMS was preferred as the initial step
16362230|NCT04242719|Active Comparator|Combined with electromagnetic stimulation and PRP|Order to augment the effect of the rEMS, sub-tenon aPRP injection was added.
16362231|NCT04242719|No Intervention|Natural course|Served as control group, and existing systemic disorder(s) were consulted and treated accordingly.
16362232|NCT04242706|Active Comparator|Control group|Endotracheal tube with evacuation lumen without Bactiguard coating.
16362233|NCT04242706|Experimental|Experimental group|Endotracheal tube with evacuation lumen with Bactiguard coating.
16362234|NCT04242693|Experimental|Experimental Group|The experimental group were asked to count the number of times they ate any red/orange vegetables and set a goal to eat one more time the next day over three days.
16362235|NCT04242693|No Intervention|Control Group|The control group uploaded photos and/or descriptions of their meals only. They did not self-monitor their vegetable intake nor set a goal to eat more.
16362236|NCT04242680|Experimental|Brainstim DLPFC|tRNS over bilateral DLPFC + cognitive training
16362237|NCT04242680|Experimental|Brainstim PPC|tRNS over bilateral PPC + cognitive training
16362238|NCT04242680|Sham Comparator|Brainstim Sham|Sham tRNS (bilateral DLPFC/bilateral PPC) + cognitive training
16362239|NCT04242667|Experimental|Actionable gene result for cancer risk|
16362240|NCT04242667|Experimental|Actionable gene result for cardiovascular disease risk|
16362241|NCT04242654|Experimental|Doppler ultrasound|Placement of Doppler US on chest to obtain newborn's heart rate.
16362242|NCT04242654|No Intervention|Stethoscope|Placement of stethoscope on chest to obtain newborn's heart rate.
16362243|NCT04242641|Experimental|WW (formally Weight Watchers)|The intervention will consist of engaging with the WW programme for 12 weeks, including weekly attendance at a local WW workshop and access to digital tools. Only the parent will take part in the WW intervention. No modifications will be made to the current WW programme to support child weight loss.
16362244|NCT04242641|No Intervention|Control|Participants randomised to the control group will receive no intervention during the 3 month period. Following final data collection control participants will receive 3 month complimentary access to WW.
16362245|NCT04242628|Experimental|Facebook course|T1 study members attended a three week course (two classes per week) on smartphones and SNS use. Specifically, the course covers the following topics: smartphone use; Facebook use; WhatsApp use, privacy rules and fraud risk prevention using Facebook. Throughout the duration of the intervention, a tutor was available every Tuesday and Thursday to assist T1 participants in using SNSs.
16362246|NCT04242628|Experimental|Lifestyle course|T2 study members attended 5 interactive 90-min meetings on lifestyle education and brain functioning in older people. These meetings covered the following topics regarding good habits for wellbeing at older age: nutrition, brain ageing, physical activity, leisure activities, resources of the city for older people. A goodbye tea was offered after the meetings.
16362307|NCT04242290||Neck pain|The group with isolated neck pain
16362247|NCT04242628|No Intervention|Waiting list|Throughout the duration of the intervention, we put C study members on a waiting list; at the end of the intervention, in June 2019, interested group C study members attended the SNSs course (held on June 2019).
16362248|NCT04242615||Prognostic score cohort|323 patients included between January 1, 2001 to December 31, 2004
16362249|NCT04242615||Prognostic score validation cohort|534 patients included between January 1, 2010 to December 31, 2013
16362251|NCT04242589|Active Comparator|Radiotherapy|Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)
16362252|NCT04242589|Experimental|Vertebroplasty + Radiotherapy|"Vertebroplasty followed by radiotherapy within 2-3 weeks
~Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)"
16362253|NCT04242576|Experimental|Action Observation|Subjects will watch 30-second videos, with a one-minute break between videos. The videos show the actions that subjects should imagine while watching the video.
16362254|NCT04242576|Experimental|Right/Left Judgment Task|"The laterality will be trained with the Recognize® application. Once the subjects have been trained, they are instructed to solve the different sections of the application, starting with the simplest tasks until reaching the most difficult ones.
~These tasks would consist of indicating left or right, among the different images that appear on the iPad screen, indicating if the image's neck is rotated to the left or right. Being every level more complicated, so that people of different skin tones, with clothes or in a work environment are added."
16362255|NCT04242576|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
16362256|NCT04242563|No Intervention|CONTROL GROUP|No virtual reality
16362257|NCT04242563|Experimental|INTERVENTION GROUP|Patient equipped with Virtual reality in transfer room.
16362258|NCT04242550|Experimental|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT with executive function training, enhancing CBT with a focus on teaching compensatory strategies, habit learning, and plan for generalization to real-world behaviors.
16362259|NCT04242550|Active Comparator|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
16362260|NCT04242537|Experimental|High flow oxygen delivery|Oxygen delivery with high flow nasal cannula with head side elevation to 30 degrees
16362261|NCT04242537|Experimental|Low Flow oxygen delivery|Low flow oxygen delivery through nasal cannula with head side elevation to 30 degrees
16362262|NCT04242537|No Intervention|Standard practice of care|No oxygen delivery either high flow or low flow through nasal cannula
16362263|NCT04242524|Experimental|Circadian Clock Alignment - High BMI|Subjects will come to the Sleep Lab three nights before their bariatric surgery procedure for an intervention that will align their central circadian clock. The intervention includes eating meals and snacks at fixed times and having lights off at a specific time at night and lights on at a specific time in the morning.
16362264|NCT04242524|Active Comparator|Circadian Clock Control - High BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
16362265|NCT04242524|Active Comparator|Circadian Clock Control - Low BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
16362266|NCT04242511||Cases|"Tuberculosis patients with diabetes mellitus:
~Subject aged 18 years of age or over
~Written, informed consent obtained.
~New diagnosis of tuberculosis and started on anti-tuberculosis treatment
~Known diagnosis of diabetes or two consecutive raised IFCC HbA1c levels (>= 48 mmol/mol) at the time of TB diagnosis"
16362267|NCT04242511||Controls|"Tuberculosis patients without diabetes mellitus:
~1), 2), 3) as above 4) IFCC HbA1c level < 48mmol/mol 5) Weight matched to cases (+/- 2kg)"
16362272|NCT04242485|Other|AFTER MATCH + OMT|Players undertook a recording session the day after a rugby match and received osteopathic manipulative treatment
16362273|NCT04242485|Other|AFTER MATCH + sham treatment|Players undertook a recording session the day after a rugby match and received sham treatment
16362274|NCT04242485|Other|NO MATCH + OMT|Players undertook a recording session the day after a resting day and received osteopathic manipulative treatment
16362275|NCT04242485|Other|NO MATCH + sham treatment|Players undertook a recording session the day after a resting day and received sham treatment
16362276|NCT04242472|Experimental|SMS group|Nutrition-related SMS messages in addition to standard of care TB treatment with directly observed therapy
16362277|NCT04242472|No Intervention|Control group|Standard care of TB treatment with directly observed therapy alone
16362278|NCT04242459|No Intervention|Feasibility Study|This is a radiotherapy planning study to evaluate the feasibility to acquire longitudinal MRI scans during radiotherapy (prior to the main study) thus, participants will receive standard-of-care chemoradiation therapy (CRT) as per departmental protocol without any treatment adaptation.
16362279|NCT04242459|Experimental|HPV associated OPC Participants|"Participants will be treated initially with the standard radiotherapy dose of:
~65 grays (Gy) in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease
~In the 2nd week and 4th week of treatment, the participants will undergo Adaptive Radiotherapy to account for anatomical changes."
16362347|NCT04241991|Placebo Comparator|Placebo laser|Each participant will receive the application of the placebo laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
16362280|NCT04242459|Experimental|HPV negative OPC Participants - Radiotherapy dose escalation|"Participants will be treated initially with the standard radiotherapy dose of:
~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease
~After 10 fractions the participants will be stratified into either responders or non-responders categories based on Apparent Diffusion Coefficients (ADC) response at week 2 of CRT.
~Participants classified as responders will complete treatment without any radiotherapy dose changes. Their radiotherapy treatment target volumes will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.
~The non-responders will undergo an increase in dose per fraction to Clinical Target Volume-1 (CTV-1) primary for fractions 11 to 30."
16362281|NCT04242459|Experimental|Base of Skull HNC Participants|"Participants will be treated initially with the standard radiotherapy dose of:
~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease
~Participants will undergo standard treatment with 3 cycles of induction chemotherapy followed by chemo-radiotherapy dose. Their radiotherapy treatment will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour."
16362282|NCT04242446|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
16362283|NCT04242446|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
16362284|NCT04242446|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
16362285|NCT04242446|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
16362286|NCT04242433||Viremic Person living with HCV|All persons enrolled in the MMPHCRF treatment programme are provided free of charge direct acting antiviral agents and followed up for outcomes.
16362287|NCT04242420|Other|Connexin genotype|Genotyping
16362288|NCT04242407|Active Comparator|DMTS|DMTS applied to the upper arm
16362289|NCT04242407|Placebo Comparator|Placebo|Placebo system (with no drug) to match DMTS applied to the upper arm
16362290|NCT04242394||Chronic gallbladder diseases|Routine ERCP participants with chronic gallbladder diseases
16362291|NCT04242394||Without Chronic gallbladder disease|Routine ERCP participants without chronic gallbladder diseases
16362292|NCT04242381|Experimental|Group 1: Cold application, Kinesiotaping treatment|"Cold application: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
~Kinesiotaping application: KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)."
16362293|NCT04242381|Experimental|Group 2: Cold application, EX treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
16362294|NCT04242381|Sham Comparator|Group 3: Cold application, sham-KT treatment|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
16362295|NCT04242368|Active Comparator|Isotonic rinse, then hypertonic rinse|Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses isotonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete hypertonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
16362296|NCT04242368|Experimental|Hypertonic rinse, then isotonic rinse|"Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses of hypertonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete isotonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
~Fluticasone propionate nasal spray - two sprays to each nare twice a day used for the entire study duration"
16362297|NCT04242355|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
16362298|NCT04242355|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
16362299|NCT04242342|Experimental|Experimental arm|Patient with a localized primary tumor (hepatocellular carcinoma or cholangiocarcinoma) or a secondary hepatic localization of a solid carcinoma, with one to three hepatic lesions accessible to a treatment by stereotactic radiotherapy.
16362300|NCT04242329|Experimental|PD1-inhibitor + surgery|Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
16362301|NCT04242329|Active Comparator|PD1-inhibitor|Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
16362302|NCT04242316|Experimental|Mirror Therapy|Patients performed customized bimanual upper limb exercises with a mirror. They can observe the mirror visual feedback of their non-paretic hand during the movements.
16362303|NCT04242316|Active Comparator|Bilateral arm training|Patients performed customized bimanual upper limb exercises without a mirror.
16362304|NCT04242303|Experimental|EM Technique|use of extramedullary technique by means of inertial sensors for the execution of femoral cuts
16362305|NCT04242303|Active Comparator|IM Technique|Use of conventional intramedullary technique for the execution of femoral cuts
16362306|NCT04242290||Cervicogenic headache|The group with cervicogenic headaches
16362308|NCT04242277||WF-OCT imaging of excised breast lumpectomy tissue|Excised lumpectomy tissue from all consented patients will be imaged on an investigational OCT-based device. No clinical decisions will be made based on the images acquired.
16362309|NCT04242264|Experimental|Group 1|Vaccine: 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
16362310|NCT04242264|Experimental|Group 2|Placebo+Vaccine: 30 ml of Placebo administered orally on Day 1 and 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
16362311|NCT04242264|Placebo Comparator|Group 3|Placebo: 30 ml of Placebo administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
16362312|NCT04242251|No Intervention|Usual Care|Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.
16362313|NCT04242251|Experimental|SPARKLE intervention group|Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.
16362314|NCT04242238|Experimental|Advanced High-grade Sarcoma|Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma
16362315|NCT04242212||Clinic-based|Women who get misoprostol from a clinic-based provider
16362316|NCT04242212||PMV-based|Women who get misoprostol from a patent medicine vendor
16362317|NCT04242199|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
16362318|NCT04242199|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
16362319|NCT04242199|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
16362320|NCT04242186|Experimental|Nursing home residents and staff|Nursing home residents at high risk for injurious falls, as well as nursing home staff at participating facilities
16362321|NCT04242173|Experimental|Cemiplimab-rwlc treatment|Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
16362322|NCT04242160|Experimental|Modified Clamshell Thoracotomy First|Participants randomized to perform the MCT first, then cross over to the perform the alternate LAT.
16362323|NCT04242160|Active Comparator|Left Anterolateral Thoracotomy First|Participants randomized to perform the LAT first, then cross over to the perform the alternate MCT.
16362324|NCT04242147|Experimental|Monotherapy|KD033 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W)
16362325|NCT04242134|Experimental|PS-DCB|"For PS-DCB group
~NC balloon dilating ostial side branch (SB) (1:1 ratio).
~DCB dilating SB. Specifically, the DCB, which had to be 2-3 mm longer on each side than the predilatation balloon, was inflated at nominal pressure for 30~ 60 s. The ratio of the DCB diameter to the nominal diameter of the SB was recommended to be between 0.8 and 1.0. DCB should be delivered to the lesion within 2 min after entering human body.
~Kissing inflation using 2 noncomplian balloons.
~Stenting side branch with T and protrusion (TAP) technique if any of the following issues was observed after kissing balloon inflation: >type C dissection or thrombolysis in myocardial infarction (TIMI) flow <3.
~Final kissing inflation and proximal optimal technique (POT)."
16362326|NCT04242134|Active Comparator|PS-NCB|"For PS-NCB group
~NC balloon dilating ostial SB (1:1 ratio).
~Kissing inflation using 2 NC balloons.
~Stenting side branch with TAP technique if any of the following issues was observed after kissing balloon inflation: >type C dissection or thrombolysis in myocardial infarction (TIMI) flow <3.
~Final kissing inflation and proximal optimal technique (POT)."
16362327|NCT04242108||Angle closure group|
16362328|NCT04242108||Open angle group|
16362329|NCT04242108||Peripheral synechia (PAS) group|
16362330|NCT04242108||Non-peripheral synechia (PAS) group|
16362331|NCT04242095||Observational (biospecimen collection, medical record review)|Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
16362332|NCT04242082||patients with psoriasis vulgaris only|
16362333|NCT04242082||patients with psoriasis vulgaris and type 2 diabetes mellitus|
16362334|NCT04242082||healthy control|
16362335|NCT04242069|Experimental|Intervention|Healthy for my Baby Intervention
16362336|NCT04242069|Other|Control|Usual care
16362337|NCT04242056|Other|Using image to diagnosis Multiple sclerosis (MS)|In current study, we will enroll 38 patients with MS and evaluate their clinical severity; measure the WM lesion and disease activity by magnetic resonance imaging (MRI); myelination state and amyloid deposition by amyloid PET scan; tau deposition by state of-art tau PET scan
16362338|NCT04242043||AI|
16362339|NCT04242030|Other|COPD group|"Participants in the COPD group will receive examination of laser doppler flowmetry(LDF).
~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian."
16362340|NCT04242030|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
16362341|NCT04242030|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
16362342|NCT04242017|Active Comparator|salvage RT + 6 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 6 months ADT
16362343|NCT04242017|Experimental|salvage RT + 24 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 24 months ADT
16362344|NCT04242004|Experimental|DHA group|
16362345|NCT04242004|Placebo Comparator|placebo group|
16362346|NCT04241991|Experimental|Active laser|Each participant will receive the application of the active laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
16362348|NCT04241978|Experimental|Intervention group|The participants will complete the baseline assessment and will be asked to read the project information sheet. Then, patients allocated to the intervention group will review the PtDA accompanied by the researcher and will complete the questionnaires assessing the outcome measures, in the same web interface.
16362349|NCT04241978|Active Comparator|Control group|Patients in the control group will follow the same procedure, but they will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
16362350|NCT04241965|Experimental|Intervention 1|Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
16362351|NCT04241965|Placebo Comparator|Placebo|Single dose; potential for a matching OPC-214870 dose to be administered.
16362352|NCT04241952|Experimental|Exercise group|Usual care and bedcycling.
16362353|NCT04241952|No Intervention|Control group|Usual care
16362354|NCT04241939|Experimental|Numberless BDS and Modified-MI|Use of numberless BDS (color coded), app, and motivational interviewing. Participants will weigh daily and receive weekly motivational interviewing at clinic visits and via a weekly phone call.
16362355|NCT04241939|Active Comparator|Digital Scale|Use standard digital scale (number readout). Participants will weigh daily.
16362356|NCT04241913|Experimental|Treatment|The treatment group receives the 10-week, group-based Mom Power intervention; intervention is provided to both mothers and children by trained providers. Treatment delivery will be consistent with the Mom Power manual.
16362357|NCT04241913|No Intervention|Waitlist control|Participants randomized to waitlist control will not receive treatment during the experimental period; they will be offered treatment following completion of post- assessments.
16362358|NCT04241900|Experimental|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
16362359|NCT04241887|Experimental|group PVB|standard analgosedation + paravertebral thoracic blockade with 20 ml 0.25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa warszawa S.A.)
16362360|NCT04241887|Active Comparator|group BB|standard analgosedation + local anesthesia of the skin and subcutaneous tissue with 5ml 0,5% lignocaine (Lignocainum hydrochlorici, WZF 1%).
16362361|NCT04241874|Experimental|Low PEEP and full inspiratory synchronization|PEEP = 5 cmH2O + clinically selected pressure support (PSVclin)
16362362|NCT04241874|Experimental|High PEEP and full inspiratory synchronization|PEEP = 15 cmH2O + clinically selected pressure support (PSVclin)
16362363|NCT04241874|Experimental|Low PEEP and inspiratory desynchronization|PEEP = 5 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
16362364|NCT04241874|Experimental|High PEEP and inspiratory desynchronization|PEEP = 15 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
16362365|NCT04241861|Experimental|High-flow oxygen therapy|Nasal high flow oxygen therapy will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort33. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
16362366|NCT04241861|Experimental|Helmet PSV|"Dedicated helmets for noninvasive ventilation will be used and size will be chosen according to neck circumference or according to manufacturer recommendations.
~Each patient will be connected to a compressed-gas based ventilator through a bitube circuit with no humidification.
~The ventilator will be set in PSV, with the following suggested settings 34-38:
~initial pressure support≥8-10 cmH2O and adequate to permit of a peak in the inspiratory flow of 100 l/min;
~positive end-expiratory pressure=10-12 cmH2O and increased to achieve the oxygenation target according to the choice of the attending physician.
~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
~Inspiratory flow trigger = 1 l/min or according to the practice of each institution;
~fastest pressurization time;
~expiratory trigger: 10-50% of the maximum inspiratory flow;
~maximum inspiratory time 1.2 second."
16362367|NCT04241861|Experimental|Helmet CPAP|"Dedicated helmets for noninvasive ventilation will be uses and size will be chosen according to neck circumference or according to manufacturer recommendations.
~Treatment will be delivered through a high-flow generator. The following settings will be applied:
~Continuous air flow=50-60 L/min.
~Expiratory positive end-expiratory pressure valve set to achieve a PEEP==10-12 cmH2O and eventually increased to achieve the oxygenation target according to the choice of the attending physician.
~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%. Pressure inside the helmet will be monitored with a manometer in order to maintain the set PEEP."
16362368|NCT04241848|Experimental|Powered Orthotic Exoskeleton Training Group|Participant in 36 session ambulation training using a powered orthotic exoskeleton.
16362369|NCT04241848|Active Comparator|Control Group|Participant in 36 session ambulation training without using a powered orthotic exoskeleton.
16362370|NCT04241835|Experimental|Open label Tazemetostat|Single and BID doses of oral tazemetostat 800 mg
16362371|NCT04241822|Experimental|Vestibular exercises combined with cognitive therapy|The intervention is in groups of 8-10 patients. The interventions consists of cognitive therapy, vestibular exercises and body awareness therapy, 8 group sessions
16362372|NCT04241822|Experimental|Exergaming|The intervention is individual and consist of non-immersive virtual reality exercises to improve balance
16362373|NCT04241809||A: Notified TB with sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.
~Repeat bioaerosol sampling will be conducted at 14 days."
16362374|NCT04241809||B: Notified TB without sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.
~Repeat bioaerosol sampling will be conducted at 14 days."
16362375|NCT04241809||C: Not Notified for TB|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.
~Repeat bioaerosol sampling will be conducted at 14 days."
16362376|NCT04241796|Experimental|Elevated Risk and Non-Elevated Risk Groups|"Two cohorts:
~Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.
~Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group."
16362377|NCT04241757||Patient with indication of ElectroCardioGram (ECG)|Patient with indication of ElectroCardioGram (ECG) will be included. They will have a collection of results ElectroCardioGram (ECG).
16362378|NCT04241744|Active Comparator|vancomycin oral solution|vancomycin oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
16362379|NCT04241744|Placebo Comparator|placebo oral solution|placebo oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
16362380|NCT04241731|Experimental|Raltitrexed Plus Cetuximab|Raltitrexed Plus Cetuximab
16362381|NCT04241718|Other|Single-arm|No comparator, placebo, or randomization
16362382|NCT04241705|Active Comparator|Control arm|The control arm will provide optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services.
16362383|NCT04241705|Active Comparator|Reactive Case Detection (RCD) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive, passively-detected index cases at the health post or health center; individuals who reside within a 100-meter radius of the index case will receive diagnosis for malaria using a conventional RDT. Positive individuals will receive treatment and follow-up as per the national treatment guidelines. 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing. Additional procedures will include the collection of a dried blood spot.
16362384|NCT04241705|Experimental|Targeted Mass Drug Administration (tMDA) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive index cases at the health post or health center, all eligible individuals who reside within a 100-meter radius of the index case will receive presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) (0.25mg/kg daily). 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing.
16362385|NCT04241692|Experimental|Application of Carnation Ambulatory Patch Monitoring System|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
16362386|NCT04241692|Experimental|Application Conventional 24-Hour Holter Monitor Recorder|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
16362387|NCT04241679|Experimental|Intervention Group|Patients undergoing a translabyrinthine approach for vestibular schwannoma resection will have the health of their auditory nerve monitored during tumor dissection. If the auditory nerve is visually confirmed to be intact, then concurrent cochlear implantation will be performed.
16362388|NCT04241666||normal renal function|individuals with renal clearance >89 ml/min/1.73m²
16362389|NCT04241666||mild renal insufficiency|individuals with renal clearance 60-89 ml/min/1.73m²
16362390|NCT04241666||moderate renal insufficiency|individuals with renal clearance 30-59 ml/min/1.73m²
16362391|NCT04241653|Active Comparator|Spontaneous Ventilation|Patients will spontaneously ventilated. Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
16362392|NCT04241653|Active Comparator|Unparalyzed Controlled Ventilation|Patients will be mechanically ventilated without muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
16362393|NCT04241653|Active Comparator|Paralyzed Controlled Ventilation|Patients will be mechanically ventilated with muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
16362394|NCT04241640|Experimental|Nefopam group[|
16362395|NCT04241640|Placebo Comparator|placebo group|
16362396|NCT04241627|Experimental|Cell Phone Support|An adherence facilitator will deliver Cell Phone Support by daily phone calls Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
16362397|NCT04241627|Experimental|Live Text Support|An adherence facilitator will deliver Live Text Support, Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
16362398|NCT04241627|Active Comparator|Automated Text Reminders|"The comparison condition will include automated text message reminders, using this template: Take [name of medication] at [set time]. To confirm intake, press REPLY, type CARE 1, and press SEND."
16362399|NCT04241614||The First Hospital of Ji Lin University|CT data and corresponding CT raw data of patients with lung nodule will be collected.
16362400|NCT04241601|Active Comparator|low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Active and Placebo doses appearing identical at point of issue and administration.
16362401|NCT04241601|Placebo Comparator|Placebo|Commercially available dextrose 5% injection with a UK marketing authorisation at equivalent dose volume will be used for the placebo formulation. Placebo and Active doses appearing identical at point of issue and administration.
16362402|NCT04241588||3D prostheses users|Children with unilateral congenital upper-limb reductions
16362403|NCT04241588||Typically Developing Children|Age- and sex-matched control group of typically developing children.
16362404|NCT04241575|Experimental|Intervention group|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:
~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.
~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
16363274|NCT04235309||Total Knee Replacement Cohort|Any patients who are scheduled to undergo a total knee replacement.
16362405|NCT04241575|No Intervention|Control group|Patients in the control group will undergo the same assessments as patients in the intervention group. Although physicians will have access to the raw liver biochemistry results and platelet count, the fibrosis score results will not be specifically shown, and there will be no electronic reminder messages regardless of the fibrosis scores. This is to mimic usual care when there is no dedicated care model for case identification.
16362406|NCT04241549|Experimental|Part 1 (Dose Finding): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
16362407|NCT04241549|Experimental|Part 2 (Dose Expansion): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.
16362408|NCT04241536|Other|No arm|This is an epidemiologic study. No arms are considered.
16362409|NCT04241523|Experimental|Treatment|The patients will receive lenvatinib treatment and will be evaluated for the feasibility of liver resection every 8 weeks. For those who underwent liver resection, they will receive lenvatinib treatment for another 48 weeks. In case of tumor recurrence, intolerance, death, or need for other antitumor treatment, the treatment shall be stopped.
16362410|NCT04241510|Active Comparator|Facilitation Tape|Diaphragm and Intercostal muscles will be taped with facilitation technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
16362411|NCT04241510|Active Comparator|Mechanical Correction Tape|Thorax will be taped with mechanical correction technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
16362412|NCT04241510|No Intervention|No Tape|Patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea with no tape.
16362413|NCT04241497|Experimental|Patients with Pulmonary Arterial Hypertension|12 weeks home-based rehabilitation
16362414|NCT04241484|Experimental|Piezowave|"Initiation of Piezowave MyACT treatment to include parameters from the user manual
~Set for frequency of five pulses per second
~Delivery of 500 to 1000 pulses over multiple injured area sites, not to exceed 4000 pulses per session
~Intensity ranging from 0.1 to 18 millijoule per square millimeter. This intensity if energy flux as the rate of transfer of the energy through the surface of the tissue is applied.
~Focal transducer
~Head size will be variable based on depth of tissue treated. The user manual will be consulted for depth of penetration recommendations"
16362415|NCT04241471|Active Comparator|traditional incision and drainage (I&D)|
16362416|NCT04241471|Experimental|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
16362417|NCT04241458|Experimental|BI 706321|
16362418|NCT04241458|Placebo Comparator|Placebo|
16362419|NCT04241445||novice observers|who have practiced GMA sporadically (def.: < = 2 GMA/week for < = 2 years), have limited experience, and do not use GMA in clinical settings
16362420|NCT04241445||GMA experts|GMA tutors and individuals who have applied GMA regularly (def.: > 2 GMA/week for > 2 years)
16362421|NCT04241432|Active Comparator|Platform type 1|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
16362422|NCT04241432|Active Comparator|Platform type 2|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
16362423|NCT04241419|Experimental|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
16362424|NCT04241406|Experimental|transcutaneous spinal cord stimulation|"Transcutaneous application of electrical (biphasic current, 1ms, 30Hz) stimulation over the back for a 10 minutes session.The intensity of the current will increase until motor reflex threshold. If it will not possible, intensity will be increase until participants report a strong but comfortable sensation.
~Transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
16362425|NCT04241406|Experimental|sham stimulation|"Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequently.
~Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
16362426|NCT04241393|Experimental|Tavapadon|
16362427|NCT04241380|Active Comparator|Conventional treatment group|Patients in this group will received conventional treatments. Drug: None. Drug: For the high-risk patients, doctors will assess their risk factors and choose continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) if needed. Aspirin 5 mg/kg may be given every eight hours subsequently for 3 months.
16362428|NCT04241380|Experimental|Anti-coagulant treatment|Continuous infusion heparin. Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5mg/kg will be given every eight hours subsequently for three months. Study will follow the intention-to-treat principle.
16362429|NCT04241354|Active Comparator|Intra-articular LP-PRP Injection|A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.
16362430|NCT04241354|Experimental|Intra- and extra- articular LP-PRP Injection|A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.
16362431|NCT04241341|Experimental|axillary lymph node dissection with ILR|
16362432|NCT04241341|Active Comparator|axillary lymph node dissection (ALND) without ILR|
16362433|NCT04241315|Experimental|Near-Infrared Imaging group|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
16362434|NCT04241315|Other|No Imaging Group|All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
16363275|NCT04235296|Active Comparator|control group|epidermal growth factor
16362435|NCT04241302|Active Comparator|Free Field Voice test|The examiner will inform the patient to repeat a sequence of Spondee words or a combination of numbers and letters whispered by the examiner initially. The examiner will be standing at the same distances as in the FFCT examination (starting with 2 feet). If the patient fails to hear the whispered voice at 2 feet, the examiner increases the loudness of voice to conversational tone at the same distance. The test is repeated thrice each time with a different set of Spondee words to avoid the patients recognizing the same sequence. If the patient is unable to respond, the examiner moves closer to 6 inches and whispers to the patient, and if no further response, then, conversational voice is used. The patient's free-field threshold is the voice and distance level at which more than 50% correct is obtained.
16362436|NCT04241302|Experimental|Free Field Click Test|The app is designed by our team by a broadband (500-3000 Hz) click sound of 30-40 dB for soft sound/whisper and 60-70dB for loud sound/conversation voice. This app is designed by the Flutter-Dart programming tool and the speaker is produced via hand-held devices of Apple and Android brands. The tone is produced 3 times, with 2 out of 3 answers are considered as the patient's hearing threshold. The examiner stands at the distance of 2 feet away behind the seated patient and a soft sound from the FFCT is tested. The patient is then asked to respond yes or to nod if able to hear the sound. When the patient is unable to answer or no response is received upon thrice testing, the examiner then moves closer to 6 inches to the patient and again the soft sound is tested thrice. Loud sound is then tested if the patient is unable to respond, starting from 2 feet distance for three times. And then, the loud sound is tested at 6 inches of distance if no further response is obtained.
16362437|NCT04241276|Active Comparator|Gemcitabine + nab-paclitaxel|Patients will receive Gemcitabine and nab-Paclitaxel in 28 day cycles until disease progression.
16362438|NCT04241276|Experimental|Gemcitabine + nab-paclitaxel + ATRA|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
16362439|NCT04241263|Other|Comparative assessment of data quality|Quantitative comparison between the current wired system and the new wireless system
16362440|NCT04241263|Other|Usability|Qualitative assessment of the new wireless system
16362441|NCT04241250|Experimental|EAW+SCES|Three months of exoskeleton training followed by 6 months of epidural stimulation.
16362442|NCT04241250|Experimental|EAW+TS|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
16362443|NCT04241237||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
16362445|NCT04241211|Active Comparator|Control group|
16362446|NCT04241211|Experimental|TP group|
16362449|NCT04241172|Experimental|Immersive Virtual Reality (HIVR)|"The HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:
~Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;
~Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving visual and auditory biofeedback."
16362450|NCT04241172|Active Comparator|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:
~exercises with patients sitting on the swimming pool edge with lower limb immersed in the water;
~flexion-extension of the knee;
~leg and hip circling;
~flexion-extension of the ankle;
~triple flexion;
~water walking exercises."
16362451|NCT04241172|Active Comparator|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:
~exercises with a patient sitting on a chair (3 minutes per exercise):
~flexion-extension of the knee;
~leg and hip circling;
~flexion-extension of the ankle;
~triple flexion;
~walking (with and without aids)."
16362452|NCT04241159|Experimental|Geriatric participants with frailty|"Geriatric participants aged 65-80 who have a diagnosis of frailty (Fried Frailty score of 3 or greater).
~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
16362453|NCT04241159|Experimental|Geriatric participants with HFpEF|"Geriatric participants aged 65-80 who have a diagnosis of HFpEF.
~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
16362454|NCT04241146|Active Comparator|Standard Blind Technique of Tube placement|FDA approved technique of enteral nutrition tube placement
16362455|NCT04241146|Active Comparator|CORTRAK enteral access system (CEAS) placement|An electromagnetic device used to enable enteral nutrition tube placement
16362492|NCT04240873|Placebo Comparator|Saline|Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis
16362524|NCT04240626|Experimental|Multi-Modal|Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.
16362456|NCT04241133|Experimental|Experimental Group|A 12 week pilot trial will be conducted at two rural food pantries in Montana with 40 low-income adults to measure within-participant changes over time. The study will provide the initial investigation of the extent to which UP3 will improve overall dietary quality as measured by the Healthy Eating Index-2015 (HEI) compared to baseline. Psychosocial factors will be measured to understand changes in knowledge, attitudes, and perceptions about processed foods. Data on biomarkers of health (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to assess the feasibility of measuring potential short-term health effects of UP3.
16362457|NCT04241133|No Intervention|Control Group|20 separate participants from a different food pantry will be enrolled into a control group. The control group will be assessed at baseline and 12 weeks for dietary intake, height, weight, waist circumference, food security, demographics, and psychosocial factors.
16362458|NCT04241120|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
16362459|NCT04241120|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
16362460|NCT04241107|Active Comparator|Laparoscopic approach group(A)|Uterine niche will be repaired through Laparoscopic approach.
16362461|NCT04241107|Active Comparator|Transvaginal approach group(B)|Uterine niche will be repaired through Transvaginal approach.
16362462|NCT04241094|Experimental|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
16362463|NCT04241081|No Intervention|Control group-no exercise|A no-exercise control. Must maintain <4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
16362464|NCT04241081|Experimental|Exercise intervention 1|Two consecutive days of <4,500 steps per day followed by an intervention day on day 3. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 2 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
16362465|NCT04241081|Experimental|Exercise intervention 2|Two consecutive days of <4,500 steps per day followed by an intervention day. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 6 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
16362466|NCT04241068|Experimental|Aducanumab|Participants will be administered 10mg/kg aducanumab by intravenous (IV) infusions every four weeks for a total duration of 100 weeks.
16362467|NCT04241055|Active Comparator|Control|"The control condition of a standard values affirmation intervention"
16362468|NCT04241055|Experimental|Values affirmation|"The treatment condition of a standard values affirmation intervention"
16362469|NCT04241042||Down syndrome volunteers|Males and females from 16 to 35 years
16362470|NCT04241042||Healthy volunteers|Males and females from 18 to 35 years
16362471|NCT04241029|Experimental|Intervention with probiotics|Intervention with the probiotic compound IDOFORM®Travel. The patient will receive four capsules orally every 24 hour (12*10^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment. The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
16362472|NCT04241016|Active Comparator|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery. Postoperative treatment consists of daily nasal douching, daily nasal steroid sprays, pain medication when necessary and at least one postoperative control visit including endoscopy two weeks after the operation. Additionally medical treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
16362473|NCT04241016|No Intervention|Control|Conservative treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
16362474|NCT04241003|Experimental|SmartDrive - baseline and intervention|One arm for all users. Baseline - two weeks data collection documenting usage of wheelchair prior to intervention. Introduction of SmartDrive, a time period to get used to the SmartDrive and then two weeks data collection documenting usage of wheelchair with the intervention.
16362475|NCT04240990|Experimental|Prospective cohort|Children included in the cohort will all be in the same arm. The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.
16362476|NCT04240977|Experimental|Treatment Group|
16362477|NCT04240964||Dd group|Patients with diabetic foot osteomyelitis
16362478|NCT04240964||ND group|Foot osteomyelitis without diabetes
16362479|NCT04240951|Other|Study Session 1|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the laboratory
16362480|NCT04240951|Other|Study Session 2 (repeat of Study Session 1)|Arm Type: Validation: Regional sweat collection with prototype vs. reference patch in the laboratory
16362481|NCT04240951|Other|Study Session 3|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
16362482|NCT04240951|Other|Study Session 4 (repeat of Study Session 3)|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
16362483|NCT04240951|Other|Study Session 5|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
16362484|NCT04240951|Other|Study Session 6 (repeat of Study Session 5)|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
16362485|NCT04240938|Other|Lacrimal sac mucocele|Adult patients with lacrimal sac mucocele
16362486|NCT04240925|Experimental|Standard NIMV protocol with sigh breaths|
16362487|NCT04240925|Active Comparator|Standard NIMV protocol without sigh breaths|
16362488|NCT04240899|Experimental|Tele-yoga|This is a single group study, therefore all subjects will be included in this single arm and will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
16362489|NCT04240886|Experimental|Cohort A: fosmanogepix (APX001)|
16362490|NCT04240886|Experimental|Cohort B: fosmanogepix (APX001)|
16362491|NCT04240873|Experimental|MASTER cell|Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis
16362493|NCT04240860|Experimental|platelet rich plasma preparation|"About 15 ml of autologous blood from the patient was collected slowly in 20 ml syringe containing 1.5 ml anticoagulant citrate dextrose solution A (ACDA) under complete aseptic precautions.
~2- Blood was mixed by swinging the syringe slowly. 3- By using 18G needle, the gathered blood was transfused into tube maintaining a slope of 45°.
~4- The centrifugation step was then done by using non digital angle type centrifuge :the tube was put with water tube on the opposite side to achieve centrifuge balance.
~5- The centrifugation occurred in one step by power 3600 RPM for 6 minutes. 6- The buffy coat was elevated up to the buffy coat line (Figure 1). 7- the buffy coat (2-3 ml PRP) was extracted from slim neck by tornado technique so that sunk platelets can be floated and drawn easily.
~8- the remaining platelet poor plasma(PPP) was drawn using 5 cc syringe. then inserted by ovum pick up needle into subendometrium"
16362494|NCT04240860|Active Comparator|endometrial scratch|using scissor of hysteroscopr 3 snips was done in the fundus
16362495|NCT04240847|Active Comparator|Midline incision|Skin incision at the midline, 1 cm medial to tibial tubercle
16362496|NCT04240847|Experimental|Lateral incision|Skin incision at 1 cm lateral to tibial tubercle
16362497|NCT04240834|Experimental|LD group|Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months
16362498|NCT04240834|Active Comparator|Control group|Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months
16362499|NCT04240821|Experimental|Open-label theophylline|Oral theophylline - either once daily capsule or q6h elixir.
16362500|NCT04240808|Experimental|UCD19 CAR T Cells|Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes
16362501|NCT04240795|Experimental|Low lubricity (LL) hydrogels containing fibre-based beads|"Participants are given a preload of 30 g of low lubricity hydrogels (alginate beads in kappa-carrageenan hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
16362502|NCT04240795|Active Comparator|High lubricity (HL) hydrogels containing no fibre-based beads|"Participants are given a preload of 30 g of high lubricity hydrogels (no beads in kappa-carrageenan and alginate mixed hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
16362503|NCT04240795|Placebo Comparator|Water|"The water containing the same watermelon flavor, color and sweetness was given as control to match the gels. Participants receive the same amount of water like hydrogels - 30 g after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
16362504|NCT04240782|Experimental|Education with Produce Allocations|Participants will attend nutrition education and hands-on cooking classes with weekly produce allocations from a local farm.
16362505|NCT04240782|Experimental|Education only|Participants will attend nutrition education and hands-on cooking classes (with produce coupons provided after intervention).
16362506|NCT04240782|No Intervention|Control group|Participants will receive a delayed intervention once the study period is over.
16362507|NCT04240769||Knee Arthroplasty Patient|Patients undergoing primary total or unicompartmental knee arthroplasty for treatment of end-stage osteoarthritis.
16362508|NCT04240756|Experimental|Parent Stimulant Medication + Child Treatment Strategy|Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
16362509|NCT04240756|Active Comparator|Child Treatment Strategy|Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired. In this arm, parents do not receive stimulant medication before behavioral parent training.
16362510|NCT04240743|Active Comparator|cephalomedullary nail|Cephalomedullary nails was inserted and fixed to the femoral head. In this study, all patients were treated with short nails (Profin®, TST).
16362511|NCT04240743|Active Comparator|sliding hip screw|Sliding hip screws was inserted and fixed to the femoral head. In this study, all patients were treated with a side plate with three holes (DHS plate, TST).
16362512|NCT04240730||extremely obese patients with early-stage endometrial cancer|
16362513|NCT04240717|Experimental|Patient Decision Aid|Patients review an interactive, web-based Patient Decision Aid regarding their treatment options. Afterwards they receive medical consultation.
16362514|NCT04240717|No Intervention|Treatment As Usual|Patients receive medical consultation.
16362515|NCT04240704|Experimental|JBH492 single agent|
16362516|NCT04240691||60-Minutes-For-Health|60-Minutes-for Health: this is a psychological intervention which seeks to correct factors underlying decisions to delay or avoid HIV care and strengthen abilities to overcome HIV care utilization barriers. This is achieved through assistance identifying and reducing misinformation guiding HIV care attendance decisions; enhancing motivation to maintain HIV care via personal health goals; building skills for coping with negative feelings related to living with HIV; and increasing self-efficacy for navigating structural barriers and maintaining HIV care amidst competing priorities.
16362517|NCT04240691||Time-and-Attention Control Session|60 Minute diet & nutrition control session
16362518|NCT04240678|Experimental|HBV Alert Group|
16362519|NCT04240678|No Intervention|Control Group|
16362520|NCT04240665|Experimental|DMN Intervention|Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
16362521|NCT04240652||Subjects with fundus photography|Subjects diagnosed with diabetes or not who have fundus images from MMCs and other medical institutes.
16362522|NCT04240639|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to MRI/US guided laser irradiation using an FDA cleared laser and an interstitial optical fiber diffuser.
16362523|NCT04240626|Active Comparator|Standard of Care|The group will receive the standard of care pain control protocol after index Bariatric Surgery which includes the use of a PCA (patient controlled analgesia) with Dilaudid or Morphine Sulphate, transitioning to oral narcotic based pain control medications.
16362525|NCT04240613|Other|women treated by TVT-O|All women treated by TVT-O during the years this study was made were included.
16362526|NCT04240600|Experimental|Hyperproteic, hypercaloric formula|Each patient will receive 2 bottles per day of Supportan DKN during the hospital stay (nutritional contribution: 600 kcal and 40 g of protein).
16362527|NCT04240600|Active Comparator|Standard formula|Each patient will receive 2 cans or bottles per day of Fresubin® Original DRINK (nutritional contribution: 474.2 kcal and 17.6 g of protein).
16362528|NCT04240587|Active Comparator|TrueTear™ intranasal neurostimulator (ITN) Active Arm|TrueTear™ intranasal neurostimulator (ITN) with active tips - The tips carry the current from the base to the nasociliary nerve.
16362529|NCT04240587|Placebo Comparator|TrueTear™ intranasal neurostimulator (ITN) Placebo/Sham Arm|"TrueTear™ intranasal neurostimulator (ITN) with sham tips - The sham tips and do not properly carry the current."
16362530|NCT04240574|Other|Micro Water Jet Technology (Debritom)|"Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
~All subject will get the Debritom."
16362531|NCT04240561|Experimental|Hearing Aid Fitting Order A|Participants wear hearing aids with a high level of signal manipulation, followed by a low level of signal manipulation
16362532|NCT04240561|Experimental|Hearing Aid Fitting Order B|Participants wear hearing aids with a low level of signal manipulation, followed by a high level of signal manipulation
16362533|NCT04240548|Experimental|Arm: A|regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation
16362534|NCT04240548|No Intervention|Arm: B|chest wall or whole breast only irradiation
16362535|NCT04240535|Experimental|Active- onabotulinumtoxinA|BOTOX Cosmetic (onabotulinumtoxinA) for injection, is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A intended for intramuscular use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The complex is dissolved in sterile sodium chloride solution containing Albumin Human and is sterile filtered (0.2 microns) prior to filling and vacuum-drying.
16362536|NCT04240535|Placebo Comparator|Placebo-Bacteriostatic 0.9% Sodium Chloride|Placebo subjects will have injections in the same manner, but will be injected with Bacteriostatic 0.9% Sodium Chloride.
16362537|NCT04240496|Other|Schizophrenic patients|"Determination of trough plasma concentration of clozapine (C0)
~Genotyping of CYP1A2 & CYP2C19 Drug: Leponex (Clozapine) : was started at a dose of 25 mg/j, the dose was gradually increased and was administered in one, two or three divided doses."
16362538|NCT04240483|Experimental|Intracutaneous sterile water injections (ISWI) group|
16362539|NCT04240483|Sham Comparator|Intracutaneous dry injections (IDI) group|
16362540|NCT04240470|Experimental|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
16362541|NCT04240457|Experimental|Pulsed, accelerated|18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
16362542|NCT04240457|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination.
16362543|NCT04240444|Experimental|SeQuent® SCB|patients will receive sirolimus (rapamycin)-coated balloon (SeQuent® SCB)
16362544|NCT04240444|Active Comparator|SeQuent® Please Neo|patients will receive SeQuent® Please Neo balloon
16362545|NCT04240431||Epiphora|Adult patients suffering from watering of the eye included in the study to detect level of obstruction
16362546|NCT04240418||Lyon University Hospital employees|
16362547|NCT04240405||Elderly people without cognitive impairment|
16362548|NCT04240405||Amnestic type mild cognitive impairment patients (aMCI)|
16362549|NCT04240405||Dysexecutive type mild cognitive impairment patients (dMCI)|
16362550|NCT04240392|Experimental|Collaborative Care (CC)|The CC team includes an obstetrical provider and a nursing case manager. The obstetrician will see all participants, initially to discuss preferences for addiction treatment, buprenorphine, methadone (MAT) or no MAT. The obstetrician will see participants every 1-2 weeks, as needed and will provide prenatal care. The care team will meet at least monthly and review the participants' status. For research purposes, the CM will obtain informed consent, collect and enter results of the urine drug screen (UDS) into a database. At enrollment and at 26 and 34 weeks' gestation the care manager will ask participants to complete an assessment battery of self-reported measures.
16362551|NCT04240392|Active Comparator|Extension for Community Healthcare Outcomes (ECHO)|ECHO is a remote education model that provides mentorship and guided practice and participation in a learning community, via video conferencing. The practice members who participate in ECHO will include obstetricians and nurses as well as other members of the care team who wish to join. Providers are given access to a password-protected website containing the recorded sessions, a discussion board, and resource library. CME credits are available for each session and can motivate providers to attend.
16362552|NCT04240366|Other|Group 1|Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone
16362553|NCT04240366|Experimental|Group 2|Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation
16362554|NCT04240353||COPD group|Patients with high-risk COPD with recent exacerbation requiring hospitalisation (within last 12 months) or hypercapnia respiratory failure and/or sleep disordered breathing meeting criteria for provision of home NIV.
16362556|NCT04240314|Experimental|Cohort 1 (Minimal Efficacious Dose)|The Minimal Effective Dose (MED) will be delivered.
16362635|NCT04239677|Experimental|RAP|Retrograde autologous priming
16362636|NCT04239664|Experimental|Acceptance Based Telephone Support (ABS+UC)|One face-to-face session to be informed of the group they have been randomised into and Acceptance Based Support, followed by five 30-minute telephone sessions of Acceptance Based Support. Usual care continues as normal.
16362559|NCT04240275||Children with Cerebral Palsy|Children diagnosed with Spastic Cerebral Palsy (Unilateral or Bilateral) among the age range of 5-15 who can walk independently
16362560|NCT04240249|Experimental|Constructive self-assertiveness with guidance|10 weeks of internet-based treatment with weekly assignments. The homework is commented on by the guide using electronic communication.
16362561|NCT04240249|Experimental|Constructive self-assertiveness without guidance|10 weeks of internet-based treatment with weekly assignments. The homework is NOT commented on by any guide. Hence, same treatment as group 1 but without guidance.
16362562|NCT04240249|No Intervention|Waitlist control|No treatment, no guidance, just waiting for 10 weeks. After the ten weeks the participants will receive the treatment.
16362563|NCT04240236|Experimental|Group S|Group S received scalp block with 20 ml of 0.5% bupivacaine
16362564|NCT04240236|Placebo Comparator|Group C|Group C will not have any intervention
16362565|NCT04240223|Experimental|50 mg Brilacidin tablet|
16362566|NCT04240223|Experimental|100 mg Brilacidin tablet|
16362567|NCT04240223|Experimental|200 mg Brilacidin (2 x 100 mg Brilacidin tablets)|
16362568|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 50 mg tablet)|
16362569|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 100 mg tablet)|
16362570|NCT04240223|Placebo Comparator|Placebo (2 x replica of shape/size of 100 mg tablets)|
16362571|NCT04240210|No Intervention|To assess degree of adherence to ART in a real world seeting.|Part I of the study is a Cohort Survey of HIV+ outpatient clinic patients currently receiving ART to assess medication adherence and tolerability by determining a change in adherence and tolerability from baseline to 4 months, measured by standardized patient reported outcome and adherence surveys
16362572|NCT04240210|Experimental|Potential changes in ART adherence when switced to Symtuza.|Part 2 of the study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
16362573|NCT04240197|Sham Comparator|Standard Pressure Transducer|Epidural pressure waveforms will be measured by using a standard invasive monitor pressure transducer
16362574|NCT04240197|Active Comparator|CompuFlo|Epidural pressure waveforms will be measured by using the CompuFlo Instrument
16362575|NCT04240171||dapagliflozin|Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
16362576|NCT04240171||glimepiride|Group 2 (n=30): are the patients who are prescribed glimepiride
16362577|NCT04240158|Experimental|IW-6463|IW-6463 tablets administered orally
16362578|NCT04240158|Placebo Comparator|Placebo|Matching placebo tablets administered orally
16362579|NCT04240132|Experimental|Adherence to hand hygene|The face-to-face interview will be held in an appropriate empty room in the intensive care unit (ICU) in a time schedule suitable for the healthcare workers. The researchers will provide training to healthcare workers working in the ICU in accordance with the World Helath Organization (WHO) Hand Hygiene Guidelines. One day training on nursing interventions related to enteral feeding treatment will be provided to nurses and their questions will be answered. At the end of the each training, trainees will be given a data collection form to assess the effectiveness of the training.
16362580|NCT04240106|Experimental|Niraparib 100mg in combination with Aromatase Inhibitors|Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
16362581|NCT04240093|Experimental|Experimental|Experimental: Behavioral Activation (8 sessions) + Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
16362582|NCT04240093|Active Comparator|Standard of Care|Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
16362583|NCT04240080|No Intervention|Control Goup|Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping
16362584|NCT04240080|Experimental|Intervention Group|Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder
16362585|NCT04240067||Acute Heart Failure|
16362586|NCT04240067||No Acute Heart Failure|
16362587|NCT04240054|Experimental|Safety Lead-in Cohort A|"Six transplant-eligible multiple myeloma patients with renal impairment will be enrolled.
~Bortezomib (1.5 mg/m^2) subcutaneous on days 1,8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
16362588|NCT04240054|Experimental|Expansion Cohort A|"15 transplant-eligible multiple myeloma patients with renal impairment will be enrolled.
~Bortezomib (1.5 mg/m^2)subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
16362589|NCT04240054|Experimental|Expansion Cohort B|"20 transplant-eligible non-renal impairment multiple myeloma patients will be enrolled.
~Bortezomib (1.5 mg/m^2) subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
16362590|NCT04240041||Pregnant women at 32-36 weeks gestational age|Pregnant women at 32-36 weeks gestational age with sure dates and crown-rump length dating ultrasound
16362637|NCT04239664|No Intervention|Usual Care (Control Group) (UC)|One face to face session to be informed of the group they have been randomised into and encouraged to ask any questions, and will be informed they will be contacted again in 8 weeks. Usual care continues as normal.
16362788|NCT04238650|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16362591|NCT04240028||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking as identified by an unintentional weight loss of ≥ 5% between two assessments, 2) Weakness as identified by a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy as identified by an answer of no to the question Do you feel full of energy? from the 30-item Geriatric Depression Scale; 4) Slowness as identified by an average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level as identified by a PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
16362592|NCT04240028||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).
~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.SCI will be defined using a proxy for subjective cognitive complaint (i.e. memory complaint) and following the procedure used in previous multicenter prevalence studies on MCR syndrome. Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item or 30-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?). Memory complaint in our study will be elicited from this item of 30-item GDS."
16362593|NCT04240028||Individuals with MCR|The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
16362594|NCT04240015||Periodontitis|Periodontitis group consisted of patients diagnosed with periodontitis
16362595|NCT04240015||Patients without periodontitis|Patients without periodontitis group constituted patients without periodontitis
16362596|NCT04240002|Experimental|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
16362597|NCT04240002|Experimental|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
16362598|NCT04240002|Experimental|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
16362599|NCT04240002|Experimental|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
16362600|NCT04239989|Experimental|Treatment (itacitinib)|Patents receive itacitinib PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity.
16362601|NCT04239976|Experimental|Supportive Care (scrambler therapy, sensory test, gait test)|Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.
16362602|NCT04239963||Healthy Controls|Subjects who have no history of clinical depression or other psychological disorder
16362603|NCT04239963||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
16362604|NCT04239950|Placebo Comparator|Placebo|Placebo, orally, twice daily after breakfast and dinner for 12 weeks.
16362605|NCT04239950|Experimental|Ethyl Icosapentate 1.8g|Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.
16362606|NCT04239950|Experimental|Ethyl Icosapentate 3.6g|Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.
16362607|NCT04239924|Experimental|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program
16362608|NCT04239911|Active Comparator|Enhanced usual care|Home health aides in the enhanced usual care arm will receive a heart failure training course .
16362609|NCT04239911|Experimental|Intervention arm|Home health aides in the intervention arm will receive a heart failure training course and an electronic tablet.
16362610|NCT04239898|Experimental|Red cabbage microgreens|2 cups of fresh red cabbage microgreens per day
16362611|NCT04239898|Experimental|Red beet microgreens|2 cups of fresh red beet microgreens per day
16362612|NCT04239872|Experimental|Participants with normal to dry mouth|"Participants with normal to dry mouth will be treated, in a crossover design, with two interventions: a fluoride mouthwash alone, or a fluoride mouthwash preceded by a calcium mouthwash.
~Participants will be randomized to determine which intervention they will use in the first experimental phase; the other intervention will the tested in the second phase."
16362789|NCT04238637|Experimental|Arm 1|Durvalumab
16362613|NCT04239859|Experimental|Secukinumab|"Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.
~secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care."
16362614|NCT04239859|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.
~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
16362615|NCT04239846|Experimental|AC-701|AC-701 Topical Gel 0.3%
16362616|NCT04239846|Placebo Comparator|Placebo|Placebo Gel
16362617|NCT04239833|Experimental|SH-1028 tablets+Placebo Gefitinib|"SH-1028 tablets (200 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
~Interventions:
~Drug: SH-1028 tablets 200 mg Drug: Placebo Gefitinib 250 mg"
16362618|NCT04239833|Active Comparator|Gefitinib+Placebo SH-1028 tablets|"Gefitinib (250 mg orally, once daily) plus placebo SH-1028 tablets (200mg orally, once daily), in accordance with the randomisation schedule.
~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).
~Interventions:
~Drug: Gefitinib 250 mg Drug: Placebo SH-1028 tablets 200mg"
16362619|NCT04239820||RRMS patients initiating cladribine|Patients will be imaged using PET and MRI at baseline prior the cladribine treatment initiation and 18 months after baseline
16362620|NCT04239807|Experimental|Group 1 WBV - training with wbv|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera
~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).
~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training
~Month 1:
~Day 1: From this day subjects are supposed to start their training accoridng to protocol
~Day 2: Telephone Visit
~Day 5: Telephone Visit
~Day 7: Telephone Visit
~Day 10: Telephone Visit
~Day 13: Telephone Visit
~Day 20: Telephone Visit
~Day 27: Telephone Visit
~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training
~Month 2:
~Week 5, Day 34:
~Week 6, Day 41:
~Week 7, Day 48:
~Week 8, Day 55:
~Month 3:
~Week 9, Day 62:
~Week 10, Day 69:
~Week 11, Day 76:
~Week 12, Day 83: Final Visit"
16362621|NCT04239807|Other|Group 2 Control - training without WBV|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera
~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).
~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training
~Month 1:
~Day 1: From this day subjects are supposed to start their training accoridng to protocol
~Day 2: Telephone Visit
~Day 5: Telephone Visit
~Day 7: Telephone Visit
~Day 10: Telephone Visit
~Day 13: Telephone Visit
~Day 20: Telephone Visit
~Day 27: Telephone Visit
~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training
~Month 2:
~Week 5, Day 34:
~Week 6, Day 41:
~Week 7, Day 48:
~Week 8, Day 55:
~Month 3:
~Week 9, Day 62:
~Week 10, Day 69:
~Week 11, Day 76:
~Week 12, Day 83: Final Visit"
16362622|NCT04239794|Active Comparator|Inhalation anesthesia|Patients are anesthetized with sevoflurane and remifentanil infusion for maintenance of anesthesia during the surgery
16362623|NCT04239794|Experimental|Total intravenous anesthesia|Patients are anesthetized with target-controlled intravenous infusion of propofol and remifentanil infusion for maintenance of anesthesia during the surgery
16362624|NCT04239768|Experimental|MonoDermà HA gel combined to a low level laser|"Monodermà HA Bio-revitalizing gel is a sterile, biodegradable, isotonic intradermal filler produced by Innate S.r.l. (Italy) and distributed by Giuliani S.p.A. (Italy) in non-pyrogenic pre-filled syringe of 2 ml containing 2% (20mg/ml) of medium chain (1.0-1.5 x 106 Dalton) hyaluronic acid (HA), obtained from bacterial fermentation, in a physiologic buffer (see Appendix 1) and used as a filler for the correction of deep skin sagging and roughness."
16362625|NCT04239755|Active Comparator|Doxycycline|Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.
16362626|NCT04239755|Placebo Comparator|Placebo|group (2) will be 25 patients will receive placebo in addition to the standard treatment.
16362627|NCT04239742|Experimental|18F-PSMA PET/CT and 18F-Fluciclovin PET/CT|patients undergo an 18F-PSMA PET/CT scan and an 18F-Fluciclovin PET/CT scan, within a time frame of two weeks.
16362628|NCT04239729|Experimental|ACT Website and Coaching Condition|Participants will be asked to complete 16 brief self-help website sessions, each taking around 15-20 minutes to finish, twice a week for eight weeks. Website exercises and examples primarily focus on hoarding, although some examples also discuss related mental health concerns such as anxiety, low mood, health behaviors, etc. The sessions use multimedia and are interactive. Participants assigned to the website condition will also receive coaching. The purpose of coaching will be to help participants engage with the website and adhere to the intervention. Coaching will consist of an initial phone call of 10-15 minutes followed by weekly email contact during the 8-week treatment period. Coaches will be graduate students trained in clinical psychology.
16362629|NCT04239729|No Intervention|Waitlist Condition|Participants assigned to the waitlist will be asked to wait 12 weeks without intervention (access to the website or coaching). They will receive access to the website after 12 weeks, but supportive coaching will not be provided to waitlist participants.
16362631|NCT04239703||Kidney transplant biopsies for cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.
16362632|NCT04239690|Experimental|Micromethods for blood sample analysis|Blood gases are analysed using 0.045 ml whole blood Levels of CRP are analysed using 0.010 ml whole blood
16362633|NCT04239690|No Intervention|Standard clinical methods for blood sample analysis|Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
16362634|NCT04239677|Active Comparator|control|Conventional crystalloid solution-based priming
16362638|NCT04239651|Active Comparator|Enrolment in rTMS sessions alone|All patients will be scheduled to receive 30 sessions of rTMS treatments over a six-week period as pre-determined by Alberta Health Services' Strategic Clinical Network for Addiction and Mental Health.
16362639|NCT04239651|Active Comparator|Enrolment in iCBT Plus rTMS|Patients in the rTMS plus iCBT arm of the study, would be assisted to register on the iCBT program (Moodgym) to receive unique login information. They would be assisted to participate in 12 one-hour sessions of iCBT at the clinic prior to receiving rTMS treatments. These in-clinic iCBT sessions would be scheduled in about three days intervals (ideally Tuesdays and Thursdays) so that patients receive two iCBT sessions each week. Patients would also be encouraged to continue with iCBT treatments on their own at home outside the sessions delivered in the clinic.
16362640|NCT04239625|Experimental|ALK-001|
16362641|NCT04239612|Other|Physical exercise|Specified circular training, 60 minutes, 1-3 times/week
16362642|NCT04239599|Experimental|Hypofractionation|Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost) + 18-36 months of Eligard Hormone injection.
16362643|NCT04239599|Active Comparator|Standard Fractination|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy + 18-36 months of Eligard Hormone injection.
16362644|NCT04239586|Experimental|Sulfonylurea treatment group|Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.
16362645|NCT04239573|Experimental|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
16362646|NCT04239573|Experimental|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
16362647|NCT04239560|Experimental|Boron-based Gel|During each radiation therapy session, 15 minutes before radiotherapy, 3% sodium pentahydrate panteurate will be used.
16362648|NCT04239560|Placebo Comparator|Radiation Traumatic Dermatitis Treated with Placebo|During each radiotherapy session, 15 minutes before radiotherapy, the gel will be free of any chemical treatments
16362649|NCT04239547|Experimental|Recruitment|Patients classified to receive recruitment maneuver + 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
16362650|NCT04239547|Experimental|Non-recruitment|Patients classified to receive only 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
16362651|NCT04239534|Other|Single Arm|In this Single Arm Study, Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access. Followed by the sue of an endocardial ablation catheter that will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.
16362652|NCT04239521||Cases|Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis.
16362653|NCT04239521||Controls|The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level.
16362654|NCT04239508||Minimal Neonatal Dataset MNDS|All Swiss live-born infants below 32 weeks gestational age or 1501g birth weight
16362655|NCT04239508||Below 34, B34|All Swiss live-born infants between 32 0/1 and 33 6/7 weeks gestational age that are above 1500g birth weight
16362656|NCT04239508||Swiss Asphyxia and Cooling Registry, ASP|Infants between 35 0/7 and 42 6/7 weeks' gestational age with moderate or severe encephalopathy due to perinatal asphyxia
16362657|NCT04239482|Experimental|L-arginine + Nitrate/Nitrite|Subjects will receive 1 L-arginine tablet per day and drink 35 mL of beetroot juice for 8 weeks.
16362658|NCT04239482|Placebo Comparator|Placebo|Subjects will receive 1 cellulose tablet per day and drink 35 mL of nitrate/nitrite depleted beetroot juice for 8 weeks.
16362659|NCT04239469|Active Comparator|KL16-012|Patients will use a liquid standardized extract of cannabis sativa. Each drop will contain 1 mg of THC and 0.45 mg of CBD. Administration will be sublingual, while dosing will begin at 3 drops per day and be escalated to 15 drops per day by week 5 according to an escalation chart.
16362660|NCT04239469|Placebo Comparator|Placebo|Patients will use a liquid placebo identical to the active principle in both appearance and taste.
16362661|NCT04239456|Experimental|Group A|Receive intervention 2 weeks after group assignment.
16362662|NCT04239456|Other|Group B|Wait List - Receive intervention 3 months after initial testing.
16362663|NCT04239443|Experimental|SHR1210 and Apatinib|"NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).
~The duration of treatment will till the disease progression, death, or unacceptable toxicity show up."
16362664|NCT04239417|Experimental|The Study group A|graduated abdominal strengthening exercises group
16362665|NCT04239417|Experimental|The Study group B|Russian stimulation group
16362666|NCT04239417|Experimental|The Study group C|combination group
16362667|NCT04239417|No Intervention|The Control group D|presume in normal activities of daily living.
16362668|NCT04239404||PMI|
16362669|NCT04239404||non-PMI|
16362705|NCT04239209|Active Comparator|Redirection|Redirection to a conversation about the values of the patient and possible future decisions.
16362790|NCT04238637|Experimental|Arm 2|Durvalumab in combination with Tremelimumab
16362670|NCT04239391|Experimental|Triferic via IV and Hemodialysate|Upon completion of the Baseline observational periods, all enrolled patients will transition to the interventional period where they will then receive Triferic. The Triferic will be administered via the liquid bicarbonate concentrate at a dialysate concentration of 2 uM or via IV at a dose of 0.1 mg Fe/kg, if the patient does not receive dialysis using liquid bicarbonate, for up to an additional 36 weeks (depending on duration of observational Baseline period). Hgb and CHr will continue to be measured bi-weekly and iron profiles will be obtained at 4 week intervals. In the Triferic phase of the study,changes in ESA dose will be allowed according to the study site existing protocol. IV iron will only be administered if ferritin meets the criteria for iron deficiency. Patients will remain in the interventional period for either 36 or 28 weeks (depending on randomization assignment), at which time a final study visit will take place
16362671|NCT04239391|No Intervention|Historic Control Observational Arm|Up to 75 patients will be enrolled in the Observational Arm. Patients who participate in the historical control observational arm will not receive any study medication, but will have Hgb, CHr and serum iron profiles collected at 4 week intervals for up to a total of 44 weeks.
16362672|NCT04239378|Experimental|Test group -Autogenous dentin matrix and collagen membrane|Test group - After atraumatic tooth extraction , socket will be augmented with autogenous dentin matrix and covered with collagen membrane and sutures are placed.
16362673|NCT04239378|Active Comparator|Control group-bovine derived xenograft and collagen membrane|control group- After atraumatic tooth extraction, socket will be augmented with bovine derived xenograft and covered with collagen membrane and sutures are placed.
16362674|NCT04239365|Experimental|Group A: WLE followed by NBI|EMR scar is interrogated using WLE followed by NBI
16362675|NCT04239365|Active Comparator|Group B: NBI followed by WLE|EMR scar is interrogated using NBI followed by WLE
16362676|NCT04239352||healthy pregnant women|"Blood samples taken from 40 healthy pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.
~this group will be the control group."
16362677|NCT04239352||preeclamptic pregnant women|"Blood samples taken from 40 preeclamptic pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.
~this group will be the study group."
16362678|NCT04239339|Placebo Comparator|Control Group|The placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo pill.
16362679|NCT04239339|Experimental|Intervention Group|The intervention group will be administered 20mg of Escitalopram daily for approximately 3 weeks.
16362680|NCT04239313|Experimental|Population I|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.
16362681|NCT04239313|Active Comparator|Population II|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.
16362682|NCT04239313|Placebo Comparator|Population III|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.
16362683|NCT04239300|Experimental|Main group|The participant in main group have water labour
16362684|NCT04239300|No Intervention|Control group|The participant in control group will not have water labour
16362685|NCT04239287||Preterm|Children age 8-16 years born at <32 weeks gestation.
16362686|NCT04239287||Control|Children age 8-16 years born at >37 weeks gestation
16362687|NCT04239274|Experimental|Transcranial Direct Current Stimulation (tDCS)|
16362688|NCT04239274|Experimental|Transcranial Pulsed Stimulation tPCS|
16362689|NCT04239274|Sham Comparator|No Stimulation|
16362690|NCT04239261|Active Comparator|Nutritional therapy|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
16362691|NCT04239261|Placebo Comparator|Placebo|Hydrolyzed gelatin 10.0 grams once daily
16362692|NCT04239248|Experimental|ACTIVE-RCT-I Tasty&Healthy intervention group|Patients with mild-moderately symptomatic disease, will follow the Tasty&Healthy dietary approach.
16362693|NCT04239248|Active Comparator|ACTIVE-RCT-I Control group|Patients with mild-moderately symptomatic disease, will receive EEN with Modulen formula only.
16362694|NCT04239248|Experimental|MH-RCT-II Tasty&Healthy intervention group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will follow the Tasty&Healthy dietary approach.
16362695|NCT04239248|No Intervention|MH-RCT-II Control group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will continue their habitual diet.
16362696|NCT04239235|Experimental|Intervention|Community Reinforcement Approach and Family Training is a 10-session rolling group for the support person.
16362697|NCT04239235|No Intervention|Control|This condition is for support persons who do not receive CRAFT. They will receive no intervention or usual care services available at the clinic.
16362698|NCT04239222|Experimental|Revo-M to Proflex XC|Transtibial amputees randomized to start with Revo-M and cross over to Proflex XC
16362699|NCT04239222|Experimental|Proflex XC to Revo-M|Transtibial amputees randomized to start with Proflex XC and cross over to Revo-M
16362700|NCT04239222|Experimental|Revo-M to Taleo|Transfemoral amputees randomized to start with Revo-M and cross over to Taleo
16362701|NCT04239222|Experimental|Taleo to Revo-M|Transfemoral amputees randomized to start with Taleo and cross over to Revo-M
16362702|NCT04239209|Placebo Comparator|Direct Communication (control)|A direct response where the intensivist acknowledges that he is not certain but believes the patient will not survive hospitalization.
16362703|NCT04239209|Active Comparator|Indirect - other patients|An indirect response describing the prognosis of other people similar to the patient in question.
16362704|NCT04239209|Active Comparator|Indirect - physiology|An indirect response describing the severe physiologic abnormalities present in the patient and potential future problems.
16362706|NCT04239196|Experimental|tocilizumab and IV steroids combination|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (with intravenous pulses of 1000 mg/day of methylprednisolone for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
16362707|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (with intravenous pulses of 1000 mg/day of methylprednisolone for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
16362708|NCT04239170|Experimental|Camrelizumab(SHR-1210) Combined With GEMOX|
16362709|NCT04239157|Experimental|Treatment (canakinumab)|Patients receive canakinumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16362710|NCT04239144|No Intervention|Medical therapy group|Arm 1 Medical Treatment Control - 10 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.
16362711|NCT04239144|Active Comparator|Catheter ablation|Intervention Arm 2 -10 patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
16362712|NCT04239144|Experimental|Left trunk sympathectomy|Interventional arm 3 - In 10 patients, left truck sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches.
16362713|NCT04239131|Other|All Patients|It is a single arm study. Skin prick testing and laboratory Tests are carried out on all patients in the same way
16362714|NCT04239118|Experimental|Applications of autoplasma, enriched with platelets and|Endoscopic applications of autoplasma, enriched with platelets and granular sorbent aseptisorb-A in bleeding gastroduodenal ulcers
16362715|NCT04239118|Other|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents.
16362716|NCT04239105||Breast cancer Group|The biopsy result is breast cancer.
16362717|NCT04239092|Experimental|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
16362718|NCT04239092|Experimental|9-ING-41 plus Irinotecan|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days (cycle duration is 21 days).
16362719|NCT04239092|Experimental|9-ING-41 plus Irinotecan plus Temozolomide|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days. Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 ((cycle duration is 21 days).
16362720|NCT04239092|Experimental|9-ING-41 plus Cyclophosphamide plus Topotecan|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5. Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5. 9-ING-41 intravenous infusion twice weekly (cycle duration is 21 days).
16362721|NCT04239079||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
16362722|NCT04239079||AD/aMCI and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)
16362723|NCT04239066|Experimental|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
16362724|NCT04239066|Experimental|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
16362725|NCT04239053||ESPB block group|Patients receiving ESPB will be enrolled to this group.
16362726|NCT04239040|Experimental|Relapsed or Refractory High Risk Neuroblastoma|"Tissue Collection of Cancerous cells during primary or clinically indicated surgical resection.
~Manufacture and cryopreservation of vaccine. Treatment with vaccine, nivolumab and ipilimumab.
~Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
~Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
~Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
16362727|NCT04239027|Experimental|RTH258/Brolucizumab|This is a single-arm study in which all patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment from Week 16/Week 20 up to Week 40/Week 44.
16362728|NCT04239014|Experimental|Arm 1 (ceralasertib+olaparib)|Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).
16362729|NCT04239014|Experimental|Arm 2 (olaparib monotherapy)|Olaparib 300 mg BD PO daily continuous.
16362730|NCT04239014|Experimental|Arm 3 (placebo)|Placebo to match olaparib BD PO daily continuous.
16362731|NCT04239001|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
16362759|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
16362760|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
16362761|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
16362732|NCT04238988|Experimental|Carboplatin-Paclitaxel-Pembrolizumab|"Patients will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).
~After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.
~After surgery, patients presenting with high risk factors will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles."
16362733|NCT04238975|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
16362734|NCT04238975|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
16362735|NCT04238962|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
16362736|NCT04238962|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
16362737|NCT04238949|No Intervention|Standard Diabetes Care Group|Patients receive standard diabetes care.
16362738|NCT04238949|Experimental|Community Health Worker Group|Patients are assigned a community health worker for the first year in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
16362739|NCT04238936||study group ; Patients with gestational diabetes|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
16362740|NCT04238936||control group ; healthy pregnant women|Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
16362741|NCT04238923|Experimental|Topical Gentamicin and Vancomycin|Immediately prior to closure of the incision, 1g of vancomycin will be mixed in 4mL of normal saline and applied as a paste directly to the muscle, fascia and subcutaneous tissue. Gentamicin-eluting collagen sponges will be cut to the appropriate size to cover the defect and applied after application of vancomycin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
16362742|NCT04238923|No Intervention|Control|The surgical wound is closed in the standard fashion with 3 layer closure with staples for skin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
16362743|NCT04238910|Experimental|Maximizing Energy|"The Maximizing Energy (MAX) intervention consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventions are delivered by occupational therapists.
~The MAX intervention was developed by combining two active ingredients - Problem Solving Therapy and energy conservation strategy education. Participants engage in two introductory sessions during the first week of the intervention. During the first session in a week, participants practice the steps of MAX Intervention with a fatigue-related problem. At the end of the session, the participants identify a clearly defined action plan for solution implementation. Participants are asked to implement the solution over the next few days. The second session takes place later in the week. The interventionist reviews the problem, the identified solution, and its implementation. Participants use a workbook to support their application of the MAX Intervention."
16362744|NCT04238910|Active Comparator|Health Education|consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventionist delivered health education using a variety of health related topics relevant to individuals with TBI (e.g., characteristics and prevalence of fatigue after TBI, diet and nutrition, importance of exercise, energy conservation strategies).Participants use a workbook to follow along with the interventionist during the weekly sessions.
16362745|NCT04238897|Experimental|Ticon Aspherical Daily Disposable Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
16362746|NCT04238897|Placebo Comparator|Ticon Daily Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
16362747|NCT04238884|Experimental|Experimental group|Based on the genetic study carried out and the patient's characteristics (age, weight, indication), the Pharmacogenetics Unit of the University Hospital La Paz will indicate the dose to be administered based on the therapeutic individualization protocol guided by pharmacogenetics.
16362748|NCT04238884|Active Comparator|Control group|No information will be provided and procedure will be carried out according to normal clinical practice, with clinical monitoring by the doctor in charge.
16362749|NCT04238871||children or adults with Idiopathic Lung Disease|
16362750|NCT04238858|Active Comparator|Before application|Forty-nine eyes belonging to 37 patients before injection aPRP.
16362751|NCT04238858|No Intervention|After application|Forty-nine eyes belonging to 37 patients after injection aPRP.
16362752|NCT04238858|Sham Comparator|Sham application|11 patients before - after aPPP injection
16362753|NCT04238845|Active Comparator|SMC + Vitamin A alone|Children under SMC Coverage, receiving AQSP and Vitamin A supplementation alone
16362754|NCT04238845|Experimental|SMC+ Vitamin A + Plumpy'Doz|Children under SMC Coverage, receiving AQSP + Vitamin A plus Plumpy'Doz supplementation
16362755|NCT04238845|Experimental|SMC+ Vitamin A + Zinc|Children under SMC Coverage, receiving AQSP + Vitamin A plus Zinc supplementation
16362756|NCT04238832|Active Comparator|Free Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and free base nicotine e-liquid to sample for one week.
16362757|NCT04238832|Active Comparator|Salt Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and salt base nicotine e-liquid to sample for one week.
16362758|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
16362762|NCT04238806|Active Comparator|Desflurane Continuous|In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
16362763|NCT04238806|Active Comparator|Desflurane Intermittent|In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
16362764|NCT04238793|Experimental|Cohort 1|KLS-2031 low dose(1x10^11 VG/DRG) or Placebo
16362765|NCT04238793|Experimental|Cohort 2|KLS-2031 medium dose(1x10^12 VG/DRG) or Placebo
16362766|NCT04238793|Experimental|Cohort 3|KLS-2031 high dose(1x10^13 VG/DRG) or Placebo
16362767|NCT04238780|Active Comparator|ESP( Erector Spinae Plane Block)|After induction parturient in the ESPB underwent bilateral ESPB at the level of T7 using a linear ultrasound (US) transducer.
16362768|NCT04238780|Sham Comparator|control group|Control group
16362769|NCT04238767||HIV-1-positive individuals|HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.
16362770|NCT04238754|Experimental|All Participants|Each participant will receive Epidiolex oral solution and Cherry syrup oral solution (placebo) in a randomized fashion.
16362771|NCT04238728|Experimental|Silverlon arm|
16362772|NCT04238715|Experimental|E7090 140 mg|Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.
16362773|NCT04238702|Experimental|Empagliflozin + Losartan|Empagliflozin + Losartan
16362774|NCT04238702|Experimental|Losartan + Placebo|Losartan + Placebo
16362775|NCT04238702|Experimental|Empagliflozin + Placebo|Losartan + Placebo
16362776|NCT04238702|Placebo Comparator|Placebo + Placebo|Placebo + Placebo
16362777|NCT04238689|Experimental|Group 1 - 0,1mg/kg TB31F|0.1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. Subjects will be observed for the occurrence of any adverse events. There will be a minimum of 48 hours between TB31F administration to each subsequent volunteer. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
16362778|NCT04238689|Experimental|Group 2 - 1mg/kg TB31F|1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
16362779|NCT04238689|Experimental|Group 3 - 3mg/kg TB31F|3 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
16362780|NCT04238689|Experimental|Group 4 - 10mg/kg TB31F|10 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
16362781|NCT04238689|Experimental|Group 5 - 100mg TB31F|100mg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
16362782|NCT04238676|Experimental|PP353|
16362783|NCT04238676|Placebo Comparator|PP353-B|
16362784|NCT04238663|Experimental|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16362785|NCT04238663|Active Comparator|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16362786|NCT04238663|Active Comparator|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16362787|NCT04238650|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16362791|NCT04238624|Experimental|BRAF-mutant ATC|Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
16362793|NCT04238598|Active Comparator|Active|intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency
16362794|NCT04238598|Placebo Comparator|Control|intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency
16362795|NCT04238598|Experimental|Experimental|intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency
16362796|NCT04238585|Active Comparator|Negative message frames|Participants will receive messages framed in a negative manner to avoid sugar-sweetened beverages
16362797|NCT04238585|Active Comparator|Sugar content information messages|Participants will receive messages framed in a positive manner to promote healthy beverage consumption
16362798|NCT04238585|Placebo Comparator|Attention Control-Infant Safety|Participants will receive messages with infant safety education materials-attention control group
16362799|NCT04238572|Experimental|Audiovisual distraction device|Audiovisual distraction device, analgesia nociception index monitoring, remifentanil added to local anesthesia technique
16362800|NCT04238572|Active Comparator|Active comparator group|Analgesia nociception index monitoring, remifentanil added to local anesthesia technique
16362801|NCT04238546|Experimental|Sirolimus-coated group|
16362802|NCT04238546|Active Comparator|Uncoated group|
16362803|NCT04238533|Active Comparator|eADAPT|This arm includes transradial amputees who will be assessed while using the eADAPT trainer.
16362804|NCT04238533|Active Comparator|Conventional program|This arm includes transradial amputees who will be assessed while using the conventional training program.
16362807|NCT04238507|Active Comparator|Guedel airway (OPA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
16362808|NCT04238507|Active Comparator|McKay Airway (MA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
16362817|NCT04238468|Experimental|Intradermal injection of stromal vascular fraction|Most lateral 5 cm of abdominal donor site will be injected with stromal vascular fraction just after the wound is closed.
16362818|NCT04238468|No Intervention|control|Most contralateral 5 cm of abdominal donor site will serve as control.
16362819|NCT04238455|Sham Comparator|Control Group|Sham serratus anterior plane block plus usual car
16362820|NCT04238455|Active Comparator|Treatment Group|Serratus anterior plane block plus usual care
16362821|NCT04238442|Experimental|BP oscillometric measurement|Oscillometric BP measurement
16362822|NCT04238429|Experimental|Toothpaste containing effective ingredients|Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
16362823|NCT04238429|Placebo Comparator|Negative control toothpaste|Use the negative control dentifrice to brush teeth twice daily for 8 weeks
16362824|NCT04238416|Experimental|IV BCAA + Lactulose|IV Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
16362825|NCT04238416|Active Comparator|Lactulose alone|Oral Lactulose alone
16362826|NCT04238403|Experimental|Behavioral Parent Training|Parent training intervention based on social learning and operant conditioning theory, generally referred to as Behavioral Parent Training.
16362827|NCT04238390|Experimental|Ceftolozane-tazobactam|Participants will receive ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins
16362828|NCT04238390|Active Comparator|Meropenem|Participants will receive meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins.
16362829|NCT04238377|Active Comparator|Stellate Group|will receive pre-operative ultrasound guided stellate ganglion block one hour before surgery and multimodal analgesia and will be followed for 6 months for neuropathic pain as the Stellate Group
16362830|NCT04238377|Placebo Comparator|Control Group|will receive multimodal analgesia only and will be followed for 6 months for neuropathic pain as the control Group
16362831|NCT04238364|Experimental|EI1071 Tablets|EI1071 tablet(s) administered orally as single ascending dose, multiple ascending daily doses
16362832|NCT04238364|Placebo Comparator|Placebo|Matching placebo tablet(s) administered orally
16362833|NCT04238351|Experimental|Control|usual mask ventilation during anethesia induction
16362834|NCT04238351|Active Comparator|THRIVE|Applying Transnasal humidified rapid insufflation ventilator exchange during anesthesia induction
16362835|NCT04238338||high MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).
~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
16362836|NCT04238338||low MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).
~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
16362837|NCT04238312|Experimental|RESPeRATE™|RESPeRATE™: 2breathe Tech. Ltd., Eshtaol, Israel. The device includes a belt-type respiration sensor worn outside of the clothing that is placed around the torso. It is connected to a computerized box that generates musical patterns listened through an earbud. The device guides the user interactively to slow breathing with a relatively prolonged expiration.
16362838|NCT04238312|Active Comparator|Tell, Show and Do technique|
16362839|NCT04238299||Main study cohort|Patients with CKD recruited from specialist nephrology clinics
16362840|NCT04238286|Experimental|Dry needling group|Patients treated with dry needling
16362841|NCT04238286|Sham Comparator|Sham group|Patients treated with a simulated dry needling
16362842|NCT04238286|No Intervention|Control|Patients never treated
16362843|NCT04238273||HHHFNC|it included 63 preterm neonates on Heated, Humidified High Flow Nasal Cannula, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
16362844|NCT04238273||NCPAP|it included 60 preterm neonates on Nasal Continuous Positive Airway Pressure, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
16362845|NCT04238260|Active Comparator|Usual Physical Therapy Care|Physical Therapists continue usual care
16362846|NCT04238260|Experimental|Enhanced Physical Therapy Usual Care|Best practice implemented
16362850|NCT04238234||study group|Participants will be adult patients (above 18 years), ASA I-II-III, scheduled for elective surgeries under general anesthesia.
16362851|NCT04238221|Experimental|Doxofylline+inhalation therapy|4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy, followed by 4-week treatment of maximal inhalation therapy only
16362852|NCT04238221|Experimental|Inhalation therapy|4-week treatment with maximal inhalation therapy only, followed by 4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy
16362853|NCT04238208|Active Comparator|Group LL|Group LL patients received the 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm containing 700 mg of Lidocaine for 60 minutes
16362854|NCT04238208|Placebo Comparator|Group LP|Group LP received an identical placebo patch
16362855|NCT04238208|Experimental|Group LC|Group LC received the 8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK).
16362856|NCT04238195|Experimental|Treatment A|600 mg TBPM-PI-HBr (2 x 300 mg tablets) and TBPM-PI-HBr-matching placebo (2 x matching placebo tablets) administered at Hour 0 on Day 1.
16362857|NCT04238195|Experimental|Treatment B|1200 mg TBPM-PI-HBr (4 x 300 mg tablets) administered at Hour 0 on Day 1.
16362858|NCT04238195|Placebo Comparator|Treatment C|TBPM-PI-HBr-matching placebo (4 x matching placebo tablets) administered at Hour 0 on Day 1.
16362859|NCT04238195|Other|Treatment D|Positive Control - unblinded: 400 mg moxifloxacin (1 x 400 mg tablet) administered at Hour 0 on Day 1.
16362860|NCT04238182|Active Comparator|wet cupping|smokers in this group will receive single wet cupping session
16362861|NCT04238182|Active Comparator|dry cupping|smokers in this group will receive single dry cupping session
16362862|NCT04238169|Experimental|SBRT+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.
~SBRT：30-50Gy/5F（2-4 locations)."
16362863|NCT04238169|Experimental|SBRT+Bevacizumab+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.
~SBRT：30-50 Grays(Gy) in 5 fractions（2-4 locations）. Bevacizumab：7.5mg/kg once every three weeks."
16362864|NCT04238156|Experimental|Hypopressive abdominal exercises|"Hypopressive abdominal exercises will be performed in basic postures (standing, sitting and supine position). In each posture, three slow cost-diaphragmatic respiration will be performed followed by an expiratory apnea and a rib cage opening, during 2 to 10 seconds, and an exhalation of 10 to 30 seconds. Each exercise will be repeated three times.
~There will be 3 stages of application throughout the 12 intervention sessions, supervised by a physical therapist:
~First stage: To explain the concept of hypopressive respiration and how to perform it.
~Second stage: To explain and apply the hypopressive abdominal exercises: 1. Axial auto-elongation (reducing curvatures in the sagittal plane); 2. Cervical auto-elongation (chin toward the neck); 3. Moving forward of gravity axis; 4. Activation of the shoulder girdle (shoulder joint decoaptation); 5. Slight knee flexion; 6. Dorsal ankle flexion.
~Third stage: To review and update all the exercises, increasing their intensity."
16362865|NCT04238143|Experimental|tSVF + PRP Arm1|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate
16362866|NCT04238143|Experimental|tSVF + PRP + cSVF Arm 2|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate + Cellular Stromal Vascular Fraction (cSVF)
16362867|NCT04238143|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Sterile Normal Saline Intravenous (IV) Introduction
16362868|NCT04238130||Perioperative ctDNA Dynamic Monitoring Group|Samples were obtained at multiple pre-specified time points including before surgery (plasma samples)，during surgery after tumor resection (tumor samples) and after surgery(plasma samples were obtained every 6 months from ctDNA positive patients at baseline in the following 2 years)
16362869|NCT04238117|Experimental|LA group|The participants in LAT group underwent 10 sessions of LAT over 2 weeks, using a gallium aluminum arsenide Laser Pen. The participants in the LAT group received 0.375 J of energy at each of the following acupoints bilaterally: BL23 (Shenshu, B2), BL25 (Dachangshu, B2), BL26 (Guanyuanshu, B2), BL40 (Weizhong, B2) and SP6 (Sanyinjiao, B2).
16362870|NCT04238117|No Intervention|Control group|The participants of the control group received standard obstetric care.
16362871|NCT04238104||sea level|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center of sea level were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
16362872|NCT04238104||altitude <1000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude less than 1000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
16362873|NCT04238104||altitude 1000-2000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 1000-2000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
16362874|NCT04238104||altitude 2000-3000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 2000-3000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
16362875|NCT04238104||altitude 3000-4000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 3000-4000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
16362876|NCT04238104||altitude 4000-5000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 4000-5000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
16362879|NCT04238078||Polycystic ovary syndrome|Women with PCOS diagnosed according to Rotterdam criteria
16362880|NCT04238078||Healthy control|Healthy women without any feature of ovulatory dysfunction or androgen excess
16362881|NCT04238065|Experimental|VR treatment|"The arm will use the virtual reality headset reproduces dynamic video content with perceptual learning and binocular perception (including stereopsis) that is visually perceived a little bit faster, brighter, and higher contrast to the amblyopia eyes .
~The each VR therapy length is 30 minutes with 5 minute break after 15 minutes' therapy sequence, 3 times per week, total 13 weeks.
~All amblyopia eyes are best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity."
16362882|NCT04238065|Placebo Comparator|control|"This arm of amblyopia eyes are all best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.
~No VR therapy."
16362883|NCT04238026|Experimental|Distal radial artery approach|Puncture in the snuff box area of the arm with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
16362884|NCT04238026|Active Comparator|Proximal radial artery approach|Puncture in the ventral side of the arm (2 cm proximal to the styloid apophysis) with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
16362885|NCT04238013|Active Comparator|Corticospinal Tract Excitability|During the Corticospinal Tract Excitability arm, corticospinal excitability will be assessed by measuring motor evoked potentials after transcranial magnetic stimulation pre-post each intervention in conjunction with other outcome measures.
16362886|NCT04238013|Active Comparator|Spinal Reflex Circuit Excitability|During the Spinal Reflex Circuit Excitability arm, spinal reflex circuit excitability will be assessed by measuring low frequency depression after Hoffmann-Reflex testing pre-post each intervention in conjunction with other outcome measures.
16362887|NCT04238000|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
16362888|NCT04238000|Placebo Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
16362889|NCT04237987|Experimental|Interleukin-2 and ciclosporin and corticosteroid|One million units of Recombinant Human Interleukin-2 (IL-2) will be administered subcutaneously every other day for 3 months. Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 3 months after withdraw of IL-2.
16362890|NCT04237987|Active Comparator|ciclosporin and corticosteroid|Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 6 months.
16362891|NCT04237961|Experimental|Upper third interference|Botox & brow lift
16362892|NCT04237961|Experimental|Middle third|Botox and fat injection
16362893|NCT04237961|Experimental|Lower third|Suspension suture
16362894|NCT04237948|Active Comparator|physical therapy plus REAL tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.
~Real Cerebellar tDCS will be applied for 10 days of time."
16362895|NCT04237948|Placebo Comparator|physical therapy plus SHAM tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.
~Sham Cerebellar tDCS will be applied for 10 days of time."
16362896|NCT04237935||Clopidogrel 75 mg|Reference group
16362897|NCT04237935||Ticagrelor 90 mg|Exposure group
16362898|NCT04237922||Clopidogrel 75 mg|Reference group
16362899|NCT04237922||Prasugrel 10 mg|Exposure group
16362900|NCT04237909|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
16362901|NCT04237883|Placebo Comparator|Arm 1: Standard Communication Arm|Monthly email communication: Monthly standard communication via email informing physicians of their health maintenance completion rate over the prior three-month period. The email will also include a link to the performance dashboard, a link to a FAQ page that outlines their incentive plan, a link to helpful resources such as care guidelines, key tips from top performers, the quality measure on which they are performing the best, and the two quality measures that they could improve on the most.
16362902|NCT04237883|Experimental|Arm 2: Arm 1 Message + Social Comparison Intervention|"Monthly email communication as in Arm 1
~Social comparison: In addition to the information given in Arm 1 email messaging, physicians in this arm will receive a list of the names of the top 25 performers from the prior month, and a high performer benchmark. Each physician in this group will receive a personalized message and subject line based on where in the performance distribution they fall (categories: top 25 performers, high performers, nearly high performers, and low performers). Message content will incorporate language utilizing principles of social comparison theory."
16362903|NCT04237883|Experimental|Arm 3: Arm 2 Interventions + Leadership training|"Monthly email communication as in Arm 1 and Arm 2.
~Social comparison as in Arm 2.
~Quality improvement leadership training: Physician leads and clinic managers within clinics randomized to Group 3 will receive an in-person quality improvement and primary care clinic performance training, using the principles of quality improvement, self-determination theory and social comparison. Clinic leaders will be trained on how to guide these conversations, formulate their own performance/quality improvement goals, design effective strategies to reach these goals, and track their clinic's progress. Check-in emails and calls will be provided on a monthly basis to follow up on clinic-based quality improvement efforts and share key take-aways from the new Primary Care Clinical Excellence Recognition Program. This program aims to support a positive and collaborative culture of clinical excellence by recognizing and sharing best practices from high performing physicians and clinical teams."
16362904|NCT04237870|Active Comparator|Active treatment|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS repeat twice with 15 min interval. Treatment will be applied in central suleus.
16362905|NCT04237870|Sham Comparator|Sham treatment|Sham rTMS will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
16362906|NCT04237857||LSG|Chinese patients who received laparoscopic sleeve gastrectomy at Prince of Wales Hospital, The Chinese University of Hong Kong for more than 36 months
16362907|NCT04237844||no BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，infants without BPD
16362908|NCT04237844||classic BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts >25%
16363082|NCT04236635|Experimental|Single CCH Subcutaneous Injection Technique|Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.
16362909|NCT04237844||BPD after RDS|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2<23% within 7 days, and the condition is aggravated to FiO2>25%.
16362910|NCT04237844||Delayed BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There is no RDS performance after birth, FiO2 lasts <25%
16362911|NCT04237844||Early, lethal BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities
16362912|NCT04237831|Experimental|Arm A: Normal Renal Function|
16362913|NCT04237831|Experimental|Arm B: Mild Renal Impairment|
16362914|NCT04237831|Experimental|Arm C: Moderate Renal Impairment|
16362915|NCT04237831|Experimental|Arm D: Severe Renal Impairment|
16362916|NCT04237818|Placebo Comparator|Placebo drink|
16362917|NCT04237818|Experimental|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|
16362918|NCT04237805|Experimental|SAF-189s|The phase I dose study will enrol patients with advanced malignant solid tumors that are ALK-positive, and the phase II study will be divided into two parts, Part I Some patients with ALK/ROS1 positive advanced non-small cell lung cancer were enrolled in the 210m,80mg,120mg and 160mg dose groups for safety evaluation.In the second part, two cohorts will be included and 110 ROS1 patients will be enrolled. Except for the PK induction period, all patients will receive oral administration of SAF189s once a day for a continuous period of 21 days.
16362919|NCT04237792|Experimental|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
16362920|NCT04237792|Experimental|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
16362921|NCT04237792|Experimental|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
16362922|NCT04237779|Experimental|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in microTESE material.
16362923|NCT04237766|Experimental|Experimental group|All patients included in the experimental group should be on prophylactic treatment with factor 8 (FVIII) or factor 9 (FIX) concentrates. Likewise, the factor should be administered on the same day that they receive each movement display therapy treatment sessions. Each session will last approximately 40 minutes, with 7 physiotherapy sessions a week taking place over a period of 4 weeks.
16362924|NCT04237766|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through mirror therapy and motion display. They will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with factor 8 (FVIII) or factor 9 (FIX) concentrates. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
16362925|NCT04237753|Active Comparator|MyHealthebladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
16362926|NCT04237753|Active Comparator|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
16362927|NCT04237740|Experimental|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
16362928|NCT04237714|Experimental|IBI-based automated support|Internet-based intervention with automated support by the system. It consistes in phone text messages twice a week for users. The content of the messages focuses on motivating and reminding users to complete the activities proposed in the program and reviewing the treatment contents. Additionally an automatic email is send if participants have not access the program for a week. The program also provides continuous feedback to users through transversal tools.
16362929|NCT04237714|Experimental|IBI-plus human support|In this condition, the participants receive automated support explained above and additionally human support for a maximum of 5 minutes that consist in a weekly phone call provided by a psychologist. The content of phone calls is related with resolve questions or doubts about the use and clinical content of the IBI and also motivating and reminding the importance to complete activities in the program.
16362930|NCT04237714|No Intervention|Control group|Waiting list control group.
16362931|NCT04237675||regional anesthesia|
16362932|NCT04237675||general anesthesia|
16362933|NCT04237662|Experimental|Test Group|"Root Instrumentation + Enamel Matrix Derivative Application
~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
16362934|NCT04237662|Active Comparator|Control Group|"Root Instrumentation
~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour."
16362935|NCT04237649|Experimental|Arm A|KAZ954
16362936|NCT04237649|Experimental|Arm B|KAZ954 + PDR001
16362937|NCT04237649|Experimental|Arm C|KAZ954 + NIR178
16362938|NCT04237649|Experimental|Arm D|KAZ954 + NZV930
16362939|NCT04237636||Patients with post-operative AKI|"Patients developing acute kidney injury (AKI) following heart valve replacement surgery.
~AKI was classified according to the KDIGO definition[10]. Stage-1 AKI: increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.5μmol/l) or increase to more than or equal to 150% to 200% (1.5≤x<2) from baseline within 7 days. Stage-2 AKI: Increase in serum creatinine to more than 200% to 300% (2≤x<3) from baseline. Stage-3 AKI: Increase in serum creatinine to more than 300% (3≤) from baseline (or serum creatinine of more than or equal to 4.0 mg/dl (≥ 353.6μmol/l) or when the patient commenced RRT."
16362940|NCT04237636||Patients without post-operative AKI|Patients with normal kidney function (without acute kidney injury (AKI)) following heart valve replacement surgery
16362941|NCT04237623|Experimental|GM-CSF post-transplant|Sargramostim (GM-CSF) will start on Day +5 and continue until ANC >1000 x3 days or >1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.
16362942|NCT04237610||Bipolar disorder type I|
16362943|NCT04237610||Bipolar disorder type II|
16362944|NCT04237610||healthy controls|
16362945|NCT04237597|Experimental|K-877 & CSG452|K-877 Single dose on Day 1 and Day 15 CSG452 Repeat dose on Day 2 Through Day 15
16362946|NCT04237584|Active Comparator|Lead-in ARB followed by Radium-223/ARB|Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Radium-223 + ARB.
16362947|NCT04237584|Placebo Comparator|Lead-in ARB followed by Placebo/ARB|Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Placebo + ARB.
16362948|NCT04237571|Experimental|CANE Adult Participants|This sample population consists of an active intervention group of prior Tanglewood to Table walking program adult participants.
16362949|NCT04237558|Active Comparator|Vaginal hysterectomy|Removal of uterus through vagina in absence of prolapse
16362950|NCT04237558|Active Comparator|Laparoscopic hysterectomy|Key hole surgery through small incisions of the abdomen
16362951|NCT04237545|Experimental|T3 short implant|The short implants are available in lengths of 5mm and 6mm and in diameters of 5mm and 6mm. For study both configurations, T3 short without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 short with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
16362952|NCT04237545|Active Comparator|T3 standard length|The T3 external hex implants available for this study will consist of lengths of 10mm, 11.5mm, 13mm, 15mm, 18mm and diameters of 4mm, 5mm, and 6mm. They have integrated platform switching (medialized implant/abutment junction). For study both configurations, T3 without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
16362953|NCT04237532|Experimental|Intranasal Dexmedetomidine|
16362954|NCT04237532|Experimental|Sublingual Dexmedetomidine|
16362955|NCT04237519|Experimental|SFL training|"Practice recommendation 3 times per week:
~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).
~Cognitive exercises: minimum of 15 min."
16362956|NCT04237519|Active Comparator|Active control training|"Practice recommendation 3 times per week:
~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).
~Cognitive exercises: minimum of 15 min."
16362957|NCT04237506|Experimental|Intervention group|All participants in this group will take the one-hour ballet dance class twice per week for six weeks
16362958|NCT04237493|Experimental|Low-dosage therapy|
16362959|NCT04237493|Active Comparator|Regular-dosage therapy|
16362962|NCT04237454|Experimental|Infrared Imaging undertaken|
16362963|NCT04237428|Experimental|hCD19 CAR-T cells Infusion|
16362964|NCT04237415|Experimental|EMG biofeedback group|
16362965|NCT04237415|No Intervention|control group|
16362966|NCT04237402|Other|Intra individual|Before and after pregnancy, hair follicles will be analysed
16362967|NCT04237389|Active Comparator|Ablation Index guided catheter radiofrequency ablation|30 patients, who undergo Ablation Index (AI) guided catheter RF ablation
16362968|NCT04237389|Active Comparator|Thoracoscopic surgical epicardial ablation|"30 patients, who undergo thoracoscopic ablation using Box-lesion set"
16362969|NCT04237376||Treatment Arm A: CHB Mothers treated with TAF during Pregnancy|120 pregnant women with double positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL were recruited from all four treatment centers. Mothers were enrolled and observed from gestational week 24-28 until postpartum week 28, and treated with TAF (25mg oral daily) from gestational week 28 until delivery (if the liver function is significantly abnormal after delivery, that is, ALT ≥ 5 × Upper Limit of Normal (ULN), the oral antiviral drug can be continued according to the wishes of the pregnant woman and the test results). All babies were given 3 HBV vaccines (0, 1, 6) and 1 routine Hepatitis B immunoglobin (HBIG) after birth. All babies were followed up to 2 years. According to the mother's wishes, if the mother agrees to collect breast milk and determine TAF concentration, breast milk was collected every day, and continuously collected 5-7 days for TAF concentration measurement. The time of last TAF dose taken as well as the time between milk collection and delivery was recorded.
16362970|NCT04237376||Comparative Arm C: CHB Pregnant Mothers|This arm C consists of 360 cases of pregnant women with HBsAg and HBeAg double-positive, and HBV DNA level ≥ 2 × 10^6 IU/mL. The mothers in this historical cohort did not receive any antiviral treatment during their pregnancy. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
16362971|NCT04237376||Comparative Arm B: CHB Pregnant Mothers treated with TDF|This retrospective cohort arm B consists of 120 cases of pregnant women with double-positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. Pregnant mothers were treated with TDF (300mg oral daily) starting from gestational week 28 and discontinued the drug at delivery. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
16362972|NCT04237363|Experimental|Exercise|Walk training
16362973|NCT04237350||visual impairment group|"The visual impairment group is defined as a VA out of the 95% reference range in at least 1 eye or worse with structural abnormalities."
16363083|NCT04236635|Experimental|Multiple CCH Subcutaneous Injection Technique|Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.
16366128|NCT04215302||laryngeal mask size|laryngeal mask size determines according to weight measurement
16362974|NCT04237350||likely healthy group|"For the likely healthy group, the visual acuity of both eyes is in the 95% referenced range with no structural abnormalities.
~The referenced range could be found in the following publication:
~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
16362975|NCT04237337||serious cancer ICSRs (cases)|
16362976|NCT04237337||other serious reactions ICSRs (non-cases)|
16362977|NCT04237324|Experimental|NAFL group|One side of the patient face has been therapied by 1565nm fiber nonablative fractional laser(Lumenis Co., Yokneam, Israel).
16362978|NCT04237324|Active Comparator|FMR group|Another side of the patient face has been therapied by FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
16362979|NCT04237298|Active Comparator|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
16362980|NCT04237298|Experimental|Modified vacuum-formed retainer covering the palate|The modified vacuum-formed retainer is designed to cover the palate. It is cheaper, easier to fabricate and more esthetic. Patients will be instructed to wear the retainer 24 hours during the study period.
16362981|NCT04237285|Experimental|Lavender 15|Participant who inhalates lavender oil for 15 minutes.
16362982|NCT04237285|Experimental|Lavender 60|Participant who inhalates lavender oil for 60 minutes.
16362983|NCT04237285|Placebo Comparator|Jojoba|Participant who inhalates jojoba oil for 15 minutes.
16362984|NCT04237272|Active Comparator|Pod System|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
16362985|NCT04237272|Active Comparator|Customizable Tank|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week sampling period.
16362986|NCT04237272|Active Comparator|Control|Participants assigned to this arm will not receive any e-cigarette
16362987|NCT04237259|Experimental|Parent-administered TCM massage group|Parents of subjects in the parent-administered TCM massage group (n=30) will attend 2 training sessions (5 hours in total) to learn and practice the parent-administered TCM massage for ADHD before treatment starts. The parents will be told to practice the TCM massage on their child every 2 days for 2 months.
16362988|NCT04237259|Active Comparator|Parent-child interaction group|Parents in the parent-child interaction group (comparison group, n=30) will attend a 3-hour training course on line and spend extra time on interacting with their child at home.
16362989|NCT04237246|Experimental|Once daily Tacrolimus (Advegraf)|
16362990|NCT04237181|Other|Acute diarrhoea or colitis presumed to be of infectious origin|
16362991|NCT04237168||DLBCL patients|newly diagnosed DLBCL (de novo, all ages) patients treated with RCHOP (first-line treatment regimen)
16362992|NCT04237155|Other|Healthy controls involved in step 1|30 healthy individuals will complete a verbal material scoring questionnaire
16362993|NCT04237155|Other|Patients with schizophrenia involved in step 1|30 patients with schizophrenia will complete a verbal material scoring questionnaire
16362994|NCT04237155|Other|Healthy controls involved in step 2|30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference
16362995|NCT04237155|Other|Patients with schizophrenia involved in step 2|30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference
16362996|NCT04237142|Experimental|Eligible patients who had consented to participate|Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation < 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.
16362997|NCT04237129|Experimental|Gan & Lee Insulin Aspart|100 units/mL, 3 ml prefilled pen
16362998|NCT04237129|Active Comparator|NovoRapid® Insulin Aspart|"Product approved and marketed in the EU
~FlexPen100 units/mL prefilled pen"
16362999|NCT04237129|Active Comparator|NovoLog® Insulin Aspart|"Product approved and marketed in the US
~FlexPen100 units/mL prefilled pen"
16363000|NCT04237116|Experimental|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
16363001|NCT04237116|Placebo Comparator|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
16363002|NCT04237103|Experimental|methotrexate|Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.
16363003|NCT04237103|Placebo Comparator|placebo|Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.
16363004|NCT04237090|Active Comparator|Diphenhydramine + placebo|"Diphenhydramine 50 mg intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.
~Lactose tablet 100 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water."
16363005|NCT04237090|Experimental|Cetirizine + placebo|"Cetirizine tablet 10 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.
~1 milliliter of sodium chloride 0,9 percent intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion."
16363006|NCT04237077|Experimental|"Group with telephone coaching program ."|subjects aged 75 years or more living at home, with telephone coaching program
16363007|NCT04237077|Active Comparator|"Group without telephone coaching program."|subjects aged 75 years or more living at home, without telephone coaching program
16363008|NCT04237064||Patients with carotid artery stenosis|In this study, patients in the age of > 18 year will be included that are scheduled for an endarterectomy procedure at CZE.
16363269|NCT04235361||EVD patients|"The samples of all subjects (male, female, adults and children) meeting the WHO case definition of suspected and probable EVD case eligible for real time RT-PCR assay, according to the currently used case definition in DRC, will be tested by differential RPA."
16363009|NCT04237038|Experimental|laparoscopic Nissen fundoplication short gastric vessel divi|Randomized clinical trial conducted in forty patients submitted to short gastric vessel division (SGVD) forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life.
16363010|NCT04237025|Experimental|Nordic walking exercise group|Supervised Nordic walking exercise training 3 times per week for the first two weeks and 2 times per week for next four weeks (total 6 weeks). In addition to independent Nordic walking exercise twice weekly during intervention phase and three times weekly during the 3-month followup phase.
16363011|NCT04237012|Experimental|Dextenza|Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
16363012|NCT04237012|Active Comparator|Over the counter Artificial tears|Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert
16363013|NCT04236999|Experimental|YSLQQ group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Unplugged in its original name, but the adaptation made by the research team for Chile is called Yo Sé Lo Que Quiero (YSLQQ). 12 one-hour sessions taught once a week by class teachers, previously trained in a 3-day course. Each session will be delivered during the time of Orientation lessons."
16363014|NCT04236999|No Intervention|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
16363015|NCT04236986|No Intervention|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
16363016|NCT04236986|Experimental|Post-LPS [11C]PBR28 PET Scan|Subjects will complete a second120-minute [11C]PBR28 PET scan 3-hours after LPS administration (1.0ng/kg; IV)
16363017|NCT04236973|Experimental|clinical performance of the Truenat™ HCV assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the Common Technical Specifications 2009/886/EC (CTS) of the CE-IVDD and WHO TSS-10 (draft) for IVDs medical devices used for the qualitative and quantitative detection of Hepatitis C RNA.
16363018|NCT04236973|Active Comparator|comparison CE-IVD marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
16363019|NCT04236960|Experimental|18~55 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
16363020|NCT04236960|Experimental|2~17 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
16363021|NCT04236960|Experimental|7~23 mos|2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.
16363022|NCT04236960|Experimental|3 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.
16363023|NCT04236960|Experimental|2 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.
16363024|NCT04236947|Experimental|SCPP-YA group|SCPP-YA adapted to Chile consist of ten sessions promoting self-regulation strategies, prosocial, and problem-solving skills. It also includes a module (6 sessions) specially designed for substance use prevention, developing social competence, and assertiveness to deal with peer pressure. These 16 sessions will be implemented during an academic year (2020), and complemented with three booster sessions the following year (2021).
16363025|NCT04236947|No Intervention|Control Group|The control schools will continue providing their traditional preventive actions.
16363026|NCT04236934||All included patients|Patients with recurrent unilateral pleural effusion
16363027|NCT04236921|Experimental|Treatment A|1 x DopaSnap® tablet, administered under fasting conditions.
16363028|NCT04236921|Active Comparator|Treatment B|1 x RLD of CD-LD tablet administered under fasting conditions.
16363029|NCT04236921|Experimental|Treatment C|Test - fed 1 x DopaSnap® tablet , administered under fed conditions.
16363030|NCT04236921|Experimental|Treatment D|DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.
16363031|NCT04236921|Experimental|Treatment E|½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose
16363032|NCT04236908|Experimental|Group 1 (NSAIDS only)|NSAIDs only (naproxen 500mg by mouth twice a day as needed)
16363033|NCT04236908|Experimental|Group 2 (Acupuncture+GV26)|Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
16363034|NCT04236908|Experimental|Group 3 (Battlefield Acupuncture+NSAIDS)|Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
16363035|NCT04236908|Experimental|Group 4 (Battlefield Acupuncture+GV26+NSAIDS)|GV26 with manual tonification + Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed).
16363036|NCT04236895|Active Comparator|Lantus ® US|Insulin glargine (Lantus®, product approved and marketed in the USA (US RLD)), 100 U/mL in 3 mL pre-filled pens
16363037|NCT04236895|Active Comparator|Lantus ® EU|Insulin glargine (Lantus®, product marketed in Germany (EU RP)), 100 U/mL in 3 ml pre-filled pens
16363038|NCT04236895|Experimental|Gan & Lee Insulin Glargine|Insulin glargine 100 U/mL in 3 mL pre-filled pens
16363039|NCT04236882|Experimental|Group I (sleep intervention, health coaching session)|Participants receive a web-based sleep intervention during weeks 1-4. Participants then receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out at weeks 5 and 7. Participants may optionally complete an interview over 1 hour at week 9.
16363040|NCT04236882|Experimental|Group II (health coaching session, sleep intervention)|Participants receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out at weeks 1 and 3. Participants then receive a web-based sleep intervention during weeks 5-8. Participants may optionally complete an interview over 1 hour at week 9.
16363084|NCT04236622||Health|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
16363041|NCT04236882|Active Comparator|Group III (health education material, health coaching session)|Participants receive educational material on healthy homes. Participants also receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out at weeks 1 and 3. Participants may optionally complete an interview over 1 hour at week 9.
16363043|NCT04236843|Active Comparator|Smal intestine once|90-g fecal transplant given into the small intestine once.
16363044|NCT04236843|Active Comparator|Small intestine twice|90-g fecal transplant given into the small intestine twice with 1 week interval.
16363045|NCT04236843|Active Comparator|Large intestine once|90-g fecal transplant given into the large intestine once.
16363046|NCT04236830|Experimental|Silver diamine fluoride/ potassium iodide group|Riva Star Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia
16363047|NCT04236830|Experimental|Silver diamine fluoride group|Advantage arrest TM, Elevate Oral Care, USA
16363048|NCT04236830|Active Comparator|Resin modified glass ionomer cement group|Riva light cure, SDI, Bayswater, Australia
16363049|NCT04236817|Experimental|Pre-packed blisters for distribution of medications|Patients in the intervention group received prescriptions pre-packaged in individual packets that were delivered by the pharmacy.
16363050|NCT04236817|Placebo Comparator|Routine distribution of medications|Patients in the control group continued to receive medications from pharmacies as they did prior to enrollment.
16363051|NCT04236804|Experimental|TMC-CP01 Intervention|Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines.
16363052|NCT04236804|No Intervention|Standard of Care|Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
16363053|NCT04236791|Experimental|Intervention group|
16363054|NCT04236791|Active Comparator|Control group|
16363055|NCT04236778|Experimental|Cohort 1|Cohort 1 received oral vancomycin followed by a single dose of VE303.
16363056|NCT04236778|Experimental|Cohort 2|Cohort 2 received oral vancomycin followed by a single day of 5 doses of VE303.
16363057|NCT04236778|Experimental|Cohort 3|Cohort 3 received oral vancomycin followed by a single day of 10 doses of VE303.
16363058|NCT04236778|Experimental|Cohort 4|Cohort 4 received oral vancomycin followed by 5 days of 10 doses daily of VE303.
16363059|NCT04236778|Experimental|Cohort 5|Cohort 5 received oral vancomycin followed by 14 days of 10 capsules daily of VE303
16363060|NCT04236778|Experimental|Cohort 6|Cohort 6 received 21 days of 10 doses daily of VE303
16363061|NCT04236778|Experimental|Cohort 7|Cohort 7 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
16363062|NCT04236778|Experimental|Cohort 8|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
16363063|NCT04236778|Experimental|Cohort 9|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
16363064|NCT04236778|Placebo Comparator|Vancomycin only|This cohort only received oral vancomycin.
16363065|NCT04236765|Experimental|TB infection-screening benefiting group|children VFRs under 15 years of age (which are children of immigrants and born or not in Spain) who travel to countries with an elevated incidence of TB will be screened for LTBI after their return.
16363066|NCT04236752|Experimental|Single arm radiotherapy|HDR Brachytherapy Boost of 15Gy to the prostate followed by Stereotactic Ablative Body Radiation (SBRT) 25 Gy in 5 fractions, once weekly to prostate, SVs and pelvic lymph nodes + 6-18 months of ADT
16363067|NCT04236739|Experimental|IMPACT|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) during one surgical procedure.
16363068|NCT04236739|No Intervention|Control|Optional physical therapy or pain medication, according to participants' desire for 9 months.
16363069|NCT04236726||Non-invasive ventilation|Users of non-invasive ventilation
16363070|NCT04236726||Long term tracheostomy ventilation|Long term tracheostomy ventilated patients
16363071|NCT04236713|Experimental|Dietary intervention 1|
16363072|NCT04236713|Experimental|Dietary intervention 2|
16363073|NCT04236700||beach workers|"Workers must undergo clinical examinations of the upper and lower lips, performed by previously calibrated researchers, through semi-technical inspection and palpation maneuvers, in order to identify injuries. Photo cameras can be used to improve the visibility of the lips using the image enhancement feature, to confirm the diagnosis. The clinical examination will include: dryness, atrophy, scaly lesions, lip swelling, erythema, ulcerations, cloudy demarcations between the vermilion of the lip and skin, demarcated folds along the lip, white spots or plaques, crusts, stained or pale areas.
~They should be evaluated with the application of a previously validated questionnaire containing information related to personal data, information on occupation and health was completed according to the responses of the volunteers. The OHIP-14 quality of life questionnaire will be applied together"
16363074|NCT04236687|Experimental|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
16363075|NCT04236687|Active Comparator|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate.
16363076|NCT04236674|No Intervention|No intervention|
16363077|NCT04236674|Experimental|Buzzy|Thermomechanical device for periprocedural analgesia
16363078|NCT04236674|Experimental|Music Selection|Patient specified music selection for procedural room
16363079|NCT04236674|Experimental|Buzzy and Music Selection|A combination of use of the Buzzy device and patient specified music selection
16363080|NCT04236661|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
16363081|NCT04236648|Other|Minimally-invasive non-surgical therapy (MINST)|Study treatment
16366129|NCT04215276|Active Comparator|Valsalva Maneuver|Patient will do valsalva maneuver for 20 seconds
16363085|NCT04236622||Peri-implantitis|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
16363086|NCT04236609|Active Comparator|Abluminus DES+ sirolimus- eluting stents (SES)|Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
16363087|NCT04236609|Active Comparator|XIENCE Everolimus-Eluting Stents (EES)|Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
16363088|NCT04236596|Experimental|Medtronic Interstim II Model 3058 Neurostimulator|
16363089|NCT04236583|Experimental|Telehealth|Eligible patients will be given the option to consent to having one virtual visit with their primary care physician within four weeks after discharge from the hospital. Usual follow-up care will occur during this visit.
16363090|NCT04236570|Other|Pain tests with the standardized protocol|This arm will consisted of pain tests using the standardized protocol (thermode(hot plate) and cold water bath)). The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the standardized protocol, the TS will consisted of a noxius heat stimulus generated by a thermode (hot plate), applied for two minutes on the non-dominant anterior forearm. The CS will consisted of a cold pressor test (CT), wherein participants immersed their dominant forearm in a cold water bath for two minutes.
16363091|NCT04236570|Other|Pain tests with the TENS protocol|This arm will consisted of pain tests using the TENS protocol. The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the TENS protocol, the TS will consisted of a noxius electrical stimulus generated by TENS, applied for 5 seconds on the non-dominant knee at a frequency of 1 Hz and 5 Hz. The CS will consisted of a noxius electrical stimulus generated by TENS' applied for 120 seconds on the non dominant knee and ankle at a frequency of 2 Hz
16363092|NCT04236557|Experimental|Intervention|
16363093|NCT04236557|Placebo Comparator|Wait-list Control|
16363094|NCT04236544|Experimental|PExMS and DECIMS-Wiki|After allocation, the intervention group will receive access to PExMS and DECIMS-Wiki for a four-week period. The former is a multimedia website providing experiential information. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
16363095|NCT04236544|Active Comparator|DECIMS-Wiki|After allocation, the control group will receive access to the DECIMS-Wiki for a four-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
16363096|NCT04236531|Experimental|individuals at ultra-high risk for psychosis (UHR)|"30 individuals meeting the UHR criteria according to the Comprehensive Assessment of at-risk mental state (CAARMS) will be recruited and will complete cognitive task and MRI scan"
16363097|NCT04236531|Experimental|patients with first episode psychosis (FEP)|30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan
16363098|NCT04236531|Sham Comparator|healthy controls|30 healthy individuals will be recruited and will complete cognitive task and MRI scan
16363099|NCT04236518|Experimental|: hypertriglyceridimic waist phenotype / animal protein source|20 men between 25 and 55 years old with a high waist circumference and high triglyceridemia receiving diets with predominantly animal protein sources
16363100|NCT04236518|Experimental|hypertriglyceridimic waist phenotype / plant protein source|20 men between 25 and 55 years old with a high waist circumference and high triglyceridemia receiving diets with predominantly plant protein sources
16363101|NCT04236505|Experimental|ACT group intervention|4 weekly 2hour group therapy interventions drawing from an Acceptance and Commitment Therapy (ACT) based protocol.
16363102|NCT04236505|Experimental|Mindfulness skills group intervention|4 weekly 2 hour group therapy interventions drawing from an Mindfulness based stress reduction (MBSR) based protocol
16363103|NCT04236505|Placebo Comparator|Wait list control group|Wait list control group who at the time of the experimental group interventions are not attending a group and receiving treatment as usual. This group are offered a Mindfulness skills group intervention after the follow up data has been collected.
16363104|NCT04236492||Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
16363105|NCT04236479|Experimental|Bone marrow-derived mesenchymal stromal cell (BM-MSC)|The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD.
16363106|NCT04236466|Experimental|hyrax group|cleft lip and palate patients with hyrax appliance
16363107|NCT04236466|Experimental|haas group|cleft lip and palate patients with haas appliance
16363108|NCT04236453|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
16363109|NCT04236453|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COB] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
16363136|NCT04236297|Other|Modified Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a modified bite block is used
16363276|NCT04235296|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
16363110|NCT04236440|Experimental|Part A: A1A2+Part B+Part C|"Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.
~Part B: After successfully completing Part A, participants will proceed to Part B of the study.
~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.
~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).
~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
16363111|NCT04236440|Experimental|Part A: A2A1+Part B+Part C|"Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.
~Part B: After successfully completing Part A, participants will proceed to Part B of the study.
~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.
~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).
~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
16363112|NCT04236427|Experimental|Treatment Group|Chinese Medicine of Angong Niuhuang Wan
16363113|NCT04236427|Placebo Comparator|Placebo Group|Placebo of Angong Niuhuang Wan
16363118|NCT04236401|Other|electrosurgery will be used inanterior abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall electrosurgically.
16363119|NCT04236401|Other|scalpel will be used in abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall sharply.
16363120|NCT04236388|Active Comparator|Dietary Ketone|Participants will consume three daily ketone drinks (one before each meal) for 2 weeks.
16363121|NCT04236388|Placebo Comparator|Placebo|Participants will consume three daily placebo drinks (one before each meal) for 2 weeks. .
16363122|NCT04236375||Normal|Subjects over 45 years old without cognitive dysfunction
16363123|NCT04236375||Mild cognitive decline|Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists.
16363124|NCT04236375||Alzheimer's disease|Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists.
16363125|NCT04236375||Vascular dementia|Subjects who are diagnosed as vascular dementia(VD) according to neurologists.
16363126|NCT04236375||Lewy body dementia|Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists.
16363127|NCT04236375||Frontotemporal dementia|Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists.
16363128|NCT04236375||Other dementia|Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD.
16363129|NCT04236362|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16363130|NCT04236349||CO1TB: observational|patients with pulmonary and extrapulmonary tuberculosis
16363131|NCT04236349||CO2TB: immunogenetics|"patient with pulmonary and extrapulmonary tuberculosis and meet the following criteria:
~informed consent form signed by the patient or by the representative of parental authority
~affiliation to social security (beneficiary or assignee)
~HIV negative"
16363132|NCT04236323|Experimental|not used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair not used intraoperative remifentanil infusion
16363133|NCT04236323|No Intervention|used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair used intraoperative remifentanil infusion maintaining target concentration of 2-6ng/ml
16363134|NCT04236310|Experimental|SHR6390+Anastrozole+Pyrotinib+Trastuzumab±Ovarian Suppression|
16363135|NCT04236297|Active Comparator|Standard Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a standard bite block is used
16363173|NCT04236076|Sham Comparator|Sham PulseHaler - CONTROL group|Patients will receive Sham device for home treatment
16363137|NCT04236284|Experimental|Home-based tDCS + Prolonged Exposure Therapy|Participants will come in person to the clinic office to complete the baseline visit and the in-person training for the use of both home-based self-administered tDCS and the home-based telehealth device (iPad) for the PE sessions. They understand that they will start the sessions of tDCS once they start the in vivo and imaginal exposures assignments at home. They will self-administer (under televideo supervision) the tDCS session before doing in vivo and/or imaginal exposures assignments. The participants will be remotely supervised by trained research staff at each stimulation to ensure the technique is correct and to monitor any adverse events. We will provide secure videoconferencing software (e.g., WebEx) and ensure the participants are comfortable using the telehealth software.
16363138|NCT04236271|Experimental|patient|interventional group
16363139|NCT04236258|Active Comparator|Nifedipine|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start nifedipine extended release 30 mg daily as their starting antihypertensive.
16363140|NCT04236258|Active Comparator|Enalapril|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start enalapril 10 mg daily as their starting antihypertensive.
16363141|NCT04236245|Other|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
16363142|NCT04236232||Patients who will be diagnosed as Subclinical Hypothyroidism|50 pt who will be diagnosed as Subclinical Hypothyroidism by elevated level of TSH (TSH: >4.5 mu/l) and normal T4
16363143|NCT04236232||Patients with normal thyroid function|50 pt with normal thyroid function (TSH &T4)
16363144|NCT04236219|Experimental|ALLN-346|ALLN-346
16363145|NCT04236219|Placebo Comparator|Placebo|Placebo
16363146|NCT04236206|Experimental|SMS Recipients|• Mobile phone SMSs will be sent to the intervention group with the aim of improving medication adherence and knowledge about diabetes, its complications, diet and physical activity.
16363147|NCT04236206|No Intervention|Non-SMS Recipients|Control group with no intervention.
16363148|NCT04236193||SIRVA|Subjects with shoulder pain >7 days after vaccination
16363149|NCT04236193||Controls|Subjects from a prospective influenza vaccine study
16363150|NCT04236180|Active Comparator|Intervention Group|Patients enrolled in the Specialised Paediatric Palliative Care (SPPC) programme at the University Children's Hospital Zurich.
16363151|NCT04236180|No Intervention|Comparison Group|Patients treated at the Children's Hospital Aarau, University Children's Hospital Basel, and the University Hospital Inselspital Bern.
16363152|NCT04236167|No Intervention|Control half of scar|one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
16363153|NCT04236167|Experimental|Laser treatment half of scar|The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment
16363154|NCT04236154|Experimental|10%|Increase exercise daily step count by 10% above individual baseline.
16363155|NCT04236154|Experimental|20%|Increase exercise daily step count by 20% above individual baseline.
16363156|NCT04236154|Experimental|30%|Increase exercise daily step count by 30% above individual baseline.
16363157|NCT04236154|Experimental|50%|Increase exercise daily step count by 50% above individual baseline.
16363158|NCT04236154|Experimental|80%|Increase exercise daily step count by 80% above individual baseline.
16363159|NCT04236141|Experimental|Polatuzumab Vedotin plus BR|
16363160|NCT04236141|Active Comparator|Placebo plus BR|
16363161|NCT04236128|Experimental|Intervention Group|The intervention group will receive the same usual care as the control group plus be enrolled in the integrated discharge monitoring system.
16363162|NCT04236128|Active Comparator|Control Group|The control group will receive usual follow up care that is currently provided at the 3 participating centres.
16363163|NCT04236115|Active Comparator|Articaine 4% with 1:00.000 Adrenaline|if the patient was in articaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
16363164|NCT04236115|Active Comparator|Prilocaine with 3% Felypressin (0.03 I.U. per ml)|if the patient was in prelocaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
16363165|NCT04236102|Experimental|EGFR, KRAS, BRAF Lung adenocarcinoma LBC|Will use residual material from existing LBC cytology samples sent to the laboratory. Routine testing will take priority. Cases identified as non small cell lung carcinoma will have the residual LBC sample tested on the Idylla platform for EGFR, KRAS and BRAF. The EGFR, KRAS and BRAF mutation results obtained using the routine diagnostic procedure (FFPE samples) will be compared to those produced using the LBC samples.
16363166|NCT04236102|Experimental|KRAS Pancreatic adenocarcinoma|Will involve testing archived FFPE clot samples from confirmed pancreatic adenocarcinoma patients since 2014 (Approximately 20 cases per year). KRAS testing will be performed using the Idylla platform to establish if there is a KRAS codon 12 mutation present in 94% percent of the cases reported at RCHT. Patients will have consented to the use of their tissue at the time of procedure. Prospectively new patients diagnosed with pancreatic adenocarcinoma will have KRAS testing on the FFPE clot made as part of the routine diagnostic work up and KRAS testing on the LBC sample.
16363167|NCT04236102|Experimental|EGFR, KRAS, BRAF Blood plasma|Will involve a blood sample being taken at the time of the procedure from patients that have a clinical suspicion of having lung or pancreatic cancer. The single blood sample will be taken from the cannula inserted for the procedure. The blood sample will be processed using the Biocartis Idylla ™ circulating tumour cell cartridges (EFGR, KRAS and BRAF for lung and KRAS for pancreas).
16363168|NCT04236089|No Intervention|mirror therapy of healthy adults|Traditional mirror therapy in electroencephalography of healthy adults.
16363169|NCT04236089|Experimental|robotic mirror therapy of healthy adults|Robotic mirror therapy in electroencephalography of healthy adults.
16363170|NCT04236089|No Intervention|mirror therapy of stroke patients|Traditional mirror therapy in electroencephalography of stroke patients.
16363171|NCT04236089|Experimental|robotic mirror therapy of stroke patients|Robotic mirror therapy in electroencephalography of stroke patients.
16363172|NCT04236076|Experimental|PulseHaler™|Patients will receive PulseHaler for home treatment
16363175|NCT04236050|Experimental|rocuronium is administered via continuous infusion|"40 patients. General anesthesia is maintained with propofol and remifentanil, with standard anesthetic monitoring, bispectral index (BIS) and train-of-four(TOF). In experimental group, rocuronium was administered via continuous infusion so that theTOF ratio was 5%. Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.
~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
16363176|NCT04236050|Active Comparator|rocuronium is administered in bolus doses|"40 patients. General anesthesia was maintained with propofol and remifentanil, with standard anesthetic monitoring, BIS and TOF. In this group, rocuronium was administered in separate bolus doses with the TOF ratio of 5%.
~Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.
~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
16363177|NCT04236037|Active Comparator|Ultrasound-guided thoracentesis|Ultrasound guided thoracentesis
16363178|NCT04236037|Experimental|Ultrasound-guided pleural biopsy and thoracentesis|Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
16363179|NCT04236024|Experimental|Experimental group|The students in this group will learn medication knowledge by using board game.
16363180|NCT04236024|Active Comparator|Comparison group|The students in this group will learn medication knowledge through tradition lecture.
16363181|NCT04236011|Experimental|GC012F treatment|BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
16363182|NCT04235998||Systematic lung ultrasound|Patients with unilateral pleural effusion of unknown course
16363183|NCT04235985|Other|All time points|
16363184|NCT04235972|Other|Arthrodesis surgery patients|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
16363185|NCT04235959|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
16363186|NCT04235959|Placebo Comparator|Placebo|Placebo administered SC.
16363187|NCT04235946|Experimental|accompanied and adapted water polo program|"16 and 20 aqua polo sessions (adapted water polo) over a period of 20 weeks, at the rate of one session per week at the Cercle des Nageurs de Marseille (CNM). They will be divided into 3 cycles imitating the preparation of the season of a high-level athlete: a first cycle intended for physical preparation, a second cycle intended for practical learning (technique and tactics) and the third cycle for preparation of a mini tournament.
~Each session will be organized as follows: 1 hour of training in the water followed by 30 min of debriefing as a team or individually with the coach. The announced duration of the session will be 2 hours, transport and changing rooms included."
16363188|NCT04235933|Experimental|Tai Ai(RC18) 80mg|·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
16363189|NCT04235933|Experimental|Tai Ai(RC18) 160mg|·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
16363190|NCT04235933|Experimental|RC18 240mg|·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18
16363191|NCT04235920||Impaired Cognition|First group was cognitively impaired test with MoCA score of 25 or less.
16363192|NCT04235920||Preserved cognition|The second group was cognitively preserved with MoCA score of higher than 25.
16363195|NCT04235894||Patients undergoing GI endoscopy at Osijek University Hospital|Observational study. A total of 130 consecutive patients undergoing gastrointestinal endoscopy were included. The anesthesia was provided with propofol, starting with 0,5 mg/kg, and titrated until a patient was unresponsive to painful stimuli and maintaining spontaneous breathing. The blood pressure, pulse and Bispectral index values were measured in 6 defined points. On the emergence from anesthesia, the patient's facial expression was rated numerically by the investigator.
16363196|NCT04235881|Experimental|MBSR group|Enforcement of the standardized program Mindfulness-Based Stress Reduction
16363197|NCT04235881|Experimental|App group.|Enforcement of the emotional regulation program based on mindfulness (ERM) through the mobile phone application REM volver a casa
16363198|NCT04235881|No Intervention|Control group|Usual care
16363199|NCT04235868|Active Comparator|control group|
16363200|NCT04235868|Experimental|experimental group|
16363201|NCT04235855|Experimental|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
16363202|NCT04235855|Active Comparator|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
16363203|NCT04235842|No Intervention|Control Group (CG)|The CG will receive the standard indications routinely provided by the hospital which consists in information about practice of regular physical activity according to World Health Organization. A leaflet with illustrations and indications will be provided and will be explained by the principal investigator.
16363204|NCT04235842|Experimental|Moderate-intensity continuous exercise training group (GMICT)|The GMICT will be submitted to a physical exercise program in which the aerobic component will be a moderate-intensity continuous exercise training, performed at 60% of the heart rate reserve, two days a week, for 30 minutes.
16363277|NCT04235283|Experimental|Group I|Primary total knee replacement by pinless navigation and minimally invasive technique
16363205|NCT04235842|Experimental|High-intensity interval training exercise group (GHIIT)|The GHIIT will be will be submitted to a physical exercise program in which the aerobic component will be a high-intensity interval exercise training, performed in a protocol consisted of four one-min sprint at 90% of the heart rate reserve, alternated with one-min rest (at week 1) and progressing until reach 10 bouts of one-min sprint alternated with one-min rest.
16363206|NCT04235816|Active Comparator|Group 1|AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age.
16363207|NCT04235816|Placebo Comparator|Group 2|Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age.
16363208|NCT04235803|Experimental|Telemedicine|Patients in the telemedicine arm will have their post-operative week one visit via a telemedicine portal.
16363209|NCT04235803|No Intervention|Routine|Patient in the routine arm will have their post-operative week one visit in clinic.
16363210|NCT04235790|No Intervention|Medical Student or Resident|Subjects will perform simulated central venous catheters (CVC) insertions.
16363211|NCT04235790|Other|Novice and Expert IBP Teachers|Expert teachers will be identified based on years as faculty, number of supervised procedures, prior teacher awards, and participation in IBP teaching at international conferences. Novice teachers will include those that have performed less than 50 CVCs. Teachers will supervise 3 simulated central venous catheters (CVC) insertions with increased complexity while wearing an eye tracking device.
16363216|NCT04235751|Experimental|Immediate Coaching Intervention|Subjects will receive 6 professional coaching sessions
16363217|NCT04235751|Experimental|Delayed Coaching Intervention|Subjects will receive no coaching for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
16363218|NCT04235699|Experimental|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood [3-OHB] ≥0.5 mM.
16363219|NCT04235699|Experimental|Low-fat mixed Diet|This arm will be provided food consisting of ~25% fat, and the remaining calories from carbohydrate (~55% after accounting for protein at ~20%).
16363220|NCT04235686|Active Comparator|Mydayis - Active|"MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.
~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
16363221|NCT04235686|Placebo Comparator|Placebo|"Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.
~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
16363222|NCT04235673|Experimental|melatonin|melatonin oral drops; 3 mg/kg/day for 15 days
16363223|NCT04235673|Placebo Comparator|placebo|oral drops manufactured to mimic melatonin
16363224|NCT04235660|Active Comparator|Yttrium-90 Radiation Segmentectomy|
16363225|NCT04235660|Active Comparator|Stereotactic Body Radiation Therapy|
16363226|NCT04235647|Experimental|Study group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
16363227|NCT04235647|Active Comparator|Control group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
16363228|NCT04235634||Intra-arterial Prostglandin therapy|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
16363229|NCT04235621||FSGS/TR-MCD|Patients with FSGS/TR-MCD
16363230|NCT04235621||Diabetic Nephropathy (DN)|Patients with DN
16363233|NCT04235595|Experimental|Connective Tissue Manipulation|The participants were administered CTM by a physiotherapist with 11 years of experience in the application from the point at which their menstrual cycles had ended to the beginning of the next cycle. Another assessment was made immediately after the treatment and this was repeated at the second, third and fourth menstrual cycles. The CTM took an average of 20-30 minutes to complete.
16363234|NCT04235595|Experimental|Transcutaneous Electrical Nerve Stimulation|Following the assessment made in the participants' first menstrual cycle, on the most painful day of their second cycle (1st or 2nd day of the cycle), high-frequency TENS was applied at a frequency of 120 Hertz, at intervals of 100 µsn for 20 minutes. The intensity of the current was increased until the participant felt it.
16363235|NCT04235582|Experimental|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
16363236|NCT04235582|Experimental|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:
~Drug adherence to prescribed SUD pharmacotherapy
~Attendance at individual and group psychotherapy sessions"
16363270|NCT04235348||BELIEVE|Consists of subjects referred to a colonoscopy between June 1, 2017, and December 1, 2019, in the hospital of Southern Denmark
16363271|NCT04235335|Other|Wait List Control|Participants receive intervention after 12 week delay
16363237|NCT04235582|Experimental|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:
~Drug adherence to prescribed SUD pharmacotherapy
~Attendance at individual and group psychotherapy sessions
~Random saliva tests"
16363238|NCT04235569|Experimental|Group I|"a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.
~Bleeding events due to overanticoagulation were monitored through the follow up period."
16363239|NCT04235569|Experimental|Group II|"a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.
~Bleeding events due to overanticoagulation were monitored through the follow up period."
16363240|NCT04235556||Historic cohort|Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
16363241|NCT04235556||Prospective cohort|All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
16363242|NCT04235543||autistic children aged 6:12 years|show the occurrance of traumatic dental injury compared to normal children
16363243|NCT04235543||normal children aged 6:12 years|show the occurrance of traumatic dental injury
16363244|NCT04235530||VAS and DVAS|To measure the pain score of patients after surgery
16363245|NCT04235517||Axial deviations in children|Children with axial deviations in the lower extremity treated with guided growth
16363246|NCT04235517||Limb length discrepancy in children|Children with limb length discrepancy treated with temporary epiphysiodesis
16363247|NCT04235504|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy (MDI+FGM or MDI+CGM) for 6 months during the Study Phase. During the Continuation Phase of 6 months Control Arm will start using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0
16363248|NCT04235504|Experimental|Treatment Arm|The Treatment Arm will use the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0 for 6 months during the Study Phase and other 6 months during the Continuation Phase.
16363249|NCT04235491||Micra AV leadless pacemaker therapy|All Medicare patients implanted with a Micra AV leadless pacemaker system
16363250|NCT04235491||Dual Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) dual-chamber transvenous pacemakers
16363251|NCT04235478|Experimental|Cervical interlaminar epidural steroid injecion|Floroscopy-guided cervical interlaminar epidural steroid injecion will be applied to the patients with cervical radiculopathy related neck and arm pain
16363252|NCT04235465||Dyslexia Group|30 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7-day interval by two evaluators
16363253|NCT04235465||Healthy Control Group|30 healthy children will be included. Dynamic Gait Index will be performed.
16363254|NCT04235452||Epileptic myoclonus|Juvenile Myoclonic Epilepsy and Progressive Myoclonic Epilepsy
16363255|NCT04235452||Non-epileptic myoclonus (secondary)|Post hypoxic myoclonus, Post ischemic stroke myoclonus, Hepatic, Chronic kidney disease, and Drug induced myoclonus
16363256|NCT04235439|Experimental|Gan & Lee Insulin Lispro Injection|Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)
16363257|NCT04235439|Active Comparator|EU - approved Humalog ®|Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
16363258|NCT04235439|Active Comparator|US - licensed Humalog ®|Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
16363259|NCT04235426|Experimental|surgical group.|30 patients went to the surgical release of carpal tunnel.
16363260|NCT04235426|Experimental|medical group.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
16363261|NCT04235426|Experimental|injection group.|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
16363262|NCT04235413|Experimental|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 6 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
16363263|NCT04235413|No Intervention|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
16363264|NCT04235400||patient with dry eye disease|
16363265|NCT04235387||Robotic prostatectomy|All patients undergoing robotic assisted prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
16363266|NCT04235387||Laparoscopic prostatectomy|All patients undergoing standard laparoscopic prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
16363267|NCT04235374|Experimental|FFC-AC-EIT|The stakeholder team will meet with the research nurse facilitator to review the details of the 12 month intervention and identify unit goals. The research nurse facilitator will then work with the identified champion for 10 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to implement Steps 1 to 4 of FFC-AC-EIT [(1) Environment and Policy Assessments; (2) Education; (3) Establishing Patient Goals; and (4) Mentoring and Motivating of Staff, Patients and Families]. The stakeholder team will meet with the Research Nurse Facilitator monthly to review progress. In addition to monthly visits, weekly emails containing motivational Tidbits will be sent to all stakeholder team members within the cohort. The Tidbits include such things as updates about benefits of engaging patients with ADRD in physical activity while hospitalized.
16363268|NCT04235374|Placebo Comparator|Education Only|Education Only (EO) Control Intervention: Hospitals randomized to EO will be provided with an in-service for nursing staff on function focused care in patients with ADRD by an EO Research Nurse Facilitator using our developed PowerPoint presentations in 30-minute sessions as is currently done in usual practice.
16363278|NCT04235283|Active Comparator|Group II|Primary total knee replacement by traditional jig and minimally invasive technique
16363279|NCT04235270|Experimental|Group 1 (Bioequivalence Part)|Participants will receive Treatment A (single oral dose of an fixed dose combination [FDC] of macitentan/tadalafil [10 milligram [mg]/40 mg] in fasted conditions [test]) or Treatment B (single oral dose of a free combination of 10 mg macitentan and 40 mg tadalafil in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment B or Treatment A on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
16363280|NCT04235270|Experimental|Group 2 (Food-effect Part)|Participants will receive Treatment C (single oral dose of an FDC of macitentan/tadalafil [10 mg/40 mg] in fed conditions [test]) or Treatment D (single oral dose of an FDC of macitentan/tadalafil (10 mg/40 mg) in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment D or Treatment C on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
16363281|NCT04235257|Experimental|Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
16363282|NCT04235257|Experimental|Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
16363283|NCT04235244|Experimental|upper right abdomen|5 minutes before and after application to the right upper abdominal region. local cold application
16363284|NCT04235244|Experimental|upper left abdomen|Thermomechanical-analgesia device will be operated 30 seconds before the injection in the right lower abdominal region and the device will be injected by sliding the device to the side of the selected region during the injection,
16363285|NCT04235244|Experimental|lower left abdomen|Coolant spray will be applied to the upper left abdominal region for 15 sec.
16363286|NCT04235244|No Intervention|lower right abdomen|SC injection will be applied to the left lower abdominal region without any cold application.
16363287|NCT04235231|Experimental|Lateral tilt bed|Bed tilting (15° lateral tilt, original product brand name LINET Eleganza 5)
16363288|NCT04235231|Experimental|Body positioning|Manual positioning of body by nurse.
16363289|NCT04235205|Experimental|Elobixibat and cholestyramine|The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
16363290|NCT04235205|Experimental|Elobixibat|The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
16363291|NCT04235205|Experimental|cholestyramine|The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
16363292|NCT04235205|Placebo Comparator|Placebo|The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
16363293|NCT04235179|Experimental|SABR|Pelvic SABR for post-op endometrial cancer
16363294|NCT04235166||Patient cohort|Different risk score was used to assess the prognosis of acute upper gastrointestinal bleeding in cirrhosis.
16363295|NCT04235153||Patients with solid or hematological cancer|All the patients complete the CANUT-QVA questionnaire
16363296|NCT04235140|Experimental|LUM/IVA|Subjects will receive LUM/IVA for 96 weeks.
16363297|NCT04235127||Catalan population|The target population consists of the dynamic cohort of all Catalan residents during the 6-year period 2014-2019. Annual total population of Catalonia is between 7.5-7.6 million, with annual rates for immigration, emigration, birth and death being ~2.5%, ~1.9%, ~0.9%, and ~0.8%, respectively. Based on these figures, we expect a maximum of ~9.1 million individuals with Catalan residency status on at least one point in time over the 2014-2019 period. However, we expect SA in Catalonia to be extremely rare before the age of 10, in line with findings that self-injurious behaviour generally occurs as from the adolescent period. We will therefore exclude cases and controls that have not reached age 10 by the end of the 2014-2019 period (i.e., ~10.9%), lowering the total expected target population to ~8.1 million.
16363298|NCT04235114|Experimental|Establish Imaging Time|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
16363299|NCT04235114|Experimental|Diagnostic Quality|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging once at the best time calculated from arm 1 participants. Vitals, blood sample and urine sample will be collected before imaging. Participants will be followed up for any adverse event until day 30 post administration
16363300|NCT04235114|Experimental|Establish Cold Dose|Participants will receive an i.v. injection of 1 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
16363301|NCT04235101|Experimental|SYD985 + Niraparib|SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
16363302|NCT04235088|Experimental|Somatosensory intensive intervention|
16363303|NCT04235075|Experimental|Pregnancy volunteer subjects|Subjects who will agree to participate in the study will be pregnant women referred to the Grenoble Alpes University Hospital for expert fetal cardiac ultrasound examination who have not revealed any abnormalities.
16363304|NCT04235062|Experimental|Fluid Expansion and Diuretic Challenge|Subject receive intravenous infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution, followed by diuretic challenge with 40mg Furosemide intravenous bolus.
16363305|NCT04235049|No Intervention|In prison treatment arm|Of patients who achieved SVR, 100 inmates will be enrolled for long-term monitoring for re-infection after they have completed treatment. Patients will be seen every 6 months to test for reinfection, however they will not be subject to any medical or behavioral interventions through the study team. Limited opioid agonist therapy may be available as per the standard practice of the DOC, however syringe exchange and other harm reduction services will not be accessible to inmates, per DOC policy.
16363306|NCT04235049|Active Comparator|Community Linkage - Rapid Initiation Arm|The rapid initiation group will receive HCV medication immediately upon release from prison/jail.
16363307|NCT04235049|Active Comparator|Community Linkage - Clinic-Based Initiation Arm|The group will receive medication after attending first ANCHOR clinic visit.
16363308|NCT04235049|No Intervention|In prison - Retrospective Review|a retrospective review of de-identified available data provided by the DOC for all patients previously treated with DAAs through standard of care in the DOC will be reviewed for rates of SVR.
16363309|NCT04235036|Experimental|Rituximab + Ibrutinib|Eligible patients will be those with a first episode of symptomatic cGVHD, requiring systemic immunosuppression for control of symptoms. Following study entry, patients will be started on rituximab plus ibrutinib.
16363310|NCT04235023|Other|OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index ≥ 15 per hour
16363311|NCT04235023|Other|non OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index < 15 per hour
16363312|NCT04235010|Experimental|Manual toothbrush|Patients used manual orthodontic toothbrush (Oral B Ortho, Procter & Gamble, USA) for four months
16363313|NCT04235010|Experimental|Genius toothbrush|Patients used genius orthodontic toothbrush (Oral B Genius 8900, Procter & Gamble, USA) for four months
16363314|NCT04234997|Experimental|Suvorexant 20 mg|
16363315|NCT04234997|Placebo Comparator|Suvorexant 0mg|
16363316|NCT04234984||Conventional radiofrequency treatment|All patients with chronic knee pain who qualify for a conventional RF treatment of the genicular nerves
16363317|NCT04234971|Experimental|Intervention group (DBM/BMP)|Patient undergoes Alveolar bone graft with DBM/BMP
16363318|NCT04234971|Active Comparator|Control group(autologous ICBG)|Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
16363319|NCT04234958|Experimental|Experimental|Participants received osteopathic treatment
16363320|NCT04234958|Sham Comparator|Sham|Participants received sham therapy
16363321|NCT04234958|No Intervention|Control|Participants received no intervention
16363322|NCT04234945|Experimental|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
16363323|NCT04234945|Placebo Comparator|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
16363324|NCT04234932|Experimental|Netarsudil alone|Topical application of netarsudil 0.02%
16363325|NCT04234932|Active Comparator|Netarsudil plus latanoprost|Topical application of netarsudil 0.02% with latanoprost 0.005%
16363326|NCT04234919||Consented adult lung transplant recipients|
16363327|NCT04234906|Active Comparator|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
16363328|NCT04234906|Active Comparator|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
16363329|NCT04234906|Active Comparator|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
16363330|NCT04234906|Active Comparator|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
16363331|NCT04234893||Drug-coated balloon|The Patients who treated with Bingo drug-coated balloon
16363332|NCT04234867|Experimental|Dapagliflozin - Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of 250µg ACTH (Synacthen)
16363333|NCT04234867|Experimental|Dapagliflozin and Placebo Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of Placebo matching Synacthen
16363334|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of 250µg ACTH (Synacthen)
16363335|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Placebo Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of Placebo matching Synacthen
16363337|NCT04234841||Surgical Aortic Valve Replacement (SAVR)|This cohort includes patients who will be undergoing surgical aortic valve replacement
16363338|NCT04234841||Transcatheter Aortic Valve Implantation (TAVI)|This cohort includes patients who will be undergoing Transcatheter Aortic Valve Implantation
16363339|NCT04234828||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings Sleep Device and overnight PSG
16363340|NCT04234815|Experimental|CETA Short Session (CSS)|A single-session, 1.5-2 hour group workshop that includes psychoeducation, self-assessment, safety screening, and training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance. On this phone call they will also be asked about their use of the cognitive coping skill over the last week, and provided feedback if using it incorrectly.
16363341|NCT04234815|Active Comparator|Enhanced Treatment as Usual (eTAU)|A single-session, approximately 1-hour group workshop that includes the same psychoeducation, self-assessment, and safety screening as the experimental condition, but no training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance.
16363342|NCT04234802|Active Comparator|HEAT intervention group|Workers in the intervention group will receive the HEAT training, and supervisors in the intervention group will receive the HEAT awareness application and training on how to use it.
16363343|NCT04234802|No Intervention|Comparison group|The comparison group will not be offered HEAT trainings or the HEAT awareness application. They will be offered an alternative training on another topic.
16363344|NCT04234789|Other|Cardiopulmonary exercising test|All patients underwent to diagnostic tests protocol
16363345|NCT04234776|Experimental|Rapid-acting antidepressant|Subjects eligible to participate in the study will receive IM ketamine and will use 2 placebo tablets as randomized.
16363346|NCT04234776|Active Comparator|Comparator|Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized
16363347|NCT04234763|Experimental|T2D patients|T2D patients (n=24) will be randomized to high GI and low GI MCT randomly.
16363348|NCT04234763|Active Comparator|Healthy individuals|Healthy individuals (n=24) will be randomized to high GI MCT only.
16363349|NCT04234750|No Intervention|control group|no intervention
16363350|NCT04234750|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
16363351|NCT04234737|Experimental|Hypnotherapy|
16363352|NCT04234737|No Intervention|Control|
16363353|NCT04234724|Experimental|Variant|Volunteers with known ANGPTL3 variants
16363354|NCT04234724|Other|Non-variant|Healthy volunteers with no ANGPTL3 variants
16363355|NCT04234711||Conventional surgical group|Patients with total pulmonary venous connection undergo conventional surgical repair
16363356|NCT04234711||Sutureless surgical group|Patients with total pulmonary venous connection undergo sutureless surgical repair
16363357|NCT04234685|Experimental|HIPL Therapy™ group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).
~The HIPL Therapy™ group will receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks. Participants will lay in a relaxed position on a therapy plinth with the light applied using the Invitalizer 2.0. The phototherapy will illuminate the affected knee for 20 minutes. In the case of bilateral knee OA, the treatment time will be doubled and applied to both knees. The knee will be positioned at a determined distance from the lamp with an intensity setting of 150 mW/cm2."
16363358|NCT04234685|Placebo Comparator|Placebo Control group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).
~The placebo control group will also receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks, in the same setting as the HIPL Therapy™ group and for the same duration. However, the intensity setting will be set at 5 mW/cm2, a dosage, at which there is no therapeutic benefit expected, but the light will still be visible to the participant."
16363359|NCT04234672|Experimental|TAK-831 500 mg + [14C]TAK-831 50 μg + [14C]TAK-831 500 mg|TAK-831 500 mg, tablet, orally, once on Day 1, followed by [14C]TAK-831 50 micrograms (μg) [approximately 1 microcurie (μCi)], infusion, intravenously (IV), once on Day 1 of Treatment Period 1, followed by a washout period of 8 days, further followed by [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, once under fasted state on Day 1 of Treatment Period 2.
16363360|NCT04234659||Individuals Receiving Mechanical Circulatory Device Support|Individuals receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
16363361|NCT04234659||Individuals Without Mechanical Circulatory Device Support|Individuals not receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
16363362|NCT04234646|Active Comparator|Group 1: One-on-One Patient Navigation|One-on-one Patient Navigation will be based on a Case Management Model where patients navigators perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources.
16363363|NCT04234646|Experimental|Group 2: Patient Navigation 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
16363364|NCT04234633||SLE patients|Any SLE patients between 18 and 40 years old.
16363365|NCT04234620||Toripalimab injection|Use of Toripalimab injection in the real world
16363366|NCT04234607|Experimental|TQB2450+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16363367|NCT04234607|Experimental|TQB2450（blank）+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+ Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16363368|NCT04234607|Active Comparator|TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16363369|NCT04234594|Experimental|QL1203|Participants only receive QL1203, 6mg/kg on Day 1.
16363370|NCT04234594|Active Comparator|Vectibix®|Participants only received Vectibix®，6 mg/kg on Day 1.
16363371|NCT04234581|Experimental|Lysulin|Participants will be randomly allocated in blocks for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) per os with breakfast, lunch and dinner.
16363372|NCT04234581|Placebo Comparator|Placebo|Subjects will be instructed to take two tablets of placebo per os with breakfast, lunch and dinner.
16363407|NCT04234347|Active Comparator|Long Axis approach|Utilize the longitudinal orientation when placing an USGPIV.
16363373|NCT04234568|Experimental|Treatment (lutetium Lu 177 dotatate, triapine)|Patients receive lutetium Lu 177 dotatate IV over 30-40 minutes on day 1 and triapine PO QD on days 1-14. Treatment repeats every 8 weeks (56 days) for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16363374|NCT04234555||Provoked vestibulodynia (PVD)|Provoked vestibulodynia (PVD) is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area or during attempts at vaginal insertional activities (i.e. provoked).
16363375|NCT04234555||Provoked vestibulodynia (PVD) + Vaginismus (VAG)|PVD is sometimes accompanied by intense, involuntary contraction of the PFMs3, termed vaginismus (VAG).
16363376|NCT04234555||Control|Participants matched by age (within 2 years), parity (parous vs nulliparous) and use of oral contraceptive medications (yes vs no) to women in the PVD group, with no signs and symptoms of PVD.
16363377|NCT04234542|Experimental|Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using a protocol developed in collaboration with BioFlexTM Laser. Each treatment will last approximately 45 minutes and will include the laser array first being applied to the skin overlying the sacral spine in a horizontal placement then in oblique placement bilaterally (red and infrared light) while a laser probe is applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light) and the focal probe will be applied to painful sites on the perineum. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. All the stages will involve use of the same array and probe placement, but at each stage the dosage will be increased according to the BioFlex protocol. During teach treatment session, women will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones.
16363378|NCT04234542|Sham Comparator|Sham Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using the same protocol developed in collaboration with BioFlexTM Laser, but at an intensity of 1% output for all sites and at all stages. Each treatment will last approximately 45 minutes. At each visit, the laser array will first be applied to the skin overlying the sacral spine in a horizontal then oblique placement bilaterally (red and infrared light) concurrently with a laser probe applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light), followed by treatment at specific painful sites using the red light probe. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. Participants randomized to this group will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones while receiving the sham laser treatment.
16363379|NCT04234529|Active Comparator|AMATEA|3x 450mg capsules of AMATEA which contains 270mg of caffeine total
16363380|NCT04234529|Active Comparator|Caffeine|3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
16363381|NCT04234529|Placebo Comparator|Placebo|3x 450mg capsules of microcellulose
16363382|NCT04234516|Active Comparator|Buprenorphine|Sublingual buprenorphine-naloxone films
16363383|NCT04234516|Active Comparator|Morphine|Oral morphine sulphate tablets
16363384|NCT04234503|Experimental|Ethics Quarter|Nurse managers perform 12 educational packages in web-page www.etiikanvartti.fi.
16363385|NCT04234503|No Intervention|Standard organisational ethics structures|Nurse managers continue in their standard organisational ethics structures
16363386|NCT04234477|Experimental|Beta-blocker strategy|MICU patients assigned to Team Blue will receive an intravenous (IV) beta-blocker strategy to manage AF with RVR
16363387|NCT04234477|Experimental|Calcium channel blocker strategy|MICU patients assigned to Team Red will receive an intravenous (IV) calcium channel blocker strategy to manage AF with RVR
16363388|NCT04234477|Active Comparator|Physician preference strategy|MICU patients assigned to Team Green will receive a physician preference strategy with usual/standard of care interventions to manage AF with RVR
16363389|NCT04234464|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027)
16363390|NCT04234464|Placebo Comparator|Placebo MDI|
16363391|NCT04234451|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
16363392|NCT04234451|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
16363393|NCT04234438|Active Comparator|Before application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa Before subliminal micropulse laser application
16363394|NCT04234438|Active Comparator|After application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa After 12 months subliminal micropulse laser application
16363395|NCT04234425|Experimental|Experimental Group|18 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
16363396|NCT04234412|Experimental|Osteoarthritic knee patients|Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.
16363397|NCT04234399||Group|All patients receiving SOC imaging and Axumin PET scans.
16363398|NCT04234386|Active Comparator|Dose Level 1: 21 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
16363399|NCT04234386|Active Comparator|Dose Level 2: 24 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
16363400|NCT04234386|Active Comparator|Dose Level 3: 27 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
16363401|NCT04234386|Active Comparator|Dose Level 4: 30 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
16363402|NCT04234373|Experimental|Low Carb dietary Intervention|
16363408|NCT04234347|Active Comparator|Short axis approach|Utilize the transverse orientation when placing an USGPIV.
16363409|NCT04234334|Experimental|Egg intake|Consumption of 2 eggs with spinach daily for breakfast for 4 weeks
16363410|NCT04234334|Experimental|Egg Subsitute|Consumption of 2 egg substitutes daily for breakfast for 4 weeks
16363411|NCT04234321|Experimental|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
16363412|NCT04234321|Experimental|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
16363413|NCT04234321|Placebo Comparator|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
16363414|NCT04234308|Experimental|Polyglycolic Acid Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
16363415|NCT04234308|Experimental|Chromic Gut Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
16363416|NCT04234308|Experimental|ePTFE Non absorbable suture|Periodontal and periimplant flaps closed with at least one suture with ePTFE Non absorbable suture, synthetic, 4-0. (TAGUM®)
16363417|NCT04234308|Experimental|Nylon Non absorbable sutures|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
16363418|NCT04234295|Active Comparator|Lean, Healthy Controls|Subjects with a body mass index (BMI) of 25 or less will have a fat tissue biopsy collected
16363419|NCT04234295|Experimental|Obese, Non-Diabetic|Subject with a BMI between 30 and 50 kg/m2 will have fat tissue biopsy collected
16363420|NCT04234282|No Intervention|Control Group|The control group will receive a 30-minute class on knee osteoarthritis diagnosis, prognosis, various treatment options, and will conclude with a question and answer session. This will account for the 30 minute face to face time provided in the treatment group
16363421|NCT04234282|Experimental|Manual Physical Therapy|The treatment group will receive one 30-minute session of orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment. The manual therapy and exercises are tailored to the individual based on their limitations and restrictions.
16363422|NCT04234269||Assessment Group|Individuals with spinal cord injury. There is one group.
16363423|NCT04234256|Experimental|Static exercise|The experimental group doing static exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
16363424|NCT04234256|Experimental|Dynamic exercise|This group doing dynamic exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
16363425|NCT04234256|No Intervention|Control group|Control group doing not the stretching exercise
16363426|NCT04234243||HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC
16363427|NCT04234243||No HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only
16363428|NCT04234230||VAD Patients|Patients with implanted ventricular assist device in the outpatient setting
16363429|NCT04234217|No Intervention|Untreated|Untreated condition (obstructive sleep apnea)
16363430|NCT04234217|Active Comparator|Continuous positive airway pressure (CPAP) treatment|Continuous positive airway pressure (CPAP) treatment
16363431|NCT04234217|Active Comparator|Niacin|Untreated, pharmacological suppression of lipolysis by Niacin
16363432|NCT04234204|Experimental|Fezolinetant group|Participants will receive fezolinetant once daily for 24 weeks.
16363433|NCT04234204|Placebo Comparator|Placebo group|Participants will receive matching placebo for 12 weeks, and then receive fezolinetant for 12 weeks once daily.
16363434|NCT04234191|Experimental|Rapid Micro-Induction|On Day 1, participants will receive 0.5mg bup/nx sublingually (SL) every 3 hours (Q3H) - total daily dose of 4mg. On Day 2, they will receive 1mg bup/nx SL Q3H - total daily dose of 8mg. On Day 3, they will receive 12mg bup/nx SL once and 1-4mg bup/nx SL Q3H as needed (PRN) - maximum daily dose of 24mg. On Day 4, their day 3 total dose will be consolidated to once daily dosing - maximum daily dose of 24mg. On Days 1 and 2, participants will concurrently receive 1-16mg hydromorphone orally, intravenously, subcutaneously, or intramuscularly (PO/IV/SC/IM) every 1-3 hours (Q1-3H) PRN to meet their opioid requirements, titrated to effect - maximum daily dose of 96mg. For the 1st dose of hydromorphone on Day 1, a maximum 8mg PO or 4mg SC/IV/IM dose will be given. Hydromorphone will be discontinued on Days 3 and 4.
16363435|NCT04234191|Active Comparator|Standard Induction|Day 1 is initiated when participants score 11 or above on the Clinical Opiate Withdrawal Scale (COWS), and when they have been abstinent from short-acting opioids for at least 6-12 hours or from long-acting opioids for 24-72 hours. On Day 1, participants will start with 2-4mg bup/nx SL. If they do not experience withdrawal symptoms 60-90 minutes after this dose, additional dosing can be done in increments of 2-4mg bup/nx SL. The suggested total dose target for Day 1 is 8-12mg. On Day 2, participants will start with a dose equal to the total amount of bup/nx SL administered on Day 1. The dose will be then titrated in increments or decrements of 2-8mg bup/nx SL to a level that holds the patient in treatment and suppresses opioid withdrawal. On Day 3, their day 2 total dose will be consolidated to once daily dosing. For both Days 2 and 3, the suggested total daily dose is at least 8mg, recommended 12-16mg, maximum daily dose of 24mg.
16363436|NCT04234178|Active Comparator|Dural puncture epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
16363437|NCT04234178|Active Comparator|Combined spinal-epidural with epidural volume extension|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
16363438|NCT04234165|Active Comparator|Monopolar arm|monopolar cautery was used for TURBT
16363439|NCT04234165|Experimental|Bipolar Arm|bipolar cautery was used for TURBT
16363440|NCT04234152|Experimental|MV Photo-protection|Includes infants in whom the new procedure of MV separation and photo-protection will be applied. This arm will be stratified to male and female 1:1
16363441|NCT04234152|Placebo Comparator|Standard of care|Includes infants in whom the standard method of preparation and infusion of PN will be applied. This arm will be stratified to male and female 1:1
16363442|NCT04234139||Retrospective Cohort|Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)
16363443|NCT04234139||Prospective Cohort 1|Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)
16363444|NCT04234139||Prospective Cohort 2|Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)
16363445|NCT04234113|Experimental|Experimental: Part A (SO-C101 Monotherapy)|Drug: SO-C101
16363446|NCT04234113|Experimental|Experimental: Part B (SO-C101 combined with pembrolizumab)|Drug: SO-C101 Drug: pembrolizumab
16363447|NCT04234100|Experimental|Orange juice rich in hesperidin and narirutin|The consumption of the orange juice will be made in a single dose of 500 ml. The juice is presented in a concentrated and frozen format, packed in opaque cans of 500 mL, for which it must be thawed and diluted with mineral water up to 1.5 L before its ingestion.
16363448|NCT04234087|No Intervention|Control group|The supervised exercise program included: continues endurance training on cycle ergometers (6 sessions a week). Every session included warm up (<50% target intensity 2 min, gradually increasing load 1-10 w/min up to target intensity within 5 - 10 min); exercise phase (100% of the target intensity (30-50% watts or 30-50% HRmax), starting with >5 minutes and gradually prolonged up to 30 min); cool down with gradual reduction of the load within 3 minutes); additional aerobic exercises performed sitting and/or standing (30 minutes, 5 days/week); respiratory muscle training (7 days/week, for 15 minutes) using ball trainer.
16363449|NCT04234087|Other|Intervention group|Exercise program as for a control group together with additional resistance and balance training 3 sessions/week. The resistance training was started with low intensity (<30% 1-RM, RPE ≤ 11, 5-10 repetitions), increased gradually to moderate intensity (30-50% and up to 60% 1-RM, RPE 12-13, after 8-15 repetitions) with 3 sets and 3 minute rest between sets, if tolerated. The balance training included exercises to improve static as well as dynamic balance ability. It was performed on 2-3 days/week for 10-15 minutes. The complexity of the balance exercises was selected and incremented individually by changing the stand-position, the base on which the stands were performed and/or using unstable surfaces. If tolerated, the visual information was varied and/or additional tasks performed while balancing. After completion participants were encouraged to continue exercise training at home according to recommendations.
16363450|NCT04234074|Other|Breathing test or sleep study|infants undertaking cardiorespiratory polysomnography
16363452|NCT04234048|Experimental|Phase 1|"Accelerated Phase 1a + Standard Phase 1a + Phase 1b
~Accelerated Phase 1a
~Up to 8 patients for accelerated phase 1a (single patient cohort); dose levels of ST-001 nanoFenretinide (mg/m^2/day X 5 days every 21 days):
~Dose Level 1 1.25 (1 patient) Dose Level 2 2.5 (1 patient) Dose Level 3 5.0 (1 patient) Dose Level 4 10 (1 patient) Dose Level 5 20 (1 patient) Dose Level 6 40 (1 patient) Dose Level 7 80 (1 patient) Dose Level 8 160 (1 patient)
~Standard Phase 1a
~Up to 18 patients for standard phase 1a (3+3 design); dose level (mg/m2/day X 5 days every 21 days):
~Dose Level 9 320 (3-6 patients) Dose Level 10 448 (3-6 patients) Dose Level 11 627 (3-6 patients)
~Phase 1b
~20 patients for phase 1b at the maximum tolerated dose (MTD)"
16363453|NCT04234035|Experimental|Shared Decision-Making (via Decision Aid)|The intervention is a decision aid, which both encourages and facilitates a shared decision-making conversation between the clinician and the patient. The decision aid educates patients regarding evidence-based approaches to the management of suspected kidney stones in the ED. Clinicians will receive training specific to this decision aid, though the decision aid is designed to be used with no additional training.
16363454|NCT04234035|Active Comparator|standardized educational intervention (pamphlet +usual care)|The control arm will receive Usual Care and a standardized educational intervention (pamphlet). This intervention (pamphlet) contains information about kidney stones. Usual care for this clinical scenario generally involves the clinician choosing the management plan. Clinicians of subjects assigned to the usual care group will be asked to practice usual, evidence-based medical care, without shared decision-making.
16363455|NCT04234022||Zn-DDC|samples to be exposed with Zn-DDC (Imuthiol) alone
16363456|NCT04234022||Lenalidomide with Zn-DDC|samples to be exposed with Lenalidomide in combination with Zn-DDC
16363457|NCT04234022||Pomalidomide with Zn-DDC|samples to be exposed with Pomalidomide in combination with Zn-DDC
16363458|NCT04234009|Experimental|Healthy lifestyle|Healthy lifestyle intervention, which includes physical activity and dietary advice according to the dutch guidelines.
16363459|NCT04234009|No Intervention|Control|Maintenance of habitual physical activity and diet
16363460|NCT04233996|Experimental|Extended infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in half time of the dosing interval
16363461|NCT04233996|Active Comparator|Intermittent infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in 30 minutes
16363462|NCT04233983|Active Comparator|Study Group|The study group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed.
16363463|NCT04233983|No Intervention|Control Group|The control group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will be performed IVF&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then.
16363464|NCT04233970|Experimental|Intervention group|Participants randomized to the intervention group will receive access to the multi-component, web-based intervention programme. The intervention programme will be developed in line with principles of patient empowerment and based on the Theory of Planned Behaviour.
16363465|NCT04233970|Active Comparator|Control group|Participants randomized to the control group will receive access to the web-based control programme with optimized standard care.
16363466|NCT04233957|Experimental|High Sodium|Consumption of an extra 3900 mg of dietary sodium per day.
16363467|NCT04233957|Placebo Comparator|Placebo|Control Condition
16363468|NCT04233944||Pregnant women and their infants|Mothers and their infants were followed throughout the first two years of the infant's life. Data were collected at enrollment, birth, 3, 6, 9,12, 18 and 24 months from the date of delivery.
16363469|NCT04233931|Experimental|participant|all participants in the study receive the mobile app.
16363470|NCT04233918|Experimental|Evinacumab|Part A: Single intravenous (IV) dose Part B: IV dose every 4 weeks (Q4W) until week 20 Part C: IV dose Q4W
16363471|NCT04233905||mute children|mute children and their mothers
16363472|NCT04233905||healthy children|healthy children control group
16363473|NCT04233905||mute adults|formerly mute adults
16363480|NCT04233866|Experimental|Arm A (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16363481|NCT04233866|Experimental|Arm B (fluorouracil, leucovorin, liposomal irinotecan)|Patients receive fluorouracil IV over 46 hours starting on day 1. Patients also receive leucovorin IV over 90-120 minutes and liposomal irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16363482|NCT04233853|Experimental|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
16363483|NCT04233853|Active Comparator|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
16363484|NCT04233840|Experimental|Sequential administration of P1101 and anti-PD1|"Phase I of Study : To determine the safety, tolerability, DLT, and potential phase 2 dose of sequential administration of P1101 and anti-PD1
~:Sequential administration 6 doses (450mcg) of P1101 and 3 doses of anti-PD1 (Escalating from 0.3, 0.75, 1.5, 3 mg/kg) for Phase I Study"
16363485|NCT04233840|Active Comparator|anti-PD1|Phase II Study Group I: anti-PD1 arm 3mg/kg 3 doses
16363486|NCT04233840|Active Comparator|P1101 monotherapy|Phase II Study Group II: P1101 arm 450mcg 12 doses
16363487|NCT04233840|Experimental|sequential administration of P1101 and anti-PD1|Phase II Study GroupIII:Sequential administration of 6 doses of 450mcg P1101 and followed by 3 doses of anti-PD1 dosage (base on Phase I study result)
16363488|NCT04233814|Sham Comparator|Placebo|Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
16363489|NCT04233814|Experimental|SAD Cohort 1|LTI-03 20 mg delivered qd x 1 day via DPI
16363490|NCT04233814|Experimental|SAD Cohort 2|LTI-03 40 mg delivered qd x 1 day via DPI
16363491|NCT04233814|Experimental|SAD Cohort 3|LTI-03 80 mg delivered qd x 1 day via DPI
16363492|NCT04233814|Experimental|MAD Cohort 1|LTI-03 dose at 20mg once daily x 14 days via DPI
16363493|NCT04233814|Experimental|MAD Cohort 2|LTI-03 dose at 40mg once daily x 14 days via DPI
16363494|NCT04233814|Experimental|MAD Cohort 3|LTI-03 dose at 2.5 mg once daily x 14 days via DPI
16363495|NCT04233814|Experimental|MAD Cohort 4|LTI-03 dose at 5 mg once daily x 14 days via DPI
16363496|NCT04233814|Experimental|MAD Cohort 5|LTI-03 dose at 5 mg twice daily x 14 days via DPI
16363500|NCT04233788||Patient Group 1 (15 Patients)|First two pulse sequence will be applied to this group at a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 2.
16363501|NCT04233788||Patient Group 2 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 1) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 3.
16363502|NCT04233788||Patient Group 3 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 2) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 4.
16363503|NCT04233788||Patient Group 4 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 3) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 5.
16363504|NCT04233788||Patient Group 5 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 4) will be applied to this group using a 3T Prisma and a 7T Terra scanner. At the end the best performing sequence will result.
16363505|NCT04233788||Healthy Control Group 1 (10 Persons)|First two pulse sequences will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used as normative data.
16363506|NCT04233788||Healthy Control Group 2 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 1) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
16363507|NCT04233788||Healthy Control Group 3 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 2) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used as normative data.
16363508|NCT04233788||Healthy Control Group 4 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 3) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
16363509|NCT04233788||Healthy Control Group 5 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 4) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
16363510|NCT04233762||Female Natural Cycle Group|Females with regular natural menstrual cycle.
16363511|NCT04233762||Female Oral Contraceptive Pill Group|Females taking the combined oral contraceptive pill.
16363512|NCT04233762||Male Group|Males with no history of anabolic steroid use.
16363513|NCT04233749|Experimental|Treatment|All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
16363514|NCT04233736|Active Comparator|Treatment group|
16363515|NCT04233736|Sham Comparator|Control group|
16363516|NCT04233710|Experimental|Robot + tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period, with 20 minutes of 1mA cathodal tDCS applied to the contralesional M1 area during first 20 minutes of robotic therapy. Robotic therapy will be conducted using the Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
16366130|NCT04215276|Placebo Comparator|control|Patient will do nothing
16363517|NCT04233710|Sham Comparator|Robot + sham tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period with 20 minutes of SHAM tDCS applied during the first 20 minutes of the robotic therapy. As with experimental arm, electrode will be placed on contralesional M1. Current will ramp up and then immediately ramp down to simulate the cutaneous sensations felt with actual tDCS. Robotic therapy will be delivered with Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
16363518|NCT04233697|Experimental|Copanlisib and Romidepsin|"Copanlisib and romidepsin will be both administered via IV (through a vein in arm) on days 1, 8, and 15 every 28 days, also called a cycle."
16363519|NCT04233684|Experimental|Study|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.
~Pathologic test for H. pylori by H&E stain and Giemsa stain
~All tissues will be sent to immunohistochemistry as a gold standard"
16363520|NCT04233671|Experimental|Mindfulness based relapse prevention and peer mentoring|MiMP is a twelve week program, meeting once per week for 12 weeks for approximately two hours. Eight weeks are facilitated by a licensed counselor, and four weeks are facilitated by a peer mentor.
16363521|NCT04233671|No Intervention|12 Step Treatment Program Control|The control group will meet for 12 weeks for standard 12 Step Facilitation meetings.
16363522|NCT04233658|Placebo Comparator|Placebo|
16363523|NCT04233658|Experimental|Cynara Scolymus|
16363524|NCT04233645|Experimental|Study Group|The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
16363525|NCT04233645|Active Comparator|Usual Care Group|The group will be given a standard scripted verbal and identical written instructions as per usual care.
16363526|NCT04233632|Active Comparator|FC2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit.
16363527|NCT04233632|Active Comparator|Cupid Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
16363528|NCT04233632|Active Comparator|Cupid 2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
16363529|NCT04233606|Placebo Comparator|Control|Participants will be infused with normal (0.9% NaCL) saline for a 120 minute period.
16363530|NCT04233606|Experimental|Hypertonic Saline|Participants will be infused with hypertonic (3% NaCL) saline for a 120 minute period.
16363531|NCT04233593|Experimental|LPS Challenge|Subjects will undergo one 120-minute [11C]PBR28 PET scan before and one scan 3-hours after LPS administration (1.0ng/kg; IV).
16363532|NCT04233593|No Intervention|LPS Follow-up|Subjects will undergo one 120-minute [11C]PBR28 PET scan 24+ hours after LPS.
16363533|NCT04233580|Active Comparator|Weekly AmnioEXCEL+ group|AmnioEXCEL+ will be applied weekly at study visits
16363534|NCT04233580|Active Comparator|PRN AmnioEXCEL+ group|AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
16363535|NCT04233567|Experimental|Treatment (infigratinib)|Patients receive infigratinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16363536|NCT04233554|Experimental|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
16363537|NCT04233554|No Intervention|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
16363538|NCT04233541||Fallers|Participants who reported one or more falls within the 12 months preceding the study consist the group of ''fallers''.
16363539|NCT04233541||Non-fallers|Participants with no fall history consist the group of ''non-fallers''
16363540|NCT04233528|Experimental|healthy volunteers|metabolically healthy eutrophic individuals (BMI ≥18.5 and <25 kg / m2) without any IDF criteria for metabolic syndrome
16363541|NCT04233528|Experimental|metabolically healthy obesity|obese individuals (BMI ≥ 30.0 kg / m2) meeting the criteria for metabolically healthy obesity
16363542|NCT04233528|Experimental|metabolically unhealthy obesity|volunteers diagnosed with metabolically unhealthy obesity
16363543|NCT04233502|Experimental|Melatonin|Slenyto® 1 mg / 5 mg prolonged release Melatonin tablets (pink and yellow) film coated 3 mm in diameter,
16363544|NCT04233502|Placebo Comparator|Placebo melatonin|Placebo melatonin will be identical in appearance (pink and yellow) and formulation to active Slenyto® tablets, but will contain no active melatonin.
16363545|NCT04233489|Experimental|Family Nurture Intervention (FNI)|This arm contains the combined GDM+FNI and control+FNI cohort.
16363546|NCT04233489|No Intervention|Non-FNI|This arm contains the combined GDM+no FNI and control+no FNI cohort.
16363547|NCT04233476|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg frequency:single dose
16363548|NCT04233463|Active Comparator|Modulen Diet|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
16363549|NCT04233463|Active Comparator|Budesonide Treatment|Crohn patients will be given Budesonide treatment
16363550|NCT04233450||Patient group|
16363551|NCT04233437|Experimental|CYP Cohort|MLC1501 & CYP cocktail drugs
16363552|NCT04233437|Experimental|Transporter Cohort|MLC1501 & Transporter cocktail drugs
16363553|NCT04233424|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
16363554|NCT04233424|Other|Standard of care|The SoC for prophylactic antibiotic treatment is based on international guidelines
16363555|NCT04233411|Active Comparator|Milk|Acute ingestion of 20 g milk protein
16363556|NCT04233411|Experimental|20g|Acute ingestion of 20 g mycoprotein
16363557|NCT04233411|Experimental|40g|Acute ingestion of 40 g mycoprotein
16363562|NCT04233385|Experimental|Myofascial Massage|Participants randomized to this group will receive 30 minutes of myofascial massage to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed 8 week protocol developed with a massage therapy consultant and the study team.
16363563|NCT04233385|Active Comparator|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months.
16363564|NCT04233359|Active Comparator|US-guided pleural biopsy and thoracentesis|"Pleural biopsy:
~Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis."
16363565|NCT04233359|Experimental|LAT and thoracentesis|Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
16363566|NCT04233346|Experimental|Ponatinib|CP-CML:Chronic Phase Chronic Myeloid Leukemia; AP-CML:Accelerated Phase Chronic Myeloid Leukemia; BP-CML:Blast Phase Chronic Myeloid Leukemia; Ph+ ALL:Ph+ Acute Lymphoblastic Leukemia;
16363567|NCT04233333|Active Comparator|mustache fixation|
16363568|NCT04233333|Experimental|W.K fixation|
16363569|NCT04233320|Experimental|silicone cream containing Allium Cepa extract|Silicone cream containing Allium Cepa extract will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
16363570|NCT04233320|Active Comparator|commercial scar gel|Commercial scar gel will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
16363571|NCT04233307|Other|Wound photographs|Telethermographic photographs of fracture wound and contralateral limb before and after propofol infusion.
16363572|NCT04233294|Experimental|chidamide in combination with camrelizumab plus decitabine|chidamide 10mg/day, days 1-4, 20mg/day, day 8, 11, 15, 18; camrelizumab 200mg d6; decitabine 10 mg/day, days 1-5, every 3 weeks
16363573|NCT04233281|Experimental|Kori-tofu added to a carbohydrate rich meal|Kori tofu as part of a carbohydrate rich meal
16363574|NCT04233281|Active Comparator|Whey protein added to a carbohydrate rich meal|Whey protein as part of a carbohydrate rich meal
16363578|NCT04233255||Patients with muscle disease(myositis, hereditary myopathy)|Includes 32 symptomatic patients with muscle disease subdivided into two subgroups (a) 16 patients with acute inflammatory myositis; And (b)16 patients with hereditary myopathy. The patients will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline,after 6 months and after 12 months. The number and location of studied muscles will be determined according to pattern of clinical presentation.
16363579|NCT04233255||Healthy volunteers as control group|Includes 32 healthy volunteers as control group. They will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline. Their age, sex, number and location of studied muscles will be matched with patients' group.
16363580|NCT04233242|Experimental|Intervention|The viral load ≥400 c/mL before enrolment triggers genotypic resistance testing (GRT), followed by GRT-informed patient management and counselling. If drug resistance mutations are present, the participant is switched to a different drug regimen line (or the drug regimen backbone is optimised) and drug selection is informed by the GRT result; if no drug resistance mutations are present, the current drug regimen is maintained and the patient receives targeted enhanced adherence support.
16363581|NCT04233242|No Intervention|Control|Standard of care according to national guidelines and recommendations of the World Health Organization: The viral load ≥400 c/mL before enrolment is followed by 3 sessions of enhanced adherence counselling and a follow-up viral load test. If the viral load remains ≥400 c/mL, the participant is switched to a different regimen line with drug selection based on empiric guidelines; if the viral load drops to <400 c/mL, the current drug regimen is maintained. The follow-up viral load test may be postponed in favour of additional counselling if there is clear evidence of poor adherence to therapy, defined as i) a pill count of <90%, and/or ii) a self-reported period of no drug intake of ≥2 days in the last 4 weeks.
16363582|NCT04233229|Experimental|closed-loop and home care services|
16363583|NCT04233229|Active Comparator|usual care|
16366365|NCT04213638|Experimental|Group：1|Intervention: Other：Single Microneedle Radiofrequency therapy
16363589|NCT04233203||Faster Aspart|All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII and insulin Faster Aspart.
16363590|NCT04233190|Experimental|Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)|Formoterol 12mcg + budesonide 400mcg / Formoterol 6mcg + budesonide 200mcg
16363591|NCT04233190|Active Comparator|Alenia® (12/400mcg e 6/200mcg)|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
16363592|NCT04233164|Experimental|1 mg/kg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
16363593|NCT04233164|Experimental|250 mg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
16363594|NCT04233151|Experimental|mFOLFOX6 + QL1203|Participants receive QL1203, 6mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity
16363595|NCT04233151|Active Comparator|mFOLFOX6 + Placebo|Participants received Placebo，6 mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
16363596|NCT04233138|Experimental|Intervention|The intervention group will have immediate access to the SUPPORT platform.
16363597|NCT04233138|Experimental|Control|The control group will have a 6-month delayed access to the SUPPORT platform.
16363598|NCT04233125|Active Comparator|Core Decompression (CD) Only|Participants in this group receive standard care
16363599|NCT04233125|Experimental|Added Polymethylmethacrylate (PMMA)|Participants in this group receive standard care with an additional treatment
16363600|NCT04233112|Placebo Comparator|Placebo/Mock|Placebo capsules; mock osteogenic loading
16363601|NCT04233112|Experimental|Melatonin/Mock|Melatonin capsules; mock osteogenic loading
16363602|NCT04233112|Experimental|Placebo/Osteogenic loading|Placebo capsules/osteogenic loading
16363603|NCT04233112|Experimental|Melatonin/Osteogenic loading|Melatonin capsules/osteogenic loading
16363604|NCT04233099||Healthy Subjects|20 Healthy subjects in a good state of health comparable by age and sex with the other selected groups
16363605|NCT04233099||Amyotrophic Lateral Sclerosis with Bulbar onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Bulbar onset, comparable by age and sex with the other selected groups
16363606|NCT04233099||Amyotrophic Lateral Sclerosis with Spinal onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Spinal onset, comparable by age and sex with the other selected groups
16363607|NCT04233099||Parkinson's Disease|20 subjects affected by Parkinson's Disease comparable by age and sex with the other selected groups
16363608|NCT04233099||Alzheimer's Disease|20 subjects affected by Alzheimer's Disease comparable by age and sex with the other selected groups
16363609|NCT04233086||Patients referred through the BNP pathway|Patients throughout 2016 referred through the BNP pathway at Queen Alexandra Hospital will retrospectively be assessed for Reddy et al (2018) H2FPEF score.
16363610|NCT04233060|Experimental|CS3005|
16363615|NCT04233021|Experimental|Osimertinib|Osimertinib 80 mg/d
16363645|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363646|NCT04232878|Active Comparator|Active Comparator: Group 3: TBD mg CVL-936|Oral suspension/solution
16366366|NCT04213638|Active Comparator|Group：2|Intervention: Other：Photodynamic therapy
16363616|NCT04233008|Experimental|6 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
16363617|NCT04233008|No Intervention|12 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 12 hours, determined by randomization. At that point health care providers will manage active labor.
16363618|NCT04232995|Experimental|Experimental Group|"Balance training by 9 positions with 1 min hold, repeated twice
~Stand with feet together, eyes remain open
~Stand with together, eyes closed
~& 4) Tandem Standing with Right and Left in front alternately
~5) Forward Reaching 6) & 7) Single Leg Standing, with Right and Left foot alternately 8) & 9) Step up, with Right and Left foot alternately
~General Exercises for 25 min
~Active Range of Motion Exercises and Foot Care Education-5 min
~Treadmill- 15 min
~Cycling -5 min
~No. Of Sessions 24, thrice a week for 8 weeks"
16363619|NCT04232995|Active Comparator|Control Group|"General Exercises for 25 min
~Active Range of Motion Exercises and Foot Care Education-5 min
~Treadmill- 15 min
~Cycling -5 min
~No. Of Sessions 24, thrice a week for 8 weeks"
16363620|NCT04232982|Experimental|MicroPulse Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered by micropulse waves will be given 4-8 weeks before the Boston keratoprosthesis surgery.
16363621|NCT04232982|Experimental|G-Probe Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered with a diode laser using the G-Probe device, will be given 4-8 weeks before the Boston keratoprosthesis surgery.
16363622|NCT04232982|No Intervention|Historical Cohort|"An historical cohort composed of patients who received a Boston keratoprosthesis between january 2017 and january 2019 will be included. Only patients who did not receive any glaucoma treatment 3 months before their surgery will be included. A total of 10 patients will be selected with the goal of matching the preoperative characteristics of the interventional patients.
~This group will serve as the control group in our study. Retrospective chart review will be performed for this branch."
16363623|NCT04232969|Active Comparator|Exenatide|Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks n=100
16363624|NCT04232969|Placebo Comparator|Placebo|Exenatide extended release placebo once weekly for 96 weeks n=100
16363625|NCT04232943|Active Comparator|IMOVAX Only|IMOVAX® Polio (Inactivated Poliomyelitis Vaccine) is to be administered by the IM route. Group 1, will receive one dose, 0.5mL of IPV.
16363626|NCT04232943|Experimental|IMOVAX + dmLT|Group 2 will receive IPV along with dmLT as an adjuvant, as a single dose. The vaccine product will be prepared in the clinical research pharmacy from the components described above on each day of vaccination as described in step by step formulation procedures summarized below and detailed in the Pharmacy Preparation Manual. The vaccine product preparation will be carried out by an unblinded qualified research pharmacist and witnessed by another study staff member. The research pharmacist will dispense the vaccine product in a blinded manner to the clinical staff.
16363627|NCT04232943|Active Comparator|bOPV|Group 3 and all the study participants later in the challenge phase of the study will receive one dose of bOPV vaccine in two drops, which are delivered from the polyethylene dropper supplied with the multi-dose container.
16363628|NCT04232930|Active Comparator|Music group|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
16363629|NCT04232930|No Intervention|Non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
16363630|NCT04232917|Experimental|2LPAPI® arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
16363631|NCT04232917|Placebo Comparator|Placebo arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
16363632|NCT04232904|Active Comparator|TAP Block Group|this is study group.
16363633|NCT04232904|No Intervention|Control Group|This patients are control group. TAP block will be not perform
16363634|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 1: 0.5mg CVL-936|Oral suspension/solution
16363635|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363636|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 2:TBD mg CVL-936|Oral suspension/solution
16363637|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363638|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 3:TBD mg CVL-936|Oral suspension/solution
16363639|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363640|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 1:TBD mg CVL-936|Oral suspension/solution
16363641|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363642|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 2:TBD mg CVL-936|Oral suspension/solution
16363643|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363644|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 3:TBD mg CVL-936|Oral suspension/solution
16366804|NCT04210596|Active Comparator|Control group|Connective tissue graft harvested from the palate
16363647|NCT04232878|Placebo Comparator|Placebo Comparator: Group 3: TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
16363648|NCT04232865|Experimental|Bןםפ Sטדאקצ|Biop Colposcopy procedure
16363649|NCT04232852|Active Comparator|Probiotics|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.
~This group will receive a probiotic mix, which will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule. During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
16363650|NCT04232852|Placebo Comparator|Placebo supplement|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.
~Patients of this group will receive an identical capsule of maltodextrin (placebo). During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
16363651|NCT04232839|Experimental|T1 (Test 1)|
16363652|NCT04232839|Experimental|T2 (Test 2)|
16363653|NCT04232839|Experimental|T3 (Test 3)|
16363654|NCT04232839|Experimental|T4 (Test 4)|
16363655|NCT04232839|Experimental|T5 (Test 5)|
16363656|NCT04232839|Experimental|T6 (Test 6)|
16363657|NCT04232839|Experimental|R1 (Reference 1)|
16363658|NCT04232826|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
16363659|NCT04232813|Active Comparator|Estradiol 10 micrograms vaginal tablets|One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
16363660|NCT04232813|Active Comparator|Promestriene 10mg./g vaginal cream|One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
16363661|NCT04232800|Experimental|Riboflavin|Participants in this group will receive 100mg riboflavin TID during study participation.
16363662|NCT04232800|Placebo Comparator|Placebo|Participants in this group will receive inert placebo capsules TID during study participation.
16363663|NCT04232787||Case|Thai patients with diagnosed Brugada syndrome by confirmed Brugada type 1 ECG.
16363664|NCT04232787||Control|Healthy volunteers without Brugada marker from ECG.
16363665|NCT04232774|Experimental|Treated by the study device|
16363667|NCT04232748||stage IV colorectal cancer|stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes
16363668|NCT04232735|Experimental|Intervention|"The Source tool is used by care givers for informing patients about the outcomes of treatment. Prediction models are developed and built in the website in order to generate a personalized prediction of the outcomes: survival, toxicity and/or complications and HRQL. These predictions are visualized in clear and comprehensible graphs with a broad variation of options available for tailoring of the visualizations.
~In order for care givers to be able to use this tool effectively, we designed the Source training. This communication skills training is comprised of an e-learning, two face-to-face group sessions and an individual booster session. Aside from an instruction video on the navigation within the Source tool, the e-learning consists of theory and tips and tricks on how to inform patients and communicate risks. The face-to-face components of the training are focused on getting the skilled use of the source tool into practice, by receiving personal feedback on the performance."
16363669|NCT04232722|Experimental|Sorafenib + arsenical|After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w
16363670|NCT04232709|No Intervention|After-hours care|Patients in the after-hours care (AH) group will receive the usual (telemedicine) care. That is, they will have the option to call the after-hours centre and receive help from the oncology nurses using the COSTaRS practice guides to manage their after-hours symptoms.
16363671|NCT04232709|Experimental|After-hours care w/personal health info|Patients in the after-hours care with personal health information (AH-PHI) group will also receive the usual (telemedicine) care. However, if they call the telemedicine service, the oncology nurses will have access to some of their personal health information from the cancer centre (i.e., a shared electronic patient record) via the MedChart platform.
16363672|NCT04232696|Experimental|Neuspera Implantable Sacral Nerve Stimulation System|Implantation of the simulator.
16363673|NCT04232683|Experimental|Preoperative Tamsulosin|The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.
16363674|NCT04232683|Placebo Comparator|Preoperative Placebo|The control group will receive one oral dose of placebo pill prior to surgery.
16363675|NCT04232670|Sham Comparator|EUS + SHAM|All subjects will undergo anesthesia administered sedation and endoscopic ultrasound (EUS). The endoscopist will assess the pancreas for parenchymal and ductal features of chronic pancreatitis and confirm the absence of exclusion criteria (such as the presence of an occult pancreatobiliary malignancy).
16363711|NCT04232423|Experimental|OLN 0-5-10|Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3
16363712|NCT04232423|Experimental|OLN 5-10-0|Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3
16363713|NCT04232423|Experimental|OLN 10-0-5|Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3
16363714|NCT04232410||OSA Pcrit-DISE|Patients diagnosed with OSA and eligible for non-CPAP treatments
16363676|NCT04232670|Experimental|EUS + Pancreatic Endotherapy|If randomized to ERCP with pancreatic endotherapy, the endoscopist will proceed with this intervention immediately following the completion of EUS and treatment allocation (during the same anesthesia). Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement. Overall technical success will be defined by the ability to insert at least one pancreatic stent across the dominant main pancreatic duct obstruction. Technical success for pancreatic stone treatment will be defined by the ability to remove all fluoroscopically visible main pancreatic duct stones.
16363677|NCT04232657|Experimental|Romosozumab Treatment (baseline to month 11)|Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
16363678|NCT04232657|Placebo Comparator|Placebo (baseline to month 12)|Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
16363679|NCT04232657|Active Comparator|Denosumab (month 12 to month 24)|Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
16363680|NCT04232644|Active Comparator|Treatment A|crushed d-amphetamine IR tablets
16363681|NCT04232644|Experimental|Treatment B|manipulated ADAIR IR capsules
16363682|NCT04232631||patients with diabetic foot ulcers|"Patient of the investigators
~Diagnosis of diabetes mellitus
~One or more moderate to severe diabetic foot ulcers/infections
~18-89 years of age"
16363683|NCT04232618||FIND cohort|Evaluation of biomarkers in serum samples from 500 people with suspected TB from non-African countries provided by FIND diagnostic biorepository.
16363684|NCT04232618||Phase 1|Evaluate the basic 3-marker multi-biomarker test (MBT) signature in 300 participants across three African sites. This will be used to lock down the final MBT signature to be used in the next phase of testing.
16363685|NCT04232618||Phase 2|Enrolment of 600 participants across three African sites using the locked down MBT signature from phase 1.
16363686|NCT04232605|Active Comparator|GLP-1|Receive intravenous infusion of GLP-1.
16363687|NCT04232605|Placebo Comparator|Placebo|Receive intravenous infusion of saline.
16363688|NCT04232592|Experimental|Stem cell preparation solution injection group|The solution of stem cells preparation will be injected.
16363689|NCT04232592|Experimental|Injected stem cell group|The stem cells will injected.
16363690|NCT04232579||Chronic obstructive respiratory disease|The out-patient population with chronic obstructive respiratory disease consulted at Nguyen Tri Phuong Hospital, Ho Chi Minh city, Vietnam.
16363691|NCT04232566|Experimental|Weight loss post surgery|Gastric bypass surgery will be followed by weight loss. Liver fibrosis by elastography will be determined before and after surgery in parallel w weight loss
16363694|NCT04232540|Experimental|Patients with undetectable viral load for at least 2 years|Patient and provider will view and discuss results of the MedViewer test.
16363695|NCT04232540|Experimental|Patients with detectable viral load once in past 2 years|Patient and provider will view and discuss results of the MedViewer test.
16363696|NCT04232527||Professional Footballers|About 110 players (out of about 400 competing in the Premier League of Bosnia and Herzegovina) would be included in the research.
16363697|NCT04232514|Experimental|Part A|Subjects will receive HEC74647 on Day 1~7 and Day13~19, co-administration with HEC110114 on Day13~19.
16363698|NCT04232514|Experimental|Part B|Subjects will receive HEC110114 on Day 1~7 and Day13~19, co-administration with HEC74647 on Day13~19.
16363699|NCT04232501|Experimental|Cirvo Compression device post surgery|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
16363700|NCT04232501|No Intervention|Standard of Care Post Surgery|Patients receive standard-issue SCDs (pneumatic compression) and wear in surgery and after surgery until they are discharged home.
16363701|NCT04232488|Experimental|Angiography performed using distal radial artery|Patients undergoing coronary angiography with or without intervention using distal radial artery ('snuff box') as a vascular access
16363702|NCT04232488|Active Comparator|Angiography performed using proximal radial artery|Patients undergoing coronary angiography with or without intervention using proximal radial artery as a vascular access
16363703|NCT04232475|No Intervention|Control|Seated control
16363704|NCT04232475|Experimental|1 minute SCD|1 minute of stair climbing and descending
16363705|NCT04232475|Experimental|3 minute SCD|3 minute of stair climbing and descending
16363706|NCT04232475|Experimental|10 minute SCD|10 minute of stair climbing and descending
16363707|NCT04232449|Active Comparator|Intervention group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of 40 mg (2 tablets of 20 mg) of prednisone (intervention group) are provided by General Physicians (GPs) to participants. PREDNISON Galepharm Tabl. 20 mg are manufactured according to Good Manufacturing Practice (GMP)-guidelines.
~The prednisone medication is manufactured by Galepharm AG, 8700 Küsnacht (ZH) and packaged and labelled by the Hospital Pharmacy of the University Hospital Basel. The PREDNISON tablets' active substance is Prednisonum; the tablets also contain Excipiens pro compresso. Swissmedic authorization 50821"
16363708|NCT04232449|Placebo Comparator|Control group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of placebo (control group) are provided by General Physicians (GPs) to participants.
~The content of the placebo tablets is as follows: Lactose monohydrate 140 mg, microcrystalline cellulose 68 mg, Croscarmellose sodium 5 mg, Magnesium stearate 2mg. The placebo tablets were manufactured by Apotheke Hotz, Zürichstrasse 176, CH- 8700 Küsnacht."
16363709|NCT04232436||Planned vaginal delivery|Planned vaginal delivery
16363710|NCT04232436||Planned cesarean delivery|Planned cesarean delivery
16363715|NCT04232397|Experimental|therapy|therapy with 1 arm. Anlotinib 8mg qd po。
16363716|NCT04232384|Active Comparator|Standard paracentesis group (SPG)|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
16363717|NCT04232384|Experimental|Rollover paracentesis group (ROG)|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
16363720|NCT04232358|Experimental|Corticosteroid injections + resistance training|Corticosteroid injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
16363721|NCT04232358|Placebo Comparator|Local anesthesia injections + resistance training|Local anesthesia injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
16363722|NCT04232345|Experimental|Cohort 1 (Part 1): AZD4831 Dose 1|Randomized subjects will receive oral suspension of AZD4831 Dose 1 once daily in the morning for a period of 10 days
16363723|NCT04232345|Experimental|Cohort 2 (Part 1): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
16363724|NCT04232345|Experimental|Cohort 3 (Part 1): AZD4831 Dose 3|Randomized subjects will receive oral suspension of AZD4831 Dose 3 once daily in the morning for a period of 10 days.
16363725|NCT04232345|Experimental|Cohort 4 (Part 2): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
16363726|NCT04232345|Experimental|Placebo (Part 1)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
16363727|NCT04232345|Experimental|Placebo (Part 2)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
16363728|NCT04232332|Experimental|3.75μg (pre test)|Single dose
16363729|NCT04232332|Experimental|7.5μg|Single dose
16363730|NCT04232332|Placebo Comparator|15μg single dose|Intramuscular injection once
16363731|NCT04232332|Placebo Comparator|30μg single dose|Intramuscular injection once
16363732|NCT04232332|Placebo Comparator|45μg single dose|Intramuscular injection once
16363733|NCT04232332|Placebo Comparator|60μg single dose|Intramuscular injection
16363734|NCT04232332|Placebo Comparator|75μg single dose|Intramuscular injection
16363735|NCT04232332|Placebo Comparator|90μg single dose|Intramuscular injection once
16363736|NCT04232332|Placebo Comparator|30μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
16363737|NCT04232332|Placebo Comparator|45μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
16363738|NCT04232319|Experimental|Sleep Hygiene Training|The intervention will be delivered online by an occupational therapist. The intervention consists of 3 weekly sessions; each session will be 30-45 minutes long. The focus of the intervention is to teach breast cancer survivors sleep hygiene strategies to improve their sleep.
16363739|NCT04232306|Experimental|Liposomal Bupivacaine + Bupivacaine HCL|Liposomal bupivacaine + bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
16363740|NCT04232306|Active Comparator|Bupivacaine HCl surgical-site incision infiltration|Bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
16363741|NCT04232293|Experimental|Blood tests|Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis
16363742|NCT04232280|Experimental|mRNA-1647 Low Dose|Participants will receive mRNA-1647 vaccine at the Low Dose by intramuscular (IM) injection on Day 1, Day 56, and Day 168.
16363743|NCT04232280|Experimental|mRNA-1647 Medium Dose|Participants will receive mRNA-1647 vaccine at the Medium Dose by IM injection on Day 1, Day 56, and Day 168.
16363744|NCT04232280|Experimental|mRNA-1647 High Dose|Participants will receive mRNA-1647 vaccine at the High Dose by IM injection on Day 1, Day 56, and Day 168.
16363745|NCT04232280|Placebo Comparator|Placebo|Participants will receive placebo matching to the mRNA-1647 vaccine dose by IM injection on Day 1, Day 56, and Day 168.
16363746|NCT04232267||Patients prescribed Polysomnology (PSG - sleep study)|Patients that are at least 18 years old but not older than 75 years old, who have been referred to a sleep clinic for sleep disturbance.
16363747|NCT04232254|Active Comparator|Animal Protein - Skewed Distribution|Animal-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
16363748|NCT04232254|Experimental|Plant Protein - Skewed Distribution|Plant-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
16363749|NCT04232254|Experimental|Animal Protein - Balanced Distribution|Animal-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
16363750|NCT04232254|Experimental|Plant Protein - Balanced Distribution|Plant-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
16363751|NCT04232241|Active Comparator|Treatment A|Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor
16363752|NCT04232241|Experimental|Treatment B|Allogeneic stem cell transplantation from haploidentical donor
16363802|NCT04231838|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
16363754|NCT04232215|Experimental|HeraBEAT™ Intervention Group|Subjects will monitor their fetal heart beat once weekly using the HeraBEAT™ device. After approximately 8 weeks of monitoring subjects will crossover to using the doppler fetal heart rate monitor
16363755|NCT04232215|Active Comparator|Standard Fetal Doppler Group|Subjects will monitor their fetal heart beat once weekly using the doppler fetal heart rate monitor. After approximately 8 weeks of monitoring subjects will crossover to using the HeraBEAT™ device
16363756|NCT04232202|Experimental|Laser|After extraction, Er:YAG and Nd:YAG lasers used for degranulation, disinfection, deepithelialization, clot stabilization and photobiomodulation.
16363757|NCT04232202|Active Comparator|Control|Standard extraction procedure.
16363758|NCT04232163|Experimental|Immediate Treatment Group|Participants will receive the intervention right away
16363759|NCT04232163|No Intervention|Delayed Treatment Group|Participants will receive usual care (no intervention), however, they will receive the intervention after a 3 week delay
16363760|NCT04232150|Experimental|Group C (control group)|control group will receive no sedation under spinal anesthesia.
16363761|NCT04232150|Experimental|Group O (single dose group)|patients will receive 0.025mg/kg midazolam sedation under spinal anesthesia.
16363762|NCT04232150|Experimental|Group M (double dose group)|patients will receive 0.025mg/kg midazolam sedation twice under spinal anesthesia.
16363763|NCT04232137|Experimental|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
16363764|NCT04232137|No Intervention|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
16363766|NCT04232111|Sham Comparator|Thermoneutral|Neither heat nor vacuum applied to hand
16363767|NCT04232111|Experimental|Heat and Vacuum|Heat and vacuum applied to hand
16363768|NCT04232111|Experimental|Heat only|Only heat applied to hand
16363769|NCT04232098|No Intervention|Thermoneutral|thermoneutral condition
16363770|NCT04232098|Experimental|Feet heated|Hot water up to ankles
16363771|NCT04232098|Experimental|Calf heated|Hot water up to top of calves
16363772|NCT04232085|Experimental|PID/IDS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).
~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.
~Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.
~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.
~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
16363773|NCT04232085|Experimental|IBMFS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).
~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.
~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.
~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
16363774|NCT04232072|Active Comparator|Group ESPB = Erector spinae plane block group|ESPB will be performed 30 min before induction of general anesthesia, with patients in the sitting position by using US. Under aseptic conditions, the high frequency linear probe will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. Local anesthetic infiltration with 2% of lidocaine will be applied under the skin. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block. The same procedure will be performed for the opposite site.
16363775|NCT04232072|Active Comparator|Group Ibuprofen = Ibuprofen|In Group Ibuprofen, a dose of 800 mg ibuprofen IV will be administrated 30 min before induction of general anesthesia.
16363776|NCT04232072|No Intervention|Group C = Control group|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
16363803|NCT04231838|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS
16363777|NCT04232059|Active Comparator|Group 1: hyperventilation|• Group 1: hyperventilation (ETco2 25-30 mm Hg) for 20 minutes that will start immediately after skin incision followed by normoventilation (ETco2 31-35 mm Hg) for another 20 minutes.
16363778|NCT04232059|Active Comparator|Group 2: normoventilation|• Group 2: normoventilation (ETco2 31-35 mm Hg) for 20 minutes immediately after skin incision followed by hyperventilation (ETco2 25-30 mm Hg) for another 20 minutes.
16363779|NCT04232046|Experimental|Intervention|Trigger point massage
16363780|NCT04232046|Active Comparator|Control|Treatment with standard drug Nortriptyline
16363781|NCT04232033|Active Comparator|Fibroblast growth factor 21 infusion|Fibroblast growth factor 21 infusion
16363782|NCT04232033|Placebo Comparator|Placebo infusion (saline)|Saline infusion
16363783|NCT04232007|Experimental|Closed-loop|Closed-loop system to titrate vasopressor during surgery
16363784|NCT04231994|Experimental|TPE|additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid
16363785|NCT04231994|No Intervention|SMT|Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines
16363787|NCT04231968|Experimental|AK0529|Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
16363788|NCT04231968|Placebo Comparator|Placebo|Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
16363789|NCT04231955|Experimental|pain rating scales|"patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10, on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end and on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
16363790|NCT04231942|Experimental|Group 1 (experimental): continuous using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).
~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;"
16363791|NCT04231942|Experimental|Group 2 (experimental): intermittent using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).
~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;"
16363792|NCT04231942|No Intervention|Group 3 (control): no use of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).
~The use of GCS will be possible on-demand when symptoms or risk factors appear after appropriate coordination with the Investigator"
16363793|NCT04231929|Experimental|BioPearl™ loaded with doxorubicin|Chemoembolization with doxorubicin-loaded BioPearl™ microspheres
16363794|NCT04231916|Experimental|Patients aged 5-18 years|"Patients with Osteogenesis Imperfecta (with known vertebral fractures)for phase one of the study.
~Patients with Osteogenesis Imperfecta for phase 2 of the study In both groups patients will be aged 5 years and over"
16363795|NCT04231903||EAC|Patients undergoing surgery endo-aortic clamp.
16363796|NCT04231903||TTC|Patients undergoing surgery through trans-thoracic aortic clamp.
16363797|NCT04231890|Experimental|IPI group|IPI monitoring
16363798|NCT04231890|No Intervention|Control group|Standard monitoring
16363799|NCT04231877|Experimental|Treatment (polatuzumab vedotin, combination chemotherapy)|Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim SC 24-72 hours after the last dose of each treatment cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16363800|NCT04231864|Experimental|Treatment (durvalumab, epacadostat)|Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice a day (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.
16363801|NCT04231851|Experimental|CPX-351 and Glasdegib|"In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.
~If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.
~In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.
~If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year"
16363807|NCT04231799|Experimental|Bathing within 24-48|Participants who will have their first bath in 24-48th hours after birth.
16363808|NCT04231799|Experimental|Bathing within 48-72|Participants who will have their first bath in 48-72th hours after birth.
16363809|NCT04231773|Experimental|12.1% Oxygen and Inhaled Nitric Oxide|Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
16363810|NCT04231773|Placebo Comparator|12.1 % Oxygen Placebo|Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
16363811|NCT04231773|Experimental|13.6 % Oxygen and Inhaled Nitric Oxide|Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
16363812|NCT04231773|Placebo Comparator|13.6 % Oxygen and Placebo|Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
16363813|NCT04231760|Experimental|Chronic Obstructive Pulmonary Disease|Mild & Moderate COPD to receive either placebo or inhaled nitric oxide (40ppm)
16363814|NCT04231760|Active Comparator|Healthy Controls|Control group to receive either placebo or inhaled nitric oxide (40ppm)
16363815|NCT04231747|Experimental|CC-97540 monotherapy|Subjects will be assigned to receive CC-97540 followed by 3 consecutive doses of lymphodepleting chemotherapy (fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day).
16363816|NCT04231734|Experimental|All Subjects|Low tumor burden, treatment-naïve MCL
16363817|NCT04231721||Healthy controls|
16363818|NCT04231708|Placebo Comparator|placebo stressor, sham rTMS|Placebo stressor (lactose) + sham (inactive) rTMS over the left dlPFC
16363819|NCT04231708|Experimental|placebo stressor, active rTMS|Placebo stressor (lactose) + active 10Hz rTMS over the left dlPFC
16363820|NCT04231708|Experimental|active stressor, sham rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + sham (inactive) rTMS over the left dlPFC
16363821|NCT04231708|Experimental|active stressor, active rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + active 10Hz rTMS over the left dlPFC
16363822|NCT04231682|Experimental|Denosumab receiving group.|Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months. (A total of 4 injections)
16363823|NCT04231682|Placebo Comparator|Placebo receiving group.|Patients in this arm will receive Placebo injection subcutaneously every 6 months. (A total of 4 injections)
16363824|NCT04231669|No Intervention|Control: bolstered care|Female adolescents in the bolstered care will receive services/education as usual in their respective schools. The usual care will be bolstered by providing school notebooks and lunch in the control arm (bolstered care will also be provided to treatment arm). Primary school education is universal and free in Ghana. Yet notebooks and lunch are costly expenses for families that create a barrier to school attendance. Hence, these will be provided to participants in all study schools.
16363825|NCT04231669|Experimental|Anzansi Family Program|In addition to bolstered care, participants in this arm will receive the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG).
16363826|NCT04231656|Experimental|Sequence A before sequence B|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence A of positioning (before the procedure), and sequence B after the procedure.
16363827|NCT04231656|Experimental|Sequence B before sequence A|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence B of positioning before the procedure, and sequence A after the procedure.
16363828|NCT04231643|Experimental|Bipolar Disorder|adults with bipolar disorder
16363829|NCT04231643|Active Comparator|Healthy Volunteers|adults with no psychiatric disease
16363830|NCT04231630|Other|Observational Case|1 infant will be enrolled as an observational case. Will receive an exclusive human milk diet at home.
16363831|NCT04231617|Active Comparator|CGRP and glibenclamide|Participants will recieve CGRP infusion after glibenclamide/placebo administration
16363832|NCT04231617|Active Comparator|CGRP and placebo|Participants will recieve CGRP infusion after glibenclamide/placebo administration
16363833|NCT04231604|Experimental|A Lust for Life programme group|A Lust for Life programme will be delivered to adolescents by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
16363834|NCT04231604|Other|Waiting list control group|Participants will be placed on a twelve-week waiting list for the programme.
16363835|NCT04231591||ACDH Pregnancy - Study group|Pregnant women with known adult congenital heart disease.
16363836|NCT04231591||Uncomplicated pregnancy - Control group|Healthy women with an uncomplicated pregnancy
16363837|NCT04231578|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
16363838|NCT04231578|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
16363839|NCT04231565|Active Comparator|TAF group|50 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long.
16363840|NCT04231565|No Intervention|Observation group|50 patients would not receive treatment from baseline to life-long.
16363841|NCT04231552|Experimental|Chemotherapy and PD1 inhibitor|CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
16363842|NCT04231539|Experimental|Low Nicotine (nicotine vapor) 24 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
16363924|NCT04230980|Experimental|Gabapentin|Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
16363843|NCT04231539|Experimental|High Nicotine (nicotine vapor) 42 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
16363844|NCT04231526|Experimental|ARM A - Pembrolizumab + Surgery|
16363845|NCT04231526|Active Comparator|ARM B - Surgery|
16363846|NCT04231513|Experimental|SAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo, as an intravenous infusion, once, on Day 1.
16363847|NCT04231513|Experimental|SAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
16363848|NCT04231513|Experimental|SAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
16363849|NCT04231513|Experimental|MAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W up to Day 57 of the Treatment Period.
16363850|NCT04231513|Experimental|MAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
16363851|NCT04231500||patients with GVHD after allo-HSCT|Exploration of the skin-microbiota in patients with GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure and additional skin biopsies from affected and healthy skin sites in case of GVHD
16363852|NCT04231500||patients without GVHD after allo-HSCT|Exploration of the skin-microbiota in patients without GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure
16363853|NCT04231487||Essential tremor|"This is not an intervention study.
~Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days"
16363854|NCT04231487||Parkinson's Disease|"This is not an intervention study.
~Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days"
16363855|NCT04231487||Huntington's Disease|"This is not an intervention study.
~Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days"
16363856|NCT04231487||Primary Focal Dystonia|"This is not an intervention study.
~Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days"
16363857|NCT04231487||Spinocerebellar Ataxia|This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
16363858|NCT04231487||Functional Movement Disorder|This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
16363859|NCT04231487||Healthy Controls|"This is not an intervention study.
~People with Healthy Controls"
16363860|NCT04231474||Demographic and clinical features of the patients|Number of patients Time from injury to hospitalization Time from injury to urodynamic evaluation Duration of hospitalization
16363861|NCT04231474||Comparison of urodynamic outcomes|Treatment options in patients with level SCI : cervical, thoracical and lumbar spinal cord injury
16363862|NCT04231448|Experimental|CR-CHOP|
16363863|NCT04231448|Placebo Comparator|R-CHOP|
16363864|NCT04231435|Experimental|Treatment Administration|"All subjects will receive the following oral doses of IP following an overnight fast in the fixed-sequence below:
~Day 1 (Period 1): 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet.
~Day 7 (Period 2): 6 × 100-mg fedratinib capsules PLUS (after approximately 1 hour from the time of fedratinib administration) 1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet."
16363865|NCT04231422||Treatment Group|Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.
16363866|NCT04231409|Active Comparator|WaveWriter Settings|WaveWriter Programming
16363867|NCT04231409|Active Comparator|Conventional Settings|Conventional Programming
16363868|NCT04231396|Other|Audiobooks for Hearing Loss|"study participants will use the Audiobooks for HL App for 12 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:
~BKB-SIN will be administered
~Conduct a comprehension test.
~Address any usability issues the participant brings up.
~Based on discussion with participant (and parent/guardian if available), the usage log, and the comprehension test results: (a) suggest adjusting the speech mode (clear vs. habitual speech, noise level); (b) suggest switching off a visual support (face, synchronized text); discuss next milestone (e.g. completion of a story or book).
~Discuss real-world rewards with parent/guardian if milestones are met."
16363869|NCT04231370|Experimental|treatment arm|Sintilimab, 200mg, iv day1 Lenalidomide, 25mg/d, oral, day 1-14 repeated every 3 weeks
16363870|NCT04231357|Experimental|Platelet rich plasma (PRP)|6-7 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
16363871|NCT04231357|Active Comparator|control|needle tenotomy with lidocaine
16363872|NCT04231331|Placebo Comparator|Placebo|All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
16363873|NCT04231331|Active Comparator|Ertugliflozin|All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
16363874|NCT04231318|Experimental|Cingal|
16363875|NCT04231318|Active Comparator|Triamcinolone Hexacetonide (TH) - Lederlon|
16363876|NCT04231318|Placebo Comparator|Placebo|
16363877|NCT04231292|Experimental|Experimental Group A +Group a|Group A: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week;Group a: refers to the weekly dose at the end of the first stage , once every two weeks, 19th~46th week
16363878|NCT04231292|Experimental|Experimental Group B +Group b|Group B: 1.2μg/kg RD01, once every two weeks, Day 1~ 18th week; Group b: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
16363925|NCT04230980|Placebo Comparator|Placebo|Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days
16363879|NCT04231292|Experimental|Experimental Group C +Group c|Group C: 1.6μg/kg RD01, once every two weeks, Day 1~ 18th week; Group c: refers to the weekly dose at the end of the first stage , once every six weeks, 19th~46th week
16363880|NCT04231292|Experimental|Experimental Group D +Group d|Group D: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week; Group d: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
16363881|NCT04231292|Active Comparator|Experimental Group E +Group e|Group E: 150IU/kg rHuEPO, once a weeks, subcutaneous administration, Day 1~ 18th week; Group e: refers to the weekly dose at the end of the first stage , once a weeks, intravenous administration, 19th~46th week
16363882|NCT04231292|Placebo Comparator|Experimental Group F +Group f|Group F: 8μl placebo, once every two weeks, for 6 weeks; 150 IU/kg rHuEPO, once week, subcutaneous injection, 7th ~ 18th week; Group f: refers to the weekly dose at the end of the first stage , once a weeks, subcutaneous administration, 19th~46th week
16363883|NCT04231292|Experimental|Experimental Group G|Group G: 1.6μg/kg RD01, once every four weeks, Day 1~ 28th week;
16363884|NCT04231279|Active Comparator|ChiRhoStim Group 1|Patients undergoing EGD with ePFT for symptoms of suspected or known pancreatic insufficiency.
16363885|NCT04231279|Experimental|ChiRhoStim Group 2|Patients undergoing diagnostic EGD that consent to undergo ePFT.
16363886|NCT04231266|Active Comparator|ManNAc|Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
16363887|NCT04231266|Placebo Comparator|Placebo|Oral Placebo will be administered three times daily.
16363888|NCT04231240||Adult cardiac surgery with normothermia|
16363889|NCT04231240||Adult cardiac surgery with hypothermia|
16363890|NCT04231240||Pediatric cardiac surgery with normothermia|
16363891|NCT04231240||Pediatric cardiac surgery with hypothermia|
16363892|NCT04231240||Adult cardiac surgery without cardiopulmonary bypass|
16363893|NCT04231214|Experimental|Treatment sequence 1|Spiolto® Respimat® on Day 1 0.9% nebulized saline on Day 9 Spiolto® Respimat® from Day 10 to Day 24
16363894|NCT04231214|Experimental|Treatment sequence 2|0.9% nebulized saline on Day 1 Spiolto® Respimat® on Day 9 Spiolto® Respimat® from Day 10 to Day 24
16363895|NCT04231188||Primary Caregiver and infant pair|Primary Caregiver and infant who is less than or equal to 12 months old
16363896|NCT04231175|Experimental|experimental arm A|patients will undergo dedicated MRI imaging of the pelvis, abdomen, and thorax. Based on the findings of the MRI scan patients will be allocated to one of the diagnostic/treatment options
16363897|NCT04231175|No Intervention|arm B|patients will undergo the current standard diagnostic work-up of DLS at indication (MDT decision) and otherwise continue to CRS-HIPEC.
16363898|NCT04231162|Experimental|probiotic powder, Bifidobacterium lactis|
16363899|NCT04231162|Placebo Comparator|Placebo|
16363900|NCT04231149|Experimental|Test product 2|Test catheter 2
16363901|NCT04231149|Experimental|Test product 3|Test catheter 3
16363902|NCT04231149|Active Comparator|Comparator|SpeediCath Flex
16363903|NCT04231136|Experimental|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg tablet once a day
16363904|NCT04231136|Active Comparator|EAPA115|Oral administration of EAPA115 once a day
16363905|NCT04231136|Active Comparator|RAPA115|Oral administration of RAPA115 once a day
16363906|NCT04231123|Experimental|PENG group|PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine
16363907|NCT04231123|Placebo Comparator|Placebo group|PENG block with 20 ml of 0,9% saline
16363908|NCT04231110|Experimental|FMT and vedolizumab|People who are initiating vedolizumab per standard of care for ulcerative colitis will also be offered FMT weekly for 6 weeks.
16363909|NCT04231097|Experimental|Virtual MBCT|Two cohorts of MBCT participants with approximately 10 participants per cohort.
16363910|NCT04231084|Active Comparator|Inhaled Nitric Oxide|Vasodilator testing will be performed with inhaled nitric oxide
16363911|NCT04231084|Experimental|Inhaled Epoprostenol|Vasodilator testing will be performed with inhaled epoprostenol
16363912|NCT04231071|Active Comparator|Sutured group|Controlled group: Primary suture repair of the small umbilical hernia defect
16363913|NCT04231071|Experimental|Onlay Mesh group|Intervention group: Primary suture repair of the small umbilical hernia defects + a small Onlay mesh on the closed defect.
16363914|NCT04231058|Experimental|Transcutaneous Electrical Nerve Stimulation (TENS)|15 experimental subjects treated withTENS and Pulmonary Rehabilitation
16363915|NCT04231058|No Intervention|Rehabilitation|15 experimental subjects treated with Pulmonary Rehabilitation only
16363916|NCT04231045||Patients on PiCCO monitoring system|ALL intensive care patients on PiCCO monitoring system and over 18 years old and on PiCCO for more than 24 hours. Those medical or surgical patients admitted in a UK NHS unit, elective, semi-elective or emergency admission.
16363919|NCT04231019||Dental practitioners (general, specialists or students)|Two self-administered questionnaires will be used in the study one to general practitioners and specialists and another one with a plain language describing the study will be distributed to the fifth year dental students in Egypt with total 1000 dentist to assess their knowledge, awareness and perception regarding MIH.
16363920|NCT04231006|Experimental|Single arm|Single arm
16363921|NCT04230993|Experimental|Ocean Bio Actif-Fluid+|Moderate hypertonic seawater solution (15 g / L NaCl) with polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
16363922|NCT04230993|Experimental|Ocean Bio Active-Stuffy nose|Moderate hypertonic seawater solution (15 g / L NaCl) without polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
16363923|NCT04230993|Active Comparator|Ocean Bio Active-Hygiene of the nose|Isotonic seawater solution (9 g / L NaCl). The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
16363995|NCT04230434|Experimental|Safety Plan Intervention|The Safety Plan Intervention (SPI) performed in ED or in ambulatory appointment
16363926|NCT04230967|Experimental|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit InspireTM devices will be set to this goal and notifications will be given on the device for the participants meeting their goals. Upon enrollment, they will be given a pamphlet with instructions to ambulate out of the room at least once per day with a goal of 2,000 steps daily and their Fitbits will be pre-programmed with this goal. Study staff will also remind participants to ambulate via email, text or in-person if they are not meeting their goal of 2,000 steps per day.
16363927|NCT04230967|Active Comparator|Routine Care|Participants in the routine care arm will be allowed ad lib activity but no encouragement to walk will be given. They will not have any goals set on their Fitbits. Upon enrollment, they will be given pamphlets with no instruction on whether or not to ambulate and their Fitbits will be pre-programmed to have no goal.
16363928|NCT04230954|Experimental|Cabozantinib (XL 184) Plus Pembrolizumab|A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
16363929|NCT04230941|Experimental|MAAT-G Intervention|MAAT-G Workshops & participant workbook use (8 workshops)
16363930|NCT04230928|Placebo Comparator|Standard GLB Control|Individuals will receive the standard Diabetes Prevention Program-Group Lifestyle Balance (GLB) program as outlined by the American Diabetes Association. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
16363931|NCT04230928|Experimental|VLC-GLB Intervention|Individuals will receive a version of the DPP-GLB program in which 4 of the 12 modules will teach a very low carbohydrate diet instead of the standard. All other components of the DPP-GLB will follow the standard. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
16363932|NCT04230915|Active Comparator|Low Dose Rocuronium|This group patients will determine as those who were administered 0.3 mg/kg rocuronium
16363933|NCT04230915|No Intervention|Strandart Dose Rocuronium|This group patients will determine as those who were administered 0.6 mg/kg rocuronium
16363934|NCT04230902|Experimental|Lipogems|The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.
16363935|NCT04230902|Active Comparator|Steroid|The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study.
16363936|NCT04230889|Other|Usual Diet Group|Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.
16363937|NCT04230889|Experimental|Group 1 Nutritional Shake|Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.
16363938|NCT04230889|Experimental|Group 2 Nutritional Shake|Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.
16363939|NCT04230863|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation.
16363940|NCT04230850|Active Comparator|Mildly Impaired Group|This group will consist of participants with 35-50 degrees of lumbar flexion.
16363941|NCT04230850|Active Comparator|Moderately Impaired Group|This group will consist of participants with 20-34 degrees of lumbar flexion.
16363942|NCT04230850|Active Comparator|Highly Impaired Group|This group will consist of participants with less than 20 degrees of lumbar flexion.
16363943|NCT04230837|Experimental|A: Abutments of 1 mm|Definitive abutments of 1 mm height were located.
16363944|NCT04230837|Experimental|B: Abutments of 3 mm|Definitive abutments of 3 mm height were located.
16363945|NCT04230824|Active Comparator|Pre-workout plus and Protein recovery plus|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise
~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
16363946|NCT04230824|Placebo Comparator|Placebo|Non-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise
16363947|NCT04230824|No Intervention|Control|This arm will receive no intervention
16363948|NCT04230798|No Intervention|Control|This group did not perform any specific exercise program nor injury prevention program. They continued their normal training routine
16363949|NCT04230798|Experimental|Prevention program|This group performed two sessions per week of the injury prevention program. The program included strength training, plyometrics and core stability training.
16363950|NCT04230785||AIS before EVT group|This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)
16363951|NCT04230785||AIS after EVT group|This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)
16363952|NCT04230772|Experimental|Natural Orifice Specimen Extraction Surgery|Natural orifice specimen extraction surgery will performed in patients assigned to this group.
16363953|NCT04230772|Active Comparator|Traditional Robotic-assisted Surgery|Traditional robotic-assisted surgery will performed in patients assigned to this group.
16363954|NCT04230759|Active Comparator|5FU+Mitomycin C|Radiochemotherapy for anal cancer
16363955|NCT04230759|Experimental|5FU+Mitomycin C+Durvalumab|Radiochemotherapy with Durvalumab for anal cancer
16363956|NCT04230746|Placebo Comparator|Placebo|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with placebo to be taken twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
16363996|NCT04230421|Experimental|Monsenso with feedback|Daily smartphone-based monitoring and treatment using the Monsenso system with a clinical feedback loop feedback.
16364746|NCT04225013||Control (no CIN)|Patients who receive contrast media but do not develop contrast-induced nephropathy
16363957|NCT04230746|Experimental|Bactrim|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with Bactrim 800/120 to take twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
16363958|NCT04230720|Experimental|Artificial Tears|One eye of each participant is randomized to receive Systane Complete artificial tears 4 times a day for 14 days
16363959|NCT04230720|No Intervention|No Artificial Tears|One eye of each participant is randomized to receive no artificial tears for 14 days
16363960|NCT04230694|Active Comparator|Control Group|Control Group subjects will wear the CGM device during their hospitalization, up to 14 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
16363961|NCT04230694|Experimental|Treatment Group|Treatment Group subjects will wear the CGM device during their hospitalization, up to 14 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.
16363962|NCT04230681|Active Comparator|Fentanyl|
16363963|NCT04230681|Active Comparator|Hydromorphone|
16363964|NCT04230655|Active Comparator|Control group|"All participants in the control group are treated with LED and CBT-based group treatment as described below.
~All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants. Two groups of about the same size start simultaneously.
~The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended."
16363965|NCT04230655|Experimental|IGB group|"All participants in the IGB group are treated with LED and CBT-based group treatment as described for the control group.
~Participants in the intervention group are treated with an IGB for 6 months from 6 months from start."
16363966|NCT04230642|Experimental|Robotic device|Needle placement to the tumor, one time, the day of the ablation procedure
16363967|NCT04230629|Active Comparator|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
16363968|NCT04230629|Active Comparator|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
16363969|NCT04230616|Active Comparator|Conventional total knee arthroplasty|conventional total knee arthroplasty with standard intramedullary alignment guide
16363970|NCT04230616|Active Comparator|NAVIO total knee arthroplasty|NAVIO assisted total knee arthroplasty
16363971|NCT04230603|Experimental|Hyperspectral imaging|diagnostic hyperspectral imaging of the human tissue an correlation with local blood parameters and local pathological examination
16363972|NCT04230590||Participants with schizophrenia spectrum disorders|Within 8 weeks post discharge from hospitalization at the Institute of Mental Health
16363973|NCT04230577|Active Comparator|Real LED Intervention|Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
16363974|NCT04230577|Sham Comparator|Sham LED Intervention|Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
16363975|NCT04230564||AML|Patients diagnosed with AML
16363976|NCT04230551|Active Comparator|Reference Group|Five symptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
16363977|NCT04230551|Experimental|Study Group|Five asymptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
16363978|NCT04230551|No Intervention|Observation Group|Five asymptomatic HOCM patients with severe LVOT obstruction will not undergo PTSMA
16363979|NCT04230538|Experimental|DJO Walker|Application of DJO Walker
16363980|NCT04230538|Active Comparator|Traditional plaster cast|Application of traditional plaster cast
16363981|NCT04230525||Bioimpedence|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia.
16363982|NCT04230512|Experimental|Locked|The prototype mechanical system is locked from compressing
16363983|NCT04230512|Experimental|Unlocked|The prototype mechanical system is free to compress normally
16363984|NCT04230499|Experimental|Cohort 1|Cohort 1 will receive 0.5mg of eRapa every other day.
16363985|NCT04230499|Experimental|Cohort 2|Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
16363986|NCT04230499|Experimental|Cohort 3|Cohort 3 will receive 0.5 mg of eRapa daily.
16363987|NCT04230473|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
16363988|NCT04230460|Placebo Comparator|0% THC/ 0% CBD|
16363989|NCT04230460|Experimental|THC (5-10% [37.5 mg]) / Low CBD (<1% [2.5 mg])|
16363990|NCT04230460|Experimental|THC (>10% [62.5 mg]) / Low CBD (<1% [2.5 mg])|
16363991|NCT04230460|Experimental|0.065% BAC|
16363992|NCT04230447||a cohort of patients with sepsis encephalopathy|This study is an observational study without drug and other interventions
16363993|NCT04230447||a cohort of patients with sepsis|This study is an observational study without drug and other interventions
16363994|NCT04230447||a cohort of patients with SIRS|This study is an observational study without drug and other interventions
16363997|NCT04230421|Active Comparator|Monsenso without feedback|Daily smartphone-based monitoring and treatment using the Monsenso system WITHOUT a clinical feedback loop feedback.
16363998|NCT04230421|Active Comparator|Control|CAG Bipolar treatment alone and daily mood monitoring using only the mood monitoring part of the Monsenso system.
16363999|NCT04230408|Experimental|DURVALUMAB (MEDI4736) + carboplatin-paclitaxel|"Induction chemo-immunotherapy phase:
~Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.
~Concurrent chemo-immuno-radiotherapy phase:
~Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.
~Concurrent chemo-immuno-radiotherapy:
~Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses"
16364000|NCT04230395|Experimental|CAP (Counseling on Alcohol Problems)|The CAP intervention is an up to 4-session alcohol reduction intervention that uses a combination of Motivational Enhancement Therapy and Cognitive Behavioral Therapy. The intervention will also include 3 booster sessions.
16364001|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
16364002|NCT04230382||Adults|Adults (above 18 years) with completed National Health and Health System Survey 2019 (without diagnosis of diabetes)
16364003|NCT04230369|Experimental|Internet-CBT|The internet-CBT will comprise 8 weekly modules with therapist-support, encouraging exposure for fear of asthma symptoms while ensuring a stable asthma medication through a written medical plan on medical adherence Participants work independently from home with the treatment and receive weekly support from their psychologist through written messages online.
16364004|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment, but psychological, from pre-assessments to 2 months after treatment completion. Participants in this arm will be crossed over to Internet-CBT after the primary endpoint at to 2 months follow up.
16364005|NCT04230356|Experimental|VSTs to Prevent|VSTs are given through an IV infusion 21 days after transplant to see if the VSTs will help prevent a viral infection.
16364006|NCT04230356|Experimental|VSTs to Treat|VSTs will be given only if a viral infection develops.
16364007|NCT04230343|Experimental|Self-benefit arm|
16364008|NCT04230343|Active Comparator|Social-benefit arm|
16364009|NCT04230330|Experimental|Nivolumab|After 4 doses of nivolumab, if the patient has complete responses (CR) or good partial response (PR), the patient will continue on nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment. During PET4-directed treatment with single agent nivolumab, if patient has PD, they will proceed to the Nivo+GDP/L-aspa arm.
16364010|NCT04230330|Experimental|Nivolumab + GDP/ L-asparaginase|After 4 doses of nivolumab, if the patient has PR, stable disease (SD), or progressive disease (PD), the patient will switch to nivolumab-GDP/L-aspa treatment. After 6 cycles of treatment, if CR is achieved, the patient will continue on single agent nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment.
16364011|NCT04230317|Experimental|Low dose chest CT simulation|VBN result driven using raw data acquired with low dose CTs taken with three different protocols
16364012|NCT04230317|Active Comparator|Standard protocol chest CT simulation|VBN result driven using raw data acquired with standard protocol CT
16364013|NCT04230304|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16364014|NCT04230291|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP
~Survey A
~Routine clinic visit
~Verbal consultation only
~Survey B
~Verbal consultation AND Written Action Plan
~Survey C"
16364015|NCT04230291|Experimental|Written Action Plan|"INTERVENTION GROUP
~Survey A
~Routine clinic visit
~Verbal consultation AND Written Action Plan
~Survey C"
16364016|NCT04230278|Experimental|START-Play Intervention|
16364017|NCT04230278|Active Comparator|Usual Care Physical Therapy|
16364018|NCT04230265|Experimental|UniCAR02-T-CD123|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the recombinant antibody derivative TM123.
16364019|NCT04230252|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
16364020|NCT04230252|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8 hour ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
16364021|NCT04230239|Experimental|CPX-351|
16364022|NCT04230226|Active Comparator|Pre-workout and Post-workout Product|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise
~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
16364023|NCT04230226|Placebo Comparator|Study Placebo|non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
16364024|NCT04230213|Experimental|Treatment Arm 1|Subcutaneous (SC) injection given every other week
16364025|NCT04230213|Active Comparator|Treatment Arm 2|SC injection given every other week
16364026|NCT04230200||Healthy cohort|People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.
16364097|NCT04229680|Placebo Comparator|Recommended Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with placebo pills.
16364027|NCT04230200||Malignancy Cohort|People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer
16364028|NCT04230187|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
16364029|NCT04230187|Active Comparator|mFOLFOX6 Plus Bevacizumab|Patients will receive mFOLFOX6 plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
16364030|NCT04230174|Experimental|Multiple sclerosis patients|Multiple sclerosis patients will be evaluated with 11C-PBR28 MR-PET at baseline before and at 12 month follow up after Ocrelizumab therapy.
16364031|NCT04230161||Standard LLIN|This group receives Yahe LN ITNs during the mass distribution campaign.
16364032|NCT04230161||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
16364033|NCT04230161||Standard LLIN and IRS|This group receives Yahe LN ITNs during the mass distribution campaign and IRS.
16364034|NCT04230148|Experimental|Egaten|All subjects will receive Egaten as two 10 mg/kg doses given 12 hours apart.
16364035|NCT04230135|Active Comparator|Generic (surface adaptation)|The generic version of Hap-pas-Hapi includes only surface adaptations (i.e., adaptation of text and illustrations that are inacceptable or non-meaningful for the target group)
16364036|NCT04230135|Experimental|Adapted (deep structure adaptation)|For the experimental intervention, Hap-pas-Hapi was adapted to Albanian immigrants' cultural concepts of distress (CCD). An ethnopsychological study was conducted for this purpose, since evidence on CCD in South Eastern Europe is scarce. Based on this study, three deep-structure adaptations were done: i) the symptom narrative provided by the narrator in the app was re-written to reflect Albanian immigrants' CCD; ii) a new explanatory model builder was implemented to address the target group's fatalistic beliefs; and iii) a goal-setting task was programmed to address the target group's socio-centric notion of the self.
16364037|NCT04230122|Experimental|LY3478006 - Intravenous (IV)|LY3478006 administered IV
16364038|NCT04230122|Placebo Comparator|Placebo - IV|Placebo administered IV
16364039|NCT04230122|Experimental|LY3478006 - Subcutaneous (SC)|LY3478006 administered SC
16364040|NCT04230122|Placebo Comparator|Placebo - SC|Placebo administered SC
16364043|NCT04230096|Experimental|applied group|low level laser therapy applied in one group
16364044|NCT04230096|No Intervention|controlled group|other group will be controlled in which low level laser will not be applied
16364045|NCT04230083|Experimental|Dienogest Test Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
16364046|NCT04230083|Active Comparator|Dienogest Reference Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
16364047|NCT04230070|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
16364048|NCT04230070|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
16364049|NCT04230057||Healthy volunteer|"In good general health and feeling well (no diagnosed disorders/illnesses)
~At least 18 years old
~BMI in the range of 18-29.9 kg/m²
~No known history of substance abuse
~No known allergies to food/drug"
16364050|NCT04230044||Fycompa® (perampanel)|Fycompa® (perampanel) (oral tablets) treatment will be initiated at 2 milligram (mg) once daily according to the approved package insert, as an add-on drug in addition to other anti-epileptic drugs (AEDs) as prescribed by physician. The dose will be increased based on clinical response and tolerability (by increments of 2 mg/day to a maintenance dose of 4 to 12 mg/day) and participants will be enrolled and observed prospectively for up to 54 Weeks.
16364051|NCT04230031|Experimental|1: Daratumumab|Pre-ASCT and Post-ASCT: Daratumumab
16364052|NCT04230018||primary and metastasis lesion|tissue of colorectal cancer primary lesion and tissue of colorectal cancer metastasis were obtained
16364053|NCT04229992|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
16364054|NCT04229992|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
16364055|NCT04229992|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
16364056|NCT04229992|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
16364057|NCT04229979|Experimental|Galinpepimut-S|"A maximum of 15 total injections will be administered as follows:
~First 6 galinpepimut-S injections: every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment. The first series of 6 injections of galinpepimut-S define the initial immunization induction phase.
~Injections 7-12: every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment. The second series of injections of galinpepimut-S define the early immune booster phase.
~Injections 13 to 15: every 6 weeks (between Weeks 40 and 52). The third series of injections of galinpepimut-S define the late immune booster phase."
16364058|NCT04229979|Active Comparator|Best Available Therapy|"Four options (per treating investigator's choice):
~Observation (whereby palliative management with hydroxyurea is allowed), or
~HMA (decitabine or azacitidine) monotherapy, or
~Venetoclax monotherapy, or
~Low-Dose Ara-C"
16364059|NCT04229953||US scan with 3D/4D VRU software|
16364060|NCT04229940|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
16364061|NCT04229940|Active Comparator|No bridging|The hernia defect is left without closure prior to application of the mesh.
16364062|NCT04229927|Experimental|Arm 1|
16364063|NCT04229927|Placebo Comparator|Arm 2|
16364064|NCT04229914|Other|stroke patients|Assessment
16364065|NCT04229901|Experimental|HepaStem|Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 millions of cells/kg (7 day interval)
16364066|NCT04229901|Placebo Comparator|Placebo|Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)
16364067|NCT04229888|Experimental|Subjects Treatment Light Based|All subjects will receive light based treatment.
16364068|NCT04229888|Experimental|Subjects Treatment LipiFlow|All subjects will receive LipiFlow treatment.
16364069|NCT04229875|Experimental|CAG Bipolar|"Patients will be treated in a localized CAG Bipolar clinic within each psychiatric centre increasing the number of bipolar patients for each clinician
~All clinicians will get certified in diagnosing and treating bipolar disorder by joining an educational course and ongoing courses continuously
~Treatment will include a group-based psychoeducation program
~Coordinated targets to improve quality of life of patients by increasing concordance between clinicians, patients and relatives on well-defined treatment goals
~Continued ongoing supervision of patient cases in CAG Bipolar staff by the Copenhagen Affective Disorder Clinic
~Three-month bidirectional exchange of two clinical staff members between the Copenhagen Affective Disorder Clinic and each CAG Bipolar clinic
~Recovery mentors"
16364070|NCT04229875|No Intervention|Control group|Standard treatment
16364071|NCT04229862|Experimental|Evaluation with 14 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 14 cm high pillow.
16364072|NCT04229862|Active Comparator|Evaluation with 7 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 7 cm high pillow.
16364073|NCT04229849|Experimental|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
16364074|NCT04229849|Active Comparator|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
16364075|NCT04229836|Experimental|Tildrakizumab|Participants will receive subcutaneous (SC) injection of tildrakizumab 100 milligrams (mg).
16364076|NCT04229823||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
16364077|NCT04229823||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
16364078|NCT04229823||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
16364079|NCT04229810|Active Comparator|STD-02|Conventional standardized lung protective ventilation.
16364080|NCT04229810|Experimental|iOLA-iHFNC|Individualized ventilatory strategy that mantains an open lung condition.
16364081|NCT04229797|Active Comparator|Comparator|Extraction of the unerupted third molars before distalization of mandibular first molar using Mandibular buccal shelf mini-screws.
16364082|NCT04229797|Experimental|Intervention|Leaving the unerupted third molars and distalizing using Mandibular buccal shelf mini-screws.
16364083|NCT04229784|Experimental|RF ARM|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
16364084|NCT04229771|Experimental|Participants with obstruction of the lacrimal system|Participants who have a blockage in their tear drainage system on probing and irrigation. Participants will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
16364085|NCT04229771|Experimental|Participants with no obstruction of the lacrimal system|Participants who do not have a blockage in their tear drainage system on probing and irrigation. Patients will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
16364086|NCT04229758|Experimental|1 week|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
16364087|NCT04229758|Experimental|2 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
16364088|NCT04229758|Experimental|4 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
16364089|NCT04229732|Experimental|ClearMate Intervention|Participants undergo passive isocapnic hyperventilation via the ClearMateTM device and have regular venous blood samples obtained to measure ethanol clearance kinetics.
16364090|NCT04229732|No Intervention|Supportive Management|Participants receive standard of care, supportive management, for alcohol intoxication, having regular venous blood samples obtained to measure ethanol clearance kinetics.
16364091|NCT04229719|Experimental|Melatonin group|Melatonin powder (N-Acetyl-5-methoxytryptamine) 1.2mg topical application in osteotomy site.
16364092|NCT04229719|No Intervention|Control group|No drug intervention
16364093|NCT04229706|Experimental|High dose group|xiangjurupining capsule ,8 capsules，tid
16364094|NCT04229706|Experimental|Lower dose group|xiangjurupining capsule, 4 capsules,tid, xiangjurupining capsule placebo ,4 capsules，tid，po
16364095|NCT04229706|Placebo Comparator|Placebo group|xiangjurupining capsule placebo ,8 capsules，tid，po
16364096|NCT04229680|Experimental|High Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 6,900 mg/d sodium.
16364101|NCT04229602|Experimental|Venlafaxine Hydrochloride Sustained-Release Capsules|During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.
16364102|NCT04229602|Active Comparator|Active Comparator: EFEXOR® XR|During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.
16364103|NCT04229589||Study population|Consecutive patients undergoing pacemaker implantation for bradyarrhythmic syncope
16364104|NCT04229576|Active Comparator|Using TENS to relief pain during hystroscopy|device intensity (amplitude) will be individually adjusted to each participant's maximum sensory level (strongest reported tingling feeling without pain and with no muscle contractions, the TENS output intensity will be increased during the treatment every time the patient accommodated to the TENS stimulus.
16364105|NCT04229576|Placebo Comparator|Using placebo TENS (not active) during hystroscopy|participants will be connected to the TENS unit in exactly the same way as participants in the active TENS group with the unit emitting the active indicator light and sound but delivering no electrical stimulation.
16364106|NCT04229563||Study patients|Eligible PAD patients who are routinely treated with atherectomy by AURYON™ Atherectomy System.
16364107|NCT04229550|No Intervention|Control subjects|1 week of normal daily life and only by the National Health Board recommendated alcohol consumption.
16364108|NCT04229550|Experimental|Festival subjects|1 week's participation in Roskilde Festival 2016
16364109|NCT04229537|Experimental|SCT-I10A combined SCT200 in ESCC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
16364110|NCT04229537|Experimental|SCT-I10A combined SCT200 in CRC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
16364111|NCT04229537|Experimental|SCT-I10A combined SCT200 plus Chemotherapy in CRC|"SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W.
~Chemotherapy: Capecitabine and Oxaliplatin."
16364112|NCT04229524|Experimental|angiographic intervention group|Enrolled patients will undergo thoracoscopy combined with a three-incision esophageal carcinoma radical mastectomy and two-field (chest-abdomen) lymph node dissection.Quantitative assessment of blood supply in the gastic conduit was performed using fluoroscopy before esophagogastric anastomosis.
16364113|NCT04229524|No Intervention|control group|The same surgical method as the experimental group.The only difference is that the position of the gastic conduit anastomosis is determined based on the experience of the doctor.
16364114|NCT04229511||Infection caused by CRKp|Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
16364115|NCT04229511||Infection caused by any other bacteria|Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
16364116|NCT04229511||No infection|Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria
16364117|NCT04229498||Carbapenem resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
16364118|NCT04229498||Carbapenem hetero-resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-heteroresistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
16364119|NCT04229472|Experimental|Normal subject control group|High density mapping of left atrial voltages in patients with supraventricular tachycardia
16364120|NCT04229472|Experimental|Atrial fibrillation group|High density mapping of left atrial voltages
16364121|NCT04229472|Experimental|AcQMap atrial fibrillation group|High density mapping of left atrial voltages and AcQMap propagation patterns alongside cardiac MRI
16364122|NCT04229459|Experimental|Neoadjuvant Treatment|All subjects will receive induction chemotherapy and chemoradiation combined with cetuximab followed by nivolumab and cetuximab as neoadjuvant treatment
16364123|NCT04229446|Experimental|Receive the music based intervention|After the healthcare workers have accomplished the MBC program the eight week intervention program will be applied by the trained staff at the intervention wards. The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement. The movement will be adapted to their physical capacity.
16364124|NCT04229446|No Intervention|Standard care group|Standard care
16364125|NCT04229433|Experimental|SHR2285|Participants received one of 3 dose levels of SHR2285 administered as multiple oral doses.
16364126|NCT04229433|Experimental|Placebo|Participants received one of 3 dose levels of placebo administered as multiple oral doses.
16364127|NCT04229420|Active Comparator|Rectus sheath block group (RSB)|After preparing the skin, a high frequency (5-10 MHz) ultrasound probe will be placed in a longitudinal orientation above the level of the umbilicus with the Patient in the supine position. After identifying the rectus abdominis muscle, A 22 G echogenic needle using the in plane technique will be inserted just below the costal margin then, a total of 20 ml of 0.25% bupivacaine will be injected into the plane between the rectus muscle and posterior rectus sheath. Negative aspiration will be confirmed every 5 ml. The block will then be repeated on the other side.
16364148|NCT04229290|Active Comparator|Protease Inhibitor|Participants in this arm will be maintained on their protease inhibitor based second line regimen
16364149|NCT04229277|Other|in tumours|consecutive enrollment of newly referred skin tumour patients
16364128|NCT04229420|Active Comparator|Erector spinae plane block group (ESPB)|After induction of anesthesia; the patient will be positioned on the lateral position. The skin will be prepared with povidone iodine, and a high frequency (5-10 MHz) ultrasound probewill be placed in a transverse orientation on the T9 spinous process which will be located by palpating and counting down from the C7 spinous process. The tip of the T9 transverse process will be identified and centred on the ultrasound screen, the probe will then be rotated into a longitudinal orientation to produce a parasagittal view. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is conﬁrmed by injecting 0.5-1 ml saline and seeing the ﬂuid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20 ml of 0.25% bupivacaine will then be injected into the ESP of both sides.
16364129|NCT04229407|Experimental|Dietary supplement|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).
~After 32 subjects in MRI strata is reached. subjects will be randomized to intake Dietary supplement twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks"
16364130|NCT04229407|Placebo Comparator|vitamin B|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).
~After 32 subjects in MRI strata is reached. subjects will be randomized to intake placebo vitamin B twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks."
16364131|NCT04229394|Experimental|2ccPA|"Only day 1 Intra-articular injection can be given under direct ultrasound guidance; the only one strength for 2ccPA injection vial is 2,400 μg (1.2 mL per vial).
~IP name: 2-carba-cyclic phosphatidic acid (2ccPA)"
16364132|NCT04229394|Placebo Comparator|Placebo|Only day 1 Intra-articular injection can be given under direct ultrasound guidance; placebo
16364133|NCT04229381|Experimental|Supportive Care (physical therapy, muscle relaxation)|Patients participate physical therapy sessions consisting of cardiovascular and resistance training exercises in person or online and also undergo progressive muscle relaxation sessions once weekly for up to 12 weeks.
16364134|NCT04229368|Active Comparator|Low Vitamin D3 Supplementation|Subjects enrolled into Group 1 (low-dose Vitamin D3 supplementation) will receive 800 IU of oral Vitamin D3 (Cholecalciferol) daily for 4 weeks prior to surgery, followed by 800 IU of oral Vitamin D3 daily for 3 months after surgery. Vitamin D3 supplementation will be given for a total of 4 months. Supplementing Vitamin D-deficient patients with a minimum of 800 IU of Vitamin D3 daily is supported by the IOM.
16364135|NCT04229368|Active Comparator|High Vitamin D3 Supplementation|Subjects enrolled into Group 2 (high-dose Vitamin D3 supplementation) will receive 50,000 IU of oral Vitamin D3 (Cholecalciferol) twice per week for 1 weeks followed by 50,000 IU once per week for 3 weeks prior to surgery. After surgery they will receive 50,000 IU of oral Vitamin D3 once per week for 4 weeks followed by 800 IU daily for 8 weeks. Vitamin D3 supplementation will be given for a total of 4 months.
16364136|NCT04229368|No Intervention|No supplementation|Subjects with serum 25(OH)D level ≥30ng/mL will not receive any Vitamin D supplementation both pre- and postoperatively, as these are considered sufficient. These control patients will be asked to take any supplements containing Vitamin D for the duration of their participation in the trial. All patients in group 3 will have their serum 25(OH)D checked at 3 months after the surgery.
16364137|NCT04229355|Experimental|DEB-TACE plus Sorafenib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive sorafenib (400 mg/d, po, bid) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
16364138|NCT04229355|Experimental|DEB-TACE plus Lenvatinib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive lenvatinib (8 mg/d, po, qd) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
16364139|NCT04229355|Active Comparator|DEB-TACE plus PD-1 inhibitor|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive PD-1 inhibitor (200 mg, iv, 3 weeks) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. PD-1 inhibitor will be taken for six months, untill tumor progression, or intolerable adverse reactions.
16364140|NCT04229342|Active Comparator|Conventional|"In the conventional group, standard posterior myotomy will be performed and the sling or the oblique fibers will not be spared beyond the gastroesophageal junction."
16364141|NCT04229342|Experimental|Oblique or sling fiber sparing group|In the oblique or sling fiber group, only the circular muscle fibers will be severed selectively and the sling fibers will be spared
16364142|NCT04229329|Experimental|Intervention|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded visually and auditory when a higher degree of finger individuation will be measured. Specifically, when the applied force of the instructed fingers hit the predefined force target and at the same, the force in the non-instructed fingers stay as low as possible
16364143|NCT04229329|Sham Comparator|Control|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded in a way that is unrelated to the degree of individuation. In other words, a successful trial considered when the applied force of the instructed fingers hits the predefined force target regardless of the force exerted in the non-instructed fingers.
16364144|NCT04229316|Experimental|zLock Facet Locking Implant System|
16364145|NCT04229303|Experimental|Active Voriconazole inhaled (ZP-059)|Part 1 - 4 separate cohorts planned to receive single doses of ZP-059 Part 2 - 3 separate cohorts planned to receive daily doses of ZP-059 on Day 1 to 10.
16364146|NCT04229303|Active Comparator|Cross-over with VFEND|Part 3 - 1 cohort randomised to receive VFEND (Cross-over with ZP-059).
16364147|NCT04229290|Experimental|Dolutegravir|Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
16364150|NCT04229264|Active Comparator|Control group|Aspirin 100 mg (oral, once-daily) for 1 year plus Clopidogrel 75 mg (oral, once-daily) for 3 months.
16364151|NCT04229264|Experimental|Apixaban group|Apixaban 2.5 mg (oral, twice daily) for 1 year plus Aspirin 100 mg (oral, once-daily) for 1 year.
16364152|NCT04229251|Experimental|Online Mindfulness-based Intervention|iMBI will be delivered to participants in 8 online sessions, approximately 2 hours per session.
16364153|NCT04229251|Sham Comparator|Online Introductory Psychology Program|An online introductory psychology courses will be delivered to participants in 8 online sessions, approximately 2 hours per session.
16364154|NCT04229238||Home-dwelling older adults|Older adults (70 +) receiving regular health care from the home nursing service. Setting is two rural municipalities in southern Norway.
16364155|NCT04229225|Experimental|UBX0101 single dose (SD)|"Cohort 1 (n=18): UBX0101 8.0 mg or placebo IA at Week 0
~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
16364156|NCT04229225|Experimental|UBX0101 repeat dose (RD)|"Cohort 2 (n=18): UBX0101 4.0 mg or placebo IA at Weeks 0 and 4
~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
16364157|NCT04229212|No Intervention|No drainage|No drainage
16364158|NCT04229212|Experimental|Drainage|a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed
16364159|NCT04229199|Experimental|intervention group (IG)|Dyads of children and parents allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
16364160|NCT04229199|No Intervention|control group (CG)|Dyads assigned to the CG were provided only the standard practice on their day admission to the hospital.
16364161|NCT04229186|Experimental|Patients with assumption of EVOO-C|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg EVOO-C
16364162|NCT04229186|Experimental|Patients with assumption of ROO|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg ROO
16364163|NCT04229173|Other|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:
~a clinical examination;
~blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;
~MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
16364164|NCT04229173|Other|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
16364165|NCT04229160|Experimental|patient with persistent atrial fibrillation|persistent atrial fibrillation is defined as lasting longer than 6 months documented by a 24h holter monitoring
16364166|NCT04229134|Other|Pilot Arm: Project CONNECT|8-week home based reciprocal peer support pain self-management program for chronic musculoskeletal pain
16364167|NCT04229121||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation positive.
16364168|NCT04229121||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation negative.
16364169|NCT04229108|Other|Healthy volunteer|Will record traditional timed up and go followed by two digitised versions
16364172|NCT04229082||lean|BMI between 18-25
16364173|NCT04229082||obese|BMI between 27.5-35
16364174|NCT04229069|Active Comparator|Basica|4-week dietary supplementation with an alkaline salt (Basica)
16364175|NCT04229069|Placebo Comparator|Placebo|4-week dietary supplementation with a placebo
16364176|NCT04229056|Experimental|Specific computer-based cognitive rehabilitation|300 patients (200 with stroke, 50 with Parkinson's disease and 50 with heart attack) will be allocated to specifif computer-based cognitive rehbailitation. This group will train with 11 exercises from the cognitive rehabilitation software 'Scientific Braintraining PRO'. These 11 exercises are designed to train various executive functions.
16364177|NCT04229056|Sham Comparator|General computer-based cognitive stimulation|300 patients (200 with stroke, 50 with Parkinson's disease and 50 with heart attack)will be allocated to general computer-based cognitive stimulation. This group will train with 11 generally mentally stimulating games on a sham-webside specifically dedigned for this trial. These 11 games are chosen because they are believed to have a low load on executive functions.
16364178|NCT04229043|Active Comparator|Early labor, no analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
16364179|NCT04229043|Placebo Comparator|Early Labor, no analgesia: Water|Subject will ingest 100 ml of water
16364180|NCT04229043|Active Comparator|Early labor, analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
16364181|NCT04229043|Placebo Comparator|Early labor, analgesia: Water|Subject will ingest 100 ml of water
16364182|NCT04229030|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL RZL-012 (5mg).
~Lipomas in the size of:
~2-3.9 cm will be dozed with 0.4mL RZL-012 (20mg). 4-5.9 cm will be dozed with 0.8mL RZL-012 (80mg). 6-7.9 cm will be dozed with 1 mL RZL-012 (100mg). 8-10 cm will be dozed with 1.2 mL RZL-012 (120mg)."
16364183|NCT04229030|Placebo Comparator|Vehicle of RZL-012|"A single-treatment injection, multiple subcutaneous injections of vehicle administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL vehicle.
~Lipomas in the size of:
~2-3.9 cm will be dozed with 0.4mL vehicle. 4-5.9 cm will be dozed with 0.8mL vehicle. 6-7.9 cm will be dozed with 1 mL vehicle. 8-10 cm will be dozed with 1.2 mL vehicle."
16364184|NCT04229017|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF)|ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.
16364185|NCT04229017|Experimental|Circumferential Cervical Fusion (CCF)|Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).
16364186|NCT04229004|Active Comparator|Gemcitabine combined with nab-paclitaxel|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed.
16364187|NCT04229004|Experimental|SM-88|"460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.
~All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal."
16364188|NCT04229004|Active Comparator|mFOLFIRINOX|Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion
16364189|NCT04229004|Experimental|pamrevlumab (FibroGen)|"Experimental: Pamrevlumab in combination with gemcitabine/nab-paclitaxel.
~Subjects enrolled to this treatment arm will receive treatment with pamrevlumab in combination with gemcitabine and nab-paclitaxel.
~Gemcitabine and nab-paclitaxel are FDA approved therapies for metastatic pancreatic cancer and will be supplied or obtained according to local clinical study agreements and in accordance with local guidelines."
16364190|NCT04228991|Active Comparator|Control|Conventional fractionation for locoregional radiotherapy
16364191|NCT04228991|Experimental|Experimental|Hypofractionation for locoregional radiotherapy
16364192|NCT04228978|Experimental|Weight loss + exercise (WL+EX)|Weight loss + home based walking exercise (WL+EX)
16364193|NCT04228978|Active Comparator|Exercise alone (EX)|Home based walking exercise (EX)
16364194|NCT04228965|Other|Co-Use Group|Cannabis and tobacco co-use group.
16364195|NCT04228965|Active Comparator|Tobacco Only Group|Tobacco only group.
16364196|NCT04228952||Smokers with very low or no CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with little or no CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of <0.6).
16364197|NCT04228952||Smokers with high CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with high CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of > 3.0)
16364198|NCT04228939|Experimental|Intervention group (IG)|
16364199|NCT04228939|Active Comparator|Control group (CG)|
16364200|NCT04228926|Experimental|0.002% ZKY001 eye drops|Experimental group A: 35 subjects .0.002% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
16364201|NCT04228926|Experimental|0.004% ZKY001 eye drops|Experimental group B: 35 subjects .0.004% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
16364202|NCT04228926|Placebo Comparator|The placebo|Placebo group C: ZKY001 simulated eye drops .4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 simulated eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
16364203|NCT04228913|Other|Ah plus|The root canals obturated with Ah plus root canal sealer (Dentsply, Sirona) and gutta-percha cones with cold lateral condensation technique.
16364204|NCT04228913|Other|ROEKO GuttaFlow® 2|The root canals obturated with GuttaFlow 2 root canal sealer (Coltene,Whaledent) and single tapered gutta-percha cone with cold free flow compaction technique.
16364205|NCT04228913|Other|GuttaCore Obturators|The root canals obturated with GuttaCore obturators (Dentsply,Sirona) and Ah plus root canal sealer with thermoplasticized solid-core carrier technique
16364206|NCT04228900|Experimental|Intervention group|Drug review and tailored nutritional supply.
16364207|NCT04228900|No Intervention|Control group|"Follow-up by home nurse service and family physician as usual."
16364208|NCT04228887|Active Comparator|Control Group|The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
16364209|NCT04228887|Active Comparator|Training Group|The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
16364210|NCT04228848|Active Comparator|Healthy adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
16364211|NCT04228848|Experimental|ACL adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
16364212|NCT04228848|Active Comparator|Healthy adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
16364213|NCT04228848|Experimental|ACL adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video.Legs muscle strength will be assessed using hand held dynamometer
16364334|NCT04227990|Experimental|TAC + Plinabulin 10 mg/m^2|
16364214|NCT04228835|Experimental|ICGFC-LC|ICG fluorescence cholangiography assisted laparoscopic cholecystectomy (ICGFC-LC) arm patients received intravenous bolus of 2.5mg of ICG before the induction of anaesthesia. Near infrared laparoscopic light camera was utilized intermittently during dissection of Calot's triangle until critical view of safety was achieved.
16364215|NCT04228835|No Intervention|Conventional LC|Conventional laparoscopic cholecystectomy (LC) arm patients underwent standard white light laparoscopic cholecystectomy without fluorescence cholangiography.
16364216|NCT04228822|Experimental|Low carb diet intervention group|Low carbohydrate diet defined as 25-35% of total energy intake
16364217|NCT04228822|No Intervention|Control|Standard diet defined as 45-65% total energy intake
16364218|NCT04228809|Experimental|anodal tDCS|anodal tDCS stimulation
16364219|NCT04228809|Active Comparator|cathodal tDCS|cathodal tDCS stimulation
16364220|NCT04228809|Placebo Comparator|sham tDCS|sham tDCS stimulation (stopped after 30 seconds)
16364227|NCT04228770|Experimental|Warfarin patients|Patients on high risk medication - warfarin
16364228|NCT04228770|Experimental|Parkinson's patients|Patients with high risk disease - parkinson's
16364229|NCT04228757|Experimental|Investigational Herbal Blend|A phytoestrogen herbal blend
16364230|NCT04228757|Placebo Comparator|Placebo|Tablet without active ingredients
16364231|NCT04228744|Experimental|Bilateral surgical implantation of DBS system|All the participants will receive bilateral surgical implantation of DBS system to VIC and NAc. The experimenter will active the DBS system and adjust the parameters for all the participants after surgery.
16364234|NCT04228705||The elders|Patients aged over 59 years old
16364235|NCT04228705||The young adults|Patients aged from 18 to 59 years old
16364236|NCT04228692|Active Comparator|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary
16364237|NCT04228692|Experimental|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.
~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
16364238|NCT04228679|Experimental|Erbium laser treatment|Women with vaginal laxity treated with real laser.
16364239|NCT04228679|Sham Comparator|Sham laser treatment|Women with vaginal laxity treated with sham laser.
16364240|NCT04228666|Experimental|HB-adMSCs|HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells.
16364241|NCT04228653|Experimental|No Arm|As this is the follow up study, there are no arms
16364242|NCT04228640|Experimental|Investigational Product|Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
16364243|NCT04228640|Placebo Comparator|Placebo|Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
16364244|NCT04228627|Active Comparator|Treatment|Intravenous Iron to correct Iron deficiency without anaemia
16364245|NCT04228627|No Intervention|Prophylaxis|Usual antenatal care
16364246|NCT04228614||Retrospective cohort|Whole exome sequencing of 2500 retrospective tissue sample.
16364247|NCT04228614||Prospective cohort|Whole exome sequencing of 500 prospectively collected tissue samples. Panel sequencing of 451 genes of prospectively collected blood samples.
16364248|NCT04228601|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
16364249|NCT04228601|Placebo Comparator|Placebo+mFOLFIRINOX|Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy
16364250|NCT04228588|Experimental|Mepolizumab|Mepolizumab 100mg, SC, every 4 weeks
16364251|NCT04228575|Experimental|Extended Contact|Clients in the Extended Contact condition will be asked at the 6 week mark if they like they can extend their treatment and receive up to 12 weeks of support. They will be informed that this may be helpful if they feel they have fallen behind in reviewing of the materials, if they would like to receive support while they work on supplementary resources or if they would like extended support while they work on core lessons. If they would like additional support, participants will answer questions presented on the website about their desire for this additional support what they would like to focus on during this time. Those clients who indicate that they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks. Those that do not request the additional support will end treatment as planned at the end of 8 weeks.
16364252|NCT04228575|Experimental|8 Week ICBT no Booster|In the standard condition, clients will receive 8 weeks of therapist support. They will not be given the option to extend their treatment and support to 12 weeks. The booster course will not be offered in this condition.
16364253|NCT04228575|Experimental|Extended Contact with Booster|"Clients in the Extended Contact condition will receive an email at the 6 week mark letting them know that they if they like they can extend their treatment and receive up to 12 weeks of support. At week 6, clients will answer questions on the website about whether they would like this additional support or not and what they would like to focus on during this time. Clients who indicate they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks.
~They will also be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks."
16364254|NCT04228575|Experimental|8 week ICBT with Booster|Clients in the booster condition will be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks.
16364255|NCT04228562|No Intervention|Non-modifiable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
16364256|NCT04228562|Experimental|Non-modifiable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
16364257|NCT04228562|Experimental|Non-modifiable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
16364258|NCT04228562|Experimental|Non-modifiable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
16364259|NCT04228549|No Intervention|Control|Usual care
16364260|NCT04228549|Experimental|MyPADMGT|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed.
16364261|NCT04228549|Experimental|MyPADMGT + Nudging|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed. In addition, nudging support available to help patients make better choices and decisions.
16364262|NCT04228523|Experimental|Therapeutic education workshop|Two group receive therapeutic education workshop already existing in Toulouse University Hospital
16364263|NCT04228523|Other|Speaking Therapy|One group receive speaking therapy already existing in Toulouse University Hospital
16364264|NCT04228510||Study group|ST elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention who will be followed up in Assiut University hospital.
16364265|NCT04228497|Active Comparator|clear fluids fasting for one hour|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml one hour before surgery
16364266|NCT04228497|Placebo Comparator|clear fluids fasting for two hours|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml two hours before surgery
16364267|NCT04228484|Placebo Comparator|Placebo|Placebo infusion
16364268|NCT04228484|Active Comparator|GIP receptor antagonization|GIP(3-30)NH2 infusion
16364269|NCT04228471|Experimental|Spontaneous Breathing Group|"Spontaneous breathing activity will be allowed during APRV within one hour after randomization throughout the first 48 hours.
~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
16364270|NCT04228471|Experimental|Controlled Mechanical Ventilation Group|"Pressure controlled mechanical ventilation will be applied throughout the first 48 hours.
~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
16364271|NCT04228458|Experimental|Thermal Imaging|Thermal Imaging acquisition
16364272|NCT04228445|Experimental|HIGH DOSE|48 subjects randomly treated with 5 mL of drug
16364273|NCT04228445|Experimental|LOW DOSE|48 subjects randomly treated with 2.5 mL of drug
16364274|NCT04228445|Placebo Comparator|Saline|96 subjects treated with 5 ml of saline than crossover to treatment arm
16364275|NCT04228432|Experimental|Patients with breast cancer treated by adjuvant hormonotherapy|
16364276|NCT04228419|Active Comparator|<-10 Degrees of Retroversion|
16364277|NCT04228419|Active Comparator|>-10 Degrees of Retroversion|
16364278|NCT04228406|Experimental|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
16364279|NCT04228393|Active Comparator|Standard treatment regimen|6-mercaptopurine was administered according to the Chinese Children Cancer Group (CCCG) protocol-ALL 2015.
16364280|NCT04228393|Experimental|Individualized treatment regimen|6-mercaptopurine was administered on the basis of Chinese Children Cancer Group (CCCG) protocol-ALL 2015 combined with Clinical Pharmacogenetics Implementation Consortium (CPIC), genotypes and the concentrations of 6-TGN in red blood cells.
16364281|NCT04228380||Inclusion|Inclusion criteria: The cohort is made up of adult patients over 18 years of age, admitted to intensive care units in Sweden, for other reason than postoperative care or simple monitoring.
16364282|NCT04228380||Exclusion|Exclusion criteria: Children under the age of 18 will be excluded as well as patients admitted for simple monitoring or postoperative care.
16364284|NCT04228354|Experimental|Semaglutide 0.68 mg/mL|Semaglutide administered with the PDS290 pen-injector
16364285|NCT04228354|Experimental|Semaglutide 1.0 mg/mL|Semaglutide administered with the PDS290 pen-injector
16364286|NCT04228341|Other|Glucose Reference 1|Glucose solution 1
16364287|NCT04228341|Other|Glucose Reference 2|Glucose solution 2
16364288|NCT04228341|Other|Glucose Reference 3|Glucose solution 3
16364289|NCT04228341|Experimental|Brown Rice|Cooked brown rice
16364290|NCT04228341|Experimental|3 % polished rice|Cooked 3 % polished rice
16364291|NCT04228341|Experimental|6 % polished rice|Cooked 6 % polished rice
16364292|NCT04228341|Experimental|9 % polished rice|9 % polished rice
16364293|NCT04228341|Experimental|20 % Polished rice|Cooked 20 % Polished rice (White Rice)
16364294|NCT04228315|Experimental|Early primaquine group|Thirty (30) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and 15 mg/day of oral primaquine for 14 days
16364295|NCT04228315|Active Comparator|Delayed Primaquine group|Sixty (60) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and the primaquine regimen (15 mg/day for 14 days) not given until 42 days after enrollment
16364296|NCT04228315|No Intervention|Healthy control group|Ten (10) age- and gender-matched controls will be enrolled for one day to obtain biological samples to be compared to the 2 intervention arms
16364297|NCT04228302|Experimental|EC5026|Single Ascending Doses of oral EC5026
16364298|NCT04228302|Placebo Comparator|Placebo|Single doses of matching oral placebo
16364299|NCT04228289|Experimental|Oxytocin|40 IU intranasal oxytocin
16364300|NCT04228289|Placebo Comparator|Placebo|intranasal saline spray
16364301|NCT04228276|Experimental|Active rTMS|Receive active rTMS
16364302|NCT04228276|Sham Comparator|Sham rTMS|Receive sham rTMS
16364303|NCT04228263|Other|hydroxychloroquine group|hydroxychloroquine 400 mg preconceptional
16364304|NCT04228263|Other|Placebo group|will receive placebo
16364305|NCT04228224|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 2 sessions per week for 12 weeks, each lasting about 1 hour.
16364306|NCT04228224|Active Comparator|Conventional Gait Rehabilitation|Participants in this group will perform conventional gait rehabilitation on a rehabilitation institution with assistance of a physical therapist. Training involve 24 sessions, 2 sessions per week, each session lasting about 1 hour.
16364307|NCT04228198||Radical cystectomy|Patients with histologically confirmed diagnosis of bladder cancer undergoing radical cystectomy surgery at 28 Urology departments in Italy
16364308|NCT04228185|Experimental|Laparoscopic banded sleeve gastrectomy|Group undergoing banded sleeve
16364309|NCT04228185|Active Comparator|Laparoscopic sleeve gastrectomy|Group undergoing standard sleeve
16364310|NCT04228172||Parkinson's disease (PD) glucocerebrosidase (GBA) carriers|Parkinson's disease subjects with GBA mutation
16364311|NCT04228172||Parkinson's disease (PD) non glucocerebrosidase (GBA) carriers|Parkinson's disease subjects without GBA mutation
16364335|NCT04227990|Experimental|TAC + Plinabulin 20 mg/m^2|
16364336|NCT04227990|Experimental|TAC + Plinabulin 30 mg/m^2|
16364337|NCT04227990|Experimental|TAC + Pegfilgrastim (1.5 mg) + Plinabulin (20 mg/m^2)|
16364338|NCT04227990|Experimental|TAC + Pegfilgrastim (3 mg) + Plinabulin (20 mg/m^2)|
16364339|NCT04227990|Experimental|TAC + Pegfilgrastim (6 mg) + Plinabulin (20 mg/m^2)|
16364312|NCT04228159|Experimental|Perturbation training|"Session1 - baseline assessment (detailed above) Session2 - 13 - each session will begin with reassessment and documentation of balance tutor parameters for each participant as were calibrated at the end of previous session.
~After reassessment the training program will include:
~Warm up - walking without perturbation.
~Perturbation during standing position.
~Perturbation during walking.
~Perturbation during tandem position.
~Perturbation with vestibular stimulation.
~Rest according to patient needs The relative duration of each component, as well as intensity and frequency of perturbations, will be adjusted to each individual according to his ability, reassessment parameters and progression.
~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
16364313|NCT04228159|Active Comparator|Balance and strengthening exercise|"Session1 - baseline assessment (detailed above).
~Session2 - 13 - each session will include:
~Warm up (free walking or cycling).
~Static balance exercise - standing position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.
~Dynamic balance exercise - walking position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.
~Strengthening exercise - general strengthening, particularly for lower limb.
~Cool down. Level of difficulty and duration of each component will be adjusted to each individual according to his ability and progression.
~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
16364314|NCT04228146|Experimental|CBT-I condition|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment six weeks after the post-intervention assessment.
16364315|NCT04228146|Other|Waitlist control condition|Participants in the waitlist control group complete the post-intervention assessment six weeks after the baseline assessment, start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment, and complete the follow-up assessment right after they finish the 6-week CBT-I.
16364316|NCT04228133|Experimental|Home-delivered attention control training (ACT)|A home-delivered ACT comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV).
16364317|NCT04228133|Placebo Comparator|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat.
16364318|NCT04228120|Experimental|intervention group|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
16364319|NCT04228120|No Intervention|control group|routine care
16364320|NCT04228107|Experimental|Cohort|"Participants will be enrolled in medication use monitoring. Their medication use patterns will be available to themselves and their guardians via a smartphone application, and to their asthma care providers via a portal. There will be no interventions to change medication use patterns. A portion of them will be asked to participate in a semistructured interview during which they will be asked questions about their perception of their asthma, health beliefs regarding medication use, and what they feel would be the most helpful to get them to take their asthma medicines.
~Additionally a small group of healthcare providers will be asked to participate in a focus group to collect qualitative data on medication use barriers and facilitators"
16364321|NCT04228094||TDApp1|This cohort will use TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
16364322|NCT04228081||UTI Positive|"In phase I of the study testing residual urine samples the aim is to include at least 50 positive samples from each bacterial species known to be commonly associated with urinary tract infections. We selected 2000 positive urines to enable capturing enough of these organisms in the development process.
~For phase II of the study, the same number of positive samples in order to include all common species causing urinary tract infection. The number of negative samples included is reduced to 1000.
~Phase 3 - approximately one third of all urine sample submitted will be positive for a uropathogen. Sample size of 3000 we expect 1000 these to be culture positive. We expect most uropathogens occurring at a frequency of 5% or more will be included with sufficient numbers in the validation process."
16364323|NCT04228081||UTI Negative Control|2000 negative urine samples are being run as controlled to ensure the false positivity rate is low.
16364324|NCT04228068|Experimental|Intervention|The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
16364325|NCT04228068|Active Comparator|Conventional care|Usual care
16364326|NCT04228055|Experimental|CLIPP2|24 Week Lifestyle Modification Intervention
16364327|NCT04228042|Experimental|Treatment (infigratinib, surgery)|Patients receive infigratinib PO QD on days 1-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. During weeks 8-9 (at least 48 hours after last dose of infigratinib), patients undergo surgery.
16364328|NCT04228029|Active Comparator|Carboxytherapy|
16364329|NCT04228029|Active Comparator|Intralesional steroids|
16364330|NCT04228029|Active Comparator|Combination of carboxytherapy and intralesional steroids|
16364331|NCT04228016|Experimental|Experimental: Device : nasal airway stent|All patients consulting for predominantly nocturnal nasal obstruction who have benefited from Nasal Respiratory Functional Exploration with detection of pathological resistance in the decubitus.
16364332|NCT04228003|Experimental|Pendulum|Pendulum Glucose Control formulation for T2D will be taken twice daily - 1 capsule with the morning meal and 1 capsule with the evening meal for 8 weeks with an option of continuing up to 6 months.
16364333|NCT04227990|Active Comparator|TAC + Pegfilgrastim (6 mg)|
16364341|NCT04227964|Experimental|Periodontal regeneration|Periodontal regeneration consisting of papilla preservation flaps, application of FDA approved CE marked periodontal regenerative devices, tooth splinting and root canal treatment as required.
16364342|NCT04227964|Active Comparator|Extraction and tooth replacement|Tooth extraction and replacement with a dental implant or a fixed partial denture following healing and reconstruction of the extraction area. Choice based on standard of practice.
16364343|NCT04227951|Sham Comparator|Drain|Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
16364344|NCT04227951|Experimental|No Drain|Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
16364345|NCT04227938|Experimental|ALPN-101|All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101-as identified in Part A-will be evaluated.
16364346|NCT04227912|Active Comparator|Group TAP|Ultrasound-guided TAP Block
16364347|NCT04227912|Active Comparator|Group Local|Ultrasound-guided Local Infiltration
16364348|NCT04227912|Active Comparator|Group Dexketoprofen|Intravenous Dexketoprofen
16364349|NCT04227899|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
16364350|NCT04227899|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
16364351|NCT04227886||Good response|TRG of 0-1 is defined as good response.
16364352|NCT04227886||Poor response|TRG of 2-3 is defined as poor response.
16364353|NCT04227886||Light toxicity|No grade 3-4 toxicities occur during neoadjuvant therapy.
16364354|NCT04227886||Heavy toxicity|Grade 3-4 toxicities occur during neoadjuvant therapy.
16364355|NCT04227860|Active Comparator|Group 1: G I primary KOA|Exercise and balance training
16364356|NCT04227860|Active Comparator|Group 2: G II primary KOA|Exercise and balance training
16364357|NCT04227860|Active Comparator|Group 3: G III primary KOA|Exercise and balance training
16364358|NCT04227860|Active Comparator|Group 4: G IV primary KOA|Exercise and balance training
16364359|NCT04227847|Experimental|Part A|SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
16364360|NCT04227847|Experimental|Part B|SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
16364361|NCT04227847|Experimental|Part C|SEA-CD70 expansion cohort in relapsed/refractory AML
16364362|NCT04227834|Active Comparator|Single education|Single health hygiene education
16364363|NCT04227834|Experimental|Repeated education|Four-monthly health hygiene education
16364364|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
16364365|NCT04227808|Experimental|Lenvatinib Arm|Experimental: Participants will be given lenvatinib (12 mg/d for body weight≥60kg, 8 mg/d for body weight < 60kg) for 12 months until disease recurrence or intolerance AEs or death.
16364366|NCT04227795|Experimental|Artificial intelligence-Assisted real time colonoscopy|AI assisted real-time detection of colonic lesions
16364367|NCT04227782||NAFLD|
16364368|NCT04227782||NASH|
16364369|NCT04227782||Cirrhosis|
16364370|NCT04227782||Healthy Volunteers|
16364371|NCT04227769|Experimental|healthy individuals|Two crossover visits with a washout period of at least 4 days in-between visits and at most two weeks: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal. Treatments will be placebo controlled, crossover, double blinded. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
16364372|NCT04227769|Experimental|obese patients with type 2 diabetes|Three crossover visits with a washout period of at least 4 days in-between: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal, C) Additionally, after the second study day, participant in group 2 will be trained to self-inject the medication for 6 days. On the 7th day, an oral standardized meal test will be performed. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
16364373|NCT04227756|Experimental|LSD-100|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
16364374|NCT04227756|Active Comparator|Psilocybin-20|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
16364375|NCT04227756|Active Comparator|Mescaline-300/500|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
16364376|NCT04227756|Placebo Comparator|Placebo|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
16364377|NCT04227743|Experimental|patients with endobronchial lesions|flexible bronchoscoy will be performed to patients with endobronchial lesions and biopsy from the lesions by forceps and cryoprope will be obtained
16364378|NCT04227730||group A|group A (+ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
16364379|NCT04227730||group B|group B (-ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
16364380|NCT04227717||Thoracic, lumbar and sacral spine lesions|Participants will have thoracic, lumbar and sacral spine lesions
16364381|NCT04227704|Placebo Comparator|Control|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection and 40-minute intravenous infusion of 0.9% sodium chloride.
16364382|NCT04227704|Experimental|Ketamine SC|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.5 mg/kg of ketamine and a 40-minute intravenous infusion of 0.9% sodium chloride.
16364383|NCT04227704|Experimental|Ketamine IVI|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.9% sodium chloride and a 40-minute intravenous infusion of 0.5 mg/kg ketamine.
16364384|NCT04227691|Active Comparator|Long-pulsed Nd YAG laser treatment|Ten patients will be randomized to receive Long-pulsed Nd:YAG in either left or right axilla. (The other axilla will serve as within-person control)
16364385|NCT04227691|Active Comparator|IPL treatment|Ten patients will be randomized to receive IPL treatment in either left or right axilla. (The other axilla will serve as within-person control)
16364386|NCT04227678|Other|Control group- A0|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);
~A0: without heparin administered"
16364387|NCT04227678|Other|LPLD group-A0|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
~A0: without heparin administered"
16364388|NCT04227678|Other|Control group-A1|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g OGTT glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);
~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
16364389|NCT04227678|Other|LPLD group-A1|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
16364390|NCT04227665|Experimental|Sea level|Sea level training camp
16364391|NCT04227665|Experimental|Altitude|Altitude training camp
16364392|NCT04227652|Experimental|Aggressive treatment strategy|The antipyretic strategy was initiated immediately upon increase of the temperature above 38.3°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
16364393|NCT04227652|Experimental|Conservative treatment strategy|The antipyretic strategy was initiated only after the body temperature exceeded 39.5°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
16364394|NCT04227639|Active Comparator|T-piece trial|In patients assigned to control group all spontaneous breathing trials will be performed using T-piece trial.
16364395|NCT04227639|Experimental|Pressure-Support trial|In patients assigned to experimental group all spontaneous breathing trials will be performed with a pressure-support level of 8 cm H2O without positive end-expiratory pressure.
16364396|NCT04227626|Experimental|GlucoSTAT|Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is > 0.75 u/kg or ≥ 2 u/kg.
16364397|NCT04227600|Experimental|Part1 JR-171|Drug: JR-171 IV infusion, dose escalation
16364398|NCT04227600|Experimental|Part2 JR-171|Drug: JR-171 IV infusion, dose escalation, low dose, high dose
16364399|NCT04227587|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx.
16364400|NCT04227587|Active Comparator|Sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse. Each subject will receive a handout and a sleep hygiene log.Subjects will be told to record their daily compliance with sleep hygiene instructions using yes/no questions in the sleep hygiene log.
16364401|NCT04227574|Experimental|Zero Time Exercise training + WhatsApp anti-inertia reminders|Subjects in this group will receive daily WhatsApp anti-inertia reminders from the research assistant to remind and encourage them to practice Zero Time Exercise.
16364402|NCT04227574|Active Comparator|Zero Time Exercise training alone|Subjects in this group will not receive any WhatsApp reminders from week 8 to 24.
16364403|NCT04227561|Active Comparator|Pudendal nerve block|Neurostimulation-guided pudendal nerve block
16364404|NCT04227561|Active Comparator|Penile nerve block|Ultrasound-guided penile nerve block
16364405|NCT04227548|Experimental|Healthy individuals|
16364406|NCT04227535||Rheumatoid arthritis - Interstitial lung disease patients|"Assessment are as follows :
~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic: chest HRCT scan
~Genetic: DNA, mRNA
~Biologic: serum"
16364407|NCT04227535||Rheumatoid arthritis - no Interstitial lung disease patients|"Assessment are as follows :
~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic: chest HRCT scan
~Genetic: DNA, mRNA
~Biologic: serum"
16364747|NCT04225013||Case (yes CIN)|Patients who receive contrast media and develop contrast-induced nephropathy
16364408|NCT04227522|Experimental|Arm A (Rucaparib)|Rucaparib treatment (starting dose 600 mg, twice daily) after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
16364409|NCT04227522|Placebo Comparator|Arm B (Placebo)|Placebo treatment after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
16364410|NCT04227509|Experimental|Experimental|
16364411|NCT04227509|Placebo Comparator|Placebo|
16364412|NCT04227496|Active Comparator|Noise1|A sound will be played while moving a body part through range of motion
16364413|NCT04227496|Active Comparator|Noise2|A sound (different from Noise 1) will be played while moving a body part through range of motion
16364414|NCT04227496|No Intervention|No noise|No sound will be played while moving a body part through range of motion
16364415|NCT04227483|Active Comparator|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
16364416|NCT04227483|Experimental|Deflazacort|Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks. Then taper by 6 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
16364417|NCT04227470|Experimental|Experimental: HBM9161, 340mg|HBM 9161 injection, 340mg, weekly administered by subcutaneous for a period of 4 weeks.
16364418|NCT04227470|Experimental|Experimental: HBM9161, 680mg|HBM 9161 injection, 680mg, weekly administered by subcutaneous for a period of 4 weeks.
16364419|NCT04227431||Tresiba®|A broad real world type 2 diabetes (T2D) patient population in China, treated with oral anti-diabetic drugs (OAD(s)) or basal insulin prior to treatment initiation with Tresiba®
16364420|NCT04227418||Mental Health|
16364421|NCT04227418||Psychiatric|
16364422|NCT04227405|No Intervention|Control group|Control group of couples will receive no intervention
16364423|NCT04227405|Experimental|Intervention|Intervention group of couples received the intervention: case management (connection to community services), 20 hour pscycho-educational workshop on communication, conflict resolution, problem-solving, stress management, and financial management, booster session, and employment support services if needed
16364424|NCT04227392|Experimental|Experimental|women who undergo radiofrequency therapy
16364425|NCT04227379|Experimental|DD-TXT|Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g. nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
16364426|NCT04227379|Active Comparator|DSE|"The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care. Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from the content of the workbook but shortened to fit the 160-character limit of a text message. There will be no customizable or interactive content for the DSE arm."
16364427|NCT04227366|Experimental|Group 1|BCD-089
16364428|NCT04227366|Placebo Comparator|Group 2|Placebo
16364429|NCT04227353|Experimental|HEAL ABC|Participants allocated to the intervention will be encouraged to follow the HEAL ABC resources in order to make a healthy eating and active lifestyle change. This will be achieved by setting specific goal(s) and by making concrete plan(s) to implement changes in their everyday life. Interventions will be delivered in the form of written resources that will guide participants. Supportive phone calls using motivational interviewing techniques will be provided to participants every two weeks to encourage lifestyle changes.
16364430|NCT04227353|No Intervention|HEALTH|Participants allocated to the control group will be referred to publicly available resources on healthy lifestyle recommendations but will not receive any additional support.
16364431|NCT04227340|Experimental|Photobiomodulation Therapy (PBM)|The PBM will be administered extra-oral and intra-oral.
16364432|NCT04227327|Experimental|Abemaciclib + aromatase inhibitors|Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily
16364433|NCT04227314|Experimental|Apremilast|apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
16364434|NCT04227314|Placebo Comparator|Placebo|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period
16364435|NCT04227301||Hyponatremic patients|Patients hospitalized at the University Hospital of Basel and presenting with hyponatremia will be screened for the study
16364436|NCT04227288|Experimental|Enstilar Foam|Eligible subjects will be provided twice daily daily Enstilar Foam (calcipotriene and betamethasone dipropionate).
16364437|NCT04227275|Experimental|Dose Escalation|Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
16364438|NCT04227262|No Intervention|the control group|Group (a) control group received traditional physical therapy program.
16364439|NCT04227262|Experimental|the study group|group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months.
16364440|NCT04227249||Experimental|women who do not undergo lymph node dissection
16364441|NCT04227236|Experimental|E-based virtual training|Participants in the e-based virtual training (up to 8 participants per session) will be placed at one of eight computers (with headphones), which we estimate will take less time (about 40 minutes), due to the individualized learning and 1:1 nature of the training instead of 1:15. Participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
16364566|NCT04226300|Experimental|Laparoscopic-Assisted|Surgeons will place TAP block laparoscopically using a camera prior to beginning a surgical procedure.
16364442|NCT04227236|Active Comparator|In-person training|Participants in-person training will participate in a class with 15-20 participants like the usual MPC training environment. The training will last 1 hour. Like the e-based virtual training, participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
16364443|NCT04227223|Experimental|Study Group|Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy
16364444|NCT04227223|Active Comparator|Control Group|Control Group - 14 patients, healthy volunteers.
16364445|NCT04227210|Experimental|RSV Vaccine: Dosage Group #1|Participants in this group will receive a single dose of the RSV vaccine at dosage #1
16364446|NCT04227210|Experimental|RSV Vaccine: Dosage Group #2|Participants in this group will receive a single dose of the RSV vaccine at dosage #2
16364447|NCT04227197|Experimental|Intervention Group|The participants randomized to the intervention group completed the DSC2U questionnaire, and received online access to a personalized Caregiver Checklist and PCP plan. Caregivers were encouraged to share and discuss the PCP plan at their next wellness visit with the PCPs.
16364448|NCT04227197|No Intervention|Control Group|The participants randomized to the control group, received usual care for 7 months, after their scheduled PCP appointment. They did not receive DSC2U during these 7 months, but did receive the online, personalized health assessment tool (DSC2U) at the end of the 7 months, after the primary and secondary outcomes were measured.
16364449|NCT04227184|Experimental|Placebo/Trospium|Placebo first for 12 weeks followed by Trospium for 12 weeks.
16364450|NCT04227184|Experimental|Trospium/Placebo|Trospium first for 12 weeks followed by Placebo for 12 weeks
16364451|NCT04227171||FSH only|GnRH agonist protocol & GnRH antagonist protocol
16364454|NCT04227132|Experimental|Labyrinth training, then Standard training|Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
16364455|NCT04227132|Experimental|Standard training, then Labyrinth training|Patients will receive at first the Standard training for 10 sessions of 45 minutes, delivered 4 days per week. Then they will undergo the Labyrinth training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
16364456|NCT04227119|Experimental|Irrigated ablation catheter and 5F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a 5F balloon tipped pulmonary artery (PA) catheter (for study purposes only).
16364457|NCT04227106|Experimental|EB-101|One-time surgical application of EB-101 on up to 6 chronic, RDEB wounds
16364458|NCT04227093|Active Comparator|Acetazolamide|Acetazolamide will be prescribed in unembellished white capsules of 250 mg. The drug will be administered twice daily in the morning and evening (approximately one hour before bedtime). The total treatment length will amount to 16 weeks. In case of side effects hampering treatment adherence, the daily dosage will be reduced to a single evening dose of 250 mg.
16364459|NCT04227093|Placebo Comparator|Placebo|The placebo regimen will be identical.
16364460|NCT04227067|Active Comparator|TENS|A TENS device consists of an electric pulse generator and pads that are attached to the skin on around the area of maximal pain. We will use the conventional mode, which provides nerve stimulation with a pulse width of 60 microseconds and a pulse rate of 60 pulses per second. The channel intensity will be gradually increased until the intensity is noticeable but not painful.
16364461|NCT04227067|Sham Comparator|SHAM TENS|In the SHAM TENS group the TENS pads will be attached to the pulse generator and the patients skin around the painful area. The investigator will turn the knobs on but the batteries will be removed from the device.
16364462|NCT04227054|Experimental|Intervention|
16364463|NCT04227041|Experimental|HER2 positive metastatic colorectal cancer|
16364464|NCT04227028|Experimental|Treatment (brigatinib, bevacizumab)|Patients receive brigatinib PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive bevacizumab IV on day 8 of cycle 1 and day 1 of subsequent cycles. Starting cycle 2, cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16364465|NCT04227015|Experimental|Administration of CTA101|Dose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.
16364466|NCT04226989|Experimental|Administration of CT-RD06|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16364534|NCT04226456|No Intervention|Control|"Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)
~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
16364467|NCT04226976|Experimental|Otoband efficacy on AUV|Participants will wear the Otoband during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Half the participants will be given the Otoband at power level 96db and half will be given the Otoband at power level 98db (all bone conduction levels re:1dyne). This will be randomized and neither the participant nor the investigator will know what power level the Otoband is set at. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
16364468|NCT04226976|Placebo Comparator|Placebo device efficacy on AUV|Participants will wear the placebo device during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. The placebo device will be set at a power level of 90db (bone conduction level re:1dyne). Neither the participant nor the investigator will know that this device is the placebo device. The participants will be fitted with the placebo device and will undergo the vestibular battery test. The investigator will record the outcome measurements.
16364469|NCT04226950|Active Comparator|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers.
16364470|NCT04226950|Experimental|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area < 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
16364471|NCT04226924|Experimental|Trehalose|Trehalose 9% solution: The dose is 0.75 g/kg administered IV over 60 ± 5 minutes once weekly.
16364472|NCT04226924|Placebo Comparator|0.9% Normal Saline|Normal saline: weight-based volume administered IV over 60 ± 5 minutes once weekly.
16364473|NCT04226911|Experimental|Sweeteners and sweetness enhancers (S&SEs)|Healthy diet < 10 energy % (E%) sugar, foods and drinks with S&SEs allowed.
16364474|NCT04226911|Active Comparator|Sugar group|Healthy diet, < 10 E% sugar, foods and drinks with S&SEs not allowed.
16364475|NCT04226898|Experimental|Synbiotic Supplement|The active synbiotic supplement consists of a stick/packet containing 4 strains of probiotic microorganisms: Lactobacillus acidophilus, LA-5® (material number 501082 FD LAK KGPharma); Lactobacillis paracasei subsp. paracasei, L. CASEI 431® (material number 684301 FD L. casei 431 HA Granulate); Lactobacillus rhamnosus, LGG® (material number 699817 FD LGG HA-W-IF); and Bifidobacterium animalis subsp. lactis, BB-12® (material number 699813 FD BB-12 HA-W-IF). In addition, the stick/sachet contains 5 g inulin. The product is a powder which participants will be asked to take with liquid or food. In this arm, the participant will take 1 powder stick of the synbiotic supplement once a day for 12 weeks after a 2-week placebo run-in.
16364476|NCT04226898|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the synbiotic supplement. In this arm, the participant will take 1 powder stick of the placebo daily for 12 weeks after a 2 week placebo run-in.
16364477|NCT04226885|Active Comparator|fentanyl|patients will be given nebulized fentanyl 2μg/kg body weight 30 min before surgery
16364478|NCT04226885|Active Comparator|midazolam|The patients will be given nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
16364479|NCT04226885|Active Comparator|dexmedetomidine|The patients will be given nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
16364480|NCT04226872|Experimental|Intervention|"The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet."
16364481|NCT04226872|No Intervention|Control|"The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet. Data collection for outcome variables will be the same as participants in the intervention group."
16364482|NCT04226833|Experimental|Mild|Participants with mild hepatic impairment will receive 1x100 milligram (mg) F06 (entrectinib) capsule administered orally with approximately 240 milliliter (mL) water within 30 minutes after consumption of a standardized meal.
16364483|NCT04226833|Experimental|Moderate|Participants with moderate hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
16364484|NCT04226833|Experimental|Severe|Participants with severe hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
16364485|NCT04226833|Experimental|Normal|Participants with normal hepatic function will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
16364486|NCT04226820|Experimental|participant|Participants are divided into 3 groups based on their diagnosis: diabetes mellitus type 1, diabetes mellitus type 2, and healthy persons. Each participant (independent of group) will have the same examinations. There is no retesting of the same participant in other conditions.
16364487|NCT04226807|Experimental|Early Postpartum Contact|Patient receive a phone call from research staff 2-3 weeks after giving birth in addition to routine postpartum visit
16364488|NCT04226807|No Intervention|Routine Postpartum Care|Patient receives routine postpartum visit only
16364489|NCT04226794|Experimental|a-tDCS and nutritional counseling|a-tDCS and nutritional counseling
16364490|NCT04226794|Active Comparator|s-tDCS and nutritional counseling|s-tDCS and nutritional counseling
16364491|NCT04226794|Active Comparator|a-tDCS|a-tDCS
16364492|NCT04226794|Active Comparator|Nutritional counseling|Nutritional counseling
16364493|NCT04226781|Active Comparator|ICG|Fluorescence imaging for blood Perfusion of the gastrointestinal tissue
16364494|NCT04226781|Experimental|HSI|Hyperspectralimaging for blood Perfusion of the gastrointestinal tissue
16364495|NCT04226768|Experimental|"Enhanced Haematology Palliative Care (Fast-track) Group"|"Patients who are assigned to enhanced haematology palliative care (fast-track group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients."
16364679|NCT04225507|Experimental|Lifestyle Plus CPAP Intervention|CPAP treatment, diet and exercise.
16364496|NCT04226768|Active Comparator|Conventional Supportive Care Group|"Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the fast-track group"
16364497|NCT04226755|Experimental|Heart failure|After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
16364498|NCT04226755|Active Comparator|Healthy volunteer|After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
16364499|NCT04226742|Experimental|Treatment|Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.
16364500|NCT04226742|Active Comparator|Control|Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.
16364501|NCT04226716|Other|Multiparous, pregnant women|
16364502|NCT04226703||Study group|Patients over the age of 18 who underwent surgery in the ear, nose and throat department.
16364503|NCT04226690|Experimental|Active Dose 1|Participants will receive the most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
16364504|NCT04226690|Placebo Comparator|Matching Placebo|Participants will receive a placebo with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
16364505|NCT04226690|Experimental|Active Dose 2|Participants will receive the second most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions
16364509|NCT04226664|Active Comparator|Intervention|Bariatric surgery will consist of laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy performed at the discretion of the surgeon and according to local standards.
16364510|NCT04226664|No Intervention|Control|Medical Weight Management (MWM) corresponds to the standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care.
16364511|NCT04226651|Active Comparator|First dental visit|Virtual Reality Exposure Therapy
16364512|NCT04226651|Placebo Comparator|Second Dental Visit|Protective Glasses
16364513|NCT04226625|Active Comparator|Propofol|Patients will receive Propofol as an intravenous (IV) agent, which is administered into a vein through an IV line as a continuous infusion.
16364514|NCT04226625|Active Comparator|Desflurane|Patients will receive Desflurane as a gas that is administered through an anesthesia machine.
16364515|NCT04226599|Experimental|Dissolve AVF Group|This group treated with Peripheral scoring drug balloon.Dissolve AVF
16364516|NCT04226599|Active Comparator|PTA Group|This group treated with plain balloon catheter.Armada 35
16364517|NCT04226586|Active Comparator|Treatment Group|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.
~Children in the treatment (intervention) arm will receive essential amino acids (EAA) twice a day.
~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.
~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.
~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
16364518|NCT04226586|Placebo Comparator|Placebo|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.
~Children in the placebo arm will receive placebo twice a day. EAA and placebo supplements will look and taste alike. The same flavoring ingredients (stevia blend, citric acid, malic acid, natural flavors, tartaric acid, fruit and vegetable juice for color) will be used in both products at the same amount.
~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.
~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.
~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
16364519|NCT04226573||Low anxiety, Middle and High anxiety|State Trait Anxiety İndex Scale: Values of less than 60, Low anxiety State Trait Anxiety İndex Scale: Values above 60, Middle and High anxiety
16364520|NCT04226560|Experimental|41% Silicone hydrogel Soft contact lenses (SHSCL)|Healthy adult males or females age ≥20-45 years of age
16364521|NCT04226560|Active Comparator|ACUVUE® VITA™|Healthy adult males or females age ≥20-45 years of age
16364522|NCT04226547|Experimental|Device Group|Randomized to Amplatzer Amulet LAA occluder
16364523|NCT04226547|Active Comparator|Control Group|Randomized to NOAC
16364524|NCT04226534|Other|Maximal effort test|Physiological database
16364525|NCT04226521|Experimental|Photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
16364526|NCT04226521|No Intervention|No prophylactic photopheresis|Standard post-transplant protocol without prophylactic extracorporeal photopheresis
16364527|NCT04226508|No Intervention|Control|
16364528|NCT04226508|Experimental|Physical exercise|
16364529|NCT04226495|Active Comparator|Sufentanil Bolus|
16364530|NCT04226495|Experimental|Sufentanil Infusion|
16364531|NCT04226482|Active Comparator|New Device|Laparoscopic appendectomy will be done using new ultrasonic shears.
16364532|NCT04226482|Experimental|Used Device|Laparoscopic appendectomy will be done using reprocessed ultrasonic shears.
16364533|NCT04226469||Subjects require canine retraction|Subjects require canine retraction during orthodontic tooth movement and their gingival crevicular fluid is collected during the tooth movement. The control is the initial timepoint.
16364748|NCT04225000|Active Comparator|Exercise Group|Hip & Knee Exercises
16364535|NCT04226456|Experimental|N-acetylcysteine|"Experimental arm (Arm B):
~0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.
~Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)
~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
16364536|NCT04226443|Active Comparator|Group 1|In Group 1(n=50); continuous infusion of intravenous midazolam (Dormicum, Deva Pharmaceutical, Turkey) at a dose of 0.02 to 0.04 mg/kg/h was started at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
16364537|NCT04226443|Active Comparator|Group 2|in Group 2 (n=49), intravenous bolus doses of midazolam at a dose of 0.015 mg/kg every 10 minutes were administered at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
16364538|NCT04226430||Before cytosorb|Arterial blood samples were taken from patients before the Cytosorb therapy course.
16364539|NCT04226430||after cytosorb|Arterial blood samples were taken from patients immediately after the Cytosorb therapy course.
16364540|NCT04226417|Active Comparator|Dual-tDCS & home program exercise|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered for 20 minutes before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
16364541|NCT04226417|Sham Comparator|Sham-tDCS & home program exercise|Sham transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered only 30 seconds before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
16364542|NCT04226404|Experimental|CSD1905-11|Subjects will be assigned to flavor variant CSD1905-11 of 4.8% ENDS products based on their preferred flavor.
16364543|NCT04226404|Experimental|CSD1905-12|Subjects will be assigned to flavor variant CSD1905-12 of 4.8% ENDS products based on their preferred flavor.
16364544|NCT04226404|Experimental|CSD1905-13|Subjects will be assigned to flavor variant CSD1905-13 of 4.8% ENDS products based on their preferred flavor.
16364545|NCT04226404|Experimental|CSD1905-14|Subjects will be assigned to flavor variant CSD1905-14 of 4.8% ENDS products based on their preferred flavor.
16364546|NCT04226404|Experimental|CSD1905-15|Subjects will be assigned to flavor variant CSD1905-15 of 4.8% ENDS products based on their preferred flavor.
16364547|NCT04226404|Experimental|CSD1905-16|Subjects will be assigned to flavor variant CSD1905-16 of 4.8% ENDS products based on their preferred flavor.
16364548|NCT04226404|Experimental|CSD1905-17|Subjects will be assigned to flavor variant CSD1905-17 of 4.8% ENDS products based on their preferred flavor.
16364549|NCT04226391||RAS Partial Nephrectomy|
16364550|NCT04226391||RAS Radical Prostatectomy|
16364551|NCT04226391||Ankle Luxation Facture Treatment|
16364552|NCT04226391||Radius Fracture Treatment|
16364553|NCT04226378||Omnipod cohort|Adults with T1D who switch from MDI therapy to insulin pump therapy with Omnipod.
16364554|NCT04226378||MDI cohort|Adults with T1D who continue MDI therapy.
16364555|NCT04226365|Experimental|Experimental|10mg capsule once daily for 4 weeks of nortriptyline
16364556|NCT04226365|Placebo Comparator|Control|10mg capsule once daily for 4 weeks of Thick-It filler
16364560|NCT04226339|Experimental|total knee arthroplasty with a kinetic alignment|
16364561|NCT04226339|Active Comparator|total knee arthroplasty with a mechanical alignment|
16364562|NCT04226326|Other|Subjects with Chronic Total Occlusion (CTO)|All subjects in this study have been scheduled for a clinically-indicated cardiac catheterization.
16364563|NCT04226313|Active Comparator|Self-sampling device sent at home|Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
16364564|NCT04226313|Experimental|Self-sampling device sent by gynecologist(s)|Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
16364565|NCT04226313|Experimental|Self-sampling device obtained from general practitioner(s)|Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
16364567|NCT04226300|Active Comparator|Ultrasound-Guided|Anesthesiologists will use ultrasound to place TAP block prior to beginning a surgical procedure.
16364568|NCT04226287|Experimental|Monterey Pneumatic Compression Device|All participants will receive treatment with the Monterey investigational pneumatic compression device
16364569|NCT04226274|Experimental|REN001|Oral
16364570|NCT04226248|Active Comparator|Active (Rivastigmine)|Rivastigmine Transdermal Patches
16364571|NCT04226248|Placebo Comparator|Placebo|Placebo Matched Transdermal Patches
16364572|NCT04226235|Experimental|1-hour vinyasa yoga session|One hour of vinyasa yoga was completed by all participants while following a DVD.
16364573|NCT04226222||Triple negative Breast Cancer|Triple Negative Breast Cancer operatable from the outset
16364574|NCT04226209|Experimental|PSSE|Physiotherapeutic Scoliosis-Specific Exercises PSSE group will receive corrective exercise for scoliosis
16364575|NCT04226209|No Intervention|Control|Control group will be taken to the queue list.
16364576|NCT04226196|Experimental|Axis 0|IOL Implantation at the 0 +/- 10 degrees axis
16364577|NCT04226196|Experimental|Axis 45|IOL Implantation at the 45 +/- 10 degrees axis
16364578|NCT04226196|Experimental|Axis 90|IOL Implantation at the 90 +/- 10 degrees axis
16364579|NCT04226196|Experimental|Axis 135|IOL Implantation at the 135 +/- 10 degrees axis
16364580|NCT04226183|No Intervention|control group|pregnant women without pregnancy workout and consume guava juice
16364581|NCT04226183|Experimental|positive control group|prenatal pregnant women with pregnancy workout but not consume guava juice
16364582|NCT04226183|Experimental|treatment group|prenatal pregnant women with pregnancy workout and consume guava juice
16364583|NCT04226170|Active Comparator|treatment|ondansetron + pyridostigmine
16364584|NCT04226170|Placebo Comparator|Placebo|placebo+ pyridostigmine
16364585|NCT04226157|Experimental|Home Blood Pressure Self Management|The HBPS group will check their blood pressure at home daily using a smart BP cuff with telemonitoring capability (Home Qardio) and guided to use a self-titration plan between office visits for persistently elevate blood pressures.
16364586|NCT04226157|Active Comparator|Usual Care|The Usual Care group will have their blood pressure monitored and medications adjusted by their primary care provider.
16364587|NCT04226144|Active Comparator|Breath Stacking Group|The lungs are inflated as fully as possible by stacking successive breaths without expiration until the patients' maximal inspiratory capacity (MIC). The participant will be instructed to sustain the air in the lung, closing the glottis. Once the lungs are maximally inflated, the compressed air volume is released under expiratory muscle force, thus generating a cough with lung and chest wall recoil. They will perform 5-8 cycles of breath stacking per session, stacking 3-5 breaths per cycle.
16364588|NCT04226144|Experimental|Breath stacking and EMT|This group will perform the breath stacking technique in addiction with EMT. It will change the one-way valve in this group to VUP (Lumiar, Sao Paulo, Brazil) one-way valve, which allows the patients blow out the air with a counter resistance during all expiratory phase. The initial expiratory pressure will be 8 cmH2O, and could be changed at each visit according to participants' tolerance (either report easy or difficult to exhale assessed by research coordinators. The participants are encouraged to blow out the most slowly that they can do it.
16364589|NCT04226131|Other|Early Rheumatoid Arthritis (RA)|"Early RA defined as duration of disease/symptoms of less than 6 months (where duration denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD) therapy"
16364590|NCT04226131|Other|Age-, Sex-, BMI-matched Healthy Controls|Healthy Controls.
16364591|NCT04226118|No Intervention|Control Group|Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
16364592|NCT04226118|Experimental|Experimental Group|Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
16364593|NCT04226105|Experimental|GP40081|Subcutaneous (SC), up to Week 26
16364594|NCT04226105|Active Comparator|NovoMix® 30 FlexPen®|Subcutaneous (SC), up to Week 26
16364595|NCT04226092|Experimental|Subjects with atopic dermatitis|
16364596|NCT04226092|Experimental|Control subjects|
16364597|NCT04226079||Normal control|Normal population with low prevalence of gastrointestinal bleeding who underwent EGD and CFS which revealed no abnormal finding.
16364598|NCT04226079||Patients with GI bleeding|Patients who visited emergency room and were highly suspected to have recent or active upper GI bleeding and scheduled for upper GI endoscopy.
16364599|NCT04226066|Experimental|T601/T601+5-FC|Part 1: Dose-escalation study of T601 single-dose; Part 2: Dose-escalation study of T601 single-dose combined with 5-FC; Part 3: Dose-escalation study of T601 multiple-dose combined with 5-FC; Part 4: Extended study of T601 multiple-dose combined with 5-FC.
16364600|NCT04226053|Experimental|Intervention Group|The treatment group will consist of 160 mothers who were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby through a combination of one-on-one sessions with an expert clinical social worker in-person every three months and provision of essential baby items and equipment.
16364601|NCT04226053|No Intervention|Control Group|The control group will consist of 160 mothers who will not receive Room to Grow services.
16364602|NCT04226040||DOW and illness perception|Exploration of the association between DOW and illness perception
16364603|NCT04226027|Experimental|T2.coach|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
16364604|NCT04226027|No Intervention|Control|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
16364605|NCT04226014||Patients with echo-endoscopic ultrasound of the pancreas|Patients requiring endoscopic ultrasound of the pancreas were included in the cohort.
16364606|NCT04226001||Patients|Patients screened for carriers infected or colonized by emerging highly resistant bacteria.
16364607|NCT04225988|Experimental|Extended-release tacrolimus|Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
16364681|NCT04225481||OA patients|Subjects undergoing prosthetic surgery as scheduled by clinic routine to obtain waste synovium and cartilage
16364608|NCT04225988|Active Comparator|Immediate-release tacrolimus|Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
16364609|NCT04225962||Women with cystic fibrosis|Women with cystic fibrosis
16364610|NCT04225949|Experimental|line graph|
16364611|NCT04225949|Active Comparator|bar graph|
16364612|NCT04225936|Experimental|Group A: Mild Hepatic Impairment|Part 1
16364613|NCT04225936|Experimental|Group B: Moderate Hepatic Impairment|Part 1
16364614|NCT04225936|Experimental|Group C: Severe Hepatic Impairment|Part 2
16364615|NCT04225936|Experimental|Group D: Normal Hepatic function (control group)|Part 1
16364616|NCT04225936|Experimental|Group E: Normal Hepatic Function (optional, control group)|Part 2
16364620|NCT04225910|Experimental|mCRPC for PSMA RLT|225Ac-PSMA 100KBq/kg, iv. Totally 2 doses, every 8 weeks.
16364621|NCT04225897|Experimental|RV521|"sisunatovir is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. The RV521 dry powder blend will be supplied in capsules containing 10, 20, or 50 mg RV521. The Investigational Medicinal Product (IMP) will be dispersed in a defined volume of water prior to oral administration on a mg/kg basis. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of water prior to administration will be provided in the Pharmacy Manual.
~The proposed dosing regimen for Part A is a single open label dose of RV521. Part B and C is RV521 or placebo administered BID, 12 hours apart, for a period of 5 consecutive days with a total of 10 doses. However, this is subject to the recommendation of the DSMC."
16364622|NCT04225897|Placebo Comparator|Placebo|The placebo capsules administered in Part B and C will contain mannitol and microcrystalline cellulose (vehicle). The placebo dry powder will be dispersed in water and given orally BID. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of water prior to administration will be provided in the Pharmacy Manual.
16364623|NCT04225884|Active Comparator|DTx for pain|Treatment A software
16364624|NCT04225884|Sham Comparator|Control|Treatment B software
16364625|NCT04225884|Other|Standard care|Pain medication
16364626|NCT04225871|Experimental|0.3 mg/kg zilucoplan (RA101495)|
16364627|NCT04225858|Experimental|Omission of sentinel lymph node biopsy|No surgical axillary staging (i.e. sentinel lymph node biopsy) will be performed.
16364628|NCT04225845|Experimental|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
16364629|NCT04225845|Experimental|Phone therapy plus cash transfer|Weekly phone calls by lay trained personnel to deliver problem solving therapy. Combined with a one-time cash transfer of Rs.1000.
16364630|NCT04225845|Experimental|Cash transfer|One-time cash transfer of Rs.1000.
16364631|NCT04225845|No Intervention|Control|Control group.
16364632|NCT04225832|Experimental|CBT Coping Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).
16364633|NCT04225832|No Intervention|Control|Participants who are randomized to the control condition will be referred to the standard of care program at Bienestar, which includes an ongoing weekly open wellness-oriented support group available to all clients.
16364634|NCT04225819|Experimental|Vitamin D3 supplement|Two- 5,000 IU capsules, taken daily with a meal
16364635|NCT04225819|Placebo Comparator|Placebo|Two placebo capsules, taken daily with a meal
16364636|NCT04225806|Experimental|Investigational|Subjects will be treated with the investigational device and followed per protocol.
16364637|NCT04225793|Active Comparator|Eziklen®|potassium, magnesium and sodium sulphates-based laxative
16364638|NCT04225793|Active Comparator|Macrogol|Macrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep
16364639|NCT04225780|Experimental|Treatment of low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group and low-dose IL-2 is defined as 1 million IU per day subcutaneously.
16364640|NCT04225780|Placebo Comparator|Treatment of ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in ganciclovir treatment group.
16364641|NCT04225767|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for malignant cutaneous and subcutaneous tumours
16364642|NCT04225741|Experimental|training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs.22,23 Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.22-24
16364643|NCT04225741|No Intervention|Control Group|None of the interventions described above were applied to the control group.
16364644|NCT04225728|Active Comparator|Iron sucrose IV arm|Perfusion of diluted iron sucrose i.v. in two weeks. Half of the total dose at Day 0 and the other half at Day 14
16364645|NCT04225728|Active Comparator|Ferric polymaltose hydroxide complex IM arm|Injection in two series, begin at Day 0 and the second at Day 14. In each series, we administered 300 mg of iron IM until reach half of the dose
16364646|NCT04225728|Placebo Comparator|Placebo arm|100 ml i.v. of normal saline administered at Day 0 and at day 14.
16364680|NCT04225481||SVF from healthy subjects from aesthetic plastic surgery|Subjects undergoing plastic surgery as scheduled by clinic routine to obtain waste adipose tissue
16364647|NCT04225715|Active Comparator|Nucleos(t)ide (NUC) Control Arm|Participants will continue their background NUC therapy for the 48-week treatment period. At the end of the treatment period, in line with current CHB treatment guidelines, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364648|NCT04225715|Experimental|CpAM (RO7049389) + TLR7 (RO7020531) + NUC|Participants will receive RO7049389 (600 mg once daily [QD]) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg once every other day [QOD]) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364649|NCT04225715|Experimental|siRNA (RO7445482) + NUC [1]|Participants will receive RO7445482 (Dose 1) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364650|NCT04225715|Experimental|siRNA (RO7445482) + NUC [2]|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364651|NCT04225715|Experimental|siRNA (RO7445482) + PEG-IFN + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. PEG-IFN will be administered at a dose of 180 μg once weekly (QW) for 48 weeks. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364652|NCT04225715|Experimental|siRNA (RO7445482) + CpAM (RO7049389) + NUC|Participants will receive RO7445482 (Dose 2) and RO7049389 (600 mg QD) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364653|NCT04225715|Experimental|siRNA (RO7445482) + TLR7 (RO7020531) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg QOD) will be administered during Weeks 13-24 and Weeks 37-48 (i.e., 2 treatment cycles of 12 weeks' duration each and 42 doses of RO7020531 for each cycle). At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
16364654|NCT04225702||Group Aspirin|The elderly patients who using Aspirin at least three months before operation were in the Group Aspirin
16364655|NCT04225702||Group Control|The elderly patients who not using Aspirin before operation were in the Group Control
16364656|NCT04225689|Experimental|CD-TREAT diet|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).
~Daily for a maximum of 21 days. Individualised diet based on energy requirements and physical activity levels."
16364657|NCT04225689|No Intervention|Unrestricted diet|Free, unrestricted diet. Daily for a maximum of 21 days.
16364659|NCT04225663|Active Comparator|Intervention group|The Intervention group will receive 30-minute sessions of guided meditation. During meditation, they will lie down with their backs and torsos elevated by a mat/soft blocks. They will undergo guided breath work.
16364660|NCT04225663|No Intervention|Control group|The Control group will not have intervention. They will have quiet, independent study for 30-minute sessions.
16364661|NCT04225637|Experimental|Slow maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw once every other day.
16364662|NCT04225637|Experimental|Rapid maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw twice daily.
16364663|NCT04225624|Experimental|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation.
16364664|NCT04225624|Active Comparator|Supportive Psychotherapy (SPT)|Individuals with repetitive negative thinking receiving Supportive Psychotherapy.
16364665|NCT04225611|Experimental|Dexamethasone|Therapeutic Contact Lens Drug Delivery System (TCL-DDS) of Dexamethasone, up to 300 μg per day with a total release of 1,100 μg over 7 days
16364666|NCT04225598|Experimental|XR-BUP|Injectable buprenorphine
16364667|NCT04225598|Active Comparator|Standard SL-BUP|Sublingual buprenorphine
16364668|NCT04225585|Experimental|Targeted Pain Coping Skills Training (Targeted-PCST)|novel pain coping skills training intervention designed specifically for women with persistent pain (PP) following breast cancer surgery (active intervention group)
16364669|NCT04225585|Placebo Comparator|General health education|general health education Intervention (control group)
16364670|NCT04225585|No Intervention|Self-guided health education|usual health care and usual medical treatment for pain
16364671|NCT04225572|No Intervention|Control Group|Patient will not receive physical therapy treatment or further instruction from the research team. The patient will receive standard care recommended by their medical provider which may or may not include physical therapy treatment.
16364672|NCT04225572|Experimental|Physical Therapy Group|
16364673|NCT04225546||Patient group|Patients with hemiplegic and diplegic cerebral palsy between 4 - 10 years of age
16364674|NCT04225546||Control group|Healthy volunteer typically developing peers
16364675|NCT04225533|Experimental|SP16|Patients will receive a single dose of SP16 0.2 mg/kg by subcutaneous injection
16364676|NCT04225520|Active Comparator|Treatment recommendation based on guidelines|Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.
16364677|NCT04225520|Experimental|Treatment recommendation based on mechanical dyssynchrony|Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.
16364678|NCT04225507|Other|Lifestyle Intervention|Diet and exercise.
16364683|NCT04225468|Experimental|Opioid Exposure Reduction Program 1 (OERP1)|Participants will engage in a brief, educational intervention at their pre-surgery appointment approximately 2-3 weeks before ACL reconstruction surgery.
16364684|NCT04225468|Experimental|Opioid Exposure Reduction Program 2 (OERP2)|"Participants will engage in the same intervention as OERP1, but those in OERP2 will also receive a 5-minute booster intervention session 3 days after surgery."
16364685|NCT04225442|Other|Fatty meal|To study how a fatty meal modifies the physiological chronobiome in young and old, an isocaloric controlled liquid high fat meal (ICLHFM) will be consumed within 5 min. The ICLHFM contains an equivalent to 35% of the estimated total daily energy requirements (TDE), 60% of kcal delivered from fat while 13% come from protein and 27 % from carbohydrate.
16364686|NCT04225403|Experimental|Telephone-based motivational interviewing|Experimental intervention consisted of a motivational intervention for smoking cessation through telephone every 3 months for one year, performed by IBD nurse
16364687|NCT04225403|No Intervention|usual care|No intervention consisted of a single telephone contact one year after the star of the study
16364688|NCT04225390|Experimental|Dacarbazine|Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy
16364689|NCT04225364|Experimental|camrelizumab plus concurrent chemotherapy|Neoadjuvant immunotherapy, PD-1, plus concurrent chemotherapy（albumin-bound paclitaxel + Cisplatin） will be applied to patients with operable esophageal squamous cell carcinoma before surgery.
16364690|NCT04225351|Experimental|MCAF+CM|Modified coronally advanced flap + collagen matrix
16364691|NCT04225351|Active Comparator|MCAT+CM|Modified coronally advanced tunnel technique + collagen matrix
16364692|NCT04225325|Active Comparator|A: SYMTUZA|TAF/FTC 245 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single tablet QD
16364693|NCT04225325|Active Comparator|B: DESCOVY+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DTG 50 mg QD
16364694|NCT04225325|Experimental|C: SYMTUZA+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DRV/cobicistat single tablet QD + +DTG 50 mg QD
16364695|NCT04225312|Experimental|Personalized extended interval dosing|Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 10mcg/ml.
16364696|NCT04225312|Experimental|Low personalized extended interval dosing|Personalized dosing based on natalizumab trough concentration with a lower aim of natalizumab trough concentration of 5mcg/ml.
16364697|NCT04225312|Other|Standard interval dosing|Patients who prefer to stay on standard interval dosing.
16364698|NCT04225312|Other|Historic cohort|Historic cohort of natalizumab treated patients on standard interval dosing.
16364699|NCT04225299|Experimental|TOOKAD®|TOOKAD® , lyophilized formulation, given at a dose of 4mg/Kg.
16364700|NCT04225299|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have intermediate risk localised prostate cancer
16364701|NCT04225286|Experimental|Intranasal human breast milk|"Human breast milk delivered intranasally to preterm infants (<33 weeks gestation at birth, stratified < and ≥28 weeks) with any grade IVH/intraparenchymal hemorrhage/infarction identified on head ultrasound in the first 10 days of life.
~Dosing: Escalating dose starting at 0.2mL into one nostril with repeat dose 10-15 minutes later 1-2x daily, depending on availability of fresh HM"
16364702|NCT04225273|Experimental|Investigational Arm in pivotal study- 43USSA1705|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection
16364703|NCT04225260|Experimental|QM1114-DP in the LCL and the GL areas|"The investigational product (QM1114-DP) is a BoNT Type A.
~At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines."
16364704|NCT04225247|Active Comparator|Group-I Single Bond Universal|"it is a seventh generation bonding agent used as desensitizer, manufactured by 3M ESPE.
~applied on the affected surface of the group-I participants."
16364705|NCT04225247|Active Comparator|Group-II Xeno V+|"it is a seventh generation bonding agent used as desensitizer, manufactured by Dentsply.
~applied on the affected surface of the group-II participants."
16364706|NCT04225247|Placebo Comparator|Group-III Bifluorid 12|it is a fluoride varnish used as desensitizer, manufactured by VOCO. applied on the affected surface of the group-III participants.
16364707|NCT04225234|Active Comparator|Weight loss incentive|Participants will receive incentive rewards based on WEIGHT LOSS outcomes.
16364708|NCT04225234|Experimental|Weigh-in incentive|Participants will receive incentive rewards based on WEIGH-INs frequency
16364709|NCT04225234|Experimental|Combination incentive|Participants will receive half of the incentive from WEIGHT LOSS and WEIGH-INs
16364710|NCT04225234|Experimental|Choice option incentive|Participants will choose one out of the three incentive programs (Weight-loss, Weigh-ins, and Combination).
16364711|NCT04225221|Experimental|Sequence A: estradiol followed by progesterone|"Participants are randomly assigned to treatment Sequence A: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence A will receive estradiol addback first, followed by progesterone.
~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
16364712|NCT04225221|Experimental|Sequence B: progesterone followed by estradiol|"Participants are randomly assigned to treatment Sequence B: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence B will receive progesterone first followed by estradiol.
~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
16364713|NCT04225208|Experimental|[14C]-AZD4205|A single dose of [14C]-AZD4205
16364744|NCT04225039|Experimental|Cohort B sub-arm #2|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 + INCAGN01876 (without SRS). Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
16364714|NCT04225195|Experimental|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"Patients with invasive candidiasis (IC) will only receive intravenous treatment with ABCD. ABCD will be administered once a day at a dose of 3-4 mg/kg.
~Patients with invasive aspergillosis (IA) will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. ABCD dosing regimen will be the same as that for IC patients."
16364715|NCT04225182|Experimental|with instrumented Orthosis|patient will follow 8 weeks of muscular strengthening with the orthosis connected to the phone app associated
16364716|NCT04225182|Active Comparator|without instrumented Orthosis|patient will follow 8 weeks of traditional muscular strengthening without orthosis
16364717|NCT04225169|Experimental|Exercises|diaphragmatic breathing exercises
16364718|NCT04225169|No Intervention|Control|Patients in the control group received routine patient care consisting of cold therapy
16364719|NCT04225156|Experimental|efgartigimod|patients receiving efgartigimod
16364720|NCT04225143|Experimental|bilateral|25 patients with an overactive bladder
16364721|NCT04225143|Active Comparator|unilateral|25 patients with an overactive bladder
16364722|NCT04225130|Experimental|Written Exposure Therapy -for Suicide|Written Exposure Therapy-for Suicide (WET-S) consists of 5 treatment sessions. Each session includes a written exposure exercise. It also includes CRP. Participants assigned to WET-S will complete the CRP prior to beginning their writing in session 1. Patient use of the CRP since the previous session will be briefly reviewed at the start of each WET-S session to manage safety and problem solve fluctuations in risk during treatment.
16364723|NCT04225130|Active Comparator|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team. TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
16364730|NCT04225104|Experimental|Yogic breathing intervention|Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.
16364731|NCT04225104|No Intervention|Control|Participants in the control group will be asked to maintain their current daily activities and will be given access to the yogic breathing video once all follow-up testing has been completed at the end of week 4.
16364732|NCT04225091|Placebo Comparator|Placebo drink|
16364733|NCT04225091|Experimental|Triple up® Collagen Drink|
16364734|NCT04225078|Experimental|Treatment Sequence 1: Treatment ADBC|Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
16364735|NCT04225078|Experimental|Treatment Sequence 2: Treatment BACD|Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
16364736|NCT04225078|Experimental|Treatment Sequence 3: Treatment CBDA|Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
16364737|NCT04225078|Experimental|Treatment Sequence 1: Treatment DCAB|Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
16364738|NCT04225065|Active Comparator|Chlorhexidine prep|Chlorhexidine prep prior to their operation
16364739|NCT04225065|Active Comparator|Betadine prep|Betadine prep prior to their operation
16364740|NCT04225052|Other|Group1|16 subjects, Cross-over, Single dose of comparator on day1, Single dose of YHP1903 on day8
16364741|NCT04225052|Other|Group2|16 subjects, Cross-over, Single dose of YHP1903 on day1, Single dose of comparator on day8
16364742|NCT04225039|Experimental|Cohort A|Subjects in this arm (N=16) receive a single priming dose of both INCMGA00012 (500mg) and INCAGN01876 (300mg) prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions). Following SRS, INCMGA00012 (500mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
16364743|NCT04225039|Experimental|Cohort B sub-arm #1|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 (500mg) + INCAGN01876 (300mg) + SRS. Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (500 mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
16364745|NCT04225026|Experimental|GC4419|
16364749|NCT04225000|Experimental|Mobilization Group|Tibiofemoral joint anterior-posterior mobilization combined Hip & Knee Exercises
16364750|NCT04224987|Active Comparator|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo to children 12-59 months old
16364751|NCT04224987|Active Comparator|Azithro 1-59|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
16364752|NCT04224987|Placebo Comparator|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
16364753|NCT04224974|Experimental|Other: Usual Care|
16364754|NCT04224974|Experimental|Behavioral: Usual Care + EASE Intervention-psy|EASE Intervention = EASE-psy + EASE-phys
16364755|NCT04224961|Experimental|Minimal to No Respiratory Weakness|MIP ≥ 70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
16364756|NCT04224961|Experimental|Mild to Moderate Inspiratory Weakness|MIP 40-70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
16364757|NCT04224948|Experimental|PET-MR arm|Every eligible patient will be scanned by PET-MR at baseline and following 1 cycle of chemotherapy. PET-CT at baseline will also be obtained as it is the current standard of care and will be used to determine trial eligibility (no evidence metastasis at baseline).
16364758|NCT04224935|Active Comparator|Leukocyte Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin will be used
16364759|NCT04224935|Active Comparator|connective tissue|connective tissue will be used
16364760|NCT04224922|Experimental|single-arm|weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
16364761|NCT04224909||Patients with Sudden Sensorineural Hearing Loss|
16364762|NCT04224896||NBI PATIENT|
16364763|NCT04224896||LUGOL PATIENT|
16364764|NCT04224883|Active Comparator|24-hours group|"The critical patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
16364765|NCT04224883|Experimental|16-hours group|"The critical patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
16364766|NCT04224883|Experimental|intermittent group|The critical patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days
16364768|NCT04224857|Experimental|AMT-101|AMT-101
16364769|NCT04224857|Placebo Comparator|Placebo|Placebo
16364770|NCT04224844|Active Comparator|Erector spinae plane block group (Group 1)|Patients will receive erector spinae plane block in addition to intravenous patient-controlled analgesia device containing tramadol.
16364771|NCT04224844|Active Comparator|Control group (Group 2)|Control group will receive only intravenous patient-controlled analgesia device containing tramadol.
16364772|NCT04224831|Active Comparator|Before application|"The chronic CSCR cases included here meet one or more of the following criteria:
~Complaints of recurrent symptoms lasting longer than 3 months;
~Recalcitrant or unresponsive to all known current treatment modalities including PDT and MPL;
~Typical B-scan SD-OCT findings of chronicity such as elongation of photoreceptor outer segments indicating chronic nature of sub-macular fluid and/or the presence of serous flat-irregular RPED and focal areas of thickened RPE that lie below the collection of SRF;
~Widespread RPE/photoreceptor damage, RPE mottling and atrophy along with chronic submacular fluid;
~Widespread multifocal areas of chronic serous retinal detachment and/or flat-irregular RPEDs in those eyes that effective and reliable laser application is impossible."
16364773|NCT04224831|Active Comparator|After application|The changes in SMT, CMT, DRCD, and BCVA before and after the interventions were compared.
16364774|NCT04224818|Experimental|Dual trigger|Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
16364775|NCT04224818|Active Comparator|hCG (standard)|HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
16364776|NCT04224805|Active Comparator|Control|Interocclusal conventional splint is used to reposition the maxilla.
16364777|NCT04224805|Experimental|Study|Bone-borne splint is used to reposition the maxilla.
16364778|NCT04224792|Experimental|Center-based exercise group|Subjects will be enrolled into a center-based exercise program.
16364779|NCT04224792|Experimental|Home-based exercise group|Subjects will be enrolled into a home-based exercise program.
16364780|NCT04224779|Experimental|Tumors and blood collection|"For all the patients included in the study :
~Blood samples will be collected at different times T1 (Baseline), T2 (1 or 2 weeks after the beginning of the treatment), T3 (3 or 4 weeks before the surgery) and T4 (1 month after the surgery).
~Tumors biopsy will be collected for some patients who will benefit from an initial biopsy in the course of his management care in our Institute (before the surgery).
~In parallel to this biological collection, imaging and clinical data will be entered into a database treatment."
16364781|NCT04224766|Experimental|suprascapular nerve block with costoclavicular infraclavicular|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL bupivacaine 0.5%, then single shot US-guided costoclavicular block (CCB) with 10 ml bupivacaine 0.5%.
16364782|NCT04224766|Active Comparator|Interscalene brachial plexus block|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL bupivacaine 0.5%.
16364783|NCT04224753|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
16364825|NCT04224428|Active Comparator|Fexofenadine group|
16364784|NCT04224740|Experimental|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy
~Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
16364785|NCT04224727|No Intervention|Control|
16364786|NCT04224727|Experimental|Group Commitment Contract + Information|
16364787|NCT04224727|Experimental|Individual Monetary Rewards + Information|
16364788|NCT04224727|Experimental|Individual Commitment Contract + Information|
16364789|NCT04224727|Experimental|Group Commitment Contract|
16364790|NCT04224727|Experimental|Individual Monetary Rewards|
16364791|NCT04224727|Experimental|Individual Commitment Contract|
16364792|NCT04224714|Experimental|Coronary heart disease patient|Quantitative coronary angiography (QCA) showed that there was a critical lesion in the proximal or middle segment of the coronary artery (diameter stenosis rate was 50% - 70%), and the diameter of the artery was more than 2.5mm
16364793|NCT04224701|Experimental|Investigational Product, 30 µg/ Placebo|30 µg IM, months 0, 2 and 6
16364794|NCT04224701|Experimental|Investigational Product, 300 µg/ Placebo|300 µg IM, months 0, 2 and 6
16364797|NCT04224675|Other|Ate|
16364798|NCT04224675|Other|Cap|
16364799|NCT04224662||Patients with Gout|Patients who have been diagnosed with Gout
16364800|NCT04224649|Experimental|Test Device Group(HARA filler)|
16364801|NCT04224649|Active Comparator|Comparator Group(Restylane® Lidocaine)|
16364802|NCT04224636|Experimental|Up-front Atezo/Bev, then TACE|Patients will receive atezolizumab and bevacizumab iv every three weeks for up to 24 months. Upon detection of at least one unequivocal progressive hepatic lesion, selective TACE directed against progressive lesion(s) (sdTACE) will be performed. RFA or MWA are permitted as alternative to TACE to treat one or more lesion that cannot be reasonably selectively targeted by TACE
16364803|NCT04224636|Experimental|Atezo/Bev combined with TACE|First TACE will be performed as selectively as possible against all viable tumor lesions. Atezo/Bev will be initiated within three days from TACE. Upon detection of at least one unequivocal progressive hepatic lesion, treatment with Atezo/Bev will be continued if RFA or MWA can be used to treat this/these progressive lesion.
16364804|NCT04224597||Patients with acne vulgaris|patients with acne vulgaris aged between 18-25 year
16364805|NCT04224597||Healthy controls|healthy controls aged between 18-25 year
16364806|NCT04224584|Active Comparator|Duloxetine|Duloxetine is a serotonin-norepinephrine reuptake inhibitor. Duloxetine will be administrated as follows: 20 mg/daily duloxetinefor 1 week, 40 mg/daily duloxetine for 1 week, 60 mg/daily duloxetine for 10 weeks, 40 mg/daily duloxetine for 1 week, 20 mg/daily duloxetine for 1 week.
16364807|NCT04224584|Placebo Comparator|Placebo|Placebo will be administrated for 14 weeks.
16364808|NCT04224571|Experimental|rituximab and bortezomib|to test whether adding rituximab in CD20 positive patients will have improvement in remission rate. (this arm terminated in October 2020) to add bortezomib in high risk patients at Induction to improve remission rate.
16364809|NCT04224558|Experimental|HSCT after mobilization and conditioning|"Mobilization and leukopheresis allow for stem cell harvest. Then conditioning is provided prior to stem cell transplantation, followed by post-transplant conditioning.
~Interventions include:
~Stem cell mobilization
~Leukopheresis
~Preparative regimen
~Peripheral blood stem cell infusion
~Post-PBSC infusion conditioning"
16364810|NCT04224545|Experimental|Colchicine|Colchicine 1 mg day
16364811|NCT04224545|Placebo Comparator|Placebo|Sugar pill
16364812|NCT04224532|Experimental|Group P|Pneumoperitoneum is induced before reverse Trendelenburg position.
16364813|NCT04224532|Experimental|Group RT|Pneumoperitoneum is induced after reverse Trendelenburg position.
16364814|NCT04224519|Experimental|Batch 1 of sIPV|The first commercial batch of sIPV
16364815|NCT04224519|Experimental|Batch 2 of sIPV|The second commercial batch of sIPV
16364816|NCT04224519|Experimental|Batch 3 of sIPV|The third commercial batch of sIPV
16364817|NCT04224506||Myasthenia Gravis|Patients who have been diagnosed with Myasthenia Gravis.
16364818|NCT04224493|Active Comparator|Tazemetostat + R2 Arm|"tazemetostat RP3D administered PO twice daily in continuous 28-day cycles.
~rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
~lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles."
16364819|NCT04224493|Placebo Comparator|Placebo + R2 Arm|"placebo administered PO twice daily in continuous 28-day cycles.
~rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
~lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles."
16364820|NCT04224480|Experimental|Treatment|Neoadjuvant treatment will consist of one dose of IV pembrolizumab. Tumor resection will be performed approximately 4 weeks after neoadjuvant pembrolizumab. Adjuvant treatment with pembrolizumab will be administered 4 weeks after the surgery.
16364821|NCT04224467|Experimental|Indocyanine Green Fluorescent Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then, a NIR imaging systems included the NIR (800-900 nm) and white-light (400-650nm) dual-channel will be used to detect In situ lesions, metastatic lesions, lymph nodes, obturator nerve, pelvic autonomic nerve, etc during surgery according to disease and clinical needs.
16364822|NCT04224454||Primary Sjögren's syndrome|111 consecutive patients with primary Sjögren's syndrome (European-American 2002 criteria)
16364823|NCT04224441|Experimental|Standard protocol plus chlorpromazine (CPZ)|Combination of chlorpromazine to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol.Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide (TMZ)
16364824|NCT04224428|Placebo Comparator|Control group|
16364826|NCT04224415|Other|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:
~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
16364827|NCT04224402|Other|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion
16364828|NCT04224389||Radiotherapy|IMRT on the primitive site and the lymph nodes. +/- Concomitant chemotherapy at the discretion of the meeting multidisciplinary
16364829|NCT04224389||Surgery|transoral resection of the primary tumor, with cervical lymph node dissection. Radiotherapy complementary according to the histological criteria of severity
16364830|NCT04224376|No Intervention|Conventional rehabilitation|Normal postoperative treatment protocol with physiotherapy after ACL surgery
16364831|NCT04224376|Experimental|Serious Gaming|In the training group each patient was additionally provided with a GenuSport knee trainer device (prototype plus tablet with software application) with the active knee extension training program for 6 weeks. Other postoperative treatment was identical.
16364832|NCT04224363|Experimental|Downward Staining|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
16364833|NCT04224363|Experimental|Upward Staining|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
16364834|NCT04224350|Experimental|Once-Daily Tacrolimus|Experimental arm: TacroBell SR Cap.
16364835|NCT04224350|Active Comparator|Twice a Day Tacrolimus|Active Comparator arm: TacroBell Cap.
16364836|NCT04224337|Experimental|Experimental|Durvalumab + doxorubicin + ifosfamide
16364837|NCT04224324||T & A patients|pediatric patients undergoing tonsillectomy and adenoidectomy
16364838|NCT04224311|Active Comparator|Low number plateletpheresis donations|Participants that have had 1-2 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
16364839|NCT04224311|Active Comparator|Medium number plateletpheresis donations|Participants that have had 3-19 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
16364840|NCT04224311|Active Comparator|High number plateletpheresis donations|Participants that have had 20-24 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
16364841|NCT04224285|Experimental|Early Dayzz|Participants receive a Sleep Health and Wellness education session and download the Dayzz app. Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries.
16364842|NCT04224285|No Intervention|Late Dayzz|Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries. At the end of nine months, participants have the opportunity to receive a Sleep Health and Wellness education session.
16364843|NCT04224272|Experimental|ZW25 (zanidatamab) + palbociclib + fulvestrant|ZW25 (zanidatamab) plus palbociclib, fulvestrant
16364844|NCT04224259|Experimental|ultrasound pre-scan group|Perform ultrasound pre-scan before central venous cannulation
16364845|NCT04224259|Sham Comparator|landmark guidance group|Use the traditional landmark method to perform central venous cannulation
16364846|NCT04224246|Experimental|One arm with Gamma-OH® treatment|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours between 10 p.m. to 4 a.m.
16364847|NCT04224233|Experimental|Home-based physical activity group|The experimental group will receive the iLiFE.
16364848|NCT04224233|Active Comparator|Control group|The control group will receive a leaflet with exercises and PA recommendations.
16364849|NCT04224220|Active Comparator|Adult Medical Care Coordination|This group will receive adult medical care coordination following discharge from a recent hospitalization.
16364850|NCT04224220|Active Comparator|Remote Patient Monitoring|This group will receive remote patient monitoring following discharge from a recent hospitalization.
16364851|NCT04224220|No Intervention|Usual Care|The usual care group will not receive additional supportive care following discharge from a recent hospitalization beyond what is typically offered through their primary care team.
16364852|NCT04224207|Active Comparator|Before application|RP patients with progressive visual acuity and visual field loss: before stem cell application.
16364853|NCT04224207|Active Comparator|After application|RP patients, after stem cell applications.
16364854|NCT04224194|Other|Interventional, Single arm to evaluate autoinjector handling|To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who selfinject AVT02 (adalimumab) subcutaneously (SC).
16364855|NCT04224181||Women with HIV|Individuals with female nascent sex who have been diagnosed with HIV.
16364856|NCT04224181||Women without HIV|Individuals with female nascent sex who do not have HIV.
16364857|NCT04224168|Experimental|Green Beans|Green beans will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from green beans will be given. This equates to 3x 4 ounce jars of green beans per day.
16364858|NCT04224168|Experimental|Liquid Pectin|Liquid pectin will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from liquid pectin will be given. This equates to 6 teaspoons or 30mL of liquid pectin per day.
16364859|NCT04224155|Experimental|enVista MX60EFH trifocal intraocular lens (IOL)|
16364860|NCT04224155|Active Comparator|enVista MX60E monofocal intraocular lens (IOL)|
16364861|NCT04224142||PKU sphere|PKU sphere (an FSMP) as per individual requirements determined by a dietitian.
16364862|NCT04224116|Experimental|Group TA|receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
16364863|NCT04224116|Placebo Comparator|Group SSI|Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
16364864|NCT04224103||Inhaled nitric oxide|
16364865|NCT04224090||Congenita coronary abnormalities (CAA)|"All the coronary arteries were differing from the definition of normal: when do not arise from the appropriate sinus of Valsalva (right or left) and not present a proper course and termination."
16364866|NCT04224077|Experimental|Intervention|Healthy volunteers
16364867|NCT04224064|Experimental|Healthy subjects cohort|A single blood sample will be made in healthy subjects.
16364934|NCT04223687|Experimental|Sugar-Sweetened Beverage Warning Label|
16364868|NCT04224064|Experimental|Liposarcoma patients cohort|Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
16364869|NCT04224051|Experimental|Metformin target dose of 2g daily|Metformin tablets taken orally with target dose of 2g daily plus standard care
16364870|NCT04224051|Active Comparator|Standard care|Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.
16364871|NCT04224025|Experimental|exercise and respiratory therapy|Rehabilitation program for three weeks in-Hospital and continuation at home
16364872|NCT04224012|No Intervention|Conventional therapy group (control group)|patients of the control Group receive usual care
16364873|NCT04224012|Experimental|Interventional group (training group)|Specialized exercise and respiratory therapy for patients with pulmonary hypertension
16364874|NCT04223999|Experimental|Intervention|In this arm, trial participants receive the intervention that is being tested, skullremodeling surgery. This is in combination with tumor treating fields and best practice medical treatment.
16364875|NCT04223999|Active Comparator|Control|"In this arm, the trial participant receives tumor treating fields and best practice medical treatment.
~This serves as an active comparative control arm to the intervention."
16364876|NCT04223986|Other|Ultrasound and Troponin T|5 images transferred to cardiologist
16364877|NCT04223973|Experimental|Active Group|Using the Medtrum Pump A7+ during 3 months
16364878|NCT04223973|Active Comparator|Control Group|using the usual Insulet Patch pump
16364891|NCT04223934|Experimental|optima4BP|"Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment.
~The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration."
16364892|NCT04223934|No Intervention|Standard of Care (SOC)|The treating physician follows usual care practices.
16364893|NCT04223921||Patients who will be discharged from hospital (acute geriatric|Patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020
16364894|NCT04223908||FCS|patient with genetically documented familial chylomicronemia syndrome
16364895|NCT04223908||MCS|patient with genetically or phenotypically documented multifactorial chylomicronemia syndrome
16364896|NCT04223895|Experimental|Group 1|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F1(1 tab, once)/ Period 3: CKD-386 F2(1 tab, once)
16364897|NCT04223895|Experimental|Group 2|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F2(1 tab, once)/ Period 3: CKD-386 F1(1 tab, once)
16364898|NCT04223895|Experimental|Group 3|Period 1: CKD-386 F1(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once) Period 3: CKD-386 F2(1 tab, once)
16364899|NCT04223895|Experimental|Group 4|Period 1: CKD-386 F1(1 tab, once) / Period 2: CKD-386 F2(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
16364900|NCT04223895|Experimental|Group 5|Period 1: CKD-386 F2(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once)/ Period 3: CKD-386 F1(1 tab, once)
16364901|NCT04223895|Experimental|Group 6|Period 1: CKD-386 F2(1 tab, once) / Period 2: CKD-386 F1(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
16364902|NCT04223882|Experimental|Group Intervention- Management of stress|Patients in the intervention group will receive usual medical care and more stress management intervention. Stress management with cognitive behavioral techniques will be implemented one month after hospital discharge in the intervention group. Group sessions will be held between 6-9 people. There will be 4 1-hour meetings for 8 weeks. The intervention will be performed by psychologist.
16364903|NCT04223882|No Intervention|Group Control|Patients in the control group will receive usual medical care.
16364904|NCT04223869|No Intervention|periodontally healthy group|Control
16364905|NCT04223869|Active Comparator|Chronic Periodontitis|non-surgical periodontal treatment was performed
16364906|NCT04223869|Active Comparator|Aggressive Periodontitis|non-surgical periodontal treatment was performed
16364910|NCT04223843|Experimental|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
16364911|NCT04223843|Placebo Comparator|Placebo Arm|Matching placebo via Respimat
16364912|NCT04223830|Experimental|Exalt DScope 01B|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
16364913|NCT04223817|Experimental|7.0 Tesla MRI of both hands|Single 7.0 Tesla MRI of both hands for all the SSc and control subjects
16364914|NCT04223804|Placebo Comparator|Stage 1: Arm A|Participants will receive placebo.
16364915|NCT04223804|Experimental|Stage 1: Arm B|Participants will receive ABBV-181 dose A.
16364916|NCT04223804|Experimental|Stage 1: Arm C|Participants will receive ABBV-181 dose B.
16364917|NCT04223804|Placebo Comparator|Stage 2: Arm D|Participants will receive Placebo.
16364918|NCT04223804|Experimental|Stage 2: Arm E|Participants will receive ABBV-181 dose C.
16364919|NCT04223791|Experimental|DOR/ISL|A fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and placebo to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) for 96 weeks.
16364920|NCT04223791|Active Comparator|BIC/FTC/TAF|50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to FDC DOR/ISL for 96 weeks. Participants will be offered the option to receive open-label FDC DOR/ISL from Week 144 to Week 156.
16364921|NCT04223778|Experimental|Immediate Switch to DOR/ISL|Participants receiving continuous antiretroviral therapy (ART) will switch to MK-8591A, a fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 96 weeks
16364922|NCT04223778|Active Comparator|Baseline Regimen with Delayed Switch to DOR/ISL|Participants receiving continuous ART for 48 weeks will switch to MK-8591A, a FDC of 100 mg DOR/0.75 mg ISL for 48 weeks
16364923|NCT04223765|Experimental|CAR.k.28/CAR.k.4-1BB|Up to 12 patients will receive a single infusion of CAR.k.28. The starting dose will be 2.5x10^5 cells/kg of each product. Up to 3 dose levels of CAR.k.28 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 8 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and bendamustine. Patients with a known history of intolerance to bendamustine may be considered for lymphodepletion with fludarabine and cyclophosphamide.
16364924|NCT04223752|Experimental|Group 1: Ceftolozane/Tazobactam 12 to <18 Years of Age|Participants 12 to <18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.
16364925|NCT04223752|Experimental|Group 2: Ceftolozane/Tazobactam 7 to <12 Years of Age|Participants 7 to <12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
16364926|NCT04223752|Experimental|Group 3: Ceftolozane/Tazobactam 2 to <7 Years of Age|Participants 2 to <7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
16364927|NCT04223752|Experimental|Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of Age|Participants 3 months to <2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
16364928|NCT04223752|Experimental|Group 5: Ceftolozane/Tazobactam Birth to <3 Months of Age|Participants from birth to <3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
16364929|NCT04223739|Active Comparator|Landiolol|Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.
16364930|NCT04223739|Active Comparator|Amiodarone|Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.
16364931|NCT04223713|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
16364932|NCT04223713|Experimental|Aortic valve replacement|Biological prosthesis, Device: Edwards Perimount
16364933|NCT04223700|Experimental|Group 1|Ultrasound scanning of the rhomboid muscle
16364935|NCT04223687|Other|Neutral label|
16364936|NCT04223674|Experimental|Serological screen and treat|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided for those with Pv seropositive and/or microscopic Pv/Po positive regardless of their symptoms.
16364937|NCT04223674|No Intervention|Routine care|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided only for symptomatic children with microscopic Pv/Po positive.
16364938|NCT04223661|Experimental|Frailty score 1|"Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg
~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
16364939|NCT04223661|Experimental|Frailty Score 2 or above|"Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.
~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
16364940|NCT04223648|Experimental|Treatment|"Subjects will receive 1 cycle of tremelimumab/durvalumab
~Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s
~TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.
~Subjects will receive 3 cycles of ipilimumab/nivolumab
~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.
~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
16364941|NCT04223635|Experimental|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
16364942|NCT04223635|Experimental|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
16364943|NCT04223596|Experimental|Experimental: Brigatinib Arm|Brigatinib 90 mg for the first 7 days and then 180 mg daily thereafter for QW4 cycles of duration (28 days +- 3 days)
16364944|NCT04223583|Experimental|Anrotenil hydrochloride capsule|Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.
16364949|NCT04223544||GPs Healthcare Workers|
16364950|NCT04223544||Hospital Healthcare Workers|
16364951|NCT04223531|Other|Saline|Each participant will receive a saline infusion of normal saline 0.9%NaCl
16364952|NCT04223518|Active Comparator|Serum Bovine Immunoglobulin|Study product: Serum bovine immunoglobulin, also known by the trade name of Enteragam Dosage form: powdered packet Dosage: Each packet (10 g net weight) consists of 5 g of serum-derived bovine immunoglobulin/protein isolate (SBI) which is the active ingredient Frequency: one packet a day Duration: 60 days
16364953|NCT04223518|Placebo Comparator|Hydrolyzed Collagen|Placebo: hydrolyzed collagen Dosage form: powdered packet Dosage: 10 g of hydrolyzed collagen per packet Frequency: one packet a day Duration: 60 days
16364954|NCT04223505|Active Comparator|TEE arm|TEE will be performed as per clinical routine using multiple standard tomographic planes to rule-out LA/LAA thrombus. Echocardiographic analysis will include: LAA-emptying velocity, and grading the severity of LAA spontaneous ECHO. The severity of the SEC will be graded on a 4 point scale with 1 = minor homogeneous contrast enhancement, 2 = significant homogeneous contrast enhancement, 3 = significant, dense, and inhomogeneous, slow-moving contrast, and 4 = dense slow-moving contrast.
16364955|NCT04223505|Experimental|CCT arm|As per local protocol, a non-contrast enhanced prospective ECG-triggered image acquisition will be acquired. This will be followed by a contrast-enhanced prospective ECG-triggered will be acquired using a tri-phasic contrast protocols. Delayed CT images will be acquired 60 seconds after the initial contrast-enhanced CT scan.Cardiac CT image interpretation will be performed as per clinical routine. The LA and LAA will be assess for filling defects and characterized based upon attenuation values. If LA/LAA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. It will be recommended that patients with thrombus will undergo TEE.
16364956|NCT04223492|Other|Neoadjuvant systemic treatment|All patients undergo standard neoadjuvant treatment and additional multi-parametric MRI and liquid biopsies during neoadjuvant treatment.
16365010|NCT04223154|Sham Comparator|Sham iTBS to the dlPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
16364957|NCT04223479|Experimental|Probiotic Formula Capsule|In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
16364958|NCT04223479|Placebo Comparator|Placebos|In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
16364959|NCT04223466|Experimental|Subxiphoid group|Subxiphoid procedure for thymectomy.
16364960|NCT04223466|Active Comparator|VATS group|Video-assisted thoracoscopic thymectomy through chest wall.
16364961|NCT04223440|Experimental|Postero-superior Rotator Cuff Tear|MRI, ultrasonographic explorations
16364962|NCT04223440|Other|Healthy Postero-superior Rotator Cuff|MRI, ultrasonographic explorations
16364963|NCT04223427|Active Comparator|Single ring STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
16364964|NCT04223427|Experimental|Directional STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
16364965|NCT04223401|Experimental|Prehabilitation group|Patients in the experimental group will undergo prehabilitation before the elective surgery for gastric cancer.
16364966|NCT04223401|No Intervention|Control group|Patients in the control group will not undergo prehabilitation.
16364967|NCT04223388|Experimental|Probiotic|
16364968|NCT04223388|Placebo Comparator|Placebo|
16364969|NCT04223375|Experimental|Nutrition Group|"After the health status of the mothers in the experimental group was stabilized, approximately 20-30 minutes of nutritional education was given at the first interview before the hospital discharge. After nutrition education, motivational messages were sent to women's phones once a week. In addition, mothers were given nutritional counseling during their home visits during the 1st and 3rd months, and their questions and problems regarding nutrition were evaluated. The mother was supported where she needed it.
~In nutritional education, information was given such as adequate and balanced nutrition in the postpartum period, adequate fluid intake, consumption and importance of prebiotic and probiotic foods, the importance of healthy microbiota for infant health and the amount of nutrients equivalent to one serving. In addition, the handbook which contains the educational content is given to the mothers to facilitate the recall."
16364970|NCT04223375|No Intervention|Control Group|No intervention was made to the control group.
16364971|NCT04223362|Experimental|Pulmonary rehabilitation + Community-based physical activity programme|After pulmonary rehabilitation, the experimental group will integrate a community-based physical activity programme.
16364972|NCT04223362|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates physical activity recommendations.
16364973|NCT04223349|Experimental|Part 1: Treatment A|Participants will receive JNJ-70033093 dose twice daily (BID) for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
16364974|NCT04223349|Experimental|Part 1: Treatment B|Participants will receive JNJ-70033093 dose BID for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
16364975|NCT04223349|Experimental|Part 1: Treatment C|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
16364976|NCT04223349|Experimental|Part 1: Treatment D|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
16364977|NCT04223349|Experimental|Part 2: Treatment Sequence EFG|Participants will receive Treatment E (JNJ-7003309 single dose in the morning in fasted condition) in treatment Period 1; followed by Treatment F (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 2; followed by Treatment G (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
16364978|NCT04223349|Experimental|Part 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
16364979|NCT04223349|Experimental|Part 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
16364980|NCT04223349|Experimental|Part 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
16364981|NCT04223349|Experimental|Part 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
16364982|NCT04223349|Experimental|Part 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
16367042|NCT04209049|Experimental|Mild renal impairment|All subjects will receive one dose of NNC0174-0833.
16364983|NCT04223336|No Intervention|Control Group|When a participant in the control group is identified via a mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will not receive any computer alerts for physical activity and fruits/vegetable consumption. However, practitioners will still have access to the physical activity and diet data as part of the baseline assessment (Screening). Practitioners will also continue to have access to all the same resources as they currently do (treatment as usual).
16364984|NCT04223336|Experimental|Intervention Group|When a participant in the intervention group is identified via mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will receive computer alerts (screening), prompting to provide participant with a brief intervention (risk communication) and a self-monitoring resource for physical activity and/or fruits/vegetable consumption.
16364985|NCT04223323|Experimental|Intervention|The intervention arm consists of daily consumption of the investigator's intervention snack over the course of 12 weeks.
16364986|NCT04223323|Placebo Comparator|Isocaloric Control|The control arm consists of daily consumption of an isocaloric snack over the course of 12 weeks.
16364987|NCT04223310|Experimental|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure
~Preselect drug with optimal antiarrhythmic effects in the patient.
~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection
~Drug selection should be decided according to the guidelines.
~A follow-up of rhythm follow-up has to be conducted according to the above study design."
16364988|NCT04223310|Active Comparator|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure
~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection
~Drug selection should be decided according to the guidelines.
~A follow-up of rhythm follow-up has to be conducted according to the above study design."
16364989|NCT04223284|Active Comparator|Experimental1|"During the Cross-Over study, patients will be randomly assigned to one of the arms:
~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with D-Limonene at visit 2 and olfactory Stimulation with lavender oil (SLVO) at visit 3"
16364990|NCT04223284|Active Comparator|Experimental2|"During the Cross-Over study, patients will be randomly assigned to one of the arms:
~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with SLVO at visit 2 and olfactory Stimulation with D-Limonene at visit 3"
16364991|NCT04223271||Acutely Decompensated Heart Failure Patients|Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing. Testing with the Indicor device will occur every day during hospitalization, and twice a day for up to 30 days after discharge.
16364992|NCT04223258|Experimental|Automatic Oxygen Control|Infants randomized to this arm will be monitored using automatic oxygen control system on the ventilator. When infants oxygen saturation are out of the target range the ventilator will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation int he target range.
16364993|NCT04223258|Active Comparator|Manual oxygen control|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
16364994|NCT04223245|Experimental|exercise+MMSF|Group of PWPD who performed a base exercise program of speed and large amplitude stepping and standing balance exercises with Multimodal real-time sensory feedback
16364995|NCT04223245|Active Comparator|exercise only|Group PWPD who did the same exercise program without MMSF
16364996|NCT04223232|Experimental|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
16364997|NCT04223219|Active Comparator|High Opioid Group|-The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate >20% of baseline or hypertension: increase of mean blood pressure >20% of baseline).
16364998|NCT04223219|Placebo Comparator|Low Opioid Group|The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).
16364999|NCT04223219|Experimental|Non-Opioid Group|The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.
16365000|NCT04223206|Experimental|Hemodialysis with sarcopenia|10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS
16365001|NCT04223206|No Intervention|Controls|10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation
16365002|NCT04223193|Experimental|Tavapadon|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.
16365003|NCT04223193|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
16365004|NCT04223180||Stroke patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with an upper limb impairment due to neurologic or orthopedic disorders.
16365005|NCT04223167|Experimental|Energy Drink 1|The participants in this group are caffeine naive and consumed 473 ml Red Bull Energy Drink
16365006|NCT04223167|Experimental|Energy Drink 2|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and consumed 473 ml Red Bull Energy Drink
16365007|NCT04223167|Experimental|Energy Drink 3|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and consumed 473 ml Red Bull Energy Drink
16365008|NCT04223167|Placebo Comparator|Control|The participants in this group are caffeine naive and consumed 473 ml water
16365009|NCT04223154|Experimental|Real iTBS to the dlPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
16365011|NCT04223141|Experimental|Study group|Robot-assisted laparoscopic resection of sigmoid colon with colorectal anastomosis constructed by the double purse-string technique
16367389|NCT04206657|Experimental|Multiple dose administration of 6mg KHK7580 for 8days|
16365012|NCT04223128|Active Comparator|Magnesium sulfate group(M)|Participants in group (M) will receive 50 mg/kg MgSO4 in 100 ml isotonic saline intravenous (I.V) over 20 minutes prior to induction of general anesthesia by 30 minutes then ultrasound guided TAPblock after closure of the abdomen
16365013|NCT04223128|Active Comparator|Dexamethasone group(D)|participants in group (D) will receive 2 mg Dexamethasone in 100 ml isotonic saline IV then ultrasound guided TAPblock after closure of the abdomen
16365014|NCT04223128|Placebo Comparator|Placebo group(C)|participants in group (C) will receive 100 ml isotonic saline IV (placebo) by the same route and over the same duration as control then ultrasound guided TAPblock after closure of the abdomen
16365015|NCT04223115|Experimental|Digitalized CBT intervention with phone coaching|Participants receive weekly sessions of internet-based CBT, including telephone coaching
16365016|NCT04223115|Active Comparator|Psychoeducation about depression|Participants receive psychoeducative material about depression in digitalized form.
16365017|NCT04223102|Other|Tissue collection|Tissue collection
16365018|NCT04223089||Revascularization|This group will include patients whose cutaneous oxygen partial pressure (PO2) around the wound of interest measures less than 40 mmHg and therefore require revascularization.
16365019|NCT04223089||Medical Management|This group will include patients whose cutaneous PO2 around the wound of interest measures greater than 40 mmHg and will be managed conservatively in wound clinic
16365020|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash control|Chlorhexidine 0.2%, Corsodyl Intervention rinsing 60 sec twice daily
16365021|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System|Chlorhexidine 0.2%, Curasept Intervention rinsing 60 sec twice daily
16365022|NCT04223063|Experimental|Exercise Intervention|Participants allocated to the exercise intervention will engage in a multimodal, home-based program including strength and endurance exercises. Participants will initially be seen in person and instructed to begin a moderate-intensity (i.e., 3-4 on 10-point Borg Scale) walking (or preferred aerobic exercise) program for a minimum of 30 minutes/day, 3-5 days/week and perform strength exercises at least 2 days/week.
16365023|NCT04223063|No Intervention|Control|Participants allocated to the control group will not receive any formal exercise prescription or guidance, however they will be offered the opportunity to participate in a home-based intervention pending the completion of data collection.
16365024|NCT04223050|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94%
16365025|NCT04223050|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92%
16365026|NCT04223037|Active Comparator|Day 0，7 immunization shedule|Japanese Encephalitis Vaccine produced by Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and Japanese Encephalitis Vaccine produced by Liaoning Chenda CO.,LTD Dosage form: 0.5mL/vial Two Dose injection with 7 days interval
16365027|NCT04223037|Experimental|Day 0，28 immunization shedule|Japanese Encephalitis Vaccine produced by IMBCAMS Dosage form: 0.5mL/vial Two Dose injection with 28 days interval
16365028|NCT04223024|Experimental|CCRT + Nimotuzumab|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
16365029|NCT04223024|Active Comparator|CCRT alone|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
16365030|NCT04223011|Experimental|In-Hospital Recovery Coach Intervention|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically in-hospital manualized sessions with the recovery coach.
16365031|NCT04222998|Experimental|Intervention group|90 villages with 1,080 caregiver-child dyads; child aged 9 - 14 months who receive the home-based growth charts
16365032|NCT04222998|Active Comparator|Control group|90 villages with 1,080 caregiver-child dyads; child aged 9 - 14 months who do not receive the home-based growth charts
16365033|NCT04222985|Experimental|Part A - Group 1|HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365034|NCT04222985|Experimental|Part A - Group 2|HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365035|NCT04222985|Experimental|Part A - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365036|NCT04222985|Experimental|Part A - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
16365037|NCT04222985|Experimental|Part A - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.
16365038|NCT04222985|Placebo Comparator|Part A - Group 6|Sodium chloride 0.9% (in both arms) at Month 0 and Month 2
16365039|NCT04222985|Experimental|Part B (Stage 1) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365040|NCT04222985|Experimental|Part B (Stage 1) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365041|NCT04222985|Experimental|Part B (Stage 1) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365042|NCT04222985|Experimental|Part B (Stage 1) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
16365043|NCT04222985|Experimental|Part B (Stage 1) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
16365044|NCT04222985|Placebo Comparator|Part B (Stage 1) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
16365045|NCT04222985|Experimental|Part B (Stage 1) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365046|NCT04222985|Experimental|Part B (Stage 2) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365047|NCT04222985|Experimental|Part B (Stage 2) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365048|NCT04222985|Experimental|Part B (Stage 2) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365049|NCT04222985|Experimental|Part B (Stage 2) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
16365050|NCT04222985|Experimental|Part B (Stage 2) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
16365051|NCT04222985|Placebo Comparator|Part B (Stage 2) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
16365052|NCT04222985|Experimental|Part B (Stage 2) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
16365053|NCT04222972|Experimental|Pralsetinib|Participants randomized to the Experimental Arm will receive Pralsetinib
16365054|NCT04222972|Active Comparator|Platinum-based chemotherapy with or without pembrolizumab|"Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology)
~Nonsquamous histology
~Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance.
~Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance.
~Squamous histology
~Carboplatin or cisplatin / gemcitabine
~Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab"
16365055|NCT04222959|Experimental|Girls Invest Intervention|Girls Invest intervention participants will have been randomized to receive the intervention immediately upon completion of the baseline survey. Intervention participants will also complete the 6 month follow-up survey. (n=50 dyads; 100 total participants)
16365056|NCT04222959|No Intervention|Wait-List Control Condition Participants|Control condition participants will be randomized upon completion of the baseline survey and put on a wait-list to receive Girls Invest behavioral intervention after the 6 month follow-up survey. (n=50 dyads; 100 total participants)
16365057|NCT04222946|Experimental|Experimental:|bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
16365058|NCT04222933|Experimental|Motorized cryotherapy|Application of motorized cryotherapy after ACL reconstruction for 6 postoperative days
16365059|NCT04222933|Active Comparator|Classical cryotherapy|Application of ice bags for 6 postoperative days
16365060|NCT04222920|Experimental|Low serum drug concentration|Adalimumab dose reduction aiming a drug level of 2 mg/L
16365061|NCT04222920|Active Comparator|High serum drug concentration|Adalimumab dose reduction aiming a drug level of 5 mg/L
16365062|NCT04222907||Women screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were screened for GBS during pregnancy
16365063|NCT04222907||Women not screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were not screened for GBS during pregnancy
16365064|NCT04222894|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 12 weeks
16365065|NCT04222894|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 12-week study period.
16365066|NCT04222881||End To Side|End to Side Anastomosis
16365067|NCT04222881||Side To Side|Side To Side Anastomosis
16365068|NCT04222855|Experimental|Diltiazem|Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
16365069|NCT04222855|Active Comparator|Nifedipine|Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).
16365070|NCT04222842|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25mg BID/50mg QD/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
16365071|NCT04222829||Megadose Shinbaro Pharmacopuncture Group|"The Megadose Shinbaro Pharmacopuncture group who are treated with korean medical treatment including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
16365072|NCT04222829||Control Group|"The control group who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
16365073|NCT04222816|Active Comparator|Lithium carbonate|Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
16365074|NCT04222816|Experimental|Add-on Sodium chloride|Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.
16365075|NCT04222790|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
16365076|NCT04222790|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
16365077|NCT04222777|Other|Heatlhy volunteers.|Healthy volunteers will undergo two cinematographic recordings of the cervical spine
16365078|NCT04222764||Real-time three-dimensional echocardiography|
16365079|NCT04222751|Experimental|Stretch Group|Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
16365109|NCT04222569|Experimental|PSV 0 PEEP 0 and T-piece and PSV 7 PEEP 0|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
16365080|NCT04222751|Placebo Comparator|No Stretch Group|Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
16365081|NCT04222738|Experimental|Non-randomized single-arm of GINOFF1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.
~The intervention consisted on the administration of Zingiber officinale Roscoe extracts, at a daily dose of 2g/day (equivalent overall daily dose of extract in simple powdered form) for a period of 6weeks. The extracts were given as capsules, either one capsule three times per day (1 capsule x 3 / day) and after meals. Each capsule contains 399mg of pure Zingiber officinale Roscoe extracts."
16365082|NCT04222725|Experimental|TRS01 low dose|
16365083|NCT04222725|Experimental|TRS01 medium dose|
16365084|NCT04222725|Experimental|TRS01 high dose|
16365085|NCT04222725|Placebo Comparator|Placebo|
16365086|NCT04222712|Experimental|TRS01 low dose|
16365087|NCT04222712|Experimental|TRS01 high dose|
16365088|NCT04222699|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
16365089|NCT04222686|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
16365090|NCT04222686|Active Comparator|Losartan Arm|100 mg Losartan tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
16365091|NCT04222673|Experimental|Peer Specialist|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
16365092|NCT04222660|Experimental|Type 2 diabetes without neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
16365093|NCT04222660|Experimental|Type 2 diabetes with neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
16365094|NCT04222660|Experimental|Normal subjects, aged match with no symptoms of diabetes|Healthy, aged matched control subjects will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
16365095|NCT04222647|Experimental|WO533|Formulation containing WO533 for intravaginal application
16365096|NCT04222634|Other|MDT for oligoprogressive lesions in CRPC|"metastasis-directed therapy:
~radiotherapy (SBRT or conventional radiotherapy in case of local recurrence or untreated primary tumor)
~metastasectomy
~salvage lymphadenectomy
~salvage prostatectomy in case of local recurrence or untreated primary tumor"
16365097|NCT04222621||Pregnant women|
16365098|NCT04222595|No Intervention|1- naive|Group 1: up to 10 children aged 4-6 years that never received LAIV before.
16365099|NCT04222595|Active Comparator|2- Fluenz Tetra nasal spray suspension|Group 2: up to 10 children aged 4-6 years that received LAIV once before. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
16365100|NCT04222595|Active Comparator|3- Fluenz Tetra nasal spray suspension|Group 3: up to 10 children aged 4-6 years that were vaccinated twice before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
16365101|NCT04222595|Active Comparator|4- Fluenz Tetra nasal spray suspension|Group 4: up to 10 children aged 4-6 years that were vaccinated 3 or 4 times before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
16365102|NCT04222582|Active Comparator|Active tDCS|"Administration of a 2 milliamp (mA) current delivered via two scalp electrodes for 20 minutes (ramp-in + ramp-out periods, 30s total) 2 times per day for 5 consecutive days, >3 hour interval between sessions, for a total of 10 tDCS sessions.
~tDCS will be administered with a constant current regulator (NeuroConn DC-Stimulator Plus®, Germany) using 2 saline-soaked sponge electrodes applied over the scalp. Using the 10-20 international EEG system for tDCS electrode placement, the anode will be positioned midway between F3 and Fp1 (left DLPFC) and the cathode midway between T3 and P3 (left TPJ)."
16365103|NCT04222582|Sham Comparator|Sham tDCS|Administration of 2mA tDCS for 30 seconds followed by 19.5 minutes of no current via two scalp electrodes for 20 min (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
16365104|NCT04222582|Other|Open-label Active tDCS|Subjects who have received sham tDCS will be given the option to subsequently receive 10 sessions of open-label active tDCS (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
16365105|NCT04222582|No Intervention|Healthy Control|Healthy volunteers will complete the same questionnaires, EEG recording procedures, and neuroimaging scans as the schizophrenia patient group, but will not undergo tDCS.
16365106|NCT04222569|Experimental|T-piece and PSV 7 PEEP 0 and PSV 0 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
16365107|NCT04222569|Experimental|T-piece and PSV 0 PEEP 0 and PSV 7 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
16365108|NCT04222569|Experimental|PSV 0 PEEP 0 and PSV 7 PEEP 0 and T-piece|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
16365326|NCT04220931|No Intervention|standard care|standard care (no endoscopy)
16365110|NCT04222569|Experimental|PSV 7 PEEP 0 and T-piece and PSV 0 PEEP 0|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
16365111|NCT04222569|Experimental|PSV 7 PEEP 0 and PSV 0 PEEP 0 and T-piece|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
16365112|NCT04222556|Experimental|Thiwáhe Gluwáš'akapi|"Weeks 1-7: Weekly in-person 2.5 hour family sessions 30 minute family meal 1 hour separate youth and adult sessions
~1 hour family session"
16365113|NCT04222556|Active Comparator|Woyute Waśte|"Respect for community and cultural values regarding research protocols precluded use of a randomized controlled design with a control group receiving no intervention, so we identified a cost-effective comparison condition program to offer value to study participants. A focus on healthy eating and exercise was of interest to community partners and not expected to directly confound the primary outcomes of the TG program (substance use and suicide risk).
~Week 1 in-person 2.5 hour family session 30 minute family meal 2 hour interactive family session (3 stations) Weeks 2-7: text messages with program content and questions"
16365114|NCT04222543|Active Comparator|HPV Negative tumours|Patients will receive four scans.
16365115|NCT04222543|Active Comparator|HPV positive tumours|Patients will receive four scans.
16365116|NCT04222530|Experimental|Linear EUS|patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy
16365117|NCT04222530|Experimental|ME-NBI|patients underwent magnifying narrowband endoscopy followed by linear endoscopic ultrasonography
16365118|NCT04222517|Experimental|Standart sublay retromuscular technique|Apply standard intervention (sublay retromuscular)
16365119|NCT04222517|Experimental|Standart sublay retromuscular technique with Hemoblock|Local hemostatic Hemoblock is used in retro-muscular and subcutaneous spaces
16365122|NCT04222491|Experimental|active peanut OIT|active peanut oral immunotherapy
16365123|NCT04222478|Experimental|Real Auriculotherapy|"Patients benefit from 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
16365124|NCT04222478|Sham Comparator|Sham Auriculotherapy|Patients are treated according to the same scheme as the experimental group but with semi-permanent needles positioned on non-specific points.
16365125|NCT04222452||Hypophosphatasia patients (HPP)|Patients with known hypophosphatasia (HPP) as diagnosed using genetic testing.
16365126|NCT04222452||Controls|Healthy individuals (controls) matched to the cases by gender and age.
16365127|NCT04222439|Experimental|AI monitoring gastrointestinal endoscopy|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
16365128|NCT04222426|Experimental|89Zr-atezolizumab PET scan|All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. The 89Zr-atezolizumab PET scan will be performed 4 days after tracer injection. Procedures within the ImaGelato study will be completed after the two 89Zr-atezolizumab PET scans, but patients will continue treatment with carboplatin combined with atezolizumab in the GELATO trial.
16365129|NCT04222413|Experimental|1/Arm 1|Escalating/de-escalation doses of metarrestin
16365130|NCT04222413|Experimental|2/Arm 2|MTD of metarrestin
16365131|NCT04222400|Active Comparator|Transplantation|Frailty assessment before, after and 6 month after surgery
16365132|NCT04222400|Active Comparator|VAD Implantation|Frailty assessment before, after and 6 month after surgery
16365133|NCT04222387|Experimental|Participants with hair dye|Hair dye product with pPD Type Aromatic Amines used up to 1 month before
16365134|NCT04222361|Experimental|KDIGO guide recommendations|Preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI
16365135|NCT04222361|No Intervention|Standard care|The patients assigned to the control group will receive the current standard care of the septic patients of the Unit according to our protocols
16365136|NCT04222348|Experimental|Metformin|850-2550 mg every 24h.
16365137|NCT04222348|Active Comparator|Insulin Detemir|Individual doses according to glycemic controls.
16365138|NCT04222335|Other|Blood sampling|Blood sampling
16365139|NCT04222322|Experimental|Epitomee Capsule|Epitomee Capsule combined with moderate intensity lifestyle counseling
16365140|NCT04222322|Placebo Comparator|Control-Placebo|Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling
16365141|NCT04222309|Experimental|Laparoscopically harvested omental free flap|"Standard neurosurgical removal of recurrent GBM,
~Removal of fat from the abdomen called omentum using a camera (laparoscopically),
~Lining the brain tumor cavity with the piece of omentum,
~Joining the blood vessels of the omentum to blood vessels in the scalp or neck to ensure that it maintains good blood flow."
16365142|NCT04222296|Other|Cochlear Implant and Hearing Aid|Comparing performance of conventional hearing aid fitting to Phonak's Bimodal Fitting formula using the Phonak Naida Link hearing aid. All patients are tested in a bimodal (hearing aid plus cochlear implant) setup. Initial tests are completed with the Advanced Bionics Naida Q70 or Q90 sound processor and the patient's own hearing aid. In this arm, a patient's own hearing aid is replaced with the Phonak Naida Link hearing aid to test if there is a benefit.
16365143|NCT04222296|Other|Cochlear Implant alone|To determine if the addition of a contralateral routing of signal (CROS) microphone on the un-implanted ear improves performance. Baseline tests are completed with Advanced Bionics Naida Q70 or Q90 sound processors. Patients are then given the Phonak Naida Link CROS aid to test if there is a benefit.
16365144|NCT04222296|Other|Hearing Aid and Hearing Aid|Comparing performance of conventional hearing aid fitting to a modified signal processing strategy more aligned with how a cochlear implant manages sound. All patients are tested initially with their own hearing aids to obtain a baseline measurement. Patients are then fitted with a modified Phonak hearing aid to determine if performance improves.
16365145|NCT04222283|Experimental|open label, multicentric, non randomized|one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.
16365146|NCT04222270|Experimental|Intervention|Caregiver peer support from Champion caregivers (Peer mentors) to caregivers of unsuppressed children living with HIV (CLHIV) on child care and medication adherence strategies to enhance achievement of viral suppression: Champion Caregivers (Peer Mentors) will be assigned to the intervention arm and will be trained to support 10-15 caregivers for 18 months post enrollment. Champion Caregivers (CCs) be trained using an adapted Mentor-Mother Peer Support curriculum and topics will include pediatric treatment gaps, ARV formulations/dosing, adherence counseling, and virological failure/suppression. Champion caregivers will conduct monthly-to-quarterly 30 min to 1 hr clinic-aligned caregiver group training sessions and home visits at least once quarterly, targeting Child living with HIV (CLHIV) adherence, age-appropriate disclosure, and keeping clinic appointments. The intervention arm will in addition to peer support intervention, receive routine standard of care at the health facility.
16365147|NCT04222270|No Intervention|Control|Unsuppressed Children living with HIV and their caregivers recruited in the control arm will receive no champion caregiver peer support intervention but will continue to receive the standard of care at their health facilities which include routine care, including age-appropriate antiretroviral therapy and clinic appointments (typically every 2-3 months). Routine, albeit brief (5-10 min) adherence counselling is provided to CLHIV/caregivers by trained healthcare workers (HCWs) at every visit. In Nigeria, routine VL is done at 6 months post-ART initiation and repeated 12 months post- initiation 20. VL is done yearly thereafter for suppressed clients. Those unsuppressed receive 3-months' enhanced adherence counselling (EAC) (15-30 min) by Healthcare workers, with intensified appointment schedules and repeat VL upon EAC completion. This rigorous intervention continues until viral suppression is achieved or ART is switched; drug resistance testing (DRT) is not routine.
16365148|NCT04222257|Experimental|Short course|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
16365149|NCT04222257|Active Comparator|Standard course|Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
16365150|NCT04222244||Headache Attributed to Rhinosinusitis Group (HAR)|No interventions will be provided.
16365151|NCT04222244||Headache-Free Control Group (Control)|No interventions will be provided.
16365152|NCT04222231|Experimental|Blood-flow restriction resistance training|Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
16365153|NCT04222231|Experimental|Classical resistance training|Resistance training with high loads (60-80% RM).
16365154|NCT04222218|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
16365155|NCT04222218|Sham Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
16365156|NCT04222205|Active Comparator|Crossover sequence 1|"Cluster-randomization crossover sequence 1:
~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
16365157|NCT04222205|Experimental|Crossover sequence 2|"Cluster-randomization crossover sequence 2:
~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
16365158|NCT04222192|Sham Comparator|Conventional Epidural application|Epidural catheter insertions with conventional (anatomical landmarks use) method
16365159|NCT04222192|Active Comparator|Paramedian sagittal application|Epidural catheter insertions with real time ultrasound guided Paramedian sagittal approach
16365160|NCT04222192|Active Comparator|Transverse Interlaminar application|Epidural catheter insertions with real time ultrasound guided Transverse Interlaminar approach
16365161|NCT04222179|Other|Naso-enteric tube placement|The participants needed nutrition from naso-enteric tube feeding are enrolled into this study. Double-blind was not needed here.
16365162|NCT04222140|Experimental|ERIPTO Protocol|Protocol arm actively being studied
16365163|NCT04222140|Active Comparator|BMAC only|bone marrow aspirate concentrate only arm
16365164|NCT04222127|Experimental|EUS-guided injection of CYA of GVs|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate & lipidol using 19G EUS-FNA needle
16365165|NCT04222127|Experimental|Direct endoscopic injection of CYA of GVs|Direct endoscopic injection of CYA of the gastric varix using standard endoscopy
16365166|NCT04222114|Experimental|Catumaxomab group|
16365167|NCT04222114|Active Comparator|IC group|IC group is defined as the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
16365168|NCT04222101|Other|cardiomyopathy|only one arm, all participants undergo oral glucose tolerance testing and results are used to evaluate association with degree of cardiac dysfunction
16365169|NCT04222088|Other|Patient|Participants recruited that pass the inclusion and exclusion criteria
16365170|NCT04222075||Acute Pancreatitis|Patients after acute pancreatitis
16365171|NCT04222062|No Intervention|Standard of Care Arm|The tumor will be removed surgically. Within 6 weeks after surgery, the resection will be treated with stereotactic radiosurgery (SRS).
16365172|NCT04222062|Experimental|GLIADEL Arm|Once the tumor has been removed, GLIADEL wafers will be applied to the resection cavity. The number of wafers used will be determined by the size of the cavity. Enough wafers should be used so that as much of the cavity is covered as possible.
16365173|NCT04222049|Experimental|spastic Tongue Dysarthria|The purpose of gadget is to transmit the mechanical vibration waves to the brain of the subjects.
16365327|NCT04220892|Experimental|Pembrolizumab plus Pemetrexed|Pembrolizumab plus Pemetrexed
16365174|NCT04222023|Experimental|IVIG group|Administration of a single dose of IVIG at day 10+/- 4 days, day 41 +/- 7 days and day 62 +/- 7 days. The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
16365175|NCT04222023|No Intervention|Control group|
16365176|NCT04222010|Experimental|serratus loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
16365177|NCT04222010|Experimental|paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
16365178|NCT04222010|Experimental|serratus and paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
16365179|NCT04221997|Experimental|sertraline|90 patients will be randomized to sertraline
16365180|NCT04221997|Placebo Comparator|Placebo|30 patient will be randomized to placebo
16365181|NCT04221997|No Intervention|Healthy Control|30 healthy comparison subjects will be followed over the course of 12 weeks
16365182|NCT04221971|Experimental|AML patients with NK cells infusion|The relapsed/refractory AML patient received Flu+CTX (Flu 25mg/m2 (-6d to -2d)，CTX 1.0g/m2 (-6d to -5d) and haploidentical NK cells infusion postchemotherapy for at least 48 hours. NK cell dose was over 1+E07/ kg with 3 consecutive infusions. NK cells infusion interval was 1 day.
16365183|NCT04221958||Electrocardiogram (ECG) Mapping|Participants will have 10 superficial electrode-patches placed on their chest in two vertical columns of 5 electrode-patches. The channels V1-V5 will be connected to one of the columns. The channel V6 will be connected to each of the electrode-patches in the second column ad recordings will be taken for approximately 2 minutes on each electrode-patch. ECG readings will be recorded.
16365186|NCT04221932||Pre Intervention|Retrospective evaluation of data from 2 years prior to the implementation of our CRRT KPI reports. This will include approximately 1500 participants.
16365187|NCT04221932||Post Intervention|This will be a prospective evaluation of all new ICU patients receiving CRRT in Alberta over a 2 year periods. This will include approximately 1500 participants
16365188|NCT04221919|Experimental|Carvedilol|
16365189|NCT04221919|Experimental|Bisoprolol|
16365190|NCT04221919|Experimental|Metoprolol tartrate|
16365191|NCT04221919|Experimental|Metoprolol succinate|
16365192|NCT04221906|Experimental|BOS-475 0.5%|Daily application of BOS-475 0.5%
16365193|NCT04221906|Experimental|BOS-475 1%|Daily application of BOS-475 1%
16365194|NCT04221906|Experimental|BOS-475 2%|Daily application of BOS-475 2%
16365195|NCT04221906|Placebo Comparator|Active ingredient-free vehicle cream|Daily application of vehicle cream
16365196|NCT04221906|Active Comparator|Daivonex cream|Daily application of Daivonex cream (calcipotriol 0.005%)
16365197|NCT04221906|Active Comparator|Betnesol-V cream (betamethasone 0.1%)|Daily application of Betnesol-V cream (betamethasone 0.1%)
16365198|NCT04221893|Experimental|Radiation therapy (RT)|Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols
16365199|NCT04221880|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine and Saline iv. bolus and infusion (same volume as Group Lidocaine)
16365200|NCT04221880|Active Comparator|Group Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion and, Ultrasound-guided erector spinae plane block with 20 ml saline
16365201|NCT04221880|Sham Comparator|Group Control|Ultrasound-guided erector spinae plane block with 20 ml saline and, Saline iv. bolus and infusion (same volume as Group Lidocaine)
16365202|NCT04221867|Experimental|Esophageal stricture patients|Patients suffering from benign esophageal stricture are treated with through-the scope CRE dilation balloon. Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
16365203|NCT04221854|Experimental|Stool-based SDC2 DNA methylation test group|Subjects will received the stool-based SDC2 DNA methylation test for the screening of colorectal advanced adenomatous polyps and cancer.
16365204|NCT04221854|Active Comparator|Fecal immunochemical test group|Subjects will received the fecal immunochemical test for the screening of colorectal advanced adenomatous polyps and cancer.
16365205|NCT04221828|Experimental|NanoPac|Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.
16365328|NCT04220892|Experimental|Pembrolizumab plus Abemaciclib|Pembrolizumab plus Abemaciclib
16365208|NCT04221789|Experimental|intervention: TB treatment assistant|Patients receiving instructions to use phone application
16365209|NCT04221789|No Intervention|Control|Patients receiving instructions for usual care self administered treatment
16365210|NCT04221776|Experimental|Intensive toilet training group|Intervention group was subjected to an intensive TT group session lasting 2-hours during 2 consecutive days in daycare centers.
16365211|NCT04221776|Active Comparator|Standard care toilet training group|Children participating in control group did not receive the intensive training, but parents got a leaflet and were encouraged to start TT their child at home, in their own manner.
16365212|NCT04221763|Experimental|Heart failure and abnormal cardiac conduction|Subjects will have an attempt at His-bundle pacing, left bundle pacing and biventricular pacing. Pacing at the His bundle and the left bundle will be attempted using a Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Biventricular pacing will utilise a left ventricular lead placed in the coronary sinus using any of the 5 manufactures of CS leads Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical or in participants receiving permanent conduction system pacing left ventricular pacing will be achieved using a Cordis ATW™ wire placed in the coronary sinus.
16365213|NCT04221750|Experimental|Lifestyle Therapy plus Metformin|Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid
16365214|NCT04221750|Placebo Comparator|Lifestyle Therapy plus Placebo|Diet-induced weight loss and Exercise Training plus Placebo
16365215|NCT04221750|Active Comparator|Healthy lifestyle plus Metformin|Healthy lifestyle and Metformin 1 gm bid
16365216|NCT04221737|Active Comparator|Conventional ventilation|Protective lung conventional strategy with volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, with low tidal volume and adequate positive end expiratory pressure (PEEP) level.
16365217|NCT04221737|Experimental|Time-controlled adaptive APRV|Airway Pressure Release Ventilation with Time-controlled adaptive ventilation method. Allowing for spontaneous breathing.
16365218|NCT04221724|Experimental|Intervention Group|Multicomponent physical exercise intervention
16365219|NCT04221711|Experimental|Repetitive pulsed magnetic stimulation|Patients randomized in this group will receive rPMS (80 milliTesla ; 2 Hertz; OMNITRON® promed; Healthfactories Holding GmbH) three times a week for a total of 12 weeks. Thereby they will be lying in a prone position or sitting for 20 minutes with the magnet coil positioned over the mid-portion of the affected Achilles tendon (manufactures instruction).
16365220|NCT04221711|Active Comparator|Eccentric Calf Muscle Training for Achilles Tendinopathy|Two types of eccentric exercises will be used. The calf muscle will be eccentrically loaded both with the knee straight and with the knee bent. Each of the two exercises will include an increasing number of repetitions (1. Week, 2-3 weeks, 4-12 weeks) done in 3 sets (e.g. 3x15, 3x20, 3x30 repetitions). The patients will be informed that muscle soreness during the first 1 to 2 weeks of training was to be expected. Patients will receive a visual exercise protocol.
16365221|NCT04221698|Experimental|Gait Retraining Group|Athletes from the Triathlon Plan in High Performance of the Valencian Community in Spain performing individual gait retraining sessions
16365222|NCT04221685|Active Comparator|Artinibsa|Powerful local anaesthetic with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.4%Articaine 1:100000.
16365223|NCT04221685|Experimental|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride,Epinephrine (D.C.I) (tartrate) 0.01 mg
16365224|NCT04221672|Experimental|Terlipressin plus standard care|Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.
16365225|NCT04221672|Other|Standard care|Participants were not administrated with terlipressin during surgery and were routinely managed after surgery.
16365226|NCT04221659|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
16365227|NCT04221659|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
16365228|NCT04221659|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
16365229|NCT04221646|Experimental|Thighs circumference reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously.
16365230|NCT04221646|Experimental|Saddlebags fat thickness reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too.
16365231|NCT04221633|Experimental|Webinar only|Participants in this arm will attend a webinar training program (3 webinars over the course of 4 to 8 weeks) to receive training in evidence-based engagement strategies, trauma, evidence-based practices, and mental health screening.
16365232|NCT04221633|Experimental|Webinar plus consultation|Participants in this arm will receive the same webinar training as subjects in arm 1, but they will also receive 10 consultation calls over the course of four months to further develop their skills in engaging families and screening for mental health services.
16365233|NCT04221633|No Intervention|Delayed training group|This group will not receive any training for the duration of the study year, in order to serve as a waitlist control group. They will be eligible to receive the training after the randomized control trial has been completed.
16365234|NCT04221620|Experimental|EEG neurofeedback|All participants will receive 20 sessions of traditional occupational therapy services while receiving EEG neurofeedback.
16365235|NCT04221607|Experimental|Feasibility|Sensate Focus Exercises aim to help couples be more present with one another through talking and through touch.
16365329|NCT04220879||Malignant Glaucoma|To determine the biometric measurements.
16365330|NCT04220879||Fellow Eyes|To determine the biometric measurements.
16365236|NCT04221594||CAD detection/risk assessment|Patients with angina referred for the assessment of CAD will undergo imaging studies to develop tools to fuse coronary anatomic data obtained from CCTA with dPET data to non-invasively measure absolute MBF, MFR and RFR along vessels centerlines and across coronary lesions.
16365237|NCT04221581||Patients receiving FHK ASYMETRIQUE prosthesis|
16365238|NCT04221555|Experimental|the main treatment group|pMMR tumor
16365239|NCT04221555|Active Comparator|the exploratory group|dMMR tumor
16365240|NCT04221542|Experimental|Dose exploration phase|"The dose exploration phase of the study will estimate the MTD of AMG 509 using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
~Recommended phase 2 dose (RP2D) may be identified based on emerging safety, efficacy, PK, and PD data, as well as patient experience prior to reaching an MTD. Alternative dosing schedule(s) (including a third step dose) may be explored based on emerging efficacy, safety, PK data and patient experience."
16365241|NCT04221542|Experimental|Dose expansion phase|A dose expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and correlative biomarker analysis.
16365242|NCT04221529|Experimental|Atezolizumab|Four 21-day cycles of induction therapy with atezolizumab+carboplatin+etoposide followed by 21-day cycles of maintenance therapy with atezolizumab.
16365243|NCT04221516|Experimental|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks), from 4 to 12 weeks after the completion of radiotherapy.
16365244|NCT04221503|Experimental|Cohort A|Cohort A is for subjects with recurrent glioblastoma who do not have clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort A will initiate and continue TTFields therapy for 5-7 days prior to starting niraparib.
16365245|NCT04221503|Active Comparator|Cohort B|Cohort B is for subjects with recurrent glioblastoma who have a clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort B will receive TTFields for 5-7 days prior to planned surgical resection, undergo surgical resection, resume TTFields postoperatively, and initiate niraparib 5- 7 days after starting TTFields postoperatively.
16365246|NCT04221490|Experimental|Treatment|Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
16365247|NCT04221477|Experimental|Obinutuzumab|"Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit.
~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.
~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
16365248|NCT04221477|Placebo Comparator|Placebo|"Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone.
~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.
~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
16365249|NCT04221464|Experimental|Tumors and blood collection|"For all the patients include in the study :
~Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression.
~Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery
~In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery"
16365252|NCT04221438|Experimental|Treatment (18F-FLT, PET/CT, encorafenib, binimetinib, surgery)|"NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.
~SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.
~ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity."
16365253|NCT04221425|Experimental|VRRS GROUP|Home rehabilitation program is provided through a virtual reality based telerehabilitation system
16365254|NCT04221425|Active Comparator|CONTROL GROUP|Home rehabilitation program is provided through illustrative booklet containing characteristics of exercises and indications for recovery
16365255|NCT04221399|Experimental|DWP16001 Single dose|Single dose
16365256|NCT04221399|Experimental|DWP16001 Multiple dose|Up to 7 days
16365257|NCT04221386|Experimental|MIT group|Subjects will receive the developed Melodic Intonation Therapy.
16365258|NCT04221386|No Intervention|Control group|Subjects will not receive any intervention.
16365259|NCT04221373|Experimental|Exoskeletal-assisted walking training group|Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
16365260|NCT04221373|Active Comparator|Standard of care group|Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.
16365261|NCT04221360|Experimental|Group 1|"Period 1: D390
~Period 2: CKD-375"
16365262|NCT04221360|Experimental|Group 2|"Period 1: CKD-375
~Period 2: D390"
16365263|NCT04221347||Group A - Hepatocellular carcinoma|"Patients with with proved hepatocellular carcinoma in cirrhosis.
~N=100"
16365331|NCT04220879||Matched Eyes|To determine the biometric measurements.
16365264|NCT04221347||Group B - Cirrhosis|"Cirrhotics of multiple aethiology will be sampled for spectroscopy in order to detect possible differences among cirrhotics with and without subsequent hepatocellular carcinoma.
~N=100"
16365265|NCT04221347||Group C - Healthy controls|Healthy controls - healthy military personnel. N=50
16365266|NCT04221334|Active Comparator|Experimental Toothbrush 1|1. A connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
16365267|NCT04221334|Active Comparator|Experimental Toothbrush 2|2. A non-connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
16365268|NCT04221321|Placebo Comparator|Atorvastatin 40 mg|Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
16365269|NCT04221321|Experimental|Atorvastatin 40 mg + Tegoprazan 50 mg|Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
16365270|NCT04221321|Active Comparator|Atorvastatin 40 mg + RAPA114|Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days
16365271|NCT04221308||single port laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
16365272|NCT04221308||Vaginal hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
16365273|NCT04221295|Experimental|Exercise Group|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
16365274|NCT04221295|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
16365275|NCT04221282||Epileptic elderly patients|Elderly patients with partial-onset seizures
16365276|NCT04221269|Active Comparator|Enhanced Treatment as Usual|Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
16365277|NCT04221269|Experimental|Coping Long-term with Active Suicide Program for Schizophrenia|Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
16365278|NCT04221256|Experimental|Administration of SSRI|Participants will be administered either 5, 10 or 20mg of SSRI escitalopram prior to paired associative stimulation.
16365279|NCT04221256|Placebo Comparator|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
16365280|NCT04221243|Experimental|Group 1: Children with 3D printed space maintainer|
16365281|NCT04221243|Active Comparator|Group 2: Children with conventional band and loop|
16365282|NCT04221230|Experimental|BTRX-335140|BTRX-335140
16365283|NCT04221230|Placebo Comparator|Placebo|Placebo
16365284|NCT04221217|Experimental|MND-2119 2g|MND-2119 2 g, orally, once daily after breakfast for 52 weeks.
16365285|NCT04221217|Experimental|MND-2119 4g|MND-2119 4 g, orally, once daily after breakfast for 52 weeks.
16365286|NCT04221204|Experimental|Open-Label, Dose-Escalation|"The starting dose in this dose-escalation study is 50 mg, and the preset 6 dose-escalation cohorts are 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively. This study adopts an i3+3 method for dose escalation.
~All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily [QD], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first"
16365287|NCT04221191||Standard of Care (SoC) Group|SoC neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice (non-coached participants).
16365288|NCT04221191||OroSEP PSP (OPSP) Group|OPSP neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice and the OroSEP PSP (coached participants).
16365289|NCT04221178||MRD-Negative Participants|
16365290|NCT04221165|Active Comparator|Opioid Analgesia|Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.
16365291|NCT04221165|Experimental|Multimodal Analgesia|Pregabalin (50 mg to 300 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)
16365292|NCT04221152|Experimental|Treatment of empagliflozin|"The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study.
~The administration is oral administration with water once daily before or after breakfast."
16365293|NCT04221139|Experimental|Healthy young adults|Healthy young adults will play four virtual reality games: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
16365294|NCT04221126|Experimental|TMFI +cream|TMFI + ALA cream
16365295|NCT04221126|Experimental|TMFI + gel|TMFI + ALA gel
16365296|NCT04221126|Active Comparator|ALA creAM|ALA cream
16365297|NCT04221126|Active Comparator|ALA GEL|ALA gel
16365298|NCT04221126|No Intervention|Control|Untreated control with no intervention
16365299|NCT04221113|Active Comparator|Group A ( Immobilization protocol)|Group A patients will receive static splints.By the end of 4 weeks the splint will be modified and patients will start doing physiotherapy. Movement at MCPJ will be from 0 to 45 degrees.
16367989|NCT04202185||G2|patients <25 years old with one or two Otoferlin mutations
16365300|NCT04221113|Active Comparator|Group B( early active mobilization protocol).|Group B patients will receive splints in such a way that from 3rd post operative day patients will be instructed to do physiotherapy. Initially MCPJ movement will be from 0 to 30 degrees.
16365301|NCT04221100|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
16365302|NCT04221100|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
16365303|NCT04221087|Placebo Comparator|Placebo Arm|Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
16365304|NCT04221087|Experimental|Dexamethasone Arm|Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
16365305|NCT04221074|Active Comparator|Modified Pectoral Plane (PECSII ) block (P)|done after induction of general anaesthesia in supine position of the patient with his arm of the side of the operation abducted 90 degree with the probe with frequency L4-12t (Logiq e machine) at the midclavicular level and angled infero-laterally,the axillary artery and vein and the second rib identified the probe moved laterally until the pectoralis minor and serratus anterior are identified,the local anesthetic was injected at two points using (echoplext guge20 length 50 mm ) needle:the first injection of 10 ml of 0.25% Bupivacaine and 4 mg dexamethasone injected between the pectoralis major and minor muscles,and the second injection of 20 ml of 0.25% Bupivacaine and 4 mg dexamethasone between the pectoralis minor and serratus anterior muscles .
16365306|NCT04221074|Active Comparator|Erector Spinae Plane ( ESP )block (E)|after induction of general anaesthesia in lateral position of the patient where the surgical side up and at T4 level the probe with frequency L4-12t (Logiq e machine) placed lateral to the spine by 3 cm in parasagittal plane the needle (echoplext guge20 length 50 mm ) advanced between the transverse process and the erector spinae muscle at that level 20 ml of 0.25% Bupivacaine and 8 mg dexamethasone injected.
16365307|NCT04221061|Other|Non-surgical candidates|In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
16365308|NCT04221061|Other|Surgical candidates|In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.
16365309|NCT04221048||PREG-GUCH|Pregnant women with congenital heart diseases
16365310|NCT04221035|Experimental|phase induction-R-I|R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.
16365311|NCT04221035|Experimental|Phase high dose chemotherapy consolidation|R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).
16365312|NCT04221035|Experimental|Phase of radiotherapy|R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease
16365313|NCT04221022|Active Comparator|Light physical activity (Group 1)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into Light Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
16365314|NCT04221022|Active Comparator|Moderate physical activity (Group 2)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into moderate Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
16365315|NCT04221022|Active Comparator|Vigorous physical activity (Group 3)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into vigorous Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
16365316|NCT04215094||infected group|Intracranial infection were diagnosed according to the Centers for Disease Control (CDC) definitions
16365317|NCT04215094||non-infected group|the postoperative recovery was uneventful with no infection
16365318|NCT04221009|Experimental|Intervention (single arm)|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
16365319|NCT04220996|Experimental|Vortioxetine|10-20 mg vortioxetine tablets
16365320|NCT04220983|Other|MR-Guided Prostate SBRT|
16365321|NCT04220970||BIA-ALCL|
16365322|NCT04220957|Experimental|Digital Impression Technique|Impression with an intraoral scanner (TRIOS 3, 3Shape, Denmark)
16365323|NCT04220957|Active Comparator|Conventional Impression Technique|Conventional impression with alginate (Orthoprint, Zhermack)
16365324|NCT04220944|Experimental|Locoregional therapies combined with Anti-PD-1 antibody|Percutaneous microwave ablation combined with simultaneous TACE was performed. Sintilimab will be initiated on day 3-7 after the first locoregional therapies. Sintilimab will be administered every three weeks (200mg fixed dose IV) until disease progression for up to one year.The second locoregional procedure will be repeated according to the enhanced CT images.
16365325|NCT04220931|Experimental|botulinum toxin injection|"Injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
~The endoscopic procedure will be performed under unconscious sedation with intravenous injection of propofol by an anesthesiologist."
16365332|NCT04220866|Experimental|Ulevostinag+Pembrolizumab|Participants receive ulevostinag 540 ug via intratumoral (IT) injection on Day 1 of every week for two 3-week cycles (Cycles 1-2), then on Day 1 of each 3-week cycle for up 33 cycles (Cycles 3-35), for a total of 35 cycles PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
16365333|NCT04220866|Active Comparator|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
16365334|NCT04220853|Experimental|Septoplasty|The patients indicated for septoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
16365335|NCT04220853|Experimental|Turbinoplasty|The patients indicated for turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
16365336|NCT04220853|Experimental|Septoplasty and turbinoplasty|The patients indicated for septoplasty and turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
16365337|NCT04220840||Study Group|All consecutive patients who underwent damage control surgery (DCS) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers
16365338|NCT04220840||Control group|All consecutive patients who underwent other than DCS surgery (resection with primary anastomosis, Hartmann´s procedure, laparoscopic lavage) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers which do not apply DCS routinely.
16365339|NCT04220827|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
16365340|NCT04220814|Experimental|Patients|
16365341|NCT04220814|Other|Healthy Volunteer|
16365342|NCT04220801|Experimental|Cohort 1 of Part 1 (SAD)|300 mg ZM-H1505R or placebo
16365343|NCT04220801|Experimental|Cohort 2 of Part 1(SAD)|450 mg ZM-H1505R or placebo
16365344|NCT04220801|Experimental|Cohort 3 of Part 1(SAD)|150 mg ZM-H1505R or placebo (2 periods)
16365345|NCT04220801|Experimental|Cohort 4 of Part 1(SAD)|75 mg ZM-H1505R or placebo
16365346|NCT04220801|Experimental|Cohort 5 of Part 1(SAD)|25 mg ZM-H1505R or placebo
16365347|NCT04220801|Experimental|Cohort 1 of Part 2 (MAD)|75 mg ZM-H1505R or placebo
16365348|NCT04220801|Experimental|Cohort 2 of Part 2 (MAD)|150 mg ZM-H1505R or placebo
16365349|NCT04220801|Experimental|Cohort 3 of Part 2 (MAD)|300 mg ZM-H1505R or placebo
16365350|NCT04220788|Experimental|Enhanced pharmacist service|The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
16365351|NCT04220788|Active Comparator|Usual care|Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
16365352|NCT04220775|Experimental|Treatment (bintrafusp alfa, SBRT)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 15 of cycle 1, patients also undergo SBRT over 5 fractions once QOD for 2 weeks in the absence of disease progression or unacceptable toxicity.
16365353|NCT04220762|Experimental|Test Group 1|The randomized patients are administered 3 tablets of the investigational product (400mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
16365354|NCT04220762|Experimental|Test Group 2|The randomized patients are administered 3 tablets of the investigational product (800mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
16365355|NCT04220762|Experimental|Test Group 3|The randomized patients are administered 3 tablets of the investigational product (1200mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
16365356|NCT04220762|Placebo Comparator|Placebo group|The randomized patients are administered 3 tablets of the placebo drug twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
16365357|NCT04220749|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
16365358|NCT04220749|Experimental|Arm 2, TOS + Neck Dissection|Trans-oral Surgery (TOS) + Neck Dissection (plus radiation is required)
16365359|NCT04220736||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
16365360|NCT04220736||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
16365361|NCT04220723||End-Stage Liver Disease|End-stage liver disease patients who are being followed up at the Department of Gastroentereology of Hacettepe University Faculty of Medicine will be included in the study. When the participants come to the gastroenterology department for control, they will be directed to us and the assessment will begin after written and verbal approval is obtained. The Liver Frailty Index will be used to assess the frailty of the participants. Accordingly, hand grip test, 5 repeat sit-up test and side, semi-tandem and tandem balance measurements will be made and a total frailty score will be obtained. Submaximal aerobic capacities and functional capacities will be evaluated by 6 Minute Walk Test. Then, maximal inspiratory muscle pressure and maximal expiratory muscle pressure of the participants will be measured and respiratory muscle strength will be evaluated. Finally, maximal aerobic capacity will be measured by Shuttle Walk Test.
16365362|NCT04220710||Marker selection group|Methalation detection of circulating free DNA and FFPF samples from pathologically confirmed patients with ovarian endometriosis(30 cases), ovarian cancer (30 cases)and other benign ovarian tumors (30 cases)will be performed to select markers for ovarian endometriosis diagnosis.
16365363|NCT04220710||Marker validation group|The selected markers will be validated in patients with ovarian cysts (300 cases )found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.
16365393|NCT04220476|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
16365364|NCT04220697|Experimental|patients undergo lateral thoracotomy for primary lung cancer|"Electroencephalography (EEG) will be acquired before surgery
~Questionnaires assessing psychological status of the patients before and after surgery
~High frequency electrical stimulation of the skin (HFS) will be delivered before surgery
~Quantification of mechanical sensitivity after HFS and after surgery"
16365365|NCT04220684|Experimental|Cohort I (fludarabine, cytarabine, NK cell therapy)|Patients who are < 60 years old, are able to tolerate intensive chemotherapy, and not insensitive to cytarabine receive fludarabine IV and cytarabine IV on days -6 to -2 in the absence of disease progression or unacceptable toxicity. All patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells via infusion on days 0, 2, 4, 7, 9, and 11.
16365366|NCT04220684|Experimental|Cohort II (fludarabine, decitabine, NK cell therapy)|Patients who are >= 60 years old, unable/unwilling to tolerate intensive chemotherapy, or disease insensitive to cytarabine (tp53, TET2 mutations) receive fludarabine IV on days -5 to -2 and decitabine IV on days -6 to -2 in the absence of disease progression or unacceptable toxicity. All patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells via infusion on days 0, 2, 4, 7, 9, and 11.
16365367|NCT04220671|Experimental|Intervention|Standard dose measles vaccine, 0.5 ml
16365368|NCT04220671|Placebo Comparator|Control|Saline injection, 0.5 ml
16365369|NCT04220645|Active Comparator|Standard of care|Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
16365370|NCT04220645|Experimental|Opportunistic treatment|Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
16365371|NCT04220632|Experimental|Itacitinib+corticosteroids|Itacitinib administered in combination with corticosteroids
16365372|NCT04220619|No Intervention|Conventional ACLS|Patients who have conventional ACLS during in-hospital Cardiac arrest, they will not have RescueTEE
16365373|NCT04220619|Experimental|RescueTEE guided ACLS|Patients who have RescueTEE guided ACLS
16365374|NCT04220606|Other|Migraine without aura subjects|Drug: Glyceryl trinitrate (GTN)
16365375|NCT04220606|Other|Healthy subjects|Drug: Glyceryl trinitrate (GTN)
16365376|NCT04220593|Experimental|aETCC before TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
16365377|NCT04220593|Experimental|aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
16365378|NCT04220593|Experimental|aETCC after TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
16365379|NCT04220593|Sham Comparator|Simulated aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
16365380|NCT04220580|Other|Cold Pressor Test|The participants are instructed to keep the non-dominant hand submerged in ice-water for as long as possible with a maximum of 10 minutes.
16365381|NCT04220567|Experimental|Exercise and Patient-centred education|
16365382|NCT04220567|Active Comparator|Exercise|
16365383|NCT04220554|Experimental|Intervention group|"Intervention group:
~All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream.
~During the study period, a nurse or pharmaconomist will deliver;
~Improved support and instructions to the patients
~Patients will receive a diary and access to more consultations."
16365384|NCT04220554|No Intervention|Non-intervention group|"All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream."
16365385|NCT04220541|Experimental|Motor learning based exercise group|
16365386|NCT04220541|Experimental|Symptomatic exercise group|
16365387|NCT04220528|Experimental|Radical chemoradiotherapy plus oral capecitabine/teggiol|Patients with newly diagnosed, non-metastatic stage N3 NPC was given Teggio 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving radical chemoradiotherapy.
16365388|NCT04220515|Experimental|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Primary 3-dose of sIPV and booster 1 dose of sIPV
16365389|NCT04220502|Experimental|Magic Shave Powder Gold|This group will receive magic shaving powder gold and instructions on how to apply it. They will keep a log for their facial hair removal
16365390|NCT04220502|Other|Traditional Methods|This group will continue using traditional razors with the standard of care directions to shave. They will keep a log of their facial hair removal
16365391|NCT04220489|Experimental|Ketamine Group|Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
16365392|NCT04220489|Placebo Comparator|Placebo Group|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
16368963|NCT04195542||women in obstetric ward in Rennes CHU|women in obstetric ward in Rennes CHU
16365394|NCT04220476|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
16365395|NCT04220463|Experimental|Hypnosis group|For the hypnosis group, hypnotic support is set up by an IDE previously trained and dedicated during the implementation of the NIV. The dedicated IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated IDE.
16365396|NCT04220463|Placebo Comparator|Control group|In the control group, in order to preserve the knowledge of the evaluator, the IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
16365397|NCT04220437||CAG and OCT group|Images of CAG and OCT patients obtained from ISR patients were retrospectively collected and analyzed.
16365398|NCT04220411|Experimental|AR100DP1 (1.25%)|topical application twice per day with at least 4 hour interval
16365399|NCT04220411|Experimental|AR100DP1 (2.5%)|topical application twice per day with at least 4 hour interval
16365400|NCT04220411|Experimental|AR100DP1 (5%)|topical application twice per day with at least 4 hour interval
16365401|NCT04220398|Experimental|NCHT Group|Neoadjuvant chemotherapy combined with hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
16365402|NCT04220398|Active Comparator|NHT Group|Neoadjuvant hormonal therapy, radical Prostatectomy (RP)+ extended lymph node dissection.
16365403|NCT04220398|Other|RP Group|Radical Prostatectomy (RP)+ extended lymph node dissection alone.
16365404|NCT04220385|Active Comparator|Wii fit Plus|"This study group will perform the following Wii fit plus exercises
~Single-Leg Extension
~Arm and Leg Lift
~Balance Bridge
~Single-Leg Twist
~Single-Leg Reach
~Sideways Leg Lift
~Single Arm Stand
~Torso Twists
~Plank"
16365405|NCT04220385|Active Comparator|Core Stability|"This study group will perform the following exercises.
~Curl-up
~Side Bridge
~Bird Dog"
16365406|NCT04220372|Experimental|Tongxinluo Capsule|
16365407|NCT04220372|Placebo Comparator|Placebo Capsule|
16365408|NCT04220346|Experimental|Tablet group|The Tablet group played the game with Tablet during the whole circumcision.
16365409|NCT04220346|No Intervention|Control group|The control group did not play game with Tablet during the procedure.
16365410|NCT04220333|Placebo Comparator|Control|Participants received the instruction: 'please, lie down, relax and pay attention to your breath'. This procedure was carried during 15 minutes. Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings.
16365411|NCT04220333|Experimental|Intervention|"The intervention protocol was divided in two steps: first, patients spent 5 minutes in the phase of harmonization with five colored stones of a size of a walnut (green, red, yellow, white and black) placed around their bodies.
~Second, in accordance to the emotion chosen by the participant, a matching mandala was placed next to the feet, on the abdomen, or next to the head depending on the self-perceived personality type, intuitive, emotive and rational for the remaining 10 minutes (Figure 3B). The researcher also checked the control subjects once during the 15 fifteen minutes of experiment.
~Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings."
16365412|NCT04220320||Classic BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation, effacement, texture, station and position.
16365413|NCT04220320||Modified BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation and effacement alone.
16365414|NCT04220320||Cervical Length|Gynecological evaluation based on cervical length measured by transvaginal sonography.
16365415|NCT04220307|Experimental|AK104|AK104 IV every 2 weeks (q2w)
16365416|NCT04220294|Active Comparator|Interrupted sutures|Subcutaneous tissue closure by interrupted sutures.
16365417|NCT04220294|Active Comparator|Continuous sutures|Subcutaneous tissue closure by continuous sutures.
16365418|NCT04220281|Active Comparator|propofol group|propofol group will receive propofol infusion
16365419|NCT04220281|Active Comparator|nitroglycerin group|will receive nitroglycerin infusion
16365420|NCT04220268||Participants|All the patients with proved malignant ground glass nodule will be enrolled.
16365421|NCT04220229|Experimental|Treatment (cabozantinib S-malate, radiation therapy)|Patients receive cabozantinib S-malate PO QD on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients also undergo standard of care radiation therapy for 5-6 weeks.
16365422|NCT04220216|Experimental|H4H fitness program|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Patients will attend the 16-week program of boxing conditioning.
~This 16-week program will include supervised exercises designed to improve strength, flexibility, balance,and cardiopulmonary fitness.
~There will be 4, 1-hour sessions each week per participant"
16365423|NCT04220190|Experimental|Single agent RAPA-501 T cells (dose level 1)|Dose level 1 is 40 x 10^6 cells/infusion
16365424|NCT04220190|Experimental|Single agent RAPA-501 T cells (dose level 2)|Dose level 2 is 160 x 10^6 cells/infusion
16365425|NCT04220190|Experimental|RAPA-501 + PC Regimen|RAPA-501 T cell therapy preceded by the pentostatin-cyclophosphamide (PC) regimen
16365468|NCT04219839|Experimental|SOC + Videos for patient education post-kidney transplant|Participants in this group receive SOC patient education following kidney transplant and access to educational videos designed specifically for post-kidney transplant patients.
16365469|NCT04219826|Experimental|CK-3773274 - Cohort 1|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
16365426|NCT04220177|Experimental|treatment arm|SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.
16365427|NCT04220164||Dyslipidemic patients|Patients who meet the criteria of high-risk category according to 2017 Taiwan Lipid Guideline for High-Risk Patients have a abnormal serum LDL-C level
16365428|NCT04220151||Hepatocellular carcinoma|Sixty patients with HCC
16365429|NCT04220151||Hepatic cirrhosis|Thirty patients with hepatic cirrhosis
16365430|NCT04220151||Healthy controls|Ten healthy controls.
16365431|NCT04220138|Other|cataract patients with poor red reflex|included cataract patients with poor red reflex
16365432|NCT04220125|Experimental|Ketamine Group|Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
16365433|NCT04220125|Active Comparator|MIdazolam Group|Midazolam 0.045 mg/kg administered via intravenous catheter.
16365434|NCT04220112|Experimental|Real Time Functional MRI (rt-fMRI)|Real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) intervention
16365435|NCT04220112|Sham Comparator|Sham|Sham-controlled group
16365436|NCT04220099||schizophrenia patients needed ECT treatment|Whether patients need ECT treatment are assessed by clinicians according to American Psychiatric Association(APA) guidelines.
16365437|NCT04220086|Experimental|Pediatric massage|Children with ASD will receive pediatric massage for 12 weeks.
16365438|NCT04220086|Sham Comparator|Waitlist control|Waitlist control
16365439|NCT04220086|Other|Healthy Control|15 healthy controls (age- and sex- matched with ASD patients) will be recruited. All of them will receive clinical evaluations, EEG and fNIRS detection.
16365440|NCT04220073|Experimental|JS005|
16365441|NCT04220073|Placebo Comparator|placebo|
16365442|NCT04220047|Experimental|Left Atrial Appendage Resection|
16365443|NCT04220047|No Intervention|off-pump coronary artery bypass|
16365444|NCT04220034||Patients receiving inhibitor checkpoint treatment|adult patients that will receive for the first time checkpoint inhibitor for a neoplasic disease in a center participating to the study
16365445|NCT04220021|Experimental|C9orf72 positive ALS|"Subjects with C9orf72 positive ALS will be instructed in the use of Metformin and receive the first dose of Metformin under supervision of the investigator during Visit 1, Day 2.
~Subjects will then continue on Metformin per the dose escalation schedule twice daily for 24 weeks."
16365446|NCT04220008|Experimental|Treatment (busulfan, vorinostat, gemcitabine, clofarabine)|"Patients receive a low-level test dose of busulfan IV over up to 1 hour on days -15 to -9, vorinostat PO QD on days -8 to -4, gemcitabine IV over about 90 minutes on days -7 and -5, clofarabine IV over about 1 hour and high-dose busulfan IV over 3 hours on days -7 to -4. Patients with CD20 positive (+) lymphoma also receive rituximab IV over 3 to 6 hours on days -15, -8, 1, and 8. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 2 hours on days 3 and 4. Beginning day 5, patients receive standard of care tacrolimus IV over 24 hours and mycophenolate mofetil IV over 2 hours TID until they can be tolerated PO. Once tolerated PO, patients receive tacrolimus PO BID for 6 months and mycophenolate mofetil PO TID for up to 30 days in the absence of disease progression or unacceptable toxicity. After 30 days, patients who develop GVHD continue treatment with mycophenolate mofetil at physician's discretion"
16365447|NCT04219995|Experimental|Interventional start|Patients who randomize to the interventional start arm will receive the study drug, methylprednisolone sodium succinate, in the first month of the study, followed by placebo in the cross-over phase of the study.
16365448|NCT04219995|Placebo Comparator|Placebo start|Patients who randomize to the placebo start arm will receive placebo in the first month of the study, followed by the study drug, methylprednisolone sodium succinate, in the cross-over phase of the study.
16365449|NCT04219982|Experimental|DPI-386 Nasal Gel|Active DPI-386 Nasal Gel
16365450|NCT04219982|Placebo Comparator|DPI-386 Placebo Nasal Gel|Placebo Nasal Gel
16365451|NCT04219982|Active Comparator|Transderm Scop® (TDS)|FDA approved Transderm Scop® (TDS).
16365452|NCT04219969|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
16365453|NCT04219956|Experimental|Polyamine deficient diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
16365454|NCT04219956|No Intervention|Control|Usual Diet plus two snacks
16365455|NCT04219943|Experimental|Conservative Treatment for Impacted Femoral Neck Fracture|Conservative Treatment for Impacted Femoral Neck Fracture
16365456|NCT04219930||epileptic children|fifty patient with epilepsy
16365457|NCT04219930||Healthy controls|thirty healthy control
16365458|NCT04219917|Experimental|Hip|Gluteus medius facilitation tape
16365459|NCT04219917|Experimental|Knee|Patellar sling tape
16365460|NCT04219917|Experimental|Hip and Knee|Gluteus medius facilitation and patellar sling tape
16365461|NCT04219904|Experimental|Diagnostic (PET/MRI)|Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.
16365462|NCT04219878|Active Comparator|Know@Home App or Website and Test Kit|Participants in this study arm will have access to Know@Home, a mobile HIV prevention app or website and will receive mail-out HIV self-testing kits.
16365463|NCT04219878|Active Comparator|Mail-Out Testing Kit Only|Participants in this study arm will receive mail-out HIV self-testing kits.
16365464|NCT04219865|Active Comparator|Compound Edaravone|10 mL per vial (containing edaravone 10 mg and 2-aminoethanesulfonic acid 200 mg)
16365465|NCT04219865|Placebo Comparator|Placebo|10 mL per vial
16365466|NCT04219852||"bariatric surgery group"|Women between 18 and 50 years, who undergone bariatric surgery at the University Hospital of Reims.
16365467|NCT04219839|No Intervention|SOC only patient education post- kidney transplant|Participants in this group will receive only SOC patient education following kidney transplant
16365471|NCT04219826|Experimental|CK-3773274 - Cohort 2|Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
16365472|NCT04219826|Placebo Comparator|Placebo - Cohort 2|Subjects will receive placebo for up to 10 weeks
16365473|NCT04219826|Experimental|CK-3773274 & disopyramide - Cohort 3|Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
16365474|NCT04219813|Other|Patients affected with Non-celiac Gluten/Wheat Sensitivity|The researchers will deliver to each patient 10 kits for the analysis of the GIP and they will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks. Both gastrointestinal and extra-intestinal symptoms which the patients will attribute to the accidental intake of gluten, will be considered.
16365475|NCT04219800|Experimental|mHealth|"Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.
~SMS text messages; reminds of activity breaks.
~Mobile video instruction for standing pause gymnastics."
16365476|NCT04219800|Other|Control|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
16365477|NCT04219787|Experimental|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
16365478|NCT04219787|Active Comparator|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
16365479|NCT04219774|Experimental|Endovascular arm|Subjects meet all inclusion criteria and were randomized to intervention
16365480|NCT04219774|Active Comparator|Medical arm|Subjects meet all inclusion criteria and were randomized to best medical management
16365481|NCT04219774|Active Comparator|Non-Randomized Arm|Subject meets all inclusion criteria EXCEPT abnormal CTP. Subjects are not randomized and are eligible for only best medical management
16365482|NCT04219748|Experimental|Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.
~Receiving the CM intervention doesn't exclude treatment as usual."
16365483|NCT04219748|No Intervention|Control|Only treatment as usual in the Emergency Department (and in the Health and Social Services Network).
16365484|NCT04219735|Experimental|Minocycline|Minocycline 100 mg BID
16365485|NCT04219735|Placebo Comparator|Placebo|Placebo capsules identical to experimental arm
16365486|NCT04219722|Active Comparator|Desirial only group|Administration of DESIRIAL® at Day 0 (Visit 1)
16365487|NCT04219722|Placebo Comparator|Placebo and Desirial group|Administration of placebo at Day 0 (Visit 1). If still eligible 12 weeks (Visit 3) after placebo injection, patient will be treated with DESIRIAL®
16365488|NCT04219709|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
16365489|NCT04219709|Active Comparator|Standard diet|Dietary Intervention, food delivery
16365490|NCT04219696|Active Comparator|1 session|Participants will complete one 45-minute session of reactive balance training. Participants will experience 40-60 perturbations during this session. Participants will also complete 5 45-minute 'traditional' balance training sessions.
16365491|NCT04219696|Experimental|3 sessions|Participants will complete three 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session. Participants will also complete 3 45-minute 'traditional' balance training sessions.
16365492|NCT04219696|Experimental|6 sessions|Participants will complete six 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
16365493|NCT04219683|Experimental|Patient with resected Mandible|Patient with resected mandible who is candidate for free fibula flap
16365494|NCT04219670||Inpatient Group|Inpatient stroke survivors who are currently undergoing rehabilitation at the Shirley Ryan AbilityLab setting
16365495|NCT04219670||Healthy Control Group|Individuals without any known significant health problems
16365496|NCT04219657|Experimental|skin grafting only|All the cases in this group are managed with skin grafting only. Every odd case are kept in skin grafting only group.
16365497|NCT04219657|Experimental|skin grafting and stem cell group|All the cases in this group are managed with skin grafting and application of stem cells. every even cases are kept in skin grafting and stem cells group.
16365498|NCT04219644|Other|Breathing test or sleep study|To evaluate the usability of the device in non-clinical and clinical settings
16365499|NCT04219631|Experimental|WINNER- FLOW-URO-MG GROUP|After admission to the delivery room, all women assigned to WF + group will have an interview with one of the midwifes responsible for the study. The latter will explain the use of the WINNER FLOW®-URO MG® device which is the expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate. Then, WF+ patients will use the expiratory mouthpiece device during all their childbirth process.
16365500|NCT04219631|No Intervention|NO WINNER-FLOW-URO-MG GROUP|Women enrolled in WF- group will be managed classically during their child birth process regardless to the study participation.
16365501|NCT04219618|Experimental|Off-Pump|
16365502|NCT04219618|Active Comparator|On-Pump|
16365503|NCT04219605||Symptomatic vaginitis patients|Symptomatic patients evaluated in the clinic for vulvovaginal symptoms.
16365504|NCT04219592||SSc|74 SSc patients aged 18 - 85
16365505|NCT04219592||Healthy controls|80 Healthy blood-donors aged 18 - 85
16365506|NCT04219579|Experimental|Continuous infusion|Immediately after operation, 2000 international unit (IU) of Antithrombin-III (AT-III) concentrate is loaded for 1 hour. AT-III concentrate 3000 IU is continuously infused through following 71 hours.
16365507|NCT04219579|Active Comparator|Intermittent infusion|Every 6 hours, 500 IU of AT-III concentrate is infused through 1 hour during the first 72 hours after liver transplantation.
16365508|NCT04219566|Active Comparator|Active VeNS|The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
16365509|NCT04219566|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
16365510|NCT04219553|Other|Retrospective group|Comparator group (pre-intervention)
16365511|NCT04219553|Experimental|Prospective group|Study group (post-intervention)
16365512|NCT04219540|Experimental|extended-release buprenorphine (XR-B)|Subjects who agree to XR-B treatment will receive an XR-B injection to the abdomen. The injection is a liquid medication in the amount of either 100 or 300 mg buprenorphine in 1.5 cc volume and will last in the body for about 30 days. The medication is stored in a small nodule under the skin of the belly where it was injected. The buprenorphine is gradually released into the body over time for a 30-day period.
16365513|NCT04219540|Experimental|extended release naltrexone XR-NTX|Subjects who agree to XR-NTX treatment will receive an injection of XR-NTX to the outer upper part of your buttock. The injection is a liquid medication in the amount of 380 mg naltrexone in 4 cc volume (about 1 teaspoon) and will last in your body for about 30 days. Following release, visits with study physicians at Bellevue Hospital will offer further counseling or medication treatment referrals, the option to receive additional XR-NTX injections once a month following the first injection and continued encouragement to avoid relapses and stay on treatment.
16365514|NCT04219540|No Intervention|Treatment as Usual (TAU)|In this group you will not receive any study medication. You will be able to receive any treatments available to individuals in the jail or prison who are not in the study. Trained study staff at the first two visits will provide counseling focusing on relapse and overdose prevention, treatment engagement, and navigating re-entry challenges.
16365515|NCT04219527|Experimental|Dual-Target injection|Corticosteroid injection into the subacromial bursa and biceps tendon
16365516|NCT04219501|No Intervention|Control Group|Subjects presenting for PVC/VT ablation will undergo ablation procedures using standard of care invasive electroanatomical mapping systems.
16365517|NCT04219501|Experimental|VIVO Arm|Subjects presenting for PVC/VT ablation, that have a previously acquired cardiac CT/MRI scan or are having a cardiac CT/MRI scan as per routine care, will undergo ablation procedures using VIVO, a novel, non-invasive mapping system.
16365518|NCT04219488|Experimental|Neuromobilization group|The neuromobilization group received a supervised home program plus radial nerve mobilization. Radial nerve mobilization exercises were performed by the physiotherapist for 3 days a week for 3 weeks. The patients in the neuromobilization group also performed self-neuromobilization exercises at home for 6 weeks. Supervised home program including patient education and eccentric exercises was administered three times daily for 6 weeks.
16365519|NCT04219488|Active Comparator|Control group|The control group received a supervised home program. Supervised home program including patient education and eccentric exercises was administered 3 times a day for 6 weeks.
16365520|NCT04219475||GBM patients|Newly diagnosed patients above 18 years of age with GBM receiving standard of care, i.e., maximal surgical resection possible followed by radiation therapy (RT) plus temozolomide (TMZ) therapy and maintenance TMZ.
16365521|NCT04219462|Active Comparator|study group|twenty men receive extracorporeal shock wave (ESWT) twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura +sildenafil 5mg once daily for 3 months.
16365522|NCT04219462|Sham Comparator|control group|twenty men will receive sham treatment underwent identical therapy with Extracorporal shock wave therapy (ESWT) application with a similar appearance and sound as the active low intensity extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
16365523|NCT04219449||study group|Diagnosed beta-thalassemia patients at Assiut University Hospital.
16365524|NCT04219436|Active Comparator|periosteal suturing technique|periosteal suture is done to close the flap
16365525|NCT04219436|Active Comparator|figure of eight suturing technique|figure of eight suture is done to close the flap
16365526|NCT04219423|Experimental|multimodal physical therapy|The multimodal intervention is 75 minutes in duration and meets two days per week for two weeks, then once per week for six weeks, followed by weekly phone calls to determine adherence to home-exercise program (HEP) for four weeks. The total duration of the intervention is twelve weeks. The intervention will be led in a group format with a ratio of one physical therapist to two participants and groups never exceeding 4 participants. All verbal and written communications in the intervention will be conducted in Spanish. The multimodal intervention consists of progressive lower extremity strengthening training targeting the quadriceps and gluteal groups in both legs, progressive stationary bicycle exercise, self-management training and education, manual therapy and home exercise program (HEP) instruction. Participants are asked to do their strengthening exercises at least three days per week for the 12-week study duration including sessions in the clinic
16365527|NCT04219410||Cases|Patients who underwent minimally invasive esophagectomy with this novel procedure at Kaiser Permanente, Northern California, Oakland Medical Center
16365528|NCT04219397|No Intervention|Control|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol. There will be no interventions provided. They will receive a follow up phone call survey and be asked to return a completed medication education calendar that is provided as a part of usual APS care.
16365529|NCT04219397|Experimental|Medication take back education intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive a standardized education intervention. This intervention will educate patients and their families about medication take back programs, and will provide tailored directions to the closest medication take back center from their home, and also an option for medication take back that is located in close proximity to Riley Hospital clinics.
16365570|NCT04219085|Experimental|Continuous Glucose Monitor|Monitoring of control of gestational diabetes with use of a continuous glucose monitor
16365530|NCT04219397|Experimental|Home disposal kit intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive standardized education about how to use the medication home disposal kit : Dispose Rx(r), and they will be instructed to use this kit to dispose of any left over opioid medications that they may have after they have competed therapy for pain management at home.
16365531|NCT04219384||Critical-illness related cardiac arrest (CIRCA)|Those experiencing a critical illness-related cardiac arrest in a participating adult, general ICU
16365532|NCT04219371||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
16365533|NCT04219358|Active Comparator|Placebo & Standard Treatment|
16365534|NCT04219358|Experimental|Imiquimod 5% & Standard Treatment|
16365535|NCT04219358|Experimental|Imiquimod 0.05% & Standard Treatment|
16365536|NCT04219358|Experimental|Imiquimod nanoencapsulated 0.05% & Standard Treatment|
16365537|NCT04219345|Active Comparator|Active group|In the group A will be administered anodic tDCS and instructed in mindfulness practices.
16365538|NCT04219345|Sham Comparator|Sham group|In the group B will be administered sham tDCS and instructed in mindfulness practices.
16365539|NCT04219332|Experimental|Subserosal injection of indocyanine green tracer group|Subserosal injection of indocyanine green, with a concentration of 0.5 mg /ml, 6 points along the lesser and greater curvature of the stomach, 1.5 ml for each point.
16365540|NCT04219332|Active Comparator|Submucosal injection of indocyanine green tracer group|Submucosal injection of indocyanine green, with a concentration of 1.25mg /ml, four points around the primary tumor, each point 0.5 ml.
16365541|NCT04219319|Experimental|Experimental: LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
16365542|NCT04219306|Experimental|Machine alert|These cardiac suspected cardiac arrest will have had an alert generated by the machine learning model in addition to standard Emergency Medical Services response.
16365543|NCT04219306|No Intervention|Usual care|These suspected cardiac arrests will receive standard Emergency Medical Services response.
16365544|NCT04219293|Other|Microneedling with NO PRP|Patient will receive Standard of Care micro needling on randomized side of the face.
16365545|NCT04219293|Active Comparator|Microneedling WITH PRP|Patient will receive Standard of care microneedling with PRP on randomized side of the face.
16365546|NCT04219280|Active Comparator|Quillivant XR|Once-daily, long-lasting MPH solution with the following dosing schedules: 10mg/20mg/30mg/40mg for children 20-25kg, 20mg/30mg/40mg/50mg for children 26-30kg, and 20mg/33mg/46mg/60mg for children > 30 mg.
16365547|NCT04219280|Placebo Comparator|Placebo|Liquid-based suspension to match the color and banana-flavor of Quillivant XR.
16365548|NCT04219267|Experimental|The intervention group|Character strengths-based intervention, 3 sessions every week for three weeks. 30 minutes each session.
16365549|NCT04219267|Placebo Comparator|The control group|Early memories for placebo control, 3 sessions every week for three weeks. 30 minutes each session.
16365550|NCT04219254|Experimental|BI-1206|BI-1206 administrated IV with a starting dose of 1 mg/kg every third week using mTPI2 Design in escalation Phase I. RP2D to be used i Phase IIa.
16365551|NCT04219241|Experimental|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
16365552|NCT04219228||Students in urban counties|All first-grade students in urban counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
16365553|NCT04219228||Students in rural counties|All first-grade students in rural counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
16365554|NCT04219215|Experimental|HBO|Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber
16365555|NCT04219215|Experimental|Ambient Air|Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber
16365556|NCT04219202|Active Comparator|Proton Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment
16365557|NCT04219202|Experimental|Carbon Ion Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment
16365558|NCT04219189|Experimental|Vaping to Control Group|Participants in this arm will undergo the vaping condition during the first visit and the control condition during the second visit.
16365559|NCT04219189|Experimental|Control to Vaping Group|Participants in this arm will undergo the control condition during the first visit and the vaping condition during the second visit.
16365560|NCT04219163|Experimental|CLL-1.CAR|Group A
16365561|NCT04219150|Experimental|Electrical cardiometry (EC)|
16365562|NCT04219150|Experimental|"Fluid and Catheter Treatment Trial FACTT Lite"|
16365563|NCT04219137||Localized Esophagogastric Adenocarcinoma|Patients diagnosed with gastroesophageal adenocarcinoma who will undergo surgical resection for curative intent, with or without neo-adjuvant chemotherapy or chemoradiotherapy.
16365564|NCT04219137||Metastatic Esophagogastric Adenocarcinoma|Patients diagnosed with de novo metastatic gastroesophageal adenocarcinoma who will undergo platinum based first line chemotherapy.
16365565|NCT04219124|Active Comparator|Dapagliflozin|Investigational product: Dapagliflozin 10 mg Dosage form and strength: Green, plain, diamond shaped, film coated 10 mg tablet with frequency of 1 tablet per day for 4 weeks
16365566|NCT04219124|Placebo Comparator|Placebo|Investigational product: Matching placebo for Dapagliflozin 10 mg. Dosage form and strength: Green, plain, diamond shaped, and film coated tablet with frequency of 1 tablet per day for 4 weeks
16365567|NCT04219098|Experimental|Treatment|Butterfly IQ utilized to inject 10cc prior to surgery the remainder after incision
16365568|NCT04219098|Active Comparator|Control|Entire injection will be given after initial incision is made.
16365569|NCT04219085|Active Comparator|Routine Care|Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
16365571|NCT04219046|Experimental|Experimental Treatment|ERAS program with administration of experimental treatment: Naloxegol 25mg administrated once daily from surgery for up to 7 days
16365572|NCT04219046|Placebo Comparator|Placebo|ERAS program with administration of placebo: Placebo administrated once daily from surgery for up to 7 days
16365573|NCT04219033||with postoperative cognitive dysfunction|
16365574|NCT04219033||without postoperative dysfunction|
16365575|NCT04219020||Children with a CP diagnosis|"Children younger than 18 years with a CP diagnosis. Intervention will be determined later based on baseline results. Self- and/or proxy-reported survey and/or participation in interviews.
~Parents of all participants will provide proxy report. Children with CP > 8 years of age and cognitively able (approx. 50%) will provide self-report."
16365576|NCT04219020||Controls|Siblings (12-17 years) of children with cerebral palsy. No intervention, self-reported survey.
16365577|NCT04219020||Health Care Professionals|Health Care Professionals identified as providers of pain care. No intervention, interview participants
16365578|NCT04219007|Experimental|Genetic Short Stature|"Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.
~Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months."
16365579|NCT04218994|Experimental|Group A|Subjects instructed on flossing technique.
16365580|NCT04218994|No Intervention|Group B|No instructions for flossing provided. Subjects asked to continue their normal oral hygiene care.
16365581|NCT04218981|Experimental|Schizophrenia group|"Schizophrenia was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks
~Choose one of the antipsychotics drugs treatment( olanzapine, risperidone, aminosulpiride) according to the patient's condition"
16365582|NCT04218981|Experimental|Bipolar disorder group|"Bipolar disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks
~Choose one of the mood stabilizer drugs treatment( lithium, valproate) according to the patient's condition"
16365583|NCT04218981|Experimental|Major depressive disorder group|"Major depressive disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks
~Choose paroxetine treatment"
16365584|NCT04218981|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
16365585|NCT04218968|Experimental|carvedilol therapy|
16365586|NCT04218955||1|Asking parents if they can accept staining from treat their children by silver Diamine Flouride or Not
16365587|NCT04218942|Experimental|Prospective non randomised feasibility study|
16365588|NCT04218929|Experimental|Study Formula (SF)|New infant formula for term infants
16365589|NCT04218929|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
16365590|NCT04218929|No Intervention|Human Milk Reference Group|Human milk
16365591|NCT04218916|Experimental|Rhodiola Rosea Capsule|
16365592|NCT04218916|Placebo Comparator|Placebo Capsule|
16365593|NCT04218903|Experimental|Combined Training 4 times per week (CT4)|The CT4 group will perform four sessions per week of combined exercise program. This intervention will last 12 weeks.
16365594|NCT04218903|Active Comparator|Combined Training 2 times per week (CT2)|The CT2 group will perform two sessions per week of combined exercise program. This intervention will last 12 weeks.
16365595|NCT04218890||SLE patients without lupus nephritis|"40 SLE patients
~40SLE patients( All SLE pt. satisfied the ACR criteria for SLE diagnosis) these patients will be without any evidences of nephritis"
16365596|NCT04218890||SLE patients with lupus nephritis|40SLE patients with evidences of nephritis
16365597|NCT04218890||healthy control group|20 healthy subjects matched age and sex with be enrolled as healthy control group
16365598|NCT04218877||Children with atopic dermatitis|Children 1-3 years old with atopic dermatitis
16365599|NCT04218877||Children without atopic dermatitis|
16365600|NCT04218877||Children with genetic predisposition|Children with genetic predisposition to atopic dermatitis, but without manifestations
16365601|NCT04218864|Experimental|Strength for U in Relationship Empowerment (SURE)|Theory-driven and derived from empirical support
16365602|NCT04218864|Active Comparator|Attention, time, and information matched control|Well-validated
16365603|NCT04218851|Experimental|Posaconazole|On Day 1 participants will receive two treatments of Posaconazole (POS)) 6 mg/kg body weight by intravenous (IV) infusion; on Days 2 through 7 participants will receive POS 6 mg/kg body weight once daily by IV infusion; beginning at Day 8 up to Day 84, participants may transition to receiving an oral formulation, or they may remain on an IV formulation
16365604|NCT04218838|Active Comparator|CornerLoc SI Joint Stabilization Group|Patient will receive the CornerLoc minimally invasive SI Joint Stabilization procedure. This procedure will be performed in an outpatient surgery center under local sedation or general anesthesia, and normally takes around 45 minutes. During the procedure, the physician will make two small incisions in the patient's lower back to access the SI joint, and place four small cadaveric bone grafts into the SI joint to help stabilize the SI joint.
16365605|NCT04218838|Active Comparator|SI Joint Steroid Injections Group|Patient will receive an injection of steroid medication directly into their SI joint. The area around the SI joint will be numbed with an injection of local anesthetic and then ultrasound guidance will be used to guide the needle of steroid medication directly into the SI joint. This procedure will be performed in the physician's office or an outpatient surgery center, and normally takes around 30 minutes.
16365606|NCT04218825|Experimental|Adult patients with early stage MF-CTCL (stage IA-IB)|Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.
16368964|NCT04195542||CHU professionals|All CHU professionals contacted via their email address
16365607|NCT04218812|Active Comparator|No electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data without ESI
16365608|NCT04218812|Experimental|Automated Electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data with ESI
16365609|NCT04218799|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|
16365610|NCT04218786|Active Comparator|Colchicine Group|This group will receive low dose colchicine, 0.5 mg.
16365611|NCT04218786|Placebo Comparator|Placebo group|This group will receive a placebo drug with a similar shape and mass as that to experimental drug
16365612|NCT04218773|Experimental|Induced hypertension|The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
16365613|NCT04218760|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.
16365614|NCT04218747|Experimental|VA 365 Demonstration Benefits|Children in treatment schools received: (1) three meals during the school day and food packages for weekends and school breaks; (2) $60 monthly Electronic Benefit Transfer (EBT) benefits during summer months if they were eligible for FRP meals; and (3) nutrition education for their parents.
16365615|NCT04218747|No Intervention|Control Group|"Schools in the control group operated under business as usual."
16365616|NCT04218734|Experimental|metformin hydrochloride+DBPR108|metformin hydrochloride 500 mg+DBPR108 100 mg
16365617|NCT04218734|Placebo Comparator|metformin hydrochloride+placepo|metformin hydrochloride 500 mg+placebo 100 mg
16365618|NCT04218721|Experimental|eHealth application|Participants get access to the eHealth application InvolveMe
16365619|NCT04218708|Active Comparator|counseling + nicotine replacement therapies NRT|A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (NRT). Participants will also receive their NRT to last them to the following visit based on their baseline smoking.
16365620|NCT04218708|Active Comparator|Counseling + Standardized Research E-cigarettes (SREC)|Participants in the SREC arm to practice using the SREC and give them instructions to return with their SREC and used refill tanks on every visit. A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (SREC). Participants will also receive their SREC to last them to the following visit based on their baseline smoking.
16365621|NCT04218695|Experimental|Treatment|1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
16365622|NCT04218695|Placebo Comparator|Placebo|Normal saline (50cc) once daily for up to one week or until end of hospitalization
16365623|NCT04218682|Experimental|Immediate Game Use|AYACS randomly assigned to this arm will immediately play the Shadow's Edge Game following enrollment for a duration of 7 weeks. Following the designated 7-week game-play period, they will continue to have access to the game. They will continue to receive all usual care health care throughout and following the study.
16365624|NCT04218682|No Intervention|Wait-List Comparison Group|AYACS randomly assigned to this arm will begin to play the Shadow's Edge game 7 weeks following enrollment. They will continue to receive all usual health care throughout and following the study.
16365625|NCT04218669|Active Comparator|T-tube drainage|The T-tube was placed for biliary drainage
16365626|NCT04218669|Experimental|Roux-en-Y Hepaticojejunostomy|biliary-enteric anastomosis was performed
16365627|NCT04218656|Experimental|Group A|111 patients with intermittent claudication
16365628|NCT04218656|Experimental|Group B|48 patients with critical limb ischemia with pain at rest and/or foot ulcers
16365629|NCT04218643|Active Comparator|Standard technique|Intravenous catheter inserted via standard technique
16365630|NCT04218643|Experimental|Ultrasound-guided technique|Intravenous catheter inserted via ultrasound guidance
16365631|NCT04218630|Experimental|Reformer pilates group|All participants were informed about the reformer machine and the treatment program by the physiotherapist in reformer pilates group. Reformer pilates exercises were applied in the form of general muscle strengthening and flexibility exercises under the supervision of physiotherapist. Exercises were performed in 2 times a week for 6 weeks. The duration of one session was 60 minutes.
16365632|NCT04218630|Active Comparator|Home mat pilates group|In home mat pilates group, clinical pilates exercises were applied as a home program. Brochures and exercise follow-up forms, which illustrated and written all the exercises in this program, which consisted of clinical pilates-based general muscle strength and flexibility exercises, were given to all participants in this group. Exercises were performed in 2 times a week for 6 weeks at home. Participants marked the follow-up form when they performed exercises. Attendance of participants to exercise was checked by phone calls.
16365633|NCT04218617|Experimental|Arm 1 - Single fraction|sSRS 18 Gy in 1 fraction
16365634|NCT04218617|Active Comparator|Arm 2 - Two fraction|sSRS 24 Gy in 2 fractions
16365670|NCT04218396|Experimental|Standard Treatment, Then Virtual Reality + Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment only. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment AND virtual reality
16365671|NCT04218396|Experimental|Virtual Reality + Standard Treatment, Then Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment AND virtual reality. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment only.
16365635|NCT04218604|Experimental|Personalized AF ablation using MDCT-derived LAWT|Pre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness < 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; > 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is > 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.
16365636|NCT04218591|Active Comparator|PRP|Intra-articular injection PRP
16365637|NCT04218591|Placebo Comparator|Saline|Intra-articular injection Saline
16365638|NCT04218578||Device group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with MitraClip
16365639|NCT04218578||Control group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with optimal medical treatment
16365640|NCT04218565|Experimental|Golimumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
16365641|NCT04218552|Experimental|Experimental 1|AD-209 High
16365642|NCT04218552|Experimental|Experimental 2|AD-209 Middle
16365643|NCT04218552|Experimental|Experimental 3|AD-209 Low
16365644|NCT04218552|Active Comparator|Active Comparator 1|Amlodipine Low
16365645|NCT04218552|Active Comparator|Active Comparator 2|Amlodipine High
16365646|NCT04218552|Active Comparator|Active Comparator 3|Telmisartan
16365647|NCT04218552|Placebo Comparator|Placebo comparator|Placebo
16365652|NCT04218526|Experimental|Vercise DBS Group|All participants will have the Vercise DBS system implanted.
16365653|NCT04218513|Experimental|Compound Edaravone|30 mL (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg)
16365654|NCT04218513|Experimental|Edaravone|30 mL (containing edaravone 30 mg)
16365655|NCT04218513|Experimental|2-Aminoethanesulfonic Acid|30 mL (containing 2-aminoethanesulfonic acid 600 mg)
16365656|NCT04218500|Active Comparator|Niacinamide 4%|Niacinamide 4%, applied twice daily for 28 days
16365657|NCT04218500|Active Comparator|Virgin coconut oil 30%|Virgin coconut oil 30%, applied twice daily for 28 days
16365658|NCT04218487|Experimental|XFZY group|2.4g (6 capsules) three times daily for 12 weeks
16365659|NCT04218487|Placebo Comparator|Control group|2.4g (6 capsules) three times daily for 12 weeks
16365660|NCT04218474|Other|patient lost sensation ant half of lower lip|patient with injured inferior alveolar nerve at one side
16365661|NCT04218448|No Intervention|Somatosensory evoked potentials without hypnorelaxation|"As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination.
~Somatosensory evoked potentials are carried out according to the usual management."
16365662|NCT04218448|Experimental|Somatosensory evoked potentials with hypnorelaxation|As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination. Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes. The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of suggestions and metaphors. The protocol is adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. The investigator, thanks to hypnosis, allows the development of a creative imagination which allows a modification of the relation to space and time.
16365663|NCT04218435||Observational|"Sacubitril/valsartan is a combination of a neprilysin inhibitor, sacubitril and an angiotensin II receptor blocker, valsartan.
~The recommended starting dose is one 49/51 mg (sacubitril/valsartan) tablet twice-daily. Double the dose of Sacubitril/valsartan after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.
~Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for:
~Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
~Patients with severe renal impairment (CrCl less than 30 ml/min)
~Patients with moderate hepatic impairment. (Child Pugh B) Double the dose of Sacubitril/valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient"
16365664|NCT04218422|Experimental|Treatment|2 treatments of battlefield acupuncture to the bilateral ears spaced one week apart
16365665|NCT04218422|Sham Comparator|Control|2 treatments with sham acupuncture to the bilateral ears at acupuncture points not associated with pain relief (2 liver and 1 stomach)
16365666|NCT04218409|Active Comparator|oxycodone+oxytocin|Combined effects of oxycodone and oxytocin
16365667|NCT04218409|Active Comparator|oxycodone+placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
16365668|NCT04218409|Active Comparator|oxytocin+placebo|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
16365669|NCT04218409|Sham Comparator|placebo+placebo|Serves as the control
16365672|NCT04218383|Active Comparator|Experimental: Active Left OFC Group|2mA will be applied for 20 minutes with the tDCS anode applied to the left OFC and Cathode applied to the right primary motor cortex.
16365673|NCT04218383|Sham Comparator|Sham Comparator: Sham left OFC Group|Current will be ramped up for 30s followed by a 30s ramp down to mimic the physical sensation of stimulation and habituation. The anode placed over the left OFC and cathode placed over the right primary motor cortex.
16365674|NCT04218370|Active Comparator|Conventional|Thrice-weekly intermittent dialysis until pre-specified criteria for recovery are met
16365675|NCT04218370|Experimental|Conservative|Conservative dialysis strategy--dialysis prescribed only when specific metabolic or clinical indications are met. These indications are: blood urea nitrogen >112 mg/dL (40 mmol/L; blood potassium concentration >6 mmol/L; blood potassium concentration >5.5 mmol/L despite medical treatment; arterial blood gas pH <7.15, or in the absence of an available blood gas, serum bicarbonate <12 mmol/L, acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min or equivalent via face mask/tracheostomy mask to maintain SpO2 >95% or requiring FiO2 >50% in patients with tracheostomy already on invasive or non-invasive mechanical ventilation and despite diuretic therapy; clinician judgement
16365676|NCT04218357|Experimental|Probenecid|2g probenecid, one pill by mouth once, for one day
16365677|NCT04218357|Placebo Comparator|matching placebo|Placebo, one pill by mouth once, for one day
16365678|NCT04218344||Acute Coronary Syndrome - Iscaemia|Patients who present with chest pain, undergo emergency angiogram and receive a cardiac stent.
16365679|NCT04218344||Acute Coronary Syndrome - Non-Ischaemic|Patients who present with chest pain but angiography reveals normal coronary arteries.
16365680|NCT04218331|Experimental|JASPER only|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
16365681|NCT04218331|Active Comparator|JASPER + PROMPT|This group will consist of the child and therapist having one-on-one, JASPER sessions plus Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT), twice a week.
16365682|NCT04218318|Active Comparator|Low-threshold group|Neonates in the low-threshold group phototherapy will be stopped if TSB reached ˃100 µmol/L below the AAP phototherapy threshold.
16365683|NCT04218318|Active Comparator|High-threshold group|Neonates in high-threshold group phototherapy will be ceased if TSB level is 50-100 µmol/L below the appropriate AAP phototherapy threshold.
16365684|NCT04218305||The first group|Include One hundred patients with type 2 diabetes mellitus with average body mass index.
16365685|NCT04218305||The second group|Include One hundred patients whose body mass index is 30 or over without diabetes.
16365686|NCT04218305||The third group|Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.
16365687|NCT04218305||The fourth group|Include One hundred apparently healthy adult person as a control.
16365688|NCT04218279|Experimental|Sleep Health Education|At baseline, the experimental group will have immediate access to 10 brief education modules focused on diverse elements of sleep health and fatigue.
16365689|NCT04218279|Active Comparator|Wait List Control|At 3 months after baseline, the wait-list control group will be provided access to the 10 education modules focused on diverse elements of sleep health and fatigue..
16365690|NCT04218266|Experimental|BAY2433334 50mg+Apixaban matching placebo|
16365691|NCT04218266|Experimental|BAY2433334 20mg+Apixaban matching placebo|
16365692|NCT04218266|Active Comparator|BAY2433334 matching placebo+Apixaban|Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
16365693|NCT04218253|Experimental|nutritional intervention|300 or 500 calories nutritional support before operation according to the level of malnutrition
16365694|NCT04218253|Other|control group|Dietary education was conducted according to preoperative nutritional requirements
16365695|NCT04218240|Experimental|PGB/LFX;|0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
16365696|NCT04218240|Active Comparator|Lofexidine and PLACEBO|0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
16365697|NCT04218227||Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
16365698|NCT04218227||Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
16365699|NCT04218227||Self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
16365700|NCT04218227||Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
16365701|NCT04218227||Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
16365820|NCT04217551|Experimental|72 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365702|NCT04218214||LIFE-DM Group|The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.
16365703|NCT04218201|Experimental|Subthreshold Opioid Use Disorder Prevention(STOP) Intervention|"Participants will receive the intervention components of brief advice from their PCP and a video doctor at the baseline primary care visit, printed educational materials, interaction with the NCM, and telephone health coaching. Patient participants in the STOP arm will receive brief advice at the baseline primary care visit, consisting of PCP-delivered counseling and viewing a video doctor and receive an educational pamphlet about opioid overdose prevention and an introduction to the role of the NCM and telephone health coaches. Brief advice will be delivered by the patient participant's PCP as part of the medical visit. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the RA or clinical staff. Following the PCP encounter, and before completing the post-visit assessments or leaving the clinic, patient participants will meet with the RA to view a video on tablet or desktop computer that reinforces the PCP's counseling."
16365704|NCT04218201|No Intervention|Enhanced Usual Care (EUC)|PCPs will conduct primary care as usual, without the support of the NCM. At the baseline visit, patient participants receive an educational pamphlet and view a short video on overdose and cancer screening. The pamphlet includes information about preventing opioid-related overdose, including how to obtain a naloxone kit. The video content will feature the health benefits of exercise. It will be viewed on a tablet or desktop computer and will be approximately 2 minutes long. All EUC patient participants receive the same video, which is not tailored to the responses given on their questionnaires. There is no study intervention after the baseline visit.
16365705|NCT04218175|Experimental|neuromobilization stretching group|In the neuromobilization stretching group; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed.
16365706|NCT04218175|Experimental|neuromobilization shifting group|In the neuromobilization shifting group, the subjects were brought to shoulder depression and 90 degrees of abduction while the dominant forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side. Thus, the participants performed median nerve shift.
16365707|NCT04218175|No Intervention|Control Group|The dominant sides of the individuals are experimental sides and the other nondominant sides of the participants are control sides. And no intervention was made. All measurements were done bilaterally before and after.
16365708|NCT04218162|Experimental|Lasmiditan 50mg|
16365709|NCT04218162|Experimental|Lasmiditan 100mg|
16365710|NCT04218162|Placebo Comparator|Placebo|
16365711|NCT04218149|Active Comparator|Group S|Serratus plane block with 25 ml %0.25 bupivacaine
16365712|NCT04218149|Active Comparator|Grup E|Erector spinae plane block with 25 ml %0.25 bupivacaine
16365713|NCT04218136||patient with head and neck cancer|Patients treated by standard treatment and have a minimum of 4 blood samples.
16365714|NCT04218123|Experimental|Venlafaxine Arm|
16365715|NCT04218123|Placebo Comparator|Placebo|
16365720|NCT04218097||Addict patients|"Obese type 2 and 3 with food addict according to the Yale Food Addiction Scale (YFAS) questionnaire.
~Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
16365721|NCT04218097||Control patients|"Obese type 2 and 3, non food addict Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
16365722|NCT04218084|Experimental|Voxelotor|Voxelotor 1500mg or equivalent daily as a tablet or as powder for oral suspension.
16365723|NCT04218084|Placebo Comparator|Placebo|Matching placebo.
16365724|NCT04218071|Experimental|9-ING-41|9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
16365725|NCT04218071|Experimental|9-ING-41 plus Ruxolitinib|9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
16365726|NCT04218058|Active Comparator|study (ultrasound guided closed reduction of zygomatic arch))|reduction of zygomatic arch guided by ultrasound
16365727|NCT04218058|Active Comparator|control (open reduction of zygomatic arch)|open reduction of zygomatic arch through coronal incision
16365728|NCT04218045|Active Comparator|Laparoscopic sleeve gastrectomy group|The group of morbidly obese patients undergoing laparoscopic sleeve gastrectomy
16365729|NCT04218045|Experimental|SASI bypass group|The group of morbidly obese patients undergoing laparoscopic single- anastomosis sleeve ileal bypass (the new procedure being evaluated)
16365730|NCT04218032|Experimental|blood pressure|blood pressure is measured from the participants, by using two methods. A new developed device and a reference device. The new device measures, using oscillometry, the blood pressure from the finger tip. The reference device is a standard sphygmomanometer.
16365821|NCT04217538||EBH|
16365731|NCT04218019|Experimental|Early Tumor Treating Fields (TTFields, Optune®) treatment|TTF will be started together with hypofractionated radiotherapy (+/- 5 days) with or without Temozolomide (according to the standard and local physician's decision). Chemoradiotherapy with temozolomide and hypofractionated radiotherapy is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator.
16365732|NCT04218019|Active Comparator|Late TTF treatment|Patients will be treated with hypofractionated radiotherapy with or without temozolomide (according to the local standard and physician's decision). Radiotherapy and treatment with temozolomide is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator. Late TTFields treatment will start 4 weeks after the end of radiotherapy.
16365733|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 100mg twice a day.|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets）dose group for twice a day.
16365734|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 150mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 150mg （3 tablets）dose group for once a day.
16365735|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 100mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets） dose group for once a day
16365736|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 200mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 200mg （4 tablets）dose group for once a day.
16365737|NCT04217980|Experimental|Lung ultrasonography (LUS) group|Group 1: Lung ultrasonography is performed as the main (first) pulmonary image test
16365738|NCT04217980|Active Comparator|Chest X ray (CXR) group|Group 2: Chest X ray is performed as main (first) pulmonary image test
16365739|NCT04217967|Active Comparator|Lenalidomide group|lenalidomide 25mg qod d1~21 days, rest 7 days
16365740|NCT04217967|Active Comparator|Ixazomib group|ixazomib 4mg orally, once a week, 3 times a month
16365741|NCT04217967|Experimental|Combination group|ixazomib 4mg orally, once a week, 3 times a month lenalidomide 25mg qod d1~21 days, rest 7 days use in combination
16365742|NCT04217954|Experimental|OXA, 5-FU and Bev plus Toripalimab|the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab
16365743|NCT04217941|Active Comparator|Health Education with practical demonstration|Participants assigned to the intervention arm received health education with practical demonstration of nasal spray and intranasal ointment .
16365744|NCT04217941|Placebo Comparator|Health education without practical demonstration|Participants assigned to the control arm received only health education regarding nasal spray and intranasal ointment .
16365745|NCT04217928|Active Comparator|Arthroscopic Debridement|Patients who are randomized into this arm will receive arthroscopic debridement
16365746|NCT04217928|Active Comparator|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Patients who are randomized into this arm will receive arthroscopic hemi-trapeziectomy with mini tightrope
16365747|NCT04217902||People living with diabetes in Grenoble and Lyon areas|Eligible patients with type 1 or type 2 diabetes 1) during or after hospitalization for decompensation, ketoacidosis, or other emergency or elective interventions such as insulin pump installation, 2) followed in routine care in specialized diabetes services, 3) participating in patient associations.
16365748|NCT04217902||Health care professionals working in diabetes care in Grenoble|Health care professionals working with diabetes care in specialized services or ambulatory care.
16365749|NCT04217889||Adherent patient|This group is composed of adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
16365750|NCT04217889||Not-adherent patient|This group is composed of not-adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
16365751|NCT04217876||Clinically suspected infarct-like acute myocarditis|Diagnosis of infarct-like AM was based on five criteria: (a) history of flu-like symptoms within 8 weeks prior admission; (b) new onset of symptoms such as fatigue/breathlessness, chest pain, mild dyspnea, and/or palpitation; (c) ischemic ECG pattern (ST-segment elevation and/or T-wave anomalies); (d) increase of inflammatory markers (non-high- sensitivity CRP > 8 mg/L and/or white blood cell count > 11.000/mm3) and cardiac enzymes; and (e) preserved global systolic function (EF > 50%). We excluded patients with New York Heart Association (NYHA) functional heart classifications II-IV, LVEF < 50% and those patients with electrocardiographic evidence of bradyarrhythmias (≥second-degree atrioventricular block) or tachyarrhythmias (ventricular or supraventricular arrhythmias).
16365752|NCT04217863|Experimental|The experimental intervention (GDP): It includes three writing|"Participants will be required to describe memories associated with traumatic event in a sequential order, with an objective and detached attitude
~They will be asked to describe
~Their opinion regarding the traumatic event and emotions perceived during the experience
~Its impact on their daily lives, and how it has altered their attitudes toward life.
~The actual situation will be focused, while reviving the whole traumatic event experience which aids in exploring the following aspects:
~Present thoughts and feelings regarding the traumatic experience, and also clarify the differences between the ones felt at the time of traumatic event in comparison to the current feelings.
~How much they understand and appreciate themselves for successfully dealing with the traumatic event
~To what extent the traumatic event has modified their vision, attitude, knowledge, and skills, and how it can help in their future;
~What will be their future reactions to other similar events."
16365753|NCT04217863|No Intervention|The control intervention:|A day prior to each writing session, the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet. Details regarding the inability to contact the subject will also be recorded in the patient form.
16365754|NCT04217850|Experimental|500 kcal Energy Deficit|The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
16365755|NCT04217837||Major Depressive Disorder|Participants who meet the DSM-5 clinical diagnostic criteria, in the opinion of the treating clinician, for primary diagnosis of unipolar, non-psychotic MDD.
16365756|NCT04217824|Active Comparator|karydakis flap|An asymmetric elliptical excision is performed, defective tissues between the lower and upper ends are removed until they reach healthy borders. The wound edge is then mobilized and the flap is slid over the corresponding wound edge by suturing to the fascia and the skin to the appropriate wound layers. Thus, the gluteal groove is lateralized. Subcutaneous tissue and skin are closed.
16365757|NCT04217824|Active Comparator|limberg flap|Rhomboid excision and pilonidal sinuses together with damaged tissue. On the right side of the patient, the intact skin is shifted to the medial area where the tissues are removed without tension. Thus, the defective part and gluteal groove are corrected.
16365758|NCT04217811||Late neutropenia|Neutrophil count < 1500
16365759|NCT04217811||No late neutropenia|Neutrophil count > 1500
16365760|NCT04217798|Experimental|Niparib combined with oral etoposide|Subjects will received niraparib 200mg or 100mg alternate once daily and oral etoposide 50mg on day 1-20 of a 30-day cycle. Oral etoposide was administered for a maximum of 6-8 cycles. Treatment was continued until disease progression, patient withdrawal or unacceptable toxic effects.
16365761|NCT04217785|Active Comparator|A-AT eye drops|Optive Fusion UD eye drops + Genteal lubricant gel
16365762|NCT04217785|Active Comparator|B-UCS eye drops|UCS eye drops + GentTeal lubricant gel
16365763|NCT04217772|Experimental|Eyes post-lensectomy|Eyes of children after cataract surgery
16365764|NCT04217772|No Intervention|Healthy Eyes|Eyes of healthy volunteers
16365765|NCT04217759|Experimental|Intervention group|Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks via face-to-face sessions and social media tools (Facebook and WhatsApp)
16365766|NCT04217759|No Intervention|Control group|Control group only received leaflets on healthy lifestyle with no further guidance.
16365767|NCT04217746|Experimental|High flow nasal cannula (HFNC) group|The HFNC group will receive heated (approximately 37 ⁰C) and humidified (100% relative humidity) oxygenated gas delivered at high flow at 50L/min. Flow could be decreased to as low as 30L/min and temperature to 31 ⁰C as per patient's tolerance.
16365768|NCT04217746|No Intervention|Conventional flow nasal oxygen (CFNO) group|The conventional flow nasal oxygen (CFNO) group is the control group which will receive ambient temperature and non-humidified oxygen delivered at flow rates of up to 8L/min (standard care).
16365769|NCT04217733|Active Comparator|Mebeverine|Mebeverine 3 times daily for 3 months
16365770|NCT04217733|Experimental|Ethosuximide|Ethosuxemide 3 times daily for 3 months
16365771|NCT04217733|Experimental|Pentoxyifylline|pentoxyifylline 2 times daily for 3 months
16365772|NCT04217720|Experimental|SNS-301|SNS-301
16365773|NCT04217707|Other|Pre- and Post-Surgical Transgender Therapeutic Support Groups|
16365774|NCT04217694|Experimental|Prevention (memantine, CogState)|Patients receive memantine PO BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT.
16365775|NCT04217681|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
16365776|NCT04217681|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
16365777|NCT04217681|Experimental|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
16365778|NCT04217681|Experimental|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
16365779|NCT04217668|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day.
16365780|NCT04217655|Experimental|Low-dose computed tomography group|Patients undergo low-dose computed tomography-guided lung biopsy for lung nodule on day 1.
16365781|NCT04217655|Active Comparator|Standard-dose computed tomography group|Patients undergo standard-dose computed tomography-guided lung biopsy for lung nodule on day 1.
16365782|NCT04217642||Delay surgery|Patients who have passed more than 48 hours from admission to surgery
16365783|NCT04217629|Experimental|SY-005 single-dose 0.75mg|4 subjects will be envolved in this group and be injected with 0.75mg of SY-005.
16365784|NCT04217629|Placebo Comparator|SY-005 single-dose 2.5mg|This group will be intiated in healthy subjects at a 2.5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
16365785|NCT04217629|Placebo Comparator|SY-005 single-dose 5mg|This group will be intiated in healthy subjects at a 5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
16365786|NCT04217629|Placebo Comparator|SY-005 single-dose 10mg|This group will be intiated in healthy subjects at a 10mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
16365787|NCT04217629|Placebo Comparator|SY-005 single-dose 15mg|This group will be intiated in healthy subjects at a 15mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
16365788|NCT04217629|Placebo Comparator|SY-005 single-dose 20mg|This group will be intiated in healthy subjects at a 20mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
16365789|NCT04217629|Placebo Comparator|SY-005 multiple-doses 5mg|This group will be intiated in healthy subjects at a 5mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
16365790|NCT04217629|Placebo Comparator|SY-005 multiple-doses 10mg|This group will be intiated in healthy subjects at a 10mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
16365791|NCT04217629|Placebo Comparator|SY-005 multiple-doses 20mg|This group will be intiated in healthy subjects at a 20mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
16365792|NCT04217616||Headache Resistant Participants|Male participants who have never had a headache.
16365793|NCT04217616||Non-Resistant Participants|Male participants who have experienced headache. Age matched.
16365794|NCT04217603|Experimental|Group 1|This group will perform a 6MWT with CPAP
16365795|NCT04217603|Sham Comparator|Group 2|This group will perform a 6MWT with a sham-CPAP
16365796|NCT04217590|Experimental|Sodium Zirconium Cyclosilicate (SZC)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
16365797|NCT04217590|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
16365799|NCT04217564|Experimental|Intervention group|The intervention group will receive a counselling session then instructed on the subsequent follow up dates and final assessment by the end of the study.
16365800|NCT04217564|No Intervention|Control group|The control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study.
16365801|NCT04217551|Experimental|6 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
16365802|NCT04217551|Experimental|12 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
16365803|NCT04217551|Experimental|18 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
16365804|NCT04217551|Experimental|24 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365805|NCT04217551|Experimental|30 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365806|NCT04217551|Experimental|36 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365807|NCT04217551|Experimental|42 Hours - shockable|Participants with shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365808|NCT04217551|Experimental|48 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365809|NCT04217551|Experimental|60 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365810|NCT04217551|Experimental|72 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365811|NCT04217551|Experimental|6 hours - non shockable|Participants with non-shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
16365812|NCT04217551|Experimental|12 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
16365813|NCT04217551|Experimental|18 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
16365814|NCT04217551|Experimental|24 hour - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365815|NCT04217551|Experimental|30 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365816|NCT04217551|Experimental|36 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365817|NCT04217551|Experimental|42 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365818|NCT04217551|Experimental|48 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365819|NCT04217551|Experimental|60 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
16365824|NCT04217512|Active Comparator|Standard hydration alone|Cisplatin with standard hydration
16365825|NCT04217512|Active Comparator|Pantoprazole high dose|Cisplatin with standard hydration with pantoprazole 1.6 mg/kg
16365826|NCT04217512|Active Comparator|Pantoprazole Low dose|Cisplatin with standard hydration with pantoprazole 0.6 mg/kg
16365827|NCT04217499||Patients with pelvic ring fractures|This retrospective study will be carried out on the data of patients who have received treatment or followed for a pelvic ring fracture, in the Orthopedic Surgery department of the Paris Saint-Joseph Hospital Group between January 2015 and September 2019.
16365828|NCT04217486|Experimental|A - will be shown their photograph at 2 weeks post-operative.|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
16365829|NCT04217486|Active Comparator|B - will not be shown their photograph|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will not be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
16365830|NCT04217473|Experimental|TILT-123|"Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.
~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
16365831|NCT04217460|Active Comparator|Intervention for fluency difficulty (controls)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for controls.
16365832|NCT04217460|Experimental|Intervention for fluency difficulty (experimental)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for experimental group
16365833|NCT04217447|Active Comparator|Experimental group|Patients intaking full-dose OAC + ASA 100mg od
16365834|NCT04217447|Placebo Comparator|Control group|Patients intaking full-dose OAC + Placebo of ASA 100mg od
16365835|NCT04217434|Experimental|Group 300µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 300 µm fibre length will be used in continuous contact mode at a power setting of 1.5 to 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
16365836|NCT04217434|Experimental|Group 300µm in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes, 300 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 - 3 W. Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
16365837|NCT04217434|Experimental|Group 400µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
16365838|NCT04217434|Experimental|Group 400µm in pulsed contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 t 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
16365839|NCT04217421|Active Comparator|Allopurinol|
16365840|NCT04217421|Placebo Comparator|Placebo|
16365841|NCT04217408|Experimental|ON stimulation followed by OFF stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of ON (active) stimulation, followed by 2 weeks of OFF (sham) stimulation
16365842|NCT04217408|Experimental|OFF stimulation followed by ON stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of OFF (sham) stimulation, followed by 2 weeks of ON (active) stimulation
16365843|NCT04217395||Reinforced support: X-ailes program users|
16365844|NCT04217369|No Intervention|Control|A control arm. The participant will be given a version of the Diabits app without predictions of blood glucose enabled. They will then use the Diabits app as if they were using their usual companion app to manage their diabetes for the duration of the study.
16365845|NCT04217369|Experimental|Intervention|The intervention arm. The participants in this arm will be provided with a version of the Diabits app which provides predictions of where their blood glucose will be one hour into the future, based on historic data and user inputs. The participant will then manage their blood glucose using these predictions for the duration of the study.
16365846|NCT04217356||Hematopoietic stem cell transplant (HCT)|Standard of care hematopoietic stem cell transplant with a matched donor.
16365847|NCT04217356||Best available non-transplant therapies (BAT)|Standard of care treatment with a janus kinase (JAK) inhibitor drug called ruxolitinib or treatment with an antimetabolite drug called hydroxyurea.
16365848|NCT04217343||non-complement mediated pAMR(H+)|
16365849|NCT04217343||complement mediated pAMR(I+)|
16365850|NCT04217330|Experimental|Intervention|Pulmonary rehabilitation programs assigned to the intervention group will offer eligible participants the choice of participating in an 8-week program of either home-based pulmonary rehabilitation or traditional centre-based pulmonary rehabilitation.
16365851|NCT04217330|Active Comparator|Control|Pulmonary rehabilitation programs assigned to the control group will offer eligible participants the opportunity to participate in an 8-week centre-based pulmonary rehabilitation program, as per current practice.
16365852|NCT04217317|Experimental|CPI-613 in Combination with Bendamustine|CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.
16365853|NCT04217304|Experimental|Sonothrombolysis|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity® plus Sonothrombolysis
16365854|NCT04217304|No Intervention|Standard of Care|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity®
16365855|NCT04217291|Experimental|SY-004-1|a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week
16365856|NCT04217291|Experimental|SY-004-2|a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.
16365857|NCT04217291|Experimental|SY-004-3|a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.
16365858|NCT04217291|Placebo Comparator|placebo|a dose of SY-004 matching placebo taken orally
16365859|NCT04217278|Active Comparator|R1: Intermediate dose Cytarabine|First Randomisation - control arm: Intermediate dose Cytarabine (1g/m^2 administered by intravenous infusion over 2 hours on days 1-5 inclusive)
16365860|NCT04217278|Experimental|R1: Vyxeos|First Randomisation - experimental arm: Vyxeos (29mg/65mg/m^2 administered by intravenous infusion over 90 minutes on days 1 and 3)
16365861|NCT04217278|Active Comparator|R2: FB4|Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
16365862|NCT04217278|Experimental|R2: TBF|Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
16365863|NCT04217278|Active Comparator|R3: FB2|Third Randomisation - 55 years and over - control arm: Fludarabine (30mg/m^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
16365864|NCT04217278|Experimental|Mini-TBF|Third Randomisation - 55 years and over - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
16365865|NCT04217265|Experimental|study group|2 tablets of Letrozole 2.5 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
16365866|NCT04217265|Placebo Comparator|control group|2 tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum three doses
16365867|NCT04217252|Experimental|the experimental group|high throughput sequencing of infectious pathogens
16365868|NCT04217252|No Intervention|the control group|no intervention
16365869|NCT04217239|Experimental|Ivor-Lewis group|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
16365870|NCT04217239|Active Comparator|McKeown group|minimally invasive esophagectomy (MIE) with cervical anastomosis
16365871|NCT04217226||study group|adult patients (18-59 years), ASA I-II-III, scheduled for elective surgeries under general anaesthesia.
16365872|NCT04217213|Experimental|ropivacaine combined with mecobalamine|Intercostal nerve block with 0.5% ropivacaine combined with mecobalamine (0.5mg).
16365873|NCT04217213|Active Comparator|ropivacaine|Intercostal nerve block with 0.5% ropivacaine alone.
16365874|NCT04217187|Experimental|Electrical Stimulation Group|This arm will receive neuromuscular electrical stimulation to the antagonist muscles of the upper extremity.
16365875|NCT04217187|Sham Comparator|Sham Stimulation Group|This arm will receive sensory stimulation without muscle contraction to the antagonist muscles of the upper extremity.
16365876|NCT04217174|Experimental|Avatar intervention app|The intervention is a mobile phone app that features a realistic talking human avatar who promotes adherence to ART and retention in care, motivates, and provides information and opportunities for HIV care-related behavioral skills.
16365877|NCT04217174|Other|Control app|The control app is a mobile phone app that features a realistic talking human avatar who primarily promotes food safety and also offers knowledge of sugar content in food. This app is expected to have no effect on ART adherence and retention in care, however, it has never been tested to determine if it may have any effect so it has been categorized as Other (arm type) rather than as placebo.
16365878|NCT04217161|Experimental|Dexcom G6 Continuous Glucose Monitor|
16365879|NCT04217148|Experimental|ATRA and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and ATRA 10mg bid po, 12 consecutive weeks
16365880|NCT04217148|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
16365881|NCT04217135|Active Comparator|conventional treatment|This group will receive conventional evidence-based medications with up-titration to maximal tolerable dose. The evidence-based medications include angiotensin converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist, ivabradine and entresto. Which evidence-based medications will be started first depends on the decision of in-charge doctors without strict regulation. However, all evidence-based medications should be up-titrated to maximal tolerable dose. (Excuse me! Up-titration of evidence-based medications in heart failure isn't multiple intervention. Those medications should be prescribed in each heart failure case if no contraindication was noted.)
16366061|NCT04215809|Experimental|APG2575 1000 mg|APG2575 1000 mg ramp up
16365882|NCT04217135|Active Comparator|high-dose hydralazine group|another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred. Since the half-life of hydralazine is around 4-6 hours and 3-5 half-life achieves the steady blood concentration, up-titration of hydralazine will be done per 1-2 days. For example, initial dose of hydralazine would be 25 mg tid and the dose would be 50 mg bid next day if no adverse effect occurred. Following this rule, one week is enough to reach high-dose hydralazine with daily dose of 300-400 mg.
16365883|NCT04217122|Experimental|Strawberry intervention group|Participants consume two packages of 13 g of standard strawberry powder in the morning and afternoon/evening per day for 4 weeks
16365884|NCT04217122|Placebo Comparator|Placebo group|Participants consume two packages of 13 grams placebo powder in the morning and afternoon/evening for 4 weeks.
16365885|NCT04217109|Experimental|Odour sampling|Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).
16365886|NCT04217096|Experimental|paclitaxel liposome + S-1|paclitaxel liposome at 175 mg/m^2 on day 1; S-1 at a dose according to the body surface area（<1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；>1.50m^2,60mg Bid，d1-14，q3w）
16365887|NCT04217083||Colorectal cancer patients|Patients with histologically proven Colorectal cancer detected during the colonoscopy
16365888|NCT04217083||healthy controls|Patients with no sign of any colorectal disease who are submitted to colonoscopy
16365889|NCT04217057|Experimental|64Cu-DOTA-ECL1i-PET/CT|-64CU-DOTA-ECL1i-PET/CT imaging consisting of a dynamic scan centered at the level of the known tumor followed by a limited body scan of the head/neck and upper chest will be performed
16365890|NCT04217031||Decision variability assessment group|Patients with angiographically confirmed 3-vessel or left main disease will be enrolled. Patients data and heart team decision will be collected to analyze the variability between different heart team decisions.
16365891|NCT04217005|Experimental|experimental group|amputees or diabetics receiving intervention
16365892|NCT04216992||Three dimensional-rotational epidurography (3D-RE)|3D-RE is obtained on a commercial digital bi-plane angiography system. Reconstruction time was 30 seconds. Detailed information regarding technical performance and reconstruction procedure has been reported. Postprocessing techniques provided by the software included real-time 3D volume rendering and multiplanar reformatting. Real-time 3D volume rendering creates a 3D model of the examined object. The software allows emphasizing bony structures or soft tissue by changing intensity, brightness, and opacity of different X-ray structures. Additionally, rotation of the 3D object in all directions is possible, as is a virtual stereoscopic view provided by the software in combination with special glasses. The multiplanar reformatting modus generates virtual sections according to the three main axes and free defined axes. The section planes can be freely chosen, and curved sectioning is also possible.
16365893|NCT04216979|Experimental|randomization|Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
16365894|NCT04216979|Experimental|group A|these are the patient with palmars point as primary entry site
16365895|NCT04216979|Experimental|group B|these are the patient with umbilicus as primary entry site
16365896|NCT04216966|Placebo Comparator|Control group|This group did not undergo any instrumentation.
16365897|NCT04216966|Experimental|Gracey Curette group|Teeth under this group were subjected to debridement with Gracey curette .
16365898|NCT04216966|Experimental|After Five group|Teeth under this group were subjected to debridement with After 5 curette .
16365899|NCT04216966|Experimental|Mini Five group|Teeth under this group were subjected to debridement with Mini Five curette .
16365900|NCT04216953|Experimental|Atezolizumab + Cobimetinib|"Atezolimumab :
~Adult Patient and patients ≥12 years-old with a BW ≥60kg: 840mg, Q2W
~Pediatric Patient including patients ≥12 years-old with a BW <60kg: 15mg/kg, Q2W with a maximum of 840mg.
~Cobimetinib :
~Pediatric patients<12 years old: 1mg/kd, D1 to D21 over a 28-day cycle. A lower DL of 0.8mg/kg could be investigated. Maximal dose of 60mg/d. Pediatric patients ≥ 12 and a BW < 60kg:1mg/kg. Pediatric patients ≥ 12 and with a BW ≥ 60kg: 60mg/d.
~Adult Patients: 60mg/d D1 to D21 over a 28-day cycle."
16365901|NCT04216940|Experimental|M-pro|
16365902|NCT04216940|Experimental|Hyflex|
16365903|NCT04216927|Experimental|Nitric Oxide|Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care
16365904|NCT04216927|Placebo Comparator|Oxygen|Standard CPB without NO administered at any point intraoperatively
16365905|NCT04216914|Experimental|Use of hand outline for bone age xray|Where children and young people are having left hand X-rays for clinical purposes the radiographer will place a template under their hand. The plate is designed not to show up on the X-ray and to not interfere with the X-ray itself. They will be asked to match their hand to the hand outline on the template.
16365906|NCT04216888|Experimental|Open label|Open label intranasal ketamine
16365907|NCT04216875||single primary care practices intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility following the best practice procedure of the diabetes score.
16365908|NCT04216875||primary care group practice intervention|Independent primary care practices with more than one medical doctor working in their responsibility following the best practice procedure of the diabetes score.
16365909|NCT04216875||single primary care practices no intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility without the intervention (not using Diabetes score)
16365910|NCT04216875||primary care group practice no intervention|Independent primary care practices with more than one medical doctor working in their responsibility without the intervention (not using Diabetes score).
16365911|NCT04216862|Experimental|Strengthening exercise treatment|This exercise targets the deep flexor muscles of the upper cervical region the longus capitis and longus colli muscles.
16365912|NCT04216862|Active Comparator|Stretching exercise treatment|The subject's forearm is stabilized by a vertical plane before the trunk is rotated in the opposite direction. Therefore the arm on the involved side is externally rotated and abducted to 90.
16365913|NCT04216849|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.
16365914|NCT04216849|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
16365915|NCT04216836|Experimental|High magnesium diet (SUP condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
16365916|NCT04216836|Experimental|Low magnesium diet (CON condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
16365917|NCT04216823||Sevoflurane Group|sevoflurane is used for anesthetic induction
16365918|NCT04216823||Propofol Group|intravenous anesthetic propofol is used for anesthetic induction
16365919|NCT04216810|Active Comparator|Exercise group|Exercise group
16365920|NCT04216810|Experimental|Exercise group and dry cupping|Exercise and dry cupping
16365921|NCT04216797|Active Comparator|Oral Administration|10 mg diazepam tablets to be taken orally once daily for 4 weeks.
16365922|NCT04216797|Active Comparator|Rectal Administration|10 mg diazepam tablets to be taken rectally once daily for 4 weeks.
16365923|NCT04216784|Active Comparator|Furosemide (Lasix) alone|Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours
16365924|NCT04216784|Active Comparator|Combination of furosemide (Lasix) and albumin|Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours
16365925|NCT04216771|Experimental|IDA with ID Cytarabine|
16365926|NCT04216771|Active Comparator|ID Cytarabine|
16365927|NCT04216758|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
16365928|NCT04216758|Experimental|tegafur + gemcitabine|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; tegafur: Body surface area < 1.25 m^2, 60 mg/d; Body surface area ≥ 1.25 m^2 to < 1.5 m^2, 80 mg/d; Body surface area ≥ 1.5 m^2, 100 mg/d; Oral (po), Bid, D1-21
16365929|NCT04216732||Observational (questionnaire, blood pressure)|"AIM I & II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease.
~AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks."
16365930|NCT04216719|Experimental|OCM-RISE|Opioid court team provided external facilitation to generate action plans to develop and roll out or improve practice of the county opioid court.
16365931|NCT04216706||Tailored treatment advise in suboptimal adaptation|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment are invited to participate in a follow-up program at four time-points during a subsequent pregnancy (i.e. at 12, 16, 20 and 30 weeks of gestational age). This program is additive to regular pregnancy check-ups, and all women are otherwise managed by their referring physicians. The aim of this program is to evaluate adaptation of maternal hemodynamic parameters in response to pregnancy, and to adjust deviant adaptation with tailored antihypertensive medication. Participation in this program is on voluntary basis, and not restricted to severity of complications in the first pregnancy.
16365932|NCT04216706||Care as usual during pregnancy|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment who do not participate in the additional follow-up program.
16365933|NCT04216693|Experimental|Digoxin tablet|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
16365934|NCT04216693|Placebo Comparator|Placebo|Digoxin-like oral placebo
16365935|NCT04216667|Active Comparator|PVI|Pulmonary vein isolation alone will be performed using radiofrequency energy
16365936|NCT04216667|Experimental|PVI + PWI|Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
16365937|NCT04216667|Experimental|PVI + PWI + LAAEI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
16365938|NCT04216667|Experimental|PVI + PWI + LAAEI + CSI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy
16365939|NCT04216654||Group(A)|52 cases of type 2 diabetic patients.They have +ve Serum antibody and Stool antigen specific for Helicobacter pylori.
16365940|NCT04216654||Group(B)|36 cases of type 2 diabetic patients. They have +ve Serum antibody and -ve Stool antigen-specific for Helicobacter pylori.
16365941|NCT04216654||Group(C)|112 cases of type 2 diabetic patients. They have -ve Serum antibody and Stool antigen-specific for Helicobacter pylori.
16365942|NCT04216641|Experimental|Intervention arm|"At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert).
~For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food):
~The standard food.
~The food refers to a more elaborate texture.
~The food refers to a food with a stronger smell.
~The food refers to a more important flavor.
~The patient will indicate the version of the food that will be preferred."
16365943|NCT04216628|Other|Early amniotomy group|Amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.
16365944|NCT04216628|Other|Late amniotomy group|Oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion
16365945|NCT04216615||patients with preoperative anxiety|
16365946|NCT04216615||patients without preoperative anxiety|
16365948|NCT04216576|Active Comparator|Standard of Care|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
16365949|NCT04216576|Experimental|Standard of Care + Intervention|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
16365950|NCT04216563|Experimental|Treatment (asciminib)|Patients receive asciminib PO BID for up to 36 months while receiving standard of care dasatinib or nilotinib in the absence of disease progression or unacceptable toxicity. Patients may continue to receive asciminib after 36 months at the discretion of investigator.
16365951|NCT04216550||Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
16365952|NCT04216524|Experimental|Treatment (SL-401, venetoclax, chemotherapy)|See detailed description.
16365953|NCT04216511||Case-Lung Cancer|Patients with definite lung cancer diagnosis
16365954|NCT04216511||Control|Either patients with benign pulmonary nodule, or healthy individuals without pulmonary nodule but with risk factors to develop lung cancer matched to lung cancer group
16365955|NCT04216498||Pre-Transfer Patients aged 10-16 years|
16365956|NCT04216498||Post-Transfer Patients aged 16-25 years|
16365957|NCT04216498||Parents/Guardians of Pre-Transfer Patients|
16365958|NCT04216485|Experimental|Lifestyle intervention|Intervention group: Intensive lifestyle intervention will be initiated from the first trimester (8-12wks) to delivery, with follow up every 2-4 weeks. Participants in the intervention group will be provided with an individualized dietary protocol with not less than 1500 calories per day in the first trimester and not less than 1800 calories per day after 13 weeks of gestation. Guidance on regular exercise is reinforced at the first and each follow up visit.
16365959|NCT04216485|Active Comparator|Standard Care|Standard care group: Participants will receive a 1.5-hour group session in which standard prenatal intervention on diet, nutrition and physical activity and recommendation for gestational weight gain are reviewed by a registered dietitian. Thereafter, participants will receive their regularly scheduled follow up visits without additional lifestyle guidance.
16365960|NCT04216472|Experimental|Treatment (alpelisib, nab-paclitaxel)|Patients receive alpelisib PO QD on days 1-21, and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then undergo surgery to remove the tumor.
16365961|NCT04216459|No Intervention|Low risk group|no specific treatment will be given
16365962|NCT04216459|No Intervention|High risk control|no specific treatment will be given
16365963|NCT04216459|Active Comparator|High risk DP|patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
16365964|NCT04216459|Active Comparator|High risk CB|Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
16365965|NCT04216446|Experimental|Mobile Health Coaching Program during pregnancy|Eligible pregnant women would be randomized to intervention or the non-intervention arm after consenting to participate. Participants in the intervention arm will receive free subscription of m-Health program for six months of coaching. The program will provide individualized coaching on diet, supplement use and physical activity. Participants would undergo dietary screening at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow-up to monitor the improvement (if any) in diet, supplement use and physical activity. Women will receive advice in the form of recommendations after completing the questionnaire. Also, push messages containing tips and recommendations for diet, supplement use and physical activity would be delivered a maximum of three times a week. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line.
16365966|NCT04216446|No Intervention|Standard Counseling|"For the non-intervention arm, dietary counseling will be provided face to face by the trained research assistant at the baseline and scheduled follow-ups using the AKUH educational leaflet Diet during Pregnancy and American College of obstetricians and gynaecologists guidelines for physical activity. Alike intervention group, the non-intervention group will complete an interviewer based paperless screening questionnaire at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow up. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line."
16365967|NCT04216420|Experimental|Electronic pillbox-enabled self-administered therapy (SAT)|Participants in the intervention arm (n = 72) will receive 15 days of HRZE-isoniazid, rifampicin, pyrazinamide, and ethambutol-fixed-dose combination therapy in the evriMED500 medication event reminder monitor device (Wisepill Technologies, South Africa) for self-administration. When returned, providers will count any remaining tablets in the device, download the pill-taking data, and refill based on preset criteria. Participants can consult the provider in cases of illness or adverse events outside of scheduled visits.
16365968|NCT04216420|No Intervention|Standard directly observed therapy (DOT)|Providers handle participants in the control arm (n = 72) according to the standard DOT.
16365969|NCT04216407|Experimental|Remote Ischemic Preconditioning|Short-term tourniquet on to the lower extremity before surgery
16365970|NCT04216407|No Intervention|Control|No intervention
16365971|NCT04216368|Experimental|experimental group|
16365972|NCT04216368|Other|controlled group|
16365973|NCT04216355|Experimental|AZA with CAG derived regimen|Azacitidine 50mg/m²/day, D1-D5 (IV) Aclarubicin 5mg/m²/day, D1-D4 (IV) Cytarabine 10mg/m²/12h, D1-D6 (IV) G-CSF 5-10ug/kg/day, D1-D7 (SC)
16366062|NCT04215809|Experimental|APG2575 1200mg|APG2575 1200mg ramp up
16366063|NCT04215796|Experimental|ReX-C intervention|Subjects use ReX-C to receive CFTR modulators medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
16369443|NCT04192032|Experimental|Preferred flavor (3% nicotine)|Preferred flavored Juul pod (3% nicotine)
16365976|NCT04216316|Experimental|Arm A (pembrolizumab, gemcitabine, carboplatin, M6620)|Patients receive pembrolizumab IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes on day 1 and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab alone IV over 30 minutes on day 1. Cycles repeat every 6 weeks for up to 1 more year in the absence of disease progression or unacceptable toxicity.
16365977|NCT04216316|Active Comparator|Arm B (pembrolizumab, gemcitabine, carboplatin)|Patients receive pembrolizumab, gemcitabine, and carboplatin as in Arm A.
16365978|NCT04216290|No Intervention|Step I, Arm A (no intervention)|ARM A: Patients registered after completion of >= 3 cycles of induction chemotherapy proceed to Step 2 - Randomization.
16365979|NCT04216290|Experimental|Step I, Arm B (chemotherapy)|Chemotherapy naive patients receive 1 of 4 chemotherapy regimens: gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 every 21 days for 3 cycles; carboplatin IV over 30-60 minutes on day 1 and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 every 21 days for 3 cycles; gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and cisplatin IV 30-60 minutes on day 1 every 21 days for 3 cycles; or methotrexate IV over 3 minutes, vinblastine sulfate IV over 3 minutes, adriamycin (doxorubicin hydrochloride) IV over 5 minutes, and cisplatin IV over 30-60 minutes on day 1 every 14 days for 3 cycles. Cycles repeat in the absence of disease progression or unacceptable toxicity.
16365980|NCT04216290|Experimental|Step II, Arm C (durvalumab, radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice weekly for 6 weeks; cisplatin IV over 30-60 minutes for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
16365981|NCT04216290|Active Comparator|Step II, Arm D (radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice weekly for 6 weeks; cisplatin IV over 30-60 minutes for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
16365982|NCT04216290|Experimental|Step III, Arm E (durvalumab)|Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
16365983|NCT04216290|Active Comparator|Step III, Arm F (observation)|Patients previously randomized to Arm D who achieve clinical CR or clinical benefit, or patients previously randomized to Arm C with no clinical CR or clinical benefit undergo observation.
16365984|NCT04216277|Experimental|Procalcitonin in addition to usual care|Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care
16365985|NCT04216277|No Intervention|Usual care|Usual best standard care. No procalcitonin values disclosed to attending physician .
16365986|NCT04216264|Other|Response|
16365987|NCT04216264|Other|Non-response|
16365988|NCT04216251|Experimental|AMR101|"Study procedures include screening for eligibility and study treatment including ARM101 Lifestyle questionnaire, Nutritional survey. Flexible sigmoidoscopy (24 biopsies of normal colorectal mucosa, one stool sample),blood, evaluations, and follow up visits.
~- AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks"
16365989|NCT04216238||Cardiovascular surgical patients|Patients who received cardiovascular surgery and was released from the hospital due to meeting and exceeding a certain walking distance.
16365990|NCT04216199|Experimental|Point of care Ultrasound|Point of care Ultrasound for placement of endotracheal tube
16365991|NCT04216199|No Intervention|Traditional|Traditional method of insertion of endotracheal tube
16365992|NCT04216186|Active Comparator|Atomoxetine and Coenzyme Q|Atomoxetine and Coenzyme Q
16365993|NCT04216186|Placebo Comparator|Placebo and Atomoxetine|Placebo and Coenzyme Q
16365994|NCT04216173|Experimental|Acupuncture|
16365995|NCT04216160|Experimental|Verum|Patients with mild to moderate acne using ACN Cream
16365996|NCT04216160|Experimental|Placebo|Patients with mild to moderate acne using the placebo cream
16365997|NCT04216147|Experimental|PNE group|Patients received 4 sessions, separated one week between them. The treatment consisted the application of a galvanic current through an acupuncture needle (0,30x30mm). The approach were performed with a transverse axis with a needle in plane, being superficial and deep interface of medium nerve the target tissue. The parameters will be 2 mA (milliamps), 10 seconds, 3 impacts (3: 3: 3).
16365998|NCT04216147|Experimental|Surgery group|Patients received surgery for median nerve release.
16365999|NCT04216134|Experimental|Diagnostic (68GA-PSMA-11 PET)|Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.
16366000|NCT04216108|Experimental|23G gauge needle vitrectomy surgery|
16366001|NCT04216108|Experimental|27G gauge needle vitrectomy surgery|
16366002|NCT04216095|Active Comparator|Electroconvulsive Therapy (ECT)|Right unilateral (RUL, N=15), or Bitemporal (BT, N=15) ECT
16366003|NCT04216095|Active Comparator|Magnetic Seizure Therapy (MST)|High-dose magnetic seizure therapy (HD-MST)
16366004|NCT04216082|Experimental|Anlotinib|Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16366005|NCT04216069|Experimental|Total 12 regimen group|This group will use the following procedure: Colgate Ultrasoft toothbrush, Colgate Total 12 toothpaste and Plax Mouthwash.
16366006|NCT04216069|Experimental|Tooth brushing alone group|This group will use Colgate Ultrasoft toothbrush and Colgate Cavity Protection toothpaste.
16366064|NCT04215770|Active Comparator|Inj Co-amoxiclav|Group A children were advised Inj Co-amoxiclav 50 units/kg/day in 3 divided doses daily
16366007|NCT04216056|Experimental|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
16366008|NCT04216056|No Intervention|Control group|Subjects in the control group will be asked to maintain their usual diet and physical activity patterns over the 12 weeks.
16366009|NCT04216043|Experimental|RUSF skimmed milk powder|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
16366010|NCT04216043|Experimental|RUSF milk protein concentrate and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
16366011|NCT04216043|Experimental|RUSF soy protein and whey permeate|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
16366012|NCT04216043|Experimental|RUSF soy and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
16366013|NCT04216030|Experimental|High iron Irish potato|Meal sequence B, IP High Fe
16366014|NCT04216030|Active Comparator|Regular Irish potato|Meal sequence A, OFSP control
16366015|NCT04216017|Placebo Comparator|Controls|Patients receiving lidocaine
16366016|NCT04216017|Active Comparator|Cases|Patients receiving Kenalog
16366017|NCT04216004|Experimental|Full-fat dairy|3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
16366018|NCT04216004|Active Comparator|Non-fat diary|3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.
16366019|NCT04216004|Placebo Comparator|Non-dairy control|3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.
16366020|NCT04215991|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously on Day 1, in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
16366021|NCT04215991|Experimental|Multiple Dose Phase: Cefiderocol|"Participants will receive cefiderocol administered intravenously every 8 hours for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
~Dosage may be adjusted based on renal function."
16366022|NCT04215991|Active Comparator|Multiple Dose Phase: Standard of Care Alone|Participants will receive standard of care treatment according to local standards.
16366023|NCT04215978|Experimental|Phase 1a: BGB-A445 Monotherapy|Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 5 increasing dose levels on day 1 of each 21-day cycle
16366024|NCT04215978|Experimental|Phase 1a: BGB-A445 + Tislelizumab Combination Therapy|Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 3 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle
16366025|NCT04215978|Experimental|Phase 1b:BGB-A445 Monotherapy or Combination with Tislelizumab|Dose Expansion: Participants will receive recommended Phase 2 doses (RP2D(s)) of IV BGB-A445 alone or in combination with tislelizumab as determined from Phase 1a Dose Escalation
16366026|NCT04215965|Experimental|Experimental Standard citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
16366027|NCT04215965|Active Comparator|Conventionnal citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Prismocal B22 (calcium and phosphate free) in the dialysate mode, and Phoxilium in the postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
16366028|NCT04215952|Experimental|SFA Experimental Intervention|A modified version of Semantic Feature Analysis will be administered.
16366029|NCT04215952|Active Comparator|SFA Active Comparator Intervention|A standard version of Semantic Feature Analysis will be administered.
16366030|NCT04215939|Experimental|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366031|NCT04215939|Experimental|Thermoneutral environment participants with spinal cord injury|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366065|NCT04215770|Active Comparator|Inj Benzyl Penicillin|Group B patients were advised inj Benzyl Penicillin 25000 units/kg/day in 3 divided doses
16366131|NCT04215263||Geriatric patient underwent general anesthesia procedure|geriatric patients (≥60 years) ware assessed for cognitive impairment after general anesthesia for non-neurologic noncardiac surgery.
16366032|NCT04215939|Experimental|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366033|NCT04215939|Active Comparator|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366034|NCT04215939|Active Comparator|Thermoneutral environment healthy male participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366035|NCT04215939|Active Comparator|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366036|NCT04215939|Active Comparator|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366037|NCT04215939|Active Comparator|Thermoneutral environment healthy female participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366038|NCT04215939|Active Comparator|Warm enviroment healthy fmale participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
16366039|NCT04215926||HIV-monoinfected outpatients|No intervention; cross-sectional study
16366040|NCT04215913||Normal lung tissue|Normal lung tissue from PSC patients
16366041|NCT04215913||PSC tissues|PSC tissues from PSC patients
16366042|NCT04215913||Metastasis tissues|Metastasis tissues from PSC patients
16366043|NCT04215900|Experimental|High-Speed Multi-Directional Yoga|The duration of the intervention is 18 weeks, with 16 weeks of training.
16366044|NCT04215900|No Intervention|Waitlist control|During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.
16366045|NCT04215887||Sleep unit|Children admitted to sleep unit for sleep study
16366046|NCT04215887||School|Healthy children in school
16366047|NCT04215887||Emergency department|Children seen in triage in emergency department at SCH
16366048|NCT04215887||General practice|Adults or children attending general practice
16366049|NCT04215887||Ambulance|Adults or children in rapid response vehicle
16366050|NCT04215874||Dorsal penile nerve block group|"Ultrasound (US) guided dorsal penile nerve block with in plane technique was done.
~Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis."
16366051|NCT04215874||Caudal epidural block group|A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed 0.25% bupivacaine at a dose of 0.2 ml/kg was administered.
16366054|NCT04215835|Experimental|study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
16366055|NCT04215835|Placebo Comparator|control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
16366056|NCT04215822||acute myeloid leukemia patients - control group|acute myeloid leukemia
16366057|NCT04215809|Experimental|APG2575 200mg|APG2575 200mg ramp up
16366058|NCT04215809|Experimental|APG2575 400mg|APG2575 400mg ramp up
16366059|NCT04215809|Experimental|APG 2575 600mg|APG2575 600mg ramp up
16366060|NCT04215809|Experimental|APG2575 800mg|APG2575 800mg ramp up
16366066|NCT04215757|Experimental|Intervention group|"Patient received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.
~For L4 radiculopathy Saphenous nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For S1 radiculopathy Sural nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%)"
16366067|NCT04215757|Placebo Comparator|Control group|"Patients received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.
~For L4 radiculopathy Saphenous nerve block with 10ml distilled water For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 10ml distilled water For S1 radiculopathy Sural nerve block with10ml distilled water"
16366068|NCT04215744|Experimental|Ice water immersion group|Ice water immersion of the left hands(30 minutes before the infusion, during the infusion, and 30 minutes after the end of infusion).
16366069|NCT04215744|No Intervention|Control group|No intervention of the right hands as control.
16366070|NCT04215731|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive neoadjuvant mFOLFOXIRI plus bevacizumab once every two weeks for 4 cycles and the same mFOLFOXIRI for 2 cycles. After completing all 6 cycles chemotherapy, the patient will have an MRI scan to examine the tumor. If MRI restaging is ycT4a/b, or MRF involved, the patient will receive concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks). If MRI restaging is ycT0-3 and MRF negative, then the patient will proceed directly to surgery.
16366071|NCT04215731|Active Comparator|Induction FOLFOX Followed by Concomitant Chemoradiotherapy|Patients will receive induction FOLFOX chemotherapy for 4 cycles and followed by concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks), then the patient will proceed to surgery.
16366072|NCT04215718|Active Comparator|fistulotomy group|46 patients with simple anal fistula underwent fistulotomy and marsupialization of wound edges
16366073|NCT04215718|Active Comparator|fistulectomy group|46 patients with simple anal fistula underwent fistulectomy and closure of the wound
16366074|NCT04215705|Active Comparator|Group Q|Patients in this group receive Quadratus Lumborum Block with 20 ml bupivacaine 0.5%
16366075|NCT04215705|Active Comparator|Group L|Patients in this group receive peritubal local infiltration at 6 and 12 o'clock position with 20ml bupivacaine 0.5%
16366076|NCT04215692|Experimental|Ultrasound Guided Fluid Therapy|
16366077|NCT04215692|No Intervention|Conventional Fluid Therapy|
16366078|NCT04215679|Experimental|Three-dimensional immersive virtual reality application|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose mini Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
16366079|NCT04215679|Active Comparator|Motor imagery|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
16366080|NCT04215679|Active Comparator|Conventional physiotherapy|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
16366081|NCT04215666||Mild ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
16366082|NCT04215666||Moderate ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
16366083|NCT04215666||Severe ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
16366084|NCT04215653|Experimental|Anaprazole Sodium + Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
16366085|NCT04215653|Active Comparator|Rabeprazole +Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
16366086|NCT04215640|Experimental|MIFI group|Patients in the MIFI group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using microfidelity (MIFI) catheter.
16366087|NCT04215640|Active Comparator|Control|Patients in the control group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using conventional ablation catheter (Blazer II).
16366088|NCT04215614|Active Comparator|Group Lateral Sagittal|Ultrasound-Guided lateral sagittal brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
16366089|NCT04215614|Active Comparator|Group Costoclavicular|Ultrasound-Guided costoclavicular brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
16366090|NCT04215588|Active Comparator|Individualized heparin and protamine titration|The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).
16366125|NCT04215341|Experimental|1|The study contains a single arm. All children participating in the study will receive the primary intervention which is physiotherapy.
16366126|NCT04215328|Experimental|Mixed-Meal|Ensure Nutrition Shake
16366127|NCT04215328|Placebo Comparator|Electrolyte Solution|Pedialyte Solution
16366091|NCT04215588|Active Comparator|Activated Clotting Time guided heparin and protamine dose|Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)
16366092|NCT04215575|Active Comparator|BGI model 101-350 placement (BGI group)|A 350 mm2 Baerveldt glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.
16366093|NCT04215575|Experimental|AGV model FP7 or S2 placement (AGV group)|A 184 mm2 Ahmed glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits. The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures
16366094|NCT04215562|Other|patients with peripheral facial palsy|collection of data from records on the outcome of rehabilitation therapy on patients with peripheral facial palsy and types of complications associated with this therapy type
16366095|NCT04215549||Participants|OCD patients come from 13 hospitals located in the north, south, east and west of China
16366096|NCT04215536||DPP4i|Reference group
16366097|NCT04215536||Empagliflozin|Exposure group
16366098|NCT04215523||Dapagliflozin|Exposure group
16366099|NCT04215523||DPP-4 inhibitor|Reference group
16366100|NCT04215510|Experimental|endonasal endoscopic surgery group|143 participants in group 1 will undergo endoscopic surgery
16366101|NCT04215510|Active Comparator|radiation therapy group|143 participants in group 2 will undergo radiation therapy(IMRT)
16366102|NCT04215497|Experimental|Physiotherapeutic Scoliosis-Specific Exercises|PSSE group will receive corrective exercise for scoliosis
16366103|NCT04215497|No Intervention|Control|Control group will be taken to the queue list.
16366104|NCT04215484||P|P (previa) : pregnant women with placenta previa on ultrasound and no suggestive signs of placenta accreta
16366105|NCT04215484||I|I (abnormal placental Invasion) : pregnant women with placenta previa on ultrasound,and suggestive signs of placenta accreta on ultrasound with or without MRI
16366106|NCT04215484||N|N (placenta normally located) : pregnant women without suggestive signs of placenta previa or accreta on ultrasound
16366107|NCT04215471|Experimental|NeoAdjuvant Therapy With PD-L1 Antibody SHR-1316 group|Patients will receive the neoadjuvant therapy with SHR-1316 followed by the operation.
16366108|NCT04215458|Other|sample collection|Collection of samples investigating for yeast colonization in either patients with inflammatory skin disease or healthy controls.
16366109|NCT04215445|Active Comparator|Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
16366110|NCT04215445|Active Comparator|Non-Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
16366111|NCT04215432|Experimental|Test group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water, Propolis Extract (2%), Ascorbic Acid (0.2%) and Tocopherol Acetate (0.2%).
16366112|NCT04215432|Placebo Comparator|Placebo group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water and E155/151 coloring.
16366113|NCT04215406||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
16366114|NCT04215393|Experimental|Conbercept eye drop (0.1mg/ mL)|Subjects in this arm will receive 0.1mg/mL Conbercept eye drop 4 times a day, one drop at a time.
16366115|NCT04215393|Experimental|Conbercept eye drop (0.5mg/ mL)|Subjects in this arm will receive 0.5mg/mL Conbercept eye drop 4 times a day, one drop at a time.
16366116|NCT04215393|Experimental|Conbercept eye drop (1.0mg/ mL)|Subjects in this arm will receive 1.0mg/mL Conbercept eye drop 4 times a day, one drop at a time.
16366117|NCT04215380|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form as 30-grams-dose for 12 weeks
16366118|NCT04215380|Placebo Comparator|Control group|This group will be provided with pectin powder provided as two-gram-dose fo
16366119|NCT04215367|Experimental|High phenolic EVOO intake|Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,
16366120|NCT04215367|Experimental|No High phenolic EVOO intake|Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.
16366121|NCT04215354|Experimental|MAGNET GROUP|Patients were exposed to very low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional using magnet mattress.
16366122|NCT04215354|Experimental|VIRTUAL REALITY|"Balance training was done using the Wii Fit plus machine which required balance board .Using video game console designed by Nintendo.
~The program consisted of three games: soccer heading, ski slalom and table tilt."
16366123|NCT04215354|Active Comparator|PLACEBO|Patients in the placebo group had identical program to magnet group. They were asked to lie down in the magnet mattress; however, the magnet was not switched on and the patient doesn't know (blind).
16366124|NCT04215354|No Intervention|HEALTHY SUBJECT|healthy subjects with age, gender and BMI matched with the patients with MS were recruited to participate in the study. This group was recruited to establish the normal balance and fatigue parameters. Subjects in this group sign the consent form of healthy subjects and all measurement was taken as balance, fatigue, depression, quality of life and urinary incontinence screening questionnaire.
16366132|NCT04215250|Active Comparator|Andropulous method|"Andropulous method uses equations to determine the depth of CVC insertion.
~For subject with <100 cm in height:
~Depth of CVC insertion (cm) = (height (cm)/ 10)-1
~For subject with >100 cm in height:
~Depth of CVC insertion (cm) = (height (cm)/ 10)-2"
16366133|NCT04215250|Active Comparator|ECG method|change in p wave from ECG
16366134|NCT04215237|Other|Atorvastatin regulates intestinal flora|
16366135|NCT04215198|Experimental|Move3™ (NEM + fish oil)|NEM, 500 mg, #0 capsule, + fish oil, 1,500 mg, softgels, once daily orally for 2 weeks
16366136|NCT04215198|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, + placebo oil, 1,500 mg, softgels, once daily orally for 2 weeks
16366137|NCT04215185|Experimental|Blood pressure monitor|Non-anesthetized subjects in the ICU (Intensive Care Unit) or in the CICU (Cardiac Intensive Care Unit) with arterial line placement in the radial artery will be fitted with the CardiacSense 1BP device. The first measurement will be of up to 24h. Subsequent measurements will be of up to 5h.
16366138|NCT04215172||macrolides group|"Every patient of this group will be educated and instructed about usage, dosing and side effects of the drug.
~Dose: azithromycin 500 mg three times weekly for 6 months. added to the conventional treatment."
16366139|NCT04215172||conventional group|Every patient of this group will receive the conventional treatment.
16366140|NCT04215159|Experimental|Samfenet and Treatment of physician's choice|"Samfenet : 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
~Treatment of physician's choice (Gemcitabine or Irinotecan)
~Gemcitabine : 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
~Irinotecan : 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks."
16366141|NCT04215146|Active Comparator|Cohort 1|Patients receive paclitaxel alone.
16366142|NCT04215146|Experimental|Cohort 2|Patients receive pelareorep + paclitaxel.
16366143|NCT04215146|Experimental|Cohort 3|Patients receive pelareorep + paclitaxel + avelumab.
16366144|NCT04215133|Experimental|İnspiratory muscle training group|
16366145|NCT04215133|Experimental|Calf muscle training group|
16366146|NCT04215133|No Intervention|Control|
16366147|NCT04215120|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
16366148|NCT04215120|Experimental|Epoetin Injection|Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
16366149|NCT04215107|Other|Control group|Crossover study Group. Each patient will be examined 2 seperate days. Randomized to standard breakfast meal or prolonged fasting. The examinator will be blinded to patient meal status.
16366150|NCT04215107|Other|IUGR group|Will only be examined one day. First ultrasound during fasting, and the second ultrasound 2 hours after a standard breakfast meal.
16366151|NCT04215081|Experimental|ExoAtlet II Safety and Efficacy|20 participants with paraplegia from SCI will participate in gait training using ExoAtlet II powered exoskeleton.
16366152|NCT04215055|Active Comparator|study group|Group I (study group); children receiving intraoral injection of local anasethia using the vibration assisted syringe.
16366153|NCT04215055|Active Comparator|control group|Group II (control group): children receiving intraoral injection of local anasethia using the standard syringe.
16366154|NCT04215042|Active Comparator|Standard hydration|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and 6 hours after procedure
16366155|NCT04215042|Experimental|Short hydration|All patients received shot intravenous saline hydration (3 ml/kg for 1 hour before the procedure and after 1ml/kg/h for 6 hours)
16366156|NCT04215029|Experimental|Group I (exercise plan, coaching calls, nutrition counseling)|Patients and their partners receive an exercise plan and printed materials that includes instructions for walking or other moderate-intensity activities. Patients and their partners also receive coaching calls discussing physical activity and diet related questions, each lasting 45-60 minutes and occurring every 2 weeks for 6 months. In addition, patients and their partners complete 2 nutrition counseling sessions over 1 hour each at baseline and before month 3 with an MD Anderson registered dietitian.
16366157|NCT04215029|Active Comparator|Group II (physical activity/healthy eating information)|Patients and their partners receive information/materials regarding physical activity and healthy eating.
16366158|NCT04215029|Experimental|Provider Interviews (interviews)|Healthcare providers participate in an interview regarding their opinions on family-focused care and its ability to improve health behaviors.
16366159|NCT04215016|Experimental|Humanized anti-CD19 and anti-CD20 dual specific CAR-T cells|
16366160|NCT04215003|Active Comparator|A|6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.
16366161|NCT04215003|Experimental|B|2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery
16366162|NCT04215003|Experimental|CL1|If patients were HR+ and HER2- without PI3K-AKT pathway mutation
16366163|NCT04215003|Experimental|CL2|If patients were HR+ and HER2- with PI3K-AKT pathway mutation
16366164|NCT04215003|Experimental|CLH1|If patients were HR+ and HER2+ without PI3K-AKT pathway mutation
16366165|NCT04215003|Experimental|CLH2|If patients were HR+ and HER2+ with PI3K-AKT pathway mutation
16366166|NCT04215003|Experimental|CH1|If patients were HR- and HER2+ without PI3K-AKT pathway mutation
16366167|NCT04215003|Experimental|CH2|If patients were HR- and HER2+ with PI3K-AKT pathway mutation
16366168|NCT04215003|Experimental|CT1|If patients were HR- and HER2- with LAR subtype
16366169|NCT04214990|Active Comparator|Aspirin|Enteric coated aspirin
16366170|NCT04214990|Placebo Comparator|Placebo|Enteric coated aspirin placebo
16366171|NCT04214977|Experimental|group S|Patients in group S had spinal anesthesia in the sitting position under complete aseptic technique through a standard mid-line approach. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
16366172|NCT04214977|Experimental|group L|Patients in group L received standard general anesthesia. Proper (weight-based) classic laryngeal mask airway was then blindly inserted.
16366173|NCT04214964||Gynecological cancer|patients who has been pathological diagnosed with Gynecological cancers between 2002 and 2022 in China
16366367|NCT04213625|No Intervention|Control Group|Information sheet with only their surgeon's educational background.
16366174|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
16366175|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.
16366176|NCT04214938|Active Comparator|Hypertonic sea water|The patient was applied intranasal hypertonic sea water (3.5% sodium chloride) before the nasoendoscopy procedure.
16366177|NCT04214938|Active Comparator|Lidocaine|The patient was applied intranasal Vemcaine as TLA (10% lidocaine; AstraZeneca, Södertälje, Sweden) before the nasoendoscopy procedure.
16366178|NCT04214938|Active Comparator|Xylometazoline|The patient was applied intranasal Otrivine (0.1% xylometazoline hydrochloride, GlaxoSmithKline, Brentford, UK ) before the nasoendoscopy procedure.
16366179|NCT04214938|Placebo Comparator|0.9% Sodium chloride|The patient was applied intranasal placebo (0.9% sodium chloride) before the nasoendoscopy procedure.
16366180|NCT04214925|Experimental|Group of Tai Chi intervention|Tai Chi exercise program will create by selecting the first-basic 10 forms from 24 short forms of Yang style. The forms' name: Beginning, Parting the Horse's Mane, Stork Spreading Its Wings, Brushing Your Knees and Stepping, Playing The Pipes, Fending Off the Monkey, Grasping the Sparrow's Tail Left, Grasping the Sparrow's Tail Right, Simple Whip, Moving Hands Like Clouds-Conclusion. All forms will be completed at 10 weeks. Each session will take 1 hour (15 min for warming up exercises, 30 min of Tai Chi forms, and 15 min for cooling down exercises). The 14 patients of SS in this group will be divided into two groups of 7.
16366181|NCT04214925|Other|Group of home exercises|The home exercise group will receive a one-hour home program, 2 days a week. The first and last 15 minutes of the exercise program will consist of warm-up and cooling- down exercises. After warm-up exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles will be performed 10 times each for 30 minutes.
16366182|NCT04214912|No Intervention|General module|"General module will serve as a roadmap plan which will cover the most common problems and major issues related to current and future treatments, side effects, psychological distress, daily function and physical condition. The contents will be developed based on empirical review, our current research findings in Taiwan, OC health care experts' suggestions."
16366183|NCT04214912|Experimental|Personalized module|Personalized Survivor Care Plan (PSCP) will deliver based on what we assess or interview about patients' distress, concerns and care needs in each interview or/and assessment. We will assess OC patients of the above items by valid assessment tools. For the factors or concerns about RTW assessment, we will develop and test a modified instrument for the study purpose. For each assessment, the computer -assisted assessment will help the OC educator to immediately catch the patients care distress and care needs. It will provide the direction for caring of their personalized distress, concerns and needs.
16366184|NCT04214886|Experimental|CAR 5 x 105 transduced T cells/kg (Dose Level -1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 5 x 105 transduced T cells/kg.
16366185|NCT04214886|Experimental|CAR 1 x 106 transduced T cells/kg (Dose Level 1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1 x 106 transduced T cells/kg.
16366186|NCT04214886|Experimental|CAR 1.5 x 106 transduced T cells/kg (Dose Level 2)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
16366187|NCT04214886|Experimental|CAR 2 x 106 transduced T cells/kg (Dose Level 3)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 2 x 106 transduced T cells/kg.
16366188|NCT04214873|Experimental|POH|Treatment of POH Using PiQo4 Laser System
16366189|NCT04214860|Experimental|APR-246|APR-246 4.5 g/day
16366190|NCT04214847|Experimental|polypropylene plate of Ahmed Glaucoma Valve|polypropylene plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The polypropylene plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
16366218|NCT04214691|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
16366219|NCT04214678|Experimental|Underwater clip closure|The post-resection defect is closed using endoscopic clips with underwater technique
16366220|NCT04214678|Active Comparator|Conventional clip closure|The post-resection defect is closed using endoscopic clips with conventional gas insufflation (CO2)
16369444|NCT04192032|Experimental|Preferred flavor (0% nicotine)|Preferred flavored Juul pod (0% nicotine)
16366191|NCT04214847|Active Comparator|silicone plate of Ahmed Glaucoma Valve|silicone plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The silicone plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
16366192|NCT04214834|Active Comparator|Rapid-wean|15% decrements from the stabilization dose of morphine/methadone
16366193|NCT04214834|Active Comparator|Slow-wean|10% decrements from the stabilization dose of morphine/methadone
16366194|NCT04214821|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366195|NCT04214821|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366196|NCT04214821|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366197|NCT04214821|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection
16366198|NCT04214821|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366199|NCT04214821|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366200|NCT04214821|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366201|NCT04214821|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366202|NCT04214808|Experimental|Avodart Soft Capsule 0.5mg to AD-208|Period 1: Avodart Soft Capsule 0.5mg, 1 Capsule Period 2: AD-208, 1 tab
16366203|NCT04214808|Experimental|AD-208 to Avodart Soft Capsule 0.5mg|Period 1: AD-208, 1 tab Period 2: Avodart Soft Capsule 0.5mg, 1 Capsule
16366204|NCT04214795||Infants born after a complete course of antenatal steroids.|Preterm Infants born with less than 32 w GA whose mothers had received a complete course (two doses of celestone in the period between 24 hours and 7 days before delivery.
16366205|NCT04214795||Infants born without a complete course of antenatal steroids|Preterm Infants born with less than 32 w GA whose mothers did not received any dose of celestone or an uncompleted course (less than 24 hours or more than 7 days from delivery).
16366206|NCT04214782|No Intervention|Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images without the help of Artificial Intelligence (AI) algorithm
16366207|NCT04214782|Experimental|AI enabled Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images with the help of Artificial Intelligence algorithm
16366208|NCT04214769||Head and Neck Cancer patients|
16366209|NCT04214756||AP Diagnosis before guidelines|All patients diagnosed with acute pancreatitis that were treated between August 2011 and December 2014 before guidelines were implemented.
16366210|NCT04214756||AP Diagnosis after guidelines|All patients diagnosed with acute pancreatitis that were treated between January 2015 and October 2018.
16366211|NCT04214730|Experimental|Combination of NK with chemotherapy group|Patients will receive NK treatments combined with Chemotherapy.
16366212|NCT04214730|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
16366213|NCT04214717|Experimental|Combination of DC-CIK with chemotherapy group|Patients will receive DC-CIK treatments combined with Chemotherapy .
16366214|NCT04214717|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
16366215|NCT04214704|Experimental|Genteel arm|In the Genteel arm, the subjects exclusively use the Genteel device for the first 12 weeks, and then switch to the conventional method of SMBG for an additional 12 weeks. This arm will use Butterfly Touch Lancets (BTL) throughout the study.
16366216|NCT04214704|Active Comparator|Conventional arm|In the Conventional arm, the subjects use the conventional method of SMBG for the first 12 weeks and then switch to the Genteel device for an additional 12 weeks. This arm will use the lancet and lancing device which they were using prior to randomization to the study.
16366217|NCT04214691|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
16366221|NCT04214665|Experimental|Test/Reference|Single dose of test tablet in period I. Followed by single dose of reference tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
16366222|NCT04214665|Experimental|Reference/Test|Single dose of reference tablet in period I. Followed by single dose of test tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
16366223|NCT04214652|Experimental|IDP-126 Gel|
16366224|NCT04214652|Placebo Comparator|IDP-126 Vehicle Gel|
16366225|NCT04214639|Experimental|IDP-126 Gel|
16366226|NCT04214639|Placebo Comparator|IDP-126 Vehicle Gel|
16366227|NCT04214626|Experimental|R-CHOP regimen Combined With Lenalidomide|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.
~PS: Methotrexate, 3mg/m2, Intravenous administration on day 3 of each 3-week cycle, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
~Maintenance Treatment: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 4 weeks, up to 2 cycles; Lenalidomide, 10mg oral administration on day 1 to 21 repeated every 4 weeks, up to 12 cycles."
16366228|NCT04214600|Experimental|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
16366229|NCT04214600|No Intervention|Control|This group will be scheduled the same number of visits as a follow up for diabetes
16366230|NCT04214587||baseline assessment group|n=150 patiënts for baseline assessment
16366231|NCT04214587||clinical need for reintervention group|n=20-30 patiënts for re-bronchoscopy
16366232|NCT04214587||clinical stable controls|n=20 stable treated control patiënts
16366233|NCT04214574|Experimental|Real time ultrasound-guided Parasagittal oblique technique|
16366234|NCT04214574|Experimental|Real time ultrasound-guided paramedian tranverse technique|
16366235|NCT04214561||SB group|Patients diagnosed with SB.
16366236|NCT04214561||Healthy controls|Patients without diagnosed SB.
16366237|NCT04214548||Eczema|Patients diagnosed with eczema
16366238|NCT04214535|Experimental|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Cervical Cage at one or two-levels
16366239|NCT04214522||Acute stroke patients|Acute stroke patients
16366240|NCT04214509||PD + LRRK2|Patients with LRRK2-associated Parkinson's syndrome
16366241|NCT04214509||no PD + LRRK2|Participants with LRRK2-mutations but without Parkinson's symptoms
16366242|NCT04214509||no PD + no LRRK2|Participants without mutations and without Parkinson's symptoms
16366243|NCT04214509||PD+ other than LRRK2|Parkinson patients with mutations in other genes than LRRK2
16366244|NCT04214509||PD+ no LRRK2|Patients with idiopathic Parkinson's disease
16366245|NCT04214496||Postoperative Delirium Risk Patients|Preoperative cognitive function testing- EEG monitorization during surgery - Postoperative function testing
16366246|NCT04214483||Diagnosis of Acne|Patients who have been diagnosed with acne, subdivided into the various types.
16366247|NCT04214470||Irritable Bowel Syndrome Patients|Patients with IBS.
16366248|NCT04214457||Myometrial tumor with suspected leiomyosarcoma|Women between 18 and 75 years of age diagnosed with a myometrial tumor (probably leiomyoma) with suspected leiomyosarcoma
16366249|NCT04214444|Active Comparator|Single-dose before treatment|12 patients will receive a single-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection
16366250|NCT04214444|Active Comparator|Single-dose after treatment|12 patients will receive a singe-dose of prevenar three weeks after the beginning of the immunochemotherapy (R-CHOP) following two months later by pneumovax injection
16366251|NCT04214444|Experimental|Double-dose before treatment|12 patients will receive a double-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection.
16366252|NCT04214431|Experimental|Mindfulness-Based Childbirth Education|Women in the experimental group received eight week mindfulness-based childbirth education program delivered one class each week.
16366253|NCT04214431|No Intervention|Control group|Women in the control group received standardized care.
16366258|NCT04214392|Experimental|Treatment (CAR T cell therapy)|Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one or two CAR T cell infusions (one at each catheter site) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
16366259|NCT04214379|Other|severe congenital ptosis|Patients with severe congenital ptosis with poor levator muscle function
16366260|NCT04214366|Experimental|Carbon Ion irradiation|22 x 3 Gy(RBE) Carbon Ions
16366261|NCT04214366|Active Comparator|Bimodal Arm|25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
16366262|NCT04214353|Experimental|Experimental arm|Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
16366322|NCT04213950|No Intervention|Historical control group|The historical control group received care prior to implementation of the quality improvement bundle.
16366323|NCT04213937|Experimental|nab-paclitaxel|nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles
16366324|NCT04213937|Active Comparator|Topotecan|Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
16366325|NCT04213924|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
16366263|NCT04214327|Active Comparator|Strengthening Families Program Online eLearning Game|This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
16366264|NCT04214327|Active Comparator|SFP Home-use DVD/video series|"This arm of the study receives an 11-session home-use DVD or coupon code for viewing the SFP videos online at home that contains the same SFP skills and lesson content as the online condition. However, the lesson material is not animated and involves simply viewing the videos at home. This arm represents an attention-control condition as the requirements of participation and exposure to the intervention will match the online condition, as participants use the Internet or a DVD player to view lesson material in a self-paced format. There are no differences in recruitment for this condition; all assignment to experimental conditions is based on their recruiter's location using a randomized control trial design. Participants in this condition will be provided a hyperlink URL to answer pre- and posttest assessments and at the 3-month follow-up. Process evaluation materials will be delivered via a hyperlink to a commercial survey vendor during the trial and at the conclusion."
16366265|NCT04214327|Active Comparator|Wait-Listed Control|"This arm of the study receives no active intervention for the initial intervention period of 22 weeks; however, following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention. During the initial trial of 22 weeks, participants in this condition receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. The intent of these weekly emails is to stimulate continued participation and reduce attrition.
~Individual families will be randomly assigned to one of the three interventions with a computerized random number generator."
16366266|NCT04214327|No Intervention|SFP Group Norms|This arm of the study provides a means to conduct a non-inferiority trial contrasting the active intervention conditions (SFP Online and Home-use DVD/videos) to the traditional 14-session in-person group-delivery format, which serves as a benchmark of effectiveness for SFP. There is no data collection as the Group Norms are part of an existing database of families that already took SFP classes. All effect size comparisons are conducted using secondary data analysis. The expected margin of equivalence is set at 10% so that any condition that exceeds another in the magnitude of effect size is considered as 'good as' the comparison condition. All effect sizes will be adjusted for demographic and site-specific factors to control for clustering and within-site contextual factors that can influence program outcomes.
16366267|NCT04214314||Control|The control group will continue to receive the integral rehabilitation provided by the center.
16366268|NCT04214314||Experimental|The participants of the experimental group, in addition to the integral rehabilitation of the center will receive the training of the attention through NeuronUp APT. There will be 3 rehabilitation sessions of one hour a week for about a month and a half or two.
16366269|NCT04214301|Experimental|BLI800|BLI800
16366270|NCT04214288|Experimental|AZD9833 Dose A|The patients will receive AZD9833 (Dose A).
16366271|NCT04214288|Experimental|AZD9833 Dose B|The patients will receive AZD9833 (Dose B).
16366272|NCT04214288|Experimental|AZD9833 Dose C|The patients will receive AZD9833 (Dose C).
16366273|NCT04214288|Active Comparator|Fulvestrant 500 mg|The patients will receive Fulvestrant (500 mg).
16366274|NCT04214275|Experimental|intervention group|standard care and participated in a pulmonary rehabilitation program
16366275|NCT04214275|No Intervention|control group|received standard care after coronary artery bypass graft
16366278|NCT04214249|Experimental|Arm I (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
16366279|NCT04214249|Active Comparator|Arm II (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
16366280|NCT04214236|Experimental|ciNPT group|Subjects will receive post-operative incisional wound care by ciNPT (125 mmHg, continuous suction) for the first 7 days after surgery.
16366281|NCT04214236|Sham Comparator|Control group|Subjects will receive post-operative incisional wound care by standard non-adherent surgical dressing (vaseline petrolatum gauze),
16366282|NCT04214223||PANE -> PAC|First, the patient carry out her Pre-Anesthesic Numerical Evaluation and then she benefits from her Pre-Anesthesic Consultation.
16366283|NCT04214223||PAC -> PANE|First, the patient benefits from her Pre-Anesthesic Consultation and then, she carry out her Pre-Anesthesic Numerical Evaluation
16366284|NCT04214210|Experimental|Tailored Family Gene Toolkit|"The tailored FGT will include 5 modules designed to increase knowledge of cancer genetics (1); provide decisional support for genetic testing (2); increase active coping to challenges faced by HBOC families (3); provide a 5-steps, skills-building communication training (4); and provide information about management of hereditary cancer risk (5).
~Messages will involve shallow tailoring (e.g. sex of mutation carrier), and deep tailoring with complex elements of relevance (e.g. coping style). Tailoring will be based on personalization, tailored feedback, and content matching, based on Swiss and Korean languages and legislation, health insurance policy, and cultural values.
~Participants will be asked to complete the 5 modules within 4 weeks after they first engage with the intervention. The 4-week interval will enable learning new information while having time to reflect and act. They will receive email alerts to complete the 5 modules with the URL link directing them to the FGT."
16366326|NCT04213924|Active Comparator|Group NSAII|lidocaine 5% gel and 800 mg ibuprofen intravenously
16366327|NCT04213911||Morbid obese|BMI>40 kg/m2
16366328|NCT04213911||Non-obese|BMI<30 kg/m2
16366285|NCT04214210|Active Comparator|Targeted intervention|The comparator will provide targeted information about HBOC and enable sharing genetic test results. The Korean team will define the contents of the comparator that will mimic the structure and function of an existing website, already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and the three Swiss national languages. Both trial arms the tailored and the targeted platform will be technically implemented in the same system, in order to track access and usage of the platform and provide a user-friendly experience to participants. The Swiss team will also provide the implementation of the comparison website.
16366286|NCT04214197|Other|Crisaborole|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
16366287|NCT04214184|Experimental|Increased Sleep Duration Intervention|Following baseline assessments, participants will complete a 4-week increased sleep duration intervention followed by one night of sleep in the lab on this increased sleep duration schedule. In the morning, participants will have blood collected for metabolomics analyses and complete oral glucose tolerance testing
16366288|NCT04214171||group 2 years|The group underwent total hip arthroplasty at 2 years
16366289|NCT04214171||group 5 years|The group underwent total hip arthroplasty at 5 years
16366290|NCT04214171||group 10 years|The group underwent total hip arthroplasty at 10 years
16366291|NCT04214171||group control|healthy patients
16366292|NCT04214158||Professional Folk Dancers|Individuals who have been actively dancing for at least two years will be included in the study.
16366293|NCT04214158||sedentary|According to the international physical activity questionnaire, individuals with low levels of physical activity will be included in the study.
16366294|NCT04214145|Experimental|Phenylephrine|
16366295|NCT04214145|Experimental|Norepinephrine|
16366296|NCT04214145|Experimental|Vasopressin|
16366297|NCT04214132|Experimental|virtual patients group|Only nursing undergraduates from AY2017/2018 cohort, who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module will receive additional training using Virtual Patients in each semester (2 semesters per year) of year 2 and year 3 before they go for the clinical posting. Students will have unlimited access to the Virtual Patients (available scenarios depend on which semester the student is in) by logging in through the school portal.
16366298|NCT04214132|No Intervention|Blended learning group|Nursing undergraduates from AY2016/2017 cohort who who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module that comprised of weekly online e-lectures and face-to-face tutorials.
16366299|NCT04214119||Control|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and does not have a diagnosis of Barrett's esophagus or esophageal/gastric malignancy.
16366300|NCT04214119||Barrett's esophagus|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and diagnosed with Barrett's esophagus via pathology.
16366301|NCT04214119||Esophageal carcinoma|Patients age 18 or greater who have diagnosis of primary esophageal carcinoma.
16366302|NCT04214119||Gastric cancer|Patients age 18 or greater who have diagnosis of primary esophageal cancer.
16366303|NCT04214106||Thiamine group|group 1: ICU patients who did not receive IV thiamine
16366304|NCT04214106||Non-thiamine group|group 2: ICU patients who received IV thiamine,100-500 mg/day for at least one day
16366305|NCT04214093|Experimental|Arm A|Dose escalation for patients with solid tumors, lymphoma and multiple myeloma with low risk of TLS. Each cohort within Arm A will test a single dose level.
16366306|NCT04214093|Experimental|Arm B|Dose escalation for patients with hematologic malignancies with an intermediate to high risk of TLS. Intrapatient dose ramp-ups within each cohort will be used.
16366307|NCT04214080|Experimental|Study Group (SG)|"In addition to feeding and oral motor intervention strategies, intensive neck and trunk stabilization exercises based on Neurodevelopmental treatment-Bobath (NDT-B) concept principles were applied to this group.
~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
16366308|NCT04214080|Placebo Comparator|Control Group (CG).|"(NDT-B) concept approaches and feeding and oral motor intervention strategies were applied to this group in routine treatment.
~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
16366311|NCT04214054|Experimental|Moldable self-hardening biphasic calcium phosphate graft|Easy graft, a moldable osteocondutive allograft formed of 60% hydroxylapatite and 40% β-tricalcium phosphate (Easy-graft, Sunstar, Gruidor, Degradable solutions AG, Swizerlard).
16366312|NCT04214054|Placebo Comparator|No graft material|
16366313|NCT04214041|Experimental|Autologous fat grafting|
16366314|NCT04214041|Active Comparator|Sub-epithelial connective tissue graft|
16366315|NCT04214028||Maviret Participants|Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
16366316|NCT04214015||Patients with metastatic mesothelioma|Patients who have been diagnosed with metastatic mesothelioma
16366317|NCT04213989|Active Comparator|Conservative Care|Conservative care (may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT)
16366318|NCT04213989|Experimental|Flexitouch Plus and Conservative Care|Flexitouch Plus with conservative care
16366319|NCT04213976||Ileostomy in continuity|Paediatric patients having had an ileostomy in continuity as part of the treatment for a complex intestinal obstruction, as described by Santulli or by Bishop-Koop.
16366320|NCT04213976||Conventional ileostomy|Paediatric patients having had a loop ileostomy as part of the treatment for a complex intestinal obstruction.
16366321|NCT04213950|Experimental|Post-implementation group|The post-implementation group will receive care that is enhanced by the rabies PEP quality improvement bundle.
16366329|NCT04213898|Experimental|SHR-1210+Albumin-bound paclitaxel+Epirubicin|Neoadjuvant therapy：SHR-1210+Albumin-bound paclitaxel+Epirubicin
16366330|NCT04213885|Experimental|Pulsed Accelerated|30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
16366331|NCT04213885|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
16366332|NCT04213872|Experimental|Meditative Movement (MM)|The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.
16366333|NCT04213859|Experimental|Virtual Reality Exposure Therapy (VRET)|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.
~nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm).
~rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session.
~th stage: After treatment, participants will complete measures of fear of flying and emotional variables."
16366334|NCT04213859|No Intervention|control|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.
~nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm)
~rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period.
~th stage: Participants will complete measures of fear of flying and emotional variables."
16366335|NCT04213846|Experimental|Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive twice daily intervention messages for three weeks and have access to other psycho-educational alcohol information.
16366336|NCT04213846|No Intervention|Assessment-only Control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
16366337|NCT04213833|Placebo Comparator|group I (control group)|patients will receive propofol 50 mg
16366338|NCT04213833|Active Comparator|group II|patients will receive propofol 50 mg + dexmedetomidine 0.5 mcg/ kg
16366339|NCT04213833|Active Comparator|group III|patients will receive propofol 50 mg +15 g palatable lidocaine gel
16366340|NCT04213820|Active Comparator|Treatment as usual|Participants will receive treatment as usual at the eating disorder unit at the Child and adolescent psychiatric clinic and at the Psychiatric clinic during 4 weeks.
16366341|NCT04213820|Experimental|TMS and body image intervention|Participants will receive TMS and a body image intervention daily 5 times/week during 4 weeks
16366342|NCT04213820|Sham Comparator|sham TMS and body image intervention|Participants will receive sham TMS and a body image intervention Daily 5 times/week during 4 weeks
16366343|NCT04213807|Experimental|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
16366344|NCT04213807|Placebo Comparator|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
16366345|NCT04213794|Experimental|Treatment (cytoreduction, HIPEC)|Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours.
16366346|NCT04213781|Other|Usual care|Sedation according to Dixon's up-and-down method.
16366347|NCT04213781|Experimental|Audiovisual distraction|Audiovisual distraction using HappyMed Video Glasses during procedure. Sedation according to Dixon's up-and-down method.
16366348|NCT04213768|Experimental|Plication|
16366349|NCT04213768|Active Comparator|Resection|
16366350|NCT04213755||patients with risks of intraoperative massive bleeding|patients with risks of intraoperative massive bleeding
16366351|NCT04213742|Active Comparator|Gratitude diary|
16366352|NCT04213742|No Intervention|No intervention|
16366353|NCT04213742|Active Comparator|Gratitude visit|
16366354|NCT04213729|Active Comparator|Crohn's Disease (CD) Control Group|Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
16366355|NCT04213729|Experimental|Experimental CD Low Fat Diet (LFD) Group|Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
16366356|NCT04213729|Experimental|Experimental CD LFD + DPS Group|Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
16366357|NCT04213716|Experimental|intracanal medication|After instrumentation of the canals and drying , using Lentulo Spiral Filler medicaments will be placed under aseptic conditions into the canals experimental Intracanal medication of 1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
16366358|NCT04213716|Active Comparator|intracanal medicament|After instrumentation of the canals and drying , using Lentulo Spiral Filler comparator intracanal medicaments will be placed under aseptic conditions into the canals which is 100 mg Ca (OH) 2 mixed with 1ml sterile water
16366359|NCT04213703||Patients with Epidermolysis Bullosa|Patients who have been diagnosed with Epidermolysis Bullosa
16366360|NCT04213690||Patients with Lupus|Patients who have been diagnosed with Lupus
16366361|NCT04213677|Experimental|Dapagliflozin|Dapagliflozin (Participants will receive dapagliflozin 10mg po qd).
16366362|NCT04213677|Placebo Comparator|Placebo|Placebo (Participants will receive placebo po qd)
16366363|NCT04213664||non-metastatic renal cell carcinoma|Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell
16366364|NCT04213651||Diabetes Mellitus|Patients with diabetes mellitus
16366368|NCT04213625|Experimental|Intervention|Experimental group will receive an information sheet with their surgeon's educational and personal background.
16366369|NCT04213612|Experimental|PLD+CTX+VCR|CTX 1g/m2/d，D1-2 VCR 1.5mg/m2，D1
16366370|NCT04213599||Anterior infarction|Patients with anterior ST-elevation myocardial infarction
16366371|NCT04213599||Inferior infarction|Patients with inferior ST-elevation myocardial infarction
16366372|NCT04213599||Lateral infarction|Patients with lateral ST-elevation myocardial infarction
16366373|NCT04213586|Experimental|Whey Protein|Each participant will be supplemented with whey protein (7 d/wk) during 10 weeks.
16366374|NCT04213586|Experimental|Leucine-matched collagen|Each participant will be supplemented with collagen (7 d/wk) during 10 weeks.
16366375|NCT04213573|Experimental|Group 1: topical application of silver diamine fluoride|38% silver diamine fluoride liquid
16366376|NCT04213573|Active Comparator|Group 2: topical application of MI varnish.|MI Varnish:5% sodium fluoride varnish which also contains RECALDENT™* (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate
16366377|NCT04213560|Experimental|Weighted waist-hooping|Participants weighted waist-hooping on their own for ten minutes a day, four days a week, for six weeks resulting in a total of 40 minutes of weighted waist-hooping each week. Participants weighted waist-hooped with a three-pound weighted hula hoop at the waist for ten minutes. Half time hooping to the left and the other half hooping to the right. If discomfort while hooping occurred participants were instructed to take breaks, change directions more frequently, or where thicker clothing to lessen the impact of the hoop around their waists. The investigators would check in on the participants weekly to provide feedback on technique and answer all questions throughout the six-week intervention.
16366378|NCT04213560|No Intervention|Control|No Intervention
16366379|NCT04213547|Experimental|Intervention|This will be a single-arm study utilizing a loss-framed incentive intervention to induce increased sleep duration.
16366380|NCT04213521|Experimental|Multisensory balance training group|The participants in the multisensory balance training group were provided with multiple-sensory balance exercises using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system-postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
16366381|NCT04213521|Active Comparator|Conventional balance training group|The participants in the Conventional balance training group performed conventional balance exercises, such as static and dynamic standing balance without altered sensory inputs.
16366382|NCT04213508|Active Comparator|Isotonic saline with frequency of 2 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
16366383|NCT04213508|Active Comparator|Hypertonic saline with frequency of 2 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
16366384|NCT04213508|Active Comparator|Isotonic saline with frequency of 5 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
16366385|NCT04213508|Active Comparator|Hypertonic saline with frequency of 5 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
16366386|NCT04213495||Patients undergoing anesthesia in Czech Republic|Patients undergoing anesthesia in Czech Republic in the selected period from the confirmed Anesthesia Center
16366387|NCT04213482||oncology patients|For this study, panoramic images were taken from pediatric patients who received radiotherapy and/or chemotherapy because of any oncologic disease.
16366388|NCT04213482||healthy|panoramic images of patients(pediatric) who have no systemic disease were collected from the archive of dental radiology clinic of the university hospital.
16366389|NCT04213469|Experimental|Quikin CD19-CART|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine 4-6 days before CART infusion. A dose of Quikin CD19-CART will be infused on day 0.
16366390|NCT04213456|Experimental|Nutritional supplementation|Powder added to water,high protein and multi vitamin and minerals
16366391|NCT04213456|Placebo Comparator|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
16366392|NCT04213443||Women of short stature|Women that are under 1.6 meters.
16366393|NCT04213430||Training dataset|Retinal images collected from hospitals and multiple screening sites all over China
16366394|NCT04213430||Validation dataset|Retinal images separated from training dataset
16366395|NCT04213430||Testing dataset|Retinal images prospectively collected from the hospitals and ocular disease screening sites totally different from training dataset
16366396|NCT04213417|Experimental|Bobath therapy plus Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the Bobath therapy was applied to the affected side of the body and lower extremity for 60 minutes in each session.
16366397|NCT04213417|Active Comparator|Bobath therapy|Both groups were treated with the Bobath therapy as a neurodevelopmental therapy.
16366398|NCT04213404|Experimental|Ribociclib-spartalizumab|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
16366399|NCT04213391|Experimental|sulforaphane group|The patients will take sulforaphane for 24 weeks, 2550mg once a day.
16366400|NCT04213391|Placebo Comparator|Placebo group|The patients will take placebo for 24 weeks, 2550mg once a day.
16366401|NCT04213378|Experimental|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent restenosis with paclitaxel eluting PTCA balloon
16366402|NCT04213378|Active Comparator|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent restenosis with SeQuent® Please paclitaxel eluting balloon
16366403|NCT04213365|Other|cognitive stimulation and adapted physical activity|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
16366404|NCT04213352|No Intervention|Control Group|The subjects will be asked to type on a computer for 5 minutes without splint or taping. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
16366405|NCT04213352|Experimental|Splint Group|The subjects will be asked to type on a computer for 5 minutes with a splint. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
16366406|NCT04213352|Experimental|Rigid Taping Group|The subjects will be asked to type on a computer for 5 minutes with rigid taping which limits the wrist flexion at the dominant side. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
16366407|NCT04213339|Experimental|Kegal Exercises|
16366408|NCT04213339|No Intervention|Control|
16366409|NCT04213326||Cancer Cohort|Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
16366410|NCT04213326||Non-Cancer Cohort|Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
16366411|NCT04213313||Control Group|health volunteers
16366412|NCT04213313||Infectious Keratitis Group|Infectious corneal patients
16366413|NCT04213300||Low carbohydrate dietary group|"Participants n = 23
~Participants:
~Male, female or unspecified gender;
~18 years of age or over;
~Type 1 diabetes for ≥1 year from diagnosis date and
~Individuals who administer insulin using multiple daily injections."
16366414|NCT04213287|Experimental|Peri-Articular Injections and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine
~At the end of surgery;
~PAI: 30 ml 0,025% bupivacaine and
~IPACK: 20 ml 0,025% bupivacaine"
16366415|NCT04213287|Active Comparator|Adductor Canal Block, and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine
~At the end of surgery;
~ADD: 20 ml 0,025% bupivacaine and
~IPACK: 20 ml 0,025% bupivacaine"
16366416|NCT04213274|Placebo Comparator|Placebo - placebo|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo
16366417|NCT04213274|Other|Placebo - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104
16366418|NCT04213274|Experimental|80 mg RPH-104 - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo
16366419|NCT04213274|Experimental|80 mg RPH-104 - 160 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104
16366420|NCT04213261|Experimental|FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts|Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.
16366421|NCT04213248|Experimental|UMSC-exo treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks.
16366422|NCT04213235|Experimental|Physical exercise|
16366423|NCT04213209||Brentuximab Vedotin 1.8 mg/kg (body weight)|The usual dosage for intravenous administration is 1.8 milligrams per kilograms (mg/kg) (body weight) as Brentuximab Vedotin (genetic recombination) once every three weeks (up to 12 months). The dose may be reduced appropriately according to the participant's condition. Participants receive interventions as part of routine medical care.
16366424|NCT04213196|Active Comparator|HSK21542 0.2 μg/kg（15 min)|Healthy volunteers 0.2 μg/kg HSK21542
16366425|NCT04213196|Placebo Comparator|HSK21542 0.5 μg/kg|Healthy volunteers 0.5 μg/kg HSK21542 or Placebo
16366426|NCT04213196|Placebo Comparator|HSK21542 1 μg/kg （15min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
16366427|NCT04213196|Placebo Comparator|HSK21542 1 μg/kg （2min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
16366428|NCT04213196|Placebo Comparator|HSK21542 0.75 μg/kg|Healthy volunteers 0.75 μg/kg HSK21542 or Placebo
16366429|NCT04213196|Placebo Comparator|HSK21542 1.5 μg/kg|Healthy volunteers 1.5 μg/kg HSK21542 or Placebo
16366430|NCT04213196|Placebo Comparator|HSK21542 2.25 μg/kg|Healthy volunteers 2.25 μg/kg HSK21542 or Placebo
16366431|NCT04213196|Placebo Comparator|HSK21542 3.375 μg/kg|Healthy volunteers 3.375 μg/kg HSK21542 or Placebo
16366432|NCT04213196|Placebo Comparator|HSK21542 0.2 μg/kg（2min)|Healthy volunteers 0.2 μg/kg HSK21542 or Placebo
16366433|NCT04213183||development dataset 01|Slit-lamp and retinal fundus images collected from Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University.
16366434|NCT04213183||development dataset 02|Slit-lamp and retinal fundus images collected from Affiliated Huadu Hospital of Southern Medical University.
16366435|NCT04213183||development dataset 03|Slit-lamp and retinal fundus images collected from Nantian Medical Centre of Aikang Health Care.
16366436|NCT04213183||test dataset 01|Slit-lamp and retinal fundus images collected from Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University.
16366437|NCT04213183||test dataset 02|Slit-lamp and retinal fundus images collected from Huanshidong Medical Centre of Aikang Health Care.
16366438|NCT04213170|Experimental|Sintilimab and Bevacizumab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 every 21 days
16366439|NCT04213144|Experimental|Magdent Cap MED|Soft and hard tissue healing with electomagnetic healing abutment.
16366440|NCT04213144|Sham Comparator|Sham MED|Soft and hard tissue healing with a regular healing abutment.
16366441|NCT04213131|Other|Rehabilitation control group|Routine rehabilitation treatment for chronic spinal cord injury and Intravenous injection of 100 mL 0.9% saline solution.
16366442|NCT04213131|Experimental|hUC-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUC-MSCs
16366443|NCT04213131|Experimental|hUC-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUC-MSCs and 5 mL of cerebrospinal fluid
16366444|NCT04213131|Experimental|hUC-MSCs local administration group|hUC-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUC-MSCs/point.
16366445|NCT04213131|Experimental|hUCB-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUCB-MSCs
16366446|NCT04213131|Experimental|hUCB-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUCB-MSCs and 5 mL of cerebrospinal fluid
16366447|NCT04213131|Experimental|hUCB-MSCs local administration group|hUCB-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUCB-MSCs/point.
16366448|NCT04213118|Experimental|Group A|Administration anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
16366449|NCT04213105|Experimental|QL1206|QL1206 injection (60mg) by subcutaneous injection once on the first day
16366450|NCT04213105|Active Comparator|Prolia®|Prolia® injection (120mg) by subcutaneous injection once on the first day
16366451|NCT04213092||ERCP+LC|Patients in this group underwent 2-stage ERCP+LC in a single setting. And, it was compared with our control group
16366452|NCT04213092||OC+CBD|This group with 2-stage OC+CBD exploration in a single setting approach was taken as a control group.
16366453|NCT04213079|Experimental|Vestibulo-ocular reflex (VOR)|Treatment by re-adaptation of the vestibulo-ocular reflex (VOR) for participants with motion triggered MdDS
16366454|NCT04213079|Experimental|Habituation of velocity storage|Participants with motion triggered MdDS
16366455|NCT04213066|Active Comparator|Control group|This group received eye-hand practice for drawing pictures.
16366456|NCT04213066|Experimental|Grating group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies.
16366457|NCT04213066|Experimental|Random dot group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies constructed by random dots of stochastic resonance.
16366458|NCT04213053|Other|Concomitant strabismus patients|Horizontal strabismus surgery
16366459|NCT04213040||Open-Heart Surgery for a six months duration|In a single group of patients including 146 patients undergoing openheart surgery during a period of six months, the collected parameters include; serum levels of procalcitonin, C-reactive protein, and lactate as well as postoperative complications and after this, depending on the development of postoperative complications or not in the intensive care unit patients were divided into two groups. The Group Without Complications, n=112, includes patients without a postoperative complication after open-heart surgery with cardiopulmonary bypass. The Group With Complications, n=34, includes patients with a postoperative complication after open-heart surgery with cardiopulmonary bypass.
16366460|NCT04213027|Active Comparator|SSLF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Sacrospinous ligament fixation (SSLF) .
16366461|NCT04213027|Active Comparator|ISFF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Ischial spinous fascia fixation (ISFF)
16366462|NCT04213014|Experimental|Guys/Girls Opt for Activities for Life Intervention (GOAL)|Receives the 4 month (16-wk) GOAL intervention, which has 3 components: (1) After-school GOAL Club: 26 events (2 d/wk; 120 min/event/day; 13 wks due to no club during 3 school break wks) for boys and girls to engage in physical activity and healthy eating and cooking activities;5 (2) Three parent-adolescent meetings (group meetings at each school): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior wk.
16366463|NCT04213014|No Intervention|Control|Received usual school activities.
16366464|NCT04213001|Other|measure|circumference measure, ultrasonographic measure
16366465|NCT04212988|Experimental|the trial group|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
16366466|NCT04212988|Placebo Comparator|the control group|In control group patients, only place the probe for NIRS monitor.
16366467|NCT04212975|Experimental|group 1|lavage by dextrose
16366468|NCT04212962|Experimental|Treatment group|The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
16366469|NCT04212962|Experimental|Control group|The control group receives usual discharge planning and post-discharge care.
16366470|NCT04212949|Experimental|Repetitive transcranial magnetic stimulation following TESI|Active repetitive transcranial magnetic stimulation will be performed to the patients with lumbar radiculopathy who receive transforaminal epidural steroid injection.
16366471|NCT04212949|Active Comparator|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection will be applied to the patients with lumbar radiculopathy.
16366472|NCT04212936|No Intervention|Control group|8 mmHg pressure group
16366473|NCT04212936|Experimental|Study group|10 mmHg group
16366611|NCT04211948|Active Comparator|open surgery|open pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
16366474|NCT04212923|Experimental|Medical Dashboard based self-management intervention|Chronic kidney disease patients in the intervention group will receive the usual care plus the tailored 'Medical Dashboard' based self-management intervention.
16366475|NCT04212923|No Intervention|Usual care services|Chronic kidney disease patients in the comparison group will receive usual care consisting of personalised in- and outpatient treatment based on symptoms experienced and disease severity, as outlined in the Kidney Disease Improving Global Outcomes (KDIGO).
16366476|NCT04212897|Experimental|Music Therapy|This group will be asked to practice a rhythmic auditory SFT intervention task at home.
16366477|NCT04212897|No Intervention|No Music Therapy|This group will not engage in an intervention task at home and will be asked to continue their normal daily routine.
16366478|NCT04212884||PLWH|PLWH followed up at the five participating HIV centers
16366479|NCT04212884||HIV-uninfected individuals|Age and sex-matched HIV-uninfected individuals
16366480|NCT04212871|Experimental|watch mukbang|"In the online study, participants were assigned to watch a ramen mukbang, by Yuka Kinoshita (https://youtu.be/ArPaid2Iuck, accessed: 2018-10-12).
~In the in-person study, participants were assigned to watch a hotpot mukbang by Alun (https://youtu.be/QCTOo9UGZD8, accessed: 2018-11-29)."
16366481|NCT04212871|Experimental|watch another food content video|"In the online study, participants were assigned to watch a donut mukbang, by Yuka Kinoshita (https://youtu.be/ntMT2y0MgHk, accessed: 2018-10-12).
~In the in-person study, participants were assigned to watch a hotpot cooking show by the Cat's kitchen (https://youtu.be/EH5Ei-sMP60, accessed: 2018-11-29)."
16366482|NCT04212871|Placebo Comparator|watch a non-food content video|"In the online study, participants were assigned to watch a silent documentary introducing the Palace Museum by China Central Television (CCTV) (https://youtu.be/hWnm1BQOTZY, accessed: 2018-10-12).
~In the in-person study, participants were assigned to watch a video introducing Cornell University is used for the non-food content video (https://youtu.be/GuM8vTq0jd4, accessed: 2018-11-29)."
16366483|NCT04212858|Experimental|case|myeloma patients
16366484|NCT04212858|Experimental|control|healthy control
16366485|NCT04212845|Active Comparator|Group ESP|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine and 8 mg dexamethasone
16366486|NCT04212845|Active Comparator|Group TF|Fluoroscopy-guided transforaminal injection with 4 ml of 0.25% bupivacaine and 8 mg dexamethasone
16366487|NCT04212832|Active Comparator|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block with 0.5 ml/kg % 0.25 bupivacaine
16366488|NCT04212832|Other|No intervention|Standard Pain Followup and Monitorization
16366489|NCT04212819|Experimental|Before erythrocyte suspension (ES) transfusion group|50 (Female/Male: 25/25) patients were included in this study. Total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients after diagnoses of anemia.
16366490|NCT04212819|Experimental|After erythrocyte suspension transfusion group|24 hours after ES transfusion, total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients.
16366491|NCT04212793|Experimental|NIR endoscopic TSS with 4.5 mg bevacizumab-800CW|IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
16366492|NCT04212793|Experimental|NIR endoscopic TSS with 10 mg bevacizumab-800CW|IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
16366493|NCT04212793|Experimental|NIR endoscopic TSS with 25 mg bevacizumab-800CW|IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
16366494|NCT04212780|Active Comparator|Treatment Naive|Participants receiving Long-term stimulation of the thalamus via dual leads for Essential Tremor
16366495|NCT04212780|Active Comparator|Refractory Participants|Patients with recurrent, debilitating intention tremor despite ongoing, optimized VIM DBS therapy
16366496|NCT04212767|Experimental|Test group|Post-extraction sockets covered with Platelet-Rich Fibrin membrane (n=16)
16366497|NCT04212767|No Intervention|Control Goroup|Post-extraction sockets left to spontaneous healing/clot and primary closure (n=16).
16366498|NCT04212754||Procedure: Emergency surgery for traumatic brain injury|
16366499|NCT04212741|Experimental|A+ HA(tm)|20 ml oral solution of hyaluronic acid mixture in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
16366500|NCT04212741|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
16366501|NCT04212728|Experimental|AMSCs plus PRP group|Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
16366502|NCT04212728|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
16366503|NCT04212715|Experimental|Experimental arm|SABR 35Gy/5 to prostate, up to 50Gy/5 to MR nodule, and 25Gy/5 to pelvic nodes and SVs
16366504|NCT04212689|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. Physiotherapy approaches include stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
16366505|NCT04212689|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
16366506|NCT04212676|Experimental|PR+BAT Group|In addition to the PR program, the BAT will be administered to the experimental group by a physiotherapist with 5 years of experience in BAT for 8 weeks.
16366739|NCT04211064|Other|Deep neuromuscular block|Patients undergoing deep neuromuscular blockade with rocuronium (TOF -- PTC 1-5)
16366507|NCT04212676|Active Comparator|PR Group|Patients in the control groups will receive a 30-minute Pulmonary Rehabilitation (PR) program every day of the week for 8 weeks.
16366508|NCT04212663|Placebo Comparator|control|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release
16366509|NCT04212663|Experimental|experiment|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release+ The tendon release of musculi tibialis posterior
16366510|NCT04212650|Experimental|Losartan|12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
16366511|NCT04212650|Placebo Comparator|Placebo|Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.
16366512|NCT04212637|Experimental|Healthy Volunteers|MRI exam
16366513|NCT04212637|Experimental|Parkinson patient|MRI exam
16366514|NCT04212624|Experimental|test arm|The 25G or 23G conjunctival seamless vitrectomy was performed on the anterior eye to remove the anterior-posterior direction and tangential direction of the rupture hole. The area outside the macular foveal lesion was selected, but 100 μl of HuRPE cell injection was injected within about 2 PD. In combination with the Medone syringe and the combined 35G or 37G needle, the silicone oil injection module is used for injection, and the injection is performed in an amount of 100 μl (depending on the cell concentration). The doses of the three dose groups from low to high were 300,000 cells, 500,000 cells, and 1 million cells, respectively, in a single injection.
16366515|NCT04212611|Experimental|Group L|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L)
16366516|NCT04212611|Experimental|Group R|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% ropivacaine (group R).
16366517|NCT04212598|Experimental|Definitive concurrent chemoradiotherapy or radiotherapy arm|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
16366518|NCT04212585||children with upper gastrointestinal symptoms|
16366519|NCT04212585||children without upper gastrointestinal symptoms|
16366520|NCT04212559||NPV group|Patients who had treated in pulmonary rehabilitation unit with NPV
16366521|NCT04212546|Placebo Comparator|Control drink|200 mL milk + 16 g maltodextrin
16366522|NCT04212546|Active Comparator|Test drink|200 mL milk + 16 g inulin + Lactobacillus casei [>106 cfu/mL]
16366523|NCT04212533|Active Comparator|supplementation arm|43 patients undergoing total thyroidectomy received 40000 IU vit D and once before operation and 500mg calcium tab 4 times in the day before surgery
16366524|NCT04212533|Active Comparator|non-supplementation arm|43 patients undergoing total thyroidectomy received rice starch tablets /6 hrs in the day before surgery
16366525|NCT04212507||1|50 psoriatic patients
16366526|NCT04212507||2|30 age and sex-matched healthy volunteers as a control group
16366527|NCT04212494|Experimental|Thrombus aspiration|Upfront manual thrombus aspiration followed by PCI
16366528|NCT04212494|Active Comparator|PCI Alone|PCI without upfront manual thrombus aspiration
16366529|NCT04212481|Experimental|single port group|Uniport video-assisted thoracoscopic surgery for NSCLC
16366530|NCT04212481|Active Comparator|two ports group|video-assisted thoracoscopic surgery for NSCLC using two ports
16366531|NCT04212481|Active Comparator|three ports group|video-assisted thoracoscopic surgery for NSCLC using three ports
16366532|NCT04212442|Experimental|Immediate Intervention|Upon enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
16366533|NCT04212442|Experimental|Wait-list Control|Two months after study enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
16366534|NCT04212429|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366535|NCT04212429|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366536|NCT04212429|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366537|NCT04212429|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366538|NCT04212429|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366539|NCT04212429|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366540|NCT04212429|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366570|NCT04212208|Experimental|Intervention group|EMLA cream + High-frequency USG probe kept for 15minutes.After 15 minutes IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
16366801|NCT04210648|Experimental|Intervention group|Those who will use the mobile app
16366541|NCT04212429|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 8-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
16366542|NCT04212416|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
16366543|NCT04212403|Active Comparator|Control|The control groups receives antimicrobial prophylaxis (AMP) as recommended by the guidelines.
16366544|NCT04212403|No Intervention|Treatment group|The treatment group receives no AMP.
16366545|NCT04212390||FISiM MDS patients|Patients receiving a diagnosis of MDS and prospectively enrolled in the FISiM registry.
16366546|NCT04212377|Experimental|exploratory|single arm exploratory, single-centre study
16366547|NCT04212364|Experimental|Peer Education|"During Session 1, participants will be trained in Peer Education and how to use Nasal Narcan. They will be given two Nasal Narcan kit that includes 2 doses. One kit if for their use and one kit is to give someone in their social network after they have trained them in how to use it.
~A week after Session 1, participants will be scheduled for Session 2.
~During session 1 and 2 participants, Index participants will be taught information and skills pertaining to overdose prevention and response and how to train network members in overdose prevention and response.
~At the 2nd session, index participants will be given 1 coupon to give to 1 member from their social network to attend Session 3.
~Session 3 will be a dyad session where Index participants will use their peer mentors' skills to train their network member in overdose prevention and response.
~Index participants will also be invited to up to 3 Booster Session (monthly) after they complete Sessions 1-3."
16366548|NCT04212364|Active Comparator|Standard of care|"Participants randomized to this condition will participate in one 1-hour session. This session will be an individual session where the participant will meet with a trained staff member in a private room at the Lighthouse.
~This session will be standard overdose prevention and response information. Participants will also be trained in Narcan administration. Participants will be given 1 nasal Narcan kit.
~At the end of this session, participants will be asked to refer a network member to the study for survey visits"
16366549|NCT04212351||Patients with NF1 and active LGGs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of low grade glioma but no clinical or radiographic evidence of plexiform neurofibroma.
16366550|NCT04212351||Patients with NF1 and active PNs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of plexiform neurofibroma but no clinical or radiographic evidence of low grade glioma.
16366551|NCT04212351||Patients with NF1 with no active LGGs or PNs|Patients with Neurofibromatosis Type 1 with no clinical or radiographic evidence of both active plexiform neurofibroma and active low grade glioma.
16366552|NCT04212338|Experimental|study group 1|Before intravitreal injection music intervention: These patients received the standard treatment and listened to music for a period of 15 minutes 30 minutes before the injection.
16366553|NCT04212338|Experimental|study group 2|During-intravitreal injection music intervention:These patients received the standard treatment and listened to music during the injection (approximately 5 minutes).
16366554|NCT04212338|No Intervention|control group|The music intervention was not conducted with the patients in the control group. These patients received the standard treatment.
16366555|NCT04212325|Active Comparator|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
16366556|NCT04212325|Active Comparator|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the single injection at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
16366557|NCT04212312||Single course of Betamethasone|Women with twin pregnancy who received 1 course of betamethasone between 24 - 34 weeks' gestation.
16366558|NCT04212312||Repeat course of Betamethasone|Women with twin pregnancy who received 2 courses (Repeat course) of betamethasone between 24 - 34 weeks' gestation.
16366559|NCT04212299|Experimental|Baseline ischial containment to subischial socket|
16366560|NCT04212286|Experimental|Diagnostic CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions with Diameters ≤ 2cm will receive CEUS and EOB-MRI examinations.
16366561|NCT04212273|Experimental|Diagnostic Sonazoid-CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.
16366562|NCT04212260|Experimental|Oro-pharyngeal exercises|Use of oro-pharyngeal exercises
16366563|NCT04212260|Sham Comparator|Sham control|Use of sham exercises.
16366564|NCT04212247|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
16366565|NCT04212247|Placebo Comparator|Control condition|The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
16366566|NCT04212234|Experimental|free ultrasound propagation velocity|ultrasound exams will be performed using several ultrasound propagation velocities
16366567|NCT04212234|No Intervention|conventional ultrasound propagation velocity|ultrasound exams will be performed using the 1540m/s conventional celerity
16366568|NCT04212221|Experimental|MGD013|MGD013 monotherapy dose escalation and expansion
16366569|NCT04212221|Experimental|MGD013+Brivanib Alaninate|MGD013+Brivanib Alaninate dose escalation and expansion
16366571|NCT04212208|Active Comparator|Control group|EMLA cream+Low frequency USG probe kept over the cream for 15 minutes. IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
16366572|NCT04212195||Part 1|Genetic determinants (n=500)
16366573|NCT04212195||Part 2|Biomarker discovery (n=40)
16366574|NCT04212182|Experimental|HFNC group|AECOPD patients receive ventilation support via HFNC.
16366575|NCT04212182|Active Comparator|NPPV group|AECOPD patients receive ventilation support via NPPV.
16366576|NCT04212169|Experimental|MEDI3506 at dose level 1|Participant will receive multiple doses of MEDI3506 at dose level 1.
16366577|NCT04212169|Experimental|MEDI3506 at dose level 2|Participant will receive multiple doses of MEDI3506 at dose level 2.
16366578|NCT04212169|Experimental|MEDI3506 at dose level 3|Participant will receive multiple doses of MEDI3506 at dose level 3.
16366579|NCT04212169|Placebo Comparator|Placebo|Participant will receive multiple doses of Placebo
16366580|NCT04212156||TMH test|Patient will be asked to lay supine while the head and neck maintained in a neutral position using a pillow under the head. By using digital depth gauge, the TMH will be measured from the anterior border of the thyroid cartilage directly on the thyroid notch till the anterior border of the mentum
16366581|NCT04212143||children with kidney disease|Kidney transplant recipients age 3 to 21 years
16366582|NCT04212143||healthy control|Healthy children age 3 to 21 years
16366583|NCT04212130|Experimental|Evaluation of environmental cleanliness|"In this study,
~fluorescent marking,
~microbiological sampling and
~BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
16366584|NCT04212117|Other|Arm 1 - Educational Platform, PALS|The Patient Activated Learning System is a free, health education platform written bu trusted MDs.
16366585|NCT04212117|Other|Arm 2 - WebMD|WebMD is a widely used educational platform for health information.
16366586|NCT04212104|Experimental|watch mukbang|participants are assigned to watch a dim sum mukbang by a famous host, Peggie Neo (https://youtu.be/2dRf535eAPK, accessed: 2018-9-12)
16366587|NCT04212104|Placebo Comparator|watch non-food content video|participants are assigned to watch the Big Bang Theory, The Euclid Alternative ( https://youtu.be/V8kUL9owk6Q, accessed: 2018-9-12).
16366588|NCT04212091|Experimental|Part A (Group 1): PGT121.414.LS (3 mg/kg)|Participants will receive 3 mg/kg of PGT121.414.LS by intravenous (IV) infusion at Month 0.
16366589|NCT04212091|Experimental|Part A (Group 2): PGT121.414.LS (10 mg/kg)|Participants will receive 10 mg/kg of PGT121.414.LS by IV infusion at Month 0.
16366590|NCT04212091|Experimental|Part A (Group 3): PGT121.414.LS (30 mg/kg)|Participants will receive 30 mg/kg of PGT121.414.LS by IV infusion at Month 0.
16366591|NCT04212091|Experimental|Part A (Group 4): PGT121.414.LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS by subcutaneous (SC) infusion at Month 0.
16366592|NCT04212091|Experimental|Part B (Group 5): PGT121.414.LS + VRC07-523LS (20 mg/kg)|Participants will receive 20 mg/kg of PGT121.414.LS and 20 mg/kg of VRC07-523LS by IV infusion sequentially in this order at Months 0, 4, and 8.
16366593|NCT04212091|Experimental|Part B (Group 6): PGT121.414.LS + VRC07-523LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS and 5 mg/kg of VRC07-523LS by SC infusion sequentially in this order at Months 0, 4, and 8.
16366594|NCT04212078|Active Comparator|A-Levofloxacin|0.1 ml/0.5mg of levofloxacin 0.5% ophthalmic solution
16366595|NCT04212078|Active Comparator|B-Intracameral Cefuroxime|0.1 ml/1mg of Cefuroxime
16366596|NCT04212065|Active Comparator|Sublingual Suboxone|Women randomized to sublingual dosing will be provided prescription to fill.
16366597|NCT04212065|Active Comparator|Subcutaneous Sublocade|Women randomized to subcutaneous administration will have drug administered by nurse during routine prenatal care visits.
16366598|NCT04212052|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 30Gy/6f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 40Gy/8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly nab-paclitaxel(50mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, or nab-paclitaxel(30mg/㎡) and nedaplatin(10mg/㎡) twice every week.
16366599|NCT04212039|Active Comparator|ultrasound guided pericapsular nerve group block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection between to iliopubic eminentia and psoas tendon
16366600|NCT04212039|Sham Comparator|ultrasound guided sham block|Ultrasound guided 0.5 ml/kg saline injection injection between to iliopubic eminentia and psoas tendon
16366601|NCT04212026|Experimental|Nivolumab|"Nivolumab treatment will be given every 2 weeks at a standard flat dose of 240 mg for a total of 5 doses, and the IRE procedure will be performed using the standard setting to ablate tumors at the level of the liver that is well tolerated by the patients. Two weeks after the last dose of nivolumab (Week 8), radiological restaging will be performed (=Week 10)."
16366602|NCT04212013|Experimental|Ibrutinib/Rituximab|All subjects meeting eligibility criteria will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 on cycle 1.
16366603|NCT04212013|Placebo Comparator|Ibrutinib/Placebo|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
16366604|NCT04212000|Experimental|Levoketoconazole|Levoketoconazole 150 mg
16366605|NCT04212000|Active Comparator|Ketoconazole|Ketoconazole 200 mg
16366606|NCT04211987|Active Comparator|Fast track care protocol|patients treated using fast track care protocol
16366607|NCT04211987|Active Comparator|Standard care protocol|patients treated using standard care protocol
16366608|NCT04211961|Placebo Comparator|Control|Participants randomised to the placebo group will receive one 15-minute IV infusion of Saline at 4 visits.
16366609|NCT04211961|Active Comparator|Treatment|Participants randomised to the treatment group will receive one 15-minute IV infusion of Scopolamine at 4 visits.
16366610|NCT04211948|Experimental|robotic pancreatectomy|robotic pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
16366802|NCT04210648|No Intervention|Non-intervention group|Those who will not use the mobile app
16366612|NCT04211935|Experimental|Patient Controlled Analgesia|This technique involves connecting a patient controlled analgesia pump to the intravenous line. The patient has the ability to push a button to obtain a predetermined dose of an intravenous opioid with a set lockout time period to minimize the potential for over sedation. PCA pumps will be connected to the intravenous line of the patient at the end of the MIRPE operation. anesthesiologists with experience in regional anesthesia.
16366613|NCT04211935|Experimental|Erector Spinae Block|This method consists of the anesthesiologist placing two catheters on each side of the vertebrae which then delivers pain medicine continuously via pumps for 2-3 days post-surgery.
16366614|NCT04211935|Experimental|Intercostal Nerve Cryoablation|The INC technique relies on multilevel freezing of the intercostal neurovascular bundle intraoperatively to block sensation and pain for approximately 2 months postoperatively. Trained pediatric surgeons will perform the INC at the time of a MIRPE procedure.
16366615|NCT04211922|Experimental|Alkotinib 400mg QD|400mg orally once daily. Take Alkotinib at least 1 hour before or at least 2 hours after a meal.
16366618|NCT04211896|Experimental|anlotinib plus nivolumab|
16366619|NCT04211883|Experimental|Active intervention|Participants will come to the Project Active clinic and be asked questions about their health history, assist in their health goals, medications will be adjusted, lab work and screening tests will be ordered. At end of each visit, current health recommendations and goals as well as previous health changes will be given after each visit.
16366620|NCT04211883|No Intervention|Standard Clinical Treatment|Participants will continue with their usual clinic care.
16366621|NCT04211870|Active Comparator|Group 1|Treatment with low-level laser therapy.
16366622|NCT04211870|Sham Comparator|Group 2|Sham treatment (simulated laser therapy).
16366623|NCT04211844||sofosbuvir plus daclatasvir|50 patients receiving 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
16366624|NCT04211844||sofosbuvir plus ledipasvir|50 patients receiving 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
16366625|NCT04211831|Experimental|Cohort 1: URO-902 24 mg; Placebo|Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
16366626|NCT04211831|Experimental|Cohort 2: URO-902 48 mg; Placebo|Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
16366627|NCT04211818|Experimental|Patients|
16366628|NCT04211805||Arm (A) TAF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Alafenamide (TAF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
16366629|NCT04211805||Arm (B) TDF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Disoproxil Fumarate (TDF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
16366630|NCT04211792||Glaucoma suspect or patients|Patients who has or suspected Glaucoma will be approached for the recruitment into this study. IOP will be measured in the sitting position with Icare tonometers in a random order in both the eyes. IOP measurements by GAT will be taken after Icare measurements followed by CCT recording with ultrasound pachymeter.
16366631|NCT04211779|Experimental|Real tDCS and Exercise|tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and active tDCS intervention at the same time.
16366632|NCT04211779|Sham Comparator|Sham tDCS and Exercise|Sham tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and sham tDCS intervention at the same time.
16366633|NCT04211779|Other|Exercise|Exercise group in which will receive the active intervention of aerobic exercise training no tDCS intervention.
16366634|NCT04211766|Active Comparator|Group I (supplemental fiber and fat followed by placebo)|Participants receive a fiber supplement daily and a fish oil supplement PO daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group II.
16366635|NCT04211766|Active Comparator|Group II (placebo followed by supplemental fiber and fat)|Participants receive a fiber supplement placebo daily and a fish oil supplement placebo daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group I.
16366636|NCT04211753|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
16366637|NCT04211753|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
16366638|NCT04211740|Active Comparator|OCH-NCNP1 3 mg|
16366639|NCT04211740|Placebo Comparator|Placebo|
16366640|NCT04211727||Cohort 1|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
16366641|NCT04211727||Cohort 2|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
16366642|NCT04211714|Experimental|EXG34217|single autologous CD34+ cells contacted ex vivo with EXG-001
16369677|NCT04190420||Healthy Controls|60 healthy control subjects, matched in age and gender
16366643|NCT04211701|Experimental|Connective Tissue Massage|Connective tissue massage will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions, respectively. The treatment will be administered for four weeks, five days a week.
16366644|NCT04211701|Experimental|Classical Massage|Classic massage will be applied to the lower back and upper back, respectively, while the patient is lying in the prone position. The treatment will be administered for four weeks, five days a week.
16366645|NCT04211688|Experimental|Combined individual + group Schema therapy|Those who will receive both individual plus group schema therapy
16366646|NCT04211688|Active Comparator|Only group Schema therapy|Those who will receive group schema therapy
16366647|NCT04211675|Other|Treatment|"The planned therapy will involve 6 cycles of 21 days each consisting of irinotecan, temozolomide, dinutuximab, and sargramostim (Cycle 1), or irinotecan, temozolomide, dinutuximab, sargramostim, and natural killer (NK) cells (Cycles 2-6).
~Treatment cycles will be repeated every 21 days based upon disease response and toxicity criteria. Tumor response will be assessed after Cycles 2, 4 and 6. Patients who do not experience dose-limiting toxicities and achieve complete response, partial response or stable disease may continue to receive the assigned therapy for as many cycles as are possible with the number of NK cells manufactured.
~Patients will be assigned an initial NK cell dose level at time of registration. If the NK cell dose is tolerated, intra-patient dose escalation will occur at cycle 4 and cycle 6."
16366648|NCT04211662|Experimental|Intervention Group|Tailored Multidimensional Intervention
16366649|NCT04211662|No Intervention|Control Group|Regarding the control group, the participants will receive a simple educational booklet through one home visit.
16366650|NCT04211649|Experimental|3 days of antibiotherapy|The patient viewed for the first time at the hospital and suspected of leptospirosis received a probabilistic antibiotherapy
16366651|NCT04211649|No Intervention|7 days of antibiotherapy (Amoxycilline or Doxycycline)|When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.
16366652|NCT04211636||Complete SCI, AIS A|Patients with complete spinal cord injury (AIS A)
16366653|NCT04211636||Incomplete SCI, AIS B, C, D|Patients with incomplete spinal cord injury (AIS B, C, D)
16366654|NCT04211636||Vertebral injuries without SCI|Patients with vertebral injuries without spinal cord injury (control)
16366655|NCT04211623|Active Comparator|Constraint induced movement therapy group|Constrained on more affected side for three hours.
16366656|NCT04211623|Active Comparator|Bimanual activities group; BIM training|Set of bimanual activities performed.
16366657|NCT04211610||Group 1 - Healthy subjects without any evidence of cardiac o|"Inclusion criteria:
~Normal serum troponin (below the 99th percentile)
~GFR 60ml/min
~Proteinuria <1gr/gr creatinine
~Blood and urine samples will be collected for troponin and other measures."
16366658|NCT04211610||Group 2 - Subjects with acute myocardial infarction and norm|"Inclusion criteria:
~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.
~GFR 60ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
16366659|NCT04211610||Group 3 - Subjects with acute myocardial infarction and decr|"Inclusion criteria - Group 3a:
~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.
~30 GFR <60ml/min/1.73m2
~Inclusion criteria - Group 3b:
~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.
~GFR <30ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
16366660|NCT04211610||Group 4 - Subjects with decreased GFR but without any eviden|"Inclusion criteria - Group 4a:
~Normal serum troponin (below the 99th percentile)
~No known past medical history of any cardiac disease and/or procedure.
~30 GFR <60ml/min/1.73m2
~Inclusion criteria - Group 4b:
~Normal serum troponin (below the 99th percentile)
~No known past medical history of any cardiac disease and/or procedure.
~GFR <30ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
16366661|NCT04211610||Group 5 - Subjects with chronic myocardial injury and normal|"Inclusion criteria:
~At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.
~GFR 60ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
16366662|NCT04211610||Group 6 - patients on RRT|"Inclusion criteria:
~a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.
~Blood and urine samples will be collected for troponin and other measures."
16366663|NCT04211597|Sham Comparator|Group 1: Control|Participants receive no scar prevention and treatment for Cesarean wounds.
16366664|NCT04211597|Active Comparator|Group 2: Silicone gel|Each participant in Group 2 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months.
16366665|NCT04211597|Experimental|Group 3: Silicone gel plus Me-EGF|"The day of Cesarean delivery was recorded as Day 0. For participants in Group 3, on day 0 prior to final dermal closure, 4ml of Me-EGF (containing 40mcg microencapsulated polysaccharide and rhEGF) was sprayed evenly along the incision site, subsequently covered with antibiotic ointment and sterile gauze. Another 0.5 ml (5 mcg of Me-EGF) was sprayed during dressing change on day 1 and day 5 respectively. At each dressing change, the sutured wound was cleaned by sterile normal saline, followed by Me-EGF sprays, and waited for two minutes to allow for absorption, then covered with dry sterile gauze.
~Each participant in Group 3 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months."
16366666|NCT04211584|Active Comparator|forearm radial artery access|traditional access (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
16366667|NCT04211584|Active Comparator|anatomic snuffbox access|access in the snuffbox area of the wrist (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
16366668|NCT04211571|Experimental|MCO group|Hemodialysis using Theranova 400 dialyzer
16366669|NCT04211571|Active Comparator|High-flux group|Hemodialysis using high-flux dialyzer (Fx CorDiax 60 and 80; Fresenius Medical Care)
16366735|NCT04211090|Experimental|Camrelizumab with pemetrexed / carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer
16366670|NCT04211558|Experimental|Ozanimod 0.46mg|Ozanimod single doses of 0.46 mg (1 x 0.46 mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
16366671|NCT04211558|Experimental|Ozanimod 0.92mg|Ozanimod single doses of 0.92 mg (1 x 0.92-mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
16366672|NCT04211545|Experimental|Administration of CC-92480 and Rabeprazole|Test Formulation CC-92480 and Reference Formulation will be administered orally at 1.6 mg. Rabeprazole will be administered orally at 40 mg.
16366673|NCT04211519|Experimental|Permanent teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
16366674|NCT04211519|Experimental|Primary teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
16366675|NCT04211506|Experimental|Sleep Arm 1|This will be the first of four arms of controlled sleep manipulation.
16366676|NCT04211506|Experimental|Sleep Arm 2|This will be the second of four arms of controlled sleep manipulation.
16366677|NCT04211506|Experimental|Sleep Arm 3|This will be the third of four arms of controlled sleep manipulation.
16366678|NCT04211506|Experimental|Sleep Arm 4|This will be the fourth of four arms of controlled sleep manipulation.
16366679|NCT04211493|Experimental|Experimental-Condition|"20 minutes whole-body-workout with simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
16366680|NCT04211493|Placebo Comparator|Placebo-Condition|"20 minutes whole-body-workout without simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout they are stimulated with the lowest possible stimulation intensity (1). This is perceptible as a slight tingling sensation but the impulse intensity lies below the muscular threshold and therefore generates no muscular activity."
16366681|NCT04211480|Experimental|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
16366682|NCT04211467||Depression|Patients who have been diagnosed with depression
16366683|NCT04211454||Migraine|Patients with migraine headaches
16366684|NCT04211428||Bipolar Disorder|Patients with bipolar disorder
16366685|NCT04211415|Experimental|Part 1: DS-2741a Cohort 1, 5 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 5 mg.
16366686|NCT04211415|Experimental|Part 1: DS-2741a Cohort 2, 15 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 15 mg.
16366687|NCT04211415|Experimental|Part 1: DS-2741a Cohort 3, 50 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 50 mg.
16366688|NCT04211415|Experimental|Part 1: DS-2741a Cohort 4, 150 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 150 mg.
16366689|NCT04211415|Experimental|Part 1: DS-2741a Cohort 5, 500 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 500 mg.
16366690|NCT04211415|Experimental|Part 1: DS-2741a Cohort 6, 1000 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 1000 mg.
16366691|NCT04211415|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
16366692|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a X mg, where X mg will be based on the maximum tolerated dose identified in Part 1.
16366693|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a Y mg, where Y mg will be based on the maximum tolerated dose identified in Part 1.
16366694|NCT04211415|Experimental|Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)|Participants will be randomized to receive a receive a single, subcutaneous injection of DS-2741a Z mg, where Z mg will be based on the maximum tolerated dose identified in Part 1.
16366695|NCT04211415|Placebo Comparator|Part 3: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
16366696|NCT04211402||Obsessive-Compulsive Disorder|Patients with obsessive-compulsive disorder
16366697|NCT04211389|Active Comparator|ARQ-151 cream 0.3%|Active comparator
16366698|NCT04211389|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
16366699|NCT04211376||Anxiety|Patients with anxiety
16366700|NCT04211363|Active Comparator|ARQ-151 cream 0.3%|Active comparator
16366701|NCT04211363|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
16366736|NCT04211077||Group 1|Occurrence of a SA according to PMSI
16366737|NCT04211077||Group 2|Occurrence of accidental opioid analgesics overdose according to PMSI code
16366702|NCT04211350|Experimental|NightBalance Sleep Position Therapy|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
16366703|NCT04211350|Experimental|Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
16366706|NCT04211324||TENS group|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
16366707|NCT04211324||electro-acupuncture group|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
16366708|NCT04211311|Experimental|FES-legcycling with voluntary arm-work|FES-legcycling combined with arm ski-ergometer or arm-cycling
16366709|NCT04211298|Active Comparator|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
16366710|NCT04211298|Placebo Comparator|Propofol|Propofol will be used for sedation during bronchoscopy
16366711|NCT04211285||community dwelling elderly|community dwelling elderly patients (60 years or older), can read and write, able to use the android software applications
16366712|NCT04211272|Experimental|Part A: Macitentan + Substrate Drug (Sildenafil/Riociguat)|Participants will receive a single dose of film-coated tablet of sildenafil under fasted condition (Treatment A1), then riociguat under fasted condition (Treatment A2) followed by macitentan under fed condition (Treatment B1), then riociguat along with macitentan under fasted conditions followed by macitentan under fed conditions (Treatment B2) and then sildenafil along with macitentan under fasted condition (Treatment B3). Macitentan will be administered in an up-titration regimen.
16366713|NCT04211272|Experimental|Part B: Macitentan + Substrate Drug (Rosuvastatin)|Participants will receive a single dose of film-coated tablet of rosuvastatin under fasted condition (Treatment A1), then macitentan under fed condition (Treatment B1) followed by rosuvastatin along with macitentan under fasted condition followed by macitentan under fed condition (Treatment B2). Macitentan will be administered in an up-titration regimen. Part B of the study will be conducted depending on the results of Part A and feedback from Health Authorities.
16366714|NCT04211259|Experimental|Cohort I (loratadine)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
16366715|NCT04211259|Placebo Comparator|Cohort II (placebo)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
16366716|NCT04211246|Active Comparator|Standard group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2.
16366717|NCT04211246|Experimental|ORI group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2 and ORI
16366718|NCT04211233|Active Comparator|Invasive subdural arm|Implantation of invasive subdural electrode in patients after surgical treatment of acute subdural hematoma
16366719|NCT04211233|Sham Comparator|Standard treatment arm|Patients with acute subdural hematoma who underwent surgical Treatment and receive Standard medical treatment
16366720|NCT04211220|Experimental|Type 1 diabetes|
16366721|NCT04211194||Patients with upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding undergoing endoscopic procedures at AdventHealth Hospitals in Central Florida
16366722|NCT04211181|Experimental|The multifaceted QI interventions|Hospitals randomized into experimental group will implement follow interventions including：the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.
16366723|NCT04211181|Active Comparator|Routine VTE prophylaxis in local clinical practice|Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.
16366724|NCT04211168|Experimental|Toripalimab Plus Lenvatinib|"Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
16366725|NCT04211155|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16366726|NCT04211155|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16366727|NCT04211155|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16366728|NCT04211155|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
16366729|NCT04211142|Active Comparator|Laparoscopic repair|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
16366730|NCT04211142|Active Comparator|Open repair|Open Inguinal Hernia Repair (Lichtenstein repair)
16366731|NCT04211129|Experimental|acupuncture group|Receiving acupuncture and moxibustion
16366732|NCT04211129|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion
16366733|NCT04211116||Pediatric patients indicated to CVC insertion|Paediatric patients indicated to central venous line insertion
16366734|NCT04211103|Experimental|Pembrolizumab single agent|"Pembrolizumab single agent as neoadjuvant treatment before surgical conization and/or partial or radical vulvectomy.
~Pembrolizumab 200 mg flat dose will be administered every 3 weeks for 5 cycles. Within 3 weeks from the last Pembrolizumab administration patients will be submitted to surgical conization or partial or radical vulvectomy."
16366738|NCT04211077||Group 3|Controls : Absence of SA and accidental opioid analgesics overdose
16366740|NCT04211064|Active Comparator|Moderate neuromuscular block|Patients undergoing moderate neuromuscular blockade with rocuronium (TOF 1-3)
16366741|NCT04211051|Experimental|Arm A|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
16366742|NCT04211038|Experimental|healthy subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
16366743|NCT04211038|Experimental|COPD subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
16366744|NCT04211025|Experimental|Modest|This approach is feasible to integrate into workflows of a wide-range of clinics, and should have a minimal impact on human resources. Materials and strategies to support staff in this work will be provided. .
16366745|NCT04211025|Experimental|Intensive|This approach is more robust, and requires a greater commitment of human resources.
16366746|NCT04211012|Experimental|Treatment Arm|
16366747|NCT04210999|Experimental|Homebased resistance training|Resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
16366748|NCT04210999|Active Comparator|Supervised resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist and avoidance of pain aggravating activities for 3 months
16366749|NCT04210986|Experimental|Fisetin|Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
16366750|NCT04210986|Placebo Comparator|Placebo|Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
16366751|NCT04210973|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
16366752|NCT04210973|Placebo Comparator|Placebo|Placebo,oral, twice per day
16366753|NCT04210960||Patients group|50 multiple sclerosis patients
16366754|NCT04210960||Control group|30 normal healthy control
16366755|NCT04210947|Experimental|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
16366756|NCT04210947|Experimental|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
16366757|NCT04210947|Experimental|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
16366758|NCT04210947|Experimental|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
16366759|NCT04210947|Experimental|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
16366760|NCT04210947|Experimental|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
16366761|NCT04210921|Experimental|Treatment group|"In the treatment group, the Park needle with a real acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi (feeling of needle sensation refers to tenseness around the needle felt by the practitioner and numbness, distension, soreness, and heaviness around the point felt by the patient), and needles will be stimulated manually at least 10 s, then the needles will be retained for 30 minutes."
16366762|NCT04210921|Placebo Comparator|Control group|In the control group, the Park sham needle will instead of the real needle. It is retractile and adopts the sleeve type blunt needle design. When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin. The sham needle may be manipulated by lifting, thrusting or twirling as the real one, but it will not insert into the skin authentically.
16366763|NCT04210908|Experimental|Biofeedback|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the study group, patients will observe the descent of the head during contraction on the ultrasound display screen.
16366764|NCT04210908|No Intervention|Control|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the control group, patients will not observe the ultrasound display screen.
16366765|NCT04210895|Experimental|Warm footbath with ginger powder|Participants receive a daily warm water footbath with added ginger powder over a two-week period
16366766|NCT04210895|Active Comparator|Warm water only footbath|Participants receive a daily warm water footbath over a two-week period
16366767|NCT04210882|Experimental|12-week Moderate-Intensity Exercise Program|"Exercise intervention: Participants will complete 57 total sessions of moderate-intensity exercise (walking while tracking heart rate) over 12 weeks. Exercise intensity, frequency, and session duration will increase during the first 4 weeks of the intervention until participants are completing five (5) sessions weekly and walking for 30 min each session at 60-75% of Heart Rate Reserve (HRR) (moderate-intensity exercise), as follows:
~Week 1: Three sessions, lasting ≥ 15 minutes, at 50-75% of HRR; Week 2: Four sessions, lasting ≥ 20 minutes, at 50-75% of HRR; Week 3: Five sessions, lasting ≥ 30 minutes, at 50-75% of HRR; Weeks 4-12: Five sessions, lasting ≥ 30 minutes, at 60-75% of HRR"
16366768|NCT04210869|Experimental|Experimental|Mixed nuts
16366769|NCT04210869|No Intervention|Control|No mixed nuts
16366770|NCT04210856|Experimental|Sequence of Landscape exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
16366773|NCT04210817||Patients|Patients who have been diagnosed with Rheumatoid Arthritis
16366774|NCT04210804|Experimental|Omega-3|1gEPA and 1gDHA in 200mls smoothie
16366775|NCT04210804|Placebo Comparator|Placebo|200mls smoothie without EPA or DHA. Looks and tastes identical to omega-3 arm
16366803|NCT04210609|Experimental|VHT treatment|Patients will be treated with VHT for 55 minutes at a minimum frequency of 2 times per week
16366776|NCT04210778|Experimental|CRAFT (Cognitive Training and Functional Treatment)|Over 12 weeks this group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training, in addition to a weekly 1 hour remote CO- OP (Meta cognitive strategy training) session. Each participant will set three occupational goals that will be the focus of the CO -OP treatment
16366777|NCT04210778|Active Comparator|Computerized Cognitive Training|This group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training
16366778|NCT04210778|No Intervention|Treatment As Usual|This group will receive no intervention
16366779|NCT04210765|Active Comparator|Clomiphene citrate group 1|Clomiphene citrate dose 50mg/day for 5 days starting on cycle day (2-4).
16366780|NCT04210765|Active Comparator|Clomiphene citrate group 2|Non-responsive to ovulation induction with Clomiphene Citrate with dose:50mg/day; and treated with dose:100mg/day in the succeeding cycle for 5 days, starting on cycle day (2-4).
16366781|NCT04210752|Experimental|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Route of administration: Intramuscular injection"
16366782|NCT04210752|Experimental|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Route of administration: Intramuscular injection"
16366783|NCT04210752|Experimental|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Route of administration: Intramuscular injection"
16366784|NCT04210752|Experimental|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Route of administration: Intramuscular injection"
16366785|NCT04210752|Experimental|Treatment 5 (Shingrix)|"Shingrix
~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.
~Route of Administration: Intramuscular injection"
16366786|NCT04210739|Experimental|trus guided betamethason injection arm|
16366787|NCT04210726|Active Comparator|Active Group - 25% Saline Bath|The Active group's patients will separately have an immersion bath in 25% Sea Salt in Water solution (made by adding pure Sodium Chloride in the form of Sea Salt to Tap Water Bath) at a temperature comfortable to every participant (please note that Solubility of Sodium Chloride in Water does not change significantly with change in temperature, therefore the concentration will remain the same regardless of water temperature), whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers.
16366788|NCT04210726|Placebo Comparator|Control Group - 0.9% Saline Bath|The Control group's patients will separately have a bath in 0.9% Sea Salt in Water (Isotonic solution, made by adding Sodium Chloride in form of Sea Salt to Tap Water) at a comfortable temperature whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers
16366789|NCT04210713|Active Comparator|AUD-Minocycline|Participants diagnosed with alcohol use disorder will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
16366790|NCT04210713|Placebo Comparator|AUD-Placebo|Participants diagnosed with alcohol use disorder will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
16366791|NCT04210713|Active Comparator|Healthy Control-Minocycline|Healthy control participants will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
16366792|NCT04210713|Placebo Comparator|Healthy Control-Placebo|Healthy control participants will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
16366793|NCT04210700|Active Comparator|Fascia iliaca compartment block|Participants will receive fascia iliaca compartment block before spinal anesthesia and operation
16366794|NCT04210700|Experimental|Pericapsular nerve group block group|Participants will receive pericapsular nerve group block before spinal anesthesia and operation
16366795|NCT04210687|Active Comparator|Trapeziectomy|Standard simple trapeziectomy, no pins.
16366796|NCT04210687|Active Comparator|trapeziometacarpal limited excision|Trapeziometacarpal limited excision; Narrow pseudarthrosis of the trapeziometacarpal joint.
16366797|NCT04210674|Experimental|The traditional medicinal product of Argan spinosa oil|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the traditional medicinal product of Argan spinosa oil on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
16366798|NCT04210674|Active Comparator|The conventional topical steroid ointment|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the conventional topical steroid ointment on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
16366799|NCT04210661|Active Comparator|classic prediction software|test with classic precition software
16366800|NCT04210661|Experimental|prediction software with spell checker|test with prediction software with spell checker
16366805|NCT04210596|Experimental|Collagen matrix|Pig-derived collagen matrix (Fibro-Gide, Geistlich Biomaterials, Wolhusen, Switserland)
16366806|NCT04210583|Experimental|Vulvovaginal Treatment|"At visit 1 -(6 months post treatment in the CS0716 study):
~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional),
~At Visit 2 (6 months post treatment in the CS0716 study):
~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional), Administer study treatment (optional: internal, mons pubis and/or labia treatment).
~Discomfort/pain 10 cm VAS, immediate response assessment (applicable only if treatment provided)
~Final AE follow-up 30 days post Visit 2 Treatment (if applicable): AE assessment (applicable only if treatment provided at Visit 2 in the FE1019 study)."
16366807|NCT04210570|Experimental|Memsorb GA|Memsorb Filter will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
16366808|NCT04210570|Active Comparator|CGA GA|Chemical CO2 absorber (CGA) will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
16366809|NCT04210570|Experimental|Memsorb low-flow|Memsorb Filter will be used during low flow general anesthesia (GA)
16366810|NCT04210570|Experimental|CGA low flow|Chemical CO2 absorber (CGA) will be used during low flow general anesthesia (GA)
16366811|NCT04210570|Experimental|Memsorb laparoscopic surgery|Memsorb Filter will be used during general anesthesia for laparoscopic surgery
16366812|NCT04210570|Experimental|CGA laparoscopic surgery|Chemical CO2 absorber (CGA) will be used during laparoscopic surgery
16366813|NCT04210557|Experimental|TMS to insula|"This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.
~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham."
16366814|NCT04210557|Experimental|TMS to cerebellum|This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
16366815|NCT04210544|Experimental|Dietary protein|Postprandial effects after consuming 20 g of a experimental dietary protein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
16366816|NCT04210544|Active Comparator|Casein|Postprandial effects after consuming 20 g of casein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
16366817|NCT04210544|Placebo Comparator|Water|Postprandial effects after consuming 20 g of water mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
16366818|NCT04210531|Experimental|BJ supplementation|Acute beetroot juice (BJ) supplementation
16366819|NCT04210531|Placebo Comparator|PLA supplementation|Acute placebo (PLA) supplementation
16366820|NCT04210518|Experimental|Neuromuscular training|"Neuromuscular training consisting of:
~Single limb balance task.
~Balance training on an unstable surface.
~Hop drills."
16366821|NCT04210518|Experimental|Stroboscopic glasses group|"This group performed the same neuromuscular training with the addition of stroboscopic glasses during the training performance.
~Single limb balance task.
~Balance training on unstable surfaces.
~Hop drills."
16366822|NCT04210518|No Intervention|Control group|This group received no intervention
16366823|NCT04210505|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
16366824|NCT04210505|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each hemodialysis center.
16366825|NCT04210492|Experimental|45 Gy|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
16366826|NCT04210479|Experimental|Filled-bladder|Bladder filling with 300ml diluted methylene blue.
16366827|NCT04210479|Active Comparator|non filled-bladder|
16366828|NCT04210466|Experimental|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|an ACT intervention + 2 sessions of explicit self-compassion meditation exercises.
16366829|NCT04210466|Active Comparator|Acceptance & Commitment Therapy (ACT)|an ACT intervention + 2 Q&A sessions.
16366830|NCT04210453|Placebo Comparator|Control group|Participants in this group are administered IV normal saline.
16366831|NCT04210453|Experimental|Vitamin C group|Participants in this group are administered IV vitamin C diluted in normal saline.
16366832|NCT04210440|Experimental|Hip avascular necrosis|patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria
16366833|NCT04210427|Experimental|Intervention with polyethylene glycol & SmartPill|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
16366834|NCT04210414|Experimental|Day 3 transfer|Transfer on day 3 when only one embryo is available
16366835|NCT04210414|Experimental|Day 5 transfer|Transfer on day 5 when only one embryo is available
16366836|NCT04210388|Experimental|AZD5718 tablet, Treatment A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions.
16366837|NCT04210388|Experimental|AZD5718 tablet, Treatment B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions.
16366838|NCT04210388|Experimental|AZD5718 tablet, Treatment C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
16366839|NCT04210388|Experimental|AZD5718 tablet, Treatment D|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
16366840|NCT04210388|Active Comparator|AZD5718 film-coated tablet|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions.
16366841|NCT04210375|Active Comparator|JK07|Single dose of JK07 administered by intravenous infusion over 60 minutes
16366842|NCT04210375|Placebo Comparator|Matching Placebo|Single dose of placebo administered by intravenous infusion over 60 minutes
16366843|NCT04210362|Experimental|Educational intervention for 30 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 30 months.
16366844|NCT04210362|Experimental|Educational intervention for 24 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 24 months.
16366845|NCT04210362|Experimental|Educational intervention for 12 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 12 months.
16366846|NCT04210362|No Intervention|Comparison group|Group comprised of children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca, Mexico. Children and their caregivers will not be exposed to the intervention at the moment of their measurements.
16366847|NCT04210349|Experimental|Group A: 6 to 35 months, previously unvaccinated, step 1|Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
16366848|NCT04210349|Experimental|Group 1: 6 to 35 months, step 2|Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16366849|NCT04210349|Experimental|Group 2: 3 to 8 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16366850|NCT04210349|Experimental|Group 3: 9 to 17 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
16366851|NCT04210349|Experimental|Group 4: 18 to 60 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
16366852|NCT04210349|Experimental|Group 5: >=61 years|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
16366853|NCT04210336|Experimental|PAPILOCARE|"Randomized patients will receive two different guidelines depending on the time of randomization:
~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).
~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
16366854|NCT04210336|Placebo Comparator|PLACEBO|"Randomized patients will receive two different guidelines depending on the time of randomization:
~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).
~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
16366855|NCT04210323|Experimental|Shotblocker group|ShotBlocker® was used by an experienced registered nurse under the researcher supervision. The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
16366856|NCT04210323|Placebo Comparator|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
16366857|NCT04210323|No Intervention|Control group|Subcutaneous injection was performed with normal subcutaneous drug administration steps by an experienced registered nurse and no additional method was applied. The application process of each patient was managed by the researcher.
16366858|NCT04210310|Experimental|high-dose intranasal oxytocin|Subjects will be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). Subjects will take 4 sprays daily of oxytocin for the entire study.
16366859|NCT04210310|Placebo Comparator|Nasal spray|Subjects swill be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). The spray can be taken with or without food. Subjects will take 4 sprays daily of the placebo for the entire study.
16366860|NCT04210297||Training cohort|Training cohort consists of the cirrhotic patients who collected from January 2018 to December 2019 of Qilu Hospital retrospectively.
16366861|NCT04210297||Internal validation cohort|Internal validation cohort consists of the cirrhotic patients who enrolled from January 2020 of Qilu Hospital prospectively.
16366862|NCT04210297||External validation cohort|External validation cohort consists of the cirrhotic patients who enrolled from January 2020 in Jinan Central Hospital prospectively.
16366863|NCT04210284|Experimental|Nutritional supplementation|Given Ensure Max Protein Nutrition shake 2 weeks before surgery and continued 2 weeks after surgery.
16366864|NCT04210284|No Intervention|No Nutritional supplementation|Treatment as usual
16366865|NCT04210271|Experimental|HIV Self-testing|brief intervention to teach and support consistent self-testing with a friend
16366866|NCT04210271|Active Comparator|Generic Self-screening|time and attention control providing basic self-screening education on a range of health outcomes
16366867|NCT04210245|Experimental|Daily 0.3 mg dose|Administered by subcutaneous injection
16366868|NCT04210245|Experimental|Daily 1 mg dose|Administered by subcutaneous injection
16366869|NCT04210245|Experimental|Daily 3 mg dose|Administered by subcutaneous injection
16366870|NCT04210245|Placebo Comparator|Placebo|Administered by subcutaneous injection
16366871|NCT04210232|Experimental|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
16367036|NCT04209088|Experimental|Pulmonary ultrasounds|All patients will be included in the experimental arm
16367037|NCT04209075|Experimental|Placebo then Prebiotic|Participant will take Placebo during Period 1 and Prebiotic during Period 2
16366872|NCT04210219|Experimental|JNJ-64264681: Dose Escalation and Expansion|Participants will receive oral administration of JNJ-64264681 capsule at a dose assigned by the sponsor Study Evaluation Team (SET), based on the available safety, pharmacokinetics, and pharmacodynamics data in dose escalation treatment group (Part 1); and recommended Phase 2 dose (RP2D) determined in Part 1 in cohort expansion treatment group (Part 2).
16366873|NCT04210206|Experimental|Diet|
16366874|NCT04210206|No Intervention|Control|
16366875|NCT04210193|Active Comparator|Active booster|After three basic open label grass allergen ILIT injections the patient is randomized to an active ILIT booster 1 year after the first treatment.
16366876|NCT04210193|Placebo Comparator|Placebo booster|After three basic open label grass allergen ILIT injections the patient is randomized to a placebo ILIT booster 1 year after the first treatment.
16366877|NCT04210180|Experimental|Varenicline plus e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.
16366878|NCT04210167|Experimental|web-based training and telephone monitoring|The heart failure patients in the intervention group were given web-based training for three months after discharge and followed up by telephone at the first, fourth, eighth and 12th weeks. At the same time, a text message was sent once a week. Scale data were collected before the patient was discharged from the hospital and at the third month of discharge.
16366879|NCT04210141|Active Comparator|Standard of care|Patients will receive an initial antivenom dose of 80mL lyophilized BPI viper antivenom, as per current national guidelines
16366880|NCT04210141|Experimental|Adaptive arm|Patients will receive an initial dose of lyophilized BPI viper antivenom determined by the adaptive model.
16366881|NCT04210128||Breast cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of breast neoadjuvant chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
16366882|NCT04210128||Pancreatic cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of pancreatic chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
16366885|NCT04210102|Other|CR + LUS|Patient will be performed first the Chest radiography then the Lung ultrasound.
16366886|NCT04210102|Other|LUS + CR|Patient will be performed first the Lung ultrasound then the Chest radiography
16366887|NCT04210089|Experimental|Soft Cast with a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast with removable cam boot.
16366888|NCT04210089|Experimental|Soft Cast without a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast.
16366889|NCT04210089|No Intervention|Conventional|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will use conventional offloading including total contact casting, removable cast boots (cam boots), CROW boots, bracing, AFO's, offloading shoes, insoles, padding, shoe modifications, crutches, wheelchairs, rollabout, and surgical correction.
16366890|NCT04210076|Experimental|Mindfulness-Based Attention Training for Teams (MBAT-T)|Teams randomized to this group will receive 2-2.5-hour session deliver over up to 5 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
16366891|NCT04210076|Active Comparator|Mindfulness-Based Attention Training for Individuals (MBAT-I)|Individuals randomized to this group will receive 2-2.5-hour session deliver over up to 5 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
16366892|NCT04210076|No Intervention|No-training|Teams will not engage in any mindfulness training
16367038|NCT04209075|Experimental|Prebiotic then Placebo|Participant will take Prebiotic during Period 1 and Placebo during Period 2
16367039|NCT04209062|Experimental|Study device|
16367040|NCT04209062|Active Comparator|Control device|
16366893|NCT04210063|Experimental|IMT Intervention|During the first month, participants will be in a month-long control wash in period where no intervention will be provided. During the second month, participants will be in a 4-week daily IMT intervention period. During the third month, participants will be in a month-long efficacy period with no intervention provided.
16366894|NCT04210050|Other|Usual care|Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
16366895|NCT04210050|Active Comparator|Usual care plus NIPPV group only|Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
16366896|NCT04210037|Experimental|APG-1252 160 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
16366897|NCT04210037|Experimental|APG-1252 240 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
16366898|NCT04210037|Experimental|APG-1252 80 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
16366899|NCT04210024|Other|Rural-Dwelling Community Members/Residents|Rural-dwelling adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. A subset of participants (~4) will be identified as Community Health Workers and will receive training with the Diabetes Empowerment Education Program (DEEP).
16366900|NCT04209985|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach will call patients up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
16366901|NCT04209985|No Intervention|Usual care|Patients assigned to usual care have access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
16366902|NCT04209972|Active Comparator|Patients on CT1|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a standard CT scanner. (Aquilion One Genesis, Canon Medical Systems)
16366903|NCT04209972|Active Comparator|Patients on CT2|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a UHRCT scanner. (Aquilion One Precision, Canon Medical Systems)
16366904|NCT04209959|Experimental|low dose group|
16366905|NCT04209959|Experimental|middle dose group|
16366906|NCT04209959|Experimental|high dose group|
16366907|NCT04209946|Active Comparator|Less Invasive Surfactant Administration (LISA)|Infants that are spontaneously breathing with a normal heart rate will be randomized to receive prophylactic surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) by the LISA procedure in the first 2 hours of life, using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. Any repeat dosing for surfactant will be based on clinical indication at the physician discretion by the conventional endotracheal approach.
16366908|NCT04209946|Active Comparator|Continuous Positive Airway Pressure (CPAP)|Infants that are spontaneously breathing with a normal heart rate will be randomized to early Continuous Positive Airway Pressure (CPAP).
16366909|NCT04209933|Active Comparator|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16366910|NCT04209933|Active Comparator|Colloidal pectin bismuth capsules containing quadruple therapy|Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16366911|NCT04209933|Active Comparator|Colloidal pectin bismuth particles A quadruple therapy|Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16366912|NCT04209933|Active Comparator|Colloidal pectin bismuth particles B quadruple therapy|Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16366913|NCT04209920|Active Comparator|PMMA crown Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
16366914|NCT04209920|Active Comparator|Cast metal coping Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
16366915|NCT04209907|Active Comparator|the group which retrolaminar block will be approved|the retrolaminar block will be made for postoperative analgesia
16366916|NCT04209907|No Intervention|the group which retrolaminar block will not be approved|the retrolaminar block will not be made for postoperative analgesia
16366917|NCT04209894||Psoriasis|They will undergo dermatological assessment and a blinded ultrasound (US) evaluation.
16366918|NCT04209894||Control|They will also undergo dermatological assessment and a blinded ultrasound (US) evaluation.
16366919|NCT04209881||Patients with Ankylosing spondylitis|"Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.
~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
16366920|NCT04209881||Healthy women as controls|"Regular menstruation with intervals of 21-35 days; cycle length variations <4 days; and both ovaries still present healthy women will create the control group.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.
~Amh will be looked for. (pmol / l). Antral folukul census in the overin folukular stage will be valued as number. Fsh (iu / l) and Estradiol (pmol / l) values will also be recorded."
16366921|NCT04209868|Placebo Comparator|Pre-PVB with saline|Placebo (20ml Saline) pre-PVB performed post-induction and pre-incision.
16366922|NCT04209868|Experimental|Pre-PVB with 0.5% Levo-bupivacaine|20ml 0.5% Levo-bupivacaine pre-PVB performed post-induction and pre-incision.
16367041|NCT04209049|Experimental|Normal renal function|All subjects will receive one dose of NNC0174-0833.
16366925|NCT04209842|Experimental|gastric ballon placement|will receive gastric balloon placed via endoscopy
16366926|NCT04209829||Patients with haematological malignancy|Patients, aged 15 years or over, with haematological malignancy (Lymphoma, ALL, MM) integrated into a CAR-T Cells program treatment
16366927|NCT04209816||ApoC-III LOF|Carriers of apo-CIII loss-of-function mutation
16366928|NCT04209816||ApoC-III GOF|Carriers of apo-CIII gain-of-function mutation
16366929|NCT04209816||TM6SF2-KK|Carriers of TM6SF2 E167K mutation
16366930|NCT04209816||PNLPLA3-MM|Carriers of PNLPLA3 I148M mutation
16366931|NCT04209816||Control|No ApoC-III, TM6SF2 E167K or PNLPLA3 I148M mutation
16366932|NCT04209816||ApoE variants|Carriers of E2/2, E3/3 or E4/4 mutation
16366933|NCT04209816||LIPG|LIPG gene LOF or GOF variant carriers
16366934|NCT04209816||ANGPTL3 or ANGPTL8|ANGPTL3 and ANGPTL8 gene LOF or GOF variant carriers
16366935|NCT04209803|Active Comparator|Minoxidil group|The first group will receive Minoxidil 5% topically twice daily for 4 months.
16366936|NCT04209803|Active Comparator|NAC group|The second group will receive NAC orally 600 mg 3 times a day for 4 months.
16366937|NCT04209803|Active Comparator|Minoxidil + NAC group|The third group will receive combined treatment of Minoxidil 5% twice daily and oral NAC 600 mg 3 times a day for 4 months.
16366938|NCT04209803|No Intervention|Control group|The fourth group will be the patients who are refusing the treatment and will be followed-up over 4 months.
16366939|NCT04209790|Other|Neoadjuvant chemoradiation and surgical resection|The experimental part of the study would be this selection of resectable patients and sequencing neoadjuvant chemoradiation prior to surgery.
16366940|NCT04209777|Active Comparator|Antibiotics|The antibiotic group is provided with amoxicillin capsules 500mg and metronidazole tablets 400mg three times a day for 7 days along with the placebo of probiotics twice daily for 30 days.
16366941|NCT04209777|Experimental|Probiotics|The probiotic group is provided with Lactobacillus-reuteri probiotics (2x10(8)CFU) twice daily after brushing for 30 days.
16366942|NCT04209751||Children with summer diarrhea|Children aged 0 to 16 years with diarrhea
16366943|NCT04209738||Eurythmy Therapy (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified therapist: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by an eurythmy manual and an exercise video. This complements the regular care.
16366944|NCT04209738||Tai Chi (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified teacher: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by a Tai Chi manual and a practice video. This complements the regular care.
16366945|NCT04209738||Standard Care|"Brochure with detailed description of different evidence-based measures for fall prevention, created for the specific age group (Gleichgewicht & Kraft - Trittsicher durchs Leben https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf) and recommendation to visit the family doctor and discuss fall prophylaxis with him."
16366946|NCT04209725|Experimental|CPX-351 and Quizartinib treatment|Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
16366947|NCT04209712|Experimental|haploid allogeneic NK cell therapy|haploid allogeneic NK cell therapy with chemotherapy
16366948|NCT04209699|Experimental|Treatment A: BMS-986165 alone, fasted|
16366949|NCT04209699|Experimental|Treatment B: BMS-986165 alone, fed|
16366950|NCT04209699|Experimental|Treatment C: BMS-986165 with famotidine pretreatment, fasted|
16366951|NCT04209686|Experimental|All Participants|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
16366952|NCT04209673||Transcutaneous nerve stimulation (TENS) patients|Patients who received a TENS unit after surgery
16366953|NCT04209673||No TENS|Historic controls- Patients who did not receive a TENS unit after surgery
16366954|NCT04209660|Experimental|recurrent/metastatic adenoid cystic carcinoma (R/M ACC)|"All eligible patients will undergo informed consent and screening for trial enrollment.
~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
16366955|NCT04209660|Experimental|recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).|"All eligible patients will undergo informed consent and screening for trial enrollment.
~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
16366956|NCT04209647|Active Comparator|Continuous Exercise|At %60 of maximal heart rate, 30-60 minutes exercise
16366957|NCT04209647|Experimental|REHIT Exercise|At %100 of heart rate 15 seconds, after this period 15 sec recovery period for all step
16366958|NCT04209634|Experimental|Active PLE|Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease
16366959|NCT04209621|Other|Single Arm|single-arm, open-label phase 2 study with a safety lead-in cohort
16366960|NCT04209595|Experimental|1/Arm 1|Escalating doses of PLX038 and rucaparib
16366961|NCT04209595|Experimental|2/Arm 2|MTD of PLX038 and rucaparib
16366962|NCT04209569|Active Comparator|NIPP|The NIPP group is a standard social behavior change (SBCC) intervention that tackles a set of underlying causes of malnutrition, with the potential to have both a curative and preventative impact on child malnutrition. The approach in this group/arm involves training and pragmatic behavior change education reinforced by practical activities over a 12-week period to both men and women in selected communities. It aims to utilize easy, viable and accessible solutions within the community that can be used to improve and protect household health and nutrition. The 12-week lesson plans for the circles are divided into 3 components, i) hands-on behavior change sessions that focus on the key pre-identified causes of malnutrition to improve awareness and practice ii) micro-gardening for improved household nutrition security and iii) participatory cooking demonstrations to stimulate improvements in nutritional status and care practices.
16366963|NCT04209569|Experimental|NIPP+|In addition to establishing the circles and implementing the three NIPP components also implemented in the NIPP arm, those randomized to the NIPP+ arm will be provided access to innovations to allow and encourage the households and communities to translate the knowledge into positive practices. The innovations and access to vendors who sell innovations will be made available during the training to the NIPP+ volunteers who will provide trainings and access to vendors during the circle meetings. Most of the additions will be made accessible at a subsidized/low cost. The NIPP+ officers from the program will support NIPP+ volunteers in collaboration with agricultural extension officers.
16366964|NCT04209569|No Intervention|Control|No Intervention
16366965|NCT04209556|Placebo Comparator|Placebo|Placebo
16366966|NCT04209556|Experimental|PF-06826647 100 mg once a day (QD)|PF-06826647 100 mg once a day (QD)
16366967|NCT04209556|Experimental|PF-06826647 300 mg QD|PF-06826647 300 mg QD
16366968|NCT04209556|Experimental|PF-06826647 600 mg QD|PF-06826647 600 mg QD
16366969|NCT04209556|Experimental|Open Label Extension, PF-06826647 400 mg QD|PF-06826647 400 mg QD
16366970|NCT04209543|Experimental|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for up to 13 consecutive weeks
16366971|NCT04209543|Experimental|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 13 consecutive weeks
16366972|NCT04209543|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for up to 13 consecutive weeks
16366973|NCT04209543|Experimental|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
16366974|NCT04209530|Experimental|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
16366975|NCT04209504||Continuous Perineural Catheter|Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.
16366976|NCT04209504||10 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
16366977|NCT04209504||20 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
16366978|NCT04209478|Experimental|TAP Block|Cases were assessed transversus abdominis plane block for postoperative analgesia
16366979|NCT04209478|Experimental|QL Block|Cases were assessed quadratus lumborum block for postoperative analgesia
16366980|NCT04209465|Experimental|Phase 1 - Dose escalation|In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
16366981|NCT04209465|Experimental|Phase 2 - Dose expansion|In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
16366982|NCT04209452|No Intervention|Control|No intervention will be provided for participants enrolled in the control group.
16366983|NCT04209452|Experimental|Rehearsal|Participants will receive instruction on rehearsal strategy.
16366984|NCT04209452|Experimental|Reinforcement|Participants will receive reinforcement for correct recall.
16366985|NCT04209452|Experimental|Rehearsal + Reinforcement|The participants in this group will receive instruction on rehearsal strategy and reinforcement for correct recall.
16366986|NCT04209439|Active Comparator|ultrasound guided erector spinae plane block|30 ml %0.25 ultrasound-guided erector spinae plane block at the level of T8
16366987|NCT04209439|Active Comparator|Dexketoprofen-trometamol|intravenous 50 mg dexketoprofen-trometamol
16366988|NCT04209426||HMB-DMR-HA|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a hydroxyapatite-coated outer surface as well as two pegs and one screw.
16366989|NCT04209426||HMB-DM-CEM|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a bare metal outer surface to be covered with bone-compatible cement.
16366990|NCT04209400|Experimental|Sci-B-Vac®|The third-generation HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
16366991|NCT04209400|Active Comparator|Engerix-B®|The second-generation HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.
16366992|NCT04209387||Control|No PTSD, TBI, and Depression
16366993|NCT04209387||PTSD|Veterans ith PTSD
16366994|NCT04209374||HMB-DMR-HA|Primary total hip arthroplasty with hemispherical dual-mobility acetabular cup
16366995|NCT04209348|Experimental|Physical Activity Intervention|The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather). The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place. The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
16366996|NCT04209348|Active Comparator|Wellness Education|The Wellness Education intervention will deliver information on mom and baby wellness that is unrelated to physical activity, diet, metabolism, or weight (e.g., immunizations during pregnancy and encouragement to immunize the baby on schedule, postpartum contraceptive options and developing a contraceptive plan, infant car seats & safety checks).
16366997|NCT04209335|Other|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
16366998|NCT04209322|Experimental|Pulsed Radiofrequency|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. PRF treatment was administered at 5 Hz and a 2 ms pulsed width for 10 minutes at 45V under the constraint that the electrode tip temperature not exceed 42°C. Finally, patients received 1 mL lidocaine 20 mg/ml mixed with 40 mg triamcinolone acetonide.
16366999|NCT04209322|Active Comparator|Transforaminal Epidural Steroid Injection|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. After 10 minutes await (as per pRF), patients received 1 mL lidocaine 20 mg/ml mixed with 40 mg triamcinolone acetonide.
16367000|NCT04209309|Experimental|leDLPFC|single session rTMS of the left dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F3)
16367001|NCT04209309|Experimental|riDLPFC|single session rTMS of the right dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F4)
16367002|NCT04209309|Sham Comparator|shamDLPFC|single session sham rTMS over the medial prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the midline with tilted coil)
16367003|NCT04209296||Major Depressive Disorder (MDD)|DSM-5 Diagnosis of MDD
16367004|NCT04209296||Bipolar Disorder|DSM-5 Diagnosis of Bipolar Disorder
16367005|NCT04209296||Obsessive Compulsive Disorder (OCD)|DSM-5 Diagnosis of OCD
16367006|NCT04209296||Post-traumatic Stress Disorder (PTSD)|DSM-5 Diagnosis of PTSD
16367007|NCT04209283|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):
~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
~Experimental: Intervention phase ('B'):
~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
~Intervention: Behavioral: Brief cognitive intervention"
16367008|NCT04209257|Experimental|Functional Electrical Stimulation protocol|Participants will be evaluated with and without the use of functional electrical stimulation while walking to determine the neuroprosthetic and neurotherapeutic effects.
16367009|NCT04209244|Experimental|Fish oil|Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)
16367010|NCT04209244|Placebo Comparator|Placebo|Rapeseed Oil, 10 ml per day
16367011|NCT04209231||chronic periodontitis|
16367012|NCT04209231||chronic gingivitis|
16367013|NCT04209231||periodontally healthy|
16367014|NCT04209218|Placebo Comparator|Routine blood pressure management + placebo|Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
16367015|NCT04209218|Experimental|Routine blood pressure management + dexamethasone|Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
16367016|NCT04209218|Experimental|Targeted blood pressure management + placebo|Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
16367017|NCT04209218|Experimental|Targeted blood pressure management + dexamethasone|Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
16367018|NCT04209205|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
16367019|NCT04209205|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
16367020|NCT04209192|Active Comparator|Control group (Amikacin)|"Patients in the control group will receive amikacin as prophylactic antibiotic. It will be administered intravenously 30 minutes before procedure. Patients with an estimated glomerular filtration rate (EGFR) greater or equal than 70 ml/min will receive 1 gram of Amikacin. Patients with an EGFR less than 70 ml/min will received a calculated dose following the next parameters.
~Patients with EGFR between 69-40 ml/min should receive: the calculated GFR x 0.18 = mg/kg.
~Patients with EGFR less than 40 ml/min should receive: the calculated GFR x 0.36 = mg/kg."
16367021|NCT04209192|Experimental|Intervention group (Fosfomycin)|Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
16367022|NCT04209179|Experimental|PCO371 Low Dose and Low administration frequency|PCO371 low dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
16367023|NCT04209179|Experimental|PCO371 High Dose and Low administration frequency|PCO371 high dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
16367024|NCT04209179|Experimental|PCO371 High Dose and High administration frequency|PCO371 high dose and high administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
16367025|NCT04209179|Placebo Comparator|Placebo|Placebo by oral administration.
16367026|NCT04209166|Experimental|FAD|the first-episode major depressive disorder with atypical feature
16367027|NCT04209166|Experimental|RAD|the recurrent major depressive disorder with atypical feature who have been medication-free for no less than 2 weeks
16367028|NCT04209166|No Intervention|BD|the depressive episode of bipolar disorder
16367029|NCT04209166|No Intervention|HC|healthy control
16367030|NCT04209140||bipolar I disorders who initiate lithium treatment|
16367031|NCT04209127|Experimental|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis
16367032|NCT04209127|Active Comparator|Control|Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof
16367043|NCT04209049|Experimental|Moderate renal impairment|All subjects will receive one dose of NNC0174-0833.
16367044|NCT04209049|Experimental|Severe renal impairment|All subjects will receive one dose of NNC0174-0833.
16367045|NCT04209036||3D laparoscopy arm|patients submitted to total hysterectomy using a 3D laparoscopic camera
16367046|NCT04209036||2D laparoscopy arm|patients submitted to total hysterectomy using a 2D laparoscopic camera (standard laparoscopic camera)
16367047|NCT04209023|Experimental|navigated TMS|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest; these areas will provide the cerebral coordinates to be validated by TMS.
16367048|NCT04209010||One-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in one stage using silicone implant and acellular dermal matrix.
16367049|NCT04209010||Two-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in two stages using expander to silicone implant technique.
16367050|NCT04208997|Experimental|Continuation of antiarrhythmic drugs|Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
16367051|NCT04208997|No Intervention|Discontinuation of antiarrhythmic drugs|Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.
16367052|NCT04208984||Control|Patients randomized to this group will receive standard of care induction of anesthesia
16367053|NCT04208984||Study|Patients randomized to this group will receive induction of anesthesia using the Lullabreath game
16367054|NCT04208984||Music Video|Patients randomized to this group will receive induction of anesthesia using the music video game
16367055|NCT04208971||BEAGLE Participants|Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
16367056|NCT04208958|Experimental|VE800 combination treatment with Nivolumab|Subjects will receive 5 days of oral vancomycin, followed by daily VE800 in combination with Nivolumab every 4 weeks.
16367057|NCT04208945|Experimental|Inhaled colistin|Inhaled colistin three times daily for 10 days
16367058|NCT04208945|No Intervention|Standard management|
16367059|NCT04208932||MDD|major depressive disorder
16367060|NCT04208932||HC|healthy control
16367061|NCT04208919|Experimental|DCreg Prior to Weaning|Regulatory dendritic cells that were derived from the recipient's liver donor will be infused into the recipient one week prior to the initiation of immunosuppression weaning.
16367063|NCT04208893|Experimental|Aerobic training only|The aerobic training intervention will include 60 minutes/session, 3 times/week for 12 weeks at an intensity of 65% - 85% of participants' heart rate reserve (HRR), as determined by the CPET. Patients will be asked to wear a fitness-tracking device to monitor their heart rate response and in order to comply with the prescribed training intensity. All training sessions will start with a 10-minute warm up, 40-minute aerobic interventions, and ends with 10-minute of cool down. One study doctor will be on call during in-hospital training. Onsite supervised aerobic interventions will include play-based activities, whereas home-based aerobic activities will include stationary bikes and exercise activities that would target desired heart rate ranges. Home exercise equipment will be provided.
16367064|NCT04208893|Experimental|Combined aerobic and strength training|Participants in this group will perform a combination of aerobic and strength training activities for 60 minutes/session, 3 times/week for 12 weeks. Aerobic activities for this group will be similar to Arm 1. Strength training will be based on participant's individual assessment findings and developmental status. Resistance level will be set at approximately 50% of the patient maximal load and increased by 3 pounds (or the next level of resistance band) once the patient is able to perform 30 repetitions. Closed kinetic chain exercises such as pushups, squats, and lunges will be made more challenging by the addition of weight or change in body position. Training sessions will include a 10-minute warm up, 40-minute aerobic and strength exercises, and a 10-minute cooldown.
16367065|NCT04208880|Experimental|TBH Brain Workout 1.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be easy to master.
16367066|NCT04208880|Experimental|TBH Brain Workout 2.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be moderately difficult to master.
16367067|NCT04208880|Experimental|TBH Memory 1.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be easy to master.
16367068|NCT04208880|Experimental|TBH Memory 2.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be moderately difficult to master.
16367069|NCT04208880|Active Comparator|Book Club|The Book Club will be given a book to read on how to improve brain health and will discuss separate chapters across 8 sessions. These sessions will be led by the participants and no formal structure will be provided. No personal challenges will be asked of participants and no log will be required. All groups will have a sign-in sheet to record individual participation.
16367070|NCT04208880|No Intervention|No Contact Wait List|The Wait List group will simply take the the surveys at each time point as the other groups.
16367071|NCT04208867|Experimental|Intervention - Women|Women who receive MH services from a facility participating in the QI collaborative to improve PCC
16367072|NCT04208867|No Intervention|Control - Women|Women who receive MH services from a facility not participating in the QI collaborative to improve PCC
16367073|NCT04208867|Experimental|Intervention - Provider|Provider working at a facility participating in the QI collaborative to improve PCC
16367074|NCT04208867|No Intervention|Control - Provider|Provider working at a facility not participating in the QI collaborative to improve PCC
16367075|NCT04208854||VINORELBINA|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.
~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.
~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
16367076|NCT04208841|No Intervention|Control - Patient|Participants who receive maternal health services at a facility not participating in the Quality Improvement Intervention or implementing the change package
16367077|NCT04208841|Experimental|Sustaining - Patients|Participants who received maternal health services at a facility where a quality improvement collaborative had been implemented
16367078|NCT04208841|Experimental|Spread - Patients|Participants who received maternal health services at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
16367079|NCT04208841|No Intervention|Control - Providers|Providers who work at a facility not participating in the Quality Improvement Intervention or implementing the change package
16367080|NCT04208841|Experimental|Sustaining - Providers|Providers who work at a facility where a quality improvement collaborative had been implemented
16367081|NCT04208841|Experimental|Spread - Providers|Participants who work at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
16367082|NCT04208815|Experimental|MPL-rich dairy beverage|Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks
16367083|NCT04208815|Placebo Comparator|Control dairy beverage|Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks
16367084|NCT04208802||Smokers|Volunteers smoking at least 10 cigarettes per day
16367085|NCT04208802||Non-smokers|Non-smoking volunteers
16367086|NCT04208789||Positive Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Positive Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
16367087|NCT04208789||Negative Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Negative Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
16367088|NCT04208776|Experimental|Midodrine+Propranolol|
16367089|NCT04208776|Active Comparator|Propranolol|
16367090|NCT04208763|Experimental|Imipenem+Tigecycline+GM-CSF|
16367091|NCT04208763|Active Comparator|Imipenem+Tigecycline|
16367092|NCT04208750|Experimental|R-Refraction|
16367093|NCT04208750|Active Comparator|S-Refraction|
16367094|NCT04208737|No Intervention|control group|"3 FRC measurements will be perforemed, whereby : First measurement; after aneshesia induction and intubation. Second measurement; after pneumoperitoneum Third measurement; end of the operation
~After the operation,Postoperative Room Air Test (RAT) will be applied."
16367095|NCT04208737|Experimental|study group|"5 FRC measurements will be performed We will apply recruitment maneuver two times to patients with 30cmH2O pressure for 15 seconds .
~First Recruitment maneuver will be applied after the fşrst measurement of FRC following intubation Second Recuitment maneuver will be applied at the end of operation
~First FRC measurement after anesthesia induction and intubation. Second FRC measurement after first recruitment maneuver Third FRC measurement; after pneumoperitoneum Fourth FRC measurement before second recruitment maneuver Fifth FRC measurement after second recruitment maneuver and at the end of operation"
16367096|NCT04208724|Experimental|Training program|Community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members.
16367097|NCT04208711|Other|positive HIV patient not treated by ARV yet|"Before starting HIV treatment, 15 patients will be included in the study and 50mL of whole blood will be taken. After treatment initiation 8 of the 15 patients will entered in the follow-up phase for 1 year (5 followup visit, M1, M3, M6, M9, M12) and 30mL of whole blood will be taken at each visit.
~The duration of the study for the 7 other patients will be 1 day."
16367098|NCT04208698|Experimental|CIN-102 Tablets Dose 1|CIN-102 tablets by mouth twice daily for 14 days
16367099|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 1|Placebo tablets by mouth twice daily for 14 days
16367100|NCT04208698|Experimental|CIN-102 Dose 2|CIN-102 tablets by mouth twice daily for 14 days
16367101|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 2|Placebo tablets by mouth twice daily for 14 days
16367102|NCT04208672|Experimental|Patient attending for PSG in Sleep Assessment Unit|Subjects referred to the SAU will be invited to participate into this study
16367103|NCT04208659|Experimental|Self-administration of Auricular Acupuncture Group|There is only one arm in this pilot project, whose purpose is to determine safety of self-administration of Battlefield Acupuncture over a six month period and how well a prosthesis facilitates needle insertion. Five ASP (Aiguille D'acupuncture semi-permanente) needles will be self-inserted into each participant's ear every two weeks according to the standardized acupuncture points in Battlefield Acupuncture.
16367104|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
16367105|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells high-dose group
16367106|NCT04208646|Placebo Comparator|No mesenchymal progenitor cells|No mesenchymal progenitor cells
16367107|NCT04208633|Other|Horizontal placement of the intraocular lens|The eyes randomised to have horizontal placement of intraocular lenses
16367108|NCT04208633|Other|Vertical placement of the intraocular lens|Fellow eye receiving vertical placement of intraocular lens.
16367109|NCT04208620|Placebo Comparator|Placebo|Placebo administered subcutaneously
16367110|NCT04208620|Experimental|Cotadutide|Cotadutide administered subcutaneously
16367111|NCT04208607|Experimental|Study group|Patients with bronchiectasis
16367112|NCT04208594|Active Comparator|GROUP (P):|will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.
16367390|NCT04206644||Systemic sclerosis patients|SSc patients according to the ACR/EULAR 2013 classification criteria
16367113|NCT04208594|Experimental|GROUP (I):|will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.
16367114|NCT04208581|Experimental|Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive Yiqi Huoxue Huatan granule in addition to Western medicine.
16367115|NCT04208581|Placebo Comparator|Placebo Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive placebo Yiqi Huoxue Huatan granule in addition to Western medicine.
16367116|NCT04208568|Active Comparator|Gallbladder retrieval from umbilical port|Gallbladder retrieved from 10 mm umbilical port.
16367117|NCT04208568|Active Comparator|Gallbladder retrieval from epigastric port|Gallbladder retrieved from 10 mm epigastric port.
16367118|NCT04208555|Experimental|Boric acid vaginal suppository|
16367119|NCT04208555|Active Comparator|Terconazole vaginal suppository|
16367120|NCT04208542|Active Comparator|Interventional|Under general anaesthesia, ultrasound guided ESP block will perform at the T5 level with 0.375% ropivacaine 20ml. Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
16367121|NCT04208542|No Intervention|Control|Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
16367122|NCT04208529||CTX001|All subjects who complete or discontinue the parent study (CTX001-111 or CTX001-121) after CTX001 infusion will be asked to participate in this long-term follow-up study.
16367123|NCT04208516|Active Comparator|Continuous nerve blocks|A total of 30 subjects equally distributed to either continuous Erector Spinae Plane block for unilateral thoracic surgery , or continuous Quadratus Lumborum block for major abdominal surgery. Patients in this group will receive 20ml 0.5% ropivacaine per block performed after positioning of the needle followed by continuous perineural infusion of 0.25% lidocaine (10ml/hr) beginning in the post-anesthesia care unit (PACU) and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
16367124|NCT04208516|Experimental|Single nerve blocks plus IV lidocaine infusion|A total of 30 subjects equally distributed to either Erector Spinae Plane block for unilateral thoracic surgery, or Quadratus Lumborum block for major abdominal surgery, will be included . Patients in this group will receive 20ml 0.5% ropivacaine, 4mg dexamethasone, and 20mcg dexmedetomidine (30mcg if only one block is performed) per block after proper positioning of the Tuohy needle. Upon patient arrival in the recovery room a continuous infusion of IV lidocaine 50 mg /hr will be started and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
16367125|NCT04208490|Other|HN-STAR|
16367126|NCT04208490|No Intervention|Usual Care|
16367127|NCT04208477|Experimental|BSG patients|
16367128|NCT04208464|Experimental|Arm A|Participants will receive 4mg baracitinib daily for 24 weeks from the baseline visit in week 0. After treatment participants will be followed up for 12 weeks.
16367129|NCT04208464|Experimental|Arm B|After the baseline visit in week 0, participants will wait for a 12 week treatment delay and will then receive 4mg baracitinib daily from week 12-week 36 (i.e. for 24 weeks). After treatment participants will be followed up for 4 weeks for safety.
16367130|NCT04208451|Experimental|Experimental group|Patients on hemodialysis who consumed one month Standardized Aronia Melanocrpa extract
16367131|NCT04208438||BVI Cohort|Cohort to have ultrasound and Mespere BVI device applied.
16367132|NCT04208425|Experimental|Project Personality|The web-based growth mindset intervention, called Project Personality, is delivered entirely via Qualtrics and takes approximately 30 minutes to complete. All intervention activities are self-administered by youth and delivered in a web-based format, including illustrations and audio-recordings of text. Intervention content is designed to maximize relevance for youths experiencing symptoms of depression, including excessive sadness and hopelessness.
16367133|NCT04208425|Active Comparator|Sharing Feelings Intervention|The Sharing Feelings Intervention is delivered entirely via Qualtrics, is self-administered by youth, and takes approximately 30 minutes to complete. It is structurally similar to the growth mindset intervention, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention is to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions.
16367134|NCT04208412|Experimental|KVD900|
16367135|NCT04208412|Placebo Comparator|Placebo|
16367136|NCT04208399|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
16367137|NCT04208399|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive a single oral dose of JNJ-56136379 in fed condition.
16367138|NCT04208399|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
16367139|NCT04208399|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
16367140|NCT04208386|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive single subcutaneous (SC) injection of JNJ-73763989 on Day 1 under fasted condition.
16367141|NCT04208386|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
16367142|NCT04208386|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
16367143|NCT04208386|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive SC injection of JNJ-73763989 on Day 1 under fasted condition.
16367144|NCT04208373|Experimental|Panel 1: JNJ 64417184 plus Itraconazole|Participants will receive single oral dose of JNJ 64417184 on Day 1 followed by itraconazole once daily on Days 6 to 13 along with a single dose of JNJ 64417184 on Day 9 orally.
16367145|NCT04208373|Experimental|Panel 2: JNJ 64417184 plus Etravirine|Participants will receive single oral dose of JNJ-64417184 on Day 1 followed by etravirine twice daily on Days 6 to 19 along with single dose of JNJ 64417184 on Day 15.
16367146|NCT04208347|Experimental|Apatinib and Camrelizumab and S-1 and Oxaliplatin|
16367147|NCT04208347|Experimental|Apatinib and S-1 and Oxaliplatin|
16367148|NCT04208347|Active Comparator|S-1 and Oxaliplatin|
16367149|NCT04208334|Experimental|Curcumin|Curcumin 4000mg/day x 60 days
16367150|NCT04208334|Placebo Comparator|Placebo|Placebo x 60 days
16367157|NCT04208308|No Intervention|Control negative group|Without supplementation
16367158|NCT04208308|Experimental|Experimental negative group I|"Chia seeds supplementation (25 g)
~On dose (25g) of chia seeds contains:
~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
16367159|NCT04208308|Experimental|Experimental negative group II|"Chia seeds supplementation (15 g)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
16367160|NCT04208308|Experimental|Experimental negative group III|"Combine supplementation: chia seeds and fish oil
~Daily dose:
~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
16367161|NCT04208308|Experimental|Experimental negative group IV|"Fish oil supplementation
~Daily dose:
~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
16367162|NCT04208308|No Intervention|Control positive group|Without supplementation
16367163|NCT04208308|Experimental|Experimental positive group I|"Chia seeds supplementation (25 g)
~On dose (25g) of chia seeds contains:
~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
16367164|NCT04208308|Experimental|Experimental positive group II|"Chia seeds supplementation (15 g)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
16367165|NCT04208308|Experimental|Experimental positive group III|"Combine supplementation: chia seeds and fish oil
~Daily dose:
~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
16367166|NCT04208308|Experimental|Experimental positive group IV|"Fish oil supplementation
~Daily dose:
~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
16367167|NCT04208295||Patients|Type 2 diabetics
16367168|NCT04208295||Healthy controls|Matched healthy controls
16367169|NCT04208282|Experimental|Trial Arm A|Quickset infusion system for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the 7 day set infusion set, entering Phase 2.
16367170|NCT04208282|Active Comparator|Trial Arm B|7 day set infusion set for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the Quickset infusion systems , entering Phase 2.
16367171|NCT04208269|Active Comparator|Postcard campaign|
16367172|NCT04208269|Active Comparator|Provider-only intervention|
16367173|NCT04208269|Active Comparator|Patient and provider intervention|
16367174|NCT04208269|No Intervention|Standard care|
16367391|NCT04206644||Healthy donors|HD healthy donors from EFS (Etablissement Français du sang)
16367177|NCT04208243|Experimental|Oncology Patient|Any Oncology patient in the CCBD who has not previously received more than two sessions of CAT in the outpatient unit and who will be receiving approximately weekly infusions of at least one hour in the infusion center will be identified by a research assistant.
16367180|NCT04208217|Experimental|Modeling to Learn (MTL)|12 clinics randomly assigned to MTL
16367181|NCT04208217|Experimental|Usual quality improvement (QI)|12 clinics randomly assigned to usual QI
16367182|NCT04208204|Experimental|Somatocognitive physiotherapy|Every participant will maximally receive 15 individual sessions of somatocognitive physiotherapy
16367183|NCT04208191|No Intervention|Control - Women|Participants who delivered or received family planning services at a facility that was not implementing a QI project on PCC
16367184|NCT04208191|Experimental|Intervention - Women|Participants who delivered or received family planning services at a facility that was implementing a QI project on PCC
16367185|NCT04208191|No Intervention|Control - Provider|Provider working in a facility that is not implementing a QI project on PCC
16367186|NCT04208191|Experimental|Intervention - Provider|Provider working in a facility that is implementing a QI project on PCC
16367187|NCT04208178|Experimental|Part 1: Alpelisib + Trastuzumab + Pertuzumab|"In the Part 1, up to 3 alpelisib dose levels may be sequentially tested in 3 cohorts of subjects (Cohort A, Cohort B, and Cohort C)
~Cohort A: Alpelisib 300mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)
~Cohort B: Alpelisib 250 mg+ trastuzumab (6mg/kg) + pertuzumab (420 mg)
~Cohort C: Alpelisib 200mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)"
16367188|NCT04208178|Experimental|Part 2: Alpelisib + Trastuzumab + Pertuzumab|trastuzumab (6mg/kg i.v.) + pertuzumab (420 mg i.v.) in combination with alpelisib at dose identified in Part 1
16367189|NCT04208178|Placebo Comparator|Part 2: Alpelisib matching Placebo + Trastuzumab + Pertuzumab|trastuzumab (6mg/kg i.v.) + pertuzumab (420 mg i.v.) in combination with alpelisib matching placebo
16367190|NCT04208165|Active Comparator|Group P (ultrasound-guided PVB)|In group P, the patient is in sitting position, a linear transducer (6-15 MHz) placed just lateral to the spinous process. Once the transverse processes and ribs are identified, the transducer is moved slightly cauded into the intercostal space between adjacent ribs to identify the thoracic paravertebral space (PVS) and the adjoining intercostal space. The hyper echoic line of the pleura and underlying hyper echoic air artifacts move with respiration. The needle stimuplex needle will be inserted and 0.5- 1 ml local anesthetic injection administered to show the displacement of pleura downward followed by 15 cc bupivacaine 0.25% into each side the PVS. A pop often is felt as the needle penetrates the internal intercostal membrane. Intravascular injection will be eliminated by negative aspiration before injection. Local anesthetic (15- 20 ml) is slowly injected in small increments, avoiding forceful high-pressure injection to reduce the risk of bilateral epidural spread.
16367191|NCT04208165|Active Comparator|Group T (ultrasound-guided TAB)|In group T, Subcostal blockage will be done in plane technique with 22 G needle (BRAUN Stimuplex D Plus 0,71 50- 80 mm 22 G). The puncture area and the ultrasound probe will be prepared in an aseptic manner. The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. On each side, The rectus abdominis and underlying transverses abdominis muscles near the costal margin and xiphoid process will be identified. In-plane image will be obtained and the needle will be inserted through the rectus muscle 2-3 cm medial to the probe. Once the tip of the needle is visualized to be in the plane, 0.25% bupivacaine will be administered incrementally. The drug will be injected along the oblique subcostal line, extending inferolaterally from the xiphoid towards the anterior part of the iliac crest by multiple punctures; a total of 15 ml will be given on each side.
16367192|NCT04208152|Active Comparator|anle138b|Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
16367193|NCT04208152|Placebo Comparator|placebo|Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
16367194|NCT04208126|Active Comparator|Early ECMO|ECMO is placed immediately after admission to the intensive care unit
16367195|NCT04208126|No Intervention|Control|Conservative therapy unless failure of therapy.
16367196|NCT04208113|Experimental|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.
~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the eight week MBSR programme (2,5 hour group meeting once a week) and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b (48 hours) The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
16367197|NCT04208113|No Intervention|Usual practice|Usual practice
16367198|NCT04208087|Experimental|SI-722|
16367199|NCT04208087|Placebo Comparator|Placebo|
16367200|NCT04208074|Experimental|Exercise|Four months of muscle resistance training (exercise) designed to increase muscle mass and strength. The exercise protocol includes four different lifts with weights including, squats, bench press, dead lift and overhead press. The weights for each lift will be optimized for each participant and increased as the participant adapts to the exercise routine.
16367201|NCT04208061|Experimental|Panel 1: Dabigatran etexilate +DRV/COBI|Participants will receive Treatment A (single dose of Dabigatran etexilate orally) on Day 1 followed by Treatment B (single dose of Darunavir/ cobicistat [DRV/COBI] as fixed dose combination tablet orally and single dose of dabigatran etexilate) on Day 4 followed by Treatment C ([DRV/COBI] as fixed dose combination tablet orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
16367202|NCT04208061|Experimental|Panel 2: Dabigatran etexilate +DRV+rtv|Participants will receive Treatment D (single dose of dabigatran etexilate orally) on Day 1 followed by Treatment E (single doses of Darunavir, and ritonavir [rtv], and single dose of dabigatran etexilate on Day 4), followed by Treatment F (DRV and rtv orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
16367203|NCT04208048||FLXfit 15|The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
16367204|NCT04208022||Healthy Musician|At least 15 hypermobile musicians and at least 15 non-hypermobile musicians will be included in the study.
16367205|NCT04208022||Healthy Individuals|The study will include at least 15 healthy non-hypermobile individuals who do not deal with music and at least 15 healthy hypermobile individuals who do not deal with music.
16367206|NCT04208009|Experimental|Advance care planning animated videos|This arm consists of viewing four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
16367207|NCT04207983|Experimental|Treatment Arm A (Re-administration)|Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
16367208|NCT04207983|Experimental|Treatment Arm B (Single administration)|One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
16367209|NCT04207970||Clients under PDS Community Team|27 adult clients under PDS Community Team
16367210|NCT04207957|Other|IV|2 h IV infusion (Groups A/B)
16367211|NCT04207957|Other|oral (fasted)|30 mg tablets given after an overnight fast (Groups A/B)
16367212|NCT04207957|Other|oral (fed)|30 mg tablets given after a high fat breakfast (Groups A/B)
16367213|NCT04207957|Other|oral (intact tablet)|30 mg tablets (Group C)
16367214|NCT04207957|Other|oral (NG tube)|30 mg tablets in water via NG tube (Group C)
16367215|NCT04207944|Experimental|Sulindac|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Patients will continue drug for 3 years during follow-up.
16367216|NCT04207944|Placebo Comparator|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus placebo. Patients will continue placebo for 3 years during follow-up.
16367220|NCT04207905||Exempt for Evaluation Purposes|Individuals who would have been subject to the Healthy Michigan Plan (HMP) work requirements but have been randomly assigned to a control group that is exempt from reporting for evaluation purposes
16367221|NCT04207905||Work Requirement|Individuals who are subject to the Healthy Michigan Plan (HMP) work requirements
16367222|NCT04207879||weight loss group|Dynamic changes in body composition, biochemical metabolomics and gut microbiome will be reported among overweight and obese patients.
16367223|NCT04207866|Experimental|Remote AT services|Experimental group will consist of participants who access auditory therapy services from a remote location. Services will be conducted with this group via teleconferencing over the Ontario Health Network.
16367224|NCT04207866|Active Comparator|In House AT|This group will receive auditory therapy services face-to-face at the treatment site.
16367225|NCT04207853|Experimental|whole body vibration in diabetics (G1)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
16367226|NCT04207853|Sham Comparator|the sham vibration group in diabetics (G2)|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
16367227|NCT04207853|No Intervention|diabetic control group (G3)|no treatment
16367228|NCT04207853|Active Comparator|whole body vibration group in non-diabetics (G4)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
16367229|NCT04207853|Sham Comparator|"the vibration group  sham in non-diabetics (G5)"|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
16367230|NCT04207853|No Intervention|non-diabetic control group (G6)|no treatment
16367231|NCT04207840|Experimental|Primatene Mist, E004|Participants who dosed with Primatene Mist.
16367232|NCT04207840|Active Comparator|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
16367233|NCT04207840|Active Comparator|Albuterol HFA|Participants who dosed with Albuterol HFA.
16367234|NCT04207827|Experimental|xSmoker app|"The xSmoker app was developed with European Commission funding. xSmoker is a digital health coaching mobile app that helps individuals stop smoking and remain smoke free. The initial version of the xSmoker application was received from the developers and translated into Romanian by the research team. The content has been divided into three main sections: Daily Tips (approximately 630 items), which includes information on the beneficial effects of quitting smoking, Panic Tips (approximately 100 items), which can be accessed at that time when risk of smoking relapse is high, as well as a section called Library (about 120 items), where detailed information on the topics included in the first two sections is provided."
16367267|NCT04207567|Experimental|Intervention Arm|Participants in this arm will be instructed to perform one set each of push-ups, angled-rows and bodyweight squats every weekday without supervision for a total of 24 weeks. They will receive the equipment necessary to perform the exercises as well as guidance on proper performance. They will also receive training in the Tiny Habits® Method at baseline and digital coaching for the duration of the study.
16367392|NCT04206644||LUPUS Patiets|Lupus patients according to the ACR 2019 classification criteria
16369865|NCT04189055|Experimental|Cohort #1|Cetuximab monotherapy (500mg/m² IV, day 1)
16367235|NCT04207827|Experimental|xSmoker app + SMSs|The xSmoker app + phone text messages with content based on the Motivation and Problem Solving approach and informed by our prior work. The investigators developed six categories of messages sent to participants: (1)Importance and trust, (2)Fear of relapse, (3)Partner support, (4)Breastfeeding, (5)The need to smoke, and (6)Relapse. Four major objectives were established based on the content of the SMS text messages, with the help of the literature: (1)supporting motivation, (2)supporting self-efficacy, (3)supporting dyadic effectiveness, and (4)developing problem-solving skills. The messages were delivered using Textit, a platform for visually building interactive SMS applications (htpps://textit.in). All the messages were uploaded in the platform and different flows and sub-flows were created for every day of the intervention to automatize the process of SMS delivery. A combination of trigger words and skip patterns was used in order to tailor the messages.
16367236|NCT04207827|Other|Control|Usual postnatal care
16367237|NCT04207814|Experimental|Cases|
16367238|NCT04207801|Experimental|Arm-1|400 mg AUR101 twice daily
16367239|NCT04207801|Experimental|Arm-2|600 mg AUR101 twice daily
16367240|NCT04207801|Placebo Comparator|Arm-3|Matching Placebo twice daily
16367241|NCT04207788|Experimental|Intervention|HIP-REP programme offers elderly with hip fracture add on activity-focused interventions.
16367242|NCT04207788|Active Comparator|Usual care|The elderly with hip fracture in the control group will receive usual care.
16367243|NCT04207775||NSCLC|Patients with confirmed EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed from first line EGFR-TKI therapy who will receive different treatment
16367244|NCT04207762||PET/CT Diagnostic Imaging|Each subject will have a PET/CT scan, using 18F-AmBF3-TATE. 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada.
16367245|NCT04207736|Active Comparator|Reproxalap Ophthalmic Solution (0.25%)|
16367246|NCT04207736|Placebo Comparator|Vehicle Ophthalmic Solution|
16367247|NCT04207723|Experimental|TENS Therapy|Tens therapy + placebo drug therapy
16367248|NCT04207723|Sham Comparator|Control|Standard treatment (paroxetine 20 mg) + sham therapy
16367249|NCT04207723|Experimental|Combination therapy|Tens therapy + standard treatment (paroxetine 20 mg)
16367250|NCT04207710|Experimental|Microbial growth after application of Pain Ease|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Pain Ease numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
16367251|NCT04207710|Experimental|Microbial growth after application of Ethyl Chloride|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Ethyl Chloride numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
16367252|NCT04207684|Experimental|Testosterone|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration (6 fractions: 0-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h post-administration).
16367253|NCT04207671|Other|Omission of chest tube|After wedge resection and the air-leak test, patients will receive complete omission of chest tube and directly close the incision.
16367254|NCT04207671|Experimental|Improved drainage strategy|After wedge resection and the air-leak test, patients willreceive a two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-removal.
16367255|NCT04207658|Experimental|Valsalva's Pushing|The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. At the expulsion phase (baby's head is visible in vulva), they are encouraged to perform the Valsalva's manoeuvre that they have practised in routines of delivery; When contractions start, breathe twice normally. Take a deep breath and hold. Compress the air with the help of diaphragm and abdominal muscles. Push strongly and long (for 10-15 sec). Breathe out and take another deep breath, hold it and push as strongly as possible for another 10-15 seconds. Stop pushing when contractions are mild. Breathe 2-3 times in normal style. Relax and have a rest until the next contraction.
16367256|NCT04207658|No Intervention|control|Practices on Spontaneous Pushing Group The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. Just after feeling the push, the gravitas are requested perform pushing as follows; Breathe normally until participants feel the push when contractions start, pull back muscles surrounding the uterus while breathing. Start pushing gradually and breathe out smoothly by minimizing lips. Push between breaths for 5-6 seconds while pushing downwards by breathing out. Breathe normally when contractions weaken.
16367257|NCT04207645||African|patients originating from Nigeria and Sudan (11 centres)
16367258|NCT04207645||Latin American|patients originating from Mexico (5 centres)
16367259|NCT04207645||South Asian|patients originating from India and Pakistan (10 centres)
16367260|NCT04207645||European|patients originating from Spain (11 centres).
16367261|NCT04207632||Intervention|The Group of patients will receive routine treatment of muscle hypertonia with botulinum toxin type A in their elbow flexors.
16367262|NCT04207619|Experimental|Arm 1|Participants will have their glial acetate metabolism measured by carbon-13 magnetic resonance spectroscopy as well as their neuroendocrine response to hypoglycemia 3 days later.
16367263|NCT04207606||Epidural Steroid Injection Patients|Patients who are to receive an epidural steroid injection as an outpatient.
16367264|NCT04207593|Active Comparator|Oxygen Therapy provided|Patients will be divided in a supplemental-oxygen group (primary intervention group) throughout the study
16367265|NCT04207593|Sham Comparator|no-supplemental-oxygen group (control group)|Patients of the control group will beginn the study without Oxygen Therapie and will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group).
16367266|NCT04207580||Inclusion and follow up of pediatric patients|"Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome, from the beginning of the disease to 18 years old or transfer of the follow-up to a nephrology unit for adults.
~130 new patients are expected to be included on an annual basis."
16367268|NCT04207567|No Intervention|Waitlist Control Arm|"Participants in the control arm will be instructed to refrain from resistance training for the initial 12 weeks of the study.
~Note that, after the 12-week follow-up assessment (at which the primary outcome of composite reps will be assessed), this group will begin the RT program. They will receive the same equipment, training, and coaching as the intervention group, and they will continue the RT program for 12 weeks, followed by a 24-week assessment."
16367269|NCT04207554||Pregnancy Positive|Pregnant subjects within 11 weeks since the first day of last period.
16367270|NCT04207554||Pregnancy Negative|Non-pregnant subjects.
16367271|NCT04207541|Experimental|Control group and Intervention group|For control group, participants will be treated with usual care. For intervention group, participants will be provided a session of education regarding insulin initiation with brief motivation interviewing.
16367272|NCT04207528|Experimental|Peer Helping Condition|Participants in the peer helping condition will be asked to write about their experiences in their first-year at UCLA (freshman or first-year after post-transfer), with an emphasis on using the experience to benefit someone who is about to be a first-year student.
16367273|NCT04207528|Active Comparator|Facts-only Control|Participants in the facts-only writing condition will be asked to write facts about their experiences in their first-year at UCLA (freshman or first-year post-transfer). Unlike the previous conditions, they will not be instructed to write for the benefit of another individual.
16367274|NCT04207515|Experimental|Removal of wisdom tooth under conscious sedation|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure, oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia , intraoperative time-after extraction , postoperative time . In this group removal of wisdom teeth was done under conscious sedation. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
16367275|NCT04207515|Active Comparator|Removal of wisdom tooth under local anesthesia|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure , oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia, intraoperative time-after extraction, postoperative time. In this group, removal of wisdom teeth was done under local anesthesia. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
16367276|NCT04207489||endoscopic submucosal injection of indocyanine green|
16367277|NCT04207476|Experimental|Treatment arm|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
16367278|NCT04207476|Placebo Comparator|Placebo|Placebo magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
16367279|NCT04207463|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16367280|NCT04207450|Placebo Comparator|Placebo Group|Placebo Gel + Placebo Solution (Distilled Water)
16367281|NCT04207450|Experimental|Placebo Gel + Glutaraldehyde (GPG)|Placebo Gel + 5% Glutaraldehyde Aqueous Solution
16367282|NCT04207450|Experimental|Phosphoric Acid + Glutaraldehyde (GAG)|37% Phosphoric Acid + Glutaraldehyde Aqueous Solution (GAG)
16367283|NCT04207437|Experimental|Vibration Therapy|Patients will hold a hand held vibrating device for 3 minutes on each hand daily for 4 weeks.
16367284|NCT04207424|Experimental|Embolization|Patients undergoing embolization of the gastro-epiploic arcade
16367285|NCT04207411|Experimental|Bupivacaine|The dose received at each injection will be 5 mg. One injection per week will be carried out over 4 consecutive weeks
16367286|NCT04207411|Sham Comparator|Lidocaine|The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
16367287|NCT04207398|Experimental|TIPS|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver.
16367288|NCT04207398|Active Comparator|NSBB+EBL|Participants randomized to this group will receive the combination therapy of non-selective beta-blocker (NSBB) and endoscopic band ligation (EBL) . NSBB, including propranolol and carvidilol, will be started at day 5 after the index bleeding and elective EBL sessions started 2 weeks after the index bleeding.
16367289|NCT04207385|Active Comparator|A group: Routine treatment group|Routine dosage of venlafaxine during the first 4 weeks.
16367290|NCT04207385|Experimental|B group: PGx-guided group|The PGx test results guide the dosage of venlafaxine during the first 4 weeks.
16367291|NCT04207385|Active Comparator|C group: Routine PGx-guided group|The PGx test results guide the dosage of venlafaxine between 4th and 8th weeks.
16367292|NCT04207385|Active Comparator|D group: The combination of PGx and TDM group|The PGx and TDM test results guide the dosage of venlafaxine between 4th and 8th weeks.
16367293|NCT04207372|Experimental|Whey protein isolate|
16367294|NCT04207372|Experimental|Zein|
16367295|NCT04207372|Placebo Comparator|Protein-free|
16367296|NCT04207359|Experimental|Creatine Supplement Group|Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
16367349|NCT04206995||Evaluation of odour capturing techniques|To evaluate two odour capturing techniques to compare VOC profiles of cancerous and healthy skin cancer.
16370652|NCT04183738|Active Comparator|SOC|darunavir/ritonavir 800/100mg + 2 NRTIs po od
16367297|NCT04207359|No Intervention|Exercise Only Control Group|Participants will not participate in the creatine intervention (creatine supplementation). Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Exercise sessions will be held by trained study staff held at the Medical Arts and Research Center Physical Therapy clinic (address listed above).
16367300|NCT04207333|Experimental|Prolonged Sitting + Mental Stress, Then Brief Sitting + Mental Stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
16367301|NCT04207333|Experimental|Brief Sitting + Mental Stress, Then Prolonged Sitting + Mental Stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
16367302|NCT04207320|Experimental|Stage I|Stage I will include eligible subjects between the ages of 10-25 years.
16367303|NCT04207320|Experimental|Stage II|Stage II will include eligible subjects between the ages of 2-25 years.
16367304|NCT04207307|Experimental|Multimodal exercise intervention|Behavioral: Multimodal exercise intervention with machine-based resistance, coordination and endurance training, 1-2 times per week for 30-45 min (increasing amount of training).
16367305|NCT04207307|Sham Comparator|Usual Care|General recommendations for healthy ageing, usual physical activity. No machine-based strength training intervention.
16367306|NCT04207294|Experimental|Vitamin D-enriched pork|One portion of Vitamin D-enriched pork
16367307|NCT04207294|Placebo Comparator|Control pork|One portion of control pork
16367308|NCT04207294|Active Comparator|Vitamin D supplement|Equivocal dose of Vitamin D supplement
16367309|NCT04207294|Experimental|Vitamin D-enriched chicken|One portion of Vitamin D-enriched chicken
16367310|NCT04207294|Placebo Comparator|Control chicken|One portion of control chicken
16367311|NCT04207281|Active Comparator|Honey|Raw honey (1.5 tablespoons)
16367312|NCT04207281|Placebo Comparator|Comparator|Honey comparator(1.5 tablespoons)
16367313|NCT04207268|Experimental|Gardening and Nutrition Advice|Participate in gardening activities, food demonstrations and nutrition advice
16367314|NCT04207268|Placebo Comparator|Nutrition Advice alone|Participate in only nutrition advice
16367315|NCT04207255|Experimental|Cohort 2: Opaganib with abiraterone|
16367316|NCT04207255|Experimental|Cohort 3: Opaganib with enzalutamide|
16367317|NCT04207255|Experimental|Cohort 1a: Opaganib with abiraterone|
16367318|NCT04207255|Experimental|Cohort 1b: Opaganib with enzalutamide|
16367319|NCT04207229||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
16367320|NCT04207203|Other|Single arm study|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
16367321|NCT04207190|Experimental|Treatment (talazoparib, gemtuzumab ozogamicin)|Patients receive talazoparib PO daily on days 1-21 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16367322|NCT04207177|Active Comparator|Mycophenolate mofetil|In the subgroup of living donor recipients included before transplantation this group will be treated with mycophenolate mofetil (750 mg BID) for one week
16367323|NCT04207177|Active Comparator|Tacrolimus|In the subgroup of living donor recipients included before transplantation this group will be treated with tacrolimus (BID, dose by weight) for one week
16367324|NCT04207151|No Intervention|Standard of Care|Participants will receive HIV and STI testing, clinical monitoring, client centered counseling and PrEP prescriptions as standard of care, this includes scheduled visits every three months.
16367325|NCT04207151|Experimental|Pre- and Post- SNAPS intervention|In addition to the standard of care treatment, approximately twenty subjects will be selected for interview pre- and post-SNAPS intervention to assess PrEP facilitators and barriers for uptake. Participants of interest include cis- and trans-women, for which there is limited data regarding PrEP and HIV prevention.
16367326|NCT04207125|No Intervention|Without multilevel intervention|patients after liver or kidney transplantation / standard care
16367327|NCT04207125|Active Comparator|With multilevel intervention|patients after liver or kidney transplantation / multilevel intervention program
16367350|NCT04206982|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
16367328|NCT04207112|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
16367329|NCT04207112|Experimental|Regimen 2: Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
16367330|NCT04207112|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
16367331|NCT04207112|Active Comparator|Control regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB
16367332|NCT04207099||ARM 1|Patients receive standard of care treatment for their diabetic foot ulcer
16367333|NCT04207099||ARM 2|Patients receive MolecuLight i:X guided treatment for their diabetic foot ulcer
16367334|NCT04207086|Experimental|6 wk pembrolizumab & lenvatinib, surgery, 46 wk pembrolizumab|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks.
16367335|NCT04207073|No Intervention|Control group|No intervention.
16367336|NCT04207073|Experimental|Exercise group|Participants in the exercise group will perform 2 sets of 5 repetitive Median nerve mobilization exercises (total of 20 sessions) per day for 10 days.
16367337|NCT04207060|Experimental|Oral indomethacin 50 mg po BID|The study intervention is oral indomethacin. Indomethacin is an FDA approved, commonly prescribed NSAID. Commercially available indomethacin will be utilized in this study. One capsule orally BID for 28 days. Those in the indomethacin arm will receive indomethacin 50 mg BID. Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication.
16367338|NCT04207060|Placebo Comparator|Placebo po BID|"Participants in both study arms will receive study medication, one capsule orally BID for 28 days. Those in the placebo arm will receive placebo capsules BID.
~Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication."
16367339|NCT04207047|Experimental|Group A|Group A (up to n=5): Genius exposure 1-3 hours before tissue resection
16367340|NCT04207047|Experimental|Group B|Group B (up to n=5): Genius exposure 30+7 days, 14+3 days, and 7+3 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
16367341|NCT04207047|Experimental|Group C|Group C (up to n=5): Genius exposure 90+14 days, 60+10 days, and 30+7 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
16367342|NCT04207047|Experimental|Group D|Group D (up to n=10): Genius, LaseMD, LaseMD FLEX, eCO2 and/or PicoPlus exposure 14+3 days, 7+3 days, and 1-3 hours before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
16367343|NCT04207034|Experimental|flap surgery and diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.
~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
16367344|NCT04207034|Active Comparator|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
16367345|NCT04207021|Experimental|intervention|"the study involves the intake of two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks of a nutritional supplement
~INTERVENTION CAPSULE COMPOSITION active substances for 2 capsules Bio Curcumin 400 mg Polydatin 00 mg Beta-Caryophyllene 48 mg"
16367346|NCT04207021|Placebo Comparator|placebo|particpants included in the placebo group will take two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
16367347|NCT04207008|Experimental|iBDecide App Decision-support Arm|Participants will download the iBDecide app on their smartphone approximately two weeks prior to the scheduled clinic visit. Approximately one week after the clinic visit, survey data, along with demographic data will be collected from all participants via a brief telephone call. We will collect data on app use between installation and the clinic visit as well as in the 3 months following the clinic visit.
16367348|NCT04207008|No Intervention|Control Arm|Control participants will not use the iBDecide app prior to their clinic visit. They will complete a brief telephone survey approximately one week from clinic visit.
16367352|NCT04206969|Experimental|Transcultural psychotherapy|In addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
16367353|NCT04206969|No Intervention|standard care|usual care provided by the referent medical team
16367354|NCT04206943|Experimental|A Low Dose|4 x 10^6 Car-T cell/ kg
16367355|NCT04206943|Experimental|B High Dose|6 x 10^6 Car-T cell/ kg
16367356|NCT04206930|No Intervention|Control|Standard support: information on alcoholic pathology, medico-psycho-social assessment, relapse prevention program
16367357|NCT04206930|Experimental|Art-Therapy|in addition to standard treatment, art therapy treatment program: 1 session of 2 hours per week in a closed group for 10 weeks
16367358|NCT04206917|Experimental|Multi Pulse Therapy|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
16367359|NCT04206891||Group 1|Bilateral lobular invasive breast cancer
16367360|NCT04206891||Group 2|Invasive lobular breast cancer with age at onset <= 45 years
16367361|NCT04206891||Group 3|Invasive lobular breast cancer with family history for breast cancer
16367362|NCT04206891||Group 4|In situ lobular breast cancer with age at onset <= 45 years
16367363|NCT04206891||Group 5|In situ lobular breast cancer with family history for breast cancer
16367364|NCT04206878||HIV-exposed infants (HEI) eligible for birth testing|All HEI live births born at, or presenting to, one of the 3 study sites, within 3 days of birth.
16367365|NCT04206865|Experimental|ARNI therapy|Patient's randomized to this arm will receive sacubitril-valsartan per study protocol and titrated per titration guidelines.
16367366|NCT04206865|Active Comparator|Standard Oral Vasodilator|Patient's randomized to this arm will receive the oral vasodilator that the clinician chooses including angiotensin receptor blocker (ARB), isosorbide dinitrate, hydralazine, and angiotensin-converting enzyme inhibitor (ACEi).
16367367|NCT04206826|Experimental|PREDELFI Film|
16367368|NCT04206826|Placebo Comparator|CONTROL Film|
16367369|NCT04206813|Experimental|Intervention group|240 eligible women will receive a 2-dose regimen of Gardasil 9 at (0 and 6 months, followed by a rescue 3rd dose at month 12)
16367370|NCT04206813|Active Comparator|Control group|120 eligible women will receive the standard 3-dose regimen of Gardasil 9 at (0, 2, 6 months)
16367371|NCT04206800|No Intervention|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
16367372|NCT04206800|Experimental|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
16367373|NCT04206787||Patients with non-small cell lung cancer (NSCLC)|
16367374|NCT04206761|Experimental|Treatment - QVM149|Participants will complete a two week treatment with QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160 μg delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication via inhalation.
16367375|NCT04206761|Active Comparator|Control|Participants will continue their clinically prescribed treatment with a high dose dual therapy of Inhaled Corticosteroid (ICS)/Long-Acting Beta2-Agonist (LABA) in any approved drug formulation and delivery device for the treatment period of two weeks. (Participants will continue receiving high dose ICS/LABA therapy at the same dose and in the same formulation as at baseline).
16367376|NCT04206748|Experimental|iGlucose Smart Meter|
16367377|NCT04206748|Placebo Comparator|Rx glucose meter|
16367378|NCT04206735|Experimental|Interprofessional Education (IPE)|Each hospital needs to assign a 'COPD-NIV' team of champions to lead the implementation strategy at the local level. We will provide virtual or in-person (if safety permits) training for the COPD-NIV teams (one RT, one RN, and one MD). The training will consist of NIV knowledge and skills through the principles of IPE and teamwork. We will use the train the trainer method; after we train the COPD-NIV team champions, the champions will promote and hold training sessions for their peers in person (if safety permits, 2-3 times a month for 4 months). At present, we are providing these training sessions as prerecorded content available whenever the clinician is available. Champions will promote the training to their clinicians for the first 4 months and then at 6 and 12 months for new staff.
16367379|NCT04206722|Experimental|Treatment group|Shock Wave therapy on the affected hip, for 10 days, 1 application every 2 days
16367380|NCT04206722|Active Comparator|Control group|Ultrasound therapy on the affected hip, for 10 days, 1 application daily
16367381|NCT04206709|Experimental|aerobic effort|Active upper limbs pedaling
16367382|NCT04206709|Sham Comparator|passive pedaling|passive pedaling
16367383|NCT04206670|Experimental|In-Home Technology System|Participants (N=300) will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over a six month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter).
16367384|NCT04206670|Other|Waiting Control|Participants (N=100) will be assigned a date for receiving and installing the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) six months after they enter the study. During that six-month period, questionnaires (e.g., health and well-being) will be administered 3 times (at the start of the study and every 3 months thereafter). At the end of the six-month period, participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over an additional six-month period with questionnaires (e.g., health and well-being) administered 2 times (every 3 months following installation).
16367385|NCT04206657|Experimental|Single dose administration of 1mg KHK7580|
16367386|NCT04206657|Experimental|Single dose administration of 3mg KHK7580|
16367393|NCT04206631|Placebo Comparator|Doxycycline Group|Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
16367394|NCT04206631|Active Comparator|Comedone Extraction Group|Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
16367395|NCT04206618||premenopausal normal|premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
16367396|NCT04206618||postmenopausal normal|postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
16367397|NCT04206618||postmenopausal osteopenia|postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage
16367398|NCT04206618||postmenopausal osteoporosis|postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage
16367399|NCT04206618||hip fracture|postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis
16367400|NCT04206618||controls (knee osteoarthitis)|postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls
16367401|NCT04206618||teriparatide group|postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months
16367402|NCT04206618||denosumab group|postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months
16367403|NCT04206605|Experimental|Lanadelumab|Participants will receive 300 milligrams (mg) of lanadelumab solution in a prefilled syringe (PFS) as subcutaneous (SC) injection once every 2 weeks (q2w) for 26 weeks.
16367404|NCT04206605|Placebo Comparator|Placebo|Participants will receive placebo matched to lanadelumab SC injection once q2w for 26 weeks.
16367405|NCT04206592|Active Comparator|i Gel LMA|The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
16367406|NCT04206592|Active Comparator|Ambu Aura Gain|It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
16367407|NCT04206579|Experimental|10% Dextrose|Oral 10% Dextrose
16367408|NCT04206579|Experimental|Natrium Dextrose|Oral Natrium Dextrose
16367411|NCT04206540|Experimental|ABVN and Vagal Maeuvers|There is only one arm and subjects can choose the intervention.
16367412|NCT04206527|Experimental|Intervention - Women|Women who receive enhanced FP counseling from an ASHA
16367413|NCT04206527|No Intervention|Control - Women|Women who receive standard FP counseling from an ASHA
16367414|NCT04206527|Experimental|Intervention - ASHA|ASHA who receive enhanced FP counseling training
16367415|NCT04206527|No Intervention|Control ASHA|ASHA who receive standard FP training
16367416|NCT04206514|Experimental|Peer Counselor|Participants receive personalized text messages and phone calls from a peer counselor- a women who had an abortion and was trained in post abortion care and PCC
16367417|NCT04206514|Experimental|Nurse|Participants receive personalized text messages and phone calls from a nurse trained in post abortion care and PCC
16367418|NCT04206514|No Intervention|control|Participants receive the standard of care for post-abortion patients in Kenya.
16367419|NCT04206501|Experimental|ICM guided Medical Management Group|A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.
16367420|NCT04206501|No Intervention|Conventional Management Control Group|Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.
16367421|NCT04206488|Experimental|JNJ-70033093 + Digoxin|Participants will receive JNJ-70033093 as oral capsules (Treatment A) in Period 1, followed by digoxin tablets as loading dose and maintenance doses (Treatment B) in Period 2, and then digoxin tablets along with JNJ-70033093 (Treatment C) in Period 3. There will be a washout period of minimum 5 days (and maximum 7 days) between the last dosing day of Period 1 and the first dosing day of Period 2. There is no washout between Periods 2 and 3 (that is, the last day of Treatment B is to be followed by the first day of Treatment C).
16367422|NCT04206475|Experimental|IM-FTP|rehabilitated over 1-month through IM-FTP, including physio-kinesis/occupational, speech, and neuropsychology treatments
16367423|NCT04206475|Active Comparator|standard rehabilitation|physio-kinesis, occupational, speech, and neuropsychology treatments
16367424|NCT04206462||Osteoarthritis|Questionnaire of eating habits, markers of oxidative stress
16367425|NCT04206449|Experimental|Infrared thermography system|Therapeutic decision taken with infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and Apnea-Hypopnea Index (AHI).
16367426|NCT04206449|Active Comparator|Standard Polysomnography (PSG)|Therapeutic decision taken with Standard Polysomnography (PSG), to determine the sleep stages and Apnea-Hypopnea Index (AHI)
16367427|NCT04206436||on CFTR|For patients on or near time of initiation CFTR modulator therapy
16367428|NCT04206436||Controls|controls will be patients not eligible for available treatment
16367429|NCT04206423||Healthy Controls|Age and sex matched healthy controls
16367430|NCT04206423||Lateral epicondylitis|"Newly diagnosed lateral epicondylitis patients.
~Pain in lateral epicondylitis region
~Pain increase with palpation
~Positivity in two diagnostic test out of three (Maudley's test, Mill's test or Cozen's test)"
16367431|NCT04206410|Experimental|Probiotic|Multistrain probiotic mixture consisting of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum and B. lactis) administered for 8 weeks in a dose 1,0E+10/day, 2x sachets/day (5,0E+9/cfu per sachet)
16367476|NCT04206150|Active Comparator|Group 3(femur length/15 cm below)|the adductor canal catheter is inserted femur length/15cm below the location where the nerve block performed in group 1.
16367432|NCT04206410|Placebo Comparator|Maltodextrin|Placebo - Maltodextrin manufactured with an appearance, taste and packaging (sachets) identical to the probiotic mixture administarted for 8 weeks 2x sachets/day
16367433|NCT04206384|Experimental|Treatment group|Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.
16367434|NCT04206371|Other|Defibrillation testing during ICD replacment|
16367435|NCT04206358|Experimental|treatment group|The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001), Once every 2 weeks
16367436|NCT04206345|Experimental|Blood Flow Restriction Group|Elbow bending exercises with resistance exercise band (%20 of 1 maximum repetition) for one session. Blood flow restriction band will be placed during exercise session. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
16367437|NCT04206345|Experimental|Exercise Group|Elbow bending exercises with resistance exercise band (%70 of 1 maximum repetition) will be performed for one session.
16367438|NCT04206345|No Intervention|Control Group|10 minutes resting period will be given between evaluation.
16367457|NCT04206293|Experimental|Juvéderm® VOLITE|Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
16367458|NCT04206280|Experimental|Pedometer group|This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
16367459|NCT04206280|Active Comparator|Control group|This is the control group. Following radical prostatectomy, subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
16367460|NCT04206267|Experimental|Acceledent group|Patients up to 18 years old who were planned first premolar extractions assigned to study group. AcceleDent Aura appliance was applied for 20 minutes per day. during canine retraction.
16367461|NCT04206267|No Intervention|Control group|Patients up to 18 years old who were planned first premolar extractions assigned to control group. The canine retractions were performed without any additional vibrational device.
16367462|NCT04206254|Experimental|gp96 group|"Patients only receive autologous gp96 vaccination after surgery (do not accept other anti-tumor treatments)
~6 times of gp96 vaccination are administered via subcutaneous injection in 25μg doses within 8 weeks after surgery. gp96 is administered once a week."
16367463|NCT04206254|No Intervention|Control group|Patients do not accept any anti-tumor treatmentsafter surgery
16367464|NCT04206241||High-risk infants|"Mother answered yes to any of the following questions on a risk-screening tool:
~Mother diagnosed with HIV in labor and delivery?
~Mother start ART after 32 weeks' gestation?
~Maternal viral load above 1000 copies/ml in the 3rd trimester?
~Mother seroconvert during pregnancy?
~Was the mother not adhering to ART during pregnancy?"
16367465|NCT04206241||Low-risk infants|Mothers did not answer affirmatively to any of the four screening questions
16367466|NCT04206228|Active Comparator|Active treatment|Active drug: Intravenous iron isomaltoside dissolved in 100 ml NaCl 0.9 %
16367467|NCT04206228|Placebo Comparator|Placebo|Placebo: Intravenous NaCl 0.9 % dissolved in 100 ml
16367468|NCT04206202|Experimental|PSI group|3D-printed patient-specific instrumentation (PSI) will be used in the total knee arthroplasty (TKA) of this group.
16367469|NCT04206189|Active Comparator|Carbohydrate group|
16367470|NCT04206189|No Intervention|Control group|
16367471|NCT04206176|Experimental|Single group crossover|The patients who are on a maintenance dose of clopidogrel 75mg once daily will be transitioned to ticagrelor 45mg twice daily after which they will be tested.
16367472|NCT04206163|Experimental|Acute myocarditis|Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
16367473|NCT04206163|Experimental|Cardiac sarcoidosis|Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
16367474|NCT04206150|Active Comparator|Group 1(femoral triangle apex)|the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal)
16367475|NCT04206150|Active Comparator|Group 2(femur length/15*2 cm above)|the adductor canal catheter is inserted femur length/15*2 cm above the location where the nerve block performed in group 1
16368749|NCT04197245|Experimental|group on treatment|saline injection has been given intradermal in atrophic scars of acne on face.
16367477|NCT04206137|Experimental|Group A (PNF rhythmic initiation group )|PNF rhythmic initiation with bilateral asymmetrical upper and lower limb pattern will administered on both sides, there will be 10 repetition and 3 sets for each side, 20 second rest between two sets.
16367478|NCT04206137|Active Comparator|Group B (Swiss ball exercise group)|Swiss ball exercises will be administered. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
16367479|NCT04206124|Experimental|Single Arm Study Group|Includes all consented patients, male and female, undergoing anterior cervical spine surgery, parathyroidectomy or thyroidectomy (18-60 years old), without history of diabetes mellitus and not pregnant or incarcerated.
16367480|NCT04206111||Preoxygenation|
16367481|NCT04206098||Sex|Male/Female
16367482|NCT04206085|Experimental|Active treatment|Radiofrequency and Cryogen
16367483|NCT04206085|Active Comparator|Cryogen-Only|Crygen-Only
16367484|NCT04206085|Sham Comparator|Sham|Sham comparator
16367485|NCT04206072|Experimental|D-0316|D-0316 (75 mg or 100 mg orally, once daily), in accordance with the randomization schedule.
16367486|NCT04206072|Active Comparator|Icotinib|Icotinib (125 mg orally, three times daily), in accordance with the randomization schedule.
16367487|NCT04206059|Experimental|CLASS-D Cohort|Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
16367488|NCT04206046|Active Comparator|General Anaesthesia|Patients will receive a general anaesthetic, together with a femoral nerve block.
16367489|NCT04206046|Active Comparator|Spinal Anaesthesia|Patients will receive a spinal anaesthetic
16367490|NCT04206020|Placebo Comparator|Placebo Comparator: SkQ1 Vehicle|Vehicle for SkQ1 Ophthalmic Solution
16367491|NCT04206020|Active Comparator|SkQ1|SkQ1 Ophthalmic Solution
16367492|NCT04206007|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
16367493|NCT04205994|Experimental|Tolcapone|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in a single 200mg dosage once in randomized, double-blind, counterbalanced fashion with a placebo.
16367494|NCT04205994|Placebo Comparator|Placebo|Placebo will be administered in a single pill once in randomized, double-blind, counterbalanced fashion with a placebo.
16367495|NCT04205981|Experimental|Aerobic exercise|Exercise intervention. The experimental group increased their energy expenditure according to American College of Sports Medicine and WHO-based physical activity recommendations for all adults to promote clinically significant weight loss and for additional health benefits: 300 min of moderate-intensity aerobic training throughout the week (WHO, 2010; Swift et al. 2014). Participants underwent five 60 min moderate-intensity cycling sessions per week for a period of 8 weeks, 40 sessions in total. Each session involved 5 min of warm up at 40 Watts, cycling for 50 min at a speed that increased their HR to a target HR obtained at 50-60% of peak VO2, and a 5 min of cool down at 40 Watts.
16367496|NCT04205981|No Intervention|Control|. In the control group, participants did not undergo any intervention and were instructed to maintain their regular physical activity and diet regime for 8 weeks.
16367497|NCT04205968|Experimental|Arm I (ramucirumab, paclitaxel)|Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15, and paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16367498|NCT04205968|Experimental|Arm II (irinotecan, leucovorin, fluorouracil)|Patients receive irinotecan IV over 90 minutes on days 1 and 15, leucovorin IV over 2 hours on days 1 and 15, and fluorouracil IV bolus on days 1 and 15. Patients also receive fluorouracil IV over 46-48 hours on days 1-3 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16367499|NCT04205955|Experimental|Arm I (diet modification coaching, motivational messages)|Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
16367500|NCT04205955|Active Comparator|Arm II (standard of care, motivational messages)|Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
16367501|NCT04205942|Experimental|Plasma|regular treatment with Argon Plasma Jet according to manufacturer's instructions, 8 times within 14 days
16367502|NCT04205942|Sham Comparator|Placebo|Sham-treatment with Argon Plasma Jet, Plasma producing electric field switched off - no Plasma is produced, just argon gas as effluent, 8 times within 14 days
16367503|NCT04205929|Placebo Comparator|Placebo group|Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
16367504|NCT04205929|Experimental|Curcumin group|Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
16367505|NCT04205916|Experimental|Experimental Group|A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.
16367506|NCT04205916|Active Comparator|Control Group|A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
16367507|NCT04205903|Experimental|Group I (paclitaxel, nilotinib hydrochloride monohydrate)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nilotinib hydrochloride monohydrate PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16367508|NCT04205903|Placebo Comparator|Group II (paclitaxel, placebo)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive placebo PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16367543|NCT04205591|Active Comparator|Autologous cortical plate|Thin autologous cortical plates that allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
16367509|NCT04205890|Experimental|Ketamine|The present study is designed as a prospective data analysis of patient response to the use of ketamine to treat treatment-resistant depression. For Phase I trail, 10 patients of any gender with an age range of 18 to 70 who have undergone the outlined procedure will be recruited for inclusion. A week before the scheduled ketamine treatment, the patients will have fMRI scans, including structural T1, Arterial Spin Labeling, and Resting BOLD. The scans take around 30 minutes at no charge to the patients. The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage will vary (see below) depending on every individual's unique treatment plan. The same scans will be taken two days after treatment.
16367510|NCT04205877||Registry Group|All participants will have the same data collected at the same time points.
16367511|NCT04205864|Active Comparator|Conventional pelvic lymphadenectomy|Conventional pelvic lymphadenectomy
16367512|NCT04205864|Experimental|Thrombin gel matrix pelvic lymphadenectomy|Thrombin gel matrix applicated after conventional pelvic lymphadenectomy
16367513|NCT04205851|Experimental|KIN-1901|Single or repeat (once weekly for 4 weeks) KIN-1901 subcutaneous injection
16367514|NCT04205851|Placebo Comparator|Placebo|Single or repeat (once weekly for 4 weeks) placebo subcutaneous injection
16367515|NCT04205838|Experimental|Prevention (anakinra, CAR T-cell therapy)|Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.
16367516|NCT04205825|Experimental|New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
16367517|NCT04205825|No Intervention|Habitual Practice|Patients randomized in this arm they will receive the habitual practice.
16367518|NCT04205812|Experimental|INCMGA00012 + chemotherapy (nonsquamous NSCLC)|INCMGA00012 with pemetrexed + cisplatin OR carboplatin followed by INCMGA00012 plus pemetrexed until progression.
16367519|NCT04205812|Active Comparator|Placebo + chemotherapy (nonsquamous NSCLC)|Placebo with pemetrexed + cisplatin OR carboplatin followed by placebo plus pemetrexed until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
16367520|NCT04205812|Experimental|INCMGA00012 + chemotherapy (squamous NSCLC)|INCMGA00012 with carboplatin + paclitaxel OR nab-paclitaxel followed by INCMGA00012 until progression.
16367521|NCT04205812|Active Comparator|Placebo + chemotherapy (squamous NSCLC)|Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
16367522|NCT04205799|Experimental|CABOZANTINIB|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
16367523|NCT04205786|Active Comparator|Control - Standard of Care|"Day 0:
~Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form
~Blood collection
~Continue Usual Care
~Day 45:
~Repeat of baseline questionnaires with addition of vitamin B12 supplements form and investigational agent accountability record
~Blood collection
~Continue Usual Care
~Day 90:
~-Repeat of day 45"
16367524|NCT04205786|Experimental|Study Medication Group (B12)|"Day 0:
~Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form
~Blood collection
~Oral intake of Vitamin B12 Daily in the morning
~Day 45
~Repeat of baseline questionnaires with addition of investigational agent accountability record
~Blood collection
~Oral intake of Vitamin B12 Daily in the morning
~Day 90:
~-Repeat of day 45 without additional study drug intake."
16367525|NCT04205760|No Intervention|Control group|Standard Care as per local guidelines
16367526|NCT04205760|Experimental|Intervention|Oral nutrition support (ONS) and bed-cycling before surgery
16367527|NCT04205721|Experimental|Scripted lesson plan life orientation curriculum|Participants in this arm were in schools where the life orientation teachers in grades 7-9 (in 2016 and 2017) and grade 10 in 2018 were trained to use the new life orientation curriculum that included scripted lesson plans for the sexual and reproductive health content of the program. There are eight lessons for grade 7, eight for grade 8, 11 for grade 9, and 10 for grade 10.
16367528|NCT04205721|No Intervention|Standard life orientation curriculum|Participants in this arm were in schools where the standard life orientation curriculum was used with no additional training and no use of the new materials.
16367529|NCT04205695|Active Comparator|CEMP (closed-ended multiport catheter) group|Infraclavicular closed-ended multiport nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
16367530|NCT04205695|Active Comparator|OESP (open-ended single port catheter) group|Infraclavicular open-ended single port nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
16367531|NCT04205682|Experimental|Cannabidiol (CBD)|Drug: Cannabidiol (day 1: 1200 mg (800 mg BD); day 2-4: 800 mg (400 mg BD); day 5: placebo BD).
16367532|NCT04205682|Placebo Comparator|Placebo|Drug: Placebo (days 1-5: placebo matched BD)
16367533|NCT04205669|Active Comparator|Individual Treatment|
16367534|NCT04205669|Active Comparator|Household Treatment|
16367535|NCT04205656|Experimental|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
16367536|NCT04205656|Experimental|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
16367537|NCT04205656|Placebo Comparator|Control|Patients randomized in the placebo arm will undergo their standard of care treatment and will not receive LP-PRP or BMC.
16367538|NCT04205643|Experimental|CT-P13 SC|
16367539|NCT04205643|Placebo Comparator|Placebo SC|
16367540|NCT04205630|Experimental|SYD985|SYD985, Intravenous, every 3 weeks (Q3W)
16367541|NCT04205617|Experimental|Healthy Food Prescription|Participants receive services through the Living Hungry program for food insecure diabetic patients.
16367542|NCT04205604|Experimental|Single Arm,|Patients with clinically diagnosed congenital hyperinsulinism
16367544|NCT04205591|Experimental|Porcine cortical plate|Thin porcine cortical platesthat allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
16367545|NCT04205578|Active Comparator|Butylphthalide (NBP)|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
16367546|NCT04205578|Placebo Comparator|Normal saline|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
16367547|NCT04205565|Active Comparator|L-oxiracetam|
16367548|NCT04205565|Active Comparator|Oxiracetam|
16367549|NCT04205565|Placebo Comparator|Plaecbo|
16367550|NCT04205552|Experimental|Nivolumab|"Nivolumab 2 cycles, every two weeks (q2w)
~o Nivolumab 240 mg i.v. over 30 min"
16367551|NCT04205552|Experimental|Nivolumab/Relatlimab|"Nivolumab/Relatlimab 2 cycles, every two weeks (q2w)
~Nivolumab 240 mg i.v. over 30 min
~Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)"
16367552|NCT04205539|Experimental|Dexmedetomidine|All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
16367553|NCT04205526|Experimental|Active rTMS|Sub-acute stroke patients will be randomized to receive actual rTMS treatment. 1Hz rTMS will be applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
16367554|NCT04205526|Sham Comparator|Sham control|Sub-acute stroke patients randomized to receive sham rTMS. For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
16367555|NCT04205513|No Intervention|Control Group|Standard titration management strategy, consisting of regular in-office visits.
16367556|NCT04205513|Experimental|Study Group|Remote titration management strategy, consisting of telephone contacts, which will utilize data from the Medly system.
16367557|NCT04205500|Experimental|Children with juvenile idiopathic arthritis|The specific carbohydrate diet has been shown to have beneficial effects on IBD and has been implemented in Seattle Children's IBD centre, with some patients using SCD either as primary or complementary therapy. The SCD is a nutritionally balanced diet focused on removing many complex carbohydrates such as grains, dairy products except for yoghurt fermented over 24 hours, vegetables rich in starch and sugars except for monosaccharides like in honey. Participants can eat meat but since it has to be unprocessed food the investigator's experience is that the amounts of meat are not very big. Fish, eggs, sea-food is allowed. Bread is baked from nut and almond flour.
16367558|NCT04205487|Experimental|Contingency Management (CM) - Only|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
16367559|NCT04205487|Experimental|Motivational Interviewing (MI) - Only|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered.
16367560|NCT04205487|Experimental|CM+MI|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription. Participants who do not fill a PrEP prescription at 3 months will then receive 2 sessions of MI.
16367561|NCT04205487|Experimental|MI+CM|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered. Participants who do not fill a PrEP prescription at 3 months will receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
16367562|NCT04205474|Active Comparator|VSRR with tricuspid aortic valve|Patients with a tricuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
16367563|NCT04205474|Active Comparator|VSRR with bicuspid aortic valve|Patients with a bicuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
16367564|NCT04205461||Programmed ventricular stimulation before PVR|
16367565|NCT04205448|Experimental|Exercize group|10 weeks of physical exercise. Testing of strength and balance.
16367566|NCT04205448|No Intervention|Control group|Testing of strength and balance.
16367567|NCT04205435|Experimental|β-globin restored autologous HSC|each subject will accept one dose of β-globin restored autologous hematopoietic stem cells
16367568|NCT04205422|Active Comparator|BIPAP group|Biphasic Intermittent Positive Airway Pressure group
16367569|NCT04205422|Active Comparator|APRV group|Airway Pressure Release Ventilation group:
16367570|NCT04205409|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16367571|NCT04205396|Experimental|Written emotional disclosure|
16367572|NCT04205396|Experimental|Resilience training|
16367573|NCT04205396|Other|Control arm|
16367574|NCT04205383||pregnancy|pregnant women with normal pregnancy
16367575|NCT04205383||pregnancy with complications|pregnant women with placental-mediated complications of pregnancy type complications
16367576|NCT04205383||healthy volunteer|healthy, non-pregnant women volunteers
16367577|NCT04205370|Active Comparator|Deactivated device|Wear deactivated pregnancy coach device for the remainder of pregnancy.
16367578|NCT04205370|Experimental|Active device|Wear active device for remainder of pregnancy (including 3 day run-in period)
16367579|NCT04205357|Other|Sulfasalazine in addition to stereotactic radiosurgery|"3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.
~The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery."
16367580|NCT04205344|Experimental|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
16367581|NCT04205344|Experimental|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
16367582|NCT04205331||obese patients|compare between ultrasonography and conventional clinical methods of airway assessment prior to induction of anesthesia correlating it to the Cormack-Lehane scoring system after induction of anesthesia in obese patients
16367583|NCT04205318||study|obese (BMI ≥25.00 kg/m2, n=200)
16367584|NCT04205318||control|non-obese (BMI= 18.50-24.99 kg/m2, n=200)
16367585|NCT04205305|Active Comparator|Conventional blood pressure control group|systolic blood pressure <180 mmHg
16367586|NCT04205305|Experimental|Intensive blood pressure control group|systolic blood pressure <140 mmHg
16367587|NCT04205292|Active Comparator|Dilatation and Evacuation (D&E)|Women in this group will receive an in-patient treatment with Dilatation and Evacuation (D&E) after two doses of Methotrexate .
16367588|NCT04205292|Experimental|hysteroscopic surgery|Women in this group will receive hysteroscopic surgery after two doses of Methotrexate .
16367589|NCT04205279|Experimental|Treadmill training|Subjects randomly assigned to the treadmill training, would undergo either a stance or walking perturbation training protocol. The stroke subjects and older adults would be assigned to either the stance or walking perturbation training protocol. All the participants would be asked to perform voluntary stepping, backward and forward with both limbs pre and post perturbation training. Also, all the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd.
16367590|NCT04205279|Experimental|Overground training|Subjects randomly assigned to overground slip will be made to walk at their comfortable natural walking speeds either for 5-8 trials on the instrumented walkway (7 m 1.5 m) at their self-selected preferred speed. All the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd. After establishing baseline walking ability, a slip will be introduced without warning which will comprise the baseline slip test followed by a trip in the form of the trip plate. This is followed by a block of 8 trials for slip training, block of 8 trials for trip training and then the mixed block consisting of slip and trip trials interspersed with walking trials. Slips and trips could be induced under either of the limbs.
16367591|NCT04205279|Experimental|Surefooted training|"Subjects randomly assigned to Surefooted (Surefooted LLC) would be donned a safety harness and instructed that when you experience slip-like or trip-like movements, try to keep walking on the platform. Subjects would undergo 4-minute training block on each of the 6 different conditions. The first 3 training blocks would be unidirectional perturbation (either slip or trip) followed by 3 training blocks of mixed directional perturbations while the subjects are walking on the platform. 3 surface conditions- slippery (vinyl surface plate), normal friction with obstacles (surface plate with 6 tall structures embedded), and a foam surface with obstacles embedded would be used."
16367592|NCT04205266|Experimental|IV Iron|Will receive 2 infusions of 510mg of ferumoxytol, administered over 15 minutes, 3-8 days apart
16367593|NCT04205266|Active Comparator|Oral Iron|Will receive 325mg ferrous sulfate tablets daily for 60 days
16367594|NCT04205253||Study|The first group is the study group. Patients aged 20 years or older and were to undergo suspension laryngoscopy procedure were eligible for inclusion in this group. Tongue areas were measured twice by submental USG. The first measurements (TA1) were done immediately after endotracheal intubation before introducing the rigid direct laryngoscope, whereas the second measurements (TA2) were done after the SL procedure and after removing the rigid direct laryngoscope just before extubation.The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
16367595|NCT04205253||Control|The second group was the control group, which included patients who did not need SL and any head and neck procedures.The tongue areas of these patients were measured twice by submental USG as in the study group. The TA1 measurements were done immediately after endotracheal intubation, whereas the TA2 measurements were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
16367596|NCT04205240|Experimental|Treatment (conditioning regimen, stem cell transplant)|Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
16367597|NCT04205227|Experimental|ENB003 150 ug + Pembrolizumab|150 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
16367598|NCT04205227|Experimental|ENB003 300 ug + Pembrolizumab|300 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
16367599|NCT04205227|Experimental|ENB003 500 ug + Pembrolizumab|500 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
16367600|NCT04205227|Experimental|ENB003 750 ug + Pembrolizumab|750 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
16367601|NCT04205227|Experimental|ENB003 1000 ug + Pembrolizumab|1000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
16367602|NCT04205227|Experimental|ENB003 RP2D from dose eascalation + Pembrolizumab|The recommended phase 2 dose (RP2D) of ENB003 will be selected from the dose escalation portion of the study and administered in combination with a fixed dose of pembrolizumab (200mg)
16367603|NCT04205214|Experimental|Integrative Cognitive Behavioural Therapy Intervention Group|The group receive 12 weekly individual Integrative Cognitive Behavioural Therapy sessions from the principal investigator and Trainee counselling Psychologist. The sessions last up to 60 minutes on a weekly basis. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week intervention.
16367604|NCT04205214|No Intervention|Wait List Control Group|The group do not receive the intervention and are told that they can start the intervention after 12 weeks. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week waiting period. After this 12-week waiting period, they are offered the individual therapy and their data is added to the experimental group data.
16367607|NCT04205188|Experimental|exercises and verbal information|therapeutic exercises 3 days in a week and total 8 weeks and 60 minutes verbal information
16367608|NCT04205188|No Intervention|verbal information|60 minutes information about effects of exercises on joint functions
16367609|NCT04205162|Experimental|Verofilcon A / Etafilcon A|The participant will wear Verofilcon A in their right eye and Etafilcon A in their left eye.
16367610|NCT04205162|Experimental|Etafilcon A / Verofilcon A|The participant will wear Etafilcon A in their right eye and Verafilcon A in their left eye.
16367611|NCT04205149||Pre-ERAS implementation arm|
16367612|NCT04205149||Post-ERAS implementation arm|
16367613|NCT04205136|Experimental|Spironolactone|Dose of 25 mg daily that may be titrated up to 50 mg daily, if tolerated and will receive treatment as usual for obstructive sleep apnea.
16367614|NCT04205136|Placebo Comparator|Placebo|Placebo and will receive treatment as usual for obstructive sleep apnea.
16367615|NCT04205123||sickle cell syndrome|Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.
16367616|NCT04205097|Placebo Comparator|Moderate NMB group|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
16367617|NCT04205097|Experimental|Deep NMB group|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2~4 mg/kg
16367618|NCT04205084|Experimental|Standard Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. The subjects will be allowed to eat meals and use their own insulin as usual, under observation, in the clinical center. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose will be collected at the same time as the CGM timestamp every 15 min and analyzed.
16367619|NCT04205084|Experimental|Hypoglycemic Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. Hypoglycemia will be induced using a hyperinsulinemic infusion and samples will be obtained at 5 - 10 min intervals. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose collected at the same time as the CGM timestamp and analyzed.
16367620|NCT04205084|Experimental|Hyperglycemic Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. Hyperglycemia will be induced using a dextrose infusion and samples will be obtained at 5 -10 min intervals. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose collected at the same time as the CGM timestamp and analyzed.
16367621|NCT04205071|Experimental|Treatment (lorcaserin)|Patients receive lorcaserin PO on day 1. The starting dose of lorcaserin will be 10 mg.
16367622|NCT04205058|Experimental|standard coffee|Hot standard coffee with caffeine (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
16367623|NCT04205058|Placebo Comparator|caffeine-free coffee|Hot caffeine-free coffee (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
16367624|NCT04205058|Sham Comparator|water|Hot water (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
16367625|NCT04205045||Non-Habitual Milk Consumers (NHMC)|"Healthy subjects who are non-habitual milk consumers because of gastrointestinal discomforts upon milk consumption.
~Lactose breath test; Gut permeability test; Milk test."
16367626|NCT04205045||Habitual Milk Consumers (HMC)|"Healthy subjects with regular milk consumption.
~Intervention to be performed:
~Lactose breath test; Gut permeability test; Milk test."
16367627|NCT04205032|Experimental|CARDIOSPACE II|Test of the different devices integrated in cardiospace II.
16367628|NCT04205019|Experimental|Neuro-Cell group|Patient receives treatment once at start of study and followed up for safety.
16367629|NCT04205006||STROKE CARD Cohort|Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).
16367630|NCT04204993|Experimental|Experimental: Influenza A|Participants will be inoculated with Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0,5mL via intranasal drops or spray. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood, respiratory tract sampling, and sensor monitoring. Following discharge, they will be followed up for up to 6 months post-inoculation.
16367631|NCT04204980|Experimental|Dose escalation and full dose|"Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
~Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab"
16367634|NCT04204954|Other|Group 1: Topical 0.3% Ciprofloxacin [Cipro]|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.
16367635|NCT04204954|Active Comparator|Group 2: Cipro + 50% diluted baby shampoo|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.
16367636|NCT04204954|Active Comparator|Group 3: Cipro + Blephaclean|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.
16367990|NCT04202172|Active Comparator|BIOFREEDOM|Implantation of Drug-eluting coronary stent without polymer in patients with myocardial infarction.
16367637|NCT04204954|Experimental|Group 4: Cipro + Tea tree oil.|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.
16367638|NCT04204941|Experimental|Tazemetostat + Doxorubicin Arm|"Tazemetostat (800 mg) administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
16367639|NCT04204941|Experimental|Placebo + Doxorubicin Arm|"Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond.
~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
16367640|NCT04204915|Active Comparator|Group A: Aortic valve replacement|Participants randomised to AVR will be investigated and managed according to local protocols and standard practice. Participants will be placed on the waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists.
16367641|NCT04204915|No Intervention|Group B: Expectant management|Participants randomised to expectant management will continue to have regular monitoring of their condition in line with the procedures and standard practices of their hospital.
16367642|NCT04204902|Experimental|Test Treatment then Reference Treatment|Participants will receive a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 1 followed by a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 2. The treatment periods will be separated by 21 day washout period.
16367643|NCT04204902|Experimental|Reference Treatment then Test Treatment|Participants will receive a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 1 followed by a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 2. The treatment periods will be separated by 21 day washout period.
16367644|NCT04204889|Experimental|Oxaloacetate|3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.
16367645|NCT04204876||patients with GCA|All patients presenting with a new diagnosis of LV-GCA and all patients already treated for LV-GCA and planned for treatment termination
16367646|NCT04204863||SE patients|
16367647|NCT04204850|Experimental|Cabozantinib|Cabozantinib, at a dose of 60 mg orally (by mouth), once a day (at bedtime), continuously.
16367648|NCT04204837|Experimental|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
16367649|NCT04204824|Experimental|Ultrasound and exercise|This group will receive ultrasound treatment, strengthening exercises and stretching exercises.
16367650|NCT04204824|Active Comparator|Sham Ultrasound and exercise|This group will receive sham ultrasound treatment, strengthening exercises and stretching exercises.
16367651|NCT04204811||Participants with Ovarian Cancer|Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)
16367652|NCT04204798|Experimental|Dexmedetomidine group|Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
16367653|NCT04204798|Placebo Comparator|Placebo group|Normal saline is infused for the same duration as in the dexmedetomidine group.
16367654|NCT04204785|No Intervention|Pre-Education|Patient and Anesthesiologist participants completing surveys prior to OR staff education sessions.
16367655|NCT04204785|Experimental|Post-Education|Patient and Anesthesiologist participants completing surveys after OR staff education sessions.
16367656|NCT04204772|Experimental|Daily AC|A total of 4 combinations (2 activated Charcoal doses and 2 solutions) is given to the participants. The dose levels are 12 and 25 of medical grade oral AC. The AC will be mixed with 4 oz of either tap water or apple juice for a total of 4 combinations.
16367657|NCT04204759|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the ventromedial prefrontal cortex and one cathodal electrode (35cm2) will be placed over the occipital cortex. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 30 seconds at the beginning and end of the stimulation period.
16367658|NCT04204759|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
16367659|NCT04204746||3 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
16367660|NCT04204746||6 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
16367661|NCT04204720|Active Comparator|Group Whitacre|Group whitacre receives the whitacre needle during caudal block
16367662|NCT04204720|Experimental|Group Chiba|Group chiba receives the chiba needle during caudal block
16367663|NCT04204707||Conservative surgery|
16367664|NCT04204707||Radical surgery (segmental resection)|
16367665|NCT04204694||Patient in septic shock|
16367666|NCT04204694||blood donor tests|
16367667|NCT04204681||Study|Patients aged 16 years or younger who were to undergo tonsillectomy surgery were eligible for inclusion in this group. Tongue areas were measured twice by submental USG.The first measurements (TA2) were done immediately after endotracheal intubation but before insertion and placement of the tonsillar retractor. The second measurements (TA1) were done after tonsillectomy surgery and after removal of the tonsillar retractor but just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
16367795|NCT04203680|Active Comparator|blood cardioplegia group|patients received one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
16367668|NCT04204681||Control|This group included patients aged 16 years or younger who did not need tonsillectomy surgery and any head and neck procedures. Tongue areas of the patients were measured twice by submental USG as in the study group. TA1s were done immediately after endotracheal intubation, and TA2s were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
16367669|NCT04204668|Active Comparator|Targeted Muscle Reinnervation (TMR)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then cleaned up to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
16367670|NCT04204668|Active Comparator|Regenerative peripheral nerve interface (RPNI)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a muscle graft. The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
16367671|NCT04204668|Active Comparator|Vascularized, denervated muscle target (VDMT )|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
16367672|NCT04204655||Cohort|rehabilitants of the phase B, C and D during neurological rehabilitation
16367673|NCT04204642||Cerebral amyloid angiopathy (CAA)|Cerebral amyloid angiopathy (CAA) patients
16367674|NCT04204629|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
16367675|NCT04204629|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
16367676|NCT04204616|Experimental|Nemolizumab|Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
16367677|NCT04204603|Placebo Comparator|Placebo|
16367678|NCT04204603|Experimental|CKD-506 Dose A|
16367679|NCT04204603|Experimental|CKD-506 Dose B|
16367680|NCT04204603|Experimental|CKD-506 Dose C|
16367681|NCT04204590|Other|Participants|The aim of this study is to test the feasibility of this algorithm as an intervention to carry out deprescribing a targeted medication group, proton pump inhibitors (PPI's) and statins, among nursing home residents.
16367682|NCT04204577|No Intervention|Thermal ablation|Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
16367683|NCT04204577|Experimental|Thermal ablation combined with apatinib|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take about half an hour after a meal (the daily dose should be as much as possible), and take it with warm water. Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib."
16367684|NCT04204577|Experimental|Ablation combined with apatinib and PD-1 antibody SHR-1210|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take it with warm water about half an hour after a meal (the daily dose should be as much as possible). Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib.
~SHR-1210, 200mg, intravenous infusion for 30 minutes (including the time of the tube,the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks; the first dose with the apatite Simultaneous administration of PD, PD-1 injection is not affected by thermal ablation."
16367685|NCT04204564||paclitaxel coated balloon angioplasty|Procedures with paclitaxel coated balloon angioplasty of the superficial femoral-popliteal artery
16367686|NCT04204564||plain balloon angioplasty|Procedures with plain balloon angioplasty of the superficial femoral-popliteal artery
16367687|NCT04204564||paclitaxel eluting stent|Procedures with paclitaxel eluting stenting of the superficial femoral-popliteal artery
16367688|NCT04204564||bare metal stenting|Procedures with bare metal self expanding stenting of the superficial femoral-popliteal artery
16367689|NCT04204551|Experimental|PD-TR|"Intervention
~exercise, dose: two cycles of 12-week HIIT program (three times a week) separated with 3 months break
~& conventional physical therapy"
16367690|NCT04204551|Active Comparator|PD-NTR|conventional physical therapy
16367691|NCT04204551|No Intervention|Healthy Controls|healthy controls without any kind of therapy
16367692|NCT04204538||Urban|Young adults living in urban communities of Rwanda
16367693|NCT04204538||Rural|Young adults living in rural communities of Rwanda
16367857|NCT04203212||Endometriosis Group|20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.
16367694|NCT04204525||Patients with chronic whiplash associated disorders|Male or female, aged between 18 and 65 years. Inclusion: 1) whiplash trauma (at least three months old) and pain since at least 3 months, self-reported mild to severe pain-related disability (score of 5/50 or more on the neck disability index), classified as wad II or wad III on the modified Quebec task force scale; 2) not undertaking exercise 1 day before the experiment; 3) not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation (to obtain a steady state); 4) native dutch speaker and 5) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments
16367695|NCT04204525||Healthy controls|Male or female, aged between 18 and 65 years. Inclusion: 1) no history of whiplash trauma, no pain with a mean pain intensity of more than 2/10 on the visual analogue scale for > 8 consecutive days in the preceding year in the neck-shoulder-arm region 2) painfree at the day of testing 3) native dutch speaker and 4) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments.
16367696|NCT04204486|Experimental|Face to face exercise intervention|Participants will participate in face to face exercise programme delivered by a strength and conditioning coach. Sessions will last 1 hour, 3 times a week, and will be offered at the work place. The coach will register attendance in order to monitor compliance.
16367697|NCT04204486|Active Comparator|Online exercise intervention|"Participants will be given the same training programme as the face to face group, but via an online app. Sessions should last 1 hour and should be completed 3 times a week. Participants will be asked to post a work-out picture on the social platform of the app as proof that they completed their session."
16367698|NCT04204486|No Intervention|Control|This group will undergo all pre and post tests, but will not receive an intervention.
16367699|NCT04204473|Experimental|TY-9591|Find maximum tolerated dose of TY-9591 given orally. Escalating doses of TY-9591 starting at 20mg daily.
16367700|NCT04204447|Experimental|Brochure intervention|Subjects will be asked to read an educational brochure about Hepatitis C
16367701|NCT04204447|Experimental|Video intervention|Subjects will be asked to watch an educational video about Hepatitis C
16367702|NCT04204421|Experimental|Experience Sampling Method (ESM)|Both patients with functional dyspepsia and healthy controls will be asked to fill out ESM questionnaires during 1 week. Moreover, at the end of this week, usual questionnaires for complaints assessment will be filled out.
16367706|NCT04204395|Experimental|Experimental group|"When complete the admission process, the caregiver will give a peanut ball to perform, besides the routine health brochure.
~The participants will be at independent compartment."
16367707|NCT04204395|No Intervention|Control group|Take the routine health brochure. The participants will be at independent compartment.
16367708|NCT04204382|Experimental|test group|"CKI was injected intravenously for 7 days, once a day, 20ml each time；
~Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time,"
16367709|NCT04204382|Other|control group|Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time.
16367710|NCT04204369|Experimental|Teaching arm|This group received the teaching intervention and was evaluated before and after the intervention. Improvement was compared to their performance prior to the intervention.
16367711|NCT04204356|Experimental|tDCS group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment with active tDCS.
16367712|NCT04204356|Sham Comparator|Sham group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment without active tDCS (sham)
16367713|NCT04204343|Active Comparator|Caudal Block|US-guided caudal block with 0.7 ml/kg 0.25% Bupivacaine
16367714|NCT04204343|Active Comparator|Erector Spinae Plane Block|US-guided erector spinae plane block with 0.5 ml/kg 0.25% Bupivacaine
16367715|NCT04204330|Experimental|CardioQVARK group|"Inclusion criteria:
~Males and females aged 20 to 96 years having one or more of the following risk factors:
~hypertensive heart disease;
~history of ischemic stroke or transient ischemic attacks;
~type 1 and 2 diabetes;
~class 1-3 obesity;
~heart failure or decreased tolerance to physical activity due to dyspnea;
~coronary artery disease (CAD) or chest pain without established CAD diagnosis;
~peripheral artery atherosclerosis;
~abnormal heart rhythms (episodes of palpitations, pauses in heartbeat).
~A patient's consent to participate in the study and the ability to sign an informed consent form.
~Exclusion criteria:
~acute coronary syndrome;
~acute ischemic or hemorrhagic stroke;
~mental illness;
~severe concomitant disease with life expectancy less than 2 years.
~Withdrawal criteria:
~1. Refusal to participate in the study."
16367716|NCT04204317||Autofluorescence|"The surgeon will perform the preplanned operation with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:
~Surgery date
~Duration of surgery
~Operation performed
~Procedure related comments
~Number and location of the visualized glands
~Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
16367717|NCT04204317||Control|"The surgeon will perform the preplanned operation without FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:
~Surgery date
~Duration of surgery
~Operation performed
~Procedure related comments"
16367718|NCT04204304|Experimental|Isotretinoin-induced adverse effect group|Patients receiving isotretinoin with dose of 0.5-1 mg/kg/day and had musculoskeletal adverse effects
16367719|NCT04204304|Active Comparator|Control group|Pateients receiving isotretinoin with dose of 0.5-1 mg/kg/day had no musculoskeletal adverse effects
16367720|NCT04204291|Experimental|All|
16367721|NCT04204278|Other|Monovisc|
16367722|NCT04204265|Other|Monovisc|
16367723|NCT04204252|Active Comparator|Inhaled AAT|"Daily inhalation of 80 mg/day Kamada-AAT for Inhalation for 104 weeks"
16367724|NCT04204252|Placebo Comparator|Placebo|Daily inhalation of a solution of NaCl in phosphate buffer solution with 0.01% TWEEN-80
16367725|NCT04204226|Experimental|Social Worker vs Autism Behavioral Health Navigation (ABHN)|"Phase 1: Families providing informed consent will then be randomized to social work consultation or to the Autism Behavioral Health Navigation (ABHN) intervention.
~Non-responders to ABHN will move to ABHN + Complex Autism Program (CAP)."
16367726|NCT04204226|Experimental|Social work + ABHN vs Social work + ABHN + CAP|"At 3 months, children who are considered to be responders to their current treatment will continue; children who are nonresponders in the social work arm of the study will be randomized to either ABHN or ABHN+CAP. Children in the ABHN arm who are non-responders will receive ABHN + CAP"
16367727|NCT04204213||8 Section Brocade Tai Chi Therapy|Subject participants with end stage osteoarthritis knee were enrolled into a customised multidisciplinary education program that consisted of one hour healthcare education seminars followed by another hour of 8 Section Brocade (Baduanjin) sitting Tai Chi classes for 4 consecutive weeks.
16367728|NCT04204200|Active Comparator|Allocated to conventional vitamin C (n= 22)|"Received allocated conventional vitamin C (n= 22)
~Did not receive allocated conventional vitamin C (n= 0)"
16367729|NCT04204200|Active Comparator|Allocated to liposomal vitamin C (n= 22)|"Received allocated liposomal vitamin C (n= 22)
~Did not receive allocated liposomal vitamin C (n= 0)"
16367730|NCT04204200|Placebo Comparator|Allocated to placebo (n= 22)|"Received allocated intervention (n= 22)
~Did not receive allocated intervention (n= 0)"
16367731|NCT04204174|Experimental|Tyrosine loading|
16367732|NCT04204161|Experimental|CAR-T19/CAR-T22|CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.
16367733|NCT04204148||Clinical characteristics of the patients|including sex,age,smoking history,tumor location and tumor diameter
16367734|NCT04204148||Logistic regression analysis of influencing factors of c|The Leicester Cough Questionnaire in Mandarin Chinese (LCQ-MC) was used to evaluate the degree of cough in patients. The LCQ-MC is divided into three dimensions: physical, psychological and social. There are a total of 19 questions, and each question has seven options (positive scoring, grades 1-7; the higher the score is, the lighter the cough).
16367735|NCT04204122|Experimental|Arm 1: Eye treated with Vigamox|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
16367736|NCT04204122|Placebo Comparator|Arm 2: Eye treated with placebo|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
16367737|NCT04204109|Experimental|Interprofessional case-based learning|The experimental intervention will be the interprofessional group receiving case-based learning about gastro-intestinal toxicities and side effects of children and adolescents with cancer.
16367738|NCT04204109|Active Comparator|Monoprofessional case-based learning|The control group is the monoprofessional group that will receive the same case-based learning as the intervention group.
16367739|NCT04204096|Experimental|Vi-DT Multi-dose|"750 participants (6 mo - 45 yrs)
~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)
~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (multi-dose formulation Vi-DT contains preservative 2 PE)
~Mode of Administration: Intramuscular injection
~Frequency of administration: Once"
16367740|NCT04204096|Experimental|Vi-DT Single-dose|"750 participants (6 mo - 45 yrs)
~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)
~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (single dose formulation Vi-DT without any preservative)
~Mode of Administration: Intramuscular injection
~Frequency of administration: Once"
16367741|NCT04204096|Active Comparator|Control|"300 participants (6 mo - 45 yrs)
~Dose: 0.5mL, Locally available Meningococcal conjugate vaccine
~Dosage form: Lyophilized white powder
~Mode of Administration: Intramuscular injection
~Frequency of administration: Once (For participants 6 months to 1 year, one more dose will be provided after the study unblinding)"
16367742|NCT04204083|Other|Monovisc|
16367743|NCT04204070|Experimental|Group I Accuro|epidural catheter insertion using the Accuro ultrasound imaging assisted technique
16367744|NCT04204070|Experimental|Group II APAD|epidural catheter insertion using the real time ultrasound guided technique combined with the use of the acoustic puncture assist device (APAD) technique.
16367745|NCT04204057|Experimental|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
16367746|NCT04204044|Experimental|GROUP A ( metformin 500 mg TDS)|Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day
16367747|NCT04204044|Experimental|GROUP B( myoinositol 2000mg x BD )|Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day
16367748|NCT04204044|Experimental|GROUP C.(both metformin,& myoinositol)|Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,& myoinositol three and two times a day respectively
16367749|NCT04204031|Other|Presentation of the adherence record|"Following a first observation period of 15 days, participants whose actual time of use will be less than prescribed will be offered an intervention which will consist of a presentation of the adherence record. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
~Only participants with an actual time of use less than prescribed will be offered this intervention and will continue the monitoring over a period of 15 additional days."
16367750|NCT04204018|Experimental|Experimental|Experimental-arm providers will complete four simulated patient cases (CPVs) with two additions described in the next column:
16367751|NCT04204018|No Intervention|Control|These providers will complete four simulated patient cases (CPVs) only.
16367752|NCT04204005|Active Comparator|Probiotics|Composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams)
16367753|NCT04204005|Placebo Comparator|Placebo|Composition: maltodextrin (2 grams)
16367754|NCT04203992|Experimental|Videogame|Educational videogame, five 60-minute sessions over one month
16367755|NCT04203992|Active Comparator|Booklet|Educational booklet, one session
16367858|NCT04203212||Control Group|20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.
16367756|NCT04203966||Common mental disorders/ versus no common mental disorders|No intervention This is a prevalence study- presence of common mental disorders (CMDs) will be assessed using the 12-item general Health Questionnaire, with responses above validated cut-points taken to indicate presence of CMDs
16367757|NCT04203966||Alcohol use disorders/ versus no alcohol use disorders|No intervention This is a prevalence study- presence of alcohol use disorders will be assessed using the World Health Organization (WHO) AUDIT, with responses above validated cutpoints taken to indicate presence of alcohol use disorders
16367758|NCT04203940|Active Comparator|Cyanoacrylate|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue (Histoacryl®).
16367759|NCT04203940|Active Comparator|Suture|mesh fixation was done with polypropylene 2/0 sutures
16367760|NCT04203927|Active Comparator|Empagliflozin + insulin infusion|vascular measurements in overnight fasted state and during insulin infusion
16367761|NCT04203927|Active Comparator|Empagliflozin + mixed meal|vascular measurements in overnight fasted state and 2 hours after mixed meal 10kcal/kg body weight ( 55% Cho, 30%Fat, 20% Pro)
16367762|NCT04203914|Experimental|Intervention|Empagliflozin 25mg daily add-on therapy
16367763|NCT04203901|Experimental|Combination Arm|CMN-001 dosing (1x10^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
16367764|NCT04203901|Active Comparator|Standard Treatment|1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
16367765|NCT04203888|Other|Massage|A licensed massage therapist will deliver 60-minute Swedish Massage in the participant's home, 2 times per week with at least 48-hours between massage sessions. Each massage arm will be 2 weeks in length, and consist of 4 total Swedish massages.
16367766|NCT04203888|Other|Yoga|"A certified yoga instructor will deliver 60-minute yoga instruction in the participant's home, 2 times per week with at least 48-hours between yoga session. Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005). Each yoga arm will be 2 weeks in length, and consist of 4 total yoga sessions."
16367767|NCT04203888|No Intervention|Usual Care|Participants will be instructed to abstain from any massage or yoga activity, and instructed to treat their chronic lower back pain as they normally would. Each usual care arm will be 2 weeks in length.
16367768|NCT04203875|Experimental|Orencia® (Abatacept)|Abatacept 125 mg, subcutaneous once a week for 6 months or up to one year if subject has a favorable response
16367769|NCT04203862|Experimental|1|Single administration of low dose NPC-22
16367770|NCT04203862|Experimental|2|Single administration of low/middle dose NPC-22
16367771|NCT04203862|Experimental|3|Single administration of middle dose NPC-22
16367772|NCT04203862|Experimental|4|Single administration of middle/high dose NPC-22
16367773|NCT04203862|Experimental|5|Single administration of high dose NPC-22
16367774|NCT04203862|Experimental|6|Single administration of placebo dose NPC-22
16367775|NCT04203836|Experimental|Fed|Single oral dose given after a full breakfast
16367776|NCT04203836|Experimental|Fasting|Single oral dose given in fasting state
16367778|NCT04203810|Experimental|Ectoin® Mouth and Throat Spray Althaea Honey|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
16367779|NCT04203810|Active Comparator|EMSER® Hals- und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
16367780|NCT04203797|Experimental|dupilumab|A loading dose at the start of the treatment followed by once every two weeks (Q2W).
16367781|NCT04203797|Experimental|Matching placebo|Matching dupilumab
16367782|NCT04203784||Meropenem treated patients|
16367783|NCT04203784||Piperacillin treated patients|
16367784|NCT04203771|Experimental|Probiotic|Orodispersible tablets containing AB-DENTALAC probiotic formula.
16367785|NCT04203771|Placebo Comparator|Control|Orodispersible tablets without probiotic strains (excipients only).
16367786|NCT04203758|Experimental|Wholegrain rye products with a high content of dietary fiber|Cereal products based on wholegrain rye
16367787|NCT04203758|Active Comparator|Refined wheat products with a low content of dietary fiber|Cereal products based on refined wheat
16367788|NCT04203745|Experimental|Single Group|Single Group - single arm study
16367789|NCT04203732||Total Joint Arthroplasty|The cohort includes patients undergoing outpatient primary total joint replacement surgeries from 2017 to 2019. Primary total joint surgery is defined as patients who undergo unilateral total knee replacement or total hip replacement for the first time during the study years
16367790|NCT04203719|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16367791|NCT04203706|Experimental|Normal-weight subjects|
16367792|NCT04203693||Cohort 1: Tildrakizumab Treated Participants|Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
16367793|NCT04203693||Cohort 2: Newly Tildrakizumab Prescribed Participants|Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
16367794|NCT04203680|Sham Comparator|HTK group|Patients received 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
16367796|NCT04203667|Other|EndoRotor Resection Arm|The mucosal resections are performed during standard flexible colonoscopy procedures. All medications given, pre- and post-procedure precautions and follow-up assessments are part of routine standard of care. This protocol concerns itself with the actual removal of the scarred mucosal lesion once the abnormal area is identified using the colonoscope.
16367797|NCT04203654|Other|Cognitive-behavior group therapy group|
16367798|NCT04203641|Experimental|L-DOS47 + doxorubicin|Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin [20 mg/m2/week] will be administered in combination with L-DOS47 across all cohorts.
16367799|NCT04203628|Experimental|Prospective cohort|"Any child with presumptive TB will be proposed to participate in the study.
~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies.
~For children identified from the routine practice, the nurse will collect 2 respiratory samples (sputum or GA) in consecutive children with presumptive TB to be tested using Ultra as done in routine care, record symptoms and refer the child for clinical exam and for chest X-ray. For the purpose of the study, 2 stool samples will be collected to be tested with Ultra. In addition, for study purpose the two respiratory samples will be tested with Mycobacterial culture as this test is not routinely prescribed for TB diagnosis in the study sites"
16367800|NCT04203628|Experimental|Enrichment cohort|"Any child with presumptive TB and a positive Xpert result from one respiratory sample (NPA, IS or GA) will be proposed to participate in the study.
~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies
~For children identified from the routine care, once enrolled, samples collected as routine practice will be tested with mycobacterial culture in addition to Xpert. If needed an additional respiratory sample will be collected (sputum or GA) and tested with Mycobacterial culture. The nurse will also record symptoms, refer the child for clinical exam and for chest Xray, and collect stool samples. HIV-testing will be offered for children with unknown HIV-status"
16367801|NCT04203615|Active Comparator|PD patients with real rTMS|Patients will receive real rTMS in a two weeks long sessions (10 sessions).
16367802|NCT04203615|Sham Comparator|PD patients with sham rTMS|Patients will receive sham rTMS in a two weeks long sessions (10 sessions).
16367803|NCT04203602|Experimental|Telepresence round|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
16367804|NCT04203602|Active Comparator|conventional round|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
16367805|NCT04203589|Experimental|The Explorer Early Intervention Program|The Explorer Early Intervention Program is used in this group.
16367806|NCT04203589|Active Comparator|Neurodevelopmental Therapy|Neurodevelopmental therapy is used in these group by two experienced and certificated physiotherapist
16367807|NCT04203576|Experimental|FIRE1 System|FIRE1 System
16367808|NCT04203563|Experimental|Group 1|Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks. Intervention Group.
16367809|NCT04203563|Other|Group 2|Group 2 participants receive twice weekly progressive strength training classes in January 2020 for 12 weeks. Delayed Intervention Group.
16367810|NCT04203550|Active Comparator|Irrigation group (IR)|A burr-hole craniostomy is performed and the dura is opened sharply and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. Subdural space is irrigated by repeated rinsing with body temperature saline solution with a syringe and blunt needle until surgeon considers exudate to be clear. Minimum volume of irrigation will be 200 ml per operated side. The subdural drain is inserted 3-5 cm underneath the skull and parallel to it. The total volume of irrigation as well as the duration of operation is recorded.
16367811|NCT04203550|Experimental|No-Irrigation group (N-IR)|A burr-hole craniostomy is performed and a small incision to the dura is made and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. The subdural drain is inserted approximately 3-5 cm underneath the skull and parallel to it. The duration of operation is recorded.
16367812|NCT04203537|Active Comparator|CA-008|Single administration
16367813|NCT04203537|Placebo Comparator|Placebo|Single administration
16367814|NCT04203524|Experimental|Procalcitonin Arm|The medical team will be provided with a daily PCT for the patient, along with the PCT-guided algorithm that outlines the suggested management based on the PCT levels.
16367815|NCT04203524|Other|Control Arm|Procalcitonin levels will be measured for those patients, but the medical team will be blinded from their results
16367816|NCT04203511|Experimental|Chemoradiation therapy + INCMGA00012|
16367817|NCT04203511|Active Comparator|Chemoradiation therapy + Placebo|
16367818|NCT04203498|Experimental|Nabiximols|
16367819|NCT04203498|Placebo Comparator|Placebo|
16367820|NCT04203485|Experimental|Camrelizumab 200mg + Apatinib Mesylate 250mg|Camrelizumab 200mg q2w ivgtt+ Apatinib Mesylate 250mg once daily po qd
16367821|NCT04203485|Experimental|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
16367822|NCT04203485|Active Comparator|Pemetrexed/Paclitaxel injection+ Carboplatin|For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin; For squamous NSCLC: Paclitaxel injection + Carboplatin
16367823|NCT04203472|Experimental|Budesonide or budeosonide/formoterol administered by DPI|In every patient cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI for 14 days
16367824|NCT04203472|Active Comparator|Budesonide or budeosonide/formoterol administered by MDI|In every patient inhaler will be changed and cough severity and tolerance of therapy will be analyzed during therapy with the same drugs administered by MDI . Order of using different types of inhalers will be accidental
16367991|NCT04202172|Experimental|COMBO|Implantation of Bioactive coronary stent in patients with myocardial infarction.
16367825|NCT04203459||Pancreatic cancer patient|(1) patients with pancreatic cancer confirmed by imaging, pathology and body fluid biopsy, or patients who recovered well one month after operation but still had residual lesions, recurrence or metastasis. ② age ≥ 30 and ≤ 75. ③ no chemotherapy, radiotherapy or targeted drugs were used before admission. ④ patients who had used immunosuppressive drugs, hormones, antibiotics and probiotics one month before admission were excluded. ⑤ patients with HIV positive and active hepatitis B or C infection were excluded. ⑥ exclude the previous history of other malignant tumors or the current combination of other malignant tumors. The patients with serious cardiopulmonary disease and liver and kidney dysfunction were excluded. ⑧ patients with obstructive jaundice were excluded.
16367826|NCT04203459||Healthy person|(1) no history of digestive tract diseases, infectious diseases or immune diseases.(2) no history of smoking or drinking.(3) did not take antibiotics and other drugs and probiotics for 1 month before enrollment.
16367827|NCT04203446||Adults with asthma or COPD|Adults (18-85 years old) with asthma or COPD diagnosed at least 3 months earlier, who are regularly treated with at least one inhlaer daily
16367828|NCT04203433|Experimental|DLX105-DMP Multi-Dose|4 Weeks of 1mg DLX105-DMP applied to a target lesion.
16367829|NCT04203420||patients with PA|patients who finally been diagnosed with primary aldosteronism
16367830|NCT04203420||patients without PA|patients who finally been diagnosed without primary aldosteronism
16367831|NCT04203407|Experimental|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
16367832|NCT04203407|Active Comparator|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
16367833|NCT04203394|Experimental|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
16367834|NCT04203394|Experimental|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
16367835|NCT04203381|Other|Transgender Participant|Transgender children at Tanner stage II or early Tanner stage III between the ages of 9 and 14. Must be a current patient at a gender patient and within 6 weeks of initiating pubertal blockade treatment
16367836|NCT04203381|No Intervention|Cisgender Control Participant|Cisgender children Tanner II or early Tanner III between 9 and 14 matched by race, age, and BMI.
16367837|NCT04203368|Active Comparator|adenosine group|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil
16367838|NCT04203368|Sham Comparator|verapamil group|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
16367839|NCT04203342|Experimental|Ketoconazole 2% cream (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Test product is Ketoconazole 2% cream manufactured by Douglas Pharmaceuticals America Ltd.
16367840|NCT04203342|Active Comparator|Ketoconazole 2% cream (Teva Pharmaceuticals USA)|Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.
16367841|NCT04203342|Placebo Comparator|Placebo (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Placebo comparator is manufactured by Douglas Pharmaceuticals America Ltd.
16367842|NCT04203329||Paroxysmal A-Fib|
16367843|NCT04203329||Persistent A-Fib|
16367844|NCT04203329||A-Fib|
16367845|NCT04203316|Experimental|Treatment (enasidenib)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16367846|NCT04203303||Observational|Observational
16367847|NCT04203290|Active Comparator|General anesthesia|Patients will be applyed 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium for anesthesia induction, after intubation sevoflurane will be used for anesthesia maintenance with low flow anesthesia (0.5 l/min).
16367848|NCT04203290|Active Comparator|General anesthesia combined with thoracic epidural anesthesia|Before anesthesia induction epidural catheter will be inserted giving 7 ml bupivacaine %0.25 in saline + 50 mcg fentanyl after confirming the location of catheter, following 15 minutes the standard anesthesia induction will be applied ( 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium ). For anesthesia maintenance epidural infusion will be applied ( 7ml/h %0.25 bupivacaine solution) together with low flow (0.5 l/min) sevoflurane anesthesia.
16367849|NCT04203277|Experimental|Step Wedge Randomized Group 1|Includes two pediatric practices randomized to the first step of the step-wedge randomized trial
16367850|NCT04203277|Experimental|Step Wedge Randomized Group 2|Includes two pediatric practices randomized to the second step of the step-wedge randomized trial
16367851|NCT04203277|Experimental|Step Wedge Randomized Group 3|Includes two pediatric practices randomized to the third step of the step-wedge randomized trial
16367852|NCT04203277|Experimental|Step Wedge Randomized Group 4|Includes two pediatric practices randomized to the fourth step of the step-wedge randomized trial
16367853|NCT04203238|Experimental|Potatoes Lean Meat (PLM)|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
16367854|NCT04203238|Experimental|Lean Meat Pulses (LMP)|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
16367855|NCT04203225|Active Comparator|Single LET|One (single) application of LET topical gel [Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)] applied for 30 minutes
16367856|NCT04203225|Experimental|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
16367859|NCT04203199|Experimental|Real rTMS to the mPFC using H7 Coil|One session of low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
16367860|NCT04203199|Sham Comparator|Sham rTMS to the mPFC using H7 Coil|One session of sham low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (sham rTMS - 20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
16367861|NCT04203199|Experimental|Real rTMS to the dlPFC using H1 Coil|One session of high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
16367862|NCT04203199|Sham Comparator|Sham rTMS to the dlPFC using H1 Coil|One session of sham high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (sham rTMS- 20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
16367863|NCT04203186|Active Comparator|Group 1 - PfSPZ, (NF54) strain|Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
16367864|NCT04203186|Active Comparator|Group 2 - PfSPZ, (7G8) strain|Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
16367865|NCT04203173|Experimental|FINANCE-DM Intervention|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
16367866|NCT04203173|Active Comparator|TIDES Intervention|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.
16367867|NCT04203160|Experimental|Phase 1 and Phase 2, Arm A (investigational)|On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.
16367868|NCT04203160|Active Comparator|Phase 2, Arm B (standard of care)|On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.
16367869|NCT04203147|Experimental|Home DM-BAT Intervention|A trained nurse educator will deliver the manualized Home DM-BAT intervention. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12 via telephone.
16367870|NCT04203147|Active Comparator|Control Group (GHE+ST)|Patients randomized to the control group will receive in-home 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12 via telephone.
16367871|NCT04203134|Experimental|Treatment Group|Patients in the randomly assigned treatment group will receive a mouthguard at first visit along with standard treatment of BMS.
16367872|NCT04203134|No Intervention|Control Group|Control group will proceed through treatment for BMS in an otherwise standard treatment protocol and will not receive a mouthguard.
16367873|NCT04203121|Experimental|arm1|"An initial 5 patients will be enrolled in the first treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.
~subjects 1-5 : 9 Gy in 5 fractions of 1.8 Gy on 5 consecutive days"
16367874|NCT04203121|Experimental|arm2|"Subjects in this arm will be enrolled in the second treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.
~subjects 6-10 : 5.4 Gy in 3 fractions of 1.8 Gy on 3 consecutive days"
16367875|NCT04203108|Experimental|ATG group|ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.
16367876|NCT04203108|Active Comparator|non-ATG group|Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.
16367877|NCT04203095||patient with PD1 antibody treatment|"Investigators will detect cfDNA CIN of lung cancer patients 1day (Day 0) before treatment with PD1 antibody, then Day 22 and Day 64 after treatment with PD1 antibody, as well as at the time of disease progression confirmed.
~The correlation of CIN and drug resistance to PD1 antibody was analyzed."
16367878|NCT04203082|Experimental|Exposure Intervention|Participants randomized to receive the Exposure Intervention will be scheduled to come to clinic for a 1-hour session for the intervention. During this time, they will receive psychoeducation and behavioral exposure to the Cesarean section procedure.
16367879|NCT04203082|Other|Usual Care|Participants randomized to the Care as Usual condition will receive the typical standard of care that is offered in the center. This involves the anesthesiologist meeting with the patient during a delivery planning meeting to provide patients with the opportunity to review anesthetic technique and ask questions.
16367880|NCT04203069|Placebo Comparator|Control group : Day-time compression sleeve|Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.
16367881|NCT04203069|Experimental|Day-time compression sleeve and Night-time MOBIDERM Autofit|Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.
16367882|NCT04203056|Experimental|AL-LAI: Long-Acting Injectable Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: For patients assigned to the AL-LAI (aripiprazole lauroxil- long-acting injections), initiation of AL-LAI will begin with a one-day initiation regimen (using AL-NCD IM (aripiprazole lauroxil NanoCrystal Dispersion)). Subsequent dosing of AL-LAI will be flexible based on clinician judgment. Treatment with AL-LAI can be initiated at a dose of 441mg or 661mg (administered monthly), 882mg (administered monthly or every 6 weeks), or 1064mg (administered every 2 months).
16367883|NCT04203056|Active Comparator|ARI-ORAL: Aripiprazole Oral Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: Patients assigned to the oral medication condition will continue with ARI-ORAL. ARI-ORAL dosage will be flexible and dosage will be at the discretion of the treating psychiatrist. Patients discontinuing ARI-ORAL study drug after Randomization to oral antipsychotic medication, can remain in active treatment and follow-up within the study, and may be prescribed any of a number of first-line oral antipsychotics.
16367884|NCT04203043|Active Comparator|Pycnogenol oral product to prevent Hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
16367885|NCT04203043|Placebo Comparator|Placebo to prevent hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
16367886|NCT04203030|Experimental|Physical Activity|16 week physical activity intervention
16367887|NCT04203017|Experimental|AutoHSCT + FMT|AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
16367888|NCT04203004|Experimental|HOPE-CytoSorb|Patients transplanted with livers preserved by HOPE with cytokine filtration by CytoSorb, a CE approved medical device for extracorporeal cytokine removal
16367889|NCT04203004|No Intervention|HOPE-standard|Patients transplanted with livers preserved by HOPE without cytokine filtration
16367890|NCT04202991||COPD with pain|People with COPD who also report pain more often than not over the previous 3 months
16367891|NCT04202991||COPD with no pain|People with COPD who do not report pain more often than not over the previous 3 months
16367892|NCT04202978|Experimental|Camrelizumab+ Apatinib +XELOX +RFA|Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer
16367893|NCT04202965|Experimental|PTG-300|PTG-300 Subcutaneous
16367894|NCT04202952|Experimental|600 mg multiple doses|Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
16367895|NCT04202952|Experimental|800 mg multiple doses|Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
16367896|NCT04202952|Experimental|1200 mg multiple doses|Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
16367897|NCT04202939||nursing homes residents|all residents present in a nursing home unit on nutritionDay
16367898|NCT04202926|Experimental|10hz group|a high frequency stimulation
16367899|NCT04202926|Sham Comparator|sham group|a sham coil which frequency is 10hz but do not induce stimulation
16367900|NCT04202913|Experimental|Health Coaching|1:1 Health coaching with student
16367901|NCT04202900|Other|Phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.
~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
16367902|NCT04202887|Active Comparator|Low Fentanyl (LF)|fentanyl cumulative dose below 100mcg
16367903|NCT04202887|Active Comparator|High Fentanyl (HF)|fentanyl cumulative dose above 100mcg
16367904|NCT04202874|Experimental|Bupivacaine|Administration of 20ml of bupivacaine 0.25% on each side, for a total of 40ml.
16367905|NCT04202874|Placebo Comparator|Saline|Administration on 20ml of normal saline on each side, for a total of 40ml.
16367906|NCT04202861|Experimental|in vitro antibiotic combination testing (iACT)|For the intervention arm, CRGNB isolates from the index culture should be transported to the Pharmacy Research Lab in Singapore General Hospital as soon as possible to begin iACT. For external sites, a licensed medical courier will be engaged. Once testing is complete, the iACT results will be sent to the physicians and the ID specialist managing the patient. Several antibiotic combinations can usually be used to treat the infection; a subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and/or the consulting infectious disease doctor may exercise their discretion in continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement, according to the clinical conditions and reactions of the patient to the treatment
16367907|NCT04202861|No Intervention|Control|The standard arm will receive standard therapy of either antibiotic monotherapy or unguided combination therapy, a choice based on treating physicians' best clinical judgment. iACT will only be performed on CRGNB isolates from the standard arm at least 30 days after enrolment for collection of microbiological, proteomic and molecular data. Antibiotic combinations found from delayed iACT will be made known to the Infectious Diseases physician caring for the participant.
16367908|NCT04202835|Experimental|ATG/PTCy|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
16367909|NCT04202835|Active Comparator|ATG|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
16367910|NCT04202822|Other|Biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) at T0 and T24
16367911|NCT04202809|Experimental|Chemo- and Radiochemotherapy + Durvalumab|
16367912|NCT04202809|No Intervention|Chemo- and Radiochemotherapy|
16367913|NCT04202783|Experimental|Treatment of Craniofacial Neuralgia|All patients will receive the same amount (5mL concentrated) of exosomes delivered via ultrasound-guided, regional epineural injection and the same amount (5mL unconcentrated) delivered via IV. Patients will be given 3 mL of the exosome product intravenously, which contains about 45mg of the exosome product containing 15-21 million neonatal stem cell products, and 3 mL of the exosome hyperconcentrate product delivered epineurally using ultrasound guidance, which contains about 15mg of the exosome product carrying 5-7 million neonatal stem cell products.
16367948|NCT04202510|Active Comparator|iStent|iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
16367949|NCT04202510|Active Comparator|iStent Inject|iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
16367914|NCT04202770|Experimental|Treatment|Patients deemed potentially appropriate candidates for exosome and focused ultrasound therapy for either treatment refractory depression (trMDD), anxiety, or neurodegenerative dementia will be treated with exosomes derived from healthy, full-term Cesarean section amniotic fluid. Up to one hour of transcranial focused ultrasound will be administered immediately prior to exosome treatment in an attempt to facilitate enhanced deployment to the subgenual cingulate for trMDD, the amygdala for anxiety, or the hippocampus for dementia. Target location will be determined by the physician upon enrollment depending on the patient's specific syndrome. Patients will be given 15cc of unconcentrated solution allogenic exosomes (equivalent to 21 million stem cells, Kimera Corporation) intravenously in 200 ccs of normal saline dripped over thirty minutes to one hour.
16367915|NCT04202757|Active Comparator|Young Fresh Frozen Plasma (yFFP)|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
16367916|NCT04202757|Placebo Comparator|Saline|0.1% riboflavin in normal saline
16367917|NCT04202744||Water Polo Group|"Participants were active water polo players who train regularly with ages in between 10-30 years.
~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
16367918|NCT04202744||Non-Water Polo Group|"Participants who do not engage in overhead sports with ages in between 10-30 years.
~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
16367919|NCT04202731|Experimental|Sleep Extension|Participants will be asked to extend their time in bed with the goal of improving the total time they sleep each night.
16367920|NCT04202718|Other|Single group|Where a wearable biosensor is being considered for use in the health management of individuals at high-risk for poor health outcomes, and in the detection or prevention of adverse events within settings where traditional monitoring devices are not currently in use, the ECG interpretation will provide Arrhythmia detection which will help ensure that irregular rhythms will be reported quickly.
16367921|NCT04202705|Experimental|SYD1875|5T4-targeting Antibody-Drug Conjugate
16367922|NCT04202692|Experimental|GERDOff Plus|Hyaluronic acid + chondroitin sulphate + magnesium trisilicate melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
16367923|NCT04202692|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period, patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
16367924|NCT04202679|Experimental|Dupilumab|Dose regimen 1 on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
16367925|NCT04202679|Placebo Comparator|Matched placebo|Placebo on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
16367926|NCT04202666|No Intervention|not convex skin barrier|no intervention
16367927|NCT04202666|Experimental|convex skin barrier|intervention
16367928|NCT04202653|Active Comparator|Naive:ETV|Entecavir 0.5 mg po daily for 24 weeks in naive patients
16367929|NCT04202653|Experimental|Naive:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in naive patients
16367930|NCT04202653|Experimental|Naive:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus inhibitor of TQ-B2450 for 24 weeks in naive patients
16367931|NCT04202653|Active Comparator|Experienced:ETV|Entecavir 0.5 mg po daily for 24 weeks in treatment experienced patients
16367932|NCT04202653|Experimental|Experienced:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in treatment experienced patients
16367933|NCT04202653|Experimental|Experienced:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus TQ-B2450 for 24 weeks in treatment experienced patients
16367934|NCT04202640|Experimental|Arm A - Mechanical Stimulation|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, mechanical stimulation
16367935|NCT04202640|Sham Comparator|Arm B - Massages|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, massages.
16367936|NCT04202601|Experimental|Neoadjuvant therapy group|
16367937|NCT04202601|Experimental|first-line therapy group|
16367938|NCT04202601|Experimental|≥second-line therapy group|
16367939|NCT04202575|No Intervention|conventional setup|Blood and gas from the coronary and cardiotomy suction devices is continuously evacuated via the additional reservoir to the standard reservoir.
16367940|NCT04202575|Experimental|Intervention setup|The connecting tube between the additional and standard venous reservoir is clamped. Thus, blood and gas from the coronary and cardiotomy suction devices are collected in the additional venous reservoir. During the intervention setup, the blood in the additional venous reservoir is only evacuated to the standard reservoir if the volume exceeded 800ml, and always with a remaining volume of 100 mL blood to keep the CO2-gas trapped in the additional venous reservoir.
16367941|NCT04202562|Experimental|Combined surgery|Participants intervened of combined ab interno trabeculectomy and cataract surgery at the same time
16367942|NCT04202562|Active Comparator|Cataract surgery|Participants intervened of cataract surgery alone
16367943|NCT04202549|Experimental|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy
16367944|NCT04202536|Experimental|TDF switch to Besifovir Dipivoxil Maleate|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate 183mg daily
16367945|NCT04202536|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
16367946|NCT04202523|Experimental|RT&RFA|
16367947|NCT04202523|Active Comparator|RFA|
16367988|NCT04202185||G1b|children under 16 years of age with audiologically proven auditory neuropathy
16367950|NCT04202510|Active Comparator|Hydrus|Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
16367951|NCT04202497|Experimental|TAK-418 1.5 mg|TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of [18F]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.
16367952|NCT04202484|Experimental|Toripalimab combine CT|
16367953|NCT04202471|Experimental|Chlorhexidine Cloth|The intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive preoperative abdominal application of 2% chlorhexidine cloths.
16367954|NCT04202471|No Intervention|Standard Preoperative Care|The no intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive standard preoperative care.
16367955|NCT04202458|Experimental|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA
16367956|NCT04202432||Coronary Artery Bypass Surgery patients|Patients undergoing coronary artery bypass surgery (on-pump / off-pump) measured perioperatively and postoperatively.
16367957|NCT04202419|Experimental|Single Group|Single Arm: All subjects will undergo treatment of pigmented lesions with a 1940 nm diode laser
16367958|NCT04202406|Experimental|Acetaminophen, codeine,and caffeine|Oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine.
16367959|NCT04202406|Experimental|Acetaminophen|Oral single dose of 1000mg acetaminophen.
16367960|NCT04202406|Placebo Comparator|Placebo|Maize starch.
16367961|NCT04202393|Experimental|Integrated Treatment Adherence Program (ITAP)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
16367962|NCT04202393|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
16367963|NCT04202380|Other|Azithromycin 1 day group|Patients will receive Azithromycin 1000mg once orally
16367964|NCT04202380|Other|Azithromycin 5 days group|Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days
16367965|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.25%|Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
16367966|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.125%|Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block
16367967|NCT04202354|Experimental|ARO-HSD|
16367968|NCT04202354|Placebo Comparator|Placebo|
16367969|NCT04202315|No Intervention|Control|Standard of care, no Virtual Reality
16367970|NCT04202315|Experimental|Virtual Reality|Standard of care plus Virtual Reality
16367971|NCT04202289|Active Comparator|Silver Sulfadiazine Cream 1%|In the control group, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of Silver Sulfadiazine Cream 1% was applied and covered with gauze and bandage. The dressing changes occurred every 48 hours. The patients were evaluated every 48 hours for the study parameters.
16367972|NCT04202289|Experimental|Nile Tilapia Fish Skin|In the test group, the treatment was Nile Tilapia Fish Skin, which have a patent registered at the National Institute of Industrial Property (INPI) under number BR 10 2015 021435 9. Nile Tilapia Fish Skin was subjected to a rigorous process of chemical sterilization, glycerolization and irradiation, followed by microbiological tests for bacteria and fungi, before storage in sterile refrigerated packaging. Prior to its use in the patient, the skin was washed thrice in sterile 0.9% saline for 5 minutes, in order to remove glycerol. Regarding application in the study patients, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, Nile Tilapia Fish Skin was applied and covered with gauze and bandage. Throughout the treatment, dressings with Nile Tilapia Fish Skin were only changed if the biomaterial was not properly adhered to the wound bed. The patients were evaluated every 48 hours for the study parameters.
16367973|NCT04202276|Other|Patients with GERD|The data of Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire to be performed in children and adolescents with GERD.
16367974|NCT04202276|Other|Control group|The same examinations as in experimental group are to be performed in patients of the control group (no GERD according to the results of the examination): Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire.
16367975|NCT04202263|Placebo Comparator|Placebo|Placebo cream without minocycline
16367976|NCT04202263|Active Comparator|Minocycline Arm|Minocycline cream (1%,2%,3%)
16367977|NCT04202250|Active Comparator|CEMP (closed-ended multiport catheter) group|closed-ended multiport femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
16367978|NCT04202250|Active Comparator|OESP (open-ended single port catheter) group|open-ended single port femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
16367979|NCT04202224|Experimental|Study|Receives pre-emptive analgesia 30min. prior to third molar extraction. NSAID: Ibuprofen 400mg and Acetaminophen 500mg/
16367980|NCT04202224|Placebo Comparator|Placebo|Receives glucose tablets as pre-emptive analgesia 30min. prior to third molar extraction.
16367981|NCT04202224|Active Comparator|Control|Receives no medication prior to third molar extraction.
16367982|NCT04202211|Placebo Comparator|Placebo oral & enema|twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema
16367983|NCT04202211|Active Comparator|LYO-FMT oral + placebo enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema
16367984|NCT04202211|Active Comparator|LYO-FMT oral + LYO-FMT enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema
16367985|NCT04202198|Experimental|pinhole surgical technique with Platelet Rich Fibrin|minimally invasive tunneling procedure followed by coronal advancement with placement of Platelet Rich Fibrin membrane
16367986|NCT04202198|Active Comparator|pinhole surgical technique only|coronal advancement following minimally invasive tunneling procedure
16367987|NCT04202185||G1a|infants under 3 years deaf severe to deep
16367992|NCT04202159||Perampanel|Participants with PGTC or SGTC seizures may receive perampanel tablets or oral suspension as only add-on therapy based on physicians decision in accordance with summary of product characteristics (SmPC) and will be observed at baseline, 6 months (intermediate visit), and 12 months (final visit).
16367993|NCT04202146|Experimental|Contingency Management + Motivational Interviewing|Participants will complete a seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling.
16367994|NCT04202133|Experimental|WW (formerly Weight Watchers)|16-weeks of the group-based WW program
16367995|NCT04202133|Other|Waitlist Control|16-weeks on waitlist then participants will be provided with 16-weeks of the group-based WW program
16367996|NCT04202120|Experimental|Age-related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with age-related primes.
16367997|NCT04202120|Active Comparator|Non-age related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with NON age-related primes.
16367998|NCT04202107||Urban|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.
~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
16367999|NCT04202107||Rural|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.
~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
16368000|NCT04202094|Experimental|Biopsy group|Young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood and who have chosen to undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy.
16368001|NCT04202094|Experimental|No biopsy group|Young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood and who have refused to undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy.
16368002|NCT04202094|No Intervention|Control group|Spontaneously conceived young adults whose data on reproductive health have already been published (Belva F et al., 2016/2017/2019).
16368003|NCT04202068|Experimental|Ceftriaxone sodium and Sulbactam Sodium for injection|combinations of β-Lactamase inhibitors
16368004|NCT04202055||Neuromyelitis optica with anti-MOG|
16368005|NCT04202055||Patients with Neuromyelitis optica with anti-AQP4|
16368006|NCT04202055||Seronegative patients with Neuromyelitis optica|
16368007|NCT04202055||Patients with recurrent-remitting multiple sclerosis|Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement
16368008|NCT04202055||Progressive multiple sclerosis patients|
16368009|NCT04202055||Symptomatic controls|
16368010|NCT04202042|Experimental|Psychological first aid|PFA responders are trained to deliver 8 core actions in the aftermath of traumatic event (: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services (within the first 24 hours)
16368011|NCT04202042|Active Comparator|Usual organisational intervention|One phone call by workplace psychologist (within the first 48 hours) and reference to employee aid program
16368012|NCT04202029|Other|pulseoxymetry arm|pulseoxymetry arm: standard monitoring: pulseoxymetry and non-invasive blood preassure monitoring
16368013|NCT04202029|Experimental|thoracic impedance monitoring arm|thoracic impedance monitoring arm: standard monitoring and additionally thoracic impedance measurement)
16368014|NCT04202016|Experimental|Piezocision on high facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
16368015|NCT04202016|No Intervention|High facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
16368016|NCT04202016|Experimental|Piezocision on average facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
16368017|NCT04202016|No Intervention|Average facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
16368018|NCT04202003|Experimental|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
16368019|NCT04201990|Experimental|treatment group|Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years
16368020|NCT04201977|Active Comparator|Exercise session followed passive recovery|Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). The interval between each exercise session will be one week. Volunteers will not perform any form of recovery for 20 min after resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
16369194|NCT04193748|Experimental|Group S|Topical pomegranate seeds extract treatment has been repeated four times per day for four weeks.
16368021|NCT04201977|Active Comparator|Exercise session followed active recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Active recovery for 20 minutes (MIKA et al., 2016; CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010);
16368022|NCT04201977|Active Comparator|Exercise session followed immersion in cold water recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will be immersed in cold water immediately after exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009).
16368023|NCT04201977|Active Comparator|Exercise session followed foam roller recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will undergo an FR session immediately after resistance exercise session (PEARCEY et al., 2015).
16368024|NCT04201964|Experimental|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
16368025|NCT04201951|Active Comparator|Tranexamic group|Group A will receive 1gm Tranexamic acide diluted in 20 ML 5% glucose water
16368026|NCT04201951|Placebo Comparator|Placebo group|Group B will receive 30ML 5% glucose water
16368027|NCT04201938|Active Comparator|Symbiter-Omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
16368028|NCT04201938|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
16368029|NCT04201925||blepharoplasty|Patients will undergo blepharoplasty surgery
16368030|NCT04201912|Placebo Comparator|control patients|Evaluation of Toll like receptor activity from whole saliva obtained from control patients
16368031|NCT04201912|Active Comparator|Periodontal patients without diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients without diabetes
16368032|NCT04201912|Active Comparator|Periodontal patients with diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients with diabetes
16368033|NCT04201886|Other|RA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
16368034|NCT04201886|Other|OA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
16368035|NCT04201873|Experimental|Group A (pembrolizumab, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
16368036|NCT04201873|Active Comparator|Group B (placebo, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
16368037|NCT04201860||Blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue handled explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
16368038|NCT04201860||Not blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue did not handle explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
16368039|NCT04201847|Active Comparator|Infertile women with normal ovarian reserve|Infertile women with normal ovarian reserve will be included.
16368040|NCT04201847|Active Comparator|Infertile women with high ovarian reserve|Infertile women with high ovarian reserve will be included.
16368041|NCT04201847|Active Comparator|Infertile women with poor ovarian reserve|Infertile women with poor ovarian reserve will be included.
16368042|NCT04201834|Experimental|Risperidone|Participants will initiate risperidone 0.5 mg nightly the day after the baseline visit. Dose assessment will occur at pre-specified intervals during the titration phase (week 2, 3, 4, 6, 7). The investigator will increase the dose by 0.5 mg at the week 2, week 3, week 4, and week 6 visits until either optimal chorea benefit has been obtained, an intolerable adverse event occurs, or the maximum allowable dose (3.0 mg) is reached.
16368043|NCT04201821|Experimental|FMT Administration|This is a single arm study in which all eligible participants will receive FMT.
16368102|NCT04201457|Experimental|Phase 1 Stratum 1 BRAF V600E LGG or HGG|LGG or HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
16368044|NCT04201808|Experimental|Single Arm Intervention Group|All approximately 100 patients experienced previous suboptimal response to other direct acting antivirals. Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence. All patients in this study are in the same arm.
16368045|NCT04201795|Experimental|pressure and traction|pressure and traction durin 5 minutes will be applied in plantar fascia
16368046|NCT04201795|Sham Comparator|Laser|Applied during 5 minutes each plantar fascia of sham laser
16368047|NCT04201782|Experimental|Cohort 1|Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.
16368048|NCT04201769|Experimental|Arm A|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.
~No further anti-emetic prophylaxis on days 2 thorough 4."
16368049|NCT04201769|Experimental|Arm B|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.
~Oral dexamethasone 4 mg once per day in the morning of days 2 and 3."
16368050|NCT04201769|Active Comparator|Arm C|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.
~Oral dexamethasone 4 mg twice per day on days 2 thorough 4."
16368051|NCT04201756|Experimental|Afatinib|
16368052|NCT04201743|Active Comparator|1 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 1 mL NyDYN injection.
16368053|NCT04201743|Active Comparator|2 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 2 mL NyDYN injection.
16368054|NCT04201730|Experimental|ERAS|Perioperative intervention with individual Enhanced Recovery After Surgery （ERAS）
16368055|NCT04201717|Active Comparator|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed.After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
16368056|NCT04201717|Experimental|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion.In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
16368057|NCT04201704|Active Comparator|Liberal IV Fluid|"Maintenance fluid rate calculated by 4-2-1 formula for patients <110kg: 4 mL/kg for first 0-10kg + 2 mL/kg for 11-20kg + 1 mL/kg for each kg >20kg
~Patients >110kg maintenance 150 mL/hr
~Bolus Criteria: change in 1 of: >20% decrease in systolic blood pressure 50th percentile for age and sex, >20% increase in heart rate over 50th percentile for age, base excess > -5mmol/L, blood lactate >2mmol/L, AND urine output (UO) <1 mL/kg/hr if <50kg or <50 mL/hr if >50kg
~If criteria met: bolus 20 mL/kg if <50kg or 1 L if ≥50 kg
~For transfusion: give 10 mL/kg packed red blood cells, platelets, or fresh frozen plasma up to 250 mL. If >25kg give 250 mL.
~Diuresis- after minimum 24hrs: if UO <2 mL/kg/hr (or <100 mL/hr if >50 kg) continue maintenance rate and bolus per initial phase. If UO >2 mL/kg/hr (or >100 mL/hr if >50kg), and lactate, systolic blood pressure, heart rate, creatinine are normal then lower IV fluid rate to ½ maintenance rate and then to keep vein open once on regular feeds"
16368058|NCT04201704|Experimental|Restricted IV Fluid|"Maintenance fluid rate calculated by 70% of 4-2-1 formula if <110 kg: 4 mL/kg for first 0-10 kg, + 2 mL/kg for 11-20 kg, + 1 mL/kg for every kg >20 kg
~Patients >110 kg: maintenance is 105 mL/hr
~If same bolus criteria met: 10 mL/kg for patients <50kg, or 500 mL if ≥50 kg
~If meet transfusion criteria: transfuse 10 mL/kg with packed red blood cells, platelets, or fresh frozen plasma by weight up to 250 mL. Patients >25 kg get 250 mL per transfusion
~Diuresis (after minimum 24 hrs): if UO <1 mL/kg/hr (or <50 mL/hr if >50 kg) then continue IV fluids at maintenance rate and bolus as needed. If UO 1-2 mL/kg/hr (or 50-100 mL/hr if >50 kg) then decrease IV rate to ½ maintenance rate. If UO >2 mL/kg/hr (or >100 mL/hr if >50 kg), and Lactate, systolic blood pressure, heart rate, creatinine normal then reduce to keep vein open and consider Furosemide for goal UO >2-4 mL/kg/hr (100-200 mL/hr if >50 kg) until euvolemic"
16368059|NCT04201691|Experimental|conventional group|Conventional group is received conventional rehabilitation program.
16368060|NCT04201691|Experimental|mobilization group|Mobilization group is received cervical mobilization in addition to conventional rehabilitation program.
16368061|NCT04201678|Active Comparator|CLIA (conventional local anesthesia infiltration) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.
~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
16368062|NCT04201678|Active Comparator|EPIAA (Extrapedicular infiltration anesthesia) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.
~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
16368103|NCT04201457|Experimental|Phase 1 Stratum 2 BRAF aberration or LGG with NF1|LGG with BRAF duplication or fusion with any partner or LGG with NF1 will received Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
16368063|NCT04201678|Active Comparator|ESP (Erector Spina Plane Block) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.
~In the ESP group, a high-frequency-50 15-6 Megahertz (MHz) linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
16368064|NCT04201665|Experimental|carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
16368065|NCT04201665|Active Comparator|oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
16368066|NCT04201652|Active Comparator|Superficial|Intervention: Superficial local anesthetic infiltration.
16368067|NCT04201652|Active Comparator|Deep|Intervention: Superficial and deep local anesthetic infiltration.
16368068|NCT04201639|Experimental|Refit|Refit and dispense patient with Verofilcon A contact lenses and evaluate lens performance.
16368069|NCT04201626|Experimental|ERAS|
16368070|NCT04201626|No Intervention|Control|
16368071|NCT04201613|Active Comparator|Early Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive one hour of treatment per day for 20 days.
16368072|NCT04201613|Active Comparator|Early Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
16368073|NCT04201613|Active Comparator|Late Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive one hour of treatment per day for 20 days.
16368074|NCT04201613|Active Comparator|Late Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
16368075|NCT04201613|Active Comparator|Control Group|This group will receive usual care with robotic assessment.
16368076|NCT04201600||Middle-aged and Older adults with Prediabetes|Middle-aged and Older adults with Prediabetes
16368077|NCT04201587|Experimental|Henna application group|
16368078|NCT04201587|No Intervention|Control group|
16368079|NCT04201574|Placebo Comparator|Vehicle Ophthalmic Solution|
16368080|NCT04201574|Experimental|ALY688 Ophthalmic Solution Concentration 1|
16368081|NCT04201574|Experimental|ALY688 Ophthalmic Solution Concentration 2|
16368082|NCT04201561|Experimental|Experimental group|The patient will receive an intravenous selenium 2000 μg/40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
16368083|NCT04201561|Placebo Comparator|Placebo group|The patient will receive an intravenous normal saline 40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
16368087|NCT04201535||Group 1A:|at least 10 patients, maximum 70,with RA in remission, but presenting p• Group 1B: at least10 patients maximum 70, with RA in remission, without bone erosion A group of 80 controls,
16368088|NCT04201535||Group 2:|10 patients with osteoarthritis (OA) who must undergo a surgical procedure.
16368089|NCT04201535||Group 3|"70 without RA and OA but hospitalized for any other orthopedics pathology who must undergo a surgical procedure.
~rogressive bone erosion who must undergo a surgical procedure."
16368090|NCT04201522|Active Comparator|Training intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance
16368091|NCT04201522|Sham Comparator|Sham intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance in the training group compared to the sham group.
16368092|NCT04201509||ADHD group|Participants in the clinical group were recruited to the project when they were assessed for and diagnosed with ADHD at the Neuropsychiatric Unit of the CAP Clinic in Lund in 2011-2012. The ADHD group was treated as usual in the clinic and re-assessed during 2014-2015.
16368093|NCT04201509||Non-clinical group|Participants in the non-clinical group were recruited recruited 2012 from schools in the same district and among children of the same average age as the ADHD-group 2012. The non-clinical group did not have any intervention during the follow-up time. Th non-clinical group was re-assessed during 2015.
16368094|NCT04201496|Experimental|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)
16368095|NCT04201496|Experimental|Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks|Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)
16368096|NCT04201496|Active Comparator|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)
16368097|NCT04201496|Active Comparator|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)
16368098|NCT04201483|Active Comparator|DCE group|DCE exercise without RUSI feedback
16368099|NCT04201483|Experimental|DCE + RUSI group|DCE exercise with RUSI feedback
16368100|NCT04201470|Experimental|MS patients|Patients with atypical MS identified in our cohort
16368101|NCT04201470|Active Comparator|Controls|
16368138|NCT04201249|Sham Comparator|Mesotherapy without piroxicam and lidocaine|
16368104|NCT04201457|Experimental|Phase 2 Stratum 3 LGG with BRAF V600 mutation|LGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
16368105|NCT04201457|Experimental|Phase 2 Stratum 4 HGG with BRAF V600 mutation|HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria
16368106|NCT04201457|Experimental|Phase 2 Stratum 5 LGG with BRAF aberration|LGG with BRAF duplication or fusion with any partner will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
16368107|NCT04201457|Experimental|Phase 2 Stratum 6 LGG with NF Type 1|LGG with Neurofibromatosis Type 1 will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
16368108|NCT04201444|Experimental|Patient group|
16368109|NCT04201444|Active Comparator|Remission control group|
16368110|NCT04201444|Active Comparator|Bilateral surrenalectomy control group|
16368111|NCT04201431|Experimental|Group 1|Up to 12 volunteers in Group 1 will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at 1, 2 and 12-18 months prior to blood-stage CHMI 2-4 weeks after the third vaccination.
16368112|NCT04201431|Experimental|Group 2|If fewer than 8 volunteers complete the study in Group 1, then new volunteers will be recruited into Group 2, to make up a total of 10 to 12 volunteers who complete 3 vaccinations and CHMI between Groups 1 and 2. Group 2 volunteers will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at monthly intervals, prior to blood-stage CHMI 2-4 weeks after the third vaccination.
16368113|NCT04201431|Experimental|Group 3|Up to 6 volunteers from Group 1 will receive a fourth dose of PvDBPII 50ug/Matrix M1 50ug, at 5 months post the third dose, prior to a second CHMI 2-4 weeks later.
16368117|NCT04201405|Experimental|Haematopoietic stem cell gene therapy for MPS IIIA|Open label
16368118|NCT04201379||neck pain patients|servical disk hernisi servical spondilosis servical problems
16368119|NCT04201379||control|healthy people
16368120|NCT04201366||Sample 1|All participants fulfilling the inclusion criteria.
16368121|NCT04201366||Sample 2|Participants fulfilling the inclusion criteria and reports no neck/shoulder pain at baseline.
16368122|NCT04201353|Experimental|Conditional Cash Transfer|Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
16368123|NCT04201353|No Intervention|Control|Participants attending control clinics will receive the standard of care.
16368124|NCT04201327|Active Comparator|PrEP information only arm|Information to for accessing HIV prevention tools will be provided to participants.
16368125|NCT04201327|Experimental|PrEP counseling arm|Stigma focused counseling (one-session) aimed at addressing barriers to health care access will be provided.
16368126|NCT04201327|Experimental|PrEP counseling plus text messaging arm|Stigma focused counseling (one-session) and interactive text messaging aimed at addressing barriers to health care access will be provided.
16368127|NCT04201327|Experimental|PrEP counseling plus text messaging and on demand counseling|Ongoing stigma focused counseling and interactive text messaging aimed at addressing barriers to health care access will be provided.
16368128|NCT04201314|Placebo Comparator|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
16368129|NCT04201314|Experimental|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
16368130|NCT04201288|Experimental|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered in person at session 1 and by telephone at session 2.
16368131|NCT04201288|Placebo Comparator|Enhanced-Treatment-as-Usual (ETAU)|In addition to receiving treatment-as-usual at the clinic, ETAU participants will receive a 2-session program of HIV education.
16368132|NCT04201275|Experimental|Cohort 1|up to HEC74647PA capsule 50 mg once daily for 3 days
16368133|NCT04201275|Experimental|Cohort 2|up to HEC74647PA capsule 100 mg once daily for 3 days
16368134|NCT04201275|Experimental|Cohort 3|up to HEC74647PA capsule 200 mg once daily for 3 days
16368135|NCT04201275|Placebo Comparator|Cohort 4|up to placebo once daily for 3 days
16368136|NCT04201262|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).
~After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first."
16368137|NCT04201249|Active Comparator|Mesotherapy with piroxicam and lidocaine|
16368139|NCT04201236|Experimental|Oropharyngeal exercises|Oropharyngeal exercises include soft palate, tongue and facial muscle exercises as well as stomatognathic function exercises. Training sessions were held once a day, 5 days a week for 12 weeks under the supervision of a mirror.
16368140|NCT04201236|Experimental|Inspiratory muscle training|The inspiratory muscle training group was administered for 12 weeks starting from 30% of maximal oral pressure, 7 days a week, 15 minutes twice a day. Patients came to the control once a week, mouth pressures were measured and training pressure was adjusted in 30% of the new value.
16368141|NCT04201236|No Intervention|Control|This group was only monitorized without any rehabilitation intervention.
16368142|NCT04201223|Experimental|FLARE Intervention|Participants will be randomized to receive an intervention that works with melanoma survivors and their children as a family unit to improve melanoma preventive behaviors.
16368143|NCT04201223|No Intervention|Standard Education|Participants will be randomized to receive information on child sun protection that is publicly available.
16368144|NCT04201210|Experimental|Experimental Arm|Patients with no matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the experimental arm
16368145|NCT04201210|Active Comparator|Control Arm|Patients with a matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the control arm
16368146|NCT04201197|Active Comparator|Inje Cocktail|Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)
16368147|NCT04201197|Experimental|Inje Cocktail + THC extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC
16368148|NCT04201197|Experimental|Inje Cocktail + THC/CBD extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC and 1350mg CBD
16368149|NCT04201184|Experimental|Little Holy One intervention|The participants will receive 12 1-hour lessons on parenting, stress, and culture over a period of 12 weeks.
16368150|NCT04201184|Active Comparator|Nutrition control|The participants will receive 6 1-hour lessons on nutrition over a period of 12 weeks.
16368151|NCT04201158||Obese Group (Girl)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria.Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
16368152|NCT04201158||Obese Group (Boy)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
16368153|NCT04201158||Control Group (Girl)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
16368154|NCT04201158||Control Group (Boy)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
16368155|NCT04201145|Experimental|Run in cohort: pembrolizumab only|"Treatment with pembrolizumab as a single agent for 56 days
~- 2 doses during treatment cycle, intravenous, at predetermined protocol dose"
16368156|NCT04201145|Experimental|Cohort 1: pembrolizumab + defactinib 12 days|"Treatment with Defactinib in combination with Pembrolizumab for 12 days
~Defactinib oral, twice daily, per predetermined dose for 12 days of treatment in combination
~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
16368157|NCT04201145|Experimental|Cohort 2: pembrolizumab + defactinib 35 days|"Treatment with defactinib in combination with pembrolizumab to 35 days
~Defactinib oral, twice daily, per predetermined dose for 35 days of treatment in combination
~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
16368158|NCT04201145|Experimental|Expansion cohort|Tolerated phase IA regimen will be administered in a phase IB expansion cohort
16368159|NCT04201132|Experimental|Carotid artery stenting|Carotid artery stenting procedure with Neuroguard IEP System
16368160|NCT04201119|Experimental|With Oxiris|
16368161|NCT04201119|No Intervention|Without Oxiris|
16368162|NCT04201106|No Intervention|Control|In the control group, the participants will not be taking any placebos or undergoing any other study-related treatments.
16368163|NCT04201106|Experimental|Open Label Placebo Group with Rationale|
16368164|NCT04201106|Active Comparator|Open Label Placebo Group without Rationale|
16368165|NCT04201093|Experimental|Tavapadon 5 mg|Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.
16368166|NCT04201093|Experimental|Tavapadon 15 mg|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.
16368167|NCT04201093|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
16368168|NCT04201080|Experimental|Part A: TRV250 for SC injection|2 SC injections of (10 mg/ml per injection)
16368169|NCT04201080|Placebo Comparator|Part A: Placebo for SC injection|2 SC injections (identical to the TRV250)
16368170|NCT04201080|Experimental|Part B: TRV250 dose 1 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
16368171|NCT04201080|Experimental|Part B: TRV250 dose 2 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
16368172|NCT04201080|Experimental|Part B: TRV250 dose 3 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
16368173|NCT04201080|Placebo Comparator|Part B: Placebo for SC injection|Placebo (using syringes identical to the TRV250 arms)
16368174|NCT04201054|Experimental|Fluconazole|Subjects receive a single-dose treatment.Urine samples will be collected after administration (4 fractions: 0-12, 12-24, 24-48, 48-72 hours post-administration).
16368175|NCT04201041|Active Comparator|trans-gluteal approach|received pudendal nerve pulsed radiofrequency through trans-gluteal approach
16368176|NCT04201041|Active Comparator|trans-vaginal approach|received pudendal nerve pulsed radiofrequency through trans-vaginal approach
16368177|NCT04201028|Experimental|Video Conferencing Health Coaching with devices|The DEV group participants will meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) to discuss exercise and diet goals. Participants in this group were provided with a blood pressure and body weight scale which connected to the CoachCare App®.
16368178|NCT04201028|Experimental|Video Conferencing Health Coaching with no devices|The NODEV group participants meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) for health coaching to discuss exercise and diet goals. Participants in this group did not receive devices.
16368179|NCT04201015|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
16368180|NCT04201015|Active Comparator|Rate-response settings off|Patients allocated to deactivated rate-response settings.
16368181|NCT04201015|Experimental|Optimized rate-response settings|Patients allocated to optimised rate-response settings.
16368182|NCT04200989|Experimental|Treatment|Peanut ILIT
16368183|NCT04200976|Experimental|Tele-CABA|Participants who engage in the Tele-CABA intervention.
16368184|NCT04200976|Placebo Comparator|Usual Care|Participants who do not engage in the Tele-CABA intervention during their time in the study. They will be eligible to receive Tele-CABA following completion of the 6-month questionnaires and cognitive assessment (as a courtesy).
16368185|NCT04200963|Experimental|IK-175 Single Agent Dose Escalation|Approximately 5 dose escalation steps are planned during the Single Agent Treatment dose escalation phase of the study. (COMPLETE)
16368186|NCT04200963|Experimental|IK-175 Single Agent Dose Expansion|A Single Agent Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D.
16368187|NCT04200963|Experimental|IK-175 and nivolumab Combination Dose Escalation|Approximately 2 dose escalation steps are planned during the Combination Treatment dose escalation phase of the study.
16368188|NCT04200963|Experimental|IK-175 and nivolumab Combination Dose Expansion|A Combination Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D.
16368189|NCT04200950|Experimental|Intervention|Previse alert arm
16368190|NCT04200950|No Intervention|Control|No alert
16368192|NCT04200924||Children with idiopathic toe walking|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
16368193|NCT04200924||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
16368194|NCT04200911|Experimental|RAPA intervention|Sirolimus 1mg orally once a day for 8 weeks
16368195|NCT04200898|Experimental|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
16368196|NCT04200885|Active Comparator|Postoperative NSAID Prescription|Patients in this arm received common postoperative prescriptions following removal of their impacted third molars for seven days; twice a day 500 mg amoxicillin+125 mg clavulanic acid, twice a day 25 mg dexketoprofen trometamol and three times a day 1.5 mg/ml clorhexidine gluconate+1.2 mg/ml benzydamine hydrochloride containing 200 ml mouthwash.
16368197|NCT04200885|Active Comparator|Preoperative Submucosal Corticosteroid Injection|Patients in this arm were administered 8mg/2ml dexamethasone 21-phosphate preoperatively after local anesthesia were obtained. Injection site was the depth of buccal sulcus near operation site. For the patients in this arm 25 mg dexketoprofen trometamol was excluded from postoperative prescription in order not to affect the anti-inflammatory effects of corticosteroid. Instead of NSAID, three times a day 500 mg paracetamol was prescribed. The patients were advised not to exceed maximal dosage of 3000 mg (6 tablets) in a day.
16368198|NCT04200885|Active Comparator|Postoperative Therapeutic Elastic Bandage Application|In this arm the therapeutic elastic bandage applications were immediately performed after removal of mandibular third molars. The distance between tragus-lateral commissura line and supraclavicular lymph nodes was measured and the tapes were then cut into 5 tails. The base of the tape was placed on supraclavicular lymph nodes and tails were placed on the site to cover parotid, submandibular, submental and superficial cervical lymph nodes. The tapes were removed on postoperative second day.
16368199|NCT04200872||biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
16368200|NCT04200872||without biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
16368201|NCT04200859|Experimental|Cold application with ice pack|Before the chest tube was removed, two ice packs with a size of 15.5x9cm were inserted around the chest tube so as to make as much contact as possible
16368202|NCT04200859|Experimental|Cold application with gel pad group|Before the chest tube was removed, a gel pad with a radius of 15 cm was completely inserted around the chest tube
16368203|NCT04200859|No Intervention|Control group|Routine analgesic drugs are not administered to patients before removal of the chest tube in thoracic surgery clinic. However, analgesic is performed according to the severity of pain after the procedure.
16368204|NCT04200846|Experimental|Exercise intervention|Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64*age in years).
16368205|NCT04200846|No Intervention|Control|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.
16368206|NCT04200833||group 1|All JIA patients that were switched from adalimumab to golimumab because of Treatment failure of their JIA associated uveitis at the Medical University of Graz Austria from 2010 to 2019
16368207|NCT04200820|Experimental|Trampoline|The participants will jump on a mini-trampoline for 30 seconds and then will have a 30 seconds break. This will be repeated 16 times. This resulted in a cumulative total intervention time of 8 minutes.
16368208|NCT04200807||Healthy preterm neonate|Neonate 26 weeks to 36 weeks + 6 days of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
16368209|NCT04200807||Healthy term neonate|Neonate from 37 weeks of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
16368210|NCT04200807||Sick neonate|Neonate of any gestation, without congenital heart defects, with clinically and laboratory-identified infection.
16368211|NCT04200794|Experimental|musical instrumental training|Bi-weekly musical string instrument training in a group setting, over 24 months, provided by professional string instrument teachers
16368212|NCT04200794|Active Comparator|sensitization to music|Bi-weekly sensitization to music in a group setting, over 24 months, involving listening, playing small percussive instruments and choir singing, provided by professional school music teachers
16368213|NCT04200781|Experimental|Shengdi Dahuang Decoction|To clarify the clinical effects of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke and to explore the possible mechanism. Participants will take the granules of Shengdi Dahuang Decoction that contains 15 grams of rehmannia and 5 grams of rhubarb, one pack per time, twice a day for 7 days.
16368214|NCT04200781|Placebo Comparator|Placebo|To explore the effective clinical therapy in acute hemorrhagic stroke. Participants will take placebo contains 2% rehmannia and rhubarb, one pack per time, twice a day for 7 days.
16368215|NCT04200768|Other|Standard|Standard of care
16368218|NCT04200729|Experimental|Irrigation with PVI|
16368219|NCT04200729|Active Comparator|Usual care|
16368220|NCT04200716|Active Comparator|Moderate intensity continuous training - session|The volunteers perform a 30-minute moderate-intensity exercise session on the exercise bike.
16368221|NCT04200716|Active Comparator|High intensity interval training - session|The volunteers perform a session of high intensity interval exercise on the exercise bike.
16368222|NCT04200703|Experimental|Intervention|Implementation of the Adult and Survivor Centered Approach.
16368223|NCT04200703|No Intervention|Comparison|No implementation of intervention.
16368224|NCT04200690|Experimental|Interdisciplinary management|Interdisciplinary combined clinical care
16368225|NCT04200690|Active Comparator|Usual-care management|Usual-care
16368226|NCT04200677|Experimental|MCN1|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
16368227|NCT04200677|Experimental|BCN05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
16368228|NCT04200677|Experimental|BCN1|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
16368229|NCT04200677|Experimental|BCN2|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
16368230|NCT04200677|Experimental|MCM1|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
16368231|NCT04200677|Experimental|BCM05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
16368232|NCT04200677|Experimental|BCM1|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
16368233|NCT04200677|Experimental|BCM2|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
16368234|NCT04200677|Experimental|BC25|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
16368235|NCT04200664||Siderosis (iSS) group|participants with a known diagnosis of infratentorial superficial siderosis (defined using standardised radiological criteria) confirmed by a consultant neurologist with expertise in this condition at University College London Hospitals National Health Service (NHS) Foundation Trust
16368236|NCT04200664||Age-related hearing loss (ARHL) group|participants with age-related hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
16368237|NCT04200664||Control group|participants with no known or previously reported hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
16368238|NCT04200651|Experimental|DEXTENZA® arm|This arm will receive the DEXTENZA® insert after cataract surgery and MIGS.
16368239|NCT04200651|Active Comparator|Prednisolone acetate 1% arm|This arm will receive the prescription for daily prednisolone acetate 1% eye drops after cataract surgery and MIGS.
16368240|NCT04200638|Experimental|ProTaper Next group|Clean and shape the necrotic canals with ProTaper instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
16368241|NCT04200638|Experimental|WaveOne Gold group|Clean and shape the necrotic canals with Wave One Gold instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
16368242|NCT04200625||Semaglutide|Patients using standard of care weekly GLP-1A analog Semaglutide
16368243|NCT04200625||Dulaglutide|Patients using standard of care weekly GLP-1A analog Dulaglutide
16368244|NCT04200625||Metformin|Patients using standard of care daily Metformin.
16368245|NCT04200612|Experimental|Intervention Group|Participants in the intervention group will go through the 5-week EAP program consisting of the clinical processing following some activities found in EAP manuals.
16368246|NCT04200612|Active Comparator|Active-control group|Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities).
16368247|NCT04200612|Placebo Comparator|Placebo-control group|Participants in the placebo-control group will undergo a 5-week movie screening of 1 hour each session that is related to horses.
16368248|NCT04200599|Experimental|Early oxytocin Infusion|labour augmentation with oxytocin was started early following amniotomy.
16368249|NCT04200599|Active Comparator|Late oxytocin infusion|oxytocin augmentation was delayed at two hours after amniotomny and this practice is currently being used as standard protocol in this hospital to manage women in labour.
16368250|NCT04200586|Experimental|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground
16368251|NCT04200573|Experimental|Normal Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
16368252|NCT04200573|Experimental|Mild Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
16368253|NCT04200573|Experimental|Moderate Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
16368254|NCT04200573|Experimental|Severe Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment
16368255|NCT04200560|Experimental|Healthy Adult Subjects|Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise
16368256|NCT04200560|Experimental|Healthy Older Adult Subjects|Healthy older adult subjects (> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.
16368257|NCT04200547|Experimental|Immunomonitoring-based follow-up|Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum.
16368258|NCT04200547|Active Comparator|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. This strategy is the standard strategy for post-operative follow-up of Crohn's disease patients.
16368261|NCT04200521||Healthy weight individuals|Cross-sectional observation on healthy participants who will be recruited from the general population from both genders (Lebanese and Emirati Subjects).
16368262|NCT04200521||Obese individuals|Prospective study of 3 months duration (pre and post design) on obese Emirati and Lebanese participants undergoing bariatric procedure irrelevant of the study, from Qassimi Hospital In sharja and Middle East Institute of Health University Hospital, Lebanon
16368265|NCT04200495||Healthy Controls|No sleep-wake disorder present
16368266|NCT04200495||Active Sleep-Wake Disorder|Presence of Sleep-Wake Disorder
16368269|NCT04200469|Experimental|QFR Intervention|Patients submitted to a coronary angiogram with at least one non-left main stable coronary stenosis between 50 and 90% and PCI indication with paired assessment of QFR, dFR, RFR and FFR, before and after PCI once informed consent is provided.
16368272|NCT04200443|Experimental|Treatment (cabozantinib, temozolomide)|Patients receive cabozantinib PO QD on days 1-28 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16368273|NCT04200417|Experimental|Lung, Endobronchial, Mediastinal or Pleural Metastases|Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy
16368274|NCT04200404|Experimental|Phase Ib arm|arms 1. Phase Ib: advanced or refractory solid tumors;
16368275|NCT04200404|Experimental|Phase II arm|arms 2.Phase II: subjects with tumor of specific types
16368276|NCT04200391|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
16368277|NCT04200378||Subjects undergoing TMVr|Subjects with severe, symptomatic primary mitral regurgitation (MR) scheduled to undergo a transcatheter mitral valve repair (TMVr) as standard of care will have intra-op baseline and post repair blood draws. Pre-procedure and post-procedure transthoracic echocardiograms (TTE) will assess the hemodynamic implications of the repair.
16368278|NCT04200365|Experimental|Itacitinib|
16368280|NCT04200339||Adolescents|Adolescents between the ages of 12 and 17 years old (inclusive).
16368281|NCT04200313|Experimental|Bionic Pancreas (BP)|Adults (RCT and Extension) and peds (RCT) will use the Bionic Pancreas (BP) with lispro or aspart for 13 weeks
16368282|NCT04200313|Experimental|Bionic Pancreas with Fiasp (BPFiasp)|Adults will use the Bionic Pancreas (BP) with Fiasp for 13 weeks during RCT Peds will use the Bionic Pancreas (BP) with Fiasp for 13 weeks during Extension
16368283|NCT04200313|No Intervention|Usual Care (UC)|Adults and peds will use their own diabetes regimen
16368284|NCT04200300||Nurses working with patients with mental disorders|Nurses in Germany currently working with patients with mental disorders
16368285|NCT04200287|Experimental|Young adult female (YA-F) cancer survivors|YA-F cancer survivors will complete a baseline survey (T1) of sociodemographic and patient reported outcomes (PRO) and then will be sent a link to access the decision aid tool (website) with instructions to review the website before their upcoming visit. A follow-up survey (T2) will be emailed 4-weeks post-baseline, prior to their clinic visit, to evaluate website access and PROs. A post-visit survey (T3) will be emailed 6- weeks post-baseline (after their survivorship care visit) to assess PROs.
16368286|NCT04200274||Mental Health Nurses in Germany|Nurses in Germany currently working with patients with mental disorders
16368287|NCT04200261|Experimental|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
16368288|NCT04200261|Placebo Comparator|placebo|sodium chloride injection Once daily for 7 days
16368289|NCT04200248|Experimental|Sham + RBM-007|Sham + RBM-007 intravitreal injection
16368290|NCT04200248|Experimental|RBM-007 + Aflibercept|RBM-007 + Aflibercept intravitreal injection
16368291|NCT04200248|Active Comparator|Sham + Aflibercept|Sham + Aflibercept intravitreal injection
16368292|NCT04200235|Experimental|High weight group|High weight group
16368293|NCT04200235|Experimental|Low weight group|Low weight group
16368294|NCT04200222||Preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
16368295|NCT04200222||Control|Pregnant women with uncomplicated pregnancies were randomly selected to serve as controls. Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications were accepted into the control group.
16368296|NCT04200209|Experimental|Hospital|Twelve wards of the hospital will be evaluated at the same time.
16368297|NCT04200196|Experimental|"Fabrique à histoire"|"Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the fabrique à histoire (Lunii(R)) arm in addition to the routine anaesthetic cream patch."
16368298|NCT04200196|Active Comparator|Usual care|Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the habitual care arm in addition to the routine anaesthetic cream patch.
16368299|NCT04200183|Experimental|iACTwithPain|
16368300|NCT04200183|Experimental|ACT-only intervention|
16368301|NCT04200183|No Intervention|Wait list (inactive control)|
16368302|NCT04200170|Experimental|Intervention Arm|Eligible participants had been scheduled for either weekly or biweekly sessions with their therapists. Participants in the intervention arm were asked to download the Rose application on to their personal mobile phones and were given their therapist's unique ID for verification in the app. During the first week of the study, participants were prompted to complete key surveys and assessments at predetermined time intervals. Participants seen weekly will use the app for a total of 5 weeks and receive weekly in-person therapy for a total of 4 weeks (one-week application only lead-in, four weeks application plus in-person psychotherapy). Participants seen biweekly will use the app for a total of 10 weeks and receive biweekly in-person therapy for a total of 8w weeks (two-week application only lead-in, eight weeks application plus in-person psychotherapy).
16368303|NCT04200170|No Intervention|Waitlist Control Arm|The participants in the waitlist control arm served as controls for the study. They completed the pre-pilot and post-pilot assessments only. The waitlist participants continued their standard care and were offered entrance to the intervention arm at the end of the study period or earlier if patients in the intervention arm dropped out mid-study. During their time on the waitlist, participants could reach out to study personnel if they needed assistance with their psychiatric care.
16368304|NCT04200157||1|"Group assigned to the following answer combination:
~2 sessions
~4 sessions"
16368305|NCT04200157||2|"Group assigned to the following answer combination:
~2 sessions
~4 sessions
~7 sessions"
16368306|NCT04200157||3|"Group assigned to the following answer combination:
~2 sessions
~7 sessions"
16368307|NCT04200157||4|"Group assigned to the following answer combination:
~2 sessions
~7 sessions
~10 sessions"
16368308|NCT04200157||5|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~4 sessions (60 minutes)"
16368309|NCT04200157||6|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~4 sessions (60 minutes)
~7 sessions (105 minutes)"
16368310|NCT04200157||7|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~7 sessions (105 minutes)"
16368311|NCT04200157||8|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~7 sessions (105 minutes)
~10 sessions (150 minutes)"
16368312|NCT04200157||9|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~4 sessions (60 minutes) - 30% chance of quitting"
16368313|NCT04200157||10|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~4 sessions (60 minutes) - 30% chance of quitting
~7 sessions (105 minutes) - 30% chance of quitting"
16370653|NCT04183738|Experimental|DOL|darunavir/ritonavir 800/100mg + dolutegravir 50mg po od
16368314|NCT04200157||11|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~7 sessions (105 minutes) - 30% chance of quitting"
16368315|NCT04200157||12|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~7 sessions (105 minutes) - 30% chance of quitting
~10 sessions (150 minutes) - 30% chance of quitting"
16368316|NCT04200144|Active Comparator|active endoscopic treatment|Patients that will undergo Endoscopic Sleeve Gastroplasty
16368317|NCT04200144|Active Comparator|standard medical therapy control diet group|Patients that will undergo diet
16368318|NCT04200131|Experimental|Moray micro-forceps|
16368319|NCT04200105|Active Comparator|EBUS TBNA|Patients will undergo a standard EBUS examination, with sampling using a standard 22G EBUS needle.
16368320|NCT04200105|Experimental|Acquire TBNB|Patients will undergo a standard EBUS examination, with sampling using an Acquire TBNB needle.
16368321|NCT04200092|Experimental|Cohort 1|Single orally-inhaled dose
16368322|NCT04200092|Experimental|Cohort 2|Single orally-inhaled dose
16368323|NCT04200092|Experimental|Cohort 3|Single orally-inhaled dose
16368324|NCT04200092|Experimental|Sequence 1|Single orally-inhaled dose
16368325|NCT04200092|Active Comparator|Sequence 2|Single IV administered dose
16368326|NCT04200079||COPD|Long term (at least 10 years) multidimensional (clinical, laboratory, physiological and radiological) follow up of chronic Obstructive Pulmonary Disease patients.
16368327|NCT04200066|Experimental|Experimental Arm|This arm will combine maprotiline with temozolomide and tamoxifen to determine the maximum tolerated dose.
16368328|NCT04200053|Experimental|Reflexology massage|Reflexology massage
16368329|NCT04200053|Experimental|Reflexology massage and passive music|Reflexology massage and passive music
16368330|NCT04200053|No Intervention|Control|Control
16368331|NCT04200040|Experimental|treatment group|"OrienX010 will be administered once every two weeks by intratumoral injection. The treatment dose , depends on the patient's tumour size, The maximum dose of OrienX010 in at each treatment , the expected accumulated dose in 10 mL. The investigator should be confirmed the injectable tumor size and adequate dose within 24 hours prior to treatment.
~OrienX010 treatment will be continuous and extend from first dose of study medication until to complete response, clinical related progression disease (PDr), untolerated toxicities, lost to follow up, death or meet end of treatment criteria."
16368332|NCT04200040|Active Comparator|Control group|Dacarbazine will be administered once every three weeks by intravenous 1000mg/square meter. Dacarbazine treatment will be continuous and extend from first dose of study medication until to progression disease (PD), untolerated toxicities, lost to follow up, death or meet end of treatment criteria.
16368333|NCT04200027||Robotic total mesorectal Excision|robotic assissted total mesorectal excision
16368334|NCT04200027||Transanal total mesorectal excision|Transanally assissted total mesorectal excision
16368335|NCT04200014||Syncope and Implantable loop recorder|Patients implanted with a subcutaneous Loop Recorder after syncope in Nancy University Hospital
16368336|NCT04200001||adjuvant hormonal therapy for breast cancer|women less than 51 years old, during adjuvant hormonal therapy for breast cancer
16368337|NCT04199988||Athletes with shoulder pain|Overhead athletes with shoulder pain
16368338|NCT04199988||Athletes without shoulder pain|Overhead athletes without shoulder pain
16368339|NCT04199975|Other|Orthoses|Only one single arm in this study
16368340|NCT04199962||pneumonia without sepsis|adult patients with community acquired pneumonia change in SOFA score <2 (other than respiratory component)
16368341|NCT04199962||pneumonia with sepsis|adult patients with community acquired pneumonia change in SOFA score greater or equal to 2 (other than respiratory component)
16368342|NCT04199949|No Intervention|Control|5 consecutive days of normal daily levels of physical activity and matched food intake
16368343|NCT04199949|Experimental|Inactivity|5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (~ 20%) to match the reduction in energy expenditure induced by inactivity
16368344|NCT04199936|Experimental|EMG leg|Quadriceps muscle group of postoperative patients randomly selected leg which will undergo electrical muscle stimulation for upto 2 hours on each postoperative day
16368345|NCT04199936|No Intervention|Control leg|Quadriceps muscle group of postoperative patients leg not selected to undergo electrical muscle stimulation
16368346|NCT04199923|Experimental|15 Day immobilisation|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 15 continuous days
16368347|NCT04199923|Experimental|5 Day immobilisation young|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
16368348|NCT04199923|Experimental|5 Day immobilisation old|The dominant leg of aged patients (65-80 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
16368349|NCT04199910||Liver cirrhosis with spironolactone|
16368350|NCT04199910||Liver cirrhosis with rifaximin|
16368351|NCT04199910||Liver cirrhosis without spironolactone or rifaximin|
16368352|NCT04199910||Pneumonia|
16368353|NCT04199910||Crohn's disease|
16368354|NCT04199910||Ulcerative colitis|
16368355|NCT04199897|Experimental|Intervention group (sucrose + probiotics)|Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
16368356|NCT04199897|Active Comparator|Intervention group (sucrose + placebo|Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
16368357|NCT04199897|Placebo Comparator|Control group (xylitol + probiotics)|Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
16368358|NCT04199897|Placebo Comparator|Control group (xylitol + placebo|Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
16368359|NCT04199884|Experimental|Active IU-focused Psychoeducation Intervention|
16368360|NCT04199884|Active Comparator|Health-focused Psychoeducation Intervention|
16368361|NCT04199871|Experimental|Group1|dichoptic 3D movies
16368362|NCT04199871|Sham Comparator|Group 2|dichoptic standard movies
16370654|NCT04183738|Experimental|D2N|dolutegravir 50mg + tenofovir + emtricitabine or lamivudine po od
16368363|NCT04199858|Experimental|Nocebo induction|Conditioning and evocation of a nocebo response to a sham (inert) medication contained in a blue or a brown jar, controlled within subjects.
16368364|NCT04199845|Experimental|PS128|PS128 will be given twice daily for 8 weeks Active capsule containing 300 mg of probiotics, equivalent to 3 x10^10 CFU of Lactobacillus plantarum PS128.
16368365|NCT04199845|Placebo Comparator|placebo|Placebo containing starch will be given twice daily for 8 weeks.
16368366|NCT04199832||Nasogastric tube|The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.
16368367|NCT04199832||gastrostomy feeding|Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.
16368368|NCT04199832||Oral intake|Patients with normal swallowing or not receiving tube feeding.
16368369|NCT04199819|Other|HBsAg-negative recipients|Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.
16368370|NCT04199806|Other|Questionnaire Review|
16368371|NCT04199793|Active Comparator|Lavare Cycle On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
16368372|NCT04199793|Active Comparator|Lavare Cycle Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
16368373|NCT04199780|Experimental|Group 1- real tDCS and real CBI|4 active treatments of tDCS and active cognitive behavioral intervention (CBI)
16368374|NCT04199780|Experimental|Group 2- real tDCS and sham CBI|4 active treatments of tDCS and education-only-control cognitive intervention
16368375|NCT04199780|Experimental|Group 3- sham tDCS and real CBI|4 sham treatments of tDCS and active cognitive behavioral intervention (CBI)
16368376|NCT04199780|Sham Comparator|Group 4- sham tDCS and sham CBI|4 sham treatments of tDCS and education-only-control cognitive intervention
16368377|NCT04199767|Experimental|20 IU Insulin first, then 40 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 40 IU) at visit 3 during second intervention period.
16368378|NCT04199767|Experimental|40 IU Insulin first, then 20 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 40 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 20 IU) at visit 3 during second intervention period.
16368379|NCT04199754|Experimental|Contrast Enhanced Cone Beam CT|60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.
16368380|NCT04199741||Phase I|Up to 12 participants with tumors that are found to be >/= 50% positive for DLL3 by IHC
16368381|NCT04199741||Phase II|Up to 18 participants with tumors that are found to be >/= 50% positive for DLL3 by IHC
16368382|NCT04199728|Experimental|Investigational group|Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased until 1.8 mg/day is reached for the 3-dose intervention and 3 mg/day is reached for the 5-dose intervention. Liraglutide will be administered by injection pen.
16368383|NCT04199728|Placebo Comparator|Control group|Participants in the control group will have placebo administered by injection pen following the same low dose titration to 3.0 mg once per day.
16368384|NCT04199715|Experimental|Heplisav-B Vaccine Recipient|There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.
16368385|NCT04199702|Other|Same day discharge|
16368386|NCT04199689|Experimental|9vHPV vaccine|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
16368387|NCT04199689|Placebo Comparator|Placebo|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
16368388|NCT04199676||Intervention|75g glucose tolerance test to be administered during postpartum hospitalization
16368389|NCT04199663||categories of Socioeconomic Status (SES)|"by proxy gender- and calendar year-specific quintiles of disposable income per household consumption unit.
~In logistic regression models of associations with secondary prevention activities and established treatment goals: highest vs. lowest income quintile.
~In multivariable Cox regression analyses with stepwise built models: quintiles of disposable income and models including covariates level of education and marital status."
16368390|NCT04199650||Mild ARDS|153mmHg<PaO2/FiO2≤230mmHg
16368391|NCT04199650||Moderate ARDS|76mmHg<PaO2/FiO2≤153mmHg
16368392|NCT04199650||Severe ARDS|PaO2/FiO2≤76mmHg
16368393|NCT04199637|Experimental|Experimental group|Experimental group is provided therapeutic video games
16368394|NCT04199637|No Intervention|Control group|Control group is provided regular care
16368395|NCT04199624|Experimental|Experimental: omeprazole and ascorbic acid|
16368396|NCT04199611|Experimental|Integrated Therapy Group|Both liposuction and psychological therapy are delivered to the participants in this group.
16368397|NCT04199611|Active Comparator|Liposuction Group|This group experiences only liposuction and do self-help care after the liposuction.
16368398|NCT04199611|Active Comparator|Psychological Therapy Group|This group experiences only cognitive behavioral therapy (CBT; psychological therapy) during the intervention period.
16368399|NCT04199611|No Intervention|Self-help Group|This group do not receive any interventions and do self-help care.
16368400|NCT04199598|Experimental|Treatment A (test product): Abediterol (2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
16368401|NCT04199598|Experimental|Treatment B (Test Product): Abediterol (4.8 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
16368441|NCT04199312|Experimental|Muscle Toning, Firming and Strengthening|The EMS device will be evaluated for muscle toning, firming and strengthening in the abdomen.
16368402|NCT04199598|Experimental|Treatment C(Test Product):Abediterol(2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via OMRON NE-C900-E nebulizer following an overnight fast of at least 8 hours
16368403|NCT04199598|Experimental|Treatment D (Reference Product): Abediterol (2.5 μg)|Randomized subjects will receive single dose treatment of Abediterol (as napadisylate) inhalation powder via dry powder inhaler (DPI) following an overnight fast of at least 8 hours
16368404|NCT04199585|Experimental|Cohort A: single-ascending oral dose|Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
16368405|NCT04199585|Experimental|Cohort B: (fasting/fed conditions)|"Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.
~B1: fed-fasting-fasting condition (spiked dosage)
~B2: fasting-fed-fasting condition (spiked dosage)
~B3: fasting-fasting-fed condition"
16368406|NCT04199572|Experimental|Diclofenac and Oral Paracetamol|Diclofenac (75mg intramuscular), Placebo (100ml intravenous Normal Saline), Paracetamol (per oral 1gm)
16368407|NCT04199572|Experimental|Diclofenac and IV Paracetamol|Diclofenac (75mg intramuscular), Paracetamol (intravenous1gm in 100ml solution), Placebo (sugar tablets)
16368408|NCT04199572|Experimental|Diclofenac and Placebo|Diclofenac (75mg intramuscular),Placebo (100ml intravenous Normal Saline),Placebo (sugar tablets)
16368409|NCT04199559|Experimental|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal.
16368410|NCT04199546|Other|A child with Coffin-Lowry Syndrome|A boy with a known CLS diagnosis with a history of coughing during eating, long-lasting wheezing, sputum and inability to intake solid food will be included.
16368411|NCT04199533||Classroom Observation|The investigators will use day-long observational and interview procedures with eight staff from four schools. The classroom observation will focus on documenting episodes of classroom disruptive behavior, including antecedents and consequences to the behaviors. The interview will involve discussing with staff decision-making processes and current needs around classroom behavioral management.
16368412|NCT04199533||RUBI Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing adaptation or pruning needs related to RUBI content and structure to ensure the redesigned curriculum (RUBIES) is contextually appropriate for schools.
16368413|NCT04199533||RUBIES Collaborative Design|Eight staff from 4 schools will attend one of four 2-hour in-person feedback sessions to support collaborative feedback around RUBI redesign, including feasibility and appropriateness and methods supporting implementation.
16368414|NCT04199533||RUBIES Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing final RUBIES adaptation or pruning needs.
16368415|NCT04199520|Experimental|surgery combined with systemic therapy|surgery combined with systemic therapy
16368416|NCT04199520|Active Comparator|systemic therapy|systemic therapy
16368417|NCT04199507||Autism|Assessment of physical activity level and physical fitness
16368418|NCT04199507||Healthy|Assessment of physical activity level and physical fitness
16368419|NCT04199468|Experimental|Active Delta-9-THC and Placebo Ketamine|Active IV Delta-9-THC and Placebo Ketamine
16368420|NCT04199468|Experimental|Active Delta-9-THC and Active Ketamine|Active IV Delta-9-THC and Active Ketamine
16368421|NCT04199468|Experimental|Placebo Delta-9-THC and Placebo Ketamine|IV Placebo Delta-9-THC and Placebo Ketamine
16368422|NCT04199468|Experimental|Placebo Delta-9-THC and Active Ketamine|IV Placebo Delta-9-THC and Active Ketamine
16368423|NCT04199455|Experimental|Integrative Treatment Group|Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
16368424|NCT04199455|Placebo Comparator|Control Group|Patients randomly assigned to the control group will receive recipe simulators as placebo, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
16368425|NCT04199429|Experimental|Experimental|"Each nurse applied the RBC model through the treatment Take 5 minutes (T5M), to parents allocated to the experimental group. This consisted in devoting some time (from 5 to 10 minutes) to improving the relationship with the parent. This treatment can be considered as the practical development of the core principles of the RBC model by the study team.
~During the T5M the nurse applied the strategies of empathic communication and active listening, learned during the education and training phase. The treatment lasted from 5 to 10 minutes and was delivered once per day during the admission of the patient.
~The T5M time was considered as additional or supplementary, but not substitutive, of the standard nursing time dedicated daily to patients and parents."
16368426|NCT04199429|Active Comparator|Control|Standard nursing time dedicated daily to patients and parents.
16368427|NCT04199416|Experimental|mRehab app|Participants randomized to the intervention group will be given the mRehab app free of charge to perform self-management of their knees in their homes.
16368428|NCT04199416|Sham Comparator|Sham app|Participants randomized to the control group will receive a sham app free of charge to perform self-management of their knees in their homes.
16368429|NCT04199403||Single Group|
16368430|NCT04199390|Active Comparator|Clinic-based Physical Therapy|
16368431|NCT04199390|Active Comparator|Home-based Physical Therapy|
16368432|NCT04199377|Experimental|hip or knee replacement|total hip or knee replacement
16368433|NCT04199364|Experimental|Low FiO2 threshold|A fraction of inspired oxygen (FiO2) of 25% to have an oxygen saturation (SpO2) of 90-92%.
16368434|NCT04199364|Experimental|Medium FiO2 threshold|A fraction of inspired oxygen (FiO2) of 35% to have an oxygen saturation (SpO2) of 90-92%.
16368435|NCT04199351|Experimental|Part A|AMG 171 or placebo, 2 SAD cohorts
16368436|NCT04199351|Experimental|Part B|AMG 171 or placebo, 1 MAD cohort
16368437|NCT04199351|Experimental|Part C|AMG 171 or placebo, 3 titration cohorts
16368438|NCT04199338|Experimental|Randomized|Randomized
16368439|NCT04199325|Experimental|Intervention group|
16368440|NCT04199325|Placebo Comparator|Control group|
16370968|NCT04181749|No Intervention|No treatment|Patients will not be prescribed aspirin and statin
16368442|NCT04199299||Persons who cannot communicate unequivocally|Persons with intellectual disability, childhood autism, and/or cerebral palsy who cannot communicate unequivocally and therefore cannot communicate their needs and wishes, e.g. whether they are uncomfortable, in pain, scared, angry, happy, pleased.
16368443|NCT04199286|Active Comparator|Asymmetrical surgery|This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery
16368444|NCT04199286|Active Comparator|Symmetrical|This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia
16368445|NCT04199273|Experimental|Magnetic stimulation and electric stimulation|The patient receive first the magnetic stimulation with MagStim 200 tool. Then 15 min after he will receive the electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
16368446|NCT04199273|Experimental|Electric stimulation and magnetic stimulation|The patient receive first electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager). Then 15 min after he will receive the magnetic stimulation with MagStim 200 tool
16368447|NCT04199260||Papilocare|all patients gonna received papilocare treatment as per usual practice.
16368448|NCT04199247|Experimental|Exercise|Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.
16368449|NCT04199247|No Intervention|Usual Care|Participants will continue with their return to play progression based upon the advice given to them at their initial post-injury evaluation.
16368450|NCT04199234|Experimental|experimental group|60 mg Encapsulated Iron
16368451|NCT04199234|Active Comparator|control group|60 mg Iron sulphate
16368452|NCT04199221|No Intervention|Lecture|an initial brief lecture with no further training
16368453|NCT04199221|Experimental|Stress management|an initial brief lecture with stress management lecture
16368454|NCT04199221|Active Comparator|Hands-on training|an initial brief lecture with addition hands-on training for the task
16368455|NCT04199221|Experimental|Stress management and hands-on training|an initial brief lecture with both stress management lecture and additional hands-on training
16368456|NCT04199208|Active Comparator|Standard Care Arm|Standard perioperative care is given.
16368457|NCT04199208|Experimental|Interventional Arm|Intervention of prehabilitation and immunonutrition is given prior to surgery
16368458|NCT04199195||Males and females aged at least 60 years.|"A longitudinal study of one cohort of 360 participants aged at least 60 years. Participants will be required to provide a stool sample, provide a blood sample and complete a health questionnaire every 6 months for 4 years. At alternate visits, participants will be required to under go cognitive assessments and physical measurements.
~Participants will be required to under go an Optical Coherence Tomography Scan 3 times over 4 years.
~Sub group 1 - During a routine care colonoscopy, at least 90 participants will have 6-8 colon tissue biopsies taken for research purposes.
~Sub group 2 - Participants from cohort 3 only will be offered an optional brain MRI until the required number of 30 participants is achieved."
16368459|NCT04199182|Experimental|Exercise|Progressive, multi-component supervised exercise training group.
16368460|NCT04199182|Active Comparator|Healthy Aging Attention Control|A health education program that addresses topics relevant to older adults.
16368461|NCT04199169|Experimental|Cohort 1, Group 1|"Ten subjects in the first cohort will receive a 10 mcg dose of HeV-sG-V on Visits 1 and 6.5 (Days 1 and 169*).
~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
16368462|NCT04199169|Placebo Comparator|Cohort 1, Group 2|"Two subjects in the first cohort will receive a dose of the placebo on Visits 1 and 6.5 (Days 1 and 169*).
~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
16368463|NCT04199169|Experimental|Cohort 2, Group 3|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) with placebo on Visit 3 (Day 29).
16368464|NCT04199169|Experimental|Cohort 2, Group 4|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) with placebo on Visit 2 (Day 8)
16368465|NCT04199169|Placebo Comparator|Cohort 2, Group 5|Twelve subjects in the second cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
16368466|NCT04199169|Experimental|Cohort 3, Group 6|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visit 1 (Day 1) and placebo on Visits 2 and 3 (Days 8 and 29).
16368467|NCT04199169|Experimental|Cohort 3, Group 7|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) and placebo on Visit 3 (Day 29).
16368468|NCT04199169|Experimental|Cohort 3, Group 8|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) and placebo on Visit 2 (Day 8).
16368469|NCT04199169|Placebo Comparator|Cohort 3, Group 9|Eighteen subjects in the third cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
16368470|NCT04199143|Experimental|healthy voluntary controls|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
16368471|NCT04199143|Experimental|Depressive Patients|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
16368472|NCT04199130|Experimental|Intervention Group 1|This arm will receive BrainHQ for the first four weeks of the study, and Goal Management Training for the second four weeks.
16368473|NCT04199130|Experimental|Intervention Group 2|This arm will receive Goal Management Training for the first four weeks of the study, and BrainHQ for the second four weeks.
16368474|NCT04199130|No Intervention|Treatment-as-usual|
16368475|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368476|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368477|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368478|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368479|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368480|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368481|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368482|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368483|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have not access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368484|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368485|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368486|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368487|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368488|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368788|NCT04196972|Experimental|Arm A (ECHO telementoring)|Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
16368489|NCT04199117|Experimental|No Incentive,Untailored,No Care Manage,IntensiveTreatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
16368490|NCT04199117|Active Comparator|No Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
16368493|NCT04199091|Experimental|Craniosacral self-help techniques (CST)|The experimental group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. The course starts with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients will also receive a script with theoretical CST basics and descriptions of the techniques, which should facilitate the correct practice at home.
16368494|NCT04199091|Active Comparator|Progressive muscle relaxation (PMR)|The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
16368495|NCT04199078|Experimental|A - papilocare alternative days treatment|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
16368496|NCT04199078|Experimental|B - papilocare semiintensive treatment|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
16368497|NCT04199078|Experimental|C - papilocare intensive treatment|Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
16368498|NCT04199078|No Intervention|D - standard of care|Arm D: usual clinical practice - no treatment
16368499|NCT04199065|Experimental|Good Practice Guidelines group|Implementation of Good Practice Guidelines
16368500|NCT04199065|No Intervention|usual practices group|Not Implementation of Good Practice Guidelines, so working as the usual way
16368503|NCT04199039|Experimental|ET fixation with ET holder|ET fixation of the patients in the study group was performed with an ET holder when they arrived at the CVS ICU
16368504|NCT04199039|No Intervention|ET fixation with plaster|ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted.
16368505|NCT04199026|Experimental|Device Feasibility (microdevice, surgery)|Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.
16368506|NCT04199013|Active Comparator|Ropivacaine With Fentanyl|2.5ml of 0.75% Isobaric ropivacaine with 0.5ml (25mcg) Fentanyl
16368507|NCT04199013|Active Comparator|Ropivacaine Without Fentanyl|2.5ml of 0.75% Isobaric Ropivacaine with 0.5ml of Normal Saline
16368508|NCT04198974|Experimental|PreVenture Training (PTtT)|Schools randomized to this arm will identify 4 staff members to participate in a 2-day training workshop + 3 hours of supervised practice and will be provided with access to screening and PreVenture intervention materials through the local trainer. Local trainers will deliver 2-day workshops and then supervise school staff in the delivery of two 90-minute group sessions (for at least one personality profile).
16368539|NCT04198766|Experimental|Part 3 INBRX-106 Escalation in Combination with Pembrolizumab|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
16368509|NCT04198974|Experimental|PreVenture Training + Implementation Facilitation (PTtT+IF)|Schools randomized this arm will receive the standard PreVenture TtT protocol plus an additional Implementation Facilitation package that will contain 3 new components designed to increase the likelihood that schools will continue to implement the program with high quality and satisfaction: 1) Youth Engagement, 2) ongoing coaching and supervision for Facilitators, and 3) access to easy-to-use performance metrics.
16368510|NCT04198974|No Intervention|Control (TAU)|For schools randomized to this arm, students will have usual access to drug and alcohol prevention through the standard curriculum and mental health care provided through student counseling at the participating schools. The schools will be incentivized to participate in the study with the promise of free PreVenture training and materials in subsequent years of the trial. Information on other drug prevention efforts implemented at the school will be collected, but the randomized design should control for any potential differences between intervention conditions on this random factor.
16368511|NCT04198961|Experimental|Electronic Intervention|Individualized opioid taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
16368512|NCT04198948|Experimental|Omeprazole, Then Placebo|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.
16368513|NCT04198948|Experimental|Placebo, Then Omeprazole|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.
16368514|NCT04198935|Experimental|Intervention|Participants will be enrolled on to a 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
16368516|NCT04198909|Experimental|Cohort 1|
16368517|NCT04198896||CAD-only|patients with diagnosed coronary artery diseases (CAD) without any other atherosclerotic cardiovascuar diseases at the entry of SHIP
16368518|NCT04198896||CAD with poly-arterial diseases|patients with diagnosed coronary artery diseases (CAD) with other atherosclerotic cardiovascuar diseases such as any of aortic and/or peripheral artery diseases at the entry of SHIP
16368519|NCT04198883|Experimental|Protheracytes|Single arm study : Stem cells injection called Protheracytes
16368520|NCT04198870|Other|Control Arm|Mitral Valve Repair Surgery
16368521|NCT04198870|Experimental|Device Arm|MitraClip™ device implantation
16368522|NCT04198857|No Intervention|Standard Care + Telemonitoring: Control|Standard care for GDM will be modifying diet& exercise and/or medication use. Participants will have consultations with a dietitian and a physical therapist to develop a diet and physical activity plan based on pre-pregnancy weight and disease severity. In addition to verbal information about managing GDM with diet and physical activity, patients will be provided with leaflets and brochures. As per the standard care protocol, GDM patients will be asked to visit the OPD for glucose testing every two weeks, and after each testing, blood glucose levels will be recorded in paper booklets assigned to each patient. In addition, the women will be provided with a glucometer and a blood pressure monitor machine. Participants will be taught to use these devices for self-monitoring and will be provided guidelines to follow at home. The OB/GYN physicians will monitor the blood glucose levels across testing, and will prescribe oral hypoglycemic medications or insulin to the patient if needed.
16368523|NCT04198857|Experimental|Standard Care + mGDM app + Telemonitoring|In addition to standard care and telemonitoring, this group will use the mGDM app. This group will be provided with the same devices as the control group and in addition, the GDM app will be set up in their cellular device. The app will be on their smart phone and will support self-management by: i) providing health education, ii) helping patients identify and set target health goals (for diet, physical activity, and glucose levels), iii) enhancing their self-efficacy to meet target goals, and iv) facilitating desired support from family members. The core component of the mGDM app will be to allow GDM patients to record and self-monitor their carbohydrate intake, physical activity and blood glucose levels. Patients will be able to manually enter their weekly blood glucose levels and blood pressure readings on to the app
16368524|NCT04198844||Warfarin user|
16368525|NCT04198844||Apixaban user|
16368526|NCT04198831|Experimental|acupuncture group|Receiving acupuncture and moxibustion treatment
16368527|NCT04198831|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion treatment
16368528|NCT04198818|Experimental|Dose escalaltion study of HH2710|to determin the MTD of HH2710 and/or Recommended Phase II dose (RP2D).
16368529|NCT04198805|Active Comparator|Vitamin E (1000 mg)|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months.
16368530|NCT04198805|Active Comparator|DHA EE (1.89 g)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months).
16368531|NCT04198805|Active Comparator|DHA EE (1.89 g) and Vitamin E (1000 mg)|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months.
16368532|NCT04198805|Placebo Comparator|Placebo|Matching soybean oil placebo (3 capsules) of all arms daily for 6 months.
16368533|NCT04198792||ECPR patients|Patients that is put om ECMO during cardiac arrest
16368534|NCT04198792||ECMO patients, non-ECPR|Patients that is put on ECMO due to circulatory failure but not cardiac arrest
16368535|NCT04198779|Experimental|APPLI|Care support with implementation of the application
16368536|NCT04198779|No Intervention|CONTROL|Conventional care support
16368537|NCT04198766|Experimental|Part 1 INBRX-106 Escalation|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
16368538|NCT04198766|Experimental|Part 2 INBRX-106 Expansion|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D.
16369195|NCT04193748|Experimental|Group P|Topical pomegranate peel extract treatment has been repeated four times per day for four weeks.
16368540|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D in combination with pembrolizumab.
16368541|NCT04198753||Parent of Peanut Allergic Child|"The researchers will identify patients or study subjects aged 1-18 who have been diagnosed with peanut allergy based on skin prick testing, serologic testing, and/or history of reaction. They will then contact mothers or fathers of these patients/subjects who are 18 and older and enroll those who do not themselves have a history of food allergy, with a goal of 40 subjects per group.
~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
16368542|NCT04198753||Parent of Non-atopic Child|"To establish normal controls, the researchers will enroll parents age 18 or older with no history of food allergy or eczema in themselves or their offspring.
~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
16368543|NCT04198740||Control group|Healthy, normal ocular surface
16368544|NCT04198740||Dry eye syndrome|"Patients suffering from either:
~Lacrimal insufficiency
~Anterior blepharitis
~Posterior blepharitis
~Sjögren syndrome"
16368545|NCT04198740||Allergic conjunctivitis|Patients suffering from allergic conjunctivitis
16368546|NCT04198740||Mucous membrane pemphigoid|Patients suffering from mucous membrane pemphigoid
16368547|NCT04198740||Infectious keratoconjunctivitis|"Patients suffering from keratitis and/or conjunctivitis of various etiology:
~Viral
~Bacterial
~Fungal
~Acanthamoeba"
16368548|NCT04198727|Experimental|DPD activity|
16368549|NCT04198714|Experimental|Pudendal block|9cc of 0.25% Marcaine + 1cc of 40mg/mL triamcinolone. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
16368550|NCT04198714|Sham Comparator|Sham injection|10cc normal saline. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
16368551|NCT04198701|Experimental|Pilot|
16368552|NCT04198701|Experimental|Pivotal - Roll-In|
16368553|NCT04198701|Experimental|Pivotal - Paroxysmal AF|
16368554|NCT04198701|Experimental|Pivotal - Persistent AF|
16368555|NCT04198688||With cancer|Patients diagnosed with cancer (with at least one of the following ICD-10 diagnoses: C00-43; C46.1-99; D09)
16368556|NCT04198688||Without cancer|Patients without cancer (without any of the following ICD-10 diagnoses: C00-99; D09; D30.1-9; D32-33; D35.2-4; D41.1-9; D44.3-5)
16368557|NCT04198675|Active Comparator|Supervised EMG Biofeedback Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
16368558|NCT04198675|Active Comparator|Home-Based Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
16368559|NCT04198675|Sham Comparator|Posture Training/Ergonomic Regulations Group|1 session, no further intervention until second evaluation for 6 weeks.
16368560|NCT04198662|Active Comparator|Cryoneurolysis|Active cryoneurolysis: 3 mL of normal SALINE will be injected into the muscle superficial to the nerve followed by an ACTIVE cryoneurolysis procedure using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
16368561|NCT04198662|Sham Comparator|Sham|Sham cryoneurolysis: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block followed by a SHAM cryoneurolysis procedure with a probe that vents the nitrous oxide prior to reaching the probe tip using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
16368562|NCT04198649|Experimental|Azithromycin|62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days
16368563|NCT04198649|Placebo Comparator|Placebo|62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days
16368564|NCT04198636|Experimental|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
16368565|NCT04198636|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
16368566|NCT04198623|Other|Montelukast (Singulair)|Montelukast(Singulair) 10mg to be taken in addition to standard institutional premedication
16368567|NCT04198610|No Intervention|healthy|Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
16368568|NCT04198610|No Intervention|chronic gingivitis|Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm, relative attachment loss (RAL) ) less than or equal to 3mm and more than to 25% sites with gingival bleeding present (BOP)
16368569|NCT04198610|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.
~Non surgical periodontal therapy (SRP) was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy"
16368570|NCT04198597|Experimental|Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
16368571|NCT04198597|Experimental|Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
16368716|NCT04197466|Experimental|Pelvic Floor Exercise Group|Pelvic floor muscle exercises will be recommended as a home program for 6 weeks every day of the week.
16368572|NCT04198597|Experimental|Process-based treatment, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
16368573|NCT04198597|Experimental|Process-based treatment, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
16368574|NCT04198584|Experimental|VC-CBCS Intervention|The VC-CBCS intervention will be delivered via WebEx videoconferencing technology and will include 14, 2-hour long sessions that include group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials include a hard copy Patient Workbook and audio-recorded relaxation techniques.
16368575|NCT04198584|No Intervention|Standard of Care (SC)|Patients randomized to SC will receive no intervention and will be followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.
16368576|NCT04198571||Zinforo Treated|Only those Adults treated with this treatment for CAP or cSSTi
16368586|NCT04198532|Experimental|Complex Regional Pain Syndrome(CRPS) group|Stroke patients with complex regional pain syndrome
16368587|NCT04198532|Other|Control Group|Stroke patients without complex regional pain syndrome
16368588|NCT04198519|Active Comparator|Poor Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Poor cardiovascular health is considered for two or less metrics.
16368589|NCT04198519|Active Comparator|Ideal-intermediate Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Ideal cardiovascular health is considered for those with five or more metrics within this qualification, and intermediate for the presence of three or four metrics.
16368590|NCT04198506|Experimental|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.
16368591|NCT04198506|Active Comparator|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
16368592|NCT04198493|Experimental|Continuous Positive Airway Pressure(CPAP)|"Patients with CPAP treatment. Titration will be performed by polysomnography CPAP to determine the optimal treatment pressure.
~This group will also be instructed in sleep hygiene and dietary counseling
~Intervention:
~Device: CPAP Other: Conservative treatment for OSA"
16368593|NCT04198493|Active Comparator|CONSERVATIVE TREATMENT for OSA|Sleep hygiene and dietary counseling. Sleep hygiene (regular sleep schedule, physical exercise) and dietary counseling Intervention: Other: Conservative treatment for OSA
16368594|NCT04198480|Experimental|JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.
16368595|NCT04198467|Experimental|PRP (100billion platelets)|platelet rich plasma having 100 billion platelets in 10 ml plasma prepared from 60 ml blood
16368596|NCT04198467|Placebo Comparator|hyaluronic acid|Four ml of high-molecular-weight hyaluronic acid (HMWHA) with a concentration of 22mg/ml
16368597|NCT04198454|Active Comparator|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
16368598|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound.
16368599|NCT04198454|Experimental|Compression bandages with FACL|Class I compression (20-30 mmHg) bandage or stocking with FACL.
16368600|NCT04198441|Active Comparator|Omeza Value-based Bundle Test|The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.
16368601|NCT04198441|Active Comparator|Standard Wound Care Control|Standard wound care control is saline wound wash and wet to dry dressing.
16368602|NCT04198428|Experimental|Receives OUD-CDS|Clinics will have access to the OUD-CDS (Opioid Wizard)
16368603|NCT04198428|No Intervention|Does not Receive the OUD-CDS|"Clinics will not have access to the OUD-CDS (Opioid Wizard). These will be usual care clinics."
16368604|NCT04198415||Venetoclax Participants|Participants prescribed and treated with venetoclax.
16368605|NCT04198402||Patient with digestive neuroendocrine tumor|naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
16368606|NCT04198402||Patient without tumor|Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
16368607|NCT04198389|Experimental|partial knee replacement|medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI
16368717|NCT04197466|Experimental|Kinesiotape Group|In addition to pelvic floor exercise,kinesio tape application will be performed by ligament technique to the sacral region.
16368718|NCT04197466|Experimental|Electrical Stimulation Group|In addition to pelvic floor exercise,electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
16368608|NCT04198376|Experimental|The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes. Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures
16368609|NCT04198376|Experimental|Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator .A second surgical site will be prepared to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site. After sutures are slid through each tunnelled interdental area the needle will be pushed through the CTG before it is guided back through the undermined tissues.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.
16368610|NCT04198363|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
16368611|NCT04198363|Active Comparator|Esomeprazole 20 mg|Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
16368612|NCT04198350|Experimental|Islet implantation|
16368613|NCT04198337|Experimental|Endoscopic Full Thickness Resection|Resection of the gastric GIST by ESD techniques followed by endoscopic closure of defect with suturing or clips and loop
16368614|NCT04198324|Active Comparator|Entire fold uterine closure|The uterus will be sewn with full fold locked sutures that pass through myometrium and endometrium.
16368615|NCT04198324|Experimental|Non-endometrial uterine closure|The uterus will be sewn with locked sutures that pass through myometrium without endometrium.
16368616|NCT04198311|Experimental|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks
16368617|NCT04198298|Active Comparator|Group 1 EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
16368618|NCT04198298|Active Comparator|Group 2 ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
16368619|NCT04198298|Active Comparator|Group 3 Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
16368620|NCT04198285|Experimental|Retrograde filled|This arm will contain patients who had retrograde bladder filling upon completion of surgery with 200 milliliters (mL) of sterile saline.
16368621|NCT04198285|No Intervention|Control|This arm will contain patients who simply had the urinary catheter removed upon completion of surgery, and were left with an empty bladder.
16368622|NCT04198272|Experimental|Facilitated|"Schools that are randomized to this arm will be exposed to all of the components in the self-service version in addition to the following:
~-Peer facilitation of the CyberRwanda platform at the school-based cyber clubs that will house an online tablet with the educational components of CyberRwanda with a facilitator."
16368623|NCT04198272|Active Comparator|Self-service|"Schools that are randomized to this arm will be exposed to the following components of the intervention:
~Availability of the fully functional online CyberRwanda web portal through school-based cyber clubs;
~SMS-based ordering of contraceptives and SMS-based FAQs Online (through web portal on computer or smartphone) ordering of contraceptives;
~Facility finder: A list of the closest health centers and pharmacies where youth can get contraceptives and other FPRH services;
~Promotion of the CyberRwanda program through school launch events; and
~Access to Youth Centers (1 per district) that will house tablets with the fully functional online CyberRwanda web portal"
16368624|NCT04198272|No Intervention|Control|Schools in this arm will not receive any intervention
16368625|NCT04198259|Active Comparator|interventional devascularization|Interventional devascularization includes BRTO and similar procedure. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils.
16368626|NCT04198259|Experimental|Transjugular intrahepatic portosystemic shunt|TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
16368627|NCT04198233|Experimental|Diazepam group|Rectal Diazepam suppository
16368628|NCT04198233|Placebo Comparator|Placebo group|Placebo suppository
16368629|NCT04198194||Participants with events|Individuals who have experienced any of the listed outcomes
16368630|NCT04198194||Participants without events|Individuals who have not experienced any of the listed outcomes
16368631|NCT04198168||ICU patients|ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.
16368632|NCT04198155|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to bilateral renal arteries determined by CT-guidance.
16368633|NCT04198142|Experimental|Imagery Rehearsal Therapy Intervention|This group receives one to two sessions of Imagery Rehearsal Therapy.
16368634|NCT04198142|Active Comparator|Treatment as Usual with dream diaries|This group receives the usual inpatient care without additional Imagery Rehearsal Therapy sessions, but also keeps dream diaries.
16368750|NCT04197232||exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
16368635|NCT04198129|Experimental|Treatment|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
16368636|NCT04198129|Active Comparator|Control|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
16368637|NCT04198116|Experimental|Varenicline + Guanfacine ER|Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.
16368638|NCT04198116|Active Comparator|Varenicline|Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
16368639|NCT04198103|Experimental|SoracteLite|Transperineal Focal Laser Ablation (TPLA)
16368640|NCT04198090|Other|Sexual & Gender Minority (SGM) Competence Training|Personnel will be trained using a validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for Oncology.
16368641|NCT04198077|Experimental|CONSERVATIVE|Participants in the conservative group will receive the lowest FiO2 to maintain SpO2 between 94 and 98 percentage, or when available a PaO2 between 70 mmHg and 100 mmHg. A SpO2 alarm limit of 99 percent will apply whenever supplemental oxygen is being administered. The FiO2 will be reduced or oxygen supplementation discontinued whenever the SpO2 or PaO2 exceeded 98 percent or 100 mm Hg. An oxygen supplementation will be given only if SpO2 falls below 94 percent. Pre-oxygenation with FiO2 1.0 will not be performed during in-hospital transports or in anticipation of diagnostic and therapeutic manoeuvres.
16368642|NCT04198077|Active Comparator|CONVENTIONAL|In the conventional group, participants will receive a FiO2 aiming to maintain a SpO2 equal or major than 98 percentage, accepting an upper limit of PaO2 of 150 mmHg and a lower limit of 70 mmHg. The use of a FiO2 of less than 0.3 whilst ventilated is discouraged. According to standard Intensive Care Unit practice, control patients will receive a FiO2 of 1.0 during endotracheal intubation manoeuvre, airway suction or in-hospital transfers.
16368643|NCT04198064|Experimental|Group A- Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/~2 cups of %0.9 saline solution) during the insertion of the cystocopy tube during their cystoscopy."
16368644|NCT04198064|Other|Group B- No Bag Squeeze|Participants will receive a standard cystoscopy procedure.
16368645|NCT04198051|Experimental|treatment group|
16368646|NCT04198038|Experimental|cognitively impaired children|This is a single-group study; all participants will be offered the songwriting intervention.
16368647|NCT04198025||Patients who underwent colorectal resection|"Patients in this observational study will have undergone CT scan as routine work up prior to resection of elective colorectal cancer.
~Psoas muscle density will be measured (in Hounsfield units from CT images) at lumbar vertebral level L3."
16368649|NCT04197999|Experimental|Single Ascending Dose followed by Multiple Doses|Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.
16368650|NCT04197986|Experimental|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
16368651|NCT04197986|Placebo Comparator|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
16368652|NCT04197960|Experimental|microwave ablation|ablate all tumors including at least 5mm safe margin except for tumors adjacent to thyroid capsule.
16368653|NCT04197960|Active Comparator|surgical resection|lobectomy + central lymph node dissection
16368654|NCT04197947|Experimental|PD patient who have FoG|
16368655|NCT04197934|Experimental|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16368656|NCT04197934|Experimental|Dose expansion Cohort I (WSD0922-FU)|Patients with GBM/AA receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16368657|NCT04197934|Experimental|Dose expansion Cohort II (WSD0922-FU, surgery)|Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16368658|NCT04197934|Experimental|Dose expansion Cohort III (WSD0922-FU)|Patients with NSCLC LM receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16368659|NCT04197921|Other|Sham/Active ExAblate Treatment Stage 1 and 2|Subject will undergo both Treatment 1 (sham) and Treatment 2 (with enhanced intensity). Subjects are blinded to the order of the sham vs active treatment.
16368660|NCT04197908|Experimental|EUS-guided gallbladder drainage (EGBD)|The procedure would be performed with a linear echoendoscope using a 10mm x 10mm or a 15 x 10mm stent. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder would be completely emptied by suction and irrigation until the effluent through the stent is clean.
16368661|NCT04197895|Experimental|test group|Socket preservation with APRF
16368662|NCT04197895|Active Comparator|control group|natural healing
16368663|NCT04197882|Experimental|treatment|"This study consisted of 3 stage of neoadjuvant treatment, surgical, and adjuvant treatment. Neoadjuvant treatment period: OrienX010 intratumoral injection in combination with Toripalimab infusion. Toripalimab : 3 mg/kg, IV infusion: Once every 2 weeks for 6 doses ; OrienX010: Maximum injection volume 8 × 108 pfu, intratumoral injection: Once every 2 weeks for 6 doses ; Surgical treatment period: 2 weeks after the last dose of neoadjuvant treatment (± 7 days), the investigator designed the surgical protocol of the melanoma radical surgery according to the patient's individual disease, and performed postoperative care according to the patient's condition.
~Adjuvant treatment period: 3 weeks after operation (± 7 days), the patient was given Toripalimab infusion. Toripalimab 3 mg/kg intravenously given every 3 weeks (every 3 weeks per cycle) for up to 1 year (the one-year duration will be counted from 1st dose in neoadjuvant treatment)."
16368664|NCT04197869|Experimental|Experimental|The experimental group will take a pre-operative course of polyethylene glycol daily for seven days prior to procedure date.
16368665|NCT04197869|No Intervention|Control|The control group will not be given any intervention preoperatively.
16368666|NCT04197856|Active Comparator|Control / Family-mediated disclosure (standard care)|Genetic counseling according to current clinical practice
16368667|NCT04197856|Experimental|Intervention / Health-care assisted disclosure|Genetic counseling according to current clinical practice with the addition of an offer from health care provider to mail letters directly to eligible at-risk relatives.
16368668|NCT04197843|Experimental|NaviCam (ANKON)|NaviCam (ANKON)
16368669|NCT04197817|Active Comparator|JS002|JS002, Subcutaneous or intravenous injection
16368670|NCT04197817|Placebo Comparator|Placebo,|Placebo,Subcutaneous or intravenous injection
16368671|NCT04197804||Tourette group|20 subjects with Tourette Syndrome undergoing an evaluation to identify the IQ. Subsequently, 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
16368672|NCT04197804||Control group|20 subjects without Tourette Syndrome subjected to an evaluation to identify the IQ. Subsequently 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
16368673|NCT04197791|Experimental|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
16368674|NCT04197791|Experimental|Core Stabilization Exercises|Core stabilization exercises will be applied to 18 patients with idiopathic pulmonary fibrosis. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
16368675|NCT04197778|Experimental|group A|
16368676|NCT04197778|Experimental|group B|
16368677|NCT04197765|Sham Comparator|Sham|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
16368678|NCT04197765|Active Comparator|Active acTBS|"For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.
~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays."
16368679|NCT04197752||Obese patients|Body mass index > 30 kg/m2
16368680|NCT04197752||Non-obese patients|Body mass index < 30 kg/m2
16368681|NCT04197739|Experimental|Fixed dose|patients will receive a fixed, single daily dose of amikacin, 500 mg, a day.
16368682|NCT04197739|Active Comparator|Adjusted body weight dose|patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram.
16368683|NCT04197726|Experimental|sbeIIa/b white bread|sbeIIa/b white bread with high resistant starch content
16368684|NCT04197726|Active Comparator|Control white bread|Reference white bread (wild-type)
16368686|NCT04197700|Other|Personalized Arm|"Personalized Arm: The target MAP will be defined as +/- 5% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements:
~Pre-operative anesthesia or surgical consultation;
~Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery;
~Inpatient measurement the night before surgery;
~Pre-anesthetic MAP
~The order of the measurements prioritizes outpatient MAPs given that temporary pre-operative discontinuation of anti-hypertensive agents could potentially raise, while fasting and/or fluid restriction pre-operatively could potentially lower resting blood pressure.39 The lower and upper safety limits of personalized MAP targets will be 50mmHg and <90mmHg, respectively."
16368719|NCT04197453||Consented Arm|Subjects with a recent (within 18 months) hospitalization for myocardial infarction, unstable angina, ischemic stroke, or critical limb ischemia, and subjects undergoing coronary, peripheral, or carotid revascularization, including surgical and percutaneous revascularization, with an LDL-C greater than or equal to 70 mg/dL who may be eligible for PCSK9 inhibitor therapy.
16368687|NCT04197700|Other|Protocolized Arm|"Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician.
~In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician."
16368688|NCT04197687|Experimental|Arm I - No pCR (trastuzumab emtansine, TPIV100, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive TPIV100 ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of TPIV100 ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
16368689|NCT04197687|Placebo Comparator|Arm II - No pCR (trastuzumab emtansine, placebo, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive placebo ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of placebo ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
16368690|NCT04197687|Experimental|Treatment (pCR)|Patients receive standard of care maintenance therapy with trastuzumab and pertuzumab for 1 year in the absence of disease progression or unacceptable toxicity.
16368691|NCT04197674||Peritoneal dialysis group|Patients who randomized to peritoneal dialysis
16368692|NCT04197674||Hemodialysis group|Patients who randomized to conventional in-center hemodialysis
16368693|NCT04197661|Active Comparator|Elderly groupⅠ|Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486
16368694|NCT04197661|Active Comparator|Elderly group Ⅱ|Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486
16368695|NCT04197661|Active Comparator|Elderly group Ⅲ|Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486
16368696|NCT04197661|Active Comparator|Non-elderly group IV|Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486
16368697|NCT04197648|Experimental|Exercise group|24 week, supervised exercise program at the PPMC (pavillon de prevention des maladies cardiaques). 3x/week. Blood pressure response evaluated during every session.
16368698|NCT04197648|No Intervention|Control goup|No exercise program. Continuation of the daily life activities. Consultation with a kinesiologist at baseline, 3 months and 6 months for advice on physical activities and lifestyle habits.
16368699|NCT04197635|Active Comparator|Dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive dapagliflozin 10 mg per day.
16368700|NCT04197635|Placebo Comparator|Placebo identical to dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive placebo (one tablet a day orally).
16368701|NCT04197622|Experimental|Hydrochlorothiazide|Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).
16368702|NCT04197596|Experimental|BK CTL|Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.
16368703|NCT04197570|Active Comparator|Opioid-based anesthetic|"Premedication
~-midazolam 2mg IV x 1 as need for anxiety, at the discretion of the anesthesiologist
~Induction
~Fentanyl 2-4 mcg/kg IV bolus
~Propofol 1-3 mg/kg IV
~Paralytic and vasoactive medications at the discretion of the anesthesiologist
~Maintenance
~Fentanyl 1-2 mcg/kg IV bolus immediately prior to sternotomy & aortic cannulation
~Fentanyl 1-2mcg/kg IV bolus immediately following removal of bypass cannula
~Dexmedetomidine 0.4 mcg/kg/hr IV infusion
~Isoflurane titrated at the discretion of the anesthesiologist
~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management
~During chest closure:
~start Propofol 25-75mcg/kg/min IV infusion
~continue dexmedetomidine 0.4mcg/kg/hr IV infusion
~titrate off isoflurane
~Acetaminophen 1000mg IV"
16368704|NCT04197570|Experimental|Opioid-free anesthetic|"Premedication
~-midazolam 2mg IVx1 as needed for anxiety, at the discretion of the anesthesiologist
~Induction
~Dexmedetomidine 1mcg/kg IV
~Propofol 1-3mg/kg IV
~Paralytic and vasoactive medications at the discretion of the anesthesiologist
~Maintenance
~Dexmedetomidine 0.8-1.0 mcg/kg/hr IV infusion
~Isoflurane titrated at the discretion of the anesthesiologist
~May add propofol infusion if clinically indicated
~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management
~During chest closure:
~start Propofol 25-75mcg/kg/min IV infusion
~continue dexmedetomidine 0.4 - 1.0 mcg/kg/hr IV infusion
~titrate off isoflurane
~Acetaminophen 1000mg IV"
16368705|NCT04197544|Experimental|Intervention group|
16368706|NCT04197544|No Intervention|Control group|
16368707|NCT04197531|Experimental|EndoActivator|
16368708|NCT04197531|Experimental|Conventional Endodontic Syringe|
16368709|NCT04197518|Experimental|Children With Enlargement Adenoid and Tonsils|Children With Enlargement Adenoid and Tonsils
16368710|NCT04197505|Experimental|Acute fracture specific|The FLIR E95 camera will be used for the study. The injured extremity will be scanned with the thermal camera and a second scan will be performed on the non-injured extremity to provide an internal control for any differences in room temperature and humidity. Prior to scanning, both the injured and non-injured extremity will remain uncovered for 10 minutes, about the length of an average office visit, and the areas to be scanned will remain free from contact by the patient or interviewer during this time period. The camera will be held 2 feet away from the extremity at a 90º angle to limit reading contamination from objects other than the patient.
16368711|NCT04197492|Experimental|HSRT With Anlotinib|"Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.
~Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance."
16368712|NCT04197479|Experimental|Open label: resmetirom|100 mg daily
16368713|NCT04197479|Placebo Comparator|Double blinded: matching placebo|Placebo daily
16368714|NCT04197479|Experimental|Double blinded: resmetirom 80 mg|80 mg daily
16368715|NCT04197479|Experimental|Double blinded: resmetirom 100 mg|100 mg daily
16369196|NCT04193735||CIPO (case)|MRI scan of gastrointestinal content and activity
16368720|NCT04197453||Electronic Health Record (EHR) arm|Subjects with an inpatient or outpatient diagnosis of clinical ASCVD within the prior 12 months including coronary heart disease, ischemic cerebrovascular disease, atherosclerotic peripheral arterial disease, or prior coronary or peripheral or carotid revascularization.
16368721|NCT04197440|Experimental|Bam8-22|
16368722|NCT04197440|Experimental|SPT pricks|
16368723|NCT04197427|Experimental|Experimental Oral Rinse|"In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days.
~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
16368724|NCT04197427|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
16368725|NCT04197414||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
16368726|NCT04197414||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
16368727|NCT04197414||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
16368728|NCT04197414||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
16368729|NCT04197375|Experimental|Pre-cooling scenario|One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
16368730|NCT04197375|Sham Comparator|Sham evaluation|Participants were monitored during a usual game without any kind of pre-cooling strategy
16368731|NCT04197362|Experimental|ASICS Women's Gel-Venture 6 Running-Shoe|ASICS Women's Gel-Venture 6 Running-Shoe
16368732|NCT04197362|Experimental|Nike Air Max 270|Nike Air Max 270
16368733|NCT04197362|Experimental|La Vida+|La Vida+
16368734|NCT04197349|Experimental|Part A Cohort 1-8|ALD1910/Placebo; Single Dose IV infusion on Day 1
16368735|NCT04197349|Experimental|Part B Cohort 9|ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
16368736|NCT04197349|Experimental|Part B Cohort 10|ALD1910/Placebo; Single dose subcutaneous injection on Day 1
16368737|NCT04197336|Sham Comparator|Control Arm|27 participants enrolled in the procedure arm. Participants randomized to the control arm will follow the same screening. Pre-procedure assessment will take the same pre-procedure meds. Procedure day, interventional radiologist will determine radial or groin access. After the participant and procedure area are prepped, participants will be under standard moderate sedation medications; all participants will receive lidocaine & a skin nick to their groin or their wrist as determined by the operating physician. Participant will have a blind fold placed & their hearing damped either with ear plugs or noise cancelling headphones. Participants randomized to the control arm will not receive other procedural intervention. Procedural team will follow a prescribed simulated protocol. Participants randomized to the control arm will be given under skin lidocaine and receive a skin nick on the wrist or groin.
16368738|NCT04197336|Active Comparator|Bariatric Embolization Procedure|27 subjects will be enrolled in the bariatric embolization(BM) procedure arm. BM procedure will be performed under moderate sedation. Procedure will take 1.5 hr to 3 hr subject will be placed on the X-ray fluoroscopy table. Radial or femoral vascular access will be achieved using a small gauge needle, dilated over a guidewire to accommodate a 5 French vascular sheath. Standard catheters, 3 dimensional imaging will be acquired of the stomach, the arteries supplying the fundus arising off the celiac vessel. Microcatheter into the left gastric and/or gastroepiploic arteries supplying the fundus and small calibrated spheres will be infused until stasis of anterograde arterial flow is achieved, with particular care to avoid infusion of non-target arteries. The left gastric and/or gastroepiploic arteries will be embolized. Repeat 3 dimensional imaging: assess bead distribution and fundal coverage. Subject will be monitored in the recovery room and will be observed overnight.
16368739|NCT04197323|Experimental|Alprostadil liposomes for injection|
16368740|NCT04197323|Active Comparator|KAISHI for injection|
16368741|NCT04197310|Experimental|Nivolumab and Cabozantinib|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Cabozantinib will be administered at a dose of 40mg orally, once daily
~Nivolumab will be given at a dose of 240mg every 14 days, intravenously
~Retreat Phase (Optional)
~Participants may elect to stop nivolumab and cabozantinib with confirmed CR after at least 24 weeks of treatment.
~Participants who elect to stop and then the condition progresses after stopping study treatment may be eligible to resume nivolumab and cabozantinib therapy.
~This resumption will be termed as a retreatment second course phase and is available only while the study remains open and the subject meets specified criteria."
16368742|NCT04197297|Other|CT and MRI Scans|Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
16368743|NCT04197284|Active Comparator|Control group|In control group subjects will undergo individual kinesitherapy- isometric exercise for strengthening of the quadriceps muscle.
16368744|NCT04197284|Active Comparator|Biofeedback group|Biofeedback group will perform physical therapy using biofeedback device for better activation control of the quadriceps muscle with audio and visual signal. They will also perform isometric exercise.
16368745|NCT04197284|Active Comparator|Electrical stimulation|Electrical stimulation group will receive electrical stimulation of the quadriceps muscle and they will also perform isometric exercise.
16368746|NCT04197271||Patients with acutely symptomatic abdominal wall hernia|Patients presenting to emergency surgical services with acutely symptomatic abdominal wall hernia (excluding parastomal).
16368747|NCT04197258|Experimental|intervention group|"For 6 months after discharge, patients in the intervention group will benefit from peer support by a trained patient (number and frequency of contacts defined according to the patient's needs).
~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon discharge at home, including identifying and seeking for the necessary health or social resources"
16368748|NCT04197258|No Intervention|control group|Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
16368751|NCT04197232||not exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
16368752|NCT04197219|Experimental|Pembrolizumab & axitinib|All participants enrolled will receive pembrolizumab as standard of care (SOC) combined with axitinib. Axitinib will be self-administered orally twice daily at 5 mg. On days when both drugs are administered, axitinib will be administered first, followed by pembrolizumab. Treatment will continue until disease progression or unacceptable grade 3/4 toxicities. For patients with a complete response to therapy, maintenance therapy with both drugs will be continued for 12 months.
16368753|NCT04197206|Experimental|Costotransverse block|The Costotransverse block will be administrated to this group before induction of anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively.
16368754|NCT04197206|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine. No block will be performed.
16368755|NCT04197180|Experimental|Hybrid Argon Plasma Coagulation|The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
16368756|NCT04197167|Experimental|Women undergoing hysteroscopy|Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or abnormal cervical or uterine findings.
16368757|NCT04197154|Experimental|1. Control nocebo group|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
16368758|NCT04197154|Experimental|2. High-pain nocebo group|Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
16368759|NCT04197154|Experimental|3. High-threat nocebo|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
16368760|NCT04197141|Active Comparator|Conventionally-fractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
16368761|NCT04197141|Experimental|Hypofractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
16368762|NCT04197128|Active Comparator|Resorbable collagen membrane and bone graft|Subjects will receive bovine derived bone graft and resorbable collagen membrane for augmentation.
16368763|NCT04197128|Experimental|Ribose cross-linked collagen matrix|Subjects will receive ribose cross linked collagen matrix for augmentation
16368764|NCT04197115|No Intervention|Phase 1|Septic patients admited to ICU whick will be treated as specified in current guidelines.
16368765|NCT04197115|Active Comparator|Phase 2|"Septic patients admitted to ICU which will be treated as specified in current guidelines adding:
~Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)"
16368766|NCT04197102|Active Comparator|CBD Isolate|300 mg/day of CBD isolate
16368767|NCT04197102|Active Comparator|CBD Broad Spectrum|300 mg/day of CBD Broad Spectrum Oil
16368768|NCT04197102|Placebo Comparator|Placebo oil|Matched Placebo Oil
16368769|NCT04197089|Experimental|Vitamin D treatment|Treatment with 10.000 IU or 50.000 IU Vitamin D weekly during 4 weeks
16368770|NCT04197076||Neoadjuvant immunotherapy|pd-1 or pd-l1 inhabitors
16368771|NCT04197076||Neoadjuvant targeted therapy|TKIs
16368772|NCT04197076||Neoadjuvant chemotherapy|chemotherapy
16368773|NCT04197063|Experimental|Current SSB restaurant portions purchase refill|Offered a menu with current SSB restaurant portion sizes with the option to purchase refills
16368774|NCT04197063|Experimental|Current SSB restaurant portions free refill|Offered a menu with current SSB restaurant portion sizes plus free beverage refills
16368775|NCT04197063|Experimental|</= 16 oz. SSB portions with the option to purchase refills|Offered a menu with </= 16 oz. SSB portion sizes with the option to purchase refills
16368776|NCT04197063|Experimental|</= 16 oz. SSB portions plus free refills|Offered a menu with </= 16 oz. SSB portion sizes plus free refills
16368777|NCT04197050|Experimental|sacubitril/valsartan group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. sacubitril/valsartan will be given.
16368778|NCT04197050|No Intervention|control group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. Valsartan will be given.
16368779|NCT04197037||People with schizophrenia treated with clozapine|People more than 18 with diagnosis of schizophrenia and treated with clozapine in a stable dose and stable status of the disease (at least 2-3 weeks).
16368780|NCT04197024|Experimental|Traditional exercise capacity test|Patients of the Ministry of the Interior and Administration hospital in Głuchołazy with a diagnosed disease unit of Chronic Obstructive Pulmonary Disease (COPD).
16368781|NCT04197024|Experimental|Immersive virtual reality exercise capacity test|Healthy volunteers, Students of Department of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
16368782|NCT04197011||Prosthesis users|Individuals with unilateral transfemoral amputation.
16368783|NCT04197011||Control|Individuals without unilateral transfemoral amputation.
16368784|NCT04196998|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
16368785|NCT04196998|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
16368786|NCT04196998|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
16368787|NCT04196985|Experimental|Patients with HNSCC|Patients who have histologically confirmed HNSCC and have received CRT for it
16369197|NCT04193735||Chronic constipation (control)|MRI scan of gastrointestinal content and activity
16368789|NCT04196972|Experimental|Arm B (wait-list, ECHO telementoring)|Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
16368790|NCT04196959|Experimental|Single Arm|All patients will receive TYR sphere, a Food for Special Medical Purposes, as part of thier restricted diet for 28 consecutive days.
16368791|NCT04196946|Experimental|Group I|25 mcg fentanyl intrathecally
16368792|NCT04196946|Experimental|Group II|250 mcg alfentanil intrathecally
16368793|NCT04196933|Experimental|Normal Controls|"normal control subjects - no history of neurologic or inner ear disease
~The investigators will characterize vestibular spatial and temporal precision by calculating perceptual thresholds and reaction times for vestibular (yaw rotation, ytranslation) stimuli in normal subjects over a wide age range. Vestibular-visual temporal binding is then performed on each subject and the relationship between the principal parameters (vestibular perceptual thresholds [inversely related to spatial precision], vestibular reaction time variability [inverse of temporal precision], and the PSS and TBW from the temporal binding paradigm) will be examined. The investigators will collect qualitative assessments of dizziness/disbalance (DHI: dizziness handicap index) and quantitative measurements of balance and vestibular function (FGA: functional gait analysis, postural sway, and standard rotational testing - VOR gain, time constant, asymmetry)."
16368794|NCT04196933|Experimental|Central Vestibular Dysfunction|"Migraine and Vestibular Migraine patients
~The investigators intend to evaluate vestibular (yaw rotation or y-translation) - visual temporal binding in people with a wide range of motion sickness sensitivities (as quantified with standard questionnaires), including normal subjects, people with migraine and with vestibular migraine. The investigators will use our standard adaption method to narrow the TBW in these subjects, and will also employ PSS adaptation if a consistent pattern emerges that relates MS sensitivity to the PSS. The investigators will induce motion sickness using a pseudo-Coriolis task (so susceptibility can be quantified pre and post training)."
16368795|NCT04196933|Experimental|Peripheral Vestibular Dysfunction|"Vestibular Schwannoma patients
~The basic approach is to characterize the precision of their vestibular information (perceptual thresholds for spatial precision, reaction times for temporal precision), and their temporal binding characteristics for vestibular (yaw rotation or y-translation)-visual inputs, in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months). At each state the investigators will also assess the quality of their vestibular-mediated behaviors through questionnaires (e.g. DHI), postural sway, functional gait analysis, and standard rotational testing (VOR gain, time constant, and asymmetry)."
16368796|NCT04196933|Experimental|Implant Subjects|"Cochlear Implant (CI)/Vestibular Implant (VI) patients
~A causative role for vestibular precision in temporal binding will be investigated in the VI patients, since the noise characteristics of the vestibular channel will be varied and to determine how this affects thresholds and temporal binding. As part of a second aim, the investigators will use VI and CI prosthetic signals in patients who have never received them together to see how the brain process sensory cues to which it is essentially naïve. Finally, after the acute experiments the investigators will provide 8 hours of 'physiologic' VI and CI stimulation by turning both implants on, sound modulates activity in the CI as usual, and angular head motion modulates activity in the VI while the subject actively explores the hospital environment."
16368797|NCT04196920||Cohort with TNF combination therapy|Cohort with TNF combination therapy (infiximab/adalimumab) with azathiorpine
16368798|NCT04196920||Cohort with anti-TNF combination therapy|Cohort with anti-TNF combination therapy (infiximab/adalimumab) with methotrexate
16368799|NCT04196907|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse Oximeter and DCI Mini sensor for measurement of hemoglobin.
16368800|NCT04196881|Experimental|Training|group will receive training about ADHD
16368801|NCT04196881|No Intervention|Control|group will not receive training about ADHD
16368802|NCT04196868|Experimental|Experimental arm|
16368803|NCT04196868|Placebo Comparator|Control arm|
16368804|NCT04196855|Experimental|Intervention - Teriparatide Treatment|Teriparatide 20ug/day from confirmation of stress fracture for 16 weeks, with the potential to extend to 24 weeks if required.
16368805|NCT04196855|No Intervention|Control - Standard Care|Standard rehabilitation care with additional monitoring to assess healing.
16368806|NCT04196842|Experimental|Telemonitoring|Blood pressure and heart rate monitoring, scale, activity tracker.
16368807|NCT04196842|No Intervention|No intervention|No intervention.
16368808|NCT04196829|Experimental|silver diamine fluoride ⁄ potassium Iodide|38% silver diamine fluoride and a saturated solution of potassium iodide
16368809|NCT04196829|Active Comparator|silver diamine fluoride|38% silver diamine fluoride
16368810|NCT04196803|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
16368811|NCT04196803|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
16368812|NCT04196803|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
16368813|NCT04196803|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
16368814|NCT04196777|Experimental|Intervention|We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
16368875|NCT04196283|Experimental|Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181|Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.
16368938|NCT04195737|Active Comparator|Root coverage with connective tissue graft|Evaluation of root coverage achieved by connective tissue graft in conjunction with coronally advanced flap in patients with multiple gingival recession
16369032|NCT04195048||Cancer patients with acute ischemic stroke|Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
16368815|NCT04196777|No Intervention|Control|"After the 3 intervention sites are identified, 3 control sites will be chosen. To qualify as a control site, a hospital's baseline rate of excessive post-procedural antimicrobial use must be comparable to that of its matching intervention site. Matching on the outcome of interest will minimize selection bias and will make the study less subject to regression to the mean, which is the key threat when selecting poor performers.To further ensure that intervention and control sites are as similar as possible, attempts will also be made to match each intervention site to a comparable control site based on academic affiliation (yes/no), VHA-defined hospital complexity, urologic procedural volume, antimicrobial stewardship resources, and location (rural versus urban).
~Feedback will not be provided to the control sites."
16368816|NCT04196751|Experimental|Clinical Supervision Intervention|All the enrolled participants will be undergoing Clinical Supervision sessions with their selected supervisors for pre-identified objectives for their skill and knowledge development.
16368817|NCT04196738|Experimental|Dual Mode first|Four consecutive steps (45 min per step) in the following order: APRV (A), Dual Mode (B) , APRV (A) and VAC (C). (ABAC)
16368818|NCT04196738|Experimental|VAC fist|Four consecutive steps (45 min per step) in the following order: APRV (A), VAC (C) , APRV (A) and Dual Mode (B). (ACAB)
16368819|NCT04196725|Experimental|Physical therapy treatment|
16368820|NCT04196725|Experimental|Lifestyle treatment|
16368821|NCT04196725|No Intervention|Control|Parallel control group, not undertaking any treatment and not part of the cross-over design
16368822|NCT04196712||Coronary angiography arm|Patient undergoing invasive coronary angiography
16368823|NCT04196686|No Intervention|Control|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors without the use of VR/AR
16368824|NCT04196686|Experimental|Sensory perception with VR/AR|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors the use of VR/AR
16368825|NCT04196686|Active Comparator|Sensory perception with Active VR/AR|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors using active VR/AR where they engage by playing a game
16368826|NCT04196686|Active Comparator|Sensory perception with Passive VR/AR|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors using VR/AR where they will passively watch a movie
16368827|NCT04196686|Experimental|Ice bath Control|250 participants will place hand in ice bath captured without the use of VR/AR and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
16368828|NCT04196686|Experimental|Ice bath with VR/AR|250 participants will place hand in ice bath captured with the use of VR/AR and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
16368829|NCT04196686|Experimental|Ice bath with with Active VR/AR|250 participants will place hand in ice bath while using active VR/AR where they will engage by playing a game and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
16368830|NCT04196686|Experimental|Ice bath with with Passive VR/AR|250 participants will place hand in ice bath while using VR/AR where they will passively watch a movie keep and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
16368831|NCT04196673|Experimental|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
16368832|NCT04196673|Experimental|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
16368833|NCT04196660|Experimental|The Dance Practitioner Spouse/Partner Group|The Dance Practitioner Spouse/Partner Group (DPSG)
16368834|NCT04196660|Experimental|The Dance Practitioner Midwife Group|The Dance Practitioner Midwife Group (DPMG) included 40 pregnant women and midwives who had received labor dance training
16368835|NCT04196660|No Intervention|The Control Group|The Control Group included 80 pregnant women who were subjected to routine treatment without dance
16368836|NCT04196634||People on sick leave|People on sick leave due to musculoskeletal conditions for at least 4 weeks.
16368837|NCT04196621|Active Comparator|High viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, high viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
16368838|NCT04196621|Active Comparator|Low viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, low viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
16368839|NCT04196608||P. aeruginosa isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
16368840|NCT04196608||Enterobacterales isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
16368841|NCT04196582|Active Comparator|Gastro-laryngeal tube Group (Group G)|Patients wear Gastro-laryngeal tube after receiving general anesthesia for biliopancreatic procedures
16368842|NCT04196582|Active Comparator|LMA Gastro Airway Group (Group L)|Patients wear LMA Gastro Airway® after receiving general anesthesia for biliopancreatic procedures
16368908|NCT04196023|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
16368939|NCT04195724|Experimental|Patients with decompensated ascites and receiving TIPS|Patients with decompensated ascites and receiving TIPS will be enrolled. In this study, diagnostic paracentesis will be performed to get the ascites sample before the patients receiving TIPS. Next, the blood sample from superior mesenteric vein and hepatic vein will be collected under the procedure of TIPS.
16368940|NCT04195711||blinq screened|Patients screened by new birefringent screener
16368844|NCT04196556|Experimental|Active Families|Usual care plus intervention active families. This intervention, based on the methodology of meaningful learning, will have two components: group education directed to parents (caregivers) and education directed to children in the reviews in consultation. The group intervention will consist of 6 sessions, with a biweekly / monthly frequency, will be taught as determined in the program monitoring annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
16368845|NCT04196556|Active Comparator|Control group|"Usual care:
~The activities included in the Service for Attention to Patients with Childhood Obesity will be carried out in the Cartera de Servicios Estandarizados de Atención Primaria de Madrid, which establishes a monthly follow-up in the first 6 months and bimonthly of month 6 to 12. To this At least the child and the primary caregiver, the child's educational agent, will be consulted and will receive support documentation to exercise and reinforce their role."
16368846|NCT04196543|Experimental|écho-doppler with ultrasonar Sonovue® injection|
16368847|NCT04196530|Experimental|Dose Escalation of BDB001 with atezolizumab|"This part of the study will follow a traditional 3+3 dose escalation design.
~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of BDB001 with atezolizumab is reached."
16368848|NCT04196530|Experimental|Dose Expansion of BDB001 with atezolizumab|"At the end of the dose escalation part of the study, the BDB001 dose to be used in combination with atezolizumab in the expansion part of the study will be established after thorough review of all available safety, preliminary efficacy, PK and PD data.
~A biologically active dose will be selected that is either the MTD, if one was established in the escalation part, or an RP2D if no MTD was established. Approximately 20 additional subjects will initially be enrolled in the dose expansion part."
16368849|NCT04196517|Experimental|Arm 1 - PALS|The Patient Activated Learning System (Palsforhealth.com)
16368850|NCT04196517|Experimental|Arm 2 - WebMD|WebMD.com
16368851|NCT04196491|Experimental|Dose Escalation|"bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10^6 CAR+ T cells.
~Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later"
16368852|NCT04196465|Experimental|Neoadjuvant IMC-001|Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma
16368853|NCT04196452||Arm A: participants 12 to under 18|
16368854|NCT04196452||Arm B: participants under 12|
16368855|NCT04196439|Active Comparator|continuous epidural analgesia|continuous lumbar epidural catheter inserted preoperatively before induction of general anaesthesia
16368856|NCT04196439|Active Comparator|continuous supra-inguinal fascia iliaca compartment block|ultrasound guided supra-inguinal FICB with insertion of catheter for continuous infusion before induction of general anaesthesia.
16368857|NCT04196426|Experimental|nutrition education group|The nutrition education group receive the intervention first, which include 2 nutrition lessons about osteoporosis and calcium and calcium rich foods. The 2 lessons are delivered in one week for 2 hours each lesson. After this week, participants in the intervention group receive handouts about osteoporosis and calcium once a week for a period of 4 weeks.
16368858|NCT04196426|Active Comparator|delayed nutrition education group|After the intervention group finish their intervention (5 weeks period), post data collection will be administered in both nutrition education and delayed nutrition education group. After this post data collection, the delayed nutrition education group receive the same intervention.
16368859|NCT04196413|Experimental|GD2-CAR T|"Dose escalation in subjects with DIPG:
~A standard 3+3 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG, starting with Dose
~Level 1:
~Dose Level 1: 1x10^6 CAR+ T cells/kg body weight (+/- 20%)
~Dose Level 2: 3x10^6 CAR+ T cells/kg body weight (+/- 20%)
~Dose Level 3: 10x10^6 CAR+ T cells/kg body weight (+/- 20%)
~Dose Level -1 will be explored if the first subject treated experiences dose limiting toxicity (DLT) or if >2 of 6 subjects treated at Dose Level 1 experiences DLT.
~Dose expansion in subjects with DIPG and spinal DMG: Once the MTD or RP2D is determined, up to 20 evaluable subjects with H3K27M-mutant DIPG and 10 evaluable subjects with H3K27M-mutant spinal DMG will be treated at the RP2D (including subjects treated during dose escalation)."
16368860|NCT04196400|Active Comparator|Steroid injection|Steroid (betamethasone) 2 ml is injected subcutaneously after finishing the operation at the repair site.
16368861|NCT04196400|No Intervention|Control Group|
16368862|NCT04196361||Ventilated72h|Patient that were ventilated for at least 72 hours
16368863|NCT04196348|Active Comparator|Short BPL RYGB in glucose-tolerant participants|Procedure: short biliopancreatic limb (BPL) Roux en Y Gastric Bypass (RYGB) Obese patients without type 2 diabetes mellitus (T2DM) to be submitted to short BPL (n=10)
16368864|NCT04196348|Active Comparator|Long BPL RYGB in glucose-tolerant participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome without T2DM to be submitted to long BPL (n=10)
16368865|NCT04196348|Active Comparator|Long BPL RYGB in diabetic participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome and T2DM to be submitted to long BPL (n=10)
16368866|NCT04196335|Experimental|single-arm|
16368867|NCT04196322||Controlled|
16368868|NCT04196322||Uncontrolled|
16368869|NCT04196309|Experimental|Tinzaparin group|LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)
16368870|NCT04196309|No Intervention|Control group|No intervention
16368871|NCT04196296|Active Comparator|Psychoeducation|
16368872|NCT04196296|Experimental|Psychoeducation plus Motivation Enhancement|
16368873|NCT04196283|Experimental|Arm 1: ABBV-368 + Tilsotolimod|Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.
16368874|NCT04196283|Experimental|Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel|Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.
16370969|NCT04181749|Active Comparator|Aspirin and Atorvastatin|Patients prescribed aspirin and atorvastatin
16368876|NCT04196270|Experimental|Ropivacaine|This double-blind dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anesthetic administered to each patient depends on the response from the previous one. The TQL block is performed preoperatively, and the first patient recruited receives 20 mL of ropivacaine 0.75%. In case of block failure, the next patient will receive a higher volume (defined as the previous volume with an increment of 2 mL). Given a successful block for the first patient, the next patient will be randomized to either a lower volume (defined as the previous volume with a reduction of 2 mL) or the same volume as the previous patient. The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume. Block success is defined as patient reported numeric rated scale (NRS) pain (NRS value ≤ 3 (0-10/10)), 30 minutes after arrival in the post anesthesia care unit (PACU).
16368877|NCT04196257|Experimental|BP1001-A monotherapy|Dose escalation of BP1001-A monotherapy
16368878|NCT04196257|Experimental|BP1001-A and Paclitaxel|Dose expansion of selected dose of BP1001-A with paclitaxel
16368879|NCT04196244|Experimental|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
16368880|NCT04196244|Active Comparator|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
16368881|NCT04196231|Active Comparator|FR insulin/GLP-1RA|Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
16368882|NCT04196231|Active Comparator|Insulin/SGLT-2i|Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
16368883|NCT04196231|Active Comparator|Basal Bolus|Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
16368884|NCT04196218|Other|Driving assessment|All subjects will undergo a driving assessment(s) following shoulder surgery.
16368885|NCT04196205|Experimental|Anti-CD19 CAR-T|Anti-CD19 CAR-T
16368886|NCT04196192||Group 1|All infants aged 0-90 days (inclusive) undergoing routine assessments for fever without source.
16368887|NCT04196179|Experimental|SAD|"A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral
~A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral
~A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral
~Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral
~A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral
~A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral
~D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg *with and without food* (n=6)/ Placebo (n=2) Oral"
16368888|NCT04196179|Experimental|MAD|"B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)
~B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)
~B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)
~B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)
~C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)
~C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)"
16368889|NCT04196166||Cases|nested from on going retrospective cohort study. Participants who had change in their surgical plan after hospitalization.
16368890|NCT04196166||Controls|nested from on going retrospective cohort study. Participants who didn't have change in their surgical plan after hospitalization.
16368891|NCT04196153|Active Comparator|Neuronavigation / O-arm group|Under neural navigation with the use of intraoperative three dimensional imaging quality O-arm , pedicle screws inserted at the thoraolumbar/lumbar spine after insertion of the reference frame at the spinous process above or below the level of instrumentation followed by O-Arm imaging and uploading the images to the stelth navigation system and pedicle tract identification using instrumented tools guided by the Navigation polyaxial screws is inserted.
16368892|NCT04196153|Active Comparator|Cervical distractor screws group|pedicle screws inserted using marker screws after posterior exposure of thoracolumbar /lumbar spine by either open midline posterior exposure or minimal invasive posterior wiltse style exposure with expandable tubular retractor, anatomical landmark for insertion of pedical screws identified and followed by inserting of a cervical distraction screw size 3 / 12 mm as a stable marker using high speed drill. C-arm floro is used to take antroposterior and lateral view to confirm the position of the marker screws at this stage.free hand technique supported by the images provided to cannulate the pedicle with the use of information on the images taken for all the marker screws simultaneously.
16368893|NCT04196140|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
16368894|NCT04196127||TTH|Patients with tension-type headache. They may not experience migraine, but can experience neck pain and/or temporomandibular dysfunction.
16368895|NCT04196127||Healthy controls|Participants without frequent headaches. They may experience neck pain and/or temporomandibular dysfunction.
16368896|NCT04196114|Experimental|All patients|All patients implanted.
16368897|NCT04196101|Experimental|EDP-938|Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days
16368898|NCT04196101|Placebo Comparator|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days
16368899|NCT04196088|Active Comparator|Ultivision AI Software enhanced screening colonoscopy|Ultivision Artificial Intelligence enhanced screening colonoscopies will be performed.
16368900|NCT04196088|Placebo Comparator|No AI enhancement screening colonoscopy|Screening colonoscopies without Artificial Intelligence enhancement will be performed.
16368901|NCT04196075|Experimental|Andrographis Paniculata treatment|Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard
16368902|NCT04196062|Experimental|Robotic ESD|Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system
16368903|NCT04196036|Active Comparator|Day 3 vitrification|Day of vitrification of supernumerary embryos is day 3
16368904|NCT04196036|Active Comparator|Day 5 vitrification|Day of vitrification of supernumerary embryos is day5
16368905|NCT04196023|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
16368906|NCT04196023|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
16368907|NCT04196023|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
16371006|NCT04181502|Experimental|Inflation of a pneumatic tourniquet|
16368909|NCT04196010|Experimental|Treatment (CI-CLAM, G-CSF)|Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
16368910|NCT04195997|Experimental|bivalurudin|Bivalirudin will be given as a bolus of 0.75 mg/kg once transseptal puncture is successully performed with no pericardial effusion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
16368911|NCT04195997|Active Comparator|heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
16368912|NCT04195984|Experimental|Treatment|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
16368913|NCT04195971|Experimental|Liver CT with dual arterial phase|
16368914|NCT04195958|Experimental|Omalizumab|
16368915|NCT04195945|Experimental|Arm I (CPX-351)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of CPX-351 intravenously IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
~POST-REMISSION: Patients who achieve a CR/CRi receive a reduced dose of CPX-351 IV over 90 minutes on days 1, 3, and 5 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
16368916|NCT04195945|Experimental|Arm II (CLAG-M)|"INDUCTION: Patients receive cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity.
~POST-REMISSION: Patients who achieve a CR/CRi receive an intermediate dose of cytarabine IV over 2 hours on days 1-6 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
16368917|NCT04195932|Experimental|Exercise|6 moths of supervised moderate intensity aerobic and resistive exercise training
16368918|NCT04195919|Experimental|Group1|Hemodialysis patients(MDRD-eGFR ≤ 15 mL/min/1.73m2)
16368919|NCT04195919|Experimental|Group2|Healthy control(MDRD-eGFR ≥ 90 mL/min/1.73m2)
16368920|NCT04195906|Experimental|SNF472 (Double-Blind Period)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
16368921|NCT04195906|Placebo Comparator|Placebo (Double-Blind Period)|Matching placebo (saline) diluted in 100 mL physiological saline.
16368922|NCT04195906|Experimental|SNF472 (Open-Label)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
16368923|NCT04195893|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to etafilcon A daily disposable lenses for one week.
16368924|NCT04195893|Active Comparator|etafilcon A|Subjects will be randomized to wear etafilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
16368925|NCT04195880|Experimental|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
16368926|NCT04195880|No Intervention|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
16368927|NCT04195867|Experimental|Salmeterol|Subjects receive a 3-day treatment and collect urine from 2 days before first administration to 24 hours post-administration.
16368928|NCT04195841|Experimental|Test group|Two horizontal incisions placed 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles.
16368929|NCT04195841|Experimental|Control group|Sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth
16368930|NCT04195828|Experimental|Camrelizumab + Apatinib + nab-paclitaxel +S-1|Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
16368931|NCT04195828|Active Comparator|nab-paclitaxel +S-1|nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
16368932|NCT04195789||Sample population|Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
16368933|NCT04195776|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
16368934|NCT04195763||Participants with Pediatric-onset HPP|Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.
16368937|NCT04195737|Experimental|Root coverage with ossix volumax collagen matrix|Evaluation of root coverage achieved by collagen matrix in conjunction with coronally advanced flap in patients with multiple gingival recession.
16368941|NCT04195698|Experimental|Upadacitinib|Participants will be administered with upadacitinib once daily (QD)
16368942|NCT04195685|Experimental|NFB Intervention and Delayed Intervention|The NFB system will read and interpret a participant's brain wave pattern which will be instantaneously fed back to the participant providing information, to which a participant can respond accordingly. The NFB specialist assumes a coaching role with people training on the NFB special use system to assist in the achievement of a focused relaxed state, which enhances the overall brain functioning. The significance and unique aspect of NFB is the direct impact on physiological dysregulation, which is the basis of this treatment approach. Twenty, one-hour, NFB training sessions will be provided to each participant in the intervention group and Delayed intervention group (those participants who completed the Control Group activities) by a trained NFB specialist over an 8-10-week period. Participants in the intervention group will receive up to 5-sessions but usually 3 sessions a week
16368943|NCT04195685|No Intervention|Control Group|Participants in the control group will continue with their usual treatment and will receive a 15-minute call once a week for eight weeks from the PI on a health topic. This will help to keep members of the control group engaged in the project and receive the same information that is offered to the intervention group members. The health topics that are generally discussed during NFB sessions include sleep hygiene, basic nutritional concepts, beverage choices, positive thinking, thought reframing, fitness, daily calming activity, and enhancement of focus strategies.
16368944|NCT04195672||Children under 3 years-old intubated/sedated in intensive care|NIPE and CBS ware measured for each included patient
16368945|NCT04195659||Top Surgery|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, and who are undergoing mastectomy and chest masculinization in one of three plastic surgery practices in Chicago.
16368946|NCT04195659||Control|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, were seen in a gender development clinic in Chicago, and who are not planning to undergo top surgery. Controls will be matched with top surgery patients on age and number of months of testosterone.
16368947|NCT04195646|Experimental|EndoVigilant CAD Software assisted Colonoscopy Procedure|The gastroenterologist performing the colonoscopy procedure will be able to observe a standard colonoscopy video on the primary monitor and video augmented by EndoVigilant CAD software on the second monitor. The gastroenterologist will primarily rely on the second monitor but the standard procedure monitor will be always operational and available for maneuvers such as fast insertion, polypectomy etc.
16368948|NCT04195633|Experimental|Arm A (high dose treosulfan)|Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is > 1,000/uL for 3 consecutive days.
16368949|NCT04195633|Experimental|Arm B (low dose treosulfan)|Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.
16368950|NCT04195620|Experimental|Low loneliness, low self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
16368951|NCT04195620|Experimental|Low loneliness, high self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
16368952|NCT04195620|Experimental|high loneliness, low self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
16368953|NCT04195620|Experimental|high loneliness, high self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
16368954|NCT04195594|Experimental|Nic's Keto Diet|
16368955|NCT04195581|Experimental|comfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
16368956|NCT04195581|Experimental|comfilcon A with All in One Light Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
16368957|NCT04195581|Experimental|comfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
16368958|NCT04195581|Active Comparator|fanfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
16368959|NCT04195581|Active Comparator|fanfilcon A with All in One Light multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
16368960|NCT04195581|Active Comparator|fanfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
16368961|NCT04195568|Experimental|Surpass Evolve Flow Diverter System|This is a prospective single arm study in which all subjects who present for flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment (Surpass Evolve Flow Diverter).
16368965|NCT04195516|Experimental|Health Promotion Group|Experimental group will be applied Health Promotion Model Basic Health Promotion Program. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.
16368966|NCT04195516|No Intervention|Control Group|The control group will be given educational brochures to develop healthy eating and physical activity behaviors.
16368967|NCT04195503|Other|liver transplantation|Surgical Intervention - Liver transplantation
16368968|NCT04195490|Other|children with disorders of sex development|children with disorders of sex development needing feminizing genitoplasty
16368969|NCT04195477|Experimental|vDPP|Participants will take part in a 4 week study to develop the program.
16368970|NCT04195464|Experimental|DN|
16368971|NCT04195464|Sham Comparator|Sham-DN|
16368972|NCT04195464|No Intervention|Control|
16368973|NCT04195451|Experimental|Live Video-Supervised Exercise Intervention Arm|Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
16368974|NCT04195451|Experimental|Live-Video-Supervised Exercise Control Arm|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
16368975|NCT04195438|Other|Intervention Arm|CO and ABG Testing Arm
16368976|NCT04195412|Experimental|tDCS|Bihemispheric tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After stimulation, individual and intensive upper limb rehabilitation will be performed.
16368977|NCT04195412|Sham Comparator|Control|Bihemispheric sham tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After sham stimulation, individual and intensive upper limb rehabilitation will be performed.
16368979|NCT04195386|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
16368980|NCT04195386|Active Comparator|Resin-Modified Glass ionomer Cement|Single placement of Resin-Modified Glass ionomer Cement on atypical cavities.
16368981|NCT04195373|Experimental|TMV-018 + 5-FC|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
16368982|NCT04195373|Experimental|TMV-018 + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
16368983|NCT04195373|Experimental|TMV-018 + 5-FC + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
16368984|NCT04195360||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
16368985|NCT04195360||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
16368986|NCT04195347|Experimental|CM4620 Treatment|"Phase I:
~Cohort 1 patients receive CM4620 IV at dose level 1 on days 1-4. Cohort 2 patients receive CM4620 IV at dose level 2 on days 1-4. Cohort 3 patients receive CM4620 IV at either dose level 1 or 2 on days 1-4
~Phase II:
~Patients will receive CM4620 IV on days 1-4 at the recommended Phase II dose (RP2D) as determined in Phase I."
16368987|NCT04195334|Experimental|IMN and union|putting an intramedullary nail in femoral shaft fractures and finding a relation between the nail diameter to femoral canal diameter and how this will affect healing or predict union
16368988|NCT04195321|Active Comparator|norepinephrine group|patients will receive NE infusion at a starting of rate of 1 ml/min of 8 mcg/ml solution (prepared by diluting 4 mg NE in 500 ml normal)
16368989|NCT04195321|Active Comparator|phenylephrine|patients will receive PE infusion at a starting rate of 1 ml/min of 100 mcg/ml solution (prepared by diluting 10 mg of PE in 100 ml normal saline)
16368990|NCT04195308|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
16368991|NCT04195308|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
16368992|NCT04195295|Experimental|periosteal membrane and egg shell graft|Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material and periosteal pedicle as barrier membrane.
16368993|NCT04195295|Experimental|only egg shell graft|Only Egg shell derived nano hydroxyapatite (EnHA) as graft material.
16368994|NCT04195295|Active Comparator|open flap debridement|open flap debridement procedure only.
16368995|NCT04195282|Active Comparator|Plasma exchange group|10 patients will receive conventional treatment plus plasma exchange
16368996|NCT04195282|Experimental|RL-1 Novel Human-derived Bio-artificial Liver treatment group|10 patients will receive conventional treatment plus RL-1 Novel Human-derived Bio-artificial Liver treatment
16368997|NCT04195269|Experimental|Pure Green Sublingual Tablet - Daily|Subjects will take 2 tablets daily, one in the morning and one in the evening, and are able to take up to 2 additional tablets per day as needed for pain.
16368998|NCT04195256|Experimental|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
16369033|NCT04195048||Control patients with acute ischemic stroke without cancer|Eighty patients with acute ischemic stroke without cancer
16369445|NCT04192019|Experimental|Micro-dose glucagon|80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
16368999|NCT04195256|Experimental|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
16369000|NCT04195256|Experimental|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
16369001|NCT04195256|Active Comparator|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
16369002|NCT04195243|Experimental|Dapagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
~Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal"
16369003|NCT04195243|Experimental|Empagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
~Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal"
16369004|NCT04195243|Placebo Comparator|Placebo|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
~Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal"
16369005|NCT04195230|Experimental|Computerized Cognitive Training (Breakfast Game)|"Participants will undergo a pilot training protocol where they will have to perform two tasks concomitantly, in a multi-tasking fashion. The tasks are related to everyday activities as cooking and setting tables."
16369006|NCT04195217|Active Comparator|With art therapy|Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care
16369007|NCT04195217|No Intervention|Without art therapy|6 consecutive sessions of cancer treatments without art therapy with other supportive care added.
16369008|NCT04195204|Experimental|Tropisetron|Patients allocated to this arm will receive intravenous Tropisetron (5mg) before anesthesia induction and once daily for 7 days after surgery.
16369009|NCT04195204|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of normal saline before anesthesia and once daily for 7 days after surgery.
16369010|NCT04195191|Placebo Comparator|Placebo|The usual practice by community pharmacies
16369011|NCT04195191|Experimental|ANM|This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.
16369012|NCT04195178||Anesthesia Providers|Clinically active anesthesia providers
16369013|NCT04195165|Experimental|SIT|Subject will be asked to take <3,000 steps for two intervention days prior to an oral glucose tolerance test on the third day.
16369014|NCT04195165|Experimental|SIT+EX|Subject will be asked to take <3,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
16369015|NCT04195165|Experimental|ACTIVE+EX|Subject will be asked to take >10,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
16369016|NCT04195152||Difficult intubation group|An intubation is called difficult if a normally trained anesthesiologist needs more than 3 attempts or more than 10 min for a successful endotracheal intubation.
16369017|NCT04195152||Non difficult intubation group|An intubation is called non difficult if a normally trained anesthesiologist needs only one attempt for a successful endotracheal intubation.
16369018|NCT04195139|Experimental|Nivolumab and Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment
16369019|NCT04195139|Active Comparator|Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment
16369020|NCT04195126|No Intervention|Control group|Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
16369021|NCT04195126|Active Comparator|Treatment group|Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
16369022|NCT04195113||Direct Oral Anticoagulants (DOACs)|In this study, DOACs include apixaban, dabigatran, edoxaban and/or rivaroxaban.
16369023|NCT04195113||Vitamin K Antagonist (VKA)|In this study, the VKA is warfarin.
16369024|NCT04195100|Active Comparator|Low dose pilocarpine|low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
16369025|NCT04195100|Active Comparator|High dose pilocarpine|high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
16369026|NCT04195087||Non-hypotension|Patients with a mean arterial pressure reduction of less than 20% and/or systolic arterial pressure above 80 mmHg after spinal anesthesia.
16369027|NCT04195087||Hypotension|Patients with a 20% reduction in mean arterial pressure and/or systolic arterial pressure below 80 mmHg after spinal anesthesia.
16369028|NCT04195074|Experimental|ETV group|100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
16369029|NCT04195074|Experimental|TDF group|100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
16369030|NCT04195074|Experimental|TAF group|100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
16369031|NCT04195061|Other|Cardiopulmonary exercise testing|
16369034|NCT04195035|Experimental|Air-Q intubating laryngeal airway mask|"Where Air-Q intubating laryngeal airway will be used for ventilation & intubation through fiberoptic bronchoscope.
~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Air-Q will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2were recorded 5 minutes after device insertion.
~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
16369035|NCT04195035|Experimental|Ambu-Aura intubating laryngeal mask|"Ambu-Aura intubating laryngeal mask will be used for ventilation & intubation through fiberoptic bronchscope.
~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Ambu-Aura laryngeal mask will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2 will be recorded 5 minutes after device insertion.
~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
16369036|NCT04195022|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
16369037|NCT04195022|Active Comparator|Bulk fill resin composite|Single placement of Bulk fill resin composite on atypical cavities.
16369038|NCT04194996||Operative|"Inclusion criteria:
~≥18 years old at time of treatment
~Diagnosis of cervical deformity- must meet one or more of the following criteria:
~C2-C7 sagittal kyphosis (Cobb > 15o)
~T1S-CL > 35o
~Segmental cervical kyphosis > 10o between any 2 vertebra between C2-T1 or > 15o across any 3 vertebra between C2-T1
~Cervical scoliosis > 10o (Cobb angle must include end vertebra within the cervical spine)
~C2-C7 SVA > 4cm
~McGregor's slope > 20 degrees or CBVA > 25 degrees
~Plan for surgical correction of cervical deformity in the next 6 months"
16369039|NCT04194983|Experimental|Fish oils and dairy fats|
16369040|NCT04194983|Placebo Comparator|Fish oils and plant fats|
16369041|NCT04194970|Experimental|Group I (monitoring with live-feedback system)|MarWAS is a product that can monitor the pressure under the foot and provide live feedback (if this option activated) to the user in case of exceeding the specified limits. Its components are insole with pressure sensors and mobile applications (IOS, Android). Post-operative patients (osteochondral lesion of the talus) will be monitored with the MarWAS product in case live feedback is turned on. We aimed to ensure the compliance of patients to specified weight bearing limits. We will follow up this grup for 6 weeks periods with MarWAS. Pre-op. and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. Also we will monitor the compliance success of patients with MarWAS during 6 week. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate.
16369042|NCT04194970|Active Comparator|Group II (monitoring without live feedback)|"The post-operative patients (osteochondral lesion of talus), follow-up with product in live-feedback closed condition.
~After surgery, we will educate the patients about weight bearing protocol on post-op first day and post op 3 week. The protocol is  first 3 weeks, %0 body weight bearing (BWB), second 3 weeks between %10-%20 BWB. Patients' compliance to BWB protocol will be monitored daily with the MarWAS product in case live-feedback is turned off. Pre-op and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate."
16369043|NCT04194957|Experimental|Wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
16369044|NCT04194957|Experimental|heterozygous carrier of c.1236G>A or c.2846A>T DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for c.1236G>A or c.2846A>T of these SNPs
16369045|NCT04194957|Experimental|Homozygous or compound heterozygous carrier of DPYD variants|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be homozygous or compound heterozygous for these SNPs
16369049|NCT04194931|Experimental|Mixed BCMA/CD19 CAR-T Transfer|Subjects with BCMA/CD19+ multiple myeloma will be infused with CD19-targeting CAR T Cells and BCMA-targeting CAR T Cells in one time or in parts
16369050|NCT04194918|Experimental|Prevention (Flexiquit+, text message, handout)|Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
16369051|NCT04194905|Experimental|Levonorgestrel Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
16369052|NCT04194905|Active Comparator|Levonorgestrel Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
16369053|NCT04194892|Experimental|Pegilodecakin Vial|Pegilodecakin administered subcutaneously (SQ) in one of two study periods.
16369054|NCT04194892|Experimental|Pegilodecakin Pre-filled syringe (PFS)|Pegilodecakin administered SQ in one of two study periods.
16369055|NCT04194879||Cancer|Case subjects (at least 50) will be men and women age 40-74 who are recently diagnosed, through colonoscopy, with different stages of colorectal cancer and have not yet had surgical intervention.
16369056|NCT04194879||Negative|Approximately 250 prospectively enrolled subjects will be men and women age 40-74 who are at average risk of developing colorectal cancer and eligible for colonoscopy. About 150 Control subjects will be enrolled prospectively, who have no colorectal neoplasia detected on colonoscopy, including cancer, advanced adenoma, sessile serrated lesions and small, non-advanced adenoma.
16369057|NCT04194866|Other|Day group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group ( 8:00-12:00)
16369058|NCT04194866|Other|Night group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
16369059|NCT04194853|Experimental|EMG Biofeedback assisted Quadriceps exercises.|Hot Pack will be applied before session for general relaxation for 10 minutes. Knee isometric exercises will be performed via an EMG Biofeedback device; patients in the EMG BF group will receive visual and auditory feedback.Knee isometrics will be performed with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets) Session will be performed thrice a week for six weeks.
16369060|NCT04194853|Active Comparator|Quadriceps exercises without EMG Biofeedback|Hot Pack will be applied before session for general relaxation 10 minutes. In the control group, the active electrode will not be connected, so subjects will not receive any feedback from the device. Knee isometrics perform with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets)Session will be performed thrice a week for six weeks.
16369061|NCT04194840|Experimental|Transplant Wellness Clinic|"Physical therapy consult
~Intake vitals
~CARG online survey, mental status exam
~Medication review
~Nutrition survey
~Social work: available on prn basis (as-needed)
~Exit survey
~Recommendations made and given to the participant and sent to the referring MD. Participant receives post clinic phone call before transplant. Referring MD receives questionnaires. Data collected depending on if participant moved forward with transplant"
16369062|NCT04194827|Experimental|Concentration guided dose reducion|Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
16369063|NCT04194827|Active Comparator|Disease activity quided dose reduction|Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
16369064|NCT04194814|Other|crisaborole and topical Corticosteroid|"crisaborole (2%) ointment on the other forearm, twice daily application for 4 weeks (randomised site allocation)
~betamethasone valerate (0.1%) cream on one forearm, twice daily application for 4 weeks (randomised site allocation)"
16369065|NCT04194801|Experimental|Fisogatinib in combination with CS1001|
16369066|NCT04194775|Experimental|CS1003|
16369067|NCT04194775|Placebo Comparator|CS1003 placebo|
16369068|NCT04194762|Experimental|treadmill training|Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
16369069|NCT04194762|Active Comparator|Cycling|Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
16369070|NCT04194749|Experimental|Digital Media Therapy|The digital media based group will receive a modified post immobilization protocol. This will include giving the patients a Universal Serial Bus (USB) drive loaded with a 12 week physical therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health & Science University website.
16369071|NCT04194749|Active Comparator|Traditional Therapy|The traditional group will have clinic-based physical therapy protocol.
16369072|NCT04194736|Experimental|Children|Minor patients hospitalized in pediatric intensive care unit having a percutaneous central venous catheter.
16369073|NCT04194723|Experimental|Antireflux Mucosectomy|Antireflux mucosectomy targeted at resection of gastric cardia muocsa to induce fibrosis and improve on the flap value over the gastroesophageal junction
16369074|NCT04194710|Active Comparator|Arthroscopic Resection|43 patients will be assigned to this arm. This is the standard technique to treat lateral epicondylitis. After randomization, patients will be informed and the surgery will be scheduled.
16369075|NCT04194710|Experimental|Cytokine rich serum injection|43 patients will be assigned to this arm. After randomization, patients will be informed and the first injection of serum rich cytokines will be scheduled. After 15 days, they will be injected again with serum rich cytokines.
16369076|NCT04194697|Experimental|Exercise group|Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.
16369077|NCT04194697|Other|Non-exercise group|Participants will not change the amount of activity or exercise in daily life from before the study.
16369078|NCT04194684|Experimental|Assigned Interventions|Nab-paclitaxel
16369081|NCT04194658|Active Comparator|Case group|Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
16369082|NCT04194658|No Intervention|Control group|Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
16369083|NCT04194645|Experimental|BI 474121|
16369084|NCT04194645|Placebo Comparator|Placebo|
16369085|NCT04194632|Experimental|Single Arm|All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.
16369086|NCT04194606|Active Comparator|Forearm radial access|Patients who undergo coronary angiography or intervention by forearm radial artery access
16369087|NCT04194606|Experimental|Distal radial access|Patients who undergo coronary angiography or intervention by accessing the distal radial artery in the area of the anatomical snuff-box
16369088|NCT04194593||Glioma|FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)
16369089|NCT04194580|Experimental|Physical activity|In the program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors
16369090|NCT04194580|No Intervention|Physical activity control|This group will not participate in the intervention
16369091|NCT04194567|Experimental|Black Ragi|During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
16369092|NCT04194567|Experimental|White Ragi|During the second week of the study, participants are to consume pancakes made from the white variety of ragi
16369093|NCT04194554|Experimental|Niraparid Dose Escalation|"Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT
~Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT
~Dose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles."
16369094|NCT04194541|Experimental|Treatment Group|Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.
16369095|NCT04194528|Experimental|Oxycodone/acetaminophen (5/325 mg) DMP|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
16369096|NCT04194515||YH1 group|
16369097|NCT04194515||Metformin group|
16369098|NCT04194502|Other|Pre-operative and intra-operative TEE|All patients enrolled in the study will undergo a pre-op research TEE and a intra-op clinical transesophageal echo.
16369099|NCT04194489|Experimental|FMF Connect Intervention|
16369100|NCT04194463|Experimental|ChemoFit exercise prehabilitation intervention|Exercise intervention consisting of walking and increasing daily step count. This is monitored by wearing a pedometer device. Other part of intervention are 5 simple strengthening exercises.
16369101|NCT04194450|Experimental|Ketone monoester|Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 ml/kg body weight)
16369102|NCT04194450|Placebo Comparator|Placebo|Acute dose of flavour-matched placebo.
16369103|NCT04194437|Experimental|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
16369104|NCT04194424|Experimental|Multidisciplinary program|Multidisciplinary weight loss program
16369105|NCT04194424|Other|Control|Standard care
16369106|NCT04194411||Valve surgery|Patients older than 65 years and undergoing elective valvular heart surgery
16369107|NCT04194398||OCS Expand Trial Cohort|All patients previously enrolled in the EXPAND Lung trial.
16369108|NCT04194385|Active Comparator|Upper trunk block|In the supraclavicular region, UTB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
16369109|NCT04194385|Active Comparator|Costoclavicular brachial plexus block|In the infraclavicular region, CCBPB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
16369110|NCT04194372||Metabolic Patient|"Patients with a metabolic desease, defined as
~Metabolic Syndrom
~Diabetic
~Obese"
16369111|NCT04194359|Experimental|Sintilimab + XELOX + Bevacizumab|Sintilimab + XELOX + Bevacizumab
16369112|NCT04194359|Active Comparator|XELOX + Bevacizumab|XELOX + Bevacizumab
16369113|NCT04194346|Experimental|Determination of local pleural strain|The average Von Mises coefficient will be calculated for each recorded ultrasound loop using a non-invasive vascular elastography platform.
16369114|NCT04194333||Standard Fluoroscopy Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and standard fluoroscopy using the C-arm under general anesthesia.
16369115|NCT04194333||Cone Beam CT Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
16369116|NCT04194320|Placebo Comparator|"Group I Placebo"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 ml 0.9% normal saline.
16369117|NCT04194320|Active Comparator|"Group II Nalbuphine "|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 10 mg nalbuphine hydrochloride (completed to 2 ml with 0.9% normal saline).
16369118|NCT04194320|Active Comparator|"Group III Dexamethasone"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 mL dexamethasone 0.4% (8 mg).
16369119|NCT04194294|Active Comparator|Liocaine|Group Lid
16369120|NCT04194294|Active Comparator|Na CL 0.9%|group C
16369121|NCT04194281|Experimental|Action Observation Therapy [AOT]|
16369122|NCT04194268|Experimental|Interventional arm|Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks
16369123|NCT04194255|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
16369124|NCT04194255|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
16369125|NCT04194255|Experimental|ferrous fumarate + 15 g FOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g FOS
16369126|NCT04194255|Experimental|ferrous fumarate + 15 g acacia gum|labelled iron as ferrous fumarate + prebiotics in the form of 15 g acacia gum
16369193|NCT04193748|Active Comparator|Control group|Topical triamcinolone acetonide 0.1% available commercially (Kenacort- in orabase) has been used. Topical corticosteroid treatment has be repeated four times per day for four weeks.
16369127|NCT04194242|Experimental|HEC96719 tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240 mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
16369128|NCT04194242|Placebo Comparator|placebo tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
16369129|NCT04194229||Group 1|Patients that receive Cytoflavin® medication i/v drop infusion at a dose of 10 ml of solution for injection per 200 ml of 0.9 % sodium chloride solution for 10 days in addition to a set of neurorehabilitation activities
16369130|NCT04194229||Group 2|Patients that subjected to the standard set of neurorehabilitation activities for 10 days without being prescribed Cytoflavin® medication
16369131|NCT04194216|Active Comparator|Treatment arm A|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."
16369132|NCT04194216|Active Comparator|Treatment arm B|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg every 4 hours or clindamycin 150mg every 6 hours, for a duration of three days."
16369133|NCT04194203|Experimental|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
16369134|NCT04194203|Placebo Comparator|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
16369135|NCT04194177|Experimental|protective|
16369136|NCT04194177|Active Comparator|conventional|
16369137|NCT04194164|Experimental|Fluid intake app|Participants in this arm will use the fluid intake app to help them decrease interdialytic fluid intake. Participants will take a survey to assess the efficacy of the fluid app..
16369138|NCT04194151|Active Comparator|2 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol
16369139|NCT04194151|Active Comparator|2 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol
16369140|NCT04194151|Active Comparator|2 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol
16369141|NCT04194151|Active Comparator|1 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol
16369142|NCT04194151|Active Comparator|1 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol
16369143|NCT04194151|Active Comparator|1 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol
16369144|NCT04194138||Operative|"A. Multicenter, prospective, nonrandomized analysis of operatively treated complex ASD patients meeting the following Inclusion Criteria
~18 years of age or greater at the time of treatment
~Diagnosis of adult congenital, degenerative, idiopathic or iatrogenic spinal deformity
~Full body EOS radiographic assessment (sagittal and coronal visualization from skull to foot)
~Complex patients are defined as and meeting any one of the subsequent criteria:
~a. Radiographic criteria: i. PI-LL ≥ 25 degrees ii. TPA ≥ 30 degrees iii. SVA>15cm iv. Thoracic scoliosis ≥ 70 degrees v. Thoracolumbar/lumbar scoliosis ≥ 50 degrees vi. Global coronal malalignment >7cm b. Procedural criteria: i. Posterior spinal fusion > 12 levels ii. 3 column osteotomy or ACR c. Geriatric criteria: i. Age >65 years and minimum 7 levels of spinal instrumentation during surgery"
16369145|NCT04194125|Experimental|177Lu-DOTATOC combined with CAPTEM|"The therapy will include 4 courses (14 days per one) with 8-week intervals;
~177Lu-DOTATOC in doses from 5,55GBq up to 7,4 GBq will be administered i.v. up to four times at 10th day;
~Concomitant amino acids will be given with each administration;
~Capecitabine will be administrated for 14 days (twice a day) followed by Temozolomide at 10-14th days in each therapy sessions."
16369146|NCT04194112|Other|NMIBC patients|Patients with primary or recurrent NMIBC for whom complete TURBT was done.
16369147|NCT04194099|Experimental|20 Hz rTMS (Brain) + Anode tsDCS (Spinal)|"Brain:
~Train pulse: 2 sec
~Inter-train: 28 sec
~Total time: 1200 sec
~Spinal:
~Continuous direct current (DC): 1200 sec"
16369148|NCT04194099|Experimental|20 Hz rTMS (Brain) + 20 Hz current square-wave pulses (Spinal)|"Brain and spinal:
~Train pulse: 2 sec
~Inter-train: 28 sec
~Total time: 1200 sec"
16369149|NCT04194099|Experimental|iTBS rTMS (Brain) + Anode tsDCS (Spinal)|"Brain:
~Train pulse: 2 sec
~Inter-train: 8 sec
~Total time: 190 sec
~Spinal:
~Continuous direct current (DC): 190 sec"
16369150|NCT04194099|Experimental|iTBS rTMS (Brain) + iTBS (Spinal)|"Brain and spinal:
~Train pulse: 2 sec
~Inter-train: 8 sec
~Total time: 190 sec"
16369151|NCT04194099|Sham Comparator|sham (no stimulation on brain nor spinal)|Sham stimulation.
16369152|NCT04194086|Experimental|posaconazole as antifungal prophylaxis|
16369153|NCT04194073|Experimental|Pulse oximeter calibration population|All subjects within this single arm of the study will undergo the calibration experiment as described in the Detailed Description
16369154|NCT04194060|Experimental|Enhanced recovery after surgery group|"ERAS GROUP
~Tracheal intubation.
~Short acting anesthetic agents,avoid opioid agents
~Omental patch repair with placement of sub hepatic drain
~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.
~Post operative nausea and vomiting prophylaxis.
~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
~Initiation of feeding-Oral sips on day 1, step up day 2 onward
~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.
~Removal of urinary catheter-after weaning from the effect of general anesthesia.
~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
~Avoid opiod analgesics."
16371520|NCT04178057|Experimental|GB222 7.5mg/kg|GB222 7.5mg/kg
16369155|NCT04194060|Active Comparator|Conventional group|"CONVENTIONAL GROUP
~Tracheal intubation
~Short acting anesthetic agents, avoid opiod anesthesia agents.
~Omental patch repair along with sub hepatic drain placement.
~Post operative nausea and vomiting prophylaxis.
~Ambulation-as per patients' own request.
~Initiation of oral feed- after passage of 1st flatus.
~Nasogastric tube removal-output <300ml/day with resolution of ileus.
~Removal of urinary catheter- when patient sits on bed side/ambulate.
~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.
~Patient will receive opiod analgesics.
~I"
16369156|NCT04194047||RBC group|Patients who received RBC transfusion
16369157|NCT04194047||crystalloids group|Patients who received fluid resuscitation with crystalloids
16369158|NCT04194034|Experimental|TG6002 and flucytosine (5-FC) combination|
16369159|NCT04194008|Experimental|Nerivio device treatment|Treatment with active Nerivio device
16369160|NCT04193995|Experimental|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
16369161|NCT04193982|Experimental|Saraglitazar|Patients will receive Saraglitazar 4 mg once daily for 6 months
16369162|NCT04193982|Experimental|Vitamin E|Patients will receive Vitamin E 400mg twice daily for 6 months
16369163|NCT04193982|Experimental|Combination|Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
16369164|NCT04193982|Active Comparator|Lifestyle|Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
16369165|NCT04193969|Experimental|Radiculopathy due to nerve root compression|"Participants with radicular leg pain due to lumbar disc herniation or to foraminal- or recess stenosis.
~Baseline assessments of pain intensities are performed through questionnaires prior to protocol. Data regarding initial pain, function, age, gender, pain-duration, weight and height is retrieved from the clinical registry SpineData.
~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit in the treatment program. The protocol is repeated at the last visit in the treatment program."
16369166|NCT04193969|Experimental|Healthy controls|"Healthy controls Healthy age and gender-matched controls. Gender, weight and height are registered on questionnaires prior to protocol.
~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit. The tests are repeated at the next visit. The interval between the two sessions will be determined by the averaged interval between tests in the patient group."
16369167|NCT04193956||POINTING|
16369168|NCT04193930|Other|Soft ovarian stimulation protocol|
16369169|NCT04193930|Other|conventional ovarian stimulation protocol|
16369170|NCT04193904|Experimental|MRx0518 with hypofractionated preoperative radiation|Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.
16369171|NCT04193891||Diet Group|Participants choosing to newly initiate the modified Atkins diet, a high fat low carb diet, for improved epilepsy control.
16369172|NCT04193891||Control Group|Participants not choosing to initiate dietary therapy for epilepsy. The participants in the control group will continue with the treatment regimen they have chosen together with their physician.
16369173|NCT04193878|Placebo Comparator|Placebo|4 ml aerosolized 0.9% saline every 12 hours x 10 doses
16369174|NCT04193878|Active Comparator|Intervention|aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
16369175|NCT04193865||Extracorporeal Life Support with Renal Replacement Therapy|"This cohort will include all subjects receiving extracorporeal life support with concurrent continuous renal replacement therapy.
~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each participants's CRRT course."
16369176|NCT04193865||Renal Replacement Therapy|"This cohort will include all subjects receiving continuous renal replacement therapy (no extracorporeal life support).
~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each patient's CRRT course."
16369177|NCT04193852|Experimental|Dienogest and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
16369178|NCT04193852|Active Comparator|Dienogest and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
16369179|NCT04193839||Paper Order Entry cohort|Patients admitted to the NICU during the pre-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the pre-intervention period will be handled with the paper order entry
16369180|NCT04193839||CPOE + BCMA cohort|Patients admitted to the NICU during the post-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the post-intervention period will be handled with the Computerized Provider Order Entry + Bar Code Medication Administration (BCMA)
16369181|NCT04193826|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the Conformal LAAC device will be performed according to the device Instructions for Use, based on ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
16369182|NCT04193813||POAF|
16369183|NCT04193813||Non POAF|
16369184|NCT04193800||Rotational paramedic pilot group|
16369185|NCT04193800||Paramedic control group|
16369186|NCT04193787|Experimental|EPIC-P|Participants will enroll in a bio-behavioral intervention aimed at preventing HIV transmission in people who inject drugs.
16369187|NCT04193774|Placebo Comparator|Drop of artificial tears|
16369188|NCT04193774|Active Comparator|Drop op anesthetic|
16369189|NCT04193761|Active Comparator|Control|
16369190|NCT04193761|Active Comparator|Chronic hepatitis|
16369191|NCT04193761|Active Comparator|Cirrhosis|
16369192|NCT04193761|Active Comparator|Hepatocellular carcinoma|
16371521|NCT04178057|Experimental|GB222 10mg/kg|GB222 10mg/kg
16369198|NCT04193722|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
16369199|NCT04193722|No Intervention|Usual care|Usual care may consist of physiotherapy, analgetics, edema therapy
16369200|NCT04193709|No Intervention|Measure symptomatic indices of autonomic dysreflexia|The purpose of this arm is to systematically measure symptomatic indices of autonomic nervous system activation and corresponding cardiovascular changes in persons with spinal cord injuries during bladder filling and bowel stimulation.
16369201|NCT04193709|Experimental|Cardiovascular spinal cord epidural stimulation|The purpose of this arm is to use spinal cord epidural stimulation for maintenance of blood pressure and heart rate in the lab during cystometry (bladder filling) and anorectal filling (bowel distension) and in the at-home setting for maintenance of normative blood pressure and heart rate that can be triggered from bladder filling and during bowel evacuation.
16369202|NCT04193696|Experimental|radiotherapy plus PD-1|
16369203|NCT04193683|Sham Comparator|Sham-Ultrasound|Intervention will include one session sham-ultrasound application to both lower extremities of participant. The total time will be 15 minutes.
16369204|NCT04193683|Experimental|Myofascial Release Technique+Sham-Ultrasound|In addition to one session sham-ultrasound, the intervention will include one session myofascial release technique to both lower extremities of participant. The total time will be 30 minutes.
16369205|NCT04193670|Experimental|Atopic dermatitis classical form|15 patients
16369206|NCT04193670|Experimental|Atopic dermatitis with atopic prurigo type|10 patients
16369207|NCT04193657||Chemotherapy|30 participants starting chemotherapy
16369208|NCT04193657||Abiraterone|20 participants starting Abiraterone
16369209|NCT04193657||Enzalutamide|20 participants starting Enzalutamide
16369210|NCT04193657||Radium-223|20 participants starting Radium-223
16369211|NCT04193644|Active Comparator|Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax).
16369212|NCT04193644|Experimental|Mindfulness and Self-Compassion focussed Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax) and additionally practice mindfulness exercises and self-compassion exercises during the 60 minutes.
16369213|NCT04193644|No Intervention|TAU-Group|Participants in this group receive no intervention.
16369214|NCT04193631|Experimental|Pure Green Tablet|A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
16369215|NCT04193618|Experimental|Conservative surgery for placenta accretta|
16369216|NCT04193605|Active Comparator|Mindfulness Based Stress Reduction|MBSR sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
16369217|NCT04193605|No Intervention|Standard of Care|The control condition will continue receiving usual care or standard of care.
16369218|NCT04193592|Experimental|Oral Pirfenidone 2403 mg per day|Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
16369219|NCT04193579|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
16369220|NCT04193579|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
16369221|NCT04193566|Active Comparator|Dapagliflozin|"Patients in the active arm will be treated with dapagliflozin 50 mg once on site for visit 2 and once at home on the evening before visit 3.
~Forxiga®, dapagliflozin 10 mg film-coated tablet.
~For further information please refer to:
~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf."
16369222|NCT04193566|Placebo Comparator|Placebo|"Patients in the placebo arm will be treated with placebo once on site for visit 2 and once at home on the evening before visit 3.
~Placebo drug:
~The composition equals the composition of Forxiga® - just with the active ingredient omitted. Active drug and placebo are similar in appearance and smell."
16369223|NCT04193553|Experimental|Lenvatinib + Best Supportive Care|
16369224|NCT04193553|Placebo Comparator|Placebo + Best Supportive Care|
16369225|NCT04193540||ACE questionnaire|Every patient under mechanical ventilation (intubated or tracheotomized), with or without sedatives, able to communicate and alert (RASS -1 to +1), and not delirious (CAM-ICU negative) will be assessed by Johns Hopkins ACE questionnaire by a person not in charge of the patient.
16369226|NCT04193527|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ (123I) ioflupane. Single photon emission computed tomography (SPECT) imaging will be performed between 3 to 6 hours post-injection and will last approximately 20 minutes to 1 hour.
16369227|NCT04193514|Experimental|Acceptance and Commitment Therapy|
16369228|NCT04193514|No Intervention|Treatment as Usual|
16369229|NCT04193501|Experimental|Experimental arms|Melatonin dose: 3mg/OD
16369230|NCT04193501|Placebo Comparator|Control arms|Placebo
16369231|NCT04193488|Active Comparator|MTP block (Group MTP)|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasaggital scan, the block needle (50 mm 22 Gauge will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
16369268|NCT04193202|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
16369269|NCT04193189|Experimental|Group A, Arm 1: HEPLISAV-B (two injections)|Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
16369232|NCT04193488|Active Comparator|ESP block (Group ESP)|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
16369233|NCT04193488|Active Comparator|no block (Group C)|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
16369234|NCT04193475||Chest pain|Individuals presenting with chest pain requiring a stress echocardiogram.
16369235|NCT04193462|Experimental|Post-partum depression- Dyadic psychotherapy|Mothers and infants will be treated with 8 weeks dyadic psychotherapy at their home using video-feedback of mother-infant interaction to discuss main issues in the mother-infant relationship.
16369236|NCT04193462|Active Comparator|Post-partum depression- Psycho-educational therapy|8 weeks of supportive therapy for the mother at her house, involving the baby. Each session will include different aspects of psycho-education regarding development of the baby.
16369237|NCT04193462|No Intervention|Control- Healthy mothers and their babies|No intervention for 8 weeks.
16369238|NCT04193449||Adult patients undergoing colonoscopy|All patients' ≥18 years of age who underwent endoscopy at Portsmouth Hospitals NHS Trust, including repeat colonoscopies performed for surveillance purposes aged ≥18 in either males or females.
16369239|NCT04193436|Experimental|PF-06835919 with severe hepatic impairement|This arm includes participants with severe hepatic impairment who will receive a 25mg oral dose of PF-06835919
16369240|NCT04193436|Experimental|PF-06835919 with moderate hepatic impairement|This arm includes participants with moderate hepatic impairment who will receive a 25mg oral dose of PF-06835919
16369241|NCT04193436|Experimental|PF-06835919 with mild hepatic impairement|This arm includes participants with mild hepatic impairment who will receive a 25mg oral dose of PF-06835919
16369242|NCT04193436|Experimental|PF-06835919 without hepatic impairment|This arm includes participants without hepatic impairment who will receive a 25mg oral dose of PF-06835919
16369243|NCT04193423|Experimental|A-Group: craniocervical and cervicothoracic extension training|
16369244|NCT04193423|Experimental|B-Group: craniocervical flexion training|
16369245|NCT04193423|Active Comparator|C-Group: control group|No intervention will be performed due to the fact that they will be still on the waiting list.
16369246|NCT04193397|Other|Physical exercise|To study the effects of a concurrent training program on physical-functional fitness, physical activity level, endothelial function, blood pressure, biochemical markers of cardiovascular risk and bone metabolism, bone density and microstructure and quality of life indicators of post-bariatric patients (Study 1). To compare bone and muscle changes in post-bariatric patients with non-bariatric controls, as well as to correlate these health indicators with the time of surgical procedure and weight loss (Study 2)
16369247|NCT04193384||Group 1≤ (G1≤)|Group 1≤ (G1≤) - patients that performed bariatric surgery for ≤ 1 year
16369248|NCT04193384||Group 1> (G1>)|Group 1> (G1>) - patients that performed bariatric surgery for > 1 year
16369249|NCT04193371|Experimental|active acupuncture + lifestyle management|Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
16369250|NCT04193371|Sham Comparator|control acupuncture + lifestyle management|Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
16369251|NCT04193358|Experimental|FERTILIS HOMME® group (group A)|Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.
16369252|NCT04193358|Placebo Comparator|Placebo group (group B)|Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months
16369253|NCT04193345||Early cord clamping|The umbilical cord will be clamped within 15 seconds from delivery of the baby
16369254|NCT04193345||Delayed cord clamping|The umbilical cord will be clamped after 60 seconds from delivery of the baby
16369255|NCT04193332|Experimental|Plus NIR optical imaging|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery
16369256|NCT04193332|No Intervention|Minus NIR optical imaging|Conventional identification of parathyroid glands during thyroid surgery
16369257|NCT04193319|Other|Single arm|
16369258|NCT04193306|Experimental|Alirocumab|alirocumab 150 mg s.c. every 2 weeks, for 48 weeks
16369259|NCT04193306|Placebo Comparator|Placebo|placebo s.c. every 2 weeks, for 48 weeks
16369260|NCT04193293|Experimental|Duvelisib BID + Pembrolizumab q3w|"Stage 1: Duvelisib BID for 1 week followed by combination therapy with duvelisib BID + pembrolizumab q3w. (Cycle 1 will be 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib. Subsequent cycles will be 3 weeks .)
~Stage 2: Duvelisib BID + pembrolizumab q3w in 3 week cycles."
16369261|NCT04193267|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
16369262|NCT04193241|Active Comparator|Conventional purse-string suture closure|A common-place conventional method of closure of chest tube or thoracostomy wound using a Prolene 1 purse-string suture (also known as U-suturing), at the time of chest tube removal.
16369263|NCT04193241|Experimental|Suture-less occlusive-absorbent dressing closure|Unconventional method of closing chest tube or thoracostomy wounds using Occlusive adhesive-absorbent dressing material (Primapore*) application i.e. Un-reapproximated wound edges, at time of chest tube removal
16369264|NCT04193228||People with distal hereditary motor neuropathy|This is a single arm, feasibility study
16369265|NCT04193215|Experimental|V114|Participants will receive an intramuscular (IM) injection.
16369266|NCT04193215|Other|Control|
16369267|NCT04193202|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
16372692|NCT04169880|Experimental|HILT & EXERCISE Group|HILT&Exercise Group (n=15)
16369270|NCT04193189|Experimental|Group A, Arm 2: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
16369271|NCT04193189|Experimental|Group A, Arm 3: ENGERIX-B (three injections)|Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
16369272|NCT04193189|Experimental|Group B: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
16369273|NCT04193176|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
16369274|NCT04193176|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
16369275|NCT04193163||Patients receiving ESOP 2 stem|
16369276|NCT04193150||Reassessment Cohort|"150 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.
~Intervention includes:
~Extensive pulmonary and allergy assessments. Questionnaires, FeNO-measurement, Skin prick-test, Spirometry, Blood sampling, Body Plethysmography and Diffusion capacity measurement, Bronchial challenge test, Induced sputum.
~Treatment optimization As per GINA and Nordic Severe Asthma Network guidelines. Treatment can either be stepped up (e.g. added biological treatment), stepped down or held constant.
~Treatment is then monitored with regard to symptoms and socioeconomical parameteres such as sick leave over a 12 month period using questionnaires and official databases."
16369277|NCT04193150||Control Cohort|"400 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.
~The control cohort is followed for 12 months using questionnaires and official databases with regard to disease control and socioeconomic parameteres such as sick leave."
16369278|NCT04193137||Primary Aldosteronism(PA)|plasma aldosterone /renin ratio (ARR)>10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC>200 pg/ml，plasma renin concentration(PRC)<2.5μIU/ml，with hypokalemia
16369279|NCT04193137||non Primary Aldosteronism|ARR<10 pg/μIU or ARR>10 pg/μIU and PAC post FST<60pg/ml
16369280|NCT04193124||Prolonged vasospasm|Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Prolonged vasospasm was defined for patients who persisted with vasospasm after day 21 of cerebral bleeding.
16369281|NCT04193111||Positive TMD pain screener|Patients who have ≥3 points on the TMD pain screener (0-7 range) are anticipated to have a painful TMD based on the DC/TMD and are therefore considered having a positive outcome on the TMD pain screener.
16369282|NCT04193111||Negative TMD pain screener|Patients who have <3 points on the TMD pain screener (0-7 range) are anticipated NOT to have a painful TMD based on the DC/TMD and are therefore considered having a negative outcome on the TMD pain screener.
16369283|NCT04193098|Experimental|Arm: CTL plus PD-1 inhibitor|CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10^9, intravenous infusion,d14; Q3W.
16369284|NCT04193085||Spinal Muscular Atrophy (SMA)|ambulatory children and adults at least 5 years old by the time of enrollment with genetically confirmed SMA
16369285|NCT04193085||Duchenne / Becker Muscular Dystrophy (DMD/BMD)|ambulatory children and adults ages at least 5 years old by the time of enrollment with genetically confirmed Duchenne or Becker muscular dystrophy or evidence on muscle biopsy with a clinical presentation consistent with DMD /BMD.
16369286|NCT04193085||Healthy Control|The healthy control group will be age and gender-matched to the SMA and DMD groups as best as possible
16369287|NCT04193072||Obstetric brachial plexus palsy|
16369288|NCT04193072||Healthy|
16369289|NCT04193059|Active Comparator|PANSY-1: EC-T|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+ cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of T (docetaxel 100 mg/m^2 ivgtt d1, 21 days per cycle)
16369290|NCT04193059|Experimental|PANSY-1: PCb|6 cycles of weekly PCb (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15+ carboplatin Area Under Curve (AUC)=2 ivgtt d1, d8, d15, 28 days per cycle)
16369291|NCT04193059|Active Comparator|PANSY-2: EC-TH(P)|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of TH(P) (docetaxel 100 mg/m^2 ivgtt d1 + trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). After 8 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
16369292|NCT04193059|Experimental|PANSY-2: PCbH(P)|6 cycles of weekly PCbH(P) (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15 + carboplatin AUC=2 ivgtt d1, d8, d15 + trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). Participants may also choose to receive trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy. After 6 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
16369294|NCT04193033|Experimental|FLOW intervention|Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
16369295|NCT04193033|No Intervention|Waitlist until Time 2|Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
16369296|NCT04193033|No Intervention|Waitlist until Time 3|Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.
16369297|NCT04193020||steroid only group (SG)|
16369298|NCT04193020||combined (steroid and adjuvant drug) group (CG)|
16369299|NCT04193020||bilogic therapy group (BTG)|
16369300|NCT04193007|Experimental|molecular targeted therapy group|Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
16369301|NCT04193007|Experimental|Brain Radiotherapy and molecular targeted therapy group|Brain Radiotherapy (stereotactic radiotherapy was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain )was used for more than 3 intracranial lesions);Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
16369302|NCT04192994|Active Comparator|Group 1: Antibiotic injection|A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.
16369303|NCT04192994|Active Comparator|Group 2: Pars Plana Vitrectomy|Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.
16369304|NCT04192981|Experimental|Concurrent GDC-0084 with Radiation|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily, with a potential de-escalation cohort to 30mg, to determine MTD in combination with whole brain radiation therapy radiation therapy to 30Gy in 10 fractions. Once MTD is determined, 12 additional patients will be treated with GDC-0084 at MTD in combination with whole brain radiation therapy.
16369305|NCT04192968||Patients|Children implanted cochlear since 3 years in uni or bilateral and followed in the pediatric otolaryngology department of Necker-Enfants Malades Hospital.
16369306|NCT04192968||Patients with disappointing language development or poor cortical responses|Children having participated in the main ImplantHear3 study and who present with disappointing language development or poor cortical responses.
16369307|NCT04192955|Active Comparator|Active|Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
16369308|NCT04192955|Placebo Comparator|Control|Lactose100-mg tablets to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
16369309|NCT04192942|Experimental|intensive care management|Administration of childern with major burn in intensive care to improve out comes
16369313|NCT04192916||MPN patients treated with DOACs|
16369314|NCT04192903|Experimental|Chidamide combined with Cisplatin|"Chidamide: 30mg,PO,biw one week before cycle 1 treatment
~Combined treatment period:
~Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off Patients whose efficacy was evaluated as Complete Response (CR) / Partial Response (PR) / Stable Disease (SD) after the end of the combined treatment period received maintenance treatment with chidamide combined with cisplatin reduction.
~Maintenance treatment period:
~Cisplatin 25mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off"
16369315|NCT04192890|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
16369316|NCT04192877||Experimental|30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits. If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead. The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest. The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI). Assessors will be blinded to their results. Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
16369317|NCT04192864|Experimental|Lingually based triangular flap|
16369318|NCT04192864|Active Comparator|Buccally based triangular flap|
16369319|NCT04192851|Experimental|Tent Pole Grafting Technique|"Bone graft [NanoBone® granulate 0,6 mm (24% Silica / 76% Hydroxylapatite)] is mixed with the patient blood and placed to cover the screws completely, the defect is overcorrected with particulate material in anticipation of future graft resorption.
~PRF membrane is prepared by:
~Ten milliliters of whole venous blood will be collected in sterile glass test tubes without anticoagulant. Then the test tubes will be placed in a table centrifuge machine at 3000 revolutions per minute (rpm) for 10 minutes.After separation of PRF, the membrane is prepared compression device."
16369320|NCT04192838|Experimental|LVHR|Laparoscopic incisional ventral hernia repair
16369321|NCT04192838|Active Comparator|OVHR|Open incisional ventral hernia repair
16369322|NCT04192812|Experimental|GnRHa|3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY
16369323|NCT04192812|Placebo Comparator|no GnRHa|NO TREATMENT
16369324|NCT04192799|Experimental|Direct Admission|Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
16369325|NCT04192799|Active Comparator|ED Admission|Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.
16369326|NCT04192786|Experimental|Treatment Group 50 Hz|
16369327|NCT04192786|Experimental|Treatment Group 100 Hz|
16369328|NCT04192786|Active Comparator|Control Group|
16369348|NCT04192617|Experimental|SM03 600 mg*2|SM03: 600 mg intravenous (IV) on week 0,2, and week 12,14; placebo: 600 mg intravenous (IV) on week 4 and16; Methotrexate: 7.5-20 mg/wk oral.
16369349|NCT04192617|Experimental|SM03 600 mg*3|SM03: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
16372693|NCT04169867||Healthy Volunteers|This cohort will consist of 1000 healthy volunteers from Poland.
16369329|NCT04192773|Experimental|IV lidocaine|"1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects.
~The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia <50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study.
~Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion."
16369330|NCT04192760|Active Comparator|Culotte Technique|Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
16369331|NCT04192760|Active Comparator|DK-Crush Technique|"Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).
~After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment)."
16369332|NCT04192747|Experimental|Elixir Bioadaptor (ELX1805J)|The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
16369333|NCT04192747|Active Comparator|Medtronic Resolute Onyx Stent|The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length
16369334|NCT04192721|Experimental|Cognitive Behavioral Therapy-Based Group Counseling|The CBT-based group counseling provided to the intervention group was carried out as a group intervention with structured sessions in which various techniques and methods of CBT, having mainly educational content, were applied, including an experiential interaction process. The counseling was performed in a total of six 60- to 90-minute sessions, comprising one session per week for four groups consisting of six to 10 members each.
16369335|NCT04192721|No Intervention|Control group|No counseling was given to the control group during the study.
16369336|NCT04192708|Experimental|DV-ICNB group|intercostal nerve block under direct vision
16369337|NCT04192708|Experimental|UG-ICNB group|intercostal nerve block under ultrasound guidance
16369338|NCT04192708|Experimental|PV group|thoracic paravertebral block under ultrasound guidance
16369339|NCT04192695|Experimental|Cytosponge|"This part of the study will have an active prospective recruitment of patients. Recruitment will involve two patient populations:
~Patients with ESCC
~Patients at high risk for ESCC
~Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a Cytosponge™ procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the Cytosponge™, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of LG-IEN, HG-IEN, and ESCC."
16369340|NCT04192682|Experimental|Anlotinib Combined With Sintilimab|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
16369341|NCT04192669||Anxio-depressive patients|Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
16369342|NCT04192656|Experimental|PAP plus medication|patients treated by both PAP and medication
16369343|NCT04192656|Active Comparator|medication|patients treated by medication only
16369344|NCT04192643|Experimental|TRANEXAMİC ACİD|. 1 gr tranexamic acid in 100 ml salin given in 15 minutes
16369345|NCT04192643|Placebo Comparator|NO TRANEXAMİC ACİD|100 ml salin solution
16369346|NCT04192630|Experimental|CVisc50 OVD|CVisc50 OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
16369347|NCT04192630|Active Comparator|ProVisc OVD|ProVisc OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
16369350|NCT04192617|Placebo Comparator|placebo*3|placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
16369351|NCT04192591|Experimental|Superion® IDS device|Superion® Indirect Decompression System (IDS)
16369352|NCT04192578|Experimental|Unilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369353|NCT04192578|Experimental|Bilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369354|NCT04192578|Experimental|Unilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369355|NCT04192578|Experimental|Bilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369356|NCT04192578|Experimental|Unilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369357|NCT04192578|Experimental|Bilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369358|NCT04192578|Experimental|Unilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369359|NCT04192578|Experimental|Bilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
16369360|NCT04192565|Experimental|Robotic Endoluminal Resection|Robotic resection of mucosal lesions of the colon and rectum
16369361|NCT04192552|Active Comparator|Apixaban|Patients currently taking apixaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
16369362|NCT04192552|Active Comparator|Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
16369363|NCT04192552|Active Comparator|Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
16369364|NCT04192539|Active Comparator|Control|
16369365|NCT04192539|Active Comparator|Inflammation|
16369366|NCT04192539|Active Comparator|Benign group|
16369367|NCT04192539|Active Comparator|Malignant group|
16369368|NCT04192513|Active Comparator|Cohort 1 DBI-001 Gel and placebo|Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
16369369|NCT04192513|Active Comparator|Cohort 2 mid dose DBI-001 Gel and placebo|Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
16369370|NCT04192513|Active Comparator|Cohort 3 high dose DBI-001 Gel and placebo|Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum. Drug: J. lividum and placebo
16369371|NCT04192500|Experimental|OVX836 - 90µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 90µg dose on Day 1.
16369372|NCT04192500|Experimental|OVX836 - 180µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180µg dose on Day 1.
16369373|NCT04192500|Active Comparator|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020. One full dose to be administered at Day 1
16369377|NCT04192474|Other|Flexible cystoscopy|50% of the patients undergo flexible diagnostic cystoscopy; 50% of the patients undergo flexible cystoscopy intervention with endoscopic accessories.
16369378|NCT04192461|Experimental|tooth guided immediate implant placement group|
16369379|NCT04192448|Experimental|AlcoholxAnger|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
16369380|NCT04192448|Experimental|AlcoholxControl|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
16369381|NCT04192448|Experimental|SoberxAnger|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
16369382|NCT04192448|Sham Comparator|SoberxControl|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
16369383|NCT04192435|Active Comparator|Tranexamic acid|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
16369384|NCT04192435|Placebo Comparator|Placebo|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
16369385|NCT04192409|Experimental|Intervention-Smartphone Application|Patients will install a smartphone application that custom-developed for the study and learn to use it with the help of researchers. The application will have the following functions: 1) providing health education information about glycemic control, postoperative management and important of drug compliance; 2) providing alert & record service on patients' DM and CAD medication treatment; 3) aiding patients to conduct self-evaluate by providing questionnaire about patients' recent basic health parameters on times. The information will be interpreted automatically by application and brief feedback will be provided to patients; 4) recording patients' fasting plasma glucose value that input by patients and generate a recent glycemic control report.
16369386|NCT04192409|No Intervention|Control|Patients will receive no additional intervention from researchers except the usual care provided by hospital.
16369387|NCT04192396||RIF patients|Repeated implantation failure patients
16369388|NCT04192396||Oocyte/embryo donation program|Patients awaiting for oocyte/embryo-donation recipient patients
16369389|NCT04192383||Cyberknife|
16369390|NCT04192370|Experimental|Cannabidiol|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.
16369391|NCT04192357|Experimental|M3F program|Participants will receive the M3F program. The M3F program is divided into three phases method, being the first two of weight loss and the third phase of weight maintenance.
16369392|NCT04192357|Active Comparator|Low-carb diet|Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases method, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.
16369393|NCT04192344|Experimental|ABSK021|"Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by3+3 escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles."
16369394|NCT04192331||2/3dose strategy|HER2 negative advanced breast cancer patient
16369395|NCT04192331||3/4dose strategy|HER2 negative advanced breast cancer patient
16369396|NCT04192318|Experimental|Hospital-based violence prevention with community initiative|Youth who are living in communities that receive Communities that Care Prevention System (CTC) will also receive Bridging the Gap (BTG), a hospital-based violence prevention program with 6-months of community case management.
16369397|NCT04192318|Experimental|Hybrid hospital based violence prevention|Youth who do not live in a community that has CTC but will receive BTG.
16369398|NCT04192318|Active Comparator|Treatment as usual|Youth living in a community without the CTC program and will receive treatment as usual (TAU) in the hospital.
16369399|NCT04192318|Experimental|Treatment as usual with community initiative|Youth living in a community with the CTC program and will receive treatment as usual (TAU) in the hospital.
16369400|NCT04192305||lung protective ventilation (LPV)|lung protective ventilation low tidal volume, minimum PEEP and higher PEEP and lung recruitment based on total lung compliance, low inspiratory oxygen concentration and CPAP during extubation without prior suctioning inside the endotracheal tube.
16369401|NCT04192305||routine lung ventilation (LV)|ventilation and adapting PEEP, LRM and oxygen only when saturation drops.
16369402|NCT04192292|No Intervention|No Treatment|No change to participants standard care
16369403|NCT04192292|Experimental|Low dose sulphonylurea alone|Participants will be given a single dose of low dose sulphonylurea once daily for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily.
16369404|NCT04192292|Experimental|DPP4 inhibitor alone|Participants will be given a single dose of DPP4 inhibitor once daily for 14 days as a physiological stimulus. The DPP inhibitor given in this study will be sitagliption 100mg orally once daily.
16369405|NCT04192292|Experimental|Low dose sulphonylurea + DPP4 inhibitor|Participants will be given a single dose of low dose sulphonylurea once daily and a single dose of DPP4 inhibitor for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily and the DPP4 inhibitor will be sitagliptin orally100mg once daily.
16369406|NCT04192279||lactate group|Lactate early guide resuscitation
16369407|NCT04192279||control group|early guide resuscitation without lactate
16369408|NCT04192266|Experimental|Prolonged Exposure (PE) therapy with estradiol|A 2.0 mg pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD. A single dose of estradiol 2mg or placebo will be taken at home by the study participant 5-6 hours before each of 5 PE treatment sessions (sessions 2 to 6)
16369409|NCT04192266|Placebo Comparator|Prolonged Exposure (PE) therapy with placebo|A 2.0 mg placebo pill will be given with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD.
16369410|NCT04192253|Experimental|neo-adjuvant Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
16369411|NCT04192240|Experimental|Training with external feedback|Sit to Stand training with external feedback for 10 minute and then, stepping training with external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
16369412|NCT04192240|Active Comparator|Training without external feedback|Sit to Stand training without external feedback for 10 minute and then, stepping training without external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
16369413|NCT04192227|Experimental|Wellness Group 1|Administered by wellness facilitator and co-facilitator.
16369414|NCT04192227|Active Comparator|Wellness Group 2|Administered by wellness facilitator and co-facilitator.
16369415|NCT04192214|Active Comparator|BC 007|The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.
16369442|NCT04192032|Experimental|Preferred flavor with HWL|Preferred flavored Juul pod (5% nicotine) with HWL
16369416|NCT04192214|No Intervention|Control|The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.
16369417|NCT04192188||Test Group|Patients undergoing supportive periodontal therapy and independently antiresorptive therapy.
16369418|NCT04192188||Control Group|Patients undergoing supportive periodontal therapy without the need for antiresorptive therapy.
16369419|NCT04192162|Experimental|Group of sulfur balneotherapy and mud pack therapy|Experimental group patients underwent sulfur balneotherapy and mud pack therapy. The duration of spa therapy program was 12 days.From the blood of patients, serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy.
16369420|NCT04192162|Active Comparator|Group of sulfur balneotherapy, mud pack therapy and exercise|Control group of patients had mud pack therapy, sulfur balneotherapy and exercise in hygienic water. This group is a hydro group. From the blood of patients we analyzed parameters od complete blood count, serotonin values, lipid status and inflammatory markers before and after the therapy.
16369421|NCT04192149|Experimental|Patients receiving Craniotomy|Patients receiving an awake or asleep craniotomy for brain tumors and/or epilepsy will undergo a brain mapping procedure using electrical stimulation as a part of their normal care. The research procedures will duplicate this mapping with an invasive Focused Ultrasound mapping.
16369422|NCT04192149|Experimental|Epilepsy Patients|Patients undergoing long term monitoring for epilepsy will receive a non-invasive form of Focused Ultrasound stimulation which will be measured by their EEG cap and intracranial electrodes which are a part of their normal care.
16369423|NCT04192149|Experimental|Tremor Patients receiving FUS|Patients undergoing high intensity FUS treatment for tremor will be asked to wear a research provided EEG cap while undergoing a non-invasive low intensity Focused Ultrasound research procedure and changes in their tremor will be monitored.
16369424|NCT04192149|Experimental|Tremor Patients receiving DBS|Patients undergoing Deep Brain Stimulation (DBS) treatment for tremor will receive a non-invasive Focused Ultrasound stimulation observed through their newly implanted electrode.
16369425|NCT04192149|Experimental|Patients receiving Spinal Surgery|Patients receiving a spinal surgery will undergo a spinal stimulation using electrical stimulation as a part of their normal care. The research procedures will duplicate this with an invasive Focused Ultrasound stimulation.
16369426|NCT04192136|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).
~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.
~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.
~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
16369427|NCT04192136|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).
~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.
~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.
~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
16369428|NCT04192136|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.
~Participants in this arm will receive both the Exercise Intervention and the NR."
16369429|NCT04192136|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.
~Participants in this arm will receive both the Exercise Intervention and the Placebo."
16369430|NCT04192123|Experimental|Experimental|"All patients will receive an occlusive patch per test treatment as follows:
~Treatment 1: HM242-Solution
~Treatment 2: HM242-Gel
~Treatment 3: HM242-Solution and HM242-Gel
~Treatment 4: Irritant control (sodium lauryl sulfate (SLS))
~Treatment 5: Negative control"
16369431|NCT04192110|Experimental|Diuretic initiation or augmentation|Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
16369432|NCT04192097|No Intervention|Traditional teaching|No specific curriculum about professionalism
16369433|NCT04192097|Experimental|Professionalism curriculum|Traditionnal teaching + professionalism curriculum
16369434|NCT04192084|Experimental|Traumatic amputations of the digits|we will perform microvascular partial toe transfer for patients with traumatic amputations of one or more digits
16369435|NCT04192071|Active Comparator|high interactive virtual human administered nutrition module|The virtual health assistant will interactively collect nutrition information (alcohol, red meat, and processed meat intake) and report risk information back to users in visual and audio format
16369436|NCT04192071|Active Comparator|low interactive virtual human module|Complete the current intervention module that includes items assessing alcohol and meat intake.
16369437|NCT04192071|Sham Comparator|attention control module|The attention control group, will complete a related module not related to colorectal cancer or nutrition
16369438|NCT04192058|Sham Comparator|sham tDCS|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
16369439|NCT04192058|Experimental|active tDCS|The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively.
16369440|NCT04192032|Experimental|Preferred flavor (5% nicotine)|Preferred flavor Juul pod (5% nicotine)
16369441|NCT04192032|Active Comparator|Classic Tobacco Flavor|Control flavor (5% Classic Tobacco flavor Juul pod)
16369446|NCT04192019|Experimental|Mini-dose glucagon|150 µg mini-dose of subcutaneous Dasiglucagon 5 min before exercise the start of exercise
16369447|NCT04192019|No Intervention|No treatment|No treatment before the start of exercise
16369448|NCT04192006|Active Comparator|Conventional|Jig-based procedure
16369449|NCT04192006|Experimental|Robotic arm-assist|Mako robotic-arm assist based procedure
16369450|NCT04191993|Experimental|Direct Superior Approach (DSA)|Direct superior incision during surgery
16369451|NCT04191993|Active Comparator|Posterior Approach (PA)|Posterior approach incision during surgery
16369452|NCT04191980||Patients with a MRI on a 3 Tesla (T) unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 3T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
16369453|NCT04191980||Patients with a MRI on a 1.5 Tesla unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 1.5T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
16369454|NCT04191967|Experimental|Thermocoagulation|Thermal ablation of cervix for treatment of CIN2/3 among HIV-positive women
16369455|NCT04191954|Active Comparator|Fasudil eye drops (concentration 0.5 percent)|twice daily
16369456|NCT04191954|Placebo Comparator|receive artificial tears drop with the same frequency|
16369457|NCT04191941|Experimental|Novel CAR-T|Novel CAR-T cells will be administered intravenously
16369459|NCT04191915||Frail|Participants with 3 or more components of Fried frailty scale
16369460|NCT04191915||Moderately Frail|Participants with 1-2 components of Fried frailty scale
16369461|NCT04191915||Not Frail|Participants without any components of Fried frailty scale
16369462|NCT04191902||1|control
16369463|NCT04191902||2|treated
16369464|NCT04191889|Experimental|TRIPLET|
16369465|NCT04191876|Experimental|Active|This study has only one arm. All patients enrolled will take part in the experimental arm.
16369466|NCT04191863||Children with enuresis|28 epileptic children with induced secondary nocturnal enuresis in valproate monotherapy.
16369467|NCT04191863||Children without enuresis|232 epileptic children without induced secondary nocturnal enuresis in valproate monotherapy.
16369468|NCT04191850|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
16369469|NCT04191850|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
16369470|NCT04191837|Experimental|Self-administered acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
16369471|NCT04191837|Active Comparator|Knee health education|A course regarding knee health will be offered to the subjects in this group.
16369472|NCT04191824|Active Comparator|Immediate Return of Results|Immediate return of results to inform participant of APOL1 status (either positive or negative).
16369473|NCT04191824|Active Comparator|Delayed Return of Results|Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.
16369474|NCT04191811||Depression Internet-delivered CBT|12 weeks of guided internet-delivered CBT for depression.
16369475|NCT04191811||Insomnia Internet-delivered CBT|12 weeks of guided internet-delivered CBT for insomnia.
16369476|NCT04191811||Health Anxiety Internet-delivered CBT|12 weeks of guided internet-delivered CBT for health anxiety.
16369477|NCT04191798|Experimental|KinexConnect|Rehab at Home Patients
16369478|NCT04191798|Active Comparator|Outpatient PT|In-person PT patients
16369479|NCT04191785|Experimental|plasmatic NGAL and MRI|
16369480|NCT04191772|Experimental|MS - training goal 1|Persons with Multiple Sclerosis (PwMS) with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
16369481|NCT04191772|Experimental|HC - training goal 1|Healthy control (HC) persons with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
16369482|NCT04191772|Experimental|MS - training goal 2|PwMS with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
16369483|NCT04191772|Experimental|HC - training goal 2|HC with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
16369484|NCT04191772|No Intervention|MS - sedentary control group|Twenty PwMS will receive no intervention, only usual care.
16369485|NCT04191772|No Intervention|HC - sedentary control group|Twenty HC will receive no intervention, only usual care.
16369511|NCT04191577|Active Comparator|CVN424 (High Dose)|Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
16372694|NCT04169867||Melanoma|This cohort will consist of 160 patients with melanoma.
16369486|NCT04191759|Experimental|Test-Retest reproducibility group|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
16369487|NCT04191746||Participants with critical limb disease|This registry will collect data from participants with critical limb disease from Duke University and approximately 40 sites in North America.
16369488|NCT04191733|Experimental|Anterior Approach with KINCISE|Anterior Approach THA using KINCISE(TM) Surgical Automated System
16369489|NCT04191733|Active Comparator|Anterior Approach without KINCISE|Anterior Approach THA with a mallet (without KINCISE)
16369490|NCT04191720|No Intervention|Control group|The control group, or usual care group, will receive occupational therapy standard of care. Occupational therapy standard of care provide training, education, and therapeutic activities including relaxation strategies. These coping mechanisms are aimed at reducing the impact of anxiety on a patient's performance and participation in necessary and meaningful activities of daily living, refeeding and medical stabilization. Specifically, these interventions will include diaphragmatic and yogic breathing exercises, mindfulness-based cognitive therapy (MBCT) education and exercises, therapeutic restorative yoga activities, occupational therapy group participation, aromatherapy, identifying and promoting engagement in meaningful leisure activities, client-centered sensory diets to provide patients with consistent preferred sensory experiences, and individualized checklists and schedules to grade the self-initiation of effective coping strategies.
16369491|NCT04191720|Experimental|Weighted blanket group|In the weighted blanket intervention group, patients will receive usual occupational therapy care in addition to a weighted blanket. The patient will be given an appropriately weighted blanket, within 1 lb +/- of 10% of body weight as measured on day of admission. Further, the occupational therapy will provide education to the patient on the use of the weighted blanket. Patients will be free to use the weighted blanket at their discretion, however, during meals, over the shoulders or head, and during ambulation, weighted blanket use will not be permitted.
16369492|NCT04191707||Outpatients with Inflammatory Bowel Disease|This study was performed with plasma samples from IBD patients recruited in a previous study after informed consent. (1) IBD outpatients attending the Hospital de Sabadell Gastroenterology Day-care unit were consecutively included for analytical monitoring of immunosuppressant treatment or infliximab infusion
16369493|NCT04191694|Other|Control|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively)
16369494|NCT04191694|Active Comparator|Chewing Gum|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively) they will also receive chewing in the recovery room and on the post-natal ward.
16369495|NCT04191681|Experimental|Sacubitril-valsartan study arm|"Start medication-naïve patients on low-dose sacubitril-valsartan (24/26 mg PO BID) without a washout period per guideline and label recommendations.
~Switch patients to equivalent dose sacubitril-valsartan if on prior ACE inhibitor (after a 36 hour washout period) or ARB therapy (after discontinuing one day prior).
~If therapeutic range MAP (65 to 85 mm Hg), discontinue other oral vasodilator (e.g., hydralazine, isordil) or non-rate limiting dihydropyridine calcium channel blocker (non-DHP CCB, e.g., amlodipine) therapy on the day prior to sacubitril-valsartan initiation. If MAP > 85 mm Hg, low-dose sacubitril-valsartan will be added with or without discontinuation of other oral vasodilator or non-DHP CCB per physician's discretion based on drug tolerability and maintenance of therapeutic range MAP.
~Sacubitril-valsartan can be up-titrated every 2-4 weeks per standard practice guidelines per physician's discretion as above."
16369496|NCT04191681|Active Comparator|Usual care (standard-of-care) arm|"1. Continue current regimen of patients on oral vasodilator therapy (e.g., ACE inhibitor, ARB, hydralazine, isordil), allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above.
~2. Start medication-naïve patients de novo on one of the oral vasodilators as below per guideline and label recommendations, allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above: i. ACE inhibitor: Enalapril 2.5 mg PO BID or Lisinopril 5 mg PO daily; ii. ARB: Valsartan 20 mg PO BID or Losartan 25 mg PO daily; iii. Other: Hydralazine 10 mg PO TID or Isordil 5 mg PO TID."
16369497|NCT04191668|Other|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
16369498|NCT04191655|Experimental|High Definition White Light Colonoscopy|
16369499|NCT04191655|Active Comparator|Dye Spraying Chromo-colonoscopy|
16369500|NCT04191629|Experimental|50K to 200K cells|
16369501|NCT04191629|Experimental|50K to 200K cells with endothelial brushing|
16369502|NCT04191629|Experimental|500K cells|
16369503|NCT04191629|Experimental|500K cells with endothelial brushing|
16369505|NCT04191603|Active Comparator|MONOPOLAR HOOC|COLPOTOMY WITH USAGE MONOPOLAR HOOC
16369506|NCT04191603|Active Comparator|PLASMAKINETIK BIPOLAR SPATULA|COLPOTOMY WITH USAGE MONOPOLAR HOOC
16369507|NCT04191590|Other|Patient with Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of Chronic Rhinosinusitis (CRS)
16369508|NCT04191590|Other|Patient without Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of endonasal surgery for nasal obstruction or patients requiring an endonasal surgical approach such as pituitary adenomas for example.
16369509|NCT04191577|Placebo Comparator|Placebo|Placebo to be administered once daily.
16369510|NCT04191577|Active Comparator|CVN424 (Low Dose)|Low dose of CVN424 to be administered once daily.
16369512|NCT04191564|Experimental|low perfusion|fluid restriction based on the goal directed fluid therapy is maintained during the whole case and a state of low perfusion is created by reducing the systolic blood pressure below 100 mmHg by vasoactive medications like cleviprex or nicardipine, by increasing positive end expiratory pressure (PEEP) and by a very short period of a high IAP of 20 mmHg only during firing.
16369513|NCT04191564|Experimental|normal perfusion|Perfusion pressure is maintained above 100 mmHg with free fluid loading iv and the lowest IAP possible during the whole procedure.
16369514|NCT04191551||Gastric intestinal metaplasia|Subjects with histologically-confirmed intestinal metaplasia found during endoscopy with protocoled biopsies.
16369515|NCT04191551||Controls|Subjects without intestinal metaplasia found during endoscopy with protocoled biopsies (age and sex matched to cases)
16369516|NCT04191538|Experimental|Conditioning electrical stimulation|Patients will receive percutaneous electrical stimulation one week prior to carpal tunnel release. They will receive sham stimulation immediately after surgery to ensure blinding.
16369517|NCT04191538|Active Comparator|Postoperative electrical stimulation|Patients will receive electrical stimulation immediately following carpal tunnel release, per out previous studies. They will receive sham stimulation 1 week prior to surgery to ensure blinding.
16369518|NCT04191538|Sham Comparator|No electrical stimulation|Patients will not receive electrical stimulation. They will receive electrical stimulation before and after surgery to ensure blinding.
16369519|NCT04191525|Experimental|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
16369520|NCT04191525|Placebo Comparator|Placebo|1 capsule/day
16369521|NCT04191512||Upper airway stimulation|
16369522|NCT04191512||Continuous positive airway pressure|
16369523|NCT04191499|Experimental|Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib, palbociclib, and fulvestrant.
16369524|NCT04191499|Placebo Comparator|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
16369525|NCT04191486|Experimental|T-817MA (448 mg)|
16369526|NCT04191486|Placebo Comparator|Placebo|
16369527|NCT04191473|Experimental|group P|
16369528|NCT04191473|Other|group C|
16369529|NCT04191460|Experimental|WP-I dose A|n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery
16369530|NCT04191460|Experimental|WP-I dose B|n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.
16369531|NCT04191460|Experimental|WP-II selected dose|n=14: expansion cohort (n=14) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.
16369532|NCT04191447|Experimental|FLAMBOYANT 200/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Flamboyant 200/12 capsule
~1 Budesonide/formoterol Placebo capsule."
16369533|NCT04191447|Active Comparator|Budesonide/formoterol 400/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Budesonide/formoterol 400/12 capsule
~1 Flamboyant 200/12 Placebo capsule."
16369534|NCT04191434|Experimental|FLAMBOYANT 125/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Flamboyant 125/12 capsule
~1 Budesonide/formoterol 200/6 Placebo capsule."
16369535|NCT04191434|Active Comparator|Budesonide/formoterol 200/6|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Budesonide/formoterol 200/6 capsule
~1 Flamboyant 125/12 Placebo capsule."
16369536|NCT04191421|Experimental|Treatment spartalizumab and siltuximab Phase I dose level 1|Arm 1 (Phase I dose level 1) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 6 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16369537|NCT04191421|Experimental|Treatment spartalizumab and siltuximab Phase I level 2|Arm 2 (Phase I dose level 2) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 11 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16369538|NCT04191421|Experimental|Treatment spartalizumab and siltuximab phase I level 2a|Arm 3 (Phase I dose level 2a) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 9 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16369539|NCT04191421|Experimental|Treatment spartalizumab and siltuximab phase II|Arm 4 (Phase II ) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab at dose determined in Arm 1 to 3 IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16369540|NCT04191408|Experimental|Mechanically ventilated patients after surgery|After ICU admission the patient's hemodynamics (MAP, HR, CO, PPV) will be measured in supine position. It will be remeasured after PEEP has been increased from +5 to +15 cmH20. Then the baseline measurement will be repeated. Then passive leg raise will be performed and all the parameters will be remeasured.
16369541|NCT04191395||Inflammatory bowel disease|
16369542|NCT04191395||Chronic inflammatory rheumatic disease|
16369543|NCT04191382|Experimental|SAR439859 dose regimen 1|SAR439859 dose regimen 1 administered for 14 days
16369544|NCT04191382|Experimental|SAR439859 dose regimen 2|SAR439859 dose regimen 2 administered for 14 days
16369545|NCT04191382|Active Comparator|letrozole|letrozole 2.5 mg administered once daily for 14 days
16369546|NCT04191369|Placebo Comparator|EGD evaluation|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
16369547|NCT04191369|Experimental|EUS evaluation|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.
~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
16369548|NCT04191343|Experimental|The control group|
16369549|NCT04191330|No Intervention|Control|Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.
16369708|NCT04190225|No Intervention|Control|Control group receives a Fitbit but none of the intervention components.
16369550|NCT04191330|Experimental|Intervention|Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.
16369551|NCT04191317|Experimental|Pain Neuroscience Education and gradual exposure|"Education explaining the neurophysiological processes that lead to chronic pain, in order to change maladaptive belief towards disease, reconceptualising them and desensitizing the Central Nervous system.
~On first session of gradual exposure the patients are challenged to create a hierarchically list with the functional activities they experience fear, and exposure begins with the one they have less. Both the therapist and participant will determine a specific group of exercises after the patient understands the benign nature of pain, and will be evaluated the maximal performance of the individual to perform each exercise separately."
16369552|NCT04191317|Active Comparator|Pilates and postural education|In the first session, basic Pilates principles will be taught and reinforced at the beginning of the follow up sessions, including: postural alignment (neutral spine position, shoulder blade and neck position) and core recruitment along with a controlled breathing. Each session will have a warm up, mobility, stability and strengthening exercises and a cool down period.
16369555|NCT04191291|Experimental|Shortened lunch period|The lunch period will last only 20 minutes.
16369556|NCT04191291|Experimental|Longer lunch period|The lunch period will last 30 minutes.
16369557|NCT04191278|Active Comparator|Varenicline|An α4β2 nicotinic acetylcholine receptor partial agonist
16369558|NCT04191278|Experimental|Varenicline + mobile app|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications
16369559|NCT04191278|Experimental|Varenicline + mobile app + contingency management|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications + monetary reinforcers for being adherent to medication
16369560|NCT04191239||PRVC|Preterm infants with need of mechanical ventilation will receive PRVC mode until extubation
16369561|NCT04191239||Bilevel VG|Preterm infants with need of mechanical ventilation will receive Bilevel VG mode until extubation
16369562|NCT04191213|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks
16369563|NCT04191213|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age & two-gram-dose for children above 5 years of age
16369564|NCT04191187|Experimental|Conditioning Regimen + Transplant|All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)
16369565|NCT04191174||Adults undergoing lung resection for lung cancer|
16369566|NCT04191161|Experimental|Brace group|patients will receive their brace 2 weeks after the first consultation (usual delay to conceive and deliver the brace), they will be asked to wear the brace all day and will be allowed to redraw it at night. Brace must be worn for 3 months. A specific eduction on how to wear the brace will also be delivered. A thermal sensor chip will be placed in the brace to assess the observance. No physiotherapy will be prescribed during this period. Patient will attend to 3 consultations, day 0, 3 months and finally at 6 months later. These three consultations are part of usual care.
16369567|NCT04191161|Placebo Comparator|Control group|patients will continue physiotherapy sessions if already prescribed but no extra sessions will be prescribed. Pain killers will be adjusted. Patients will also attend to three consultations such as described above. Main outcome will be assessed at M3. After M3, patients who did not receive the brace will have the choice to receive it for the next 3 months and secondary outcome will be assessed at 6 months.
16369568|NCT04191148|Experimental|LBP-EC01|crPhage cocktail
16369569|NCT04191148|Placebo Comparator|Placebo|Lactated Ringer's solution, injection, USP
16369570|NCT04191135|Experimental|pembrolizumab + carboplatin and gemcitabine|Participants receive both carboplatin Area Under The Curve (AUC) 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will continue to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
16369571|NCT04191135|Experimental|pembrolizumab + olaparib|Participants receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
16369572|NCT04191122|Active Comparator|COPESS and Treatment as usual|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible, and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.
~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."
16369602|NCT04190914|Experimental|necrotic primary molar treated with regeneration using triple|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then triple antibiotic paste will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
16369573|NCT04191122|No Intervention|Treatment as usual only|The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
16369574|NCT04191109||1|Subacute stroke patients admitted to an inpatient rehabilitation facility.
16369575|NCT04191096|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
16369576|NCT04191096|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
16369577|NCT04191083|Experimental|Motor Imagery|
16369578|NCT04191083|Experimental|Double Time Motor Imagery|
16369579|NCT04191083|Experimental|Action observation|
16369580|NCT04191083|Placebo Comparator|Placebo group|
16369581|NCT04191070|Experimental|Class II correction using infrazygomatic crest miniscrews|class II correction by distalization using infrazygomatic crest miniscrews (G1)
16369582|NCT04191070|Experimental|Class II correction using zygomatic miniplates|class II correction by distalization using zygomatic miniplates (G2)
16369583|NCT04191057|Experimental|Healthy twin|Free light chains of twins compared to non-twin siblings
16369584|NCT04191044||NAFLD with mild steatosis and grade <3 fibrosis in patients|NAFLD with mild steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
16369585|NCT04191044||NAFLD with severe steatosis and grade <3 fibrosis in patients|NAFLD with severe steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
16369586|NCT04191044||NAFLD with advanced fibrosis|NAFLD with advanced fibrosis (i.e. grade 3 or 4 fibrosis) without previous portal hypertension-related complications
16369587|NCT04191044||Decompensated NAFLD cirrhosis|Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points)
16369588|NCT04191031|Experimental|Superficial Genicular Nerves|Subjects will receive iovera° cryoneurolysis treatment of superficial genicular nerves (anterior femoral cutaneous nerve [AFCN] and infrapatellar branches of the saphenous nerve [ISN]) of the target knee
16369589|NCT04191031|Sham Comparator|Sham Comparator|Subjects will receive sham iovera° treatment of superficial genicular nerves (AFCN and ISN) of the target knee
16369590|NCT04190992|Experimental|Application (APP) group|After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based & personalized breast reconstruction surgery decision aid at clinic.
16369591|NCT04190992|Other|Usual care group|After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
16369592|NCT04190979|Experimental|Single arm|TrackCath
16369593|NCT04190966|Active Comparator|Integrated smoking cessation|Integrated smoking cessation delivered by trained health-care practitioners in the thoracic surgical pathway: a three part package of behaviour interventions and pharmacotherapy as per NICE/NCSCT guidance which is supported by an adjunct web-based application.
16369594|NCT04190966|No Intervention|Usual care smoking cessation|Usual care of standard community/hospital based NHS smoking cessation.
16369595|NCT04190953|Experimental|Twin Block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
16369596|NCT04190953|Experimental|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
16369597|NCT04190953|No Intervention|Control|Patients will wait 1,5 years before the start of treatment
16369598|NCT04190940|Experimental|High Intensity Focused Ultrasound|Patients receiving high intensity focused ultrasound as a treatment will be asked to complete the behavioral task pre and post their treatment.
16369599|NCT04190940|Experimental|Deep Brain Stimulation|"Patients receiving deep brain stimulation as a treatment will be asked to complete the behavioral task while their DBS electrode is on and off."
16369600|NCT04190927|Experimental|Treatment|All patients will be symptomatic peri or post menopausal and will all be started on the same protocol. The Dosing schedule of topical estradiol and topical progesterone will be modified for each subject in the first three months to address individual symptoms. The dosing will be relatively unique to each patient. Patients will remain on their dosing schedule for the remainder of the three year study and will be assessed during at the end of the study for changes in mood, symptoms of menopause, breast health, BMD and thickness of uterine lining .
16369601|NCT04190914|Active Comparator|necrotic primary molar treated with pulpectomy followed by SSC|control group treated by pulpectomy under rubber dam isolation access cavity will be prepared by a round bur then filling and irrigation will be performed and the tooth will be restored with a temporary filling. After one week all signs and symptoms will be assessed in case of absence of signs and symptoms the tooth will be restored with zin oxide and eugenol and SSC
16369633|NCT04190732|Experimental|Physician phone call|Participants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
16369809|NCT04189419|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow derived mesenchymal stem cells
~Dose: 1x10^6 cells/Kg"
16369603|NCT04190914|Experimental|necrotic primary molar treated with regeneration using metape|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then calcium hydroxide with iodoform (metapex) will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After 2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
16369604|NCT04190901|Experimental|Simulated Black Male Physician|Participants are randomized to view the clinical vignette with a simulated Black Male physician.
16369605|NCT04190901|Experimental|Simulated Black Female Physician|Participants are randomized to view the clinical vignette with a simulated Black Female physician.
16369606|NCT04190901|Experimental|Simulated White Male Physician|Participants are randomized to view the clinical vignette with a simulated White Male physician.
16369607|NCT04190901|Experimental|Simulated White Female Physician|Participants are randomized to view the clinical vignette with a simulated White Female physician.
16369608|NCT04190888||Sickle Cell Disease|Patients with sickle cell disease will be followed prospectively
16369609|NCT04190862|Experimental|Cell Therapy Treatment|Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
16369610|NCT04190849||Non-alcoholic fatty liver disease patients|Children (<18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.
16369611|NCT04190836|Experimental|Self-Managed Exercise Strategy|
16369612|NCT04190823|Experimental|RC98|
16369613|NCT04190810|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures that are not related to smoking by swiping/pulling them towards themselves, whereas pictures with tobacco-related content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
16369614|NCT04190810|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon non-smoking related images by swiping/pulling towards themselves the picture. Pictures containing tobacco-related content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
16369615|NCT04190810|Sham Comparator|Control group|This type of active control group receives the instructions to swipe tobacco-related pictures to the left and non-tobacco related pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
16369616|NCT04190797|Experimental|Experimental|Photobiomodulation + patiente controled anaethesia (PCA) group (G1): patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
16369617|NCT04190797|Active Comparator|Control|Placebo + PCA group (G2): patients undergoing knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve blockade (femoral nerve and obturator nerve). With conventional analgesia and with the PCA apparatus.
16369618|NCT04190784|Experimental|60 seconds stretching group|"Stretching exercises for upper Trapezius and Levator scapula .
~From supine position , the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times."
16369619|NCT04190784|Experimental|30 seconds stretching group|The same procedures while the therapist will maintain the stretch for 30 seconds.
16369620|NCT04190784|Experimental|15 seconds stretching group|The same procedures while the therapist will maintain the stretch for 15 seconds.
16369621|NCT04190784|Placebo Comparator|60 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 60 seconds
16369622|NCT04190784|Placebo Comparator|30 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 30 seconds
16369623|NCT04190784|Placebo Comparator|15 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 15 seconds
16369624|NCT04190771|Experimental|TAU + multicomponent treatment NAT-FM|NAT-FM is a multicomponent non-pharmacological program based on mindfulness ingredients, pain neuroscience education, and nature exposure. NAT-FM is conceived as an add-on therapy.
16369625|NCT04190771|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for fibromyalgia, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
16369626|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
16369627|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
16369628|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
16369629|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
16369630|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
16369631|NCT04190745|Experimental|The control group|
16369632|NCT04190745|Experimental|The experimental group|
16369634|NCT04190732|No Intervention|Routine care|Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test.
16369635|NCT04190719|Experimental|Paprika group|Patients coming for elective major surgery will participate to Paprika program
16369636|NCT04190719|No Intervention|Historical group|Patients previously operated with same characteristics
16369637|NCT04190706|Experimental|bioactive components fortified food products|
16369638|NCT04190706|Placebo Comparator|control food products|
16369639|NCT04190693|Placebo Comparator|Follow-up|No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
16369640|NCT04190693|Experimental|IMCY_0098|No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
16369641|NCT04190680|Experimental|Kokkerelli Learning Street|The classes included in this group will participate in the Kokkerelli Learning Street; a school-based nutrition education programme included classroom-based lessons, a visit to a grower's farm and a cooking workshop.
16369642|NCT04190680|No Intervention|Control group|The classes included in this group will not participate in the Kokkerelli Learning Street and will continue with their regular curriculum.
16369643|NCT04190654|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh class A score of 5 or 6)
16369644|NCT04190654|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh class B score of 7 to 9)
16369645|NCT04190654|Experimental|Healthy Subjects|Healthy adults matched with the subjects in Group A and Group B at 1:1 for age (± 10 years), sex, and BMI (± 20%)
16369646|NCT04190641|Other|Flexible cystoscopy|Visualization of the urethra and bladder with the Ambu® aScope™ 4 Cysto and aView™ Urologia
16369647|NCT04190628|Experimental|Monotherapy Dose Escalation|"A classic 3+3 design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 continuously until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
16369648|NCT04190628|Experimental|Combination Therapy Dose Escalation|"A classic 3+3 design will guide the dose escalation in Part B. At each dose level, ABM-1310 will be administered in combination with cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy."
16369649|NCT04190615||0 to 3 months|0 (term newborns) to 3 month of age
16369650|NCT04190615||4 to12 months|infants from 4month to 12month of age
16369651|NCT04190615||13 to 24 months|children from 13month to 2years of age
16369652|NCT04190615||2 to 5 years|children from 2 to 5 years of age
16369653|NCT04190615||6 to 10 years|children from 2 to 10 years of age
16369654|NCT04190615||11 to16 years|children from 11 to 16 years of age
16369655|NCT04190589|Experimental|Robotic CME|Robot-assisted extended right colectomy
16369656|NCT04190576|Experimental|Minimally invasive ridge augmentation with LLLT|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) and low-level laser therapy
16369657|NCT04190576|Active Comparator|Minimally invasive ridge augmentation|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) alone
16369658|NCT04190563|Experimental|Pain De-Catastrophizing|Brief behavioral education on how to modify the interpretation of pain.
16369659|NCT04190563|Placebo Comparator|Pain Education|Brief behavioral education on pain.
16369660|NCT04190550|Experimental|Treatment (AMG 232, cytarabine, idarubicin)|Patients receive AMG 232 PO QD on days 1-7, cytarabine IV over 3 hours BID on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease may receive cytarabine IV BID over 3 hours for 5 days and idarubicin IV over 10-15 minutes for 2 days starting between days 14-21 of cycle 1 or the second cycle of AMG 232, cytarabine, and idarubicin. Patients who achieve a CR or a CRi in either cycle 1 or 2 may receive cytarabine IV BID over 3 hours on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
16369662|NCT04190511|Experimental|Prebiotic-containing dairy intervention group|
16369663|NCT04190511|Active Comparator|Dietary intervention group|
16369664|NCT04190511|No Intervention|Conventional care group|
16369665|NCT04190498||NASH-related HCC|The study is focused on patients suffering from NASH-induced HCC. Each patient with NASH-related HCC will be paired with 2 patients with non NASH-related HCC (HCV-induced CHC).
16369666|NCT04190498||HCV-related HCC|HCV-related HCC has been chosen as control population for several reasons: HCV represent a common etiology of HCC; with a distinct pathophysiology distinct from that of post-NASH HCC; populations with post-NASH and post-HCV CHC share similar epidemiological characteristics.
16369667|NCT04190485|Experimental|Placebo and GMNL-143 Probiotic Toothpastes|Subjects will receive placebo and GMNL-143 probiotic toothpastes.
16369668|NCT04190485|Experimental|Placebo and GMNL-464 Probiotic Toothpastes|Subjects will receive placebo and GMNL-464 probiotic toothpastes.
16369669|NCT04190472||IOP VPH test|Immediately after the LEEP, a cervical sample is token for the IOP-HPV test
16369670|NCT04190459||LSG|laparoscopic sleeve gastrectomy
16369671|NCT04190459||LRYGB|laparoscopic Roux-en-Y gastric bypass
16369672|NCT04190446|Experimental|Arm I (proton beam radiation therapy)|Patients undergo proton beam radiation therapy 5 days a week over 3 weeks.
16369673|NCT04190446|Experimental|Arm II (IMRT)|Patients undergo IMRT 5 days a week over 5 weeks.
16369674|NCT04190433|Active Comparator|Standard Therapy Group|Carvedilol and Lisinopril titrated to maximally tolerated doses as per standard practice
16369675|NCT04190433|Experimental|Expanded Therapy Group|Pravastatin 40 mg per day and Spironolactone 25 mg per day in addition to maximally titrated Carvedilol and Lisinopril doses
16369678|NCT04190407|Other|Pediatric patients scheduled for day case surgery|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
16369679|NCT04190394||Patients following the CONT program|"In the  CONT continuous training group, the control group, the patient benefits from a retraining program according to the continuous mode (see details in section 3.4) for 8 weeks, with three 40-minute sessions per week."
16369680|NCT04190394||Patients following the IT program|"In the IT intermittent training group, group, (the experimental group), the patient benefits from a retraining program according to the intermittent mode (see details in section 3.4) for 8 weeks, with three 45-minute sessions per week."
16369681|NCT04190381|Experimental|FR-Mask application|
16369682|NCT04190368|Other|Team Clinic Care: No VTC Groups|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient and yearly team visit as needed
~• Providers will utilize a patient centered care approach to conducting appointments"
16369683|NCT04190368|Other|Team Clinic: Virtual Team Clinic Group|"Participants will be invited to participate in online/virtual thematic group sessions led by Team Clinic group facilitators (e.g., RD, SW, RN) aimed at improving glycemic control and treatment adherence, increasing social supports and diabetes care satisfaction, and aid in the transition from caregiver led treatment to self care.
~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
16369684|NCT04190368|Other|Standard Care: No VTC Groups|Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).
16369685|NCT04190368|Other|Standard Care: Virtual Team Clinic|"Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).
~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
16369686|NCT04190355|Active Comparator|5.25% NaOCl solution|5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation
16369687|NCT04190355|Active Comparator|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation
16369688|NCT04190342|Other|control group|standard care (intervention provided after the completion of the trial)
16369689|NCT04190342|Experimental|tai chi group|Tai chi intervention + standard care
16369690|NCT04190329||10 non-frail (robust) study patients|Patients fulfill 0 criteria according to modified Fried frailty score.
16369691|NCT04190329||10 pre-frail study patients|Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
16369692|NCT04190329||10 frail study patients|Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.
16369693|NCT04190316|Other|Evaluation of patient and patient-care environment ESBL|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
16369694|NCT04190303||Baseline (pre-intervention)|Current routine care
16369695|NCT04190303||Post-intervention|Care following development and delivery of the system-level intervention
16369696|NCT04190290|Experimental|Intervention|Mobilizations and exercises training Respiratory exercises Body image exercises
16369697|NCT04190290|Active Comparator|Control|Muscle strength evaluation and Eating behavior evaluation and Quality of life
16369698|NCT04190277|Experimental|36-week Closed-Loop|2-week baseline period in open-loop condition, then 12-week period in closed-loop condition followed by a 24-week extension period in closed-loop condition
16369699|NCT04190277|Active Comparator|12-week open-loop and 24-week closed-loop|2-week baseline period in open-loop condition, then 12-week period in open-loop condition followed by a 24-week extension period in closed-loop condition
16369700|NCT04190264|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
16369701|NCT04190264|Active Comparator|Cold Water Immersion|Participants, following exercise-induced hyperthermia, will be cooled using cold water immersion. Participants will be immersed up to their chest in cold water (~50-55 Degrees Fahrenheit).
16369702|NCT04190264|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
16369703|NCT04190251|Other|Intervention group A|Intervention group A will benefit of the medication adherence support program during 12 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
16369704|NCT04190251|Other|Intervention group B|Intervention group A will benefit of the medication adherence support program during 6 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
16369705|NCT04190238|Experimental|Spasticity after stroke 1|Physical therapy with super inductive system on the agonist and antagonist muscles
16369706|NCT04190238|Active Comparator|Spasticity after stroke 2|Physical therapy with super inductive system on the agonist muscles
16369707|NCT04190225|Experimental|Multi-technology physical activity intervention|Digital/social media
16369709|NCT04190212|Experimental|High-intensity interval training|Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
16369710|NCT04190212|No Intervention|Standard care|Participants will not participate in on-site supervised exercise sessions.
16369711|NCT04190199||Type 2 diabetes mellitus (T2DM)|Subjects in this group are diagnosed with type 2 diabetes mellitus. They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
16369712|NCT04190199||Pre-diabetes (IFG or IGT)|Subjects in this group are diagnosed with pre-diabetes (impaired fasting glucose [IFG] or impaired glucose tolerance [IGT]). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
16369713|NCT04190199||Non-type 2 diabetes mellitus (healthy)|Subjects in this group are not diagnosed with type 2 diabetes mellitus or pre-diabetes (healthy). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
16369714|NCT04190186|Active Comparator|BioMonitor3®-guided AF management|ICM obtained data will be actively used to guide and monitor treatment .
16369715|NCT04190186|No Intervention|Conventional AF Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
16369716|NCT04190173|Experimental|Prucalopride|Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C
16369717|NCT04190173|Placebo Comparator|Placebo|Placebo tablet to mimic Prucalopride made by starch
16369718|NCT04190160|Experimental|6 months treatment|replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients
16369719|NCT04190147||Moderate-to-late preterm group|
16369720|NCT04190147||Full-term group|
16369721|NCT04190134|Experimental|Immediate Robot|One month after study entry, participants will receive the robot at home for two months, followed by a three month observation period without the robot.
16369722|NCT04190134|Active Comparator|Delayed/Waitlist Robot|Three months after study entry, participants will receive the robot at home for three months.
16369723|NCT04190121|Experimental|GROUP A|
16369724|NCT04190121|No Intervention|GROUP B|
16369725|NCT04190108||Case patients|All consecutive, new patients older than 18 years with PsA (CASPAR criteria) at onset observed over 3-year period, who had any abdominal symptoms.
16369726|NCT04190108||Controls|All consecutive new patients meeting the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) at onset.
16369727|NCT04190095|Experimental|User Interaction with Device|A user will wear motion sensors and VR device to interact with object or another user in VR environment
16369728|NCT04190082||Group Control|Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
16369729|NCT04190082||Group BIS|Group who maintain deep sedation using Bispectral Index (BIS) score.
16369730|NCT04190069|No Intervention|OPTIFAST only|Control group will consist of participants that have not undergone behavioral modifications with the Prescription for Wellness Program. These are participants that only go through the OPTIFAST Program.
16369731|NCT04190069|Experimental|UPMC PFW followed by OPTIFAST|The intervention group will consist of participants that have undergone behavioral modifications with the Prescription for Wellness Program. These are participants who undergo the Prescription for Wellness Program prior to the OPTIFAST Program.
16369732|NCT04190056|Experimental|Arm A (pembrolizumab, vorinostat, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1, vorinostat PO QD for 4 days weekly, and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
16369733|NCT04190056|Experimental|Arm B (pembrolizumab, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1 and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
16369734|NCT04190030|Experimental|Mindfulness|
16369735|NCT04190030|Active Comparator|Cognitive reappraisal|
16369736|NCT04190004|Experimental|vasopressin|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
16369737|NCT04190004|Placebo Comparator|Placebo|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
16369738|NCT04189991|Active Comparator|Manual then automated oxygen titration|First will be performed the manual oxygen titration and then the automatic oxygen titration.
16369739|NCT04189991|Active Comparator|Automatic then manual oxygen titration|First will be performed the automatic oxygen titration and then the manual oxygen titration.
16369740|NCT04189978||2001-2002 study participants|Children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period.
16369741|NCT04189965|Other|Pilot group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.
~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses to validate it.
~The subject will also have headphones and different shouts or noises will be broadcast and he will have to rate the level of dislike of each sound stimulation."
16369742|NCT04189965|Other|Experimental group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.
~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.
~3 sessions of stimulation will be done (D0, D2 and D30)"
16369773|NCT04189666|Active Comparator|Group R: patients receive Rivastigmine patch|receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
16369774|NCT04189666|Active Comparator|Group M: patients receive Melatonin patch|receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
16369744|NCT04189939||subjects with treatment-resistant depression|approximately 48 subjects with treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
16369745|NCT04189939||healthy subjects|approximately 48 healthy subjects will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
16369746|NCT04189900|Experimental|Triptorelin|The subjects in this group receive a single dose treatment. Biologic sample collection (urine) from 48 hours pre-administration to 48 hours post administration.
16369747|NCT04189887||PD+AEX|The group of people with PD which will perform aerobic exercise after motor skill acquisition
16369748|NCT04189887||PD-AEX|The group of people with PD which will not perform aerobic exercise after motor skill acquisition
16369749|NCT04189887||CON+AEX|The group of control participants which will perform aerobic exercise after motor skill acquisition
16369750|NCT04189887||CON-AEX|The group of control participants which will not perform aerobic exercise after motor skill acquisition
16369751|NCT04189874|Active Comparator|Conventional stool testing|"All patients randomly allocated to this arm will have their stools tested for the following:
~a) Bacterial culture for Salmonella, Shigella, E.coli O157 and Campylobacter - specimen in Enteric Pathogen Transport medium (EPT) planted to: i) MacConkey agar, Sorbitol-MacConkey agar, Hektoen agar and Selenite broth all incubated overnight at 350C ii) Campylobacter agar incubated for 48 hours at 420C in a microaerophilic atmosphere b) Bacterial culture for Yersinia (≤ 18 years old): EPT specimen sent to Dynacare Laboratories for processing, results back in 10-14 days c) Ova & Parasites investigation: Sodium acetate-Acetic Acid-Formalin specimen sent to the Public Health Laboratories (PHL) for testing, results back in 7-10 days d) Viral culture: rarely requested, requires a specimen in a sterile container, sent to the PHL for testing, results back in 5-7 days e) Clostridioides difficile: specimen in sterile container, results in 1h (GeneXpert)"
16369752|NCT04189874|Experimental|BioFire FilmArray Gastrointestinal Panel|All patients randomly allocated to this arm will have their stools tested using a PCR-based molecular assay that can simultaneously test for 22 different infectious pathogens with a turnaround time of approximately 1 hour. As results become available, they will be available for review by the patient's healthcare providers in the electronic medical record.
16369753|NCT04189848|Experimental|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
16369754|NCT04189848|Experimental|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
16369755|NCT04189835||Kidney transplant recipients|Adults and children undergoing kidney transplantation in Norway and the western part of Denmark.
16369756|NCT04189796|Active Comparator|Jarlsberg|Daily intake of Jarlsberg Cheese in at least 6 weeks
16369757|NCT04189796|Sham Comparator|Camembert|Daily intake of Camembert Cheese in 6 weeks
16369758|NCT04189783|Active Comparator|Arm I (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.
16369759|NCT04189783|Experimental|Arm II (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.
16369760|NCT04189770||Observational (questionnaire, accelerometer, EMA, survey)|Patients and partners complete questionnaires over 60 minutes about demographic information, stress, coping, and lifestyle behaviors at baseline and end of study. Patients and partners also receive an accelerometer and complete EMA questionnaire on stress, coping, physical activity, and eating behaviors over 5-10 minutes QID (7:30 am, 11:30 am, 3:30 pm, and 7:30 pm) via an smartphone app for 14 days. Patients and partners also complete a survey on nutrition BIW for a total of 4 surveys.
16369761|NCT04189757|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16369762|NCT04189744|Placebo Comparator|IPTp-SP plus MTZ placebo (control)|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
16369763|NCT04189744|Active Comparator|IPTp-SP plus MTZ|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
16369764|NCT04189744|Active Comparator|IPTp-DP plus MTZ|3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
16369765|NCT04189731||supra-scapular block|Patient will have a short ISB (between 2h and 4h) relayed by a supra-scapular block (SSB) long (72h) through the placement of a perineural catheter thus allowing a continuous diffusion of Naropein® by an elastomeric pump
16369766|NCT04189718|Experimental|osseodensification protocol|Experimental: In the test group, osteotomy site preparation was performed using Osseodensification technique at 1100 rpm and implant was placed
16369767|NCT04189718|Active Comparator|conventional implant site preparation protocol|Control: in the control group, osteotomy site was prepared using conventional drilling protocol at 1100 rpm and implant was placed.
16369768|NCT04189705|Experimental|MCT-SR|Drug: MCT-SR 2 times/day for 2 weeks
16369769|NCT04189705|Active Comparator|Mucosta Tab.|Drug: Mucosta Tab. 3 times/day for 2 weeks
16369770|NCT04189692||Patients with Inflammatory Bowel Disease and fatigue|Patients with Inflammatory Bowel Disease and fatigue that participated in the two studies (1,2).
16369771|NCT04189679||First line|20 patients in first line of treatment
16369772|NCT04189679||Second or third line|40 patients in second and third line of treatment
16369775|NCT04189653||General Ward Inpatients 2017-2018|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
16369776|NCT04189653||General Ward Inpatients 2018-2019|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
16369777|NCT04189640|Active Comparator|Group 20 = 20 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20ml will be injected here.
16369778|NCT04189640|Active Comparator|Group 30 = 30 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30ml will be injected here.
16369779|NCT04189640|Active Comparator|Group 40 = 40 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 40ml will be injected here.
16369780|NCT04189627||Participants Treated with GLE/PIB|Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study. Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
16369782|NCT04189601||Study subjects|Patients with Fabry disease, Gaucher disease, or Niemann-Pick disease, type D
16369783|NCT04189601||Controls|Age- and sex-matched to Study subjects
16369784|NCT04189588|Active Comparator|Cohort A|Cetirizine HCl 10 mg/mL: a single 1 mL injection.
16369785|NCT04189588|Active Comparator|Cohort B|Diphenhydramine 50 mg/mL: a single 1 mL injection.
16369786|NCT04189575|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
16369787|NCT04189562|Experimental|SMS Intervention|All parents of participants will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
16369788|NCT04189536|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
16369789|NCT04189523|Active Comparator|Standard of Care Pain Management|
16369790|NCT04189523|Experimental|Early Administration of US Guided Nerve Blocks|
16369791|NCT04189510|Experimental|Artificial Pancreas (AP) Insulin Group|
16369792|NCT04189510|Active Comparator|Multiple Daily Injections (MDI) Insulin Group|
16369793|NCT04189484|Experimental|Arm A: Evolocumab low dose|Single dose of evolocumab 21 mg subcutaneous (SC)
16369794|NCT04189484|Experimental|Arm B: Evolocumab intermediate low dose|Single dose of evolocumab 35 mg SC
16369795|NCT04189484|Experimental|Arm C: Evolocumab intermediate high dose|Single dose of evolocumab 70 mg SC
16369796|NCT04189484|Experimental|Arm D: Evolocumab high dose|Single dose of evolocumab 140 mg SC
16369797|NCT04189484|Experimental|Arm E: Alirocumab low dose|Single dose of alirocumab 15 mg SC
16369798|NCT04189484|Experimental|Arm F: Alirocumab intermediate low dose|Single dose of alirocumab 25 mg SC
16369799|NCT04189484|Experimental|Arm G: Alirocumab intermediate high dose|Single dose of alirocumab 50 mg SC
16369800|NCT04189484|Experimental|Arm H: Alirocumab high dose|Single dose of alirocumab 100 mg SC
16369801|NCT04189484|Placebo Comparator|Arm I: Placebo|Single dose of placebo SC
16369802|NCT04189458|Experimental|Multimodal exercise program|The experimental group intervention will attend the multimodal exercise program. The program integrates 3 sessions / week of 60 minutes on alternated days. The multimodal exercise program includes exercises promoting simultaneous motor and cognitive stimulation.
16369803|NCT04189458|No Intervention|Control Group|Usual care. After the study, it will be offered the opportunity to integrate a similar exercise program for the control group (CG) participants.
16369804|NCT04189445|Experimental|Futibatinib (Cohort A)|Advanced or metastatic solid tumors harboring FGFR1-4 rearrangements
16369805|NCT04189445|Experimental|Futibatinib (Cohort B)|Advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification
16369806|NCT04189445|Experimental|Futibatinib (Cohort C)|Myeloid or lymphoid neoplasm harboring FGFR1 rearrangement
16369807|NCT04189432|Experimental|SCM-CGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells
~Dose: 1x10^6 cells/Kg"
16369808|NCT04189432|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
16369811|NCT04189406||Girls with Turner syndrome|"Girls with a pre- or perinatal diagnosis TS who are born in a medical centre in the Netherlands during the duration of the study.
~The subjects will have an extra venapuncture of 3.5 mL blood at 3 and 9 months."
16369812|NCT04189380|Experimental|Cohort 1|liver transplanted patient
16369813|NCT04189367|Experimental|Western medicine + TCM|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.
~Blood test and physiological assessment, and do the TCM model.
~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks
~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.
~TCM therapy: one bag of Qingre Liangkou Ningxin Fang, three times a day for 12 weeks."
16369814|NCT04189367|Active Comparator|Western medicine|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.
~Blood test and physiological assessment, and do the TCM model.
~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks
~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks."
16369815|NCT04189354|Experimental|Active t-DCS|Use of the t-DCS machine with the following stimulation parameters: current intensity of 2mA, electrode size of 25 cm2, duration of stimulation 20 minutes (excluding the fade-in and fade-out periods of 15 seconds).
16369816|NCT04189354|Sham Comparator|Sham t-DCS|"The condition of use in sham mode follows the same procedure as the active t-DCS except that the active stimulation lasts only 30 seconds at 3mA (60 seconds of active stimulation taking into account the periods of fade in and fade out).
~The stimulator remains switched on during the procedure but does not deliver current. The devices are fully automatic and deliver an active or sham current according to a randomized stimulation code whose meaning is unknown by the operator, in order to respect the triple blind."
16369817|NCT04189341|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
16369818|NCT04189341|Active Comparator|Group T = mTLIP group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
16369819|NCT04189341|No Intervention|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16369820|NCT04189328|Active Comparator|control group|conventional macrosurgical implant placement
16369821|NCT04189328|Experimental|test group|microsurgical implant placement
16369822|NCT04189315|Experimental|Group 1 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 36 weeks.
16369823|NCT04189315|Experimental|Group 2 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 12 weeks and then asfotase alfa at a lower dose for 24 weeks.
16369824|NCT04189302|Experimental|palatal connective tissue graft harvest with KPM blade|palatal connective tissue graft is harvested using single incision technique using KPM blade
16369825|NCT04189302|Active Comparator|palatal connective tissue graft harvest with 15C blade|palatal connective tissue graft is harvested using single incision technique using 15 C blade
16369826|NCT04189289|Active Comparator|ESP block group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. patient controlled analgesia (PCA) protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
16369827|NCT04189289|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. PCA analgesia protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
16369828|NCT04189276|Active Comparator|Group1|T101+ETV(Entecavir) /TDF(Tenofovir)
16369829|NCT04189276|Active Comparator|Group2|T101+ETV/TDF
16369830|NCT04189276|Active Comparator|Group3|ETV or TDF
16369831|NCT04189276|Active Comparator|Group4|Peg-IFNα-2b+ETV/TDF
16369832|NCT04189263|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
16369833|NCT04189263|Active Comparator|No dietary intervention|Standard of care aromatase inhibitors
16369834|NCT04189250|Placebo Comparator|Optimized carbonmonoxid rebreathing protocol (oCO)|2 min rebreathing period seated position capillary blood sampling
16369835|NCT04189250|Active Comparator|Automatized carbonmonoxide rebreathing protocol (aCO)|10 minutes rebreathing period supine position venous blood sampling
16369836|NCT04189237|Experimental|electroacupuncture|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of two times per week for six weeks, for a total of twelve times.
~Acupoint selection: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints."
16369837|NCT04189237|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of two times per week for six weeks, for a total of twelve times.
16369838|NCT04189224|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
16369839|NCT04189224|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
16369840|NCT04189211|Experimental|1.2mg/kg of BAT8001|BAT8001 100mg/box, 1.2mg/kg IV infusions
16369841|NCT04189211|Experimental|2.4mg/kg of BAT8001|BAT8001 100mg/box, 2.4mg/kg IV infusions
16369842|NCT04189211|Experimental|3.6mg/kg of BAT8001|BAT8001 100mg/box, 3.6mg/kg IV infusions
16369843|NCT04189211|Experimental|4.8mg/kg of BAT8001|BAT8001 100mg/box, 4.8mg/kg IV infusions
16369844|NCT04189211|Experimental|6.0mg/kg of BAT8001|BAT8001 100mg/box, 6.0mg/kg IV infusions
16369845|NCT04189198|Experimental|Articaine group|Patients in this group are assigned to recieve 30 ml of Articaine 2%
16369846|NCT04189198|Experimental|Bupivacaine|Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%
16369847|NCT04189185|Active Comparator|K-wire tension band wiring|The patient is treated with 1.6 mm k-wires and 1 mm cerclage
16369848|NCT04189185|Active Comparator|Suture fixation|The fracture is reduced and fixed with 2.0 Orthocord suture.
16369849|NCT04189172||Neuro-Patch|Patients receiving Neuro-Patch® for duraplasty
16369850|NCT04189159|Experimental|PROMPT Treated|PROMPT treatment, twice a day, for 5 days a week, for 3 consecutive weeks
16369851|NCT04189159|No Intervention|Control|Usual treatment
16369852|NCT04189146|Other|Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
16369853|NCT04189133|Experimental|Study group|The study group will receive the daily administration sc of Luveris with increasing dosages two weeks (Treatment phase) as follows: Rec-LH 75 IU daily for 2 weeks; Rec-LH 150 IU daily for 2 weeks; Rec-LH 300 IU daily for 2 weeks; Rec-LH 600 IU daily for 2 weeks.
16369854|NCT04189133|Active Comparator|Control group|"The control group will receive the administration im of Gonasi HP as follows:
~hCG 500 IU two times weekly, for 2 weeks; hCG 1000 IU two times weekly, for 2 weeks; hCG 1500 IU two times weekly, for 2 weeks; hCG 2000 IU two times weekly, for 2 weeks."
16369855|NCT04189120|Active Comparator|Thoracic epidural analgesia (TEA)|Under full aseptic conditions and wearing sterile gloves while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine, then an 18-G Epidural needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal or IV injection. After negative response, 15 ml of 0.25% epidural bupivacaine will be injected and the patient will be turned to the supine position.
16369856|NCT04189120|Active Comparator|Ultrasound-guided superficial serratus plane block (SSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. The muscles will be identified easily overlying the fifth rib, the latissimus dorsi , teres major and serratus muscles . A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle beneath the latissimus dorsi. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected
16369857|NCT04189120|Active Comparator|Ultrasound-guided deep serratus plane block (DSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane between the posterior border of the serratus anterior muscle and the corresponding surface of the rib. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected deep to the serratus muscle separating the serratus anterior muscle from the external intercostal muscle.
16369858|NCT04189107|Experimental|Experimental|High dose Dexamethasone
16369859|NCT04189107|Placebo Comparator|Control|Standard dexamethasone dosage and placebo
16369860|NCT04189094|Experimental|Sintilimab + CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions). After PCI, Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
16369861|NCT04189094|Active Comparator|CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
16369862|NCT04189081|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
16369863|NCT04189081|Sham Comparator|Water Control|Water will be used as a mouth rinse and can be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using water, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
16369864|NCT04189081|Active Comparator|Positive Control|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
16369866|NCT04189055|Experimental|Cohort #2|Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
16369867|NCT04189042||Parkinson Group|Patients with Parkinson's Disease (Hoehn and Yahr stage 1-4)
16369868|NCT04189042||Healthy Control|Healthy People
16369869|NCT04189029||HFpEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≥ 50%, 1000 patients anticipated among which 300 with extensive phenotyping
16369870|NCT04189029||HFrEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≤ 40%, 1000 patients anticipated among which 100 with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
16369871|NCT04189029||Subjects apparently without heart failure|Subjects without history or signs of heart failure, 100 subjects anticipated with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
16369872|NCT04189016|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
16369873|NCT04189016|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
16369874|NCT04188990|Active Comparator|Intervention arm|"The Intervention arm includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients"
16369875|NCT04188990|Placebo Comparator|By demand arm|"The By demand arm will include patients in whom the nutritional intervention, if given, is performed by demand by the medical staff responsible for each patient."
16369876|NCT04188990|Placebo Comparator|Usual care arm|"In the Usual care arm usual hospital practice is followed without any explicit nutritional intervention"
16369877|NCT04188977|Other|Usual Practice|OTPs are able to request from state and federal health department officials to utilize interim methadone treatment to address admission delays in their OTP.
16369878|NCT04188977|Experimental|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
16369879|NCT04188964|Experimental|Treatment|Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
16369880|NCT04188951|Other|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|
16369881|NCT04188938||Occult pneumothorax in trauma patients|Age>16, multi-trauma, consulted thoracic surgeon, underwent CXR- CT.
16369882|NCT04188925|Experimental|Group A|True LA with EA
16369883|NCT04188925|Sham Comparator|Group B|Sham LA with EA
16369884|NCT04188912||Observational (sample collection, survey, imaging, spirometry)|Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomography before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed.
16369885|NCT04188873|Active Comparator|12-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369886|NCT04188873|Active Comparator|12-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 12 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369887|NCT04188873|Active Comparator|24-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369908|NCT04188808|Active Comparator|Peripheral artery disease|Patients with peripheral artery disease defined as (ankle - brachial index, ABI <0.5 or typical symptoms); intermittent claudication (IC), or resting pain and/or minor tissue loss. Will undergo surgery with a femoropopliteal/femorodistal bypass
16370301|NCT04186143|Active Comparator|Active Comparator|In addition to the conservative treatment of the control group, opened cinetic chain exercises were applied for 12 weeks.
16369888|NCT04188873|Active Comparator|24-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369889|NCT04188873|Active Comparator|12-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369890|NCT04188873|Active Comparator|12-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369891|NCT04188873|Active Comparator|24-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369892|NCT04188873|Active Comparator|24-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369893|NCT04188873|Active Comparator|12-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369894|NCT04188873|Active Comparator|12-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief 15-30 minute phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369895|NCT04188873|Active Comparator|24-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369939|NCT04188613|Active Comparator|ETT|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed through the vocal cords.
16369940|NCT04188613|Active Comparator|LMA|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed and laryngeal mask airway device inserted.
16370051|NCT04187885|Experimental|Group/Cohort 2: PAP|"Label : physical activity program without stress Type : experimental
~Description: outside academic stress period (exams), with the physical activity program:60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday."
16370302|NCT04186143|Other|Control Group|Conservative treatment was applied for 12 weeks.
16369896|NCT04188873|Active Comparator|24-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
16369897|NCT04188873|Active Comparator|12-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369898|NCT04188873|Active Comparator|12-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369899|NCT04188873|Active Comparator|24-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369900|NCT04188873|Active Comparator|24-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
16369901|NCT04188860|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
16369902|NCT04188847|Experimental|Study group|The patients would accept the regimen of apatinib combined with cisplatin and paclitaxel
16369903|NCT04188834|Experimental|Sensory Flicker Stimulation|"Patients will be exposed to Sensory Flicker Stimulation.
~In one experiment, patients will be exposed, for about 10 minutes at a time, to a sequence of sensory flicker trials each lasting a few seconds. Each trial may include the following modalities and frequencies of flicker:
~Modalities: auditory only, visual only, or audiovisual combined. Subjects may be exposed to individual pulses of light and/or sound (i.e. around or less than 1 pulse per second).
~Frequencies: random, or anywhere from 5Hz to 100Hz. Subjects may be exposed to sensory flicker at a given frequency or random frequency for up to 1h at a time
~In another experiment, patients will undergo a behavioral task in which they will be exposed to one of 2 flicker conditions on separate days.
~Comfortable parameters (e.g., light intensity and volume intensity) for the subject will be found. If such parameters cannot be found, exposure of the patient to visual and/or auditory stimuli will be stopped."
16369904|NCT04188834|Active Comparator|Electrical Flicker Stimulation|"Patients will be exposed to direct electrical brain stimulation with low-amplitude current, at given flicker frequencies. Patients will be exposed to frequencies ranging from 5-100Hz, for up to 10 seconds at a time. Initially, frequencies of 5.5Hz and 40Hz will be tested.
~During brain stimulation sessions, bipolar electrical stimulation will be applied to one or more areas of the brain at a time either with or without associated behavioral task. Stimulation in the absence of any behavioral task will be applied in order to assess the subject's neurophysiological response to stimulation and to identify the optimal stimulation parameters for use during behavioral task. Stimulation during behavioral task will be applied in an attempt to affect the subject's behavior."
16369905|NCT04188821|Active Comparator|output based group|Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days with no further signs of infection, fluid collection or impaired wound healing
16369906|NCT04188821|Experimental|early-removal group|Investigators remove the drains at hospital discharge, 3-4 days after surgery, regardless of the output at that time
16369907|NCT04188808|Experimental|Popliteal artery aneurysm|Asymptomatic popliteal artery aneurysm patients will undergo surgery with a femoropopliteal/femorodistal bypass
16373263|NCT04165993|Experimental|A combination treatment of KN026 and KN046|KN026 combined with KN046
16369909|NCT04188795|Experimental|Intervention|"Participants who met the criteria for inclusion in the study and volunteered to participate in the study were divided into experimental and control groups by block randomization method.
~After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.
~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
16369910|NCT04188795|No Intervention|Control Group|After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Routine nursing care was applied to hip fracture patients in the control group. Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
16369911|NCT04188782||Pediatric patients undergoing radiotherapy|"Pediatric patients undergoing general anesthesia for radiotherapy treatment. General anesthesia will be accomplished exclusively by the administration of sevoflurane.
~The inhalatory induction will be performed with sevofluorane at 8% with O2 4Lt/min. The maintenance will be with sevofluorane at an end tidal of 2.5% with 1Lt/min of O2.
~The EEG will be obtain with SedLine monitor"
16369912|NCT04188769|Sham Comparator|uninflated - rest|splint around the arm is not inflated both arms are in rest during the entire trial
16369913|NCT04188769|Sham Comparator|uninflated - triggered|splint around the arm is not inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
16369914|NCT04188769|Active Comparator|constantly inflated - rest|splint around the arm is constantly inflated both arms are in rest during the entire trial
16369915|NCT04188769|Active Comparator|constantly inflated - triggered|splint around the arm is constantly inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
16369916|NCT04188769|Experimental|intermittently inflated - rest|splint around the arm is intermittently inflated both arms are in rest during the entire trial
16369917|NCT04188769|Experimental|intermittently inflated - triggered|splint around the arm is intermittently inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
16369918|NCT04188756|Other|Exercise|Group under exercise training for 15 weeks with High intenstiy interval training under medical control
16369919|NCT04188756|No Intervention|Control|Group with standard care according to current guidelines
16369920|NCT04188743|Experimental|Allogenic FMT|Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It's frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
16369921|NCT04188743|Placebo Comparator|Autologous FMT|Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It's processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
16369922|NCT04188743|No Intervention|No intervention|"Participants in the No intervention-group will not receive any treatment but will be monitored similarly as the Allogenic FMT and Autologous FMT groups."
16369923|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fasted|Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.
16369924|NCT04188730|Active Comparator|LUCEMYRA (lofexidine) tablets, fasted|Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours
16369925|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fed|Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.
16369926|NCT04188704|Placebo Comparator|Anterior cruciate ligament normal|normal Anterior cruciate ligament reconstruction
16369927|NCT04188704|Experimental|Anterior cruciate ligament reconstruction|Anterior cruciate ligament reconstruction and Position screw fixation
16369928|NCT04188691|Experimental|vaccine group 1|vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
16369929|NCT04188691|Experimental|vaccine group 2|vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
16369930|NCT04188691|Experimental|vaccine group 3|vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
16369931|NCT04188691|Placebo Comparator|Normal saline|（0.5ml / dose）produced by NVSI
16369932|NCT04188691|Placebo Comparator|Aluminum adjuvant|（0.5ml / dose）produced by NVSI
16369933|NCT04188678|Other|Interventional Arm- Bone Marrow Transplant|"Study visits will include the performance of assessments prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. Assessments include:
~Physical function assessments
~questionnaires about general health and current health compared to health one year ago
~assessments that measure cognition, attention and memory
~assessments regarding personality and psychological and social stressors
~Physiological measures including
~blood tests- 160 mL of blood during evaluations, and 90mL of blood at the day 180 visit.
~bone marrow aspirate collected during standard of care bone marrow biopsies pre-transplant and at day 180
~Saliva collections pre-transplant
~ACTH Stimulation Test
~Oral Glucose Tolerance Test
~Holter Monitor- to record hear rate variability
~MRI pre-transplant and at Day 180 in a subset of 10 subjects"
16369934|NCT04188665|Experimental|MASL treated|Patients treated with lozenge containing MASL
16369935|NCT04188665|Placebo Comparator|Placebo treated|Patients treated with lozenge without MASL
16369936|NCT04188639|Experimental|Treatment with emicizumab|
16369937|NCT04188626|Experimental|Driving session|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving.
16369938|NCT04188613|Experimental|HFJV|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. The patient was extubated, and the jet ventilator catheter was inserted to trachea and ventilation will be start.
16369941|NCT04188600|Experimental|treatment group|"The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations:
~Responding patients: this population, defined by FSFI score > 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks).
~Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks)."
16369942|NCT04188600|Active Comparator|active control group|The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
16369943|NCT04188587|Experimental|177Lu-PSMA-I&T|177Lu-PSMA-I＆Tradioligand therapy with 2.0-8.0GBq in every circle were performed. And then 177Lu-PSMA post-therapy scans were performed at 24 h and 48 h respectively, and the fusion phenomenon was performed at the second day to pre evaluate the efficacy of the patients.
16369944|NCT04188574|Experimental|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
16369945|NCT04188574|Experimental|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
16369946|NCT04188574|Experimental|BB2603-1|Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
16369947|NCT04188561|Active Comparator|Intraarticular injection Group|Patients included in the study had been received 2 ml hyaluronic acid with concentration of 22mg/ml . Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval
16369948|NCT04188561|Active Comparator|Radiofrequency Group|Radiofrequency Generator is a four electrode pain management for interventional pain management procedures. Patients had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
16369956|NCT04188535|Experimental|Esophageal Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
16369957|NCT04188535|Experimental|Glioblastoma Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
16369958|NCT04188535|Experimental|Glioblastoma Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
16369959|NCT04188535|Experimental|Prostate Cancer Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.
~Genomic testing of biopsy sample"
16369960|NCT04188535|Experimental|Prostate Cancer Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.
~Genomic testing of biopsy sample"
16369961|NCT04188535|Experimental|Vulvar Cancer Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
16369962|NCT04188535|Experimental|Pediatric Glioma Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
16369963|NCT04188522||Minor Stroke|"We will enroll a cohort of 15 adult patients previously admitted to Johns Hopkins Bayview Medical Center with small/minor acute ischemic stroke visible on neuroimaging. Patients will follow-up in clinic 4-6 weeks following hospital discharge. To be eligible for the study, patients must have a minor stroke, defined as NIH Stroke Scale score at follow-up of less than or equal to 8, modified Rankin score of 0-2, be competent speakers of English, and have no prior history of stroke, dementia, or untreated psychiatric disease. Those with proximal large vessel (M1) or branch (M2) occlusions will be excluded.
~*Based on preliminary results we have expanded our trial and will continue to recruit up to 40 patients with minor stroke."
16369964|NCT04188522||Controls|For comparison, we will recruit a group of age-similar controls (n=15) without neurologic disease or prior clinical history of stroke.
16370050|NCT04187885|Active Comparator|Group/Cohort 1 : CTL|"Label : control
~Type : comparator
~Description: Outside academic stress period (represented by exams), without the physical activity program (no Intervention)."
16370356|NCT04185805|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
16369965|NCT04188509|Experimental|Voxelotor|"All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years will receive a voxelotor dose of 1500 mg QD, regardless of their body weight. Participants aged < 12 years will receive a voxelotor dose based on their body weight, to provide exposure corresponding to the adult dose of 1500 mg QD. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. The dose should be adjusted if the participant's weight increases or decreases over 2 consecutive clinic visits.
~Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source."
16369966|NCT04188496|Experimental|PULMONARY FUNCTION TEST (PFT) GROUP|"Thoracic joint Mobilization was applied on Experimental group.
~Thoracic Flexion:
~Patient sits on the treatment table with arms across the chest and hands on opposite shoulders. Stand facing the patient's left side.
~Thoracic Extension:
~Performed by asking sits on a treatment chair with arms folded across the chest and hands on opposite shoulders.
~Thoracic Segment Rotation:
~Performed by asking the patient to lie on left side. Place a pillow under patient's waist to assist left side bending. Position the patient's arms are folded across the chest with hands on opposite shoulders to stabilize the shoulder girdle and minimize movement there."
16369967|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
16369968|NCT04188483|Experimental|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. Thirty days after the start of the supplementation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
16369969|NCT04188483|Other|Non-Selenium Supplementation|The control group will not receive selenium supplementation. Thirty days after allocation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
16369970|NCT04188470|Experimental|person-centered care model|healthcare multidisciplinary team will review the appropriateness of medication by a person-centered care model and then the healtcare team will propose changes in the therapeutic plan to the patient or caregiver
16369971|NCT04188470|No Intervention|usual care|the healthcare team will practice usual care
16369972|NCT04188457||Stroke - usual follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with regular follow-up
16369973|NCT04188457||Stroke - intensive follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with intensive follow-up
16369974|NCT04188457||myocardial infarction - usual follow-up|Patient who has had a first or recurrent myocardial infarction with usual follow-up
16369975|NCT04188457||myocardial infarction -intensive follow-up|Patient who has had a first or recurrent myocardial infarction with intensive follow-up
16369976|NCT04188444||Agonist|Ovarian stimulation with agonist of GnRH
16369977|NCT04188444||Antagonist|Ovarian stimulation with antagonist of GnRH
16369978|NCT04188431|Experimental|Dexamethasone|Single intraoperative administration of 0.15 mg/kg of Dexamethasone intravenously with a maximum dose of 5 mg
16369979|NCT04188431|Placebo Comparator|Sodium chloride|Single intraoperative administration of Sodium Chloride (NaCl) 0.9% intravenously
16369984|NCT04188392|Experimental|open-label treatment|pimavanserin 34mg at bedtime for 6 weeks
16369985|NCT04188379|Experimental|efgartigimod|Patient receiving efgartigimod
16369986|NCT04188379|Placebo Comparator|Placebo|Patients receiving placebo
16369987|NCT04188366|Experimental|FAMES Modification|3-month trial of FAMES. Results from modifications will be used to by stakeholders (i.e., family members, client, providers, organizational leadership,) to inform finalization and implementation of FAMES
16369988|NCT04188366|Experimental|FAMES Pilot Trial|Pilot testing of FAMES and implementation toolkit
16369989|NCT04188340|Placebo Comparator|control group|using bergamot massage oil apply to GV20, GV24 SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
16369990|NCT04188340|Experimental|test group|using Su-Man formula massage oil ap-ply to GV20, GV24, SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
16369991|NCT04188327|Sham Comparator|Control group(Group I)|Patients will receive sham stellate ganglion block weekly for three times
16369992|NCT04188327|Experimental|Stellate Ganglion block group (Group II)|Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
16369993|NCT04188314|Experimental|Desflurane Interventional Group|"The intervention group will receive desflurane for maintenance of anaesthesia. Standard protocols for induction and maintenance of anaesthesia will be followed, as discussed with Prof. F. Puehringer, an international expert in the field of desflurane use. A detailed leaflet describing the protocol has been developed, which will be handed to the treating anaesthetist on the day of surgery.
~After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the desflurane vaporiser is opened to 12%. This is maintained until 1MAC is reached. The fresh gas flow will then be turned down to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand."
16370090|NCT04187599|Experimental|Paragon CRT®100 Contact Lens|participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.
16369994|NCT04188314|Active Comparator|Isoflurane Control Group|The control group will receive Isoflurane for maintenance of anesthesia. After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the Isoflurane vaporiser is opened and adjusted to attain 1MAC. Once 1MAC is attained, the fresh gas flow will be reduced to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser will be adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand.
16369995|NCT04188301|Active Comparator|IVM + ALB|Single dose of oral IVM (150 µg/kg) plus ALB (400 mg)
16369996|NCT04188301|Experimental|IDA x 1 dose|Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
16369997|NCT04188301|Experimental|IDA x 3 doses|Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
16369998|NCT04188288|Experimental|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
16369999|NCT04188288|Other|Control feedback|Three imaging (fMRI) sessions of control feedback.
16370000|NCT04188275||Metastatic Castration Resistant Prostate Cancer|Metastatic Castration Resistant Prostate Cancer patients who are eligible for endocrine therapy with ARTA plus LHRH agonist.
16370001|NCT04188262|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
16370002|NCT04188249||RA patients|"Patients (or a representative) must provide informed consent before any procedures occur.
~Main Inclusion Criteria:
~18 years and older
~Fulfil the ACR/EULAR classification criteria for RA in 2010
~Patients able to understand and complete self-evaluation questionnaires.
~General Exclusion Criteria:
~Contraindications for golimumab
~Prior exposure to TNFi/JAKi"
16370003|NCT04188223|Experimental|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
16370004|NCT04188223|Active Comparator|Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
16370005|NCT04188197|Experimental|e-Cigarette Matched to Usual Brand Cigarette|"JUUL and cigarette flavor matched (Mint for menthol smokers and Virginia Tobacco for non-menthol smokers);"
16370006|NCT04188197|Experimental|e-Cigarette Unmatched to Usual Brand Cigarette|"JUUL and cigarette flavor unmatched (Virginia Tobacco for menthol smokers and Mint for non-menthol smokers)."
16370007|NCT04188184|Active Comparator|tranexmic acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
16370008|NCT04188184|Active Comparator|Epinephrine roup|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
16370009|NCT04188171|Experimental|Polidocanol foam sclerotherapy|"During the intervention period the participants are observed at 3-week intervals (maximum of 3 sessions).
~The required number of polidocanol foam sclerotherapy sessions (maximum of 3) is determined by clinical and anoscopic evaluation (if the participant is non-symptomatic and/or there is no significant hemorrhoidal disease on anoscopy, the patient will not be a candidate for additional instrumental therapy moving directly to the follow-up period). After each session all patients were instructed to adopt dietary measures and adequate hydration maintaining therapy with systemic venotropic, topical and laxative if necessary.
~After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
16370010|NCT04188158|Experimental|Intervention Group|3 cycles XELOX + Surgery+ 5 cycles XELOX
16370011|NCT04188158|Other|Control group|Surgery + 8 cycles XELOX
16370014|NCT04188132|Experimental|EEG BCI closed loop feedback for rehabilitation of upper limb|"This study is a pilot study to examine the feasibility of a SMR based EEG BCI using motor task and motor imagery and involve a gaming feedback for same.
~The first two days will be used for calibrating the BMI using commands in computer screen followed by further two days for testing the BMI and feedback control during gaming in computer to move the ball in the computer screen."
16370015|NCT04188119|Experimental|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
16370016|NCT04188119|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
16370017|NCT04188106|Experimental|Hydroxyzine and Varenicline|Participants enrolled in the study will take the FDA approved starter kit of varenicline for the first week of medication administration (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7). During the first week, participants will also receive hydroxyzine dosed in a similar manner, 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night. After the first week, participants will receive the FDA-approved dose of varenicline (1 mg twice daily) combined with hydroxyzine, 25 mg in the morning and 50 mg at nighttime. All medications will be dosed orally.
16370018|NCT04188080|Experimental|Jarlsberg cheese starting dose|The participants obtaining an Osteocalcin increase > 10% during the previous 6 weeks intake of Jarlsberg cheese, will get a percent reduction in the daily cheese-dose equal to the increase in the Osteocalcin level
16370019|NCT04188067|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic, the non-fluent variant or the semantic variant. All participants will receive the same study interventions in a within-subject crossover design.
16370020|NCT04188054|Experimental|Intervention|Will be asked to change the position they lie on their bed when sleeping; that is, to re-position themselves when lying on their back so that their feet (and ankles) hang over the end of the mattress.
16370021|NCT04188054|Placebo Comparator|Control|Will be asked to make no change in the way they normally lie on their mattress when sleeping
16370022|NCT04188041|No Intervention|Qualitative|"Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.
~In Aim 1, 30 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO)."
16370023|NCT04188041|Other|Quantitative|Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 20 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
16370024|NCT04188041|Other|Retrospective chart review|Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.
16370025|NCT04188028|Experimental|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
16370026|NCT04188028|Experimental|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
16370027|NCT04188015|Experimental|2.5mg ANX007|1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.
16370028|NCT04188015|Experimental|5.0mg ANX007|1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.
16370029|NCT04188015|Sham Comparator|Sham Procedure|1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.
16370030|NCT04188002|Other|Control - Fruit and Vegetable|Participants in this arm will receive usual care.
16370031|NCT04188002|Other|Physical Activity Intervention|Participants in this arm will be encouraged via tailored newsletters and email/or text reminders to improve diet and physical activities.
16370032|NCT04187989|Experimental|Social Media Intervention|Facebook page that will deliver health information focused on increasing well-being and reducing risky behaviors.
16370033|NCT04187989|No Intervention|Control|An Attention-Control E-News (control) condition
16370034|NCT04187976||Patients with moderate to severe uncontrolled asthma|Patients with moderate to severe uncontrolled asthma defined on clinical assessment and spirometric criteria. Non controlled asthma is considered when ACQ score ≥ 1.5 or in case of acute exacerbation
16370035|NCT04187976||Patients with recalcitrant CRSwNP requiring sinus surgery|The medical failure in CRSwNP is defined as persistent disease in spite of 3 courses of oral corticosteroid and double dose of local corticoid over 12 months
16370036|NCT04187976||Patients with concomitant CRSwNP and uncontrolled asthma|Patients with concomitant CRSwNP and moderate to severe uncontrolled asthma
16370037|NCT04187976||Healthy subjects|Patients without any airway inflammatory disease or atopy
16370038|NCT04187963|Experimental|Group physical therapy|Groups of 6 patients and 1 physical therapist for the 1.5 hour physical therapy session
16370039|NCT04187963|Active Comparator|Individual physical therapy|1.5 hour physical therapy session 1 on 1 (1 patient and 1 physical therapist)
16370040|NCT04187950|Placebo Comparator|Yogurt with inactivated B. lactis and added cane sugar|Participants will consume yogurt with heat inactivated B. lactis and added cane sugar twice daily for 14 days.
16370041|NCT04187950|Experimental|Yogurt with B. lactis and added honey|Participants will consume yogurt with B. lactis and added honey twice daily for 14 days.
16370042|NCT04187937|Experimental|Experimental|Stereotactic image-guided non-anatomical resection
16370043|NCT04187924|Active Comparator|Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage. Sputum will be collected during the session.
16370044|NCT04187924|Active Comparator|SIMEOX + Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during the session.
16370045|NCT04187911|Experimental|Intervention - Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. DDP aims to treat trauma-related problems and Attachment Disorders over about 20 1-hour sessions using the core communication techniques of Playfulness, Acceptance, Curiosity and Empathy (PACE)
16370046|NCT04187911|Active Comparator|Control - Services as Usual (SAU)|SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise.
16370047|NCT04187898|Experimental|Eflapegrastim @ 30mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).
~Supplied in prefilled single-use syringes for subcutaneous injection.
~Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.
~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
16370048|NCT04187898|Experimental|Eflapegrastim @ 3 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).
~Supplied in prefilled single-use syringes for subcutaneous injection.
~Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.
~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
16370049|NCT04187898|Experimental|Eflapegrastim @ 5 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).
~Supplied in prefilled single-use syringes for subcutaneous injection.
~Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.
~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
16370357|NCT04185805|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
16370052|NCT04187885|Experimental|Group/Cohort 3: AS|"Label : academic stress Type : experimental
~Description: during academic stress period (exams), without the physical activity program (no Intervention)"
16370053|NCT04187885|Experimental|Group/Cohort 4: ASPAP|Label : academic stress and physical activity program Type : experimental Description: during academic stress period (exams), with the physical activity program: 60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday.
16370054|NCT04187872|Experimental|Patients with Recurrent Brain Metastes|Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed SRS treatment will receive LITT per standard of care in combination with Pembrolizumab 200mg IV every 3 weeks (+/-3 days) up to 2 years.
16370055|NCT04187859|Other|Education Session|The participant will receive an education session in their home, lasting between 15-30 minutes from a District Nurse. The District Nurses will advise the participant on how to drink more fluids, the importance of hydration and the effects of dehydration.
16370056|NCT04187859|Other|Prompting Cup|Participants will receive a Droplet Cup with an electronic prompting device and a brief tutorial session from the District Nurse. The Droplet Cup will encourage the participant to stay hydrated during the day, by emitting a voice or light to encourage them to drink more.
16370057|NCT04187859|No Intervention|Control Group|There will be no change to the care the participant receives from the District Nurse.
16370058|NCT04187859|Other|Prompting Cup and Education|Participants will receive a Droplet Cup with an electronic prompting device and an education session on the importance of hydration and the effects of dehydration.
16370059|NCT04187833|Experimental|Nivolumab + Talazoparib|Nivolumab 480mg intravenously every 4 weeks (28 days) + Talazoparib 1mg orally daily
16370060|NCT04187820|Experimental|Acupuncture group|Participants receiving acupuncture and mild moxibustion.
16370061|NCT04187807|Experimental|Melatonin 5mg|Melatonin 5mg, every 24 hours for 14 days
16370062|NCT04187807|Placebo Comparator|Placebo|Starch based placebo, every 24 hours for 14 days
16370063|NCT04187781|Other|external microphone old|
16370064|NCT04187781|Other|external microphone new|
16370065|NCT04187768||Healthy Group|Healthy volunteers will donate a sample of blood to be used as controls
16370066|NCT04187768||NSCLC Group|Patients with advanced NSCLC will have blood collected prior to treatment and after completing 3 cycles of immune checkpoint therapy. . If a patient is noted to have progressive disease after 2 cycles of treatment, a sample will be collected after the 2nd cycle. If a patient is noted to have pseudoprogression (determined at the discretion of the treating physician), an additional sample may be collected after 3 cycles of therapy.
16370067|NCT04187755|Active Comparator|Group I|Participants were given ceftazidime as the antibiotic therapy with standard regimens and dose of antibiotic
16370068|NCT04187755|Experimental|Group II|Participants were given cefepime as the antibiotic therapy with standard regimens and dose of antibiotic
16370069|NCT04187742|Active Comparator|LTC Physicians Receive Social Comparison Email|All LTC physicians who receive a social comparison email
16370070|NCT04187742|No Intervention|LTC Physicians Do Not Receive Social Comparison Email|All LTC physicians who do not receive a social comparison email
16370071|NCT04187742|Active Comparator|LTC Physicians Receive Maintenance Certification Email|All LTC physicians who receive a maintenance certification email
16370072|NCT04187742|No Intervention|LTC Physicians Do Not Receive Maintenance Certification Email|All LTC physicians who do not receive a maintenance certification email
16370073|NCT04187742|Active Comparator|LTC Physician Has (or has not) Opened Prior Report|LTC physicians who opened (or has not opened) at least one report receive an email informing them of their report opening status
16370074|NCT04187742|No Intervention|LTC Physician Has (or has not) Opened Prior Report (Control)|LTC physicians who opened (or has not opened) at least one report receive a standard email without report opening status
16370075|NCT04187729||Diseased|Subjects with a known disease.
16370076|NCT04187729||Non-diseased|Subjects without a known disease and reportedly healthy.
16370077|NCT04187716|Experimental|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.
~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
16370078|NCT04187716|Other|remedies|Treatment for anemia will include remedies such as iron (oral or intravenous), hematopoietic accelerators, and blood transfusions, and will be determined by researchers at each institution to provide optimal treatment for patients.
16370079|NCT04187703|Experimental|5AZA-alt-DEC|"Participants will be treated for a minimum of 24 weeks in the absence of clear evidence of progressive disease. Patients who have any response will be permitted to continue treatment until relapse or progression of disease that is not sensitive to protocol defined dose escalation.
~Treatments will include:
~5-azacytidine (50mg/m^2) Day 1 every week
~Decitabine (5mg/m^2) Day 4 every week
~Weeks 1-8 will be an induction phase, and weeks 9+ will be a long-term treatment phase"
16370080|NCT04187690|Experimental|Jin-shui Huan-xian granule|Participants in this arm will be given Jin-shui Huan-xian granule.
16370081|NCT04187690|Placebo Comparator|Jin-shui Huan-xian granule placebo|Participants in this arm will be given Jin-shui Huan-xian granule placebo.
16370082|NCT04187677|Active Comparator|Hand Therapy Group|
16370083|NCT04187677|Experimental|Sensory Training Group|
16370084|NCT04187664|Experimental|EXCARE Pathway Group|The proposed pathway comprises a range of actions that include individual patient-centered risk assessment by the SAMPE Risk Model (30-day probability of death), specialized care in Post-Anesthetic and Intensive Care Units, and also in the surgical wards performed by the nursing, anesthesia, clinic and surgery teams.
16370085|NCT04187651|Experimental|PRP gel application|PRP application for perianal fistula
16370086|NCT04187638|Experimental|Olive oil|Participants will receive 30ml/day of olive oil for two weeks
16370087|NCT04187638|Placebo Comparator|Butter|Participants will receive 30g/day of butter also for two weeks.
16370088|NCT04187625|Experimental|Intervention|Patients will be given autologous endothelial progenitor cells
16370089|NCT04187612||Total body water measurement|Total body water will be measured using Bioelectrical Impedance Analysis (BIA).
16370358|NCT04185792||Patients with spinal cord injury|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
16370091|NCT04187586||Extracorporeal shock wave therapy group|The ESWT group received shock waves with low-energy flux density (0.05-0.30 mJ/mm2). The interval between treatments is a 1-week. To evaluate the effect of ESWT, we reviewed the skin test results (thickness, melanin, erythema, TEWL, sebum, and skin elasticity levels) immediately before ESWT and immediately after the sixth session. And also the ESWT group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
16370092|NCT04187586||conventional therapy without extracorporeal shock wave therapy|Conventional therapy group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
16370093|NCT04187560|Active Comparator|Part A Cohort 1|LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day
16370094|NCT04187560|Active Comparator|Part A Cohort 2|LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day
16370095|NCT04187560|Active Comparator|Part A Cohort 3|LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day
16370096|NCT04187560|Active Comparator|Part A Cohort 4|LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day
16370097|NCT04187560|Active Comparator|Part A Cohort 5|LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day
16370098|NCT04187560|Active Comparator|Part B Cohort 6|LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
16370099|NCT04187560|Active Comparator|Part B Cohort 7|LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
16370100|NCT04187560|Active Comparator|Part B Cohort 8|LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
16370101|NCT04187547|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
16370102|NCT04187547|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
16370103|NCT04187534|Experimental|Albumin Fluid Resuscitation Optimization Intervention|Our quality improvement intervention seeking to improve appropriate use and reduce inappropriate use of albumin for fluid resuscitation will consist of establishing a clinical champion, educating clinicians, changing the process for albumin ordering through development of an albumin order sheet, and providing quarterly unit-level audit/feedback data to clinicians on albumin utilization.
16370104|NCT04187534|Active Comparator|Usual Practice|Stepped-wedge roll out of 'Albumin Fluid Resuscitation Optimization Intervention' will permit those ICUs wherein intervention has not yet been implemented to serve as controls. These ICUs will prescribe albumin according to usual practice and not be exposed to any components of the intervention.
16370105|NCT04187521|Other|Sensitivity defect|Participants defined as having abnormal insulin sensitivity without an absolute defect in insulin secretion.
16370106|NCT04187521|Other|Secretory defect|Participants defined as having abnormal insulin secretion without a defect in insulin sensitivity.
16370107|NCT04187521|Other|Unclassified|Participants who cannot be classified as having abnormal insulin secretion or abnormal insulin sensitivity or who have both abnormal insulin sensitivity and abnormal insulin secretion.
16370108|NCT04187508|Experimental|AZD8154|Subjects will receive AZD8154 QD dosing for 10 days
16370109|NCT04187508|Placebo Comparator|Placebo|Subjects will receive AZD8154 matching placebo QD dosing for 10 days
16370110|NCT04187495|Experimental|MAX-40279-01|
16370111|NCT04187482|Experimental|Exercise training group|All participants will be receiving same exercise training intervention
16370112|NCT04187469|Experimental|Regimen 1: 2HRM/4HR|Two month of chemotherapy with Moxifloxacin, Isoniazid and Rifampicin, followed by four month of Isoniazid and Rifampicin only.
16370113|NCT04187469|Active Comparator|Regimen 2: 2HRZE/4HR (control regimen)|Two month of chemotherapy with Isoniazid, Rifampicin, Pyrazinamide and Ethambutol, followed by four month of Isoniazid and Rifampicin only.
16370114|NCT04187456|Experimental|Midazolam + Savolitinib|"Treatment Period 1: Single administration of midazolam (1 mg) will occur on Study Day 1, after a high fat, high calorie breakfast, followed by PK sampling for 24 hours.
~Treatment Period 2: Single administration of midazolam 1 mg in combination with a single administration of savolitinib (600 mg), after a high fat, high calorie breakfast will occur on Study Day 5 and PK sampling will occur for 24 hours."
16370115|NCT04187443|Experimental|MS-553 low dose|low dose of MS-553 taken orally
16370116|NCT04187443|Experimental|MS-553 mid dose|mid dose of MS-553 taken orally
16370117|NCT04187443|Experimental|MS-553 high dose|high dose of MS-553 taken orally
16370118|NCT04187430||Retrospective group|
16370119|NCT04187430||Prospective group|
16370120|NCT04187417|Experimental|Topical tetracaine|Topical tetracaine hydrochoride 1%
16370121|NCT04187417|Placebo Comparator|Balanced artificial tear solution|Balanced artificial tear solution (Systane)
16370122|NCT04187404|Experimental|5-cohort study design|"Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.
~Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 2A and 2B) with adrenal carcinoma.
~Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 3A and 3B) with progressive malignant pheochromocytoma/paraganglioma."
16370123|NCT04187391|Experimental|Active tDCS plus individual language training|Active tDCS plus individual language training
16370124|NCT04187391|Active Comparator|placebo tDCS plus individual language training|placebo tDCS plus individual language training
16370125|NCT04187391|Active Comparator|Active tDCS plus unstructured cognitive stimulation|Active tDCS plus unstructured cognitive stimulation
16370126|NCT04187378|No Intervention|Control Group|Body temperature of the patients will be measured in the pre-operative service and in the waiting room. Sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
16370165|NCT04187092|Active Comparator|Standard Rehabilitation group|Participants in this group will perform exercises with the same focus and frequency. No exercises will be performed with the KneeBright device.
16370127|NCT04187378|Experimental|Underbody Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
16370128|NCT04187378|Experimental|Surgical Access Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown surgical access blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
16370129|NCT04187365|No Intervention|GROUP 1 (NonSevere PUR and women without PUR)|Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.
16370130|NCT04187365|Experimental|GROUP 2 (Severe PUR)|Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.
16370131|NCT04187352|Experimental|CS1001+ Fluorouracil+Cisplatin|
16370132|NCT04187352|Active Comparator|Placebo+ Fluorouracil+Cisplatin|
16370133|NCT04187339|Experimental|NGM395 Dose 1|NGM395 Subcutaneous Injection
16370134|NCT04187339|Experimental|NGM395 Dose 2|NGM395 Subcutaneous Injection
16370135|NCT04187339|Experimental|NGM395 Dose 3|NGM395 Subcutaneous Injection
16370136|NCT04187339|Experimental|NGM395 Dose 4|NGM395 Subcutaneous Injection
16370137|NCT04187339|Experimental|NGM395 Dose 5|NGM395 Subcutaneous Injection
16370138|NCT04187339|Experimental|NGM395 Dose 6|NGM395 Subcutaneous Injection
16370139|NCT04187339|Placebo Comparator|Placebo|Placebo
16370140|NCT04187326|Experimental|6 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test.
16370141|NCT04187326|Experimental|12 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. Participants in this group will complete this task twelve month after their first visit.
16370142|NCT04187313|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention package (i.e. private practitioners in the selected areas who agree to participate).
16370143|NCT04187313|No Intervention|Control|Private practitioners in the control areas will receive no intervention.
16370144|NCT04187300|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (Formulation D)
16370145|NCT04187300|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (Formulation B)
16370146|NCT04187287|Active Comparator|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will be given for 3 weeks, 1 days in a week. Moreover 10-12 minutes cold pack will apply for every session.
16370147|NCT04187287|Active Comparator|Deep Friction Massage|Deep Friction Massage treatment will be given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
16370148|NCT04187235||Keyhole rapair|74 patients who undervent parastomal hernia repair with keyhole technique 1997-2009
16370149|NCT04187235||Sugarbaker repair|61 patients who undervent parastomal henia repair a.m. Sugarbaker 2009-2015
16370150|NCT04187222|Experimental|Test Group|Mechanical treatment + Bifidobacterium animalis subsp. lactis
16370151|NCT04187222|Placebo Comparator|Control Group|Mechanical treatment + Placebo
16370152|NCT04187209|Other|Non-traumatic hemiplegia in post stroke acute subacute phase|
16370153|NCT04187196|Experimental|Sedation with propofol group|Participants in this group will be randomized to sedation with bolus dosing of propofol for cardioversion.
16370154|NCT04187196|Experimental|Sedation with methohexital group|Participants in this group will be randomized to sedation with bolus dosing of methohexital for cardioversion.
16370155|NCT04187183|Experimental|Fresh PRP with concentrate Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma with concentrated Leukocytes
~1 infiltration weekly, for 3 weeks."
16370156|NCT04187183|Active Comparator|Fresh PRP without concentrated Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma without concentrated Leukocyte.
~1 infiltration weekly, for 3 weeks."
16370157|NCT04187170|Experimental|Healthy sedentary subjects exposed to the training program|
16370158|NCT04187157||Blue-light filtering intraocular lens (IOL)|Bilateral implantation of blue-filtering intraocular lens. Blue-IOL, in addition to ultraviolet, also impede the transmission of the lower visible blue spectrum between 400 and 500nm.
16370159|NCT04187157||Conventional intraocular lens (IOL)|Bilateral implantation of conventional ultraviolet light-blocking intraocular lens
16370160|NCT04187144|Experimental|Gepotidacin|Participants will be administered oral doses of 1500 mg gepotidacin plus nitrofurantoin matching placebo BID; approximately every 12 hours for 5 days
16370161|NCT04187144|Active Comparator|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
16370162|NCT04187131|Experimental|augmented reality|
16370163|NCT04187118||Lymphoma patients|Patients being in complete response after a first therapy for malignant lymphoma.
16370164|NCT04187092|Experimental|KneeBright group|Participants in this group will perform exercises aimed to improve the muscle strength, balance and precision. Participants will perform exercises three times a week for 12 weeks. Each session will last for an hour. Some of the exercises will be performed with the KneeBright Device while playing a video game.
16370166|NCT04187079||IPF|Patients diagnosed with idiopathic pulmonary fibrosis after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
16370167|NCT04187079||Other ILDs|Patients diagnosed with other interstitial diseases other than IPF after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
16370168|NCT04187066||Obese|severe obesity
16370169|NCT04187066||Control|Control group with normal weight
16370170|NCT04187053|Experimental|Conventional mechanical therapy with aPDT adjunct|Traditional non-surgical mechanical debridement along with antimicrobial photodynamic therapy will be done at implant sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. The dye will be applied topically confined to the epithelialized space surrounding the implant fixture and will not be internalized. After 5 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the implant using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
16370171|NCT04187053|Sham Comparator|Conventional mechanical therapy with sham aPDT treatment|"Control group will have conventional mechanical instrumentation of implant site with Sham aPDT treatment with saline and non-light emitting laser"
16370172|NCT04187040|Active Comparator|3-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 3-step hand hygiene technique.
16370173|NCT04187040|Active Comparator|6-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 6-step hand hygiene technique.
16370176|NCT04187014|Active Comparator|Tranexamic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid are 650 mg each. The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
16370177|NCT04187014|Experimental|Aminocaproic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic tablets are 1000 mg each.The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For the aminocaproic acid, a total dose of 6 grams (6 tablets) divided between the 3 administrations (2 gram each, ie 2 tablets of 1000 mg) will be administered."
16370178|NCT04187001||Judges|Professionals that assess the content validity of the exercise protocol
16370179|NCT04187001||Target population|People that assess the exercise protocol for cultural adaptation
16370180|NCT04186988|Experimental|Diagnostic ([18F]-AraG)|Patients receive [18F]-AraG IV and then undergo PET/CT over 2 hours at baseline and within 2 weeks after starting immunotherapy. Patients may also undergo blood sample collection.
16370181|NCT04186975||Low-risk pregnant women|Normal cohort: this cohort consists of pregnancies which are not at risk. Data are recorded during the normal checkup happening as part of the usual care pathway
16370182|NCT04186975||High-risk pregnant women|Risk cohort: this cohort consists of pregnancies at risk and which are regularly recorded for the purpose of fetal surveillance. Specifically, the investigators recruit pregnancies with intra uterine growth restricted fetuses for this study.
16370183|NCT04186962|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
16370184|NCT04186962|No Intervention|Usual care|Usual care
16370185|NCT04186936|Experimental|Treatment Sequence AB|Participants will receive Test Product A (single dose of 2 caplets [Combination caplet with loperamide hydrocloride [HCl] 2 milligram [mg] + simethicone 125 mg]) orally on Day 1 followed by Reference Product B (single dose of 2 Imodium Express tablets-lyophilizate [2*2 mg loperamide HCl] + 6 Espumisan capsules [6*40 mg simethicone]) orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
16370186|NCT04186936|Experimental|Treatment Sequence BA|Participants will receive Reference product B orally on Days 1 followed by Test product A orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
16370187|NCT04186923|Experimental|Intervention group (IG)|Families receive permanent contact persons to support in the organisation of everyday life, financial applications, during emotional coping with illness and open communication within the family.
16370188|NCT04186923|No Intervention|Control Group|In the control group the families are treated according to the standard of care.
16370189|NCT04186910|Placebo Comparator|Control group|The control group will not receive any feedback on levels of physical activities but will receive any planned usual care rehabilitation activities
16370190|NCT04186910|Experimental|Feedback group|The feedback group will have an active feedback intervention of physical activities, consisted of daily feedback, received through a Fitbit application, and weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. The experimental group will receive any planned usual care rehabilitation activities.
16370191|NCT04186897|Experimental|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
16370192|NCT04186897|Sham Comparator|No occlusal reduction|Occlusal surfaces kept intact. No actual occlusal reduction..
16370193|NCT04186884||Observational (questionnaires)|Patients and caregivers visiting SCC for a consult or admitted to PCU complete questionnaires over 35 minutes.
16370200|NCT04186858||Symptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.
16370201|NCT04186858||Asymptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.
16370202|NCT04186845|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
16370203|NCT04186832|Active Comparator|Group I (pedometer)|Patients wear a pedometer for step count monitoring over 6 weeks.
16370204|NCT04186832|Experimental|Group II (FitBit)|Patients wear a FitBit for step count monitoring over 6 weeks.
16370205|NCT04186819|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
16370206|NCT04186806|Experimental|3M Dry Mouth Moisturizing Spray|Dry mouth agent
16370207|NCT04186806|Active Comparator|Biotene Moisturizing Mouth Spray|Dry mouth agent
16370208|NCT04186793|Experimental|Guided Grocery Shopping|Participants in this study arm will receive a guided grocery shopping intervention for four weeks.
16370209|NCT04186793|Experimental|Diet Provision Group|"Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low free sugars diet (goal of <3% of total calories)."
16370210|NCT04186780|Experimental|Intervention group|Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
16370211|NCT04186780|Placebo Comparator|Placebo group|Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.
16370212|NCT04186767|Experimental|Weight loss|
16370213|NCT04186754|Experimental|Comprehensive functional care plan|"The intervention will be carried out thanks to the reeducation to the effort carried out in the individuals, which will have the following interventions:
~The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy."
16370214|NCT04186754|Active Comparator|Traditional intervention without rehabilitation|"Nursing care.
~Medical care.
~Spiritual attention."
16370215|NCT04186741||HBO Group|Patients already recieving hyperbaric oxygen therapy for treatment of other medical conditions requiring it as in diabetic foot , cerebral infarctions
16370216|NCT04186728|Placebo Comparator|Placebo to magnesium|Participants will be asked to consume a daily placebo (cellulose) capsule for 12 weeks. They will then cross-over and consume 200mg of elemental magnesium in the form of magnesium glycinate daily for 12 weeks.
16370217|NCT04186728|Experimental|Magnesium to placebo|Participants will be asked to consume 200mg of elemental magnesium in the form of magnesium glycinate daily. They will then cross-over and consume a daily placebo (cellulose) capsule for 12 weeks.
16370218|NCT04186715||TOETVA|The demographic data of the patients undergoing TOETVA surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
16370219|NCT04186715||Open thyroidectomy|The demographic data of the patients undergoing open thyroidectomy surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
16370220|NCT04186702|Active Comparator|visual acuity letter score|visual acuity letter score is used to compare between the two groups after interventional procedures
16370221|NCT04186702|Active Comparator|macular thickness(CST)|macular thickness(CST)is used to compare between the two groups after interventional procedures
16370222|NCT04186689||children in fully food secure households (G1)|preschool children live in a fully food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
16370223|NCT04186689||children in marginally food secure households (G2)|preschool children live in a marginally food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
16370224|NCT04186689||children in food insecure households (G3)|preschool children live in a food-insecure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
16370225|NCT04186676||MINOCA patients|Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites
16370226|NCT04186663|Experimental|Advantage Arrest|38% silver diamine fluoride, topical, 1 drop, single application
16370229|NCT04186624|Experimental|Supervised Exercise Program|The exercise program that applied at the hospital includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
16370230|NCT04186624|Active Comparator|Home-based Exercise Program|The home-based exercise program given with a brochure that includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
16370231|NCT04186611|Experimental|Early daily occupational therapy intervention|A daily occupational therapy intervention is performed with the patients included. The intervention will consist of assessment as well as early positioning and/or rehabilitation in activities of daily living.
16370232|NCT04186598|Experimental|Experimental: CPAP|Participants will be treated with CPAP. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
16370233|NCT04186598|Placebo Comparator|Control: High flow oxygen|Participants will be treated with an altered CPAP mask that will deliver high flow oxygen. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
16370359|NCT04185792||Patients with multiple sclerosis|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
16370234|NCT04186585|Experimental|First design level|All the 8 patients receives a daily oral dose of BP-C2 in ml equals the body weight divided by 5 for 4 weeks. This represents 15 ml for a patient of 75 kg
16370235|NCT04186585|Experimental|Second design level|Based on the results from the first design level, the daily BP-C2 dose will individually be increased by a factor of 1.4 or 1.2 in case of none or mild toxicity increase. If moderate or severe increase in toxicity is observed, the individual dose will be reduced by 0.8 or 0.6, respectively. Duration of the treatment is 4 weeks
16370236|NCT04186585|Experimental|Third design level|Based on the results from the second design level, the daily BP-C2 dose will individually be increased in case of none or mild toxicity increase and reduced if moderate or severe increase in toxicity is observed. Duration of the treatment is 4 weeks
16370237|NCT04186559|Experimental|Topical pentoxifylline (PTX) gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical PTX gel in their initial course of treatment will receive topical placebo gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
16370238|NCT04186559|Placebo Comparator|Topical placebo gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical placebo gel in their initial course of treatment will receive topical PTX gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
16370239|NCT04186546||Cases|Zephyr Valve Procedure
16370240|NCT04186533|Experimental|Default Intervention|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
16370241|NCT04186533|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read brief nutrition education handouts before online grocery shopping.
16370242|NCT04186520|Experimental|8/12 Day Production of CAR-T|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.
~Phase 1b: Six to nine patient expansion cohorts at eight or 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
16370243|NCT04186520|Experimental|12-Day Production of Car-T Cells|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.
~Phase 1b: Six to nine patient expansion cohorts at 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
16370244|NCT04186520|Experimental|Phase 2 - Efficacy of CAR-20/19-T cells in MCL|"Single-stage Phase II design with 3-month CR as the target endpoint.
~Optimal production times will be determined following phase 1 of the study."
16370245|NCT04186507||Prelaminary group|To confirm that Li+ is detectable in sweat .
16370246|NCT04186507||Spectrophon LTD biosensors for Li+ detection in sweat|In this group will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat
16370247|NCT04186494|Active Comparator|Continuous positive airway pressure (CPAP)|Standard CPAP Therapy
16370248|NCT04186494|Experimental|Liraglutide-based weight loss regimen|Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
16370249|NCT04186494|Experimental|Combination CPAP/Liraglutide|Combination of both interventions
16370250|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
16370251|NCT04186468|Experimental|ICU follow-up clinic|Participants will be invited to visit the ICU follow-up clinic.
16370252|NCT04186468|No Intervention|Usual care|Participants will solely receive usual care.
16370253|NCT04186455|Active Comparator|insertion time|lma pro seal and basks-mask in patients undergoing ups
16370254|NCT04186455|Active Comparator|oropharyngeal leak pressure|lma baska-mask undergoing urs
16370255|NCT04186442|Experimental|Botulinum toxin type A (Botulax®)|
16370256|NCT04186442|Active Comparator|Botulinum toxin type A (Botox®)|
16370257|NCT04186429||traumatic brain injury|Children with traumatic brain injury
16370258|NCT04186429||orthopedic injury|Children with orthopedic injury
16370259|NCT04186416||Patients less than 6 months old|Patients less than 6 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
16370260|NCT04186416||Patients between 6 and 12 months old|Patients between 6 and 12 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
16370261|NCT04186416||Patients between 1 and 6 years old|Patients between 1 and 6 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
16370262|NCT04186416||Patients between 6 and 10 years old|Patients between 6 and 10 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
16370263|NCT04186403|Experimental|Study Drug|2 to 3 mg per day
16370264|NCT04186390||Medical doctors|Medical doctors with no prior experience in the evaluation of small bowel capsule endoscopy.
16370265|NCT04186377|Active Comparator|Standard-of-care managed group|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
16370266|NCT04186377|Experimental|S26E|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application
16370267|NCT04186364|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the ED visit will serve as our intervention group. The participants will be assigned an Ambassador throughout the child's ED visit and will complete a patient satisfaction survey afterwards. The investigators hold to enroll 120 controls.
16370655|NCT04183725|Experimental|Experimental group|Reduning injection +Oseltamivir phosphate granule simulants
16370268|NCT04186364|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the ED visit will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the ED visit, however no ambassador will be assigned during the ED visit. The investigators hope to enroll 120 controls.
16370269|NCT04186351|Experimental|Encounter notification service|For participants randomized to the intervention group, their encounter information stored in the eHRSS will be provided to the SCHSA via the automated notification service. Healthcare professionals of the SCHSA would access the electronic health record and provide caring support and services via telephone calls during the 12-month study period.
16370270|NCT04186351|No Intervention|Usual care service|For participants randomized in the control group, no notification will be sent to the SCHSA. Usual care service will be provided during the 12-month study period. In addition, each control participant will receive placebo phone calls at least once every three months (e.g., the calls could be about greeting and general checking).
16370271|NCT04186338||Patients with myelomeningocele|Patients diagnosed myelomeningocele with the neurological level between L5 and S3
16370272|NCT04186338||Healthy controls|age-, sex-, and body mass index-matched healthy controls
16370273|NCT04186325|No Intervention|Group C|Group C: the regular mechanical ventilation protocol will be followed.
16370274|NCT04186325|Experimental|Group T|Group T: inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
16370275|NCT04186312|Experimental|Immediate Treatment|Cognitive-Behavioral Treatment program known as ACCESS
16370276|NCT04186312|Other|Delayed Treatment|Allowed to receive treatment as usual during study, then received ACCESS after delay of two-semesters
16370277|NCT04186299|Experimental|Clonidine + articaine/epinephrine|1.7mL of 4% articaine/epinephrine(1:100,000) + clonidine (15ug/ml)
16370278|NCT04186299|Active Comparator|articaine/epinephrine|1.7mL of 4% articaine with 1:100,000 epinephrine
16370279|NCT04186286|Active Comparator|1st drug Ivabradine|Patients will take Ivabradine first followed by Propranolol and Placebo
16370280|NCT04186286|Active Comparator|2nd drug Ivabradine|Patients will take either Propranolol or placebo first and then Ivabradine
16370281|NCT04186286|Active Comparator|3rd drug Ivabradine|Patients will take Propranolol and placebo first and then Ivabradine
16370282|NCT04186273|Sham Comparator|Donor Site Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
16370283|NCT04186273|Experimental|Donor Site Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
16370284|NCT04186273|Experimental|Donor Site Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
16370285|NCT04186273|Sham Comparator|Skin Graft Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.
16370286|NCT04186273|Experimental|Skin Graft Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
16370287|NCT04186273|Experimental|Skin Graft Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
16370288|NCT04186260|Experimental|NAFLD-specific weight loss intervention|Participants will attend 12 weekly 30-45-minute individual counseling sessions and receive tailored lesson materials focused on behavioral strategies for adopting and maintaining healthy eating and physical activity (PA) behaviors. Participants will self-monitor their body weight, eating, and PA behaviors in a weekly journal. Dietary recommendations will follow nutritional guidelines for the treatment of NAFLD. To facilitate the adoption of the dietary recommendation, participants will be provided culturally-tailored meal plans and grocery lists that allow them to make small, practical dietary changes of ~100 calories. Participants will be prescribed weekly exercise goals with the duration increasing from 15-45 minutes, 5 days/week, over the 12-month program. After the completion of 12 weekly individual counseling sessions, participants will complete a 12-week follow-up including bi-weekly phone calls, followed by a 6-month follow-up period in which no intervention contact is made.
16370289|NCT04186260|Other|Wait-list control|The wait-list control group will receive the same intervention strategies described for the NAFLD-specific weight loss intervention after study comparisons have been made.
16370290|NCT04186247|Other|Standard of Care|SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
16370291|NCT04186247|Experimental|Standard of Care + Antibiotics|"SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
~Azithromycin (weeks 4-12)
~Metronidazole (weeks 4-12)"
16370292|NCT04186234|Experimental|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 35 to 50 Grays in 5 fractions over 5 to 14 days.
16370293|NCT04186221|Experimental|Treatment arm|
16370294|NCT04186195||Diabetic children aged 1-16 years and their families|Diabetic children aged 1-16 years and their families. A child's disease duration must be over 1 year so that possible remission period is over.
16370295|NCT04186182|Other|CICI - Feasibility trial study group|The feasibility of the entire CICI-protocol will be evaluated. See details above.
16370296|NCT04186169|Placebo Comparator|Arm 1: Paroxysmal AF - PVI arm|The subjects with paroxysmal AF undergo pulmonary vein isolation (PVI).
16370297|NCT04186169|Placebo Comparator|Arm 2: Persistent AF - PVI arm|The subjects with persistent AF undergo pulmonary vein isolation (PVI).
16370298|NCT04186169|Experimental|Arm 3: Persistent AF - PVI + Fat-targeted ablation|The subjects with persistent AF undergo pulmonary vein isolation (PVI) and additional ablation to target the inflammatory fat tissue
16370299|NCT04186156|Experimental|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
16370300|NCT04186143|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, closed cinetic chain exercises were applied for 12 weeks.
16370303|NCT04186130||SB|Children over 3 years old and under 12 years old who have been diagnosed with spinal bifida with spinal MRI. They should not have known inflammatory bowel disease or cloacal anomaly
16370304|NCT04186130||Control|Children over 3 years old and under 12 years without known inflammatory bowel disease or cloacal anomaly
16370305|NCT04186117|Experimental|Biological collection|"For all the patients include in the study :
~- Blood samples collected at before any treatment
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16370306|NCT04186104|Experimental|Patients with routine outpatient service process|After registration, the patient waits in line at the door of the doctor's office. His doctor uses traditional methods to enter medical records by hand and make diagnosis independently. Then the patient waits in line to pay the bill and queues up for examination. Finally, the patient would take the examination report back to the doctor.
16370307|NCT04186104|Experimental|Patients with AI assisted outpatient service process|After registration, the patient binds his information to the mobile phone application through outpatient' number. First, AI system would ask the patient a series of questions. Then it would make a judgment based on the patient's response. The system transmits the examination items to the doctor's computer and, with the doctor's approval, sends items back to the patient. So, patient could go straight to do the examination. While waiting for his turn, the patient enters the phone program again, and the AI system collects his medical history. The information is sent back to the doctor. When the patient goes to the doctor's office with the examination report, the doctor's computer already has his medical records. The doctor only needs to adjust the history according to the actual situation. After writing the medical history, the AI system could automatically make the diagnosis. Doctor uses the AI' results and his own judgment to make a comprehensive diagnosis.
16370308|NCT04186078||obstructive sleep apnea (OSA)|5 or more predominantly obstructive respiratory events [obstructive and mixed apneas, hypopneas or respiratory effort-related arousals (RERAs)] per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
16370309|NCT04186078||central sleep apnea (CSA)|"PSG shows all of the following:
~5 or more central apneas and/or central hypopneas per hour of sleep.
~The number of central and/or central hypopneas is > 50% of the total number of apneas and hypopneas."
16370310|NCT04186078||control|apnea-hypopnea index < 5 per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
16370311|NCT04186052|Experimental|BCMA CAR-T cells Infusion|
16370312|NCT04186039|Experimental|Congenital diaphragmatic and parietal malformations|Patients with fetal magnetic resonance imaging as part of their usual medical care, for fetal / placental indications of diaphragmatic hernia, omphalocele or gastroschisis.
16370313|NCT04186026|Other|Saline+Saline|
16370314|NCT04186026|Other|Neurotensin+Saline|
16370315|NCT04186026|Other|GLP-1+Saline|
16370316|NCT04186026|Other|Neurotensin + GLP-1|
16370317|NCT04186013|Experimental|Experimental arm|Atezolizumab 1200 mg intravenous infusion every 3 weeks for a total of 6 doses combined with External Beam Radiation Therapy (EBRT) (dosage: 60 Gy in 30 fractions overs 6 weeks at 2Gy/day)
16370318|NCT04186000|Experimental|group 1|Booster vaccine with AD26.ZEBOV after 1 year
16370319|NCT04186000|Experimental|group 2|Booster vaccine with AD26.ZEBOV after 2 years
16370320|NCT04185987|Experimental|Microbial colonisation|microbial sample collection was done at the end of the time periods T1 (6 weeks after bonding ), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
16370321|NCT04185987|Experimental|Plaque index|Plaque index was measured prior to bonding (T0), 6 weeks after bonding (T1),10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
16370322|NCT04185987|Experimental|Gingival index|Gingival index was measured prior to bonding (T0), 6 weeks after bonding (T1), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
16370323|NCT04185987|Experimental|surface roughness|surface roughness was measured before usage and after 4-weeks usage
16370324|NCT04185974|Experimental|C12 irradiation|Evaluation of Safety and Toxicity of C12 ion reirradiation
16370325|NCT04185974|Active Comparator|Photon irradiation|Evaluation of Safety and Toxicity of photon re-irradiation
16370326|NCT04185961|Experimental|EVERA-RAPHA with 60mmHG|EVERA-RAPHA apply 15 minutes with 60mmHG every day for 4 weeks
16370327|NCT04185961|Experimental|EVERA-RAPHA with 100mmHG|EVERA-RAPHA apply 15 minutes with 100mmHG every day for 4 weeks
16370328|NCT04185948|Experimental|Mediterranean diet plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
16370329|NCT04185948|Active Comparator|Eatwell guide plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
16370330|NCT04185935||Ancillary-correlative (biospecimen collection)|Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
16370331|NCT04185922|Experimental|Hemopatch|The RARP and BPLND are performed in the usual manner. Towards the end of the operation, Hemopatch is laid over the ends of raw truncated lymphatic tissue.
16370332|NCT04185922|No Intervention|Control|The RARP and BPLND are performed in the usual manner. Hemopatch will not be applied to control group.
16370333|NCT04185909|Experimental|All Subjects|Subjects will be treated with the Renuvion Dermal System.
16370456|NCT04185116|Experimental|3D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
16370349|NCT04185870|Experimental|3D scan and standard photography arm|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum. In addition, all participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
16370350|NCT04185857||Patients with primary aldosteronism (PA)|"After two biochemical and clinical evaluations under baseline conditions PA patients will be treated with canrenone 50-100 mg orally once a day.
~After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1). After, they will continue with a combination therapy with canrenone, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension.
~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2)."
16370351|NCT04185831|Experimental|NF1/MAP2K1|Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
16370352|NCT04185831|Experimental|MTOR/TSC1/TSC2|Everolimus, 10mg po daily.
16370353|NCT04185831|Experimental|Mutation burden|Atezolizumab. 1200mg iv every 3 weeks.
16370354|NCT04185818|Experimental|Reading group|"Participants will:
~Read a book for 15 to 30 mins
~Read immediately before trying to go to sleep."
16370355|NCT04185818|No Intervention|Control Group|"Participants will:
~1. Not read a book"
16373293|NCT04165707|Active Comparator|Weight Watchers comparator arm|Weight Watchers app
16370360|NCT04185779||Group A (Cross-sectional arm)|This group will comprise of 10,000 patients who have been referred for a colonoscopy. We will be collecting information on their past medical history, smoking history, alcohol history, medication history and family history in addition to their colonoscopy findings. In 6000 of these patients, they will have blood tests, Faecal Immunochemical Test (FIT) level, blood or saliva for DNA extraction and stool microbiome taken. In 4000 of these patients, we will record recent blood tests of interest and they will have no new samples taken. All 10000 patients will also either complete a food frequency questionnaire or endoscopy patient experience questionnaire.
16370361|NCT04185779||COLO-SPEED (Group B, consent for contact arm)|This will be 10,000 patients who will consent for future contact for future research studies.
16370362|NCT04185766|Placebo Comparator|Placebo (0,5 ml/Kg)|
16370363|NCT04185766|Placebo Comparator|Placebo (1 ml/Kg)|
16370364|NCT04185766|Experimental|Destrogel (0,5 ml/Kg)|
16370365|NCT04185766|Experimental|Destrogel (1 ml/Kg)|
16370366|NCT04185753||Obese adolescents with CI|Obese adolescents with chronotropic incompetence
16370367|NCT04185753||Control group|Obese adolescents without chronotropic incompetence
16370368|NCT04185740|Experimental|Home-based validation|The home-based validation of the TTT will give insight in the task performance of patients OFF-medication compared to ON-medication and on different time points in the medication cycle during 7 days
16370369|NCT04185727|No Intervention|Standard of Care (SOC)|Therapy control group
16370370|NCT04185727|Experimental|Standard of Care (SOC) + strength training|Strength training intervention as add on to therapy
16370371|NCT04185714|Experimental|Experimental group|Experimental group will be applied Kinesotaping , exercise programme will be given.
16370372|NCT04185714|No Intervention|Control group|Exercise programme will be given.
16370373|NCT04185714|Placebo Comparator|Placebo group|Sham taping will be applied, exercise programme will be given.
16370374|NCT04185701|Experimental|Eye examination by expert and SiVIEW software|Eye examination by an expert and by a technician with the SiVIEW system.
16370375|NCT04185688||Multiple Sclerosis|"Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
~Biodex Balance System: Biodex Balance System is used to evaluate limits of stability. The limits of stability test consists of standing on the platform and leaning in eight directions to make a cursor displayed on the system's screen hit a target.
~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).
~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
16370376|NCT04185688||Healthy People|Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
16370377|NCT04185675|Active Comparator|Macintosh laryngoscope|
16370378|NCT04185675|Experimental|nonadjustable videolaryngoscope|
16370379|NCT04185675|Experimental|adjustable videolaryngoscope|
16370380|NCT04185662|Placebo Comparator|placebo|intake 200 ml water daily for 3 months
16370381|NCT04185662|Experimental|low dose sucrolose group|intake 12.3mg sucralose in 200 ml water daily for 3 months
16370382|NCT04185662|Experimental|moderate dose sucrolose group|intake 73.8mg sucralose in 200ml water daily for 3 months
16370383|NCT04185649|Experimental|BAT8001 for injection|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
16370384|NCT04185649|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
16370385|NCT04185636||Skin Graft Patients|There will only be 1 group, patients receiving a skin graft and MolecuLight i:X imaging
16370386|NCT04185623||Group A (immediate denudation)|Oocytes were denudated immediately after oocyte retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
16370387|NCT04185623||Group B ( 2hs denudation after ovum pickup)|Oocytes were denudated 2 hours after retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
16370388|NCT04185610|Experimental|Qi Gong|Weekly QiGong for Chemotherapy-Induced Neuropathy classes for 10 weeks
16370389|NCT04185597|Experimental|HFP Intervention: Delivery by Community Farmers|"HFP- Delivered by community farmers, supported by the study and linked to eligible households to educate on growing nutritious food and poultry rearing or fish culture
~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female community nutrition promoters (CNPs) will refer PLW to service delivery points; gradually this will be completed by peer leaders
~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices
~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will later be replaced by peer leaders"
16370457|NCT04185116|No Intervention|2D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
16370656|NCT04183725|Active Comparator|Control group|Oseltamivir phosphate granules+ Reduning injection simulants
16370390|NCT04185597|Experimental|HFP Intervention: Delivery by agricultural Retailers|"HFP- Delivered by agricultural Retailers, supported by the study and linked to eligible households to educate on growing nutritious food and either poultry raring or fish culture
~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female CNPs will refer PLW to service delivery points; gradually this will be completed by peer leaders
~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices
~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will be replaced by peer leaders"
16370391|NCT04185597|Active Comparator|Standard of Practice|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
16370392|NCT04185571|Experimental|PEPA membrane|PEPA membrane is an adsorbant synthetic copolymer (Poly Ester Poly Arylate)
16370393|NCT04185571|No Intervention|non adsorbent membrane|Comparison with non adsorbent membrane used in routine
16370394|NCT04185558|Experimental|ActiGraft|Whole blood clot (WBC) gel
16370395|NCT04185558|Active Comparator|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
16370396|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 1|3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
16370397|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 2|3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
16370398|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 3|3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
16370399|NCT04185545|Placebo Comparator|Immunogenicity Group - Placebo|3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
16370400|NCT04185545|Experimental|Other Efficacy Group - RV3 Vaccine (Bio Farma)|3 oral doses of RV3 vaccine (Bio Farma) administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
16370401|NCT04185545|Placebo Comparator|Other Efficacy Group - Placebo|3 oral doses of Placebo administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
16370402|NCT04185532|Experimental|Rebound ACL brace and physiotherapy|The intervention will be the use of rebound ACL brace for 9 weeks, which initially is locked followed by a gradually increased range of motion. A standardized rehab protocol is applied.
16370403|NCT04185532|Active Comparator|Physiotherapy|A standardized rehab protocol comparable to the experimental group but with no brace
16370404|NCT04185519|Experimental|AI (model)|This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
16370405|NCT04185519|No Intervention|DR1|Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
16370406|NCT04185506|Experimental|DBT and behavioral weight loss|The intervention is a 16-week group-based behavioral program consisting of a combination of Dialectical Behavioral Therapy (DBT) skills and behavioral weight loss techniques.
16370407|NCT04185493||CCTA Cohort|Consecutive patients with suspected coronary artery disease and low/intermediate pre-test probability
16370408|NCT04185480|No Intervention|Conventional|Historical cohort of patients that underwent axillary clearance without hemopatch.
16370409|NCT04185480|Experimental|Intervention|Prospective cohort of patient undergoing axillary clearance with hemopatch
16370410|NCT04185467|No Intervention|Usual care(both arms)|Usual care (both arms): Patients in both arms will receive usual medical, physiotherapy and nursing care according to usual protocols. This does not involve exercise rehabilitation or advice.
16370411|NCT04185467|Experimental|Intervention (exercise rehabilitation)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
16370412|NCT04185454|Experimental|First design level|Three Healthy Voluntary (HV) women were give the same starting daily dose of 100 g Jarlsberg
16370413|NCT04185454|Experimental|Second design level|Based on the results from the starting dose 5 + 5 HV get a new daily doses of Jarlsberg cheese
16370414|NCT04185454|Experimental|Third design level|Based on the results from the second design level, the daily dose of Jarlsberg cheese for the next 7 HVs was given
16370415|NCT04185441|Experimental|TANZÂNIA|"The study is double-dummy. The patient must take 2 pills, as follow:
~1 capsule Tanzânia association, oral, once a day, and
~1 tablet tamsulosin placebo, oral, once a day."
16370416|NCT04185441|Active Comparator|Omnic Ocas|"The study is double-dummy. The patient must take 2 pills, as follow:
~1 tablet Omnic Ocas, oral, once a day, and
~1 capsule Tanzânia association placebo, oral, once a day."
16370417|NCT04185428|Experimental|Standard of care with integrative therapy|For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
16370657|NCT04183712|Experimental|target therapy with GEMOX|Target therapy
16370418|NCT04185428|No Intervention|Standard of care only|For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
16370419|NCT04185415|Experimental|bepranemab|Subjects will be randomized to receive bepranemab.
16370420|NCT04185415|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo.
16370421|NCT04185402|Active Comparator|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
16370422|NCT04185402|No Intervention|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
16370423|NCT04185389||Control|Women in the original HPV FOCAL control arm who completed the 48 month exit screen (HPV/LBC co-test) and who had no CIN2+ detected during the trial or at trial exit will be invited to submit another LBC sample for HPV and cytology co-testing.
16370424|NCT04185376||group A 200 patients|patients with one or more PFDs significant psychological strain in at least one pelvic floor domain
16370425|NCT04185376||group B 200 patients|patients without any pelvic floor complaints
16370426|NCT04185363|Experimental|Maralixibat|All subjects will receive Maralixibat oral solution
16370427|NCT04185350|Experimental|68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 60 min later.
16370428|NCT04185337|Experimental|Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)|Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
16370429|NCT04185324|Experimental|Standard zippering vest|Children receive three supervised sessions for them to practice engaging and pull up a zipper, using a standard teaching zippering vest.
16370430|NCT04185324|Experimental|Modified zippering vest|Children receive three sessions of specially designed zippering instruction using a modified zippering vest, where they can practice engaging and pulling up a zipper after being read a related story.
16370431|NCT04185311|Experimental|Treatment (talimogene laherparepvec, nivolumab, ipilimumab)|Participants receive talimogene laherparepvec intratumorally on days 1, 22, and 36, nivolumab IV over 60 minutes on days 1, 15, 29, and 43, and ipilimumab IV over 90 minutes on days 1 and 43 in the absence of disease progression or unacceptable toxicity.
16370432|NCT04185298|Active Comparator|Group 1 (No treatment)|Group 1: Participants will have continuous activity monitoring (via Fitbit)
16370433|NCT04185298|Experimental|Group 2 (Experimental)|Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)
16370434|NCT04185272|Experimental|non-metastatic colon cancer|
16370435|NCT04185272|Experimental|metastatic colon cancer|
16370436|NCT04185259|Experimental|Acupuncture group|
16370437|NCT04185259|Sham Comparator|Sham acupuncture|
16370438|NCT04185259|No Intervention|Waitlist control group|Participants will receive no treatment for their heel pain for a period of 16 weeks after randomization, and subsequently have the option of 4 weeks (12 sessions) of acupuncture with free of charge at the end of follow-up.
16370439|NCT04185246|Experimental|Single arm|"Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg.
~Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day"
16370440|NCT04185233|Experimental|iPad distraction|"Children of this group will receive the iPad when the nurse will prepare the material for the venous track. They will choose a game adapted to their age and will be able to play it during all the procedure time.
~Intervention : game on iPad"
16370441|NCT04185233|Active Comparator|Nitrous Oxide|"Children of this group will receive the Nitrous Oxide 3 minutes before the intervention (venous track). They will keep the mask during all the procedure time.
~Intervention : Nitrous Oxide"
16370442|NCT04185220|Experimental|1- Experimental Treatment: Dose Escalation|IL-15 by CIV infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with mogamulizumab by IV infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle to determine MTD.
16370443|NCT04185220|Experimental|2- Experimental Treatment: Dose Expansion|IL-15 by CIV infusion at the MTD on days 1- 5 of each 28-day cycle (max 6 cycles) with mogamulizumab by IV infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle.
16370444|NCT04185194|Active Comparator|group A|received especially designed physical therapy program
16370445|NCT04185194|Experimental|group b|received pulsed ultrasound in addition to physical therapy program
16370446|NCT04185194|Experimental|group c|received lidocaine phonophoresis in addition to physical therapy program
16370447|NCT04185181|Active Comparator|virtual reality|
16370448|NCT04185181|Active Comparator|propreoceptive neuromuscular facilitation|
16370449|NCT04185168|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 tablets)
16370450|NCT04185168|Placebo Comparator|control|2 tablets of placebo
16370451|NCT04185155|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
16370452|NCT04185155|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
16370453|NCT04185142||combined procedure group|patients underwent cryoballoon ablation and left atrial appendage closure
16370454|NCT04185129|Experimental|Foster|uncontrolled asthma patients were randomized into Foster treatment group
16370455|NCT04185129|Active Comparator|Relvar|uncontrolled asthma patients were randomized into Relvar treatment group
16370458|NCT04185116|Experimental|3D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
16370459|NCT04185116|No Intervention|2D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
16370460|NCT04185103||Sacubitril-Valsartan cohort|Patients with left systolic disfunction (left ventricle ejection fraction<40%) heart failure and diagnosed with grade II heart failure that have been treated with an ACE or ARA II+betablocker at stable doses during the last 4 weeks and after being evaluated by the cardiologist start Sacubitril-Valsartan treatment.
16370461|NCT04185090|Active Comparator|ID1801|qd daily for 6days Intervention: Drug: administration of ID1801 for 6days.
16370462|NCT04185090|Active Comparator|ID1803|qd daily for 10days Intervention: Drug: administration of ID1803 for 10days.
16370463|NCT04185090|Experimental|ID1801 and ID1803|qd daily for 7days Intervention: Drug: administration of ID1801 and ID1803.
16370464|NCT04185077|Experimental|Experimental|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
16370465|NCT04185077|Active Comparator|Control|a bolus dose of 100 U/kg Heparin was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
16370466|NCT04185064|Experimental|Cryopnematic Device (Randomized Component)|Game Ready shoulder wrap is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises.
16370467|NCT04185064|Active Comparator|Standard Care|Ice is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the ice will be applied by the patient or a health care provider; as cold as comfortable; 30 min on:60 min off; use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off; use minimum of twice/day. The patients in the control group will receive pain management strategies as would be normally dictated by the physician/therapist. This may include the use of ice, ice packs and compression bandages, as well as pain medications, range of motion, and positioning exercises
16370468|NCT04185064|Other|Cryopneumatic Device (Observational Cohort)|Game Ready® shoulder wrap is applied in the operating room and used in the recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises
16370469|NCT04185051|Experimental|Cohort 1: JNJ-67953964 or Placebo|Participants will receive JNJ-67953964 or matching placebo oral capsules once daily (QD) over 4 weeks (28 days).
16370470|NCT04185051|Experimental|Cohort 2: JNJ-67953964 or Placebo|Participants in this cohort will receive JNJ-67953964 only or will be randomly assigned to receive JNJ-67953964 or matching placebo.
16370471|NCT04185038|Experimental|ARM A (Tumor Cavity Infusion)|Patients with non-DIPG supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
16370472|NCT04185038|Experimental|ARM B (Ventricular System Infusion)|Patients with non-DIPG either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the ventricular system
16370473|NCT04185038|Experimental|ARM C (DIPG)|Patients with DIPG for whom CAR T cells will be delivered into the ventricular system
16370474|NCT04185025|Experimental|CeraVe Moisturising Lotion|
16370475|NCT04185025|Active Comparator|Half Mu ceramide body milk|
16370476|NCT04185012|Experimental|Benralizumab|Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
16370477|NCT04185012|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
16370478|NCT04184999|Experimental|Intracameral dexamethasone 9% + postoperative topical prednisolone acetate|dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
16370479|NCT04184999|Active Comparator|postoperative topical prednisolone acetate|topical ophthalmic prednisolone acetate for 3 weeks post-operatively
16370480|NCT04184986||inflammatory bowel disease|100-150 pts with dg. inflammatory bowel disease
16370481|NCT04184986||unspecific GI symptoms|100-150 pts unspecific GI symptoms
16370482|NCT04184973|Experimental|CG-100|Patients receive CG-100 during rectal cancer surgery
16370483|NCT04184973|Active Comparator|SOC|Patients receive a protective stoma during rectal cancer surgery
16370484|NCT04184960||Gastric cancer cohort|Cohort of patients with gastric cancer
16370485|NCT04184960||Non-gastric cancer cohort|Cohort of patients without gastric cancer
16370486|NCT04184947||SGLT2i|Patients who received new prescription of a SGLT-2 inhibitor
16370487|NCT04184947||GLP-1RA|Patients who received new prescription of a GLP-1 receptor agonist
16370488|NCT04184921||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
16370658|NCT04183712|Active Comparator|conventional chemotherapy|The patients wil receive conventional chemotherapy(GEMOX).
16370489|NCT04184921||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
16370490|NCT04184908|Experimental|GROUP EXPERIMENTAL|Gel xerostomia Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
16370491|NCT04184908|Placebo Comparator|CONTROL GROUP|Gel placebo Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
16370498|NCT04184869|Other|Wild Type UGT1A1|"Cohort A: Wild Type, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
16370499|NCT04184869|Other|Heterozygous UGT1A1*28|"Cohort B: Heterozygous, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
16370500|NCT04184869|Other|Homozygous UGT1A1*28|"Cohort C: Homozygous, UGT1A1, Belinostat IV Dose: 750 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
16370501|NCT04184869|Other|Belinostat & Atazanavir|"Arm: Homozygous UGT1A1*28 genotype subjects with Belinostat IV & Atazanavir
~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir)
~Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
16370502|NCT04184856||Binge eating disorder (BED) patients|Individuals with BED diagnosis.
16370503|NCT04184856||non-BED controls|Individuals that do not experience binges
16370504|NCT04184856||subsyndromal BED controls|individuals that experience binges but do not fulfill the requirements for BED diagnosis.
16370505|NCT04184843|Experimental|iWalk Toolkit|"Intervention period: 5 months
~Intervention:
~A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.
~Access to a clinical expert by email or phone"
16370506|NCT04184830|Experimental|tDCS arm|"Active stimulation:
~Direct current will be transferred using a pair of saline-soaked surface sponge electrodes (5x7). For anodal stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 minutes, which will result in current density of 0.08 mA/cm².In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
16370507|NCT04184830|Sham Comparator|tDCS sham|"Sham stimulation:
~During the sham stimulation a pair of saline-soaked surface sponge electrodes (5x7) will be places on the scalp For sham stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 seconds.In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
16370508|NCT04184817||Medical data collection|The medical data of patients diagnosed by Achondroplasia will be collected. The radiological data will analyse to evaluate the severity of stenosis as well as its clinical tolerance and evolution.
16370509|NCT04184804|Experimental|Behavioral Intervention|School-based intervention
16370510|NCT04184804|No Intervention|Control|Control. No intervention (usual education). The school does not receive any material and gets the information that they are part of a study on eating habits of primary school children.
16370511|NCT04184791|Experimental|Deep Brain Stimulation(DBS) OFF Medication|Subthalamic-DBS in the Levodopa OFF state.
16370512|NCT04184791|Experimental|Deep Brain Stimulation(DBS) ON Medication|Subthalamic-DBS in the Levodopa ON state.
16370513|NCT04184778|Experimental|Woman tube size 6.0|Smaller tube than normal
16370514|NCT04184778|No Intervention|Woman tube size 7.0|Usual tube size
16370515|NCT04184778|Experimental|Man tube size 7.0|Smaller tube than normal
16370516|NCT04184778|No Intervention|Man tube size 8.0|Usual tube size
16370517|NCT04184765||Total laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
16370659|NCT04183699|Experimental|MRI targeted + systematic random biopsy|
16370518|NCT04184765||Abdominal hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
16370519|NCT04184752||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
16370520|NCT04184752||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
16370521|NCT04184752||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
16370522|NCT04184739|Active Comparator|Group A|Standard treatment information (verbal and written) and access to a basic version of the App with a toothbrushing timer. The timer is necessary as the health behaviour outcome is toothbrushing duration.
16370523|NCT04184739|Experimental|Group B|As for group A, however, additionally the App will provide generic treatment information (a combination of videos and text)
16370524|NCT04184739|Experimental|Group C|As for group B, however, the patients will have access to the full functionality of the App and the App will allow patients to input their own personalised treatment information (including progress photographs), set goals, develop plans for achieving these and provide the patient and clinicians with appropriate dashboards to monitor progress.
16370525|NCT04184726|Experimental|MBCT-vision|8 x once weekly group sessions, and home practice between sessions
16370526|NCT04184713|Experimental|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
16370527|NCT04184713|Active Comparator|Control group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
16370528|NCT04184700|Experimental|EHCF + LGG|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
16370529|NCT04184700|Active Comparator|RHF|Extensively hydrolyzed rice formula
16370530|NCT04184700|Active Comparator|EHWF|Extensively hydrolyzed protein formula
16370531|NCT04184700|Active Comparator|AAF|Amino acid based formula
16370532|NCT04184687|Experimental|Nanofractures treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction with concomitant treatment of the cartilaginous lesions with nanofractures technique.
16370533|NCT04184687|Active Comparator|no treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction. Cartilaginous lesions won't be treated
16370534|NCT04184674|Other|Acute Respiratory Distress Syndrome|Children of more than one month of age and adults hospitalized in Intensive Care Unit for Acute Respiratory Distress Syndrome.
16370535|NCT04184661||hypophosphatemic rickets patients|30 hypophosphatemic rickets patients older than 2 years will be included in this study
16370536|NCT04184661||controls patients|10 controls patients from pediatric nephrology unit without hypophosphatemic rickets, older than 2 years will be included in this study
16370537|NCT04184648||There was no adverse systems outcome after PMA36 weeks|Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
16370538|NCT04184648||Death or adverse respiratory outcome after 36 weeks of pma|Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
16370541|NCT04184622|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16370542|NCT04184622|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16370543|NCT04184622|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16370544|NCT04184622|Placebo Comparator|Placebo|Placebo administered SC once a week.
16370545|NCT04184609|Experimental|Exercise test|"All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design:
~Control
~Albuterol
~Ipratropium Bromide"
16370546|NCT04184596||Stated-Preferences Observational Group|A discrete choice experiment will be conducted with participants with peripheral neuropathic pain in the stated-preferences observational group. The instrument will measure patient preferences for topical versus systemic pain treatment.
16370547|NCT04184557|Experimental|"App Staying Calm in the OR"|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) or Mindfulness Self Compassion (MSC)."
16370548|NCT04184557|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) arm will not download the app until the study is completed.
16370549|NCT04184544|Experimental|Maternal and Newborn health districts|Group one included maternal and newborn health districts. These districts are further divided into three sub groups. Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (, Lasbila and Badin).
16370660|NCT04183686|Experimental|Part A (SAD): Dose A1|Single dose A1 of ACT-1014-6470; soft capsule for oral use.
16370661|NCT04183686|Experimental|Part A (SAD): Dose A2|Single dose A2 of ACT-1014-6470; soft capsule for oral use.
16370550|NCT04184544|Experimental|Child Health|Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD [4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad).
16370551|NCT04184531||Children with Sensenbrenner Syndrome|Children with Sensenbrenner followed from 2005. Variable phenotype related to the mutation gene will be analysed to determine some possible prognostic factors of the risk of developing end-stage kidney disease.
16370552|NCT04184518|Experimental|Cediranib plus durvalumab|
16370553|NCT04184505|Active Comparator|Standard clinical treatment|"If BM-blasts >= 10%: Conventional chemotherapy: induction one cycle (3+7 protocol) and one optional consolidation cycle, followed by HSCT if a suitable sibling or unrelated donor is available versus
~If BM blasts are <10%: HSCT upfront"
16370554|NCT04184505|Experimental|Experimental treatment|"If BM-blasts >= 10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available
~If BM blasts are <10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available"
16370555|NCT04184492|Experimental|GP-40081|Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg
16370556|NCT04184492|Active Comparator|NovoMix® 30 Penfill®|Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg
16370557|NCT04184479|Active Comparator|A-LEVAmetoden by Bertz et al|Individual dietary advices for weight loss, based on the participants' food record of 4 consecutive days aimed to achieve an energy intake reduction of 500 kcal/d with a nutrient composition according to the Nordic Nutrition Recommendations. Follow up visits after 3 months, 1 year and 2 years after baseline. Follow up by electronic platform every other week until 3 months after baseline and each month after 3 months until 1 year after baseline.
16370558|NCT04184479|Placebo Comparator|B-Ordinary treatment|Dietary advices for weight loss aimed to achieve calorie restriction. Follow up visits after 3 months, 1 year and 2 years after baseline. Additional visits, up to 4 times in the first year after baseline.
16370559|NCT04184466|Experimental|Insulin Aspart|Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg
16370560|NCT04184466|Active Comparator|NovoRapid® Penfill®|Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg
16370561|NCT04184453|Experimental|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patient.
16370562|NCT04184440|Placebo Comparator|placebo|corn starch；capsule，2 g/day，2 times/day；3 months
16370563|NCT04184440|Experimental|Cyclocarya paliurus extract|aqueous extract of Cyclocarya paliurus；capsule，2 g/day，2 times/day；3 months
16370564|NCT04184440|Experimental|Cyclocarya paliurus compounds|mixed aqueous extract of Cyclocarya paliurus and other traditional Chinese herbal medicines including Astragalus propinquus Schischkin，Dioscorea oppositifolia L.，Dendrobium nobile Lindl.，Salvia miltiorrhiza Bge. and Inulin；capsule，2 g/day，2 times/day；3 months
16370565|NCT04184427|Active Comparator|Group I|6 mm height of power arm
16370566|NCT04184427|Experimental|Group II|3 mm height of power arm
16370567|NCT04184427|Experimental|Group III|9 mm height of power arm
16370568|NCT04184414|Experimental|CART cells|dosage：Once dose，1.0*10^6cells/kg CART cells Administration mode:Intravenous infusion
16370569|NCT04184401|Experimental|Replacement with albumin|"Check drain amount every 4 hour after SICU admission
~Replacement of 70% of drainage from previous 4 hours over next 4 hours
~30% of the drainage with 5% albumin
~40% of drainage with Hartmann's solution
~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution
~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
16370570|NCT04184401|Active Comparator|Replacement with Hartmann's solution|"Check drain amount every 4 hour after SICU admission
~Replacement of 70% of drainage from previous 4 hours with Hartmann's solution over next 4 hours
~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution
~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
16370571|NCT04184388|Experimental|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng extract for 1g/day
16370572|NCT04184388|Placebo Comparator|Placebo|Hydrolysed Red Ginseng extract for 0g/day
16370573|NCT04184375|Experimental|TONIC|"The cognitive stimulation sessions are carried out using Liliane Israël's TRAIN YOUR MEMORY software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient.
~This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules."
16370574|NCT04184375|No Intervention|Control|The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.
16370575|NCT04184362|Experimental|Experimental group tested at the active treatment site|The theranova empower device will be tested at the active treatment site.
16370576|NCT04184362|Sham Comparator|Control sham group tested at the sham control treatment site|The theranova empower device will be tested the sham control treatment site.
16370577|NCT04184349|Active Comparator|Local Anesthetic (LA Group)|
16370578|NCT04184349|Active Comparator|B group|
16370579|NCT04184336||Persons of all ages|Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
16370580|NCT04184323|Active Comparator|EX-527|The drug will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
16370581|NCT04184323|Placebo Comparator|Placebo|The placebo will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
16370582|NCT04184310|Experimental|old patient with rectal prolapse|old co-morbid patient with complete rectal prolapse unfit for abdominal operation
16370583|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
16370584|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
16370585|NCT04184284||Primary Study Cohort - Anti-IL5/IL5R naïve patients|Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
16370586|NCT04184284||Secondary Study Cohort - Biologic experienced patients|Patients that previously received a biologic treatment for severe asthma (at least one dose).
16370587|NCT04184271|Experimental|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
16370588|NCT04184258|Experimental|SLE patients MSC treatment|Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols
16370589|NCT04184258|Active Comparator|SLE patients standard treatment|Patients with SLE, who receive standard treatment according to the Clinical protocols
16370590|NCT04184232|Experimental|Dendritic cells|Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
16370591|NCT04184232|Active Comparator|Control|Patients with the recurrent bladder cancer receiving standard treatment
16370592|NCT04184219||Group|People potentially interested in health issues
16370593|NCT04184206|Active Comparator|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness influence
16370594|NCT04184206|Active Comparator|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness influence
16370595|NCT04184206|Active Comparator|attention training intervention 3|14-day smartphone-based audio-guided intervention without mindfulness emphasis
16370596|NCT04184193||Pulmonary Rehabilitation|
16370597|NCT04184167|Active Comparator|intermittent fasting|intermittent fasting before ICSI
16370598|NCT04184167|Placebo Comparator|No intermittent fasting|Usual diet
16370599|NCT04184141|Experimental|alprazolam|
16370600|NCT04184141|Experimental|hydroxyzine|
16370601|NCT04184141|Placebo Comparator|control|
16370602|NCT04184128||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
16370603|NCT04184128||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
16370604|NCT04184128||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
16370605|NCT04184115|Experimental|DPI-386 Nasal Gel + placebo patch|DPI-386 Nasal Gel: Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
16370606|NCT04184115|Placebo Comparator|Placebo nasal gel + Placebo patch|Placebo
16370607|NCT04184115|Active Comparator|placebo nasal gel + TDS patch|Transderm Scop® is a commercial transdermal scopolamine (TDS) patch worn behind the ear containing a 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period.
16370608|NCT04184102|Experimental|Intervention exercise|The experimental group received education and exercise training before a mastectomy.
16370609|NCT04184102|No Intervention|Control|Received routine hospital care which did not include any exercise education
16370610|NCT04184089|No Intervention|Control group|High flow rate of 5 L/min and FiO2 of 40%
16370611|NCT04184089|Experimental|Group 1|Nasal cannula at flow rate of 15 L/min and FiO2 of 40%
16370612|NCT04184089|Experimental|Group 2|Nasal cannula at flow rate of 30 L/min and FiO2 of 40%
16370613|NCT04184089|Experimental|Group 3|Nasal cannula at flow rate of 60 L/min and FiO2 of 40%
16370614|NCT04184076|No Intervention|Dietary counseling alone|"Controls will be instructed to maintain their weight throughout the trial, and not to change their eating or physical activity habits. Controls will visit the research center on a weekly basis for weigh-ins. Body composition and metabolic disease risk variables will be assessed in control subjects every 12 weeks.
~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.
~The blood draws will be taken at approximately 11:00 am. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
16370615|NCT04184076|Experimental|Time-restricted feeding (TRF) with dietary counseling|"Subjects will be instructed to eat ad libitum from 10:00 to 18:00 h daily, and fast from 18:00 to 10:00 h daily. During the 8-h feeding window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, subjects will be encouraged to drink plenty of water and will be permitted to consume energy-free beverages.
~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.
~The blood draws will be taken at approximately 11:00 am, especially prior to the first consumption of food by subjects in the TRF group. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
16370616|NCT04184063|Experimental|active treatment with NBMI|
16370617|NCT04184063|Placebo Comparator|Placebo|
16370618|NCT04184050|Experimental|Part 1 (Dose Escalation)|HPN217 is IV administered 1x weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
16370619|NCT04184050|Experimental|Part 2 (Dose Expansion)|HPN217 is IV administered 1x weekly for about 1 hour. Doses will be determined from Part 1 (dose escalation)
16370647|NCT04183816|Experimental|Total cold-water immersion group|"Participants allocated to the TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C. Each Participant was totally immersed in a pool while his/her head and neck remained above water level. The water's temperature was continuously measured by a mercury-in-glass thermometer and maintained at the aforementioned temperature by continuously adding ice blocks.
~With respect to depth of immersion, TCWI is more efficient than partial CWI since exposing a larger area of the body is needed for cardiovascular changes to occur (Murray and Cardinale, 2015; Stephens et al., 2016)."
16370648|NCT04183816|Active Comparator|Ice massage group|Participants in the IM group were seated. The investigator in charge of this intervention group applied Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
16370620|NCT04184037|Experimental|Auditory neurofeedback (NFB)|Participants in this arm will meditate with the help of a custom version of the Muse app, which guides users in meditation while providing auditory neurofeedback on their state of mindfulness. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app. The neurofeedback consists of changing weather sounds that are heard against a background soundscape (e.g., a beach or rainforest sound). When a user is in a focused state, the weather in the soundscape is good (e.g., it is quiet or a light breeze can be heard). When a user starts mind-wandering, the weather sounds change for the worse: it begins to rain, the wind gets louder, and there may be thunder. When the user returns to a calm state, the weather sounds quiet down again and only the background soundscape is heard. Participants are asked to pay attention to the weather sounds and to use this feedback to train their mind to remain focused on the present moment.
16370621|NCT04184037|Active Comparator|No neurofeedback (no-NFB)|Participants in this arm will meditate using a custom version of the Muse app that is identical in all respects to the mobile app used by the NFB group, expect that the auditory neurofeedback is not active. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app, but the soundscape during the sessions will only contain the background sounds (e.g., the breach or rainforest scene), without any changes to the weather.
16370622|NCT04184024|Active Comparator|Massage group|Patients in this group were applied to massage plus neck stabilization exercise.
16370623|NCT04184024|Active Comparator|Kinesio taping group|Patients in this group were applied to Kinesio taping plus neck stabilization exercise.
16370624|NCT04184011||SRT for keloid scars|Individuals who are voluntarily scheduled to be treated at one of the participating study sites with SRT (SRT-100™, SRT-Vision™ or SRT-100+™) for the treatment of one or more recurrent keloids.
16370625|NCT04183998|Experimental|tsES|trans-spinal Electrical Stimulation (tsES)
16370626|NCT04183985|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
16370627|NCT04183985|Active Comparator|Conventaional total knee arthroplasty|Use conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
16370628|NCT04183972|Experimental|Image collecting Group|An computer algorithm will be developed and evaluated by these image data.
16370629|NCT04183959|Active Comparator|Group- video stylet intubation (VS)|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
16370630|NCT04183959|Active Comparator|Group- fiberoptic intubation (FO)|: intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
16370631|NCT04183946|Other|Online Cognitive Behavioural Therapy|Screened participants diagnosed with minor to moderate anxiety and/or depression will receive online CBT therapy (8 interactive sessions) aiming to treat their symptomatology. Each session can be completed at one's own pace.
16370632|NCT04183933|Active Comparator|Pilates Exercise Group|Pilates exercises will given for 6 weeks, 3 days in a week.
16370633|NCT04183933|Active Comparator|Combined Exercise group|Combined exercises will given for 6 weeks, 3 days in a week.
16370634|NCT04183920|Active Comparator|Group A|Participants in this arm will be provided cranberry juice to consume for 42 days in total. After a 10-21-day washout period participants will receive placebo juice for 42 days.
16370635|NCT04183920|Active Comparator|Group B|Participants in this arm will be provided placebo juice to consume for 42 days in total. After a 10-21-day washout period participants will receive cranberry juice to consume for 42 days
16370636|NCT04183907|No Intervention|Control group|The control group completes three questionnaires in months 1, 3 and 6, including questions on health behaviours, workaholism and work outcomes.
16370637|NCT04183907|Experimental|Transform|Intervention (see next page)
16370638|NCT04183894|Experimental|Personalized Intervention Based on Network|Participants will receive personalized interventions based on their personalized network.
16370639|NCT04183881|Experimental|Brodalumab 210mg SC|Brodalumab 210mg subcutaneous injection
16370640|NCT04183868|Experimental|Empagliflozin|"Eligible patients (meeting all inclusion criteria) will be randomized to receive empagliflozin in addition to existing metformin background therapy (daily dose of ≥1.500 mg, which has to remain unchanged throughout the study) for 26 weeks.
~At the end of 26 weeks of treatment, subjects belonging to empagliflozin arm will be shifted to glimepiride treatment."
16370641|NCT04183868|Active Comparator|Glimepiride|"Eligible patients will be randomized to receive glimepiride (starting dose: 2 mg daily) treatment arm, can undergo to up-titration of glimepiride to a maximum of 6 mg/day, if they experience fasting plasma glucose (FPG) levels > 112 mg/dl (6,2 mmol/l) at scheduled visit at 6th week or at any later scheduled visit.
~Whereas, glimepiride-treated patients experiencing recurrent hypoglycemic episodes should down-titrate glimepiride to a dose, considered as appropriate by Investigator.
~Hypoglycemic events are defined as symptoms suggestive of low blood glucose confirmed by self monitored blood glucose (SMBG) < 56 mg/dl (3,1 mmol/l).
~Severe hypoglycemia is defined as any hypoglycemic episode requiring the assistance of another party for recovery.
~At the end of 26 weeks of treatment, subjects belonging to glimepiride arm will be shifted to treatment with empagliflozin for 26 weeks."
16370642|NCT04183855|Experimental|control|no supplement will be provided on the day of the experiment
16370643|NCT04183855|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
16370644|NCT04183855|Experimental|Mirexus PhytoSpherix|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
16370645|NCT04183842|Experimental|LACIME Anti-hangover|Combination of plant extracts under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
16370646|NCT04183842|Placebo Comparator|Placebo|Carrot juice under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
16370649|NCT04183803|Experimental|rosa robot assistance|Patients with ACL rupture requiring surgical treatment will be included. The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
16370650|NCT04183790|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
16370651|NCT04183764|Experimental|MAX-40279-01|capsule, 5mg and 25mg
16370662|NCT04183686|Experimental|Part A (SAD): Dose A3|Single dose A3 of ACT-1014-6470 under fasted and fed conditions, separated by at least 18 days; soft capsule for oral use.
16370663|NCT04183686|Experimental|Part A (SAD): Dose A4|Single dose A4 of ACT-1014-6470; soft capsule for oral use.
16370664|NCT04183686|Experimental|Part A (SAD): Dose A5|Single dose A5 of ACT-1014-6470; soft capsule for oral use.
16370665|NCT04183686|Experimental|Part A (SAD): Dose A6|Single dose A6 of ACT-1014-6470; soft capsule for oral use.
16370666|NCT04183686|Experimental|Part B (MAD): Dose B1|Multiple doses B1 of ACT-1014-6470; soft capsules for oral use.
16370667|NCT04183686|Experimental|Part B (MAD): Dose B2|Multiple doses B2 of ACT-1014-6470; soft capsules for oral use.
16370668|NCT04183686|Experimental|Part B (MAD): Dose B3|Multiple doses B3 of ACT-1014-6470; soft capsules for oral use.
16370669|NCT04183686|Experimental|Part B (MAD): Dose B4|Multiple doses B4 of ACT-1014-6470; soft capsules for oral use.
16370670|NCT04183673|Experimental|Laser-cryo-usual care|Sessions 5 days a week for 3 weeks. Each session includes laser therapy+ cryo-thermal followed by standard rehabilitation program
16370671|NCT04183673|Active Comparator|usual care|Sessions 5 days a week for 3 weeks. Each session includes only standard rehabilitation program
16370672|NCT04183647|Active Comparator|Local Vibration / Whole body vibration|"Local vibration will be sequentially applied to the bilateral gastrosoleus complex with the Vibrasens © device. Application, the largest part of the muscle, each limb 5'er for a total of 10 minutes, static semi-squat position will be done.
~The vibration frequency is 80 Hz and the amplitude is 1 mm."
16370673|NCT04183647|Active Comparator|Whole body vibration/local vibration|Whole body vibration application will be done with Compex® Winplate device. During this application, patients will be asked to continue static semi-squat position with 5 minutes of vibration and then 5 minutes of vibration.Vibration frequency, 30 Hz amplitude will be selected 2 mm.
16370674|NCT04183634|Experimental|Period 1: Rotigotine TTS (Test) - Period 2: Neupro (Reference)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
16370675|NCT04183634|Active Comparator|Period 1: Neupro (Reference) - Period 2: Rotigotine TTS (Test)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
16370676|NCT04183608|Active Comparator|Group Standard of care|In standard of care, patient only visits every 3 months the doctor so the optimization of treatment can be done only at this frequency.
16370677|NCT04183608|Active Comparator|Groupe T2T with telemonitoring and patient education|Treatment with e-Monitoring, home fecal calprotectin testing and therapy education.
16370678|NCT04183595|Experimental|Arm A: NBMI (Study Medication)|400mg / day N1, N3-BIS- (2-MERCAPTOETHYL) ISOPHTHALAMIDE (NBMI) treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours.
16370679|NCT04183595|Placebo Comparator|Arm B: Placebo|((Excipients microcrystalline cellulose, silica and magnesium stearate)) capsules will be administered every 24 hours for 14 days.
16370680|NCT04183582|Experimental|Intervention Group|Single arm group receiving Behavioural Activation, a facilitated self-help programme delivered by trained Health Visitors as six one hour sessions over four weeks.
16370681|NCT04183569||Primary diffuse cutaneous B-cell lymphoma, leg type|Cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international standards through RCP monthly cutaneous lymphomas managed by Professor Beylot-Barry and inclusion of cases in the national database of rare cancer network French Study Group of Cutaneous Lymphomas in Bordeaux managed by Prof. Beatrice Vergier.
16370682|NCT04183556|Active Comparator|1/NSAI(nonsteroidal anti-inflammatory agent) group|Patients with naproxen drug therapy for early onset dysmenorrhea.
16370683|NCT04183556|Placebo Comparator|2/NSAI+ Turmeric (1 gram oral powder formula per day )|NSAI(nonsteroidal anti-inflammatory agent) + Turmeric for early onset dysmenorrhea (1 gram oral powder formula in mens time)
16370684|NCT04183543|Experimental|Pulsed Electromagnetic Field Therapy|Study participants will receive 20 minutes of PEMFs (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
16370685|NCT04183543|Sham Comparator|Sham Therapy|Study participants will receive 20 minutes of placebo treatment (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
16370686|NCT04183530||SCOPD|Participants with stable COPD diagnosed according to GOLD criteria and hasn't encountered acute exacerbations in the past six months, generally include outpatient clinical patient and community patients.
16370687|NCT04183530||AECOPD|Participants with COPD diagnosed according to GOLD criteria and suffered from acute exacerbations, characterized by worsening clinical symptoms(such as acute worsening of dyspnea, and/or cough and sputum production, and/or increased sputum purulence) and positive laboratory biomarkers suggesting AECOPD (such as serum CRP and serum neutrophilia or eosinophilia) at the time of registering into the group, particularly include inpatient.
16370688|NCT04183530||Smoking healthy controls|Participants with a smoking history of more than ten years and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
16370689|NCT04183530||Non smoking healthy controls|Participants without a smoking history and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
16370690|NCT04183517|Experimental|Fasted|PXS-5382A administered as a single dose in the fasted state
16370691|NCT04183517|Experimental|Fed|PXS-5382A administered as a single dose in the fed state
16370692|NCT04183517|Experimental|Twice daily|PXS-5382A administered twice daily for 5 days in the fed state
16370693|NCT04183504|Experimental|Early Steps Coaching|Coaching session on positive parenting practices and promoting child development.
16370694|NCT04183491|Experimental|Arm A: Interferon beta-1a low dose|Single dose of interferon beta-1a 7.5 µg intramuscular (IM)
16370695|NCT04183491|Experimental|Arm B: Interferon beta-1a intermediate dose|Single dose of interferon beta-1a 15 µg IM
16370696|NCT04183491|Experimental|Arm C: Interferon beta-1a high dose|Single dose of interferon beta-1a 30 µg IM
16370697|NCT04183491|Experimental|Arm D: Peginterferon beta-1a low dose|Single dose of peginterferon beta-1a 31.25 µg subcutaneous (SC)
16370698|NCT04183491|Experimental|Arm E: Peginterferon beta-1a intermediate dose|Single dose of peginterferon beta-1a 62.5 µg SC
16370699|NCT04183491|Experimental|Arm F: Peginterferon beta-1a high dose|Single dose of peginterferon beta-1a 125 µg SC
16370700|NCT04183491|Placebo Comparator|Arm G: Placebo|Single dose of placebo
16370701|NCT04183478|Experimental|Best Support Care Plus K-001|Best support care including analgesic treatment, anti-infection therapy, biliary obstruction treatment, nutritional support, psychological support, reasonable advice from physicians, good communication with patients and etc. K-001 9,720mg per day which means that take K-001 capsule 18 tablets (270mg per tablet) orally twice a day (morning and evening), 56 days as a cycle.
16370702|NCT04183478|Placebo Comparator|Best Support Care Plus placebo|Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.
16370703|NCT04183465|Active Comparator|Health Education|All patients randomized to health education during the inclusion visit are managed according to current guidelines and as follows. Quality of life, functional capacity and home physical activity are assessed by proper tools.
16370704|NCT04183465|Experimental|Exercise Intervention|All patients randomized to physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge [T0]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed.
16370705|NCT04183452||17-Hydroxyprogesterone Caproate 250 mg IM Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 250 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
16370706|NCT04183452||17-Hydroxyprogesterone Caproate 275 mg SC Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 275 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
16370707|NCT04183439||Surgeons Interviewed|We recruited surgeons from two University academic health centers, one specializing in adults and the other in children. The surgeons were selected through a snowball technique and emailed to participate. DK and GS interviewed eleven surgical attendings representing 10 surgical specialties. (Table 2) Each subject had at least 10 years of experience in their respective fields and regularly taught residents.
16370708|NCT04183413|No Intervention|Standard of Care|Health services for diabetes and hypertension are provided as was the standard of care prior to the healthcare reform. Healthcare for diabetes and hypertension is provided only through physician-led teams at hospitals and health centers.
16370709|NCT04183413|Experimental|PEN|Screening for diabetes and hypertension, as well as all care for uncomplicated cases of diabetes and hypertension, will be provided through nurse-lead teams at primary healthcare facilities.
16370710|NCT04183413|Experimental|enhanced PEN (ePEN)|"This arm consists of all activities of arm 2 (the PEN arm) plus additional responsibilities for community health workers."
16370711|NCT04183400|Experimental|Safety Awareness For Empowerment (SAFE)|Brief mindfulness-based cognitive-behavioral skill-building intervention
16370712|NCT04183400|No Intervention|Usual case management only|Control condition receives only services as usual
16370713|NCT04183387|Experimental|Simvastatin and standard treatment|40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
16370714|NCT04183387|No Intervention|standard treatment|conventional treatment of uveitis
16370715|NCT04183374|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
16370716|NCT04183361||Patients with noise exposure and salivary cortisone|"male and female
~ages 19-35
~exposure to noise level ≥ 85 dB (A) per week at the workplace
~work in noise from 1 to 16 years
~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)
~unilaterally or bilaterally normal otoscopic findings
~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
16370717|NCT04183361||Patients without noise exposure and salivary cortisone|"male and female
~ages 19-35
~no exposure to noise level ≥ 85 dB (A) per week at the workplace
~work in noise from 1 to 16 years
~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)
~unilaterally or bilaterally normal otoscopic findings
~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
16370718|NCT04183348|Experimental|Group A|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
16370719|NCT04183348|Experimental|Group B|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
16370722|NCT04183322||Women of childbearing age|Healthy non-pregnant women between 18 and 45 years old living in Goroka, Papua New Guinea, will receive one dose of 13-valent pneumococcal conjugate vaccine (PCV).
16370723|NCT04183309||Pediatric anesthetized patients|Pediatric anesthetized patients undergoing abdominal laparoscopy surgery (simple-arm study).
16370761|NCT04183088|Experimental|Groups (1) of part 2: Tislelizumab intravenously + regorafenib|Tislelizumab 200 mg intravenously on Day 1+Regorafenib its dosage in the randomized cohort will be determined according to results in the safety cohort.
16370724|NCT04183296|Experimental|TIVA(Total Intravenous Anesthesia and Volatile Anesthesia )|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
16370725|NCT04183296|Active Comparator|Inhalation|Arm Description: In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
16370726|NCT04183283|Experimental|LY3526318|LY3526318 administered orally in three of four study periods.
16370727|NCT04183283|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
16370728|NCT04183270||Patients|Non-valvular atrial fibrillation (NVAF) patients who will start treatment with a non-VKA oral anticoagulants (NOAC).
16370729|NCT04183270||Physicians|Treating physicians for NVAF patients.
16370730|NCT04183257|Experimental|vitamin D|vitamin D arm will receive oral vitamin D in escalating dosage.
16370731|NCT04183257|No Intervention|Conventional|This arm will receive conventional treatment only.
16370732|NCT04183244|Active Comparator|Erector spinae block|"Ultrasound guidance will be used to visualize the transverse processes of T2 and the overlying muscles.
~Under sterile conditions, a 5-cm, 21-gauge needle will be inserted using the out-of-plane technique parallel to the sagittal plane directly over the transverse process,then 30mL of the local anesthetic solution will be injected and observed for the linear spread of LA the under direct ultrasound visualization"
16370733|NCT04183244|Active Comparator|infraclavicular subomohyoid block|Performing posterior approach infraclavicular BP block followed by subomohioid block via the same puncture site under ultrasound guidance.
16370734|NCT04183231|Experimental|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
16370735|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
16370738|NCT04183192|Experimental|Arm A: Mepolizumab low dose|Single dose of mepolizumab 3 mg SC
16370739|NCT04183192|Experimental|Arm B: Mepolizumab low intermediate dose|Single dose of mepolizumab 6 mg SC
16370740|NCT04183192|Experimental|Arm C: Mepolizumab high intermediate dose|Single dose of mepolizumab 12 mg SC
16370741|NCT04183192|Experimental|Arm D: Mepolizumab high dose|Single dose of mepolizumab 24 mg SC
16370742|NCT04183192|Experimental|Arm E: Reslizumab low dose|Single dose of reslizumab 0.1 mg/kg IV
16370743|NCT04183192|Experimental|Arm F: Reslizumab intermediate low dose|Single dose of reslizumab 0.2 mg/kg IV
16370744|NCT04183192|Experimental|Arm G: Reslizumab high intermediate dose|Single dose of reslizumab 0.4 mg/kg IV
16370745|NCT04183192|Experimental|Arm H: Reslizumab high dose|Single dose of reslizumab 0.8 mg/kg IV
16370746|NCT04183192|Placebo Comparator|Arm I: Placebo|Single dose of placebo
16370747|NCT04183179|Experimental|Program|"The 14-week healthy eating program activities including four components:
~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home
~Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges
~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children
~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
16370750|NCT04183153|Experimental|Healthy Arm|
16370751|NCT04183140|Active Comparator|Transradial|
16370752|NCT04183140|Active Comparator|Transulnar|
16370753|NCT04183127||ACP|ACPs, either qualified or in training, working in the South Yorkshire and Bassetlaw area.
16370754|NCT04183114|Experimental|IP batch MRUK-0317|135 Subjects received Bio Farma's vaccine batch MRUK 0317
16370755|NCT04183114|Experimental|IP Batch MRUK-0417|135 Subjects received Bio Farma's vaccine batch MRUK 0417
16370756|NCT04183114|Experimental|IP Batch 550118|135 Subjects received Bio Farma's vaccine batch MRUK 0417
16370757|NCT04183114|Active Comparator|Control|135 Subjects received SII's MR vaccine batch 012W72230Z
16370758|NCT04183101|Experimental|Aliskiren treatment|Patients will be randomized to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for 6 months. After 6 months the patients will be switched to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for the coming 2,5 years.
16370759|NCT04183101|Active Comparator|Enalapril treatment|Patients will be randomized to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for 6 months. After 6 months the patients will be switched to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for the coming 2,5 years.
16370760|NCT04183088|Experimental|Part 1: Tislelizumab intravenously + regorafenib orally|Part 1 is a single-arm study. All eligible patients will receive tislelizumab 200 mg intravenously on day 1 every 3 weeks plus regorafenib orally 80 mg per day.
16370870|NCT04182412|Active Comparator|Suture|laparoscopic narrowing of linea alba with continuous suture
16370762|NCT04183088|Active Comparator|Groups (2) of part 2: regorafenib|"Daily dose of regorafenib 80mg/day is for week 1; Daily dose of regorafenib 120mg/day is for week 2; Daily dose of regorafenib 160mg/day is for week 3; Dosing-free interval is for week 4.
~The dose of regorafenib will not be escalated if treatment-related AE > grade 1 occurs at the previous dose level.
~For subjects in the group 2, when imaging evaluation of tumor response indicates stable disease or progressive disease, according to RECIST v1.1, study treatment will be shifted to regorafenib + tislelizumab combination regimen."
16370763|NCT04183075|Experimental|FontActiv Superprotein/Hypercaloric Fiber|Full Nutritional Supplement
16370764|NCT04183075|Active Comparator|Carbohydrates and C Vitamin|Nutritional Supplement
16370765|NCT04183062|Experimental|Chemotherapy plus BIO-11006|Patients will receive BIO-11006 in addition to GemTax chemotherapy. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles of GemTax and then will be stopped. Subjects will continue with GemTax treatment for three additional cycles. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
16370766|NCT04183036|No Intervention|Small EST combined with EPLBD|
16370767|NCT04183036|Experimental|Large EST combined with ECPP|
16370768|NCT04183023||Single arm|"There is a unique arm in which all the participants will be included. The intervention consists in the collection of a salivary sample Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.
~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and a subset of 4,000 DNA will be sequenced.
~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.
~Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.
~Finally, a bioinformatics analysis will be performed on sequencing data."
16370769|NCT04183010|No Intervention|Control|At the end of this initial week of monitoring, participants will be randomized to a control group or an intervention group. Both groups will be followed for three months, with outcome measurements collected monthly. Both arms will continue to receive their seven day physical activity assessment using the phone's core motion sensors and HealthKit/ Google Health step count. Both groups will also be prompted to complete monthly fitness tests: the 6-minute walk test, a 12 minute run test, and the Tecumseh step test.
16370770|NCT04183010|Experimental|Physical activity coaching|"In addition to the tasks performed and feedback received by the Control arm (see above), the intervention arm will also undergo daily coaching with the goal of increasing their daily step count. Members of this arm will receive daily app notifications indicating that they have activities to complete. They will be provided with 5 exercise options:
~Low intensity activity options (i.e. walking in the part, bicycling to the store, etc.).
~Moderate to vigorous endurance activity, performed on their own (running, bicycling, rowing, swimming, etc)
~An on demand group session video
~No exercise today
~Alternate physical activity -- the participants will have the option to record alternate physical activity that they performed
~Participants will be asked to indicate if they completed the exercise with three options:
~Yes
~No
~Request for a different exercise to be shown"
16370771|NCT04182997|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
16370772|NCT04182997|Active Comparator|Dexamethasone Group|Patients in this group will be given the study drug (dexamethasone).
16370773|NCT04182984||Patients with autoimmune ocular MG|Newly-onset OMG patients who agreed to join the follow-up cohort
16370774|NCT04182971|Active Comparator|Whole fruit|Phase 1 of study is an orange, Phase 2 of study is an apple
16370775|NCT04182971|Active Comparator|Juice|Phase 1 of study is orange juice, Phase 2 of study is apple juice
16370776|NCT04182971|Experimental|Juice plus pomace fiber|Phase 1 is orange juice with added fiber, Phase 2 is apple juice with added fiber
16370777|NCT04182958|Experimental|(14C)-OPC-61815|
16370778|NCT04182945|Other|Unobtrusive data collection|Unobtrusive data collection using noninvasive sensor systems.
16370779|NCT04182932|Experimental|CJ-40010 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16370780|NCT04182932|Experimental|CJ-40010 EV71 B dose|Inactivated EV71 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16370781|NCT04182932|Experimental|CJ-40010 CVA16 C dose|Inactivated CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16370782|NCT04182932|Experimental|CJ-40010 CVA16 D dose|Inactivated CVA16 vaccine(D dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16370783|NCT04182932|Experimental|CJ-40010 Bivalent E dose|Inactivated EV71/CVA16 vaccine(E dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16370784|NCT04182932|Experimental|CJ-40010 Bivalent F dose|Inactivated EV71/CVA16 vaccine(F dose) or placebo in 10 healthy adults (three doses, 28 days interval)
16370785|NCT04182919|Experimental|Arm 1|Phlai 2 capsules (compound D 8 mg) od evening after meal x 4 weeks
16370786|NCT04182919|Experimental|Arm 2|Phlai 1 capsules (compound D 4 mg) and placebo 1 capsule od evening after meal x 4 weeks
16370787|NCT04182919|Placebo Comparator|Arm 3|Placebo 2 capsules od evening after meal x 4 weeks
16370788|NCT04182906|Active Comparator|No ACEs screen|Participants complete all measures except an ACEs screening tool
16370789|NCT04182906|Experimental|Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences.In this version, specific ACEs items are reported, Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
16370790|NCT04182906|Experimental|De-Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences. In this version,total number of ACEs items are reported, only. Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
16370791|NCT04182893||Pulmonary nodules population|We will enroll 300 pulmonary nodules penplein this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
16370965|NCT04181788|Experimental|Arm B2 (Phase 2)|
16370792|NCT04182893||Healthy population|We will enroll 100 healthy penple in this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
16370793|NCT04182880|Placebo Comparator|Placebo|Placebo
16370794|NCT04182880|Experimental|CPL-01|CPL-01
16370795|NCT04182867|Experimental|UK dietary guideline diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.
16370796|NCT04182867|Other|Shift worker diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). Typical 'shift diet' based on previous research investigating what UK night workers eat. The 'shift diet' will contain ~15% energy from added sugar, 15g fiber, 2.5 portions fruit/vegetable, no whole grains. Required energy intake (calories) for each day to maintain their current body weight. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.
16370797|NCT04182854|Experimental|diuretics|
16370798|NCT04182841|Other|RheOx Treatment|RheOx is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
16370799|NCT04182828|Placebo Comparator|Placebo Group(PG)|It will be normal saline 0.9%
16370800|NCT04182828|Active Comparator|Lidocaine Group(LG)|It will be lidocaine 2%
16370801|NCT04182815||Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
16370802|NCT04182802||eosinophilic asthma|
16370803|NCT04182789|Experimental|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
16370804|NCT04182776||Pelvis fracture type II to IV|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
16370805|NCT04182763|Experimental|CoA-Z dose 1|6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
16370806|NCT04182763|Experimental|CoA-Z dose 2|6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
16370807|NCT04182763|Experimental|CoA-Z dose 3|6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
16370808|NCT04182763|Placebo Comparator|Placebo|6 months of placebo, followed by 18 months of CoA-Z at dose 2
16370809|NCT04182750|Experimental|Intervention group|Pharmacist consultation in early pregnancy (gestation week <12)
16370810|NCT04182750|No Intervention|Control group|Standard care.
16370811|NCT04182737|Experimental|IgM titer-based treatment|The treatment with IgM preparation will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The calculation of the dose is based on IgM single compartment distribution. The first dose of IgM preparation will be calculated on IgM serum concentration obtained within 24 hours after shock appearance to achieve serum titers above 100mg/dl. In the next days, the daily IgM preparation dose will be assessed individually on the basis of IgM serum titers assessment performed in the morning with the purpose of maintaining IgM serum titers above 100 mg/dl, up to discontinuation of vasoactive drugs or day 7 after enrolment. Daily, the calculated dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg per hour (20mg/kg per hour). IgM preparation will be administered up to the withdrawal of vasoactive drugs with a maximum allowed of 7 days of therapy and a maximum dose of 350mg/Kg/day.
16370812|NCT04182737|Active Comparator|IgM Flat treatment|The IgM treatment will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The dose of IgM preparation will be 250mg/kg for 3 days, the dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg (20mg/kg per hour) until reaching 250mg/kg.
16370813|NCT04182724|Experimental|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib 250 mg p.o. qd Nab-paclitaxel 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
16370814|NCT04182711|Experimental|Device Arm|The aim in the 1st phase is to benchmark the device against manual counting of respiration (number of breaths per minute). The aim in the 2nd phase is to benchmark the device against existing technologies, namely lead-based-ECG sensing, acoustic sensing and capnography. This phase can have a mix of patients having either COPD, asthma, pneumonia or any other respiratory diseases
16370815|NCT04182698|Experimental|Experimental|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.
~. Group II: 10 mg po qd, Group III: 12 mg po qd;
~Combined chemotherapy:
~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).
~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
16370816|NCT04182685||ZIKV-exposed children|Children age 5-15 with a positive Zika virus PCR test result.
16370817|NCT04182685||ZIKV-unexposed children|Children age 5-15 who have not had a Zika virus infection as determined by serological assays.
16370819|NCT04182659|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
16370820|NCT04182659|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
16370821|NCT04182646|Experimental|Single arm|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.
16370822|NCT04182633|Experimental|Group A - Treatment Group|This group will receive vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota for 2 days at high dose, then intestinal microbiota for 12 weeks at a maintenance dose
16370823|NCT04182633|Placebo Comparator|Group B - Control Group (Miralax only for 1 day)|This group will receive placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota for 2 days at high dose, then placebo intestinal microbiota for 12 weeks at a maintenance dose
16370824|NCT04182620|Experimental|Catheter ablation + renal denervation|Catheter ablation + renal denervation
16370825|NCT04182620|Active Comparator|Catheter ablation only|Catheter ablation
16370826|NCT04182607||hand-assisted kidney transplant|Kidney donors and recipients who underwent a hand-assisted kidney transplant
16370827|NCT04182607||robotic kidney transplant|Kidney donors and recipients who underwent a robotic kidney transplant
16370828|NCT04182594|Experimental|Degarelix|GnRH Antagonist
16370829|NCT04182594|Active Comparator|GnRH-agonist|GnRH Agonist
16370830|NCT04182581|Experimental|CAR-T treatment group|The patients will receive one dose of BCMA/CD19 dual-target CAR-T. BCMA/CD19 dual-target CAR-T dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.
16370831|NCT04182568|Experimental|nab-paclitaxel|
16370832|NCT04182568|Active Comparator|Docetaxel|
16370833|NCT04182555|Experimental|Newborns in St.Olavs Hospital and Haugesund Hospital|All newborns will be examined through 4 different methods of determining jaundice.
16370834|NCT04182542|Experimental|RF|The right side will be treated with radiofrequency
16370835|NCT04182542|No Intervention|NI|The left side will not receive treatment.
16370836|NCT04182529|Experimental|Photoneuromodulation Therapy|In this study low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800 will be used. The United States Food and Drug Administration (FDA) has approved this type of device as imposing insignificant risk (FDA-cleared for home treatment, 2005). At each visit, LED clusters will be applied simultaneously for 20 minutes on the Fp1, Fp2 and Pz regions according to the International 10-20 system (Homan, Herman and Purdy, 1987) (energy density, 13 Joules/cm2 [J/cm2] per each LED cluster head placement). The total LED treatment time per visit was 20 minutes.
16370837|NCT04182529|Sham Comparator|Control Group|Subject will not be given any active stimulation
16370838|NCT04182516|Experimental|Dose Escalation Part|Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
16370839|NCT04182516|Experimental|Dose Expansion Part - Epithelial Ovarian Cancer|Patients with gBRCA mutation and epithelial ovarian cancer previously treated with a PARP inhibitor.
16370840|NCT04182516|Experimental|Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
16370841|NCT04182516|Experimental|Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
16370842|NCT04182516|Experimental|Dose Expansion Part - CRPC|Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC) who have not received prior therapy with a PARP inhibitor.
16370843|NCT04182516|Experimental|Dose Expansion Part - Pancreatic Cancer|Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
16370844|NCT04182503||Beijing|
16370845|NCT04182503||Guangzhou|
16370846|NCT04182503||Jinan|
16370847|NCT04182503||Nanjing|
16370848|NCT04182503||Hangzhou|
16370849|NCT04182503||Wuhan|
16370850|NCT04182503||Zunyi|
16370851|NCT04182503||Xiangyang|
16370852|NCT04182503||Nantong|
16370853|NCT04182503||Suizhou|
16370854|NCT04182503||Huangshi|
16370855|NCT04182503||Changzhou|
16370856|NCT04182503||Suqian|
16370857|NCT04182503||Shiyan|
16370858|NCT04182503||Xiaogan|
16370859|NCT04182503||Huanggang|
16370860|NCT04182490|Active Comparator|3000-mg cohort|LMN-101, six 500-mg capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7)
16370861|NCT04182490|Active Comparator|1000-mg cohort|LMN-101, two 500-mg capsules and four 500-mg placebo capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7)
16370862|NCT04182490|Active Comparator|300-mg cohort|LMN-101, one 300-mg capsule and five 500-mg placebo capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7)
16370863|NCT04182477||Patients with at least one general anesthesia in anamnesis|Patients who underwent during their life at least one anesthesia in anamnesis
16370864|NCT04182477||Patient without general anesthesia in anamnesis|Patients who never underwent general anesthesia during their life
16370865|NCT04182464|Experimental|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
16370866|NCT04182464|Placebo Comparator|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
16370867|NCT04182451|Experimental|Meso Wound Matrix and Standard of Care|This is a single arm study
16370868|NCT04182438|Experimental|Low potassium then normal potassium|After giving the vegetables with low potassium content vegetables for 2 weeks, the serum potassium level was recorded; after 2 weeks of washing time, the normal potassium content vegetables was given for 2 weeks, and the serum potassium concentration was recorded and the test was terminated.
16370869|NCT04182438|Experimental|Normal potassium then low potassium|After giving the normal potassium content vegetables for 2 weeks, the serum potassium concentration was recorded; after 2 weeks of washing time, the low potassium content vegetables use for 2 weeks, then the serum potassium level was recorded at the time. The test was terminated.
16370871|NCT04182412|Active Comparator|suture and mesh|narrowing of linea alba with continuous suture and mesh
16370872|NCT04182399|Active Comparator|Patients 25 ZNS|30 patients receive oral 25 mg ZNS daily
16370873|NCT04182399|Active Comparator|Patients 50 ZNS|30 patients receive oral 50 mg ZNS daily
16370874|NCT04182399|Placebo Comparator|Patients Placebo|30 patients receive placebo
16370875|NCT04182386||rPVE|Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery.
16370876|NCT04182386||rPVE+S4|Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.
16370877|NCT04182373|Experimental|KW-3357|72 IU/kg
16370878|NCT04182373|Placebo Comparator|placebo|
16370885|NCT04182347|Other|People with IDD and caregivers|
16370886|NCT04182334|Experimental|Slow Tempo Music|Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
16370887|NCT04182334|Sham Comparator|Attention Control|One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.
16370888|NCT04182321|Experimental|Combination Therapy|Adding Metformin to the standard treatment for patients with HBeAg-negative chronic hepatitis B
16370889|NCT04182321|Placebo Comparator|Standard Therapy|The standard treatment for patients with HBeAg-negative chronic hepatitis B
16370890|NCT04182295|Experimental|real acupuncture-full disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
16370891|NCT04182295|Experimental|real acupuncture-partial disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
16370892|NCT04182295|Sham Comparator|sham acupuncture-full disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
16370893|NCT04182295|Sham Comparator|sham acupuncture-partial disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
16370894|NCT04182282|Experimental|Immediate|Immediate participants receive the intervention (online training and certification exam) during the study.
16370895|NCT04182282|Experimental|Control|Control participants do not receive the intervention (online training and certification exam) during the study. However, they do receive access to the intervention program (at no cost) at the conclusion of the study.
16370896|NCT04182269||Study Group|Multiple Sclerosis Patients
16370897|NCT04182269||Control Group|Healthy Subjects
16370898|NCT04182256|Experimental|MS group|In the MS group, the MS grips the HVC through the magnet adsorbed onto the wall of the basin containing the liver. By changing the position of the MS on the wall of the basin, the surgeon is able to expose the surgical field.
16370899|NCT04182256|No Intervention|MA group|In MA group, assistants use vessel forceps to pull the HVC according to the attending's requirements.
16370900|NCT04182243|Other|Emergency Health Care Provider|Working in emergency health services in Northern Cyprus
16370901|NCT04182204|Experimental|Pola-R-GemOx (Stage 1)|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
16370902|NCT04182204|Experimental|Pola-R-GemOx (Stage 2)|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg/cycle administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
16370903|NCT04182204|Active Comparator|R-GemOx (Stage 2)|Participants will receive rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
16370904|NCT04182191|Experimental|Interventional group|89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
16370905|NCT04182178||Gastroesophageal reflux|Laparoscopic total (Nissen) or posterior 270 degree (Toupét) partial fundoplication for the treatment of gastroesophageal reflux disease.
16370906|NCT04182165|Experimental|Subjects measured by the study staff|Subjects measured by the study staff via the investigational device at the hospital (up to 50 subjects).
16370907|NCT04182165|Experimental|Subjects measuring themselves autonomously|Subjects measuring themselves autonomously with the investigational device at their homes (up to 10 subjects from the first arm).
16370908|NCT04182152|Experimental|Bronchoscopic ICG localization|The nodule will be located preoperatively by ENB-Guided bronchoscopic ICG injection; During the VATS operation, a near-infrared fluorescence thoracoscopy will be used to identify ICG distribution in the visceral pleura to guide an accurate surgical resection.
16370909|NCT04182152|Active Comparator|percutaneous hook-wire localization|The nodule will be located preoperatively by percutaneous placement of hook wire; During the VATS operation, the resection scope is determined by the location relationship between hook wire and the nodule under CT scan.
16370910|NCT04182139|Experimental|30 seconds and %50 intensity stretching|The participants in this group performed an 30 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
16370911|NCT04182139|Experimental|30 seconds and %75 intensity stretching|The participants in this group performed an 30 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
16370912|NCT04182139|Experimental|30 seconds and %100 intensity stretching|The participants in this group performed an 30 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
16370913|NCT04182139|Experimental|60 seconds and %50 intensity stretching|The participants in this group performed an 60 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
16370914|NCT04182139|Experimental|60 seconds and %75 intensity stretching|The participants in this group performed an 60 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
16370915|NCT04182139|Experimental|60 seconds and %100 intensity stretching|The participants in this group performed an 60 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
16370916|NCT04182126|Placebo Comparator|Regular long-lasting insecticidal nets|All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
16370917|NCT04182126|Experimental|Piperonyl butoxide-treated LLIN|"All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction.
~PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO."
16370918|NCT04182126|Experimental|PBO-LLIN plus larval source management|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including both physical and chemical methods by physical filling or removal of temporary larval habitats and larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. We will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
16370919|NCT04182126|Experimental|PBO-LLIN plus enhanced methods|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2. The enhanced intervention is determined by machine learning method.
16370920|NCT04182126|Experimental|LLIN plus indoor residual spraying|All participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the recommended frequency of once a year.
16370921|NCT04182126|Experimental|LLIN+IRS+LSM|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. LSM will be added on these clusters at Stage 2 interventions. LSM at Stage 2 will be the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
16370922|NCT04182126|Experimental|LLIN+IRS plus enhanced method|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is determined by machine learning method.
16370923|NCT04182113|Experimental|1 Hz rTMS Stimulation|
16370924|NCT04182113|Experimental|20 Hz rTMS Stimulation|
16370925|NCT04182113|Sham Comparator|Sham rTMS Stimulation|
16370926|NCT04182100|Experimental|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
16370927|NCT04182087||Focal Brain Injury|Patients with focal brain injury (post-stroke or post-cortical resection)
16370928|NCT04182061|Experimental|The AMTE Protocol|"Will receive the AMTE (Aprende a Manejar tus Emociones) Protocol; this is a modified UP-A adapted as an internet-based program of T-CBT, consisting in 10 modules delivered over 12 weeks."
16370929|NCT04182061|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
16370930|NCT04182048||All patients|
16370931|NCT04182035|Experimental|Patient-tailored treatment group|Objectives & approach: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
16370932|NCT04182035|Active Comparator|Non patient-tailored treatment group|Objectives & approach: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
16370933|NCT04182035|No Intervention|Control group|The subjects randomized to the control group will not receive any intervention, if necessary medication use is permitted and will be monitored using the iMTAQ. Patients will be asked not to seek other treatment options (if possible). If this is not possible, patients will be considered lost to follow-up.
16370934|NCT04182022|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
16370935|NCT04182022|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
16370936|NCT04182009|Other|Omron|Omron group will undergo sputum induction with the Omron nebuliser at Visit 1, followed by the Akita Jet nebuliser at Visit 2.
16370937|NCT04182009|Active Comparator|Akita|Akita group will undergo sputum induction with the Akita Jet nebuliser at Visit 1, followed by the Omron nebuliser at Visit 2.
16370938|NCT04181996|Placebo Comparator|Placebo|Placebo: Sugar pill manufactured to mimic colchicine 0.6 mg capsule. Placebo to be taken once a day.
16370939|NCT04181996|Experimental|Colchicine|Colchicine: 0.6 mg colchicine capsule to be taken once a day.
16370940|NCT04181983|Experimental|Personalized exercise program|A home-based personalized exercise program using a smartphone app
16370941|NCT04181983|Active Comparator|Active Control WHO guidelines|A standard exercise program based upon WHO guidelines
16370942|NCT04181983|No Intervention|Control|No exercise program
16370943|NCT04181957|Placebo Comparator|Placebo|Participants receive placebo tablet composed of lactose.
16370944|NCT04181957|Active Comparator|Active|Participants receive a 50mg tablet of lisdexamfetamine dimesylate (LDX) once.
16370945|NCT04181944|Experimental|Exercise Treatment Group|
16370946|NCT04181931|Experimental|neo-TACE-HAIC with surgery|neoadjuvant TACE-HAIC with surgery for HCC patients with PVTT
16370947|NCT04181931|Active Comparator|surgery alone|surgery alone for HCC patients with PVTT
16370948|NCT04181918|Experimental|AOT|This group will observe videos depicting daily actions and afterwards they will execute the seen actions
16370949|NCT04181918|Experimental|MI|This group will imagine motorically the same action as the first group and afterwards they will execute the imagined actions
16370950|NCT04181918|No Intervention|Control|This group will neither observe nor imagine actions, but simply observe videos with no motor content. Afterwards they will execute the same actions as in AOT and MI.
16370951|NCT04181892|Experimental|CAF+ CTG positioned apical to the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG apical of the CEJ level
16370952|NCT04181892|Other|CAF+CTG positioned on the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG on the CEJ level
16370953|NCT04181879|Experimental|Intervention|GPs will receive the intervention package and conduct medication reviews with recruited patients
16370954|NCT04181879|No Intervention|Usual care|GPs will continue to treat recruited patients as usual
16370955|NCT04181853|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
16370956|NCT04181853|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
16370957|NCT04181853|No Intervention|No Intervention: Control group|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
16370958|NCT04181840|Experimental|Impedance spectroscopy|"Maximum 56 women up to 16 weeks from a natural delivery, with at least one perinatal anal sphincter injury risk factor, such as: the extended second delivery phase, instrumental delivery (vacuum or forceps), shoulder dystocia, birth weight of the child > 4kg, episiotomy, uncontrolled perineal laceration (in patients with crotch protection).
~The planned interventions are:
~Blood and faeces tests
~Impedance spectroscopy test
~Full gynecological and proctological examination
~Transanal ultrasonography
~Anorectal manometry"
16370959|NCT04181827|Experimental|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
16370960|NCT04181827|Experimental|Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])|Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 (cilta-cel) along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 (cilta-cel) infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
16370961|NCT04181814||Diabetic patients|Diagnosed as diabetes
16370962|NCT04181788|Experimental|Arm A1 (Phase 1b)|
16370963|NCT04181788|Experimental|Arm B1 (Phase 1b)|
16370964|NCT04181788|Experimental|Arm A2 (Phase 2)|
16370970|NCT04181736|Experimental|Guanfacine Treatment Group|Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg.
16370971|NCT04181736|Placebo Comparator|Placebo Group|Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
16370972|NCT04181723|Experimental|Drug - Trofinetide|Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
16370973|NCT04181723|Placebo Comparator|Placebo|Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
16370974|NCT04181710|Experimental|HEMO2life|HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.
16370975|NCT04181710|Other|Control|Organ preserved in preservation solution routinely used according to the local practice
16370976|NCT04181697||PwH A|People with Haemophilia (PwH) A, moderate or severe.
16370977|NCT04181697||Controls|Demographically and seasonally matched non-haemophilia controls.
16370978|NCT04181684|Experimental|Experimental: LITT with Hypofractionated radiation therapy|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.
16370979|NCT04181671|Experimental|Low Resistance Training Group|The experimental group will receive low resistance blood flow restriction training with 30% of 1 RM.
16370980|NCT04181671|Active Comparator|High Resistance Training Group|Participants of this group will receive High resistance training (80% of 1 RM) without blood flow restriction.
16370981|NCT04181658|Experimental|Real tDCS and Physical Therapy|This arm combines tDCS and Physical Therapy intervention. The real tDCS will be delivered before each physical therapy visit for up to 10 combined sessions. The tDCS montage was designed to target the left dorsal lateral prefrontal cortex (DLPFC) for around 20 minutes. The direct current delivered by any electrode will not exceed 2.0 milliamp(mA) and the total amount of current from all electrodes will not exceed 4 mA.
16370982|NCT04181658|Sham Comparator|Sham stimulation and Physical Therapy|This arm combines sham stimulation and Physical Therapy intervention. The sham stimulation will be delivered before each physical therapy visit for up to 10 combined sessions. We will use an active sham stimulation in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This montage was designed to deliver currents not significantly influence their cortical tissue, but still, mimic the cutaneous sensations induced by tDCS over the same brain site (i.e. left DLPFC).
16370983|NCT04181645|Experimental|SHR-120, Paclitaxel-albumin and Gemcitabine|"Subjects receive SHR-1210 200mg (Day 1) and Paclitaxel-albumin 125mg/m2 (Day1 and Day8) and gemcitabine 1000mg/m2 (Day 1 and Day 8) of each 21-day cycle for at most 6 cycles until documented PD or intolerable adverse event or new anti-cancer treatment or loss to follow-up or death.
~Subjects receive SHR-1210 200mg (Day1) to maintain after 6 cycles treatment without PD or listed situation to terminate."
16370984|NCT04181632|Active Comparator|Shot Blocker|The three interventional groups are currently marketed distraction devices. Arm 1 will be Shot Blocker® Number 1-25 (RED).
16370985|NCT04181632|No Intervention|Control Group|The control group is the current clinical standard of care option for pre-allergy injection application. Ethyl Chloride/Pain Ease Spray Number 76-100 (YELLOW).
16370986|NCT04181632|Active Comparator|Buzzy I|The three interventional groups are currently marketed distraction devices. Arm 2 will be Buzzy® I (vibrating only) Number 26-50 (GREEN).
16370987|NCT04181632|Active Comparator|Buzzy II|The three interventional groups are currently marketed distraction devices. Arm 3 will be Buzzy® II (vibrating and ice wings) Number 51-75 (BLUE).
16370988|NCT04181619|Experimental|Coffeeberry beverage|300 mg Coffeeberry extract in 300 ml beverage
16370989|NCT04181619|Placebo Comparator|Color and flavor matched beverage|0 mg Coffeeberry extract in 300 ml flavor and color-matched beverage
16370992|NCT04181593|Experimental|OmegaD|OmegaD Softgels
16370993|NCT04181593|Placebo Comparator|Placebo|Placebo Softgels
16370994|NCT04181580|Other|Fit test of made-to-measure garments|Healthy subjects will test maximum 2 compression garments out of 6 garments under investigation
16370995|NCT04181567|Experimental|electroconvulsive therapy + agomelatine|electroconvulsive therapy 2 times weekly + agomelatine 50 mg daily
16370996|NCT04181567|Active Comparator|electroconvulsive therapy + placebo|electroconvulsive therapy 2 times weekly + placebo
16370997|NCT04181554||DRAM group|The post-partum women with DRAM
16370998|NCT04181541|Active Comparator|Women receiving abortion care by physicians|Patients who receive second trimester medical abortion care from a physician.
16370999|NCT04181541|Experimental|Women receiving abortion care from midlevel providers|Patients who receive second trimester medical abortion care from a midlevel provider.
16371000|NCT04181528|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned TKA implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
16371001|NCT04181528|Active Comparator|Conventaional total knee arthroplasty|Use conventional TKA implant (Legion total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
16371002|NCT04181515|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor (lactose), sham rTMS (inactive coil)
16371003|NCT04181515|Active Comparator|placebo stressor, active rTMS|placebo stressor (lactose), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
16371004|NCT04181515|Active Comparator|stressor, sham rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), sham rTMS (inactive coil)
16371005|NCT04181515|Active Comparator|stressor, active rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
16371007|NCT04181502|Sham Comparator|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
16371008|NCT04181489|Experimental|Sintilimab + R-CHOP|
16371009|NCT04181476|Other|Topical products and Untreated areas|The subject will serve as their own control. Four different products will be tested.
16371010|NCT04181463|Experimental|Arm I (isopropyl alcohol)|Patients receive isopropyl alcohol via nasal inhalation.
16371011|NCT04181463|Placebo Comparator|Arm II (placebo)|Patients receive placebo via nasal inhalation.
16371012|NCT04181437|Experimental|NVP-1203-R1|"Drug: NVP-1203-R1
~1 tablet, oral dosing"
16371013|NCT04181437|Experimental|NVP-1203-R2|"Drug: NVP-1203-R2
~1 tablet, oral dosing"
16371014|NCT04181437|Experimental|NVP-1203-R1 and NVP-1203-R2|Drug: NVP-1203-R1 1 tablet and NVP-1203-R2 1 tablet co-administration(oral dosing)
16371015|NCT04181424|Active Comparator|Group 1- Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
16371016|NCT04181424|Experimental|Group 2 - Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
16371017|NCT04181424|Experimental|Group 3 - Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
16371018|NCT04181424|Experimental|Group 4 -- Diabetes Education Plus Combination of Monthly Food|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
16371019|NCT04181398|Experimental|Baseline high hs-CRP|"Anthropometry:
~Actual Height and weight
~Calculated BMI from measured weight and height.
~Pubertal development (Tanner stage)
~Waist circumference
~Skin fold measurement (Triceps and Subscapular)
~Waist-to-height ratio.
~Blood pressure (mean of 3 measurements)
~Peripheral arterial tonometry
~Questionnaire
~Blood sample (hsCRP)"
16371020|NCT04181398|Experimental|Baseline low hs-CRP|"Anthropometry:
~Actual Height and weight
~Calculated BMI from measured weight and height.
~Pubertal development (Tanner stage)
~Waist circumference
~Skin fold measurement (Triceps and Subscapular)
~Waist-to-height ratio.
~Blood pressure (mean of 3 measurements)
~Peripheral arterial tonometry
~Questionnaire
~Blood sample (hsCRP)"
16371021|NCT04181385|Experimental|Olanzapine|Olanzapine, 10mg, oral, single dose
16371022|NCT04181385|Experimental|Olanzapine plus bromocriptine|Olanzapine, 10mg, oral, single dose Bromocriptine, 5mg, oral, single dose
16371023|NCT04181385|Placebo Comparator|Placebo|Placebo, oral, single dose
16371024|NCT04181372|Experimental|Anlotinib plus Platinum-based chemotherapy|"Take anlotinib hydrochloride 12mg once daily for two weeks, stop for one week, the program repeats every 21 days for 2 cycles.
~Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles."
16371025|NCT04181372|Active Comparator|platinum-based chemotherapy|Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
16371026|NCT04181359|Experimental|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
16371027|NCT04181359|Placebo Comparator|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
16371028|NCT04181346|Experimental|Pregabalin|Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5
16371029|NCT04181346|Experimental|Placebo|Placebo, twice a day, from the night before chemotherapy to day 5
16371030|NCT04181320|No Intervention|Venous Leg Ulcer Standard of Care|Subjects will recieve standard of care treatment.
16371031|NCT04181320|Experimental|Venous Leg Ulcer Standard of Care with Granulox|Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.
16371032|NCT04181307|No Intervention|standard EPIC instantiation|As per standard procedure at NewYorkUniversity Langone Health
16371033|NCT04181307|Experimental|standard EPIC instantiation plus the BE-EHR module.|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
16371034|NCT04181294|Experimental|Pre-intervention|Baseline data on patient characteristics and outcomes will be collected for 4 months prior to intervention.
16371035|NCT04181294|Experimental|Post-intervention|The quality improvement intervention will be conducted sequentially at all 3 medical centers (LAC-USC, Olive View, and Harbor-UCLA Medical Centers). Data on patient characteristics and outcomes will be collected for 4 months after the intervention
16371036|NCT04181281||young adult|18 - 40 years old (n=10) Healthy male or female and able to give informed, written consent.
16371037|NCT04181281||older adult|70 years or older (n=10) Healthy male or female and able to give informed, written consent.
16371038|NCT04181281||AKI patients|Admitted patients with AKI stage 3
16371089|NCT04180930||Cohort 1|Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
16371039|NCT04181268|Active Comparator|Rotational Atherectomy|"The procedure is performed by using a Rotablator system, which consists of a spring coil shaft with a burr at the tip. The front edge of the burr is the ablating portion, oval shaped, and covered with fine diamond crystals.
~The rotational atherectomy catheter is introduced into the coronary artery over a dedicated long rotational atherectomy wire, which consists of a monofilament stainless steel 0.09-inch wire.
~The device is connected to a console that houses the turbine that rotates the burr with pressurized nitrogen gas. Typically the rpm is set at 150,000 to 180,000 rpm.
~After the lesion is crossed with the wire, the lesion is crossed with multiple pecking movements of the burr, with each run lasting not more than 20 seconds. After successful rotational atherectomy with one or more burrs, the procedure is completed with balloon angioplasty and stent placement. This can be achieved by exchanging the rota wire with a workhorse wire and using standard equipment."
16371040|NCT04181268|Active Comparator|Intravascular Lithotripsy|"The procedure is perforemed with a Coronary intravascular lithotripsy (IVL) System that consists of a generator, a connector cable with a push button to allow manually controlled delivery of electric pulses, and semi-compliant balloon catheter.
~The balloon integrates two radiopaque lithotripsy emitters 6 mm that receive electrical pulses from the generator vaporising the fluid within the balloon and creating a rapidly expanding and collapsing bubble. This bubble can transmit unfocused circumferential pulsatile mechanical energy into the vessel wall, in the form of sonic pressure waves equivalent to approximately 50 atmospheres (atm). The IVL therapy consists on a maximun of 8 runs of 10 pulses (80 pulses). The number of therapies needed per lesion will depend on lesion resistance; however, a mínimum of 20 pulses is recommended.
~Alter IVL, an optional additional post-dilatation with non-compliant balloons, a stent is implanted"
16371041|NCT04181268|Active Comparator|Excimer Laser|"Excimer laser is pulsed gas laser that use Xenon chloride (XeCl) as the active medium to generate pulses of short wavelength, high-energy ultraviolet (UV) light.
~Excimer laser tissue ablation is mediated through three distinct mechanisms: photochemical, photo-thermal and photomechanical. UV laser light is absorbed by intra-vascular material and breaks carbon-carbon bonds (photochemical). It elevates the temperature of intra-cellular water, causing cellular rupture and generates a vapor bubble at the catheter tip (photo-thermal). Expansion and implosion of these bubbles disrupts the obstructive intra-vascular material (photomechanical). The laser catheter is advanced slowly over a conventional wire while the therapy is aplied and saline is inffused. After laser, balloon dilatation is usually performed finishing the procedure with stent implantation"
16371042|NCT04181255|Experimental|Curosurf|
16371043|NCT04181255|Placebo Comparator|Sham (air)|
16371044|NCT04181229|Experimental|DBS Treatment|Patients in the treatment arm will receive DBS of bilateral centromedian nucleus (2 electrodes per patient). DBS is a standard of care treatment option for drug-resistant epilepsy patients who have previously failed VNS at 12 months or more after instigation and optimization of therapy.
16371045|NCT04181229|No Intervention|Continued VNS (control)|For the control arm, the patients will be monitored for one year with the same standard assessments used for the measurement of seizure frequency and severity. No changes will be made to these patients' treatment plan. These patients will be placed on a wait list for CM-DBS treatment of seizures if that is the desire of the patient and/or their family. After the 12 months of observation, these patients can choose to undergo DBS surgery.
16371046|NCT04181216|Experimental|anatomically aligned total knee arthroplasty prosthesis|Total knee arthroplasty with anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew)
16371047|NCT04181216|Active Comparator|Conventaional total knee arthroplasty group|Total knee arthroplasty with conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew)
16371048|NCT04181203|Active Comparator|SRT + 6 months of LHRHa|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.
~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
16371049|NCT04181203|Experimental|SRT + 6 months of LHRHa + 6 months of Apalutamide|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.
~Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.
~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
16371050|NCT04181190||Mepolizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL-5 monoclonal antibody (Mepolizumab)
16371051|NCT04181190||Benralizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL5 receptor monoclonal antibody (Benralizumab)
16371052|NCT04181177||Informed group|This group will receive the Cosmetic product RV4429A balm and targeted educational action between V1 and V2 or between V2 and V3 according to the randomization
16371053|NCT04181177||Control group|"The control group, in the first period between V1 and V2, is a group not informed about his skin condition, not receiving any emollient product and not receiving targeted educational action. It's representative of the real life called best supportive care/Supportive care: the doctor prescribes what it seems to be the best for his patient according to his opinion in view of his condition, at a given moment.
~A high variability exists within this group. In order to answer the investigator's hypothesis and demonstrate the effectiveness of the RV4429A balm, the parallel group design is chosen for the first follow-up period and then a second follow-up period is chosen for the initial control group to replace the inter-individual variability by intra-individual variability."
16371054|NCT04181164||HPP-Group|Adults with hypophosphatasia.
16371055|NCT04181164||Control-Group|Healthy control subjects.
16371056|NCT04181151||Stroke patients|
16371057|NCT04181151||Healthy Subjects|
16371058|NCT04181125||Children with increased femoral anteversion|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
16371157|NCT04180514||Intradialytic hypotension|subjects with intradialytic hypotension episode
16371158|NCT04180514||Non-intradialytic hypotension|subjects without intradialytic hypotension episode
16371059|NCT04181125||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
16371060|NCT04181112|Experimental|Fecal microbiota transplantation|
16371061|NCT04181112|Experimental|Fecal microbiota transplantation with antibiotic pre-treatment|
16371062|NCT04181112|No Intervention|No intervention follow-up|
16371063|NCT04181099|Other|Zirconia structure|The participants will carry an orthodontic device containing 4 discs of differently structured zirconia and titanium to test the biofilm formation in order to determine the ideal structure for the neck area of zirconia dental implants.
16371064|NCT04181073|Active Comparator|Jet Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Jet Nebuliser
16371065|NCT04181073|Experimental|Vibrating Mesh Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Vibrating Mesh Nebuliser
16371068|NCT04181047|Experimental|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
16371069|NCT04181047|Active Comparator|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
16371070|NCT04181034|Experimental|PYD|Case managers meet with participating pregnant and parenting females at least two times a month over 12 months. In the short term, the program seeks to improve social competence, problem-solving skills, autonomy, increased sense of purpose, improved knowledge and use of contraceptives, increased linkages and support networks, improved quality of relationships, increased access to and strengthen relationship with a trusted adult, increased knowledge of and access to healthcare and improved health and well-being of expectant or parenting mother. In the long term, the program aims to delay subsequent pregnancy and reduction in health risk behaviors, improved health and well-being of parent and child, improved educational and employment outcomes and increased self-sufficiency.
16371071|NCT04181034|Active Comparator|AFLP|Case managers meet with participating pregnant and parenting females once a month over 24 months to deliver older, business-as-usual version of the program that does not have positive youth development component.
16371072|NCT04181021|Experimental|Intervention|Providers and community-based promoters will participate in the VCAT workshop. Providers and community-based promoters will take part in two different workshops at different times.
16371073|NCT04181021|No Intervention|Control|Providers and promoters in the control arm will not be invited to participate in the VCAT workshop.
16371074|NCT04181008|Experimental|0.2 mg|
16371075|NCT04181008|Experimental|0.4 mg|
16371076|NCT04181008|Experimental|0.6 mg|
16371077|NCT04180995|Experimental|Toripalimab, Axitinib|The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
16371078|NCT04180982|Experimental|Treatment group A|SHR4640 dose1 Oral Tablet plus Febuxostat dose1 Oral Tablet Day1~Day28 qd.
16371079|NCT04180982|Experimental|Treatment group B|SHR4640 dose1 Oral Tablet plus Febuxostat dose2 Oral Tablet Day1~Day28 qd.
16371080|NCT04180982|Experimental|Treatment group C|SHR4640 dose2 Oral Tablet plus Febuxostat dose3 Oral Tablet Day1~Day28 qd.
16371081|NCT04180969|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil
16371082|NCT04180969|Experimental|placebo stressor, active rTMS|placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
16371083|NCT04180969|Experimental|active stress, sham rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil
16371084|NCT04180969|Experimental|active stress, active rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
16371085|NCT04180956|Experimental|Intervention|The bias-reduction intervention opened with a didactic on health disparities, stereotypes, microaggressions, interracial provider-patient interactions and racism. Then, a guided, interracial eye-contact mindfulness exercise was performed to increase providers' awareness and acceptance of subtle bias that occurs in interracial interactions. Then, in small, mixed-race groups, participants practiced the above mindfulness skills while reciprocally sharing and responding with empathy to each other's personal life histories and personal narratives of loss and/or betrayal. The intervention ended with explicit practice component, involving practice and feedback.
16371086|NCT04180956|No Intervention|Control|The control condition was a waitlist condition. Doctors were given workshop materials after the study ended.
16371087|NCT04180943|Active Comparator|liposomal bupivicaine|interscalene nerve block using liposomal bupivacaine (Exaprel) 10 ml mixed with 0.5% bupivacaine in same syringe - volume of bupivacaine per MD based on pt weight, etc but CANNOT EXCEED 13mL
16371088|NCT04180943|Active Comparator|bupivicaine|interscalene block using standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%) (volume per MD based on pt weight) + decadron
16371159|NCT04180501|Experimental|SRS sequential sintilimab|
16371090|NCT04180930||Cohort 2|Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
16371091|NCT04180930||Cohort 3|Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
16371092|NCT04180930||Cohort 4|Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
16371093|NCT04180904|Active Comparator|Diet 1|Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
16371094|NCT04180904|Active Comparator|Diet 2|Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
16371095|NCT04180904|No Intervention|Diet 3|Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.
16371096|NCT04180891||successful test|Students that have successfully passed the test procedure (directly with written exam or after written and oral interviews) and that can enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery).
16371097|NCT04180891||failed test|Students that have failed to enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery) after the selection procedure.
16371098|NCT04180878|No Intervention|Control Arm|Participants in this group were informed to continue to receive usual care.
16371099|NCT04180878|Experimental|Intervention Arm|Received an interactive physical activity monitoring system (the Gruve®).
16371100|NCT04180878|Experimental|Intervention Arm 2|Received an interactive physical activity monitoring system (the Gruve®) and group based phone counseling (GBPC).
16371101|NCT04180865||Parkinson's disease patients|150 de novo treatment naive Parkinson's disease patients.
16371102|NCT04180865||Healthy control subjects|150 Healthy sex- and age-matched controls, also matched according to presence and severity of constipation, serving as a control group for microbiome composition analyses.
16371103|NCT04180852||Neurosurgical patients|"Non-elective admission to the neurosurgical ICU with one of the following acute intracranial pathologies which also serve as predefined subgroups:
~Intracranial hemorrhage (subarachnoid, subdural hemorrhage or intracerebral hemorrhage)
~Acute and severe head trauma with an initial Glasgow Coma Scale ≤10"
16371104|NCT04180852||Elderly patients|Age ≥ 70 years, predefined subgroups: ≥ 70 years and ≥80 years
16371105|NCT04180852||Obese patients|BMI ≥ 35 kg/m2, furthermore predefined subgroups of patients with BMI ≥ 40 kg/m2 and BMI ≥ 45 kg/m2
16371106|NCT04180852||Cardiac surgery patients|"Admission to the cardiosurgical ICU after one of the following procedures using cardiopulmonary bypass, which also serve as predefined subgroups:
~Coronary revascularization (coronary artery bypass graft)
~Heart valve surgery
~Combined or complex heart surgery"
16371107|NCT04180852||Abdominal surgical patients|Admission to the abdominal surgery ICU after abdominal surgery
16371108|NCT04180839|Experimental|gaming-related retrieval-extinction|about 30 individuals with IGD will be randomly assigned to the R-E training group
16371109|NCT04180839|Other|nongaming-related retrieval-extinction|about another 30 individuals with IGD will be randomly assigned to the NR-E training group
16371110|NCT04180826||Stenosis|Patients with stenosis
16371111|NCT04180826||No stenosis|Patients without stenosis
16371112|NCT04180813||Subjects with Diabetes Mellitus, Type 2|
16371113|NCT04180800||Folic acid deficiency|Those with a folic acid defiency
16371114|NCT04180800||No deficiency|Those with no folic acid deficiency
16371115|NCT04180787|Experimental|Keto Coffee|VPX Bang® Keto Coffee beverage
16371116|NCT04180787|Placebo Comparator|Placebo|Flavor-matched placebo beverage
16371117|NCT04180774|Experimental|Melanoma Adjuvant|Patients with completely resected stage III or IV melanoma receiving GMV in the adjuvant setting
16371118|NCT04180774|Experimental|Melanoma Therapeutic|Patients with incompletely resected stage III or IV melanoma receiving GMV in the therapeutic setting
16371119|NCT04180774|Experimental|Renal Cell Adjuvant|Patients with completely resected stage III or IV kidney cancer receiving GMV in the adjuvant setting
16371120|NCT04180774|Experimental|Renal Cell Therapeutic|Patients with incompletely resected stage III or IV kidney cancer receiving GMV in the therapeutic setting
16371121|NCT04180761|Experimental|HIPEC-Treatment|"Doxorubicin (15 mg/m²/body surface) Cisplatin (75 mg/m²/body surface) applied as hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy.
~All drugs used are approved."
16371122|NCT04180748||Normal skin|
16371123|NCT04180748||Oily skin|
16371124|NCT04180748||Dry skin|
16371125|NCT04180748||Combination skin|
16371126|NCT04180748||Sensitive skin|
16371127|NCT04180735||Perforation|Perforation
16371128|NCT04180735||No perforation|No perforation
16371129|NCT04180722|Experimental|Intervention|Participants will receive multi-component Virtual Transition Intervention facilitated through the aTouchAway™ platform including the usual care provided by specialist HMV programs.
16371130|NCT04180722|No Intervention|Control|Usual care will be delivered in accordance with the Canadian Thoracic Society (CTS) clinical practice guidelines and includes scheduled face-to-face clinic visits with the ventilator team with the ventilator team within the first month of starting HMV and then every 3, 6, or 12 months depending on medical stability with additional telephone calls/email contact for equipment trouble shooting and management of intercurrent illnesses as needed.
16371131|NCT04180709|Experimental|Sleepio Intervention + Treatment As Usual (TAU)|Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis care team.
16371132|NCT04180709|No Intervention|Treatment As Usual (TAU) alone|Participants will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis care team. They will however be offered access to the Sleepio intervention during the follow-up period of the study.
16371133|NCT04180696|Experimental|AdaptivCRT ON (aCRT ON, treatment group)|"AdaptivCRT programmed to Adaptive Bi-V and LV The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise."
16371134|NCT04180696|Active Comparator|AdaptivCRT OFF (aCRT OFF, control group)|"AdaptivCRT programmed to Nonadaptive CRT (standard CRT). Control group subjects will be optimized per physician's discretion. The method of AV and VV optimization in the control group will be collected."
16371135|NCT04180683||Semi-structured interview group|Participants assigned to this group will be administered the GDS-30, GDS-15, GDS-10 nad GDS-5, and also the BDI-II and a semi-structured interview based on the DSM-5 criteria. The psychologists performing the assessment will answer a questionnaire about which GDS version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
16371136|NCT04180683||No semi-structured interview group|Participants assigned to this group will be administered the GDS-30 and the GDS-15, and also the BDI-II.
16371137|NCT04180657||Patients with protein C deficiency|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
16371138|NCT04180657||Healthy controls|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
16371139|NCT04180644||Atopic Dermatitis|Participants with atopic dermatitis active lesions
16371140|NCT04180644||Healthy Control|Participants without a history of atopic dermatitis
16371141|NCT04180631|Experimental|Quantitative ultrasound imaging parameter|Quantitative ultrasound imaging parameter (QUS)
16371142|NCT04180618|Experimental|Patients(Care givers)|"1,000 patients(caregivers) are enrolled and use the personal health wallet service.
~They fill out questionnaire to evaluate the service
~Some of them are invited for an in-depth interview."
16371143|NCT04180618|Experimental|Medical staffs|"12 medical staffs are enrolled and use the personal health wallet service.
~After that, they are invited for an in-depth interview."
16371144|NCT04180605|Active Comparator|Standard of care treatment arm|"When patients are randomized to the standard treatment arm, patients will be treated according to the participating site's routine practice. As pre-procedural imaging, a cardiac CT-scan has to be performed; this can also be complemented with TEE at the discretion of the operator. The LAA closure procedure should be performed according to routine practice of the participating site - either in general or local anesthesia.
~For those cases randomized to the standard treatment arm, the pre-procedural CT-scans will still be collected at completion of the study and FEops HEARTguideTM simulations will be generated, blinded for the procedural images and outcome. These simulations will be compared with the final device size and implant position and will be used for an additional comparative PREDICT-LAA sub-study."
16371145|NCT04180605|Experimental|Computational simulation arm|When patients are randomized to the computational simulation arm, the procedure will still be performed according to the participating site's routine practice - however, the procedure will only be performed after careful review of the FEops HEARTguideTM simulation results. The only prerequisite is that all patients randomized to this arm will have to undergo a pre-procedural cardiac CT-scan that will be uploaded into the FEops HEARTguideTM platform. Following this upload, a pre-procedural simulation plan will be provided to the operator, containing a set of optimal and suboptimal closure device sizes and implant positions. Software and technology upgrades of the FEops HEARTguideTM platform will be allowed during the course of the study.
16371146|NCT04180592|Experimental|CT Fusion Biopsy + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
16371147|NCT04180592|Other|Transrectal U/S Guided Prostate Biopsy + CT Fusion Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
16371148|NCT04180579|Experimental|Participants with Breast Cancer|Any adult woman with a new diagnosis of breast cancer, Stage I-III
16371149|NCT04180566|Other|Weekly antenatal testing|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
16371150|NCT04180566|Other|Growth ultrasound examination every 4 weeks|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.
16371151|NCT04180553|Experimental|Point-Of-Care Ultrasound Guided Resuscitation|Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment.
16371152|NCT04180553|Active Comparator|Usual Care|The comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria
16371153|NCT04180540|Experimental|Percutaneous Closure|Participants randomized to undergo percutaneous closure with PerClose after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
16371154|NCT04180540|Active Comparator|Manual Compression|Participants randomized to undergo manual compression after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
16371155|NCT04180527||Pre-Quality Improvement Initiative|This group of patients have not received previous patients' stories about their hip or knee surgery before undergoing their own hip or knee surgery.
16371156|NCT04180527||Post-Quality Improvement Initiative|This group of patients have received previous patients' stories regarding about their hip or knee surgery before undergoing their own hip or knee surgery.
16371164|NCT04180475|Experimental|MedRem application|MedRem smartwatch application
16371167|NCT04180449||Dysphagia screening positive|
16371168|NCT04180449||Dysphagia screening negative|
16371169|NCT04180436|Experimental|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
16371170|NCT04180436|Experimental|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
16371171|NCT04180436|Experimental|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
16371172|NCT04180436|Experimental|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
16371173|NCT04180423||Off-the-Shelf Total Knee Arthroplasty Patients|
16371174|NCT04180423||Conformis iTotal Total Knee Arthroplasty Patients|
16371175|NCT04180410|Other|EIT|Electrical Impedance Tomography is performed before extubation, during follow up visits of extubation and 48H after extubation
16371176|NCT04180397|Active Comparator|Furosemide|Bolus of 5-40 mg (0.5 - 4 ml) of furosemide iv at physicians discretion followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
16371177|NCT04180397|Placebo Comparator|Placebo|Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 0.5-4 ml at physicians discretion. Infusion rate: 0 - 4 ml/hour. Infusion is started at 2 ml/hour and adjusted according to effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
16371178|NCT04180384|Experimental|Oraxol (paclitaxel capsules+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules
~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
16371179|NCT04180384|Active Comparator|Oraxol (paclitaxel tablets+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg tablets
~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
16371180|NCT04180371|Experimental|Phase I - Dose escalation (BT5528)|Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 48 participants will participate in this dose escalation arm.
16371181|NCT04180371|Experimental|Phase I - Dose escalation combination (BT5528 & nivolumab)|Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose escalation combination arm.
16371182|NCT04180371|Experimental|Phase II - Dose expansion 1 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 40 patients with non-small cell lung cancer (NSCLC) with EGFR mutation and confirmed EphA2 tumor expression will participate in this dose expansion arm.
16371183|NCT04180371|Experimental|Phase II - Dose expansion combination (BT5528 & nivolumab)|A cohort of participants will receive the selected dose of BT5528 in combination with a standard dose of nivolumab. It is expected that up to 14 participants with non-small cell lung cancer without EGFR mutation and confirmed EphA2 tumor expression will participate in this dose expansion arm.
16371184|NCT04180371|Experimental|Phase II - Dose expansion 2 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 40 patients with NSCLC without EGFR mutation and confirmed EphA2 tumor expression will participate in this dose expansion arm.
16371185|NCT04180358|Experimental|Impact group|The impact group will receive the interventions in the classrooms
16371186|NCT04180358|Placebo Comparator|Comparison group|Comparison group will not receive the intervention
16371187|NCT04180345||Validation of the questionnaire|Items reduction, ajustment and psychometric validation of the questionnaire
16371188|NCT04180332|Experimental|Healthy|The patients were healthy subjects without Periodontal disease or any systemic manifestation
16371189|NCT04180332|Experimental|Periodontal disease without diabetes|Patients with periodontal diseases without diabetes
16371190|NCT04180332|Experimental|Periodontal disease with diabetes|Patients with periodontal disease and diabetes
16371191|NCT04180306|Other|Inpatient pediatric oncology patients|All patients admitted to the pediatric oncology ward will be in the cohort
16371192|NCT04180293|Other|Military Veterans and their families|This group will participate in both the pilot psychoeducation program and its evaluation.
16371193|NCT04180280|Active Comparator|Phone Delivered|Participants receive 5 sessions of phone-delivered behavioral counseling to improve HIV care.
16371194|NCT04180280|Active Comparator|Office Delivered|Participants receive 5 sessions of office-delivered behavioral counseling to improve HIV care.
16371195|NCT04180267|No Intervention|Control Group|Subject assigned to Control Group will not receive LMHFV
16371196|NCT04180267|Active Comparator|LMHFV group|Subject assigned to LMHFV group will receive LMHFV (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year.
16371197|NCT04180254|Experimental|Experimental: normal-hearing and hearing-impaired participants|normal and hearing-impaired participants
16371198|NCT04180241|Active Comparator|total division of the muscle layer|POEM- total division of the circular muscle layer into the gastroesophageal junction
16371199|NCT04180241|Active Comparator|partial division of the muscle layer|POEM - partial division of the circular muscle layer into the gastroesophageal junction
16371200|NCT04180228||Systemic lupus erythematosus|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire with systemic lupus erythematosus.
16371201|NCT04180228||Idiopathic juvenile arthritis|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire, with idiopathic juvenile arthritis.
16371202|NCT04180215|Experimental|Ph I, Group 1|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
16371203|NCT04180215|Experimental|Ph I, Group 2|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
16371204|NCT04180215|Experimental|Ph I, Group 3|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
16371205|NCT04180215|Experimental|Ph I, Group 4|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
16371206|NCT04180215|Experimental|Ph II, Group A|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
16371207|NCT04180215|Experimental|Ph II, Group B|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care and are eligible to receive immune checkpoint inhibitor as part of standard of care.
16371208|NCT04180215|Experimental|Ph II, Group C|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
16371209|NCT04180215|Experimental|Ph II, Group D|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
16371210|NCT04180215|Experimental|Ph II, Group E|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care and are eligible to receive immune checkpoint inhibitor as part of standard of care.
16371211|NCT04180215|Experimental|Ph II, Group F|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
16371212|NCT04180215|Experimental|Ph I, Group 5|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
16371213|NCT04180215|Experimental|Ph I, Group 6|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy
16371214|NCT04180215|Experimental|Ph I, sub-study|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy
16371215|NCT04180189|Active Comparator|Weighted fiber blanket|Using a weighted blanket
16371216|NCT04180189|Placebo Comparator|Regular fiber blanket|Using a specially designed fiber blanket without extra weight.
16371217|NCT04180176|Experimental|All-Comer Cohort|Participants with mNSCLC or ES-SCLC will give blood samples at three separate timepoints for ctDNA profiling.
16371218|NCT04180176|Experimental|Front-line Immunotherapy Re-enrollment Cohort|Participants with mNSCLC or ES-SCLC that have received front-line treatment as defined by the protocol will give blood samples at three separate timepoints for ctDNA profiling.
16371219|NCT04180163|Experimental|Lanadelumab|Participants will receive 300 milligram (mg) lanadelumab solution once every 2 weeks (q2w) for 26 weeks (treatment period A), followed by treatment period B during which participants may remain on treatment period A regimen or will receive 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well tolerated with overall treatment period of 52 weeks.
16371220|NCT04180150|Experimental|TQ-A3334 combined with entecavir|Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks
16371221|NCT04180150|Placebo Comparator|Placebo combined with entecavir|Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks
16371222|NCT04180137|Experimental|Surgical treatment with subsequent pharmacotherapy|
16371223|NCT04180137|Other|Isolated surgical treatment|
16371224|NCT04180124|Experimental|GaitRite|"Patients will walk on the GaitRite.
~forward walking at comfortable gait speed (6 x 10 meter)
~backward walking at comfortable gait speed (4 x 10 meter)"
16371225|NCT04180124|Experimental|Treadmill walking self-paced|"Patients will walk on the treadmill in self-paced mode. They can control walking speed by themselves.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
16371226|NCT04180124|Experimental|Treadmill walking fixed speed - comfortable speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at comfortable gait speed, which is determined in the familiarization period.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
16371227|NCT04180124|Experimental|Treadmill walking fixed speed - fast speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at a gait speed, which is 1 minimal clinical difference faster than their comfortable gait speed.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
16371228|NCT04180124|Experimental|Treadmill walking fixed speed - backward walking|"Patients will walk on the treadmill in fixed speed mode. Patient will walk backwards on the treadmill if they are able to.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
16371229|NCT04180098|Experimental|Context specific C-mill training|Five week C-mill training on gait adaptability.
16371230|NCT04180098|Other|Usual care|Usual care for participants with HSP. May vary per individual.
16371231|NCT04180085|Experimental|BELATACEPT|
16371232|NCT04180072|Experimental|Atezolizumab plus bevacizumab|Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Study treatment will continue until documented tumor progression or occurrence of unacceptable toxicity.
16371233|NCT04180059|Experimental|CTL 19 : T cell therapy|Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg.
16371234|NCT04180033|Other|Colonoscopy surveillance in TC survivors|TC survivors treated with platinum-based chemotherapy will be invited to undergo a colonoscopy surveillance.
16371235|NCT04180020|Active Comparator|TAU|Treatment as Usual (TAU).
16371236|NCT04180020|Experimental|ID/LAB|Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).
16371237|NCT04180007|Experimental|Neoadjuvant arm|Patients receive Apatinib orally qd up to 12 wk.
16371238|NCT04179994|Experimental|Miswak extract-containing toothpaste group|Test group.
16371239|NCT04179994|Active Comparator|Toothpaste containing Potassium Nitrates|Positive control.
16371240|NCT04179994|Placebo Comparator|Placebo group|Toothpaste contains same ingredients of test group except for the active ingredient as negative control.
16371241|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
16371242|NCT04179981|Active Comparator|PAP therapy arm|PAP Therapy will be provided to eligible patients with OVS. This is the active therapy arm.
16371243|NCT04179968|Experimental|Patients with suspected prostate cancer|Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy
16371244|NCT04179942|Active Comparator|Patients|full night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured
16371245|NCT04179942|Placebo Comparator|control|CRP level was measured
16371246|NCT04179929|Other|CHEMOTHERAPY|Pediatric-type of chemotherapy
16371247|NCT04179929|Other|allogeneic HSCT|allogeneic HSCT
16371248|NCT04179916|Experimental|Healthy volunteers|Participants between 21 and 25 years, the Faculty of Physical Education and Physiotherapy of the Opole University of Technology Students
16371249|NCT04179903|Active Comparator|Gym Trainer|Physical Activity program is performed in a group in a gym (Gym Group Training-GGT), with activity sessions conducted by a trainer graduated in Science and Techniques of Preventive and Adapted Physical Activity
16371250|NCT04179903|Active Comparator|Individual Home|Physical Activity program is performed at home individually (Individual Home Training-IHT), without the supervision of a trainer during the exercise session.
16371251|NCT04179890||Uncommon mutation cohort|Patients with non-small-cell lung cancer (NSCLC)
16371252|NCT04179890||Sequencing cohort|Patients with non-small-cell lung cancer (NSCLC)
16371253|NCT04179877|Experimental|Individual placement and support|Group of patients receiving IPS to increase workforce participation.
16371254|NCT04179877|No Intervention|Control|Group of patients receiving treatment as usual.
16371255|NCT04179864|Experimental|Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone|In Phase 1b, Abiraterone/prednisone will be administered on cycle 1 day 1 and Tazemetostat on cycle 1 day 2
16371256|NCT04179864|Experimental|Phase 1b: Tazemetostat in Combination with Enzalutamide|In Phase 1b, Enzalutamide will be administered on cycle 1 day 1 and Tazemetostat on cycle 1 day 2
16371257|NCT04179864|Experimental|Phase 2: Tazemetostat in Combination with Enzalutamide|In Phase 2, Enzalutamide and Tazemetostat will be administered on cycle 1 day 1
16371258|NCT04179864|Active Comparator|Phase 2: Enzalutamide only|In Phase 2, Enzalutamide will be administered on cycle 1 day 1
16371259|NCT04179838|Experimental|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
16371260|NCT04179838|Experimental|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
16371261|NCT04179799||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
16371262|NCT04179786|Other|Sci-B-Vac™|Single arm study in healthy volunteers who had never been vaccinated with any hepatitis B vaccine and who were seronegative for antibodies to HBsAg, HBc and HBs at baseline.
16371263|NCT04179773||Cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
16371264|NCT04179773||Non-cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
16371265|NCT04179760|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells
~Dose: 1x10^6 cells/Kg"
16371266|NCT04179760|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
16371267|NCT04179747|Experimental|Group A|The cognitive behavior psychotherapy was administered to participants in this treatment arm.
16371268|NCT04179747|Active Comparator|Control Group|This group received the administration of pharmacotherapy (PDE5i) for treatment of Erectile Dysfunction.
16371269|NCT04179734|Experimental|Intervention|Bremelanotide 1.75 mg - prefilled subcutaneous autoinjector containing 1.75 mg Bremelanotide in a 0.3 mL solution volume.
16371270|NCT04179734|Placebo Comparator|Placebo|1.75 mg equivalent - prefilled subcutaneous autoinjector containing Bremelanotide formulation without the active ingredient in a 0.3 mL solution volume.
16371271|NCT04179721|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and NAs who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of hospital caregivers towards patients. IV. Staff Training
16371272|NCT04179721|Active Comparator|The attention control condition|The control group consists of NAs that work on a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 NA (1:8 ratio), that primarily cohorts older patients with geriatric syndromes. All components of the intervention arm are the same with the exception of the PES staff. The control arm (NAs) will receive the same training as the intervention arm.
16371273|NCT04179708|Experimental|pain neuroscience education|
16371274|NCT04179708|Active Comparator|Conventional education|"patient receiving a classical education on spinal physiology and ergonomics"
16371275|NCT04179695|Experimental|consultation with Parkinsun|
16371276|NCT04179695|Active Comparator|consultation as usual without Parkinsun|
16371277|NCT04179682|Active Comparator|4-week 2-hours/day CIMT program|a 4-week 2-hours/day constraint program, total 40 hours CIMT, in preschool education.
16371278|NCT04179682|Active Comparator|2-week 4-hours/day CIMT program|one was a 2-week 4-hours/day constraint program, total 40 hours CIMT, in preschool education.
16371279|NCT04179669|Experimental|IBI306|Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
16371280|NCT04179669|Experimental|placebo|Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
16371281|NCT04179656|Experimental|Pyrotinib Treatment|This arm for HER2-postive solid tumor
16371282|NCT04179643|Experimental|3 x 10e13vg NAN-101|Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects
16371283|NCT04179643|Experimental|1 x 10e14vg NAN-101|Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects
16371284|NCT04179643|Experimental|3 x 10e14 vg NAN-101|Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects
16371285|NCT04179630|Experimental|Aldafermin (NGM282)|Administered by subcutaneous injection
16371286|NCT04179617|Experimental|Preferred nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 5% nicotine content pod (their preferred pod)
16371287|NCT04179617|Experimental|Low nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 3% nicotine content pod (non-preferred pod)
16371288|NCT04179604|Experimental|Levosimemdam|Levosimendan 2.5 mg / ml concentrate for solution for infusion. A 5 ml vial contains 12.5 mg of levosimendan. The concentrate is a clear solution, yellow or orange, for dilution before administration. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
16371289|NCT04179604|Placebo Comparator|Placebo|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
16371290|NCT04179591|Experimental|Exercise|Exercises will be performed three times per week for six weeks.
16371291|NCT04179591|Experimental|Insole|Customized arch support insoles will be worn for six weeks.
16371292|NCT04179591|Experimental|Exercise plus Insole|Exercises will be performed three times per week, and customized arch support will be worn for six weeks.
16371293|NCT04179578|Active Comparator|Crura|Closure of the diaphragmatic hiatus by a running suture alone
16371294|NCT04179578|Active Comparator|Crura and lateral release|Closure of the diaphragmatic hiatus by a running suture and an incision of 4 cm of the left diaphragm (lateral release)
16371295|NCT04179565|Active Comparator|Immediate intervention|The immediate education (IE) group will receive the intervention, Healthy Children, Healthy Families: Parents Making a Difference! in period 1. In period 2, IE will receive no education and will be followed longitudinally for periods 2 and 3.
16371296|NCT04179565|Active Comparator|Delayed intervention|The delayed education (DE) group will serve as controls in period 1, receiving no intervention. In period 2, the treatments will cross over, so DE will receive the Healthy Children, Healthy Families: Parents Making a Difference! intervention.
16371297|NCT04179552|Experimental|PAAG-OA|All subjects receive treatment with PAAG-OA
16371298|NCT04179539|Experimental|Intervention|"Patients with suspected acute PE undergo CTPA and V/Q PET/CT imaging within 24 hours. V/Q PET/CT images are not used for patients management.
~After completion of inclusion, central readings will be independently conducted:
~CTPA will be interpreted by two radiologists, blinded to the results of any clinical information or imaging test results. The results of this interpretation will be used as a reference standard.
~V/Q PET/CT will be interpreted by two independant nuclear medicine physicians, blinded to the results of any clinical information or imaging test results (including the reference standard)."
16371299|NCT04179526|Experimental|Transdiagnostic Internet-delivered REBT|Protocol is based on Rational Emotive Therapy (Ellis, 1962, 1994), structured in 8 modules delivered over 6 weeks (Module 1- Introduction and psychoeducation about emotions, Module 2 - Psychoeducation anxiety and depression, Module 3 - Relaxation, Module 4 - Negative patterns of thinking and cognitive restructuring, Module 5 - Problem solving, Module 6 - Exposure and Behavioral activation, Module 7 - Positive emotions and Module 8 - Gaining maintenance)
16371300|NCT04179526|No Intervention|Waitlist|Participants in the control group will complete pre-treatment and post-treatment assessments. After participants in the experimental group complete post-treatment assessment, they will receive the intervention.
16371301|NCT04179513|Experimental|GB224 10mg|GB224 10mg
16371302|NCT04179513|Experimental|GB224 20mg|GB224 20mg
16371303|NCT04179500|Experimental|Study Participants|Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.
16371304|NCT04179487||Pregnant Patients with Suspected PE|Pregnant Patients with Suspected pulmonary embolism undergoing low dose CT pulmonary angiogram
16371305|NCT04179474|Experimental|Part 1 (Intervention A then B then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
16371306|NCT04179474|Experimental|Part 2 (Intervention A then C then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
16371307|NCT04179461|Experimental|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.
~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
16371308|NCT04179448|Experimental|Side Access Mucosal Releasing Incision (SAMRI)|SAMRI incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
16371309|NCT04179448|Active Comparator|Sulcular Tunnell access|Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
16371310|NCT04179435|Other|Tourette syndrome|Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures
16371311|NCT04179435|Other|Controls|Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures
16371312|NCT04179409|Experimental|Casimersen|This arm will involve the treatment of boys with DMD who have a duplication of exon 45, for which casimersen will target skipping of this exon.
16371313|NCT04179409|Experimental|Eteplirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 51, for which eteplirsen will target skipping of this exon.
16371314|NCT04179409|Experimental|Golodirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 53, for which golodirsen will target skipping of this exon.
16371315|NCT04179396|Experimental|Arm A: Oral rucaparib and enzalutamide|
16371316|NCT04179396|Experimental|Arm B: Oral rucaparib and abiraterone|
16371317|NCT04179383|Other|Patient|"Patient presenting a Reversible Cerebral Vasoconstriction Syndrome (RCVS) :
~Questionnaires about anxiety, depression ;
~Constitution of a biobank (if specific consent) at inclusion and at 3 months"
16371318|NCT04179383|Other|Volunteers|"Volunteers admitted for a non neurological or non vascular pathology or healthy volunteers accompanying a patient :
~Questionnaires about anxiety, depression ;
~Constitution of a blood biobank (if specific consent)"
16371319|NCT04179344||Integrated e-healthcare services (IeHS) web-based app|This usability study is conducted under 3 steps: IeHS simulation, user experience survey using SUS questionnaire, and qualitative study through the in-depth interview.
16371320|NCT04179331|Experimental|Neurotensin|
16371321|NCT04179331|Experimental|Saline|
16371322|NCT04179318||low risk|BCT Score <4
16371323|NCT04179318||high risk|BCT Score ≥4
16371324|NCT04179305|Experimental|Oncolo_GIST Arm|Physicians assigned to this arm will receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.
16371325|NCT04179305|Placebo Comparator|Usual Care Arm|Physicians assigned to this arm will not receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.
16371326|NCT04179292|Experimental|Physiotherapy Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist for 3 sessions per week. On the other days, it will be implemented as an 8-week home program with 5 sessions per week.
16371327|NCT04179292|Experimental|Home Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients as home program. Motivation will be provided by contacting by phone / call once a week for follow-up.
16371328|NCT04179279||Pilot|
16371329|NCT04179279||Pivotal|
16371330|NCT04179253|Other|Unexplained infertility|"The patient was placed in the dorsal lithotomy position. Normal saline was used for uterine distension connected to the inflow channel on the sheath with intravenous tubing. The tip of the hysteroscope was positioned in the vaginal introitus, the labia being slightly separated with fingers. The vagina was distended with saline.
~The uterine cavity was systematically explored by rotating the fore-oblique scope in order to identify any anomaly in the uterine walls and/or the right and left tubal ostia. At this stage it was crucially important to avoid lateral movements as much as possible to reduce patient discomfort to a minimum. After that, the scope was removed Finally the evaluation and the data that had been found were written in details by the surgeon. Operative intervention was done if needed. Any complication in the form of pain, bleeding, vasovagal attack and perforation, were registered in the patient sheet."
16371331|NCT04179240|Experimental|audio and animated cartoon questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with audio and animated cartoon questionnaire. The animation was an 8-minute cartoon video divided into different parts according to different questions. The first part of the animation was the introduction of biospecific nonspecimen specimen and our survey, while the other parts showed the content of the questionnaire about donating biospecific nonspecimen specimen in a vivid way. The background music built a relaxed and pleasant atmosphere, and some cartoon pictures were made into question options to simplify the understanding and data analysis.
16371332|NCT04179240|No Intervention|text questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
16371333|NCT04179240|Other|Parent group|After a brief introduction to our survey, participants(parent) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
16371334|NCT04179227||Observational (focus group)|Participants attend a focus group session and review printed copies of planned posts for the to-be-developed Facebook intervention over 90 minutes to 2 hours.
16371335|NCT04179214|Experimental|Group I Experimental: thoracic manipulation|The experimental group will receive thoracic manipulation along with conventional pt protocol.
16371336|NCT04179214|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol
16371337|NCT04179201||IBD with CDI|Inflammatory bowel disease with clostridium difficile infection
16371338|NCT04179201||IBD without CDI|Inflammatory bowel disease without clostridium difficile infection
16371339|NCT04179188||Bariatric OSA Group|Bariatric surgery plannified intervention patient with obstructive sleep Apnéa
16371340|NCT04179188||Bariatric without OSA Group|Bariatric surgery plannified intervention patient without obstructive sleep Apnéa
16371341|NCT04179175|Active Comparator|secukinumab 1 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 2 weeks
16371342|NCT04179175|Active Comparator|secukinumab 2 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 4 weeks
16371343|NCT04179175|Placebo Comparator|placebo 1 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300mg every 2 weeks
16373294|NCT04165681|Experimental|Limbix Spark|A 5 week mobile + virtual reality CBT-based program
16371344|NCT04179175|Placebo Comparator|placebo 2 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300 mg every 4 weeks
16371345|NCT04179175|Active Comparator|HiSCR non-responders|non-responder to core trial treatment; secukinumab 300mg every 2 weeks
16371346|NCT04179162|Experimental|Bacillus Calmette-Guérin (BCG) and Gemcitabine|Eligible patients will receive combination intravesical chemoimmunotherapy. Treatment is sequential, with twice-weekly intravesical gemcitabine given at weeks 1, 4, 7, and 10, for a total of 8 doses, administered in a standard fashion. In phase I, the dose of gemcitabine will depend on the dose level being assessed for the determination of the MTD. phase II, 1 dose level will be given (the MTD from phase I). Fixed doses of once-weekly intravesical BCG therapy (TICE strain, 50 mg) will be given at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6 (+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days), for a total of 6 doses, also administered in a standard fashion. All intravesical therapy will be administered in the chemotherapy suite on an outpatient basis, in accordance with standard clinical practice. Intravesical therapies will be retained in the bladder for up to 2 h (BCG) or 1 h (gemcitabine), or as tolerated.
16371347|NCT04179149|Experimental|Environmental enrichment|Subjects randomized to the intervention condition will receive the EE intervention (social support, open spaces, novel stress relief activities) as an adjuvant to standard gynecological care consisting of hormonal, analgesic or surgical treatment as necessary according to their symptoms during the study period.
16371348|NCT04179149|No Intervention|Controls|Participants randomized to the control condition will receive only standard care as necessary according to their symptoms during the study period PLUS an online patient training module.
16371349|NCT04179136|Active Comparator|High enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
16371350|NCT04179136|Placebo Comparator|High enterolactone producer's (Control)|Placebo treatment matching intervention
16371351|NCT04179136|Active Comparator|Low enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
16371352|NCT04179136|Placebo Comparator|Low enterolactone producer's (Control)|Placebo treatment matching intervention
16371353|NCT04179123|Experimental|Healthy|Conventional and customised PAP interfaces
16371354|NCT04179123|Experimental|Patients|Conventional and customised PAP interfaces
16371355|NCT04179110|Experimental|Pembrolizumab and Ramucirumab|Patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor will receive Pembrolizumab and Ramucirumab.
16371356|NCT04179084|Experimental|fruquintinib + Sintilimab|
16371357|NCT04179071|Experimental|Savolitinib|Subjects will receive single dose of 600mg savolitinib after a high-fat, high-calorie meal.
16371358|NCT04179071|Experimental|Savolitinib + Famotidine|Subjects will receive savolitinib 600mg single dose after high-fat, high-calorie meal and after 1.5 hours (Part A) or 5.5 hours (Part B) of famotidine 40mg dose. Famotidine will be administered after an overnight fast of at least 8 hours with approximately 240 mL of water.
16371359|NCT04179058||IPAF patients|IPAF definition according to 2015 ERS/ATS criteria
16371360|NCT04179058||non-IPAF patients|
16371361|NCT04179045|Experimental|Bioheart|Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.
16371362|NCT04179032|Experimental|Participants receiving belimumab 200 mg|In Part A, participants will receive 200mg/ml belimumab via auto-injector for 12 weeks. Frequency of administration will be based on body weight. Participants who weigh >=50 kilogram (kg) at Baseline will be assigned to Cohort 1 and receive 200 mg/mL belimumab QW SC. Participants who weigh >=30 kg and <50 kg at Baseline will be assigned to Cohort 2 and receive 200 mg/mL belimumab Q10d SC. Participants who weigh <30 kg at Baseline will be assigned to Cohort 3 and receive 200 mg/mL belimumab Q2W SC. In Part B (optional), dosing of SC belimumab will continue at the same frequency or may require a change in frequency according to changes in participant's body weight for 40 weeks.
16371363|NCT04179019|Experimental|Amlodipine|Amlodipine (dose 10 mg, once daily)
16371364|NCT04179006|Active Comparator|LF chocolate + antidepressant(s)|Participants with LF chocolate add-on to their antidepressants regimen.
16371365|NCT04179006|Active Comparator|Erinacine A-enriched Hericium chocolate + antidepressant(s)|Participants with Erinacine A-enriched Hericium chocolate add-on to their antidepressants regimen.
16371366|NCT04179006|Placebo Comparator|Plain chocolate + antidepressant(s)|Participants with plain chocolate add-on to their antidepressants regimen.
16371367|NCT04178993|Placebo Comparator|Placebo Comparator: Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16371368|NCT04178993|Active Comparator|Active Comparator: Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
16371369|NCT04178980|Active Comparator|case|
16371370|NCT04178980|Placebo Comparator|control|
16371371|NCT04178967|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W."
16371372|NCT04178967|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W."
16371373|NCT04178967|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebikizumab injection."
16372558|NCT04170829|Experimental|Group 2 (n=9)|will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
16371374|NCT04178967|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):
~Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
16371375|NCT04178941|Experimental|Intervention (Single Arm)|The intervention is a combined educational outreach and audit and feedback strategy that includes providing the hospital's own continuous pulse oximetry use data back to them on a weekly basis. The data will be accompanied by staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
16371376|NCT04178928|Active Comparator|group A|patiWill receive L-T4 treatment at a dose 1 µg/kg/day for 12 weeks. And the dose will be titrated every 4 weeksents with SCH will be subjected to clinical, laboratory and imaging assessment and
16371377|NCT04178928|No Intervention|Group B|.pWill not receive treatment.atients with SCH will be subjected to clinical, laboratory and imaging assessment and
16371378|NCT04178915||Patients with severe bacterial infections|
16371379|NCT04178902|Experimental|Part A: ABBV-467 Dose Escalation|ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended phase 2 dose is determined.
16371380|NCT04178902|Experimental|Part B: ABBV-467 Dose Expansion|ABBV-467 administered by intravenous (IV) infusion at recommended phase 2 dose as identified in Part A.
16371381|NCT04178876|Experimental|Aspiration and Sclerotherapy of endometriomas|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
16371382|NCT04178876|Active Comparator|laparoscopic stripping technique|cystectomy of endometriomas during laparoscopy
16371383|NCT04178863|Active Comparator|lataprost|latanoprost use
16371384|NCT04178863|Active Comparator|timolol|timolol group
16371385|NCT04178850|Experimental|GB242|3mg/kg
16371386|NCT04178850|Active Comparator|Infliximab|3mg/kg
16371390|NCT04178811|Active Comparator|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia
16371391|NCT04178811|Active Comparator|Prostatic Uretheral Lift|Use of Holmium Prostatic Uretheral Lift in Management of Benign Prostatic Hyperplasia
16371392|NCT04178798|Experimental|Arm A_Acalabrutinib|Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.
16371393|NCT04178798|No Intervention|Arm B_Standard of care|"Patients assigned to arm B, will receive standard of care for the management of early Binet stage A patients clinical observation (watch & wait) until disease progression or early withdrawal."
16371394|NCT04178785|Active Comparator|REMIFENATIL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
16371395|NCT04178785|No Intervention|FENTANYL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
16371396|NCT04178772|Experimental|JJVC Marketed Contact Lens|Eligible subjects that have no experience with soft multifocal lenses for more than 2 years will be assigned to a single study lens type worn in both eyes daily for at least 6 hours per day, everyday for approximately 12 weeks.
16371397|NCT04178759|Active Comparator|Control|Patients with benign liver disease, who undergo liver resection
16371398|NCT04178759|Experimental|Experimental|Patients with liver metastases and received chemotherapy, who undergo liver resection
16371399|NCT04178746||IVH subjects in the Hyper-Acute Phase|The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in approximately 20 subjects with intracerebral hemorrhages utilizing the Artemis Neuro Evacuation Device in the hyper-acute phase. For the purposes of this registry, the hyper-acute phase as defined by initiation of the MIS procedure no longer than 12 hours from initial NCCT scans and no longer than 18 hours since time patients last known well.
16371400|NCT04178733|Experimental|LY3493269 - Subcutaneous (SC)|LY3493269 administered SC.
16371401|NCT04178733|Placebo Comparator|Placebo - SC|Placebo administered SC.
16371402|NCT04178733|Experimental|LY3493269 - Intravenous (IV)|LY3493269 administered IV.
16371405|NCT04178707|Other|Intervention|Using microdialysis the patients inner enviorment of the anal fistula will be measured - levels of lactate, glucose and pyruvate.
16371406|NCT04178694|Experimental|non-invasive ventilation|All subjects will be submitted to non-invasive ventilation with different settings. During the whole period indirect calorimetry will be performed and haemodynamic parameters will be monitored using a non-invasive device. Reversed combined RPE scale will be asked on a regular base.
16371407|NCT04178681|Experimental|V-A-C|"Order of administration:
~100% vegetable fat blend
~100% Anhydrous Milk Fat (AMF)
~100% Cream (AMF + milk fat globular membranes)"
16371408|NCT04178681|Experimental|V-C-A|"Order of administration:
~100% vegetable fat blend
~100% Cream (AMF + milk fat globular membranes)
~100% Anhydrous Milk Fat (AMF)"
16371409|NCT04178681|Experimental|A-V-C|"Order of administration:
~100% Anhydrous Milk Fat (AMF)
~100% vegetable fat blend
~100% Cream (AMF + milk fat globular membranes)"
16371410|NCT04178681|Experimental|A-C-V|"Order of administration:
~100% Anhydrous Milk Fat (AMF)
~100% Cream (AMF + milk fat globular membranes)
~100% vegetable fat blend"
16371411|NCT04178681|Experimental|C-A-V|"Order of administration:
~100% Cream (AMF + milk fat globular membranes)
~100% Anhydrous Milk Fat (AMF)
~100% vegetable fat blend"
16371412|NCT04178681|Experimental|C-V-A|"Order of administration:
~100% Cream (AMF + milk fat globular membranes)
~100% vegetable fat blend
~100% Anhydrous Milk Fat (AMF)"
16371413|NCT04178668|Experimental|20-40 years old|33 patients between 20 and 40 years old
16371414|NCT04178668|Experimental|70-90 years old|33 patients between 70 and 90 years old
16371415|NCT04178655|Experimental|Tranexamic Acid Treatment|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
16371416|NCT04178655|Placebo Comparator|Placebo|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
16371417|NCT04178642|Experimental|(experimental group)|Evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group)
16371418|NCT04178642|Active Comparator|(standard group)|The absence of adjuvant treatment (standard group).
16371419|NCT04178616|Other|systemic sclerosis patients population|All the patients with systemic sclerosis disease followed in day-care in a tertiary hospital are eligible to be enrolled in the study.
16371420|NCT04178603|Experimental|Acute Exercise Trial|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise. Glucose metabolism is investigated before exercise (basal), during exercise and for 120 min of recovery.
16371421|NCT04178603|Experimental|Insulin Sensitivity post Exercise|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action is investigated by a 120 min euglycemic-hyperinsulinemic euglycemic clamp.
16371422|NCT04178590|Experimental|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
16371423|NCT04178590|Placebo Comparator|SRP + placebo|Scaling and root planing in conjunction with saline
16371424|NCT04178577|Experimental|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
16371425|NCT04178564|Experimental|Intervention Group|Intervention group will receive 47 sessions of group CS and participate in 3 evaluation sessions. The CS program will last 1 year and each group CS session will last approximately 60 minutes.
16371426|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
16371427|NCT04178551|No Intervention|Comparison Cohort|All other sites in VA not receiving CONDUIT implementation support or participating in other dedicated MOUD implementation activities during the same time period
16371428|NCT04178538|Experimental|25 years and older- ACL recon with DBM, Internal brace|Patients in this arm will be 25 years of age and over and receive ACL reconstruction augmented with demineralized bone matrix, bone marrow, and internal brace
16371429|NCT04178538|Active Comparator|25 years and older- Standard ACL reconstruction|Patients in this arm will be 25 years of age and over will receive an allograft All-Inside ACL reconstruction
16371430|NCT04178538|Experimental|24 years and younger- ACL recon with DBM, Internal brace|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft augmented with demineralized bone matrix, bone marrow, and internal brace
16371431|NCT04178538|Active Comparator|24 years and younger- Standard ACL reconstruction|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft standard all inside technique
16371432|NCT04178525|Experimental|Arm A (Experimental group|ChitoCare gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
16371433|NCT04178525|Placebo Comparator|Arm B (Control group)|Placebo gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
16371434|NCT04178512|Active Comparator|group Dexamethasone|Patients will receive 8 mg of dexamethasone(2ml) in addition to 2ml of hyperbaric bupivacaine 0.5% (total volume 4 ml) intrathecal injection.
16371435|NCT04178512|Active Comparator|group Fentanyl|patients will receive 20 microgram fentanyl(diluted in sterile normal saline0.9% to 2ml)in addition to 2ml of hyperbaric bupivacaine 0.5%(total volume 4 ml) intrathecal injection.
16371436|NCT04178512|Active Comparator|group Control|patients will receive 2ml of sterile normal saline0.9% in addition to 2ml of hyperbaric bupivacaine o.5% (total volume 4 ml) intrathecal injection.
16371437|NCT04178499||smokers|active smokers
16371438|NCT04178499||non-smokers|never smokers
16371439|NCT04178486|Experimental|Amnesia|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions to experience amnesia for the food pictures they had just seen.
16371440|NCT04178486|Experimental|Cognitive Rehearsal|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a future where they will control their eating behaviors.
16371441|NCT04178486|Experimental|Memory Substitution|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a past where they have always controlled their eating behaviors.
16371442|NCT04178486|Placebo Comparator|Control|Hypnosis formed from only hypnotic induction (an adapted version from Barber Suggestibility Scale).
16371443|NCT04178473|Active Comparator|total abdominal hysterectomy|Total abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
16371444|NCT04178473|Active Comparator|subtotal abdominal hysterectomy|subtotal abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
16371445|NCT04178460|Experimental|Assigned Interventions|Niraparib combined with MGD013
16371446|NCT04178447|Experimental|Group 1: ESRD subjects not on dialysis or severe RI|subjects with eGFR <15 mL/min/1.73 m2) or (eGFR 15 to <30 mL/min/1.73 m2)
16371447|NCT04178447|Experimental|Group 2: normal renal function|subjects with eGFR ≥90 mL/min/1.73 m2
16371448|NCT04178447|Experimental|Group 3: moderate RI|subjects with eGFR 30 to <60 mL/min/1.73 m2
16371449|NCT04178447|Experimental|Group 4: mild RI|subjects with eGFR 60 to <90 mL/min/1.73 m2
16371452|NCT04178421|Experimental|Experimental Group|A computerized eye -tracking program training the eye gaze fixation with the target to improve impulse control and sustained attention of children with special needs
16371453|NCT04178421|Placebo Comparator|Control Group|Computerized program
16371454|NCT04178408||Cases|Cases of inflammatory bowel disease
16371455|NCT04178408||Controls|Two controls per case. 1. Sibling or other second degree relative of similar age. 2. neighbourhood control matched for age
16371456|NCT04178395|Experimental|real tDCS group|Patients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric transcranial direct stimulation and repetitive peripheral stimulation for 5 consecutive days.
16371457|NCT04178395|Sham Comparator|sham group|Patients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days.
16371458|NCT04178382|Experimental|experiment group|Combined detection of PCR and CRISPR/Cas12a in alveolar lavage fluid to guide early target adjustment of antibiotics
16371459|NCT04178382|No Intervention|control group|Guide the target adjustment of antibiotics according to traditional microbiological detection methods
16371460|NCT04178369|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proximal and distal tibiofibular joint manipulations will be applied for 6 weeks.
16371461|NCT04178369|Active Comparator|Control Group|All participants were given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept (conservative treatment) for 5 days a week, 45 minutes each.
16371462|NCT04178356|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proprioceptive neuromuscular facilitation techniques will be applied for 4 weeks.
16371463|NCT04178356|Active Comparator|Control Group|Conservative treatment of low back pain will be applied for 4 weeks.
16371464|NCT04178343|Experimental|Group A|Meningeal Metastases, with or without brain metastases
16371465|NCT04178330|Experimental|Group A|patients with multiple brain metastases (no less than 3 lesions) ,who have not recived whole brain radiotheray (WBRT).
16371466|NCT04178317||Venetoclax Participants|Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.
16371467|NCT04178304|Experimental|G1 patients receive prolotherapy|Intra and extra articular dextrose 25%
16371468|NCT04178291|Experimental|Conventional debridement and air polishing|All participants will receive full mouth EPAP as an adjunct to RSD using ultrasonic scalers and Gracey currettes. The EPAP procedure will be performed using the Air-Flow Master R (EMS) equipment. For supragingival biofilm removal, the Air-Flow handpiece will be used, while the Perio-Flow handpiece with a disposable nozzle will be used for subgingival debridement at sites with PPD ≥ 5mm. No time limit is applicable for supragingival air polishing. However, for subgingival debridement, the nozzle will be inserted for 5 seconds into each pocket, and moved vertically up and down. Gracey currettes will be used at sites with PPD ≥ 5mm.
16371469|NCT04178291|Active Comparator|Conventional debridement|All participants will receive full mouth RSD using ultrasonic scalers and Gracey currettes. Gracey currettes will be used at sites with PPD ≥ 5mm.
16371470|NCT04178278|Experimental|Shuttle walking test group|Patients will performed shultte walking test.
16371471|NCT04178278|Active Comparator|Exercise stress test group|Patients will performed exercise stress test.
16371472|NCT04178278|Active Comparator|6 minutes walking test group|Patients will performed 6 minutes walking test.
16371473|NCT04178265|Experimental|Electroacupuncture group|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of three times per week for four weeks, for a total of twelve times.
~Acupoint selection: needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints."
16371474|NCT04178265|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of three times per week for four weeks, for a total of twelve times.
16371475|NCT04178252|Active Comparator|standard drug|Standard treatment of primary headache with 10 mg metoclopramide IV in 150 ml saline given over 10 minutes
16371476|NCT04178252|Active Comparator|drug mask|Standard treatment plus eye mask
16371477|NCT04178252|Active Comparator|drug headset|Standard treatment plus headset
16371478|NCT04178252|Active Comparator|drug mask headset|Standard treatment plus headset plus eye mask
16371479|NCT04178239||Chronic Fatigue|MFI score >53 points
16371480|NCT04178239||No Chronic Fatigue|MFI score < 54 points
16371481|NCT04178226|No Intervention|Control|conventional therapy (NSAIDs and OCP)
16371482|NCT04178226|Experimental|Manual Acupuncture|manual acupuncture therpy
16371483|NCT04178226|Experimental|Laser Acupuncture|laser acupuncture therapy
16371484|NCT04178213|Experimental|ADAPT 3D ALR|Patients treated with ADAPT 3D ALR
16371485|NCT04178200||1.5 ml Dose|For retrobulbar anesthesia, 1.5 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
16371486|NCT04178200||3 ml Dose|For retrobulbar anesthesia, 3 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
16371645|NCT04177303|Placebo Comparator|Placebo|Patients will continue with their standard insulin therapy and will additionally receive placebo
16371487|NCT04178187|Active Comparator|Lactolevure|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics
16371488|NCT04178187|Placebo Comparator|Placebo|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo
16371489|NCT04178174|Experimental|SABR boost and de-escalated chemoradiation|SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.
16371490|NCT04178174|Active Comparator|Standard chemoradiation|The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.
16371491|NCT04178161|Experimental|Treated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.
~Treatment side receives laser treatment of the sweat glands."
16371492|NCT04178161|No Intervention|Untreated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.
~Control side is untreated."
16371493|NCT04178148|Experimental|BestDose|Therapeutic drug optimization of amikacin using the BestDose software algorithm
16371494|NCT04178148|No Intervention|Control|
16371495|NCT04178135|Experimental|rLH supplementation from day 1 of stimulation|rLH supplementation from day 1 of stimulation
16371496|NCT04178135|Active Comparator|rLH supplementation from day 6 of stimulation|rLH supplementation from day 6 of stimulation
16371497|NCT04178122|Experimental|Immediate Results|Participants in the Immediate Results arm will receive their genetic testing results from a genetic counselor at baseline following randomization.
16371498|NCT04178122|Experimental|Delayed Results|Participants in the Delayed Results arm will receive their genetic testing results from a genetic counselor 6 months after randomization.
16371499|NCT04178109|Active Comparator|Group A|"Group A was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.
~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.
~Group A was given the oral combination dexketoprofen/tramadole (25mg/75mg) 2h after surgery every 8h for 72h."
16371500|NCT04178109|Placebo Comparator|Group B|"Group B was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.
~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.
~Group B received postoperative analgesia with intravenous tramadole 75mg and paracetamol 1g every 8h with the first dose beginning 2h after the end of the surgery. For 72h"
16371501|NCT04178096|Other|Quality Improvement Intervention|Twelve low-performing sites will receive a package of strategies which have been empirically determined to be associated with successful implementation of evidence based practices that lead to improved health outcomes for Veterans with cirrhosis.
16371502|NCT04178096|No Intervention|Control Arm|All sites besides the pre-selected twelve, a total of one hundred eighteen sites, will not receive the intervention and will provide care as usual.
16371503|NCT04178083||Laparoscopic Sacrohysteropexy,|"Under general anesthesia,laparoscopic approach is used to enter the abdomen.Following this, visceral peritoneum is held with forceps from the point where the sacro-uterine ligaments adhere to the uterus.
~cut with unipolar scissors to the sacrouterin ligaments approximately 2-4 cm in the midline a transverse incision is made and the posterior wall of the cervix is reached. Approx. 10-15 x2 cm polypropylene mesh 5 mm trocar is inserted into the abdomen with the help of grasper and one end three points with 2/0 non-absorbable prolene sutures in the midline cervix Intracorporeal suture technique.
~After the sacral promontorium on peritona about 2 The transverse incision is made to the normal anatomical position and the appropriate mesh length is determined and the other end is fixed to the area prepared on the sacral promontorium at 3 points with 2-0 prolene. Bleeding reperitonization according to intracorporeal suture technique with 2/0 vicry"
16371504|NCT04178083||Modified Laparoscopic Lateral Suspension|A 10 cm diameter trocar is passed through a 1 cm infraumbical incision. In addition, two 5 mm diameter trocar are placed on 4 cm on both sides of the spinal iliac crest, and a 5 mm diameter trocar is placed laterally in the rectus muscle at the left lateral level of the umbilicus. A Prolene network of 25 cm in length is prepared. Dissection of the uterine cavity is performed to expose a mustache. The bottom of the web is secured by suturing the web in the midline and sides of the web with 2-0 prolene. The left and right modified lateral ports are then removed by moving under the bottom of the planet with the help of the planet until the isthmus reaches the bottom of the round ligament. The lateral ports are again slid onto the mesh, placed and sutured with peritoneal 2-0 vicryil, the mesh ends are cut at the skin level and the procedure is terminated.
16371505|NCT04178083||Laparoscopic Pectopexy|"First, the peritoneal layer on the top and side of the bladder opens parallel to the round ligament toward the right pelvic sidewall.
~The iliopectineal ligament is then located under the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medially of the outer iliac vein.
~iliopectineal (Cooper) ligament exposing a segment of approximately 3-4 cm is formed.
~After completion of the dissections, the ends of the mesh are sutured to both iliopectineal ligaments by intracorporeal suture using nonabsorbable sutures. The middle of the net is fixed with three sutures to the lower anterior segment of the uterus. The peritoneum on the mesh is sutured with an absorbable suture material."
16371506|NCT04178070|Experimental|GB224 2mg|single dose
16371507|NCT04178070|Experimental|GB224 5mg|single dose
16371508|NCT04178070|Experimental|GB224 10mg|single dose
16371509|NCT04178070|Experimental|GB224 15mg|single dose
16371510|NCT04178070|Experimental|GB224 20mg|single dose
16371511|NCT04178070|Experimental|GB224 30mg|single dose
16371512|NCT04178070|Placebo Comparator|Placebo 2mg|single dose
16371513|NCT04178070|Placebo Comparator|Placebo 5mg|single dose
16371514|NCT04178070|Placebo Comparator|Placebo 10mg|single dose
16371515|NCT04178070|Placebo Comparator|Placebo 15mg|single dose
16371516|NCT04178070|Placebo Comparator|Placebo 20mg|single dose
16371517|NCT04178070|Placebo Comparator|Placebo 30mg|single dose
16371518|NCT04178057|Experimental|GB222 3mg/kg|GB222 3mg/kg
16371519|NCT04178057|Experimental|GB222 5mg/kg|GB222 5mg/kg
16371522|NCT04178044|Experimental|GB223-group 1|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg,single dose administration; 2 subjects receive placebo.
16371523|NCT04178044|Experimental|GB223-group 2|21mg/kg
16371524|NCT04178044|Experimental|GB223-group 3|63mg/kg
16371525|NCT04178044|Experimental|GB223-group 4|119mg/kg
16371526|NCT04178044|Experimental|GB223-group 5|140mg/kg
16371527|NCT04178031|Experimental|IUD insertion group|All participants will have IUD inserted and follow up for occurance of complications
16371528|NCT04178018|Experimental|Transvaginal photoacoustic imaging/ultrasound|"Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled
~Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound
~For the exploratory outcome measure for high risk participants (approximately 50 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally at 6 months, 12 months, 18 months, 24 months, and at the time of surgery
~For the exploratory outcome measure for high risk participants (approximately 10 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally every 2 weeks at follicular phase and at the luteal phase for 3 months"
16371529|NCT04178005|Other|Cladribine|"All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI.
~Each treatment course is divided into 2 treatment cycles:
~Administration of first treatment course (year 1 treatment):
~First cycle: Starts on Day 1 of the study
~Second cycle: Administered 23 to 27 days after the last dose of first cycle.
~Administration of second treatment course (year 2 treatment):
~First cycle: Administered at least 43 weeks after the last dose of year 1 treatment
~Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment.
~The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days."
16371530|NCT04177992|Experimental|Servo control|"Automated control of oxygen. The oxygen saturation target range will be set to 93%.
~Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
16371531|NCT04177992|No Intervention|Manual control|Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
16371532|NCT04177979|Experimental|Near assisted learning group|Participants in this arm were supervised by the trained peer-instructors.
16371533|NCT04177979|No Intervention|Self directed learning group|Participants in this arm were practicing independently. They were not supervised by any instructors.
16371534|NCT04177966|Experimental|women watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term The day before surgery the women will watch a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation
16371535|NCT04177966|Placebo Comparator|women not watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term Women will receive general information about the surgery as part of informed consent, without watching a pre- prepared film.
16371536|NCT04177953|Active Comparator|Carboplatin or Cisplatin and Pemetrexed|"Four cycles (q4w) platinum-based adjuvant chemotherapy i.v.:
~carboplatin AUC5 or cisplatin 75 mg/m2
~pemetrexed 500 mg/m2"
16371537|NCT04177953|Experimental|Carboplatin or Cisplatin and Pemetrexed + Nivolumab|"Four cycles (q4w) of a combination of platinum-based adjuvant chemotherapy and immunotherapy i.v.:
~carboplatin AUC5 or cisplatin 75 mg/m2
~pemetrexed 500 mg/m2
~nivolumab 480 mg flat-dose.
~Followed by up to 12 cycles (q4w) maintenance immunotherapy:
~- nivolumab 480 mg flat-dose i.v."
16371538|NCT04177940|Active Comparator|Denosumab (DMAB) to Alendronate (ALN)|Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)
16371539|NCT04177940|Active Comparator|"DMAB to Early Zoledronic Acid (ZA)"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one early zoledronic acid infusion (5 mg; 6 months after last denosumab dose)"
16371540|NCT04177940|Active Comparator|"DMAB to Late ZA"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one late zoledronic acid infusion (5 mg; 9 months after last denosumab dose)"
16371541|NCT04177927|Experimental|endtidalcarbondioxide monitoring group|The patients performed gastrointestinal endoscopy will be monitored with Capnostream 20p / Coviden for etCO2 (End tidal CO2), RR (Respitarory rate), SpO2 and PR (heart rate).
16371542|NCT04177927|Active Comparator|Control Group|Rutine monitorization will be performed to control group of patients.
16371545|NCT04177901|Active Comparator|Brachial plexus blockage group|
16371546|NCT04177901|Active Comparator|local anesthesia group|
16371547|NCT04177888|Experimental|Experimental group|Experimental group with 45 participants, received hot pack, which was a single-use pack filled with magnesium sulfate and water, squeezed between the hands to activate the warming effect, applied to the lower back area for 30 minutes followed by 10 minutes rest then again applied for 30 minutes. This procedure was repeated till delivery.
16371548|NCT04177888|No Intervention|Control group|Control group with 46 participants received the hospital routine care that included Entonox inhalation as optional labor pain management.
16371549|NCT04177875|Experimental|Chemoradiation and pd-1|Subjects in Arm A receive 2 cycles of Docetaxel /Albumin-bound Paclitaxel + Cisplatin, for neoadjuvant therapy Neoadjuvant radiotherapy for 40Gy/20F
16371550|NCT04177862|Experimental|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
16371551|NCT04177862|Active Comparator|IV Fentanyl|single dose of IV fentanyl for acute pain.
16371552|NCT04177849|Active Comparator|Anterior Cervical Decompression and Fusion (ACDF)|Patients entered into this arm are treated via an anterior approach with disk excision, root canal decompression and fusion of the affected segment with a cage and plate.
16371646|NCT04177290|Experimental|sintilimab (M1b) 200mg|
16371647|NCT04177290|Active Comparator|sintilimab (approved) 200mg|
16371553|NCT04177849|Experimental|Posterior Foraminotomy (PF)|Patients entered into this arm are treated via a posterior approach through intermuscular planes. The root canal is decompressed by burring the medial third of the facet joint. No fusion is performed.
16371554|NCT04177836|Experimental|MIndfulness|This arm was developed to increase attention towards and acceptance of current experiences.
16371555|NCT04177836|Active Comparator|Active Control|This arm is a relaxation-based active treatment comparison intervention, developed to parallel the structure of the mindfulness intervention without the attention towards or acceptance of present experiences.
16371556|NCT04177823|Experimental|Chinese participants with relapsed/refractory multiple myeloma|Participants will be administered belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
16371557|NCT04177810|Experimental|Cemiplimab and Plerixafor|All participants will receive Cemiplimab and Plerixafor.
16371558|NCT04177797|Experimental|Toripalimb|Single arm, non randomized, open label study.The patients will receive Toripalimb concurrently caboplatin and paclitaxel treatment.
16371559|NCT04177784|Experimental|Intervention (I)|This arm was randomized to a 20 min video that emphasized information about factors other than individual behaviors that influence weight, weight loss and ability to maintain weight. It also indirectly addressed weight bias by explaining how to have conversation about weight and health with a patient with obesity that is free of biases.
16371560|NCT04177784|Active Comparator|Weight Control (C1)|This arm was randomized to a 20 min video that emphasized the controllable aspects of weight and gave dietitians an overview of a tool to help plan and monitor weight loss.
16371561|NCT04177784|Placebo Comparator|Weight Neutral Control (C2)|The arm was randomized to a 20 min video about the role dietitians play in society, that made no mention of weight or obesity.
16371562|NCT04177758|Placebo Comparator|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
16371563|NCT04177758|Experimental|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
16371564|NCT04177745|Experimental|Hot Application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
16371565|NCT04177745|Experimental|Cold Application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
16371566|NCT04177745|No Intervention|Standard Practice|The standard practice of the clinic was made. Accordingly, the researcher performed the vein assessment after the participants filled out the questionnaire, and then inserted the 20-G catheter into the inner surface of their forearm without any application. Afterwards, she assessed the pain and anxiety levels of the patients twice before and after the catheter insertion procedure.
16371567|NCT04177732|Other|Healthy peri-implant status|Patient with healthy peri-implant status
16371568|NCT04177732|Other|Presence of peri-implant diseases|Patients with presence of peri-implant diseases
16371569|NCT04177719|Experimental|Oxytocin|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
16371570|NCT04177719|Placebo Comparator|Placebo|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
16371571|NCT04177706|Experimental|Group A (Ketamine)|
16371572|NCT04177706|Placebo Comparator|Group B (Placebo)|
16371573|NCT04177693|Experimental|EGCG daily alone.|EGCG daily alone. 800mg
16371574|NCT04177693|Experimental|EGCG with clomiphene citrate|EGCG 800 mg daily with clomiphene citrate 100mg for 5 days.
16371575|NCT04177693|Experimental|EGCG with letrozole|EGCG 800mg daily with letrozole 5mg for 5 days.
16371576|NCT04177680|Experimental|Omega-3 pentaenoic acid (MAT9001)|2g MAT9001 capsules twice daily with meals
16371577|NCT04177680|Active Comparator|Icosapent ethyl (Vascepa)|2g Vascepa capsules twice daily with meals
16371578|NCT04177667|Active Comparator|Proxeed arm|Subjects received 2 packets per day for 6 months of supplement (1000 mg of L-carnitine, 725 mg of fumarate, 500 mg of acetyl-L-carnitine, 1000 mg of fructose, 50 mg of citric acid, 50 µg of selenium, 20 mg of coenzyme Q10, 90 mg of vitamin C, 10 mg of zinc, 200 µg of folic acid and 1.5 µg of vitamin B12)
16371579|NCT04177667|Placebo Comparator|Placebo arm|Subjects received 2 packets per day for 6 months of placebo
16371580|NCT04177654||Cambodia|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371581|NCT04177654||Bangladesh|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371582|NCT04177654||Vietnam|The group of school-aged children from Vietnam who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371583|NCT04177654||Lao PDR|The group of school-aged children from Lao PDR who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371584|NCT04177654||Ghana|The group of school-aged children from Ghana who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371585|NCT04177654||Senegal|The group of school-aged children from Senegal who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371586|NCT04177654||Rwanda|The group of school-aged children from Rwanda who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371587|NCT04177654||Haiti|The group of school-aged children from Haiti who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
16371588|NCT04177641||low grade squamous intraepithelial lesion(LGSIL)|low grade squamous intraepithelial lesion(LGSIL) n=100
16371589|NCT04177641||high grade squamous intraepithelial lesion(HGSIL)|high grade squamous intraepithelial lesion(HGSIL) n=100
16371590|NCT04177641||Healthy controls|Healthy volunteers n=100
16371591|NCT04177628|Experimental|Arm A: Shared decision making|Patients will be informed by a doctor randomized to practice shared decision making and use the in-consultation PtDA during the consultation on adjuvant radiotherapy.
16371592|NCT04177628|No Intervention|Arm B: Usual practice|Patients will be informed by a doctor randomized to inform about adjuvant radiotherapy according to usual practice.
16371593|NCT04177615|Experimental|Thromboectomy and rTPA|use thromboectomy and rtpa for patient with basilar artery occlusion stroke in 24 hour
16371594|NCT04177615|No Intervention|rTPA( recombinant tissue plasminogen activator )|use rtpa for patient with basilar artery occlusion stroke in 24 hour
16371595|NCT04177602|Experimental|Trifluridine/tipiracil based radiotherapy|Trifluridine/tipiracil based chemoradiotherapy (CRT)
16371596|NCT04177602|Active Comparator|standard calibration arm (internal control)|capecitabine based chemoradiotherapy
16371597|NCT04177576||Patients with myeloproliferative neoplasms (MPN)|Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
16371598|NCT04177563|Experimental|a group of ten students with high physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.
~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
16371599|NCT04177563|Experimental|a group of eight students with moderate physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.
~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
16371600|NCT04177537||Pre-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work with traditional therapies selected from one rehabilitation facility
16371601|NCT04177537||Post-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies selected from one rehabilitation facility
16371602|NCT04177524|Experimental|Arm 1|Participants alternate between using the Manual Mode of the app for 2 weeks and Auto-Detect Mode of the app for 2 weeks, for a total of 4 periods (8 weeks).
16371603|NCT04177524|Experimental|Arm 2|Participants use the Auto-Detect Mode of the app for 4 weeks, followed by the Manual Mode for 4 weeks.
16371604|NCT04177524|Experimental|Arm 3|Participants use the Background Mode of the app for 4 weeks, followed by the Auto-Detect Mode of the app for 4 weeks.
16371605|NCT04177511|Experimental|Transcutaneous auricular vagus nerve stimulation|"A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus.
~Standard treatment will be continued by the patients of this arm."
16371606|NCT04177511|No Intervention|Standard treatment|Patients of this arm will continue their standard treatment.
16371607|NCT04177498|Experimental|Treatment (rigosertib sodium)|Patients receive rigosertib sodium either oral or IV over a 52 week period. Patients will take oral rigosertib continuously for a total of three weeks, every four-week cycle (three weeks on, one week off drug). For IV, rigosertib is administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter.
16371608|NCT04177485|Experimental|Standard of Care + SMS text reminders|Standard of Care + SMS text reminders to be sent to caregivers for each of their subsequent vaccination visits, as per the EPI schedule (Penta2/OPV2/PCV2, Penta3/OPV3/PCV3, and MCV)
16371609|NCT04177485|No Intervention|Standard of Care|*Standard of care was defined as the health worker providing vaccination cards (home based records) to caregivers, as available, and providing verbal instruction of when to return for the next visit.
16371610|NCT04177472|Experimental|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
16371611|NCT04177472|No Intervention|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
16371612|NCT04177459|Experimental|Health promoting dialogue in addition to treatment as usual|Health promoting dialogues in addition to follow-up from primary and secondary health care, and from schools, which is individually customized due to fatigue and other symptoms present.
16371735|NCT04176523||Methylmalonic_acidemia|Patients with confirmed diagnosis of methylmalonic acidemia, and treated with carglumic acid, at any dose form, any dosage,
16371613|NCT04177459|Active Comparator|Treatment as usual|Follow-up from primary and secondary health care, and from Schools, which is individually customized due to fatigue and other symptoms present..
16371614|NCT04177446|Placebo Comparator|control group|Patients will be given basic energy intake according to their weight, and will be extra maltodextrin as the placebo
16371615|NCT04177446|Experimental|intervention group|Patients will be given basic energy intake according to their weight, and will be extra protein intake
16371616|NCT04177433|Experimental|Corticosteroid Injection|Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
16371617|NCT04177433|Placebo Comparator|Saline|Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
16371618|NCT04177420|Experimental|Experiment Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night.
16371619|NCT04177420|Placebo Comparator|Control Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night. the FIR-C mattress and the FIR-C abdominal pad is malfunction and it can not produce the FIR-C.
16371620|NCT04177407|Experimental|BPF group|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
16371621|NCT04177407|No Intervention|control group|Regarding to the pelvic peritoneum reconstruction, in control group, the pelvic peritoneum will be closed with running suturing. If not possible, the peritoneum covering the surface of the bladder will be secured on the anterior surface of the sacrum with nonabsorbable sutures at the level where the anatomic structure obliterates the pelvic entrance. If neither method was feasible, the pelvic peritoneum defect will be left unclosed.
16371623|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue with dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue with drain
16371624|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue without dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue without drain
16371625|NCT04177381|Active Comparator|non closure of subcutaneous tissue with drain|In the drain group,a closed non vacuum drain will be inserted in the tissue and exit from the skin through a separate opening and stitch to the skin
16371626|NCT04177381|Active Comparator|non closure of subcutaneous tissue and no drain|75 women without subcutanous sutures and without drain
16371627|NCT04177368||assess nutrition with regular dialysis|This study aims to assess the growth and the nutritional status in children with end-stage kidney disease on regular hemodialysis to define the degree of malnutrition , predict and quantify the risk for complications deriving from impaired nutritional status .Giving them theragran 60ml ,twice daily for 3 month.
16371628|NCT04177355|Experimental|Part A, Group 1 (T1): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 1 mcg of 3M-052-AF and 500 mcg of Aluminum Hydroxide Suspension (Alum), as one intramuscular (IM) injection at Months 0 and 2.
16371629|NCT04177355|Placebo Comparator|Part A, Group 1 (P1): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
16371630|NCT04177355|Experimental|Part A, Group 2 (T2): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 5 mcg of 3M-052-AF and 500 mcg of Alum, as one IM injection at Months 0 and 2.
16371631|NCT04177355|Placebo Comparator|Part A, Group 2 (P2): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
16371632|NCT04177355|Experimental|Part B, Group 3 (T3): BG505 SOSIP.664 gp140 + CpG 1018 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 300 mcg of CpG 1018 and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
16371633|NCT04177355|Placebo Comparator|Part B, Group 3 (P3): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
16371634|NCT04177355|Experimental|Part B, Group 4 (T4): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with either 1 mcg or 5 mcg of 3M-052-AF (the highest tolerated dose from Part A), and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
16371635|NCT04177355|Placebo Comparator|Group 4 (P4): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
16371636|NCT04177355|Experimental|Part B, Group 5 (T5): BG505 SOSIP.664 gp140 + GLA-LSQ|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with GLA-LSQ (GLA 5 mcg, and QS-21 2 mcg), as one IM injection at Months 0, 2, and 6.
16371637|NCT04177355|Placebo Comparator|Part B, Group 5 (P5): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
16371638|NCT04177355|Experimental|Part B, Group 6 (T6): BG505 SOSIP.664 gp140 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 500 mcg of Alum, administered as one IM injection at Months 0, 2, and 6.
16371639|NCT04177355|Placebo Comparator|Part B, Group 6 (P6): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
16371640|NCT04177342|Active Comparator|fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
16371641|NCT04177342|Experimental|oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
16371642|NCT04177316||hypermethylation|The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.
16371643|NCT04177316||hypomethylation/no change|The hypomethylation were defined as differential methylation status of tumor- normal <5%
16371644|NCT04177303|Active Comparator|Metformin|Patients will continue with their standard insulin therapy and will additionally receive orally metformin 2gr/day.
16371648|NCT04177264|Experimental|Osteopathic Manipulative Treatment (OMT)|In 4 randomized study sessions, combinations of two different osteopathic manipulative treatment (OMT) techniques (occipito-atlantal decompression [OA DC] and splenic lymphatic pump technique [SpLPT]) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of OMT techniques or sham interventions will be performed.
16371649|NCT04177264|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
16371650|NCT04177264|No Intervention|Time Control|In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
16371651|NCT04177238|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no anthocyanin content
16371652|NCT04177238|Experimental|Cherry juice|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
16371653|NCT04177238|Experimental|Blueberry|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
16371654|NCT04177225||Patients with normal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their normal left ventricular diastolic function.
16371655|NCT04177225||Patients with abnormal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their abnormal left ventricular diastolic function.
16371656|NCT04177186|Experimental|strength training group|ST group only strength training will be provided.
16371657|NCT04177186|Experimental|strength training with botulinum toxin|BT-ST group, strength training will be provided after the administering Botulinum toxin into the muscle belly guided under Ultra sound imaging.
16371658|NCT04177173|Experimental|Simvastatin & Methotrexate|Methotrexate 10 mg once a week per oral for 6 months and Statins (Simvastatin) 20 mg once a day per oral
16371659|NCT04177173|Active Comparator|Methotrexate|Methotrexate 10 mg once a week for 6 months
16371660|NCT04177160|Experimental|SCD subjects|Patients were diagnosed with subjective cognition decline and referred by neurologists.
16371661|NCT04177160|Experimental|Healthy controls|Voluntary healthy elderly recruited from the community.
16371662|NCT04177147|Experimental|Clinical decision support via alert tool|Clinicians received access to the electronic alert tool, which automatically displayed patients' risk of hypoglycemia.
16371663|NCT04177147|No Intervention|Usual care|Clinicians did not receive access to the electronic alert tool.
16371664|NCT04177108|Experimental|Cohort 1 Arm A|PD-L1 Non-Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1:1 ratio.
16371665|NCT04177108|Experimental|Cohort 1 Arm B|PD-L1 Non-Positive Participants receiving Paclitaxel, Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
16371666|NCT04177108|Active Comparator|Cohort 1 Arm C|PD-L1 Non-Positive Participants receiving Paclitaxel, Placebo for Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
16371667|NCT04177108|Experimental|Cohort 2 Arm A|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1 ratio.
16371668|NCT04177108|Active Comparator|Cohort 2 Arm B|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Placebo for Ipatasertib. Participants will be randomised in a 1:1 ratio.
16371669|NCT04177095|Experimental|Belatacept treated patients|Renal transplant recipients treated with a combination of belatacept and any of the following: mycophenolate, sirolimus, everolimus and prednisone
16371670|NCT04177082|Experimental|Pulsed 6mW/cm2|6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time
16371671|NCT04177082|Experimental|Pulsed 4mW/cm2|4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time
16371672|NCT04177069||Visucomplex Plus monotherapy|Patients with early dry AMD will be treated with Visucomplex Plus monotherapy.
16371673|NCT04177069||anti-VEGF drug plus Visucomplex Plus|Dry or wet AMD patients under treatment with a stable dose of an anti-VEGF drug, Visucomplex Plus will be added-on, upon physician decision.
16371674|NCT04177056|Experimental|Stereotactic Body Radiotherapy|High dose SBRT to lesion(s) of interest.
16371675|NCT04177043|Other|Screening|
16371676|NCT04177030|Experimental|Group A-Morning First|Within the first week of the study, Group A will consume fruits and vegetables within time-restriction morning window (9am-12pm). Following washout week, Group A will consume fruits and vegetables within time-restriction night window (7pm-10pm) for one week.
16371736|NCT04176523||Propionic_Acidemia|Patients with confirmed diagnosis of propionic acidemia, and treated with carglumic acid, at any dose
16371677|NCT04177030|Experimental|Group B-Night First|Within the first week of the study, Group B will consume fruits and vegetables within time-restriction night window (7pm-10pm). Following washout week, Group B will consume fruits and vegetables within time-restriction morning window (9am-12pm) for one week.
16371678|NCT04177017|Experimental|Experimental group|The experimental group is the one that participates in the intervention
16371679|NCT04177017|No Intervention|Control group|The control group belonged to the same school but did not participate in the intervention. Instead, they continued with regular curricular classes
16371680|NCT04177004|Experimental|Group A (conditioning, goat milk, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
16371681|NCT04177004|Active Comparator|Group B (conditioning, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
16371682|NCT04176991|Experimental|CTI-1601|
16371683|NCT04176991|Placebo Comparator|Placebo|
16371684|NCT04176978|Experimental|T2T + statin|Patient in this arm will receive treat-to-target strategy with rousavastin 20mg
16371685|NCT04176978|Active Comparator|T2T only|Patient in this arm will receive treat-to-target strategy only.
16371686|NCT04176952|Experimental|FOLFOX-A|"FOLFOX A arm (14-day cycle)
~nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.
~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.
~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
~Patients will also receive daily G-CSF as primary prophylaxis against neutropenic events for all cycles. This should be given as per local policy for chemotherapy regimens given every 14 days e.g. it may be started on day 4 for 7 days (preparation and dose should be given as per local policy)."
16371687|NCT04176952|Active Comparator|Abraxane and Gemcitabine|"Nab-Paclitaxel + Gemcitabine (AG) arm (28-day cycle)
~nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).
~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
16371688|NCT04176939|Experimental|HZ/su Group|Eligible participants who had a complete 2-dose HZ/su vaccination course in the primary study (NCT02058589) will be enrolled in this extension study, to receive 2 doses of HZ/su vaccine- first dose at Month 24 and second dose at Month 25 and will be followed up until the study end.
16371689|NCT04176926||Group 1: SR|Group 1: Subjects in the sinus rhythm (SR) cohort should not have any history of atrial fibrillation and should not be in atrial fibrillation or other atrial arrhythmia at the time of enrollment based on the screening ECG.
16371690|NCT04176926||Group 2: AF|Group 2: Subjects in the atrial fibrillation (AF) cohort must have a known history of AF and must be in AF at the time of enrollment based on the screening ECG.
16371691|NCT04176913|Experimental|Anti-CD20 Allogeneic CAR-T Cell Therapy|An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
16371692|NCT04176900|Experimental|Alternating 3D boluses|Both rigid and flexible 3D printed boluses made for each patient. Each is used on alternate days during radiation therapy.
16371693|NCT04176887|Experimental|Levetiracetam|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
16371694|NCT04176887|Active Comparator|Phenytoin|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
16371695|NCT04176874||Diastasis of the rectus abdominis muscles|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
16371696|NCT04176861|Experimental|Home based intervention|Participants using hBET technology at home (all participants).
16371697|NCT04176848|Experimental|CFI-400945 + Durvalumab|
16371698|NCT04176835|Experimental|oxytocin|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
16371699|NCT04176835|Placebo Comparator|Placebo|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
16371700|NCT04176822|Experimental|Educational Animated Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched an educational animated movie through VR Goggles. The educational animated movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
16371730|NCT04176575|Experimental|Acupuncture|This study will provide acupuncture treatment to patients with moderate to severe pain from their advanced cancer. Participants will attend acupuncture sessions at CIM ideally twice a week their first 4-6 weeks of study involvement and then once per week for up to 12 total study visits for no longer than 12 weeks after their study enrollment. Participants will also be asked to complete a follow-up 4 to 6 weeks after their last study visit. Their total study involvement will range from 12 to 18 weeks.
16371731|NCT04176549||Ectopic Pregnancy|Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast
16371701|NCT04176822|Experimental|Documentary Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched a documentary movie through VR Goggles. The documentary movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
16371702|NCT04176822|No Intervention|Control Group|No intervention was made, pain and fear levels were measured using scales only.
16371703|NCT04176809|Experimental|Interventional arm|The intervention will consist in an electronic measurement of HRQoL before each consultation with delivery scores to clinicians, who can discuss it with patients and coupled with therapeutic information. Patients will complete the EORTC-Quality of Life Questionnaire (QLQ)-C30 and the EORTC-QLQ-Breast (BR) 23 questionnaires using the CHES software before their consultation, via a touch pad or from their home via a secure web portal. Therapeutic information will consist on workshops on various themes. Only attendance Workshop 1 will be required, other workshops will be optional. The aim of workshop 1 is to inform patients about their ET and treatment benefits. Two additional optional workshops on nutrition (Workshop 2) and fatigue (Workshop 3) will be offered. This workshops will be collective. Every month, a letter encouraging patients to regularly take their medication will be sent. This letter will also include some tips on how to deal with some particular side effects of ET.
16371704|NCT04176809|No Intervention|Control arm|Participants in the control arm will receive standard care. They will not undergo digital HRQoL collection, and therapeutic information workshops will not be proposed.
16371705|NCT04176796|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
16371706|NCT04176796|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
16371707|NCT04176783|Active Comparator|Opioid|The opioid-based arm utilizes traditional, standard-of-care treatment for each applicable surgery. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.
16371708|NCT04176783|Active Comparator|Opioid-Free|The opioid-free arm utilizes medications that do not belong to the opioid family of medications. All medications used are FDA-approved and no experimental medications are being used. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.
16371709|NCT04176770|Experimental|ESP group|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
16371710|NCT04176770|Experimental|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
16371711|NCT04176757|Experimental|ZN-c5|
16371712|NCT04176744|Experimental|Magnetic Phrenic Nerve Stimulation|Each participant will be tested with 4 different stimulation setups (coils and stimulator) on 3 different days.
16371713|NCT04176731|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm
16371715|NCT04176705|Experimental|Laser|
16371716|NCT04176705|Placebo Comparator|No laser|
16371717|NCT04176666|Experimental|Intervention group receiving NettOpp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
16371718|NCT04176666|No Intervention|Control group|The control group will receive the intervention after study completion.
16371719|NCT04176653|Placebo Comparator|Placebo|
16371720|NCT04176653|Experimental|0.3 mg/kg|
16371721|NCT04176653|Experimental|1.0 mg/kg|
16371722|NCT04176653|Experimental|3.0 mg/kg|
16371723|NCT04176653|Experimental|10.0 mg/kg|
16371724|NCT04176614|Experimental|cereal-legume snack|Certain amount of cereal-legume snack daily for 12 weeks
16371725|NCT04176614|Active Comparator|cereal snack|Certain amount of cereal snack daily for 12 weeks
16371726|NCT04176601|Experimental|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
16371727|NCT04176588|Experimental|Experimental: Etrasimod 2mg|2mg/tablet, administratered orally, once daily
16371728|NCT04176588|Placebo Comparator|Placebo Comparator: Placebo|matching tablet, administratered orally, once daily
16371729|NCT04176588|Experimental|Etrasimod 2mg (optional open-label extension period)|2mg/tablet, administratered orally, once daily
16371732|NCT04176549||Surgical termination of pregnancy|Patients undergoing elective surgical termination of pregnancy Samples collected: Plasma, Serum, Urine, Oral swab Vaginal swab, Trophoblast
16371733|NCT04176549||Elective hysterectomy and salpingo-oophorectomy|Patients undergoing elective hysterectomy and salpingo-oophorectomy Samples collected: Fallopian tube, peritoneal washing
16371734|NCT04176536|Experimental|All participants|
16371737|NCT04176510|Experimental|Patient Centered Medical Home (PCMH) plus Health Coach|A health coaching intervention that employs a positive affect/self-affirmation intervention to help motivate patients to succeed at implementing self-management by setting life goals, in addition to the usual care provided for patients with multiple chronic diseases by the The Patient-Centered Medical Home (PCMH).
16371738|NCT04176510|No Intervention|Patient Centered Medical Home (PCMH)|Usual care provided for patients with multiple chronic diseases by the Patient-Centered Medical Home (PCMH).
16371739|NCT04176497|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
16371740|NCT04176484||Survey|Women, 18 years of age or older, who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be given a handout (attached) by clinic staff during routine pre-op counseling informing them that they may be called and asked to participate in a research survey. Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview. Participation will be voluntary and all data collected will be recorded without any identifiers.
16371741|NCT04176484||Operating Room Feasibility|A list of women 25 or older who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be generated to include MRN, procedure date, and pocedure type. A medical record review will be undertaken of these women and we will collect information about conditions that would facilitate or hinder the ability to perform a salpingectomy. No patient interaction will occur by the study team and all data will be de-identified at the time of collection.
16371742|NCT04176471|Experimental|Therapeutic Hypothermia|Therapeutic hypothermia will be achieved using a servo-controlled temperature regulating blanket that is approved for use in neonates and is currently used for the treatment of neonates with moderate-severe HIE. The goal target temperature is 33.5°C ± 0.5°C for 72 hours and the subject will then be rewarmed at a rate of 0.5°C per hour to a goal of 36.5°C.
16371743|NCT04176471|Active Comparator|Normothermia|Normothermia will be achieved using a servo-controlled temperature regulating blanket with the temperature goal of 36.5-37.3°C for 72 hours.
16371744|NCT04176458|Other|MBT in liver disease|Methacetin Breath test (MBT) intervention
16371745|NCT04176445|Other|Bedside Sitting followed by Orthostatic Board|Bedside sitting posture protocol followed by orthostatic board posture protocol.
16371746|NCT04176445|Other|Orthostatic Board followed by Bedside Sitting|Orthostatic board posture protocol followed by bedside sitting posture protocol.
16371747|NCT04176419|Experimental|Treatment Group|"Perioperative intervention (preoperative acetaminophen, gabapentin, and celecoxib and intraoperative ketamine and lidocaine).
~The Investigational Drug Service will mix and prepare the study medications necessary for each participant. An Investigational Drug Service staff member will deliver the oral medications to the nursing team in the preoperative holding unit and the IV medications to the anesthesia team in the OR unit."
16371748|NCT04176419|Placebo Comparator|Control Group|"Perioperative placebo
~Placebo oral drugs will be encapsulated versions provided by the Investigational Drug Service and will appear identical to the interventional oral drugs. Placebo IV infusions will be prepared by Investigational Drug Service as per institutional guidelines and will appear identical to the interventional IV drugs."
16371749|NCT04176406|Active Comparator|rTMS over a node within the fronto-parietal network|excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
16371750|NCT04176406|Sham Comparator|Sham rTMS over a node within the fronto-parietal network|electrical sham coil applied over a node within the fronto-parietal network.
16371751|NCT04176406|Active Comparator|rTMS over the DLPFC|excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
16371752|NCT04176406|Sham Comparator|Sham rTMS over the DLPFC|electrical sham coil applied over the DLPFC.
16371753|NCT04176393|Experimental|Ivosidenib (CS3010) tablet|Ivosidenib (CS3010) tablet
16371754|NCT04176380|Experimental|Administration of RAPA-201 cells|
16371755|NCT04176367|Experimental|Test: Nicergoline manufactured in China|
16371756|NCT04176367|Active Comparator|Reference: Nicergoline manufactured in Italy|
16371757|NCT04176354||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
16371758|NCT04176354||Palbociclib + Letrozole|Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
16371759|NCT04176354||Letrozole|Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
16371760|NCT04176341|Other|Intervention group|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
16371761|NCT04176341|No Intervention|Control group|chronic pain patient consulting in Lyon University Hospital who will receive usual care.
16371762|NCT04176328|Experimental|Cystic Fibrosis patients treated with Teicoplanin|Hospitalized male and female patients aged ≥ 18 years, suffering of Cystic Fibrosis.
16371763|NCT04176315|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty autonomously
16371764|NCT04176315|Experimental|ReHub Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty but use the telerehabilitation platform ReHub to do the exercises at home and to have their progress monitored.
16371765|NCT04176302|Active Comparator|Parkinson Holter|The neurologists in the study will receive information from the Parkinson Holter (device being studied)
16371766|NCT04176302|Active Comparator|Parkinson's diary|The neurologists in the study will receive information from a motor fluctuations diary
16371767|NCT04176302|Placebo Comparator|Traditional clinical practice|The neurologists in the study will receive no additional information other than what is obtained during the visit
16372559|NCT04170829|Experimental|Group 3 (n=9)|will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
16371768|NCT04176289|Active Comparator|PPI-guided pain therapy|At the end of anesthesia a PPI targeted opioid pain therapy will be performed by gradual administration of piritramid in 3 mg steps up to a PPI score ≤ 3.
16371769|NCT04176289|No Intervention|Non-PPI-guided pain therapy|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
16371770|NCT04176276||Patients with Type2 Diabetes|200 patients with type 2 diabetes consecutively enrolled among those referring to our Diabetes outpatient clinic.
16371771|NCT04176276||Patients without Type2 Diabetes|100 patients without diabetes among those referring to our outpatient clinic most of them affected by hypercholesterolemia, obesity or CV disease.
16371772|NCT04176263|Experimental|SBT|The SBT group will receive a 4-week split-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
16371773|NCT04176263|Active Comparator|TBT|The TBT group will receive a 4-week tied-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
16371774|NCT04176250|Experimental|TBA-7371 100 mg QD|
16371775|NCT04176250|Experimental|TBA-7371 100 mg BID|
16371776|NCT04176250|Experimental|TBA-7371 200 mg QD|
16371777|NCT04176250|Experimental|TBA-7371 100 mg TID|
16371778|NCT04176250|Experimental|TBA-7371 400 mg QD|
16371779|NCT04176250|Active Comparator|HRZE|
16371780|NCT04176237|Experimental|Intervention|Schools receive 3 one hour lessons on sun safety, followed by a 1 hour UV dosimtery laboratory session.
16371781|NCT04176237|No Intervention|Control|Schools receive 3 one hour lessons on sun safety.
16371782|NCT04176237|No Intervention|Observation|Schools do not receive any lessons.
16371783|NCT04176224|Experimental|MT-1186|Patients receive the edaravone oral suspension.
16371785|NCT04176185|Experimental|Active|HDM SLIT-tablet once daily for approximately 24 weeks
16371786|NCT04176185|Placebo Comparator|Placebo|Placebo tablet once daily for approximately 24 weeks
16371787|NCT04176172|Active Comparator|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
16371788|NCT04176172|Active Comparator|NMR-Tailored Medication & Standard Cessation Counseling|varenicline or nicotine patch plus standard behavioral smoking cessation treatment
16371789|NCT04176172|Experimental|Varenicline & Standard Cessation Counseling + MAPS|varenicline plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
16371790|NCT04176172|Experimental|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
16371791|NCT04176159|Experimental|Motor imagery and task-oriented training group|Two modules. A first module of motor imagery. A second module of task-oriented training and the incorporation of collective activities.
16371792|NCT04176159|No Intervention|Usual school routines group|Children continue with the usual school routine. Once the study is completed and the corresponding measurements have been made, the subjects included in this group will be subjected to the same program detailed in the intervention, to not deprive them of their benefits.
16371793|NCT04176146|Experimental|Nudge Letter|Participants receive a letter that highlights their performance vs. peer organizations on up to seven care delivery practices featured in the National Survey of Healthcare Organizations and Systems (NSHOS). The letter includes a link to access technical assistance resources and is sent alongside the participant's NSHOS respondent report.
16371794|NCT04176146|No Intervention|Control Letter|Participants receive a letter with a link to technical assistance resources; the letter is sent alongside the participant's NSHOS survey respondent report.
16371795|NCT04176133|Experimental|Dose Level 1|Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)
16371796|NCT04176133|Experimental|Dose Level 2|Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)
16371797|NCT04176133|Experimental|Dose Level 3|Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)
16371798|NCT04176133|Placebo Comparator|Placebo|Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.
16371799|NCT04176120|Experimental|TTAX01|TTAX01 plus standard care
16371800|NCT04176120|Other|Control|Standard Care alone
16371801|NCT04176107|Other|Study group- video+questionnaire|"The study group will be exposed to a video at admission to an elective cesarean delivery. The video will have information regarding the admission, pre-operation preparation and post- operation recovery.
~All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate the impact of exposure to informative video before caesarean delivery on anxiety and stress measured by State-Trait Anxiety Inventory (STAI)."
16371802|NCT04176107|No Intervention|Control group- questionnaire only|All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate anxiety and stress measured by State-Trait Anxiety Inventory (STAI) without intervention.
16371803|NCT04176094|Experimental|16 hour schedule|All residents assigned to an ICU randomized to a 16h overnight schedule will complete 16h overnight calls not preceded by an 8h daytime shift.
16371804|NCT04176094|Active Comparator|24 hour schedule|All residents assigned to an ICU randomized to a 24h overnight schedule will complete 24h shifts when scheduled for overnight calls (8h daytime shift followed by a 16h overnight call).
16371805|NCT04176081|Active Comparator|Group 1: Radiation Therapy Only|Participants randomized to Group 1 will receive radiation therapy only.
16371806|NCT04176081|Experimental|Group 2: Radiation Therapy + darolutamide + degarelix|Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.
16372586|NCT04170569|No Intervention|Control Group|No yoga program.
16371807|NCT04176068|Experimental|Combined microfocused ultrasound and calcium hydroxylapatite|One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks. Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.
16371808|NCT04176055|Experimental|HALO|
16371809|NCT04176042|Experimental|Track 1|"Subjects will be randomized to one of two 4-week tracks.
~Track 1 (intervention + follow-up) will consist of the following:
~Subjects will be randomized to one of two 4-week tracks. Track 1 (intervention + follow-up) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention participants will complete a baseline questionnaire battery consisting of measures including demographics, medical history and sleep. After completion, a 2-hour educational presentation will take place with a question-and-answer session. Participants will then complete post-intervention questionnaires to assess immediate impact of the session on knowledge, beliefs and practices. After 4 weeks, Track 1 participants will be contacted and will be asked to re-complete all baseline questionnaires (see above), in order to evaluate changes over 4 weeks."
16371810|NCT04176042|Active Comparator|Track 2|"Subjects will be randomized to one of two 4-week tracks. Track 2 (wait list + intervention) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention for Track 1 participants will complete the same baseline questionnaire battery.
~An identical intervention session, scheduled 4 weeks into the future. At that time, an identical procedure to the other track will be followed, including the pretest questionnaires, 2-hour session, and post-session assessment. No additional 4-week follow-up will be performed."
16371811|NCT04176029||Children admitted with confirmed severe malaria|
16371812|NCT04176016|Experimental|Single Study Arm, no competitor|
16371813|NCT04176003||Patients with CPPD|
16371814|NCT04176003||Healthcare professionals working with CPPD patients|
16371815|NCT04176003||Stakeholders working on behalf of CPPD patients|
16371816|NCT04175990|Experimental|Progestogen|Oral Dydrogesterone 10mg tds was given from day 1 of menses till day of trigger
16371817|NCT04175990|No Intervention|standard combine minimal stimulation protocol|Oral clomiphene citrate 100mg daily given from day 1 till day 10 of menses with additional gonadotrophin (Menopur 225mg daily) from day 3 of menses till trigger day
16371818|NCT04175977|Experimental|Aliviado Dementia Care-Hospice Edition|A multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
16371819|NCT04175977|Active Comparator|Control phase|PWD subjects will receive usual care as provided by their hospice agency during the control phase
16371820|NCT04175964|Experimental|Group 1|PCO patients that will receive ketogenic diet only
16371821|NCT04175964|Experimental|Group 2|PCO patients that will receive caloric diet with Metformin
16371822|NCT04175964|Experimental|Group 3|PCO patients that will receive caloric diet only
16371823|NCT04175951|Active Comparator|Tecnis Eyhance|Tecnis Eyhance hydrophobic IOL is a monofocal IOL with added advantage of slightly better unaided intermediate vision at 60 cms.
16371824|NCT04175951|Active Comparator|Rayner RayOne|Rayner Rayone is a monofocal hydrophilic IOL which is not intended to give better unaided or near vision.
16371825|NCT04175938|Active Comparator|Subjects with Fuch's Endothelial Dystrophy|Persons with a diagnosis of Fuch's Endothelial Dystrophy will wear a contact lens in an affected eye for three hours.
16371826|NCT04175938|Other|Subjects with healthy eyes|Persons with healthy eyes will wear a contact lens in one eye for three hours.
16371827|NCT04175925|Experimental|Part A: BMS-986322|
16371828|NCT04175925|Experimental|Part B: BMS-986322 Placebo|
16371829|NCT04175925|Experimental|Part C: BMS-986322 with famotidine|
16371832|NCT04175899|Experimental|POCCP (Pharmacist-led Oral Chemo Care Program)|"Intervention Group :
~Subjects undergo structured intensified pharmaceutical care program (POCCP) led by oncology experienced pharmacist (run alongside oncologist patient review at the clinic or daycare) in addition to Current Standard Best Care (SBC)"
16371833|NCT04175899|No Intervention|SBC (Current Standard Best Care)|"Control Group :
~Subjects undergo usual procedure which is Current Standard Best Care (SBC) for oral chemotherapy treatment which includes pre-chemotherapy review by doctor and prescribing of chemotherapy and supportive medications according to patient's chemotherapy protocol at each visit. Subsequently the patients will collect their prescribed oral medications at the ambulatory pharmacy counter according to the standard procedure of medication dispensing which includes prescription screening, medication filling, double checking, dispensing and counselling at the pharmacy counter as per usual practice of pharmaceutical care of patients."
16371834|NCT04175886||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day
16371835|NCT04175886||Healthy subjects|Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)
16371836|NCT04175873|No Intervention|Group C|Control group.
16371837|NCT04175873|Experimental|Group M|Music group.Preoperative 1 hour and during the operation of Classical Turkish Music (Acemaşiran makam) listening group
16371838|NCT04175860|Experimental|Intervention group|"Consists of a series of non-pharmacological preventive interventions that will focus on the - transition-discharge-hospital program including individualized non-pharmacological interventions such as dyad characterization, competency assessment, risk assessment, inherent program strategies, and monitoring.
~The intervention or program  Hospital Discharge Plan to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes an educational session and weekly telephone follow-up according to the patient's risk characterization."
16371839|NCT04175860|No Intervention|Control group|This group of patients-family caregivers will be carried out the discharge activities that are regularly developed in the second level institution and recorded in a check-sheet and field diary.
16371840|NCT04175847|Experimental|RC88|
16371841|NCT04175834|Other|diphenhydramine|25 mg diphenhydramine capsule, generic, sourced from Major Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
16371842|NCT04175834|Active Comparator|cetirizine|10 mg cetirizine tablet, generic, sourced from Mylan Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
16371843|NCT04175808|Experimental|Part A|After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
16371844|NCT04175808|Experimental|Part B|"Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences:
~Placebo
~50 mg omecamtiv mecarbil
~400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days."
16371845|NCT04175795|Experimental|Dashboard group|The intervention group will receive their personal profile via this e-mail along with instructions on goal-setting and tips to improve brain health.
16371846|NCT04175795|No Intervention|No Dashboard group|The control group will receive only the goal-setting instructions and tips.
16371847|NCT04175782|Experimental|ERAS group|A standardized ERAS protocol is applied to the ERAS group based on the latest guidelines. Smoking and alcohol consumption is stopped 4 weeks before the surgery. Preoperative anemia is corrected with intravenous iron supplementation. Prolonged fasting, bowel preparation, and premedication are avoided in this group. Clear fluids are allowed up to 2 h and solids rich in carbohydrate up to 6 h hours prior to induction of anesthesia. Warmed up intravenous fluids are administered to maintain normothermia intraoperatively. This group of subjects receives general anesthesia. Volume and salt overload and drain usage are avoided to the utmost. Intravenous paracetamol is administered for postoperative analgesia before the completion of the surgical procedure. Nasogastric tube placement is avoided and catheters are removed as soon as possible. Nonopioid oral analgesics and NSAIDs are utilized for postoperative pain medication.
16371848|NCT04175782|No Intervention|Control|This group will receive conventional pre-and postoperative care.
16371849|NCT04175769|Experimental|Experimental intervention|Standard intervention of chemotherapy, immunotherapy or combination of immunotherapy and chemotherapy, plus the experimental intervention nutritional product.
16371850|NCT04175769|Placebo Comparator|Non-experimental intervention|Standard intervention of chemotherapy, immunotherapy or combination of immunotherapy and chemotherapy, plus the non-experimental intervention placebo product.
16371851|NCT04175743|Experimental|200 mg CT-044 HCl or Placebo|200 mg of CT-044 HCl administered every 8 hours vs placebo
16371852|NCT04175743|Experimental|400 mg CT-044 HCl or Placebo|400 mg of CT-044 HCl administered every 8 hours vs placebo
16371853|NCT04175743|Experimental|600 mg CT-044 HCl or Placebo|600 mg of CT-044 HCl administered every 8 hours vs placebo
16371854|NCT04175730|Other|MRI and Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI positive for suspected prostate cancer followed by MRI/ultrasound fusion directed prostate needle biopsies
16371855|NCT04175730|Other|Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI negative for suspected prostate cancer followed by standard ultrasound guided prostate needle biospies
16371856|NCT04175717|Experimental|physiotherapy-led follow-up programme|
16371857|NCT04175704|Other|Cohort 1|0.2 mg/kg UB-221 or placebo
16371858|NCT04175704|Other|Cohort2|0.6 mg/kg UB-221 or placebo
16371859|NCT04175704|Other|Cohort 3|2 mg/kg UB-221 or placebo
16371860|NCT04175704|Other|Cohort 4|6 mg/kg UB-221 or placebo
16371861|NCT04175691||AIS group|This group includes patients with acute ischemic stroke (AIS).
16371862|NCT04175691||HC group|This group includes healthy controls (HC).
16371863|NCT04175678|No Intervention|Normal/Active|No intervention
16371864|NCT04175678|No Intervention|Obese/Inactive|Observational clinic visits
16371865|NCT04175678|Experimental|Diet|low fat/low caloric diet
16371866|NCT04175678|Experimental|Exercise Training|≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
16371867|NCT04175678|Experimental|Diet and exercise training|low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
16371868|NCT04175652|Experimental|Laughter yoga group, group doing laughter yoga|The duration of the laughter yoga was 30 minutes and a total of 16 sessions were performed on a twice-weekly basis.
16371869|NCT04175652|No Intervention|No laughter yoga group, group not doing laughter yoga|
16371870|NCT04175639|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
16371871|NCT04175639|No Intervention|mHealth-Education (mHealth-Ed)|mHealth-Education (mHealth- Ed): Participating in mHealth will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic with a nurse about cancer care.
16371872|NCT04175626||Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
16371873|NCT04175613|Experimental|Patients treated with Apremilast|Subjects with a weight between 20 kg to < 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
16371876|NCT04175587|Experimental|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Induction: a) RIF: 60 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR; Consolidation: a) RIF: 60 mg/kg daily, in a 4-week on 4-week off regimen for four cycles in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles
16371877|NCT04175587|Other|Arsenic trioxide Plus Retinoic Acid|Induction: a) Arsenic trioxide: 0·15 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR Consolidation: a) Arsenic trioxide: 0.15mg/kg daily, in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles Expected Efficacy: Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for achieving 2-year EFS.
16371878|NCT04175574|Experimental|Intervention group|The intervention consist of the patients in the experimental group listening to pre-recorded music played through a set of noise cancelling Sony headphones which are padded for extra comfort from a Sony Digital Walkman. The duration of the intervention is 30 minutes without interruption, such as eating, talking and being on their mobile phones.
16371879|NCT04175574|No Intervention|Control group|Whereas, patients in the control group will be given similar headphones but without any music. They will also be briefed not to eat, talk and being on their mobile phones.
16371880|NCT04175561|Experimental|Intervention|Participants in the intervention arm will be given a green prescription (gardening activities).
16371881|NCT04175561|No Intervention|Control|Participants in the control arm will not be given the intervention.
16371882|NCT04175548||surgery for a pertrochanteric fracture|Patients having had surgery for a pertrochanteric fracture at the CHU Brugmann Hospital between January 2013 and May 2019.
16371883|NCT04175535|Other|The experimental group|PPECD was performed in the experimental group
16371884|NCT04175535|Other|control group|ACDF was performed in the control group
16371885|NCT04175522|Experimental|Experimental|Investigational product(IP)
16371886|NCT04175509|Active Comparator|Rectal acetaminophen|Patients will receive two 650mg suppositories rectally of acetaminophen for a total dose of 1300mg at the end of surgery.
16371887|NCT04175509|Active Comparator|Intravenous acetaminophen|Patients will receive one dose of 1000mg of acetaminophen, administered intravenously, at the end of surgery.
16371888|NCT04175496|Experimental|Test Foods|Blueberry Cake, Snack with Cheese and spicy Crackers will be used as test foods.
16371889|NCT04175496|Experimental|Reference Food|Glucose solution will use as reference food.
16371890|NCT04175470|Experimental|Arm A: Discontinue treatment after first treatment cycle|
16371891|NCT04175470|Experimental|Arm B: Continue treatment until progression|
16371892|NCT04175457|Experimental|e-cigarette inhalation with nicotine|inhalation of e-cigarette vapor with nicotine for 30 minutes.
16371893|NCT04175457|Active Comparator|e-cigarette inhalation without nicotine|inhalation of e-cigarette vapor without nicotine for 30 minutes.
16371894|NCT04175444||Normal Subjects|This is a study of normal subjects to establish a normative database.
16371895|NCT04175431|Active Comparator|Group I (fluciclovine PET/CT)|Patients undergo fluciclovine PET/CT and who do not have any abnormalities outside the prostatic fossa by fluciclovine PET/CT imaging undergo PSA recheckes every 3 months, and undergo fluciclovine PET/CT once PSA is > 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA recheckes every 3 months, and undergo fluciclovine PET/CT once PSA is > 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml.
16371896|NCT04175431|Experimental|Group II (surgery, radiotherapy, abiraterone, prednisone)|Patients undergo fluciclovine PET/CT and who have =< 3 regions of metastatic disease outside of the prostatic fossa that are amenable to metastasis-directed therapy undergo lymphadenectomy or radiation therapy. 6 weeks after surgery, patients receive abiraterone acetate PO QD and prednisone PO QD. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may start radiation therapy after 2 cycles abiraterone acetate and prednisone.
16371897|NCT04175431|Experimental|Group III (abiraterone, prednisone)|Patients undergo fluciclovine PET/CT and who have > 3 regions of metastatic disease receive abiraterone acetate and prednisone as in Group II.
16371898|NCT04175418|Experimental|Supervised Exercise Program Group|Participants in the supervised exercise group were included to a program that consisted of 16 individual physiotherapist supervised sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
16371899|NCT04175418|Experimental|Online Education Program Group|Participants in the online education group were included to a program that consisted of 16 online sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
16371900|NCT04175405|Experimental|Right side of the maxilla|The 635-nm laser parameters; dose: 10J per point (20J/cm2), time: 100 sec per point, 2 points (irradiation on a buccal, and a palatal side of the alveolus/implant), the total energy per session 20J.
16371901|NCT04175405|No Intervention|Left side of the maxilla|
16371902|NCT04175392|Active Comparator|Treatment Group: Probiotic|Probiotic 1 billion units Supplement Once Daily
16371903|NCT04175392|Placebo Comparator|Control Group: Placebo|Placebo Capsule Once Daily
16371904|NCT04175379|Experimental|group 40|In group 40, target PaCO2 is 40 during surgery
16371905|NCT04175379|Experimental|group 50|In group 50, target PaCO2 is 50 during surgery
16371906|NCT04175379|Experimental|group 60|In group 60, target PaCO2 is 60 during surgery
16371907|NCT04175366|Experimental|Shared Decision Making|Intervention with Shared Decision Making procedure regarding decision on planning of care and treatment before discharge.
16371908|NCT04175366|No Intervention|Care as usual|Discharge planning as usual.
16371909|NCT04175353|Experimental|Dairy snack|Drink high in milk protein, 250 ml
16371910|NCT04175353|Active Comparator|Orange juice|Regular orange juice, 250 ml
16371911|NCT04175353|Experimental|Berry snack 1|Bilberry-blackcurrant purée, 139 g
16371912|NCT04175353|Experimental|Berry snack 2|Lingonberry purée, 122 g
16371913|NCT04175353|Active Comparator|Berry soup|Bilberry soup, 250 ml
16371957|NCT04175002||Anovulatory PCOS women with a BMI greater than 27|
16371958|NCT04175002||Anovulatory PCOS women with a BMI lower than 25|
16371914|NCT04175327||CardioCel group|Patients who require repair of cardiac and vascular defects including intracardiac defects; septal defects, valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing
16371915|NCT04175314||Case -|Patient presenting one or more periodontal recession more than 1mm of height
16371916|NCT04175314||Control-|Patient presenting no periodontal recession or recession of less than 1 mm of height
16371917|NCT04175301|Experimental|Hydrogen|Five times per day for 6 weeks subjects will dissolve a hydrogen generating tablet into water and drink the effervescent water. Dissolving one tablet in 250 mL of water will achieve a saturating hydrogen concentration of approximately 1.6 ppm.
16371918|NCT04175301|Placebo Comparator|Placebo|Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
16371919|NCT04175288|Experimental|Ultrasound, manual therapy and exercise|This group will receive Ultrasound, manual therapy and exercise
16371920|NCT04175288|Active Comparator|manual therapy and exercise|This group will receive manual therapy and exercise
16371921|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
16371922|NCT04175249|Experimental|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
16371923|NCT04175223|Experimental|probiotics|probiotic administration
16371924|NCT04175223|No Intervention|without probiotic|no change from the usual care
16371925|NCT04175210|Experimental|ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
16371926|NCT04175210|Experimental|ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
16371927|NCT04175197||Study Cohort|Subjects with symptoms of intermittent claudication and/or critical limb ischemia (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee arterial occlusion or stenosis
16371930|NCT04175171|Experimental|GB221|Coprelotamab Injection, 8mg/kg, single dose
16371931|NCT04175171|Active Comparator|Herceptin|Trastuzumab Injection, 8mg/kg, single dose
16371932|NCT04175158|Experimental|GB222|1mg/kg
16371933|NCT04175158|Active Comparator|Bevacizumab|1mg/kg
16371934|NCT04175132|Experimental|Healthy subjects|
16371935|NCT04175132|Experimental|PD patients|
16371936|NCT04175119|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses.
16371937|NCT04175106|Experimental|a phytochemical-rich blueberry variety|Single-time consumption of 150 g phytochemical-rich blueberry per participant.
16371938|NCT04175106|Experimental|a phytochemical-poor blueberry variety|Single-time consumption of 150 g phytochemical-poor blueberry per participant.
16371939|NCT04175106|Experimental|"a minimally processed blueberry-rich protein bar"|Single-time consumption of blueberry-rich protein bar matched for 150 g blueberry phytochemicals.
16371940|NCT04175106|Placebo Comparator|a blueberry control beverage of matched-nutritive content|Single-time consumption of control beverage matched for the macronutrient content of the blueberry-rich protein bar.
16371941|NCT04175093||Mild persistent asthma|• Group I, patients with mild persistent asthma.
16371942|NCT04175093||Moderate persistent asthma|• Group II, patients with moderate persistent asthma.
16371943|NCT04175093||Severe persistent asthma|• Group III ,patients with severe persistent asthma.
16371944|NCT04175080||Control|
16371945|NCT04175080||HFpEF group|
16371946|NCT04175080||Hypertensive group|Patients in which the results of BNP/NT-proBNP did not confirm the diagnosis of HFpEF were classified as hypertensive group.
16371947|NCT04175067||Endometrium cancer|stage I endometrium cancer n=57
16371948|NCT04175067||Healthy controls|Healthy volunteers n=60
16371949|NCT04175054|Active Comparator|Low Intensity Group|Less than 40% Heart Rate Reserve
16371950|NCT04175054|Experimental|Vigorous Intensity Group|More than 60% Heart Rate Reserve
16371951|NCT04175041|Other|ADHD|Patients with ADHD.
16371952|NCT04175041|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
16371953|NCT04175028|Other|ADHD|Patients with ADHD.
16371954|NCT04175028|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
16371955|NCT04175015|Experimental|Experimental|Participants will be randomised to eat an orange coloured smartie©
16371956|NCT04175015|Active Comparator|Control Group|Participants will be randomised to eat a pink coloured smartie ©
16371961|NCT04174989|Experimental|Plasminogen-Depleted Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
16371962|NCT04174989|Other|Fresh-Frozen Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of FFP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
16371963|NCT04174976||Wall hernia repair|"All patients admitted for wall hernia repair with mesh between 28/12/2017 and 28/12/2020.
~."
16371964|NCT04174963|Experimental|eToke + TPsy|All participants will receive the intervention (eToke+TPsy). The intervention consists of eToke (a brief computerized intervention that uses motivational enhancement therapy to improve readiness to decrease cannabis use and increase motivation to engage in substance use treatment) AND 6-8 interactive text messages regarding cannabis use reduction over 4 weeks . Text messages will contain written content, and queries, as well as links to publicly available websites and YouTube videos.
16371965|NCT04174950|Active Comparator|control group|Routine perioperative nursing intervention
16371966|NCT04174950|Experimental|experimental group|Perioperative ERAS Based Nursing Model
16371967|NCT04174937|Experimental|Potentiator of antibiotics (PA)|Potenciator of antibiotics (PA) , albumin complex of tetraiodid was given per os, single and multiple doses for the different periods (but not exceeding 14 days)
16371968|NCT04174937|Placebo Comparator|Patients taking placebo PA|Placebo without any active pharmaceutical ingredients was given per os dosed for the patients in same periods of time as per experimental group, single and multiple doses for the different periods (but not exceeding 14 days)
16371969|NCT04174924||Phakic intraocular lens (pIOL) explantation|Patients with pIOLs where a combined pIOL explantation and cataract surgery is needed.
16371970|NCT04174924||Cataract extraction|Healthy control group of patients scheduled for regular cataract surgery without comorbidities affecting an immune response.
16371971|NCT04174911|Experimental|BOL-DP-o-08|BOL-DP-o-08
16371972|NCT04174911|Placebo Comparator|Placebo|Placebo
16371973|NCT04174898|Experimental|Treatment Population|100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours
16371974|NCT04174885|Other|AF epicardial ablation|Patient with persistent AF will receive an epicardial ablation.
16371975|NCT04174872|Other|Dexmedetomidine|It has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
16371976|NCT04174872|Other|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
16371978|NCT04174846|Active Comparator|Treatment of SAM children with RUTF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with standard ready-to-use therapeutic food (RUTF)
16371979|NCT04174846|Experimental|Treatment of SAM children with RUSF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with ready-to-use-supplementary food (RUSF)
16371980|NCT04174820||Retrospective Low-Grade Glioma|Inclusion of patients with Low-Grade Glioma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
16371981|NCT04174820||Retrospective Medulloblastoma|Inclusion of patients with Medulloblastoma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
16371982|NCT04174820||Prospective patients|Inclusion of prospective patients with an indication to surgery of a Posterior Fossa Tumor, with evaluation of post-operative mutism and then one year after the end of mutism, an evaluation with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
16371983|NCT04174820||Control patients|Inclusion of patients without Posterior Fossa Tumor, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
16371984|NCT04174807||Cohort|
16371985|NCT04174781|Experimental|TACE-DEB in combination with Sintilimab Injection|Treatment will be divided into 4-week cycles from the starting date of TACE-DEB. The first TACE-DEB session and Sintilimab Injection will be initiated simultaneously. The repetition of TACE-DEB procedures will be initiated on demand according to tumour response assessment. Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression for up to one years.
16371986|NCT04174768|Experimental|Bariatric surgery patients|Bariatric patients undergoing sleeve gastrectomy or Roux-en-Y gastric bypass
16371987|NCT04174755|Experimental|Semaglutide 0.25/0.5/1 mg plus standard of care|
16371988|NCT04174755|Other|Standard of care alone|
16371989|NCT04174742||A|Subjects 45 years of age or younger
16371990|NCT04174742||B|Subjects over 45 years of age
16372018|NCT04174547||Innovative predictive models in MDS (AIM2)|"The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.
~The investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value."
16373509|NCT04164316|Active Comparator|Kinesio Tape with Tension|Kinesio Tape with Tension
16371991|NCT04174729|Experimental|Hand strength|"The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength. The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength.
~In the first session, the volunteers performed the movements 3 times in each device of daily living activities with the right limb, with a 1-minute rest interval between the 3 measurements. The entire procedure performed in the session was repeated again after 30 minutes to verify the reliability and reproducibility of the Intra-evaluator test. The Inter-rater test was repeated after 7 days by the second rater to analyze reliability between the rater."
16371992|NCT04174716|Experimental|IDX-1197|Patient will be receive IDX-1197HCl once daily for 28 continuous days
16371993|NCT04174703|Experimental|Self-compassionate letter-writing intervention|An online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks
16371994|NCT04174703|No Intervention|Control condition|
16371995|NCT04174690|Experimental|Balance|Volunteers aged from 18 years to over 60 years were selected without compromise. The tests were performed in a single session lasting 1 hour where the volunteers will do the tests on the force platform.
16371996|NCT04174677|Experimental|Inebilzumab Treatment|Infusion of Inebilizumab
16371997|NCT04174677|Experimental|VIB4920 Treatment|Infusion of VIB4920
16371998|NCT04174677|Experimental|Inebilzumab+VIB4920 Treatment|Infusion of Inebilizumab and VIB4920
16372003|NCT04174638|Experimental|"Intervention Group"|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
16372004|NCT04174638|No Intervention|"Control Group"|The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.
16372005|NCT04174625|Experimental|Omega3-FA group|Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
16372006|NCT04174625|Experimental|Control group|VD3 group 50,000 IU/week
16372007|NCT04174612|Active Comparator|Standard clinical treatment|"Patients will complete 3+7 + Midostaurin induction course."
16372008|NCT04174612|Experimental|Experimental treatment|"The experimental arm will provide 2 main modifications compared to standard:
~i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status"
16372009|NCT04174599|Experimental|F-627|Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
16372010|NCT04174599|Active Comparator|GRAN®|Subjects will receive GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
16372011|NCT04174586|Experimental|cord blood group|standard induction and consolidation chemotherapy with cord blood microtransplantation
16372012|NCT04174573|Experimental|Group therapy only (GTO)|Patients in GTO group will receive structured group therapy programme
16372013|NCT04174573|Experimental|Group therapy with tDCS (GT-tDCS)|Patients in this group will receive group therapy along-with tDCS intervention
16372014|NCT04174560|Experimental|Cohort 1|Single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
16372015|NCT04174560|Experimental|Cohort 2|Single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
16372016|NCT04174560|Experimental|Cohort 3|Single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
16372017|NCT04174547||Clonal hematopoiesis (AIM 1)|"The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: Health and Anemia study [Haematologica 2010;95:1849], and Monzino 80-plus study [BMC Neurol.2011;11:54, validation cohort]. Overall in 5000 subjects aged >65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations."
16372749|NCT04169425||Group 1|patients who underwent to laparoscopic TME, with elective diverting ileostomy for rectal cancer
16372019|NCT04174547||Predictive biomarkers in MDS (AIM3)|The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal.
16372020|NCT04174521||Mother-Child|Mothers who have delivered at VUMC and their children who are seen by Vanderbilt-affiliated physicians.
16372021|NCT04174495||Obese patients followed at Nancy University Hospital|
16372022|NCT04174482|Experimental|flat foot patients|20 patients recruited consecutively and candidates for surgery to correct the adult flat foot according to the Grice technique.
16372023|NCT04174456|Experimental|Olmesartan group|olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
16372024|NCT04174456|Active Comparator|Valsartan group|valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
16372025|NCT04174443|Experimental|Pulsed radiofrequency + Continuous radiofrequency|
16372026|NCT04174443|Active Comparator|Pulsed radiofrequency|
16372027|NCT04174430||mild to moderate bronchiolitis|Bronchiolistis patients without Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks, Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency and Neurologic disease
16372028|NCT04174417|Active Comparator|systolic blood pressure (SBP)|Systolic blood pressure (SBP) for group 1 patients 80-90 mmHg
16372029|NCT04174417|Active Comparator|mean blood pressure (MBP)|Mean blood pressure (MBP) for group 2 patients 50-65 mmHg
16372030|NCT04174404|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Circumcision which is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
16372031|NCT04174404|Active Comparator|Control group|The participants in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care.
16372032|NCT04174391|Experimental|Mediterranean diet supplemented with extra-virgin olive oil|
16372033|NCT04174391|Active Comparator|Low-fat diet|
16372034|NCT04174378||GnRH agonist with progestogen support|
16372035|NCT04174378||progestogen support only|
16372036|NCT04174365|Experimental|Brexpiprazole|
16372037|NCT04174365|Placebo Comparator|Placebo|No Intervention
16372038|NCT04174352|Experimental|Tamoxifen Dose Levels|"Three participants will be enrolled to each dose level of oral tamoxifen (n = 12)
~Dose Level 1 = 20 mg daily Dose Level 2 = 80 mg daily Dose Level 3 = 160 mg daily Dose Level 4 = 200 mg daily
~Tamoxifen should be started within 14 days of the FES-PET/CT scan, at least 24 hours after FES injection. Participants will continue tamoxifen therapy until there is radiologic or clinical evidence of progressive disease or drug intolerance."
16372039|NCT04174339|Experimental|camrelizumab plus apatinib and POF|Participants will receive camrelizumab in combination with apatinib plus POF until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16372040|NCT04174326|Experimental|Intervention group|A weekly 2 hour CBT for chronic pain group intervention for a duration of 6 weeks
16372041|NCT04174326|No Intervention|Delayed intervention group|A waiting list for CBT for chronic pain group intervention.
16372042|NCT04174313||VILI VORTEX and No VILI VORTEX|Measurement of pulmonary pressures and volumes in the same patient
16372043|NCT04174300|Experimental|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
16372044|NCT04174287|Experimental|F-18-AV45|F-18-AV45 imaging
16372045|NCT04174274||positive|ventilator-associated pneumonia-developed group followed by mechanical ventilation
16372046|NCT04174274||negative|not ventilator-associated pneumonia-developed group followed by mechanical ventilation
16372047|NCT04174261|Experimental|Ticagrelor - Remote Ischemic Preconditioning|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
16372048|NCT04174261|Other|Ticagrelor - Control|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. BP-cuff uninflated around the non-dominant arm
16372049|NCT04174261|Active Comparator|Clopidogrel - Remote Ischemic Preconditioning|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
16372050|NCT04174261|Other|Clopidogrel - Control|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. BP-cuff uninflated around the non-dominant arm
16372051|NCT04174248|Experimental|Experimental group|Experimental group with BCSMS App using
16372052|NCT04174248|No Intervention|Control group|Control group without BCSMS App using
16372053|NCT04174222|Active Comparator|Moderate block|5-10mg rocuronium is administered to maintain train-of-four count 1-2. At the end of surgery, sugammadex 2mg/kg is administered IV for reversal of neuromuscular block.
16372054|NCT04174222|Experimental|Deep block|5-10mg rocuronium is administered to maintain train-of-four count 0, and post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
16372055|NCT04174209|Experimental|Cohort 1|70 patients are involved and will perform the three conditions.
16372056|NCT04174196|Experimental|Participants with Plasmacytoma|Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas
16372057|NCT04174183|Experimental|Prevena (right side) - Dry dressing (left side)|
16372058|NCT04174183|Experimental|Prevena (left side) - Dry dressing (right side)|
16372059|NCT04174170|Experimental|Brexpiprazole + Sertraline|3 pills: Fixed dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
16372060|NCT04174170|Experimental|Sertraline|3 pills: Fixed dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
16372061|NCT04174170|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
16372062|NCT04174157||Prospective observational registry|This is a prospective, multi center, multinational, non-interventional observational registry.
16372063|NCT04174144||TLIF group|Participants with degenerative spondylolysthesis who underwent a single-level TLIF procedure.
16372064|NCT04174131|Experimental|Treatment A (right) B (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
16372065|NCT04174131|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
16372066|NCT04174118|Experimental|belcesiran|Healthy volunteers will be administered a single dose of belcesiran.
16372067|NCT04174118|Placebo Comparator|Placebo|Healthy volunteers will be administered a single dose of matching placebo.
16372068|NCT04174105|Experimental|Initial Dose Cohort|3x10^13 vg/kg of AT845 administered via intravenous infusion
16372069|NCT04174105|Experimental|Second Dose Cohort|6x10^13 vg/kg of AT845 administered via intravenous infusion
16372070|NCT04174092|Experimental|rheumatoid arthritis|Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months
16372071|NCT04174092|Experimental|spondyloarthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).
~Patients will be seen at 3, 6 and 12 months"
16372072|NCT04174092|Experimental|Psoriatic arthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).
~Patients will be seen at 3, 6 and 12 months"
16372073|NCT04174079|Experimental|Experimental group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
16372074|NCT04174079|No Intervention|control group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma were reviewed regularly after surgery.
16372075|NCT04174066||SNLGM|70 patients with an SNLGM
16372076|NCT04174066||primary FSH|74 with a primary FSH
16372077|NCT04174053|Experimental|Temperature measurement|"enteric capsule will be ingested every 24 hours during aplasia. Temperature measurement will be made continuously during aplasia.
~In parallel, auricular temperature will be measure every 4 hours during aplasia."
16372078|NCT04174040|No Intervention|Control 1|Applied any intervention.
16372079|NCT04174040|Active Comparator|Control 2|Gross's Process of Emotion Regulation Model interventions applied.
16372080|NCT04174040|Active Comparator|Control 3|Musical rhythm interventions applied.
16372081|NCT04174040|Experimental|Experimental|Musical rhythm integrated Gross's Process of Emotion Regulation Model interventions applied.
16372082|NCT04174014|Experimental|Recruitment manoeuvre|"Volume control (VC) ventilation mode with a tidal volume of 6 mL/kg of ideal body weight
~P/V tool assessment
~Baseline measurements
~CT scan of chest without EIT belt
~Re-establishment of EIT belt, continuous EIT and transpulmonary pressure measurement during the recruitment and de-recruitment manoeuvre.
~increment phase:
~constant volume settings
~increasing PEEP with 4 cmH2O following each 10 consecutive controlled breath until reaching a peak pressure of 40 cmH2O
~decrement phase:
~constant volume settings
~decreasing PEEP with 4 cmH2O following each 10 consecutive controlled breath not lower than 2 cmH20 from target PEEP
~target PEEP level is defined where the end-expiratory transpulmonary pressure is 0-1 cmH2O
~P/V recruitment with target end-PEEP level
~Removal of EIT belt, CT scan of chest
~Continuous EIT and transpulmonary pressure measurement with the initial FiO2 and the new PEEP settings"
16372083|NCT04174001||Neuro group|"Patients who meet the following criteria:
~18 years of age or younger
~diagnosed with one or more of the following neurological disorders: moyamoya disease, congenital anomalies of the brain, hypoxic-ischemic encephalopathy, brain tumor, Chiari malformation, epilepsy and stroke
~planned for any surgical procedures that require general anesthesia
~planned to receive intraoperative and/or postoperative invasive arterial blood pressure monitoring
~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or are scheduled for a cardiac procedure will be excluded."
16372084|NCT04174001||Control group|"Patients who meet the following criteria:
~18 years of age or younger-planned for any surgical procedures that require general anesthesia
~planned postoperative invasive blood pressure monitoring
~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or have symptoms of neurological disorders will be excluded."
16372085|NCT04173988|Experimental|alloCART-19|"For the very first patient, the initial dose could be administered via one or three intravenous infusions within 1 to 5 days. Starting from the second patient, the investigator will decide whether to use single or multiple alloCART-19 infusions, based on the treatment experience at previous dose level(s) and the patient's baseline disease burdens.
~A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before alloCART-19 infusion."
16372119|NCT04173793|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
16372086|NCT04173975|Experimental|With knee exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).
~Each session will be 45 minutes long. Three time per week, for three weeks.
~The patients allocated in this arm will perform the training wearing the BELK device."
16372087|NCT04173975|No Intervention|Without exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).
~Each session will be 45 minutes long. Three time per week, for three weeks.
~The patients allocated in this arm will perform the training without any exoskeleton."
16372088|NCT04173962|Experimental|Ketamine group|One 0.5mg/kg intravenous dose of ketamine
16372089|NCT04173962|Active Comparator|Midazolam group|One 0.045mg/kg intravenous dose of midazolam
16372090|NCT04173949|Experimental|Ramipril 2.5 MG|Ramipril 2.5 MG orall, daily.
16372091|NCT04173936||Tai Chi|All participants enrolled in a 12 week community-based tai chi program.
16372092|NCT04173910||LPEC/Sellick ultrasound|
16372093|NCT04173897|Experimental|Intervention arm|12 weeks access to LIBERATE online supportive intervention (dose not specified) including symptom monitoring questionnaire component, with questionnaire results integrated within electronic medical records for clinician review.
16372094|NCT04173897|No Intervention|Waiting list control arm|Care and support as usual; no access to intervention. Placed on waiting list to receive intervention following study completion.
16372095|NCT04173884|Active Comparator|Live Surgical Peer Coaching|Coaches will facilitate an initial, individual, introductory phone call with participants prior to the first formal coaching session. The objective of this call is to develop rapport, explore each other's background, experience, and motivation for participation in the program, set overall goals for the program, set specific goals for the first coaching session, develop an action plan including identification of the key characteristics of the first case for review, and develop a timeline and plan for meetings. Peer coaching sessions will be scheduled at three national meetings that are commonly attended by ACHQC surgeons. In advance of each meeting, participants will record and upload a self-selected video to a secure server maintained by the study team, and coaches will have the opportunity to review the video if they wish to prepare. A live coaching session will be organized at the meeting where the coaches and participants will have parallel one-hour coaching sessions.
16372096|NCT04173884|Active Comparator|Asynchronous Video-based Constructive Feedback|There will be no real-time interpersonal contact between coaches and participants in this arm. Participants will upload their self-selected procedural video to the video review platform, together with a short description of the case and any specific questions. The coach will review the video within one week of its posting and provide time-stamped feedback on the video platform. Participants will then review the coach's feedback within one week with the ability to respond to the comments. The coach and participant will continue communication via the internet-based review platform until no further comments are made by either party. Coach-participant dyads are expected to review three videos during the 6 month intervention period.
16372097|NCT04173884|Active Comparator|Wait-List Control|One-third of participants will be randomized to an intervention, but wait-listed to provide a control group. These surgeons will submit two videos for technical skill evaluation during each of the baseline and follow-up periods, and ACHQC data will be tracked for short-term outcomes prior to their crossover to the intervention for long-term follow-up. Selecting the control group using the identical sampling frame of ACHQC surgeons participating in the interventions affords the opportunity for a comparable group with outcome metrics recorded systematically.
16372098|NCT04173871|Experimental|Intervention|Intervention group
16372099|NCT04173871|No Intervention|Control|Control group
16372100|NCT04173858||Experimental|Patients with confirmed opioid-induced constipation diagnosis and inadequate response to laxatives.
16372101|NCT04173845|Experimental|Tianqi Pingchan Granule group|Tianqi Pingchan Granule were manufactured according to Good Manufacturing Practice (GMP) by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. , granule, twice a day, for six months.
16372102|NCT04173845|Placebo Comparator|Tianqi Pingchan Granule Placebo group|placebo, granule, twice a day, for six months.
16372103|NCT04173832|Experimental|Tianqi Pingchan Granule Combined With Amantadine|
16372104|NCT04173832|Placebo Comparator|placebo Combined With Amantadine|
16372105|NCT04173819|Experimental|Group 1|Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo
16372106|NCT04173819|Experimental|Group 2|Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo
16372107|NCT04173819|Experimental|Group 3|Single agent intravenous injection 10:2 ratio for Ab:placebo
16372108|NCT04173819|Experimental|Group 4|Single agent intravenous injection 10:2 ratio for Ab:placebo
16372109|NCT04173819|Experimental|Group 5|Combined agent intravenous injection 10:2 ratio for Ab:placebo
16372110|NCT04173819|Experimental|Group 6|Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo
16372111|NCT04173819|Experimental|Group 7|Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo
16372112|NCT04173819|Experimental|Group 8|Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo
16372113|NCT04173819|Experimental|Group 9|Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
16372114|NCT04173819|Experimental|Group 10|Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
16372115|NCT04173806|Experimental|Facebook group|"Participants will be included in an online classroom through a closed group of Facebook to receive an asynchronous course of telemedicine."
16372116|NCT04173806|Active Comparator|Control group|In this group the participants are exposed to the same course of telemedicine but on the Moodle educational platform.
16372117|NCT04173793|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
16372118|NCT04173793|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
16372120|NCT04173793|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
16372121|NCT04173793|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
16372122|NCT04173780|Experimental|Atropine 0.01%|
16372123|NCT04173780|Placebo Comparator|Placebo|
16372124|NCT04173767|Experimental|HFNC|
16372125|NCT04173754||MSAT Group|"The MSAT group who are treated with korean medical treatment including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
16372126|NCT04173754||Control Group|"The control group who are treated with Korean medical treatment not including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
16372127|NCT04173741||Leg Rise Position - 3 Minutes|Patients who stayed in passive leg rise position for 3 minutes
16372128|NCT04173741||Leg Rise Position - 1 Minute|Patients who stayed in passive leg rise position for 1 minute
16372129|NCT04173728|Experimental|young and normal weight|20 subjects aged 20-29 years with normal body weight(18.5≤BMI<24), male:female = 1:1
16372130|NCT04173728|Experimental|normal weight|40 subjects aged 30-70 years with normal body weight(18.5≤BMI<24), male:female = 1:1
16372131|NCT04173728|Experimental|overweight or obesity|40 subjects aged 30-70 years with overweight or obesity (BMI≥24), male:female = 1:1
16372132|NCT04173728|Experimental|Mets|20 objects with Mets, male:female = 1:1
16372133|NCT04173715||General Group|All those who are over 65 years old and capable of walking by themselves.
16372134|NCT04173715||Low Physical Function Status Group.|All those who present a low physical function status will be included in this group.
16372135|NCT04173715||Medium Physical Function Status Group.|All those who present a medium physical function status will be included in this group.
16372136|NCT04173715||High Physical Function Status Group.|All those who present a high physical function status will be included in this group.
16372137|NCT04173702|Experimental|Healthy Group|Postural sway and stability limits in assessment of healthy individuals
16372138|NCT04173689|Active Comparator|Inspiratuar muscle training group|This group will be given inspiratory muscle training (IMT) at home for 15 minutes twice a day for 7 days a week with the resh Threshold IMT 'device. In the IMT group, the initial training intensity will be determined by measuring the maximal inspiratory muscle strength (MRP) with the intraoral pressure measuring device, 30% of the measured MRP value will be started at the first evaluation and the new training intensity will be determined by calculating 30% of the measured value by repeating the MRP measurement every week.
16372139|NCT04173689|Active Comparator|Exercise group|This group will perform upper extremity and trunk exercises combined with breathing exercises at home for 7 days, twice a day for 15 minutes. Patients in both groups will perform a single 15-minute session once a week at the hospital under the supervision of a physiotherapist.
16372140|NCT04173676|Experimental|use of indocyanine green|submucosal injection of ICG is by gastroscopy on the superior and inferior edge of the esophageal tumor,Dose of 0.5mg
16372141|NCT04173663|Experimental|ASSIST intervention group|This group will attend the 12 sessions of the ASSIST training program (one 2-hour session per week for 12 weeks).
16372142|NCT04173663|Other|Written materials only control group|This group will receive the ASSIST curriculum and written materials developed for the program but will not attend the in-person sessions.
16372143|NCT04173650|Experimental|AGLE 102|Treatment arm
16372144|NCT04173637|Experimental|AK101 45mg every 8 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 8 weeks
16372145|NCT04173637|Experimental|AK101 45mg - every 12 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 12 weeks
16372146|NCT04173637|Experimental|AK101 90mg - every 8 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 8 weeks
16372147|NCT04173637|Experimental|AK101 90mg -every 12 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 12 weeks
16372148|NCT04173637|Experimental|AK101 135mg -every 8 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 8 weeks
16372149|NCT04173637|Experimental|AK101 135mg -every 12 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 12 weeks
16372150|NCT04173637|Placebo Comparator|Placebo to AK101|Placebo on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously at Week 12, 16 and then every 12 weeks
16372151|NCT04173624|Experimental|Endosonography|Endosonography is endoscopic method to diagnose pancreatic and biliary disorders. Participants randomized to this arm will undergo diagnostic endosonography under propofol sedation in supervision of trained anesthesiologists. If choledocholithiasis is diagnosed on endosonography, patient will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
16372152|NCT04173624|Experimental|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for diagnosis of pancreatic and biliary disorders. Participants randomized to this arm will undergo MRCP. If choledocholithiasis is diagnosed on MRCP, participants will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
16372153|NCT04173611|Experimental|EXPAREL®|For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
16372218|NCT04173117|Experimental|Intervention|Low energy meal replacement plan 12 weeks
16372154|NCT04173611|Active Comparator|Bupivacaine|In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.
16372155|NCT04173611|Active Comparator|Placebo|Subjects in the placebo arm will receive normal saline intrathecal injection
16372156|NCT04173598|Experimental|Intervention Group|An intervention group consisting of a dyad (patient + family carer) benefiting in addition to the usual treatment from the intervention for the family carer.
16372157|NCT04173598|Active Comparator|Control Group|A group consisting of a dyad (patient + caregiver) with usual care (control group)
16372158|NCT04173585|Experimental|Bortezomib-Gemtuzumab Ozogamicin Treatment|"one cycle of combined chemotherapy:
~Bortezomib (1.3 mg/m2) sc on day 1 and 3. Dose will be given 3 hours prior to Cytarabine on day 1 and 3
~Cytarabine (1g/m² twice daily) iv over 3 hours on day 1, 2 and 3 Gemtuzumab Ozogamicin (3 mg/m²,up to a maximum of one 5 mg vial) iv over 2 hours on day 1 after first dose of Cytarabine and day 4
~Pegfilgrastim 6 mg sc on day 8 (optional)"
16372159|NCT04173572|Experimental|Walking Group|Participants will be walking two times a week in supervised virtual walking groups on a secure online platform (Zoom) and will also participate in independent walks done at a location of their own choosing outside group participation.
16372160|NCT04173572|Active Comparator|Fitbit Alone|Participants will be provided with a Fitbit wristband and instructed how to use it. Participants will also be given information on current recommended physical activity guidelines and told that study staff may be contacting them on a weekly basis if it looks like participants are not wearing their Fitbit for a certain number of days or to troubleshoot any issues.
16372161|NCT04173559|No Intervention|Usual care|Women randomized to this group will receive no guidance regarding exercise / activity / sleep during pregnancy.
16372162|NCT04173559|Experimental|Activity Intervention|Women randomized to this group will receive detailed information and reminders about physical activity and sleep in pregnancy. .
16372165|NCT04173507|Experimental|Treatment (talazoparib, avelumab)|Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16372166|NCT04173494|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match danazol
16372167|NCT04173494|Active Comparator|Danazol|Participants will receive danazol plus placebo to match momelotinib
16372168|NCT04173481|Experimental|Rood's Group|Rood's sensory motor training along with CIMT
16372169|NCT04173481|Active Comparator|Conventional Physical Therapy Group|Conventional Physical Therapy including Proprioceptive Neuromuscular Facilitation technique.
16372170|NCT04173468|Active Comparator|MWM Group|This group will receive Mobilization with Movement (MWM) i.e. straight leg raised with traction,Tibial Gliding
16372171|NCT04173468|Active Comparator|Mulligan Taping Group|This group will receive Mulligan knee taping
16372172|NCT04173455|Experimental|HZ-A-018|"In the dose-escalation part, the 3+3 design will be applied. If the subject does not have a DLT during the first 28-day cycle, those who with stable or remission of disease may continue to receive treatment until disease progression, intolerable toxicity or the subject no longer benefits.
~In the dose-expansion part, HZ-A-018 will be administered for several 28-day cycles until disease progression, intolerable toxicity or the subject no longer benefits."
16372173|NCT04173442||Cohort 1: Dupilumab-Exposed Cohort|Pregnant women with approved indications exposed to dupilumab during pregnancy
16372174|NCT04173442||Cohort 2: Disease-Matched Comparison Cohort|Pregnant women with approved indications not exposed to dupilumab during pregnancy
16372175|NCT04173442||Cohort 3: Healthy Comparison Cohort|Pregnant women who are not diagnosed with any dupilumab-approved indications, and not exposed to dupilumab during pregnancy
16372176|NCT04173429|Experimental|nadroparin calcium-warfarin sequential therapy group|nadroparin calcium every 12 hours for 1 month followed by an oral administration of warfarin for 5 months
16372177|NCT04173429|No Intervention|Control group|No anticoagulation therapy.
16372178|NCT04173416|Experimental|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
~The specific components of YORS will be refined and adapted based on feedback from interviews and focus groups with various stakeholders. However, the basic framework outlined above is expected to persists."
16372179|NCT04173416|No Intervention|Treatment As Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, contingency management, and home delivery of medication. This often includes a referral and warm hand off to intensive outpatient SUD services and/or mental health care.
16372180|NCT04173403|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;
16372181|NCT04173390|Experimental|pregabalin|
16372182|NCT04173390|Placebo Comparator|placebo|
16372183|NCT04173364|Experimental|Experimental group : ropivacaine 0.1%|Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine
16372184|NCT04173364|Active Comparator|control group : ropivacaine 0.5%|Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine
16372220|NCT04173078|Experimental|Computerized Distress Intolerance Intervention|Two, 1-hour computerized sessions that include psychoeducation about emotional avoidance, idiographic emotional exposure, and construction of idiographic implementation intentions to practice distress tolerance skills outside of session.
16373510|NCT04164290|Active Comparator|treatment group 1|Jiashen tablet, 0.47g, oral, once a day
16372185|NCT04173351|Experimental|Intervention|Pregnant women in intervention group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Date of the next antenatal follow-up of the participants in the intervention group was recorded and they were given an appointment for the antenatal education. Women, whose date of next antenatal follow-up was unknown, were asked to inform the researchers about their appointment. Following the antenatal follow-up, the pregnant women in the intervention group were given an antenatal childbirth education and an educational brochure after the education. Also, provided telephone counseling to the intervention group one week after the education. Participants in the intervention group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
16372186|NCT04173351|No Intervention|Control|Pregnant women in control group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Participants in the control group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
16372187|NCT04173338|Experimental|Cabozantinib + Pemetrexed|Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
16372188|NCT04173325|Experimental|Nivolumab and Irinotecan|Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)
16372189|NCT04173312|Active Comparator|Infused analgesic|Patients will be assigned to receive local anesthetic through continuous infusion by pump.
16372190|NCT04173312|Placebo Comparator|Infused saline|Patients will be assigned to receive saline through continuous infusion by pump.
16372191|NCT04173299||Early Tips|Patients wtih early tips for Acute esophageal variceal bleeding
16372192|NCT04173299||stantard treatment|patients with standard treatment (medical + endoscopic) for Acute esophageal variceal bleeding
16372193|NCT04173286||short term antibiotics|< 7 days
16372194|NCT04173286||long terms antibiotics|> 7 days
16372195|NCT04173273|Experimental|Etrasimod Dose A|
16372196|NCT04173273|Experimental|Etrasimod Dose B|
16372197|NCT04173273|Placebo Comparator|Placebo|
16372198|NCT04173260|Experimental|Intervention arm - Oral Deutetrabenazine|This is the only arm for this trial. All subjects will receive oral Deutetrabanazine.
16372199|NCT04173247|Experimental|KeraStat Skin Cream Arm|Patients randomized to the KeraStat arm will be provided with KeraStat Skin Cream for application as often as needed but at least twice daily, morning and evening using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
16372200|NCT04173247|Active Comparator|Routine Skin Care Arm (RSC Arm)|Patients randomized to this arm will apply commercially available products from a list provided at least twice daily using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
16372201|NCT04173234|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
16372202|NCT04173234|Active Comparator|Control Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 5 days a week.
16372203|NCT04173221|Experimental|Intervention|
16372204|NCT04173221|Other|Control|
16372205|NCT04173208|Experimental|Fecal microbial transplant|The participants of the experimental arm will receive an oral fecal microbial transplant after delivery
16372206|NCT04173208|Placebo Comparator|Placebo group|The participants of the placebo arm will receive an oral placebo after delivery
16372207|NCT04173195|Experimental|Intervention arm|The CT intervention will be administered by the nurse in charge of the chemotherapy 5 min after the initiation. the CT content will be partially script.
16372208|NCT04173195|No Intervention|No intervention arm|Patients assigned to this arm will received current care.
16372209|NCT04173182||Inflammation on pCLE|Patients with inflammatory findings in the peridiverticular and colonic mucosa (crypt fusion and distortion, bright epithelium, and dilated-prominent branching vessels)
16372210|NCT04173182||No inflammation on pCLE|Patients with normal findings on pCLE evaluation of the peridiverticular and colonic mucosa (absence of inflammation)
16372213|NCT04173156|Experimental|Oscillating Chitosan Device|The brush bristles of the test device (Labrida BioClean®, LABRIDA AS, Oslo, Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed, thus not causing harm to the tissues.surrounding the tooth. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
16372214|NCT04173156|Active Comparator|Regular Curettes|Standard non surgical treatment of active periodontal disease includes supra and subgingival scaling and root planing with periodontal medical grade Gracey system steel curettes
16372215|NCT04173143|Experimental|Group 1|This group will receive Cranio cervical flexion training with pressure biofeedback protocol.
16372216|NCT04173143|Active Comparator|Group 2|This group will receive Cranio cervical flexion training without pressure biofeedback protocol
16372217|NCT04173130|Experimental|Injection of botulinum toxin with investigational device|
16372221|NCT04173078|Placebo Comparator|Computerized Healthy Behaviors Intervention|Two, 1-hour computerized sessions that focus on psychoeducation about the importance of a healthy lifestyle.
16372222|NCT04173065|Placebo Comparator|Placebo|
16372223|NCT04173065|Experimental|1.0 mg|
16372224|NCT04173065|Experimental|2.5mg|
16372225|NCT04173065|Experimental|5.0 mg|
16372226|NCT04173065|Experimental|10 mg|
16372227|NCT04173052|Experimental|Infertile Males|It represents the participants, all the participants in the study are infertile.
16372228|NCT04173039|Other|Controls|Patients with psoriasis and without psoriatic arthritis.
16372229|NCT04173039|Other|Cases|Patients with psoriatic arthritis and with personal or familial psoriasis.
16372230|NCT04173026|Active Comparator|Provider intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates.
16372231|NCT04173026|Active Comparator|Provider and Patient level intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.
16372232|NCT04173000|Experimental|Intervention|All adolescent/parent dyads enrolled at each practice will have access to the meHealth for ADHD software without medication continuity tools prior to being given access to the medication continuity tools.
16372233|NCT04172987|Experimental|Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)|EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)
16372234|NCT04172987|Experimental|EE/NGM + Tirzepatide (Period 2)|"EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)
~Tirzepatide administered by subcutaneous injection (SC)."
16372235|NCT04172974|Experimental|Treatment for depression and anxiety|Treatment
16372236|NCT04172974|Other|Usual care|Usual Care
16372237|NCT04172961|Experimental|Nanomicellular Cyclosporine 0.09 prior to surgery|50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
16372238|NCT04172961|Active Comparator|Lifitegrast 5.0%|50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery
16372239|NCT04172948|Experimental|Virtual reality arm|This arm will receive diaphragmatic breathing teaching by a medical professional and virtual reality module that teaches diaphragmatic breathing. This arm will be sent home with the virtual reality equipment and practice this breathing technique through the virtual reality module for 8 weeks.
16372240|NCT04172948|Placebo Comparator|Control|This arm will receive diaphragmatic breathing teaching by a medical professional only. They will practice this breathing technique with a paper handout of diaphragmatic breathing technique instructions for 8 weeks.
16372241|NCT04172935|Experimental|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal working distance as measured before intervention.
16372242|NCT04172935|No Intervention|Control Group|Will be deferred to receive spectacles as above, after the 4 weeks evaluation period.
16372243|NCT04172922|Experimental|Open label, topical sirolimus arm|Single arm, open label study of1% sirolimus ointment applied to affected area twice daily for the first four weeks followed by once daily for 5 months.
16372244|NCT04172909|Experimental|Child life group with LEGO bricks|Patients in this group will be prepped by a Certified Child Life Specialist with the use of LEGO bricks model MR
16372245|NCT04172909|No Intervention|Control group|Age matched controls will be found retrospectively, and will be patients of the same age, undergoing their first non-contrast brain MRI with no Child Life intervention.
16372246|NCT04172909|Experimental|Child life group with Mock MRI tube|Patients in this group will be prepped by a Certified Child Life Specialist with the use of a Mock MRI tube
16372247|NCT04172896|Active Comparator|Intraperitoneal Group|Vaginal intraperitoneal uterosacral ligament suspension group
16372248|NCT04172896|Active Comparator|Extraperitoneal Group|Vaginal extraperitoneal uterosacral ligament suspension group
16372249|NCT04172883|No Intervention|Control arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the standard device setting or MINERVA setting ( control arm)
16372250|NCT04172883|Active Comparator|Treatment arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the reduced sequence programming ( treatment arm)
16372251|NCT04172870||Group I|Healthy group ( No generalised periodontitis and no CAD)
16372252|NCT04172870||Group II|Generalised periodontitis patients without CAD
16372253|NCT04172870||Group III|CAD patients without generalised periodontitis
16372254|NCT04172870||Group IV|Generalised periodontitis with CAD
16372255|NCT04172844|Experimental|Pevonedistat Dose Escalation|This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
16372256|NCT04172844|Experimental|Dose Expansion Phase|Patients will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase.
16372750|NCT04169425||Group 2|patients who underwent to laparoscopic TME, without elective diverting ileostomy for rectal cancer
16372257|NCT04172831|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
16372258|NCT04172831|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
16372259|NCT04172818|Experimental|Patients with diary|Evaluation the psychological impact of a diary on the patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives.
16372260|NCT04172805|Experimental|anlotinib combined with Toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks.
16372261|NCT04172792|Active Comparator|high-caloric fatty diet|intake of 405 kcal (45g fat) per day in addition to normal food intake
16372262|NCT04172792|Experimental|ultra-high-caloric fatty diet|intake of 810 kcal (90g fat) per day in addition to normal food intake
16372263|NCT04172792|Experimental|ultra-high-caloric carbohydrate-rich diet|intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake
16372264|NCT04172792|No Intervention|control|normal food intake (no intervention)
16372265|NCT04172779|Experimental|Erlotinib treatment|
16372266|NCT04172766|No Intervention|Basic|"Participants in the first (Basic) group will have the iOS version 13.2 or later shipping user interface (UI) that provides ability to review exposure level data for headphone audio levels and environmental sound levels in the Health app."
16372267|NCT04172766|Active Comparator|Advanced|"Participants in the second (Advanced) group will have a UI that includes notifications prompting personal data pattern review in the Health app and then prompting to do an abbreviated Pure Tone Audiometry module completed 0-24 hours after loud headphone audio level exposure (equivalent continuous average noise level, or LEQ, to >97 A-weighted decibels, or dBA for >30 minutes) to evaluate for a temporary threshold shift from baseline."
16372268|NCT04172753|Experimental|Rectal and anal cancer|In this arm patients with rectal and anal cancer are recruited.
16372269|NCT04172753|Experimental|Prostate cancer|In this arm patients with prostate cancer are recruited.
16372270|NCT04172753|Experimental|Head and neck cancer|In this arm patients with head and neck cancers are recruited.
16372271|NCT04172753|Experimental|Esophageal cancer|In this arm patients with esophageal cancer are recruited.
16372272|NCT04172753|Experimental|Breast Cancer|In this arm patients with breast cancer are recruited.
16372273|NCT04172753|Experimental|Central nervous system tutors|In this arm patients with tumors of the central nervous system are recruited.
16372274|NCT04172753|Experimental|Palliative treatments|In this arm patients with palliative treatments are recruited.
16372275|NCT04172753|Experimental|Other|In this arm patients with other tumors are recruited.
16372276|NCT04172753|Experimental|Imaging only|In this arm patients receive only imaging on the MR-Linac
16372277|NCT04172740|Experimental|Treatment|
16372278|NCT04172727|Active Comparator|ultrasound guided transversalis fascia plane block|20 mL of 0.25% bupivacaine
16372279|NCT04172727|Placebo Comparator|ultrasound guided sham block|20 mL of saline
16372280|NCT04172714|Experimental|Second mapping with low-dose Y90|Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
16372281|NCT04172701||Subjects with Chronic Obstructive Pulmonary Disease|
16372282|NCT04172688|Placebo Comparator|Placebo|Two 3.3g doses/day (12 kcal/dose) of maltodextrin
16372283|NCT04172688|Experimental|Prebiotic|Two 8g doses/day (12 kcal/dose) of oligofructose-enriched inulin
16372284|NCT04172675|Experimental|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ [CIS], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
16372285|NCT04172675|Active Comparator|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC)/hyperthermic MMC. Participants who are randomized to gemcitabine or MMC/hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
16372286|NCT04172675|Experimental|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
16372287|NCT04172675|Experimental|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
16372288|NCT04172662|Experimental|Music therapy group|Receive Music therapy in addition to standard treatment
16372289|NCT04172662|No Intervention|Control group|Receive standard treatment
16372290|NCT04172649|Experimental|Acu Arm|press tack needle acupuncture (ACU) and routine postoperative analgesic care
16372291|NCT04172649|Sham Comparator|SHAM Arm|press tack placebo acupressure (SHAM) and routine postoperative analgesic care
16372292|NCT04172649|No Intervention|CONTROL Arm|Patients in the control group will receive only routine postoperative analgesic care
16372293|NCT04172623|Experimental|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
16372294|NCT04172623|Active Comparator|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
16372295|NCT04172597|Experimental|Poziotinib|"Cohort 1: Patients that have HER2-positive or HER2-negative breast cancer with HER2 activating mutations
~Cohort 2: Patients that have colorectal cancer with HER2 activating mutations
~Cohort 3: Patients that have solid tumors (except NSCLC, breast cancer, or colorectal cancer) with HER2 activating mutations
~Cohort 4: Patients that have high-grade glioma with EGFR activating mutations
~Cohort 5:Patients that have solid tumors (except NSCLC or high-grade glioma) with EGFR activating mutations"
16372296|NCT04172571|Experimental|AK105 and anlotinib|
16372297|NCT04172558|Active Comparator|BTX100 group|ICI of Botox 100 U
16372298|NCT04172558|Active Comparator|Trimix group|ICI of Trimix
16372299|NCT04172532|Experimental|Phase I (hypofractionated radiation therapy, M3814)|Patients in Phase I undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
16372300|NCT04172532|Experimental|Phase II Group I (hypofractionated radiation therapy M3814)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
16372301|NCT04172532|Active Comparator|Phase II Group II(hypofractionated radiation therapy, placebo)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
16372302|NCT04172519|Experimental|Group A|Patients who before prostate cancer surgery will receive: psychological consultation, nursing consultation, physiotherapy consultation and intervention (4 visits which will be implemented pelvic floor muscle training). Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Then, 6 months after the surgery, there will also be a physiotherapy consultation.
16372303|NCT04172519|Experimental|Group B|Patients who will receive: psychological consultation, nursing consultation, physiotherapy consultation before prostate cancer surgery. Subsequently, patients will have the procedure performed laparoscopic radical prostatectomy, immediately after which they receive psychological consultation, nursing consultation. The physiotherapist consultation will be two weeks after the surgery, during which the physiotherapist will provide an instruction pelvic floor muscle training. Patients do the exercises themselves at home according to the instructions, 3 times a day for 3 months). Physiotherapeutic consultation 6 months after surgery.
16372304|NCT04172519|Experimental|Group C|Patients who will not receive any intervention before prostate cancer surgery. Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Physiotherapeutic consultation 6 months after surgery.
16372305|NCT04172519|No Intervention|Group D|Control group, patients after radical laparoscopic prostatectomy, without additional interventions
16372306|NCT04172506|Experimental|AK105|AK105 200 mg, every 2 weeks
16372307|NCT04172493|Experimental|Diagnostic|Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.
16372308|NCT04172480||acute HIV1 infection|Patient infected by HIV1, prior treatment initiation
16372309|NCT04172480||chronic HIV1 infection|Patient infected by HIV1, untreated or without treatment since at least 3 months
16372310|NCT04172480||HIV2 infection|Patient infected by HIV2, untreated or without treatment since at least 3 months
16372311|NCT04172454|Experimental|AK104|AK104 in subjects with advanced melanoma and other selected advanced solid tumor including PD-1/PD-L1 relapsed/refractory tumors)
16372312|NCT04172441|Experimental|dasiglucagon first then placebo|48 hours of dasiglucagon sc infusion starting at 10 µg/hr with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
16372313|NCT04172441|Experimental|placebo first then dasiglucagon|48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hr (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
16372314|NCT04172428||Healthy volunteers|Young healthy volunteers between the ages of 18-55.
16372315|NCT04172415||Retrospective cohort|Patients that received procedural sedation in a community Emergency Department.
16372316|NCT04172402|Experimental|NGS|"Eligible patients will receive Nivolumab 240mg on day 1, gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
~BSA < 1.25 m2: 80 mg/day
~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day
~BSA ≥ 1.5 m2: 120 mg/day The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
16372317|NCT04172376|Experimental|Minimally invasive puncture aspiration plus rt-PA|
16372318|NCT04172376|Active Comparator|Conservative medical treatment|
16372319|NCT04172363|No Intervention|Standard Care|Octenisept will be used as standard care antiseptic for dressing change
16372320|NCT04172363|Experimental|Resistance testing|Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
16372321|NCT04172350|Experimental|Intervention group: iCareBreast plus routine care|Participants in the intervention group will receive the routine care provided by the hospital (the same as the control group) plus the iCareBreast mobile app, which provides i) pre-surgery education and instructions; ii) post-surgery education, instructions, and recovery plan; iii) positive psychological support; and iv) social support. The total intervention period is 29 days (14 days before surgery, operation day, and 14 days after the surgery).
16372322|NCT04172350|Active Comparator|Control group: Routine care|Participants in the control group will only receive routine care provided by the attending Hospital. Participants being allocated to the control group may freely use the Internet to search for information regarding breast cancer but will not be granted to access the iCareBreast app.
16372323|NCT04172337|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display FOP labels on any products.
16372324|NCT04172337|Experimental|HCS-only|Arm 2 (termed HCS-only) displayed the HCS on eligible products, crossed referenced via the Health Promotion Board's HCS database (https://www.hpb.gov.sg/food-beverage/healthier-choice-symbol). Out of the 4,177 products available on NUSMart, 311 (7·45%) carried the HCS. This was comprised of 150 foods and 161 beverages.
16372325|NCT04172337|Experimental|HCS+PAE|Arm 3 displayed the HCS on eligible products as in Arm 2 and the PAE label on all products (termed HCS+PAE). PAE was calculated as the minutes required to burn off the calories of a single serving for a 73 kg person jogging at 8 km per hour.
16372326|NCT04172324|Experimental|Hibbot|
16372327|NCT04172324|Active Comparator|Standard Care|
16372328|NCT04172311|Experimental|Modified Atkins Diet|"Modified Atkins Diet administration
~Carbohydrates will be restricted to 10 grams per day.
~Recipes will be provided to be prepared from easy home available foods, to have 2.5 gram per meal. Along with this, a list of carbohydrate free foods will be provided.
~Fats intake will be actively encouraged. Protein intake will be unrestricted.
~Medications will be changed to carbohydrate free preparations.
~A multivitamin and calcium supplementation will be added."
16372329|NCT04172311|Active Comparator|Levetiracetam|Levetiracetam will be started at a dose of 10 mg/kg/day in two divided doses and increased to 20 mg/kg/day after 1 week. Syrups will be used in children younger than 5 years of age, and tablets will be used in children > 5 years of age. Further dose titration will be done as per the seizure control, in 10 mg/kg/day increments in 2 weekly intervals, to a maximum of 60mg/kg/day.
16372330|NCT04172298|Placebo Comparator|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
16372331|NCT04172298|Experimental|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
16372332|NCT04172298|Experimental|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
16372333|NCT04172285|Experimental|Physical activity group|
16372334|NCT04172285|Experimental|Physical activity and supplementation group|
16372335|NCT04172285|Experimental|Control group|
16372336|NCT04172272|Active Comparator|Systemic multimodal analgesia only|"In the first group, patients will receive intravenous, systemic, multimodal analgesia: paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
16372337|NCT04172272|Experimental|TAP block only|In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacaine in 40 ml bilaterally. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
16372338|NCT04172272|Experimental|Combined TAP block with systemic multimodal analgesia|In the third group there will be patients who will be treated with TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
16372339|NCT04172259|Experimental|ACH-TH|Doxorubicin liposome（PLD）35 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Docetaxel（DOC）75 mg/m2 every 3 weeks
16372340|NCT04172259|Active Comparator|EC-TH|Epirubicin（EPI）90 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Docetaxel（DOC）75 mg/m2 every 3 weeks
16372341|NCT04172246|Experimental|Zanubrutinib|
16372342|NCT04172233|Experimental|Phase I: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0 and 4 by subcutaneous injection
16372343|NCT04172233|Experimental|Phase I: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0 and 4 by subcutaneous injection
16372344|NCT04172233|Experimental|Phase I: AK101 270 mg|Biological: AK101 AK101 270 mg on Week 0 and 4 by subcutaneous injection
16372345|NCT04172233|Placebo Comparator|Phase I: Placebo|Biological: Placebo Placebo on Week 0 and 4 by subcutaneous injection
16372346|NCT04172233|Experimental|Phase II: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0, 4 and 16 by subcutaneous injection
16372347|NCT04172233|Experimental|Phase II: AK101 90 mg|Biological: AK101 AK101 90 mg on Week 0, 4 and 16 by subcutaneous injection
16372348|NCT04172233|Experimental|Phase II: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0, 4 and 16 by subcutaneous injection
16372349|NCT04172233|Placebo Comparator|Phase II: Placebo to AK101|Drug: Placebo Placebo on Week 1 and 4 by subcutaneous injection, and then AK101 on Week 12 16 by subcutaneous injection
16372350|NCT04172220|Experimental|PECS + Opioid-free GA|Loco-regional anesthesia with PEC I and serratus plane block with an echoguided technique and opioid-free general anesthesia
16372351|NCT04172220|Active Comparator|GA|General anesthesia
16372352|NCT04172207||Results of study groups.|
16372353|NCT04172194||PT Group|patients with hepatocellular carcinoma treated by percutaneous thermoablation alone
16372354|NCT04172194||PT+TAC group|patients with hepatocellular carcinoma treated by pecutaneous thermoablation comined in a single session with trans-arterial chemoembolization
16372355|NCT04172181||UCBT-SCID-Case|SCID patients who underwent cord blood stem cell transplantation.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.
16372356|NCT04172168||Heart rupture|Include left ventricular free-wall ruptrue after AMI
16372357|NCT04172168||Non heart rupture|AMI with non heart rupture
16372358|NCT04172142||Control group|Healthy individuals of similar age and sex who meet the inclusion criteria
16372359|NCT04172142||Pectus Excavatum|Individuals with pectus excavatum that meet the inclusion criteria
16372360|NCT04172142||Pectus Carinatum|Individuals with pectus excavatum that meet the inclusion criteria
16372361|NCT04172129||NANOS|NANOS™ Neck Preserving Hip Stem
16372362|NCT04172116||long pouch RYGB|Patients with the variation of a long and narrow pouch (hypothesis: slower transit of food)
16372363|NCT04172116||short pouch RYGB|Patients with the variation of a short and wide pouch (hypothesis: faster pouch emptying as compared with long and narrow pouch)
16372364|NCT04172090|Other|Control|2 consecutive days of standardised daily levels of moderate physical activity (PAL=1.85 reflecting their habitual levels), and matched energy (food) intake
16372365|NCT04172090|Experimental|SIT+E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst maintaining the level of food intake prescribed in the Control trial, thus creating a positive energy balance
16372366|NCT04172090|Experimental|SIT=E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst reducing food intake to match the reduction in energy expenditure induced by inactivity, thus maintaining energy balance
16372367|NCT04172064||377patients evaluated by MPS and DSE|
16372368|NCT04172051|Experimental|Experimental Group|"Subjects will be admitted into the Tony Robbins event for free, or receive a voucher for an event in the future. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
16372369|NCT04172051|No Intervention|Control Group|"The control group will be asked to engage in gratitude journaling every day for a month. The control group will NOT attend the event. This exercise will take 10 minutes to complete. The subject will write down three things that went well each day and provide an explanation about why they went well. This will be written down in a journal. The subjects will follow these instructions:
~Give the event a title (e.g., co-worker complimented my work on a project)
~In the space below, write down exactly what happened in as much detail as possible, including what you did or said, and if other people were involved, what they did or said.
~Include how this event made you feel at the time and how this event made you feel later (including now, as you remember it)."
16372370|NCT04172051|Active Comparator|Motivated Experimental Group|"The Motivated Experimental Group (M Experimental) will consist of participants who registered and paid for Tony Robbins Date with Destiny (DWD). They are chosen as the motivated experimental as they will be paying full price for the event. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
16372371|NCT04172038|Experimental|Phase I: Physical Therapy (PT)|Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
16372372|NCT04172038|Experimental|Phase I: Move to Health (M2H)|"Initial Randomization: M2H is a key component of Army Medicine's System for Health, along with the Performance Triad. It is a person-centered, holistic, and experience-centric approach to promoting healthy behaviors (nutrition, physical activity, sleep, instrinsic factors, extrinsic factors). Precise dosage (i.e, number of M2H sessions) will be at the discretion of the health coaches. Sessions may be delivered in-person or utilize technology including text messaging, telephone, e-mail, video chat, app-based self-management etc."
16372373|NCT04172038|Experimental|Phase II: Combine PT & M2H|Sequential Randomization: Participants randomized to receive a combination of PT and M2H as a Phase II intervention will continue their Phase I treatment (either M2H or PT). The participant will begin the treatment component that was not part of their Phase I intervention.
16372374|NCT04172038|Experimental|Phase II: MORE Mindfulness|Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
16372375|NCT04172025||Patients with colonization or infections with a pathogen|All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data
16372376|NCT04172012|Active Comparator|Probiotic|Study subjects receive probiotic mixture for 4 weeks
16372377|NCT04172012|Placebo Comparator|Placebo|Study subjects receive placebo mixture for 4 weeks
16372378|NCT04171999|Experimental|Usual Care + Intervention (Case)|Cases will receive the CommunityRx Intervention.
16372379|NCT04171999|No Intervention|Usual Care (Control)|Controls will receive the usual standard care, which consists of information about hospital food resources and access to Feed1st hospital food pantries prior to discharge.
16372380|NCT04171986|Experimental|Test Group|
16372381|NCT04171973|Other|Driving an electric wheelchair in real condition|In order to be able to evaluate the feasibility of virtual reality driving training, the driving performance will be evaluated on the same 3 standardized circuits: for the control group, 3 circuits of test of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
16372382|NCT04171973|Experimental|Driving an electric wheelchair in virtual condition|In order to be able to evaluate the feasibility of driving training in virtual reality, the driving performance will be evaluated on the same 3 standardized circuits: for the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
16372385|NCT04171947|Experimental|Matuzalem|Tea extract vaginal ovule daily for 7 consecutive days
16372386|NCT04171947|Sham Comparator|Vehicle|Polyethylene glycol vaginal ovule daily for 7 consecutive days
16372387|NCT04171921|Active Comparator|Robotic ventral hernia repair|
16372388|NCT04171921|Active Comparator|Open ventral hernia repair|
16372389|NCT04171908|Active Comparator|Conventional therapy|Conventional Physical therapy for the upper limb
16372390|NCT04171908|Experimental|Nintendo Switch Joy-Con plus conventional therapy|Conventional Physical therapy for the upper limb plus Nintendo Switch Joy-Con
16372391|NCT04171895||Enhanced Usual Care (EUC)|
16372392|NCT04171895||Communication Training|
16372791|NCT04169165||non-compliant patient|Patients without compliance to suggestions on metabolic evaluation and dietary/medical advices
16372395|NCT04171843|Experimental|PBCAR269A at Dose Level 1 (Cohort A)|The starting dose of PBCAR269A will be 6 x 10^5 CAR T cells/kg body weight.
16372396|NCT04171843|Experimental|PBCAR269A at Dose Level 2|2 × 10^6 CAR T cells/kg body weight.
16372397|NCT04171843|Experimental|PBCAR269A at Dose Level 3|6 × 10^6 CAR T cells/kg body weight.
16372398|NCT04171843|Experimental|PBCAR269A at Dose Level 2 (Cohort B)|2 × 10^6 CAR T cells/kg body weight.
16372399|NCT04171843|Experimental|PBCAR269A at Dose Level 1 (Cohort B)|6 x 10^5 CAR T cells/kg body weight.
16372400|NCT04171843|Experimental|PBCAR269A at Dose Level 3 (Cohort B)|6 × 10^6 CAR T cells/kg body weight.
16372401|NCT04171817|No Intervention|Control|Dog-handler teams will follow established hospital and therapy dog program guidelines for infection control with no changes for eight sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
16372402|NCT04171817|Experimental|CHX Intervention A|"Dog-handler teams will follow a modified protocol for infection control, with Treatment A first for four sessions, and cross-over to Treatment B for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
~Treatment A consists of a pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine) within 24 hours prior to the session, and wiping with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival at the session and every 20 minutes during the session, or between participants if the flow of participants is structured in a way that allows this (such as visits from one room to the next to visit individual patients)."
16372403|NCT04171817|Experimental|CHX Intervention B|"Dog-handler teams will follow a modified protocol for infection control, with Treatment B first for four sessions, and cross-over to Treatment A for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
~Treatment B will consist of the same pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine), with a single wipe with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival. This treatment will depend on the residual activity of chlorhexidine throughout the visit."
16372404|NCT04171804|Active Comparator|Active|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
16372405|NCT04171804|Sham Comparator|Sham|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
16372406|NCT04171791|Experimental|ABT-199 (Venetoclax)|Patients with Cutaneous T Cell Lymphoma (CTCL) will receive ABT-199 (Venetoclax).
16372407|NCT04171778|Experimental|Intervention|Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
16372408|NCT04171778|Other|Wait List Control|Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.
16372415|NCT04171752|Experimental|Young Adults|Single oral dose of elafibranor 120mg
16372416|NCT04171752|Experimental|Elderly|Single oral dose of elafibranor 120mg
16372417|NCT04171739|Other|Cohort A|Itraconazole DDI
16372418|NCT04171739|Other|Cohort B|Rifampicin DDI
16372419|NCT04171726|Experimental|Edoxaban|treatment with edoxaban
16372420|NCT04171713|Experimental|Grup 1|MBHP protocol + TAU
16372421|NCT04171713|Experimental|Grup 2|ABCT protocol + TAU
16372422|NCT04171713|Active Comparator|Grup 3|TAU
16372423|NCT04171700|Experimental|Rucaparib|"Eligible patients will be enrolled in either Cohort A or Cohort B.
~Cohort A: Up to 200 patients with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.
~Cohort B (Exploratory): Up to 20 patients with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B."
16372424|NCT04171687|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
16372425|NCT04171687|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days
16372426|NCT04171687|Experimental|Clopidogrel 75 mg + RAPA113|Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days
16372427|NCT04171674|Experimental|Patients treated with high-dose ceftobiprole|
16372428|NCT04171661|Experimental|SASS|SASS applied on chronic skin wounds as skin graft
16372429|NCT04171648|Experimental|Roasted Peanut Group 1|Arm 1 is the arm of participants that will receive the roasted peanut treatment first and then will crossover to the boiled peanut treatment.
16372430|NCT04171648|Experimental|Boiled Peanut Group 1|Arm 2 is the arm of participants that will receive the boiled peanut treatment first then will crossover to the roasted peanut treatment.
16372431|NCT04171635||Patients with transfusional iron overload|The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
16372432|NCT04171635||Healthy subjects|Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI
16372626|NCT04170270|Active Comparator|intravenous omeprazole|intravenous omeprazole in bleeding peptic ulcer after endoscopic therapy as continuous infusion at rate of 8 mg/hour for 72 hours
16372433|NCT04171622|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenvatinib PO daily on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16372434|NCT04171609|Experimental|Cancer survivors|Adult survivors of any kind of cancer (except for minor skin cancer) are eligible to participate
16372435|NCT04171596|Experimental|Primary care coordination|
16372436|NCT04171583||mucoid S. aureus|CF patients with mucoid S. aureus
16372437|NCT04171583||non-mucoid S. aureus|CF patients with non-mucoid S. aureus
16372438|NCT04171570|Other|Distal Transradial Access|Distal Transradial Access
16372439|NCT04171570|Other|Conventional Transradial Access|Conventional Transradial Access
16372440|NCT04171557||Patients with diabetes at the baseline assessement in EPIC|Self-reported and confirmed diabetes (validated by a second source (at least 1), including repeated self-report, contact with physician, linkage to register later point, intake of diabetes medicine, registration of diabetic chiropody, baseline glycated hemoglobin>=6.0%, five annual blood glucose measurements or two blood glucose measurements per year for five consecutive years) cases were included in the analyses. No information is available to distinguish between type 1 and type 2 diabetes across the population but type 1 is rare by comparison.
16372441|NCT04171531|Active Comparator|Botox A® injection|A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
16372442|NCT04171531|Active Comparator|Mid-urethral sling|Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
16372443|NCT04171518||Catalys Precision Laser System|Cataract Surgery with use of Catalys Precision Laser System
16372444|NCT04171505||vaccinated women|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.
~Women who sign informed consent.
~Patients with negative results in the first post-surgery control.
~Patients who have received HPV vaccination and provide vaccination card."
16372445|NCT04171505||non vaccinated woman|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.
~Women who sign informed consent.
~Patients with negative results in the first post-surgery control.
~Patients who have NOT received HPV vaccination and provide vaccination card."
16372448|NCT04171479||Manual|Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.
16372449|NCT04171479||Remote Magnetic Navigation|Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.
16372450|NCT04171466|Active Comparator|Broad Spectrum Antibiotic Therapy + Microbial Consortia|
16372451|NCT04171466|Placebo Comparator|Broad Spectrum Antibiotic Therapy + Placebo|
16372452|NCT04171466|Active Comparator|No Antibiotic Therapy + Microbial Consortia|
16372453|NCT04171466|Placebo Comparator|No Antibiotic Therapy + Placebo|
16372454|NCT04171453||Open-label|This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
16372455|NCT04171440|Experimental|Cohort A-minimally invasive pancreaticoduodenectomy|Patients randomized to Cohort A will undergo pancreaticoduodenectomy through small incisions with state-of-the-art robotic-assisted technology or endoscopic techniques.
16372456|NCT04171440|Active Comparator|Cohort B-open pancreaticoduodenectomy|Patients randomized to this arm will undergo open pancreaticoduodenectomy.
16372457|NCT04171427|Other|Lithium liposome and placebo A|• Group A : 4 patients; Lithium liposome 1 application / day (evening) on target lesions on one side of the body, placebo 1 application / day (evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
16372458|NCT04171427|Other|Lithium liposome and placebo B|Group B : 4 patients; Liposomal Lithium 2 applications / day (morning and evening) on target lesions on one side of the body, placebo 2 applications / day (morning and evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
16372459|NCT04171427|Other|Lithium liposome and placebo C|Groupe C : 4 patients; Lithium liposome 2 applications / day (morning and evening) on one side, placebo 2 applications / day (morning and evening) on contralateral target lesions.
16372460|NCT04171414|Experimental|"CT-P17 SC AI (adalimumab)"|
16372461|NCT04171401||Participants post stroke|Severly affected patients in the subacute phase post stroke that are unable to walk without the help of one or two therapists to assist for balance and weight-carrying. Participants were able to sit independently for two minutes. Participants post stroke performed limits of stability testing in sitting, and tests for trunk control and functional balance.
16372462|NCT04171401||Healthy controls|Healthy control subjects who matched patients post stroke for age and gender, and had no limitations to perform measurements. Healthy controls performed limits of stability measurements and a clinical measurements for balance.
16372463|NCT04171388|Placebo Comparator|Routine care: Placebo|"In all pregnancies presenting at all centers, routine antenatal care will be strengthened:
~Provision of iron-folic acid and tetanus toxoid vaccine
~Screening for anemia and blood pressure
~Screening/treatment of HIV, syphilis, malaria, tuberculosis
~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
16372464|NCT04171388|Experimental|Routine care: Azithromycin|Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later.
16372465|NCT04171388|Experimental|Routine care: Enhanced Infection Management Package (EIMP)|At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrhea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment.
16372684|NCT04169893|Placebo Comparator|Arm Title: Placebo (fasting)|fasting
16372685|NCT04169893|Placebo Comparator|Placebo (feeding)|after meal
16372466|NCT04171388|Experimental|Enhanced Nutrition Package (ENP): Placebo|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.
~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
16372467|NCT04171388|Experimental|ENP: Azithromycin|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.
~Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
16372468|NCT04171388|Experimental|ENP: EIMP|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.
~At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrohea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment."
16372469|NCT04171375|Experimental|trans-spinal Electrical Stimulation (tsES)|
16372470|NCT04171362|Experimental|Migraine group|The study included patients diagnosed by migraine according to International Headache Community criteria with18-65 years of age followed by routine controls and who were volunteered
16372471|NCT04171362|Active Comparator|Control group|The study included patients diagnosed by migraine according to International Headache Community criteria with 8-65 years of age followed by routine controls and were volunteered
16372472|NCT04171349|Active Comparator|Group A|Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
16372473|NCT04171349|Experimental|Group AD|Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).
16372474|NCT04171336|Experimental|Animal-assisted group therapy|
16372475|NCT04171323|Experimental|CTa|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
16372476|NCT04171323|Experimental|CTab|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
16372477|NCT04171323|Experimental|CTac|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
16372478|NCT04171323|Experimental|CTabc|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
16372479|NCT04171323|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
16372480|NCT04171310|Experimental|SAR442168|Single oral dose of SAR442168 (as a nonsalified compound) containing (NMT) 3.7 MBq of [14C]-SAR442168
16372481|NCT04171284|Experimental|SCT-I10A plus Docetaxel|SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
16372482|NCT04171284|Active Comparator|Placebo puls docetaxel|Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
16372483|NCT04171284|Experimental|Maintenance therapy of SCT-I10A|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
16372484|NCT04171284|Placebo Comparator|Maintenance therapy of Placebo|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
16372485|NCT04171271|Experimental|Activating kinesthetic motor imagery training|
16372486|NCT04171271|Active Comparator|Relaxing kinesthetic motor imagery training|
16372487|NCT04171271|No Intervention|Control (no specific intervention)|
16372488|NCT04171258|Experimental|Botulax®|
16372489|NCT04171258|Active Comparator|Botox®|
16372490|NCT04171245|Experimental|Experimental|One minute laughter prescription 3x a day Tracking sleep using equipment
16372491|NCT04171245|Active Comparator|Control|Tracking sleep using equipment
16372492|NCT04171232|Active Comparator|Balance It (Group 1)|Children with spastic hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Balance It group. Each subject in first group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
16372493|NCT04171232|Active Comparator|Bubble Pop (Group 2)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Bubble Pop group. Each subject in second group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
16372529|NCT04171037|Active Comparator|Arm II (oxygen via non-rebreather mask)|Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3 minutes prior to anesthetic induction and maintain the same flow rate until the end of procedure.
16372686|NCT04169893|Experimental|TS-142, 1 mg|fasting
16372494|NCT04171232|Active Comparator|Scoop'd (Group 3)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Scoop'd group. Each subject in third group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance
16372495|NCT04171219|Experimental|Treatment (talabostat, pembrolizumab)|Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16372496|NCT04171206|Experimental|Free From Abuse|This is a brief internet-delivered intervention designed to boost participants' ability to recognise abusive behaviour, reduce acceptance of myths related to domestic violence and IPV, as well as decrease abuse perpetration and victimisation.
16372497|NCT04171206|Placebo Comparator|Technology and crime|This is a brief internet-delivered placebo intervention designed to inform participants about how the development of technology could affect crime.
16372498|NCT04171193|Experimental|ISO|Patients not taking oral medications for depression. They will receive the study intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes.
16372499|NCT04171193|Experimental|ISOAD|Patients in treatment with oral medications for depression, will receive intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes
16372500|NCT04171193|Experimental|ISOPOT|Patients that where from ISO arm, that did not respond to intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes They will now, start taking sertraline as oral medication for depression to asset the enhancement of oral treatment after Isoflurane challenge.
16372501|NCT04171180|Active Comparator|Controlled group|Controlled group: budesonide/formoterol(SYM) 160/4.5ug 1 inhalation bid* 3 months (n=250).
16372502|NCT04171180|Experimental|Study group|Study group: SYM 160/4.5ug 2 inhalation bid* 3 months (n=250).
16372503|NCT04171167|Active Comparator|Frequently treated acute rhino sinusitis|Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
16372504|NCT04171167|Active Comparator|CRSsNP|Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score < 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
16372505|NCT04171167|Active Comparator|Severe CRSsNP and CRSwNP|Meets the European position paper criteria of CRS and not included in the first two groups.
16372506|NCT04171167|No Intervention|Healthy volunteers|No nasal symptoms or complaints. No interventions done.
16372507|NCT04171154|Experimental|Expectation|Participants are asked to think of three strength which have helped them in prior stressful events. They then have to think of ways how these strength may help them in future stressful situations, i.e. a test in this experiment.
16372508|NCT04171154|Experimental|Acceptance|Participants listen to an audio-instruction on cognitive defusion. They shall observe the thoughts and feelings of stress and, with the help of the instruction, distance themselves from it.
16372509|NCT04171154|No Intervention|Control|Participants wait for the stress-test to start.
16372510|NCT04171141|Experimental|Dose Escalation|Single Agent Dose Escalation
16372511|NCT04171141|Experimental|Dose Finding Anti-PD-1 Combination|Part 1B PF-07062119 plus anti-PD-1
16372512|NCT04171141|Experimental|Dose Finding anti-VEGF Combination|Part 1B PF-07062119 plus anti-VEGF
16372513|NCT04171141|Experimental|Dose Expansion Arm A|PF-07062119 as a Single Agent in CRC
16372514|NCT04171141|Experimental|Dose Expansion Arm B|PF-07062119 in Combination with anti-PD-1 in CRC
16372515|NCT04171141|Experimental|Dose Expansion Arm C|PF-07062119 in Combination with anti-VEGF in CRC
16372516|NCT04171141|Experimental|Dose Expansion Arm D|PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
16372520|NCT04171102|Active Comparator|Short term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-5 weeks post implantation
16372521|NCT04171102|Active Comparator|Mid term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-4 months post implantation
16372522|NCT04171102|Active Comparator|Long term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 6-8 months post implantation
16372523|NCT04171089|Experimental|Child-Safety Plan Intervention|A Child Safety Plan to prevent suicidal behavior will be developed with the children and their parents. The parents and child will complete feasibility and acceptability questionnaires.
16372524|NCT04171076|Experimental|Intervention|Intervention: non-invasive spinal cord stimulation
16372525|NCT04171063|Other|Bracing arm|Patients that will be using the thoracic compressor
16372526|NCT04171050|Active Comparator|Group 1: Local Anesthesia|Standard of care with local anesthesia used during surgery
16372527|NCT04171050|Active Comparator|Group 2: Local Anesthesia plus Pudendal Nerve Block|Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery
16372528|NCT04171037|Experimental|Arm I (oxygen via Optiflow THRIVE)|Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes prior to anesthetic induction and at a higher flow rate until the end of procedure.
16372557|NCT04170829|Experimental|Group 1 (n=6)|will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
16372530|NCT04171024|Sham Comparator|Sham Group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.
~Transcutaneous electrical stimulation settings: Frequency (2 hertz); wave length (300 µs);"
16372531|NCT04171024|Experimental|Transcutaneous diaphragm electrical stimulation group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.
~Transcutaneous electrical stimulation settings: Frequency (35 hertz); wave length (300 µs); Intensity to achieve a visual contraction"
16372532|NCT04171011|Experimental|Nerve Stimulation|Participants will undergo brief NVB stimulation during the esophagectomy procedure.
16372533|NCT04170998|Experimental|Evogliptin 5mg group|Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
16372534|NCT04170998|Placebo Comparator|Evogliptin Placebo group|Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
16372536|NCT04170972|Experimental|Exercise and vivo insulin stimulation in TBC1D4 gene-variants|Acute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
16372537|NCT04170972|Experimental|Exercise and vivo insulin stimulation in matched controls|Acute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
16372538|NCT04170959|No Intervention|A: Observational arm|Radiotherapy as per standard of care without metformin, no additional biomarkers/imaging will be performed
16372539|NCT04170959|Other|B: Control arm|Radiotherapy as per standard of care without metformin, with additional biomarkers/imaging
16372540|NCT04170959|Active Comparator|C: Interventional arm|Radiotherapy as per standard of care with metformin, with additional biomarkers/imaging
16372541|NCT04170946|Experimental|Talazoparib in Combination with Low Dose RT|Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of RT (until day 20-23). Patient will start low dose RT on day 6-9, and will continue for 10 fractions throughout 2 weeks. Talazoparib dose levels will start at 0.5mg daily and increase to 1mg if dose limiting toxicites are not observed. Toxicities include renal impairment and other treatment related toxicities Grade ≥3. Patients will be monitored weekly during study treatment, and followed up at 3 weeks, and every 3 months after for 1 year.
16372542|NCT04170933|Experimental|Magnetic recanalization|The subjects in this group will be treated by magnetic recanalization
16372543|NCT04170920|Experimental|Mobile Health Application Intervention|"LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
16372544|NCT04170907|Other|Nicotine salt 20 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 20 mg/mL.
16372545|NCT04170907|Other|Nicotine salt 40 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 40 mg/mL.
16372546|NCT04170907|Other|Free-base nicotine 20 mg/mL|Vaping of free-base nicotine e-liquids with a nicotine concentration of 20 mg/mL.
16372549|NCT04170881||CHILDREN|Children from involved daycares (Paris region)
16372550|NCT04170881||WORKERS|workers in involved daycares (Paris region)
16372551|NCT04170868|Other|Video 1|Ten-day exposure to one of two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
16372552|NCT04170868|No Intervention|Video 1 Washout|Ten-day washout period between access to the first and second videos.
16372553|NCT04170868|Other|Video 2|Ten-day exposure to the second of the two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
16372554|NCT04170855|Other|Furosemide Injection|"Patients with diuretic resistance:
~The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). Fluid overload is defined as the presence of at least two of the following clinical features:
~Peripheral or sacral oedema
~Jugular venous distension ≥ 7 cm
~Radiographic pulmonary oedema or pleural effusion
~Enlarged liver or ascites
~Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea
~Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration"
16372555|NCT04170842|Experimental|Music intervention|"The music intervention used in the study will be a patient selected list of songs or other music delivered to the participant by passive listening via in-ear or on-ear headphones. They will be given the choice of using their own personal headphones or use a pair provided by the hospital. If choosing to use a hospital device, the earphones provided will be disposable to minimise infection risk from re-use.
~Patient preferred music has shown to be more effective than preselected, or prescriptive music. Prescriptive music, if not of the patient's preference, could cause further discomfort, distress or anxiety. Therefore, investigators will use streaming services to provide a bank of music containing a wide range of music and genres to suit the majority of music preferences. Music will also be curated based on feedback from age-appropriate sources to identify common and popular music in the target participant age group."
16372556|NCT04170842|No Intervention|Control|Wound dressing procedure conducted according to clinical practice
16372560|NCT04170816|Active Comparator|DN plus KT group|"DN plus KT therapy is going to be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy is going to be applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
~Kinesio Taping Application: Tapes is going to be left on the patient's body for 5 days."
16372561|NCT04170816|Active Comparator|DN group|DN will be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy was applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
16372562|NCT04170803|Experimental|True Dry Needling|"Active duty DoD beneficiaries, with shoulder pain will be recruited from Army Medical Department Center and School (AMEDDC&S) and the Brooke Army Medical Center (BAMC) Outpatient Physical Therapy Clinic who meet inclusion and exclusion criteria. The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the infraspinatus muscle using FDA approved (FDA regulation # 880.5580) disposable 0.25 x 40 mm stainless steel Seirin J-type needles (Seirin, Japan). Each shoulder will undergo this treatment. Each needle insertion will last approximately 2-3 seconds using the sparrow pecking (in and out) technique to the depth of the scapula at 3 locations in the infraspinatus muscle on the affected (painful) side. When detectable, the needle insertion will specifically target palpably painful and/or taut bands of tissue. Immediately after use, all needles will be disposed of in approved sharps containers."
16372563|NCT04170803|Sham Comparator|Sham Dry Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a blunted instrument in a needling guide tube against the skin. The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in previous studies performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants..
16372564|NCT04170790|Experimental|Healthy volunteer|Day 1: Sildenafil 50 mg single dose Day 2-Day 8: Washout period Day 9-12: Saxagliptin 5 mg Once/day Day 13: Sildenafil 50 mg+ Saxagliptin 5 mg
16372565|NCT04170777||Arm A|The CBCT imaging involved for Arm A is considered part of the study treatment. Pre and post treatment images will be acquired of the patient treated on Perfexion Gamma Knife using the 'Leksell Coordinate Frame'.
16372566|NCT04170777||Arm B|Arm B will be undergoing standard treatment on Gamma Knife Perfexion for Stereotactic Radiosurgery using the 'relocatable mask'. Patients with lesions that are >3 cm at the largest diameter will be treated with the relocatable mask for which a hypo fractionated approach may be beneficial.
16372567|NCT04170751|Experimental|group N|In group N, 16 mcg / cc of norepinephrine was infused to patients.
16372568|NCT04170751|Experimental|group V|In group V, 0.4 unit / cc of vasopressin was infused to patients.
16372569|NCT04170738|Experimental|Adderall|dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
16372570|NCT04170725|Experimental|Patients and Healthy volunteers|Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
16372571|NCT04170712||Surgical or High Risk|Patients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer.
16372572|NCT04170699|Experimental|PECS 1 Block|40 patients who had PECS 1 block for peroperative analgesia in port-a-cath replacement. All patients will receive IV Midazolam (0.05mg/kg) premedication. Standard monitorization of EKG, non- invasive blood pressure and pulseoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the intervention and in the supine positon the PECS 1 block will be done. 10 % povidone - iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done as a single injection of local anaesthetic between pectoralis major and pectoralis minor muscles at the level of the 3rd rib to anaesthetise the lateral and medial pectoral nerves. The USG probe will be replaced inferior to the clavicle. Identify the pectoralis muscles with the axillary artery and axillary vein on sonography. The brachial plexus should be visible underneath. After confirmation with 20 mL %0.25 bupivacaine will be administered.
16372573|NCT04170699|Experimental|Infiltrative Anesthesia|40 patients who had port-cath replacement will receive infiltrative anesthesia.
16372574|NCT04170686|Experimental|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
16372575|NCT04170686|No Intervention|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
16372576|NCT04170634||Patients with bone metastases at risk of fracture|Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency…). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) and bone treatments are allowed if administered for less than 3 months.
16372577|NCT04170621|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
16372578|NCT04170608|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
16372579|NCT04170595|Experimental|GB221,2mg/kg|Coprelotamab Injection, 2 mg/kg, Single dose,
16372580|NCT04170595|Experimental|GB221,6mg/kg|Coprelotamab Injection, 6 mg/kg, Single dose,
16372581|NCT04170595|Active Comparator|Herceptin,6mg/kg|Trastuzumab Injection, 6 mg/kg, Single dose,
16372582|NCT04170595|Experimental|GB221,8mg/kg|Coprelotamab Injection, 8 mg/kg, Single dose,
16372583|NCT04170595|Experimental|GB221+ Capecitabine|Multiple dose groups
16372584|NCT04170595|Active Comparator|Herceptin+Capecitabine|Multiple dose groups
16372585|NCT04170569|Experimental|Experimental Group|Yoga program was applied.
16372587|NCT04170556|Experimental|Regorafenib plus Nivolumab|Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8, regorafenib will be continued in combination with nivolumab, until symptomatic tumor progression, unacceptable adverse events, patient decision or death
16372593|NCT04170530|Experimental|mFOLFOXIRI|patients received FOLFOXIRI alone for 6 cycles before surgery.
16372594|NCT04170504|Experimental|Qing Re Huo Xue (QRHX) plus methotrexate (MTX)|QRHX XXmg bid and methotrexate (MTX) 10 mg once a week for 24 weeks
16372595|NCT04170504|Active Comparator|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)
16372596|NCT04170491|No Intervention|control|The standard medical care (Control) group will receive sequential portable EEGs, performed according to clinical demand. These patients usually have 2 recordings of 20-30 minutes each within 24 or 48 hours. The studies include baseline recoding and recording after auditory, tactile and nociceptive stimulation. The EEGs will be visually reviewed and reported within 4 hours after the recording completion by a Consultant Clinical Neurophysiologist or other doctor with equivalent qualifications.
16372597|NCT04170491|Experimental|cEEG|The treatment (cEEG) group will have cEEG applied within 12 hours of RSE diagnosis, which will continue until 24 hours after cessation of clinical and electrical seizure activity. Reactivity testing with auditory, tactile and nociceptive stimulation will be repeated at least once daily. The cEEG will be visually interpreted twice daily by a Consultant Clinical Neurophysiologist and the results will be communicated within two hours of their completion to the treating clinical team.
16372598|NCT04170465|Experimental|Metformin group|Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
16372599|NCT04170465|Active Comparator|Control group|Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)
16372600|NCT04170452||Chronic Hepatitis Delta patients|Patients infected with delta virus
16372601|NCT04170439|Other|clomiphene plus metformin plus N acetyle cysteine|Women who will receive clomiphene citrate plus metformin plus n acetyle cysteine
16372602|NCT04170439|Other|clomiphene plus metformin plus chromium|Women who will receive clomiphene plus metformin plus chromium
16372603|NCT04170439|Other|clomiphen citrate plus metformin|Women who will receive clomiphene plus metformin
16372604|NCT04170426|Experimental|Phase 1 ARM 0|9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
16372605|NCT04170426|Active Comparator|Phase 2 ARM 1|30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
16372606|NCT04170426|Placebo Comparator|Phase 2 ARM 2|15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
16372607|NCT04170413||CeVUS Urodynamic|patients undergoing urodynamic study with CeVUS
16372608|NCT04170387|Experimental|Relaxometer fibromyalgia cases|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
16372609|NCT04170387|Active Comparator|Relaxometer controls|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
16372610|NCT04170374||Patients who initiated HIV treatment|
16372611|NCT04170374||Service providers at study facilities|
16372612|NCT04170361|Active Comparator|Control Group|Patients will be admitted to chest physiotherapy program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization.
16372613|NCT04170361|Experimental|Training Group|In addition to conventional chest physiotherapy program, patients in this group will also be taught to use Triflo ® and apply at two-hour intervals.
16372614|NCT04170348|Experimental|Daily oral vitamin D3|Oral vitamin D3, 3,333 IU
16372615|NCT04170348|Active Comparator|Monthly bolus oral vitamin D3|Bolus oral vitamin D3, 100,000 IU
16372616|NCT04170335||Bariatric surgery group|Women older than age 40 and younger than age 74 undergoing primary bariatric surgery and having a BMI of ≥35 will be enrolled in this study. Pre operative and postoperative mammograms, inflammatory markers and breast cancer risk scores will be compared.
16372617|NCT04170322|Experimental|thin pvc gasrtric calibration tube|thin pvc gastric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy.
16372618|NCT04170322|Active Comparator|thick silicone gastric calibration tube|thick silicone gastrric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy
16372619|NCT04170309||With medical condition of interest|"Participants treated with ceftobiprole with at least one of the following conditions:
~Renal Insufficiency
~Hepatic Insufficiency
~Immunosuppression"
16372620|NCT04170309||Without medical condition of interest|"Patients treated with ceftobiprole without any of the following conditions:
~Renal Insufficiency
~Hepatic Insufficiency
~Immunosuppression"
16372621|NCT04170296|Experimental|Cohort 1: Posterolateral Thigh|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
16372622|NCT04170296|Experimental|Cohort 2: Buttocks|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
16372623|NCT04170283|Experimental|Zanubrutinib (BGB-3111)|All participants to receive open-label zanubrutinib
16372624|NCT04170283|Experimental|Zanubrutinib in combination with Tislelizumab|Participants to receive the combination as in the parent study (Australia Only)
16372625|NCT04170270|Experimental|oral omeprazole|oral omeprazole in bleeding peptic ulcer after endoscopic therapy 40 mg twice daily for 72 hours
16372627|NCT04170257|Experimental|Opportunistic screening cohort|This opportunistic screening cohort is constructed among patients aged 45-69 years who undergo endoscopic examinations at the endoscopy center in any of the five hospitals included in this study. Enrolled participants are requested to complete a computer aided one-on-one questionnaire regarding demographic factors, smoking and alcohol drinking status, dietary habits，digestive tract symptoms and family history of ESCC. Then experienced endoscopists will perform the upper gastrointestinal endoscopic examination for each participant, and the entire esophagus will be visually examined with the white light, NBI and iodine staining endoscopic examination.
16372628|NCT04170244||Atopic Dermatitis|
16372629|NCT04170244||Healthy control|
16372630|NCT04170244||Psoriasis|
16372631|NCT04170192||UCBT-IBD-Case|Very early onset IBD patients who underwent Cord Blood Stem Cell Transplantation.
16372632|NCT04170179|Experimental|Systemic chemotherapy plus lenvatinib and toripalimab|Systemic chemotherapy of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
16372633|NCT04170166|Active Comparator|Anterolateral Approach|The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach
16372634|NCT04170166|Active Comparator|Posterior Approach|The randomised group of patients receiving the subacromial steroid injection via a posterior approach
16372635|NCT04170153|Experimental|Part A1: Monotherapy Dose Escalation|Participants will initially receive M1774 once daily under fasting conditions. Additional schedules may be evaluated if needed.
16372636|NCT04170153|Experimental|Part A2 - Preliminary Food Effect Assessment|Participants in the food effect assessment will receive M1774 at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of M1774 will be administered on Day -7 under a fed (high-fat meal) or fasted condition, followed by a 1-week washout period. After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1. Participants will be administered M1774 at a dose and schedule determined as RDE in Part A1.
16372637|NCT04170153|Experimental|Part A3 - Monotherapy Expansion|Part A3 is an expansion of Part A1 where M1774 will be administered as a single agent at the RDE established in Part A1. Participants with defined loss-of-function mutation in ARIDIA, ATRX and/or DAXX, and ATM will be enrolled.
16372638|NCT04170153|Experimental|Part B1a: Combination Therapy Dose Finding|Participants with baseline body weight less than (<) 77 kilogram (kg) or platelets <150,000 cubic per millimeter (mm^3) will receive Niraparib once daily combined with different doses of M1774.
16372639|NCT04170153|Experimental|Part B1b: Combination Therapy Dose Finding|Participants with baseline body weight greater than or equal to (>=) 77 kg and or platelets >= 150,000 mm^3 will receive Niraparib once daily combined with different doses of M1774 and schedule determined as recommended dose for expansion (RDE) in Part B1a.
16372640|NCT04170140||Prescribers of Dengvaxia|Healthcare professionals who are current or past prescribers of Dengvaxia
16372641|NCT04170127|Experimental|Right side of the maxilla|the right side of the maxilla
16372642|NCT04170127|No Intervention|Left side of the maxilla|left side of the maxilla
16372643|NCT04170114|Experimental|Cystic Fibrosis|Children with cystic fibrosis
16372644|NCT04170114|Experimental|Bronchiectasis|Children with bronchiectasis
16372645|NCT04170101|Experimental|a continuous deep NMB (group A)|after 0,6 mg/kg LBW Rocuronium for intubation Rocuronium is given in a continuous infusion starting at 1 mg/kg/h and adapted to keep PTC below 5 and note.
16372646|NCT04170101|Placebo Comparator|non deep NMB (group B)|after 0,6 mg/kg LBW Rocuronium for intubation no extra NMB is given and depth is measured by TOF/PTC to note depth.
16372647|NCT04170088|Experimental|Tranexamic acid|"Left side of face of each participant was selected for intradermal Tranexamic acid injections.
~generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months"
16372648|NCT04170088|Experimental|0.9% Normal saline|Right side of face of each participant was selected for intradermal normal saline injections generic name : Normal Saline Dose : 0.9 % Normal Saline Dose : Frequency : every 2 weekly total 6 doses. Duration : 6 months
16372649|NCT04170075|No Intervention|Usual Care (UC)|Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
16372650|NCT04170075|Experimental|Whole body vibration (WBV)|Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
16372651|NCT04170062|Experimental|Baseline followed by intervention 1a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
16372652|NCT04170062|Experimental|Baseline followed by intervention 1b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
16372653|NCT04170062|Experimental|Baseline followed by intervention 1c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
16372687|NCT04169893|Experimental|TS-142, 3 mg|fasting
16372688|NCT04169893|Experimental|TS-142, 10 mg (fasting)|fasting
16372689|NCT04169893|Experimental|TS-142, 10 mg (feeding)|after meal
16372690|NCT04169893|Experimental|TS-142, 30 mg|fasting
16372691|NCT04169880|Experimental|HILT Group|HILT Group (n=15)
16372654|NCT04170062|Experimental|Baseline followed by intervention 1d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
16372655|NCT04170062|Experimental|Baseline followed by intervention 1e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
16372656|NCT04170062|Experimental|Baseline followed by intervention 1f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
16372657|NCT04170062|Experimental|Baseline followed by intervention 2a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
16372658|NCT04170062|Experimental|Baseline followed by intervention 2b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
16372659|NCT04170062|Experimental|Baseline followed by intervention 2c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
16372660|NCT04170062|Experimental|Baseline followed by intervention 2d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
16372661|NCT04170062|Experimental|Baseline followed by intervention 2e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
16372662|NCT04170062|Experimental|Baseline followed by intervention 2f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
16372663|NCT04170049|Experimental|Behavioral: The sensory stimulative activity interventions|
16372664|NCT04170036||Protein supplement group|The group of subjects who use protein supplements at least for the preceding three months
16372665|NCT04170036||Control group|The group of subjects who never used protein supplements
16372666|NCT04170023|Experimental|Open-label ALXN2050 Monotherapy|"Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered
~Group 1: Patients with PNH who are treatment naïve
~Group 2: Patients with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months and who continue to experience anemia (hemoglobin [Hgb] < 10 g/dL) and reticulocytes above the upper limit of normal (ULN)
~Group 3: Patients with PNH receiving danicopan monotherapy in study ACH471-103"
16372667|NCT04170010||Conservatively managed group|Individuals with conservatively managed obesity
16372668|NCT04170010||Surgically managed group|Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity
16372669|NCT04169997|Experimental|IMP4297|The starting dose is 100mg QD
16372670|NCT04169997|Placebo Comparator|Placebos|The starting dose is 100mg QD
16372671|NCT04169984|Active Comparator|Myofunctional Therapy|This therapy consists of the practice of isotonic, isokinetic and isometric exercises that improve mobility and coordination and increase the muscular strength of the orofacial structures that contribute to the obstructive sleep apnea etiopathogenesis.
16372672|NCT04169984|Placebo Comparator|Placebo|The placebo group will be instructed in simulation exercises that do not alter the function or morphology of the upper airway.
16372673|NCT04169971|Experimental|Music group|Will receive music during the operation conducted under spinal anaesthesia
16372674|NCT04169971|No Intervention|Control group|Will not receive music during the operation conducted under spinal anaesthesia
16372675|NCT04169945|Experimental|Ultrasonic instrumentation and Air Polishing|All participants will receive full mouth conventional ultrasonic subgingival debridement, followed by air-polishing with erythritol powder which include activating device for 5 seconds of each surface (Petersilka 2003). Subsequently, Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm. Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm
16372676|NCT04169945|Active Comparator|Ultrasonic instrumentation|All participants will receive full mouth conventional ultrasonic subgingival debridement only. No time limit (Flemmig 2012), until dental surfaces feel smooth.
16372677|NCT04169932|Experimental|CD20 CAR-T|
16372678|NCT04169919|Active Comparator|Modified method|Povidone Iodine
16372679|NCT04169919|Active Comparator|Ordinary method|normal saline
16372680|NCT04169906|Placebo Comparator|Placebo|
16372681|NCT04169906|Experimental|TS-142 10 mg|
16372682|NCT04169906|Experimental|TS-142 20 mg|
16372683|NCT04169906|Experimental|TS-142 30 mg|
16372695|NCT04169854|Experimental|Lidocaine Patch|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked Lidocaine 5% patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
16372696|NCT04169854|Placebo Comparator|Placebo|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked placebo patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
16372697|NCT04169841|Experimental|GUIDE2REPAIR patients|olaparib + immunotherapy (durvalumab + tremelimumab) during 4 months followed by durvalumab alone as maintenance in patients with solid cancer and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.
16372698|NCT04169828|Experimental|Ondansetron premedication|Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if <15Kg, 4 mg if 15-30Kg, 8 mg if >30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate.
16372699|NCT04169828|Active Comparator|Ondansetron as needed|Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if <15Kg, 4 mg if 15-30Kg, 8 mg if >30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion
16372700|NCT04169815||ED Setting|An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.
16372701|NCT04169802||Normal subjects|Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.
16372702|NCT04169802||Subjects with neovascular AMD|Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.
16372703|NCT04169789|Active Comparator|L. reuteri Low Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E8 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total dose of either 1x10E9 L.reuteri CFU and 400 IU of cholecalciferol per day.
16372704|NCT04169789|Active Comparator|L. reuteri High Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day.
16372705|NCT04169789|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 24 months.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day.
16372706|NCT04169776|Experimental|Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
16372707|NCT04169776|Experimental|Steroid Resistant Idiopathic Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
16372708|NCT04169763|Experimental|Treatment (nelfinavir, cisplatin, EBRT)|Patients receive nelfinavir PO BID for up to 8 weeks. Starting week 2, patients also receive cisplatin IV over 60-90 minutes once weekly during weeks 2-8. Patients undergo EBRT for 5 consecutive days between weeks 2-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
16372709|NCT04169750|Experimental|Exergames|
16372710|NCT04169750|Active Comparator|Adaptive COGNI-TRAcK|
16372711|NCT04169750|Sham Comparator|Sham COGNI-TRAcK|
16372712|NCT04169737|Active Comparator|Arm I (acalabrutinib, venetoclax, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 3, patients receive venetoclax PO BID on days 1-28. Patients who are BM MRD4-positive or in PR also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 15 and day 1 of cycles 16-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16372713|NCT04169737|Experimental|Arm II (acalabrutinib, venetoclax, early obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 beginning cycle 2 and venetoclax PO BID on days 1-28 beginning cycle 3. Patients also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and day 1 of cycles 2-6. Patients who are BM MRD4-positive or in PR receive obinutuzumab IV over 4-6 hours on day 1 cycles 15-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16372714|NCT04169724|Experimental|Calm|Participants will be asked to download the Calm app on their smartphone. Participants will then receive an email containing login credentials to access the Calm app. Once they receive this email and they receive their study start date, they will be asked to meditate for at least 10 minutes a day for 8 weeks. This prescription mimics how a new, paying member would use the app. Participants in the intervention group will be emailed weekly reminders.
16372715|NCT04169724|No Intervention|Waitlist|Participants randomized to the control group will be asked to maintain their normal routine for 8 weeks and to avoid using the Calm meditation app.
16372716|NCT04169711|Experimental|ARO-HIF2|
16372717|NCT04169698|No Intervention|Control group|Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
16372718|NCT04169698|Experimental|Denosumab group|Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
16372792|NCT04169152||Internal hemorrhoids and rectal prolapse|Participants were treated with Cap-assisted endoscopic sclerotherapy (CAES).
16372719|NCT04169698|Experimental|Alendronate group|Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
16372720|NCT04169685||with dexmedetomidine|Drugs provided moderate sedation during procedure including dexmedetomidine
16372721|NCT04169685||without dexmedetomidine|Drugs provided moderate sedation during procedure without dexmedetomidine
16372722|NCT04169672|Experimental|Surufatinib & Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
16372723|NCT04169672|Experimental|Surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
16372724|NCT04169659|Experimental|Kyphoplasty with Titanium spheres|Patients treated with kyphoplasty with baloons and insertion of titanium microspheres inside the body vertebra.
16372725|NCT04169659|Active Comparator|Kyphoplasty with Polymethylmethacrilate|Patients treated with Kyphoplasty with baloons and insertion of Polymethylmetacrylate inside the body vertebra.
16372726|NCT04169646|Other|Intervention|Multi-component intervention
16372727|NCT04169646|Other|Control|Control
16372728|NCT04169620|Experimental|variable aquatic Ai Chi|"The 15 patients assigned to the aquatic therapy group (experimental group) received 20 twice-weekly sessions in total, during the same period of time as the control group. These 20 sessions consisted of group sessions lasting 45-minutes.
~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
16372729|NCT04169620|Placebo Comparator|variable dry land|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
16372730|NCT04169607|Experimental|individualized PEEP|"Basic ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，
~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.
~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.
~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.
~Randomization: Subsequently patient was randomized, the PEEP was then maintained (individualized PEEP arm) until extubation.
~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
16372731|NCT04169607|Active Comparator|PEEP 8|"Bacis ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，
~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.
~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.
~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.
~Randomization: Subsequently patient was randomized , the PEEP was then reduced to 8cm H2O (PEEP8 arm) until extubation.
~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
16372734|NCT04169581||Experimental Group|The experimental group received 18F-FDG PET examination
16372735|NCT04169581||Control Group|The control group received 18F-FDG PET examination
16372736|NCT04169568||OI manuel cuff BP|Patients with diagnosis of Osteogenesis Imperfecta from ages 1 to 35 who are admitted to our institution to the inpatient, non-ICU setting, following orthopedic surgery for lower extremity realignment and IM rodding
16372737|NCT04169555|Experimental|Ultrasound|
16372738|NCT04169555|Other|Standard care|
16372739|NCT04169542||Observational (questionnaire)|Patients complete up to 4 electronic questionnaires over 15 minutes before surgery and at 6, 12, and 24 months after surgery.
16372740|NCT04169490|Experimental|FS2 Emulsion Moisturizer|The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.
16372741|NCT04169490|Experimental|Active Comparator + FS2 Emulsion Moisturizer|The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.
16372742|NCT04169477|Experimental|cTENS-mTENS|Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form
16372743|NCT04169477|Experimental|mTENS-cTENS|Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode
16372744|NCT04169464|Other|group I|A group of HCV infected patients treated with DAA therapy including Sofospovir
16372745|NCT04169451|Experimental|letrozole group|Women will be given IUI treatment with ovarian stimulation with letrozole 5mg/day starting from day 3-5 of menstrual cycle for 5 days.
16372746|NCT04169451|No Intervention|natural cycle group|Women will be given IUI treatment without ovarian stimulation.
16372747|NCT04169438|Placebo Comparator|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Vehicle Cream Base Emulsion Moisturizer + Petrolatum
16372748|NCT04169438|Experimental|FS2 Emulsion Moisturizer + Petrolatum|FS2 Emulsion Moisturizer + Petrolatum
16372751|NCT04169412||Resuscitation Failure, High PCO Level, High RIPK3 Level|"Resuscitation failure was defined as lactate level ≥2 mmol/L or lactate reduction <20% hour-4 after initial sepsis recognition.
~High PCO level was defined as PCO level ≥ cut off point.
~High RIPK3 level was defined as PCO level ≥ cut off point."
16372752|NCT04169412||Resuscitation Success, Low PCO Level, Low RIPK3 Level|"Resuscitation success was defined as lactate level <2 mmol/L or lactate reduction ≥20% hour-4 after initial sepsis recognition.
~Low PCO level was defined as PCO level < cut off point.
~Low RIPK3 level was defined as PCO level < cut off point."
16372753|NCT04169399|Experimental|Toripalimab plus SBRT|Participants received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Participants recevied Stereotactic body radiotherapy. Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
16372754|NCT04169386|Experimental|AK102 75mg|AK102 75mg
16372755|NCT04169386|Experimental|AK102 150mg|AK102 150mg
16372756|NCT04169386|Experimental|AK102 300mg|AK102 300mg
16372757|NCT04169386|Experimental|AK102 500mg|AK102 500mg
16372758|NCT04169386|Placebo Comparator|Placebo|Matching placebo
16372763|NCT04169360|Experimental|ANS-6637|ANS-6637 600mg once daily for 12 weeks
16372764|NCT04169360|Placebo Comparator|Placebo arm|Placebo 600 mg once daily for 12 weeks
16372765|NCT04169347|Other|Active|This is an open label study single arm
16372766|NCT04169334|No Intervention|Control group|Group receiving care as usual
16372767|NCT04169334|Experimental|Intervention group|Intervention group receiving a standardized preventive program (5 days at the Obstetric department)
16372768|NCT04169321|Experimental|Single Arm|All participants will receive a mass dose of 40 μg or less of [68Ga]-NOTA-hGZP (radioactivity dose of 3 mCi to 15 mCi) and have a PET scan.
16372769|NCT04169308|Experimental|Experimental: Restylane-L® Filler injection|
16372770|NCT04169295|Experimental|Intervention group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized IVF-prognosis
16372771|NCT04169295|Sham Comparator|Control group|At the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos.
16372772|NCT04169282|Experimental|nPEP Recipients|Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
16372773|NCT04169269|Active Comparator|Enoxaparin|enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days
16372774|NCT04169269|Active Comparator|Rivaroxaban|rivaroxaban oral 10 milligram tablet daily for 20 days
16372775|NCT04169256|Experimental|HYR-PB21 & Placebo|
16372776|NCT04169256|Active Comparator|Liposome Bupivacaine & Placebo|
16372777|NCT04169243|Experimental|Intervention|Women randomized to the New Nordic Diet meet the study dietician at week 30 for 1.5 hr of individual diet treatment according to the New Nordic Diet and a cognitive behavioral approach. The diet advice include evenly distributed meals over the day, foods low in fat and rich in fibre, 500 g fruit and vegetables daily, fish 2-3 times a week and keyhole foods. Participants will prepare their own food but are provided with recipes and food bags containing all the foods to be consumed during the two-week intervention At gestational age 32 weeks, women meet with a dietitian and will be instructed to continue with the New Nordic Diet diet throughout pregnancy on their own.
16372778|NCT04169243|Active Comparator|Control|The control women receive diet advice according to usual care.
16372779|NCT04169230|Experimental|Citalopram|Single acute oral dose 20 mg Citalopram (tablet encapsulated in opaque capsule)
16372780|NCT04169230|Placebo Comparator|Placebo|Single acute oral dose Lactose Placebo (tablet encapsulated in opaque capsule)
16372781|NCT04169217|No Intervention|Control arm|This arm will not be in the prehabilitation group- as is current standard practice
16372782|NCT04169217|Active Comparator|Group 2|This arm will be subject to a one off prehabilitation workshop and provided with a prehab booklet
16372783|NCT04169217|Experimental|Group 3- Mentored group|This arm will be subject to a one off workshop and provided with a prehab booklet- and additional mentoring by means of 1. an educational app, 2. push notifications,3. weekly communication with physiotherapy team member.
16372784|NCT04169191|Experimental|Sildenafil|
16372785|NCT04169178|Experimental|HLX55, dose finding stage, advanced solid tumor|Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.
16372786|NCT04169178|Experimental|HLX55, dose expansion stage, gastric cancer|Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.
16372787|NCT04169178|Experimental|HLX55, dose expansion stage, NSCLC|Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.
16372788|NCT04169178|Experimental|HLX55, dose expansion stage, colorectal cancer|Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.
16372789|NCT04169178|Experimental|HLX55, dose expansion stage, other solid cancer|Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.
16372790|NCT04169165||compliant patients|Patients with compliance to suggestions on metabolic evaluation and dietary/medical advices
16372793|NCT04169139|Active Comparator|MIST - minimally invasive surgical therapy|"Beginning with the papilla preservation technique (Takei et al), further improved by Cortellini et al (1995) and combined with minimally invasive approaches (Harrel et al 1995), MIST, using minimally invasive surgical approaches and micro-surgery instruments, has evolved into a decision tree guideline for treating periodontitis based on periodontal pocket morphology and papilla width/ interdental space (Cortellini P, Tonetti MS (2007) J Clin Periodontol;34(1):87-93)."
16372794|NCT04169139|Experimental|REPaiR - laser periodontal therapy|The REPaiR regimen is a step-by-step protocol for using the Waterlase Express Er,Cr:YSGG laser for periodontitis. The protocol steps and associated laser delivery is controlled by a computer interface that dictates laser tip, energy and associated air and water mixes. Like MIST, REPaiR uses a set, decision tree approach for periodontal therapy, with prescribed steps and laser settings to quantify and standardize treatment. Potential clinical benefit, as with MIST, are not only effective periodontal therapy with reduced recession compared with traditional surgical approaches, but also reduced patient morbidity (Arnabat-Domínguez et al (2010). Lasers Med Sci;25(3):459-64).
16372795|NCT04169126|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
16372796|NCT04169113|Active Comparator|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
16372797|NCT04169113|Active Comparator|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
16372798|NCT04169100|Experimental|Prednisone Group|These patients have CTD and QTc over 500 msec. Prednisone is administered as a preventative measure against arrhythmia via QTc shortening.
16372799|NCT04169087||General anesthesia|Patients undergoing general anesthesia
16372800|NCT04169074|Experimental|Treatment with abemaciclib|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 150 mg PO twice daily on Days 1-21 (+7 days).
16372801|NCT04169061|Experimental|All participants|"Participants receive:
~a shot of Acthar (80 units) under the skin twice a week for 12 weeks
~a shot of Acthar (40 units) twice a week for 2 weeks
~a shot of Acthar (40 units) once a week for 2 more weeks
~At each visit they will have medical tests and answer questions about their symptoms."
16372802|NCT04169048|Experimental|Intervention group (BPD)|Participants (N=60) receive the weekly conducted intervention (group training for mothers with BPD) over the period of 12 weeks (12 sessions). Assessments of each participant: T0 (pre-intervention), T1 (post-intervention) and follow-up (6 months after T1).
16372803|NCT04169048|No Intervention|waiting control group (BPD)|Members of this group (N=60) receive no intervention but treatment as usual (TAU). After completing all assessment points (T0, T1, T2), they can receive the intervention of the intervention group (group training).
16372804|NCT04169048|No Intervention|clinical control group (AD/MDD)|Mothers with anxiety and/or depression (N=60) receive no intervention. Assessment point only T0.
16372805|NCT04169048|No Intervention|healthy control group|Mothers with no actual mental disorder (N=60) receive no intervention.# Assessment points T0, T1, T2.
16372806|NCT04169035|Experimental|Odon device|The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assiste vaginal birth. Odon trained practitioner available to assist the birth.
16372807|NCT04169035|Active Comparator|Forceps or ventouse|"The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assisted vaginal birth.
~The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth."
16372808|NCT04169022|Experimental|AML patients at diagnosis|AML patients at diagnosis (except AML3)
16372809|NCT04169022|Experimental|AML patients at relapse|AML patients at relapse after chemotherapy, targeted therapy or allograft
16372810|NCT04169009|Active Comparator|ZVL >5 years previously|Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
16372811|NCT04169009|Active Comparator|ZVL 6-12 months previously|Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.
16372812|NCT04169009|Active Comparator|No previous ZVL|Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.
16372813|NCT04169009|Active Comparator|SRX >5 years previously|Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
16372814|NCT04168996|Experimental|rib fracture patients group|Individualized discharge planning in rib fracture patients with different severity of lung injury
16372815|NCT04168996|No Intervention|Control group|Patients included in control group received standard conservative treatment during hospitalization
16372816|NCT04168983|No Intervention|Control|Usual care: local anesthesia + nitrous oxide and oxygen administration
16372817|NCT04168983|Experimental|Experimental|"Usual care: local anesthesia + nitrous oxide and oxygen administration
~In this arm : sophrology is added"
16372818|NCT04168970||PSGB group|MD will perform PSGB using Lidocaine. The PGSB will be performed after the administration of the 4th shock if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. PSGB will be performed after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.).
16372819|NCT04168970||Control group|Historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Cardiac Arrest Registry of the Province of Pavia
16372820|NCT04168957|Experimental|Oraxol|Subjects in KX-ORAX-008 will begin treatment at the last oral paclitaxel dose they received in Study KX-ORAX-007.
16373336|NCT04165434|Experimental|Experimental|Untrained unilateral transtibial amputees who underwent the assessment and recommended training.
16372821|NCT04168944|Experimental|lenvatinib group|Participants are given the same anti-rejection therapy as the control group after liver transplantation. 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mgor 12 mg orally once a day. The initial dose was 8 mgor 12 mg orally once a day.
16372822|NCT04168944|Placebo Comparator|Placebo group|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
16372823|NCT04168931|Experimental|Interventional|Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.
16372824|NCT04168918|Experimental|Group Psychological Intervention|One topic will be discussed at each of the six sessions using some principles from cognitive behavioral therapy and psychoeducation.
16372825|NCT04168918|No Intervention|Treatment-as-usual|Participants will receive their usual care which involves being seen by a mental health professional (psychologist, psychiatrist/resident in psychiatry, or mental health nurse).
16372826|NCT04168905|Experimental|Active arm|After receiving standard treatment and AOTI Inc. TWO2 topical oxygen therapy equipment training, patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
16372827|NCT04168905|Placebo Comparator|Controlled arm|patients receive standard treatment.
16372828|NCT04168892||Female age ≤ 35 years: 150 IU of HMG|For controlling the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age ≤ 35 years, COS will be carried out by daily injections of 150 IU of Human Menopausal Gonadotropins (HMG) and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the Gonadotropin-releasing Hormone (GnRH) antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary human Chorionic Gonadotropin (hCG) 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
16372829|NCT04168892||Female age >35 years: 225 IU of HMG|In order to control the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age >35 years, the controlled ovarian stimulation will be carried out by daily injections of 225 IU of HMG and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the GnRH antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary hCG 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
16372830|NCT04168879|Active Comparator|bupivacaine group|
16372831|NCT04168879|Placebo Comparator|saline group|
16372832|NCT04168866|Experimental|Surgery|Patients who choose operations will have surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
16372833|NCT04168866|Active Comparator|Non-operative management|If a patient chooses non-operative management and if an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
16372834|NCT04168853|Other|Roller pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Maquet® for the roller pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
16372835|NCT04168853|Other|Centrifugal pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Sorin® for the centrifugal pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
16372836|NCT04168840||Patient undergoing general anesthesia with intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway
16372837|NCT04168827||Relatives of severe traumatized child|Relatives of a child who has been hospitalized in intensive care of Necker hospital following a severe trauma
16372838|NCT04168814||Oncology patients (Immunotherapy alone or in combination))|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).
~Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: PD1, PDL1 inhibitors. At least 12 weeks of treatment."
16372946|NCT04168086|Experimental|Non-Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to a non-motor area of the right cerebellum prior to completing a motor learning task.
16372839|NCT04168814||Oncology Patients (Chemo-Radiotherapy group).|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).
~Patients under active treatment either in combination with chemotherapy or radiotherapy. At least 12 weeks of treatment."
16372840|NCT04168801|Experimental|Early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, if he did not have them, then receives diet indicated between 16 and 24 hours after admission.
16372841|NCT04168801|Active Comparator|Usual oral refeeding|usual oral refeeding (UOR) Once the attending physician decided according to his clinical judgment to restart the oral feeding
16372842|NCT04168788|Other|Nephrobalstoma or ALL|Pateints treated for a nephrobalstoma or ALL in childhood or adolescence
16372843|NCT04168775|Other|Home PIFR monitoring|Measurement of PIFR using the InCheck Dial® device and quantification of respiratory symptoms and COPD exacerbations using standardized questionnaires in the patient's home setting and during research visits in the clinic setting
16372844|NCT04168762|Experimental|TUMS and Sham Group|During the subjects two visits they will receive a TUMS stimulation and a sham (placebo) stimulation at both visits.
16372845|NCT04168762|Experimental|TUMS or Sham Group|During the subjects first of two visits they will receive either a TUMS stimulation or a sham (placebo) stimulation and at the second visit they will receive the other.
16372846|NCT04168749||local compounding group|the first 100 preterm babies born as from January 1 2015 with a birth weight between 1250-2000g that received at least 10 days of TPN.
16372847|NCT04168749||Numeta G13 group|the first 100 preterm babies as from January 1 2017 with a birth weight between 1250-2000g that received at least 10 days of TPN
16372848|NCT04168723|Experimental|Group A-MD1003|Group A=32 subjects Placebo for MD1003 on Day -1. Daily dose of 1200 mg of MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Day 9
16372849|NCT04168723|Active Comparator|Group B-Moxifloxacin|"Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.
~Subgroup B1: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Moxifloxacin 400 mg on Day 1 and Placebo for moxifloxacin on Day 9 Subgroup B2: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Moxifloxacin 400 mg on Day 9"
16372850|NCT04168710|Experimental|erector spinae plane block (ESP block) with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
16372851|NCT04168710|Placebo Comparator|ESP block with saline/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
16372852|NCT04168697|Experimental|Controls|Control subjects undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
16372853|NCT04168697|Experimental|BAD|Patients with bipolar affective disorder (BAD) undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
16372854|NCT04168684|Experimental|Attachment and Biobehavioral Catch-up (ABC)|10 sessions that focused on parental nurturance, and sensitivity
16372855|NCT04168684|Active Comparator|Developmental Education for Families (DEF)|10 sessions that focused on cognitive development
16372856|NCT04168671|Other|Asthma|Asthma and symptomatic during exercise
16372857|NCT04168671|Other|Severe asthma|Severe asthma and symptomatic during exercise
16372858|NCT04168658|Experimental|Physical activity and education intervention|
16372859|NCT04168658|Active Comparator|Education intervention|
16372860|NCT04168645|Experimental|Presence of SUD with CBT|Patients diagnosed with SUD who are randomly assigned to receive CBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
16372861|NCT04168645|No Intervention|Presence of SUD with TAU|Patients diagnosed with SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
16372862|NCT04168645|Experimental|Absence of SUD with CBT|Patients without SUD who are randomly assigned to receive CBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
16372863|NCT04168645|No Intervention|Absence of SUD with TAU|Patients without SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
16372864|NCT04168632|Experimental|Intervention|A new 4-week menu plan
16372865|NCT04168619||Transient elastography (TE)|All patients who had MTX taken
16372866|NCT04168619||Two dimensional shear wave elastography (2D SWE)|For patients who has cumulative more than 3.5g methotrexate
16372867|NCT04168619||Liver biopsy|For patients who has cumulative more than 3.5g methotrexate and had 2D SWE done
16372868|NCT04168606||Cases with placental abruption|"Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination.
~All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis."
16372869|NCT04168593|Sham Comparator|A- Placebo|Sham Acupuncture and Sham Cupping
16372870|NCT04168593|Active Comparator|B -Cupping|Sham Acupuncture and Real Cupping
16372871|NCT04168593|Active Comparator|C - Acupuncture|Real Acupuncture and Sham Cupping
16372872|NCT04168593|Active Comparator|D - Acupuncture + Cupping|Real Acupuncture and Real Cupping
16372873|NCT04168580||OA- Older Athlete|Older adults who are regularly engaged in endurance exercise
16372874|NCT04168580||OS- Older Sedentary|Older adults who are sedentary
16372875|NCT04168567|Experimental|Obese patients|Patients who have BMI higher than 30
16372876|NCT04168567|Experimental|Normal weight patients|Patients who have BMI between 20 and 25.
16373337|NCT04165434|No Intervention|Control|Untrained unilateral transtibial amputees who after the evaluation were not included for the recommended training.
16372877|NCT04168554||Phase 1 and Phase 2|"20 patients studied in the emergency room with a pediatrician not presen in the ER performing the telemedicine examination from a distance (ie an office down the hall) followed directly by a face-to-face
~20 patients included in the general practitioners office, telemedicine is performed from within the hospital to the GPs office.
~Patient is then still referred to the hospital in order to check whether the telemedicine and face-to-face examination are somewhat similarce physical examination"
16372878|NCT04168541|Active Comparator|Oral Nutrition Supplement A|Product containing calories from carbohydrate, protein, and fat
16372879|NCT04168541|Active Comparator|Oral Nutrition Supplement B|Product containing calories from carbohydrate, protein, and fat
16372880|NCT04168541|Active Comparator|Oral Nutrition Supplement C|Product containing calories from carbohydrate, protein, and fat
16372881|NCT04168541|Active Comparator|Oral Nutrition Supplement D|Product containing calories from carbohydrate, protein, and fat
16372882|NCT04168541|Active Comparator|Oral Nutrition Supplement E|Product containing calories from carbohydrate, protein, and fat
16372883|NCT04168541|Active Comparator|Oral Nutrition Supplement F|Product containing calories from carbohydrate, protein, and fat
16372884|NCT04168528|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|Phase I
16372885|NCT04168528|Experimental|Part II: tumor targeting potential and correlation to ICH|Phase II
16372886|NCT04168515||Patient|
16372887|NCT04168515||Caregiver|
16372888|NCT04168515||Healthcare provider|
16372889|NCT04168502|Experimental|Experimental arm|"Induction:
~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7
~Consolidation:
~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6
~Allogeneic transplantation or Autologous transplantation according to MRD level
~Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse"
16372890|NCT04168502|Active Comparator|Standard arm|"Induction:
~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7
~Consolidation:
~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6
~Allogeneic transplantation or Autologous transplantation according to MRD level
~clinical observation"
16372891|NCT04168489|Active Comparator|active rTMS|
16372892|NCT04168489|Sham Comparator|sham rTMS|
16372893|NCT04168476|Experimental|Treatment group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:
~Visual Analogue Scale
~Range of movement
~Hand grip strength. After a first assessment, scapula mobilization techniques were performed and participants reassessed."
16372894|NCT04168476|Placebo Comparator|Control group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:
~Visual Analogue Scale
~Range of movement
~Hand grip strength. The procedure was a contralateral calcaneus abduction and adduction mobilization technique was carried out."
16372895|NCT04168463|Experimental|Immediate Intervention|This cluster of four homes will receive robot animals immediately at commencement of the eight month trial.
16372896|NCT04168463|Other|Delayed Intervention|This cluster of four homes will receive robot animals four months after commencement of the 8 month trial. The four months without robots will serve as a control period.
16372897|NCT04168450|Other|WiSAT Passive|This arm is composed of participants who meet their activity threshold over the 4-week period.
16372898|NCT04168450|Other|WiSAT Active|This arm is composed of participants who do not meet their activity threshold over the 4-week period.
16372899|NCT04168437|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report.
16372900|NCT04168437|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report following completion of the study.
16372901|NCT04168411|Experimental|Symptomatic treatment group|The patients were allocated to wear a double layered elasticated bandage for treatment 5th metatarsal base fractures (Zone 1).
16372902|NCT04168411|Active Comparator|Cast group|The patients were given a below-knee cast for treatment 5th metatarsal base fractures (Zone 1).
16372903|NCT04168398|Experimental|Plavix 75mg and juspirin 81 mg therapy|Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.
16372904|NCT04168398|Experimental|Eliquis 2.5mg and juspirin 81 mg therapy):|Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin (juspirin) 81 mg.
16372905|NCT04168385|Experimental|Maralixibat|Participants will all receive Maralixibat oral solution
16372906|NCT04168372|Experimental|High fructose meal, with fructose label|2-13C fructose incorporated into a meal with high fructose content
16372907|NCT04168372|Experimental|High fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with high fructose content
16372908|NCT04168372|Experimental|Low fructose meal, with fructose label|2-13C fructose incorporated into a meal with low fructose content
16372909|NCT04168372|Experimental|Low fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with low fructose content
16372910|NCT04168359|Experimental|Semi-barbed Sutures Localization Group|Patients with pulmonary nodules requiring CT-guided puncture positioning before thoracoscopic surgery
16372911|NCT04168346|Experimental|Intervention|IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.
16372912|NCT04168346|Placebo Comparator|Placebo|Placebo is NaCl 0.9% solution, which is administrated in the same way as the study drug
16372913|NCT04168333|Active Comparator|T101 Group|"The study will consist of 2 cohorts:
~Single Dose (SD) Cohort:
~9 chronic hepatitis B patients will be enrolled and be divided into 3 groups, with 3 patients in each group.
~Multiple Dose (MD) Cohort:
~18 chronic hepatitis B patients will be enrolled and be divided into 2 groups, with 9 patients in each group."
16372914|NCT04168333|Placebo Comparator|Placebo Group|"The study will consist of 2 cohorts:
~Single Dose (SD) Cohort:
~3 chronic hepatitis B patients will be enrolled in this group.
~Multiple Dose (MD) Cohort:
~6 chronic hepatitis B patients will be enrolled in this group."
16372915|NCT04168320|Active Comparator|Less favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.
~SBRT-PATHY will be administered to this arm at an estimated less favorable time-Position in immune cycle."
16372916|NCT04168320|Experimental|Most favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.
~SBRT-PATHY will be administered to this arm at an estimated most favorable time-position in immune cycle."
16372917|NCT04168307|Experimental|Ankle trainer device|The patients were instructed in the use of a new spring loaded ankle trainer
16372918|NCT04168307|Active Comparator|Conventional physiotherapy|The patients were instructed in passive stretching exercises by the use of a non-elastic band
16372919|NCT04168294||sedation group|Patients undergo sedative esophagogastroduodenoscopy (EGD) and are intravenous injected propofol in bolus
16372920|NCT04168294||control group|patients undergo conventional EGD
16372921|NCT04168281|Experimental|PCI- free after response to radical chemoradiotherapy|Patients with no metastases will be followed-up with MRI: at the qualifying visit before MRI-1, and then every 6 months +/- 2 weeks), the patients will have a cognitive examination performed using dedicated neuropsychological tests and QoL assessment using the QLQ-C30 questionnaire. The tests will be conducted in the following order: California verbal learning test (CVLT) with a delay of 15 min, Color connection test (CTT), CVLT (after delay), Benton visual memory test (BNRT), Verbal fluency test by the certified psychologist.
16372922|NCT04168255|Other|Retinal detachment|Retinal detachment with proliferative vitreoretinopathy and inferior breaks
16372923|NCT04168242|Experimental|Experimental arm|Patients have scalp cooling during the chemotherapy period
16372924|NCT04168242|Placebo Comparator|Control arm|Patients do not have scalp cooling during the chemotherapy period
16372925|NCT04168229|Experimental|ITE Hearing Aid|The subjects will wear the ITE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
16372926|NCT04168229|Active Comparator|BTE Hearing Aid|The subjects will wear the BTE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
16372927|NCT04168203|Experimental|Extended Duration Thromboprophylaxis|apixaban 2.5 mg orally twice daily for a duration of 12 months
16372928|NCT04168203|Placebo Comparator|Control|oral placebo for a duration of 12 months
16372929|NCT04168190|Experimental|Phase 1: pPCV-1|Single intramuscular (IM) 0.5 mL vaccination on Day 1
16372930|NCT04168190|Experimental|Phase 1: pPCV-2|Single IM 1.0 mL vaccination on Day 1
16372931|NCT04168190|Active Comparator|Phase 1: Pneumovax™23|Single IM 0.5 mL vaccination on Day 1
16372932|NCT04168190|Experimental|Phase 2: pPCV|Single IM vaccination on Day 1 at dose to be determined.
16372933|NCT04168190|Active Comparator|Phase 2: Pneumovax™23|Single IM 0.5 mL vaccination on Day 1
16372934|NCT04168177|Active Comparator|control group|
16372935|NCT04168177|Active Comparator|ESP Group|
16372936|NCT04168164|Experimental|Ai Chi|Ai Chi aquatic therapy Dry land therapy
16372937|NCT04168151|Experimental|hypoxic group|hypoxic patients (hypoxic index less than 250)
16372938|NCT04168138|Experimental|Newly diagnosed AML in elderly patient|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when WBC>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
16372939|NCT04168125|Experimental|Tilapia skin|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a tilapia skin as an occlusive biological dressing for palatal wound healing.
~Device: Tilapia skin. A xenogeneic collagen dressing will be placed over palate wound and stabilized with sutures during the healing process."
16372940|NCT04168125|Active Comparator|Surgical Wound Dressing|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a surgical wound dressing as a mechanical protection during palatal wound healing.
~Device: Surgical wound dressing A surgical wound dressing will be placed over palate wound during the healing process to provide mechanical protection."
16372941|NCT04168112|Experimental|Group A|Intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days).
16372942|NCT04168112|Active Comparator|Group B|Patients are placed on standard postoperative regimen of postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: QID x1 week, TID x 1 week, BID x 1 week, and Qday x 1 week.
16372943|NCT04168099|Experimental|Cefotaxime|Cefotaxime intravenous
16372944|NCT04168099|Active Comparator|Gemifloxacin|Oral Gemifloxacin
16372945|NCT04168086|Experimental|Right Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to motor area of the right cerebellum prior to completing a motor learning task.
16373432|NCT04164862|Active Comparator|use ACCUVEIN AV400|Device to facilitate cannulation of the great saphenous vein at the ankle in infants
16372947|NCT04168086|Sham Comparator|Control|Participants will have the Focused Ultrasound transducer placed on their neck without stimulation as a Sham present prior to completing a motor learning task.
16372948|NCT04168073|Experimental|High sodium diet|
16372949|NCT04168073|Experimental|Low sodium diet|
16372950|NCT04168060|Experimental|Crura Dissection|Participants with a visually detectable hiatal hernia at the time of sleeve gastrectomy procedure will undergo a crura dissection and hiatal hernia repair.
16372951|NCT04168060|Experimental|National Practice|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 2 participants will be treated to the national practice patterns of complete dissection of the curvature of the stomach without dissection of the crura.
16372952|NCT04168060|Experimental|Standard of Care|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 3 participants will undergo the institutional standard of care with the dissection of the crura.
16372953|NCT04168047|Other|Healthy volunteers|
16372954|NCT04168047|Other|Patients with insomnia|
16372955|NCT04168047|Other|Patients with irritable bowel syndrome|
16372956|NCT04168047|Experimental|Patients with irritable bowel syndrome and insomnia|
16372957|NCT04168034|Experimental|Experimental: iParent2Parent Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 2 to 3 months
16372958|NCT04168034|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iParent2Parent program
16372959|NCT04168021|No Intervention|Group 90 individuals, baseline assessment before intervention|Baseline Cognitive status assessment
16372960|NCT04168021|Experimental|Remote ischemic condition of the brain|Intermittent claudication induction on a daily basis for 1 month
16372961|NCT04168021|No Intervention|Late cognitive assessment|Late cognitive status assessment 6 months later
16372962|NCT04168008|Experimental|Adherence|Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for ART adherence and engagement in HIV care.
16372963|NCT04168008|Active Comparator|Parenting|Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
16372964|NCT04167995|Active Comparator|Patient with attention deficit hyperactive disorser|patients (n=40) will receive probiotic preparation once daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
16372965|NCT04167995|No Intervention|ADHD not receiving probiotics|ADHD patient (40) not receiving probiotics
16372966|NCT04167982|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid(ALA) cream for 30min. A repeat treatment was administered once weekly for a maximum of 5 times. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and after treatment.
16372967|NCT04167982|Active Comparator|conventional-dose isotretinoin group|Patients in the conventional-dose isotretinoin group were given oral isotretinoin 0.5 mg/kg daily for 6 months, and the cumulative dose was 90 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
16372968|NCT04167982|Active Comparator|low-dose isotretinoin group|Patients in the low-dose isotretinoin group were given oral isotretinoin 0.2 mg/kg daily for 6 months, and the cumulative dose was 36 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
16372969|NCT04167969|Experimental|Prostate cancer patients|Patients will receive an intravenous (IV) injection of approximately 5 mCi (+/- 10%) of PSMAtargeting C' dot tracer up to 48 hours before surgery. Patients will then undergo serial preoperative PET/MR imaging to help characterize the safety, biodistribution/pharmacokinetics, and dosimetry of this agent. To assess total radioactivity in whole blood/plasma and urine samples, as well as radioactive metabolites, blood and urine samples will be collected at approximately 30 min post-injection as well as before each imaging session
16372970|NCT04167956|Experimental|ultrasound combined with CT guided|ultrasound combined with CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
16372971|NCT04167956|Sham Comparator|CT guided|CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
16372972|NCT04167943|Experimental|indirect pulp capping|TheraCAL PT will be applied to affected dentin covering the pup.
16372973|NCT04167943|Experimental|Direct pulp Capping|TheraCAL PT will be applied to pinpoint pulp exposures surrounded by sound dentin.
16372974|NCT04167943|Experimental|Partial Pulpotomy|Pulp exposure will be enlarged to a depth of 1-3 mm by a sterile round diamond bur, and then TheraCAL PT will applied after hemostasis.
16372975|NCT04167943|Experimental|pulpotomy|complete removal of coronal pulp tissue will be attempted with the first encounter of pulp exposure. TheraCAL PT will be applied thereafter, after achieving hemostasis.
16372976|NCT04167917|Experimental|NTX-301|
16372977|NCT04167891||Patients admitted in the intensive care unit|Patients with return of spontaneous circulation after cardiac arrest regardless of initial rhythm, and admitted in intensive care unit for post cardiac arrest care
16372978|NCT04167878|Experimental|ACDF with 3D printed biodegradable cervical fusion cage|A resorbable cervical interbody cage made of PCL-TCP.
16372979|NCT04167878|Active Comparator|ACDF with PEEK cage|A structural PEEK cage with autologous bone.
16373433|NCT04164862|Active Comparator|ULTRASOUND GUIDED CANNULATION|Ultrasound cannulation of the great saphenous vein in infants
16372980|NCT04167865|No Intervention|Control group|All patients will be instructed to wear the device for 1 hours for 12 weeks after being instructed on how to use the vacuum bell. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
16372981|NCT04167865|Active Comparator|Exercise Group|In addition to the applications to the control group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PE. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
16372982|NCT04167852|Experimental|Treatment group|Subject to receive daily short message service (SMS) text message with a link to a mindfulness intervention.
16372983|NCT04167852|Experimental|Text group|Subject to receive daily text message but without the link to the mindfulness intervention.
16372984|NCT04167852|No Intervention|Standard of Care group|Subject will not receive any text message reminders or the mindfulness meditation intervention.
16372985|NCT04167813|Active Comparator|Active Treatment|"Participants randomised to the active treatment arm will take 8-24mg/day of ondansetron.
~The dose will increase from a single daily 8mg tablet (AM) (weeks 1 and 2), to 16mg/day (8mg twice daily) (weeks 3 and 4), with a further increase to 24mg/day (8mg AM, 16mg PM) (weeks 5 and 6). Dose escalation will be guided by telephone safety monitoring prior to each dose increase, and a face to face assessment at the end of week 6."
16372986|NCT04167813|Placebo Comparator|Matched placebo|"Participants randomised to the placebo treatment arm will take 8-24mg/day of matched placebo.
~The dose will increase from a single daily 8mg tablet (AM) (weeks 1 and 2), to 16mg/day (8mg twice daily) (weeks 3 and 4), with a further increase to 24mg/day (8mg AM, 16mg PM) (weeks 5 and 6). Dose escalation will be guided by telephone safety monitoring prior to each dose increase, and a face to face assessment at the end of week 6."
16372987|NCT04167800|No Intervention|Control group|All patients will be instructed to wear the device for 23 weeks for 12 weeks after being instructed on how to use the appropriate compression orthosis. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
16372988|NCT04167800|Active Comparator|Exercise Group|In addition to the applications to the first group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PC. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
16372989|NCT04167774|Experimental|Camrelizumab +nb-Paclitaxel|Participants receive Camrelizumab 200mg(3mg/kg for underweight patients) iv and nb-Paclitaxel 260mg/m2 iv every 3 weeks until disease progression or unacceptable toxicity
16372990|NCT04167761|Experimental|Ertugliflozin|
16372991|NCT04167761|Active Comparator|Glipizide|
16372992|NCT04167748|Experimental|PGT-A transfer|Transfer of single chromosomally normal (euploid) blastocyst after PGT-A
16372993|NCT04167748|No Intervention|Untested blastocyst transfer|Transfer of single untested blastocyst based on embryo morphology criteria.
16372994|NCT04167735|Active Comparator|Hearing Aid without Reverberation Canceller (no_RevC)|Hearing Aid without Reverberation Canceller (RevC)
16372995|NCT04167735|Experimental|: Hearing Aid Reverberation Canceller enabled (RevC_1)|Hearing Aid Reverberation Canceller enabled (RevC_1)
16372996|NCT04167722||Obese patients|BMI > 25
16372997|NCT04167722||Lean patients|BMI < or = 25
16372998|NCT04167709|Experimental|Allocated CHS nurses|Primary and secondary baseline data are collected from the allocated CHS nurses before the study starts. The CHS nurses are then given the educational intervention and afterwards primary and secondary outcomes are collected again.
16372999|NCT04167696|Experimental|Dose Escalation Dose Level 1|"in case of no dose limiting toxicity (DLT) and no replacement of patients, 3 consecutive patients at the dose of 1x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.
~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.
~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
16373000|NCT04167696|Experimental|Dose Escalation Dose Level 2|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 3x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.
~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.
~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
16373001|NCT04167696|Experimental|Dose Escalation Dose Level 3|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 1x10e9 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.
~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.
~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
16373002|NCT04167683||Cohort 1 - Patients referred to myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
16373003|NCT04167683||Cohort 2 - Patients referred to non myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
16373004|NCT04167670|Experimental|Vonoprazan dual therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
16373005|NCT04167670|Experimental|Vonoprazan triple therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
16373006|NCT04167670|Active Comparator|Lansoprazole triple therapy|Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
16373007|NCT04167657|Experimental|Arm1|Sintilimab monotherapy every 3 weeks, after a radiation targeting a single location no less than dose 30Gy/5f.
16373008|NCT04167644||Unfavorable outcome|80 patients with poor outcome were classified according to mRS score after discharge (mRS range from 3 up to 6).
16373009|NCT04167644||Favorable outcome|70 patients with better outcome were classified according to mRS score after discharge (mRS range from 0 up to 2) .
16373010|NCT04167631|Other|Multiparametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
16373012|NCT04167605||Breast cancer metastatic to bone|No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).
16373013|NCT04167605||Bone metastasis|No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins
16373014|NCT04167592|Active Comparator|Benzydamine Hydrochloride Group|Subjects who were allocated in benzydamine group would gargle with 15 of ml benzydamine hydrochloride 0.15% before sedation started.
16373015|NCT04167592|Placebo Comparator|Control Group|Subjects who were allocated in control group would gargle with 15 ml of water before sedation started.
16373016|NCT04167566|Other|Intervention Communities|All participants confirmed using rapid diagnostic test (RDTs) to be carrying the malaria parasite will be treated using artemisinin combination therapy (ACT) following the Ghana National Malaria Treatment Guidelines and followed up on days 1, 2, 3 during treatment as DOTs (Directly observed therapy) and on day 7 post treatment. The research team together with Community volunteers will be provided the treatment guidelines which specify the dosage for each treatment regimen. Participants who receive the treatment will be observed for five minutes to ensure that they retain the drug. Those who vomit within this period will have the treatment repeated.
16373017|NCT04167553|Experimental|HM15136|
16373018|NCT04167553|Placebo Comparator|Placebo|
16373021|NCT04167527|Experimental|Immediate mechanical thrombectomy(iMT)|Treatment initiation within 8 hours of symptom onset. Arterial puncture and revascularization will be performed using EmboTrap II Retriever. The procedure will be completed within two hours of arterial access.
16373022|NCT04167527|Active Comparator|Initial medical management (iMM)|Standard medical therapy based on current AHA (American Heart Association) guidelines. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
16373025|NCT04167501||Non exposed|Women born between 1972 and 1982 who were not exposed to HPV vaccination
16373026|NCT04167501||exposed|Women born between 1983 and 1993 who were potentially exposed to HPV vaccination
16373027|NCT04167488|Experimental|Actigraphic measurement|
16373028|NCT04167475|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
16373029|NCT04167475|Placebo Comparator|Placebo capsule|The participants consume one placebo capsule a day for 8 weeks
16373030|NCT04167462|Experimental|Arm A:BMS-986165 oral administration|
16373031|NCT04167462|Placebo Comparator|Arm B: Placebo oral administration|
16373032|NCT04167449|Active Comparator|Hydroponic Red Ginseng|
16373033|NCT04167449|Active Comparator|Conventional White Ginseng|
16373034|NCT04167449|Placebo Comparator|Placebo|
16373035|NCT04167436|Experimental|Prehabilitation|Patients receive multi-modal prehabilitation with exercise three times weekly, protein supplements, vitamin supplements, dietitian consultation and medical optimization prior to surgery. A minimum of four weeks.
16373036|NCT04167436|No Intervention|Standard of Care|Receives standard of care
16373037|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2017 American Thyroid Association Guideline.
16373038|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
16373039|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
16373040|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2017 American Thyroid Association Guideline.
16373075|NCT04167202|Active Comparator|RICE protocol for acute injury|RICE protocol include: (1) rest, (2) ice packs every 20 min every 3 hours (total of 8 sessions), (3) compression with elastic bandage for 24 h, and (4) leg elevation at all possible times of the injured area above the level of the heart
16373076|NCT04167189|Other|Observational study of prevalence in hard-to-treat ADHD|Subjects will be tested with lidocaine gel.
16373077|NCT04167176|Active Comparator|Erector spinae plane block|ultrasound guided ESP Block after anaesthesia induction
16373507|NCT04164329||Not exposed group|The non-exposed group, or control group, will be composed by the patients undergo PM implantation (without anesthesia)
16373041|NCT04167410|No Intervention|control group|We did not perform any intervention on the patients in the control group. These patients received routine glycaemia control and healthcare provided to diabetic patients undergoing surgical intervention in the department of general surgery.After receiving written informed consent, the first part of the data collection form on the socio-demographic and disease characteristics of the patients were completed face-to-face. The BG levels of the patients and the medications and insulin used for glycaemic control were recorded one night before surgery. The anxiety levels of the patients were evaluated on the morning of surgery using State-Trait Anxiety Inventory . The second part of the data collection form , which included information on glycaemic management, glycaemia levels and the medications and insulin used on the morning of surgery and during surgery, intensive care stay and the clinical period, was filled in by the nurse on the monitoring and anaesthesia forms.
16373042|NCT04167410|Experimental|intervention group|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. management was conducted by nurses in line with the protocol. Data on glycaemic management of the intervention group was similar to the control group.the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protoco
16373043|NCT04167397|Experimental|Single training|Initial training individually
16373044|NCT04167397|Experimental|Dyad training|Initial training in groups of 2
16373045|NCT04167397|Experimental|Triad training|Initial training in groups of 3
16373046|NCT04167397|Experimental|Tetrad training|Initial training in groups of 4
16373047|NCT04167384|Experimental|Hard nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
16373048|NCT04167384|Experimental|Soft nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
16373049|NCT04167371|Experimental|Biofeedback|
16373050|NCT04167371|Placebo Comparator|Placebo|
16373051|NCT04167358|Experimental|Participants receiving linerixibat|Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER [Group 1]) and Phase 3 study (212620 GLISTEN [Group 2]), will receive linerixibat.
16373052|NCT04167345|Experimental|VX-814|Subjects will be randomized to receive different dose levels of VX-814.
16373053|NCT04167345|Other|Placebo|Subjects will receive placebo matched to VX-814.
16373054|NCT04167332||NMIBC|"Patients diagnosed with primary non-muscle-invasive bladder (NMIBC) cancer.
~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.
~The clinical (demographic, operative and follow-up) and pathological data, and biosamples (blood, urine, bladder cancer tissue) of the patients will be collected in a completely anonymous way."
16373055|NCT04167319||Paclitaxel|Patients scheduled to receive paclitaxel as part of their standard treatment
16373056|NCT04167319||Oxaliplatin|Patients scheduled to receive oxaliplatin as part of their standard treatment
16373057|NCT04167306|Experimental|1) Varenicline + Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Investigational medicinal product (IMP) 2: Bupropion SR 150 mg
16373058|NCT04167306|Experimental|2) Varenicline + Placebo for Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Placebo capsule for IMP 2 (bupropion)
16373059|NCT04167306|Experimental|3) Bupropion + Placebo for Varenicline|Investigational medicinal product (IMP) 2: Bupropion SR 150 mg and Placebo capsule for IMP 1 (varenicline)
16373060|NCT04167306|Placebo Comparator|4) Placebo for Varenicline + Placebo for Bupropion|Placebo capsule for IMP 1 (varenicline) and Placebo capsule for IMP 2 (bupropion)
16373061|NCT04167293|Experimental|SBRT + PD-1 Arm|Patients assigned to this arm will receive SBRT followed by sintilimab. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
16373062|NCT04167293|Other|SBRT Arm|Patients assigned to this arm will receive SBRT alone. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
16373063|NCT04167280|Active Comparator|Ipratropium bromide|20mcg bronchodilator inhaler
16373064|NCT04167280|Placebo Comparator|placebo|matching bronchodilator inhaler
16373065|NCT04167267|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
16373066|NCT04167267|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
16373067|NCT04167254|Experimental|Sit Down and Play|
16373068|NCT04167254|No Intervention|Usual Care|
16373069|NCT04167241||Patients submitted to right pneumonectomy or bi-lobectomy|Consecutive, elective surgical patients submitted to right pneumonectomy or bi-lobectomy
16373070|NCT04167228||CRE infected patients treated with ceftazidime-avibactam|Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam
16373071|NCT04167228||CRE infected patients treated with best available treatment|Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment
16373072|NCT04167215|Experimental|perforator flap augmentation|Doppler probe is used to locate perforating vessels from the superior gluteal artery. . Flaps or lumbar artery flap will be designed to allow deepithelialization and dissection laterally to medially to identify the perforator . then sketolization is performed A gluteal pocket will then create for the augmentation flaps by undermining in a plane just superficial to the gluteal muscle extending to within 5 cm of the inferior gluteal crease. The deepithelialized flaps will then transpose inferomedially , and tacked to the fascia with several sutures.to be used as autologus buttock augmentation flap
16373073|NCT04167215|Experimental|fat injection|liposuction is performed firstly to parts where excess fat is exist and we will prepare the aspirated fat for injection as a graft in subcutaneous tissue of the buttock regoin
16373074|NCT04167202|Experimental|Hydrogen-rich water|Six 30-min ankle baths with hydrogen-rich water (one hydrotherapy every 4 hours)
16373115|NCT04166942|Experimental|Severe Hepatic Impairment (Group 4)|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10 to 14
16373078|NCT04167176|Active Comparator|Port site infiltration technique|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of Local anesthetic (LA) mixture that will be divided equally between port sites
16373079|NCT04167163|Active Comparator|Treatment group|"Those with clinical osteoporosis who elect ABL treatment.
~ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay."
16373080|NCT04167163|No Intervention|Comparator group|Those with clinical osteopenia who receive no treatment.
16373081|NCT04167150|Active Comparator|Dose 1|Participants consume 8 fl oz of tart cherry juice per day.
16373082|NCT04167150|Experimental|Dose 2|Participants consume 2 x 8 fl oz of tart cherry juice per day.
16373083|NCT04167137|Experimental|Arm 1: SYNB1891 Monotherapy|SYNB1891 is to be administered as an intratumoral injection in up to four 21-day cycles of escalating doses on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-4. The starting dose of SYNB1891 in the first cohort will be 1 × 10^6 live cells and will be increased in approximately 3-fold increments in subsequent cohorts until MTD determination. A de-escalation dose of 3 × 10^5 live cells is available if the starting dose is deemed not tolerable. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 on day 1 of each cycle for up to 24 months after initial dose of study treatment.
16373084|NCT04167137|Experimental|Arm 2: SYNB1891 in Combination with Atezolizumab|Once the MTD has been established in Arm 1, dosing of SYNB1891 will begin in Arm 2 at a 10-fold lower dose than the Arm 1 maximum tolerated dose (MTD) and will be increased in approximately 3-fold increments in subsequent cohorts until recommended Phase 2 dose (RP2D) determination. SYNB1891 is to be administered in the same manner and frequency as Arm 1. Atezolizumab will be administered in accordance with its recommended dose and schedule (1200 mg IV every 3 weeks) on day 1 of each of the 4 planned cycles. On days when atezolizumab and SYNB1891 are both administered, SYNB1891 will be administered first, followed by at least 1 hour of observation prior to the atezolizumab infusion. Combination doses will not be escalated above the SYNB1891 single-agent MTD established in Arm 1. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 and atezolizumab on day 1 of each cycle for up to 24 months after initial dose of study treatment.
16373085|NCT04167124|Experimental|multi-sensor lifestyle intervention|
16373086|NCT04167111|Active Comparator|Vitamin D 4000|At baseline, if subjects 25(OH)D levels are 12-19.9, they will be started on 4000 IU per day.
16373087|NCT04167111|Active Comparator|Vitamin D 2400|At baseline, if subjects 25(OH)D levels are 20-30, they will be started on 2400 IU per day.
16373088|NCT04167098|Experimental|Platelet-Rich Plasma|
16373089|NCT04167098|Active Comparator|Corticosteroid|
16373090|NCT04167098|Placebo Comparator|0.9% saline|
16373091|NCT04167085|Experimental|Doxycycline, then Placebo|Doxycycline for a period of 2 months followed by a 1-month washout period, and then placebo for a further 2 months period followed by a 1-month washout period.
16373092|NCT04167085|Experimental|Placebo, then Doxycycline|Placebo for a period of 2 months followed by a 1-month washout period, and then Doxycycline for a further 2 months period followed by a 1-month washout period.
16373093|NCT04167072|Experimental|Scheduled removal|This group involves patients who will have the LAMS removed immediately after all the stones have been cleared from the gallbladder
16373094|NCT04167072|Active Comparator|Observation|This group involves patients who will be followed closely for 1 year after all the stones have been removed from the gallbladder. These patients will keep the stent in place for 1 year and at that time the patients will be offered removal of the stent.
16373095|NCT04167059|Experimental|Waitlist-Control Group|The 'waitlist control' group will receive the 12-week non-intervention period first, followed by 12 week intervention period.
16373096|NCT04167059|Experimental|Immediate Treatment|The 'immediate treatment' group will receive the 12-week intervention period first, followed by 12 week non-intervention period.
16373097|NCT04167046||Control|Patients in this group did not receive an erector spinae block. Data are obtained retrospectively (years 2017 and 2018).
16373098|NCT04167046||Erector spinae block|Patients in this group receive an erector spinae block. Data will be obtained prospectively.
16373101|NCT04167007|Active Comparator|Group I|Gemcitabine at 1000 mg/m²
16373102|NCT04167007|Active Comparator|Group II|Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²
16373103|NCT04166994|Experimental|IMPACT Intervention|Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
16373104|NCT04166994|Other|Usual Care|No exercise or diet specialization.
16373105|NCT04166981|Active Comparator|Non-instrumented arm|Decompression with concomitant non-instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft.
16373106|NCT04166981|Experimental|Instrumented arm|Decompression with concomitant instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft and supplementary pedicle screw fixation.
16373107|NCT04166968|Sham Comparator|Control Group|neuromotor training and placebo stimulation
16373108|NCT04166968|Experimental|Group 1|neuromotor training and cathodal stimulation over the unaffected hemisphere
16373109|NCT04166968|Experimental|Group 2|neuromotor training and anodal stimulation over the affected hemisphere
16373110|NCT04166955|Experimental|(Intervention)|Participants will be provided with weekly messages including information for promoting physical activity.
16373111|NCT04166955|No Intervention|(Control)|Participants will be evaluated without providing any intervention.
16373112|NCT04166942|Experimental|Normal Hepatic Function (Group 1--Control)|Matched healthy subjects with normal hepatic function
16373113|NCT04166942|Experimental|Mild Hepatic Impairment (Group 2)|Subjects with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6
16373114|NCT04166942|Experimental|Moderate Hepatic Impairment (Group 3)|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9
16373118|NCT04166916|Active Comparator|Slow waves enhancing acoustic stimulation|During non-rapid eye movement (NREM) sleep, acoustic stimuli will be played to increase slow wave amplitude.
16373119|NCT04166916|Sham Comparator|SHAM: no application of acoustic stimuli|During NREM sleep no acoustic stimuli will be played.
16373120|NCT04166916|Active Comparator|Slow waves decreasing acoustic stimulation|During NREM sleep acoustic stimuli will be played to decrease/modulate slow waves amplitude in a dose-dependent way (e.g. less pronounced than arm 1).
16373121|NCT04166890|Experimental|NS Lower right molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
16373122|NCT04166890|Active Comparator|SD Lower Left molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
16373123|NCT04166890|Experimental|NS Lower left molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
16373124|NCT04166890|Active Comparator|SD Lower right molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
16373125|NCT04166877|Experimental|Magnesium Group|The magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours.
16373126|NCT04166877|Placebo Comparator|Control Group|The control arm will receive the same volume and rate of saline as if they were in the experimental group.
16373127|NCT04166864|Experimental|SCC-Determined TMS|
16373128|NCT04166851|Experimental|Open contest messages|Participants will view the top PrEP-promotion messages developed via an open contest.
16373129|NCT04166851|Active Comparator|Social marketing messages|Participants will view the PrEP-promotion messages developed via social marketing.
16373130|NCT04166838|Experimental|CD19 UCAR-T|
16373131|NCT04166825|Active Comparator|Long protocol|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day
16373132|NCT04166825|Active Comparator|Short protocol|Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg
16373133|NCT04166825|Active Comparator|Clomiphene citrate|Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle
16373134|NCT04166825|Active Comparator|Letrozole|Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle
16373135|NCT04166825|Active Comparator|Gonadotropins|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).
16373136|NCT04166812||patients with early COPD|diagnosis according to current GOLD recommendations
16373137|NCT04166812||patients at risk for COPD|no current diagnosis according to GOLD recommendations, but at risk for COPD
16373138|NCT04166799|Experimental|Mepitel Film Arm|Patients randomized to the Mepitel Film arm will receive the film for the entire duration of their radiation treatment and will be worn up to 2 weeks after completion of radiotherapy.
16373139|NCT04166799|No Intervention|Standard of Care Arm|Patients randomized to the Standard of Care arm will be instructed to use the institutional standard of care skin treatments for the entire duration of their radiation treatment and up to 2 weeks after completion of radiotherapy.
16373140|NCT04166786|Experimental|Testosterone + Ethanol|Subjects receive a 3-day treatment with testosterone in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
16373141|NCT04166786|Other|Testosterone placebo + Ethanol|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
16373142|NCT04166786|Other|Testosterone + Ethanol placebo|Subjects receive a 3-day treatment with testosterone in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
16373143|NCT04166786|Placebo Comparator|Testosterone placebo + Ethanol placebo|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
16373148|NCT04166760|Active Comparator|WHE (regular whey protein)|Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
16373149|NCT04166760|Experimental|speWHE (specific whey protein compound)|Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
16373150|NCT04166747|Experimental|Intervention Group|The participants in this group will receive virtual reality based intervention for 15 minutes at a time, twice in a week for six weeks.
16373151|NCT04166747|No Intervention|Control Group|The participants in this group will not receive virtual reality based intervention for six weeks.
16373186|NCT04166513|Experimental|Targeted tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions before.
16373152|NCT04166734|Other|Initial safety cohort|Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
16373153|NCT04166734|Other|Expansion cohort|An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
16373154|NCT04166721|Experimental|DKN-01 and atezolizumab|"DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d).
~During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.
~Atezolizumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 840mg on the first day of a two week cycle. (Day 1 q 14d) from cycle 2 onwards.
~In the first cycle of treatment, patients will be treated with only DKN-01, and following this they will be treated with both DKN-01 and atezolizumab"
16373155|NCT04166695|Experimental|Monolithic / facially veneered zirconia|Participants receive one monolithic / facially veneered zirconia fixed partial denture.
16373156|NCT04166695|Other|Completely veneered CoCr|Control group. Participants receive one completely veneered metal ceramic fixed partial denture.
16373157|NCT04166682|Placebo Comparator|Control Group|Routine care
16373158|NCT04166682|Experimental|Interventional Group|Home-based cardiac rehabilitation
16373159|NCT04166669|Experimental|Cohort 1|Drugs: APX001, itraconazole
16373160|NCT04166669|Experimental|Cohort 2|Drugs: APX001, rifampin
16373161|NCT04166656|Other|Arm A : Trumenba®: Standard vaccination|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
16373162|NCT04166656|Other|Arm B:Bexsero®: standard vaccination regimen|Two doses of 0.5 ml each at one month intervals
16373163|NCT04166656|Other|Arm C : Bexsero® Innovative vaccine strategy|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
16373164|NCT04166643|Experimental|WHHIP-PLUS|"Component I: Stakeholder Group Involvement:
~Component II: Environment Assessment:
~Component III: Organizational Changes To Reduce Job Stress:
~Component IV- Worker Health Behavior Change:"
16373165|NCT04166643|Active Comparator|Education only|Education
16373166|NCT04166630|Experimental|ICU Acquired Weakness Group|Participants with a score less than 48 on the Medical Research Council (MRC) Scale will be classified as having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
16373167|NCT04166630|Experimental|No ICU Acquired Weakness Group|Participants with a score of 48 or greater on the Medical Research Council (MRC) Scale will be classified as not having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
16373168|NCT04166617|Active Comparator|Conventional therapy|Conventional physical therapy for upper limb in stroke patients
16373169|NCT04166617|Experimental|Leap motion plus conventional therapy|Leap motion plus conventional physical therapy for upper limb in stroke patients
16373170|NCT04166604|Experimental|trifluridine/tipiracil|35mg/m² BID (PER OS) (one cycle every 4 weeks)
16373171|NCT04166591|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
16373172|NCT04166591|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
16373173|NCT04166578||Mydrane group|Patients were randomly selected to the group receiving intracameral 0.2 ml Mydrane (a solution of 1% lidocaine and 0.025% of adrenaline ) during phacoemulsification.
16373174|NCT04166578||Reference group|Patients were randomly selected to the group receiving intracameral a combination of intracameral solution of lignocaine 1% and adrenalin 0.025% (0.2 ml) during phacoemulsification.
16373175|NCT04166565|Experimental|Daratumumab/bortezomib/cyclophospamide/dexamethasone (daraVCD)|"Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
~Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
~Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).
~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
16373180|NCT04166539||Metallosis Patients|Patients who are being seen by surgeons for metal-related issues in the blood, pain, or revision surgery.
16373181|NCT04166539||Control Group|Patients who have had total hip or knee arthroplasty no less than 5-10 years ago, who have no symptoms.
16373182|NCT04166526||Group 1: Typically developing children|Participants of this group will not have a diagnosis of SCD. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
16373183|NCT04166526||Group 2: Children with SCD not receiving treatment|Participants of this group have a diagnosis of SCD, but do not receive chronic transfusions, gene therapy or bone marrow transplants. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
16373184|NCT04166526||Group 3: Children with SCD who have undergone gene therapy|Participants of this group have a diagnosis of SCD and have had gene therapy at least one month prior to enrollment. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
16373185|NCT04166526||Group 4: Children with SCD who have chronic transfusions|Participants of this group have a diagnosis of SCD and receive chronic transfusions. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
16373262|NCT04165993|Experimental|KN026 monotherapy|KN026 monotherapy
16373187|NCT04166513|Active Comparator|Active Control tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with active control tDCS for 10 therapy sessions.
16373188|NCT04166513|Experimental|Targeted tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions.
16373189|NCT04166513|Active Comparator|Active Control tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with active control tDCS for 10 therapy sessions.
16373190|NCT04166500|Experimental|Intervention|
16373191|NCT04166500|No Intervention|Control|
16373192|NCT04166487|Experimental|Pembrolizumab Cycles 1-2|"For the first two cycles, Pembrolizumab will be administered at a predetermined dose every 3 weeks.
~InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1, with return of results to the treating oncologist prior to Cycle 3 Day 1.
~At Cycle 3, patients will be re-registered per the inclusion criteria into 3 arms;
~PEMBROLIZUMAB Alone
~PEMBROLIZUMAB + Doublet Chemotherapy"
16373193|NCT04166487|Experimental|Pembrolizumab Alone, Cycle 3+|"- Following imaging assessment at Cycle 3, participants will continue pembrolizumab alone if the following responses are observed:
~Response of Partial Response/Complete Response
~Response of Stable Disease with plasma response
~Response of Progressive Disease without worsening cancer symptoms AND plasma response"
16373194|NCT04166487|Experimental|Pembrolizumab + Doublet Chemotherapy, Cycles 3+|"Following imaging assessment at Cycle 3, participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response, OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label, per treating oncologist.
~PEMBROLIZUMAB
~Chemotherapy multiple agents systemic
~PEMETREXED
~CARBOPLATIN
~PACLITAXEL"
16373195|NCT04166474|Experimental|Dolutegravir|
16373196|NCT04166448||Group 1: High risk IUGR patients|EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, EPF or PA<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
16373197|NCT04166448||Group 2: Low risk IUGR patients|EPF et PA>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
16373198|NCT04166435|Experimental|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
16373199|NCT04166422|Active Comparator|Conventional group|Conventional rehabilitation treatment
16373200|NCT04166422|Experimental|Experimental group|Virtual reality plus conventional rehabilitation treatment
16373203|NCT04166396|Experimental|A: Cystic fibrosis|Patients with CF will be randomly assigned to resveratrol or placebo.
16373204|NCT04166396|Experimental|A: Healthy Controls|Healthy controls will be randomly assigned to resveratrol or placebo
16373205|NCT04166396|Experimental|B: Cystic Fibrosis|Patients with CF will be randomly assigned to NR or placebo.
16373206|NCT04166396|Experimental|B: Healthy Controls|Healthy controls will be randomly assigned to NR or placebo
16373207|NCT04166383|Experimental|1/Arm 1|VB-111 and nivolumab
16373208|NCT04166370|Active Comparator|Standard of Practice|Current Standard of Practice
16373209|NCT04166370|Experimental|Strengthened Services and Social Behavioral Change (SBCC)|Increase referrals to health services, strengthen health services, and provide enhanced social and behavior change communication (SBCC)
16373210|NCT04166370|Experimental|Strengthened Services and SBCC plus Conditional Cash Transfer|Increase referrals to health services, strengthenhealth services, provide enhanced SBCC, as well as cash transfers that are conditional on a mother attending antenatal care (ANC) and monthly nutrition education SBCC group sessions.
16373211|NCT04166357||Respiratory and autonomic complications of GBS|"Early detection of respiratory failure is among the main challenges raised by the management of GBS. Careful monitoring by an experienced team of nurses and physicians is crucial. The classic signs of respiratory failure occur late, and the early manifestations consist only of tachypnea, tachycardia, air hunger, broken sentences, and a need to pause between sentences; later, use of the accessory respiratory muscles, paradoxical breathing, and orthopnea indicate severe diaphragmatic weakness.
~Autonomic dysfunction occurred in the affected patients, including cardiac arrhythmia, hypertension or hypotension, ileus, and urinary retention."
16373212|NCT04166344|Experimental|Intervention Group|Participants in the IG will be given free access to the HappyAir platform during a 6-month period. This platform combines online/offline content to help patients with chronic respiratory diseases monitor their symptoms and improve self-management. In addition to tailored information on their condition, participants will be encouraged to fill in daily data on their physical activity levels, symptomatology, use of rescue medication and mood. In children under 12 years, parents or caregivers will fill in this information. Patients will be asked to record their peak expiratory flow using an electronic peak flow meter twice daily and to fulfil the Asthma Control Questionnaire once a week. They will also have a device connected to their inhaler to record adherence to the medical treatment and will get daily reminders in their smartphones. Every patient will be assigned a respiratory coach who will monitor patient during the study and whom the patients can contact at any time.
16373213|NCT04166344|No Intervention|Control Group|Subjects in the CG will receive standard care consisting of periodic visitations at the Allergology or Paediatric Pulmonology Unit in their respective hospitals every 4 - 8 weeks according to their physician's criteria. In addition, patients and caregivers in both groups will receive one educational session regarding the correct use of their inhalers.
16373214|NCT04166331|Placebo Comparator|Control|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
16373215|NCT04166331|Experimental|Experimental|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
16373216|NCT04166318|Active Comparator|Arm A (standard-dose chemoradiation)|Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
16373217|NCT04166318|Experimental|Arm B (de-intensified chemoradiation)|Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
16373218|NCT04166305||Drug responders|60 patients are drug responders
16373219|NCT04166305||Drug resistant|60 patients are drug resistant
16373220|NCT04166305||The control|The control consists of 60 Age and gender matched healthy individual with negative past and family history of epilepsy and febrile convulsion.
16373221|NCT04166292|Experimental|Treated face|The device will be injected on V1 (D0) in the cheekbones (upper part of the cheek) for all subjects and in the chin for 20 subjects minimum and if needed (optional areas) in the temple, and facial oval (mandibular angle and border). A touch-up is possible in one or several of these areas on V2 (M1). Optional treated areas will be at the discretion of subjects and injectors.
16373222|NCT04166279|Experimental|Single rehabilitative Treatment|Patients treated within single rehabilitative protocol
16373223|NCT04166279|Experimental|Group rehabilitative Treatment|Patients treated within group rehabilitative protocol
16373224|NCT04166253|No Intervention|Control group|Control group of breast cancer patients will receive adjuvant AC chemotherapy
16373225|NCT04166253|Experimental|Vitamin D group|Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily
16373226|NCT04166240|Experimental|SAFER TRACKS Intervention|Each cluster starts receiving the intervention in sequence per cluster randomized control trial designs. Each cluster will participate in attending monthly coaching calls and compare their data on test results from pre-intervention to receiving the intervention.
16373227|NCT04166240|No Intervention|Non-intervention period|When the cluster is not in active intervention, they are in the non-intervention period. The amount of time that each site contributes to the intervention depends on which cluster they belong to.
16373228|NCT04166227|Active Comparator|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
16373229|NCT04166227|Active Comparator|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
16373230|NCT04166214|Experimental|tele-mentoring intervention|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
16373231|NCT04166201|Other|modified chevrel technique|hernioplasty done with double mesh modification of chevrels technique
16373232|NCT04166188|Experimental|Cadavers|"20ml of 0.01% methylene blue solution (50mg of methylene blue diluted in 0.9% saline 500ml) will be injected, simulating the LESP block technique: injection between the transverse process of the fourth lumbar vertebra (L4) and the erector muscle of the underlying spine.
~The injection will be performed with a Quincke 20G 100-150mm ultrasound-guided needle with a low-frequency curvilinear transducer (4-8 MHz - SonoSite) in the plane between the transverse process of L4 and the spinal erector muscle, bilaterally in each cadaver. by the same operator.
~After injection of the solution the cadavers will be submitted to posterior lumbar region dissection by an anatomist and analyzed the dispersion and impregnation of the blue solution. The anatomical structures with the dye dispersion will be photographed and stored."
16373233|NCT04166175|Active Comparator|group 1 botox group|48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions
16373234|NCT04166175|Active Comparator|group 2 lateral sphincterotomy group|48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position
16373235|NCT04166162|Experimental|Focus Group|The Focus Group consists of the participating parents who are BTC employees with child/children in the range of 8 to 16 years old. The Focus Group will receive a total of 6 weekly sessions of the TBD Intervention.
16373236|NCT04166162|Experimental|Social Development Strategy (SDS) Group|All participating BTC workers will be receiving SDS intervention for a minimum of 1 session.
16373237|NCT04166162|Experimental|Brief Intervention Motivational Interviewing (BIMI) Group|Participating 11 to 16 year old children of BTC employees will be receiving the BIMI intervention.
16373238|NCT04166162|Experimental|Business that Care (BTC) Coalition Group|Participating BTC employees who are selected by the respective directors of the participating companies to be part of the BTC Coalition will receive a total of 8 BTC training sessions in the space of 6 months.
16373239|NCT04166149||University of Maryland|Pancreas and pancreas kidney patients enrolled at University of Maryland. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
16373240|NCT04166149||University of Wisconsin|Pancreas and pancreas kidney patients enrolled at University of Wisconsin. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
16373241|NCT04166149||Georgetown University|Pancreas and pancreas kidney patients enrolled at Georgetown University. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
16373242|NCT04166136|Active Comparator|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
16373243|NCT04166136|Active Comparator|Transition from the Rearfoot to the Forefoot and Midfoot|"Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. The participants will receive verbal command Try to touch first with the middle region of the foot on the treadmill. In the last four sessions, feedback will be gradually removed. At the end of each session, participants will be asked a question about the naturalness of running the new foot touch pattern on the ground. A scale from 0 to 10 will be used, where 0 means very difficult to perform and 10 indicates easy pattern. The perception of pain will also be evaluated with the numerical scale of pain of 11 points (0 to 10), where 0 means no pain and 10 the greatest pain possible."
16373244|NCT04166136|Active Comparator|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
16373245|NCT04166110|Active Comparator|Physician's prescription|Antibiotic treatment duration according to physician, following the French national guidelines: 7 to 14 days.
16373246|NCT04166110|Experimental|Duration according to stability|"Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%).
~Minimum of duration of antibiotic treatment: 3 days."
16373247|NCT04166097|Experimental|Heart Smart Interventional Program|"Subjects participate in this 6-week intervention which include a weekly didactic session, with each week devoted to a different theme (food, exercise, etc). The intervention will follow the program outlined in the book Heart Smart for Women: Six S. T. E. P. S. in Six Weeks to Heart-Healthy Living."
16373248|NCT04166084|Active Comparator|Control Group|Patients in this group will receive active ROM exercises, 10 repeats X 3 times a day, 5 days a week for 6 weeks. All exercises will be performed at home .
16373249|NCT04166084|Experimental|Training group|I addition to active ROM exercises, patients in this group will also receive trunk stabilization exercises training for 45 minutes, 2 times a week for 6 weeks. All exercises sessions will be supervised by a physiotherapist in a clinic per week.
16373250|NCT04166071|Active Comparator|Naltrexone|
16373251|NCT04166071|Placebo Comparator|Placebo|
16373252|NCT04166058|Active Comparator|72 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
16373253|NCT04166058|Active Comparator|145 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
16373254|NCT04166058|Active Comparator|290 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
16373255|NCT04166045|Sham Comparator|Sham|Treatment at the bicep location
16373256|NCT04166045|Active Comparator|Verum|Treatment at the hand location
16373260|NCT04166006|Experimental|Experimental|"7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by Interleukin (IL) - 2 (IL-2), at a dose of 3 Million Units (MU), given by subcutaneous injection daily for five days (days 3-7). This constitutes a treatment cycle.
~Treatment cycles are repeated every 28 days up to a maximum of six cycles."
16373261|NCT04165993|Experimental|Concurrent chemotherapy and KN026|KN026 combined with docetaxol
16373264|NCT04165980|Sham Comparator|Sham transcranial direct current stimulation (sham tDCS)|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
16373265|NCT04165980|Active Comparator|Active transcranial direct current stimulation (activetDCS)|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
16373266|NCT04165967|Experimental|Tumor-infiltrating lymphocyte product (TIL) transfer|The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
16373267|NCT04165941|Experimental|DRI cell therapy|The only arm will receive the DRI modified gamma delta T cells following standard therapy with radiation and temozolomide chemotherapy concurrent.
16373268|NCT04165902|Experimental|steroid plus hyaluronic acid|steroid plus hyaluronic acid injection, one time per week, for 3 weeks
16373269|NCT04165902|Active Comparator|dextrose plus hyaluronic acid|dextrose plus hyaluronic acid injection, one time per week, for 3 weeks
16373270|NCT04165876|Active Comparator|Primary motor cortex|
16373271|NCT04165876|Active Comparator|Dorsolateral prefrontal cortex|
16373272|NCT04165876|Active Comparator|Multi-modal stimulation (DLPFC+M1)|
16373273|NCT04165876|Sham Comparator|Sham-stimulation|
16373274|NCT04165863|Experimental|A|treatment of the surgical wound healing process with Platelet-rich-fibrin in patients undergoing total knee replacement surgery
16373275|NCT04165863|Active Comparator|B|Gold standard treatment of the surgical wound healing process without Platelet-rich-fibrin in patients undergoing total knee replacement surgery
16373276|NCT04165850|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
16373277|NCT04165837|Experimental|Active|
16373278|NCT04165837|Placebo Comparator|Placebo|
16373279|NCT04165824|Experimental|MT-1186|
16373280|NCT04165811|Experimental|Aerobic Dance based Exercise|The exercise program will be administered 60 minutes, 2 days a week for 8 weeks. The exercise program will be created by physiotherapists as a group exercise program.
16373281|NCT04165811|Experimental|Counseling of physical activity|Physical activity counseling is aimed at increasing the physical activity levels of the individuals who are waiting for bariatric surgery in the preoperative period.
16373283|NCT04165785|Experimental|OPT IPL followed by MGX|"Subjects in the experimental arm will receive OPT IPL followed by MGX: OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
~Interventions:
~Device: IPL Procedure: MGX"
16373284|NCT04165785|Sham Comparator|Sham OPT IPL followed by MGX|"Subjects in the sham comparator arm will receive Sham OPT IPL followed by MGX: Sham OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
~Interventions:
~Device: Sham IPL Procedure: MGX"
16373285|NCT04165772|Experimental|Cohort 1|Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy.
16373286|NCT04165772|Other|Cohort 2|The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory
16373287|NCT04165759||patients|Patients with lung cancer who are candidates for surgery.
16373288|NCT04165746|Experimental|Enhanced Institutional Care|"Caregivers at institutions will participate in a caregiving training, called Video Feedback Intervention to Promote Positive Parenting (VIPP). During VIPP a trained interventionist meets with a caregiver and child in the home environment.
~The VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
16373289|NCT04165746|Experimental|Enhanced Foster Care|"Foster parents will be recruited, consented to background checks, and trained in Portuguese. Hired foster parents will supported and monitored by project social workers and psychologists from local Foster Care programs. Foster parents will received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Project social workers will consult weekly with US staff experienced in dealing with young children in foster care.
~Additionally, foster parents will participate in the VIPP caregiving training, in the same format as that described in the Enhanced Institutional Care Arm: the VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
16373290|NCT04165733||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
16373291|NCT04165720||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
16373292|NCT04165707|Experimental|Keyto intervention arm|Keyto device + app
16373295|NCT04165668||Dispatched lay responders|Nearby mobile phone located and dispatched lay responders who reached the place of the suspected OHCA before EMS and first responders (fire and police services).
16373296|NCT04165668||Non-dispatched lay responders|Nearby mobile phone located lay responders who have neither actively, nor technically responded due to either human or technical factors.
16373297|NCT04165655|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 10-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 10-weeks. The activity sessions will include semi-structures free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
16373298|NCT04165655|No Intervention|Waitlist control group|Participants in this group will not receive the 10-week group based activity intervention throughout the duration of this study. Participants will be able to participate in the 10-week activity intervention once this research has ended.
16373299|NCT04165629||Aspirin responders|On impedance aggregometry- Multiplate analyzer, if ASPI < 600 or ASPI/TRAP < 0.5
16373300|NCT04165629||Aspirin non-responders|On impedance aggregometry- Multiplate analyzer, if ASPI > 600 or ASPI/TRAP > 0.5
16373301|NCT04165629||Clopidogrel responders|On impedance aggregometry- Multiplate analyzer, if ADP < 500 or ADP/TRAP < 0.5
16373302|NCT04165629||Clopidogrel non-responders|On impedance aggregometry- Multiplate analyzer, if ADP > 500 or ADP/TRAP > 0.5
16373303|NCT04165616||Individuals with stroke|
16373304|NCT04165603|Active Comparator|5mg/kg of ICG, 24h before surgery|5mg/kg of indocyanine green, intravenously injection 24 hours before surgery
16373305|NCT04165603|Experimental|1mg/kg of ICG, 24h before surgery|1mg/kg of indocyanine green, intravenously injection 24 hours before surgery
16373306|NCT04165603|Experimental|5mg/kg of ICG, 48h before surgery|5mg/kg of indocyanine green, intravenously injection 48 hours before surgery
16373307|NCT04165603|Experimental|1mg/kg of ICG, 48h before surgery|1mg/kg of indocyanine green, intravenously injection 48 hours before surgery
16373308|NCT04165590|Experimental|Blood-stage infection of P.vivax|This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
16373309|NCT04165577|Experimental|OCD, Active TMS|Participants with OCD who receive active rTMS
16373310|NCT04165577|Sham Comparator|OCD, Sham TMS|Participants with OCD who receive sham rTMS
16373311|NCT04165577|Other|Healthy Control, Active TMS|Healthy control participants who receive active rTMS
16373312|NCT04165577|Other|Healthy Control, Sham TMS|Healthy control participants who receive sham rTMS
16373313|NCT04165564||Group 1 - Screening|Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)
16373314|NCT04165564||Group 2 - Incidental|Participants in this group will be > 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)
16373315|NCT04165551|Experimental|Probiotic|Volunteers will take 1 capsule per day containing 6x109 cfu of Lactobacillus BSL_PS71 in maltodextrin.
16373316|NCT04165551|Placebo Comparator|Placebo|Volunteers will take 1 capsule per day containing maltodextrin.
16373317|NCT04165538|Experimental|TEG group|
16373318|NCT04165538|No Intervention|Non-TEG group|
16373319|NCT04165525|Active Comparator|HelixAR Electrosurgical Generator (HEG)|Argon gas and high frequency electrical current ablation device
16373320|NCT04165525|Active Comparator|Conventional Electrosurgical Coagulation (CEC) Systems|Standard Bovie electrosugical device without argon gas
16373321|NCT04165512|Experimental|stellate ganglion block in breast cancer related lymphedema|US-guided stellat ganglion block will be applied to the patients with breast cancer related lymphedema twice at two-week intervals.
16373322|NCT04165499|Experimental|Combination of Plant Extracts (BSL_EP026)|Volunteers will take 1 capsule twice daily with the combination of the plant extracts (BSL_EP026).
16373323|NCT04165499|Placebo Comparator|Control|Volunteers will take 1 capsule twice daily with maltodextrin.
16373324|NCT04165486|Experimental|BIIB101 Low Dose|Participants will be administered BIIB101 low dose and matching placebo via intrathecal (IT) injection at regular intervals.
16373325|NCT04165486|Experimental|BIIB101 Medium Dose|Participants will be administered BIIB101 medium dose and matching placebo via IT injection at regular intervals.
16373326|NCT04165486|Experimental|BIIB101 High Dose|Participants will be administered BIIB101 high dose and matching placebo via IT injection at regular intervals.
16373327|NCT04165473|Experimental|Intervention Group|In a 6-module course, with four 3-day modules and two 5-day modules in the timeframe of one year, participants learn ways to strengthen their personal resources to establish effective social relationships and to develop skills as a social being. In between the module courses, the participants take 5 single sessions with an instructed trainer and document 10 conversations/social situations where they successfully applied the new skills.
16373328|NCT04165473|No Intervention|Intervention Group - Close Relationship|Individuals having a close relationship to participants of the Intervention Group
16373329|NCT04165473|No Intervention|Control Group|Individuals matched to the participants of the Intervention Group
16373330|NCT04165473|No Intervention|Control Group - Close Relationship|Individuals having a close relationship to participants of the Control Group
16373331|NCT04165460|Experimental|"A Intervention"|Psychoeducation, Relaxation, Cognitive Reestructuring and Problem Solving
16373332|NCT04165460|Active Comparator|"B Intervention"|Psychoeducation, Relaxation
16373333|NCT04165447|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display the label on any products.
16373334|NCT04165447|Experimental|Within-category labeling|Arm 2 displayed the label on the 20% of products that were lowest in calories per serving within each product category (termed Within-category Labeling, WC).
16373335|NCT04165447|Experimental|Across-category labeling|Arm 3 displayed the label on the 20% of all products that were lowest in calories per serving (termed Across-category Labeling, AC).
16373508|NCT04164316|Sham Comparator|Kinesio Tape No Tension|Kinesio Tape No Tension
16373338|NCT04165421|Experimental|Family intervention group|The intervention starts with a two hour group session for AF-patients and family members designed by the PhD student and the project nurses based on clinical guidelines of AF-management and theory from multifamily group intervention. Project nurses who are also Nurse specialists will facilitate knowledge to patients and family members about AF and how to support self-management in their daily living. Furthermore the (Family focused nursing) FFN intervention will consist of 3 -5 Family Strength Orientated Therapeutic Conversations (FAM-SOTC) accordingly to the needs of patient and the family. The FAM-SOTC conversations will be used as health promoting conversations and a way to enhance family health and psychological resilense
16373339|NCT04165421|No Intervention|Control group|"The control group will receive conventional care and treatment according to guidelines.
~Conventional care is characterized by ad hoc management as per usual standards of clinical care (with access to routine medical care, hospital care, and pharmacotherapy)."
16373340|NCT04165408|Experimental|Device Use|Only one arm
16373341|NCT04165395|No Intervention|Control group|The control group will receive the standard of care adopted at Hôpital du Sacré-Coeur de Montréal in terms of pressure ulcers prevention in the SCI population.
16373342|NCT04165395|Experimental|Intervention group|In addition to undergoing the identical standard-of-care as the control group, all patients in this group will receive a prophylactic five-layer foam dressing placed directly on the sacral area and a Heelmedix boot installed alternately on both legs
16373343|NCT04165382|Other|Pre-implementation study group|Preterm infants receiving NIV before the implementation of the guideline
16373344|NCT04165382|Other|Post-implementation study group|Preterm infants receiving NIV after the implementation of the guideline
16373345|NCT04165369||Patients with extended surgical exposures|Patients with extended surgical exposures requiring postoperative observation.
16373346|NCT04165356|Experimental|Mouth-rinse with clorhexidine|Mouth-rinse with 0.12% clorhexidine + tooth brushing twice daily
16373347|NCT04165356|Active Comparator|Mouth-rinse with bicarbonate isotonic solution|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate + tooth brushing twice daily
16373348|NCT04165343||Non-Alcoholic Fatty Liver Disease (NAFLD)|"Cohort: Patients with known Non-Alcoholic Fatty Liver Disease (NAFLD)
~All patients will undergo the following interventions:
~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood test"
16373349|NCT04165343||Healthy Control Subjects|"Cohort: Healthy controls
~All healthy subjects will undergo the following interventions:
~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood tests"
16373350|NCT04165330|Experimental|AL3818 plus nivolumab|"Part 1: All participants will be assigned to receive AL3818 capsules orally, once daily at sequential deescalating doses (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (on Day 1 and Day 15) for a single 21-day cycle. Participants may continue study treatment at the AL3818 cohort dose at investigator discretion.
~Part 2: All participants will receive AL3818 capsules orally, once daily at the RP2D determined from Part 1 (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (every 2 weeks starting on Cycle 1, Day 1) in 21-day cycles, for up to 24 cycles of total AL3818 therapy."
16373351|NCT04165317|Experimental|PF-06801591 + BCG induction and maintenance|PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
16373352|NCT04165317|Experimental|PF-06801591 + BCG induction only|PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
16373353|NCT04165317|Active Comparator|BCG induction and maintenance|Bacillus Calmette Guerin (induction and maintenance).
16373354|NCT04165304|No Intervention|control|the range of products offered by the vending machines remains unchanged
16373355|NCT04165304|Other|Intervention group 1|vending machines will be re-equipped to contain 60% drinks containing a maximum of 6.7g sugar/100ml, 20% drinks containing more than 6.7g sugar/100ml and 20% water
16373356|NCT04165304|Other|Intervention group 2|In the second intervention group, the vending machines offer 80% water and 20% products with a maximum of 6.7g sugar/100ml.
16373357|NCT04165291|Experimental|F4C|Participants randomized to the Fathers for Change (F4C) program.
16373358|NCT04165291|Active Comparator|BIP|Participants randomized to the Batterer Intervention Program (BIP).
16373359|NCT04165278|Experimental|Hyperthermic baths|On the first, third and fifth day of the first week, each subject will take the Hyperthermic Baths (HTB) at the same time. They will receive subjective measures before and after HTB. In the second week, no subjects accepted any intervention. On the fifteenth, seventeenth and nineteenth days of the third week, these subjects will receive two subjective measures without HTB in the same environment and scoring time as the experimental group.
16373360|NCT04165265|Experimental|Responders and Partial/non-responders|"The definition of responders to glucocorticoids is: Bowel movements ≤ 3/day without blood and normalization of CRP. In the study, this is supported by CC.
~The definition of non-responders is: Bowel movements > 8/day or 3-8/day and CRP > 45 mg/l. The decision if the patient is a non-responder is supported by CC.
~Questionnaires in CC and FC analysis with CalproSmart are performed every day until discharge or when classified as green in CC. After discharge questionnaires in CC and FC analysis are performed once every week in the following 7 weeks and a final registration at week 52. In case of disease relapse between week 7 and 52 registration in CC and FC analysis are performed on demand. Fecal samples for future use (biobank) and FC Elisa as well as blood samples are done before administration of IFX (week 2 and 6). At follow-up (week 52) it is considered whether the patient underwent colectomy or not."
16373361|NCT04165252||Term Birth|Delivery between 37-41 weeks of gestation
16373362|NCT04165252||Preterm birth|Delivery between 24-37 weeks of gestation
16373366|NCT04165226|Active Comparator|Low level light therapy (LLLT)|Low level light therapy using 808/915 nm infra red diode laser
16373367|NCT04165226|Active Comparator|Fractional CO2|Fractional carbon dioxide laser 10600 nm
16373368|NCT04165226|Active Comparator|Combined fractional CO2 and LLLT|Combined fractional CO2 laser and low level light therapy
16373369|NCT04165213|Experimental|Online training site|"Ten participating Trinity PACE Organizations will participate via webinar in a brief orientation/ training to the study and project logistics. Next, Trinity Health PACE organizations will be randomized into two groups using the re-randomization procedures described in the paragraph below; 5 PACE organizations will serve as the control site in which training will be provided via the traditional high intensity face-to-face.; 5 PACE organizations will serve as the comparison and be trained through the online training site. Prior to randomization, we will carefully examine PACE organizations on important variables such as size, location (urban; rural) percent of persons with dementia, and staff: participant ratio. In each site, one occupational therapist (OT) and one nurse (RN) will be trained (e.g., 5 OTs and 5 RNs in traditional sites; 5 OTS and 5 RNS in online training sites for a total of 10 OTs and 10 RNs or 20 health providers)."
16373370|NCT04165213|Experimental|COPE-PACE participant outcomes with online training|The efficacy of the COPE program training on PACE participant outcomes by type of COPE training will be evaluated in this arm. Each of the PACE organizations will enroll 5 persons with dementia and their caregivers in the study. This will yield 50 family dyads or 100 subjects (25 dyads in traditional training sites and 25 dyads in online training sites). Dyads will be followed for 4 months. Non-inferiority analysis will be used to assess whether dyads will yield the same or better outcomes regardless of how PACE staff were trained.
16373371|NCT04165200|Active Comparator|Patients receiving FMT capsules and ART|"ART Start at week 0 non-stop.
~FMT. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.
~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.
~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.
~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
16373372|NCT04165200|Placebo Comparator|Patients receiving placebo capsules|"ART Start at week 0 non-stop.
~Placebo capsules. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.
~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.
~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.
~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
16373373|NCT04165187|Experimental|BAT+Home exercise program|The patients in this group will participate in BAT for 3 days a week for 6 weeks in addition to home exercise program.
16373374|NCT04165187|Active Comparator|Home exercise program|The patients in the control group will perform home exercise program, two times a day, 7 days a week for 6 weeks.
16373375|NCT04165174|Experimental|PAS|PD-1:240mg,ivdrip,Q3W,begin with SBRT Apatinib:250mg,po,QD,begin with SBRT SBRT:6-10Gy/F,5-8F
16373376|NCT04165161|Other|superior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure
16373377|NCT04165161|Other|superior with 10 cmH2O positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
16373378|NCT04165161|Other|inferior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure
16373379|NCT04165161|Other|inferior with 10 cmH2O positive tele-expiratory pressur|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
16373380|NCT04165148|Experimental|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the Intelligent Flow System (iFS) AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
16373381|NCT04165148|Active Comparator|conventional laparoscopy|conventional laparoscopy
16373382|NCT04165135||Haemophilia A Without FVIII Inhibitors|
16373383|NCT04165122|Experimental|HDIT101 + Valaciclovir placebo|"Group A:
~Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days."
16373384|NCT04165122|Active Comparator|HDIT101 placebo + Valaciclovir|"Group B:
~Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days."
16373385|NCT04165109||Trial Ready Cohort|Non-demented adults with Down syndrome (DS)
16373394|NCT04165057|Active Comparator|Group OMT|Optimal muscle tension management
16373395|NCT04165057|No Intervention|Group Control|Conventional anesthetic management
16373396|NCT04165044|Active Comparator|L-PRF+CAF|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
16373397|NCT04165044|Active Comparator|CTG+CAF|Connective Tissue graft plus Coronally Advanced Flap
16373398|NCT04165031|Experimental|LY3499446 Phase 1|Participants given LY3499446 monotherapy orally.
16373399|NCT04165031|Experimental|LY3499446 + Abemaciclib Phase 1|Participants given LY3499446 and abemaciclib orally.
16373400|NCT04165031|Experimental|LY3499446 + Cetuximab Phase 1|Participants given LY3499446 orally and cetuximab intravenously (IV).
16373401|NCT04165031|Experimental|LY3499446 + Erlotinib Phase 1|Participants given LY3499446 and erlotinib orally.
16373402|NCT04165031|Experimental|LY3499446 Phase 2|Participants given LY3499446 monotherapy orally.
16373403|NCT04165031|Experimental|LY3499446 + Abemaciclib Phase 2|Participants given LY3499446 and abemaciclib orally.
16373404|NCT04165031|Experimental|LY3499446 + Erlotinib Phase 2|Participants given LY3499446 and erlotinib orally.
16373405|NCT04165031|Experimental|LY3499446 + Cetuximab Phase 2|Participants given LY3499446 orally and cetuximab IV.
16373406|NCT04165031|Active Comparator|Docetaxel Phase 2|Participants given docetaxel IV.
16373407|NCT04165005|Experimental|decentering group|"MBSR focused on a decentering component (i.e. individuals observe their feelings and thoughts as ephemeral events, with no reactivity, alongside with acceptance)."
16373408|NCT04165005|Experimental|guided imagery group|a group practicing in guided imagery sessions.
16373409|NCT04165005|No Intervention|control group|usual care group
16373410|NCT04164992|Experimental|not resectable pancreatic cancer patients|Patients with not-resectable pancreatic adenocarcinoma will be treated with endoscopic ultrasound radio frequency ablation
16373411|NCT04164979|Experimental|Cabozantinib and Pembrolizumab|Subjects receive Cabozantinib 40mg PO daily on days 1-21 and Pembrolizumab 200mg IV on day 1 every 21 days.
16373412|NCT04164966||New onset Type 1 Diabetes|
16373413|NCT04164966||Healthy Normal Volunteers (HNV)|
16373414|NCT04164953|Experimental|Dupuytren's|Surgical intervention as second-line surgery for the treatment of Dupuytren's disease.
16373415|NCT04164940||Age 21-30|Patients aged 21-30 when admitted to hospital and receiving brief alcohol intervention
16373416|NCT04164940||Age 31-40|Patients aged 31-40 when admitted to hospital and receiving brief alcohol intervention
16373417|NCT04164940||Age 41-50|Patients aged 41-50 when admitted to hospital and receiving brief alcohol intervention
16373418|NCT04164940||Age 51-60|Patients aged 51-60 when admitted to hospital and receiving brief alcohol intervention
16373419|NCT04164940||Age 61-70|Patients aged 61-70 when admitted to hospital and receiving brief alcohol intervention
16373420|NCT04164940||Age 71-80|Patients aged 71-80 when admitted to hospital and receiving brief alcohol intervention
16373421|NCT04164940||Age 81 and older|Patients aged 81 and older when admitted to hospital and receiving brief alcohol intervention
16373422|NCT04164927|Active Comparator|Kinesio Taping|Lymphatic correction method is applied via Kinesiotaping depending on the size of the leg two or three fan-cut tape was applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Certified Kinesio Tape practitioner applied Kinesiotaping on the second day (day 2) post-surgery and once a week.
16373423|NCT04164927|Active Comparator|Manual Lymphatic Drainage|A standardized 30-minute manual lymphatic drainage (MLD) treatment is applied to MLD group. On the second day (day 2) post-surgery, patients allocated to the MLD group underwent a standardized 30 minute MLD treatment on the operated limb by an experienced remedial massage therapist trained in delivering MLD.
16373424|NCT04164927|No Intervention|Control|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
16373425|NCT04164914|Experimental|Healthy subjects|Prebiotic administration
16373426|NCT04164901|Experimental|Vorasidenib|Vorasidenib 40 mg, continuous daily dosing.
16373427|NCT04164901|Placebo Comparator|Matching Placebo|Matching placebo 40 mg, continuous daily dosing. Participants who experience centrally-confirmed radiographic disease progression and who were receiving placebo will have the option to cross-over to vorasidenib, provided certain criteria are met.
16373428|NCT04164888|Experimental|CIVI 007, Dose A|Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice
16373429|NCT04164888|Experimental|CIVI 007, Dose B|SC injection of PCSK9 inhibitor- dose titration
16373430|NCT04164888|Experimental|CIVI 007, Dose C|SC injection of PCSK9 inhibitor- high dose given twice
16373431|NCT04164888|Placebo Comparator|Placebo|Placebo SC injection matching PCSK9 inhibitor given twice
16373434|NCT04164849|Experimental|5-ALA photopheresis|All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light or red light photopheresis. The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes. 5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
16373435|NCT04164836|No Intervention|control group|nose selection will be done by random table
16373436|NCT04164836|Experimental|rhinoscope group|nose selection will be done by rhinoscopy
16373437|NCT04164823|Experimental|Medical Taping|"Medical taping will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).
~Patients will be taped for four days. It will start at the beginning of pain associated to the menstruation."
16373438|NCT04164823|Active Comparator|Analgesic self-medication (OTC)|"Participants will use the usual analgesic self-treatment for primary dysmenorrhea.It will start at the beginning of pain associated to the menstruation.
~They will note the treatment indicating the analgesic and the dosage in a calendar."
16373439|NCT04164810|Experimental|Hydrotherapy|Hydrotherapy intervention will receive the treatment for 9 weeks (2 days per week) , resulting in a total of 18 sessions of Hydrotherapy. Each session will be held for a duration of 45 minutes to 1 hour.
16373440|NCT04164810|Active Comparator|Physical therapy|Physical therapy inthervention will have 18 standard physical therapy treatment sessions during 9 weeks. Each session will be held for a duration of 45 minutes to 1 hour.
16373441|NCT04164797|Experimental|treatment group|endostar : 7.5mg/m2/d,continuous infusion for 5 days in week 1、3、5、7, chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
16373442|NCT04164797|Active Comparator|control group|chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
16373443|NCT04164784|Experimental|therapeutic monitoring|"Based on the dietary habits from guidelines, the patients will be instructed to adjust the diet according to the ambulatory glucose profile (AGP) and the recorded log monitored by the continuous glucose monitoring system, thereby implementingtherapeutic monitoring."
16373444|NCT04164784|No Intervention|The control group|Patients will be given the basic diet, lifestyle instructions according guidelines.
16373445|NCT04164771|Experimental|Moringa Group|Participants will receive 5-7g of moringa diet daily for 6 weeks.
16373446|NCT04164771|Experimental|Aerobic training Group|Participants will receive 5-7g of moringa diet daily and will do 30 minutes of aerobic training daily for 6 weeks.
16373447|NCT04164771|Experimental|Moringa and Aerobic training|Participants will do 30 minutes of aerobic training daily for 6 weeks
16373448|NCT04164771|No Intervention|Control Group (T4)|Participants will not recieve any treatment
16373449|NCT04164758|Experimental|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
16373450|NCT04164758|Placebo Comparator|Placebo|Placebo encapsulated tablet
16373451|NCT04164758|Active Comparator|Quetiapine|Immediate release Quetiapine encapsulated tablets
16373452|NCT04164745|Experimental|Experimental: Anlotinib plus Pembrolizumab|
16373455|NCT04164719|Experimental|Treatment A|TNX-102 SL 2.8 mg, under fasting conditions
16373456|NCT04164719|Experimental|Treatment B|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fasting conditions
16373457|NCT04164719|Experimental|Treatment C|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fed conditions
16373458|NCT04164706|Experimental|HumiGard (plus standard care)|HumiGard device will be used to provide warmed humidified CO2 for insufflation during laparoscopic surgery. The device will be used alongside standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
16373459|NCT04164706|Sham Comparator|Standard Care (with sham HumiGard device).|"Patients will receive standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
~A sham HumiGard device will be used in the standard care arm. This will be the same HumiGard device as is in the intervention arm. However, the sham device will be turned off so that the gas delivered to the peritoneal cavity for insufflation is not heated or humidified. The sham device will deliver CO2 (as is the case for current standard practice in the hospital) through the HumiGard tubing. The sham device will look and sound the same as the active intervention arm where the HumiGard device is switched on and is delivering warm, humidified CO2 to the peritoneal cavity."
16373460|NCT04164693|Experimental|anticoagulant therapy group|during hospitalization, patients began to use low molecular weight heparin subcutaneously after arteriovenous fistula operation, once or twice a day, 4000iu-8000iu a day. After discharge, the patients took warfarin sodium tablets orally, 1.25mg on dialysis day, 2.5mg on non dialysis day, for a total course of 4 weeks.
16373461|NCT04164693|Other|non anticoagulant therapy group|no anticoagulant was used after operation, but both groups could take antiplatelet drugs.
16373462|NCT04164680||Patients with disorders of consciousness|
16373463|NCT04164667|Active Comparator|Self-Guided|Participant's do not receive text message direction from the VA Annie Text Messaging System. Participant's create their own method for accomplishing app-based exercise and mindfulness practice without detailed instructions.
16373464|NCT04164667|Experimental|Directed Messaging|Participant's receive text message directions from the ANNIE VA messaging system. The directed messaging system provides text message details of the participant's app-based meditation and exercise instructions.
16373465|NCT04164654|Experimental|Experimental-Immediate Access to the Nod app|The experimental group will have immediate access to all content in the Nod app and will be free to engage with it as much or as little as they like for four weeks. They will retain access to the Nod app for an additional four weeks.
16373466|NCT04164654|Other|Waitlist Control-Delayed Access to the Nod app|The waitlist control group will have full access to the Nod app approximately four weeks after the experimental group gains access.
16373467|NCT04164641|Experimental|Noraxon myoRESEARCH™ Software|All participants will be assigned to this group to receive study intervention.
16373468|NCT04164628|Experimental|Experimental Group: quality of life assessment|Women's quality of life will be evaluated.
16373469|NCT04164615|Experimental|GB221+ Capecitabine tablets|test drug+capecitabine
16373470|NCT04164615|Placebo Comparator|Placebo control + capecitabine tablets|placebo+capecitabine
16373471|NCT04164602||elderly patients with newly diagnosed diabetes|"Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)
~Control Group: without exposure; patients over 60 years, without diabetes."
16373472|NCT04164589|Placebo Comparator|Control|The Neuro-Adaptative Regulation will be carried out in the regime of switched off power supply in vulvo-perineal and sacral area.
16373473|NCT04164589|Experimental|Experimental|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacarl area.
16373474|NCT04164563|No Intervention|Control|Standard CAM boot treatment without Even-Up device.
16373475|NCT04164563|Experimental|Study|CAM boot treatment with Even-Up for contralateral extremity.
16373476|NCT04164537||Latina adolescents and parents|Latina adolescent young women experiencing depression and their parents will be recruited from community and primary care settings for one-time individual interviews.
16373477|NCT04164537||Healthcare providers|Primary care and mental health providers who commonly work with Latina adolescent patients will be recruited for focus groups from an integrated primary care clinic.
16373478|NCT04164524||Group; A|Open technique Hernioplasty for abdominal hernia in which 160 mg Gentamycin spray applied over the mesh
16373479|NCT04164524||Group; B|Open technique Hernioplasty for abdominal hernia in which no Gentamycin spray applied over the mesh
16373480|NCT04164511||Patients with post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy and receiving 2 daily ice creams for 2 weeks after surgery. Standard analgesic therapy available.
16373481|NCT04164511||Patients without post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy, not receiving any ice cream for 2 weeks after surgery. Standard analgesic therapy available.
16373482|NCT04164498|Experimental|Music exposure|will be exposed to music to investigate effects on preventing noise Adverse effects
16373483|NCT04164498|No Intervention|Control|no exposure to music
16373484|NCT04164485|Experimental|Functional collagen scaffold transplantation|
16373485|NCT04164485|Experimental|Autologous adipose cell transplantation|
16373486|NCT04164472|Experimental|Friend to Friend with Coaching|Program for relationally aggressive girls and their classmates delivered by school personnel who have been coached by study team.
16373487|NCT04164472|No Intervention|Control|Referral to school counselor as needed as per standard practice.
16373488|NCT04164459|Experimental|Xalost S|
16373489|NCT04164459|Active Comparator|Xalatan|
16373490|NCT04164459|Active Comparator|Taflotan-S|
16373491|NCT04164446|Placebo Comparator|Placebo|Two capsules containing starch and glucose, once per day, 60 days duration
16373492|NCT04164446|Active Comparator|Oil Palm Phenolics 250 mg|One capsule 250 mg active compound (OPP) and one capsule containing starch and glucose, once per day, 60 days duration
16373493|NCT04164446|Active Comparator|Oil Palm Phenolics 1000 mg|One capsule containing 1000 mg active compound (OPP) and one capsule starch and glucose, once per day, 60 days duration
16373494|NCT04164446|Active Comparator|Oil Palm Phenolics 2000 mg|Two capsules, 1000 mg active compound (OPP) each, once per day, 60 days duration
16373495|NCT04164433|Experimental|Workplace-based HIV Self-Testing|"i. Explain the procedure of conducting HIVST & interpret HIV self- test result to the user.
~ii. Demonstrate how to perform the self-test and how to interpret the self-test result.
~iii. Provide appointment card including information on linkage for HIV prevention services and further testing for diagnosis among those with a reactive self-test. Participants with a non-reactive self-test will be referred to HIV prevention services.
~iv. Provide a toll free number for continued consultation"
16373496|NCT04164433|No Intervention|Workplace-based standard HIV Testing Services (HTS)|Standard of care following the HIV testing algorithm .
16373497|NCT04164420|Experimental|Oral neuromuscular training and orofacial sensory-vibration|Intensive training with oral neuromuscular training and orofacial sensory-vibration stimulation for 5 weeks. The oral neuromuscular training is performed three times per session, and three times daily before eating. Regarding the orofacial sensory-vibration stimulation, the instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal by using a toothbrush.
16373498|NCT04164420|Active Comparator|Orofacial sensory-vibration stimulation|Orofacial sensory-vibration stimulation by using an electrical toothbrush for five weeks. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
16373499|NCT04164394|Placebo Comparator|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
16373500|NCT04164394|Experimental|Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
16373501|NCT04164381|Experimental|Robotic assisted intervention|Upper limb robotic therapy using a set of robotic and sensor based devices and exercises specifically selected to train cognitive functions.
16373502|NCT04164368|Experimental|R2-CHOP|Lenalidomide combined with rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
16373503|NCT04164355||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months
16373504|NCT04164355||Control Group|Healthy controls without previous surgery of radical prostatectomy.
16373505|NCT04164342|Experimental|Single ARM|This is an observational study, all patients will be followed at 3, 6 and 12 months by phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done).
16373506|NCT04164329||Exposed group|The exposed group will be composed by the patients that undergo CRT/ICD implantation (general anesthesia).
16373511|NCT04164290|Active Comparator|treatment group 2|Jiashen tablet, 0.94g, oral, once a day
16373512|NCT04164290|Active Comparator|treatment group 3|Jiashen tablet,1.88g, oral, once a day
16373513|NCT04164290|Active Comparator|treatment group 4|Jiashen tablet,2.82g, oral, once a day
16373514|NCT04164290|Active Comparator|treatment group 5|Jiashen tablet,3.76g, oral, once a day
16373515|NCT04164290|Active Comparator|treatment group 6|Jiashen tablet,4.23g, oral, once a day
16373516|NCT04164290|Placebo Comparator|control group 1|Jiashen placebo tablet,0.47g, oral, once a day
16373517|NCT04164290|Placebo Comparator|control group 2|Jiashen placebo tablet,0.94g, oral, once a day
16373518|NCT04164290|Placebo Comparator|control group 3|Jiashen placebo tablet,1.88g, oral, once a day
16373519|NCT04164290|Placebo Comparator|control group 4|Jiashen placebo tablet,2.82g, oral, once a day
16373520|NCT04164290|Placebo Comparator|control group 5|Jiashen placebo tablet,3.76g, oral, once a day
16373521|NCT04164290|Placebo Comparator|control group 6|Jiashen placebo tablet,4.23g, oral, once a day
16373522|NCT04164277|Experimental|Intervention|"The 16-week intervention includes three components:
~Caregiver Component. Facebook-based program including four new habit-formation tasks/week, and 3 face-to-face or virtual caregiver meetings: MSU research staff will lead the meetings at Head Start centers (weeks 1, 8, & 16) to connect caregivers to each other, offer health information, and discuss behavioral change strategies.
~Caregiver-Preschooler Learning. Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent privately to each caregiver , and caregivers will be asked to respond to the letters.
~Center-based Preschooler Component. Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators."
16373523|NCT04164277|No Intervention|Control|Control group will receive usual Head Start activities during intervention period. After post-intervention data collection, each control caregiver will receive all intervention supplies and a mini program including a face-to-face or virtual caregiver meeting and 1-week preschooler program. The caregiver meeting will cover contents on alternative cooking ingredients, food labels, and portion sizes.
16373524|NCT04164264|Experimental|Intravenous Propofol Infusion|Quantification of the dose of propofol required to produce loss of consciousness and apnea.
16373525|NCT04164251|Experimental|Inpatient screening mammography for non-adherent and high risk|All non-adherent women were offered inpatient screening mammography during hospitalization
16373526|NCT04164238|Experimental|Arm A|Toripalimab 240mg IV, every 3 weeks;
16373527|NCT04164238|Experimental|Arm B|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Carboplatin AUC 5, IV, Q3W
16373528|NCT04164238|Experimental|Arm C|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Cisplatin 25mg/m^2 IV,d1-d3, Q3W; 5-FU 3000mg/m^2 CIV 72h, Q3W
16373529|NCT04164225|Experimental|Qigong|Qigong exercises, focused on a mind-body connection
16373530|NCT04164225|Active Comparator|P.Volve|P.Volve exercises, focused on just physical movement
16373531|NCT04164212|Other|open label|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
16373532|NCT04164199|Experimental|Tislelizumab monotherapy|
16373533|NCT04164199|Experimental|Pamiparib Monotherapy|
16373534|NCT04164199|Experimental|Tislelizumab and Pamiparib Combination Therapy|
16373535|NCT04164199|Experimental|Tislelizumab and Pemetrexed Combination Therapy|
16373536|NCT04164199|Experimental|Tislelizumab and Capecitabine Combination Therapy|
16373537|NCT04164199|Experimental|Experimental: Pamiparib and temozolomide|
16373538|NCT04164173|Experimental|EzPAP|The patient will have EzPAP postoperative respiratory therapy as 3 x 10 breaths at a 1:4 ratio four times daily
16373539|NCT04164173|Experimental|Metaneb|The patient will have Metaneb postoperative respiratory therapy as 10 minutes Continuous Positive End Expiratory Pressure (CPEP) four times daily
16373540|NCT04164173|Experimental|Intermittent Positive Pressure Breathing (IPPB)|The patient will have Intermittent positive pressure breathing (IPPB) postoperatively for 10 minutes four times daily
16373541|NCT04164160|Experimental|integrated-care-model benefiting group|Chronic patients whose clinical and social data will be added in the integrated care model application software.
16373542|NCT04164147|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
16373543|NCT04164147|Active Comparator|Persona MC Retained PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Retained PCL prosthesis
16373544|NCT04164147|Active Comparator|Persona MC Sacrificed PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Sacrificed PCL prosthesis
16373545|NCT04164134||Retinoblastoma patients (children)|Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
16373546|NCT04164134||Controls (children)|Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
16373547|NCT04164134||Retinoblastoma survivors (adults)|"Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past.
~Blood will be collected and a short questionnaire has to be filled."
16373548|NCT04164134||Controls (adults)|Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
16373549|NCT04164134||Retinoblastoma survivors with Secondary primary malignancies|"Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy.
~Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery."
16373550|NCT04164121|Experimental|FLZ-150mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
16373650|NCT04163471||TR Band|Randomized to use of TR Band radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
16373551|NCT04164121|Placebo Comparator|FLZ-150mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
16373552|NCT04164121|Experimental|FLZ-600mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
16373553|NCT04164121|Placebo Comparator|FLZ-600mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
16373554|NCT04164121|Experimental|FLZ-900mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
16373555|NCT04164121|Placebo Comparator|FLZ-900mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
16373556|NCT04164108|Experimental|Intermittent feed participants|Patients admitted to medical ICU #1 (of 2 at our hospital) will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
16373557|NCT04164108|No Intervention|Control participants|Patients admitted to the medical ICU #2 (of 2 at our hospital) will receive usual care.
16373558|NCT04164095|Experimental|lappg|
16373559|NCT04164095|Active Comparator|ladgbi|
16373561|NCT04164069|Experimental|Prevention (dasatinib, mFOLFOX, bevacizumab)|Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
16373562|NCT04164056|Experimental|stimulation on the hippocampus|deep brain stimulation on the hippocampus
16373563|NCT04164056|Active Comparator|stimulation on the anterior nucleus of the thalamus|deep brain stimulation on the anterior nucleus of the thalamus
16373564|NCT04164043|Experimental|Recreational Therapy Wellness Recovery Program Group|All participants will enter a baseline data collection period for two weeks. They will then participate in a 12-week community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (WRP).
16373565|NCT04164030|Active Comparator|Nutrition Education Control|An evidence-based nutrition program entitled Eating Smart Being Active. Delivered in a group: Meets weekly for 2 hours for 9 weeks.
16373566|NCT04164030|Experimental|Nutrition Education +OT+Yoga|9 week group that meets twice a week for two hours each. Group occupational therapy and group yoga will be added to the nutrition program.
16373567|NCT04164017|Experimental|EUS-guided FNB with syringe suction|
16373568|NCT04164017|Active Comparator|EUS-guided FNB without syringe suction|
16373569|NCT04164004|Experimental|Early Implementation of Health Status Measurement|Patients in the early implementation arm will undergo KCCQ-12 assessment of patient-reported heart failure health status at each heart failure clinic visit beginning at the start of the trial. Assessment results will be available to clinicians when making treatment decisions during each clinic visit.
16373570|NCT04164004|Active Comparator|Delayed Implementation of Health Status Measurement|Patients in the delayed implementation will start receiving the KCCQ-12 assessment at each clinic visit beginning one year after randomization.
16373571|NCT04163991|Experimental|VIB4920 Dose1 (dosing interval 1)|Participants will receive intravenous (IV) infusion of VIB4920 Dose1 in dosing interval 1.
16373572|NCT04163991|Experimental|VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)|Participants will receive IV infusion of VIB4920 Dose1 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.
16373573|NCT04163991|Experimental|VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)|Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.
16373574|NCT04163991|Experimental|VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)|Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 4 and placebo matched to VIB4920 in dosing interval 5.
16373575|NCT04163991|Placebo Comparator|Placebo (dosing interval 1)|Participants will receive IV infusion of placebo matched to VIB4920 in dosing interval 1.
16373576|NCT04163978|Experimental|Nitric oxide releasing solution (NOSi)|DailyTopical sinus irrigation delivery of 240mL NOSi
16373577|NCT04163978|Active Comparator|Budesonide -saline|Daily Topical sinus irrigation delivery of 240 mL of 1 mg Budesonide-saline
16373578|NCT04163965|Other|Patients having a pacemaker|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology. Simultaneously standard routine ECG measurements will take place.
16373579|NCT04163952|Experimental|Treatment (talimogene laherparepvec, panitumumab)|Patients receive talimogene laherparepvec IM on day 1. Patients then receive talimogene laherparepvec IM and panitumumab IV over 30-90 minutes on day 22. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive up to 3 additional cycles of treatment per physician discretion.
16373580|NCT04163939|Experimental|Collar|This group will wear a cervical collar for at least 30 minutes per day, 5 out of 7 days of the week
16373581|NCT04163939|Placebo Comparator|Control|This group will not wear the cervical collar
16373582|NCT04163926|Experimental|Intervention group - Post op follow up by trained optometrist|Intervention group will have cataract follow up conducted by a trained optometrist 4-6 weeks after surgery in community clinic
16373583|NCT04163926|Active Comparator|Usual care group - Consultant led post op follow up|Follow-up at 4-6 weeks after surgery led by consultant ophthalmologist
16373750|NCT04162691||Malignant thymoma|
16373584|NCT04163913|Experimental|Cirvo Device|The CirvoTM device (Figure 1) is a lightweight, mobile, active, intermittent leg compression device placed on the calf of the leg, using hook and loop (e.g. Velcro) straps in the similar manner as commercially available intermittent leg compression devices The system utilizes an electro-mechanical drive system to intermittently compress the calf from the ankle toward the knee for a duration and compression level prescribed by the physician. The level of compression delivered by the CirvoTM therapy will be in the same range as existing devices which corresponds to the type of pressure applied by a blood pressure cuff.
16373585|NCT04163913|Active Comparator|ActiveCare DVT|A commercially available device was previously used to assess patient satisfaction with compression therapy for DVT prophylaxis as per standard of care.
16373586|NCT04163900|Experimental|A - NUC-1031 and cisplatin|725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
16373587|NCT04163900|Active Comparator|B - gemcitabine and cisplatin|1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
16373588|NCT04163887|Other|laparoscopic liver resection|Laparoscopy allows some surgical procedures to be performed through small incisions that enable the operator to access the abdominal cavity, often at the pubic area, and surgical instruments are introduced through these small incisions. This technique avoids large abdominal incisions and significantly reduces the duration of hospitalization.
16373589|NCT04163887|Other|open liver resection|standard of care
16373590|NCT04163874|Experimental|Fiasp-plus-Placebo with Full Carbohydrate Counting|Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
16373591|NCT04163874|Placebo Comparator|Fiasp-plus-placebo with Simple Meal Announcement|Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
16373592|NCT04163874|Active Comparator|Fiasp-plus-Pramlintide with Simple Meal Announcement|Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.
16373593|NCT04163861||1|"31 patients diagnosed as heart failure with preserved ejection fraction per ESC guidelines 2016 on the basis of history, clinical examination and investigations presenting to the department of cardiology, BSMMU were selected inclusion criteria
~Patients with regional wall motion abnormality in 2D echocardiography.
~Patients with moderate to severe valvular heart diseases.
~Patients with prosthetic valves and pacemakers.
~Patients with congenital heart diseases.
~Patients currently having arrhythmia such as atrial fibrillation on ECG screening during enrollment of patient.
~Patients with poor echo window.
~Patients who were not interested to take part in the study."
16373594|NCT04163861||2|31 normal healthy control subjects of similar age and sex of HFpEF subjects were taken. Normal echocardiograms will be defined as normal LV size and geometry, normal LVEF >55%). patients are free from cardiovascular diseases.
16373595|NCT04163848||Desflurane|desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows
16373596|NCT04163848||Sevoflurane|sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography
16373597|NCT04163835|Experimental|Low-dose Group|The intervention is half-dose of Wenxin Granules (1/2 normal dose).
16373598|NCT04163835|Experimental|Medium-dose Group|The intervention is medium-dose of Wenxin Granules (normal dose).
16373599|NCT04163835|Experimental|High-dose Group|The intervention is twice-dose of Wenxin Granules (twice normal dose).
16373600|NCT04163835|Placebo Comparator|Placebo Group|The intervention is a placebo.
16373601|NCT04163822||group with typical imaging changes in early stages|the BPD infants with typical BPD radiographic changes within the first 14 days after birht, including fibrosis and cyst.
16373602|NCT04163822||group with typical imaging changes in late stages|the BPD infants with typical BPD radiographic changes after 14 days of birht, including fibrosis and cyst.
16373603|NCT04163822||group without typical imaging changes|the infants meet the diagnosis criteria of BPD at postmenstrual age of 36weeks, but lack of typical radiographic changes.
16373604|NCT04163809|No Intervention|Control Group (no VR)|Patients will be randomly allocated to the control group, which receives no Virtual Reality (VR) during the regional anesthesia procedure.
16373605|NCT04163809|Experimental|Experimental Group (VR)|Patients will be randomly allocated to the the experimental group, which receives VR during the regional anesthesia procedure.
16373606|NCT04163796|Experimental|UPnRIDE Training|During each session, heart rate (HR), blood pressure (BP), total session time, time in standing posture, count of sit-to-stand positioning, total distance of overground movement, and rating of perceived exertion (Borg scale) for mobility skills will be monitored. At all study visits during the training period, participants will be asked to answer general health questions about the occurrence of any pressure ulcers or infections.
16373607|NCT04163783|Experimental|Arm A|Subjects will be administered a single oral dose of 320 mg of [14C]-BGB-3111
16373608|NCT04163770|Experimental|performance of pacemaker at time of implantation|
16373609|NCT04163770|Experimental|performance of pacemaker 6 months after implantation|
16373610|NCT04163757|Placebo Comparator|placebo|
16373611|NCT04163757|Active Comparator|crocin|
16373612|NCT04163731||stable patient, referred for a VO2 peak test|All stable patients above 18 years, referred for a VO2 peak test as part of their standard management in the Louis Pradel Hospital (Hospices Civils de Lyon, Lyon) and without acute clinical event in the last 3 months. All patients who accept to participate will undergo a self-questionnaire of 10 minutes.
16373613|NCT04163718|Experimental|Treatment with Umbralisib|
16373614|NCT04163705||Gram negative|"The presence of one or more positive samples will be considered positive blood cultures.
~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.
~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
16373649|NCT04163471||VasoStat|Randomized to use of VasoStat radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
16373751|NCT04162691||Benign thymoma|
16373615|NCT04163705||Gram positive|"The presence of one or more positive samples will be considered positive blood cultures.
~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.
~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
16373616|NCT04163692|Experimental|Exercise Group|Progressive relaxation exercises (PRE) as 1 day supervised and 3 days home based program in a week, for 6 weeks
16373617|NCT04163692|No Intervention|Control Group|Information was provided about pain and its treatment and the importance of relaxing exercises without any intervention, up to 6 weeks.
16373618|NCT04163679|Experimental|Vaginal Preparation|In addition to standard care, subjects will undergo vaginal preparation (VP). A VP kit includes sponge sticks and sponges soaked in a povidone-iodine 10% solution.
16373619|NCT04163679|Sham Comparator|Standard Infection Procedures|The very staff will follow hospital protocols for the cesarean delivery. The subject and the infant will be provided care in accordance with current medical standards and be discharged at the discretion of the attending physician.
16373620|NCT04163666|Experimental|Mirror therapy group|The mirror therapy group will receive a treatment based on this therapy, combined with task-oriented motor learning.
16373621|NCT04163666|Experimental|Cognitive therapeutic exercise group|The cognitive therapeutic exercise group will receive a treatment based on this therapy, combined with task-oriented motor learning.
16373622|NCT04163666|No Intervention|Control Group|No additional intervention with the participants of this group will be completed.
16373623|NCT04163653||Fontan Group|Fontan patients operated at the two centres between 1991 and 2014.
16373624|NCT04163653||Healthy Control Group|Age, gender and weight matched healthy controls.
16373625|NCT04163640|Experimental|Intervention Group|Patients randomized to this group will receive the intra-ovarian platelet rich plasma injection
16373626|NCT04163640|No Intervention|Control Group|Patients randomized to this group will not receive the intra-ovarian platelet rich plasma injection
16373627|NCT04163614|No Intervention|Control|Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.
16373628|NCT04163614|Experimental|IBPS (Intradialytic Blood Pressure Slope) Arm|IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
16373629|NCT04163588|Active Comparator|Standard therapy|intravenous loop diuretics as recommended by current guidelines plus placebo
16373630|NCT04163588|Experimental|SNB|loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
16373631|NCT04163575|Experimental|experimental:1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
16373632|NCT04163575|Experimental|experimental:2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
16373633|NCT04163575|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
16373634|NCT04163562|Experimental|INP20 (Oral Immunotherapy)|
16373635|NCT04163562|Placebo Comparator|Placebo|
16373636|NCT04163549|Experimental|Safe at Home Cycle 1|The experimental arm will receive the Safe at Home program which is a community-based discussion group series aiming to prevent and respond to intimate partner violence and child maltreatment in conflict-affected communities. It includes once weekly, single-sex discussion groups with coupled men and women and once monthly family discussion groups with couples and children. During the weekly sessions men and women reflect critically and engage in dialogue related to gender, power, and privilege, learn about the causes and consequence of violence against women and children and gain skills in stress management, psychosocial support and positive parenting strategies. Family sessions focus on improving relationship quality and shared decision-making among partners and participation of children in family decision-making.
16373637|NCT04163549|No Intervention|Safe at Home Cycle 2|During the period of the study, this group will not receive an intervention. Rather, this arm will receive the Safe at Home program after endline data collection is completed for a waitlisted group.
16373638|NCT04163536|Active Comparator|cortisteroids arm|
16373639|NCT04163536|Placebo Comparator|placebo arm|
16373640|NCT04163523|Experimental|Treatment Sequence 1|5 Subjects received Period 1- 320 mg BGB-3111 administered after an overnight fast; Period 2- 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 3 - Day 15: 320 mg BGB-3111 administered after Low Fat/Calorie Meal
16373641|NCT04163523|Experimental|Treatment Sequence 2|5 Subjects received Period 1 - Day 1: 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 2- Day 8: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 3- Day 15: 320 mg BGB-3111 administered after an overnight fast
16373642|NCT04163523|Experimental|Treatment Sequence 3|Approximately 5 Subjects receive Period 1-Day 1: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 2-Day 8: 320 mg BGB-3111 administered after an overnight fast; Period 3- Day 15: 320 mg BGB-3111 administered after High Fat/Calorie Meal
16373643|NCT04163510|Experimental|Reading Intervention Group|A group of parents and their children will participate in this single arm, pre-/post-intervention study. This 10-week study will include 10 sets of parents of low-reading elementary school children, recruited from Harlem Grown Community Center. Intervention will be implemented in a 9-week period, with data collection during the first intervention week and one week post-intervention. Three large-group sessions will be held in a central location (at Harlem Grown Community Center), to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. The reading program will help parents identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading.
16373644|NCT04163497|Experimental|Diary reading|
16373645|NCT04163497|No Intervention|No diary reading|
16373646|NCT04163484||Stable coronary artery disease|
16373647|NCT04163484||ST-elevation myocardial infarction|
16373648|NCT04163484||Non-ST-elevation myocardial infarction|
16373651|NCT04163458|Experimental|MENOPUR liquid|MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing can be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose will be 450 IU/day and the minimum dose will be 75 IU/day. The dosing can continue for a maximum of 20 days.
16373652|NCT04163458|Active Comparator|MENOPUR powder|MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing can be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose will be 450 IU/day and the minimum dose will be 75 IU/day. The dosing can continue for a maximum of 20 days.
16373653|NCT04163445|Active Comparator|Depuy Attune|Subjects will have been implanted with the Depuy Attune PCR TKA
16373654|NCT04163445|Active Comparator|MicroPort Medial Pivot|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
16373655|NCT04163432|Experimental|Arm A: Chemo-Immuno|ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
16373656|NCT04163432|Experimental|Arm B: Immuno-Chemo|ArmB receives immunotherapy on D1 and chemotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
16373657|NCT04163419|Experimental|Arm A (treatment)|Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
16373658|NCT04163419|Placebo Comparator|Arm B (placebo then treatment)|Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
16373662|NCT04163393|Experimental|R-One|Patients treated with robotic assistance
16373663|NCT04163380|Experimental|Early Follicular Phase (EFP)|
16373664|NCT04163380|Experimental|Late Follicular Phase (LFP)|
16373665|NCT04163380|Experimental|Early Luteal Phase (ELP)|
16373666|NCT04163380|Experimental|Late Luteal Phase (LLP)|
16373667|NCT04163367|Active Comparator|Intervention as usual|The social services standard process for families reported for violence or abuse towards children. The standard process always includes a formal investigation of the suspected violence/abuse. The investigation may or may not result in voluntary or mandatory interventions, such as family support or parent training.
16373668|NCT04163367|Experimental|Intervention as usual + Safer Kids|The procedure in this arm is exactly the same as in the active comparator arm (i.e., investigation that may be followed by interventions). In addition, the general parent training program Safer Kids is offered during the investigation to all participants in this arm.
16373669|NCT04163354|Active Comparator|NaF varnish|Application of a 5% NaF varnish (Duraphat, Colgate-Palmolive Ltd, Waltrop, Germany) on the occlusal surfaces of primary second molars and all other teeth, every 3 months during the study period;
16373670|NCT04163354|Experimental|GI sealant|Glass ionomer sealant (GC Fuji VII® (pink)) on all primary second molars included in the studies, with no further repair/replacement of the sealant
16373671|NCT04163341|Experimental|CETA protocol|
16373672|NCT04163341|No Intervention|Enhanced Usual Care|
16373673|NCT04163328|Experimental|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
16373674|NCT04163328|Placebo Comparator|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
16373675|NCT04163315|Experimental|dMRI, fMRI and electrocorticography|With this exploratory pilot study, the investigator propose a multimodal evaluation of the structural and functional connectivity of patients with brain tumours, in order to better understand the tumor-induced lesion mechanisms on brain connectivity as well as the brain plasticity mechanisms that the brain develops to maintain a level of overall function neurological. The investigator hope to obtain multimodal brain mapping of locally brain-damaged patients, with a view to improving onco-functional neurosurgical practices.
16373676|NCT04163302|Experimental|CD19+ Lymphoma|This study is to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with Relapsed/Refractory B Cell Lymphoma.
16373677|NCT04163289|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation combined with approved standard of care treatment with nivolumab and ipilimumab.
16373678|NCT04163276||Group 1|20 patients without anomaly of brain metabolism
16373679|NCT04163276||Group 2|20 patients with Alzheimer's disease
16373680|NCT04163263|Experimental|Cohorts 1-3: BOS-356|Twice daily application of BOS-356 0.1%, 0.4%, and 0.7% gel in Cohorts 1, 2, and 3, respectively
16373681|NCT04163263|Placebo Comparator|Cohorts 1-3: Vehicle|Twice daily application of vehicle gel
16373682|NCT04163263|Experimental|Cohort 4: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
16373683|NCT04163263|Placebo Comparator|Cohort 4: Vehicle|Twice daily application of vehicle gel
16373684|NCT04163263|Experimental|Cohort 5: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
16373685|NCT04163263|Placebo Comparator|Cohort 5: Vehicle|Twice daily application of vehicle gel
16373686|NCT04163250||Patients with ACS undergoing cardiac catheterization|"Adults with moderate / high risk acute coronary syndrome undergoing coronary intervention.
~The sample will be selected consecutively, including patients admitted to the Cardiac Coronary Unit and who require a radiological test with intra-arterial IC administration, for diagnostic or diagnostic / therapeutic purposes"
16373687|NCT04163237|Experimental|PD-1 & Sorafenib|
16373688|NCT04163237|Other|Sorafenib|
16373689|NCT04163211||Group 1|Patients with complicated appendicitis who had a drain inserted
16373690|NCT04163211||Group 2|Patients with complicated appendicitis who did not have a drain inserted
16373691|NCT04163198|Experimental|Insufflation optimisation|Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.
16373692|NCT04163198|Experimental|Exsufflation optimisation|Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF
16373693|NCT04163185|Experimental|AXS-07|Taken once upon migraine
16373694|NCT04163185|Placebo Comparator|Placebo|Taken once upon migraine
16373695|NCT04163172|Active Comparator|Elbow hemiarthroplasty|The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.
16373696|NCT04163172|Active Comparator|Open reduction and internal fixation|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.
16373697|NCT04163146|Experimental|Healthy children and adolescents|Healthy children and adolescents aged 6 to 18 years (N=100) for the assessment of normal PEF and FEV1 variability.
16373698|NCT04163146|Experimental|Asthmatic children and adolescents|Children and adolescents aged 6 to 18 years with diagnosed asthma (N=100) for the assessment of PEF and FEV1 variability in asthmatics.
16373699|NCT04163133|Experimental|two days delay of trigger group|Two days later of trigger than regular trigger timing day (three follicles reach 17mm) .
16373700|NCT04163133|No Intervention|regular trigger group|regular trigger timing when three follicles reach 17mm bilateral.
16373701|NCT04163120|Experimental|Intervention|In this single arm study subjects follow a low calorie mediterranean ketogenci diet
16373702|NCT04163107|Experimental|Combination treatment of carfilzomib/dexamethasone/HCQ|
16373703|NCT04163094|Experimental|Treatment arm|Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.
16373704|NCT04163081|Experimental|Quit Card Intervention (QCI)|Study intervention group.
16373705|NCT04163081|No Intervention|Usual Care (UC)|Study control group.
16373706|NCT04163068||Interview with researcher|All participants will participate in an interview with a researcher
16373707|NCT04163055|No Intervention|Standard of Care|Wounds will be assessed using the Clinical Signs and Symptoms Checklist (CSSC). After initial assessment, a white-light (WL) photo will be taken of the wound. The wound bed will be prepared as indicated by clinical staff based on standard of care (SoC), including irrigation and debridement. A second WL image will be taken and a swab/biopsy will be obtained from the wound. Wounds will be dressed based on SoC.
16373708|NCT04163055|Experimental|Autofluorescence guided Standard of Care|Wounds will be assessed by autofluorescence (AF)-guided SoC. A baseline WL and AF photo will be taken of the wound. AF images will guide SoC including targeted debridement of areas of bacterial growth (AF+) and targeted sampling in areas of residual bacterial growth post-debridement. If no bacterial AF is detected, sample will be obtained from the wound center by curettage technique. If AF is detected, AF-guided debridement will be repeated and additional images will be obtained until 1) no AF is detected or 2) further debridement is not medically advised. After wound bed preparation, a second set of WL and AF images will be taken. Wounds will be dressed as per SoC. At all visits, samples will be sent for microbiology analysis. At 6- and 12-week visits (or any other scheduled visits in between), microbiology reports will be shared with clinicians if they were not collected outside of SoC.
16373709|NCT04163042|Experimental|Group A: Videoconferencing intervention|Participants allocated to group A will receive a behavioural support intervention via real-time videoconferencing.
16373710|NCT04163042|No Intervention|Group B: Usual care|Participants allocated to group B will receive usual care and will be advised to continue with their regular activities of daily living.
16373711|NCT04163029||preoperative oral care|
16373712|NCT04163016|Experimental|Pharmacokinetics Sampling|"This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label.
~From all study participants blood samples will be drawn for pharmacokinetics during the study."
16373713|NCT04163003|Experimental|TAPAS|Participants will participate in the TAPAS intervention, which will consist of one in-person engagement session with a therapist and 8 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week.
16373714|NCT04163003|Experimental|Sleep monitoring only, then TAPAS|Participants will participate in sleep monitoring only first, then participate in the TAPAS intervention. First, participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.TAPAS will consist of one engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the targeted intervention in this arm.
16373715|NCT04162990|Experimental|Lifestyle remodeling|
16373716|NCT04162990|Active Comparator|Does Comparator: regular treatment|
16373717|NCT04162977|Experimental|High-risk youth|The 23-item Substance Use Risk Profile Scale (SURPS) will be used to identify high-risk adolescents who enter the intervention trial. Adolescents who score high on one of SURPS subscales (i.e., high-risk youth) will be invited to participate in two group-based intervention sessions which target their dominant personality profile. The criterion for high scores on SURPS personality traits are determined based on norms from high-risk adolescents in the same age range who participated in previous trials on personality-targeted interventions.
16373718|NCT04162951|Experimental|Ordinary approach group|The patients in this group will receive ordinary ultrasound-guided thoracic paravertebral block. by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
16373786|NCT04162431||non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
16373719|NCT04162951|Experimental|Retro-laminar approach group|The patients in this group will be receive real ultrasound-guided Retrolaminar thoracic paravertebral block by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
16373720|NCT04162938|Experimental|Patient-Centered Electronic App Group|Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
16373721|NCT04162938|No Intervention|Reference Group|Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
16373722|NCT04162925|Experimental|Cancer screening cohort|"All women in this study to be evaluated for cancer screening utilization rates (breast, colon and oral cancers) and cancer screening perspectives of these hospitalized women.
~The intervention will be a cancer screening education."
16373723|NCT04162912|Experimental|Experimental group|Participants in the experimental group will receive a MotivationaI Interviewing tailored ACP programme.
16373724|NCT04162912|No Intervention|Control group|The participants in the control group will receive usual care offered by the palliative care team under study and its affiliated day care centres, home care team and outpatient clinics.
16373725|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
16373726|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
16373727|NCT04162899|Active Comparator|Placebo Comparator: Placebo|Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.
16373728|NCT04162886|Experimental|Exercise Group|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
16373729|NCT04162886|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
16373730|NCT04162873|Experimental|Celecoxib Arm|Patients receive celecoxib PO or via feeding tube BID starting 5 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
16373731|NCT04162873|Placebo Comparator|Placebo Arm|Patients receive placebo PO or via feeding tube BID starting 5 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
16373732|NCT04162860|Experimental|minimally invasive esophagectomy with preemptive ENP|Patients will undergo a standard total minimally invasive transthoracic Ivor Lewis esophagectomy with preemptive ENP. After completion of the esophago-gastric anastomosis, an Eso-SPONGE® system will be inserted via an intraoperative gastroscopy. ENP will be carried out upon completion of the esophago-gastrostomy, but no later than 12 hours after the surgical intervention. Postoperatively, secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg. ENP will remain for 4 days and will be monitored with clinical parameters.
16373733|NCT04162860|No Intervention|Standard minimally invasive esophagectomy|Patients in the control group will undergo a standard minimally invasive transthoracic Ivor Lewis esophagectomy without preemptive ENP.
16373734|NCT04162847|Experimental|Mobile Coached Intervention|This group will receive access to the mobile intervention for 6 months. They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for. If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with. They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for. After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
16373735|NCT04162847|No Intervention|Referral to Counseling Center|This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
16373736|NCT04162834|Experimental|Papaverine group|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
16373737|NCT04162834|Active Comparator|Normal saline group|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
16373738|NCT04162821|Experimental|60mg group|
16373739|NCT04162821|Experimental|90mg group|
16373740|NCT04162821|Experimental|120mg group|
16373741|NCT04162795|Experimental|Loratadine chewable tablet|Participants received one dose of loratadine chewable tablet to chew completely before swallowing.
16373742|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod Dose A|
16373743|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod Dose B|
16373744|NCT04162769|Placebo Comparator|12-Week Double-Blind Treatment Period: Placebo|
16373745|NCT04162769|Experimental|52-Week Open-Label Extension Period: Etrasimod Dose B|
16373746|NCT04162743|Active Comparator|Trazodone|take trazodone 100mg hs
16373747|NCT04162743|Placebo Comparator|Placebo|take placebo pill hs
16373748|NCT04162717|Experimental|The Effect of Telephone Symptom Triage Protocols|"Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles.
~Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later."
16373749|NCT04162717|No Intervention|Control group|The control group received standard nursing care applied at the hospital
16373752|NCT04162678||Diagnostic (blood collection via fluid biopsy, lab analysis)|Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
16373753|NCT04162665|Experimental|Preoperative MR-guided Radiation Therapy|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25 Gy at 5 Gy per fraction. The clinical target volume will include the entire stomach and locoregional lymph nodes. Radiation must be delivered with MR guided radiation therapy (MRgRT) and daily adaptive planning. The stomach and OARs must be redrawn each day for the adaptive plan. Plans should be adapted to meet OAR constraints or improve coverage as needed for each day's unique anatomy
~Chemotherapy will be given as per standard of care. It should begin 2 to 4 weeks after completion of radiotherapy and will consist of CAPOX (capecitabine/oxaliplatin) for 5 cycles.
~Standard of care gastrectomy or esophagogastrectomy within 2-4 weeks following completion of chemotherapy
~All stage II-III patients should receive 3 cycles of CAPOX postoperatively for a total of 8 cycles of CAPOX. Postoperative CAPOX should start within 3 months of surgery."
16373754|NCT04162639|Experimental|One donor|Participants will receive skin allograft from 1 distinct cadavers.
16373755|NCT04162639|Experimental|Two donors|Participants will receive skin allograft from 2 distinct cadavers.
16373756|NCT04162639|Experimental|Three donors|Participants will receive skin allograft from 3 distinct cadavers.
16373757|NCT04162639|No Intervention|Control|Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.
16373758|NCT04162626|Experimental|Intervention|Supportive home visits by public health nurses to new parents from 28 weeks in pregnancy until the child is two years.
16373759|NCT04162626|Other|Control|Follow up as usual at the Child health center
16373760|NCT04162613||Patients with ACL reconstruction in Lund and Umeå|Persons who have suffered a unilateral anterior cruciate ligament injury treated with reconstruction
16373761|NCT04162600|Experimental|Group 1|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^9 vp vaccination intramuscularly.
~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
16373762|NCT04162600|Experimental|Group 2|"Volunteers will receive a standalone dose of ChAdOx2 RabG 2.5 x 10^10 vp vaccination intramuscularly.
~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
16373763|NCT04162600|Experimental|Group 3|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^10 vp vaccination intramuscularly.
~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
16373764|NCT04162587||1)Patients with significant carotid stenosis only|Patients with significant carotid stenosis without intracranial stenosis.
16373765|NCT04162587||2) Patients with carotid and intracranial stenosis.|Patients with carotid and intracranial stenosis.
16373766|NCT04162587||3) Patients with lone intracranial stenosis.|Patients with lone intracranial stenosis.
16373767|NCT04162587||4) Patients with no significant stenosis|Patients with no significant carotid or intracranial stenosis.
16373768|NCT04162574||BEGIN Case|Enrolled participants with BN/BED will participate in a 30-day observational study.
16373769|NCT04162548||cardio-relay|"Cardio-relay is a novel collaboration model between hospital-based specialists and primary care, to provide high-quality care to frail patients, relieving their burden to attend multiple hospital specialist visits.
~Using telemedicine, it is possible to make measurements where the patient is (at the family clinic at the patient's home). Data are available for all the involved. That is, primary the patient, the relatives and caregivers that the patient wishes help from and health professionals from the family clinics and the hospital. Thereby, the hospital-based specialist supports the family clinic with expert knowledge, the need for attending the hospital facilities reduced to focus on what is strictly needed as specialized provider. Ultimately, the patient can be reached for high-quality care, relieving the patient's burden to attend multiple hospital specialist visits."
16373770|NCT04162535|Experimental|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
16373771|NCT04162535|Experimental|Total intravenous anesthesia|Patients will receive a general anesthesia with Propofol as anesthetic agent
16373772|NCT04162535|Experimental|Total intravenous anesthesia and Lidocaine|Patients will receive a general anesthesia with Propofol as anesthetic agent and will also receive a fully lidocaine infusion according to the lidocaine protocol
16373773|NCT04162535|No Intervention|Placebo|10 presumed healthy volunteers that have donated 10 ml of venous blood for serum comparison
16373774|NCT04162522|Active Comparator|escitalopram (10-20 mg)|"Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as responders or non-responders. Responders will continue on escitalopram until the study endpoint (16 weeks)."
16373775|NCT04162522|Active Comparator|brexpiprazole (0.5-2 mg)|"At week 8, participants classified as non-responders will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram."
16373776|NCT04162509|Experimental|Exposure|The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.
16373777|NCT04162509|No Intervention|Control|The control group will not receive any active treatment (untreated comparison group).
16373778|NCT04162496|Experimental|Treatment with Restylane Refyne Group 1|Treat right side with Restylane Refyne with a cannula and left side with a needle
16373779|NCT04162496|Experimental|Treatment with Restylane Refyne Group 2|Treat left side with Restylane Refyne with a cannula and right side with a needle
16373780|NCT04162470|Experimental|REGN3918|Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)
16373781|NCT04162457|Experimental|Stevia beverage|Participants receive 4 study beverages in the 4 imaging sessions in randomised and counterbalanced order.
16373782|NCT04162457|Experimental|Glucose beverage|330 ml of water with glucose (equal sweetness with the stevia beverage)
16373783|NCT04162457|Experimental|Maltodextrin beverage|330 ml of water with maltodextrin (equal amount of calories as the glucose beverage)
16373784|NCT04162457|Placebo Comparator|Water|330 ml water
16373785|NCT04162444||Cohort 1|We will study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease.
16373787|NCT04162431||hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
16373788|NCT04162431||squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
16373789|NCT04162431||reactive|patients diagnosed with a reactive (non-cancerous) lymph node
16373790|NCT04162431||other|none of the above. Other cancer and non-cancer conditions
16373791|NCT04162418|Other|Intervention|Treatment with Temporary Spur Stent System and a commercially available, limus-base, drug coated balloon
16373792|NCT04162405||Patients with tinnitus and hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold >30 dB
16373793|NCT04162405||Patients with tinnitus without hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold <30 dB
16373794|NCT04162392|Experimental|Experimental group|
16373795|NCT04162392|Active Comparator|Control group|
16373796|NCT04162379|Other|Prospective quizi-pre-post oral predensolone|single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mgs for 3 successive dosing every 4th day then stop the drug totally).
16373797|NCT04162366|Experimental|Aprocitentan 25 mg|
16373798|NCT04162366|Experimental|Placebo|
16373799|NCT04162366|Experimental|Aprocitentan 25 mg or Placebo|
16373800|NCT04162353|Experimental|BCMA-CD19 cCAR|Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg
16373801|NCT04162340|Experimental|CD4 CAR T cells|Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg
16373802|NCT04162327|Experimental|Ia stage - IBI315 Dose escalation|
16373803|NCT04162327|Experimental|Ib stage - IBI315 monotherapy|
16373804|NCT04162314|Experimental|Experimental|This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
16373805|NCT04162314|Placebo Comparator|Control|This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
16373806|NCT04162301|Experimental|CS3002 CDK4/6 inhibitor|
16373807|NCT04162288|Experimental|Online training on SDM in prenatal screening|
16373808|NCT04162288|Placebo Comparator|Online training on prenatal screening|
16373809|NCT04162275|Experimental|pre-trial, fasting administration|2 cases were given 150mg Finamine tablets（pre-trial，fasting administration）
16373810|NCT04162275|Experimental|pre-trial,after high fat meal|2 cases were given 150mg Finamine tablets (pre- trial，after high fat meal)
16373811|NCT04162275|Placebo Comparator|formal trial-150mg|4 cases were given 150mg Finamine tablets 2 cases were given placebo
16373812|NCT04162275|Placebo Comparator|formal trial-300mg|6 cases were given 300mg Finamine tablets 2 cases were given placebo
16373813|NCT04162275|Placebo Comparator|formal trial-600mg|6 cases were given 600mg Finamine tablets 2 cases were given placebo
16373814|NCT04162275|Placebo Comparator|formal trial-1200mg|6 cases were given 1200mg Finamine tablets 2 cases were given placebo
16373815|NCT04162262|Experimental|Stretching, Strengthening, and IASTM|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. This group will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
16373816|NCT04162262|Active Comparator|Strengthening and Stretching|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. To equalize visit time with the Stretching, Strengthening, and IASTM group, subjects will perform 15 minutes of self-paced bicycle riding at the beginning of each session. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
16373817|NCT04162262|Other|Pain-free Comparison Group|The third group is a pain-free comparison group. This group will come to the laboratory once. They will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. These measurements will be compared to the same measures from the Stretching, Strengthening, and IASTM group to examine outcome measure differences in those with and without plantar fasciopathy following a single IASTM treatment.
16373818|NCT04162249||Conventional ablation (CONTROL GROUP)|"Pulmonary veins ablation.
~Anterior aspect: power 30 W, catheter dragging (30 s per point).
~Posterior aspect: point-by-point ablation using 30 W/30 s applications. If esophageal temperature measured with two independent esophageal probes exceeded 49 ºC radiofrequency settings were modified to 20 W/ 60 s and the number of radiofrequency applications minimized in areas with esophageal temperature rise.
~Al procedures were performed with continuos intracardiac echo image and esophageal temperature monitoring."
16373819|NCT04162249||High-power and short-duration ablation|"Pulmonary veins ablation.
~Subgroup 50W: power 50 W, application duration ≤ 30 s, target lesion index: LSI ≥ 5 or Ablation Index ≥ 350 (posterior wall) or ≥400 (anterior wall).
~Subgroup 60W: power 60 W, application duration 7-10 s, contact force ≥5 g.
~Subgroup 70W: power 70 W, application duration 9 s, contact force ≥5 g.
~Intracardiac echo was not used. Esophageal temperature probes were used only in 6 patients in the subgroup 50W."
16373881|NCT04161703|Experimental|focused ultrasound, diet and exercises|
16373820|NCT04162236||High Risk of Preeclampsia|"Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they meet the following criteria:
~1)High risk for preeclampsia according to first trimester screening (maternal risk factors, blood preassure, PPAP-A, mean pulsatility index (PIm) of the uterine arteries (UtA) at 11.0 to 13.6 weeks of gestation (n=280).
~Women in this group will be subdivided in cases and controls according to the later development of preeclampsia:
~cases: women developing PE (estimated n=40)
~controls: women not developing PE (estimated n=240)"
16373821|NCT04162236||Patients with Preeclampsia|Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they develop PE. Inclusion criteria: Patients presented with clinical signs and symptoms of preeclampsia (N=60).
16373822|NCT04162236||Control group|Healthy pregnant women with at low risk PE screening at 11.0 to 13.6 weeks of gestation (n=100).
16373823|NCT04162223|Experimental|Subcutaneous Fat Vaccine Injection|Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.
16373824|NCT04162223|Experimental|Intramuscular Vaccine Injection|Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.
16373825|NCT04162210|Experimental|Participants receiving Belantamab mafodotin|Participants will receive belantamab mafodotin single agent dose of 2.5 mg/kg on Day 1 of Q3W
16373826|NCT04162210|Active Comparator|Participants receiving pom/dex|Participants will receive pomalidomide orally starting dose of 4 mg daily on Days 1 to 21 of each 28-cycle, with dexamethasone at an oral dose of 40 mg once weekly or a lower dose of 20 mg once weekly on Days 1, 8, 15 and 22.
16373827|NCT04162197|Experimental|Experimental 1: Gait Group (GG)|Gait Group (GG) will perform, in addition to conventional therapy, gait training using only an end effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 12 sessions/month. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/ h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
16373828|NCT04162197|Experimental|Experimental 2: Balance Group (GHG)|Balance Group (GHG) will receive, in addition to conventional therapy, a combined robotic treatment program with the same end-effector robotic system and a robotic proprioceptive platform, 3 times/week for 12 sessions/month. The time of the single session (45 minutes) is dived in gait training and balance training. The balance training will consist in static and dynamic exercises during sitting and standing position, dual-task exercises and exercises aimed to improve trunk control.
16373829|NCT04162184|Other|Health Educator Intervention|As the population of focus in this study is diverse, including men and women regardless of pregnancy desire, the primary focus for the intervention for this study will be education, particularly for men. All participants that enroll in the study will be offered the intervention. The study health educator will use the PATH (Parenthood/Pregnancy Attitude, Timing, and How) framework questions to initially guide the conversation. Depending on the participant's desires, the educator will provide education on other topics such as sexually transmitted infections (STIs) and we will also navigate to clinical services as needed. The health educator will use a study manual to guide all intervention activities including engagement. Additionally, the health educator will collect data on intervention outreach, engagement, topics discussed, participant needs and outcomes.
16373830|NCT04162171|Experimental|Imaging & SBRT Treatment for Ventricular Tachycardia|
16373831|NCT04162158|Experimental|Targeted drug combined with allogeneic NK cell treatment group|In addition to traditional symptomatic supportive treatment, Sorafenib, regolfinib or levabinib will be administered in combination with allogeneic NK cells (3 cycles).
16373832|NCT04162158|No Intervention|Targeted drug treatment group|Sorafenib, regolfinib or levabinib will be administered in addition to traditional symptomatic supportive care.
16373833|NCT04162145|Active Comparator|Active Device|Patients in the Active Device arm will receive placement of an active BRIDGE device.
16373834|NCT04162145|Sham Comparator|Sham Device|Patients in the Sham Device arm will receive placement of an inactive, or sham, BRIDGE device. The inactive device will be identical in appearance to the active device but will have no electrical current.
16373835|NCT04162132||DynamiCare group|Patients at Morgan Street location of BrightView who were given the DynamiCare smartphone app.
16373836|NCT04162132||Non-DynamiCare group|Patients at Colerain location of BrightView who were not given the DynamiCare smartphone app.
16373837|NCT04162119|Experimental|multiple myeloma|This study is to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with Relapsed/Refractory Multiple Myeloma.
16373838|NCT04162106|Active Comparator|Ultravision™ System|Smoke management during laparoscopic cholecystectomy performed with the Ultravision™ System
16373839|NCT04162106|Active Comparator|Airseal® iFS|Smoke management during laparoscopic cholecsystectomy performed with the Airseal® iFS
16373840|NCT04162093|Experimental|single trough|
16373841|NCT04162028|Experimental|Nebulized Ketamine|sub-dissociative dose ketamine administered prehospitally via breath-actuated nebulizer at 1.0 mg/kg for patients with acute pain
16373842|NCT04162015|Experimental|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
16373843|NCT04162002|Experimental|Restylane® Lyft Filler Injection|
16373844|NCT04161989|Other|Group I (omega-3 fatty acids group)|
16373845|NCT04161989|Other|Group II (vaginal progesterone plus omega-3 group)|
16373846|NCT04161976|Experimental|LY900027|LY900027 administered to participants with type 1 diabetes mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) in one of two dosing periods.
16373847|NCT04161976|Active Comparator|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII in one of two dosing periods.
16373848|NCT04161963||Phaco|tandard ultrasound phacoemulsification cataract surgery
16373849|NCT04161963||FLACS|femtolaser assisted cataract surgery
16373850|NCT04161963||phaco+MIGS|combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery
16373882|NCT04161703|Experimental|diet and exercises|
16373851|NCT04161950||Tested device model (EG-UR5-S50 )|Tested device model: The EG-UR5 echoendoscope manufactured by SonoSscope Medical Crop. That used with the HD-500 image processor, HDL-500X light source and S50 ultrasonic processor.
16373852|NCT04161950||Compared device model (GF-UE260-ME2)|Compared device model: The GF-UE260 echoendoscope manufactured by Olympus and its compatible light source, image processor and ME2 ultrasonic processor.
16373853|NCT04161937|Experimental|Behavioural Intervention|Half of the randomly selected participants will get behavioural intervention based on Diabetes Prevention Program module.The behavioural intervention classed will be administered by trained nurse weekly for 16 weeks.After completion of behavioural intervention both the experimental and control arm will get cafeteria intervention.
16373854|NCT04161937|Experimental|Control|Half of the participants will act as a control and will not receive any form of behavioural intervention.
16373855|NCT04161924||X-ray imaging with physical grid using conventional processing|
16373856|NCT04161924||X-ray without physical grid using conventional processing|
16373857|NCT04161924||X-ray imaging without physical grid using experimental SimGrid|
16373858|NCT04161911||Advanced Hepatocellular Carcinoma (aHCC) cohort|aHCC cohort selected from the Flatiron Health Oncology electronic health record (EHR) data from January 2011 to the most recent data available. The index date will be defined as the start of second or third line nivolumab therapy for aHCC between January 1, 2011 and the most recent data available.
16373859|NCT04161898|Experimental|Arm 1: Upadacitinib|Participants will be administered updadacitinib once daily (QD) along with prednisolone
16373860|NCT04161898|Experimental|Arm 2: Placebo for Upadacitinib|Participants will be administered placebo once daily (QD) along with prednisolone
16373864|NCT04161872|Active Comparator|Uricemin|
16373865|NCT04161872|Placebo Comparator|Placebo|
16373866|NCT04161846|Experimental|Virtual World Program|Participants take part in a group training delivered using a virtual world approach.
16373867|NCT04161846|Active Comparator|In Person Program|Participants take part in a group training delivered using an in person approach.
16373868|NCT04161833|Experimental|OPERA|Women receiving adjuvant aromates-inhibitor with arhtralgia grade ≥ 1 (CTACAE 4.03)
16373869|NCT04161820|Experimental|Education and telephone follow ups based on the CCM|"After the pre-tests (self-management, quality of life and patient satisfaction were assessed by scales at the first interview), the patients were given discharge training with a booklet prepared based on the Chronic Care Model (CCM) and containing information and recommendations on self-management strategies during their stay in the hospital (0 months). Trainings were performed in a single session and in the patient room at the clinic, not to exceed 45-50 minutes. The patients who were included in the intervention group were followed up by phone on the 7th day, 15th day, 1st month and 2nd month after discharge. Patients were referred to the hospital in unexpected / unpredictable situations during the three-month period.
~Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later."
16373870|NCT04161807|Experimental|Nerivio device treatment|participant will receive the Nerivio device for treating their migraine attacks. Treatment will be perform as soon as the participant feel that the migraine attack started
16373871|NCT04161794|Experimental|Intervention group|2 g EPA/DHA via fish oil daily Regular dietary counselling Twice weekly strength and cardiovascular exercise
16373872|NCT04161794|No Intervention|Historical control group|Standard of Care
16373873|NCT04161781||Cohort 1|10 participants will receive one injection of 18F-BMS-986229 (370 MBq) and will then undergo whole-body PET/CT (80 mA) encompassing the vertex of the skull to the proximal thigh performed at 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging.
16373874|NCT04161781||Cohort 2|25 participants may receive 370 MBq of 18F-BMS-986229 given intravenously and will undergo a single PET/CT scan 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging. If the participant agrees, they will receive a second injection while undergoing nivolumab treatment (after at least 2 cycles or 6 weeksof therapy).
16373875|NCT04161768|Active Comparator|Norfloxacin|Norfloxacin 400 mg daily
16373876|NCT04161768|Experimental|Norfloxacin and Itopride|Norfloxacin 400 mg daily and Itopride 50 mg three times daily.
16373877|NCT04161755|Experimental|Pancreatic Cancer|Radiologically resectable primary pancreatic tumors
16373878|NCT04161729|Active Comparator|Magnesium sulfate|Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
16373879|NCT04161729|Placebo Comparator|Isotonic solution 0.9%|Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
16373880|NCT04161716|Experimental|NIRS module|Each patient has a NIRS module during a diagnosis urodynamic assessment provided for by the usual practice.
16373883|NCT04161690|Active Comparator|Group IV|Dexketoprofen 50mg is given intravenous 10 min before the start of the surgery. Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
16373884|NCT04161690|Active Comparator|Group Periarticular|Dexketoprofen 50mg is given as part of the local infiltration analgesia with 300mg ropivacaine. Local infiltration analgesia is proceeded by the orthopedic surgeon.
16373885|NCT04161690|Placebo Comparator|Group P|Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
16373886|NCT04161664|Experimental|neo adjuvant Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
16373887|NCT04161651|Experimental|single arm|
16373888|NCT04161638|Experimental|High Blood Pressure|Ambulatory BP measurement was used to confirm the laboratory BP group classification according to the European Society of Hypertension. Participants were placed in the high blood pressure (HBP) group if they met any of the following criteria: 1) 19-hour average systolic BP/diastolic BP (SBP/DBP) > 130/80 mmHg, 2) daytime (awake) average SBP/DBP > 135/85 mmHg, or 3) nighttime (sleep) average SBP/DBP > 120/70 mmHg.
16373889|NCT04161638|Experimental|Normal Blood Pressure|Participants were placed in the normal BP (NBP) group if they met all of the following criteria: 1) 19-hour average SBP/DBP < 130/80 mmHg, 2) daytime (awake) average SBP/DBP < 135/85 mmHg, and 3) night-time (asleep) average SBP/DBP <120/70 mmHg.
16373890|NCT04161625|Experimental|Safe Step - digital exercise program|"All included participants will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
~Additional support to promote reach and exercise adherence will be provided in the format of technical support and try-out group exercises throughout the recruitment period."
16373891|NCT04161599|Experimental|Oral + Parenteral prophylaxis + Mechanical Bowel Preparation|"Drug: Extra dosage - cefuroxime (750mg) I.V
~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.
~Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.
~Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
16373892|NCT04161599|Active Comparator|Oral + Parenteral prophylaxis|"Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.
~Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
16373893|NCT04161573||TBI group|15 people in this group. Each should be post TBI for 6 months.
16373894|NCT04161573||Control group to TBI|15 people in this group. Their gender and age accord with TBI group.
16373895|NCT04161573||Aging group 1- 20 to 39|Normal people whose age range from 20 to 39.
16373896|NCT04161573||Aging group 2- 40 to 59|Normal people whose age range from 40 to 59.
16373897|NCT04161573||Aging group 3- above 60|Normal people whose age are above 60.
16373898|NCT04161560|Experimental|use of the cetuximab-IRDye800|four groups : control group, 1% dose group (1% of therapeutic dose; 2.5 Mg/m2) and 10% dose groups (10%of therapeutic dose ;25mg/m2) and 25% dose group (25%of therapeutic dose; 62.5mg/m2)
16373899|NCT04161547|Experimental|Cohort A1: CSPCHA115 100 mg|"CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
16373900|NCT04161547|Experimental|Cohort A2: CSPCHA115 200 mg|"CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
16373901|NCT04161547|Experimental|Cohort A3: CSPCHA115 400 mg|"CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
16373902|NCT04161547|Experimental|Cohort A4: CSPCHA115 600 mg|"CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
16373905|NCT04161521|Other|Placenta Accreta patients|of 60 pregnant female diagnosed as placenta previa accreta recuirted from Obstetrics and Gynecology Department , Menoufia University Hospital.
16373906|NCT04161508|Experimental|Sugammadex|sugammadex 2 mg/ Kg for the reversal of neuromuscular blockade at the end of surgery
16373907|NCT04161508|Active Comparator|Neostigmine|neostigmine 50 mcg/Kg + glycopyrrolate 10 mcg/kg for the reversal of neuromuscular blockade at the end of surgery
16373908|NCT04161495|Experimental|Prophylaxis|Participants will receive BIVV001 once-weekly (QW) during a prophylaxis treatment regimen for 52 weeks
16373909|NCT04161495|Experimental|On Demand|Participants will receive BIVV001 on demand for 26 weeks, followed by a switch to a prophylaxis treatment regimen with BIVV001 for 26 weeks.
16373910|NCT04161482|Experimental|Cohort One|A bi-phasic delivery over 5 hours
16373911|NCT04161482|Experimental|Cohort 2a|Continuous infusion over 2 hours
16373912|NCT04161482|Experimental|Cohort 2b|Bi-phasic delivery over 2 hours
16373913|NCT04161482|Experimental|Cohort 3|Continuous infusion over 1 hour.
16373914|NCT04161482|Experimental|Cohort 4|Continuous infusion over 30 minutes.
16373915|NCT04161469|Other|Group 1|Patients diagnosed with anal fistula treated by laser closure of the tract
16374046|NCT04160559|Experimental|Test group|chemotherapy plus green tea
16373916|NCT04161469|Other|Group 2|Patients diagnosed with anal fistula treated by laser closure of the tract with an additional surgical technique as the closure of the internal orifice with a purse-string suture using 2-0 polyglactin
16373917|NCT04161456|Experimental|Apremilast|Apremilast twice daily 30 mg
16373918|NCT04161443|Experimental|Experimental|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.
~i. MET Quadratus lumborum ii. Ultrasound iii. Gluteus medius exercises iv. Hamstring stretch Posture advice and home exercise program"
16373919|NCT04161443|Active Comparator|Comparator|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.
~i. Ultrasound ii.Gluteus medius exercises iii.Hamstring stretch"
16373920|NCT04161430|Experimental|DRBP108|Phase A (Weeks 1-24): DBPR108 100mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
16373921|NCT04161430|Active Comparator|Sitagliptin|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
16373922|NCT04161430|Placebo Comparator|Placebo|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
16373923|NCT04161417|Other|Biopsy Material Required for Registration|The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
16373924|NCT04161404|Experimental|Period 1|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
16373925|NCT04161404|Experimental|Period 2|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
16373926|NCT04161404|Experimental|Period 3|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
16373927|NCT04161391|Experimental|TPX-0046|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.
~A food-effect sub-study will be conducted once the RP2D has been determined.
~The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.
~Phase 2 Cohorts:
~Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)
~Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)
~Cohort III (MTC + RET mutation, RET TKI Therapy Naive)
~Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)
~Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)
~Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)"
16373928|NCT04161378||RHB-SG 01|Patients with early mobilization (< 2 days after the onset of symptoms)
16373929|NCT04161378||RHB-SG 02|Patients with delayed mobilization after AMI (>2 days after the onset of symptoms)
16373930|NCT04161365|Experimental|Urethral stricture patients|Patients suffering from urethral stricture are treated with direct visual internal urethrotomy (DVIU). Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
16373931|NCT04161339|Experimental|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
16373932|NCT04161339|Placebo Comparator|Placebo|
16373933|NCT04161313||Cystic fibrosis|children with cystic fibrosis
16373934|NCT04161313||primary ciliary dyskinesia|children with primary ciliary dyskinesia
16373935|NCT04161313||healthy controls|Age-matched healthy volunteers
16373936|NCT04161300|Active Comparator|Foam Rolling Group (FR)|
16373937|NCT04161300|Active Comparator|Orthopaedic Manual Physical Therapy Group (OMPT)|
16373938|NCT04161300|Other|Control Group (CG)|
16373939|NCT04161287||SBRT with TACE|
16373940|NCT04161287||SBRT alone|
16373941|NCT04161274|Active Comparator|Traditional method: Electrosurgery|"Local anaesthesia and excision with a scalpel connected to the electric current, according to the voltage. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
16373942|NCT04161274|Active Comparator|Traditional method: Cryotherapy|"Application of liquid nitrogen to cause freezing. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
16373943|NCT04161274|Active Comparator|Traditional method: Silver nitrate|"Excision is made with the scissors and a rod is applied containing silver nitrate with caustic power on the wound.
~Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
16373944|NCT04161274|Experimental|Moist healing environment|"Excision is made with the scissors, afterwards pressure, clorhexidine and a hydrocolloid dressing when the skin is dry.
~Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
16373945|NCT04161261|Experimental|IntraOperative Group|The intra-operative group consists of patients who have met criteria for cochlear implants. We monitor the facial nerve EMG intraoperatively in all patients, and often get some facial nerve activation when we are testing the implant intraoperatively when we are looking to see if we are getting any hearing nerve responses from electrical stimulation of the implant. We will also measure the facial nerve responses for some other charge-balanced pulse shapes, which are asymmetric and in which either the positive or negative charge is expected to stimulate the nerve. We will only measure these for two electrodes, not for all 12-22 electrodes They will be then invited back post operatively for a second testing during a standard of care visit post switch on for other pulse shapes.
16373946|NCT04161261|Experimental|PostOperative Group|The post-operative group, are patients who are actually having facial nerve stimulation on one or more electrodes, and for whom these electrodes are turned down so much they can't hear very well, or are actually turned off because of the facial nerve stimulation. For these patients, we will slowly increase the current levels on the offending electrodes (maximum of two) until they get some facial nerve twitching, and then turn down the current until they do not have stimulation any more. We will do this for all pulse shapes and determine which shape produces the greatest loudness without stimulating the facial nerve. This will be the only testing session for the second group.
16373947|NCT04161248|Experimental|Venetoclax + R-GDP|
16373948|NCT04161235||Treatment|Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
16373949|NCT04161222|Experimental|Experimental group|The control group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
16373950|NCT04161222|Experimental|Control group|The control group will perform a typical warm-up of competitive football.
16373951|NCT04161209|Experimental|Drug: Citalopram|20mg oral dose of citalopram (tablet encapsulated in opaque capsule)
16373952|NCT04161209|Placebo Comparator|Placebo|Lactose placebo (tablet encapsulated in opaque capsule)
16373953|NCT04161196|Active Comparator|patients with post - tonsillectomy suturing tonsil pillars|
16373954|NCT04161196|Placebo Comparator|patients without post - tonsillectomy suturing tonsil pillars|
16373955|NCT04161183|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
16373956|NCT04161183|Experimental|Extracoporeal shock wave therapy|Extracoporeal shock wave therapy (shock wave probe w/ energy)
16373957|NCT04161170|No Intervention|Control A|no intervention conventional diabetes treatment and clinic visit every 3 months
16373958|NCT04161170|Active Comparator|Intervention B|apply digital integrated healthcare platform clinic visit every 3 months
16373959|NCT04161170|Experimental|Intervention C|apply digital integrated healthcare platform, CGMS, and medical team monitoring, and education clinic visit every 3 months
16373960|NCT04161157|Experimental|Pathways|Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
16373961|NCT04161144|Active Comparator|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
16373962|NCT04161144|Placebo Comparator|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
16373963|NCT04161131|Experimental|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
16373964|NCT04161118|Experimental|Tisagenlecleucel (CTL019)|All patients will receive a single target dose of 0.6 to 6.0 × 108 of autologous tisagenlecleucel (CTL019) transduced T-cells with a viability of at least 70% administered via IV infusion after optional bridging with chemo- or immunotherapy and lymphodepleting (LD) chemotherapy with cyclophosphamide and fludarabine.
16373965|NCT04161105|Experimental|Rectus femoris dry needling group|The rectus femoris dry needling group will have their strength assessed. They will then receive one treatment of dry needling to a trigger point in their rectus femoris muscle. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
16373966|NCT04161105|Experimental|Gluteus maximus dry needling group|The gluteus maximus dry needling group will have their strength assessed. They will then receive one treatment of dry needling to trigger points in their gluteus maximus muscle only. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
16373967|NCT04161105|No Intervention|Control|This group will receive no intervention. They will have their strength assessed at baseline and 24, 48 & 72 hour follow-up
16373968|NCT04161092|Other|Liver transplantation + best alternative care|"Patients subjected to Ltx will during the waiting time receive individualized chemotherapy, with the aim to avoid side effect that make them not transplantable.
~If possible, patients randomized to Ltx should be treated within 12 weeks after randomization.
~If the patients progress systemically they will be treated with best alternative care.
~If they progress only within the liver they continue to be transplantable until they are deemed technically not transplantable by the transplant surgeon."
16373969|NCT04161092|Other|Best alternative care|The treating physician will together with the patient decide the treatment.
16373970|NCT04161079||MAR population|Subjects, who underwent MV repair operation with successful MAR implantation in clinical investigation 2010-040
16373971|NCT04161066|Experimental|Open-label|Psilocybin with guided counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
16373972|NCT04161053|Active Comparator|Rifaximin|550 mg Rifaximin tablets twice daily for six months.
16373973|NCT04161053|Experimental|Nitazoxanide|500 mg Nitazoxanide tablets twice daily for six months.
16373974|NCT04161040|Experimental|Relapse (experimental) Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. For the Relapse (experimental) Group, the second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Then, during the third phase, the incentives will be discontinued.
16373975|NCT04161040|Experimental|Fatigue Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. The second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Participants in this arm will continue to earn incentives during Phase 3 to control reductions in physical activity due to fatigue.
16373976|NCT04161040|No Intervention|No-Incentive Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. Participants in this arm will not earn incentives during any of the three phases to control for the possibility that participants will engage in some physical activity in the absence of incentives.
16373977|NCT04161027|Experimental|Pregabalin|
16373978|NCT04161027|Placebo Comparator|Placebo|
16373979|NCT04161014|Other|Treatment Arm|Nintedanib 150mg twice daily for 3 years
16373980|NCT04161001|Experimental|Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe
16374145|NCT04159831|Experimental|400,000 U LTI-01|400,000 U LTI-01 qd x 3 days administered intrapleurally
16373981|NCT04161001|Placebo Comparator|Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan and Rosuvastatin, Ezetimibe
16373982|NCT04161001|Placebo Comparator|Amlodpine, Olmesartan|co-administration of Olmesartan, Amlodipine
16373983|NCT04160975|Experimental|Black R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
16373984|NCT04160975|Experimental|Black R/Race C/Layperson/Standard Script|Video which contains a racially concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
16373985|NCT04160975|Experimental|Black R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
16373986|NCT04160975|Experimental|Black R/Race D/Doctor/Acknowledgement Script|Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script. The receiver of the message will be Black.
16373987|NCT04160975|Experimental|White R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
16373988|NCT04160975|Experimental|White R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
16373989|NCT04160962||lappg|
16373990|NCT04160962||ladgbi|
16373991|NCT04160949||Patients|Patients who have been diagnosed with Fatty Liver.
16373992|NCT04160936|Active Comparator|study group ,infiltration with 0.25% ropivacaine post-op|At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
16373993|NCT04160936|No Intervention|control group , no anesthesia infiltration post-op|
16373994|NCT04160910|Active Comparator|5-hydroxytryptophan|"Dosage of 5-hydroxytryptophan will be determined by weight:
~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
16373995|NCT04160910|Placebo Comparator|Placebo|"Dosage of placebo will be determined by weight:
~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
16373996|NCT04160897||ETV cohort|CHB patients with entecavir naive treatment
16373997|NCT04160897||TDF cohort|CHB patients with naive tenofovir disopropyl naive treatment
16373998|NCT04160884|Active Comparator|A|0.6mg/kg of ICG, iv
16373999|NCT04160884|Experimental|B|0.2mg/kg of ICG, iv
16374000|NCT04160871|Experimental|Family Connections|Experimental group
16374001|NCT04160871|Active Comparator|Treatment As Usual|Control group
16374002|NCT04160858|Experimental|Exercise Condition|The intervention is a personalized exercise prescription based on the International Scientific Spinal Cord Injury (SCI) Exercise Guidelines. Participants begin at the Starting Level guideline: 20 min aerobic exercise, 2x/wk, at 70% of heart rate reserve (or a Borg Continuous Ratio 0-10 rating of 6), & 3 sets of 10 repetitions of strengthening exercises (each major functioning muscle group at 50-80% of 1-rep max), 2x/wk. Participants will gradually increase aerobic exercise to 30 min, 3x/wk (i.e. the Advanced Level guideline). Exercise implementation will be supported by a fitness trainer and an exercise counsellor with SCI-specific training and experience.
16374003|NCT04160858|Active Comparator|Wait-list Control|Control participants will not get an exercise prescription. They will be asked to refrain from lifestyle changes for 6 mos. After the 6-month waitlist period, Controls will receive the same resources as Exercisers.
16374004|NCT04160819|Experimental|individualized nutritional intervention programs (iNIPs)|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs. Anthropometry (i.e., body mass index, limb circumference, and subcutaneous fat thickness), blood parameters (i.e., albumin and total lymphocyte count), hospital stay, Mini-Nutritional Assessment-Short Form (MNA-SF) score, target daily calorie intake, total calorie intake adherence rate, and three-major-nutrient intake were assessed during hospitalization and 3 and 6 months after discharge. Both groups received regular follow-up through phone calls. Furthermore, the rate of readmission resulting from pneumonia was recorded after discharge.
16374005|NCT04160819|No Intervention|standard care (SC) group|SC group was only provided standard nutritional supplements according to the Kaohsiung Chang Gung Memorial Hospital Nutrition Department, and patients' family members were not provided dietary advice.
16374006|NCT04160806|Active Comparator|Active Group|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
16374007|NCT04160806|Sham Comparator|Sham Group|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
16374008|NCT04160793|Other|Genital Nerve Stimulation|Stimulation of the DNP
16374009|NCT04160780|Experimental|L-PRF as sole graft material|lateral sinus augmentation using L-PRF as sole graft material
16374010|NCT04160780|Experimental|xenograft as sole graft material|lateral sinus augmentation using xenograft as sole graft material
16374011|NCT04160780|Experimental|Xenograft mixed with L-PRF as graft material|lateral sinus augmentation using L-PRF mixed with xenograft as graft material
16374012|NCT04160767|Active Comparator|Probiotic|
16374013|NCT04160767|Placebo Comparator|Placebo|
16374014|NCT04160754|Experimental|MBRP|The experimental group will receive treatment as usual plus eight Mindfulness based relapse prevention (MBRP) therapy sessions.
16374015|NCT04160754|Active Comparator|Control (CTL)|The CTL group will receive treatment as usual plus information on the neurobiology of addiction and healthy behaviors.
16374016|NCT04160741|Experimental|Hot environment with radiation|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
16374017|NCT04160741|Experimental|Hot environment without radiation|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
16374018|NCT04160741|Experimental|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
16374019|NCT04160741|Active Comparator|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
16374020|NCT04160728|Experimental|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
16374021|NCT04160728|Experimental|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work.
16374022|NCT04160728|Experimental|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts.
16374023|NCT04160728|Experimental|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
16374024|NCT04160728|Sham Comparator|Business as usual scenario|No interference with the usual work day of the participants.
16374025|NCT04160728|Sham Comparator|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment.
16374026|NCT04160702|Experimental|Motivate-The-Bystander|Participants assigned to the MTB condition arm.
16374027|NCT04160702|No Intervention|Assessment only control condition|Participants assigned to the assessment only condition arm.
16374028|NCT04160689|Active Comparator|Group 1|Anyridge (Mega'Gen, Korea) 5° conical internal hexed connection
16374029|NCT04160689|Active Comparator|Group 2|Core (Bioimplant, Italy) 35° conical internal hexed connection (screw-vent style)
16374030|NCT04160676|Active Comparator|Group I|"The patients in this group will be managed only according to the surviving sepsis campaign 2016 and the surviving sepsis campaign bundle 2018 update.
~The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline I.V / 6 h, 5 ml normal saline I.V / 12 h."
16374031|NCT04160676|Experimental|Group II|The patients will receive the conventional therapy of sepsis and combined therapy of hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5 gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12 h This combined therapy will be given for 4 days or to the time of discharge if the admission period is less than 4 days
16374032|NCT04160663|Experimental|Subjects with atrial fibrillation|Subjects with atrial fibrillation that have been clinically scheduled for an electrical cardioversion procedure will have carotid ultrasound testing done before and after the procedure
16374033|NCT04160650|Experimental|Educational nursing intervention|"Patients in experimental group receive standard care and one-hour educational session. Patients are provided knowledge of
~healthy diet
~malnutrition, its prevalence and consequences for patients with CRC undergoing CT
~side effects impairing nutrition intake during CT treatment.
~prevention and self-care methods of the side effects Teach-back is used to verify participants' understanding. Empowering effect is confirmed by using active listening and asking patients' individual side effects, self-care strategies and need of additional knowledge in the beginning of the session and supporting patients' self-care methods when they have been applicable and effective. Additional knowledge of each theme is offered. To reinforce the intervention effect patients receive after the first CT a self-monitoring diary including assessment of side effects prevalence and intensity (NRS 0-10) before and after the self-care strategies. They return diaries by the 5th cycle of CT."
16374034|NCT04160650|No Intervention|Standard care|"Patients in control group receive standard care, information of
~general CT induced side effects and their self-care; nausea, diarrhoea, obstipation and sores in the mouth, peripheral neuropathy symptoms, local venous irritation, heart symptoms, mucous and skin irritation
~side-effects' self-monitoring, fluid intake, medication dose changes, effect of CT
~weight control
~taste alteration
~cold sensitivity
~variable diet
~dietary supplements
~available dietitian services
~They receive a self-monitoring diary, which includes only side effects and their intensity (NRS 0-10)."
16374035|NCT04160637||Patients with post-thyroidectomy hypocalcemia|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
16374036|NCT04160637||Patients without post-thyroidectomy hypocalcemia|Patients without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
16374037|NCT04160624|Active Comparator|Non-ECLS GROUP|For AS/R patients with normal EF, only TAVR was performed
16374038|NCT04160624|Experimental|ECLS GROUP|For AS/R patients with low EF, TAVR under ECLS-assisted was performed
16374039|NCT04160611|Experimental|Premedication with Midazolam|Patients will be randomly divided into two groups, control and midazolam. The midazolam group will receive midazolam premedication in such a way that 7.5mg midazolam will be taken orally 30 minutes before the aspiration procedure. Because midazolam causes sedation, the woman will be monitored by midazolam after medical premedication to avoid possible complications and will not be allowed to get out of bed on her own for 30 minutes. After 30 min, all women, both test and control group, will begin aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
16374040|NCT04160611|No Intervention|No Premedication with Midazolam|Women in the control group will undergo aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
16374041|NCT04160598|Placebo Comparator|Placebo group|bolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
16374042|NCT04160598|Experimental|IV Mg ++ group|continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
16374043|NCT04160572|Experimental|Morning-evening sleep schedule|
16374044|NCT04160572|Active Comparator|Evening-morning sleep schedule|
16374045|NCT04160559|Placebo Comparator|Control group|chemotherapy plus water
16374047|NCT04160546|Experimental|Ponatinib plus ASA treatment|Patients will be treated with ponatinib 15 mg/day plus 100 mg/day ASA for 104 weeks. After that, ponatinib and ASA will be stopped.
16374048|NCT04160520|Experimental|Pramipexole and half-standard dose of morphine|0.25 mg oral tablet of pramipexole in combination with 0.05mg/kg of IV morphine
16374049|NCT04160520|Active Comparator|Standard dose of morphine and placebo|0.1mg/kg of IV morphine in combination with a placebo pill
16374050|NCT04160507||Healthy black adults 50 and over|Healthy black adults age 50 and over with no known history of kidney disease will be recruited as controls in this study.
16374051|NCT04160507||black adult cases with non-diabetic nephropathy|black adult cases with non-diabetic nephropathy
16374052|NCT04160494|Experimental|D2C7-IT (6920 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (6920 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
16374053|NCT04160494|Experimental|D2C7-IT (4613.2 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (4613.2 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
16374054|NCT04160481|Active Comparator|Tomato extract|
16374055|NCT04160481|Placebo Comparator|Placebo|
16374058|NCT04160455||Cohort A, group A1|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase : CD4 count less than 500 cells / ml at the time of inclusion in the study
16374059|NCT04160455||Cohort A, group A2|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase: CD4 count above 500 cells / ml at the time of inclusion in the study
16374060|NCT04160455||Cohort B|20 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)
16374061|NCT04160455||Cohort C, group C1|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during primary infection (within 4 months of infection)
16374062|NCT04160455||Cohort C, group C2|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells/ml at the time of inclusion in the study
16374063|NCT04160455||Cohort C, group C3|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells/ml at the time of inclusion in the study
16374064|NCT04160455||Cohort D|20 patients who have undetectable plasma HIV RNA (HIV RNA <50 copies / ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers).
16374065|NCT04160429||Device feasibility (Macroduct Sweat Collection System)|Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.
16374066|NCT04160416|Experimental|mXELOXIRI|"Induction therapy is followed by the maintenance therapy. Induction treatment: XELOXIRI+CET/BEV Administered for 6 cycles (a maximum of 8 cycles).Bevacizumab (BEV): 5mg/kg (d.i.v.); Cetuximab 500mg/sq.m (d.i.v.)；Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) Irinotecan (IRI):135 mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-10) Administered every 2 weeks.
~Maintenance treatment: CAP+CET/BEV. The following CAP+BEV/CET therapy will be repeated in 2-week cycles."
16374067|NCT04160403|Experimental|factors ( SES,age, sex,severity) and progress|the relation between progress in gross motor functions
16374068|NCT04160390||Arm I (biospecimen collection)|Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
16374069|NCT04160390||Arm II (biospecimen collection)|Patients undergo collection of blood prior to transplant and on days 0, 3, and 4. Patients also undergo collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
16374070|NCT04160377|Experimental|melancholic depression|patients with melancholic depression undergo the treatment of Fluvoxamine
16374071|NCT04160377|Experimental|non-melancholic depression|patients with non-melancholic depression undergo the treatment of Fluvoxamine
16374072|NCT04160351|Experimental|MCO Dialyser|12 treatments (4 weeks) with Medium Cut-Off Dialyzer
16374073|NCT04160351|Active Comparator|High Flux Dialyser|12 treatments (4 weeks) with High Flux Dialyzer
16374074|NCT04160325|Experimental|3 months exclusive enteral nutrition plus azathioprine|patients underwent surgery in this arm will given 3 months exclusive enteral nutrition,and free diet after 3 months. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
16374075|NCT04160325|Active Comparator|normal diet plus azathioprine|patients underwent surgery in this arm will given free diet all through. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
16374076|NCT04160312|Experimental|Mitopure™ (Proprietary Urolithin A)|Fruit flavored food sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
16374077|NCT04160312|Experimental|Pomegranate Juice|100% Pomegranate juice equivalent to a glass of juice
16374078|NCT04160299|Experimental|Dance-based exergaming|This will be an intervention-based study with single-group design, where participants will receive VR-based dance training for ten weeks. An anticipated 20 participants with a diagnosis of mild cognitive deficits will be recruited for initial screening
16374079|NCT04160286||ECT (Work Package 1)|Group of patients receiving ECT during their hospitalization.
16374080|NCT04160286||Non-ECT (Work Package 1)|Group of patients not receiving ECT during their hospitalization.
16374081|NCT04160286||Work Package 2|Group of discharged patients who during their hospitalization received ECT. At the time of assessment, the discharged patients received their last session of ECT six months ago.
16374142|NCT04159844|Active Comparator|Short stretch bandage|Application with 50% overlap in combinaison with wading
16374082|NCT04160273|Experimental|Diagnosis and follow-up arm|"Patients are informed during the 9th month pregnancy consultation consultation at Angers University Hospital by the midwife or obstetrician in charge of the consultation. They are included in the 48 hours following the delivery after their hospitalization in the maternity ward.
~During hospitalization, socio-demographic and medical data are collected and the IDP scale is completed before returning home.
~Follow-up at one month and one year is carried out by the investigators by means of a telephone call during which the patient answers the PCL-S questionnaire. Also collected during this call are information on the physical and mental state of the patient, the state of health of her newborn and the progress of the return home.
~Patients are considered at high risk of PTSD if they have a PCL-S score ≥ 44 at 1 month. A consultation with a psychiatrist is offered to these patients at risk of PTSD in order to make the diagnosis and offer them appropriate care if necessary."
16374083|NCT04160260|Experimental|Omadacycline: Omadacycline Tablets|
16374084|NCT04160247|Active Comparator|Angulated screw-retained crown|Restorations are connected to the implants by angulated screw channel system
16374085|NCT04160247|Placebo Comparator|Cemented crown|Restorations are cemented onto the implant abutment
16374086|NCT04160234||Elderly patient|Preoperative elderly patients, who are planned for a surgical intervention
16374087|NCT04160221|Active Comparator|12 hours interval|Mifepristone followed by Misoprostol treatment
16374088|NCT04160221|Active Comparator|24 hours interval|Mifepristone followed by Misoprostol treatment
16374089|NCT04160208||IUI - Insemination|Males of couples undergoing their first IUI treatment
16374090|NCT04160208||IVF - In vitro fertilisation|Males of couples undergoing their first IVF treatment. Including males of couples who have had previous IUI treatments.
16374091|NCT04160208||ICSI - Micro Insemination|Males of couples undergoing their first ICSI treatment. Including males of couples who have had previous IUI treatments.
16374092|NCT04160195|Active Comparator|1/Conditioning chemotherapy plus CAR T-cells dose escalation|All patients will be receiving escalating dose of Anti-CD19 and anti-CD20 CAR T cells/kg + conditioning chemotherapy
16374093|NCT04160195|Active Comparator|2/Conditioning chemotherapy plus CAR T-cells expansion phase|MTD dose of Anti- CD19 and anti- CD20 CAR T cells/kg + Conditioning chemotherapy
16374094|NCT04160182|Experimental|Energy Conservation Work Simplification Education|The intervention will be delivered online by an occupational therapist. The intervention consists of 6 weekly sessions; each session will be 45 minutes long. The focus of the intervention is to teach breast cancer survivors strategies to manage their fatigue.
16374095|NCT04160156||Type 1 diabetes|Subjects attending metabolic clinic who were suggested to use long term sensor due to persistent hyperglycemia and hypoglycemia
16374096|NCT04160143|Experimental|SBRT followed by pulmonary metastasectomy|SBRT+Surgery
16374097|NCT04160130|Experimental|SAPIEN 3 or SAPIEN 3 Ultra|Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.
16374098|NCT04160130|Active Comparator|any surgical bioprosthetic aortic valve|Any commercially available surgical bioprosthetic valve
16374099|NCT04160117|Experimental|Intervention|Colchicine 0.6 mg p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
16374100|NCT04160117|Placebo Comparator|Control|Matching placebo p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
16374101|NCT04160104||Training cohort|This cohort was used to establish the bowel preparation score (BPS).
16374102|NCT04160104||Validation cohort|This cohort was used to verify the bowel preparation score (BPS).
16374103|NCT04160091|Experimental|FX006 32mg in Glenohumeral OA Population|Single intra-articular (IA) injection
16374104|NCT04160091|Placebo Comparator|Normal Saline in Glenohumeral OA Population|Single intra-articular (IA) injection
16374105|NCT04160091|Experimental|FX006 32mg in Adhesive Capsulitis Population|Single intra-articular (IA) injection
16374106|NCT04160091|Placebo Comparator|Normal Saline in Adhesive Capsulitis Population|Single intra-articular (IA) injection
16374107|NCT04160078|Experimental|Mindfulness Intervention Arm|A stress reduction plus sleep education intervention to improve sleep health
16374109|NCT04160052|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax orally PO QD on days 1-7 or 1-14 and azacitidine SC or IV over 15 minutes on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
16374110|NCT04160039|Experimental|Cycle Ergometry + Standard PT/OT|
16374111|NCT04160039|No Intervention|Standard PT/OT alone|
16374112|NCT04160026|Active Comparator|IPTp-SP|Arm 1. Standard single-day stat course of quality-assured SP (Fansidar ®) of 3 tablets (500 mg of sulphadoxine and 25 mg of pyrimethamine). SP given monthly
16374113|NCT04160026|Experimental|IPTp-DP|Arm 2. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy). DP given monthly
16374114|NCT04160026|Experimental|IPTp-DP Plus|Arm 3. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy) plus targeted information for health providers.
16374115|NCT04160013|Experimental|Discipline education|Education about discipline using the Play Nicely program (www.playnicely.org).
16374116|NCT04160013|Placebo Comparator|Cavity prevention|Education about cavity prevention using a 2 page handout.
16374143|NCT04159844|Active Comparator|Multi componant bandage|Application with 50% overlap
16374144|NCT04159844|Active Comparator|Short stretch bandage bis|Application with 50% overlap in combinaison with wading
16374117|NCT04160000|Active Comparator|Phase 1 Catheter Ablation|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They randomly assigned to catheter ablation as one arm. They will undergo a catheter ablation procedure within 14 days of randomization. This procedure will include isolation of all four pulmonary veins in the antrum using catheter delivered radiofrequency current, cryothermal or laser ablation energy with standard FDA approved ablation catheter systems used in atrial fibrillation ablation. Patients will be monitored for a minimum period of 9 months after the catheter ablation intervention.
16374118|NCT04160000|Active Comparator|Phase 1 Antiarrhythmic drug therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They will be randomly assigned to antiarrhythmic drug therapy for Rate or Rhythm control in this arm. They will undergo drug dose titration within 14 days of randomization. . Patients will be monitored for a minimum period of 9 months after the AAD therapy initiation
16374119|NCT04160000|Active Comparator|Phase 2 Guided Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to insertion of an implantable hemodynamic monitor in this arm and heart failure therapy guided by wireless hemodynamic monitoring. Patients will be monitored for a minimum period of 9 months after the implantable hemodynamic monitor insertion on guided drug therapy
16374120|NCT04160000|Active Comparator|Phase 2 Empiric Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to heart failure management with empirical selection of heart failure therapy. Patients will be monitored for a minimum period of 9 months after the initiation of empirically selected heart failure drug therapy
16374121|NCT04159987|Experimental|Spinal muscular atrophy patient|
16374122|NCT04159974|Experimental|Durvalumab|Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
16374123|NCT04159974|Experimental|Durvalumab + Tremelimumab|Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).
16374124|NCT04159961|Experimental|GroupA|Inject the Drug into submental fat and abdominal fat via subcutaneous
16374125|NCT04159961|Experimental|GroupB|Inject the Drug into submental fat and abdominal fat via subcutaneous
16374126|NCT04159961|Experimental|GroupC|Inject the Drug into submental fat and abdominal fat via subcutaneous
16374127|NCT04159948|Placebo Comparator|Water|Patients will be allowed to drink water up to 2 hours before their caesarean section.
16374128|NCT04159948|Active Comparator|Carbohydrate drink|Patients will be allowed to drink a designated carbohydrate drink up to 2 hours before their caesarean section.
16374129|NCT04159948|Active Comparator|Apple juice|Patients will be allowed to drink apple juice up to 2 hours before their caesarean section.
16374130|NCT04159935|Experimental|iLux® treatment|The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
16374131|NCT04159935|Experimental|Delayed iLux® treatment|Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.
16374132|NCT04159922||Type 2 diabetic patients with foot wounds|
16374133|NCT04159909|Experimental|VNS transcutaneous stimulation|"5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.
~The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve."
16374134|NCT04159909|Sham Comparator|Sham stimulation|"5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.
~The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve."
16374135|NCT04159896|Experimental|Treatment (ESK981, nivolumab)|Patients receive ESK981 PO QD for 5 consecutive days per week, followed by a 2-day break. Patients also receive nivolumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16374136|NCT04159883|Experimental|app|For the App group, we installed the app from the store in their smart phone or tablets, made their account using the same email they use in their smart phone store. the participant was informed if they cannot follow the animated image in the app, they can re-launch the program and start to follow.
16374137|NCT04159883|Active Comparator|paper|For the paper group, the participants were provided with a hard copy of the exercise program; we gave one paper of all nine exercises.
16374138|NCT04159870|Experimental|Intervention Group|Rifaximin 1200 mg/day in 3 doses
16374139|NCT04159870|Active Comparator|Control Group|Norfloxacin 400 mg/day in one dose
16374140|NCT04159857|Active Comparator|One-hand|During LTCS, the fetal head traditionally is delivered by one-hand manual extraction (a surgeon inserts one hand into the uterus via the hysterotomy and lifts the fetal head out of maternal pelvis, subsequently significant abdominal pressure is required to squeeze the fetal head out of hysterotomy) along with application of significant abdominal/fundal pressure.
16374141|NCT04159857|Experimental|Two-hand|An innovative approach to manual head extraction, with surgeon's both hands formed as a pair of forceps, has been used by the PI of this study for years during the LTCS for head extraction in the difficult situations described above without complication, often time it was used after one hand approach failed to deliver the infant, vacuum/forceps and abdominal pressure usually was not needed in these cases.
16374146|NCT04159831|Experimental|800,000 U LTI-01|800,000 U LTI-01 qd x 3 days administered intrapleurally
16374147|NCT04159831|Experimental|1,200,000 U LTI-01|1,200,000 U LTI-01 qd x 3 days administered intrapleurally
16374148|NCT04159831|Placebo Comparator|Placebo|placebo (normal saline) 6ml qd x 3 days administered intrapleurally
16374149|NCT04159818|Experimental|Control group|no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks
16374150|NCT04159818|Experimental|Cisplatin induction|Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
16374151|NCT04159818|Experimental|Low dose doxorubicin induction|Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
16374152|NCT04159805|Experimental|TAK-079 Dose 1|TAK-079 dose 1 injection, subcutaneously, once weekly for 8 weeks.
16374153|NCT04159805|Experimental|TAK-079 Dose 2|TAK-079 dose 2 injection, subcutaneously, once weekly for 8 weeks.
16374154|NCT04159805|Placebo Comparator|TAK-079 Placebo-matching|TAK-079 placebo-matching injection, subcutaneously, once weekly for 8 weeks.
16374155|NCT04159792||stroke|Those with standard treatment as usual.
16374157|NCT04159766|Active Comparator|NLY01 (2.5 mg)|
16374158|NCT04159766|Active Comparator|NLY01 (5.0 mg)|
16374159|NCT04159766|Active Comparator|NLY01 (10 mg)|
16374160|NCT04159766|Placebo Comparator|Placebo|
16374161|NCT04159753|Other|Spinal Cord Stimulator|Burst neurostimulation
16374162|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
16374163|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
16374164|NCT04159727|Experimental|IBD or PD patients|20 patients suffering from IBD 10 patients suffering from PD
16374165|NCT04159727|Active Comparator|Asymptomatic subjects|30 asymptomatic subjects matched to patients on age, sexe and BMI
16374166|NCT04159714|Experimental|Bandage Contact Lens (BCL) group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have a bandage contact lens soaked in antibiotic solution placed in the affected eye
16374167|NCT04159714|No Intervention|Usual Care Group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have usual care provided in the Emergency Department
16374168|NCT04159701|Experimental|LY3454738|LY3454738 administered intravenously (IV).
16374169|NCT04159701|Placebo Comparator|Placebo|Placebo administered IV.
16374170|NCT04159688|Experimental|Alcohol Challenge|Alcohol Challenge, I.V. infusion, 60 mg/dL in 6% saline (v/v), Given once
16374171|NCT04159675||control patients|Patients with idiopathic craniosynostosis
16374172|NCT04159675||HR patients|Patients with craniosynostosis due to HR
16374173|NCT04159662|Experimental|Cognitive Intervention|
16374174|NCT04159662|Active Comparator|Active Control Intervention|
16374175|NCT04159649|Experimental|letrozole, gonadotropins and fixed GnRH antagonist|letrozole (2.5 mg) will be given from the second day of the cycle and for 5 days, gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF (interventional group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
16374176|NCT04159649|Active Comparator|gonadotropins and fixed GnRH antagonist (control group).|gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF(control group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
16374177|NCT04159636|No Intervention|Fasting group|Participants will be remained fasted until surgery
16374178|NCT04159636|Experimental|Carbohydrate group|Participants will be allowed to drink carbohydrate beverage before 2 hours of surgery
16374179|NCT04159623|Experimental|Belk Device|With Belk Device
16374180|NCT04159623|Other|Standard Rehabilitative treatment|With the standard rehabilitative treatment
16374181|NCT04159610|Experimental|WO 3970|Formulation containing WO 3970 for topical application
16374182|NCT04159610|Active Comparator|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
16374183|NCT04159584|Experimental|Enrolled Subject|All subjects will undergo the medical music intervention.
16374184|NCT04159571|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
16374185|NCT04159571|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
16374186|NCT04159571|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
16374187|NCT04159571|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
16374188|NCT04159558|Experimental|experimental hypertension|The subjects with Hypertension will be trained in the use of the personalized help tool and will use it during a period of 3 months.
16374189|NCT04159558|Experimental|experimental diabetes|The subjects with Diabetes will be trained in the use of the personalized help tool and will use it during a period of 3 months.
16374190|NCT04159558|Experimental|experimental heart failure|The subjects with Heart failure will be trained in the use of the personalized help tool and will use it during a period of 3 months.
16374191|NCT04159558|Experimental|experimental copd|The subjects with COPD will be trained in the use of the personalized help tool and will use it during a period of 3 months.
16374192|NCT04159558|Experimental|experimental asthma|The subjects with Asthma will be trained in the use of the personalized help tool and will use it during a period of 3 months.
16374193|NCT04159558|Experimental|experimental obesity|The subjects with Obesity will be trained in the use of the personalized help tool and will use it during a period of 3 months.
16374194|NCT04159545||Participants treated with DAAs|"Participants identified through the standard pathway of care as receiving Direct-Acting Antiviral (DAA) drugs to treat chronic hepatitis C with a history of problematic substance use.
~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.
~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
16374195|NCT04159545||Control Group|"Participants identified through the standard pathway of care as having HCV positive antibodies who spontaneously clear the infection.
~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.
~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
16374196|NCT04159532|Experimental|Monoglyceride (MAG)|Group A will receive the omega-3 fatty acids in monoglyceride formulation (MAG). Subjects will receive 1.5g per day of MAG-EPA/MAG-DHA in a proportion of 460:200 for 12 consecutive weeks.
16374197|NCT04159532|Active Comparator|Triglyceride (TG)|Group B will receive the omega-3 fatty acids in triglyceride formulation (TG). Subjects will receive 1.5g per day of TG-EPA/TG-DHA in a proportion of 460:200 for 12 consecutive weeks.
16374198|NCT04159532|Active Comparator|Ethyl Ester(EE)|Group C will receive the omega-3 fatty acids in Ethyl ester formulation (EE). Subjects will receive 1.5g per day of EE-EPA/EE-DHA in a proportion of 460:200 for 12 consecutive weeks.
16374199|NCT04159519|Experimental|Treatment reduction arm|All participants will receive Fasenra® 30 mg Q8W + SMART or Symbicort® reliever only (starting with medium-dose Symbicort® 200/6 μg ×2 inhalations BID maintenance + Symbicort® 200/6 μg reliever PRN; tapering to Symbicort® 200/6 μg reliever only, as per tapering scheme and depending on degree of asthma control). The reduction period in this arm will last 32 weeks.
16374200|NCT04159519|Experimental|Reference arm|All participants will receive Fasenra® 30 mg Q8W + high-dose Symbicort® maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm will continue on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment for 32 weeks.
16374201|NCT04159506|Experimental|The Equus Effect (TEE)|TEE is a 4-session intervention. Each session is 4 hours and includes: 1) mindfulness-based activities; 2) didactics about emotion regulation and interpersonal skills; and 3) experiential learning activities with horses that provide opportunities to practice emotion regulation and interpersonal skills. At the end of each session, Veterans debrief about what they learned and identify how they might apply this knowledge to manage their mental health concerns and function better socially.
16374202|NCT04159506|Active Comparator|Attention Control (AC)|AC will exclude equine-related activities or discussions but maintain mindfulness-based activities, emotion regulation and interpersonal skills didactics, and experiential learning activities with between-session application. Instead of experiential equine activities, AC will rely on team-building activities, which aim to enhance social relations by involving participants in collaborative tasks and providing opportunities for emotion regulation and interpersonal skills practice.
16374203|NCT04159493|Placebo Comparator|Placebo|"Subjects will be randomized to placebo.
~Placebo, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
16374204|NCT04159493|Active Comparator|Ovestin|"Subjects will be randomized or assigned to varying doses of Ovestin (500, 50, 25, 12.5, 10, 5, 2.5, 0.5, 0.25 mcg) as determined by the dose de-escalation constraints specified in the protocol.
~Active, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
16374205|NCT04159480|Experimental|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
16374206|NCT04159480|Active Comparator|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
16374207|NCT04159467|Active Comparator|Group 1- diet therapy (control)|Control group undergoing a low calorie diet will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and after 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
16374242|NCT04159168|Experimental|Arm 3: R33 FAST|Individuals randomized this Arm of the R33 phase will receive the FAST intervention, with the aim of replicating FAST target engagement (as demonstrated in the R61 phase) with a new high-CU sample, and to evaluate the FAST intervention in comparison to an active control condition (Arm 4, implicit eye gaze training).
16374243|NCT04159168|Active Comparator|Arm 4: R33 Active Control|Individuals in this Arm will receive the active control component, which is an implicit gaze training intervention.
16374208|NCT04159467|Experimental|Grupo 2 - low calorie diet + PFMT (experimental)|"Experimental group will receive supervised pelvic floor muscle training additionally to a low calorie diet. Women will be instructed to perform daily pelvic floor muscle training at home. 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The 4 sets will be performed in 2 different positions (sitting and standing). Twice a month (once every 15 days), they will receive a supervised session using the same protocol described above except for the position that will be only sitting and standing. In addition, they will be instructed to perform the the knack maneuver."
16374209|NCT04159454|Experimental|PITA Participants|"All patients in the study are part of the PITA arm, where PITA will be on for Weeks 0-8, and off from Weeks 8-12."
16374210|NCT04159415|Experimental|Treatment A|
16374211|NCT04159415|Experimental|Treatment B|
16374212|NCT04159389|No Intervention|traditional teaching|theoretical courses and procedural simulation on airway management during rapid sequence induction
16374213|NCT04159389|Experimental|Mental visualization|traditional teaching completed by mental visualization : theoretical courses and procedural simulation on airway management during rapid sequence induction + mental visualization (theoretical courses, audioguide for individual practice and experience sharing session)
16374214|NCT04159376|Experimental|Bone Metastases Patients|
16374215|NCT04159363|Experimental|Intervention group|Participants in the intervention group will receive an interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage) in addition to routine care provided by the respective hospitals.
16374216|NCT04159363|No Intervention|Control group|Participants in the control group will receive routine care provided by the respective hospitals . The routine care includes normal consultation with their attending physician, information concerning treatment plans, such as surgical procedures and its associated risks, preoperative preparations and postoperative care, treatment after discharge and/or subsequent adjunct therapy if required.
16374217|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Feasibility|Feasibility Phase.
16374218|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Validation|Validation Phase.
16374219|NCT04159324|Experimental|StroCare treatment group|Optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
16374220|NCT04159324|No Intervention|control group|routine aftercare stroke treatment
16374221|NCT04159311|Active Comparator|Treated group|"The treated group will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3."
16374222|NCT04159311|Sham Comparator|Untreated group|"The untreated group will have 4 sessions of only testing osteopathy (M0, M1, M2, M3)."
16374223|NCT04159298|Experimental|Intervention|Intervention group who will undergo the Top Spin 360 study protocol.
16374224|NCT04159298|No Intervention|Traditional|Control group who undergo traditional usual clinical care comprised of bi-weekly physiotherapy sessions and home-based exercise programs.
16374225|NCT04159285|Experimental|Group CBT|15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
16374226|NCT04159285|Experimental|Treatment as Usual|Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
16374227|NCT04159272|Experimental|Mindfulness Training|The MT programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on our ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
16374228|NCT04159272|No Intervention|Control|Participants follow their regular course curriculum.
16374229|NCT04159259|Experimental|Diet intervention|All participants will stay weight stable while undergoing 3 phases of a dietary intervention
16374230|NCT04159246||Sovaldi group|patients with a documented diagnosis of chronic hepatitis C , normal renal functions And Rheumatoid factor tests (to exclude Purtscher like retinopathy as a rare presentation of cryoglobuinemia which considered one of extra hepatic manifestations of HCV)
16374231|NCT04159233|Other|Adapted 'Brief Behavioral Therapy for Insomnia' (BBTI)|All participants will receive the same intervention in this pilot study.
16374232|NCT04159220|No Intervention|Control group|The transport will be released without a clamping of endotracheal tube before each disconnection from ventilator.
16374233|NCT04159220|Experimental|Clamping group|The transport will be released with a clamping of endotracheal tube before each disconnection from ventilator.
16374234|NCT04159207||A Longitudinal Study of Inflammatory Pathways in Depression|We target to recruit 80 patients with Major Depression Disorder diagnosis and 80 patients with Major Depression Disorder with suicidal behavior.
16374235|NCT04159194|Active Comparator|Normal CHO|
16374236|NCT04159194|Experimental|High CHO|
16374237|NCT04159181|Experimental|Day A|After an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).
16374238|NCT04159181|Experimental|Day B|After an overnight fast participants will drink 200mL of water
16374239|NCT04159181|Experimental|Day C|After an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
16374240|NCT04159168|Experimental|Arm 1: R61 FAST|Individuals in this Arm will receive the FAST intervention, as described in the Intervention section of the Clinical Trials form below, with a focus on demonstrating target (facial affect sensitivity) engagement.
16374241|NCT04159168|No Intervention|Arm 2: R61 No-Treatment Control|Individuals in this Arm will not receive any intervention.
16374244|NCT04159155|Experimental|Early Stage Cohort - Arm A|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
16374245|NCT04159155|Experimental|Early Stage Cohort - Arm B1|"External beam radiotherapy, 5 days per week, for 4-5 weeks
~Cisplatin intravenously, on the first and fourth week of radiotherapy.
~Brachytherapy will be given if needed Then
~Carboplatin, intravenously, once every 3 weeks for 4 cycles
~Paclitaxel, intravenously, once every 3 weeks for 4 cycles"
16374246|NCT04159155|Experimental|Advanced Stage Cohort Arm C|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
16374247|NCT04159155|Experimental|Advanced Stage Cohort Arm D1|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles Then Niraparib daily continuous dosing for 28 day cycles
16374248|NCT04159155|No Intervention|Exploratory Cohort|Observation on Standard of care
16374249|NCT04159142|Experimental|Nab-paclitaxel + Carboplatin|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
16374250|NCT04159142|Experimental|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
16374251|NCT04159116|Experimental|Suctioned Prior to Endoscope|This group will be suctioned prophylactically after sedation but prior to introduction of endoscope.
16374252|NCT04159116|Other|Standard of Care|This group will be suctioned by anesthesia providers when clinically indicated by copious secretions, coughing, choking or desaturation.
16374259|NCT04159090|Experimental|Prostate cancer patients|
16374260|NCT04159077|Experimental|Tamsulosin Hydrochloride (HCL)|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of tamsulosin HCL to be started 3 days prior to their date of surgery.
16374261|NCT04159077|Placebo Comparator|Placebo|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of placebo to be started 3 days prior to their date of surgery.
16374262|NCT04159064||Minimal Invasive Extracorporeal Circulation(MIECC)|"Monitoring coagulation using thromboelastometry and platelet function using impedance aggregometry. Samples at the following phases:
~Time 0: Baseline, upon arrival at the operation room (samples for thromboelastometry and impedance aggregometry), Time 2: after aortic cross clamp off (only sample for thromboelastometry), Time 2': 20 minutes post protamine administration (only sample for impedance aggregometry )."
16374263|NCT04159051|Experimental|Combined regional hyperthermia and salvage radiotherapy|
16374264|NCT04159038|Experimental|Immediate Intervention Group|Parents in the immediate intervention arm sign a study consent that is integrated into the WIC Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by EI/ECSE. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.
16374265|NCT04159038|Other|Delayed Intervention Group|6 months after the immediate intervention group receives their training, the delayed intervention group will receive the training. Prior to implementation of the training in the delayed intervention group, the study team will meet with the Stakeholder Advisory Board. It will review interim results and consider the efficacy of the intervention as a whole. Based on actual use patterns and stakeholder feedback, the investigators will make improvements to the intervention prior to implementing it in the delayed intervention group.
16374266|NCT04159025|Experimental|Endobronchial ultrasound guided miniforceps biopsy|"Standard of care convex-probe endobronchial ultrasound and transbronchial needle aspiration followed by rapid on-site evaluation. If evaluation yields a diagnosis of nonsmall cell lung cancer then EBUS-MFB will be performed.
~With the EBUS bronchoscope, 6 needle punctures will be made into the targeted lymph node with the 22 gauge aspiration needle. The needle will be removed and the 1mm miniforceps will be passed through the working channel of the EBUS-bronchoscope into the targeted lymph node through the puncture site made using the 22 gauge needle using continuous endobronchial ultrasound guidance. The miniforceps will be used to obtain a core biopsy of the targeted lymph node - 8 core biopsies will be obtained from each targeted lymph node using this technique"
16374267|NCT04159012|Experimental|Active transcranial direct current stimulation|Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
16374302|NCT04158739|Experimental|Treatment (cytarabine, flotetuzumab)|Patients receive cytarabine IT on days -6 to 0 prior to cycle 1. Patients may receive additional doses of cytarabine on day 1 of subsequent cycles per physician discretion. Patients also receive flotetuzumab IV continuously for 28 days. Treatment repeats every 29 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16374268|NCT04159012|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
16374269|NCT04158999||Mother milk|Step 1: Mothers who meet the sample selection criteria will be informed about the scope of the study and their written and verbal consent will be obtained. Data collection form will be applied to mothers who accept to participate in the study by using face to face interview technique. Mothers and newborns will be weighed and 4 ml breast milk sample will be taken from the mother for manual milking.
16374270|NCT04158986|No Intervention|Standard treatment|Receives standard post-discharge care with planned follow-up in the clinic for liver failure or ambulatory.
16374271|NCT04158986|Experimental|Nurse-driven post-discharge intervention|Participates in a nurse-driven post-discharge intervention program.
16374272|NCT04158973|Experimental|VTE prophylaxis based on bleeding risk assessment|Patients will undergo a bleeding risk assessment to determine their entering VTE prophylaxis. Low bleeding risk patients will have once daily sc LMWH prophylaxis. Intermediate bleeding risk patients will have q 12 h sc low dose unfractionated heparin prophylaxis. High bleeding risk patients will have mechanical prophylaxis. Assigned prophylaxis can be interrupted as clinical judgement requires, e.g., for peri-procedural reasons. When patients are discharged, if they have low risk of bleeding at the time of discharge, whatever their bleeding risk assessment at the time of randomization, will begin 5 mg rivaroxaban prophylaxis (two 2.5 mg tablets) once daily with food, starting on the day of discharge, for 15 days.
16374273|NCT04158973|Active Comparator|Routine VTE prophylaxis in local clinical practice|VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge.
16374274|NCT04158960|No Intervention|Control|Control period; no equine-assisted activities or brain-building activities occurred
16374275|NCT04158960|Active Comparator|Equine-assisted activities period|Period in which only equine-assisted activities were performed
16374276|NCT04158960|No Intervention|Washout|Washout period; no equine-assisted activities or brain-building activities occurred
16374277|NCT04158960|Experimental|GaitWay period|Period in which both equine-assisted activities and brain-building activities were performed
16374278|NCT04158947|Experimental|T-DM1 + Afatinib|"Trastuzumab emtansine (T-DM1) : 3.6 mg/kg IV Day 1 every 21 days.
~Afatinib: the highest dose of Afatinib with T-DM1 found in Phase I, po every day"
16374279|NCT04158947|Active Comparator|T-DM1|Trastuzumab emtansine (T-DM1) :3.6 mg/kg IV Day 1 every 21 days.
16374280|NCT04158934||Haemophilia A Group|Participants with haemophilia A in the study will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national summary of product characteristics (SmPC).
16374281|NCT04158921|Other|The Control:Diabetes mobile app for Diabetes self-management.|This is a single arm open label pilot clinical trial that will assess patient-reported blood glucose levels before and after using the Control:Diabetes mobile app.
16374282|NCT04158908|Experimental|Oncolo_GIST Arm|Patients in this arm will receive care from a clinician that received the Oncolo-GIST Version 1.0 intervention training.
16374283|NCT04158895||Patients enrolled in differentiated service delivery models|
16374284|NCT04158895||Patients not enrolled in DSD models|
16374285|NCT04158882||Patients enrolled in differentiated service delivery models|
16374286|NCT04158882||Patients not enrolled in DSD models|
16374287|NCT04158869||Cases|Patients with pMDD, enrolled in the Investigator-initiated clinical trial IICT (ClinicalTrials.gov Identifier: NCT03167307)
16374288|NCT04158869||Controls|Controls matched to cases according to age, sex and school education
16374289|NCT04158856|Experimental|Experimental Arm|adjuvant Pyrotinib plus Trastuzumab
16374290|NCT04158843|Experimental|Radical local treatment|Radical resection is performed, and the cutting edge is negative, or radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy). Systemic endocrine therapy and targeted therapy are allowed after radical local therapy. However, whether systemic chemotherapy should be used is determined by clinicians according to clinical experience or guidelines.
16374291|NCT04158843|Active Comparator|Palliative treatment|No radical surgical resection or radical surgical resection or radiotherapy is performed in this group. But palliative internal fixation or radiotherapy for pain relief is permitted. Moreover, systemic chemotherapy, endocrine therapy and targeted therapy are allowed.
16374292|NCT04158830|Other|Group 1 - ACOG recommended dose|oral dose: 81 mg aspirin daily; designated by odd number assignment [1-001, 1-003, 1-005, etc. to 899]
16374293|NCT04158830|Active Comparator|Group 2 - Comparison Dose|oral dose: 162 mg aspirin daily; designated by even number assignment [2-002, 2-004, 2-006, etc. to 900]
16374294|NCT04158817|Experimental|Experimental Arm|All Prostate cancer patients recruited to the study will be administered 2.11 MBq/kg of 68Ga-THP-PSMA in a single dose injection.
16374295|NCT04158804|Experimental|Procalcitonin algorithm+stewardship team|antibiotic prescription guided by PCT values
16374296|NCT04158804|No Intervention|standard group|standard of care guided by current guidelines
16374297|NCT04158791||EMM-I|Group with an intact IS/OS junction
16374298|NCT04158791||EMM-D|Group with a disrupted IS/OS junction
16374299|NCT04158778|Experimental|MDMA assisted Psychotherapy|All participants receive 2 sessions of MDMA-assisted psychotherapy
16374300|NCT04158765||Infertile men|Men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
16374301|NCT04158752|Experimental|Open Label Galcanezumab|Participants will receive their 1st injectable dose during the Day 30 visit. Participants will then inject themselves at home on Day 60 and again on Day 90.
16374303|NCT04158713|Placebo Comparator|CTX-alone|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
16375096|NCT04153383||TMAD|Tissue motion annular displacement (TMAD) transesophageal echocardiography
16374304|NCT04158713|Experimental|CTX-DP|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.
16374305|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 1)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).
16374306|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 2)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.
16374307|NCT04158700|Experimental|LY3200882 and Pembrolizumab Expansion|Participants with urothelial carcinoma, non-small cell lung cancer, or hepatocellular carcinoma: LY3200882 administered orally twice in combination with pembrolizumab administered IV.
16374308|NCT04158687|Experimental|1 g CTP-692|Powder for oral solution, taken once daily
16374309|NCT04158687|Experimental|2 g CTP-692|Powder for oral solution, taken once daily
16374310|NCT04158687|Experimental|4 g CTP-692|Powder for oral solution, taken once daily
16374311|NCT04158687|Placebo Comparator|Placebo|Powder for oral solution, taken once daily
16374312|NCT04158674|Experimental|Levosimendan|
16374313|NCT04158674|Sham Comparator|Placebo|
16374314|NCT04158661||Tmin-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG
~age ≥ 18 years
~thymectomy ≥ three years"
16374315|NCT04158661||T0-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG
~a very long disease history OR
~age ≥ 18 years
~rejecting a thymectomy or have contraindications for thymectomy"
16374316|NCT04158661||"MGTX-group (historical control group)"|"from MGTX-trial (Randomized Trial of Thymectomy in Myasthenia Gravis)"
16374317|NCT04158648|Experimental|Emicizumab|Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
16374319|NCT04158622|Experimental|Pneumatic Retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy + laser/cryotherapy
16374320|NCT04158622|Experimental|Pars Plana Vitrectomy|Patients with retinal detachment allocated to pars plana vitrectomy + laser/cryotherapy
16374321|NCT04158609||Group 1|Pregnant women with CPR value below 1, based on Doppler indices assessment
16374322|NCT04158609||Group 2|Pregnant women with CPR value equal to or above 1, based on Doppler indices assessment
16374323|NCT04158596|Experimental|Treatment|The applied therapeutic vibrations generated by an acoustic coil have a defined sweeping frequency range.
16374324|NCT04158596|Active Comparator|Control|A control device with a different vibration pattern will be used as comparator intervention
16374325|NCT04158583|Experimental|Part A|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682. RO7296682 will be administered by intravenous (IV) infusion in a three-weekly schedule (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
16374326|NCT04158583|Experimental|Part B|Dose-Expansion: Will start once MTD/RP2D dose is defined in Part A. Participants will receive a fixed dose of RO7296682 at the dosing regimen established in part A (Q3W schedule).
16374327|NCT04158544||Checkpoint Inhibitors|Patients with metastatic melanoma receiving systemic therapy with checkpoint inhibitors
16374328|NCT04158544||Kinase Inhibitors|Patients with metastatic melanoma receiving systemic therapy with kinase inhibitors
16374329|NCT04158531|Experimental|REC2Stim|Use electrocorticography (ECoG)-based seizure detection and cortical network stimulation upon seizure onset detection.
16374330|NCT04158518|Experimental|Toxicities reduced treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).
16374331|NCT04158518|Active Comparator|Conventional treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by concurrent cisplatin chemotherapy with standard radiation dose when responses to induction chemotherapy are less than 50% Partial Response(PR).
16374332|NCT04158505||non-interventional study|
16374333|NCT04158492|Active Comparator|Standard diagnostic tests|Patients who will undergo only the standard diagnostic procedures
16374334|NCT04158492|Experimental|Experimental + standard diagnostic tests|Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).
16374335|NCT04158479||Pulmonary Support|ECMO support for acute respiratory failure, ARDS
16374336|NCT04158479||Cardiac Support|ECMO support for heart failure, cardiogenic shock
16374337|NCT04158479||Extracorporeal Cardiopulmonary Resuscitation|ECMO support for cardia arrest
16374338|NCT04158466|Experimental|Kalifilcon A Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
16374339|NCT04158466|Active Comparator|Biotrue ONEday Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
16374340|NCT04158453|Active Comparator|AUT00201|
16374341|NCT04158453|Placebo Comparator|Placebo|
16374447|NCT04157751|Placebo Comparator|Placebo|
16374342|NCT04158440|Experimental|4cycles Toripalimab+platinum doublet chemotherapy,13 cycles Toripalimab Neoadjuvant Chemotherapy|Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during peioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
16374343|NCT04158440|Experimental|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo ); Neoadjuvant Chemotherapy|Participants receive totally 4 cycles of Placebo combined with platinum doublet chemotherapy during peioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
16374344|NCT04158427|Experimental|Fecal transplant|A single dose fecal transplant is given (via colonoscopy) from a healthy donor
16374345|NCT04158427|Placebo Comparator|Placebo|A single dose patient's own feces is given (via colonoscopy)
16374346|NCT04158414|Experimental|Different types of cancer Patients|Lymphoma,Nasopharyngeal Cancer; Esophageal Cancer, Cervical cancer; Hepatobiliary and pancreatic cancer; Sarcoma; Prostate Cancer
16374347|NCT04158401||Control group|Pregnant patients between 12w0d and 22w0d who present for prenatal care.
16374348|NCT04158401||Cerclage group A|Patients who present for a history-indicated cerclage placement.
16374349|NCT04158401||Cerclage group B|Patients who present for an ultrasound-indicated cerclage placement.
16374350|NCT04158401||Cerclage group C|Patients who present for an exam-indicated cerclage placement.
16374351|NCT04158388|Experimental|EXPERIMENTAL DIET GROUP|
16374352|NCT04158388|Other|CONTROL GROUP|
16374353|NCT04158388|Experimental|EXPERIMENTAL MASSAGE GROUP|That group received moderate pressure digital manual therapy.
16374354|NCT04158388|Experimental|EXPERIMENTAL PLACEBO GROUP|That group was treated with a US (in off mode) without conductive gel. Placebo group.
16374355|NCT04158375|Experimental|Insulin Resistant Exercise Group|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Resistance training will be performed using a combination of upper and lower body exercises using machine and free weights. Upper body exercises are chest press, incline press, seated row, lat pull down, triceps extension, biceps curl and lateral raises. Major muscle groups for upper body exercises will include chest (pectoralis major and minor), arm (biceps and triceps), shoulder (deltoids) and back (latissimus dorsi and rhomboids). Lower body exercises are leg press, lunge (with body weight progressing to dumbbells), seated leg extension, seated leg curl, calf raises and abdominal crunches. Major muscle groups for the lower body exercises will be thighs (quadriceps and hamstrings), calves (gastrocnemius and soleus) and core (rectus abdominus and obliques).
16374356|NCT04158375|No Intervention|Insulin Resistant Control Group|Participants in this group will perform no exercise for the 3 month study period.
16374357|NCT04158375|No Intervention|Insulin Sensitive Lean Group|Participants in this group will have a baseline study for comparison to the insulin resistant groups.
16374358|NCT04158362|Experimental|Standard Chemotherapy regimen|"* Paclitaxel: administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle.
~OR
~* Capecitabine: given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks."
16374359|NCT04158362|Experimental|Standard Endocrine therapy (ET) regimen + Abemaciclib|"* Letrozole: continuous orally administration of 2.5 mg/day (1 tablet/day) OR anastrozole continuous orally administration of 1 mg/day (1 tablet/day) in combination with oral abemaciclib 150 mg (BID: twice a day) continuous for patients NSAI naïve or relapsing >1 year after the end of adjuvant ET.
~OR
~* Fulvestrant: 500 mg intramuscular on D1-D15-D29 (loading dose). Then 500 mg every 28 days (maintenance dose) with oral abemaciclib 150 mg BID continuous for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
~For women with a non-menopausal status at inclusion, a concomitant Luteinizing hormone-releasing hormone (LH-RH) agonist will be administered in combination with ET every 28 days. The LH-RH agonist drug to be used will be left to the investigator's choice."
16374360|NCT04158349|Experimental|Dose Level 0|Dose Level 0: 85 mg/m2 Oxaliplatin IP every 2 weeks
16374361|NCT04158349|Experimental|Dose Level 1|Dose Level 1: 95 mg/m2 Oxaliplatin IP every 2 weeks
16374362|NCT04158349|Experimental|Dose Level 2|Dose Level 2: 105 mg/m2 Oxaliplation IP every 2 weeks
16374363|NCT04158336|Experimental|Single Agent Dose Escalation and Expansion|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
16374364|NCT04158310||Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
16374365|NCT04158310||Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD.
16374366|NCT04158297|Active Comparator|ESWL|Extracorporeal shock wave lithotripsy for the treatment of pancreatic duct stones
16374367|NCT04158297|Active Comparator|SOPIL|Single Operator Pancreatoscopy and intraductal lithotripsy for the treatment of pancreatic duct stones
16374368|NCT04158271|Experimental|Prone Position|Evaluation of Techniques for tracheal tube Exchange in prone position
16374369|NCT04158271|Experimental|Laryngeal tube|Evaluation of Techniques for tracheal tube Exchange in patients with laryngeal tube (LT)
16374370|NCT04158271|Experimental|Endotracheal tube Leackage|Evaluation of Techniques for tracheal tube Exchange in critical care patients with a endotracheal tube and a high leackage
16375503|NCT04150614|Active Comparator|ARM 2|ARM 2 -intravenous ondansetron plus intravenous dexamethasone
16374377|NCT04158245|Experimental|18F-fluciclovine PET Scan|Single intravenous administration of 18F-fluciclovine for PET Scan.
16374378|NCT04158232|Active Comparator|Blood clotting protocol for pulp regeneration|pulp regeneration for mature teeth using blood clotting protocol
16374379|NCT04158232|Experimental|platelet rich fibrin for pulp regeneration|pulp regeneration for mature teeth using platelet rich fibrin (PRF)
16374380|NCT04158219|Experimental|Treatment|Behavioral activation for health and depression (BA-HD)
16374381|NCT04158206|Experimental|Maternal voice|The mother's voice recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group were explored maternal voice, which start from 3 minutes before the procedure, once a day and for three consecutive days.And then recorded the process by the camera, uploaded to YouTube within 24 hours and sent to their mother.
16374382|NCT04158206|No Intervention|control group|When the premature infants undergoing heel lance procedure, the control group were under routine care.And then recorded the process by the camera for three consecutive days, uploaded to YouTube within 24 hours and sent to their mother.
16374383|NCT04158193|Experimental|Acupuncture group|Subjects in the acupuncture group are given acupuncture treatment.
16374384|NCT04158193|Experimental|Sham acupuncture control group|Subjects in the sham acupuncture control group are given non-acupoint shallow acupuncture.
16374385|NCT04158167|Other|oxytocin|All subjects will receive both oxytocin and placebo in a counterbalanced design
16374386|NCT04158154|Experimental|Primary Health Care Centers|Selected primary health care centers in Abuja will implement a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment.
16374387|NCT04158141|Experimental|Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.
~STEP 2: Patients receive no treatment."
16374388|NCT04158141|Experimental|Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.
~STEP 2: Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions IMRT or PBS proton therapy 5 days per week over 6 weeks."
16374389|NCT04158115|Experimental|Entire Spinal Mobilization|Entire Spinal Mobilization( All spinal segment from Co-C1to L5-S1 Moist heat. Soft tissue Mobilization Exercises. (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
16374390|NCT04158115|Active Comparator|Segmental Mobilization|Segmental Mobilization. (All lumbar segment from L1-L2 to L5-S1) Moist heat. Soft tissue Mobilization Exercises (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
16374391|NCT04158102|Experimental|20 mg single dose cohort|Subjects would receive a 20 mg single dose of EXPAREL®
16374392|NCT04158089|No Intervention|No intervention|"Participants in the No intervention group will receive treatment (e.g., prenatal care) as usual."
16374393|NCT04158089|Experimental|Attachment Exercises|"Participants in the Attachment Exercises group will receive daily texts over the 2-week intervention period with activities to do from home that are designed to increase feelings of attachment (e.g., read a children's book aloud; sing a nursery rhyme; picture giving the baby a bath; tell the baby a story; etc.)."
16374394|NCT04158076|Experimental|Co-administered of AD-2071 and AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2073(Telmisartan/Amlodipine) for 8 weeks."
16374395|NCT04158076|Active Comparator|Co-administered of AD-2071 and AD-2072|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2072(Telmisartan) for 8 weeks."
16374396|NCT04158076|Active Comparator|AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2073(Telmisartan/Amlodipine) for 8 weeks."
16374397|NCT04158063|Experimental|Dual Task Training (DTT)|
16374398|NCT04158063|Active Comparator|Single Mobility Training (SMT)|
16374399|NCT04158050||anti-IL5/IL5R-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
16374400|NCT04158050||anti-IgE-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy
16374401|NCT04158037|Experimental|mHealth App|Participants will receive the gambling disorder mHealth app.
16374402|NCT04158037|No Intervention|Wait List Control|Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.
16374403|NCT04158024|No Intervention|Volatile Anesthetic Control|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.
~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
16374404|NCT04158024|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.
16374405|NCT04158011||CNS ALL at lymphodepletion|Patients with active CNS leukemia at the time of lymphodepletion
16374406|NCT04158011||CNS ALL at inclusion|Patients who were referred to CAR T-cells with CNS disease, which was cleared by the time of lymphodepletion
16374407|NCT04157998|Placebo Comparator|control|patient receive 10 ml normal saline intravenous
16374408|NCT04157998|Active Comparator|metoclopramide group|"patient receive 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
~intravenous"
16374779|NCT04155580|Experimental|Part 3|ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
16374409|NCT04157985|Active Comparator|Continue Treatment with PD-1/PD-L1 inhibitor|Continued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
16374410|NCT04157985|Experimental|Discontinue Treatment with PD-1/PD-L1-1 inhibitor|Discontinued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
16374411|NCT04157972|Active Comparator|SIMEOX|Participants will have to perform 20 minutes of SIMEOX. Passive exhalation is required using the SIMEOX, starting from tidal volume and going until achieving residual volume.
16374412|NCT04157972|Active Comparator|PEP|Participants will have to perform 20 minutes of PEP. Active exhalation is required using a PEP device, starting from tidal volume and going until achieving residual volume.
16374413|NCT04157959|Experimental|SHR4640|SHR4640 dose1 Oral Tablet Day1~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.
16374414|NCT04157959|Experimental|Febuxostat|Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8~Day14 qd.
16374415|NCT04157946||Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
16374416|NCT04157946||Non-Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
16374417|NCT04157933|Experimental|A-1a|Part A, Arm 1 (active), Dose 1 (009-A1)
16374418|NCT04157933|Experimental|A-2a|Part A, Arm 2 (active), Dose 2 (009-A2)
16374419|NCT04157933|Experimental|A-3a|Part A, Arm 3 (active), Dose 3 (009-A3)
16374420|NCT04157933|Placebo Comparator|A-0p|Part A, placebo comparator in all 3 arms, placebo dose (009-A0)
16374421|NCT04157933|Experimental|B-1 (009-B3 -> 009-B0)|Crossover (active to placebo)
16374422|NCT04157933|Experimental|B-1 (009-B0 -> 009-B3)|Crossover (placebo to active)
16374423|NCT04157920|Other|Patients treated with Medtronic Evolut R/Pro|TAVI patients treated with Medtronic Evolut R - Evolut PRO Transcatheter Heart Valves, participated in the DIRECT trial
16374424|NCT04157920|Active Comparator|Patients treated with Acurate NEO/TF|TAVI patients treated with Symetis Acurate NEO/TF Transcatheter Heart Valve recruited prospectively.
16374425|NCT04157907||Patients with borderline personality disorder|Patients with borderline personality disorder included in the MBT program
16374426|NCT04157894||Standard LLIN|This group receives Interceptor ITNs during the mass distribution campaign.
16374427|NCT04157894||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
16374428|NCT04157894||Piperonyl butoxide LLIN|This group receives PBO ITNs during the mass distribution campaign.
16374429|NCT04157881|Other|APO-Dabigatran|Single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
16374430|NCT04157881|Other|APO-Dabigatran and Rabeprazole|4-7 doses of rabeprazole followed by single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
16374431|NCT04157868|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
16374432|NCT04157868|Placebo Comparator|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
16374433|NCT04157842|Experimental|total hip replacement with subtrochanteral osteotomy|subtrochanteral osteotomy is applied during total hip replacement
16374434|NCT04157842|Sham Comparator|total hip replacement with no osteotomy|no osteotomy is applied during total hip replacement.
16374435|NCT04157829|Experimental|Scintilling lamp- Classic lamp|
16374436|NCT04157829|Experimental|Classic lamp- Scintilling lamp|
16374437|NCT04157816|Experimental|Digital Training (DGT)|Participants allocated to this arm receive a low-intensity digital program accessible by smart phone app for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
16374438|NCT04157816|Experimental|Digital Training with Coaching Support (DGT+)|Participants allocated to this arm receive a high-intensity digital program accessible by smart phone app augmented with weekly telephone coaching support for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
16374439|NCT04157816|Active Comparator|Face-to-Face Training|Participants allocated to this arm receive a traditional classroom-based (face-to-face) program hosted in community settings for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
16374440|NCT04157803|Other|Patient cohort|Patients with polyps> 5mm with suspicion of tubular, tubulovillious or serrated adenomas, found during a videcolonoscopy.
16374441|NCT04157790|No Intervention|Neutral|Suggested to follow European Society of Cardiology guidelines for NSTEMI
16374442|NCT04157790|Active Comparator|CARE score|calculation of the CARE score and prescription for troponins assays or not according to the result (score > 1: troponins assays ; score < 2: no troponins assays)
16374443|NCT04157777|Experimental|massage|Among women who applied to Maternity Hospital 350 pregnant women were assigned to massage group. Participants in massage group filled out an information form including socio-demographic characteristics. Perineum massage with olive oil in the second period of delivery was performed to massage group.In massage group when they progressed to full dilatation of the cervix, the midwife inserted two fingers inside vagina and using a sweeping motion gently stretched the perineum with lubricant 5 up to 10 minutes, in and between mother's pushing in the second stage of labour.
16374444|NCT04157777|Experimental|control|Among women who applied to Maternity Hospital 350 pregnant women were assigned to control group. Participants in control group filled out an information form including socio-demographic characteristics.And, no other interventions except for applications performed routinely in the delivery room were done.In control group just Ritgen Maneuver was applied. At last, we com-pared the rate of intact perineum, episiotomy and laceration, mean duration of the second stage of labor and Apgar score in 1 and 5 minutes be-tween two groups.
16374445|NCT04157764|Experimental|APD|
16374446|NCT04157751|Experimental|Empagliflozin|
16374448|NCT04157738|Experimental|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
16374449|NCT04157738|Active Comparator|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
16374450|NCT04157725|Experimental|Group A (mild stimulation protocol)|
16374451|NCT04157725|Active Comparator|Group B (conventional stimulation protocol)|
16374452|NCT04157712|Experimental|Cohort A Capsule - Fasted|ALZ-801 171 mg or matching placebo once daily Day 1, ALZ-801 171 mg or matching placebo twice daily Days 2-7, ALZ-801 256.5 mg or matching placebo once daily Days 8-14
16374453|NCT04157712|Experimental|Cohort B Capsule - Fasted|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 or matching placebo mg twice daily Days 2-7, ALZ-801 340 mg or matching placebo once daily Days 8-14
16374454|NCT04157712|Experimental|Cohort C Capsule - Fed|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 mg or matching placebo twice daily Days 2-7, ALZ-801 340 mg or matching placebo twice daily Days 8-13, ALZ-801 340 mg or matching placebo once daily Day 14
16374455|NCT04157712|Experimental|Cohort D Tablet - Fed|ALZ-801 265 mg or matching placebo once daily Day 1, ALZ-801 265 mg or matching placebo twice daily Days 2-6, ALZ-801 265 mg or matching placebo once daily Day 7
16374456|NCT04157699|Experimental|QL-007 100 mg QD + TDF|QL-007 tablet 100 mg QD was combined with TDF tablet 300mg
16374457|NCT04157699|Experimental|QL-007 200 mg QD + TDF|QL-007 tablets 200 mg QD were combined with TDF tablet 300mg
16374458|NCT04157699|Experimental|QL-007 400 mg QD+ TDF|QL-007 tablets 400 mg QD were combined with TDF tablet 300mg
16374459|NCT04157699|Experimental|QL-007 200 mg BID+ TDF|QL007 tablets 200 mg BID were combined with TDF tablet 300mg
16374460|NCT04157699|Active Comparator|TDF monotherapy|TDF tablet 300mg
16374461|NCT04157686|Experimental|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL.
16374462|NCT04157686|Experimental|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL.
16374463|NCT04157686|Experimental|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 will be injected into the LCL.
16374464|NCT04157673|Experimental|Episodic Future Thinking introduced at 6 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 8-week period following a 6-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
16374465|NCT04157673|Experimental|Episodic Future Thinking introduced at 8 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 6-week period following a 8-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
16374466|NCT04157673|Experimental|Episodic Future Thinking introduced at 10 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 4-week period following a 10-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
16374467|NCT04157660|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
16374468|NCT04157660|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
16374469|NCT04157647|Active Comparator|CytoSorb|Patients assigned to this arm group will receive hemadsorption witbhCytoSorb during the surgery and in the next 24 hours after surgery.
16374470|NCT04157647|Sham Comparator|Control|Patients assigned to this arm group will undergo to a normal CPB without the use of any hemoadsorption system.
16374471|NCT04157634|Experimental|Prognostication model|In a prospective cohort of children hospitalized in a PICU, development of a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
16374472|NCT04157621|Active Comparator|Active taVNS|
16374473|NCT04157621|Sham Comparator|Sham Stimulation|
16374474|NCT04157608|Active Comparator|Habitual Prosthesis|Participant's existing baseline prescribed prosthesis
16374475|NCT04157608|Experimental|e-MIP|Experimental ankle-foot prosthesis
16374476|NCT04157595|Experimental|Participating Couples|Reproductive Genetic Carrier Screening
16374477|NCT04157582|Experimental|Study group|will consist of 20 hemiparetic patients and will receive Pilates training in addition to conventional physical therapy program consists of (manual stretching exercises, Strengthening Exercises and Wobble board training ) for 18 sessions every other day for one and half month , 3 sessions /week ,each session for 1.30 hours (40 minutes for pilates then 10 minutes rest then 40 minutes conventional physical therapy).
16374829|NCT04155216|Experimental|Guided imagery|Relaxation and guided imagery program
16374478|NCT04157582|Experimental|Control group|will consist of 20 hemiparetic patients and will receive conventional physical therapy program only same as group I for 18 sessions every other day for one and half month, 3 sessions /week, each session for (40 minutes ).
16374479|NCT04157556|Experimental|Group of athletes|Age: 18-35 Gender: Male Basketball, volleyball, handball players who have been training regularly for at least last 3 months.
16374480|NCT04157556|Experimental|Group of sedentary people|Age: 18-35 Gender: Male Individuals with similar physical characteristics to the group of athletes and who have not exercise regularly for at least last 3 months.
16374481|NCT04157543|Experimental|electroacupuncture|electroacupuncture at points after surgery
16374482|NCT04157543|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
16374483|NCT04157543|No Intervention|Control group|only injection painkiller were used before surgery
16374484|NCT04157530|Sham Comparator|sham group|15 subjects with seeds of wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
16374485|NCT04157530|Experimental|acupuncture group|15 subjects with acupuncture applied to Qingming and Qiuhou with Der-qi
16374486|NCT04157530|Experimental|Electroacupuncture group|15 subjects wth acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi
16374492|NCT04157504|Experimental|Experimental Group: Physical Function|Forty patients with burn injury will be evaluated in this study. Lower extremity function, functional capacity, functional mobility, quality of life an scar tissue will be evaluated.
16374493|NCT04157491|Experimental|anlotinib and anti PD-1 antibody|
16374494|NCT04157478|Experimental|Radiation therapy, Temozolomide and anlotinib|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
16374495|NCT04157478|Active Comparator|Radiation therapy and temozolomide|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
16374496|NCT04157465|Other|Early Empiric group|Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
16374497|NCT04157465|Active Comparator|Pre-emptive group|Participants will receive standard medical therapy along with the pre-emptive strategy of treatment of invasive fungal infection (based on risk factors, clinical suspicion and radiological or mycological evidence of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
16374498|NCT04157452||proximal ureteral stone patient|
16374499|NCT04157439|Active Comparator|Control Group|Hot fermentation, Sustain pressure on trigger point, Self-stretches
16374500|NCT04157439|Experimental|Experimental Group|Integrated Neuromuscular Inhibition Technique Post isometric stretch (MET) Strain counter strain
16374501|NCT04157426|Experimental|Ultrasound-guided percutaneous electrolysis|
16374502|NCT04157426|Active Comparator|ultrasound-guided dry needling|
16374830|NCT04155203|Experimental|Perrigo active|
16374831|NCT04155203|Active Comparator|Reference Active|
16374503|NCT04157413||Stunted Group|A comparative cross sectional study will compare stunted group and non-stunted group on amino acid intake, blood amino acid and intestinal permeability. Stunted group is defined as children who have LAZ <-2 SD
16374504|NCT04157413||Non-stunted Group|Non-stunted group will be those with LAZ >= 0.5 SD matching by age and sex with stunted group. Other criteria will be similar. No Intervention will be given to the groups in this proposed protocol.
16374505|NCT04157400|Experimental|Epidural Spinal Cord Stimulation|Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.
16374506|NCT04157387|Experimental|Cyriax inferior capsular stretching + Manual Therapy|"Cyriax inferior capsular stretching
~+ Electrotherapy Manual therapy : Kaltenborn grade 1 and 2 Mobilization
~Active ROM exercises :
~Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction"
16374507|NCT04157387|Active Comparator|Manual Therapy|Analgesic short-wave diathermy Manual Therapy: Kalternbon grade 1 and 2 Mobilization :, Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction.
16374508|NCT04157374|Experimental|EXPERIMENTAL GROUP|AOT and Active exercises
16374509|NCT04157374|Active Comparator|Control group|Active exercises
16374510|NCT04157361||Asthma|Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.
16374511|NCT04157361||Cystic fibrosis|Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.
16374512|NCT04157361||Healthy control|Healthy control children/adults without chronic or autoimmune disease
16374513|NCT04157348|Experimental|Benralizumab arm|1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
16374514|NCT04157348|Active Comparator|Mepolizumab arm|3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
16374515|NCT04157335|Experimental|Benralizumab|Benralizumab administered subcutaneously
16374516|NCT04157335|Placebo Comparator|Placebo|Placebo administered subcutaneously
16374517|NCT04157296|Experimental|CBT and computerized cognitive training (CCT)|Participants will play CCT games at home 5 times per week for two weeks before beginning CBT and for two weeks after the first CBT session. Then participants will have CCT games immediately prior to CBT for nine more weeks (one time a week).
16374518|NCT04157296|Active Comparator|Cognitive behavioral therapy|Participants will receive CBT sessions once a week for 12 weeks.
16374519|NCT04157283||Group 1|60 male patients
16374520|NCT04157283||Group 2|60 female patients
16374521|NCT04157270||Patients with acute ischemic stroke|Patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO)
16374522|NCT04157257|Experimental|QL-007 +TDF|QL-007 200 mg BID +TDF 300 mg QD
16374523|NCT04157257|Experimental|QL-007 +Entecavir|QL-007 200 mg BID +Entecavir 0.5 mg QD
16374524|NCT04157257|Active Comparator|TDF monotherapy|TDF tablet 300 mg QD
16374525|NCT04157257|Active Comparator|Entecavir monotherapy|Entecavir tablet 0.5 mg QD
16374526|NCT04157244|Experimental|Experimental: Tailored Music|4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet.
16374527|NCT04157244|No Intervention|4-week Wait-list control|4-week wait-list control (Note: participants will be crossed over to 4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet)
16374528|NCT04157231|No Intervention|Usual Care|Usual care to be provided to patients as per hospital guidelines for 3 months
16374529|NCT04157231|Other|Intervention arm|"The intervention consists of training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. This intervention will run for 3 months.
~Refresher training will be given monthly during the intervention."
16374530|NCT04157218|Active Comparator|Treatment with HIFU and immediately after insertion of threads|
16374531|NCT04157218|Active Comparator|Treatment with HIFU and 6 months later insertion of theads|
16374532|NCT04157218|Active Comparator|Treatment with lifting threads alone|
16374533|NCT04157205|Experimental|Test arm|All patients. Single arm study
16374534|NCT04157192|Active Comparator|Patients receiving real acupuncture treatment|Treatment with needle insertion
16374535|NCT04157192|Sham Comparator|Patients receiving sham acupuncture treatment|Treatment without needle insertion
16374536|NCT04157179|Active Comparator|Healthy Controls|
16374537|NCT04157179|Active Comparator|Extracorporeal Membrane Oxygenation survivors|
16374538|NCT04157179|Active Comparator|Sickle Cell Anemia participants|
16374539|NCT04157166|Other|group 1 in pair week|In pair week, patients will inclued in group1: the conventional recording followed by complementary images SPECT/CT, will be realized in first intention and the procedure of recording in camera VERITON will be recorderd in second intention
16374540|NCT04157166|Other|group 2 in odd week|in odd week, patients will inclued in group2: the procedure of recording of 25 minutes in camera VERITON-CT ™, will be realized in first intention and the procedure of conventional recording followed by complementary images SPECT/CT will be recorded in second intention
16374541|NCT04157153|Experimental|Treatment|All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 36 monts.
16374542|NCT04157140|Experimental|Anlotinib+ TACE+ RFA|Anlotinib+ TACE+ RFA
16374543|NCT04157127|Experimental|Autologous DC Vaccine Cohort 1|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 1:
~st vaccine - 0.5 million cells
~nd vaccine - 1 million cells
~rd vaccine - 2 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
16374832|NCT04155203|Placebo Comparator|Vehicle control|
16374544|NCT04157127|Experimental|Autologous DC Vaccine Cohort 2|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 2:
~st vaccine - 1 million cells
~nd vaccine - 2 million cells
~rd vaccine - 4 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
16374545|NCT04157127|Experimental|Autologous DC Vaccine Cohort 3|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 3:
~st vaccine - 2 million cells
~nd vaccine - 4 million cells
~rd vaccine - 8 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
16374546|NCT04157127|Experimental|Autologous DC Vaccine Cohort 4|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 4:
~st vaccine - 6 million cells
~nd vaccine - 6 million cells
~rd vaccine - 6 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
16374547|NCT04157127|Experimental|Autologous DC Vaccine Cohort 5|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 5:
~st vaccine - 7 million cells
~nd vaccine - 7 million cells
~rd vaccine - 7 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
16374548|NCT04157127|Experimental|Autologous DC Vaccine Cohort 6|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 6:
~st vaccine - 8 million cells
~nd vaccine - 8 million cells
~rd vaccine - 8 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
16374549|NCT04157114|Active Comparator|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
16374550|NCT04157114|Placebo Comparator|Placebo|Subjects will receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
16374551|NCT04157101|Experimental|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
16374552|NCT04157101|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
16374555|NCT04157075|Placebo Comparator|No injection|No injection will be performed
16374556|NCT04157075|Sham Comparator|Normal Saline Injection|Normal saline will be injected into the uterosacral ligaments prior to colpotomy
16374557|NCT04157075|Active Comparator|Bupivacaine Injection|Bupivacaine will be injected into the uterosacral ligaments prior to colpotomy
16374640|NCT04156542|Experimental|Implement intervention for 12 weeks|In this school, we collected baseline data for three weeks and then implemented the intervention for the remaining twelve weeks.
16374558|NCT04157062|Experimental|Study Group|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive excitatory rTMS with a stimulation frequency of 10 Hz or higher.
16374559|NCT04157049||Alpha-1 Diagnosed Individuals|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
16374560|NCT04157049||Carriers of Alpha-1|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
16374561|NCT04157036|Experimental|800mg Ibuprofen|Subject will take 800mg of Ibuprofen 45 minutes prior to anesthetic delivery.
16374562|NCT04157036|Experimental|40mg Methylprednisolone|Subject will take 40mg of Methylprednisolone 45 minutes prior to anesthetic delivery.
16374563|NCT04157023|Other|Medical Students|Simulator training of 7 patient cases adapted to medical students.
16374564|NCT04157023|Other|Ophthalmologist|Simulator training of 7 patient cases adapted to ophthalmologists.
16374565|NCT04157023|Other|Neurologist/Neurosurgeon/Neonatologist|Simulator training of 7 patient cases adapted to neurologists, neurosurgeons and neonatologists.
16374566|NCT04157010|Experimental|TCZ monotherapy|Tocilizumab (TCZ) monotherapy 8mg/kg 4-weekly for a total of 48 weeks.
16374567|NCT04157010|Experimental|TCZ+MTX combination therapy|Tocilizumab (TCZ) and methotrexate (MTX) combination therapy 8mg/kg 4-weekly for a total of 48 weeks.
16374568|NCT04156997||Patients with extreme lipid phenotypes|Adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and deranged lipoprotein metabolism
16374569|NCT04156997||Healthy volunteers|Healthy adult volunteers with normal lipid metabolism will be recruited for the purpose of comparison
16374570|NCT04156984|Other|Study arm|Subjects treated with optimized dose of golimumab, irrespective of weight: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4 weeks. In case of disease flare: discontinuation of drug.
16374571|NCT04156984|Other|Control arm|"Subjects treated according to current European Label (2019) based on body weight:
~<80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 50 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): dose optimization to 100 mg sc q4wk starting at week 6 or at any time during first year.
~≥80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): discontinuation of drug."
16374572|NCT04156971|Experimental|Intervention Group|stage-based lifestyle modification intervention and fish oil supplement (omega-3). Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring' Participants in the intervention group were also given fish oil capsules containing n-3 LCPUFA (DHA and EPA) for a duration of 16 weeks. The participants were required to consume two fish oil capsules, providing 1320 mg n-3 LCPUFA (792 mg EPA, 20:5n-3 and 528 mg DHA, 22:6n-3), and 6 IU vitamin E (D-alpha tocopherol) daily. The EPA and DHA ratio was 1.5:1.
16374573|NCT04156971|Other|Control Group|Only received Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring'
16374574|NCT04156958|Other|Fruquintinib Arm|Fruquintinib, 5 mg once daily for 21 days, followed by 7 days off (28 days/cycle) treatment until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
16374575|NCT04156945|Experimental|Intervention I: behavioural intervention|Participants will receive the behavioural Intervention in addition to standard of care.
16374576|NCT04156945|Experimental|Intervention II: home-based testing intervention|Participants will receive the home-based testing intervention in addition to standard of care.
16374577|NCT04156945|Experimental|Intervention III: combined intervention|Participants will receive the behavioural intervention and the home-based testing intervention in addition to standard of care.
16374578|NCT04156932|Active Comparator|OUC|Origin uterine artery closure
16374579|NCT04156932|Active Comparator|IUC|Cervical-isthmic uterine artery closure
16374580|NCT04156919|Experimental|Playful condition|Children in the playful and non-playful conditions will receive the fooya! intervention but will be varied in the psychological state of playfulness. Children in the playful condition will play a health game called fooya! Drawing on the playfulness literature, we will manipulate four dimensions of play. First, to manipulate the voluntariness of tasks, children in the playful condition will be asked/invited to participate in the study. Second, to manipulate adult presence, there will be little to no teacher involvement in the playful condition. Third, to manipulate the timing of the activity, children in the playful condition will be given an option to play anytime, including after school hours. Fourth, to manipulate the goal perception, the children in the playful condition will be told that their activity is not graded-i.e., autotelic.
16374581|NCT04156919|Experimental|Non-playful condition|As mentioned earlier, we will manipulate four dimensions of play. First, participation will be mandatory for children in the non-playful condition. Second, teacher presence will be more salient in this condition. Third, children in the non-playful condition will participate during school hours. Fourth, the children in the non-playful condition will be told that their activity is graded.
16374582|NCT04156919|Active Comparator|Control condition|Children in the control condition will play a video game unrelated to diet and lifestyle called Wordsearch.
16374583|NCT04156906|Experimental|D+ RH genotype matched Red Blood Cell Transfusion|Investigators will provide one red cell unit of D+ RH genotype matched RBCs at the first transfusion study visit. The remainder of units will be provided per clinical standard of care, i.e. D-, CEK-matched, and negative for all other antigens the patient is alloimmunized against. If laboratory monitoring shows no reappearance of anti-D and no signs of increased red cell hemolysis, the patient will receive one unit of D+ RH genotype matched RBCs at the 2nd transfusion study visit, and if tolerated, D+ red cell exposures will increase by one unit per study visit until all units required are D+.
16374641|NCT04156542|Experimental|Implement intervention for 9 weeks|In this school, we collected baseline data for six weeks and then implemented the intervention for the remaining nine weeks.
16374584|NCT04156893|Experimental|RH genotype matched red cell transfusions|Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.
16374585|NCT04156867|Experimental|simple discectomy|traditional simple discectomy
16374586|NCT04156854|Experimental|Subjects with heart failure|Subjects admitted to the hospital for acute decompensation of chronic systolic heart failure will have a Quantitated Blood Volume Analysis blood test done
16374587|NCT04156841||performed SLNB using a single mapping agent|
16374588|NCT04156841||performed SLNB by combination of blue dye and radiotracer|
16374589|NCT04156841||underwent SLN surgery receiving neoadjuvant chemotherapy|
16374590|NCT04156841||underwent SLN surgery not receiving neoadjuvant chemotherapy|
16374591|NCT04156828|Experimental|Treatment (copanlisib, R-GCD)|Patients receive copanlisib IV and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone PO or IV 30-60 minutes prior to chemotherapy on day 1 and PO in AM or 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim SC on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16374592|NCT04156815|Active Comparator|1,565nm NAFL only group|Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas. A facial sheet mask (skin repair dressing, Panion & BF Biotech Inc, Zhuhai, China) was used to clean the face after laser treatment, and the face was cooled by air cooler for 10 minutes. The patients received three treatment sessions with a 6-week interval between each session.
16374593|NCT04156815|Active Comparator|Oral isotretinoin only group|Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
16374594|NCT04156815|Active Comparator|Double therapy group|The patients first received 2-4 weeks of oral isotretinoin medication (1mg/kg/d), followed by 1565nm M22-ResurFx NAFL treatment. Subjects were then given isotretinoin with a dosage of 0.5 mg/kg/d for the next 12-14 weeks. Laser treatment parameters and procedures were as same as in the group one above.
16374595|NCT04156815|Experimental|Triple therapy group|The patients received the same treatments as the subjects in group (3) with additional PBT. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
16374596|NCT04156802|Experimental|Real iTBS to the mPFC|Two sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real cTBS total) (1 train of stimulation over the mPFC (AFZ); (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
16374597|NCT04156802|Sham Comparator|Sham iTBS to the mPFC|Two sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real cTBS total) (1 train of stimulation over the mPFC (AFZ); (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
16374598|NCT04156802|Experimental|Real iTBS to the MC|Two sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real iTBS total) (20 trains of stimulation over MC; each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
16374599|NCT04156802|Sham Comparator|Sham iTBS to the MC|Two sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real iTBS total) (20 trains of stimulation over MC; each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
16374600|NCT04156789||Sarcoidosis group|Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
16374601|NCT04156789||Control group|Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
16374602|NCT04156776|Experimental|Group A (MET)|Muscle Energy Technique Conventional Treatment
16374603|NCT04156776|Experimental|Group B (AIS)|Active Isolated Stretching Conventional Treatment
16374604|NCT04156750|Experimental|LY3556050 (Part A)|LY3556050 administered orally.
16374605|NCT04156750|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
16374606|NCT04156750|Other|Iohexol (Part B)|Iohexol given intravenously (IV). (Part B is optional.)
16374607|NCT04156750|Other|Metformin (Part B)|Metformin given orally. (Part B is optional.)
16374608|NCT04156750|Experimental|LY3556050+ Iohexol (Part B)|Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)
16374609|NCT04156750|Experimental|LY3556050 + Metformin (Part B)|Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)
16374610|NCT04156737|Experimental|Investigational Lens|TECNIS Symfony plus IOL Model ZHR00V
16374611|NCT04156737|Active Comparator|Control Lens|Trifocal Intraocular Lens
16374612|NCT04156724|Experimental|HV|6MWT with helmet ventilation
16374613|NCT04156724|No Intervention|Control|6MWT alone according to ATS guideline
16374614|NCT04156711|Experimental|Remote Ischemic Preconditioning|Remote ischemic preconditioning is carried out before the induction of general anesthesia. All four cycles will be completed before general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg (if systolic blood pressures exceeds 185 mmHg, the cuff will be inflated to at least 15 mmHg above the systolic blood pressure) resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia, the cuff is deflated, and the limb is reperfused for 5 minutes. This cycle is repeated 4 times. Pulse oximetry is performed on the RIPC limb to make sure that the blood flow is completely interrupted during ischemia
16374615|NCT04156711|No Intervention|Control|Will receive no intervention, but will go through same tests at the same time-points (endothelial function measured by reactive hyperemia index, blood samples, Heart rate variability and questionaires)
16374616|NCT04156698|Experimental|Camrelizumab (PD-1 inhibitor) group|"Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:
~Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;
~Radical radiotherapy followed by concurrent immunotherapy:
~Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;
~Maintenance period:
~After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w and apatinib 250 mg d1-5 qw will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy)."
16374617|NCT04156685|Experimental|PartA, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
16374618|NCT04156685|Experimental|PartA, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
16374619|NCT04156685|Experimental|PartB, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
16374620|NCT04156685|Experimental|PartB, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
16374622|NCT04156646|Experimental|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
16374623|NCT04156646|Experimental|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
16374624|NCT04156633||conventional identification methods (controls)|Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
16374625|NCT04156633||new identification method (cases)Biofire FilmArray© BCID panel|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
16374626|NCT04156633||new identification method (cases) WGS approaches|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.
16374627|NCT04156620|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
16374628|NCT04156620|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
16374629|NCT04156607|Experimental|Kinesio taping group (KT)|"Kinesio taping applied to plantar soles of these children with Down Syndrome. Epidermis-Dermis-Fascia technique was used for providing sensory input from soles.
~The application was performed on both feet."
16374630|NCT04156607|Sham Comparator|Sham taping group (ST)|A random taping was performed using Kinesio tape but without using Kinesiotaping techniques for sham taping. The application was performed on both feet
16374631|NCT04156607|No Intervention|Healty control group|This group took no intervention but all balance assessments once.
16374632|NCT04156581|Active Comparator|ESPB with Bupivacaine and Dexamethasone|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.375% bupivacaine plus 2 mg preservative free dexamethasone, 25-30 mL total per side according to patient weight.
16374633|NCT04156581|Placebo Comparator|ESPB with saline placebo|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with saline placebo, 25-30 mL total per side according to patient weight.
16374634|NCT04156568|Experimental|6INH Group|10mg/kg 6INH were used in this group.
16374635|NCT04156568|Experimental|3INH+RFT group|3INH+RFTwere used in this grroup.
16374636|NCT04156555|Experimental|Study drug|
16374637|NCT04156542|No Intervention|Control|In this school, we collected data throughout the entire study without implementing any intervention.
16374638|NCT04156542|Experimental|5-week Intervention with Post-intervention Data Collection|In this school, we collected baseline data for 5 weeks, implemented the intervention for five weeks, then removed the intervention and collected post-intervention data for five weeks.
16374639|NCT04156542|Experimental|Implement intervention for 15 weeks|In this school, we implemented the intervention on January 11, 2016, the day the study began.
16374642|NCT04156542|Experimental|Implement intervention for 6 weeks|In this school, we collected baseline data for nine weeks and then implemented the intervention for the remaining six weeks.
16374643|NCT04156529|Experimental|ESU position|Firstly, the semi-elevated supine position was given to participants during tube feeding
16374644|NCT04156529|Experimental|ESRL position|Firstly, the semi-elevated right lateral position was given to participants during tube feeding
16374645|NCT04156516|Experimental|HEART|sexual health intervention that focuses on communication skills
16374646|NCT04156516|Active Comparator|HealthyMinds|Attention-matched control: Growth mindset intervention
16374647|NCT04156503|Experimental|Test fat: Palm olein|One high fat muffin will be serves together with a glass of low fat milk shake.
16374648|NCT04156503|Experimental|Test fat: Lard|One high fat muffin will be serves together with a glass of low fat milk shake.
16374649|NCT04156477|Experimental|Ketone ester|Intake of a ketogenic drink.
16374650|NCT04156477|Active Comparator|Isocaloric and -volumetric glucose drink|Intake of a taste matched glucogenic drink.
16374651|NCT04156477|Placebo Comparator|Isovolumetric tap water drink|Intake of a taste matched tap water drink.
16374652|NCT04156464|Active Comparator|Phenobarbital based treatment|"The phenobarbital group will undergo management with a phenobarbital based treatment protocol with additional symptom triggered therapies.
~On day 1, the phenobarbital group receive a loading dose of phenobarbital intravenous 10mg/kg (actual body weight) with a maximum dose of 1 g/100 mL
~On day 2 of study protocol, and no sooner than 12 hours after loading dose, phenobarbital 64.8 mg is administered every 12 hours for two doses.
~On day 3 of study protocol, patients will receive phenobarbital 32.4 mg every 12 hours for two doses.
~On day 4 of study protocol, patients will receive phenobarbital 32.4 mg once, to be given 24 hours after last scheduled dose.
~Throughout the 4 day protocol, the patient will have phenobarbital 65 mg every 6 hours as needed available either IM or IV, starting no sooner than 30 minutes after the loading dose."
16374653|NCT04156464|Active Comparator|Lorazepam based treatment|"The lorazepam group will undergo management with a lorazepam based treatment protocol with additional symptom triggered therapies.
~On Day 1, the lorazepam group will be started on scheduled lorazepam 4 mg every 6 hours
~After day 1, the scheduled lorazepam dose will be modified based on the total lorazepam requirements from the previous day and divided into 4-6 doses.
~A lorazepam infusion, at physician discretion, will be available at any point if the dose of scheduled and PRN lorazepam being given is too high or frequent to effectively be administered.
~Once symptoms are well controlled on lorazepam based therapy, the total dose given over the past 24 hours will be calculated and weaned by approximately 10-20% per day when clinically appropriate.
~Throughout the entire protocol, 2-4 mg lorazepam IV q 30 minutes PRN will be available for a goal CIWA <6 or RASS -1 to 0."
16374654|NCT04156451|Active Comparator|Central Venous Pressure 8 - 10 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 8-12 mmHg is reached
16374655|NCT04156451|Experimental|Central Venous Pressure 0 - 4 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 0-4 mmHg is reached
16374656|NCT04156438|Active Comparator|Low tidal volume ventilation|Conventional low tidal volume ventilation
16374657|NCT04156438|Experimental|Airway pressure release ventilation|Early use of airway pressure release ventilation
16374658|NCT04156425|Experimental|escitalopram + golimumab|Patients will be treated with escitalopram from the minimum dosage and golimumab according to direction for use.
16374659|NCT04156425|Experimental|escitalopram + calcium tablet|Patients will be treated with escitalopram from the minimum dosage and calcium tablet according to direction for use.
16374660|NCT04156425|Active Comparator|escitalopram|Patients will be treated with escitalopram from the minimum dosage.
16374661|NCT04156412|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
16374662|NCT04156399|Experimental|Acupuncture|All subjects will receive active acupuncture.
16374663|NCT04156386|Active Comparator|Animal Protein|
16374664|NCT04156386|Active Comparator|Vegan Protein|
16374665|NCT04156386|Placebo Comparator|Placebo|
16374666|NCT04156373|Experimental|Fuerte|This group will receive the Fuerte prevention program over the span of six to eight weeks.
16374667|NCT04156373|No Intervention|Delayed waitlist control|This group will be the delayed waitlist control group. They will not receive the Fuerte prevention program until the following semester.
16374668|NCT04156360||Healthy Volunteers|
16374669|NCT04156360||Patients With Pulmonary Nodule|
16374670|NCT04156347|Experimental|Phase I Open Label Study|Phase I Single Arm
16374671|NCT04156334|Experimental|computer-controlled intraosseous anaesthesia|Patients will receive the local anaesthetic using computer-controlled intraosseous anaesthesia (Quicksleeper 5) before the tooth extraction in general anaesthesia.
16374672|NCT04156334|Experimental|infiltrative or conductive local anaesthesia|Patients will receive a local anaesthetic using carpule before the tooth extraction in general anaesthesia.
16374673|NCT04156321|Experimental|Intervention|Group I (intervention) will receive 150 gm of Sajna shak/bora (Moringa) added with 25 gm concenstrated dal with 100 gm of rice as mid-morning snack in selected school 5 times a week for 6 months
16374674|NCT04156321|No Intervention|Control arm|Group II (Control) will rice, concenstrated dal and potato vaji. Both groups will receive calorie matched meal (411 kcal)
16374675|NCT04156308|Experimental|Combined exercises+OMT weekly|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions with a weekly frequency (with + -2 days of margin: between 5 and 9 days)."
16374676|NCT04156308|Experimental|Combined exercises+OMT once every 3 weeks|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions at the rate of one session every 3 weeks (with + -2 days of margin: between 19-23 days)."
16374775|NCT04155606|Active Comparator|Interventional Therapy|Neurosurgery or Endovascular procedure
16374677|NCT04156308|Experimental|Combined exercises|This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality.
16374678|NCT04156282|Active Comparator|classical closure.|In this group, the rectus sheath closure will be done by simple running continuous sutures with the knots beneath the subcutaneous layer.
16374679|NCT04156282|Active Comparator|knot burial technique|The surgeon holds the left angle of the rectus sheath incision with an Allis. Using (Polyglactin 910) suture,The needle is taken from the inside outward on the upper edge.The needle is then taken lateral to the Allis and brought back into the wound by taking it through the inferior edge from outside to inside . A square knot is tied with three or four throws. The needle is then taken out of the wound through the upper edge and continuous running stitches . As the right angle is approached, the angle is held with an Allis. the suture, will be taken through the lower edge, is brought outside the wound and passed between the blades of a closed Allis before taking it inside out on the upper edge. One more bite is taken but this time just lateral to the Allis holding the angle, and the needle is brought back into the wound and to the outside between the edges of the rectus sheath. Using the loop of polyglactin held with the Allis , an Aberdeen knot is tied after removing the Allis.
16374680|NCT04156269|Experimental|BCMA-CD33 cCAR T cells|BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs
16374681|NCT04156256|Experimental|CD123-CD33 cCAR T cells|C123-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs
16374682|NCT04156243|Experimental|CD19 CARvac T cells|CD19 CARvac T cells transduced with a lentiviral vector to express
16374683|NCT04156230|Experimental|Deep vein thrombosis|Subjects with Deep vein thrombosis will receive a single IV injection of [18F] GP1
16374684|NCT04156217|Experimental|EBV-TCR-T cells|Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
16374685|NCT04156204|Experimental|Adolescent and Young Adult (AYA) Kidney Transplant Recipients|AYA kidney transplant recipients will receive a Medication Event Monitoring System (MEMS) in the form of a medication bottle and cap system and once daily tacrolimus XR 1-10mg
16374686|NCT04156191|Experimental|ARQ-151 cream 0.15% or 0.05%|Open-label study of 0.15% or 0.05% active concentration
16374687|NCT04156178|Experimental|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs
16374688|NCT04156165|Active Comparator|VLCD-Control|Very low calorie diet, 700 kcal pr day for eight weeks.
16374689|NCT04156165|Experimental|VLCD-Active|Very low calorie diet plus additional 25 g protein powder, 800 kcal pr day for eight weeks.
16374690|NCT04156165|Active Comparator|Maintenance-Control|"12-week weight maintenance diets: Moderate protein weight maintenance diet (MP-WMD): Recommended healthy diet including 25 g beef daily.
~The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar)."
16374691|NCT04156165|Experimental|Maintenance-Active|12-week weight maintenance diets: High protein weight maintenance diet (HP-WMD): The macronutrient distribution will be 25 energy percentage (E%) from protein, 45 E% from carbohydrate and 30 E% from fat. The diet will include 150 g beef as a daily source of protein, The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar).
16374692|NCT04156152|Active Comparator|Grupo I|16 patients
16374693|NCT04156152|Active Comparator|Grupo II|16 patients
16374694|NCT04156139|Active Comparator|Control group|NPPV treatment for patients will be performed for patients immediately after extubation in control group.
16374695|NCT04156139|Experimental|intervention group|HFNC treatment will be performed for patients immediately after extubation in the intervention group.
16374696|NCT04156126||Infertility - Frozen Embryo Transfer|Adult females undergoing a frozen embryo transfer
16374697|NCT04156126||Spontaneous Conception|Adult females presenting with positive pregnancy test to the Obstetrics Department
16374698|NCT04156113|Experimental|Athletes Group|"The athletes group will be composed of healthy, non obese (body mass index < 30), male basketball, volleyball and handball players aged between 18 and 35 years who have been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.
~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
16374699|NCT04156113|Experimental|Sedentary Group|"The sedentary group will be composed of healthy, non obese (body mass index < 30), male aged between 18 and 35 years who have not been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.
~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
16374700|NCT04156100|Experimental|AGEN1223|AGEN1223 is a bispecific antibody.
16374701|NCT04156100|Experimental|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody
16374702|NCT04156087|Experimental|MIMIPAC|Intervention: MIS-MWA plus immunotherapy using the combination of durvalumab with tremelimumab
16374703|NCT04156074|Experimental|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
16374704|NCT04156074|Active Comparator|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
16374705|NCT04156074|Placebo Comparator|Placebo coconut oil emulsion drink|30 mL placebo drink consumed daily for 4 weeks
16374706|NCT04156074|Active Comparator|Vitamin D supplement (20 mcg/day)|Vitamin D supplement consumed daily for 4 weeks
16374776|NCT04155606|No Intervention|Conservative Management|Monitoring with pharmacological therapy if need arises.
16374777|NCT04155580|Experimental|Part 1|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
16374778|NCT04155580|Experimental|Part 2|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
16374707|NCT04156061|No Intervention|ASSIGN score|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.
~Patients randomised to standard care with ASSIGN score alone (n=200) will be invited back approximately 6 months after baseline assessment. The detailed questionnaire, breath test, blood pressure monitoring, and 2-week activity monitor will be repeated. Bloods will be retaken to look at change in lipid levels and HbA1c where appropriate - no more than 30mls will be required."
16374708|NCT04156061|Active Comparator|CTCA - visual report|"Those in the CTCA group will be further randomised into review with or without CT images.
~The review WITH images (VISUAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
16374709|NCT04156061|Active Comparator|CTCA - verbal report|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.
~Those in the CTCA group will be further randomised into review with or without CT images.
~The review WITHOUT images (VERBAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
16374710|NCT04156035|Experimental|Lamotrigine + Ketamine|Pretreatment with lamotrigine will occur 2 hours before the ketamine infusion
16374711|NCT04156035|Experimental|Placebo + Ketamine|Pretreatment with placebo will occur 2 hours before the ketamine infusion
16374712|NCT04156035|Placebo Comparator|Placebo + Placebo|Pretreatment with placebo will occur 2 hours before the placebo infusion
16374713|NCT04156009|Experimental|Treatment (+aromatherapy) group|
16374714|NCT04156009|Sham Comparator|Control (-aromatherapy) group|
16374715|NCT04155996||data collection|20 patients
16374716|NCT04155983|Active Comparator|High ACB|In the pre-operative cohort, the adductor canal block is administered by anesthesia staff immediately prior to patient transport to the operating room. The thigh is prepped with cholorhexidine at the midpoint between the anterior superior iliac spine and the patella and sterile drapes are applied. An ultrasound probe is then used to localize the adductor canal and confirm that the femoral artery, femoral vein and saphenous nerve can be visualized deep to the sartorious. The probe is moved proximally or distally until the neurovascular bundle is centered under the sartorius. A 20cc syringe with a blunt tip 1.5in 18ga needle is then used to inject 15cc of 0.5% ropivocaine. Following this, the wound is prepped and draped in usual sterile fashion for the arthroplasty procedure.
16374717|NCT04155983|Active Comparator|Low ACB|Surgeon Administered Group In the intra-operative cohort, the block will be administered after the final components are in place and cement debris is removed. The knee joint is irrigated with dilute hibiclens or betadine followed by pulsatile lavage per institutional protocol. A blunt tip 1.5in 18ga needle was then used to administer 15cc of 0.5% ropivocaine.. The location of the saphenous nerve as it exits the adductor canal will be estimated to be 1.5x the TEA proximal to the medial epicondyle in men and 1.3x the TEA proximal in women as described by Kavolus et al. The 60cc of the anesthetic will then injected through the vastus medialis musculature in a field extending from 1cm proximal to one cm distal to the assumed location of the nerve with the needle directed in from 20° to 45° medial. The wound is then irrigated pulsatile lavage one final time and closed in layered fashion.
16374718|NCT04155970|Experimental|Manual Therapy Arm|The group will receive manual therapy, as well as an evidence-informed home management booklet.
16374719|NCT04155970|Experimental|Non-Manual Therapy Arm|The group will receive an evidence-informed home management booklet only.
16374720|NCT04155957|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty and perform a daily 5-exercise plan autonomously.
16374721|NCT04155957|Experimental|ReHub Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty but use the telerehabilitation platform ReHub to do the exercises in their rehabilitation plan at home and to have their progress monitored.
16374722|NCT04155931||body temperature measurement|The investigators planned to perform prospectively in 80 children with ASA I according to the American Society of Anesthesia (ASA) Anesthesia Risk Scale between 6 months and 7 years of age in both sexes who underwent inguinal hernia, undescended testes and hydrocele surgery
16374723|NCT04155918|Experimental|AR882/FBX|
16374724|NCT04155918|Experimental|AR882/ALLO|
16374725|NCT04155905|Active Comparator|group A fistulotomy group|35 patients with simple anal fistula subjected to fistulotomy
16374726|NCT04155905|Active Comparator|group B marsupialization group|35 patients with simple anal fistula subjected to fistulotomy and marsupialization of fistulotomy wound
16374727|NCT04155892||URI group|This group includes participants <8 years of age undergoing elective procedures with a score of at least 3 on our pre-operative URI survey.
16374728|NCT04155892||non-URI group|This group includes participants <8 years of age undergoing elective procedures with no URI symptoms or recent URI.
16374729|NCT04155879|No Intervention|Control Group|Cardioversion without treatment with Colchicine
16374730|NCT04155879|Active Comparator|Treatment group|This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
16374731|NCT04155866||Healthy participants|Measurement of lower-limb muscle activation from healthy participants.
16374732|NCT04155866||Chronic Stroke Survivors|Measurement of lower-limb muscle activation from chronic stroke survivors
16374733|NCT04155853|Active Comparator|Interposition Arthroplasty|Fascia lata interposition arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
16374734|NCT04155853|Active Comparator|Hematoma and Distraction Arthroplasty|Hematoma and Distraction Arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
16374735|NCT04155840|Experimental|Treatment (copanlisib, rituximab, bendamustine)|Patients receive copanlisib IV over 1 hour on days 1, 8 and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. Patients who achieve at least a partial response (MRD-positive) continue on treatment for 2 additional cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 7, patients receive copanlisib IV over 1 hour on days 1 and 15 for an additional 6 cycles in the absence of disease progression or unacceptable toxicity.
16374736|NCT04155827|Experimental|SIT for males|
16374737|NCT04155827|Experimental|SIT for females|
16374738|NCT04155814|Experimental|Iron Sucrose Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
16374739|NCT04155814|Active Comparator|Venofer Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
16374740|NCT04155801|Experimental|Salix Probiotic Blend|Participants will receive a Salix Probiotic Blend capsule orally once a day for 30 days.
16374741|NCT04155788|Experimental|Food Exposure|
16374742|NCT04155775||Best Practice Alert|Platelet transfusion orders for patients with a recent platelet count exceeding 50,000 per microliter (50k/uL) will trigger an alert in the electronic health record that displays current guidelines for platelet transfusion. The alert will allow providers to bypass the recommendation and continue with platelet ordering by selecting a clinical acknowledgement / exception to recommendation.Exclusions will be built into the alert to avoid triggering in operative or procedural settings, for neurosurgery providers, or patients on anti-platelet medications.
16374743|NCT04155775||No Best Practice Alert|For this group, no visible best practice alert will activate in the electronic health record for platelet transfusion orders and recent counts above 50k/uL.
16374744|NCT04155762|Experimental|Intervention|Both suspension systems were applied consecutively to the participants. Initially, participants used the Pin Suspension System (PSS) for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period. They then employed the Vacuum-Assisted Suspension System (VASS) for three months after a similar training period.
16374745|NCT04155749|Experimental|ARM 1|Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
16374746|NCT04155736|Experimental|Renew with coaching|Users will be assigned a study staff member as a support person who is notified when the user engages with the app or if they have not engaged for 7 days. Support persons are provided with psychoeducation material including information about how to be an effective support person for the user and direct messaging capacity to respond to app notifications about user engagement (e.g., user earned X points, user achieved a new level).
16374747|NCT04155736|Active Comparator|Renew without coaching|"Same as Renew with coaching except that the users will not be assigned a study staff member as a support person."
16374748|NCT04155736|No Intervention|Wait list|No intervention is provided
16374749|NCT04155723||Phase 1 group|During phase 1, Midlines are inserted only by doctors.
16374750|NCT04155723||Phase 2 group|During Phase 2, Midlines are preferentially inserted by ICU nurses, and if needed, by doctors.
16374751|NCT04155710|Experimental|Cohort 1a|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + low dose IL-2.
16374752|NCT04155710|Experimental|Cohort 1b|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
16374753|NCT04155710|Experimental|Cohort 2|CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
16374754|NCT04155710|Experimental|Cohort 3|CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
16374755|NCT04155697|Active Comparator|Hand washing with soap for thirdhand smoke removal|
16374756|NCT04155697|Active Comparator|Ethyl alcohol-based sanitizer for thirdhand smoke removal|
16374757|NCT04155684||HIV + with COPD|COPD will be defined as Subjects with FEV1/FVC<0.70 or FEV1 and DLco < 80% predicted
16374758|NCT04155684||HIV+ normal|Normal PFT's
16374759|NCT04155671|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
16374760|NCT04155671|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
16374761|NCT04155658|Experimental|Experimental SMFP Toothpaste|Toothpaste containing 1450ppm SMFP with additional calcium and phosphate
16374762|NCT04155658|Active Comparator|SMFP Toothpaste|Toothpaste containing 1450ppm SMFP
16374763|NCT04155658|Placebo Comparator|Negative control toothpaste|Toothpaste with no fluoride
16374764|NCT04155645|Experimental|Cohort 1|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 1 injection (8 subjects) or matching placebo (3 subjects).
16374765|NCT04155645|Experimental|Cohort 2|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 2 injection (8 subjects) or matching placebo (3 subjects).
16374766|NCT04155645|Experimental|Cohort 3|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 3 injection (8 subjects) or matching placebo (3 subjects).
16374767|NCT04155632|Experimental|N-acetylcysteine + Theta Burst Stimulation|
16374768|NCT04155632|Sham Comparator|N-acetylcysteine + Sham Theta Burst Stimulation|
16374769|NCT04155632|Placebo Comparator|Placebo + Theta Burst Stimulation|
16374770|NCT04155632|No Intervention|Placebo + Sham Theta Burst Stimulation|
16374771|NCT04155619|Active Comparator|No change in eating or light exposure habits|
16374772|NCT04155619|Experimental|Early Time-Restricted Feeding|
16374773|NCT04155619|Experimental|Timed Light Therapy|
16374774|NCT04155619|Experimental|Early Time-Restricted Feeding and Timed Light Therapy|
16374780|NCT04155567|Experimental|TAK-123|TAK-123 as 3.75 gram per square meter (g/m^2) of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m^2 of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 24 hours.
16374781|NCT04155554|Experimental|Bictegravir/emtricitabine/tenofovir alafenamide|Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD
16374782|NCT04155554|Active Comparator|Dolutegravir/lamivudine/abacavir|Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD
16374783|NCT04155541||VIZIMPRO(dacomitinib hydrate)|Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
16374784|NCT04155528|Experimental|Study group|The intervention group will receive routine hospital care alongside 30 minutes of music therapy per day for three consecutive days. The music therapy will be initiated on the second day postoperatively. The assessment of baseline data and the music therapy will be applied at least three hours after analgesics administration.
16374785|NCT04155528|No Intervention|Control group|Patients in the control group will receive routine hospital care only.
16374786|NCT04155515|Other|Non-cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
16374787|NCT04155515|Other|Cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
16374788|NCT04155502||Social media sites.|These participants will be recruited from advertisements posted on social media websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
16374789|NCT04155502||Informational sites|These participants will be recruited from advertisements posted on informational websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
16374790|NCT04155502||Dating applications|These participants will be recruited from advertisements posted on dating applications. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
16374791|NCT04155489|Active Comparator|restrictive|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started.
16374792|NCT04155489|Experimental|Liberal|In the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
16374793|NCT04155476|Experimental|Nitroglycerin exposure|
16374794|NCT04155476|Placebo Comparator|Non-Nitroglycerin exposure|
16374795|NCT04155463|Experimental|Organic Diet|Participants will be allowed to order one week's worth of food from a grocery store website (capped by price), with the restriction that they may only order foods certified by the US Department of Agriculture (USDA) as organically grown. This food will be delivered to the researcher's laboratory, packaged, and delivered to each participants' home. Participants will log their food intake using a custom food diary phone app provided by the study.
16374796|NCT04155463|Experimental|Conventional Diet|Participants will be allowed to order one week's worth of food from a grocery store website (capped by price), with the restriction that they may only order foods NOT certified by the USDA as organically grown. This food will be delivered to the researcher's laboratory, packaged, and delivered to each participants' home. Participants will log their food intake using a custom food diary phone app provided by the study.
16374797|NCT04155450|Experimental|McKenzie Extension with External Limb Loading Protocol|"Moist Heat Pack for 10 mins
~McKenzie Extension Exercise Protocol
~Static:
~Lying Prone
~Lying prone in extension
~Sustained extension
~Posture correction
~Dynamic:
~Extension in lying
~Extension in lying with clinician overpressure
~Extension mobilization
~Extension in standing
~Limb loading for basic stabilization progression of the lumbar extensors. Begin in the quadruped position and progress the intensity by
~Flexing one upper extremity
~Extending one lower extremity with a leg slide
~Extending one lower extremity by lifting it off the mat
~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.
~Progress to prone position:
~Extending one lower extremity
~Extending both lower extremity"
16374798|NCT04155450|Active Comparator|McKenzie Extension Group|"Moist Heat Pack for 10 mins
~McKenzie Extension Protocol Sequence
~Static:
~Lying Prone
~Lying prone in extension
~Sustained extension
~Posture correction
~Dynamic:
~Extension in lying
~Extension in lying with clinician overpressure
~Extension mobilization
~Extension in standing"
16374799|NCT04155437|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities.
16374800|NCT04155437|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities.
16374801|NCT04155424|Experimental|Eculizumab|"All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.
~After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks."
16374802|NCT04155411|Experimental|Dasatinib 70 mg|
16374803|NCT04155398||Study group|Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
16374804|NCT04155385|Active Comparator|Measurement-only|Patients will complete weekly measures of treatment progress and goals; however, the information from these measures will not be shared with clinicians or patients.
16374805|NCT04155385|Experimental|Measurement and feedback|Patients will complete weekly measures of treatment progress and goals; the information from these measures will be shared with clinicians.
16374806|NCT04155372|Experimental|30min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 30 min.
16374807|NCT04155372|Experimental|60min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 60 min.
16374808|NCT04155372|Experimental|90min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 90 min.
16374809|NCT04155346|Experimental|Facility-based prehabilitation (FBP)|"Exercise
~Three supervised exercise training sessions of aerobic and resistance exercises. Includes high-intensity interval aerobic training and whole-body resistance exercises (60 min/session)
~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery
~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist
~Nutrition
~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a Registered Dietitian (60 min/session)
~Participants will also receive 20g of protein supplementation daily
~Stress management and behavioural support
~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a psychologist (60 min/session)"
16374810|NCT04155346|Experimental|Home-based prehabilitation (HBP)|"Exercise
~Three unsupervised, home-based exercise training sessions of aerobic and resistance exercises. Includes continuous moderate-intensity aerobic training and whole-body resistance exercises (60 min/session)
~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery
~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist
~Nutrition
~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a Registered Dietitian (60 min/session)
~Participants will also receive 20g of protein supplementation daily
~Stress management and behavioural support
~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a psychologist (60 min/session)"
16374811|NCT04155346|No Intervention|Usual Care|- This group will receive no additional intervention from the routine care.
16374812|NCT04155333|Experimental|Active anodal stimulation|active anodal stimulation at F3, cathode placed on contralateral bicep
16374813|NCT04155333|Experimental|Active cathodal stimulation|active cathodal stimulation at F3, anode placed on contralateral bicep
16374814|NCT04155333|Sham Comparator|Sham stimulation|sham stimulation that will be counterbalanced between subjects such that half will receive sham stimulation configured as condition 1 (anode F3, cathode bicep) and half will receive condition 2 (cathode F3, anode bicep)
16374815|NCT04155320|Active Comparator|Group A|Subjects are encouraged to disclose their HIV status to their partner(s) with or without a counselor present (Options 1 & 2).
16374816|NCT04155320|Experimental|Group B|Subjects may choose to notify their partners themselves, with or without a counselor present (Options 1 & 2), or choose to have one or more partners notified anonymously by project staff (Option 3).
16374817|NCT04155307|Experimental|Detection of anismus in patients with distal constipation|
16374818|NCT04155281||suspicion of intoxication|New Psychoactive Substances research in urine
16374819|NCT04155268|Experimental|Floatation-REST|Participants will float in a shallow pool of water with about 1000 pounds of epsom salt, in a light and sound attenuated device, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
16374820|NCT04155268|Active Comparator|Dark Room|Participants will lay on an air mattress in a dark and quiet room, with reduced environmental stimulation, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
16374821|NCT04155255|No Intervention|Control|Age-matched overweight and obese students were selected from control schools. The students participated in their usual health and physical education classes plus any other curriculum activities provided by the school.
16374822|NCT04155255|Experimental|Intervention|Overweight and obese students were recruited from intervention schools. Students underwent MyBFF@school intervention programme that consisted of physical activity, nutrition and psychological modules for the duration of 6 months. MyBFF@school intervention programme were conducted by trained personnel that were stationed full-time at each intervention school.
16374823|NCT04155242|Experimental|Study group|As part of the post RFA treatment follow up patients will receive a Cytosponge test followed by an endoscopy with NBI magnification and biopsies. Four endoscopies will be performed during 2 years of active follow up together with up to 2 Cytosponge procedures. Molecular biomarkers including a methylation panel on DNA and immunohistochemical markers on formalin fixed paraffin embedded samples obtained during the examinations will be assessed. Patients will be then followed up for up to 3 years with standard endoscopy to assess for relapse of Barrett's oesophagus/IM/dysplasia.
16374824|NCT04155229|Experimental|Null setting, forced entry|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at -blank-. This setting required the prescriber to enter a quantity in order to write a prescription."
16374825|NCT04155229|Experimental|5 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at 5."
16374826|NCT04155229|Experimental|10 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at 10."
16374827|NCT04155229|Experimental|15 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at 15."
16374828|NCT04155229|Active Comparator|Status quo default setting|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at the status quo value for each site (20 for site 1, 12 for site 2)."
16374833|NCT04155190|Experimental|Patidegib Topical Gel, 2%|Participants will be randomized (1:1) to receive Patidegib Topical Gel, 2% for 9 months
16374834|NCT04155190|Active Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized (1:1) to receive Patidegib Topical Gel, Vehicle for 9 months
16374835|NCT04155177||begining of curriculum|trainees in obstetrics and gynecology who have achieved less than 2 years of their hole curriculum
16374836|NCT04155177||mid curriculum|trainees in obstetrics and gynecology who have achieved at least 2 years and less than 4 years of their hole curriculum
16374837|NCT04155177||Advanced|trainees in obstetrics and gynecology who have achieved at least 4 years of their hole curriculm
16374838|NCT04155164|Experimental|Metformin|Participants will receive Metformin for 12 months.
16374839|NCT04155164|Placebo Comparator|Placebo|Participants will receive placebo for 12 months.
16374840|NCT04155151|Experimental|Single Arm|6 Minute Walking Test
16374841|NCT04155138|Other|Naida Hearing Aid|"Adults (> 18 years of age)
~Unilaterally implanted with an Advanced Bionics implant (CII or later)
~At least six months of CI use experience
~Limited bimodal benefit as perceived by the recipient and/or the clinician
~Participants may or may not currently be using a hearing aid in the unimplanted ear.
~Open set performance with current device configuration:
~≥40% AzBio sentence score in quiet (S0)
~If currently bimodal:
~Hearing aid ear only CNC score <50%
~AzBio Scores bimodal benefit <15%
~Unaided audiometric threshold of ≤100 dBHL up to 500 Hz
~Ability and willingness to participate in multiple sets of open speech testing (and chronically evaluate HA and CROS benefit)"
16374842|NCT04155138|Other|Naida CROS Device|The same cohort will cross over to each arm.
16374843|NCT04155125|Experimental|efepoetin alfa|"Route of administration: Subcutaneous Injection.
~The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period."
16374844|NCT04155125|Placebo Comparator|Mircera|"Route of administration: Subcutaneous Injection.
~The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL."
16374845|NCT04155112|Active Comparator|Exercise|Participants randomized to exercise will receive exercise sessions of 50 minutes twice weekly for 4 weeks led by experienced exercise instructors, thereafter once weekly with an instructor and twice weekly without an instructor (up to 6 month)
16374846|NCT04155112|Active Comparator|Mediterranean diet|Participants randomized to dietary group will be counseled by experienced dietitians to follow the Mediterranean diet with Nordic modifications with follow up sessions at biweekly intevals to reinforce changes (up to 6 month)
16374847|NCT04155099|Experimental|High dose|Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
16374848|NCT04155099|Experimental|Low dose|Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
16374849|NCT04155099|Placebo Comparator|pill quantity-matched Placebo|Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
16374850|NCT04155086|Experimental|Exposed group (patient with an autoimmunise disease)|Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
16374851|NCT04155086|Other|Non Exposed group (patient without an autoimmunise disease)|
16374852|NCT04155073|Experimental|COPD/smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking, quitting smoking, and respiratory symptoms, 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit, and if needed, 3) a home spirometry test with instructions on how to video themselves completing a lung functioning test via the device within an additional e-visit.
16374853|NCT04155073|Active Comparator|Treatment as Usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
16374854|NCT04155060||DM group , non-DM group|Septic patients were divided into the DM group and non-DM group, based on their comorbidity
16374855|NCT04155060||high lactate group,low lactate group|high lactate group (lactate > 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.
16374856|NCT04155047|Active Comparator|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
16374857|NCT04155047|Placebo Comparator|Placebo|Placebo Inhalation Solution administered by Magair
16374858|NCT04155034|Active Comparator|Arm I (PCI, MRI)|Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
16374859|NCT04155034|Experimental|Arm II (MRI)|Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
16374860|NCT04155008|Active Comparator|Patients with fair to good appetite|The patients with fair-good appetite (score on CNAQ more than 24) will not receive any pharmacological agents and will receive nutrition intervention alone.
16374861|NCT04155008|Experimental|Patients with poor to fair appetite|The patients with poor-fair appetite (score on CNAQ less than 24) will be provided nutrition intervention by the Registered Dietitian and then put into one of three pharmacological groups.
16374862|NCT04154995||Long-term ICU patients|Patients with a ICU length of stay of at least 48 hours.
16374863|NCT04154982|Experimental|Pharmacological treatment|Patients are treated with NAC prior to carrying out CAP.
16374864|NCT04154982|No Intervention|Standard procedure|Patients are not treated with NAC. No placebo treatment is performed.
16374865|NCT04154969|Experimental|intervention|daily physiotherapy session as part of the rehab plan, which includes 10 minutes of vestibular exercize.
16374866|NCT04154969|Active Comparator|control|daily physiotherapy session as part of the rehab plan
16374867|NCT04154956|Experimental|SAR408701 (tusamitamab ravtansine)|Administered intravenously once every 2 weeks
16374868|NCT04154956|Active Comparator|Docetaxel|Administered intravenously once every 3 weeks
16374869|NCT04154943|Experimental|Cemiplimab|Will receive IV infusion Q3W
16374870|NCT04154930|Experimental|Treatment|"Restylane-L® injected with optional touch at 1 month and optional retreatment at 12 months
~,"
16374871|NCT04154930|No Intervention|No Treatment Control|No treatment control with optional treatment at 12 months
16374872|NCT04154917|Experimental|Experimental|HOME will be delivered by a community-based OT, who will be involved in the hospital discharge planning, trained by the PI. The HOME intervention comprises 4 phases: Phase 1 (in hospital): The clinician will focus on building a rapport with the patient and family members. Information will be gathered about the participant's home environment and functional ability. Phase 2 (± 5 days prior to expected discharge): Clinician will conduct a pre-discharge home assessment with patient and family to evaluate the environment, identify potential problems, and suggest appropriate ways to address them. Phase 3 (<1 week after discharge): Post-discharge home assessment will be conducted to provide additional in-home training and follow up on any of the patient's unmet needs. Phase 4 (2-4 weeks post-discharge): Follow-up telephone calls will be made to provide ongoing support to participant and family and encourage self-problem solving and independence.
16374873|NCT04154917|No Intervention|Usual care|Usual care group will receive the customary discharge planning assessment by a different clinician (OT). During this assessment, according to usual care, information regarding the participants' ability to perform activities of daily living and regarding their home environment is gathered and used to plan for discharge. Usual care group will not receive an OT home assessment as this is not part of usual care. If the clinician identifies a potential need for assistive equipment and home modification needs, patients will be referred to community-based homecare services as is the current practice, and a home visit may be performed following discharge, typically after an lengthy wait (weeks, months) for service.
16374874|NCT04154904|Experimental|Aerobic exercise|
16374875|NCT04154904|Experimental|Resistance exercise|
16374876|NCT04154904|Experimental|High intensity interval exercise|
16374877|NCT04154878||Pacemaker Optimization|Participants were referred for pacemaker optimization following implantation of a device. All had an intact atrial contraction either intrinsic or by device stimulation. A standard baseline echo was performed prior to programming changes with a final echo scan completed after all programming complete. Device programming consisted of adjusting atrial ventricular and right to left ventricular stimulation delays.
16374878|NCT04154878||Healthy|A brief cardiac history questionnaire and complete echocardiogram will be performed.
16374879|NCT04154865|Experimental|Enrolled, eligible|Single arm for eligible subjects
16374880|NCT04154852|Experimental|TNF-antagonist|Adalimumab, 40 mg, 2-weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
16374881|NCT04154852|Active Comparator|Placebo + MTX|Placebo, 2 weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
16374882|NCT04154839||Atopic dermatitis group|Number of subjects in atopic dermatitis group 0 - < 6 years : 50 subjects 6 - <12 years : 50 subjects 12 - <18 years : 50 subjects Adult (>= 18 years) : 150 subjects Total no. of cases: 300 cases
16374883|NCT04154839||Control group|>= 40 yrs : 150 subjects
16374884|NCT04154826|Experimental|low dose|CYT107 10µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 10µg/kg/week for 4 weeks (wk9-12)
16374885|NCT04154826|Experimental|high dose|CYT107 20µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 20µg/kg/week for 4 weeks (wk9-12)
16374886|NCT04154813|Experimental|Topiramate group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is topiramate group.During this group the initial dose of 25mg/day is rapidly increased to the target dose (100mg/day) or below the maximum tolerable dose if the patient can tolerate it.
16374887|NCT04154813|Experimental|Fluoxetine+DBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+DBT group. Group cognitive behavioral therapy was performed while fluoxetine was maintained. Target dose of fluoxetine is 60mg/day.Treatment was divided into three stages: the initial stage, the main stage and the end stage. The treatment was conducted once a week for a total of 12 times, followed by maintenance treatment for 6 months.
16374888|NCT04154813|Experimental|Fluoxetine+CBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+CBT group.Target dose of fluoxetine is 60mg/day. DBT therapy was performed while the original fluoxetine dose was maintained.The core treatment stage was 1 time per week, 12 times in total, and 6 months of maintenance treatment followed.
16374889|NCT04154800|Active Comparator|Part A: Fasting|Single ascending dose (SAD).
16374890|NCT04154800|Active Comparator|Part A: Fed|Single Ascending Dose (SAD)
16374891|NCT04154800|Active Comparator|Part B: Fasting|Multiple Ascending Dose (MAD)
16374892|NCT04154800|Active Comparator|Part B: Fed|Multiple Ascending Dose (MAD)
16374893|NCT04154787|Experimental|LNP023|LNP023
16374894|NCT04154787|Active Comparator|Rituximab|Rituximab
16374895|NCT04154774|Experimental|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
16374896|NCT04154774|Experimental|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
16374897|NCT04154748|Experimental|APC 90W / PPI 120mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
16374898|NCT04154748|Active Comparator|APC 90W / PPI 40mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
16374899|NCT04154748|Active Comparator|APC 60 W/ PPI 120mg|treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
16374900|NCT04154735|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with fludarabine, cyclophosphamide, mesna, and alemtuzumab. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant until engraftment. Rifaximin and tacrolimus will be administered for 6 and 12 months, respectively, beginning one day before the infusion of stem cells.
16374901|NCT04154722|Experimental|meropenum and azithromycin group|inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.
16374902|NCT04154722|Active Comparator|meropenum group|inj meropenum 20mg/kg/dose I/v in 3 divided doses
16374903|NCT04154709|Experimental|CTA101|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
16374904|NCT04154696|Experimental|Normothermic perfusion of a graft|
16374905|NCT04154683|Experimental|group using Cellvizio® optical biopsy|
16374906|NCT04154670|Experimental|Normal kidney function|MGTA-145 single dose
16374907|NCT04154670|Experimental|Mild decrease in GFR|MGTA-145 single dose
16374908|NCT04154670|Experimental|Moderate decrease in GFR|MGTA-145 single dose
16374909|NCT04154657|Experimental|biventricular conductance catheter|patients with indication for invasive assessment receive right and left heart catheter and parallel biventricular conductance catheter at rest and stress
16374910|NCT04154644|Experimental|Cervical Cytology|100 women with abnormal cervical cytology will receive cryotherapy with the experimental CryoPop device
16374911|NCT04154631|Experimental|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
16374912|NCT04154631|Experimental|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
16374913|NCT04154631|Active Comparator|UC-DT|Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
16374914|NCT04154605|Active Comparator|ClariFix|Cryotherapy of the nasal passages with the ClariFix device.
16374915|NCT04154605|Sham Comparator|Sham|Sham cryotherapy of the nasal passages with the ClariFix device
16374916|NCT04154592|Experimental|Experimental Group|In addition to the conservative treatment of the control group, humeral head depressor muscle co-activation training will be applied for 14 weeks.
16374917|NCT04154592|Active Comparator|Control Group|The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., & Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).
16374918|NCT04154579|Experimental|HeRe We Arts|This is an 8 week, arts-based session that includes educational & experiential components. Topics include: Introduction to Arts & Health; Music, Well-Being, & Resilience; Movement & Physical Activity; Art & Well-Being; Writing & Communication/Self-Expression; Theater & Socialization; Art Appreciation & a Healthy Brain; & Summary/Integration of the Arts into Daily Lives.
16374919|NCT04154579|Active Comparator|HeRe We Ed (Health Education Group)|This is an 8 week, non-arts-based health education session that includes educational & some experiential components. Topics include: Introduction to Health, Resilience, & Well-Being; Nutrition & Healthy Eating; Exercise, Chair Yoga, & Sleep; Mental Health, Stress Management, & Life Satisfaction; Holistic Approaches: Wellness, Integrative Medicine, & Complementary & Alternative Medicine; Chronic Illnesses & Chronic Pain; Health & Behaviors; Summary & Navigating the Healthcare System.
16374920|NCT04154566|Experimental|the study group|Group (A) the study group received aerobic exercise in addition to selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
16374921|NCT04154566|No Intervention|the control group|group (B) the control group received the same selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment only.
16374922|NCT04154540|Experimental|demyelinating hereditary neuropathy|adult patients with demyelinating hereditary neuropathy type CMT 1A.
16374923|NCT04154540|Experimental|demyelinating inflammatory neuropathy|adult patients with acquired demyelinating inflammatory neuropathy.
16374924|NCT04154527||postpartum women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.
~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.
~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz) curved linear array ultrasound transducer was used (LOGIQe Ultrasound,General Electric Healthcare, USA) with the ultrasound unit set in B mode."
16374925|NCT04154527||nulliparous women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.
~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.
~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz)curved linear array ultrasound transducer was used (LOGIQe Ultrasound,GE eneral Electric Healthcare, USA) with the ultrasound unit set in B mode."
16374926|NCT04154514|Experimental|Delivering FES to stroke survivors|"In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. We are going to employ the wearable to deliver personalized muscle-synergy-based FES stimulations to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors as they walk on a treadmill for gait rehabilitation. We hypothesized that the subject will essentially be walking with his/her abnormal muscle pattern superimposed with the artificially introduced normal muscle pattern coming from FES."
16374927|NCT04154501|Placebo Comparator|Cohort 1 Placebo|Oral Placebo Capsule
16374928|NCT04154501|Experimental|Cohort 1 Drug|25 mg Oral Capsule
16374929|NCT04154501|Placebo Comparator|Cohort 2 Placebo|Oral Placebo Capsule
16374930|NCT04154501|Experimental|Cohort 2 Drug|50 mg Oral Capsule
16374931|NCT04154501|Placebo Comparator|Cohort 3 Placebo|Oral Placebo Capsule
16374932|NCT04154501|Experimental|Cohort 3 Drug|100 mg Oral Capsule
16374933|NCT04154501|Placebo Comparator|Cohort 4 Placebo|Oral Placebo Capsule
16374934|NCT04154501|Experimental|Cohort 4 Drug|300 mg Oral Capsule
16374935|NCT04154501|Placebo Comparator|Cohort 5 Placebo|Oral Placebo Capsule
16374936|NCT04154501|Experimental|Cohort 5 Drug|450 mg Oral Capsule
16374937|NCT04154501|Placebo Comparator|Cohort 6 Placebo|Oral Placebo Capsule
16374938|NCT04154501|Experimental|Cohort 6 Drug|600 mg Oral Capsule
16374939|NCT04154501|Placebo Comparator|Cohort 7 Placebo|Oral Placebo Capsule
16374940|NCT04154501|Experimental|Cohort 7 Drug|800 mg Oral Capsule
16374941|NCT04154501|Placebo Comparator|Cohort 9 Placebo|Oral Placebo Capsule
16374942|NCT04154501|Experimental|Cohort 9 Drug|1000 mg Oral Capsule
16374943|NCT04154501|Experimental|Cohort 8 Fasted|Participant will take 300 mg Oral Capsule in a fasting state, and then fed state.
16374944|NCT04154501|Experimental|Cohort 8 Fed|Participant will take 300 mg Oral Capsule in a fed state, and then fasting state.
16374945|NCT04154488|Experimental|Mavorixafor|Adult participants and adolescent participants who weigh more than 50 kilograms (kg) will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each) once on Day 1. Adolescents weighing less than or equal to 50 kg will receive mavorixafor 200 mg (2 capsules of 100 mg each) once on Day 1.
16374946|NCT04154475|Experimental|yogurt diet|yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium)
16374947|NCT04154475|Active Comparator|dairy diet|dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products
16374948|NCT04154475|Active Comparator|standard diet|standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt
16374949|NCT04154462|No Intervention|No intervention|The VAMC sites randomized to the comparison arm will not have medical scribes introduced into emergency departments or specialty clinics.
16374950|NCT04154462|Experimental|Treatment|The VAMC sites randomized to the treatment arm are each expected to have four medical scribes, with two being VA employees and two being contractors, introduced into emergency departments or specialty clinics to assist providers during patient encounters.
16374951|NCT04154449||Control group.|
16374952|NCT04154449||Surgical group Received intranasal insulin.|
16374953|NCT04154449||Surgical group Received placebo.|
16374954|NCT04154436|Experimental|Sodium Bicarbonate (NaHCO3) Plus Solution|15 cc of Sodium Bicarbonate (NaHCO3) plus Solution will be sprayed on left or right side of the patient's face based on randomisation
16374955|NCT04154436|Placebo Comparator|Water (H2O)|15 cc of Water (H2O) will be sprayed on the left or right side of the patient's face based on randomisation
16374956|NCT04154423|Active Comparator|Glow! Group Prenatal Care|Group prenatal care with wrap around services.
16374957|NCT04154423|Active Comparator|Individual Prenatal Care- CPSP|Individual prenatal care with supplemental services covered by CPSP.
16374958|NCT04154397|No Intervention|error-enhancing feedback|The project of the first arm was to investigate how visualized error size affects postural training effect of the elderly, with a particular focus on error amplification strategy to optimize training benefits for postural training that favors the use of feedback mechanism on postural control and error correction. All participants were randomly assigned into the control and error amplification groups. The control group was trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. For the error amplification group, they were trained with the same postural paradigm, except that the visual guidance was virtually manipulated so that the participants visually perceived twice of the execution errors during stabilometer stance. We contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
16374959|NCT04154397|Experimental|positive cerebellar transcranial stimulation|The project of the second arm was to investigate the training benefits of using combined cerebellar transcranial direct current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance.They were randomly assigned into the control (traditional error amplification)and cerebellar transcranial direct current stimulation groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
16374960|NCT04154397|Experimental|sham cerebellar transcranial stimulation|The project of the third arm was to investigate the training benefits of using combined cerebellar transcranial random current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance. All participants were randomly assigned into the control (sham stimulation) and cerebellar transcranial random current stimulation and visual error amplification (ES) groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
16374961|NCT04154384|Experimental|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse. Participants will be followed for one year post operation. An official pain management protocol will be developed during the pilot portion of this study.
16374962|NCT04154384|Experimental|Life Care Specialist (LCS) Intervention|In addition to receiving current standard-of-care for pain management in the aftermath of trauma, participants will have the full communication of opioid risk - via the validated Opioid Risk Tool (ORT) and a detailed substance abuse and mental health screening. As part of the daily LCS intervention, the inpatients will engage in behavioral pain management, opioid education and harm-reduction strategies (naloxone education), while also being screened for eligibility for respective referrals for complex needs, such as mental health and substance use disorders. Upon discharge, each participant will be educated by the LCS on future available modes of contact (telephone, email, video-call, follow up- visits at 2-, 6- and 12-weeks).
16374963|NCT04154384|Active Comparator|Standard of Care with Clinical Coordination|Participants will receive the current standard-of-care for pain management in the aftermath of trauma, including a standardized prescription protocol, and hospital-system approved discharge instructions which provide written instruction on how to taper opioid use and links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
16374964|NCT04154371|Experimental|Single-arm or non-randomized trial|Six post-stroke patients, in the chronic recovery stage, will receive a treatment in which motor execution is promoted by virtual and augmented reality using serious gaming controlled by myoelectric pattern recognition. The aim of this treatment is to improve upper limb functionality.
16374965|NCT04154358|Experimental|HPV Testing|Will perform HPV testing with self-collected specimen
16374966|NCT04154345|Experimental|Painful exercises|The pain allowed during exercises ranges between 4 and 7 on NPRS (Numeric Pain Rating Scale)
16374967|NCT04154332||Healthy Controls|
16374968|NCT04154332||Preeclampsia Group|
16374969|NCT04154319|Active Comparator|HPV Vaccination|Mothers participated in educational/behavior change sessions to promote HPV vaccination among their 9-12 year old daughters
16374970|NCT04154319|Active Comparator|Healthy Eating|Mothers and daughters participated in educational/behavior change sessions to promote healthy eating and appropriate nutrition label interpretation
16374971|NCT04154306|Placebo Comparator|Placebo|
16374972|NCT04154306|Experimental|Red clover|
16374973|NCT04154293|Placebo Comparator|Vehicle Ointment (Control)|Topical, BID (Twice daily)
16374974|NCT04154293|Experimental|TMB-001 Ointment, 0.05%|Topical, BID ( twice daily)
16374975|NCT04154293|Experimental|TMB-001 Ointment, 0.1%|Topical, BID (Twice daily)
16374976|NCT04154280|Experimental|prostate cancer Patients|patients over the age of 18 with diagnosed prostate cancer at different stages of the disease.
16374977|NCT04154267|Experimental|Intervention|In addition to the routine evaluation commonly carried-out at this post-transplant period, protocol biopsies will be performed at the 10th-week post-transplantation in high-risk transplant recipients. Biopsy fragments will be evaluated for tissue immune aggression (mainly cellular and antibody-mediated rejections) and other conditions such as infections, particularly polyomavirus and cytomegalovirus and medication toxicities.
16374978|NCT04154267|No Intervention|Control|Patients will only undergo routine noninvasive evaluation at this post-transplant period
16374979|NCT04154254|Experimental|Dementia Patients|
16374980|NCT04154241|Experimental|neuroendocrine tumor Patients|A cohort of patients that were diagnosed with NET using biopsy.
16374981|NCT04154228|Experimental|Lymphoma Patients|
16374982|NCT04154215|Experimental|Dementia with Lewy Body (DLB) patients|
16374983|NCT04154202|Experimental|Bone inaction patients|Three months or more post joint replacement, or post tibial ORIF, or last surgical intervention adult patients suspected of bone infection and or mechanical loosening.
16374986|NCT04154176||POD CAM Nu-DESC|Patients undergoing surgery under general anesthesia assessed for POD with CAM and Nu-DESC
16374989|NCT04154150|Experimental|Ketamine + Cognitive Training|
16374990|NCT04154150|Sham Comparator|Ketamine + Sham Training|
16374991|NCT04154137||Patients undergoing digestive endoscopy|"All the patients, age ranged from 18 to 90 years, referred to Digestive Endoscopy Outpatients Clinic of the Department of Gastroenterology of the University Hospital Paolo Giaccone of Palermo, Italy"
16374992|NCT04154124|Experimental|Rectal Cancer Patients|
16374993|NCT04154111|Experimental|Real cTBS to the vmPFC|Thirty sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% rMT, MagPro; 600 pulses total)
16374994|NCT04154111|Sham Comparator|Sham cTBS to the vmPFC|Thirty sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% rMT, MagPro; 600 pulses total)
16374995|NCT04154111|Experimental|Real iTBS to the dlPFC|Thirty sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
16374996|NCT04154111|Sham Comparator|Sham iTBS to the dlPFC|Thirty sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
16374997|NCT04154098|Experimental|NO-OA-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
16374998|NCT04154098|Experimental|NO-MA-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
16374999|NCT04154098|Experimental|OA-NO-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
16375000|NCT04154098|Experimental|OA-MA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
16375001|NCT04154098|Experimental|MA-NO-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
16375002|NCT04154098|Experimental|MA-OA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
16375003|NCT04154085|Experimental|Study Group|This study only has one arm; all patients receive the treatment intervention.
16375004|NCT04154072|Active Comparator|NLY01 (2.5 mg)|NLY01 2.5 mg injection
16375005|NCT04154072|Active Comparator|NLY01 (5.0 mg)|NLY01 5.0 mg injection
16375006|NCT04154072|Placebo Comparator|Vehicle|inactive drug, injection
16375007|NCT04154059|Experimental|Intervention Group|Patients will receive a physical therapy intervention three times per week, for 8 weeks.
16375008|NCT04154059|No Intervention|Control Group|Patients will not receive any exercise treatment but they will keep their recommended clinical treatment.
16375009|NCT04154046|Experimental|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
16375010|NCT04154046|No Intervention|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
16375011|NCT04154033|No Intervention|Arm A: Circadian Rhythm of Itch|For the study arm A, to evaluate circadian rhythm of itching, patients will record for 7 days 6 times daily in a booklet the itch intensity on a visual analog scale (VAS) scale. These time points for itch intensity recording will be hours after time of awakening (AW), so they will be AW+2h, AW+4h, AW+6h, AW+8h, AW+10h, AW+12h. Patients are to document all their pruritus attacks at these time points. On day 8 the investigators will collect suction blisters (4-5 10mm blisters) at these 6 time points from unaffected skin on the trunk. For this purpose, the investigators will use the commercially available 47mm orifice plate (Electronic Diversities, Finksburg MD, USA) with 4-5 x10mm openings for each time point and use the 4-5 1mm blister roofs for harvesting.
16375012|NCT04154033|Experimental|Arm B: Topical Naltrexone Cream|Patients will start with placebo in week 2 and move on to naltrexone treatment in week 3. There will be a wash-in phase during week 1. Following week 2 and week 3, at visits 3 and 4, patients will be asked for the area where they are experiencing most intense itch and the investigators will take suction blisters from that area before any treatment. They will be told to bring the medication they have been using and they will apply this topically. After an hour, another suction blister will be taken from the same area. This will ensure the study is still blinded as neither the physician or the participant will know whether the medication was a placebo or not. Participants may apply their topical treatment as often as he wishes.
16375013|NCT04154033|Placebo Comparator|Arm C: Placebo Cream|Patients will start with naltrexone treatment in week 2 and move on to placebo treatment in week 3. Other than this, all procedures will be the same as in study arm B.
16375016|NCT04154007||Adult Patients who met the diagnosis of ARDS|ARDS patients were followed for the development of AKI during their ICU stay
16375017|NCT04153994|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique.
16375018|NCT04153994|No Intervention|Erector Spinae Plane Blockade Control - Standard of Care|Patients will receive the standard of care for pediatric scoliosis surgery including multi-modal opioid pain management. If the patient declines to consent to enrollment into the randomized study, patients may still participate by allowing prospective data and samples collection/analysis with respect to perioperative choice.
16375019|NCT04153981|Experimental|Insulin Glargine|Insulin glargine administered subcutaneously (SC).
16375020|NCT04153968|Experimental|Phase 1|Determination absorption and bioconversion kinetics of [13C14]β-cryptoxanthin and provide external validation for single-sample prediction methods.
16375021|NCT04153968|Experimental|Phase 2|Test the bioefficacy of provitamin A carotenoids (pVACs) in maize by comparing a high β-cryptoxanthin:β-carotene (βCX:βC) variety to a low βCX:βC variety in combination with external [13C]-labelled pVACs.
16375022|NCT04153955|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
16375023|NCT04153955|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
16375024|NCT04153942|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after receiving IV thrombolysis therapy per usual care
16375025|NCT04153942|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after receiving IV thrombolysis therapy per usual care
16375033|NCT04153916|Other|Single use and continuous use|"Patients with a continuous unilateral facial paralysis that underwent an operation for facial reanimation will be enrolled at least one year after the operation according to review of medical records of the Department of plastic surgery.
~Patients with temporary unilateral facial paralysis secondary to Bell's palsy as was identified in the admission to the Hospital Department of Plastic Surgery or to the Department of Ear, Nose and Throat."
16375034|NCT04153903||Patients with intermediate lesions|Imaging cohort will be performed invasive angiography and optical coherence tomography (or Coronary CT angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70% stenosis)
16375035|NCT04153890|Experimental|FamPALcare|Standard Care plus FamPALcare
16375036|NCT04153890|No Intervention|Standard Care|The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
16375037|NCT04153864|Experimental|Non-specialist|Trained nurses or midwives with general health care professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
16375038|NCT04153864|Active Comparator|Specialist|Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
16375039|NCT04153864|Experimental|Telemedicine|A brief, manualized behavioral activation treatment delivered over Zoom in Toronto, via the UNC TelePsychiatry Program in Chapel Hill, and via Zoom in Chicago
16375040|NCT04153864|Active Comparator|In-Person|A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore Chicago
16375041|NCT04153851|Other|neurectomy of nasopalatine nerve|"Prophylactic preoperative antibiotic will be administered prior to surgery.
~Oral disinfection will be performed before surgery.
~Labial infiltration anesthesia and nasopalatine nerve block anasthesia.
~The nasopalatine foramen will be exposed after reflection of a palatal and buccal flap.
~Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal.
~Dental implant will be inserted in the central incisor location."
16375042|NCT04153838||Children|A group of 'typically' developing children (aged between 6 years and 16 years 11 months) from the general paediatric population will be recruited; with the sample distributed evenly across 6 age bands (i.e. ages 6-7 years, 8-9 years, 10-11 years, 12-13 years, 14-15 years, and 16 years+).
16375043|NCT04153825|Active Comparator|Active TENS Group|Ten sessions of active conventional TENS and hydrocollator hot-pack.
16375044|NCT04153825|Active Comparator|Active IFC Group|Ten sessions of active interferential current and hydrocollator hot-pack.
16375045|NCT04153825|Sham Comparator|Sham TENS Group|Ten sessions of sham TENS and hydrocollator hot-pack.
16375046|NCT04153825|Sham Comparator|Sham IFC Group|Ten sessions of sham IFC and hydrocollator hot-pack.
16375047|NCT04153799|Experimental|EGFR CAR-T|Group: 3 dose levels
16375048|NCT04153786|Experimental|Cohort|Pacemakers will be programmed to BiV pacing, left ventricular (LV) pacing, right ventricular (RV) pacing and no pacing for five minutes each. LVAD flow will be recorded every thirty seconds for five minutes with each setting. Once the interventions have been completed, all pacemakers will be returned to their original setting.
16375049|NCT04153773||Group 1|60 Patient
16375050|NCT04153773||Group 2|30 Control subject
16375051|NCT04153760|Active Comparator|Aspirin|Aspirin 81 mg daily for six weeks post-randomization (postpartum)
16375052|NCT04153760|Placebo Comparator|Placebo|Placebo daily for six weeks post-randomization (postpartum)
16375053|NCT04153747|Active Comparator|Conventional ablation|"Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.
~Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI>=6 or Ablation index >=500.
~Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI>=5 or Ablation index >=350."
16375054|NCT04153747|Experimental|High-power and short-duration ablation|Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force > 5 g.
16375055|NCT04153734|Experimental|Immunotherapy plus chemotherapy|Combination of CDDP at 75 mg/m2 (day 1) or CBDCA at Area Under the Curve=6 (AUC=6) (day 1) + PEM at 500 mg/m2 (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, CBDCA at AUC=6 (day 1) + nab-PTX at 100 mg/m2 (days 1, 8, and 15) will be administered at 3-week intervals. If there is no progression after the 4th course of induction therapy, it will be switched to maintenance therapy. For maintenance therapy, the combination of PEM at 500 mg/m2 (day 1) + Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
16375056|NCT04153721|Experimental|Digital Solution|The proposed digital solution aims to improve the patient's preparation for his colorectal surgery and follow his rehabilitation after surgery, by reinforcing his compliance with existing protocols and enriching it with complementary practices
16375057|NCT04153708|Experimental|Retrieval by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
16375058|NCT04153708|Active Comparator|Retrieval by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
16375059|NCT04153695|Experimental|Experimental|To listen flamenco music during 30 minuts per day, during 2 weks
16375060|NCT04153695|No Intervention|Control|No intervention
16375061|NCT04153682|Active Comparator|Antimicrobial stewardship (= AMS)|Management of HAP according to current practice, including intervention of the AMS team.
16375062|NCT04153682|Experimental|Antimicrobial Stewardship + Rapid Diagnostic Testing|Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.
16375063|NCT04153669|No Intervention|Control|This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
16375064|NCT04153669|Experimental|Exercise-No NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions."
16375065|NCT04153669|Experimental|Exercise-NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions. Additionally, this group will receive neuromuscular electrical stimulation (NMES) concomitant to the strength training."
16375066|NCT04153656|Other|Nurses|Subjects will be asked to commit to reading and studying Spiritual Flow.
16375067|NCT04153630|Experimental|Haploidentical MSCs derived from bone marrow|Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
16375068|NCT04153617|Placebo Comparator|Control honey|"Orange blossom honey.
~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.
~Short term trial: 20g/day in a single day."
16375069|NCT04153617|Experimental|Modified honey with soluble fiber and polyphenols|"Honey modified with soluble fiber and polyphenols
~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.
~Short term trial: 20g/day in a single day."
16375070|NCT04153565|Experimental|PBZ @ 200 mg/m2 IV + CIS @ 75 mg/m2 IV + PMX @ 500 mg/m2 IV|PBZ @ 200 mg/m2 IV every 3 weeks (Q3W) in combination with CIS @ 75 mg/m2 IV, and PMX @ 500 mg/m2 IV for 4-6 cycles followed by monotherapy of PBZ up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years)
16375071|NCT04153552||Study Participants who Suffer from Heartburn or indigestion|Subjects who meet the inclusion/exclusion criteria for the trial will be invited to participate in the trial. Subjects will be asked to sign a consent and complete screening survey. At the onset on an episode of the subject will start a symptom diary and completed and rate the symptoms using a 4-point Likert scale for each symptom. The participant will take 2 capsules per indigestion and heartburn episode. With a max of 6 capsules per day. • After taking the test product, the participant will complete a 4-point Likert scale assessment for each symptom at 15 minutes, 30 minutes, and 1 hour after taking the test product.
16375072|NCT04153539|Experimental|Walking along a busy road|Participants in this group will be asked to walk along a busy road for 4.5 hours.
16375073|NCT04153539|Active Comparator|Walking in a traffic-free park|Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.
16375074|NCT04153526||Surgical Cohort|Surgical Cohort: Patients offered surgery, with or without adjuvant chemotherapy.
16375075|NCT04153526||Non Surgical Cohort|Non-Surgical Cohort: Stage I/II/IIIB patients undergoing radical radiotherapy (with or without chemotherapy) or stereotactic ablative radiotherapy (SABR).
16375076|NCT04153513|Experimental|Lanolin|
16375077|NCT04153513|Active Comparator|Mother's milk|
16375078|NCT04153500|No Intervention|Traditional Methodology|A professor/lecturer of anatomy will carry out the session in the control group. The traditional (40 minutes total) will consist of 30 minutes of lecture (75% out of the total time), where female pelvic floor will be presented throughout theory and images. In the 2nd part, during 10 min (25%), participants will review anatomical drawings /atlases.
16375079|NCT04153500|Experimental|Pelvic+ method|The second researcher will carry out the session in the intervention group. The interventional session (40 minutes total) will consist of two parts: The 1st one is a lecture of 10 minutes (25% out of the total time) on female pelvic floor anatomy. In the 2nd part, during 30 min (75%), participants, in small groups of 4 people, will assemble the female pelvic floor interactive model, following the indications suggested by the second researcher. Pelvic+ is supported by an assembling manual that participants will be allowed to use.
16375080|NCT04153487|Experimental|ASTRALI Group|ASTRALI (AScorbic acid in TRALI) group (n=40)
16375081|NCT04153487|Placebo Comparator|Control Group|Control group (n=40)
16375082|NCT04153474|Active Comparator|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
16375083|NCT04153474|Active Comparator|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
16375084|NCT04153461|Active Comparator|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
16375085|NCT04153461|Active Comparator|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
16375086|NCT04153448||Bronchiectasis|Children with bronchiectasis
16375087|NCT04153448||Healthy Controls|Age-matched healthy volunteers
16375088|NCT04153435|Experimental|Calcium|The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
16375089|NCT04153435|Placebo Comparator|Placebo|"The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, normal saline) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline."
16375090|NCT04153422|Experimental|Treatment (IVIG)|Patients in the treatment arm will receive 2g/kg Gammagard IVIG initially (1g/kg dose on Day 1 and 1g/kg dose on Day 2) and then 1g/kg maintenance infusions for 5 additional months (six months total).
16375091|NCT04153422|Placebo Comparator|Placebo|Patients in the placebo arm will receive 0.9% NaCl during the initial infusion and at maintenance infusions for 5 additional months (six months total).
16375092|NCT04153409|Experimental|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
16375093|NCT04153409|Placebo Comparator|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
16375094|NCT04153396|Experimental|The Treatment Group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
16375095|NCT04153396|Active Comparator|The Control group|The local infiltration solution in the control group will consist of ropivacaine.
16375097|NCT04153370|Active Comparator|intubation time airtraq|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
16375098|NCT04153370|Active Comparator|intubation time glidescope|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
16375099|NCT04153370|Active Comparator|intubation time c-mac|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
16375100|NCT04153357|Active Comparator|intubation time airtraq|intubation time of Airtraq
16375101|NCT04153357|Active Comparator|intubation time glidescope|intubation time of glidescope
16375102|NCT04153357|Active Comparator|intubation time of c-mac|intubation time of c-mac
16375103|NCT04153344||Infrared hyperreflective area|Patients with neurofibromatosis type 1 and with infrared hyperreflective areas
16375104|NCT04153344||No infrared hyperreflective areas|Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas
16375105|NCT04153344||Controls|Patients with no neurofibromatosis type 1
16375106|NCT04153331|Experimental|Patients admitted to emergency department with medical cause|Patient included in emergency with a nasal swab
16375107|NCT04153292|Experimental|TMVR - Main Cohort|Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).
16375108|NCT04153292|Experimental|TMVR - Failed TEER Registry|Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.
16375109|NCT04153279|Experimental|CMV-TCR-T cells|The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10^6 to 1×10^6 TCR+T/Kg.
16375110|NCT04153266||Patients with oral epithelial dysplasia|"INCLUSION CRITERIA
~These include:
~Adults aged 18 or above at the time of the screening visit.
~Good command of English language both written and spoken [this is necessary as questionnaires are in English and cannot be translated unless through a cross-cultural validation study].
~Being able to consent.
~Diagnosed with OED as per current standard diagnostic criteria.
~No concurrent malignancy in the head and neck or elsewhere."
16375111|NCT04153253|Active Comparator|Group I|Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
16375112|NCT04153253|Active Comparator|Group II: Early vitrectomy.|Early vitrectomy.
16375113|NCT04153240|Experimental|Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'THERAPY' mode (ie. vibration feedback will be given in response to supine position)
16375114|NCT04153240|Sham Comparator|Sham Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'MONITOR' mode (ie. no vibration feedback will be given)
16375115|NCT04153214|Experimental|Cycling workstation|Participants will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 6 months
16375116|NCT04153214|Placebo Comparator|control|Daily activities unchanged during 3 months. Then they will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 3 months.
16375117|NCT04153201|Experimental|Hydroxychloroquine|Patients with primary antiphospholipid syndrome started on hydroxychloroquine while continuing standard care (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents, depending on primary APS subgroup)
16375118|NCT04153201|No Intervention|Standard care|Patients with primary antiphospholipid syndrome continuing standard care only (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents
16375119|NCT04153188|Experimental|Pulsed Dye Laser & Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream for 4 weeks prior to 1st of 3 monthly Vbeam® Prima PDL treatments. Subjects will continue with once daily application of Oxymetazoline HCL 1% Cream during the 6-month post-baseline study with a 3-day washout of cream prior to each of the 3 PDL treatments.
16375120|NCT04153188|Active Comparator|Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream during the 6-month study.
16375121|NCT04153175|Active Comparator|CT-010 Active Therapy|Subjects in the active comparator arm will have been randomized to receive active therapy through the implanted drug delivery system through the 3-month blinded period.
16375122|NCT04153175|Placebo Comparator|Placebo|Subjects in the placebo comparator arm will have been randomized to receive placebo therapy through the implanted drug delivery system for the 3-month blinded period.
16375123|NCT04153162|Experimental|Stereotactic body radiation therapy|In patients with HCM and refractory symptoms from LVOTO, stereotactic body radiation therapy will be delivered locally to relieve symptoms
16375126|NCT04153136|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
16375127|NCT04153136|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
16375128|NCT04153123|Experimental|Lidocaine with epinephrine|Peribulbar anesthesia with lidocaine and epinephrine
16375129|NCT04153123|No Intervention|Lidocaine without epinephrine|Peribulbar anesthesia with lidocaine
16375130|NCT04153110|Experimental|Real tDCS - Real tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
16375131|NCT04153110|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks).
16375132|NCT04153097||pembrolizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with pembrolizumab
16375204|NCT04152629|Experimental|FOQUEST adults|adult (≥18 years or older) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, or 100 mg/day)
16375133|NCT04153084||High volume electrolytes Polyethylene Glycol (PEG 4000) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using high volume electrolytes PEG (Bohm solution®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
16375134|NCT04153084||Low volume electrolytes PEG (PEG 3350) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using low volume electrolytes PEG (Movicol®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
16375135|NCT04153084||Sodium picosulfate cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using sodium picosulfate (Picoprep®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
16375136|NCT04153071|Experimental|Unipolar microplasma RF treatment|Single cutaneous unipolar microplasma RF treatment, with variable treatment parameters
16375137|NCT04153058|Experimental|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
16375138|NCT04153058|Active Comparator|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
16375139|NCT04153045|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
16375140|NCT04153045|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
16375141|NCT04153032|Experimental|DTZ arm|The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
16375142|NCT04153032|Experimental|MEBO arm|The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
16375143|NCT04153032|Experimental|MEBO and DTZ arm|The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
16375144|NCT04153019|Other|Cancer cachexia|Psycho-educational session: 3 weekly face-to-face consultations between a dyads (patients-caregivers) and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
16375145|NCT04153006||Chest pain patients|"Patients who are admitted to the cardiac ED because of chest pain for ruling out acute coronary syndrome by troponin analysis are eligible for participation.
~Troponin analysis will be performed according to standard protocol (0-1h protocol). From every included patient capillary blood samples and an extra venous blood sample will be drawn to evaluate HS cTnI levels obtained with the POC instrument and central laboratory (CL)."
16375146|NCT04152993|Experimental|RNS group|This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
16375147|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 3 hours.|This is a dose optimization study, different dosages will be tested, the lowest dosage that will be tested is 2,5 mg/kg/h for 3 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
16375148|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 6 hours|The second lowest dosage that will be tested is 2,5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
16375149|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 6 hours.|The third lowest dosage, is the start dosage and the dosage that is already used in other clinical studies: 5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
16375150|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 12 hours.|The fourth dosage that is tested is 5 mg/kg/h for 12 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease..
16375151|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 18 hours.|The fifth dosage that is tested is 5 mg/kg/h for 18 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
16375152|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 24 hours.|The sixth dosage that is tested is 5 mg/kg/h for 24 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
16375155|NCT04152954|Active Comparator|Traditional cannula|
16375156|NCT04152954|Experimental|Multi-tined cannula|
16375157|NCT04152928|Experimental|Neuroendocrine Tumors Patients|Patients with confirmed NET
16375158|NCT04152915|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (semaglutide D, test formulation)
16375159|NCT04152915|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (semaglutide reference formulation)
16375160|NCT04152902||PULL-DOWN HELLER-DOR|The PD-HD procedure aimed to restore the vertical axis of the intraabdominal portion of the oesophagus as much as possible. In brief, before performing the myotomy and the anterior fundoplication according to Dor, at least 6 cm of the mediastinal oesophagus was fully isolated; two or more U intramuscular stitches were applied on the curling of the right side of the oesophagus, pulled down and rotated towards the right side of the gastro-oesophageal junction. The PD-HD operation was performed under manometric control
16375313|NCT04151875|Experimental|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
16375161|NCT04152902||OESOPHAGECTOMY|OE was performed with open technique, or recently, with a minimally invasive technique. The stomach was always the oesophageal substitute, and the oesophagogastric anastomosis was preferably located at the thoracic dome or at the neck to minimize the risk of postoperative reflux oesophagitis or cancer growth in the residual dilated oesophagus
16375162|NCT04152889|Experimental|Camrelizumab+chemotherapy|
16375163|NCT04152876||Cases|Patients with rare disease
16375164|NCT04152876||controls|Healthy parents and relatives
16375165|NCT04152863|Experimental|IV V937 + Pembrolizumab|Participants receive V937 at a dose of 1 X 10^9 TCID50 by IV infusion on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
16375166|NCT04152863|Experimental|ITu V937 + Pembrolizumab|Participants receive V937 at a dose of 3 X 10^8 TCID50 by ITu injection on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
16375167|NCT04152863|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
16375168|NCT04152850|Experimental|Lifestyle Medicine Group|
16375169|NCT04152850|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
16375170|NCT04152837|Experimental|Lixivaptan|Lixivaptan oral capsules, 100-200 mg twice daily
16375171|NCT04152824|Experimental|Leader Intervention|Leaders in the intervention group will go through the Resilience-Supportive Leadership Training (RESULT)
16375172|NCT04152824|No Intervention|Control Group|Leaders in the control group will be usual practice
16375173|NCT04152811|Active Comparator|Waitlist 1|usual diabetes care
16375174|NCT04152811|Experimental|Intervention 1|6-weeks of cooking matters for diabetes classes
16375175|NCT04152811|Active Comparator|Waitlist 2|usual diabetes care
16375176|NCT04152811|Experimental|Intervention 2|6-weeks of cooking matters for diabetes classes
16375177|NCT04152798|Active Comparator|ProGrip™ mesh repair|Laparoscopic hiatal hernia repair with ProGrip™ mesh
16375178|NCT04152798|Active Comparator|Primary crural repair|Primary posterior crura repair
16375179|NCT04152785|Experimental|GHG|Information given regarding greenhouse gas emissions via a GHG score
16375180|NCT04152785|Experimental|Nutrition|Information given regarding nutrition via a nutrient profiling score
16375181|NCT04152785|Experimental|GHG+nutrition|Information given regarding GHG and nutrition via a combined score
16375182|NCT04152785|Placebo Comparator|No logo|No information given
16375183|NCT04152772|Active Comparator|Active during extinction learning / Sham during consolidation|Active tDCS stimulation will be applied during the extinction learning phase. Sham tDCS stimulation will be applied during the consolidation phase.
16375184|NCT04152772|Active Comparator|Sham during extinction learning / Active during consolidation|Sham tDCS stimulation will be applied during the extinction learning phase. Active tDCS stimulation will be applied during the consolidation phase
16375185|NCT04152772|Sham Comparator|Sham during extinction learning / Sham during consolidation|Sham tDCS stimulation will be applied during both the extinction learning phase and the consolidation phase.
16375186|NCT04152759|Experimental|BAT2506 injection|50mg ；subcutaneous injection
16375187|NCT04152759|Active Comparator|Sinponi(EU-licensed)|50mg ；subcutaneous injection
16375188|NCT04152746||Adenoid group|Periostin levels in the adenoid group
16375189|NCT04152746||Control Group|Periostin levels in the control group
16375190|NCT04152733|No Intervention|Control group|Children in the control group receive oxygen via conventional nasal cannula during deep sedation. Oxygen flow is determined to set the fraction of inspired oxygen of 50%.
16375191|NCT04152733|Experimental|High flow (HF) group|Children in the HF group receive oxygen via high flow nasal cannula during deep sedation. Fraction of inspired oxygen is set to 50%.
16375192|NCT04152720|Active Comparator|Prevention of infection Foley catheter|
16375193|NCT04152720|Active Comparator|Conventional Foley catheter|
16375194|NCT04152707|Experimental|Splendor X|
16375195|NCT04152694|Other|Ceftaroline in CRRT|Ceftaroline levels measured in patients receiving continuous renal replacement therapy
16375196|NCT04152681|Experimental|Assigned Interventions|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
16375197|NCT04152668|Active Comparator|Titanium curette and ultrasonic.|Control implants will be debrided with titanium curette and ultrasonic device without time limit.
16375198|NCT04152668|Experimental|Titanium curette, ultrasonic and air-polishing.|Test implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit also without time limit.
16375199|NCT04152655|Active Comparator|Group 1: idebenone|Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
16375200|NCT04152655|Placebo Comparator|Group 2: placebo|Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
16375201|NCT04152642|Active Comparator|Marketed Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
16375202|NCT04152642|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
16375203|NCT04152642|Sham Comparator|Water/Negative Control|subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
16375205|NCT04152629|Active Comparator|VYVANSE adults|adult (≥18 years or older) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
16375206|NCT04152629|Experimental|FOQUEST pediatric|pediatric (6 to 17 years old) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg or 70 mg/day)
16375207|NCT04152629|Active Comparator|VYVANSE pediatric|pediatric (6 to 17 years old) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
16375208|NCT04152616|Experimental|Optitrack®|Instrumental evaluation of posture
16375209|NCT04152603|No Intervention|Control|Individuals in this arm will go through the partner study's standard recruitment and consent process
16375210|NCT04152603|Experimental|Intervention|Individuals in this arm will be exposed to our intervention during the partner study's recruitment and consent process
16375211|NCT04152590|Experimental|Uincare|Exercise using Uincare
16375212|NCT04152577|Experimental|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX
~R2-CHOP :
~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
~R2-DA-EPOCH:
~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
~R2-HD MTX:
~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
16375213|NCT04152577|Active Comparator|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX
~R-CHOP :
~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
~R-DA-EPOCH:
~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
~R-HD MTX:
~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
16375214|NCT04152564|Active Comparator|levo-bupivacaine continuous epidural infusion [CEI])|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
16375215|NCT04152564|Active Comparator|Levo-bupivacaine continuous preperitoneal infusion [CPI]),|At the end of surgery and after the closure of the peritoneal layer, the preperitoneal catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered.
16375216|NCT04152551|Experimental|Adult Treatment Arm|Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.
16375217|NCT04152551|No Intervention|Child (Bisphosphonate Arm)|Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
16375218|NCT04152551|No Intervention|Child (Control Arm)|Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
16375219|NCT04152538||healthy subjects|Healthy subjects matched with TKA patients
16375220|NCT04152538||TKA patients|age greater than 18 years old and a recent TKA.
16375221|NCT04152525|Experimental|experimental group|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
16375222|NCT04152525|No Intervention|control group|Routine care
16375223|NCT04152512||Whole Cohort|Whole cohort administration of questionnaire at 7 times
16375224|NCT04152499|Experimental|Phase I: Dose Escalation|Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264
16375225|NCT04152499|Experimental|Phase II: Triple Negative Breast cancer|Histologically documented, incurable, locally advanced or metastatic cancer
16375226|NCT04152499|Experimental|Phase II: Ovarian Epithelial cancer|Histologically documented, incurable, locally advanced or metastatic cancer
16375227|NCT04152499|Experimental|Phase II: Non-Small Cell Lung Cancer|Histologically documented, incurable, locally advanced or metastatic cancer
16375228|NCT04152499|Experimental|Phase II: Gastric Adenocarcinoma|Histologically documented, incurable, locally advanced or metastatic cancer
16375229|NCT04152499|Experimental|Phase II: Small Cell Lung Cancer|Histologically documented, incurable, locally advanced or metastatic cancer
16375230|NCT04152499|Experimental|Phase II: Urothelial Carcinoma|Histologically documented, incurable, locally advanced or metastatic cancer
16375231|NCT04152486|Experimental|Intervention arm|The vaccine Ad26.ZEBOV (5x10^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
16375232|NCT04152473|Experimental|Proglumide|Open labelled proglumide treated
16375233|NCT04152460|Active Comparator|Thermo-Viscous preheated bulk fill resin composite|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
16375234|NCT04152460|Placebo Comparator|Conventional Bulk Fill resin Composite|GrandioSo X-tra (Voco,Cuxhaven
16375235|NCT04152447|No Intervention|Standard of care|
16375236|NCT04152447|Active Comparator|VR device|
16375272|NCT04152213|Placebo Comparator|Control group|"The components of the control group include:
~(1) Pamphlets from the Department of Health about obesity and a balanced diet based on the food pyramid will be distributed. (2)Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after receiving the pamphlets."
16375440|NCT04151043|Other|Verbal suggestion|
16375237|NCT04152434||Reduction in monthly migraine days all cohorts at 4 months|Migraineurs with 15-30 headache days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly headache days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)
16375238|NCT04152434||Selection of elegible paitients|A total of 158 patients were involved in this study. 118 patients (75%), received Erenumab 140 mg., and 40 patients (25%) received 70 mg. In the Botox cohort, of 650 patients, 90 (13%) patients were eligible. In the no Botox cohort, 533 patients, 83 (15%) patients were eligible.
16375239|NCT04152434||Rate of adverse events related to Erenumab|72 adverse events were experienced during the 4 months of treatment, mostly with the 140 mg. dose. The most frequent were: constipation 34%, fatigue 19%, itching 7.5%, muscle cramps 6.3%, increased headache 4.4%, rhinitis 4.4%, injection site discomfort 3.7%, lack of energy 3.1%
16375240|NCT04152421|Experimental|Software user|
16375241|NCT04152408|Experimental|FiberSense System|6 diabetic patients will wear a FiberSense system at the upper arm for up to 30 days. and a comparator CGM system at the abdomen (replaced every 7 days).
16375242|NCT04152395||Metabolic group|Patients with metabolic syndrome undergoing EVAR
16375243|NCT04152395||Control group|Patients without metabolic syndrome undergoing EVAR
16375250|NCT04152369|Active Comparator|24 hour prophylaxis|In this group patients received a AMP for the day of the procedure
16375251|NCT04152369|Active Comparator|72 hour prophylaxis|In this group patients received a AMP one day prior, on the day of the procedure and the following day.
16375252|NCT04152356||PD-1|
16375253|NCT04152356||Sorafenib|
16375254|NCT04152343|Experimental|RFA Physics Library- PGP|The RFA Physics Library will be used during during percutaneous liver RFA procedures.
16375255|NCT04152330|Other|Comparison between intervention and control group|"Subjects will be randomized to two groups, intervention group (IG) and Control group (CG). Each GI Parents-Baby dyad will receive 4 interventions, which will take place at predetermined dates (at 30 days, 3 months, 6 months, and 9 months) with groups of up to 5 pairs of participants. Parents is understood to be a generalist nomenclature and will be considered as parent, parent or primary caregiver.
~CG subjects will receive standard guidelines from the pediatric and pediatric cardiology outpatient clinic."
16375256|NCT04152317|Experimental|Misoprostol 200mcg|In this group, the participants will receive 200mcg of misoprostol, single dose, via the vaginal route.
16375257|NCT04152317|Active Comparator|Misoprostol 800mcg|In this group, the participants will receive 800mcg of misoprostol, single dose, via the vaginal route.
16375258|NCT04152304|Experimental|Feasibility of the SINEX for treatment of shoulder instability|Feasibility of the SINEX program for treatment and evaluation of of traumatic anterior shoulder instability eligible for surgery
16375259|NCT04152291|Experimental|E-EPA-diet group|All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.
16375260|NCT04152278||study group|The study group included 300 women presenting with unexplained spontaneous miscarriage or missed abortion during the first and early second trimester of pregnancy (8-16 weeks gestational age). The included women aged 18 to 45 years old.
16375261|NCT04152278||control group|The control group included 300 women with normal pregnancy, recruited from women attending the antenatal clinic of gestational age 8-16 weeks. The included women aged 18 to 45 years old.
16375262|NCT04152265|Other|No Intervention: Current screening practice.|Patients will be asked to complete the Food Frequency Questionnaire (FFQ) and the questionnaire about The World Health Organization Quality Of Life (WHOQOL-BREF), also and will be collected the demographic and anthropometric data
16375263|NCT04152265|Experimental|Experimental: Sequential screening strategy|People aged between 50-65, will take part in the study. Patients, which will take in a screening colonoscopy, will be divided into two groups according to the result obtained. The first group, will be constitute the patients with a positive test result, while the second group (control) will be constitute the patients with the negative test result. In addition, from the Subjects the samples of blood and faeces will be collected.
16375264|NCT04152252||Baseline|No CPR feedback during CPR
16375265|NCT04152252||Real-time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
16375266|NCT04152252||Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
16375267|NCT04152239||Study group|Study group includes consecutive patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy. Patients fulfilling the inclusion criteria and without exclusion criteria would undergo MSE per study protocol.
16375268|NCT04152226|Active Comparator|Cohort 1|Cohort 1 low dose of J. lividum
16375269|NCT04152226|Active Comparator|Cohort 2|Cohort 2 medium dose of J. lividum
16375270|NCT04152226|Active Comparator|Cohort 3|Cohort 3 - high dose of J. Lividum
16375271|NCT04152213|Experimental|Low GI diet group|"The components of the Low GI diet group include:
~(1) A one-off, 60-minute, face-to-face, educational session conducted by the research nurse for GI knowledge input. (2) An informational booklet will be given out during the education session. (3) Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after completing the face-to-face education session."
16375441|NCT04151043|Other|No suggestion|
16375274|NCT04152187|Experimental|Inspiratory muscle training (IMT)|Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe). During training, patients will be instructed to maintain diaphragmatic breathing. Inspiratory load will be set at 40-60% of maximum inspiratory pressure. Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
16375275|NCT04152187|No Intervention|Control|No additional intervention
16375276|NCT04152174|Experimental|Combined extracorporeal blood purification|CRRT with CVVHDF mode plus treatment with CytSorb adsorber
16375277|NCT04152174|Active Comparator|Control|CRRT with CVVHDF mode
16375278|NCT04152161|Experimental|Bacille Calmette Guerin (BCG) group|
16375279|NCT04152161|Placebo Comparator|Placebo group|
16375280|NCT04152148|Experimental|500mg BAT4306F|3 weeks of a cycle
16375281|NCT04152148|Experimental|750mg BAT4306F|3 weeks of a cycle
16375282|NCT04152148|Experimental|900mg BAT4306F|3 weeks of a cycle
16375283|NCT04152148|Experimental|1000mg BAT4306F|3 weeks of a cycle
16375284|NCT04152122||Intermittent exotropia group|Intermittent exotropia group
16375285|NCT04152122||Normal group|Normal group
16375286|NCT04152109|Other|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, an average of 8 weeks.
16375287|NCT04152109|Sham Comparator|Laying on of hands without Spiritual connection subgroup|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, an average of 8 weeks.
16375288|NCT04152109|Experimental|"Laying on of hands by Spiritual connection Passe subgroup"|"The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist pass. Patients remain in the supine bed blindfolded for 5 minutes, an average of 8 weeks."
16375289|NCT04152096|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
16375290|NCT04152096|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
16375291|NCT04152083|Experimental|Eptinezumab|Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
16375292|NCT04152083|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
16375293|NCT04152070||Community-dwelling older adults|Community-dwelling older adults living in the Valencia region (Spain).
16375294|NCT04152057|Experimental|Pyrotinib Combined With Albumin Paclitaxel and Trastuzumab|"Preoperative
~-Drug: Pyrotinib Maleate Tablets combined with Albumin Paclitaxel and Trastuzumab.
~Surgery:Subjects should be evaluated by tumor-enhanced MRI combined with mammary gland ultrasound during the preoperative neoadjuvant administration, and evaluated every 2 cycles. The subjects who were evaluated for CR and PR for the first time should be confirmed after at least 4 weeks. The confirmed tumor assessment cannot change the previously fixed examination time point.
~Postoperative
~Drug: Epirubicin hydrochloride combined with Cyclophosphamide
~At the same time, according to the recommendation of the clinician, choose whether to accept the same anti-HER2 treatment plan before surgery. For patients with tumors positive for estrogen receptor (ER) and/or progesterone receptor (PR), endocrine therapy should be given at the end of adjuvant chemotherapy, and if there is clinical indication at the end of adjuvant chemotherapy, radiotherapy should be given."
16375295|NCT04152044||Liver biopsy, Visceral and subcutaneous obesity|Those with histology and LFT's and quantificaiton of obesity
16375296|NCT04152018|Experimental|Dose Escalation|Single Agent Dose Escalation
16375297|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
16375298|NCT04152018|Experimental|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
16375299|NCT04152018|Experimental|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
16375300|NCT04152005||Control|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
16375301|NCT04152005||Periodontitis|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
16375302|NCT04152005||Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
16375303|NCT04152005||Periodontitis+Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
16375304|NCT04151966||Cardioversion Group|Subjects scheduled to undergo direct current cardioversion (DCCV) as part of the clinical plan of care
16375305|NCT04151953||Subjects with cardiac implantable electronic device (CIED)|Subjects with previously implanted cardiac implantable electronic device (CIED) who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
16375306|NCT04151940||Observational (PET/CT scan)|Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
16375307|NCT04151927|Experimental|Normobaric Hypoxia (NH)|Overnight exposure (8 hours) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
16375308|NCT04151927|Sham Comparator|Normobaric Normoxia (NN)|Overnight exposure (8 hours) to NN conditions (~20% oxygen; achieved with nitrogen dilution, equivalent to ~1000 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
16375309|NCT04151901|Experimental|Male Rehabilitation (M-REHAB)|Disuse + resistance exercise rehabilitation
16375310|NCT04151901|Experimental|Male Control (M-CON)|Disuse + ambulatory control rehabilitation
16375311|NCT04151901|Experimental|Female Rehabilitation (F-REHAB)|Disuse + resistance exercise rehabilitation
16375312|NCT04151901|Experimental|Female Control (F-CON)|Disuse + ambulatory control rehabilitation
16375314|NCT04151875|Active Comparator|Non-extraction orthodontic treatment|non-extraction orthodontic treatment
16375315|NCT04151862|Active Comparator|tight eye bandage|Both eyes will be operated at two separate sessions. In the first session the first 25 patients will be bandaged postoperatively with tight eye bandage patching.
16375316|NCT04151862|Active Comparator|therapeutic contact lenses (TCL)|Both eyes will be operated at two separate sessions. In the second session the 25 patients will be bandaged postoperatively with therapeutic contact lenses (TCL).
16375317|NCT04151849||GLP-1 receptor agonist treatment|Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.
16375318|NCT04151849||SGLT-2 inhibitor treatment|Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.
16375319|NCT04151836|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity 30 minutes of exercise in week 1-4,40 minutes of exercise in 5-8 weeks,50 minutes in the 9-12 week,three times weekly in three month.We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 65%-70% of the target Maximal heart rate(HRmax).
16375320|NCT04151836|No Intervention|control group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
16375321|NCT04151823|Experimental|Postbiotic &vitamin D3, lifestyle intervention.|Postbiotics will be given at the dose of 80 mg/day (2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN; immunofos from Lactobacillus paracasei CNCM I-5220). 2 mL of product will give 1600 UI/die of VIT D3. Healthy living habits will be encouraged at t0, t1 and t2 visit.
16375322|NCT04151810|Experimental|anti-EGFR monoclonal antibody|"Single-dose Phase:This is a dose-escalation trial, all participants will receive treatment with CDP1. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.
~Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;
~Multi-dose Phase:Multiple administrations of three Cohorts of subjects were followed by continuous administration of CDP1."
16375323|NCT04151797|Experimental|Medication therapy management|Medication therapy management by pharmacist-led medication review
16375324|NCT04151784||Pulmonary Group|Pulmonary Group who have evidence of pulmonary diseases
16375325|NCT04151784||Healthy Control|Health Group who have no evidence of pulmonary diseases
16375326|NCT04151771|Experimental|LL-BFRT group|Participants randomised into intervention group are attending pulmonary rehabilitation in which strengthening exercises of the lower limb are performed using LL-BFRT.
16375327|NCT04151771|Active Comparator|Usual pulmonary rehabilitation group|Participants randomised into control group are attending usual pulmonary rehabilitation as established.
16375328|NCT04151758|Experimental|Docosahexaenoic Acid Supplementation, lifestyle intervention|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day. Physical activity and healthy eating habits will be encouraged.
16375329|NCT04151745|Other|study group|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
16375330|NCT04151719|Experimental|MNTX 450 mg QD|Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.
16375331|NCT04151706|Experimental|fTBI/Thiotepa/fludarabine|Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide.
16375332|NCT04151693|Experimental|Research group CFS|"Research treatment for patients with CFS (diagnosed G 93.3). CBT- based group therapy
~8 sessions in 4 months. n=35-40 patients
~Special focus on autonomic nervous system and how it affects the individual (hyperarousal, cognitive disabilities) Psychoeducation and tasks (for example abdominal respiration and mindfulness) learning new coping skills Stress management in every day life"
16375333|NCT04151693|Experimental|Control group CFS|"Control group
~6 sessions in 3 months n=35-40 patients
~Health, lifestyle and wellbeing counselling (sleep, nutrition, performance)"
16375334|NCT04151680|Experimental|Intermittent anticoagulation|Patients will be given anticoagulation if continuous electrocardiographic monitoring will detect an atrial fibrillation episode lasting more than an hour
16375335|NCT04151680|Experimental|Chronic anticoagulation|Patients will be given chronic oral anticoagulation regardless findings at continuous electrocardiographic monitoring
16375336|NCT04151667|Experimental|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
16375337|NCT04151667|Experimental|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
16375338|NCT04151667|Experimental|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m^2 Days 1,8 and 15 of each 28 day treatment cycle.
16375339|NCT04151654|Other|assessment1|İt is assessment study. Assessment1 was evaluated for all test with and without footwear.
16375340|NCT04151641|Experimental|Sequence 1|
16375341|NCT04151641|Experimental|Sequence 2|
16375342|NCT04151628|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
16375343|NCT04151615||Patients|Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation
16375344|NCT04151602||PWUD with active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease
16375345|NCT04151602||PWUD with no active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease
16375346|NCT04151602||non-PWUD with active TB|People who do not use meth/mandrax who have active TB disease
16375347|NCT04151589|Experimental|Interventional Site|"The process below will be allocated in Interventional Sites:
~At each interventional sites, implementing full assessment of current emergency work flow of acute ischemic stroke patients who eligible for endovascular treatment. All interventional sites would undergo assessment in order to form a baseline.
~Drafting intervention approaches based on the assessment results of all interventional sites. These approaches are executable, reproducible, and measurable.
~Emergency work flow management APP would be installed on smartphones of designated personnel at each interventional sites.
~Both intervention approaches and APP would be incorporated with original work flow at each interventional site.
~Training sessions would be held in interventional sites or online every 3 month once the patient enrolment begin.
~Outcome data would be analysed and dispatched every 3 month for each interventional sites."
16375348|NCT04151589|No Intervention|Control Site|The control site would not undergo any emergency work flow modification for acute ischemic stroke patients who eligible for endovascular treatment.
16375349|NCT04151576|Experimental|Experimental|The patients received medical treatment. The intervention: An aromatic oil mixture (lavender and peppermint) was massaged for 15 minutes on the temple and root of the neck of the patients, and this application continued for three weeks
16375350|NCT04151576|No Intervention|Control|The patients received only medical treatment
16375351|NCT04151563|Experimental|Arm A: cabozantinib + nivolumab + ipilimumab|
16375352|NCT04151563|Experimental|Arm B: cabozantinib + nivolumab|
16375353|NCT04151563|Experimental|Arm C: nivolumab + ramucirumab + docetaxel|
16375354|NCT04151563|Experimental|Arm D: lucitanib + nivolumab|
16375355|NCT04151563|Experimental|Arm E: nivolumab + docetaxel|
16375356|NCT04151563|Active Comparator|Arm F: docetaxel|
16375361|NCT04151537|Active Comparator|Intervention|The intervention group is provided with a PA tracker that enables self-monitoring of PA and are instructed to obtain a personalized PA goal on a weekly basis.
16375362|NCT04151537|Active Comparator|Control|The control group is recommended to follow national PA guidelines, which can be considered as the 'intervention' offered to the public.
16375363|NCT04151511|Other|Continuous Thoracic Epidural|Continuous Thoracic Epidural Analgesia for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
16375364|NCT04151511|Experimental|Continuous Erector Spinae Plane Block|Continuous Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
16375365|NCT04151498|Experimental|Intervention Group|This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
16375366|NCT04151498|Other|Usual Care Reengagement Group|This group will complete a qualitative interview about barriers and facilitators to HIV care.
16375367|NCT04151498|No Intervention|Non-enrolling Group|This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
16375368|NCT04151485|Experimental|Mind/Body Group|All persons allocated to the intervention group will take part in a 10-week Mind/Body skills development fertility program parallel with fertility workup and treatment.
16375369|NCT04151485|Active Comparator|Support Group|All persons allocated to the comparison intervention group will take part in a 10-week fertility support program parallel with fertility workup and treatment.
16375370|NCT04151472|Experimental|90mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 30mg table by mouth, three times a day for next 3 months
16375371|NCT04151472|Experimental|270mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 90mg table by mouth, three times a day for next 3 months
16375372|NCT04151472|Placebo Comparator|Placebo|Placebo by mouth, three times a day for 4 months
16375373|NCT04151459|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy on severe obesity PCOS patients
16375375|NCT04151433|Active Comparator|The combined technique|First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.
16375376|NCT04151433|Active Comparator|CO2 laser vaporization only|CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.
16375377|NCT04151420||Adult IBD patients|
16375378|NCT04151407|Experimental|601 dose level 1 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
16375379|NCT04151407|Experimental|601 dose level 2 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once
16375380|NCT04151407|Experimental|601 dose level 3 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once
16375381|NCT04151407|Experimental|601 dose level 4 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
16375500|NCT04150627|Active Comparator|deep breathing|
16375382|NCT04151407|Experimental|601 dose level 5 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;
16375383|NCT04151407|Experimental|601 dose level 6 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.
16375384|NCT04151407|Experimental|601 dose level 7 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.
16375385|NCT04151381|Placebo Comparator|the control group|the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .
16375386|NCT04151381|Active Comparator|Amiophylline (2mg)|Aminophylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia
16375387|NCT04151381|Active Comparator|Aminophylline(4mg)|Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
16375388|NCT04151368|Experimental|Robotic Nipple Sparing Mastectomy Arm|Patient cohort undergoing nipple sparing mastectomy with use of robotic dissection.
16375389|NCT04151355|Experimental|Atorvastatin group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) in addittion to atorvastatin (20 mg once daily)
16375390|NCT04151355|No Intervention|Control group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks)
16375391|NCT04151342||Prospective|Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR exon 20, ROS1, and BRAF, from participating sites/cancer centres across Canada.
16375392|NCT04151342||Retrospective|Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR exon 20, ROS1, and BRAF, from participating sites/cancer centres across Canada.
16375393|NCT04151342||Comparator group|All cancer patients without rare molecular alterations in their tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy.
16375394|NCT04151329|Experimental|2.4mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box, 2.4mg/kg IV infusions
16375395|NCT04151329|Experimental|3.6mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box,3.6mg/kg IV infusions
16375396|NCT04151316|Experimental|vertical group|
16375397|NCT04151316|Experimental|horizontal group|
16375398|NCT04151303||Cerclage 1|Time to delivery after cerclage removal Between 36-36.6 weeks' gestation - group 1
16375399|NCT04151303||Cerclage 2|Time to delivery after cerclage removal Between 37-37.6 weeks' gestation - group 2
16375400|NCT04151303||Cerclage 3|Between 38-38.6 weeks' gestation - group 3
16375401|NCT04151303||Cerclage 4|Time to delivery after cerclage removal Beyond 39 weeks' gestation - group 4
16375402|NCT04151277|Experimental|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first)
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1
~Folinic acid: 350 mg flat dose, IV over 2 hours, day 1
~5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours (or 48 hours as per standard practice))"
16375403|NCT04151277|Active Comparator|Abraxane and Gemcitabine|"nab-paclitaxel: 125 mg/m2 IV over 30 minutes, day 1, 8, and 15 (administered first)
~Gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 (immediately following nab-paclitaxel)"
16375404|NCT04151264|No Intervention|Control Arm|blinded HPI monitoring
16375405|NCT04151264|Active Comparator|Intervention Arm|HPI monitoring to predict hypotension
16375406|NCT04151251|Active Comparator|Sleep Kit Alone|Patients who are not randomized into the I-SLEEP intervention will receive a sleep kit that includes an eye mask, earplugs, and headphones.They will still receive the usual standard of care provided by clinicians which includes measures to reduce unnecessary nighttime disruptions and limiting excessive noise within the hospital setting.
16375407|NCT04151251|Experimental|Sleep Kit + Empowerment|"A short video will be shown on iPads and a brochure will be given that both describe the importance of good sleep and how to facilitate it with good sleep hygiene.
~The video will show a few reasons why someone might not get optimal sleep while in a hospital, and offer advice to address this from a doctor. The brochure will be kept to no higher than a 6th grade reading level, considered optimal for health education materials. Text will be kept brief and to the point. To account for vision problems, we will use >12-point font & leave a large portion of each page empty. Visual Aids & graphics will be employed when possible.
~All of this is given in addition to the usual standard of care provided by clinicians."
16375408|NCT04151238|Experimental|Exercise intervention|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary.
16375409|NCT04151225|Placebo Comparator|Participants receiving placebo|Participants will receive placebo loading dose followed by placebo for 12 weeks during Induction phase. Participants with clinical response at Week 12 will continue to receive placebo into a 40-weeks blinded maintenance period. Participants without a clinical response at Week 12 will receive a 450mg GSK2330811 SC loading dose at Week 12, followed by 150 mg SC every week from Week 13 until Week 23, followed by 150 mg SC every 2 weeks until Week 50.
16375501|NCT04150627|No Intervention|normal breathing|
16375410|NCT04151225|Experimental|Participants receiving GSK2330811 450mg loading dose/150mg Q1W|Participants will receive 450mg GSK2330811 SC as loading dose followed by 150 mg GSK2330811 Q1W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
16375411|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q2W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q2W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
16375412|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q4W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q4W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q4W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
16375413|NCT04151225|Experimental|Participants receiving GSK2330811 150mg Q8W|Participants will receive GSK2330811 SC 150 mg Q8W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q8W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
16375414|NCT04151212|Experimental|BAT5906 injection|Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.
16375415|NCT04151199|No Intervention|No Intervention Control|The control group does not engage in any exercise during acute testing protocol.
16375416|NCT04151199|Active Comparator|Endurance Exercise|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
16375417|NCT04151186|Experimental|TM4SF1 and EpCAM positive CAR-T cells for solid tumors|The present study is proposed to study advanced malignant solid tumors in adults, and the three escalating doses, namely, 2.0~2.5. 4.0~5.0 and 8.0~10.0 (×10 ^6/kg), will be given.
16375418|NCT04151173|Experimental|aspiration/electrocoagulation|
16375419|NCT04151173|Active Comparator|cystectomy|
16375420|NCT04151160||Case Subjects|Infants with hemodynamically significant congenital heart disease.
16375421|NCT04151160||Control Subjects|Healthy infants with no heart disease or non-hemodynamically significant congenital heart disease.
16375422|NCT04151147|Experimental|CGF application in the extraction socket|Partially impacted third molar was extracted with the help of straight elevator and third molar forceps. After extraction, any remains of the dental follicle were removed and the extraction sockets were irrigated with 60 mL of sterile saline. CGF fibrin gel was then randomly placed into one socket and wound closure was completed with silk suture.
16375423|NCT04151147|Experimental|non-CGF application in the extraction socket|Opposite side of the patient was considered as the control. After extraction of the third molar, dental follicle were removed and to prevent the flap laceration, bone contouring was also performed under sterile saline irrigation. Finally, wound closure was completed with silk suture.
16375424|NCT04151121|Experimental|Intervention|The participants will receive MBCT (Mindfulness-Based Cognitive Therapy) as 2-hourly sessions over 8-weeks including a 6-hour session at the end of 6th week. The MBCT will be adapted for chest pain.
16375425|NCT04151121|No Intervention|Control group|These participants will continue to receive any treatment (or no treatment) by their primary care physicians.
16375426|NCT04151108||Old medical patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.
~Will be assessed at admission"
16375427|NCT04151108||Geriatric patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, gait-speed, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.
~Blood tests, physical function measures and body composition will be assessed at both admission and discharge."
16375428|NCT04151095|Experimental|BFR|
16375429|NCT04151095|Experimental|CTL|
16375430|NCT04151082|Experimental|Supportive care (steroid therapy)|Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.
16375431|NCT04151069||At home group|Participants with allergy to tree nuts who follow the introduction procedure A (at home)
16375432|NCT04151069||At the hospital group|Participants with allergy to tree nuts who follow the introduction procedure B (at the hospital)
16375433|NCT04151069||Control group|Participants with allergy to tree nuts who follow strict avoidance of the offending nuts.
16375434|NCT04151056||Patients without social determinant of health|"Patients without any of the five selected social determinants of health / Patients without any of the five selected social diagnosis. Patient with a registered diagnostic  Health check (Z00.00)"
16375435|NCT04151056||"Patients with the social determinantstressful work hours"|"Patients with the selected social determinant of health. Patients with a registered diagnostic stressful work hours  (Z56.3)"
16375436|NCT04151056||"Patients with the social determinant of health living alone"|"Patients with the select social determinant of health . Patients with the selected social determinant of health . Patients with a registered diagnostic  living alone problems (Z60.2)"
16375437|NCT04151056||"Patients with the social determinant of health acculturation"|"Patients with the selected social determinant of health. Patients with a registered diagnostic difficulty acculturation  (Z60.3)"
16375438|NCT04151056||"Patients with the social determinant near surrounding"|"Patients with the selected social determinant of health. Patients with a registered diagnostic other specific problems related to the nearest surroundings (Z63.8)"
16375439|NCT04151056||"Patients with the social determinant unemployment"|"Patients with the selected social determinant of health. Patients with a registered diagnostic unemployment not specified (Z56.0)"
16375442|NCT04151030|Experimental|Endoscopic-PEG|"The patients who are unable to undergo an endoscopic pull PEG placement, will undergo an Endoscopic introducer style Direct-PEG procedure at the time of the index endoscopy"
16375443|NCT04151030|Active Comparator|IR-PEG|Patients who underwent PEG placement by interventional radiology (IR-PEG).
16375444|NCT04151017|Experimental|Autologous fibrin glue|
16375445|NCT04151017|Active Comparator|Sutures|
16375446|NCT04151004|Experimental|Patient group|Incremental cycling test to volitional exhaustion. Constant load cycling test to volitional exhaustion. Respiratory and leg muscle endurance test to volitional exhaustion. Three respiratory muscle training interventions.
16375447|NCT04151004|Active Comparator|Control group|The control group executes the same tests as the patient group.
16375448|NCT04150991|Experimental|Fiber intervention|The investigator's targeted supplemental fiber mixture (35 g total) will be composed of 6g of fiber from oligofructose + 10g from resistant maltodextrin + 12g from acacia gum + 4g from whole foods + 3g from RS2; and will be split into three meals each day.
16375449|NCT04150991|Placebo Comparator|Placebo treatment|Maltodextrin will be used as a placebo control, as it is digested in the small intestine and thus does not exert local effects in the colon.
16375450|NCT04150978|Active Comparator|5% Dextrose|the parenteral formulation as prescribed by the intensive care specialist
16375451|NCT04150978|Experimental|High Protein Polymeric Formula|"Procedure :
~The daily calorie and protein prescriptions were calculated from standard recommendations (calories 25-30 kcal/kg/d, proteins 1.2-2 g/kg/d)
~Administered as boluses via a nasogastric tube. A total of 5 aliquots were administered at 4-hourly intervals in a daily feeding period of 24 hours, with the participant positioned 30° head-up."
16375452|NCT04150978|Experimental|Oligomeric Formula|Similar to the High Protein Polymeric Formula Procedure
16375453|NCT04150965|Active Comparator|Arm A - Elotuzumab|Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.
16375454|NCT04150965|Experimental|Arm B - Anti LAG-3 Single Agent|Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.
16375455|NCT04150965|Experimental|Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.
16375456|NCT04150965|Experimental|Arm C - Anti-TIGIT Single Agent|Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.
16375457|NCT04150965|Experimental|ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.
16375458|NCT04150952|Experimental|HRV-Group|Athletes will train according to their basal HRV scores. If the resting HRV is higher tan their basal HRV, they will perform a high or moderate intensity training. If the resting HRV is lower, they will perform a low intensity training. If the resting HRV still lower, they will rest. They will not accumulate two or more days of high-moderate intensity training, nor two or more days of rest.
16375459|NCT04150952|Active Comparator|TRAD-Group|Athletes will train according to their trainer plan. Training will not be guided by their basal HRV scores.
16375460|NCT04150939|Experimental|Treatment (cryoablation)|Beginning 1 week prior to the next scheduled standard of care immunotherapy infusion, patients undergo core biopsy of the lesion to be ablated and a non-ablated lesion and also undergo cryoablation. Patients undergo a mandatory second core biopsy of the non-ablated lesion at 4 weeks after cryoablation.
16375461|NCT04150926|Experimental|Black currant puree|Black currant puree
16375462|NCT04150926|Active Comparator|Black currant-quinoa product|Black currant-quinoa product
16375463|NCT04150926|Active Comparator|Quinoa base|Quinoa base is used for the black currant-quinoa product.
16375464|NCT04150926|No Intervention|Liquid with glucose, fructose and sucrose|Liquid with glucose, fructose and sucrose
16375465|NCT04150913|Experimental|Anakinra and Axicabtagene Ciloleucel|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.
~Screening
~Enrollment/Leukapheresis period
~Bridging therapy (if applicable)
~Lymphodepleting chemotherapy period
~Investigational Product (IP) treatment period
~Anakinra
~Axicabtagene Ciloleucel
~Post treatment assessment period
~Long term follow-up period"
16375466|NCT04150900|Experimental|Pembrolizumab + Bavituximab|Pembro and Bavituximab for progressive recurrent/metastatic squamous cell carcinoma of head and neck
16375467|NCT04150887|Experimental|Experimental: Cohort 2: Cusatuzumab + Venetoclax|Participants enrolled in this cohort will receive venetoclax ramp-up to 400 mg orally (as background therapy) starting on Cycle 1 Day 1 and followed by 400 mg daily dosing starting on Cycle 1 Day 4 plus cusatuzumab IV on Day 3 and Day 17 of each 28-day cycle. Cohort 2 will not be enrolled in the US.
16375468|NCT04150887|Experimental|Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA)|Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
16375469|NCT04150874|Experimental|Lumason Microbubbles|Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered
16375470|NCT04150861|Experimental|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
16375471|NCT04150861|Experimental|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
16375472|NCT04150861|Experimental|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
16375473|NCT04150848|Experimental|Goal Focused Emotion-Regulation Therapy (GET)|GET is a 6-session intervention delivered over 8 weeks to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses. GET has an emphasis on goal navigation skill building. This includes work on goal setting with a focus on assessing progress toward achieving specific, realistic, and measurable goals. Emotion regulation components include basic cognitive restructuring skills, cognitive distancing, and coping efficacy skills (matching the correct coping skill to specific circumstances).
16375502|NCT04150614|Active Comparator|Arm 1|ARM 1 -transdermal granisetron plus intravenous dexamethasone
16375474|NCT04150848|Active Comparator|Individual Supportive Psychotherapy (ISP)|"ISP includes 6-sessions of individual supportive psychotherapy and includes components of genuineness, unconditional positive regard, and empathic understanding through reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis. ISP emphasizes maintaining focus on the cancer experience, supporting participants in the here and now, fostering expression of emotion and discussion of difficult topics, and creating a sense of being understood."
16375475|NCT04150835|Experimental|Xingnaojing|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
16375476|NCT04150835|Placebo Comparator|Placebo|Subjects will receive intravenously administered Xingnaojing placebo, combined with guidelines-based standard care.
16375477|NCT04150809||Patients|Patients who have been diagnosed with ALS.
16375478|NCT04150796|Experimental|Enhanced-view Totally Extraperitoneal (eTEP) Hernia Repair|Initial access into the retromuscular space is achieved using an optical trocar. Insufflation of CO2 is performed under direct visualization. Multiple assistant ports will be placed medial to the semilunar line to continue developing the retromuscular space. The medial insertion of the posterior rectus sheath will be incised to enter the preperitoneal plane and facilitate reduction of hernia contents. The contralateral posterior rectus sheath will be incised and the contralateral retrorectus space will be matured. Suture will be used to close any defect in the hernia sac. The defect will be measured, as will be the retrorectus space. The fascial defect will be closed with suture. Non-barrier coated mesh will be placed in the retrorectus space and flat positioning will be confirmed. Ports will be removed under direct visualization, and the abdomen desufflated. Anterior fascia of any larger ports (8mm or greater) will be closed.
16375479|NCT04150796|Active Comparator|Intraperitoneal Onlay Mesh (IPOM) Hernia Repair|Access is achieved using an optical trocar. Insufflation of CO2 is performed. Two additional trocars are placed on the left side along the anterior axillary line. If necessary, auxiliary ports may be placed on the right side. When present, hernia contents are reduced using graspers. Adhesions between abdominal contents and the abdominal wall are lysed. The hernia defect is identified and measured internally with a sterile plastic ruler with the abdomen insufflated. Defect closure is performed using nonabsorbable suture. Mesh repair is performed using polypropylene mesh with an absorbable hydrogel barrier. Mesh is chosen to achieve a minimum 3 to 5-centimeter overlap from the edges of the closed defect. Inside the abdomen, the mesh is unrolled and positioning against the anterior abdominal wall is confirmed. Mesh edges are fixed circumferentially with permanent fixation. Ports are removed and the abdomen is desufflated. The anterior fascia of the 12mm port is closed.
16375480|NCT04150783||Unilateral Cleft Lip Nasal Deformity (uCLND)|uCLND patients who are scheduled to undergo surgical treatment for nasal obstruction as standard of care.
16375481|NCT04150783||Healthy Subjects|Existing data from healthy subjects with no prior symptoms of nasal obstruction used to create normative ranges for comparison to uCLND cohort.
16375482|NCT04150770|Experimental|Patients with Childhood Uveitis|5mg/kg/dose of infliximab IV initially two weeks, then 4 weeks and then every 6-8 weeks
16375483|NCT04150757|No Intervention|Standard Analgesia|"Patients receiving no intervention will receive no intranasal ketamine while awaiting intravenous line placement for parenteral pain control."
16375484|NCT04150757|Active Comparator|Intranasal Ketamine + Standard Analgesia|Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg).
16375485|NCT04150744|Experimental|RFA plus carrizumab|
16375486|NCT04150744|Placebo Comparator|carrizumab|
16375487|NCT04150731|Experimental|Breast cancer and FES|Only one arm: All included are patients with disseminated breast cancer and all have an experimental FES-PET/CT done
16375488|NCT04150718|Experimental|Subjects with Major Depressive Disorder|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine is they meet criteria for MDD.
16375489|NCT04150718|Active Comparator|Control|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine they do not meet criteria for MDD.
16375490|NCT04150705|Experimental|FDG PET/MRI|-Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 6 time-points at which it would normally be performed in their care for the period of time extending 30-36 months from the time of enrollment (depending on enrollment point). In the surveillance period, when patients typically undergo pelvic MRI every 3 months, the FDG-PET/MRI will be done in lieu of the standard pelvic MRI on an approximately every-other-scan basis. In other words, the FDG-PET/MRI will occur roughly once every 6 months.
16375491|NCT04150692|Experimental|Arm 1: Dara-SC Re-Escalation|-Re-escalation will include weekly dosing for two 4-week cycles (8 doses, Days 1, 8, 15, and 22 of each 28-day cycle) followed by dosing every-other-week thereafter (Days 1 and 15 of each 28-day cycle). Patients will remain on study treatment until meeting clinical progression.
16375492|NCT04150692|Active Comparator|Arm 2: Dara-SC|-Continued subcutaneous daratumumab and and hyaluronidase-fihj (1,800mg/30,000U, [Dara-SC])
16375493|NCT04150679|Active Comparator|group I retrospective non access loop|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy without access loop
16375494|NCT04150679|Active Comparator|GROUP II access loop group|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy with duodenojejunostomy access loop
16375495|NCT04150666|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 2.0 to 2.5 L of water per day (depending on sex), in addition to usual consumed beverages, for 3 months
16375496|NCT04150666|No Intervention|Control|
16375497|NCT04150653||AAA patients|"All patients enrolled in phase 1 will undergo:
~Multiphase scan CT
~Non-invasive vascular ultrasound elastography by ultrasound (NIVE)"
16375498|NCT04150640|Experimental|Cohort 1: HER2 Negative|Participants in Cohort 1 (HER2-negative) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
16375499|NCT04150640|Experimental|Cohort 2: HER2 Positive|Participants in Cohort 2 (HER2-positive)will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
16375504|NCT04150601|Active Comparator|Spontaneous slow vital capacity|Participants will have to perform a slow vital capacity according to the guidelines, from total lung capacity to residual volume
16375505|NCT04150601|Active Comparator|SIMEOX|Participants will have to perform a passive exhalation using the SIMEOX, starting from total lung capacity and going until achieving residual volume
16375506|NCT04150601|Active Comparator|PEP|Participants will have to perform an active exhalation using a PEP device, starting from total lung capacity and going until achieving residual volume
16375507|NCT04150588||Good reaction to Efrin test|
16375508|NCT04150588||Unsatisfied reaction to Efrin test|
16375509|NCT04150575|Experimental|HLX10|HLX10+albumin-bound paclitaxel
16375510|NCT04150562|Experimental|1- Experimental Treatment: Safety Run-in|IL-15 by CIV infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 4 cycles) with avelumab by IV infusion at a dose of 800mg on Day 8 and 22 of each cycle
16375511|NCT04150562|Experimental|2-Experimental Treatment: Doe Expansion|IL-15 by CIV infusion at 4 mcg/kg/day on days 1-5 of each 28- day cycle (max 4 cycles) with avelumab by IV infusion at a dose of 800mg on Day 8 and 22 of each cycle
16375512|NCT04150549|Placebo Comparator|Autologous Transplants|
16375513|NCT04150549|Active Comparator|Allogeneic Transplants|
16375514|NCT04150536|Experimental|Lidocaine Topical System with Moderate Exercise (Treatment A)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. Subjects are instructed to exercise 30 minutes on an exercise bicycle, achieving at heart rate of approximately 108 bpm. Exercise is performed after 2.5 hours, 5.5 hours, and 8.5 hours after topical system application.
16375515|NCT04150536|Experimental|Lidocaine Topical System with Heat Applied (Treatment B)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. A heating pad is applied for 20 minutes at 2.5, 5.5, and 8.5 hours after the product is applied.
16375516|NCT04150536|Experimental|Lidocaine Topical System under normal conditions (Treatment C)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. No heat application or exercise is performed during this period.
16375517|NCT04150510||Online Survey|Individuals who are willing to participate in this online survey
16375518|NCT04150497|Experimental|Dose Escalation|"Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish Recommended Phase 2 Dose (RP2D)
~Dose Expansion: UCART22 administered at the RP2D"
16375519|NCT04150484|Other|interventional group|dietary intervention, physical exercise and mindfulness
16375520|NCT04150484|No Intervention|control group|Group without any intervention.
16375521|NCT04150458|Experimental|Fluorocholine PET/CT|The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.
16375522|NCT04150445|Experimental|Internet treatment for overweight and obese patients|The intervention is a treatment of overweight and obesity based on cognitive behavioural therapy provided via the Internet. The treatment lasts for six months and comprises 12 treatment modules. The patient works with each module for two weeks. The modules conclude with one or more exercise tasks to be performed before the next module is activated. The patient has written contact with the therapist via the Internet platform.
16375523|NCT04150432|Experimental|propofol|propofol general anesthesia, exhaled measurement of propofol
16375527|NCT04150406|Active Comparator|Flexofytol|2 capsules containing 42mg of curcumin will be administered twice a day for a duration of 4 months.
16375528|NCT04150406|Placebo Comparator|Placebo|2 capsules of the placebo, identical in appearance to Flexofytol, will be administeres twice a day for a duration of 4 months.
16375529|NCT04150393|Experimental|MaaT033 treatment|A Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule
16375532|NCT04150367||Study group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
16375533|NCT04150367||Control group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
16375534|NCT04150354|Experimental|Participants allocated to Cogito Companion|Participants will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators.
16375535|NCT04150341|Experimental|TD-8236 Dose A (low dose)|TD-8236 Dose A (QD x 14 days)
16375536|NCT04150341|Experimental|TD-8236 Dose B (high dose)|TD-8236 Dose B (QD x 14 days)
16375537|NCT04150341|Placebo Comparator|Placebo|Placebo (QD x 14 days)
16375538|NCT04150315||Coronary bypass with DM type 2|
16375539|NCT04150315||Coronary bypass without DM type 2|
16375540|NCT04150276|Active Comparator|ZEEP during awakening|ZEEP will be used during emergence preoxygenation and awakening.
16375541|NCT04150276|Active Comparator|PEEP during awakening|PEEP is maintained throughout emergence preoxygenation and awakening.
16375542|NCT04150263|Other|Traditional IOL repositioning|Intraocular lens (IOL) ab externo scleral suture fixation
16375543|NCT04150263|Other|Modification of traditional IOL repositioning|Modified intraocular lens (IOL) ab externo scleral suture fixation
16375587|NCT04150003|Experimental|Pulmonary Rehabilitation program|10-weeks structured exercise-based intervention protocol on the restoration of lung blood flow after an acute PE
16375544|NCT04150250|Experimental|iOWH032|On Day 1, participants were challenged with 10^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
16375545|NCT04150250|Placebo Comparator|Placebo|On Day 1, participants were challenged with 10^6 CFU of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral matching iOWH032 placebo tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
16375546|NCT04150237||Novices|Medical students
16375547|NCT04150237||Intermediates|Endoscopy (EGD) assisting nurses. No prior self-performed endoscopies
16375548|NCT04150237||Experienced|Medical doctors in medical Gastroenterology or surgery, who have self-performed more than 500 EGD
16375549|NCT04150224|Experimental|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
16375550|NCT04150224|Experimental|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
16375551|NCT04150224|Experimental|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
16375552|NCT04150224|Experimental|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
16375553|NCT04150224|Experimental|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
16375554|NCT04150224|Experimental|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
16375555|NCT04150211|Active Comparator|Exten(d)|Subjects have to take Exten(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
16375556|NCT04150211|Placebo Comparator|Placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
16375557|NCT04150198|Experimental|Patients with Alzheimer (<65 years) (AD-Y)|15 patients with a diagnostic of MA-J
16375558|NCT04150198|Experimental|Patients with posterior Cortical Atrophy (PCA)|15 patients with a diagnostic of PCA
16375559|NCT04150198|Active Comparator|Control|15 controls
16375560|NCT04150185||live liver donors|Live liver donors undergoing donor hepatectomy
16375561|NCT04150172|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.
~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
16375562|NCT04150172|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.
~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
16375563|NCT04150159|Experimental|Fasting Mimicking Diet (FMD) Arm|The ProLon® FMD diet is made up of nut bars, dehydrated soups, tea, olives, kale crackers, electrolyte beverages, and a chocolate crisp bar consumed for 5 days every 30 days for 4 months.
16375564|NCT04150159|Active Comparator|Mediterranean Diet Arm|"The Mediterranean diet is based on the traditional foods that people used to eat in countries like Italy and Greece in the 1960s.
~Eat every day: vegetables, fruits, nuts, seeds, legumes, potatoes, whole grains, breads, yogurt, dairy, fish/seafood, herbs, spices and extra virgin olive oil.
~Eat three or fewer servings each week: poultry, eggs, cheese.
~Eat two or fewer servings each week: red meat, potatoes.
~Eat two or fewer servings each week: sweets, sodas, processed meat, refined grains, refined oils and other highly processed foods."
16375565|NCT04150146|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
16375566|NCT04150146|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
16375567|NCT04150133|Active Comparator|Traditional Clear Liquid Arm|Following instructions with FDA-labeled clear liquids
16375568|NCT04150133|Experimental|Low Residue Diet Arm|Following instructions for a low residue diet along with FDA-labeled clear liquids
16375569|NCT04150120|Active Comparator|Reconstructive paediatric surgery (Area I)|The overall incidence of congenital malformations in the gastrointestinal and urinary tract needing surgical interventions is about 1:1000 (Swedish national malformation registers) with a morbidity during childhood about 20-60%. Advanced paediatric surgery for the diagnosis Hirschsprung's disease, anorectal malformations, bladder extrophy, congenital diaphragmal hernia, and esophageal atresia is from July 2018 only performed at two NCSM in Sweden. The NCSM at Skåne University Hospital (SUS) in Lund forms one context. The quality of postoperative care is of immense importance both for short and long-term outcome. Legal guardians describe their situation after leaving the hospital as extremely stressful as they have not only to take responsibility for their new-born child but also of surgical wounds, medications, treatments, and special nutritional needs.
16375570|NCT04150120|Active Comparator|Congenital heart disease (Area II)|In Sweden, about 8-10 in 1000 children per year are born with congenital heart disease (CHD). CHD is a birth defect that leads to frequent hospitalisation, long hospital stays, and extreme anxiety for parents (18). In Sweden, paediatric heart surgery is concentrated to two NCSM of which one is situated at SUS, Lund where 250-300 children have cardiac surgery every year. Children with complicated CHD require contact and follow-up visits for a long time after the heart surgery and many families have to travel long for surgery (for example from Iceland), postoperative care and follow-up visits. Telemedicine after reconstructive cardiac surgery in children is shown to be feasible, although challenging and reduced unscheduled visits.
16375588|NCT04150003|Active Comparator|Usual care|Protocolized usual care for patient suffering PE
16375571|NCT04150120|Active Comparator|Preterm born (Area III)|Most prematurely born children grow up to be healthy, but as a group, they are at a greater risk of developing cognitive, emotional and behavioural problems. Every year 7% of all children are born prematurely (gestational age of less than 37 weeks) and the numbers of preterm births are rising in Sweden as well as internationally. Preterm births often involve long hospitalisations for children and parents, and discharge from the hospital often means a difficult transition for parents in both short and long-term perspectives. Traditionally, communication with parents following discharge has been through home visits or telephone calls. By communicating through digital technology, it may be possible to improve the support to parents and thereby make the transition from hospital to home less stressful.
16375572|NCT04150120|Active Comparator|Paediatric oncology (Area IV)|For children with cancer, treatment and follow-up at home is common. At the same time, families wish to minimize the negative impact on family members' social and everyday life. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care and regular follow-up in their home with an increased need for education as well as clinical management support. At present, there are no, or limited, professional outreach support to support them and their families. Communication with parents following discharge has been through e-mail and/ or telephone calls. By communicating through digital technology, it may be possible to improve the support to children and parents.
16375573|NCT04150120|Active Comparator|Intravenous infusion therapy at home (Area V)|For children with LTI administration of intravenous infusion therapy at home is an increasingly important area. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care in their home with an increased need for educational as well as clinical management support during home infusion therapy. At present, children and adolescents with LTI at the University Hospital of Copenhagen receive home infusion therapy by a portable pump with no assistance from an outreaching team to support them and their families.
16375574|NCT04150120|Active Comparator|Children with cerebral palsy (VI)|Cerebral palsy (CP) is the most common physical disability in childhood. Approximately 2-2.5/1000 children have CP with affected muscle tone, movement and motor skills, often accompanied by pain, epilepsy and intellectual, communicational and behavioural impairment. Early detection is challenging but important for minimizing the consequences from neurodevelopmental impairment by an early and right treatment. General Movement Assessment (GMA), an observational method for classification of spontaneous movements in young infants, is currently the most accurate method for early identification of CP. Video recordings are taken with a standardised video set-up in the hospitals regular follow-up clinics when the child is 10 to 20 weeks post-term age. Performing video recordings at home by the parents at a time, which suits the family and the child, would optimize the chances for a successful recording.
16375575|NCT04150107|Experimental|Treatment A|Treatment A is 24 mg (16 mg + 8 mg capsules) Once Daily (QD) at Bedtime of ORMD-0801
16375576|NCT04150107|Experimental|Treatment B|Treatment B is 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
16375577|NCT04150094|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training without stimulus.
16375578|NCT04150094|Experimental|Pelvic floor muscle training + intravaginal vibratory stimulus|Pelvic floor muscle training with intravaginal vibratory stimulation.
16375582|NCT04150055|Experimental|Intervention|Everyone in the study will get Mindfulness Coach and an orientation session. Mindfulness Coach is a self-guided mHealth intervention designed to help individuals learn MT, an evidence-based treatment to enhance health, wellness and mental health. The intervention will be introduced during 1 in-person session by a trained research assistant with 1-2 booster instructional phone call at 7 and 14-days to ensure that the participant knows how and is encouraged to use the app. The participant will also be provided with a laminated card that provides the basic instructions. We will encourage the participant to use Mindfulness Coach weekly for 8 weeks, or more if desired, as this treatment dose is commensurate with most in-person MT psychotherapy treatment protocols.
16375583|NCT04150042|Experimental|Chemotherapy/stem cell treatment|
16375584|NCT04150029|Experimental|MBG453+Venetoclax +Azacitidine|Patients will receive MBG453 in combination with Venetoclax and Azacitidine
16375585|NCT04150016|Experimental|Firehawk implantation|22 subjects will be enrolled to receive Firehawk™ sirolimus target-eluting stent(s).
16375586|NCT04150016|Active Comparator|XIENCE implantation|22 subjects will be enrolled to receive XIENCE™ everolimus target-eluting stent(s).
16375589|NCT04149990|Active Comparator|Entresto|Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks
16375590|NCT04149990|Placebo Comparator|Placebo|Matching placebo B.I.D. for 26 weeks
16375591|NCT04149977|Experimental|blood flow restriction therapy (pressure cuff)|The cuff will be placed around the upper thigh of the injured leg and set at a pressure that will prevent approximately 80% arterial blood flow. The machine will determine what pressure is required to reach that 80%, when placed on the leg and turned on.
16375592|NCT04149977|Placebo Comparator|blood flow restriction therapy (placebo)|Patients with a placebo pressure will have a pressure setting, 50% lower than the effective setting as stated in the experimental arm
16375593|NCT04149964|Active Comparator|Standard of Care arm|Standard of Care Post-operative pain medication, Acetaminophen 325 mg every 6 hours as needed for pain plus acetaminophen/hydrocodone 7.5 mg/325 mg 1 tab every 4 hours as needed for pain.
16375594|NCT04149964|Experimental|Study Arm|Acetaminophen 650 mg 1 tab every 6 hours round the clock plus Oxycodone 5 mg 1 tab every 6 hours as needed for breakthrough pain,.
16375595|NCT04149951|Experimental|Active|Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
16375596|NCT04149951|Placebo Comparator|Control|Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
16375597|NCT04149938|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
16375598|NCT04149938|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.
16375599|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
16375600|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
16375601|NCT04149912||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
16375602|NCT04149899|Experimental|Study Treatment 1|WB007 Formulation 1
16375603|NCT04149899|Experimental|Study Treatment 2|WB007 Formulation 2
16375604|NCT04149899|Experimental|Study Treatment 3|WB007 Formulation 3
16375605|NCT04149899|Active Comparator|Timolol 0.5%|Timolol maleate ophthalmic solution, 0.5%
16375606|NCT04149886|Experimental|Ablation group(Ablation+pacemaker)|"The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.
~After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group)."
16375607|NCT04149886|Sham Comparator|Control group(only pacemaker)|The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.
16375608|NCT04149873|Placebo Comparator|Control group|Control group' has the treatment with [Physical chest care ]
16375609|NCT04149873|Placebo Comparator|Experimental group-A|'Experimental group-A' has the treatment with [Mechanical-Insufflation- Exsufflation]
16375610|NCT04149873|Experimental|Experimental group-B|'Experimental group-B' has the treatment with [Mechanical-Insufflation- Exsufflation] and [Physical chest care]
16375611|NCT04149860|Experimental|Part A|Cohorts A1-A5, 8 healthy subjects per cohort. Dose levels 1 - 5
16375612|NCT04149860|Experimental|Part B|Cohorts B1-B3, 8 healthy Japanese and Chinese subjects per cohort. Dose levels 3 - 5
16375613|NCT04149860|Experimental|Part C|Cohorts C1-C4, 8 subjects with Alzheimer's disease per cohort. Dose levels 3 - 6
16375614|NCT04149847|Experimental|Nylon darn repair|a nylon #1 suture to be used to reconstruct the posterior inguinal wall
16375615|NCT04149847|Experimental|polypropylene mesh repair|a commercially available 7.5cm x 15cm sheet of polypropylene mesh to be trimmed to fit the posterior inguinal wall
16375616|NCT04149834|Active Comparator|Modified Minimally Invasive Surgical Technique|Comparator: Modified Minimally Invasive Surgical Technique The defect will be gained through the tiny buccal triangular ﬂap: from the buccal 'window' the soft tissue ﬁlling the defect (i.e. the so-called granulation tissue) will be sharply dissected from the papillary supra-crestal connective tissue and from the bony walls with a micro-blade and will be removed with a mini-curette (The soft tissue will be sharply dissected from the osseous defect)
16375617|NCT04149834|Other|Non- incised papilla surgical approach|intervention: Non- incised papilla surgical approach Apical horizontal incision on the buccal mucosa, as far as possible from the interdental papillae and marginal KT will be performed. Soft tissue will be reflected apico-coronally by a full-thickness flap showing the granulation tissue filling the bony defect after exposing the coronal limit of the intra-bony component of the defect, while the marginal tissue will be kept unaltered.
16375618|NCT04149821|Experimental|Cohort A Post BTKi Therapy|Patients who progress after a BTKi containing regimen
16375619|NCT04149821|Experimental|Cohort B Post BCL-2 Therapy|"Patients who progress after BCL-2 containing regimens
~Patients who progress on a regimen containing both a BTKi and a BCL-2 inhibitor"
16375620|NCT04149808|Active Comparator|Xeroform Control|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with xeroform dressing, which is the standard of care.
16375684|NCT04149340|Other|Sufentanil sedation|3 microgram of Sufentanil IV
16375621|NCT04149808|Experimental|Mepilex Ag Intervention|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with Mepilex Ag; the product being tested.
16375622|NCT04149795||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
16375623|NCT04149782||Patients enrolled in differentiated service delivery models|
16375624|NCT04149782||Patients not enrolled in DSD models|
16375625|NCT04149769|Other|Interventional|Walking in an exoskeleton within the home and community.
16375626|NCT04149756||overweight or obese adults|overweight or obese adults who participate the trial (NCT03675191)
16375627|NCT04149743|No Intervention|Randomized Standard of Care|Standard of Care
16375628|NCT04149743|Active Comparator|Randomized Standard of Care with HEMOTAG|Standard of Care with HEMOTAG
16375629|NCT04149730||Patients with primary PEA.|Patients at St. Olavs hospital who suffer cardiac arrest and pulseless electrical activity (PEA) as primary rhythm during 2018-2021. 120 episodes from St. Olavs hospital were collected previously (2010-2013). In addition 200 cases will be available from the hospital of The University of Pennsylvania, Philadelphia, USA.
16375630|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution A and Exercise|"Subject baseline HR, BP, EKG recorded.
~Subject will ingest sucrose (150g):
~30 min later, subject will exercise on a treadmill
~Subjects will return each week to repeat the above procedures with a different test solution."
16375631|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution B and Exercise|"Subject baseline HR, BP, ECG recorded.
~Subject will ingest sucrose (150g); caffeine (400 mg)
~30 min later, subject will exercise on a treadmill
~Subjects will return each week to repeat the above procedures with a different test solution."
16375632|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C and Exercise|"Subject baseline HR, BP, ECG recorded.
~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)
~30 min later, subject will exercise on a treadmill"
16375633|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C|"Subject baseline HR, BP, ECG recorded.
~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)"
16375634|NCT04149704|Experimental|ACP video decision aid|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.
~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care
~10 minute video decision aid: describing the goals-of-care options .
~Follow telephone interview at 3 months"
16375635|NCT04149704|Active Comparator|Standard Care|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.
~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care
~Receive the verbal description of the three types of care
~Follow telephone interview at 3 months"
16375636|NCT04149691|Experimental|CPL304110|CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.
16375637|NCT04149678|Experimental|Treatment Group A - Ozanimod|Subjects will receive a single oral dose of ozanimod 0.46 mg
16375638|NCT04149678|Experimental|Treatment Group B - Ozanimod plus Cyclosporine|Subjects will receive a single oral dose of ozanimod 0.46 mg plus a single oral dose of cyclosporine 600 mg
16375639|NCT04149652|Other|Patients with COPD or fibrosis|Subjects, enrolled on either an inpatient or outpatient basis, with stable COPD or fibrosis documented by anamnestic, imaging and functional tests. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
16375640|NCT04149652|Other|Smokers with no signs of COPD|Subjects with an active smoking habit or a personal history of hard smoking dating back to maximum 5 years before, without clinical and functional signs of COPD. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
16375641|NCT04149652|Other|Healthy non-smoking volunteers|Healthy volunteers who have never smoked and who have no clinical or functional sign of COPD or other respiratory diseases. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
16375642|NCT04149639|Experimental|NeuroQ|Directions: take 2 capsules at the same time daily
16375643|NCT04149626|Active Comparator|Group A|Dexmedetomidine sedation
16375644|NCT04149626|Active Comparator|Group B|Midazolam sedation
16375645|NCT04149626|Active Comparator|Group C|Remifentanil sedation
16375646|NCT04149613||Colorectal Cancer Patients|Newly diagnosed stage IV colorectal cancer patients
16375647|NCT04149613||Controls|cancer free
16375648|NCT04149600||Bicuspid aortic valve|We wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
16375649|NCT04149600||Tricuspid aortic valve|Data and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
16375651|NCT04149574|Experimental|Arm A: nivolumab|
16375652|NCT04149574|Placebo Comparator|Arm B: placebo +BCG|
16375653|NCT04149561||Cerebral Palsy|100 patients over 2 years of age with a diagnosis of cerebral palsy will be included in the study. Demographic information form prepared for the study in terms of demographic information such as age, gender, clinical type of cerebral palsy, drugs used, comorbid diseases will be completed. Communication Function Classification System and Functional Communication Classification System will be used to evaluate patients' communication skills. In addition, patients; The Gross Motor Function Classification System for cerebral palsy and based on child-initiated movements with emphasis on sitting, displacement and mobility, and to hold objects during the daily activities of children with cerebral palsy. The Manual Ability Classification System, which classifies how they use their hands, will also be completed.
16375654|NCT04149548||pregnant diabetic women|Fetal Ultrasound to diabetic pregnant women
16375655|NCT04149548||non diabetic pregnant women|Fetal ultrasound to non diabetic pregnant women
16375656|NCT04149535|Experimental|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
16378093|NCT04132739|No Intervention|Control|
16375657|NCT04149535|No Intervention|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
16375658|NCT04149522|Active Comparator|Medial Breast Tissue|Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
16375659|NCT04149522|Active Comparator|Lateral Breast Tissue|Women assigned to the lateral breast tissue arm will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the lateral breast tissue only, by trained staff on day 1 of radiotherapy. The in-field ipsilateral axilla will be included with lateral breast segment to extent necessary to cover breast or chest wall only. The skin is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to skin and paper frame is removed. Multiple sheets of non-overlapping film will be used to cover the treatment area. During course of therapy, new film may be applied as often as necessary, by trained staff if film no longer adheres to skin or comes off. If there are signs of infection (e.g. redness, feeling warm or swollen), the film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or trained staff.
16375660|NCT04149509||Exposed|Infants born ≥ 37 weeks gestation with second or third trimester opioid exposure as determined by maternal urine toxicology screen at delivery; maternal history; and/or infant urine, meconium, or umbilical cord toxicology screen.
16375661|NCT04149509||Unexposed - Controls|Infants born ≥ 37 weeks gestation with no antenatal drug exposure as determined by maternal urine toxicology screen at delivery and/or maternal history. We will match control infants to exposed infants based on Clinical Site and up to 60 days after the date of birth of the exposed infant , recruiting 1 control for every other exposed infant at each site.
16375662|NCT04149496|Experimental|All|Patients requiring IVF treatment with PCOS or a PCO pattern in their ovaries who wish to undertake IVM (as a variant of their IVF procedure)
16375663|NCT04149483|Experimental|Atorvastatin|Atorvastatin tablets, 20mg once a day, for six months.
16375664|NCT04149483|Placebo Comparator|Placebo|Same color and size coated tablet, 20mg once a day, for six months.
16375665|NCT04149470|Experimental|Omeprazole|Participants will receive high dose PPI therapy (Omeprazole 20mg twice daily) and will be evaluated for histological improvement.
16375666|NCT04149457|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
16375667|NCT04149457|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
16375668|NCT04149444|Experimental|ARM 1|"Dose escalation cohort - First 10 patients enrolled on study.
~Trifluridine/Tipiracil 30mg/m2 - to start, if no significant dose limiting side effects the dose will be increased to 35mg/m2 for the duration of the trial.
~After first 10 patients enrolled on study - Trifluridine/Tipiracil 35mg/m2
~Each cycle is 28 days. Two doses per day during days 1-5 with a two day rest for days 6 and 7. Then two doses per day for days 8-12, followed by a rest period for days 13-28 with the next cycle starting the day after day 28."
16375669|NCT04149431|Active Comparator|Derinat|nasal drops
16375670|NCT04149431|Placebo Comparator|Placebo|nasal drops
16375671|NCT04149418|Experimental|Yogurt-Control|Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.
16375672|NCT04149418|Experimental|Control-Yogurt|Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.
16375673|NCT04149405|Active Comparator|Group A|"Subjects with chronic periodontitis and osteoporosis.
~Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
16375674|NCT04149405|Active Comparator|Group B|"Subjects with chronic periodontitis and systemically healthy.
~Phase 1 periodontal theraphy was administered to the subjects."
16375675|NCT04149405|Active Comparator|Group C|"Subjects with periodontally healthy and osteoporosis.
~Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
16375676|NCT04149405|No Intervention|Group D|"Systemically and periodontally healthy controls
~No intervention has been made."
16375677|NCT04149392|Experimental|CGM intervention|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge which will be downloaded at their outpatient follow up clinic visit 6-14 days later. At the follow-up visit medications may be modified based on downloaded glucose data. During the already scheduled post-discharge follow up appointment the CGM sensor data will be downloaded by clinic staff. The diabetes medications will be reconciled and the downloaded data will be reviewed with the patient. Based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
16375678|NCT04149379|Experimental|Treatment group|One group of 6 patients undergoing 20 sessions of hyperbaric therapy at table 14/90.
16375679|NCT04149366||group 1 (Wrapround retainer)|
16375680|NCT04149366||Group 2 (Essix retainer 1mm)|
16375681|NCT04149366||Group 3 (Essix retainer 1.5 mm)|
16375682|NCT04149366||Group 3 (Essix retainer 2mm)|
16375683|NCT04149353|Experimental|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
16375685|NCT04149340|Placebo Comparator|Placebo sedation|1 ml de NaCl 0,9%
16375686|NCT04149340|Other|Multimodal sedation|Clonidine, sufantil, midazolam, dihydrobenzperidol, ketamine
16375687|NCT04149327|Experimental|Antibiotics group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
16375688|NCT04149327|Active Comparator|Control group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
16375689|NCT04149314|Active Comparator|Interventional|Interventional group (hemodynamic optimization based on HPI).
16375690|NCT04149314|No Intervention|Control|Control group (blinded HPI monitoring, standard anesthesia care).
16375691|NCT04149301||Typically developing children|Children who do not have a problem with their walking ie children who do not have cerebral palsy
16375692|NCT04149301||Children with cerebral palsy without foot deformity|
16375693|NCT04149301||Children with cerebral palsy with mild foot deformity|
16375694|NCT04149301||Children with cerebral palsy with severe foot deformity|
16375695|NCT04149288|Active Comparator|High-polyphenol olive oil|Participants will consume 40 mL of high-polyphenol olive oil each day at home for 2 weeks.
16375696|NCT04149288|Active Comparator|Low-polyphenol olive oil|Participants will consume 40 mL of low-polyphenol olive oil each day at home for 2 weeks.
16375697|NCT04149275|Experimental|Cabozantinib + Nivolumab + Ipilimumab|All recurrent carcinosarcomas
16375698|NCT04149262|Active Comparator|Fiasp/Novorapid|4 weeks on Fiasp® then crossover to 4 weeks on NovoRapid® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
16375699|NCT04149262|Active Comparator|Novorapid/Fiasp|4 weeks on NovoRapid® then crossover to 4 weeks on Fiasp® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
16375700|NCT04149249|Experimental|Experimental: Intervention Group (CONNECT)|Patients complete CONNECT, the Video Doctor over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
16375701|NCT04149249|Active Comparator|Control Group|"Patients complete CONNECT assessment only over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
~Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources."
16375702|NCT04149223|No Intervention|Control|Current practice at baseline, routine cirrhosis care.
16375703|NCT04149223|Experimental|Intervention|Use of a standardized cirrhosis order set.
16375704|NCT04149223|Active Comparator|Intervention + EMR|Use of a standardized cirrhosis order set embedded within an electronic medical record.
16375705|NCT04149210|Experimental|fluorometholone|Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks
16375706|NCT04149210|Placebo Comparator|Artificial Tears|one drop two times daily for four weeks
16375707|NCT04149171|Experimental|conventional treatment|red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)
16375708|NCT04149171|Active Comparator|conventional treatment added to Crystalloids and TXA|administration of Crystalloids and TXA
16375709|NCT04149158|Placebo Comparator|Placebo|
16375710|NCT04149158|Experimental|Verum|Sinetrol® Xpur
16375711|NCT04149145|Experimental|M4344+Niraparib|all PARP resistant, recurrent ovarian cancer
16375712|NCT04149132||Patients without sepsis|Patients admitted and hospitalized for infections without sepsis and for other reasons in departments of Internal Medicine and Intensive Care Units
16375713|NCT04149119|Experimental|Intervention arm|ATSB+LLINs+Standard Care for Malaria case management
16375714|NCT04149119|No Intervention|Standard arm or arm 2|LLINs+Standard Care for MalarIA case management
16375715|NCT04149106|Active Comparator|Standard|The Mali National Malaria Control program has initiated SMC for children less than 5 years since 2016 (countrywide) with SPAQ. This standard care will not change in this arm
16375716|NCT04149106|Active Comparator|SMC with SPAQ extended to older children|Within this arm, SMC with SPAQ will be extended to children 5-9 years old
16375717|NCT04149106|Active Comparator|SMC with DHAPQ|Children less than 10 years within this arm will received Dihydroartemisin piperaquin for SMC instead of SPAQ
16375718|NCT04149080|Experimental|SIM Group|Alveolar socket post-extraction filled with Simvastatin covered with polypropylene membrane
16375719|NCT04149080|Placebo Comparator|Control Group|Alveolar socket post-extraction covered with polypropylene membrane
16375720|NCT04149067||Dapagliflozin cohort|Patients diagnosed with type 2 diabetes that started dapagliflozin treatment at least 6 months before the beginning of the study.
16375721|NCT04149067||Sitagliptin cohort|Patients diagnosed with type 2 diabetes that started sitagliptin treatment at least 6 months before the beginning of the study.
16375722|NCT04149028|Experimental|PRP injection|injection of PRP inside ovary by the assistance of laparoscopy
16375788|NCT04148599|Placebo Comparator|placebo|saline infusion will be administered preoperatively and continued intraoperatively
16375723|NCT04149015|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles
16375724|NCT04149002|Other|Intervention Arm: Weekly IP3 text messages|"A narrated powerpoint presentation describing the logistical details and medical rationale for components of the IP3. Participants will view the chapters of the presentation that are relevant to their specific IP3. There are a total of 4 possible chapters (lifestyle modifications, cervix length screening/cerclage, progesterone therapy, low dose aspirin). Each chapter of the presentation is ~ 10 - 15 min in length. Each chapter also includes a 4- 5 questions pre-test and the same questions are delivered as a post-test after the presentation.
~Print materials including a letter explaining the importance of prenatal care for preterm birth prevention to employers.
~Text messages sent weekly to encourage the patient to continue with their IP3 and provide basic pregnancy information
~Formal letter of encouragement from provider at 28 weeks gestation"
16375725|NCT04149002|Active Comparator|Control Arm: General pregnancy text messages|"a pre-intervention questionnaire
~a narrated powerpoint with general information about the clinic
~a post-presentation questionnaire
~text messages sent approximately weekly with general pregnancy information (e.g. today your baby is about the size of an apple)
~an exit interview"
16375726|NCT04148989|No Intervention|Pre-implementation usual care (intervention site)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
16375727|NCT04148989|Experimental|Code Sepsis post-implementation (intervention site)|Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
16375728|NCT04148989|No Intervention|Pre-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
16375729|NCT04148989|No Intervention|Post-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
16375730|NCT04148976|Placebo Comparator|Placebo (P)|The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
16375731|NCT04148976|Experimental|Dietary Portfolio (DP)|The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
16375732|NCT04148963|Experimental|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
16375733|NCT04148963|Placebo Comparator|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
16375734|NCT04148950|Experimental|Kinesio Taping|Kinesio Taping group consisted of 29 patients with CVD. Kinesio Taping was applied once a week for a period of 4 weeks. Closed Fan and Closed Basketweave techniques were applied according to the clinical manifestations, intensity of symptoms, and the needs for the areas to be taped. Basketweave technique was used generally for the thigh, and the areas rich in lymph nodes while closed fan technique was used for cruris, and regions of less severe venous reflux or obstruction. Kinesio Taping was slowly removed by the patient 4 days after the application to prevent any allergic reactions. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
16375735|NCT04148950|Active Comparator|Compression Stockings|Compression stockings group consisted of 29 patients with CVD. Patients were recommended medium pressure (23-32 mmHg) compression stockings by the physician. Knee high or thigh high compression stockings were given according to the level of symptoms and signs. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
16375736|NCT04148937|Experimental|Cohort A LY3475070|LY3475070 administered orally.
16375737|NCT04148937|Experimental|Cohort B LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered intravenously (IV).
16375738|NCT04148937|Experimental|Cohort C1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
16375739|NCT04148937|Experimental|Cohort C2 LY3475070|LY3475070 administered orally.
16375740|NCT04148937|Experimental|Cohort D1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
16375741|NCT04148937|Experimental|Cohort D2 LY3475070|LY3475070 administered orally.
16375742|NCT04148937|Experimental|Cohort E LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
16375743|NCT04148924||Patients|Anyone who is hospitalized in the palliative care service of the Lyon Sud Hospital Center.
16375744|NCT04148924||Doctors|Doctors taking care of patients in the study will be solicited by the research nurse or a study investigator.
16375745|NCT04148924||Nurses|Nurses taking care of patients in the study will be solicited by the research nurse or a study investigator.
16375746|NCT04148924||Caregivers|Caregivers taking care of patients in the study will be solicited by the research nurse or a study investigator.
16375748|NCT04148898|Experimental|osimertinb group|Osimertinib 80 mg oral daily
16375749|NCT04148898|Experimental|osimertinb combined with bevacizumab group|"Osimertinib 80 mg oral daily;
~.bevacizumab 7.5 mg/kg intravenous every 3 weeks"
16378094|NCT04132739|Experimental|Exercise only|
16375750|NCT04148885|Experimental|nab-paclitaxel + Carboplatin|nab-paclitaxel at 260 mg/m^2 on days 1; Carboplatin AUG=5, d1, 21 days in one cycle, 3 cycles in total
16375751|NCT04148872|Active Comparator|Neuromuscular Retraining Therapy|Neuromuscular retraining therapy alone for four months, with botulinum toxin injection added during an additional four month period.
16375752|NCT04148872|Active Comparator|Chemodenervation|Ipsilateral chemodenervation with botulinum toxin injections alone for four months (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin, Merz), with neuromuscular retraining therapy added for an additional four months.
16375753|NCT04148859|Experimental|pregnant women|women who have to undergo amnioreduction due to TTTS
16375754|NCT04148846|Active Comparator|Clinical treatment - old protocol|In group I, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache.
16375755|NCT04148846|Active Comparator|Clinical treatment - new protocol|In group II, patients will receive clinical treatment, according to the new protocol of the institution.
16375756|NCT04148846|Experimental|Sphenopalatine block|In group III patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block.
16375757|NCT04148833|Experimental|LDE-Paclitaxel|Paclitaxel carried by a lipid nanoparticle (LDE-Paclitaxel)
16375758|NCT04148833|Placebo Comparator|LDE-Placebo|Lipid nanoparticle (LDE)
16375759|NCT04148820|Experimental|Once daily drug administration|Patients will be given cardiovascular drugs once daily
16375760|NCT04148820|Experimental|Twice daily drug administration|Patients will be given cardiovascular drugs twice daily
16375761|NCT04148807|Experimental|Progressive walking program with gait retraining|Participant will receive 8 gait-retraining intervention sessions.
16375762|NCT04148807|Active Comparator|Progressive walking program|Participant receives 8 sessions of a graded walking program.
16375763|NCT04148794|Experimental|Intervention group|Participants who join the class of eALS
16375764|NCT04148781|Experimental|Fampridine-SR|Fampridine-SR 10 mg Orally Twice Daily for 8 weeks.
16375765|NCT04148768|Active Comparator|Inferential therapy|Interferential therapy will be given using 4 electrode methods. The 'medium frequency' currents (medium frequency in electromedical terms is usually considered to be 1KHz-100KHz). These medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross & they literally interfere with each other. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation. Pre-Post Y balance test will be used after 4 sessions to measure the improvement in balance in the population
16375766|NCT04148768|Active Comparator|Shortwave diathermy|4 sessions of treatment will be given to the participants with SWD. Pre-post Y balance test will be used to measure balance in the population
16375767|NCT04148755||Elastography guided FNA|Those patients are going to have EUS elastography guided FNA
16375768|NCT04148755||EUS. FNA|From records we are going to compare them with patients who had EUS without elastography guided FNA
16375769|NCT04148742|Experimental|daily dose of DZD9008|daily dose of DZD9008
16375770|NCT04148729|Active Comparator|bupivacaine+lidocaine|15 ml bupivacaine+ 5 ml lidocaine will use for USG guided ESP block under general anaesthesia with Sevuflurane and remifentanil. This block will perform at the T10 level bilaterally after induction of anaesthesia at the prone position. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with 11-point numerical rating scale. If the score over 4 points, rescue analgesic 0.4 mg/kg meperidine will be apply intravenously.
16375771|NCT04148729|Sham Comparator|saline|In this group, the same volume saline will apply to the block region. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with 11-point numerical rating scale. If the score over 4 points, rescue analgesic 0.4 mg/kg meperidine will be apply intravenously.
16375772|NCT04148716||patients|recruitement of 9 patients
16375773|NCT04148716||control|recruitement of 9 control person
16375774|NCT04148703|Experimental|Active group|in-office follow-up at 30 days post-implantation and after by remote monitoring (daily) without scheduled in-office follow-up during the study period (48 months). A remote FU will be planned every 9 months.
16375775|NCT04148703|Active Comparator|Control group|The patients randomized in the control group will be followed accordingto the guidelines; i.e. with an in-office follow-up at 30 days post-implantation and after followed with in-office follow-ups according to clinical practice.
16375776|NCT04148690|Experimental|Group ANC Intervention|Clinics in the group ANC intervention arm offer group Antenatal Care to women who present for their initial visit prior to 24 weeks provided that they intend to remain in the area for the duration of the pregnancy, and agree to participate in GANC. Women not enrolled in group ANC will receive standard ANC per ministry of health protocols.
16375777|NCT04148690|Active Comparator|Routine ANC|Clinics will offer only standard ANC per ministry of health protocols.
16375778|NCT04148677||Protoves M1® syrup|A combination of two alkaloid, Protopine and Nuciferine
16375779|NCT04148677||No treatment|Patients will not receive a treatment
16375780|NCT04148664|Active Comparator|Standard Catheter Settings|Group 1 - Standard RF ablation settings
16375781|NCT04148664|Experimental|High Power Short Duration (HPSD)|Group 2 - High power short duration RF
16375782|NCT04148651|Experimental|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
16375783|NCT04148625||atrial fibrillation, persistent|Subjects with documented symptomatic persistent or longstanding persistent AF (> than 3 months and < 3 years continuous AF duration) who has failed a previous PVI catheter ablation procedure and/or needs LAA exclusion; and catheter ablation or minimally surgical approach is planned.
16375784|NCT04148612|Experimental|Opti-Me|Patients in this group will be treated based on the Opti-Me algorithm recommended treatment.
16375785|NCT04148612|No Intervention|Randomization|Patients in this group will be treated by random assignment of treatment.
16375786|NCT04148599|Active Comparator|dexmedetomidine|dexmedetomidine ( precedex) infusion will be administered preoperatively and continued intraoperatively
16375787|NCT04148599|Active Comparator|lidocaine|Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively
16375789|NCT04148586|Experimental|One week Whole Breast Irradiation|WBI: 27 Gy/5 fractions/1 week. 5.4 Gy /fraction ± boost to tumor bed 5.4 Gy/ 1 fraction, 2 days after the end of WBI.
16375790|NCT04148586|Experimental|Once weekly Whole Breast Irradiation|WBI: 28.5 Gy/ 5 fractions/ 5 weeks. 5.7 Gy/fraction ± boost to tumor bed 5.7 Gy/ 1 fraction, one week after the end of WBI. WBI is given on the same day each week.
16375791|NCT04148586|Active Comparator|3 weeks Whole Breast Irradiation|WBI: 40.05 Gy/ 15 fractions/ 3 weeks. 2.67 Gy/ fraction ± boost to tumor bed 10 Gy/ 4 fraction / 4 days after the end of WBI
16375792|NCT04148573|Active Comparator|Arm NFX88 - 1|1.05 g/day NFX88
16375793|NCT04148573|Active Comparator|Arm NFX88 - 2|2.10 g/day NFX88
16375794|NCT04148573|Active Comparator|Arm NFX88 - 3|4.20 g/day NFX88
16375795|NCT04148573|Placebo Comparator|Arm PLACEBO - 4|Placebo
16375796|NCT04148560|Other|Study sample|Individuals who participate in this validation study
16375797|NCT04148547|Experimental|transcranial direct current stimulation|
16375798|NCT04148547|Placebo Comparator|Sham transcranial direct current stimulation|
16375799|NCT04148534|Active Comparator|muscle relaxant|Facial motor evoked potential monitoring in patient who will receive muscle relaxant, patients will receive rocronium infusion by (5 mcg/kg/min) , twenty minutes after induction. maintain partial NMB TOF count 2 and targeting BIS = (30-40)
16375800|NCT04148534|Placebo Comparator|without muscle relaxant|Facial motor evoked potential monitoring in patient who will not receive muscle relaxant, will recieve normal saline targeting BIS = 30-40 after ending of monitoring of neurophysiology propofol dose will be adjusted to 4-6 mg\kg\hr. targeting Bispecteral index 40-60.
16375801|NCT04148521|Experimental|Behavioral Health - Virtual Patient Navigation|All patients who meet eligibility criteria at sites where the virtual patient navigation behavioral health program is offered will be considered exposed to the intervention.
16375802|NCT04148521|No Intervention|Usual care Behavioral Health|All patients who meet eligibility criteria at sites where the virtual patient navigator behavioral health program is not offered will be considered exposed to usual care.
16375803|NCT04148508|Experimental|Tailored Emotional Competence|Self-help Tailored Emotional Competence delivered via mobile app
16375804|NCT04148508|Active Comparator|Cognitive-behavioural Approach|Self-help cognitive-behavioural approach delivered via mobile app
16375805|NCT04148508|Placebo Comparator|Self-monitoring|Self-help self-monitoring delivered via mobile app
16375806|NCT04148495|Experimental|Treatment group|Morphine IV and the placebo of acetaminophen IV.
16375807|NCT04148495|Active Comparator|Control group|Morphine IV and acetaminophen IV
16375808|NCT04148482|Active Comparator|Genotype of interest group|Individuals with desired genetic susceptibility will receive a standardized and an election meal in a full-day clinic visit.
16375809|NCT04148482|Placebo Comparator|Control|Individuals without genotype of interest (i.e., carrying the opposite genotype) will receive a standardized and an election meal in a full-day clinic visit.
16375810|NCT04148469|Experimental|dry needling and TENS|A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
16375811|NCT04148469|Placebo Comparator|Placebo|A placebo dry needling was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
16375812|NCT04148469|Experimental|dry needling|A dry needling treatment was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
16375813|NCT04148456|Other|Aortoiliac occlusive disease|This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
16375814|NCT04148443|Experimental|3 minutes period of preoxygenation|3 minutes of preoxygenation : participants in this group will receive 3 minutes of preoxygenation before intubation
16375815|NCT04148443|Experimental|5 minutes period of preoxygenation|5 minutes of preoxygenation: participants in this group will receive 5 minutes of preoxygenation before intubation
16375816|NCT04148430|Experimental|Arm 1 (CART Cell Group)|"Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.
~Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days"
16375817|NCT04148430|Experimental|Arm 2 (COVID-19 Group)|Patients will receive anakinra 100mg IV q6h for 7 days.
16375818|NCT04148417|Experimental|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
16375819|NCT04148404|Active Comparator|Group NT|1.Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).
16375820|NCT04148404|Active Comparator|Group HT|2.Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
16375821|NCT04148391|Placebo Comparator|Placebo|Matching placebo Capsules
16375822|NCT04148391|Experimental|NYX-458 30 mg|Single oral dose taken daily for 12 weeks.
16375823|NCT04148378||Patients|Patients who have been diagnosed with colorectal cancer.
16375824|NCT04148365||Paediatric Uveitis|Patients with Uveitis below the age of 18 years.
16375825|NCT04148352|Experimental|Dupilumab|24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab
16375826|NCT04148352|Placebo Comparator|Placebo|24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo
16375827|NCT04148339||Patients|Patients with Elevated Cholesterol
16375828|NCT04148326||Patients|Patients who have been diagnosed with Parkinson's Disease
16375829|NCT04148313||Patients|Patients with diagnosis of Multiple Sclerosis.
16375830|NCT04148287|Experimental|APX001|APX001 IV or oral for up to 42 days
16375831|NCT04148274||Patients|Patients with Ulcerative Colitis diagnosis
16378095|NCT04132739|Experimental|Diet only|
16375832|NCT04148261|Active Comparator|Healthy Arm, CORT + EPI, then PLB + EPI|Healthy participant will receive cortisol pill and epinephrine infusion
16375833|NCT04148261|Active Comparator|Healthy Arm, PLB + EPI, then CORT + EPI|Healthy participant will receive placebo pill and epinephrine infusion
16375834|NCT04148261|Experimental|Depression Arm, CORT + EPI, then PLB + EPI|Depressed participant will receive cortisol pill and epinephrine infusion
16375835|NCT04148261|Experimental|Depression Arm, PLB + EPI, then CORT + EPI|Depressed participant will receive placebo pill and epinephrine infusion
16375836|NCT04148248||Patients|Patients with a diagnosis of chronic constipation
16375837|NCT04148235||Patients|Patients who have been diagnosed with Celiac Disease
16375838|NCT04148222||Patients|Patients who have been diagnosed with Lyme Disease
16375839|NCT04148209|Experimental|Treatment|Participants receiving PF-07081532
16375840|NCT04148209|Placebo Comparator|Placebo|Participants receiving Placebo
16375841|NCT04148196|No Intervention|Control group|older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.
16375842|NCT04148196|Experimental|Experimental group|Intervention group: older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.The researcher will perform 16 sessions of progressive relaxation exercises twice a week for 8 weeks. Each PMR exercise was conducted under the guidance of the researcher. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate and blood pressure.
16375843|NCT04148183|Experimental|Metformin Group|Metformin (850 mg/day) treatment was administered for 8 weeks
16375844|NCT04148183|Experimental|Rosiglitazone Group|Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
16375845|NCT04148183|Placebo Comparator|Placebo Group|Placebo treatment was administered for 8 weeks
16375846|NCT04148170|Active Comparator|classic intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.
16375847|NCT04148170|Active Comparator|endodiathermy probe|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
16375848|NCT04148144||Adolescents with low back pain|Adolescents aged 8-19 with low back pain.
16375849|NCT04148144||Parents of included adolescents|Parents recruited for the parallel cohort, are required to be a parent or a legal guardian of the included adolescent. Siblings, grandparents or a similar person are not eligible for inclusion in the parallel cohort.
16375850|NCT04148131||Group 1, 0-5 months old|Children which is Obstetric brachial plexus palsy and 0-5 months old age have Naracas type 2 lesion.
16375851|NCT04148131||Group 2, 6-24 months old|Children which is Obstetric brachial plexus palsy and 6-24 months old age have Naracas type 2 lesion.
16375852|NCT04148131||Group 3, 25-36 months old|Children which is Obstetric brachial plexus palsy and 25-36 months old age have Naracas type 2 lesion.
16375853|NCT04148118|Experimental|NE+50µg rPA - sprayer|
16375854|NCT04148118|Experimental|NE+50µg rPA - pipette|
16375855|NCT04148118|Experimental|NE+100µg rPA - sprayer|
16375856|NCT04148118|Experimental|NE+100µg rPA - pipette|
16375857|NCT04148118|Placebo Comparator|Saline - sprayer|
16375858|NCT04148118|Placebo Comparator|Saline - pipette|
16375859|NCT04148118|Active Comparator|BioThrax - SC|
16375860|NCT04148105|Placebo Comparator|Placebo|Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
16375861|NCT04148105|Experimental|Experimental|Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.
16375862|NCT04148066|Other|Osimertinib and Crizotinib|"Osimertinib will be administered according to label: 80 mg once daily.
~Crizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily."
16375863|NCT04148053||Active TB|"Subjects met the following:
~Either Pulmonary or Extra-pulmonary tuberculosis patients
~TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen."
16375864|NCT04148053||Latent TB|"Subjects met the following:
~TB Contact in history.
~Chest X-ray suggestive of non-TB.
~without any symptoms suggestive of TB.
~TST and/or IGRA positive."
16375865|NCT04148040|Experimental|G-POEM for infantile hypertrophic pyloric stenosis|The procedure includes four steps: a) a transversal mucosal incision was performed at the proximal antrum. b) a submucosal longitudinal tunnel was created across the pyloric ring. c) full-thickness pyloromyotomy was performed, with a little extension of the antrum. After pyloromyotomy, an ultrathin gastroscope was used to inspect the mucosa and pyloric outlet. d) after careful hemostasis, the mucosal entry was closed by clips.
16375866|NCT04148014|Experimental|Adjunctive Emotion Regulation Skills Training|Participants will receive a 5 session once a week group emotion regulation skills training adjacent to treatment as usual provided by the eating disorder unit at the child and adolescent psychiatric clinic, Linköping, Sweden.
16375867|NCT04147988|Other|DONALD T list|adults on the DONALD T list seeking diagnostic advice on autism spectrum disorder or asperger's syndrome
16375868|NCT04147975||Patients Suspected of Bloodstream Infection|No intervention(s) to be administered.
16375869|NCT04147962||Patients with dry eye disease with meibomian gland dysfunction|"Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).
~- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light"
16375870|NCT04147949|Experimental|AV-101|1440 mg of L-4-chlorokynurenine administered twice a day orally
16375871|NCT04147949|Placebo Comparator|Placebo|Matching capsules of placebo
16375872|NCT04147936|Active Comparator|AXA1665 29.4g|Dietary Supplement: AXA1665 Amino acids, food study
16375873|NCT04147936|Active Comparator|AXA1665 53.9 g|Dietary Supplement: AXA1665 Amino acids, food study
16375874|NCT04147936|Placebo Comparator|Placebo 29.4 g|Dietary Supplement: Placebo
16375875|NCT04147923|Active Comparator|Floradapt Mature Immune Defense|A multivitamin will also be consumed.
16375876|NCT04147923|Placebo Comparator|Placebo|A multivitamin will also be consumed.
16375877|NCT04147910|Experimental|KW-6356|Single oral dose of carbon-14-KW-6356.
16375878|NCT04147897|Active Comparator|Internal Facilitation|mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.
16375879|NCT04147897|Active Comparator|External Facilitation|mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.
16375881|NCT04147871|Active Comparator|ADV7103 1.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
16375882|NCT04147871|Active Comparator|ADV7103 3.0 mEq/Kg/day|Patients receive ADV7103 twice a day.
16375883|NCT04147871|Active Comparator|ADV7103 4.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
16375884|NCT04147871|Placebo Comparator|Placebo|Patients receive placebo twice a day.
16375885|NCT04147858|Experimental|NYX-2925 50 mg|NYX-2925 50 mg administered orally.
16375886|NCT04147858|Experimental|NYX-2925 100 mg|NYX-2925 100 mg administered orally.
16375887|NCT04147858|Placebo Comparator|Placebo|Placebo administered orally.
16375888|NCT04147845|Experimental|Fractional Carbon dioxide laser and triamcinolone acetonide|"Group I:Fractional Carbon dioxide laser (CO2 Laser) and triamcinolone acetonide (TrA; 10 mg/ ml) (14, 15) The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.
~Laser treatment will be given to the affected area, and immediately after the treatment, triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
16375889|NCT04147845|Experimental|Microneedling with Dermapen and triamcinolone acetonide|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.
~Triamcinolone acetonide in concentration of 10 mg/ml (0.1 ml containing 1 mg of triamcinolone) will be applied on each lesion twice, before and after performing microneedling.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
16375890|NCT04147845|Experimental|Fractional Carbon dioxide laser and Platelet-rich plasma|"The same laser parameters as group I will be used, followed by application of freshly prepared PRP. The applied PRP will be spread over the whole affected area.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
16375891|NCT04147845|Experimental|Microneedling with Dermapen and Platelet-rich plasma|"Microneedling using dermapen is performed as Group II. Microneedling is preceeded and followed by intermittent application of freshly prepared PRP. The applied PRP will be spread over the whole affected area and again rolled till pinpoint bleeding points are noticed.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
16375893|NCT04147819|Experimental|Dose escalation of BAY2701439|The target population consists of participants with advanced HER2-expressing/amplified breast, gastric or gastroesophageal cancer.
16375894|NCT04147819|Experimental|HER2 overexpressing breast cancer|Dose expansion of BAY2701439
16375895|NCT04147819|Experimental|HER2 low expressing breast cancer|Dose expansion of BAY2701439
16375896|NCT04147819|Experimental|Other HER2 overexpressing advanced carcinomas|Dose expansion of BAY2701439
16375897|NCT04147806|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
16375898|NCT04147806|Experimental|IGRT 24 Gy single dose|single fraction IGRT at a prescription dose of 24 Gy
16375899|NCT04147793||Controls|patients attneding for surgery with no known bladder disease
16375900|NCT04147793||Overactice sphincter|those with evidence of dysfunctional voiding
16375901|NCT04147793||Underactive sphincter|those with genuine stress incontinence
16375902|NCT04147780||Primary vulvar cancer, tumor ≥ 4cm|"Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:
~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
16375903|NCT04147780||Primary vulvar cancer, multifocal tumor|"Patients with primary squamous cell vulvar cancer, multifocal tumor:
~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
16375904|NCT04147780||Local recurrence after vulvar cancer, no earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:
~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
16375905|NCT04147780||Local recurrence after vulvar cancer, earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:
~Sentinel node biopsy if detectable, otherwise no groin treatment"
16376044|NCT04146779|Experimental|Video, Written Yoga Instruction Plus Guided Yoga Sessions|Videos and written instructions on Hatha yoga and instructor guided session on Hatha yoga will be provided
16375906|NCT04147767|Experimental|Phytosterols Arm|"The investigational food product Cholesterol Reducing Strawberry Yogurt Drink (Tesco) is a strawberry yogurt drink with added plant sterols. A 100g bottle (one serving) of cholesterol lowering strawberry yogurt drink contains 2g of free plant sterols. The magnitude of the effect given by this enriched food product, providing a daily intake of 1,5-2,4 g plant sterols/stanols, refers to the lowering/reducing blood cholesterol effects in the range 7 % to 10 % within 2 to 3 weeks of treatment, as specified by Commission Regulation (EU) 384/2010 of 05/05/2010.
~The dietary intervention will consist in 8 weeks consumption of PSS enriched Yogurt Drink, which provide a daily PSS intake of 3.4g/100g bottle plant sterols ester equivalent to 2g/100g bottle of free plant sterols."
16375907|NCT04147767|Placebo Comparator|Placebo Arm|"The investigational food product Low Fat Strawberry Yogurt Drinks (Morrisons) is a strawberry flavoured yogurt drink with sweetener and sugar, vitamin C, B6 and D, British milk.
~Placebo intervention consists in 8 weeks consumption of PSS non-enriched Yogurt Drinks. The placebo intervention is needed for the study design chosen (randomized double-blind placebo-controlled cross-over clinical trial). Placebo will be used in order to determine the efficacy of PSS intervention, comparing the effects of the two compounds (PSS and placebo) in the same experimental conditions and then avoiding bias."
16375908|NCT04147754||Epidural anesthesia|At physician discretion (observational study)
16375909|NCT04147754||Intrathecal morphine|At physician discretion (observational study)
16375910|NCT04147754||Erector spinae block|At physician discretion (observational study)
16375911|NCT04147741|Experimental|Pre-Workout Supplement|A 60 g dose of a commercially available pre-workout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine 1 g, yerba mate 0.3 g and caffeine 0.4 g. With 250 ml of water.
16375912|NCT04147741|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 250 ml of water.
16375913|NCT04147728|Experimental|SRS Combination With Anlotinib|Stereotactic Radiosurgery Combination With Anlotinib
16375923|NCT04147702|Experimental|Experimental Group: Balance analysis|fifty dancers will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
16375924|NCT04147702|Active Comparator|Control Group:Balance Analysis|fifty healthy subjects will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
16375925|NCT04147689|Experimental|Treated labia majora|Labia majora are treated at Baseline visit (V1) and a touch-up may be performed 4 weeks after Baseline (V2) if needed
16375926|NCT04147676||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study.
~The specimens will be tested with
~Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex
~Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid
~Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid"
16375927|NCT04147650|Experimental|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
16375928|NCT04147650|Experimental|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
16375929|NCT04147650|Experimental|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
16375930|NCT04147650|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
16375931|NCT04147637|Experimental|FSL-M|FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
16375932|NCT04147637|Active Comparator|FSL-A|FreeStyle Libre alone
16375933|NCT04147624|Experimental|Treatment Group|Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 6 consecutive months.
16375934|NCT04147624|Placebo Comparator|Placebo Group|Participants in the treatment group will receive 125 mL of iso-caloric placebo taken by mouth, once daily, for 6 consecutive months.
16375935|NCT04147611|Experimental|Remote Microphone (RM) Technology Group|"The RM technology group will limited to the pediatrics participants.
~Participants will be tested separately on the three following conditions:
~Bone Conduction Device (BAHA) only
~BAHA + Wireless Audio-Streaming Accessory
~BAHA + Digital Adaptive RM System"
16376076|NCT04146532|Placebo Comparator|Placebo|Single dose of a 500mg placebo tablet.
16378096|NCT04132739|Experimental|Diet + Exercise|
16375936|NCT04147611|Active Comparator|Normal Hearing Controls|"The normal hearing controls will be limited to 15 adults.
~Participants will be tested separately on the six following conditions:
~Unaided
~Unilateral hearing aid with contralateral plug.
~Unilateral hearing aid + Digital Adaptive RM System (using Roger™, Sonova)
~Bone Conduction Device (BAHA) only
~BAHA + Wireless Audio-Streaming Accessory
~BAHA + Digital Adaptive RM System"
16375937|NCT04147598|Experimental|Low Fat Diet (LFD) to Standard American Diet (SAD)|Week 1 to 4 participants will receive a LFD followed by a washout period of 2 weeks and then week 6 to 10 SAD.
16375938|NCT04147598|Experimental|SAD to LFD|Week 1 to 4 participants will receive a SAD followed by a washout period of 2 weeks and then week 6 to 10 LFD.
16375939|NCT04147585|Experimental|Intervention Arm|Three cycles of a 5-day Intermittent Reduced Calorie Diet
16375940|NCT04147585|No Intervention|Control Arm|Regular Diet
16375941|NCT04147572|Experimental|Inhaler A, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type A
16375942|NCT04147572|Experimental|Inhaler B, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type B
16375943|NCT04147572|Placebo Comparator|Reference product, Spiriva modified HandiHaler|Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
16375944|NCT04147572|Experimental|Substudy Test product Placebo Tiotropium Easyhaler|The substudy subjects will demonstrate the use of the inhaler.
16375945|NCT04147572|Placebo Comparator|Substudy Reference product Placebo Spiriva® HandiHaler|The substudy subjects will demonstrate the use of the inhaler.
16375946|NCT04147546|Experimental|Intervention arm|"A full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.
~At each ANC visit, study nurses will perform an HS-RDT for participants in this arm. Reminders will be sent in this group in order to improve IPTp-SP uptake"
16375947|NCT04147546|No Intervention|Control arm|"A full course of artemether-lumefantrine (AL) over 3 days. The first dose of AL will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.
~At each ANC visit, study nurses will perform a conventional RDT for participants in this arm if the participant have symptoms suggestive of malaria. No reminder will be sent"
16375948|NCT04147533|Experimental|initially treated patients|The dose of tyrosin kinase inhibitors (imatinib, or nilotinib, or dasatinib) in patients meeting all of the inclusion criteria and none of the exclusion criteria will be reduced in two consequent steps, during the first 6 months after study entry by 50%, during the second 6 months by 50% again; the medication is discontinued then and the patients are followed each month in the first 6 months after withdrawal, each 1,5 month in the next 6 months, and each 3 months in the next 12 months.
16375949|NCT04147520|Active Comparator|Brief Motivational Interview|Single-session in person conversation focusing on risks associated with alcohol use.
16375950|NCT04147520|No Intervention|Natural History Control|No contact.
16375951|NCT04147507|Experimental|Music Therapy|
16375952|NCT04147507|Other|Control|Life style Modification.
16375953|NCT04147494|Experimental|Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes. Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).
16375954|NCT04147481|Experimental|Group Abdominal Nerve Block|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
16375955|NCT04147481|Placebo Comparator|Group control|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
16375956|NCT04147468|Active Comparator|Virtual Reality Gaming Intervention|A newly developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child, will be used. The research team will loan the system to the family. The child will be asked to move their arms to 'pop' as many virtual objects as possible with the focus on outwards, upwards, and across midline.
16375957|NCT04147468|Experimental|Functional Strength Training|Children will receive repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises which are designed to move their arms.
16375958|NCT04147455|Experimental|RealConsent|Participants randomized to this study arm will receive an adapted program of RealConsent.
16375959|NCT04147455|Active Comparator|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
16375960|NCT04147442|Experimental|Music program fine-tuned and standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
16375961|NCT04147429|No Intervention|Usual care|Newborns randomized to the usual care group will receive standard education about safe sleep practices, measuring temperatures and newborn feeding needs. This information will be accompanied by printed instructions that will be added to the family's discharge instructions. This reflects current practice in the Duke Hospital Newborn Nursery.
16375962|NCT04147429|Experimental|Intervention|In addition to usual care, families randomized to the intervention group will receive an early literacy intervention, delivered by a trained research assistant. To ensure intervention and delivery fidelity, the PI will meet with research assistants at bi-weekly intervals to review procedures and perform structured observations of intervention delivery.
16375963|NCT04147416|Experimental|HSK3486|
16375964|NCT04147416|Active Comparator|Propofol|
16375965|NCT04147390|Active Comparator|usage mycophenolate mofetil|
16375966|NCT04147390|Active Comparator|usage tacrolimus|
16375967|NCT04147377|Experimental|PD with FOG|Patients with Parkinson's disease who complain of freezing of gait
16375968|NCT04147351|Experimental|Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin|
16375969|NCT04147338|Experimental|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
16375970|NCT04147338|Experimental|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
16375971|NCT04147338|Experimental|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
16375972|NCT04147325||Prospective Cohort|Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.
16375973|NCT04147325||Historical Cohort|Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.
16375974|NCT04147312|Experimental|Treatment group|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
16375975|NCT04147312|Placebo Comparator|control group|Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
16375976|NCT04147299||HFrEF|Heart Failure with Reduced Ejection Fraction
16375977|NCT04147299||HFpEF|Heart Failure with Preserved Ejection Fraction
16375978|NCT04147299||Elite Athletes|Endurance athletes
16375979|NCT04147286|Active Comparator|Atorvastatin (Arm B)|12 weeks of 40 mg atorvastatin therapy per os daily
16375980|NCT04147286|Placebo Comparator|Placebo (Arm C)|Identical placebo tablet is taken per os daily
16375981|NCT04147273|Other|Evaluation of CGM compared with standard measurements|Two products were studied: white bread (Butter Toast®, Golden Toast, Wittenberg, Germany) and whole grain bread (1688 Mehrkorn®, Harry-Brot, Schenefeld, Germany). One portion (containing 50 g digestible carbohydrates) was eaten immediately before the beginning of the test in the morning after an overnight fast of at least 10 h. Before testing, participants ate as usual on the previous day without a standard meal and refrained from consuming alcohol and exercising for 72 h. A 200-ml glucose drink (Accu-Chek Dextrose O.G.-T. Saft®, Roche Diabetes Care, Mannheim, Germany), containing also 50 g of carbohydrates, was used as the reference product.
16375982|NCT04147260|Experimental|BI 730357 low dose|
16375983|NCT04147260|Active Comparator|Ciprofloxacin|
16375984|NCT04147260|Experimental|BI 730357 high dose|
16375985|NCT04147260|Placebo Comparator|Placebo|
16375986|NCT04147247|Experimental|BI 905681|
16375987|NCT04147234|Experimental|Arm A: BI 1387446|superficial lesions
16375988|NCT04147234|Experimental|Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)|superficial lesions
16375989|NCT04147234|Experimental|Arm C: BI 1387446 in combination with ezabenlimab (BI 754091)|deep lesions
16375990|NCT04147221|Experimental|Imipenem-Relebactam|Participants will receive a single dose of intravenous imipenem-relebactam (500mg-250mg) as a 30 minute infusion.
16375991|NCT04147208|Experimental|Combination group|Subjects will receive 96 weeks of GLS4+RTV+ETV.
16375992|NCT04147208|Active Comparator|Entecavir monotherapy|Subjects received 96 weeks of entecavir treatment
16375995|NCT04147182|Experimental|Patient with low grade TCC|"Patients of 18 years or older able to sign informed consent
~A previous diagnosis of low grade bladder cancer
~A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion
~Serum creatinine levels ≤ 2.0 mg/dl
~Serum sodium levels <146 mg/ml
~Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months
~Patient is candidate for TURBT"
16375996|NCT04147169||Dying patients|Dying patients admitted to the Intensive Care Unit who are approaching end-of-life.
16375997|NCT04147156|Active Comparator|Epley's Maneuver|Treatment of posterior canal BPPV with Epley's maneuver in the ROTUNDUM-chair.
16375998|NCT04147156|Experimental|Semont Maneuver|Treatment of posterior canal BPPV with the Semont maneuver in the ROTUNDUM-chair.
16375999|NCT04147156|Active Comparator|360 degree vertical rotation|Treatment of posterior canal BPPV with a 360 degree vertical rotation in the ROTUNDUM-chair.
16376000|NCT04147130|Experimental|MultiPAP Plus intervention|Complex intervention with general practitioners and patients
16376001|NCT04147130|Active Comparator|Usual care|Patients will recieve the usual clinical care
16376002|NCT04147117|Experimental|Pessary Group|"A pessary certified is inserted through the vagina with the woman in recumbent position and is placed around the cervix.
~Correct placement of the pessary is assessed by ultrasound. Patients on the pessary group are specially awarded about adverse symptoms and the need of immediate report in case of pain, bleeding and symptomatic contractions.
~The pessary is not removed when symptoms of infection occur after pessary insertion, but appropriate treatment is given.
~The pessary is removed at 37 weeks of pregnancy. Indications for pessary removal before 37 weeks are: active vaginal bleeding, premature labor not responding to tocolysis or severe patient discomfort."
16376003|NCT04147117|No Intervention|Control group|Current management for the follow-up of these women in the PBPC.
16376004|NCT04147104|Active Comparator|Standard-of-care plus invasive mechanical ventilation|Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.
16376005|NCT04147104|Experimental|ECCO2R plus invasive mechanical ventilation|Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.
16376006|NCT04147091|Experimental|domestic nanohydroxyapatite gel ApaCare & Repair|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
16376007|NCT04147091|Experimental|in-office ozone therapy OzonyTron|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
16376008|NCT04147091|Experimental|both remineralizing gel and ozone therapy|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
16376009|NCT04147078|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
16376010|NCT04147065|Experimental|7-day triple therapy and 7-day bismuth quadruple therapy|7-day triple therapy is consisted of proton pump inhibitor (PPI), amoxicillin and clarithromycin for seven days 7-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for seven days
16376011|NCT04147065|Active Comparator|14-day triple therapy and 14-day bismuth quadruple therapy|14-day triple therapy is consisted of PPI, amoxicillin and clarithromycin for fourteen days 14-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for fourteen days
16376012|NCT04147052|Experimental|iSLEEPms|Participants randomized to iSLEEPms complete a 4-week online program with telephone support, based on CBT-I.
16376013|NCT04147052|No Intervention|Treatment As Usual|Participants randomized to TAU continue their usual care and are encouraged to avoid starting any new sleep treatment unless deemed necessary by a health care provider.
16376014|NCT04147039|Experimental|Intervention|Receives the MINISTOP 2.0 mobile phone app for 6 months
16376015|NCT04147039|No Intervention|Control|Receives standard care through primary child health care
16376016|NCT04147026|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from rheumatoid arthritis. Prescription of an original or biosimilar biotherapy (rituximab, adalimumab, abatacept) is possible.
16376017|NCT04147026|Active Comparator|Current practice|Prescription of biotherapy without the SinnoTest® software which corresponds to current practice (all biotherapies).
16376018|NCT04147013|Experimental|Celecoxib Group|Patients will receive the interventional drug for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
16376019|NCT04147013|Placebo Comparator|Control Group|Patients will receive the placebo for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
16376020|NCT04146987|Active Comparator|Open rotator cuff repair|Patients will be positioned in a beach chair position with the affected limb pending off the table, allowing manipulation and full range of motion range. After asepsis, antisepsis and placement of sterile surgical fields, anterolateral incision will be made in the shoulder in question; the deltoid muscle belly will be gently divided along its fibers until exposure of the subdeltoid / subacromial bursa, which will be partially excised for exposure of the subacromial space and rotator cuff tendons. After mobilization and release of the ruptured tendons and debridement of the rotator cuff footprint, the tendon repair to the bone will be performed using 5.5m metal anchors, according to the preference and technique chosen by the surgeon. In all cases, the release of the coracoacromial ligament and acromioplasty will be performed.
16376021|NCT04146987|Active Comparator|Arthroscopic rotator cuff repair|The patients will be positioned in lateral decubitus position, with the arm to be operated attached to a skin traction device, which trough a traction post and 07 kg, will maintain the shoulder in the following position: abduction of 30 to 60 and flexion of 20 to 30 degrees. After asepsis, antisepsis and placement of impermeable sterile surgical fields, a posterolateral incision will be made in the shoulder for optic introduction, with a 50 mmHg pressure pump and a 0.90 flow, and inspection of the GU joint. After joint inspection, the optic will be introduced into the subacromial space with detachment of the subacromial and subdeltoid. Using shaver blades, partial bursectomy will be performed as well as debridement of the rotator cuff footprint. The tendon will then be reinserted to the bone using metallic 5.5mm anchors. After tendon repair, the coracoacromomial ligament will be released, as well as acromioplasty.
16376022|NCT04146948||COPD group|No intervention 40 years or older, clinical diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease stages I to IV)
16376023|NCT04146948||healthy group|40 years or older, not with the clinical diagnosis of COPD
16376024|NCT04146935|Experimental|Patients with XLH|Patients will receive Burosumab monthly at visits 1,2 and 3 subcutaneously at a dose of 1.0 mg/kg. Dose may be adjusted as needed.
16376025|NCT04146922|Active Comparator|IV Group|Eligible patients randomized to complete their antimicrobial therapy course through intravenous (IV) administration.
16376026|NCT04146922|Experimental|Oral Group|Eligible patients randomized to step down to oral antimicrobial therapy for the remainder of their treatment course.
16376027|NCT04146909|Active Comparator|Breast Feeding|This group will consist of women who exclusively or mostly breast-fed for at least 4-6 months (< 6 ounces of formula/24 hours at 6-9 weeks of delivery)1 and who delivered within the past 18 months.
16376028|NCT04146909|Active Comparator|Formula Feeding|This group will consist of women who exclusively or mostly formula-fed (no breastfeeding or < 3 weeks of breastfeeding)1 and who delivered within the past 18 months.
16376031|NCT04146883|Experimental|Post procedural antibiotics treatment|This group was treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin) and post procedural oral prophylactic antibiotics
16376032|NCT04146883|No Intervention|Pre procedural antibiotics treatment only|This group was only treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin).
16376033|NCT04146857|Placebo Comparator|Normoxia|20.9% oxygen
16376034|NCT04146857|Active Comparator|Hypoxia 1|15.0% oxygen
16376035|NCT04146857|Active Comparator|Hypoxia 2|12.8% oxygen
16376036|NCT04146831|Experimental|Sintilimab|Sintilimab is administered in this arm.
16376037|NCT04146818|Experimental|Adapted Tango Dancing arm|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months)
16376038|NCT04146818|Placebo Comparator|Control arm|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
16376039|NCT04146805|Experimental|Part 1SAD/Part 2 MAD:Active Treatment(BLD-0409)|For each cohort in both study parts, 6 subjects will be randomized to active (BLD-0409). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)
16376040|NCT04146805|Placebo Comparator|Part 1SAD/Part 2 MAD:Control(Matched Placebo)|For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
16376041|NCT04146792|Experimental|body acceptance program|
16376042|NCT04146792|Active Comparator|writing creativity program|
16376043|NCT04146779|Experimental|Video and Written Yoga Instruction|Videos and written instructions on Hatha yoga will be provided
16376045|NCT04146766|Experimental|eHealth|Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
16376046|NCT04146766|Experimental|wait list control|wait list control for 3 months and then Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
16376047|NCT04146740|Experimental|Structured Exercise Group|"Structured Exercise Group will receive medical and dietary interventions like insulin plus structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min The combination of Stabilization exercise (10 repetitions) and PFM training ( 20 repetitions set).
~Relaxation therapy including Mitchells physiological relaxation technique (10 repeatitions) alongwith deep breathing exercises.
~Life style modification with postural guidance and back care would also be followed.
~Exercise dosage would be twice a week for 05 weeks while exercise duration will be 45 to 50 min session under Physio supervision and home plan of 10 min exercise daily. Total 150 min per week. Data will be recorded at baseline then after treatment of 5 weeks."
16376048|NCT04146740|Active Comparator|Control Group|Control Group will receive no structured exercise regime only the group will be receiving medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist due to ethical concerns and their outcomes will be observed at the baseline and then after 05 weeks.
16376049|NCT04146727||ICU Duration|The total study duration is determined by their length of stay in the ICU.
16376050|NCT04146727||Transplant through 1 month at Home|Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
16376051|NCT04146714|Experimental|Substance use screening|Participants complete a substance use questionnaire (=intervention).
16376052|NCT04146714|Active Comparator|Physical activity screening|Participants complete a physical activity questionnaire (=control).
16376053|NCT04146701||Acute heart failure|All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376054|NCT04146701||STEMI|All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376055|NCT04146701||NSTEMI|All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376056|NCT04146701||Ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376057|NCT04146701||Non-ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376058|NCT04146701||Sepsis|All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376059|NCT04146701||Healthy controls|Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
16376060|NCT04146688|Active Comparator|Patients with neurodegenerative disease|Patients with neurodegenerative disease (AD or related disease)
16376061|NCT04146688|Active Comparator|People with no neuropathological disease|
16376062|NCT04146675|Experimental|TRICOT JERSEY VANISE DOUBLE FACE|
16376063|NCT04146675|Placebo Comparator|TRICOT JERSEY SIMPLE|
16376064|NCT04146649|Experimental|Primary Osteoarthritis|Patients with native knees and effusions will participate in this arm.
16376065|NCT04146649|Experimental|Primary TKA|Patients with total knee replacements will participate in this arm.
16376066|NCT04146636|Other|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
16376067|NCT04146623|Placebo Comparator|Normal Saline Placebo|Saline (0.9%)
16376068|NCT04146623|Experimental|CodaVax-H1N1|Live-attenuated influenza vaccine
16376069|NCT04146610|Experimental|Dp303c|Multiple dose grouping
16376070|NCT04146597|Experimental|Neural mobilization|The intervention is always performed after Jiu Jitsu practice and at the training site itself. Neural mobilization consisted of the execution of a sciatic nerve sliding technique in three sets of one minute for each lower limb with an interval of one minute between sets, twice a week, for five consecutive weeks, totaling 10 interventions (Garber et al., 2011). The order of the first lower limb to be submitted to the intervention is not standardized, being at the discretion of the subjects.
16376071|NCT04146584|Experimental|Sofwave Treatment|In this arm (single) patients would be treated twice with Sofwave on the face and/or submental and neck.
16376072|NCT04146558|Experimental|Internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.
~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
16376073|NCT04146558|Active Comparator|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
16376074|NCT04146545|Experimental|Cases|Community Rx-Caregiver Resources
16376075|NCT04146545|No Intervention|Control|Usual Standard Care
16376320|NCT04144894|Other|Healthy Controls|
16376077|NCT04146532|Active Comparator|Aspirin 500MG|Single dose of a 500 mg aspirin tablet.
16376078|NCT04146519|Experimental|Study group|Autologous MMSC
16376079|NCT04146519|Placebo Comparator|control group|
16376080|NCT04146506||Male|Static Muscle stretching exercises of the knee flexors
16376081|NCT04146506||Female|Static Muscle stretching exercises of the knee flexors
16376082|NCT04146493||Vascular surgery group|Patients which are given unfractionated heparin during their vascular surgery.
16376083|NCT04146493||Thromboprophylaxis group|Patients which are given low molecular heparins as a thrombosprofylax after major surgery
16376084|NCT04146493||Cardiothoracic surgery|Patients which are given high dose unfractionated heparin during their open heart surgey
16376085|NCT04146480|Experimental|Cardiac amyloidosis patients|
16376086|NCT04146467|Experimental|Arm 1|Subjects will be treated with the Renuvion APR device.
16376087|NCT04146454|Experimental|Smartphone-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with a smartphone-based wearable telerehabilitation system.
16376088|NCT04146454|No Intervention|Paper-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with typical paper-based instructions.
16376089|NCT04146441|Experimental|SonoVue|SonoVue + chemotherapy
16376090|NCT04146441|Active Comparator|control|chemotherapy
16376091|NCT04146428|Experimental|clinician-mediated JASPER|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
16376092|NCT04146428|Experimental|parent-mediated JASPER|This group will consist of the therapist assisting the parent implement JASPER on the child twice a week.
16376093|NCT04146415|Experimental|Cardiac amyloidosis patients|
16376094|NCT04146402|Experimental|SCT-I10A + Chemotherapy|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
16376095|NCT04146402|Active Comparator|Placebo + Chemotherapy|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
16376096|NCT04146376||Non-Corrector|Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
16376097|NCT04146376||Corrector|Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
16376098|NCT04146363|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W."
16376099|NCT04146363|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W."
16376100|NCT04146363|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebrikizumab injection."
16376101|NCT04146363|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):
~Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
16376102|NCT04146350|No Intervention|Control|
16376103|NCT04146350|Active Comparator|PPV+/-Cat|
16376104|NCT04146350|Active Comparator|PPV+/-Cat+Gas|
16376105|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Gas|
16376106|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Oil|
16376107|NCT04146350|Active Comparator|PSR|
16376108|NCT04146350|Active Comparator|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|
16376109|NCT04146350|Active Comparator|Gas|
16376110|NCT04146337|Experimental|Fecal microbiota transplantation (FMT)|FMT regimen: Patients will be given capsulized FMT 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
16376111|NCT04146337|No Intervention|Control|Routine follow-up
16376112|NCT04146324||Adjuvant nivolumab therapy|Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
16376113|NCT04146311|Active Comparator|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) is injected into the left infrapatellar fat pad.
16376114|NCT04146311|Placebo Comparator|Isotonic saline|A bolus injection (0.25 ml) of isotonic saline (0.9 %) is injected into the left infrapatellar fat pad.
16376115|NCT04146311|Experimental|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
16376116|NCT04146298|Experimental|TCR Transduced T cell therapy|"Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine
~TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9~1e11)
~Anti-PD-1 therapy: anti-PD-1 will be administered if needed."
16376117|NCT04146285|Experimental|BAT4406F|
16376118|NCT04146272|Active Comparator|Moderate Hearing loss current Mermaid first, then new|Participants were randomized to wear the current Mermaid hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new Mermaid Hearing aid for another 10 days.
16376119|NCT04146272|Active Comparator|Moderate Hearing loss new Mermaid first, then current|Participants were randomized to wear the new Mermaid hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current Mermaid Hearing aid for another 10 days.
16376120|NCT04146272|Active Comparator|Severe hearing loss current Power first, then new|Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
16376121|NCT04146272|Active Comparator|Severe hearing loss new Power first, then current|Participants were randomized to wear the new power hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current power Hearing aid for another 10 days.
16376122|NCT04146259||group A|Control
16376123|NCT04146259||Group B|Post-surgical hypoparathyroidism
16376124|NCT04146246||Adult|Adults aged 18 years or older. Collect whole blood sample via venous/arterial puncture and, where possible, finger stick.
16376125|NCT04146246||Neonate|Neonates gestational age >35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
16376126|NCT04146233|Other|Orange Juice without pulp|Drink orange juice without pulp and have gastric ultrasound performed 2 hours later
16376127|NCT04146233|Other|Orange juice with pulp|Drink orange juice with pulp and have gastric ultrasound performed 2 hours later
16376128|NCT04146220|Experimental|Low dose group|Prednisolone 0.5 mg/kg/day
16376129|NCT04146220|Active Comparator|High dose group|Prednisolone 1 mg/kg/day
16376130|NCT04146207|Experimental|combination therapy|"Experimental: combination therapy There is only 1 arm. Combination therapy arm includes SHR0302 and Prednisone
~Prednisone 1mg/kg/d po，At the same time give SHR0302 QDpo；"
16376131|NCT04146181|Experimental|SCT-I10A|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
16376132|NCT04146168||VenaSeal|Complete closure of previously treated veins will be assessed via ultrasound
16376133|NCT04146155|Experimental|Liraglutide+standard-of-care treatment|Intervention: Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies.
16376134|NCT04146155|Active Comparator|standard-of-care treatment|standard-of-care treatment with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
16376135|NCT04146142|Active Comparator|Transperineal prostate biopsy with antibiotic profylaxis|Cefuroxim 1.5 g will be applied intramuscularly before prostate biopsy
16376136|NCT04146142|Experimental|Transperineal prostate biopsy without antibiotic profylaxis|No antibiotics will be used before or after prostate biopsy
16376137|NCT04146129|Experimental|CDX-0159|Eligible subjects will receive a single dose of CDX-0159
16376138|NCT04146129|Placebo Comparator|Normal saline|Subjects assigned to receive placebo will receive a single dose of normal saline
16376139|NCT04146116|Experimental|Nasal povidone-iodine|Intranasal povidone-iodine (PDI PROFEND) will be applied to the patients' noses before orthopedic trauma surgery and after surgery. This intranasal povidone-iodine was developed under the Tentative Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket # 75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules. However, the product need not be controlled like a pharmaceutical drug. The product may be stored and controlled similarly to an iodine or alcohol skin preparation product.
16376140|NCT04146103|Experimental|Experimental arm|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally, for 3 months.
16376141|NCT04146090|Active Comparator|Low-pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
16376142|NCT04146090|Placebo Comparator|Standard pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
16376143|NCT04146064||Validation cohort: NSCLC|"Patients with advanced/metastatic NSCLC planned for IO-treatment in one of the following categories
~Pembrolizumab monotherapy first-line
~Pembrolizumab or nivolumab monotherapy in second or later line"
16376144|NCT04146064||Cohort 1: NSCLC|Patients with advanced/metastatic NSCLC planned for Pembrolizumab-chemotherapy combination therapy first-line
16376145|NCT04146064||Cohort 2: Melanoma|"Patients with advanced/metastatic melanoma planned for IO-treatment in one of the following categories
~Nivolumab/ipilimumab combination treatment 1L
~Pembrolizumab or nivolumab monotherapy treatment 1L
~Ipilimumab monotherapy 2L"
16376146|NCT04146064||Cohort 3: Mixed solid tumor cohort|Patients with advanced/metastatic solid tumors such as Head&Neck tumors, kidney cancer and urothelial cancer planned for IO-treatment
16376147|NCT04146064||Cohort 4: NSCLC|Patients with advanced/metastatic NSCLC planned for treatment with Chemotherapy-only (either platinum-based combination treatment or docetaxel monotherapy)
16376148|NCT04146051|Experimental|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
16376149|NCT04146051|Experimental|Phase IIa Expansion|Generalized Myasthenia Gravis
16376150|NCT04146038|Experimental|Treatment (salsalate, decitabine, azacitidine, venetoclax)|"CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.
~CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.
~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16376151|NCT04146025|Experimental|Nature Coach Intervention|The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.
16376152|NCT04146025|No Intervention|Control Group|Education only
16376153|NCT04146012|Active Comparator|Early Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation.
16376154|NCT04146012|Active Comparator|Normal Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU.
16376155|NCT04145999|Experimental|PRP + PBM group|This group will receive both PRP application and photobiomodulation.
16376156|NCT04145999|Experimental|PRP + placebo PBM|This group will receive PRP application and placebo photobiomodulation.
16376157|NCT04145999|Experimental|PBM + placebo PRP|This group will receive placebo PRP application with a saline solution and active photobiomodulation.
16376158|NCT04145986||young ladies|Young ladies≤ 35 years old.
16376159|NCT04145973||recurrence and metastasis|breast cancer patients with recurrence and metastasis after surgery
16376160|NCT04145960||Lymph node metastasis|Axillary lymph node metastasis ≥ 4 Lymph nodes
16376161|NCT04145947||triple negative breast cancer|triple negative breast cancer patients with age ≤ 60 years old
16376162|NCT04145934|Experimental|training|The subjects receive the ADSTEP intervention
16376163|NCT04145934|No Intervention|waitlist|These subjects receive two brochures on fall prevention and walking aid selection, and a letter is sent to their care provider informing them that the subject has reported falling. Subjects in this group will be offered the ADSTEP intervention once their study participation is complete.
16376164|NCT04145921|Experimental|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
16376165|NCT04145921|Active Comparator|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
16376166|NCT04145908|Active Comparator|preperitoneal mesh|patients underwent preperitoneal mesh mesh placement
16376167|NCT04145908|Active Comparator|onlay mesh|patients underwent preperitoneal mesh mesh placement
16376168|NCT04145895|Other|Physician-directed Postoperative Activity Restriction|Postoperative activity restrictions prescribed by physician.
16376169|NCT04145895|Other|Self-directed Postoperative Activity Restriction|Postoperative activity restrictions self-determined (parent/guardian and/or patient).
16376170|NCT04145882|Active Comparator|No additional osteotomy|
16376171|NCT04145882|Experimental|varisation osteotomy addition|
16376172|NCT04145882|Experimental|supination osteotomy addition|
16376173|NCT04145882|Experimental|both (varisation + supination) osteotomies addition.|
16376174|NCT04145869|Experimental|Fluorescent cholangiography|Intraoperative fluorescent cholangiography using an intravenous injection of 5mg Indocyanine green
16376175|NCT04145869|Active Comparator|X-ray cholangiography|Intraoperative X-ray cholangiography using an intraductal (cystic duct) injection of Iohexol
16376176|NCT04145856|Placebo Comparator|Placebo|- Control arm
16376177|NCT04145856|Experimental|Probiotic|- Arm with active probiotic alone
16376178|NCT04145856|Experimental|Probiotic + Antispasmodic/Antifoam|- Arm with active probiotic combined to antispasmodic/antifoam drug
16376179|NCT04145830|Experimental|Ultrasound Cyclo Plasty (UCP)|Ultrasound Cyclo Plasty (UCP) using focused ultrasound
16376180|NCT04145817|Experimental|genetic counselling|Genetic counselling (PRS for risk estimation) and questionnaires in the participating Cancer Genetic Clinics for healthy woman relative of a person first tested in the family (index case) who received a positive genetic test result or a negative non-informative test result
16376181|NCT04145791|No Intervention|No Ice|Patients will receive standard postoperative pain control methods as defined by the participating institution
16376182|NCT04145791|Experimental|Ice|Patients will receive ice packs to the abdomen, in addition to standard postoperative pain control methods as defined by the participating institution
16376183|NCT04145778||Patient|
16376184|NCT04145778||Control|
16376185|NCT04145752|Experimental|Nurse-led femoral nerve block|"Trained nurses in ED provide ultrasound guided single-shot femoral nerve block shortly after (at arrival emergency department) the patient is diagnosed with a hip fracture.
~Drug: Ropivacaine 3 mg/kg, single-shot"
16376186|NCT04145752|Active Comparator|Standard of care|Nurses do not provide ultrasound guided single-shot FNB and the patient follows the standard of care course.
16376187|NCT04145739|Experimental|Mastectomy group|Patients undergoing mastectomy
16376188|NCT04145739|Experimental|Quadrantectomy group|Patients undergoing quadrantectomy
16376189|NCT04145726||Patients undergoing esophageal resection|All patients undergoing esophageal resection will be included and tested if frail or non-frail. Which means there is no intervention
16376190|NCT04145713|Experimental|Probiotic group|
16376191|NCT04145713|Placebo Comparator|Placebo group|
16376194|NCT04145687|Active Comparator|Metformin|
16376195|NCT04145687|Placebo Comparator|Placebo|
16376196|NCT04145674|Active Comparator|25 mg d-Methadone|25 mg d-Methadone Tablet and one 0 mg Placebo Tablet
16376197|NCT04145674|Experimental|50 mg d-Methadone|2 x 25 mg d-Methadone Tablet
16376198|NCT04145674|Placebo Comparator|Placebo|2 x Non-active substance Tablet
16376199|NCT04145661|Experimental|DR group|Participants who have cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
16376200|NCT04145661|Experimental|No DR group|Participants who have no cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
16376201|NCT04145635|Experimental|Aortix Device|Aortix Pump, Aortix Delivery System, Introducer Set, Aortix Control System, Aortix Retrieval System
16376202|NCT04145622|Experimental|Dose escalation|All participants enrolled in the dose escalation part
16376203|NCT04145622|Experimental|Dose expansion|All participants enrolled in the dose expansion part
16376204|NCT04145609|Experimental|Intensified care|Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic Participants randomized to this arm will receive multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist and dietitian. Besides intensified care, participants of this arm receive evaluation of biochemical and physiological renal function more frequently. In order to provide seamless care of this group, post-discharge acute kidney disease (AKD) clinic will also be arranged for them. Clinic visits consist of evaluation of renal function, reconciliation of medication and steering necessity of renal replacement therapy.
16376205|NCT04145609|No Intervention|Usual care|No intervention: Usual care Participants randomized to this arm will receive usual care according to the medical decisions of principal care physician. Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patient will not have access to MDT care and AKD clinic.
16376206|NCT04145596|Active Comparator|Compensated Chronic Liver Disease (Child-Pugh A)|
16376207|NCT04145596|Active Comparator|Decompensated Chronic Liver Disease (Child-Pugh B)|
16376208|NCT04145596|Active Comparator|healthy volunteers（Normal liver functions）|
16376209|NCT04145583|Experimental|HSK3486|0.4 mg/kg
16376210|NCT04145583|Experimental|voriconazole , HSK3486|400 or 200 mg; 0.4 mg/kg
16376211|NCT04145570|Experimental|Erlotinib HCl 150 mg|Crossover
16376212|NCT04145570|Active Comparator|Tarceva® 150 mg|Crossover
16376213|NCT04145557|Placebo Comparator|skaling root planing|
16376214|NCT04145557|Active Comparator|skaling root planing and diode laser|
16376215|NCT04145544|Experimental|Treatment arm|"Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.
~Post operation the subject will stay at the hospital according to site standards and physician discretion."
16376216|NCT04145544|Active Comparator|Control|"Same procedure as for the treatment arm but using a commercial suturable dural substitute.
~Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use."
16376218|NCT04145518|Active Comparator|Naproxen/Placebo Crossover|"Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill. Randomization with a block size only known by the statistician, will be programmed to be allocated out of REDcap.
~Our clinical research pharmacy will provide naproxen and an identical looking placebo in containers with codes only known to the statistician to provide a double-blinded experimental design.
~On a subsequent episode of menstrual pain (1-2 months later), participants will receive the opposite treatment and undergo the exact same assessments."
16376219|NCT04145518|Placebo Comparator|Placebo/Naproxen Crossover|Participants will receive placebo first in this arm.
16376220|NCT04145492|Active Comparator|Vitamin K2 group|15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.
16376221|NCT04145492|Active Comparator|Cholecalciferol group|15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.
16376222|NCT04145492|Active Comparator|Vitamin K2 and Cholecalciferol group|15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.
16376223|NCT04145492|No Intervention|Control group|15 patients will take the standard therapy.
16376224|NCT04145479|Experimental|low-resistance|women will perform low-resistance physical activity
16376225|NCT04145479|Experimental|aerobic|women will perform aerobic physical activity
16376226|NCT04145466|Experimental|Fat responders (1)|receiving high-fat diet
16376227|NCT04145466|Experimental|Carbohydrate responders (1)|receiving high-fat diet
16376228|NCT04145466|Experimental|Fat responders (2)|receiving high-carbohydrate diet
16376229|NCT04145466|Experimental|Carbohydrate responders (2)|receiving high-carbohydrate diet
16376233|NCT04145440|Experimental|MOR202|9 doses of MOR202 will be administered as an intravenous infusion over 6 treatment cycles at 28-days each. Dosing occurs weekly in cycle 1 (C1) and every four weeks in cycles 2-6.
16376234|NCT04145427|Experimental|Low Carbohydrate Diet|This arm will be randomized to low carbohydrate diet
16376235|NCT04145427|Active Comparator|Standard Dietary Advice Control Group|This arm will be randomized to control diet
16376236|NCT04145414|Experimental|Cerebral magnetic resonance imaging x2|Cerebral MRI performed at enrolment visit and at +6 weeks (maximum)
16376321|NCT04144894|Other|Vascular Surgery Subjects|
16378615|NCT04129281|Other|Surgery|Surgery
16376240|NCT04145375|Experimental|Experimental: ZEN003694 in Combination with Enzalutamide|Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
16376243|NCT04145336|Active Comparator|5cm PDS group|All patients in this group receive 5cm 5-Fr PDS.
16376244|NCT04145336|Experimental|7cm PDS group|All patients in this group receive 7cm 5-Fr PDS.
16376245|NCT04145323|Experimental|ICG microangiography for necrotic tissue determination|During flap procedure, the study area of the patient will be imaged with a white light digital camera prior to a 5 mg dose of ICG as per FDA approved protocol for use of SPY device in microangiography. Following ICG injection, the study area will undergo fluorescence imaging using the SPY system to obtain microangiography perfusion data (baseline imaging - Standard of Care). During the standard postoperative evaluation (approximately 4 hours after baseline) and 24 hours after baseline, the study area will undergo repeat digital photography and fluorescence imaging using SPY for necrosis avid detection of ICG (Research only session). This evaluation with digital photography and fluorescence imaging will continue every 24 hours for the first 3 days after surgery or one day prior to discharge(Research only session).
16376246|NCT04145310|Experimental|Arm A|
16376247|NCT04145310|Placebo Comparator|Arm B|
16376248|NCT04145297|Experimental|Treatment: all patients|"Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily.
~Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level. Both medications will be administered in 28-day cycles"
16376249|NCT04145258|Other|WHO TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
16376250|NCT04145258|Other|WHO TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
16376251|NCT04145258|Other|Intensified TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
16376252|NCT04145258|Other|Intensified TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
16376253|NCT04145245|Experimental|Intervention or group a|Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation
16376254|NCT04145245|Placebo Comparator|Placebo or group b|Diabetic neuropathy patients with antidiabetic treatment in addition with placebo
16376255|NCT04145232||NSCLC|This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).
16376256|NCT04145219|Experimental|Active treatment|HDM SLIT-tablet plus allergy and asthma rescue medication
16376257|NCT04145219|Placebo Comparator|Placebo|Placebo oral tablet plus allergy and asthma rescue medication
16376258|NCT04145206||experimental group|the experimental group is characterized by the practice of flamenco dance
16376259|NCT04145206||control group|not practice of flamenco dance
16376260|NCT04145193|Active Comparator|Control Arm (mFOLFOX6)|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
16376261|NCT04145193|Experimental|Durvalumab|Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
16376262|NCT04145193|Experimental|Oleclumab|Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
16376263|NCT04145193|Experimental|Monalizumab|Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
16376264|NCT04145180|Experimental|Manual Therapy|Manual Therapy-based intervention
16376265|NCT04145180|No Intervention|Control|Patients waiting list
16376266|NCT04145167||Medical Treatment|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication.
16376267|NCT04145167||Percutaneous intervention|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team.
16376268|NCT04145167||Surgical treatment|This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision.
16376269|NCT04145154|Experimental|Plasma|Subjects to whom platelet rich plasma is applied
16376270|NCT04145154|No Intervention|Advanced cure|Subjects to whom advanced healing is performed
16376271|NCT04145141||1/ Cohort 1|Subjects with a diagnosis or suspicion of PLC
16376272|NCT04145128|Experimental|AG-881|Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.
16376274|NCT04145102|No Intervention|negative control|restoration will applied without any treatment
16376275|NCT04145102|Experimental|hesperidine|hesperidine will be applied for remaining caries then restoration will be applied
16376322|NCT04144881|Experimental|coronary computed tomography|
16376276|NCT04145102|Experimental|propolis|propolis will be applied for remaining caries then restoration will be applied
16376277|NCT04145102|Experimental|silver diamine fluoride|silver diamine fluoride will be applied for remaining caries then restoration will be applied
16376278|NCT04145089|Active Comparator|C-Mac intubation|Intubation with C-MAC video laryngoscopy
16376279|NCT04145089|Active Comparator|Glidescope intubation|Intubation with Glidescope video laryngoscopy
16376280|NCT04145076|Experimental|Placebo, Citalopram, Tianeptine|Dose order: Placebo, Citalopram, Tianeptine
16376281|NCT04145076|Experimental|Placebo, Tianeptine, Citalopram|Dose order: Placebo, Tianeptine, Citalopram
16376282|NCT04145076|Experimental|Citalopram, Placebo, Tianeptine|Dose order: Citalopram, Placebo, Tianeptine
16376283|NCT04145076|Experimental|Citalopram, Tianeptine, Placebo|Dose order: Citalopram, Tianeptine, Placebo
16376284|NCT04145076|Experimental|Tianeptine, Placebo, Citalopram|Dose order: Tianeptine, Placebo, Citalopram
16376285|NCT04145076|Experimental|Tianeptine, Citalopram, Placebo|Dose order: Tianeptine, Citalopram, Placebo
16376286|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent will be placed (usually the standard of care)
16376287|NCT04145063|Active Comparator|uncomplicated ureteroscopic lithotripsy without US|Following uncomplicated uretroscopic lithotripsy no uretric stent will be placed
16376288|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US-string|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent with an extraxtion string will be placed
16376289|NCT04145050|Experimental|Carbohydrate Dose: 0 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
16376290|NCT04145050|Experimental|Carbohydrate Dose: 30 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
16376291|NCT04145050|Experimental|Carbohydrate Dose: 60 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
16376292|NCT04145037|Experimental|Switch Stable|Switch-stable arm: Subjects who have undergone ERT ≥15 U/kg and ≤60 U/kg every other week (or equivalent; ie, any combination of infusions resulting in a total monthly ERT dose of >30 U/kg and <120 U/kg) for ≥24 consecutive months for Type 1 Gaucher disease at the time of Screening. Switch-stable subjects must discontinue ERT at least 2 weeks before the scheduled transplant day. Switch-stable subjects who have been on ERT and substrate reduction therapy (SRT) must not have received SRT within 12 months of Screening.
16376293|NCT04145037|Experimental|Treatment-naïve|Treatment-naïve arm: Subjects with Type 1 Gaucher disease who have never received either ERT or SRT for Gaucher disease or have not received either ERT or SRT for Gaucher disease within 12 months of Screening (ie, treatment-naïve subjects). Enrollment will follow a similar scheme as for the switch-stable subjects.
16376294|NCT04145024||Pulmonary arterial hypertension|Group 1 PH
16376295|NCT04145024||Pulmonary hypertension due to left heart disease|Group 2 PH
16376296|NCT04145024||Pulmonary hypertension due to lung disease|Group 3 PH
16376297|NCT04145024||Chronic thromboembolic pulmonary hypertension|Group 4 PH
16376298|NCT04145024||Miscellaneous|Group 5 PH
16376299|NCT04145024||Exclusion PH|Patient with invasively excluded PH
16376300|NCT04145011|Experimental|COOLIEF Cooled Radiofrequency Probe|Cooled radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
16376301|NCT04145011|Active Comparator|Conventional (Standard) Radiofrequency Probe|Standard (non-cooled) radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
16376302|NCT04144985|Active Comparator|Eyelid Speculum|Eyelid retraction was performed with an eyelid speculum.
16376303|NCT04144985|Experimental|Cotton Tipped Applicator|Eyelid retraction was performed with the cotton tipped applicator eyelid retraction technique.
16376304|NCT04144985|Experimental|Unimanual Eyelid Retraction|Eyelid retraction was performed with the unimanual eyelid retraction method.
16376305|NCT04144972|Active Comparator|Active DBS|Chronic brain recordings and stimulation with bilateral implantations in pain-related brain regions. All participants will participate in active DBS, blinded to the participant.
16376306|NCT04144972|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. brain recordings will remain active during this period. All participants will participate in inactive DBS, blinded to the participant.
16376307|NCT04144959||Patients with lower extremity acute limb ischemia|
16376308|NCT04144946||Healthy control group (CTRL)|Sports active individuals with no history of patellar tendinopathy.
16376309|NCT04144946||Early tendinopathy group (ET)|Sports active individuals with clinical signs of early tendinopathy and debut of symptoms within 90 days.
16376310|NCT04144946||Chronic tendinopathy group (CT)|Sports active individuals with clinical signs of tendinopathy and duration of symptoms >90 days.
16376311|NCT04144933|Experimental|Opioid-free General Anesthesia (OFA)|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis.
16376312|NCT04144933|Active Comparator|Traditional Opioid-containing General Anesthesia (TOA)|Opioid-sparing preoperative medications, Opioid-containing pre-intubation medications, Opioid-containing maintenance medications, postoperative nausea and vomiting prophylaxis.
16376313|NCT04144920|Other|Block 1|Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
16376314|NCT04144920|Other|Block 2|Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
16376315|NCT04144920|Other|Block 3|Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
16376316|NCT04144920|Other|Block 4|Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
16376317|NCT04144920|Other|Block 5|Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
16376318|NCT04144920|Other|Block 6|Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
16376319|NCT04144907|Experimental|Phenylalanine intake|
16376323|NCT04144881|No Intervention|conservative (ischemia-guided) management|
16376324|NCT04144868|Experimental|Experimental: NBO group|"For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours.
~Regular treatment is based on associated guidelines for ICH ."
16376325|NCT04144868|No Intervention|Control group|"Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours.
~Regular treatment is based on associated guidelines for ICH ."
16376326|NCT04144855|Experimental|TQB3474 injection|Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
16376327|NCT04144842|Experimental|ATOR-1017|ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent
16376328|NCT04144829|Active Comparator|HIFU|3 cycles of HIFU treatment in 6-week intervals
16376329|NCT04144829|Active Comparator|Fibrin|3 cycles of platelet-rich fibrin injection treatment in 6-week intervals
16376330|NCT04144816||Passive Birth Cohort|"This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.
~Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon."
16376331|NCT04144803||Cerebral desaturation group|absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
16376332|NCT04144803||Control group|no absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
16376333|NCT04144790||ADHD+RLS|Twelve participants between the ages of 5 and 18 years with a clinical diagnosis of either RLS or ADHD, and iron deficiency.
16376334|NCT04144777|Experimental|Treatment|Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
16376335|NCT04144777|No Intervention|Placebo|Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
16376336|NCT04144764|Experimental|Workplace-based exercise group|
16376337|NCT04144764|Sham Comparator|Control group|
16376338|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
16376339|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
16376340|NCT04144725||Suspected coronary artery disease|Patients hospitalized for suspected acute coronary syndrome who are referred to CCTA or patients referred to CCTA from outpatient clinics for evaluation of stable coronary artery disease.
16376341|NCT04144712|Experimental|High Dose arm|subjects will receive the high dose of the drug
16376342|NCT04144712|Active Comparator|low dose arm|subject will receive low dose of the drug
16376343|NCT04144699||Wheezing 3~11months|Patient has wheezing, age 3 to 11 months
16376344|NCT04144699||Wheezing 12~23months|Patient has wheezing, age 12 to 23 months
16376345|NCT04144699||Wheezing 24~35months|Patient has wheezing, age 24 to 35 months
16376346|NCT04144699||Wheezing 36~107months|Patient has wheezing, age 36 to 107 months
16376347|NCT04144699||No wheezing 3~11months|Patient do not have wheezing, age 3 to 11 months
16376348|NCT04144699||No wheezing 12~23months|Patient do not have wheezing, age 12 to 23 months
16376349|NCT04144699||No wheezing 24~35months|Patient do not have wheezing, age 24 to 35 months
16376350|NCT04144699||No wheezing 36~107months|Patient do not have wheezing, age 36 to 107 months
16376351|NCT04144686|Active Comparator|Group A|Vestibular participants undertaking a single-task vestibular rehabilitation
16376352|NCT04144686|Experimental|Group B|Vestibular participants undertaking a dual-task vestibular rehabilitation
16376353|NCT04144673|Experimental|Investigational Product|
16376354|NCT04144673|Placebo Comparator|Placebo|
16376355|NCT04144660||Cardiogenic Shock Treated with ECMO|This cohort of participants required clinical intervention with ECMO for treatment of their index cardiogenic shock episode while pregnant or post delivery of their infant.
16376356|NCT04144647|Experimental|Healthy adults 18-80 years old|Healthy adults 18-80 years old
16376357|NCT04144634|Experimental|Intervention/Strengthening|
16376358|NCT04144634|Sham Comparator|Control/Stretching|
16376359|NCT04144621||Normal SDF|Couples with male partners having SDF lower than 20% using TUNEL assay
16376360|NCT04144621||Abnormal SDF|Couples with male partners having SDF greater than 20% using TUNEL assay
16376361|NCT04144608|Experimental|Toripalimab Combined With Platinum-containing Dual-agent|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
16376362|NCT04144595||Low plasma glucose|This group will be formed by women with low plasma glucose: fasting plasma glucose (<10th percentile, <65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.
16376363|NCT04144595||Normal plasma glucose|This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but < 92 mg/dL), 1 or 2-hour normal glucose (< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.
16376364|NCT04144582|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer
16376365|NCT04144569|Experimental|PD-1 Combined With Pyrotinib|PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
16376366|NCT04144556|Experimental|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
16387138|NCT04070222||Cesarean scar group|
16376367|NCT04144556|Active Comparator|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
16376368|NCT04144543|Experimental|White Noise|"The white noise used in our study is a fragment called Bebeğiniz ağlamasın-2 from Kolik album of Buzuki Orhan Osman, which was used in similar studies (Balci, 2006; Karakoc & Turker, 2014; Kucukoglu et al., 2016).Since the white noise is a continuously monotonous sound, which is in the form of a hum, it resembles the sounds in mother's womb (Balci, 2006)."
16376369|NCT04144543|Experimental|Facilitated Tucking|Facilitated tucking is the procedure of holding the baby's arms and legs in a flexed position close to the midline of the torso, and the baby is able to move his/her extremities during this procedure (Caglayan, 2011).
16376370|NCT04144543|Experimental|White Noise+Facilitated Tucking|Both applications performed together.
16376372|NCT04144504|Active Comparator|Plastic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given balloon dilatation and plastic stenting for treatment.
16376373|NCT04144504|Active Comparator|Retrievable metallic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given retrievable metallic stenting for treatment.
16376374|NCT04144491|Experimental|Yoghurt|Yoghurt, containing Lactobacillus rhamnosus yoba 2012, Streptococcus thermophilus C104, whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence.
16376375|NCT04144491|Placebo Comparator|Custard|Custard, containing whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence, 4% modified corn starch.
16376376|NCT04144478|Experimental|experimental|Web based education intervention
16376377|NCT04144478|No Intervention|No intervention|Normal polyclinics application
16376378|NCT04144465|Active Comparator|NORADRENALIN|NORADRENALINE INFUSION
16376379|NCT04144465|Active Comparator|PHENYLEPHRINE|PHENYLEPHRINE INFUSION
16376380|NCT04144452|Active Comparator|Patient Education Session|Educational session will be given twice a day for three months. Individualized instructional booklet about back care for each patient will be designed, reviewed and finalized by operating surgeons according to the needs of patients.
16376381|NCT04144452|Experimental|Therapeutic exercises plus educational sessions|Trunk and lower musculature strength and endurance training will be performed twice a week for three months. Therapeutic exercises incorporating mat exercises will be performed. Progression will be made according to patient status.
16376382|NCT04144439|No Intervention|Before treatment|no intervention
16376383|NCT04144439|Active Comparator|After treatment|GABA
16376384|NCT04144426|Experimental|Normal diet then modified diet|Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM. Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.
16376385|NCT04144426|Experimental|Modified diet then normal diet.|Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM.
16376386|NCT04144413|Experimental|Period 1 Open-label Ikervis|Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
16376387|NCT04144413|Experimental|Period 2 Masked Ikervis|"Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.
~IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
16376388|NCT04144413|Other|Period 2 Masked Vehicle|"Other: Vehicle Comparator. Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.
~Vehicle. Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
16376389|NCT04144400|Experimental|BRAVE Group|The BRAVE program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of quiet ego characteristics. The BRAVE intervention (delivered over four weeks) will ask study participants to use the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
16376390|NCT04144400|Active Comparator|Time Management Group|The time management program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of time management characteristics. The time management intervention (delivered over four weeks) will ask study participants to use the time management version of the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
16376391|NCT04144387|Experimental|Test group|Each patient included in the study will be followed for 5 years
16376392|NCT04144374|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 5 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
16376393|NCT04144374|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
16376394|NCT04144361|Experimental|sleeve without plication|sleeve gastrectomy on bougie 36 without plication
16376395|NCT04144361|Active Comparator|sleeve with plication|sleeve gastrectomy on bougie 42 without plication
16376396|NCT04144348|Experimental|mRNA-1653, Adult participants|Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
16376397|NCT04144348|Experimental|mRNA-1653 Pediatric participants|Participants will receive 1 of 3 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
16376398|NCT04144348|Placebo Comparator|Placebo, Adult participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
16376399|NCT04144348|Placebo Comparator|Placebo, Pediatric participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
16376400|NCT04144335|Active Comparator|Group 1: N-803 and bNAbs Only|Group 1 will receive only N-803 and the bNAbs; they will not receive the haNK™ cells
16376401|NCT04144335|Experimental|Group 2: N-803 and bNAbs with haNK™ Cells|The protocol for Group 2 will be identical to the one followed by Group 1, except that they will receive haNK™ cells on the same day as each dose of N-803.
16376402|NCT04144322|Other|Short Implant|17 patients will receive a 5 mm short implant.
16376403|NCT04144322|Other|Long Implant|17 patients will receive a sinus lift procedure, bone graft, and 10 mm implant.
16376404|NCT04144309|Active Comparator|True acupuncture group|12 sessions of acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
16376405|NCT04144309|Placebo Comparator|Sham acupuncture group|12 sessions of sham acupuncture treatment (SE+SA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
16376406|NCT04144296|Other|Study Arm|All patient will be included in this arm
16376407|NCT04144283|Experimental|NAP|The NAP group will undergo a post-learning 2-hour sleep opportunity in Experiment 1.
16376408|NCT04144283|Active Comparator|WAKE|The WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness in Experiment 1.
16376409|NCT04144270||Included patients|One-arm study. All included patients will have muscle mass and muscle function evaluated
16376410|NCT04144257|Experimental|Subjects diagnosed with Multiple Sclerosis (MS)|We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).
16376411|NCT04144244|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips will be used when preparing sperm of male partner and IUI will be made with separated sperm
16376412|NCT04144244|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and IUI will be made with separated sperm
16376413|NCT04144231|No Intervention|Treatment-as-usual (TAU)|Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.
16376414|NCT04144231|Experimental|Internet-Based Cognitive Behavioral Therapy for Insomnia|"TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks.
~HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
~During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes."
16376415|NCT04144231|Experimental|Cognitive Behavioral Group Therapy for Insomnia|TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.
16376416|NCT04144218|Placebo Comparator|Control group|
16376417|NCT04144218|Experimental|Experimental group|
16376418|NCT04144205|Experimental|Fraction of inspired oxygen setting change|
16376419|NCT04144192|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
16376420|NCT04144192|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
16376421|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 1|1 injection of Quadrivalent RIV containing H3 strain 1
16376422|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 2|1 injection of Quadrivalent RIV containing H3 strain 2
16376423|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 3|1 injection of Quadrivalent RIV containing H3 strain 3
16376424|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 4|1 injection of Quadrivalent RIV containing H3 strain 4
16376425|NCT04144179|Active Comparator|Quadrivalent RIV Control|1 injection of Quadrivalent RIV containing 2018-19 NH recommended H3 strain
16376426|NCT04144153|Experimental|Opioid Free Anesthesia Group|
16376427|NCT04144153|Active Comparator|Opioid Anesthesia Group|
16407329|NCT03927443|Experimental|Test|
16376430|NCT04144127|Experimental|Soccer Group|Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week). They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics). During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
16376431|NCT04144127|Active Comparator|mHealth Education Group|"The mHealth education group receive brochures on the American Heart Association (AHA) Life's Simple 7 and encouraged to visit the AHA's My Life Check website for customized lifestyle recommendations. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
~Participants will be offered (for free) 4 sessions of recreational soccer instruction on the basics of the program."
16376432|NCT04144114|Experimental|Whey + ProHydrolase®|Subjects received 250mg of ProHydrolase® along with 25g of whey protein mixed in a drink every visit for 4 weeks
16376433|NCT04144114|Active Comparator|Whey|Subjects received 25g whey protein in a drink every visit for 4 weeks
16376434|NCT04144114|Placebo Comparator|Placebo|Subjects received 25g maltodextrin in a drink every visit for 4 weeks
16376435|NCT04144101|Experimental|Etoricoxib|Etoricoxib 60 mg QD
16376436|NCT04144101|Experimental|Aceclofenac|Aceclofenac 100 mg BID
16376437|NCT04144088|Active Comparator|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
16376438|NCT04144088|Active Comparator|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
16376439|NCT04144088|Placebo Comparator|Placebo|Drug : 1/10 Wu Ling San
16376440|NCT04144075|Experimental|Mindful Self-Compassion|Protocolized training program in mindfulness and self-compassion skills.
16376441|NCT04144075|Active Comparator|Cognitive Behaviour Therapy Group|A control intervention designed to develop a control group suitable for comparison with experimental groups receiving interventions based on mindfulness and compassion.
16376442|NCT04144075|Placebo Comparator|Treatment as Usual|Es variable según las características clínicas y personales del paciente.
16376443|NCT04144062|Active Comparator|Zirconia crowns|
16376444|NCT04144062|Active Comparator|CAD/CAM crowns|
16376445|NCT04144049|Experimental|MT921|1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
16376446|NCT04144049|Placebo Comparator|Placebo|Subcutaneously administered at most 50 injections per treatment.
16376447|NCT04144036|Experimental|Neihulizumab Dose Escalation, 3 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
16376448|NCT04144036|Experimental|Neihulizumab Dose Escalation, 6 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
16376449|NCT04144036|Experimental|Neihulizumab Dose Escalation, 9 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
16376450|NCT04144036|Experimental|Neihulizumab Dose Expansion|Upon determination of the maximum-tolerated dose, an expansion cohort of 4-7 patients will be enrolled so that a total of 10 patients are enrolled at the potential Phase II dose. This will be done to preliminarily assess efficacy.
16376451|NCT04144023|Experimental|Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)|Prior to standard of care surgery, patients receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16376452|NCT04143997||PPCM with Diastolic Dysfunction & Normal Systolic Function|The patient population examined will include patients diagnosed with peripartum cardiomyopathy who have diastolic dysfunction and normal systolic function.
16376453|NCT04143984|Active Comparator|Arm-C|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE).
16376454|NCT04143984|Experimental|Arm-CC|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy and camrelizumab. In details, patients will receive carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE); in addition, patients will also receive camrelizumab of 200 mg (IV.), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year.
16376455|NCT04143971|Placebo Comparator|Continiuous Low calorie diets|Low calorie diet with daily calorie restriction
16376456|NCT04143971|Active Comparator|Intermittent Fasting|Intermittent fasting every other day, in which daily calorie intake will be up to 30% of required calorie.
16376457|NCT04143958|Experimental|agalsidase beta|Commercially available agalsidase beta treatment at approved dose and regimen;administered once every 2 weeks as an IV infusion
16376458|NCT04143958|Active Comparator|agalsidase alfa|Commercially available agalsidase alfa treatment at approved dose and regimen; administered once every 2 weeks as an IV infusion
16376459|NCT04143945|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
16376460|NCT04143945|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
16376461|NCT04143919|Experimental|Subjects with CV risk factors|Subjects with 2 or more CV risk factors will be identified. Cardiovascular risk factors include hypertension, dyslipidemia, obesity, vascular disease, diabetes mellitus, chronic kidney disease, arrhythmia requiring therapy, moderate to severe valvular disease, history of alcohol abuse, smoking, cancer chemotherapy, or thoracic radiotherapy, and abnormal findings in the most recent ECG or thoracic X-ray.
16376462|NCT04143906|Experimental|Vinorelbine/Carboplatin|Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
16376463|NCT04143906|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
16376464|NCT04143893||Cardiogenic shock with MCS|Patients with cardiogenic shock who underwent MCS
16376465|NCT04143893||Cardiogenic shock without MCS|Patients with cardiogenic shock who did not undergo MCS
16376466|NCT04143880|Experimental|experimental group|Progesterone
16376467|NCT04143880|Placebo Comparator|control grou|saline
16376468|NCT04143867|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
16376469|NCT04143854|Experimental|MBA-P01 24U|Experimental group; Dose: 24U
16376470|NCT04143854|Experimental|MBA-P01 12U|Experimental group; Dose: 12U
16376471|NCT04143854|Placebo Comparator|Placebo|Placebo group; normal saline
16376472|NCT04143841|Active Comparator|Single treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
16376473|NCT04143841|Sham Comparator|Single sham treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
16376474|NCT04143828|Experimental|Mobile Mindfulness Programme|The mobile mindfulness program is delivered via a mobile application.
16376475|NCT04143828|No Intervention|Wait-list control condition|When assigned to the control condition, participants will be wait-listed for 3 months during the study. After the final assessment participants will receive access to the mobile mindfulness program.
16376476|NCT04143815|Experimental|MBA-P01 30U|Experimental group, Dose: 30U
16376477|NCT04143815|Experimental|MBA-P01 20U|Experimental group, Dose: 20U
16376478|NCT04143815|Experimental|MBA-P01 10U|Experimental group, Dose: 10U
16376479|NCT04143815|Placebo Comparator|Placebo|Placebo group, Normal saline
16376480|NCT04143802|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
16376481|NCT04143802|Active Comparator|Dulaglutide|Dulaglutide administered SC
16376482|NCT04143802|Placebo Comparator|Placebo|Placebo administered SC
16376483|NCT04143789|Experimental|Tablets to be taken orally daily for 14 of 21 day cycle|AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days
16376484|NCT04143763|Active Comparator|Intervention group|receive mobile messages supporting caregivers' psychological well-being, according to the participants' preferences in intervention group.
16376485|NCT04143763|No Intervention|Control group|receive general health information through a mobile message.
16376486|NCT04143750|Experimental|[14C]Vicagrel|
16376487|NCT04143737|Other|Intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
16376488|NCT04143737|No Intervention|Control|22 women participated in the control group. They were recruited from a community center in the old city of Jerusalem and did not receive any intervention. Baseline data was collected.
16376489|NCT04143724|Experimental|Cohort 1: 12 to < 18 years - Luspatercept 0.75 mg/kg|Luspatercept 0.75 mg/kg, administered SC once every 21 days (for up to 4 cycles)
16376490|NCT04143724|Experimental|Cohort 2: 12 to < 18 years: Luspatercept 1.0 mg/kg,|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
16376491|NCT04143724|Experimental|Cohort 3 (Expansion Cohort): 12 to <18 years|Luspatercept administered SC once every 21 days (for up to 12 months)
16376492|NCT04143724|Experimental|Cohort 4: 6 to < 12 years: Luspatercept 1.0 mg/kg|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
16376493|NCT04143724|Experimental|Cohort 5: 6 to <12 years: Luspatercept 1.25 mg/kg|Luspatercept 1.25 mg/kg, administered SC once every 21 days (for up to 4 cycles)
16376494|NCT04143711|Experimental|Monotherapy DF1001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
16376495|NCT04143711|Experimental|Monotherapy DF1001 PK/PD Expansion|Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
16376496|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Urothelial Bladder Cancer|Monotherapy expansion cohort enrolling up to 40 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
16376497|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer|Monotherapy expansion cohort enrolling up to 50 patients with metastatic breast cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
16376498|NCT04143711|Experimental|Monotherapy DF1001 Expansion in HER-2 High Expressing Cancers|Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented high levels HER-2 expression using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
16376499|NCT04143711|Experimental|Combination Therapy with DF1001 and nivolumab|Combination dose escalation of DF1001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.
16376500|NCT04143711|Experimental|Combination Therapy with DF1001 and Nab paclitaxel|Combination dose escalation of DF1001 in combination with a PD-L1 checkpoint inhibitor in patients with select solid tumors.
16376501|NCT04143698|Active Comparator|Disposable (single-use) duodenoscope|This group will be using the disposable (single-use) duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
16376502|NCT04143698|Active Comparator|Reusable duodenoscope|This group will be using the reusable duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
16376503|NCT04143685|Active Comparator|misoprostol|misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six
16376504|NCT04143685|Active Comparator|oxytocin|Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)
16376505|NCT04143672|Experimental|study group|"The following tests will be performed on the study subjects.
~Pain catastrophizing scale
~Hospital Anxiety and Depression scale-Anxiety Subscale (HADS-A)
~Pain sensitivity questionnaire
~Pain pressure threshold using electronic digital pressure algometer"
16376506|NCT04143659|Experimental|LB injection 40mg intramuscular (IM) with 20 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg intramuscular (IM) using 20 mg/ml concentration
16376507|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SC) with 20 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 20 mg/ml concentration
16376508|NCT04143659|Experimental|LB injection 80mg intramuscular (IM) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 80mg intramuscular (IM) using 70 mg/ml concentration
16376509|NCT04143659|Experimental|LB injection 80mg Subcutaneous (SC) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 80mg subcutaneous (SC) using 70 mg/ml concentration
16376510|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SC) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 70 mg/ml concentration
16376511|NCT04143646|Active Comparator|Web-based prevention program|"Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts.
~In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure."
16376512|NCT04143646|No Intervention|Usual Care|Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).
16376513|NCT04143633|Experimental|FODMAP diet in Irritable Bowel Syndrome|Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
16376514|NCT04143633|Experimental|FODMAP diet in Ulcerative Colitis|Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
16376515|NCT04143633|Active Comparator|FODMAP diet in healthy patients|Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
16376516|NCT04143620|Other|Neovascular glaucoma|Neovascular glaucoma patients underwent triple procedure
16376517|NCT04143607|Experimental|ASK120067+ placebo Gefitinib|ASK120067 (160 mg or 80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
16376518|NCT04143607|Active Comparator|Gefitinib + placebo ASK120067|Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (160 mg or 80 mg orally, twice daily), in accordance with the randomization schedule. Following objective disease progression according to RECIST1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label ASK120067 (crossover to active ASK120067).
16376716|NCT04142294|Experimental|12 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 12 g/day
16376523|NCT04143581|Experimental|IMP|
16376524|NCT04143568||Control|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
16376525|NCT04143568||Periodontitis|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
16376526|NCT04143555||endoscopic submucosal injection of indocyanine green|
16376527|NCT04143542|Experimental|Groups Q|"In abdominal surgeries, USG guided Quadratus Lumborum 2 blocks are performed for postoperative analgesia. For this purpose, Quadratus Lumborum Block 2 (QLB 2) are frequently used blocks.
~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
16376528|NCT04143542|Experimental|Groups T|"In abdominal surgeries, USG guided TAP blocks are performed for postoperative analgesia. For this purpose, TAP blocks are frequently used blocks.
~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
16376529|NCT04143542|No Intervention|Groups C|There was no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg, and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with the target of EtCO2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC). Anesthesia will be discontinued and tracheal extubation will be done once the patient fulfills the extubation criteria.Tramadol 100 mg i.v. Before 15 min end of surgery. The patient control analgesia device will administer all patients.
16376530|NCT04143529|Experimental|Personalized acceptance-based mindfulness exercise|The purpose of this study is to identify whether a brief 60-second acceptance based mindfulness intervention at specific time points will reduce state trait anxiety, Mini-Mental Adjustment to Cancer Scale score, pain intensity, distress, anxiety, depression and anger
16376531|NCT04143529|Placebo Comparator|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 second at specific timepoints.
16376532|NCT04143516|Experimental|Patients with Colon Cancer Liver Metastases|The standard of care thermal ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.
16376533|NCT04143503||adult critically ill patients|
16376534|NCT04143490|Experimental|UC Patients|Patient group
16376535|NCT04143490|Active Comparator|Healthy controls|Control group
16376536|NCT04143477|Experimental|Peficitinib dose-A|Participants will receive a single dose of A under fasted condition Day 1, followed by multiple doses of A under fed condition once daily in the morning from Day 8 till Day 13.
16376537|NCT04143477|Experimental|Peficitinib dose-B|Participants will receive a single dose of B under fasted condition Day 1, followed by multiple doses of B under fed condition once daily in the morning from Day 8 till Day 13.
16376538|NCT04143477|Experimental|Peficitinib dose-C|Participants will receive a single dose of C under fasted condition Day 1, followed by multiple doses of C under fed condition once daily in the morning from Day 8 till Day 13.
16376539|NCT04143464|Experimental|Intervention group|"The participants in this group will receive group kyphosis-specific exercise classes given by the certified physical trainer and kyphosis-specific exercise videos.
~The intervention arrangement is:
~Group learning and practice: a 1-hour kyphosis-specific exercise training session will be provided two times in the first week,
~Weekly follow-up: a 1-hour kyphosis-specific exercise will be conducted with reinforcement of learning and remedial teaching by a certified physical trainer once a week for five consecutive weeks after the group learning and practice,
~Self-practice: the participant will following the kyphosis-specific exercise videos doing self-practice every day for the whole intervention period lasting six weeks."
16376540|NCT04143464|No Intervention|Control group|No special arrangement
16376541|NCT04143451|Active Comparator|IQ|"Year 1: a single dose ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream
~Year 2: randomised into 3 subgroups. Group IQ1: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream Group IQ2: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IQ3: ID normal saline vaccination with pre-treatment of the injected skin with imiquimod (Aldara) cream.
~Year 3: IQ1 and IQ2 same treatment as second year. IQ3 same as first year."
16376542|NCT04143451|Active Comparator|IM|"Year 1: a single dose IM QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream
~Year 2: randomised into 3 subgroups. Group IM1: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IM2: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream. Group IM3: IM normal saline vaccination with aqueous cream pretreatment.
~Year 3: IM1 and IM2 same treatment as second year. IM3 same as first year."
16376543|NCT04143451|Active Comparator|HD|"Year 1: a single high-dose IM TIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream
~Year 2: Group HD1: IM QIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream. Group HD2: IM normal saline vaccination with aqueous cream pretreatment.
~Year 3: Group HD1 same treatment as second year. HD2 same as first year."
16376544|NCT04143438|Experimental|Undergoing EOS 3D imaging|Patients with patello-femoral instability will undergo EOS 3D Imaging protocol before and after undergoing corrective surgery
16376545|NCT04143425||Received bevacizumab treatment|Recurrent glioblastoma patients with received anti-angiogenic treatment
16376546|NCT04143412|Active Comparator|Tritace (Ramipril)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks
16376547|NCT04143412|Active Comparator|Eraloner (Eplerenone)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks
16376548|NCT04143412|Active Comparator|Tritace/Eraloner (Ramipril/Eplerenone)combination therapy|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks
16376549|NCT04143399|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
16376550|NCT04143399|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
16376551|NCT04143373|Experimental|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
16376552|NCT04143373|No Intervention|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
16376553|NCT04143360|Experimental|New Closed Drainage Device|We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.
16376554|NCT04143360|Experimental|Traditional Closed Drainage Device|We use traditional closed drainage devices for patients with hemothorax and pneumothorax.
16376555|NCT04143347||Community Hospitals - CH|Patients with head injury managed at Community Hospitals
16376556|NCT04143347||Level 1 Trauma Center - L1TC|Patients with head injury presenting to level 1 trauma center directly
16376557|NCT04143347||Transfer|Patients with head injury presenting at a community hospital but then getting transferred to the level 1 trauma center
16376558|NCT04143334||RAAB survey|We will examine 3700 Chaonan County residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (PPS). The cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes Visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined.
16376559|NCT04143334||conventional survey|All the recruited participants underwent ophthalmic examination according to the RAAB protocol and then 60% of them were re-examined with instruments in a mobile eye clinic set up in a village center on the same day. Examination in the mobile clinic included standardized visual acuity (VA) tests using logarithm of the minimum angle resolution charts, refraction, slit-lamp biomicroscopy, and dilated fundal examination with a binocular indirect ophthalmoscope.
16376560|NCT04143321|Experimental|empagliflozin|following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
16376561|NCT04143321|Placebo Comparator|No drug|following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done
16376562|NCT04143308|Experimental|Simultaneous training of walking and cognitive group|"Wearable technology (fitness wristband & App)
~SWATCH system (App & controller)
~3 times a week (30 mins/ each time)
~Lasts for 12 weeks
~Simultaneous walking and cognitive training"
16376563|NCT04143308|Active Comparator|Cognitive training group|"Wearable technology (fitness wristband & App)
~SWATCH system (App)
~3 times a week (30 mins/ each time)
~Lasts for 12 weeks
~Cognitive training while sitting"
16376564|NCT04143308|Active Comparator|Treatment as usual group|1. Keep treatment as usual group at health care system.
16376565|NCT04143282|Experimental|Metformin group|Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy
16376566|NCT04143282|Other|control group|Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only
16376567|NCT04143269|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the GammaCore device (ElectroCore LLC)
16376568|NCT04143269|Sham Comparator|Sham Treatment|Inactive sham vagus nerve stimulation applied by the GammaCore sham device (ElectroCore LLC)
16376569|NCT04143256|Experimental|Group I|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
16376570|NCT04143256|Experimental|Group II|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
16376571|NCT04143256|Experimental|Group III|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
16376572|NCT04143256|Experimental|Group IV|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
16376573|NCT04143256|Experimental|Group V|Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
16376574|NCT04143256|Experimental|Group VI|Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
16376575|NCT04143243|Active Comparator|ACT on Life|"Acceptance and Commitment Therapy plus Education, Resources and Support ('ACT on Life').
~The ACT+ERS intervention will include: 1) Acceptance and Mindfulness Training (2-3 hours); 2) Committed Action Training (2-3 hours) involving helping Veterans clarify what matters most to them and what they want to stand for in life, how they want to behave, and what sorts of strengths and qualities they want to develop; and; 3) Education, Resources, and Support (1 hour)."
16376576|NCT04143243|Placebo Comparator|Education, Resources, and Support|Information provided in the ERS workshop was compiled from existing VHA and community resources. Veterans will be educated about 1) symptoms of depression, anxiety and PTSD and how these conditions do and do not impact daily life and functional ability; 2) common difficulties and challenges with reintegration into civilian life; 3) mild TBI, differences between civilian and Veteran TBIs, shared/crossover symptoms (for example, memory and concentration difficulties, sleep disturbance, irritability can be symptoms of depression, PTSD, and mild TBI); 4) chronic pain; how it is often often misinterpreted as on-going damage, leading to fear of physical activities and resulting in increased sedentary behavior and declines in physical functioning; and 5) treatment options and resources. Basic resource counseling will include guidance on the evidence-based treatments available at VHA. Problem solving, relaxation, and deep breathing techniques will be covered
16378253|NCT04131621|Experimental|Nivolumab/Ipilimumab|
16376577|NCT04143230|Active Comparator|Extended Screening Tool (EST)|The SIAARTI/NCCN (EST) screening tool is, in fact, an instrument validated by many scientific societies, but it is very articulated and its compilation is too much time-consuming.
16376578|NCT04143230|Experimental|Simplified Screening Tool (SST)|The Simplified Screening Tool (SST) has been created through a statistical process in order to include all the critical variables, with the advantage of being shorter and therefore easier to administer in a routinely use.
16376579|NCT04143217|Experimental|Open-Label Treatment|SPN-812 Open-Label Treatment 200mg to 600mg SPN-812 once daily for up to 156 weeks
16376580|NCT04143204||very preterm infants cohort|A prospective cohort of very preterm or very low birth weight infants from birth to corrected age 18 months.
16376581|NCT04143191|Active Comparator|Sorafenib|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
16376582|NCT04143191|Experimental|Sorafenib plus TACE|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.
16376583|NCT04143178|Experimental|Expressive Writing Group|Writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the disease, the transplant, and their best expectations after the operation.
16376584|NCT04143178|Other|Control Group|The control group participant has been asked to describe an objects in their room, in a neutral way, without mentioning emotions or feelings,for 3 consecutive days, 20 minutes each day.
16376585|NCT04143165|Active Comparator|Epidural block|Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
16376586|NCT04143165|No Intervention|control group|patients did not receive injection
16376587|NCT04143152||Diagnostic/prognostic cohort|Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.
16376588|NCT04143152||Surveillance Cohort|Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma
16376589|NCT04143126|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.
~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
16376590|NCT04143126|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
~Time commitment: about 2 hours per week; Location: Pittsburgh, PA only"
16376591|NCT04143113|No Intervention|Usual Care (n=20)|Control: general information about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
16376592|NCT04143113|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
16376593|NCT04143087||Withdrawal TKIs|
16376594|NCT04143087||halve TKIs|
16376595|NCT04143074|Other|intervention|multidisciplinary intervention arm - behavioral intervention by physician, dietician, psychologist and physical activity trainer
16376596|NCT04143061|Experimental|Group 1|MenACYW conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
16376597|NCT04143061|Active Comparator|Group 2|Menactra® conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
16376598|NCT04143061|Experimental|Group 3|MenACYW conjugate vaccine, 1 vaccination, adults in India aged ≥ 56 years
16376599|NCT04143061|Active Comparator|Group 4|Quadri Meningo™, 1 vaccination, adults in India aged ≥ 56 years
16376600|NCT04143061|Experimental|Group 5|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in India aged 2 to 17 years
16376601|NCT04143061|Active Comparator|Group 6|Menactra®, 1 vaccination, children and adolescents in India aged 2 to 17 years
16376602|NCT04143061|Experimental|Group 7|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
16376603|NCT04143061|Active Comparator|Group 8|Menactra®, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
16376604|NCT04143048||The construction of Gene detection technology flow|At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
16376605|NCT04143048||Establishment of non-invasive gene testing technology process|In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
16376630|NCT04142866|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
16376606|NCT04143048||Prospective cohort (double-blind recommended)|Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
16376607|NCT04143022|Active Comparator|group A (acupuncture press needle)|Group A subjects first receive acupuncture press needle treatment at acupoint of Jin's 3-tongue point and EX-HN25. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
16376608|NCT04143022|Active Comparator|group B (acupuncture press needle)|Group B subjects first receive acupuncture press needle treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of Jin's 3-tongue point and EX-HN25. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
16376609|NCT04143009|Experimental|Adapted Friendship Bench (AFB)|35 women seeking ANC services at Mitundu Clinic in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Adapted Friendship Bench intervention from date of enrollment through 6 months post-partum.
16376610|NCT04143009|Experimental|Enhanced Friendship Bench (EFB)|35 women seeking ANC services at Lumbadzi Clinic in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Enhanced Friendship Bench intervention from date of enrollment through 6 months post-partum.
16376611|NCT04143009|Active Comparator|Enhanced Standard Care (ESC)|35 women seeking ANC services at Nathenje Clinic will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will received the Enhanced Standard Care intervention from date of enrollment through 6 months post-partum.
16376612|NCT04142996|Active Comparator|Unilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
16376613|NCT04142996|Active Comparator|Bilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
16376614|NCT04142996|Active Comparator|Maintenance Phase: Fixed|The fixed protocol will consist of two sessions per week for the first month, followed by a weekly TBS session for two months, biweekly sessions for two months and a monthly session for the last month (total of 21 sessions over 6 months).
16376615|NCT04142996|Active Comparator|Maintenance Phase: Flexible|The flexible maintenance protocol will be based on symptom emergence. Participants will receive a fixed TBS (2x/week) schedule for the first month. For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.
16376616|NCT04142983|Experimental|Study Group|Participants will receive a single dose of Tdap vaccine (Adacel) every 3 months for a total of 5 immunizations over a period of 12 months.
16376617|NCT04142970|Active Comparator|Mild renal impairment|Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)
16376618|NCT04142970|Active Comparator|Moderate renal impairment|Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)
16376619|NCT04142970|Active Comparator|Subjects with normal renal functions|Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)
16376620|NCT04142957||Focus Groups|"The investigators will invite 13-15 participants to attend the focus groups, of which it is expected that 10-12 to attend. Participants will be asked to bring a smart phone. An Informed Consent Form will be signed by the participant and a delegated researcher before the focus groups begin.
~The current generation of COPD Pal will be downloaded onto the participants' own smart phones (see Appendix 1 for current screenshots of app), participants will then be explained the purpose of the app, and asked to interact with it for 15-60 minutes, as required.
~A semi-structured focus group will then be conducted with the participants to facilitate conversation and discussion regarding COPD Pal. Once introductions have been completed, questions will be asked relating to the usability and acceptability of COPD Pal (see the Interview Schedule, Appendix 2). The focus group will last 30-60 minutes, as required."
16376621|NCT04142944|Experimental|Dexcom G6 with predictive hypo alert|
16376622|NCT04142944|Active Comparator|Dexcom G6 without predictive hypo alert|
16376623|NCT04142931|Active Comparator|filtration of 2X PV|filtration of 2X PV through the ImmunicomAIAC
16376624|NCT04142931|Active Comparator|filtration of 2X PV combined with Nivolumab 240mg|filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
16376625|NCT04142905||Patients With Asthma|Subjects with sleep disordered breathing with asthma
16376626|NCT04142905||Patients Without Asthma|Subjects with sleep disordered breathing without asthma
16376627|NCT04142892|Experimental|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD). 3 weeks of (+/-3 days) of ONA treatment
16376628|NCT04142879||Non-Interventional Centers|"Cohort A: Viz Subjects Initially Presenting to a Non-Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a non- interventional center.
~Cohort B: Subjects Initially Presenting to a Non-Interventional Center The standard of care group will be comprised of subjects randomized to not have Viz notification and who initially present to a non-interventional center."
16376629|NCT04142879||Interventional Centers|"Cohort C: Viz Subjects Initially Presenting to an Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a interventional center.
~Cohort D: Subjects Initially Presenting to a Interventional Center The standard of group will be comprised of subjects randomized to not have Viz notification and who initially present to an interventional center."
16376692|NCT04142424|Experimental|Cohort 4 healthy subjects: AZD2693 Dose 4|Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376631|NCT04142866|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
16376632|NCT04142853|Experimental|Persons with MS, dance group|
16376633|NCT04142853|Active Comparator|Persons with MS, art group|
16376634|NCT04142840|Experimental|Dexmedetomidine Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.
~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the dexmedetomidine group will be infused with a single dose of 0.7ug/kg dexmedetomidine."
16376635|NCT04142840|Active Comparator|Propofol Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.
~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the propofol group will be infused with a single dose of 0.5mg/kg propofol."
16376636|NCT04142827|Experimental|Therapy with high flow humidification|The patients will be activated after enrollment with myAirvo2 device at home for 6 months before first observations
16376637|NCT04142827|No Intervention|Therapy with usual care|The patients will be under usual care for observational
16376638|NCT04142814|Experimental|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.
~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).
~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.
~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.
~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
16376639|NCT04142814|Active Comparator|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.
~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).
~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.
~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.
~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
16376640|NCT04142801|Experimental|MeMo group|MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
16376641|NCT04142801|Placebo Comparator|Control group|Regular follow up at the memory center without cognitive training
16376642|NCT04142788|No Intervention|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
16376643|NCT04142788|Experimental|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
16376644|NCT04142775||intracranial hemorrhage (ICH)|ARDS patients treated with ECMO developing ICH
16376645|NCT04142775||no intracranial hemorrhage|ARDS patients treated with ECMO not developing ICH
16376646|NCT04142762|Experimental|Cohort 1: ABI-H2158 + Itraconazole|Oral ABI-H2158 on Days 1 and 9; oral itraconazole once-daily (QD) on Days 6 through 13
16376647|NCT04142762|Experimental|Cohort 2: ABI-H2158 + Rifampin|Oral ABI-H2158 on Days 1 and 12; oral rifampin QD on Days 6 through 16
16376648|NCT04142762|Experimental|Cohort 3: ABI-H2158 + Esomeprazole|Oral ABI-H2158 on Days 1 and 11; oral esomeprazole QD on Days 6 through 11
16376649|NCT04142762|Experimental|Cohort 4: ABI-H2158 + Midazolam|Oral midazolam on Days 1 and 11; oral ABI-H2158 QD on Days 2 through 11
16376650|NCT04142762|Experimental|Cohort 5: ABI-H2158 + Oral Contraceptive|Cycle 1: active oral contraceptive (ethinyl estradiol/levonorgestrel) QD on Days 1 through 21 and oral placebo QD on Days 22 through 28; Cycle 2: active oral contraceptive QD on Days 1 through 21, oral placebo QD on Days 22 through 26, and oral ABI-H2158 QD on Days 11 through 24
16376651|NCT04142749|Active Comparator|Oltipraz|Oltipraz 30mg
16376652|NCT04142749|Placebo Comparator|Placebo|Placebo 30mg
16376653|NCT04142736|Experimental|Prone position|Patients with acute hypoxemic respiratory failure from any cause
16376654|NCT04142736|No Intervention|Supine position|Patients with acute hypoxemic respiratory failure from any cause
16376655|NCT04142710|Experimental|Follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements.
16376656|NCT04142710|No Intervention|Standard clinical care|Participants in this arm receive standard clinical care in accordance with their medinal needs.
16376715|NCT04142294|Experimental|8 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 8 g/day
16376657|NCT04142710|Experimental|Non-randomized follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements. This arm is not randomized, but otherwise identical to the randomized experimental arm.
16376658|NCT04142697|Active Comparator|Healthy subjects|
16376659|NCT04142697|Active Comparator|Vestibular Disease patients|
16376660|NCT04142671|Experimental|Individualised Gait Modification Intervention|"Patients will carry out several walking trials to test the efficacy of an individualised gait modification intervention.
~Pre-intervention over ground walking, pre-intervention treadmill walking, intervention treadmill walking with real-time biofeedback on their knee loading, intervention treadmill walking with no feedback, and post-intervention over ground walking."
16376661|NCT04142658|Experimental|Apixaban|Apixaban 5 mg twice daily(BID) or 2.5 mg BID
16376662|NCT04142658|Active Comparator|Warfarin|Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)
16376663|NCT04142645|Experimental|Intervention|The intervention group (i.e. all eligible and consented residents of 2 NHs) will receive the OptiMEDs intervention: the combination of an electronic decision support tool (for the appraisal of potentially inappropriate medication use, anticholinergic use, or medications that can be de-prescribed in view of limited life expectancy) with focused nurse observations (using a list of potential medication-related symptoms based on the individual medication chart of the nursing home residents), that will serve as the basis during a multidisciplinary medication review with the input of GPs, trained community pharmacists and nurses.
16376664|NCT04142645|No Intervention|Control|The control group (i.e. all eligible and consented residents of one control NH) will receive usual care .
16376665|NCT04142632||long term evaluation of hypospadias surgery|
16376667|NCT04142606||Control Group (Group 1)|Having prenatal ultrasound screening without detected abnormality
16376668|NCT04142606||Non Optimal Ultrasound Scan Group (Group 2)|Having an ultrasound examination without abnormality detected but in whom ultrasound examination is not optimal (poor technical conditions, multiple pregnancies, obese patients)
16376669|NCT04142606||Malformation Group (Group 3)|Standardized prenatal screening with ultrasound examination finding an isolated anomaly that does not currently constitute a commonly accepted indication of fetal MRI
16376670|NCT04142606||TOP Group (Group 4)|A medical termination of pregnancy, (TOP), in addition to a fetopathological examination (virtopsy)
16376671|NCT04142554|Experimental|Single Arm: Parsaclisib ( Dose De-Escalation )|Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days.
16376672|NCT04142541|Experimental|Carotid artery stenting with Neuroguard IEP System|To evaluate the safety and feasibility of the Neuroguard IEP System when used in patients with clinically significant carotid artery stenosis requiring revascularization.
16376673|NCT04142528||Parkinson's Disease|Smartwatch-based sensor assessment of PD symptoms during standard care
16376674|NCT04142502|Active Comparator|Propofol group|Using propofol as a sedation drug Infusion rate control Effect site concentration 0.3~1.0 mg/ml using target concentration infusion Bispectral index 60~80
16376675|NCT04142502|Active Comparator|Dexmedetomidine group|Using dexmedetomidine as a sedation drug First 10 minutes 1.0 mcg/kg loading After 10 minutes 0.3-1.0 mcg/kg/hr maintenance Bispectral index 60~80
16376676|NCT04142489|Other|UV and biopsy|"Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= 6.4 photoproducts, and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure."
16376677|NCT04142476|Experimental|Pharmaceutical Interview|Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
16376678|NCT04142463|No Intervention|Before-group|This arm comprises patients who are recruited in phase 3 of the study, i.e. before the implementation of the care pathway. It is intended that patients included in phase 3 serve as a control-group for patients included in phase 6.
16376679|NCT04142463|Experimental|After-group|This arm comprises patients who are recruited in phase 6 of the study, i.e. after the implementation of the care pathway.
16376680|NCT04142450|Experimental|CoolSculpting® System|Participants underwent a single CoolSculpting® treatment session on Day 1 that was comprised of timed segments of cooling followed by 2 minutes of manual massage. Each treated arm had up to two timed segments (or cycles) in the treatment session, each treated thigh had one timed segment (or cycle) in the treatment session.
16376681|NCT04142437||GI|adult patients with gastrointestinal (GI) cancer
16376682|NCT04142437||H&N|adult patients with head and neck (H&N) cancer
16376683|NCT04142437||STS|adult patients with soft tissue sarcoma (STS)
16376684|NCT04142437||CNS|adult patients with primary central nervous system (CNS) cancer
16376685|NCT04142437||Lung|adult patients with lung cancer
16376686|NCT04142437||Melanoma|adult patients with melanoma
16376687|NCT04142437||Pediatric|all pediatric patients regardless of tumor type will be enrolled under this cohort
16376688|NCT04142437||other|patients with other tumor types
16376689|NCT04142424|Experimental|Cohort 1 healthy subjects: AZD2693 Dose 1|Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376690|NCT04142424|Experimental|Cohort 2 healthy subjects: AZD2693 Dose 2|Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376691|NCT04142424|Experimental|Cohort 3 healthy subjects: AZD2693 Dose 3|Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1.
16378616|NCT04129281|No Intervention|Active surveillance|Follow up
16376693|NCT04142424|Experimental|Cohort 5 healthy subjects: AZD2693 Dose 5|Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376694|NCT04142424|Experimental|Cohort 6 healthy subjects: AZD2693 Dose 6|Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376695|NCT04142424|Experimental|Cohort 7 healthy Japanese subjects: AZD2693 Dose 7|Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376696|NCT04142424|Experimental|Cohort 8 healthy Japanese subjects: AZD2693 Dose 8|Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376697|NCT04142424|Experimental|Cohort 9 healthy Chinese subjects: AZD2693 Dose 9|Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1.
16376698|NCT04142411|Experimental|Insulin and Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin and 20 mg of Sodium Hyaluronate
16376699|NCT04142411|Active Comparator|Insulin Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin
16376700|NCT04142411|Active Comparator|Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 20 mg of Sodium Hyaluronate
16376703|NCT04142359||Cohort A: CIS (either study)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
16376704|NCT04142359||Cohort B: High-Grade Ta/T1 Papillary Disease (either study)|Patients with histologically confirmed presence of BCG-unresponsive high-grade Ta/T1 papillary disease
16376705|NCT04142359||Cohort C: CIS (QUILT-3.032)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
16376706|NCT04142346|No Intervention|Uninterrupted sitting|Participants remained seated throughout 7 hours. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
16376707|NCT04142346|Experimental|Sitting + moderate intensity breaks|Participants were instructed to sit throughout 7 hours, while interrupting the sitting position every 30 minutes to perform 2 minutes of moderate-intensity physical activity. The breaks consisted of walk up and down stairs and squats. Each person performed these exercise alternately. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
16376708|NCT04142333|Other|GIA Access|All patients consented to this study will be given access to the GIA technology to share with their family members.
16376709|NCT04142320|Experimental|Closed-loop rTMS|Closed-loop rTMS will be delivered to determine the target engagement compared to open-loop rTMS. Closed loop rTMS will be applied for two consecutive days for 30 minutes to determine dose response. Closed- loop rTMS will be delivered using neuro-navigation based on participants' own MRI images. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
16376710|NCT04142320|Active Comparator|Open-loop rTMS|A series of open-loop rTMS protocols will be delivered to determine the most effective standard and individualized rTMS. Active rTMS will be delivered using neuro-navigation based on participants' own MRI images. For each clinically-utilized rTMS protocol (1Hz, 5Hz, 10Hz, 20Hz), 3000 pulses will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
16376711|NCT04142320|Placebo Comparator|Sham rTMS|Sham rTMS will be delivered for two consecutive sessions to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
16376712|NCT04142307|Active Comparator|Group A (treatment)|Each session includes 20 minutes of training each with rest as needed. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. A fixation training target (FTT) will be selected by the trainer at a perceived better fixation point. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look in the direction of the FTT and listen simultaneously to the audio feedback. As performing this task, the participant will actively control the eye movements until the audio feedback becomes more frequent and then becomes a continuous sound pattern. This continuous sound will signalize to the patient that the FTT location was reached. Participants will be given take-home efficiency reading exercises.
16376713|NCT04142307|Sham Comparator|Group B (control)|"The simulated biofeedback training for Group B involves the following procedure:
~For four weeks, presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button. Participants will be given take-home efficiency reading exercises."
16376714|NCT04142294|Experimental|4 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 4 g/day.
16379554|NCT04122443|Active Comparator|Acetaminophen|Acetaminophen alone
16376717|NCT04142294|Experimental|16 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 16 g/day. The 16 g /day dose will be administered if no adverse effects are observed for doses 4-12 g/day
16376718|NCT04142268||Preeclampsia group|PE was defined as diastolic BP of at least 110 mmHg on one occasion or diastolic BP of at least 90 mmHg on two consecutive occasions more than 4 hours apart, in combination with proteinuria (≥300 mg total protein in a 24-hour urine collection and, if this was not available, ≥+2 proteinuria by dipstick analysis on two consecutive occasions at least 4 hours apart) that develops after 20 weeks of gestation in previously normotensive women
16376719|NCT04142268||Control group|Normal pregnancy group
16376720|NCT04142255|Experimental|FMT|20 subjects will be enrolled in this arm to receive FMT treatment.
16376721|NCT04142242|Experimental|Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MEQ00066).
16376722|NCT04142242|Experimental|Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single IM dose of MenACYW Conjugate vaccine at Day 0 in the present study (MEQ00066).
16376723|NCT04142242|Experimental|Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
16376724|NCT04142242|Experimental|Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
16376725|NCT04142242|Other|Group 5: Menomune-primed Participants (MET44)|Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
16376726|NCT04142242|Other|Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
16376727|NCT04142229|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
16376728|NCT04142229|Active Comparator|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
16376729|NCT04142216|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
16376730|NCT04142216|No Intervention|Control group|The patients will not chewing gum during three months.
16376731|NCT04142203||23 h surgery|Adult patients who were treated in 23 h surgical unit
16376732|NCT04142190||ELONVA|Patients stimulated with Elonva
16376733|NCT04142190||PUREGON|Patients stimulated with Puregon
16376740|NCT04142164|Active Comparator|MacInfo presentation|MacInfo presentation prior to intravitreal drug injection
16376741|NCT04142164|Placebo Comparator|Placebo presentation|Placebo presentation prior to intravitreal drug injection
16379652|NCT04121663|Active Comparator|Polyether ether ketone bone anchor|
16376742|NCT04142151|Active Comparator|SanchiTongshu group|"Drug: SanchiTongshu The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
~Drug: Aspirin or Clopidogrel"
16376743|NCT04142151|Placebo Comparator|SanchiTongshu Placebo group|"Drug: placebo of Sanchitongshu The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
~Drug: Aspirin or Clopidogrel"
16376744|NCT04142138|Experimental|nutrition implementation|Volunteers with prehypertension, but otherwise healthy, will complete a screening visit, then be admitted to the In-Patient Unit for fourteen (14) days. Participants will be admitted for 5 days during the week and then go on pass for 2 weekend days each week with packed DASH diet meals. During hospitalization we will: 1) collect samples of blood and urine daily 2) monitor blood pressure, weight and pulse twice daily 3) collect 24-hour urine, twice during the period of two weeks 4) serve participants a menu based on DASH principles, namely low in sodium and high in potassium.
16376745|NCT04142125|Experimental|Experimental (riva + ASA)|Rivaroxaban 2.5mg bid + aspirin 81mg qd
16376746|NCT04142125|Active Comparator|Control (ASA alone)|Aspirin 81 mg qd
16376747|NCT04142112|Experimental|Ohana IVF Sperm Preparation Kit|Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.
16376748|NCT04142112|Active Comparator|Standard IVF Preparation Kit|Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.
16376749|NCT04142099|Experimental|skin to skin contact 60 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.
~Observe the time of newborn spent in suctioning the maternal nipple in 60 minutes of skin to skin contact.
~No intervention or forced neonatal suction."
16376750|NCT04142099|Active Comparator|skin to skin contact 20 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.
~Observe the time of newborn spent in suctioning the maternal nipple in 20 minutes of skin to skin contact.
~No intervention or forced neonatal suction."
16376751|NCT04142086|Experimental|Group 1|1 injection of vYF vaccine Dosage 1
16376752|NCT04142086|Experimental|Group 2|1 injection of vYF vaccine Dosage 2
16376753|NCT04142086|Experimental|Group 3|1 injection of vYF vaccine Dosage 3
16376754|NCT04142086|Active Comparator|Group 4|1 injection of YF-VAX
16376755|NCT04142073||Children under 18 years of age|
16376756|NCT04142060|Experimental|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously
16376757|NCT04142047||HIV|Participants (ages 60 and above) with HIV
16376758|NCT04142047||Control|Participants (ages 60 and above) without HIV
16376761|NCT04142021||patients with 3-vessel disease with or without left main|Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
16376762|NCT04142008|Experimental|Walk with Me app|
16376763|NCT04141995|Experimental|Treatment|Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.
16376764|NCT04141982||Suspected of having TB infection|These donors are suspected of having TB infection and live in a high endemic area for TB infection
16376765|NCT04141982||No (or minimal) TB risk factors|These donors must have no previous medical record of TB infection and live in low endemic area for TB infection
16376766|NCT04141982||low/intermediate risk of TB infection population|These donors must live in an low/intermediate endemic area for TB infection
16376767|NCT04141969|Active Comparator|RLP|ReaLife+
16376768|NCT04141969|Placebo Comparator|Inert|Inert brown powder to look similar to RLP
16376769|NCT04141969|No Intervention|Control|Not given RLP or the placebo
16376770|NCT04141943|Experimental|VR|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality
16376771|NCT04141943|No Intervention|Printed document|The patients who are allocated to the Printed document arm will receive information about radiotherapy via printed document.
16376772|NCT04141930|Other|Study Drug Eligible|Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant
16376773|NCT04141917|No Intervention|Standard influenza surveillance|Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
16376774|NCT04141917|Active Comparator|Point-of-care molecular testing and treatment of influenza|Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A & B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .
16376775|NCT04141904|Experimental|Tofacitinib|Tofacitinib 5mg capsule twice a day for 7-10 days
16376776|NCT04141904|Placebo Comparator|Placebo|Placebo capsule twice a day for 7-10 days
16376777|NCT04141891|Experimental|Driving Decision Aid|Web-based Driving Decision Aid
16376778|NCT04141891|Active Comparator|Older Drivers Website|National Institute on Aging (NIA) Older Drivers website
16376873|NCT04141189|Active Comparator|bi-weekly (twice-weekly)|bi-weekly fetal surveillance
16376874|NCT04141176|Experimental|Spiri+|new CPAP device
16376779|NCT04141878|Active Comparator|Aerobic Exercise Group|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.
16376780|NCT04141878|Active Comparator|Diet Skills Group|Participants will attend weekly classes focused on incorporating heart healthy foods (e.g., fruits and vegetables) into their existing dietary plan. We will ask them to limit the number of calories they take in and will show them how to use portion control with the goal of losing body weight. Participants will also learn hands-on skills for preparing healthy meals at home in cooking classes led by professional chefs.
16376781|NCT04141865||Xen|Patients treated with a Xen microstent for glaucoma.
16376782|NCT04141865||Aqueous shunt|Patients treated with an aqueous shunt for glaucoma.
16376783|NCT04141852|Experimental|AVF surgery with device|
16376784|NCT04141852|No Intervention|AVF surgery conventional|
16376785|NCT04141839|Other|Control|Delayed intervention: baseline and 3-month assessment prior to receiving the Safer Bars training.
16376786|NCT04141839|Experimental|Intervention|This arm with consist of bars randomized to have the Safer Bars training on their premises attended by all their liquor serving staff with assessment directly before and after training (pre/post), and at 3 and 6 months post-training follow-up.
16376787|NCT04141826|Experimental|Hydrolysed whey|Hydrolysed whey
16376788|NCT04141826|Active Comparator|Intact whey|Intact whey
16376789|NCT04141826|Placebo Comparator|Caseinate|Caseinate
16376790|NCT04141813||"Pilgrims doing the Camino de Santiago (any route)"|"In the present study we utilized the Ultreya dataset. The Ultreya study is an online longitudinal study aimed at evaluating the effects of the pilgrimage on the Way of Saint James on mental health and wellbeing (www.estudiocamino.org). This pilgrimage involves hundreds of paths around Europe with a common termination at Santiago de Compostela (Spain), and it was one of the most important Christian pilgrimages during the Middle Ages. Currently, it is walked by thousands of people (>300,000 per year)."
16376791|NCT04141800||Heart failure (HF) outpatients with reduced ejection fraction|"Heart Failure (HF) with reduced ejection fraction (REF): Patients with confirmed diagnosis of HF and with ejection fraction<40%.
~Hyperkalaemia: K+values> 5,4 mEq/L.
~Optimal doses: the maximum doses of renin-angiotensin-aldosterone related drugs that, according to the physician's judgement, the patient can receive. If any of these drugs (ACIEs, ARB-II, MRAs or sacubitril-valsartan) is de novointroducedat the initial visit, optimal doses will be not considered established.
~A previous personal history of diseases and/or outcomes will be registered according to the usual practice of every centre."
16376792|NCT04141787|Active Comparator|Ceftriaxone|Ceftriaxone 2g IV q24hvia Gravity (or q12h in the case of CNS infections) Duration dependent on site of infection, determined by treating infectious diseases (ID) clinicians based on accepted clinical guidelines.
16376793|NCT04141787|Active Comparator|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Usual Antibiotics to treat methicillin-susceptible Staphylococcal infections
~Cloxacillin 2g IV q4h via Pump (dose adjusted for renal function)
~Cefazolin 2g IV q8h via Preloaded Syringe (dose adjusted for renal function)
~Daptomycin 6-10mg/kg IV daily via Gravity (dose will be determined based on the severity of infection as per discretion of the ID clinician and in accordance with most recent evidence)
~Duration dependent on site of infection, determined by treating infectious diseases clinicians based on accepted clinical guidelines."
16376796|NCT04141761|Experimental|Treatment Group|
16376797|NCT04141761|Placebo Comparator|Placebo Group|
16376798|NCT04141748|Active Comparator|Hand Casting|hand cast will be taken using a circumferential plaster of Paris or fiber glass wrap of the residual limb with the subject in a seated position
16376799|NCT04141748|Active Comparator|standing hydrostatic pressure casting with a water cylinder|hand cast will be taken using a circumferential plaster of Paris wrap of the residual limb with the subject in a seated position. The residual limb is then placed into the Symphonie Aqua System while in a weight bearing standing position.
16376800|NCT04141735||patients from September 2016 to September 2018|all patients underwent allogeneic hematopoietic stem cell transplantation
16376801|NCT04141722|Experimental|Sleep|
16376802|NCT04141722|Experimental|Wake|
16376803|NCT04141709|Experimental|local ablative radiotherapy|The therapy is performed for all patients in the intervention arm using high-dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy.
16376804|NCT04141709|No Intervention|Observational group|"Effectiveness is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml).
~There is a 2:1 randomization between intervention and observation group."
16376805|NCT04141696|Experimental|Ketamine|Given intravenously over 40 minutes
16376806|NCT04141696|Active Comparator|Midazolam (Placebo)|Given intravenously over 40 minutes
16376807|NCT04141670|Experimental|Low dose group|Experimental: Low dose group Group of three participants who are treated with a low dose of S48168 (ARM210) for 28 days.
16376808|NCT04141670|Experimental|High dose group|Experimental: High dose group Group of seven participants who are treated with a high dose of S48168 (ARM210) for 28 days.
16376809|NCT04141657||Group 1 (0-17 years)|We will observe the treatment course in ICU pediatric patients, register adverse events (AEs) and serious adverse events (SAEs) if occur, and assess patient health status at the end of the performed therapy.
16376877|NCT04141150|Experimental|[18F]APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
16376810|NCT04141644|Experimental|Treatment: all patients|Patients entering trial should be on stable dose of osi for ≥4 weeks. Patients will self-administer osi by mouth regardless of food once daily. Doses should be taken at about the same time every day (±6hrs) and recorded on the patient dosing diary. Doses missed outside of the dosing window should not be made up but patients should be instructed to take their next dose at their regularly scheduled time. Ipi will be administered at the assigned dose level every 21 days (±3days) for a max of 4 doses. Ipi must be infused using a volumetric pump over 90min (±10min) through an IV line. Upon completion of the ipilimumab regimen, patients will continue osimertinib daily until disease progression, initiation of new anti-cancer therapy, or death by any cause.
16376811|NCT04141631|Experimental|STOP Group|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if
~Hb < 12g/dL the day before surgery
~Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay
~Postoperative Transfusion will be guided by ScvO2 values :
~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb < 7g/dL independently of ScVO2 value"
16376812|NCT04141631|No Intervention|Control Group|"Only postoperative anemia will be managed:
~RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)
~Iron sucrose administration if Hb > 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg."
16376813|NCT04141605||SherpaPak CTS Patients|Patients whose donor heart was transported with the SherpaPak CTS
16376814|NCT04141605||Standard Transport Patients|Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
16376815|NCT04141592||Healthy Control|non-obese individuals without fatty liver disease
16376816|NCT04141592||Non-alcoholic fatty liver disease without NASH|
16376817|NCT04141592||Non-alcoholic steatohepatitis|
16376818|NCT04141592||Obese without non-alcoholic fatty liver disease|
16376819|NCT04141579|Experimental|Treatment arm|Evolocumab (140mg) will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of 140 mg/mL Evolocumab.
16376820|NCT04141579|Placebo Comparator|Comparator arm|Placebo will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of placebo.
16376821|NCT04141566||PCPC|pseudocontinent perineal colostomy using shmidt technique for perineal reconstruction after abdominoperineal resection
16376822|NCT04141566||PLIC|Permanenet left iliac colostomy , the standard technique after abdominoperineal resection and primary closure of the perineal wound
16376823|NCT04141553|Active Comparator|Diltiazem IV push|In the standard IV push group, diltiazem will be administered at a dose of 0.25 mg/kg, to a max dose of 25 mg, over 2 minutes. At time 0, these participants will also receive 30 mg of immediate release oral diltiazem. After 15 minutes, if adequate rate control of <110 BPM has not been achieved, an additional dose 0.35 mg/kg to a max dose of 35 mg will be administered. In order to maintain the blind, the control group will also receive 50 mL of 0.9% NS IV over 20 minutes.
16376824|NCT04141553|Active Comparator|Diltiazem IV Slow Infusion|In the slow infusion group, 50 mg of diltiazem will be diluted in 50 mL of 0.9% NS and infused over 20 minutes. Similar the other group, these participants will also receive 30 mg of immediate release oral diltiazem. In order to maintain the blind, this slow infusion group will receive the equivalent volume of IV 0.9% NS over 2 minutes as a placebo.
16376825|NCT04141540|Other|"Groupe Twin 1"|Twin 1 with psychotic symptoms (PANSS +) Molecular analyses 1
16376826|NCT04141540|Other|"Groupe Twin 2"|Twin 2 without psychotic symptoms (PANSS +) Molecular analyses 2
16376827|NCT04141527||Primiparous women|82 primiparous obstetrical patients given intrathecal sufentanil for labor pain.
16376828|NCT04141527||Multiparous women|82 multiparous obstetrical patients given intrathecal sufentanil for labor pain.
16376829|NCT04141514|Experimental|intervention group|therapeutic fasting
16376830|NCT04141514|No Intervention|control group|usual alimentation
16376831|NCT04141501|Placebo Comparator|Control: Placebo|30 Patients will receive placebo
16376832|NCT04141501|Active Comparator|Intervention: Psilocybin|30 Patients will receive psilocybin
16376833|NCT04141488|Experimental|Experimantel Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own. The experimantel group was given strengthening exercises of the upper trapezoidal, middle trapezoidal and serratus anterior muscles with extra scapula muscles.
16376834|NCT04141488|Other|Control Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
16376835|NCT04141475|Active Comparator|Alpha-Lipoic Acid group|
16376836|NCT04141475|Placebo Comparator|placebo group|
16376837|NCT04141462|Experimental|Patients with a a constitutional genetic alteration|one genetic consultation and one blood test
16376875|NCT04141163|Experimental|Metformin|Subjects randomized to metformin will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
16376876|NCT04141163|Placebo Comparator|Placebo|Subjects randomized to placebo will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
16376838|NCT04141449|Experimental|Potlako intervention|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation
~Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer
~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.
~Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program
~Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer."
16376839|NCT04141449|Active Comparator|Enhanced Care|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation.
~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer."
16376840|NCT04141436|Experimental|Intervention|Intervention Based on Hypnofertility
16376841|NCT04141436|Active Comparator|Control|Routine clinical procedure
16376842|NCT04141423|Active Comparator|Tregopil 30 mg|Dose level cohort with a sentinel dosing design
16376843|NCT04141423|Active Comparator|Tregopil 45 mg|Dose level cohort with a sentinel dosing design
16376844|NCT04141423|Active Comparator|Tregopil 60 mg|Dose level cohort with a sentinel dosing design
16376845|NCT04141423|Active Comparator|Derived Dose level|Derived Dose level cohort with a sentinel dosing design (60 mg fixed preprandial dose plus an additional 30 mg postprandial rescue dose, if required)
16376846|NCT04141397||POG patients|Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
16376847|NCT04141397||Usual care controls|Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
16376848|NCT04141384|Other|General rehabilitation+Modular Interactive Tiles System, MITS|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment. In the experimental group, external stimulation (MITS) was added, and the training time was 65 minutes. Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
16376849|NCT04141384|No Intervention|General rehabilitation|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment.In the control group, each training time was 45 minutes.Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
16376850|NCT04141371|Active Comparator|Molar Sodium Lactate|
16376851|NCT04141371|Placebo Comparator|physiological serum|
16376852|NCT04141358||Study group|Patients with end-stage renal disease who will undergo arteriovenous fistula (AVF) surgery will be recruited and follow-up them up to 6 weeks or until the AVF become suitable for hemodialysis.
16376853|NCT04141345||Heart failure with chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
16376854|NCT04141345||Heart failure without chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. HF patients who did not have chronic lung disease were assigned as a non-CLD group.
16376855|NCT04141332||Group 1|80 Patient
16376856|NCT04141332||Group 2|80 Control subject
16376857|NCT04141319|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
16376858|NCT04141319|Active Comparator|The control group|In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.
16376859|NCT04141293|Experimental|Eligible patients|
16376860|NCT04141280||Insomnia group|According to the inclusion and exclusion criteria, 150 patients with insomnia were selected, which were divided into five groups: liver stagnation fire syndrome, phlegm heat syndrome, yin deficiency fire dysfunction syndrome, heart spleen deficiency syndrome and heart deficiency biliary syndrome.
16376861|NCT04141280||Normal group|According to the inclusion and exclusion criteria, 30 normal people were selected.
16376862|NCT04141254|Experimental|Debriefing|"a standardized follow-up visit at one month associated with debriefing and enhanced educative component"
16376863|NCT04141254|Other|Without debriefing|"a standardized follow-up visit at one month alone (i.e.; without debriefing and educative component)"
16376864|NCT04141241|Experimental|Low Dose PH100: 800mg/day|"PH100 (Ecklonia cava Phlorotannin) 200mg/tablet
~PH100 2 tablets (400mg) and Placebo 2 tablets BID during 12wks"
16376865|NCT04141241|Experimental|High Dose PH100: 1600mg/day|- PH100 4 tablets (800mg) BID during 12wks
16376866|NCT04141241|Placebo Comparator|Placebo|"Placebo 200mg/tablet
~Placebo 4 tablets BID during 12wks"
16376867|NCT04141228||Patients receiving apixaban|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
16376868|NCT04141228||Patients receiving warfarin|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
16376869|NCT04141215|Experimental|BIOBank bone paste (PPT322)|Allogeneic bone paste derived from human living donor femoral heads
16376870|NCT04141215|Active Comparator|BIOBank cortico-cancellous bone powder (PPT6)|Allogeneic bone powder derived from human living donor femoral heads (used in current practice)
16376871|NCT04141202||Exercise group|
16376872|NCT04141189|Experimental|weekly|weekly fetal surveillance
16449433|NCT03639753|Other|Usual Practice|
16376878|NCT04141137|Experimental|TricValve® System Single-Arm|Two self-expanding biological valves for implantation into the inferior and superior vena cava.
16376879|NCT04141124|Sham Comparator|Control|5 minutes of reading fictitious biological medical results that are almost normal and unrelated to the upcoming scenario. This condition reflects a likely activity in relation to other patients in charge, pending an announced critical situation.
16376880|NCT04141124|Active Comparator|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
16376881|NCT04141124|Experimental|Breathing exercise combined with HRV|5 minutes of relaxing breathing, guided by a computer helping to follow inspiration and expiration and coupled with direct biological feedback on HRV.
16376882|NCT04141111|Experimental|CGM intervention|Underwent intervention defined by the intermittent use of a continuous glucose monitoring (CGM) device.
16376883|NCT04141098|Experimental|Total Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
16376884|NCT04141085||Healthy volunteers without infertility|Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
16376885|NCT04141085||Infertile Patients|Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
16376886|NCT04141059|Experimental|Oligopin|Intervention group that will intake 100 mg of Oligopin® for 6 weeks
16376887|NCT04141059|Placebo Comparator|Placebo|Placebo group that will intake 250 mg of Maltodextrin
16376888|NCT04141046|Sham Comparator|Sham Stimulation|This is a sham/placebo arm that receives some stimulation, mimicking the skin sensations associated with tACS to enhance success of patient blinding.
16376889|NCT04141046|Active Comparator|Theta-tACS|This arm targets theta oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
16376890|NCT04141046|Experimental|Alpha-tACS|This arm targets alpha oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
16376891|NCT04141033|Other|saliva neopterin levels|assessment of saliva neopterin levels in pre and post-menopausal women
16376892|NCT04141033|Other|GCF neopterin levels|assessment of GCF neopterin levels in pre and post-menopausal women
16376893|NCT04141020|Experimental|Microsurgical Clipping Treated with Sirolimus|Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.
16376894|NCT04141020|Experimental|Endovascular Treatment Treated with Sirolimus|Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.
16376895|NCT04140994|Active Comparator|Intermittent theta burst stimulation|"Volunteers will be submitted to non-invasive parietal stimulation before a mirror drawing task.
~A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver interrmittent bursts of bipolar magnetic pulses exerting an excitation on the underlying brain tissue (iTBS). The stimulation coil will be placed over the parietal cortex. Stimulation consisted of a burst of three pulses administered at 50Hz, repeated at a frequency of 5Hz, delivered in 2 s trains followed by an 8 s interval for a total of 600 pulses12. Stimulation intensity was set at 70% of RMT.
~Each session will consist of two spaced neuronavigated iTBS applications, separated by 15 minutes."
16376896|NCT04140994|Sham Comparator|Sham intermittent theta burst stimulation|For sham iTBS, the protocol is the same, except the sham coil produces no magnetic field.
16376897|NCT04140981||group 1|difficult intubation according to antropometric measurements
16376898|NCT04140981||group 2|not difficult intubation according to antropometric measurements
16376899|NCT04140981||group 3|difficult intubation according to ultrasound measurements
16376900|NCT04140981||group 4|not difficult intubation according to ultrasound measurements
16376901|NCT04140968|Experimental|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg)by mouth,every day in the second and third menstrual cycle daily from cycle day 15 to 26.
16376902|NCT04140955|Experimental|Tapering plan and telephone counselling|Patients receive an individually customized tapering plan at discharge and telephone counselling 5-7 days after discharge.
16376903|NCT04140955|No Intervention|Control group|Patients receive standard care and treatment, i.e. no tapering plan or telephone counselling.
16376904|NCT04140942|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual, participants will participate in Virtual Reality Job Interview Training.
16376905|NCT04140942|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but not limited to vocational skill training, and social skill training.
16376906|NCT04140929|Experimental|Intervention group|In the intervention group, a range of clinical parameters are recorded and the dentists prepares an individual oral hygiene and care recommendation, based on the Oral Health Tool Box. The Box is also used for instructing the dental assistants and the nursing staff for each patient individually. It is then determined when and how the dental assistants re-evaluates the oral hygiene and care process and reinstructs and remotivates the nursing staff. If the examination reveals a need for dental treatment (possibly requiring referral and transport), this will be communicated to the nursing staff. The dental assistant will further receive a training in communication, enabling them in reinstruction and remotivation. Dentists and dental assistants will further receive a training in geriatric dentistry by the State Commissioner of the German Society for Geriatric Dentistry.
16376907|NCT04140929|No Intervention|Control group|In the control group, the residents receive care as usual. This includes the recording of the same parameters are recorded as in intervention group, a standardized form is filled out and handed over to the nursing staff. As in the case of Intervention group, the nursing staff is informed in the event of a need for treatment. No further measures are applied.
16376908|NCT04140916|Experimental|Midline catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
16376993|NCT04140253|Active Comparator|Standard Duloxetine treatment|Peroral treatment with duloxetine at a dose of 40 mg twice a day
16376909|NCT04140916|Active Comparator|PICC-line catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
16376910|NCT04140903|Experimental|Oral antibiotics|Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
16376911|NCT04140903|Active Comparator|Standard treatment|Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
16376912|NCT04140890|Experimental|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
16376913|NCT04140890|Placebo Comparator|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last ~15 minutes. Control condition participants receive no further intervention.
16376914|NCT04140877|Other|Visu OD, Control OS|Contralateral eye study
16376915|NCT04140877|Other|Control OD, Visu OS|Contralateral eye study
16376916|NCT04140851|Experimental|overweight/obesity diet intervention group|Dietary fiber intervention
16376917|NCT04140851|Placebo Comparator|overweight/obese normal diet group|Normal diet
16376918|NCT04140851|No Intervention|healthy control group|Healthy people
16376919|NCT04140838|Experimental|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
16376920|NCT04140838|Experimental|TAU + Behavioral Activation Therapy for Depression (BATD)|Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.
16376921|NCT04140838|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
16376922|NCT04140825||Group 1|Subjects>=18 years old will measure as a minimum FOT and spirometry.
16376923|NCT04140812|Active Comparator|Term infants (≥37+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
16376924|NCT04140812|Experimental|Preterm infants (≤32+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
16376925|NCT04140786|Experimental|Daily IV Gentamicin|Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
16376926|NCT04140786|Experimental|Biweekly IV Gentamicin|Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
16376929|NCT04140760|Active Comparator|Probiotic|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.
~Participants will take the liquid probiotic (Symprove) daily following manufacturers guidelines for a period of 12 weeks."
16376930|NCT04140760|Placebo Comparator|Placebo|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.
~Participants will take the liquid placebo daily for a period of 12 weeks following the same guidelines as for the probiotic."
16376931|NCT04140747||non-pregnant women|Samples will be collected from 30 healthy, non-pregnant women in the reproductive age: blood, urine, stool, saliva, oral swabs, vaginal swabs
16376932|NCT04140747||pregnant women delivering vaginally|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:
~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; cord blood, colostrum, meconium, infant oral swabs"
16376933|NCT04140747||pregnant women undergoing C-section|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:
~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; amniotic fluid, cord blood, colostrum, meconium, infant oral swabs"
16376934|NCT04140734|Experimental|Hard Palate|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use hard palate
16376935|NCT04140734|Active Comparator|Autologous Ear Cartilage|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use autologous ear cartilage
16376936|NCT04140734|Active Comparator|Porcine Acellular Dermal Matrix|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use porcine acellular dermal matrix
16376937|NCT04140721|Experimental|Moxonidine then Placebo|After 5 days of screening/baseline evaluations, patients will be discharged home on moxonidine 0.2-0.4 mg/day PO. On days 29, 30 and 31, the patients will be re-admitted for study testing while on moxonidine. At completion of this testing, patients will start taking matching placebo once daily PO to be continued at home. On days 58, 59 and 60, the patients will be re-admitted for study testing while on placebo.
16376938|NCT04140721|Experimental|Placebo then Moxonidine|After 5 days of screening/baseline evaluations, patients will be discharged home on placebo identical to moxonidine once daily PO. On days 29, 30 and 31, the patients will be re-admitted for study testing while on placebo. At completion of this testing, patients will start taking moxonidine 0.2-0.4 mg/day PO to be continued at home. On days 58, 59 and 60, the patients will be re-admitted for study testing while on moxonidine.
16376939|NCT04140708|Experimental|Exercise--Rock Steady Boxing class|Participants will be going twice a week to a Rock Steady Boxing class for an hour/class. Participants will be going to this class for a total of three months.
16376940|NCT04140695|Experimental|Tradipitant|Oral Capsule
16376941|NCT04140695|Placebo Comparator|Placebo|Oral Capsule
16376942|NCT04140682|Experimental|PAV+ mode|Weaning with PAV+ mode
16376943|NCT04140682|Active Comparator|PSV mode|Weaning with PSV mode
16376944|NCT04140669||Fetal Surgery Procedures|All pregnant women with a fetus diagnosed with a fetal abnormality and planning to undergo a fetal surgical procedure will be included in this single arm of the study.
16376945|NCT04140656|Active Comparator|Plantar sensitive exercise group|Plantar sensitive exercises:
16376946|NCT04140656|Active Comparator|Textured insole group|Textured insole group
16376947|NCT04140643|Experimental|Ozone therapy|Oral hygiene instructions given by dental hygienist and home daily use of ozonated water delivering system.
16376948|NCT04140643|Active Comparator|Only oral hygiene instructions|Oral hygiene instructions given by dental hygienist.
16376949|NCT04140630||E-cigarette users and bystanders|Households with one e-cigarette user (adult (18 years old and above); e-cigarette exclusive user for at least 1 month; daily use of e-cigarettes inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of any tobacco products or e-cigarettes) and one bystander cohabiting with the user
16376950|NCT04140630||Conventional cigarette smokers and bystanders|Households with one smoker (adult (18 years old and above; manufactured cigarette exclusive smoker for at least 6 months; daily smoking inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the smoker
16376951|NCT04140630||Heated tobacco product users and bystanders|Households with one user of the heated tobacco product, HTP (adult (18 years old and above; • HTP exclusive user for at least 1 month; daily use of HTP inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the user
16376952|NCT04140630||Non-smokers and non-users (control)|Smoke free households (participants should be adult (18 years old and above), non e-cigarette user (never or former e-cigarette user >1 month), non-user of any kind of tobacco product (never or former user >1 month), and other household members should not be users of tobacco products or e-cigarettes
16376953|NCT04140617|Experimental|E-cigarette aerosol exposure in a room|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a 25 m3 room.
16376954|NCT04140617|Experimental|E-cigarette aerosol exposure in a car|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a car.
16376955|NCT04140604|Experimental|Lactobacillus salivarius AP-32|AP-32 is a 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Lactobacillus salivarius subsp. salicinius AP-32 and maltodextrin.
16376956|NCT04140604|Experimental|Bifidobacterium lactis CP-9|CP-9 is a 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Bifidobacterium animalis subsp. lactis CP-9 and maltodextrin.
16376957|NCT04140604|Placebo Comparator|Placebo|Placebo capsules are identical to the L. salivarius AP-32 and B. lactis CP-9 capsules except for the probiotics.
16376958|NCT04140591|Placebo Comparator|Proton-pump inhibitor|PPI: Pariet EC 20 mg/QDAC
16376959|NCT04140591|Active Comparator|Propranolol+Proton-pump inhibitor|"Propranolol:
~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
~PPI: Pariet EC 20 mg/QDAC"
16376960|NCT04140578|Experimental|Antibiotic|Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
16376961|NCT04140578|No Intervention|Control|Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
16376962|NCT04140539|Experimental|Gene Therapy|Infusion OTL-101
16376963|NCT04140526|Experimental|ONC-392 Treatment as single agent|"The Part A study will test ONC-392 intravenous (IV) infusion up to five predefined dose levels: 0.1 mg/kg (cohort 1), 0.3 mg/kg (cohort 2), 1 mg/kg (cohort 3), 3 mg/kg (cohort 4) and 10 mg/kg (cohort 5) of ONC-392 as monotherapy every 21 days (Q3W). The treatment will continue for up to 1 year, or discontinued upon disease progression, or unacceptable toxicity, or voluntary withdraw. The Part A study will determine the maximal tolerable dose (MTD) and the recommended Phase 2 dose in monotherapy (RP2D-M).
~In Part C, Arms A, B, and C monotherapy expansion cohorts will further assess the safety and efficacy of ONC-392 in dose level of RP2D-M as monotherapy in pancreatic cancer, triple negative breast cancer and non small cell lung cancer with driver mutations."
16376964|NCT04140526|Experimental|ONC-392 in combination with pembrolizumab|"The Part B1 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of pembrolizumab. The dose for pembrolizumab will be fixed at 200mg/cycle dosed every 21 days (Q3W).
~The Part B1 will start at one level below RP2D-M dose for ONC-392 and 200mg of pembrolizumab. When 2 DLTs occur before 6 patients are enrolled, the ONC-392 dose will be decreased to the next dose level until ≤ 1/6 patients treated at that dose develops a DLT. This dose level will be designated RP2D-C.
~In Part C, the expansion cohorts Arm D to H will assess the safety and efficacy of ONC-392 in RP2D-C dose level and Pembrolizumab combination therapy in non small cell lung cancer, melanoma and Merkel cell carcinoma."
16462942|NCT03546166|Experimental|TREATMENT|
16376965|NCT04140526|Experimental|ONC-392 in combination with Osimertinib|The Part B2 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of Osimertinib of 80 mg PO, QD in non small cell lung cancer with EGFR mutations. The Part B2 will start at one level below RP2D-M dose for ONC-392. The goal is to define the RP2D-C-TKI.
16376966|NCT04140513|Experimental|Diagnostic (dPET)|Patients receive fludeoxyglucose F-18 via injection and undergo dPET over 20 minutes after standard of care computed tomography (CT) imaging (week -2), after receiving 20-26 Gy and 40-46 Gy of radiation (weeks 3 and 5), and 3 months after completion of treatment. Patients with concern for residual disease may receive an additional dPET 6 months after treatment.
16376969|NCT04140487|Experimental|Treatment (azacitidine, venetoclax, gilteritinib)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16376970|NCT04140474|Experimental|Archimedes procedure|All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.
16376971|NCT04140461|Experimental|Trial|Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks
16376972|NCT04140461|Active Comparator|Control|Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks
16376973|NCT04140448||UWFA-RVO-ME|Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab
16376974|NCT04140435||TTNB group|Patients with PCLs suitable for biopsy.
16376975|NCT04140422|Experimental|Hyperosmolar Eye Drops|5% sodium chloride eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
16376976|NCT04140422|Placebo Comparator|Lubricating Eye Drops|Lubricating eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
16376977|NCT04140409|Experimental|Treatment|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
16376978|NCT04140396|Placebo Comparator|Placebo Comparator|Participants will receive placebo infusion consisting of normal saline
16376979|NCT04140396|Active Comparator|Active Comparator|Participants will receive a lidocaine infusion
16376980|NCT04140383||Group 1, patients aged 85 years and older|75 eyes of 75 patients (39 female, 36 male) Mean age: 86,8 ± 1,8 years
16376981|NCT04140383||Group 2, patients aged 65 and 85 years|77 eyes of 77 patients (34 female, 43 male) Mean age:73,3 ± 5,2 years
16376982|NCT04140344|Experimental|ARM 1: Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
16376983|NCT04140344|No Intervention|ARM 2: Control group|The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.
16376984|NCT04140331||complicated post-operative evolution|Patients with a postoperative intensive care unity length of stay ≥ 5 days after elective cardiac surgery. They will have an accelerometer.
16376985|NCT04140331||simple post-operative evolution|Patients with a postoperative intensive care unity length of stay < 5 days after elective cardiac surgery. They will have an accelerometer.
16376986|NCT04140318|Experimental|treatment|combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w
16376987|NCT04140305|Experimental|Administration of RPC-1063|Patients with relapsing MS will receive RPC-1063 orally:
16376988|NCT04140292|Experimental|Vitamin D3 + Photodynamic therapy (PDT)|Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
16376989|NCT04140279|Experimental|Latanoprostene Bunod|Participants will receive LBN ophthalmic solution 0.024% in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
16376990|NCT04140279|Placebo Comparator|Placebo|Participants will receive Renu MultiPlus Lubricating and Rewetting Drops (placebo) in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
16376991|NCT04140266|Experimental|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
16376992|NCT04140266|Experimental|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
16376994|NCT04140253|Experimental|Standard Duloxetine treatment with PFMT|Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
16376995|NCT04140240|Experimental|İntervention group|Experimental: İntervention group
16376996|NCT04140240|No Intervention|Control group|Control group: No intervention
16376997|NCT04140227|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
16376998|NCT04140214|Experimental|Standard Care and HTS|Standard care and twice-daily nebulised HTS (MucoClear 6%, PARI Pharma). Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser and eTrack controller (PARI Pharma).
16376999|NCT04140214|Experimental|Standard Care and Carbocisteine|Standard care and carbocisteine (750 mg three-times-per-day until visit 3, reducing to 750 mg two times per day) over 52 weeks.
16377000|NCT04140214|Experimental|Standard Care and Combination of HTS and Carbocisteine|Standard care and combination of twice-daily nebulised HTS (MucoClear 6%, PARI Pharma) and carbocisteine. Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser eFlow rapid nebuliser and eTrack controller (PARI Pharma). They will also be given carbocisteine (750 mg of three times per day until visit 3, reducing to 750 mg twice per day) over 52 weeks.
16377001|NCT04140214|No Intervention|Standard Care Only|Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
16377002|NCT04140201|Active Comparator|Receive oral hypoglycemic +omega 3|Eicosapentanoic acid + standard treatment
16377003|NCT04140201|Active Comparator|Receive oral hypoglycemic +statin|Simvastatin + standard treatment
16377004|NCT04140201|Active Comparator|Receive oral hypoglycemic +fibrate|Fenofibrate +standard treatment
16377005|NCT04140201|No Intervention|Receive oral hypoglycemic only|Standard treatment only
16377006|NCT04140188|Active Comparator|Axilla no touch|Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM
16377007|NCT04140188|Active Comparator|Axilla with previous SLNB|Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM
16377008|NCT04140175||Women with suspected or confirmed endometriosis|Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions.
16377009|NCT04140162|Experimental|Dara-Rd followed by Dara-RVd|"Induction regimen with Daratumumab, Lenalidomide and Dexamethasone (Dara-Rd) in all study subjects, weeks 1-24
~Consolidation regimen with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (Dara-RVd) in post-induction MRD+ population, weeks 25-36
~Maintenance regimen with Daratumumab and Lenalidomide (Dara-R) in all study subjects, weeks 37-88
~Maintenance regimen with lenalidomide (R) until progression or intolerance"
16377010|NCT04140149||Participants|Adults who have made a suicide attempt in the past 3 months who have been referred to, and enrolled in, the Living with Hope class.
16377011|NCT04140136|Active Comparator|Treatment group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients.The investigational product is to be administered twice daily, at a dose of 400mg per day.
16377012|NCT04140136|Placebo Comparator|Placebo group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients. The placebo is similar in appearance but does not contain tocotrienols and consist of palm oil.
16377013|NCT04140123|Experimental|ZSP1601-Dose 1|ZSP1601-50mg once daily
16377014|NCT04140123|Experimental|ZSP1601-Dose 2|ZSP1601-50mg twice daily
16377015|NCT04140123|Experimental|ZSP1601-Dose 3|ZSP1601-100mg once daily
16377016|NCT04140123|Placebo Comparator|Placebo|Placebo
16377017|NCT04140110|Experimental|Intervention group|Achieving SBP level of <120 mmHg within 1 hour after randomisation, and maintaining this level at least 72 hours.
16377018|NCT04140110|No Intervention|Control group|Maintaining SBP 140-180mmHg, and BP lowering treatment can be given only when BP level ≥150 mmHg in order to achieve the target of ≥140 mmHg, and maintaining this level at least 72 hours.
16377019|NCT04140097||COPD patients with acute exacerbation|
16377020|NCT04140097||COPD patients without acute exacerbation|
16377021|NCT04140084|No Intervention|Translation, Redesign and Rapid prototyping with clinicians|This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
16377022|NCT04140084|No Intervention|Rapid prototyping with patients|This step will include the assessment of the tools by patients (or parents of patients) that have had a previous mTBI at the CISSS-CA (Hotel-Dieu de Levis). The comments about the adult and pediatric prototypes (5 adult patients, 5 parents of pediatric patients) will be collected through interviews. A revision of the prototypes is scheduled at the end of this step.
16377023|NCT04140084|Experimental|Real-life clinical meetings|This step will include a presentation of the tools to 5 emergency physicians so that they can use the tools with patients (5 adults, 5 parents of pediatric patients) in a realistic setting to identify any problems of use. The clinicians and patients that had used the tools during the clinical encounters will be then met during cognitive interviews to collect their comments on the tools and to address any usability issues. A final revision of the prototypes is scheduled at the end of this step.
16377051|NCT04139902|Experimental|Dostarlimab (TSR-042) and TSR-022 (combination)|"Pre-Operative Phase:
~Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.
~Post-Operative Phase:
~Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered."
16377052|NCT04139889||normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
16377600|NCT04136327|Experimental|[14C]-GLPG1972 oral solution|[14C]-GLPG1972 oral solution
16377024|NCT04140084|No Intervention|Training session developement|This step includes the development of a training session on how to perform SDM with patients facing the decision to undergo head CTs for mTBI and about how to use our newly developed decision aids in this clinical setting. The content of the training session will be adapted to the needs, goals, strengths and limitations observed during the focus groups (departmental meetings) exploring health professionals' barriers to using a decision aid about head CTs in mTBI. The expertise of SAVIE (www.savie.ca) in producing online and interactive elearning programs will be mobilized in order to produce a training program that will integrate the content the investigators will have identified as the main skills, knowledge and competencies needing development among our health professionals to stimulate the use of SDM and our decision aids. SAVIE will produce a virtual elearning program adaptable to all media (PC, mobile device, tablet) and different health professionals.
16377025|NCT04140084|No Intervention|Retrospective analysis|This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
16377026|NCT04140058|Active Comparator|group O4|Patients received 4mg ondansetron.
16377027|NCT04140058|Active Comparator|group O6|Patients received 6mg ondansetron.
16377028|NCT04140058|Placebo Comparator|group C|Patients received normal saline.
16377029|NCT04140045|Experimental|Hypohydrated|Participants will be required to restrict their water intake during cycling in the heat (90-120 minutes at 35°C), in order to achieve a body mass loss of approximately 3%.
16377030|NCT04140045|Experimental|Euhydrated|Participants will be provided with water intake that matches their sweat losses during cycling in the heat (90-120 minutes at 35°C)
16377031|NCT04140032|Experimental|Intervention group|Centers in the group will participate in the A-B-C Healthy Me/Soy Saludable multi- component nutrition and physical activity preschool intervention.
16377032|NCT04140032|No Intervention|Control group|"Preschools in the group will continue with usual care practices. Control group preschools will receive intervention materials and accompanying instructions after follow-up measures are collected for each cohort."
16377033|NCT04140019||NSTEMI|
16377034|NCT04140006|Active Comparator|Alendronate Gel (ALN)|After preparation, 0.05 ml of the gel containing 100 µg of ALN will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
16377035|NCT04140006|Active Comparator|Bone Morphogenic Protein Gel (BMP)|After preparation, 0.05 ml of the gel containing 100 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
16377036|NCT04140006|Active Comparator|Mixture Gel of ALN and BMP|After preparation, 0.05 ml of mixture gel containing 50 µg of ALN and 50 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
16377037|NCT04140006|Sham Comparator|Control|After preparation, the fixture will be inserted without topical application of any medication (20 fixtures)
16377038|NCT04139993|Experimental|Estrogen receptor (ER) and/or progesterone rec|RBX7455 given at least minimum 2 weeks to (maximum 4 week)s prior to surgery in patients with stage I-III breast cancer;Estrogen receptor (ER) and/or progesterone receptor (PR) positive ≥ 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression.
16377039|NCT04139993|Experimental|Human epidermal growth factor receptor 2(HER2)|RBX7455 given at least minimum 2 weeks to (maximum 4 week)s prior to surgery in patients with stage I-III breast cancer;Human epidermal growth factor receptor 2 (HER2) amplification with FISH ratio ≥ 2.0 or overexpression by immunohistochemistry 3+ with any ER and/or PR.
16377040|NCT04139993|Experimental|Triple negative.|RBX7455 given at least minimum 2 weeks to (maximum 4 week)s prior to surgery in patients with stage I-III breast cancer;Triple negative. Estrogen receptor (ER) and/or progesterone receptor (PR) negative < 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression.
16377041|NCT04139980|Experimental|Virtual Reality supported therapy|"The Virtual Reality (VR) interface will be used during patients stay at the rehabilitation center. A research employee will install the VR system in the patient's room. Participants will be comfortable sitting while in VR session. Each interface consists of a head mounted display (HMD) allowing participants to see their arms and legs represented in the virtual environment. Participants will be able to control their virtual legs using hand controllers, which will allow them to walk through several virtual environments and gather points (no additional gaming elements are included)."
16377042|NCT04139967|Experimental|Elderly rectal cancer patients|
16377043|NCT04139954||Rheumatoid arthritis and Spondyloarthritis|Patients using Biological or Targeted Synthetic DMARDs
16377044|NCT04139941||Individuals with known or unknown HCV status|
16377045|NCT04139928|Experimental|Picometer-ionic form of magnesium chloride|
16377046|NCT04139928|Active Comparator|Magnesium citrate or magnesium oxide|
16377047|NCT04139928|Placebo Comparator|Placebo|
16377048|NCT04139915|Experimental|10 mg daily RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 16 weeks
16377049|NCT04139915|Placebo Comparator|Placebo|Oral matching placebo once daily for 16 weeks
16377050|NCT04139902|Experimental|Dostarlimab (TSR-042) (singly)|"Pre-Operative Phase:
~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.
~Post-Operative Phase:
~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
16377053|NCT04139889||non-malignant lesions|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of non-malignant lesions after intravenous injecting 10% fluorescein.
16377601|NCT04136314|Experimental|Gain-Frame Survey [A]|
16377054|NCT04139889||malignant lesions|pCLE images of malignant lesions were associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
16377055|NCT04139876|Active Comparator|Minimal open hemorrhoidectomy|Patients randomized to Minimal open hemorrhoidectomy
16377056|NCT04139876|Active Comparator|LigaSure hemorrhoidectomy|Patients randomized to LigaSure hemorrhoidectomy
16377057|NCT04139863|Other|aMMP-8 chairside test|Test group. The aMMP-8 chairside mouth rinse test is performed for the test group.It identifies adolescents with poor oral hygiene at risk for subclinical periodontitis without detectable and visible manifestations of the illness, such as periodontal deepened pockets.
16377058|NCT04139863|No Intervention|No test|The other group is control group. No test administered.
16377059|NCT04139850||Korean chronic hepatitis B patients cohort|Korean patients with chronic hepatitis B with or without antiviral therapy on a regular follow-up in tertially medical institution
16377060|NCT04139824|Experimental|Cohort|Period 1: LC350189 200mg (QD) Day 1~ Day 4, Period 2: Naproxen 500 mg (BID) Day 8 ~ Day 12 , Period 3 : LC350189 200mg (QD) + Naproxen 500 mg (BID) Day 13~19
16377061|NCT04139811|Other|non-ILM peeling group|vitrectomy without ILM peeling is done to all cases
16377062|NCT04139811|Other|ILM peeling group|vitrectomy with ILM peeling is done to all cases
16377063|NCT04139798|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
16377064|NCT04139798|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.6% sodium chloride solution) 4 times daily (QID)
16377065|NCT04139785|Experimental|Intervention|Guided Cognitive Behavioural Therapy based app
16377066|NCT04139785|No Intervention|Care as usual|Care as usual
16377067|NCT04139772|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
16377068|NCT04139772|Experimental|Abiraterone or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.
~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.
~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
16377069|NCT04139759|Experimental|hand massage group|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
16377070|NCT04139759|Experimental|Foot massages group|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
16377071|NCT04139759|No Intervention|control group|The patients in the control group (n = 28) were not administered except nursing interventions in the HD unit.
16377072|NCT04139746|Active Comparator|Scleral Buckling|Scleral Buckling represents the gold standard for retinal detachment in young phakic patients.
16377073|NCT04139746|Experimental|Drainage-Injection-Pneumoretinopexy|Drainage-Injection-Pneumoretinopexy is a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (BSS) in the vitreous chamber.
16377074|NCT04139733|Experimental|Prone group|"Prone position within 6 hours after randomization.
~Prone position for at least conservative hours per days during a minimum of 5 days."
16377075|NCT04139733|Other|Supine group|1. Supine group on ECMO.
16377076|NCT04139720|Experimental|e-book|e-book learning mode of sexual harassment prevention training
16377077|NCT04139720|No Intervention|audio-visual and booklet|sexual harassment prevention audio-visual and booklet learning mode
16377078|NCT04139707|Experimental|Caring4Dementia Group|The experimental group will receive Careing4Dementia downloadable on their smartphone or tablet. Caring4Dementia will tell and show caregivers of a person living with dementia how to 1) manage difficult behaviors, 2) deal with refusal, 3) deal with tensions and 4) manage work-life demands. The app is self-administered and self-paced and contains surveys referring to the outcome measurements tools used in the study. The intervention will be for 30 days without any restriction or limitation in terms of timing, location or frequency of use.
16377079|NCT04139707|Active Comparator|White Paper Group|The White Paper group will receive a white paper on the principles of communicating efficiently with persons living with dementia.
16377080|NCT04139707|No Intervention|Control Goup|The control group will not receive any intervention.
16377081|NCT04139694|Experimental|Cinnamon with Food Plan|Group of ladies who will undergo testing, receive dietary intervention, and take cinnamon supplements.
16377082|NCT04139694|Active Comparator|Food Plan Only|Group of ladies who will undergo testing, receive dietary intervention, but will not get cinnamon supplements.
16377083|NCT04139681|Experimental|A. Vogels Sore Throat Lozenges|Each patients receives 1 glass containing 20 A.Vogel Sore Throat lozenges at inclusion visit 1. They first suck under supervision in the study centre one Vogel Sore Throat lozenge and document every 15 minutes the pain 90 minutes. Patients will receive the rest of the bottle still containing 19 Vogel Sore Throat lozenges and have to take them for 4 days (5 lozenges per day, throughout the day) and record tonsillitis pain.
16377084|NCT04139668|Experimental|Vivitrol + MET/CBT|All participants will receive three 4ml doses of extended-release naltrexone 380mg (Vivitrol), administered by intramuscular injection. Three injections will be administered to each participant; one injection every 4 weeks for 12 weeks of treatment. In addition, all participants will receive weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy for 12 weeks.
16377085|NCT04139655|Experimental|Intervention Group|Administration of oral colchicine at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
16377086|NCT04139655|Placebo Comparator|Control Group|Participants allocated to the control group will receive a placebo pill at the same dosing regimen as with treatment group. Perioperative and surgical care will not be different from standard clinical practice.
16377602|NCT04136314|Experimental|Loss-Frame Survey [B]|
16377087|NCT04139642||Group AB|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
16377088|NCT04139642||Group BA|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
16377089|NCT04139629|Other|antibody positive (CAT+)|patients found positive for one of the assayed antichlamydial antibodies
16377090|NCT04139629|Other|antibody negative (CAT-)|women with negative antichlamydia antibody test
16377091|NCT04139616||No ECG changes in patients without pre-existing RBBB|Patients with no new conduction disturbances on the ECG performed immediately post-TAVR (and no episodes of HAVB/CHB during the procedure) have a very low risk of developing HAVB/CHB or any conduction disturbance within the hours-days following the procedure. In these cases, temporary pacing will be discontinued at the end of the procedure. However, continuous ECG monitoring until hospital discharge is recommended. A 12-lead ECG is recommended 24 hours after the procedure. If no arrhythmic episodes and no ECG changes occur within the 24 hours post-procedure, the patient can be safely discharged (the day after TAVR) with no other monitoring measures in case of otherwise uneventful clinical course (absence of other TAVR related adverse events). If the patient has to remain hospitalized because of other reasons or TAVR complications, telemetry would be recommended (but no strictly required) for the detection of post-TAVR tachyarrhythmias or late ECG changes.
16377092|NCT04139616||Patients with pre-existing RBBB|A temporary pacing wire is recommended to be maintained for 24 hours (or at least overnight) in all patients with prior RBBB, along with telemetry and daily ECG during the entire hospitalization period (minimum of 2 days). If any ECG changes occur during the initial 2-3 days, patients can be managed according to the proposed strategy (see management strategies for groups 3 and 5). If no ECG changes or significant bradyarrythmias occur within the 2-3 days following the procedure, the patient can be discharged. Considering that the increased risk of life threatening bradyarrhythmias in these patients may extend beyond the hospitalization period, the use of continuous ECG monitoring systems (minimum of 48 hours, up to 4 weeks) may be considered.
16377093|NCT04139616||ECG changes in patients with prior conduction disturbances|"Any significant increase in PR or QRS interval will indicate to continuing the temporary pacing for 24 hrs, with daily ECG and telemetry for 1-2 days. If the ECG changes regress in <24 hrs, an earlier removal of the temporary pacing may be considered. Also, a strategy of multiple ECGs during the first 24 hrs may be considered. If ECG changes regress or no further changes occur the patient can be discharged with no PPM at 2 days post-TAVR.
~If 24 hrs post-TAVR, the PR and QRS interval remain stable but >240 or >150 ms, respectively, and ≥20 ms longer than baseline, maintaining the temporary pacing wire for another 24 hrs is recommended. If no decrease in the PR or QRS duration occurs at day 2, the patient can be considered at risk for more advanced conduction disturbances requiring PPM. The use of an EP study may be a reasonable option for deciding PPM in those patients with prior conduction disturbances with worsening of ECG changes post-TAVR"
16377094|NCT04139616||New-onset LBBB|"Temporary pacing for 24 hrs is recommended, in all patients with new-onset LBBB post-TAVR. Earlier removal of the temporary pacing and discharged at day 1 can be considered if LBBB resolves in <24 hrs.
~If LBBB persists but no further progression of the duration of the QRS or PR interval is observed at day 1, temporary pacing can be discontinued. If no further ECG changes are observed up to day 2-3 post-TAVR, the patient can be discharged. These patients are however at increased risk of HAVB/CHB requiring PPM, and continuous ECG monitoring and/or EP studies may be considered.
~If further prolongation of the QRS or PR interval is observed at day 1, the temporary pacing is recommended for an additional 24 hrs. If the prolongation of the QRS or PR intervals continues at day 2, evaluation with EP studies or PPM implantation may be considered.
~The occurrence of any episode of HAVB/CHB following TAVR in a patient with new-onset LBBB will be considered an indication for PPM"
16377095|NCT04139616||HAVB/CHB during the periprocedural period|"Maintaining temporary pacing in patients with procedural persistent HAVB/CHB, and monitoring in intensive care unit are recommended. If HAVB/CHB persists at 24 hrs, PPM is recommended. If HAVB/CHB recovers the day after TAVR, the temporary pacing can be removed and the patient can remain hospitalized for 1 day. If another episode of HAVB/CHB occurs, PPM is recommended. If no other episode of HAVB/CHB occurs, and no other features potentially justifying PPM exist the patient can be discharged.
~Temporary pacing is recommended for 24 hrs in patients with transient HAVB during the procedure, with telemetry and daily ECG for 2 days. Discontinuing temporary pacing may be considered in those cases with brief episodes of HAVB/CHB and normal ECG. If no recurrent episodes of HAVB/CHB occur, and the patient has no other potential indications for PPM the patient can be discharged at day 2. PPM would be indicated if any recurrent episode of HAVB/CHB occurs during the hospitalization period."
16377096|NCT04139603|Active Comparator|Lumbopelvic kinesio taping (LPKT)|Two I-shaped kinesio tapes in 40 cm length will be applied bilaterally, beginning from 5 cm below the spina iliaca posterior superiors (SIPSs) to the level of the 12th costae, in maximum trunk flexion position, on the paravertebral muscles, by inhibition technique of muscle correction techniques. The tapes will be placed with no tension at 5 cm of both ends, and with 15-25% tension in between. In addition, an extra I-shaped tape will be placed perpendicullar to these tapes with the ligament correction technique, while the pregnant women are in the vertical upright position, at the level of the sacroiliac joints, starting with a tensile strength of 75-100% from the middle, and then with no tension at two ends.
16377097|NCT04139603|Experimental|Abdominal supported lumbopelvic kinesio taping (ALPKT)|An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
16377139|NCT04139343||SMA cohort|Individuals who have a diagnosis of SMA who are NOT receiving Spinraza (nusinersen).
16377098|NCT04139603|Placebo Comparator|Placebo taping|A Micropore™ surgical plaster of the same color with KT will be applied with no tension, as described in the LPKT technique.
16377099|NCT04139590|Placebo Comparator|Visual Analogue Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Visual Analogue Scale."
16377100|NCT04139590|Active Comparator|Visual Analogue Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Visual Analogue Scale."
16377101|NCT04139590|Placebo Comparator|Numeric Rating Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Numeric Rating Scale."
16377102|NCT04139590|Active Comparator|Numeric Rating Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Numeric Rating Scale."
16377103|NCT04139577|Experimental|Fecal Microbiota Transplant (FMT) FOR HIGH-RISK ACUTE GVHD|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~this research study for up to 6 months. You may receive up to 2 cycles of the study treatment.
~- Fecal Microbiota Transplant ( FMT)- Oral Study Drug, predetermined dosage and timings, up to 2 cycles.
~One cycle of treatment consists of one induction week of FMT followed by three weeks of maintenance FMT.
~The maintenance weeks happen for 3 weeks after the induction week.
~All doses will be administered in the clinic.
~A second cycle of treatment as deemed appropriate"
16377104|NCT04139564|Experimental|EaseVRx group|Each subject will be asked to complete a 56-day program using the EaseVRx virtual reality headset with assigned modules each week. Each week, subjects will be asked to complete 7 modules (one per day), each approximately 5 minutes in duration, for a total of 56 modules across the program.
16377105|NCT04139564|Active Comparator|Active control group VR Sham|Each subject will be asked to complete a program accessible via VR that includes 2d visual wildlife scenes similar to some EaseVRx content
16377106|NCT04139551||1XXX Denono PD|Newly diagnosed unmedicated PD patients
16377107|NCT04139551||2XXX Mild /Moderate PD|Early to moderate stage PD patients well controlled on medication(typically fewer than 8 years since diagnosis)
16377108|NCT04139551||3XXX Advanced PD|Advanced PD patients (typically greater than 8 years duration)
16377109|NCT04139551||4XXX DBS patients|PD patients with deep brain stimulation systems
16377110|NCT04139551||5XXX PSP patients|PSP patients
16377111|NCT04139551||6XXX Healthy Controls|Age-frequency matched healthy controls
16377112|NCT04139538|Experimental|Invisalign treatment|Aligner patients will be treated with Invisalign® aligners to correct malocclusion
16377113|NCT04139538|Active Comparator|selfligating bracket treatment|Multibracket patients will be treated with self ligating orthodontic brackets
16377114|NCT04139525|Experimental|unfractionated heparin and 8% trisodium citrate|Unfractionated heparin and 8% trisodium citrate.
16377115|NCT04139512|Other|guided surgery|test group, using a full digital workflow procedure
16377116|NCT04139512|Other|conventional technic|free- hand technic to place implant
16377117|NCT04139499||Adults with OSA|Adults with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
16377118|NCT04139499||Children with OSA|Children with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
16377119|NCT04139499||Adult control|Adult without any obstruction at four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent a control.
16377120|NCT04139499||Children control|Children exam will be done for all the participants. Subject without obstruction represent a control.
16377121|NCT04139486|Experimental|combined EMBOTRAP II or III and Contact Aspiration|
16377122|NCT04139486|Active Comparator|Contact Aspiration alone|
16377123|NCT04139473|Active Comparator|Hepaticojejunostomy|Patients undergo right lobe living donor liver transplantation will receive hepaticojejunostomy
16377124|NCT04139473|Active Comparator|Duct-to-duct anastomosis|Patients undergo right lobe living donor liver transplantation will receive duct-to-duct anastomosis
16377125|NCT04139460|Active Comparator|CRT-D|Implantation of cardiac resynchronization therapy with a defibrillator (CRT-D)
16377126|NCT04139460|Active Comparator|CRT-P|Implantation of cardiac resynchronization therapy pacemaker (CRT-P)
16377127|NCT04139447||Healthy subjects|
16377128|NCT04139434|Experimental|Dose Escalation Phase|"Three to 6 subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-108 on a once daily schedule for 28 days (a Cycle starting at a dose of 100 mg."
16377129|NCT04139434|Experimental|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups. One or more RP2D may be explored.
16377130|NCT04139421|Active Comparator|Urban Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in urban green space.
16377131|NCT04139421|Experimental|Rural Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in rural green space.
16377132|NCT04139408|Experimental|Disposable Pulmonary Surgical Marker|Locate the pulmonary nodules with Disposable Pulmonary Surgical Marker before VATS.
16377133|NCT04139395|Experimental|Diagnostic 68Ga-Citrate PET/MRI Imaging|Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
16377134|NCT04139382|Experimental|Intervention|Telephone Consultation for women requesting abortion
16377135|NCT04139382|Active Comparator|Control|Face-to-face consultation for women requesting abortion
16377136|NCT04139369||Type 1 Diabetes Mellitus (T1DM)|Type 1 Diabetes Mellitus (T1DM) Children and adolescents with Type 1 Diabetes Mellitus
16377137|NCT04139369||Controls (C)|Controls (C) Healthy individuals matched for gender and age without any autoimmune disease of their own or their first degree relatives
16377138|NCT04139356|Experimental|Patients with rest O2 desaturation|Patient will undergo an experimental protocol consisting of 10 deep inspirations to measure and characterize changes on pulse-oxymetry values
16463493|NCT03542253||micorRNA-R in plasma|
16377140|NCT04139343||SMA Spinraza cohort|Individuals who have a diagnosis of SMA who are receiving Spinraza (nusinersen).
16377141|NCT04139343||Control cohort|Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
16377142|NCT04139330|Experimental|NPC-06 (high dose)|Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
16377143|NCT04139330|Experimental|NPC-06 (low dose)|Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
16377144|NCT04139330|Placebo Comparator|NPC-06 (placebo)|Infuse NPC-06 (placebo) over 12 minutes or 18 minutes
16377147|NCT04139304|Experimental|Treatment (daratumumab, DA-EPOCH)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3, and on day 1 of cycles 4-6. Patients also receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuous over 96 hours on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for up to 6 cycles in absence of disease progression or unacceptable toxicity.
16377148|NCT04139291|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema
16377149|NCT04139265||Hospitalized patients aged 65 and over|- Patients aged 65 and over hospitalized in the department of Internal Medicine and Geriatry
16377150|NCT04139239||Patients with disorders of consciousness|
16377151|NCT04139226|Experimental|Administration of CC-11050|Part 1: Single Ascending Dose Part 2: drug-drug interaction/ food effect (DDI/FE)
16377152|NCT04139213|Active Comparator|Usual care|usual medication assisted treatment for maintenance care of opioid use disorder
16377153|NCT04139213|Experimental|Pharmacy MAT|pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
16377156|NCT04139187|Experimental|Experimental|Individuals randomized to experimental group.
16377157|NCT04139187|No Intervention|No Intervention Control|Individuals without quadriceps dominance randomized to no intervention group.
16377158|NCT04139174||adolescent group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).
~measurements will be done on the radiograph using digital software."
16377159|NCT04139174||adult group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).
~measurements will be done on the radiograph using digital software."
16377160|NCT04139161|Experimental|Q-Factor Intervention|Participants will progress through three increasing Q-Factors for each cycling workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated.
16377161|NCT04139148|Active Comparator|True tDCS Combined With CCAT|Ture transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including drug knowledge every week, self-evaluation every two weeks and outpatient follow-up reminder every four weeks.
16377162|NCT04139148|Sham Comparator|Sham tDCS Combined With CCAT|Sham transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including only outpatient follow-up reminder every four weeks.
16377163|NCT04139148|No Intervention|Control group|During the treatment, the participants in control group only received treatment such as education of psychology, health and judicature, physical training as well as vocational training as usual in the compulsory rehabilitation center.
16377164|NCT04139135|Experimental|HLX10|HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
16377165|NCT04139135|Placebo Comparator|Placebo|Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
16377166|NCT04139122|Experimental|Cohort 1-4: SJP-0132|Each cohort will receive a single dose of 1 of 4 strengths of SJP-0132
16377167|NCT04139122|Placebo Comparator|Cohort 1-4: Placebo|Single dose of placebo
16377168|NCT04139122|Experimental|Cohort 5-6: SJP-0132|Cohort 5 SJP-0132 will receive the second maximum acceptable dose from Cohorts 1-4 for 4 weeks. Cohort 6 SJP-0132 will receive the maximum acceptable dose from Cohorts 1-4 for 4 weeks
16377169|NCT04139122|Placebo Comparator|Cohort 5-6: Placebo|Multiple dose placebo for 4 weeks
16377170|NCT04139083||TVM group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with TVM
16377171|NCT04139083||LSC mesh suspension group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with LSC mesh suspension
16377172|NCT04139070|Experimental|Treátment group|8 patients are expected to be included in this study. The patients will be treated once with bleomycin in combination with elektroporation
16377173|NCT04139057|Experimental|EBV TCR-T|EBV-specific TCR-T cell with anti-PD1 auto-secreted element
16377174|NCT04139044|Experimental|Stable Ankle Training Group (SG)|Balance Exercise Training for Only The Stable Ankle
16377175|NCT04139044|Experimental|Unstable Ankle Training Group (UG)|Balance Exercise Training for Only The Unstable Ankle
16377176|NCT04139044|No Intervention|Control Group (CG)|No balance exercise training
16378097|NCT04132726|Experimental|Test|Experimental group which employed with massage treatment
16377177|NCT04139031||Fluid loading group|Mechanically ventilated patients with low tidal volume in the intensive care unit whom clinician decided to provide fluid for correction of hypovolemia
16377178|NCT04139018|Experimental|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
16377179|NCT04139018|Placebo Comparator|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
16377180|NCT04139005|Experimental|Awareness-Connection|
16377181|NCT04139005|Experimental|Awareness-Insight|
16377182|NCT04139005|No Intervention|Wait list|
16377183|NCT04138992|Experimental|study group A|"bevacizumab combined with neoadjuvant chemotherapy and concurrent chemoradiotherapy：
~bevacizumab combined with neoadjuvant chemotherapy for 2 cycles: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; Docetaxel 75mg/m2, intravenous injection，once three week;
~bevacizumab combined with concurrent chemoradiotherapy: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor"
16377184|NCT04138992|Experimental|study group B|study arm: bevacizumab combined with concurrent chemoradiotherapy： Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
16377185|NCT04138992|Active Comparator|control|standard concurrent chemoradiotherapy: DDP 40mg/m2, intravenous injection，once a week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
16377186|NCT04138979||Control group|20 healthy volunteers were included in the healthy control group
16377187|NCT04138979||Disease group|First chemotherapy for breast cancer
16377188|NCT04138966||Patients undergoing general anesthesia|Patients are monitored with Nol-Index, skin conductance, and antinociception-index
16377189|NCT04138953|Experimental|TMS over premotor cortex|Noninvasive brain stimulation in the premotor cortex
16377190|NCT04138953|Experimental|TMS over primary motor cortex|Noninvasive brain stimulation in the motor cortex
16377191|NCT04138953|Sham Comparator|Sham TMS over premotor cortex|Sham brain stimulation in the premotor cortex
16377192|NCT04138940|Experimental|Distributed, Short Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 5 sentence-long script.
16377193|NCT04138940|Experimental|Distributed, Long Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 10 sentence-long script.
16377194|NCT04138940|Experimental|Massed, Short Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 5 sentence-long script.
16377195|NCT04138940|Experimental|Massed, Long Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 10 sentence-long script.
16377196|NCT04138927|Experimental|Fostamatinib|"Subjects who at any time during the C-935788-057 study achieved a hemoglobin response will continue at their dose and regimen from the Week 22 visit in the C-935788-057 study.
~All other subjects who enter the extension study will initially receive fostamatinib 100 mg PO bid. Starting at Week 4, the initial fostamatinib dose of 100 mg PO bid will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug, based on the Investigator's judgment."
16377197|NCT04138914|Experimental|Focal Cryotherapy|Focal Cryotherapy using 2 freeze-thaw cycles
16377198|NCT04138901|Experimental|Group T|Patients receiving bilateral subcostal TAP block.
16377199|NCT04138901|No Intervention|Group C|Patients not receiving bilateral subcostal TAP block.
16377200|NCT04138888|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in Period 1 and a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16377201|NCT04138888|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in Period 1 and a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16377202|NCT04138875|Active Comparator|Low Risk|Low risk patients (those in complete response (CR) after induction) will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 of 21 day cycles, for 4 cycles.
16377203|NCT04138875|Active Comparator|High Risk|High risk patients (those who do not achieve a CR after induction), will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 and bendamustine (90mg/m2) on day 1-2 of 21 day cycles for up to 8 cycles. Interim imaging will be performed in cycle 4 (days 14-21) and patients achieving CR will receive additional 2 cycles for a total of 6, patients achieving partial response (PR) will receive 4 additional cycles.
16377204|NCT04138862|Active Comparator|Sensory Matched/Unlabelled|Sensory-matched covert calorie reduction, unlabelled
16377205|NCT04138862|Experimental|Sensory Matched/Labelled|Sensory-matched explicit calorie reduction, labelled
16377206|NCT04138862|Experimental|Sensory Reduced/Labelled|Sensory-reduced explicit calorie reduction, labelled
16377207|NCT04138862|Experimental|Sensory Enhanced/Labelled|Sensory-enhanced explicit calorie reduction, labelled
16377208|NCT04138849|Experimental|BBT-877 Low Dose|
16377209|NCT04138849|Experimental|BBT-877 Mid Dose|
16377210|NCT04138849|Experimental|BBT-877 High Dose|
16377211|NCT04138849|Placebo Comparator|Placebo|
16377212|NCT04138836|Experimental|Midazolam|
16377213|NCT04138836|Experimental|Itraconazole|
16377214|NCT04138836|Experimental|Esomeprazole|
16377215|NCT04138823|Experimental|Part A: BI 891065 followed by Part B: BI 891065 + BI 754091|
16377216|NCT04138810|Experimental|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
16377217|NCT04138810|Active Comparator|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
16377218|NCT04138797|Experimental|Electrophysiological exploration & ECG Biosemi|
16377219|NCT04138784|Experimental|Comprehensive Rehabilitation program|19 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks individualized comprehensive rehabilitation program administered once a day.
16377220|NCT04138784|Experimental|Aquatic training|18 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks hydrotherapy intervention once a day.
16377221|NCT04138771|Experimental|Eligible patients for AI test|Device: an artificial intelligence system for postoperative management of cataract patients. These patients are enrolled in primary healthcare units and the AI clinic at Zhongshan Ophthalmic Center.
16377222|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
16377223|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
16377224|NCT04138745||Control|Historical control patients that are matched to the surgery type
16377225|NCT04138745||Experimental|After the practice change of TTP was initiated, the future pediatric patients were put into a database.
16377226|NCT04138732|Experimental|Intervention treatment group|This arm will receive the intervention treatment aimed to help improve their health behaviors. Interventions will include nutrition workshops and personal consultation for employees at risk, environmental intervention that includes brief exercise session prior to weekly meetings, placement of sports equipment in the department, and pedometer program, and stress reduction workshops. Healthy options will be demarcated in the hospital cafeteria.
16377227|NCT04138732|Other|Control group|This arm will be the control group and not receive the intervention treatment aimed to help improve their health behaviors.Once completing their time as the control group, they will continue into another phase of the trial and receive the intervention treatment.
16377228|NCT04138719|Experimental|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
16377229|NCT04138719|Active Comparator|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；
16377230|NCT04138706|Placebo Comparator|Control: Placebo|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive a placebo for an additional 14 days (twice a day x 7 days, then once a day for 7 days).
16377231|NCT04138706|Active Comparator|Intervention: Extended vancomycin regimen|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will will receive active vancomycin for an additional 14 days (125mg twice a day x 7 days, then 125mg once a day for 7 days).
16377232|NCT04138693|Experimental|Cohort 1: 2 x 2.0 g G-PUR® oral suspension|
16377233|NCT04138693|Experimental|Cohort 2: 1 x 2.0 g G-PUR® oral suspension|
16377234|NCT04138693|Placebo Comparator|Cohort 3: Placebo oral suspension|
16377235|NCT04138680|Experimental|Active Biofeedback|The patients in the active group will receive one active biofeedback training session.
16377236|NCT04138680|Sham Comparator|Sham Biofeedback|The patients in the sham group will receive one sham biofeedback training session.
16377237|NCT04138667|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema who will undergo complex decongestive therapy
16377238|NCT04138654|Experimental|Normal nitrite levels|Processed meat products enriched with natural compounds will contain normal nitrite levels.
16377239|NCT04138654|Experimental|Reduced nitrite levels|Processed meat products enriched with natural compounds will contain reduced nitrite levels
16377240|NCT04138628|Experimental|ctDNA screening arm|Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months
16377241|NCT04138615|Experimental|Morphine|Morphine will be administered intravenously
16377242|NCT04138615|Placebo Comparator|Placebo|Saline will be administered intravenously
16377243|NCT04138602|Active Comparator|Emsella Chair Active Treatment with Dietary Counseling|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%. During the visit the subject will also receive dietary counseling.
16377244|NCT04138602|Placebo Comparator|Emsella Sham Treatment with Dietary Counseling|Sham subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power). During the visit the subject will also receive dietary counseling.
16377245|NCT04138589||CF patients aged 6-18 years homozygeous for delta F508|CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor
16377246|NCT04138563||Case|Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
16377247|NCT04138563||Control|Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years
16377248|NCT04138537|Other|Acromegaly group|CCCRC test and OB volume results
16377249|NCT04138537|Other|Control Group|CCCRC test and OB volume results
16377375|NCT04137770|Experimental|intervention|Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs
16377250|NCT04138524|Experimental|interventional|All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
16377251|NCT04138511|Experimental|Experimental group (ECOFISIO)|Ecofisio Group received the ECOFISIO mobile application after students had received theoretical-practical lessons about ultrasound skills in sports pathologies areas, to study the subject.
16377252|NCT04138511|No Intervention|Control Group|Students received theoretical-practical lessons about ultrasound skills in sports pathologies areas and used traditional study models, to study the subject
16377253|NCT04138498|Experimental|Sequence 1 (ADBC)|Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
16377254|NCT04138498|Experimental|Sequence 2 (BACD)|Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
16377255|NCT04138498|Experimental|Sequence 3 (CBDA)|Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
16377256|NCT04138498|Experimental|Sequence 4 (DCAB)|Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
16377257|NCT04138485|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
16377258|NCT04138485|Placebo Comparator|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
16377259|NCT04138472|Experimental|Dexmedetomidine|Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
16377260|NCT04138472|Experimental|Fentanyl|Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
16377261|NCT04138472|Experimental|Lidocaine|Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
16377262|NCT04138459||Qualitative exploration|Ten community mental health service users will be interviewed with their most important mental health worker to explore how recovery orientation of services affects roles and collaboration.
16377263|NCT04138446|Experimental|200-3000|Day 1: 200m (above sea level) asl Day 2: 3000m asl
16377264|NCT04138446|Experimental|3000-200|Day 1: 3000m asl Day 2: 200m asl
16377265|NCT04138446|Experimental|200-5000|Day 1: 200m asl Day 2: 5000m asl
16377266|NCT04138446|Experimental|5000-200|Day 1: 5000m asl Day 2: 200m asl
16377267|NCT04138446|Experimental|3000-5000|Day 1: 3000m asl Day 2: 5000m asl
16377268|NCT04138446|Active Comparator|5000-3000|Day 1: 5000m asl Day 2: 3000m asl
16377269|NCT04138433|Experimental|Real tDCS|Behavioural anomia treatment plus anodal tDCS
16377270|NCT04138433|Sham Comparator|Sham tDCS|Behavioural anomia treatment plus sham tDCS
16377271|NCT04138420||Patients receiving Bevacizumab|Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.
16377272|NCT04138407|Experimental|Intervention|
16377273|NCT04138407|Other|Control|Usual rehabilitation exercise
16377276|NCT04138381|Other|selinexor as a single agent and in combination with imatinib|"This is a single-arm, two-cohort, open label phase Ib/II trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of:
~Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by en expansion phase (II) testing for safety and preliminary evidence of antitumor activity
~Cohort B: single-agent, fixed selinexor dose in the same target population"
16377277|NCT04138368|Experimental|dyadic treatment|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
16377278|NCT04138368|Active Comparator|supportive treatment|mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
16377279|NCT04138355|Experimental|Extracorporeal shock wave therapy group|. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
16377280|NCT04138355|No Intervention|conventional manual therapy|the same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy.
16377281|NCT04138342|Active Comparator|Quantum dots nanoparticles group|A group of female volunteers infected with breast cancer will receive topical Quantum dots in different dosage forms.
16377282|NCT04138342|Placebo Comparator|Topical approved placebo cream|A group of female volunteers infected with breast cancer will receive placebo cream as a negative control.
16377283|NCT04138329|Active Comparator|Lichtenstein Technique|In this arm the inguinal hernia repair was made with the Lichtenstein technique by surgeons with experience in this kind of plasty using the conventional polypropylene mesh.
16378098|NCT04132726|Placebo Comparator|Placebo|Placebo group which employed with non-effective treatment
16377284|NCT04138329|Experimental|Onstep Technique|In this arm the inguinal hernia repair was made with the Onstep technique by one surgeon with experience using the Bard's 3DMAX mesh.
16377285|NCT04138316||Migraine patients|
16377286|NCT04138303|Experimental|Exercise Only Group (EX)|Participants will only receive the exercise protocol without nutrition education or counseling and instructed to continue to consume their regular diet.
16377287|NCT04138303|Experimental|Exercise with CR-LC Group|Participants will receive the exercise protocol and CR-LC Diet regimen.
16377288|NCT04138303|Experimental|Exercise with Ancestral Diet (AD) Group|Participants will receive the exercise protocol and AD regimen.
16377289|NCT04138290|Experimental|Predictix Antidepressant Software tool|Predictix Antidepressant Software tool will be used when prescribed with a medication for their MDD, by their treating physician.
16377290|NCT04138277|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
16377291|NCT04138264|Active Comparator|Peroperative counseling|
16377292|NCT04138264|No Intervention|No preoperative counseling|
16377293|NCT04138251|Experimental|Treatment|Oral empaglifozin 5 mg 1x/day, increase up to 10 mg 1x/day if no 25% decrease of blood1,5-anhydroglucitol level
16377294|NCT04138238||Supraflex Cruz Sirolimus-eluting Stent|
16377295|NCT04138225||Healthy|Healthy participants are those without IBS, IBD or any other gastrointestinal disorder
16377296|NCT04138225||Irritable bowel syndrome (IBS)|Participants with Rome IV diagnosed IBS
16377297|NCT04138225||Inflammatory bowel disease (IBD)|Patients with IBD - either ulcerative colitis (UC) or Crohn's disease (CD)
16377298|NCT04138212|Active Comparator|Chemotherapy group|Patients in this group will receive neoadjuvant chemotherapy.
16377299|NCT04138212|Experimental|Chemoradiation group|Patients in this group will receive neoadjuvant chemoradiation therapy.
16377300|NCT04138199||Participants with Human Immunodeficiency Virus-1 Infection|Human Immunodeficiency Virus-1 (HIV-1) infected and clinically stable patients on dual or triple HAART including Kaletra who switched or planned to switch to generic product of lopinavir/ritonavir
16377301|NCT04138186|Experimental|2.0g G-PUR® capsules|
16377302|NCT04138186|Placebo Comparator|Placebo capsules|
16377303|NCT04138173|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
16377304|NCT04138173|No Intervention|Usual care group|Usual care
16377305|NCT04138160|Experimental|5:2 intermittent energy restriction|The 5:2 intermittent energy restriction (IER) of 70% restriction (~600 kcal) delivered for two non-consecutive days/week and no restriction (so sufficient energy to meet the requirement of participants) on the other 5 days/week.
16377306|NCT04138160|Other|Continuous energy restriction|The continuous energy restriction (CER) of 20% restriction below the estimated requirement of participants (~1600 kcal) 7 days/week.
16377307|NCT04138147|Active Comparator|Superficial cervical plexus with auriculotemporal nerve blocks|
16377308|NCT04138147|Experimental|Cervical retrolaminar with auriculotemporal nerve blocks|
16377309|NCT04138134||Group 1|Patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins
16377310|NCT04138134||Group 2|Patients with atherosclerotic obstructive disease of lower limbs
16377311|NCT04138121|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
16377312|NCT04138108|Experimental|Experimental Group|Two sessions of psychoeducation were given to the parents in the experimental group.
16377313|NCT04138108|No Intervention|Control Group|The parents in the control group did not undergo any intervention and the children of the parents in this group continued their current treatment plans.
16377314|NCT04138095|Other|Virtual Reality|As this is a within subject design, participants will act as their own control. Participants will have access to their baseline opioids and benzodiazepines for pain and anxiety. Every second day they will have access to virtual reality as an adjunct to their opioids and benzodiazepines to manage their symptoms
16377315|NCT04138082|Experimental|High-dB Environment|While performing the spinal anesthesia, the participants were exposed to a pre-recorded soundtrack of one of the investigators' operating rooms while the anesthesiology team was performing a spinal anesthesia. It included instruments noise and discussion but alarms, pulse oximetry and discussion with the patient were removed. The level of the soundtrack was set to be at 70 dB with peaks up to 100 dB, this level was recorded for every participant with Iphone™ application SoundMeter X 10.3 by Faber Acoustical, which has been both choosed in accordance with similar studies. The average noise was measured using the LEq value on a ''A'' scale (dB(A)) which correlate with frequencies perceived by the human ear. Speakers where placed at each corner of the room. Since literature describe that noise can initially enhance performance but is a transitory effect, the investigators decided to expose the experimental group to the maximum level of noise without any gradation.
16377316|NCT04138082|No Intervention|Low-dB Environment|The control group performed the same spinal anesthesia simulation scenario but without any soundtrack. The ambient noise in the room was recorded with the same method for each participant.
16377317|NCT04138069|Experimental|PLB+Aerobic Bicycling|Pursed Lip Breathing + Aerobic Bicycling
16377318|NCT04138069|Active Comparator|Aerobic Bicycling|Only Aerobic bicycling
16377319|NCT04138056|Experimental|XRSV formulation 3_dTpa Group|Subjects randomized to the XRSV formulation 3_dTpa group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377320|NCT04138056|Placebo Comparator|XPlacebo_RSV formulation 3 Group|Subjects randomized to the XPlacebo_RSV formulation 3 group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of Placebo in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377376|NCT04137757|Experimental|Lower Body Negative Pressure (LBNP)|Participants complete mental tasks and imaging while undergoing lower body negative pressure (LBNP).
16470535|NCT03494803||Prostate Cancer|
16377321|NCT04138056|Experimental|XRSV formulation 2_dTpa Group|Subjects randomized to the XRSV formulation 2_dTpa group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377322|NCT04138056|Placebo Comparator|XPlacebo_RSV formulation 2 Group|Subjects randomized to the XPlacebo_RSV formulation 2 group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of Placebo in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377323|NCT04138056|Placebo Comparator|XPlacebo_dTpa Group|Subjects randomized to the XPlacebo_dTpa group receive a single dose of Placebo in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377324|NCT04138056|Experimental|URSV formulation 3_dTpa Group|Subjects randomized to the URSV formulation 3_dTpa group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377325|NCT04138056|Placebo Comparator|UPlacebo_RSV formulation 3 Group|Subjects randomized to the UPlacebo_RSV formulation 3 group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of Placebo in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377326|NCT04138056|Experimental|URSV formulation 2_dTpa Group|Subjects randomized to the URSV formulation 2_dTpa group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377327|NCT04138056|Placebo Comparator|UPlacebo_RSV formulation 2 Group|Subjects randomized to the UPlacebo_RSV formulation 2 group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of Placebo in the right arm during vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377328|NCT04138056|Placebo Comparator|UPlacebo_dTpa Group|Subjects randomized to the UPlacebo_dTpa group receive a single dose of Placebo in the left arm, a single dose of dTpa vaccine in the right arm during vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 (12 to 18 months post 1st vaccination) vaccine in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
16377329|NCT04138043|Experimental|GSK2330811 450 mg|Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter [mg/mL]).
16377330|NCT04138043|Placebo Comparator|Placebo|Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
16377331|NCT04138030|Active Comparator|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
16377332|NCT04138030|Active Comparator|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
16377333|NCT04138017|Experimental|ViviGen Cellular Bone Matrix|Patients will receive the vivigen cellular bone matrix
16377334|NCT04138004|Experimental|2-L PEG with LB|"PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The patients were instructed to take 250 mL every 15 min untill the entire solution was consumed.
~In this group (2-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day)."
16377335|NCT04138004|Active Comparator|4-L PEG|In this group (4-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day.
16377336|NCT04137991|Experimental|Nol-Guided Analgesia Group|In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
16377337|NCT04137991|Active Comparator|Standard Analgesia Group|Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
16377338|NCT04137978|Active Comparator|ADV7103|"Patients receive ADV7103 twice a day at optimal dose. Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
~Other Names:
~• Potassium Citrate and Potassium Bicarbonate"
16377339|NCT04137978|Active Comparator|Standard of care comparator|Alkalinising treatment (SoC) taken at the usual dose and frequency
16377340|NCT04137965||Testicular torsion group|Men having undergone surgery for testicular torsion between 01.01.2003 and 12.31.2012
16377341|NCT04137965||Control group|Men without knowledge of their fertility status and who have never had their semen analyzed
16378099|NCT04132726|No Intervention|Control|no treatment
16377342|NCT04137952|Experimental|deterministic visual error gain|"Day1(Pretest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min
~Day2 to Day5:
~Exp.group:27 times of posture tracking with high visual error gain.
~Control group:27 times of posture training with normal visual error gain.
~Day6 (Posttest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min"
16377343|NCT04137952|Experimental|stochastic visual noise|"Day1(Pretest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min
~Day2 to Day5:
~Exp.group A:27 times of posture training with posture tracking signal-to-noise ratio=2:1.
~Exp.group B:27 times of posture training with posture tracking signal-to-noise ratio=4:1.
~Control group:27 times of posture training with normal visual error gain.
~Day6(Posttest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min"
16377344|NCT04137952|Experimental|intermittent visual gain|"Day1 (Pretest):
~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec
~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec.
~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec
~air pillow stance, 8 times/1 min
~Day2 (training section):
~Exp. group:Posture tracking with wearing flash glasses (low frequency with opaque ratio 50%), 12 times/45 sec.
~Control group:Posture tracking with wearing flash glasses (clear), 12 times/45 sec.
~Day3 (Posttest):
~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec
~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec
~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec
~air pillow stance, 8 times/1 min"
16377345|NCT04137939|No Intervention|Control group|Ctrl group is instructed to maintain their original daily life
16377346|NCT04137939|Experimental|Smart Exercise group|SE group are instructed to perform one session of upper extremity ergometer and one session of lower extremity ergometer in a week, 30 minute per session, lasting for 12 weeks.
16377347|NCT04137926|Experimental|Alzheimer's disease|
16377348|NCT04137926|Experimental|MCI due to AD|
16377349|NCT04137926|Experimental|Normal Elderly|
16377350|NCT04137913|Experimental|Music Group|Individuals in the music group will complete two assessment visit (pre-intervention and post-intervention). After their baseline visit, they will participate in a 6-week group music class, scheduled for 2 hours a day, 3 days a week. The daily music workshops will be led by a musician associated with the Rice Shepherd School of Music. Each week will be carefully scaled in difficulty, with the workshops becoming progressively more sophisticated. For instance, the first week's listening will focus on short and more familiar works such as instrumental etudes and folk songs. Gradually, the instructor will build towards symphonic movements, as well as more unfamiliar and experimental music. The course will culminate in creating a final composition.
16377351|NCT04137913|No Intervention|Non-music group|Individuals in the non-music group will complete two assessment visits separated by 2-3 months. They will be asked not to participate in any other music-related courses during the time they are enrolled in the study. At the end of participation, participants will be given resources to seek out music classes.
16377352|NCT04137900|Experimental|TAB004 0.3 mg/kg repeat dose every 21 days up to 2 years|
16377353|NCT04137900|Experimental|TAB004 1 mg/kg repeat dose every 21days up to 2 years|
16377354|NCT04137900|Experimental|TAB004 3 mg/kg repeat dose every 21 days up to 2 years|
16377355|NCT04137900|Experimental|TAB004 10 mg/kg repeat dose every 21 days up to 2 years|
16377356|NCT04137900|Experimental|TAB004 200mg repeat dose every 21 days up to 2 years|
16377357|NCT04137900|Experimental|TAB004 20mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
16377358|NCT04137900|Experimental|TAB004 70mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
16377359|NCT04137900|Experimental|TAB004 200mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
16377360|NCT04137900|Experimental|TAB004 500mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
16377361|NCT04137887|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
16377362|NCT04137887|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
16377363|NCT04137874|Experimental|eSTROKE|
16377364|NCT04137874|Active Comparator|Control|Conventional prehospital care
16377365|NCT04137861|Active Comparator|Mineral Trioxide Aggregate (MTA)|Root repair material
16377366|NCT04137861|Experimental|bioceramics|Root repair material
16377367|NCT04137848|Experimental|Experimental|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
16377368|NCT04137848|Sham Comparator|Control|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
16377369|NCT04137835|Experimental|Showmotion|"Performing an analysis requires the positioning of sensors on the patient's skin in predetermined positions, according to the related protocols. Each sensor positioned on patient's skin provides both raw data (accelerometer, magnetometer, gyroscope) and the orientation matrix, representing the orientation of the local System of Reference (SoR) with respect to a fixed SoR. A proprietary sensor-fusion algorithm allows provides an accurate estimate of the orientation, as assessed by stereo-photogrammetric system-based testing.
~Data from each sensor are sampled at 50 Hz and transferred wirelessly to a laptop with a proprietary software that processes the data according to the biomechanical model chosen for the analysis."
16377370|NCT04137809|Experimental|Robot Group|1-arm study where eligible volunteers will undergo robotic testing for safety, comfort, and fit.
16377371|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
16377372|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
16377373|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
16377374|NCT04137770|No Intervention|control|Patients will receive routine post-operative analgesics
16483039|NCT03408977|Experimental|Women|
16377377|NCT04137757|Sham Comparator|Sham Pressure|Participants complete mental tasks and imaging with pressure noise but no pressure.
16377378|NCT04137744|Active Comparator|ARM preservation ALND|ARM +ve LN PRESERVED , ALND COMPLETED LATER ON
16377379|NCT04137744|Active Comparator|conventional ALND|ARM +VE NODES MARKED AND TAKEN WITH ALND
16377380|NCT04137731|Experimental|IFC Treatment|The IFC treatment will be used for 30 minutes, twice a day for two days after the total knee arthroplasty
16377381|NCT04137731|Placebo Comparator|Placebo|One set of device is programmed to be used as Placebo, the subject will feel the vibration but will not receive a therapeutic signal.
16377382|NCT04137718||Rare driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation positive.
16377383|NCT04137718||Rare driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction(PCR)panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation negative.
16377384|NCT04137692|Experimental|Red Blood Cell Transfusion|Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
16377385|NCT04137679|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
16377386|NCT04137679|Active Comparator|Neoadjuvant Radiochemotherapy followed by surgery|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
16377387|NCT04137653|Experimental|nab-Paclitaxel group|749 patients will be assigned into nab-Paclitaxel group.
16377388|NCT04137653|Active Comparator|paclitaxel group|749 patients will be assigned into paclitaxel group
16377389|NCT04137640|Other|endocrine group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into endocrine group.
16377390|NCT04137640|Other|chemotherapy group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into chemotherapy group
16377391|NCT04137627|Experimental|Melatonin|The group received standard treatment with the oral administration of Melatonin
16377392|NCT04137627|Placebo Comparator|Placebo|The group received standard treatment with the oral administration of Placebo
16377393|NCT04137614|Placebo Comparator|Digital substraction angiography|
16377394|NCT04137614|Experimental|Drug-coated balloon|
16377395|NCT04137588||Group A|antiangiogenesis 7.5mg/Kg q3w+pemetrexed 500mg/m2 q3w+ platinum 75mg/m2 q3w
16377396|NCT04137588||Group B|immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
16377397|NCT04137588||Group C|antiangiogenesis 7.5mg/Kg q3w+immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
16377398|NCT04137575|Experimental|ConquerFear-Group|ConquerFear-Group is a psychological intervention developed specifically for fear of cancer recurrence
16377399|NCT04137575|Placebo Comparator|Relaxation Training|The Relaxation Training serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence.
16377400|NCT04137562|Experimental|ADSTEM Inj.|ADSTEM Inj. hAD-MSC 1.0x10^8 cells
16377401|NCT04137562|Placebo Comparator|Placebo|0.9% Normal Saline Inj.
16377402|NCT04137549||Nocturnal controlled hypertension|Nocturnal blood pressure was controlled under 120/70 mmHg after aggressive anti-hypertensive therapy.
16377403|NCT04137549||Nocturnal uncontrolled hypertension|Nocturnal blood pressure was still over 120/70 mmHg after aggressive anti-hypertensive therapy.
16377404|NCT04137536|Experimental|Pancreatic Adenocarcinoma|Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.
16377405|NCT04137510|Experimental|Orsiro|
16377406|NCT04137510|Active Comparator|Resolute Onyx|
16377407|NCT04137497||Patients with disorders of consciousness|
16377408|NCT04137497||Patients with unresponsive wakefulness syndrome|
16377409|NCT04137497||Patients with minimally conscious state|
16377411|NCT04137445|Experimental|Study Provided Diet|A group of complementary foods provided to participants by researchers.
16377412|NCT04137445|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
16377413|NCT04137432|Experimental|Oxytocin (24 IU)|Intranasal administration of 24 international units (IU) of oxytocin (OT) 30 minutes before the start of four intervention sessions
16377414|NCT04137432|Placebo Comparator|Placebo|Intranasal administration of a placebo spray 30 minutes before the start of four intervention sessions
16377415|NCT04137419|Experimental|ProlacSan|Patient will get ProlacSan lozenges after nonsurgical treatment of periodontitis.
16377416|NCT04137419|Placebo Comparator|Placebo|Patients will get placebo lozenges after nonsurgical periodontal treatment
16377417|NCT04137406||T1 tumor with lymph node metastasis|patients with T1 tumor and lymphnode positive
16377418|NCT04137406||T2 or T3 tumor with lymph node negative|patients with T2 or T3,lymph node negative
16377419|NCT04137393|Experimental|Salvadora persica|"brush teeth with Salvadora persica Miswak"
16377420|NCT04137393|Active Comparator|tooth brush|brush with fluoridated tooth paste
16377421|NCT04137380|Experimental|Mirikizumab - Intravenous (IV)|Mirikizumab administered IV
16377422|NCT04137380|Placebo Comparator|Placebo - IV|Placebo administered IV
16377423|NCT04137380|Experimental|Mirikizumab - Subcutaneous (SC)|Mirikizumab administered SC
16377424|NCT04137380|Placebo Comparator|Placebo - SC|Placebo administered SC
16377425|NCT04137367|Experimental|Active Affective Bias Modification|Computer based Affective Bias Modification
16377426|NCT04137367|Sham Comparator|Sham Affective Bias Modification|Computer based sham Affective Bias Modification
16380496|NCT04115657|Experimental|Sugar 2|Blend of sucrose and palatinose
16377427|NCT04137354|Placebo Comparator|Control Iron&Vitamin A Placebo|Children randomly assigned to the placebo iron & vitamin A control group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months).
16377428|NCT04137354|Experimental|Vitamin A & Placebo Iron Supplements|Children is this group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive a high dose vitamin A capsule (200,000IU) at baseline and after 4.5 months (at mid-line)
16377429|NCT04137354|Experimental|Intermittent Iron Supplements & Placebo Vitamin A|"Children is this group will receive weekly three tablets of iron (42mg of elemental iron once a week) for 9 months (equivalent to a one school year).
~They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months)."
16377430|NCT04137354|Experimental|Intermittent Iron Supplements & High dose Vitamin A|Combined weekly iron supplementation (42mg of elemental iron once a week) for 9 months and high dose vitamin A (200,000IU) at baseline and after 4.5 months (mid-line).
16377431|NCT04137341|Experimental|Tablet A|A single oral 300-mg dose of GLPG1972 in fasted state
16377432|NCT04137341|Experimental|Tablet B|A single oral 300-mg dose of GLPG1972 in fasted state
16377433|NCT04137341|Experimental|Tablet C|A single oral 300-mg dose of GLPG1972 in fasted state
16377434|NCT04137341|Experimental|Food effect|selected tablet B or C under fed conditions
16377435|NCT04137328|Experimental|liraglutide group|Mecobalamin tablets (0.5mg/day, oral) and liraglutide (0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection) were used for 3 months.
16377436|NCT04137328|Active Comparator|control group|Take Mecobalamin (0.5mg/day, oral), add or adjust insulin (when basic insulin is preferred for those who do not use insulin, if insulin has been used, adjust the dose or program according to the condition, inject subcutaneously) for 3 months.
16377437|NCT04137302|Active Comparator|Topical hydrocortisone administration|dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)
16377438|NCT04137302|Active Comparator|Systemic hydrocortisone administration|tablets (once a day, 50 mg, morning, during 50 days)
16377439|NCT04137289|Experimental|Phase Ia: BI 905711 - dose escalation|
16377440|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 1|
16377441|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 2|
16377442|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 3|
16377443|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 4|
16377444|NCT04137276|Experimental|vitamin C and thiamine|patients who received intravenous vitamin C and thiamine
16377445|NCT04137276|Active Comparator|thiamine|patients who received thiamine
16377446|NCT04137263|Experimental|Treatment|Subjects will receive dose formulation for treatment of melasma
16377447|NCT04137250|Active Comparator|Hamstring|It is the group in which the hamstrings are surgically removed to be used as an autograft for the reconstruction of the anterior cruciate ligament. The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament.
16377448|NCT04137250|Experimental|Quadriceps tendon|It is the group in which a portion of the quadriceps tendon will be surgically removed for later use as an autograft for the reconstruction of the anterior cruciate ligament. The intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
16377451|NCT04137211|Experimental|Prolonged sitting with social break|
16377452|NCT04137211|Experimental|Prolonged sitting with walk break|
16377453|NCT04137211|Experimental|Prolonged sitting with simple resistance activities|
16377454|NCT04137198|No Intervention|control|classic analgetic protocol
16377455|NCT04137198|Experimental|intervention|intranasal Sufentanil
16377456|NCT04137185|Experimental|rhTSH|Phase 1: 0.9mgx1d、0.9mgx2d、1.8mgx1d、1.8mgx2d, intramuscularly (IM) ; Phase 2: patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the Phase 1.
16377457|NCT04137172|Experimental|group1|underwent laparoscopic IPOM hernioplasty without repair
16377458|NCT04137172|Experimental|group2|underwent laparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
16377459|NCT04137172|Experimental|group3|underwent laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
16377460|NCT04137159|Experimental|FES rowing|Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
16377461|NCT04137159|No Intervention|Wait list|During the 12-week treatment as usual program, subjects will not participate in FES-rowing.
16377462|NCT04137146|Experimental|Sacral Nerve Stimulation|Intervention: Sacral nerve Stimulation Stimulation sites：S3 Postoperative study visits lasted approximately 3 hours and were conducted in 3 months.
16377463|NCT04137146|No Intervention|No SNS Intervention|
16377464|NCT04137133|Experimental|collection of expectoration, stools and blood|
16377465|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
16377466|NCT04137107|Experimental|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
16377467|NCT04137107|Experimental|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
16377468|NCT04137107|Placebo Comparator|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
16377469|NCT04137107|Experimental|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
16377470|NCT04137107|Placebo Comparator|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
16377471|NCT04137094|Experimental|PHCI with HIV/HCV counselor|A persuasive health communication intervention will be performed by a community HIV/HCV test counselor
16377472|NCT04137094|Experimental|PHCI with ED Medical Staff|A persuasive health communication intervention will be performed by ED medical staff
16377473|NCT04137081|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
16377474|NCT04137068|Other|Sedentary to Active|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their normal level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks, and then maintain baseline activity level for two weeks. The fifth week will be maintaining baseline activity level. Participants will visit the laboratory once every week during these 5 weeks.
16377475|NCT04137068|Other|Active to Sedentary|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their normal level of physical activity. After the baseline visit, participants will maintain their baseline level of physical activity for one week, and then reduce their step count for two weeks. The fifth week will be maintaining baseline activity level. Participants will visit the laboratory once every week during these 5 weeks.
16377476|NCT04137055|Experimental|ZSP0678-10mg (single dose)-Cohort 1|ZSP0678/Placebo 10mg
16377477|NCT04137055|Experimental|ZSP0678-30mg (single dose)-Cohort 2|ZSP0678/Placebo 30 mg Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.
16377478|NCT04137055|Experimental|ZSP0678-60mg (single dose)-Cohort 3|ZSP0678/Placebo 60mg Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.
16377479|NCT04137055|Experimental|ZSP0678-120mg (single dose)-Cohort 4|ZSP0678/Placebo 120mg Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.
16377480|NCT04137055|Experimental|ZSP0678-180mg (single dose)-Cohort 5|ZSP0678/Placebo 180mg Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.
16377481|NCT04137055|Experimental|ZSP0678-240mg (single dose)-Cohort 6|ZSP0678/Placebo 240mg Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.
16377482|NCT04137055|Experimental|ZSP0678-320mg (single dose)-Cohort 7|ZSP0678/Placebo 320mg Enrollment into Cohort 7 will begin upon assurance of safety for Cohort 6.
16377483|NCT04137055|Experimental|ZSP0678 (food effect)-Cohort FE|"Period 1: Group A and Group B receive ZSP0678/Placebo under the fasting or fed condition ,respectively on Day1.
~Period 2: Group A and Group B receive ZSP0678/Placebo under the fed or fasting condition ,respectively on Day8.
~Enrollment into Cohort FE will begin upon assurance of safety for Cohort 4."
16377484|NCT04137055|Experimental|ZSP0678 Dose1 (multiple doses)-Cohort 8|ZSP0678/Placebo Dose1 will be administrated according to the results of Cohort 2&3
16377485|NCT04137055|Experimental|ZSP0678 Dose2 (multiple doses)-Cohort 9|ZSP0678/Placebo Dose2 will be administrated according to the results of Cohort 3&4
16377486|NCT04137055|Experimental|ZSP0678 Dose3 (multiple doses)-Cohort 10|ZSP0678/Placebo Dose3 will be administrated according to the results of Cohort 4&5
16377487|NCT04137042|Active Comparator|Saline|intraoperative fluid therapy by using 0.9% saline
16377488|NCT04137042|Experimental|Balanced crystalloid|intraoperative fluid therapy by using balanced crystalloid
16377489|NCT04137029|Experimental|smoking|Healthy smoking volunteers
16377490|NCT04137029|Experimental|non-smoking|Healthy non-smoking volunteers
16377491|NCT04137016|Experimental|HIV-subjects with APP|HIV-infected patients using the App + standard clinical management (SCM)
16377492|NCT04137016|No Intervention|Control group|HIV-infected patients, who only receive Standard Clinical Management (without the App)
16377493|NCT04137003|Experimental|Rouge et Or program|Rouge et Or program group follow a detailed program that they do on their own. It is made of three cycles of four weeks each. Every cycle contains 3 training sessions by week with a minimum of 24 hours between sessions. The training volume is modulated for every cycle and every week. Each training sessions is made of 6 warm-up exercises followed by 6 training exercises. The exercises are a mix of strengthening, endurance, plyometric, neuromuscular control and dynamic stability. The exercises change every month with a progressively increasing difficulty towards the end to mimic return to sport demands.
16377494|NCT04137003|Active Comparator|CHU intervention guide|CHU intervention guide group follow the standard CHU protocol. At three months post-surgery, the protocol suggests progressing the exercises without precisely suggesting exercise, parameter or frequency.
16377495|NCT04136990|Active Comparator|Isolated ACL reconstruction|Isolated ACL reconstruction only.
16377496|NCT04136990|Experimental|ACL + LEAT|ACL reconstruction combined with Lateral Extra-Articular Tenodesis (LEAT).
16377599|NCT04136327|Experimental|GLPG1972 oral and [14C]-GLPG1972 IV|GLPG1972 film-coated tablet followed by [14C]-GLPG1972 solution for infusion
16377497|NCT04136964||Patients group|Patients who have pain located in the anatomical region of the neck for more than three months due to mechanical causes; with or without radiation to the head, trunk, and upper limbs. Posteriorly, pain may be present in the neck region from the superior nuchal line to the spine of the scapula and the side region down to the superior border of the clavicle and the suprasternal notch.
16377498|NCT04136951|Experimental|Experimental phase|The PREVENT recommendation about patient homecare priority will be shared in homecare referral communication with the homecare intake coordinators. Homecare intake coordinators will be instructed to prioritize high risk patients for care.
16377499|NCT04136938||Intervention group (social marketing campaign)|People aged 60 and over will be included. They will receive a social marketing campaign.
16377500|NCT04136938||Control group|People aged 60 and over will be included.
16377501|NCT04136925||"runner participating of the Grand Raid"|
16377502|NCT04136912|Experimental|Breast Imaging Cohort|A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
16377503|NCT04136912|Experimental|Thyroid Imaging Cohort|A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
16377504|NCT04136912|Experimental|Healthy Volunteers Cohort|A total of 5 participants will be included to optimize imaging parameters.
16377505|NCT04136886|Active Comparator|IMRT and concurrent cisplatin|IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction
16377506|NCT04136886|Experimental|IMRT alone|IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction
16377507|NCT04136873|Active Comparator|Part A: 5 mg QD CVL-231|Oral Dose
16377508|NCT04136873|Placebo Comparator|Part A: 5 mg QD Placebo|Matching Placebo; Oral Dose
16377509|NCT04136873|Active Comparator|Part A: 10 mg QD CVL-231|Oral Dose
16377510|NCT04136873|Placebo Comparator|Part A: 10 mg QD Placebo|Matching Placebo; Oral Dose
16377511|NCT04136873|Active Comparator|Part A: 20 mg QD CVL-231|Oral Dose
16377512|NCT04136873|Placebo Comparator|Part A: 20 mg QD Placebo|Matching Placebo; Oral Dose
16377513|NCT04136873|Active Comparator|Part A: 5-10-20 mg BID CVL-231|Oral Dose
16377514|NCT04136873|Placebo Comparator|Part A: 5-10-20 mg BID Placebo|Matching Placebo; Oral Dose
16377515|NCT04136873|Active Comparator|Part A: 30 mg QD CVL-231|Oral Dose
16377516|NCT04136873|Placebo Comparator|Part A: 30 mg QD Placebo|Matching Placebo; Oral Dose
16377517|NCT04136873|Active Comparator|Part B 30 mg QD CVL-231|Oral Dose
16377518|NCT04136873|Placebo Comparator|Part B 30 mg QD Placebo|Matching Placebo; Oral Dose
16377519|NCT04136873|Active Comparator|Part B 20 mg BID CVL-231|Oral Dose
16377520|NCT04136873|Placebo Comparator|Part B 20 mg BID Placebo|
16377521|NCT04136860||Conservative management|Patients refused to accept any interventional treatment or patients were not suitable for any interventional treatment.
16377522|NCT04136860||Microsurgical resection|All microsurgical procedures were performed with intraoperative neuronavigation, ultrasonography, indocyanine fluorescence angiography (ICG), continuous monitoring of electroencephalogram and somatosensory evoked potential.
16377523|NCT04136860||Embolization|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Multi-stage embolization and target embolization were widely used within the embolization. Onyx was the main embolization material.
16377524|NCT04136860||Embolization+Radiosurgery|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Radiosurgery management was recommended for the residual lesions about 3 months after the embolization if necessary.
16377525|NCT04136860||Single-stage hybrid surgery|Hybrid surgery is a new surgical strategy defined as single-stage combined microsurgical resection and embolization in which embolization is performed firstly on the deep feeding artery, aneurysm, AVF, and meningeal arteries involved in blood supply of the nidus, and then, the microsurgical resection was performed immediately. Intraoperative angiography was performed repeatedly before the skull was closed, confirming complete occlusion of the malformation.
16377526|NCT04136847|Experimental|Hand Aging|Microneedling treatment of the dorsum of the hands
16377527|NCT04136834|Experimental|Pegtomarginase (PT01)|To determine the MTD of PT01 based on the toxicity observed during Cycle 1 of the Dose Escalation Phase and to investigate the safety and tolerability of PT01 when administered intravenously(IV) to subjects with advanced malignancies
16377528|NCT04136821|Placebo Comparator|Placebo|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
16377529|NCT04136821|Experimental|Oceanix™|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
16377530|NCT04136795||Conventional surgery|Patients having had esophageal atresia (type III, long gap excluded) repair by conventional surgery (right thoracotomy) or patients having had minimally invasive surgery converted to thoracotomy between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
16377531|NCT04136795||Minimally invasive surgery|Patients having had esophageal atresia (type III, long gap excluded) repair through minimally invasive surgery between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
16377532|NCT04136782|Experimental|Trial group|55 cases of triple-negative breast cancer will be assigned into a trial group.
16377533|NCT04136782|Active Comparator|Control group|55 cases of triple-negative breast cancer will be assigned into a control group.
16377560|NCT04136600|Placebo Comparator|Placebo arm|12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
16381018|NCT04112043|Active Comparator|NR plus Walking Exercise|
16377534|NCT04136769|Experimental|Intervention|"After trial enrolment, patients undergo visceral debranching.
~After visceral debranching, patients proceed to neoadjuvant chemotherapy. The therapy as such is not a formal part of the trial protocol. The specific chemotherapy regimen and its duration are decided individually by treating physicians.
~Tumor resection should be performed two to four weeks after completion of chemotherapy. Prior to resection, re-staging and verification of vascular reconstruction patency are carried out. The specific procedure for tumor resection and intestinal tract reconstruction is at the choice of the treating surgeon. It should follow oncological principles and aim at complete removal of the tumor and regional lymph nodes. Usually, resection will be done as pancreatoduodenectomy with or without distal gastrectomy (Whipple's procedure or pylorus-preserving Whipple's procedure), distal pancreatectomy with splenectomy, or total pancreatectomy with splenectomy."
16377539|NCT04136743|Active Comparator|Corticosteroid|Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg [triamcinolone acetonide]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.
16377540|NCT04136743|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
16377541|NCT04136730|No Intervention|Control|Usual Care
16377542|NCT04136730|Active Comparator|Home-based|Home-based resistance exercise training
16377543|NCT04136717|Other|COPD patients|Patients with acute exacerbation of COPD and respiratory acidosis under oxygen therapy.
16377544|NCT04136717|Other|Bariatric surgery patients|Obese patients after gastric surgery under CPAP.
16377545|NCT04136704||Sleeve Gastrectomy in Pediatric Patients|Laparoscopic Sleeve Gastrectomy will be offered as an adjuvant to a multidisciplinary family-based program that focuses on nutrition, physical activity, and behavioral counseling.
16377546|NCT04136704||Sleeve Gastrectomy in Adult Patients|This comparison group will be composed of adult patients who undergo sleeve gastrectomy
16377547|NCT04136691|Experimental|simulation training|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed. In the research, the application of burn patient scenario was performed only with the intervention group.
16377548|NCT04136691|No Intervention|Control|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed.
16377549|NCT04136678|Experimental|treadmill back walking training|15 minutes conventional walking training, 15 minutes of treadmill back walking training, 15-minute treadmill forward walking training
16377550|NCT04136665|Experimental|Physical Activity Adapted program|
16377551|NCT04136652|Placebo Comparator|Sham|The women are randomized, by a computer program, to a sham laser-treatment with the laser not active.
16377552|NCT04136652|Active Comparator|Laser|The women are randomized, by a computer program, to a vaginal CO2 laser-treatment with 30 w.
16377553|NCT04136639|Experimental|Miswak|Miswak sticks used twice daily, every 12 hours, for three months.
16377554|NCT04136639|Experimental|Grape Seed Extract|Grape seed extract 6.5% mouthwash used twice daily, every 12 hours, for three months.
16377555|NCT04136639|Active Comparator|Fluoride Mouthwash|0.05% fluoride mouthwash used twice daily, every 12 hours, for three months.
16377556|NCT04136626|Experimental|Perspectives OCD|12 week Smartphone-delivered CBT for OCD.
16377557|NCT04136626|Active Comparator|The Health and Well-Being Program|12 week health and well-being education
16377558|NCT04136613|Experimental|Post placental intra uterine device insertion|There was immediate post-partum insertion of CuT 380 A intrauterine device after delivery of placenta during cesarean delivery. To overcome the considerable expulsion rate in the previous studies, we stabilize the IUD in place at the fundus be an absorbable suture; vicryl 0 that was introduced through the fundus, held the needle with sponge holder that was introduce up the fundus and taken out the vicryl through the lower uterine inscion, cutting the needle, hold the vicryl around the the T arm of the IUD and withdrawn back to be placed inside the fundus. Before closing the uterine incision, the threads were placed in the lower uterine segment, then the uterine incision was then closed routinely.
16377559|NCT04136600|Experimental|EGFR antibody arm|Participants received a dose of 500 mg/m2 Cetuximab iv on Day 1 of cycle every 3 weeks, or 400mg Nimotuzumab on Day 1 of cycle, every week, until disease progression. 12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
16377597|NCT04136340|Active Comparator|In-person follow-up|Due to the COVID-19 pandemic, patients originally randomized to the in-person group received telemedicine visits. Thus, the researchers will expand our sample for these interviews to include patients who have completed at least 2 telemedicine follow-up visits whether they were originally randomized to the in-person group or the home telemedicine group.
16377561|NCT04136587|Active Comparator|Healthy Controls|"Inclusion criteria:
~Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss
~Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia
~Exclusion criteria:
~Diagnosis of IBD or any other inflammatory condition of the small and large intestine
~Diagnosis of irritable bowel syndrome (IBS)
~Autoimmune disorders
~Obesity (BMI> 30)
~Regular intake of NSAIDs (> 2 tablets/ week), immunosuppressants
~Intake of antibiotics within the last 3 months
~Intestinal infection by enteric pathogens
~Probiotic therapy"
16377562|NCT04136587|Active Comparator|Crohn's disease|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)
~Inclusion criteria:
~Colonoscopy indicated by routine clinical care
~Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)
~Exclusion criteria:
~• Intestinal infection by enteric pathogens"
16377563|NCT04136587|Active Comparator|Ulcerative Colitis|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)
~Inclusion criteria:
~Colonoscopy indicated by routine clinical care
~Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)
~Exclusion criteria:
~• Intestinal infection by enteric pathogens"
16377564|NCT04136587|Active Comparator|Colorectal carcinoma|"Inclusion criteria:
~• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology
~Exclusion criteria:
~• None"
16377565|NCT04136587|Active Comparator|Colitis/Enteritis of other origin|"Inclusion criteria:
~Diagnosis of intestinal inflammation at endoscopy or histology
~E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause
~Exclusion criteria:
~• None"
16377566|NCT04136561|Experimental|CVC and Midline Catheter|Existing standard of care CVC. Midline catheter placed within 24 hours of CVC placement.
16377567|NCT04136561|No Intervention|CVC|Standard of care CVC: case-matched controls using baseline data.
16377568|NCT04136548|Experimental|Fentanyl|Fentanyl will be administered intravenously
16377569|NCT04136548|Placebo Comparator|Placebo|Placebo will be administered intravenously
16377570|NCT04136535|Experimental|Pemetrexed and Carboplatin with Anlotinib|Pemetrexed and Carboplatin with Anlotinib
16377571|NCT04136535|Active Comparator|Pemetrexed and Carboplatin without Anlotinib|Pemetrexed and Carboplatin without Anlotinib
16377572|NCT04136522|Active Comparator|conventional|The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
16377573|NCT04136522|Experimental|total mesopancreas excision with arterial first approach|The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
16377574|NCT04136509|Experimental|allograft|The filler used in sinus floor elevation is albumin impregnated allograft.
16377575|NCT04136509|Experimental|xenograft|The filler used in sinus floor elevation is anorganic bovine bone mineral.
16377576|NCT04136496|Active Comparator|Ink placed before chemotherapy (Study A)|In Study A, 0.5 mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy
16377577|NCT04136496|Active Comparator|Ink placed after chemotherapy (Study B)|In Study B, 0.5 mL of Black Eye Ink will be placed before neoadjuvant therapy
16377578|NCT04136483|Experimental|CBT-I|
16377579|NCT04136470||NSCLC|This cohort will consist of 100 patients with non-small cell lung cancer (NSCLC).
16377580|NCT04136470||MEL|This cohort will consist of 30 patients with melanoma (MEL).
16377581|NCT04136457|Experimental|Endurance|Endurance training
16377582|NCT04136457|Experimental|Resistance|Resistance training
16377583|NCT04136457|Experimental|Sprint|Sprint training
16377584|NCT04136444|Experimental|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
16377585|NCT04136444|Experimental|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
16377586|NCT04136431|Experimental|Intervention group|
16377587|NCT04136431|Placebo Comparator|Control group|
16377588|NCT04136418|Active Comparator|Usual care|Patients currently self-manage their condition using antibiotics and steroids when their disease symptoms match the criteria in information provided by a clinician
16377589|NCT04136418|Experimental|Mobile App device|Patients enter their health status onto an App which is relayed to the healthcare team, who can then provide further information or clinical intervention should they so choose
16377590|NCT04136392||Eligible Patients|The population to be enrolled in this study includes patients whose intended treatment is to receive mechanical circulatory support with the ABIOMED, Inc. hemodynamic support devices per the treating physician's discretion and best practices.
16377591|NCT04136379||Clinic monitoring|Patients who attend a warfarin clinic for management of their INR
16377592|NCT04136379||Home monitoring|Patients who undertake home monitoring of their INR using a CoaguChek POC device
16377593|NCT04136366|Experimental|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
16377594|NCT04136366|Active Comparator|Standard surgical care procedure|Standard procedure performed.
16377598|NCT04136340|Experimental|Home Telemedicine follow-up|
16377603|NCT04136301|Experimental|Informative video arm|"Nuliparus women admitted to an induction will be exposed to informative video with data regarding labor and possible obstetric emergencies such as cesarean delivery.
~All patients will answer the State-Trait Anxiety Inventory (STAI) before and after intervention"
16377604|NCT04136301|No Intervention|control arm|no intervention. All patients will answer the State-Trait Anxiety Inventory (STAI) before and after delivery.
16377605|NCT04136288|Experimental|Males with erectile dysfunction (ED)|Males diagnosed with erectile dysfunction (ED) for over a year, but less than 5 years, will receive shock wave therapy via MoreNova device
16377606|NCT04136275|Experimental|CAR-37 T cells|"CAR-37 will be administered intravenously on day 0
~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.
~Subjects will receive 3 days of lymphodepleting chemotherapy starting Day -5, before the infusion of CAR-37 T cells on Day 0"
16377607|NCT04136275|Experimental|CAR-37 T cells Dose Escalation|"CAR-37 will be administered intravenously on day 0
~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.
~CAR-37 will undergo dose escalation"
16377608|NCT04136262|Experimental|Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
16377609|NCT04136262|Placebo Comparator|TwHF (dummy) plus MTX|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
16377610|NCT04136249|No Intervention|Control chimiotherapeutic arm|Standard care as comparaison procedure that includes chemotherapy
16377611|NCT04136249|Experimental|Physical over-activity|The procedure under study which includes a re-training mixing EMS and EXC with a nutrition adapted to the needs related to the physical over-activity following the chemotherapy
16377612|NCT04136236||esophageal mucosal lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
16377613|NCT04136223||RA-ILD|"Consecutive adult patients (aged >18 years) with RA* and interstitial lung disease
~*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010"
16377614|NCT04136184|Experimental|AKCEA-TTR-LRx|AKCEA-TTR-LRx by subcutaneous injection once every 4 weeks
16377615|NCT04136184|Active Comparator|Inotersen|Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to AKCEA-TTR-LRx administered subcutaneously once every 4 weeks until the end of study
16377616|NCT04136171|Experimental|AKCEA-TTR-LRx|ACKEA-TTR-LRx by subcutaneous injection once every 4 weeks
16377617|NCT04136171|Placebo Comparator|Placebo|Matching placebo by subcutaneous injection once every 4 weeks
16377618|NCT04136145|Experimental|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
16377619|NCT04136145|Experimental|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
16377620|NCT04136132|Experimental|Biological collection|"Biological collection
~For all the patients include in the study :
~blood and tissue samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database"
16377621|NCT04136119||healthcare professionals|doctors, pharmacists and dieticians who are involved in prescribing vitamins and micronutrients to critically ill patients
16377622|NCT04136106||Low-dose IL-2 group|Patients in this group were treated with low-dose IL-2 combined with corticosteroid and immunosuppressor, and low-dose IL-2 is defined as 100IU subcutaneously every other day for two weeks, followed by two-week break, as one treatment cycle, and at least three cycles.
16377623|NCT04136106||Non IL-2 group|Patients in this group were only treated with corticosteroid and immunosuppressor,
16377624|NCT04136093|Experimental|the MED|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the MED group
16377625|NCT04136093|Experimental|the DASH|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the DASH group
16377626|NCT04136093|Experimental|The control group|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the control group.
16377627|NCT04136080|Other|chronic hypertension group|septic patients with chronic hypertension
16377628|NCT04136080|Other|denying chronic hypertension group|septic patients without chronic hypertension
16377629|NCT04136067|Experimental|NNC0268-0965|Participants will receive NNC0268-0965
16377630|NCT04136067|Active Comparator|Insulin glargine|Participants will receive insulin glargine
16377631|NCT04136054|Experimental|Adjusted group CBT-i for Anxiety and Affective disorders|Cognitive Behavioral group intervention for sleep problems in patients with Anxiety and Affective disorders, based on Cognitive Behavioral Therapy for insomnia
16377632|NCT04136054|Active Comparator|Care as usual wait-list control group|Treatment as Usual. (After about five months, participants in this condition are offered the experimental group treatment.)
16377633|NCT04136041|Experimental|Smartphone Application|Participants watch a video using the Smartphone Application displaying positive word stimuli.
16377634|NCT04136041|No Intervention|No Intervention|No Intervention.
16377635|NCT04136028|Experimental|intervention/treatment|Anakinra (Kineret)
16377636|NCT04136015||Dasatinib group|
16377637|NCT04136015||Imatinib group|
16377638|NCT04135989|Other|Cre8 AES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.
~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
16377639|NCT04135989|Other|Cre8 AES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.
~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
16377640|NCT04135989|Other|Synergy EES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.
~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
16378100|NCT04132713||Control group|20 healthy volunteers were included in the healthy control group
16377641|NCT04135989|Other|Synergy EES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.
~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
16377642|NCT04135963||Participants with MM|Participants diagnosed with MM from 8 investigative sites will be observed retrospectively for previous 3 years before enrollment until Day 1.
16377643|NCT04135937|Experimental|MESH|Mobile Evidence-Based Smoking Cessation for Veterans Living with HIV is an intervention that is tailored for participants. It can include cognitive behavioral therapy, relapse-prevention text messaging, and/or pharmacotherapy with nicotine replacement therapy, bupropion, or varenicline.
16377644|NCT04135924|Active Comparator|walking nordic and respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will be submitted to respiratory muscle training (TMR) associated with the Nordic walking(NC) training .
16377645|NCT04135924|Active Comparator|walking nordic group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to Nordic walking training.
16377646|NCT04135924|Active Comparator|respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to respiratory muscle training protocol.
16377647|NCT04135898|Experimental|SIBP-04|
16377648|NCT04135898|Active Comparator|Bevacizumab|
16377649|NCT04135885|Experimental|Intervention group|Intervention group: patients took 7 days of folic acid tablets before surgery (0.3mg/d for children aged 1-3, 0.4mg/d for children aged 4~5 years, dissolved in 20ml brown sugar water.)
16377650|NCT04135885|Experimental|Placebo group|Placebo group: The patient received the same dose of brown sugar water for 7 days before surgery. Folic acid dose selection is based on the maximum daily intake of children（tolerable upper intake levels，UL）
16377651|NCT04135872||hypoalbuminemia|hypoalbuminemia was classified as serum albumin level (SAL) <35g/L
16377652|NCT04135872||normal albumin level|patients with serum albumin level (SAL) of 35g/L or higher
16377653|NCT04135859|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
16377654|NCT04135859|Experimental|Fibit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
16377655|NCT04135846|Experimental|doxazosin|16 mg, or maximum tolerated dose (MTD)
16377656|NCT04135846|Placebo Comparator|placebo|matching placebo
16377657|NCT04135833|Experimental|Itraconazole and BPI-7711|BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.
16377658|NCT04135833|Experimental|Rifampicin and BPI-7711|BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.
16377659|NCT04135820|Experimental|Fasted|BPI-7711 following a period of fasting
16377660|NCT04135820|Experimental|High-fat meal|BPI-7711 following a high-fat meal.
16377661|NCT04135807|Experimental|Microdevice|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Patients with newly found supratentorial lesions, or patients previously diagnosed with supratentorial gliomas at time of recurrence, whose treatment plan includes partial or total resection surgery as a component of standard-of-care treatment will be included.
~- Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.
~-- The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs microdoses for intratumor release of the following 8 approved drugs: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
16377662|NCT04135781|Experimental|AS|Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles
16377663|NCT04135781|Active Comparator|XELOX|Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles
16377664|NCT04135768|Experimental|Treatment|Participants who will undergo both volar locking plate fixation of the distal radius and the study procedure (wrist joint haematoma washout)
16377665|NCT04135768|Placebo Comparator|Placebo|Participants who will undergo volar locking plate fixation of the distal radius only
16377666|NCT04135755||vertebral compression fracture|No drugs intervention
16377667|NCT04135755||older adult without spinal deformity|No drugs intervention
16377668|NCT04135755||young adults|No drugs intervention
16377669|NCT04135742|Experimental|active tACS+ Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.
~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
16377670|NCT04135742|Sham Comparator|sham tACS+Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.
~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min."
16377671|NCT04135742|Sham Comparator|active tACS+ sham Cognitive Training group|"Subjects will watch neutral pictures on iPad for a period of 3 months, 24 times, twice a week for 20 minutes each time.
~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
16377672|NCT04135729||Personal trainer (PT)|Cross-sectional study on mental health symptoms in personal trainers
16377673|NCT04135729||Group instructors (GI)|Cross-sectional study on mental health symptoms in group instructors
16377674|NCT04135729||Combined instructors (PT + GI)|Cross-sectional study on mental health symptoms in personal trainers
16377675|NCT04135716|Experimental|Exposed group|Patients will receive colonoscopy with assistance of Endo.Angel
16377676|NCT04135716|Sham Comparator|Non-exposed group|Patients will receive colonoscopy without assistance of Endo.Angel
16377677|NCT04135703|Experimental|Risk Prevention Services +Housing|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP) as well as rental and utility assistance for 6 months.
16377678|NCT04135703|Experimental|Risk Prevention Services Only|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP).
16377679|NCT04135690|Experimental|HAIC plus toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Toripalimab 240mg intravenously every 3 weeks.
16377680|NCT04135690|Active Comparator|HAIC plus sorafenib|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Sorafenib 400mg twice daily (Bid) oral dosing.
16377681|NCT04135677|Active Comparator|low-dosage group|rivaroxaban 10mg qd for for 3 months and continued DAPT for 6 months.
16377682|NCT04135677|Active Comparator|high-dosage group|rivaroxaban 20mg qd for for 3 months and continued DAPT for 6 months.
16377683|NCT04135677|Active Comparator|DAPT group|asprin 100mg qd together clopidogrel 75mg for 6 months
16377684|NCT04135664|Active Comparator|Patients undergoing adjuvant esophagectomy|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.
~Patients randomized into undergoing adjvant esophagectomy."
16377685|NCT04135664|Experimental|Patients undergoing adjuvant chemoradiation|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.
~Patients randomized into undergoing adjvant chemoradiation."
16377686|NCT04135664|Active Comparator|Prospective registry of patients that cannot be randomized|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.
~Patients cannot be randomized into undergoing adjvant esophagectomy or chemoradiaton.
~This arm includes patients undergoing adjuvant esophagectomy; adjuvant chemoradiation and active surveillance."
16377687|NCT04135651|Experimental|Paralaryngeal pressure|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
16377688|NCT04135651|Active Comparator|Cricoid pressure|During the induction of anesthesia, cricoid pressure is applied by 30N force with three fingers.
16377689|NCT04135638|Other|Cover Group (CG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.
~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.
~In the Cover Group the ILM flap will be folded as a single layer to bridge tissue dehiscence during air-fluid exchange. All eyes will recive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
16377690|NCT04135638|Other|Fill Group (FG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.
~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.
~In the Fill Group, multiple layers of ILM will be deliberately folded within the loss of tissue before air-fluid exchange. All eyes will receive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
16377691|NCT04135625|Active Comparator|Full Intervention|The full intervention group will receive three egg laying chickens that will be presented as a gift to the child by their religious leader (imam or priest) during a gifting ceremony, as well as Integrated nutrition and agricultural (INA) education training sessions.
16377692|NCT04135625|Active Comparator|Education Only|The education only intervention group will receive 3 chickens given in manner similar to animal distribution programs and the INA training sessions.
16377693|NCT04135625|No Intervention|Control|The control group will receive no chickens gifted and no INA training sessions.
16377694|NCT04135612|Experimental|Smartphone group|"application installed to their smartphones. This application will be in Hebrew language, simple to use, and specifically designed to the needs of the current study.
~Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles. In addition, patients will be encouraged to use the platform to ask questions and receive immediate answers regarding any aspect lactation. As per the study protocol, medical treatment will only be initiated in a formal clinic appointment and not via the application."
16377695|NCT04135612|No Intervention|Control group|The routine prenatal care provided by our institute includes lactation consulting during the 48-72 hour postpartum hospitalization.
16377696|NCT04135599|Active Comparator|real tDCS|Participants received 1.5mA tDCS for 20 minutes in 10 consecutive days.
16377697|NCT04135599|Sham Comparator|sham tDCS|Participants received sham tDCS for 20 minutes in 10 consecutive days.
16377698|NCT04135586|Experimental|Exercise|The patients in this arm will follow an exercise program for 24 weeks (i.e., during neo-adjuvant treatment), with two sessions per week including both aerobic and resistance training. Exercise intensity will range between 65% and 100% of the maximum score in the scale of Rated Perceived Exertion (RPE).
16377699|NCT04135586|Other|Control|The patients follow their usual habits as well as a Yoga program. They will also receive educational sessions on the benefits of regular physical activity (brisk walking).
16377700|NCT04135573||New untreated GD patients|Before treatment and application of anti-thyroid drugs (methimazole) or radioactive iodine treatment
16377701|NCT04135573||Healthy control|No thyroid related diseases and other immune diseases
16377702|NCT04135560|Experimental|Part A Cohort 1 (1% Body Surface Area)|Each participant in this cohort will receive both PF-07038124 0.06% and vehicle applied to the skin (1% Body Surface Area)
16377703|NCT04135560|Experimental|Part B Cohort 1 (10% Body Surface Area)|
16377704|NCT04135560|Experimental|Part B Cohort 2 (10% Body Surface Area)|
16377705|NCT04135560|Experimental|Part B Cohort 3 (10% Body Surface Area)|
16377706|NCT04135560|Experimental|Part B Cohort 4 (10% Body Surface Area)|
16377707|NCT04135560|Experimental|Part B Cohort 5 (20% Body Surface Area)|
16377708|NCT04135560|Experimental|Part B Cohort 6 (10% Body Surface Area)|Optional cohort of Japanese participants
16377709|NCT04135547|Experimental|intra-osseous access, IO at the humeral site|the OHCA patients receiving IO at the humeral site by paramedics in the field
16377710|NCT04135547|Active Comparator|intravenous access; IV at the upper limb|the OHCA patients receiving IV at the upper limb by paramedics in the field
16377711|NCT04135534|Active Comparator|group A|mutonpain 0.05 mg/kg
16377712|NCT04135534|Active Comparator|Group B|mutonpain 0.1 mg/kg
16377713|NCT04135534|Active Comparator|Group C|mutonpain 0.2 mg/kg
16377714|NCT04135508|Experimental|BAT1406|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
16377715|NCT04135508|Active Comparator|Humira|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
16377716|NCT04135495|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
16377717|NCT04135482||CD|patients with severe crohn's disease
16377718|NCT04135469|Active Comparator|Referral for tax preparation|Participants will be given contact information on financial services, including all the free tax preparation services in the city, including Boston Medical Center.
16377719|NCT04135469|Experimental|BMC tax preparation|A navigator will help the participants with using free tax preparation services located at Boston Medical Center or a service located elsewhere in the city.
16377720|NCT04135456|Experimental|Low dose group|0.5g/kg of 20% mannitol administered at skin incision.
16377721|NCT04135456|Experimental|Medium dose group|1.0g/kg of 20% mannitol administered at skin incision.
16377722|NCT04135456|Experimental|High dose group|1.5g/kg of 20% mannitol administered at skin incision.
16377723|NCT04135443|Experimental|3T Tune in! Turn on! Turn up!|The intervention is a mobile app delivered sexual health promotion program designed specifically for young black men who have sex with men or who are attracted to men. The mobile app will include more than 30 interactive activities including resource maps, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) content, and communication forums. The app helps participants to become clearer about what they do/don't want to do sexually, to communicate their choices. It also focuses on ways to increase healthy relationships, enhance sexual experience if having sex while reducing HIV/STI risk. The intervention/app is intended to be used regularly (e.g., two times per week) during the 90 day active participation period.
16377724|NCT04135443|Active Comparator|General Health App|Participants will download a general health mobile app (focused on promoting drinking water). The control mobile app is intended to be used regularly during the 90 day active participation period.
16377725|NCT04135430||Survey|Practice of an updated questionnaire at D0, D2 and D7
16377726|NCT04135417|Experimental|HAV|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. HAV for this study will be manufactured using the commercial manufacturing system.It will be implanted in the forearm or upper arm using standard vascular surgical techniques. All subjects will be required to start taking daily aspirin (75 or 325 mg) on Day 1 after surgical implantation of HAV unless they are already taking another antiplatelet agent. If low molecular weight heparin (LMWH) is administered post-operatively, aspirin or other antiplatelet agents should be initiated after stopping LMWH. Subjects who are known to be aspirin-sensitive should take another antiplatelet agent at the discretion of the Principal Investigator.
16377727|NCT04135404||Pulmonary Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; pulmonary group are those who have reported any pulmonary diseases and they will be included in this study as pulmonary group.
16377728|NCT04135404||Control Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; The control group are subjects without pulmonary diseases and they will be included as (control group).
16377729|NCT04135391|Experimental|Pre- and Post- exercise training effects|All recruited subjects received aerobic exercise training (HIIT or MICT). VO2peak, cardiac output (CO), bilateral frontal cortex blood volume (∆[THb]), oxyhemoglobin (∆[O2Hb]) and deoxyhemoglobin (∆[HHb]), ventilation efficiency, serum brain-derived neurotrophic factor (BDNF) levels, cognitive and life quality questionnaire, percentage of neuroblastic cell bearing neurites (% neurites), and cell fluorescent staining were examined before and after interventions.
16377730|NCT04135378|Experimental|student- ascorbic acid|Student that have presentation given ascorbic acid ( 500 mg per day) for one week before presentation .
16377731|NCT04135378|Placebo Comparator|Control- ascorbic acid like|ascorbic acid like placebo for one week before presentation
16377732|NCT04135365||Pediatric T1D|A sample of 20 children with Type 1 Diabetes and their caregivers will be asked to stay after their diabetes clinic appointment to complete enrollment, or they may choose to come back for a study visit. Trained study staff will describe the study in detail to interested families. They will be encouraged to ask questions before giving consent. After obtaining informed consent/assent, children and caregivers will schedule time for a neurocognitive assessment and neuroimaging assessment. Children and caregivers will complete assessments again approximately 12 months later.
16377733|NCT04135365||Comparison|Children with no known chronic medical conditions or intellectual disability will undergo the same procedure listed for the Pediatric T1D group
16377734|NCT04135352|Experimental|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
16377798|NCT04134923||[11C] Pittsburgh Compound-B (PIB)|Using [11C] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
16377735|NCT04135352|Experimental|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
16377736|NCT04135352|Experimental|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
16377737|NCT04135352|Experimental|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
16377738|NCT04135352|Experimental|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
16377739|NCT04135352|Experimental|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
16377740|NCT04135352|Experimental|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
16377741|NCT04135352|Experimental|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
16377742|NCT04135352|Experimental|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
16377743|NCT04135339|Experimental|Group A. Eccentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
16377744|NCT04135339|Experimental|Group B. Concentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
16377745|NCT04135339|Experimental|Group C. Isometric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
16377746|NCT04135339|No Intervention|Group D. Control.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
16377747|NCT04135326|Experimental|Supportive care (tDCS)|Patients undergo tDCS QD over 20 minutes 5 days each week (Monday-Friday) for 3 weeks.
16377748|NCT04135313|Experimental|Neoadjuvant chemotherapy|Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy
16377749|NCT04135313|Active Comparator|Chemoradiotherpy|Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.
16377750|NCT04135300|Experimental|Arm of BBM-H901|Subjects will be dosed with single dose of BBM-H901 at 5x10·12 vg/kg via intravenous infusion.
16377751|NCT04135287|Experimental|Arm 1|Treatment with GLP-1 RA
16377752|NCT04135274||Sepsis group|
16377753|NCT04135274||Non Sepsis group|
16377754|NCT04135261|Experimental|Part 1: Dose escalation|"QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w)
~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee."
16377755|NCT04135261|Experimental|Part 2: Dose expansion|Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.
16377756|NCT04135248||IDF-DAR arm|Insulin management according to IDF-DAR guidelines (IDF-DAR arm) during the fasting period.
16377757|NCT04135248||DAFNE arm|Insulin management according to local experience (DAFNE arm) during the fasting period.
16377758|NCT04135235||TAF group|take propofol fumarate for Maternal and child blockade treatment
16377759|NCT04135235||TDF group|take difenofurate fumarate for Maternal and child blockade treatment
16377760|NCT04135209||Healthy controls|Healthy individuals of age-matched
16377761|NCT04135209||Myopic patients|Patients with myopia who meet the inclusion criteria
16377762|NCT04135196|Experimental|Low Magnitude|voluntary forearm compression by leaning onto the palm of the hand with low target strain
16377763|NCT04135196|Experimental|High Magnitude|voluntary forearm compression by leaning onto the palm of the hand with high target strain
16377764|NCT04135196|Experimental|Low Rate|"voluntary forearm compression by leaning onto the palm of the hand with low strain rate (task performed slowly and evenly)"
16377765|NCT04135196|Experimental|High Rate|"voluntary forearm compression by leaning onto the palm of the hand with high strain rate (task performed as quickly as possible, with a bump)"
16377766|NCT04135196|No Intervention|Control|observation only
16377840|NCT04134650|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
16377767|NCT04135183|Experimental|Comprehensive evaluation group|The effectiveness of initial treatment and the next treatment plan were determined based on the CAP guidelines of Chinese Thoracic Society (CTS) or Infectious Diseases Society of America/American Thoracic Society(IDSA/ATS). The evaluation process was independently evaluated and documented by at least two clinicians. In case of disagreement, the final determination shall vote on the majority of votes.
16377768|NCT04135183|Experimental|PSI evaluation group|The changes of PSI scores and serum CRP were used to evaluate the therapeutic effects. If both PSI scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of PSI scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both PSI scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
16377769|NCT04135183|Experimental|Expand-CURB evaluation group|The changes of Expand-CURB scores and serum CRP were used to evaluate the therapeutic effects. If both Expand-CURB scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of Expand-CURB scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both Expand-CURB scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
16377770|NCT04135183|No Intervention|Prospective observational group|Patients' Expand-CURB scores, PSI scores and serum CRP before and after 3-5 days of initial treatment will be recorded. And the initial treatment, whether the initial treatment was changed 3-5 days of initial treatment and the final outcomes (ICU admission, 30-day mortality, average length of stay) will be recorded.
16377771|NCT04135170|Experimental|Plain bone cement|
16377772|NCT04135170|Active Comparator|Antibiotic loaded bone cement|
16377773|NCT04135157|Experimental|PECS II or ESP|PECS II or ESP block are performed 30 minutes before general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
16377774|NCT04135157|Active Comparator|Control|In the control group, patients will have only general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
16377775|NCT04135144|Active Comparator|Group 1 (printed materials),|Group 1 was given home exercise method with printed materials
16377776|NCT04135144|Active Comparator|Group 2 (video phone reminder)|Group 2 was given exercise with home exercise method with video phone reminder
16377777|NCT04135131|Experimental|PILATES MAT EXERCISE EFFECT ON LOW BACK PAIN|Patients were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. The evaluations were made at the beginning and end of the treatment. Outcome parameters were VAS, Oswestry Disability Index, Qubec Disability Scale, Short Form-36, Beck Depression Questionnaire, sit and reach, Modified Schöber and sit up tests. Multifidus and abdominal muscle thickness were measured by ultrasound image
16377778|NCT04135131|Placebo Comparator|HOME EXERCISE|The exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises. Patients were asked to perform three sets of exercises (10 repetitions) for three times a week for 8 weeks. Exercise training was provided by a physiotherapist. Patients were also provided an illustrated exercise brochure along with an exercise diary to record the number of days on which exercise was performed. They were followed up by phone calls every 2 weeks
16377779|NCT04135105||Normal hearing group|Right-handed, normal hearing, no reported neurological disorders
16377780|NCT04135053|Experimental|Challenge|Challenge participants will inoculated intranasallly with reconstituted lyophilised Neisseria lactamica (lyoNlac). The initial dose will be 10^5 colony-forming units (CFU) and will be escalated or de-escalated by 1/2 - 1 log depending upon the proportion of volunteers colonies with viable N. lactamica.
16377781|NCT04135040|Experimental|Lysine metabolic availability|Lysine metabolism from pure amino acids and cereal foods in children.
16377782|NCT04135027||CD group|no interventions
16377783|NCT04135014|Placebo Comparator|Midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
16377784|NCT04135014|Experimental|Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 2ug/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
16377785|NCT04135014|Experimental|Midazolam and Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 1ug.kg-1 and oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
16377786|NCT04135001|Experimental|HBM Training|
16377787|NCT04135001|Placebo Comparator|Placebo Training|
16377788|NCT04134988|Experimental|Medimoov|Bi-weekly 35-minute sessions of an adaptated physical activity administered by a psychomotor therapist for 8 weeks.
16377789|NCT04134988|Active Comparator|Standard rehabilitation|Bi-weekly 35-minute sessions of the standard psychomotor therapy for 8 weeks.
16377790|NCT04134975|Experimental|Scanner Group|lumbar spine surgical procedure with guided pedicle screw placement coupled with intraoperative scanning (BODYTOM, Samsung).
16377791|NCT04134975|Active Comparator|fluoroscopy group|lumbar spinal surgery with pedicle screw placement guided by fluoroscopy, a fluoroscopic control being performed with each set screw.
16377792|NCT04134962||Ankel surgery group|Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
16377793|NCT04134962||control foot group|"Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
~Will be retained only results of normal aligment FAO"
16377794|NCT04134949|Experimental|CBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
16377795|NCT04134949|Experimental|MCBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
16377796|NCT04134936|Experimental|Arm A|Tafasitamab in addition to R-CHOP
16377797|NCT04134936|Experimental|Arm B|Tafasitamab plus lenalidomide in addition to R-CHOP
16377799|NCT04134910|Experimental|Physical therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
16377800|NCT04134897|Experimental|Neoadjuvant chemotherapy|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
16377801|NCT04134897|Active Comparator|Neoadjuvant radiotherapy|Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
16377802|NCT04134884|Experimental|ASTX727 + Talazoparib|
16377803|NCT04134871|Experimental|Intervention group|Participants randomised to the intervention group will be invited to attend a group education session where they will be given a step counter and activity diary, they will be invited to weekly group walks and fortnightly coaching 1-1 sessions aimed at setting and reviewing goals to increase physical activity and reduce sedentary behaviour
16377804|NCT04134871|No Intervention|Control group|Participants randomised to the control group will be given an information leaflet about being more active during a one-off 1-1 consultation.
16377805|NCT04134858|Experimental|The health coaching group|The experimental group (n = 52) consisted of frequent attenders who had chosen the health-coaching program. The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
16377806|NCT04134858|No Intervention|The control group|The control group consisted of 58 frequent attenders. They, along with the experimental group, received the usual care regarding their health problems from the physicians and nurses at the primary healthcare centres if they needed it. The usual care for frequent attenders included assessment for the need of treatment, physical examination, problem assessment, laboratory and X-ray tests, medical advice and patient support and education during their visits.
16377807|NCT04134845|Experimental|Dantrolene/Ryanodex|Dantrolene/Ryanodex; intravenous administration of dantrolene; 1 mg/ kg IV over 3 minute, one time dose
16377808|NCT04134845|Placebo Comparator|Placebo|controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
16377809|NCT04134819||Vaginally Delivered Babies- No antibiotic treatment|Adult healthy pregnant females (in total 400) as well as their infants will be recruited. It is expected 67% of babies will be vaginally delivered and that 60% will not have antibiotic treatment during pregnancy. This will be up to 161 mother/infant dyads.
16377810|NCT04134819||Vaginally Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 67% of babies will be vaginally delivered and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 107 mother/infant dyads.
16377811|NCT04134819||C-section Delivered Babies- No antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by C section and that 60% will not have antibiotic treatment during pregnancy. This will be up to 80 mother/infant dyads All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
16377812|NCT04134819||C-section Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by c section and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 52 mother/infant dyads .All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
16377813|NCT04134806||Young Adults|Neurologically healthy young adults between ages 18 and 40
16377814|NCT04134806||Older Adults|Neurologically healthy older adults between ages 60 and 85
16377815|NCT04134806||Mild Cognitive Impairment/Mild Dementia|Older adults between ages 60 and 85 with Mild Cognitive Impairment or Mild Dementia
16377816|NCT04134793||Sinus group|Six-month follow-up, by holter ECG record，the patients keep normal sinus after atrial fibrillation radiofrequency ablation.
16377817|NCT04134793||atrial fibrillation recurrence group|Six-month follow-up, by holter ECG record，the patients again suffer from atrial fibrillation after atrial fibrillation radiofrequency ablation.
16377818|NCT04134780||Breast Characterization|
16377819|NCT04134767|Experimental|Health Linkage|Research staff will: 1) meet with participants in a community setting, by phone, or video call to ask them questions about drug use and related behaviors, access to needed health and social services, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct saliva drug testing, offer HIV and hepatitis C testing and counseling, naloxone, and harm reduction supplies, and connect participants with needed services; 2) follow up with participants once a month for three months to help participants overcome challenges; and 3) six months after enrollment to the study, contact participants to conduct saliva drug testing. Participants will complete surveys at baseline, 3 months, and 6 months. The baseline will be conducted in jail for incarcerated participants preparing for re-entry, or in a community setting for those recruited in the community. The 3 and 6-month surveys will be conducted in a community setting.
16377839|NCT04134650|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5mg + metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
16377901|NCT04134091|Experimental|Treatment B|LPCN 1144 Formulation B
16377902|NCT04134091|Placebo Comparator|Treatment C|Placebo
16377820|NCT04134767|Other|Overdose Education|"The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit.
~As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort."
16377821|NCT04134754|Other|Respiratory physiology testing|Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.
16377822|NCT04134741|Experimental|Kinetic Control Group|"The players participated in the classic training and for 4 weeks (3 times a week) underwent the Kinetic Control neuromuscular training with assistance of a physical therapist.
~The duration of one training was 20-30 minutes."
16377823|NCT04134741|No Intervention|Traditional Training Group|Players participated in the classic training.
16377824|NCT04134728|Experimental|GSK3196165 90 mg|Entire treatment period (24 Weeks): GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
16377825|NCT04134728|Experimental|GSK3196165 150 mg|Entire treatment period (24 Weeks): GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
16377826|NCT04134728|Active Comparator|Sarilumab 200 mg|Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
16377827|NCT04134728|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
16377828|NCT04134728|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
16377829|NCT04134728|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
16377830|NCT04134715|Experimental|PF-06826647 alone then OC alone then OC+PF-06826647|In Period 1 (Period 1 is 2 days), participants will receive a single dose of PF-06826647 600 mg on Day 1. Period 2 (Period 2 is 14 days) will immediately follow Period 1 without any washout. In Period 2, the participants will receive OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet, orally starting from Period 2 Day 1 until Period 3-Day 16 (Period 3 is 17 Days). Period 3 will immediately follow Period 2 with no washout. In Period 3 on Day 1, the participants will receive a single dose of PF-06826647 600 mg. On Day 2 in Period 3, PF-06826647 will not be dosed. From Day 3, the participants will receive PF-06826647 600 mg QD for 14 days followed by OC in the form of 1 PORTIA (EE and LN) or equivalent tablet.
16377831|NCT04134702|Experimental|Acupuncture|30 patients will receive acupuncture additionally to standard pharmacological therapy of postoperative pain
16377832|NCT04134702|No Intervention|No intervention|30 patients will receive just standard pharmacological therapy of postoperative pain
16377833|NCT04134689|Active Comparator|DOT Selfie Intervention Arm|"The DOT Selfie Intervention will comprise a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders.
~Patients in this arm will receive detailed training (in English or Luganda) on VDOT use prior to starting treatment. Each patient will be required to record and submit daily videos as they self-administer their medication. Patients who successfully submit their videos for seven consecutive days will receive a weekly incentive in the form of social bundles of airtime minutes. A prepaid internet bundle will also be uploaded to each mobile phone weekly to allow for daily video uploads. Additionally, patients will receive text message medication reminders to encourage treatment compliance."
16377834|NCT04134689|Active Comparator|In-person DOT Control Arm.|Patients in this arm will be managed according to the usual clinical practice in Uganda i.e. community- or home-based directly observed treatment .Patients in this arm will make prior arrangements with a study nurse to determine a convenient meeting place (e.g. at the patient's work, home etc.) The study nurse will then meet the patient at this location. At each daily meeting, the patient will self-administer the TB drugs as the study nurse directly observes and documents (date, time, drug dosing etc.) At the end of each meeting, the patient and nurse will agree on a convenient meeting place for the next day's dosing. These daily meetings will continue until treatment completion. The study nurse will record patient's medication intake, as well as the time taken to reach the patient, amount of money spent on round-trip transportation, and total amount of time spent during each patient encounter.
16377835|NCT04134676|Experimental|Conditioned Medium Group|"In this group, the subjects will use Conditioned Medium topical therapy for 2 weeks The Conditioned Medium gel will be applied to the wound and closed by transparent dressing.
~The evaluation and dressing replacement will be done every week for 2 weeks."
16377836|NCT04134663|Experimental|vasoconstrictor + intranasal oxytocin group|subjects receive the vasoconstrictor followed by oxytocin
16377837|NCT04134663|Active Comparator|vasoconstrictor's placebo + intranasal oxytocin group|subjects receive the vasoconstrictor's placebo followed by oxytocin
16377838|NCT04134663|Placebo Comparator|vasoconstrictor + intranasal oxytocin placebo group|subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
16378101|NCT04132713||Disease group|30 patients with advanced breast cancer developed hand-foot syndrome after capecitabine administration
16377841|NCT04134637|Experimental|PIFB group|"For carrying out PIFB bilaterally the skin on either side of the sternum will be prepared with povidone iodine solution. Then a linear ultrasound probe will be placed on the right and left sides at 2 cm from the sternal body.
~A 22 gauge, 4 inch needle will be advanced until contacting the 4th costal cartilage following the lower edge of US probe, directing the tip from the bottom of the sternum and positioning the needle tip between the pectoralis major and the external intercostal muscles. Group A will receive twenty milliliters of a solution of 0.25% bupivacaine plus epinephrine (5 mcg/ml). Boluses of 5 ml are introduced to perform hydrodissection of the interfascial plane."
16377842|NCT04134637|No Intervention|control group|the block will not be given
16377843|NCT04134624|Active Comparator|Prehospital intervention|All subjects enrolled in this study will receive a sepsis intervention bundle in the prehospital setting, including blood cultures, IV fluids, and antibiotics. These patients will be compared to historical controls.
16377844|NCT04134624|No Intervention|Control arm|Historical controls without prehospital sepsis intervention.
16377845|NCT04134611|Active Comparator|Knee arthroscopy with Hyaluronic acid injection|Those patients who received hyaluronic acid injection
16377846|NCT04134611|Active Comparator|Knee arthroscopy without Hyaluronic acid injection|Knee arthroscopy who did not Hyaluronic acid injection
16377847|NCT04134598|Experimental|Partial Breast Irradiation (PBI)|Partial Breast Irradiation (PBI)
16377848|NCT04134598|Active Comparator|Endocrine Therapy (ET)|Endocrine Therapy (ET)
16377849|NCT04134585||People aged 60|People aged 60 and over who had refused to participate in fall prevention workshops will be included. They will have semi-structured interviews.
16377850|NCT04134572||Ollier Disease and Maffucci Syndrome patients|The group comprises all patients affected by Ollier Disease and Maffucci Syndrome.
16377851|NCT04134559|Experimental|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a dose of 2mg/kg/dose (max: 200mg) with 21 consecutive days defined as a treatment cycle.
16377852|NCT04134546|Experimental|group with biliary injury|group for Early versus late intervention after biliary tract injury post cholecystectomy
16377853|NCT04134533||Oral Feeding Group|Children with cerebral palsy who fed orally according to the Functional Oral Intake Scale
16377854|NCT04134533||Non-Oral Feeding Group|Children with cerebral palsy who fed non-orally according to the Functional Oral Intake Scale.
16377855|NCT04134520||Generally healthy subjects with no known cancer disorder|
16377856|NCT04134520||Subjects with a pathological diagnosis of cancer|
16377857|NCT04134507||Extended Depth of Focus IOL|Post-LASIK patients with implantation of a presbyopia-correcting IOL
16377858|NCT04134507||Monofocal IOL|Post-LASIK patients with implantation of a monofocal IOL
16377859|NCT04134494|Experimental|Intervention|Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
16377860|NCT04134481||low intervention group|from 0-7 clustered nursing intervention
16377861|NCT04134481||high intervention group|from 8-15 clustered nursing intervention
16377862|NCT04134468|Experimental|Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine|Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.
16377863|NCT04134455|Active Comparator|Onlay Mesh Reinforcement group|The midline fascia was closed with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis. A Lightweight polypropylene mesh was used and placed on the anterior rectus fascia with an overlap of 3 cm. The mesh was fitted in the dissected space and it was fixed with PDS 2-0 suture. Fixing points are placed taking the mesh and the anterior fascia of the rectus muscle, at a distance of 3 cm between each point until completing its circunference.
16377864|NCT04134455|Experimental|RTL reinforcement group|The RTL suture is placed parallel at a distance of 0.5 cm from the fascial margin. Ideally the thread should lie between the anterior and the posterior rectus muscle sheath; there should be no contact with the rectus muscle. A nonabsorbable monofilamental polypropylene thread and a 65-mm ½ needle are used. Around this longitudinal thread, the continuous suture for fascial closure is introduced immediately lateral to the thread; with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis
16377865|NCT04134442|Experimental|Bupivacaine Liposome|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist).
~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
16377866|NCT04134442|Active Comparator|Standard therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist).
~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
16377867|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
16377868|NCT04134416|Experimental|Anodal transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive 10 20-minute sessions while receiving REGIAplus (online). Group 1 will receive active stimulation (anodal stimulation, A-tDCS).The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
16378090|NCT04132765||Patients with cerebral palsy|Patients with cerebral palsy at between the ages of 4-16 years and at Gross Motor Function Classification Levels of 3,4,5
16377869|NCT04134416|Sham Comparator|Sham transcranial direct current stimulation|Group 2 will receive sham stimulation (S-tDCS). In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the assay.
16377870|NCT04134403|Experimental|Arm 1: Intervention|Arm will be those that are randomized to receive usual care plus hydrocortisone, thiamine and ascorbic acid.
16377871|NCT04134403|No Intervention|Arm 2: Usual care|Arm will be those that are randomized to receive usual care alone.
16377872|NCT04134390|Experimental|Cabozantinib|Cabozantinib 40 mg p.o. once daily in 28-day cycles.
16377873|NCT04134377|Experimental|Protein Food Snack|Provide a high protein food snack the first 2 weeks of each month for 6 months. Each participant will receive an 8 ounce food snack after dialysis for a total of 6 food snacks for each month.
16377874|NCT04134364|No Intervention|control|no medication after gastric biopsy
16377875|NCT04134364|Experimental|treatment|oral administration of sodium alginate (LaminaG) after gastric biopsy
16377876|NCT04134325|Experimental|Single Arm PD-1 Inhibitors after CD30.CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
16377877|NCT04134312|Experimental|MVA-BN-Brachyury IV|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
16377878|NCT04134299|Experimental|AXA4010|AXA4010
16377879|NCT04134273|Experimental|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
16377880|NCT04134273|Active Comparator|Clindamycin Phosphate Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
16377881|NCT04134273|Placebo Comparator|Vehicle of the test product|Placebo (vehicle of the test product), applied to the face twice a day for 84 days.
16377882|NCT04134260|Active Comparator|Arm I (hormone therapy, radiation therapy)|Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 7-8 weeks beginning within 56 days after first hormone injection if the injection is not started prior to registration or within 90 days after first hormone injection if the injection is started prior to registration in the absence of disease progression or unacceptable toxicity.
16377883|NCT04134260|Experimental|Arm II (apalutamide, abiraterone acetate, prednisone)|Patients receive standard of care hormone therapy and radiation therapy as in Arm I. Patients also receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD or BID on days 1-90. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
16377884|NCT04134247|Experimental|PD-1 combined with chemotherapy|21 days every cycle, assessment after 3-cycle
16377885|NCT04134247|Active Comparator|chemotherapy|21 days every cycle, assessment after 3-cycle
16377886|NCT04134208|Experimental|Diagnostic (fluciclovine F18, PET-CT)|Within 4 weeks before starting SST, patients receive fluciclovine F18 IV then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.
16377887|NCT04134195|Experimental|Real transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of real transcranial direct current stimulation over two distinct brain areas.
16377888|NCT04134195|Experimental|Sham transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of sham transcranial direct current stimulation over two distinct brain areas.
16377889|NCT04134182|Experimental|Nivolumab + Ipilimumab|Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.
16377890|NCT04134169||Rheumatoid arthritis|
16377891|NCT04134156|Active Comparator|Sleeve gastrectomy|5-port standard sleeve gastrectomy was conducted
16377892|NCT04134156|Active Comparator|one anastomosis gastric bypass|5-port standard one-anastomosis gastric bypass was performed
16377893|NCT04134143|Experimental|Cohort 1: One Application|Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876)
16377894|NCT04134143|Experimental|Cohort 2: Up to Five Applications|Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing
16377895|NCT04134143|Experimental|Cohort 3: Up to Ten Applications|Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing
16377896|NCT04134130|Other|GnRH antagonist + FSH + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.
~After 3 weeks: 1000 mg testosterone once."
16377897|NCT04134130|Other|GnRH antagonist + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).
~After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once."
16377898|NCT04134117|Experimental|Tisagenlecleucel|"Study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.
~- Tisagenlecleucel will be administered intravenously as a one-time rapid infusion predetermined dose following lymphodepleting chemotherapy."
16377899|NCT04134104||Bowel, Bladder, and Sexual Dysfunction group|Out of 38 patients included for surgery 12 were excluded due to poor follow up and those patients who underwent upfront surgery. Only 26 patients were included in the study. There were 20 (76.9%) males and 6 (23.1%) females respectively. The mean age of the patient was 43.577yrs (26-75) and mean BMI was 20.78. The number of patients that underwent LAR was 24 (92.30%) and those who underwent APR were 2( 7.6%) after neoadjuvant chemoradiotherapy respectively.
16377900|NCT04134091|Experimental|Treatment A|LPCN 1144 Formulation A
16377903|NCT04134078|Experimental|inhaled nitric oxide|Inhaled Nitric Oxide at 40 ppm will be administered in adults who suffer in hospital cardiac arrest. The administration of inhaled nitric oxide at 40 ppm will be provided upto 24 hours once ROSC is achieved.
16377904|NCT04134065|Placebo Comparator|Control group|The physical properties such as appearance, size, color, dosage form, weight, taste and odor of placebo should be as much as possible as the test drug, but should not contain the Vitamin D (such as tablets containing lactose).
16377905|NCT04134065|Experimental|Vitamin D group|Liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL)
16377906|NCT04134052|Experimental|ketamine sedation|Sedation will be performed with ketamine dose 5-20mcg / kg / min in infusion with 100 ml Na Cl solution 0.9% during surgery
16377907|NCT04134052|Active Comparator|midazolam sedation|Sedation will be performed with midazolam dose 5 - 35mcg / kg / hr in infusion with 100 ml Na Cl solution 0.9% during surgery
16377908|NCT04134039|Experimental|Polyurethane (PU) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
16377909|NCT04134039|Experimental|Natural Rubber Latex (NRL) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
16377910|NCT04134026|Experimental|HIF-PHI|HIF-PHI will be dosed orally three times a week.
16377911|NCT04134026|Active Comparator|Epoetin alfa|Epoetin alfa wull be disoensed per the package insert or the country-specific product labeling.
16377912|NCT04134013|Experimental|Nutrition and Chiropractic|LBP chiropractic adjustment per protocol and 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
16377913|NCT04134013|Active Comparator|Chiropractic Adjustment ONLY|LBP chiropractic adjustment per protocol
16377914|NCT04134000|Experimental|Atezolizumab + BCG|"Ten patient will be enrolled in first cohort, starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).
~The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)"
16377915|NCT04133987|Experimental|Tetravalent live attenuated dengue vaccine admixture TV005|Tetravalent live attenuated dengue vaccine admixture TV005
16377916|NCT04133987|Placebo Comparator|placebo|Plasma-Lyte A
16377917|NCT04133974|No Intervention|Methadone|The subjects take methadone as usual.
16377918|NCT04133974|Experimental|Methadone-10min-Extinction|The subjects were given extinction training 10 min following methadone administration.
16377919|NCT04133974|Sham Comparator|Methadone-6h-Extinction|The subjects were given extinction training 6h following methadone administration.
16377920|NCT04133961|Experimental|Group A (Phenylephrine)|Phenylephrine infusion started immediately after administration of spinal block
16377921|NCT04133961|Placebo Comparator|Group B (Saline)|Normal saline infusion started immediately after administration of spinal block
16377922|NCT04133948|Experimental|A|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks)
16377923|NCT04133948|Experimental|B|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
16377924|NCT04133948|Experimental|C|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
16377925|NCT04133948|Experimental|D|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + ipilimumab 80 mg (q3weeks) + domatinostat. Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200 mg, on days 1-14 (q3weeks). Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200 mg BID, days 1-14, q3weeks), a lower dosing scheme (100 mg OD, days 1-14, q3weeks), or the same dosing scheme (200 mg OD, days 1-14, q3weeks).
16377926|NCT04133935|Experimental|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment
16377927|NCT04133935|Active Comparator|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
16377928|NCT04133922|Active Comparator|GLP-1|GLP-1 infusion 1.2 pmol/kg/min for 150 min
16377929|NCT04133922|Active Comparator|GLP-1 + Insulin clamp|GLP-1 infusion 1.2 pmol/kg/min for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min
16377930|NCT04133922|Active Comparator|Saline + Insulin clamp|Saline infusion at 30 ml/hr for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min.
16377931|NCT04133909|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously once every 4 weeks over a treatment period of 52 weeks.
16377932|NCT04133909|Experimental|Mepolizumab|Participants will receive mepolizumab subcutaneously once every 4 weeks over a treatment period of 52 weeks.
16377933|NCT04133896||Group 1 Male|group 1 (22 lean men),
16377934|NCT04133896||Group 2 Male|group 2 (22 class I obese men),
16377935|NCT04133896||Group 3 Male|group 3 (22class II obese men),
16377936|NCT04133896||Group 4 Male|group 4 (22 class III obese men).
16377937|NCT04133896||Group 1 Female|group 1 (22 lean women),
16377938|NCT04133896||Group 2 Female|group 2 (22 class I obese women),
16377939|NCT04133896||Group 3 Female|group 3 (22 class II obese women),
16377940|NCT04133896||Group 4 Female|group 4 (22 class III obese women).
16377941|NCT04133883|Other|Haemophilia A patients|Treated on-demand or prophylaxis with any Factor VIII (FVIII) product, plasma derived or recombinant (conventional or extended-half life) FVIII, according to routine clinical practice.
16377942|NCT04133857|Active Comparator|Group A|undergo HIIT first then SSMIT protocol
16377943|NCT04133857|Active Comparator|Group B|undergo SSMIT first then HIIT protocol
16377944|NCT04133844||Extracorporeal membrane oxygenation|
16378195|NCT04132063||Generic levetiracetam|
16377945|NCT04133831|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
16377946|NCT04133831|Experimental|Condition 2: Combined plus Total|Participants randomized to Condition 2 will view combined transplant survival and total survival outcome information when making a choice between the two hospitals.
16377947|NCT04133831|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
16377948|NCT04133831|Experimental|Condition 4: Stratified plus Total|Participants randomized to Condition 4 will view stratified transplant survival and total survival outcome information when making a choice between the two hospitals.
16377949|NCT04133831|Experimental|Condition 5: Total only|Participants randomized to Condition 5 will view only total survival outcome information when making a choice between the two hospitals.
16377950|NCT04133818||Multidisciplinary program.|Patients with subacute or chronic LBP for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program was not indicated.
16377951|NCT04133792|Experimental|Simvastatin|Simvastatin 40 mg administered orally daily for 5 years.
16377952|NCT04133792|Placebo Comparator|Placebo|Placebo for Simvastatin 40 mg administered orally daily for 5 years.
16377953|NCT04133779||Group A (MS)|"Age 18-55 years;
~Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;
~Course of the disease: RR-SP-PP-CIS;
~Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;
~Not in clinical relapse (at least 30 days after the last clinical relapse);
~Subjects treated or non-treated with immunomodulatory and immunosupressive drugs;
~Signature of the informed consent."
16377954|NCT04133779||Group B (HC)|"Age 18-55 years;
~Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);
~Signature of the informed consent.
~The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study, or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres."
16377955|NCT04133779||Group C (OND)|"Aged 18-55 years;
~Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.
~Signature of the informed consent."
16377956|NCT04133779||Group D (ONDi)|"Age 18-55 years;
~subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;
~Signature of the informed consent."
16377957|NCT04133766|Experimental|Community-Based Nutrition Package|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
16377958|NCT04133766|No Intervention|Standard of care|Current standard of existing community health services.
16377959|NCT04133753|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
16377960|NCT04133753|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
16377961|NCT04133740|Active Comparator|Standard regime|Supplementary oxygen is given according to the standard regime with a fraction of inspired oxygen (FiO2) of at least 0.60 during mechanical ventilation and 3 liter/minute or more after weaning from the ventilator in the intensive care unit (ICU).
16377962|NCT04133740|Active Comparator|Oxygenation targeting|Supplementary oxygen is given to achieve a partial pressure of arterial oxygen (PaO2) within the normal range defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.
16377963|NCT04133727|Experimental|Intervention|Intervention group will wear a simulation suit in which will mimic the physical limitations experienced by older adults. In addition, they will participate in a polypharmacy workshop which allows them to communicate with older adults
16377964|NCT04133727|Active Comparator|Control|This group will participate in a polypharmacy workshop which allows them to communicate with older adults
16377965|NCT04133714|Experimental|multi-channel tDCS|"In the multi-channel tDCS stimulation group, a 1:4 (anode: cathode) approach was applied, with the central anode placed in the left dorsolateral prefrontal cortex (dlPFC) (reference 10-20 standard lead EEG), and the remaining cathode distributed around the central electrode.
~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
16377966|NCT04133714|Experimental|single-channel tDCS|"The anode electrode of the single-channel tDCS stimulation group was placed in the left dlPFC, and the cathode electrode was placed in the right orbital forehead.
~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
16377967|NCT04133714|Sham Comparator|sham stimulation|The shame stimulation group had only 30 seconds of up and down stimulation, with no intermediate stimulation.
16377968|NCT04133701|Experimental|Time-Restricted Feeding|"Control (Baseline): Blood pressure and neurovascular control will be measured.
~Post-Intervention: Blood pressure and neurovascular control will be measured."
16377971|NCT04133675|Active Comparator|Emsella Chair Active Treatment|Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
16377972|NCT04133675|Sham Comparator|Emsella Sham Treatment|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
16377973|NCT04133662|Experimental|Group 1|Restricted sleep condition first, longer sleep condition second
16377974|NCT04133662|Experimental|Group 2|Longer sleep condition first, restricted sleep condition second
16377975|NCT04133649|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
16377976|NCT04133636|Experimental|JNJ-68284528|Single group assignment-After lymphodepletion, JNJ-68284528 will be administered as single infusion to participants in cohort A (Progressive disease after 1-3 prior lines of therapy), cohort B (Early relapse after front-line), cohort C (Relapsed/refractory multiple myeloma after PI, IMiD, anti-CD38, and anti- BCMA therapy), cohort D (Less than CR after ASCT front-line therapy; some participants will be administered JNJ-68284528 followed by lenalidomide), cohort F (Newly diagnosed multiple myeloma [NDMM] with standard risk [international staging system {ISS} Stage I and II] and after initiation of therapy). Participants in cohort E (NDMM, transplant not planned, high risk disease) will first be administered with quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), followed by lymphodepletion and JNJ-68284528, followed by consolidation regimen of daratumumab and lenalidomide (D+R).
16377977|NCT04133623|Experimental|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
16377978|NCT04133623|Active Comparator|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
16377979|NCT04133610|Experimental|Self-sampling device in media|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using self-sampling device in STM media. HPV will be detected by hybridization technique.
16377980|NCT04133610|Experimental|Dry self-sampling device|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using dry self-sampling device. HPV will be detected by hybridization and PCR techniques.
16377981|NCT04133597|Experimental|Interventional|Two experimental steps: baseline skin conductance measurements (step 1, three minutes) and measurements of SC after social media stimulation with Line messages or calls (step 2, three minutes). With a 5-minute rest period after these two steps completed, then each participant fill out questionnaires for assessing anxiety and problematic smartphone use.
16377982|NCT04133584|Experimental|Group 1 EV71 +SIV|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV) simultaneously with 28 days apart
16377983|NCT04133584|Active Comparator|Group 2 EV71|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) with 28 days apart
16377984|NCT04133584|Active Comparator|Group 3 SIV|Give 2 doses of seasonal influenza vaccine(SIV) simultaneously with 28 days apart
16377985|NCT04133571|No Intervention|Control group|Control group: using normal saline for bladder irrigation
16377986|NCT04133571|Experimental|Study group|Study group: using 0.05% Lidocaine normal saline solution for bladder irrigation
16377987|NCT04133545||DOAC|Direct oral anticoagulant
16377988|NCT04133545||OAC|Vitamin K anticoagulant
16377989|NCT04133532|Experimental|metoprolol-no metoprolol|After a washout period of one month following discontinuation of preceding beta-blocker medication patients will be given metoprolol 50 mg daily. The effect will be evaluated after three months of treatment. After that, another one-month washout period will commence followed by three months without metoprolol medication. Then, a final reevaluation will be performed.
16377990|NCT04133532|Experimental|no metoprolol-metoprol|After a one-month washout period following discontinuation of preceding beta-blocker medication patients will continue another three months without a metoprolol medication. After that, an evaluation will be performed. Then they will be given metoprolol 50 mg daily for three months followed by a reevaluation.
16377991|NCT04133519|Active Comparator|Arm 1|Arm 1 is an active behavioral treatment for IBS (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD).
16377992|NCT04133519|Active Comparator|Arm 2|Arm 2 is a behavioral treatment (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
16377993|NCT04133506||acute eczema|acute eczema patients with eczema <72 hours no drugs
16377994|NCT04133506||chronic eczema|chronic eczema with eczema > 72 hours no drugs
16377995|NCT04133506||allergic contact dermatitis|allergic contact dermatitis with a clear allergen identified no drugs
16377996|NCT04133506||psoriasis patients|patients with plaque psoriasis no drugs
16377997|NCT04133506||healthy volunteers|dithranol or DNCB (used to induce irritant or allergic eczema used safely in similar research studies for decades) aspirin to half the group to assess the effects on downstream mediators
16377998|NCT04133493|Placebo Comparator|Standard of Care Group|Fibracol Dressing covered with gauze and wrapped with kerlix and wrap. Change 3Xper week
16377999|NCT04133493|Active Comparator|Intervention Group|Kerecis affixed with steri-strips, cover with gauze and change one per week .
16378000|NCT04133480|Experimental|GWP42003-P|For the first 7 days of the treatment period, participants are to take GWP42003-P at a dose of 5 milligrams per kilogram per day (mg/kg/day), administered as 2 equally divided doses (i.e., 2.5 mg/kg in the morning and 2.5 mg/kg in the evening). On Day 8, participants are to increase the dose to 10 mg/kg/day, administered as 2 equally divided doses (i.e., 5 mg/kg in the morning and 5 mg/kg in the evening). The 10 mg/kg/day dose should be maintained for the remainder of the treatment period; however, per labeling, investigators may increase the dose to a maximum of 20 mg/kg/day if clinically warranted by titrating an additional 5 mg/kg/day each week until reaching the maximum dose. GWP42003-P will be taken b.i.d. (morning and evening).
16378001|NCT04133467||Group SB|Scalp block performed with Levobupivacaine 0.125% (total dose 2 mg/kg) in combination with intraoperative intravenous acetaminophen (15 mg/kg if body weight >10Kg, 7 mg/kg if body weight < 10 kg).
16378002|NCT04133467||Group ST|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg
16378003|NCT04133454|Experimental|subjects treated with LGT|subjects will be treated with a single dose of LGT (AAV-hTERT)
16378091|NCT04132752|Experimental|Intervention|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
16378004|NCT04133428||Sacubitril-Valsartan cohort|Patients with severe systolic disfunction (left ventricle ejection fraction<40%) heart failure that remain functional class II, III or IV after at least 3 months of optimal treatment and after being evaluated by the cardiologist by doing an echocardiography, blood test and clinical evaluation, start Sacubitril-Valsartan treatment.
16378005|NCT04133415|Experimental|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
16378006|NCT04133389|Experimental|Growth Mindset of Personality|Experimental intervention
16378007|NCT04133389|Placebo Comparator|Growth Mindset of Athletic Ability|Control intervention
16378008|NCT04133376|Experimental|Vascular Endothelial Function|
16378009|NCT04133376|Experimental|Biomarkers of oxidative stress and inflammation|
16378010|NCT04133376|Experimental|Vascular endothelial cells|
16378011|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA Layered|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
16378012|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
16378013|NCT04133363|Experimental|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF alone
16378014|NCT04133350|Experimental|Active Patient Engagement|All patients are enrolled into the Active Patient Engagement (APE) arm. This arm will receive the APE intervention.
16378015|NCT04133337|Experimental|Apatinib Combined With SHR-1210 Injection|"Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery.
~Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion.
~Surgery:
~The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose."
16378016|NCT04133324||Main group|One groupe in the study
16378017|NCT04133311|Active Comparator|DE-130A|Instillation of one drop, once daily in the evening (9 pm ±1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
16378018|NCT04133311|Active Comparator|Xalatan®|Instillation of one drop, once daily in the evening (9 pm ± 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
16378019|NCT04133298|Active Comparator|Tunneling with laser de-epithelized gingival graft.|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
16378020|NCT04133298|Active Comparator|Tunnelingwith subepithelial connective tissue graft.|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid.
16378021|NCT04133285||Multiple Osteochondromas patients|Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
16378022|NCT04133272||Ehlers-Danlos Syndrome patients|The group comprises all patients affected by Ehlers-Danlos Syndrome, including prenatal and fetal diagnosis of Ehlers-Danlos Syndrome
16378023|NCT04133259|Experimental|HLX10, in patients with CHB|HLX10: 1 mg/kg at 0, 4th, 8th week (maximum 3 doses). Concomitant antiviral medications: take Nucleoside/nucleotide analogues (NAs) starting from at least 2 weeks before the first dose of HLX10 until 12 weeks after the last dose of HLX10 infusion.
16378024|NCT04133246|Other|Group arm|Includes subjects enrolled in focus groups
16378025|NCT04133246|Other|Interview arm|Includes subjects with individual interviews
16378026|NCT04133233|Experimental|active treatment|"IL-2 (ILT-101) Sub-cutaneous
~1 million UI/j"
16378027|NCT04133233|Placebo Comparator|placebo|placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).
16378028|NCT04133220||Cases|Patients with acute myeloid leukemia, associated to hyper leukocytosis
16378029|NCT04133220||Control|Patients with acute myeloid leukemia, without hyper leukocytosis
16378030|NCT04133207||Patients with advanced HR-positive breast cancer|patients with histologically confirmed HR-positive, HER2-negative advanced (recurrent or metastatic) breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
16378031|NCT04133194|Experimental|1600 mg Asacol (mesalazine)|1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year
16378032|NCT04133194|Active Comparator|800 mg Asacol (mesalazine)|800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year
16378033|NCT04133181|Experimental|Guided endodontic surgery|Use of a 3D surgical guide in endodontic surgery
16378034|NCT04133181|Placebo Comparator|Conventional endodontic surgery|Use of a mock guide in endodontic surgery
16378035|NCT04133168|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the POLARx™ Cardiac Cryoablation System
16378036|NCT04133155||nab-P + GEM|Nab-paclitaxel plus gemcitabine
16378037|NCT04133142|No Intervention|Medical treatment|"Patients receive the standard medical medication for herpes pain
~Oral administration of Gabapentin
~300 mg/d on day 1 and 2
~600 mg/d on day 3 and 4 if pain persists
~900 mg/d on day 5 and 6 if pain persists
~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation"
16378038|NCT04133142|Experimental|Early block Single|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment
16378092|NCT04132752|No Intervention|Control|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
16378039|NCT04133142|Experimental|Early Repeated block|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery.
16378040|NCT04133142|Experimental|Late block single|"Patients receive the standard medical medication for herpes pain
~Oral administration of Gabapentin
~300 mg/d on day 1 and 2
~600 mg/d on day 3 and 4 if pain persists
~900 mg/d on day 5 and 6 if pain persists
~Oral administration of Paracetamol up to 3 g per day at day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block . Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment"
16378041|NCT04133142|Experimental|late block repeated|"Patients receive the standard medical medication for herpes pain
~Oral administration of Gabapentin
~300 mg/d on day 1 and 2
~600 mg/d on day 3 and 4 if pain persists
~900 mg/d on day 5 and 6 if pain persists
~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation At day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery."
16378042|NCT04133129|Experimental|LV-High Intensity Interval Training|2 x 4 minutes at 85%-95% of Heart rate max.
16378043|NCT04133129|Experimental|Moderate Intensity Continuous Training|1 x 45 minutes at 65%-75% of Heart rate max.
16378044|NCT04133129|No Intervention|Control Group|They will not be prescribed any training and will be asked to continue with their normal lifestyle.
16378045|NCT04133116|Experimental|LY3471851|LY3471851 administered by subcutaneous (SC) injection.
16378046|NCT04133116|Placebo Comparator|Placebo|Placebo administered by SC injection.
16378047|NCT04133103|No Intervention|First ambulation at 24 hours after operation|
16378048|NCT04133103|Experimental|First ambulation at 4 hours after operation|
16378049|NCT04133090|Active Comparator|Autogenous block bone graft|Surgical site as control group was treated with autogenous block bone graft. Augmentation site was covered with a mixture of particulate allograft and leukocyte and platelet-rich fibrin (L-PRF) membrane.
16378050|NCT04133090|Active Comparator|i-PRF enriched allograft material+screw tent pole technique|Surgical site as test group was treated with injectable platelet rich-fibrin (i-PRF) enriched allograft material. To avoid soft tissue collapse, screws were used. Augmentation site was covered with leukocyte and platelet-rich fibrin (L-PRF) membrane.
16378051|NCT04133077|Other|Succeed PDX|Genetic analysis will be performed in patients who got a successful PDX
16378052|NCT04133064|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 10 or more cigarettes per day
16378053|NCT04133051|Active Comparator|Quadratus Lumborum Block|17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.
16378054|NCT04133051|Active Comparator|Epidural Analgesia|17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).
16378055|NCT04133038||Children consulting|Children consulting in the expert center for food difficulties.
16378056|NCT04133038||Pierre Robin sequence|Children with Pierre Robin sequence following for food difficulties.
16378057|NCT04133038||Cardiac malformations|Children with cardiac malformations followed for food difficulties.
16378058|NCT04133038||Oesophageal atresia|Children with oesophageal atresia followed for food difficulties.
16378059|NCT04133038||Cleft lip and palate|Children with cleft lip and palate followed for food difficulties.
16378060|NCT04133038||Autism spectrum disorders|Children followed for congenital pathology that cause food difficulties.
16378061|NCT04133038||Ex-prematurity < 32 AG|Children born premature followed for food difficulties.
16378062|NCT04133038||Chromosomal anomalies|Children with chromosomal anomalies followed for food difficulties.
16378063|NCT04133025|Active Comparator|Conventional vestibular rehabilitation|Conventional vestibular rehabilitation
16378064|NCT04133025|Active Comparator|Vestibular rehabilitation with software|
16378065|NCT04133012|Other|Single Arm|Single arm composed by 34 HIV-1 infected male subjects
16378066|NCT04132999|Active Comparator|Family-informed intervention (INT)|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.
16378067|NCT04132999|Active Comparator|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
16378069|NCT04132960|Experimental|HER2 status|"Three cohorts of advanced breast cancer patients:
~Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)
~Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)
~Cohort 3: HER2 non-expressing (IHC0+)"
16378070|NCT04132947||Cohort|Cohort Study correlating self reported exercise activity and spiroergometry results
16378071|NCT04132921||Patients with AKI|Patients with AKI after joint replacement
16378072|NCT04132921||Patients without AKI|Patients without AKI after joint replacement
16378073|NCT04132908|Experimental|Sclerocarya birrea|
16378074|NCT04132908|Placebo Comparator|Placebo|
16378089|NCT04132778|No Intervention|Control group - Traditional asthma management|Traditional self-management is defined as all other types of non-digital asthma management. This could be treatment plan written on paper or by oral communication to patient/caregiver on asthma treatment.
16378075|NCT04132869|Experimental|Experimental Group|In Spring of 2020, all 6th graders in Wave 1 intervention schools (6 schools), which include 561 total 6th graders, will be invited to participate the intervention. Those in the experimental group will complete all measures according to the timeline. Those not in the experimental group will also complete the intervention, but will not participate in measurements. In Fall 2020 all 6th graders who attend the Wave 2 intervention schools (schools that were the control schools in Spring), will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule. *Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
16378076|NCT04132869|No Intervention|Control group|Wave 1 comparison schools (2 Schools) have a total of 267 6th graders. Students will be invited to join the comparison group. and will have measurements taken at baseline and 6 months. Wave 2 comparison schools (3 Schools) have a total of 363 6th graders adn will be invited to join the comparison group and will have measurements taken at baseline and 6 months. These students will continue with their normal activities as usual.*Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
16378077|NCT04132856|Experimental|Intervention Group|The Intervention group will receive the services of the Psychosocial Navigator (PSN) monthly for the full 12 months of the study. At baseline, the PSN will provide the health care providers (HCPs) and family with recommendations for mapping and triaging of resources to levels of psychosocial risk (PAT: Universal, Targeted, Clinical) and level of depression and anxiety (mild, moderate, and high mental health problems; as determined by the standardized norms for the measures). This information will be summarized in the Communication Summary Profile and shared with the treating team (oncologist, nurse, and Social Worker, core psychosocial staff involved in the child's care) and family within 48 hours of completion. The PSN will conduct follow-up psychosocial screenings on a monthly basis, using the Distress Thermometer for children and caregivers. Results of the monthly assessments and recommended resources will also be communicated to the caregiver/parent and treating team of the youth.
16378078|NCT04132856|No Intervention|Treatment as Usual Group|Current psychosocial care services will be accessible to Treatment as Usual Group (e.g., social work, child life, psychology, art and music therapy, and psychiatry).
16378079|NCT04132843|Experimental|Diagnostic (MRI, gadobutrol, gadobenate dimeglumine)|Within 21 days before standard of care chemotherapy and/or radiation therapy, patients undergo an MRI scan for the first set of images. Patients then receive either gadobutrol or gadobenate dimeglumine IV and undergo an MRI for the second set of images. All MRI scans take a total of 60 minutes to complete. Patients then repeat the MRI scans 120 days after standard of care chemotherapy and/or radiation therapy.
16378080|NCT04132830||HIV-Exposed Uninfected Dyads|Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
16378081|NCT04132830||HIV-Unexposed Uninfected Dyads|Mothers and young adults without HIV
16378082|NCT04132817|Experimental|Group A Target class A-1: Nivolumab+nab-paclitaxel|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
16378083|NCT04132817|Experimental|Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
16378084|NCT04132817|Experimental|Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
16378086|NCT04132791|Other|aspirin after awakening + placebo before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.
~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study."
16378087|NCT04132791|Experimental|placebo after awakening +aspirin before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.
~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study."
16378088|NCT04132778|Experimental|Intervention - Asthmatuner|Asthmatuner (Medituner AB, Stockholm, Sweden) is a CE-marked cloud-computing-based system with a healthcare interface and a downloadable patient app (Android or iOS).The intended use of Asthmatuner is to automate asthma self-management by letting patients register symptoms and measure forced expiratory volume in one second (FEV1) with a Bluetooth spirometer (MIR, SmartOne). The patient then receives immediate feedback on the status of symptom control (controlled, partly controlled or uncontrolled), and a treatment recommendation, with an image of the correct inhaler or other type of medication and the dose. Symptom control is quantified based on lung function; litre to percentage of personalised best FEV1, using a cut-off ≤80% and symptoms during the last week based on four questions: 1) need for rescue medication more than twice due to asthma symptoms, 2) any daytime symptoms, 3) nocturnal symptoms/awakenings, and 4) limitation in physical activities.
16378102|NCT04132700|Experimental|ICU Patients|Patients admitted to the ICU will be monitored using the Q-NRG for up to 30 mins.
16378103|NCT04132687|Other|autologous blood patch|autologoust blood patch therapy
16378104|NCT04132674|Other|B/F/TAF|Switching participants who are currently on multi-tablet HIV antiretroviral therapy, including multi-tablet regimens and/or two drug combinations (dual therapy) to one oral tablet of B/F/TAF once-daily for 72 weeks
16378105|NCT04132661|Experimental|bisacodyl|5 mg bisacodyl, one tablet once
16378106|NCT04132661|Placebo Comparator|placebo|placebo, one tablet once
16378107|NCT04132648|Experimental|Curcumin|Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
16378108|NCT04132648|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
16378109|NCT04132635|Experimental|artificial dermis with growth factor|
16378110|NCT04132635|Experimental|artificial dermis only|
16378111|NCT04132622|Experimental|Experimental therapy group|Besides Traditional therapy，patients in this group will also receive thyroid replacement therapy.
16378112|NCT04132622|Sham Comparator|Traditional therapy group|Patients in Standard therapy group will receive treatments according to guideline worldwide.
16378113|NCT04132609|Active Comparator|Cognitive Bias Intervention|Complete cognitive bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
16378114|NCT04132609|Placebo Comparator|Control|Complete standard attentional bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
16378115|NCT04132596|Experimental|Motor Complete Tetraplegia|C4-T1 American Spinal Injuries Association (ASIA) Impairment Scale Classification A or B spinal cord injury tscs with activity based therapy intervention
16378116|NCT04132596|Experimental|Motor Complete Paraplegia|T2-12 ASIA Impairment Scale A or B spinal cord injury tscs with activity based therapy intervention
16378117|NCT04132596|Experimental|Motor incomplete SCI|C4-T12 ASIA Impairment Scale C or D spinal cord injury tscs with activity based therapy intervention
16378118|NCT04132583|Experimental|First Deflox®, Then Cataflam DD®|Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2.
16378119|NCT04132583|Experimental|First Cataflam DD®, Then Deflox®|Participants received single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 1 followed by single oral dose of Deflox® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between Treatment Periods 1 and 2.
16378120|NCT04132570|Experimental|Budesonide 256 mcg per Day (Treatment A)|Participants will self-administer 2 nasal sprays of Budesonide (64 microgram [mcg]/spray) in each nostril once daily (every morning) up to 10 +\- 3 Days.
16378121|NCT04132570|Placebo Comparator|Placebo (Treatment B)|Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\- 3 Days.
16378122|NCT04132557||Cohort 1 (Target): Methylphenidate Monotherapy|Participants will be analyzed for Attention Deficit Hyperactive Disorder (ADHD) who are new users of methylphenidate monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
16378123|NCT04132557||Cohort 2 (Comparator [C]): Lisdexamfetamine Monotherapy|Participants will be analyzed for ADHD who are new users of lisdexamfetamine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
16378124|NCT04132557||Cohort 3 (C): Atomoxetine Monotherapy|Participants will be analyzed for ADHD who are new users of atomoxetine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
16378125|NCT04132557||Cohort 4 (C):Amphetamine/Dextroamphetamine Combo Therapy|Participants will be analyzed for ADHD who are new users of amphetamine/dextroamphetamine combo therapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
16378126|NCT04132544|Experimental|Intervention group|"a standardized gerontological evaluation (EGS) and a fall balance performed at home by an IDEG
~the proposal for a Proposal for a personalized intervention plan (PIP) to correct potentially reversible and modifiable factors
~a close follow-up by the IDEG for the implementation of the PIP throughout the follow-up period of 24 months (6 home visits and 5 telephone follow-ups)."
16378127|NCT04132544|Active Comparator|Comparison group - usual care|Usual Care with the provision of documentation on simple recommendations for the prevention of falls and aging well.
16378128|NCT04132531||Normal weight control|Individuals who are generally healthy and have a body mass index less than 25 kg/m^2.
16378129|NCT04132531||Bariatric Surgery Group|Individuals electing to undergo bariatric surgery (generally with a body mass index between 35 and 40 kg/m^2 with an additional co-morbidity such as type 2 diabetes, or individuals with a body mass index greater than 40 kg/m^2) and who are willing to participate for 2 visits, one before and one after surgery. The intervention in this group is bariatric surgery.
16378130|NCT04132518|Experimental|Treatment Group|Each subject assigned to Treatment Group will receive up to 4 injection sessions with 5(±1) weeks intervals.
16378131|NCT04132518|No Intervention|Control Group|Subjects assigned to the Control Group will not receive treatment during the study.
16378132|NCT04132505|Experimental|Treatment (binimetinib, hydroxychloroquine)|Patients receive binimetinib PO BID and hydroxychloroquine PO BID on days 1-14. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16378133|NCT04132479|Experimental|Sequential therapy|Sequential Clarithromycin + Amoxycillin + Tinidazole + rabeprazole by mouth (Both amoxycillin 1000mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days, followed by clarithromycin 500 mg every 12 hours, tinidazole 500mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days)
16378134|NCT04132479|Active Comparator|Concomitant therapy|Concomitant clarithromycin 500mg every 12 hours + amoxycillin 1000mg every 12 hours + tinidazole 500mg every 12 hours + rabeprazole 20mg every 12 hours (all drugs by mouth for 14 days).
16378135|NCT04132466|Experimental|Enrolled Subjects|Adult subjects who met eligibility criteria and provided written informed consent to participate
16378136|NCT04132440||Observational (questionnaire, interview)|Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.
16378137|NCT04132427|Experimental|Group A: Treatment|Vancomycin, magnesium citrate, microbiota
16378138|NCT04132427|Placebo Comparator|Group B: Placebo|placebo vancomycin, real magnesium citrate (because it obviously empties the bowels) and placebo microbiota
16378139|NCT04132414|Experimental|NIRS open|Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia
16378140|NCT04132414|No Intervention|NIRS blinded|NIRS monitoring applied and masked for caregiver.
16378141|NCT04132401|Experimental|family medicine physicians|Retina reading
16378142|NCT04132401|Experimental|retina specialists|Retina reading (gold standard)
16378143|NCT04132388|Active Comparator|Standard-of-Care|Subjects will be instructed to take adalimumab according to the labeled dosing regimen. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
16378144|NCT04132388|Experimental|Electronic Reporting|"Subjects will be instructed to take adalimumab according to the labeled dosing regimen. The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.
~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
16378145|NCT04132375|Active Comparator|Stage 1 - high treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
16378146|NCT04132375|Active Comparator|Stage 1 - Low treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
16378147|NCT04132375|Placebo Comparator|Stage 1 - Placebo arm|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
16378148|NCT04132375|Active Comparator|Stage 2 - Selected active treatment arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of 4 mg/kg INM004 and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
~In the case, the low treatment regime is selected subjects will receive an intravenous dose of 4 mg/kg INM004"
16378149|NCT04132375|Active Comparator|Stage 2 - Placebo arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo, each dose separated by 24 h (± 2 h)
~In the case, low treatment regime is selected subjects will receive a single intravenous dose of Placebo"
16378150|NCT04132362||People living with dementia, their families and carers|The cohort consists of people living with dementia. Each of them will be accompanied, throughout the study, by a family member or friend. They will take part together in a one hour music listening session, to discover their personalised playlist. Where possible, a care home staff member will join in, in order to witness the benefits of the music to the dementia resident and learn how to provide the music, as part of their care in the care home.
16378151|NCT04132349|Experimental|Ullipristal Acetate|Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months
16378152|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 1|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
16378153|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 2|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
16378154|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 3|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
16378155|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 4|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
16378156|NCT04132336|Active Comparator|Naproxen sodium|Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
16378157|NCT04132336|Active Comparator|Caffeine|Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
16378158|NCT04132336|Placebo Comparator|Placebo|Participants received a single dose of two tablets of matching placebo after extraction of third molars
16378159|NCT04132323|Active Comparator|hypertonic glucose|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
16378160|NCT04132323|Active Comparator|0.05% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
16378161|NCT04132323|Active Comparator|0.1% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
16378251|NCT04131647|Experimental|Weight Maintenance + Intermittent Fasting|Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
16378162|NCT04132323|Active Comparator|0.15% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
16378163|NCT04132310||MINT Participants|Up to 60 MINT maternal participant are linked with 60 infant participants, and 60 partner participants.
16378164|NCT04132297|Experimental|Virtual Asthma Academy Training + Telehealth Visit Group|Participants will receive the Asthma Academy Training virtually. One week after the virtual training, participants will be scheduled to complete a Telehealth visit via zoom through their smart phones or computers.
16378165|NCT04132297|Experimental|Virtual Asthma Academy Training|Participants will receive the virtual Asthma Academy Training via zoom through their smart phones or computers.
16378166|NCT04132284|Experimental|DBT IOP plus DBT PI|Standard Dialectical Behavior Therapy (DBT) delivered in the context of an intensive outpatient program (DBT IOP) for adolescents plus an 8-10 session DBT-based parenting intervention (DBT PI)
16378167|NCT04132284|Active Comparator|DBT IOP alone|No parenting intervention provided beyond what is part of the DBT IOP treatment as usual.
16378168|NCT04132271|Experimental|Personalized diet|Personalized diet during the swallowing rehabilitation
16378169|NCT04132271|Active Comparator|Control|Nutritional recommendations during the swallowing rehabilitation
16378170|NCT04132245|Experimental|obesity prevention|Families were randomized to an obesity prevention intervention arm or a general health control arm.
16378171|NCT04132245|Experimental|behavioral intervention|there are two arms in this study. An active intervention arm and a control arm
16378172|NCT04132232|Experimental|Treatment Group|"The patient will exhaled into the Smokerlyzer® device will at each visit
~Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient
~Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided."
16378173|NCT04132232|No Intervention|Control Group|"The patient will exhale into the Smokerlyzer® device at each visit.
~Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient
~No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided"
16378174|NCT04132219|Experimental|Immediate Intervention Group|"Dyads randomized to the Immediate Intervention Group will receive a Welcome Box at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on."
16378175|NCT04132219|Other|Delayed Intervention Group|"Participants assigned to the Delayed Intervention Group will receive a Welcome Box which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments."
16378176|NCT04132206||ScS patients|Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
16378177|NCT04132206||Healthy subjects|Healthy subjects will provide one stool sample at inclusion.
16378178|NCT04132180|Experimental|Early mobilization|
16378179|NCT04132180|Active Comparator|Late mobilization|
16378180|NCT04132167|Experimental|training group|perturbation balance training
16378181|NCT04132167|Active Comparator|control group|traditional physical therapy that including strengthening and stretching
16378182|NCT04132154||No Warming|Patients in this group were treated according to our institution's old protocol and did not receive any warming intervention during the surgical procedure.
16378183|NCT04132154||Active Warming|This group will include the patients treated after the implementation of the S3 Guidelines for prevention of hypothermia. For this purpose convective warming through an underbody blanket was used during the surgical procedure
16378184|NCT04132141|Other|VR intervention|each subject will be own control. subjects breaks will be randomly assigned to VR or WT until they complete 3 for each type or a total of 6
16378185|NCT04132128|Experimental|study|6 meetings with a dietician diabetes educator assimilating simple CC tool
16378186|NCT04132128|Other|control|meeting with dietician as needed with regular education of CC
16378187|NCT04132102|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
16378188|NCT04132089|No Intervention|Control|This was the control group for the messaging component of the study (push notifications). These participants only received the mobile health application called capABILITY without messages.
16378189|NCT04132089|Other|Facilitator Message Group|This group of participants received the mobile health application called capABILITY and received three facilitator messages per week. Facilitator messages are designed to help people who lack ability to do something.
16378190|NCT04132089|Other|Spark Trigger Group|This group of participants received the mobile health application called capABILITY and received three spark messages per week. Spark messages are designed to help people who lack ability to do something.
16378191|NCT04132076||Group A: Osteochondral lesion of talus (OLT)|Patients with OLT treated operatively (debridement, microfracture, allograft, mesenchymal stem cells implantation) in Department of Orthopaedic Surgery, University Medical Centre Ljubljana (UMC).
16378192|NCT04132076||Group B: Ankle joint osteoarthrosis|Patients with ankle joint osteoarthrosis treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
16378193|NCT04132076||Group C: Ankle Impingement syndrome|Patients with ankle impingement syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
16378194|NCT04132076||Group D: Ankle instability syndrome|Patients with ankle instability syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
16378196|NCT04132050|Experimental|R788|Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
16378197|NCT04132050|Placebo Comparator|Placebo|Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
16378198|NCT04132037||patient with multiple sclerosis|At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated
16378199|NCT04132024|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
16378200|NCT04132011|Active Comparator|Shortened interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals less than every 12 hours.
16378201|NCT04132011|Active Comparator|Standard interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals every 12 hours
16378202|NCT04131985|Experimental|Erector spina block|"After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
~All anesthesia procedure will be the same as control group"
16378203|NCT04131985|No Intervention|Control|There were no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1-2μg/kg, propofol 2 - 4 mg/kg and rocuronium 0.6 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCO2≈ 35-40 mmHg. Anesthesia was maintained using remifentanil 0.05-0.1 mcg/kg/min and propofol 80-100 mcg/kg/min via total intravenous micro pump until the surgery was completed. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria.Tramadol 100 mg i.v. will be used before 15 min end of surgery and 20 mL of 25% bupivacaine will be infiltrated to the trochar sites at the end of the surgery. Patient control analgesia device will administer all patients.
16378204|NCT04131972|Experimental|Single arm 1|Each patient will be planned to perform 7 study visits and at the second visit excision / lumpectomy and REGENERA implant will be performed during the same surgical intervention.
16378205|NCT04131959|Experimental|Pharmacodynamic population|Single arm
16378206|NCT04131946|Experimental|Community Intervention Group/Arm 1|"Community navigators will work with local businesses (barber shop, hair salon) to identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT.
~Community navigators will attend community events to post the informational flyer and provide education about CRC to community members. At these events, they will identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT."
16378207|NCT04131946|No Intervention|Standard of Care (Control) Arm 2|"These procedures are a detailed summary of the existing lay navigation program at Mile Square Health Center (MSHC). These procedures are unrelated to our research, except to demonstrate how the existing navigation program from which we will obtain deidentified data works.
~Lay clinic navigator use clinic schedules and walk-ins to identify and screen eligible participants within the Englewood MSHC. The navigator engages with each potential participant using standard scripted language. For interested patients, the navigator documents interest and FIT dispensing as appropriate, and assists the patient in obtaining and returning their FIT.
~Lay clinic navigators attend community events as normally scheduled to provide community-based health education and referral to the MSHC. At these events, they identify and screen eligible community members within the Englewood community area."
16378208|NCT04131920||Phase 1 and 2|10 male patients with severe Hemophilia A from the Washington Center for Bleeding Disorders
16378209|NCT04131920||Phase 3|20 subjects who are also participating in the EmiMSKUS study
16378210|NCT04131907|Experimental|Optilume™ BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
16378211|NCT04131907|Sham Comparator|Sham Device|The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.
16378212|NCT04131907|Experimental|Pharmacokinetics Optilume Arm|A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System
16378213|NCT04131894|No Intervention|Control|Extraction sockets with spontaneous healing (16 sockets).
16378214|NCT04131894|Active Comparator|Dentin|Extraction sockets were filled with undemineralized autogenous dentin graft (20 sockets).
16378215|NCT04131894|Active Comparator|Dentin+PRF|Extraction sockets were filled with mixture of undemineralized autogenous dentin graft and platelet rich fibrin (PRF) (21 sockets).
16378216|NCT04131868|Experimental|Extended sleep opportunity|
16378217|NCT04131868|Active Comparator|Typical sleep opportunity|
16378218|NCT04131855|Active Comparator|Pumice prophylaxis.|Will receive pumice prophylaxis in a slurry of plain pumice and water for 5 seconds per tooth using a rubber cup in a slow contra-angle handpiece. The teeth involved will then be washed and dried prior to using the self etch primer.
16378219|NCT04131855|Experimental|No pumice prophylaxis.|Will not receive pumice prophylaxis. Teeth will be washed and dried before using the self etch primer.
16378220|NCT04131842|Experimental|ExFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive external focus of attention visual feedback.
16378221|NCT04131842|Experimental|ExFOCUS Auditory|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive auditory feedback.
16378222|NCT04131842|Experimental|InFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive internal focus of attention visual feedback via video.
16378223|NCT04131842|Active Comparator|NoFeedback|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and receive no feedback.
16378224|NCT04131829|No Intervention|Healthy Controls|The healthy control group will be an age matched sample of unmedicated healthy adults who will be recruited and imaged once at baseline and the data compared with that of OCD subjects at baseline.
16378225|NCT04131829|Experimental|OCD Group|The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms. OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
16378226|NCT04131816|Experimental|HeartHome Intervention|Participants will be in the HeartHome program for a total of 12 weeks.
16378227|NCT04131816|No Intervention|Control|De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
16378228|NCT04131803|Experimental|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
16378229|NCT04131803|Experimental|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
16378230|NCT04131790|Experimental|Tele-Behavioral Activation|Manualized Behavioral Activation (BA) protocol delivered via videoconferencing by a trained BA interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist guides participants in learning BA skills, focusing on strategies to decrease barriers to social connectedness (e.g., limited mobility, inadequate caregiving resources).
16378231|NCT04131790|Active Comparator|Tele-Friendly Visiting|Friendly Visitor (FV) calls delivered via videoconferencing by a trained FV interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist provides social support to participants through good listening and provision of genuine regard.
16378232|NCT04131777||Roll-in|Initial patients enrolled until optimal RF algorithm is determined
16378233|NCT04131777||Optimized|Patients treated using optimal RF algorithm
16378234|NCT04131764||Optic neuritis diagnosis only|Patients who have a diagnosis of optic neuritis, without a diagnosis of MS or NMOSD.
16378235|NCT04131764||ON and multiple sclerosis|Patients who have a diagnosis of optic neuritis AND multiple sclerosis.
16378236|NCT04131764||ON and NMOSD|Patients who have a diagnosis of optic neuritis and neuromyelitis optica spectrum disorder.
16378237|NCT04131738|Experimental|Baricitinib 2 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice
~Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100
~After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
16378238|NCT04131738|Experimental|Baricitinib 4 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice
~Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100
~After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
16378239|NCT04131725||Cardiac Function Monitoring|Subjects will wear Cardiac Performance System (CPS) non-invasive device for brief periods during procedures including assessment by Pulmonary Artery Catheter (PAC) methods.
16378240|NCT04131712|No Intervention|Ambulatory Control|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. Atrophy will not be induced and massage intervention will not be applied.
16378241|NCT04131712|Sham Comparator|Ambulatory Massage|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. No atrophy induction. Four massage treatments will be applied every other day until the end of the study.
16378242|NCT04131712|No Intervention|Immobilization Control|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Massage intervention will not be applied.
16378243|NCT04131712|Experimental|Immobilization Massage|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Four massage treatments will be applied every other day until the end of the study.
16378244|NCT04131699||pediatric thoracoscopic group|record hemodynamic changes and cardiac output at different intrathoracic pressures ( insufflation pressures 4, 5, 6 mmHg)
16378245|NCT04131686||Control sites|Group of patients receiving standard treatment for symptomatic acute rhinosinusitis
16378246|NCT04131686||Test sites|Group of patients receiving NAC inhalation in addition to standard treatment for symptomatic acute rhinosinusitis
16378247|NCT04131673||African Americans with MS|African American patients seen in the University of Kentucky's Multiple Sclerosis Clinic between the ages of 18 and 80 who have been diagnosed with MS
16378248|NCT04131660|Experimental|AVAPS-AE mode|A volume targeted pressure support ventilation mode
16378249|NCT04131660|Active Comparator|S/T mode|A pressure support ventilation mode
16378250|NCT04131647|Active Comparator|Weight Maintenance|Heart Healthy nutrition, walking, resistance band exercise
16378252|NCT04131634|Experimental|SAbR 6 measurable lesions|PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)
16378254|NCT04131608||diabetic foot ulcer (1and2)with iron defic|"50 diabetic patients with diabetic foot ulcer grade (1and2) with iron deficiency anemia will be applied TO
~cbc
~ferritin
~HBA1C
~ankle brachial index by duplex"
16378255|NCT04131608||diabetic foot ulcer grade(1and2)without iron deficiency anemia|"50 patients with diabetic foot ulcer grade (1and2) without iron deficiency anemia will be applied to
~CBC
~Ferritin,
~HBA1C
~ankle brachial index by duplex"
16378256|NCT04131595|Experimental|MVA-BN-WEV Dose 1|Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.
16378257|NCT04131595|Experimental|MVA-BN-WEV Dose 2|Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL
16378258|NCT04131595|Experimental|MVA-BN-WEV Dose 3|Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL
16378259|NCT04131582|Experimental|Empagliflozin + linagliptin + metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5 mg + metformin 850 mg every 12 hours and empagliflozin 12.5 mg + metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
16378260|NCT04131582|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the complete dose. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
16378261|NCT04131569||ESBL-E fecal carriers|Patients with a positive ESBL-E fecal carriage according to routine screening
16378262|NCT04131569||non ESBL-E fecal carriers|Patients without positive ESBL-E fecal carriage according to routine screening
16378263|NCT04131556|Experimental|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
16378264|NCT04131556|Experimental|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
16378265|NCT04131556|Experimental|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
16378266|NCT04131556|Experimental|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
16378267|NCT04131556|Experimental|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
16378268|NCT04131556|Experimental|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
16378269|NCT04131556|Experimental|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
16378270|NCT04131556|Experimental|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
16378271|NCT04131556|Experimental|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
16378399|NCT04130672|Other|Hot saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 50 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 50 ° C saline irrigation was applied.
16378644|NCT04129060|Experimental|Placebo Challenge|One of the two study days will be the oral placebo.
16378272|NCT04131556|Experimental|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
16378273|NCT04131543|Experimental|Cabozantinib|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
16378274|NCT04131530||Colon mucosa observed by pCLE|pCLE is used to evaluate the inflammation activity in different parts of the colon mucosa
16378275|NCT04131517|Experimental|Oral contraceptive|Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.
16378276|NCT04131517|Experimental|Oral contraceptive + padsevonil|Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.
16378277|NCT04131504||Phase I - Cross-sectional Study (CD and Suspected IBD)|150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
16378278|NCT04131504||Phase I - Cross-sectional Study (healthy volunteers)|20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
16378279|NCT04131504||Phase II - Longitudinal Study of Participants with CD|70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
16378280|NCT04131491|Other|Patients with Mild Cognitive Impairment (MCI) due to AD|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, magnetic resonance imaging (MRI), blood sample with deep genetic profiling and Apolipoprotein E (APOE) determination.
16378281|NCT04131491|Other|Healthy volunteers|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, MRI, blood sample with deep genetic profiling and APOE determination.
16378282|NCT04131478||Cases|Cachectic lung, pancreas, or colon cancer patients.
16378283|NCT04131478||Control|Non- cachectic lung, pancreas, or colon cancer patients.
16378284|NCT04131465|Experimental|Home HIV self-testing|Fieldworkers will visit potential participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing.
16378285|NCT04131465|Experimental|Home HIV rapid testing|Fieldworkers will visit potential participants in their homes and offer home-based HIV rapid testing and counselling.
16378286|NCT04131465|Experimental|Home HIV self-testing and rapid testing|Fieldworkers will visit participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing as well as home-based HIV rapid testing and counselling.
16378287|NCT04131452||Fresh embryo transfers|those undergoing fresh embryo transfer
16378288|NCT04131452||Frozen embryo transfers|those undergoing frozen embriyo transfer
16378290|NCT04131426|Experimental|Remune dosed twice daily|A nutritional supplement taken twice per day each day and standard care for your cancer as prescribed by your oncologist
16378291|NCT04131426|Experimental|Remune dosed twice daily and daily exercise with EXCAP|A nutritional supplement taken twice by day each day and a home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
16378292|NCT04131426|No Intervention|Usual Care|Usual standard care as prescribed by your oncologist
16378293|NCT04131413|Other|Vaccination Arm Level 1|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; Level 1 dose of 0.3 mg
16378294|NCT04131413|Other|Vaccination Arm Level 2|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 2 at dose 1.0 mg
16378295|NCT04131413|Other|Vaccination Arm Level 3|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 3 dose of 3.0 mg
16378296|NCT04131400||Patients with Inherited Retinal Dystrophy|known patients with a diagnosis of inherited retinal dystrophy (IRD) will be recruited to identify the type of IRD diagnosis. The comprehensive ophthalmic examinations and retinal imaging will be performed. Additionally, blood sample of all participants and their family members will be kept in our bio- bank for genetic testing.
16378297|NCT04131387|Experimental|Test Group|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
16378298|NCT04131387|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
16378299|NCT04131374|Experimental|Virtual Reality Intervention|Virtual Reality Intervention: Each Person Living with Dementia-caregiver dyad will receive 10 weekly sessions of tailored reminiscence therapy delivered via virtual reality. Each session will last for a period of 15-30 minutes.
16378300|NCT04131361|Active Comparator|Crystalloid -control group:|
16378301|NCT04131361|Experimental|Colloid- study group:|
16378302|NCT04131348|Other|CSG|patients underwent open CST (component separation group or CSG)
16378303|NCT04131348|Other|BTG|patients with preoperative BT administration and following open RSR (botulinum toxin group or BTG).
16378304|NCT04131335|Experimental|Experimental Arm|Experimental arm receives lubricant eye-drops (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks following cataract surgery (in addition to the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks).
16378305|NCT04131335|Active Comparator|Control Arm|The control arm group receive the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks after cataract surgery.
16378306|NCT04131322|Experimental|switch-cohort|Adalimumab biosimilar
16378307|NCT04131322|Active Comparator|non-switchcohort|Adalimumab original
16378308|NCT04131309|Experimental|Daratumumab|"Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter.
~Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone."
16378309|NCT04131283|Experimental|Epinephrine effect throught keratinized ginigva|1 mg/ml epniephrine vs physiologocal saline
16378310|NCT04131283|Experimental|Epinephrine effect throught gingival sulcular epithelium|1 mg/ml epniephrine vs physiologocal saline
16378311|NCT04131270|Experimental|Planning + Education|"3 education sessions + 1 planning session (integrated into the 3rd education session); delivered face-to-face over 3 weeks (after the baseline measurement), individually.
~Planning: The planning materials and forms have sections: (a) instructions of what should be included in a good plan (the when, where, and how components), (b) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties) will be formed. After forming the plans individually, experimenters will discuss the plans with the participants."
16378312|NCT04131270|Active Comparator|Education|"3 education sessions; delivered face-to-face over 3 weeks (after the baseline measurement), individually.
~The education includes extended physical activity and sedentary behavior education using participant-educator discussions and printed materials."
16378313|NCT04131257|Experimental|Continuum of care|Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.
16378314|NCT04131257|Active Comparator|Usual care|The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.
16378315|NCT04131231|Experimental|microparticles packaging methotrexate (MPs-MTX) group|"Patients are first treated with microparticles packaging methotrexate (MPs-MTX) via intrapleural infusion four times on day5,6,7,8 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.
~MPs-MTX: 5 U of MPs-MTX containing a total dose of more than 25μg of MTX dissolving in 50ml of physiological saline solution"
16378316|NCT04131231|Active Comparator|recombinant human interleukin-2(rhIL-2) group|"Patients are first treated with rhIL-2 via intrapleural infusion three times on day5,8,11 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.
~rhIL-2: 2 million IU of rhIL-2 dissolving in 50ml of physiological saline solution"
16378317|NCT04131218|Experimental|Obese group|n=8, 25≤BMI≤39.9kg/m²
16378318|NCT04131218|Experimental|Morbidly obese group|n=8, BMI≥40kg/m²
16378319|NCT04131205||Minimal Hepatic Encephalopathy|Patients with hyperammonemia and minimal hepatic encephalopathy
16378320|NCT04131205||Control|Healthy controls
16378321|NCT04131192|Experimental|z650 and Gemcitabine|Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles
16378322|NCT04131179|Experimental|Youth culturally adapted therapy (Y-CMAP)|Youth Culturally adapted manual assisted (Y-CMAP) psychological therapy
16378323|NCT04131179|No Intervention|Treatment as Usual|"TAU will be standard routine care delivered by local medical, psychiatric and primary care services according to clinical judgement. A record will be kept of any treatment received by each participant.
~Assessment will be done at 3rd,6th,9th and 12 month after randomization along with TAU"
16378324|NCT04131166|Other|Metabolically normal lean|Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
16378325|NCT04131166|Experimental|Metabolically normal obese - Mediterranean diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
16378326|NCT04131166|Experimental|Metabolically normal obese - Low-carbohydrate ketogenic diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
16378327|NCT04131166|Experimental|Metabolically normal obese - Low-fat diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
16378328|NCT04131166|Experimental|Metabolically abnormal obese - Mediterranean diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
16378329|NCT04131166|Experimental|Metabolically abnormal obese - Low-carbohydrate ketogenic diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
16378330|NCT04131166|Experimental|Metabolically abnormal obese - Low-fat diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
16378331|NCT04131153|Other|Conventional radiofrequency ablation group|Conventional radiofrequency ablation procedures
16378643|NCT04129060|Experimental|Mecamylamine Challenge|One of the two study days will be the oral mecamylamine.
16378332|NCT04131153|Experimental|Three-step radiofrequency ablation group|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
16378333|NCT04131101|Experimental|Community Organizing|All tenants in three TCHC buildings will be invited to participate in a survey on their building conditions at baseline, 6 months and 12 months. Once baseline data collection is complete, there will be a community organizing campaign involving tenants to advocate for improved building conditions.
16378334|NCT04131075||Study group|Patients with CAD undergoing FFR-guided revascularisation. FFR, coronary flow reserve (CFR) and the index of hyperemic microvascular resistance (HMR) will be measured with the Doppler guidewire (Combowire, Volcano - Philips corporation) under steady state hyperemia.
16378335|NCT04131062|No Intervention|Control (no intervention)|Consented using the traditional, human-mediated consent process already in use for MyCode consenting.
16378336|NCT04131062|Experimental|Electronic Consent (iPad)|Consented using the Sage eConsent framework, which presents participants with an iPad that describes MyCode and allows participants to choose to learn more information at various steps along the process.
16378337|NCT04131049|Experimental|Carbohydrate Counting|The insulin doses of the breakfasts were calculated according to carbohydrate counting.
16378338|NCT04131049|Experimental|Food Insulin Index|The insulin doses of the breakfasts were calculated according to food insulin index.
16378339|NCT04131036||Arm A|Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough >1%.
16378340|NCT04131036||Arm B|Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.
16378341|NCT04131023|Experimental|Metabolic Tracking|Metabolism (indirect calorimetry) tracking was performed
16378342|NCT04131023|No Intervention|Standard Care|Metabolic (indirect calorimetry tracking was not performed
16378343|NCT04131010|Experimental|SpyGlass Pancreatoscopy|ERP with direct pancreatoscopy
16378344|NCT04130997|Experimental|Ublituximab Infusions|"All subjects who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab followed by a 1-hour infusion of 450 mg ublituximab 14 days later. Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks.
~Infusion treatment will continue for 168 weeks, or until physician or subject decision to withdraw from the study."
16378345|NCT04130984|Experimental|Group IO|Intraosseous assess will be established in group IO, using EZ-IO for drug or fuild resuscitation. Proximal tibia is the insertion site,locating at 1 cm medial tibial tuberosity. IO access should be retained for less than 1 day, and venous access should be established as soon as possible after winning rescue time to continue treatment. Other treatment measures refer to 2015 AHA guidelines.
16378346|NCT04130984|No Intervention|Group IV|Intravenous access will be established in group IV, choosing any available peripheral venous for the administration of drugs or fluids.The antecubital vein is the preferred choice. If failed, the next catheterization plan will be determined by the physician in charge of the scene.Other treatment measures also refer to 2015 AHA guidelines.
16378347|NCT04130971||Patients without neoadjuvant treatment|
16378348|NCT04130971||Patients with short course radiotherapy|
16378349|NCT04130971||Patients with long course chemoradiotherapy|
16378350|NCT04130971||Patients with short course radiotherapy and deferred surgery|
16378351|NCT04130958|Experimental|MDD and Active iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving active iTBS-TMS.
16378352|NCT04130958|Experimental|BPD and Active iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
16378353|NCT04130958|Sham Comparator|MDD and Sham iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving sham iTBS-TMS.
16378354|NCT04130958|Sham Comparator|BPD and Sham iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.
16378355|NCT04130945|Active Comparator|group 1|patients with erector spine plane block
16378356|NCT04130945|No Intervention|group 2|patients without erector spine plane block
16378363|NCT04130906|Active Comparator|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
16378364|NCT04130906|Sham Comparator|Sham Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
16378365|NCT04130893|Experimental|A stimulation of G13 then G15|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G13 auricular stimulation At the Third session: Cold water hand immersion + G15 auricular stimulation
16378366|NCT04130893|Experimental|B: stimulation of G15 then G13|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G15 auricular stimulation At the Third session: Cold water hand immersion + G13 auricular stimulation
16378367|NCT04130880||Children with cerebral palsy|Children with CP who aged between 18 months and 6 years will be evaluated.
16378368|NCT04130880||Children with typical development|Children with typical development who aged between 18 months and 6 years will be evaluated.
16378369|NCT04130867||Group A: Swallow Therapy Oropharyngeal Strengthening|"Participants receiving any standard of care swallow therapy with oropharyngeal strengthening as the primary goal
~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post -therapy)"
16378370|NCT04130867||Group B: Surgical Treatment Esophageal Sphincter|"Participants receiving surgical treatment for relief of upper esophageal sphincter outlet obstruction.
~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post therapy)"
16378371|NCT04130867||Group C: Healthy Controls|Healthy controls (n=50) will also undergo data collection at parallel time points, without completion of a treatment paradigm.
16378372|NCT04130854|Experimental|APX005M on day 3 of RT & day 3 of cycles 1-5 of mFOLFOX|On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
16378373|NCT04130854|Active Comparator|Radiation Therapy 5Gy x 5 days, mFOLFOX|Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
16378374|NCT04130841|Experimental|Spontaneous ILM peeling|
16378375|NCT04130841|Active Comparator|Active ILM peeling|
16378376|NCT04130841|No Intervention|No ILM peeling|
16378377|NCT04130828|Experimental|Thrice-weekly group|Ferrous fumarate 200 mg PO PC Thrice-weekly
16378378|NCT04130828|Active Comparator|Thrice-daily group|Ferrous fumarate 200 mg PO PC Thrice-daily
16378379|NCT04130815|Active Comparator|Slow/Deep/Large|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration
16378380|NCT04130815|Active Comparator|Slow/Deep/Small|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
16378381|NCT04130815|Active Comparator|Fast/Shallow/Large|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration.
16378382|NCT04130815|Active Comparator|Fast/Shallow/Small|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
16378383|NCT04130802|Experimental|OCS-01 1.5% mg/mL QD|eye drops
16378384|NCT04130802|Experimental|OCS-01 1.5% mg/mL BID|eye drops
16378385|NCT04130802|Placebo Comparator|Placebo (Vehicle) BID|eye drops
16378386|NCT04130789||patients with sepsis (cases)|patients who developed or were admitted with sepsis to the ICU (cases)
16378387|NCT04130789||patients without sepsis (controls)|patients who did not develop sepsis (controls).
16378388|NCT04130763|Experimental|FMT Capsule in Combination with Anti-PD-1 Therapy|
16378389|NCT04130750|Active Comparator|treatment of physician's choice|Patients in this arm will receive neoadjuvant chemotherapy according physician's choice.
16378390|NCT04130750|Experimental|treatment of drug screening|Patients in this arm will receive neoadjuvant chemotherapy according results of drug screening vitro.
16378391|NCT04130737|Experimental|TORUS Stent Graft System|The TORUS Stent Graft System (SGS) is comprised of a Stent Graft (SG) and a Stent Graft Delivery System (SGDS).
16378392|NCT04130724||Ketogenic diet|Subjects consuming either a ketogenic (<30g carbohydrate per day) or a low-carb (<100g carbohydrate per day) diet.
16378393|NCT04130724||High-carbohydrate diet|Subjects consuming a high carbohydrate (>100g carbohydrate per day) diet.
16378394|NCT04130711|Other|TEST 1: Visual virtual Conditions|"50 subjects (30 healthy volunteers and 20 patients after stroke)
~3 different situations of vibration applications, without EGG neurofeedback session"
16378395|NCT04130711|Other|TEST 2: Standard EEG|"20 subjects (healthy volunteers)
~3 separate electroencephalographic recording conditions without Neurofeedback"
16378396|NCT04130711|Other|TEST 3: Neurofeedback Training Stroke Patients|"26 patients after stroke
~12 neurofeedback sessions spread over 6 weeks according to the feedback modality that will be drawn (visual or visuo-vibratory)"
16378397|NCT04130698|Experimental|Distress Tolerance|"Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address all 3 key factors. This condition includes both key factors in the control but introduces the third key factor distress tolerance (DT). Toward that end, modules will include: a values discussion; experiential avoidance; distress tolerance; and mindfulness-based ways to manage distress.
~Module 1: Orientation & ACT; Module 2: Avoidance; Module 3: Cognitive Fusion vs. Defusion; Module 4: Self-As-Context; Module 5: Present-Moment-Awareness; and Module 6: Values and Committed Action."
16378398|NCT04130698|Active Comparator|Active Health Control|"Treatment rationale: RAs will explain that there are 2 key factors that maintain smoking behavior and excess weight: 1) learned habits and 2) the addictive properties of smoking and food. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address both key factors. Toward that end, modules will include standard treatment on: the dangers of smoking, excess weight, unhealthy diets and sedentariness; the importance of healthy behaviors; and relaxation exercises to manage stress. These are all key aspects of standard treatment for smoking cessation and weight loss.
~Module 1: Orientation and Health; Module 2: Game Plan; Module 3: Stress and Coping Strategies; Module 4: Physical Activity; Module 5: Changes in Activities, Habits and Lifestyle; and Module 6: Long-Term Rewards."
16378516|NCT04129879|Experimental|1|all patients treated by conventional bare eye technique and then the use of methylene blue contrast technique to visualize endometriotic lesions perioperatively
16378400|NCT04130672|Other|Cold saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 22 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 22 ° C saline irrigation was applied.
16378401|NCT04130659|Experimental|Marial® + PPI (generic omeprazole)|Marial® + PPI (generic omeprazole) Application: following the Summary of Product Characteristics Marial®: 1 stick of Marial® twice a day after meals from day 1 to 28 Omeprazole 20 mg cps: once a day from day 1 to 28
16378402|NCT04130659|Active Comparator|PPI alone (generic omeprazole)|PPI alone (generic omeprazole) Application following the Summary of Product Characteristics Omeprazole 20 mg cps: once a day from day 1 to 28
16378403|NCT04130646|Active Comparator|Active taVNS, Active TMS|
16378404|NCT04130646|Sham Comparator|Sham taVNS, Active TMS|
16378405|NCT04130646|Sham Comparator|Active taVNS, Sham TMS|
16378406|NCT04130646|Sham Comparator|Sham taVNS, Sham TMS|
16378407|NCT04130633|Placebo Comparator|Placebo|Placebo (5mL distilled water)
16378408|NCT04130633|Experimental|Vaporized high THC alone|25mg of vaporized pure THC
16378409|NCT04130633|Experimental|Vaporized low alpha-pinene|0.5mg of vaporized alpha-pinene
16378410|NCT04130633|Experimental|Vaporized high alpha-pinene|5mg of vaporized alpha-pinene
16378411|NCT04130633|Experimental|Vaporized high THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 25mg vaporized THC
16378412|NCT04130633|Experimental|Vaporized high THC and high alpha-pinene|5mg of vaporized alpha-pinene with 25mg vaporized THC
16378413|NCT04130633|Experimental|Vaporized low THC alone|10mg of vaporized pure THC
16378414|NCT04130633|Experimental|Vaporized low THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 10mg vaporized THC
16378415|NCT04130633|Experimental|Vaporized low THC and high alpha-pinene|5mg of vaporized alpha-pinene with 10mg vaporized THC
16378416|NCT04130607|Experimental|Analytical|Students will receive brief instruction in probability, sensitivity, specificity, and likelihood ratios, with distributions and calculations. Pretest and posttest probabilities will be computed for two cases for each of the three conditions listed above.
16378417|NCT04130607|Active Comparator|Experiential|"Students will receive a brief instruction conceptually discussing sensitivity and specificity (e.g. a sensitive test will be positive at even low levels of disease. However, this can lead to a number of false positive errors, when the test is positive even when there is no disease. As a result, it is most useful for ruling out a diagnosis). They will then work through a total of 30 cases, 10 for each condition, in blocked sequence. For each brief written case they will be asked for a probability of diagnosis after the clinical information is presented. The test result will then be given and they will be asked for a post-test probability. Their estimate will be compared to the computed value based on published estimates of sensitivity and specificity and feedback provided."
16378418|NCT04130607|Placebo Comparator|No Explicit Instruction or Examples|Students will receive 3 passages from a clinical text related to each of the 3 conditions in the study and asked to study them for 15 min each.
16378419|NCT04130594|Experimental|phase 1, vaccine half dose|half dose of BVRS-GamVac vaccine single administration
16378420|NCT04130594|Experimental|phase 1, vaccine full dose|full dose of BVRS-GamVac vaccine single administration
16378421|NCT04130594|Experimental|phase 2, vaccine selected dose|selected dose of BVRS-GamVac vaccine single administration
16378422|NCT04130594|Placebo Comparator|phase 2, placebo|placebo single administration
16378423|NCT04130581|Experimental|TMS|Six 30-pulse trains of 20 Hz repetitive Transcranial Magnetic Stimulation to left primary motor cortex hand area, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
16378424|NCT04130581|Sham Comparator|Sham|Six 30-pulse trains of 20 Hz repetitive sham Transcranial Magnetic Stimulation above, but not in contact with, the head, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
16378425|NCT04130555||CELLIS Rectopexy|Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix
16378426|NCT04130542|Experimental|LVGN6051|The dose escalation phase includes 10 dose levels of LVGN6051, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
16378427|NCT04130529|Experimental|Adjusted group CBT-i for Bipolar disorder|"The experimental group receives group-CBT-i adjusted for Bipolar disorder. This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the population with Bipolar Disorder. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the Bipolar population.
~Treatment is given as 8 weekly group sessions."
16378428|NCT04130529|Active Comparator|Sleep lectures|The control group is offered a series of 3 lectures on sleep during the same time-period.
16378429|NCT04130516|Other|Active|Phase 1 open-label
16378430|NCT04130503|Experimental|PAP treatment- Acute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.
~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
16378431|NCT04130503|Active Comparator|Usual Care (HLE)|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
16378432|NCT04130503|Experimental|PAP treatment- Subacute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.
~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
16378553|NCT04129593|Experimental|Snooze|Participant will set multiple alarms before bed to wake at a specific time.
16378433|NCT04130477|Experimental|Clear aligners with tunnel attachment|Participants will receive traditional clear aligner therapy with virtual set up and will be supplemented by virtually planned tunnel attachments which will be threaded by a light Nickel-Titanium wire
16378434|NCT04130477|Active Comparator|Clear aligners|Participants will receive traditional clear aligner therapy with virtual set up
16378435|NCT04130464|Experimental|Ropivacaine|Subjects will receive a continuous intraperitoneal infusion of ropivacaine
16378436|NCT04130464|Experimental|Ropivacaine + Ketorolac|Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac
16378437|NCT04130464|Placebo Comparator|Normal Saline|Subjects will receive a continuous intraperitoneal infusion of normal saline
16378438|NCT04130451|Active Comparator|Pre pleurodesis Procedure Fever Pulse rate Respiratory rate Pa|Pre pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procedure 24 hours before 16 hours before 8 hours before
16378439|NCT04130451|Active Comparator|After Pleurodesis procedure Fever Pulse rate Respiratory rate|Post pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procdure 24 hours before 16 hours before 8 hours before
16378440|NCT04130438|Active Comparator|Beta Blocker (nebivolol)|
16378441|NCT04130438|Active Comparator|Calcium Channel Blocker (diltiazem)|
16378442|NCT04130438|Placebo Comparator|Placebo|
16378443|NCT04130425|Experimental|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely & Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
16378444|NCT04130412|Active Comparator|Open release of lateral retinaculae|This group was treated by open release of lateral retinaculae after diagnosis of lateral compression syndrome by arthroscopy
16378445|NCT04130412|Active Comparator|Arthroscopic release of lateral retinaculae|This group was treated by arthroscopic release
16378446|NCT04130399|Experimental|Preoperative Chemotherapy + SBRT|"Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines.
~After 6 cycles of neoadjuvant therapy are completed, patients will undergo imaging with pancreatic protocol CT and PET-MRI to assess disease status . Patients without evidence of disease progression at the end of 6 cycles of neoadjuvant treatment will proceed to SBRT followed by surgical resection.
~Following surgery, patients will receive an additional 6 cycles of FOLFIRINOX chemotherapy."
16378447|NCT04130386|Experimental|Motivational Interviewing|Participants assigned to this arm will complete three MI sessions over 10 weeks.
16378448|NCT04130386|Active Comparator|E-education|The e-education group receives three educational modules lasting approximately 10 minutes each over a period of 10 weeks.
16378449|NCT04130373||Women receiving autologous fat grafting|Women who received breast reconstruction and autologous fat grafting.
16378450|NCT04130373||Control|Women who received breast reconstruction only.
16378451|NCT04130360|Experimental|Problem-solving|
16378452|NCT04130360|No Intervention|Control|
16378453|NCT04130347||Pancreatic resection|
16378454|NCT04130347||Liver resection|
16378455|NCT04130347||HIPEC surgery|
16378456|NCT04130347||Gynecological debulking surgery|
16378457|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to horizontal|horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
16378458|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to vertical|horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
16378459|NCT04130321|Experimental|Camu camu|
16378460|NCT04130321|Placebo Comparator|Placebo|
16378461|NCT04130308|Experimental|ACL-R|
16378462|NCT04130308|No Intervention|Control|
16378463|NCT04130295|Experimental|Wearable intensive nerve stimulation|The device will be worn on the upper calf with each session of stimulation lasting 60 minutes after which the device will turn off for 60 minutes before turning back on. Participants will be instructed to wear the device for 5 hours a day in order to receive three one our sessions of stimulation.
16378464|NCT04130282|Experimental|Group 1|8 volunteers receiving 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
16378465|NCT04130269||Patients with MCI|Patients with myocardial infarction (STEMI/NSTEMI) aged 19-90
16378466|NCT04130256|Experimental|Active Reminders|43 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will provide daily medication reminders for participants to take their pill.
16378467|NCT04130256|Experimental|Passive Adherence Monitoring|42 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will not provide medication reminders and will only track medication use.
16378468|NCT04130243||Congenital Heart disease|In patients with (a history of) pressure- and/or volume loaded right ventricle due to congenital heart disease extra blood will be withdrawn for a blood test; serumbiomarker
16378469|NCT04130243||Pulmonary Arterial Hypertension|In patients with (a history of) pressure- and/or volume loaded right ventricle due to pulmonary arterial hypertension extra blood will be withdrawn for a blood test; serumbiomarker
16378470|NCT04130230|Experimental|Neostigmine group|This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
16378471|NCT04130230|Placebo Comparator|Standard group|This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.
16378472|NCT04130217|No Intervention|Control group|patients will be intraoperatively mechanically ventilated without PEEP nor RM.
16378473|NCT04130217|Experimental|PEEP Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
16378474|NCT04130217|Experimental|PEEP and RM Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
16378475|NCT04130204|Experimental|Active|DYV700
16378476|NCT04130204|Placebo Comparator|Placebo|Placebo
16378477|NCT04130191||Participants with hereditary angioedema (HAE)|Participants who initiate treatment with lanadelumab according to current product labelling will be enrolled and followed for up to 36 months after the enrollment in the study.
16378478|NCT04130178|Active Comparator|Bupivacine injected|Half ml of Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was injected through a 27G needle at the level of the volar proximal digital crease of the 2nd and 3rd PIP on each side of the selected joint.
16378479|NCT04130178|Placebo Comparator|Control group|Saline was injected subcutaneously in the 2nd and 3rd PIP on each side of the selected joint.
16378480|NCT04130165|Experimental|Matched donor human milk|Infants randomized to the matched donor human milk arm, will receive donor human milk which is matched to their mother's secretor status.
16378481|NCT04130165|No Intervention|Standard issue donor human milk|Infants randomized to the standard issue donor human milk arm, will receive donor human milk which is prepared without consideration of secretor status as per standard practice.
16378482|NCT04130152|Experimental|Palbociclib + Letrozole|"Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
~If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues (ie, triptorelin 3.75 mg intra-muscular (IM) or Goserelin 3,6 mg SC) must be initiated at least 2 weeks before palbociclib plus letrozole administration."
16378483|NCT04130139||residents|obstetrics and gynecology residents from France with or without previous experience in oocyte pick up
16378484|NCT04130126|No Intervention|Warm showers|Participants in the warm showers condition are instructed to continue their normal warm showers throughout the study
16378485|NCT04130126|Experimental|Cold showers|Participants in the cold showers condition will be asked to take cold showers over a time period of 3 months
16378486|NCT04130100|Experimental|Low Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of low dose of mesenchymal stem cells.
16378487|NCT04130100|Experimental|High Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of high dose of mesenchymal stem cells.
16378488|NCT04130100|Active Comparator|Sodium Hyaluronate|Patients receiving intraarticular injection of Sodium Hyaluronate
16378489|NCT04130087|Experimental|Selegiline Group|27 healthy participants who will be administered a single 10mg tablet of selegiline hydrochloride.
16378490|NCT04130087|Placebo Comparator|Placebo Group|27 healthy participants who will be administered a single lactose tablet (placebo)
16378491|NCT04130061|Experimental|Randomized|
16378492|NCT04130061|No Intervention|Control|
16378493|NCT04130022|Other|Fasted Children|
16378494|NCT04130009|Active Comparator|TKA with tourniquet|This group was treated by TKA with the use of tourniquet
16378495|NCT04130009|Active Comparator|TKA without tourniquet|This group was treated by TKA without tourniquet
16378496|NCT04129996|Experimental|camrelizumab in combination with nab-paclitaxel and famitinib|
16378497|NCT04129983|Experimental|Prednisone acetate + somatosensory stimulation|Prednisone acetate 1 mg/kg body weight * 7 days and somatosensory stimulation 30 days were given to sudden deafness patients.
16378498|NCT04129983|Experimental|Prednisone acetate + hyperbaric oxygen|Prednisone acetate 1mg / kg body weight * 7 days and hyperbaric oxygen 15 days were given to sudden deafness patients.
16378499|NCT04129970|Experimental|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
16378500|NCT04129957||Patients who underwent placement of dental implants|The study only includes one cohort. That is the patients who underwent placement of dental implants at baseline.
16378501|NCT04129944|Placebo Comparator|Placebo|
16378502|NCT04129944|Experimental|UBX0101 0.5 mg|
16378503|NCT04129944|Experimental|UBX0101 2.0 mg|
16378504|NCT04129944|Experimental|UBX0101 4.0 mg|
16378505|NCT04129931|Experimental|Medium Chain Triglycerides (MCT)|Participants in this arm will receive Medium Chain Triglycerides (MCT) powder packets (10 g each) at each treatment visit at any point in the study. Participants will mix 1-2 packets of MCT supplement powder into liquids or semi-solid food and ingest 3 times a day during the 16-week treatment period. Participants will be randomized to the treatment sequence and will receive either the active MCT or the matching placebo first or vice versa.
16378506|NCT04129931|Experimental|Clazakizumab|Participants randomized to this arm will receive a 12.5 mg dose of Clazakizumab via a subcutaneous injection at every study visit, every 4 weeks, during the 16-week treatment period at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Clazakizumab or the matching placebo first or vice versa.
16378507|NCT04129931|Experimental|Broncho-Vaxom|Participants randomized to this arm will receive 7 mg of Broncho-Vaxom once a day on an empty stomach for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Broncho-Vaxom or the matching placebo first or vice versa.
16378508|NCT04129931|Experimental|Imatinib|At any point in the study, participants randomized to this arm will take two 100 mg Imatinib tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Participants will then take four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Participants will be randomized to the treatment sequence and will receive either the active Imatinib or the matching placebo first or vice versa.
16378509|NCT04129931|Experimental|Cavosonstat|Participants randomized to this arm will take one 50 mg Cavosonstat capsule orally twice a day for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Cavosonstat or the matching placebo first or vice versa.
16378510|NCT04129918|Experimental|experimental group|ear plugs and eye mask for 3 successive nights
16378511|NCT04129918|No Intervention|control group|without ear plugs and eye mask
16378512|NCT04129905|Experimental|Symptomatic HCM patients|30 subjects (25-26 sarcomeric, 4-5 Fabry).
16378513|NCT04129905|Active Comparator|Healthy controls subjects|10 subjects (matched in age and sex to HCM patients) to obtain reference values of endothelial dysfunction.
16378514|NCT04129892|Experimental|Course participants|Students that enroll in the Resilience-based course during their Bachelor of science or Bachelor of social studies.
16378515|NCT04129892|No Intervention|Control group- no intervention|Students in their Bachelor of science or Bachelor of social studies that did not attend the course, but agreed to fill out the study questionnaires.
16378611|NCT04129307|Experimental|Motor Imagery|
16378612|NCT04129307|Experimental|Double time Motor imagery|
16378517|NCT04129866|Experimental|M-IBM|M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
16378518|NCT04129866|Placebo Comparator|Control IBM|Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
16378519|NCT04129853|Experimental|Crossover|Performing a sit to stand with the Cyberlegs Xleg and comparing with their current prosthesis.
16378520|NCT04129853|Experimental|Case study|Comparing the cyberlegs xleg with other devices.
16378521|NCT04129840|Active Comparator|Intervention 1: dual combination|dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
16378522|NCT04129840|Active Comparator|Intervention 2: triple combination|triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
16378523|NCT04129840|Placebo Comparator|Standard of care|start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point
16378524|NCT04129814|Experimental|test group|Non-surgical periodontal treatment consisted of oral hygiene instructions (OHI), single session full-mouth scaling and root planing (SRP)
16378525|NCT04129814|No Intervention|control group|no periodontal treatment was performed during the follow-up period in the control group.
16378526|NCT04129801||Prospective analysis|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
~Evaluation of Muscle Strength was used The Biodex Multi-joint System 3 dynamometer (Biodex Medical Systems, Inc., Shirley, New York, USA) to measure isokinetic extension (Ext) and flexion (Flex) MVC torques for both legs."
16378527|NCT04129788|Experimental|bisacodyl|bisacodyl 5mg tablet, once a day on three consecutive days
16378528|NCT04129788|Placebo Comparator|placebo|tablet, once a day on three consecutive days
16378531|NCT04129762|Experimental|Diet without NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
16378532|NCT04129762|Active Comparator|Diet with NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS
16378533|NCT04129762|Experimental|Diet without NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
16378534|NCT04129762|Active Comparator|Diet with NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS
16378535|NCT04129749||Real-Time Analysis Interactive Lab|walk spontaneously or at prescribed speeds of cerebral palsy patient to a standstill in a virtual and secure virtual reality environment.
16378536|NCT04129736|Other|Teriflunomide 14 mg tablets|Single arm
16378537|NCT04129723|Experimental|Perianal Crohn's patient|Stopping biological therapy
16378538|NCT04129710|Experimental|I-MRE|"Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
~Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.
~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
16378539|NCT04129710|Experimental|L-MRE|"Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
~Rituximab 375 mg/m2 conventional infusion d1.
~Etoposide 250 mg/m2 over 3 hours on day3.
~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
16378540|NCT04129710|Active Comparator|MRE|"Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
~Rituximab 375 mg/m2 conventional infusion d1.
~Etoposide 250 mg/m2 over 3 hours on day3.
~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.
~Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups."
16378541|NCT04129697|Active Comparator|Dexamethasone|
16378542|NCT04129697|Active Comparator|Methylprednisolone|
16378543|NCT04129684|Experimental|Test group|SRP+BioGaia Prodentis oil drops and lozenges
16378544|NCT04129684|Placebo Comparator|Control group|SRP+subgingival delivery of placebo and placebo lozenges
16378545|NCT04129658||Intervention|The patients are registered at PHCCs who agreed to participate into the study, the patients have provided an informed consent. The PHCCs (seventeen according to the power calculation) will receive an educational outreach visit by a cardiologist, discussing evidence-based treatment. The physician will decide afterwords if the treatment will be adjusted. Blood samples and electrocardiography will be collected before the intervention, data from the EMR will be collected before and after the intervention.
16378546|NCT04129658||Control|The control group will be the rest of the patients with heart failure in Southern Sweden. Data from the regional data base on medication and heath care consumption will be collected at base line and 6 and 12 months after.
16378547|NCT04129632|Other|IEPF intervention|Survey respondent voluntary decides to do a 4 weeks mindfulness intervention
16378548|NCT04129619|Experimental|ORP-101 50 mg|ORP-101 (50 mg) once daily
16378549|NCT04129619|Experimental|ORP-101 100 mg|ORP-101 (100 mg), once daily
16378550|NCT04129619|Placebo Comparator|Placebo|Matching placebo, once daily
16378551|NCT04129606|Other|TURBT|Transurethral resection of bladder tumour
16378552|NCT04129593|Experimental|Self Awakening|Participant will intend to wake up at a specific time before going to bed.
16378554|NCT04129580|Experimental|Treatment-As-Usual (TAU) + reSET-O|Participants randomly assigned to this arm will receive their TAU alongside the use of the app, reSET-O.
16378555|NCT04129580|No Intervention|TAU only|Participants randomly assigned to this arm will receive their TAU only (no use of the app, reSET-O).
16378556|NCT04129567|Experimental|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
16378557|NCT04129567|Experimental|Dry air|Delivering dry air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
16378558|NCT04129567|Placebo Comparator|Humidified air|Delivering humidified air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
16378559|NCT04129567|Active Comparator|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
16378562|NCT04129541|Active Comparator|SDD|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
16378563|NCT04129541|Active Comparator|OH|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
16378564|NCT04129528|Active Comparator|CFZ533|Randomized in a 2:1 ratio: 2 Active / 1 Placebo
16378565|NCT04129528|Placebo Comparator|Placebo|Similar in appearance to active study drug
16378566|NCT04129515|Experimental|PHASE 1: NovoTTF-200A + PEMBROLIZUMAB|"The Phase I portion of the study will have a 3 + 3 design and consist of one cohort treated
~NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.
~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
16378567|NCT04129515|Experimental|PHASE 2: NovoTTF-200A + PEMBROLIZUMAB|"NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.
~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
16378568|NCT04129502|Experimental|TAK-788 Group (Arm A)|TAK-788 160 mg, capsules, orally, once daily until the participants experience progressive disease (PD) as assessed by blinded independent review committee (IRC), intolerable toxicity, or another discontinuation criteria.
16378569|NCT04129502|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|Pemetrexed 500 mg/m^2 plus Cisplatin 75 mg/m^2, infusion, intravenously, once on Day 1 of 21-day cycle pemetrexed 500 mg/m^2 plus Carboplatin, infusion, intravenously, once at a dose calculated to produce area under curve (AUC) of 5 mg*min/mL on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/Cisplatin or pemetrexed/Carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m^2, on Day 1 of a 21-day cycle thereafter.
16378570|NCT04129489|Experimental|Sintetic Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day
16378571|NCT04129476|Experimental|Cooperative Education Program|We explore the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression.
16378572|NCT04129476|No Intervention|Control|We provide routine care for these people during pregnancy
16378573|NCT04129463|Active Comparator|SST with Iris incarceration|infants that underwent SST with iris incarceration procedure
16378574|NCT04129463|Active Comparator|Conventional trabeculotomy|infants that underwent Conventional trabeculotomy
16378575|NCT04129450|Experimental|Mindfulness Pain Program + Usual PCP Care|Participants will undergo 8 weekly 90 minute sessions of Mindfulness-Based Stress Reduction in addition to receiving usual PCP care for chronic lower back pain.
16378576|NCT04129450|Active Comparator|Usual PCP Care|Participants will receive usual PCP care for chronic lower back pain.
16378577|NCT04129437|Active Comparator|NSAID|Ibuprofen, 800 mg, one time dose
16378578|NCT04129437|Active Comparator|OMT/NSAID|Ibuprofen, 800 mg, one time dose
16378579|NCT04129437|Active Comparator|OMT alone|low velocity osteopathic manipulative medicine
16378580|NCT04129424|Experimental|Type 1 diabetes mellitus_7-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378581|NCT04129424|Experimental|Type 1 diabetes mellitus_14-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378582|NCT04129424|Experimental|Type 1 diabetes mellitus_28-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378583|NCT04129424|Experimental|Type 2 diabetes mellitus_7-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378584|NCT04129424|Experimental|Type 2 diabetes mellitus_14-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378613|NCT04129307|Active Comparator|Action observation|
16378614|NCT04129294|Experimental|NS-089/NCNP-02|NS-089/NCNP-02
16378585|NCT04129424|Experimental|Type 2 diabetes mellitus_28-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378586|NCT04129424|Experimental|Gestational diabetes mellitus_7-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378587|NCT04129424|Experimental|Gestational diabetes mellitus_14-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378588|NCT04129424|Experimental|Gestational diabetes mellitus_28-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378589|NCT04129424|Experimental|Pregestational diabetes mellitus_7-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378590|NCT04129424|Experimental|Pregestational diabetes mellitus_14-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378591|NCT04129424|Experimental|Pregestational diabetes mellitus_28-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378592|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _7-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378593|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _14-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378594|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _28-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378595|NCT04129424|Experimental|Diabetes patients in perioperative period _7-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378596|NCT04129424|Experimental|Diabetes patients in perioperative period _14-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378597|NCT04129424|Experimental|Diabetes patients in perioperative period _28-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
16378598|NCT04129411|Experimental|RFA Group|
16378599|NCT04129398|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
16378600|NCT04129385|No Intervention|Group S|Control group (Group S: 54 patients); this group will undergo the standard laparoscopic procedure (the procedure is done in Trendelenburg position). While in Trendelenburg position and prior to wound closure and with laparoscopic port valves open, the patient's abdomen will be passively deflated. The patients will be placed in supine head up position in the post anesthesia care unit (PACU).
16378601|NCT04129385|Experimental|Group T|Intervention group (Group T: 54 patients); the patients will be subject to the same maneuver as in arm 1 prior to wound closure but will be positioned in a 20 degree Trendelenburg position once fully awake and cooperative in the PACU and will remain in this position for the first 24 hours post operatively, even after they are transferred to their rooms on the American University of Beirut Medical Center (AUBMC) floors. The maximum time allowed in a straight-up position will be three 15-minute intervals over a 24-hour period (the first interval being a clear fluids intake at 12 hours postoperatively).
16378602|NCT04129372|Experimental|New Foods Take Time|"Head Start classrooms will receive New Foods Take Time, a series of five interactive weekly lessons designed to promote children's willingness to try new foods, particularly fruits and vegetables. Lessons will be delivered by nutrition educations. Children will also receive three tastings per week of the new foods discussed during the lessons."
16378603|NCT04129359|Experimental|FamilieTrivsel|Enhanced care as usual in general practice plus training in the use of the online mentalisation programme
16378604|NCT04129359|Active Comparator|control|Enhanced care as usual in general practice
16378605|NCT04129346|Experimental|Fit2ThriveMB|Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
16378606|NCT04129346|Active Comparator|Healthy Living Control|Participants in the healthy living group will receive the American Society of Cancer Oncologists smartphone app, cancer.net. They will also receive calls during the intervention period and the Fitbit following completion of 12 week assessments
16378607|NCT04129333|Experimental|Hypnosis group|A hypnosis group with standard care during the invasive procedure according to the usual practice of the care team and setting up a hypnotic accompaniment by an nurse trained beforehand and dedicated throughout the gesture. The hypnosis session will end at the same time as the invasive procedure.
16378608|NCT04129333|Placebo Comparator|Control group|A control group with standard care during the invasive procedure according to the usual practice of the care team.
16378609|NCT04129320|Experimental|Experimental Arm 1|Enoblituzumab plus MGA012
16378610|NCT04129320|Experimental|Experimental Arm 2|Enoblituzumab plus MGD013
16378617|NCT04129268|Other|No exercise control|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
16378618|NCT04129268|Experimental|175kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
16378619|NCT04129268|Experimental|350kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
16378620|NCT04129268|Experimental|700kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
16378621|NCT04129255|Other|OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)|OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
16378622|NCT04129242|Active Comparator|"paired taVNS + Task Specific Training"|
16378623|NCT04129242|Active Comparator|"unpaired taVNS + Task Specific Training"|
16378624|NCT04129229|Experimental|LTR Treatment|Eligible subjects will undergo insertion of the LTR device in their tongue. Initiation of treatment will occur 7 days post insertion procedure and will be monitored over the course of 1 year.
16378625|NCT04129216|Experimental|Tamoxifen arm|for premenopausal patients
16378626|NCT04129216|Experimental|Letrozole arm|for postmenopausal patients
16378627|NCT04129216|Experimental|Exemestane arm|for postmenopausal patients
16378628|NCT04129203|Experimental|Trial arm|Mechanical thrombectomy using Versi Retriever
16378629|NCT04129190|Experimental|Single|
16378630|NCT04129164|Experimental|VIB4920 Dose 1 in Population 1|Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
16378631|NCT04129164|Placebo Comparator|Placebo in Population 1|Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
16378632|NCT04129164|Experimental|VIB4920 Dose 1 in Population 2|Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
16378633|NCT04129164|Placebo Comparator|Placebo in Population 2|Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
16378634|NCT04129151|Experimental|PALBOCICLIB and GANITUMAB|"The research study procedures include screening for eligibility and study treatment including evaluations for testing and follow up visits.
~The study treatment will be 12 months in duration and follow up will be one year from when the participant receives the last dose of study drug.
~The names of the study drugs involved in this study are:
~Palbociclib-Oral, per protocol pre determined dosage, once a day for 21 days
~Ganitumab-Intravenous, per protocol predetermined dosage, twice per cycle
~Cycle is 28 days"
16378635|NCT04129138||Observational (survey)|Participants complete a survey over 30 minutes.
16378636|NCT04129125|Experimental|Zoom Reperfusion System|"The subject will undergo the endovascular thrombectomy procedure under general anesthesia or conscious sedation. The Imperative Care .088 Catheter will be used to gain access to the vasculature and direct aspiration of the clot will be attempted where feasible. The Zoom Reperfusion System must be the initial and primary device used to remove thrombus."
16378637|NCT04129112||Patients without body movements|Patient who, under general anesthesia without curare agents, during surgery has no body movements
16378638|NCT04129112||Patients with body movements|Patient who, under general anesthesia without curare agents, during surgery has any body movements that are no reflexes movements
16378639|NCT04129099|Experimental|CAR-T treatment group|The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
16378640|NCT04129086|Experimental|Ketamine plus Usual care|
16378641|NCT04129086|Active Comparator|Usual care|
16378642|NCT04129073||Cardiac arrest patients admitted to Intensive Care treatment|Intensive Care treatment; Utilization of neuroprognostication tools
16381019|NCT04112043|Active Comparator|Walking Exercise plus Placebo|
16378645|NCT04129047|Experimental|Omnichroma (one shade universal) composite by Tokuyama|class V cavities will be made under isolation. Omnichroma (one shade universal) composite by Tokuyama will be placed according to guidelines.
16378646|NCT04129047|Active Comparator|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA)|class V cavities will be made under isolation. A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA) will be placed according to guidelines.
16378647|NCT04129034|Experimental|Treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
16378648|NCT04129021|Experimental|High-resolution retinal imaging through adaptive optics|High-resolution retinal imaging through adaptive optics, full field OCT and holographic systems
16378649|NCT04129008|Experimental|Indobufen|
16378650|NCT04129008|Active Comparator|Aspirin|
16378651|NCT04128995|Active Comparator|Bariatric Surgery|
16378652|NCT04128995|Active Comparator|Medical Therapy|
16378653|NCT04128982||Videolaryngoscopy|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
16378654|NCT04128969|Experimental|Carnitine supplementation (CS+)|Carnitine supplementation in liquid form, sugar free.
16378655|NCT04128969|Placebo Comparator|Placebo (CS-)|Placebo comparator liquid similar in appearance and taste to CS+.
16378656|NCT04128956|Experimental|Aspirin®|"To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.
~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment."
16378657|NCT04128956|No Intervention|Control group|Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).
16378658|NCT04128930|Experimental|Fixed CPAP titration at home|"Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:
~After 3 nights: median obstructive AHI<5/h: decrease pressure with 2 cmH2O; median obstructive AHI>5/h: increase with 2cmH2O
~After 7 nights: median obstructive AHI>5/h of 4 nights after last adaptation: increase with 2 cmH2O"
16378659|NCT04128930|Active Comparator|APAP titration at home|Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
16378660|NCT04128917|Experimental|Tegoprazan 50 mg|Tegoprazan 50 mg Triple Therapy
16378661|NCT04128917|Experimental|Tegoprazan 100 mg|Tegoprazan 100 mg Triple Therapy
16378662|NCT04128917|Active Comparator|RAPAE01|RAPAE01 Triple Therapy
16378663|NCT04128904|Active Comparator|Standard in vitro fertilisation (IVF)|"Oocytes are fertilised with standard IVF. For details please see Project Description."
16378664|NCT04128904|Active Comparator|Intracytoplasmic sperm injection (ICSI)|"Oocytes are fertilised with ICSI. For details please see Project Description."
16378665|NCT04128891|Experimental|Sacubitril/Valsartan|30 participants to be administered Sacubitril/Valsartan (Entresto) tablets, minimum dose of 49/51mg or maximum dose of 97/103 mg twice daily for the duration of the study (two years).
16378666|NCT04128891|Active Comparator|Valsartan|30 participants to be administered Valsartan tablets, minimum dose 80 mg or maximum dose of 160 mg twice daily for the duration of the study (two years).
16378667|NCT04128878||Atrial Fibrillation Cohort|Adult patients with known or new diagnosis of either paroxysmal or persistent atrial fibrillation seen at the electrophysiology outpatient clinic and admitted to the electrophysiology service for initiation of anti-arrhythmic medications (dofetilide or sotalol).
16378668|NCT04128852|Other|MagnetOs Putty|MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.
16378669|NCT04128826|Experimental|Partial Range of Motion (PROM)|
16378670|NCT04128826|Experimental|Full Range of Motion (FROM)|
16378671|NCT04128826|No Intervention|Control (CON)|
16378672|NCT04128813|Active Comparator|Vertical whole body vibration platform.|Use of a rotational whole body vibration platform.
16378673|NCT04128813|Active Comparator|Rotational whole body vibration platform|Use of a rotational whole body vibration platform.
16378674|NCT04128813|No Intervention|Control group|No intervention.
16378675|NCT04128800|Experimental|Apatinib and S-1 group|
16378676|NCT04128787|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
16378677|NCT04128787|Experimental|Treatment Sequence BCAD|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
16378678|NCT04128787|Experimental|Treatment Sequence CABD|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
16378681|NCT04128761|Experimental|Scarcity Narrative|Participants assigned to the scarcity group will be asked to read and consider a hypothetical narrative about a sudden loss of resources.
16378682|NCT04128761|Sham Comparator|Neutral Narrative|Participants assigned to the neutral group will be asked to read and consider a hypothetical narrative about a neutral change in resources.
16378683|NCT04128748|Experimental|Treatment (CPX-351, quizartinib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3 and 5 and quizartinib PO on days 6-19. Patients who do not respond to treatment during cycle 1 receive CPX-351 IV on days 1 and 3 and quixartinib PO on days 6-19 during cycle 2. Treatment repeats every 28 days for up 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive CPX-351 over 90 minutes on days 1 and 3 and quizartinib PO on days 4-28 of cycle 1. Treatment with CPX-351 repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive quizartinib PO on days 1-28 in the absence of disease progression or unacceptable toxicity."
16378684|NCT04128722|Experimental|Sirolimus 1mg/mL|Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.
16378685|NCT04128722|No Intervention|Control condition|Usual care, i.e. no intervention
16378686|NCT04128709|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
16378687|NCT04128696|Experimental|Participants receiving feladilimab and pembrolizumab|Participants were administered feladilimab (humanized anti-ICOS immunoglobulin G4 [IgG4] monoclonal antibody [mAb]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.
16378688|NCT04128696|Active Comparator|Participants receiving placebo and pembrolizumab|Participants were administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.
16378689|NCT04128683|Experimental|Healthy Controls|Healthy Control Subjects
16378690|NCT04128683|Experimental|Anorexia Nervosa|Anorexia Nervosa Subjects
16378691|NCT04128670|Experimental|Kinesiotape (KT)|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
16378692|NCT04128670|Placebo Comparator|Placebo Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
16378693|NCT04128670|No Intervention|No Tape|This group will not receive any intervention.
16378694|NCT04128644|Other|Standard of care+Thoughts & health|12 sessions of Thoughts & Health. Baseline questionnaires and follow up assessments
16378695|NCT04128644|Other|Standard of care|Baseline questionnaires and follow up assessments, intervention as usual Student Health
16378696|NCT04128631||PET/CT|group of patients will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels.
16378697|NCT04128618|Experimental|Active NMES|
16378698|NCT04128618|Sham Comparator|Modified NMES sham|
16378699|NCT04128605|Experimental|Intervention: Suprascapular nerve block (SSNB)|SSNB performed by skilled interventionist who is not blinded for safety reason. 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline.
16378700|NCT04128605|Active Comparator|Control: Intraarticular shoulder steroid injection (IAS)|"IAS performed by skilled interventionist who is blinded on patient's initial measurement.
~40 mg of Triamcenolone Acetate + 2 ml of Lidocaine 1%"
16378701|NCT04128592|Other|Wheezing|
16378702|NCT04128592|Other|Rattling|
16378703|NCT04128579|Experimental|EQ001 Type A cohort|EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg).
16378704|NCT04128579|Experimental|EQ001 for Type B cohort|EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg).
16378705|NCT04128566|Experimental|Group 1: healthy subjects aged between 20 and 30 years|healthy subjects aged between 20 and 30 years
16378706|NCT04128566|Experimental|Group 2: previous ACL injury aged between 20 and 30 years|subjects with previous Anterior cruciate Ligament (ACL) injury aged between 20 and 30 years
16378707|NCT04128566|Experimental|Group 3: healthy subjects aged between 40 and 60 years|healthy subjects aged between 40 and 60 years
16378708|NCT04128566|Experimental|previous ACL injury aged between 40 and 60 years|subjects with previous ACL injury aged between 40 and 60 years
16378709|NCT04128553|Experimental|Intervention motivational interview group|Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.
16378710|NCT04128553|No Intervention|Control|The control group will be pre-tested and post-tested and the average number of steps will be calculated with a pedometer.
16378711|NCT04128540|Other|Control group|This group will receive fentanyl infusion only
16378712|NCT04128540|Active Comparator|ESPB group|This group will receive fentanyl infusion plus Ultrasound guided ESPB
16378713|NCT04128514||Enrolled subjects|"Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.
~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects."
16378714|NCT04128501|Experimental|Treatment (azacitidine, venetoclax)|Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16378715|NCT04128488||Transgender women without HIV|
16378716|NCT04128488||Transgender women with HIV|
16378785|NCT04128020|Experimental|Nivolumab + Azacitidine|Azacitidine 8,16, 24 mg/m^2, days 1-5 Nivolumab @MTD (1.0 mg/kg or lower), days 8 & 15
16378717|NCT04128462|Experimental|MNK6105 + SoC|"Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:
~Loading dose: 20 g infused over 6 hours
~Intermediate dose: 15 g infused over 18 hours
~Maintenance dose: 15 g infused over 24 hours for up to 4 days"
16378718|NCT04128462|Placebo Comparator|Placebo + SoC|Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.
16378719|NCT04128449|Experimental|docosahexaenoic acid|1,66 grams/24 hours (5 dragees)
16378720|NCT04128449|Placebo Comparator|Placebo|sunflower oil (5 dragees)
16378721|NCT04128436|Other|Progesterone levels|Patients will be divided into groups according to quartiles (25/50/75) of progesterone levels. Optimal range of progesterone levels for ongoing pregnancy rate will be calculated.
16378723|NCT04128410||T1|At 5 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378724|NCT04128410||T2|At 10 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378725|NCT04128410||T3|At 15 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378726|NCT04128410||T4|At 20 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378727|NCT04128410||T5|At 25 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378728|NCT04128410||T6|At 30 minutes after flurbiprofen axetil injected intravenously, 14 patients' samples were required to be collected,including 7 younger patients
16378729|NCT04128410||T7|At 35 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378730|NCT04128410||T8|At 40 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378731|NCT04128410||T9|At 45 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378732|NCT04128410||T10|At 50 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
16378733|NCT04128397|Experimental|traditional stimulation site transcranial magnetic stimulation（TMS）|arm:experimental:perform TMS to patients for 5days ,3times a day(0 minute ,15 minute ,60 minute ).The Globus Pallidus internus (GPi) is the traditional stimulation site .
16378734|NCT04128397|Experimental|precise stimulation site TMS|arm:experimental:perform TMS to patients for 5days ,3times a day(0 minute ,15 minute ,60 minute ).The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule.
16378735|NCT04128384|Other|EPS arm|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
16378736|NCT04128371|Experimental|1|Subjects will receive mepolizumab 700 mg IV x 3 doses at approximately one month intervals, at predicted eosinophil nadir (2-3 weeks after peak), at study visits 4, 6, and 7.
16378737|NCT04128358|Experimental|Group on high dose dexamethasone, cyclosporin and rituximab|Egyptian patients with idiopathic thrombocytopenic purpura on high dose dexamethasone together with cyclosporine and rituximab.
16378738|NCT04128358|Active Comparator|Group on steroids only|Egyptian patients with idiopathic thrombocytopenic purpura on parenteral or oral steroids.
16378739|NCT04128358|Placebo Comparator|Placebo group|Egyptian normal healthy volunteers who share on the President Initiative (100 Million Health).
16378740|NCT04128345||SBN arm|We will evaluate the feasibility of using an integrated navigation system incorporating pre-operative MRI and intraoperative ultrasound images
16378741|NCT04128332|Other|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
16378742|NCT04128319|Experimental|T-Guard Treatment|Patients will receive T-Guard for treatment of steroid-refractory acute GVHD.
16378743|NCT04128306|Experimental|Patient group|"A total of 120 patients with brain tumors will be divided into our two groups, divided as follows:
~In the group Pre-Per, 20 patients will be included by localization of electrical stimulation (60 patients in total). A patient who would be stimulable in two different areas could be included in two different groups.
~In the group Pre-End, the subjects will be distributed by localization of the brain tumor, by lobe. A total of 20 participants will be included per lobe, corresponding to the frontal, temporal or parietal lobes (as a reminder, a tumor in the occipital lobe is an exclusion criterion), for a total of 60 participants"
16378744|NCT04128306|Active Comparator|Control group|A maximum of 120 healthy matched sex and age subjects with patients will also be included
16378745|NCT04128293|Experimental|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16378746|NCT04128293|Experimental|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16378782|NCT04128033|Experimental|puncture of the RP6 point|The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
16378783|NCT04128033|Placebo Comparator|puncture of the placebo point|The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
16378784|NCT04128020|Experimental|Nivolumab|Nivolumab: 0.3, 0.5, or 1.0 mg/kg IV, days 1 & 15
16378747|NCT04128293|Experimental|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16378748|NCT04128293|Experimental|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
16378749|NCT04128280|Experimental|Test Group|Test group: Patients will receive a surgery: transurethral dilation of prostate with a columnar balloon
16378750|NCT04128280|Active Comparator|Control Group|Control group: Patients will receive a surgery: transurethral incision of bladder neck.
16378751|NCT04128267|Experimental|Response to Pain|Brain's response to pain using magnetic resonance imaging (MRI)
16378752|NCT04128254|Experimental|Apixaban|
16378753|NCT04128254|Placebo Comparator|Placebo|
16378754|NCT04128241||Panel of Spanish consumers|A panel of Spanish consumers recruited from various audited and validated internet databases.
16378755|NCT04128228|Other|Alcohol use disorder|All patients with alcohol use disorder will receive the same 8 week outpatient treatment.
16378756|NCT04128228|No Intervention|Controls|Control participants with and without early trauma will receive baseline assessment and no outpatient treatment.
16378757|NCT04128215|Active Comparator|Older Men|
16378758|NCT04128215|Active Comparator|Postmenopausal Women|
16378759|NCT04128202|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
16378760|NCT04128202|Experimental|Sunnyside Plus|An online intervention to better manage mood and promote and support breastfeeding during and after pregnancy.
16378761|NCT04128189|Active Comparator|Transplanted subject|In addition to receiving standard dose (2) of Shingrix prior to transplantation, participant may receive a 3rd dose several months after transplantation if they meet criteria related to no rejection.
16378762|NCT04128189|Sham Comparator|Non-Transplanted subject|Receives standard Shingrix dose (2), but not transplanted within 16 month time frame post-dose, so does not receive additional Shingrix dose.
16378763|NCT04128176|Experimental|Rituximab combined with Omalizumab|All patients will receive daily doxycycline, nicotinamide, and high-potency topical steroids. Additionally, all patients will receive rituximab combined with omalizumab.
16378764|NCT04128163|Experimental|QL1206|"QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times.
~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
16378765|NCT04128163|Placebo Comparator|Placebo|"placebo injection (1ml) by subcutaneous injectionevery 6 month for two times.
~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
16378766|NCT04128137|Experimental|fludrocortisone|FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.
16378767|NCT04128137|Placebo Comparator|Placebo|placebo of flucortac and same diagram of administration
16378768|NCT04128124||self-extubation|patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
16378769|NCT04128124||spontaneous breathing trial|patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
16378770|NCT04128111||Acute Exacerbation|Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient's usual status that is sufficient to require a change in treatment.
16378771|NCT04128111||Non-acute exacerbation|Non-acute exacerbation of asthma includes chronic remission and clinical delays.Clinical remission stage refers to an absence of wheezing, chest tightness, cough and other symptoms for more than 1 year.Chronic duration refers to that symptoms, such as wheezing, chest tightness, cough and so on, attack at different frequency and different degrees every week.
16378772|NCT04128111||Healthy Volunteer|Health is not only the absence of disease or infirmity, but also a state of physical, mental, and social perfection.
16378773|NCT04128085|Experimental|TQB3804|TQB3804 tablet administered orally , once daily in 28-day cycle.
16378774|NCT04128072|Experimental|Mogamulizumab + Total Skin Electron Beam Therapy (TSEB)|"Treatment with mogamulizumab will be continued until disease progression or the occurrence of another withdrawal criterion as specified in the protocol.
~TSEB will start 28 days after mogamulizumab cycle 2 day 1 at a dose of 12 Gy in 8 fractions over two weeks (4 fractions per week)."
16378775|NCT04128059|Experimental|phase 1, component 1|component 1 of vaccine
16378776|NCT04128059|Experimental|phase 1, half dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half dose
16378777|NCT04128059|Experimental|phase 1, full dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in full dose
16378778|NCT04128059|Experimental|phase 2, selected dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in selected dose
16378779|NCT04128059|Placebo Comparator|phase 2, placebo|vaccination with placebo with an interval of 21 days
16378780|NCT04128046|Experimental|PRFM|Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
16378781|NCT04128046|Placebo Comparator|Saline|Hemi-face injected with saline.
16378786|NCT04128007|Experimental|ARQ-154 foam 0.3%|active
16378787|NCT04128007|Placebo Comparator|ARQ foam VehicleRQ-154 foam Vehicle|placebo
16378788|NCT04127994|Experimental|3 meals|"Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.
~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
16378789|NCT04127994|Experimental|6 meals|"Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.
~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
16378790|NCT04127981|Active Comparator|Patients with cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia.
16378791|NCT04127981|Active Comparator|Patients without cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC) or pancreatic cancer without cachexia.
16378792|NCT04127968|Experimental|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
16378793|NCT04127968|Placebo Comparator|control group|Septic children with vitamin A deficiency who will receive placebo.
16378794|NCT04127955|Experimental|Intervention|"Quasi-experimental design with one-group, pre-post test
~A nurse-led Theory of Planned Behavior based Physical Activity intervention consists of five component. These are a health education, a group walking, an individually tailored counseling session grounded on motivational interview technique, having the individuals keep track their physical activity levels with a pedometer, and use of physical activity pamphlet and posters as a reminder was planned. This intervention will be completed in eight weeks."
16378795|NCT04127942|Experimental|platelet-rich plasma injection|1cc platelet-rich plasma(PRP) injection in the superior temporomandibular disk joint space by ultrasound guidance.
16378796|NCT04127942|Placebo Comparator|normal saline injection|1cc normal saline injection in the superior temporomandibular disk joint space by ultrasound guidance.
16378797|NCT04127929|Active Comparator|Glass carbomer|
16378798|NCT04127929|Active Comparator|Tokuyama Estelite Posterior|
16378799|NCT04127903|Experimental|the Length of Right Main Stem Bronchus >=15mm|
16378800|NCT04127903|Experimental|the Length of Right Main Stem Bronchus <15mm|
16378801|NCT04127890|Experimental|Intervention Arm|1.5 L of ELO Water to be drunk daily for 24 weeks
16378802|NCT04127890|Placebo Comparator|Control Arm|1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks
16378803|NCT04127877|Experimental|CHRONIC HEMODIALYSIS PATIENTS, NICAS-ASSISTED MONITORING|Chronic hemodialysis patients, NICAS-assisted monitored
16378804|NCT04127877|No Intervention|Control hemodialysis patients|Chronic hemodialysis patients, conventional clinical care and monitoring.
16378805|NCT04127851|Experimental|Sodium Hyaluronate 0.15%|
16378806|NCT04127851|Active Comparator|Cyclosporin 0.05%|
16378807|NCT04127851|Other|Combination therapy|
16378808|NCT04127838|Experimental|Low Vision Occupational Therapy|The anticipated low vision occupational therapy intervention strategy includes training participants to compensate for their vision more effectively for increased participation in ADLs and IADLs.
16378809|NCT04127825|Experimental|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a blood conservation technique that entails the removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement.
16378810|NCT04127825|No Intervention|Standard of Care|Standard of care for blood volume maintenance during surgery
16378811|NCT04127812|Experimental|Savor the Flavor|"The Savor the Flavor curriculum is a series of five interactive lessons designed to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. The intervention also teaches attention control techniques so that children are better able to delay consumption of high energy, low nutrition foods, when appropriate, as well as general mindfulness practices (e.g. breathing exercises). Lessons are delivered in the Head Start classroom by a nutrition educator."
16378812|NCT04127799|Experimental|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
16378813|NCT04127799|Active Comparator|Subjects with AF conventional treatment|Subjects with AF via conventional clinic visit according to the latest relevant guidelines
16378814|NCT04127786|Experimental|Group 1: VRVg-2|VRVg-2, 3 injections at Day 0, Day 7, and Day 28
16378815|NCT04127786|Active Comparator|Group 2: Verorab|Verorab, 3 injections at Day 0, Day 7, and Day 28
16378816|NCT04127786|Active Comparator|Group 3: Imovax Rabies|Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28
16378817|NCT04127773||NEX group|oro gastric tube placement using NEX insertion length predictor
16378818|NCT04127773||NEMU group|oro gastric tube placement using NEMU insertion length predictor
16378819|NCT04127760|No Intervention|control|Follow-up at several time frames
16378820|NCT04127760|Experimental|treatment|Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
16378821|NCT04127747|Active Comparator|Standard dose group|
16378822|NCT04127747|Experimental|Individualized dose group|
16378823|NCT04127721|Experimental|Prevention (itacitinib, busulfan, fludarabine, ASCT)|"CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.
~ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.
~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor)."
16378853|NCT04127526|Active Comparator|Baseline Period of 4 weeks|2 participants will be randomly allocated to a baseline of 4 weeks before commencing CONNECT intervention.
16378881|NCT04127344|Experimental|Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.
~Patients randomised to a music therapy intervention will receive an individualised music therapy intervention."
16379055|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
16378824|NCT04127708|Placebo Comparator|sham acupuncture|Ten acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
16378825|NCT04127708|Active Comparator|acupuncture|en acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
16378826|NCT04127695|Experimental|ABBV-0805 Dose 1 or Placebo|Participants will receive ABBV-0805 Dose 1 or Placebo.
16378827|NCT04127695|Experimental|ABBV-0805 Dose 2 or Placebo|Participants will receive ABBV-0805 Dose 2 or Placebo.
16378828|NCT04127695|Experimental|ABBV-0805 Dose 3 or Placebo|Participants will receive ABBV-0805 Dose 3 or Placebo.
16378829|NCT04127695|Experimental|ABBV-0805 Dose 4 or Placebo|Participants will receive ABBV-0805 Dose 4 or Placebo. Note: This dosing group may be added after a review of data from dosing groups 1-3.
16378830|NCT04127682||Physicians|Physicians dealing with cases of pediatrics' acute URIs at PHC units either urban or rural, insurance hospitals or Assiut university hospitals.
16378831|NCT04127669|Experimental|Arm A|Active substance treatment with OSU6162. Starting dose for all patients in the OSU6162 treatment group is 15 mg BID. The dose is taken orally as one circular coated tablet of 15 mg together with a light meal in the morning and one tablet around lunch unless otherwise agreed upon. In order to aim at optimal dosing of OSU6162, some flexibility is allowed. The investigators are able to modify the dose for individual patients based on how well the treatment is tolerated and how well the patients respond to it. In the case where there is no clear response, the dose can be increased to maximally 30 mg BID (intermediate dosage is allowed) after 4 weeks of treatment; it is also possible to decrease the dose to a lower level (even below 15 mg BID) if a higher dose is not tolerated and/or there is a perceived weakened therapeutic effect with the higher dose. All dose changes will be performed while retaining the blind.
16378832|NCT04127669|Placebo Comparator|Arm B|Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
16378833|NCT04127656|Experimental|Amino Acid-Based Experimental Study Formula|Not commercially available amino acid-based study formula
16378834|NCT04127643||S-ICD patients|patients who have received the EMBLEM S-ICD system
16378835|NCT04127630||mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
16378836|NCT04127617|Experimental|Osteopathic Manipulative Treatment|the treatment group will receive 5 osteopathic manipulative treatment. The treatment will last 45 - 60 minutes with the following frequency: the subjects will receive 3 OMT on a weekly basis, the two following twice weekly. The osteopathic treatment protocol will therefore last 7 weeks. Each individual patient will be taken in charge by two operators during the entire duration of the study.
16378837|NCT04127617|Active Comparator|Nursing Care|The conventional treatment consists in educational nursing care.
16378838|NCT04127604|Experimental|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
16378839|NCT04127604|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
16378840|NCT04127591||myocardial infarction group|Patients admitted with the diagnosis of myocardial infarction.
16378841|NCT04127591||Blank control group|Patients admitted without the diagnosis of myocardial infarction.
16378842|NCT04127578|Experimental|Low dose|
16378843|NCT04127578|Experimental|High dose|
16378844|NCT04127565||Pre-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2013 to March 2014.
~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units."
16378845|NCT04127565||Post-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2015 to March 2016.
~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units.
~Additionally analysis of all ambulance calls with telemedical support."
16378846|NCT04127552||Patients with non-functioning adrenal adenoma|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels lower than 50 nmol/L
16378847|NCT04127552||Patients with pACS receiving conservative management|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving conservative management
16378848|NCT04127552||Patients with pACS receiving adrenalectomy|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving adrenalectomy according to the 2016 European Society of Endocrinology guidelines
16378849|NCT04127552||Healthy controls|Patients without adrenal masses
16378851|NCT04127526|Active Comparator|Baseline Period of 2 weeks|2 participants will be randomly allocated to a baseline of 2 weeks before commencing CONNECT intervention.
16378852|NCT04127526|Active Comparator|Baseline Period of 3 weeks|2 participants will be randomly allocated to a baseline of 3 weeks before commencing CONNECT intervention.
16379192|NCT04125173|Active Comparator|2. Pneumoperitoneum pressure = 12mmHg|2.Pneumoperitoneum will be set at 12mmHg
16378854|NCT04127513|Experimental|12% AMMONIUM LACTATE|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 12% ammonium lactate. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
16378855|NCT04127513|Active Comparator|10% UREA|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 10% urea. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
16378856|NCT04127500|Experimental|DEX group|use DEX
16378857|NCT04127500|No Intervention|control group|use placebo
16378858|NCT04127487||Periodontitis group|35 Generalized chronic periodontitis subjects without coronary heart diseases
16378859|NCT04127487||periodontitis with CAD group|35 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease
16378860|NCT04127474||Group I|25 Generalized chronic periodontitis subjects without coronary heart disease.
16378861|NCT04127474||Group II|25 Generalized chronic periodontitis subjects diagnosed with coronary heart disease.
16378862|NCT04127474||Group III|25 Periodontally healthy subjects diagnosed with coronary heart disease.
16378863|NCT04127461|Active Comparator|Open vessel harvesting|Arm 1 is the conventional procedure
16378864|NCT04127461|Experimental|Medtronic endoscope|Arm 2 - is the minimally invasive procedure
16378865|NCT04127448|Experimental|Exergaming Training Group|Training was given using X-box 360 Kinect.
16378866|NCT04127448|Active Comparator|Aerobic Exercise Group|Session using treadmill (model no TMX58 220).
16378867|NCT04127435||High-Dose-Rate 192Ir Brachytherapy|"All patients underwent computed tomography (CT) 3-5 days before surgery. The collimation is 2.5 mm and CT Planning System.
~Delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs);
~Determination of the needle tract of the implanted insertion direction, distribution, and depth. Then calculation of the dose distribution of the target volume and OARs.
~Depending on B-TPS data, we establish a digital model for the individual template.
~Local anesthesia or intraspinal anesthesia was induced in all patients. The three-dimensional printing noncoplanar templates (3D-PNCT) was placed on the surface of the treatment area of the patient. The 3D-PNCT was aligned accurately with the outer-contour features. Through the guide hole of the 3D-PNCT, we inserted to pre-planned depths.
~Delineation of the GTV and design planning .
~Connect the source tube and 192Ir high dose rate interorganizational brinotherapy
~At the end pressed to stop bleeding."
16378868|NCT04127422||Study group|"Patients presenting with current symptoms related to the breast. Adult females aged 18-39 years presenting to the breast outpatient clinic with either mastalgia, nodularity and/or discharge.
~A questionnaire, physical examination and bilateral breast ultrasonography will be obtained for all patients.
~A- The questionnaire will contain the following items:
~symptoms related to the breast.
~other medical history.
~menstrual history.
~obstetric history.
~rapid screener for beverages and fast food consumption.
~rapid screener for vegetables and fruit consumption.
~B- Physical examination will specifically records the following:
~breast tender point(s).
~breast nodularity.
~nipple discharge.
~weight, height, body mass index (BMI).
~C- bilateral breast ultrasonography for all patients.
~D- breast biopsy when clinically indicated as per hospital policy."
16378869|NCT04127422||Control group|"Age-matched healthy volunteers with no current medical conditions. Adult females aged 18-39 years with no current breast problems. These healthy volunteers will be asked to complete the same questionnaire as per the Study group and have anthropometric measure.
~A- The questionnaire will contain the following items:
~other medical history.
~menstrual history.
~obstetric history.
~rapid screener for beverages and fast food consumption.
~rapid screener for vegetables and fruit consumption.
~B- Physical examination will specifically records the following:
~1- weight, height, body mass index (BMI)."
16378870|NCT04127409|Placebo Comparator|Control Chicken-meat & Control Eggs|Participants will be provided with control chicken-meat and control eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three control eggs/week, for 6 months.
16378871|NCT04127409|Experimental|Control Chicken-meat & Omega-3 Eggs|Participants will be provided with control chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three omega-3-enriched eggs/week, for 6 months.
16378872|NCT04127409|Experimental|Omega-3 Chicken-meat & Control Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and control eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three control eggs/week, for 6 months.
16378873|NCT04127409|Experimental|Omega-3 Chicken-meat & Omega-3 Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three omega-3-PUFA enriched eggs/week, for 6 months.
16378874|NCT04127396|Experimental|lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
16378875|NCT04127396|Active Comparator|Sorafenib and TACE|Patients in Sorafenib + TACE group will take oral sorafenib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
16378876|NCT04127383|Experimental|ABCC-tool|The intervention group will use the ABCC-tool during consultation with their healthcare provider. Healthcare providers in the intervention group will receive a short instructional film about the ABCC-tool before the start of the study. Additionally, healthcare providers from 12 practices will be invited for interviews, evaluating the context and process of implementation.
16378877|NCT04127383|No Intervention|Usual care|The control group will receive usual care, and healthcare providers will not be instructed
16378878|NCT04127370|Experimental|Obese Patients With NAFALD Undergoing Bariatric Surgeries|
16378879|NCT04127357|Other|A - Control|Brushing with 1450 ppm fluoride toothpaste.
16378880|NCT04127357|Experimental|B - Test|Resin sealing (FluroShield, Dentsply, Brazil).
16378882|NCT04127344|No Intervention|Non-Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.
~Patients allocated to Non-Music Therapy Intervention received standard treatment."
16378883|NCT04127331|Active Comparator|Routine|Patients who are scheduled for routine outpatient surgery.
16378884|NCT04127331|Active Comparator|Urgent|Patients who are scheduled for urgent surgery.
16378885|NCT04127331|Active Comparator|Emergent|Patients who are scheduled for emergency surgery.
16378886|NCT04127318|Experimental|Pedaling Group|During their 30 minute immunotherapy infusions, participants will pedal using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. A research personnel will monitor the patient's heart rate, blood pressure, and RPE at baseline and every 10 minutes throughout the pedaling session. Participants will also have treatment response biomarkers gathered at baseline and before and within 10 minutes of completing their first and fourth immunotherapy infusions. Lastly, participants will complete both a physical activity questionnaire and a quality of life questionnaire at baseline and following their fourth treatment.
16378887|NCT04127305||VA ECMO|Patients will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
16378888|NCT04127305||VA EMCO + RRT|Patients with RRT will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
16378889|NCT04127305||VV ECMO|Patients will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
16378890|NCT04127305||VV ECMO + RRT|Patients with RRT will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
16378891|NCT04127305||Control|Patients will be included within 24-48h after start of an antiinfective therapy
16378892|NCT04127292|Experimental|Emotional Self Awareness Group (Clinician participants)|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
16378893|NCT04127292|No Intervention|Emotional Self Awareness Group (Patient participants)|Patients provided care by clinicians trained in ESA
16378894|NCT04127292|Sham Comparator|Control Group (Clinician participants)|The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
16378895|NCT04127292|No Intervention|Control Group (Patient participants)|Patients provided care by clinicians not receiving ESA feedback
16378896|NCT04127279|Experimental|Enriched Cream|The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.
16378897|NCT04127279|Active Comparator|Placebo Cream|Cream devoid of essential oils, self-administered
16378898|NCT04127253|Experimental|transcranial direct current plus Brain training tools|20 minutes of transcranial direct current stimulation along with the application of motor imagery and action observation
16378899|NCT04127253|Placebo Comparator|Placebo transcranial direct current plus Brain training tools|A placebo intervention of direct transcranial stimulation being active during 15 seconds and then it will be turned off the rest of the time until 20 minutes. This group will also carry out the training of action observation and motor imagery.
16378900|NCT04127253|Sham Comparator|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
16378901|NCT04127240|Experimental|Meat assignment in DASH intervention|Participants consumed 3 ounces of red meat per day as a part of the DASH diet.
16378902|NCT04127240|Experimental|Meat allocation in DASH intervention|Participants consumed 6 ounces of red meat per day as a part of the DASH diet.
16378903|NCT04127227|Experimental|Sintilimab With P-GemOx|Sintilimab, 200mg, d1, intravenous drip; pegaspargase, 2000U/m2, d1, intravenous drip; gemcitabine, 1000mg/m2, d1,d8, intravenous drip; oxaliplatin, 130mg/m2, d1, intravenous drip; All patients received up to 6 treatment cycles of 21 days. Stage IV patients with localized disease will be treated with consolidative RT. Patients with CR or PR will receive Sintilimab maintenance therapy.
16378904|NCT04127201|Experimental|Online intervention, en_línea|Participants will be provided with a username and a password to acess to a website. en_línea program is an online adaptation of the LEARN program. The five treatment areas are: Lifestyle, Exercise, Attitudes, Relationships and Nutrition. We have designed and developed a website (www.programaenlinea.org) with 17 weekly treatment sessions and an exclusive mobile application for self-recording.
16378905|NCT04127201|Active Comparator|Standard group therapy|Participants in this arm will received a 10 sessions of standard primary care group therapy. Sessions 1 and 2 will be weekly and sessions from 3 to 10 will be biweekly. Sessions, between 8 and 10 participants, will be conducted by a specialized psychologist and they will last 90 minutes. Treatment areas will be the same as en_línea, beginning with nutrition and exercise and a progressive incorporation of the other topics. Material to work at home and self-recording will be provided in paper.
16378906|NCT04127201|No Intervention|Control group|Participants in the control group only will receive a biweekly newsletter by email without feedback. They will be provided with material and instructions to self-record their daily meals and exercise. The newsletter only will content basic information about nutrition and exercise.
16378907|NCT04127162||alive|
16378908|NCT04127162||dead|
16378909|NCT04127149|Experimental|Group with ultrasound|The first group consists of nine general practitioners having received a brief training on the use of ultrasound scanners in general practice. The general practitioner includes all adult patients who are consulting for one of the 8 medical conditions studied and perform an ultrasound scan. Two weeks later, he/she calls each patient to collect the necessary data.
16378910|NCT04127149|No Intervention|Group without ultrasound|The second group consists of nine general practitioners. Each physician includes all adult patients who are consulting for one of the 8 medical conditions studied and performs a standard consultation. Two weeks later, he/she calls each patient to collect the necessary data.
16379010|NCT04126395||Developmental Coordination Disorder + Autism Spectrum Disorder|"This groups consists of children now aged 6-12y:
~With a multidisciplinary diagnosis of DCD
~With motor problems (M-ABC-2 and DCD-Q)
~With social responsiveness problems (SRS-2)"
16379011|NCT04126382|Active Comparator|INSURE|Intubate-Surfactant-Extubate(INSURE) technique is a Important treatment in premature infants with RDS.
16378911|NCT04127136|Experimental|Study Group|The cases were analyzed for the change in the severity of binge eating disorder in the program. The data collection was performed via socio-demographic information form, binge eating disorder evaluation (BEDE) form, and progress record forms. BEDE was a structured form exclusively using DSM-5 BED diagnosis and the severity criteria. Progress record form included weekly session content that was administered by a physician, dietitian, psychologist, and the physiotherapist and the monthly individual meetings data. BEDE and progress record forms were applied before the trainings that focuses on cognitive change and repeated every four weeks for 20 weeks. The patients were planned to receive 80 hours of training by the physician, dietitian, psychologist, and the physiotherapist.
16378912|NCT04127110|Experimental|Lorlatinib|"Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
~Lorlatinib will be taken continuously on a daily basis until disease progression, unacceptable toxicity, occurrence of any withdrawal criterion, whichever comes first."
16378913|NCT04127097|Experimental|cartoon group|
16378914|NCT04127097|No Intervention|control group|
16378915|NCT04127084|Experimental|normal albuminuria|baseline urinary albumin creatinine ratio [UACR]< 30 mg/g
16378916|NCT04127084|Experimental|moderately increased albuminuria|baseline UACR 30~300 mg/g
16378917|NCT04127084|Experimental|severely increased albuminuria|baseline UACR>300mg/g
16378918|NCT04127084|No Intervention|blank Comparator|normal participant
16378919|NCT04127071|Active Comparator|Surgical I&D Procedure|The abscess cavity will be evaluated thoroughly with ultrasonography. The site will be prepared and draped. The skin surface will be infiltrated with local anesthetic with a 25-gauge needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Incision of the skin surface with a number 11-blade scalpel will be performed over the largest area of infection; the incision will be extended into the abscess cavity. A blunt instrument will then be used to break up internal loculations if present. Repeated instrumentation through the initial incision or extension of the original incision will be performed if needed. Lastly, iodoform packing will be inserted through the incision into the cavity. The decision to send the abscess contents for microbiological culture and susceptibility analysis will be at the discretion of the treating clinician.
16378920|NCT04127071|Experimental|Ultrasound-guided Needle Aspiration Procedure|The abscess cavity will be evaluated thoroughly with US. The site will be prepared and draped. The skin surface and anticipated needle track will be infiltrated with local anesthetic with a 25g needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Under direct US-guided visualization, a 14g 2in steel needle attached to a 40mL syringe will be advanced into the abscess cavity with manual negative pressure. The needle tract will be extended obliquely 2-3 cm between the skin and abscess to prevent fistulization. Purulent material will be aspirated until no further purulence can be aspirated. Multiple aspiration attempts on the initial visit will be permitted to maximally drain the abscess cavity. Additionally, irrigation of the abscess cavity with sterile saline will be permitted to break up internal loculations if present, as has reported previously for trunk and breast abscesses.
16378921|NCT04127058|Other|CYP2D6 non-poor metabolizers|titrated up to 24 mg daily (12 mg b.i.d.)
16378922|NCT04127058|Other|CYP2D6 poor metabolizers|titrated up to 12 mg daily (6 mg b.i.d.)
16378923|NCT04127045||IMN-Group|Patients treated with intramedullary nailing
16378924|NCT04127045||HA-Group|Patients treated with Hemiarthroplasty
16378925|NCT04127032|Experimental|Tailored ICBT for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
16378926|NCT04127019|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
16378927|NCT04127019|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
16378928|NCT04127019|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).
16378932|NCT04126993|Experimental|Camrelizumab+ Apatinib test group|Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
16378933|NCT04126993|Active Comparator|Apatinib single drug control group|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
16378934|NCT04126980||ED group|The ED group who had less than 72 hours of hospitalization (including the preparation period which commonly took approximately 1 day) for the surgery.
16378935|NCT04126980||Comparison group|The comparison group who were hospitalized for more than 72 hours but less than 12 days.
16378936|NCT04126967|Other|allo-PBSCT patients with no NGS text|
16378937|NCT04126954||Cinacalcet|Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet
16378938|NCT04126941||Teriparatide|Patients with hypoparathyroidism treated by teriparatide
16378939|NCT04126928|Other|Participant|Each participant will go through (i) screening using DMFT and PUFA, (ii) orthopantomography assessment using PAI, and (iii) comprehensive clinical examination to derive pulpal and periapical diagnoses
16379012|NCT04126382|Experimental|LISA|Less invasive surfactant administration(LISA) technique is a Important treatment in premature infants with RDS.
16379013|NCT04126369|Experimental|mindfulness intervention|12 mindfulness sessions for 3 months (1 session per week)
16379014|NCT04126369|Active Comparator|Psycho educative programme|12 psycho educative sessions for 3 months (1 session per week)
16378940|NCT04126902||late-onset preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
16378941|NCT04126902||Control|The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
16378942|NCT04126876|Experimental|Tilsotolimod (IMO-2125)|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
16378943|NCT04126876|Placebo Comparator|Placebo|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
16378944|NCT04126837|Other|Patient admitted for Ankle and foot injuries|Diagnosis and treatment of Ankle and foot injuries by an accelerated nursing branch in emergency department
16378945|NCT04126824|Active Comparator|Bupivacaine|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine and contrast to enable visualization of the nerve block under fluoroscopy.
16378946|NCT04126824|Experimental|Bupivacaine and Triamcinolone|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine plus triamcinolone mixed with contrast to enable visualization of the nerve block under fluoroscopy.
16378947|NCT04126811|Experimental|Apatinib and Chemotherapy Test Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
16378948|NCT04126811|Active Comparator|Apatinib Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
16378949|NCT04126811|Active Comparator|Chemotherapy Group|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
16378950|NCT04126798||Healthy adults|Standardization and collecting normative age-related data for cognitive and motor single tasks, as well as cognitive-motor dual-tasks
16378951|NCT04126798||Bilateral vestibulopathy|Validation of cognitive and motor single tasks, as well as cognitive-motor dual-tasks
16378952|NCT04126798||Unilateral vestibular impairment|Cross-sectional study on cognitive and motor single tasks, as well as cognitive-motor dual-tasks, in persons with unilateral vestibular impairment
16378953|NCT04126785|Placebo Comparator|Control without exercise in heated water-based|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the xiphoid process level for 30 min.
16378954|NCT04126785|Experimental|High Intensity Interval Exercise in Heated Water|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
16378955|NCT04126785|Experimental|Continuous Moderate Exercise in Heated Water|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light) level of RPE.
16378956|NCT04126772||Active MS patients|10 MS patients with an active lesion of 0,5 cm diameter
16378957|NCT04126772||Healthy controls|20 healthy controls
16378958|NCT04126772||SPMS patients|10 SPMS patients
16378959|NCT04126759|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
16378960|NCT04126733|Experimental|Regorafenib + Nivolumab|
16378961|NCT04126720|Active Comparator|vitamin E|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and Vitamin E capsule (Vitamin E 400: 400 mg vitamin E capsules - Pharopharmaceuticles) daily.
16378962|NCT04126720|Placebo Comparator|Placebo|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and placebo capsule daily
16378963|NCT04126707|Experimental|[14C] HQP1351|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of [14C] HQP1351 to healthy Chinese male subjects.
16378964|NCT04126694|Experimental|CBT with smartphone application|12 weeks of CBT with SenseSupport smartphone application
16378965|NCT04126681|Experimental|HQP1351 therapy cohort|HQP1351 40 mg, taken orally once every other day of a 28-day cycle
16378966|NCT04126681|Active Comparator|Best Available Therapy (BAT) cohort|Best available therapy (BAT) will be selected by the investigator for each participant.
16378967|NCT04126668|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast
16378968|NCT04126668|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
16378969|NCT04126655|Experimental|Arfolitixorin.|Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU
16378970|NCT04126655|Active Comparator|Calciumfolinate.|Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU
16378971|NCT04126642|Other|Assessment only group|Standard care + Daily ecological momentary assessments (EMAs)
16378972|NCT04126642|Experimental|Intervention group|"Intervention group will receive same measures and interventions as the assessment only group AND will receive messaging that is tailored to patient responses on EMAs. When participants provide a pattern of responses that are suggestive of heightened emotional distress, they will receive feedback and/or a prompt to complete one of the self-management exercise. The app will prompt participants to complete a brief educational video on relaxation strategies and guided relaxation exercises. Participants will have access to: 1) a Help me Cope button in the app that contains links to evidenced-based self-management techniques, and 2) a Contact Counselor button that will send a secure email to a study psychologist requesting a call. Participants will receive a coping focused message at the completion of the Report Distress EMAs. Participants can access these on demand intervention components and review them at any time in addition to receiving the tailored intervention messages."
16378973|NCT04126629||Normotensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the normotensive group. Every attempt will be made to stratify both groups equally between second and third trimesters.
16378974|NCT04126629||Hypertensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the hypertensive group.Every attempt will be made to stratify both groups equally between second and third trimesters.
16378975|NCT04126616|Experimental|patients with COPD and PH|
16378976|NCT04126616|Active Comparator|patients with COPD without PH|
16378977|NCT04126616|Active Comparator|healthy subjects|
16378978|NCT04126603|Placebo Comparator|Group A Placebo|Metformin + Placebo.
16378979|NCT04126603|Active Comparator|Group B Active|Metformin + Placebo
16378980|NCT04126590|Experimental|KN044 0.03 mg/kg dose group|KN044 0.03 mg/kg dose group,once every 3 weeks，a total of four cycles
16378981|NCT04126590|Experimental|KN044 0.1 mg/kg dose group|KN044 0.1 mg/kg dose group,once every 3 weeks，a total of four cycles
16378982|NCT04126590|Experimental|KN044 0.3mg/kg dose group|KN044 0.3mg/kg dose group,once every 3 weeks，a total of four cycles
16378983|NCT04126590|Experimental|KN044 1 mg/kg dose group|KN044 1 mg/kg dose group,once every 3 weeks，a total of four cycles
16378984|NCT04126590|Experimental|KN044 3 mg/kg dose group|KN044 3 mg/kg dose group,once every 3 weeks，a total of four cycles
16378985|NCT04126590|Experimental|KN044 6mg/kg dose group|KN044 6mg/kg dose group,once every 3 weeks，a total of four cycles
16378986|NCT04126590|Experimental|KN044 10mg/kg dose group|KN044 10mg/kg dose group,once every 3 weeks，a total of four cycles
16378987|NCT04126577||Patients with suspected peritonitis|Secondary peritonitis, sepsis and endotoxemia
16378988|NCT04126564|Experimental|IEO Intervention Group|The Group 1 is the active study group which receives the online mindfulness intervention first.
16378989|NCT04126564|Active Comparator|Control Group|Group 2 will be asked to read a book or journal of their choice for first 30 days, and then recieve online mindfulness intervention (IEO).
16378990|NCT04126551||Lean, healthy control|Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
16378991|NCT04126551||Overweight/obese nondiabetic|Overweight/Obese nondiabetic subjects. Overweight and obesity will be defined using the standard body mass index cutoffs. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
16378992|NCT04126551||Type 2 diabetes|Participants with type 2 diabetes will be diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
16378993|NCT04126538|Experimental|Patient group|Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
16378994|NCT04126538|Experimental|Control group|Healthy subjects take pirfenidone capsule 400mg once orally
16378995|NCT04126525|Experimental|neoadjuvant pyrotinib|pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days
16378996|NCT04126512||Bedside ligation|Infants admitted to St. Orsola-Malpighi Hospital (SOM) NICU had their PDA ligated at bedside, with a timing of surgery dependent on the time schedule of the surgeons and anaesthesiologists.
16378997|NCT04126512||Referred to specialist paediatric cardiac surgery centre|Due to the unavailability of local cardiac surgery, infants admitted to the Cambridge University Hospital (CUH) NICU were referred to specialist paediatric cardiac surgical centres, where PDA ligation was performed. In these cases, the surgical timing depended on both bed availability at the referral centre and the availability of the neonatal transfer team.
16378998|NCT04126486|Other|Zio®XT Monitor Arm|
16378999|NCT04126486|No Intervention|Usual Care Arm|
16379000|NCT04126473|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
16379001|NCT04126460|Experimental|Toripalimab|Injection; dosage form: 6ml: 240mg; frequency: 240mgQ3W; duration: 17cycles (12 months) or randomization to the date of the first documented progression
16379002|NCT04126434|Sham Comparator|no masking|not wearing facemask
16379003|NCT04126434|Active Comparator|masking|wearing facemask
16379004|NCT04126421|Active Comparator|E1 Vitamin E infused HXLPE|E1 Vitamin E infused highly cross-linked polyethylene (HXLPE)
16379005|NCT04126421|Active Comparator|Marathon HXLPE|Marathon highly cross-linked polyethylene (HXLPE)
16379006|NCT04126408|Sham Comparator|Sham arm|gammaCore sham device which will not provide stimulation of the vagus nerve
16379007|NCT04126408|Active Comparator|Treatment group|Active gammaCore device that supplies non-invasive stimulation of the cervical branch of the Vagus nerve
16379008|NCT04126395||Controls|"This groups consists of children now aged 6-12y:
~Without a medical diagnosis possibly influencing motor development
~Without motor problems (M-ABC-2 and DCD-Q)
~Without social reponsiveness problems (SRS-2)"
16379009|NCT04126395||Developmental Coordination Disorder|"This groups consists of children now aged 6-12y:
~With a multidisciplinary diagnosis of DCD
~With motor problems (M-ABC-2 and DCD-Q)
~Without social responsiveness problems (SRS-2)"
16379054|NCT04126200|Experimental|Belantamab mafodotin+ isatuximab cohort expansion(Sub-study 5)|
16379015|NCT04126343|Experimental|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
16379016|NCT04126343|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
16379017|NCT04126343|Active Comparator|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
16379018|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Elderly|
16379019|NCT04126330|Placebo Comparator|Placebo- Elderly|
16379020|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Obese|
16379021|NCT04126330|Placebo Comparator|Placebo- Obese|
16379024|NCT04126304||Common cold|A cold is a clinical diagnosis.Complaints may include a stuffy nose, sore throat, cough and headache.Objective signs are rare, but may include fever, enlarged anterior cervical lymph nodes, nasal mucosa and oropharyngeal erythema, and nasal mucus.
16379025|NCT04126304||acute bronchitis|In 2011, the European society of respiratory diseases (ERS) defined acute disease in patients with non-chronic lung disease. Symptoms include cough, with or without expectoration of phlegm, and other symptoms and signs may indicate lower respiratory tract infection and cannot be explained by other diseases (e.g., sinusitis, asthma).The main symptoms of acute bronchitis are cough, may be accompanied by fever, fatigue, asthma and dyspnea.
16379026|NCT04126304||Post-infection cough|The definition in the 2013 guidelines for diagnosis and treatment of chronic cough in Chinese children: cough refers to a recent history of respiratory tract infection;The cough lasted > for 4 weeks, presenting an irritating dry cough or a little white phlegm.Chest x - ray examination showed no abnormality or only increased lung veins.The pulmonary ventilation function was normal, or presented transient high airway response.Coughs are usually self-limited, and other diagnoses should be considered if the cough is more than 8 weeks old.In addition to other causes of chronic cough.
16379027|NCT04126304||community-acquired pneumonia|According to the 2019 guidelines for the diagnosis and treatment of community-acquired pneumonia in children, it is defined as infectious pneumonia developed outside the hospital (community), including pneumonia developed after admission due to infection of pathogens with a clear incubation period outside the hospital (community).
16379028|NCT04126291|Experimental|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived change in self-efficacy/ confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
16379029|NCT04126278|Experimental|Barbotage Injection|Subjects receiving barbotage with saline injection
16379030|NCT04126278|Active Comparator|Barbotage with Cortisone Injection|Subjects receiving barbotage with cortisone injection
16379031|NCT04126265|No Intervention|Routine colonoscopy group|The patient underwent routine colonoscopy.
16379032|NCT04126265|Experimental|Artificial intelligence assisted colonoscopy group|The real-time automatic polyp detection system was used to assist the endoscopist.
16379033|NCT04126252|Experimental|Group A|This arm received pharmacotherapy for erectile dysfunction.
16379034|NCT04126252|Experimental|Group B|This arm received cognitive behavior psychotherapy for erectile dysfunction.
16379035|NCT04126252|Experimental|Group C|This arm received combined treatment approach.
16379036|NCT04126252|Placebo Comparator|Group D|This arm acted as a control group and received placebo or no intervention.
16379037|NCT04126239||Participant suffering from obesity|Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2
16379038|NCT04126239||healthy volunteer|
16379039|NCT04126226|Experimental|Study group|
16379040|NCT04126226|No Intervention|Control Group|
16379041|NCT04126213|Experimental|RSV MAT formulation 2 Group|Maternal subjects randomized to RSV MAT formulation 2 Group will receive a single dose of RSVPreF3 formulation 2 vaccine in the deltoid region of the non-dominant arm and will be followed up until the study end.
16379042|NCT04126213|Experimental|RSV MAT formulation 3 Group|Maternal subjects randomized to RSV MAT formulation 3 group will receive a single dose of RSVPreF3 formulation 3 vaccine in the deltoid region of the non-dominant arm and will be followed up until the study end.
16379043|NCT04126213|Placebo Comparator|Control Group|Maternal subjects randomized to the Control Group will receive a single dose of Placebo in the deltoid region of the non-dominant arm and will be followed up until the study end.
16379044|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)|
16379045|NCT04126200|Experimental|Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)|
16379046|NCT04126200|Experimental|Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)|
16379047|NCT04126200|Experimental|Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)|
16379048|NCT04126200|Experimental|Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)|
16379049|NCT04126200|Active Comparator|Belantamab mafodotin monotherapy cohort expansion|
16379050|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)|
16379051|NCT04126200|Experimental|Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)|
16379052|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat cohort expansion(Sub-study 3)|
16379053|NCT04126200|Experimental|Belantamab mafodotin+ dostarlimab cohort expansion(Sub-study 4)|
16379056|NCT04126174|Active Comparator|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
16379057|NCT04126174|Active Comparator|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
16379058|NCT04126161|Active Comparator|CT|Patients have standard of care CT prior to primary hip replacement
16379059|NCT04126161|Experimental|Ultrasound|Patients have ultrasound scans together with standard of care CT prior to primary hip replacement
16379060|NCT04126148||Age matched Healthy participants (150)|Healthy Participants Age: > 40y No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system
16379061|NCT04126148||Coronary Artery Disease (CAD) Patients (200)|Coronary Artery Disease (CAD) Patients Age > 18 y Patients with an Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.
16379062|NCT04126135|Active Comparator|Usual Care Group|Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
16379063|NCT04126135|Experimental|Treatment Group|Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
16379064|NCT04126096|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive beta lactam containing antibiotics during surgery (other than penicillin) in order to determine Negative Predictive Values and Non-Irritant Concentrations.
16379066|NCT04126070|Experimental|COHORT 1: DNA damage repair defects (DDRD) +/- Inflamed Tumor|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.
~Androgen Deprivation Therapy: Given per standard care for duration of study
~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage
~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
16379067|NCT04126070|Experimental|COHORT 2: Inflamed Tumor without DNA repair defects (DDRD)|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.
~Androgen Deprivation Therapy: Given per standard care for duration of study
~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage
~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
16379068|NCT04126070|Experimental|COHORT 3: Biomarker Negative|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.
~Androgen Deprivation Therapy: Given per standard care for duration of study
~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage
~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6"
16379069|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method A|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A
16379070|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method B|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B
16379071|NCT04126044|Active Comparator|Reference: bevacizumab - EU|
16379072|NCT04126044|Experimental|Test: PF-06439535 (CN)|
16379075|NCT04126018||Mitral Valve Regurgitation|Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.
16379076|NCT04126018||Aortic Valve Regurgitation|Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.
16379077|NCT04126018||Aortic Stenosis|Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.
16379078|NCT04126018||Patients referred for CRT Implantation|Patients who meet clinical guideline criteria for CRT implantation with EF < 40%
16379079|NCT04126005||Cohort 1 (Age < 18 Months)|"In-home visits every 2 months
~Clinic assessments every 6 months"
16379080|NCT04126005||Cohort 2 (Age ≥ 18 Months - 3 Years)|"In-home visits every 4 months
~Clinic assessments every 6 months"
16379081|NCT04126005||Cohort 3 (Age > 3 - 5 Years)|"In-home visits every 6 months
~Clinic assessments every 6 months"
16379082|NCT04126005||Cohort 4 (Age > 5 Years)|"In-home visits every 12 months
~Clinic assessments every 12 months"
16379083|NCT04126005||Cohort 5 (Deceased)|• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.
16379084|NCT04125992|Experimental|Distal Radial|Patients who undergo coronary catheterization by accessing the distal radial artery in the snuff-box of the hand.
16379085|NCT04125992|Active Comparator|Forearm Radial|Patients who undergo conventional coronary catheterization by accessing the forearm radial artery.
16379086|NCT04125979|Experimental|Preservation of pulmonary vagus nerve|Preservation of pulmonary branches of vagus nerve in minimally invasive surgery for lung cancer
16379087|NCT04125979|Experimental|No pulmonary vagus nerve preservation|In minimally invasive surgery for lung cancer, the pulmonary branches of vagus nerve were severed
16379088|NCT04125953|Experimental|Intervention|A 3 week intervention with Andullation will be performed, 3 times a week for 20 minutes after completion of the radiotherapy session
16379089|NCT04125953|Placebo Comparator|Control|This group will follow the same intervention protocol, but without the application of the Andullation technology
16379090|NCT04125940|Placebo Comparator|Placebo-controlled Arm|Placebo - 12oz water with food coloring
16379091|NCT04125940|Active Comparator|1 serving Resync Arm|12oz water + 7.5g Resync
16379092|NCT04125940|Active Comparator|2 servings Resync Arm|12oz water + 15g Resync
16379093|NCT04125940|Active Comparator|1 servings Resync+Collagen Arm|12oz water + 17g collagen + 2g Resync + 1g Carbohydrates
16379094|NCT04125927|Experimental|Open-label arm|
16379555|NCT04122443|Active Comparator|Oxycodone/ acetaminophen|Oxycodone + acetaminophen
16379095|NCT04125914|Experimental|Prevention (weight management, health behavior intervention)|Participants undergo weight management and health behavior intervention with a combination of 4 components for 16 weeks. TELEPHONE COACHING: Participants receive 1 phone call each week from a coach over 30-45 minutes to discuss diet, physical activity and goal setting. EMAIL COACHING: Participants receive 1 phone call to discuss the process over 10-15 minutes and then receive 1 email each week for 16 weeks. NO COACHING: Participants receive 1 phone call the first week over 10-15 minutes to discuss the process. TEXT MESSAGING: Participants receive 7-12 text messages comprising information about diet and physical activity each week for 16 weeks. SELF-MONITORING: Participants record their food intake and weight directly into the Fitbit website or application 4-7 days each week or 1 day each week for 16 weeks. FAMILY TEAM INTERVENTION: Participants receive 2 group phone calls and join a Facebook group that is monitored by research staff where they can interact with each other and coaches.
16379096|NCT04125901|Experimental|Pain Neuroscience Education and Exercise|Participants will received an 8-week intervention consisting of exercise and pain neuroscience education. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, endurance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
16379097|NCT04125901|Other|Exercise|Participants will received an 8-week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
16379098|NCT04125888||AIT Cohort|Allergic rhinitis patients with and without asthma treated with AIT
16379099|NCT04125888||Control Cohort|Allergic rhinitis patients with and without asthma not treated with AIT
16379100|NCT04125875||Patients with cirrhosis of esophageal varices|
16379101|NCT04125875||Patients with gastric polyps|
16379102|NCT04125862|Other|Fibrous Dysplasia/McCune-Albright Syndrome|20, Fibrous Dysplasia/McCune-Albright Syndrome Patients with or without pain
16379103|NCT04125862|Other|Healthy Controls|20, matched healthy controls
16379104|NCT04125849|Active Comparator|Thoraco-laparoscopic esophagectomy|Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
16379105|NCT04125849|Active Comparator|Mediastinoscopy-assisted transhiatal esophagectomy|Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
16379106|NCT04125836|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
16379107|NCT04125823|Experimental|Video game-based physical activity training|
16379108|NCT04125823|Active Comparator|Conventional physiotherapy program|
16379109|NCT04125810|Experimental|Probiotic|Probiotic
16379110|NCT04125810|Placebo Comparator|Placebo|Placebo
16379111|NCT04125797|Active Comparator|Adhesive 1|This arm investigates one type of silicone adhesive (3M2475P) on adult female skin.
16379112|NCT04125797|Active Comparator|Adhesive 2|This arm investigates one type of silicone adhesive (RX1449P) on adult female skin.
16379113|NCT04125797|Active Comparator|Adhesive 3|This arm investigates one type of silicone adhesive (PS-1243) on adult female skin.
16379114|NCT04125784||Lipid-profile|The cohort includes male and female patients diagnosed and confirmed HIV diagnosis who receive HIV related treatment in an extramural setting. All patients are adults (older than 18 years old) and have participated in the original study in 2014.
16379115|NCT04125771|Other|Diclofenac + HBB|Women who will receive Diclofenac + HBB
16379116|NCT04125771|Other|Diclofenav + placebo|Women who will receive Diclofenav + placebo
16379117|NCT04125758|Experimental|Mindfulness training|Participants will listen to one to two 3-30 minute audio recordings each day for 4 weeks between study visits (28 days total) through the Healthy Minds @Work smartphone app and record when they listen to each recording on a paper log. The app will also collect data on which recordings, when, and for how long participants listen.
16379118|NCT04125758|Active Comparator|Tracking time spent on mobile device|Participants will record how much time they estimate they have spent on their phone in the past 24 hours, each day for 4 weeks (28 days total) between study visits.
16379119|NCT04125745|Experimental|CXA-10|Oral CXA-10 300 mg once daily for 12 weeks
16379120|NCT04125732|Experimental|AdVEGFXC1 at 1x10^9 vp|
16379121|NCT04125732|Experimental|AdVEGFXC1 at 1x10^10 vp|
16379122|NCT04125732|Experimental|AdVEGFXC1 at 4x10^10 vp|
16379123|NCT04125732|Experimental|AdVEGFXC1 at 1x10^11 vp|
16379124|NCT04125719|Experimental|Primay PD-1 resistance|Cohort 1 will include 15 patients who progressed within 3 months (primary resistance) of starting PD-1 therapy
16379125|NCT04125719|Experimental|Secondary PD-1 resistance|Cohort 2 will include 15 patients who progressed after at least 3 months of PD-1 therapy
16379126|NCT04125706|Experimental|Mincycline hydrochloride 2% oral gel|Minocycline will be delivered locally in the periodontal pocket.
16379127|NCT04125706|Experimental|Metronidazole hylcate 0.75 % oral gel|Metronidazole gel will be delivered locally in the periodontal pocket.
16379128|NCT04125693|Experimental|Cancer patients|Patients from completed Bayer clinical trials, who received rogaratinib as monotherapy or combination therapy for the treatment of cancer.
16379129|NCT04125680|Other|ESL Health Literacy Classes|The program will last 8 weeks with classes held online during evening hours. The curriculum will focus on using pedagogies for health literacy as a practice. Assessments will be administered pre-post intervention.
16379130|NCT04125654|Experimental|Patients with ascites enrolled for mNGS testing|Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).
16379131|NCT04125641||Elxaban group|AF patients taking Elxaban
16379193|NCT04125173|Active Comparator|3. Pneumoperitoneum set at 10mmHg|3. Pneumoperitoneum will be set at 10mmHg
16379132|NCT04125628|Experimental|Exercise with cooling|Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
16379133|NCT04125628|Active Comparator|Exercise without cooling|10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise session performed without cooling. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
16379134|NCT04125615|Experimental|Protected Non-Clinical Time|Protected non-clinical time
16379135|NCT04125615|No Intervention|Control Period|No protected non-clinical time
16379136|NCT04125602|Experimental|High fat low carbohydrate diet|
16379137|NCT04125602|Experimental|Low fat high carbohydrate diet|
16379138|NCT04125589|Experimental|Speaking Activity and Talking Activity|Participants will engage in a speaking activity first and a talking activity second.
16379139|NCT04125589|Experimental|Talking Activity and Speaking Activity|Participants will engage in a talking activity first and a speaking activity second.
16379140|NCT04125576||Burn patients|The subjects complaine of severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
16379141|NCT04125576||Healthy controls|age and sex matched healthy controls
16379142|NCT04125563|Placebo Comparator|Placebo capsules|Soft gel capsules with placebo: Sorbitol and colorant.
16379143|NCT04125563|Active Comparator|Active substance - oral capsaicin in soft gel capsules|"This is a phase 2 clinical study in humans for therapeutic use of Capsicum oleoresin - (capsaicin) in CIC. The study has a randomised, double-blind and cross-over design. During 4 weeks the participants take either active capsules (Capsicum oleoresin), or matching placebo capsules. This period follows by 2 weeks of wash out and then another 4 weeks with active capsules or placebo in accordance with the trial profile below."
16379144|NCT04125550|Experimental|Group P|In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 10 mg/kg/h propofol infusion and 5 µg/kg/h fentanyl infusion will be administered.
16379145|NCT04125550|Active Comparator|Group S|In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of anesthesia.
16379146|NCT04125537||Dialysis Centers|Dialysis Center staff participating in the collaborative learning activities. These staff then implement the best practices for seriously ill patients in their setting via quality improvement activities around identifying seriously ill patients, shared-decision making/advanced care planning, palliative dialysis and dialysis withdrawal.
16379147|NCT04125537||Chronic Kidney Disease Clinics|Chronic Kidney Disease Clinic staff participating in the collaborative learning activities. These staff then implement the best practices for seriously ill patients in their setting via quality improvement activities around identifying seriously ill patients, shared-decision making/advanced care planning, and medical management without dialysis.
16379148|NCT04125511|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
16379149|NCT04125498|Active Comparator|OMT|Osteopathic manual treatment
16379150|NCT04125498|Active Comparator|OMT plus self-massage|Patients will be submitted to OMT and then they will be invited to practice a self-massage at home.
16379151|NCT04125498|Sham Comparator|Placebo|Similar to OMT without pressure.
16379152|NCT04125498|Active Comparator|Placebo plus self-massage|Patients will be submitted to placebo manual treatment and then they will be invited to practice a self-massage at home.
16379153|NCT04125485||Person with Parkinson's|"Inclusion criteria for interview/focus group with people with PD: people with PD living at home, Hoehn & Yahr stage 1-4 (Hoehn and Yahr, 1967), cognitively able to participate, able to speak a conversational level of English, and at different stages of PD (early, mid, later by years of diagnosis) and ages (younger and older).
~Exclusion criteria: any hospital admission within the last 1 year, whether for Parkinson's or anything else, that was for more than 24 hours i.e. not day surgery/brief checks in the emergency department after falls; patients diagnosed with PD less than 6 months ago to confirm the diagnosis and allowed them to have time for using the resources for people with PD; unwillingness to participate."
16379154|NCT04125485||Healthcare professional|"Inclusion criteria for interview/focus group for health professionals: Professionals from different disciplines (physician, neurologist, General Practitioners, nurses/specialist nurses, social worker, occupational therapist, mental health workers, physiotherapist, pharmacist, speech therapist) that provide support directly or indirectly to patients with PD and family carers.
~Exclusion criteria: Not involved in direct care or support of people with PD or unwillingness to participate."
16379155|NCT04125485||Family carer|"Inclusion and exclusion criteria for all are the same for Interviews and Focus Groups.
~Family carers:
~Inclusion criteria: family caregivers of PD patients at different stages (early, mid, late) or friends involved in the care process. Also, family caregivers of patients with cognitive impairment will be included.
~Exclusion criteria: not being involved in the care of the person with PD or unwillingness to participate in the project, and an ability to speak a conversational level of the English language.
~Family carers do not need to have the person they care for in the study also and vice-versa."
16379190|NCT04125186||Main Part|After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
16381020|NCT04112043|Active Comparator|NR Alone|
16379156|NCT04125485||Stakeholder|"Stakeholders:
~Inclusion criteria: non-NHS professionals or volunteers involved in policy making or working or collaborating in voluntary organisations or from different sectors; (non-NHS) Health Care, Social Services, voluntary sector, employment, food, Pharmaceutical, Education, Political, that have an impact directly or indirectly in the management of PD and development of care pathways for PD or other long-term conditions (when relevant). Exclusion criteria: unwillingness to participate in the project or lack of involvement in strategic planning or involvement in provision of community PD care."
16379157|NCT04125459||Individuals with Gout|This arm will be getting a biopsy as well as a blood draw
16379158|NCT04125459||Controls|These individuals will not be getting a joint biopsy and will just get a blood draw
16379159|NCT04125446||Cancer in pregnancy chemo treated|Patients that received at least one of the following treatments: Carboplatin, Cisplatin, Cyclophosphamide, Paclitaxel and/or anthracyclines, the latter being the most given type of CT during pregnancy
16379160|NCT04125446||Cancer in Pregnancy not chemo treated|Women who were not treated with CT during pregnancy, including those who were solely surgically treated or did not receive any treatment during pregnancy, will be included in the CT-unexposed control arm
16379161|NCT04125446||healthy pregnancies|A group of healthy pregnant women without cancer will form the second control group
16379162|NCT04125433|Experimental|Medicaid Emergency Department High Utilizers|"This Arm will include the following individuals
~Up to 400 Adults age 18 to 65
~New York State Medicaid Managed Care Members
~Have utilized emergency department services 6 or more times in a 12-month period
~Have been assigned to the Pilot Project by their Medicaid Managed Care Plan"
16379163|NCT04125407|Experimental|Interventional|"Experimental group will receive one customized pair of sensorimotor foot orthoses (insoles).
~Intervention: Other: Sensorimotor foot orthoses with any other supplementary treatment."
16379164|NCT04125407|No Intervention|Control|Control group will receive neither orthotic nor other supplementary intervention.
16379165|NCT04125394|Experimental|NaCl 5%|Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.
16379166|NCT04125381||Exposed to high Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with high Arsenic concentration in drinking water, were enrolled
16379167|NCT04125381||Exposed to low Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with low Arsenic concentration in drinking water, were enrolled
16379168|NCT04125368|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities
16379169|NCT04125368|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities
16379170|NCT04125355|Placebo Comparator|Placebo|Placebo control
16379171|NCT04125355|Experimental|Reflexology|foot reflexology
16379172|NCT04125342|Experimental|Conditioned NIV in High Risk Patients|
16379173|NCT04125342|Active Comparator|HFOT in High Risk Patients|
16379174|NCT04125342|Experimental|Conditioned NIV in Obese Intermediate Risk Patients|
16379175|NCT04125342|Active Comparator|HFOT in Obese Intermediate Risk Patient|
16379176|NCT04125329|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
16379177|NCT04125316||Asthma|Asthma patients
16379178|NCT04125303|Experimental|Intervention Group|Based on NANDA diagnosis recommendations, entertainment-sector workers were asked to record their perceptions and the meaning of their substance-use problem in a diary. The intervention was subsequently designed based on brief motivational psychoeducational therapy (BMPT).
16379179|NCT04125277|Experimental|Imaging|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
16379180|NCT04125264|Experimental|Intense therapeutic Ultrasound|"During the trial two applications of 1000 pulses each one (day one and day thirty) will be applied. Pulse regulation could be modified from 4 to 5 joules depending the presence or not of pain.
~Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching."
16379181|NCT04125264|No Intervention|Control group|Non ITU application. Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching.
16379182|NCT04125251|Active Comparator|BISP,CT & LSB to Couples|In this arm 1, the LSB intervention will be offered to the BISP-CT beneficiary women and their spouses
16379183|NCT04125251|Active Comparator|BISP,CT & LSB to Women|In this arm, the LSB intervention will be offered to the BISP-CT beneficiary women only.
16379184|NCT04125251|No Intervention|BISP,CT & No LSB|This is the control group, where neither BISP-CT beneficiary women nor their spouses will be offered the LSB intervention
16379185|NCT04125238|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at five time points in the future (1 day, 1 week, 1 month, 3 months, 1 year, 5 years, and 25 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
16379186|NCT04125238|Sham Comparator|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at five time points in the recent past (last night from 7pm-10pm, yesterday between 4pm-7pm, yesterday between 1pm-4pm, yesterday from 10am-12pm, yesterday between 7am-10am, the night before last between 7pm-10pm, and evening before last between 4pm-7pm). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
16379187|NCT04125199|Experimental|experimental group|
16379188|NCT04125199|Placebo Comparator|control group|
16379189|NCT04125186||Pilot Part|After providing consent, participants with nocturia will complete web-based baseline EpiNP survey followed by 3-day bladder diary and then a qualitative interview.
16379191|NCT04125173|Active Comparator|1. Pneumoperitoneum pressure = 15mmHg|1. Pneumoperitoneum will be set at 15mmHg
16379194|NCT04125160||Type 2 diabetes and peritoneal dialysis|Case group with type 2 diabetes undergoing peritoneal dialysis for at least 3 months.
16379195|NCT04125160||Type 2 diabetes and eGFR above 60ml/min|Control group with type 2 diabetes and no nephropathy (defined as eGFR above 60ml/min and UACR below 300mg/g).
16379196|NCT04125147|Experimental|Montage Bone Hemostat|Use of Montage Settable Resorbable Hemostatic bone putty on the cut surfaces of bleeding bone at the osteotomy site
16379197|NCT04125147|No Intervention|Standard of Care: No bone hemostat|Use of no bone hemostat on the cut surfaces of bleeding bone at the osteotomy site
16379198|NCT04125134|Experimental|Hypertonic Saline Responders|Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
16379199|NCT04125134|Experimental|Hypertonic Saline Non-responders|Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
16379200|NCT04125121|Active Comparator|Sevoflurane-Propofol|"Session one: Sevoflurane as maintenance anaesthetic during general anaesthesia.
~Session two: Propofol as maintenance anaesthetic during general anaesthesia."
16379201|NCT04125121|Active Comparator|Propofol-Sevoflurane|"Session one: Propofol as maintenance anaesthetic during general anaesthesia.
~Session two: Sevoflurane as maintenance anaesthetic during general anaesthesia."
16379202|NCT04125108|Experimental|pulmonary rehabilitation group|The experimental group was to participate in a 12-week pulmonary rehabilitation program supplemented with an individualized and supervised exercise-training program.
16379203|NCT04125108|No Intervention|control group|The control group was to participate in a 12-week conventional rehabilitation program.
16379204|NCT04125095||Head Scans|Includes patients receiving proton therapy for tumors in the brain, skull, and head and neck region. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
16379205|NCT04125095||Body Scans|Includes proton irradiation to shoulders, thorax, abdomen, pelvis, spine (thoracic or lumbar), extremities, and other body sites. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
16379206|NCT04125082|Other|Type 2 Diabetics|"Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks. Participants will attend study visits at Day 0, Weeks 1, 2, 3, 4, 8, 12 and 16, where insulin titration may be performed based on CGM readings. Participants will receive instruction in carbohydrate counting and corrective insulin dose adjustments.
~Participants will wear CMG throughout the study.
~At final study visit, CGM system will be collected. A1c, FEV1 and Quality of Life Questionnaires will be collected. Pregnancy test will be collected for all females of child-bearing potential. Participants will be transitioned back to Multiple Daily Injections plus basal or may choose to continue on commercial Afrezza® inhaled insulin plus basal"
16379207|NCT04125069||Patients aged from 18 to 85 years|Cardiac surgery patients aged from 18 to 85 years,programmed for Coronary artery bypass graft requiring ECC.
16379208|NCT04125056|Experimental|test group|Hydronidone capsules (Specification: 30 mg / capsule）
16379209|NCT04125056|Placebo Comparator|Control group|Hydronidone capsules (Specification: 15 mg / capsule）
16379210|NCT04125043||RRT Group|Pediatric patients undergoing ocular screening tests
16379211|NCT04125017|Other|effect of using LASER pulse|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
16379212|NCT04125017|Other|Micro-needle Technique|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
16379213|NCT04125004|Experimental|virtual reality|Patients will use virtual reality headset during procedure
16379214|NCT04125004|No Intervention|general anesthesia|Patients will undergo general anesthesia for their procedure
16379215|NCT04124991|Experimental|Yttrium-90 Microspheres in Combination with Durvalumab|Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.
16379216|NCT04124978|Experimental|Intervention group|prospective, single armed, single centre trial study using the MyTAP device on a daily basis for a period of 3 months
16379217|NCT04124965|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
16379218|NCT04124965|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
16379219|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
16379220|NCT04124939|Active Comparator|10 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 10 cc of sterile saline for the purpose of 10 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
16379221|NCT04124939|Active Comparator|20 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 20 cc of sterile saline for the purpose of 20 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
16379222|NCT04124926|Experimental|Healing Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
16379223|NCT04124926|Active Comparator|Healing Phase: Lansoprazole 30 mg|Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
16379224|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 10 mg|Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
16379225|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
16379226|NCT04124926|Active Comparator|Maintenance Phase: Lansoprazole 15 mg|Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
16379227|NCT04124913|Experimental|Dydrogesterone|
16379228|NCT04124913|Active Comparator|Vaginal progesterone|
16379229|NCT04124900||patients at prostate cancer risk diagnosed|"The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:
~Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason >6).
~Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer ( No cancer o Non-significant prostate cancer (Gleason ≤6))."
16379230|NCT04124887|Active Comparator|Sodium fluoride|Duraphat Varnish containing 5% Sodium fluoride
16379231|NCT04124887|Experimental|Tricalcium phosphate|Clinpro™ White Varnish containing 5% NaF with TCP
16379232|NCT04124887|Experimental|Xylitol-coated calcium and phosphate|Embrace ™ Varnish containing 5% NaF with CXP
16379233|NCT04124887|Experimental|Casein phosphopeptide amorphous calcium phosphate|MI Varnish containing 5% NaF with CPP-ACP
16379234|NCT04124861|Experimental|Drug free|Drug：free Glucocorticoid（GC）is tapered and stopped in 8 weeks. Immunosuppressant treatment is also stopped after admission.
16379235|NCT04124861|Experimental|IS monotherapy|Drug: Immunosuppressant Glucocorticoid（GC）is tapered and stopped in 8 weeks. The same type and dosage of immunosuppressive agent before admission, including Mycophenolate mate(<= 1g/d) or Leflunomide (<=20mg/d) or Methotrexate (<=12.5mg/w) or Azathioprine (<=100mg/d)
16379236|NCT04124861|Experimental|GC combined with IS|Drug: GC+Immunosuppressant Both Glucocorticoid(GC) (no more than 7.5mg/d) and immunosuppressant are kept as maintaining dose.
16379237|NCT04124848||Somali Descent|Study participants who are of Somali origin.
16379238|NCT04124848||Non-Somali Descent|Study participants who are not of Somali origin.
16379239|NCT04124835|Experimental|Intervention Group|In the intervention group, the use of the Swiss Ball will be performed through active exercises of pelvic anteversion and retroversion, lateralization and circumduction according to the obstetric evaluation.
16379240|NCT04124835|Other|Control Group|The control group will receive the usual routine care of the service.
16379241|NCT04124822|No Intervention|control|group 1 , is no intervention group in which root canal procedure will be done without drug as ideal protocol .
16379242|NCT04124822|Experimental|Piroxicam|group 2 is given Piroxicam 20 mg half an hour before root canal treatment to manage post operative pain.
16379243|NCT04124822|Experimental|Prednisolone|group 3 is given Prednisolone 20mg half an hour before root canal treatment to manage post operative pain.
16379244|NCT04124809|Experimental|Study group (artificially laser-collapsed blastocysts)|laser was used as an intervention before blastocyst vitrification to assist rapid blastocyst collapse with vitrification
16379245|NCT04124809|No Intervention|& control group (blastocysts were vitrified, no laser collapse|blastocyst were vitrified without laser assisted collapse
16379246|NCT04124796|Experimental|target subjects|"target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit."
16379247|NCT04124796|Active Comparator|health care team|the health care team managing these patients
16379248|NCT04124783|Experimental|Cooling Bolero|
16379249|NCT04124757|No Intervention|Standard neuromuscular blockade|Subjects will receive regular rocuronium induction dose, followed by bolus foses of 10 mg in case of insufficient conditions
16379250|NCT04124757|Experimental|Deep neuromuscular block|Subjects will receive high dose rocuronium induction dose followed by continuous rocuronium administration, to achieve a depth of neuromuscular block of 1-2 twitches post tetanic count
16379251|NCT04124744|Experimental|Intervention|Will receive the Health Champion intervention
16379252|NCT04124744|Active Comparator|Control|Treatment as usual
16379253|NCT04124731|Experimental|Sintilimab plus anlotinib|Sintilimab and anlotinib combination therapy
16379254|NCT04124731|Active Comparator|Control|Standard platinum-based chemotherapy
16379255|NCT04124718||high caries experience|80 adults will be allowed in the high caries experience group according to DMFT index DMFT>13.9
16379256|NCT04124718||low caries experience|80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4
16379257|NCT04124705|Experimental|Armour® Thyroid|Oral administration
16379258|NCT04124705|Active Comparator|Synthetic T4|Oral administration
16379259|NCT04124692|No Intervention|No-treatment control group|
16379260|NCT04124692|Experimental|Treatment group|
16379261|NCT04124679|Experimental|TAES group|In TEAS group, an experienced acupuncturist performed 30 minutes of TEAS treatment at the HT7 (Shenmen) and Neiguan (PC6) acupoints on bilateral side, which were identiﬁed in accordance with the TCM anatomic localizations on the first night before surgery by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no.: SDZ-II; Suzhou Medical Appliances Co. Ltd, Suzhou, China). And after surgery, ST36 (Zusanli) and LI4 (Hegu) acupoints were added for the effect of relieving postoperative complications. 30 minutes of TEAS treatment was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints on the first three nights after surgery
16379262|NCT04124679|No Intervention|Control group|Patients in the control group were attached the gel electrodes at the sham acupoints
16379263|NCT04124666|Experimental|Granulocytes infusion only|Fresh, non-irradiated granulocytes from ABO, Rh, CMV compatible, unrelated donors; bioactivity of anti-cancer ability meets the criteria.
16379264|NCT04124653|Experimental|PF-06842874/Placebo|Single dose administration of PF-06842874 or placebo
16379265|NCT04124653|Experimental|Relative Bioavailability|Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation
16379266|NCT04124640||treatment group|The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal
16379267|NCT04124627|Experimental|Single arm study|Ultrasound plus radiographic guidance
16379268|NCT04124614|Experimental|Brexpiprazole + Sertraline|3 pills: Dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
16379269|NCT04124614|Experimental|Sertraline|3 pills: Dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
16379270|NCT04124614|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
16379271|NCT04124601|Other|Neoadjuvant Chemoradiotherapy|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days)
16379272|NCT04124601|Experimental|Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days) with sequential Ipilimumab (1 mg/kg IV on day 7) and Nivolumab (3 mg/kg IV on day 14, 28 and 42)
16379273|NCT04124588|Experimental|Test group|"After achieving initial hemostasis only with the standard-of-care, endoscopic hemostatic therapie(s)"
16379274|NCT04124588|Active Comparator|Control gruop|"After achieving initial hemostasis only with the standard-of-care, Wrap up the first endoscopy without adding an additional procedure."
16379275|NCT04124549|Sham Comparator|Stand of Care|Patients in the control group received usual care with sham exercise.
16379276|NCT04124549|Experimental|Combined Exercise|The intervention was a 24-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours. Each exercise lasted about 40 minutes.
16379277|NCT04124536|Experimental|Intervention|In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
16379278|NCT04124536|No Intervention|Control|Standard partner notification services, regardless of HIV status.
16379279|NCT04124510|Experimental|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
16379280|NCT04124497|Experimental|Daratumumab Pomalidomide dexamethasone|"Therapy consists in cycles of the DPd combination as follows:
~Pomalidomide 4 mg once daily on days 1-21;
~Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22;
~Daratumumab 16 mg/kg intravenously at following schedule:
~cycle 1 and 2: days 1, 8, 15, and 22
~cycle 3 through 6: days 1, and 15
~from cycle 7 until disease progression: day 1."
16379281|NCT04124484|Experimental|50mg group|Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.
16379282|NCT04124484|Experimental|100mg group|Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.
16379283|NCT04124484|Experimental|200mg group|Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.
16379284|NCT04124484|Placebo Comparator|placebo group|Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg
16379285|NCT04124458|Active Comparator|Pulsed Radiofrequency Ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
16379286|NCT04124458|Active Comparator|Bilateral Occipital Nerve Block|In this arm all steps are the same as other arm, except the generator will not be on and patient will have pain relief by injecting numbing medications beside the sensory nerves.
16379287|NCT04124445|Active Comparator|Pulsed Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine with Maximum allowable temperature 50° rotation: 90.; Pulse rate: 3 Hz; pulse duration: 50 ms; 3 minutes
16379288|NCT04124445|Active Comparator|Continuous Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine, burn will be made at 80° for 60 seconds.
16379289|NCT04124432|Experimental|Active cannabis without nicotine|Smoked cannabis containing 10mg THC + No nicotine/tobacco
16379290|NCT04124432|Experimental|Active cannabis with own brand cigarettes|Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes
16379291|NCT04124432|Experimental|Active cannabis with low nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
16379292|NCT04124432|Experimental|Active cannabis with high nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
16379293|NCT04124432|Experimental|placebo cannabis with own brand cigarettes|Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes
16379294|NCT04124432|Experimental|Placebo cannabis with low nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
16379295|NCT04124432|Experimental|Placebo cannabis with high nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
16379296|NCT04124419|Experimental|Treatment Arm|Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
16379297|NCT04124406||Adults Prescribed Cologuard|Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
16379324|NCT04124198|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|"Patients with clinical T1N0 stage are offered accelerated radiotherapy to 66 Gy/33fractions with concurrent nimorazole.
~Patients with clinical T2N0 stage are offered either accelerated radiotherapy to 66 Gy/33fractions with the option of weekly cisplatin to fit patients or hyper-fractionated accelerated radiotherapy to 76 Gy/56fractions both with concurrent nimorazole.
~Patients with clinical T1-T2, N1 stage are offered accelerated radiotherapy to 66 Gy/33 fractions and nimorazole with the addition of concurrent weekly cisplatin 40 mg/sqm to fit patients."
16379325|NCT04124185||Patients with Achromatopsia|
16379690|NCT04121377|Experimental|Resistance exercise program|Early resistance exercise sessions and home program
16379298|NCT04124393|Active Comparator|Water Exchange (WE) Colonoscopy|In the WE group, the air pump will be turned off before starting the procedure. During the insertion phase, the colon will be irrigated with warm water (32C-35C). WE entails the infusion of water to open the lumen and simultaneous suction if the endoscope has two channels, and sequentially if the endoscope has only one channel. When the cecum is reached and after most of the water is suctioned to collapse the cecal lumen, CO2 will be opened. The colonoscope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The colonoscope will then be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
16379299|NCT04124393|Active Comparator|CO2 Insufflation Colonoscopy|In the CO2 group, colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the colonoscope will be withdrawn from the cecum to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then, the colonoscope will be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
16379300|NCT04124380|Experimental|Imaginal Exposure First, then Alcohol Skills|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. After imaginal exposure, alcohol skills targeting alcohol misuse after sexual assault.
16379301|NCT04124380|Experimental|Alcohol Skills First, then Imaginal Exposure|Alcohol skills targeting alcohol misuse after sexual assault. After alcohol skills training, imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault.
16379302|NCT04124380|Active Comparator|Supportive Counseling/Telehealth|Internet-based intervention focusing on providing support.
16379303|NCT04124380|Experimental|Alcohol Skills First, no additional treatment|Alcohol skills targeting alcohol misuse after sexual assault only. No additional treatment.
16379304|NCT04124380|Experimental|Imaginal Exposure First, no additional treatment|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. No additional treatment.
16379305|NCT04124367|Active Comparator|Verum|
16379306|NCT04124367|Placebo Comparator|Control|
16379307|NCT04124354|Experimental|Immediate Experimental Group|Participants will immediately begin an experimental supervised moderate-intensity treadmill walking intervention program.
16379308|NCT04124354|No Intervention|Delayed Intervention Control Group|Participants will be asked to maintain their usual physical activity during the initial 8-week intervention period but will undergo all data collection procedures. Following the initial intervention period, these participants will be given the option to complete the 8-week intervention, with identical data collection procedures employed.
16379309|NCT04124341|Experimental|Epidural Prefrontal Cortical Stimulation (EpCS)|Stereotactically implanted bilateral EpCS
16379310|NCT04124328|Active Comparator|ALINE only group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria
16379311|NCT04124328|Active Comparator|VoM group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion
16379312|NCT04124315||PAD Patients Completing SET|This single-group study includes patients with peripheral artery disease (PAD) who are completing a physician-prescribed supervised exercise training (SET) program.
16379313|NCT04124302|Active Comparator|IPF|Total meal bolus will consist of insulin for carbohydrates (IC) and insulin for proteins and fats (IPF) based on individual insulin-to-carbohydrate ratio (ICR). Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
16379314|NCT04124302|Experimental|30%IC|Total meal bolus will consist of insulin for carbohydrates (IC) calculated based on individual insulin-to-carbohydrate ratio (ICR) and insulin for proteins and fats (IPF) estimated as 30% of IC. Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
16379315|NCT04124289||Pain post surgery|Patients who have completed surgery will be assessed with three types of pain scales. A new pain scale, a functional pain scale (FPS), will be compared to two pain scales that are routinely used: the FACES pain scale and the numeric rating scale (NRS).
16379316|NCT04124276|Experimental|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day) for 6 weeks
16379317|NCT04124276|Placebo Comparator|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
16379318|NCT04124263|Experimental|Medication Time Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
16379319|NCT04124263|Experimental|Educational Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
16379320|NCT04124224||Unidos Participants|In the Unidos intervention the county/community-based CHWs will: 1) support and connect participants to health promotion resources; 2) provide individual and group-based support guided by a novel framework for understanding Latino's health advantages, the sociocultural resiliency model; and, 3) leverage community resources to help individuals address SDH-related needs.
16379321|NCT04124224||Non-Unidos Participants: Comparison Group|Using propensity score matching, the investigators will use the medical records of Unidos participants and the electronic health record comparison group to compare health outcomes.
16379322|NCT04124211|Experimental|FMT Arm|10 Participants will be enrolled in this arm to receive FMT treatment
16379323|NCT04124198|Experimental|Transoral robotic surgery (TORS)|
16379357|NCT04123951|No Intervention|Control|"In this arm patients will continue 'as normal' with daily activities.
~Patients in this arm will be offered the exercise intervention once they have completed post 12 week assessments."
16379837|NCT04120376|Experimental|Counseling Intervention|All participants will receive contraception counseling.
16379326|NCT04124172|Active Comparator|Real rTMS|"rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). M1 is defined like the hot spot to elucidated a motor evoked potential in the Abductor Pollicis Brevis (APB) muscle of the contralateral hand. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
16379327|NCT04124172|Sham Comparator|Sham rTMS|"Sham rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). Investigators will make the simulation disconnecting the coil but keeping its position during the same time as the real one. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
16379328|NCT04124146||Patients with Surgery more than 10 years|Patients with surgery for spinal lumbar stenosis between 2006 and 2008 will be purposed to participate to the study.
16379331|NCT04124107|Experimental|Prostate biopsy with 68Ga-PSMA PET/MRI|Both targeted biopsy and 12-core systematic biopsy with positive 68Ga-PSMA PET/MRI
16379332|NCT04124094|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg|Test Product
16379333|NCT04124094|Active Comparator|SERETIDE DISKUS 100/50|reference Product
16379334|NCT04124081|Experimental|Drug group|
16379335|NCT04124068|Experimental|GLO Science Professional Chairside Teeth Whitening|
16379336|NCT04124068|Experimental|GLO Science Professional At-Home Teeth Whitening Device|
16379337|NCT04124068|Experimental|GLO Brilliant At-Home Teeth Whitening Device|
16379338|NCT04124068|Experimental|GLO Lit At-Home Teeth Whitening Device|
16379339|NCT04124068|Experimental|GLO Lit Whitening GLO Vials|
16379340|NCT04124055|Experimental|Therapeutic drug monitoring (TDM)|Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples
16379344|NCT04124029||Younger mild Traumatic Brain Injury|mTBI subjects aged 30-59 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the Test of Memory Malingering (TOMM) and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
16379345|NCT04124029||Older mild Traumatic Brain Injury|mTBI subjects aged 60- 90 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
16379346|NCT04124029||moderate Traumatic Brain Injury|TBI control subjects, age-, education- and sex-matched with mTBI subjects (aged 30-90) will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). Moderate TBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
16379347|NCT04124029||Mild Cognitive Impairment (MCI)|MCI control subjects, age-, education- and sex-matched with older mTBI subjects (aged 60-90) will be recruited if they meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria. Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function (i.e. will not meet diagnostic criteria for dementia). MCI subjects will be matched for their Montreal Cognitive Assessment (MoCA) score with older mTBI subjects. Of note, subjects with MCI may or may not meet diagnostic criteria for MCI due to AD. The intent of this control group is to recruit a broad range of MCI subjects without TBI as controls for subjects with cognitive impairment who have a history of mTBI.
16379348|NCT04124029||Younger Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with younger mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
16379349|NCT04124029||Older Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with older mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
16379350|NCT04124016|Experimental|Inulin|Inulin_ extract of chicory fermentable fiber
16379351|NCT04124016|Experimental|green tea extract|green tea extract_rich in tri-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursor)
16379352|NCT04124016|Experimental|grape seed|grape seed extract - rich in di-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursors)
16379353|NCT04124016|Experimental|grape seed exctract|grape seed extract - rich in di-hydroxylated flavan-3-ol oligomers (1 mmol of PVL precursors)
16379354|NCT04124003|Experimental|rosuvastatin + BMS-963272|
16379355|NCT04123990|Experimental|IBD|
16379356|NCT04123951|Experimental|Home-based Exercise|Patients in this arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
16379358|NCT04123938|Experimental|Pea Protein|Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
16379359|NCT04123938|Active Comparator|Whey Protein|Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
16379360|NCT04123938|Placebo Comparator|Maltodextrin|Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
16379361|NCT04123925|Experimental|Nivolumab|Patients will receive nivolumab at a flat dosage of 240 mg every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to +7 days
16379362|NCT04123912|Experimental|KT-FMPT group|
16379363|NCT04123912|Placebo Comparator|Control group|
16379364|NCT04123899|Experimental|IGAD→GSTD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
16379365|NCT04123899|Experimental|GSTD→IGAD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
16379366|NCT04123886|Experimental|SCB-313|
16379367|NCT04123873|Experimental|Group A|"Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus placebo (matching DXM) IV administered after induction of anaesthesia"
16379368|NCT04123873|Experimental|Group B|"Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus DXM 24 mg IV after induction of anaesthesia"
16379369|NCT04123873|Experimental|Group C|"Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus DXM 24 mg IV after induction of anaesthesia"
16379370|NCT04123873|Experimental|Group D|"Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus DXM 24 mg IV after induction of anaesthesia"
16379371|NCT04123860|Experimental|buccal fat pad|will undergo sinus lifting using intralift technique then placement of buccal fat pad followed by immediate implant placement.
16379372|NCT04123860|Active Comparator|prf|will undergo sinus lifting using intralift technique the prpration of PRF and immediate implant placement.
16379373|NCT04123847|Experimental|Stand, Step and Voluntary Training|
16379374|NCT04123834|Experimental|implantless Arthroscopic ACL reconstruction|implantless Arthroscopic ACL reconstruction using press-fit femoral technique
16379375|NCT04123834|Experimental|Arthroscopic ACL reconstruction with implant|ACL reconstruction with implant (hamstring autograft fixed with bioscrew and endo-button)
16379376|NCT04123821|Experimental|Group A|
16379377|NCT04123821|No Intervention|Group B|
16379378|NCT04123808|Experimental|IpsiHand Treatment|All participants will receive treatment with IpsiHand device
16379379|NCT04123795|Experimental|Cohort A - certolizumab pegol|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent 104-Week Open-Label Extension Period.
16379380|NCT04123795|Placebo Comparator|Cohort A - placebo|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of placebo from Week 1 to 16 and certolizumab pegol to Week 52 and through the subsequent 104-Week Open-Label Extension Period.
16379381|NCT04123795|Experimental|Cohort B - certolizumab pegol|Enrolling study participants aged 6 to 11 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent 104-Week Open-Label Extension Period.
16379382|NCT04123782|Active Comparator|Group A (F-ESWT group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.12 mJ/mm2 per session)
16379383|NCT04123782|Placebo Comparator|Group B (placebo group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.01 mJ/mm2 per session)
16379384|NCT04123769|Experimental|Drug group|
16379385|NCT04123743|Experimental|Experimental Group|The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.
16379386|NCT04123743|Placebo Comparator|Control Group|The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33
16379387|NCT04123730|Active Comparator|Fixed dose oxygen|O2Matic deliver the usual fixed-dose oxygen treatment during walking.
16379388|NCT04123730|Experimental|Automated oxygen titration|O2Matic deliver a variable oxygen dosage set at an SpO2-target of 90 to 94 % and a O2-flow of 0 - 15 liters/min during walking.
16379389|NCT04123717|Active Comparator|Arm1 - IV Ibuprofen|Patients will receive IV Ibuprofen 10 mg/kg to a maximum of 400 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with 100 ml normal saline.
16379390|NCT04123717|Active Comparator|Arm 2 -IV Paracetamol|Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with normal saline.
16379391|NCT04123717|Active Comparator|Arm 3- Both IV Paracetamol and IV Ibuprofen|Patients will receive an infusion of both IV Paracetamol and IV Ibuprofen. They will initially receive IV Ibuprofen and the IV catheter will then be flushed with 10 ml of normal saline, and the patient will receive IV Paracetamol
16379392|NCT04123717|Active Comparator|Arm 4 -PO Brufen|Patients will receive PO ibuprofen given as a 100mg/5ml syrup or 200 mg tablets to a maximum of 400 mg. The treating nurse will ask the parental preference to use syrup or tablets. If they vomit the medication within 15 minutes of administration, another full dose will be administered.
16379393|NCT04123704|Experimental|Sitravatinib|Sitravatinib 120 mg daily
16379423|NCT04123496|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379394|NCT04123678||All|Patients attending a Medical Photography facility with at least 1 suspicious skin lesion will be approached to participate in the study. Participants will have an additional macro and dermoscopic image of each suspicious skin lesions suitable for photography. Photographs will be taken by a healthcare professional using an iPhone XR smart phone camera with a DL1 dermoscopic lens attachment. The images will be encrypted and electronically transmitted to Skin Analytics' cloud servers for analysis by DERM. The suspected diagnosis determined by DERM will be compared with dermatologist review and histologically confirmed diagnosis, where obtained. Healthcare resource utilization information and patient satisfaction data will also be collected
16379395|NCT04123665|Experimental|Experimental Test Dentifrice|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
16379396|NCT04123665|Placebo Comparator|Control Dentifrice|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate [SMFP] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
16379397|NCT04123652|Other|Lidocaine and ketamine infusion|
16379398|NCT04123626|Experimental|QR-1123 Single dose - dose level 1|Open label Single dose cohort: dose level 1
16379399|NCT04123626|Experimental|QR-1123 Single dose - dose level 2|Open label Single dose cohort: dose level
16379400|NCT04123626|Experimental|QR-1123 Single dose - dose level 3|Open label Single dose cohort: dose level 3
16379401|NCT04123626|Experimental|QR-1123 Single dose - dose level 4|Open label Single dose cohort: dose level 4
16379402|NCT04123626|Experimental|QR-1123 Single dose - dose level 5|Open label Single dose cohort: dose level 5
16379403|NCT04123626|Experimental|Repeat dose cohort 1|Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
16379404|NCT04123613|Experimental|2.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
16379405|NCT04123613|Experimental|5.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
16379406|NCT04123587|Experimental|Sulfonylurea-dependent|Sulfonylurea is replaced by alternative oral hypoglycemic agent.
16379407|NCT04123574|Experimental|Single Arm|BXCL701 will be administered for one week at a dose of 0.2 mg, twice daily (BID). If BXCL701 is well-tolerated after the first week of treatment, the dose will be increased to 0.3mg BID for a total daily dose of 0.6mg to all patients for the second week of treatment.
16379408|NCT04123561|Experimental|TLC599|TLC599 (1mL) IA injection
16379409|NCT04123561|Active Comparator|Dexamethasone sodium phosphate|DSP 4mg (1mL) IA injection
16379410|NCT04123561|Placebo Comparator|Normal Saline|Normal saline (1mL) IA injection
16379411|NCT04123535|Experimental|Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|Pre-operative MRgFUS with the ExAblate 2000/2100 MRgFUS system 1-4 weeks prior to surgical resection of their tumor
16379412|NCT04123522||anterior cervical spine surgery|The patients will be enrolled for elective anterior cervical spine surgery.
16379413|NCT04123522||posterior cervical spine surgery|The patients will be enrolled for elective postieor cervical spine surgery
16379414|NCT04123496|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is 5 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379415|NCT04123496|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379416|NCT04123496|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379417|NCT04123496|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379418|NCT04123496|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379419|NCT04123496|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379420|NCT04123496|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379421|NCT04123496|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379422|NCT04123496|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 45 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16379485|NCT04123028||eosinophilic COPD patient|COPD patient with blood eosinophil equal or > 300 cells/µL
16379424|NCT04123483|Experimental|EnBrace HR for Acute Treatment of PMS and MRMD|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 weeks. Participants are currently experiencing clinically significant MRMD symptoms, defined as a ≥ 30% increase in the total Daily Record of Severity of Problems Scale (DRSP) score from the mid-follicular phase (average of DRSP scores for days 6-10) to the late-luteal phase (average of DRSP scores for last 5 days prior to menstrual bleeding).
16379425|NCT04123470|Experimental|Treatment|Delolimogene mupadenorepvec plus atezolizumab
16379426|NCT04123444|Experimental|Iloprost|Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
16379427|NCT04123444|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
16379428|NCT04123431||ACE Acetabular Cup System with XLPE Liner|
16379429|NCT04123431||ACE Acetabular Cup System with Ceramic Liner|
16379430|NCT04123431||ACE Acetabular Cup System with Dual Mobility Insert|
16379431|NCT04123418|Experimental|WVT078 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
16379432|NCT04123418|Experimental|WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
16379433|NCT04123405|Experimental|acetylcysteine 600 mg|600 mg acetylcysteine: one tablet test product plus three tablets placebo per day
16379434|NCT04123405|Experimental|acetylcysteine 1200 mg|two tablets test product plus two tablets placebo per day
16379435|NCT04123405|Experimental|acetylcysteine 2400 mg|four tablets test product per day
16379436|NCT04123405|Placebo Comparator|Placebo|four tablets placebo per day
16379437|NCT04123392|Experimental|Decitabine + BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, Decitabine +BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16379438|NCT04123392|Active Comparator|BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16379439|NCT04123379|Experimental|Cohort A|NSCLC: Nivolumab + BMS-813160
16379440|NCT04123379|Experimental|Cohort B|NSCLC: Nivolumab + BMS-986253
16379441|NCT04123379|Experimental|Cohort C|HCC: Nivolumab
16379442|NCT04123379|Experimental|Cohort D|HCC: Nivolumab + BMS-813160
16379443|NCT04123379|Experimental|Cohort E|HCC: Nivolumab + BMS-986253
16379445|NCT04123340|Experimental|Additional intraprocedural CT-scan|Additional intraprocedural CT-scan
16379446|NCT04123314|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
16379447|NCT04123301|Active Comparator|Active TBS Arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
16379448|NCT04123301|Sham Comparator|Sham TBS Arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
16379449|NCT04123288|Experimental|Test drug formulation|Test drug 60 mg single dose
16379450|NCT04123288|Active Comparator|Reference drug formulation|60 mg single dose
16379451|NCT04123262|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
16379452|NCT04123249|Experimental|Group Propofol|In the Group P, propofol 4-6 mg/kg/h and remifentanil 0.2μg/kg/min were infused by intravenous pump separately for assisted sedation and assisted analgesia.
16379453|NCT04123249|Experimental|Group Sevoflurane|sevoflurane (concentration: 2%-3%, mixed with 50% air and 50% oxygen to keep the minimum alveolar concentration (MAC) at 1.0-1.1) was inhaled to maintain assisted sedation, and remifentanil 0.2 μg/kg/min was infused by intravenous pump for assisted analgesia.
16379454|NCT04123236||Oral Health Impact Profile|To evaluate the Oral Health-related Quality of Life, Turkish version of Oral Health Impact Profile-14 was used. Responses were made on a scale 0 (never), 1(hardly ever), 2 (occasionally), 3 (fairly often),and 4 (very often).Oral Health-related Quality of Life impairment was characterized by the Oral Health Impact Profile-14 summary score (the sum of all 14 items, potential range 0-56). Higher Oral Health Impact Profile-14 scores mean worse Oral Health-related Quality of Life and vice versa.
16379455|NCT04123236||Helkimo's anamnestic dysfunction index|As a method based on patient feedback for the determination of the degree of temporomandibular disorders, anamnestic index was used. For this purpose eight questions were asked to the patients that includes answers as 'yes' or 'no'. (Table 2) The analyses of the questionnaire was done according to anamnestic scale as 0: no symptoms; I: mild symptoms (sensation of the jaw fatigue, jaw stiffness, and temporomandibular joint sounds as clicking or crepitus) and II:severe symptoms (included one or more of the following: Difficulty in the mouth opening, jaw locking, mandible dislocation and its painful movement and painful temporomandibular joint region and/or masticatory muscles)
16379456|NCT04123236||Visual analog scale (VAS) for facial pain:|Facial pain was measured by asking the patients if they had had any pain during last 12 months and made them mark the intensity of the pain on a visual analog scale which had the anchor points at the left (no pain) and right (worse pain) ends of a 10 cm horizontal line. The analyses of the facial pain was done as fallowing: if the patient marked no facial pain the Visual analog scale value was accepted as 0 and if the patient marked any level of facial pain Visual analog scale value was accepted as 1.
16379486|NCT04123028||non-eosinophilic COPD patient|COPD patient with blood eosinophil < 300 cells/µL
16379457|NCT04123236||Helkimo's clinical dysfunction index (DI):|Maximum opening of mandible, deviation during opening, dysfunction of temporomandibular joint, pain in the temporomandibular joint and pain in the masticatory muscles was evaluated
16379458|NCT04123223|Experimental|Restorative CR Intervention|The restorative remediation intervention will consist of a target of 50 hours (5 hours per week, 1 hour per day, over 3 months) of a sequence of computerized cognitive exercises designed to improve cognitive function through repeated drill-and-practice of exercises largely focused on attention, working memory and verbal episodic memory. Cognitive deficits will be directly targeted by these exercises. Exercises will be started at individually determined levels of difficulty at which each client will be successful, e.g., 80% accuracy. Task difficulty will be increased as performance improves.
16379459|NCT04123223|Experimental|Strategy CR Intervention|Participants in this intervention will be treated for 24 hours (2 hours per week, one day per week over 3 months) with Compensatory Cognitive Training (CCT). The therapy targets four cognitive domains: (a) prospective memory, (b) attention and vigilance, (c) learning and memory, and (d) executive function. The program is a group-based intervention that teaches strategies via interactive, game-like activities to maintain interest and enhance motivation and engagement.
16379460|NCT04123223|Placebo Comparator|Computer Games|Three months of 1-hour, 5-times per week, client-selected computer games.
16379461|NCT04123210|Experimental|Vitamin A supplement|Subjects receive a vitamin A supplement containing 175 or 525 micrograms of vitamin A as retinyl palmitate daily
16379462|NCT04123210|Placebo Comparator|Placebo|Subjects receive an oil placebo containing no vitamin A
16379463|NCT04123197|Other|Young Participants with Prior MI|Participants aged 60 or less who experienced a MI within the last 8 months will undergo a stress challenge to assess MSI and will then be followed for 3 years.
16379464|NCT04123171||The Three Villages Cohort|Individuals aged 60 years or more identified by means of door-to-door surveys, living in Atahualpa, El Tambo, and Prosperidad. Individuals will be interviewed with validated field instruments, and there will be invited for the practice of complementary exams to recognize markers of aterosclerosis and cerebral small vessel disease.
16379465|NCT04123158||WHITE|If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
16379466|NCT04123158||GREEN|"Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.
~If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card
~In case of negative Orange Criteria (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of positive Orange Criteria the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately."
16379467|NCT04123158||ORANGE|- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
16379468|NCT04123145|Experimental|CDK-ND|
16379469|NCT04123132||Patients with metabolic syndrome|
16379470|NCT04123132||Healthy controls|
16379471|NCT04123119|Experimental|Rotarix Arm|
16379472|NCT04123106|Experimental|ESP block|Ultrasound-guided, performed below erector spinae plane (ropivacaine 0.5% 20 mL each side).
16379473|NCT04123106|Active Comparator|Wound infiltration|Ropivacaine 0.5% 20-40 mL, performed by surgeon.
16379474|NCT04123093|Experimental|Healthy Volunteers|The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
16379475|NCT04123093|Experimental|Wound care|The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
16379476|NCT04123080|Experimental|EBL group|Removal of large long-stalked pedunculated colonic polyps using band ligations
16379477|NCT04123067|Experimental|Pioglitazone treatment group|oral administration of 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
16379478|NCT04123067|Placebo Comparator|Placebo group|Oral administration of placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
16379479|NCT04123054|Active Comparator|Sensor-Augmented MDI + Mobile App (control)|Participants will continue their usual multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data.
16379480|NCT04123054|Experimental|Sensor-Augmented MDI + Mobile App + Basal-Bolus Optimization Algorithm|Participants will undergo multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data. Every week, participants' insulin doses will be updated by the optimization algorithm's recommendations.
16379481|NCT04123041|Experimental|Virginia Tobacco|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Virginia Tobacco ENDS, JUUL 3% Virginia Tobacco ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
16379482|NCT04123041|Experimental|Mint|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mint ENDS, JUUL 3% Mint ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
16379483|NCT04123041|Experimental|Menthol|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Menthol ENDS, JUUL 3% Menthol ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
16379484|NCT04123041|Experimental|Mango|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mango ENDS, JUUL 3% Mango ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
16379487|NCT04123002|Experimental|Interventional group|Miswak chewing sticks would be provided to the participants and they would be explained the method of use
16379488|NCT04123002|No Intervention|Comparison group|They would use only tooth brush and paste
16379489|NCT04122989|Experimental|MS-SUPPORT|Group receives access to an online shared decision making tool (an interactive decision aid) for multiple sclerosis.
16379490|NCT04122989|No Intervention|Control|Usual care
16379491|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
16379492|NCT04122963|Active Comparator|High power group|The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).
16379493|NCT04122963|Active Comparator|Standard group|The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)
16379494|NCT04122950|Experimental|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
16379495|NCT04122950|No Intervention|Control|Continue with normal daily routine.
16379496|NCT04122937||Ovarian cancer|Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.
16379497|NCT04122937||Colon cancer|Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).
16379498|NCT04122924|Experimental|Intervention Group|A three months home-based abdominal muscle training program.
16379499|NCT04122924|No Intervention|Control Group|The control group will have no intervention, and will be asked not to attend any specific supervised abdominal muscle training program during the 3 months intervention period.
16379500|NCT04122911|Experimental|Temozolomide|Temozolomide 75mg/m2 metronomic schedule: one week on/one week off in a cycle of 28 days
16379501|NCT04122898|Experimental|Intervention Group|Three months home-based PFM training program with weekly follow-up by a physiotherapist
16379502|NCT04122898|No Intervention|Control Group|No intervention
16379503|NCT04122885||CRS and HIPEC|Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
16379504|NCT04122885||PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
16379505|NCT04122872||Patients with bone or soft tissue sarcomas or carcinosarcomas|Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone [GCTB], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
16379506|NCT04122859|Active Comparator|Zip Skin Closure Device|The device is a class IIa device as per Annex II of the MDD 93/42EEC, as amended by Directive 2007/47/EEC. A CE-mark was affixed in 2014. The Zip device adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives. A combination of acrylic and hydrocolloid adhesives is used to provide a skin-friendly environment while providing the necessary tack to maintain skin adhesion during a maximum wear time of 14 days. In addition to the pressure-sensitive adhesives, the device's closure and force distribution components are made up of polyurethane monofilm, polyethylene tape, polyester and nylon.
16379507|NCT04122859|Active Comparator|Standard of Care Sutures|Conventional sutures used for laceration repair
16379508|NCT04122846|Experimental|Treatment (Emotional Awareness and Expression Therapy)|Internet-based Emotional Awareness and Expression Therapy
16379509|NCT04122820|Other|Presence of HV-Labile|Presence of vertical heterophoria labile with proprioceptive Maddox
16379510|NCT04122820|Other|Absence of HV-Labile|Presence of stable vertical heterophoria or stable orthophoria with proprioceptive Maddox
16379511|NCT04122807|Active Comparator|Mapping|Standard treatment involving ablation of the slow pathway with cryotherapy
16379512|NCT04122807|Experimental|Ablation|Mapping and ablation of the retrograde fast pathway with cryotherapy
16379513|NCT04122781|Experimental|with novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation and novel K-wire fixation devices
16379514|NCT04122781|Active Comparator|without novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation
16379515|NCT04122768|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
16379516|NCT04122768|Sham Comparator|Sham coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application.
16379517|NCT04122755|Experimental|Cohort1|Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).
16379518|NCT04122755|Experimental|Cohort2|Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose
16379519|NCT04122755|Experimental|Cohort3|Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose
16379520|NCT04122755|Experimental|Cohort4|Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose
16379521|NCT04122755|Experimental|Cohort5|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose
16379522|NCT04122755|Experimental|Cohort6|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing
16379523|NCT04122742||Patients with RSTS|
16379524|NCT04122716|Active Comparator|Liraglutide + exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.
~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
16379553|NCT04122456|Experimental|Night Shift Work Schedule|Night shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
16379525|NCT04122716|Other|Liraglutide + non-exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.
~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
16379526|NCT04122716|Other|Placebo + exercise|"Placebo: 3mg/day sc.
~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
16379527|NCT04122716|No Intervention|Placebo + non-exercise|"Placebo: 3mg/day sc.
~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
16379528|NCT04122703|Experimental|Percutaneous tibial nerve stimulation (PTNS)|The patients in the PTNS group will receive 1 PTNS treatments per week for 12 weeks.
16379529|NCT04122703|Sham Comparator|Transcutaneous electrical nerve stimulation (TENS)|The patients in the Sham group will receive one sham (TENS) treatment per week for 12 weeks
16379530|NCT04122690|Experimental|Partnered Dance Aerobic Exercise|Partnered Dance-Aerobic Exercise (PDAE) is an adapted form of Argentine tango, aka Adapted tango. Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
16379531|NCT04122690|Active Comparator|Walking Aerobic Exercise|Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
16379532|NCT04122664|Active Comparator|RayOne® Hydrophilic lens 600C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophilic lens 600C
16379533|NCT04122664|Active Comparator|RayOne® Hydrophobic lens 800C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophobic lens 800C
16379534|NCT04122651|Experimental|Experimental Arm|Patients will be receiving a toric intraocular lens with either a 2.00 or 4.00 diopter (D) correction, depending on the degree of pre-operative astigmatism, and the astigmatic refractive error will be refined with the use of adjunctive limbal relaxing incisions LRIs and/or off axis rotation of the toric IOL (based on a standardized protocol) so the full amount of corneal astigmatism can be targeted for correction for each patient.
16379535|NCT04122651|Active Comparator|Control Arm|The patient will receive a toric intraocular lens individually tailored to and ordered for each patients' precise degree of corneal astigmatism.
16379537|NCT04122599|Other|Melatonin versus standard care|Melatonin is tested versus standard care
16379538|NCT04122586|No Intervention|health control group|
16379539|NCT04122586|Experimental|Tongxieyaofang granule group|
16379540|NCT04122573||Acute chest pain|The population in this study are characterized by acute chest pain as the first symptom for consultation within 24 hours.
16379541|NCT04122560|Experimental|Obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg
~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
16379542|NCT04122560|Active Comparator|Non-obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg
~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
16379543|NCT04122547|Active Comparator|Roflumilast|Roflumilast 500 microgram one tab oral per day
16379544|NCT04122547|Placebo Comparator|Placebo|One tablet oral per day
16379545|NCT04122534|Experimental|Treatment Group|Treatment groups receives the intervention training.
16379546|NCT04122521||Glioma|Patients suspected of glioma
16379547|NCT04122495|Experimental|Probiotic|Bifidobacterium lactis M8 at 10 log CFU/day for 4 weeks
16379548|NCT04122495|Placebo Comparator|Placebo|Intervention consists of daily administration of 1g of maltodextrin, administered daily for 4-weeks
16379549|NCT04122482|Experimental|Intervention Group|In this arm, participants will be given access to the course material shortly after eligibility criteria is confirmed. They will be asked to complete post-measures questionnaires at 4 weeks and 8 weeks following completion of the course material.
16379550|NCT04122482|Experimental|Wait-list Control|In this arm, participants will be given access to the course material 8 weeks following confirmation of their eligibility. During, the 8-week waiting period they will be asked to complete questionnaires at 4 weeks and 8 weeks. At 8 weeks they will be given access to the course material and will be asked to complete the same questionnaires 4- and 8-weeks following completion of the course material.
16379551|NCT04122469|Experimental|Intervention|Receiving SBRT.
16379552|NCT04122456|Experimental|Day Shift Work Schedule|Day shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
16379556|NCT04122430||GCT treated with first line chemotherapy|"Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT
~."
16379557|NCT04122417||Control Group|"The mothers and infants in the experimental and control groups were assigned to the groups by randomization method. Therapeutic touch didn't apllied to control group.
~Babies in the control group who took care practices in accordance with normal hospital procedures."
16379558|NCT04122417||Yakson Group|"The touch method was taught to the mothers in the Yakson group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.
~In yakson method, mother's fingers are closed, and she should touch in a way that does not apply excessive pressure. The method is applied for a total of 15 minutes in three cycles. First 5 minutes is resting the hand, 5 minutes is gentle caressing, and another 5 minutes of resting the hand."
16379559|NCT04122417||Gentle Human Touch Group|"The touch method was taught to the mothers in the Gentle Human Touch group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.
~Mother slowly places one hand on the baby's hand and the other over pelvic cavity, covering the waist and hips of the baby.
~The touch is preserved for 15 minutes. In order to ensure equal touch for the duration of gentle human touch, the mother sits on a stool and her elbows have to be at the same level with baby's bed"
16379560|NCT04122404|Other|Intervention|"Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture) + Intervention
~Intervention: LF-LAM is made available at the study site for the clinical staff to use; Training of clinical staff in national TB guidelines and LF-LAM use together with staff from the National TB Programme in Ghana"
16379561|NCT04122404|No Intervention|Standard of care|Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture)
16379562|NCT04122391||control|team will work in OR with volume of 85 dB
16379563|NCT04122391||intervention|team will work in OR with volume of 100 dB
16379564|NCT04122378|Experimental|Treatment Arm|Acupuncture will be provided up to once daily for one or more days till the day of discharge or 5 days, whichever occurs first. Patients will continue to receive their standard pain management regime including IV opioids, ketorolac and fluids. Minimum number of sessions received by the acupuncture group will be one.
16379565|NCT04122378|No Intervention|Control Arm|Standard of care for SCD patients who are hospitalized for acute pain and typically includes IV opioids, ketorolac and fluids.
16379566|NCT04122365|Experimental|Interventional group|Chest Wall Mobilization Program
16379567|NCT04122365|Other|Control Group|Routine limbs exercises and education
16379568|NCT04122352|Experimental|Exercises + ischemic compression group|volunteer patients with temporomandibular joint dysfunction with trigger points
16379569|NCT04122352|Other|Exercises group|volunteer patients with temporomandibular joint dysfunction with trigger points
16379570|NCT04122339|Experimental|MAX-10181|tablet
16379571|NCT04122326|Experimental|Posture Sequence|Participants will complete computer work on a provided monitor and keyboard for two hours. During the first hour, the research personnel will alter the workstation every ten minutes to test various different postures of the neck, shoulder, arms, and trunk. The sequence will include 3 seated postures and 3 standing postures. At the end of the first hour, the participant will be instructed to adjust the workstation independently and continue to work for 60 minutes for an observational session.
16379572|NCT04122313||Patients with Dupuytren's Contracture Disease|Patients with Dupuytren's Disease following the current treatment pathway
16379573|NCT04122300|Experimental|Euphrasia arm|Euphrasia eye drops® (Weleda AG, Arlesheim) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
16379574|NCT04122300|Placebo Comparator|Placebo arm|Placebo (0.9% NaCl) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
16379575|NCT04122287|Experimental|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
16379576|NCT04122287|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
16379577|NCT04122274|Sham Comparator|Education Sheet and Sham Intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of the sham intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
16379578|NCT04122274|Experimental|Education Sheet and Decision-based interactive intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of a decision- based interactive concussion education platform intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
16379581|NCT04122248||M6-C|Subjects treated with an M6-C device
16379582|NCT04122248||ACDF|Subjects treated with Anterior Cervical Discectomy and Fusion (ACDF)
16379583|NCT04122235|Experimental|Intervention arm|New follow-up model
16379584|NCT04122235|No Intervention|Control arm|Usual care
16379585|NCT04122222|Active Comparator|Hemodialysis|ESRD patients treated by hemodialysis
16379586|NCT04122222|Active Comparator|Hemodiafiltration|ESRD patients treated by on-line hemodiafiltration
16379587|NCT04122209|Experimental|HIIE-First|60-min of exercise split into; firstly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest). Secondly 30-min of continuous exercise (50% peak maximal oxygen uptake).
16379894|NCT04120038|Experimental|SMART & Peer Support|
16379588|NCT04122209|Experimental|Continuous-First|60-min of exercise split into; firstly 30-min of continuous exercise (50% peak maximal oxygen uptake). Secondly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest)
16379591|NCT04122183|Experimental|Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation) and asked to complete the iManage Program. Six months after the screening participants will be asked if they visited an audiologist.
16379592|NCT04122183|No Intervention|Delayed Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation). Six months after the screening participants will be asked if they visited an audiologist and they will be given the opportunity to complete the iManage Program.
16379593|NCT04122170|Active Comparator|PB2452|PB2452 18 g Intravenous Infusion over a 16 hour duration.
16379594|NCT04122170|Placebo Comparator|Placebo|Placebo (0.9% Sodium chloride) intravenous Infusion over a 16 hour duration.
16379595|NCT04122144|Experimental|Intervention|ENHANCED-SPS intervention implemented
16379596|NCT04122144|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV care visits at the health facilities include ART card documentation as required, general/routine counseling, and adherence counseling to the non suppressors, ART drug supply based on the clinicians prescription and laboratory monitoring.
16379597|NCT04122118|Experimental|Hearth services research (pharmacist-led education)|"PHASE I: Patients' medical records are reviewed.
~PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider."
16379598|NCT04122105|Experimental|intervention|sildenafil administration perioperative to renal transplant
16379599|NCT04122105|Active Comparator|control|renal transplant recipients
16379600|NCT04122092||MM patients have curative effect at least VGPR|We will detect cfDNA CIN of multiple myeloma patients who have the curative effect at least very good partial response (VGPR) after front line therapy, and then monitoring cfDNA CIN every two treatment cycles or every three months during follow up，the result will be compared with bone marrow aspiration MFC.
16379601|NCT04122079||Clinical|Patients receiving mental health treatment at the University outpatient clinic
16379602|NCT04122079||Students|University undergraduate students
16379603|NCT04122079||Community|Members of the community
16379604|NCT04122066||respiratory symptoms reported in studied patients|If Sofosbuvir\Daclatasvir regimen has respiratory side effects or not and the factors increase incidence of respiratory complications
16379605|NCT04122053|Experimental|study group|group will receive dietary advice and genotype information
16379606|NCT04122053|Active Comparator|Control group|group will receive dietary advice
16379607|NCT04122040|Active Comparator|roxithromycin|roxithromycin 300 mg oral per day
16379608|NCT04122040|Placebo Comparator|placebo|placebo one tablet per day
16379609|NCT04122027|Active Comparator|Control|Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
16379610|NCT04122027|Active Comparator|Intervention|Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
16379611|NCT04122014|Experimental|Control group|Usual daily activities
16379612|NCT04122014|Experimental|Training group|Each subject will participate in 2 sessions each week during 3 months.
16379613|NCT04122001|Experimental|Active HD-tDCS+word intervention then Sham+word intervention|Participants will receive active HD-tDCS + Word List Learning Intervention (WordLLI) and then receive Sham + WordLLI after a three-month washout period.
16379614|NCT04122001|Experimental|Sham+word intervention then active HD-tDCS+word intervention|Participants will receive Sham + Word List Learning Intervention (WordLLI) and then active HD-tDCS + WordLLI after a three-month washout period.
16379615|NCT04121988||Denoising MRI group|Patients suspected of Cushing disease undergoing deep learning based denoising MRI
16379616|NCT04121975|Experimental|Chemoradiotherapy|"Radiation:
~Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
~Drug: Endostar 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
~Drug: Cisplatin 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29."
16379617|NCT04121962|Experimental|Peer Mentor|Peer Mentor Training is 5 groups with a 30 day reunion session. This condition is focused on training participants with communication skills to promote HIV and STI home-based testing and treatment and pre-exposure prophylaxis (PrEP) to individuals in their social networks. Participants will also learn how to use the Star website to request home-based testing kits. Peer Mentor training is conducted by a two health educators. The sessions are held once a week and will last approximately 90 minutes.
16379618|NCT04121962|Active Comparator|Control|Participants will receive information on how to use the website to request at-home test kits
16379619|NCT04121949|No Intervention|Control group|The control group will receive standard-of-care treatment recommended by current ESC guidelines for patients with low to intermediate likelihood of stable CAD using the Diamond-Forrester (DF) score only: Rule-out if DF-score <15%; NIT if DF-score 15-85%.
16379620|NCT04121949|Experimental|Intervention group|The intervention group will undergo a modified diagnostic pathway where a CAD-score <30 rules out stable CAD in the group of patients having a DF-score <15% and a CAD-score ≤20 rules out stable CAD in the group of patients having a DF-score in the range 15-85%, and thus not tested with NIT. Otherwise NIT is performed.
16379621|NCT04121923|Experimental|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG) will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device.
16379650|NCT04121676|Experimental|2-Week Combination Therapy with AGEN2373 and AGEN2034|3+3 Dose escalation of AGEN2373 in combination with Balstilimab (AGEN2034) administered by IV.
16379651|NCT04121663|Experimental|Full seam anchor|
16379622|NCT04121910|Experimental|Savolitinib and/or Itraconazole|Treatment Period 1: Single administration of savolitinib (200 mg) will occur on Study Day 1 after a high-fat, high-calorie breakfast followed by PK sampling for 48 hours Treatment Period 2: Itraconazole will be administered (200 mg BID) on Study Day 15, and (200 mg QD) on Study Days 16 and 17, 1 hour before breakfast (and before dinner, when applicable) Treatment Period 3: A single combination of itraconazole (200 mg) 1 hour before breakfast + savolitinib (200 mg) after a high-fat, high-calorie breakfast on Study Day 18, and a single dose of itraconazole (200 mg) on Study Day 19, 1 hour before breakfast
16379623|NCT04121897|Experimental|TEMPO|The Therapist Education and Massage for Parent-Infant Outcomes program (TEMPO) is a structured, therapist-led physical therapy program. TEMPO trains and supports parents to deliver physical therapy interventions including massage and developmental play during hospitalization and in the home setting.
16379624|NCT04121884|Experimental|ART Treatment|A broad patient representation of male and female adults; aged > 18 years; English speaking; and significant clinical symptoms of any of the following conditions: PTSD, Depression, ASD, Complicated Grief, and Alcohol Abuse.
16379625|NCT04121858|Experimental|Brain Safe App|1)Brain Safe App provides conversation starters for older adult patients on target anticholinergics. The conversation starters assist the patient to have discussions with their physicians regarding reduction in exposure to prescription anticholinergics. 2) Provides anticholinergic risk assessment.
16379626|NCT04121858|Sham Comparator|Attention Control App|1) Attention Control App provides a medication list for older patients to use but lacks the conversation starters for patient to use with there physicians aimed at reduction in exposure to prescription anticholinergics.2) No anticholinergic risk assessment.
16379627|NCT04121845|Active Comparator|Treatment group|Coronary sinus reducer implantation through right internal jugular vein.
16379628|NCT04121845|Sham Comparator|Sham group|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
16379629|NCT04121832|Experimental|Case|"25 people with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio Hospital. All patients over the age of 18 will be included.
~Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Patients with cognitive difficulties and / or diagnoses of intellectual disability and male patients will not be included in the study. In addiction to standard therapies, the sample will be treated with 10 sessions of biofeedback training."
16379630|NCT04121832|Active Comparator|Controls|25 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio. All patients over the age of 18 will be included. Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Moreover, patients with cognitive difficulties and / or diagnoses of mental retardation and male patients will not be included in the study. The sample will be treated only with standard therapies without the use of biofeedback training
16379631|NCT04121819|Experimental|AraC|cytarabine 100mg/m2 d1-5 subcutaneous
16379632|NCT04121806|Experimental|Ulcerative colitis patients with mild to moderate activity|Participants will be followed for 14 days on their traditional diet followed by an 8 week intervention with the specially designed and provided treatment diet.
16379633|NCT04121793||Parkinson's Disease|Parkinson's Disease patients
16379634|NCT04121780|Experimental|Growth Hormone|Norditropin® (somatropin [rDNA origin] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).
16379635|NCT04121780|Placebo Comparator|Saline|Saline-placebo via auto-injector pens (Haselmeier Inc).
16379636|NCT04121767|Experimental|Edoxaban group|patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke
16379637|NCT04121767|Active Comparator|Warfarin group|patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke
16379638|NCT04121741|Active Comparator|Singing intervention 1|Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
16379639|NCT04121741|Active Comparator|Singing intervention 2|In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
16379640|NCT04121741|Sham Comparator|Control/sham intervention|"Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest."
16379641|NCT04121728|Other|Group Ginkgo-Placebo|Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.
16379642|NCT04121728|Other|Group Placebo-Ginkgo|Cross-over design:In Group Placebo-Ginkgo participants are allocated first to the placebo during 6 months and after 2 months of wash-out period are allocated the IMP Symfona® for 6 months.
16379643|NCT04121715|Active Comparator|standard medication|"standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
16379644|NCT04121715|Experimental|standard medication+fastigial nucleus stimulation|"fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.
~standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
16379645|NCT04121702|Active Comparator|PEP-H|Physical exercise program at a hospital
16379646|NCT04121702|Experimental|PEP-PSC|Physical exercise program with tele-monitoring in a public sport centre
16379647|NCT04121689|Experimental|Milk Protein Concentrate|Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate
16379648|NCT04121676|Experimental|4-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
16379649|NCT04121676|Experimental|2-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
16379653|NCT04121637|Experimental|Aerobic exercise+Frenkel coordination Study group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set. Following this, an aerobic exercise of 30 minutes will be performed on the bicycle ergometer with electronic brake. Subjects will be advised not to do any exercise two days before or on that day and to eat only a light meal at least two hours before the test. The intensity of the exercise will be adjusted based on maximum oxygen consumption (VO2 max) specific to each individual.
16379654|NCT04121637|Active Comparator|Frenkel coordination exercise group - Control group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set.
16379655|NCT04121611|Experimental|Optical coherence tomography confirmed residual thrombus|Early antithrombotics
16379656|NCT04121611|No Intervention|Optical coherence tomography confirmed no residual thrombus|Best medical management
16379657|NCT04121598||Normal Weight Control|Adolescents with a BMI percentile under 85%.
16379658|NCT04121598||Overweight/Obese Control|Adolescents with a BMI percentile at 85% or higher.
16379659|NCT04121598||Overweight/Obese Experimental|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes.
16379660|NCT04121585||SL-PLUS™ hydroxylapatite coated cement free hip stem|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
16379661|NCT04121559|Experimental|Intervention|A&T intervention areas: adolescent-nutrition-focused behavior change interventions delivered through government primary schools and communities
16379662|NCT04121559|No Intervention|Control|Comparison areas: standard activities at government primary schools
16379663|NCT04121546|Experimental|Treatment Arm|Patients will receive the telecare intervention.
16379664|NCT04121533|Placebo Comparator|Placebo|Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
16379665|NCT04121533|Experimental|Vitamin D|Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
16379666|NCT04121533|Experimental|Vitamin D, glucosamine sulfate, and omega-3 fatty acids|Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).
16379667|NCT04121520||Observational|At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.
16379668|NCT04121507|Experimental|alloSCT|defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)
16379669|NCT04121494|Experimental|Group A|BCG-vaccinated, 1x10^9 vp, aerosol
16379670|NCT04121494|Experimental|Group B|BCG-vaccinated, 5x10^9 vp, aerosol
16379671|NCT04121494|Experimental|Group C|BCG-vaccinated, 1x10^10 vp, aerosol
16379672|NCT04121494|Experimental|Group D|BCG-vaccinated, highest tolerated dose aerosol + placebo IM; Randomized with Group E, blind
16379673|NCT04121494|Experimental|Group E|BCG-vaccinated, highest tolerated dose IM + placebo aerosol; Randomized with Group D, blind
16379674|NCT04121494|Experimental|Group F|BCG-non vaccinated, highest tolerated dose, aerosol
16379675|NCT04121481|Placebo Comparator|Placebo|Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
16379676|NCT04121481|Active Comparator|Treatment Group|Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
16379677|NCT04121468|Other|Group A|"Placebo for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.
~Metformin for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
16379678|NCT04121468|Other|Group B|"Placebo for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.
~Metformin for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
16379679|NCT04121468|Other|Group C|"Placebo for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.
~Metformin for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
16379680|NCT04121455|Experimental|200 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
16379681|NCT04121455|Experimental|400 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
16379682|NCT04121455|Experimental|600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
16379683|NCT04121442|Experimental|Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor|Patients will receive specified dose of Isunakinra as monotherapy for three weeks, followed by combination with a PD-(L)1 inhibitor
16379684|NCT04121416|Experimental|Oxycodone group|
16379685|NCT04121416|Experimental|Sufentanil group|
16379686|NCT04121403|Active Comparator|Rituximab|Biosimilar rituximab concentrate for solution for infusion
16379687|NCT04121403|Active Comparator|Cladribine|Mavenclad oral cladribine tablets
16379688|NCT04121390||Newborn Parenting Class|New Mother who attended the Newborn Parenting Class
16379689|NCT04121390||New Mothers|New Mothers who expressed interest, but did not attend the Newborn Parenting Class
16379691|NCT04121364|Experimental|Tetranite|All patients enrolled in study will receive the dental adhesive with a dental implant. The robustness of the dental implant stability will be assessed at various time points.
16379692|NCT04121338|Experimental|Test group|10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance
16379693|NCT04121325||Gastroparesis patients with abdominal pain|Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain.
16379694|NCT04121312|Experimental|Facilitation Intervention|"A brief, web-based facilitation guide (called Weight Loss Your Way Kickoff Materials) that encourages initial and sustained engagement in online tracking and social network tools for weight loss.The intervention also includes 8 emails sent over 12 weeks to further motivate use of the online tools and weight loss."
16379695|NCT04121299|Experimental|Carvedilol 40mg Extended Release Once Daily|participants will be randomized to carvedilol 40 mg extended release once daily for the 1st or 2nd 4 week treatment period
16379696|NCT04121299|Active Comparator|Amlodipine 10mg Once Daily|participants will be randomized to amlodipine 10 mg once daily for the 1st or 2nd 4 week treatment period
16379697|NCT04121286|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
16379698|NCT04121273|Experimental|CAR-T cells|CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.
16379699|NCT04121260|Experimental|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase [rHuPH20] 30,000 units [U] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 [Day 1] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
16379700|NCT04121247|Experimental|Experimental: Parents in Chad will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
16379701|NCT04121247|Experimental|Experimental: Parents in Turkey will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
16379702|NCT04121221|Experimental|GA Depot|Monthly IM injection
16379703|NCT04121221|Placebo Comparator|Placebo|Monthly IM injection
16379704|NCT04121208|Active Comparator|Active drug: JNJ-40346527|"A single initial randomisation site will be set up for Part 1 that will assign participants to JNJ-40346527 300 mg Bis in die - twice a day (BID) or placebo in a 2:1 ratio.
~A second randomisation site will be setup for Part 2 depending on which scenario is adopted.
~Either a Part 2, Scenario 1 site will assign participants to JNJ-40346527 150 mg BID, JNJ-40346527 50 mg BID or placebo in a 2:2:1 ratio or a Part 2, Scenario 2 site will assign participants to JNJ-40346527 150-50 mg BID or placebo in a 2:1 ratio."
16379705|NCT04121208|Placebo Comparator|Placebo|Non-active study drug
16379706|NCT04121195|Other|Dose escalation sequence (all participants)|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
16379707|NCT04121182|Experimental|Nursing home with On-line training|"25 randomized residents will be included by nursing home Half of the institutions (randomized too) will benefit from an on-line training on the prevention and management of resident lung diseases"
16379708|NCT04121182|Active Comparator|Nursing home with usual practice|This group of Institutions continue their usual practice (routine care) and will not benefit from training during the study period.
16379709|NCT04121169|Other|Adults subjects with CDI receiving 10g a day|5 g twice a day for 10 - 14 days
16379710|NCT04121169|Other|Adults subjects with CDI receiving 20g a day|10 g twice a day for 10 - 14 days
16379711|NCT04121169|Other|Adults subjects with CDI receiving 40 g a day|20 g twice a day for 10 - 14 days
16379712|NCT04121156|Active Comparator|2 milli Amp dose of HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
16379713|NCT04121156|Sham Comparator|Sham (placebo) dose of HD-tDCS treatment|Sham (placebo) dose of HD-tDCS treatment for 20 minutes, for 5 consecutive twice daily sessions
16379714|NCT04121143|Active Comparator|Treatment group A|SHR-1314 low dose short intervals of subcutaneous injection
16379715|NCT04121143|Active Comparator|Treatment group B|SHR-1314 high dose long intervals of subcutaneous injection
16379716|NCT04121143|Active Comparator|Treatment group C|SHR-1314 high dose short intervals of subcutaneous injection
16379717|NCT04121143|Placebo Comparator|Placebo group|Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection
16379718|NCT04121130|Active Comparator|Group A (F-ESWT Group)|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
16379719|NCT04121130|Placebo Comparator|Group B (sham F-ESWT):|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
16379720|NCT04121117||Tobacco detoxication cohort|Patients appointed in a tobacco detoxication consultation
16379721|NCT04121104|Experimental|SCS off|
16379722|NCT04121104|Experimental|SCS on|
16379723|NCT04121091|Experimental|Pramipexole|
16379800|NCT04120636|Experimental|Phase I open label study|"Drug: Episcleral Celecoxib
~Other Names:
~Sequestered, Transscleral, Controlled-Release Celecoxib
~Sustained Release Transscleral Celecoxib"
16379724|NCT04121078|Experimental|Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg|TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
16379725|NCT04121078|Experimental|Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.
16379726|NCT04121065||Relapsing MS patients|Single Arm: Relapsing Multiple Sclerosis patients ADA SNPs and other biomarkers analyses in blood samples.
16379727|NCT04121052|Experimental|Treatment Sequence 1|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379728|NCT04121052|Experimental|Treatment Sequence 2|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379729|NCT04121052|Experimental|Treatment Sequence 3|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379730|NCT04121052|Experimental|Treatment Sequence 4|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379731|NCT04121052|Experimental|Treatment Sequence 5|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379732|NCT04121052|Experimental|Treatment Sequence 6|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379733|NCT04121052|Experimental|Treatment Sequence 7|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379734|NCT04121052|Experimental|Treatment Sequence 8|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379735|NCT04121052|Experimental|Treatment Sequence 9|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379736|NCT04121052|Experimental|Treatment Sequence 10|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379737|NCT04121052|Experimental|Treatment Sequence 11|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379799|NCT04120649||endomterial cancer|All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
16381781|NCT04106830||Multiple sclerosis(MS)|Patients with multiple sclerosis
16379738|NCT04121052|Experimental|Treatment Sequence 12|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions ( low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379739|NCT04121052|Experimental|Treatment Sequence 13|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379740|NCT04121052|Experimental|Treatment Sequence 14|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379741|NCT04121052|Experimental|Treatment Sequence 15|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379742|NCT04121052|Experimental|Treatment Sequence 16|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16379743|NCT04121039|Experimental|Apatinib plus POF|Participants will receive apatinib in combination with POF,total 9-12 cycles.Then receive apatinib plus S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16379744|NCT04121039|Active Comparator|POF|Participants will receive POF,total 9-12 cycles.Then receive S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16379745|NCT04121013|Active Comparator|Mothership|Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center
16379746|NCT04121013|No Intervention|drip'n'ship|Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol
16379747|NCT04121000|Experimental|Erector Spinae Block for VATS Group|40 patients who had VATS will receive erector spinae block for postoperative pain management. All patients will receive IV Midazolam (0.05mg/kg) premediacation. Standard monitorization of EKG, non- invasive blood pressure and pulsoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the induction and in the prone positon the ESB procedure will be done. 10 % povidon- iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done at the 8th thoracic vertebra line. The USG probe will be replaced 2-3 cm lateral to the spinous process in sagittal plane. When the erector spinae muscle is identified in the USG the needle will be guided caudally.0.5-1 ml local anesthetics will be given in order to confirm the needle is in the right place. After confirmation with 20 mL %0.25 bupivacaine the procedure will be performed.
16379748|NCT04121000|Experimental|Patient - Controlled Analgesia for VATS Group|40 patients who had VATS will receive IV PCA for postoperative analgesia managemnet.
16379749|NCT04120987|Active Comparator|Lifitegrast|One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
16379750|NCT04120987|No Intervention|Control|No treatment
16379751|NCT04120974|Experimental|Optimal insulin injection|Study subjects will receive personal training from the Investigator on how to optimally inject insulin to treat their Diabetes Mellitus. In addition, each subject receives instruction how to use a web-based platform with online video training modules on optimal injection technique.
16379752|NCT04120961|Experimental|prolonged continuous use of bivalirudine|A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
16379753|NCT04120961|Other|bivalirudin use during ePCI|A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.
16379754|NCT04120948|Experimental|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
16379755|NCT04120948|Active Comparator|Tongue scraper|tongue scraping
16379756|NCT04120935||Cohort of CRC patients|Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.
16379757|NCT04120922|Other|calcium carbonate|"Calcium based P-binder - calcium carbonate: Typical dose is 500mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.
~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
16379895|NCT04120025|No Intervention|Control Group|Subject will continue standard of care for GERD symptoms
16379758|NCT04120922|Other|sevelamer carbonate|"Calcium (Ca) free P-binder - sevelamer carbonate: Typical dose is 800mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.
~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
16379759|NCT04120896|Experimental|Karate group|
16379760|NCT04120896|Active Comparator|Kung Fu group|
16379761|NCT04120883|Experimental|HCQ treatment 1|In treatment arm 1, the dose of study drug will be 4 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
16379762|NCT04120883|Experimental|HCQ treatment 2|In treatment arm 2, the dose of the study drug will be 5 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
16379763|NCT04120870|Active Comparator|Etomidate|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
16379764|NCT04120870|Experimental|Ketamine|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
16379765|NCT04120857|No Intervention|Educational Control Group|Education provided for optional use
16379766|NCT04120857|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly
16379767|NCT04120844|Experimental|Intervention|Patients in the intervention group (n=117) received a four-session PEP in small groups over one month by trained nurses and doctors.
16379768|NCT04120844|Placebo Comparator|Control|The control group (n=108) received the traditional lecture-style health education on Diabetes Mellitus.
16379769|NCT04120831|Experimental|Rituximab + Abatacept + MTX|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
16379770|NCT04120831|Active Comparator|Rituximab + MTX (standard of care)|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
16379771|NCT04120818||SIOL group|aphakic children diagnosed with congenital cataract who underwent secondary IOL implantation
16379772|NCT04120818||PIOL group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary IOL implantation
16379773|NCT04120805|Experimental|Group 1 (Hemostatic Agents Plus +)|
16379774|NCT04120805|Active Comparator|Group 2 (Hemostatic Agents Negative -)|No Hemostatic Agent
16379775|NCT04120792|Experimental|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
16379776|NCT04120792|Active Comparator|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
16379777|NCT04120792|Active Comparator|Cognitive training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
16379778|NCT04120792|Active Comparator|Neutral Video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
16379779|NCT04120779|Experimental|The EMPOWER-SUSTAIN e-Health Intervention|The EMPOWER-SUSTAIN intervention is a multifaceted chronic disease management strategies based on the Chronic Care Model (CCM) and persuasive technology (PT) theory. It consists of training physicians and patients to use the EMPOWER-SUSTAIN web-based self-management intervention mobile apps, strengthening patient-physician relationship and reinforcing the use of relevant clinical practice guidelines for management and prescribing.
16379780|NCT04120779|No Intervention|Control|The control group will continue to receive usual care at the university primary care clinic. They will be given the EMPOWER-SUSTAIN Global CV Risks Self-Management Booklet©, as this is considered as usual care at the university primary care clinic. The EMPOWER-SUSTAIN web-based self-management tool will be made available to the control group at the end of the study. During the course of the study, there will be no limit to the number of clinic visits that a patient is allowed to make in either the intervention or control groups.
16379781|NCT04120766|Experimental|Treatment|Nicorandil 20mg qd
16379782|NCT04120766|Placebo Comparator|Placebo|Matched placebo qd
16379783|NCT04120753|Experimental|1|
16379784|NCT04120753|Experimental|2|
16379785|NCT04120753|Active Comparator|3|
16379786|NCT04120727||Patient|patients with predominant osteoarthritis of the knees
16379787|NCT04120727||Health professionals|health professionals with a link to osteoarthritis (physical and rehabilitation doctor, Rheumatologist, Physiotherapist, family doctor, pharmacist, Adapted physical activity teacher)
16379788|NCT04120714|Experimental|Active tDCS group|Active tDCS
16379789|NCT04120714|Placebo Comparator|Placebo tDCS group|Inactive tDCS
16379793|NCT04120688|Active Comparator|Effect on surgery|Duration of surgery, degree of manipulation of the transplant
16379794|NCT04120688|Active Comparator|Success of transplantation|Normal eruption and root development of the transplant
16379795|NCT04120675|Experimental|Experimental group|"Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).
~Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
16379796|NCT04120675|Active Comparator|Control group|10 patients will not receive treatment with Extra Virgin Olive Oil
16379797|NCT04120662|Active Comparator|Group A: Surgery group|Surgical procedure according to the injury type
16379798|NCT04120662|Active Comparator|Goup B: Shockwave group|3 weekly sessions of Focused Shock Wave Treatment (F-ESWT), using an electrohydraulic device set to an energy flux density (EFD) of 0.21 mJ/mm2 and 2000 impulses
16379801|NCT04120623|Experimental|Dapagliflozin combined with CSII|Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
16379802|NCT04120623|Active Comparator|CSII alone|Aspart infused by CSII alone as glucose lowering therapy.
16379803|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
16379804|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
16379805|NCT04120597|Experimental|Therapy group|
16379806|NCT04120597|Placebo Comparator|Control group|
16379807|NCT04120584|Experimental|Forma Eye treatment|
16379808|NCT04120571|Experimental|experimental|Sleep Audiological Intervention Device (SleepAID)
16379809|NCT04120571|Sham Comparator|control|no sound
16379810|NCT04120558||Through knee amputees|Community dwelling individuals with through knee amputation of all mobility levels.
16379811|NCT04120558||Above knee amputees|Community dwelling individuals with above knee amputation of all mobility levels.
16379812|NCT04120545|Experimental|Microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
16379813|NCT04120545|Placebo Comparator|Placebo microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
16379814|NCT04120532|Experimental|Education group|
16379815|NCT04120532|No Intervention|Usual care group|
16379816|NCT04120519|Experimental|TCD|thalidomide 100mg qn cyclophosphamide 300mg/m2 d1,8,15 dexamethasone 40mg d1,8,15,22
16379817|NCT04120506|Experimental|Rapid infusion of Vpriv|: Infusions at Baseline and during step-wise rate increases and End-of-study will be performed in the Shaare Zedek Medical Center (SZMC) by the Study Nurse who will monitor vital signs (see below) for a total of 8 visits at SZMC. Home therapy will be approved if the patient so desires for 5 infusions in Phase 1 and for the first 5 infusions in Phase 3. All routine hematological and biochemical tests will be performed in the SZMC clinical labs. Abdominal quantitative MR Imaging (MRI) for spleen and liver volumes will be performed at SZMC
16379818|NCT04120493|Experimental|Cohort 1|Low dose rAAV5-miHTT (6x10^12 gc/subject).
16379819|NCT04120493|Experimental|Cohort 2|High dose rAAV5-miHTT (6x10^13 gc/subject).
16379820|NCT04120493|Sham Comparator|Cohorts 1 and 2|Imitation (sham) surgery
16379821|NCT04120480|Experimental|Testing|Participants randomized to this arm will be sent a kit to collect a genetic sample from a swab of their mouths. The kit will have instructions on how to collect the genetic sample and how to send it in a postage-paid envelope to the testing laboratory (OneOme). OneOme will process the sample and The study pharmacist will scan the results and enter any related information into the participant's KPCO electronic health record. If any changes to the participant's medication(s) are recommended (for example: a dose decrease or increase, stop taking your current medication and start another), the study pharmacist will contact the participant's KPCO prescriber directly to discuss the recommendations. The prescriber may contact the participant to change the participant's medication(s).
16379822|NCT04120480|No Intervention|Usual Care|Participants randomized to this arm will NOT be tested. They will receive usual care and the research will not involve study visits or in-person contact.
16379823|NCT04120467|Experimental|Dance|Dance Standard rehabilitation post-stroke
16379824|NCT04120467|Active Comparator|Control|Standard rehabilitation post-stroke
16379825|NCT04120454|Experimental|Treatment (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16379826|NCT04120441|Experimental|Group mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
16379827|NCT04120441|No Intervention|Routine care/control|Study participants randomized to control will receive information about community resources. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
16379828|NCT04120428|Experimental|Experimental protocol|24-week aquatic exercise training program
16379829|NCT04120428|No Intervention|Control protocol|Maintain lifestyle routine as usual
16379830|NCT04120415|Experimental|Vaccine and Vedolizumab infusion|"Vaccine:
~The vaccine is MVA HIV-B which is a solution of HIV MVA vectors in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).
~Vedolizumab infusion (Entyvio):
~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)."
16379831|NCT04120415|Experimental|Placebo vaccine and Vedolizumab infusion|"Placebo vaccine:
~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).
~Vedolizumab infusion (Entyvio):
~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)"
16379832|NCT04120415|Placebo Comparator|Placebo vaccine and placebo infusion|"Placebo vaccine:
~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).
~Placebo infusion:
~Sodium Chloride (NaCl) 0.9% administered as an intravenous infusion (255ml)"
16379833|NCT04120402|Experimental|EP-104IAR 25 mg|A single use intra-articular injection containing 25 mg of EP-104IAR
16379834|NCT04120402|Placebo Comparator|Placebo (vehicle)|A single use intra-articular injection containing no active ingredients
16379835|NCT04120389|Experimental|BCL group|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)
16379836|NCT04120389|Active Comparator|control group|
16379838|NCT04120363|Placebo Comparator|Placebo|single intramuscular injection of 3 mL sesame oil solution on Day 8
16379839|NCT04120363|Experimental|Testosterone|single intramuscular injection of 750 mg testosterone undecanoate on Day 8
16379840|NCT04120350|Experimental|R2-MTX-LEN|"Phase Ib：Experimental arm will be treated with R2-MTX regimen for 6 cycles as initiate induction, the dose of lenalidomide was escalated from 15mg， 20mg， 25mg to test DLT by 3+3 design, meanwhile the dose of rituximab and methotrexate is fixed. If the patients achieved CR or PR by MRI and CSF evaluation, they processed to lenalidomide maintenance for 2 years.
~Phase II: the patients will be treated by fixed dose of R2-MTX regimen (established lenalidomide dose from phase Ib study) for 6 cycles. the efficiency evaluation will be performed every 2 cycles, the patients who achieved CR or PR will finish the total 6 cycles of induction therapy, then begin the stage of lenalidomide maintenance for 2 years. Follow-ups should be taken for 5 years."
16379841|NCT04120337|Experimental|RemovAid Device + lidocaine patch|Test device with lidocaine patch for local anesthesia
16379842|NCT04120337|Experimental|RemovAid Device + lidocaine injection|Test device with lidocaine injection for local anesthesia
16379843|NCT04120337|Active Comparator|Standard removal technique + lidocaine injection|Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia
16379844|NCT04120324||Eligible & Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty and is discharged home on the day of surgery.
16379845|NCT04120324||Eligible but NOT Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty but is NOT discharged home on the same day as the surgery, and remains in hospital for a minimum of one night following surgery. Reasons for not being discharged same day include potential problems related to Surgery (eg. complication), Anesthesia (eg. prolonged effect), or patient factors (egs. pain, nausea, mobility difficulties, etc.).
16379846|NCT04120324||Not Eligible for Discharge Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and/or Anesthesia deems the patient to NOT be eligible for Same Day Discharge. The patient undergoes Primary Single Joint Total Hip Arthroplasty and remains for a minimum of one overnight in hospital following hip replacement surgery.
16379847|NCT04120311|Experimental|Phase I open label study|"Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone
~Other Names:
~• Sustained Release Transscleral Dexamethasone"
16379848|NCT04120298|Experimental|Supervised exercise group|"The intervention group will participate in a 9-month exercise intervention. The exercise program will start with a 6-month period, where patients participate in a supervised multimodal exercise program twice a week supplemented with unsupervised exercises. The multimodal exercise program comprises aerobic-, resistance- and balance components. After completing the initial six-month period, one supervised session will be replaced by one unsupervised session until month nine.
~Unsupervised exercises will be supported by an activity tracker (FitBit) and an exercise App specifically designed for the EFFECT trial"
16379849|NCT04120298|No Intervention|Control group|Patients randomized to the control group will also receive an activity tracker (like the intervention group). We will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.
16379850|NCT04120285|No Intervention|Primary Care Treatment|The participant will receive treatment as usual as prescribed by the primary care physician for MDD.
16379851|NCT04120285|Active Comparator|Primary care treatment with eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of eCBT for MDD.
16379852|NCT04120285|Active Comparator|Primary care treatment with guided eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of guided eCBT for MDD.
16379853|NCT04120272||Delirium group|Group of patients with postoperative delirium
16379854|NCT04120272||Non delirium group|Group of patients without postoperative delirium
16379855|NCT04120259|Active Comparator|Group 1|Intervention: Metformin Tablet oral 750 mg OD
16379856|NCT04120259|Experimental|Group 2|Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD
16379858|NCT04120233|Placebo Comparator|Placebo|Participants will receive placebo.
16379859|NCT04120233|Experimental|Dose 1|Participants will receive 10 mg of MW151.
16379860|NCT04120233|Experimental|Dose 2|Participants will receive 20mg of MW151.
16379861|NCT04120233|Experimental|Dose 3|Participants will receive 40mg of MW151.
16379862|NCT04120233|Experimental|Dose 4|Participants will receive 80mg of MW151.
16379863|NCT04120233|Experimental|Dose 5|Participants will receive 160mg of MW151.
16379864|NCT04120220|Experimental|Heavy Cream|Participants will receive a meal containing 30 g of fat prepared with heavy cream.
16379865|NCT04120220|Experimental|Soybean Oil|Participants will receive a meal containing 30 g of fat prepared with soybean oil.
16379866|NCT04120207|Experimental|Home-based Pilates|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
16380150|NCT04118062|Other|Pediatric Cancer|Questionnaires and semi-structured individual interviews with parents of children with cancer.
16379867|NCT04120207|Other|Delayed-Start Control|Participants randomized to Delayed-start will be instructed to maintain their pre-intervention physical activity levels during the trial and will be contacted by the lead researcher by email or telephone to ensure timely completion of the on-line outcome assessments at biweekly intervals. Following the 8-week intervention, Delayed start participants will be provided with the Pilates DVD for their own use, but no data will be collected. For both groups, participants who experience a relapse will be immediately withdrawn from the study, which will be recorded by the lead researcher.
16379868|NCT04120194|Experimental|NanoFlu|NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
16379869|NCT04120194|Active Comparator|Fluzone Quadrivalent|Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
16379870|NCT04120181||Control|The control group consists of 13 age- and gender-matched subjects who underwent CI surgery but showed no complications. The members of the control group were selected based on hospital records.
16379871|NCT04120168||DMD and Pompe Disease Cohort|The aim of this study gropu was to determine the frequency of Duchenne muscular dystrophin in boys and adolescents with unexplained transaminase elevation for at least 3 months and in late onset Pompe disease in girls and boys and to determine the demographic and clinical characteristics of these patients.
16379872|NCT04120155|Other|Dissecting the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary dessection during the upper lobe thoractomy.
16379873|NCT04120155|Other|Preserving the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary preservation during the upper lobe thoractomy.
16379874|NCT04120142|Experimental|IMT goup|Inspiratory muscle training + aerobic exercice
16379875|NCT04120142|Active Comparator|Control group|aerobic exercice
16379876|NCT04120129|Experimental|TMS treatment|participants receive TMS treatment
16379877|NCT04120129|Sham Comparator|sham TMS|participants receive control TMS treatment
16379878|NCT04120129|No Intervention|non intervention|control group
16379883|NCT04120103|Experimental|Doll therapy|"Experimental: Doll Therapy Intervention A total of 30 patients were included in the study. All patients that meet the study inclusion criteria will be included in the study The patients in the intervention group will have Doll therapy for 60 days and weekly patient visits. The study will be started with control group patients. At the beginning of the study and after 60 days, Introductory Information Form, Mini Standard Mini Mental Test and Cohen-Mansfield Agitation Inventory will be applied to patients in intervention and control groups for data collection. Dementia patients will be given a baby, patients will be followed for two months. There will be monitoring once a week."
16379884|NCT04120103|Active Comparator|Routine nursing care|"The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
~There was no intervention other than routine care. The patients were followed up for two months.The patients were followed up for two months.Data collection forms were applied at the beginning, first and second months of the study."
16379885|NCT04120090|Active Comparator|Low dose|
16379886|NCT04120090|Experimental|High dose|
16379887|NCT04120077|Placebo Comparator|DSME + placebo supplement (group 1)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects be instructed to consume two capsules (canola oil soft-gels) per day in the morning and two capsules per day in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
16379888|NCT04120077|Experimental|DSME + DVS supplement (group 2)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (canola oil placebo) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
16379889|NCT04120077|Experimental|DSME + DVS supplement + omega-3 supplement (group 3)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (EyePromise EZTears) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
16379890|NCT04120064|Experimental|Large bolus|
16379891|NCT04120064|Active Comparator|Standard|
16379892|NCT04120051|Experimental|Fermented canola-seaweed supplement|Ingredients: Canola meal, seaweed, wheat, glucose, Vitamin D and lactic acid bacteria
16379893|NCT04120051|Placebo Comparator|Placebo|Ingredients: Rye flour, water, iodized salt, brown sugar
16379896|NCT04120025|Experimental|Treatment Group|Subjects will continue with usual care but will also receive diaphragm training (belly breathing) instructions using verbal, visual and tactile cues for proper contraction of the diaphragm as a home program
16379897|NCT04119999|Active Comparator|CPAP|Continuous Positive Airway Pressure
16379898|NCT04119999|Experimental|MAD|Mandibular Advancement Device
16379899|NCT04119986|Experimental|drug coated balloon|A total of 110 patients with ISR are assigned to drug coated balloon treated group after randomization schedule.
16379900|NCT04119986|Other|drug eluted stent implantation|A total of 110 patients with ISR are assigned to drug eluted stent treated group after randomization schedule.
16379901|NCT04119947|Experimental|SY-009 dose 1|A single dose of SY-009 (0.5-40mg) taken orally.
16379902|NCT04119947|Experimental|SY-009 dose 2|A single dose of SY-009 (0.5-40mg) taken orally.
16379903|NCT04119947|Experimental|SY-009 dose 3|A single dose of SY-009 (0.5-40mg) taken orally.
16379904|NCT04119947|Experimental|SY-009 dose 4|A single dose of SY-009 (0.5-40mg) taken orally.
16379905|NCT04119947|Experimental|SY-009 dose 5|A single dose of SY-009 (0.5-40mg) taken orally.
16379906|NCT04119947|Experimental|SY-009 dose 6|A single dose of SY-009 (0.5-40mg) taken orally.
16379907|NCT04119947|Placebo Comparator|SY-009 matching placebo|from 2-40mg
16379908|NCT04119934||Control - None|A retrospective chart review will assess physician behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.
16379909|NCT04119934||Intervention - Smoking cessation infographic|Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians (for eligible patients). Chart review will be conducted for the patient's physician within a three-month window of receiving the infographic to assess outcomes.
16379910|NCT04119921|Active Comparator|usage of topical ketorolac in group1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
16379911|NCT04119921|Active Comparator|usage of artificial tear in group 2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
16379912|NCT04119921|Active Comparator|usage of artificial tear in group 1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval
16379913|NCT04119921|Active Comparator|usage of topical ketorolac in group2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval
16379914|NCT04119908|Experimental|Patients with haemorrhagic disease|Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia
16379915|NCT04119908|Other|Control group|Patients with moderate or severe hemophilia A or women carrying the hemophilia gene
16379916|NCT04119895|Experimental|NMES and exercise|Neuromuscular electrical stimulation and core stabilization exercise
16379917|NCT04119895|Sham Comparator|Sham NMES and exercise|Sham neuromuscular electrical stimulation and core stabilization exercise
16379918|NCT04119882||Positive for ischaemia|Blood test for 121 patients with confirmed cardiac ischemic event
16379919|NCT04119882||Negative for ischaemia|Blood test for 283 patients with no cardiac ischemic event
16379920|NCT04119869|Experimental|iaya Smart Phone Application|"Pre-study evaluation
~Access to the smartphone intervention over the course of 12 weeks
~Post-study evaluation and interview"
16379921|NCT04119856|Other|Intervention group|"Affiliation with outgoing lung team
~Instructions and teaching by the outgoing lung team.
~Needs-based consultation at Dept. of Respiratory Diseases and Allergy.
~Contact to the outgoing lung team in case of exacerbation of COPD."
16379922|NCT04119856|No Intervention|Control group|"The usual practice
~Scheduled consultations at Dept. of Respiratory Diseases and Allergy.
~Contact to GP/doctor on call in case of exacerbation of COPD."
16379923|NCT04119843|Experimental|Mangoral|All participants will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate [MnCl2 4H2O]).
16379924|NCT04119830|Experimental|Treatment (rintatolimod, pembrolizumab)|Patients receive rintatolimod IV over 30 minutes on days 1-3 and pembrolizumab IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 4, patients receive rintatolimod IV over 30 minutes and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months from the first dose in the absence of disease progression or unacceptable toxicity.
16379925|NCT04119817|Experimental|Mucosave® capsules|60 healthy volunteers taking 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day after dinner before going to bed.
16379926|NCT04119817|Placebo Comparator|Placebo|40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed.
16379927|NCT04119804||septic loosening|Septic loosening of primary hip implants according to the 2014 CDC criteria (as routinely performed in the clinical setting), adding another major and necessary criterion: at least 3 positive intraoperative tissue samples (same micro-organism).
16379928|NCT04119804||aseptic loosening|aseptic loosening of primary hip implants not meeting the CDC 2014 criteria
16379929|NCT04119791|Experimental|Wild rice|Participants will consume one serving of the test food containing wild rice every day over 28 days.
16379930|NCT04119778|Experimental|Aerobic Exercise|The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
16379966|NCT04119492|Experimental|CO-OP Treatment Group|Participants in the treatment group will receive occupational therapy once weekly for 10 weeks using the published protocol for the CO-OP approach.
16379931|NCT04119778|Experimental|Tai chi|Our tai-chi classes will be based on a 16-form tai-chi exercise set. The classes will run twice a week for 16 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 16 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
16379932|NCT04119778|No Intervention|Self Management Group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 16 weeks and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
16379933|NCT04119752|Active Comparator|Curcumin powder|Curcumin powder - 10g
16379934|NCT04119752|Placebo Comparator|Placebo ( curcumin depleted)|Placebo- sucralose -1g
16379935|NCT04119739|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
16379936|NCT04119739|Active Comparator|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
16379937|NCT04119739|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
16379938|NCT04119726|Other|Control Group|The control group will receive a simplified tool including only the education message. The methodology will ensure that potential confounders by differences in nonspecific support and attention could be adjusted. Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behavior. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
16379939|NCT04119726|Experimental|Intervention Group|The intervention group will receive a complete social medial tool (web-based application ) installed on mobile phones including general education about coronary disease、personalized reminders and internet-based counseling. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
16379940|NCT04119713||Study Population|Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).
16379941|NCT04119700|Active Comparator|Muco-muscular endorectal advancement flap|After fistulectomy a muco-muscular endorectal advancement flap is mobilised and fixed to anoderma
16379942|NCT04119700|Experimental|Primary sphincter reconstruction|After fistulectomy the defect in anal sphincters is closed
16379943|NCT04119687|Experimental|Low Dose FX201|Single low dose FX201 injection
16379944|NCT04119687|Experimental|Mid Dose FX201|Single mid dose FX201 injection
16379945|NCT04119687|Experimental|High Dose FX201|Single high dose FX201 injection
16379946|NCT04119674|Experimental|Arm|Experimental: arm Biological: Anlotinib Drug: Temozolomide Radiotherapy:2.0 Gy/fraction ×30 fractions Monday to Friday total dose of 60Gy
16379947|NCT04119661|Experimental|Max-i-Probe|
16379948|NCT04119661|Active Comparator|NaviTip|
16379949|NCT04119648|Experimental|CAMS-4Kids|Participants will receive up to 10 sessions of CAMS-4Kids
16379950|NCT04119622|Experimental|XELOX combined with Toripalimab|
16379951|NCT04119596||Diagnosed Parkinson's disease|Patients with incident Parkinson's disease
16379952|NCT04119596||Control|Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
16379953|NCT04119583|Experimental|U-shape Automatic Electric Toothbrush|
16379954|NCT04119583|Active Comparator|Usual home toothbrushing procedure|
16379955|NCT04119583|No Intervention|No toothbrushing|
16379956|NCT04119583|Active Comparator|Conventional Electric Toothbrush|
16379957|NCT04119570|No Intervention|No intervention|Participants will have their clinic visit as per usual care.
16379958|NCT04119570|Active Comparator|CKD Report Card|Participants will receive the CKD Report Card prior to the clinic visit.
16379959|NCT04119557|Experimental|LY3471851|LY3471851 administered subcutaneously (SC)
16379960|NCT04119557|Placebo Comparator|Placebo|Placebo administered SC
16379961|NCT04119544|Active Comparator|Conventional Rehabilitation|at least 4 sessions/week for 6 weeks, from 1 hour of conventional upper limb rehabilitation by an occupational therapist.
16379962|NCT04119544|Experimental|Intensive Visual Simulation|at least 4 sessions/week for 6 weeks, of 1 hour of upper limb rehabilitation including 45 minutes of conventional rehabilitation (occupational therapy) and 15 minutes of work with a medical device allowing intensive visual digital simulation.
16379963|NCT04119531||Patients with insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
16379964|NCT04119531||Patients without insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
16379965|NCT04119518|Other|Healthy and hypertensive subjects|Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.
16379967|NCT04119492|No Intervention|Waitlist Control Group|Participants in the waitlist control group not receive CO-OP intervention during this time. They will receive their CO-OP intervention 12 weeks after their baseline assessment.
16379968|NCT04119466|Experimental|Protrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
16379969|NCT04119466|Experimental|Extrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
16379970|NCT04119453|Experimental|Oral rivoceranib, 700 mg daily during 28-day cycles|Subjects will be treated with oral rivoceranib, 700 mg daily during 28-day cycles. Subjects will be monitored for clinical and/or radiographic evidence of disease progression as assessed by tumor growth or the discovery of additional tumors. Restaging scans will be performed approximately every 8 weeks for the first year and then approximately every 12 weeks and at End of Treatment (EOT), or as clinically indicated. Subjects who discontinue treatment for reasons other than progression will have scans at the EOT visit (unless their previous restaging was performed within 6 weeks) and approximately every 12 weeks thereafter (or with the standard of care restaging frequency for their disease) until initiation of a new therapy.
16379971|NCT04119440|Experimental|Low Dose|Vaccination with 2x10^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
16379972|NCT04119440|Experimental|High Dose|Vaccination with 2x10^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
16379973|NCT04119440|Placebo Comparator|Placebo|Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.
16379974|NCT04119427|Experimental|Test Group|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
16379975|NCT04119427|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
16379976|NCT04119414|Experimental|S&S + LFLS Group|300 expecting couples totaling 600 participants will be completing the S&S program followed by the LFLS Program.
16379977|NCT04119401|Active Comparator|doppler-guided|ligation of hemorrhoidal arteries with doppler guidance
16379978|NCT04119401|Experimental|finger-guided group|ligation of hemorrhoidal arteries without doppler guidance but with finger detection
16379979|NCT04119388|Experimental|Adapted sports practice|patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.
16379980|NCT04119375|Active Comparator|Control|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
16379981|NCT04119375|Experimental|SMS-Only|"Patients in the SMS reminder group will receive a single, medication reminder SMS once daily at their indicated treatment time. The reminder message will read Please take the medication on time consistent with messages used by Liu and colleagues (2015)."
16379982|NCT04119375|Experimental|Social Behavior Change Communication (SBCC)|"Patients assigned to this intervention will have access to a mobile health platform that provides reminders, information and motivation - designed with behaviorally-informed strategies - but no follow up support from a human beyond what the standard of care allows. Further details of the intervention can be found in the study protocol section.
~The intervention will send automated motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. Clinicians can view individual or aggregate patient histories to leverage limited resources."
16379983|NCT04119375|Experimental|Keheala|"An automated system sends motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. If a patient fails to correctly verify her compliance, the system automatically alerts the support-sponsor, who then intervenes with a supportive dialogue. Clinicians can view individual or aggregate patient histories to leverage limited resources.
~Further details of the intervention can be found in the study protocol section."
16379984|NCT04119362||Patients with pancreatic adenocarcinoma|Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
16379985|NCT04119349|Experimental|Counseling|Women are given extra 15-minute counseling on the pros and cons of all different methods for prenatal testing including no testing at all
16379986|NCT04119349|No Intervention|Standard care|Women receiving standard care by means of counseling
16379987|NCT04119336|Experimental|Nivolumab and Ixazomib|"- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.
~Oral:
~Ixazomib given weekly on days 1, 8, 15
~Dexamethasone given weekly during cycle
~Infused:
~Nivolumab given once per cycle
~Cyclophosphamide given on days 1, 8, 15 during cycle"
16379988|NCT04119310|Experimental|Lumbar thrust-mobilization|The investigator will perform a lumbar thrust-mobilization with the subject in right and then left sidelying position
16379989|NCT04119310|Sham Comparator|Sham-mobilization|No lumbar-thrust mobilization will be performed. Subject will receive simple passive inter-vertebral range of motion.
16379990|NCT04119297|Active Comparator|Control|Routine care (Irregular cold application or gauze bandages wetted with isotonic solution or once daily heparinoid cream application) of the clinic was applied.
16379991|NCT04119297|Experimental|Cold application|Cold application was applied for three days after craniotomy.
16379992|NCT04119297|Experimental|Heparinoid group|Heparinoid cream was applied for three days after craniotomy
16379993|NCT04119284|Experimental|Anterior Vertebral Tethering|Anterior Vertebral Tether Vertebral body tethering done through anterior spine surgery under anesthesia.
16379994|NCT04119271|Other|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:
~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
16379995|NCT04119258||Psychiatric patients|Psychiatric outpatient care patients with major depressive disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, or illness anxiety disorder who have just completed cognitive-behavioral therapy.
16379996|NCT04119245|Experimental|study group|"after induction of general anesthesia, a proper size of Igel will be inserted after compelete muscle relaxation. In order to confirm proper positioning of the I-gel,a fiberoptic bronchoscope will be pass through the device and pushed forward up to1 cm proximal to it to obtain a glottic view, leak airway pressure test will be done.
~Afterwards the same patient will be placed in the lateral decubitus position ,confirmation of I-gel position using fiberoptic bronchoscope will be done and recorded.The leak air way pressure test will be done as previously done in supine position and recorded.
~The patient will be returned to supine position."
16379997|NCT04119232|No Intervention|Control|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
16379998|NCT04119232|Experimental|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
16379999|NCT04119219|Active Comparator|Ranibizumab|Arm 1
16380000|NCT04119219|Active Comparator|Aflibercept|Arm 2
16380001|NCT04119206||Control|Normonatremic control, no intervention.
16380002|NCT04119206||Fluid restriction|Hyponatremic patients (serum sodium <135mmol/L): restriction of fluid intake < 1L
16380003|NCT04119206||Tolvaptan 3.75mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 3.75 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
16380004|NCT04119206||Tolvaptan 7.5mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 7.5 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
16380005|NCT04119180|Experimental|Sedation|The child receives sedatives approved for use in an outpatient setting, directed by a doctor, to accomplish the dental treatment.
16380006|NCT04119180|Other|Control|The child does not receive sedatives. As s/he exhibits negative behavior for the dental procedure, s/he will be restrained by a family member and dental team.
16380007|NCT04119154|Experimental|Standard diagnosis and CEM platform|Participants will receive standard diagnostic approach and assessment by CEM platform
16380008|NCT04119141|Active Comparator|Standard Arm|the first acquisition will be carried out without a tin filter in supine position and the second with tin filter in procubitus.
16380009|NCT04119141|Experimental|Tin filter Arm|the first acquisition will be carried out with tin filter in supine position and the second without tin filter in procubitus.
16380010|NCT04119128|Active Comparator|Active tDCS|Patients in this group will receive 5 active sessions of low-intensity transcranial electrical stimulation for 20 minutes.
16380011|NCT04119128|Sham Comparator|Sham tDCS|Patients in this group will receive 5 sessions of sham transcranial electrical stimulation for 20 minutes.
16380012|NCT04119115||Interstitial Lung Disease (ILD)|CT-V and metabolite analysis of breath and serum at baseline
16380013|NCT04119115||COPD/Emphysema: Age-matched control|CT-V and metabolite analysis of breath and serum at baseline
16380014|NCT04119115||Healthy Volunteers: Age-matched + /- 10 yrs controls|Metabolite analysis of breath and serum at baseline
16380015|NCT04119102|Experimental|Open Label Duobrii|Duobrii QD
16380016|NCT04119076|Experimental|Intervention Group|Teacher delivered a 10 minute classroom-based physical activity on school days for eight weeks.
16380017|NCT04119076|Other|Control Group|Children in the control schools continued with their usual school routine
16380018|NCT04119063|Experimental|Exoskeleton Assistance|Walking with exoskeleton assistance to make walking easier.
16380019|NCT04119063|Experimental|Exoskeleton Resistance|Walking with exoskeleton resistance for functional gait training.
16380025|NCT04119037|Experimental|Group I (cordotomy)|Patients undergo a cordotomy over 1-2 hours.
16380026|NCT04119037|Sham Comparator|Group II (morphine, fake cordotomy)|Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.
16380146|NCT04118075|Experimental|PT-CY-FK +/- ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
16380027|NCT04119024|Experimental|Treatment (chemotherapy, IL13Ralpha2, Il-2)|Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 15-30 minutes on days -4 to -1. Patients then receive IL13Ralpha2 CAR T cell IV on day 0. Patients may also receive recombinant interleukin-2 SC BID on days 1-7.
16380028|NCT04119011|Experimental|Probiotic|Probiotic in powder form containing lactobacillus and bifidobacterium strains, sugar, milk powder and flavoring, taken 2 sachets daily for 3 months
16380029|NCT04119011|Placebo Comparator|Placebo|Placebo in powder form containing sugar, milk powder, flavoring, taken 2 sachets daily for 3 months
16380030|NCT04118998|Experimental|Abduction Loading|
16380031|NCT04118998|Active Comparator|Supported Reaching|
16380032|NCT04118985|Active Comparator|Self-implementation|Individuals randomized to this group will be given all the materials about cognitive compensations techniques and brain health behavior guidelines and encouraged to implement those on their own.
16380033|NCT04118985|Experimental|Health-behavior intervention|Individuals randomized to this group will attend 10 weekly classes designed to provide information about cognitive compensation techniques and brain health behaviors as well as interventional support to implement those recommendations with homework and follow-up classes.
16380034|NCT04118972|Experimental|Functionality Mirror Exposure & Journal|"A text-based functionality gratitude journaling prompt three times weekly paired with three weeks of weekly functionality-based guided mirror exposure sessions in the lab (the IM FAB program)"
16380035|NCT04118972|Active Comparator|Pure Mirror Exposure & Gratitude Journal|Thrice weekly generic (non body-focused) gratitude text prompts and pure mirror exposure in the lab. Participants are not given instructions on how to examine body parts, only instructed to examine the same specific body parts as the Functionality group to control specifically for impacts of the body functionality focus.
16380036|NCT04118972|No Intervention|Assessment only control|Assessments at Week 1, Week 3, and 1- and 4-month follow-ups, identical to those received by participants in the active condition
16380037|NCT04118946|Active Comparator|intravesical instillation|Intravesical instillation of platelet enriched plasma every week for 6 weeks
16380038|NCT04118946|Active Comparator|submucosal injection|submucosal injectionof platelet enriched plasma
16380039|NCT04118933|Experimental|MSI-H advanced colorectal cancer|
16380040|NCT04118920|Experimental|Topical insulin|Patients will receive topical insulin eye drops.
16380041|NCT04118907|Experimental|acoustic stimulation|Pink noise in both ears is given to tinnitus patients. The pink noise is removed by notch filter from tinnitus frequencies that are 20 decibel higher than the threshold.
16380042|NCT04118907|Experimental|somatic stimulation|Three stimulation points were selected for each ear of tinnitus patients, namely ear door (CN.V), auditory Palace (CN.VII) and Yifeng (C2/3). The stimulation intensity should be needle-sensed.
16380043|NCT04118907|Experimental|vestibular stimulation|The patient sat on a rotating chair with sinusoidal harmonic acceleration and rotated without causing the greatest frequency of discomfort.
16380044|NCT04118907|Experimental|acoustic + somatic stimulation|Combination of auditory and somatic stimulation for tinnitus patients
16380045|NCT04118907|Experimental|acoustic + vestibular stimulation|Combination of auditory and vestibular stimulation for tinnitus patients
16380046|NCT04118907|Experimental|acoustic + somatic + vestibular stimulation|Combination of auditory stimulation, somatic stimulation and vestibular stimulation for tinnitus patients
16380047|NCT04118894||Foot and Ankle Devices|
16380048|NCT04118881|Experimental|treatment group|The treatment group was given intradermal needling at ear acupoints: cardia (CO3), stomach (CO4), sympathetic (HX4)
16380049|NCT04118881|Sham Comparator|control group|The control group was given intradermal needling at ear acupoints: spiral area (HX7 and HX8).
16380050|NCT04118868|Experimental|All participants|Pembrolizumab administered intralymphatically using the Sofusa® DoseConnect™device
16380051|NCT04118855|Experimental|Neoadjuvant arm|Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.
16380052|NCT04118842|Experimental|Savolitinib and/or Rifampicin|Treatment Period 1 consists of 16 days starting with admission on Study Day -1, followed by a single dose administration of savolitinib on Day 1, followed by a washout period of at least 14 days. Subjects will be discharged from the Study Centre on Study Day 3, after the last PK sample is collected Treatment Period 2 consists of 6 days, starting with admission on Study Day 14, followed by QD dose administrations of rifampicin for 5 consecutive days (Study Day 15 to Study Day 19) Treatment Period 3 consists of 4 days, starting immediately after Treatment Period 2, comprising of a single dose administration of savolitinib on Study Day 20 and QD dose administration of rifampicin on Study Day 20 and Study Day 21. Subjects will be discharged from the Study Centre on Study Day 22, after the last PK sample is collected
16380053|NCT04118829|Experimental|Group one|The Group 1 patients will be taking PER up to 14 days following surgical intervention as per discretion of the treating neurosurgeon.
16380054|NCT04118829|Experimental|Group Two|The Group 2 patients will be taking PER as part of their maintenance AED regimen and will continue on the same maintenance dosage postoperatively.
16380055|NCT04118816||Control|Healthy subjects, 7-75 y/o
16380056|NCT04118816||Study|7-75 y/o, diagnosed with Prader-Willi syndrome.
16380057|NCT04118790||Minor Stroke patients|"Clinical Assessment
~MRI scan session"
16380058|NCT04118790||TIA patients|"Clinical Assessment
~MRI scan session"
16380059|NCT04118790||Healthy Controls|MRI scan session
16380060|NCT04118777|Active Comparator|0.2 % Ropivacaine|An ON-Q pain pump will be placed into the pelvic cavity and 0.2% Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr.
16380061|NCT04118777|Placebo Comparator|Saline|An ON-Q pain pump will be placed into the pelvic cavity and saline will be continuously administered intraperitoneally at a rate of 6 mL/hr
16380063|NCT04118751||parents of preterm babies (born before 37 weeks of pregnancy|
16380064|NCT04118751||parents of full-term babies (over 37 weeks of pregnancy)|
16380147|NCT04118062|Other|Metastatic Uveal Melanoma|Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
16382990|NCT04098419|Experimental|Williams Implementation|
16380065|NCT04118738||ZIKV-Exposed|Children born to women with documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery or the children's laboratory documentation of confirmed or presumptive in-utero ZIKV exposure within five days of birth.
16380066|NCT04118738||ZIKV-Unexposed|Children born to women without documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery and the children have no laboratory documentation of confirmed or presumptive in-utero ZIKV exposure at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.
16380067|NCT04118725|Experimental|Muscular explorations|Pulmonary function test and diaphragmatic electromyography
16380068|NCT04118699|Experimental|Rifaximin|Two tablets of the investigational product per dosing (400 mg of rifaximin) are orally administered 3 times daily for 4 weeks.
16380069|NCT04118699|Placebo Comparator|Placebo|Two tablets of the placebo are orally administered 3 times daily for 4 weeks.
16380070|NCT04118686|Experimental|Experimental group|The group receives CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
16380071|NCT04118686|Sham Comparator|Control group|The group receives CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
16380072|NCT04118673|No Intervention|Control (Standard Care)|Standard care during consultations. Advice and guidance offered by clinicians verbally and sometimes the addition of leaflets or a referral.
16380073|NCT04118673|Experimental|Intervention (Standard Care plus Lifestyle prescription - LRx)|Standard care during consultations with the addition of a physical lifestyle prescription. Advice and guidance will be offered by clinicians verbally, whilst being supported with a lifestyle prescription and a possible referral if required.
16380074|NCT04118660||Thoracic Disease|Thoracic Diseases (which includes but not limited to the following: thoracic neoplasms (masses/nodules) malignant or benign, interstitial lung diseases (ILD), chronic obstructive pulmonary disease (COPD), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.
16380075|NCT04118647|Experimental|Wu-Chu-Yu tang|
16380076|NCT04118634||Group with PE|"The criteria for confirmation of PE are:
~PE on spiral computed tomography (CT) proximal deep vein thrombosis on ultrasound (US) thromboembolic events objectively confirmed during the follow up"
16380077|NCT04118634||Group without PE|"The criteria for exclusion of PE are:
~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up low and moderate clinical probability and negative CT and negative follow up high clinical probability and negative CT, US and follow up."
16380078|NCT04118595|Experimental|Full Intervention (Video + Telecare + PCP communication)|Patients in this arm will watch an interactive pain management video; receive a pain assessment phone call and be given medication and behavioral pain management strategy recommendations; and an index visit and telecare summary will be shared with patient's primary care provider.
16380079|NCT04118595|Experimental|Video-only Intervention|Patients in this arm will watch an interactive pain management video.
16380080|NCT04118595|No Intervention|Usual Care|Patients will receive the typical care provided by medical personnel for their acute pain.
16380081|NCT04118582||Prospective analisys|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
~Evaluation of RMR For the evaluation of the RMR, the values of VO2 and VCO2 will be collected by the indirect calorimetry (IC) method using the Ultima CPX metabolic analyzer (MedGraphics, USA), calibrated with each test."
16380082|NCT04118569|Experimental|Narrative Intervention Group|Patients in the narrative intervention group will participate in an interview and the resulting narrative will be uploaded to the electronic medical record. This group will also complete outcome measures (questionnaires) and exit interview.
16380083|NCT04118569|No Intervention|Usual Care Group|Patients in the usual care group will complete outcome measures (questionnaires) and exit interview only.
16380084|NCT04118556|Experimental|Decidua Stroma Cells (DSC)|"Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10^6/kg and 3x10^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.
~The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response."
16380085|NCT04118556|Active Comparator|Best Available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
16380086|NCT04118543|Experimental|Intervention Group|The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
16380087|NCT04118543|Sham Comparator|Sham-Exercise Group|The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
16380088|NCT04118530||Hematopoietic Stem Cell Transplant (HSCT) Patients|- Patients with incidence of AF/AFL in the first 30 days of transplant
16380089|NCT04118517|Experimental|test meal|The study comprises one arm of 12 healthy Jamaican male and female adults with normal body mass inex, aged 20 to 45 years, receiving a test meal containing the common bean that was intrinsically labelled with deuterium .
16380090|NCT04118504|Experimental|Intervention group|Lifestyle intervention on through mobile application
16380091|NCT04118504|No Intervention|Control group|Usual care
16380092|NCT04118491|Sham Comparator|sham1st|40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
16380093|NCT04118491|Active Comparator|sham second|"iii. We will divide the subjects into two groups of five. One group will receive 40 Hyperbaric Oxygen (HBO2) treatments (100% oxygen at twice normal air pressure (2 ATA)) followed by 40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
~iv. Neurological and psychologic assessments will be done prior to starting treatments, after the first block of 40 and again after the second block of 40."
16380094|NCT04118478|Experimental|Multi-component phased training program|"The intervention of the program consists of conducting a multi-component training in a neighborhood unit.
~The intervention will consist of the realization of a multi-component program in a training center adapted for the elderly. The duration of the program will be 27 weeks with a frequency of two weekly sessions and an intervention duration of 45 to 60 minutes"
16380095|NCT04118478|No Intervention|CONTROL|Older people assigned to the GC do not do any training programming. Only attend the measurement dates.
16380096|NCT04118465|Active Comparator|ECV with Full urinary bladder|ECV with Full urinary bladder
16380097|NCT04118465|Active Comparator|ECV with empty urinary bladder|ECV with empty urinary bladder
16380098|NCT04118452|Experimental|Intervention + Usual Care + Developmental Screening Results|Intervention group families will receive usual care and developmental screening results will be shared with each child's primary care provider. In addition, they will be connected via telephone to 2-1-1 prior to their scheduled well-child visit for the telephone-based early childhood development care coordination intervention.
16380099|NCT04118452|No Intervention|Usual Care + Developmental Screening Results|This group will receive usual care. In addition, developmental screening results will be shared with each child's primary care provider.
16380100|NCT04118439|Experimental|Motor Imaginery|Patients allocated in this arm will recieve a training on the first day after recruitment on a motor imaginery task and will be asked to do the task every day during 30 days until they start the usual care. Then after the physical therapy treatment with a pragmatic perspective will be meassured just inthe last session, after 1 month an.d after 3 moths of the treatment for the follow up
16380101|NCT04118439|No Intervention|Control Group|Patients allocated in this arm will be meassured at the start, again after 30 days and at the end of the physical therapy usual care with a pragmatic perspective. Then will be meassured again after 1 and 3 months.
16380102|NCT04118426||Radiotherapy group|Patients receiving radiotherapy after surgery for brain tumor
16380103|NCT04118426||No radiotherapy group|Patients NOT receiving radiotherapy after surgery for brain tumor
16380104|NCT04118413|Experimental|Erector spinae plane block|Erector spinae plane block will be administrated to this group at end of the surgery under spinal anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively and sheduled paracetamol will be given.
16380105|NCT04118413|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine and sheduled paracetamol. No block will be performed.
16380106|NCT04118400||Experimental: NIN-NAVA|"Premature>30weeks with respiratory distress
~PI to determine eligibility or exclusion
~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~Place the catheter to optimize position
~ABG or VBG to be obtained at 2 hrs. post NIV-NAVA
~NIV-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
16380107|NCT04118400||Active Comparator: Nasal CPAP or NIMV|"Premature>30weeks with respiratory distress
~PI to determine eligibility or exclusion
~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~Place the catheter to optimize position
~ABG or VBG to be obtained at 2 hrs. post Nasal CPAP or NIMV
~NCPAP or NIMV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
16380108|NCT04118387|Active Comparator|acetazolamide|To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
16380109|NCT04118387|Active Comparator|zolpidem|To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
16380110|NCT04118387|Active Comparator|buspirone|To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
16380111|NCT04118374|Experimental|Standard Carb Diet then Low Carb Diet|
16380112|NCT04118374|Experimental|Low Carb Diet then Standard Carb Diet|
16380113|NCT04118361|Experimental|Patients with AVS isolated at emergencies|Enrollment of patients with AVS isolated at emergencies
16380114|NCT04118348|No Intervention|Passive Control|Will consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
16380115|NCT04118348|Experimental|Best Practice Alert (BPA-only)|Will consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
16380116|NCT04118348|Experimental|Health Maintenance Topic (HMT-only)|Will consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
16380117|NCT04118348|Experimental|BPA+HMT|Will consist of both the BPA and HMT presented simultaneously in Epic.
16380148|NCT04118062|Other|Triple Negative Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
16380149|NCT04118062|Other|Luminal B Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Luminal B Breast Cancer
16380118|NCT04118335|Experimental|Intervention Group|The individuals in the intervention group were asked to gargle with 5 ml black mulberry syrup three times a day after meals and wait average one minute in the mouth and then swallow, in addition to the standard practice of the clinic. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. The patients were followed for 15 days. The 15-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
16380119|NCT04118335|No Intervention|Control Group|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
16380120|NCT04118322|Experimental|intervention group|The patients in the intervention group applied peppermint oil (3%) on lips three times a day, during the five days following chemotherapy administration, in addition to the standard antiemetic treatments. The data were collected using a Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching (INVR), Visual Analog Scale (VAS) Patient Nausea Severity Follow-up Form, Patient Watch Chart, and Oil Application Protocol. Besides, patients in the intervention group were questioned thoughts associated with peppermint oil application using individual in-depth interview method.
16380121|NCT04118322|No Intervention|control group|The control group underwent only the routine treatment.
16380122|NCT04118309|Experimental|High-intensity interval training|Three sessions of high-intensity interval training per week for nine weeks. Following a three minute warm up, a session contained twenty minutes of alternating between a sprint (80% of maximum workload, 90-95% of maximum heart rate) and active rest (30% of maximum workload) at a one minute to one minute ratio. Every session ended with a two and a half minute cool down.
16380123|NCT04118309|Placebo Comparator|Placebo exercise group|No changes in physical activity behaviour occurred (already engaging in less than 150 minutes per week, instructed to maintain their current inactivity). They were told they needed to stay inactive since they were part of an 'acute' exercise group, aiming to see how long the effects of their baseline maximal exercise test would last. Thus, the cover story gave them the impression they were also in an exercise group, as oppose to a non-exercise control group.
16380124|NCT04118296|Experimental|Intervention|Intervention will be given in the form of the use of anti-acne combination creams that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
16380125|NCT04118283|Experimental|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
16380126|NCT04118283|Active Comparator|Health and Wellness|Health & Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health & Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
16380127|NCT04118270|Experimental|AFib 2gether(TM) App|Patients with known Atrial Fibrillation will be assigned to download and use an app targeted at determining stroke risk and increasing knowledge of Atrial Fibrillation and stroke risk along with treatment options and will use this information to facilitate a discussion with their cardiovascular provider.
16380128|NCT04118257|Experimental|Fruit Juice|Participants consumed 2 bottles of 100% fruit juice daily for 3 weeks.
16380129|NCT04118257|Experimental|Soda|Participants consumed 2 cans of caffeine-free Coca Cola daily for 3 weeks.
16380130|NCT04118257|Other|Water|Participants consumed 2 bottles of water daily for 3 weeks.
16380131|NCT04118231|Experimental|Dry needling|
16380132|NCT04118231|No Intervention|Control group|
16380133|NCT04118179||Suspected Sepsis Group|Participants suspected of potential to develop sepsis recruited at the emergency department.
16380134|NCT04118179||Surgical Group|Participants undergoing non-emergency scheduled surgery, including ear/nose and throat cases, orthopaedic surgery of the major joints including hip, knee, ankle, shoulder, and wrist.
16380135|NCT04118179||Healthy Group|Healthy participants
16380136|NCT04118166|Experimental|Ipilimumab/nivolumab+ cryotherapy|1 mg/kg with nivolumab 3 mg/kg every 3 weeks x 4 doses. (One cycle of treatment is 3 weeks). Cryotherapy (cryoablation) will be performed between investigational agent treatment Cycles 1 and 2
16380137|NCT04118153|Experimental|Abatacept|Abatacept will be given by a subcutaneous (SC) formulation weekly for three months.
16380138|NCT04118140|Experimental|True SA (Somatic Acupressure ) group|Receiving true somatic acupressure+usual care
16380139|NCT04118140|Sham Comparator|Sham SA group|Receiving sham somatic acupressure+usual care
16380140|NCT04118140|Other|Usual care group|Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)
16380141|NCT04118127|Experimental|2mg conventional tablet, once-weekly tablets|
16380142|NCT04118114|Experimental|PRL3-ZUMAB Monotherapy|
16380143|NCT04118101|Active Comparator|ESPB group|A total of 25 ml bupivacaine 0.5% willbe injected into the ESP.
16380144|NCT04118101|Placebo Comparator|Control group|The ESPB will not be performed.
16380151|NCT04118062|Other|Expert Patients|Focus groups (or group interviews) and DELPHI consensus method with expert patients
16380152|NCT04118062|Other|Researchers and Clinicians|Focus groups (or group interviews) and DELPHI consensus method with Researchers and Clinicians
16380153|NCT04118049|Experimental|Vaginal Probiotic Arm|"BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) is offered over the counter. It contains a total of 5 billion lactobacilli: L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus.
~RestoreTM gel: moisturizing personal lubricant.
~We will recommend to participants to use the probiotic supplement and vaginal lubricant as a vaginal suppository three times weekly at night for 3 months."
16380154|NCT04118049|Other|Standard Care Arm|Women will perform standard care which includes follow up at 3 months for pessary removal/care.
16380155|NCT04118036|Experimental|Surgery Arm|"In the surgical arm participants who require reoperation and have evidence of CDKN2A/B or C loss and intact RB from a prior tumor sample will receive
~Pembrolizumab-prior to surgery, at predetermined dose and time point
~Abemaciclib: every 12 hours from the day of pembrolizumab infusion to the morning of surgery
~Post surgery Participants with receive
~Abemaciclib, twice daily oral at specified dose for 21 day cycle
~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
16380156|NCT04118036|Experimental|Non Surgery Arm|"The treatment arm will be comprised of participants not requiring surgery.
~- Participants will receive treatment with
~Abemaciclib, twice daily oral at specified dose for 21 day cycle
~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
16380157|NCT04118023||7T MRI Group|Patient group that receives 7 Tesla Magnetic Resonance Imaging
16380158|NCT04118010|Active Comparator|Vitamin D3 and Inulin|Vitamin D3 50,000 IU/week and 12 g/day chicory-derived prebiotic inulin for 12 weeks
16380159|NCT04118010|Active Comparator|Vitamin D3 and placebo Inulin|Vitamin D3 50,000 IU/week and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
16380160|NCT04118010|Active Comparator|Placebo vitamin D3 and Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day chicory-derived prebiotic inulin for 12 weeks
16380161|NCT04118010|Placebo Comparator|Placebo vitamin D3 and placebo Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
16380162|NCT04117971||Staff members|Staff members in different clinical departments at Faculty of Dentistry, Cairo University.
16380163|NCT04117971||PhD students|PhD candidates in different clinical departments at Faculty of Dentistry, Cairo University.
16380164|NCT04117971||Master's students|Master's candidates in in different clinical departments at Faculty of Dentistry, Cairo University.
16380167|NCT04117945|Experimental|Arm A (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
16380168|NCT04117945|Experimental|Arm B (cetuximab, panitumumab, irinotecan)|Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
16380169|NCT04117932|Experimental|"Arm ustekinumab"|Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids
16380170|NCT04117919|Experimental|chinese medicine medicated bath|we used the leaf of paper mulberry as chinese medicine medicated bath. Two packs per day ,and the period of treatment will be two month.
16380171|NCT04117919|Active Comparator|control group|Topical steroids
16380172|NCT04117906|Experimental|STAGE course|
16380173|NCT04117906|No Intervention|Wait-list control|The wait-list control group will receive access to the STAGE course after the trial is complete.
16380174|NCT04117893|Experimental|Duloxetine combined with intra-articular injection|
16380175|NCT04117893|Active Comparator|Intra-articular injection|
16380176|NCT04117880|Experimental|Ataluren|Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
16380177|NCT04117867||Intraoperative hypotension|
16380178|NCT04117841||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
16380179|NCT04117841||Arm II: Prior treatment at centre|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
16380180|NCT04117841||Arm III: Prior treatment at outside centre|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
16380181|NCT04117828|Active Comparator|Control|50 g of glucose will be given to the individuals
16380182|NCT04117828|Experimental|1st Intervention group|50 g of Aseel dates will be given to the individuals
16380183|NCT04117828|Experimental|2nd Intervention group|50 g of Ajwa dates will be given to the individuals
16380184|NCT04117828|Experimental|3rd Intervention group|50 g of Karbala dates will be given to the individuals
16380185|NCT04117815||study group|"Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.
~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older"
16380186|NCT04117815||reference group|"For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria:
~Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.
~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older
~Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal."
16380187|NCT04117802|Experimental|Maple|
16380188|NCT04117802|Placebo Comparator|Placebo|
16380189|NCT04117789|Experimental|Therapist-guided ICBT for depression|"Participants will receive internet-delivered CBT with therapist support. The treatment consists of 8 online chapters with interactive features as videos and illustrations, delivered over a maximum of 10 weeks. The treatment has the main focus on behavioral activation.
~The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The parent program also consists of eight chapters, including psychoeducation about depression and how to support their adolescent in treatment.
~The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support."
16380190|NCT04117789|Experimental|Self-guided ICBT for depression|The self-guided ICBT for depression is identical to the therapist-guided ICBT intervention, however without the therapist support. To ensure patient-safety, there will be clear instructions to the patients and primary caregivers how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
16380191|NCT04117789|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both. The content of TAU and the treatment techniques used, will be monitored.
16380192|NCT04117776||Patients|Patient benefiting during the same hospitalization of the loss or the gain of a central venous catheter.
16380193|NCT04117763|Experimental|Empagliflozin|Empagliflozin 25 mg once daily for 3 months
16380194|NCT04117750|Active Comparator|intervention group|55 female patients with PCO
16380195|NCT04117750|Placebo Comparator|non -intervention group|40 female patients with PCO and 50 healthy women matched to PCOS women as regard age and ethnic origin.
16380196|NCT04117737|Experimental|Intervention|Single-arm
16380197|NCT04117711|Experimental|AT-007|
16380198|NCT04117711|Placebo Comparator|Placebo Comparator|
16380199|NCT04117698|Experimental|Antitubercular treatment and local corticosteroid therapy|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:
~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months
~associated with a treatment similar to the control group."
16380200|NCT04117698|No Intervention|Local Corticosteroid Therapy Only|"Treatment of Ocular Inflammation by Local Corticosteroid Therapy Only comprising:
~Dexamethasone (DEXAFREE® eye drops) at an attack dose for one week (4 to 6 drops / d maximum and if severe inflammation 1 drop / hour) then decrease and stop over 3 weeks, with relay by fluorometholone (Flucon®) for 2 months maximum. The modalities of the decrease of the local steroids are left to the ophthalmologists own judgment. Maximum total duration of 3 months.
~Mydriatic (tropicamide) 1gx3 / d if necessary.
~Neosynephrine 5% if posterior synechiae.
~Atropine (Alcon 0.3%) if pain."
16380201|NCT04117685||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
16380202|NCT04117685||Arm II: Prior treatment at center|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
16380203|NCT04117685||Arm III: Prior treatment at outside center|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
16380204|NCT04117672|Placebo Comparator|Placebo|Egg yolk powder not enriched for antisecretory powder
16380205|NCT04117672|Experimental|Salovum|Egg yolk powder enriched for antisecretory powder
16380206|NCT04117659|Experimental|Phosphodiesterase-5 inhibitor withdrawal|In this single arm pretreatment with an oral phosphodiesterase-5 inhibitor will be discontinued
16380207|NCT04117646||Patients|Patients of 2 and 12 years of age with chronic rhinosinusitis.
16380208|NCT04117646||Controls|Subjects of 2 and 12 years of age without chronic rhinosinusitis.
16380209|NCT04117633|Active Comparator|Mesh Rectopexy|Using Laparoscopy
16380210|NCT04117633|Active Comparator|Suture Rectopexy|Using Laparoscopy
16380211|NCT04117620||Patients|Patients from 7 to 17 years of age with vestibular deficiency.
16380212|NCT04117620||Controls|Subjects from 7 to 17 years of age without vestibular deficiency
16380213|NCT04117607|Experimental|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
16380214|NCT04117607|Experimental|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
16380215|NCT04117607|Experimental|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
16380216|NCT04117607|Experimental|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
16380217|NCT04117607|Experimental|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
16380218|NCT04117607|Experimental|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
16380219|NCT04117607|Experimental|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
16380220|NCT04117607|Experimental|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
16380221|NCT04117607|Experimental|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
16380222|NCT04117607|Experimental|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
16380223|NCT04117607|Experimental|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
16380224|NCT04117607|Experimental|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
16380225|NCT04117581|Active Comparator|Vitamin D3 supplement|Participant will be asked to take one capsule of vitamin D3 supplement (5000 IU) (125 μg) daily for a total duration of 12 weeks.
16380226|NCT04117581|Placebo Comparator|Placebo|Participants will be asked to take one capsule of placebo (inert filler) daily for a total duration of 12 weeks.
16380227|NCT04117555||Control|Diagnostic Test: Pupillometry
16380228|NCT04117555||Parkinson patients|Diagnostic Test: Pupillometry
16380229|NCT04117542||Overweight/Obesity Control|Adolescents who have overweight/obesity, but do not report loss of control eating.
16380230|NCT04117542||Overweight/Obesity Experimental|Adolescents who have overweight/obesity, and report loss of control eating.
16380231|NCT04117529|Experimental|Experimental Arm|Pemphigus or other autoimmune diseases.
16380232|NCT04117516|Active Comparator|Open surgery|30 patients will be operated with an open carpal tunnel release.
16380233|NCT04117516|Experimental|Percutaneous surgery|30 patients will be operated with a percutaneous carpal tunnel release.
16380234|NCT04117490|Active Comparator|Epiitalis low dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
16380235|NCT04117490|Active Comparator|Epiitalis mid dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
16380236|NCT04117490|Active Comparator|Epiitalis high dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
16380237|NCT04117490|Placebo Comparator|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
16380238|NCT04117477|Experimental|Xylitol wipes|
16380239|NCT04117477|Placebo Comparator|Placebo wipes|
16380240|NCT04117464|Experimental|Behavioral activation therapy|Behavioral activation therapy was applied following the protocol designed by Martell, Dimidjian & Herman-Dunn (2013).
16380241|NCT04117464|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment therapy was applied following the protocol designed by Hayes, Strosahl & Wilson, (2011).
16380242|NCT04117464|Experimental|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy was applied following the protocol designed by Barlow, Allen and Choate (2004).
16380243|NCT04117464|Other|Wait List Group|Participants at Wait List Group will be evaluated pre-post and 3, 6, 9 and 12 months follow up periods, like experimental groups.
16380244|NCT04117451|Sham Comparator|Chlorhexidine|Chlorhexidine mouthwash will be provided to participants for a week to rinse the mouth twice a day.
16380245|NCT04117451|Experimental|Propolis|Propolis mouthwash will be provided to participants for a week to rinse the mouth twice a day.
16380246|NCT04117425|Other|Pregnant women|"40 Pregnant women and 10 Pregnant women that have a medical interruption of pregnancy who were already treated by levetiracetam.
~Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.
~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption"
16380247|NCT04117412|Other|Patients with COPD|Patients with COPD will undergo two different one bout of exercise training after maximal exercise test.
16380248|NCT04117399|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
16380249|NCT04117399|Active Comparator|Control group|aerobic exercice
16380250|NCT04117386||Primary pterygium group|Participants who was diagnosed with primary pterygium
16380251|NCT04117386||Secondary pterygium group|Participants who was diagnosed with secondary pterygium
16380252|NCT04117386||Healthy participants as control group|Participants who have no pterygium and other inflammation disease in eyes
16380253|NCT04117373||Cohort 1|Patients from the existing Optum insurance claimed database with a confirmed diagnosis of melanoma, basal cell carcinoma, or squamous cell carcinoma who have undergone skin cancer excision surgery followed by interpolated flap repair between the years 2001-2006.
16380254|NCT04117360||Dentofacial Disharmony Patients|Dentofacial disharmony patients who are seeking jaw surgery in UNC oral and maxillofacial surgery department and are seen in UNC orthodontic dentofacial disharmony clinic.
16380255|NCT04117347|Experimental|Light therapy A via the Re-Timer®|-15 minutes/day
16380256|NCT04117347|Experimental|Light therapy B via the Re-Timer®|-30 minutes/day
16380257|NCT04117347|Experimental|Light therapy C via the Re-Timer®|-60 minutes/day
16380258|NCT04117334||Bracing AIS patients|These are patients undergoing brace treatment for AIS
16380262|NCT04117308|Active Comparator|Control group|Patients who received a classic information.
16380263|NCT04117308|Experimental|Educated group|Who have been educated to the active fetal movements count.
16380264|NCT04117295|Experimental|Treatment|Subjects implanted with the Carmat TAH
16380265|NCT04117282|Active Comparator|control group|15 children received the regular exercise program including classical gait training for diplegic children (30 minutes exercises + 30 minutes gait training)
16380266|NCT04117282|Experimental|study group|15 diplegic child received the same exercise program including the use of the antigravity shoes for gait training (30 minutes exercises + 30 minutes gait training)
16380267|NCT04117269|Experimental|External shoe lift|Those patients allocated in the experimental group will be supplemented with a external shoe lift in the contralateral limb in their conventional shoes to compensate the differences with the affected foot (using a offloading device to active ulcer).
16380268|NCT04117269|No Intervention|Standard of care|Those patients allocated in the control group will not be supplemented, they will be treated with a standard of care treatment.
16380269|NCT04117256|Active Comparator|Transcranial Stimulation|Transcranial stimulation on the primary motor cortex (M1) with anode located on the point C3 (10/20 EEG system), and the cathode on contralateral supraorbital zone.
16380270|NCT04117256|Active Comparator|Suboccipital Stimulation|Suboccipital stimulation with anode located at the upper cervical level and cathode was placed on the lateral part of right shoulder.
16380271|NCT04117243|Active Comparator|Tranexamic group|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).
16380272|NCT04117243|Active Comparator|Misoprostol group|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision.
16380273|NCT04117243|Active Comparator|oxytocin only group|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby
16380274|NCT04117217||Central venous lines|Patients having a central venous catheter placed at Banner University Medical Center, University of Arizona
16380275|NCT04117217||Cardiac catheterization|Patients undergoing a cardiac catheterization procedure done at Banner University Medical Center, University of Arizona
16380276|NCT04117204|Experimental|Fruits and Vegetables|This group will receive a prescribed amount of free fruits and vegetables (F&V) for 6 weeks of pick-up at a farm stand or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 6 weeks with minimal contact.
16380277|NCT04117204|No Intervention|Wait List Control|This group will not receive a prescribed amount of free fruits and vegetables (F&V) for 12 weeks. They will serve as the control group. After 12 weeks of control and data comparisons, they will be given 12 weeks of vouchers with minimal contact.
16380278|NCT04117191|Experimental|Tryptophan loading|All participants are introduced to receive tryptophan loading test.
16380279|NCT04117178|Active Comparator|Standard of care|Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.
16380280|NCT04117178|Experimental|Intervention arm|Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.
16380281|NCT04117165|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from chronic inflammatory rheumatism, in particular, rheumatoid arthritis. Prescription of bDMARD or their biosimilars is possible.
16380282|NCT04117165|Active Comparator|Patient Current care|Current care of patients with rheumatoid arthritis, based on the recommendations of the French Society of Rheumatology. Prescription of bDMARD or their biosimilars is possible.
16380283|NCT04117139|Other|Study Group|In addition to other standard imaging modalities in the fast track cancer program, included patients will have a PET/MRI done.
16380284|NCT04117126|Experimental|urinary incontinence|Recruitment, 3-day voiding record, initiate a individualized prompted voiding schedule based on the client's toileting needs until discharge, 1, 3 and 6 month follow-up post-discharge.
16380285|NCT04117113||Elderly, 60+ hospitalized with Invasive ExPEC Disease|Patients 60 years or older hospitalized with Invasive Extraintestinal Pathogenic Escherichia coli Disease.
16380286|NCT04117100||Endoscopic mucosal resection (EMR)|It has become the standard treatment for superficial tumors of the gastrointestinal tract, either flat or sessile: precancerous lesions and superficial cancers with no or low ganglionic risk. The pre-injection of physiological serum detaches the lesion from the deep plane and allows, with great security, the resection of the mucosa, muscularis mucosae with part of the submucosa, whatever the size and location of the lesion. Compared to other techniques, it allows a histological analysis which dictates the subsequent conduct and the possible need for a complementary surgery.
16380287|NCT04117100||Endoscopic mucosal dissection (ESD)|This technique uses submucosal injection and special knives to make a peri-lesional circumferential incision, followed by dissection through the submucosal sub-lesion.
16380288|NCT04117100||Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC)|This is a mucosal thermo-destruction technique. It uses a generator that delivers a sinusoidal current of high frequency to a probe covered with bipolar electrodes in tight network ensuring a uniform diffusion of the thermal effect. The tissue penetration is superficial on 1mm, intended to eradicate the epithelium up to the muscularis mucosae. Circumferential or focal probes are used as a function of the length of the segment to be treated.
16380289|NCT04117100||Per Oral Endoscopic Myotomy (POEM)|"This technique allows a myotomy on the 8 cm of the lower esophagus extended on the gastric side of the cardia, totally endoscopically, after having approached and tunneled the esophageal submucosa.
~Less invasive, it gradually replaces the pneumatic dilatation and surgical myotomy of Heller.
~It requires a general anesthesia, an expert operator and a trained nursing team, ESD instruments, carbone dioxide insufflation."
16380290|NCT04117087|Experimental|KRAS peptide vaccine, Nivolumab, and Ipilimumab|
16380291|NCT04117074|Experimental|Arm 1: Thoracic Epidural Analgesia with bupivicaine|Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter [mL] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
16380292|NCT04117074|Experimental|Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine|Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
16380293|NCT04117061|No Intervention|Control|Patient gets usual diagnostic path: after inconclusive ultrasound is refered to CT scan.
16380294|NCT04117061|Active Comparator|Observation|Patient after inconclusive primary evaluation is observed in emergency room for 8-12 hours and after the clinical evaluation, laboratory results and ultrasound examination is repeated.
16380295|NCT04117048|Experimental|At home INR measurement with LabPad®|All at home INR measurements will be performed with the LabPad® point-of-care
16380296|NCT04117035|Placebo Comparator|Control arm|Standard care
16380297|NCT04117035|Experimental|Intervention|
16380298|NCT04117022|Experimental|supplemented arm|Each subject will receive DVS formula, 2 softgels per day for 6 months.
16380299|NCT04117009|Experimental|Remifentanil 2 ng/mL|Following baseline echocardiographic evaluation, Remifentanil (ultiva at a concentration of 20 micg/ml) infusion will be started at a rate to reach a target plasma level of 2 ng/mL. A target Controlled Infusion pump will be used to infuse the study drug. Once the target drug concentration is reached (which is expected to reach around 10-15 minutes), the final echocardiographic examination will be performed.
16380300|NCT04117009|Experimental|Baseline|Baseline transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure and study drug infusion begins.
16380301|NCT04116983||All patients|Recruited participants will be attending a dermatology clinic with at least one skin lesion where there is a suspicion of skin cancer. All suspicious lesions suitable for photographing will be photographed six times in a single visit. A macro and dermoscopic image of each lesion will be captured by three different mobile phones: an iPhone, a Samsung and a Nokia smart phone, without (macro image) or with (dermoscopic image) a Dermlite DL1 lens attached. Dermoscopic images of healthy skin will also be captured by each camera. Images of the lesions will be analysed by DERM. The DERM results for lesions biopsied will be compared to the biopsy result; the DERM results for lesions not biopsied will be compared to the clinical assessment.
16380302|NCT04116970|Experimental|Diagnostic (bronchoscopy with EBUS-TBNA with/without vacuum)|Patients undergo bronchoscopy with EBUS-TBUA first without and then with applied vacuum.
16380303|NCT04116957|Other|Time 1|First two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
16380304|NCT04116957|Other|Time 2|Second two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
16380305|NCT04116944|Experimental|Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults with analogue-Generalized Anxiety Disorder
16380306|NCT04116944|Other|Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
16380307|NCT04116944|Experimental|Non-Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults without analogue-Generalized Anxiety Disorder
16380308|NCT04116944|Other|Non-Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
16380309|NCT04116931|Experimental|clopidogrel-600 mg-12h|clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
16380310|NCT04116931|Experimental|clopidogrel-600 mg-24h|clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
16380311|NCT04116931|Experimental|clopidogrel-75 mg-12h|clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor
16380312|NCT04116931|Experimental|clopidogrel-75 mg-24h|clopidogrel 75 mg maintenance dose（MD) 24 hours after the last MD of ticagrelor
16380313|NCT04116905|Experimental|Intensive Lifestyle Intervention|Participants in the intensive lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain a 15% weight loss.
16380314|NCT04116905|Active Comparator|Conventional Treatment|The conventional treatment arm provides group sessions on metabolic syndrome management and social support, aimed at a 5% weight loss.
16380315|NCT04116892|Active Comparator|the peeling group|the internal limiting membrane was discarded
16380316|NCT04116892|Experimental|the Cover group|the internal limiting membrane was peeled centripetally all the way up to the MH rim and the hinged ILM flap folded upside-down on top of the MH in order to bridge the entire retinal defect with a single layer.
16380317|NCT04116892|Experimental|the Fill group|"the internal limiting membrane was folded in multiple layers and deliberately stuffed or packed within the MH defect using a forceps."
16380318|NCT04116853|Experimental|ADAPTIVE Extended-Care Group|"Participants randomized to the ADAPTIVE extended-care program will receive extended-care intervention phone delivered only if either 1) an algorithm developed by our study team detects that a participant is at high risk for weight regain or 2) the participant self-initiates a request for a session."
16380319|NCT04116853|Active Comparator|STATIC Extended-Care Group|Participants randomized to the STATIC extended-care program will receive the extended-care intervention phone calls on a fixed, once-per-month schedule (the schedule currently used in gold-standard weight maintenance programs).
16380320|NCT04116840|Experimental|MT1002 for Injection|Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects
16380425|NCT04116138|Experimental|Salovum|Salovum®, an egg powder enriched for anti secretory factor.
16380321|NCT04116827||Tamoxifen group|Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin
16380322|NCT04116801|Experimental|Fluorescence arm|fluorescence guided microsurgical resection (under 560 nm filter) in addition to the usual techniques, after iv injection of 200 mg (i.e. 3-4 mg/kg) of fluorescein sodium at the time of skin incision.
16380323|NCT04116801|Active Comparator|Standard excision|microsurgical resection with usual techniques
16380324|NCT04116775|Experimental|Treatment|"INITIAL TREATMENT PHASE: Patients progressing on enzalutamide will receive 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy.
~ASSESSMENT PHASE: After completion of the initial treatment phase, patients will have their disease assessed by tumor imaging. Patients who respond to treatment will become stool donors to patients who do not respond. Non-responders will move on to the retreatment phase.
~RETREATMENT PHASE: Non-responders will undergo a fecal transplant and be retreated with 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for an additional 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy."
16380325|NCT04116762|Experimental|Intervention|Placement of TissuePatchDS-P™ at time of operation. No surgical drain is used.
16380326|NCT04116762|Active Comparator|Control|No use of TissuePatchDS-P™. Wound is closed with a surgical drain (Surgeon's choice) in situ.
16380327|NCT04116749||Non-obese women|body mass index lower than 30 (kg/m^2) at term
16380328|NCT04116749||Obese women|body mass index equal or greater than 30 (kg/m^2) at term
16380329|NCT04116736||TEST Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with the ACUVUE® OASYS with Transitions™ will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
16380330|NCT04116736||CONTROL Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with spherical non-photochromic reusable marketed silicone hydrogel contact lenses (of any brand) will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
16380331|NCT04116723|Experimental|Flexible brace|The design of the flexible brace incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) artificial hinge bone for the strategical application and fixation of corrective panel, 3) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
16380332|NCT04116710|Experimental|Phase 1: HS-130 + HS-110 (viagenpumatucel-L)|Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
16380333|NCT04116697|Experimental|Acupuncture with Anti-Emetics|
16380334|NCT04116697|Experimental|Aromatherapy with Anti-Emetics|
16380335|NCT04116697|No Intervention|Control Group|
16380336|NCT04116684|Experimental|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
16380337|NCT04116684|No Intervention|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
16380338|NCT04116671|Experimental|Neuromechanical Gait Assist|All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance.
16380339|NCT04116658|Experimental|Cohort 1|Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab
16380340|NCT04116658|Experimental|Cohort 2|Multiple dose of EO2041 in combination with nivolumab
16380341|NCT04116658|Experimental|Cohort 3|Multiple dose of EO2041 in combination with nivolumab and bevacizumab (US only)
16380342|NCT04116645||Group 1|singleton pregnancies
16380343|NCT04116645||Group 2|Twin pregnancies
16380344|NCT04116632|Experimental|BMS-963272 or Placebo once daily (QD)|
16380345|NCT04116632|Experimental|BMS-963272 or Placebo every 12 hours (Q12H)|
16380346|NCT04116632|Experimental|BMS-963272 or Placebo every 8 hours (Q8H)|
16380347|NCT04116619||Individuals with Cannabis Use Disorder|Participants who meet criteria for Cannabis Use Disorder will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
16380348|NCT04116619||Light Cannabis Users|Participants who are light cannabis users (<1 joint/week) will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
16380349|NCT04116606|Active Comparator|Active JNJ-54175446|JNJ-54175446 is an unlicensed drug currently being developed by Janssen Pharmaceuticals. The drug is presented in oral capsules, each capsule containing 50 mg of JNJ-54175446. Participants will be asked to self-administer one capsule daily for 8 weeks.
16380350|NCT04116606|Placebo Comparator|Matching placebo|
16380351|NCT04116593|Experimental|Intervention|
16380352|NCT04116593|No Intervention|Control|
16380353|NCT04116580||Allergic patients to raw apple and birch|Single-group studies about 28 patients allergic to birch and no longer eating raw rosaceae for at least 6 months. Patients brought back into contact with this family of fruits via the raw golden apple according to an Ultra-Rush protocol.
16380354|NCT04116554|Active Comparator|intervention group (A)|which will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.
16380355|NCT04116554|Sham Comparator|control group (B)|which will have sham block bilaterally by injection of 20 ml of 0.9%saline will be injected on each side.
16380356|NCT04116541|Experimental|HDM201 + Ribociclib|Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
16380357|NCT04116541|Experimental|Cabozantinib|Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.
16380358|NCT04116541|Experimental|Alectinib|Patient with ALK alterations: translocation, mutation or amplification
16380359|NCT04116528|Other|Ketamine|Every eligible participant will receive 0.5mg/kg IV given over 40 minutes
16380360|NCT04116528|Active Comparator|Buprenorphine or Placebo|Buprenorphine or placebo once daily for 4 weeks
16380361|NCT04116515|Active Comparator|Care Only|A third of the participants will have standard clinical care only.
16380362|NCT04116515|Experimental|Care + AVG|A third of the participants will have the same standard clinical care plus an Xbox and active games.
16380363|NCT04116515|Experimental|Care + AVG + Narratives|A third of the participants will have the same standard clinical care, an Xbox and active games, plus the stories delivered to their Xbox consoles.
16380364|NCT04116502|Experimental|A- Ruxolitinib|Treatment with Ruxolitinib
16380365|NCT04116502|Active Comparator|B- Hydroxycarbamide OR Interferon A|Best Available Therapy (BAT), Treatment with hydroxycarbamide OR Interferon A
16380366|NCT04116489|Experimental|Wildlife Immersion Activity|We will use a crossover design in which each participant receives an introductory forest walk followed by 3 wildlife immersion activity experiences in different settings .
16380367|NCT04116476|Experimental|Moderate Hepatic Impairment|
16380368|NCT04116476|Experimental|Normal Healthy Matches|
16380369|NCT04116476|Experimental|Mild Hepatic Impairment|
16380370|NCT04116463|Experimental|CDSMP|Chronic Disease Self-Management Program (CDSMP) - a 6-week, group-based behavioral intervention delivered in a 2.5 hour session each week by a trained facilitator.
16380371|NCT04116463|Active Comparator|Financial Self-Management|Financial self-management course delivered in 3 modules, with a delivery time of approximately 1 hour per module.
16380372|NCT04116450|Other|primary congenital glaucoma|Glaucolight illuminated microcatheter trabeculotomy in primary congenital glaucoma
16380373|NCT04116437|Experimental|Zanubrutinib|"Cohort 1: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with ibrutinib
~Cohort 2: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with acalabrutinib alone/with ibrutinib"
16380374|NCT04116424|Experimental|nurse training of the patient|
16380375|NCT04116424|Active Comparator|simple information of the patient by neurologist|
16380376|NCT04116411|Placebo Comparator|Placebo|Patients will receive placebo tablets with similar appearance as the active drug. Patients receive two 450 mg tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg tablet once daily for an additional 22.5 months; a total treatment time of 24 months.
16380377|NCT04116411|Active Comparator|Valganciclovir|Patients will receive valganciclovir tablets with similar appearance as the placebo tablets. Patients receive two 450 mg valganciclovir tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg valganciclovir tablets once daily for an additional 22.5 months; a total treatment time of 24 months.
16380378|NCT04116398|Experimental|Ozurdex®, 700µg dexamethasone intravitreal injection|Intravitreal injection of dexamethasone (Ozurdex®)
16380379|NCT04116385||Cancer surgery patients|Adult subjects (18 years or older) undergoing an oncologic surgical procedure.
16380380|NCT04116372|Experimental|Empty Nest Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
16380381|NCT04116372|Experimental|Retirement Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
16380382|NCT04116372|No Intervention|Empty Nest Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
16380383|NCT04116372|No Intervention|Retirement Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
16380384|NCT04116359|Experimental|Non-BRD4 exploratory cohort (molibresib, cisplatin, etoposide)|Patients receive molibresib besylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive molibresib besylate, etoposide phosphate and cisplatin as in Phase I and II Cohort at the discretion of the principal investigator.
16380422|NCT04116164|Experimental|Dosimetry and targeting|"Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.
~In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point"
16380385|NCT04116359|Experimental|Phase I and II cohort (molibresib, etoposide, cisplatin)|Patients receive molibresib besylate PO QD on days 1-14 (may switch to days 1-21 after completion of etoposide and cisplatin cycles). Patients also receive etoposide phosphate IV over 60 minutes on days 1-3 and cisplatin IV over 60 minutes on day 1 of cycles 1-4. Treatments repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of cycle 4, patients may receive etoposide phosphate and cisplatin for up to 8 cycles total in the absence of disease progression or unacceptable toxicity at the investigator's discretion.
16380386|NCT04116346|No Intervention|Fasting group|Fasting for both solids and fluids for up to 6 hours pre-procedure
16380387|NCT04116346|Experimental|Non Fasting group|Usual meal on the day of the procedure and allowed to drink as usual
16380388|NCT04116333|Experimental|ML + ETI|Intubation with using endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
16380389|NCT04116333|Active Comparator|ML|Intubation with using the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
16380390|NCT04116320|Experimental|Cohort 1, primary regimen (Regimen 1a)|FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.
16380391|NCT04116320|Experimental|Cohort 1, secondary regimen (Regimen 2a)|FUSA therapy will be administered on day 8.
16380392|NCT04116320|Experimental|Cohort 2, primary regimen (Regimen 1b)|FUSA therapy, standard of care PD-1 blockade, and imiquimod. FUSA therapy will be administered on day 1.
16380393|NCT04116320|Experimental|Cohort 2, secondary regimen (Regimen 2b)|FUSA therapy and imiquimod. FUSA therapy will be administered on day 1.
16380394|NCT04116307|Experimental|Polymethylsiloxane|Polymethylsiloxane (Enterosgel) is given 3 x 10 g for the initial two days, and 3 x 5 g for the next three days.
16380395|NCT04116307|Active Comparator|Lactobacillus reuteri|Probiotic Lactobacillus reuteri (BioGaia) is given 3 x 20 drops (which means 3 x 400,000.000 CFU) per day for five days.
16380396|NCT04116294|No Intervention|Before|Standard of care for informatic prescription.
16380397|NCT04116294|Active Comparator|After|Computer-assisted prescription for radiological procedure
16380398|NCT04116281|Experimental|Supervised group|Supervised group
16380399|NCT04116281|Other|No supervised group|Control group
16380400|NCT04116268||Obesity|BMI >23kg/m2
16380401|NCT04116268||Control|BMI 18-22.9kg/m2
16380402|NCT04116255|Experimental|exercises group|exercises group apply regular therapeutic home exercises programme
16380403|NCT04116255|Experimental|splint group|splint group use mandibular oral occlusal splint
16380404|NCT04116242||cirrhosis of the liver, stadium Child A|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
16380405|NCT04116242||cirrhosis of the liver, stadium Child B|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
16380406|NCT04116242||cirrhosis of the liver, stadium Child C|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
16380407|NCT04116242||cirrhosis of the liver, acutely decompensated|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
16380408|NCT04116242||acute liver failure|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
16380409|NCT04116242||healthy controls|sampling of biological material and health related data collection on day 1 (Baseline)
16380410|NCT04116229||Normal-weight|Participants who have a body mass index within the normal-weight category.
16380411|NCT04116229||Obese|Participants who have a body mass index within the obese category.
16380412|NCT04116216|Active Comparator|High frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
16380413|NCT04116216|Active Comparator|Low frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
16380414|NCT04116216|Sham Comparator|Sham rTMS + physical therapy|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
16380415|NCT04116203|Other|Fish Oil|Fish oil capsules 1200mg 6 tablets/day 12 weeks
16380416|NCT04116203|Other|Metformin|Metformin tablets (500 mg) 2/day 12 weeks
16380417|NCT04116203|Other|Fish Oil and Metformin|Combo of other 2 arms
16380418|NCT04116190|Experimental|Telerehabilitation (TR)|Shortened inpatient rehabilitation mixed with home-based telerehabilitation.
16380419|NCT04116190|Experimental|Conventional rehabilitation (CR)|Traditional inpatient rehabilitation
16380420|NCT04116177|Active Comparator|Standard Stimulation|Standard stimulation using contact 3-6 to achieve best therapeutic stimulation
16380421|NCT04116177|Experimental|Flexible stimulation|Flexible stimulation using all available stimulation strategies provided by the VerciseTM system including stimulation of contacts 1-8 and variable pulse width and frequency.
16380423|NCT04116151|Experimental|Intervention group|Local administration of the Alantel (R) cream on the affected skin
16380424|NCT04116151|Placebo Comparator|Control group|Local administration of the Placebo cream on the affected skin
16380493|NCT04115657|Experimental|Starch 3|Kithul flour
16380426|NCT04116125|Placebo Comparator|Sentinel lymph node biopsy|Perform conventional sentinel lymph biopsy
16380427|NCT04116125|Experimental|Adjuvant radiation without Sentinel lymph node biopsy|Perform radiotherapy instead of sentinel lymph node biopsy
16380428|NCT04116112|Experimental|Higher Systolic Blood Pressure (SBP) Target|Lower systolic blood pressure to ≤180 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain ≥160 mmHg.
16380429|NCT04116112|Experimental|Lower SBP (<160 mmHg) Target|Lower systolic blood pressure to <160 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain >140 mmHg.
16380430|NCT04116112|Experimental|Lower SBP (<140mmHg) Target|Lower systolic blood pressure to <140 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain >110 mmHg.
16380431|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
16380432|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
16380433|NCT04116086|Other|PSMA PET-CT exam|Ga 68 -PSMA PET/CT scanning will be performed using a combined PET/CT protocol with a 16-detector-row helical CT scanner (Philips Gemini GXL). This scanner allows simultaneous acquisition of up to 45 transaxial PET images with interslice spacing of 5 mm in one bed position and provides an image from the vertex to the thigh in about 10 bed positions. The use of (68)Ga-PSMA HBED-CC results in a relatively low radiation exposure, delivering organ doses that are comparable to those of other (68)Ga-labelled PSMA-inhibitors used for PET-imaging. Total effective dose is lower than for other PET-agents used for prostate cancer imaging (e.g. (11) C- and (18) F-Choline).
16380434|NCT04116073|Experimental|INCMGA00012 (PD-1 antibody)|All participants will receive the interventional study drug; INCMGA00012.
16380435|NCT04116060|Experimental|Nitrate|Dietary nitrate dissolved in water (0,12 mmol sodium-nitrate/kgBW/day) Dietary Supplement: Dietary nitrate 200 ml tab water with 0,12 mmol/kgBW sodium-nitrate
16380436|NCT04116060|Placebo Comparator|Control|Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day) Dietary Supplement: Dietary sodium-chloride 200 ml tab water with 0,12 mmol/kgBW sodium-chloride
16380437|NCT04116047|Active Comparator|Arm 1 (control): chemoradiotherapy|Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.
16380438|NCT04116047|Experimental|Arm 3: Dose-escalated chemoradiotherapy|Dose-escalated chemoradiotherapy using intensity modulated radiotherapy (IMRT) 64Gy in 25F + Cisplatin 100mg/m2 day 1 of week 1 and of week 5 or weekly 40mg/m2. Neck dissection as indicated by clinical and radiological assessment at 3-months post-treatment.
16380439|NCT04116047|Experimental|Arm 5: Durvalumab + Arm 1|One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months
16380440|NCT04116034|Experimental|DSR|Up to 10 subjects will be treated with alfapump DSR system for a total treatment period of 59 days post-implantation
16380441|NCT04116021|Active Comparator|PECS block|Ultrasound-guided pectoral nerve block with bupivacaine 0.5 % 30 mL before surgical incision
16380442|NCT04116021|Active Comparator|Wound infiltration|Wound infiltration with bupivacaine 0.5 % 30 mL at the end of surgery
16380443|NCT04116008|Active Comparator|Erector Spinae Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16380444|NCT04116008|Active Comparator|Subcostal Abdominis Plane Block|Ultrasound-guided bilateral STAP block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16380445|NCT04115982|Experimental|Cholecalciferol|Cholecalciferol (Vitamin D3) 100 000 IU/2 mL
16380446|NCT04115982|Placebo Comparator|Placebo|Placebo of Cholecalciferol (Vitamine D3) 100 000 IU/2 mL
16380447|NCT04115969||Patients with non-invasive ventilation|
16380448|NCT04115956|Experimental|Melflufen and dexamethasone in combination|Intravenous infusion of melflufen Day 1 of 28 day cycles, in combination of dexamethasone on Days 1 and 2 of each 28-day cycle.
16380449|NCT04115943|Experimental|Experimental Group|The experimental group (EG) will be submitted to a clinical method considered the gold standard for the treatment of neck pain together with a tongue muscle release protocol.
16380450|NCT04115943|Active Comparator|Control Group|The control group (CG) will only receive the gold standard method for the treatment of neck pain.
16380451|NCT04115930||Patient|Fatigue, cognition and quality of life measurements with different kind of tests and forms. EDSS and SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
16380452|NCT04115930||Control|Healthy volunteers. Fatigue, cognition and quality of life measurements with different kind of tests and forms. SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
16380453|NCT04115917|Experimental|Schocket Scleral Depressor|Scleral Depression with Schocket Scleral Depressor
16380454|NCT04115917|Active Comparator|Cotton Tipped Applicator|Scleral Depression with Cotton Tipped Applicator
16380455|NCT04115904|Experimental|Post-endodontic Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg takena week after. Incidence of flare ups after a single vsmultiple visits root canal treatments.
16380456|NCT04115904|Experimental|Acute pain|Acetaminophen 325 mg for Acute pain. Taken secondday after. Incidence of Post operative pain after rootcanal treatment in one vs two visits
16380494|NCT04115657|Experimental|Starch 4|Sago flour
16380495|NCT04115657|Experimental|Sugar 1|Pure palatinose
16380457|NCT04115891|Experimental|Lavender oil group|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to tooth extractions.
~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale 2 (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
16380458|NCT04115891|Sham Comparator|Control group|"No application prior to interventions. No lavender oil inhalation.
~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
16380459|NCT04115878|Active Comparator|High dose ato-oxy|
16380460|NCT04115878|Active Comparator|Low dose ato-oxy|
16380461|NCT04115852||CON|Healthy Controls
16380462|NCT04115852||BED|Patients with Binge-Eating-Disorder
16380463|NCT04115839|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
16380464|NCT04115839|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 16 weeks.
16380465|NCT04115839|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
16380466|NCT04115839|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 2 years.
16380467|NCT04115839|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 2 years.
16380468|NCT04115826|Placebo Comparator|Extracorporeal Shock-Wave Lithotripsy|Stone localization will first be performed by obtaining high-quality plain films of the pancreatic area in left and right oblique positions using a two-dimensional radiologic targeting system.Depending on the stone localization, ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
16380469|NCT04115826|Active Comparator|Per-oral Pancreatoscopy-guided Lithotripsy|Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.
16380470|NCT04115813|Experimental|Intervention Arm|The intervention arm participants received the Project YES! intervention for the first phase and then after midline data collection went into a maintenance phase.
16380471|NCT04115813|Other|Comparison Arm|The comparison arm was a usual care arm during the first phase (and primary analysis). After midline data collection the comparison arm began receiving the Project YES! intervention.
16380472|NCT04115800|Experimental|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
16380473|NCT04115800|Placebo Comparator|Liposomal|Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease
16380474|NCT04115774||Osteogenesis Imperfecta patients|The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
16380475|NCT04115761|Other|Investigational Group|ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens. The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
16380476|NCT04115761|Other|Control Group|the conventional treatment (RT and chemotherapy) will be given after tumor resection, followed by subsequent evaluations by an approximately 8-week interval.
16380477|NCT04115748|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
16380478|NCT04115748|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg + PTM adalimumab for up to 16 weeks.
16380479|NCT04115748|Active Comparator|Adalimumab (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + adalimumab 40 mg injection for up to 16 weeks.
16380480|NCT04115748|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
16380481|NCT04115748|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 2 years.
16380482|NCT04115748|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 2 years.
16380483|NCT04115722||Agroup of IBD patients in activity|
16380484|NCT04115722||Normal controlled group|
16380485|NCT04115709|Experimental|Intervention: Device attached with advice activated|Beacon Caresystem device will be attached to the patients and its ventilator advice will be activated.
16380486|NCT04115709|Active Comparator|Control: standard care with device attached without advice|Beacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated.
16380487|NCT04115683|Experimental|Intervention Group|
16380488|NCT04115683|Active Comparator|Control Group|
16380489|NCT04115670|Experimental|specific intervention (experimental)|Specific intervention (experimental). The intervention group will carry out 3 sessions of specific pain education + 15 sessions of physical training.
16380490|NCT04115670|Active Comparator|control group (no intervention)|NO intervention
16380491|NCT04115657|Experimental|Starch 1|Tapioca starch
16380492|NCT04115657|Experimental|Starch 2|High amylose
16380497|NCT04115644|Placebo Comparator|Group 1 (control)|will receive an injection of 5 cc 0.25% Marcaine without epinephrine
16380498|NCT04115644|Experimental|Group 2 (ketorolac)|will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
16380499|NCT04115644|Other|Group 3 (kenalog)|Pt will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone. Group 3 is standard of care
16380500|NCT04115631|Experimental|Arm A (bendamustine, rituximab, cytarabine)|Patients receive bendamustine IV on days 1 and 2 and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive rituximab IV on day 1 and cytarabine IV every Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16380501|NCT04115631|Experimental|Arm B (acalabrutinib, bendamustine, rituximab, cytarabine)|Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16380502|NCT04115631|Experimental|Arm C (acalabrutinib, bendamustine, rituximab)|Patients receive acalabrutinib PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16380503|NCT04115618|Experimental|SIB|Simultaneous integrated boost intensity-modulated chemoradiotherapy
16380504|NCT04115592|Experimental|Liquid oil type 1|Cocoa butter (CB)
16380505|NCT04115592|Experimental|Solid oil type 1|Cocoa butter oleogel (CBOG)
16380506|NCT04115592|Experimental|Liquid oil type 2|Sal seed oil (SL)
16380507|NCT04115592|Experimental|Solid oil type 2|Sal seed oleogel (SLOG)
16380508|NCT04115579|Experimental|Biscuit 1 Control|Consumption of control biscuit for breakfast and afternoon snack and impact on postprandial glucose and insulin
16380509|NCT04115579|Experimental|Biscuit 2 Test|Consumption of test biscuit for breakfast and afternoon snack on postprandial glucose and insulin
16380510|NCT04115553|Experimental|idiopathic intracranial hypertension|patients with idiopathic intracranial hypertension
16380511|NCT04115553|Sham Comparator|healthy subjects|Healthy subjects
16380512|NCT04115540|Experimental|TENS penile nerve stimulation group|"The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to prime their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use)."
16380513|NCT04115527|Active Comparator|Standard lymphadenectomy|Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction
16380514|NCT04115527|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).
16380515|NCT04115514|Experimental|Active treatment|Liothyronine Sodium (T3), 5-10-25-50µg instilled directly into the airways in a total volume of 10 ml (T3+0.9% sodium chloride). Progressive dosing every 24 hours for total 96 hours.
16380516|NCT04115514|No Intervention|Control arm|Standard of Care
16380517|NCT04115501|Experimental|Restrictive Oxygen|The restrictive oxygen patients' Fraction of Inspired Oxygen (FiO2) will be set at a minimum of 0.3 to maintain their oxygen saturations (SpO2) greater than or equal to 95% intraoperatively. During CPB a blended air/oxygen mixture will be titrated to arterial blood gas analysis with aim of maintenance of PaO2 between 100 and 150 mmHg. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
16380518|NCT04115501|No Intervention|Liberal Oxygen|The liberal oxygen group will consist of subjects exposed to a Fraction of Inspired Oxygen (FiO2) set at 1.0 throughout the intraoperative period, including during cardiopulmonary bypass. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
16380519|NCT04115488|Experimental|Biosimilar Natalizumab, solution for infusion|Biological: Biosimilar (INN: Natalizumab), 15 milliliter solution for infusion in a vial at a concentration of 20 milligrams per milliliter and a total dose of 300 milligrams, for intravenous (IV) infusions after dilution with 100 milliliter sodium chloride solution at a concentration of 0,9 percent, concentration of solution for infusion will be 2,61 milligrams per milliliter, total volume of solution for infusion will be 115 milliliter, a total of 12 doses of 300mg each will be administered every 4 weeks, duration of each infusion is 1 hour at a rate of 2 milliliters per minute
16380520|NCT04115488|Active Comparator|"EU licensed Natalizumab (Tysabri®)"|"Biological, EU licensed Natalizumab (INN), (tradename Tysabri®), 15 milliliter solution for infusion in a vial at a concentration of 20 milligrams per milliliter and a total dose of 300 milligrams, for intravenous (IV) infusions after dilution with 100 milliliter sodium chloride solution at a concentration of 0,9 percent, concentration of solution for infusion will be 2,61 milligrams per milliliter, total volume of solution for infusion will be 115 milliliter, a total of 12 doses of 300mg each will be administered every 4 weeks, duration of each infusion is 1 hour at a rate of 2 milliliters per minute"
16380521|NCT04115475|Active Comparator|Healthy Volunteers (HV)|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
16380549|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Pancreatic|SMART will be administered per each individual disease site standards
16380550|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Renal|SMART will be administered per each individual disease site standards
16381021|NCT04112017|Experimental|YVOIRE Y-Solution 360|Maximum 5 ml including touch-up
16380522|NCT04115475|Experimental|Spinal Muscular Atrophy (SMA) patients|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
16380523|NCT04115462|Active Comparator|Morphine|Each participant will receive a single dose of 20 mg morphine tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
16380524|NCT04115462|Placebo Comparator|Placebo|Each participant will receive a single dose of an identical placebo tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
16380525|NCT04115449|Experimental|Dexa group|"Spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort.
~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
16380526|NCT04115449|Placebo Comparator|Control group|"Normal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort.
~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale.Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
16380527|NCT04115436||stroke (+)|Patients experiencing thromboembolic events following a brief discontinuation of anticoagulant or having thrombus on the LAA occlusion device
16380528|NCT04115436||No-stroke|Patients remaining stroke-free months after discontinuation of anticoagulants
16380529|NCT04115423||Tocilizumab initiators|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving tocilizumab at least once from January 2013 to December 2018. Tocilizumab initiators are required to have no record of tocilizumab within 1 year prior to the first prescription of tocilizumab.
16380530|NCT04115423||Tumor necrosis factor inhibitors (TNFi) users|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving TNFi at least once from January 2013 to December 2018. TNFi users will be patients who had no record of tocilizumab and given specific TNFi during 1 year before the first prescription of TNFi.
16380531|NCT04115410||PD-1 inhibitor|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received PD-1 inhibitors as a second line treatment from cytotoxic chemotherapy or as a third line for those received tyrosine kinase inhibitors as a first line, from August 2017 (the first month PD-1 inhibitors were reimbursed in South Korea) to September 2018.
16380532|NCT04115410||Chemotherapy Drugs, Cancer|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received cytotoxic chemotherapy or tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) from August 2017 to September 2018. Each patient switching to PD-1 inhibitor will be matched to three reference standard chemotherapy users.
16380533|NCT04115397|Experimental|Bisphophonate|Zolendronic acid, one infusion iv
16380534|NCT04115397|Placebo Comparator|Placebo|Placebo, one infusion iv
16380535|NCT04115384|Experimental|Insulin (Novolin-R)|Regular insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril) BID
16380536|NCT04115371|No Intervention|Control|Standard emergency department care
16380537|NCT04115371|Other|Intervention|Standard emergency department are plus GEDI consult
16380538|NCT04115358|Experimental|Hyaluronic acid|Gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar.
16380539|NCT04115358|Active Comparator|Formocresol|0,1 ml to the orifice of the root canals of the primary molar.
16380540|NCT04115358|Active Comparator|Ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar.
16380541|NCT04115345|Experimental|REACT -renal autologous cell therapy|The dose of Renal Autologous Cell Therapy (REACT) for subjects in the Phase 1 clinical trials (TNG-CL010 and TNG-CL011) was 3 x 106 SRC /g estimated kidney weight. Similarly, in the present study, each REACT injection will contain 3 x 106 cells/g. Since the concentration of selected renal cells (SRC) is 100 x 106 cells/mL of REACT, the dosing volume will be 3.0 mL for each 100 g of kidney weight. The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula (Length x width AP plane x width Transverse plan x .62).
16380542|NCT04115332|Experimental|Interventional|"EEG Recording The one-channel EEG sensor was recorded from Cz with linked-ear reference based on the International 10-20 system. EEG signals were recorded using BioGraph Infiniti software (Version 6.0.4, n.d.) with a band-pass between 1-30 Hz. The sample rate was 256 Hz with 60-Hz notch filters, and the electrode impedances were lower than 5 kΩ.
~A lead II electrocardiogram (ECG) was collected for 5 minutes at baseline using the ProComp InfinitiTM system (Thought Technology Ltd., Montreal, Canada), which was installed on a laptop. A sampling rate of 2,048/second was set in order to acquire real-time interbeat intervals."
16380543|NCT04115319|Experimental|SEP363856|SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
16380544|NCT04115319|Active Comparator|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
16380545|NCT04115306|Experimental|PMD-026|Oral PMD-026 (dose: 25 - 1000 mg), given daily until disease progression or unacceptable toxicity
16380546|NCT04115293|Experimental|0.3 mg/kg zilucoplan (RA101495)|
16380547|NCT04115293|Placebo Comparator|Placebo|
16380548|NCT04115267||Combined modality|Patients receiving radiotherapy and a molecular agent for the treatment of cancer
16381782|NCT04106830||Health control(HC)|Healthy people without any neuroinflammation disease
16380551|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Lung|SMART will be administered per each individual disease site standards
16380552|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-ADRENAL METASTASES|SMART will be administered per each individual disease site standards
16380553|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-LIVER METASTASES|SMART will be administered per each individual disease site standards
16380554|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- METACHRONOUS OLIGOMETASTATIC NODES|SMART will be administered per each individual disease site standards
16380555|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- OLIGOPROGRESSIVE OLIGOMETASTATIC NODES/SOFT TISSUE|SMART will be administered per each individual disease site standards
16380556|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SYNCHRONOUS OLIGOMETASTATIC NODES/SOFT TISSUE METASTASES|SMART will be administered per each individual disease site standards
16380557|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE CANCER|SMART will be administered per each individual disease site standards
16380558|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BORDERLINE RESECTABLE PANCREAS|SMART will be administered per each individual disease site standards
16380559|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BRAIN METASTASIS|SMART will be administered per each individual disease site standards
16380560|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- MESOTHELIOMA|SMART will be administered per each individual disease site standards
16380561|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE BOOST|SMART will be administered per each individual disease site standards
16380562|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PELVIC RE-IRRADIATION|SMART will be administered per each individual disease site standards
16380563|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SPINE|SMART will be administered per each individual disease site standards
16380564|NCT04115228|Experimental|Study device|Subjects who provide informed consent, meet all inclusion criteria, and no exclusion criterion, will have a study device implanted and followed closely for 26 weeks.
16380565|NCT04115215|Experimental|Arm 1|Physical exercise (PE)
16380566|NCT04115215|Experimental|Arm 2|Transcranial current stimulation (tCS)
16380567|NCT04115215|Active Comparator|Control|Educational sessions on healthy aging
16380568|NCT04115202||posterior spinal approach group|Lumbar arthrodesis performed by a posterior spinal approach.
16380569|NCT04115202||anterior spinal approach group|Lumbar arthrodesis performed by a anterior spinal approach.
16380570|NCT04115189||Patients with Metastatic RCC|Patients diagnosed with metastatic RCC with clear cell histology who switched from a 4/2 schedule to a 2/1 schedule of sunitinib in first-line metastatic treatment between January 1, 2014 and June 30, 2018
16380571|NCT04115176||smokers + periodontitis|Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.
16380572|NCT04115176||nonsmoker + periodontitis|Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.
16380573|NCT04115163|Experimental|Treatment (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16380574|NCT04115150||self-gripping mesh|
16380575|NCT04115150||non-self-gripping mesh|
16380576|NCT04115137||Women with pelvic congestion syndrome|Women older than 18 years At least 1 birth Present symptoms
16380577|NCT04115124|Experimental|E-PAR Arm|Exposed to media, information and communication technology through ethnographic participatory action research.
16380578|NCT04115111|Experimental|Durvalumab arm|"Patients will receive Durvalumab at the dose and regimens described above every 4 weeks until evidence of disease progression or occurrence of unacceptable toxicity.
~Patients who show evidence of disease progression but appear to tolerate Durvalumab well, for whom no other treatment options exist and who, at the judgement of the investigator, may still enjoy clinical benefit, will be classified as failures and offered the possibility to continue treatment with extended follow up."
16380585|NCT04115085|Experimental|Hand therapy|9 weeks of standard hand therapy including two 20 min slots per week.
16380586|NCT04115085|Experimental|Therapeutic ultrasound|9 weeks of standard ultra sound therapy including two 10 min slots per week.
16380587|NCT04115085|Experimental|Combined hand therapy and therapeutic ultrasound|9 weeks of standard hand therapy plus therapeutic ultrasound including two 30 min slots per week.
16380588|NCT04115072|Active Comparator|A - Single dose og PZQ|Single dose of Praziquantel 40 mg/kg Standard treatment of schistosomiasis as recommended by WHO
16380589|NCT04115072|Experimental|B - Five doses of PZQ|"Five doses of Praziquantel
~1 x 40 mg/kg Praziquantel after enrollment in the study plus two single doses (40 mg/kg) after 12 and 24 hours after the first treatment
~1 x 40 mg/kg Praziquantel five weeks following the 1st dose
~1 x 40 mg/kg Praziquantel ten weeks following the 1st dose"
16380590|NCT04115059|Experimental|Dasatinib|"-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.
~Dasatinib: Oral Study Drug(s):
~Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.
~This will continue for up to 24 cycles."
16380591|NCT04115046||Treatment Arm|Consecutive, eligible patients reporting for an ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. Each subject will undergo both procedures (FibroScan and EUS with SW Elastography).
16380631|NCT04114812|Active Comparator|Standard course|Participants in the standard course or control group will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training.
16380695|NCT04114305||Intervention|HIV-infected pregnant women enrolled in ECD program implemented by m2m program; women followed during pregnancy and 18 months post-partum with their infants.
16380592|NCT04115033|Experimental|True CES|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to cranial electrical stimulation (CES), which involves transfer of current from the alpha-stim device using earclip electrodes. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The treatments can be self administered by the participants. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
16380593|NCT04115033|Sham Comparator|Sham CES|Veterans with fibromyalgia who meet study criteria and are randomized to the sham comparator group will receive standard therapy in addition to a CES device that does not deliver active electrical stimulation. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
16380594|NCT04115020|Experimental|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
16380595|NCT04115020|Experimental|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
16380596|NCT04115007|Experimental|Arm A|Standard of care + Stereotactic Body Radiotherapy to oligometastases
16380597|NCT04115007|Active Comparator|Arm B|Standard of care
16380598|NCT04114994||Alzheimer's Disease|
16380599|NCT04114994||Mild Cognitive Impairment|
16380600|NCT04114994||Frontotemporal Dementia|
16380601|NCT04114994||Vascular Dementia|
16380602|NCT04114994||Parkinson Disease|
16380603|NCT04114994||Traumatic Brain Injury (TBI)|
16380604|NCT04114994||Multiple Sclerosis|
16380605|NCT04114994||No diagnosis|
16380606|NCT04114981|Active Comparator|Arm I (SSRS)|Patients undergo SSRS over 1 session.
16380607|NCT04114981|Experimental|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
16380608|NCT04114968||Intervention group|Eligible women residing in the Central Denmark Region will be assigned to intervention group. Women in the intervention group receive an invitation for HPV-based cervical cancer screening by attending either 1) GP-based screening or 2) HPV self-sampling. The self-sampling kit includes the dry Evalyn brush self-sampling device (Rovers Medical Devices B.V, Oss, Netherlands), written and picture-based user instructions on how to collect and mail the self-sample, and a prestamped return envelope addressed to the Department of Pathology, Randers Regional Hospital.
16380609|NCT04114968||Control group|Eligible women residing in the other five Danish regions (North, Central, South, Zealand and Capital ) will be assigned to control group. Women in the control group will receive usual care, which for 65-69 year-old women is opportunistic cervical cancer screening at the GP
16380610|NCT04114955|Active Comparator|Intervention|Intervention condition comprised of two components designed to address intersectional stigma: 1) a group-level, peer-led intervention and 2) an individual-level peer navigation program to increase uptake of HIV testing and PrEP.
16380611|NCT04114955|Other|Wait-list control|Control participants will receive the intervention after a one-year waiting period.
16380612|NCT04114942|Experimental|Constant Coach|Randomized to have coach during didactic training and internship.
16380613|NCT04114942|Experimental|Internship Only Coach|Randomized to have coach during internship only.
16380614|NCT04114942|Experimental|Never Coach|Randomized to never have coach.
16380615|NCT04114929|Experimental|Threshold-Based|Patients will be prescribed exercise based on ventilatory thresholds from a maximal cardiopulmonary exercise test
16380616|NCT04114929|Active Comparator|Standard Care|Patients will be prescribed exercise based on standard guidelines
16380617|NCT04114916|Experimental|Apigenin, luteonin, grapefruit extract and citrolive|One capsules a day. It will be consumed at breakfast for eight weeks.
16380618|NCT04114916|Placebo Comparator|maltodextrina|One capsules a day. It will be consumed at breakfast for eight weeks.
16380619|NCT04114903||Study A|Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users.
16380620|NCT04114903||Study B|Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity.
16380621|NCT04114890|Experimental|Pregnant woman with second trimester and third trimester|
16380622|NCT04114877|Experimental|attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. Attentional retraining (AR) is the most commonly used CBM intervention in the study of addiction-related attentional bias.
16380623|NCT04114877|Active Comparator|visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues.
16380624|NCT04114864|Experimental|Experimental|This arm will be receiving the 7 ME-WE sessions psycho-educational intervention. The experimental group will involve a blended approach with 'face to face' meetings in three European partner countries and online sessions (via a ME-WE mobile app) and a purely 'f2f' approach in a further three European partner countries.
16380625|NCT04114864|Placebo Comparator|Control|The control-group will be a wait-list, receiving relaxation exercises during waiting.
16380626|NCT04114851|Experimental|Active|Patients who get active monitor NoL
16380627|NCT04114851|No Intervention|control|control no NoL
16380628|NCT04114825|Experimental|RV001V|Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
16380629|NCT04114825|Placebo Comparator|Placebo|Total of 12 SC vaccinations with placebo. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
16380630|NCT04114812|Experimental|Blended learning|Participants in the blended learning group will be taught abdominal ultrasound by an e-learning platform and practical near-peer tutoring classes over 16 weeks, summing up to 5 hours of e-learning and 16 hours of near-peer tutoring classes.
16380632|NCT04114799|Active Comparator|Group A invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.
16380633|NCT04114799|Experimental|Group B non-invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).
16380634|NCT04114786|Experimental|3D-printed mask|Patients will undergo the standard CT SIM, and MR SIM necessary for radiation therapy, creating the masks from the MRIs. Prior to the start of their treatment, patients will have an additional CT scan with the 3D printed mask to confirm safety and treatment accuracy. Patients will then proceed with their standard radiation therapy, immobilized with the mask.The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
16380635|NCT04114786|Active Comparator|Control group|Control group that will be treated with the standard thermoplastic mask, as a comparison measure. The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
16380636|NCT04114773|Experimental|SCARF|"The participants will take part in a rehabilitation intervention focused on the physical, mental, and social consequences of cardiac arrest with an overarching theme of managing fatigue. This will consist of:
~a 5-day residential rehabilitation stay
~followed by a 12 week home-based programme including one telephone call by a member of the clinical rehabilitation team,
~after the 12 week home intervention there will be a further 2-day rehabilitation stay."
16380637|NCT04114760|Active Comparator|Group A : defibrillator ECG to patchy-type ECG|"Group A subject will performing ECG examination to a mock patient in the ambulance.
~First ECG performance will be using defibrillator which contain 12-lead ECG checking function. And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using patchy-type wireless device.
~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
16380638|NCT04114760|Experimental|Group B : patchy-type ECG to defibrillator ECG|"Group B subject will performing ECG examination to a mock patient in the ambulance.
~First ECG performance will be using patchy-type wireless device.
~And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using defibrillator which contain 12-lead ECG checking function.
~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
16380639|NCT04114747|Experimental|Starting at high blood pressure|Patients in this arm are randomized to have high target blood pressure at MAP 80-90 mmHg during the first recordings, thereafter they will receive low blood pressure target 60-70 mm Hg
16380640|NCT04114747|Experimental|Starting at low blood pressure|Patients in this arm are randomized to have low target blood pressure at MAP 60-70 mmHg during the first recordings, thereafter they will receive high blood pressure target 80-90 mm Hg
16380641|NCT04114734|Experimental|Park Rx|Participants will be given a park prescription as part of their treatment plan
16380642|NCT04114734|No Intervention|No Park Rx|Usual care only
16380643|NCT04114708|Other|ACLR|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
16380644|NCT04114708|Other|ACLR with lateral extra-articular tenodesis|All LETs will be performed in a standardized fashion using the modified Lameire technique.
16380645|NCT04114695||Non-CKD (eGFR >60 ml/min/1.73 m2)|Patients with renal function considered normal for age (eGFR >60 ml/min/1.73 m2) without proteinuria or structural kidney disease.
16380646|NCT04114695||CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)|Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)
16380647|NCT04114695||CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)|Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)
16380648|NCT04114695||CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)|Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)
16380649|NCT04114695||CKD stage 5 (eGFR <15 ml/min/1,73 m2)|Patients with CKD stage 5 (eGFR <15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.
16380650|NCT04114669|Experimental|Regret lottery|"Will receive a lottery incentive (regret lottery) for 6 months"
16380651|NCT04114669|Placebo Comparator|Control Condition|Will complete a total of 3 in-person study visits, approximately one hour each.
16380652|NCT04114656|Placebo Comparator|Participants receiving Placebo|All participants will receive a single dose of placebo in either one or two of the three study periods, as per the randomization schedule.
16380653|NCT04114656|Experimental|Participants receiving GSK3858279|All participants will receive a single dose of GSK3858279 in either one or two of the three study periods, as per the randomization schedule.
16380654|NCT04114643|Active Comparator|Prothrombin Complex Concentrate|
16380655|NCT04114643|Active Comparator|Frozen Plasma|
16380656|NCT04114630|Experimental|erenumab|Solution for s.c injection. Prefilled autoinjector
16380657|NCT04114617|Experimental|Healthy Adults|"Participants will be asked to swallow a series of up to 54 liquid stimuli: a) liquid barium (different brands and concentrations); b) a 20% w/v concentration liquid barium thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; c) lemon-flavored water thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; and/or d) foods representative of minced and moist, soft-and-bite-sized or regular consistency."
16380658|NCT04114604|Experimental|Spinal Cord Injury|Adults who have sustained a spinal cord injury at the cervical or upper thoracic level (T6 or higher). Participants will swallow 20% w/v barium (E-Z-Paque) thickened to different consistencies using starch or xanthan-gum based food thickeners.
16380659|NCT04114591||LARS symptoms|Patient suffering from LARS as identified through LARS questionnaire
16380660|NCT04114591||No LARS symptoms|Absence of LARS symptoms
16380661|NCT04114578||Neonatal profile|ECHO in first 24 hours of life - ideally ECHO at Day 3-5 of life ECHO at 2-3 weeks of life or before discharge (whichever comes first) Data collected at each echocardiography: blood pressure at beginning of ECHO, pre and post-ductal saturation, respiratory support, use of inotropes and dosages, use of iNO and dosage and last blood gas
16380662|NCT04114578||Infant profile ( 4 month and/or 9 month)|Echocardiography Age and stage questionnaires CAT/CLAMS assessment
16380663|NCT04114578||Pediatric profile 3, 5 and/or 8years|Echocardiography Age and stage questionnaires CAT/CLAMS assessment Results from 18 months PMA Bailey will be retrieved
16380664|NCT04114578||Pre-adolescent/adolescent profile 11,14 and/or 17 years|Echocardiography Pediatric Quality of Life inventory survey
16380665|NCT04114539|Experimental|Ecopipam|
16380666|NCT04114526|Experimental|Community Health Advisor 4-step Program|
16380667|NCT04114513|Placebo Comparator|Maltodextrin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
16380668|NCT04114513|Experimental|Inulin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
16380669|NCT04114513|Experimental|Pectin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
16380670|NCT04114513|Experimental|Beta-glucan|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
16380671|NCT04114513|Experimental|Galactooligosaccharides|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
16380672|NCT04114487|No Intervention|control 1|The control 1 group will not be subjected to any application except education.
16380673|NCT04114487|Active Comparator|control 2|The control 2 group will be the control group and will be taken to the balance training in addition to normal education.
16380674|NCT04114487|Experimental|intervention|In theintervention group, dual task balance training will be applied within the scope of cognitive rehabilitation.
16380675|NCT04114461|Experimental|HL-TOF tab. 5mg|Tofacitinib freebase
16380676|NCT04114461|Active Comparator|Xeljanz tab. 5mg|Tofacitinib citrate (5mg as tofacitinib)
16380677|NCT04114448|Experimental|Therapeutic exercise|Patients will be trained to perform a therapeutic exercise intervention protocol. The program will be based on active physical activity including strength, balance an coordination exercises, among others. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
16380678|NCT04114448|Active Comparator|Usual care|Patients will be instructed to perform an usual care physical therapy intervention protocol. Participants in this group will be told to undergo gentle self-performed joint mobilization and stretching exercises. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
16380679|NCT04114435||Neonatal profile|"Echocardiography at:
~7 to 10 days of chronological age
~35 to 37 weeks post-menstrual age (PMA = corrected age);
~39 to 44 weeks PMA; Term equivalent"
16380680|NCT04114435||Infant profile ( between 4 months and 9 months)|"Echocardiography
~Ages & stages questionnaires CAT/CLAMS assessment"
16380681|NCT04114435||Pediatric profile (36 months and 5 years)|"Echocardiography
~Ages & stages questionnaires CAT/CLAMS assessment
~Results from 18 months PMA Bayley will be retrieved Figure 1: Premature population - Groups Recruited simultaneously"
16380682|NCT04114422|Experimental|Seven-day preoperative exercise training program|All patients will undergo to seven-day preoperative exercise training program that includes aerobic and resistance exercises
16380683|NCT04114409||1|OSAS and type D personality
16380684|NCT04114409||2|OSAS without type D personality
16380685|NCT04114396||Severe asthma|Untreated by anti-IL5 treatment for severe asthma at point of recruitment. To be prescribed anti-IL5 as part of their treatment following consent. Note: Anti-IL5 treatment is prescribed as per agreed multidisciplinary team meeting, outside of the decision to enrol the patient on the study, and is administered by the clinical team as part of the patient's clinical care outside of the research study.
16380686|NCT04114396||Healthy control|Control group without respiratory condition
16380687|NCT04114370|Experimental|Participants with Glioma|[F18]fluciclovine will be utilized to assess tumor viability compared with F-18 FDG PET or diagnostic MRI.
16380688|NCT04114357|Experimental|Intervention Group|This arm will consume the supplement daily for 4 weeks.
16380689|NCT04114357|No Intervention|Control Group|This arm will not receive the supplement for 4 weeks.
16380690|NCT04114344|Active Comparator|TAPP (Trans Abdominal PrePeritoneal)|Trans Abdominal PrePeritoneal approach to inguinal hernia repair
16380691|NCT04114344|Experimental|TEP (Totally Extra Peritoneal)|Totally Extra Peritoneal approach to inguinal hernia repair
16380692|NCT04114331|Experimental|Manual therapy and exercise|"The intervention (3 times a week for 4 weeks, for a total of 12 sessions) consisted primarily of manual therapy (soft tissue and joint mobilization) followed by therapeutic exercises (muscular control and coordination).
~Manual therapy:
~Joint mobilizations (Grades I-V) to cervical spine, thoracic spine and ribs Soft tissue mobilization to the pectoralis, scaleni, upper traps, thoracolumbar fascia, erector spinae, and suboccipital musculature
~Therapeutic exercises:
~Strengthening of mid and lower traps, lats, glut med, and glut max. Active & passive stretching of thoracic and lumbar rotation, hip flexors, and plantarflexors.
~The treating therapists agreed on a protocol with treatment individualized to each patient."
16380693|NCT04114318|Experimental|Cognitive-Cycling|Dual-task cognitive-cycling training; cognitive and cycling training simultaneously
16380694|NCT04114318|Active Comparator|Cycling|Single-task cycling training; stationary bicycle exercise training
16380696|NCT04114305||Control|HIV-infected pregnant women receiving routine care in clinics without ECD program; women followed during pregnancy and 18 months post-partum with their infants.
16380697|NCT04114292|Experimental|TUDCA|1.75-2 grams daily in divided dosing
16380698|NCT04114279|Experimental|Laparoscopic Duodenal Atresia Repair|All participants will attempt a laparoscopic duodenal atresia repair on the synthetic high fidelity simulator.
16380699|NCT04114253||Liver transplant patients|Adult patients undergoing deceased donor liver transplantation.
16380700|NCT04114240||Xybilun: mild erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with mild ED (score IIEF-6 between 22 and 25) and begin treatment at 50 mg
16380701|NCT04114240||Xybilun: moderate erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with moderate ED (score IIEF-6 between 11 and 21) and begin treatment at 50 mg
16380702|NCT04114240||Xybilun: severe erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with severe ED (score between 6 and 10) and begin treatment at 50 mg
16380703|NCT04114240||Xybilun switch|Substitution dose to dose of previous treatment by Xybilun whatever the severity of ED.
16380704|NCT04114227|Active Comparator|Acceptance and Commitment Therapy|Participants will learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors.
16380705|NCT04114227|Active Comparator|Supportive Psychotherapy|Participants will talk about their experiences to date.
16380706|NCT04114214||patients with suspected infection or sepsis|All patients admitted with suspected infection or sepsis from January 2018 to February 2018 at Prince of Wales Hospital
16380707|NCT04114201|Experimental|PSI|Patients received TKA using patient-specific Instrumentation.
16380708|NCT04114201|Active Comparator|Conventional|Patients received TKA conventional Instrumentation.
16380709|NCT04114188|Experimental|Antithymocyte Immunoglobulin (Rabbit)|rATG induction on day 0 & 1 post op
16380710|NCT04114175|Active Comparator|Control Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
16380711|NCT04114175|Experimental|Spinal Stabilization Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
16380712|NCT04114149|Active Comparator|TENS (transcutaneous electrical nerve stimulation)|High frequency, high intensity TENS treatment. Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
16380713|NCT04114149|Active Comparator|Conventional treatment with iv opioid|Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
16380714|NCT04114149|No Intervention|Control|Patients who report postoperative pain intensity according to NRS (numeric rating scale) < 3 during the time spent in post-anesthesia care unit.
16380715|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Metformin|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
~Metformin - 500 mg by mouth twice daily"
16380716|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Rosiglitazone|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
~Rosiglitazone - 4 mg by mouth once daily"
16380717|NCT04114136|Active Comparator|Anti-PD-1 mAb (nivolumab or pembrozilumab)|nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
16380718|NCT04114123||Longitudinal|The researchers will be evaluating baseline indicators of wanting salience and liking between 2 and 6 month olds, with the goal of following up with these families at 24 months and beyond by reviewing the dyads' medical charts. The researchers will also examine direct and indirect associations between reward-driven eating, and maternal and infant characteristics and infant weight-for-length.
16380719|NCT04114123||Cross-sectional|The researchers will as the mother to answer questionnaires and participate in up to two video taped behavioral protocols when the infant is 6 months old.
16380720|NCT04114110||Admitted inpatients|no intervention
16380721|NCT04114110||Staff with RTLS badges|no intervention
16380722|NCT04114097|Experimental|Betamethasone-17-valerat + placebo ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (Betnovate, betamethasone dipropionate ointment 0.1%) and placebo"
16380723|NCT04114097|Active Comparator|Tacrolimus ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (Protopic, tacrolimus ointment 0.1%)"
16380724|NCT04114084||A. patients with MGUS and sleep apnea|
16380725|NCT04114084||B. patients with MGUS and no sleep apnea|
16380726|NCT04114084||C. patients with MM and sleep apnea|
16380727|NCT04114084||D. patients with MM and no sleep apnea|
16380728|NCT04114071|Experimental|Physical Activity intervention group|Older overweight or obese Black women who participate in the physical activity intervention group will receive a daily text message from the TOSS study for 12 weeks, a Fitbit device plus have access to the Fitbit community option on their Fitbit app as an opportunity for virtual peer support. They will also receive an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention.
16380729|NCT04114071|Active Comparator|Control group|The control will only receive a weekly neutral text message during the 12-week intervention. For this project, a neutral text message is defined as a message that only provides facts about a topic.They will also receive a Fitbit device, an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention
16380730|NCT04114058|Active Comparator|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
16380804|NCT04113577||unformal cargivers|usability assessment after 30 minutes to test the app with their relatives
16380731|NCT04114058|Active Comparator|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
16380732|NCT04114045|Experimental|Whey protein|Whey protein isolate
16380733|NCT04114045|Active Comparator|Isoenergetic control - Carbohydrate|Carbohydrate or maltodextrin
16380734|NCT04114045|Placebo Comparator|Placebo control - Water|Water - chocolate flavoured
16380735|NCT04114032||High-risk elective surgical patients|"The patient population to be studied are elective patients for non-cardiac surgery.
~Age ≥ 45 years of age.
~Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in hospital.
~With at least one of the following criteria:
~History of ischaemic heart disease or peripheral vascular disease (coronary equivalent)
~History of stroke or transient ischaemic attack
~History of congestive cardiac failure
~Diabetes currently on an oral hypoglycaemic agent or insulin
~Serum creatinine >175 µmol/L (>2.0mg/dl)"
16380736|NCT04114019||Stress urinary incontinence|Women suffering from stress urinary incontinence
16380737|NCT04113993|Experimental|Oral Bazedoxifene|Oral Bazedoxifene dosed at 40 mg daily
16380738|NCT04113993|Placebo Comparator|Placebo|Identically packaged placebo capsule daily
16380739|NCT04113980|Experimental|music group|The children in the groups were distracted by listening music 2 minutes before venipuncture, until the process was over.
16380740|NCT04113980|Experimental|kaleidescope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
16380741|NCT04113980|Experimental|video group|The children in the groups were distracted by watching cartoon 2 minutes before the blood collection, until the process was over.
16380742|NCT04113980|No Intervention|control group|No intervention was made to children in the control group
16380743|NCT04113967|Experimental|Biodanza Group|The biodanza program will consist of 12 sessions, one per week, during three months. Each session will last approximately 60 minutes and an introductory phase (10-15 minutes) and an experience phase (45 minutes) will be divided. It involves moving / dancing according to the suggestions of the monitor and the rhythm of the music.
16380744|NCT04113967|No Intervention|Treatment as usual Group|The control group will continue with its usual treatment and activities, without suffering any alteration. A measurement of the groups (control group and biodanza group) will be carried out before the start and after the end of the sessions.
16380745|NCT04113954|Experimental|Leg 1 ACB + low dose SNB-PF|Right leg and 0.375% mepivacaine popliteal fossa-sciatic
16380746|NCT04113954|Experimental|Leg 1 ACB + high dose SNB-PF|Right leg and 1.5% mepivacaine popliteal fossa-sciatic
16380747|NCT04113954|Experimental|Leg 2 ACB + low dose SNB-PF|Left leg and 0.375% mepivacaine popliteal fossa-sciatic
16380748|NCT04113954|Experimental|Leg 2 ACB + high dose SNB-PF|Left leg and 1.5% mepivacaine popliteal fossa-sciatic
16380749|NCT04113954|Experimental|Leg 1 ACB only|Right leg and 1.5% mepivacaine ACB
16380750|NCT04113954|Experimental|Leg 2 ACB only|Left leg and 1.5% mepivacaine ACB
16380751|NCT04113941|Experimental|Neuronox®|Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
16380752|NCT04113941|Placebo Comparator|Placebo|Normal saline, same volume with Experimental arm
16380753|NCT04113928|Experimental|Broccoli & mustard seed soup|200ml acute feed
16380754|NCT04113928|Active Comparator|Broccoli soup|200ml acute feed
16380755|NCT04113915||Group 1|Group of ITP patients received triple therapy
16380756|NCT04113915||Group 2|Group of ITP patients received steroids
16380757|NCT04113915||Group 3|Normal control group
16380758|NCT04113902|Experimental|intervention group|Health education is given intervention group and 12 weeks follow up.
16380759|NCT04113902|No Intervention|control group|Control group takes standard health care and 12 weeks follow up.
16380760|NCT04113889|Active Comparator|Combination therapy group|Arm 1: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
16380761|NCT04113889|Placebo Comparator|Standard therapy group|Arm 2: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Placebo
16380762|NCT04113863|Active Comparator|ARM A - Anastrozole|Anastrozole at the dosage of 1 mg/die. Treatment will last 28 days
16380763|NCT04113863|Experimental|ARM B - Anastrozole + ATRA|Anastrozole at the dosage of 1mg/die in combination with ATRA at the total dosage of 45mg/m2/die (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
16380764|NCT04113850|Experimental|Sitting|Subjects will undergo acoustic startle testing in the sitting position.
16380765|NCT04113850|Experimental|Standing|Subjects will undergo acoustic startle testing in the standing position.
16380766|NCT04113837|Experimental|verum|"The food range is comprised of:
~sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)"
16380767|NCT04113837|Active Comparator|control|In the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.
16380768|NCT04113824|Experimental|trapezius motion style acupuncture treatment|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.
~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
16380769|NCT04113824|Active Comparator|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
16380805|NCT04113577||health professionals|usablity assessment after the enrollement of all patients and unformal caregivers
16380806|NCT04113564|Experimental|IV remimazolam|IV remimazolam administration of 0.025 mg/kg body weight
16380807|NCT04113564|Experimental|Oral remimazolam|Oral remimazolam Administration of 0.14 mg/kg Body weight
16380835|NCT04113473|No Intervention|Control Group|Control group were given education session and continued on usual care for 12-weeks.
16382991|NCT04098419|Experimental|Pittsburg Implementation|
16380770|NCT04113811|Experimental|Microwave needle thermoablation of prostate cancer|The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.
16380771|NCT04113798|Experimental|Moderate Intensity Exercise|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
16380772|NCT04113798|Active Comparator|Control|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
16380773|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
16380774|NCT04113772|Active Comparator|Orfandin .5 mgm/kg mgm bid|Two participant will receive .5 mgm/kg mgm of orfadin
16380775|NCT04113772|Experimental|Nitinosine .5 mgm/kg bid|Two participant will receive .5 mgm/kg of nitinosine
16380780|NCT04113733||Crohn's Disease|This group consists of patients with a diagnosis of Crohn's disease undergoing colonoscopy for clinical care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
16380781|NCT04113733||Control|This group will include patients undergoing screening colonoscopy as part of standard of care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
16380782|NCT04113733||Cooperative Human Tissue Network|This group will consist of non-IBD patients and Crohn's disease patients participating in the Cooperative Human Tissue Network (CHTN). The CHTN will be utilized to obtain surgical specimens from these patients. The patients will be screened and consented via the CHTN protocol. No additional samples in the form of blood or stool will be collected. Associated clinical data will be collected through medical record review.
16380783|NCT04113720|Experimental|Group A|children will receive levobupivacaine 0.25% by peritonsillar infiltration after intubation 3- 5 min before the start of surgery.
16380784|NCT04113720|Active Comparator|Group B|children will receive levobupivacaine 0.25% plus dexmedetomidine 1µg/kg diluted in 4 ml saline 0.9% and given by peritonsillar infiltration (2 ml per tonsil), after intubation 3- 5 min before the start of surgery.
16380785|NCT04113707|Experimental|Motor Lab|Group A will receive 20 minutes of motor lab intervention daily.
16380786|NCT04113707|No Intervention|Standard of Care|Group B will receive standard of care which will be 20 minutes of reading per day.
16380787|NCT04113694|Experimental|Extended Wear Infusion Set|Each subject is given 12 Extended Wear Infusion Sets to wear.
16380788|NCT04113681|Experimental|Geniculate Artery Embolization Arm|Single-arm prospective study of geniculate artery embolization for symptomatic knee osteoarthritis
16380789|NCT04113668|Experimental|Arm A: Single Dose (BMS-986165)|
16380790|NCT04113668|Experimental|Arm B:Diflunisal and Single Dose (BMS-986165)|
16380791|NCT04113655||acellular pertussis vaccine|Antibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202
16380792|NCT04113642||single group|healthy subjects
16380793|NCT04113629|Other|Sofosbuvir/Daclatasvir|standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir
16380794|NCT04113616|Experimental|Part A - Arm 1|"KRT-232+LDAC:
~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle."
16380795|NCT04113616|Experimental|Part A - Arm 2|"KRT-232(7-Day)+Decitabine:
~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
16380796|NCT04113616|Experimental|Part A - Arm 3|"KRT-232(14-Day)+Decitabine:
~KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
16380797|NCT04113616|Experimental|Part B - Arm 1|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle
16380798|NCT04113616|Experimental|Part B - Arm 2|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle in Cycle 1, followed by 240 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day cycle, in the subsequent cycles.
16380799|NCT04113616|Experimental|Part B - Arm 3|KRT-232 administered at 180 mg orally, once daily (QD) on Days 1-7 with 14 days off on a 21-day treatment cycle.
16380800|NCT04113603|Experimental|A_Single bolus|Single bolus computed tomography urography (CTU)
16380801|NCT04113603|Experimental|B_Split bolus|Split bolus computed tomography urography (CTU)
16380802|NCT04113590|Experimental|Transvaginal cholecystectomy under laparoscopic guidance|The removal of the gallbladder through several small incisions using a camera to see is called laparoscopic cholecystectomy. This study is being done to evaluate whether cholecystectomy can be performed through a natural orifice (the vagina) with minimal laparoscopic assistance (only one abdominal trocar versus four in the routine laparoscopic cholecystectomy).
16380803|NCT04113577||geriatric inpatients with neurocognitive disorder|usability assessment after 30 minutes to test the app
16383842|NCT04092452|Placebo Comparator|Cohort placebo|placebo
16380808|NCT04113551||Cohort T1: Methylphenidate (MPH) (Concerta)|Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380809|NCT04113551||Cohort T2: MPH (Ritalin)|Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380810|NCT04113551||Cohort T3: MPH (Concerta and Ritalin)|Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
16380811|NCT04113551||Cohort T4: Atomoxetine (ATO)|Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380812|NCT04113551||Cohort T5: Guanfacine (GFC)|Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380813|NCT04113551||Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
16380814|NCT04113551||Cohort T7: MPH (Concerta or Ritalin)|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.
16380815|NCT04113551||Cohort T8: MPH (Concerta) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380816|NCT04113551||Cohort T9: MPH (Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380817|NCT04113551||Cohort T10: ATO All Exposures|Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380818|NCT04113551||Cohort T11: GFC All Exposures|Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
16380819|NCT04113551||Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
16380820|NCT04113551||Cohort T13: MPH (Concerta or Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
16380821|NCT04113551||Cohort T14: MPH (Concerta and Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
16380822|NCT04113538|Active Comparator|Standard|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study
16380823|NCT04113538|Experimental|Treat and Extend|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability
16380824|NCT04113525|Experimental|Active Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve active stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
16380825|NCT04113525|Sham Comparator|Sham Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve sham stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
16380826|NCT04113512|Experimental|Yoga Nasal Irrigation Group|Saline nasal irrigation using neti pot was practiced.
16380827|NCT04113512|No Intervention|Wait list Control group|Group was given usual pain medication. After trial period, they were offered the intervention.
16380828|NCT04113499|Active Comparator|Direct Endoscopic Necrosectomy|The subject will have endoscopic drainage and necrosectomy at the time of the index intervention.
16380829|NCT04113499|Active Comparator|Step-up Endoscopic Interventions|The subject will only have endoscopic drainage of the pancreatic necrotic collection at the time of index intervention.
16380830|NCT04113486||Renal cancer group|Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
16380831|NCT04113486||Urothiasis group|Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
16380832|NCT04113486||Renal cysts group|Patients which imaging studies have found renal cysts (simple or complex) about 100.
16380833|NCT04113486||Liver cancer group|Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
16380834|NCT04113473|Experimental|Yoga Group|Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks.
16383843|NCT04092439|Experimental|Watermelon juice|100% watermelon juice
16380836|NCT04113460|Experimental|Yoga Group|The yoga group received the 8-week yoga sessions at work setting once a week by trained teacher followed by self practices.
16380837|NCT04113460|No Intervention|Control Group|Participants had one introductory session on proper physical position and stretching exercises to be practiced daily during work.
16380838|NCT04113421||Anticoagulation|Inpatients diagnosed with acute PE, in whom clinical providers have elected to prescribe anticoagulation alone for treatment based on clinical grounds at BWH. In this population, a single follow-up contrast-enhanced chest CT will be performed to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
16380843|NCT04113369|Sham Comparator|TENS group|30 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training program, patients will receive 30 minutes of conventional antalgic TENS (100 Hz) program as controls with electrostimulation device to the non-paretic wrist flexors.
16380844|NCT04113369|Active Comparator|EMS group|0 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training, the patients will receive 20 minutes of electrical stimulation to their non-paretic forearm upon wrist flexors by an intermittent maximum strength program (6 seconds of contraction, 10 seconds of rest) along with 5 minutes of pre and post warm-up with the same device.
16380845|NCT04113356||ST-Elevation Myocardial Infarction|Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
16380846|NCT04113343|Active Comparator|Treatment A: remimazolam|Oral administration of 360 mg remimazolam
16380847|NCT04113343|Experimental|Treatment B: remimazolam + 5% v/v alcohol|Oral administration of 360 mg remimazolam and 5% v/v alcohol
16380848|NCT04113343|Experimental|Treatment C: remimazolam + 15% v/v alcohol|Oral administration of 360 mg remimazolam + 15% v/v alcohol
16380849|NCT04113343|Experimental|Treatment D: remimazolam + 40% v/v alcohol|Oral administration of 360 mg remimazolam + 40% v/v alcohol
16380850|NCT04113343|Placebo Comparator|Treatment E: placebo + 40% v/v alcohol|Oral administration of Placebo + 40% v/v alcohol
16380851|NCT04113330||Study Group|Participant vaccinated with CYD Dengue Vaccine and classified as seronegative or undetermined at baseline in previous dengue studies in Colombia
16380852|NCT04113317|Experimental|Treatment Group|Subcutaneous injection of G-CSF with dose of 5μg/kg/day for 5 days consecutively, in addition to a single dose every 3 days up to 12 times, as well as liver cirrhosis standard regimen
16380853|NCT04113317|No Intervention|Control Group|Liver cirrhosis standard treatment only
16380854|NCT04113291|Experimental|DASH diet group|Participants randomized to receive the DASH diet will be prescribed an isocaloric DASH diet using meals (lunch, dinner, snacks) prepared by a Clinical Research Metabolic Kitchen under the direction of a registered dietician. Participants will prepare their own breakfast from a menu. The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
16380855|NCT04113291|Active Comparator|Attention Control Group|Participants randomized to attention control will continue their usual diet, but they will be instructed to limit their sodium intake to 2300 mg/day. They will be requested and voluntarily agree to not make additional diet or exercise changes during the 12-week study.
16380856|NCT04113265|Experimental|SUNEKOS ® Body|The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated 3 more times with an interval of 1 week (T2i, T3i and T4i).
16380857|NCT04113252|Experimental|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
16380858|NCT04113252|Experimental|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
16380859|NCT04113252|Experimental|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
16380860|NCT04113239||Diagnosed Type 2 Diabetes Mellitus|Patients with incident type 2 diabetes mellitus
16380861|NCT04113239||Control|Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria
16383844|NCT04092439|Placebo Comparator|Placebo|Fructose matched control
16380862|NCT04113226|Active Comparator|classical rituximab-based chemotherapy|Rituximab-based physician's choice chemotherapy
16380863|NCT04113226|Experimental|rituximab plus lenalidomide|Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression.
16380864|NCT04113213|No Intervention|Control|Standard care during consultations.
16380865|NCT04113213|Experimental|Intervention|Standard care during consultations with the addition of a physical lifestyle prescription.
16380866|NCT04113200|Experimental|F+ALG|An alginate containing feed: MerMed One (Kaneka Corporation). 300mls administered nasogastrically over one hour.
16380867|NCT04113200|Other|F-ALG|A standard enteral feed commonly used in practice. Nutricomp Soy Fibre (B.Braun). 300mls administered nasogastrically over one hour.
16380868|NCT04113187|Experimental|Propranolol arm|
16380869|NCT04113187|Placebo Comparator|Placebo arm|
16380870|NCT04113174||SAIL databank|Anonymised records from around 5 million people in Wales, with linked primary care, ED attendance, hospital admissions, outpatient data, social care, Welsh Care Homes Dataset, and ONS mortality data. SAIL includes eFI summary scores and individual components.
16380871|NCT04113174||ResearchOne|Nationally representative, de-identified data from around 6 million primary care electronic health records on the TPP SystmOne clinical system. ResearchOne includes eFI summary scores and individual components.
16380872|NCT04113174||Leeds Data Model|Anonymised, linked primary, secondary, community and social care data from 810,000 patients across 108 practices in Leeds, including eFI summary scores and individual components.
16380873|NCT04113174||CARE75+|National prospective cohort study (n≈1,200) collecting detailed sociodemographic information, frailty measures (including eFI scores), simple instruments suitable for use in primary care (e.g. gait speed, timed-up-and-go test; activities of daily living; informal care; loneliness), and key outcomes at six, 12, 24 and 48 months. CARE75+ is a very rich dataset that provides a highly efficient method to investigate how simple instruments might augment eFI performance.
16380874|NCT04113161|Active Comparator|Standard Care|Standard care will consist of 1) community-based screening and referral and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
16380875|NCT04113161|Experimental|Child Behavioral Health Navigators (cbhN)|CbhNs will engage in a series of face to face and phone contacts with families to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
16380876|NCT04113148||Healthy volunteer|Physiological measurements from heel over 60 minute period
16380877|NCT04113148||At risk of Pressure Ulcer|Physiological measurements from heel over 60 minute period
16380878|NCT04113148||Confirmed Catefory I Pressure Ulcer|Physiological measurements from heel over 60 minute period
16380879|NCT04113148||Suspected Deep Tissue Injury|Physiological measurements from heel over 60 minute period
16380880|NCT04113135|Experimental|Journaling, meditations, education, yoga intervention Arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post testing will take approximately 45 minutes to one hour. Session 1 for all participants will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The intervention sessions (2-6) for the experimental group participants consist will include a group discussion of the objectives for the week, 20-30 minutes of education and journaling (Attachment B), 45-60 minutes of PA consisting of various yoga poses followed by SMART goal setting and guided relaxation..
16380881|NCT04113135|Active Comparator|Journaling, meditation, education arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post-testing will take approximately 45 minutes to one hour. Session 1 for all participants (control and experimental) will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The control group will participate in a 45-60 minute session for weeks 2-6 consisting of goal setting to facilitate behavior change, education on MS, and meditation. Session 7 will conclude the study with reassessment of all outcome measurements as listed above.
16380882|NCT04113122|Experimental|Cross-sectional study:|Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
16380883|NCT04113122|Experimental|Longitudinal study - chemotherapy group|"Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits:
~Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy"
16380884|NCT04113122|Other|Longitudinal study - stage I control group|"Patients with stage I testicular cancer will serve as control group with three study visits:
~Visit 1: at time of orchidectomy Visit 2: one month Visit 3: one year after orchidectomy"
16380947|NCT04112641|Placebo Comparator|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
16380948|NCT04112641|Experimental|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
16380885|NCT04113109|Experimental|placebo, icatibant, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
16380886|NCT04113109|Experimental|placebo, icatibant, icatibant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
16380887|NCT04113109|Experimental|icatibant, placebo, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
16380888|NCT04113109|Experimental|icatibant, placebo, icatibant placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
16380889|NCT04113096|Experimental|Breast Cancer Stage IV|Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months
16380890|NCT04113096|Experimental|Colon Cancer Stage IV|Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months
16380891|NCT04113096|Experimental|Cervical Cancer Stage IV|Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
16380892|NCT04113096|Experimental|Cancer of the Prostate Stage IV|Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
16380893|NCT04113070||Overweight and obesity group|"Children with BMI cutoff points greater than 25.0 or 30.0 at 18 years old were defined overweight or obesity according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.
~Willingness to comply with study requirements"
16380894|NCT04113070||Non-overweight group|"Children with BMI smaller than 25.0 at 18 years old were defined non-overweight according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.
~Willingness to comply with study requirements"
16380895|NCT04113057|Experimental|Remote Coaching|All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The remote coaching arm will receive regular provider feedback based on LIVMOR data.
16380896|NCT04113057|No Intervention|Remote health monitoring without provider feedback|"All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The no intervention arm will have access to LIVMOR data, but without provider feedback on the LIVMOR data."
16380897|NCT04113031|Experimental|Flywheel group|The players allocated to the flywheel group will perform six weeks of squat resistance exercise using a flywheel device.
16380898|NCT04113031|Experimental|Barbell free weight group|The players allocated to the barbell free weight group will perform six weeks of squat resistance exercise using a an olympic barbell and free weight of high loads.
16380899|NCT04113031|Active Comparator|Control|All players in all three groups (including control group) will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match).
16380900|NCT04113018|Experimental|1|Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
16380901|NCT04113005|Experimental|Desmopressin|Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
16380902|NCT04112979|Experimental|Auditory stimulation 1 (Music)|45 deciBel Sensation Level (dB SL), normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
16380903|NCT04112979|Experimental|Auditory stimulation 2 (Mother's lap)|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
16380904|NCT04112979|Experimental|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 deciBel (dB)
16380905|NCT04112979|No Intervention|No stimulation|Current standard of care
16380906|NCT04112966|Experimental|Early Manual Lymph Drainage|14 sessions of manual lymphatic drainage technique in the three months following surgery and received health education on the prevention of lymphedema.
16380907|NCT04112966|Other|Health education for lymphedema prevention|Only the health education for lymphedema prevention.
16380908|NCT04112953||Upcoming cardiac surgery|Subjects in this group will have an upcoming cardiac surgery with the use of cardiopulmonary bypass and no pre-existing renal insufficiency or failure
16380909|NCT04112940|Experimental|Adults with oropharyngeal cancer|Adult participants who have completed radiation therapy for oropharyngeal cancer within the past 3 months will undergo a swallowing x-ray study in which they will swallow up to 15 liquid stimuli prepared to different consistencies using starch and gum based thickeners.
16380910|NCT04112927||OSA Participants|"Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.
~Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study."
16380949|NCT04112615||Patients and/or carers|Patients and/or their nominated carers come in to give feedback on the device and the system as a whole, from usability to design.
16380950|NCT04112615||Healthcare professionals|Healthcare professionals come in to give feedback on the device and the system, from what results they would like to see and their concerns about patients using it.
16380911|NCT04112927||Healthy Controls|"Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.
~Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.
~Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent."
16380912|NCT04112914|No Intervention|Education as usual|Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
16380913|NCT04112914|Experimental|New education|Participants receive the newly developed educational toolkit
16380914|NCT04112901||People with trans-femoral amputation or knee dis-articulation|include individuals with unilateral transfemoral amputation or knee disarticulation, with ≤ K2 mobility grade OR SIGAM grade D or below; i.e. able to walk ≤ 50 meters on level ground, who have been users of either microprocessor-controlled knee or non-microprocessor-controlled knee joint for at least 6 months prior to the recruitment date.
16380915|NCT04112888|Experimental|Collagen group|"Patients will receive 3 to 5 infiltrations of collagen on the scar once a week.
~Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes."
16380916|NCT04112888|Active Comparator|Control group|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes.
16380917|NCT04112875|Active Comparator|L-arginine|L-arginine supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
16380918|NCT04112875|Placebo Comparator|Maltodextrin|Maltodextrin supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
16380919|NCT04112862|Experimental|Intervention|three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
16380920|NCT04112849||Heart failure subjects|Subjects who have heart failure, and meet inclusion/exclusion criteria, who will be enrolled in this study and will have their heart sounds measured with Nanowear vest (NCHFMS).
16380921|NCT04112836||Normal nutritional status|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of 24-30 points.
16380922|NCT04112836||Malnourished|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of fewer than 17 points.
16380923|NCT04112823|Active Comparator|Dexamethasone 4mg|Dexamethasone 4mg, administered intravenously
16380924|NCT04112823|Active Comparator|Dexamethasone 16mg|Dexamethasone 16mg, administered intravenously
16380925|NCT04112810|Experimental|Tildrakizumab|Tildrakizumab (IluymaTM) is a humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function.
16380926|NCT04112771||Penehyclidine group|Penehyclindine hydrochloride was administered before anesthesia induction.
16380927|NCT04112771||Placebo group|Penehyclindine hydrochloride was not administered before anesthesia induction.
16380928|NCT04112758|Experimental|Exercise group|The group will receive twice a week for 5 week
16380929|NCT04112758|No Intervention|Control group|The group will be maintained their normal after school activities
16380930|NCT04112745|Experimental|Experimental group|
16380931|NCT04112745|Placebo Comparator|Control group|
16380932|NCT04112732|Experimental|Multivitamin|1 multivitamin tablet administered by mouth daily for 12 weeks, to be taken with main meal.
16380933|NCT04112732|Placebo Comparator|Placebo|1 placebo tablet administered by mouth daily for 12 weeks, to be taken with main meal.
16380934|NCT04112719||Control arm/pregnant patients at term|Control arm where the term pregnant patient will be lying on the bed at 45 degrees.
16380935|NCT04112719||Experimental/Supine|Term pregnant patient will be positioned in supine. Changes in hemodynamics will be measured.
16380936|NCT04112719||Experimental/15 degrees lateral tilt|Term pregnant patient will be positioned at 15 degrees in lateral tilt. Changes in hemodynamics will be measured.
16380937|NCT04112719||Experimental/30 degrees lateral tilt|Term pregnant patient will be positioned at 30 degrees in lateral tilt. Changes in hemodynamics will be measured.
16380938|NCT04112693|Experimental|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.
~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
16380939|NCT04112680|Experimental|Intervention group 1|Audio messages in this group are focussed on providing a Plausible Alternative to the misinformation
16380940|NCT04112680|Experimental|Intervention group 2|Audio messages in this group focus on Avoiding the Misinformation and instead only provide the correct information
16380941|NCT04112680|Placebo Comparator|Control group|Audio messages in this control group are on a different topic
16380942|NCT04112667||Normal Macular Health|>=60 years old with no macular disease
16380943|NCT04112667||Early Macular Degeneration|>=60 years old with early age-related macular degeneration
16380944|NCT04112667||Young Normals|20-30 years old with normal macular health
16380945|NCT04112654|Active Comparator|Conventional laparoscopy|Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.
16380946|NCT04112654|Experimental|Low pressure laparoscopy|Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®
16386217|NCT04076319|Other|CAPABLE|CAPABLE Intervention
16380951|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
16380952|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
16380953|NCT04112589|Experimental|Level dose 1 - 40mg, 14 days|Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
16380954|NCT04112589|Experimental|Level dose 2 - 60mg, 14 days|Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
16380955|NCT04112589|Experimental|Level dose -1 - 60mg 7days|Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
16380956|NCT04112589|Experimental|Level dose -2 - 40mg 7 days|Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
16380957|NCT04112576||HFrEF|Participants that are diagnosed with NYHA class II or III heart failure with reduced ejection fraction.
16380958|NCT04112576||HFpEF|Participants that are diagnosed with NYHA class II or III heart failure with preserved ejection fraction.
16380959|NCT04112563|Active Comparator|WLI-LCI group|a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI
16380960|NCT04112563|Active Comparator|LCI-WLI group|a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)
16380961|NCT04112550|Active Comparator|Methadone|This cohort will receive oral methadone 15mg po tablet pre-operatively
16380962|NCT04112550|Active Comparator|Oxycodone|This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
16380963|NCT04112524||Patients from routine treatment|all 30 patients from Routine Treatment, only observational
16380964|NCT04112498|Experimental|nivolumab + relatlimab + rHuPH20|
16380965|NCT04112485|Other|Open discectomy|This group of patients are treated by open discectomy
16380966|NCT04112485|Other|Microdiscectomy|This group of patients are treated by Microdiscectomy
16380967|NCT04112472|Experimental|Examination of participants|Examination of participants by means of the investigational device as well as the comparative devices.
16380968|NCT04112446|Experimental|Study Treatment|4 mg [14C]-saroglitazar magnesium (approximately 100 μCi) oral suspension
16380969|NCT04112433||PURE EP 2 Group|Enrolled and consented patients who are indicated for and receive an elective cardiac ablation procedure using the PURE EP 2 system for monitoring and collection of intracardiac electrogram signals.
16380970|NCT04112420|Other|Group A|200 Participants more than 60 yrs old having Trans-esophageal Echocardiography examination upon admission to ICU
16380971|NCT04112407|Experimental|Control|Standard preparation of the surgical site without P. acnes pretreatment
16380972|NCT04112407|Experimental|BPO Group|Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry.
16380973|NCT04112407|Experimental|BPO and Phototherapy|2 days of benzoyl peroxide washes and 3 treatments of blue light phototherapy. Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry. The blue light phototherapy is administered to the shoulder for 3 minutes on three occasions; 2 days before, the day before surgery and in the preoperative area by the patient.
16380974|NCT04112394|Experimental|ESP Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive a single shot of local anesthetic injection at the erector spinae plane.
16380975|NCT04112394|Other|Control|Patients will receive standard perioperative and postoperative analgesia protocol.
16380977|NCT04112368|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
16380978|NCT04112368|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
16380979|NCT04112355||6 months of age|"Visit 1
~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Provided a temperature diary to fill out for the next week Visit 2
~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Collect temperature diary if not already mailed in"
16381016|NCT04112069|Experimental|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
16380980|NCT04112355||12 months of age|"Visit 1
~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Provide a temperature diary to fill out for the next week Visit 2
~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Collect temperature diary if not already mailed in"
16380981|NCT04112355||5 years of age|"Visit 1
~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Provide a temperature diary to fill out for the next week Visit 2
~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Collect temperature diary if not already mailed in"
16380982|NCT04112342|Other|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin.
16380983|NCT04112342|Other|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin
16380984|NCT04112342|Other|Cohort 3|Patients who will receive palliative radiation (+/-concurrent systemic therapy) for any tumor involving the skin.
16380985|NCT04112342|Other|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin.
16380986|NCT04112329|Experimental|Exergaming|Will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks
16380987|NCT04112329|No Intervention|Control|Asked to continue with their normal daily routine
16380988|NCT04112316|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
16380989|NCT04112316|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
16380990|NCT04112303|Experimental|SOF/VEL|Participants will receive SOF/VEL for up to 12 weeks.
16380991|NCT04112264|Experimental|Monopolar radiofrequency ablation|Patients will receive ultrasound-guided monopolar radiofrequency ablation
16380992|NCT04112264|Active Comparator|Bipolar radiofrequency ablation|Patients will receive ultrasound-guided bipolar radiofrequency ablation
16380993|NCT04112251|Placebo Comparator|Placebo|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg oral placebo capsule (Cornstarch) every 12 hours for 12 weeks.
16380994|NCT04112251|Experimental|Supplement|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg capsule every 12 hours (100 mg / day of epicatechin) for 12 weeks.
16380995|NCT04112225|Active Comparator|Positive affect condition|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
16380996|NCT04112225|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16380997|NCT04112212|Experimental|IV administration of vedolizumab-800CW|The tracer will be intraveniously administrered 2 or 3 days before the colonoscopy procedure (with the near infrared fluorescence endoscopy platform).
16381000|NCT04112186|Experimental|Behavioral group therapy 1|8-weeks of group therapy
16381001|NCT04112186|Active Comparator|Behavioral group therapy 2|8-weeks of group therapy
16381002|NCT04112173|Experimental|Intervention|perturbation-based balance training
16381003|NCT04112160|Placebo Comparator|control|normal saline 0.9%
16381004|NCT04112160|Active Comparator|Ketorolac|30 mg of Ketorolac
16381005|NCT04112147|Experimental|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
16381006|NCT04112147|Experimental|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
16381007|NCT04112147|Placebo Comparator|Placebo oral capsule|Patients will receive 12-week of 50mg BID Antroquinonol placebo
16381008|NCT04112121|Experimental|Patients Meeting the Chaplain at the Bedside|First meeting with the chaplain, coupled with biblical readings at the bedside.
16381009|NCT04112121|Experimental|Patients Meeting the Chaplain at the Chapel|First meeting with the chaplain, coupled with biblical readings at the hospital's chapel
16381010|NCT04112121|No Intervention|Patients Not Meeting the Chaplain|In the control group we enrolled patients whose diagnoses and number of days in the hospital was similar to the intervention groups (covariate-adaptive, blocked, stratified randomization method).
16381011|NCT04112108||mitral stenosis post percutaneous mitral commissurotomy(PTMC)|successful PTMC after follow up
16381012|NCT04112095|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time every day for up to 24 weeks
16381013|NCT04112082|Experimental|Home-Based Neurofeedback Training|
16381014|NCT04112082|Active Comparator|Treatment as Usual|
16381015|NCT04112069|Active Comparator|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
16381017|NCT04112056|Experimental|Study formula|The infants recruited are provided with the study formula named NAN Comfort producted by Nestle Deutschland AG, Werk Biessenhofen containing moderately hydrolyzed protein and low lactose for free during study, and asked to drink the study formula more than half of the total diet daily.
16381022|NCT04112017|No Intervention|No-treatment|No-treatment. At 12 weeks after the assessment, treatment maximum 5 ml including touch-up
16381023|NCT04112004||Liver Transplant Recipients|All elective liver transplant recipients done between study period
16381024|NCT04111991|Active Comparator|Usual Care|Usual care in the NCH Complex Concussion Clinic
16381025|NCT04111991|Experimental|Usual Care + C-STEP|Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
16381026|NCT04111978|Experimental|Letrozole (aromatase inhibitor)|Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease
16381027|NCT04111978|Placebo Comparator|Placebo|Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease
16381028|NCT04111965|Experimental|Nanodrop® (PRO-176)|- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.
16381029|NCT04111965|Active Comparator|Systane® Balance|"Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc.
~Route of administration: Ophthalmic."
16381030|NCT04111952|Experimental|Additional laser treatment|Women receiving a single laser treatment.
16381031|NCT04111952|Sham Comparator|Sham laser treatment|Women receiving sham laser treatment.
16381032|NCT04111939|Experimental|Wave 1 - Intervention|Communities in Wave 1 will receive the CTH intervention during the first 30 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
16381033|NCT04111939|Other|Wave 2 - Wait-list comparison|Communities in Wave 2 will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
16381034|NCT04111926|Experimental|Intervention group|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
16381035|NCT04111926|Placebo Comparator|Control group|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
16381036|NCT04111913|Experimental|anlotinib and chemoradiotherapy|"anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.
~EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1~5, d29~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60~66Gy/30~33 times/6~7 weeks."
16381037|NCT04111900|Experimental|Sleep/Circadian Friendly|initiation of sleep/circadian rhythm friendly intervention the first night spent in MICU after enrollment until patient transfers/discharges, ceases participation, or meets exclusion criteria.
16381038|NCT04111900|No Intervention|Usual Care|Usual care within intensive care unit
16381039|NCT04111887|Experimental|Change Ahead|Each of the 6 weekly 1-hour sessions begins with a voluntary commitment to actively participate and to try something new in the upcoming week; includes a section devoted to selecting and publicly committing to one change focused on reducing negative/increasing positive cognitions and one change focused on increasing pleasant activities; and ends with home practice assignments. Additional exercises designed to increase dissonance induction include (a) group discussions for changing conditions, (b) roleplays to generate quick comebacks to written negative thoughts provided by other group members, (c) in-session writing exercises on the benefits of doing fun activities, (d) discussion of methods for creating internal and external accountability for positive change, (e) home practice assignment of engaging in actions to help someone else' mood, (f) writing a letter to my future self about positive intentions, and (g) providing positive feedback to other group members at the last session.
16381040|NCT04111887|Active Comparator|Blues Program|The 6 weekly 1-hour sessions begin with a review of concepts and (after Session 1) review of past home practice assignments; all sessions conclude with home practice assignments. Each session has a portion devoted to thought identification/recording and cognitive restructuring and a portion devoted to increased involvement in pleasant activities. We use motivational enhancement exercises to maximize willingness to use the new skills, behavioral techniques to reinforce use of the new skills, and group activities to foster feelings of group cohesion.
16381041|NCT04111887|Placebo Comparator|Brochure control|"NIMH brochure that describes major depression and recommends treatment for depressed youth (Let's Talk About Depression NIH Pub. 01-4162), as well as information about local treatment options."
16381042|NCT04111874|Experimental|Low-Intensity Therapist Assistance (LTA)|Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
16381043|NCT04111874|Active Comparator|Standard Therapist Assistance (STA)|Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.
16381044|NCT04111861|Experimental|Intevention|To see if singing can be used as a detractive method from patients experiencing ongoing pain.
16381045|NCT04111848|Experimental|ketamine group : group (k)|-Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
16381046|NCT04111848|Experimental|ketamine and magnesium group: group (KM)|- Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
16381047|NCT04111835|No Intervention|Conventional exfoliative cytology/LBC|"According to current Polish guidelines:
~ASC-US: repeat Pap testing in 6 months - current standard protocol
~LSIL - repeat Pap testing in 6 months or refer for colposcopy (by the decision of cytologist) - current standard protocol
~ASC-H and higher and all glandular lesions - refer for colposcopy - current standard protocol
~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.
~If screening cytology is negative -> rescreening after 3 years."
16381048|NCT04111835|Experimental|hrHPV molecular testing|"hrHPV-positive - reflex LBC:
~Abnormal reflex LBC (ASC-US or worse) -> colposcopy
~Normal reflex LBC -> repeat LBC in 6 months
~Positive - colposcopy
~Negative -> The CINtec PLUS Cytology and The QIASURE methylation test
~The CINtec PLUS Cytology Positive -> colposcopy Negative -> rescreen in 3 years
~The QIASURE methylation test Positive -> colposcopy Negative -> rescreen in 3 years
~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.
~HPV-negative - rescreen in 5 years"
16381049|NCT04111822|Active Comparator|Conventional treatment of septic shock|Conventional treatment of septic shock according to current management guidelines
16381050|NCT04111822|Experimental|Current management plus ascorbic acyd,thiamine and vitamin C|"Conventional treatment of septic shock according to current management guidelines associated with:
~i. Hydrocortisone 50 mg every 6 hours for 7 days or until discharge from the ICU with subsequent withdrawal in descending pattern for 3 days ii. Vitamin C (ascorbic acid) 1.5 gr diluted in 100 ml of 5% SG every 6 hours for 4 days (16 doses) iii. Thiamine 200 mg diluted in 100 ml of SG 5% or SF 0.9% every 12 hours for 4 days iv. Measurement of vitamin C levels prior to administration of the first dose of vitamin C"
16381051|NCT04111809||intravenous biphosphonate|Patients treated with intravenous bisphosphonate until 12 months in routine care
16381052|NCT04111796|Experimental|group in nature|they participate in nature based-program during work hours
16381053|NCT04111796|No Intervention|control group|they participate don't in nature based-program during work hours and perform their normal work schedule
16381054|NCT04111783|Experimental|POU ultrasound intervention test group|The experimental group used POU protocol ultrasound to perform a heart scan and a standard scan, a large vascular scan under the xiphoid, a body cavity scan, a standard section, and a lung scan in 10 minutes. Comprehensive preoperative circulation and assessment of systemic conditions, and guided intraoperative anesthesia management with assessment results.
16381055|NCT04111783|No Intervention|Control group|the anesthesiologist performed according to the existing preoperative evaluation program and existing experience, and guided the anesthesia management with the evaluation results.
16381056|NCT04111770|Experimental|IVUS guided PCI|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
16381057|NCT04111770|Active Comparator|QCA guided PCI|QCA will be used to determine lesion characteristics
16381058|NCT04111757|Experimental|Technolas TENEO 317 Model 2|One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.
16381059|NCT04111744|Experimental|Training Group|Preoperative Exercise Training Optimal medical therapy,
16381060|NCT04111744|Other|Control Group|Optimal medical therapy, inactive control group
16381061|NCT04111731|Active Comparator|Group one|Cryoballoon pulmonary vein isolation
16381062|NCT04111731|Active Comparator|Group two|Radiofrequency pulmonary vein isolation
16381063|NCT04111718|Experimental|Viewing of preparation|The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
16381064|NCT04111718|Sham Comparator|Blinded to preparation|The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
16381065|NCT04111705|Experimental|Lorlatinib|100 mg once daily
16381066|NCT04111679|Experimental|Music|During laparoscopic task performance; participants will wear a noise cancelling headphone that plays music that is chosen by the participant.
16381067|NCT04111679|No Intervention|No music|During laparoscopic task performance; participants will wear a noise cancelling headphone that does not play music.
16381068|NCT04111666|Experimental|AL101 IV|Up to four single ascending doses of AL101 administered IV
16381069|NCT04111666|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 8 active and 3 placebo subjects
16381070|NCT04111666|Experimental|AL101 SC|A single dose of AL101 administered SC
16381071|NCT04111653|Experimental|Single arm|Healthy volunteers
16381072|NCT04111640|Experimental|Experimental group|A computer-supported cognitive training for the training of logical-executive and working-memory functions (CoRe software)
16381073|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
16381074|NCT04111627|Experimental|Aerobic exercise plus Duloxetine|Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
16381075|NCT04111614|Experimental|Arm 1|Single dose of 5 mL tofacitinib oral solution on Day 1 of Period 1 and Singe dose of 5 mg tofacitinib tablet on Day 1 of Period 2
16381076|NCT04111614|Experimental|Arm 2|Single dose of 5 mg tofacitinib tablet on Day 1 of Period 1 and Singe dose of 5 mL tofacitinib oral solution on Day 1 of Period 2
16381077|NCT04111588||Glioma|"20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET/MRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET/MRI at baseline for comparison with 18F-FACBC.
~30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET/MRI at treatment/baseline and 1 month after radiosurgery."
16381078|NCT04111588||Brain Metastases|Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET/MRI at baseline, 1 month after surgery/stereotactic radiosurgery (St. Olavs Hospital/UNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.
16381410|NCT04109391|Experimental|Test Product|IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles
16381079|NCT04111575|Experimental|music therapy group 1|The mothers in the experimental group 1 received music therapy for 30 minutes a day.They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
16381080|NCT04111575|Experimental|music therapy group 2|The mothers in the experimental group 1 received music therapy for 30 minutes twice a day. They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
16381081|NCT04111575|No Intervention|control group|the control group were made to rest in bed for 30 minutes a day for two consecutive days, considering the first day after the C-section as the beginning day.
16381082|NCT04111562|Other|polymethyl methacrylate Cranioplasty|The Cranioplastic kit used (Teknimed, Biomaterials Innovation, Gentafix 1 ®, France) a biocompatible material that is composed of powder and liquid form of polymethyl methacrylate.
16381083|NCT04111549|Experimental|Home-based telehealth GOALS|Participants in this arm will receive the GOALS intervention via in-home video telehealth.
16381084|NCT04111549|Active Comparator|In-person GOALS|Participants in this arm will receive the GOALS intervention in the traditional in-person format.
16381085|NCT04111536|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
16381086|NCT04111536|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets, dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
16381087|NCT04111523|Experimental|SY-007 dose 1|The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
16381088|NCT04111523|Experimental|SY-007 dose 2|The study will be intiated in healthy subjects at a 4mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
16381089|NCT04111523|Experimental|SY-007 dose 3|The study will be intiated in healthy subjects at a 10mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
16381090|NCT04111523|Experimental|SY-007 dose 4|The study will be intiated in healthy subjects at a 20mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
16381091|NCT04111523|Experimental|SY-007 dose 5|The study will be intiated in healthy subjects at a 30mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
16381092|NCT04111523|Experimental|SY-007 dose 6|The study will be intiated in healthy subjects at a 45mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
16381093|NCT04111510|Experimental|LN-145|LN-145 will be delivered as a single therapy in patients with Metastatic Triple Negative Breast Cancer.
16381094|NCT04111497|Experimental|Treatment (glasdegib)|Patients receive glasdegib PO QD on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16381095|NCT04111484|Active Comparator|Adrenomedullin|Will received 19.9 picomol/kg/min of adrenomedullin over 20 min
16381096|NCT04111484|Placebo Comparator|Saline|Saline
16381097|NCT04111471|Placebo Comparator|Placebo Arm|20 patients will receive 5.6 g of placebo product (maltodextrin) daily for a total of 21 days (7 days before and until 2 weeks after transplant)
16381098|NCT04111471|Experimental|Prebiotic (Inulin) Arm|20 patients will receive 10 g of inulin product daily for a total of 21 days (7 days before and until 2 weeks after transplant)
16381099|NCT04111458|Experimental|BI 1701963 monotherapy|
16381100|NCT04111458|Experimental|BI 1701963 + Trametinib|
16381101|NCT04111445|Experimental|ADG116|
16381102|NCT04111432|Experimental|Group I-EV71 and EPI vaccines Concomitant administration|EV71 Vaccine (intramuscular injection,0.5ml,first dose)/measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and EV71 Vaccine (intramuscular injection, 0.5ml,second dose)/ encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
16381103|NCT04111432|Active Comparator|Group II-EPI vaccine only Single injection of EPI vaccine:|measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
16381104|NCT04111432|Active Comparator|Group III-EV71 vaccine only EV71 Vaccine only|the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 andday 30 respectively
16381105|NCT04111419|Experimental|Intensive blood pressure and cholesterol control|
16381106|NCT04111419|Active Comparator|Intensive blood pressure and routine cholesterol control|
16381107|NCT04111419|Active Comparator|Routine blood pressure and intensive cholesterol control|
16381108|NCT04111419|Active Comparator|Routine blood pressure and cholesterol control|
16381109|NCT04111406|Other|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
16381110|NCT04111406|Experimental|Protocol based|Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based
16381111|NCT04111380|Experimental|Nab-paclitaxel and Cisplatin|cisplatin and nab-paclitaxel: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
16381112|NCT04111367|Experimental|Genotype 2 and 6 Subjects|Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12
16381113|NCT04111367|Experimental|Genotype 3 Subjects|Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24
16381114|NCT04111354|Active Comparator|Short-term (4-hours) immobilization.|Short-term (4-hours) immobilization after primary pacemaker implantation.
16381115|NCT04111354|Active Comparator|Long-term (16-24 hours) immobilization.|Long-term (16-24 hours) immobilization after primary pacemaker implantation.
16381116|NCT04111341|Experimental|TCM Gan-Lu-Yin (GLY)|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
16381117|NCT04111341|Placebo Comparator|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
16381118|NCT04111328|Experimental|sufentanil administration intravenously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
16381119|NCT04111328|Experimental|sufentanil administration subcutaneously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
16381120|NCT04111328|Experimental|hydromorphone administration intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
16381121|NCT04111328|Experimental|hydromorphone administration subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
16381122|NCT04111328|Experimental|sufentanil and dexmedetomidine intravenously|The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
16381123|NCT04111328|Experimental|sufentanil and dexmedetomidine subcutaneously|The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
16381124|NCT04111328|Experimental|hydromorphone and dexmedetomidine intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.
16381125|NCT04111328|Experimental|hydromorphone and dexmedetomidine subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.
16381126|NCT04111315|Active Comparator|metamizole + educational intervention|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
16381127|NCT04111315|Active Comparator|metamizole + standard care|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Standard care will be prescribed by the GP."
16381128|NCT04111315|Active Comparator|ibuprofen + educational intervention|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
16381129|NCT04111315|Active Comparator|ibuprofen + standard care|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Standard care will be prescribed by the GP."
16381130|NCT04111302|Experimental|IV-PCA|use IV-PCA for postoperative pain
16381131|NCT04111302|Experimental|IV-dezocine|use IV-dezocine for postoperative pain
16381132|NCT04111302|Experimental|IV-PCA+AA|use IV-PCA and AA for postoperative pain
16381133|NCT04111302|Experimental|IV-dezocine+AA|use IV-dezocine and AA for postoperative pain
16381134|NCT04111289|Active Comparator|Patient received upstream high bolus dose of tirofiban|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )
~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)
~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
16381135|NCT04111289|Active Comparator|Patients did not receive upstream high bolus dose of tirofiban|Patient receive tirofiban downstream selectively according to operator discretion
16381136|NCT04111276|Experimental|Subjects diagnosed with osteoarthritis of the knee|Subjects must be diagnosed with marked unicompartimental degenerative joint space narrowing.
16381137|NCT04111263|Sham Comparator|PL+SHAM|Placebo intervention + sea level exposure
16381138|NCT04111263|Placebo Comparator|PL+HA|Placebo intervention + high altitude exposure
16381139|NCT04111263|Experimental|FP+HA|Fiber and polyphenol supplementation + high altitude exposure
16381197|NCT04110808|Active Comparator|Nitroglycerine|Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
16381198|NCT04110808|Other|Phentolamine|Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
16381199|NCT04110795||Cases|Atypical Femur fracture cases
16381200|NCT04110795||Control|matched to AFF cases by race, age, length of ART use
16381201|NCT04110782||Radium223|
16381140|NCT04111250|Experimental|Crestal sinus lift using iRasie implant|"Device: iRaise Sinus Lift implant (Maxillent, Herzliya, Israel). Procedure: crestal sinus lift augmentation.
~We tested crestal versus lateral approach to the sinus. Crestal approach is made by a novel device (iRaise, implant system). Lateral approach is made conventionally with gold standard procedure (lateral approach).
~The iRaise Sinus Lift implant is made of Titanium-6 Aluminum-4 Vanadium alloy, have a surface treated with grit blasting using an apatitic calcium phosphate media, followed by acid etching, and have an internal hexagon connection. Implants have an internal l-shape channel to allow saline and graft passage.
~This implants system is made to perform crestal sinus lift procedure at the same time of the implant placement using the same device. After implant site preparation and initial implant placement, the hydraulic system is connected to the implant to allow the injection of saline and then graft the material. Then, the implant, is inserted for its full length."
16381141|NCT04111250|Active Comparator|Lateral sinus lift|"Conventional procedure.
~Lateral approach to the sinus was made following the conventional procedure.
~A window on the lateral wall of the sinus is performed according to a conventional surgical lateral approach to the sinus cavity. Graft materials is filled inside the sinus cavity. Finally, iSure implants [Maxillent] are placed, and flap is sutured."
16381142|NCT04111237|Active Comparator|Two Finger|two finger method for performing chest compressions
16381143|NCT04111237|Experimental|Two Thumb Technique|Two Thumb Technique
16381144|NCT04111211||Individuals at high risk of developing Alzheimer's dementia|
16381145|NCT04111198||coronary artery disease in diabetic and non diabetic patients|
16381146|NCT04111185|Experimental|Receive Blood Volume Analysis Guided Treatment|The health care team will be provided with BVA results and may use the information to make decisions regarding the participant's treatment.
16381147|NCT04111185|No Intervention|Receive Standard of Care Treatment|The health care team will not be provided with the BVA results. The participant will receive the same treatment they would have received if they weren't in the study.
16381148|NCT04111172|Experimental|Arm A (low dose)|Patients receive low dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
16381149|NCT04111172|Experimental|Arm B (medium dose)|Patients receive medium dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
16381150|NCT04111172|Experimental|Arm C (high dose)|Patients receive high dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
16381151|NCT04111159|Experimental|HSK3486|Subjects < 65 years old:0.4mg/kg/0.15mg/kg;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
16381152|NCT04111159|Active Comparator|Propofol|Subjects < 65 years old:2mg/kg/0.75mg/kg;Subjects≥ 65 years old:75% of the dose for subjects < 65 years old.
16381153|NCT04111146||1|Liver transplant patients with severe vitamin D deficiency (<10ng/ml)
16381154|NCT04111146||2|Liver transplant patients with vitamin D insufficiency (10-20ng/ml)
16381155|NCT04111146||3|Liver transplant patients with normal vitamin D status (>20ng/ml)
16381156|NCT04111133|Experimental|Carvedilol + Ivabradine|
16381157|NCT04111133|Active Comparator|Carvedilol|
16381158|NCT04111120||Cirrhosis with variceal bleeding|Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7
16381159|NCT04111120||Cirrhosis without Bleeding|Control group of 25 subjects
16381160|NCT04111107|Experimental|Drug Administration Based on Next Gen Sequencing Report|Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.
16381161|NCT04111094||HF|Diagnosed heart failure as described by recent guidelines. Inclusion criteria will be applied: i) minimum one symptom typical of HF: positive physical examination (e.g., bilateral oedema, increased jugular pressure) or positive clinical history (e.g., orthopnoea, history of coronary vascular disease, history of arterial hypertension, exposition to cardiotoxic drug/radiation, diuretic use); b-type natriuretic peptide (BNP) or N-terminal pro-BNP levels ≥35 or ≥125 pg/ml, respectively; and iii) classification as New York Heart Association (NYHA) functional class 2 or 3. There is no prespecified inclusion criterion with respect to left ventricular ejection fraction as congestive symptoms and prevalence of kidney dysfunction are comparable in patients with HF across the left ventricular ejection fraction spectrum.
16381162|NCT04111094||Diabetes|Diagnosed diabetes mellitus, with/without treatment
16381163|NCT04111094||Hypertension|Diagnosed hypertension, with/without treatment
16381164|NCT04111081|Experimental|Auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
16381165|NCT04111081|Sham Comparator|Sham auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
16381166|NCT04111068|Experimental|Active then Sham|Participants in this arm will be exposed to active stimulation during session 1 and sham/placebo stimulation during session 2
16381167|NCT04111068|Experimental|Sham then Active|Participants in this arm will be exposed to sham/placebo stimulation during session 1 and active stimulation during session 2
16381168|NCT04111055|Experimental|Closed-loop group|The MAP of the patient will be managed by the CLV system to avoid hypotension. The MAP target selected in the closed-loop system will be the patient's MAP target ( same target as patient's MAP value preoperatively). Then the closed-loop system will have to adjust norepinephrine infusion rate to keep that MAP value within 10% of patient's target.
16381169|NCT04111029||Unresectable HCC undergoing locoregional therapy|Patients with unresectable HCC who have no curative option like tumour ablation, resection or transplantation and are being taken for locoregional therapy will be recruited
16381202|NCT04110769|Experimental|Responders|"The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers.
~The patients who undergo surgery after neoadjuvant chemotherapy will be included responders."
16381343|NCT04109898|Experimental|Modified I-gel insertion technique|Investigator will apply the modified (interventional) I-gel insertion technique in patients
16381170|NCT04111016||Participants able to access the intervention|These group sessions will be delivered by government health workers, and include behavioral recommendations about responsive stimulation, nutrition, water, sanitation and hygiene, lead poisoning prevention, and maternal mental health. Pregnancy groups and caregiver-child groups will be held separately, and mothers and caregivers who attend sessions will receive simple toys and books to use during some of the intervention sessions, which they will be permitted to take home with them. In addition, mothers and caregivers who attend intervention sessions will receive 30 sachets containing 1 gm multiple micronutrient powder (MNP) per month. Beginning as soon as pregnancy is confirmed, health workers will facilitate pregnant women in receiving the Iron and Folic acid supplements already provided by the Government of Bangladesh and will continue the supplementation up to three months post-partum period.
16381171|NCT04111003|Experimental|SFRC direct filling|Restoration of endodontically treated tooth Endodontically treated molars are restored with direct composite restorations, using a short-FRC base filling.
16381172|NCT04111003|Active Comparator|CEREC endocrown|Restoration of endodontically treated tooth Endodontically treated molars are restored with indirect ceramic CAD/CAM restorations.
16381173|NCT04110977|Experimental|Standard Care supported by a Reminder App (Arm A)|Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
16381174|NCT04110977|Active Comparator|Standard Care alone (Arm B)|Treatment with Standard Care alone, starting at the beginning of radiotherapy.
16381175|NCT04110964|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
16381176|NCT04110951|Experimental|Pranayama group|Kapalbhati, Ujjayi and Anuloma-Viloma pranayama techniques were applied to the experimental group. Within this scope, a three days of applied training program was prepared and a guide involving the steps of Pranayama breathing technique was formed. The patients in of pranayama group were trained by the researcher who had yoga trainer certificate. After completing three days of training and observations regarding their accomplishment of applications properly, a pranayama breathing technique video showing how the pranayama breathing technique is done with its details was downloaded to their smartphones and a guide including the application steps was distributed to the patients. The patients were required to apply pranayama technique, in company with the video, 20 min every day and a month in total.
16381177|NCT04110951|Active Comparator|Relaxation group|As there was not placebo breathing control treatment appropriate to yoga breathing technique, relaxation technique was decided to apply in the second group to equalize psychological effects of the treatment. Progressive relaxation technique was taught to the relaxation group during the same training span.A three days of applied training program and Relaxation Technique Application Guide, including steps of progressive relaxation technique, were prepared within this scope. After completing three days of training and observations regarding their accomplishment of applications properly, a relaxing music to listen during applications and a training video involving progressive relaxation directives were downloaded to smartphones of the patients. Also, Relaxation Technique Application Guide involving application steps were distributed to the patients. The patients were required to apply relaxation technique, in company with the video, 20 min every day and a month in total.
16381178|NCT04110925|Other|MDS patients|All Canadian MDS patients on the MDS-database to be included.
16381179|NCT04110912||Cardiac arrest|Ischaemic heart disease is the leading cause of death worldwide. However, this is a registry and no interventions are taking place
16381180|NCT04110912||Trauma|Worldwide, trauma is the number one cause of death and disability in people younger than 40 and confirmed for Canada as well for those under the age of 45. However, this is a registry and no interventions are taking place
16381181|NCT04110912||Sepsis|Sepsis is a clinical syndrome that results from dysregulation of the inflammatory response to severe infection. However, this is a registry and no interventions are taking place
16381182|NCT04110912||Stroke|Stroke is the second leading cause of death worldwide, and the leading cause of chronic disability. However, this is a registry and no interventions are taking place
16381183|NCT04110899|Experimental|Different paratracheal force|Esophageal occlusion is assessed by inserting an esophageal stethoscope under different paratracheal forces.
16381184|NCT04110886|Experimental|HSK21542 single ascending doses|
16381185|NCT04110886|Placebo Comparator|Placebo single dose|
16381186|NCT04110873|Experimental|Antroquinonol capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
16381187|NCT04110873|Experimental|Antroquinonol capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
16381188|NCT04110873|Placebo Comparator|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
16381189|NCT04110860|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
16381190|NCT04110860|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
16381191|NCT04110860|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
16381192|NCT04110847|Active Comparator|TCM OA1|"JING CEIH SHERN YUAN EXTRACT PILL CHUANG SONG ZONG 3 TABLET For 2 Times per day"
16381193|NCT04110847|Placebo Comparator|Placebo|Placebo 3 TABLET For 2 Times per day
16381194|NCT04110834|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
16381195|NCT04110834|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
16381196|NCT04110834|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to assure that the results obtained from other arms are only due to the effects of the active ingredient in the prepared gel.
16381340|NCT04109911|Experimental|Fermented oyster extract group|This group takes fermented oyster extract for 12 weeks
16381203|NCT04110769|Active Comparator|Non-responders|The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
16381204|NCT04110756|Experimental|ChangeGradients|100 adolescents will be enrolled in the CHANGEGRADIENTS intervention.
16381205|NCT04110756|No Intervention|Comparison, non-intervention condition|100 participants will not participate in the ChangeGradients intervention, and will continue to have treatment as usual at the clinic.
16381206|NCT04110743|Other|delayed imaging acquisition|10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
16381207|NCT04110743|Other|low FDG dose imaging|0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
16381208|NCT04110743|Other|comparison PET images reconstructed using CT-based attenuation|10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
16381209|NCT04110730|Experimental|3D Prostheses Users|Children with unilateral congenital upper-limb reductions
16381210|NCT04110730|Active Comparator|Typically Developing Children|Age- and sex-matched control group of typically developing children.
16381211|NCT04110717|Experimental|Active Device Group|25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.
16381212|NCT04110717|Placebo Comparator|Control Device Group|25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.
16381213|NCT04110704|Active Comparator|Transvaginal cerclage|
16381214|NCT04110704|No Intervention|Active monitoring|
16381215|NCT04110678|Active Comparator|NeuroEPO|The dose of NeuroEPO was a vial with a dose of 1 mL/1mg administered intra-nasally for five consecutive weeks.
16381216|NCT04110678|Placebo Comparator|Placebo|The dose of placebo was a vial with a dose of 1 mL/1mg of an intranasal inert solution administered intra-nasally for five consecutive weeks.
16381217|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
16381218|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+ Nefopam and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and Nefopam 120 mg intravenously were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
16381219|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
16381220|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+Opioid delayed release and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and 20 mg of opioid delayed release (Oxycodone) were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
16381221|NCT04110652|Active Comparator|patient|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.(20-22) in addition to pulmonary rehabilitation program.
16381222|NCT04110652|Placebo Comparator|control group|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.
16381223|NCT04110639|Active Comparator|Validation Group|A validation group of 10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
16381224|NCT04110639|Experimental|Study Group|A study group of 20 patients with displaced femoral neck fracture patients (Garden 2-4) treated with open or closed reduction and internal fixation
16381225|NCT04110626||Expériences Animées Programme|The Expériences Animées programme involves supervised short movies and talks with secondary school and high school pupils about the use of psychoactive substances.
16381341|NCT04109911|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
16381342|NCT04109898|No Intervention|standard I-gel insertion technique|Investigator will apply the recommended (standard) I-gel insertion technique in patients
16381228|NCT04110600|Active Comparator|Coffee group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia And will have 100 ml of coffee after 2,4 and 6 hours
~Then outcomes will be assessed as per time frame"
16381229|NCT04110600|Active Comparator|Pepper mint oil group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia This group will have 100 ml of pepper mint oil After 2,4 and 6 hours
~Then outcomes will be assessed as per time frame"
16381230|NCT04110587|Placebo Comparator|arthroscopy|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
16381231|NCT04110587|Active Comparator|arthroscopy plus hyaluronic Acid|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.
16381232|NCT04110561|Other|Spinal Cord Injury patients with motor complete paralysis|
16381233|NCT04110548|Experimental|HCs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the emotion regulation task on the computer.
16381234|NCT04110548|Experimental|IGDs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on.They are instructed to complete the emotion regulation task on the computer.
16381235|NCT04110548|Experimental|IGDs on Craving Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the craving regulation task on the computer.
16381236|NCT04110535|Experimental|Remimazolam 5 mg|IV administration of remimazolam 5 mg
16381237|NCT04110535|Experimental|Remimazolam 10 mg|IV administration of remimazolam 10 mg
16381238|NCT04110535|Active Comparator|Midazolam 2.5 mg|IV administration of midazolam 2.5 mg
16381239|NCT04110535|Active Comparator|Midazolam 5 mg|IV administration of midazolam 5 mg
16381240|NCT04110535|Placebo Comparator|Placebo|Saline injection
16381241|NCT04110522|Experimental|Intervention with Direct Access to Rheumatologist|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation
16381242|NCT04110522|Experimental|Intervention with Standard of Care Referral|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist
16381243|NCT04110522|No Intervention|Control|Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire
16381244|NCT04110496|Experimental|RTX-134|Escalating doses of RTX-134 will be administered by intravenous infusion one time
16381245|NCT04110483|Active Comparator|TURBT|A step-by-step resection of a tumor. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
16381246|NCT04110483|Experimental|Tm-fiber ERBT|A circumferential incision around the tumor is made in the visually intact bladder mucosa. After that, the incision is continued deeper into the muscular layer. Than the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers.
16381247|NCT04110470|Active Comparator|Control Group|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
16381248|NCT04110470|Experimental|Treatment Group|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
16381249|NCT04110444||sildenafile group A|received sildenafil citrate orally 20mg every 8 hours based on previous studies18,21 (Respatio tablet, pharma Egypt group) in addition to low molecular weight heparin daily according to the bodyweight at the booking visit (Clexane 20,40,60 mg, Sanofi eventis company) plus small dose of aspirin 75 mg (Aspocid 75mg tablet, CID pharmaceutical) once daily
16381250|NCT04110444||control group B|received low molecular weight heparin as subcutaneous injection once daily plus low dose aspirin 75mg orally once daily in addition to placebo three times daily prepared by a local pharmacy from a domestic manufacturer
16381251|NCT04110431|Experimental|LBBP group|In this arm, An right artrial (RA) lead and an implantable cardioverter defibrillator (ICD) lead are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed. If LBBP failed, a left ventricular(LV) pacing lead is implanted instead.
16381252|NCT04110431|Active Comparator|BivP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed. If the implantation of LV pacing lead is unsuccessful due to unavailable coronary sinus branches(venae cordis magna or venae cordis media is not recommended), capture above 3.5V/0.5ms or refractory phrenic nerve stimulation,a LBBP lead is placed instead.
16381253|NCT04110418|Active Comparator|Methylene Blue group (Group MB)|"Methylene Blue is supplied in 1 ml or 10 mL single-dose ampules. Each 1 mL ampule contains 10 mg of methylene blue as a clear dark blue solution
~Any unused product or waste material should be disposed of in accordance with local practice,
~For administration to be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the paediatric population. Use the diluted solution immediately after preparation.
~Do not mix with sodium chloride 9 mg/mL (0.9%) solution for injection, because it has been demonstrated that chloride reduces the solubility of methylene blue."
16381254|NCT04110418|Placebo Comparator|Terlipressin Group (Group TP )|"The active substance is terlipressin acetate. Each ampoule contains
~1 mg of terlipressin acetate in 8.5 ml solution for injection. This is equivalent to 0.12 mg terlipressin acetate per ml.
~The powder is to be dissolved in the enclosed solvent and slowly administered intravenously. Further dilution up to 10 ml with sterile isotonic sodium chloride solution is possible.
~Store in a refrigerator at 2-8˚C.
~Keep the ampoules in the outer carton in order to protect from light"
16381255|NCT04110405|Experimental|Stepped Care|To assess the effectiveness of the stepped care model with 420 women who have depression and potential co-occurring anxiety, recruited from 12 primary care clinics in Tajikistan.
16381256|NCT04110405|Active Comparator|Standard of Care plus Healthy Lifestyle|To compare standard of care plus healthy lifestyle materials with 210 women recruited from 6 primary care clinics in Tajikistan.
16381257|NCT04110392|Experimental|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
16381258|NCT04110379|Experimental|Virtual Reality (VR)|Child behavior management will be done using virtual reality glasses distraction (Remax Fantasy Land virtual reality glasses (Schenzen Remax Co.,Ltd))
16381259|NCT04110379|Active Comparator|Conventional Behavior Management|Child behavior management will be done using conventional behavior management techniques
16381260|NCT04110366|Experimental|Live attenuated influenza vaccine|Participants receiving live attenuated influenza vaccine (LAIV)
16381261|NCT04110353|Active Comparator|Conservative dressings|Use of simple dressings on wound post operatively - to be placed at end of operation
16381262|NCT04110353|Active Comparator|Prevena dressing|Use of Prevena(KCI) dressing on wound post operatively - to be placed at end of operation
16381263|NCT04110353|Active Comparator|ciVAC dressing|Use of closed incision VAC (vacuum assisted closure) dressing on wound post operatively - to be placed at end of operation
16381264|NCT04110340|Active Comparator|Ciprofloxacin Arm|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;
~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.
~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
16381265|NCT04110340|Other|Control arm|"Control arm adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those who cannot take it orally) for an additional 7 days.
~Control arm children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.
~Patients who start taking intravenous ciprofloxacin may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
16381266|NCT04110327||Claudication|Subjects presenting with claudication, identified as Rutherford category 1, 2, or 3
16381267|NCT04110327||Critical Limb Ischemia|Subjects presenting with rest pain (Rutherford category 4) or minor tissue loss (Rutherford category 5)
16381268|NCT04110327||Critical Limb Ischemia with major tissue loss|Subjects presenting with major tissue loss (Rutherford 6)
16381269|NCT04110314|Active Comparator|Gain-framed portal reminders + Pre-commitment Prompts|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
16381270|NCT04110314|Active Comparator|Gain-framed portal reminders + No pre-commitment prompt|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
16381271|NCT04110314|Active Comparator|Loss-framed portal reminders + Pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
16381272|NCT04110314|Active Comparator|Loss-framed portal reminders + No pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
16381273|NCT04110314|Active Comparator|No portal reminder + Pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal but do receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
16381274|NCT04110314|No Intervention|No portal reminders + No pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal and do not receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
16381275|NCT04110301|Experimental|MIL62 + Lenalidomide|MIL62 plus Lenalidomide
16381276|NCT04110288||Uncoated Balloon Treatment|Patients treated for PAD with balloon angioplasty, without use of stent.
16381277|NCT04110288||Bare Metal Stent Treatment|Patients treated for PAD with implantation of bare metal stent.
16381278|NCT04110288||Paclitaxel Coated Balloon|Patients treated for PAD with drug coated balloon angioplasty, without use of stent.
16381279|NCT04110288||Paclitaxel Eluting Stent|Patients treated for PAD with implantation of Paclitaxel DES.
16381376|NCT04109651|Other|No Intervention: Control Group|Receive routine nursing care
16381280|NCT04110275|Experimental|low dose group|"Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more.
~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
16381281|NCT04110275|Experimental|high dose group|"Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes.
~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
16381282|NCT04110275|Active Comparator|comparative group|Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.
16381283|NCT04110262|Experimental|High-low dietary sodium|High sodium diet (3400 mg/day) feeding period followed by low sodium diet (2300 mg/day) feeding period
16381284|NCT04110262|Experimental|Low-high dietary sodium|Low sodium diet (2300 mg/day) feeding period followed by high sodium diet (3400 mg/day) feeding period
16381286|NCT04110236|Experimental|Immediate PriCARE|Caregiver-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 1-2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
16381287|NCT04110236|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
16381288|NCT04110236|Experimental|Immediate PriCARE Positive Discipline Module|A subset of participants (up to 40 caregiver-child pairs) who were assigned to the immediate PriCARE group will be offered to participate in the PriCARE Positive Discipline Module if they attended at least 4 PriCARE sessions and completed both main study interviews. If they are randomized to the immediate PriCARE Positive Discipline group, they will attend an additional 4-6 sessions 4-6 weeks after completion of the 6-week PriCARE intervention. This module teaches techniques related to behavior reward charts, appropriate timeout protocol, and other positive discipline techniques for handling persistent behaviors not addressed by the other PriCARE skills.
16381289|NCT04110236|No Intervention|Delayed PriCARE Positive Discipline Module|The delayed Positive Discipline group will not receive the Positive Discipline Module intervention until after their third interview data collection is complete (in 2-3 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
16381290|NCT04110223||non-smell cell lung cancer (NSCLC)|Advanced NSCLC patients receiving radiotherapy or chemo-radiotherapy
16381291|NCT04110223||Rectal cancer|Rectal cancer patients receiving neoadjuvant radiotherapy or chemo-radiotherapy
16381292|NCT04110223||Smell cell lung cancer (SCLC)|SCLC patients receiving radiotherapy or chemo-radiotherapy
16381293|NCT04110223||Esophageal cancer|Esophageal cancer patients receiving radiotherapy or chemo-radiotherapy
16381294|NCT04110223||Cervical cancer|Cervical cancer patients receiving radiotherapy or chemo-radiotherapy
16381295|NCT04110223||Liver cancer|Liver cancer atients receiving radiotherapy or chemo-radiotherapy
16381296|NCT04110210|Active Comparator|Group A(Ultrasound guided ESP block after indtiucon of GA).|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
16381297|NCT04110210|Active Comparator|Group B(GA with conventional analgesia)|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
16381298|NCT04110184||active systemic lupus erythematosus|
16381299|NCT04110184||inactive systemic lupus erythematosus|
16381300|NCT04110145|Other|Cohort 1|linaclotide 18 μg or matching placebo once daily for 4-week Study Intervention Period.
16381301|NCT04110145|Other|Cohort 2|linaclotide 36 μg or matching placebo once daily for 4-week Study Intervention Period
16381302|NCT04110145|Other|Cohort 3|linaclotide 72 μg or matching placebo once daily for 4-week Study Intervention Period.
16381303|NCT04110145|Other|Final Cohort|linaclotide at the highest dose tested/determined to be safe or matching placebo once daily for 4-week Study Intervention Period
16381304|NCT04110132|Active Comparator|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.
~Patient will have hemorrhoidectomy."
16381305|NCT04110132|Placebo Comparator|Ganglion impar block with Saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Patient will have hemorrhoidectomy.
16381440|NCT04109183|Experimental|Postive Comparator: 3TC+ TDF+EFV|
16381306|NCT04110119|Active Comparator|Control: Drug-Only Group|Patients with acute lower-back pain who have undergone routine conventional drug treatment at the first visit to the emergency department (49 patients). The drug treatment consists of analgesic-anti-inflammatory (diclophenac sodium 75 mg IM) and myorelaxant (thiocolchicoside 4 mg IM), administered only once.
16381307|NCT04110119|Experimental|Case: Drug and Chiropractic Group|Patients, who received chiropractic treatment immediately after the conventional drug treatment as in the control group (49 patients). The chiropractic treatment consists of high speed and low amplitude spinal manipulation techniques, applied only once.
16381308|NCT04110093|Experimental|Immunotherapy Combination treatment|All colorectal cancer patients received regorafenib plus PD-1 inhibitor
16381309|NCT04110080|Experimental|Enhanced recovery after surgery|Preoperatively, patients will be counseled on optimization of physical and nutritional status. They will receive carbohydrate loading drinks prior to surgery. Intraoperatively, standard ASA monitors will be utilized, and patients will receive general anesthesia. Goal directed fluid management will be enforced with bolus options based on hemodynamics. Transabdominal plane and rectus sheath block will be performed in the operating room by the regional anesthesia team. Post-operatively pain management will include multimodal analgesic medications. Regular diet will be allowed and encouraged on post-operative day 0 (POD). Lines and drains will be minimized to encourage early mobilization and bowel function. Patients will be counseled on expectations of discharge criteria POD0.
16381310|NCT04110080|Active Comparator|Standard of care|Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
16381311|NCT04110067||1|SMILE - Correction of eyes with myopia of more than -7.75 D
16381312|NCT04110054|Experimental|S-600918 50 mg|Participants will receive 50 mg S-600918 orally once a day for 28 days.
16381313|NCT04110054|Experimental|S-600918 150 mg|Participants will receive 150 mg S-600918 orally once a day for 28 days.
16381314|NCT04110054|Experimental|S-600918 300 mg|Participants will receive 300 mg S-600918 orally once a day for 28 days.
16381315|NCT04110054|Placebo Comparator|Placebo|Participants will receive placebo to S-600918 orally once a day for 28 days.
16381316|NCT04110041|Experimental|Moderate Intensity|Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
16381317|NCT04110041|Experimental|High Intensity|Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
16381318|NCT04110028|Experimental|Nicotinamide riboside 250 mg|One capsule of 250 mg each morning for three months
16381319|NCT04110028|Experimental|Nicotinamide riboside 500 mg|One capsule of 250 mg each morning and afternoon for three months
16381320|NCT04110028|Experimental|Nicotinamide riboside 1000 mg|Two capsules of 250 mg each morning and afternoon for three months
16381321|NCT04110028|Experimental|Nicotinamide riboside 2000 mg|Four capsules of 250 mg each morning and afternoon for three months
16381322|NCT04110028|Placebo Comparator|Placebo for 250 mg nicotinamide riboside|One capsule each morning for three months
16381323|NCT04110028|Placebo Comparator|Placebo for 500 mg nicotinamide riboside|One capsule each morning and afternoon for three months
16381324|NCT04110028|Placebo Comparator|Placebo for 1000 mg nicotinamide riboside|Two capsules each morning and afternoon for three months
16381325|NCT04110028|Placebo Comparator|Placebo for 2000 mg nicotinamide riboside|Four capsules each morning and afternoon for three months
16381326|NCT04110015||Neurology patients|Any patients with neurological disorders
16381327|NCT04110015||Glaucoma patients|Any patients with chronic open angle and chronic angle closure glaucoma of all stages
16381328|NCT04110015||Retina patients|Any patients with known retinal conditions
16381329|NCT04110002|Experimental|Injury Prevention Program|Those allocated to the injury prevention program will be instructed on the program, the added exercises, and the additional time commitment.
16381330|NCT04110002|No Intervention|Control|The control group will practice and perform with no change to pre-existing years' standard operating practice.
16381331|NCT04109989|Experimental|HominisTM Surgical System|Gynecological surgical procedure will be performed with the HominisTM Surgical System
16381332|NCT04109976|Experimental|Bimekizumab-SS|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
16381333|NCT04109976|Experimental|Bimekizumab-AI|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
16381334|NCT04109963|Active Comparator|RIC once per day|RIC performed once a day on one arm. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
16381335|NCT04109963|Active Comparator|RIC twice per day|RIC performed twice a day on one arm, approximately 12 hours apart. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
16381336|NCT04109950|Experimental|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
16381337|NCT04109937|No Intervention|Surgery Alone|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction but will not receive any post-operative radiation therapy.
16381338|NCT04109937|Active Comparator|Surgery and Post-Operative Radiation Therapy|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction and will receive any post-operative radiation therapy.
16381339|NCT04109924|Experimental|Treatment (irinotecan, bevacizumab, TAS-102)|Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16381344|NCT04109885|Experimental|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
16381345|NCT04109885|Active Comparator|Standard treatment|Intravenous administration of prochlorperazine and diphenhydramine.
16381346|NCT04109872||Mantle cell lymphoma treated with lenalidomide cohort|Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.
16381347|NCT04109859|Experimental|Methylene blue group|Before the anesthesia was intubated, the patients in the methylene blue group were given a 2 mg/Kg methylene blue 50 ml intravenously for 10 min; continuous constant speed pumping methylene blue(0.5mg/Kg/h).
16381348|NCT04109859|Placebo Comparator|Placebo group|Before the anesthesia was intubated, the placebo group was given 50 ml of normal saline for 10 min.continuous constant speed pumpingnormal saline (10ml/h).
16381349|NCT04109846|Experimental|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
16381350|NCT04109846|Active Comparator|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
16381351|NCT04109833||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation without antibiotic treatment in the first week of life
16381352|NCT04109833||ABT in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation with antibiotic treatment in the first week of life
16381353|NCT04109820|Experimental|Sickle cell patients|Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
16381354|NCT04109820|Active Comparator|Non Sickle cell Control subjects|Normal control subjects administered oral MitoQ (20mg once a day for 14 days)
16381355|NCT04109807|Experimental|6 hour Filtered Air (FA) followed by O3 exposure|For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone for 6 hours. The ozone levels will start at 0.06ppm increasing to 0.08 ppm in the first hour and holding there for an hour, decreasing to 0.06ppm over the next hour and holding for an hour, increasing back to .08 over the next hour and holding there until the exposure is complete (a total of 6 hours).
16381356|NCT04109807|Experimental|6 hour O3 exposure followed by FA exposure|For the first exposure session, a participant will be exposed to ozone for 6 hours. The ozone levels will start at 0.06ppm increasing to 0.08 ppm in the first hour and holding there for an hour, decreasing to 0.06ppm over the next hour and holding for an hour, increasing back to .08 over the next hour and holding there until the exposure is complete (a total of 6 hours). For the second exposure session, the same participant will be exposed to FA for 6 hours.
16381357|NCT04109794|Active Comparator|E-CTG|Envelope connective tissue graft
16381358|NCT04109794|Active Comparator|SCAF|Semilunar connective tissue graft
16381359|NCT04109781|Other|Patients with Lumbar disc herniation|Patients with lumbar disc herniation with no response to conservative treatment and were treated with Microdiscectomy
16381360|NCT04109768|Experimental|Hands on Nutrition Education|Nutrition and activity intervention to improve behaviors pre to post
16381361|NCT04109755|Experimental|Experimental|Short Course Radiation Therapy (5 x 5 Gy in 1 week, SCRT) with 4 injections of Pembrolizumab starting on the first day of radiotherapy and surgery
16381362|NCT04109742|Active Comparator|Curcumin 500mg capsules|Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
16381363|NCT04109742|Active Comparator|Curcumin 1000mg capsules|Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
16381364|NCT04109742|Placebo Comparator|Placebo curcumin capsules|Dose will be matching placebo capsules daily, orally for 24 weeks
16381365|NCT04109729|Experimental|Treatment: all patients|
16381366|NCT04109716|Experimental|Interpersonal Psychotherapy-Adolescent Skills Training|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) is an indicated group depression prevention program. In IPT-AST, adolescents learn communication (e.g., using I statements, striking while the iron is cold) and interpersonal problem-solving strategies and apply these strategies to their relationships to decrease conflict, increase social support, and improve overall social functioning. IPT-AST consists of 1 or 2 individual pre-group sessions, 1 mid-group session, 8 weekly group sessions, and up to 6 individual booster sessions. Parents are invited to attend the mid-group session so the adolescents can apply the interpersonal strategies in a conversation with a parent. The purpose of the booster sessions is to monitor symptoms and apply the interpersonal strategies to current stressors. These sessions are designed to help solidify the interpersonal skills and address current problems before they result in a worsening of symptoms.
16381367|NCT04109716|Active Comparator|Services as Usual (SAU)|Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
16381368|NCT04109703|Active Comparator|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
16381369|NCT04109703|Placebo Comparator|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
16381370|NCT04109690|Experimental|CPX-351|Phase I will evaluate the safety and tolerability of CPX-351 (44mg/m2 of daunorubicin and 100mg/m2 of cytarabine) administered on 2 days (day 1 and day 5) to determine the Phase II dose. Phase II will evaluate the efficacy of the RP2D.
16381371|NCT04109677||SHE player|Female player in the top Swedish handball league
16381372|NCT04109677||Handbollsligan player|Male player in the top Swedish handball league
16381373|NCT04109664||antral preservation|The patients were grouped according to the distance of gastric division as Antral preservation group (6cm from pylorus)
16381374|NCT04109664||Antral resection|The patients were grouped according to the distance of gastric division as Antral preservation group (2 cm from pylorus)
16381375|NCT04109651|Experimental|Nursing İntervention|Intervention: Other: Nursing intervention
16381377|NCT04109638|Active Comparator|Active PEMF Group|Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
16381378|NCT04109638|Sham Comparator|Placebo PEMF Group|Participants will have a 1 in 2 chance to get the placebo treatment device post-operatively. The device will be attached to the post-operative dressing. The Endonovo SofPulse placebo device does not emit a pulsed electromagnetic field (PEMF). Single blind randomization.
16381379|NCT04109625|Experimental|Non-immunized Hepatitis B|subjects non-immunized against hepatitis B (naive)
16381380|NCT04109625|Experimental|Vaccine Hepatitis B|subjects vaccinated against hepatitis B
16381381|NCT04109625|Experimental|Old or cured Hepatitis B|subjects with hepatitis B (old or cured)
16381382|NCT04109625|Experimental|Ongoing Hepatitis B|subjects with hepatitis B (ongoing)
16381383|NCT04109599|Experimental|PlaySmart|Adolescents, boys and girls, aged 16-19 will participate in the pilot testing of the adapted game.
16381384|NCT04109586|Experimental|Personalized nutrition therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
16381385|NCT04109586|No Intervention|Standard treatment|Standard treatment includes dietitian-led group session on nutrition after SCI and patient visits / consultations on request from doctor.
16381386|NCT04109573|Experimental|Anorectal function post anal laser|"Intervention:
~Device: laser"
16381387|NCT04109547|Experimental|Oral semaglutide 3mg|Subjects will remain on 3 mg for the entire treatment period (26 weeks)
16381388|NCT04109547|Experimental|Oral semaglutide 7mg|Subjects will receive 3 mg for for the first 4 weeks, 7 mg for the remainder of the treatment period
16381389|NCT04109547|Experimental|Oral semaglutide 14mg|Subjects will receive 3 mg for the first 4 weeks, 7 mg for the next 4 weeks and 14 mg for the remainder of the treatment period
16381390|NCT04109547|Placebo Comparator|Placebo (oral semaglutide)|Subjects will receive placebo tablets for the entire treatment period
16381391|NCT04109534|Placebo Comparator|Placebo|Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator
16381392|NCT04109534|Active Comparator|Verum|PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator
16381395|NCT04109508|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
16381396|NCT04109508|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
16381397|NCT04109508|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
16381398|NCT04109508|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
16381399|NCT04109508|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
16381400|NCT04109508|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
16381401|NCT04109495|Other|Smart phone application(NOOM)|
16381402|NCT04109495|Other|Non-user|
16381403|NCT04109482|Experimental|Relapsed or Refractory BPDCN|Treatment with MB-102.
16381404|NCT04109456|Experimental|Part 1, Monotherapy Arm|The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.
16381405|NCT04109456|Experimental|Part 2, Combination Arm|"The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.
~A modified 3+3 design will be used."
16381406|NCT04109443|Experimental|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
16381407|NCT04109443|Active Comparator|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
16381408|NCT04109417|Experimental|osteotomy filled with PRP-gel and covered with PRP-biomembrane|the defect was filled with the previously activated autologous Platelet-rich plasma (PRP) gel and its supernatant. The site was then externally covered with the prepared bio-membrane composed of activated PRP which acted as an adjunct to the mucoperiosteal flap to stimulate tissue regeneration
16381409|NCT04109417|Sham Comparator|osteotomy site left empty|osteotomy site following the surgical intervention was left empty
16381441|NCT04109170||Dry Eye Group|This group of subjects were diagnosed with dry eye.
16381411|NCT04109391|Active Comparator|Reference Therapy|IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles
16381412|NCT04109378|Active Comparator|Patients operated with conventional laparoscopic technique|Patients operated with conventional laparoscopic technique for colorectal DIE
16381413|NCT04109378|Active Comparator|Patients operated with NOSE laparoscopic technique|Patients operated with NOSE technique for colorectal DIE
16381414|NCT04109365|Experimental|Electrical Epidural Stimulation Test (EST)|Laboring women are given EST test initially before local anesthetic is administered and 1 hour post-anesthetic in order to measure sensory and motor responses.
16381415|NCT04109339|No Intervention|group 1 with no oxytocin|
16381416|NCT04109339|Experimental|group 2 with oxytocin 10 U IM + oxytocin 10 U IV|
16381417|NCT04109339|Experimental|group 3 with oxytocin 20 U IM + oxytocin 0 U IV|
16381418|NCT04109339|Experimental|group 4 with oxytocin 0 U IM + oxytocin 20 U IV|
16381419|NCT04109326|Experimental|Adapted Physical Activity and Dietetique|tailored PA program associated with individual nutritional counseling whilst hospitalization and at home during the 26-week duration of adjuvant treatment
16381420|NCT04109326|No Intervention|Control|Standard of care
16381421|NCT04109313|Experimental|LOU064|Participants will be asked to take selected dose of LOU064 twice daily for 52 weeks
16381422|NCT04109300|Experimental|preemptive screening|prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
16381423|NCT04109300|Active Comparator|standard of care|administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.
16381424|NCT04109287|Experimental|Two ultrasound scans and activation of NMES device|Participants will have their leg scanned using an ultrasound machine, before being asked to use the REVITIVE® device for 30 minutes. Their leg will then be scanned again.
16381425|NCT04109274|Experimental|Institution-Based Exercise and Self-Management (EXSM)|Eight session of supervised exercise within the cancer institution plus 8 self-management modules focusing on goal setting and action planning for safe and effective exercise strategies (this is based on our team's successful pilot intervention). Four booster sessions will be provided to this group.
16381426|NCT04109274|Experimental|Institution-Based Self-management only (SM)|Eight SM sessions for safe and effective exercise strategies will be provided to this group (described above). Four booster sessions will be provided to this group.
16381427|NCT04109274|No Intervention|Usual care|Participants in this group will receive care as normally provided by their treating oncologist. This can be heterogeneous between different physicians and centres, but usually includes oncologists encouraging their patients to 'stay active'
16381428|NCT04109261||Palbociclib treatment|
16381429|NCT04109235|Active Comparator|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
16381430|NCT04109235|Experimental|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
16381431|NCT04109222|Experimental|Group 1: Fluzone Quadrivalent Influenza vaccine: 6 to < 36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
16381432|NCT04109222|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to < 9 years|Participants aged 3 to 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
16381433|NCT04109222|Experimental|Group 3: Fluzone High-Dose Influenza Vaccine: >= 65 years|Participants aged >=65 years received a of 0.5-mL dose of Fluzone high-dose vaccine, intramuscularly, at Day 0.
16381434|NCT04109209|Active Comparator|Usual Care Group|"60 Participants will be randomized to receive usual care for caregivers of patients with malignant brain tumors
~Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician
~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
16381435|NCT04109209|Experimental|Psychosocial Intervention Group|"60 Participants of caregivers of patients with malignant brain tumors will be randomized into the psychosocial intervention arm
~Caregivers assigned to the intervention arm will receive usual care and the psychosocial intervention. The intervention entails six one-on-one sessions with an interventionist (psychologist or social worker)
~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
16381436|NCT04109196|Experimental|Intensive 5-day Cognitive Processing Therapy for PTSD|Participants who are eligible for and enrolled in the study will receive a 5-day CPT treatment for PTSD. All participants will be asked to complete clinician-rated and self-report assessments at multiple time points during the study. Participants will also be asked to provide fecal and saliva samples as part of the study, however, they may opt out of biological sample collection.
16381437|NCT04109183|Experimental|Active Comparator: FNC 2 mg+ TDF+EFV|
16381438|NCT04109183|Experimental|Active Comparator: FNC 3 mg+ TDF+EFV|
16381439|NCT04109183|Experimental|Active Comparator: FNC 4 mg+ TDF+EFV|
16381442|NCT04109170||Normal Control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
16381443|NCT04109157|Other|Study population|Women who had fulfilled the standardization of terminology of lower urinary function from ICS were diagnosed as urodynamic stress incontinence (USI) after urodynamic study (UDS) and enrolled for analysis in this study.
16381444|NCT04109144|Experimental|Large Volume Paracentesis (LVP) with Fresh Frozen Plasma (FFP)|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters of fluid are removed
16381445|NCT04109144|Active Comparator|Large Volume Paracentesis (LVP) with Albumin|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the first and third drainage participants will receive 1 bottle, or 50 ccs, of 25% albumin intravenously for every two liters of fluid removed
16381446|NCT04109131|Other|CNS metastases from solid tumours|"The study will be organised on three time-periods based on the time of the 1st CNS event:
~Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event"
16381447|NCT04109118|Other|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|"This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
16381448|NCT04109105||NHS-PEG coated collagen patch cohort|Patients diagnosed of colon adenocarcinoma that have ileocolic anastomosis after undergoing a laparoscopic right hemicolectomy surgery.
16381449|NCT04109092|Experimental|Dose Escalation: NMIBC And BCG Unresponsive NMIBC|
16381450|NCT04109092|Experimental|Dose Expansion: CIS With/Without Ta or T1|
16381451|NCT04109092|Experimental|Dose Expansion: High-grade Ta or T1, Without CIS|
16381456|NCT04109027|Experimental|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
16381457|NCT04109027|Active Comparator|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
16381458|NCT04109014|Other|FASTLANE II Group|Participants will participate in the FASTLANE II Intervention. Counseling sessions will focus on: 1) depressive symptoms, 2) methamphetamine use, and 3) sexual risk behaviors. Three sessions will be devoted to each topic area. Trained staff will use a client-centered approach and develop a goal for each area alongside the participant. Counseling sessions will remain confidential and will not be audio recorded.
16381459|NCT04108988|Experimental|InvestiDate Intervention|One Night Stan will be adapted as a multiplayer videogame called InvestiDate based on the card game prototype with a focus on a slightly younger age group.
16381460|NCT04108988|Placebo Comparator|Non-Health Related Game|Participants in the non-health related game group will play a multiplayer game unrelated to the content of InvestiDate.
16381461|NCT04108975|Active Comparator|Rectus muscle reapproximation group|Rectus muscle reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures
16381462|NCT04108975|Active Comparator|Rectus muscle non reapproximation group|No rectus muscle reapproximation will be done based on the fact that rectus muscle can regain its position
16381463|NCT04108962|Experimental|Treatment|Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
16381464|NCT04108949|Experimental|Tuning in to Kids|Eight weekly two-hour sessions delivered in groups of up to six parents.
16381465|NCT04108949|Active Comparator|Treatment as usual|Treatment as usual, may consist of any psychosocial intervention the therapist sees fit, which is the type of intervention the participants ordinarily receives in the participating clinics. No limit on number of sessions or format of delivery.
16381466|NCT04108936||Peritoneal Carcinomatosis|Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies
16381467|NCT04108936||Control group|Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis
16381468|NCT04108923|Active Comparator|Ligasure ( group A)|
16381469|NCT04108923|Active Comparator|Conventional vessel ligation (group B)|
16381470|NCT04108910||Traditional Urine Culture|Patients treated based upon traditional urine culture
16381471|NCT04108910||Guidance PCR/Pooled Sensitivity|Patients treated based upon multiplex UTI PCR/pooled sensitivity results
16381472|NCT04108897|Experimental|Doxycycline 40mg/day|Doxycycline 40mg will be administered once a day per oral for 28 days.
16381473|NCT04108897|Experimental|Doxycycline 50mg/day|Doxycycline 50mg will be administered once a day per oral for 28 days.
16381474|NCT04108897|Experimental|Doxycycline 100mg/day|Doxycycline 100mg will be administered once a day per oral for 28 days.
16381475|NCT04108897|Experimental|Doxycycline 200mg/day|Doxycycline 100mg will be administered twice a day per oral for 28 days.
16381476|NCT04108897|Experimental|Topical ivermectin(1%)|Topical ivermectin will be applied once a day for 28 days.
16381477|NCT04108897|No Intervention|Control|No intervention will be performed.
16381478|NCT04108884|Experimental|App Group|In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.
16381479|NCT04108884|Other|Standard Care Group|The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.
16381480|NCT04108871|Experimental|Transperineal Prostate Biopsy|The biopsy needed is inserted to the prostate through the perineal skin, with the assistance of an access system device known as PrecisionPoint. It utilises a single access needle cannula mounted directly on to the ultrasound probe, which acts as an access point traversing through the perineal skin. 4 - 5 cores are obtained from the anterior, mid and posterior zone of each side of the prostate.
16381481|NCT04108871|Active Comparator|Transrectal Prostate Biopsy|The biopsy needle penetrates through the bowel (rectum) to the prostate to obtain 12 cores of prostate tissues from the lateral and medial base, midzone and apex of each side of the prostate (1 core each).
16381484|NCT04108845|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine, 0.5 ml/dose
16381485|NCT04108832|Experimental|TCM OA2|TCM OA2 3G BID FOR 8 WEEKS
16381486|NCT04108832|Placebo Comparator|PLACEBO|PLACEBO
16381487|NCT04108819|Experimental|Ketogenic Diet|Participants will receive the ketogenic diet.
16381488|NCT04108806|Experimental|Endovascular therapy|Outcome of endovascular therapy on PAC
16381489|NCT04108793|Experimental|Intervention Arm|The Intervention group will be given a program of progressive balance and lower limb strengthening exercises twice a week for 3 months. All exercises will include 5 minutes warm-up exercises. The lower limb extensor muscle groups (hip & knee extensors and ankle plantar flexors) will be targeted with exercises designed to enhance postural control (i.e. balance) and muscle strength. The balance exercises include standing with a decreased base of support, forwards and sideways stepping/walking, and graded reaching activities in standing. Strengthening exercises will include sit-to-stand, forward and lateral step-ups onto a small block, semi squats and heel raises in standing. Standard principles governing frequency, volume, duration, intensity and progression of exercise will be applied. Cueing strategies will be used to reduce freezing. T
16381490|NCT04108793|No Intervention|Control Arm|The control arm will receive the usual standard postoperative rehabilitation after a bipolar hemiarthroplasty/ total hip arthroplasty which will include in hospital rehabilitation and a maximum of 5 visits postoperatively
16381491|NCT04108780||CBD exploration with T-tube|repair of CBD after CBD exploration over T-tube
16381492|NCT04108780||CBD exploration with primary repair|primary repair of CBD after CBD exploration
16381493|NCT04108767||Health students enrolled in the 3rd year at the University Cla|Health students enrolled in the 3rd year at the University Claude Bernard Lyon 1, aged over 18 years.
16381494|NCT04108754||Diagnosis of AIT|Patients in the neurovascular unit of the Neurological Hospital of Lyon between 01/01/2016 and 30/12/2017 with a probable diagnosis of AIT and having an MRI within 7 days of TIA.
16381495|NCT04108741|Experimental|treadmill training with augmented reality dual tasking|
16381496|NCT04108741|Experimental|treadmill training with random number generation dual tasking|
16381497|NCT04108741|Active Comparator|treadmill training|
16381498|NCT04108728|Experimental|HIV exposed children during pregnancy|children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
16381499|NCT04108728|Other|control children|children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
16381500|NCT04108715|Active Comparator|ESPB GROUP|Erector spina plane block group
16381501|NCT04108715|Active Comparator|SAPB group|Deep Serratus anterior plane block group
16381502|NCT04108702|Experimental|VR heart|
16381503|NCT04108702|Sham Comparator|VR control|
16381504|NCT04108702|Active Comparator|Standard control|
16381505|NCT04108689|Experimental|I-ACT|I-ACT is short for Internet-Acceptance and Commitment Training
16381506|NCT04108676|Experimental|single arm|Drug: Fluzoparib Drug: Omeprazole
16381507|NCT04108663|Sham Comparator|Sham|Sham tDCS (ramp up and ramp down of electrical current before as well as after task performance to elicit physical sensations similar to verum tDCS)
16381508|NCT04108663|Active Comparator|L1A|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: anodal"
16381509|NCT04108663|Active Comparator|R1A|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: anodal"
16381510|NCT04108663|Active Comparator|L2A|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: anodal"
16381511|NCT04108663|Active Comparator|R2A|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: anodal"
16381512|NCT04108663|Active Comparator|L1C|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: cathodal"
16381513|NCT04108663|Active Comparator|R1C|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: cathodal"
16381514|NCT04108663|Active Comparator|L2C|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: cathodal"
16381515|NCT04108663|Active Comparator|R2C|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: cathodal"
16381657|NCT04107753|No Intervention|Control group|"No other intervention than the usual care (range between the not mentioning the subject at all, to a general advice to quit without bringing any evidence or any structured counseling)."
16381516|NCT04108650|Experimental|Fit & Strong! group|The experimental group (23 participants) was enrolled in the intervention, the Fit & Strong! program. The program consists in 24 sessions each divided in two parts. The first part is the exercise component (60 minutes) and the second is the educational component (30 minutes). The program was provided in two classes, the first class took place from October to December 2017 and the second class took place from October to November 2018. The experimental group was enrolled in the intervention (8 weeks).
16381517|NCT04108650|No Intervention|Control group|To participants in the control group (8 participants) were offered the possibility of enrolling in the program the following year after posttest measurement for both the intervention and control groups was complete.
16381518|NCT04108637|Experimental|penicillin allergy assessment pathway|"Those in the PAAP intervention arm will complete stage 2&3 of the PAAP pathway:
~Stage-2 assessed for skin testing (ST) and ST done or straight to stage 3
~Stage-3 oral challenge test (OCT) All completing PAAP will receive a letter from the immunology clinic giving the results of the test. Also, patients who have tested negative will receive the Post-test Intervention Booklet and Patient Intervention Card Materials.
~Additionally, all participants in the PAAP arm will be called by the trial team at days 4-6 and 28-30 post testing to collect safety data. During the call at days 28-30 patients will complete the patient questionnaire on allergy beliefs.
~Practices will be informed of the test result and instructed to update the participant's electronic health records accordingly."
16381519|NCT04108637|No Intervention|Control Arm|The usual care arm receive no intervention but will be followed up as per intervention arm with monitoring of any symptoms following an antibiotic prescription.
16381520|NCT04108624|Experimental|MRD2STOP ARM|
16381521|NCT04108611|Experimental|systemic lupus in activity|Sixty systemic lupus patients in activity will receive conventional therapy (47 patient as cases 1) and immunadsortion (13 patients as cases 2) will be provided to the non responders
16381522|NCT04108611|Other|Control group 30 subjects|controls 1 (20 healthy volunteers, controls 2 (10 patients with glomerular diseases other than lupus) will do routine laboratory investigations
16381523|NCT04108598||Adults presenting with SSNHL|Adults presenting with SSNHL to NHS
16381524|NCT04108585||HFO group|HFO therapy
16381525|NCT04108585||CPAP group|CPAP therapy
16381526|NCT04108572|Experimental|Infant feeding intervention|The intervention will be delivered to parents by practice nurses and/or GPs in MPHC at each of the vaccination visits, prior to administration of the vaccination. These vaccination visits take place at 2, 4, 6, 12 and 13 months. This intervention consists of 1) verbally delivered pre-specified infant feeding messages, and 2) provision of additional infant-feeding resources including an information leaflet, a magnet, an infant bib and access to an informational website.
16381527|NCT04108559|Experimental|Kinesiologic Tape Group|After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
16381528|NCT04108559|Experimental|Surgical Drain Group|After routine impacted third molar surgery, plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa.
16381529|NCT04108559|Placebo Comparator|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
16381530|NCT04108546|Experimental|massage-electroacupuncture|Electroacupuncture will be applied throughout the back of the body, upper limbs and ears.Massage will follow the same paths of acupuncture points respectively
16381531|NCT04108546|Active Comparator|Epidural analgesia|Epidural analgesia will be applied using ropivacaine 0.2%, 5-7% ml and Fentanyl 25 mcg
16381532|NCT04108533|Experimental|Text-Based Support|"Text-Based Support - Women randomized to this arm will receive text-based support via the Way to Health platform as described below.
~Supportive texts - Encouraging text messages with prompts to ask questions will be sent twice weekly during the first four weeks postpartum and once weekly thereafter for the remaining two weeks of the program
~Inquiry texts - Questions regarding infant feeding with prompts to answer will be sent three times weekly during the first two weeks postpartum and twice weekly thereafter for the remaining 4 weeks of the program.
~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.
~Women in this group will also have the option to send a text with a question or concern at any time during the study. Weekdays from 8am to 5 pm these will be fielded by a trained obstetrician. If a text is received after-hours or on the weekend, women will be instructed to reach out to their primary OBGYN provider."
16381533|NCT04108533|No Intervention|Usual Care|"Usual care - Women randomized to this arm will receive usual postpartum care with the following exceptions:
~Inquiry texts- Questions regarding infant feeding with prompts to answer will be sent once weekly for all 6 weeks of the program.
~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.
~Women in this group will be directed to their physician with any questions or concerns during the study period."
16381534|NCT04108520|Experimental|Intervention Group|Exercises on respiratory muscle, 3 times per week, 1 hour peer day
16381535|NCT04108507|Experimental|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP)operation
16381536|NCT04108507|No Intervention|without posterior branch block of spinal nerve|without posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
16381537|NCT04108494|Experimental|Experimental group|D2 radical gastrectomy with partial omentectomy
16381538|NCT04108494|No Intervention|Control group|D2 radical gastrectomy with total omentectom
16381579|NCT04108208|Placebo Comparator|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
16381580|NCT04108195|Experimental|Part 1: Dose Escalation|Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
16381540|NCT04108468|Experimental|Golimumab & Methotrexate|
16381541|NCT04108468|Active Comparator|Methotrexate|
16381542|NCT04108455||With Diabetes|Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
16381543|NCT04108455||Controls|Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
16381544|NCT04108442|Active Comparator|Traditional|
16381545|NCT04108442|Experimental|Virtual|
16381546|NCT04108429|Experimental|Mobile self-help intervention|Participants will have open access to the IntelliCare system.
16381547|NCT04108403|Experimental|Pain Inducing Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
16381548|NCT04108403|Active Comparator|Pain Inducing Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
16381549|NCT04108403|Active Comparator|Pain Free Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
16381550|NCT04108403|Active Comparator|Pain Free Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
16381551|NCT04108390|Experimental|Intervention group|Individuals for this group will be treat with a dry needling intervention at the gluteus medius trigger point.
16381552|NCT04108390|Active Comparator|Control group|Individuals for this group will be treat with a dry needling technique at 1,5 cm from the trigger point (not in the trigger point).
16381553|NCT04108377|Experimental|Roflumilast|Roflumilast 500mcg by mouth, once daily, for 70 days (10 weeks).
16381554|NCT04108377|Placebo Comparator|Placebo|Placebo by mouth, once daily, for 70 days (10 weeks).
16381555|NCT04108364|Experimental|VoiceAdapt Intervention|PWA who train with VoiceAdapt app
16381556|NCT04108364|No Intervention|No Intervention|PWA who are on the waitlist and not training with VoiceAdapt app
16381557|NCT04108351|Experimental|Zopiclone|
16381558|NCT04108351|Placebo Comparator|Placebo|
16381559|NCT04108338||CCRT-randomized clinical trial|Trial patients receiving CCRT
16381560|NCT04108338||CCRT-real-world database|Patients receiving CCRT from real-world database
16381561|NCT04108338||IC+CCRT-randomized clinical trial|Trial patients receiving IC+CCRT
16381562|NCT04108338||IC+CCRT-real-world database|Patients receiving IC+CCRT from real-world database
16381563|NCT04108325|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
16381564|NCT04108312||Autism Spectrum Disorders|
16381565|NCT04108312||Typical Control|
16381566|NCT04108299|Placebo Comparator|wait-list control|Standard of care
16381567|NCT04108299|Experimental|SMS intervention|The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.
16381568|NCT04108286|Experimental|TEST/CONTROL|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
16381569|NCT04108286|Experimental|CONTROL/TEST|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
16381570|NCT04108273|Experimental|OST Intervention|
16381571|NCT04108273|Other|Waitlist|
16381572|NCT04108260|Experimental|Single arm_Idelvion treated|
16381573|NCT04108247|Experimental|Abiraterone+SHR3162|
16381574|NCT04108234|Experimental|Treatment group A|HR071603,nasal spray,dose escalation.
16381575|NCT04108234|Placebo Comparator|Treatment group B|Placebo, nasal spray
16381576|NCT04108221|Experimental|Arm A : c-TAP Block performed by surgeon|c-TAP Block Block performed by surgeon
16381577|NCT04108221|Active Comparator|Arm B : us-TAP Block performed by anesthetist|us-TAP Block by anesthetist
16381578|NCT04108208|Experimental|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
16381658|NCT04107740|Experimental|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
16381659|NCT04107740|Placebo Comparator|Placebo (0mg Taltirelin Hydrate)|BID for 24 weeks
16381581|NCT04108195|Experimental|Part 2: Dose Expansion|Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1 until disease progression, unacceptable toxicity, withdrawal of consent, otherwise deemed necessary by the investigator or the sponsor, or end of study.
16381582|NCT04108169|Active Comparator|Active Comparator|
16381583|NCT04108169|No Intervention|Sham Comparator|
16381586|NCT04108143|Experimental|Intervention|MonitorMe device
16381587|NCT04108130|No Intervention|Usual Care|Patients in this arm will receive usual anesthetic and postoperative care as provided in each site.
16381588|NCT04108130|Experimental|Intervention|This arm will receive the bundle of interventions.
16381589|NCT04108117||Robotic nipple sparing mastectomy group/RNSM|"Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
~The estimated sample size for this arm is 300 cases."
16381590|NCT04108117||Conventional nipple sparing mastectomy group/CNSM|"Cases or Patients who underwent conventional nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Conventional nipple-sparing mastectomy should not be performed using robotic or endoscopic surgical systems. Axillary or lateral incisions that are similar to incisions in robotic nipple-sparing mastectomy are not allowed. Other than axillary or lateral incisions can be performed for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with nipple-sparing mastectomy without immediate reconstruction are excluded.
~The estimated sample size for this arm is 300 cases."
16381591|NCT04108104|Experimental|Low-dose group|Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
16381592|NCT04108104|Experimental|High-dose group|Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)
16381593|NCT04108104|Placebo Comparator|Placebo group|Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
16381594|NCT04108091||Treatment for TTR amyloidosis|Transthyretin amyloid cardiomyopathy (wild-type or variants) patients administered Vyndaqel
16381595|NCT04108078|Experimental|Intervention|This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention.
16381596|NCT04108078|No Intervention|Wait listed|Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study.
16381597|NCT04108065||Patients with gestational diabetes mellitus (GDM)|GDM diagnosed according to current Danish guidelines (plasma glucose (PG) concentration at 120 min after a 75 g oral glucose tolerance test (OGTT) ≥9.0 mM)
16381598|NCT04108065||Pregnant women with normal glucose tolerance (control group)|Pregnant women with normal glucose tolerance (fasting plasma glucose (PG) concentration ≤6.0 mM and PG concentration at 120 min after a 75 g-OGTT <7.8 mM)
16381600|NCT04108039|Active Comparator|GnRH antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering.
16381601|NCT04108039|Experimental|Micronized progesterone|In the progesterone cycle, endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg) once a day at bed time, from stimulation day 1 and continuing until ovulation triggering.
16381602|NCT04108026|Experimental|Immunotherapy|Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
16381603|NCT04108013|Experimental|SHR-1210+Carboplatin+Paclitaxel-albumin|Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
16381604|NCT04108013|Active Comparator|Carboplatin+Paclitaxel-albumin|Subject will receive carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
16381605|NCT04108000|Experimental|SPIRIT-Dementia|Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
16381606|NCT04108000|Active Comparator|Usual Care|Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
16381607|NCT04107987|Active Comparator|Reglicemi|Reglicemi is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
16381608|NCT04107987|Placebo Comparator|Placebo|Placebo
16381656|NCT04107753|Experimental|Intervention: Brief counseling based on the 5As model|The intervention group received a brief counseling based on the 5As model. It mainly consists of the following steps: ask, advice, asses, assist, arrange. It is performed by the nurse who take clinical care of the patient. The patients receive an information card about the Smoke cessation center's (CTT) and the patients who agree are contacted by the CTT's staff.
16381719|NCT04107272|Experimental|Experimental group|Real rTMS
16381720|NCT04107272|Sham Comparator|Control group|Sham rTMS
16381609|NCT04107974|Experimental|Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. Two T-fasteners are inserted into the stomach approximately 4cm apart. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate. The gastropexy/T-fastener sutures are cut after one week.
16381610|NCT04107974|Experimental|Non-Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate.
16381611|NCT04107961|Experimental|Vaccine arm|Vaccine in 1 ml, single dose
16381612|NCT04107961|Placebo Comparator|Placebo|1 ml normal saline , single dose
16381613|NCT04107948|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
16381614|NCT04107948|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
16381615|NCT04107935|Experimental|Intervention|
16381616|NCT04107935|Other|Usual Care|
16381617|NCT04107922|Active Comparator|Glicoset|Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
16381618|NCT04107922|Placebo Comparator|Placebo|
16381619|NCT04107909|Other|3 ports|3port operation
16381620|NCT04107909|Other|4 port|4 port operation
16381621|NCT04107896|Experimental|Silodosin|8 mg daily by mouth, 12 weeks
16381622|NCT04107896|Active Comparator|Tamsulosin|0.4 mg daily by mouth, 12 weeks
16381623|NCT04107883|Experimental|control group|Do not perform plasma transfusion during operation.
16381624|NCT04107883|Experimental|anhapetic group|Perform plasma transfusion during anhapetic phase.
16381625|NCT04107883|Experimental|neohepatic group|Perform plasma transfusion during neohepatic phase.
16381626|NCT04107870|Experimental|Virtual Reality Exposure Therapy|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
16381627|NCT04107870|Active Comparator|Psychomotor Therapy|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
16381628|NCT04107857||Smoking Cessation|"Patients enter the program through clinic appointments or community outreach programs.
~Patients will be given brief advice to quit smoking and referral options to receive evidence-based treatment through Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov dependent on the patient's preference for counseling
~Patient can also be prescribed smoking cessation pharmacotherapy"
16381629|NCT04107844||Athletes without concussion|We follow the athletes in terms of injuries and make a baseline test each season.
16381630|NCT04107844||Athletes suffering a concussion|We follow the athletes in terms of injuries and make a baseline test each season and when they suffer a concussion, then we follow them with the same test as at baseline every 14th day for 3 months, after that they will get enrolled in another study.
16381631|NCT04107831|Experimental|Pulmonary rehabilitation|Participants who are participating in a 6-week pulmonary rehabilitation program are enrolled in the study.
16381632|NCT04107805|Experimental|Part 1: Dose Group 1|
16381633|NCT04107805|Experimental|Part 1: Dose Group 2|
16381634|NCT04107805|Experimental|Part 1: Dose Group 3|
16381635|NCT04107805|Experimental|Part 1: Dose Group 4|
16381636|NCT04107805|Experimental|Part 1: Dose Group 5|
16381637|NCT04107805|Placebo Comparator|Part 1: Placebo|
16381638|NCT04107805|Experimental|Part 1: Dose Group 6|
16381639|NCT04107805|Experimental|Part 2: Dose Group 1|
16381640|NCT04107805|Experimental|Part 2: Dose Group 2|
16381641|NCT04107805|Experimental|Part 2: Placebo|
16381642|NCT04107792|Experimental|Experimental|Parents of children with sensory processing issues who attend Workshop 1
16381643|NCT04107792|No Intervention|Waitlist Control|parents of children with sensory processing issues who attend Workshop 2
16381644|NCT04107779|Experimental|JUUL 5% Virginia Tobacco ENDS|JUUL 5% Virginia Tobacco flavored ENDS product [6 days] in confinement.
16381645|NCT04107779|Experimental|JUUL 3% Virginia Tobacco ENDS|JUUL 3% Virginia Tobacco flavored ENDS product [6 days] in confinement.
16381646|NCT04107779|Experimental|JUUL 5% Mint ENDS|JUUL 5% Mint flavored ENDS product [6 days] in confinement.
16381647|NCT04107779|Experimental|JUUL 3% Mint ENDS|JUUL 3% Mint flavored ENDS product [6 days] in confinement.
16381648|NCT04107779|Experimental|JUUL 5% Menthol ENDS|JUUL 5% Menthol flavored ENDS product [6 days] in confinement.
16381649|NCT04107779|Experimental|JUUL 3% Menthol ENDS|JUUL 3% Menthol flavored ENDS product [6 days] in confinement.
16381650|NCT04107779|Experimental|JUUL 5% Mango ENDS|JUUL 5% Mango flavored ENDS product [6 days] in confinement.
16381651|NCT04107779|Experimental|JUUL 3% Mango ENDS|JUUL 3% Mango flavored ENDS product [6 days] in confinement.
16381652|NCT04107779|Experimental|Dual-use of JUUL 5% and UB of Combustible Cigarette|JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette [6 days] in confinement.
16381653|NCT04107779|Active Comparator|UB of Combustible Cigarette|Usual brand combustible cigarette [6 days] in confinement.
16381654|NCT04107779|Other|Tobacco/Nicotine Abstention|Smoking abstention (no smoking) [6 days] in confinement.
16381655|NCT04107766||Population|Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
16381660|NCT04107727|Experimental|Quizartinib|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days"
16381661|NCT04107727|Placebo Comparator|Placebo|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
16381662|NCT04107714|Experimental|Intervention (STC)|"Study participants randomized to the experimental group receive the intervention (STC). STC is a peer-led and web-based group intervention containing four two-hour sessions within four weeks plus an additional booster session one month later.
~Fidelity to manual is rated in each session by study staff."
16381663|NCT04107714|No Intervention|No intervention|Participants randomized to the control group do not receive the group program but get the accompanying workbook at the end of the study.
16381664|NCT04107688|Experimental|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
16381665|NCT04107688|Experimental|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
16381666|NCT04107675|Experimental|L-CsA 10 mg plus Standard of Care|Liposomal Cyclosporine A 10 mg bid for 12 weeks
16381667|NCT04107675|Experimental|L-CsA 5 mg plus Standard of Care|Liposomal Cyclosporine A 5 mg bid for 12 weeks
16381668|NCT04107675|Placebo Comparator|Liposomal Placebo plus Standard of Care|Liposomal Placebo 2.5 mL bid for 12 weeks
16381669|NCT04107662||Traumatic Brain Injury|
16381670|NCT04107649|Other|Arm1|Participants in this arm receive usual post-operative care and complete all basic study activities, which include: attending 2 in-clinic visits at designated time-points, wearing and returning waist-worn activity trackers at 5 time points over two years, and completing 6 study surveys.
16381671|NCT04107649|Experimental|Arm2|Participants in this arm receive usual post-operative care, complete all basic study activities, receive the wrist-based activity tracker intervention, and receive regular calls from study personnel about improving their general well being.
16381672|NCT04107649|Experimental|Arm3|Participants in this arm receive usual post-operative care, complete all basic study activities, and receive the TAC(MI)+FI and wrist-based activity tracker interventions.
16381673|NCT04107636|Experimental|Assigned Interventions|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location. After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
16381676|NCT04107597|Experimental|Core stabilization exercises|Patients with CLBP who practice core stabilization exercises
16381677|NCT04107597|Experimental|Core stabilization exercises and paced breathing training|Patients with CLBP who practice core stabilization exercises combined with paced breathing training
16381678|NCT04107597|Experimental|Myofascial trigger point release|Patients with CLBP who receive myofascial trigger point release therapy
16381679|NCT04107597|Experimental|Myofascial trigger point release and paced breathing training|Patients with CLBP who receive myofascial trigger point release therapy combined with paced breathing training
16381680|NCT04107571||Cohort|
16381681|NCT04107558|Experimental|Painful stimuli with Hypnosis and Virtual Reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes. This session takes place under hypnosis
16381682|NCT04107558|No Intervention|Painful stimuli without Hypnosis and Virtual reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes.
16381683|NCT04107545|Experimental|athletes|48 elite athletes, 24 men and 24 women, experiencing regular weight cycling.
16381684|NCT04107532|Other|Virtual Reality Therapy for Acrophobia|There were a total of 5 treatments in the VR treatment group, followed by cliffs, cliffs, cliffs, single-plank bridges, and high-altitude rescues. The difficulty of the scene increased in turn. The frequency of treatment twice a week, about 30 minutes each time, fills in the motion sickness questionnaire before and after each treatment to understand the safety of VR treatment. In the course of treatment, physiological data such as skin electricity, skin temperature, heart rate, and blood volume were measured, and the state of the subjects was objectively evaluated. At the same time, every two minutes, participants were asked about sud values and recorded.
16381685|NCT04107532|Other|Imagination Exposure Therapy for Acrophobia|The imaginary exposure treatment program is to convert the five scenes of VR exposure treatment through language, guide the subjects through the guidance language, guide the subjects to expose, and achieve the purpose of adaptation. Both treatment groups were required to collect scales and nuclear magnetic data before, after and after six months of follow-up.
16381686|NCT04107519|Experimental|Immediate GRIT (ImT) training intervention|
16381687|NCT04107519|No Intervention|Delayed Training (DeT) control|
16381721|NCT04107259||Patient with diabetes|60 newly diagnosed type 2 diabetes
16381722|NCT04107259||Control|60 non-diabetic control subjects
16381723|NCT04107246||Newly transplanted corneal patients|
16381724|NCT04107233|Experimental|Intervention|Audit and feedback directed at family physicians, including reports a one-on-one meeting.
16381688|NCT04107506|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
16381689|NCT04107506|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
16381690|NCT04107493|Active Comparator|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
16381691|NCT04107493|Experimental|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
16381692|NCT04107480|Experimental|Intervention|Patients in the intervention groups will be referred to one of the participating neurosurgical centers, for surgical consultation. After this consultation, the patient may choose to continue with surgery or not.
16381693|NCT04107480|Active Comparator|Standard care|Patients in the standard care groups will receive treatment as usual as described by the US Endocrine Society.
16381694|NCT04107454|Active Comparator|Active group|The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
16381695|NCT04107454|Placebo Comparator|Placebo group|Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
16381696|NCT04107441|Experimental|Part 1 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg, 10 mg, 20 mg or 40 mg AX-8 twice daily (8 hours apart, i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of treatment periods 1, 2, 3 or 4, respectively.
16381697|NCT04107441|Experimental|Part 2 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg AX-8 and one ODT with 40 mg AX-8 8 hours later (i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of the treatment period.
16381698|NCT04107428|Active Comparator|Somatostatin|
16381699|NCT04107428|Placebo Comparator|Placebo|
16381700|NCT04107415|Experimental|Yoga group|group doing yoga
16381701|NCT04107415|No Intervention|No yoga group|group not doing yoga
16381702|NCT04107402|Experimental|Septic shock|Septic shock Patients admitted to the ICU
16381703|NCT04107402|Other|Control group|Patients recruited at the central lab of the hospital, with matched age, gender and comorbidities
16381704|NCT04107402|Experimental|Covid-19|Covid-19 patients admitted to the ICU for Acute Respiratory Distress Syndrom with PaO2/FiO2 < 200
16381705|NCT04107389|Active Comparator|Intervention Group|Receives Art Therapy assessment and intervention
16381706|NCT04107389|Active Comparator|Wait List Control Group|Added to wait list to receive intervention at a later date, participant is made aware of this
16381707|NCT04107376|Experimental|Retroviewing endoscopy (RVE)|Withdrawal in every colonic segment with SFV (standard forward view) followed by another withdrawal with the retroviewing endoscope. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
16381708|NCT04107376|Active Comparator|standard forward viewing endoscopy (SFVE)|Withdrawal in every colonic segment with SFV followed by another withdrawal with SFV. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
16381709|NCT04107363|Experimental|Experimental group:|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes.
~After the oropharyngeal aspiration was completed, the patient's position was changed."
16381710|NCT04107363|Other|Control group|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
16381711|NCT04107350|Experimental|whole body vibration on|vibration machine on combined with conventional physical therapy
16381712|NCT04107350|Sham Comparator|whole body vibration off|vibration machine off combined with conventional physical therapy
16381713|NCT04107337|Experimental|Experimental group|Experimental group (N=10): this group will conduct a vocal work session based on semi-occluded vocal-tract exercises with a straw.
16381714|NCT04107337|Other|Control group|Control group (N=10): the second group acting as control group will perform a vocal work session based on open mouth exercices (vocalizations).
16381715|NCT04107324|Other|PVE (Portal vein embolisation)|Standard of care when FLR is small.
16381716|NCT04107324|Experimental|ARAPS (Portal vein embolisation and associating RFA)|Experimental arm with PVE combined with RFA to induce accelerated liver hypertrophy.
16381717|NCT04107298|Experimental|SUNDANCE™ Drug Coated Balloon|SUNDANCE™ Drug Coated Balloon
16381718|NCT04107285||Neurocognitive evaluation prior to and following CART|
16381725|NCT04107233|No Intervention|Control|Usual care; may receive the intervention at the end of the study if successful
16381726|NCT04107220|Other|one arm|One arm study patients where NT-proBNP and BNP tests will be monitored.
16381727|NCT04107207|Active Comparator|Kombucha Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
16381728|NCT04107207|Placebo Comparator|Placebo Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
16381729|NCT04107194|Experimental|Tailored therapy|"Clarithromycin-sensitive strain (10 day-therapy):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)
~Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):
~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)
~Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)
~Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)"
16381730|NCT04107194|Active Comparator|Empiric therapy|"Either one of the two following 10-day regimens (according to physician's decision):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)
~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)"
16381731|NCT04107181|Experimental|Patient surveillance|The introducer will be used during annual Pap smears for cervical cancer screening.
16381732|NCT04107181|Experimental|Healthy Volunteers|There will be 2 types of healthy volunteers recruited to participate in this arm. The home study is to determine ease of use/feasibility of the introducer. The other group of healthy volunteers will be interviewed only. The goal of this study is to better understand how to improve women's health through learning about women's perceptions of their reproductive anatomy, specifically the cervix, comfort in discussing reproductive health topics with providers, and thoughts on two tools used to see the cervix.
16381733|NCT04107168||Cohort 1|"Disease: Unresectable AJCC (American Joint Committee on Cancer) stage 3 or 4 melanoma.
~Anti-PD-1 monotherapy (Nivolamab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted."
16381734|NCT04107168||Cohort 2|Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolamab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381735|NCT04107168||Cohort 3|Disease: Advance renal cell carcinoma. Nivolamab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381736|NCT04107168||Cohort 4|Disease: Advanced renal cell carcinoma Nivolamab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381737|NCT04107168||Cohort 5|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolamab, Pembrolizumab or Atezolizumab) monotherapy in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381738|NCT04107168||Cohort 6|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolamab, Pembrolizumab or Atezolizumab) + chemotherapy +/- antiangiogenic (Bevacizumab) in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381739|NCT04107168||Cohort 7|Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolamab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381740|NCT04107168||Cohort 8|Disease: Resected renal cancer Durvalumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381741|NCT04107168||Cohort 9|Disease: Resected renal cancer Durvalumab + Tremelimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
16381742|NCT04107155|Experimental|Weight Management Program|Dietary Supplement: Saffron extract and Gynostemma extract with hesperidin and a handout with suggestions for healthy eating and overall health
16381743|NCT04107155|Placebo Comparator|Placebo|Placebo and handout with suggestions for healthy eating and overall health
16381744|NCT04107142|Experimental|CAR-T Cell Therapy Group|"One arm study consisting of 3 + 3 dose escalation study design ranging from 3 x 10^8 - 3 x 10^9 cells CAR-γδ T cell.
~Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart."
16381745|NCT04107129||Known Endometriosis|Known Endometriosis undergoing IVF with PGTA
16381746|NCT04107129||Unexplained Infertility|Unexplained Infertility undergoing IVF with PGTA
16381747|NCT04107129||Low Risk Controls|Low Risk Controls undergoing IVF with PGTA
16381748|NCT04107116|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
16381749|NCT04107116|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by their local oncologists.
16381750|NCT04107103|Experimental|Single Arm|A single-arm combining nivolumab with pemetrexed
16381780|NCT04106830||NMOSD|Patients with neuromyelitis optica spectrum disorders
16381751|NCT04107090|Experimental|US guided lung recruitment|Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.
16381752|NCT04107090|Other|Non US guided lung recruitment|Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group.
16381753|NCT04107077|Experimental|Drug Administration Period|
16381754|NCT04107064|Experimental|Neurodiversity at Work (NaW) Group|Individuals in this group will receive a 6-week Autism at Work pre-employment training. Upon onboarding, each individual will be supported by a team manager, a team buddy, a peer mentor, a job/life skills coach, a vocational rehabilitation counselor, and a personal counselor. Ongoing support for members of support circles will be provided during the 12 weeks immediately after onboarding.
16381755|NCT04107064|Experimental|Neurodiversity at Work - Delayed Start (NaW-DS)|Participants in this group will receive typical orientation for neurotypical employees after onboarding. The support of peer mentor, job/life skills coach, vocational rehabilitation counselor, and a personal counselor will start 6 months after onboarding. Managers, co-workers, team buddies and mentors for all recruited and hired employees in both groups will receive the same specialized training to enhance their abilities to work with individuals with ASD.
16381756|NCT04107038|Active Comparator|General|Participants randomized to group A will receive general endotracheal anesthesia as their anesthetic procedure.
16381757|NCT04107038|Active Comparator|Sedation|Participants randomized to group B will receive monitored anesthesia care as their anesthetic procedure.
16381758|NCT04107025|Experimental|Intervention|As part of the intervention, along with legal opinions, advise and support, participants were provided counselling support during their time to help survivors with trauma of legal proceedings.
16381759|NCT04107025|No Intervention|Usual Care|Participants were scheduled for legal consultancy only.
16381760|NCT04107012|Experimental|Clear Aligner|Group 1 treated with clear aligners
16381761|NCT04107012|Active Comparator|Fixed appliance|Group 2 treated with conventional fixed appliances
16381762|NCT04106999|Placebo Comparator|Placebo|Normal Saline will be infused as per the protocol
16381763|NCT04106999|Experimental|Intervention group|Dexmedetomidine will be infused as per the protocol
16381764|NCT04106986|Experimental|PEMF and PRE|The PEMF and PRE group received 24 sessions (3 sessions/week for 8 weeks) of combined treatment group (pulsed electromagnetic field with PRE training)
16381765|NCT04106986|Experimental|PRE|The PRE group received 24 sessions (3 sessions/week for 8 weeks) of only progressive resistance exercise
16381766|NCT04106973||Pleural mesothelioma|Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.
16381767|NCT04106973||Asbestos exposed without pleural mesothelioma|Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.
16381768|NCT04106947||Patients with Hirschsprung and anorectal malformation|Patients with Hirschsprung and anorectal malformation living in Norway
16381769|NCT04106921|Experimental|Universal Health Coverage Mode|The NGOs Muso and Medic Mobile have partnered to develop Universal Health Coverage Mode, a smartphone app tool that provides visual cues to help CHWs track the quantity of household visits they have conducted at each household in a given month.
16381770|NCT04106921|No Intervention|Work as usual|For the control arm, all households within the CHW's household list in the app will have the same appearance. There will be no visual differentiation between households on the list to indicate the frequency of home visits.
16381771|NCT04106908||Eqwilate|
16381772|NCT04106895||Fibryga|
16381773|NCT04106882|Experimental|Arm 1: Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
16381774|NCT04106882|Experimental|Arm 2: Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
16381775|NCT04106882|Experimental|Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
16381776|NCT04106869|Active Comparator|Hyperventilation|"Ventilatory settings will be the following:
~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
16381777|NCT04106869|Placebo Comparator|Hypoventilation|"Ventilatory settings will be the following:
~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 ( 40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
16381778|NCT04106856|Experimental|Treatment (losartan, hypofractionated radiation therapy)|Beginning on day 1, patients receive losartan potassium PO QD. Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks. Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy.
16381779|NCT04106843|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
16381783|NCT04106817|Experimental|Cohort 1|1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10^6TCID50/dose)
16381784|NCT04106817|Experimental|Cohort 2|1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
16381785|NCT04106817|Experimental|Cohort 3|1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
16381786|NCT04106791|Experimental|Closed-loop|Pilot study: one single group of 10 ICU patients.
16381787|NCT04106778|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
16381788|NCT04106778|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
16381789|NCT04106765||: epileptic LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom
~Evaluated items:
~Number of seizures
~Type of seizures
~Presence of EEG abnormalities
~Presence of IRM abnormalities
~Time before cognitive disorders"
16381790|NCT04106765||cognitive LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom
~Evaluated items:
~Presence of EEG abnormalities
~Presence of IRM abnormalities
~Time before epileptic seizures"
16381791|NCT04106752|Active Comparator|meal followed by caffeine|A standardized meal consisting of 2 slices of toast bread, organic peanut butter and jam was given to the participant. One and a half hours later, the participant ingested a caffeinated drink (3 mg per kg body weight of caffeine powder dissolved in water). After 30 mins, resting EE was measured using FM for 15 min while seated on the comfortable seat, and then for 5 min while seated on a cycle ergometer. Participants were then asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively. During cycling, EE was being measured using the FM, HR was monitored and rating of perceived exertion (RPE) was recorded in the last minute of every load cycle.
16381792|NCT04106752|Active Comparator|Caffeine followed by meal|Caffeine was given to the participant. After 1.5 hours the standardized meal was given followed by the same protocol mentioned above.
16381793|NCT04106752|Active Comparator|caffeine only|Caffeine will be given to the participant. 2 hours later the same protocol mentioned above will be applied
16381794|NCT04106752|Active Comparator|Meal only|A standardized meal will be given to the participant. 2 hours later the same protocol mentioned above will be applied.
16381795|NCT04106752|Active Comparator|meal plus caffeine|A standardized meal + a caffeinated drink (3 mg/kg of body weight of caffeine powder dissolved in water) will be given to the participant. 2 hours later resting EE is measured using a facemask (FM) for 10 min while seated on a cycle ergometer . The participant will be asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively.
16381796|NCT04106739|Active Comparator|Active Arm|Active arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate the outer auditory canal. It will deliver with a pulse width of 500 ms. The stimulation frequency pattern is 1.12Hz(hertz), 2.24Hz,4.56Hz, 9.12Hz, 100Hz then 9.12Hz, 4.56Hz,2.28Hz,1.12Hz. This cycle will keep on continuing. An input voltage will be 4.2V(volt).
16381797|NCT04106739|Sham Comparator|Sham Arm|Sham arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate centre of the left ear lobe to a pulse width of 500 ms at same pattern of stimulation frequency mentioned in active PENFS with an input voltage of 4.2V
16381798|NCT04106726|Experimental|Test: Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.
16381799|NCT04106726|Active Comparator|Reference: Soolantra® cream, 1%|Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.
16381800|NCT04106726|Placebo Comparator|Placebo: Placebo for Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.
16381801|NCT04106713|Experimental|Individual Therapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
16381802|NCT04106713|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
16381803|NCT04106713|Experimental|Group CBT|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
16381804|NCT04106713|No Intervention|Delayed Waitlist|Participants in the Waitlist group will be recruited from those referred for psychotherapy and who are not assigned to either group or iCBT and not planned for psychotherapy at IMH for 8 weeks or more from the point of consent.
16381805|NCT04106713|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group are individuals who are not assigned to psychotherapy at IMH. They will be recruited from outpatient services and emergency services at IMH.
16381806|NCT04106700|Experimental|Apixaban (single arm)|
16381825|NCT04106570|Experimental|MAOMD|Middle-Age obese with metabolic disorders Description: Aged from 40 to 50 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l.
16382020|NCT04105140|Experimental|male oxytocin group|male subjects with oxytocin treatment
16381807|NCT04106687|Active Comparator|Caudal Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided caudal block wil performe with bupivacaine 1 ml/kg as 0.25%.
16381808|NCT04106687|Active Comparator|Sacral Erector Spinae Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided sacral erector spinae block wil performe with bupivacaine 1 ml/kg as 0.25%.
16381809|NCT04106674|No Intervention|Non-surgical|No surgery
16381810|NCT04106674|Active Comparator|Surgical|Surgeons preference
16381811|NCT04106661|Experimental|Tai Chi Intervention 1|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
16381812|NCT04106661|Experimental|Tai Chi Intervention 2|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
16381813|NCT04106635|Experimental|PP group|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
16381814|NCT04106635|Active Comparator|CP group|During the induction of anesthesia, cricoid pressure is applied by 30N force with three finger.
16381815|NCT04106622||Wolff Parkinson White patients|"The investigators will decide the location of the AP by:
~- Invasively: if the patient is subjected to (EPS)
~• There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF.
~The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions."
16381816|NCT04106609|Experimental|Exercise Group|Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.
16381817|NCT04106609|Active Comparator|Control Group|The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
16381818|NCT04106596||Patients with antibodies against LGI1|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
16381819|NCT04106596||Patients with antibodies against CASPR2|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
16381820|NCT04106596||Patients with antibodies against GAD|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
16381822|NCT04106570|Experimental|YOMH|Young obese metabolically healthy Description: Aged from 20 to 40 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l.
16381823|NCT04106570|Experimental|YOMD|"Young obese with metabolic disorders
~Description: Aged from 20 to 40 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
16381824|NCT04106570|Experimental|MAOMH|"Middle-Age obese metabolically healthy
~Description: Aged from 40 to 50 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
16381863|NCT04106297|Placebo Comparator|Placebo SAD|Single doses of placebo
16381826|NCT04106570|Experimental|EOMH|"Elderly obese metabolically healthy
~Description: Aged from 50 to 70 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
16381827|NCT04106570|Experimental|EOMD|"Elderly obese with metabolic disorders
~Description: Aged from 50 to 70 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
16381828|NCT04106557|Experimental|OV101 once daily (weight-based dosing) Other Name:Gaboxadol|OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration
16381829|NCT04106557|Placebo Comparator|Placebo once daily|Matching placebo,oral, provided once daily at bedtime for 12 week duration
16381831|NCT04106518||cirrhosis|Patients with alcoholic liver disease without alcoholic hepatitis
16381832|NCT04106518||severe alcoholic hepatitis|Patients with severe alcoholic hepatitis ( Maddrey score ≥32)
16381833|NCT04106518||non-severe alcoholic hepatitis|Patients with non-severe alcoholic hepatitis (Maddrey score <32)
16381834|NCT04106505|Experimental|Biofeedback|The treatment comprises an app containing biofeedback training, instructions for self-delivery and a headache diary. The treatment utilizes these functionalities by a push-reminder in the app to complete a daily headache diary entry and a biofeedback session of 10 minutes duration daily. Prior to commencing treatment participants will be given basic information on the rationale behind biofeedback treatment, given instructions on how to use the equipment and software and instructions on how to complete a biofeedback session. The biofeedback is based on wireless sensors measuring muscle tension, finger temperature and heart rate.
16381835|NCT04106505|Sham Comparator|Sham-biofeedback|Sham-biofeedback will be made by disrupting the connection between input of physiological parameters and the feedback. Thus, the feedback will simply be displayed as positive feedback occurring at random intervals throughout the sessions. The looks and contents of the normal app and the sham-app will be completely similar. The participants being allocated to the sham-goup will also use exactly the same sensor setup as the biofeedback group. The only difference between the two arms/interventions is the internal software algorithm, which will be inaccessible to the user. All participants in both groups will be given the same information and instructions.
16381836|NCT04106492|Experimental|SQ3370|
16381837|NCT04106466|Experimental|Deep Brain Stimulation (DBS)|Open label active Deep Brain Stimulation (DBS)
16381838|NCT04106453|Experimental|navigated microwave ablation|microwave ablation is performed laparoscopically with navigation
16381839|NCT04106453|Active Comparator|ultrasound guided microwave ablation|microwave ablation is performed laparoscopically with ultrasound guidance
16381840|NCT04106440|Experimental|Application Use|Participants will be asked to use applications to track food intake, carbohydrate counts, insulin delivered, and blood sugar values and share the data with the study team.
16381841|NCT04106440|No Intervention|Standard of Care|The control group will receive usual care during their hospitalizations at the time of diabetes diagnosis, and during the time between hospital discharge and first visit to the UCD Pediatric Diabetes clinic.
16381842|NCT04106427|Experimental|cTBS plus SCRT|10 daily sessions of continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
16381843|NCT04106427|Placebo Comparator|Placebo plus SCRT|10 daily sessions of placebo continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
16381844|NCT04106427|Sham Comparator|Sham SCRT|16 sessions of sham social cognitive remediation therapy (SCRT) twice per week over an eight week period. Participants will engage in non-effective group activities
16381845|NCT04106414|Experimental|Nivolumab alone|Nivolumab 480 mg every 4 weeks.
16381846|NCT04106414|Experimental|Nivolumab with IDO-inhibitor, BMS- 986205|Nivolumab 480 mg every 4 weeks with BMS-986205 100 mg.
16381847|NCT04106401|Experimental|hypoxia & confinement|Participants exposed to high-altitude hypoxia and confinement during a one-year stay at Concordia station, Antarctica (3200 m)
16381848|NCT04106401|Active Comparator|confinement|Participants exposed to confinement during a one-year stay at Dumont d'Urville station, Antarctica (sea level)
16381849|NCT04106388|Experimental|Virtual Behavioral Health Integration|All patients who meet eligibility criteria at sites where the virtual behavioral health program is offered will be considered exposed to the intervention.
16381850|NCT04106388|No Intervention|Usual Care - Behavioral Health|All patients who meet eligibility criteria at sites where the virtual behavioral health program is not offered will be considered exposed to usual care.
16381851|NCT04106375|Experimental|Intervention Group|Women with a history of depression and no other mental health disorders undergoing Mindfulness Based Cognitive Therapy.
16381852|NCT04106375|No Intervention|Control|Healthy women with no prior history of depression or other mental health disorders as a control group for time-repetition effects on brain activity and task performance
16381853|NCT04106362|Active Comparator|Arm I (radiation therapy, cisplatin)|Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions. Patients also receive cisplatin IV over 1-2 hours on days 0 and 21.
16381854|NCT04106362|Experimental|Arm II (cetuximab, radiation therapy, cisplatin)|Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks. Patients also undergo radiation therapy and receive cisplatin as in Arm I.
16381855|NCT04106349||1st line|
16381856|NCT04106349||2nd line|
16381857|NCT04106349||later lines|
16381858|NCT04106336|No Intervention|non cannabis addict|30 non cannabis addict will be control group
16381859|NCT04106336|Active Comparator|cannabis addict|30 cannabis addict will undergo rTMS
16381860|NCT04106310|Active Comparator|Theranova|Patients will be receiving hemodialysis using Theranova dialyzer. The other hemodialysis parameters are kept the same.
16381861|NCT04106310|Active Comparator|High-flux|Patients will be receiving hemodialysis using a high-flux dialyzer. The other hemodialysis parameters are kept the same
16381862|NCT04106297|Experimental|GLPG3970 SAD|Single doses of GLPG3970 at up to 6 dose levels in ascending order
16381864|NCT04106297|Experimental|GLPG3970 MAD|Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days
16381865|NCT04106297|Placebo Comparator|Placebo MAD|Multiple doses of placebo
16381866|NCT04106297|Experimental|GLPG3970 FE-rBA|Single dose of GLPG3970 in fed and fasted state
16381867|NCT04106297|Experimental|GLPG3970 FE|Single dose of GLPG3970 in fed and fasted state
16381868|NCT04106297|Experimental|GLPG3970 in psoriasis subjects|
16381869|NCT04106297|Experimental|Placebo in psoriasis subjects|
16381870|NCT04106271|Experimental|Experimental group|dyadic pain management program will be accessible by the intervention group
16381871|NCT04106271|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
16381872|NCT04106258|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
16381873|NCT04106258|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
16381874|NCT04106245|Experimental|Supportive care (PACK health coach, survey)|Patients are contacted once weekly by a health coach by text message, phone call, email, or a mobile application, for 3 months. The total time interacting with the health coach is about 3.5-4.5 hours across the study. Patients also complete surveys over 30 minutes each time at baseline and every 30 days for 3 months.
16381875|NCT04106219|Experimental|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
16381876|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
16381877|NCT04106219|Experimental|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
16381878|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
16381879|NCT04106206|Experimental|LY3372689|LY3372689 administered orally
16381880|NCT04106206|Placebo Comparator|Placebo|Placebo administered orally
16381881|NCT04106193|Experimental|Toolkit + Implementation as Usual|Participating clinics assigned to this arm will receive a guiding toolkit and implementation as usual regarding IPV screening practices.
16381882|NCT04106193|Experimental|Toolkit + Blended Facilitation|Participating clinics assigned to this arm will receive a guiding toolkit and blended facilitation to support IPV screening practices.
16381883|NCT04106180|Experimental|SBRT + sintilimab + GM-CSF|
16381885|NCT04106154|Experimental|Intervention|The kinesiology intervention will involve physical activity education appropriate to the MC&D delivered in a group format through twelve 2.5-hour weekly sessions49 (30 hours of kinesiology support). The sessions will combine participation in physical activities appropriate to the MC&D with education and goal-setting discussions. Each week, children will be guided to develop an individualized SMART (Specific, Measurable, Agreed upon, Realistic, Time-based) plan for changing their activity behaviour. Their weekly SMART plan, which will require an additional 2 hours per week, will specify the home/community activities they will do prior to the next session.
16381886|NCT04106154|No Intervention|Control|Patients in the control group will continue with clinical care as usual. To encourage their cooperation, children in the control group will be offered the intervention after all of their study visits have been completed.
16381887|NCT04106141|Other|control group|
16381888|NCT04106141|Active Comparator|intervention group|
16381889|NCT04106128|Experimental|ultrasound examination|Assess the prevalence of acute diaphragmatic dysfunction by ultrasound
16381890|NCT04106115|Experimental|Durvalumab + S-488210/S-488211|Trial treatment for up to 24 weeks of Durvalumab (1500 mg IV infusion every 4 weeks for up to 7 doses) in combination with S-488210/S-488211 vaccine (given as 2 subcutaneous injections of S-488210/Montanide and S-488211/Montanide starting day after first durvalumab dose, then weekly for the first 6 weeks, and then every 2 weeks for a further 9 doses).
16381891|NCT04106102|Active Comparator|Transcramial Direct current stimulation|Implement of Transcramial Direct current stimulation
16381892|NCT04106102|Placebo Comparator|Placebo|
16381895|NCT04106076|Experimental|Dose escalation|Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.
16381896|NCT04106063||deaf children|All Children between 7 and 17 years old attending medical appointment for temporary or persistent deafness in our Ear, Nose and Throat (ENT) department
16381897|NCT04106050|Experimental|Part A: BIIB095 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 1 capsules from Day 1 to Day 8.
16381898|NCT04106050|Experimental|Part A: BIIB095 Dose 2|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 2 capsules from Day 1 to Day 8.
16381899|NCT04106050|Experimental|Part A: BIIB095 Dose 3|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 3 capsules from Day 1 to Day 8.
16381900|NCT04106050|Placebo Comparator|Part A: BIIB095 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB095 capsules from Day 1 to Day 8.
16381901|NCT04106050|Active Comparator|Part A: Lidocaine|Healthy participants and participants with DPN will receive single injection of lidocaine for partial nerve conduction block and single injection of lidocaine for skin infiltration on Day 8.
16381902|NCT04106050|Experimental|Part B: BIIB074 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB074 Dose 1 tablets from Day 1 to Day 8.
16381903|NCT04106050|Placebo Comparator|Part B: BIIB074 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB074 tablets from Day 1 to Day 8.
16381904|NCT04106037||Legionnaires' disease|All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
16381905|NCT04106011||Patients with Neuropathic Pain|
16381906|NCT04105998|Experimental|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU) at the first visit. Then at the next visit, they will receive Intramuscular injection of (1 milliliter) saline.
16381907|NCT04105998|Experimental|Placebo, Then Oxytocin|Subjects in this arm will receive intramuscular injection of (1 milliliter) saline at the first visit. Then at the next visit, they will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU).
16381908|NCT04105985|Experimental|Kovanaze Nasal Spray (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
16381909|NCT04105985|Active Comparator|Articaine Injections (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
16381910|NCT04105972|Active Comparator|TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
16381911|NCT04105972|Experimental|ELX/TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
16381912|NCT04105959|Experimental|RIST4721 300mg|RIST4721 as once-daily 300mg oral solution for 6 days with a placebo crossover.
16381913|NCT04105959|Experimental|RIST4721 150mg|RIST4721 as once-daily 150mg oral solution for 6 days with a placebo crossover.
16381914|NCT04105946|Active Comparator|OFA Group|patients undergoing FESS under opiod free anesthesia
16381915|NCT04105946|Active Comparator|TIVA Group|patients undergoing FESS under total intravenous anesthesia
16381916|NCT04105933|Experimental|CS-CBT|Culturally sensitive-CBT intervention was comprised of 16 sessions of cognitive behavioral therapy focused on culturally-specific beliefs and attitude.
16381917|NCT04105933|Active Comparator|CBT|CBT intervention was comprised of 16 sessions of cognitive behavioral therapy.
16381918|NCT04105920|Experimental|hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
16381919|NCT04105920|Active Comparator|Conventional brachytherapy|Patients included in this arm will have the conventional brachytherapy.
16381920|NCT04105907|Experimental|Partial root canal treatment with the Sonendo GentleWave|
16381921|NCT04105881||Full term labor|Measured by flow cytometry and ELUSA
16381922|NCT04105881||Preterm labor|Measured by flow cytometry and ELISA
16381923|NCT04105881||Control|For comparison
16381925|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
16381926|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
16381927|NCT04105842|Experimental|Delfilcon A|All study participants will be refit with Delfilcon A (Dailies Total 1) lenses which they will wear for 1 month.
16381928|NCT04105829|Experimental|Tooth color measurement|Tooth color changes between times (before retainer bonding, after retainer bonding, in 1 month, 3 months, 6 months and a year)
16381929|NCT04105816|Placebo Comparator|Adult Healthy Controls|Subjects included in part I of this study will be healthy adult volunteers with no known musculoskeletal injury. Exclusion criteria will be those with identified musculoskeletal injury, non-English speaking persons, and women who are pregnant.
16381930|NCT04105816|Experimental|Adult ACL Reconstruction Patients|Subjects included in part II of the study will be adult volunteers undergoing anterior cruciate ligament reconstruction at the University of Iowa. Exclusion criteria will be non-English speaking persons, women who are pregnant, patients undergoing multi-ligament repair, patients undergoing ACL reconstruction revision, patients undergoing concomitant cartilage or meniscal repair procedures, and patients undergoing bilateral ACL reconstructions.
16381931|NCT04105803||De novo HTx|"Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.
~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).
~Procedure: is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.
~Diagnostic test: Echocardiography and coronary angiography is part of the scheduled standard HTx follow-up visits."
16381932|NCT04105803||Longterm HTx|"Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).
~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.
~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
16381933|NCT04105803||PET-scan de novo HTx|"Radiation: Two PET-scans with 11C-acetate tracer will be performed.
~Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.
~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).
~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.
~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
16381934|NCT04105790|Experimental|Participants|Participants in class-based mental health intervention.
16381935|NCT04105777||Standard Low Glucose Parenteral Nutrition using Eurotubes®|Patients receive standard PN reduced in glucose in Eurotubes®.
16381936|NCT04105777||Standard Parenteral Nutrition using Eurotubes®.|Patients receive standard PN in Eurotubes®.
16381937|NCT04105777||Standard Parenteral Nutrition using 2/3-chamber bags|Patients receive PN according to the routine used by the participating site.
16381938|NCT04105764|Active Comparator|DEEP BLOCK|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
16381939|NCT04105764|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
16381940|NCT04105751|Experimental|Use of Device with post-use interview/questionnaire|All patients will be asked to utilize device and will then be asked to provide feedback on their experiences. This may be done by interview or a questionnaire. There could be up to three sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, session could last up to one hour.
16381941|NCT04105738||Difficult airways|Documented history of difficult airways.
16381942|NCT04105738||Control (Not difficult airways)|Age matched with normal airways to be used as controls
16381943|NCT04105725|Experimental|BMI+Substance-Free Activity Session|Two 50-minute text messaging sessions that discuss alcohol use and experiences related to alcohol use, as well as the individual's college, career, and personal goals. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that return to the individual's goals and progress.
16381944|NCT04105725|Active Comparator|Alcohol + Nutrition Education Session|Two 50-minute text messaging sessions the provide information on alcohol and nutrition. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that provide additional information and review previous information about alcohol use and nutrition.
16381945|NCT04105712|Experimental|Pre and Post Dietary Change (within subjects)|Participants do an initial call for baseline data. Then the active assessment period (pre / post dietary change) begins. Pre - dietary change procedure is 5 days of standard high HP diet while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Post - dietary change is 5 days of lower HP diet (food provided for 3 of 5 days) while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Daily assessments of affect, craving, and withdrawal are all virtual. On day 4-5 of post assessment, participants complete a food journal to report foods they ate to ensure compliance to low HP food diet. The pre / post-dietary change phone appointments include 1) psychosocial stress task, 2) cue reactivity task, 3) questionnaires 4) self-reported weight. Participants may also complete a follow up period of questionnaires every other day and self-report weight at the end of follow up.
16381946|NCT04105699||Device: Blood sampling|
16381947|NCT04105686|Active Comparator|Control Infant Formula|Milk-based study product
16381948|NCT04105686|Experimental|Experimental Infant Formula|Milk-based study product with oligosaccharides
16381949|NCT04105686|No Intervention|Reference Group|Human milk-fed group
16381950|NCT04105673||Shaken Baby Syndrome|Realization of a clinical examination and survey on children with a past history of a Shaken Baby Syndrome
16381953|NCT04105647|Experimental|Experimental group|Patients in the experimental group will receive a face-to-face group session and a package of healthy lifestyle instant messages, including lifestyle-integrated exercise and physical activity.
16381954|NCT04105647|Placebo Comparator|Control group|The control group will receive a face-to-face group session and a package of healthy lifestyle instant messages, but not related to lifestyle-integrated exercise and physical activity.
16381955|NCT04105634|Experimental|Inflammation group|Patient diagnosed with Cardiac Amyloidosis
16381956|NCT04105634|Experimental|Amyloid group|Patient diagnosed with Cardiac Amyloidosis
16381957|NCT04105621||Drug addicts|This group included drug addicts lived in drug rehablitation center.
16381958|NCT04105621||Healthy population|We recruited the healthy participants from the Westlake N-of-1 Trials for Macronutrient Intake (NCT04125602) as healthy control
16381959|NCT04105608|Experimental|HFV meal|A vegetarian meal high in dietary carbohydrate and fiber
16381960|NCT04105608|Active Comparator|MED meal|A Mediterranean-like meal
16381961|NCT04105595||ASD patients|
16381962|NCT04105595||PFO patients|
16381963|NCT04105582|Experimental|Neo-antigen pulsed Dendritic cell|Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)
16381964|NCT04105569|Experimental|Healthy Volunteers|Enrolled subjects will be included in an experimental gingivitis model (SIBO) for 21 days and use an acrylic stent fabricated before and dispensed at the baseline appointment
16381965|NCT04105556|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
~Care was given when the child and his / her parents applied to the outpatient clinic for anesthesia consultation on the working day before the operation, and care was continued in the day surgery unit. On the 1st and 3rd days after discharge, the researcher provided tele-monitoring and consultancy services. In addition, communication with the parents was maintained at all times as needed. Care was terminated on the 10th day after discharge. The time of the study was approximately 12-14 days for each child and his / her parents.
~Nursing care consists of 3 types of comfort-oriented care interventions. These interventions;
~Standard maintenance interventions,
~Emotional focused comfort care interventions,
~Cognitive and functional comfort care interventions."
16381966|NCT04105556|No Intervention|Routine hospital schedule|"The researcher sincerely answered all questions asked by the control group during the perioperative period.
~After the post-discharge post-tests, the control group was given a gift of medal of courage, a story book and a training booklet prepared for the parents after the policlinic control on the 10th postoperative day, and the training was given to the intervention group."
16381967|NCT04105543|Experimental|CLR 131 Dose Escalation|"Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.
~Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m^2 Dose Level 1 (beginning dose) = 15.6 mCi/m^2 Dose Level 2 (escalation dose) = 18.75 mCi/m^2
~Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed."
16382021|NCT04105140|Placebo Comparator|male placebo group|male subjects with placebo treatment
16381968|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 1|"One stimulation will be conducted using Anodal treatment.
~The Direct Current Anodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session."
16381969|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 2|A final stimulation will be conducted using Cathodal stimulation. Direct Current Cathodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
16381970|NCT04105530|Placebo Comparator|Sham treatment|"The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes.Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial:"
16381971|NCT04105504|Experimental|Glutathione Group|Subjects were randomised to receive Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
16381972|NCT04105504|Placebo Comparator|Placebo Group|Subjects were randomised to receive Placebo capsules, which were identical in appearance and packaged in identical-looking containers with the Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
16381973|NCT04105491||Aligner Patients|Patients who decided to be treated with Invisalign® aligners
16381974|NCT04105478|Experimental|Un-cemented Comprehensive Nano stemless shoulder arthroplasty|"By using a stemless humeral component stem-related complications can be reduced. Furthermore, the canal preserving design may also facilitate further surgery should the need of a revision prosthesis arise.
~Currently, little is known about the results of the stemless design. The initial results have been promising, but as with the stemmed design migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
16381975|NCT04105478|Active Comparator|Un-cemented Comprehensive stemmed total shoulder arthroplasty|A design with a metal stem in the humeral bone canal is currently regarded as the best treatment option, but complications related to the stem including humeral fractures can have devastating consequences.
16381976|NCT04105465|No Intervention|Surgery without trial (PJ) device|All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
16381977|NCT04105465|Active Comparator|Surgery with trial (PJ) device|Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.
16381978|NCT04105439||control|healthy subjects who do not have the disease
16381979|NCT04105439||patients with Behçet's disease|subjects who do have the disease ( Behçet's disease )
16381980|NCT04105426|Active Comparator|Antioxidants|This arm of patients received one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
16381981|NCT04105426|Placebo Comparator|Placebo|This arm of patients received placebo for 3 months.
16381982|NCT04105387|No Intervention|Control Group|Tracheostomy change at day 7
16381983|NCT04105387|Experimental|Treatment Group|Tracheostomy change at day 4
16381984|NCT04105374|Active Comparator|Arm I (surgery, radiation therapy, temozolomide)|Beginning on week 5 following standard of care surgery, patients undergo radiation therapy over 30 fractions 5 days per week for up to 6 weeks, and receive temozolomide PO QD for up to 49 days. At the discretion of treating physician, patients may also receive novoTTF-100A (Optune) device 0-7 weeks following radiation and temozolomide treatment. One month following completion of radiation therapy, patients continue to receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16381985|NCT04105374|Experimental|Arm II (Toca 511, Toca FC, radiation therapy, temozolomide)|Patients receive vocimagene amiretrorepvec via intracranial injection during surgery on day 1. Beginning on week 5 following surgery, patients receive extended release flucytosine PO TID for 7 consecutive days every 7 weeks. Patients also undergo radiation therapy and receive temozolomide as in arm I. After completion of radiation therapy and at the discretion of the treating physician, patients may continue to receive extended release flucytosine PO TID for 7 consecutive days every 8 weeks in the absence of disease progression or unacceptable toxicity.
16381986|NCT04105361|Experimental|Study group|We will do posterior nasal neurectomy in patients with allergic rhinitis after FESS in one side of the nose
16381987|NCT04105361|Experimental|Control group|We will do FESS only in the other side of the nose
16381988|NCT04105348||IBD with DM|
16381989|NCT04105348||IBD without DM|
16381990|NCT04105335|Experimental|Cohort 1 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 70mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
16381991|NCT04105335|Experimental|Cohort 2 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 98mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
16381992|NCT04105335|Experimental|Cohort 3 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 130mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
16381993|NCT04105335|Experimental|Expansion Cohort MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA RP2D administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
16381994|NCT04105322|Experimental|Kinesio Taping on Abdominal Muscles|
16381995|NCT04105322|Experimental|Kinesio Taping on Back Muscles|
16381996|NCT04105322|No Intervention|Control|
16382019|NCT04105153||TKI-treated advanced EGFR+ NSCLC|Patients with advanced EGFR-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors
16381997|NCT04105309|Experimental|Implementation Intention (IMP)|"Following review of a psychoeducational packet regarding making changes for weight loss, all participants were assigned five dietary goals (e.g. avoiding high-fat foods, eating five servings of fruits and vegetables a day) and a goal to weight daily. Participants in the IMP condition formed an implementation intention for each of the goals at the baseline session. Two examples of implementation intentions were provided for each goal as a model. Participants thought about how they would best be able to achieve the outlined goals in their life on a daily basis (goal-aligned behavior), as well as when, where, and how they would initiate these new behaviors (retrieval cue). Participants then created and wrote down a unique implementation intention for each of the goals using the sentence structure If/When I _______, then I will ______. No repetitions or combinations of implementation intentions were allowed for standardization across participants."
16381998|NCT04105309|Experimental|Enhanced Implementation Intention (IMP+)|Participants completed all tasks of the IMP group and additionally, individuals in the IMP+ condition received fluency training and text message reminders. Fluency training occurred weekly using an online survey tool. On fluency training days, participants received a survey link via email, which consisted of six multiple-choice questions for participant's unique implementation intentions. Participants had to correctly identify their matching goal-aligned behavior among three distractor behaviors as quickly as possible and were given corrective feedback if they chose incorrectly. Text messages containing all six implementation intentions as well as goal reminders that were obtained by asking participants to write down their reasons for wanting to lose weight were sent on four days each week of the intervention (16 days total). At baseline, participants chose how text messages were bundled and when they were sent. Text schedules stayed constant across the study.
16381999|NCT04105309|Active Comparator|Goal Intentions (GOL)|Participants in the GOL condition were assigned the five dietary goals and the daily weighing goal. No additional intervention was given.
16382000|NCT04105296|Experimental|EKSO+ES|6 months of exoskeleton training with spinal cord epidural stimulation.
16382001|NCT04105283|Experimental|Tc99m-MAA|"Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof.
~Administration will occur over a period of 30-240 seconds"
16382002|NCT04105270|Experimental|Arm A (RMT)|
16382003|NCT04105270|Experimental|Arm B (Placebo)|
16382004|NCT04105270|Experimental|Safety Run-in|10 patients are enrolled in this safety run-in arm. Patients are directly assigned to RMT treatment arm. After safety- run-in period of 4 weeks after the first dose of RMT, in the 10 patients if no new safety signal are seen enrollment moves to randomization
16382005|NCT04105257|Other|All patients|All patients seen at emergency with acute neurological deficit will be assessed if eligible to CTP/MRI
16382006|NCT04105244|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post-enrollment plus the current standard of care, whereby caregivers phone their healthcare providers when they have questions or concerns
16382007|NCT04105244|Experimental|Resourcefulness Training Intervention©|The Resourcefulness Training© arm will receive (a) individually tailored instruction on personal and social resourcefulness skills via the Resourcefulness Video and intervention nurse, (b) journal-writing instruction to describe resourcefulness application, (c) access to the study website with videotape vignettes and Resourcefulness Video, and (d) boosters at 2 and 4 months post-enrollment that will include reinforcement of skills learned and additional journal writing.
16382008|NCT04105231|Experimental|Cannabidiol|"Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks.
~AND Risperione placebo, encapsulated tablet."
16382009|NCT04105231|Active Comparator|Risperidone|"Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks
~AND Cannabidiol placebo, oral suspension"
16382010|NCT04105218|Experimental|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
16382011|NCT04105218|Placebo Comparator|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
16382012|NCT04105205|Experimental|Apramycin injection in escalating doses|Apramycin, solution for infusion.
16382013|NCT04105205|Placebo Comparator|Placebo|Physiological saline, solution for infusion.
16382014|NCT04105192|Experimental|experimental group (Lippia citriodora + sabdariffa)|"Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.
~Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days."
16382015|NCT04105192|Placebo Comparator|control group Placebo (sucrose)|Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg or Placebo (sucrose) Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days.
16382016|NCT04105179|Experimental|Implant Groups|Group will receive the Smith & Nephew Journey II knee implant or the Zimmer NexGen LPS-Flex knee implant
16382017|NCT04105179|No Intervention|Healthy Control Group|Control group that will not be undergoing a total knee arthroplasty
16382018|NCT04105166|Experimental|RP-L301|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
16382022|NCT04105127|Active Comparator|Anterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the palatal surfaces of central upper incisors
16382023|NCT04105127|Active Comparator|Posterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the occlusal surfaces of first or second upper/lower molars
16382024|NCT04105114|Experimental|Complete Spinal Cord Injury - Gravity Neutral Stepping|Group 1 will begin with a 3-4-month preparation phase and up to 12 sessions in the gravity neutral device (GND) will occur. The training sessions in the GND will be used to obtain the optimal stimulation parameters. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. This will be done in the GND in the presence of stimulation. Afterwards, Intervention 2 will include the same training procedures with the addition of Buspirone or Placebo in a cross-over fashion halfway through this phase.
16382025|NCT04105114|Experimental|Complete Spinal Cord Injury - Exoskeleton Assisted Stepping|Group 2 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours in the Ekso overground, in the presence of stimulation and Buspirone/placebo. The second phase will include the same training procedures except for the removal of Buspirone/placebo administration. The third phase will include sessions twice per week in the Ekso overground with stimulation and one day per week using a rolling walker with stimulation. The last phase will include 2 sessions per week using the rolling walker and one day per week in the Ekso, both in the presence of stimulation and Buspirone/placebo.
16382026|NCT04105114|Experimental|Incomplete Spinal Cord Injury - Overground Stepping|Group 3 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. The first hour will be done in the Ekso overground and the second hour will use the rolling walker overground, both in the presence of stimulation. Afterwards, the second phase will include the same training procedures with the addition of Buspirone/placebo.
16382027|NCT04105101|Experimental|Prototype exoskeleon|The experimental trial will be performed with the prototype exoskeleton
16382028|NCT04105101|Experimental|Skel-Ex|The experimental protocol will be performed with the commercially available Skel-Ex 360 (Skel-Ex, Rotterdam, The Netherlands)
16382029|NCT04105101|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
16382030|NCT04105088||Randomly-Sampled|Adults aged 30+ living in one of the First Nations communities whose household was randomly-sampled.
16382031|NCT04105088||Walk-in Volunteers|Adults aged 30+ living in one of the First Nations communities who is a walk-in study volunteer, not randomly-sampled.
16382032|NCT04105075||Patients with COPD and obesity|Patients consented to have a blood sample taken
16382033|NCT04105075||Normal body weight patients with COPD|Patients consented to have a blood sample taken
16382038|NCT04105036||45-54 years of age|Divided into two subgroups: individuals who are and are not socially deprived
16382039|NCT04105036||54-64 years of age|Divided into two subgroups: individuals who are and are not socially deprived
16382040|NCT04105036||65-74 years of age|Divided into two subgroups: individuals who are and are not socially deprived
16382041|NCT04105036||75-85 years of age|Divided into two subgroups: individuals who are and are not socially deprived
16382042|NCT04105023|Experimental|genistein|Genistein capsules of 25 mg each, 50mg/day
16382043|NCT04105023|Placebo Comparator|placebo|Maltodextrin capsules, administered orally once every 12 hours
16382044|NCT04105010|Experimental|AZD4205 Group A|Group A: Open label AZD4205 at dose A, once daily (Phase 1)
16382045|NCT04105010|Experimental|AZD4205 Group B|Group B: Open label AZD4205 at dose B, once daily (Phase 1)
16382046|NCT04105010|Experimental|AZD4205 Group C|Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
16382047|NCT04105010|Experimental|AZD4205 Group D|Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
16382048|NCT04104997|Experimental|The A group in 5% GLH8NDE|Three times administration both eyes, each 1 drop in Korean
16382049|NCT04104997|Placebo Comparator|The A group in placebo|Three times administration both eyes, each 1 drop in Korean
16382050|NCT04104997|Experimental|The B group in 5% GLH8NDE|Six administration both eyes, each 1 drop in Korean
16382051|NCT04104997|Placebo Comparator|The B group in placebo|Six administration both eyes, each 1 drop in Korean
16382052|NCT04104997|Experimental|The C group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Korean
16382053|NCT04104997|Placebo Comparator|The C group in placebo|Six administration both eyes, each 2 drop in Korean
16382054|NCT04104997|Experimental|The D group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Caucasian
16382055|NCT04104997|Placebo Comparator|The D group in placebo|Six administration both eyes, each 2 drop in Caucasian
16382056|NCT04104984|Experimental|control group not follow NICE guide lines|All pregnant women who fulfil the same inclusion criteria, exclusion criteria, diagnoses established as short cervix , and do not managed according to NICE guide lines will be treated and managed according to their units as a control group.
16382057|NCT04104984|Experimental|study group follow NICE guide lines|- All pregnant women will attend hospital between 14-24 weeks and fulfil inclusion and exclusion criteria will be approached for possibility to be included in the study . and will be managed according NICE guide lines
16382058|NCT04104971||with complications|children who did liver transplantation and develop complications
16382059|NCT04104971||without complications|children who did liver transplantation and do not develop complications
16382060|NCT04104958||Group 1|"Group 1 (n=50): women (age 20-40year) with PCOS who are diagnosed according to the criteria of the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003), which require two of the following 3 manifestations:
~oligo- or anovulation,
~clinical and/or biochemical signs of hyperandrogenism (> 2.08 nmol/l),
~polycystic ovaries on ultrasound examination (the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume > 10 cm)"
16382061|NCT04104958||Group 2|Group 2 (n=50): women (age 20-40 year) with male factor infertility.
16382062|NCT04104945|Experimental|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
16382063|NCT04104932||Surgical group|Patients with isolated minor rib fractures received surgical stabilization.
16382064|NCT04104932||Conservative group|Patients with isolated minor rib fractures received conservative treatment, such as NSAIDs.
16382065|NCT04104919|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
16382066|NCT04104919|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
16382067|NCT04104906|Experimental|motor control training|8-week exercise program, twice a week, with motor control training
16382068|NCT04104906|Active Comparator|exercises|8-week exercise program, twice a week.
16382069|NCT04104893|Experimental|Single Arm|This is a single-arm, open-label study of the checkpoint inhibitor, pembrolizumab, in Veterans with mCRPC who have progressed on at least 1 prior novel androgen receptor (AR) signaling inhibitor, inclusive of abiraterone acetate, enzalutamide, apalutamide, and darolutamide. In addition to progressive mCRPC, a patient must have a somatic tumor mutation characterized by dMMR or CDK12-/- detected by next generation sequencing (NGS). Patients enrolled in this study will be treated with pembrolizumab at the FDA approved dosage of 200 mg intravenously every 3 weeks (21 days) until disease progression or unacceptable toxicity. During study, patients will maintain a castrate level of testosterone, = 50 ng/dL by ongoing treatment with a GnRH analogue or prior bilateral orchiectomy. Prior to initiating treatment with pembrolizumab, patients will undergo a baseline biopsy of a metastatic lesion. An additional biopsy of a metastatic lesion at the time of progression will be encouraged as well.
16382070|NCT04104880|Experimental|Continuous Positive Airway Pressure (CPAP) group|Three-month CPAP use
16382071|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Itopride|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
16382072|NCT04104867|Placebo Comparator|Colonoscopy preparation by PEG-EL with Placebo|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
16382073|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Domperidone|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
16382074|NCT04104854|Experimental|drug coated balloon|A total of 110 patients are assigned to drug coated balloon treated group after randomization schedule.
16382433|NCT04102423||CHIP|Subjects will be split into five cohorts depending on specific mutations
16382075|NCT04104854|No Intervention|drug eluted stent implantation|A total of 110 patients are assigned to drug eluted stent treated group after randomization schedule.
16382076|NCT04104841|Experimental|Behaviorally Enhancing Adolescents' Mood in Schools (BEAMS)|8-session modified behavioral activation program
16382077|NCT04104841|Active Comparator|Usual Care|Referrals to usual care
16382078|NCT04104828||Grass/tree AIT with Allergovit|Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.
16382079|NCT04104828||Grass/tree AIT with Polvac|Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.
16382080|NCT04104828||Grass/tree AIT with Pollinex Quattro|Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.
16382081|NCT04104815|Experimental|Experimental Thickener|Powder thickener
16382082|NCT04104789|Experimental|Kovanaze Nasal Spray (General Practice)|Adults who require restorations in the maxillary teeth that would need local anesthesia
16382083|NCT04104789|Active Comparator|Articaine Injections (General Practice|Adults who require restorations in the maxillary teeth that would need local anesthesia
16382084|NCT04104776|Experimental|Phase 2: Monotherapy|"CPI-0209 will be dosed once per day orally in 28 day cycles.
~Cohort M1: Open to patients with urothelial carcinoma (with known ARID1A mutation)
~Cohort M2: Open to patients with ovarian clear cell carcinoma (with known ARID1A mutation)
~Cohort M3: Open to patients with endometrial carcinoma (with known ARID1A mutation)
~Cohort M4: Open to patients with lymphoma (of either B-cell or T-cell histology), including germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) patients with EZH2 mutation
~Cohort M5: Open to patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss
~Cohort M6: Open to patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease"
16382085|NCT04104776|Experimental|Phase 2: Combination Therapy|"CPI-0209 will be dosed once per day orally in 21 day cycles. Irinotecan iv will be dosed once every 3 weeks (Q3W).
~• Cohort C1: Open to patients with small cell lung cancer (SCLC)"
16382086|NCT04104737|Experimental|Spire Medical Health Tag|Spire Medical Health Tag is worn by all subjects The study is open label
16382087|NCT04104724|Experimental|Self-help|Immediate access to self-help materials
16382088|NCT04104724|No Intervention|Control|Wait-list control - treatment as usual (no intervention)
16382089|NCT04104711|Experimental|Home visits+Health education group|"Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals.
~Nursing interventions were applied in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants and were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, oral care and foot care. In addition, the importance of annual monitoring of HBA1c, blood lipid, albumin/ creatinine levels, fundus examination, blood pressure monitoring, sleep hygiene, avoidance of smoking and alcohol was also explained."
16382090|NCT04104711|No Intervention|No nursing intervention group|"The participants in the control group who have standart care by other health services were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools only. They have no nursing intervention by the researcher.
~At the end of the study, for ethical statement the participants in the control group were given health training and the training booklet was distributed to them."
16382091|NCT04104698||Study Group (MDD with SIs)|25 Egyptian patients diagnosed with major depression (with suicidal ideations)
16382092|NCT04104698||Control group (MDD without SIs)|25 Egyptian patients diagnosed with major depression (without suicidal ideations)
16382093|NCT04104685|Experimental|FCD105 Foam|FCD105 Foam
16382094|NCT04104685|Active Comparator|3% Minocycline Foam|3% Minocycline Foam
16382095|NCT04104685|Active Comparator|0.3% Adapalene Foam|0.3% Adapalene Foam
16382096|NCT04104685|Placebo Comparator|Vehicle Foam|Vehicle Foam
16382097|NCT04104672|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.
16382098|NCT04104672|Experimental|Dose Expansion (AB680 + Zimberelimab + NP/Gem)|The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with Zimberelimab at the RP2D and the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.
16382099|NCT04104672|Experimental|Dose Expansion (AB680 + NP/Gem)|The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.
16382100|NCT04104659||MK 6240|
16382101|NCT04104646|Experimental|CHF6563|Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
16382102|NCT04104646|Active Comparator|Morphine|Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.
16382103|NCT04104633|Other|Patients with breast or colorectal cancer|10 patients with invasive breast carcinoma, not otherwise specified (NOS) (Stade I to III) and 10 patients with invasive colorectal adenocarcinoma (Stade I to III)
16382104|NCT04104620||patients with neurological syndromes and GAD-Ab|This is a non-interventional study involving clinical data already stored in the database of the Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, or collected by the referral physicians the day of ordinary consultations. No biological sample is necessary to perform this study.
16382105|NCT04104607|Experimental|CC-1 therapy|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation. In case of clinical benefit, additional cycles with a total of up to six are possible.
16382106|NCT04104594|Experimental|patients with chronic rhinosinusitis with nasal polyps|
16382107|NCT04104594|Other|Patients with an indication for septoplasty = control group|
16382108|NCT04104581|Placebo Comparator|Control|Volunteers will consume a diet in which all grain foods are made from refined grains.
16382109|NCT04104581|Experimental|Low Whole Grain Oat Diet|Volunteers will consume a diet with a low level of whole grain oat incorporated into some of the foods.
16382110|NCT04104581|Experimental|High Whole Grain Oat Diet|Volunteers will consume a diet with a high level of whole grain oat incorporated into some of the foods.
16382111|NCT04104581|Experimental|Low Whole Grain Wheat Diet|Volunteers will consume a diet with a low level of whole grain wheat incorporated into some of the foods.
16382112|NCT04104581|Experimental|High Whole Grain Wheat Diet|Volunteers will consume a diet with a high level of whole grain wheat incorporated into some of the foods.
16382113|NCT04104568|Experimental|iSupport for dementia - European-Portuguese version|Access, for 3 months, to an online self-help training and support program: iSupport for dementia - European-Portuguese version. The e-program offers information, skills training and support for informal caregivers of people with dementia. It comprises five modules, including twenty-three lessons on dementia and caregiver support. In line with good practices on digital engagement, the education plan can be personalized by the caregiver. This means that it can be adjusted to the person's availability and lessons can be selected according to particular needs. Each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques including psycho-education, behavioral activation, cognitive reframing, relaxation and antecedent-behavior-consequence (ABC) analysis.
16382114|NCT04104568|Active Comparator|Education-only e-book|The control group will receive a minimal education-only intervention, consisting on an e-book. The manual contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
16382115|NCT04104555|Active Comparator|Usual supportive care - exercises and footwear advice|"OSTRICH main trial:
~Participants will be offered an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
16382116|NCT04104555|Experimental|Prefabricated, off-the-shelf orthoses|"OSTRICH main trial:
~A pair of prefabricated, off-the-shelf orthoses (i.e. mass produced to a generic shape but can be adapted by a clinician) plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
16382117|NCT04104555|Experimental|Custom-made foot orthoses|"OSTRICH main trial:
~A pair of custom-made foot orthoses, where the shape of the insole is made for a specific person based on a 3D impression of the patient's foot, using materials of the clinicians choosing. Plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
16382118|NCT04104555|Experimental|Pen arm|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will be given a pen with a picture of an ostrich on it in the OSTRICH recruitment pack.
16382119|NCT04104555|Experimental|Signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting to multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
16382120|NCT04104555|Experimental|Pen and signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will be given a pen with a picture of an ostrich on it and signposting to multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
16382121|NCT04104555|No Intervention|No pen and no signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will not be given a pen or signposting to multimedia trial information resources in the participant information sheet, when sent to the OSTRICH recruitment pack.
16382122|NCT04104555|Experimental|Birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a standard birthday card on or shortly before their birthday to encourage completion of questionnaires..
16382123|NCT04104555|Experimental|Birthday card informed by nudge theory|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a birthday card informed by nudge theory to encourage completion of questionnaires.
16382124|NCT04104555|No Intervention|No birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will not be sent a birthday card during the trial.
16382125|NCT04104542|Experimental|Mindfulness MTHM|online mindfulness based stress reduction training
16382126|NCT04104542|Experimental|Mindfulness JBSA|online mindfulness based stress reduction training
16382127|NCT04104542|Sham Comparator|Healthy Lifestyle MTHM|online healthy lifestyle training
16382128|NCT04104542|Sham Comparator|Healthy Lifestyle JBSA|online healthy lifestyle training
16382129|NCT04104529|Experimental|Biological collection|"Biological collection
~For all the patients include in the study :
~samples of blood samples collected before and during treatment.
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16382130|NCT04104503|Experimental|Part A|
16382131|NCT04104503|Experimental|Part B group 1|"Treatment period 1: Fasted + iv;
~Treatment period 2: Fasted;
~Treatment period 3: High-fat meal"
16382132|NCT04104503|Experimental|Part B group 2|"Treatment period 1: High-fat meal;
~Treatment period 2: Fasted + iv;
~Treatment period 3: Fasted"
16382133|NCT04104503|Experimental|Part B group 3|"Treatment period 1: Fasted;
~Treatment period 2: High-fat meal;
~Treatment period 3: Fasted + iv"
16382134|NCT04104490||Severe pulmonary arterial hypertension.|"This cohort will consist of patients with severe pulmonary arterial hypertension.
~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of severe disease.
~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.
~This is an observational study with no interventions."
16382166|NCT04104243|Experimental|Power-Up|Participants randomized to this arm will undergo 16 classes tailored for men, that discuss food choices, physical activity, and managing stress over 6 months, which are called the core, and 6 classes over the following 6 months, which is called the maintenance phase.
16382135|NCT04104490||Mild-moderate pulmonary arterial hypertension|"This cohort will consist of patients with mild-moderate pulmonary arterial hypertension.
~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of mild-moderate disease.
~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.
~This is an observational study with no interventions."
16382136|NCT04104490||Reference subjects without pulmonary hypertension|Reference subjects will be healthy people, age- and sex-matched to the other two cohorts, who have no pulmonary artery hypertension.
16382137|NCT04104477|Active Comparator|CMC OA Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
16382138|NCT04104477|Active Comparator|Age-Matched Control Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
16382142|NCT04104438|Active Comparator|Basiliximab with Delayed TAC|"Basiliximab
~Dose #1: 20mg IV within 2 hours of transplant
~Dose #2: 20mg IV Post-operative day #4
~Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL
~Mycophenolate mofetil
~o 1000 mg po bid
~Corticosteroids (SOC): Per UCLA protocol
~Post-operative taper:
~Post-op day 1- methylprednisolone 50mg IVP Q6H
~Post-op day 2- methylprednisolone 40mg IVP Q6H
~Post-op day 3- methylprednisolone 30mg IVP Q6H
~Post-op day 4- methylprednisolone 20mg IVP Q6H
~Post-op day 5- methylprednisolone 20mg IVP Q12H
~Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM"
16382143|NCT04104438|Active Comparator|Basliximab, Delayed TAC with Everolimus|"Basiliximab
~Tacrolimus (with basiliximab induction)
~o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL
~Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated
~Corticosteroids (SOC): Per UCLA protocol
~Everolimus (delayed)
~o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml."
16382144|NCT04104438|No Intervention|Control: standard TAC with steroids and MMF|"Tacrolimus (without basiliximab induction)
~Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL
~Six months to one year: maintain whole blood trough concentration of 5-10ng/mL
~Mycophenolate mofetil
~o 1000 mg po bid
~Corticosteroids (SOC): Per UCLA protocol"
16382145|NCT04104412|Experimental|treatment group A （with mesenchymal stem cell intervention）|observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2*10^7/ml normal saline) and Low temperature plasma vaporization ablation
16382146|NCT04104412|No Intervention|control group B|observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation
16382147|NCT04104399|Experimental|XC101-D13H|single dose
16382148|NCT04104399|Placebo Comparator|Placebo|single dose
16382149|NCT04104386|Experimental|Disclosure of Telomere Length Arm|Telomere Length results were provided (personal value, means, and standard deviation of the group), and categorized as 'short' telomere length (bottom quartile) and 'not short' (above the bottom quartile) based on age related norms available from research literature.
16382150|NCT04104386|No Intervention|Non-Disclosure|Telomere Length results were not provided.
16382151|NCT04104360|Experimental|Galacto-oligosacchardies|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
16382152|NCT04104360|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks
16382153|NCT04104347|Experimental|Metacognitive training (MCT)|
16382154|NCT04104347|Active Comparator|Support group|
16382155|NCT04104334|Active Comparator|"Monitored group M (optimized controlled anesthesia)"|"Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume."
16382156|NCT04104334|Active Comparator|"Control group C (standard of care anesthesia)"|"Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100."
16382159|NCT04104295|Experimental|Ultrasound following X-ray|An ultrasound scan of the abdomen within 2 hours of the routine X-ray will be performed by a physician blinded to the X-ray results.
16382160|NCT04104269||Mechanical Complications|Include free wall ventricular rupture and ventricular septal rupture
16382161|NCT04104269||Non-Mechanical Complications|Mechanical complications were not included in patients with AMI
16382162|NCT04104256|Experimental|Alert 1|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
16382163|NCT04104256|Experimental|Alert 2|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
16382164|NCT04104256|Experimental|Alert 3|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
16382165|NCT04104256|Experimental|Control|Pre-op clinic physicians will not receive interventions and perform duties as usual.
16382426|NCT04102475|Experimental|eatline group|
16382167|NCT04104243|No Intervention|Standard NDPP (National Diabetes Prevention Program)|Participants randomized to this arm will undergo 16 mixed gender classes that discuss food choices, physical activity, and managing stress over 6 months which are called the core and 6 classes over the following 6 months which is called the maintenance phase.
16382168|NCT04104230||Individuals Affected With Pancreatic Cancer|Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
16382169|NCT04104230||Individuals Affected with Related Cancer|Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
16382170|NCT04104230||Individuals Affected With Pancreatic Neoplasm|Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
16382171|NCT04104230||High-Risk Individuals|Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
16382172|NCT04104230||Healthy Controls|Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
16382173|NCT04104217||patients|Participate in 30-60 minute interviews after each music therapy session.
16382174|NCT04104217||caregivers|Participate in 30-60 minute interviews after each music therapy session (ideally within 3 days).
16382175|NCT04104217||nurses|Participate in 10-15 minute interviews after initial music therapy session.
16382176|NCT04104217||music therapists|Music therapist will notify the researcher if he/she has provided music therapy for a patient who is identified as having delirium. Music therapists will also be interviewed about the clinical process after initial and follow up music sessions.
16382177|NCT04104204|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.1 mg, A sham subcutaneous injection of 0.5 ml normal saline at inguinal area
16382178|NCT04104204|Experimental|Ultrasound guided supra-inguinal fascia iliaca block|0.25% bupivacaine 40 ml
16382179|NCT04104191|Experimental|L-1000AF System|Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
16382180|NCT04104178|Active Comparator|Clindamycin|600 mg clindamycin, 3 times daily for 10 days, orally
16382181|NCT04104178|Placebo Comparator|Placebo|
16382182|NCT04104165|Active Comparator|Intermittent catheterization|women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours
16382183|NCT04104165|Active Comparator|Continous catheterization|women which will have an indwelling catheter inserted for 24 hours
16382184|NCT04104152|Experimental|ENDS 2.4% nicotine|Subjects will be assigned to one of four flavors variants of 2.4% ENDS products based on their preferred UB flavor.
16382185|NCT04104152|Experimental|ENDS 5.0% nicotine|Subjects will be assigned to one of four flavors variants of 5.0% ENDS products based on their preferred UB flavor.
16382186|NCT04104139|Experimental|Treatment (TAS-102, IMRT, 3D-CRT)|Patients receive TAS-102 PO BID Monday-Friday on weeks 1, 3, and 5. Patients also undergo IMRT or 3D-CRT 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX.
16382187|NCT04104126|Active Comparator|Standard of Care Physical Therapy|Patients with Achilles injury are prescribed PT for their treatment, therefore physical therapy is a standard of care treatment for patients with tendon pathology.
16382188|NCT04104126|Experimental|Blood flow restriction (BFR) therapy|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff.
16382189|NCT04104113|Experimental|XBYRT decoction|Participants assigned to receive the modifed Xiang Bei Yang Rong Tang granules
16382190|NCT04104113|Placebo Comparator|Placebo|Participants assigned to receive placebo (contains 5% of XBYRT) granules
16382191|NCT04104100||Women with nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
16382192|NCT04104100||Women without nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
16382193|NCT04104087|Experimental|deepithelializ free gingival graft|performing tunneling technique with deepithelialized free gingival graft in treating RT2 gingival recession
16382194|NCT04104087|Active Comparator|subepithelial connective tissue graft|performing tunneling technique with sub epithelial connective tissue graft in treating RT2 gingival recession
16382195|NCT04104074|Experimental|Radiotherapy Plus Sintilimab|HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.
16382196|NCT04104048||patients who were diagnosed as Anterior STEMI|"Patients who were diagnosed as Anterior STEMI according to criteria developed by the European Society of Cardiology.
~Onset of maximal intensity of chest pain within 12 hours before procedure"
16382197|NCT04104035||BCR-ABL-positive hematopoiesis|Patients with BCR-ABL-positive hematopoiesis (newly diagnosed CML patients, CML patients with leukocytosis, CML patients without a hematological and/or cytogenetic and/or molecular response, CML patients whose BCR-ABL status becomes negative and then positive) will be included.
16382198|NCT04104035||BCR-ABL activity inhibition under TKI|Patients with CML with BCR-ABL activity inhibition under TKI therapy (patients with MMR and/or deeper response) will be included.
16382199|NCT04104022|No Intervention|OAT as usual|Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12.
16382200|NCT04104022|Active Comparator|OAT+PET|In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist.
16382201|NCT04104022|Experimental|OAT+PET+|OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions
16382202|NCT04104009|Experimental|Interventional group|"In the exam group there will be group training for four meetings of one hour each.
~After completing the training program with the test group, a break of 5 weeks will follow, during which a new test and control group will be formed. The procedure will be carried out until the estimated sample size (99 subjects per group) is met."
16382203|NCT04104009|Active Comparator|Control group|In the control group there will not be any group training.
16382204|NCT04103983|Active Comparator|Sensory Retraining Interactive Device|The interactive device is a sensory retraining device. A pad consisting of twelve equally spaced electrodes is placed over the residual limb. This pad is connected to a handheld device which delivers an electrical current to the electrodes. The type of electrical current is similar to a TENS device. The device stimulates the skin via one of the electrodes, with either a single, or a rapid burst of pulse(s). The device touch screen then presents the questions, Which electrode (location) was stimulated? Was a single continuous or a rapid burst of pulses given (stimulation type)? The user responds via the screen and is told if they are correct. If correct, a new stimulus is delivered (different location and type) and the process repeated. If incorrect, the user is informed of the correct response, the same stimulation (location and type) is repeated once before moving onto to a new stimulus.
16382205|NCT04103983|Active Comparator|Sensory Retraining Non-Interactive Device|The non-interactive device is physically visually identical to the interactive device. There is no interaction required with this device i.e. there is no Q&A element, feedback nor response dependent progression.
16382206|NCT04103970|No Intervention|Control group|"Usual care:
~Before surgery all patients are invited to participate in a pre-surgery seminar, where they receive information and advice about the time before, during and after the LSF. The seminar will be guided by nurses, surgeons, anesthesiologist, occupational therapists and physiotherapist.
~After the surgery the patient will be hospitalized on an average of 3-4 days. During hospitalization a physiotherapist consults the patients on a daily basis to provide information, guidance on mobilization and instructions in gradually progressing movement. The patients will have no restrictions on movement after surgery and should gradually return to normal activity level.
~Three months post-operatively all patients will receive physical rehabilitation delivered by physiotherapists in a community care center."
16382207|NCT04103970|Experimental|Intervention group: Graded Activity and Pain Education (GAPE)|"Patients in the intervention-group will receive usual care and 9 sessions of GAPE, 4 sessions at the hospital, 2 sessions in the patient's home and 3 sessions by telephone.
~Pain education in GAPE is viewed as an approach which target cognitive attitudes and beliefs about pain. The pain education will target 3 overall questions: 1. What is pain and is my pain normal? 2. What can affect my pain? 3. What can I do to relieve my pain? The education will be individually adjusted to each patient, so the patient's context and concerns regarding pain and movement are included.
~The aim of Graded activity is to improve the patient's functional ability by positive reinforcement of health behaviors and activity levels. Graded activity will be based on which short-term activity-goals the patient evaluates as the most important for the treatment outcome. In close collaboration with the patient the physiotherapist will set quotas for the selected exercises/activities."
16382208|NCT04103944|Experimental|Osteonecrotic Repair Device|A biphasic osteochrondral composite method to support the regeneration of articular cartilage in vivo. With its concept that could be securely installed by press-fit without additional fixation, this approach can present an alternative to perform graft harvest and implantation in a single surgery.
16382209|NCT04103944|Active Comparator|Core Decompression|Core decompression is a common surgical procedure that aims to improve vascular inflow by decreasing intraosseous pressure in the femoral head. It is performed that involves removing a cylindrical core of bone from the proximal femur.
16382210|NCT04103931|No Intervention|Usual Care|Participants will receive usual care and will not get the decision aid to review.
16382211|NCT04103931|Experimental|Patient Decision Aid|"Participants in this arm will receive the patient decision aid, titled Treatment Choices for Aortic Stenosis to review."
16382212|NCT04103918|Other|Jalucomplex® 2|Jalucomplex® 2 (Linear Hyaluronic Acid) Injection: follow the instruction for use
16382213|NCT04103905|Experimental|MIL62|
16382216|NCT04103879|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen.
~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.
~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
16382217|NCT04103866|Experimental|Pressure Offloading Innersole System|Use of Juvederm Voluma in the foot for fat pad restoration
16382218|NCT04103853|Experimental|Proxalutamide|"Stage one - Dose climbing:
~Each dose cohort will assess toxicity within the 35 days following the first dose of GT0918.
~Stage two- the expansion cohort :
~30 patients will be enrolled to the 200mg cohort . 15 patients will be enrolled to the 300mg cohort."
16382219|NCT04103840||Severe alcohol- associated hepatitis|Severe alcohol associated hepatitis as defined by probable/ conformed National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria
16382220|NCT04103840||Control|Apparently healthy Family controls
16382221|NCT04103827||old patients|"During the first 24 hours of the hospitalisation in the equiped room and before the presentation of the device, A first series of questions will be asked a priori to the patients. Patient will freely use Le Qoos during all his hospitalisation. After this use, a survey concerning the usability of Le Qoos will be administered to the patient, during the 48 hours before his discharge from hospital."
16382222|NCT04103827||relatives / unformal caregivers|"Before the presentation of the device, a first series of questions will be asked a priori to the unformal caregiver. Unformal caregiver will freely use Le Qoos during the hospitalization of his relative. After this use, a survey concerning the usability of Le Qoos will be administered to the unformal caregivers, 48 hours before the discharge of his hospitalized relative from hospital."
16382223|NCT04103827||profesional caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Le Qoos will be administered to professional caregivers."
16382224|NCT04103814|Active Comparator|Mg-CBDa cream|Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
16382427|NCT04102475|Sham Comparator|control group|
16382225|NCT04103814|Placebo Comparator|Placebo cream|Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
16382226|NCT04103801|Experimental|Sucrose group|This group received the 2 ml of sweet solution (sucrose)
16382227|NCT04103801|Placebo Comparator|Water group|This group received the 2 ml of water
16382228|NCT04103788|Active Comparator|95% Curcuminoid Powder|Curcumin powder standardized to >95% curcuminoids, single dose, used to determine standard absorptivity of unformulated powder.
16382229|NCT04103788|Experimental|BIOCURC|Highly absorbed curcumin emulsion, single dose, used to produce serum samples for analytical comparison of sample preparation methodologies.
16382230|NCT04103775|Experimental|Cognitive Remediation|Cognitive Remediation comprises of six exercises supplied by BrainHQ by Posit Science Corporation: Sound Sweeps (targets auditory processing speed): Two successive frequency-modulated tone sweeps are presented and participants indicate whether the frequency increased or decreased within each tone: Fine Tuning (targets auditory perception and processing speed): Participants indicate which one of two confusable syllables were presented; Syllable Stacks (targets auditory memory); Users report the order of presented syllables in a serial memory span task; Memory Grid (targets auditory memory); Participants match identical cards representing syllables; To do List Training (targets auditory memory): Participants see a g rid of everyday items (e.g., plant, carrots, shovel) and select the items in accordance with spoken instructions; Rhythm Recall (target auditory memory): Participants recreate auditory melodies
16382231|NCT04103775|Active Comparator|Active Control|Active Control Comprises six exercises also supplied by Post Science Corporation: A Maze Race, Reversi, Bricks Breaking Hex, Word Search II, Bricks Squasher II, and CircloO. These are all common computer games freely offered online.
16382232|NCT04103762|Experimental|indocyanine green|During the surgery, intraoperative cholangiography using indocyanine green will be performed
16382233|NCT04103762|Active Comparator|standard cpo|"During the surgery, intraoperative cholangiography using a contrast product gold standard will be performed"
16382234|NCT04103749|Experimental|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
16382235|NCT04103736|Experimental|Beet Juice Supplement|A single, acute dose of Beet It Sport Shot containing ~12.6mmol naturally occurring dietary nitrates.
16382236|NCT04103736|Placebo Comparator|Placebo juice|A single, acute dose of nitrate-depleted Beet It Sport Shot
16382237|NCT04103723||patients with premedication|Patients receiving preoperative premedication with midazolam before surgery.
16382238|NCT04103723||patients without premedication|Patients without preoperative premedication before surgery.
16382239|NCT04103697|Experimental|4xCapOx|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
16382240|NCT04103697|Active Comparator|Surgery|Patients will receive standard surgery for rectal cancer with partial or total mesorectal excision (based on exact tumor location and surgeons discretion). The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
16382241|NCT04103684|Experimental|Patients will receive steroid pulse therapy|
16382242|NCT04103684|Active Comparator|Patients will receive low dose steroids|
16382243|NCT04103671|Experimental|Group A|Prompt panretinal photocoagulation
16382244|NCT04103671|Experimental|Group B|Micro-invasive Pars-plana vitrectomy
16382245|NCT04103658|No Intervention|Standard of care (control)|This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
16382246|NCT04103658|Experimental|NIR heating|This will be the NIR heating group, where the excision of the non-melanoma skin cancer will be based on the lesion margins based on the application of near-infrared radiation (with 4-6mm margins).
16382247|NCT04103645|Experimental|Treatment arm|Vactosertib intra-patient dose finding cohort.
16382248|NCT04103632|Experimental|Young recreational athletes (12-18 years)|"Young recreational athletes (12-18 years) of different sport disciplines:
~Indoor sports
~Outdoor sports
~Swimming
~Winter sports"
16382249|NCT04103619|Active Comparator|AccuTite|15 patients will receive AccuTite treatment only
16382250|NCT04103619|Active Comparator|AccuTite & Morpheus 8 Arm|15 patients will receive AccuTite and Morpheus8 treatment and additional 2 monthly Morpheus8 treatments
16382251|NCT04103606|Experimental|immediate-use App group (iApp group)|Participants in the iApp group start using the app immediately (Time 0; T0) for 16 consecutive days (until Time 1; T1).
16382252|NCT04103606|Active Comparator|delayed-use App group (dApp)|Participants in the dApp group start using the app at Time 1 (T1; 16 days after the iApp group) and use the app for the following 16 days (Time 2; T2).
16382253|NCT04103593|Experimental|exercise group|High-intensity circuit exercise training will be performed 3 times weekly for 12 weeks in a group setting. Circuit training is an exercise modality consisting of a series of exercises at different stations. Exercise training will be delivered by VTEL broadcast from the Salem VAMC to participants at the Atlanta VAMC and Baltimore VAMC. Rooms will be equipped with steps, hand and ankle weights, dumbbells, chairs and bands. No stationary exercise equipment will be used in either AEX or RT.
16382254|NCT04103593|No Intervention|control group|Sedentary activity (confirmed at eligibility no more than 1 structured physical activity/week) will be continued in participants randomized to the control group. Participants have the option after 12-week intervention phase to enter ?delayed? exercise training to assure that all participants can receive exercise training.
16382255|NCT04103580|No Intervention|Control|Will receive usual hospice care plus measures
16382256|NCT04103580|Experimental|Intervention|Will receive photo elicitation intervention and will join a secret Facebook group to share photos with other caregivers
16382257|NCT04103567|Experimental|Biological collection|"Fecal samples collected at different times : During inclusion consultation with surgeon, after neoadjuvant treatment and before surgery,
~In parallel to this fecal collection, standardized clinical data will be entered into a database"
16382258|NCT04103554|Experimental|sacubitril/valsartan|
16382259|NCT04103554|Active Comparator|Standard of care|Standard of care for treating blood pressure per center protocols
16382260|NCT04103541|Experimental|IP-Colombia|
16382261|NCT04103541|No Intervention|Waitlist control|
16382262|NCT04103528|Other|morning group(from 8:00 to 12:00)|
16382263|NCT04103528|Other|afternoon group(from 14:00 to 18:00)|
16382264|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
16382265|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
16382266|NCT04103502||MicroPort Medial Pivot|Subjects will have been implanted with the MicroPort Medial Pivot TKA
16382267|NCT04103502||DePuy Attune|Subjects will have been implanted with the DePuy Attune PCR TKA
16382268|NCT04103489|Experimental|HELLP Syndrome at less than 30 weeks gestation|Women diagnosed with HELLP syndrome at 23-30 weeks gestation will receive eculizumab.
16382269|NCT04103476|Experimental|BZA/CE|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
16382270|NCT04103476|Placebo Comparator|Placebo|Oral matching placebo
16382271|NCT04103463|Experimental|Interactive stepping exercise group|
16382272|NCT04103463|Active Comparator|Home exercise group|
16382273|NCT04103450|Experimental|Vibegron|Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).
16382274|NCT04103437||recreational runners|Recreational runners (minimum of 2 running session and 20km of total mileage per week), with seasonal best on half-marathon comprised between 1h20' and 2h00'. Age > 18 and < 60 years. Free from musculoskeletal injuries from at least three months.
16382275|NCT04103424|No Intervention|Pre-training Metabolic Study Visit|Participants will first complete a pre-training metabolic study visit.
16382276|NCT04103424|Experimental|Post-training Metabolic Study Visit|Participants will complete a second, identical metabolic study visit following 2-weeks of exercise training.
16382277|NCT04103411|Experimental|High Intensity Interval Training (HIIT)|For the twelve weeks of intervention, participants will have three training sessions per week. Each session will be done on a cycle ergometer and will last approximately 40 minutes. Participants will be supervised by certified kinesiologists and their training programs will be revised every four weeks.
16382278|NCT04103411|Active Comparator|HydroChloroThiazide|For this group, participants have to take a diuretic (12,5 mg of Hydrochlorothiazide) daily prescribed by the doctor of this study, for twelve weeks. Participants should also maintain the same lifestyle habits that they had before the study.
16382279|NCT04103398|Experimental|Transarterial chemoembolization combined with sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
16382280|NCT04103398|Active Comparator|Transarterial chemoembolization alone|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
16382281|NCT04103385|Experimental|Reconnecting to Internal Sensations and Experiences|"Aims to improve interoception or connection to the body's emotions & internal sensation and reduce suicidal ideation."
16382282|NCT04103385|Active Comparator|Restoring Individual Strength and Energy|Aims to reduce life stressors and improve physical health
16382283|NCT04103372|Active Comparator|Low risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 0. (Margin Clear >0mm from the diathermy margin and Sm1/2 or Haggitt 1/2/3) Six monthly follow up from date of surgery.
16382284|NCT04103372|Active Comparator|Moderate Risk - RT&Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to receive radiotherapy (RT) and regular surveillance, with 3 monthly follow-up from the date of surgery.
16382285|NCT04103372|Active Comparator|Moderate Risk - Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to surveillance arm with regular surveillance, with 3 monthly follow-up from the date of surgery.
16382286|NCT04103372|Active Comparator|High Risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of >2. (Margin positive - 0mm to the diathermy margin, Margin positive/or unassessable due to piecemeal removal - 0mm to the tumour margin, Sm3 or Haggitt 4, Poorly differentiated/mucinous, LVI, T2) Patient is considered for surgery, receives radiotherapy and surveillance, with 3 monthly follow-up from date of surgery.
16382287|NCT04103372|Active Comparator|TME (Total mesorectal excision) Surgery|For patients where it is considered technically feasible to do LE but MR staged<1mm muscularis preserved, or it is considered not feasible to perform a local excision. Patients undergo TME surgery. Pathology assessment on sample with confirmation of adenocarcinoma. Patient receives 6 monthly follow-up from date of surgery.
16382288|NCT04103359|Experimental|MDS patients|MDS patients receiving blood transfusion
16382289|NCT04103346|Active Comparator|air filtration with hepa filter|air purifier used is the Holmes HAP8650B-NU-1 with the hepa filter inserted.
16382290|NCT04103346|Sham Comparator|air filtration with hepa filter removed|sham comparator uses the Holmes HAP8650B-NU-1 air purifier to be operated with the filter removed.
16382291|NCT04103333|Experimental|Angelman Syndrome: Group 1|Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382292|NCT04103333|Experimental|Angelman Syndrome: Group 2|Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382293|NCT04103333|Experimental|Angelman Syndrome: Group 3|Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382294|NCT04103333|Experimental|Angelman Syndrome: Group 4|Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382295|NCT04103333|Experimental|Dup15q Syndrome: Group 1|Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382296|NCT04103333|Experimental|Dup15q Syndrome: Group 2|Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382297|NCT04103333|Experimental|Dup15q Syndrome: Group 3|Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382298|NCT04103333|Experimental|Dup15q Syndrome: Group 4|Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
16382299|NCT04103307|No Intervention|Control: Standard of care|Participants in the control group will receive standard-of-care CRRT prescriptions, and have the returning venous blood warmed with an external blood warmer to a temperature of 37°C. The blood warmer temperature will be adjusted by the CRRT nurse as per usual practice to maintain normothermia.
16382300|NCT04103307|Experimental|Intervention: Cooling|Participants in the intervention group will receive standard of care CRRT prescriptions and have the blood warmer set to 35.5°C, as long as the nasopharyngeal temperature remains above 35.5°C.
16382301|NCT04103294|Experimental|cowpea variety #1|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
16382302|NCT04103294|Experimental|cowpea variety #2|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
16382303|NCT04103281||Sepsis Patients|
16382304|NCT04103281||Control Patients|
16382305|NCT04103268||Sepsis|
16382306|NCT04103268||Control|
16382307|NCT04103255|Experimental|High frequency and intensive prevention|"High frequency and intensive prevention program -
~Goal management training (Ariane Giguere-Rancourt et al., 2018) - is a home-based approach for PD patients with Mild Cognitive Impairment (MCI)
~Physiotherapy
~Rhythmic Music Gymnastic
~Speech therapy"
16382308|NCT04103255|No Intervention|Control group (Stepped-wedge trial)|Best Medical Treatment
16382309|NCT04103229|Experimental|10 ml sterile distilled water|The indwelling urinary catheterization was inflated with 10 ml sterile distilled water (SDW) of the balloon.
16382310|NCT04103229|Experimental|15 ml sterile distilled water|The indwelling urinary catheterization was inflated with 15 ml sterile distilled water (SDW) of the balloon.
16382311|NCT04103229|Experimental|10 ml 0.9% sodium chloride (NaCL)|The indwelling urinary catheterization was inflated with 10 ml 0.9% sodium chloride (NaCL) of the balloon.
16382312|NCT04103229|Experimental|15 ml 0.9% sodium chloride (NaCL)|The IUC was inflated with 15 ml 0.9% sodium chloride (NaCL) of the balloon.
16382313|NCT04103216|Active Comparator|Intervention arm|"Child will be receive the Nitazoxanide treatment for 3 days with probiotics (L reuteri DSM 17938 ) for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.
~L reuteri DSM 17938 will be 2×108 CFU and will receive 5 drops orally twice daily for a consecutive 7 days."
16382314|NCT04103216|Placebo Comparator|Control arm|"Child will be receive the Nitazoxanide treatment for 3 days with placebo for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.
~Placebo will receive 5 drops orally twice daily for a consecutive 7 days."
16382315|NCT04103203|No Intervention|New diagnostic results NOT available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.
16382316|NCT04103203|Experimental|New diagnostic results available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
16382317|NCT04103177|Experimental|Intervention group|20 participants to receive physical activity educational booklet with instructions on chair based exercises, Instructor-led training on how to perform the chair based exercises, two times a week, over a 6 week period, and motivational interviewing and prompts.
16382318|NCT04103164|Experimental|Cutera® excel V laser arm|After the PWS is be divided into five equal portions, four of those portions treated once with a different laser fluence using the multiple-pass approach (2 J/cm² vs 4 J/cm² vs 6 J/cm² vs 8 J/cm²), and one of the portions treated with single-pass approach at 8 J/cm²
16382319|NCT04103151||Febrile infants|Febrile Infants less than 3 months presenting to the emergency department with a temperature of ≥ 38oC.
16382320|NCT04103151||Afebrile infants|Afebrile Infants less than 3 months presenting to the emergency department
16382321|NCT04103138|Experimental|EEG-Guided Anaesthesia|Patients will have Sedline EEG sensor placed and anaesthesia guided by the EEG characteristics, patient state index (PSI) and suppression ratio (SR), in addition to routine clinical parameters.
16382322|NCT04103138|Active Comparator|Routine Care|Patients will have Sedline EEG sensor placed but the monitor is concealed so the clinician is blinded to the EEG response. Anaesthesia is guided by routine clinical parameters.
16382323|NCT04103125|Other|Janesse|Janesse® 20 (Cross-linked Hyaluronic Acid) Injection: follow the instruction for use
16382324|NCT04103112|No Intervention|Standard clinical care|Standard clinical care (anticoagulation) with no graduated compression stocking
16382325|NCT04103112|Experimental|Graduated compression stocking and standard clinical care|A graduated compression stocking and the standard clinical care (anticoagulation)
16382326|NCT04103099||Single (virtual) Arm|Observational one arm virtual study of HLNatural Immune supplement
16382327|NCT04103086|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol). All participants will receive the standard inhalation method training before hospital discharge.
~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
16382328|NCT04103086|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
16382329|NCT04103073||Study group|The patient with OSAS 35-70 years of age, clinically stabile, symptoms such as snoring, breathing cessations, and daytime sleepiness, and polysomnographic evidence consistent with mild (5<apnea hypopnea index (AHI)< 15) to moderate (16 < AHI < 30) OSAS.
16382330|NCT04103060|Experimental|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily
16382331|NCT04103060|Placebo Comparator|Vehicle gel|Vehicle gel applied topically twice daily
16382332|NCT04103047||SAD group|Adult surgical patients who are due to undergo general anaesthesia and requiring SAD insertion will be identified on the day of surgery.
16382333|NCT04103034|Experimental|BT200 0.18mg|Subjects will receive a single subcutaneous dose of BT200 0.18mg
16382334|NCT04103034|Experimental|BT200 0.6mg|Subjects will receive a single subcutaneous dose of BT200 0.6mg
16382335|NCT04103034|Experimental|BT200 1.8mg|Subjects will receive a single subcutaneous dose of BT200 1.8mg
16382336|NCT04103034|Experimental|BT200 6.0mg|Subjects will receive a single subcutaneous dose of BT200 6.0mg
16382337|NCT04103034|Experimental|BT200 12.0mg|Subjects will receive a single subcutaneous dose of BT200 12.0mg
16382338|NCT04103034|Experimental|BT200 24.0mg|Subjects will receive a single subcutaneous dose of BT200 24.0mg
16382339|NCT04103034|Experimental|BT200 24.0mg repeat|Subjects will receive a single subcutaneous dose of BT200 24.0mg
16382340|NCT04103034|Placebo Comparator|Placebo SAD|Subjects will receive a single subcutaneous dose of placebo
16382341|NCT04103034|Experimental|BT200 loading dose 24.0mg, maintenance doses of 12.0 mg|Subjects will receive an initial subcutaneous loading doses of BT200 24.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg
16382342|NCT04103034|Experimental|BT200 loading doses 48.0mg, maintenance doses of 24.0 mg|Subjects will receive an initial subcutaneous loading dose of BT200 48mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg
16382343|NCT04103034|Placebo Comparator|Placebo MAD|Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo
16382344|NCT04103034|Experimental|BT200 48.0mg + desmopressin challenge|Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200
16382345|NCT04103034|Placebo Comparator|Placebo + desmopressin challenge dose|Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo
16382346|NCT04103034|Placebo Comparator|Placebo infusion|Subjects will receive a single IV dose of placebo administered over 24 hours
16382347|NCT04103034|Experimental|BT200 36.0mg|Subjects will receive a single subcutaneous dose of BT200 36.0mg
16382348|NCT04103034|Experimental|BT200 48.0 mg|Subjects will receive a single subcutaneous dose of BT200 48.0mg
16382349|NCT04103021|Experimental|Port-a-cath|Ultrasound guided Port-a-cath insertion
16382350|NCT04103008||Group A|single coronary artery lesion
16382351|NCT04103008||Group B|multiple coronary artery lesions
16382352|NCT04102995|Experimental|Sepranolone (UC1010) low dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
16382353|NCT04102995|Experimental|Sepranolone (UC1010) high dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
16382354|NCT04102995|Placebo Comparator|Placebo|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
16382355|NCT04102982|Active Comparator|Microwave ablation plus camrelizumab group|Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
16382356|NCT04102982|Placebo Comparator|Camrelizumab group|Patients in the group are treated with camrelizumab alone.
16382357|NCT04102969|Experimental|Intervention group|"Intervention group will be instructed by an interventionist who is qualified in stress management and relaxation will perform the Benson relaxation technique to the intervention group to perform the Benson relaxation technique two times a day for 10 minutes during the study period ( two months).
~Training session of the technique will be repeated if necessary over one or two sessions until the interventionist confirm that the participants acquired sufficient skills. A total of two hours will be scheduled for each session and will be coordinated with the nursing manager of the hemodialysis department."
16382358|NCT04102969|Other|Control Group|A qualified nutritionist will run out a nutrition package session for hemodialysis patients in the control group. This nutrition package session will be for one session for one hour.
16382428|NCT04102462|Experimental|Multiple rising dose part|
16382359|NCT04102956|Experimental|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
16382360|NCT04102956|No Intervention|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
16382361|NCT04102943|Experimental|Tacrolimus1|Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
16382362|NCT04102943|Active Comparator|Tacrolimus2|Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
16382363|NCT04102930||Retrospective|A patient who has a diagnosis of GCA or PMR
16382364|NCT04102930||Prospective|Patient with suspected GCA and PMR
16382365|NCT04102917||QFR group|915 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, acute myocardial infarction with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
16382366|NCT04102891|Experimental|Study arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the Flemish food-based dietary guidelines. Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
16382367|NCT04102891|No Intervention|Control arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the guidelines from the newly developed microbiota modulation diet (MMD). Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
16382368|NCT04102878|Active Comparator|Transcutaneous anaesthetic|
16382369|NCT04102878|Active Comparator|Transconjunctival anaesthetic|
16382370|NCT04102865|Other|single use NPWT dressing|single use NPWT dressing
16382371|NCT04102852|Experimental|LGG regular dose|Patients taking LGG 1.2 × 10^10 CFU/day, 2 capsules a day, for 1 month
16382372|NCT04102852|Experimental|LGG double dose|Patients taking LGG 2.4 × 10^10 CFU/day, 4 capsules a day, for 1 month
16382375|NCT04102800|Other|Treatment|Benralizumab 30mg by subcutaneous injection, 18 months treatment for the first 75 participants enrolled, 12 months treatment for participants 76-150
16382376|NCT04102787|Experimental|experimental group|Experimental group who received the Cardiac educational program and will be applied for Coronary Artery Disease patients, and measure the level of knowledge and satisfaction in pre and post test.
16382377|NCT04102787|No Intervention|control group|Control group who received the usual care and measure the level of knowledge and satisfaction in pre and post test.
16382378|NCT04102774|Experimental|myAIRVO2|Patients will receive a myAIRVO2 at home over-night with humidifier on top of standard therapy for bronchiectasis according to international guidelines (ERS 2017).
16382379|NCT04102774|No Intervention|Control|Patients will receive standard therapy for bronchiectasis according to international guidelines (ERS 2017).
16382380|NCT04102761|Placebo Comparator|Trigger Point Needling|The first group will receive a deep trigger point injection of saline into deep tissue.
16382381|NCT04102761|Active Comparator|Platelet Rich Plasma Injection|The Platelet Rich Plasma group will receive an injection of approximately 1-2 mL of Platelet Rich Plasma into the painful disc/discs.
16382382|NCT04102761|Active Comparator|Bone Marrow Aspirate Injection|The third group will receive an injection of approximately 1-2 mL of Bone Marrow Concentrate into the painful disc/discs.
16382383|NCT04102748|Active Comparator|Conventional|
16382384|NCT04102748|Active Comparator|I-incision|
16382385|NCT04102748|Active Comparator|M-flap|
16382386|NCT04102735|Active Comparator|Over-the-nose facemask|The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
16382387|NCT04102735|Experimental|Under-the-nose facemask|The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
16382388|NCT04102722|Experimental|Single Arm|All enrolled subjects will undergo breast cancer screening with mammography and the MUST device
16382389|NCT04102696|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.
~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
16382390|NCT04102696|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
16382429|NCT04102462|Experimental|Midazolam part|
16382430|NCT04102449|Other|Treatment with Apremilast|"Single group:
~Apremilast will be prescribed according to the patient information leaflet, i.e.:
~Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment duration at the discretion of the treating physician."
16382432|NCT04102423||CCUS|All participants meeting the criteria for CCUS
16382391|NCT04102683|Experimental|Intervention Group|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
16382392|NCT04102683|No Intervention|Control Group|
16382393|NCT04102670|Experimental|Treatment|Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream
16382394|NCT04102657|Experimental|Intermittent Fasting with Left Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
16382395|NCT04102657|Experimental|Intermittent Fasting with Right Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
16382396|NCT04102657|Experimental|Free-living Diet with Left Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
16382397|NCT04102657|Experimental|Free-living Diet with Right Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
16382398|NCT04102644||Pregnant Women|15,000 pregnant women and their fetuses/newborns (including a pilot phase of up to 500 participant pairs)
16382399|NCT04102631|Experimental|exposed group|patients will receive colonoscopy with assistance of Endo.Angel
16382400|NCT04102631|Sham Comparator|non-exposed group|patients will receive colonoscopy without assistance of Endo.Angel
16382401|NCT04102618|Experimental|Cohort 1|HR+/HER2-neg patients who will receive pelareorep plus letrozole
16382402|NCT04102618|Experimental|Cohort 2|HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
16382403|NCT04102618|Experimental|Cohort 3|TNBC patients who will receive pelareorep plus atezolizumab
16382404|NCT04102618|Experimental|Cohort 4|HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
16382405|NCT04102618|Experimental|Cohort 5|HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
16382406|NCT04102605|Experimental|Nunap Vision|Nunap Vision , 5 days a week for 12 weeks
16382407|NCT04102605|Sham Comparator|Nunap Vision-C|Nunap Vision-C, 5 days a week for 12 weeks
16382408|NCT04102592|Experimental|Intervention Group|Participants in this arm receive Lesu (baby wrap) treated with 0.5% permethrin
16382409|NCT04102592|Placebo Comparator|Control Group|Participants in this arm receive Lesu (baby wrap) soaked with water only to mimic re-treatment and mask allotment
16382410|NCT04102579|Experimental|Valbenazine|Capsule, administered orally once daily for 12 weeks.
16382411|NCT04102579|Placebo Comparator|Placebo|Capsule, administered orally once daily for 12 weeks.
16382412|NCT04102566|No Intervention|Standard of care arm|"The standard of care group will group will receive the following regimen while inpatient:
~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours
~Acetaminophen 1000mg every 8 hours standing
~Oxycodone 5mg PO every 4 hours as needed pain
~Phenazopyridine 100mg TID as needed for urinary burning
~Senna 1 tab every 12 hours
~Miralax 17g powder once daily as needed for constipation
~The standard of care group will get the following prescriptions on discharge:
~Oxycodone 5mg every 4 hours as needed pain - 15 tabs
~Acetaminophen 1000mg every 8 hours standing for two days then as needed
~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs
~Senna 1 tab every 12 hours - 10 tabs"
16382413|NCT04102566|Experimental|Multi-modal group|"The multi-modal group will receive the following regimen while inpatient:
~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours
~Acetaminophen 1000mg every 8 hours standing
~Ibuprofen 600mg every 6 hours standing
~Oxycodone 5mg PO every 4 hours as needed pain
~Phenazopyridine 100mg TID as needed for urinary burning
~Senna 1 tab every 12 hours
~Miralax 17g powder once daily as needed for constipation
~Patient Education (Figures 2 & 3)
~The multi-modal group will receive the following prescriptions on discharge:
~Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs
~Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs
~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs
~Senna 1 tab every 12 hours - 10 tabs"
16382414|NCT04102553|Experimental|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
16382415|NCT04102553|Active Comparator|F-18-Fluorocholine|Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
16382416|NCT04102540|Experimental|Infographic intervention group|Participants in the infographic intervention group will receive health education using infographics during a study visit scheduled immediately following their regularly scheduled clinic visits.
16382417|NCT04102527||Patients|Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis for at least three months in stable condition
16382418|NCT04102514|Other|Real-time Group Video|
16382419|NCT04102514|Other|Enhanced Usual Care|
16382420|NCT04102501|Experimental|RT001|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.
~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
16382421|NCT04102501|Placebo Comparator|Placebo|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.
~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
16382422|NCT04102488|Experimental|6-step hygiene technique, application time of 30 seconds|
16382423|NCT04102488|Experimental|6-step hygiene technique, application time of 15 seconds|
16382424|NCT04102488|Experimental|3-step hygiene technique, application time of 30 seconds|
16382425|NCT04102488|Experimental|3-step hygiene technique, application time of 15 seconds|
16382434|NCT04102410|Experimental|Experimental group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program composed of two 2 training strategies.
16382435|NCT04102410|Sham Comparator|Control group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program of usual practice.
16382436|NCT04102397|Experimental|Standard plus Vojta therapy (SVT)|The physiotherapist's hands produce the activation with no need for medication or external equipment, thus guaranteeing the patient's safety.this therapy is able to change pathological patterns to painless patterns that reduce the use of energy caused by movement difficulty. The end result is to facilitate movement without strain.
16382437|NCT04102397|Active Comparator|Standard therapy (ST)|It consists of one or more of the following procedures: transcutaneous electrical nerve stimulation (TENS), ultrasound therapy, kinesiotherapy, and cryotherapy.
16382438|NCT04102384|No Intervention|Control Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using an electronically link sent via email. Additionally, participants will be asked to fill out one survey once a week during the study period.
16382439|NCT04102384|Experimental|Intervention Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using the e-PRO app. Additionally, participants will be asked to fill out one survey once a week during the study period. A subgroup of these participants will be asked to complete an additional interview to collect more information on their experiences using the mobile app.
16382440|NCT04102371|Experimental|Balanced fluids (BF)|Balanced fluids (BF), including Lactated Ringer's and PlasmaLyte, will be administered to patients randomized to the experimental arm. BF will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
16382441|NCT04102371|Active Comparator|"0.9% Normal Saline Fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
16382442|NCT04102358||Single injection|Patients who received an infraclavicular block with a single injection technique were included in Group-S.
16382443|NCT04102358||Triple injection|Patients who received an infraclavicular block with a triple injection technique were included in Group-T.
16382444|NCT04102345|Experimental|Lavender|1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.
16382445|NCT04102345|Active Comparator|Zolpidem|Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.
16382446|NCT04102332||Before arm|usual infusion practices (neutral solvent-purged infusers)
16382447|NCT04102332||After arm|Safe Infusion Device
16382448|NCT04102306||Temporomandibular disorder group (TMD)|"Patients with temporomandibular disorder coming at the Cabinet Saint Alexandre for orofacial rehabilitation.
~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a rehabilitation session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next rehabilitation session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 45 days).
~Questionnaires were performed during the course of the patient rehabilitation that was instructed not to perform imagined movement during the interval."
16382449|NCT04102306||Control healthy group (CTL)|"Healthy individuals with no temporomandibular disorder (i.e., no orofacial medical consultation or rehabilitation) aged-matched and gender-matched to TMD group.
~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 8 days).
~Questionnaires were performed with no additional rehabilitation and participants were instructed not to perform imagined movement during the interval."
16382450|NCT04102293|Experimental|Rotary instrumentation using MM files 1|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
16382451|NCT04102293|Active Comparator|Manual instrumentation using K-files 1|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
16382452|NCT04102293|Experimental|Rotary instrumentation using MM files 2|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Disposable syringe technique.
16382453|NCT04102293|Active Comparator|Manual instrumentation using K-files 2|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Disposable syringe technique
16382454|NCT04102280|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
16382455|NCT04102267|Experimental|Liposomal bupivacaine injection (Group 1)|Liposomal bupivacaine 266 mg via injection
16382456|NCT04102267|Experimental|Bupivacaine HCl continuous infusion (Group 2)|Bupivacaine HCl 300 mg via continuous infusion
16382492|NCT04101994|Experimental|VCT and real rTMS|In virtual cycling training and intermittent theta burst stimulation group (VCT + iTBS group), they received VCT and iTBS (80% of active motor threshold) on affected hemisphere.
16382493|NCT04101994|Experimental|VCT and sham rTMS|In virtual cycling training and sham theta burst stimulation group (VCT + iTBS group), they received VCT and sham TBS stimulation.
16382457|NCT04102254|Experimental|ANT recording and stimulation|Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation [130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
16382458|NCT04102241|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
16382459|NCT04102241|Experimental|15mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
16382460|NCT04102241|Experimental|30mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 30mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
16382461|NCT04102241|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
16382462|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
16382463|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
16382464|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
16382465|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
16382466|NCT04102215|Experimental|ARCI25|Robot assited Cochlear implant surgery.
16382467|NCT04102202|Experimental|BOL-DP-o-05|
16382468|NCT04102202|Placebo Comparator|Placebo|
16382471|NCT04102176|Active Comparator|Continue nucleos(t)ide analogue|patients will be given open label tenofovir alafenamide
16382472|NCT04102176|Experimental|Stopping nucleos(t)ide analogue|patients will stop nucleos(t)ide therapy (such as entecavir, tenofovir, lamivudine or adefovir)
16382473|NCT04102163||All Participants|Participants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.
16382474|NCT04102150|Experimental|DS-3201b|
16382475|NCT04102137||3|Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
16382476|NCT04102124|Experimental|SHR3680+SHR3162|Participants will receive SHR3680 combined with SHR3162 orally
16382477|NCT04102124|Experimental|SHR3680+SHR3162(Placebo)|Participants will receive SHR3680 combined with SHR3162(Placebo) orally
16382478|NCT04102124|Placebo Comparator|SHR3680(Placebo)+SHR3162(Placebo)|Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
16382483|NCT04102085||Mothers under 30|no intervention will be administered
16382484|NCT04102072|Experimental|Trendelenburg Maneuver|The Trendelenburg position is a common treatment in medicine.It is used either as a diagnostic tool to assess fluid loading response or as a therapeutic maneuver pending fluid resuscitation.With the advantage of autotransfusion readily available,the Trendelenburg position is used for expected instantaneous effect on cardiovascular performance.
16382485|NCT04102072|Experimental|dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
16382486|NCT04102020|Experimental|Part 1: Dose Confirmation|Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 24 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
16382487|NCT04102020|Experimental|Part 3 (Dose Finding): Dose Escalation|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
16382488|NCT04102020|Experimental|Part 3 (Dose Finding): Safety Expansion|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.
16382489|NCT04102020|Experimental|Part 3 (Randomization): Venetoclax + CC-486|Participants will receive venetoclax QD, CC-486 QD on Days 1-14 of each 28-day cycle for 24 cycles.
16382490|NCT04102020|Experimental|Part 3 (Randomization): Placebo + CC-486|Participants will receive Placebo for venetoclax QD, CC-486 QD on Days 1-14 of each 28-day cycle for 24 cycles.
16382491|NCT04102007|Other|Risankizumab|Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
16382494|NCT04101994|Experimental|real rTMS|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
16382495|NCT04101994|Sham Comparator|sham rTMS|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
16382496|NCT04101994|Experimental|VCT and real TES|In virtual cycling training and transcranial electric stimulation group (VCT + TES group), they received TES stimulation over motor cortex.
16382497|NCT04101994|Experimental|VCT and sham TES|In virtual cycling training and sham transcranial electric stimulation group (VCT + sham TES group), they received VCT and sham TES stimulation.
16382498|NCT04101994|Experimental|real TES|In transcranial electric stimulation group (TES group), they received TES stimulation over motor cortex.
16382499|NCT04101994|Sham Comparator|sham TES|In sham transcranial electric stimulation group (sham TES group), they received sham TES stimulation.
16382500|NCT04101981||healthy subjects|10 subjects
16382501|NCT04101981||oncological patients|10 subjects
16382502|NCT04101968||GBA-PD|People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
16382503|NCT04101968||Asymptomatic GBA|Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
16382504|NCT04101955|Other|Incisionless Threaded Carpal Tunnel|
16382505|NCT04101955|Other|Standard Mini-Open Carpal Tunnel|
16382506|NCT04101942|Experimental|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in the experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours on weekdays
16382507|NCT04101942|No Intervention|Control condition (assessment only)|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 7 weeks.
16382508|NCT04101929|Experimental|Experimental: Apatinib + S-1+ Irinotecan|Apatinib: 250mg po qd； S-1 capsule: According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle; Irinotecan: According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks.
16382509|NCT04101916|Experimental|Paired Associative Stimulation|
16382510|NCT04101916|Sham Comparator|Sham|
16382511|NCT04101903|Experimental|Diagnostic Aid|The experimental group will use the trial diagnostic aid for all 6-week infant hip checks
16382512|NCT04101903|No Intervention|Standard of Care|The control group will assess infants according to standard practice, during the 6-week hip check. This group will receive a leaflet about the national best practice recommendation for this check.
16382513|NCT04101890|Experimental|Diaper care with Theraworx|Participants will be given a 4 week supply of Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000), to apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks.
16382514|NCT04101890|No Intervention|Routine diaper care|Participants continue their typical diaper care.
16382515|NCT04101877|Experimental|Avastin|bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
16382516|NCT04101877|Active Comparator|Eylea|aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)
16382517|NCT04101864|Experimental|Electromagnetic navigation|In the study group acetabular components in total hip arthroplasty will be placed with the help of electromagnetic image-less navigation system. Reference plane will be anterior pelvic plane.
16382518|NCT04101864|Active Comparator|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
16382519|NCT04101851|Experimental|No axillary SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0) at the final pathology of lumpectomy.
16382520|NCT04101838|Active Comparator|Fluzone Younger|10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
16382521|NCT04101838|Active Comparator|Flucelvax|10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
16382522|NCT04101838|Active Comparator|Fluzone Older|10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
16382523|NCT04101838|Active Comparator|Fluzone High Dose|10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
16382524|NCT04101838|Active Comparator|Fluad|10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine
16382525|NCT04101825|Experimental|Auralya|Auralya® 25 (Cross-linked Hyaluronic Acid) Injection
16382526|NCT04101812|Experimental|Experimental group|Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.
16382527|NCT04101812|Active Comparator|Control group|PD-1 every 3 weeks, for 6 cycles.
16382528|NCT04101799|Experimental|Intervention|Participating in the For our children's sake intervention, 10 group sessions, 2 hours each
16382529|NCT04101799|Active Comparator|Control|Participating in everyday activities that may include parenting activities in the control prisons
16382530|NCT04101773|Other|Rubber Band Ligation (RBL)|RBL is generallya simple, inexpensive procedure. It entails a ligation of haemorrhoids using rubber bands. In RBL, a disposable suction device applies a rubber band at least 2 cm proximal to the dentate line at the base of each haemorrhoidal cushion by using an anoscope. The banding process causes necrosis of the banded tissue and slough. The resultant inflammatory reaction causes refixation of the mucosa to the underlying tissue, helping to eliminate haemorrhoidal prolapse.The end result is a return of the haemorrhoidal cushions to a more normal size and configuration, with resolution of haemorrhoidal symptoms.
16382531|NCT04101773|Other|Sutured mucopexy|A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
16382564|NCT04101526|Other|Waitlist control group|No intervention until 6 weeks after the baseline assessment, at which point participants complete a follow-up assessment and then are offered the new CBT-I intervention.
16382532|NCT04101773|Other|Haemorrhoidectomy|Haemorrhoidectomy involves excision of the haemorrhoidal tissue. An elliptical incision is made in the external haemorrhoidal tissue extending proximally through the dentate line to the upper limit of the haemorrhoids. The base of the haemorrhoidal complex is ligated and the haemorrhoid is excised.
16382533|NCT04101760|Experimental|Study group|Patients in study group accept prophylactic treatment of long-acting granulocyte colony stimulating factor
16382534|NCT04101760|Active Comparator|Control group|Patients in control group accept regular or prophylactic treatment of short-acting granulocyte colony stimulating factor according to current guidelines
16382535|NCT04101734||Double Lumen Endotracheal Tube|Group of patients intubated with Double Lumen Endotracheal Tube.
16382536|NCT04101734||Double Lumen Video Endotracheal Tube|Group of patients intubated with Double Lumen Video Endotracheal Tube.
16382537|NCT04101721|Experimental|Aflibercept Group|Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
16382538|NCT04101721|Experimental|Laser Group|Patients will undergo laser treatment in each eligible eye at baseline.
16382539|NCT04101708|Experimental|high dose dual group|Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d
16382540|NCT04101708|Active Comparator|half-dose clarithromycin-containing bismuth quadruple group|Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d
16382541|NCT04101695|Active Comparator|sham tDCS- washout period- anodal tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.
~For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds. At least 7 days of washout period is in between two tDCS. For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA."
16382542|NCT04101695|Active Comparator|anodal tDCS- washout period- sham tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.
~For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA. At least 7 days of washout period is in between two tDCS. For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds."
16382543|NCT04101682|Active Comparator|Single Shot|Patients will receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine
16382544|NCT04101682|Active Comparator|Continuous Block|Patients will have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days
16382545|NCT04101669|Experimental|EndoBarrier|Patients in ARM 1, will receive an upper endoscopy and will be treated with the EndoBarrier Liner
16382546|NCT04101669|Sham Comparator|Sham|Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the EndoBarrier Liner.
16382547|NCT04101656||Experimental: APBI (Accelerated Partial Breast Irradiation)|APBI 28 Gy in 5 fractions of 5.6 Gy, using external radiotherapy with modulated intensity technique (IMRT)
16382548|NCT04101643|Experimental|Evolocumab group|Eligible patients receive subcutaneous injections of evolocumab 420 mg
16382549|NCT04101630||Participants with Pulmonary Hypertension|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
16382550|NCT04101630||Healthy Volunteers|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
16382551|NCT04101617|Experimental|Experimental group|Participants will receive previously designed educational material with recommendations for healthy habits and oral health recommendations. Also, pediatricians will give the parents oral health education. Parents and their children will receive toothbrushes as well as toothpaste.
16382552|NCT04101617|No Intervention|Control Group|Parents and their children will receive toothbrushes as well as toothpaste.
16382553|NCT04101604||Patients with VKH, BD, DR, AMD, or PCV|Collection of blood samples and clinical information from patients with VKH, BD, DR, AMD, or PCV
16382554|NCT04101604||Healthy subjects|Collection of blood samples and clinical information
16382555|NCT04101578||Ocular MG|Patients with autoimmune MG whose symptoms restricted to extraocular muscles
16382556|NCT04101578||Generalized MG|Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
16382557|NCT04101565|Experimental|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
16382558|NCT04101565|No Intervention|Usual care|Usual care that is consistent with typical maternity care in involving expectant fathers.
16382559|NCT04101552|Experimental|grafted versus graft less socket shield technique|
16382560|NCT04101539|Active Comparator|Standard Ablation (PVI)|Patients in this arm will receive standard ablation for atrial fibrillation (wide-area circumferential ablation to achieve pulmonary vein isolation [PVI]).
16382561|NCT04101539|Experimental|OPTIMA Ablation|Patients in this arm will receive standard PVI ablation and supplemental ablation of reentrant driver sites identified by OPTIMA analysis as sites likely supportive of persistent atrial fibrillation.
16382562|NCT04101526|No Intervention|Pre-Intervention Qualitative Interviews|Qualitative interviews will be conducted with breast cancer survivors, survivors' caregivers, cancer support group leaders and clinicians regarding sleep disturbance in breast cancer survivors and preferences for an intervention for sleep disturbance.
16382563|NCT04101526|Experimental|Videoconference Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Behavioral: New Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
16382674|NCT04100759|Experimental|Cigarette Smokers|Subjects administer one tablet of sildenafil 50mg
16382565|NCT04101500|Placebo Comparator|AECOPD(P+C1)|Placebo Tablets(P) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
16382566|NCT04101500|Experimental|AECOPD(C1+C2)|Compound Sodium Chlolate and Aminophylline Tablets(C2) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
16382567|NCT04101487|No Intervention|Control|Participants in this arm will receive routine monthly visits along with survey administration and the regular package of health services provided at the facility level and at home by community health assistants
16382568|NCT04101487|Experimental|Cash Transfers|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants and unconditional cash transfers every month
16382569|NCT04101487|Experimental|Cash Transfers and Nutrition Education|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants, unconditional cash transfers every month, and structured nutrition education provided at household level by community health assistants based on a structured nutrition education handbook.
16382570|NCT04101474|Active Comparator|Ketamine group|half of participants will take ketamine
16382571|NCT04101474|No Intervention|Placebo group|the other half of participants will not take any drugs
16382574|NCT04101448||Group A|COPD patients with bronchiectasis
16382575|NCT04101448||Group B|COPD patients without bronchiectasis
16382576|NCT04101435|Experimental|Group A|Aged 3 to 8 years old vaccine naïve subject (without prior seasonal influenza vaccine exposure)
16382577|NCT04101435|Active Comparator|Group B|Aged 3 to 8 years old vaccine non-naïve subject (with prior seasonal influenza vaccine exposure)
16382578|NCT04101435|Experimental|Group C|Aged 9 to 17 years old subject
16382579|NCT04101422|No Intervention|Development of Augmented Reality (AR) Application|Investigators will collaborate with an AR software specialist to develop AR stimuli that are embedded within a basic digital application.
16382580|NCT04101422|Experimental|Pilot Testing of AR Application|AR stimuli (smoking, e.g, cigarette, ashtray, lighter; and non-smoking, e.g., pen, notebook, eraser) will be piloted on a small group of smokers to receive feedback and modify as needed. Participants will answer questions from a 10 point Likert scale that will asses urge from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke) and reality/co-existence (how realistic the item looks, and it's integration into the environment), from 1 (Not at all) to 10 (Very Much). Participants will then be asked additional open-ended questions about the quality of the images following the ratings of the images.
16382581|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 1: Cue Reactivity|142 study participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
16382582|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 2: Extinction|Participants will be randomized into either the extinction or control group. 28 trials of AR cues will be presented for each group. Both groups will receive the same neutral cue in Trial 1 (to establish baseline urge) and the same smoking cue in Trial 2 (for pre-test cue-reactivity). The extinction group will receive smoking cues for trials 3-26, whereas the control group will receive neutral cues. Both groups will receive matched smoking cues for trial (27) followed by matched neutral cues for the final trial (28), for post-test cuereactivity. Each cue will be presented for 1 minute and will be shown 4 times in trials 3-26. Following each cue, participants will complete the single-item measure of urge. Following the final trial (28) for both groups, participants will be presented with one of their own cigarettes and asked to take at least one puff. Latency to smoke will later be determined using time stamps on the video recording. Session 2 is expected to last 1.25 hours.
16382583|NCT04101422|Experimental|Testing AR Application|20 Participants will be instructed to use the AR app that presents smoking-related stimuli (cigarette, ashtray, lighter) in locations/situations where they typically smoke with the goal of at least 5 uses per day for 7 days. Usage and rating data will be collected in real-time. Participants will also be asked to rate their urge to smoke on the smartphone app at selected times. Participants will then return to the lab to provide additional feedback on the app, answer questions related to smoking behavior, and receive an in-person interview on their perceptions of the app as a potential cessation tool. Participants will use the smart phone application for 7 days.
16382584|NCT04101409|Experimental|DAs group|Shared decision making using decision aids
16382585|NCT04101409|No Intervention|Control group|Standard oral explanation guided with booklets
16382586|NCT04101396|Other|4 points blood glucose monitoring|4 points of self monitoring blood glucose which comprises of fasting, 1 hour post breakfast, 1 hour post lunch and 1 hour post dinner
16382587|NCT04101396|Other|7 points blood glucose monitoring|7 points of self monitoring blood glucose which comprises of fasting,1 hour post breakfast, 1 hour pre and post lunch, 1 hour pre and post dinner, pre bed at 10 pm
16382588|NCT04101383|Experimental|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
16382589|NCT04101383|Active Comparator|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
16382590|NCT04101370|Experimental|Bosentan|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
16382591|NCT04101370|Active Comparator|Tracleer®|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
16382592|NCT04101357|Experimental|Part 1A - monotherapy dose escalation|BNT411 monotherapy
16382593|NCT04101357|Experimental|Part 1B combination dose escalation|BNT411 in combination with atezolizumab, carboplatin and etoposide
16382594|NCT04101357|Experimental|Part 2 expansion cohorts|BNT411 either as monotherapy or in combination with other anti-cancer agents
16382595|NCT04101344|Experimental|Fiber-blend|All participants will receive a two fiber-blend snack and then a four fiber-blend snack. Stool, blood, and urine will be monitored for changes throughout the study.
16382596|NCT04101331|Experimental|Cohort A|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%
16382597|NCT04101331|Experimental|Cohort B|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to <10%
16382598|NCT04101331|Experimental|Cohort C|TMF (transformed mycosis fungoides) patients with CD30 expression ≥1%
16382599|NCT04101318|Experimental|New Stoma Baseplate with Protective Layer|New Stoma baseplate with Protective layer
16382600|NCT04101318|Active Comparator|Standard of Care|1-piece and 2-piece stoma devices already on the market.
16382601|NCT04101305||Localised prostate cancer|Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
16382602|NCT04101305||Stage 3 prostate cancer|Patients with diagnosed stage 3 prostate cancer
16382603|NCT04101305||Stage 4 prostate cancer|Patients with diagnosed stage 4 prostate cancer
16382604|NCT04101305||Healthy controls|Age-matched healthy individuals free from diagnosed cancer, but with benign inflammatory prostatitis or other benign urological condition
16382605|NCT04101292|Experimental|Fluorescence characterization|
16382606|NCT04101279|Experimental|Midurethral synthetic tape with tension control mechanism|
16382607|NCT04101279|Active Comparator|midurethral tension free tape|
16382608|NCT04101266|Active Comparator|Interscalene nerve block|preoperative interscalene nerve block to be applied with ultrasound guidance.
16382609|NCT04101266|Active Comparator|suprascapular and infraclavicular nerve block|preoperative suprascapular and infraclavicular nerve block to be with ultrasound guidance
16382610|NCT04101253|Experimental|Interventional|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
16382611|NCT04101227|Experimental|Treatment Arm|AD04 (ondansetron)
16382612|NCT04101227|Placebo Comparator|Placebo Arm|Matching Placebo
16382613|NCT04101214|Experimental|Dry needling|One session of dry needling technique will be applied by a physiotherapist specialized in the technique. Dry needling technique will be performed in the muscle of the lower limb whose MMAS score is >1 by locating a sensitive point within a taut band. After that, a thin needle (0,32x40mm) is introduced directly into those muscle that present spasticity, decide by the clinician expert.
16382614|NCT04101214|Sham Comparator|Sham Dry needling|A physiotherapist specialized in dry needling technique will use a sham needle in order to simulate the active intervention. Sham acupuncture uses non-penetrating needles.The palpation and evaluation of the spastic muscle will be exactly the same that in the active group.
16382615|NCT04101201|Other|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
16382616|NCT04101201|Placebo Comparator|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
16382617|NCT04101188|Experimental|Moderate Potassium/Low Sodium|Subjects will be provided with a diet that is moderate in potassium and low in sodium.
16382618|NCT04101188|Experimental|Moderate Potassium/High Sodium|Subjects will be provided with a diet that is moderate in potassium and high in sodium.
16382619|NCT04101188|Experimental|High Potassium/High Sodium|Subjects will be provided with a diet that is high in both potassium and sodium.
16382620|NCT04101175||Request for abortion|Patient in first trimester of pregnancy in request for abortion
16382621|NCT04101162|Other|liver biopsy|
16382622|NCT04101162|Other|ATI|
16382623|NCT04101149||Group 1|Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.
16382624|NCT04101136|Active Comparator|Atorvastatin 20 mg|Study pharmacist will make code (A and B) for atorvastatin and placebo, then save the code in safe place. Pharmacist will record each subject as participant received A or B intervention.
16382625|NCT04101136|Placebo Comparator|Placebo 20 mg|The placebo tablets will be prepared by Cipto Mangunkusumo hospital pharmacist, were composed of starch and were similar to atorvastatin tablets in size, shape, and colour.
16382626|NCT04101123||Children and adolescents with cancer|Children and adolescents between 10-18 years with newly diagnosed leukemia, brain tumors, and sarcomas
16382627|NCT04101097||training group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
16382628|NCT04101097||validation group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
16382629|NCT04101084|Experimental|Rocking chair therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
16382630|NCT04101071|Experimental|Modular ketogenic enteral feed|Ketogenic enteral feed to be administered continuously for 10 days.
16382631|NCT04101071|Active Comparator|Standard enteral feed|Standard enteral feed to be administered continuously for 10 days.
16382632|NCT04101045|Active Comparator|Poorly-controlled T1D|Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).
16382633|NCT04101045|Active Comparator|Controlled T1D|Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).
16382634|NCT04101045|Active Comparator|Lean controls|Patients in this group will not have T1D.
16382675|NCT04100759|Experimental|Cannabis Smokers|Subjects administer one tablet of sildenafil 50mg
16382635|NCT04101032|Experimental|eBEfree|eBEfree is a ICT-delivery version of BEfree - eBEfree that comprises 12 online sessions, based on mindfulness,values and compassion components for women with Binge Eating.
16382636|NCT04101032|No Intervention|Waiting List|Participants will remain in a waiting list. After 12 weeks, they will be offered the same intervention.
16382637|NCT04101019|Placebo Comparator|Control|The patient will undergo the SPGB block with saline.
16382638|NCT04101019|Active Comparator|Active drug|The patient will undergo the SPGB block with the active drug which will include 10% lidocaine diluted to 5%.
16382639|NCT04100993||Patient group|60 participants ≥16 years of age with a confirmed diagnosis of a childhood-onset NMD
16382640|NCT04100993||Exploratory reference group|20 healthy adults ≥16 years of age
16382641|NCT04100980||Chronic UTI|Patients who have been diagnosed with chronic urinary tract infections (UTI).
16382642|NCT04100954|Experimental|Reinforced prosthesis|Implementation of a reinforced prosthesis with silver coating and double valve, whatever which type of prosthesis the patient previously had.
16382643|NCT04100954|Active Comparator|Standard prosthesis|Implementation of a standard prosthesis (simple valve, not reinforced), similar to the prosthesis the patient previously had.
16382644|NCT04100941|Experimental|standard suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the standard suction technique with 10ml negative pressure
16382645|NCT04100941|Experimental|slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
16382646|NCT04100941|Experimental|wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
16382647|NCT04100915||Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Patients diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
16382648|NCT04100902|Active Comparator|Odactra 12-sq HDM sublingual tablet|House Dust Mite, sublingual tablet
16382649|NCT04100902|Placebo Comparator|Placebo sublingual tablet|Placebo, sublingual tablet
16382650|NCT04100889||Alzheimer's disease patients|Patients who have been diagnosed with Alzheimer's disease
16382651|NCT04100876||primary ITP patients .|60 primary ITP patients .
16382652|NCT04100876||healthy subjects .|30 healthy age and sex matched control subjects .
16382653|NCT04100863||Individuals with Autism|Individuals who have been diagnosed with autism
16382654|NCT04100850|Experimental|Aquatic Exercises|Aquatic Exercises (AE) are water aerobics exercises and resistance exercises, classes will be supervised by a Physical Educator, in collective sessions of up to 30 people per class, twice a week, lasting 50 minutes, for two months.
16382655|NCT04100850|Active Comparator|Watsu|The Watsu (water shiatsu) will be applied by a physical therapist, in individual sessions, twice a week, lasting 50 minutes, for two months in a warn pool (± 34°C). Watsu in particular prescribes transition of movements, once they are instituted, the therapist can create and adapt according to the limitations and restrictions that are encountered.
16382656|NCT04100850|No Intervention|Control|The control group will not receive any of these treatments (aquatic exercises and Watsu).
16382657|NCT04100837||transportal group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transportal technique (femoral tunnel drilling) , before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
16382658|NCT04100837||transtibial group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transtibial technique (femoral tunnel drilling), before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
16382659|NCT04100824|Experimental|Bupivacaine 0.5%|patient will take stellate ganglion block 10 ml bupivacaine 0.5% and nimodipine
16382660|NCT04100824|Active Comparator|Nimodipine|patient will take nimodipine 60 mg every 4 h.
16382661|NCT04100798|Experimental|Entire Papilla Preservation (EPP) technique|A minimally invasive surgical technique that involves using a vertical incision away from the defect area in order to preserve the integrity of the related interdental papilla and elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
16382662|NCT04100798|Active Comparator|Modified Minimally invasive Surgical Technique (M-MIST)|A minimally invasive surgical technique that involves using a horizontal interdental incision that extends to the buccal aspect of the two teeth adjacent to the intraosseous defect then elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
16382663|NCT04100785|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|The iCBT programme comprised of 6 online modules, delivered over 4 weeks, with 3 face-to-face sessions provided by a clinician.The face-to-face sessions were conducted at week 1, 3 and 4. The objectives of the face-to-face sessions was for participants to discuss with the clinician about the application of the content of the modules and the active therapeutic interventions were all found in the online modules.
16382664|NCT04100785|No Intervention|Delayed Wait-list control|The delayed wait-list control did not receive any therapy interventions for 4 weeks from the pre-treatment assessment and from the fifth week onwards, they received the same intervention as the iCBT experimental group.
16382665|NCT04100772|Experimental|vaccine 1A|Subjects received one dose of PCV13i at 18 to 49 years old
16382666|NCT04100772|Experimental|vaccine 2A|Subjects received one dose of PCV13i at 50 years old and above
16382667|NCT04100772|Experimental|vaccine 3A|Subjects received one dose of PCV13i at 6 to 17 years old
16382668|NCT04100772|Experimental|vaccine 4A|Subjects received one dose of PCV13i at 2 to 5 years old
16382669|NCT04100772|Experimental|vaccine 5A|Subjects received two doses of PCV13i at 7 months to 2 years old
16382670|NCT04100772|Experimental|vaccine 6A|Subjects received three doses of PCV13i at 3,4,5 months of age
16382671|NCT04100772|Experimental|vaccine 7A|Subjects received three doses of PCV13i at 2,4,6 months of age
16382672|NCT04100772|Active Comparator|vaccine 7B|Subjects received three doses of PCV13 at 2,4,6 months of age
16382673|NCT04100759|Experimental|Non-Smokers|Subjects administer one tablet of sildenafil 50 mg
16382676|NCT04100733|Active Comparator|Control|Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
16382677|NCT04100733|Experimental|Intervention|Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
16382678|NCT04100720|Experimental|Cardiovalve Transfemoral Tricuspid Valve|Replacement (Implant) delivered through a transfemoral access
16382679|NCT04100707|Experimental|Operated|Genicular block will aply to the patients with knee pain who was operated before
16382680|NCT04100707|Sham Comparator|Nonoperated|Genicular block will aply to the patients with knee pain who wasn't operated before
16382681|NCT04100681|Active Comparator|Active FlowOx™|The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
16382682|NCT04100681|Sham Comparator|Sham FlowOx™ (Placebo)|The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
16382683|NCT04100668|Experimental|Data collection|Comparing radial arterial line, Sensifree's Alpha sensor and PPG sensor pressure waveforms
16382684|NCT04100655|Experimental|GM-CSF|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.
~3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice."
16382685|NCT04100655|Experimental|Control|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.
~After hysteroscopy examination, nothing was applied to the uterine cavity."
16382686|NCT04100642|Active Comparator|1% Hemay808 apply to 25%BSA|8 subjects use 1% Hemay808
16382687|NCT04100642|Experimental|3% Hemay808 apply to 25%BSA|8 subjects use 3% Hemay808
16382688|NCT04100642|Experimental|3% Hemay808 apply to 55%BSA|6 subjects use 3% Hemay808
16382689|NCT04100642|Experimental|7% Hemay808 apply to 25%BSA|8 subjects use 7% Hemay808
16382690|NCT04100642|Placebo Comparator|placebo apply to 25%BSA|6 subjects use placebo apply to 25%BSA
16382691|NCT04100642|Placebo Comparator|placebo apply to 55%BSA|2 subjects use placebo apply to 55%BSA
16382692|NCT04100629|Placebo Comparator|Control Group|The control group will receive medical facts and are not meant to support newly licensed nurses and are not known to affect stress, resilience, perceived social support, or Intention To Leave one's job.
16382693|NCT04100629|Experimental|Experimental Group|Texts sent to the experimental group will be based on nurturant support messages and are intended to decrease stress, Intention To Leave, increase resilience, and perceived sense of support.
16382694|NCT04100616||Obsese individuals|Patients with a BMI greater than or equal to 30
16382695|NCT04100603||Patients with CDI|Patients who are infected with C. diff
16382696|NCT04100590|Experimental|Active Cannabis|In this session, the participant will smoke two-thirds of one active cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
16382697|NCT04100590|Placebo Comparator|Placebo Cannabis|In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
16382698|NCT04100577|Experimental|TNT PISP intervention|Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
16382699|NCT04100577|No Intervention|Control|Participants in control group will have no enhanced prenatal care support. They will attend visits on their own with their prenatal care provider and participation in this research study will not interfere with the prenatal care.
16382700|NCT04100564|Active Comparator|Standard airway method arm|Standard airway management strategy
16382701|NCT04100564|Experimental|Supraglottic airway method arm|Supraglottic first airway management strategy
16382702|NCT04100538|Experimental|Intervention group|The intervention group will receive the technology-assisted program by health coach twice a week during the 10-week treatment period. The health coach will be an experienced master-prepared nurse who has extensive and in-depth knowledge about fibromyalgia and has previously worked in direct contact with patients with fibromyalgia in a research project.
16382703|NCT04100538|No Intervention|control group|The control group will receive technology-assisted informational support twice a week during the 10-week treatment period. Each technology-assisted informational support will last for approximately 10-30 min consisting of 15-min questions-and-answers regarding the educational materials and 15-min debriefing.
16382704|NCT04100525|Active Comparator|Standard Care|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
16382738|NCT04100265|No Intervention|Panel 3 - Postoperative ileus arm with standard of care|Standard of care control group of patients with clinical signs of postoperative ileus requiring a standard nasogastric feeding tube for symptom relief. Symptoms will be surveyed as control group to assess safety and tolerability of the investigational medical device.
16382937|NCT04098848|No Intervention|Control group|not participate in cycling exercise during hemodialysis
16382705|NCT04100525|Experimental|Experimental Treatment|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
16382706|NCT04100512|Active Comparator|Incentive spirometry|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
16382707|NCT04100512|Experimental|Oscillating Positive Expiratory Pressure Device|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
16382708|NCT04100486||Healthy, Able-Bodied Individuals|This study will only enroll healthy, able-bodied individuals.
16382709|NCT04100473|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
16382710|NCT04100473|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
16382711|NCT04100460|Experimental|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
16382712|NCT04100460|Experimental|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
16382713|NCT04100460|Placebo Comparator|Control - No Arabinoxylan (Maltodextrin)|Participants are given no Arabinoxylan
16382714|NCT04100447|Experimental|Treatment Arm|All subjects will receive 1 dose of study drug (split into 2 administrations), over the 12 hours prior to surgery.
16382715|NCT04100434|Experimental|the evolocumab plus statin therapy|Patients with ACS are treated with atorvastatin (20mg) daily and evolocumab (140 mg) every two weeks throughout the study period
16382716|NCT04100434|No Intervention|the statin alone therapy|Patients with ACS are treated with atorvastatin (20mg) daily throughout the study period.
16382717|NCT04100421||Mild renal injury|CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
16382718|NCT04100421||Moderate renal injury|CKD patients with eGFR between 30 ml∙min-1∙(1.73 m2)-1 to 60 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
16382719|NCT04100421||Severe renal injury|CKD patients with eGFR < 30 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
16382720|NCT04100421||Hemodialysis|uremic patients on hemodialysis therapy
16382721|NCT04100421||Peritoneal dialysis|uremic patients on peritoneal dialysis
16382722|NCT04100421||Healthy control|Healthy volunteers with no history of kidney diseases or any chronic diseases which may lead to renal injury.
16382723|NCT04100408||Ancillary-Correlative (biospecimen collection)|LCH patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal brushing will be sequenced, genotyped, and analyzed.
16382724|NCT04100382|Experimental|Laser and SLA implants|Surgical placement of short implants in maxillary posterior teeth with Laser surface treated and SLA surface treated dental implants
16382725|NCT04100356|Experimental|Normal diet|The group ingests normal diet, recommended by the health authorities
16382726|NCT04100356|Experimental|LCHF diet|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat
16382727|NCT04100356|Experimental|Normal diet + exercise|The group ingests normal diet, recommended by the health authorities in addition to exercise program 3x week.
16382728|NCT04100356|Experimental|LCHF diet + exercise|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat, in addition to exercise program 3x week.
16382729|NCT04100330|Experimental|Ficlatuzumab with HiDAC|Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.
16382730|NCT04100330|Active Comparator|HiDAC alone|Cytarabine 2 g/m2 IV per day on Days 1 through 6
16382731|NCT04100304|Other|patient under going liver resection|
16382732|NCT04100291|Active Comparator|FMT|Faecal microbiota transplantation
16382733|NCT04100291|Placebo Comparator|Placebo|Placebo mixture
16382734|NCT04100278|No Intervention|Traditional therapy group|All patients in this group will be given routine diabetes management, including lifestyle education, health guidance, monitoring blood sugar guidance and drug adjustment.
16382735|NCT04100278|Active Comparator|Shared Care group|The patients download the Shared Care mobile application and connect with the smart-glucometer Bg1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
16382736|NCT04100265|Experimental|Panel 1 - High risk for postoperative ileus|Intervention in patients at high risk to develop prolonged postoperative ileus. Monitoring postoperative gastric motility for 2 consecutive days in patients who require preventive placement of a nasogastric feeding tube due to a high risk to develop postoperative ileus. Allowing to explore associations between gastric motility and general clinical evolution.
16382737|NCT04100265|Experimental|Panel 2 - Postoperative ileus arm with investigational device|Intervention in a population of patients with clinical signs of postoperative ileus, requiring a nasogastric feeding tube for symptom relief. The investigational medical device will be applied. Allowing to explore the association of gastric motility and clinical signs of postoperative ileus in an enriched population with true postoperative ileus.
16387139|NCT04070222||Cesarean with diverticulum (PCSD) group|
16382739|NCT04100252||Group 1 (Women with AFI<5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI<5 were enrolled in the Group 1.
16382740|NCT04100252||Group 2 (Women with AFI≥5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI≥5 were enrolled in the Group 2.
16382741|NCT04100239|Experimental|Intervention Arm|Open continuous recruitment of participants to trial where all participants begin the study as 'control participants' and at regular 'steps' participants are allocated to next available intervention group and cross from the control to the intervention condition, until all groups have completed the intervention.
16382742|NCT04100226|Experimental|Interstitial lung patients with low vitamin D|Arm 1:(interventional group): interstitial lung diseases patients with low vitamine D will receive Vitamin D supplementation in form of Vitamin D3 (1.25(OH)2 cholecalciferol) in dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for deficient vitamin D level patients and every month for 3 months for insufficient vitamin D level patients beside ca supplementation in form ca carbonate 600 mg oral capsule once daily for 3 months for all patients in addition to current treatment.
16382743|NCT04100226|No Intervention|interstitial lung diseases patients with low vitamin D|Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive their current treatment only without vitamin D supplementation.
16382744|NCT04100213|Experimental|TSST|
16382745|NCT04100200|Active Comparator|Mixed Berries|Strawberry and red raspberry composite served as a frozen drink
16382746|NCT04100200|Active Comparator|FOS|Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
16382747|NCT04100200|Active Comparator|Combination|Mixed berry composite + FOS served as a frozen drink
16382748|NCT04100200|Placebo Comparator|Control|Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
16382749|NCT04100187|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
16382750|NCT04100161|Experimental|Protein supplementation|20g protein supplementation twice daily for 3 months
16382751|NCT04100161|Active Comparator|Carbohydrate supplementation|20g maltodextrin supplementation twice daily for 3 months
16382752|NCT04100148|Experimental|SyncAV Arm|Treatment Arm
16382753|NCT04100148|Active Comparator|Fixed AV Delay Arm|Control Arm
16382754|NCT04100135|Experimental|Test Arm|Device PFO closure with the GORE® CARDIOFORM Septal Occluder
16382755|NCT04100135|Sham Comparator|Control Arm|Sham device PFO closure (PFO not closed)
16382756|NCT04100122||Cutaneous only|Cutaneous and mucosal involvement only; generalized hives, pruritus or flushing, swollen lips-tongue-uvula (n=15)
16382757|NCT04100122||Wheat anaphylaxis sIgElo|Anaphylaxis (using the clinical diagnostic criteria according to World Allergy Organization; WAO 2011) with specific Immunoglobulin E (sIgE) to wheat <100 kUA/L (n=15)
16382758|NCT04100122||Wheat anaphylaxis sIgEhi|Anaphylaxis (using the clinical diagnostic criteria according to World Allergy Organization; WAO 2011) with specific Immunoglobulin E (sIgE) to wheat ≥100 kUA/L (n=15)
16382759|NCT04100122||Wheat tolerant|Patients with confirmed IgE-mediated wheat allergy for more than 12 months, and a negative oral food challenge (OFC) result to wheat during the past 12 months will be include as a control group (n=15)
16382760|NCT04100109|Active Comparator|Polylactose|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
16382761|NCT04100109|Active Comparator|Placebo|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
16382762|NCT04100096|Experimental|Intervention|2-3 mg/day tablet
16382763|NCT04100096|Placebo Comparator|Placebo|Placebo tablet
16382764|NCT04100083|Active Comparator|Group 1|Patients taking 50mg Spironolactone
16382765|NCT04100083|Active Comparator|Group 2|Patients taking 100mg Spironolactone
16382766|NCT04100083|Active Comparator|Group 3|Patients taking 200mg Spironolactone
16382767|NCT04100070|Other|Standard monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls.
~Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)"
16382768|NCT04100070|Other|Intensive monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study.
~Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits)."
16382769|NCT04100057|Experimental|Cognitive Behavioral Therapy for Insomina (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
16382770|NCT04100057|Active Comparator|Desensitization Therapy for Insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
16382771|NCT04100044|Experimental|Health Services Research (physical therapist, exercise)|Patients meet with a physical therapist on day 0 and at 3 and 6 months and receive a personalized home exercise intervention consisting of aerobic and resistance training for 6 months. Patients also receive face-to-face sessions, video chats, or text message check-ins with physical therapist weekly for 6 weeks and then every other week for up to 24 weeks.
16382772|NCT04100031|Experimental|BCL group|
16382773|NCT04100031|Active Comparator|control group|
16382776|NCT04100005||Crohn's disease|Patients who have been diagnosed with Crohn's disease
16382777|NCT04099992|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
16382778|NCT04099992|Active Comparator|Health enhancement program (HEP)|Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions with a day-long retreat.
16382779|NCT04099992|Experimental|MBSR+tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD) ."
16382780|NCT04099992|Active Comparator|MBSR+sham-tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
~Sham stimulation will be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
16382781|NCT04099992|Experimental|HEP+tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator (a registered dietician) in a group setting for 8 weekly 2.5-hour sessions.
~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD)."
16382782|NCT04099992|Active Comparator|HEP+sham-tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions.
~Sham stimulation is be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency (0.1 Hz) biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
16382783|NCT04099979||Psoriasis patients|Patients who have been diagnosed with Psoriasis
16382784|NCT04099966|Experimental|alpha beta cell depletion|Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.
16382785|NCT04099953|Experimental|dialysis patients|Dialysis patients were evaluated by objective diagnostic tests.
16382786|NCT04099953|Experimental|Control group|Healthy individuals
16382787|NCT04099940|Experimental|Virtual Reality Avatar Therapy (VRAT)|In the VRAT, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent.
16382788|NCT04099940|Active Comparator|Assertiveness Training Program (ATP)|The ATP is a transdiagnostic cognitive behavioural treatment programme, which aims to increase self-confidence and social competence in patients with a psychiatric disorder.
16382789|NCT04099927|Experimental|SHR0410|Experimental: SHR0410 dose escalation.
16382790|NCT04099901|Experimental|Anakinra|Dosage form: intravenous. Dosage: 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
16382791|NCT04099901|Placebo Comparator|Placebo|Dosage form: intravenous. Dosage: not applicable. Frequency: once daily. Duration: 15 days (day -2 until day +12).
16382792|NCT04099888|Experimental|PCI treatment in conjunction with Standard of Care (SoC)|Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy
16382793|NCT04099888|Active Comparator|Standard of Care (SoC)|Arm B: Gemcitabine/cisplatin chemotherapy
16382794|NCT04099862||ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
16382795|NCT04099862||EUS-BD|Endoscopic UltraSound Biliary Drainage
16382796|NCT04099849|Experimental|Group A|"Diet-ZnBfR zinc biofortified rice-based diet
~Diet- CR conventional rice-based diet"
16382797|NCT04099849|Experimental|Group B|"Diet-ZnBfR zinc biofortified rice-based diet
~CR + Zn conventional rice-based diet plus zinc fortificant (Diet-CR+Z)."
16382798|NCT04099836|Experimental|atezolizumab and bevacizumab|Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)
16382799|NCT04099823|Other|MR brain|"Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
~Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
~Those who meet eligibility criteria for the study and have agreed to participate will be taken to the MRI suite when MR imaging of the brain will be performed."
16382853|NCT04099420||Italian university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
16382800|NCT04099810|Other|Patients undergoing Cardiac MRI|Patients scheduled to undergo cardiac magnetic resonance for clinical reason will be asked if they are willing to undergo additional non invasive testing (three-dimensional echocardiography) which will take about 15-20 minutes
16382801|NCT04099797|Experimental|C7R-GD2.CAR T cells|This is a single arm study. Patients will be treated at 4 dose levels. At dose level 0, patients will only receive GD2.CART cells without C7R and they will receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
16382802|NCT04099784||Freeze-only|Children born from freeze-only group and frozen embryo transfer
16382803|NCT04099784||Fresh|Children born from fresh embryo transfer
16382804|NCT04099771|Experimental|Ketamine|A total of 20 patients identified as having suicidal ideation will receive ketamine at 0.5mg/kg infused intravenously over 40 minutes.
16382805|NCT04099758|Experimental|Mindfulness of the breath meditation|10 minute mindfulness of the breath meditation practice delivered online via audio-recording.
16382806|NCT04099758|Placebo Comparator|Audio-recording control|10 minute non-fiction audio-recording delivered online
16382807|NCT04099745|Experimental|CGM（continuous glucose monitoring）|Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.
16382808|NCT04099745|Experimental|FGM（Flash glucose monitoring）|Each diabetic patient received one FGM test for 14 days.
16382809|NCT04099732|Experimental|Part 1: Reference 1 followed by Test 1|Reference 1 - Rosuvastatin. Test 1 - Rosuvastatin + BI 1358894
16382810|NCT04099732|Experimental|Part 2: Reference 2 followed by Test 2|Reference 2 - Dabigatran etexilate. Test 2 - Dabigatran etexilate + BI 1358894
16382811|NCT04099719||Anyone (>16 years old) registered with services providing drug|retrospective data, no intervention to be administered
16382812|NCT04099706|Experimental|Intervention - Fat grafting|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the intervention group, the fat will be purified using decanting and injected into the painful areas of skin.
16382813|NCT04099706|Sham Comparator|Control - Saline|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the control group, the fat will be discarded and saline will be injected into the painful areas of skin.
16382814|NCT04099693||General Anesthesia|"All the patients will be intubated and ventilated using cisatracurium (0.15 mg/kg) as a muscle relaxant and propofol (1.5-2mg/kg) for induction. The inhalational anesthetic, sevoflurane, will be used to maintain the depth of anesthesia using 50% mix of nitrous oxide and oxygen.
~Fentanyl will be used in both groups at a rate of 1-2 microgram /kg to achieve an adequate level of analgesia in both groups."
16382815|NCT04099693||Anesthetist Administered sedation for ERCP|To ensure a steady level of AAS each patient in this group will be sedated using propofol. An induction bolus of propofol (0.5 - 1 mg/kg) will be administered followed by continuous infusion with variable doses depending on the patients' age, weight, and clinical condition. In addition, fentanyl 1.5 μg/kg will be used at the anesthetist discretion.
16382816|NCT04099680|Active Comparator|Partial-thickness bed preparation|Partial-thickness bed preparation for free gingival graft procedure.
16382817|NCT04099680|Experimental|Full-thickness bed preparation|Full-thickness bed preparation with bone screw placement for anchoring the sutures.
16382818|NCT04099667|Experimental|Phase 2: MYOBLOC 15,000 U, IM|Subjects will receive a single total limb dose of 15,000 Units of MYOBLOC via intramuscular (IM) injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
16382819|NCT04099667|Experimental|Phase 2: MYOBLOC 20,000 U, IM|Subjects will receive a single total limb dose of 20,000 Units of MYOBLOC via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
16382820|NCT04099667|Placebo Comparator|Phase 2: Placebo|Subjects will receive a single total dose of volume-matched placebo via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
16382821|NCT04099667|Experimental|Phase 3: recommended Phase 3 dose (RP3D)|Subjects will receive the recommended dose of MYOBLOC (determined after analysis of the Phase 2 data) via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
16382822|NCT04099667|Placebo Comparator|Phase 3: Placebo|Subjects will receive a single total dose of volume-matched placebo via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
16382823|NCT04099654|Experimental|Core-Stabilization Exercise|
16382824|NCT04099654|Experimental|Counseling of physical activity|
16382825|NCT04099641|Experimental|bavituximab and pembrolizumab|Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks
16382826|NCT04099628|Experimental|Diagnostic tests|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
16382851|NCT04099433|Experimental|Oral Bacteriotherapy Arm|Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
16382852|NCT04099433|Placebo Comparator|Placebo Arm|Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
16382827|NCT04099615||Endovascular urgent stroke treatment group|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
16382828|NCT04099602|Experimental|Massage group|Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.
16382829|NCT04099602|No Intervention|Control group|The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
16382830|NCT04099589|Experimental|MIBC Group|Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.
16382831|NCT04099589|Experimental|UTUC Group|Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.
16382832|NCT04099576|Experimental|Physiotherapy plus Education|The experimental group received a three-week program consisting of 15 sessions of physiotherapy and six sessions of therapeutic neuroscience education.
16382833|NCT04099576|Active Comparator|Control group|The control group received a three-week program consisting of 15 sessions of physiotherapy alone. .
16382834|NCT04099563|Experimental|PF-04965842|Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
16382835|NCT04099550|Active Comparator|SMBG with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
16382836|NCT04099550|Experimental|RT-CGM with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
16382837|NCT04099537|Experimental|Approach cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to pull the joystick toward (approach) them when seeing skin stimuli on a computer screen.
16382838|NCT04099537|Experimental|Avoidance cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push the joystick away (avoidance) from them when seeing skin stimuli on a computer screen.
16382839|NCT04099537|Placebo Comparator|Placebo cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push and pull the joystick towards or away from them (no rule) when seeing skin stimuli on a computer screen.
16382840|NCT04099524|Experimental|active tDCS|We will apply the stimulation for 20 minutes using current at 1.5mA with a ramp up and ramp down period of 30 seconds at the start and end of the session.
16382841|NCT04099524|Sham Comparator|sham tDCS|tDCS will ramp up for 30 seconds with 1 mA current and then ramp off within 10 seconds. As 30 seconds is too short for tDCS to have any effects, this will be the control condition. tDCS is on for 30 seconds because that is usually the only time individuals would experience tingling and itching - a factor we aim to equate between experimental and control conditions.
16382842|NCT04099511|Active Comparator|Usual Care Occupational Therapy-Outpatient|
16382843|NCT04099511|Experimental|Cognitive Orientation to daily Occupational Performance|
16382844|NCT04099498|No Intervention|Standard Control group|This group will not partake in the intervention but will be assessed with the same protocol at the same moments.
16382845|NCT04099498|Experimental|Online-Intervention group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator.
16382846|NCT04099498|Experimental|Enhanced-online-Intervention Group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator. In addition, gamification strategies (e.g., points for each complete activity, feedback) will be implemented in order to promote engagement with the program and activities.
16382847|NCT04099485|No Intervention|Current State|Clinicians of patients randomized to this arm will have access to the Atrial Fibrillation Decision-Support Tool (AFDST) embedded in our EHR (as they do now), but will not receive BPAs alerting them to patients who might benefit significantly from a change in anticoagulation treatment.
16382848|NCT04099485|Experimental|AFDST with BPA|Clinicians of patients randomized to this arm will receive BPAs when they are in the medical record of an AF patient who might gain significantly from a change in anticoagulation treatment. In addition, clinicians will have the ability to refer patients to a pharmacist-staffed AF Thromboprophylaxis Shared Decision-Making Service based in our Anticoagulation Clinic.
16382849|NCT04099472|Placebo Comparator|Control Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. The intervention group will also receive the same pamphlet.
16382850|NCT04099472|Experimental|Intervention Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. Additionally, they will receive delirium education on prevention and management of delirium.
16382854|NCT04099420||Spanish university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
16382855|NCT04099407|Experimental|Antifibrotic plus standard of care treatment|Prolonged release pirfenidone formulation in combination with standard of care treatment.
16382856|NCT04099394|Experimental|Behavioral Health|Ten behavioral health classes.
16382857|NCT04099394|Active Comparator|Health Education|Ten health education classes covering healthy aging.
16382858|NCT04099381|Experimental|Group 1 Low HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
16382859|NCT04099381|Experimental|Group 2 High HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or more HLA compatibility degree in A, B, DRB1 loci will be used.
16382860|NCT04099381|Other|Group 3 Control|Patients with standard therapy as a control group.
16382861|NCT04099368|Experimental|Auditory|Group receives training on listening to musical pitch differences between sounds as the first component of a crossover trial. The intervention is the listening exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
16382862|NCT04099368|Active Comparator|Visual|Group receives training on visual differences between objects on a computer screen as the first component of a crossover trial. This is a control measure for the auditory training exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
16382865|NCT04099342|Experimental|A: FEAST|Focally Electrically-administered Seizure Therapy (FEAST) is a form of Electroconvulsive therapy (ECT) that combines unidirectional stimulation, control of polarity, and an asymmetrical electrode configuration.
16382866|NCT04099342|Experimental|B: RP FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Polarity (RP) utilizes the same electrode placement as FEAST but a reversed directionality of current flow.
16382867|NCT04099342|Experimental|C: RC FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Configuration (RC) utilizes the same current flow as FEAST but a reversed electrode configuration.
16382868|NCT04099329|Experimental|Pre-game Safety Huddles|Pre-game safety huddles will occur before each game and athletes and coaches will be surveyed.
16382869|NCT04099329|No Intervention|Control|No intervention will be delivered by athletes and coaches will be surveyed.
16382870|NCT04099316|Experimental|Older adults|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
16382871|NCT04099316|Experimental|Older adults-Control|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
16382872|NCT04099316|No Intervention|No intervention|Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
16382873|NCT04099303|Experimental|Vaccine 1A|Subjects received one dose of DTaP aged 4 to 6 years.
16382874|NCT04099303|Active Comparator|Vaccine 1B|Subjects received one dose of DT aged 4 to 6 years.
16382875|NCT04099303|Experimental|Vaccine 2A|Subjects received one dose of DTcP aged 18 to 24 months.
16382876|NCT04099303|Active Comparator|Vaccine 2B|Subjects received one dose of DTaP aged 18 to 24 months.
16382877|NCT04099303|Experimental|Vaccine 3A|Subjects received three doses of DTcP at 3,4,5 months of age.
16382878|NCT04099303|Active Comparator|Vaccine 3B|Subjects received three doses of DTaP at 3,4,5 months of age.
16382879|NCT04099303|Active Comparator|Vaccine 3C|Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.
16382880|NCT04099303|Experimental|Vaccine 4A|Subjects received three doses of DTcP at 2,3,4 months of age.
16382881|NCT04099303|Active Comparator|Vaccine 4B|Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.
16382882|NCT04099303|Experimental|Vaccine 4C|Subjects received three doses of DTcP at 2,4,6 months of age.
16382883|NCT04099277|Experimental|Part A: 10 milligrams (mg) LY3435151|Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
16382884|NCT04099277|Experimental|Part B: LY3435151 + Pembrolizumab Dose Escalation|Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
16382885|NCT04099277|Experimental|Part C: LY3435151 Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
16382886|NCT04099277|Experimental|Part D: LY3435151 + Pembrolizumab Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
16382887|NCT04099264|Experimental|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
16382888|NCT04099264|Active Comparator|Control: Audio Books|Control will consist of audio books.
16382889|NCT04099251|Experimental|Nivolumab|
16382890|NCT04099251|Placebo Comparator|Placebo|
16382891|NCT04099238||Subjects with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018
16382892|NCT04099238||NVAF patients with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018 and had a diagnosis of NVAF prior to ischemic stroke (Subgroup)
16382893|NCT04099212||Cases|Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
16382894|NCT04099186|Experimental|hydro-mechanical pulmonary embolism fragmentation|Those patients will undergo catheter directed fragmentation followed by injection of 100 ml of heparinized saline via power injector
16382895|NCT04099186|No Intervention|thrombolytic treated arm|patients with high risk and intermediate high risk PE who received thrombolysis as only treatment modality
16382896|NCT04099173|Experimental|Brief Mindfulness Based Intervention|
16382897|NCT04099173|No Intervention|Treatment as Usual|
16382898|NCT04099147||ETHON|Subjects from the general population identified in the ETHON
16382899|NCT04099147||HEPAmet|Subjects belonging to the Spanish registry of NAFLD (HEPAmet)
16382900|NCT04099121|Other|Patients with Pelvic Organ Prolapse|Patients who meet the inclusion criteria will be recruited. Ultrasound images of the pelvic floor and vaginal cavity will be analyzed to predict pessary size and type. This will be compared against the pessary size and type being used already by the patient.
16382901|NCT04099108|Experimental|Intervention|Combined cycle ergometry and bolus amino acid supplementation, along with standard of care
16382902|NCT04099108|No Intervention|Control|Standard of care only
16382903|NCT04099095|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed
16382904|NCT04099095|Active Comparator|Delayed Appointment|Wait-list control group who receive Social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed
16382905|NCT04099082||Cases|eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
16382906|NCT04099082||Controls|eligible patients free of 10% FEV1 decline at 2 months
16382907|NCT04099069|Placebo Comparator|trachial intubation|patient was insert trachial intubation with normal frequency jet ventilation
16382908|NCT04099069|Experimental|rigid bronchoscopy|patient was insert trachial intubation with high frequency jet ventilation
16382909|NCT04099056|Active Comparator|Participants with Major Depressive Disorder (MDD)|Participants with MDD will complete computer tasks while receiving TMS.
16382910|NCT04099056|Active Comparator|Healthy Control|Participants without MDD will complete computer tasks while receiving TMS.
16382911|NCT04099043|Experimental|Continuous Monitoring|Single Arm, Randomized
16382912|NCT04099030||Opioid shortage|Patients undergoing laparoscopic cholecystectomy during time of Fentanyl drug shortage
16382913|NCT04099030||Normal Opioid supply (no shortage)|Patients undergoing laparoscopic cholecystectomy during time of normal Fentanyl drug supply
16382914|NCT04099017|Experimental|Mulligan mobilization group|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.
~The following are the brief detail of therapy
~Mulligan joint mobilization in Non-weight bearing (NWB):
~Knee strengthening
~Kinesiotaping"
16382915|NCT04099017|Experimental|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.
~The following are the brief detail of therapy:
~Trunk stabilization i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:
~Iv. lateral step up:
~Knee strengthening i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:
~Kinesiotaping:"
16382916|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.
~The following are the brief detail of therapy:
~Knee strengthening i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:
~Kinesio-taping:"
16382918|NCT04098991||Participants with primary hypothyroidism|All participants will receive the same treatment (levothyroxine, a synthetic T4 hormone replacement) at a dose that will be titrated using serum thyrotropin (TSH) levels as a goal, according to the American Thyroid Association Task Force recommendations
16382919|NCT04098978|Experimental|Pharmacist Drug Therapy Management|
16382920|NCT04098965|Experimental|Experimental|Physical Therapy Techniques
16382921|NCT04098965|Other|Control|physician treatment
16382922|NCT04098952|Active Comparator|Control group|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and myofascial technique for the decompression of the temporals.
16382923|NCT04098952|Experimental|Experimental group|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
16382924|NCT04098939||Healthy participants|Participants without any known cardiac or pulmonary disease.
16382925|NCT04098939||Heart disease participants|Participants with heart disease.
16382926|NCT04098939||Lung disease participants|Participants with lung disease.
16382927|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN0|Lymph node negative breast cancer
16382928|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN1|Lymph node positive breast cancer
16382929|NCT04098913|Experimental|Reduced screen-based media use|Reducing recreational screen-based media use for a period of 2 weeks.
16382930|NCT04098913|No Intervention|Control group|Participants are asked to continue their habitual screen-based media use.
16382931|NCT04098887|Experimental|Lattice stereotactic body radiation therapy|Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease. For lesions less than 4.5 cm, traditional SBRT will be used. For sites 4.5 cm or greater, Lattice SBRT will be used. For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
16382932|NCT04098874|Experimental|Bupropion|Participants randomized to extended-release bupropion. Once-daily
16382933|NCT04098874|Placebo Comparator|Placebo|Participants randomized to placebo. Once-daily
16382934|NCT04098861|Experimental|once daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.
~For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day."
16382935|NCT04098861|Experimental|twice daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.
~For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day."
16382936|NCT04098848|Experimental|Intradialytic exercise|Cycling exercise 30 minutes a time, three times a week during hemodialysis
16382938|NCT04098835|Experimental|ASCEND|ASCEND combines computer-based cognitive training exercises, homework exercises to enhance cognition, and coaching sessions delivered in-person and via telephone/videoconference by a neuropsychologist. ASCEND includes 24 total computer training sessions of 30 minutes each, for a total of 12 hours. ASCEND includes 8 coaching sessions of 45 minutes each. The computer exercises aim to improve attention, working memory (WM), and cognitive control through a series of engaging and interactive computer games (e.g., card games, driving simulation). The homework exercises and coaching sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to daily life and to develop further strategies to compensate for attention and WM difficulties in daily life.
16382939|NCT04098809|Active Comparator|Catheter 16 French|16 French urinary catheter
16382940|NCT04098809|Active Comparator|Catheter 20 French|20 French urinary catheter
16382941|NCT04098796|Experimental|Experimental: Anti-PD-1 antibody＋XELOX|Every patient will receive anti-PD-1 antibody (200 mg intravenous drip every 3 weeks) and XELOX regimen chemotherapy (Oxaliplatin 130 mg/m2, intravenous drip, d1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14;every 21 days). Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years. XELOX will be administered 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
16382942|NCT04098783|Experimental|Nursing interventions (home visit and health education) group|Nursing interventions group: Home visit, health education At the Intervention group; the researcher made pretest (baseline measurements) before the nursing interventions at the first home visit. The researcher offered education and guide about prevention of lymphedema after the baseline measurements at the first home visit. Second and third home visits were made three and six months after the first visit. At the second and the third home visits, the measurements were repeated, and the nursing interventions were maintained in the direction of the patients' individual needs.
16382943|NCT04098783|No Intervention|No Nursing interventions group|No Nursing interventions group; the researcher administered the pretests at first home visit. The measurements were repeated in the third and sixth months after the first home visit. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
16382944|NCT04098770|Experimental|Conventional treatment plus Allogeneic Adoptive Immune Therapy|Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
16382945|NCT04098770|No Intervention|Conventional treatment|Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received
16382946|NCT04098757||Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
16382947|NCT04098757||acupuncture|2 sessions a week, for a total of 10 (5 weeks), performed by the same operator, repeatable if necessary, after a therapeutic interval of at least one month. Each session lasts about 20-30 minutes per patient. Tewa J Type sterile disposable needles, coated, with a Chinese-style copper wire handle, with a guide tube, of 22x13 mm (CJ 2213) and 30x25 mm (CJ 3025) will be used. Acupuncture will be carried out by same trained operator.
16382948|NCT04098744|Experimental|Artesunate vaginal insert|Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
16382949|NCT04098744|Placebo Comparator|Placebo vaginal inserts|Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4. Unblinding will take place at week 15. Participants who do not have histologic regression at week 15 will have the opportunity to cross over to the experimental arm, and start treatment with artesunate vaginal inserts within 4 weeks of the week 15 visit.
16382950|NCT04098718|Other|PO open label prednisolone (in low blood eosinophils)|Standard care Prednisolone 30mg given daily for 5 days to treat an exacerbation.
16382951|NCT04098718|Experimental|Benralizumab SC + PO placebo|Benralizumab as a single 100mg sub cut injection and oral placebo tablet daily for 5 days
16382952|NCT04098718|Experimental|Benralizumab SC + PO prednisolone|Benralizumab as a single 100mg sub cut injection and oral prednisolone 30mg daily for 5 days
16382953|NCT04098718|Active Comparator|Placebo SC + PO prednisolone|Placebo sub cut injection and oral prednisolone 30mg daily for 5 days.
16382954|NCT04098705|No Intervention|Pre-intervention|Pre-intervention period
16382955|NCT04098705|Experimental|Post-intervention|Post-intervention period
16382956|NCT04098692|Experimental|Single-Arm: Derazantinib (Part 1 and Part 2)|"Part 1: 300 mg Derazantinib oral administration followed by 100 μg [14C]-Derazantinib intravenous microdose
~Part 2: 300 mg [14C]-Derazantinib oral administration"
16382957|NCT04098666|Experimental|metformin users|Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
16382958|NCT04098666|Placebo Comparator|metformin non-users|Placebo tablets identical to dxtended release metformin 500 mg tablets up to 4 tablets a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
16382959|NCT04098653|Experimental|Decitabine + BUCY|For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16382960|NCT04098653|Active Comparator|BUCY|For myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16382961|NCT04098640|Other|FMI|FoundationOne CDx will be performed using archival tumor tissue
16382962|NCT04098627|Experimental|Intervention|Once weekly 30-minute long group laughter therapy session for 8 weeks while patients are on dialysis
16382963|NCT04098627|No Intervention|Usual Care|Usual care
16382988|NCT04098445||Pediatric and young adult HSCT recipients|Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).
16387631|NCT04066712|Experimental|D: Severe impairment renal function|
16382964|NCT04098614|Experimental|Recovery Coach Intervention|"Experimental: Recovery Coach Intervention Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR)
~- Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants."
16382965|NCT04098614|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
16382966|NCT04098601|Experimental|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
16382967|NCT04098601|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
16382968|NCT04098588|Experimental|BEAST|There are 3 parts to BEAST. Part 1 involves the Behavioral Nudge technique using previously collected injunctive and descriptive norms from a National Guard sample. Soldiers will be given a customized feedback form that shows norms relevant to the target behavior they selected. The soldier will be given a chance to ask any follow-up questions. Part 2 of the intervention focuses on the principle of targeting others, considering how a change would impact those closest to them. Part 3 will utilize the Reciprocal Concessions procedure combined with the Reducing Barriers technique.
16382969|NCT04098588|Active Comparator|Descriptive Feedback|This condition will involve a presentation of descriptive data based on the soldiers' tests scores and an opportunity to ask any follow-up questions. This process is a component of some behavioral change interventions (e.g., motivational interviewing); therefore this should be a more useful control condition (mirroring parts 1 and 2 of the active condition) versus a more passive or waitlist control condition. Participants in the control condition will also be given standard referral information to the USM Psychology Clinic (mirroring part 3 of the active condition).
16382970|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
16382971|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
16382972|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
16382973|NCT04098562|Experimental|Treatment|0.5 mg/mL LL-37 cream, administered twice a week for 4 weeks
16382974|NCT04098562|Placebo Comparator|Placebo|Placebo cream, administered twice a week for 4 weeks
16382975|NCT04098549|Experimental|Rapid-Slow|"This arm will begin with intervention rapid (rapid rate of fall in plasma glucose) for the first study visit and proceed to intervention slow (slow rate of fall in plasma glucose) for the second study visit."
16382976|NCT04098549|Experimental|Slow-Rapid|"This arm will begin with intervention slow (slow rate of fall in plasma glucose) for the first study visit and proceed to intervention rapid (rapid rate of fall in plasma glucose) for the second study visit."
16382977|NCT04098536|Experimental|Diesel Exposure|
16382978|NCT04098536|Placebo Comparator|Filtered Air Exposure|
16382979|NCT04098523|Other|Epidemiologic screening|All subjects are screened by duplex ultrasound for abdominal aortic aneurysm (AAA) and carotid artery stenosis (CAS). A questionnaire is completed to obtain information on demographic information, risk factors as well as prior treatment for AAA or CAS and current medication. No treatment is given.
16382980|NCT04098510|Experimental|MitoQ|Subjects ingest 160 mg of MitoQ
16382981|NCT04098497|Experimental|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.
~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).
~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
16382982|NCT04098484|Active Comparator|Normal-weight|Subjects with a BMI of 18-25 kg/m2
16382983|NCT04098484|Experimental|Obese|Subjects with a BMI of > 30 kg/m2
16382984|NCT04098471|Experimental|single transanal loca excision|
16382985|NCT04098471|Experimental|transanal local excision following radiotherapy|
16382986|NCT04098471|Experimental|total mesorectal excision|
16382987|NCT04098458|Experimental|NDURE|NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.
16382989|NCT04098432|Experimental|Arm 1|4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks
16382992|NCT04098406|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
16382993|NCT04098406|Experimental|30 mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
16382994|NCT04098393|Experimental|patients hematologic malignancies other than multiple myeloma|A. Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels. B. Melphalan (70mg/m2/day) administered on days -6 and -5. C. Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
16382995|NCT04098393|Experimental|patients with multiple myeloma|A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
16382996|NCT04098380|Active Comparator|Small bite|The needle bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
16382997|NCT04098380|Active Comparator|Large bite|The needle bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
16382998|NCT04098367|Experimental|VIVITY|VIVITY IOL implanted in the eye during cataract surgery
16382999|NCT04098367|Active Comparator|SYMFONY|SYMFONY IOL implanted in the eye during cataract surgery
16383000|NCT04098367|Active Comparator|AT LARA|AT LARA implanted in the eye during cataract surgery
16383001|NCT04098354|Active Comparator|home-based BP telemonitoring|The intervention is a working prototype of a home BP telemonitoring system whereby a patient pushes a single button on a home BP monitor to initiate measurement, and data are auto-transmitted via Bluetooth to an Android smartphone and relayed to a secured web portal for review. Patients will receive a validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) and an Android smartphone. Patients will take four measurements daily for 1 week. If BP is uncontrolled (high or low), this 1-week protocol will be followed each month until BP is in the therapeutic range. Once controlled, the 1-week protocol will be repeated every 3 months. Teletransmitted BP readings will be summarized within the health portal using telemonitoring software to the study case manager, who will also review telemonitored health portal BP summaries, make protocol-based therapeutic adjustments and send summaries to participants' PCPs to inform them of treatment changes.
16383002|NCT04098354|Placebo Comparator|usual care|For the control arm (usual standard care), participants' home BP series mean, trends, and individual readings will be sent via secure electronic medical records (EMR) to their PCP along with a 1-page summary of Canadian guidelines for BP thresholds, targets, and treatments relevant for CKD.
16383003|NCT04098341|Other|Screening|All eligible migrants will be offered opt-out IGRA blood test to screen for for latent Tuberculosis infection
16383004|NCT04098302|Active Comparator|dutasteride|two 0.5 mg capsules of dutasteride daily
16383005|NCT04098302|Placebo Comparator|placebo capsule|inactive placebo matched in appearance with dutasteride capsules
16383006|NCT04098289||Hysteroscopic septum resection without in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with natural conception (without the use of in vitro fertilization techniques).
16383007|NCT04098289||Hysteroscopic septum resection with in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
16383008|NCT04098289||Natural conception, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with natural conception (without in vitro fertilization techniques).
16383009|NCT04098289||In vitro fertilization, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
16383010|NCT04098276|Experimental|Online weWomen Intervention|For first stage randomization, women in the intervention group receive the online safety planning intervention informed by culturally specific danger assessment (DA) tool.
16383011|NCT04098276|No Intervention|Online usual care or no treatment control|Women in the control group receive the non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
16383012|NCT04098276|Experimental|WeWomen Plus Text messaging only|For second stage randomization, the text messaging intervention will follow-up with non-responder group of immigrant women (those who did not improve in intervention or control arms above) on their enactment of tailored (tailored to the DA Score and priorities) safety plan provided in the online weWomen intervention or non-tailored (standard list of resources) safety recommendations provided in the usual care control arm
16383013|NCT04098276|Experimental|WeWomen Plus Text messaging and phone|Second stage randomization will involve both text (described above) and phone calls for non-responder group of women in intervention or control arm. The phone calls will draw from motivational interviewing adapted for abused women, solution focused therapy and a strengths perspective to discuss women's safety concerns and other needs, and strategies to strengthen social support networks
16383014|NCT04098263|Active Comparator|Part B: Cohort 1|300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days
16383015|NCT04098263|Active Comparator|Part B: Cohort 2|1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days
16383016|NCT04098263|Active Comparator|Part B: Cohort 3|3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days
16383017|NCT04098263|Other|Part A|3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally
16383018|NCT04098250|Experimental|Erenumab|140 mg erenumab
16383019|NCT04098250|Placebo Comparator|Placebo|placebo comparator
16383020|NCT04098237|Experimental|Standard of care treatment with Pancreaze (pancrelipase)|Pancrelipase capsules; 84,000 IU lipase units per main meal and 42,000 IU lipase units per snack; for 24 weeks
16383023|NCT04098198||Participants with an Inborn Error of Metabolism|Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years
16383024|NCT04098172|Experimental|Pressure Guidewire test subject|Stable patients with suspected or known CAD, who are scheduled for diagnostic angiography and pressure wire assessment, and signed the informed consent, will be screened for enrollment in this study.
16383025|NCT04098159|Experimental|ESRD Patients have functioning or failing VAs (AVFs or AVGs).|
16383026|NCT04098146||Mandibular Reconstruction|Patients undergoing segmental mandibular defect reconstruction. The decision of one stage or two stage reconstruction is done according to the patient and treating surgeon preferences following the local standard of care
16383027|NCT04098107|Experimental|Throwing Device Phase 1|During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
16383028|NCT04098081|Experimental|galeterone|galeterone orally once daily
16383029|NCT04098081|Experimental|galeterone+gemcitabine|daily dose galeterone and weekly dose of gemcitabine
16383030|NCT04098068|Experimental|MSI (Microsatellite Unstable) Negative with Mutator Phenotype|
16383031|NCT04098055|Experimental|Custom-made foot orthoses|
16383032|NCT04098055|Placebo Comparator|Control Group|
16383033|NCT04098042||Scaffold|"Patients receiving during PCI the implantation of at least one Magnesium Made Bioresorbable Scaffold Magmaris"
16383034|NCT04098029|Experimental|Group 1 Low HLA compatibility|The patients in the first group will receive two CBU of low-level HLA matched infusions within a 6-month interval. The low-level match is 3 or less HLA compatibility degree by A, B, DRB1 loci.
16383035|NCT04098029|Experimental|Group 2 High HLA compatibility|The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
16383036|NCT04098029|Other|Standard therapy|Patients with standard therapy as a control group
16383037|NCT04098016|Experimental|Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training.
16383038|NCT04098003|Experimental|Rosuvastatin|rosuvastatin 20 mg daily for eight weeks
16383039|NCT04098003|Placebo Comparator|Placebo|placebo daily for eight weeks
16383040|NCT04097990|Other|healthy participants|healthy participants
16383041|NCT04097990|Other|hypertriglyceridemia without prior pancreatit|
16383042|NCT04097990|Other|hypertriglyceridemia and at least one case of|
16383043|NCT04097977|Experimental|Intervention: RENEW in a psychiatric ward|Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group that will form the basis of real user involvement.
16383044|NCT04097977|No Intervention|Conventional clinical practice in a psychiatric standard ward|The comparison group patients were admitted to a standard psychiatric ward that offered conventional care.
16383047|NCT04097951|Experimental|Montelukast|
16383048|NCT04097951|Experimental|Bepotastine|
16383049|NCT04097951|Experimental|Montelukast + Bepotastine|
16383050|NCT04097938|Experimental|GLPG3667 SAD|Single doses of GLPG3667 at up to 6 dose levels in ascending order
16383051|NCT04097938|Placebo Comparator|Placebo SAD|Single doses of placebo
16383052|NCT04097938|Experimental|GLPG3667 MAD|Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days
16383053|NCT04097938|Placebo Comparator|Placebo MAD|Multiple doses of placebo
16383054|NCT04097938|Experimental|GLPG3667 FE fasted|Single dose of GLPG3667 in fasted state
16383055|NCT04097938|Experimental|GLPG3667 FE fed|Single dose of GLPG3667 in fed state
16383056|NCT04097938|Experimental|GLPG3667 oral suspension rBA-FE fed|Single dose of GLPG3667 oral suspension in fed state
16383057|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fasted|Single dose of GLPG3667 capsules in fasted state
16383058|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fed|Single dose of GLPG3667 capsules in fed state
16383059|NCT04097925|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks
16383060|NCT04097912||Low-dose aspirin users|Patients who receive low-dose aspirin (75-100mg) for either the primary or secondary prevention of cardiovascular disease (CVD).
16383061|NCT04097899||Group A in preimplementation phase|Patient and antibiotic related data were collected to calculate and define; ventilator associated pneumonia incidence, mean ventilation days and mean length of stay, antibiotic selection, antibiotic cost, antibiotic susceptibility pattern, antibiotic consumption.
16383062|NCT04097899||Group B in postimplementation phase|The appropriateness of antibiotic use (selection, initiation, duration & time of discontinuation) before and after implementing the educational program was compared, calculation of the change in the ventilator associated pneumonia incidence & length of ICU stay, calculation of the change in the rate of antibiotic resistance and calculation of the cost change of antibiotics used after implementing the educational program.
16383063|NCT04097886|Experimental|Morning Exercise Group|Participants perform moderate exercise in the morning.
16383064|NCT04097886|Experimental|Evening Exercise Group|Participants perform moderate exercise in the evening.
16383065|NCT04097873|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
16383066|NCT04097873|Active Comparator|Isolated high-intensity inspiratory muscle training|
16383067|NCT04097860|Experimental|Intervention group|Will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
16383068|NCT04097860|No Intervention|Control group|Will only be sent text messages that include the same general lactation information sent to the treatment group
16383069|NCT04097834||PrEP Prescription at Enrollment|
16383070|NCT04097834||No PrEP Prescription at Enrollment|
16383071|NCT04097821|Experimental|Part 1 Arm 1: Ruxolitinib + Siremadlin|Dose escalation of siremadlin added to existing stable dose of ruxolitinib
16383072|NCT04097821|Experimental|Part 1 Arm 2: Ruxolitinib + Crizanlizumab|Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib
16383073|NCT04097821|Experimental|Part 1 Arm 3: Ruxolitinib + Sabatolimab|Safety run-in of Sabatolimab added to existing stable dose of ruxolitinib
16383074|NCT04097821|Experimental|Part 2 Arm 1: Ruxolitinib + Siremadlin|Siremadlin added to existing stable dose of ruxolitinib
16383075|NCT04097821|Experimental|Part 2 Arm 2: Ruxolitinib + Crizanlizumab|Crizanlizumab added to existing stable dose of ruxolitinib
16383076|NCT04097821|Experimental|Part 2 Arm 3: Ruxolitinib + Sabatolimab|Sabatolimab added to existing stable dose of ruxolitinib
16383077|NCT04097821|Active Comparator|Part 2 Arm 6: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 2
16383078|NCT04097821|Experimental|Part 3 Arm 1: Ruxolitinib + Compound X|Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib
16383079|NCT04097821|Experimental|Part 3 Arm 2: Ruxolitinib cessation|Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy
16383080|NCT04097821|Active Comparator|Part 3 Arm 3: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 3
16383081|NCT04097821|Experimental|Part 1 Arm 4: Ruxolitinib + LTT462|Dose escalation of LTT462 added to existing stable dose of ruxolitinib
16383082|NCT04097821|Experimental|Part 1 Arm 5: Ruxolitinib + NIS793|Safety run-in of NIS793 added to existing stable dose of ruxolitinib
16383083|NCT04097821|Experimental|Part 2 Arm 4: Ruxolitinib + LTT462|LTT462 added to existing stable dose of ruxolitinib
16383084|NCT04097821|Experimental|Part 2 Arm 5: Ruxolitinib + NIS793|NIS793 added to existing stable dose of ruxolitinib
16383085|NCT04097808|Experimental|collagen peptide bovine high molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
16383086|NCT04097808|Experimental|collagen peptide bovine low molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
16383087|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 1|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1
16383088|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 2|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2
16383089|NCT04097808|Experimental|collagen peptide fish low molecular weight-Water|source: fish; standardized to 10 g provided as single dose. Orally applied in water.
16383090|NCT04097808|Experimental|collagen peptide porcine low molecular weight-Water|source: porcine; standardized to 10 g provided as single dose. Orally applied in water.
16383091|NCT04097795||Prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which offer prehabilitation.
16383092|NCT04097795||No prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which do not offer prehabilitation.
16383093|NCT04097782|No Intervention|Control Group|"Prior to the study, primiparous pregnant women presented to the outpatient clinic for routine pregnancy control were introduced with free prenatal education classes and they were invited to participate in the study.
~Primiparous women who volunteered to participate in the study and met the inclusion criteria were included in the study and they formed the experimental and control group. Control group did not receive antenatal education and they received prenatal care service routinely provided at the polyclinics of the same hospital."
16383094|NCT04097782|Experimental|Experimental Group|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
16383095|NCT04097769|Other|HX009|Study treatment: HX009 administered every 2 weeks (14 [±1] days) via intravenous infusion.
16383096|NCT04097756|Experimental|Part1：dose escalation|The investigational product for this study is LX-039 tablets,which can be administered orally. 6~8 ascending dose level until MTD and the specification included 50 mg, 100 mg, 200 mg, 400 mg, 600 mg , 800 mg,1050 mg and 1400 mg. LX-039 tablets will be administered in a therapeutic cycle of 28 days once a day orally. The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
16383097|NCT04097756|Experimental|Part 2：dose expansion|2~3 selected tolerable dose will be selected according to the tolerance and FES PET results of dose escalation phase.The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
16383098|NCT04097743|Experimental|Coping statement|Daily practice of pain coping statements for 7 days
16383099|NCT04097743|No Intervention|Control|No instruction about pain coping statement.
16383210|NCT04096989|Sham Comparator|Sham comparator group|The participants accept mobile health application intervention.
16383100|NCT04097730|Placebo Comparator|Standard Therapy|Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.
16383101|NCT04097730|Experimental|Early Steroids|Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.
16383102|NCT04097730|Experimental|Cross-Linking plus Early Steroids|Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.
16383103|NCT04097717|Experimental|Decision Aid Arm|Participants will use the web-based decision aid plus usual medical care.
16383104|NCT04097717|Other|Usual Care Arm|Participants will receive usual medical care.
16383105|NCT04097691||on subcutaneous glucose|this group was on subcutaneous glucose 0.5 ml per site around subcutaneous nerves in the foot region both on palm and sole.which is repeated every 2 weeks for 2 months.
16383106|NCT04097691||control(not receiving treatment)|the second group is considered as control.received no treatment.
16383107|NCT04097678|Experimental|Retained Sponge Group|Just prior to imaging, the surgeon will purposely place a sponge in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
16383108|NCT04097678|No Intervention|No Retained Sponge Group|No sponge will be placed in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
16383109|NCT04097665||patients with expanded flaps|Patients will undergo tissue expansion. When the expanded flaps are harvested and transplanted, ICGA will be conducted intraoperatively. Meanwhile, the possible area of necrosis will be marked according to clinical experience. And then this area will be further divided into perfusion units (1*1 square centimeter for each). The center of each perfusion unit will be marked as observation point, of which the fluorescence value will be recorded. After 1 week's follow-up postoperatively, the flap tissue will be determined by superimposing digital photography over ICGA imaging results, and the outcome of each observation point will be recorded. By analyzing the fluorescence value and outcome of each observation point, a cut-off point can be further identified to achieve both higher positive and negative predictive value, improving the utility and accuracy of ICGA in predicting the postoperative skin viability of expanded flaps.
16383110|NCT04097652|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
16383111|NCT04097626|Experimental|experimental|This group will receive nutrition education during the first week of the study. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
16383112|NCT04097626|Active Comparator|control|This group will receive no nutrition education. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
16383113|NCT04097613|Experimental|Betadine Treatment|Study subjects will use betadine saline sinus rinse for period of 6 weeks.
16383114|NCT04097600|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
16383115|NCT04097600|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
16383116|NCT04097600|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
16383117|NCT04097600|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
16383118|NCT04097600|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
16383119|NCT04097600|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
16383120|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
16383121|NCT04097574|Active Comparator|NPO-13 0.8%|Low dose
16383122|NCT04097574|Active Comparator|NPO-13 1.6%|High dose
16383123|NCT04097574|Placebo Comparator|NPO-13 0%|Placebo
16383124|NCT04097561|Experimental|Single arm, open-label|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
16383125|NCT04097548|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care.
16383126|NCT04097548|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care.
16383127|NCT04097522|Active Comparator|real neurofeedback|Participants receive neurofeedback from a region of the brain thought to be associated with increasing pain resilience
16383128|NCT04097522|Sham Comparator|sham neurofeedback|Participants receive neurofeedback from a region of the brain thought to be unrelated with increasing pain resilience
16383129|NCT04097509|Experimental|autologous fibrin glue (AFG) group|In the test groups, polymerized AFG was applied to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
16383130|NCT04097509|Experimental|injectable platelet rich fibrin (i-PRF) group|In the test groups, polymerized i-PRF was applied to the donor area. Donor palate was closed with sterile aluminum foil and periodontal pack.
16383131|NCT04097509|Placebo Comparator|Control Group|In the control group, only moist sterile tamponade was applied following graft removal to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
16383132|NCT04097496|Experimental|Act Out! Intervention|Eligible classrooms will be randomized to attend a 1-hour ACT OUT! interactive, semi-improvisational psychodrama performance. The ACT OUT! intervention is an established theater program (https://www.claudemcnealproductions.com/act-out-ensemble/). The ACT OUT! production will include three to five vignettes paired with moderated discussions between the audience and the actors, the latter who will remain partly in character for the duration of the intervention. Vignettes will be different for each grade level included in the study (4th, 7th, and 10th). Public documentation of the guidelines for the ACT OUT! intervention will be made available as a supplemental file attached to the primary outcomes paper for the study.
16383211|NCT04096976||Hospital survival|
16383212|NCT04096976||No hospital survival|
16383133|NCT04097496|No Intervention|Control|Classrooms randomized to this arm will continue with their school day as normal, except that they will complete the data collection tools.
16383134|NCT04097483|Experimental|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention, centered on motivational interviewing and cognitive behavioural therapy for adherence and depression.
16383135|NCT04097483|No Intervention|Control group|Control group with treatment as usual (TAU).
16383136|NCT04097470|Active Comparator|Arm A: Decitabine|"Cycles 1-3: Decitabine 10-day; depending on day +28 bone marrow (BM) blasts after the previous cycle, next cycle consists of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks); continuation of these cycles until progression.
~Dosage for Decitabine 20 mg/m2 i.v."
16383137|NCT04097470|Experimental|Arm B: Decitabine and Midostaurin|"Cycle 1:Decitabine; 10-day schedule (start day +1) + midostaurin (start day +11). Midostaurin is given until 2 days before start next cycle of decitabine. Cycles 2-3: Decitabine 5 or 10-day schedule; depending on day +28 bone marrow blasts of the previous cycle, next cycle consist of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine + midostaurin (daily, starting the day after the last dose of decitabine (i.e. day +6 or +11). Midostaurin is given until 2 days before start next cycle. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks) followed by midostaurin starting at day +6 until two days before start of next cycle of decitabine; continuation of these cycles until progression. Midostaurin is given until 2 days before start next cycle of decitabine.
~Dosage for Decitabine 20 mg/m2 i.v.
~Dosage for Midostaurin 50 mg b.i.d."
16383138|NCT04097457|Experimental|Parent mediated intervention (PMI) group|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. The protocol is administered to groups of 4 families.
16383139|NCT04097457|Experimental|Waitlist control|Families will be recruited and will fill out measure for 3 months prior to participation and will then join the active intervention
16383140|NCT04097457|Experimental|Individual|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. In this arm the protocol is administered individually to families.
16383141|NCT04097444|Experimental|Step 1 (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.
~[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
16383142|NCT04097444|Experimental|Step 2 Arm A (FOLFOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment: FOLFOXIRI+BEV] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks."
16383143|NCT04097444|Experimental|Step 2 Arm B (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.
~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
16383144|NCT04097431|Experimental|Precursors as Response Chain or Class|The precursor behavior occurs as a part of a sequence, or for the same maintaining variable, leading up to the severe problem behavior.
16383145|NCT04097418|Experimental|Aerobic training in healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
16383146|NCT04097418|Active Comparator|Conventional motor training of healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
16383213|NCT04096963||The WATCHMAN FLX Delivery System|Patients who are eligible for a WATCHMAN FLX device according to current international and local guidelines (and future revisions) and per physician discretion;
16383214|NCT04096950|Experimental|MT-3921|Intravenous, single dose
16383147|NCT04097418|Experimental|Aerobic training in MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
16383148|NCT04097418|Active Comparator|Conventional motor training of MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
16383149|NCT04097405|Active Comparator|D-0120 Dose Ascending Cohorts 1-4|D-0120 dose daily for up to 7 days.
16383150|NCT04097405|Placebo Comparator|Placebo Dose Ascending Cohorts 1-4|Placebo dose daily for up to 7 days
16383151|NCT04097405|Experimental|D-0120/Uric Acid Lowering Agent Cohort 6|D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy
16383152|NCT04097392|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
16383153|NCT04097392|Active Comparator|Isolated high-intensity inspiratory muscle training|
16383154|NCT04097379|Experimental|LRX712 Arm 1|"Randomized in a 1:1:1 ratio:
~LRX712 Arm 1:LRX712 Arm 2:placebo"
16383155|NCT04097379|Placebo Comparator|Placebo|"Randomized in a 1:1:1 ratio:
~LRX712 Arm 1:LRX712 Arm 2:placebo"
16383156|NCT04097379|Experimental|LRX712 Arm 2|"Randomized in a 1:1:1 ratio:
~LRX712 Arm 1:LRX712 Arm 2:placebo"
16383157|NCT04097366|No Intervention|Standard of Care|Control arm, no supplementary imaging is given. Participants have mammographic screening 3-yearly as per current standard of are.
16383158|NCT04097366|Active Comparator|Abbreviated MRI (ABB-MRI)|Supplementary imaging with abbreviated MRI at study entry and 18 months after baseline mammogram.
16383159|NCT04097366|Active Comparator|Automated Breast Ultrasound (ABUS)|Supplementary imaging with automated breast ultrasound at study entry and 18 months after baseline mammogram.
16383160|NCT04097366|Active Comparator|Contrast Enhanced Mammography (CESM)|Supplementary imaging with contrast enhanced spectral mammography at study entry and 18 months after baseline mammogram.
16383161|NCT04097353|Experimental|Harvesting Hope for Kids (HH4K)|Eight weekly, 60-minute sessions at a university-based farm with booster sessions. Learning is structured around fun activities to provide information about the impact of cancer treatment on children's health, as well as the importance of nutrition and physical activity in survivorship. Each session is manualized and devoted to education, a behavioral strategy applied toward a weekly goal, a cooking demonstration/taste testing, and harvesting produce from the survivor garden. Modules are offered in a group format with families together.
16383162|NCT04097353|Sham Comparator|Surviving Strong for Kids (SS4K)|Families assigned to enhanced usual care (SS4K) group will receive education in the form of standardized guidelines for nutrition and physical activity for survivors of childhood cancer. In a one-hour session, they will learn about the impact of cancer treatment on health and the importance of nutrition and physical activity for survivors. Families will receive websites for other educational resources. They will not have access to harvesting, remote coaching, the web portal, or behavioral training to address their child's nutrition or activity.
16383165|NCT04097314|Experimental|Zibotentan|
16383166|NCT04097314|Placebo Comparator|Placebo|
16383167|NCT04097301|Experimental|MLM-CAR44.1 T-cells infusion|"PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.
~PHASE IIa: i.v. dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD)."
16383168|NCT04097288|Experimental|Single dose citalopram|A blinded single dose 40 mg citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
16383169|NCT04097288|Active Comparator|Single dose reboxetine|A blinded single dose 8 mg reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
16383170|NCT04097288|Placebo Comparator|Single dose placebo citalopram|A blinded single dose visually identical placebo pill to citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
16383171|NCT04097288|Placebo Comparator|Single dose placebo reboxetine|A blinded single dose visually identical placebo pill to reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
16383172|NCT04097275||Participants with an Inborn Error of Metabolism|
16383173|NCT04097262|Experimental|Own-Price Elasticity|"The price of fruit will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
16383174|NCT04097262|Experimental|Cross-Price Elasticity|"The price of fruit will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
16383175|NCT04097249||Healthy subjects|Participants free from any pain specific to the upper limb, chronic pain or other disease.
16383178|NCT04097223||Subjects with Pulmonary Disease, Chronic Obstructive|
16383179|NCT04097197|Experimental|Patients receiving information|Patients in the experimental arm will receive a brief educational intervention if they initially refuse flu vaccination. The intervention was designed towards the most common barriers to flu vaccination that were found after a brief review of the literature. After the intervention, patients will be asked again whether or not they wish to receive the flu vaccine.
16383180|NCT04097184|Active Comparator|"active tDCS group"|Patients will benefit from a series of 10 double-blind effective tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
16383181|NCT04097184|Sham Comparator|"sham tDCS group"|Patients will benefit from a series of 10 double-blind placebo tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
16383182|NCT04097171|Experimental|High Carbohydrate Diet|Participants will consume a high carbohydrate diet (65-75% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
16383183|NCT04097171|Experimental|Ketogenic Diet|Participants will consume a low carbohydrate diet (<5-10% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
16383184|NCT04097158||Upper Motor Neuron predominant ALS|
16383185|NCT04097158||Lower Motor Neuron predominant ALS|
16383186|NCT04097158||Bulbar predominant ALS|
16383187|NCT04097158||Generalized ALS|
16383188|NCT04097145|Experimental|Edwards PASCAL System & OMT|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
16383189|NCT04097145|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
16383190|NCT04097132||ischemic stroke patients|all patient admitted with acute ischemic stroke either their ECG was AF or sinus rythm
16383191|NCT04097119|Other|Dietary supplement arm|Subjects to receive a specific dietary supplement
16383192|NCT04097106||Lean BMI (19-25)|
16383193|NCT04097106||Obese BMI (30-35)|
16383194|NCT04097093||Study 62005-STBSG patients treated with imatinib > 10 years|
16383195|NCT04097080|Experimental|NBTX-001|30% medical grade xenon/70% Oxygen
16383196|NCT04097080|Placebo Comparator|Standard of Care|Reconstituted air
16383197|NCT04097067|Experimental|Treatment (low-dose radiation therapy)|"Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT & IGRT).
~Blood draw for biomarker-analysis (at baseline visit/ after 4 Gy/ after 10 Gy / after 20 Gy RT/ at 3 and 6 months after RT)"
16383198|NCT04097054|Experimental|Intervention|Patients in the interventional arm are operated after augmented planning of the procedure. The plan is prepared by the surgeon and made available to the study team a day prior to the procedure and on a screen in the OR during the procedure. The plan includes the current and next operative step, the used equipment and the approximate time used as well as the estimated time of when the procedure will end.
16383199|NCT04097054|No Intervention|Control|In the control cases no particular planning and distribution of operative plan is performed. The standard preparation only includes the distribution of information on the desired positioning of the patient, necessary special equipment and the overall estimated OR time.
16383200|NCT04097041|Active Comparator|Surgical Arm|Surgery arm - patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).Patient has routine follow up - H&P, 2 weeks after surgery and then H&P, Audiometry and Tympanometry over 12 months post surgery (3rd month, 6th month and 12th month).
16383201|NCT04097041|Active Comparator|Non-Surgery|"Non surgery arm - patient has audiological consult and fitting of masking device.
~The Patient has a routine follow up - H&P, 2 weeks after masking fitting and then H&P, Audiometry, Tympanometry over 12 months (3rd month, 6th month and 12th month). Patient cross over to change arms, at 6 months, if they have no resolution of symptoms."
16383202|NCT04097028|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care chemoradiation therapy followed by surgery.
16383203|NCT04097015|Experimental|Treatment|The treatment or intervention is the use of NI-ES using a signal generator, Alpha-Stim M, with an Ocular Interface connected to one channel and a Spinal Interface to the other channel. The treatment is done at home for 40 minutes at a time, twice a day. The upper lids of the closed eyes are treated for 10 minutes and the lower lids of the closed eyes are treated for 10 minutes, alternated throughout the treatment time. The Spinal Interface is placed above the SCI for 40 minutes. The entire procedure is repeated for another 40 minutes for a second time. The participant will treat himself at home.
16383204|NCT04097002|Experimental|Phase I, Part A, Cohort 1|"Single dose-escalation of ORCA-010, Dose Cohort 1: 1x10*11 viral particles.
~Single dose of ORCA-010 will be administered for the first subject only and all relevant safety data for this subject will be reviewed by the DSMB prior to enrolling additional subjects.
~After the DSMB review, subjects will be enrolled in groups of three (including the first subject) and assessed for safety and Dose-Limiting Toxicity (DLT) after a single dose of ORCA-010.
~Group of 3 subjects.
~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
16383205|NCT04097002|Experimental|Phase I, Part A, Cohort 2|"Single dose-escalation of ORCA-010, Dose Cohort 2: 5x10*11 viral particles.
~Group of 3 subjects.
~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
16383206|NCT04097002|Experimental|Phase I, Part A, Cohort 3|"Single dose-escalation of ORCA-010, Dose Cohort 3: 1.5x10*12 viral particles.
~Group of 3 subjects.
~Dose will be considered as the Maximum Tolerated Dose based on safety and toxicity results from the 3 treated subjects."
16383207|NCT04097002|Experimental|Phase IIa, Part B, Cohort 4|"Two dose administration of ORCA-010 seperated by 2 weeks, Dose Cohort 4: The Maximum Tolerated Dose depending on Phase I/ Part A results.
~Group of 12 subjects."
16383208|NCT04096989|No Intervention|Control group|Routine care.
16383209|NCT04096989|Experimental|Experimental group|The participants accept TCM regimen-based lifestyle mobile health application intervention.
16383215|NCT04096937||Appalachian adults|Adults in Appalachia invested in well-being of youth.
16383216|NCT04096937||Appalachian youth|Youth from 7th through 12th grade.
16383217|NCT04096924|Experimental|Treatment Group|Experimental group is allocated to use novel interventional guidewire for the echocardiography guided percutaneous interventions for ASD.
16383218|NCT04096924|Active Comparator|Control Group|Control Group is allocated to use Cook lunderquist guidewire for the echocardiography guided percutaneous interventions for ASD.
16383219|NCT04096911|Experimental|Sintilimab and HPV Vaccine|Sintilimab 200 mg intravenously every 3 weeks ，3 doses of quadrivalent HPV vaccine intramuscularly at day 1,60,180
16383220|NCT04096885||InSurg cohort|Patients who undergo elective or emergency surgery at the Department of Visceral Surgery and Medicine, Inselspital, Bern, who gave informed consent.
16383222|NCT04096833|Experimental|Intervention Group|Participants use as a distracting measure Virtual Reality glasses during the vaccination.
16383223|NCT04096833|No Intervention|Control Group|Participants use usual non-virtual distracting measures during the vaccination.
16383225|NCT04096781|Experimental|Shared Decision Making Tool (SDMT)|
16383226|NCT04096781|Active Comparator|Usual Care|
16383227|NCT04096768|Experimental|Dexmedetomidine + Ketamine|
16383228|NCT04096768|Placebo Comparator|Dexmedetomidine + Placebo|
16383229|NCT04096755||DVT group|40 patients with a confirmed deep venous thrombosis (DVT) on Duplex ultrasound will be recruited into this group. All patients will have serum and urine samples for analysis.
16383230|NCT04096755||Control Group|40 volunteers without a DVT will be recruited for the control group. They will have urine and serum samples taken for analysis.
16383231|NCT04096742|Experimental|Altreno|tretinoin 0.05% lotion (Altreno)
16383232|NCT04096742|Sham Comparator|Vehicle|Vehicle lotion not containing tretinoin
16383233|NCT04096729||patients who have consulted and need compression therapy using|1) age from 18 to 75 years; 2) compression therapy prescribed by a phlebologist. The exclusion criterion is hearing impairment, which could interfere with a telephone questionnaires.
16383239|NCT04096703|No Intervention|Expectant management of EGJOO Group|The participants randomized to this group will receive expectant management of EGJOO. Expectant management is evaluating whether symptoms improve over time without an intervention
16383240|NCT04096703|Experimental|Pneumatic dilation of EGJOO Group|The participants randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific).
16383241|NCT04096690|Experimental|Anti-PD-1 antibody plus pegaspargase|Participants will receive induction treatment for six cycles of Anti-PD-1 antibody plus pegaspargase (21-day cycle) and Anti-PD-1 antibody monotherapy maintenance treatment for about 2 years (21-cycle)
16383242|NCT04096677||hysteroscopy repair|patients with post cesarean scar defect
16383243|NCT04096677||transvaginal repair|patients with post cesarean scar defect
16383244|NCT04096664|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
16383245|NCT04096664|No Intervention|Control|Usual care
16383246|NCT04096651|Other|PSP Classic|"15 patients with a classical form of PSP are recruited to realize all the tests of the multimodal approach."
16383247|NCT04096651|Other|Caribbean PSP|"15 patients with a Caribbean PSP are recruited to realize all the tests of the multimodal approach."
16383248|NCT04096651|Other|Healthy controls|15 persons with no PSP are recruited to realize all the tests of the multimodal approach.
16383249|NCT04096638|Experimental|Part 1a: Monotherapy Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses (0.3-14 SB 11285 µg/Kg)
16383250|NCT04096638|Experimental|Part 1b: PD-L1 Combination Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses (0.3-3.0 SB 11285 µg/Kg) plus 1680mg every 4 weeks (Q4W) atezolizumab
16383286|NCT04096482|Experimental|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
16383251|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort A)|"Cohort A: Patients with Melanoma
~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
16383252|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort B)|"Cohort B: Patients with HNSCC
~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
16383253|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort C)|"Cohort C: Patients with tumor types other then Cohort A and B (Naïve or relapsed refractory to anti PD-1/PD-L1)
~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
16383254|NCT04096625|Experimental|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
16383255|NCT04096625|Sham Comparator|Sham tDCS|Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
16383256|NCT04096612|Experimental|Orbital decompression combined MPT|Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
16383257|NCT04096612|Experimental|Separate MPT|MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
16383258|NCT04096599|Experimental|Test group|
16383259|NCT04096599|Active Comparator|Control group|
16383260|NCT04096586|Active Comparator|Red juice|Subjects consume 8 fl oz of red juice daily for 8 weeks
16383261|NCT04096586|Experimental|Watermelon juice|Subjects consume 8 fl oz of watermelon juice daily for 8 weeks
16383262|NCT04096573|Experimental|LC51-0255 low dose|Oral, daily, low dose for induction period, high dose for OLE period
16383263|NCT04096573|Experimental|LC51-0255 middle dose|Oral, daily, middle dose for induction period, high dose for OLE period
16383264|NCT04096573|Experimental|LC51-0255 high dose|Oral, daily, high dose for induction period, high dose for OLE period
16383265|NCT04096573|Placebo Comparator|placebo|Oral, daily, placebo for induction period, high dose for OLE period
16383266|NCT04096560|Placebo Comparator|Part A, Cohorts A1a and Cohorts A1b and A2 (Optional), NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT1.
16383267|NCT04096560|Experimental|Part A, Cohort A1a, NT1 Participants: TAK-994 TBD|TAK-994, tablets, dose level 1 for 28 days, in participants with NT1.
16383268|NCT04096560|Experimental|Part A, Cohort A1b, NT1 Participants: TAK-994|TAK-994 tablets, dose to be determined (TBD) based on safety, tolerability and/or efficacy in Cohort A1a participants with NT1.
16383269|NCT04096560|Experimental|Part A, Cohort A2 (Optional), NT1 Participants: TAK-994 TBD|TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort A1, for 28 days.
16383270|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 1|TAK-994 dose 1, tablets, for 56 days in participants with NT1.
16383271|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 2|TAK-994 dose 2, tablets, for 56 days in participants with NT1.
16383272|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 3|TAK-994 dose 3, tablets, 56 days in participants with NT1.
16383273|NCT04096560|Placebo Comparator|Part B, NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 56 days in participants with NT1.
16383274|NCT04096560|Placebo Comparator|Part C, NT1 Participants in China: Placebo|TAK-994 placebo-matching tablets for 56 days, in participants with NT1 in China.
16383275|NCT04096560|Experimental|Part C, NT1 Participants in China: TAK-994|TAK-994 tablets, dose TBD based on safety and tolerability in Part B, for 56 days in participants with NT1 in China.
16383276|NCT04096560|Placebo Comparator|Part D, Cohort D1a, D1b and D2, NT2 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT2.
16383277|NCT04096560|Experimental|Part D, Cohort D1a, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety, tolerability and/or efficacy in Part A , for 28 days in participants with NT2.
16383278|NCT04096560|Experimental|Part D, Cohort D1b, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety and/or tolerability efficacy in Cohort D1a participants with NT2.
16383279|NCT04096560|Experimental|Part D, Cohort D2, NT2 Participants (Optional) : TAK-994 TBD|TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort D1, for 28 days.
16383280|NCT04096534|Experimental|Normotonic partial nephrectomy|Performing a partial nephrectomy under normal body blood pressure
16383281|NCT04096534|Active Comparator|Hypotonic partial nephrectomy|Performing a partial nephrectomy under hypotonic body blood pressure
16383282|NCT04096521||East Jakarta Cohort Study|One group included in the study was originated from mothers who participated in the first data collection pregnancy. The follow-up study included mothers and their children born as the subject in the follow-up in the study. This study also includes peer of the subjects that lived in the same neighbourhood since the first cohort study and have children in the same age with cohort participant
16383283|NCT04096508|Experimental|Group A|Patients sit comfortably in a chair for 20 min listening classic music before the procedure.
16383284|NCT04096508|Experimental|Group B|Patients sit comfortably in a chair for 20 min listening popular music before the procedure.
16383285|NCT04096508|No Intervention|Control group|Patients sit comfortably in a chair for 20 min without music listening before the procedure.
16388553|NCT04059666|No Intervention|Mother's-own Breast Milk|
16383287|NCT04096469|Experimental|Motivational Interviewing|The intervention group received a guidance regarding their diet and physical activity using the motivational interviewing strategy to improve adherence to healthy behaviors. Participants received a guide with a motivational interviewing approach, which served as the basis for the interview process. The objectives in the intervention group were to consume four vegetables and two fruits a day, seven days a week, increase fiber consumption to more than 30 g daily, reduce fat consumption to no more 20% of the total energy consumed, decrease the consumption of sugary drinks and increase protein intake. Another goal was to increase the number of steps to 4,000 additional steps to those who have already walked.
16383288|NCT04096469|Active Comparator|Traditional Education|The comparison group received a guide on medical care and nutrition with a traditional educational approach. The indication was to read and learn about the health-related topics included in the booklet that was given to them. These participants were visited in the same way as the intervention group to answer questions and monitor participation throughout the intervention.
16383289|NCT04096443|Experimental|Intervention|Fecal microbial transplant capsules
16383290|NCT04096430|Experimental|ENGAGE approach (child-oriented goal-setting)|Therapists will receive training on our principles-based goal setting approach and strategies in the goal setting toolbox. Training will include an overview of tools and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS) and the Pediatric Activity Card Sort (PACS). In addition, we will provide training on Goal Attainment Scaling and administration of the Canadian Occupational Performance Measure (COPM). We will introduce simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
16383291|NCT04096430|No Intervention|Usual care|The control group will comprise of usual care.
16383292|NCT04096417|Experimental|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16383293|NCT04096404|No Intervention|Control|no advice
16383294|NCT04096404|Active Comparator|Non genetic personalised advice|dietary and physical activity advice based on reported dietary intake and physical activity
16383295|NCT04096404|Experimental|Genotype- based personalised advice|dietary and physical activity advice based on genotype, reported dietary intake and physical activity
16383296|NCT04096391|Active Comparator|Intrathecal Drug Delivery System|Subjects randomized to the Intrathecal Drug Delivery System group will be implanted with the Prometra System under sterile technique in accordance with the Instructions for Use. The pump will be filled at the time of implantation with the prescribed medication.
16383297|NCT04096391|Active Comparator|Conventional Medical Management|Subjects randomized to the Conventional Medical Management group will continue with the standard of care procedures.
16383298|NCT04096378|Experimental|EMBRace Intervention Group|Over 13 weeks, participants will engage in a pretest (week 1) 5 weekly sessions (weeks 2-6), a posttest (week 7) and a follow-up (week 13). The intervention (Engaging, Managing, and Bonding through Race: EMBRace) seeks to reduce racial trauma for both youth and caregivers and increase family functioning via psychoeducation and therapy.
16383299|NCT04096378|Other|EMBRace Waitlist Group|Participants will wait for thirteen weeks without receiving EMBRace or alternative therapeutic sessions. The waitlist group will subsequently become the intervention group with the opportunity to participate in the EMBRace intervention protocol above.
16383300|NCT04096365|Experimental|Subcostal temporary extracardiac pacing lead|All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
16383301|NCT04096352|Experimental|Indirect+Direct method|"Indirect method: one session of information on voice function and voice hygiene.
~Direct method: three sessions of voice training using virtual reality simulations over a course of 3 weeks."
16383302|NCT04096352|Active Comparator|Indirect method|Indirect method: one session of information on voice function and voice hygiene.
16383303|NCT04096339|Active Comparator|EGD followed by Colonoscopy|Randomized to group Esophagogastroduodenoscopy followed by Colonoscopy
16383304|NCT04096339|Active Comparator|Colonoscopy followed by EGD|Randomized to group Colonoscopy followed by Esophagogastroduodenoscopy
16383305|NCT04096326|Experimental|AGN-151586|
16383306|NCT04096326|Placebo Comparator|Placebo|
16383307|NCT04096287|Experimental|PNT001|Single escalating doses of intravenous PNT001 administered as a 30 minute infusion at doses of 33mg, 100mg, 300mg, 900mg, 2700mg, and as a 60 minute infusion at 4000 mg
16383308|NCT04096287|Placebo Comparator|Placebo|Single intravenous dose of vehicle administered as a 30 minute infusion up to 2700 mg and as a 60 minute infusion at 4000 mg
16383309|NCT04096274|Experimental|LOCI (Intervention)|Agencies in the intervention group will receive leadership training and coaching in addition to training and technical assistance to implement the digital measurement based care system.
16383310|NCT04096274|Placebo Comparator|Implementation As Usual (Control)|Agencies in the control group will receive web-based leadership training in addition to training and technical assistance to implement the digital measurement based care system.
16383311|NCT04096261||Healthy controls|Healthy controls recruited through public advertisement.
16383312|NCT04096261||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement
16383313|NCT04096261||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
16383314|NCT04096261||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
16383315|NCT04096261||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
16383316|NCT04096235|Experimental|RAM Cannula|
16383368|NCT04095819|Experimental|Middle Meningeal Artery Embolization|Middle Meningeal Artery Embolization
16391752|NCT04037501|Experimental|Intervention|
16383317|NCT04096222||Active pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactuve disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
16383318|NCT04096222||Inactive pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactuve disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
16383319|NCT04096222||Healthy subjects|Healthy subjects will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) Demographic data will be documented, 2) biometric data, 3) A 34 ml blood sample will be taken
16383320|NCT04096209|Experimental|Graft-less and grafting using xenograft and autograft|Extraction of badly decayed teeth with immediate implant placement using graft-less and grafting using autogenous bone and xenograft between the implant and labial socket bone
16383321|NCT04096196|Experimental|Game intervention group|Participants assigned to the intervention group will be given a manual containing instructions to play the Safe City game. A research assistant will provide a briefing session on the game in each participating school. A unique username and password set will be created for each user to log in the game. This login information will be provided to the student participants in a sealed envelope after the briefing session. The participants will be instructed to play the game as many times as desired within a 4-week time frame. The players ranked in the top 20 will receive a reward in the form of book coupon after the intervention ends.
16383322|NCT04096196|Active Comparator|"Health education (control) group"|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
16383323|NCT04096183|Other|Ventilation of healthy volunteers|
16383324|NCT04096170|Experimental|IV Lidocaine|100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
16383325|NCT04096170|Placebo Comparator|Placebo|Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
16383326|NCT04096157|Experimental|Isavuconazonium sulfate IV solution then capsules|Participants will first receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 2.
16383327|NCT04096157|Experimental|Isavuconazonium sulfate capsules then IV solution|Participants will first receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 2.
16383328|NCT04096144|Experimental|Neostigmine|This is the standard Neuromuscular reversal drug that has been in standard care for the past thirty years. Dose: -Neostigmine: 0.03-0.07 mg/kg by intravenous route.
16383329|NCT04096144|Experimental|Sugammadex|"Used for Neuromuscular reversal; Sugammadex is devoid of the parasympathetic effects caused by Neostigmine.
~Dose: -Sugammadex: 2-4 mg/kg (4 mg/kg if no twitch responses after initial stimulation), intravenous route."
16383330|NCT04096131||SURGERY|subjects with early DME undergoing cataract surgery
16383331|NCT04096131||OBSERVATION|subjects with early DME
16383332|NCT04096105|Experimental|CC-93538 in Japanese subjects|Twenty-four Japanese subjects will be randomized into 1 of 2 dose levels in a 1:1 fashion so that 12 subjects will receive a 180 mg or 360 mg dose via SC injection.
16383333|NCT04096105|Experimental|Administration of CC-93538 in Caucasian subjects|Twenty-four Caucasian subjects will be matched to Japanese subjects by weight (± 20%) and receive a 180 mg or 360 mg dose via SC injection
16383334|NCT04096079||OHCA patients|Patients who suffered an out-of-hospital cardiac arrest between 2015 and 2018 in Province of Pavia (Italy), Ticino Region (Switzerland), Wien area (Austria) and Nicosia area (Cyprus) who underwent a coronary angiography.
16383335|NCT04096066|Experimental|KRd (Experimental Arm)|"Carfilzomib (K):
~20 mg/m2 IV on day 1 of cycle 1;
~56 mg/m2 IV on days 8 and 15 in cycle 1;
~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
~56 mg/m2 on days 1 and 15 from cycle 13 and onwards.
~Lenalidomide (R):
~- 25 mg orally on days 1-21 of each cycle.
~Dexamethasone (d):
~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.
~Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration."
16383336|NCT04096066|Active Comparator|Rd (Control Arm)|"Lenalidomide (R):
~-25 mg orally on days 1-21 of each cycle.
~Dexamethasone (d):
~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.
~Until PD or intolerance."
16383369|NCT04095819|Active Comparator|Traditional Surgery|Craniotomy/Burr hole
16383393|NCT04095611|Active Comparator|LATERAL|hemiarthroplasty surgery, the standard lateral approach
16383337|NCT04096053|Experimental|TEACHH|The training workshop is designed as a 3-hour session for care providers. The training will be delivered by trans women. During this training, we plan to have providers: 1) discuss human rights for trans women; 2) teach providers about common words with which to discuss gender identity and expression, and develop a basic understanding of trans healthcare, HIV prevention, and HIV treatment, and how these types of healthcare affect trans women living with and affected by HIV; 3) discuss what it means to be trans-affirming in their work and how they can make their organizations more trans- affirming; and 4) have participants complete a case study to apply what they have learned to practice. These case studies will address issues affecting trans women who are immigrants/newcomers, trans women who are living with HIV, and trans women who experience other vulnerabilities.
16383338|NCT04096040|Experimental|Device Data Engagement Assessment|This arm will assess the endpoints of investigator engagement with the device data.
16383339|NCT04096027|Experimental|Early administration|Cabergoline administered the day before egg collection.
16383340|NCT04096027|Experimental|Late administration|Cabergoline administered after egg collection.
16383341|NCT04096014|Active Comparator|Ensure Enlive|
16383342|NCT04096014|Placebo Comparator|Standard of Care|
16383343|NCT04095988|Experimental|Verum-AMR|Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy
16383344|NCT04095988|Placebo Comparator|Placebo-AMR|Patients receiving Placebo(Saline)-Infusion via gastroscopy
16383345|NCT04095975|Active Comparator|Baking Soda|Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.
16383346|NCT04095975|Active Comparator|LithoLyte|Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.
16383347|NCT04095962|Experimental|Experimental Group|Training protocol will be held for 6 months, twice per week/ 60 min per sessions.
16383348|NCT04095962|No Intervention|Control Group|Participants in the control group will receive monthly sessions regarding physical activity and health related topics as a complement to standard care. No specific exercise intervention will be conducted for this group.
16383349|NCT04095949|Experimental|Artichokes|1 day of artichokes intake
16383350|NCT04095936|Experimental|AMG531|
16383351|NCT04095923|Experimental|Social media game|Private Facebook group with weekly walking challenges, Fitbit wearable activity monitor, and brief counseling
16383352|NCT04095923|Active Comparator|Standard self-regulation|Fitbit wearable activity monitor and brief counseling
16383353|NCT04095910|Experimental|Planet Nutrition program|multidisciplinary school- based program
16383354|NCT04095910|No Intervention|Control Group|Normal curricular classes
16383355|NCT04095897||conventional analgesic therapy|Patient underwent mastectomy with conventional analgesic therapy
16383356|NCT04095897||Pecs II block|Patient underwent mastectomy with conventional analgesic therapy with pre induction Pecs II block
16383357|NCT04095884||Urinary Tract Infection|"Inclusion criteria (one from the list below):
~Positive leukocytes, positive nitrites on dipstick
~Negative leukocytes, Positive nitrites on dipstick
~Positive leukocytes, negative nitrites, plus bacteriuria on microscopy
~Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.
~Exclusion criteria (one from the list below):
~1. No evidence of UTI on dipstick"
16383358|NCT04095884||Upper respiratory tract infection|"Inclusion criteria (one from the list below)::
~Evidence of nasal discharge AND/OR
~Inflammation throat/ tonsils on direct examination AND/OR
~Inflammation of middle or outer ear on direct examination
~History of fever AND history of stridor/ barking cough
~History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough
~Exclusion criteria (one from the list below)::
~Foreign body inserted in either nose/ ear
~Traumatic perforation of ear drum
~Allergic rhinitis i.e. good contact history
~Evidence of LRTI"
16383359|NCT04095884||Lower respiratory tract infection|"Inclusion criteria (one from the list below):
~Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry
~Fever > 38.5C AND chest recessions AND/OR raised respiratory rate
~Radiological evidence of LRTI
~Exclusion criteria (one from the list below):
~1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever"
16383360|NCT04095884||Diarrhoea/ gastroenteritis|"Inclusion criteria (one from the list below):
~Abrupt onset of 3 or more loose/liquid stools/ day
~Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting
~Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI
~Exclusion criteria (one from the list below):
~Normal breast milk stool
~Neurological cause of vomiting"
16383361|NCT04095871||Patients included|"Patients over 18 years old performed CISC for more than 1 month, exclusive or not, are included.
~At home, patients have to complete one diary on the specific duration of a 24-hour CISC and the next day a second diary on the total duration of CISC.
~The specific time of CISC described by the timed duration from the moment when the circumstances of care are combined to carry it out : isolated place, nearby equipment.
~The total time of CISC described by the timed duration from the moment of the intention to self-catheter until the return to the initial activity."
16383362|NCT04095858|Experimental|CD24Fc Treatment|CD24Fc: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV [0.03 mg/kg/day] or by mouth (PO) [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after hematopoietic cell transplantation (HCT), and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.
16383363|NCT04095858|Placebo Comparator|Placebo|Placebo (Saline solution): 100 ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.
16383364|NCT04095845|Active Comparator|CO THA|Computerised tomography based planning of conventional total hip arthroplasty
16383365|NCT04095845|Experimental|Mako THA|Mako robotic-arm assisted total hip arthroplasty
16383366|NCT04095832||Parturients with preeclampsia|Parturients who were diagnosed with preeclampsia
16383367|NCT04095832||Healthy parturients|Healthy full-term parturients
16383371|NCT04095780|Experimental|Advanced oral hygiene care programme|Patients with stroke will receive the advanced oral hygiene care programme (AOHCP) comprising powered tooth brushing and mouth rinsing with chlorhexidine (with a supply of standardized power tooth brushes, mouth rinse, tooth paste and oral hygiene instruction).
16383372|NCT04095780|Experimental|Oral hygiene instruction|Patients with stroke will only receive the oral hygiene instruction.
16383373|NCT04095767|Experimental|Treatment arm|The thrombectomy in eligible patients will be carried out by making use of the device under investigation.
16383374|NCT04095754|Other|Group I (control group)|Patients will be positioned supine.
16383375|NCT04095754|Experimental|Group II|patients will be positioned 10° anti-trendelenburg position.
16383376|NCT04095754|Experimental|Group III|patients will be positioned 20° anti-trendelenburg position.
16383377|NCT04095728|Experimental|Investigational Product|
16383378|NCT04095728|Placebo Comparator|Placebo|
16383379|NCT04095715||Children and adults with unexplained hemorrhagic syndrome|Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.
16383380|NCT04095702|Experimental|Weighted Pacifier|Patient will receive a weighted pacifier for 48 hours of their stay in the NICU.
16383381|NCT04095702|Placebo Comparator|Non-Weighted Pacifier|Patient will receive a standard non-weighted pacifier for 48 hours of their stay in the NICU.
16383382|NCT04095689|Experimental|Experimental|docetaxel chemotherapy and pembrolizumab plus IL-12 gene therapy followed by docetaxel chemotherapy and pembrolizumab plus the pan-nitric oxide synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA)
16383383|NCT04095676|Experimental|VATS / surgical group|The VATS procedure must be completed as soon as possible and no later than 48 hours after randomisation. The surgery is performed with the patient in a 90 degree sideways position, using general anesthesia. Access is obtained through one to three ports, followed by purification and possibly decortication, and insertion of one pleural drain (sizes 24 - 32F) at the end of surgery. 20 ml Marcain is used as local analgetic and applied at the incision sites or as a nerve block. In the VATS group, suction on drain (- 15 cm H20) is applied in the first day after the procedure. Operator must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be registered and approved by the steering committee.
16383384|NCT04095676|Active Comparator|Drain and intrapleural therapy group|"Pigtail is applied as soon as possible and within 48 hours after randomisation. Drain placement is carried out using ULS. Operators (conductors of the procedure) must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be approved by the steering committee to conduct the procedure. A pigtail catheter (minimum 10F) is inserted. Operator determines the size of drain and whether drain placement is done with one-step or Seldinger technic.
~The intrapleural therapy consists of treatment with the following two drugs:
~intrapleural Actilyse® (alteplase) 10 mg twice daily for three days
~intrapleural Pulmozyme® (DNase) 5 mg twice daily for three days"
16383385|NCT04095663|Active Comparator|Partial Colectomy|Elective segmental colectomy for diverticular disease involves removal of the segment of colon (most commonly sigmoid and/or left colon) where there has been disease identified by computed tomography imaging or colonoscopy. Elective colectomy usually removes the affected colon along with adjacent segments that have diverticula, with a primary anastomosis performed to reestablish bowel continuity. Most surgeons now perform the procedure using a laparoscopic approach, when possible, and sometimes use a temporary, protective stoma if the re-connection is considered high-risk. The technique for laparoscopic resection is not specified by the protocol (allows for any number of laparoscopic port sites, all incision types, hand-assistance and robotic) with details of the technique recorded. If randomized to elective colectomy, patients will be encouraged to undergo the procedure within 6 weeks of assignment.
16383386|NCT04095663|Active Comparator|Medical Management|"Medical management for diverticular disease has been used for over 30 years and includes a set of interventions, all components of which have been the subject of small, but often positive trials. All patients randomized to medical management or who select it as their treatment in the observational cohort will view a video (provided in English and Spanish) that explains each element of the medical management toolbox: diet and exercise recommendations, fiber supplementation (e.g., augmenting dietary fiber or over the counter fiber supplements), with mesalazine tablets or suppositories, probiotics and rifamycin. In consultation with their physician, they will be recommended to a regimen of diet and exercise and fiber supplementation. Clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
16383387|NCT04095650|Experimental|Intervention|Participants will engage in a 7-week chronic pain self-management program.
16383388|NCT04095637|Experimental|Mako medial UKA|Mako medial unicondylar knee arthroplasty
16383389|NCT04095637|Active Comparator|Oxford media UKA|Oxford unicompartmental knee arthroplasty with navigation control
16383390|NCT04095624|Experimental|Opioid Taper Group|Patients randomized to the taper group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive a scheduled tapering protocol, with a goal of 10-15% reduction in their weekly opioid use, along with weekly phone calls from a study coordinator assessing their ability to taper and pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
16383391|NCT04095624|Active Comparator|Control Group|Patients randomized to the control group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive no recommendation or guidance in their preoperative opioid pain medication use, but will received weekly phone calls from a study coordinator assessing their preoperative pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
16383392|NCT04095611|Experimental|SPAIRE|hemiarthroplasty surgery, the muscle-sparing modification of the posterior approach (SPAIRE).
16391753|NCT04037501|No Intervention|care as usual|
16383394|NCT04095598||Syndesmotic injured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
16383395|NCT04095598||Syndesmotic uninjured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
16383396|NCT04095585||Patients presenting with WBS and ASD|patients with WBS and ASD. The diagnosis of WBS was confirmed by fluorescent in situ hybridization. All patients met formal ASD criteria.
16383397|NCT04095572|Active Comparator|intervention group A|50 ml of a sterile sodium HA (800 mg)- CS (1g) solution (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Via Martiri di Cefalonia 2, 26900 Lodi, Italy) weekly for four weeks, then every second week in the second month and four weeks later
16383398|NCT04095572|Placebo Comparator|control group B|50 ml sterile purified water weekly for four weeks, then every second week in the second month and four weeks later
16383399|NCT04095533||Sepsis|"Starting at admission to ICU, patients admitted to a mixed medical-surgical ICU will be assessed every second day to determine their muscle size as measured by ultrasound, and their muscle strength as measured clinically using the Medical Research Council strength assessment at the bedside.
~One-time Measures:
~Illness severity as measured by the SOFA score within the first 24 hours of admission.
~duration of mechanical ventilation
~duration of stay in the ICU
~duration of stay in the hospital"
16383400|NCT04095520|Active Comparator|Paste Type Traditional Composite-GC G Aenial Anterior|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with microhybrid composite
16383401|NCT04095520|Experimental|Injectable Composite- GC G Aenial Universal Injectable|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with injectable form composite
16383402|NCT04095507|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
16383403|NCT04095481||Obalon NTS|Patients who commercially purchased the NTS Compatible Obalon Balloon System
16383404|NCT04095468||Resectable rectal cancer|
16383405|NCT04095468||Rectal cancer with threatened mesorectal fascia|
16383406|NCT04095455|Active Comparator|pectoral nerves block group|modified pectoral nerves block was performed on the side of surgery
16383407|NCT04095455|Active Comparator|Ktamine plus Magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump
16383408|NCT04095455|Active Comparator|Control Group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo
16383409|NCT04095442|Active Comparator|Cepacol|
16383410|NCT04095442|Sham Comparator|Tom's Natural Mouthwash|
16383411|NCT04095429|Experimental|Expect Respect Support Group|"Experimental: Expect Respect Support Group Expect Respect is a program intended to create safe, trauma-informed space for young people who have been exposed to violence, to promote positive bystander intervention and healthy relationship skills, to alter norms that foster TDV/SV perpetration, and reduce violence perpetration through weekly support groups with students at elevated risk for such perpetration. Youth with prior history of exposure to violence are invited to in-school gender specific support groups that take place over 24 in-classroom sessions.
~Expect Respect addresses violence perpetration prevention with youth already exposed to violence by recognizing violence as a problem that is fueled by gender norms that promote dominance and challenging the need to control and exert power in relationships especially with the use of violence, while simultaneously strengthening emotion regulation, social skills, and connectedness."
16383412|NCT04095429|Active Comparator|Enhanced Usual Care|Comparator: Enhanced Usual Care The control arm will receive enhanced usual care. Enhanced care means that the investigators will ensure each school has information, resource lists, and connection to services for individual youth who are referred to the study, including warm referrals to victim service agencies, behavioral health services, as well as resources (e.g., assistance with food insecurity, and so forth).
16383413|NCT04095416|Experimental|Intervention|Bilateral lower extremity ACE compression wraps in addition to standard medical care
16383414|NCT04095416|No Intervention|Control|Standard medical care
16383415|NCT04095403|Experimental|Tarp assisted cooling|Whole body cooling in a small amount of 20'C water.
16383416|NCT04095403|Sham Comparator|Passive cooling|Supine lying
16383417|NCT04095390|Experimental|Arm A|Hormone receptor positive,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Letrozole until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16383418|NCT04095390|Experimental|Arm B|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Capecitabine until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16383419|NCT04095390|Experimental|Arm C|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16383420|NCT04095377||healthy|
16383421|NCT04095377||CVA|
16383422|NCT04095377||Hammorhage|
16383423|NCT04095377||TBI|
16383424|NCT04095377||Concussion|
16383425|NCT04095377||Fibromyalgia|
16383426|NCT04095377||ABD|
16383427|NCT04095377||ADHD|
16383428|NCT04095377||MCI|
16383429|NCT04095377||DEMENTIA|
16383430|NCT04095377||COGNITIVE IMPAIRMENT|
16383431|NCT04095377||COGNITIVE DECLINE|
16383432|NCT04095377||MS|
16383435|NCT04095338|Active Comparator|control group|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks
16383436|NCT04095338|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks.
16383437|NCT04095338|Experimental|robotic treadmill arm|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks.
16383438|NCT04095325|Active Comparator|transversus abdominis plane block|Group 1 (n: 50): those who underwent TAP block after induction of propofol atropine and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
16383439|NCT04095325|Active Comparator|erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
16383440|NCT04095312|Experimental|pancreaticobiliary disease|10 pancreaticobiliary disease cases
16383441|NCT04095312|Experimental|Urinary tract disease|13 urinary tract disease cases
16383442|NCT04095312|Experimental|Colon disease|10 colon disease cases
16383443|NCT04095299|Active Comparator|A: Standard chemoradiotherapy|50.4 Gy to the tumor and elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays.
16383444|NCT04095299|Experimental|B: High-dose radiotherapy|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays
16383445|NCT04095286|Experimental|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
16383446|NCT04095286|Experimental|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
16383447|NCT04095286|Experimental|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
16383448|NCT04095286|Experimental|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
16383449|NCT04095286|Experimental|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
16383450|NCT04095286|Experimental|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
16383460|NCT04095260||high school athletes|High school athletes, ages 14 to 18, who are participating in an organized sports training program.
16383461|NCT04095234|Experimental|Acupuncture|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
16383462|NCT04095234|Active Comparator|Massage|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
16383463|NCT04095221|Experimental|Prexasertib and Irinotecan|Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required). Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.
16383464|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm A|Combination of nivolumab and relatlimab.
16383465|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm B|Treatment by nivolumab alone.
16383466|NCT04095195||Familial pancreatic cancer relatives|
16383467|NCT04095195||Peutz-Jeghers syndrome|
16383468|NCT04095195||BRCA 1/2, PALB2, p16 mutations with familiarity for PC|Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
16383469|NCT04095195||Lynch syndrome with familiarity for pancreatic cancer|
16383470|NCT04095195||FAMMM syndrome|
16383471|NCT04095195||Hereditary and genetic pancreatitis|
16383472|NCT04095182|Experimental|Zebinix 400mg|
16383473|NCT04095182|Placebo Comparator|Placebo for Zebinix 400mg|
16383474|NCT04095182|Experimental|Zebinix 800mg|
16383475|NCT04095182|Placebo Comparator|Placebo for Zebinix 800mg|
16383476|NCT04095182|Experimental|Zebinix 1600mg|
16383477|NCT04095182|Placebo Comparator|Placebo for Zebinix 1600mg|
16383478|NCT04095169||axSpA|Patients with low back pain ≥three months who a) fulfilled the ASAS definition for a positive MRI scan of sacroiliac joints (definite inflammation) or b) were HLA-B27 positive with at least one concomitant clinical spondyloarthritis feature.
16383479|NCT04095169||non-axSpA|Patients with a) positive MRI according to the ASAS definition, but no additional clinical spondyloarthritis features, or b) positive HLA-B27 and one clinical spondyloarthritis feature.
16383480|NCT04095169||Controls|Patients with non-specific low back pain without spondyloarthritis-related features and negative MRI SIJ.
16383481|NCT04095156||Prospective cohort|Patients with biopsy-proven idiopathic MN, who are candidate to receive a B-cell depleting treatment as per center clinical practice.
16383482|NCT04095156||Retrospective cohort|Patients with biopsy-proven idiopathic MN, who already received a B-cell depleting treatment as per center clinical practice.
16383483|NCT04095156||Healthy volunteers cohort|Subjects > 18 years not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
16383484|NCT04095143||New onset of stage ≥2 acute kidney injury|"Either:
~A ≥ 2-fold increase in serum creatinine OR
~A serum creatinine ≥ 354 μmol/L with evidence of a minimum increase of 27 μmol/L OR
~Urine output < 6.0 mL/kg over the preceding 12 hours OR
~Initiation of RRT for severe acute kidney injury less than 72 hours before recruitment"
16383485|NCT04095130||Healthy subjects|those without a condition
16383486|NCT04095130||Psoriasis patients|those with a condition
16383487|NCT04095104|Experimental|Phentermine & Topiramate|"Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration:
~4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning
~+
~Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning
~+
~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
16383488|NCT04095104|Placebo Comparator|Placebo Drugs|"Placebo Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration: 4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning
~+
~Placebo Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning
~+
~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
16383489|NCT04095091||Control Group|"Healthy volunteers will be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.
~A substudy including patients undergoing radiotherapy for malignancies of the abdomen and pelvis. They will also be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan."
16383490|NCT04095091||Patient Group|Patients receiving radiotherapy for malignancies of the abdomen and pelvis will be asked to complete two research visits lasting approximately one hour. Each visit will include a 30 minute combined 4D ultrasound and 4D MRI scan.
16383491|NCT04095078|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
16383492|NCT04095078|No Intervention|Control|Usual care
16383493|NCT04095065|Experimental|itMatters|Participants will have access to content focused on general knowledge and injunctive and descriptive norms for a period up to 3 weeks.
16383494|NCT04095065|Experimental|itMatters and itMatters Sexual Violence Prevention|Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
16383495|NCT04095065|Experimental|itMatters Well-being and itMatters Sexual Violence Prevention|Participants will have access to content focused on basic information related to sleep wellness and time management. In Addition, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
16383496|NCT04095065|Experimental|itMatters Well-being|Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
16383497|NCT04095052|Experimental|Methyl Folate|Participants will receive a capsule containing 1,000 mcg methyl folate and microcrystalline cellulose orally once per day for 15 days.
16383498|NCT04095052|Placebo Comparator|Placebo|Participants will receive a microcrystalline cellulose capsule orally once per day for 15 days.
16384384|NCT04088643|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
16383499|NCT04095039|Experimental|Hi Arm|Patients to allow blood serum phosphate levels to rise to 6.5 mg/dl or above
16383500|NCT04095039|No Intervention|Lo Arm|Patients to titrate blood serum phosphate levels to the standard <5.5mg/dl
16383501|NCT04095026||Patients|Patients age >18 years and <= 65 years enrolled in 11-N-0051 Epilepsy Surgery
16383502|NCT04095013|Experimental|Group BF|hyperbaric Bupivacaine 10mg with fentanyl 10micrograms
16383503|NCT04095013|Experimental|Group BD|hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
16383504|NCT04095000|Experimental|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
16383505|NCT04095000|Active Comparator|Treatment As Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
16383506|NCT04094987|Experimental|Quadratus Lumborum block|We will use the ultrasound guided anterior Quadratus Lumborum Block.A peripheral nerve block catheter will be placed between the quadratus lumborum muscle and the psoas muscle with ultrasound
16383507|NCT04094961|Experimental|ixazomib plus pomalidomide and dexamethasone|"The study drugs will be administered within a 21-day cycle
~Phase I will follow a standard 3 +3 dose escalation design: Starting with the first cohort, 3 to 6 patients will be treated at this and each subsequent dose level.
~The Phase II portion of the study will be a single-arm open-label enrollment with dosing based on the MTD determination in the Phase I portion of the study"
16383508|NCT04094948|Experimental|clenbuterol|The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
16383509|NCT04094948|Placebo Comparator|placebo|Initially, one capsule each morning for one week, followed by one capsule BID for the next 5 weeks until Week 6. If tolerated, the dose will be increased to two capsules each morning and 1 capsule each evening for one week, followed by two capsules BID for the next 5 weeks until the Week 12 visit. If two capsules BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
16383510|NCT04094922|Experimental|Intervention|Free access to the Swedish PTSD Coach smartphone app for three months.
16383511|NCT04094922|No Intervention|Waitlist|Delayed access to the Swedish PTSD Coach smartphone app. Access is given after post-intervention data collection at three months.
16383512|NCT04094909|Experimental|Rh-endostatin + chemotherapy+Pembrolizumab|The subjects are 186, including Squamous and Non-Squamous NSCLC. Squamous NSCLC receives rh-endostatin at a dose of 15mg/m2 for 5 days and 200 mg of pembrolizumab at day 1 in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. all the patients with squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and [nab]-paclitaxel (100mg/m2) for the first 4 cycles. For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. Non-squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and pemetrexed (500mg/m2,d1) for the first 4 cycles.
16383513|NCT04094896|Experimental|Arm A: TCHP|docetaxel/carboplatin/trastuzumab/Pertuzumab
16383514|NCT04094896|Active Comparator|Arm B: EC-THP|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab
16383515|NCT04094883|Experimental|4CMenB Vaccine|Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.
16383516|NCT04094870|Active Comparator|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
16383517|NCT04094870|Active Comparator|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
16383518|NCT04094857|Experimental|HBN-1 Plus Standard of Care|Subjects will receive an intravenous loading dose of HBN-1 followed by a 12 hour maintenance infusion plus standard of care targeted temperature management
16383519|NCT04094857|No Intervention|Standard of Care|Subjects will receive standard of care targeted temperature management only
16383520|NCT04094844|Active Comparator|Roadmap 2.0|"Roadmap 2.0 mobile app + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).
~Includes caregivers of adult patients and caregivers of pediatric patients"
16383521|NCT04094844|Experimental|Roadmap 2.0 with Positive Activities|"Roadmap 2.0 mobile app (patients), Roadmap 2.0 with mobile Positive Activities app (caregivers) + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).
~Includes caregivers of adult patients and caregivers of pediatric patients"
16383522|NCT04094831|Active Comparator|Intervention arm|Intervention group (Health education through CKD campaign and mHealth) technology
16383523|NCT04094831|Active Comparator|Control|No intervention
16383524|NCT04094805|Active Comparator|Rocaltrol Combining HD-DXM|Rocaltrol 0.25 μg once per day, 1 month; HD-DXM (orally at 40 mg daily for 4d )
16383525|NCT04094805|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
16383526|NCT04094792|Experimental|Intervention|For the intervention group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later). Intervention group subjects will use the Breather app twice daily, five minutes each time, for a period of 21 days.
16383527|NCT04094792|No Intervention|Control|For the control group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later).
16383528|NCT04094779|Active Comparator|Usual relational care|Isolate the patient from the group of other patients in order to propose to him a a relationship dual with the caregiver to the aim to calm the agitation
16383529|NCT04094779|Experimental|"Flash activity breath of fresh air"|Isolate the patient from the group of other patients in order to propose to him in a relationship dual with the caregiver a physical activity outside the service that promotes relaxation by focusing his attention to the environment during 15 minutes
16383530|NCT04094766|Experimental|BLLCAR-L10D treatment group|In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 2.0×10^6 CAR-T cells/kg.
16383531|NCT04094740|Experimental|Needle-free Jet Injector|Subjects will be instructed to use a needle-free syringe to inject insulin during the study period. The dosage and frequency of insulin are determined by the responsible physician according to the patient's condition.
16383532|NCT04094740|No Intervention|Conventional Insulin Pen|Patients allocated to the control group will be instructed to use conventional insulin pens to inject insulin. Except for the syringe, all of them are the same as the experimental group.
16383533|NCT04094740|No Intervention|Routine Care|Subjects can receive the education provided by health-care professionals and training in the outpatient department and inpatient departments.
16383534|NCT04094727|Experimental|Presumptive treatment and enhanced vector control|"For all eligible HRPs in intervention areas, after obtaining informed consent, presumptive treatment for malaria will be carried out using artemether-lumefantrine (AL) at two time points.
~Enhanced vector control activities will include: (1) a mop up indoor residual spraying (IRS) campaign and (2) distribution of long-lasting insecticide-treated nets (LLINs) and/or vector control packs with topical repellent.
~The intervention arm will also receive the standard of care in Namibia."
16383535|NCT04094727|No Intervention|Standard of care|The control arm will receive the standard of care in Namibia: passive case detection through health facilities and health extension workers, routine indoor residual spraying (IRS), and reactive case detection (RACD) accompanied by reactive IRS.
16383536|NCT04094701|Placebo Comparator|Control Group|"Control Group will receive the following pain medication regimen:
~- Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills
~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
16383537|NCT04094701|Experimental|Experimental Group - Opioid Reduced|"Experimental - opioid reduced: 50% less oxycodone relative to control group
~Tylenol extra strength (1000 mg, three times daily for 10 days following surgery)
~Gabapentin (300 mg at night for 10 days following surgery)
~Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
16383538|NCT04094688|Experimental|Arm I (bevacizumab, chemotherapy, high-dose vitamin D3)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV on days 1-3 or irinotecan hydrochloride IV on day 1, leucovorin calcium IV over 90 minutes on day 1, and fluorouracil IV on days 1-3. Patients also receive high-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
16383539|NCT04094688|Active Comparator|Arm II (bevacizumab, chemotherapy, standard-dose vitamin D3)|Patients receive bevacizumab and chemotherapy as in Arm I. Patients also receive standard-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
16383540|NCT04094675|Experimental|Treatment arm|"There will be a clinic visit and colonoscopy at study entrance with standard of care sampling and assessment of polyps, including resection of concerning polyps. The investigators will also collect data on well-being via the SF-36 health survey (a validated questionnaire to help monitor this aspect given anecdotal patient-level reports of improvement while on therapy).
~Study subjects will then begin sirolimus 2 mg by mouth daily for 1 year.
~Laboratories will be checked at 4 days after initiation, at 2 weeks after initiation, then every 4 weeks for 3 months, then every 3 months to complete the year of therapy
~Participants will have a clinic visit at 3, 6 and 9 months and include well-being assessment with the SF-36 health survey.
~Participants will have a clinic visit with well-being assessment and perform colonoscopy at study closure at 12 months. The investigators will perform standard of care sampling and assessment of polyps, including resection of concerning polyps."
16383541|NCT04094662|Experimental|Mirogabalin|Mirogabalin 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
16383542|NCT04094662|Placebo Comparator|Placebo|Placebo (14-weeks)
16383543|NCT04094649|Sham Comparator|Sham vs Active Stimulation Positions|Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design. Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle ~2 cm away from the vagus nerve.
16383544|NCT04094649|Active Comparator|Active uVNS|Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.
16383545|NCT04094636|No Intervention|No intervention: Control|Control group
16383546|NCT04094636|Experimental|In-bed cycling|Supervised in-bed cycling
16383547|NCT04094636|Experimental|Exercise booklet|Supervised physical training with exercises from exercise booklet
16383548|NCT04094623|Experimental|NSSI-DBT|Dialectical behavior therapy, 2 hours every week for 13 weeks.
16383549|NCT04094623|Active Comparator|NSSI-SSGT|Social support group therapy, 2 hours every week for 13 weeks.
16383550|NCT04094610|Experimental|Repotrectinib (TPX-0005)|"Phase 1
~Oral repotrectinib (TPX-0005):
~Safety and tolerability at different dose levels
~Phase 2
~Oral repotrectinib (TPX-0005): 3 cohorts
~Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ALK/ROS1/NTRK alterations or fusions in tumors and ALCL"
16383551|NCT04094597|Placebo Comparator|placebo|saline is given orally in dose of 2 ml per day for one month
16383552|NCT04094597|Active Comparator|lacoferrin|Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month
16383553|NCT04094584|Experimental|Multimodal Intervention|"The intervention is multimodal and consists of:
~Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 6 months.
~Case Management services
~Access to telemedicine counseling services to be used as needed by study participants."
16383554|NCT04094571|Experimental|Healthy Individuals and those with Movement Disorders|Participants will perform the FES cycling protocol along with the FES angle protocol.
16383555|NCT04094558|Experimental|Single Arm|Participant swallows and retrieves capsule in stool. Capsule and stool samples are analyzed for bacterial density and composition.
16383556|NCT04094545||Nasopharyngeal carcinoma(NPC)|The patients (1) were diagnosed with NPC; 2)18< Age <75.
16383557|NCT04094545||Health adults|(1) 18< Age <75, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; None of the patients had rhinitis or used any antibiotics during the three months last 3 months.
16383558|NCT04094532|Active Comparator|ultrasound guided transverse thoracic muscle plane block|
16383559|NCT04094532|Sham Comparator|ultrasound guided sham block|
16383560|NCT04094519|Experimental|digoxin plus rosuvastatin and enzalutamide|Participants will receive a single oral dose cocktail containing digoxin and rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and enzalutamide once daily on Days 8 through 71.
16383564|NCT04094493|Experimental|A1|vit D + no hypocalcemia
16383565|NCT04094493|Experimental|A2|Vit D + hypocalcemia
16383566|NCT04094493|No Intervention|B1|NO vit D + no hypocalcemia
16383567|NCT04094493|No Intervention|B2|NO vit D + hypocalcemia
16383568|NCT04094480|Active Comparator|endoloop ligation|securing appendicular base with endoloops
16383569|NCT04094480|Active Comparator|non absorbable polymeric clips|securing appendicular base with non absorbable polymeric clips
16383570|NCT04094467|Experimental|Study group|"the antagonist protocol group where they will do intra-cytoplasmic injection using classical antagonist protocol"
16383571|NCT04094467|Active Comparator|control group|"agonist stop/antagonist protocol group where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol"
16383572|NCT04094454|Experimental|Tampon with extended vaginal dilatation|Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
16383573|NCT04094454|Active Comparator|Commercially available tampon|Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
16383575|NCT04094428||Intensive care unit patient|All intensive care unit patients staying for at least 72 hours on the ICU and patients dying within 72 hours
16383576|NCT04094415||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
16383577|NCT04094389|Experimental|Orthotic continuous wear group|Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance.
16383578|NCT04094389|Experimental|Orthotic wear during waking hours only group|Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping.
16383579|NCT04094389|Experimental|Orthotic wear only while sleeping group|In the night-wear group, participants will be told to wear their orthosis only at night.
16383580|NCT04094376|Other|Day group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00)
16383581|NCT04094376|Other|Night group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
16383582|NCT04094363|Experimental|Product usage order ABCD|Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
16383583|NCT04094363|Experimental|Product usage order BDAC|Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
16383584|NCT04094363|Experimental|Product usage order CADB|Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
16383585|NCT04094363|Experimental|Product usage order DCBA|Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
16383586|NCT04094350|Experimental|ACF with a seed-and-recruit model|Active case finding with a seed-and-recruit model to be implemented by KHANA. Target group: key populations for TB (people living with HIV, TB contacts, people with diabetes, people who use/inject drugs) and presumptive TB cases
16383587|NCT04094350|Experimental|ACF targeting household and neighborhood contacts|Active case finding targeting household and neighborhood contacts to be implemented by CENAT. Target group: household contacts, immediate neighbors of people diagnosed with TB in the last 2 years, and other presumptive TB cases
16383588|NCT04094350|Experimental|ACF targeting the older population|Active case finding targeting the older population (people aged 55 and older) using mobile screening units to be implemented by CATA. Target group: elderly above age of 55 and other presumptive TB cases
16383589|NCT04094350|No Intervention|Passive case finding|Passive case finding strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
16383590|NCT04094337|Experimental|Internet-assisted treatment|The intervention group will receive internet-assisted treatment comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
16383591|NCT04094337|No Intervention|Control group|The control group will receive treatment as usual, which is no specific treatment. The control group can however use the general health system as they like.
16383592|NCT04094324||Children and youth at obesity clinic|Children 11-18 who are patients at obesity clinics in region Skåne SUS.
16383593|NCT04094324||Children and youth at a pediatric gastrointestinal clinic|Children 11-18 who are patients at a gastrointestinal clinic i region Skåne SUS.
16383594|NCT04094311|Other|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel per the Health Authority-approved tisagenlecleucel product information in the respective country/region are considered eligible for this study . Patients will be divided into 2 groups:
~Group A: Pediatric and young adult patients with B-cell ALL (pALL) who meet the indication in Health Authority-approved tisagenlecleucel product information in the respective country/region whose final manufactured product is OOS for commercial release.
~Group B: Adult patients with r/r LBCL including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the product information for tisagenlecleucel in respective country/region but whose final manufactured product is OOS for commercial release/acceptance."
16383595|NCT04094298|Experimental|Treatment Group|Patients receiving the 32-unit injection of FX006.
16383596|NCT04094285|Experimental|1|
16383597|NCT04094285|Experimental|2|
16383598|NCT04094272||Chronic hepatitis C participants|Participants with a newly started DAA medication for HCV infection were included in the study.
16383601|NCT04094233|Experimental|Beetroot Extract|Capsule containing 600mg of beetroot extract.
16383602|NCT04094233|Experimental|Placebo|Capsule containing 600mg of starch.
16383603|NCT04094220|Experimental|Lateral lumbar interbody fusion|Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.
16383604|NCT04094220|Experimental|Lateral lumbar interbody fusion plus posterior decompression|Patients in this group received lateral lumbar interbody fusion plus posterior decompression.
16383605|NCT04094207|Placebo Comparator|Control group|Equivalent Placebo will be given
16383606|NCT04094207|Experimental|Pentoxifylline group|Pentoxifylline will be given orally at 800 mg a day for 8 weeks
16383607|NCT04094181||VPRIV Participants|Participants who has been transitioned from ERTs/SRTs to VPRIV, the data will be collected retrospectively from time of transition until the point at which participant begins in this study and then will be followed up prospectively for 12 months.
16383608|NCT04094168|Experimental|Del Nido Cardioplegia solution|1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.
16383609|NCT04094168|Active Comparator|Cold blood Cardioplegia solution|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
16383610|NCT04094155|Experimental|Retinal fundoscopy|Retinal vascular analysis by retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
16383611|NCT04094142|Experimental|Treatment arm|"Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.
~Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21"
16383612|NCT04094129|Placebo Comparator|Placebo|Subjects received two placebo sachets per day
16383613|NCT04094129|Experimental|Probiotic|Subjects received two Wismemo sachets with 1x10^10 cfu/day
16383614|NCT04094116|Active Comparator|ear wax syringing with pre ear oil treatment|patients in Fanling Family Medicine Centre with ear wax will be given ear oil one week before performing ear syringing.
16383615|NCT04094116|Sham Comparator|ear wax syringing without pre ear oil treatment|Patients in Wong Siu Ching Clinic and Tai Po Clinic who are found to have ear wax after physical examination will have ear syringing done, without pre-ear oil application.
16383616|NCT04094103|Experimental|Active strawberry powder|Participants will consume a 39g freeze-dried active strawberry powder beverage once per day for 4-weeks.
16383617|NCT04094103|Placebo Comparator|Placebo strawberry powder|Participants will consume a 39g freeze-dried strawberry powder placebo beverage once per day for 4-weeks.
16383618|NCT04094103|Active Comparator|Mixed active/placebo strawberry powder|Participants will consume a 39g mixed active/placebo strawberry powder beverage once per day for 4-weeks.
16383619|NCT04094090|Experimental|Pulsed, accelerated|4 mW, 10 sec on, 10 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
16383620|NCT04094090|Experimental|Pusled, accelerated|8 mW, 10 sec on, 10 sec off, 11.25 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
16383621|NCT04094077|Experimental|Aguix + Stereotactic Radiation|
16383622|NCT04094064|Experimental|CGM Use while on Hemodialysis Therapy|All subjects will use a CGM for 10 days. Subjects will continue their standard of care hemodialysis treatments during the study period.
16383623|NCT04094038|Experimental|Intervention|Intradialytic parenteral nutrition three times weekly during 16 weeks
16383624|NCT04094038|Placebo Comparator|Placebo|5% glucose three times weekly during 16 weeks
16383625|NCT04094025|Experimental|dATS patch|dATS, placebo and saline will be administered simultaneously
16383837|NCT04092478||Lateral Decubitis Position|We are going to use the Lateral Decubitis Position on each patients.
16383628|NCT04093999||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction with additional sensory nerve coaptation.
16383629|NCT04093999||Noninnervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction without sensory nerve coaptation.
16383630|NCT04093986||Retrospective Chart Review|Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
16383631|NCT04093986||Participant Survey and Retrospective Chart Review|Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
16383632|NCT04093973||MAC subjects|Outpatients with moderate to severe mitral annular calcification on echocardiogram who are able to perform supine bicycle exercise.
16383633|NCT04093973||Controls|Sex matched individuals who are within 5 years of age of the paired MAC subject and who have the same left ventricular wall thickness as measured by echocardiography.
16383634|NCT04093960|Experimental|escitalopram plus128|escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily)
16383635|NCT04093960|Active Comparator|escitalopram|10 mg/d of escitalopram
16383636|NCT04093934|Experimental|Intervention|Children in the intervention arm will receive sessions of psychosocial stimulation every two weeks at the community clinics for one year. The intervention includes songs, games, book and toy activities for undernourished children and nutritional and developmental messages for their mothers.
16383637|NCT04093934|No Intervention|Wait-listed control|The wait-listed controls will be only tested at baseline and after a year. Following completion of the 2nd test, they will be included in the study and receive the same intervention provided to children in the experimental arm.
16383638|NCT04093921|Experimental|Intervention|Receive motivational enhancement training based, telehealth-delivered 6-8 session intervention aimed at increasing readiness to engage in pain self-management, in addition to all recommended outpatient treatments.
16383639|NCT04093921|Active Comparator|Standard Care|Participate in all recommended outpatient pain treatments while awaiting PPRC admission.
16383640|NCT04093908||multi-center validation cohort|We collect retrospective data from several international centers containing preoperative variables (demographical and clinical) and postoperative outcome (UPDRS II, III, IV) one year postoperatively, and merge these data to one validation cohort.
16383641|NCT04093895|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept® drug administration
16383642|NCT04093882||Healthy controls|Healthy controls recruited through public advertisement.
16383643|NCT04093882||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement.
16383644|NCT04093882||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
16383645|NCT04093882||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
16383646|NCT04093882||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
16383647|NCT04093869|Experimental|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX intervention will consist of 12, 30 minute weekly sessions conducted by a respiratory therapist knowledgeable about lung transplantation and trained in motivational interviewing, Cognitive Behavioral Therapy (CBT), and exercise therapy.
16383648|NCT04093869|Experimental|Standard of Care plus Education (SOC-ED)|The SOC-ED intervention will consist of 12, 30 minute weekly sessions conducted by a health educator knowledgeable about transplantation and skilled in educational instruction.
16383649|NCT04093856||Diabetic|20 men and women with type 2 diabetes and obesity
16383650|NCT04093856||Non-diabetic|20 normoglycemic men and women with obesity matched for age and sex with diabetic group
16383651|NCT04093843|Experimental|Open label|Open label single arm study to determine safety and effectiveness of TMS for post stroke depression
16383652|NCT04093830|Experimental|pre-lingually deafened children with cochlear implant|pre-lingually deafened children with cochlear implant who continuously used bimodal hearing.
16383653|NCT04093817||on pump CABG|patients under going CABG with cardiopulmonary bypass machine
16383654|NCT04093817||off pump CABG|patients under going CABG without cardiopulmonary bypass machine
16383655|NCT04093804|Active Comparator|32mm Glenosphere|The control group will receive the standard 32mm glenosphere.
16383656|NCT04093804|Experimental|36mm Glenosphere|The experimental group will receive a 36mm glenosphere.
16383657|NCT04093791|Experimental|"Collective Intervention G"|"HAPPY MAMA intervention will follow the following steps: listening and establishing relationship phases; analysis of the problems; definition of the problem and the goal of intervention.
~The duration will be of 3.5 hours in one day and the intervention will happen in Sapienza University of Rome, in a group of 15 women.
~This group fill in an on line questtionarie for four times, the first before the intervention."
16383658|NCT04093791|Experimental|"Individual Intervention I"|"The same intervention of G group (HAPPY MAMA), but at individual level and the intervention will happen at the participants' house.
~This group fill in an on line questtionarie for four times, the first before the intervention."
16383659|NCT04093791|No Intervention|"Control group C"|The women from this group will not receive any intervention. This group fill in an on-line questtionarie for four times.
16383660|NCT04093778|Experimental|SDA intervention|Low dose high frequency training of all health workers in maternity and pediatric ward and dissemination of a Safe Delivery Application
16383661|NCT04093765|Experimental|Sustained high incidence villages|Villages classified as high incidence, low probability of elimination (P. falciparum cumulative incidence >84 cases/1000/year, in spite of >1 year of functioning malaria post) will be eligible to be included in group 1. Villages in this group will be addressed by MSAT waves of 10-15 villages. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
16383662|NCT04093765|Experimental|Seasonal focal transmission villages/locations|"This group will follow the NMCP case/and foci investigation guidelines, but use URDT instead of standard RDT for screening. MSAT group 2 locations will be cluster of houses, villages or clusters of villages selected based on the results of case or foci/outbreak investigation. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
~Village inclusion after case investigation
~Village inclusion after outbreak investigation"
16383663|NCT04093752|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly.
16383664|NCT04093752|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly.
16383665|NCT04093752|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly.
16383666|NCT04093752|Active Comparator|Insulin Glargine|Insulin glargine administered SC once daily.
16383667|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
16383668|NCT04093726|Experimental|lollipop|
16383669|NCT04093726|No Intervention|control|
16383670|NCT04093713|Other|participants|participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks
16383671|NCT04093700||SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
16383672|NCT04093687|Experimental|Intervention Arm|"The intervention will consist of one training session, focusing on technical and non-technical aspects identified in the study Phase I (according to the evaluation questionnaire). The training will be conducted by a team consisting of (i) supervisors (researchers) and (ii) teachers experienced in the previous trial (Train-Colonoscopy-Leaders course - TCL; this methodology has already been evaluated (citation)). There will be 7 trainees per session: 1 under-, 4 average and 2 overperformers.
~The training session will be divided into two parts: theoretical and practical. During the first, theoretical part of the training, the body of research on the phenomenon of colonoscopy pain will be presented. The second, practical part of the training, will consist of a one-day session of 7 colonoscopies.
~Each average and underperforming endoscopist who underwent training in the randomized phase will receive a written, customized feedback on his/her performance during the training session."
16383673|NCT04093687|No Intervention|Control Arm|The endoscopists in the control arm will not be informed about participation in the study and will receive only tailored feedback on adjusted painful colonoscopy rate (practice as usual). They will receive a reminder, that dedicated report on painful colonoscopy rate is provided in the Polish Colonoscopy Screening Program database and they will be monitored for endpoints through Polish Colonoscopy Screening Program database.
16383674|NCT04093674|Experimental|Clinical evaluation|Clinical periodontal parameters
16383675|NCT04093674|Experimental|Laser Doppler Flowmetry|Laser Doppler Flowmetry evaluation
16383676|NCT04093674|Experimental|Patient centered outcomes|Pain and discomfort/ Esthetics
16383677|NCT04093661||Children below 1 year|Children <= 1 year for elective surgery
16383678|NCT04093648|Experimental|TEGAR T cells + Fludarabine and Cytoxan|GPC3-CAR (TEGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
16383679|NCT04093635||Group I|Those patients that will be treated by NPWT.
16383680|NCT04093635||Group II|Those patients will be treated with standard saline moist wound care and dressing.
16383681|NCT04093622||Genetically engineered NK Cell - treated|Long term follow-up of subjects who have received lentivirus-mediated genetically engineered NK Cells.
16383682|NCT04093609||cases|
16383683|NCT04093609||control|
16383684|NCT04093596|Experimental|ALLO-647, ALLO-715, Nirogacestat|
16383685|NCT04093583|Active Comparator|Simple suture|
16383686|NCT04093583|Experimental|PRGF-Endoret|
16383687|NCT04093570|Experimental|ASTX727|The recommended starting dose is the fixed-dose combination (FDC) tablet, containing 100 mg cedazuridine and 35 mg decitabine, Daily×5 in 28-day cycles. Subjects should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
16383688|NCT04093557|Active Comparator|Orton Score Cohort - High|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they score highly, they will receive an extended GoLytely bowel prep."
16383689|NCT04093557|Placebo Comparator|Prospective Orton Score Cohort - Low|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they do not score highly, they will receive a standard GoLytely (or Suprep) bowel prep."
16383690|NCT04093557|Other|Retrospective Cohort (before Orton Score)|
16383691|NCT04093544|Active Comparator|Standard Stimulation|Participants will receive stimulation using the best contact combination in ring mode.
16383692|NCT04093544|Experimental|Directional Stimulation|Participants will receive stimulation using the best segmented (steered) contacts.
16383693|NCT04093531|Experimental|Ustekinumab|All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit. 650mg acetaminophen and 60mg allegra will be given as premedication to the infusion. All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits. Subcutaneous injections do not require any premedication. Drug will be administered by qualified personnel.
16383694|NCT04093518|Active Comparator|Active Comparator|Estradiol 200µg
16383695|NCT04093518|Placebo Comparator|Placebo Comparator|Placebo
16383696|NCT04093505|Experimental|GO147_G|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
16383697|NCT04093505|Placebo Comparator|GO147_P|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
16383698|NCT04093505|Experimental|GO1_G|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
16383699|NCT04093505|Placebo Comparator|GO1_P|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
16383702|NCT04093479||BMI, oxytocin|Repeteadly blood samples will be taken
16383703|NCT04093466|Experimental|Treatment (CX1003)|Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
16383704|NCT04093453|Placebo Comparator|Placebo + Fasting|Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
16383705|NCT04093453|Placebo Comparator|Placebo + Exercise|Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.
16383706|NCT04093453|Placebo Comparator|Placebo + Post-prandial|Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.
16383707|NCT04093453|Experimental|Propionate and Fasting|Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
16383708|NCT04093453|Experimental|Propionate and Exercise|Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.
16383709|NCT04093453|Experimental|Propionate and Post-prandial|Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.
16383710|NCT04093440|Other|Observation|lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
16383711|NCT04093427|Active Comparator|softSTOPP active|
16383712|NCT04093427|No Intervention|softSTOPP inactive|
16383713|NCT04093414|Active Comparator|Selective or Non selective His Bundle Pacing|Pacemaker wires placed in Bundle of His
16383714|NCT04093414|Active Comparator|Left Bundle Area Pacing|Pacemaker wires placed in Left Bundle Branch area
16383715|NCT04093401|No Intervention|Control|Subjects will be assigned to the control arm if their subject ID is an odd number. Control arm subjects will not receive counseling for individualized risk assessment for developing a second basal cell carcinoma.
16383716|NCT04093401|Experimental|Individualized risk assessment|Subjects will be assigned to the intervention arm (i.e., informed of their individualized risk assessment) if their subject ID is an even number. Subjects in the intervention arm will be informed of their estimated 1-year, 3-year, and 5-year risk of developing a second basal cell carcinoma.
16383717|NCT04093388|Experimental|Self-PAP|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the self-administered Papanicolaou (Pap) smear. They will be compared to each other for congruence and accuracy.
16383718|NCT04093388|Experimental|Traditional Pap|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the traditional, healthcare provider obtained Papanicolaou (Pap) smear specimen. They will be compared to each other for congruence and accuracy.
16383719|NCT04093375|Experimental|Radical Prostatectomy|Patients with locally advanced prostate adenocarcinoma receives Radical Prostatectomy with or without enlarged lymph node dissection
16383720|NCT04093375|Active Comparator|Radical Radiotherapy|Patients with locally advanced prostate adenocarcinoma receives Radical Radiotherapy with adjuvant androgen deprivation therapy
16383721|NCT04093362|Experimental|TAS-120|TAS-120 tablets, oral; 21-day cycle
16383722|NCT04093362|Active Comparator|Cisplatin/Gemcitabine|"• On Days 1 and 8 of a 21-day cycle, patients will receive:
~Cisplatin 25 mg/m2 in 1000 mL 0.9% saline by intravenous (I.V.) infusion over 1 hour, followed by 500 mL 0.9% saline over 30 minutes; and
~Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline by I.V. infusion over 30 minutes, beginning after completion of the cisplatin and saline infusions."
16383723|NCT04093349|Experimental|SPK-3006|All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.
16383727|NCT04093310|Experimental|Word catheter|The abscess is incised and the Word catheter is inserted into the residual cavity to create a neo-channel to prevent recurrence. The catheter is removed after 4 weeks during a consultation
16383728|NCT04093310|Active Comparator|Incision-drainage|This procedure performed under general or loco-regional anaesthesia consists in incising the abscess, draining the pus build-up and placing a wick in the residual cavity to promote progressive healing from the inside out.
16383729|NCT04093297|Active Comparator|Group Ring|Patients in Group Ring will undergo tricuspid rigid ring annuloplasty
16383730|NCT04093297|Active Comparator|Group Band|Patients in Group Band will undergo flexible band annuloplasty
16383731|NCT04093284|Experimental|Group A|The needle-free jet injector Continuous insulin therapy for 9 days, then changed to conventional insulin pen therapy for 9 days
16383732|NCT04093284|Experimental|Group B|The conventional insulin pen therapy for 9 days, then changed to needle-free jet injector Continuous insulin therapy for 9 days
16383733|NCT04093271|Experimental|Randomized to consume Rest-ZZZ, comparator, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Rest-ZZZ dietary supplement in Study Period 1, Comparator (Diphenhydramine HCl) in Study Period 2, and Placebo in Study Period 3.
16383734|NCT04093271|Experimental|Randomized to consume comparator, placebo, then Rest-ZZZ|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Comparator (Diphenhydramine HCl) in Study Period 1, Placebo in Study Period 2, and the Dietary Supplement, Rest-ZZZ in Study Period 3.
16383735|NCT04093271|Experimental|Randomized to consume placebo, Rest-ZZZ, then comparator|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Dietary Supplement, Rest-ZZZ in Study Period 2, and Comparator (Diphenhydramine HCl) in Study Period 3.
16383736|NCT04093258|Experimental|Test/Control|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
16383737|NCT04093258|Experimental|Control/Test|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
16383738|NCT04093245|No Intervention|Phase I-A (Local project set-up)|An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
16383739|NCT04093245|Experimental|Phase I-B (Implementation):|The investigators will implement the context-adapted ACE program with the support of administrators and local implementation teams who will have the responsibility to roll out the different elements of the intervention within their respective hospitals. It may include a series of systematic pre-discharge, post-discharge and across transitions period interventions for eligible patients: 1) a GEM nurse to support patients during the post-discharge transition period, 2) pre- and post-hospitalization medication list reconciliation, 3) systematic discharge summaries given to patients and/or caregiver, and sent to their family physician, 4) a planned follow-up appointment with their family physician, 5) a systematic follow-up phone call, 6) access to wiki-based patient-oriented KT tools, 7) access to a community-based telemonitoring service.
16383740|NCT04093245|Experimental|Phase IC (Study description)|Results from each center will be analysed over time. Guided by previous work in healthcare governance, the investigators will analyze the impact of the sequential interventions within the context of a major health reform in Quebec aiming at implementing an integrated health system and within the PI program's overall goal of creating a Learning Health System. This will be accomplished by conducting a comparative case study across the four study sites to compare the barriers, facilitators and local solutions implemented to gain a better understanding about how the ACE program could eventually be scaled up elsewhere.
16383741|NCT04093219|Experimental|IV Acetaminophen|1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
16383742|NCT04093219|Placebo Comparator|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
16383743|NCT04093206|Experimental|EpiCor and Vitamin C|EpiCor (90mg/5ml) and Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
16383744|NCT04093206|Active Comparator|Vitamin C|Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
16383745|NCT04093193|Experimental|Debridement group|Patients receive routine post-operative debridement at their Day 6, 30 and 60 follow up appointments.
16383746|NCT04093193|No Intervention|Non Debridement Group|Patients will not receive debridement at any follow up visit after surgery. They will continue with saline irrigation.
16383747|NCT04093180|Experimental|Experimental group|Experimental group undergoing treatment course according to INRS
16383748|NCT04093180|Other|Control group|Wait-list delayed intervention. Control group continues usual activity and care while staying in the waiting list.
16383749|NCT04093167|Experimental|Pembrolizumab|200mg (or 2mg/kg) IV every 3 weeks for cycles 1-3 then as per standard of care for patients with PD-L1+ EGFR/ALK-NSCLC
16383750|NCT04093154|Experimental|Virtual Reality|Standard Care + VR VR applications introduced to the child or adolescent by the researcher before the procedure. Three VR applications were used in this study; riding a rollercoaster (Rilix VR), swimming with marine animals in underwater world (Ocean Rift) and exploring the forest though the eyes of woodland species (In the eyes of animal). Children/adolescent chose one of these three applications. When the child is ready for the procedure, the researcher started the application by wearing virtual glasses to the child/adolescent. VR intervention was started 2-3 min before the procedure and continued until the procedure was completed.
16383751|NCT04093154|No Intervention|Control|Standart Care Control group children did not receive any distraction techniques.
16383752|NCT04093141|Experimental|Intervention|
16383753|NCT04093128|Experimental|adults aged 19-57|adults aged 19-57 years old living in Amman Jordan, body mass index between 19-57
16383754|NCT04093115|Experimental|CX1106|CX1106 740 mg/m2 as a 24-hour continuous infusion for 5 days every 3 weeks (3 weeks/cycle, 4-6 cycles)
16383755|NCT04093102||cases|cases with obsrtuctive sleep apnea
16383756|NCT04093102||control|cases without obstructive sleep apnea.
16383757|NCT04093089|Experimental|Test Group|
16383758|NCT04093089|Placebo Comparator|Control Group|
16383838|NCT04092478||Abdominal Crunch Position|We are going to use the Abdominal Crunch Position on each patients.
16383839|NCT04092452|Experimental|Cohort 1|PF-06650833
16383763|NCT04093063|Experimental|Intervention Group|Subjects in the intervention group were tasked with building a micro-stellated icosahedron using a detailed instruction manual. They were each provided with a dissecting microscope and necessary materials to complete the task at home at their leisure. They were given two weeks to complete the task. They were asked to return for a second in-person meeting two weeks.
16383764|NCT04093063|No Intervention|Control Group|Subjects in the non-intervention control group were not given any task or any materials. They were asked to return for a second in-person meeting in two weeks.
16383765|NCT04093050|Experimental|TT Genotype|
16383766|NCT04093050|Experimental|AA/AT Genotype|
16383767|NCT04093037|Experimental|Patient with dry eye disease|"Patient with dry eye disease will be included. They will have:
~Time #1: LacryDiag examination without dye
~Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score
~Time #3: Standard Break-Up Time (SBUT)
~Time #4: Schirmer test
~Satisfaction questionnaire to the patient"
16383768|NCT04093024|Experimental|Nintedanib (Ofev®)|
16383769|NCT04093024|Placebo Comparator|Placebo|
16383770|NCT04092998|Experimental|Thermocautery VS scalpel circumcision|Thermocautery circumcision in comparison to circumcision with traditional scalpel
16383771|NCT04092985||Patients suspected with Cardiac Arrhythmia|iECG + 12-lead ECG recording in patients suspected with any type of cardiac arrhythmias at the time of recruitment
16383772|NCT04092972|Experimental|Atherectomy|Atherectomy and drug-coated balloon (DCB)
16383773|NCT04092972|Active Comparator|Standard care|Standard care with predilation (POBA) and DCB
16383774|NCT04092959|Experimental|Walking group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
16383775|NCT04092959|Experimental|Chinese Square Dancing group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
16383776|NCT04092959|Experimental|Control group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
16383777|NCT04092946|Experimental|Patients with chronic musculoskeletal disorders|Tailored digital programs for individuals working for organizations that enter into a commercial agreement with SWORD Health, which acts as a service provider.
16383778|NCT04092920|Experimental|laser and SLA implants|extraction of badly broken maxillary and mandibular teeth with immediate implant placement using laser surface treated and SLA surface treated dental implants
16383779|NCT04092907|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
16383780|NCT04092907|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
16383781|NCT04092894|Active Comparator|Suvorexant|Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
16383782|NCT04092894|Placebo Comparator|Placebo|Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
16383783|NCT04092881|Active Comparator|Short pulsed Nd-YAG laser treatment side|"Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.
~Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections."
16383784|NCT04092881|Active Comparator|Fractional ablative CO2 laser treatment side|"Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.
~CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.
~Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae."
16383785|NCT04092868||cardiac surgery with extracorporeal circulation|"during the operation
~Intervention Blood sample :
~- Choay Heparin (pharmacokinetic) concentration: t = 5, 15, 30 minutes after the start of the heparin injection + t = 5, 30, 60 minutes after the start of extracorporeal circulation
~protamine dosage: t = 2, 5, 8, 10 and 15 min after protamine injection
~anti-X activity t = 0 before administration and at time 2, 5, 8, 10 and 15 min then at time 1, 3, 5, 6 and 7 hours after protamine injection
~thrombin generation test (TGT) activity (thrombinography) : t = 2, 5, 8, 10 and 15 min after protamine injection"
16383786|NCT04092842|Experimental|Group intervention: Silicone prothesis|Breast cancer conservative surgery will be performed by removing the tumor according to the usual technique and then the defect generated will be filled with a silicone prosthesis of the same size. Said prosthesis will be covered with fat and subcutaneous cellular tissue and then the skin will be closed.
16383840|NCT04092452|Experimental|Cohort 2|PF-6700841
16383841|NCT04092452|Experimental|Cohort 3|PF-06826647
16383787|NCT04092842|Active Comparator|Group control: Usual surgical technique|Breast cancer conservative surgery will be performed according to the usual surgical technique, that is, removing the tumor and covering the defect by mobilizing the breast tissue and then closing the skin.
16383788|NCT04092829|No Intervention|FROZEN EMBRYO TRANSFER IN NATURAL CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
16383789|NCT04092829|Active Comparator|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol >100 pg/ml and serum progesterone < 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.
16383790|NCT04092816|Experimental|FAMILY|Patient-co-parent dyads will participate in the FAMILY intervention in-person.
16383791|NCT04092803|No Intervention|GA for LP|Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
16383792|NCT04092803|Experimental|VR for LP|"The patients in this study will be presented the opportunity to use VR instead of undergo GA for a LP. Patients who agree to undergo an LP with VR will be assessed by a certified child life specialist (CCLS) to determine whether the patient is an appropriate candidate for using VR.The system includes a VR headset with VR software already loaded in to it. The VR software to be used is either a game called Pebbles the Penguin or SpacePups (Weightless Studios)."
16383793|NCT04092790|Experimental|Virtual Gate Device (VGD)|The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.
16383794|NCT04092777|Experimental|Strong Minds Program|This is a 10-session, culturally-adapted intervention, that includes cognitive behavioral therapy techniques combined with mindfulness exercises, led by a Community Health Worker.
16383795|NCT04092777|Other|Enhanced Usual Care|Enhanced usual care includes check in calls by a Care Manager 4 times over the course of 6 months and educational materials about depression and anxiety.
16383796|NCT04092764|Experimental|Participants Receiving Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks.
16383797|NCT04092751|Experimental|Treatment A|Single oral 20-mg dose of PRA on Day 1 AM
16383798|NCT04092751|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later.
16383799|NCT04092738|Experimental|Intervention Group|"In the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to sit less and move more at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks."
16383800|NCT04092738|No Intervention|Control Group|Subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.
16383801|NCT04092725|Experimental|Treatment A|Single oral 150-mg dose of DAB on Day 1 AM.
16383802|NCT04092725|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
16383803|NCT04092712|Experimental|Investigational Product|[14C]-CTP-543
16383804|NCT04092699|Other|patient|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
16383805|NCT04092699|Other|skulls|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
16383809|NCT04092673|Experimental|sequential escalation|eFT226 is administered IV weekly in 21 day cycles. eFT226 doses will be escalated in sequential cohorts after subjects enrolled in a given cohort have completed the 21-day dose-limiting toxicity (DLT) evaluation period. Starting dose is 0.005mg/kg/week, potentially escalating to 0.12mg/kg/week until MTD and RP2D are established
16383835|NCT04092491||1 blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:
~2 PAXgene RNA tubes of 2 ml each
~1 dry tube for creatinine and IgA assay
~1 tube of NFs (5ml)"
16383810|NCT04092660|Experimental|Intervention Care Group|"The Intervention care group will receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard. Additionally, they will also receive special support in the form of behaviour change interventions. The behavior change interventions consist of motivational interviewing, will be shown a video highlighting the negative consequences of sleep apnoea.
~Booster calls at week 3,6, 18 and 12 for verbal encouragement and to resolve any technical problems with the device.
~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life."
16383811|NCT04092660|Active Comparator|Standardized Care Group|"The standardized care group will only receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard along with routine care and will be called for follow up at 3rd and 6th month of treatment to assess their use and to resolve any technical problems with the device.
~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life at the initial visit and subsequent follow-up."
16383812|NCT04092647|Experimental|ashwagandha|Ashwagandha
16383813|NCT04092647|Placebo Comparator|placebo|Placebo
16383814|NCT04092634|Experimental|Dual mobility|Patients in this group will receive a dual mobility hip implant
16383815|NCT04092634|Active Comparator|Single bearing, traditional hip implant|Patients in this group will receive a traditional, single-bearing hip implant.
16383816|NCT04092621|Experimental|Rhythm-control strategy|The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
16383817|NCT04092621|Active Comparator|Rate-control strategy|At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
16383818|NCT04092608|Active Comparator|Low CVP group (restrictive group)|"Standard practice: the goal is to keep the CVP < 7 mmHg during surgery.
~Baseline of crystalloid of 2ml/kg/h max in all patients.
~EV 1000 monitoring device (Edwards Lifesciences, Irvine, USA) will be used but values will be blinded to the anesthesiologist in charge of the patient.
~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion
~Additionnal fluid administration is given to the patient at the end of the surgery (standard practice)
~UPi is blinded in all groups"
16383819|NCT04092608|Experimental|GDFT group|"The goal is to keep stroke volume variation below 13% during surgery with mini fluid challenge of 100 ml of balanced crystalloid using the monitoring device (Edwards Lifesciences, Irvine, USA). Of course, the values will not be blinded to the anesthesiologist in charge of the patient.
~All patients have a baseline crystalloid: 2ml/kg/h and mini fluid challenges per 100 ml as described above.
~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion
~UPi is blinded in all groups"
16383820|NCT04092595|Experimental|PF-06651600 and Rosuvastatin|Period 1 is 4 days in length. On Day 1 of Period 1 participants will receive a single dose of Rosuvastatin 10 mg given as a tablet orally. Period 2 is 11 days in length and will immediately follow Period 1 with no washout. In Period 2, participants will be dosed with oral 200 mg PF-06651600 once-daily (QD) for 7 days. On Day 8 of Period 2, a single dose of 10 mg Rosuvastatin oral tablet will be administered following administration of the 200-mg dose of PF-06651600. Dosing with oral 200 mg PF-06651600 QD will continue until Day 10 of Period 2.
16383821|NCT04092582|Experimental|MTPS9579A|
16383822|NCT04092582|Placebo Comparator|Placebo|
16383823|NCT04092569|Active Comparator|Intervention group|Pre-medical consultation structured diabetes self-care education programme
16383824|NCT04092569|No Intervention|Control group|Usual care
16383825|NCT04092556|Active Comparator|tDCS (M1)|The participants will be submit to tDCS applied over the motor cortex (M1)
16383826|NCT04092556|Active Comparator|tDCS (Cerebellar cortex)|The participants will be submit to tDCS applied over the cerebellar cortex
16383827|NCT04092556|Sham Comparator|Sham stimulation|The participants will be submit to sham stimulation
16383828|NCT04092543||Stroke patients|All patients diagnosed with a stroke are collected in the database.
16383829|NCT04092530|Experimental|Intervention - Aim 2|During the intervention period, staff will capture women during the first well-baby visit (WBV) and offer to have the next visit co-scheduled for infant and contraception care. Appointments are scheduled during the discharge process at the end of each WBV. During the discharge process all women 0-6 months postpartum will be identified by clerical staff through review of each pediatric clinic beforehand and through an electronic flag alert in the infant's electronic medical record. The pre-review of pediatric clinic schedules and the use of the flag will remind staff to offer the mother a co-scheduled visit for newborn and contraceptive care at the time of the next newborn visit.
16383830|NCT04092530|No Intervention|Control - Aim 2|Clinics will schedule postpartum contraception using normal clinic procedures.
16383831|NCT04092517|Active Comparator|Control Corn Soya Diet|Control Corn Soya Diet will be prepared to a formulation for Corn Soya Blend (SUPER CEREAL) product adopted by the WFP as complementary food for children over than 6 months.
16383832|NCT04092517|Experimental|Test Corn Moringa Diet|Test Corn Moringa Diet will be prepared to the same formulation as Corn Soya Blend, but the Soya content will be replaced with Moringa and no micronutrient premix will be added.
16383836|NCT04092478||Traditional Sitting Position|We are going to use the Traditional Sitting Position on each patients.
16383845|NCT04092426||patients with keratoconus|"patients with keratoconus attending refractive surgery centers in Assiut will be subjected to the following :-
~Full history and clinical evaluation.
~collection of individual data ( residency , occupation , special habbit , chronic illness )
~Analysis of results to assess prevelance of keratoconus and its distribution geographically in Assiut"
16383846|NCT04092400||Micro-Invasive Glaucoma Surgical devices|Patients implanted With Micro-invasive Glaucoma Surgical (MIGS) devices at the National University Hospital, Singapore
16383847|NCT04092387|Experimental|RC 1 only|Research cigarettes #1
16383848|NCT04092387|Experimental|RC 2 only|Research Cigarettes #2
16383849|NCT04092387|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
16383850|NCT04092387|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
16383851|NCT04092374|Experimental|Case arm|
16383852|NCT04092361||anisometropic amblyopia|
16383853|NCT04092361||strabismic amblyopia|
16383854|NCT04092361||deprivational amblyopia|
16383855|NCT04092348||study group|children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia
16383856|NCT04092348||control group|healthy age- and sex-matched children without ahistory of any malignancies
16383857|NCT04092322||Patients with subacute chronic stroke|Patients with subacute chronic stroke between the ages of 40-80
16383858|NCT04092309|Other|ACE group|patients after bone marrow transplantation will be treated with ACE inhibitor
16383859|NCT04092309|Other|Sacubitril Valsartan group|patients after bone marrow transplantation will be treated with sacubitril valsartan
16383860|NCT04092309|Other|Control group|patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan
16383861|NCT04092296|Experimental|resin infiltration|resin infiltrant (Icon product, DMG, Hamburg,Germany)
16383862|NCT04092296|Active Comparator|remineralization|
16383866|NCT04092257|Experimental|VIA and thermocoagulation|Participants will undergo same day VIA and thermocoagulation
16383867|NCT04092231||1|Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
16383868|NCT04092205|Experimental|Experimental: Treatment|28 days treatment with NBMI 600 mg/day
16383871|NCT04092179|Experimental|Venetoclax and Enadisenib|"Enasidenib and venetoclax will be taken by mouth (orally), once a day, every day, continuously.
~Every 28-day period will be called a cycle. Participants will start venetoclax alone on Cycle 1 Day 1 and continue the study drug alone until Day 15. On Day 15, participants will take enasidenib and venetoclax together and will continue to take the combination of study drugs until intolerable side effects or disease worsening."
16383872|NCT04092166|No Intervention|Controlled|Participants will have no intervention.
16383873|NCT04092166|Other|Cardiac Rehab Exercise: Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
16383874|NCT04092153|Active Comparator|Mechanically aligned|Neutral limb alignment irrespective of the patient's native knee anatomy and joint mechanics
16383875|NCT04092153|Experimental|Functionally aligned|Restore the patient's own pre-arthritic knee anatomy
16383876|NCT04092140||diabetic complaining of neuropathy or not|using of ultrasound in examination and nerve conduction study
16383877|NCT04092140||carpal tunnel syndrome|using of ultrasound in examination and nerve conduction study
16383878|NCT04092127||premature infants (<32 weeks of Gestation Age)|premature babies (<32 weeks of Gestation Age) to be screened with RetCam for retinopathy of prematurity and who will be filmed during the screening procedure to evaluate pain with the PIPP score (Premature Infant Pain Profile)
16383879|NCT04092114|Other|Control|Receives Standard of Care (SOC) services established in accordance with the South African Department of Health (DoH) PrEP (Pre-exposure Prophylaxis) guidelines.
16383917|NCT04091880|Active Comparator|control group A|378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
16384421|NCT04088370||Alcoholic Hepatitis|No intervention-blood draw only
16383880|NCT04092114|Experimental|CHARISMA Intervention|"Receives SOC (Standard of care) per control arm plus provider-administration of HEART (HEAlthy Relationship Assessment Tool) and provider-administration of CHARISMA (the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence) counseling modules, as applicable:
~Module A: General Partner Communication and Relationship Skills
~Module B: Partner Disclosure and Communication around PrEP Use
~Module C: Responding to Intimate Partner Violence and Safety Planning"
16383881|NCT04092101|Experimental|RC 1 only|Research Cigarettes #1
16383882|NCT04092101|Experimental|RC 2 only|Research Cigarettes #2
16383883|NCT04092101|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
16383884|NCT04092101|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
16383885|NCT04092088|Active Comparator|tDCS-r+TENS-r|Real transcranial direct current stimulation (tDCS-r) + real transcutaneous electrical nerve stimulation (TENS-r)
16383886|NCT04092088|Experimental|tDCS-r+TENS-s|Real transcranial direct current stimulation (tDCS-r) + sham transcutaneous electrical nerve stimulation (TENS-s)
16383887|NCT04092088|Experimental|tDCS-s+TENS-r|Sham transcranial direct current stimulation (tDCS-s) + real transcutaneous electrical nerve stimulation (TENS-r)
16383888|NCT04092088|Sham Comparator|tDCS-s+TENS-s|Sham transcranial direct current stimulation (tDCS-s) + sham transcutaneous electrical nerve stimulation (TENS-s)
16383889|NCT04092075|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
16383890|NCT04092075|Sham Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
16383891|NCT04092062|Experimental|Treatment - ToothWave brush|Subjects using the Silk'n ToothWave, Radio frequency (RF)-utilizing toothbrush.
16383892|NCT04092062|Sham Comparator|Control - powered toothbrush|Subjects using a regular ADA-Accepted Powered Toothbrush, no RF
16383893|NCT04092049|Experimental|lollipop|
16383894|NCT04092049|No Intervention|control|
16383895|NCT04092036||Unstable patients|Patients on mechanical ventilation, 18 years or older and developing hypotension (Mean arterial blood pressure) <65 mmHg
16383896|NCT04092023|Other|Control group|Participants in control group will be received usual care. They will be gone through yearly DM complication screening. A screening report and information sheet on general DM management will be issued to participants. Therapeutic goals will be set and further conventional health care education intervention will be referred.
16383897|NCT04092023|Other|Intervention group|The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
16383898|NCT04092010|Experimental|Stepped-care intervention (SCI) group|In the SCI group, mothers with low baseline depressive symptoms are offered the problem-solving education (PSE) prevention intervention, and mothers with greater depressive symptoms are offered Engagement Sessions.
16383899|NCT04092010|Active Comparator|Usual care control group|Families in the control group will receive usual Head Start services.
16383900|NCT04091997||endometriosis|laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
16383901|NCT04091997||control|diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
16383902|NCT04091984||Prospera Arm|There is no intervention in this study. Adult patients who have received a kidney allograft from a genetically different donor within 60 days and who have been selected by their healthcare provider to receive Prospera dd-cfDNA testing according to their regular interval testing schedule as part of their clinical care will have medical records pertaining to their kidney rejection status collected at each study visit.
16383903|NCT04091984||Control Arm|The control arm will consist of retrospective data review of cases where a renal allograft from a genetically different donor was performed. Data pertaining to to their kidney rejection status from a minimum of 3 time points per year post allograft (up to 5 years) or until renal allograft failure will be collected.
16383904|NCT04091971|Experimental|Depressed adults with current MDD|Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.
16383905|NCT04091958|Experimental|Post-tumourectomy reconstruction with myo-glandular flap.|Standard tumourectomy followed by reconstruction with myo-glandular flap.
16383906|NCT04091945|Active Comparator|LT3001 Drug Product|
16383907|NCT04091945|Placebo Comparator|Placebo|
16383908|NCT04091932|Experimental|Pembrolizumab treatment|Pembrolizumab dosage form:100mg/4ml dosage:2mg/kg weight frequency: once per 4 weeks duration:12 weeks
16383909|NCT04091919||ASD group|Isolated ostium Secundum ASD patients who are involving in this study have been already selected for intervention before the starting time of the study. The ASD patients who will be scheduled for transcatheter closure have either haemodynamically significant shunt fraction (Qp/Qs > 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms. 2-D TTE derived Tissue Doppler and Strain Imaging will be done for all patients at baseline, 24 hours and 1-3 month post-procedure. Correlation between the device size and echocardiographic variables will be performed. Comparison between the results of the 2D-TTE derived Strain Imaging procedures will be done between baseline data and those obtained one day after the procedure and at one month follow up.
16383910|NCT04091919||Controlled group|Age matched controlled subjects without ASD
16383911|NCT04091906|Experimental|Healthy donor|
16383912|NCT04091893|Active Comparator|Usual care/wait list|
16383913|NCT04091893|Experimental|Art Rx|
16383914|NCT04091893|Experimental|Artful Meditation|
16383915|NCT04091893|Experimental|Art Rx + Artful Meditation|
16383916|NCT04091880|Experimental|experimental group|378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
16383918|NCT04091880|Active Comparator|control group B|378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
16383919|NCT04091867|Experimental|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
~Cetuximab:
~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
~RT:
~6930 cGy IMRT starting D15-D18"
16383920|NCT04091854||HMS5552 treatment|
16383921|NCT04091841|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
16383922|NCT04091841|Placebo Comparator|Carbo Mass|Control patients will be received protein diet (1.2 g/kg/day) and Carbo Mass for 1 month after surgery.
16383923|NCT04091828||Biplar patients|diagnosed by DSM-5 and divided to manic,depressed and mixed last episod
16383924|NCT04091828||controlled subject|not have any medical or psychatric problem affect cognition
16383925|NCT04091815|Active Comparator|I group - general anaesthesia|General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), opioids (fentanyl and morphine), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture.
16383926|NCT04091815|Experimental|II group - combined - spinal and general anaesthesia|"Spinal anesthesia: L3-4 interspace, 27G needle, bupivacaine hyperbaric, 16 mg, morphine sulfate 0.1% - 0.1ml.
~General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture."
16383927|NCT04091802|Experimental|single layer of L-PRF|single layer of L-PRF will be put in the vertical incision
16383928|NCT04091802|Experimental|multiple layers of L-PRF|multiple layers of L-PRF will be put in the vertical incision
16383929|NCT04091789|Experimental|Test Article|Subjects will take Pure Femme sublingual tablets as directed, one tablet 2 days before, one tablet 1 day before, and then up to 3 tablets per day for 3 days (72 hours) during menstruation.
16383930|NCT04091763|Experimental|Polidocanol foam sclerotherapy|"Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);
~Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;
~Patients treated in a maximum of 3 sessions at 3 weeks intervals;
~Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;
~In each session more than one hemorrhoid cushion could be treated."
16383931|NCT04091763|Experimental|Rubber band ligation|"Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;
~A maximum of 3 sessions of ligation at 3-week intervals were performed;
~More than 1 band per session could be applied."
16383932|NCT04091750|Experimental|Single Arm|"Induction phase:
~Nivolumab 3mg/kg IV plus Ipilimumab 1mg/kg IV every 3 weeks x 4 cycles (12 week period)
~Cabozantinib 40mg PO daily for 12 weeks
~Maintenance phase:
~Nivolumab 480mg IV every 4 weeks for up to 92 weeks
~Cabozantinib 40mg PO daily for up to 92 weeks
~Maintenance therapy will continue for up to 92 weeks to complete 2 years total of treatment if tolerating therapy well and disease is controlled."
16383933|NCT04091737|Experimental|CSL200|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
16383934|NCT04091724||Delirium is determined by PAED score|
16383935|NCT04091724||No delirium is determined by PAED score|
16383936|NCT04091711|Experimental|ReX-C intervention|Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
16383937|NCT04091698|Active Comparator|topical Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
16383938|NCT04091698|Placebo Comparator|topical corticosteroid|will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.
16383939|NCT04091672|Experimental|All Participants (within patient control)|All subjects will receive both RECELL and skin graft. Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment (RECELL) will be randomly allocated to either Area A or Area B
16383940|NCT04091659|Active Comparator|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
16383941|NCT04091659|Experimental|Virtual Reality|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
16383942|NCT04091646|Active Comparator|ARQ-154 foam 0.3%|active
16383943|NCT04091646|Placebo Comparator|ARQ-154 foam Vehicle|placebo
16383974|NCT04091438|Placebo Comparator|Placebo + TAK-925 Dose A|TAK-925 placebo-matching 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 Dose A, 9-hour IV infusion once on Day 3, Treatment Period 2.
16383975|NCT04091425|Experimental|TAK-925 Dose A|TAK-925 dose A intravenous (IV) infusion in each treatment sequence (crossover design).
16383944|NCT04091633|Active Comparator|School Mental Health Program-Conventional (cSMHP)|The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
16383945|NCT04091633|Experimental|Enhanced-School Mental Health Program (eSMHP)|The teachers of schools randomized to intervention arm will receive online training in adapted version of School Mental Health Program. The online training in adapted School Mental Health Program consists of 4-5 hour, self-paced online training course for teachers. The teachers will register themselves in the online course in the form of a group of 4-5 teachers from each school. The teachers will complete the online training course in a group, with interactive group activities and role plays. Progress to the next module in the online training is conditional upon completion of post-module mental health literacy quiz. A certificate of training completion in adapted SMHP shall be awarded to those teachers who complete the post-test. Teachers will be supported online and in-person by the trainers who are trained in SMHP in monthly supervision meeting of teachers for 9-months.
16383946|NCT04091620|Experimental|Transanal Total Mesorectal Excision|For transanal total mesorectal excision, a two team approach will be adopted. One surgical team will be performing the abdominal phase dissection using standard laparoscopic approach, while the other will be simultaneously performing the transanal dissection and total mesorectal excision in a 'down-to-up' fashion using laparoscopic instruments.
16383947|NCT04091620|Active Comparator|Robotic Total Mesorectal Excision|For robotic total mesorectal excision, a fully robotic approach will be adopted. Left-sided colonic mobilization, division of lymphovascular pedicle, and 'top-to-down' total mesorectal excision will be performed using the robotic platform.
16383948|NCT04091607|Active Comparator|Music Therapy Intervention Group|listen to preferred choice of music during the Lumbar Medial Branch Block procedure.
16383949|NCT04091607|No Intervention|Control Group|No music will be provided but will be provided earbuds. The sound environment will be standard for procedures by closing procedure room door and minimizing extraneous sounds.
16383950|NCT04091594|Experimental|Flexible orthotic|Sensory input flexible ankle foot orthotic (SIAFO) with appropriate lycra garments
16383951|NCT04091594|Active Comparator|Standard of care|Standard of care solid ankle foot orthotic (AFO)
16383952|NCT04091581|Experimental|Assessment|Instill eye drop and perform followup assessments
16383953|NCT04091568||Awake fibre-optic intubation|Awake fibre-optic intubation
16383954|NCT04091568||Asleep fibre-optic intubation|Asleep fibre-optic intubation
16383955|NCT04091542|Experimental|FiO2 group 1|FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
16383956|NCT04091542|Experimental|FiO2 group 2|FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
16383957|NCT04091542|Experimental|Duration 1|In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
16383958|NCT04091542|Experimental|Duration 2|In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
16383959|NCT04091542|Experimental|respiratory rate 1|In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
16383960|NCT04091542|Experimental|respiratory rate 2|In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
16383961|NCT04091542|Experimental|Position 1|The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
16383962|NCT04091542|Experimental|Position 2|The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
16383963|NCT04091529|Experimental|Radiofrequency myolysis of uterine fibroids|54 premenopausal participants with symptomatic uterine myomas
16383964|NCT04091516|Other|Low-fat plant-based diet|For 12 weeks, participants will follow a diet comprised of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
16383965|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 75 mg/M2 per day|75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
16383966|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 150 mg/M2 per day|150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
16383967|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 200 mg/M2 per day|200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
16383968|NCT04091490|Experimental|Patients with relapsed/refractory Hodgkin's lymphoma|A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
16383969|NCT04091464|Experimental|TRAIN-BW|1x/week for 8 weeks + home exercise program
16383970|NCT04091464|Active Comparator|TRAIN-FW|1x/week for 8 weeks + home exercise program
16383971|NCT04091451|Experimental|HZ/su Group|Subjects randomized to the HZ/su group will receive 2 doses of HZ/su vaccine at visit day 1 and visit month 2 and will be followed up until the study end.
16383972|NCT04091451|Placebo Comparator|Placebo Group|Subjects randomized to Placebo group will receive placebo at visit day 1 and visit month 2 and will be followed up until the study end.
16383973|NCT04091438|Experimental|TAK-925 Dose A + Placebo|TAK-925 Dose A, 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour IV infusion once on Day 3, Treatment Period 2.
16384422|NCT04088370||Healthy Controls|No intervention- blood draw only
16383976|NCT04091425|Experimental|TAK-925 Dose B|TAK-925 dose B IV infusion in each treatment sequence (cross over design).
16383977|NCT04091425|Placebo Comparator|Placebo|TAK-925 placebo-matching IV infusion in each treatment sequence (crossover design).
16383978|NCT04091412|Experimental|Long-term administration of Butylphthalide Soft Capsules|In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.
16383979|NCT04091412|No Intervention|Standard secondary prevention group|patients in this group take atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets as standard secondary prevention.
16383980|NCT04091399|Experimental|Patient cohort|Patients suffered from alveolar osteitis and treated using a Stomatological tamponade Contipro, composed of the Hyaluronic acid and Octenidine dihydrochloride. Firstly, the extraction wound had been irrigated with 2 ml of 3% solution of H2O2 to disinfect the site and then flushed by 2 ml of Aqua pro injectione to clear any remaining debris. After, the tested drug was applied into the extraction wound. This procedure was repeated on a daily basis for a maximum of 7 days or until the pain subsided below 20 mm and remained there for at least 2 days.
16383982|NCT04091373|Experimental|Sequence 1|100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
16383983|NCT04091373|Experimental|Sequence 2|100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
16383984|NCT04091373|Experimental|Sequence 3|100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
16383985|NCT04091373|Experimental|Sequence 4|100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
16383986|NCT04091373|Experimental|Sequence 5|100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
16383987|NCT04091373|Experimental|Sequence 6|100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
16383988|NCT04091360|Experimental|Experimental dose 1 - 100ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 1; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 100ug; Inhaler No.1 = 50ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
16383989|NCT04091360|Experimental|Experimental dose 2 - 300ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 2; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 300ug; Inhaler No.1 = 150ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
16383990|NCT04091360|Experimental|Experimental dose 3 - 1000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 3; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 1000ug; Inhaler No.1 = 500ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
16383991|NCT04091360|Experimental|Experimental dose 4 - 3000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 4; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 3000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug"
16383992|NCT04091360|Experimental|Experimental dose 5 - 6000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 5; each patient will be instructed to take four puffs (inhalations) from each of Inhalers 1 through 3, for a total of twelve inhalations.
~No. of Puffs per Inhaler = 4; Total Dose = 6000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug"
16383993|NCT04091360|Placebo Comparator|Placebo comparator - placebo|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 6; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = Placebo; Inhaler No.1 = Placebo; Inhaler No.2 = Placebo; Inhaler No.3 = Placebo"
16383994|NCT04091347|Experimental|Intervention Arm|The intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
16383995|NCT04091347|Active Comparator|Wait List Control Arm|Once the intervention group has completed the intervention the wait list control group will complete the intervention.
16383996|NCT04091334|Experimental|Serial ultrasound group|"Will received standard care and monitoring and in addition, have focused ultrasound examination of the heart and the lungs done twice.
~The investigator is supposed to titrate the treatment according to the findings on the ultrasound examinations."
16383997|NCT04091334|Active Comparator|Standard care group|Standard care and monitoring.
16383998|NCT04091321||Chronic Headache|Women who endorse chronic headache
16383999|NCT04091321||Chronic Back Pain|Women who endorse chronic back pain
16384000|NCT04091308|Active Comparator|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
16384001|NCT04091308|Experimental|Usual Care with Protein Supl.|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
16384002|NCT04091308|Experimental|Individualized Physical Exercise Training with Protein Supl.|This group is also called EXER group, and will receive individually tailored physical exercise programs, based on their strength and weaknesses from the baseline testing.
16384003|NCT04091269|Placebo Comparator|PSV-10%|PSV mode using E5 ventilator with fixed flow trigger and Esense 10%
16384004|NCT04091269|Placebo Comparator|PVS-30%|PSV mode using E5 ventilator with fixed flow trigger and Esense 30%
16384005|NCT04091269|Placebo Comparator|PSV-50%|PSV mode using E5 ventilator with fixed flow trigger and Esense 50%
16384423|NCT04088370||Healthy Heavy Drinkers|No intervention- blood draw only
16384006|NCT04091269|Experimental|PSV-auto|PSV mode using automatic adjustmen of inspiratory triger and cycling-off based on waveform
16384007|NCT04091269|Active Comparator|PSV-neuro|NAVA mode using NAVA level of 15 cmH2O/uV and pressure limit function to simulated EAdi triggered PSV.
16384008|NCT04091256|Experimental|Clinical trials with a single arm|: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
16384009|NCT04091243|Experimental|Romosozumab|Romosozumab (210mg) subcutaneously every month for 12 doses
16384010|NCT04091243|Active Comparator|Denosumab|Denosumab subcutaneously (60mg) every 6 months for 2 doses
16384011|NCT04091230|Experimental|novel needle|TRUSbx using the 18 gauge (G) 25 centimeter(cm) novel needle with 19 millimeter (mm) sample notch and a new actuator. 12 biopsies / patient.
16384012|NCT04091230|Active Comparator|standard tru cut needle|TRUSbx using a standard tru cut biopsy needle (Mermaid Medical M-biopsy 18G 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator ( Moller Medical Blue RBG-1000-10-1000). 12 biopsies/ patient.
16384013|NCT04091217|Experimental|Atezolizumab + Bevacizumab|
16384014|NCT04091204|Experimental|Olaparib|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
16384015|NCT04091191|Active Comparator|Specialized nutraceutical|Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
16384016|NCT04091191|Placebo Comparator|Placebo|Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
16384017|NCT04091178|Experimental|VITAMIN D SUPPLEMENTATION ARM|"On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).
~In parallel,a calcium supplementation is prescribed."
16384018|NCT04091165||Study Group|"Participants will be identified for inclusion by leaders of the GI Clinic after GI surgery has been scheduled. Upon consenting, participants will be instructed how to download and use the mobile phone application My Plate Calorie Counter."
16384019|NCT04091152||old patients|"Patient will freely use Ardoiz during their hospitalisation for a maximum of 9 days.
~After this use, a survey concerning the usability of Ardoiz will be administered to the patient, before their discharge from hospital."
16384020|NCT04091152||relatives / unformal caregivers|"Unformal caregivers will freely use Ardoiz during the hospitalization of their relatives and a maximum of 9 days.
~After this use, a survey concerning the usability of Ardoiz will be administered to the unformal caregivers, before the discharge of their hospitalized relatives from hospital."
16384021|NCT04091152||profesionnal caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Ardoiz will be administered to professional caregivers."
16384022|NCT04091139|Experimental|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).
~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
16384023|NCT04091139|Active Comparator|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
16384024|NCT04091126|Experimental|Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.9 milligram /kilogram (mg/kg) three -weekly (Q3W) dose of belantamab mafodotin intravenously (IV) on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.9 mg/kg four-weekly (Q4W) dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.
16384025|NCT04091126|Experimental|Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.4 mg/kg six-weekly (Q6W) dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.4 mg/kg eight-weekly (Q8W) dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.
16384026|NCT04091126|Experimental|Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.9 mg/kg Q8W dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.
16384027|NCT04091126|Experimental|Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin intravenously on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.0 mg/kg Q4W dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.
16384028|NCT04091126|Experimental|Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin intravenously on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.4 mg/kg Q4W dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.
16384029|NCT04091126|Experimental|Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd|Based on emerging data, participants will receive either 1.9 mg/kg or 2.5 mg/kg Q9W dose of belantamab mafodotin intravenously on Day 1 of every third 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive either 1.9 mg/kg or 2.5 mg/kg Q12W dose of belantamab mafodotin intravenously on Day 1 of every third 28-day cycle in combination with Rd.
16384061|NCT04090905||Cohort|
16384030|NCT04091126|Experimental|Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd|Based on emerging data, participants will receive a total dose of either 1.9 mg/kg or 2.5 mg/kg of belantamab mafodotin intravenously (split in to two equal doses of 0.95 mg/kg or 1.25 mg/kg to be given on Day 1 and Day 8) Q6W of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive a total dose of either 1.9 mg/kg or 2.5 mg/kg of belantamab mafodotin intravenously (split in to two equal doses of 0.95 mg/kg or 1.25 mg/kg to be given on Day 1 and Day 8) Q8W of every other 28-day cycle in combination with Rd.
16384031|NCT04091126|Experimental|Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd|Based on emerging data, participants will receive 2.5 mg/kg Q6W dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 2.5 mg/kg Q8W dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.
16384032|NCT04091113||Participants with Hereditary Angioedema|Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment
16384033|NCT04091100|Active Comparator|electroacupuncture|The individuals in the electroacupuncture group were administered the therapy by a certified acupuncturist. Two Shenlong acupuncture needles were inserted in each of the trapezius and levator scapulae muscles at intervals of 0-3 mm and clips were attached to their ends. Afterwards, an electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes.
16384034|NCT04091100|Active Comparator|myofascial release|Firstly, longitudinal stretching was done with forearm to the muscles in the person's neck in order to relax. Afterwards, the researcher placed one hand under the person's head and placed their fingertips on the muscles under the occipital bone in the neck area. The researcher applied lateral flexion to the neck with one hand while placing the other hand on the trapezius and levator scapulae muscles and then stretched the muscles with friction massage. After this step, the participant's neck was guided back into a neutral position and the pinching technique was applied to the muscles. During the administration of therapies, the trigger points on muscles were identified and friction was applied to these sites until a loosening could be felt. The myofascial release sessions concluded with the administration of the friction massage technique once again to the muscles.
16384035|NCT04091087|Experimental|crisaborole ointment|crisaborole ointment
16384036|NCT04091087|Sham Comparator|vehicle ointment|vehicle ointment
16384037|NCT04091074|Active Comparator|aspirin + ticagrelor before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + ticagrelor 90mg for 15 days before carotid stenting
16384038|NCT04091074|Active Comparator|aspirin + clopidogrel before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + clopidogrel 75 mg for 15 days before carotid stenting
16384039|NCT04091061|Experimental|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
16384040|NCT04091061|Experimental|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
16384041|NCT04091061|Experimental|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
16384042|NCT04091061|Experimental|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
16384044|NCT04091022|Active Comparator|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms twice per day and topical DFMO to bilateral forearms once per day.
16384045|NCT04091022|Placebo Comparator|Placebo + placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms twice per day and placebo for topical DFMO to bilateral forearms once per day.
16384046|NCT04091009|Active Comparator|Continue Group|Those who continue taking their standard dose of buprenorphine before, during and after surgery.
16384047|NCT04091009|Active Comparator|Reduce Group|Those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. Once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine.
16384048|NCT04090996|Experimental|DT patients|
16384049|NCT04090983|Active Comparator|Cognitive-behavioral therapy (Hesslinger protocol)|
16384050|NCT04090983|Experimental|Cognitive-behavioral therapy (CADDI protocol)|
16384051|NCT04090957|Experimental|Estetrol 15 mg - Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for 52 consecutive weeks.
16384052|NCT04090957|Experimental|Estetrol 20 mg - Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.
16384053|NCT04090957|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for 52 consecutive weeks.
16384054|NCT04090957|Experimental|Estetrol 20 mg - Safety Part|Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.
16384055|NCT04090944|Active Comparator|1st group (group B)|"The LMA LarySeal Multiple will be inserted using the blind technique which involves holding the LMA like a pen guided into the pharynx with the index finger of the operator at the junction of the tube and the bowl, with the operator at the head of the patient and the LMA facing caudally.
~The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
16384056|NCT04090944|Active Comparator|2nd group:(group U)|"The LMA LarySeal Multiple will be inserted under the guide of B-mode US on the anterior neck . Transverse scans , Sagittal view and Parasagittal view.
~-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
16384057|NCT04090931|Experimental|Heat-Activated Nickel-Titanium Archwires|"Heat-activated NiTi (HANT) Group (TruFlex™ Thermal Nickel-Titanium, Ortho Technology, USA):
~0.014-inch HANT
~0.016-inch HANT"
16384058|NCT04090931|Experimental|Superelastic Nickel-Titanium Archwires|"Superelastic NiTi (SENT) Group (TruFlex™ Nickel-Titanium, Ortho Technology, USA):
~0.014-inch SENT
~0.016-inch SENT"
16384062|NCT04090892||Persons with spasticity 4.0-20.11 years|Study personnel are not carrying out the surgical intervention but are assessing the outcomes of the surgery on gait and motor function.
16384063|NCT04090879|Experimental|RC 1 only|Research Cigarettes #1
16384064|NCT04090879|Experimental|RC 2 only|Research Cigarettes #2
16384065|NCT04090879|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
16384066|NCT04090879|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
16384067|NCT04090853|Other|Patient Treatment Group|Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
16384068|NCT04090840|Experimental|Intermittent Fasting|Patients will follow intermittent fasting for 16 hours with time restricted eating during an 8 hour window. The subjects are also advised to minimize sugar intake to <15g per serving.
16384069|NCT04090827|No Intervention|Control/ iheartchange Only|Access to the iHeartChange website only
16384070|NCT04090827|Experimental|Intervention|Nurse-led transition intervention and access to the iHeartChange website
16384071|NCT04090814|Experimental|Movement-Evoked Pain during TENS treatment|Participants performed several physical tasks while using the HeatTens device (HV-F311-E). During these tasks, participants needed to rate their pain.
16384072|NCT04090814|No Intervention|Movement-Evoked Pain|Participants performed several physical tasks during with their pain was assessed.
16384073|NCT04090801|Active Comparator|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|Group A applied topical minoxidil 5% in 90% ethanol and 5% propylene glycol
16384074|NCT04090801|Active Comparator|Topical minoxidil 5% in pure ethanol alone|Group B applied topical minoxidil 5% in pure ethanol alone
16384075|NCT04090801|Placebo Comparator|Placebo|Group C applied pure ethanol (placebo)
16384076|NCT04090788|Experimental|dried bitter-gourd supplements|2.4 gram per day for 4 weeks
16384077|NCT04090788|Active Comparator|dried cucumber supplements|2.4 gram per day for 4 weeks
16384078|NCT04090775|Other|Single arm. Subjects receiving treatment.|Cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
16384079|NCT04090762|No Intervention|Control|Women in the control arm will complete the baseline and follow up surveys but will not receive any intervention.
16384080|NCT04090762|Active Comparator|Risk information only|Women in the risk only arm who exhibit characteristics associated with a greater risk of a poor birth outcome will be informed that they possess these characteristics. Risk characteristics (identified from the medical and epidemiological literature) include age, prior pregnancy and birth history (e.g., previous stillbirth).
16384081|NCT04090762|Active Comparator|Conditional Cash Transfer only|Women in this arm will be eligible to receive conditional cash transfers. To receive the transfer, pregnant women must attend prenatal care and give birth in a health facility.
16384082|NCT04090762|Active Comparator|Conditional Cash Transfer and risk information|Women in this arm will be provided with risk information at the time of baseline survey administration AND be eligible to receive conditional cash transfers, pending attendance at prenatal care and delivery at a health facility.
16384083|NCT04090749|Experimental|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
16384084|NCT04090749|Other|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
16384085|NCT04090749|Experimental|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
16384086|NCT04090736|Experimental|Arm A: Pevonedistat plus Azacitidine|Pevonedistat 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine 75 mg/m2 subcutaneous administered on a 5-on/2-off [weekend]/2-on schedule in 28-day cycles (intravenous Azacitidine can be administered for any patients who have non-tolerated local reactions)
16384087|NCT04090736|Active Comparator|Arm B: Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle (intravenous azacitidine can be administered for any patients who have non-tolerated local reactions)
16384088|NCT04090723|Experimental|Computer-delivered brief alcohol intervention (CBI-CC)|Participants will be offered only the Computer-delivered brief alcohol intervention with peer navigation from beginning of study to the end.
16384091|NCT04090697|Experimental|Oxandrolone Cohort 1|Participants randomized to Oxandrolone Cohort 1 will receive 0.1mg/kg of oxandrolone suspended in a multi-chain triglyceride (MCT) oil buccally twice per day.
16384092|NCT04090697|No Intervention|Standard of Care|Participants randomized to standard of care will receive the standard therapies provided at the institution at which they are being treated. Control subjects will receive standard therapy with no placebo and no oxandrolone.
16384424|NCT04088357|Active Comparator|5 Percent TolaSure Topical Gel|5%(w/w) TolaSure Gel
16384093|NCT04090684|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
16384094|NCT04090671|Active Comparator|COPD Exacerbation|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
16384095|NCT04090671|Active Comparator|CHF|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
16384096|NCT04090671|Active Comparator|COPD|In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.
16384097|NCT04090671|Active Comparator|OSA|The questionnaire MDP will be administered once during the first visit in the sleep laboratory.
16384098|NCT04090658|Experimental|Group RSV_PreF3_AS01B|Subjects aged 60 to 80 years receiving 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Days 1 and 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
16384099|NCT04090658|Placebo Comparator|Group Placebo|Subjects aged 60 to 80 years receiving 2 doses of placebo as control, at Days 1 and 61, by IM injection into the deltoid region of the non-dominant arm preferably.
16384100|NCT04090645|Other|TheraShere in treatment of primary & secondary liver carcinoma|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
16384101|NCT04090632|Experimental|closed kineTic chain upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
16384102|NCT04090619||Observational (questionnaires)|Participants complete 8 questionnaires about appetite, quality of life, symptoms, history of weight loss, nutritional status, body image, and nutritional support over 30 minutes.
16384103|NCT04090606||FTC Method|
16384104|NCT04090606||Massachusetts Method|
16384105|NCT04090606||Health Canada Intense Method|
16384106|NCT04090593|Experimental|Educational Module Intervention|Intervention arm patients receive educational mobile module related to chronic condition that contributed to reason for admission.
16384107|NCT04090593|No Intervention|Hospital Practice Control|Control arm patients receive current, standard practice as related to patient education in the hospital (this does not include an educational mobile module).
16384108|NCT04090580|Experimental|Daily dosage of dapagliflozin and metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks
16384109|NCT04090580|Experimental|Daily dosage of metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks
16384110|NCT04090567|Experimental|Arm I (olaparib plus cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16384111|NCT04090567|Experimental|Arm II (olaparib plus ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16384112|NCT04090554|Other|Cytosponge™|Single intervention arm of feasibility study
16384113|NCT04090541|No Intervention|Control|Tests were applied with any taping.
16384114|NCT04090541|Sham Comparator|Sham Taping|In ST stage; medical purpose, hypoallergenic OctaCare® Rigid Transparent Plaster was applied as a rigid tape. This tape is also used under rigid tapes for protecting the skin. In this study investigators didn't prefer extra rigid tape on the plaster because that was very light and less sensitive material to our knowledge so it suited our aim of placebo control.
16384115|NCT04090541|Experimental|Kinesiology Taping|In KT stage; the original Kinesio Tex® Tape Classic was applied as a kinesiology tape. In this study, investigators applied the tape with muscle activation technique and paper of tension (it was declared %10) according to Kenzo Kase's Kinesio Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
16384116|NCT04090541|Experimental|Biomechanical Taping|In BT stage; Dynamic Tape® was applied as a biomechanical tape. In this study, investigators applied the tape with offload technique and paper of tension according to Ryan Kendrick's Biomechanical Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
16384117|NCT04090528|Experimental|Arm 1: One DNA vaccine|"100 µg pTVG-HP administered intradermally (i.d.) days 1, 8 plus 200 mg Pembrolizumab, administered intravenously on day 1 of 21-day cycles (for 8 cycles)
~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles
~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 of 21-day cycles x 4 cycles"
16384118|NCT04090528|Experimental|Arm 2: Two DNA vaccines|"100 µg pTVG-AR administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 1, 2, 5, and 6 alternating with 100 µg pTVG-HP administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 3, 4, 7, and 8.
~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles
~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-AR i.d days 1, 8 + 200 mg pembrolizumab IV day 1 of q 21-day cycles, for cycles 1 and 2 followed by 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 in 21-day cycles, for cycles 3 and 4"
16384147|NCT04090281|Other|Precision medicine implementation|Patients will receive a precision medicine approach, incorporating both CYP2C19 genotyping and platelet reactivity phenotyping, to guide dual antiplatelet therapy selection for patients with ACS, post PCI and followed over a 12 month period.
16384148|NCT04090268|Experimental|Children with malignant hemopathies|Children with malignant hemopathies attending a precision exercise training
16384119|NCT04090515|Experimental|Project Health|Project Health has three aims: 1) encourage participants to explore the costs of obesity, an unhealthy diet, and sedentary behavior and the benefits of physical fitness, a healthy diet, and regular exercise; 2) help participants gradually reduce caloric intake and increase physical activity, such that the participant reaches energy balance (i.e., is not eating more calories than they need); and 3) reduce attitudinal and behavioral risk factors for eating disorders and obesity. The intervention will be administered in Spanish.
16384120|NCT04090515|Placebo Comparator|Educational Video Control|The educational video control condition will include an educational video series on obesity in Spanish.
16384121|NCT04090502|Experimental|Grupo A. Dry needling in Trigger point|Participants will be treated in the most hyperalgesic foci within the hamstring musculature.
16384122|NCT04090502|Placebo Comparator|Grupo B. Dry needling in non-hyperalgesic areas|Participants will be treated in non-hyperalgesic areas within the hamstring muscles.
16384123|NCT04090476|Experimental|BIG for Life Exercise Group|This arm includes the entire cohort enrolled who will participate in the three times a week one hour community exercise group for a total of 8 weeks
16384124|NCT04090463|Experimental|IORT group|"Intraoperative administration of 10 to 20 Gy after surgery or as an in situ treatment in case resection will not be performed"
16384125|NCT04090437|Active Comparator|Group1 - PVI first step|"Catheter ablation procedure:
~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)
~PVI as first step
~Remap to assess any change in activation
~Ablate all rotors (API) in LA until SR or DCCV
~Deployment of RA CTI line and demonstration of bidirectional block"
16384126|NCT04090437|Active Comparator|Group2 - PVI last step|"Catheter ablation procedure:
~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)
~Ablate all rotors (API) in LA until SR or DCCV
~Remap to assess any change in activation
~PVI as last step even when SR achieved earlier
~Deployment of RA CTI line and demonstration of bidirectional block"
16384133|NCT04090398|Experimental|Arm I (paclitaxel, radium Ra 223 dichloride)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and radium Ra 223 dichloride IV over 1 minute on day 1. Treatment with radium Ra 223 dichloride repeats every 28 days for 6 cycles and treatment with paclitaxel repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16384134|NCT04090398|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16384135|NCT04090385|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
16384136|NCT04090385|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
16384137|NCT04090385|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
16384138|NCT04090372|Active Comparator|Control group|Control group will be assessed by standard preop planning using implants templates.
16384139|NCT04090372|Active Comparator|TraumaCad Group|TraumaCad Group will be assessed by preop planning using Traumacad
16384140|NCT04090359|Experimental|Dual Mobility|If patients are randomized to the dual mobility cohort, they will receive a dual mobility prosthesis at the surgeon's discretion. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
16384141|NCT04090359|Active Comparator|Conventional, Single-bearing hip implant|If patients are randomized to the conventional, single bearing cohort, surgeons will use their preferred implant design at their discretion using a 36 or 40mm head, depending on the diameter of the cup and manufacturer specifications. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
16384142|NCT04090346|Experimental|Clostridium difficile infection|Clostridium difficile infection (CDI) is due to a toxin-producing bacteria that causes a more severe form of antibiotic associated diarrhea. The disease ranges from mild diarrhea to severe colon inflammation that can even be fatal.
16384143|NCT04090320|Experimental|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
16384144|NCT04090307|Experimental|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
16384145|NCT04090307|No Intervention|Traditional Prenatal Care|Subjects randomized to routine care will receive their prenatal care with their primary obstetric provider. Patients are seen for 10-15 minutes every four weeks until 28 weeks' gestation, every two weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits focus on routine screening tests and prenatal care. Traditional care participants will receive a phone call once a month, until 28 weeks gestation, from a nurse practitioner to check-in on pregnancy goals, healthy eating, and exercise. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
16384146|NCT04090294|Experimental|Roflumilast -non roflumilast|"35 patients will receive Roflumilast for three months and improvement regarding dyspnea scales , Pulmonary function Test , Six minutes walking test and bronchectasis severity index (FACED) score pre and post therapy will be assessed.
~patients will receive Roflumilast 500 Mcg. Tablet Once daily for Three months and then base line assessment will be repeated to evaluate improvement."
16384149|NCT04090268|No Intervention|Healthy children|Healthy children
16384150|NCT04090255|Experimental|Ultrasonographic guided renal access|The use of ultrasound to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
16384151|NCT04090255|Experimental|Fluoroscopic guided renal access|The use of fluoroscopy to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
16384152|NCT04090242|Active Comparator|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
16384153|NCT04090242|No Intervention|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
16384154|NCT04090229|Experimental|ASLAN004|
16384155|NCT04090229|Placebo Comparator|ASLAN004 Placebo|
16384156|NCT04090216||Addict patients|patients with substance use disorders presented with STEMI & undergoing Primary PCI
16384157|NCT04090216||Non Addict patients|patients without substance use disorders presented with STEMI & undergoing Primary PCI
16384158|NCT04090203|Experimental|Boiled Peanut Powder|Boiled Peanut Powder
16384159|NCT04090190|Other|standard of care anticholinergic treatment|Women presenting to the Urogynecology clinic with urgency urinary incontinence symptoms will receive standard of care anticholinergic treatment and will have their urinary microbiome evaluated before and after treatment
16384160|NCT04090177|Experimental|Intervention-TEAM Wheels|The treatment group will receive the TEAM Wheels program over a 4-week period. Session 1 will be virtually delivered via MS Teams teleconference. The peer trainer is an experienced MWC user trained to deliver the TEAM Wheels program. At least 2 peers will be trained at each site to offer multiple trainer attributes; a male and female, one being at least 50 years old. Participants will pre-select a peer trainer from a biosketch to optimize training effect (e.g., preference for age, sex factors); comparability in age has been identified as preferential among older adults and influential to self-efficacy. After Session 1, participants engage in 4 weeks of eHealth home program training. They are instructed to practice for 75-150 minutes/week. Consistent with motor learning principles, we encourage training in 15-30 minute blocks 1-2 times/day, 3-5 days/week. The peer trainer arranges the remaining two virtual teleconference sessions with the participant, about 1 week apart.
16384161|NCT04090177|No Intervention|Control-Wait List|"The control group receives no specific intervention over the course of the 4-week period. This reflects usual practice/typical experience of a MWC user in their provincial context. Control group participants placed on the wait-list will receive the TEAM Wheels program following completion of the study (i.e. after post-treatment data collection). The site Research Coordinator/Assistant will make telephone or email contact with control group participants at the end of weeks 2 and 4 during the study period to deter attrition/drop-out. When contact is made at week 4, the Research Coordinator will schedule an appointment for post-treatment data collection (week 7). Any formal MWC training received during the wait-list period will be documented for potential post-hoc analysis as a confounding variable; research evidence and investigators' clinical experience confirm that in all 3 provinces formal training is not provided once MWC users are discharged from hospital."
16384162|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
16384163|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
16384164|NCT04090151||Austrian HIV Cohort Study (AHIVCOS)|
16384165|NCT04090151||The Australian HIV Observational Database (AHOD)|
16384166|NCT04090151||CHU Saint-Pierre|
16384167|NCT04090151||University Hospital Cologne|
16384168|NCT04090151||The EuroSIDA cohort|
16384169|NCT04090151||Frankfurt HIV Cohort Study|
16384170|NCT04090151||Georgian National AIDS Health Information System (AIDS HIS)|
16384171|NCT04090151||Modena HIV Cohort|
16384172|NCT04090151||San Raffaele Scientific Institute|
16384173|NCT04090151||Swiss HIV Cohort Study (SHCS)|
16384174|NCT04090151||Royal Free HIV Cohort Study|
16384175|NCT04090151||The ATHENA national observational HIV cohort|ATHENA: AIDS Therapy Evaluation in the Netherlands
16384176|NCT04090151||Nice HIV Cohort|
16384177|NCT04090151||Italian Cohort Naive Antiretrovirals (ICONA)|
16384178|NCT04090151||PISCIS Cohort Study|
16384179|NCT04090151||Swedish InfCare HIV Cohort|
16384180|NCT04090151||Bonn University Hospital|
16384181|NCT04090138|Active Comparator|Setria performance blend|l-citrulline + glutathione
16384182|NCT04090138|Placebo Comparator|Placebo|
16384183|NCT04090125|Experimental|Physical Activity and Symmetry (PAS) Intervention|Participants assigned to the PAS intervention will receive 4 sessions on balance training and physical activity coaching delivered by a physical therapist, in addition to their usual post-TKA physical therapy (PT) care.
16384184|NCT04090125|Placebo Comparator|Attention Control|Participants assigned to the ATT group will receive usual post-TKA physical therapy (PT) care, followed by two additional sessions with their physical therapist.
16384185|NCT04090112|Experimental|the study group (Group A)|Patients received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
16384186|NCT04090112|Active Comparator|Comparator group (Group B)|Patients received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
16384187|NCT04090099|No Intervention|Group C|PCA (Patient controlled analgesia) and morphine consumption will be monitored in the postoperative period.
16384188|NCT04090099|Active Comparator|Group ES (Erector Spina Plane)|A high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle. A dose of 0.25% bupivacaine will be injected which is shown to spread both above and below the T5 level. The same process will be implemented on the other side.
16384189|NCT04090099|Active Comparator|Group PS (Para Sternal Block)|Before the wire is inserted into the sternum, the sternotomy and mediastinal tube regions will be infiltrated with a mixture of bupivacaine and saline.
16384190|NCT04090086|Experimental|Treatment Sequence 1: Treatment ABC|Participants will receive Treatment A (JNJ-53718678 once daily for 7 days) in Treatment Period 1, followed by Treatment B (JNJ-64417184 once daily for 7 days) in Treatment Period 2, followed by Treatment C (JNJ-53718678 once daily + JNJ-64417184 once daily for 7 days) in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
16384191|NCT04090086|Experimental|Treatment Sequence 2: Treatment BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
16384192|NCT04090086|Experimental|Treatment Sequence 3: Treatment CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
16384193|NCT04090086|Experimental|Treatment Sequence 4: Treatment ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
16384194|NCT04090086|Experimental|Treatment Sequence 5: Treatment BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
16384195|NCT04090086|Experimental|Treatment Sequence 6: Treatment CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
16384196|NCT04090073|Experimental|Electroacupuncture Plus Fast-track Perioperative Program|Patients who are randomized to the intervention arm will receive Electroacupuncture combined with Fast-track program. Each session of Electroacupuncture will last for 20 minutes. The patients will undergo one session of Electroacupuncture daily from day 1 till day 4, or until the time when the primary outcome has occurred, whichever is earlier.
16384197|NCT04090073|Active Comparator|Fast-track Perioperative Program|Patients who are randomized to the control arm will receive Fast-track program alone.
16384198|NCT04090060|Experimental|Practice Self-/Companion Exams|300 individuals and 50 couples will be randomized to practice arm.
16384199|NCT04090060|Other|Control Arm|300 individuals and 50 couples will neither be encouraged nor discouraged to practice self-/companion exam.
16384200|NCT04090047|Experimental|PF-06700841 and Itraconazole|This fixed sequence, 2-period arm will consist of two treatments. Participants will receive a single oral dose of 30 milligrams (mg) PF-06700841 on Day 1 in Period 1. On Days 1-7 in Period 2, Itraconazole 200mg will be administered once daily(QD). On Day 4 of Period 2, co-administration of Itraconazole 200 mg and 30 mg PF-06700841 tablets will occur.
16384202|NCT04090021|Experimental|Genotypic resistance-guided triple therapy|"In the group of genotypic resistance-guided triple therapy, a molecular assay based on DNA-strip technology was used to determine the genotypic resistance of H. Pylori to clarithromycin (23SrRNA mutations) and fluoroquinolones (gyrA mutations) from gastric biopsy specimens. According to 23SrRNA and gyrA mutational analyses, a 7-day tailored triple therapy therapy was given as follows:
~Wild-type 23SrRNA: Clarithromycin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.
~23SrRNA mutated/wild-type gyrA: Levofloxacin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and levofloxacin 500 mg b.i.d.
~23SrRNA mutated/gyrA mutated: Rifabutin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g t.i.d. and rifabutin 150 mg b.i.d."
16384203|NCT04090021|Active Comparator|Empirical concomitant therapy|In the empirical concomitant group, patients received esomeprazole 40mg, amoxicillin 1gr, clarithromycin 500mg and metronidazole 500mg, all b.i.d., for 10-14 days.
16384204|NCT04090008|Active Comparator|PRP gel|PRP gel was applied to the ulcer twice per week after preparation and then the ulcer was covered with Vaseline gauze, few layers of sterile gauze and crepe bandage.
16384205|NCT04090008|Active Comparator|Saline dressing|daily dressing of the ulcer with normal saline was done
16384206|NCT04089995||Coats + and LCC syndrome|
16384207|NCT04089982|Active Comparator|Varenicline|Varenicline BID
16384208|NCT04089982|Placebo Comparator|Placebo|
16384210|NCT04089956||Extubation Success|extubation Success which defined as no need for need for ventilatory support after extubation using tracheal intubation or non-invasive mechanical ventilation during ICU stay
16384211|NCT04089956||Extubation Failure|Extubation Failure was defined as need for any ventilatory support after fist extubation during ICU stay or tracheostomy befor any extubation attempt.
16384212|NCT04089943|Experimental|Revascularization group|Participants will be randomized to either an endovascular or an open bypass procedure.
16384213|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited as control group
16384214|NCT04089930||Vaccine|Those SLE patients who had been given herpes zoster vaccine in our original RCT
16384215|NCT04089930||Placebo|Those SLE patients who had been given placebo vaccination in our original RCT
16384216|NCT04089917||Q Aspiration Catheter|mechanical thrombectomy for acute ischemic stroke
16384217|NCT04089904|Experimental|ARM 1|
16384218|NCT04089878|Experimental|PARTO/BRTO + SMT|PARTO/BRTO with SMT will be given.
16384219|NCT04089878|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
16384220|NCT04089865|Experimental|Oral Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1950 mg of oral TXA in the pre-operative area.
16384425|NCT04088357|Placebo Comparator|Topical Vehicle Gel|Vehicle Gel
16384426|NCT04088344|Placebo Comparator|Isocaloric diet (7 days)|Protocole A
16384221|NCT04089865|Active Comparator|Intravenous (IV) Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1 g of intravenous (IV) TXA upon transfer to the operating room.
16384222|NCT04089852|Experimental|Inhaled nitrous oxide anesthesia|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The treatment group will receive inhaled N2O/O2. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2. N2O/O2 will be administered per Boston Children's Hospital (BCH) N2O sedation protocol. Prior to speculum placement, treatment group participants will receive the inhaled gas until minimal sedation is achieved per BCH sedation guidelines, such that the patient is cooperative, oriented, and tranquil. Inhaled N2O will be administered throughout the duration of the procedure."
16384223|NCT04089852|Placebo Comparator|Inhaled oxygen placebo|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The control group will receive inhaled O2 alone. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered throughout the duration of the procedure."
16384224|NCT04089839||CP-CML participants initiating dasatinib|
16384225|NCT04089813||Metformin|Patients use metformin to control blood sugar
16384226|NCT04089813||Insulin|Patients use Insulin to control blood sugar
16384227|NCT04089800|Experimental|Intervention|For 9 months, each of the 40 women in the intervention condition will use their phones to access the multimedia-based antenatal videos and audios tailored to their pregnancy stages. Participants will use the prototype until six weeks after giving birth. The intervention implementation is estimated to take 9 months including a 6 weeks follow-up after delivery, which implies that the implementation will be completed by November/ December 2019. The investigators will install the final prototype on a phone and give each participant in the intervention group a phone with a prototype installed, and explain how it works. Women will get support in resolving technical issues that may arise with the application between March and May 2019.
16384228|NCT04089800|No Intervention|Control|The 40 women in the control condition will receive the usual standard care of antenatal check-up and counselling but no multimedia intervention.
16384229|NCT04089787|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
16384230|NCT04089787|Active Comparator|Control group|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
16384231|NCT04089774|Experimental|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
16384232|NCT04089774|No Intervention|Kiné|Standard physiotherapy treatment, at least 20 sessions, renewed at least once, spread over 12 months
16384233|NCT04089761|Experimental|Active Device|Treatment of acute migraine with an active form of Nerivio device
16384234|NCT04089748||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
16384235|NCT04089748||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
16384236|NCT04089735|Experimental|APP13007 0.05% twice daily (BID)|1 drop 0.05% APP13007 twice daily for 21 days to the operated eye
16384237|NCT04089735|Experimental|APP13007 0.05% Placebo twice daily (BID)|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 21 days to the operated eye
16384238|NCT04089735|Experimental|APP13007 0.05% twice daily (BID) and once daily (QD)|1 drop 0.05% APP13007 twice daily followed by 1 drop once daily to the operated eye
16384239|NCT04089735|Experimental|APP13007 0.05% Placebo twice daily (BID) and once daily (QD)|1 drop matching vehicle placebo for 0.05% APP13007 twice daily followed by 1 drop once daily to the operated eye
16384240|NCT04089735|Experimental|APP13007 0.1% twice daily (BID) and once daily (QD)|1 drop 0.1% APP13007 twice daily followed by 1 drop once daily to the operated eye
16384241|NCT04089735|Experimental|APP13007 0.1% Placebo twice daily (BID) and once daily (QD)|1 drop matching vehicle placebo for 0.1% APP13007 twice daily followed by 1 drop once daily to the operated eye
16384242|NCT04089722|Other|Open-Label: Deoxycholic Acid Injections|Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity. Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid. Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
16384243|NCT04089709|Experimental|Study arm|Patients randomized to this group will be provided exercises to perform with the uninjured arm once daily for 3 months.
16384244|NCT04089709|No Intervention|Control arm|"Patients randomized to this group will not be provided exercises for the well-arm and will be managed according to the current standard of care."
16384245|NCT04089696|Experimental|ExSpiron|10 patients with ALS
16384246|NCT04089683||Doctors|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
16384247|NCT04089683||Nurses|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
16384248|NCT04089683||OT Technicians|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
16384249|NCT04089683||House keeping staff and cleaners|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
16384327|NCT04089085|Other|One group pilot|The experimental group will receive the intervention, which is an 8-week (30 minute session per week) asthma educational and cognitive behavioral skills program.
16384250|NCT04089670|Active Comparator|Online Acceptance and Commitment Therapy Intervention|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Each module has a practice assignment at the end with the goal of having the participant engage in the material over the next week. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls, one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. During the call the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
16384251|NCT04089670|No Intervention|Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
16384252|NCT04089657|Experimental|Apatinib+Sintilimab|Apatinib 500mg qd p.o and Sintilimab 200mg intravenously on day 1 every 3 weeks until disease progression or intolerable toxicity or patients withdrawal of consent
16384253|NCT04089644|Active Comparator|manual group|Hypotension will be corrected by manual infusion of norepinephrine
16384254|NCT04089644|Experimental|closed-loop group|Hypotension will be corrected by closed-loop control of norepinephrine infusion
16384255|NCT04089631|Experimental|Chemotherapy|"Capecitabine mono or Capecitabine/Oxaliplatin as investigator choice:
~Patients who are positive for postoperative ctDNA (ctDNApos) and not microsatellite instable are randomized (2:1) to adjuvant chemotherapy with capecitabine or to follow up.
~Capecitabine 2 x 1250 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m^2. Treatment duration: 8 cycles (approx. 6 months)
~Capecitabine, if combined with Oxaliplatin (investigator choice):
~If the investigation decides to add oxaliplatin, the following schedule should be used:
~[Oxaliplatin 130 mg/m^2 i.v. (2 hours on d1)] Capecitabine 2 x 1000 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days) Treatment duration: 4 or 8 cycles (approx. 3 or 6 months)"
16384256|NCT04089631|No Intervention|Follow-up|Patients negative for postoperative ctDNA (ctDNAneg) are randomized (1:4) to follow-up within CIRCULATE or to routine follow up outside the Trial protocol.
16384257|NCT04089618|Experimental|Baseline 10 Days|10 days baseline before intervention starts.
16384258|NCT04089618|Experimental|Baseline 17 Days|17 days baseline before intervention starts.
16384259|NCT04089618|Experimental|Baseline 24 Days|24 days baseline before intervention starts.
16384260|NCT04089605|Experimental|intravitreal dexamethasone implant|The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
16384261|NCT04089605|Active Comparator|intravitreal ranibizumab|As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.
16384262|NCT04089592|Experimental|Dex Group|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
16384263|NCT04089592|Experimental|Fent Group|intravenous fentanyl at 2mcg/kg in 100ml saline
16384264|NCT04089579|Experimental|MSC|One dose of 6x10e6 cells/kg administered intravenously.
16384265|NCT04089579|Placebo Comparator|Placebo Infusion|Placebo infusion
16384270|NCT04089553|Experimental|Module 1|"Module 1 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with durvalumab in post-standard of care therapy for metastatic castration resistant prostate cancer (mCRPC) patients. In Module 1 approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635.
~Patients will receive AZD4635 75 mg PO QD monotherapy for 2 weeks (Cycle 0). Starting with Cycle 1, durvalumab 1500 mg IV Q4W will be added to continuous AZD4635 dosing."
16384271|NCT04089553|Experimental|Module 2|"Module 2 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with oleclumab in post-standard of care therapy for metastatic castration resistant prostate cancer (mCRPC) patients. In Module 2 approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635 plus oleclumab.
~Patients will receive a dose of AZD4635 75 mg PO QD and oleclumab 1500 mg IV Q2W for the first 4 doses and Q4W thereafter. Patients who began treatment at the AZD4635 50 mg dose will continue with that dose. The first dose of oleclumab will begin on Cycle 0 Day 1. For Cycle 1, oleclumab will be administered on Day 1 and Day 15. For Cycle 2 and beyond, oleclumab will be administered on Day 1 of each cycle Q4W."
16384427|NCT04088344|Experimental|Hypercaloric diet enriched with carbohydrate food (7 days)|Protocole B
16384272|NCT04089553|Experimental|Module 3|"Module 3 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with durvalumab and oleclumab in post-standard of care therapy metastatic castration resistant prostate cancer (mCRPC) patients. In Module 3, approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635.
~Patients will receive a starting dose of AZD4635 75 mg PO QD, durvalumab 1500 mg IV infusion on Day 1 and Q4W thereafter, and oleclumab 1500 mg Q2W for the first 4 doses and Q4W thereafter. The first dose of durvalumab will be delayed for 2 weeks in Cycle 1 only. For Cycle 2 and beyond, durvalumab will be administered on Day 1 of each cycle. The first dose of oleclumab will begin on Cycle 0 Day 1. For Cycle 1, oleclumab will be administered on Day 1 and Day 15. For Cycle 2 and beyond, oleclumab will be administered on Day 1 of each cycle Q4W."
16384273|NCT04089540|Experimental|Study group: New intubation method|In the new intubation method the respirator is connected to the tube prior to insertion into the mouth (oral intubation) or into the nose (nasopharyngeal intubation). Therefore an oxygen flow is already administered via the tube during the intubation process.
16384274|NCT04089540|Other|Control group: Conventional intubation|In the control group the respirator is connected to the tube and ventilation is started after the insertion of the tube into the trachea. Therefore there is no oxygen flow administered during the intubation process.
16384275|NCT04089527|Experimental|CC-95775|Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A.
16384276|NCT04089514||Adalimumab Therapy|Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy
16384277|NCT04089501||Inflammatory Bowel Disease (IBD)|Subjects will be asked to provide a stool sample (if no colonoscopy is to be performed) or if clinically indicated, a colonoscopy will be performed per standard medical routine. During colonoscopy, stool will be collected for analysis and 3 additional biopsies will be taken each from the ileum and colon for research purposes. Alternatively, subjects who are undergoing intestinal and/or colonic resection will provide stool prior to surgery and a portion of their pathology specimens will be used for research purposes following complete pathologic evaluation.
16384278|NCT04089501||Subjects not affected by IBD (Control Group)|Results of subjects with IBD will be compared to subjects in the control group.
16384279|NCT04089488||Observational (respond to surveys, medical record review)|Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
16384280|NCT04089462|Other|"1. Five sessions per period - Two sessions per period"|
16384281|NCT04089462|Other|"2. Two sessions per period - Five sessions per period"|
16384282|NCT04089449|Experimental|PRT811|PRT811 will be administered orally
16384283|NCT04089436||patients with encephalitis|children above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar
16384284|NCT04089410|Active Comparator|Hyperthermic Fitness Treatment|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the HFT.
16384285|NCT04089410|Placebo Comparator|Attenuated heating|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the placebo-HFT.
16384286|NCT04089397|Experimental|Light therapy group|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis (at home, for patients dialyzing the afternoon, or during dialysis for patients dialyzing in the morning)
16384287|NCT04089397|No Intervention|Control group|Usual care, without light therapy
16384288|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
16384289|NCT04089384|Active Comparator|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
16384290|NCT04089384|Placebo Comparator|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment
16384291|NCT04089371||Arm A Total Shoulder Arthroplasty / Hemiarthroplasty|Total Shoulder Arthroplasty (TSA) Humeral & Glenoid components as a Hemiarthroplasty or Total Shoulder Replacement.
16384292|NCT04089371||Arm B Reverse Shoulder Arthroplasty|Reverse Shoulder Arthroplasty (RSA) Humeral & Glenoid Components as a primary, fracture or revision total shoulder replacement
16384295|NCT04089345|Experimental|Open label ustekinumab|All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from baseline through Week 4. Intravenous induction doses will be 260mg for patients <55kg, 390mg for patients between 55 and 85kg, and 520mg for patients with a body weight >85 kg.
16384296|NCT04089332|Experimental|Enrolled, eligible|Single arm for eligible subjects
16384297|NCT04089319|Experimental|Acupuncture + mindfulness|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen to a 15-minute mindfulness recording followed by music for 30 minutes. Acupuncture needles will then be removed.
16384298|NCT04089319|Other|Acupuncture control|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen music for 45 minutes. Acupuncture needles will then be removed.
16384299|NCT04089280|Experimental|Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: Sanprobi Barrier-multispecies probiotic product, 2,5 x10 9 cfu/gram or placebo, cross-over design
16384526|NCT04087577|Experimental|experimental group|conventional physical therapy with mirror therapy
16384300|NCT04089280|Placebo Comparator|carrier material of Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: placebo comparator (carrier material of Sanprobi Barrier-multispecies probiotic product , not containing bacterial strains,similar appearance as the probiotic, cross-over design
16384301|NCT04089267|Experimental|experimental group 1|rhTPO injection7500 U ;one time a day; 14 times of administration
16384302|NCT04089267|Experimental|experimental group 2|rhTPO injection15000 U;one time a day;14 times of administration
16384303|NCT04089267|Experimental|experimental group 3|rhTPO injection15000 U;1 time every other day, 7 times;
16384304|NCT04089267|Experimental|experimental group 4|rhTPO injection30000 U；1 time every other day, 7 times;
16384305|NCT04089254|Active Comparator|Inpatient Psychiatry|Child and adolescent inpatient treatment
16384306|NCT04089254|Active Comparator|Outpatient Crisis Intervention Clinic|OCIC is outpatient crisis intervention clinic
16384307|NCT04089241|Experimental|all cohort|Patients will perform CTA 1 months after the EVAR procedure. Following CTA, an ultrasound examination which will include a 3D reconstruction and CEUS will be performed using SONOVIEW contrast agent. The dimensions and volume of the aorta will be compared to the measurements in CTA using the fusion method. In the case of endoleak type 1 or 3 the patient will be urgently refered to endovascular repair . In the case of endoleak type 2 or a normal exam the patient will undergo another fused exam with CEUS at 6 month . In the case of endoleak type 2 with a growth of more than 1 cm in the aneurysm diameter , the patient will be refered to endovascular repair. In the case of a normal exam or an endoleak type 2 with a shrinkage of 1 cm or more ,the patient will undergo another fused exam with CEUS at 12 months. At any case of a new endoleak type 1 or 3 the patient will undergo CTA.
16384308|NCT04089228|Experimental|Kinesiotape Group and INIT|Kinesiotaping and Integrated Neuromuscular Inhibition Technique (KT + INIT )
16384309|NCT04089228|Active Comparator|INIT Group|Integrated Neuromuscular Inhibition Technique (INIT)
16384310|NCT04089215|Experimental|JWCAR029 treatment|JWCAR029 be administrated in two dose level
16384311|NCT04089202|Active Comparator|In-person visit arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to an in-person visit with an Endocrinologist. This is currently the standard of care for patients referred for diabetes specialty care.
~Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
~Surveys will be administered to measure patient burden and self efficacy."
16384312|NCT04089202|Experimental|Freestyle Libre sensor arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to have the Freestyle Libre Pro continuous glucose monitor (CGM) placed at their primary care clinic. The data collected from the diagnostic CGM will be utilized in conjunction with diet, exercise and medication logs provided by the patient and information from the patient's electronic medical record to complete an eConsult with treatment recommendations. Implementation of these recommendations will be per the primary care provider's discretion in conjunction with conversation with the patient in follow up visits.
~Surveys will be administered to measure patient burden and self efficacy."
16384313|NCT04089189|Experimental|IMP4297|100 subjects to receive IM4297 orally.
16384314|NCT04089176|Active Comparator|protocal A|Carbetocin versus placebo
16384315|NCT04089176|Active Comparator|protocal B|Oxytocin versus placebo
16384316|NCT04089163|Experimental|Sequential Dose Cohorts|Doses of Toca 511 will be evaluated in sequential cohorts. Toca 511 will be administered as a single intravesical instillation. Following Toca 511 administration, Toca FC will be administered orally at a dose of 220 mg/kg/day for 7 days every 6 weeks.
16384319|NCT04089137|No Intervention|Control|This is an assessment only control condition.
16384320|NCT04089137|Experimental|ASAP (Alcohol and Sexual Assault Prevention)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault.
16384321|NCT04089124|Other|repair using General anesthesia ( control group)|Surgery repair zone 2 under GA
16384322|NCT04089124|Other|repair using Walant|Surgery repair zone 2 under WALANT
16384323|NCT04089111|Experimental|1.1. ASV, MV target 100%|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
16384324|NCT04089111|Active Comparator|1.2. Volume control, MV target %100|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3 Ventilation frequency will be adjusted to reach the same volume target calculated in arm1.
16384325|NCT04089111|Experimental|2.1. ASV, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
16384326|NCT04089111|Active Comparator|2.2. Volume control, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3. Ventilation frequency will be adjusted to reach the target PaCO2 level
16384328|NCT04089072|Experimental|Control group|Patients in the control group will have phenylephrine infusion starting at 50 mcg/min and titrated to maintain a MAP >65 mmHg as a third line vasopressor. Maximum dose of Phenylephrine is 300 mcg/min.
16384329|NCT04089072|Experimental|Intervention group|Patients enrolled in the intervention group will receive 2 mg/kg IBW (Ideal Body Weight) bolus, given over 15 mins, of ProvayBlue® followed by a concomitant infusion at 2 mg/kg/hr (IBW) mixed in D5W, which will continue for 24 hours. ProvayBlue® ( Methylene Blue) will be used as the third-line vasopressor.
16384330|NCT04089059|Other|Treatment Arm|Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).
16384331|NCT04089059|Other|Control Arm|"Proactive subject management according to GDMT leveraging also the vital signs collected by CHFS.
~After month 12 all data (including PAP measurements) will be available for both the subject and the clinician and the clinician will then treat the subject's HF per PAPGHFM and GDMT considering daily PAP measurements and the vital signs collected by CHFS."
16384332|NCT04089046|Experimental|TEAM-UP for Teens Intervention|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
16384333|NCT04089046|Active Comparator|Enhanced Care Comparison|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
16384334|NCT04089033||Primary Retinal Detachment 1|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pneumatic Retinopexy
16384335|NCT04089033||Primary Retinal Detachment 2|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pars Plana Vitrectomy
16384336|NCT04089020|Experimental|Psychosocial intervention|Text messaging and health coaching over the telephone to address goal setting, monitoring, motivation, problem solving, and related skills, delivered over 6 weeks.
16384337|NCT04089007|Experimental|SOmNI intervention group|"Participants will receive an iPhone with the SOmNI app and will be instructed to move their bedtime earlier by 5 minutes (from their average baseline week bedtime) on each school night (Sunday to Thursday). Participants will also be given sleep hygiene information related to the embedded features of the SOmNI app. A research assistant will help the participant to enter the appropriate goal bedtime in the SOmNI app and orient them to the features of the SOmNI app. Participants will also be instructed to aim for <1 hour difference between school night and weekend bedtimes and wake times (i.e. avoid staying up late and sleeping in on weekends).
~The SOmNI application will allow the user to graphically track sleep behaviour across the four-week intervention period as recorded by the wearable sensor (e.g. bedtimes, wake times, amount of sleep achieved will all be displayed in the app)."
16384338|NCT04089007|Active Comparator|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
16384339|NCT04088994|Experimental|pathological model|The children assigned to the experimental group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a model with a similar manipulation strategy but improved with respect to the child's current abilities.
16384340|NCT04088994|Active Comparator|Healthy model|The children assigned to the control group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
16384341|NCT04088981|Active Comparator|Low-fat, vegan diet|For a 22-week period, participants will be asked to follow a low-fat vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
16384342|NCT04088981|Active Comparator|Portion-controlled diet|For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
16384343|NCT04088968|Experimental|Prehabilitation|Intervention: Patients allocated to the intervention group receive weekly counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.
16384344|NCT04088968|No Intervention|Treatment as usual|Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.
16384345|NCT04088942|Experimental|High-intensity group|"Will receive high-intensity intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later."
16384346|NCT04088942|Active Comparator|Low-intensity group|Encouraged to quit smoking via own doctor and is prescribed varenicline.
16384347|NCT04088929|Experimental|CBD for Treatment of Diabetic Neuropathic Pain|Patients are instructed to take 3 total tablets a day, under the tongue, six hours apart for three weeks. Patients are to enter their pain scale score into the smartphone app as instructed during the initial site visit. Patients are to enter into the notes section of the app any additional information such as side effects (positive or negative), medication changes.
16384382|NCT04088656|No Intervention|Control|Eight (8) health facilities will not receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
16384383|NCT04088643|Experimental|tACS group|NEXALIN ADI transcranial alternating current stimulator
16384348|NCT04088903|Experimental|Daratumumab infusion|"Participants will receive an intravenous infusion of daratumumab weekly for 8 doses and then every other week for 2 doses.
~For this dose-escalation study, the initial patients will receive a 2 mg/kg dose of daratumumab. In subsequent patients, the dose will be uptitrated to 16 mg/kg as tolerated.
~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
16384349|NCT04088890|Experimental|R/R ALL|"Relapsed/refractory ALL
~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:
~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3
~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3
~Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10^5cells/kg (± 20%) 10"
16384350|NCT04088890|Experimental|R/R aggressive B-cell NHL|"Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:
~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3
~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3
~Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.
~Dose1: 1 x 10^6 cells/kg (± 20%) Dose2: 3 x 10^6 cells/kg (± 20%) Dose3: 1 x 10^7 cells/kg (± 20%)"
16384351|NCT04088877|Experimental|Exercise and Art Sculpting Class|Participants will take part in a twelve week exercise program twice per week as well as an eight week art sculpting class once a week.
16384352|NCT04088864|Experimental|R/R B-ALL|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.
~Lymphodepletion:
~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2
~Cyclophosphamide 900 mg/m2 per day IV on day -2
~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
16384353|NCT04088864|Experimental|Lymphoma|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.
~Lymphodepletion:
~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2
~Cyclophosphamide 900 mg/m2 per day IV on day -2
~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
16384354|NCT04088851|Experimental|Metformin - T2D|Patients with type-2 diabetes and from their GP described Metformin Therapy (1 g per day) will undergo MRS and PINTA measurement.
16384355|NCT04088851|Placebo Comparator|No Metformin - T2D|Patients with type-2 diabetes and from their GP described Metformin Therapy (1 g per day) will pause the medication for 2 weeks and undergo MRS and PINTA measurement. After their visit they will continue the anti-diabetic treatment according to the GP's presription.
16384356|NCT04088851|No Intervention|No Metformin - Healthy Controls|Healhy controlls will undergo the MRS and PINTA measurments, matched in BMI and age.
16384357|NCT04088838||Patients undergoing abdominal surgery|All adult patients undergoing elective abdominal surgery are eligible. Abdominal surgery includes each operation in which the peritoneal cavity is openen, i.e. laparotomy or laparoscopy.
16384358|NCT04088812|Placebo Comparator|Placebo meat derivative + Placebo satiating compound|60 g Placebo meat derivative 25 g Placebo satiating compound
16384359|NCT04088812|Experimental|Placebo meat derivative + Satiating compound|60 g Placebo meat derivative 25 g Satiating compound
16384360|NCT04088812|Experimental|Experimental meat derivative + Placebo satiating control|60 g Experimental meat derivative 25 g Placebo satiating compound
16384363|NCT04088773||Aim 1 Crohn Disease participants (B2 phenotype)|Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
16384364|NCT04088773||Aim 2 Crohn Disease participants (B1 phenotype)|Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
16384365|NCT04088773||Aim 2 Healthy Controls|No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale
16384366|NCT04088760|Experimental|TCRαβ+/CD19+ depleted HSCT|
16384367|NCT04088747||Fibromyalgia|Patients who display symptoms and have a history of Fibromyalgia, between 20-65 years of age.
16384368|NCT04088747||Healthy Controls|Age-matched, healthy controls, between 20-65 years of age who present no signs of chronic pain.
16384369|NCT04088734|Experimental|ABO-102|
16384370|NCT04088721|Experimental|AD17002 20μg|Intranasal weekly dosing of AD17002 for three times
16384371|NCT04088721|Experimental|AD17002 40μg|Intranasal weekly dosing of AD17002 for three times
16384372|NCT04088721|Experimental|AD17002 60μg|Intranasal weekly dosing of AD17002 for three times
16384373|NCT04088721|Placebo Comparator|Placebo|Intranasal weekly dosing (placebo) for three times
16384374|NCT04088708|Experimental|Aerobic Exercise Training|Progressive aerobic exercise training sessions supervised by exercise specialists who have experience training cancer survivors.
16384375|NCT04088708|Active Comparator|Attention Control|The non-aerobic exercise attention control condition will control for the effects of attention with flexibility/toning activities.
16384376|NCT04088695|Experimental|Intervention|The arm exposed to the intervention video
16384377|NCT04088695|Active Comparator|Control|The control group exposed an informative text.
16384378|NCT04088682||All hospitals|"All hospitals will take the treatment quality improvement strategies and tools into implementation.
~Intervention: Behavioral: Quality improvement strategies and tools"
16384379|NCT04088669|Experimental|Intervention group|A home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist.
16384380|NCT04088669|Active Comparator|Control group|A training session about the disease and the correct inhaler use, booklets that include breathing exercises and aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks.
16384381|NCT04088656|Experimental|Hypertension Systems Analysis and Improvement|Eight (8) health facilities will receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
16384385|NCT04088630|Experimental|Fingolimod Group|In addition to Standard of care treatment, those participants randomized to the fingolimod group will receive a single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset.
16384386|NCT04088630|Placebo Comparator|Control Group|In addition to Standard of care treatment, those participants randomized to the control group will receive a single dose placebo pill within 24 hours of symptom onset
16384387|NCT04088617|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
16384388|NCT04088617|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
16384389|NCT04088604|Experimental|LY01610-Dose Escalation|The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
16384390|NCT04088604|Experimental|LY01610-Dose Extension|According to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 were further evaluated in 6 - 8 patients. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
16384391|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Escalation|"Dose Escalation:
~Based on the results of the first stage, three doses of low, medium and high doses were selected in combination with a fixed dose of 5-Fu to determine the DLT, MTD, PK characteristics and the preliminary efficacy. 5-Fu, 400mg/m2 will be administered intravenously on days 1, followed by 600 mg/m2 given as a 22-hour continuous infusion on day 1 and 2, every 2 weeks."
16384392|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Extension|"Similarly, according to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 combined with a fixed dose of 5-Fu were further evaluated in additional 6 - 8 patients.
~In dose escalation and dose extension stages, both LY01610 and fixed dose 5-Fu will be given once every 2 weeks."
16384393|NCT04088604|Active Comparator|Hydrochloride Injection- pharmacokinetics comparative study|After receiving the MTD of LY01610, another 8 subjects were enrolled and given Irinotecan Hydrochloride Injection（captol ®） (180mg/m2) once every 2 weeks. Upon completion of the pharmacokinetics study, the sponsor will continue to provide the study drug treatment free of charge, and the researcher will conduct treatment and examination according to the subject's situation, without collecting any safety and efficacy data of the subject.
16384396|NCT04088578|Experimental|Vagus nerve stimulation (VNS)|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. VNS will be delivered when a minimum level of accuracy has been achieved.
16384397|NCT04088578|Sham Comparator|Sham stimulation|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. Sham stimulation will be delivered when a minimum level of accuracy has been achieved.
16384398|NCT04088565|Experimental|PAS+VNS|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with VNS in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
16384399|NCT04088565|Sham Comparator|PAS+Sham|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with sham stimulation in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
16384401|NCT04088539|Experimental|Group A|"CSD participants will receive a combined intervention:
~Brief intervention using AWARD advice at baseline,
~Video-based health education"
16384402|NCT04088526|Experimental|intervention group|Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.
16384403|NCT04088513|Experimental|Aspirin|Drugs:Aspirin
16384404|NCT04088513|Active Comparator|Clopidogrel|Drugs:Clopidogrel
16384405|NCT04088500|Experimental|Nivolumab + Ipilimumab (combination)|Nivolumab + Ipilimumab (combination) Q3W for 4 doses
16384406|NCT04088487|Experimental|Experimental group|Participants gain access to the internet intervention after the baseline measurement (pre-test).
16384407|NCT04088487|Other|Waitlist control group|Participants gain access to the internet intervention 8 weeks after the baseline measurement (pre-test).
16384408|NCT04088474|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
16384409|NCT04088474|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
16384410|NCT04088461|Experimental|Linagliptin + Metformin and lifestyle|Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
16384411|NCT04088461|Active Comparator|Metformin|Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.
16384412|NCT04088448|Placebo Comparator|Control group|Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
16384413|NCT04088448|Experimental|Metformin group|Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks
16384414|NCT04088422||B-cell lymphoma|
16384415|NCT04088409|Experimental|Baricitinib|Baricitinib given orally.
16384416|NCT04088409|Active Comparator|Adalimumab|Adalimumab given subcutaneously (SC).
16384419|NCT04088383|Other|Amnios™ RT|
16384420|NCT04088383|Placebo Comparator|Saline|
16384428|NCT04088331||AMS 800 Artificial Urinary Sphincter Recipients|Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
16384429|NCT04088318|Experimental|OQL011 Dose I|OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks
16384430|NCT04088318|Experimental|OQL011 Dose II|OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks
16384431|NCT04088318|Experimental|OQL011 Dose III|OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks
16384432|NCT04088318|Other|Vehicle Ointment|Vehicle ointment, to be applied topically, three times a day, for up to six weeks
16384433|NCT04088305|Experimental|Study group|Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.
16384434|NCT04088305|No Intervention|Control group|Patients of control group will accept vancomycin dosages decided by attending physician.
16384435|NCT04088292|Active Comparator|USAT + low dose thrombolysis|UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization
16384436|NCT04088292|Active Comparator|Low dose thrombolysis|Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).
16384437|NCT04088292|No Intervention|Heparin alone|UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)
16384438|NCT04088266|Other|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA® sublingual film 16 mg buprenorphine with 4 mg naloxone
16384439|NCT04088253|Experimental|cirrhotic patient|cirrhotic patient with umbilical hernia to be operated
16384440|NCT04088240|Experimental|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
16384441|NCT04088240|Active Comparator|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
16384442|NCT04088240|Placebo Comparator|Placebo|"4 g/d placebo control (light olive oil)"
16384443|NCT04088227|Active Comparator|Control Group|The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
16384444|NCT04088227|Experimental|Experimental Group|The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
16384445|NCT04088214|Experimental|ArtDSTP|Arthroscopic lateral soft tissue release
16384446|NCT04088201|Experimental|Measuring glucose|Measuring glucose from interstitial fluid
16384447|NCT04088188|Experimental|Arm A (ivosidenib, cisplatin, gemcitabine)|Patients receive ivosidenib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16384448|NCT04088188|Experimental|Arm B (pemigatinib, cisplatin, gemcitabine)|Patients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16384449|NCT04088175|Experimental|Group 1 - Virginia Tobacco and Menthol|Subjects randomized to Group 1 will use JUUL ENDS Virginia Tobacco and Menthol flavors
16384450|NCT04088175|Experimental|Group 2 - Mint and Mango|Subjects randomized to Group 2 will use JUUL ENDS Mint and Mango flavors
16384451|NCT04088162|No Intervention|Standard Dressing|In case of Control group. After Ileostomy closure skin will be closed by 6 to 8 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures, and sterile standard dressing will be placed.
16384452|NCT04088162|Experimental|Postoperative NPWT dressing|"In case of NPWT group. After Ileostomy closure skin will be closed by 3 or 4 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures. Between them small sponge tongues 1x 0,5x2 cm were placed and over whole incision an NANOVA (KCI USA) negative pressure dressing will be placed. In control group first dressing change was made in 48 hours after operation and then every day until suture removal at 7 postoperative day. In NPWT group NANOVA dressing was taken out at 72 hours. 3 steri-streps were placed between sutures and standard sterile dressing was placed. After it dressing was changed every 24 hours until suture removal at 7 postoperative day."
16384453|NCT04088149|Experimental|GXNPC1|"There are 2 dose levels Cohort 1: Low dose (1 ± 0.1 × 10^8 GXNPC1) of IPs will be administered in parallel.
~Cohort 2: High dose (2 ± 0.2 × 10^8 GXNPC1) of IPs will be administered sequentially."
16384454|NCT04088136|Experimental|Everyday Metacognitive Memory|Training in techniques for managing memory demands in everyday life
16384455|NCT04088136|Active Comparator|Memory Strategy Control|Trains the use of memory strategies for learning new associations and concepts
16384457|NCT04088110|Experimental|Pyrotinib and trastuzumab plus aromatase inhibito|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16384458|NCT04088097|Experimental|Cognitive-Behavioral Therapy|Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
16384459|NCT04088097|Other|Control Condition|Educational materials related to adolescent health and nutrition.
16384460|NCT04088084|Experimental|standard of care+palmitoylethanolamide|PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)
16384461|NCT04088084|No Intervention|standard of care|patients were only on topical IOP lowering therapy (SOC)
16384462|NCT04088071||Patients with atrial fibrillation|Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
16384463|NCT04088058|Experimental|GXHPC1|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
16384464|NCT04088045|Experimental|Receiving PRP injections or PRP plus neural prolotherapy|"This experiment compares the effect of injecting PRP alone into the knee joint and pes anserinus complex with when dextrose solution is also injected to the genicular nerves.
~The injection of dextrose solution is to decrease the inflammation of the genicular nerves, hoping to further effectively alleviate the knee pain condition. Therefore, upon the conclusion of this study, we can see whether the inclusion of dextrose injection in addition to PRP treatment can really be effective in treating patients with more severe degrees of knee OA."
16384465|NCT04088032|Experimental|Active|Experimental treatment
16384466|NCT04088019||Observational cohort group|"Subjects: idiopathic uveitis with IGRA positive.
~Examinations:
~Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.
~Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods."
16384467|NCT04088006|Experimental|Treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area treated
16384468|NCT04088006|No Intervention|Non-treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area non-treated
16384469|NCT04087993|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
16384470|NCT04087993|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
16384471|NCT04087993|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
16384472|NCT04087980|Experimental|Poseidon System Treatment|
16384473|NCT04087967|Experimental|Decitabine combined with HAAG|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
16384474|NCT04087967|Active Comparator|IA Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
16384475|NCT04087954|Experimental|Intervention vs control|
16384476|NCT04087954|No Intervention|Control|
16384477|NCT04087941|Placebo Comparator|Placebo|
16384478|NCT04087941|Experimental|VM-202|
16384479|NCT04087928|Experimental|Group Flexors (A)|Group A was treated by applying FMV to the flexor muscles of the upper limb (brachial biceps and carpal flexors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
16384480|NCT04087928|Experimental|Group Extensors (B)|Group b was treated by applying FMV to the extensors muscles of the upper limb (triceps brachial and carpus extensors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
16384481|NCT04087915||High risk coronary artery disease|Participants with high risk coronary artery disease.
16384482|NCT04087863||Atopic Dermatitis|
16384483|NCT04087850|Experimental|Making Socially Accepting Inclusive Classrooms (MOSAIC)|
16384484|NCT04087850|No Intervention|Typical Practice Control|
16384485|NCT04087837|Experimental|bougie group|The bougie group: The end of the endotracheal tube was guided to the glottis using the endotracheal tube in the bougie mode under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
16384486|NCT04087837|Experimental|Nasogastric(NG) tube group|NG tube group: The end of the endotracheal tube is guided to the glottis by using the endotracheal tube in the nasogastric tube under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
16384487|NCT04087837|No Intervention|control group|Control group: The general anesthesia method of placing the endotracheal tube through the nasal cavity is used to guide the tip of the endotracheal tube to the glottis under the direct view of the electronic imaging laryngoscope.
16384488|NCT04087824|Experimental|AI monitoring colonoscopy|Patients in this group go through colonoscopy under the AI monitoring device.
16384489|NCT04087811||Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) - Interspinous Spacer
16384490|NCT04087798|Active Comparator|Control|Eligible patients enrolled from the control group clinics will be given a Control-EDI which has information about kidney disease in general (not tailored to the patient) during their clinic visit.
16384491|NCT04087798|Experimental|Intervention|Eligible patients enrolled from the intervention group clinics will be given an Intervention-EDI which has personalized information about kidney disease. There will be space on this for the provider to type in any goals or key points they want the patient to remember. Additionally, patients in this group will also receive health coaching.
16384492|NCT04087785||Positive metastasis|Positive occult lymph node metastasis pathology
16384493|NCT04087785||Negative metastasis|Without lymph node metastasis pathology
16384494|NCT04087772|Active Comparator|Mental Health-Enhanced PBIS|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
16384495|NCT04087772|Experimental|Mental Health-Enhanced PBIS + RED|PBIS-MH+RED involves the components of PBIS-MH integrated with racial/ethnic discrimination interventions (RED) to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
16384496|NCT04087759|Experimental|Treatment Sequence BAE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
16384497|NCT04087759|Experimental|Treatment Sequence CAF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet II under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
16384498|NCT04087759|Experimental|Treatment Sequence DAG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
16384499|NCT04087759|Experimental|Treatment Sequence ABE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
16384500|NCT04087759|Experimental|Treatment Sequence ACF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 2, thereafter will receive bedaquiline oral test tablet 2 under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
16384501|NCT04087759|Experimental|Treatment Sequence ADG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
16384502|NCT04087746|Active Comparator|AFLIBERCEPT|Intra-vitreal injection of AFLIBERCEPT
16384503|NCT04087746|Active Comparator|RANIBIZUMAB|Intra-vitreal injection of RANIBIZUMAB
16384504|NCT04087733|Experimental|GROUP / TREATED EYE|OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
16384505|NCT04087733|No Intervention|GROUP / CONTROL EYE|Saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
16384506|NCT04087720|Experimental|Pegloticase|Participants will receive 8 mg pegloticase by IV infusion every 2 weeks from Day 1 through Week 22
16384507|NCT04087707|Experimental|Step 1;TS-142|
16384508|NCT04087707|Experimental|Step 2;TS-142|
16384509|NCT04087707|Placebo Comparator|Step 2;Placebo|
16384510|NCT04087694|Other|Open|Open laminectomy and posterior stabilization with pedicle screws for symptomatic lumbar spine stenosis
16384511|NCT04087694|Other|Microscope|Microscopically done decompression of lumbar spine stenosis who are symptomatic
16384512|NCT04087681||Elderly 60+ preferably those with increased risk of IED|Study participants are aged 60 years or older in stable health, preferably with a history of urinary tract infection in the previous 10 years.
16384513|NCT04087668|Other|Monitored Anesthesia Care|Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.
16384514|NCT04087668|Other|General Anesthesia|Patients in this arm will receive standard general anesthesia with neuromuscular blockade.
16384515|NCT04087668|Other|General Anesthesia Without Neuromuscular Blockade|Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.
16384516|NCT04087655|Experimental|Exercise training|Eight weeks of interval exercise training
16384517|NCT04087642|Experimental|Intraoperative Crede manoeuver|"Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.
~In this group, the intraoperative Crede manoeuver will determine if a mid-urethral sling should be placed concomitantly."
16384518|NCT04087642|Active Comparator|Preoperative prolapse reduction cough stress test|"An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.
~In this group, the preoperative prolapse reduction cough stress test will determine if a mid-urethral sling should be placed concomitantly."
16384519|NCT04087629|Experimental|CTCL group|Patients with CTCL being treated with mechlorethamine gel will receive StrataCTX® gel.
16384520|NCT04087629|Experimental|Skin Toxicity group|Patients with skin toxicity secondary to chemo/immunotherapy will receive StrataCTX® gel.
16384521|NCT04087616|Experimental|CBIT|ICBIT. Intervention delivered through an internet platform called Managing children's' tics (www.cbteamathome.co.il), based on CBIT protocol (Woods et al., 2008) adapted to an online parent-guided self-help format.
16384522|NCT04087616|Placebo Comparator|Waiting List|Participants initially assigned to the wait list receive no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants receive ICBIT.
16384523|NCT04087603|Experimental|Weekend Morning Bright Light & Early Bedtime|"Assigned a set sleep schedule for 2 weeks
~Receives evening time management goals to help facilitate scheduled bedtime
~Receives morning bright light from 2 light boxes (Phillips EnergyLights) on two weekend mornings."
16384524|NCT04087603|No Intervention|Healthy Control|- Sleep as usual at home for 2 weeks
16384525|NCT04087590|Experimental|PT003 treatment|
16384527|NCT04087577|Active Comparator|control group|conventional physical therapy
16384528|NCT04087551|Experimental|Developing the list of items for BRFES|Two groups of six community-dwelling older adults will participate in a focus group session. Each focus group session will begin with a trained facilitator using a session guide welcoming the participants and introducing the participants in the group. The session will adopt a nominal group method which includes silent generation of ideas, sharing of an idea in a 'round robin' fashion, group discussion to clarify ideas and then completing the session with anonymous voting to include items into a list of items to be included in the Balance Recovery Falls-Efficacy Scale (BRFES).
16384529|NCT04087538||Patients treated using troponin T|
16384530|NCT04087538||Patients treated using troponin I|
16384531|NCT04087525|Experimental|Sequence 1|Period 1 : Fasted state + HIP1701, Period 2 : Fasted state + HGP1809
16384532|NCT04087525|Experimental|Sequence 2|Period 1 : Fasted state + HGP1809, Period 2 : Fasted state + HIP1701
16384533|NCT04087512|Experimental|Instrumented perturbation-based balance training|
16384534|NCT04087512|Experimental|Conventional perturbation-based balance training|
16384535|NCT04087512|No Intervention|Control|
16384536|NCT04087499|Sham Comparator|regular medication treatment|regular medication treatment
16384537|NCT04087499|Experimental|acupuncture and regular medication treatment|acupuncture and regular medication treatment
16384538|NCT04087473||Prior 2nd generation ALKi|
16384539|NCT04087473||Prior 1st and 2nd generation ALKi|
16384540|NCT04087460|Experimental|Low-dose Group A|Subjects received three doses of PBPV with 20μg each antigen
16384541|NCT04087460|Placebo Comparator|Low-dose Group B|Subjects received three doses of placebo
16384542|NCT04087460|Experimental|Middle-dose Group A|Subjects received three doses of PBPV with 50μg each antigen
16384543|NCT04087460|Placebo Comparator|Middle-dose Group B|Subjects received three doses of placebo
16384544|NCT04087460|Experimental|High-dose Group A|Subjects received three doses of PBPV with 100μg each antigen
16384545|NCT04087460|Placebo Comparator|High-dose Group B|Subjects received three doses of placebo
16384546|NCT04087447||Thyroidectomy group|patient undergoing thyroidectomy for simple nodular goiter
16384547|NCT04087434||Retrospective|retrospective review of 300 records of patients following concussive diagnosis to track recovery and adherence to progressive return to activity recommendations.
16384548|NCT04087434||Prospective|300 prospective patients enrolled following concussive diagnosis to track recovery, clinical diagnosis and brain gauge performance.
16384549|NCT04087434||Control Group|75-100 Healthy Controls recruited by Fort Bragg to assess performance in a healthy population for brain gauge performance.
16384550|NCT04087421|Experimental|Transanal irrigation|Participants receiving TAI will irrigate once/day with stepwise volumes; 1. month 150 ml, 2. month 300 ml, and 3. month 500 ml.
16384551|NCT04087421|Active Comparator|Glycerol suppositories|Participants treated with glycerol suppositories will administer one glycerol suppository once/day.
16384552|NCT04087408|No Intervention|control group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU
~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.
~Trigger will be done using HCG followed by OPU 36 h later.
~Retrieved oocytes will be fertilized by ICSI.
~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.
~6 - Blood sampling will be performed for progesterone 7 days after OPU.
~7-Quantative BHCG will be performed 14 days after OPU."
16384553|NCT04087408|Active Comparator|study group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU
~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.
~Trigger will be done using HCG followed by OPU 36 h later.
~Retrieved oocytes will be fertilized by ICSI.
~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.
~GnRH agonist 0.1 mg will be given 6 days after OPU.
~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg
~Quantative BHCG will be performed 14 days after OPU."
16384554|NCT04087395|Experimental|RHA®4 with new anesthetic agent|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.
~Up to 3 mL injected per side."
16384555|NCT04087395|Experimental|RHA®4-Lidocaine|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.
~Up to 3 mL injected per side."
16384556|NCT04087382|Active Comparator|Intervention group|it included 32 patients with acute ischemic stroke beyond the time of window (more than 6 hours) assigned to mechanical thrombectomy) plus the conventional treatment (Aspirin 150 mg and atorvastatin 40 mg).
16384557|NCT04087382|Other|non-intervention group|it included 25 patients with acute ischemic stroke beyond the time of window (more than 6 hours) who received medical treatment (Aspirin 150 mg and atorvastatin 40 mg).
16384558|NCT04087369|Experimental|Bundled NCD WHO PEN Intervention|Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
16384559|NCT04087356||RMD+ Patients|Age-related macular degeneration patients with reticular macular disease
16384560|NCT04087356||RMD- Patients|Age-related macular degeneration patients without reticular macular disease
16384561|NCT04087343|Experimental|Meals plus exercise|
16384562|NCT04087343|Active Comparator|Meals only|
16384563|NCT04087330|Experimental|Group 1 Experimental group|Stretching, facilitation exercises with whole body vibration
16384564|NCT04087330|Active Comparator|Group 2 Control group|Stretching and facilitation exercises
16384565|NCT04087317|Experimental|Fixed time interval group.|Once the patient will arrive at the maternity ward the patient will receive paracetamol 1 gram and a tablet of ibuprofen 400 mg. Six hours after patient arrival and every 6 hours the patient will receive a tablet of paracetamol 500 mg and a tablet of ibuprofen 400 mg.
16384601|NCT04087135|Experimental|participant VLS|
16384602|NCT04087122|Experimental|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
16384566|NCT04087317|Experimental|'On-demand' group.|Patients allocated to this group will receive the same medications in the same combinations and order as described in the 'fixed time interval' group protocol, patients in this group will receive pain treatment only following demand, and the time intervals described above will be considered as the minimal time for giving the next combination of drugs.
16384567|NCT04087304|No Intervention|Low Risk Group|
16384568|NCT04087304|No Intervention|Mild Risk Group|
16384569|NCT04087304|Active Comparator|Moderate Risk Group|
16384570|NCT04087304|Active Comparator|High Risk Group|
16384571|NCT04087291|Active Comparator|Phase 1: Low Dose (1-5 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
16384572|NCT04087291|Active Comparator|Phase 1: Higher Dose (8-12 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
16384573|NCT04087291|Active Comparator|Phase 2: CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care for 10 months.
16384574|NCT04087291|No Intervention|Phase 2: No CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive no CCPM in which they will receive no chiropractic care for 10 months.
16384579|NCT04087265|Other|Study Population (All Participants)|Patients who are referring for scheduled screening colonoscopy
16384580|NCT04087252|Experimental|vaccinated group|Neoantigen vaccination will be performed with 6 doses in total, once per week
16384581|NCT04087239||Pregnant women from >20 weeks gestation|1,200 pregnant women (600 HIV infected mothers and 600 HIV uninfected controls) at least 20 weeks gestation were enrolled from January 2016 to June 2019. Participants are being followed as mother-baby pairs at birth, within 10 days of life 6, 10, 14 24, 48, 72 and 96 weeks of age. At each visit clinical examinations are being used to assess health and the impact of environmental factors. In addition, questionnaires are administered and bio-samples for laboratory tests. The design of the study is non-interventional cohort but participants are being offered advice regarding health and hygiene.
16384582|NCT04087226|Active Comparator|Conventional Retraction Cord|
16384583|NCT04087226|Experimental|PTFE Retraction Cord|
16384584|NCT04087213|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
16384585|NCT04087187|Experimental|Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
16384586|NCT04087187|Experimental|Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
16384587|NCT04087187|Experimental|Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
16384588|NCT04087187|Experimental|Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
16384589|NCT04087187|Experimental|Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
16384590|NCT04087187|Experimental|Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
16384591|NCT04087174|Experimental|Part A1: Capivasertib + enzalutamide|From day 1 to day 28 of this study treatment, patients will continuously enroll on a starting dose of capivasertib in combination with 160 mg enzalutamide.
16384592|NCT04087174|Experimental|Part A1: Capivasertib dose level 1 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+1 along with 160 mg enzalutamide.
16384593|NCT04087174|Experimental|Part A1: Capivasertib dose level 2 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+2 along with 160 mg enzalutamide.
16384594|NCT04087174|Experimental|Part A2: Capivasertib + abiraterone|Patients will continuously enroll on a starting dose of capivasertib in combination with 1000 mg abiraterone.
16384595|NCT04087174|Experimental|Part B1: Capivasertib + enzalutamide|This optional expansion will treat patients at the recommended dose regimen of capivasertib and enzalutamide.
16384596|NCT04087174|Experimental|Part B2: Capivasertib + abiraterone|This optional expansion will treat patients at the recommended dose regimen of capivasertib and abiraterone.
16384597|NCT04087148||patients|patients who were diagnosed as having CAH of at least 1 y duration. and On glucocorticoid replacement therapy .
16384598|NCT04087148||controls|A comparable number of age and sex matched apparently normal children will be included as control.
16384599|NCT04087135|Experimental|participant LD|
16384600|NCT04087135|Experimental|participant VL|
16384603|NCT04087109|Experimental|Intervention: MedSafer|In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
16384604|NCT04087109|No Intervention|Control: Baseline (no MedSafer)|During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
16384605|NCT04087096|Experimental|Denosumab|Denosumab 60mg subcutaneous injection every 6 months
16384606|NCT04087096|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months
16384607|NCT04087083|Experimental|technological intervention arm|Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
16384608|NCT04087083|Active Comparator|Control arm|Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
16384609|NCT04087070||biosignal derived blood pressure|"Blood pressure is measured by an automated oscillometric device or arterial waveform from IntelliVue MX800 Bedside patient monitor (Philips Healthcare, Amsterdam, Netherlands).
~Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.
~PAT(time between R peak of ECG and beginning of the pulse of PPG)
~PEP(time between R peak of ECG and peak of accelerometer signal)
~PTT(PAT-PEP)"
16384610|NCT04087057||Observational (interview, medical records review)|Patients complete questionnaires and participate in an interview to answer questions about information patients received before starting chemotherapy, any medical problems after surgery that could have been related to the start of the chemotherapy, how chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.
16384611|NCT04087044|Experimental|Vestibular dysfunction|66 patients: 30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine
16384612|NCT04087044|Other|Control|120 aged matched controls
16384613|NCT04087031|Active Comparator|control arm|Ten traditional treatment sessions divided into 2 training sessions per week for 5 weeks
16384614|NCT04087031|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
16384615|NCT04087031|Experimental|robotic treadmill arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
16384618|NCT04087005|Experimental|Hominis placental pharmacopuncture|The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
16384619|NCT04087005|Active Comparator|Transcutaneous electrical nerve stimulation|The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).
16384620|NCT04086992|No Intervention|Control Group|This group will continue to receive standard care for ACTH monitoring and follow-up with includes blood pressure by the patient's PCP while on therapy, a one week nursing follow-up phone call, and a two-week EEG and Neurology appointment.
16384621|NCT04086992|Experimental|Intervention Group|This group will be provided remote monitoring technology where they will be able to monitor blood pressure at home. In addition, they will receive a nurse-led telemedicine visit at one week and three weeks of therapy. Like the control group, they will still receive a two-week EEG and Neurology appointment.
16384622|NCT04086979|Experimental|Parental Friendship Coaching (PFC)|
16384623|NCT04086979|Active Comparator|Coping with ADHD through Relationships and Education (CARE)|
16384625|NCT04086953|Experimental|Chronic Respiratory Disease Group|"Each patient receive the same intervention : 4 visits with different exercise tests.
~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)
~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)
~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)
~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire"
16384626|NCT04086953|Experimental|Cardiovascular diseases Group|"Each patient receive the same intervention : 4 visits with different tests.
~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)
~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)
~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)
~Visit 4 : Reproducibility of the WTLT (WTLT x2)"
16384627|NCT04086940|Active Comparator|esmolol(breviblock) group|Patients in group E received a loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline over 30 minutes before induction of anesthesia, then followed by an infusion of esmolol 10 µg/kg/min until the end of the surgery.
16384759|NCT04086134|Experimental|Intervention fruit products 2|Three servings of fruit products per day for 4 weeks.
16384628|NCT04086940|Active Comparator|non esmolol group|Patients in group N received 50 ml of isotonic saline over 30 min, followed by an infusion of isotonic saline at same rate of group E till the end of the surgery.
16384629|NCT04086927|No Intervention|Control Group|Patients will not receive compression dressing
16384630|NCT04086927|Experimental|Experimental Group|Patients will receive compression dressing
16384631|NCT04086914|No Intervention|Non nerve block|Receives no nerve block
16384632|NCT04086914|Experimental|Nerve block|Receives nerve block
16384633|NCT04086901|Experimental|Dose escalation Arm|Chemo-radiotherapy with radiotherapy dose escalation based on Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG/PET) scans
16384634|NCT04086901|No Intervention|Standard|Standard chemo-radiotherapy
16384635|NCT04086875|Experimental|Phase 1 (focus groups)|Participants attend focus groups on adherence to hormone therapy.
16384636|NCT04086875|Experimental|Phase II Group 1 (text messages)|Participants receive text messages twice weekly for 6 months to remind and motivate participants about AHT adherence.
16384637|NCT04086875|Active Comparator|Phase II Group II (usual care)|Participants receive usual care.
16384638|NCT04086862|Active Comparator|The 1 MHz group|The 1 MHz group will receive therapeutic ultrasound at the 1 MHz setting.
16384639|NCT04086862|Experimental|The 3 MHz group|The 3 MHz group will receive therapeutic ultrasound at the 3 MHz setting.
16384640|NCT04086836||Patient suffering a late stroke after TAVR|All patients suffering a stroke after TAVR will be studied
16384641|NCT04086823|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 48 sites in the submental fat (0.05/0.1mL per site):
~Up to 120mg administered at 48 sites in a volume of 0.05 ml at each injection site (total injected volume 2.4mL)
~Up to 240 mg administered at 48 sites in a volume of 1 ml at each injection site (total volume injected 4.8mL)"
16384642|NCT04086823|Placebo Comparator|Vehicle|"Subject receive a single-treatment injection. Multiple injections of the Placebo are administered at 48 sites (0.05/0.1mL per site) into the submental fat.
~Up to a total of 2.4 mL will be injected for placebo subjects enrolled during cohort 1.
~Up to a total of 4.8 mL will be injected for placebo subjects enrolled during cohort 2."
16384643|NCT04086810|Experimental|DCCR|25 - 450 mg DCCR
16384644|NCT04086797|Experimental|IQP-AE-103|2 capsules after 3 main meals per day (total 1980 mg)
16384645|NCT04086797|Placebo Comparator|Placebo|2 capsules after 3 main meals per day
16384646|NCT04086784||3D-printed Cage|Patients undergoing posterior lumbar interbody fusion with 3D-printed Porous Titanium Alloy Cages at the lowest fusion segment
16384647|NCT04086784||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages at the lowest fusion segment
16384648|NCT04086771|Experimental|Intervention Group (Navigation)|Participants will be contacted by CHAs by phone one week after giving informed consent and completion of the baseline survey. CHAs will contact participants once a week for up to 10 weeks (a maximum of 10 attempts or until a clinic appointment is made, whichever comes first). Using the TIMS© message library, the CHAs will engage participants in conversations about breast and cervical cancer screening and navigate the participants to overcome any barriers to screening and motivate them to make a clinic appointment. Personal messages from mothers to daughters and vice versa and screening reminder notecards will be sent at 12-months (T3). At 18-months (T4), CHAs will follow-up with navigation group participants who reported completing a mammogram during the navigation process. Screening completion will be measured by self-report and confirmed via medical record check.
16384649|NCT04086771|Placebo Comparator|Control Group (Information only)|Participants will be mailed an informational brochure on mammography and Pap testing one week after enrollment into the study. At 3-months post enrollment, CHAs will conduct a follow-up phone call with each participant to assess mammogram and/or Pap testing completion (primary outcomes). At 12-months (T3) post enrollment, CHAs will contact all control group participants by phone to confirm a scheduled appointment or screening completion. For those who completed a mammogram within the 12 months since enrollment, generic screening reminder notecards will be sent by mail. At 18-months (T4), CHAs will follow-up with those control group participants who reported scheduling a mammogram, Pap smear, or both at the 12-month (T3) time point.
16384650|NCT04086758|Experimental|Zolbetuximab|Participants will receive a loading dose-1 of zolbetuximab on Day 1 of Cycle 1, consists of 21 days, followed by subsequent lower dose-2 every 3 weeks until they meet the discontinuation criteria.
16384654|NCT04086732|Experimental|Temporomandibular disorder|
16384655|NCT04086732|Experimental|Healthy control|
16384656|NCT04086719|Experimental|BMS- 986185 + Pyrimethamine|
16384657|NCT04086719|Experimental|BMS-986185|
16384658|NCT04086706||Consecutive Patients with complete colonoscopy|Inclusion criteria were as follows: Patients older than 18 years, with a complete colonoscopy, for CRC screening or post-polypectomy surveillance or diagnostic assessment. Exclusion criteria precluded patients with previous colectomy or an abdominal surgery in the last 6 months, patients with polyposis syndromes or inflammatory bowel diseases and if they were unfit for polypectomy or the polyp specimen was not retrieved for histology.
16384659|NCT04086693|Active Comparator|Standard IV dressing|Polyurethane dressing with clear tape
16384660|NCT04086693|Experimental|Standard IV dressing plus Adhezion SecurePortIV|Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).
16384661|NCT04086667|Experimental|Pain group|"The segment on the lower back marked as most painful"
16384662|NCT04086667|Experimental|Stiff group|"The segment on the lower back marked as most stiff"
16384663|NCT04086654|Other|International Trauma Interview (ITI)|
16384664|NCT04086641|Experimental|Foot 1: Crossover Foot, Foot 2: Energy Storing Foot|Participant randomized to crossover foot as first condition, energy storing foot as second condition
16384665|NCT04086641|Experimental|Foot 1: Energy Storing Foot, Foot 2: Crossover Foot|Participant randomized to energy storing foot as first condition, crossover foot as second condition
16384666|NCT04086628||Asthmatic children vaccinated|
16384667|NCT04086628||Asthmatic children unvaccinated|
16384668|NCT04086615|Experimental|NMES and exercise supplemented with high BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.
~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The High BFR group will have the pressure set at 80% of limb occlusion pressure."
16384669|NCT04086615|Sham Comparator|NMES and exercise supplemented with low BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.
~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The Low BFR group will have the pressure set at 20 mmHg."
16384670|NCT04086602|Experimental|Single Ascending Dose|Once daily oral IZD334 or Placebo
16384671|NCT04086602|Experimental|Multiple Ascending Dose|Once or twice daily oral IZD334 or Placebo
16384672|NCT04086589||Young|Observational study without intervention
16384673|NCT04086589||Elderly|Observational study without intervention
16384674|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
16384675|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
16384676|NCT04086563|Experimental|Action observation|The patients will observe a 25 minutes clip of neurodynamic exercises of the hand.
16384677|NCT04086563|Experimental|Mirror Therapy|With a mirror glasses, the patients will execute neurodynamic movements of their non-dominant hand during 25 minutes.
16384678|NCT04086563|Active Comparator|Strength Training|Strength protocol for the dominant hand.
16384679|NCT04086563|Experimental|Neurodynamic exercise|Active neurodynamic exercises for the dominant hand.
16384680|NCT04086550|Experimental|Investigational arm|Application of LIQOSEAL after closure of dura mater
16384681|NCT04086550|Active Comparator|Control arm|Application of Adherus or DurSeal after closure of dura mater
16384682|NCT04086537||BMPR2-mutation carriers|Patients affected by pulmonary arterial hypertension (PAH) with already determined BMPR2 mutation status (hereditary PAH, HPAH) or patients with idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted positive for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
16384683|NCT04086537||non-BMPR2 mutation carriers|Patients affected by Pulmonary arterial hypertension (PAH) who resulted negative at the routinely-performed (according to current guidelines) BMPR2 analysis (Idiopathic PAH, IPAH) or patients with Idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted negative for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
16384684|NCT04086537||healthy controls|Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
16384685|NCT04086524|Experimental|Binocular cartoon treatment at home|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL at home. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
16384686|NCT04086524|Active Comparator|Control group|"Participants will patch for 2 hours every day at home. After 2 weeks, they will be given the option to crossover to the teratment group for an additional 2 weeks (total of 4 weeks). Patching is a common treatment for amblyopia, often considered the golden standard. It is the most common comparison as a control group in amblyopia and vision therapy literature."
16384687|NCT04086524|Experimental|Binocular cartoon treatment in office|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL in office. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
16384688|NCT04086511||Children with PKU|
16384689|NCT04086511||Age- and sex-matched non-PKU comparison subjects|
16384721|NCT04086329|Other|Healthy Controls|Adult healthy volunteers will be individually matched with corresponding MM cases based on age, biological sex, and body mass index.
16384722|NCT04086316||Depression Group|Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
16391999|NCT04035668|Experimental|LOU064 Dose 4|low orally
16384690|NCT04086498|Experimental|ketogenic-mediterranean diet with phytoextracts|The KEMEPHY diet (Paoli et al., 2011) is a mediterranean calorie-controlled ketogenic protocol (about 900 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (Lodi et al., 2016).
16384691|NCT04086498|Active Comparator|Ketogenic Diet|The KD is a protocol in which all foods containing carbohydrate are excluded, whereas meat, eggs, fish, ham, green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants can be eat without any limit. This protocol allows the use of oil, lemon juice (2 tbs/day), spices and aromatic herbs with a limitation of the use of saturated fats like butter, margarine and lard. Coffee, tea and herbal tea could be sweetened with sweeteners
16384692|NCT04086498|Active Comparator|Mediterranean Diet|The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
16384695|NCT04086472|Experimental|MK-1654 100 mg|Participants receive a single IV infusion of MK-1654 100 mg on Day 1.
16384696|NCT04086472|Experimental|MK-1654 200 mg|Participants receive a single IV infusion of MK-1654 200 mg on Day 1.
16384697|NCT04086472|Experimental|MK-1654 300 mg|Participants receive a single IV infusion of MK-1654 300 mg on Day 1.
16384698|NCT04086472|Experimental|MK-1654 900 mg|Participants receive a single IV infusion of MK-1654 900 mg on Day 1.
16384699|NCT04086472|Placebo Comparator|Placebo|Participants receive a single IV infusion of placebo on Day 1.
16384700|NCT04086459|Active Comparator|Active repetitive transcranial magnetic stimulation|
16384701|NCT04086459|Sham Comparator|Sham repetitive transcranial magnetic stimulation|
16384702|NCT04086459|No Intervention|No repetitive transcranial magnetic stimulation|
16384703|NCT04086446|Active Comparator|active tDCS|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
16384704|NCT04086446|Sham Comparator|sham tDCS|The sham transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
16384705|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
16384706|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
16384707|NCT04086420|Experimental|Mindfulness|Delivered through an audio-recording consisting of a single meditation exercise that lasted for 30 minutes
16384708|NCT04086420|Active Comparator|Heart-Rate|Given a heart rate monitor and instructed to use it to determine the intensity of their exercise
16384709|NCT04086407|Experimental|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
16384710|NCT04086394|Experimental|PECS Block|Group who was randomly selected to receive the intraoperative nerve block.
16384711|NCT04086394|Sham Comparator|Control|Patient who was randomly selected not to receive intraoperative nerve block
16384712|NCT04086381|Active Comparator|Intervention|Oral injestion of 20 grams of creatine monohydrate daily
16384713|NCT04086381|Placebo Comparator|Placebo|Oral injestion of 20 grams of cellulose daily
16384714|NCT04086368|Active Comparator|The Synthes Pediatric LCP Plate System|Open osteotomy and osteofixation with the pediatric LCP hip plate
16384715|NCT04086368|Experimental|The adolescent Lateral Femoral Nail|Percutaneous osteotomy and intramedullary nailing
16384716|NCT04086355|Experimental|Effect of electrical stimulation on dysphagia in cp|the study group that was treated by selected oromotor exercise program in addition to neuromuscular electrical stimulation, Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
16384717|NCT04086355|Experimental|effect of oromotor exercise on dysphagia in cp|the control group was treated by the same oromotor exercise program in addition to placebo effect of neuromuscular electrical stimulation. Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
16384718|NCT04086342|Active Comparator|CHI-902|Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
16384719|NCT04086342|Placebo Comparator|Placebo|Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
16384720|NCT04086329|Other|Affected MM Cases|Key eligibility criteria for MM cases includes physically-capable adults (male and females, ages 18 to 65 years, inclusive) with genetically-confirmed MM with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.
16384723|NCT04086316||Healthy Group|Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
16384724|NCT04086303|Experimental|young handball players|The first group was named young players (n = 19; age = 18.05 ± 2.58 years, body mass index = 22.0 ± 2.21 kg, sport participation ≤ 10 years)
16384725|NCT04086303|Active Comparator|adult handball players|The second group was named old players (n =23; age = 28,91 ± 3.39 years, body mass index = 22.20 ± 2.75 kg, sport participation ≥ 11 years).
16384726|NCT04086290|Experimental|RARP + SBRT + ADT|Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
16384727|NCT04086277|Experimental|Women in labor with continuous intrapartum support|Continuous intrapartum support was based on three basic aspects: 1) emotional support, 2) physical support and comfort measures and 3) information and advice.
16384728|NCT04086277|No Intervention|Women in labor without continuous intrapartum support.|The no intervention group received the usual obstetric care, without continuous intrapartum support.
16384729|NCT04086264|Experimental|Regimen A|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azaciditine dose in subsequent cohorts may be reduced.
16384730|NCT04086264|Experimental|Regimen B|IMGN632, administered intravenously on Day 7 of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on the day 3 up to Day 21 of a 21 day cycle. Alternate schedules with reduced venetoclax administration may be explored.
16384731|NCT04086264|Experimental|Regimen C|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 35-75 mg/m2 given for Days 1 to 7 of a 28 day cycle and venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on Day 3 up to Day 28 of a 28 day cycle. Alternate schedules with reduced venetoclax administration or reduced azacitidine dose or administration may be explored.
16384732|NCT04086264|Experimental|Regimen D|IMGN632, administered intravenously on Day 1 of a 21 day cycle at 0.045 mg/kg, as a monotherapy for Fit and Unfit MRD+ patients
16384733|NCT04086251|Experimental|Gaido Intervention|All patients enrolled in the study will participate in the Gaido Intervention, which entails wearing the Biovotion Everion continuously and take blood pressure and oral temperature spot checks per clinician orders. Patients will also be responsible for filling out PRO surveys and any surveys that trigger as a result of their vital signs falling outside of tailored thresholds.
16384734|NCT04086238|Other|Formulation A Fasted|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
16384735|NCT04086238|Experimental|Formulation A Fed|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
16384736|NCT04086238|Other|Formulation B Fasted|EPI01 Formulation B (slow reelase): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
16384737|NCT04086238|Experimental|Formulation B Fed|EPI01 Formulation B (slow release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
16384738|NCT04086238|Other|Formulation C Fasted|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
16384739|NCT04086238|Experimental|Formulation C Fed|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
16384740|NCT04086212|Experimental|IXC Peritoneal dialysis solution|IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution
16384741|NCT04086212|Active Comparator|Icodextrin|Extraneal® (7.5% Icodextrin) Peritoneal dialysis solution
16384742|NCT04086199||Anterior discectomy|The discectomy is made by an anterior muscle sparring approach (extraperitoneal).
16384743|NCT04086199||Posterior discectomy|The discectomy is made by a posterior approach (posterior midline incision).
16384744|NCT04086186|Active Comparator|Adductor Canal Block Group|Standard method for peri-operative pain control. Adductor canal block is performed by anesthesiologist prior to surgery.
16384745|NCT04086186|Experimental|Liposomal Bupivacaine Group|Experimental method for peri-operative pain control. Liposomal bupivacaine peri-articular injection is performed by surgeon during surgery.
16384746|NCT04086173|Experimental|Study group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.
16384747|NCT04086173|Placebo Comparator|Control group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.
16384748|NCT04086160|Experimental|schizophrenia- tDCS|
16384749|NCT04086160|Sham Comparator|schizophrenia- sham|
16384750|NCT04086160|Experimental|at risk- tDCS|
16384751|NCT04086160|Sham Comparator|at risk- sham|
16384752|NCT04086160|Experimental|healthy controls for schizophrenia- tDCS|
16384753|NCT04086160|Sham Comparator|healthy controls for schizophrenia- sham|
16384754|NCT04086160|Experimental|healthy controls for at risk- tDCS|
16384755|NCT04086160|Sham Comparator|healthy controls for at risk- sham|
16384758|NCT04086134|Experimental|Intervention fruit products 1|Three servings of fruit products per day for 4 weeks.
16392000|NCT04035668|Placebo Comparator|Placebo|0 mg orally
16384760|NCT04086134|Placebo Comparator|Control fruit products|Three servings of control fruit products per day for 4 weeks.
16384761|NCT04086121|Experimental|All Subjects|
16384762|NCT04086108|Experimental|Tomato|Single oral administration
16384763|NCT04086108|Experimental|GABA supplement|Single oral administration
16384764|NCT04086108|Experimental|Glutamate supplement|Single oral administration
16384765|NCT04086108|No Intervention|Placebo|Single oral administration, same volume of water that is distributed in the other arms
16384766|NCT04086095|Experimental|Intervention Group|Surfactant administration will be done via videolaryngoscopy and the application aid Neofact in neonates with respiratory distress syndrome and airway support with CPAP. Alveofact is used as Surfactant in its standard dosage of 100 mg / kg
16384767|NCT04086082|Experimental|Markerless Image Guidance Arm|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
16384768|NCT04086069|Experimental|Standard Training+Sit-to-stand trainer|Training using a sit-to-stand trainer device in addition to standard training of standing-up with the help of a physiotherapist
16384769|NCT04086069|No Intervention|Standard Training|Standard training of standing-up with the help of a physiotherapist
16384770|NCT04086056||Children with craniosynostosis|Children with craniosynostosis who will be operated in prone position.
16384771|NCT04086043|Experimental|Endovascular Denervation|
16384774|NCT04086017|Experimental|Reiki teaching|Reiki Master will perform the teaching and attunement process for Level 1 Reiki and teach the caregiver(s) how to complete a simple 10-minute Reiki session with the patient and a 10-minute self-Reiki session for the caregiver(s). The Reiki Master will explain that Reiki sessions can be given whenever the patient and caregiver feel it is appropriate, but sessions should be at minimum twice per 24-hour period for at least 10 minutes with at least two hours between sessions. Reiki sessions may be more frequent than twice per day and/or longer than 10 minutes. Self-Reiki sessions should be performed daily for at least 10 minutes but maybe more frequent and/or longer in length. Each family caregiver will receive a copy of the book. The patient and caregiver will wear a Holter monitor continuously for 48 hours beginning when the caregiver(s) are trained in Reiki to measure HRV, a valid measure for stress.
16384775|NCT04086017|No Intervention|Usual care|Patients and caregivers will complete all measures expected of the intervention cohort including daily symptom checklist for 10 days. The patient and caregiver will wear a Holter monitor for the first 48 hours of study participation to measure heart rate variability (HRV), a valid measure for stress. The patient and/or caregiver may opt out of the Holter monitor if requested and still participate in the rest of the study.
16384776|NCT04086004|Experimental|Group I Experimental Motor Imagery|Motor imagery practice
16384777|NCT04086004|Experimental|Group II Dual Task Training|Dual-task balance training
16384778|NCT04085991|Experimental|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses
16384779|NCT04085978||Pre implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2014 - November 30, 2016 who qualify for hypoglycemia protocol
16384780|NCT04085978||Post implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2018 - November 30 2018 who qualify for hypoglycemia protocol
16384781|NCT04085965|Experimental|CAMP|Children randomized to CAMP were enrolled in the Boys and Girls Club Camp in one of two low-income Rhode Island communities in summer 2017 or 2018 for 7-weeks in 2017 and 8-weeks in 2018 due to a delayed end to the 2017 school year (i.e. snow days). Camp was offered daily from 8:30 to 4:30.
16384782|NCT04085965|No Intervention|Summer As Usual|Children randomized to the SAU group were asked to experience an unstructured summer as otherwise planned by their parent / guardian. They agreed to not attend structured summer programming (i.e. camp, summer school, or day care) for more than one week over the summer so as to provide an inactive control group for comparison to those in CAMP.
16384783|NCT04085952|Experimental|anterior colporrhaphy with dermal graft|Patients randomized to this arm underwent anterior colporrhaphy with dermal graft augmentation (ARUCS) during their surgery for pelvic organ prolapse.
16384784|NCT04085952|Active Comparator|anterior colporrhaphy suture based|Patients randomized to this arm underwent anterior colporrhaphy with suture based repair (native tissue) during their surgery for pelvic organ prolapse. This is and was the most common practice for anterior colporrhaphy.
16384785|NCT04085926|Experimental|Sealed shoe|"Therapeutic footwear including off-the-shelf therapeutic shoes and custom-made insoles. The shoe on the ulcerated foot is sealed, i.e., made irremovable, with a plastic band."
16384786|NCT04085926|Active Comparator|Total contact cast|A irremovable custom-made total Contact cast enclosing the foot and shin
16384787|NCT04085913|Active Comparator|Current Practice|Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
16384788|NCT04085913|Experimental|Bupivicaine HCL|Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
16384789|NCT04085913|Experimental|Exparel Injection|Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
16384790|NCT04085900||Screening cohort|All participants will be tested for EBV associated biomarkers, including EBNA1/IgA, VCA/IgA, BNLF2b/IgG et al. And in males, EBV-DNA will be tested.Screening positive people will be followed up annually. And screening negative are invited to retest every four year.
16384791|NCT04085887|Experimental|Cohort 1-0.006 Panitumumab-IRDye800|Dose: 0.006 Panitumumab-IRDye800 (mg/kg)
16384792|NCT04085887|Experimental|Cohort 2-0.25 Panitumumab-IRDye800|Dose: 0.25 Panitumumab-IRDye800 (mg/kg)
16384793|NCT04085887|Experimental|Cohort 3-0.50 Panitumumab-IRDye800|Dose: 0.50 Panitumumab-IRDye800 (mg/kg)
16384794|NCT04085887|Experimental|Cohort 4-1.0 Panitumumab-IRDye800|Dose: 1.0 (with max cap dose 50 mg) Panitumumab-IRDye800 (mg/kg)
16384795|NCT04085874|Experimental|FBR group|weekly home visit and monthly group meeting for 12 weeks
16384796|NCT04085874|Active Comparator|non-FBR group|once nutrition counseling from standard health care services
16384797|NCT04085861|Experimental|Dancers|Recruited group of professional dancers from the Norwegian University of dance
16384798|NCT04085861|No Intervention|Control|Recruited group of professional art students from the Oslo Academy of the Arts (Norway)
16384799|NCT04085861|Experimental|Dance teachers|Recruited group of dance teachers from the Norwegian University of dance
16384800|NCT04085848|Experimental|Groupe intervention|Usual care and music therapy
16384801|NCT04085848|No Intervention|Groupe contrôle|Usual care
16384802|NCT04085822|Experimental|Multiple Abdominal Injections|Ten injections per patient: 7 of SMA-001 and 3 of control device.
16384803|NCT04085809|Experimental|Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment|AmLactin® Rapid Relief, BID application for 14 days on left leg and no treatment on right leg
16384804|NCT04085809|Experimental|Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days on right leg and no treatment on left leg
16384805|NCT04085783|Experimental|endometrial PRP|In study group (75 patients), intrauterine infusion of PRP was done 48 hrs. before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5- 1 ml of PRP was infused into the uterine cavity with embryo transfer catheter (Wallace - Smiths, UK). On the other side, No PRP was done in control group. Pregnancy tests were done 12 days after ET.
16384806|NCT04085770|Experimental|Alfacalcidol|Patients allocated to the alfacalcidol group received 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay.
16384807|NCT04085770|No Intervention|Control|Control group were exposed to the same conditions as the treatment group except they were not given one-alfacalcidol.
16384808|NCT04085757|Experimental|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
16384809|NCT04085757|Active Comparator|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
16384810|NCT04085744|No Intervention|control group|In this group any drug will be applied on the cuff of the intubation tube
16384811|NCT04085744|Active Comparator|lidocaine group|10% lidocaine spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
16384812|NCT04085744|Active Comparator|steroid group|mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
16384813|NCT04085718||Study arm|All included patients will undergo FDGPET/CT scan
16384815|NCT04085692|Experimental|Intervention|"The intervention group begins LDHF dispatcher training with one introduction week followed by twelve weeks of LDHF training.
~During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs."
16384816|NCT04085692|No Intervention|Comparison|During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs.
16384817|NCT04085679||MMU active group|Subjects residing in nursing homes where the MMU care model has already been implemented
16384818|NCT04085679||MMU control group|Subjects residing in nursing homes where the MMU care model has not yet been implemented (ED visits performed in case of urgent clinical situations)
16384819|NCT04085666|Experimental|1st Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
16384820|NCT04085666|Experimental|2nd Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
16384852|NCT04085419|Active Comparator|zoledronic acid|zoledronic acid 5 mg intravenously once a year
16384910|NCT04085055|Active Comparator|22 Gauge FNB Needle - ProCore|The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
16384821|NCT04085640|Experimental|Obturator nerve block with Ropivacaine|Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needlewill be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
16384822|NCT04085640|Sham Comparator|Obturator nerve block with isotonic salin|The same procedure will be performed and 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles
16384823|NCT04085627|Experimental|T Test|Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
16384824|NCT04085627|Active Comparator|R Reference|Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
16384825|NCT04085614|Experimental|Dynamic Coronary Roadmap group|Patients will be treated via standard of care for PCI with navigation support of Dynamic Coronary Roadmap.
16384826|NCT04085614|Active Comparator|Control group|Patients will be treated via standard of care for PCI without navigation support of Dynamic Coronary Roadmap.
16384827|NCT04085601|No Intervention|Standard of Care (SOC) excluding complement inhibitors|
16384828|NCT04085601|Experimental|1,080mg APL-2 administered subcutaneously twice weekly|
16384829|NCT04085588||Group 1|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.
~Before the skin incision, when sensorial block reached T10 dermatome level 2 μg / kg / min ketamine was started in Group 1. By the end of the operation ketamine infusion was reduced to 1 μg / kg / min."
16384830|NCT04085588||Group 2|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.
~Before the skin incision, when sensorial block reached T10 dermatome level 4 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 2 μg / kg /min and continued."
16384831|NCT04085588||Group 3|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.
~Before the skin incision, when sensorial block reached T10 dermatome level 6 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 3 μg / kg /min and continued."
16384832|NCT04085575|Active Comparator|tranexamic acid - The G1 group|The G1 group received 1 g of intra-articular tranexamic acid (TXA). The G1 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
16384833|NCT04085575|Active Comparator|tranexamic acid - The G2 group|The G2 group received 2 g of intra-articular tranexamic acid (TXA). The G2 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
16384834|NCT04085562|Experimental|Amlodipine|Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
16384835|NCT04085562|Experimental|Bisoprolol|Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.
16384836|NCT04085549|Experimental|Berry Oil Cream|Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
16384837|NCT04085549|No Intervention|Control|Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.
16384838|NCT04085549|Active Comparator|Reference cream|A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
16384839|NCT04085536|Other|Chronic maxillary sinusitis(for more than 12 weeks)|Patients for whom chronic maxillary sinusitis will be diagnosed in the first ENT consultation, will then be seen in a stomatology consultation to determine whether or not a dental cause is objective.
16384840|NCT04085523|Other|TransCon CNP 6 mcg|TransCon CNP 6 mcg CNP/kg or placebo mimicking TransCon CNP 6 mcg delivered once weekly by subcutaneous injection
16384841|NCT04085523|Other|TransCon CNP 20 mcg|TransCon CNP 20 mcg CNP/kg or placebo mimicking TransCon CNP 20 mcg delivered once weekly by subcutaneous injection
16384842|NCT04085523|Other|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
16384843|NCT04085523|Other|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
16384844|NCT04085523|Other|TransCon CNP >100 mcg|TransCon CNP >100 mcg CNP/kg delivered once weekly by subcutaneous injection (to be determined after completion of 100 mcg cohort)
16384845|NCT04085510|Experimental|Contrast-enhanced mammogram|All women will receive both 3D mammography and contrast-enhanced mammography for breast cancer screening; the order of interpretation will vary for each of two radiologists
16384846|NCT04085497|Experimental|Treatment|KT was applied once a week, 6 times in total. Exercises were performed for all patients for 5 weeks 5 days a week, 3 sets 15 repetitions each day.
16384847|NCT04085497|Placebo Comparator|Group 2|The exercise program included quadriceps set exercise, straight leg lifting, mini squat, stretching to hamstring and gastrosoleus muscle groups.
16384848|NCT04085484||Infants born between 1 Feb 2010 and 18 Feb 2012|Infants born between 1 February 2010 and 18 February 2012, before the concentrated PN regime was implemented (Original PN group: n = 81).
16384849|NCT04085484||Infants born between 19 Feb 2012 and 30 Sep 2013|Infants born between 19 February 2012 and 30 September 2013, after the concentrated PN regime was implemented (Concentrated PN group: n = 53).
16384851|NCT04085419|Active Comparator|denosumab|denosumab 60 mg subcutaneously every 6 months
16397014|NCT04000477|Experimental|Kevorkian curette|
16384853|NCT04085406|Experimental|Active Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label period) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
16384854|NCT04085406|Sham Comparator|Sham Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label phase) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
16384855|NCT04085393|Active Comparator|GERSC for patients receiving highly emetogenic chemotherapy|Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
16384856|NCT04085393|Active Comparator|GERSC on patients receiving moderately emetogenic chemotherapy|Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
16384857|NCT04085367|Placebo Comparator|Vehicle|Two treatments of Day light DLT two weeks apart
16384858|NCT04085367|Active Comparator|Treatment|Two treatments of Day light DLT two weeks apart
16384859|NCT04085354|Placebo Comparator|Placebo|Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
16384860|NCT04085354|Active Comparator|Dapoxetine|Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
16384861|NCT04085354|Active Comparator|Dapoxetine and folic acid.|Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
16384862|NCT04085354|Active Comparator|Dapoxetine and vitamin B12|Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
16384863|NCT04085341|Experimental|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
16384864|NCT04085341|Experimental|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
16384865|NCT04085315|Experimental|Dose Escalation|Patients will continue to receive osimertinib 80 mg PO daily as part of standard of care therapy during screening and study treatments. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose will be 30 mg twice daily (dose level 1). All patients at a given dose level must complete the DLT period before any additional cohorts can be opened.
16384866|NCT04085315|Experimental|Dose Expansion: Cohort A|Stage IV EGFR-mutant NSCLC currently receiving and progressing on osimertinib who are chemotherapy and immunotherapy naive. Patients will receive treatment at the recommended dose (30 mg taken orally twice per day, intermittent dosing schedule) until disease progression or unacceptable toxicity
16384867|NCT04085315|Experimental|Dose Expansion: Cohort B|Stage IV EGFR-mutant NSCLC patients who have received at least 3 months, but no more than 6 months, of osimertinib with a best response of partial response (PR) or stable disease (SD). Patients will receive treatment at the recommended dose (30 mg orally, twice per day, intermittent dosing schedule) until disease progression or unacceptable toxicity.
16384868|NCT04085302|Experimental|All subjects|
16384869|NCT04085289|Experimental|Galcanezumab|Participants received single subcutaneous (SC) doses of 120 milligram (mg) or 240 mg Galcanezumab.
16384870|NCT04085289|Placebo Comparator|Placebo|Participants received a single SC dose of Placebo.
16384871|NCT04085276|Experimental|JS001 Plus Nab-Paclitaxel|Patients will receive both JS001 and Nab-Paclitaxel.
16384872|NCT04085276|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Patients will receive both placebo and Nab-Paclitaxel.
16384873|NCT04085263|Sham Comparator|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
16384874|NCT04085263|Experimental|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
16384875|NCT04085250|Experimental|Nivolumab Consolidation|Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
16384876|NCT04085250|Active Comparator|Observation|Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
16384877|NCT04085237|Experimental|Ultrasound-guided continuous ESP block with opioid PCA|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
16384878|NCT04085237|Sham Comparator|Ultrasound-guided sham block and catheter with opioid PCA|The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.
16384879|NCT04085224|Active Comparator|1|
16384880|NCT04085224|Experimental|2|
16384881|NCT04085224|Experimental|3|
16384882|NCT04085211||Inflammatory Bowel Disease|Patients with an established diagnosis of ulcerative colitis or Crohn's Disease who require either a flexible sigmoidoscopy or colonoscopy as part of routine care (e.g. surveillance or staging disease activity)
16384883|NCT04085211||Patients with symptoms of gastro-oesophageal reflux disease|Patients with symptoms of gastro-oesophageal reflux disease requiring a gastroscopy as part of routine clinical care.
16384884|NCT04085211||Atrophic gastritis|Patients with known or suspected atrophic gastritis that require a gastroscopy to either confirm the diagnosis or surveillance for pre-cancerous changes.
16384885|NCT04085211||Neuroendocrine Tumours|Patients with an established history of gastric neuroendocrine tumours requiring surveillance
16384908|NCT04085068||Study group (group A):|15 women take cranioscaral treatment
16384909|NCT04085068||control group (group B):|shame group
16384886|NCT04085198|Active Comparator|No-touch technique with the application of light physics rules|This procedure will be performed by the gynecologists who are familiar to the rules of the 'lights physics' and are currently 'lights physics' rules in their clinical practice. The brightness or darkness of the tissue which reflects the distance between the light source and the surrounding tissue will be used to find the correct route from the vagina introitus to the uterine cavity.
16384887|NCT04085198|Placebo Comparator|Control|Patients in this arm of the study protocol will receive standard hysteroscopy with 'no-touch' technique without the utilization of the 'lights physics' rules. The gynecologist performing this procedure will find their route from the vagina introitus to the uterine cavity by the identification of the anatomical structures on their way.
16384888|NCT04085185|Experimental|Phase Ia Dose-Escalation Stage:IBI110|Participants will be treated with escalating doses of IBI110 to determine the MTD.
16384889|NCT04085185|Experimental|Phase Ia Expansion Stage:IBI110|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.
16384890|NCT04085185|Experimental|Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab|Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.
16384891|NCT04085185|Experimental|Phase Ib Expansion Stage:IBI110+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.
16384892|NCT04085172|Experimental|Part A: Guanfacine hydrochloride (TAK-503)|Participants randomized to TAK-503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet once daily (QD) for 52 weeks.
16384893|NCT04085172|Active Comparator|Part A: Atomoxetine hydrochloride|Participants who weigh less than (<) 70 kilograms (kg) at baseline will receive active Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 milligram per kilogram (mg/kg) which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 52 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh >= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 52 weeks. The total dose for participants who weigh >= 70 kg at baseline will not exceed 100 mg.
16384894|NCT04085172|Placebo Comparator|Part A: Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to TAK-503 and aged 13 to 17 years will receive 5 to 7 mg tablets of placebo matched to TAK-503 orally QD for first 18 weeks. Participants who weigh < 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of first 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh >= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.
16384895|NCT04085172|Experimental|Part B: Guanfacine hydrochloride (TAK-503)|Participants from Part A roll over into Part B, where participants received placebo in Part A will roll over after first 18 weeks and participants received TAK-503 or atomoxetine will roll over after 52 weeks of Part A. During Part B all the participants will receive TAK-503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet QD for 52 weeks of Part B.
16384896|NCT04085159|Experimental|CART/CTL/DCvac cells to treat cancer|
16384899|NCT04085120|Experimental|Ropivacaine/dexamethasone group|3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
16384900|NCT04085120|Experimental|10% lignocaine injection group|4 ml of 10% lignocaine
16384901|NCT04085107||243 PwMCI|
16384902|NCT04085094||1. Healthy and pre-menopausal women without CKD|"A total of 45 healthy and pre-menopausal women (<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.
~Three visits will take place:
~V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.
~V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated
~V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).
~The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion."
16384903|NCT04085094||2. Pre-menopausal women with CKD|A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
16384904|NCT04085094||3. Post-menopausal women without CKD|Fifteen post-menopausal women will undergo the same exams as outlined above
16384905|NCT04085094||4. Healthy men|A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
16384906|NCT04085094||5.Men with CKD|Fifteen men with CKD will undergo the same exams as outlined above
16384907|NCT04085081|Experimental|Supportive care (coaching call, motivational messages)|Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
16397015|NCT04000477|Experimental|Cytobrush|
16384911|NCT04085055|Active Comparator|22 Gauge FNB Needle - Acquire|The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
16384912|NCT04085055|Active Comparator|22 Gauge FNB Needle - SharkCore|The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
16384913|NCT04085055|Active Comparator|22 Gauge FNB needle - EZ Shot 3 Plus|The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
16384914|NCT04085042|No Intervention|Usual Care|Usual care during peripheral venous catheterization. Nurses will continue with the normal routine practice, by preparing all needed material individually.
16384915|NCT04085042|Experimental|PIVC pack|Nurses will use a sterile pack that includes all needed devices for peripheral intravenous catheterization according to the latest evidence (eg, cannula, swabs, disposable tourniquet, antiseptic).
16384916|NCT04085016||meibography of statin group|patients with regular HMG CoA reductase inhibitor (statin) treatment
16384917|NCT04085016||meibography of non-statin group|patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
16384918|NCT04085003||Intact abdominal aortic aneurysm|
16384919|NCT04085003||Ruptured abdominal aortic aneurysm|
16384920|NCT04084990|Experimental|aPAP|Nightly use of aPAP when sleeping through the date of delivery
16384921|NCT04084990|No Intervention|No aPAP|No use of aPAP (standard of care)
16384922|NCT04084977||Sydenam Chorea (SC)|individuals with SC
16384923|NCT04084977||tonsilitis|children with tonsilitis in the past 3 months
16384924|NCT04084977||control|children wit no tonsilitis
16384925|NCT04084964|Experimental|Study group|These patients receive the home-hospitalisation platform
16384926|NCT04084951|Experimental|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-PBMC-HPV as a monotherapy is administered every 3 weeks for up to a year. There are at least 3 groups (Cohorts) in this Phase as follows:
~Cohort 1: low dose SQZ-PBMC-HPV
~Cohort 2: high dose SQZ-PBMC-HPV
~Cohort 3: high dose SQZ-PBMC-HPV double-priming"
16384927|NCT04084951|Experimental|Part 2 Combination Safety Phase|"In Part 2, SQZ-PBMC-HPV in combination with immune checkpoint inhibitors (1) atezolizumab, (2) ipilimumab, (3) nivolumab, or (4) nivolumab and ipilimumab, is administered every 3 weeks for up to a year except atezolizumab may be given up to 2 years; and ipilimumab will be administered four times (in a timeframe less than a year) if safety allows. There are 4 groups (Cohorts) in this Phase as follows:
~Cohort 4: SQZ-PBMC-HPV RP2D (Recommended Phase 2 Dose) plus atezolizumab
~Cohort 5: SQZ-PBMC-HPV RP2D plus ipilimumab
~Cohort 6: SQZ-PBMC-HPV RP2D plus nivolumab
~Cohort 7: SQZ-PBMC-HPV RP2D plus nivolumab and ipilimumab"
16384928|NCT04084951|Experimental|Part 3 Monotherapy Dose Expansion Phase|"In Part 3, SQZ-PBMC-HPV is administered at the RP2D to patients enrolled in HPV16+ cancer-type specific cohorts. There are 4 groups (Cohorts) in this Phase as follows:
~Cohort 8: SQZ-PBMC-HPV RP2D in HPV16+ head and neck cancer patients
~Cohort 9: SQZ-PBMC-HPV RP2D in HPV16+ cervical cancer patients
~Cohort 10: SQZ-PBMC-HPV RP2D in HPV16+ anal cancer patients
~Cohort 11: SQZ-PBMC-HPV RP2D in other HPV16+ cancer patients"
16384929|NCT04084938|Active Comparator|Prostate operation|You will have a surgery to remove the prostate gland. The surgery will be done during general anesthesia. If your prostate gland is small the surgery will be done through a catheter into the penis. If your prostate gland is large the surgery will be through an incision in your lower abdomen.
16384930|NCT04084938|Active Comparator|Prostate artery embolization|The embolization is done in the Department of Radiology. There will be placement of a catheter into the artery in one of the groins during local anesthesia. Through this catheter small particles will be injected into the arteries of the prostate gland. When finished, the hole in the artery will be closed.
16384931|NCT04084925||Diabetics with NAFLD|Diabetics whose abdominal ultrasound showed that they have NAFLD
16384932|NCT04084925||Diabetics without NAFLD|Diabetics whose abdominal ultrasound showed that they do not have NAFLD
16384933|NCT04084912|Active Comparator|Dexamethasone group|this group will receive one ampoule Intravenous injection of Dexamethasone Sodium Phosphate 2 ml . 8 mg once by the anesthesiologist immediately before skin incision
16384934|NCT04084912|Placebo Comparator|Placebo group|this group will receive one ampoule Intravenous injection of Saline once by the anesthesiologist immediately before skin incision
16384935|NCT04084899||Continuous Positive Airway Pressure|Patient treated with continuous positive airway pressure
16384936|NCT04084873|Experimental|Experimental PBrE|Participants are exposed to several words of emotional contents (positive, and negative). The differences between these words will allow the regulation and counter regulation of emotional processes (Schwager y Rothermund, 2013). The words are related to clinical and personal characteristics of the patients and they will promote an emotional identification that improve the emotional regulation (Kashdan, Barret y McKnight, 2015).
16384937|NCT04084873|Placebo Comparator|Control PBrE|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
16384938|NCT04084873|Other|Control|Participants do not receive the intervention.
16384939|NCT04084860|Experimental|CI-581a + MET/MBRP|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
16384940|NCT04084860|Experimental|CI-581a + Medication Management|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment ( no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
16384941|NCT04084860|Active Comparator|CI-581b + MET/MBRP|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
16384942|NCT04084860|Active Comparator|CI-581b + Medication Management|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
16384943|NCT04084847|Active Comparator|Barberry|Daily consumption of barberry in powder form.
16384944|NCT04084847|Placebo Comparator|placebo|Daily consumption of placebo powder.
16384971|NCT04084665|Experimental|Intervention|Guselkumab 200mg q4 weekly
16384972|NCT04084652|Experimental|Mycoprotein|Mycoprotein in its full food matrix
16385009|NCT04084457|Placebo Comparator|Placebo|Matched for macronutrients, micronutrients and fibre
16384945|NCT04084834|Experimental|Intervention group|Participants allocated to the intervention group will be familiarized with exercise intensity levels (heart rate and Borg RPE) during the assessment at Diakonhjemmet Hospital. Further, the patients will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital. Thereafter, the participants will get access to a web-based exercise program and guided to choose the appropriate exercise-level. Weekly, based on the individual progression, all participants will receive an exercise program by email consisting of individually tailored exercise sessions and motivational messages. At the end of each week, the participants complete an electronic exercise diary for monitoring adherence. All participants will be offered the possibility to seek peer-support; however, if preferred they may also follow the exercise program by themselves.
16384946|NCT04084808|Experimental|Maple Syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
16384947|NCT04084808|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
16384948|NCT04084808|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
16384949|NCT04084808|Active Comparator|Sports drink|A commercial sports drink of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
16384950|NCT04084808|Placebo Comparator|Water|A solution containing stevia (sugar substitute) labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
16384951|NCT04084795|Active Comparator|EMDR plus MtCS|MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
16384952|NCT04084795|Placebo Comparator|EMDR plus sham-MtCS|Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
16384953|NCT04084795|No Intervention|Treatment as Usual|Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
16384954|NCT04084782||Onychomycosis group|Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
16384955|NCT04084769|Experimental|Group 1: MenACYW Conjugate vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
16384956|NCT04084769|Experimental|Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)|Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
16384957|NCT04084769|Experimental|Group 3: MenACYW Conjugate vaccine + Trumenba vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
16384958|NCT04084769|Experimental|Group 4: MenACYW Conjugate vaccine + Bexsero vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
16384959|NCT04084756|Experimental|Couples Crisis Response Plan|
16384960|NCT04084756|Active Comparator|Mental Health Education|
16384961|NCT04084743|Experimental|Virtual reality training and Dual task intervention|Cognitive and motor Dual-task intervention and virtual reality training intervention in patients with Parkinson's disease
16384962|NCT04084743|Active Comparator|Conventional physiotherapy and Dual task intervention|The dual-task intervention without virtual reality training intervention in patients with Parkinson's disease
16384963|NCT04084730|Experimental|Participants with Breast Cancer|Participants will have unicentric pathological stage I invasive ductal breast cancer or Grade 1 or 2 DCIS measuring <3cm in longest diameter on pathology and/or mammogram that is histologically confirmed at MSKCC.
16384964|NCT04084717|Experimental|ROS1 Rearrangement|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
16384965|NCT04084717|Experimental|MET-activating Mutation (exon 14)|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
16384966|NCT04084717|Experimental|MET-amplification|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
16384967|NCT04084704|Other|Cingal injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
16384968|NCT04084691|Experimental|Single Arm|Every patient will undergo every combination of physical exercise/meal type (3x3 combinations), one following the other. Each combination is replicated three times.
16384973|NCT04084652|Experimental|Protein Isolated from Mycoprotein|Protein from mycoprotein isolated from the food matrix
16384974|NCT04084639|Experimental|Ingestion of 20g Mycoprotein Drink|Milkshake containing 20g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
16384975|NCT04084639|Experimental|Ingestion of 40g Mycoprotein Drink|Milkshake containing 40g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
16384976|NCT04084639|Placebo Comparator|Ingestion of Isocaloric Control Drink|Milkshake containing 250ml full-fat milk, 50g glucose, 19g dried skim milk and 9g full-fat dried milk
16384977|NCT04084626|Experimental|PD-1 antibody|PD-1 antibody and lenalidomide administered in 2 week cycles for 6 cycles.
16384978|NCT04084613||Patients with uncontrolled severe eosinophilic asthma|Asthmatic patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants.
16384979|NCT04084600|Experimental|Intervention Group|Once a week for 6 consecutive weeks, this group will receive a manual therapy protocol with an approach based on Taylor et al., 1990; Schleip et al., 2012; Bienfait, 1999 and Myers, 2016, lasting 20 minutes, focused on the upper quadrant homolateral to the surgery. Shortly thereafter, this group will participate in a kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
16384980|NCT04084600|Sham Comparator|Sham Group|Once a week for 6 consecutive weeks, this group will receive a soft and shallow traditional massage, lasting 20 minutes. Shortly thereafter, this group will participate to the same kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
16384981|NCT04084587|Experimental|Treated Group|"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.
~Exams performed before and after treatment:
~BCVA (ETDRS)
~Reading speed (MNREAD)
~Contrast sensitivity (Pelli-Robson)
~Microperimetry and analysis of fixation (OCT-SLO OPTOS)
~QoL (VFQ-25)"
16384982|NCT04084587|No Intervention|Control Group|"Group B: 9 patients control group without rehabilitation.
~Exams performed twice, at the same time interval elapsed for the treated group:
~BCVA (ETDRS)
~Reading speed (MNREAD)
~Contrast sensitivity (Pelli-Robson)
~QoL (VFQ-25)"
16384983|NCT04084574|Experimental|Behavioral Diet Counseling|Groups of 4-6 participants will attend 12 weekly dietitian-led counseling sessions and receive coaching on practical strategies to enhance DASH diet adherence and reduce daily sodium intake.
16384984|NCT04084574|Other|Standard of Care|Participants will meet one-on-one with the study dietitian for a single 30- minute encounter and be advised to limit daily sodium intake per current clinical practice guidelines for hypertension in patients with CKD. Educational handouts and tip sheets about practical strategies to reduce dietary sodium will be distributed.
16384985|NCT04084561|Experimental|HRHA|High Risk, High Ancestry
16384986|NCT04084561|Experimental|LRLA|Low Risk, Low Ancestry
16384987|NCT04084561|Experimental|HRLA|High Risk, Low Ancestry
16384988|NCT04084561|Experimental|LRHA|Low Risk, High Ancestry
16384989|NCT04084548|Experimental|Lidocaine and placebo|Lidocaine and placebo
16384990|NCT04084548|Experimental|Ketamine and placebo|Ketamine and placebo
16384991|NCT04084548|Experimental|Lidocaine and ketamine|Lidocaine and ketamine
16384992|NCT04084548|Placebo Comparator|Placebo and placebo|Placebo and placebo
16384993|NCT04084535|Active Comparator|High intensity interval training|It will apply a HIIT program for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
16384994|NCT04084535|Active Comparator|Inspiratory muscle training|It will apply an inspiratory muscle training for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
16384995|NCT04084522|Placebo Comparator|Standard Treatment Group|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40 kcal. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30% from fat, a fixed amount of 50g of oil would be given and the remaining amount of fat would be met by the invisible dietary fat. The source of visible dietary fat would be refined soyabean oil. This group would not receive any fat in the form of Desi ghee or butter or any nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
16384996|NCT04084522|Active Comparator|Intervention Arm|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40kcal and 1.2-1.5gm protein per kg ideal body weight per day. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30-35% from fat, a fixed amount of 50g of ghee would be given in 3 divided doses of 30 ml to be taken raw, 20 ml to be used for cooking and the remaining amount of fat would be met by the invisible dietary fat. The source of visible fat would be exclusively Desi ghee. This group would not receive any fat in the form of butter or any other oil or any other nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
16384997|NCT04084509||Healthy Controls|
16384998|NCT04084509||Idiopathic Parkinson's Disease|
16384999|NCT04084509||Symptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
16385000|NCT04084509||Asymptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
16385001|NCT04084496|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
16385002|NCT04084483|Experimental|Group 1|K-161 Ophthalmic Solution Dose A.
16385003|NCT04084483|Experimental|Group 2|K-161 Ophthalmic Solution Dose B.
16385004|NCT04084483|Experimental|Group 3|K-161 Ophthalmic Solution Dose C.
16385005|NCT04084483|Placebo Comparator|Group 4|Vehicle Solution Dose.
16385006|NCT04084470|Active Comparator|Bread types 1 & 2|Daily consumption of 5 slices of allocated bread type for 3 consecutive days.
16385007|NCT04084470|Active Comparator|Bread types 3 & 4|Daily consumption of 5 slices of allocated bread type for 3 consecutive days.
16385008|NCT04084470|Active Comparator|Bread types 5 & 6|Daily consumption of 5 slices of allocated bread type for 3 consecutive days.
16385010|NCT04084457|Active Comparator|Wild Blueberry Powder|Formulation of a 100% blueberry (freeze-dried whole fruit) drink
16385011|NCT04084444|Experimental|T8 tablet 0.5mg|Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week
16385012|NCT04084444|Experimental|T8 tablet 1mg|Oral T8 tablet with HARRT, 1mg, once daily for 48 week
16385013|NCT04084444|Placebo Comparator|Placebo|Oral Placebo with HARRT, once daily for 48 week
16385014|NCT04084431|Active Comparator|WBRT (10 x 2 Gy) + OSC|Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
16385015|NCT04084431|Experimental|Optimal Supportive Care (OSC) alone|Symptomatic treatment including steroids, pain medication, nutritional support, etc
16385016|NCT04084418|Experimental|Control diet followed by VLCHF diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet
~Phase 2 (6 weeks): Control diet (50% of energy from carbohydrates)
~Phase 3 (4 weeks): Washout period
~Phase 4 (6 weeks): VLCHF diet (10% of energy from carbohydrates)"
16385017|NCT04084418|Experimental|VLCHF diet followed by Control diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet
~Phase 2 (6 weeks): VLCHF diet (10% of energy from carbohydrates)
~Phase 3 (4 weeks): Washout period
~Phase 4 (6 weeks): Control diet (50% of energy from carbohydrates)"
16385018|NCT04084405|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
16385019|NCT04084405|Active Comparator|Control group|aerobic exercice
16385020|NCT04084392|Active Comparator|Usual Care|Participants randomized to this arm will receive care as usual.
16385021|NCT04084392|Active Comparator|Bridge Clinic|Participants randomized to this arm will be referred to the Bridge Clinic to facilitate identification and referral to an outpatient provider for addiction treatment.
16385022|NCT04084366|Experimental|OBI-999 Escalation phase|Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
16385023|NCT04084366|Experimental|OBI-999 Expansion Phase|Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
16385024|NCT04084353||Delivered women|Maternal and perinatal outcomes will be collected prospectively on all patients that deliver in Government Medical College (GMC) Hospital before, during and after the training over the study period (8 months) in order to evaluate the impact of the training.
16385025|NCT04084340|Experimental|Anodal tDCS + Exercises therapies|"Real transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes, 2mA"
16385026|NCT04084340|Sham Comparator|Sham tDCS + Exercises therapies|"Sham transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes (30 seconds ON), 2mA"
16385028|NCT04084301|No Intervention|Normal CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.4 L/min/m2 throughout the CPB period.
16385029|NCT04084301|Experimental|High CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.9 L/min/m2 throughout the CPB period.
16385030|NCT04084288|Experimental|Postoperative Acupuncture|"Neuraxial anesthesia (spinal or combined spinal epidural (CSE) with up to 4cc mepivacaine 1.5%) and 2 blocks for postoperative pain (IPACK and adductor canal peripheral nerve blocks). Sedation will be provided. Tranexemic acid (TXA) will be dosed per surgeon request.
~A certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed. If an epidural is placed, it may be redosed with lidocaine as needed (up to 100mg total) and will be removed prior to transfer to the recovery room.
~A periarticular injection (PAI) will be placed by the surgeon during the surgery (timing at the discretion of the surgeon)"
16385031|NCT04084275|Experimental|experimental group|Levine's conservation model was used as the theoretical framework for this study. A literature review was used to determine the contents of the intervention program. A nursing care program which consisted of 8 sessions, the first of which was at the hospital and the others at the homes of puerpera and which were held at different times and lasted 12 weeks in total, based on Levine's Conservation Model was provided to the women in the intervention group. Each session lasted approximately 60-120 minutes, according to the educational and practical contents.The puerpera were given trainings on different subjects based on the module during each session. For these trainings, the investigators prepared, in the light of the literature data, leaflets containing information about breastfeeding, personal hygiene, fatigue, nutrition and pilates exercises
16385032|NCT04084275|No Intervention|control group|The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
16385033|NCT04084262||All Study Participants|Phantom® Intramedullary Nail combined with a supinating reduction technique
16385034|NCT04084249|Experimental|ctDNA guided surveillance|ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the FCRI questionnaire.
16385065|NCT04084080|Active Comparator|Standard of care|Randomized to standard of care
16385066|NCT04084067|Experimental|Indocyanine green (ICG)|Participants will receive a single dose of 1.5 mg/kg of ICG intravenously over 15 minutes prior to surgery.
16385067|NCT04084041|Experimental|Device|Device group
16385035|NCT04084249|No Intervention|Standard Danish follow-up program|Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
16385036|NCT04084236|Active Comparator|Active TENS|
16385037|NCT04084236|Sham Comparator|Sham TENS|
16385038|NCT04084223|Experimental|Active RA patients group|"64 active RA patients (DAS28>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2) with an inadequate response to methotrexate (MTX) starting a treatment with JAKi (tofacitinib ou baricitinib) will be evaluated at baseline, 1, 3 and 6 months in 5 centres.
~A clinical joint assessment will be performed and CRP will be tested to calculate DAS28-CRP. Several PROs will be completed: RAPID3, HAQ, pain, and patient global assessment of disease activity on a VAS.
~An US exam on 40 joints and 12 tendons will be performed by an independent investigator, looking for synovitis and tenosynovitis with B-Mode and Power Doppler. A Global US score (GLOESS) will be collected at each visit."
16385039|NCT04084210|Active Comparator|Juul + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
16385040|NCT04084210|Active Comparator|Juul + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
16385041|NCT04084210|Active Comparator|VLNC + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
16385042|NCT04084210|Active Comparator|VLNC + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
16385043|NCT04084210|Other|No Product + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given no alternative nicotine delivery products but in Switch Week 1, participants will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
16385044|NCT04084210|Other|No Product + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given no alternative nicotine delivery products for two weeks but in Switch Week 1 participants will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
16385045|NCT04084197|Experimental|Sequence 1|Period 1 : Fasted state + HIP1402, Period 2 : Fasted state + HIP1801
16385046|NCT04084197|Experimental|Sequence 2|Period 1 : Fasted state + HIP1801, Period 2 : Fasted state + HIP1402
16385047|NCT04084197|Experimental|Sequence 3|High fat diet + HIP1402, Period 2 : High fat diet + HIP1801
16385048|NCT04084197|Experimental|Sequence 4|High fat diet + HIP1801, Period 2 : High fat diet + HIP1402
16385049|NCT04084184|Experimental|Sequence 1|Period 1 : Fasted state + HGP1812, Period 2 : Fasted state + HGP1602
16385050|NCT04084184|Experimental|Sequence 2|Period 1 :Fasted state + HGP1602, Period 2 : Fasted state + HGP1812
16385051|NCT04084171|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia.
16385052|NCT04084158|Experimental|Toripalimab+chemoradiation|"Induction immunotherapy: Toripalimab injection (JS001) 3mg/kg IV q 14 days x 2 cycles.
~Concurrent Chemoradiotherapy: Starting within 4 weeks after the first cycle induction immunotherapy. carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.
~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation and adjuvant therapy.
~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles.
~Adjuvant immunotherapy:Toripalimab injection (JS001) 3mg/kg IV q 14 days up to 1 year."
16385053|NCT04084158|Active Comparator|chemoradiation|"Concurrent Chemoradiotherapy: carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or Liposome paclitaxel 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.
~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation therapy.
~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles."
16385054|NCT04084145||CKD|Chronic Kidney Disease stage 1 - 4 followed up in secondary care
16385055|NCT04084132|Experimental|Early re-valving|60 patients who are assigned to early re-valving undergo pulmonary valve replacement within 3 months from randomization.
16385056|NCT04084132|Experimental|Later re-valving|60 patients who are assigned to later re-valving undergo pulmonary valve replacement when the current European guideline criteria are met.
16385057|NCT04084119|Experimental|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
16385058|NCT04084119|Active Comparator|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
16385059|NCT04084106|Experimental|phenoximethylpenicillin|phenoximethylpenicillin, tablet, 1 g 3 times daily for 5 days.
16385060|NCT04084106|Active Comparator|amoxicillin|amoxicillin, tablet, 500 mg 3 times daily for 5 days.
16385061|NCT04084106|Active Comparator|amoxicillin-clavulanic acid|amoxicillin-clavulanic acid tablet, 500/125 mg 3 times daily for 5 days.
16385062|NCT04084106|No Intervention|No intervention|No intervention
16385063|NCT04084093|Experimental|Surfactant Gel|
16385064|NCT04084080|Experimental|Exchange transfusion plus standard of care|Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
16402697|NCT03959995|Sham Comparator|control|active control group
16385068|NCT04084041|Active Comparator|Conventional chest physiotherapy|Control group
16385069|NCT04084028|Experimental|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.
~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
16385070|NCT04084028|Active Comparator|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
16385071|NCT04084028|Active Comparator|Meal Kits only|Participants will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
16385072|NCT04084028|No Intervention|Control|Participants will receive no interventions.
16385073|NCT04084015|Experimental|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
16385074|NCT04084002||Patients with subacute chronic stroke|Patients with subacute chronic stroke
16385075|NCT04084002||Control group|Healthy control group age and sex matched
16385076|NCT04083989||Multimodal treatment for AN|Adolescent patients with AN attending an integrative medicine-based inpatient treatment program
16385077|NCT04083989||Healthy controls|Healthy volunteers assessed once to collect comparative data
16385078|NCT04083976|Experimental|Erdafitinib|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, or decision by the investigator to discontinue treatment.
16385079|NCT04083963|Other|Single arm|Low dose weekly carboplatin in combination with standard neoadjuvant chemotherapy
16385080|NCT04083950|Experimental|Single group|All participants will receive the vaccine and aspirin.
16385081|NCT04083937|Active Comparator|70.0/ 2.0 Gray (RBE)|Normofractionated radiotherapy with photons (70.0/ 2.0 Gray)
16385082|NCT04083937|Experimental|57.0/ 3.0 Gray (RBE)|Hypofractionated radiotherapy with photons (57.0/ 3.0 Gray)
16385083|NCT04083937|Experimental|57.0/ 3.0 (RBE)|Hypofractionated radiotherapy with protons (57.0/ 3.0 Gray relative biological effectiveness [RBE]).
16385084|NCT04083924|Experimental|Basic cardiac ultrasound training|Single group education intervention study. No control group. Pre-post educational outcomes only.
16385085|NCT04083911|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.
16385086|NCT04083898|Experimental|Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
16385087|NCT04083898|Experimental|Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
16385088|NCT04083898|Experimental|Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
16385089|NCT04083898|Experimental|Phase II: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
16385090|NCT04083885|Experimental|Virtual Reality|Participants receive 8 weeks of home-based or facility-based virtual reality training, supervised remotely and asynchronously, in addition to their Extra-Mural (homecare) rehabilitation.
16385091|NCT04083885|No Intervention|Usual Care|Participants receive their usual Extra-Mural (homecare) rehabilitation.
16385092|NCT04083872|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug"
16385093|NCT04083872|Experimental|Group 2|"Period 1: Test drug
~Period 2: Reference drug"
16385094|NCT04083859|Experimental|mPATH-Lung|Participants randomized to the mPATH arm will complete a self-survey and a brief video decision aid, and then invites them to estimate their personal risks and benefits of screening by completing 8 survey items needed to calculate their predicted risk of developing lung cancer based on the validated Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Model 2012.
16385095|NCT04083859|Placebo Comparator|Usual care (CONTROL)|Participants randomized to the control arm will see an animated video about exercise for lung health based on recommendations from the European Lung Foundation. They will not be offered the opportunity to estimate their predicted benefits and harms of screening or to request a lung cancer screening visit.
16385096|NCT04083846|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug 1
~Period 3: Test drug 2"
16385097|NCT04083846|Experimental|Group 2|"Period 1: Test drug 2
~Period 2: Reference drug
~Period 3: Test drug 1"
16385098|NCT04083846|Experimental|Group 3|"Period 1: Test drug 1
~Period 2: Test drug 2
~Period 3: Reference drug"
16385099|NCT04083846|Experimental|Group 4|"Period 1: Test drug 2
~Period 2: Test drug 1
~Period 3: Reference drug"
16385100|NCT04083846|Experimental|Group 5|"Period 1: Test drug 1
~Period 2: Reference drug
~Period 3: Test drug 2"
16385101|NCT04083846|Experimental|Group 6|"Period 1: Reference drug
~Period 2: Test drug 2
~Period 3: Test drug 1"
16403689|NCT03953092|Experimental|MAD Cohort 1|5 mg YG1699 or placebo
16385102|NCT04083833|Experimental|Treatment Arm|(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)
16385103|NCT04083833|Placebo Comparator|Control|"Treatment D:
~(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo
~Treatment E:
~(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin
~Treatment F:
~(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo
~Treatment G:
~(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin
~Treatment H:
~(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo
~Treatment I:
~(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin"
16385104|NCT04083820||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
16385105|NCT04083807|Experimental|TISSEEL Lyo|Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.
16385106|NCT04083807|Active Comparator|Manual compression with surgical gauze pads|Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.
16385107|NCT04083794|Other|Laboratory based assessments|The current study has no arms; it is a cross-sectional assessment where all participants will undergo the same procedures.
16385108|NCT04083781|Experimental|Arm 1: No prophylaxis|Haemophilia A with inhibitors (HAwI) and haemophilia B with inhibitors (HBwI) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension part, patients in arm 1 will receive daily concizumab subcutaneous (s.c., under the skin) injections.
16385109|NCT04083781|Experimental|Arm 2: Concizumab prophylaxis|HAwI and HBwI patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
16385110|NCT04083781|Experimental|Arm 3: Concizumab prophylaxis|The HAwI and HBwI patients enrolled into the concizumab phase 2 trial (NN7415-4310) at time of transfer will be offered enrolment into this trial. It is required that these patients are on concizumab prophylaxis up until enrolment into the trial. These patients will continue concizumab prophylaxis.
16385111|NCT04083781|Experimental|Arm 4: Concizumab prophylaxis|Patients previously on prophylaxis with by-passing agents and on-demand patients who are screened at a timepoint where the required number of patients in arms 1 and 2 have been randomised. These patients will, if eligible, be enrolled into the trial and will initiate concizumab prophylaxis at visit 2a (week 0).
16385112|NCT04083768|Placebo Comparator|Supine group|After the patient completes the spinal anesthesia, the cesarean section is completed in the supine position.
16385113|NCT04083768|Active Comparator|15° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 15°, and the cesarean section was completed using the supine position after the skin was cut.
16385114|NCT04083768|Active Comparator|30° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 30°, and the cesarean section was completed using the supine position after the skin was cut.
16385115|NCT04083755|Active Comparator|Line A|One dose of Ferric carboxymaltose (1000mg) intravenous. Duration of administration 15 minutes.
16385116|NCT04083755|Other|Line B|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
16385117|NCT04083729|Active Comparator|Patients with persistent pulmonary hypertension|Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy
16385118|NCT04083729|Active Comparator|Patients without persistent pulmonary hypertension|Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy
16385119|NCT04083716|Experimental|Group 1|ABI-H2158 Reference Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation after a high-fat meal on Day 15 (Period 3)
16385120|NCT04083716|Experimental|Group 2|ABI-H2158 Test Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation after a high-fat meal on Day 8 (Period 2), then ABI-H2158 Reference Formulation in a fasting state on Day 15 (Period 3)
16385121|NCT04083716|Experimental|Group 3|ABI-H2158 Test Formulation after a high-fat meal on Day 1 (Period 1), then ABI-H2158 Reference Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation in a fasting state on Day 15 (Period 3)
16385122|NCT04083703|Experimental|Simple lumbar discectomy|
16385123|NCT04083703|Experimental|Lumbar discectomy with inter vertebral cage|
16385124|NCT04083690|Active Comparator|Standard CRT Programming, then ECG CRT Optimization|The control arm patients will have standard CRT programming for the first 6 months, and then will be reprogrammed based on the ECG CRT optimization information for the following 6 months
16385125|NCT04083690|Experimental|ECG CRT Optimization|The experimental arm patients will have CRT device reprogrammed based on the ECG CRT optimization information for 12 months.
16385126|NCT04083677||Control GROUP|healthy adult fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
16385127|NCT04083677||trauma GROUP|trauma patients fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
16385128|NCT04083664||Control healthy subjects without anemia.|"Adults > 18 years.
~Age and sex matched.
~No active infection or inflammation."
16385129|NCT04083664||ESRD with Hgb <11 g/dl.|"Adults > 18 years.
~ESRD patients on regular hemodialysis.
~Hgb < 11g/dl.
~No apparent infection or inflammation."
16385130|NCT04083664||ESRD with Hgb ≥ 11 g/dl|"Adults > 18 years.
~ESRD patients on regular hemodialysis.
~Hgb ≥ 11g/dl.
~No apparent infection or inflammation."
16385131|NCT04083651|Experimental|Methylnaltrexone Bromide (MNTX)|Participants will receive methylnaltrexone bromide (MNTX) 450 mg (3 tablets of 150 mg each) QD orally. If the initial interim analysis suggests a lack of efficacy, subsequent participants will receive 450 mg MNTX twice daily (BID) or three times daily (TID). Treatment will continue until participant's death or early withdrawal from study or study completion at Day 168.
16385132|NCT04083651|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX until participant's death or early withdrawal from study or study completion at Day 168.
16385133|NCT04083638||Group 1|Control group
16385134|NCT04083638||Group 2|Feeding will not stop during the transfusion
16385135|NCT04083625|Experimental|carbetocin|100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
16385136|NCT04083625|Placebo Comparator|placebo|10 cm syringe normal saline IV given just before skin incision of myomectomy.
16385137|NCT04083612|Other|Standard of care - ixekizumab|Patient will continue to receive ixekizumab according to standard of care dosing regimen, i.e. loading dose first (160 mg) at week 0; 80 mg every 2 weeks until week 12, then 80 mg every 4 weeks
16385138|NCT04083599|Experimental|GEN1042 monotherapy dose escalation (phase 1a)|• All NON-CNS solid tumors
16385139|NCT04083599|Experimental|GEN1042 monotherapy expansion (phase 2a)|"NSCLC
~Melanoma
~CRC"
16385140|NCT04083599|Experimental|Combination safety run-in (phase 1b) for NSCLC, HNSCC and Melanoma|"1L NSCLC
~1L HNSCC
~1L Melanoma"
16385141|NCT04083599|Experimental|Combination safety run-in (phase 1b) for HNSCC|• 1L HNSCC
16385142|NCT04083599|Experimental|Combination safety run-in (phase 1b) for PDAC|• 1L PDAC
16385143|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for Melanoma|• 1L Melanoma
16385144|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for NSCLC|• 1L NSCLC
16385145|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab|• 1L HNSCC
16385146|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy|• 1L HNSCC
16385147|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for PDAC|• 1L PDAC
16385148|NCT04083560|Experimental|Intervention group|Group A Intervention: 360 pregnant women will receive 250 mcg of B-12 daily orally from 1st trimester to 6 months postpartum
16385149|NCT04083560|Active Comparator|Control group|Group B- Control: 360 pregnant women will receive 50 mcg of B-12 daily orally from 1st trimester to 6 months post partum
16385150|NCT04083547||HIPEC group|All patients undergoing HIPEC will asked to join this prospective study.
16385151|NCT04083534|Experimental|REGN5459|Cohorts of multiple REGN5459 dose levels
16385152|NCT04083521|Experimental|Treatment|Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.
16385153|NCT04083521|No Intervention|Placebo|Subjects received a once daily dose of maltodextrin for 90-days.
16385154|NCT04083508|Experimental|Malaria challenge|Malaria Sporozoite Challenge by mosquito bites.
16385155|NCT04083495|Experimental|ATLCAR.CD30 cells|The cellular product consisting of ATLCAR.CD30 cells will be administered via intravenous injection over 5 - 10 minutes through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2 - 14 days after completing the lymphodepleting chemotherapy regimen
16385156|NCT04083482|Experimental|Septic patients require CVVH|continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
16385157|NCT04083469|Experimental|Peer-Led Peer-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated the peer-leader.
16385158|NCT04083469|Other|Adult-Led Intervention|The e-cigarette intervention program will be administered to students by an adult educator.
16385159|NCT04083469|Other|Peer-Led Non-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated a different peer-leader.
16385160|NCT04083456|Experimental|Walking Biobehavioral Intervention (EXP)|The EXP group will receive biobehavioral training that is integrated into the conventional outpatient training component and is delivered over 5 months. There will be 10 biobehavioral sessions, 1 of which will be a combined biobehavioral/conventional outpatient session and the other 9 being telehealth sessions.
16385161|NCT04083456|Active Comparator|Attention Control (CTL)|The CTL group intervention will include the same conventional outpatient training (10 sessions) as the EXP group and receive the same computer tablets with telehealth software as the EXP group (week 3 of prosthetic training).
16385162|NCT04083443||Patients with blood stream infections|Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment. There will be an additional blood sampling for these patients, which is the only intervention in the study.
16385164|NCT04083417|Active Comparator|Phenoxymethylpenicillin group|Patients randomized to oral phenoxymethylpenicillin 1000 mg three times daily for ten days
16385165|NCT04083417|Experimental|No antibiotic treatment group|Patients randomized to no antibiotic treatment
16385166|NCT04083391||CAI group|assessment had been done to this group that include patients with ankle sprain injury from more than one year and complain with repetitive injuries, giving way and instability feelings
16385167|NCT04083391||non injured ankle group|assessment had been done to this group that include control participants had not injured their ankle before and matched with CAI in age, gender, dominant side
16385168|NCT04083378|Active Comparator|Arm I (standard of care ablation)|Patients undergo standard of care ablation.
16385169|NCT04083378|Experimental|Arm II (standard of care ablation, software-aided imaging)|Patients undergo standard of care ablation with software-aided imaging (Morfeus).
16385170|NCT04083365|Experimental|CAPECITABINE + concomitant RT + Durvalumab|After careful staging, patients will be initiated to a standard concomitant chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks and 5040 cGy radiotherapy for 5 days per week for 5 weeks. At the end of treatment patients will undergo a lesion biopsy. One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations. From week 9 to 10 after neoadjuvant therapy will be performed re-staging with CT and MRI scan. Surgery will be performed at week 10-12 from the end of CT/RT and the surgical piece will be analyzed
16385171|NCT04083352|Experimental|6-week ketone supplementation|Participants took a ketomax ketone salt supplementation for 6-weeks. They took 2 servings per day.
16385172|NCT04083352|Placebo Comparator|6-week placebo supplement|Participants took a placebo supplement for 6-weeks. The placebo was calorie, sodium, and flavor-matched to the experimental supplement.
16385173|NCT04083339|Experimental|AT-001 High dose|The total daily doses will be of 3g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 3g/day of AT-001 is capable of producing the maximum inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
16385174|NCT04083339|Experimental|AT-001 Low Dose|The total daily doses will be of 2g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 2g/day of AT-001 is capable of producing a sufficient inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
16385175|NCT04083339|Placebo Comparator|Placebo Comparator|Placebo capsules will be used as comparator
16385176|NCT04083326|Experimental|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
16385177|NCT04083326|No Intervention|Conventional care group|Conventional care consists of specialist assessment in conjunction with pre-operative surgical visits and patient education. Patients in the conventional care group are provided with pre- and postoperative information face-to-face by paper-based method. Patients will be admitted and mobilised on the day of the surgery, and discharged one to three days after surgery. The follow-up visit, conducted by a physiotherapist, is conducted after 6 to 8 weeks post-discharge for patients with TKA and after 8 to 12 weeks for patients with THA.
16385178|NCT04083313|Active Comparator|Endoloop|Patients in which appendiceal stump was ligated using Endoloop
16385179|NCT04083313|Active Comparator|Endostapler|Patients in which appendiceal stump was ligated using Endostapler
16385180|NCT04083313|Active Comparator|Endoclip|Patients in which appendiceal stump was ligated using Endoclip
16385181|NCT04083287|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
16385182|NCT04083287|Active Comparator|Group I = ISCB group|In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
16385183|NCT04083274|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
16385184|NCT04083274|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
16385185|NCT04083261||High daily dose users|Total Cannabinoid Daily Dose greater than 50 mg
16385186|NCT04083261||Control|"Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg"
16385187|NCT04083261||Low daily dose users|Total Cannabinoid Daily Dose less than 10 mg
16385188|NCT04083248|Experimental|Feasibility group|"Intervention components:
~Personalized group diabetes education.
~Fitbit Charge 3 wrist activity monitor for real-time monitoring of steps, active minutes and heart rate. The Fitbit will be used by the women to set activity goals, self-assess their progress and aid in motivation to be more active.
~Freestyle Libre (Abbott Labs, Alameda, CA) Personal CGM (FDA approved). The Libre CGM will be used to self-monitor glucose goals and monitor the real-time effects of activity and eating choices by the women.
~Final guided interview for study acceptability and feasibility. The interviews will be audiotaped, transcribed. Thematic content analyses will be performed."
16385189|NCT04083235|Experimental|Irinotecan liposome injection + Oxaliplatin + 5-FU/LV|Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
16385190|NCT04083235|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
16385191|NCT04083222|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx administered subcutaneously once-weekly for 8 weeks
16385192|NCT04083222|Placebo Comparator|Placebo|Placebo matching solution administered subcutaneously once-weekly for 8 weeks
16385193|NCT04083209|Experimental|Counseling group|"Patients randomized into the counseling group will be given a 1-2 minute presentation over the risks of opioid pain medications during their preoperative visit."
16385351|NCT04082299||Non pregnant women|Non pregnant women expected to be vaccinate with Tdap vaccine
16385194|NCT04083209|No Intervention|Control group|The control group will undergo the standard preoperative evaluation by the senior author without any additional formal opioid counseling.
16385195|NCT04083196|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
16385196|NCT04083196|Placebo Comparator|placebo group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
16385197|NCT04083183|Experimental|Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)|Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365.
16385200|NCT04083157|Experimental|Intradermal hepatitis B vaccine with imiquimod|Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
16385201|NCT04083157|Active Comparator|Intramuscular hepatitis B vaccine with aqueous cream|Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.
16385202|NCT04083144|Active Comparator|Deep rTMS active + Varenicline|Participants undergoing deep rTMS (active) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
16385203|NCT04083144|Sham Comparator|Deep rTMS sham + Varenicline|Participants undergoing deep rTMS (sham) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
16385204|NCT04083118||Bicuspid aortic valve|80 patients with bicuspid aortic valve with or without an aortic aneurysm
16385205|NCT04083118||controls|20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
16385206|NCT04083105|Experimental|30% Nitrous Oxide with Midazolam|30 percent nitrous oxide/70 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
16385207|NCT04083105|Experimental|70% Nitrous Oxide with Midazolam|70 percent nitrous oxide/30 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
16385208|NCT04083079|Experimental|PEG-rhG-CSF cohort|"PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once.
~Dosage: 6mg for weight ≥45kg，3mg for weight <45kg, subcutaneous injection"
16385209|NCT04083079|Experimental|rhG-CSF cohort|"rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10^9/L.
~rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10^9/L.
~Dosage: 5μg/kg/d, subcutaneous injection"
16385210|NCT04083066|Experimental|Rituximab combined with formoterol, pemetrexed, dexamethasone|Rituximab 375mg/m2D0 is soluble in 0.9% NS, concentration 1mg/ml, micro pump is pumped for 4h Fotemustine 100mg/m2 D1 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light Pemetrexed 600mg/m2 D1 dissolved in 100ml 0.9% NS, intravenously 1h Dexamethasone 40mg D1-5 Dissolved in 100 ml 5% GS, intravenously (21 days is a cycle)
16385211|NCT04083053|Experimental|Perianal Exam First|Perianal exam that is a part of anal cancer screening will be performed prior to the intraanal portion of the exam (high-resolution anoscopy with biopsy).
16385212|NCT04083053|Experimental|Perianal Exam Last|Perianal exam that is a part of anal cancer screening will be performed after the intraanal portion of the exam (high-resolution anoscopy with biopsy).
16385213|NCT04083040|Other|TAVI patients|Patient undergone TAVI
16385214|NCT04083014|Experimental|study group|The treatment regimen is a single dose anti-CD20 antibody injection (500mg iv drip，day0) combined with bortezomib injection (1.3mg/m2 subcutaneous injection，twice a week for two weeks，day1，4，8，11). The treatment course will be repeated three months later.
16385215|NCT04083001|Experimental|OTR4132MD|"one medical device (10mL) of one of the 5 available concentrations (20 μg/mL, 50 μg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL) will be administrated as a one shot-dose to the patient.
~The respective total dose of OTR4132 received by a patient will be one of the following: 0,20 mg, 0,50 mg, 1 mg, 1,5 mg and 2 mg."
16385216|NCT04082988|Other|Nivolumab|"Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.
~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation"
16385217|NCT04082975|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
16385218|NCT04082975|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
16385219|NCT04082962|Experimental|Treatment Group|Participants receiving dexamethasone implant.
16385220|NCT04082962|No Intervention|Non-treatment group (control)|Participants not receiving dexamethasone implant.
16385221|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths:5-6mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
16385222|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths≥7mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
16385223|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths:5-6mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
16385224|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths≥7mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
16385225|NCT04082936|Experimental|Part 1: Dose-Escalation Phase|Subjects will receive IGM-2323 via intravenous (IV) infusion on Days 1, 8, and 15, of 21-day cycles. Subjects will be treated with 4 cycles (3 weeks each). Subjects benefiting from therapy can receive up to 8 cycles or longer with good response. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
16385226|NCT04082936|Experimental|Part 2: Dose-Expansion Phase|Subjects will receive IGM-2323 via intravenous (IV) infusion at a RP2D dose and schedule to be determined after reviewing all available response and safety data.
16385227|NCT04082923|Other|Gastric bypass operated patients|Two test days in a randomized, patient-blinded, cross-over design
16385228|NCT04082923|Other|Gastric sleeve operated patients|Two test days in a randomized, patient-blinded, cross-over design
16385229|NCT04082923|Other|Control arm|Two test days in a randomized, patient-blinded, cross-over design
16385230|NCT04082910|Experimental|Therapeutic group|Patients with predicted experiencing ≤ grade 2 CRS after CAR T cells infusion, will be enrolled therapeutic group (metoprolol monotherapy, 12.5mg per time, bid; from the peak phase to extinction phase of CRS, up to 7 days).
16385231|NCT04082910|Experimental|Prophylactic group|Patients with predicted experiencing ≥ grade 3 CRS after CAR T cells infusion, will be enrolled prophylactic group (metoprolol plus anti-TNFα antibody. 1) metoprolol, 12.5mg per time, bid; from one day before cells infusion to extinction phase of CRS, up to 14 days. 2) anti-TNFα antibody will be used at the peak period of CRS).
16385232|NCT04082897|Experimental|Combination of Obinutuzumab, Atezolizumab and Venetoclax|"Obinutuzumab will be administered iv from cycle 1 to cycle 8 :
~cycle1: 100 mg iv (day 1) and 900 mg iv (day 2) 1000mg iv (day 8 and day 15)
~Cycle 2-8: 1000 mg iv on day 1
~Atezolizumab will be administered iv at 1.200 mg fixed dose from C1 to C18:
~Cycles 1: day 2
~Cycle 2-18: day 1
~Venetoclax will start from day 15 of cycle 1 on a weekly ramp-up basis:
~week 1: 20 mg (from day 15 cycle 1) week 2: 50 mg (from day 1 to day 7 cycle 2) week 3: 100 mg (from day 8 to day 14 cycle 2) week 4 200 mg (from day 15 to day 21 cycle 2) week 5: 400 mg (from day 1 cycle 3) venetoclax will be thereafter continued until day 21 of cycle 35"
16385233|NCT04082884|Experimental|Very Low Carbohydrate Diet|Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
16385234|NCT04082871|Active Comparator|Intervention|"All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist.
~A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied.
~If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist."
16385235|NCT04082871|Active Comparator|Control|"Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations.
~After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist"
16385236|NCT04082858|Experimental|Ketamine|Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
16385237|NCT04082858|Active Comparator|Midazolam|Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
16385238|NCT04082845|Experimental|Experimental Group|The experimental group will be educated via a website that was created by the researchers.
16385239|NCT04082845|No Intervention|Control Group|The control group will take rutin patient care.
16385240|NCT04082832|Active Comparator|Cu(II)ATSM|Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
16385241|NCT04082832|Placebo Comparator|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
16385242|NCT04082819|Other|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
16385243|NCT04082819|Other|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
16385244|NCT04082819|Other|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
16385245|NCT04082806|Experimental|healthy controls|
16385246|NCT04082806|Experimental|Major Depressive Disorder|
16385247|NCT04082793|Experimental|Photobiomodulation group|Low-level laser therapy will be given to the PTMB group along with mandibular mobilization and stabilization exercises
16385248|NCT04082793|Experimental|Sonophoresis group|Ultrasonic massage with diclofenac gel will be given to the sonophoresis group along with mandibular mobilization and stabilization exercises
16385251|NCT04082767|Active Comparator|Dexmedetomidine|
16385252|NCT04082767|Active Comparator|Midazolam|
16385382|NCT04082000|Experimental|BOL-DP-o-04|
16385253|NCT04082754|Experimental|CSL311 Cohort A1 (SAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)
16385254|NCT04082754|Experimental|CSL311 Cohort A2 (SAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385255|NCT04082754|Experimental|CSL311 Cohort A3 (SAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385256|NCT04082754|Experimental|CSL311 Cohort A4 (SAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385257|NCT04082754|Experimental|CSL311 Cohort A5 (SAD Dose 5)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385258|NCT04082754|Experimental|CSL311 Cohort A6 (SAD Dose 6)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385259|NCT04082754|Experimental|CSL311 Cohort A7 (SAD Dose 7)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385260|NCT04082754|Experimental|CSL311 Cohort A8 (SAD Dose 8)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
16385261|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
16385262|NCT04082754|Experimental|CSL311 Cohort B2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
16385263|NCT04082754|Experimental|CSL311 Cohort B3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
16385264|NCT04082754|Experimental|CSL311 Cohort B4 (MAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
16385265|NCT04082754|Placebo Comparator|Placebo|0.9% sodium chloride solution administered intravenously
16385266|NCT04082754|Placebo Comparator|Placebo (2)|0.9% sodium chloride solution administered subcutaneously
16385267|NCT04082754|Experimental|CSL311 Cohort C1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously (SC)
16385268|NCT04082754|Experimental|CSL311 Cohort C2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
16385269|NCT04082754|Experimental|CSL311 Cohort C3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
16385270|NCT04082754|Experimental|CSL311 Cohort D1 (Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously in healthy volunteers
16385271|NCT04082741|Experimental|Monotherapy SAD BMS-986318 or Placebo|Single Ascending Dose (SAD)
16385272|NCT04082741|Experimental|Monotherapy MAD BMS-986318 or Placebo|Multiple Ascending Dose (MAD)
16385273|NCT04082728|Active Comparator|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
16385274|NCT04082728|Placebo Comparator|Placebo|Patients in the experimental group will be instructed to take a placebo orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
16385275|NCT04082715|Experimental|carbidopa/levodopa+celecoxib|carbidopa/levodopa+celecoxib treatments will be effective.
16385276|NCT04082715|Placebo Comparator|placebo1+celecoxib|A placebo comparator for carbidopa/levodopa+celecoxib .
16385277|NCT04082715|Placebo Comparator|placebo1+placebo2|A placebo comparator for carbidopa/levodopa+celecoxib and placebo1+celecoxib.
16385278|NCT04082702|Experimental|Faith-enhanced DPP|A total of six churches were randomized to this arm that included 119 participants and received 10-month DPP with faith components.
16385279|NCT04082702|Active Comparator|Standard DPP|A total of five churches were randomized to this arm that included 102 participants who received the standard DPP on the church settings.
16385282|NCT04082676|Experimental|Height and weight based group|"Patients in Height and weight based group will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)"
16385283|NCT04082676|Active Comparator|Height based group|"Patients in Height based group will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)"
16385284|NCT04082663|Experimental|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
16385285|NCT04082650|Experimental|Vitamin D|Participants in the intervention group will be treated with vitamin D 4000IU (800IU per pill, take five pills once each day) per day for around 12 weeks (till the triggering day).
16385286|NCT04082650|Placebo Comparator|Placebo|Participants in the control group will be treated with equal amount of placebo tablets per day for the same duration.
16385287|NCT04082637|Experimental|MABT* + Medication Assisted Treatment|Mindful Awareness in Body-oriented Therapy + Medication-assisted Treatment
16385288|NCT04082637|No Intervention|Treatment as Usual|Treatment as Usual is buprenorphine medication for the treatment of opioid use disorder
16385383|NCT04082000|Placebo Comparator|Placebo|
16403690|NCT03953092|Experimental|MAD Cohort 2|20 mg YG1699 or placebo
16385289|NCT04082624|Active Comparator|Nutrition condition|Received nutrition information such as the comparison of nutritional information between orange juice and soda pop. Received intervention following measurements at baseline, week 4, and week 8.
16385290|NCT04082624|Experimental|Affective condition|Learned about the affective benefits (e.g., less depression) of reduced office sitting time through taking active breaks. Received intervention following measurements at baseline, week 4, and week 8.
16385291|NCT04082624|Experimental|Instrumental condition|Learned about instrumental benefits such as the relationship between sitting and cardiovascular disease and absenteeism at work. Received intervention following measurements at baseline, week 4, and week 8.
16385292|NCT04082624|Experimental|Self-regulation condition|Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
16385293|NCT04082611|Active Comparator|Group 1 - Data-driven clinical recommendations (CR)|Data-driven clinical recommendations (CR)
16385294|NCT04082611|Experimental|Group 2 - Data-driven coached multi-modal intervention (MMIC)|Data-driven coached multi-modal intervention (MMIC)
16385295|NCT04082598|Experimental|Tooth extraction and antibiotic treatment|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days
16385296|NCT04082598|Experimental|tooth extraction and antibiotic treatment + dietary supplement|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days
16385297|NCT04082598|No Intervention|Tooth extraction|tooth extraction without antibiotics and/or Bifidobacterium longum and Lactoferrin
16385298|NCT04082572|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who do not respond to pembrolizumab and stop the treatment after 2 doses may undergo surgery within 6 months.
16385299|NCT04082559|Other|Antibiotic treatment|"Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.
~Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks
~Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks"
16385300|NCT04082559|Other|Combination therapy (Antibiotics + diet)|"Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.
~Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks."
16385301|NCT04082559|Other|Nutritional prevention|"Patients in clinical remission will be recruited to a dietary prevention study.
~Mediterranean diet
~Control- based on the American Dietetic Association recommendations for patients with IBD
~Personalized nutrition group- based on prior results from study- NCT02858557"
16385302|NCT04082546||Surgical unroofing|Refractory angina to medical treatment (beta-blockers or calcium channels blockers)
16385303|NCT04082546||Medical treatment|Responders to medical treatment for angina relief
16385304|NCT04082533|Active Comparator|Stiffness Intravenous Hydrocortisone|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
16385305|NCT04082533|Placebo Comparator|Stiffness Intravenous Placebo|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
16385306|NCT04082533|Active Comparator|Non-stiff Intravenous Hydrocortisone|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
16385307|NCT04082533|Placebo Comparator|Non-stiff Intravenous placebo|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
16385308|NCT04082520|Experimental|Treatment (gallium Ga 68-DOTATATE PET/MRI, Lutathera)|Patients receive gallium Ga 68-DOTATATE IV and undergo a PET/MRI before cycles 1 and 4. Patients then receive lutetium Lu 177 dotatate IV over 30-40 minutes. Cycles repeat every 8 for up to 6 months in the absence of disease progression or unacceptable toxicity.
16385309|NCT04082507||Non_adherent plcenta|placenta separated within 15 minutes after delivery of fetus
16385310|NCT04082507||Adherent placenta|placenta dosenot separated within 15 minutes after delivery of fetus
16385311|NCT04082494|No Intervention|Regular Treatment|"No intervention is planned for the first period. Baseline treatment assesment."
16385312|NCT04082494|Experimental|Music|Optional music via internet and noise canceling headphones will be offered.
16385313|NCT04082494|Experimental|Music and Beverages|Additionally to the offered optional music via internet and noise canceling headphones, there will be beverages optionally offered (with and without sugar, warm or cold).
16385319|NCT04082455|Experimental|carbon ion radiotherapy|carbon ion radiotherapy
16385320|NCT04082442|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in ACS patients.
16385321|NCT04082442|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in ACS patients .
16385326|NCT04082416|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
16385327|NCT04082416|Placebo Comparator|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 52 times.
16385328|NCT04082403|Active Comparator|Pre SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway
16385329|NCT04082403|Experimental|Post SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway after receiving SALAD training
16385330|NCT04082390|Experimental|RELEASE Supplement|
16385331|NCT04082390|Placebo Comparator|Placebo|
16385332|NCT04082377|Experimental|Recruitment maneuver with tidal volume (RM TV)|RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW ,RR at 7 breaths/min, PEEP at 5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM. The ventilation protocol could be changed at any time when concerned about patient safety.
16385333|NCT04082377|Active Comparator|Recruitment maneuver by PEEP (RM PEEP)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia 5 cmH2O PEEP.
~RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver."
16385339|NCT04082351|Active Comparator|Magnalife|the group of patients receiving the nanotechnology structured water
16385340|NCT04082351|Placebo Comparator|Ordinary water|the group of patients receiving ordinary water
16385341|NCT04082338|Experimental|VPN Toolkit+TM|The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application) format.
16385342|NCT04082338|Active Comparator|Text Messages|Receive TM respectively once a week for 5 weeks for every 6 months in the 18-month study period
16385343|NCT04082325|Experimental|Part A Lu AF88434 or Placebo|6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo
16385344|NCT04082325|Experimental|Part B1 Lu AF88434 Fed-Fasting-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.
16385345|NCT04082325|Experimental|Part B2 Lu AF88434 Fasting-Fed-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.
16385346|NCT04082325|Experimental|Part B3 Lu AF88434 Fasting-Fasting-Fed|4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.
16385347|NCT04082312||Group 1|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
16385348|NCT04082312||Group 2|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
16385349|NCT04082312||Group 3|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI
16385350|NCT04082299||Pregnant women|pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
16385352|NCT04082286|Experimental|Radioimmunotherapy|Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
16385353|NCT04082273|Experimental|Femtosecond Laser for Cataract Surgery|Capsulotomy, lens fragmentation and Clear Corneal Incisions with FEMTO LDV Z8, followed by ultrasound phacoemulsification and IOL implantation.
16385354|NCT04082273|Active Comparator|Conventional Cataract Surgery|Clear Corneal Incisions, conventional capsulorhexis and ultrasound phacoemulsification and IOL implantation. Control treatment where the clear corneal incisions and capsulorhexis are performed manually and the lens fragmentation is performed with the phacoemulsification device.
16385355|NCT04082260||De novo patients with alemtuzumab|De novo patients prior and after alemtuzumab treatment initiation
16385356|NCT04082260||Alemtuzumab treatment|Patients under alemtuzumab treatment
16385357|NCT04082260||Extended alemtuzumab treatment|Patients requiring more than two alemtuzumab infusions
16385358|NCT04082247|Experimental|Experimental group|The education and training of early childhood educators (developed by the researchers) and their intervention on children.
16385359|NCT04082247|No Intervention|Control group|Receive the standard care.
16385360|NCT04082234|Experimental|Integrated Individualized Behavioral Parent Training|Partnering to Achieve School Success (PASS) is a personalized, enhanced behavioral intervention for ADHD that includes evidence-based behavior therapy strategies and enhancements to promote family engagement in treatment, team-based care, and high quality therapy. Caregivers engage in up to 12 sessions with a behavioral health provider over the course of 16 weeks that are specifically tailored to caregiver goals and values.
16385361|NCT04082234|Active Comparator|Treatment as Usual|The control condition will be TAU informed by AAP guidelines for managing ADHD and facilitated by electronic practice supports, which have been successfully incorporated into the electronic health record (EHR) to guide primary care providers (PCPs) in implementing ADHD guidelines. At CHOP, PCPs across the primary care network were invited to participate in a distance learning, quality improvement initiative to promote implementation of AAP guidelines,including strategies to educate families about ADHD and evidence-based treatments, engage families in shared decision making, titrate medication, and monitor treatment effects. The five practices participating in this study participated in that project.
16385362|NCT04082208|Experimental|Intervention Group|High Flow nasal cannula (HF)
16385363|NCT04082208|Active Comparator|Standar Care Group|Standar Care: low flow device (LF)
16385364|NCT04082195|Experimental|Fooya mobile game|An arm that receives a mobile-app-based treatment.
16385365|NCT04082195|Active Comparator|Uno board game|An arm that receives a non mobile-app-based treatment.
16385366|NCT04082182|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIX4-LUNG autologous DC vaccine
16385367|NCT04082156|Active Comparator|Active TENS|
16385368|NCT04082156|Sham Comparator|Sham TENS|
16385369|NCT04082143|Experimental|Implant with prophylactic allograft|
16385370|NCT04082143|Active Comparator|Implant without prophylactic allograft|
16385371|NCT04082130|Experimental|(XCM)+(CAF)|"Surgical protocol for test treatment with CAF + XCM:
~After local anesthetizing the recipient site,CAF elevation will be done using (De Sanctis & Zucchelli 2007) design.Horizontal incisions will be done at the recession site,another two slightly divergent vertical incisions will be done at the end of previous incisions extending to the mucogingival junction.The resulting flap will be split thickness in the surgical papillae area,then will be full thickness exposing 3-4 mm of the bone apically of the dehiscence and after that it will be split thickness in the apical direction,all the muscle insertions will be eliminated,the root surface will be prepared by curettes and chemically treated with 24% EDTA gel.De-epithelialization of the interdental papillae will be done.The XCM will be trimmed and fix onto the root surface 1-2mm coronally of the CEJ using absorbable sutures,and the flap will be coronally advanced to fully cover the XCM and then sutured to the de-epithelialized papillae."
16385372|NCT04082130|Active Comparator|(SCTG)+(CAF)|"The surgical protocol in the control group will be identical with test group protocol with these exceptions:
~The entire flap will be elevated as split thickness instead of split-full-split thickness flap.
~A SCTG harvested from the palate will be used to cover the exposed denuded root surface in lieu of placement of XCM in the test group. And absorbable sutures will be used to stabilize it 2 mm coronally from the CEJ.
~As in the test group the mucosal flap will coronally advanced to completely cover the SCTG then sutured to the de-epithelialized papillae."
16385373|NCT04082117|Other|Open Label|Educational genetic counseling video
16385374|NCT04082065|Active Comparator|conventional physical therapy|Myofacial release Stretching of hamstring and Piriformis
16385375|NCT04082065|Experimental|cyriax lumber manipulation group|Myofacial Release stretching of hamstrings and Piriformis Cyriax Lumbar Manipulation Techniques
16385376|NCT04082052|Experimental|Single Session Intervention for Self-Dislike|A 30-45 minute intervention delivered in a web browser that focuses on reducing self-dislike using facts about the brain, testimonials from peers, and writing exercises.
16385377|NCT04082052|Placebo Comparator|Single Session Intervention for Feelings Disclosure|A 30-45 minute intervention delivered in a web browser that focuses on encouraging feelings disclosure using facts about the brain, testimonials from peers, and writing exercises.
16385378|NCT04082039|Active Comparator|1-channel PCA|Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
16385379|NCT04082039|Experimental|2-channel PCA|Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
16385380|NCT04082026|Experimental|Early Adolescent Skills for Emotions (EASE)|EASE has four core features: Seven group sessions for young adolescents and three for their caregivers; Delivered by non-specialists; Trans-diagnostic: addressing depression, anxiety, distress, and other problems as defined by the young people themselves; and Designed for young people and their caregivers in low- and middle-income countries living in communities affected by adversity.
16385381|NCT04082026|Placebo Comparator|Enhanced Treatment As Usual (ETAU)|The Enhanced Treatment as Usual (ETAU) consisted of a single psychoeducation individual session, jointly for eligible adolescents and their caregivers, that included information on: (i) the results of the screening; (ii) self-care strategies; and, (iii) seeking services from local health or community services offering psychosocial / mental health care support.
16385384|NCT04081974||Minimally invasive cardiac surgery|All consecutive patients presenting for minimally invasive cardiac surgery will be screened for participation to the study.
16385385|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
16385386|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
16385387|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
16385388|NCT04081948|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
16385389|NCT04081948|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
16385390|NCT04081935|Experimental|Reduce pain and fair|To determine whether the virtual reality as a distracting intervention could reduce pain and fear in school-age children receiving intravenous injections at an emergency department.
16385391|NCT04081935|No Intervention|Compared|Normal treatment
16385392|NCT04081922|Experimental|Regional analgesia using erector spinae plane block|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.
16385393|NCT04081922|No Intervention|Control|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.
16385394|NCT04081909|Active Comparator|Opioid Based Anesthesia(OBA)|
16385395|NCT04081909|Experimental|Opioid Free Anesthesia(OFA)|
16385396|NCT04081896||In Clinic Rehabilitation|Participants who are undergoing supervised exercise based rehabilitation in the SpineZone clinic
16385397|NCT04081896||Online Rehabilitation|Participants who will be undergoing online-based coaching and exercise as prescribed via telephone, online chat, or web-based interactions with SpineZone rehabilitation staff (physical therapists and physicians)
16385398|NCT04081883|Experimental|Biosensor algorithm|The biosensor DIABLO algorithm is compared to Continuous Glucose Monitoring Systems (CGMS) utilisation.
16385399|NCT04081870||ICSI cases|All women underwent long agonist protocol for controlled ovarian hyperstimulation The GnRH agonist was started in the previous mid-luteal phase . After the confirmation of pituitary down regulation , the HMG ampoules were started by 225 IU/day . During the follow up of overstimulation, the doses were adjusted according to the response of patient. All women underwent serial TVS until at least three dominant follicles were reached in every woman. When the dominant follicles reached 18-20 mm, HCG 10000 was administered. Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day . Five days following ovum pick up, the embryos were transferred at the blastocyst stage.
16385400|NCT04081857|Experimental|Sequence 1|Period 1 : Fasted state + HGP1810 Period 2 : Fasted state + HCP1704
16385401|NCT04081857|Experimental|Sequence 2|Period 1 : Fasted state + HCP1704 Period 2 : Fasted state + HGP1810
16385402|NCT04081844|Experimental|Fixed-Sequence|Period 1: Fasted state+HCP1306, Period 2: Fasted state+HGP0904+HGP0608, Period 3: Fasted state+HCP1306+HGP0904+HGP0608
16385403|NCT04081831||New-users of Low-dose aspirin (exposed group)|New-users of low-dose aspirin is defined as patients who did not receive any prescriptions of low-dose aspirin one year prior to the index date.
16385404|NCT04081831||Users of Paracetamol (non-exposed group)|Users of Paracetamol is defined as patients who receive first prescription of paracetamol during the study period. Since the patients receiving low-dose aspirin are potentially less healthy compared to non-users of aspirin, patients receiving paracetamol as the control group can minimise healthy user bias.
16385405|NCT04081818|Active Comparator|Intervention group (Nutritious Mushrooms)|
16385406|NCT04081818|No Intervention|Control group|
16385407|NCT04081805|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
16385408|NCT04081805|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
16385409|NCT04081805|Active Comparator|Promestriene|The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
16385410|NCT04081792|Experimental|1. Trial (Amputation) Soft tissue - short antibiotic arm|The intervention group consists of 1 day of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
16385411|NCT04081792|Active Comparator|1. Trial (Amputation) Soft tissue - long antibiotic arm|The control group consists of 4 days duration of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
16385412|NCT04081792|Experimental|1. Trial (Amputation) Bone - short antibiotic arm|The intervention group consists of 1 week of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
16385443|NCT04081597|Placebo Comparator|Placebo|Matching placebo in one of three periods
16385444|NCT04081558|Experimental|Electronic follow-up|
16385413|NCT04081792|Active Comparator|1. Trial (Amputation) Bone - long antibiotic arm|The intervention group consists of 3 weeks of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
16385414|NCT04081792|Experimental|2.Trial (soft tissue infection) - short antibiotic arm|The intervention group consists of 10 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
16385415|NCT04081792|Active Comparator|2. Trial (soft tissue infection) - long antibiotic arm|The control group consists of 20 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
16385416|NCT04081792|Experimental|2. Trial (osteomyelitis) - short antibiotic arm|The intervention group consists of 3 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
16385417|NCT04081792|Active Comparator|2. Trial (osteomyelitis) - long antibiotic arm|The control group consists of 6 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
16385418|NCT04081779|Active Comparator|Arm I (patient-generated SCP)|Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).
16385419|NCT04081779|Experimental|Arm II (patient-generated SCP, educational counseling)|Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
16385420|NCT04081766|Active Comparator|SUGAR Handshake|"Participants assigned to the intervention group will receive an individualised, pharmacist-led patient counselling session (SUGAR Handshake package) at the inclusion visit.
~Participants will also receive a pictogram with the main instructions for easy recall of the counselling contents.
~They will also receive a glucometer and test strips with a demonstration on proper use, to measure their fasting blood glucose levels on a daily basis for 12 weeks.
~At week 6, participants will receive a phone call to reinforce the intervention and to remind them of the study protocol. For the qualitative evaluation of the intervention, a number of participants are interviewed and asked questions through the sixth week-phone call.
~Additionally, participants in this group will be provided with the usual care that is normally provided in the outpatient clinics at King Abdullah University Hospital."
16385421|NCT04081766|No Intervention|Control|"Participants within this group will receive the usual care provided by the health care professionals in the outpatient clinics at King Abdullah University Hospital.
~They will also be provided with instructions on hypoglycemia diagnosis, and treatment and a demonstration on glucometer use at the inclusion visit. They will be asked to measure their fasting blood glucose level daily for 12 weeks.
~Participants will receive a phone call at week 6 of the inclusion visit to remind them of measuring blood glucose levels and documenting hypoglycemic episodes on the diaries., plus a counselling session about hypoglycaemia recognition and treatment at the inclusion visit.
~For the qualitative evaluation of the study, a number of participants will be interviewed and asked questions through the sixth week-phone call."
16385422|NCT04081753|Experimental|TMD Group|Temperature Monitoring Device Group - The interventional group, who will be given the temperature monitoring device and will be monitored remotely.
16385423|NCT04081753|No Intervention|Historic cohort Group|Historic cohort group will be enrolled from medical record
16385424|NCT04081740||Asthma|The patients included in this group will have asthma, as specified in the inclusion criteria.
16385425|NCT04081740||COPD|The patients included in this group will have COPD, as specified in the inclusion criteria.
16385426|NCT04081740||Bronchiectasis|The patients included in this group will have bronchiectasis, as specified in the inclusion criteria.
16385427|NCT04081727|Experimental|Test Article - Zip-stitch(TM) Clips|Zip-stitch(TM) clips for vaginal cuff closure during laparoscopic hysterectomy
16385428|NCT04081727|Other|Reference Group - V-Loc Barbed Suture|Will not be comparative against the test article, but will be performed for reference and safety.
16385429|NCT04081701||Meningioma|Cohort of 30 subjects with meningioma.
16385430|NCT04081701||Non-Meningioma|"Cohort of 60 subjects with non-meningioma:
~(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)"
16385431|NCT04081688|Experimental|Treatment (varlilumab, atezolizumab, SBRT)|Patients receive varlilumab IV over 90 minutes and atezolizumab IV over 30-60 minutes every cycle. Cycles repeat every 21 days for up to 1 year (18 cycles) in the absence of disease progression or unacceptable toxicity. Between cycle 1 and 2, patients also receive SBRT.
16385432|NCT04081662|Experimental|compACT Intervention|"At every time-point of the study, participants will complete self-reports of stress, (as measured by the PSS-4) distress (as measured by the PHQ-2), and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.
~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).
~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
16385433|NCT04081649||Cardiac surgery|Patients undergoing non-emergent cardiac surgery for coronary bypass graft and/or valvular replacement
16385434|NCT04081636|Active Comparator|Systematic Transrectal biopsy (TR-Bx)|Ultrasound guided; needle inserted through the rectum to reach the prostate
16385435|NCT04081636|Active Comparator|Targeted Transrectal biopsy (TR-Bx)|MRI-guided; needle inserted through the rectum to reach the prostate
16385436|NCT04081636|Experimental|Systematic Transperineal biopsy (TP-Bx)|Ultrasound guided; needle inserted directly through the skin to reach the prostate
16385437|NCT04081636|Experimental|Targeted Transperineal biopsy (TP-Bx)|MRI-guided; needle inserted directly through the skin to reach the prostate
16385438|NCT04081623||Clinic|This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)
16385439|NCT04081623||Labor and Delivery|This group is in active labor.
16385440|NCT04081610|Experimental|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
16385441|NCT04081610|Active Comparator|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
16385442|NCT04081597|Experimental|STAR-101|Doses in two of three crossover periods
16403691|NCT03953092|Experimental|MAD Cohort 3|50 mg YG1699 or placebo
16385445|NCT04081545|Active Comparator|Control Goup A- Opioid-based regimen|"Preop - Multimodals unless contraindicated
~Induction
~Fentanyl (50mcg IV)
~Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)
~Propofol 2-3mg/kg IV bolus
~Neuromuscular blockade per Anesthesiology team discretion
~Maintenance
~Sevoflurane
~Neuromuscular blockade at discretion of anesthesiology team
~May use fentanyl to treat SBP or HR > 20% of baseline
~Emergence
~Neuromuscular reversal, dosed according to Virginia Mason protocol
~May titrate fentanyl per anesthesiology team throughout the case.
~Patient extubated and brought to PACU
~PACU opioid orders per anesthesiology team
~Post-operative Nausea/Vomiting Prophylaxis
~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
16385446|NCT04081545|Experimental|Experimental Group B- Opioid-free regimen|"Preop - Multimodals unless contraindicated
~Induction
~Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW
~Lidocaine 1.5mg/kg IV bolus using IBW
~Propofol 2-3mg/kg IV bolus
~Neuromuscular blockade per Anesthesiology team discretion
~Ketamine 0.5mg/kg IV bolus (based on IBW)
~Maintenance
~Sevoflurane
~Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)
~Lidocaine 2mg/kg/hr IV infusion using IBW
~May use esmolol as needed to treat SBP or HR > 20% of baseline
~Neuromuscular blockade at the discretion of anesthesiology team
~Emergence
~Dexmedetomidine infusion turned off during laparoscopic desufflation
~Lidocaine infusion turned off at skin closure
~Neuromuscular reversal, dosed according to VM protocol
~Pt extubated and brought to PACU
~PACU opioid orders per anesthesiology team
~Post-operative Nausea/Vomiting Prophylaxis
~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
16385447|NCT04081532|Active Comparator|Surgical treatment|
16385448|NCT04081532|No Intervention|No surgical treatment|
16385449|NCT04081519|Active Comparator|DLPFC-DLPFC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over DLPFC
16385450|NCT04081519|Experimental|DLPFC-LPC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over LPC
16385451|NCT04081519|Sham Comparator|DLPFC-SHAM|15 sessions of active rTMS over DLPFC + 15 sessions of sham rTMS over DLPFC or LPC
16385452|NCT04081506|Experimental|Group A|Individualized care
16385453|NCT04081506|No Intervention|Group B|Conventional care
16385454|NCT04081493|Experimental|Group 1 (BFRE)|Low-load blood flow restricted exercise 3/weekly for 8 weeks before TKR 10-min warm-up followed by unilateral leg press and unilateral knee extension
16385455|NCT04081493|No Intervention|Group 2 (CON)|No training before TKR
16385456|NCT04081480|Other|Valacyclovir oral solution|Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.
16385457|NCT04081467|Experimental|bed rest condition|Bed rest condition without any additional intervention
16385458|NCT04081454||Children with chronic pain|
16385459|NCT04081454||Caregivers of children with chronic pain|
16385460|NCT04081441|Experimental|Inyenyeri clean cookstove/fuel|A tier 4 clean Mimi-moto cookstove/pellet system
16385461|NCT04081441|Experimental|I-ACT behavioral empowerment intervention|A culturally adapted 2-day personal empowerment workshop (based on the Individual, Agency-Centered Training (I-ACT) to women and modified, condensed 1-day training for their male partners, if applicable
16385462|NCT04081441|Experimental|Cookstove and I-ACT empowerment|Access to both the clean cookstove system and I-ACT empowerment training
16385463|NCT04081441|Other|I-ACT Waitlisted control|These households include those that were offered cookstoves after 6 months (from baseline) and are waitlisted to receive the I-ACT intervention
16385464|NCT04081415||Group with FPIES|Not yet healed children with FPIES
16385465|NCT04081402|Experimental|HU-014 Inj|
16385466|NCT04081402|Active Comparator|Botox Inj|
16385467|NCT04081389|Experimental|CKM weeks 1-3, doxorubicin, cyclophosphamide)|Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
16385468|NCT04081376|Experimental|Treatment group|Subjects receive a single-dose treatment.Urine samples will be collected after administration (8 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-60h, 60-72h post-administration).
16385469|NCT04081363|Experimental|Intervention|Single oral dose (50 mg) capsule of extended-release centanafadine
16385470|NCT04081350|Active Comparator|LY3471851|LY3471851 administered subcutaneously (SC)
16385471|NCT04081350|Placebo Comparator|Placebo|Placebo administered SC
16385472|NCT04081337|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
16385473|NCT04081337|Placebo Comparator|Placebo|Placebo administered SC.
16385474|NCT04081324|Placebo Comparator|Placebo|Participants received placebo administered orally on Day 1 and repeated doses on Days 4 to 10 (7 days of dosing).
16385475|NCT04081324|Experimental|50 milligram (mg) Lasmiditan|Participants received 50 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 50 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
16385476|NCT04081324|Experimental|100 mg Lasmiditan|Participants received 100 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 100 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
16385477|NCT04081324|Experimental|200 mg Lasmiditan|Participants received 200 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 200 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
16385478|NCT04081311|Experimental|water flosser|patient will be provided with Waterpik Water Flosser and instructed to water floss around the implant once a day, preferably at nighttime
16385479|NCT04081311|Active Comparator|dental floss|patient will be instructed to floss with TePe Bridge and Implant Floss once a day, preferably at nighttime
16385480|NCT04081298|Experimental|Arm I (health education, FitBit, actigraph)|Patients attend 6 online nutrition and PA education classes, cooking sessions, and participate in physical activities over 120 minutes each. Patients wear a FitBit and Actigraph to monitor physical activity.
16385481|NCT04081298|Active Comparator|Arm II (text message, website, FitBit, actigraph)|Patients receive motivational text messages 2-3 times per week and access to a nutrition website for 3 months. Patients wear a FitBit and Actigraph to monitor physical activity.
16385482|NCT04081272||G6PD-normal|Donated blood from G6PD-normal subjects
16385483|NCT04081272||G6PD-deficient|Donated blood from G6PD-deficient subjects
16385484|NCT04081259|Experimental|Arm B: Dose Escalation LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients with inhibitors for fungal prophylaxis/treatment
16385485|NCT04081259|Experimental|Arm A: Dose Expansion LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients without inhibitors for fungal prophylaxis/treatment
16385486|NCT04081246|Experimental|Modified en bloc resection|For patients undergoing modified en bloc resection, piecemeal resection of the exophytic part of the bladder tumour will be performed, followed by en bloc resection of the tumour base.
16385487|NCT04081233|Experimental|Early surgical stabilization|This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
16385488|NCT04081233|Active Comparator|Usual care|This arm will be usual care only. Usual care will include pain managment.
16385489|NCT04081220|Experimental|IMG-7289|
16385490|NCT04081207|Experimental|AAC-LaRc|all participants receive the experimental treatment
16385491|NCT04081194||case group, Melanoma Patients|"15 patients of with Melanoma, Age between 40 and 90 years.
~-Withdrawal of Blood sample, Isolation of Exosomes:
~Bradford protein assay And Qubit protein assay.
~Bioanalyzer.
~Real time PCR."
16385492|NCT04081194||control group|"10 Persons without Melanoma, age > 40 years
~-Withdrawal of Blood sample, Isolation of Exosomes:
~Bradford protein assay And Qubit protein assay.
~Bioanalyzer.
~Real time PCR."
16385493|NCT04081181|Experimental|CT_ guided percutaneous microwave ablation|The procedure will be done under anaesthesia by interventional radiologist
16385494|NCT04081168|Active Comparator|Stereotactic Body Radiotherapy|Patients included will undergo Stereotactic Body Radiotherapy (SBRT) of hepatic metastases.
16385495|NCT04081168|Active Comparator|Microwave Ablation|Patients included will undergo Microwave Ablation (MWA) of hepatic metastases.
16385496|NCT04081142||acute respiratory failure group|acute respiratory failure (ARF) group: arterial oxygen partial pressure to fractional inspired oxygen ratio, PaO2/FiO2<300 mmHg and/or peripheral oxygen saturation SaO2<94% under air condition and/or severe dyspnea with respiratory rate >30bpm.
16385497|NCT04081142||control group|postoperative ICU patients without ARF were included
16385498|NCT04081129||ICU patients with early mobilization|
16385499|NCT04081116|Experimental|MI-E testing symmetric settings|Symmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
16385500|NCT04081116|Experimental|MI-E testing assymetric settings|Asymmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
16385501|NCT04081116|Sham Comparator|Settings in use|Settings in use is one of 3 different settings that will be tested on the same day but in randomized order
16385502|NCT04081103|Experimental|NEXAGON High Dose Concentration|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.
~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
16385503|NCT04081103|Experimental|NEXAGON Low Dose Concentration|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.
~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
16385504|NCT04081103|Placebo Comparator|NEXAGON Vehicle|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.
~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
16385505|NCT04081090|Experimental|Brain HQ adaptive Cognitive Therapy Modules|Brain HQ licensed modules that adapt to each individuals unique strengths and weaknesses to address deficits and improve neuroplasticity.
16385506|NCT04081090|Active Comparator|Brain HQ Active Control Modules|Participants in this arm will complete puzzles such as crossword puzzles, Sudoku, etc.
16385507|NCT04081077|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
16385508|NCT04081077|Experimental|Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
16385509|NCT04081077|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
16385510|NCT04081064|Experimental|Non-obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >18.5 and <30.0 kg/m2
16385911|NCT04078373||Without urinary disorders|Subacute stroke patients without urinary disorders
16385511|NCT04081064|Experimental|Obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >30.0 to <40.0 kg/m2
16385512|NCT04081051|Experimental|Intervention|Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers
16385513|NCT04081051|No Intervention|control|Standard of care practices for acute febrile illness
16385514|NCT04081025||Adults|Age Groups 35, 50, 65, 75 and 85
16385515|NCT04081012|Experimental|N-acetyl Cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before endarterectomy or balloon angioplasty.
16385516|NCT04081012|Placebo Comparator|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals. All study medications will be prepared by the Pharmacology department, which is not involved in patient care; the name of the medication and dose of the original ampule will be erased and also an identification label will be placed with the name, registration number, bed number, date and will be indifferent for groups with the same type of ampoule, with the same type of labeling
16385517|NCT04080999|Experimental|r-TMS Group|"r-TMS Parameters International 10/20 system for the location of the target area (non-lesioned left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.
~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
16385518|NCT04080999|Sham Comparator|Sham Group|Sham stimulation and Visual scanning training
16385519|NCT04080986|No Intervention|Standard Arm|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
16385520|NCT04080986|Active Comparator|Double Sequential Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
16385521|NCT04080986|Active Comparator|Vector Change Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
16385522|NCT04080973|Experimental|osteopenic patients|patients with a kidney stone and osteopenic changes.
16385523|NCT04080947|Placebo Comparator|Control group|26 patients will receive placebo (Control group)
16385524|NCT04080947|Experimental|Montelukast group|26 patients will receive montelukast 10 mg/ day
16385525|NCT04080934|Experimental|Experimental Group|In the experimental group, patients allocated to the swimming/experimental group will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum. They will be asked to undergo a range of motion (ROM) assessment by a registered kinesiologist, as well as a few short questionnaires administered over the phone by a research assistant, once at the onset of the intervention and once a month for 3 months during the intervention.
16385526|NCT04080934|No Intervention|Control Group|The control group will include patients who receive standard of care. This includes the recommendation to undertake exercise and physiotherapy; however, no formal exercise program will be provided. In the control group, participants will be asked to answer a few short questionnaires administered over the phone by a research assistant once per month for 4 months.
16385527|NCT04080921|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
16385528|NCT04080908|Experimental|Ferumoxytol injection treatment|
16385529|NCT04080895|Experimental|group A|
16385530|NCT04080895|Experimental|group B|
16385531|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
16385532|NCT04080882|Placebo Comparator|placebo|placebo injected into platysma bands
16385533|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
16385534|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 3|AbobotulinumtoxinA dose 3 injected into platysma bands
16385535|NCT04080869|Experimental|retinyl palmitate ethosomes arm|All patients will be instructed to apply a thin film of the new formula on one side of the face
16385536|NCT04080869|Active Comparator|tretinoin arm|All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face
16385537|NCT04080856||Participants with endometriosis|Premenopausal participants with endometriosis receiving elagolix in real-world setting
16385538|NCT04080843|Experimental|Group A|"Patients in the study group will receive the following treatment:
~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).
~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression."
16385539|NCT04080830||Acute ischemic stroke/transient ischemic attack (TIA) with AF|patients with Acute ischemic stroke/TIA and Atrial fibrillation (observational -no intervention)
16385540|NCT04080817|Experimental|Neolexon Therapy|
16385541|NCT04080817|Active Comparator|Standard logopedic therapy|
16404371|NCT03948243|Experimental|G.Glabra|single arm
16385545|NCT04080791|Experimental|Experimental Group- Virtual Reality (VR) Treatment|The participants in the experimental group will complete the educational/training session on how to use the VR equipment and programs (30 minutes). The following day, participants will begin the VR intervention attending a daily 30-minute sessions for 8 days or until a discharge date has been set, whichever comes first.
16385546|NCT04080791|Active Comparator|Standard of care group|The control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol. Prior to discharge, control group participants will meet with a licensed clinical therapist to complete the cognitive and physical assessments for the posttest evaluation.
16385547|NCT04080778|Experimental|MST|
16385548|NCT04080778|Active Comparator|ECT|
16385549|NCT04080765|Experimental|HIV-ASSIST + DHHS arm|Decision-making support for ARV selection through DHHS guidelines in conjunction with HIV-ASSIST
16385550|NCT04080765|Active Comparator|DHHS-alone arm|Decision-making support for ARV selection through DHHS guidelines alone
16385551|NCT04080752|Experimental|JNJ-61393215 135 milligram (mg)|Participants will receive JNJ-61393215 135 mg (3*45 mg capsules) orally once daily for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
16385552|NCT04080752|Placebo Comparator|Placebo|Participants will receive matching placebo for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
16385553|NCT04080739|Experimental|Experimental Group|US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.
16385554|NCT04080739|No Intervention|Control Group|No regional anesthetic of any kind during the surgical procedure.
16385555|NCT04080726|Experimental|HIP1601+HGP1705 Placebo|HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks
16385556|NCT04080726|Experimental|HGP1705+HIP1601 Placebo|HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks
16385557|NCT04080713|Experimental|Budesonide|
16385558|NCT04080687||Fallers|The patients who had fallen during the 6 months prior to the study onset
16385559|NCT04080687||Non-fallers|The patients who had not fallen during the 6 months prior to the study onset
16385560|NCT04080674||Parkinson's disease|30 participants
16385561|NCT04080674||Essential Tremor|10 participants
16385562|NCT04080674||Dystonia|20 participants
16385563|NCT04080661|Experimental|Standard of care - secukinumab|Patients will continue to receive secukinumab according to the standard dosing schedule: subcutaneous injections once a week for 5 weeks, then every 4 weeks (300 mg).
16385564|NCT04080648|Other|Standard of case - guselkumab|Patients will continue to receive guselkumab according to the standard dosing schedule; subcutaneous injection of 100 mg at weeks 0 and 4 and then every 8 weeks
16385565|NCT04080635|Experimental|Standard of care - brodalumab|Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
16385566|NCT04080622|Placebo Comparator|Placebo|Usual care
16385567|NCT04080622|Active Comparator|Selenium|Usual care + selenium 300 µg/day (IV infusion)
16385568|NCT04080609|Experimental|Sequential arm|Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8.
16385569|NCT04080596|Experimental|Sequential arm|Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.
16385570|NCT04080583||Usual Care|People with a chronic lung condition who are physically inactive
16385571|NCT04080570|Experimental|Remote Visit|After an initial physical in-home visit, the physician will see home hospitalized patients by facilitated video each day.
16385572|NCT04080570|No Intervention|In-Home Visit|The physician will see home hospitalized patients physically in their homes each day, as is usual care.
16385573|NCT04080557||AAA patients that went to the ICU postoperatively|An retrospective cohort study was conducted that included all patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
16385574|NCT04080544|Experimental|Follow up DLBS participants|Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
16385575|NCT04080531|Experimental|Arm I (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
16385576|NCT04080531|Experimental|Arm II (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
16385577|NCT04080518|Active Comparator|Experimental|Dapagliflozin, 10mg, oral dose, once every day
16385578|NCT04080518|Placebo Comparator|Control|Matching placebo for dapagliflozin, oral dose, once every day
16385579|NCT04080505|Active Comparator|SSKI (Potassium Iodide)|Participants randomized to receive 7 days of pre-operative SSKI
16385580|NCT04080505|No Intervention|NO SSKI|Participants randomized to not receive any drug pre-operative
16385581|NCT04080492||Inherited Cardiac Disease|Patients being seen for the first time at the Cleveland Clinic for Hypertrophic Cardiomyopathy or Thoracic Aortic Aneurysm.
16385582|NCT04080492||Non-inherited Cardiac Disease|Patients being seen for the first time at the Cleveland Clinic for Radiation-Induced Heart Disease.
16385583|NCT04080479|Experimental|Bolus enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions:
~Quadriceps Muscle Layer Fitness measurement
~Muscle Strength measurement
~Acute Physiology and Chronic Health Evaluation
~Sequential Organ Failure Assessment
~Nutritional Risk Screening
~Energy and Protein Intake"
16385734|NCT04079465|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic is used in monitoring mode to measure SpO2 continuously.
16404414|NCT03947957|Other|collection of expectoration, stools and blood|
16385584|NCT04080479|Experimental|Continuous enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding.
~The study subjects will undergo the following interventions:
~Quadriceps Muscle Layer Fitness measurement
~Muscle Strength measurement
~Acute Physiology and Chronic Health Evaluation
~Sequential Organ Failure Assessment
~Nutritional Risk Screening
~Energy and Protein Intake"
16385585|NCT04080466|Experimental|Cam Group|This group will consist of patients that are scheduled for surgery to undergo cam resection by hip arthroscopy.
16385586|NCT04080466|Active Comparator|Control Group|This group will consist of a matched cohort of control participants.
16385587|NCT04080453||Septic shock|Plasma of 100 patients presenting a septic shock will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
16385588|NCT04080453||Systemic Inflammatory Response Syndrome|Plasma of 100 patient presenting a systemic inflammatory response syndrome = SIRS will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
16385589|NCT04080440|Active Comparator|Standard of care|Clinicians decide whether to extubate or not following their ICU protocol
16385590|NCT04080440|Experimental|Extubation readiness clinical score|Clinicians decide whether to extubate or not following the extubation readiness clinical score
16385591|NCT04080427|Placebo Comparator|Placebo capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.
~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
16385592|NCT04080427|Experimental|Dronabinol 7.5 milligram oral capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.
~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
16385593|NCT04080414|Experimental|Home-based high-intensity interval training|
16385594|NCT04080414|Active Comparator|Home-based moderate-intensity continuous exercise|
16385595|NCT04080401|Experimental|Fun-Knee Mobile Application|Participants will use a mobile application paired to a knee sleeve with embedded inclinometer sensors. The sensor system will compute knee movement, and feed towards game-based rehabilitation exercises for Total Knee Arthroplasty rehabilitation. game-based and supported on mobile device running on Android or Inter-network Operating System platforms. The mobile apps is able to capture the angle and position data from the two inclinometers on smart knee sleeve.
16385596|NCT04080401|Active Comparator|Conventional Exercise Brochures|Participants will be guided to do their Total Knee Arthroplasty rehabilitation exercises using conventional, paper-based exercise brochures.
16385597|NCT04080388|Active Comparator|Control Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The control group (half of the patients) will be discharged without additional intervention.
16385598|NCT04080388|Active Comparator|Interventional Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The interventional group (half of the patients) will continue anti-congestive treatment while hospitalized until achieving a suitable level of decongestion.
16385599|NCT04080375|Experimental|dinoprostone 3 mg|patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery
16385600|NCT04080375|Placebo Comparator|placebo|patients will take 1 tablet of placebo 1 hour before the surgery
16385601|NCT04080362|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
16385602|NCT04080349|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
16385603|NCT04080349|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
16385604|NCT04080349|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
16385605|NCT04080336|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
16385606|NCT04080336|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
16385607|NCT04080336|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
16385608|NCT04080323|Experimental|dinoprostone 3 mg|60 minutes before the surgery 3 mg of dinoprostone inserted vaginally
16385609|NCT04080323|Placebo Comparator|placebo|60 minutes before the surgery 1 tablet of placebo inserted vaginally
16385610|NCT04080310|Active Comparator|combination therapy group|The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.
16385611|NCT04080310|Other|intensive statin group|The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.
16385612|NCT04080297|Experimental|100 mg Q-122|10 patients treated with Q-122, 100 mg. Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.
16385613|NCT04080297|Experimental|200 mg Q-122|11 patients treated with Q-122, 200 mg. Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
16385614|NCT04080284|Experimental|Niraparib|"Oral niraparib
~-Cohort - Uterine serous carcinoma"
16385773|NCT04079192|Active Comparator|Sequent ® Please Paclitaxel coated balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon
16385615|NCT04080258|Experimental|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMTh). Patients in the OMTh group will receive 5 Osteopathic manipulative therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The protocol will last for three months.
16385616|NCT04080258|Sham Comparator|Light Touch Therapy|Participants to the LTT group will receive the protocol at the same date of the OMTh group.
16385618|NCT04080232|Experimental|Lung MRI|lung MRI concordance as compared to chest CT-scan for the description of morphological abnormalities necessary for the diagnosis of BOS after HSCT. It will be evaluated using lung MRI performed after inclusion (D0) using a standardized procedure
16385619|NCT04080219||Normal|Patients with Oxygen desaturation index <5
16385620|NCT04080219||Sleep-disordered breathing|Patients with Oxygen desaturation index ≥5
16385621|NCT04080206|Experimental|188-0551 Spray|Investigational Topical Spray Product
16385622|NCT04080206|Active Comparator|Reference Listed Drug (RLD)|FDA Approved Topical Cream
16385623|NCT04080193|Experimental|Intervention Group|The study will be a Smartphone-based interventional trial. To assess the effectiveness of the intervention weight- and eating-related behavior and cognitive and emotional responding as well as body-weight will be assessed using questionnaires and ecological momentary assessment (EMA) for one week at a pre- (T0), post- (T1) and two follow-up-assessments after six (T2) and 12 months (T3).
16385624|NCT04080193|No Intervention|Control Group|Members of the control group will participate at each assessment. During the intervention phase they will receive treatment as usual.
16385625|NCT04080180|Active Comparator|Contingency Management (CM)|CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.
16385626|NCT04080180|Active Comparator|BMI+SFAS|Participants will receive the BMI+SFAS intervention at 4 timepoints.
16385627|NCT04080180|Active Comparator|CM+BMI+SFAS|CM+BMI+SFAS is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.
16385628|NCT04080167|Other|Arm 1 (InCharge Health app)|Patient receives the InCharge Health app for 6 months
16385629|NCT04080167|Other|Arm 2 (HU Toolbox app)|Provider receives the HU Toolbox app for 9 months
16385630|NCT04080154|Experimental|Anlotinib|Anlotinib p.o., qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
16385631|NCT04080141||PD+|Subjects with personality disorder
16385632|NCT04080141||PD-|Subjects without personality disorder
16385633|NCT04080128|Other|Contact lens|Depending upon the study lens proven to be the most effective in the BLINK Study, this contact lens will be used for the first two years of the study. The last year of the study, all subjects will be wearing single vision contact lenses.
16385634|NCT04080115|Experimental|Attention Training Technique (ATT)|
16385635|NCT04080115|Active Comparator|Sham intervention control condition|
16385636|NCT04080102|Experimental|High intensity interval training (HIIT)|
16385637|NCT04080102|Experimental|Essential Amino Acid Supplement|
16385638|NCT04080102|Experimental|High intensity interval training + Essential Amino Acid|
16385639|NCT04080102|No Intervention|Control|
16385640|NCT04080089||Case group|Children over the age of 6 who came to the outpatient clinic of our hospital received the informed consent of the parents, and then included in the case group, conducted a self-made sleep questionnaire, established a file, and monitored the sleep on the Mofeh Time Sleep Apnea Monitor. The results were uploaded to the cloud system for analysis. 50 children with OSAHS were screened. Voluntary participation in the study; ability to complete all tests as well as magnetic resonance studies. Exclusion criteria: 1 mental retardation, generalized developmental disorders, severe physical and endocrine diseases, neurological diseases and other mental disorders; 2 visual and auditory diseases affecting the processing of cognitive information. 3 Psychiatric drugs were used in January.
16385641|NCT04080089||Control group|Children in the same age group of children with health checkups were screened for sleep and questionnaires without sleep. After receiving parental informed consent, 30 children were included in the control group. Exclusion criteria: 1 mental retardation, generalized developmental disorder, learning disabilities, conduct Disorders, severe physical and endocrine diseases, neurological diseases and other mental illnesses. 2 There are visual and auditory diseases that affect the processing of cognitive information.
16385642|NCT04080076|Active Comparator|ACTHar gel combined with Tacrolimus|ACTH gel 80 units 2er week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks
16385643|NCT04080076|Active Comparator|ACTHar gel|ACTHar gel 80 units 2 er week for 52 weeks
16385644|NCT04080063|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
16385645|NCT04080050||RGX-501|Study participants who have received RGX-501 gene therapy in a separate parent trial
16385646|NCT04080037|Experimental|Study Participants|All eligible and consented participants will be asked complete a multiple-choice opioid assessment based on the latest CDC opioid guidelines, then care for 6 online QualityIQ patient simulations and receive feedback on their care decisions. They will then all complete an other multiple-choice assessment at the conclusion of the study.
16385647|NCT04080024|Experimental|Single dose (i.v.) SN132D|
16385648|NCT04080011|Experimental|NP-PWD application|All patients enrolled into the study will have the negative pressure- platform wound device applied to their surgical incision.
16385649|NCT04079998|Experimental|Procellera® dressing|The Procellera® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use.
16385650|NCT04079998|Active Comparator|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
16385651|NCT04079985|Experimental|Experimental Group|"The experimental Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus. The experimental group also underwent AAT. We conducted a total of 12 weekly sessions of 60 minutes each with 10 participants."
16385652|NCT04079985|Active Comparator|Control Group|"The Control Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus without the presence of the therapy dog."
16385653|NCT04079972|Experimental|personalized lifestyle intervention|to provide personalized lifestyle guidance for weight loss through SNP testing
16385654|NCT04079972|Active Comparator|general lifestyle intervention|to provide general lifestyle guidance for weight loss
16385655|NCT04079959||women who are undergoing frozen embryo transfer|endometrial biopsy will be done one cycle before the frozen embryo transfer
16385656|NCT04079946|Active Comparator|patients for whom Complete mesocolic excision will be done|
16385657|NCT04079946|Active Comparator|patients had conventional surgery before|
16385658|NCT04079933|No Intervention|Group 1: Continue Smoking|Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks
16385659|NCT04079933|Experimental|Group 2: OTDN|Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint) also under ad libitum conditions
16385660|NCT04079907|Experimental|Ketone|This arm will receive a supplement with 25g ketone ester. It is a commercially available supplement and will be provided as a standard dose.
16385661|NCT04079907|Placebo Comparator|Placebo|This arm will receive an isocaloric supplement.
16385662|NCT04079894||LSS Participants|Patients with lumbar spinal stenosis
16385663|NCT04079894||Healthy Participants|Healthy Participants
16385664|NCT04079881|Experimental|Pre-prandial insulin|will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.
16385665|NCT04079881|Experimental|Post-prandial insulin|will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.
16385666|NCT04079868|Experimental|Bone Health Service arm|Interventional arm
16385667|NCT04079868|No Intervention|Usual care (control) arm|"This arm represents a no practice management support control group."
16385668|NCT04079855|Experimental|Diet composition 1|A diet with a specified macronutrient composition different from arms 2, 3, and 4.
16385669|NCT04079855|Experimental|Diet composition 2|A diet with a specified macronutrient composition different from arms 1, 3, and 4.
16385670|NCT04079855|Experimental|Diet composition 3|A diet with a specified macronutrient composition different from arms 1, 2, and 4.
16385671|NCT04079855|Experimental|Diet composition 4|A diet with a specified macronutrient composition different from arms 1, 2, and 3 based on the current information about the US macronutrient composition.
16385672|NCT04079803|Placebo Comparator|Placebo Cohort|Subjects administered placebo oral tablets twice daily (BID)
16385673|NCT04079803|Experimental|Simufilam (PTI-125) 100 mg tablets Cohort|Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)
16385674|NCT04079803|Experimental|Simufilam (PTI-125) 50 mg tablets Cohort|Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)
16385675|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
16385676|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
16385677|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
16385678|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
16385679|NCT04079777||Clinical diagnosis of severe acute pancreatitis|"1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation.
~2. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases.
~3. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology.
~4, can except other similar clinical manifestations of lesions."
16385680|NCT04079777||mtDNA|"Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria.
~They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother."
16385681|NCT04079764||active surveillance|Patient with Bosniak III or IV lesion that decide to be followed under active surveillance
16385682|NCT04079764||Surgery|Patient with Bosniak III or IV lesion that decide to undergo a definitive treatment such as surgery
16385683|NCT04079751|Active Comparator|Neutral Mechanical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
16385684|NCT04079751|Active Comparator|Anatomical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
16385685|NCT04079738|Experimental|Phase I:TAK-659 + Ixazomib|Phase I: TAK-659 (Days 1-15) + Ixazomib dose escalation (Days 1, 8, 15)
16385686|NCT04079738|Experimental|Phase II:TAK-659 + Ixazomib|Phase II: TAK-659 at MTD (Days 1-15) + Ixazomib at MTD (Days 1, 8, 15)
16385687|NCT04079725|Experimental|Experimental : Infants with primary congenital glaucoma|
16385774|NCT04079179|Experimental|Patients < 30 years with recurrent LCH (Grp1)|Children and young adults (<30 years) with recurrent active LCH lesions (may also have LCH-ND).
16385689|NCT04079699|Experimental|Liquid Biopsy|"Experimental arm where the liquid biopsy decides whether to perform an prostate biopsy or not"
16385690|NCT04079699|Other|Standard Biopsy|Standard arm, where every patient receives a standard prostate biopsy
16385691|NCT04079686|Experimental|Cephazolin|Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
16385692|NCT04079686|Placebo Comparator|Sterile saline|Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
16385695|NCT04079660||Surgical patients|Diabetic patients scheduled to undergo non-cardiac surgery
16385696|NCT04079647||Patient with endocrinopathy after immunotherapy|Patient with endocrinopathy after immunotherapy
16385697|NCT04079634|Experimental|Treatment|Placement of study device (EnsoETM) for temperature management
16385698|NCT04079634|Active Comparator|Control|Placement of standard temperature probe
16385699|NCT04079621|Experimental|(P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days plus a low dose course of primaquine (PQ) (3.5mg/kg total dose) given 7 days during schizontocidal treatment
16385700|NCT04079621|Experimental|(P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (3.5mg/kg total dose) given over 7 days during schizontocidal treatment.
16385701|NCT04079621|No Intervention|Standard care (P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days (plus a single dose PQ)
16385702|NCT04079621|No Intervention|Standard care (P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (total dose 3.5mg/kg) over 14 days
16385703|NCT04079608|Experimental|FLASH curriculum|Students who will receive the FLASH high school curriculum.
16385704|NCT04079608|Active Comparator|Sexual Health Education for Adolescents|Students will receive a five-session knowledge-based sexual health curriculum designed for classroom settings.
16385705|NCT04079595|Experimental|Open-faced head immonbilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with openings for the face
16385706|NCT04079595|Active Comparator|Closed-face head immobilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with the face closed
16385707|NCT04079582|Experimental|Higher dialysate magnesium|
16385708|NCT04079582|Active Comparator|Lower dialysate magnesium|
16385709|NCT04079569|Experimental|Tobacco|"Participants will receive education delivered by a lay health worker on Quit Smoking For a Healthy Family. Participants will receive written information on nutrition and physical activity."
16385710|NCT04079569|Active Comparator|Healthy Living|"In this comparison arm, participants will receive education delivered by the lay health worker about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
16385711|NCT04079556|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
16385712|NCT04079543|Other|Strict NPO|NPO after midnight. No solids or liquids after midnight.
16385713|NCT04079543|Other|Liberal NPO|No solids after midnight. Clear liquids up to 2 hours prior to surgery.
16385714|NCT04079530|Experimental|Treatment A|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
16385715|NCT04079530|Experimental|Treatment B|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
16385716|NCT04079530|Experimental|Treatment C|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
16385717|NCT04079530|Experimental|Treatment D|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
16385718|NCT04079530|Experimental|Treatment E|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
16385719|NCT04079530|Experimental|Treatment F|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
16385720|NCT04079530|Experimental|Treatment G|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
16385721|NCT04079530|Experimental|Treatment H|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
16385722|NCT04079530|Experimental|Treatment I|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
16385723|NCT04079530|Experimental|Treatment J|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
16385724|NCT04079530|Experimental|Treatment K|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
16385725|NCT04079530|Experimental|Treatment L|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
16385726|NCT04079517|Experimental|Tamoxifen 10mg|Randomised dose of daily oral Tamoxifen 10mg, for 180 days
16385727|NCT04079517|Active Comparator|Tamoxifen 20mg|Randomised dose of daily oral Tamoxifen 20mg, for 180 days
16385728|NCT04079504|Active Comparator|Ligation|Ligation of indirect inguinal hernia sac in inguinal hernioplasty patients
16385729|NCT04079504|Experimental|Non-ligation|Non-Ligation of Indirect inguinal hernia sac/ simple inversion/reduction of indirect inguinal hernia sac in inguinal hernioplasty patients
16385730|NCT04079491||dental hygienists|all dental hygienists members in the trade union for dental hygienists
16385731|NCT04079478||AI|Artificial Intelligence colonoscopy
16385732|NCT04079478||Control|White light colonoscopy
16385733|NCT04079465|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 24 hours or until weaning from oxygen supplementation
16385912|NCT04078373||With urinary disorders|Subacute stroke patients with urinary disorders
16385735|NCT04079452|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks
16385736|NCT04079439|Other|Intervention|Tailored e-heath support for physical activity with a focus on communication and rewards, using commercial accelerometers for measurements
16385737|NCT04079439|No Intervention|Control group|Standard care
16385738|NCT04079413|Experimental|GP40071|Subcutaneous (SC), before meals intake, up to Week 26
16385739|NCT04079413|Active Comparator|NovoRapid® Penfill®|Subcutaneous (SC), before meals intake, up to Week 26
16385740|NCT04079400||Tb group|Subjects who underwent bronchoscopy for suspicious endobronchial pulmonary tuberculosis (Tb) observed on chest computed tomography
16385741|NCT04079400||NTM-PD group|Subjects who underwent bronchoscopy for suspicious non-tuberculous mycobacterial pulmonary disease (NTM-PD) observed on chest computed tomography
16385742|NCT04079400||LC group|Subjects who underwent bronchoscopy for suspicious endobronchial lung cancer (LC) observed on chest computed tomography
16385743|NCT04079400||HM group|Subjects who underwent bronchoscopy for hemoptysis
16385744|NCT04079400||Control group|Subjects who underwent bronchoscopy to rule out endobronchial lesion observed on chest computed tomography. Endbronchial lesion should not be typical for any category of respiratory diseases including tuberculosis, NTM-TB and lung cancer.
16385745|NCT04079387|Experimental|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°."
16385746|NCT04079387|Active Comparator|ENDOTRACHEAL TUBE ALONE|The control group consists in intubating the trachea with an endotracheal tube alone (i.e, without stylet).
16385747|NCT04079374|Experimental|Etanercept|Patients receive Etanercept in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
16385748|NCT04079374|Active Comparator|Enbrel|Patients receive Enbrel in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
16385749|NCT04079361|Other|Pregnancy complication|Intervention: blood samples
16385750|NCT04079348|Active Comparator|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application Oasis Extracellular Matrix to their donor site wound.
16385751|NCT04079348|Active Comparator|Standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
16385752|NCT04079322|Experimental|Exercise|During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
16385753|NCT04079322|Experimental|Rest|"The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (<6 miles at a self-described easy pace) later in the afternoon."
16385754|NCT04079309|No Intervention|No Intervention|No mist will be diffused into the environment.
16385755|NCT04079309|Active Comparator|Lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
16385756|NCT04079309|Active Comparator|Orange|0,3 ml orange oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
16385757|NCT04079296|Experimental|Phase 1 ASP7517 Dose Escalation|Two single doses of ASP7517 will be administered intravenously at up to 3 dose levels and will be based on the assessment of safety variables, including the occurrence of dose limiting toxicities (DLTs).
16385758|NCT04079296|Experimental|Phase 2 ASP7517 Dose Expansion|Up to six single doses of ASP7517 will be administered intravenously at the dose levels determined from the Dose Escalation phase.
16385759|NCT04079283||Monotherapy|Patients who has received mono-therapy of immune checkpoint inhibitor.
16385760|NCT04079283||Combined therapy|Patients who has received immune checkpoint inhibitor combining chemotherapy.
16385761|NCT04079270|Experimental|Personalized algorithm-based diet|The intervention arm will be an 'algorithm-based' arm in which patients will receive personally tailored dietary recommendations, based on their microbiome, and other clinical data such as blood tests and lifestyle features.
16385762|NCT04079270|Active Comparator|standard Mediterranean low-fat diet|The control arm will receive nutritional recommendations according to the standard Israeli dietary approach Mediterranean-style low-fat diet.
16385763|NCT04079257||Patients with paroxysmal nocturnal hemoglobinuria|Patients are already treated with eculizumab. The only intervention is the collection of extra blood samples to measure peak concentrations of eculizumab
16385764|NCT04079244|Active Comparator|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.
~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children"
16385765|NCT04079244|Active Comparator|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.
~The cartoon used is L'âge de glace, an animated cartoon geared to children."
16385766|NCT04079231|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
16385767|NCT04079231|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
16385768|NCT04079218|Experimental|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
16385769|NCT04079218|No Intervention|No treatment|No intervention
16385770|NCT04079205|Experimental|Home rehabilitation using Wearable Device|Home rehabilitation using Wearable Device(exoRehab)
16385771|NCT04079205|Active Comparator|Control|Standard home rehabilitation program
16385772|NCT04079192|Experimental|Biolimus A9™ Drug Coated Balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon
16385946|NCT04078152|No Intervention|Off Treatment|Follow up Only
16385775|NCT04079179|Experimental|Patients of any age with LCH-ND (Grp2)|Patients of any age with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
16385776|NCT04079179|Experimental|Patients <30 years with other histiocytic disorders (Grp3)|Newly diagnosed or relapsed/refractory children and young adults (<30 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
16385777|NCT04079179|Experimental|Patients ≥ 30 years with LCH/histiocytic disorders (Grp4)|Adults (≥30 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
16385778|NCT04079166|Experimental|SCIB1|SCIB1 administered using the TDS-IM v2.0 device
16385779|NCT04079153|Active Comparator|25% of maximal mandibular advancement|25% of maximal mandibular advancement of individual protrusion range
16385780|NCT04079153|Active Comparator|50% of maximal mandibular advancement|50% of maximal mandibular advancement of individual protrusion range
16385781|NCT04079140|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
16385782|NCT04079140|Placebo Comparator|placebo|one tablet of placebo self-administered by the patient 12 hours before IUD insertion.
16385783|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
16385784|NCT04079101|Experimental|BIIB104 0.15 mg|Participants will receive multiple oral doses of BIIB104 0.15 mg capsules twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10.
16385785|NCT04079101|Experimental|BIIB104 0.5 mg|Participants will receive multiple oral doses of BIIB104 0.5 mg capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
16385786|NCT04079101|Experimental|Placebo|Participants will receive multiple oral doses of placebo-matched BIIB104 capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
16385787|NCT04079088|Placebo Comparator|Placebo|Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
16385788|NCT04079088|Experimental|BIIB061 Dose 1|Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
16385789|NCT04079088|Experimental|BIIB061 Dose 2|Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
16385790|NCT04079088|Experimental|BIIB061 Dose 3|Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
16385791|NCT04079075|Experimental|Non-pharmacological intervention|"Non-pharmacological strategy, implemented in groups of 10 participants, over 10 consecutive months, based on five different interventions:
~cognitive training, physical activity; nutrition education; adaption to memory loss; detection and correction of hearing impairment."
16385792|NCT04079062|Experimental|ONO-4685 (PartA, D)|
16385793|NCT04079062|Placebo Comparator|Placebo (PartA, D)|
16385794|NCT04079062|Experimental|KLH+placebo (Part B)|
16385795|NCT04079062|Experimental|KLH+ONO-4685 (PartC)|
16385796|NCT04079062|Experimental|KLH+placebo (PartC)|
16385797|NCT04079049|Experimental|Surgical intervention|Surgical and oncological treatment
16385798|NCT04079049|Active Comparator|Control|Oncological treatment
16385799|NCT04079036||Underweight Adult Male|Male patients with Underweight BMI classification and more than 20 years old https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
16385800|NCT04079036||Healthy Weight Adult Male|Male patients with Healthy Weight BMI classification and more than 20 years old
16385801|NCT04079036||Overweight Adult Male|Male patients with OverWeight or Obese BMI classification and more than 20 years old
16385802|NCT04079036||Underweight Adult Female|Female patients with Underweight BMI classification and more than 20 years old
16385803|NCT04079036||Healthy Weight Adult Female|Female patients with Healthy Weight BMI classification and more than 20 years old
16385804|NCT04079036||Overweight Adult Female|Female patients with Overweight or Obese BMI classification and more than 20 years old
16385805|NCT04079036||Underweight children Male|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
16385806|NCT04079036||Healthy Weight children Male|Male patients less than 20 year old, and with Healthy Weight BMI classification
16385807|NCT04079036||Overweight children Male|Male patients less than 20 year old, and with Overweight or Obese BMI classification
16385808|NCT04079036||Underweight children Female|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
16385809|NCT04079036||Healthy Weight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
16385810|NCT04079036||Overweight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
16385811|NCT04079023||Obese|30 obese patients (12 M/ 18 F) with a mean BMI of 46 candidate to SG Alcohol drink mean volume: 158 Ml administered in 10 minutes
16385812|NCT04079010|Placebo Comparator|Control|Participants will adhere to resistance training protocol.
16385813|NCT04079010|Active Comparator|BFR (blood flow restriction)|Participants will adhere to resistance training protocol, while also applying a blood flow restriction cuff during resistance training.
16385814|NCT04079010|Active Comparator|BFR (blood flow restriction), plus Arginine|Participants will adhere to resistance training protocol, apply a blood flow restriction cuff during resistance training, and will take the clinically safe dose of arginine prior to training sessions.
16385815|NCT04078997||PCV13-vaccinated,15-24 months of age|"Recruitment for carriage surveillance (primary endpoint) will take place at randomly selected households within each of the catchment areas (zones) of the 20 selected health centers.
~Sampling: Random sampling from populations will occur preferentially around the health centers and not from the population on the zonal interfaces. Researchers will designate two geographic sampling areas within each zone around each health center that allows a buffer against zonal borders. If the recruitment target within first sampling area is not met, sampling will move into the second area."
16386511|NCT04074408|Experimental|Cohort 1|low dose hUMSCs or high dose hUMSCs
16385816|NCT04078997||PCV13-vaccinated, 5-10 years of age|"Six schools will be selected: three located centrally in each of the 3+0 zones, and three in the 2+1 zones.
~Sampling: Children will be randomly chosen and recruited from each school. NP swab collection will occur during two surveys, starting 21 and 34 months after the switch to 2+11.
~Mapping analysis from our current surveillance activities shows good clustering of recruited children living around the school, suggesting limited movement and thus low risk of contamination between zones with different vaccination schedules."
16385817|NCT04078997||PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of|"Adults will be recruited from the Queen Elizabeth Central Hospital (QECH), Lighthouse ART clinic in Blantyre.
~Sampling: Mapping analysis from current surveillance activities shows good distribution throughout the Blantyre area, suggesting it is possible to achieve balance between those adults residing in 2+1 vs 3+0 areas. Sample collection will be on a rolling basis throughout the study period, starting 18 months after switch to 2+1."
16385818|NCT04078997||PCV13-vaccinated, 9 months of age|"Recruitment will take place at vaccination centers.
~Sampling: A convenience sample of NP swabs will be collected at the 9-month (measles-1) visit. Sample collection will occur 9 months after the switch to 2+1 schedule."
16385819|NCT04078984||Experimental|Experimental group is composed by patients that enter the weaning phase following a moderate to severe Acute Respiratory Distress Syndrome (ARDS) equiped with a nasogastric allowing measures of Electrical Activity of diaphragm (EAdi) will be included. Driving Pressure will be measured following the method used by Bellani et al. A weaning test will be conducted daily.
16385820|NCT04078971|Experimental|Ketogenic diet|Ketogenic diet: less than 30 g/day of carbohydrate. Subjects can eat beef, veal, poultry, fish, raw and cooked vegetables without restriction, cold cuts such as dried beef, eggs and seasoned cheese (parmesan), ketogenic pasta (selected with a ketogenic ratio of 4:1), fruits with the lowest glycemic index (blueberry, raspberry), raw nuts and seeds, ghee butter, plant oils and fats from avocado, coconut and olives
16385821|NCT04078971|Active Comparator|Western diet|The western diet (WD) is composed mainly of whole cereals (spelt, rye, oat) and pseudo-cereals (buckwheat, quinoa, amaranth), whole grain pasta, potatoes, meet, fish, vegetables, fruit, legumes, olive oil, milk and red wine (at most 1 glass per day). It ensure a constant energy and macronutrient balance: protein 1.8g x Kg-1 x body weight-1 x day-1, (30%), fats 20-25% and carbohydrate 50-55%.
16385822|NCT04078958|Experimental|Salmon fishmeal|5 g fishmeal in capsules, single oral dose
16385823|NCT04078958|Active Comparator|Whey|5 g whey in capsules, single oral dose
16385824|NCT04078932|Experimental|Intervention|Cohort of residents trained in the conversation script who will utilize the script at pediatric clinic visits. Will evaluate baseline feelings of comfort and self-efficacy prior to being trained in the script (pre-intervention measures). After being trained in the conversation script (the intervention), the following will be measured (post-intervention measures): frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
16385825|NCT04078932|No Intervention|Control|Cohort of residents at another clinical site with a similar community demographic make-up who do not receive the intervention. In the control group, we will measure frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
16385826|NCT04078919|Active Comparator|Low calorie diets with nuts|Low calorie diet in which 20 percent of daily calories will be provided from nuts
16385827|NCT04078919|Placebo Comparator|Low calorie diet|Low calorie diet
16385828|NCT04078906|No Intervention|Control group|Conventional IVLE (Intralipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
16385829|NCT04078906|Experimental|Experimental group|n3-LCPUFA enriched IVLE (SMOFlipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
16385830|NCT04078893|No Intervention|control group|
16385831|NCT04078893|Experimental|on need group|
16385832|NCT04078893|Experimental|communication group|
16385833|NCT04078880|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus ascorbic acid, other than the standard of care.
16385834|NCT04078880|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
16385835|NCT04078867||DeVega|The DeVega repair is performed when the patient had minimal annular dilation and lower severity of pulmonary hypertension
16385836|NCT04078867||MC3 ring|MC3 ring annuloplasty is performed in patients with severe tricuspid annular dilation and severe pulmonary hypertension
16385837|NCT04078854|Experimental|Foot amputation, sexual health|Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health
16385838|NCT04078854|Active Comparator|Foot amputation, no sexual health|Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health
16385839|NCT04078841|Active Comparator|ReaLife+ (RLP)|Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
16385840|NCT04078841|Placebo Comparator|Inert Brown Powder|"Brown powder
~Inert brown powder to look similar to RLP"
16385841|NCT04078841|No Intervention|Control|Control
16385842|NCT04078828|Active Comparator|PR|
16385843|NCT04078828|Active Comparator|Non-PR|
16385844|NCT04078802|Experimental|VNOTES ARM|treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.
16385845|NCT04078802|Experimental|Vaginal hysterectomy Arm|treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.
16385846|NCT04078776||Lean Individuals|waist circumference ≤94 cm (men) and 80 cm (women) and BMI ≥ 21.0 kg/m2
16385847|NCT04078776||Obese Individuals|waist circumference ≥102cm (men) and 88 cm (women) and BMI ≥ 30.0kg/m2
16385848|NCT04078763|Experimental|visual-auditory feedback|Patients included in this arm will follow the rehabilitation protocol with visual-auditory feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
16385849|NCT04078763|Experimental|visual feedback|Patients included in this arm will follow the rehabilitation protocol with visual feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
16385850|NCT04078750|Sham Comparator|Phase I. Control group|"The standard of care will be provided to the control group pre- and post-transplant. This does not involve any direct pre-transplant assessment of medication adherence or risk factors for non-adherence.
~Tacrolimus capsules will be dispensed in Medication Event Monitoring System (MEMS) caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.
~Patients will be asked to complete Basel Assessment of Adherence to Immunosuppressive Medication instrument (BAASIS) questionnaire and Long-term Medication Behaviour Self-efficacy Scale at 3 months after transplantation."
16385851|NCT04078750|Experimental|Phase II. Intervention group|Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial. Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules. MEMS® is designed to record the date/time of opening and closure of the drug vial. Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day. Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant.Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence. Patients will also undergo health literacy, cognition testing, self-efficacy tests, with a customized post-transplant plan.
16385852|NCT04078737|Experimental|Ticagrelor plus Aspirin Group|Ticagrelor of loading dosing of 180mg followed by 90mg bid for 3 months plus aspirin of loading dose of 75-300mg followed by 75mg daily for 21 days
16385853|NCT04078737|Active Comparator|Clopidogrel plus Aspirin Group|Clopidogrel of loading dosing of 300mg followed by 75mg daily for 3 months plus aspirin loading dose of 75-300mg followed by 75mg daily for 21 days
16385854|NCT04078724|Active Comparator|Normal subject without 5-HTP|Subjects with normal cognition will be randomly assigned to not consuming 5-HTP.
16385855|NCT04078724|Experimental|Normal subject with 5-HTP|Subjects with normal cognition will be randomly assigned to consuming 100 mg of 5-HTP.
16385856|NCT04078711|Experimental|losartan & qianyangyuyin|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
16385857|NCT04078711|Placebo Comparator|Losartan & Placebo|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
16385858|NCT04078685|Active Comparator|CONVENTIONAL group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter
16385859|NCT04078685|Experimental|CONTACT-FORCE group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter
16385860|NCT04078672|Experimental|AMD|NOTAL-OCT V3.0 scan
16385861|NCT04078659|Experimental|Propofol infusion|Patients received intravenous Propofol infusion
16385862|NCT04078659|Experimental|Magnesium Sulfate infusion|Patients received intravenous Magnesium Sulfate infusion
16385863|NCT04078646|Experimental|Dietary intervention|Intervention with test meal only
16385864|NCT04078646|Experimental|Dietary intervention 2|Intervention with test meal and whey protein isolate (30 g)
16385865|NCT04078646|Experimental|Dietary intervention 3|Intervention with test meal and soy protein (30 g)
16385866|NCT04078633|Experimental|Normal Liquid Soap (250mL)|A normal hygiene kit will be distributed to the households. In addition, a liquid soap will be added to see the impact of having a liquid soap for hand washing on hygiene behaviors.
16385867|NCT04078633|Experimental|Bar soap (250gram)|A normal hygiene kit will be distributed to the households. In addition, a nice bar soap will be added to see the impact of having a nicer bar soap for hand washing on hygiene behaviors.
16385868|NCT04078633|Experimental|Mirror (50x30cm)|A normal hygiene kit will be distributed to the households. In addition, a mirror will be added to see the impact of having a mirror by the handwashing stand on handwashing behaviour. The mirror will have a plastic edge and be 30x 50cm in size.
16385869|NCT04078633|No Intervention|Control|A normal hygiene kit will be distributed to the households. No additional interventions will be given.
16385870|NCT04078633|Experimental|Nurture story for hygiene promotion|Hygiene promoters will share a story of being a good parent through teaching their children to do hand washing with soap at critical times. A story about a good mother who every day reminds her child to wash her/his hands before eating or preparing food and after going to the toilet will be shared with participants. The story ends with the child growing up healthy, happy and with a good education. This story if belived to increae handwashing with soap in the household/
16385871|NCT04078633|Experimental|Comfort story for hygiene promotion|Hygiene promoters will deliver hygiene promotion through an activity that provoke the feeling of comfort by having clean hands. Hygiene promoters will deliver this intervention to up to 5 neighbor households at the time, sharing a story about a family that keeps good hygiene behaviors and therefore are clean, healthy and happy. This story is believed to encourage families to increase handwashing with soap in the household.
16385872|NCT04078633|No Intervention|Education session for hygiene promotion|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
16385873|NCT04078633|Experimental|Hygiene Promotion Activity - Disgust|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will use 5 buckets of clean water and place them in front of households. They will then ask a member of one of the households to rinse their hands in the first bucket. Some dirt will come of their hands. Then the participant rinses their hands again in bucket number 2, then 3 and then 4. Before the 5th bucket the participant receives a bar of soap to use when they rinse their hand. When they do the water will have a dirty colour as the dirt comes of their hands. This activity is believed to encourage handwashing with soap.
16385906|NCT04078412||NTM pulmonary disease|Cohort Description: adults NTM pulmonary disease patients diagnose by criteria of American thoracic society guideline
16385907|NCT04078399|Experimental|patients with recurrence after allogeneic transplantat|One arm
16385908|NCT04078386|Experimental|RC18 240mg|
16385909|NCT04078386|Experimental|RC18 160 mg|
16385910|NCT04078386|Placebo Comparator|Placebo|
16385874|NCT04078633|Experimental|Hygiene Promotion Activity - Comfort|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will bring some food oil and ask participants to cover their hands in food oil. They will then ask the participants to cover their hands in turmeric powder. The participants will then be asked to wash their hands with water only. This will have little effect on the cleanliness of their hands. Then participants will be given a bar of soap. The participants will then be asked to wash their hands again. This will leave their hands nice comfortable and clean. They will experience the comfort of clean hands and the activity hope to increase regular handwashing.
16385875|NCT04078633|No Intervention|Education Hygiene Promotion Activity|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
16385876|NCT04078607|Experimental|Distraction|Distraction during eating using the Rapid Visual Information Processing task as the distraction
16385877|NCT04078607|Placebo Comparator|Control|No distraction during eating
16385878|NCT04078594|Experimental|Experimental wards|Active sepsis e-alert
16385879|NCT04078594|No Intervention|Contol wards|"Masked sepsis e-alert.
~The wards will have masked sepsis e-alert."
16385880|NCT04078581|Experimental|healthy controls|Questionnaire and fecal sample collection
16385881|NCT04078568|Active Comparator|the standard group|"IVIG 2g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
16385882|NCT04078568|Experimental|the standard+prednisolone group|"IVIG 2g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
~Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued."
16385883|NCT04078555|Experimental|ENERGI-F703 GEL|topical application on target venous leg ulcer, twice daily
16385884|NCT04078555|Placebo Comparator|ENERGI-F703 GEL matched vehicle|topical application on target venous leg ulcer, twice daily
16385885|NCT04078542||Chronic cough|Subject complaining cough from at least 8 weeks
16385886|NCT04078529|Experimental|Intervention group|This group will complete a 5 day falls prevention training programme, followed by a 12 week home exercise programme, then a repeat 5 day training intervention.
16385887|NCT04078529|Active Comparator|Comparison group[|This group will complete the home exercise programme only.
16385888|NCT04078516||Type 1 diabetes and painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
16385889|NCT04078516||Type 1 diabetes and non-painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
16385890|NCT04078516||Type 1 diabetes and no neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
16385891|NCT04078516||Matched controls without diabetes|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
16385892|NCT04078503||Case|All patients aspected to stay in ICU for at least 3 days who will develop delirium
16385893|NCT04078503||Control|All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).
16385894|NCT04078477|Experimental|Lateral tilt bed|Special lateral tilt bed.
16385895|NCT04078477|No Intervention|Body positioning|Standard NICU preventive strategy
16385896|NCT04078464|Experimental|Acute Physical Activity + Mindfulness training|20 minutes of walking on a treadmill at a moderate pace while listening to a pre-recorded guided mindfulness meditation.
16385897|NCT04078464|Experimental|Mindfulness training|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 20 minutes.
16385898|NCT04078464|Experimental|Acute Physical Activity|20 minutes of walking on a treadmill at a moderate pace.
16385899|NCT04078451|Experimental|the experimental group|"The experimental group operated by the left side of laparoscopic cholecystectomy preserving the main cystic artery.
~The operation area of cystic artery dissection is moved from the traditional triangular area to the gallbladder neck plane, away from the hepatic duct and hepatic portal.Only the superficial and even more minute branches of the cystic artery were isolated and coagulated."
16385900|NCT04078451|No Intervention|the control group|treated with conventional laparoscopic cholecystectomy cutting the cystic artery
16385901|NCT04078438|Experimental|neurofeedback augmentation group|The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
16385902|NCT04078438|Active Comparator|medication-only (treatment as usual, TAU) group|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
16385903|NCT04078438|No Intervention|healthy controls|The healthy controls provided blood samples using the same procedure at baseline only.
16385904|NCT04078425|Experimental|HF with preserved EF|50patients of heart failure with preserved ejection fration will receive anti.failure treatment(lanoxin,beta blocker,diuretics) for one month with follow up echocardiography before and after
16385905|NCT04078425|Experimental|HF with preserved EF recive eplernone|50 patients with heart failure with preserved ejection frationnwill receive traditional anti-failure treatment in addition to aldosterone antagonist (Eplernone) with follow up echocardiography and aldosterone level before and after
16385913|NCT04078360|Experimental|Mobile-based intervention (AMBIT)|This arm will receive a mobile based program delivered over messages/IVR calls.
16385914|NCT04078360|Active Comparator|Face-to-face counselling|This arm will receive a brief counselling session from a trained health worker.
16385915|NCT04078360|Active Comparator|Active control|This arm will receive an educational BI leaflet.
16385916|NCT04078347||Successful Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
16385917|NCT04078347||Failed Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
16385918|NCT04078334|Experimental|Group 1|PATH Tool : Prescription of exercise programs at discharge
16385919|NCT04078334|Experimental|Group 2|PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
16385920|NCT04078334|Experimental|Group 3|MATCH tool: Prescription of physical exercise programs during hospitalization
16385921|NCT04078334|No Intervention|Group 4|Control group: Usual care by the clinical teams
16385922|NCT04078321|Experimental|Single case design|Single case studies
16385923|NCT04078308|Experimental|Mesenchymal Stem Cells Transplantation|The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells
16385924|NCT04078308|Placebo Comparator|Placebo|The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)
16385925|NCT04078295|Experimental|Phase 1b: E7389-LF + Nivolumab|Participants will receive specified doses of E7389-LF (intravenous) and nivolumab (intravenous) on specified days.
16385926|NCT04078295|Experimental|Phase 2, Cohort-1: E7389-LF + Nivolumab|Participants with gastric cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
16385927|NCT04078295|Experimental|Phase 2, Cohort-2: E7389-LF + Nivolumab|Participants with esophageal cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
16385928|NCT04078295|Experimental|Phase 2, Cohort-3: E7389-LF + Nivolumab|Participants with small cell lung cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
16385929|NCT04078282|Experimental|Active treatment group|Patients will meet in a joint consultation with their family physician and a psychiatrist for evaluation. Then it follows three treatment sessions with the family physician before a new joint consultation with the psychiatrist. The intervention ends with three more treatment sessions with the family physician.
16385930|NCT04078282|Active Comparator|Control group|Patients belonging to family physicians who constitute the control group will be assessed and given treatment according to usual care. This may include treatment by the family physician, medication, referrals to specialized care.
16385931|NCT04078269|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIXNEO-LUNG autologous DC vaccine
16385932|NCT04078256|Experimental|Experimental group|Group will carry out the proprioceptive exercise program during 8 weeks at the begining of the season
16385933|NCT04078256|Placebo Comparator|Control group|Control group will continue with their usual training routine
16385934|NCT04078243||CardioMEMS HF System|Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.
16385935|NCT04078230|Experimental|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
16385936|NCT04078230|No Intervention|Regional LymphAdenectomy|Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.
16385937|NCT04078217|Experimental|Jintronix|Jintronix Rehabilitation System uses Microsoft Kinect cameras to track patient's movements in 3D during exercises. They are programmed as games that are visualized on a TV and for which performance feedback is provided to the participant. Individualized asynchronous supervised home-base exercise program using the Jintronix System, 3 times/week for 12 weeks (36 sessions). A trained kinesiologist will install the system and supervise the exercise program, in person and remotely.
16385938|NCT04078217|Active Comparator|Control|Participants in this group will follow an individualized non-supervised home-based exercise program (booklet format). The exercise program will include 3 sessions per week for 12 consecutive weeks, as for Jintronix group. Actually, all movements of the booklet program are selected to match the exercise-games of the technology (similar movement, muscles engagement, etc.). A trained kinesiologist will explain and supervise the exercise program for the first sessions. The communication frequence will be the same as the Jintronix group.
16385939|NCT04078204|Experimental|Butylphthalide Soft Capsules|Two Butylphthalide soft capsules will be taken three times a day before meals.
16385940|NCT04078204|Placebo Comparator|Placebo Soft Capsules|Two placebo soft capsules will be taken three times a day before meals.
16385941|NCT04078191|Experimental|RA Subjects on Stable Therapy|RA subjects who are on stable treatment will receive a single dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m.
16385942|NCT04078178|Other|Randomized Crossover|The primary outcome of this study will be objective measures of cognitive performance measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, crossover, and the end of study. Subjects will receive 1200 mg Niagen and PBO dispensed in randomized blocks. All subjects will receive both.
16385943|NCT04078165|Experimental|Zero-Gravity|In this group, the operator uses the Zero-Gravity protection system
16385944|NCT04078165|Active Comparator|Conventional|In this group, the operator uses conventional radiation protection
16385945|NCT04078152|Experimental|Treatment|Durvalumab Monotherapy
16385947|NCT04078139|Experimental|The MP/RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 40mg methylprednisolone, plus 10ml saline;
16385948|NCT04078139|Active Comparator|The RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10ml saline;
16385949|NCT04078126|Experimental|Budesonide and formoterol fumarate (MDI BFF)|Subject treated with MDI BFF followed by washout period
16385950|NCT04078126|Active Comparator|Symbicort Turbuhaler|Subject treated with Symbicort followed by washout period
16385951|NCT04078113|Experimental|Experimental group|Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.
16385952|NCT04078113|No Intervention|Control group|"Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.
~Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not."
16385953|NCT04078100||group A|underwent mitral valve surgery through transseptal approach.
16385954|NCT04078100||group B|underwent mitral valve surgery through conventional left atrial approach.
16385955|NCT04078087||Non obese|"Non obese (whether normal weight or overweight) = Group NO"
16385956|NCT04078087||Obese|"obese = Group O"
16385957|NCT04078074|Experimental|Maxillary OSS|
16385958|NCT04078074|Experimental|Mandibular OSS|
16385959|NCT04078074|Experimental|Modified farrar splint|
16385960|NCT04078061|Active Comparator|MABA|
16385961|NCT04078061|Active Comparator|EIBI|
16385962|NCT04078048|Experimental|Vitamin C Group|Tablet Vitamin C 500 mg Once a day
16385963|NCT04078048|Experimental|Vitamin E Group|Tablet Vitamin E 600 I U Twice daily
16385964|NCT04078048|Placebo Comparator|Placebo Group|Capsule Paraffin oil 500 mg Once a day
16385965|NCT04078035|Experimental|Socio-evaluative Speech Stress, then Control|Participants will attend two laboratory sessions. At the first session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated. At the second session, participants will rest quietly for the same period as the speech task, in the absence of the stressor.
16385966|NCT04078035|Experimental|Control, then Socio-Evaluative Speech Stress|Participants will attend two laboratory sessions. At the first session, participants will rest quietly for 5 minutes. At the second session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated.
16385967|NCT04078022|Experimental|Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
16385968|NCT04078022|Experimental|Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
16385969|NCT04078022|Experimental|Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
16385970|NCT04078022|Experimental|Cohort 4: Shigella Vaccine Only, No Challenge|All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.
16385971|NCT04078009|Experimental|Aquagen (Starts with Aquagen and finish with Grazax)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
16385972|NCT04078009|Experimental|Grazax (Starts with Grazax and finish with Aquagen)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
16385973|NCT04077996|Active Comparator|Peritonitis treatment with one exchange in CAPD|This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
16385974|NCT04077996|Experimental|Peritonitis treatment placed in APD|This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
16385975|NCT04077983|Experimental|combined therapy using nab-paclitaxel and gemcitabine chemo|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2
~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2
~Three weeks is a course of treatment with a total of 4 courses."
16385976|NCT04077970|Experimental|Intrauterine flushing follicular fluid|Women underwent intrauterine flushing with follicular fluid plus granulosa cells
16385977|NCT04077970|No Intervention|Without intrauterine flushing with follicular fluid|Women without intrauterine flushing with follicular fluid
16385978|NCT04077957|Experimental|Group 1. Experimental|Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.
16385979|NCT04077957|Active Comparator|Group 2. Positive Control|Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.
16385980|NCT04077944||Preterm prelabor rupture of membranes|"The diagnosis of Preterm prelabor rupture of membranes was made in the case of apparent spontaneous leakage of AF from the cervical canal during sterile speculum inspection before the onset of active labor at 37 weeks of pregnancy. The study population consisted of 55 women with a singleton pregnancy who were diagnosed with pP-ROM between 24+0 and 36+6 weeks of gestation.
~The Amnisure test (AmniSure International LLC, Boston, MA) was used when there was inconclusive results to confirm the final diagnosis. The gestational age was determined by calculation from the last menstrual period and supported by the ultrasonography measurements at the first trimester of gestation."
16385981|NCT04077944||Control|The control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. Sixty healthy pregnant women who delivered at term were included in the study as the control group.
16385982|NCT04077931|Experimental|Aerobic exercises|She asked to start walking with the speed of the machine was adjusted at 0.8 km/hour, so her resting pulse rate increases, then we increased the speed by 0.2 km/hour gradually every 2 minute (to give a time for adjustment of heart rate) till reaching our target heart rate (not less than 60% and not more than 75% of target heart rate). So the intensity of exercises can be increase or decrease only by changing the speed of treadmill according to target heart rate [13]
16385983|NCT04077931|Experimental|Deep breathing exercises|Technique of breathing exercises: Regular aerobic exercises in a form breathing exercises included duration of 30 min. at 40-70% VO2 max. performed 2-3 per week. Each woman practiced deep breathing exercises 30 min. in the of form (diaphragmatic breathing exercises, 15 min. and lateral costal breathing exercises 15 min.) 3 times per week for 12 weeks.
16385984|NCT04077918|Active Comparator|Plant protein diet|18 g of plant protein diet added every day for 3 months , and after washout for 1 month, 18 g of animal protein diet added every day for 3 months
16385985|NCT04077918|Active Comparator|Animal protein diet|18 g of animal protein diet added every day for 3 months, and after washout for 1 month, 18 g of plant protein diet added every day for 3 months
16385986|NCT04077905|Experimental|DEP regimen|pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles
16385987|NCT04077892|Experimental|combination of budesonide and montelukast|receive treatment with either a combination of budesonide (Rhinorcort Astra Zeneca AB), 1 spray per nostril twice daily (total 256 μg/d) and 10mg oral montelukast tablet (Merck Sharp & Dohme Australia Pty Ltd) in the evening for 14 days (BD+MNT treatment group)
16385988|NCT04077892|Active Comparator|only intranasal budesonide|treatment with only intranasal budesonide 1 spray per nostril twice daily for 14 days (BD treatment group)
16385989|NCT04077879|Experimental|Single ascending dose of ASP1617|This is composed of 5 sequential cohorts (cohorts 1.1 to 1.5). Participants (6-9 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of ASP1617 under fasting conditions.
16385990|NCT04077879|Placebo Comparator|Single ascending dose of Placebo|Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
16385991|NCT04077879|Experimental|Single dose of ASP1617 (Food Effect)|Participants (6 Japanese and 3 non-Asian) will receive a single dose of ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
16385992|NCT04077879|Experimental|Multiple ascending dose of ASP1617|"This is composed of 3 sequential cohorts (cohorts 2.1 and 2.3). Participants (9 for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3) will receive ASP1617 for 14 consecutive days at the same dose level.
~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
16385993|NCT04077879|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3.
16385994|NCT04077866|Active Comparator|Temozolomide alone|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
16385995|NCT04077866|Experimental|Temozolomide + B7-H3 CAR-T|"Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
~The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide treatment in the cycles of B7-H3 CAR-T treatment will be stopped."
16385996|NCT04077853|Experimental|study group|women will be given 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter in addition to other conservative measures of early-onset PE
16385997|NCT04077853|No Intervention|control group|No intervention will be given apart from the usual conservative measures of early-onset PE
16385998|NCT04077840||NCGS/NCWS patients|Adult patients with a definitive diagnosis of NCWS, based on DBPC wheat challenge, most of them suffering from IBS-like-clinical presentation, according to Rome IV criteria. The patients were consecutively recruited between January 2016 and October 2017 at the outpatient clinics of the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (both in southern Italy)
16385999|NCT04077840||Heathy blood donors|Consecutive healthy blood donors sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients.
16386000|NCT04077840||IBS patients|"Consecutive patients with a diagnosis of IBS unrelated to NCWS or other types of food intolerance/allergy, who were consecutively recruited during the study period and sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients."
16386001|NCT04077827|Experimental|Total intravenous anesthesia|"The patients will recieve intravenous anesthesia (propofol-remifentanyl)
~Recommended dosage:
~Propofol: Induction dosage 1,5-2,5 mg/kg Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
16386002|NCT04077827|Experimental|volatile anesthesia|"The patients will recieve volatile anesthesia (desflurane-remifentanyl)
~Recommended dosage:
~Desflurane dosage 6-7 MAC Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
16386003|NCT04077814|Active Comparator|ShamtDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Sham Transcranial direct brain stimulation (tDCS)
16386004|NCT04077814|Experimental|tDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Transcranial direct brain stimulation (tDCS)
16386005|NCT04077801||Study group (group A)|"Maximal vertical mouth opening (MIO):
~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.
~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
16386006|NCT04077801||Control group (group B):|"Maximal vertical mouth opening (MIO):
~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.
~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
16386007|NCT04077788||Study group (group A):|It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
16386008|NCT04077788||control group (group B):|It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).
16386009|NCT04077775||Study group (group A):|"Study group (group ) Diagnostic Test: Study group (group A)24 women who have cyclic CPP
~I) Pelvic tilt angle:
~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
16386010|NCT04077775||Study group(group B):|"included 20 women who have non-cyclic CPP and the other 16 women of the participants were normal I)
~Pelvic tilt angle:
~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately. In contrast, the woman was in a standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer
~Diagnostic Test: Study group (group A)"
16386011|NCT04077775||Control group (group C):|"16 women of the participants were normal and considered the control group
~I) Pelvic tilt angle:
~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
16386012|NCT04077762|Active Comparator|Radial access|Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
16386013|NCT04077762|Active Comparator|State-of-the-art femoral access|Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
16386014|NCT04077749|Experimental|Probiotic|
16386015|NCT04077749|Placebo Comparator|Placebo|
16386016|NCT04077736|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
16386020|NCT04077697||ITBA group|ITBA group is : invasive tracheobronchitis aspergillosis form.
16386021|NCT04077697||IPA without tracheobronchial involvement|IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement
16386022|NCT04077684|Placebo Comparator|Placebo|placebo s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
16386023|NCT04077684|Active Comparator|IL-2 at 0.2MIU|0.2 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
16386024|NCT04077684|Active Comparator|IL-2 at 0.5MIU|0.5 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
16386025|NCT04077684|Active Comparator|IL-2 at 1.0MIU|1.0 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
16386026|NCT04077671|Experimental|SAD - Cohort A - CHF6467 0.3 µg/mm2|Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.
16386027|NCT04077671|Experimental|SAD - Cohort B - CHF6467 1 µg/mm2|Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.
16386028|NCT04077671|Experimental|SAD - Cohort C - CHF6467 3 µg/mm2|Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.
16386029|NCT04077671|Experimental|SAD - Cohort D - CHF6467 6 µg/mm2|Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.
16386030|NCT04077671|Experimental|MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2|Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
16386031|NCT04077671|Experimental|MAD - Cohort F - CHF6467 1 or 3 µg/mm2|Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
16386032|NCT04077658|Experimental|HeartMath|
16386033|NCT04077658|Active Comparator|Waitlist Control|
16386034|NCT04077645|Experimental|Sun salutations|Sun salutations, breathing exercises, and relaxation, at a low to moderate intensity, for 30 minutes.
16386035|NCT04077645|Active Comparator|Aerobic exercise|Walking on a treadmill at low to moderate intensity for 30 minutes.
16386036|NCT04077645|Other|Seated rest (attentional control)|Watching educational videos for 30 minutes.
16386037|NCT04077632|Experimental|tDCS (anodal)|Real transcranial direct current stimulation tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
16386038|NCT04077632|Sham Comparator|tDCS (sham)|Sham transcranial direct current stimulation tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
16386039|NCT04077619|Experimental|Modern pain neuroscience approach|Behavioral: Modern pain neuroscience approach
16386040|NCT04077619|Active Comparator|Usual care evidence-based physiotherapy|Behavioral: Usual care evidence-based physiotherapy
16386041|NCT04077606|Active Comparator|ceramo-metallic crown|ceramo-metallic crown preparation
16386042|NCT04077606|Active Comparator|monolithic zirconia crown|monolithic zirconia crown preparation
16386043|NCT04077580|Experimental|Methenamine hippurate|Tablets containing 1 g methenamine hippurate, dosage 1 tablet morning and evening.
16386044|NCT04077580|Placebo Comparator|Placebo|Placebo tablets containing 1 g of lactose, with identical size, shape and stamps
16386045|NCT04077567|Experimental|TS-152 30mg SC|TS-152 30mg subcutaneously (SC) every 4 weeks
16386046|NCT04077567|Experimental|TS-152 80mg SC|TS-152 80mg subcutaneously (SC) every 4 weeks
16386047|NCT04077554||Study group|women and men with excess body mass
16386048|NCT04077554||Control group|women and men with proper body mass
16386049|NCT04077541|Experimental|The experimental group|The trauma care bundles combined with the internet platform.
16386050|NCT04077541|No Intervention|The control group|Only trauma care bundles.
16386051|NCT04077515|Active Comparator|high blood concentration group|The blood concentration is maintained at 10-15ng/ml (not including 10ng/ml).
16386052|NCT04077515|Experimental|low blood concentration group|The blood concentration is maintained at 7-10ng/ml (including 10ng/ml).
16386053|NCT04077502|Active Comparator|stimulated group|The group stimulated by real coil of rTMS.
16386054|NCT04077502|Sham Comparator|controle group|The group stimulated by sham coil of rTMS.
16386055|NCT04077489|Other|MT|Macular thickness
16386056|NCT04077476|Active Comparator|Online Yoga|Participants in both groups will follow a prescription of classes the research team (including a 200-hour yoga instructor) developed, and is safe and appropriate for this study population. The yoga prescription will be based on the prescription used in the current R34 study (see reference for description), and modified based on results (i.e., participant feedback). Participants will be given instructions about how to use the online yoga class platform (Udaya) during the intake appointment.
16386057|NCT04077476|Experimental|Online Yoga + Facebook|"In addition to what is described above, participants will be provided instructions on how to join the private Facebook group. The Facebook group will be an informal platform where participants can connect with other people in the online + SN group to share their experiences with yoga as it relates to their stillbirths. Current social media intervention research suggests careful consideration must be given to the intervention. The current intervention will be designed based on results of focus groups asking stillbirth moms who have completed an online yoga intervention what they would find helpful in a Facebook intervention. For instance, preferences included having a moderator, rules about what they can post (e.g., no rainbow babies), and discussion about both stillbirth and life in general."
16386058|NCT04077463|Experimental|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive Lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of Lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
16386059|NCT04077463|Experimental|Phase 1b (combination): Lazertinib and Amivantamab|Participants will receive Lazertinib and Amivantamab, after the safety of RP2D of Lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of Amivantamab is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
16386148|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
16386060|NCT04077463|Experimental|Phase 1b (combination): Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP)|Participants will receive Lazertinib starting dose administered orally once daily (QD) in combination with Amivantamab, and doses of platinum-based chemotherapy (carboplatin and pemetrexed) per standard of care according to local guidance in a 21-day cycle for 4 cycles followed by maintenance with Lazertinib, Amivantamab and pemetrexed until disease progression or unacceptable toxicities.
16386061|NCT04077463|Experimental|Phase 1b (expansion) Cohort A: Lazertinib and Amivantamab|"This cohort A will further characterize the safety, tolerability, and preliminary antitumor activity of Lazertinib and Amivantamab based combinations within specific NSCLC population who have progressed after osimertinib and subsequent platinum-based chemotherapy, and platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR TKI is allowed if administered prior to osimertinib. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter."
16386062|NCT04077463|Experimental|Phase 1b (expansion) Cohort B: Lazertinib and Amivantamab|This Cohort B will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants previously treated with advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
16386063|NCT04077463|Experimental|Phase 1b (expansion) Cohort C: Lazertinib and Amivantamab|This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
16386064|NCT04077463|Experimental|Phase 1b (expansion) Cohort D: Lazertinib and Amivantamab|Cohort D will seek to validate one or both potential biomarker strategies (next generation sequencing [NGS] and Immunohistochemical [IHC]), previously identified in Cohort E of Study 61186372EDI1001, in participants with osimertinib-relapsed, but chemotherapy-naive, EGFR Exon19del or L858R mutated NSCLC. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
16386065|NCT04077450|No Intervention|Modified Waitlist Control Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. Two weeks later, participants will be asked to complete post-intervention data collection (T2), which consists of a questionnaire and heart rate variability assessment. After the completion of data collection, participants will be offered the online heart-focused breathing intervention.
16386066|NCT04077450|Experimental|Intervention Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. These participants will receive an online heart-focused breathing intervention. Participants will be asked to practice their breathing skills while monitoring their heart rate variability using the Welltory app on their smart device for the following two weeks. Participants will be instructed to maintain a log to record the date and time of each practice session. Research staff will make biweekly reminder calls to participants. After the two-week period, participants will complete post-intervention data collection (T2), which includes a questionnaire and HRV assessment.
16386067|NCT04077437|Experimental|Experimental: MDMA-assisted psychotherapy|Administration of 80 to 120 mg MDMA in combination with psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.
16386068|NCT04077437|Placebo Comparator|Placebo Comparator: Placebo|Administration of inactive placebo in combination with psychotherapy.
16386069|NCT04077424|Active Comparator|Fluzone-High Dose|FDA approved high dose inactivated influenza vaccine (HD-Fluzone)
16386070|NCT04077424|Active Comparator|Fluad|Adjuvanted (MF59) inactivated influenza vaccine (Fluad)
16386071|NCT04077424|Active Comparator|Recombinant Hemagglutinin vaccine (Flublok)|Recombinant hemagglutinin vaccine
16386072|NCT04077411||Children with severe TBI|Children with severe Traumatic Brain Injury
16386073|NCT04077398|Experimental|low volume High concentration group|1.Low Volume: 30 subjects randomized to Low Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,75% ropivacaine x 15 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
16386074|NCT04077398|Experimental|high volume low concentration|2.High Volume: 30 subjects randomized to High Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,375% ropivacaine x 30 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
16386075|NCT04077385|Experimental|Retrieval Extinction (R-E) Training Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the R-E training group will observe 5-min of high calorie pictorial food cues during retrieval which will purportedly retrieve cue-reward associative memories. This will be followed by 60-min of extinction training to high calorie food cues. The R-E training group will only differ from the extinction control group in regards to the 5-min exposure to high calorie food cues prior to the 60-min of extinction training to high calorie food cues."
16386076|NCT04077385|Active Comparator|Extinction Control Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the extinction control group will observe 5-min of non-food-related cues (e.g., pictures of office supplies, tools) during retrieval, which will purportedly avoid retrieval of the food cue-reward associative memories that are targeted in the R-E training group. The 5-min of exposure to non-food-related cues will be followed by the same 60-min of extinction training to high calorie food cues that the R-E training group receives."
16386077|NCT04077372|Experimental|Serious illness conversation guide (SICG)|"Patients have serious illness conversation within 3 wks of randomization and every 3 months thereafter."
16386078|NCT04077372|Active Comparator|Conversations by treating team|Patients have conversations as determined by treating team (but not using SICG tool).
16386079|NCT04077359|Experimental|nephrographic phase CT|the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series
16386080|NCT04077359|Active Comparator|gold standard|all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm
16386212|NCT04076345||Bacterial group|Newborns or infants less dans 3 months old with fever and positive bacterial sample.
16386081|NCT04077346|Experimental|Transcutaneous Spinal Stimulation- Acute and with Training.|"For Aim 1: Participants will receive transcutaneous stimulation (TcStim) in supine or side lying position at a single or multi site spinal levels to produce stepping/locomotor activity in lower limbs.
~For Aim 2: TcStim will be delivered while participants are stepping on a computerized treadmill with an overhead partial body weight support (BWS) system and while stepping overground.
~For Aim 3: Participants will first receive a combination of Activity-based locomotor training (AB-LT)+TcStim for 60 sessions."
16386082|NCT04077333|Experimental|MISA group|minimal invasive surfactant administration group
16386083|NCT04077333|No Intervention|EISA group|conventional treatment: endotracheal intubation surfactant administration group
16386084|NCT04077320|Experimental|Memory Self-Efficacy Training|
16386085|NCT04077320|Active Comparator|General Education Group|
16386086|NCT04077307|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
16386087|NCT04077294||Preoperative BNP used for cardiac risk stratification|Cohort of patients recruited in the pre-admission clinic who qualified for, and underwent, preoperative BNP screening according to CCS guidelines.
16386088|NCT04077294||Preoperative BNP not used for cardiac risk stratification|Cohort of patients from patient care database (SPOR) who qualified for preoperative BNP screening according to CCS guidelines, but did not receive screening due to surgery occurring before the implementation of the CCS guidelines.
16386089|NCT04077281|Experimental|Intervention Arm|Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists.
16386090|NCT04077281|No Intervention|Control Arm (Usual care)|Patients will receive a best possible medication history (BPMH) as do the intervention patients, then usual care by their primary team.
16386091|NCT04077255|Experimental|anti-EGFR|Participants will receive GC-1118 in combination with weekly paclitaxel.
16386092|NCT04077242|Active Comparator|"Parryscope-group"|"In these patients, Fallopian tube patency is assessed using the Parryscope technique. A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed."
16386093|NCT04077242|Active Comparator|"Tubal flow-group"|"In these patients, Fallopian tube patency is assessed using the flow technique. a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
16386094|NCT04077229|Experimental|Intervention|A total of 28 intervention text messages (1/day for 4 weeks) will be sent to participants following the baseline self-report assessment. After each message is sent, participants will receive a second text message asking them to rate the utility of the message. Following the 4-week intervention, participants will complete the same self-report assessments as in the baseline assessment (via phone) and will provide feedback about the program. Finally, 4 weeks later (at 8 weeks), participants will repeat the self-report questionnaires by phone.
16386095|NCT04077216|Experimental|Group A|Initially received the test meal with EVOO, then on crossover, received the meal without EVOO
16386096|NCT04077216|No Intervention|Group B|Initially received the test meal without EVOO, then on crossover, received the meal without EVOO
16386097|NCT04077203|Sham Comparator|Control|Those receiving no visual feedback because the handheld device monitor will be occluded with black tape (the control group).
16386098|NCT04077203|Experimental|Test|Those receiving the ability to visualize their glucose levels via the handheld device (the biofeedback group).
16386099|NCT04077190|Experimental|adipose-derived stem cell injection|Ultrasound guided injection of 5cc adipose derived stem cells
16386100|NCT04077190|Active Comparator|cortisone injection|Ultrasound guided injection of cortisone
16386101|NCT04077177|No Intervention|Assessment Only|
16386102|NCT04077177|Experimental|Intervention|
16386103|NCT04077164||Individuals with Chronic Pain|Individuals who identify as having a chronic musculoskeletal pain condition.
16386104|NCT04077164||Partners|Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.
16386105|NCT04077151|No Intervention|Standard of Care|PrEP prescribed with no intervention
16386106|NCT04077151|Experimental|Intervention Recipients|PrEP Demonstration Project intervention will be given
16386107|NCT04077138||Focus Groups|"Ten focus groups with transgender women and transgender men will be conducted. . The structure of the focus groups will utilize an interactive Rapid Approach, which differs from traditional focus groups by asking fewer questions and tightly focusing on specific areas of inquiry."
16386108|NCT04077138||In-Depth Interviews|Participants for the IDIs, 10-15 TW and TM, will be selected from among Phase 1 participants. We will create a purposive sample that represents a range of experiences that occurred during Phase 1.
16386109|NCT04077125||Cirrhosis no MHE|Patients with liver cirrhosis without signs of minimal hepatic encephalopathy
16386110|NCT04077125||Cirrhosis MHE|Patients with liver cirrhosis with minimal hepatic encephalopathy
16386111|NCT04077125||Controls|Healhty subjects
16386112|NCT04077112|Active Comparator|traditional PCIT|once a week parent training
16386113|NCT04077112|Experimental|intensive PCIT|every day for two weeks parent training
16386115|NCT04077086|Experimental|Intervention|Children at Intervention schools will receive free spectacles of a design they select, based on the child's measured refractive power and dispensed at school by the study optometrist. Additionally, teachers (but not children) in eligible classes will be informed that if 80% spectacle compliance as measured across three separate unannounced inspections was achieved, they will be given an incentive of an conditional cash transfer. The cash transfer will be deposited into the teacher's bank accounts directly.
16386213|NCT04076345||Viral group|Newborns or infants less dans 3 months old with fever and positive viral sample.
16386116|NCT04077086|No Intervention|Control|Children at Control schools will receive a glasses prescription and letter to the parents informing them of the refractive status of their child, with free glasses provided only at the end of the trial. No teacher incentive will be offered. Service offered to the Control group exceeds standard care, in that no school-based programs of vision screening and refraction currently exist in the study area, or in most of rural China.
16386117|NCT04077073|Experimental|ReIn-hand and robot|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand and of robot to reduce the shoulder load."
16386118|NCT04077073|Active Comparator|ReIn-Hand|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand."
16386119|NCT04077060|Experimental|NIPT|Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.
16386120|NCT04077060|Other|Combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
16386121|NCT04077047|Other|Intervention pilot|
16386122|NCT04077034|Experimental|Experimental group|Probiotic DE111®
16386123|NCT04077034|Placebo Comparator|Control group|Placebo
16386124|NCT04077021|Experimental|Part 1: Dose Escalation|CCW702 is administered subcutaneously with ascending dose levels to determine maximal tolerated dose (MTD).
16386125|NCT04077021|Experimental|Part 2: Dose Expansion|CCW702 is administered subcutaneously at the recommended phase 2 dose (RP2D). Different dosing regimens will be compared.
16386126|NCT04077008|Other|Bilaterally Obstructed Kidneys by benign cause|
16386127|NCT04077008|Other|Bilaterally Obstructed Kidneys by malignant cause|
16386128|NCT04076995|Experimental|High Water intake|High water intake of 3.0 L/day in males and 2.0 L/day in females
16386129|NCT04076995|Active Comparator|Low Water Intake|Low water intake of 0.5 L/day in males and 0.4 L/day
16386130|NCT04076982|Experimental|mung bean|daily oral administration of protein supplement
16386131|NCT04076982|Placebo Comparator|biscuit|daily oral administration of control supplement
16386132|NCT04076969|Experimental|Integrated Educational Session|The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
16386133|NCT04076969|Other|Routine follow up|Routine follow up
16386134|NCT04076943|Experimental|Roxadustat (FG-4592)|
16386135|NCT04076930||ACEI/ARB users|
16386136|NCT04076930||ACEI/ARB non-users|
16386137|NCT04076891|Active Comparator|Cohort 1 - Dercum's disease|Nodule size - diameter (cm) 2-2.9 3-3.9 4-8 Total Dose of RZL-012 (mg) 10 15 20 Dose per NOAEL* 1/25th 1/18.75th 1/12.5th Number of Injections 2 3 4
16386138|NCT04076891|Active Comparator|Cohort 2 - Lipedema|Total Dose RZL-012 (mg) 60 80 Dose per NOAEL* 1/4.688 1/3.125 Number of Injections 12 16
16386139|NCT04076878|Experimental|Intervention in a Mechanism and a Clinical substudy|"Mechanism substudy: 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo). Patients and datacollectors were blinded in terms of the randomised order of the treatment at each of the 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo).
~Clinical substudy: Use of the fitted and individually set body suit, Mollii, in the home setting for 6 weeks"
16386140|NCT04076865|Experimental|EMLA|
16386141|NCT04076839|Experimental|Goal Management Training (GMT)|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Participants assigned to this group will attend 9 weeks of GMT group sessions, each 2 hours in length, occurring once per week.
16386142|NCT04076839|No Intervention|Wait-list Control|Following baseline testing, participants randomly assigned to the wait-list control group will have no intervention during the 9 weeks that the GMT group attends their group sessions. Following the completion of the GMT group intervention, the wait-list control will attend a a testing session, and subsequently, a 3 month follow-up testing session, the results of which will be compared to those of the GMT group. This group will then be offered a complimentary 9-week GMT program once the final testing session is complete. Again, during these sessions participants will be required to complete questionnaires every third session in order to monitor their progress and symptoms. Following the completion of the complimentary 9-week GMT program, individuals in the WLC will complete post-intervention testing
16386143|NCT04076826|Experimental|Protocol A (Dexmedetomidine)|Dexmedetomidine will be administered in accordance with hospital standard operating procedures (SOP).
16386144|NCT04076826|Active Comparator|Protocol B (Propofol / Midazolam)|Propofol and/or Midazolam will be administered in accordance with hospital standard operating procedures (SOP).
16386145|NCT04076813||STEMI/NSTEMI|Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
16386146|NCT04076800|Experimental|Acupuncture|
16386147|NCT04076800|Sham Comparator|Sham acupuncture|
16386149|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
16386150|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
16386151|NCT04076774|Experimental|Wondaleaf female condom|Participants will be provided with 5 Wondaleaf condoms first at enrolment and switched to 5 FC2 condoms at the first follow up visit
16386152|NCT04076774|Active Comparator|FC2 Female condom|Participants will be provided with 5 FC2 condoms first at enrolment and switched to 5 Wondaleaf condoms at the first follow up visit
16386154|NCT04076748|Experimental|Experimental|"* Intra Nasal Sufentanil (50 µg.ml-1): Load dose : 0.3 µg. kg-1, Followed by bolus : 5 µg / 10 minutes with 2 bolus maximum.
~As soon as the venous route and ten minutes after the last administration of sufentanil:
~Morphine IV: 3 mg / 5 minutes.
~Objective: numeric rating scale (NRS) ≤ 3/10."
16386155|NCT04076748|Active Comparator|Control|"* EMONO : Given by respiratory administration via a face mask at a rate suitable for patient ventilation (generally at least 9l.min-1), Until a venous route is obtained and without exceeding 30 minutes.
~* Morphine IV: Load dose: 0.1mg. kg-1 as soon as possible; Then bolus: 3mg / 5 minutes.
~* Objective: NRS ≤ 3/10"
16386156|NCT04076735|Experimental|Distal femoral replacement (DFR)|"Distal femoral replacement will be performed by excising the distal portion of the femur (up to two thirds) and replacing with a prosthesis incorporating a hinged total knee replacement.
~Surgical approach and implant selection will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in arthroplasty."
16386157|NCT04076735|Active Comparator|Surgical Fixation (ORIF)|Surgical fixation of the distal femoral fracture will be performed with the goals of obtaining and maintaining anatomic reduction and stable fixation of the distal portion of the femur. Surgical approach and implant selection for the surgical fixation (ORIF) will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in trauma of the knee.
16386158|NCT04076722|Experimental|Stress reactivity weight stigma|This study arm received a stress reactivity paradigm that involved weight stigma content in the form of an evaluated speech task.
16386159|NCT04076722|Active Comparator|Stress reactivity non-weight stigma.|This study arm received a stress reactivity paradigm that involved non-weight stigma content in the form of an evaluated speech task.
16386160|NCT04076709|No Intervention|Standard Care|
16386161|NCT04076709|Experimental|Goal directed anesthesia|Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia
16386162|NCT04076696|Experimental|Scatter corrected s-DCT|The study scan, s-DCT and correction scan, will be performed within two weeks of the patient's clinical evaluations by chest CT and x-ray. The study scan may be done within 2 weeks prior or two weeks following standard of care imaging. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the standard of care (SOC) imaging and the s-DCT. All patients will have a breath held s-DCT scan in an anterior-posterior direction.
16386163|NCT04076683|Experimental|Algorithm (arm A)|Frequency and volume for apherisis proposed by algorithm and validated by the physician
16386164|NCT04076683|No Intervention|Usual care (arm C)|Frequency and volume for apherisis only decided by the physician (usual care)
16386165|NCT04076670|No Intervention|Control group|Group pf participants that received usual psychological attention.
16386166|NCT04076670|Experimental|Experimental group|Group of participants that received usual psychological attention plus the structured psychological intervention prosed in the study.
16386167|NCT04076657|Experimental|Brock String|Participants will receive instruction on Brock String therapy after first clinic visit (<48 hours post) injury, and will complete home therapy exercise twice daily
16386168|NCT04076657|Active Comparator|Standard of Care|Participants will receive standard of care (i.e., no Brock String therapy within the first week post injury) but will be informed they will receive any therapy deemed necessary at follow up visit 7-10 days post injury, consistent with standard of care
16386169|NCT04076644|Active Comparator|TMS Treatment Arm|Subjects will receive either a 20min 10hz TMS treatment, or a 3min theta-burst TMS treatment at certain monthly intervals. The TMS treatment protocol they receive depends on what they received in their acute clinical treatment. Subjects in the arm will be tapered off antidepressant medication before TMS treatment begins. Subjects will be assessed monthly for depression using QIDS and PHQ9.
16386170|NCT04076644|No Intervention|No TMS Arm|Subjects will be followed and assessed for depressive symptoms at monthly time intervals similar to the active treatment arm using QIDS and PHQ9. This group does not receive TMS treatment.
16386171|NCT04076631||Hepatocellular Carcinoma|Patients with hepatocellular carcinoma undergo open hepatectomy.
16386172|NCT04076618|Experimental|Weight Loss plus Vest|
16386173|NCT04076618|Active Comparator|Weight Loss Plus Resistance Exercise Training|
16386174|NCT04076618|Active Comparator|Weight Loss|
16386175|NCT04076579|Experimental|Olaparib + Trabectedin|"There are 2 cohorts. Both cohorts receive the same treatment:
~Cohort 1: Leiomyosarcoma and liposarcoma
~Cohort 2: Other bone or soft tissue sarcoma histologies
~Treatment consists of 21-day cycles for a maximum of 18 months."
16386176|NCT04076553|Active Comparator|CBT + ICT|"Participants randomized to the ICT condition will complete a computerized ICT training at home during the first 4 weeks of treatment and ICT boosters following their treatment sessions during weeks 5-12."
16386177|NCT04076553|Sham Comparator|CBT + sham|"Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT boosters following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component."
16386178|NCT04076540|Experimental|AZD4041|
16386179|NCT04076540|Placebo Comparator|Placebo|
16386214|NCT04076345||Negatives Microbiological samples|Newborns or infants less dans 3 months old with fever and negatives microbiological samples.
16386215|NCT04076332|No Intervention|Controlled group|Standard oral explanation with booklet
16386180|NCT04076527||Group 1 - Incomplete Responder|"Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).
~Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment."
16386181|NCT04076527||Group 2 - Responder|PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment.
16386182|NCT04076527||Group 3|Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study.
16386183|NCT04076514||patients with node negative papillary thyroid carcinoma|
16386184|NCT04076501|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
16386185|NCT04076501|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
16386186|NCT04076488|Experimental|Dividat FIT: Computer based exercise|Tablet based interactive physical training.
16386187|NCT04076475|Experimental|electrical stimulation|receive daily NMES for 30 min/session for 10 days.
16386188|NCT04076475|Sham Comparator|Control|receive similar electrical stimulation (ES) procedure as those in the intervention group but with ES machine power off.
16386189|NCT04076462|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
16386190|NCT04076462|Placebo Comparator|Matching placebo|Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
16386191|NCT04076449||Cerebral Cavernous Malformation with Epilepsy|Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
16386192|NCT04076449||Cerebral Cavernous Malformation without Epilepsy|Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
16386193|NCT04076436||Fosfomycin cohort:|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous fosfomycin
16386194|NCT04076436||Quinolones or beta-lactams cohort|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous quinolones or beta-lactams.
16386195|NCT04076423|Experimental|Experimental arm:|they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.
16386196|NCT04076423|Active Comparator|Comparator arm|they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.
16386197|NCT04076410|Experimental|5 Lenses|"The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).
~Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).
~Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK)."
16386198|NCT04076397|Other|lipofilling group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:
~Make EVA (evaluation of the pain),
~Complete DASH questionnaire
~Complete DN4 questionnaire
~Patients in the lipofilling group will also have:
~the repair of the last dressing during the consultation at J15
~Ablation of any threads
~Control of the digital and abdominal scar
~Making a photo of their finger at V1 and M6"
16386199|NCT04076397|Other|desensitization group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:
~Make EVA (evaluation of the pain),
~Complete DASH questionnaire
~Complete DN4 questionnaire"
16386200|NCT04076384|Experimental|Team-based consultations|Guided Self-Determination
16386201|NCT04076384|Experimental|Standard care|Standard consultation
16386202|NCT04076371|Experimental|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
16386203|NCT04076371|Placebo Comparator|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
16386204|NCT04076371|Experimental|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
16386205|NCT04076371|Placebo Comparator|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
16386206|NCT04076371|Experimental|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
16386207|NCT04076371|Placebo Comparator|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
16386208|NCT04076371|Experimental|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
16386209|NCT04076371|Placebo Comparator|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
16386210|NCT04076358|Experimental|Tab-CBI|The Tab-CBI group receives a tablet preloaded with the Tab-CBI application and an accelerometer. During the study period, the participants have four weekly educational sessions plus one booster session by the research assistant through a videoconferencing tool. The educational modules were developed based on the principles of cognitive behavioral therapy. The key elements of the modules include activity-pacing, adjustment of goal-setting to the current physical condition, setting priorities and structured planning of a simple walking activity and time off, and cognitive restructuring of activity demands (see attached, outline of education modules).
16386211|NCT04076358|No Intervention|Usual Care|The usual care group receives Arthritis related fatigue management which are currently offered to the participants at the recruitment sites. Participant are also instructed to maintain usual activity during the study period. The control group participants also receive an accelerometer to count steps, but without a tablet.
16386216|NCT04076332|Experimental|Decision aid group|Shared decision making using decision aid
16386218|NCT04076306|Other|iSTEP Feasibility Study Protocol|All participants will be asked to undergo the entire protocol: iSTEP exercise test, 10 metre incremental shuttle walk test, myometry, accelerometry and Haemophilia Joint Health Score.
16386219|NCT04076293|Experimental|HM15912|
16386220|NCT04076293|Placebo Comparator|Placebo|
16386221|NCT04076280|Experimental|SWAP Intervention|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the Sodium Watcher Program.
16386222|NCT04076280|Active Comparator|Usual Care|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the usual care group.
16386223|NCT04076267||Patients with cancer|
16386224|NCT04076254|Experimental|albumin|albumin 5%
16386225|NCT04076254|Active Comparator|fluid|Ringer Lactate
16386226|NCT04076241|Experimental|Combined intervention|Combined intervention group consisted of 16 pulmonary arterial hypertension (PAH) patients. Three different yoga breathing exercises were applied after osteopathic manipulative treatment (OMT). This combined intervention was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
16386227|NCT04076241|Active Comparator|Osteopathic manipulative treatment|OMT group consisted of 16 PAH patients. Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions. The same osteopathic manipulative treatment techniques applied to combined intervention group were used for this study group. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
16386228|NCT04076241|No Intervention|Control|Control group also consisted of 16 PAH patients and serves as the controls. No interventions were applied for the patients in this group. Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
16386229|NCT04076228||Pembrolizumab|Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
16386230|NCT04076215|Experimental|Pariticapnts with PTSD|
16386231|NCT04076215|Experimental|Pariticapnts without PTSD (controls)|
16386232|NCT04076202|Experimental|Cementless Vanguard DD RP|Patients receiving a total knee prosthesis
16386233|NCT04076189|Experimental|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
16386234|NCT04076189|Active Comparator|No endotracheal suctioning|Procedure includes: Initiation of positive pressure ventilation without endotracheal suctioning
16386235|NCT04076176|Active Comparator|L-amino Acids|"The specific amount and timing of L-amino acid consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.
~Consumption period: 12 weeks."
16386236|NCT04076176|Experimental|PKU Sphere|"The specific amount and timing of PKU sphere consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.
~Consumption period: 12 weeks."
16386237|NCT04076163|No Intervention|control group|group of students participating to a face-to-face learning
16386238|NCT04076163|Other|intervention group|group of students using serious game
16386239|NCT04076150|Experimental|Patients Receiving Optimum TAV|Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure
16386240|NCT04076137|Experimental|Targeted T-cell|This study is a pre-phase I immunotherapy trial in 10 people with malignant solid tumor consisting of 9 infusions of bispecific antibody armed anti-CD3-Actibated T cells(ATC) to determine safety, maximum tolerated dose (MTD), technical feasibility, immune responses.
16386241|NCT04076124|Experimental|Active rTMS-DLPFC|This active group will receive high-frequency repetitive TMS stimulation.
16386242|NCT04076124|Experimental|Active iTBS-DLPFC|This active group will receive intermittent theta-burst TMS stimulation.
16386243|NCT04076124|Sham Comparator|Sham TBS-DLPFC or Sham rTMS-DLPFC|Patients in the sham group will receive the same iTBS or rTMS parameter stimulation, performing by a sham coil.
16386244|NCT04076098|Experimental|Minocycline|Minocycline gel
16386245|NCT04076098|Placebo Comparator|Placebo|Similar gel without the active agent
16386246|NCT04076085|Active Comparator|Unsupported Upper extremity exercise|Specially designed unsupported Arm exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
16386247|NCT04076085|Active Comparator|Lower extremity exercise|Specially designed Lower extremity exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
16386248|NCT04076085|No Intervention|Control|Here no active intervention will be given only standard care as prescribed by the hospital will be given
16386249|NCT04076072|Active Comparator|Alcon Advanced Ultravit High-Speed Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
16386302|NCT04075682|No Intervention|Standard cigarette packs (control)|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with the only alteration being the small health warning message on the side of the pack, whose textual content will be the same as that used for the pictorial warning label conditions.
16386250|NCT04076072|Active Comparator|Alcon Non-Beveled Tip Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
16386251|NCT04076059|Experimental|Double-blind treatment: Enzalutamide plus androgen deprivatio|Participants will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC ) and provided by the site's pharmacy stock.
16386252|NCT04076059|Placebo Comparator|Double-blind treatment: Placebo plus androgen deprivation ther|Participants will receive placebo once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) will be maintained during study treatment as per SOC and provided by the site's pharmacy stock.
16386253|NCT04076059|Experimental|Open-Label Phase: Enzalutamide|Participants who will receive placebo in double-blind phase and remain on study treatment until confirmed radiographic disease progression will receive enzalutamide in open-label phase.
16386254|NCT04076033|Experimental|ECF ESPIRAL|The volunteer is submitted to four-layer spiral functional compressive bandage, then performs Taylor's Jebsen manual function test with comprehensive functional bandage (ECF).
16386255|NCT04076033|Experimental|ECF OITO|The volunteer is submitted to functional compressive bandage in eight with four layers, then performs the Taylor Jebsen manual function test with the comprehensive functional bandage (ECF).
16386256|NCT04076020|Experimental|Intervention arm|Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
16386257|NCT04076020|Active Comparator|Usual care arm|"Receive a brochure on atrial fibrillation that is published by the American Heart Association and a smartphone with the WebMD application.
~Participants are directed to use the WebMD application as often as they would like."
16386258|NCT04076007|Active Comparator|Active|Nitrate rich beetroot juice (7.5 mmol nitrate in 250mls beetroot juice) once daily.
16386259|NCT04076007|Placebo Comparator|Placebo|Nitrate depleted beetroot juice (0.002 mmol nitrate in 250 ml beetroot juice) once daily.
16386260|NCT04075994|Experimental|Intervention arm|Receive the relational agent coupled with the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
16386261|NCT04075994|Active Comparator|Usual care arm|Receive a brochure on atrial fibrillation, the WebMD app and the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
16386262|NCT04075981|Experimental|Botulinum toxin|"All patients from the experimental group will receive botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 200 U dissolved in 4 mL of 0.9% normal saline and 50 U/1 mL will be injected at each fat pad).
~Botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
~The whole estimated dosage would be therefore 200 units of incobotulinumtoxin A,"
16386263|NCT04075981|Placebo Comparator|Placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo dissolved in 4 mL of 0.9% normal saline will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
16386264|NCT04075968||group 1|exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
16386265|NCT04075968||group 2|control group; patients will be given physical and cognitive home exercise program individually.
16386266|NCT04075955|Experimental|Study treatment group|Olanzapine in combination with ondansetron and dexamethasone
16386267|NCT04075955|Active Comparator|Standard treatment group|Aprepitant in combination with ondansetron and dexamethasone
16386268|NCT04075942|Other|Atrophic Anterior Maxillary Ridges participants|Using customized Xenograft bone shell with equal mixture of autogenous and xenograft particulate bone as a graft with the modified cortical shell technique, with atrophic anterior maxilla with less than 5 mm Bucco-lingual
16386269|NCT04075929|Other|4x8 min|4x8-min intervals with 2-min recovery periods. The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x8-min = 32 min
16386270|NCT04075929|Other|4x(8x40/20s)|4x(12x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group:4x(12x40/20-sec) = 32 min if the 20-sec recovery is not included in the total time of HIT
16386271|NCT04075929|Other|4x(12x40/20s)|4x(8x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x(8x40/20-sec) = 32 min if the 20-sec recovery is included in the total time of HIT
16386272|NCT04075916|Experimental|Epclusa (sofosbuvir/velpatasvir)|Epclusa is taken by mouth for 12 weeks as per the FDA label.
16386273|NCT04075903|Experimental|Intervention|"Storytelling A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
16386274|NCT04075903|No Intervention|Control|Usual Care
16386275|NCT04075890|Active Comparator|Healthy subjects|
16386276|NCT04075890|Active Comparator|OCD subjects|
16386303|NCT04075682|Experimental|Cigarette packs with inserts only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four different rotating messages to promote response efficacy beliefs (2 inserts on the benefits of cessation) or self-efficacy to quit (2 inserts with cessation tips).
16386304|NCT04075682|Experimental|Cigarette packs with pictorial warnings only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include four different rotating pictorial warnings showing the consequences of smoking and that cover 50% of the front and back of the pack.
16386409|NCT04075097|Experimental|Yoga|44 minutes of Iyengar yoga.
16386277|NCT04075877|Experimental|FOCUS|"Participants will complete a baseline survey battery and learn about The Hero's Journey. Starting at hospital discharge for 10 days, they will do the following: 1) identify which stage of The Hero's Journey they are experiencing; 2) take a picture of something good and write a caption describing the picture and provide advice; and 3) take a picture of something difficult or challenging during the day and write a caption for the photo and provide advice.
~Daily text messages will remind participants to take the photographs, write the advice captions, upload both to the server, as well as to take a very brief daily survey. At the conclusion of day 10, participants will be asked to review their photos and captions and provide final advice in the form of a letter to other adolescents with SCD or cancer. Finally, they will complete a post-intervention battery."
16386278|NCT04075877|No Intervention|Control|"In a 30-min visit (in person or virtual) with adolescents during hospitalizations, we will have participants complete a baseline survey battery.
~Daily text messages will remind participants to take a very brief daily survey. At the conclusion of day 10, participants will complete a post-intervention battery."
16386280|NCT04075851||Hashimoto or Grave's disease patients in treatment|Draw 10 ml venous blood
16386281|NCT04075851||Hashimoto or Grave's disease patients on initial treatment|10 ml of venous blood was extracted every month for three months
16386282|NCT04075851||Pregnant woman with Hashimoto or Grave's disease|10 ml venous blood was extracted every month to postpartum for 6 months
16386283|NCT04075851||Healthy crowd|Draw 10 ml venous blood
16386284|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001). The group gathered for a one-hour session once a week for 18 weeks.
16386285|NCT04075825|Experimental|Darvadstrocel|Participants who received a single dose of darvadstrocel, 120 million cells, intralesionally or darvadstrocel matching placebo previously in the ADMIRE-CD II study will be observed for efficacy and safety. No drug administration in this study.
16386286|NCT04075812|Experimental|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
16386287|NCT04075799|Experimental|training|8 weeks using stair climbing with a frequency of thrice a week. For the first week of the stair training exercise program subjects will meet at UNM's Teaching Education Building (Stair Case 2). The following 7 weeks subjects can perform the exercise program at a staircase most convenient to them and approved by the research team. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will be comprised of 6-12 x 30-seconds bout of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. After the exercise session the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks.
16386288|NCT04075786||Gynecologists|Gynecologists in active clinical practice and resident (in training) gynecologists.
16386289|NCT04075773|Experimental|Religious Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
16386290|NCT04075773|Sham Comparator|Age Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported age. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
16386291|NCT04075760|Experimental|EUS-guided combined therapy|Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
16386292|NCT04075760|Placebo Comparator|Beta Blocker (Propranolol)|o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.
16386293|NCT04075747|Experimental|Arm A|
16386294|NCT04075747|Experimental|Arm B|
16386295|NCT04075747|Experimental|Arm C|
16386296|NCT04075734|Experimental|RCT Intervention|The intervention consists of (1) online self-management educational modules and (2) weekly peer mentor calls to facilitate engagement with the modules and offer specialized support over approximately six weeks.
16386297|NCT04075734|No Intervention|RCT Usual Care|Participants receive usual care.
16386298|NCT04075721|Experimental|Part A (Dose Escalation): M3258|
16386299|NCT04075721|Experimental|Part B (Dose Expansion): M3258|
16386300|NCT04075708||Case-group|The case group will consist of women diagnosed with PE after 34 weeks of gestation.
16386301|NCT04075708||Control-group|The control group will include 165 participants who were not diagnosed with PE in their pregnancies.
16386305|NCT04075682|Experimental|Cigarette packs with inserts and pictorial warnings|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four rotating efficacy messages (see description above) and four rotating pictorial warnings (see above).
16386306|NCT04075656|Experimental|UrApp|Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
16386307|NCT04075656|Active Comparator|Standard of Care|Participants randomized to this study arm will use receive the standard of care for one year.
16386308|NCT04075643|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug"
16386309|NCT04075643|Experimental|Group 2|"Period 1: Test drug
~Period 2: Reference drug"
16386310|NCT04075617|Experimental|intervention group|electronic habit reminder will fabricated to treat thumb/finger sucking habit containing two parts: acrylic part specially fabricated for the child finger/thumb connected to the reminder in the shape of wrist watch.
16386311|NCT04075617|Active Comparator|control group|palatal crib will be cemented after impression taking and fabrication
16386312|NCT04075604|Experimental|Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)|
16386313|NCT04075604|Experimental|Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ|
16386314|NCT04075604|Active Comparator|Arm C: Palbociclib+ANZ|
16386315|NCT04075591|Experimental|Wavefront-guided Lasik Monovision Treatment|Wavefront-guided LASIK monovision treatment of myopic subjects with presbyopia using the STAR S4 IR® Excimer laser System with the iDesign Refractive Studio.
16386316|NCT04075578||female with urinary incontinence|Female ≥ 18 years, suffers from urinary incontinence by idiopathic overactive bladder, inadequately treated by 2 anticholinergic medicines during a period of 3 months for each of them or stopped for intolerance or adverse events
16386317|NCT04075565|Active Comparator|Simulated altitude|The participants are exposed to simulated altitude in a normobaric situation.
16386318|NCT04075565|Experimental|Terrestrial altitude|The participants are exposed to terrestrial altitude in a hypobaric situation.
16386319|NCT04075565|No Intervention|Control|the participants are exposed to a normoxic and normobaric environment.
16386320|NCT04075552|Experimental|Participants|Participants are students from a specialized school for children with autism.
16386321|NCT04075539|Experimental|Home-based cycling program associated to usual care|
16386322|NCT04075539|Other|Outpatient physiotherapy|
16386323|NCT04075526|Experimental|Povidone iodine and vancomycin powder|
16386324|NCT04075526|Experimental|Povidone iodine alone|
16386325|NCT04075526|Active Comparator|Vancomycin powder alone|
16386326|NCT04075526|Active Comparator|Conventional|neither povidone iodine, vancomycin powder, nor polymyxin/bacitracin irrigation
16386327|NCT04075513|Experimental|Toujeo|Toujeo (Insulin Glargine, 300U/ml) once daily for 12 weeks on top of rapid acting insulin analog
16386328|NCT04075513|Active Comparator|Tresiba|Tresiba (Insulin Degludec, 100U/ml) once daily for 12 weeks on top of rapid acting insulin analog
16386329|NCT04075500|No Intervention|Arm 1|Control arm, 24-h Holter monitoring
16386330|NCT04075500|Other|Arm 2|Interventional arms, prolonged cardiac monitoring
16386332|NCT04075474|Experimental|silver diamine fluoride|38% silver diamine fluoride
16386333|NCT04075474|Active Comparator|sodium fluoride|5% sodium fluoride
16386334|NCT04075461|Experimental|Undisplaced FNF + Arthroplasty|Arthroplasty is the typical surgery for a displaced femoral neck fracture
16386335|NCT04075461|Active Comparator|Undisplaced FNF + Internal fixation|Internal fixation is the typical surgery for an undisplaced femoral neck fracture
16386336|NCT04075448|Experimental|Control - 50g Walnut|Control condition followed by experimental condition.
16386337|NCT04075448|Experimental|50 g Walnut - Control|Experimental condition followed by control condition.
16386338|NCT04075435|Other|All subjects|This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.
16386339|NCT04075422||Prospective cohort|64 patients treated with Bezlotoxumab
16386340|NCT04075422||Retrospective Cohort (Control)|All the first episodes diagnosed in each participating sites during the previous year that meet the inclusion criteria
16386341|NCT04075409|Experimental|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
16386342|NCT04075409|Experimental|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
16386343|NCT04075409|Experimental|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
16386344|NCT04075396|Experimental|Part D: Outside of Korea|Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety, tolerability, efficacy and pharmacokinetics (PK) of Lazertinib.
16386345|NCT04075383|Other|immediate dental implant|The implant is installed immediately after tooth extraction.
16386346|NCT04075383|Other|immediate-delayed dental implant|The implant is installed 8 weeks after tooth extraction.
16386347|NCT04075370||Single arm study|In this feasibility study, longitudinal mixed methods will be used to measure cognitive function and symptoms by objective tests, interviews, and biomarker assay in adults with brain cancer over time: prior to radiation (XRT; T1), 2-weeks post-XRT (T2), 2-3 months post-XRT (T3).
16386348|NCT04075357|No Intervention|Control|The patients underwent conventional CTS surgery
16386349|NCT04075357|Experimental|Experimental|The patients underwent conventional CTS surgery and transplantation of amniotic membrane
16386350|NCT04075344|Experimental|Experimental RCHEs staff|Experimental RCHEs staff will received a multimodal ICP regarding the NG tube feeding. Knowledge and skills of NG tube feeding will be measured before and after the multimodal ICP. In addition, 10 fingertips of RCHEs staff, enteral milk and NG tube hubs of residents will be taken for bacterial counts before and after the intervnetion.
16386351|NCT04075344|No Intervention|Control RCHEs staff|No multimodal ICP will be offered to the staff of control RCHEs.
16386352|NCT04075331|Experimental|Mepolizumab|Mepolizumab
16386353|NCT04075331|Placebo Comparator|Placebo|Saline solution
16386362|NCT04075305||Brain cancer|
16386363|NCT04075305||Lung cancer|
16386364|NCT04075305||Esophageal cancer|
16386365|NCT04075305||Breast Cancer|
16386366|NCT04075305||Head and Neck Cancer|
16386367|NCT04075305||Pancreatic cancer|
16386368|NCT04075305||Gynecological cancer|
16386369|NCT04075305||Rectal cancer|
16386370|NCT04075305||Prostate cancer|
16386371|NCT04075305||Bladder cancer|
16386372|NCT04075305||Oligometastases|
16386373|NCT04075305||Liver cancer|
16386374|NCT04075305||Other types of cancer|
16386375|NCT04075292|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
16386376|NCT04075292|Active Comparator|Rituximab and Chlorambucil|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
16386381|NCT04075253|Experimental|VO2 peak test|All participants enrolled in the planned study on physical activity and ventricular arrhythmias and on baseline will complete an exercise treadmill test to determine VO2 peak
16386382|NCT04075240|Active Comparator|THA-control arm|Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin
16386383|NCT04075240|Experimental|THA-study arm|Total Hip Arthroplasty: 35 days of aspirin
16386384|NCT04075240|Active Comparator|TKA-control arm|Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin
16386385|NCT04075240|Experimental|TKA-study arm|Total Knee Arthroplasty: 14 days of aspirin
16386386|NCT04075227|Experimental|0.2% loteprednol etabonate|This group was treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
16386387|NCT04075227|Active Comparator|0.1% dexamethasone|This group was treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph) every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
16386388|NCT04075214|Sham Comparator|delayed-active tAN|
16386389|NCT04075214|Experimental|active tAN|
16386390|NCT04075201|Experimental|Adults-Experimental group|One dose of investigational vaccine
16386391|NCT04075201|Experimental|Children-Experimental group|One dose of investigational vaccine
16386392|NCT04075201|Active Comparator|Children-Control group|One dose of control vaccine
16386393|NCT04075201|Experimental|Neonates-Experimenatal group|Three doses of investigational vaccine
16386394|NCT04075201|Active Comparator|Neonates-Control group|Three doses of control vaccine
16386395|NCT04075188|Experimental|Combined therapy|Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.
16386396|NCT04075175|Experimental|S315 human monoclonal antibody|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
16386397|NCT04075175|Placebo Comparator|0.9% sodium chloride (NaCl)|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9% Sodium Chloride)) with escalation of a fixed dose of S315
16386398|NCT04075162||Low charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
16386399|NCT04075162||No charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at no charge
16386400|NCT04075149|Experimental|Spironolactone|16 weeks without medication, then 16 weeks with medication, then 12 months without medication; spironolactone 50 mg tablets: 50-100 mg orally twice daily (1.7-3.3 mg/kg/24 hr)
16386401|NCT04075136|Active Comparator|Arm A: Lucentis|A standard of care treatment of 0.05ml/0.5mg Lucentis given every 4 weeks for 48 weeks.
16386402|NCT04075136|Experimental|Arm B: Lucentis & PDT Laser|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence.
16386403|NCT04075136|Experimental|Arm C: Lucentis, PDT Laser and Triescense|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence and an intravitreal injection of 0.5ml-2mg Triescence at the time of PDT treatment.
16386404|NCT04075123||CPAP GROUP|Suggested PEEP range 5-10 cmH2O; Minimum required PEEP WILL BE 8 cm water (7 cm water if using bubble CPAP); Maximum allowable† PEEP: 12 cmH2O
16386405|NCT04075123||NIPPV GROUP|Suggested Ranges: PIP 12 to 24 cm water; PEEP 5 to 10 cm water; Rates 20-40 bpm; iTime 0.4-1.0 seconds; Minimum required settings on NIPPV: PEEP 8 cm water; Difference of pressure 6 cm water; Rate 20 bpm; Maximum allowable settings: PEEP 10 cm water; PIP 24 cm water; Rate 60 bpm
16386408|NCT04075097|Experimental|Aerobic exercise|44 minutes of moderate intensity walking on a treadmill.
16386410|NCT04075071|Experimental|TCIT-U|Four teachers from two Head Start classrooms will be assigned to Teacher-Child Interaction Training - Universal (TCIT-U). TCIT-U occurs in two phases (6 weeks per phase): Child-Directed Interaction (CDI; focusing on relationship building) and Teacher-Directed Interaction (TDI; focusing on managing behavior problems). The TCIT-U Trainer (a licensed clinical child psychologist) will provide teachers with group didactic sessions (6 hours per phase) and individualized live coaching in their classrooms (20 minutes, once per week). Strategies include the use of PRIDE skills (Praise, Reflection, Imitation, Behavior Description, and Enthusiasm) or specific verbalizations that promote warm, responsive interactions, as well as classroom-appropriate behavior modification strategies which include using effective commands, prompts, natural consequences, differential social attention, and a modified time-out appropriate for use in a classroom.
16386411|NCT04075071|No Intervention|Usual Care|Four teachers from 2 PreK Counts classrooms will be assigned to the Usual Care (UC) group. They will continue their existing behavioral management strategies and techniques. Teachers will report on specific training in and use of other behavior management and social-emotional learning programs at baseline. At the conclusion of the study, UC teachers and staff will be offered didactic training in TCIT-U principles and strategies.
16386412|NCT04075058|Experimental|Study|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 34Gy in 10 fractions over 2 weeks.
16386413|NCT04075058|Active Comparator|Control|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 35Gy in 15 fractions over 3 weeks
16386414|NCT04075045|No Intervention|"Group A. Standard Care (Control)"|Does not receive Wellth app.
16386415|NCT04075045|Experimental|"Group B. Wellth App (Treatment 1)"|Receives Wellth app without additional financial rewards tied to adherence.
16386416|NCT04075045|Experimental|"Group C. Wellth App (Treatment 2) with targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at local pharmacies for using the app to track adherence.
16386417|NCT04075045|Experimental|"Group D. Wellth App (Treatment 3) with non-targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at many stores for using the app to track adherence.
16386418|NCT04075032|Experimental|Pomegranate extract-1|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks
16386419|NCT04075032|Placebo Comparator|Placebo-1|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks
16386420|NCT04075032|Placebo Comparator|Placebo-2|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out
16386421|NCT04075032|Experimental|Pomegranate extract-2|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.
16386422|NCT04075019|Experimental|full intervention|students assigned to intervention classrooms in grades 1 through 4 and who remained in schools assigned to the intervention condition in grades 5 or 6
16386423|NCT04075019|Experimental|late intervention|students in intervention classrooms in grades 5 and 6 only
16386424|NCT04075019|Experimental|parent-training only|students whose parents were offered parent training only when their children were in grades 5 and 6 and no other intervention
16386425|NCT04075019|No Intervention|control|students in schools assigned to receive no intervention in grades 5 and 6 and who were not in intervention classrooms in grades 1 through 4
16386426|NCT04075006|Experimental|Ketamine Group|adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
16386427|NCT04075006|No Intervention|Control Group|Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
16386428|NCT04074993|Experimental|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
16386429|NCT04074980|Experimental|Venous only|One venous whole blood draw will be performed into two anti-coagulated collection tubes
16386430|NCT04074980|Experimental|Fingerstick and Venous|One finger-stick sample of capillary blood (~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. From each patient, one venous whole blood draw will also be performed into two anti-coagulated collection tubes.
16386431|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab|Participants with advanced solid tumors will receive ARRY-614 in combination with nivolumab.
16386432|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab + ipilimumab|Participants with advanced solid tumors will received ARRY-614 in combination with nivolumab + ipilimumab.
16386433|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab|Participants with of NSCLC and HNSCCC will receive ARRY-614 combined with nivolumab.
16386434|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab + ipilimumab (melanoma)|Participants with melanoma will receive ARRY-614 combined with nivolumab + ipilimumab.
16386435|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab + ipilimumab (RCC)|Participants with RCC will receive ARRY-614 combined with nivolumab + ipilimumab.
16386436|NCT04074954||Cataracts present, no surgery|Adult patients undergoing bilateral cataract surgery
16386437|NCT04074954||Cataracts present, yes surgery|adult patients who have cataracts but are not undergoing cataract surgery
16386438|NCT04074941|Experimental|Low sodium diet|This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
16386439|NCT04074941|Active Comparator|Usual sodium diet|This group will get a usual sodium diet (~2 mg per kcal of energy intake).
16386440|NCT04074928|Experimental|QIVc|Cell-derived Quadrivalent Influenza Vaccine
16386441|NCT04074928|Active Comparator|Comparator QIV|Comparator Quadrivalent Influenza Vaccine
16386442|NCT04074915|Placebo Comparator|Placebo rinse|Normal saline
16386443|NCT04074915|Experimental|Chlorhexidine mouth rinse|Chlorhexidine mouth rinse
16386444|NCT04074915|Experimental|Test group|Chamomile mouth rinse
16386507|NCT04074434||All Participants|
16386445|NCT04074889|Active Comparator|Group A|Patients will be given Lactobacillus & Bifidobacterium containing probiotics [Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg], to be taken 1 sachet twice daily for 6 months.
16386446|NCT04074889|Placebo Comparator|Group B|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.
16386447|NCT04074876||patients with femur fracture|"Group is composed of patients more of 65 years of age with femur fracture undergoing urgent orthopedic surgery.
~During normal pre-operative evaluation and classification based on principal scores and laboratory data, patients will be subjected to bedside pulmonary ultrasound.
~Pulmonary ultrasound will evaluate the presence of one of four patterns (normal pattern, isolated B lines, coalescent B lines and consolidation) defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient.
~These patients will be later subjected to spinal anaesthesia and orthopedic surgery.
~They will be follow for evaluation of MACE (major adverse cardiovascular events: atrial fibrillation, flutter, acute heart failure and non-fatal acute myocardial infarction)"
16386448|NCT04074863|Active Comparator|Darrach|Surgical procedure: resection of distal ulna
16386449|NCT04074863|Active Comparator|Prosthesis|Surgical procedure: ulnar head replacement
16386450|NCT04074850||TBI group|"A cohort of patients admitted to UZ Leuven from 1999 to 2019 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.
~Inclusion criteria will be: ≥ 65 years old at the time of the accident, admitted to UZ Leuven from 1999 and 2019, all injury severities, classified by the Glasgow Coma Scale (GCS) (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.
~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven in a different period from 1999-2019, diagnosis of other neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology before the TBI, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
16386451|NCT04074837|Placebo Comparator|Placebo|Placebo liquid suspension.
16386452|NCT04074837|Active Comparator|NNI-362, 10 mg|NNI-362 at 10 mg in liquid suspension
16386453|NCT04074837|Active Comparator|NNI-362, 20 mg|NNI-362 at 20 mg in liquid suspension
16386454|NCT04074837|Active Comparator|NNI-362, 60 mg|NNI-362 at 60 mg in liquid suspension
16386455|NCT04074837|Active Comparator|NNI-362, 120 mg|NNI-362 at 120 mg in liquid suspension
16386456|NCT04074824||Necrotizing enterocolitis|Neonates diagnosed with NEC based on the Modified Bell criteria for NEC including clinical, radiological and Laboratory findings.
16386457|NCT04074824||Non-NEC|Neonates diagnosed with other conditions including low birthweight, prematurity, infection, metabolic, cardiovascular, CNS, respiratory or gastrointestinal problems.
16386458|NCT04074811|Sham Comparator|Sham rTMS|Sham rTMS will be applied over the left dorsolateral prefrontal cortex using a sham figure of 8 coil (within-subject crossover). Sham rTMS will consist of the same auditory and tactile stimuli as the active condition, but does not induce an electromagnetic field and does not affect cortical excitability.
16386459|NCT04074811|Active Comparator|Active rTMS|Active rTMS will be applied over the left dorsolateral prefrontal cortex using an active figure of 8 coil (within-subject crossover). In the active rTMS condition, the investigators will use high-frequency (10Hz) dorsolateral prefrontal cortex (dlPFC) stimulation with intensity of 110% of resting motor threshold. rTMS will consist of 120 trains with 50 stimuli per train (i.e. 5-sec long at 10 Hz) and 10-sec intertrain interval for a total of 6000 pulses. The entire protocol will last 30 min (120 trains with 5-sec on/10-sec off).
16386460|NCT04074798|Active Comparator|Patients with low back pain|
16386461|NCT04074798|Sham Comparator|Healthy controls|
16386462|NCT04074785|Experimental|Safety Run-In|Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
16386463|NCT04074785|Experimental|Abemaciclib with Bevacizumab|Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
16386464|NCT04074772||Healthy Controls|This group will consist of healthy controls between the ages of 18 and 70-years-old. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be used to train a neural network to identify points of interest in a generalized patient population.
16386465|NCT04074772||Movement Disorder Patients|This group will consist of movement disorder clinic patients between the ages of 18 and 70-years-old with a diagnosed or putative movement disorder. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
16386466|NCT04074772||Age-Matched Controls|This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
16386467|NCT04074759|Experimental|FPT155 monotherapy|The study consists of dose escalation and cohort expansions
16386468|NCT04074759|Experimental|FPT155 in combination with pembrolizumab|The study consists of dose escalation and cohort expansions
16386469|NCT04074746|Experimental|Treatment (AFM13-NK, AFM13)|Patients receive two cycles of standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -4 to -2, AFM13-NK IV over 30 minutes on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.
16386470|NCT04074733||Patients with fractures|
16386471|NCT04074720|Other|Standard of Care|patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
16386472|NCT04074707|Experimental|oral iron supplementation|Participants go through 3 cycles of oral iron Supplementation (daily dosing, alternate-day dosing, every third-day dosing)
16386473|NCT04074694|No Intervention|Watchfull waiting|
16386474|NCT04074694|Active Comparator|Interventional|
16386508|NCT04074421|Active Comparator|Rifaximin group|Repeating treatment of Rifaximin
16386509|NCT04074421|Sham Comparator|Probiotics group|Sequential treatment of probiotics called Bacillus subtilis and Enterococcus faecium
16386510|NCT04074421|Placebo Comparator|Placebo group|Placebo control group
16386475|NCT04074681|Experimental|Gambling Internet-based Protocol|Intervention group that carries out the Gambling Internet-based Protocol based on Cognitive and Behavioral Therapy (CBT) and receives support by the therapist (a weekly 10-minute phone call without clinical content). In addition, they will receive one notification per day to respond to the EMI questions at 8 PM. The EMI includes immediate automatic feedback depending on the participant's responses.
16386476|NCT04074681|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
16386477|NCT04074668||Type 1 Diabetes|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
16386478|NCT04074668||Healthy Controls|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
16386479|NCT04074655|Experimental|Intervention Arm|Participants of the study will play the driving simulator daily (5 days/week) for 15-20 minutes/day over a period of 2 consecutive weeks.
16386480|NCT04074642|No Intervention|Non compressive adenoma|Optical Coherence Tomography Angiography without surgery
16386481|NCT04074642|Experimental|Compressive adenoma|Optical Coherence Tomography Angiography before and after neurosurgery
16386482|NCT04074629|Experimental|Skin related VOCs collected by Polydimethylsiloxane patch|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
16386485|NCT04074603|Experimental|Group A|needle-free before needle
16386486|NCT04074603|Experimental|Group B|needlebefore needle-free
16386489|NCT04074577|Active Comparator|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. The first colonoscopy will be performed without automated polyp detection software (standard technique) followed immediately by another colonoscopy with automated polyp detection software (combination technique).
16386490|NCT04074577|Active Comparator|Combination +followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. In this arm, the first colonoscopy with be performed with automated polyp detection software (combination technique) followed immediately by another colonoscopy without automated polyp detection software (standard technique)
16386491|NCT04074564|Experimental|A group|MASCT-I A+PD1 antibody+Apatinib combination therapy
16386492|NCT04074564|Experimental|B group|MASCT-I B+PD1 antibody+Apatinib combination therapy
16386493|NCT04074551|Experimental|Experimental|HCP1701
16386494|NCT04074551|Active Comparator|Active Comparator 1|HGP0904, HGP0608
16386495|NCT04074551|Active Comparator|Active Comparator 2|HGP0608, HCP1306
16386496|NCT04074499||Group-1|"The patients were classified based on the frequency of falls in the last 12 months.
~Group-1 consists of COPD patients whose have at least one fall (fallers)"
16386497|NCT04074499||Group-2|"The patients were classified based on the frequency of falls in the last 12 months.
~Group-2 consists of COPD patients whose have no history of falls (non-fallers)."
16386501|NCT04074473|Placebo Comparator|Propranolol alone|TPropranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
16386502|NCT04074473|Active Comparator|Esophageal variceal ligation alone|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
16386503|NCT04074473|Experimental|Esophageal variceal ligation(DC inderal after EV eradication)|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
16386504|NCT04074473|No Intervention|Propranolol(Keep BB after EV eradication)|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
16386505|NCT04074460|Active Comparator|Propofol (TIVA)|Propofol-based total intravenous anaesthesia
16386506|NCT04074460|Active Comparator|Volatile|Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia
16386512|NCT04074408|Experimental|Cohort 2|best dose of hUMSCs (from cohort 1) or placebo
16386513|NCT04074382||Prospective Cohort|Prospective cohort (Phase 1, and Phase 2 Group A: explained in detailed description earlier) We will recruit and consent patients on the ward in the first few weeks following their admission for major trauma when the consultant in charge of their care feels that they are physically and emotionally/mentally ready and appropriate to take part in the study. A member of the research team will ask whether they want to take part in the study and offer them the participant information sheet. If happy to take part, the patient will have an account set up on the online questionnaire service we will be using called QTool. The consent form will be completed online at baseline along with the initial baseline PROM questionnaires. This group of people will then be sent reminders at 3, 6, 9 and 12 months to complete follow-up questionnaires, up to 28 days before or after these timepoints. They will then enter Phase 2 (Group A).
16386514|NCT04074382||Retrospective Cohort|"Retrospective cohort (Phase 1/2):
~Patients between 1 to 10 years following their major trauma will be identified using a database. We will randomly select which of these patients to include in our study, using computer software, to reduce selection bias, and those selected will be sent a recruitment pack in the post. We have calculated that we need at least 320 patients in the retrospective cohort to show any important changes.
~This group of patients will only complete the questionnaires once in phase 1, and once per year up to 10 years after their trauma in phase 2 (Group B)."
16386515|NCT04074369||Pulmonary Tuberculosis Suspects|Individuals with suspected TB infection
16386516|NCT04074356|Active Comparator|Healthy Controls|Healthy volunteers with no known gastrointestinal complications will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
16386517|NCT04074356|Active Comparator|Achalasia subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of achalasia will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
16386518|NCT04074356|Active Comparator|Hypercontractile/spastic disorder subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of hypercontractile/spastic disorder will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
16386519|NCT04074343|Experimental|TAS-102 and Irinotecan|Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
16386520|NCT04074330|Experimental|Phase 1, aNHL/iNHL: TAK-981 (10-160 mg) + Rituximab 375 mg/m^2|TAK-981 (at increasing dose levels from 10 milligram [mg] to 160 mg), infusion, intravenously, once on Days 1 and 8 of each 21 day treatment cycle in combination with rituximab 375 milligram per square meter (mg/m^2), infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to disease progression (PD) or unacceptable toxicity. Dose levels will be escalated based on available safety, pharmacokinetic (PK) and pharmacodynamic data.
16386521|NCT04074330|Experimental|Phase 2, Cohort A: r/r DLBCL Progressed to CAR T-cell therapy|TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants with r/r diffuse large B-cell lymphoma (DLBCL) progressed or relapsed after a prior chimeric antigen receptor (CAR) T-cells therapy that has received approval by a health authority for the treatment of DLBCL.
16386522|NCT04074330|Experimental|Phase 2, Cohort B: r/r DLBCL with no CAR T-cell Prior Therapy|TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21 day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants with r/r DLBCL that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy and no prior therapy with CAR T-cells.
16386523|NCT04074330|Experimental|Phase 2, Cohort C: r/r FL Progressed to Systemic Therapies|TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21 day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants with r/r follicular lymphoma (FL) that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy.
16386524|NCT04074317|Experimental|PRAM9|Xeris pramlintide + insulin co-formulation
16386525|NCT04074317|Experimental|Regular Insulin + Pramlintide|Humulin® + Symlin® pen as separate injections
16386526|NCT04074317|Active Comparator|Regular Insulin|Humulin®
16386527|NCT04074304|Other|I-HoME prototype|Participants will be shown prototype of I-HoME and provide feedback as part of the user-center design process.
16386528|NCT04074278||development groups|The development groups included 150 patients derived from outpatients in Peking University First Hospital, between March 1st, 2014 and November 26th 2014.
16386529|NCT04074278||validation groups|The validation groups included 150 patients derived from outpatients in Peking University First Hospital, between November 27th 2014 and December 1st, 2015.
16386530|NCT04074265|Active Comparator|Pain injection|This group will be injected with a cocktail totaling 40mL (20mL on each side) that will be composed of ropivicaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), ketorolac 30mg/mL (0.5mg/kg).
16386531|NCT04074265|Placebo Comparator|Normal saline|The control group will receive an injection of 40mL of 0.9% sodium chloride solution.
16386532|NCT04074252|Active Comparator|Lofstrand Crutches|This group is given a set of Lofstrand crutches.
16386533|NCT04074252|Active Comparator|Axillary Crutches|This group is given a set of axillary crutches.
16386534|NCT04074239|Experimental|Video triage|The sick child will be triaged on video by the operator.
16386535|NCT04074239|No Intervention|Telephone triage|The sick child will be triaged solely on telephone by the operator.
16386629|NCT04073589|Experimental|Treatment A|Single SC injection of Dose A
16386630|NCT04073589|Experimental|Treatment B|Single SC injection of Dose B
16386631|NCT04073589|Experimental|Treatment C|Single SC injection of Dose C
16386632|NCT04073589|Experimental|Treatment D|Single SC injection of Dose D
16386633|NCT04073576|Experimental|AHCL|Advanced Hybrid Closed Loop
16386634|NCT04073576|Active Comparator|SAP+PLGM|Sensor Augmented Pump with Predictive Low Glucose Monitoring
16386829|NCT04072380|Placebo Comparator|Placebo|Orally taken once daily for 14 days
16386536|NCT04074226|Experimental|Ultrasound-guided ESP block with liposomal bupivacaine|For the ESP block, the transducer will be placed parasagittally at the level of the tip of the scapula and the anesthesiologist will scan in a craniocaudal manner to identify the ipsilateral T10 transverse process and overlying erector spinae muscle. Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the muscle and transverse process. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.
16386537|NCT04074226|Active Comparator|Ultrasound-guided QL block with liposomal bupivacaine|"For the QL block, the transducer will be placed transversely over the lumbar spine at the level of the iliac crest. Then, the anesthesiologist will scan laterally to identify the ipsilateral L3 transverse process, psoas muscle, and quadratus lumborum muscle to identify the Shamrock Sign (7). Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the quadratus lumborum muscle and psoas muscle. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the two muscles. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site."
16386538|NCT04074213||Haematologic malignancies with clozapine|Cases reported in the World Health Organization (WHO) database of patients treated by Clozapine, with a chronology compatible with the drug toxicity
16386539|NCT04074200||Open Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using an open surgical approach.
16386540|NCT04074200||Laparoscopic Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a laparoscopic surgical approach.
16386541|NCT04074200||Robotic-assisted Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a robotic-assisted surgical approach.
16386542|NCT04074187|Experimental|Caplacizumab|Eligible study participants will receive caplacizumab in addition to standard of care such as daily plasma exchange (PE) and corticosteroid treatment (mandatory), immunosuppressive treatment (if needed)
16386543|NCT04074174|Experimental|NNC0174-0833 treatment-free period; NNC0174-0833 treatment|During the NNC0174-0833 treatment-free period participants will receive OC tablets and acetaminophen. During the NNC0174-0833 treatment period participants will receive OC tablets and acetaminophen in addition to NNC0174-0833.
16386544|NCT04074161|Experimental|Semaglutide|Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
16386545|NCT04074161|Placebo Comparator|Placebo (semaglutide)|Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
16386546|NCT04074161|Active Comparator|Liraglutide|Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
16386547|NCT04074161|Placebo Comparator|Placebo (liraglutide)|Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
16386548|NCT04074148|Experimental|Diabetes Prevention Education Program|Diabetes Prevention Education Program
16386549|NCT04074148|Experimental|control|Diabetes Prevention Education brochure
16386550|NCT04074135|Experimental|1/ Arm 1|Study natural history of VHL pancreatic neuroendocrine tumors with yearly 68-Gallium DOTATATE PET/CT research scans.
16386551|NCT04074135|No Intervention|2/ Arm 2|Study natural history of VHL pancreatic neuroendocrinetumors without research scans.
16386552|NCT04074122||Symptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
16386553|NCT04074122||Asymptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
16386554|NCT04074122||Healthy controls|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
16386555|NCT04074109|Experimental|Teleyoga|group will receive instruction via computer tablet
16386556|NCT04074109|Active Comparator|In-person yoga|group will receive instruction in-person
16386557|NCT04074096|Experimental|Encorafenib + binimetinib + pembrolizumab|Encorafenib 450 mg oral route (PO) once daily (QD) + binimetinib 45 mg PO twice daily (BID) + pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W).
16386558|NCT04074096|Experimental|SRS followed by encorafenib + binimetinib + pembrolizumab|Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID + pembrolizumab 200 mg IV Q3W. The treatment should be started more than 24 hours and less than 8 days (excluded) after the SRS
16386561|NCT04074070||Psoriasis with and without musculoskeletal complains|psoriasis with and without musculoskeletal complains
16386562|NCT04074070||Healthy individuals|
16386563|NCT04074070||Psoriatic arthritis|
16386564|NCT04074057|Other|Control arm|the control group will undergo a conventional weekly CR programme lasting 8-12 sessions. Components of each session will include warm up, aerobic training, resistance exercises and cool down. Patients are encouraged to continue their home exercises, exercising another 2 times a week at home and record down using an activity diary. The importance of CR programme and exercise advice will be explained and reinforced by the CR Physiotherapist. The submaximal exercise test and a body composition analysis will be repeated on the final assessment. Every week research coordinator will call the subject to remind them to exercise.
16386830|NCT04072367|Other|Active Treatment Group|NeVa Stent Retrievers
16386565|NCT04074057|Other|Intervention arm|"During the initial assessment, the importance of CR and regular exercise will be explained and reinforced by CR physiotherapist. A research assistant will teach the patient how to use Heart Track. The patient will then bring Heart Track home to continue their CR program. Patient will then undergo the whole CR programme to exercise for 3 times a day for 8-12 weeks using Heart Track. Each Heart Track session will include warm up, aerobic training, resistance exercises and cool down (same as the traditional CR session). After 8-12 weeks, patient will be called back to the clinic by the research assistant to complete the final assessment (sub-maximal exercise test and a body composition analysis) with the blinded assessor. Every week research coordinator will call the subject to remind them to exercise."
16386566|NCT04074044|Experimental|BHmApp users|Participants using BHmApp tor bladder education and training
16386567|NCT04074031|Experimental|minimally invasive method for performing thalamotomy|We will study patients with essential tremor with significant disability despite well-conducted drug therapy who have a contraindication to deep brain stimulation or who refuse treatment. In this population, unilateral thalamotomy of Vim by radiosurgery is already considered a valid indication and performed routinely with proven efficacy and morbidity deemed acceptable. It is therefore the population of choice to evaluate for the first time in France the efficacy and safety of a new, minimally invasive method for performing thalamotomy: targeted ultrasound thermal injury at high intensity. This same population will also make it possible to study, for the first time in humans in this indication, the potential of neuromodulation by low frequency low frequency ultrasound beams to improve the guidance before the lesion is achieved.
16386568|NCT04074018|Experimental|Experimental group|Self-rehabilitation guided program with investigator PMR specialist
16386569|NCT04074018|Active Comparator|Control group|Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation
16386570|NCT04073992|Experimental|Cognitive behavioral treatment of insomnia (CBT-I)|Eight weeks of cognitive behavioral treatment of insomnia.
16386571|NCT04073979|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
16386572|NCT04073953|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15mg of RPQ every day for 5 days. Cohort 2 will receive 22.5 mg of RPQ every day for five days.
16386573|NCT04073953|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.
16386574|NCT04073953|Placebo Comparator|Placebo|Cohort 1 will receive placebo capsules every day for 5 days. Cohort 2 will receive placebo capsules every day for five days.
16386575|NCT04073940|Experimental|Targeted Ballet Program|A 16-week (32 sessions of 1 hour each) ballet-based intervention targeted to improve motor function in persons with multiple sclerosis.
16386576|NCT04073927|Active Comparator|Sodium butyrate|3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.
16386577|NCT04073927|Placebo Comparator|Placebo|Placebo. 6 capsules twice daily for 12 weeks.
16386578|NCT04073914|Active Comparator|Intervention|Type 1 Teamwork program
16386579|NCT04073914|No Intervention|Control|Standard of care
16386580|NCT04073901|Experimental|Endocrown|Adhesive monoblock restoration for pulpotomized primary molars
16386581|NCT04073901|Active Comparator|Zirconia crowns|Prefabricated primary full coverage crown
16386582|NCT04073888|Other|Single arm|Men with Fabry Disease
16386583|NCT04073875||Bioprosthetic aortic valve|Single 18F-GP1 PET-CT
16386584|NCT04073875||Bioprosthetic aortic valve thrombus - repeat imaging|18F-GP1 PET-CT at baseline and 3 months
16386585|NCT04073862|Other|Stepped-Care TF-CBT|The study participants will receive Stepped-Care Trauma-Focused Cognitive-Behavioral-Therapy (SC-TF-CBT).
16386586|NCT04073849|Active Comparator|Cohort A|EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
16386587|NCT04073849|Sham Comparator|Cohort B|Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
16386588|NCT04073823|Active Comparator|Flexitouch Plus|
16386589|NCT04073823|Experimental|Flexitouch Plus with SW|
16386590|NCT04073810||Myocardial infarction|Patients with recent MI
16386591|NCT04073797|Experimental|Stable CVD - treatment|Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor
16386592|NCT04073797|Placebo Comparator|Stable CVD - placebo control|Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control
16386593|NCT04073797|Experimental|HeFH - treatment|HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor
16386594|NCT04073797|Placebo Comparator|HeFH - placebo control|HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control
16386595|NCT04073784|Experimental|Gemcitabine combined with Apatinib and Toripalimab|Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.
16386596|NCT04073771||Cohort study|Patients with septic shock undergoing continuous renal replacement therapy
16386597|NCT04073758|Sham Comparator|Remifentanil group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC). As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.
16386831|NCT04072367|Other|Control Device|Solitare Stent Retrievers
16386598|NCT04073758|Active Comparator|Dexmedetomidine group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.
16386599|NCT04073745|Experimental|Treatment (SBRT)|Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
16386600|NCT04073732||family physician team|Family physician team in four regions (Beijing, Shanghai, Hangzhou and Xia'men), including general practitioners, nurses and public health personnel.
16386601|NCT04073719|Experimental|Apple Cider Vinegar + Coconut Water|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
16386602|NCT04073719|Experimental|Apple Cider Vinegar + Citric Soda|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
16386603|NCT04073719|Experimental|Apple Cider Vinegar + Lemonade|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
16386604|NCT04073719|Experimental|Coconut Water + Apple Cider Vinegar|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
16386605|NCT04073719|Experimental|Coconut Water + Citric Soda|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
16386606|NCT04073719|Experimental|Coconut Water + Lemonade|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
16386607|NCT04073719|Experimental|Citric Soda + Apple Cider Vinegar|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
16386608|NCT04073719|Experimental|Citric Soda + Coconut Water|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
16386609|NCT04073719|Experimental|Citric Soda + Lemonade|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
16386610|NCT04073719|Experimental|Lemonade + Apple Cider Vinegar|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
16386611|NCT04073719|Experimental|Lemonade + Coconut Water|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
16386612|NCT04073719|Experimental|Lemonade + Citric Soda|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
16386613|NCT04073706|Experimental|TH BSO with SNB|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG) (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.
16386614|NCT04073706|Active Comparator|TH BSO without retroperitoneal node dissection|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.
16386615|NCT04073693|Active Comparator|BRCA|They were in treatment with BRCA and standard treatment based on nutritional intervention and physical exercise.
16386616|NCT04073693|Placebo Comparator|Placebo|They only were on standard treatment based on nutritional intervention and physical exercise.
16386617|NCT04073680|Experimental|Serabelisib|"Part 1 is dose escalation of Serabelisib Cohort 1 = 600mg; Cohort 2 = 900mg; Cohort 3 = 1200mg
~Part 2 is expansion of mutational cohorts with selected dose as follows:
~Cohort 4 = PIK3CA-mutated breast cancer; Cohort 5 = PIK3CA-mutated Non breast cancer; Cohort 6 = KRAS mutated"
16386618|NCT04073667|Experimental|Early Rehabilitation Group|The first six weeks (1st-6th) will be followed as an exercise group and the second six weeks (7th-12th) will be followed as a control group without any intervention.
16386619|NCT04073667|Experimental|Late Rehabilitation Group|The first six weeks (1st-6th) will be followed as a control group without any intervention and the second six weeks (7th-12th) will be followed by exercise.
16386620|NCT04073654|Active Comparator|SA Implants|Dental implant with sandblasted and Acid-etched (SA) surface
16386621|NCT04073654|Experimental|SOI Implants|Same dental implant with sandblasted and Acid-etched surface modified with pH buffering agent
16386622|NCT04073641||Survey population|Adults with type 1 and type 2 diabetes and caregivers of people with diabetes including parents of children and young people with diabetes.
16386623|NCT04073628|Active Comparator|Active Lighting intervention|The active lighting intervention will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, the intervention will allow us to: (1) use a light source that will stimulate the circadian system and (2) provide the participants with options as to how the light treatment will be delivered
16386624|NCT04073628|Placebo Comparator|Control Lighting Intervention|The control lighting intervention will consist of low levels of a warm light source designed not to impact the circadian system.
16386625|NCT04073615|Experimental|Rivoceranib|Rivoceranib, 700 mg po, qd
16386626|NCT04073615|Active Comparator|Trifluridine/tipiracil|35 mg/m2 po, bid
16386627|NCT04073615|Experimental|Rivoceranib and trifluridine/tipiracil|Rivoceranib, recommended phase 2 dose (RP2D) Trifluridine/Tipiracil, 35 mg/m2, po, bid
16386628|NCT04073602|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
16386635|NCT04073563|Experimental|Group #1|Investigational Infuse™ 2.1 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
16386636|NCT04073563|Experimental|Group #2|Investigational Infuse™ 4.2 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
16386637|NCT04073563|Active Comparator|Control|Local bone autograft and supplemented with cancellous allograft as needed.
16386638|NCT04073550|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
16386639|NCT04073550|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
16386640|NCT04073537|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
16386641|NCT04073537|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m^2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
16386642|NCT04073524|Experimental|Nature-Body-Mind-Community (NBMC) + treatment as usual|9 weeks of nature-based therapy (Nature-Body-Mind-Community (NBMC)) treatment as usual
16386643|NCT04073524|Other|Treatment as usual|Treatment as usual
16386644|NCT04073511|Experimental|Eungyosan|Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
16386645|NCT04073511|Experimental|Samsoeum|3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
16386646|NCT04073511|Placebo Comparator|Placebo|Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
16386647|NCT04073498|Experimental|Part 1a - Cohort 1|A single IV infusion of 0.0003 mg/kg SerpinPC in healthy subjects.
16386648|NCT04073498|Experimental|Part 1a - Cohort 2|A single IV infusion of 0.001 mg/kg SerpinPC in healthy subjects.
16386649|NCT04073498|Experimental|Part 1a - Cohort 3|A single IV infusion of 0.003 mg/kg SerpinPC in healthy subjects.
16386650|NCT04073498|Experimental|Part 1a - Cohort 4|A single IV infusion of 0.01 mg/kg SerpinPC in healthy subjects.
16386651|NCT04073498|Experimental|Part 1a - Cohort 5|A single SC dose of 0.03 mg/kg SerpinPC and a single SC dose of placebo in healthy subjects.
16386652|NCT04073498|Experimental|Part 1b - Cohort 6|A single SC dose of 0.1 mg/kg SerpinPC and a single SC dose of placebo in patients.
16386653|NCT04073498|Experimental|Part 1b - Cohort 7|A single SC dose of 0.3 mg/kg SerpinPC and a single SC dose of placebo in patients.
16386654|NCT04073498|Experimental|Part 1b - Cohort 8|A single SC dose of 0.6 mg/kg SerpinPC and a single SC dose of placebo in patients.
16386655|NCT04073498|Experimental|Part 1b - Cohort 9|Two single SC doses of 0.6 mg/kg SerpinPC in patients.
16386656|NCT04073498|Experimental|Part 2|Up to 3 SC doses may be selected for Part 2 and each patient will be assigned a single SerpinPC dose level (and placebo). The dose for Part 2 will be determined from ongoing review of the Part 1 data. The dose in Part will not exceed 1.2 mg/kg, or the highest dose deemed safe from Part 1b.
16386657|NCT04073498|Experimental|Part 3|A single flat SC dose of SerpinPC will be administered every 4 weeks for 48 weeks (13 doses) to up to 25 patients who have completed Week 24 of Part 2. The dose level will be chosen after reviewing Part 2 data and will not exceed maximum dose level in Part 2.
16386658|NCT04073485|Other|Microwave ablation|The uterine fibroid will be identified and located with ultrasonography. A microwave electrode appropriate for the size of target lesion is placed into the target lesion under ultrasound guidance. Appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
16386659|NCT04073472|Experimental|mesenchymal stem cells (MSCs)|Direct injection of 60 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed.
16386660|NCT04073459|Experimental|L dose of Hexavalent|Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
16386661|NCT04073459|Experimental|M dose of Hexavalent|Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
16386662|NCT04073459|Experimental|H dose of Hexavalent|High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
16386663|NCT04073459|Active Comparator|Pentavalent+IPV|Co-administration of EupentaTM Inj and Imovax Polio
16386664|NCT04073446|Active Comparator|Dorsal Column (DC) Perception|Use of DC Perception based programming
16386665|NCT04073446|Active Comparator|Dorsal Root (DR) Perception|Use of DR Perception based programming
16386666|NCT04073446|Active Comparator|Dorsal Column (DC) Sub-perception|Use of DC sub-perception based programming
16386667|NCT04073446|Active Comparator|Dorsal Root (DR) Sub-perception|Use of DR sub-perception based programming
16386668|NCT04073433|Experimental|Experimental: MDMA-assisted psychotherapy|One session of MDMA-assisted psychotherapy with a dose of MDMA 120 mg and optional supplemental dose of 60 mg 1.5 to 2 hours later
16386670|NCT04073407|Active Comparator|AXA1957|AXA1957 20.4g
16386671|NCT04073407|Placebo Comparator|Placebo|Placebo 24g
16386672|NCT04073394|Other|Diet Intervention|
16386673|NCT04073381|Experimental|Prehabiliation Program|100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study ad participate in the prescribed prehabilitation exercise and nutrition program.
16386674|NCT04073368|Active Comparator|AXA1957 high dose|AXA1957 20.3g
16386675|NCT04073368|Active Comparator|AXA1957 low dose|AXA1957 13.5g
16386676|NCT04073368|Active Comparator|AXA1125|AXA1125 24g
16386677|NCT04073368|Placebo Comparator|Placebo|Placebo 24g
16386678|NCT04073355|Experimental|Physical Activity|Smartphone-delivered physical activity intervention
16386679|NCT04073342||Surgical Necrotizing enterocolitis|Cases of preterm infants with necrotizing enterocolitis need surgical intervention
16404628|NCT03946488|Experimental|Active neuroprosthesis|
16386680|NCT04073342||Non Necrotizing enterocolitis|babies with intestinal operations for non necrotizing enterocolitis pathologies like congenital intestinal obstruction.
16386681|NCT04073329||Plain x ray|measurement the accuracy of post operative reduction by Matta method
16386682|NCT04073329||CT|measure the accuracy of reduction by Verbeek method
16386683|NCT04073316|Experimental|"Intervention group"|
16386684|NCT04073316|Active Comparator|"Control group"|
16386685|NCT04073303|Active Comparator|Botulinum Toxin Type A (BOTOX®)|Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
16386686|NCT04073303|Placebo Comparator|Placebo|Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
16386687|NCT04073290|Active Comparator|Rifaximin and lactulose|Rifaximin 550 milligram b.i.d. combined with lactulose
16386688|NCT04073290|Placebo Comparator|Placebo and lactulose|Placebo b.i.d. combined with lactulose
16386689|NCT04073277|Experimental|SCF-N-treated needle acupuncture|For each participant, one hand was randomly assigned to the experimental group with SCF-N-treated needle acupuncture .
16386690|NCT04073277|Sham Comparator|untreated needle acupuncture|The other hand of participant in experimental group was assigned to the control group with untreated needle acupuncture.
16386691|NCT04073264|Experimental|monofilament|monofilament absorbable suture
16386692|NCT04073264|Active Comparator|polifilament|synthetic absorbable braided (polifilament) suture
16386693|NCT04073251|Experimental|KalobaTuss children|KalobaTuss children syrup 5 ml for 4 times a day supplied for 8 consecutive days.
16386694|NCT04073251|Placebo Comparator|Placebo|Placebo syrup 5 ml for 4 times a day supplied for 8 consecutive days.
16386695|NCT04073238|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
16386696|NCT04073238|Experimental|Repeated low-level red-light therapy|Single vision lens & repeated low-level red-light therapy
16386697|NCT04073225|Experimental|MindPod Dolphin Arm|Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke.
16386698|NCT04073225|Active Comparator|Hand Bike Arm|Pedal Exerciser, a single-component upper-arm aerobic play. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
16386699|NCT04073212|Experimental|Intervention 1 DN+HSLE|Patients in the intervention 1 Dry Needling (DN)+heavy Slow Load Exercise (HSLE) group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon followed by DN, HSLE and a standardized shoulder strengthening exercise program.
16386700|NCT04073212|Active Comparator|Intervention 2 Control|"Patients in the control group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon and a standardized exercise program. Dry needling nor heavy slow load exercise will not be integrated into the control plan of care."
16386701|NCT04073199|Active Comparator|Long Lever Group|This arm receive the protocolized treatment along with the long passive stretch of the Teres Major in Long Lever with the patient in supine position.
16386702|NCT04073199|Active Comparator|Short Lever Group|This arm receive the protocolized treatment along with the short lever stretch according to the Orthopaedic Manual Therapy of the Teres Major.
16386703|NCT04073199|No Intervention|Control Group|only receive the protocolized physiotherapy treatment for the Subacromial syndrome that is applied in the Rehabilitation Service, without the addition of any additional stretch technique.
16386704|NCT04073186|Experimental|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
16386705|NCT04073173|Experimental|LISA-analgesic|Less Invasive Surfactant Administration (LISA) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
16386706|NCT04073173|Experimental|LISA-no analgesic|Less Invasive Surfactant Administration (LISA) without an analgesic drug.
16386707|NCT04073173|Experimental|INSURE-analgesic|INtubation-SURfactant-Extubation (INSURE) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
16386708|NCT04073173|Experimental|INSURE-no analgesic|INSURE without an analgesic drug.
16386709|NCT04073160|Experimental|Decipher Bladder test subtype non-basal|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype non-basal
16386710|NCT04073160|Experimental|Decipher Bladder test subtype basal and cisplatin-ineligible|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype basal and the subject is cisplatin-ineligible
16386711|NCT04073147|Experimental|Dosing group 1|Venetoclax 600mg + Obinutuzumab 1000mg
16386712|NCT04073147|Experimental|Dosing group 2|Venetoclax 800mg + Obinutuzumab 1000mg
16386713|NCT04073147|Experimental|Dosing group 3|Venetoclax 1000mg + Obinutuzumab 1000mg
16386714|NCT04073134|Active Comparator|Evolocumab|Participants will receive evolocumab 140 mg subcutaneous injections once every 2 weeks.
16386715|NCT04073134|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injections once every 2 weeks.
16386716|NCT04073121|Experimental|Luminor DCB and Angiolite DES|Study Devices
16386748|NCT04072900|Experimental|Intervention/Treatment|"Personalized NeoAntigen Cancer Vaccine- Neo-Vac-Mn (peptides + rhGM-CSF+anti-PD1+Imiquimod 5% Topical Cream)
~NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161
~Anti-PD-1 Toripalimab: 3mg/kg, ivgtt, Q2w
~rhGM-CSF: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
~Imiquimod 5% Topical Cream:topical application on the injection site 6 hours before each NeoAntigen peptides injection"
16386717|NCT04073095|Active Comparator|Group T = mTLIP block group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
16386718|NCT04073095|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
16386719|NCT04073095|No Intervention|Group C = Control group|Patients in control group will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
16386720|NCT04073069|Experimental|The DR group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, 0.5ml diprospan, plus 14.5ml saline;
16386721|NCT04073069|Active Comparator|The R group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, plus 15ml saline;
16386722|NCT04073056|Active Comparator|Quadratus Lumborum II Group|The QL 2 group will receive 15 mL bupivacaine 0.25% on both sides for a total of 30 mL once the surgery is done but prior to extubation under ultrasound guidance.
16386723|NCT04073056|Active Comparator|Conventional Therapy|Conventional therapy consists of the injection of 30 mL of bupivacaine 0.25% directly into the incision sites by the surgeon at the end of the procedure.
16386724|NCT04073043|Experimental|Intervention Group|The intervention group will have access to the web-based intervention along with telephone coaching. Participants in the intervention will receive 7 coach calls over a period of 12 weeks.
16386725|NCT04073043|No Intervention|Control Group|The control group will have access only to the web-based intervention without telephone support
16386726|NCT04073017|Experimental|Enterade|Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
16386727|NCT04073017|Experimental|Experimental|Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
16386728|NCT04073004|Experimental|Rapid Resolution Therapy|"RRT is a talk therapy that uses Neurolinguistic Programming Language and trance states to cause a shift in how the mind is processing incoming data.
~The understanding is that the part of the mind that is causing the disturbing emotion, thought or sensation is causing them to cause the person to take an action to ensure the organisms survival. RRT therapists employ psycho-therapeutic techniques taht are designed to cause the mind to process information differently so that the disturbing content and distorted meaning shift."
16386729|NCT04072991|Active Comparator|Low FODMAP diet|As part of their treatment for IBS participants may be randomised to a low FODMAP diet
16386730|NCT04072991|Active Comparator|Gluten Free Diet|As part of their treatment for IBS participants may be randomised to a gluten free diet
16386731|NCT04072991|Active Comparator|British Dietetic Association diet|As part of their treatment for IBS participants may be randomised to the BDA diet
16386732|NCT04072978||Intraocular lens implantation: AC IOL|"Patients who are scheduled to undergo AC IOL (anterior chamber intraocular lens) implantation for any of the following indications:
~primary or secondary aphakia
~primary or secondary lens subluxation or dislocation"
16386733|NCT04072978||Intraocular lens implantation: SF IOL|"Patients who are scheduled to undergo SF IOL (scleral fixated intraocular lens) implantation for any of the following indications:
~primary or secondary aphakia
~primary or secondary lens subluxation or dislocation"
16386734|NCT04072965|Experimental|Cross eduacation of balance|10 females with Chronic Ankle Instability will receive balance training for the non affected side for a six weeks
16386735|NCT04072965|Experimental|Traditional training|10 females with Chronic Ankle Instability will receive balance training for the affected side for a six weeks
16386736|NCT04072965|No Intervention|control|balance of 15 females with Chronic Ankle Instability will be assessed before and after six weeks of no intervention
16386737|NCT04072952|Experimental|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
16386738|NCT04072952|Experimental|ARV-471 and palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days.
16386739|NCT04072939||Single arm|dilated fundus exam
16386740|NCT04072926|Experimental|PDT+/BIOROOT|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with BioRoot in combination with guttapercha points.
16386741|NCT04072926|Experimental|PUI/BIOROOT|This arm will only get PUI (passive ultrasound irrigation) with 2,5ml of 2,5% sodium hypochlorite, then 2ml of 15% EDTA which will be activated for 60seconds (EndoUltra MicroMega, France) and finally 2,5ml of 2,5% of sodium hypochlorite will be also activated for 30 seconds. Root canal filling in combination with BioRoot and guttapercha points.
16386742|NCT04072926|Active Comparator|PDT+/AH+|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with AH+ epoxy based cement in combination with guttapercha points.
16386743|NCT04072926|Active Comparator|PUI/AH+|This arm will only get PUI (passive ultrasound irrigation) in combination with AH+ epoxy based cement and guttapercha points.
16386744|NCT04072913|Other|Control group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
16386745|NCT04072913|Other|Low grade lesion group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
16386746|NCT04072913|Other|High grade lesions group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
16386747|NCT04072913|Other|Cancer group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
16386755|NCT04072874|Active Comparator|Régimen 1|"Regimen 1: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 4 weeks.
~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
16386756|NCT04072874|Active Comparator|Régimen 2|"Regimen 2: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 6 weeks.
~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
16386757|NCT04072861|Other|Administer 9mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 9 mg of Stannous Protoporphyrin and be followed for 28 days.
16386758|NCT04072861|Other|Administer 27mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 27 mg of Stannous Protoporphyrin and be followed for 28 days.
16386759|NCT04072861|Other|Administer 90mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 90 mg of Stannous Protoporphyrin and be followed for 28 days.
16386760|NCT04072861|Other|Administer 27mgSnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 27 mg of Stannous Protoporphyrin and be followed for 28 days.
16386761|NCT04072861|Other|Administer 90mgSnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 90mg of Stannous Protoporphyrin and be followed for 28 days.
16386762|NCT04072861|Other|Administer 27mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 27mg of Stannous Protoporphyrin and be followed for 28 days.
16386763|NCT04072861|Other|Administer 90mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 90mg of Stannous Protoporphyrin and be followed for 28 days.
16386764|NCT04072835|Experimental|Etripamil NS 70mg|Patients will self-administer etripamil NS.
16386765|NCT04072822|Active Comparator|Prednisone|Standard of care plus prednisone 40 mg orally once daily on Days 1-30 and matching placebos for Anakinra (1 syringe s.c. once daily on Days 1-14), and zinc (matched pill once daily on Days 1-90).
16386766|NCT04072822|Active Comparator|Anakinra and Zinc|Standard of care plus Anakinra (100 mg s.c.) once daily on Days 1-14 zinc sulfate 220 mg once daily on Days 1-90, and placebo for prednisone (matched pill once daily on Days 1-30).
16386767|NCT04072809||All participants|All participants in the study will experience the same procedures.
16386768|NCT04072796||Case group|Case group reported urinary complaints
16386769|NCT04072796||Control group|Control group did not have any urinary complaints.
16386770|NCT04072783|Other|Patients with craniosynostosis|Patients with craniosynostosis will undergo pre - and post-operative imaging studies. The surgery will be performed for these patients as standard of care. They will also be tested fro neurodevelopment.
16386771|NCT04072770|Experimental|Pea|Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
16386772|NCT04072770|Active Comparator|Casein|Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
16386773|NCT04072757|Active Comparator|Intervention Group|The cooking skill building/nutrition education workshops will be led by a multidisciplinary team comprised of: a chef/instructor, a nutritionist and/or registered dietitian, MD and/or Preventive Medicine Resident, and Yale-Griffin Prevention Research Center staff. The cooking/nutrition education workshop sessions will be approximately 45 minutes and will: include a plant forward approach to healthy eating; integrate nutrition and health-related information and cooking instruction (i.e. knife skills, equipment use); show participants how to prepare meals that are simple, nutritious, affordable, and delicious; provide recipes and nutrition information aimed at improving dietary intake and health status; and provide an enjoyable program that participants will look forward to attending. Fruit and vegetable prescription vouchers will be redeemed at ShopRite grocery stores (Ansonia and Shelton locations) and Griffin Hospital's farmers market, where redemption will be tracked.
16386774|NCT04072757|Placebo Comparator|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
16386775|NCT04072744||Participants|General Study Participants
16386776|NCT04072731||thyroid cancer|the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
16386777|NCT04072731||the adjacent thyroid tissues|the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
16386778|NCT04072718|Other|Single arm|
16386779|NCT04072705||1. Poor and intermediate metabolizer group|Poor and intermediate metabolizer group: acute ischemic stroke patients with poor and intermediate metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
16386780|NCT04072705||2. Extensive metabolizer group|Extensive metabolizer group: acute ischemic stroke patients with Extensive metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
16386781|NCT04072692|No Intervention|1st part: The gliding properties of the tendons|No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
16386782|NCT04072692|No Intervention|1st part: The gliding properties of the median nerve|No intervention. Subjects are measured by ultrasound under under 6 different postures of the wrist and hand and 5 different movement patterns of the wrist and hand for forty minutes.
16386783|NCT04072692|Experimental|2nd part: New hybrid rehabilitation strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.
~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.
~For post-test, the same procedure is repeated again after completing all training.
~For follow-up, the same procedure is repeated again 6 months after completing all training.
~After pre-test, 8 times hybrid rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
16386832|NCT04072354|Experimental|SEP-363856 50mg|SEP-363856 50mg dosed once daily
16386833|NCT04072354|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
16386834|NCT04072354|Placebo Comparator|Placebo|Placebo dosed once daily
16386784|NCT04072692|Experimental|2nd part: Traditional strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.
~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.
~For post-test, the same procedure is repeated again after completing all training.
~For follow-up, the same procedure is repeated again 6 months after completing all training.
~After pre-test, 8 times traditional rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
16386785|NCT04072692|No Intervention|3rd part: The effect of carpal tunnel release|"No intervention. The program includes pre-test, post-test and two times follow-up tests.
~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.
~For post-test, subjects perform the functional assessment of both hands one week after carpal tunnel release surgery. It takes 20 minutes.
~For first follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands one month after carpal tunnel release surgery. It takes 40 minutes.
~For second follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands two month after carpal tunnel release surgery. It takes 40 minutes."
16386786|NCT04072692|Experimental|3rd part: Wearable anti-bowstringing orthosis (WABO)|"The program includes pre-test, post-test and two times follow-up tests.
~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.
~Subjects wear WABO in the morning and a splint at night within a week after carpal tunnel release surgery.
~For post-test, subjects perform the functional assessment of both hands with and without wearing WABO and a splint one week after carpal tunnel release surgery. It takes 40 minutes.
~From the third weeks after carpal tunnel release surgery, subjects wear WABO only in the morning.
~For first follow-up, the same procedure in pre-test is repeated again one month after carpal tunnel release surgery. It takes 40 minutes.
~For second follow-up, the same procedure in pre-test is repeated again two month after carpal tunnel release surgery."
16386787|NCT04072679|Experimental|Sintilimab+IBI305|Sintilimab: 200mg (D1, q3w） IBI305: 7.5mg/kg or 15mg/kg (D1, q3w）
16386788|NCT04072666|Experimental|ASSIP plus SPP|Participants in the ASSIP group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the ASSIP psychological intervention where they will receive three therapy sessions followed by regular ongoing contact through individually focused letters sent over 24 months.
16386789|NCT04072666|Experimental|CBT plus SPP|Participants in the CBT group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the CBT psychological intervention where they will receive five CBT 60-minute individual sessions.
16386790|NCT04072666|Active Comparator|SPP alone|"The Suicide Prevention Pathway (SPP) comprises seven steps:
~i) Initial screening - persons experiencing suicide ideation and who may also have a history of, or recent, suicide attempt, are placed on the pathway; ii) Assessment of suicide risk iii) Formulation of suicide risk (based on a prevention oriented approach) iv) Safety planning (collaboratively developed with the client) and Counselling on access to lethal means v) Structured follow-up (within 24-48 hrs); vi) Transition of care plan; and vii) Caring contacts - ongoing contact/support for the person for the next 2 years (through personalised letters or phone texts)."
16386791|NCT04072653|Experimental|Observation group( SLNB is spared)|In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.
16386792|NCT04072640|Experimental|voriconazole treatment|induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
16386793|NCT04072640|Active Comparator|amphotericin treatment (0.7-1.0mg/kg/d)|Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
16386794|NCT04072640|Experimental|amphotericin B treatment (0.4-0.5mg/kg/d)|Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
16386795|NCT04072601|Experimental|Atorvastatin|Atorvastatin 10-20 mg for 18 months of treatment. Start dose is 10 mg, adjusted to 20 mg after 15-30 days if no sideeffects occurs.
16386796|NCT04072601|Placebo Comparator|Control|Placebo of atorvastatin 10 mg, 1-2 tablets for 18 months of treatment. Start dose is 1 tablet (10 mg placebo), adjusted to 2 tablets (20 mg placebo) after 15-30 days if no side effects occurs.
16386800|NCT04072562|Experimental|AZD7594 0.7 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 0.7 mg, delivered dose 1 inhalation
16386801|NCT04072562|Experimental|AZD7594 1.6 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 1.6 mg, delivered dose 1 inhalation
16386802|NCT04072562|Active Comparator|AZD7594 720 μg|The study subjects will receive AZD7594 via DPI: 0.72 mg, delivered dose (792 µg nominal dose) 1 inhalation
16386803|NCT04072549|Experimental|Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
16386804|NCT04072549|No Intervention|Comparison/Control|The children in the control group will be children enrolled in the same schools as those randomized to receive summer programming. The comparison/control group will not receive a voucher to attend a summer camp.
16386805|NCT04072536|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
16386806|NCT04072536|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
16386807|NCT04072523||Observational Study Investigational Product NA|Patients : Type 2 Diabetic Patients
16386808|NCT04072510|Experimental|Case: Self-esteem group + Treatment as Usual|"Self-esteem group is based on a cognitive behavioral model of low self-esteem addressing thoughts, feelings and behaviour. The self-esteem group is designed to be administered in 6 weekly sessions.
~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.Treatment as usual occurred alongside the self-esteem group."
16386809|NCT04072510|Active Comparator|Control: Treatment as Usual Only|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
16386810|NCT04072497|Experimental|Zoster vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
16386811|NCT04072497|Active Comparator|Varicella vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=3.3 LgPFU per dose)
16386812|NCT04072497|Placebo Comparator|Placebo|Placebo with no live virus
16386813|NCT04072484|No Intervention|Room Air|The reduced oxygen breathing device will be set to deliver room air. (i.e., no oxygen is removed from the gas mixture. The subject will perform CPR while breathing through mask and tubing that is connected to the device.
16386814|NCT04072484|Experimental|Hypoxia|The reduced oxygen breathing device will be set to deliver a gas mixture with15% oxygen. (Equivalent to the partial pressure of oxygen at 2,438 meters.) The subject will perform CPR while breathing through mask and tubing that is connected to the device.
16386815|NCT04072471||Zurampic®|Patients exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) (lesinurad+XOI)
16386816|NCT04072471||Control group: xanthine oxidase inhibitor monotherapy|Patients exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat).
16386817|NCT04072458|Experimental|BP1002 monotherapy|L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m^2.
16386818|NCT04072445|Experimental|Treatment (trifluridine and tipiracil, irinotecan)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and irinotecan hydrochloride IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16386819|NCT04072432|Experimental|120 mg FeS IV infusion|A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
16386820|NCT04072432|Experimental|240 mg FeS infusion|A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
16386821|NCT04072432|Experimental|360 mg FeS Infusion|A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
16386822|NCT04072419||enhanced recovery after surgery group|"weaning mechanical ventilation after surgery (less than 48h),
~no post-operative chest tube and urinary catheterization)
~Establishment of early feeding (D3 post-operative)"
16386823|NCT04072419||control group|"the time of mechanical ventilation after surgery is more than 48 hours
~routine postoperative indwelling chest tube and urinary catheterization)
~Establishment of feeding after D3 post-operative"
16386824|NCT04072406|Active Comparator|Arm I: Usual Care|"Participants assigned to usual care will receive a packet of instructions with information about how to complete weekly surveys via a link that will be emailed to them
~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
16386825|NCT04072406|Experimental|Arm II: Mindfulness Meditation|"Participants will listen to mindfulness meditations daily over the course of three weeks.
~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
16386826|NCT04072393|Experimental|Home-based cardiac rehabilitation|"The intervention consists of a prescribed course of home-based cardiac rehabilitation: 36 sessions, three times a week, one hour each, over a period of 12 weeks.
~Each customized exercise session includes three phases:
~a 5- to 10-minute warm-up which consists of stretching, flexibility movements, and aerobic activity which gradually raises the heart rate to the desired level
~a conditioning or training phase, which consists of 20 to 45 minutes of continuous or discontinuous aerobic activity
~a cool down for 5 to 10 minutes consisting of low-intensity exercise that permits a gradual recovery from the conditioning phase
~The patient will complete a brief questionnaire on the teleHeart application after completing each exercise session on how well they tolerated the exercise. The patient's CR team will receive daily updates from the patient's teleHeart application. Based on feedback from the application, the CR team may modify the patient's exercise program going forward."
16386827|NCT04072380|Experimental|SUVN-G3031 2mg|Orally taken once daily for 14 days
16386828|NCT04072380|Experimental|SUVN-G3031 4mg|Orally taken once daily for 14 days
16386835|NCT04072341|Experimental|Propolis Period|Hemodialysis patients will be under regular treatment of their comorbidities and using Propolis.
16386836|NCT04072341|Experimental|Control Period|Hemodialysis patients will be under regular treatment of their comorbidities, but without using Propolis.
16386837|NCT04072328|Experimental|Propofol alone|Participants who receive propofol alone during sedative endoscopy.
16386838|NCT04072328|Active Comparator|Midazolam with propofol|Participants who receive midazolam + propofol during sedative endoscopy.
16386839|NCT04072315|Experimental|PLN-74809 Dose Level 1|PLN-74809 Dose Level 1
16386840|NCT04072315|Experimental|PLN-74809 Dose Level 2|PLN-74809 Dose Level 2
16386841|NCT04072315|Experimental|PLN-74809 Dose Level 3|PLN-74809 Dose Level 3
16386842|NCT04072315|Experimental|PLN-74809 Dose Level 4|PLN-74809 Dose Level 4
16386843|NCT04072302|Experimental|KAF156 800 mg pre-challenge|Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
16386844|NCT04072302|Placebo Comparator|Placebo 800 mg pre-challenge|Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
16386845|NCT04072302|Experimental|KAF156 800 mg post-challenge|Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386846|NCT04072302|Placebo Comparator|Placebo 800 mg post-challenge|Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386847|NCT04072302|Experimental|KAF156 300 mg post-challenge|Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386848|NCT04072302|Placebo Comparator|Placebo 300 mg post-challenge|Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386849|NCT04072302|Experimental|KAF156 100 mg post-challenge|Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386850|NCT04072302|Placebo Comparator|Placebo 100 mg post-challenge|Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386851|NCT04072302|Experimental|KAF156 20 mg post-challenge|Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386852|NCT04072302|Placebo Comparator|Placebo 20 mg post-challenge|Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386853|NCT04072302|Experimental|KAF156 50 mg post-challenge|Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386854|NCT04072302|Placebo Comparator|Placebo 50 mg post-challenge|Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
16386855|NCT04072289|Experimental|Low cylinder (treatment)|0.25D and 0.50D cylinder treatments will be measured and treated by the laser.
16386856|NCT04072289|No Intervention|Low cylinder (no treatment)|0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.
16386857|NCT04072276||EV71 Vaccine with Adjuvant AlPO4|EV71 Vaccine Produced in Vero Cells with Adjuvant AlPO4
16386858|NCT04072276||Adjuvant AlPO4|Placebo (Adjuvant AlPO4 only)
16386859|NCT04072263|Experimental|Cohort 1|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus
~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x."
16386860|NCT04072263|Experimental|Cohort 2|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus
~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus
~Interferon Alpha 2A (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."
16386861|NCT04072237|Experimental|Study Population|MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)
16386862|NCT04072211|Other|Vaccine arm|Engerix-B vaccine will be administered. This arm will include all those at risk of hepatitis B virus infection
16386863|NCT04072198|Experimental|FOLFOXIRI/Bevacizumab + Nivolumab|Bevacizumab 5 mg/m2 Nivolumab 240 mg Irinotecan 165 mg/m2 iv (max 8 cycles) Oxaliplatin + leucovorin 200 mg/m2 (max 8 cycles) Fluorouracil 3200 mg/m2 (max 8 cycles)
16386864|NCT04072185|Experimental|Physical activity group|
16386865|NCT04072185|No Intervention|Control group|
16386866|NCT04072172|Experimental|Female with leg spider veins|Females at the age of 20 to 45 not known diabetics or hypertensive complaining of leg spider veins.
16386867|NCT04072159|Experimental|Intervention group|For the intervention group, primary care providers will refer patients who have received the initial HPV vaccine to receive the additional doses at patients' community retail pharmacy.
16386868|NCT04072159|No Intervention|Control group|Control group participants will return to the primary care practitioner to complete the HPV vaccine series (usual care).
16386869|NCT04072146|Experimental|OC-01 (varenicline) nasal spray|
16386870|NCT04072146|Active Comparator|Chantix®|
16386871|NCT04072133|Experimental|Meditative Movement Intervention|Participants will complete the following components of baseline (T1) data collection: demographics, biometric measurements, a heart rate variability assessment, and questionnaires. Participants will be asked to provide six saliva samples via passive drool to measure cortisol levels. Participants will be assigned into hour-long meditative movement (MM) classes for eight weeks total. Participants will be asked to practice their MM skills at home for at least 30 minutes most days per week. The study will distribute hard-copy movement manuals and DVD instruction videos for guidance. Participants will be asked to provide a log of all dates and lengths of their at-home practice. After the eighth class, participants will return for post-intervention (T2) data collection, consisting of biometric measurements, a heart rate variability assessment, and questionnaires. Participants will provide six more saliva samples via passive drool method.
16386872|NCT04072120||R1|"Norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 registered in the FS-data during this period.
~Sub-sample those attending a cardiovascular health survey who later developed stroke."
16386873|NCT04072120||R2|All Norwegians born in the period 1 January 1940 to 31 December 1959 who survived to 1991.
16386874|NCT04072120||R3|Norwegian citizens aged 45 and above 1.1.2016.
16386875|NCT04072107|Experimental|Arm I|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy + capecitabine AC. All patients will receive concurrent cisplatin (100 mg/m2) every 3 weeks, in a total of three cycles. All patients will receive low-dose metronomic capecitabine (650 mg/m2 bid, oral, d1-21, q3w) until disease progression, or intolerable toxicity or 6 months.
16386876|NCT04072107|Experimental|Arm II|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy and anti-PD-1 therapy (sintilimab) + anti-PD-1 therapy (sintilimab) AC. All patients will receive concurrent cisplatin (100 mg/m2) and sintilimab (200 mg, IV drop 30-60 min) every 3 weeks in a total of three cycles. All patients will receive adjuvant anti-PD-1 therapy (sintilimab, 200 mg, IV drop 30-60 min, q3w) in a total of nine cycles until disease progression, or intolerable toxicity or 6 months.
16386877|NCT04072094|Experimental|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
16386878|NCT04072094|Active Comparator|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
16386879|NCT04072081|Experimental|Drug-coated ballon|Treatment of in suit coronary lesions with drug-coated balloon
16386880|NCT04072081|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
16386881|NCT04072068|Experimental|Edoxaban|edoxaban 60 mg daily
16386882|NCT04072055||MOTO medial|Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.
16386883|NCT04072042|Experimental|Apatinib monotherapy|patient will receive Apatinib 250mg tablet by mouth, bid.
16386884|NCT04072029||Cataract - FECD|Eyes with FECD undergoing cataract surgery
16386885|NCT04072016|Experimental|Beacon Aqueous Microshunt|
16386886|NCT04072003||IVUS-guided PCI|In this group, intravascular ultrasound(IVUS) in addition to coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
16386887|NCT04072003||CAG-guided PCI|In this group, coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
16386888|NCT04071990|Active Comparator|Family-based cognitive behavioral group therapy (FB-CBGT)|One family member of each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session.
16386889|NCT04071990|Placebo Comparator|Cognitive-behavioral group therapy (CBGT) without family|Each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session., without the involvement of family members.
16386890|NCT04071977|Active Comparator|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
16386891|NCT04071977|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
16386892|NCT04071964||Groupe 1|Patients with colorectal cancer undergoing resection with anastomosis
16386893|NCT04071964||Groupe 2|Patients with colorectal cancer undergoing resection without anastomosis (Abdominoperineal resection)
16386894|NCT04071964||Groupe 3|"Patients with rectal cancer without surgery (Watch and wait)"
16386895|NCT04071964||Groupe 4|Control group consisting of patients who do not have surgical pathologies of the colon and rectum
16386896|NCT04071951|Experimental|Pharmacist Arm|Pharmacist-Led Medication Reconciliation, Regimen Review, and Adherence and Literacy Assessment and Counseling
16386897|NCT04071951|No Intervention|Usual Care|Patients in this study will receive usual care. Clinically-indicated services, including pharmacist services, may be provided to control group patients.
16386898|NCT04071938|Active Comparator|Intervention group|"Physicians: 10 GPs from 10 practices who treat patient with Spinal cord injury (SCI) and 10 SCI specialists.
~Patients: 270 people with SCI within 25 minutes vehicle driving distance to the GP practices will be in the intervention group"
16386899|NCT04071938|No Intervention|Control group|"Physicians: 20 GPs who treat patient with SCI will not receive any intervention. They will be completing the questionnaire (DOC) and assessed for satisfaction with collaboration with the SCI specialist.
~Patients: 210 people with spinal cord injury outside the catchment area of the intervention group will be receiving usual care (no intervention)"
16386900|NCT04071912||ACL|All sports patients who had a muscle evaluation at 3-4 months and 6-8 months after ACL ligamentoplasty since January 2016
16386901|NCT04071899||Patients|patients with RBD
16386902|NCT04071899||Bedpartners|Subjects which are the bedpartners of patients with RBD
16386903|NCT04071886|Experimental|Mindfulness-Based Training|Participants in the Mindfulness-Based Training arm will receive 2 weeks of Mindfulness-Based Training for at least 30 minutes every day.
16386904|NCT04071886|Active Comparator|Relaxation Training|Participants in the Relaxation Training arm will receive 2 weeks of Relaxation Training for at least 30 minutes every day.
16386905|NCT04071873|Experimental|Point-of-care HIV testing (intervention)|Participants will be offered voluntary point-of-care HIV testing during a traditional healer visit.
16386906|NCT04071873|Active Comparator|Education on community HIV resources (control)|Participants will be offered education regarding HIV testing and community resources during a traditional healer visit.
16386907|NCT04071860||discovery and learning cohort|Data from this cohort will be used to develop the software algorithms
16386908|NCT04071860||Validation|Data from this cohort will be used to validate the software algorithms
16386909|NCT04071847||Deep brain stimulation|Subjects implanted with an Abbott DBS system
16386910|NCT04071834||Diabetes mellitus group|Diabetic patients undergoing spinal anesthesia for lower extremity surgery
16386911|NCT04071834||Non-diabetic group|Non-diabetic patients undergoing spinal anesthesia for lower extremity surgery
16386912|NCT04071821|Experimental|A: Test under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
16386913|NCT04071821|Active Comparator|B: Reference under Fasted Condition|Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
16386914|NCT04071821|Experimental|C: Test under Fed Condition|Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
16386915|NCT04071821|Experimental|D: Test under Fasted Condition with No Water|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
16386916|NCT04071821|Experimental|E: Test Swallowed Whole with Water, under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
16386917|NCT04071808||Coronary angiography group|In diabetic patients without symptoms of myocardial ischemia, coronary angiography showed no stenosis or stenosis less than 75%.
16386918|NCT04071808||Coronary angiographic stent implantation group|Coronary angiographic stenosis was more than 75% in diabetic patients without myocardial ischemia symptoms, and coronary stents were implanted.
16386919|NCT04071795|Experimental|Opt Out|Training and Academic Detailing
16386920|NCT04071795|Experimental|Opt In|Training and Academic Detailing
16386922|NCT04071769|Experimental|Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
16386923|NCT04071756|Experimental|Topical Tazarotene 0.1% Gel Plus BPS|"Pharmacy teaching call
~DFCI approved teaching sheets will be provided
~20% urea applied to the palms and soles in the morning + tazarotene 0.1% gel, applied to the palms and soles nightly"
16386924|NCT04071756|Placebo Comparator|Placebo Gel Plus BPS|"A substance that has no therapeutic effect, used as a control in testing new drugs
~Pharmacy teaching call
~DFCI approved teaching sheets will be provided
~20% urea applied to the palms and soles in the morning with placebo gel applied in the evening."
16386925|NCT04071743|Active Comparator|Treatment|Treatment and Prevention with active gammacore device(vagus nerve stimulator)
16386926|NCT04071743|Sham Comparator|Sham|Treatment and Prevention with sham gammacore device(vagus nerve stimulator)
16386927|NCT04071730|Experimental|Immulina Dietary Supplementation|Immulina Dietary Supplementation - 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration
16386928|NCT04071730|Placebo Comparator|Placebo|Placebo - inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration
16386929|NCT04071717|Experimental|NIRS group|Participants with obesity, 12 sessions of NIRS feedback
16386930|NCT04071717|Sham Comparator|Sham NIRS group|Participants with obesity, 12 sessions of sham NIRS feedback
16386931|NCT04071717|Other|Healthy control group|Healthy participants, 12 sessions of NIRS feedback
16386932|NCT04071704||Patients|Patients who have been or are being treated for sarcoma.
16386933|NCT04071704||Health care professionals|Health care professionals with extensive experience in sarcoma care (medical oncologists, radiation oncologists, surgical oncologists, orthopaedic surgeons, nurse specialists, psychologists, physiotherapists)
16386934|NCT04071691||Active LVV|Patients with active LVV
16386935|NCT04071691||Stable LVV|Patients with inactive LVV
16386936|NCT04071678||A: Model A|Mode A was silent mode, back-to-back with endoscopic physicians to simultaneously display endoscopic images and record video, but did not interfere with the operation of endoscopic physicians.After the operation, the AI model automatically generates an endoscopy report, which is compared with the official report given by the endoscopy doctor in the endoscopy system. If the difference is large, video verification shall be played back immediately or endoscopic examination shall be performed again before the patient wakes up
16386937|NCT04071678||B: Model B|Mode B is a delayed reminder mode. If the lesion is found during the operation, it is required to be moved to the middle of the visual field within 5 seconds. If the lesion has been detected by the AI model (the lesion has been circled in the picture), but the doctor does not move the lesion to the middle of the visual field within 5 seconds, the AI system will give an alarm prompt
16386938|NCT04071678||C: Model C|Mode C is a real-time reminder mode, which is an alarm prompt when the focus is captured in the visual field.
16386939|NCT04071665|Experimental|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion for treatment of scoliosis
16386940|NCT04071665|Active Comparator|transforaminal lumbar interbody fusion|transforaminal lumbar interbody fusion
16386941|NCT04071652|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
16386942|NCT04071639|Experimental|Group 1|Mild to moderate HD patients receive medicine treatment with different doses of Deutetrabenazine(Austedo), Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Deutetrabenazine(Austedo) should be taken 6mg once a day, or increase dose according to AUSTEDO® tablets Prescribing Information. Idebenone should be taken 30mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.
16386991|NCT04071314||Obstructive sleep apnoea|Children diagnosed with obstructive sleep apnoea. Children aged between 0 and 18 years.
16387365|NCT04068649|Experimental|Arm II (SBRT)|Patients undergo single fraction SBRT.
16386943|NCT04071639|Experimental|Group 2|Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Haloperidol should be taken 0.5mg~1mg three times a day. The administration of Zoloft, Risperidone and Idebenone are same as group 1. Study drug can be taken irrespective of meals. Duration:5 years.
16386944|NCT04071626|Experimental|Ertugliflozin Treatment Arm|Ertugliflozin 5 mg tablet once a day for 12 weeks
16386945|NCT04071626|Placebo Comparator|Placebo|Placebo tablet once a day for 12 weeks
16386948|NCT04071600|Placebo Comparator|Placebo|Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
16386949|NCT04071600|Active Comparator|Neuropeptide Y|The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
16386950|NCT04071600|No Intervention|Control|The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.
16386951|NCT04071587|Experimental|BCI training|Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
16386952|NCT04071587|Active Comparator|Control|Patients randomized to this control group will receive standard physiotherapy and occupational therapy for their impaired upper limb.
16386953|NCT04071574|Active Comparator|"Protocol A"|"Protocol with gonadotropins alone without agonist or antagonist:
~Gonadotropin treatment begins after spontaneous menses. The gonadotropins (e.g. Menopur, 150-225IU) are injected daily from D2/3 of the cycle (Gonadotropin dose varies based on the follicular response). The moment to trigger ovulation by administration of HCG (e.g. Ovitrelle or Pregnyl, 10.000IU) is determined by monitoring ovulation (folliculogenesis) approximately 14 days after gonadotropins regimen and the presence of at least 3 follicles with 18 mm sizes and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
16386954|NCT04071574|Active Comparator|"Protocol B"|"Short GnRH agonist protocol:
~For the short GnRH agonist protocol, the administration of gonadotropins begins at the same time as that of the agonist, which makes it possible to take advantage of the action of endogenous gonadotropins released by the flare-up effect of the agonist. A low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg/day)) is administered in parallel to gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
16386955|NCT04071574|Active Comparator|"Protocol C"|"Multiple-dose antagonist protocol:
~For the GnRH antagonist protocol, a low dose of GnRH antagonist (0.25 mg/day) is administered. The protocol starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU). 36 h after HCG triggering, the mature oocytes are retrieved."
16386956|NCT04071574|Active Comparator|"Protocol D"|"Long GnRH agonist protocol:
~For the long GnRH agonist protocol, a low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg)) is administered on cycle-day 21 followed by gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 after menses (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm. 36 h after HCG triggering, the mature oocytes are retrieved."
16386957|NCT04071574|Active Comparator|"Protocol E"|"Combined GnRH antagonist and agonist protocol:
~For the combined protocol, it starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till GnRH agonist injection (e.g., triptorelin (Decapeptyl 0.1mg/day)). 36 h after agonist injection, the mature oocytes are retrieved."
16386958|NCT04071561||Non-conversion|In 13 patients, 14 posterior retroperitoneal adrenalectomy procedures were successfully completed and form the non-conversion group
16386959|NCT04071561||Conversion|Conversion to lateral transperitoneal adrenalectomy was necessary in 1 patient after starting posterior retroperitoneal adrenalectomy.
16386960|NCT04071548|Experimental|HIIT Exercise|All individuals recruited in exercise portion will be on an active exercise intervention
16386961|NCT04071522||LBP|110 literate Turkish speaking patients suffering from low back pain (LBP) for over 3 months, within the age range 18-65 were included in the study.
16386962|NCT04071509|Experimental|Percutaneous Lung Biopsy|
16386963|NCT04071483|Experimental|Moderate stenosis|Moderate cervical neural foraminal stenosis is narrowest width of the neural foramen was >50% of the width of the width of the extraforaminal nerve root at the level of the anterior margin of the superior articular process.
16386964|NCT04071483|Active Comparator|Severe stenosis|Severe cervical neural foraminal stenosis is narrowest width of the neural foramen was ≤50% of the extraforaminal nerve root width
16386965|NCT04071470|Active Comparator|Standard of Care|Standard of care for pregnant women at risk of HIV seroconversion includes couples counseling and access to PrEP (women) and ART (men)
16386966|NCT04071470|Experimental|Storytelling Intervention|Participants in this group will receive the same services as those in the SOC but will also be provided three storytelling sessions for themselves and their families as a way to educate and de-stigmatize PrEP services.
16386967|NCT04071457|No Intervention|Study Entry / Screening|Study entry/screening to follow patient until Maintenance.
16386968|NCT04071457|Active Comparator|Arm 1: Lenalidomide|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment.
16386969|NCT04071457|Experimental|Arm 2: Lenalidomide + Daratumumab/rHuPH20|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 2 years from starting treatment.
16386970|NCT04071457|Active Comparator|Arm 1a: Continue Lenalidomide|MRD+ or MRD- and randomized to Arm 1a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment.
16386971|NCT04071457|No Intervention|Arm 1b: Stop Lenalidomide|MRD- and randomized to Arm 1b: Discontinue protocol therapy.
16386972|NCT04071457|Active Comparator|Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20|MRD+ or MRD- and randomized to Arm 2a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 7 years from starting treatment.
16386973|NCT04071457|No Intervention|Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20|MRD- and randomized to Arm 2b: Discontinue protocol therapy.
16386974|NCT04071444|Experimental|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
16386975|NCT04071444|No Intervention|Control group|The control group (CG) received routine care.
16386976|NCT04071431|No Intervention|Control|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.
~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.
~The RFQ results of this group are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
16386977|NCT04071431|Experimental|Risk shown|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.
~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.
~The RFQ results of this group are known by the endoscopists before and during the endoscopy."
16386978|NCT04071418||I-125 Seeds Implantation|All the enrolled patients were treated with CT-guided radioactive I-125 seeds implantation assisted by 3D printing template. Prescription dose 140-160gy.
16386979|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.
~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
16386980|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.
~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
16386981|NCT04071379|Experimental|HepB + Penta batch 1|Recombinant Hepatitis B + DTP-HB-Hib batch 1
16386982|NCT04071379|Active Comparator|Hep B + Pentabio (registered)|Recombinant Hepatitis B + Pentabio (registered)
16386983|NCT04071366|Experimental|Itacitinib|
16386984|NCT04071353||Interferon combined with ribavirin group|Interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) in patients with chronic hepatitis C, collect basic data before antiviral therapy, and during the PR antiretroviral treatment period, Follow-up was performed every 3-6 months in March, June, September, December, DAAs antiviral treatment during January, March, and withdrawal follow-up, and clinical biochemistry, HCV RNA, and serological markers were used during follow-up ( anti-HCV), AFP and liver imaging (liver ultrasound) examination.
16386985|NCT04071353||DAAs treatment group|Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
16386986|NCT04071327||Pulmonary arterial hypertension (PAH)|Patients with newly diagnosed or established PAH, within 6 months of first outpatient visit to a PH Care Center
16386987|NCT04071327||Chronic thromboembolic pulmonary hypertension (CTEPH)|Patients with newly diagnosed or established CTEPH, within 6 months of first outpatient visit to a PH Care Center
16386988|NCT04071327||Group 3 PH due to Developmental Lung Disease|Pediatric patients with newly diagnosed or established Group 3 PH due to developmental lung disease, within 6 months of first outpatient visit to a PH Care Center.
16386989|NCT04071314||Cystic fibrosis|Children diagnosed with cystic fibrosis. Children aged between 0 and 18 years.
16386990|NCT04071314||Hirschsprung's disease|Children diagnosed with Hirschsprung's disease. Children aged between 0 and 18 years.
16386992|NCT04071314||Healthy controls|Children free of any chronic health condition. Children aged between 0 and 18 years.
16386993|NCT04071301|Experimental|Investigational Device|TENA SmartCare Change Indicator
16386994|NCT04071288||laparoscopic burch colposuspension|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing laparoscopic burch colposuspension
16386995|NCT04071288||mid urethral sling operations|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing mid-urethral sling operations
16386996|NCT04071275|Active Comparator|Mirror therapy|Subjects will be asked to perform specific movements (using the unaffected limb while watching its mirrored reflection for 20 minutes per day, for 10 treatment days, completed during two weeks (every weekday, excluding weekends)
16386997|NCT04071275|Sham Comparator|Mirror therapy + sham tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, a sham tDCS treatment will be applied.
16386998|NCT04071275|Experimental|Mirror therapy + active tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, an active tDCS treatment will be applied.
16386999|NCT04071262|Experimental|Abemaciclib + Abiraterone Acetate + Prednisolone|Abemaciclib, abiraterone acetate and prednisolone given orally.
16387000|NCT04071249||Control|Patients who use symptomatic medication as therapy for their allergic rhinoconjuntivitis as recommended by their physician
16387001|NCT04071236|Active Comparator|Arm A (radium-223 dichloride)|Patients receive radium-223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16387002|NCT04071236|Active Comparator|Arm B (radium-223 dichloride, nedisertib)|Patients receive radium-223 dichloride as in Arm A and peposertib PO or BID on days 3-26. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16387003|NCT04071236|Experimental|Arm C (radium-223 dichloride, nedisertib, avelumab)|Patients receive radium-223 dichloride IV as in Arm A and peposertib PO QD or BID as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 15 of cycles 2-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16387004|NCT04071223|Experimental|Arm A (radium Ra 223 dichloride, cabozantinib s-malate)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1 of cycles 1-6 and cabozantinib S-malate PO QD on days 1-28 of every cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16387005|NCT04071223|Active Comparator|Arm B (cabozantinib s-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16387006|NCT04071210|Experimental|Experimental|Probiotic tablets (containing a mix of Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307, 1*10(9) CFU) 2 times/day for 12 weeks
16387007|NCT04071210|Placebo Comparator|Placebo Comparator|Placebo tablets 2 times/day for 12 weeks
16387008|NCT04071197|Experimental|Gastrostomy-biliary tube|The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
16387009|NCT04071197|Experimental|Other biliary diversion modalities|The control group will include those cases with other modalities of therapy as external biliary diversion, internal biliary diversion, and nasobiliary tube
16387010|NCT04071184|Experimental|Dose cohorts|"Part 1 (dose escalation): 3+3 design will be used. Alofanib (dose levels of 50, 100, 165, 250, 350 mg/m2) will be given i.v. daily (1-5 days on, 6-7 days off, every week) till progression or unacceptable toxicity.
~Part 2 (dose expansion): Afterwards the dosing regimen identified in Part 1 will be evaluated in a single-arm study focused on clinical efficacy."
16387011|NCT04071171|Active Comparator|Phoxilium®|
16387012|NCT04071171|Experimental|Biphozyl®|
16387013|NCT04071158|Experimental|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
16387014|NCT04071158|Experimental|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
16387015|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
16387016|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
16387017|NCT04071158|Placebo Comparator|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
16387018|NCT04071132||Participants diagnosed with PTSD|
16387019|NCT04071132||Non-PTSD participants|
16387020|NCT04071119|Active Comparator|Oxytocin nasal spray|
16387021|NCT04071119|Placebo Comparator|Placebo|
16387022|NCT04071106|Active Comparator|Turmeric Extract group|10 psoriasis patients receiving turmeric based ointment levigated in glycerin twice daily and assessed for response and side effects weekly for 12 weeks
16387023|NCT04071106|Active Comparator|Turmeric extract + olive oil group|10 psoriasis patients receiving turmeric extract levigated in olive oil instead of glycerin. The ointment will be applied twice daily for 12 weeks & will be assessed weekly
16387024|NCT04071106|Placebo Comparator|Petrolatum group|10 Psoriasis patients will receive the base of the therapeutic ointment which is the petrolatum. Patients will apply it twice daily and will be assessed weekly clinically and dermoscopically for 12 weeks
16387025|NCT04071106|Active Comparator|NBUVB group|10 Psoriasis patients will receive two sessions of NBUVB weekly for 12 weeks and will be assessed weekly clinically and with dermoscope.
16387026|NCT04071106|Active Comparator|Established ttt group|10 Psoriasis patients will receive topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks and will be assessed on weekly basis clinically and by dermoscope
16387027|NCT04071093|Other|Telemonitoring|
16387028|NCT04071093|No Intervention|Usual Care|
16387029|NCT04071080|Experimental|100mg Fluorescein disodium|100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
16387030|NCT04071080|Placebo Comparator|Placebo|500mL of Gatorade taken orally by the participant
16387031|NCT04071067||Emergency Clinical County Hospital Group|
16387032|NCT04071067||Municipal Clinical Hospital Group|
16387033|NCT04071054||Hemodialysis patients|
16387034|NCT04071041|Experimental|Standard care plus albumin|"Patients will receive human albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
~Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team."
16387035|NCT04071041|No Intervention|Standard care alone|Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team.
16387036|NCT04071028|Active Comparator|Footbath group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes,"
16387037|NCT04071028|No Intervention|Control group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
16387038|NCT04071002|Active Comparator|surgical group|distal radius fractures that treated volar plate
16387039|NCT04071002|Active Comparator|conservative group|distal radius fractures that treated plaster of paris
16387040|NCT04070989|Experimental|Posterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the posterior approach
16387041|NCT04070989|Experimental|Lateral Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the lateral approach
16387042|NCT04070989|Experimental|Anterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the anterior approach
16387043|NCT04070976|Active Comparator|Standard treatment|Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.
16387044|NCT04070976|Experimental|Experimental treatment|Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.
16387045|NCT04070963||Cohort|We propose a prospective, observational single-centre pilot study in the PAC (SGH), on participants aged 21 years and above. A HbA1c test will be added to their routine preoperative blood tests. The incidence of newly-diagnosed DM/pre-diabetes (HbA1c ≥6.1%) and poorly controlled DM (HbA1c ≥ 8%), demographic details and presence of significant comorbidities will be analysed.
16387046|NCT04070950||Single group|Interview of patients with cancer of the cervix or uterine body, or ovary between the time of diagnosis and 3 months after the end of their last cancer treatment (not the object of the study).
16387047|NCT04070937||study group|all patients at least 18 years of age who present bilateral vestibulopathy on vestibular investigations according to the Barany criteria
16387048|NCT04070937||control group|DFNA9 patients carrying the p.P51S mutation in COCH gene presenting bilateral vestibulopathy according to the Barany criteria
16387049|NCT04070924|Active Comparator|Conventional post-operative bulky soft tissue dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal
~Postoperative: Non-opioid medications only; Conventional post-operative bulky soft tissue dressing (Xeroform, 4x4s, Webril, Ace Wrap; Worn until first postoperative visit)"
16387050|NCT04070924|Experimental|Bandaid post-operative dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal
~Postoperative: Non-opioid medications only; Bandaid over incision (Patient given an edema glove to wear starting post-operative day 1; Dressing change be changed post-operative day 2 and as needed after that)"
16387051|NCT04070911|Experimental|patients in the water group|water group: Patients in the water group were performed oral water after their accession to PACU.
16387052|NCT04070911|Experimental|patients in the ice group|ice group, Patients in the ice group were performed oral ice popsicle after their accession to PACU.
16387053|NCT04070911|No Intervention|no intervention group|control group, the control group patients have performed rutin treatment and care without any other intervention
16387054|NCT04070898|No Intervention|control group|Bladder catheter removal 24 hours after surgery
16387055|NCT04070898|Experimental|experimental group|Removal of the bladder catheter after the surgical intervention
16387056|NCT04070872|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
16387057|NCT04070872|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
16387058|NCT04070846|Experimental|[14C] LC350189|Single oral dose
16387059|NCT04070833|Active Comparator|Vitamin D + fish oil|
16387060|NCT04070833|Active Comparator|Vitamin D + fish oil placebo|
16387061|NCT04070833|Active Comparator|Vitamin D placebo + fish oil|
16387062|NCT04070833|Placebo Comparator|Vitamin D placebo + fish oil placebo|
16387063|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fasting)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fasting condition
16387064|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fed)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fed condition
16387136|NCT04070235|Experimental|SH229/DCV|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily
16387065|NCT04070781|Experimental|Itacitinib + Tocilizumab|"A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose:
~Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level
~Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level
~Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles."
16387066|NCT04070781|Experimental|Dose Expansion|Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.
16387068|NCT04070755|Experimental|FMX-101|
16387069|NCT04070742|Experimental|FMX-101|
16387070|NCT04070729|Placebo Comparator|Negative control|Placebo gel
16387071|NCT04070729|Experimental|Test group 1|Hyaluronic acid gel
16387072|NCT04070729|Experimental|Test group 2|injectable prf
16387073|NCT04070716|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
16387074|NCT04070716|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
16387075|NCT04070703|Experimental|Cognitively enhanced Tai Ji Quan|Participants in this arm will exercise a series of Tai Ji Quan-based movements with configurations that are specifically designed for older adults to improve cognitive function, dual-task ability, strength/balance, and mobility.
16387076|NCT04070703|Active Comparator|Standard Tai Ji Quan|Serving as an active comparison arm, participants in this intervention will exercise a series of Tai Ji Quan-based movements that are specifically designed for older adults to improve strength/balance, cognitive function, and mobility.
16387077|NCT04070703|Sham Comparator|Stretching|Serving as a control arm, participants in this intervention will engage in a series of light exercise activities consisting of breathing, stretching, and body relaxation.
16387078|NCT04070690|Other|Intervention-Control group|"In this group, the participants will receive intervention for 2 months first, followed by a wash-out period of 1 month and control for 2 months.
~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements.
~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients)."
16387079|NCT04070690|Other|Control-Intervention group|"In this group, the participants will receive control for 2 months first, followed by a wash-out period of 1 month and intervention for 2 months.
~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients).
~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements."
16387080|NCT04070677|Experimental|Ziverel arm|Patients included will receive treatment with ZIVEREL®, initially 10 mL every 8 hours, 30 minutes after meals, to avoid physical entrainment by food, during a minimum of 8 weeks, recruited during a period of 12 months. The treatment will be indicated when the patient develops a radiation-induced esophagitis of degree ≥ 2.
16387081|NCT04070664||Central vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
16387082|NCT04070664||Peripheral vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
16387083|NCT04070625||Communication book group|Speech therapy with communication book
16387084|NCT04070625||Control group|Simple speech therapy
16387085|NCT04070612||children with autoimmune haemolytic anemia|A blood sample of 2 times 2 to 5 ml additional maximum
16387086|NCT04070612||Children with Evans syndrome|A blood sample of 2 times 2 to 5 ml additional maximum
16387087|NCT04070612||Children with Immune thrombocytopenic purpura|A blood sample of 2 times 2 to 5 ml additional maximum
16387088|NCT04070599|Experimental|Single arm|Study of lymphocyte subpopulations, cytokine assays, identification of autoantibodies, study of CD40 platelet ligand, thrombopoietin assay
16387089|NCT04070586||4DCBCT images|4DCBCT images are acquired and assessed offline.
16387090|NCT04070573|Active Comparator|81mg ASA|Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
16387091|NCT04070573|Active Comparator|162mg ASA|Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.
16387092|NCT04070560|Active Comparator|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table Other Name: Immediate clamping
16387093|NCT04070560|Active Comparator|Intact cord (≥ 180 seconds) resuscitation|"If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
~Other Names:
~Late cord clamping Deferred cord clamping Optimal cord clamping"
16387094|NCT04070547|Experimental|Early tVNS|First 2 weeks this group will receive transcutaneous vagal nerve stimulation 4 hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28) without any intervention. Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
16387095|NCT04070547|Experimental|Early Sham|First 2 weeks this group will receive sham stimulation 4hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
16387137|NCT04070222||Natural labour group|
16387096|NCT04070547|Experimental|Late tVNS|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
16387097|NCT04070547|Experimental|Late Sham|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive sham stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
16387099|NCT04070521|Experimental|Observational EEG Monitoring|
16387100|NCT04070495|Experimental|Clarithromycin|
16387101|NCT04070495|Experimental|Rifampicin|
16387102|NCT04070482||HIV-exposed uninfected infants|These are children to women who are living with HIV but who are not infected with the virus (HIV PCR results at 6 weeks is negative)
16387103|NCT04070482||HIV-unexposed uninfected infants|These are children born to women who are not infected with HIV
16387104|NCT04070469|Experimental|Patient reveiving amoxycillin|all patient included in this study
16387105|NCT04070456|Experimental|Intervention sites-Tablet-based SDH tool|All clinicians and primary care teams at a practice that are randomized to the intervention will receive the tablet-based SDH tool.
16387106|NCT04070456|No Intervention|Control sites|Care as usual, no tablet-based SDH tool.
16387107|NCT04070443|Experimental|Induction phase with Ponatinib followed by Imatinib|"Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda & Incyte Biosciences.
~Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)"
16387108|NCT04070430|Active Comparator|2 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
16387109|NCT04070430|Active Comparator|4 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
16387110|NCT04070417|Experimental|Treatment Group|Lifestyle Medicine Group
16387111|NCT04070417|No Intervention|CAU Group|Care-As-Usual Group
16387112|NCT04070391|Experimental|vitamin B6|One pill (100 mg) ingested daily for 4 weeks.
16387113|NCT04070391|Placebo Comparator|control|One vinegar pill ingested daily for 4 weeks
16387114|NCT04070378|Experimental|Open-label Treatment|This is an open-label pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease. During the treatment phase, eligible subjects will receive daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion over 3-5 minutes (15 mL) once weekly for 8 weeks followed by daratumumab SC 1800 mg every 2 weeks for 16 weeks.
16387115|NCT04070365||FLEX Vessel Prep followed by angioplasty|
16387116|NCT04070352||clostridium difficile infection (CDI)|This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
16387117|NCT04070326|Experimental|Lanadelumab|Participants aged 2 to < 6 years will receive lanadelumab at a dose of 150 milligrams (mg) for every 4 weeks (q4wks) with a total of 14 doses over 52-week treatment period and participants aged 6 to <12 years will receive lanadelumab at a dose of 150 mg for every 2 weeks (q2wks) with a total of 27 doses over 52-week treatment period.
16387118|NCT04070313|Experimental|S-1|single-arm
16387119|NCT04070300|Experimental|Interval training group|Aerobic interval training during 12 weeks 3 times a week.
16387120|NCT04070300|No Intervention|Control group|No lifestyle recommendations. Usual daily life.
16387121|NCT04070287|Active Comparator|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
16387122|NCT04070287|Active Comparator|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
16387123|NCT04070287|Active Comparator|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
16387124|NCT04070287|Active Comparator|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
16387125|NCT04070287|Active Comparator|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
16387126|NCT04070274|Experimental|New surgery platform for calcaneal surgery|"The lateral position surgical platform for calcaneus surgery is designed with a bottom board, mats in front and at back of calf and thigh, and two sizes of cover plates, using tunnel principle according to physiological curve of lower limbs."
16387127|NCT04070274|Experimental|Traditional lateral platform|"The traditional lateral position makes the surgery platform bread-shaped arch surface by using medical mats and putting lower limbs superimpose on each other"
16387128|NCT04070261||User|
16387129|NCT04070248||Group 1|50 HIV-seropositive with spirometry confirmed COPD
16387130|NCT04070248||Group 2|50 HIV-seropositive without COPD
16387131|NCT04070248||Group 3|50 HIV-seronegative with spirometry confirmed COPD
16387132|NCT04070248||Group 4|50 HIV-seronegative without COPD
16387133|NCT04070235|Experimental|SH229/DCV 400mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks
16387134|NCT04070235|Experimental|SH229/DCV 600mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40).
16387135|NCT04070235|Experimental|SH229/DCV 800mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40).
16387140|NCT04070209|Experimental|Darolutamide (BAY1841788)+ SBRT|"CRPC subjects will receive LHRH agonist in combination with the new generation of hormonal therapy Darolutamide (300mg).
~Subjects who progress on LHRH + Darolutamide and develop oligometastases will receive SBRT"
16387141|NCT04070196|Other|Leucocyte testing|The PD effluent will be sent to the laboratory for leucocyte testing for patients presented with suspected PD peritonitis.
16387142|NCT04070183|Other|Attention Control (Home Safety Evaluation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
16387143|NCT04070183|Experimental|Intervention (POST Facilitation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form. The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
16387144|NCT04070170|Experimental|Low-level laser therapy and no orthodontic force|No orthodontic force. Laser is applied on the first day and the premolars is extracted after 24 hours
16387145|NCT04070170|Experimental|Low-level laser therapy and application of orthodontic force|Orthodontic force and Laser is applied on the first day and the premolars is extracted after 24 hours
16387146|NCT04070170|Active Comparator|Orthodontic force only|Orthodontic force is applied and the premolars is extracted after 24 hours, with no laser therapy
16387147|NCT04070170|Experimental|Low-level laser therapy and orthodontic force|Orthodontic force and Laser is applied and the orthodontic tooth movement is evaluated
16387148|NCT04070170|Active Comparator|Orthodontic force with no laser therapy|Orthodontic force is applied and the orthodontic tooth movement is evaluated, with no laser therapy
16387149|NCT04070157|Experimental|Lofexidine|
16387150|NCT04070157|Placebo Comparator|Placebo|
16387151|NCT04070144|Experimental|IQ-Tip|At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
16387152|NCT04070131|No Intervention|Control Group|Regular follow ups.
16387153|NCT04070131|Experimental|Intervention Group|One weekly session (1 hour) of Horse-Assisted Rehabilitation, 24 weeks.
16387154|NCT04070118||patients with previous cesarean section|presenting to the emergency department with pain, previous cesarean section; Patients measured niche thickness before operation
16387155|NCT04070105|Active Comparator|Conventional Prosthetic Foot|In this condition, participants will walk with their standard prosthetic foot
16387156|NCT04070105|Experimental|CAESER Prosthetic Foot|In this condition, participants will walk with a new prosthesis with enhanced energy storage and return and increased range of motion. They will only wear this device in the lab for an approximately 4 hour period of time
16387157|NCT04070092||TBI group|"A cohort of patients admitted to UZ Leuven from 2019 to 2023 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.
~Inclusion criteria will be: ≥ 65 years old, admitted to UZ Leuven between 2019 and 2023 due to TBI, all injury severities (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.
~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven before 2019, diagnose of neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
16387158|NCT04070092||Control group|"A cohort of healthy volunteers with similar demographic characteristics will be recruited as a control group.
~Inclusion criteria will be: ≥ 65 years old and having signed the informed consent to participate in the study.
~Exclusion criteria will be: < 65 years old, diagnose of neurodegenerative diseases, cognitive and motor disturbances caused by any pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
16387159|NCT04070079|Other|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Dosed orally, once daily with or without food.
16387160|NCT04070066|Experimental|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
16387161|NCT04070066|Active Comparator|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
16387162|NCT04070053|Experimental|TheraPPP Pathway|"We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation.
~All mechanically ventilated patients will enter the pathway during the one month implementation and one year post-implementation periods.
~To assess Pathway feasibility we will collect patient data for approximately two years and one month: one year immediately prior to implementation, one month during, and one year following implementation.
~To assess acceptability of the pathway we will conduct a survey to clinicians who used the Pathway."
16387163|NCT04070040|Experimental|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
16387164|NCT04070027|Active Comparator|Total Hip Arthroplasty|A standard fast-track multimodal surgical program comprising patient information, optimised pain management, and early mobilisation. Total hip arthroplasty (THA) will be performed by experienced orthopaedic surgeons in accordance with the standard posterior surgical approach. Patients will receive standard postoperative rehabilitation consisting of either a standard leaflet with a hospital-specific home-based exercise program aimed at increasing hip muscle strength and range of motion or, if considered necessary, a referral to supervised hip-specific exercise therapy delivered at private physiotherapist clinics or municipal rehabilitation. Furthermore, postsurgical procedures will follow hospital-specific procedures ranging from no postsurgical control to postsurgical assessment of the hip and rehabilitation at the physiotherapy department (after six-weeks).
16387165|NCT04070027|Active Comparator|Progressive Resistance Training|"A 12-week supervised explosive-type progressive resistance training (PRT) program with two training sessions a week. All training sessions will be conducted in municipal rehabilitation centres with one-to-one supervision and ≥48 hours of rest in between sessions. The standardised PRT program will consist of warm-up on a stationary bicycle (10 min) followed by four lower extremity exercises (50 min). Exercises will be performed unilaterally with as full range of motion as possible in sets of three separated by 60 sec of rest in the following order: leg press, hip extension, hip flexion, and hip abduction. Patients will be instructed to complete the concentric phase of each repetition as fast as possible, maintain full extension for 1 sec, and perform the eccentric phase in 2-3 sec. Hip-related pain up to 5 rated on a Numerical Rating Scale (0-10) is considered acceptable during exercises. After the 12-weeks, patients will be offered three-months of optional unsupervised PRT."
16387166|NCT04070001|Active Comparator|Ibuprofen group|Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
16387167|NCT04070001|Active Comparator|Laser group|Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
16387168|NCT04070001|Placebo Comparator|Control group|Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
16387169|NCT04069988|No Intervention|Control group|The control group (CG) received routine care and was required to physical activity for thirty minutes
16387170|NCT04069988|Experimental|Baduanjin program|The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks ; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
16387171|NCT04069975||No sedation|The group of patients who did endoscopies without sedation.
16387172|NCT04069975||Sedation|The group of patients who did endoscopies with sedation.
16387173|NCT04069962|No Intervention|Control group|Patients in the control group will receive CGA coordinated by the oncology team as standard of care, including geriatric recommendations for interventions communicated to the treating physician (eg. referral to the social worker, psychologist, dietician).
16387174|NCT04069962|Experimental|Intervention group|Patients in the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching.
16387175|NCT04069949|Experimental|sorafenib plus toripalimab|"Stage I：Subjects (n=3) in cohort A received oral sorafenib (400 mg qd), in combination with intravenous toripalimab (240 mg d1, q3w). Subjects (n=3) in cohort B received oral sorafenib (400 mg bid) and the administration of toripalimab is consistent with cohort A. If dose-limiting toxicity (DLT) does not occur within 42 days of the first administration, the dose is escalated.
~Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39."
16387176|NCT04069936|Experimental|MILs™ - NSCLC plus nivolumab with or without tadalafil|Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.
16387177|NCT04069923|Experimental|Treatment (OsteoCrete)|Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
16387178|NCT04069910|Experimental|Arm A (SRS/SRT, surgery)|Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.
16387179|NCT04069910|Active Comparator|Arm B (surgery, SRS/SRT)|Within 2-5 weeks after standard of care surgery, patients undergo 1, 5, or 10 fraction of SRS/SRT.
16387180|NCT04069897|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
16387181|NCT04069897|Placebo Comparator|Controls|Placebo injections
16387182|NCT04069884|Active Comparator|Arm I (Clinical high-risk, RecurIndex low-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
16387183|NCT04069884|Experimental|Arm II (Clinical high-risk, RecurIndex low-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
16387184|NCT04069884|Active Comparator|Arm III (Clinical low-risk, RecurIndex high-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
16387185|NCT04069884|Experimental|Arm IV (Clinical low-risk, RecurIndex high-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
16387186|NCT04069871|Active Comparator|TENS|
16387187|NCT04069871|Sham Comparator|Control|
16387188|NCT04069858|Experimental|Baracle|Chronic hepatitis B patients who swiched to Baracle® 1 mg from Baraclude® 1 mg treatment as mono- or combination therapy after the development of antiviral resistance to nucleos(t)ide analogues
16387189|NCT04069845||liposomal doxorubicin treatment|intravenous liposomal doxorubicin
16387190|NCT04069832|Other|Intervention|SINGLE-SESSION CONSULTATION
16387191|NCT04069819|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 6 week plus placebo tablet twice daily for 6 weeks
16387192|NCT04069819|Experimental|Cilostazol group|Escitalopram 20 mg tablet once daily for 6 week plus Cilostazol 50mg tablet twice daily for 6 weeks
16387193|NCT04069806|Experimental|Preoperative oral carbohydrate load|6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.
16387194|NCT04069806|No Intervention|Standard preoperative fasting|6 hours for solid food and 2 hours for liquids.
16387195|NCT04069793|Active Comparator|Home Trial Condition A|Subject will use a pattern recognition controlled prosthesis that includes a powered wrist rotation, passive wrist flexion/extension, and a single DOF powered hand.
16387196|NCT04069793|Experimental|Home Trial Condition B|Subject will use at pattern recognition controlled prosthesis that includes a powered wrist rotation, powered flexion/extension and a single DOF powered hand.
16406116|NCT03936036||Linagliptin|Exposure group
16387197|NCT04069780|Active Comparator|Study group I : Intravitreal injection|A single intravitreal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
16387198|NCT04069780|Active Comparator|Study group II: Suprachoroidal injection of full dose|A single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
16387199|NCT04069780|Active Comparator|Study group III : Suprachoroidal injection of half dose|They will receive a single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 2 mg / 0.1 ml.
16387200|NCT04069767|Experimental|ICoreDIST|The intervention starts with an assessment by the physiotherapist to identify the patient's movement problems in order to choose among the 48 exercises in the intervention. Each session lasts for 60 minutes + exercises 5-10 minutes outside of therapy and is performed 5-6 days/per week in the rehabilitation units, and 3 sessions/week + home exercises 30 minutes 3 days per week in home based or outpatient treatment during the 12 weeks period.To allow for individualisation, each exercise contains five levels of difficulty. All exercises demand enhancement of dynamic trunk stability and functional movements.
16387201|NCT04069767|Active Comparator|Standard Care|Consists of standard inpatient rehabilitation, home-based and outpatient-based physiotherapy with the same dose as the intervention group.
16387202|NCT04069754|Experimental|Adapted Passport to Freedom Intervention Arm|The intervention consists of 5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections
16387203|NCT04069741|Other|Usual care, no depression|Participants without symptoms of depression who have the opportunity to use a Decision Aid but otherwise receive Usual care
16387204|NCT04069741|Other|Usual care, depression|Participants with symptoms of depression who are randomized to receive Usual care (in addition to the Decision Aid)
16387205|NCT04069741|Active Comparator|Toolkit, depression|Participants with symptoms of depression who are randomized to receive the Toolkit intervention in addition to Usual care
16387206|NCT04069728|Other|Standard clinic appointment|Patients who undergo a routine clinic outpatient appointment using standard explanation of their fistula with words, diagrams and MRI images, as per Consultant preference
16387207|NCT04069728|Experimental|Clinic appointment with 3D model|Patients who undergo a routine clinic outpatient appointment using a 3D printed model to assist explanation of their fistula
16387208|NCT04069715|Experimental|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
16387209|NCT04069715|Placebo Comparator|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
16387210|NCT04069702|Experimental|VR Blue|VR Blue is a protocol for patients with advanced stage colorectal cancer who experience persistent pain. Participants will complete a single 30-minute laboratory-based virtual reality underwater/sea environment (VR Blue) session. VR Blue is an immersive computer-generated environment featuring calming scenic graphics and relaxing nature music.
16387211|NCT04069689|Experimental|EPX-100|Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)
16387212|NCT04069689|Placebo Comparator|Placebo|Single and multiple doses of 20, 40, 80mg of placebo
16387213|NCT04069676||Autism Spectrum Condition (ASC)|Adults males and females with a formal autism diagnosis, without intellectual disability
16387214|NCT04069676||Typically developped (TD)|Adults males and females without any neurodevelopemental issue (or health issue which could impaired task performances)
16387215|NCT04069650||None-malnutrition|normal nutritionnal status
16387216|NCT04069650||Malnutrition|"weight loss was superior to 5% in the past month;
~a weight loss was superior to 10% in the past 6 months;
~a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to > 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to <35g/L (if age superior to 70 years old)."
16387217|NCT04069637||Early onset Scoliosis|Patients with early onset scoliosis treated with growth-sparing instrumentation (TGR, MCGR, and, VEPTR).
16387218|NCT04069637||Control group|Patients with operative fractures.
16387222|NCT04069611|Experimental|Test Group|Subjects in the test group will receive scaling and root planing, plus the take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
16387223|NCT04069611|Placebo Comparator|Control Group|Subjects assigned to the placebo group will receive scaling and root planing, and will take lozenges exactly like the test ones but without bacteria.
16387224|NCT04069585|Experimental|RHA®1 with new anesthetic agent|"Split-face injection of RHA®1 with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA®1-Lidocaine in the perioral rhytids in the other side of the mouth.
~Up to 3 mL injected per side."
16387225|NCT04069585|Experimental|RHA®1-Lidocaine|"Split-face injection of RHA®1-Lidocaine in the perioral rhytids on one side of the mouth and RHA®1 with new anesthetic agent in the perioral rhytids in the other side of the mouth.
~Up to 3 mL injected per side."
16387226|NCT04069572|Experimental|Vibrotactile Stimulation|
16387227|NCT04069572|Sham Comparator|Sham Stimulation|
16387228|NCT04069559|Experimental|Intervention Group|Intervention contain education and application about refugees health.
16387229|NCT04069559|No Intervention|Control Group|Students of control group performed routine public health nursing practices.
16387230|NCT04069546|Experimental|AIS-RIC|RIC is a physical strategy performed through cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times. This group of patients received regular therapy of acute ischemic stroke plus unilateral arm of RIC intervention.
16387231|NCT04069546|No Intervention|AIS|This group of patients received regular therapy of acute ischemic stroke.
16387232|NCT04069533|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
16387235|NCT04069494||patients|People diagnosed with advanced lung cancer and scheduled to receive palliative RT will be invited to participate between 1st July 2019 and 31st January 2020.
16387236|NCT04069494||care giver|Patients' family caregivers will also be invited to participate
16387237|NCT04069481|Experimental|Dance intervention|Participants will receive a 1-hour group dance class twice a week for 12 weeks. Classes will include a seated warm up, dance exercises in standing, dance activities moving across the floor, throughout the space and conclude with a bow exercise. Music and dance styles will vary and personal preference of participants will also be taken into account.
16387238|NCT04069481|Active Comparator|Exercise and mindfulness meditation|Participants will receive a 1-hour group exercise class twice a week for 12 weeks. Classes will include resistance training exercises with resistance bands, stretching and range of motion exercises in seated and standing positions. Classes will also include mindfulness exercises. During active exercises music will be played and personal preference of participant will be taken into account.
16387239|NCT04069468||TheraSphere®|"Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A*(1-S)*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel [GBq]), S=Percentage of pulmonary shunt, 1 assuming that the lung mass=1 kilograms [kg]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung."
16387240|NCT04069455|Experimental|EPRO group|Clinical usual care plus ePRO App self-management online during postoperative adjuvant chemotherapy
16387241|NCT04069455|No Intervention|Control group|Clinical usual care during postoperative adjuvant chemotherapy
16387242|NCT04069442||cDC-1 positive|cDC-1 positive patients according to RNAseq and in situ analysis
16387243|NCT04069442||cDC-1 negative|cDC-1 negative patients according to RNAseq and in situ analysis
16387244|NCT04069429|Experimental|Healthy Controls|7 controls (subjects without GI symptoms and known GI disease), subjects will receive the radiopharmaceutical agent orally
16387245|NCT04069429|Experimental|Eosinophilic Esophagitis Patients|10 patients with diagnosed EoE (greater than 15 eosinophils per HPF) on esophageal biopsy will be included as the diseased population, subjects will receive the radiopharmaceutical agent orally
16387246|NCT04069416||Group I|175 patients who fall within the Milan criteria.
16387247|NCT04069416||Group II|36 patients who fall within up-to-7 criteria
16387248|NCT04069416||Group III|30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).
16387249|NCT04069403|Experimental|Intervention Arm- Automated Reports|Receives automated reports on prescription patterns monthly
16387250|NCT04069403|No Intervention|Control Arm: Usual clinical education and feedback|Receive no reports
16387251|NCT04069390|Experimental|Cardioskin-Neuronaute|
16387252|NCT04069377||Manuel chest compression|Manuel chest compressions will be handled by human efforts.
16387253|NCT04069377||Mechanical chest compression|In the study, chest compression in the mechanical cardiopulmonary resuscitation group was performed with the Lund University Cardiopulmonary Assist System (LUCAS) Chest Compression System (LUCAS 2).
16387254|NCT04069351|Experimental|Overfeeding Plus Resistance Training Arm|6-week overfeeding plus resistance training arm
16387255|NCT04069338|Active Comparator|Device Storz Modulith SLX-F2|Patients receive standard of care treatment for their urolithiasis using the Device Storz Modulith SLX-F2
16387256|NCT04069338|Active Comparator|Dornier Delta III Treatment|Patients receive standard of care treatment for their urolithiasis using the Dornier Delta III lithotripter
16387257|NCT04069325|Experimental|simiaowan 6g + febuxostat 40mg|
16387258|NCT04069325|Placebo Comparator|placebo 6g + febuxostat 40mg|
16387259|NCT04069312|Active Comparator|Roflumilast arm|Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months
16387260|NCT04069312|Active Comparator|Azithromycin arm|Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months
16387261|NCT04069299||Participants receiving PET scan|Participants with metastatic poorly-differentiated neuroendocrine carcinomas of the GI tract
16387262|NCT04069286|Experimental|Treated Group|in which dry Aroeira extract (Schinus terebinthifolius raddi, 640mg / tablet) will be administered + amoxicillin 500mg 2 tablets + clarithromycin, 500mg 1 tablet given twice daily (12/12 hours).
16387263|NCT04069286|Active Comparator|Control Group|in which 1 tablet of 20mg of omeprazole will be administered + amoxicillin 2 tablets of 500mg + clarithromycin, 1 tablet of 500mg administered twice daily (12/12 hours).
16387266|NCT04069260|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
16387267|NCT04069247|Experimental|E-based cognitive behavioral therapy for insomnia (eCBT-I)|The eCBT-I will be delivered by a mobile application (eSleep) developed by BestCare & SuMian BioTech Co., Ltd. which contains a digital, self-paced, and highly interactive programme. It consists of six weekly sessions with animated elements, including an overview of sleep, sleep restriction, stimulus control, cognitive therapy, structured worry time and relapse prevention. Participants will have access to the eCBT-I treatment for 12 weeks.
16387268|NCT04069247|Active Comparator|Health education (HE)|The HE, a psychoeducation/information-approach, also consists of six consecutive sessions which contains information about general sleep knowledge, functions of human organs, nutrition, environmental health, brain health, identification and treatments of common diseases, but the contents are not related to any active therapeutic components of cognitive behavioral therapy for insomnia (CBT-I).Participants will have access to the intervention for 12 weeks.
16387269|NCT04069234|Experimental|Ticagrelor|ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily
16387270|NCT04069234|Active Comparator|Clopidogrel|clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily
16387271|NCT04069221|Experimental|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a [14C]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:
~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg [14C]-OZ439 (47 kBq [1.27 μCi]) beginning 3 hours after the oral dose administration."
16387272|NCT04069221|Experimental|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
16387273|NCT04069221|Experimental|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
16387274|NCT04069221|Experimental|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
16387275|NCT04069208|Experimental|IA14|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
16387276|NCT04069195|Active Comparator|DHA supplement|Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
16387277|NCT04069195|Placebo Comparator|corn oil: Soybean oil placebo|Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.
16387278|NCT04069182|Other|Behavioral Activation Therapy|Psychological intervention
16387279|NCT04069169|Experimental|Intravenous lidocaine|1% preservative free lidocaine 10 mg/ml in 0.9% NaCl
16387280|NCT04069169|Placebo Comparator|Intravenous saline control|0.9% sodium chloride, also known as normal saline
16387281|NCT04069156|Placebo Comparator|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
16387282|NCT04069156|Active Comparator|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
16387283|NCT04069143|Experimental|Part 1:18F-BMS-986327 (Safety Study)|
16387284|NCT04069143|Experimental|Part 2: 18F-BMS-986327 (Test/Retest Study)|
16387285|NCT04069143|Experimental|Part 3: 18F-BMS-986327 (Distribution in Partcipants with IPF)|
16387286|NCT04069130|Experimental|BIA 5|single oral dose of 400 mg as an oral capsule
16387287|NCT04069117|Active Comparator|• Study group|It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.
16387288|NCT04069117|No Intervention|• Control group|It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation
16387301|NCT04069091|Experimental|CBT intervention|Participants in the CBT intervention arm will undergo standard antenatal care and the 'Enjoy your Bump' online self-help intervention employing elements of cognitive behavioral therapy (CBT)
16387302|NCT04069091|No Intervention|Standard care|Participants in the Standard Care arm will undergo standard antenatal care.
16387303|NCT04069078|Active Comparator|Hyoscine butylbromide|
16387304|NCT04069078|Placebo Comparator|Control|
16387305|NCT04069065|Experimental|Conversion to Once-daily Tacrolimus|Conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) at least one year after liver transplantation
16387306|NCT04069052|Experimental|Inhaled Nitric Oxide|Inhaled nitric oxide administered throughout 4 min exercise protocol at 800 ppm.
16387307|NCT04069052|Placebo Comparator|Placebo|Inhaled room air administered throughout 4 min exercise protocol at FiO2 = 0.21.
16387308|NCT04069026|Experimental|Dose escalation of BAY2416964|Approximately 8 dose levels of BAY2416964 are planned
16387309|NCT04069026|Experimental|Dose expansion of BAY2416964 in tumor type specific|Patients with NSCLC, HNSCC, Urothelial cancer and Colorectal cancer MSS
16387310|NCT04069013|Active Comparator|Standard PCNL|Patients receive a standard PCNL procedure using a 24 fr tract
16387311|NCT04069013|Active Comparator|Mini-PCNL|Patients receive a mini-PCNL procedure using a 16 fr tract
16387312|NCT04069000|Active Comparator|Regular grade 3 classrooms|Students in this condition will participate in the regular grade 3 program. Educators will use their usual teaching methods to meet educational outcomes, including standards for social-emotional learning.
16387313|NCT04069000|Experimental|First time MindUP participants|Students in this condition will participate in MindUP for the first time. Their classroom teachers will receive training and implement the program during the school year.
16387314|NCT04069000|Experimental|Repeat MindUP participants|Students in this condition are in schools where MindUP has been implemented since they were in kindergarten (although some students may not have participated in those first three years, depending on when they moved to the school). Their classroom teachers will receive training and implement the program during the school year.
16387315|NCT04068987||Healthy Volunteers|"Healthy volunteers
~Recruited from the public
~Patients who have scheduled imaging scans for non-cardiac reasons and without a prior history or suspected history of cardiac disease"
16387316|NCT04068987||Children undergoing clinically indicated cardiac MRI|Patients who are scheduled to have a clinically indicated cardiac MRI
16387317|NCT04068974|Experimental|Test group|Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
16387318|NCT04068948|Active Comparator|Midazolam, Hydroxyzine, Meperidine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, Hydroxyzine 1.0mg/kg, and Meperidine 1.5mg/kg prior to their dental procedure.
16387319|NCT04068948|Experimental|Midazolam, Hydroxyzine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, and Hydroxyzine 1.0mg/kg prior to their dental procedure.
16387320|NCT04068935|Experimental|Buddy taping|Buddy taping of the fractured finger to ist neighbouring uninjured finger.
16387321|NCT04068935|Active Comparator|splint immobilization|A forearm-based palmar Hand Splint in an intrinsic plus Position, enclosing all fingers without the thumb.
16387322|NCT04068922|Experimental|Resilience Intervention|Participants will initially complete a baseline assessment assessing study eligibility. The Resilience intervention consists of seven weekly 1.5-hour group sessions guided by trained clinicians. Due to the COVID-19 pandemic, these group session may be conducted through Zoom. Skills and content will be directed toward improving pain management by enhancing positive emotions, setting goals, learning to live a life according to one's values, and boosting self-confidence in one's ability to manage pain. Self-administered activities include the identification of personal strengths, pleasant activity scheduling, expressing gratitude, values clarification, mindfulness practice, goal setting, positive reappraisal, and noting positive events.
16387323|NCT04068909||acute coronary syndrome|All patients should receive standard therapy for acute coronary syndrome and concomitant diseases. All drugs are prescribed according current guidelines and approved indications.
16387324|NCT04068896|Experimental|NGM120 Dose 1|NGM120 Subcutaneous Injection
16387325|NCT04068896|Experimental|NGM120 Dose 2|NGM120 Subcutaneous Injection
16387326|NCT04068896|Experimental|NGM120 Dose 3|NGM120 Subcutaneous Injection
16387327|NCT04068896|Experimental|NGM120 Dose 4|NGM120 Subcutaneous Injection
16387328|NCT04068896|Experimental|NGM120 Dose 5|NGM120 Subcutaneous Injection
16387329|NCT04068896|Experimental|NGM120 Dose 6|NGM120 Subcutaneous Injection
16387330|NCT04068896|Placebo Comparator|Placebo|Placebo
16387331|NCT04068883|Experimental|Collar group|group of athletes that will wear the collar device
16387332|NCT04068883|No Intervention|Non Collar group|group of athletes that will not wear the collar device
16387333|NCT04068870|Experimental|Contraceptive management program|
16387334|NCT04068870|No Intervention|Usual care|
16387335|NCT04068857|Experimental|rTMS|
16387336|NCT04068857|Sham Comparator|Sham|
16387337|NCT04068844|Experimental|Central HFpEF whole body exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to whole body cycle training.
16387338|NCT04068844|Experimental|Central HFpEF isolated single leg exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to isolated single leg training.
16387339|NCT04068844|Experimental|Peripheral HFpEF whole body exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to whole body cycle training.
16387340|NCT04068844|Experimental|Peripheral HFpEF isolated single leg exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to isolated single leg training.
16387341|NCT04068831|Experimental|Talazoparib and Avelumab (VHL-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
16387342|NCT04068831|Experimental|Talazoparib and Avelumab (FH- or SDH-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
16387343|NCT04068805|Active Comparator|Positive affect condition|Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
16387344|NCT04068805|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16387345|NCT04068792|Other|Part 1-Observational Phase|Participants will not receive any intervention in the observation phase. All infants will be closely monitored for early signs and symptoms of Respiratory Syncytial Virus (RSV) disease using a mobile RSV application on the parent/caregiver's mobile phone, upon an alert, the RSV will be tested, if RSV negative participants (RSV [-] diagnosed at site) will return to the pre-diagnostic phase and RSV positive participants (RSV [+] diagnosed at site) can be enrolled in the interventional stage of the study after obtaining informed consent for the interventional stage at that time. RSV (+) participants whose parent(s)/caregiver(s) do not consent for enrollment in the interventional stage and participants who are screening failures in the interventional stage will enter the post-diagnostic phase of the observational stage (hospitalized or outpatients).
16387346|NCT04068792|Experimental|Part 2-Interventional Phase|Participants will be randomized to receive either JNJ-53718678 (for Age Group 1 (greater than or equal to [>=] 28 days and less than [<] 3 months): 2.5 milligram per kilogram [mg/kg]; for Age Group 2 (>=3 and <6 months): 3 mg/kg and for Age Group 3 (>=6 months): 4.5 mg/kg) or placebo (Age Group 1, 2 and 3) twice daily for 7 days.
16387347|NCT04068766|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
16387348|NCT04068766|Placebo Comparator|Paracervical block with normal saline|ck with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
16387349|NCT04068753|Experimental|Niraparib + dostarlimab|
16387350|NCT04068740||Mitral valve disease|
16387351|NCT04068740||Aortic valve disease|
16387352|NCT04068727|No Intervention|Control|Control Patients will be provided with educational materials. Control patients will receive no additional guidance.
16387353|NCT04068727|Experimental|Clinical Pharmacist Intervention|Two intervention pharmacists will deliver the intervention. First, a pharmacy technician will call the patient to ensure access and affordability. Next the clinical pharmacist will call to conduct an initial consultation and educational session, documenting the findings and recommendations related to this consultation in the Electronic Medical Record (EMR). Finally, the intervention staff will send educational materials customized to the patient preference - short video clips, print materials, or an email with links to print materials. Over the remaining weeks of the study, the intervention pharmacists will field questions from patients, perform two follow up monthly phone calls, order and follow up on renal and hepatic function lab work, and write an off-service note.
16387354|NCT04068714||Endovascular repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through endovascular repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
16387355|NCT04068714||Open repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through open repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
16387356|NCT04068701|Experimental|MaNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
16387357|NCT04068701|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
16387358|NCT04068688|Experimental|Caregiver-Chid Dyads with ASD (Autism Spectrum Disorder)|Participants in this arm will be caregivers and children with ASD.
16387359|NCT04068688|No Intervention|Children with typical development|Participants in this arm will be children with typical development.
16387360|NCT04068688|No Intervention|Children with developmental delay|Participants in this arm will be children with developmental delay.
16387361|NCT04068675|Experimental|Group counseling arm|There is only one(1) arm in this study. All patients that enroll in the study will receive the group counseling intervention and be compared to historical controls.
16387362|NCT04068662|Experimental|Pregnant Moms' Empowerment Program|Five session group therapy program covering safety planning, resilience and coping, infant care and parenting.
16387363|NCT04068662|Active Comparator|Nondirective Support Group|Five session nondirective support group with two co-leaders who assist in facilitating open discussion on women's self-identified discussion topics.
16387364|NCT04068649|Experimental|Arm I (palliative RT)|Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
16387366|NCT04068636|Experimental|Flexible endoscopy guided SNB in larynx and pharynx cancers.|Patients with larynx and pharynx cancers will undergo sentinel node biopsy via flexible endoscopy. In this procedure, a radioactive tracer will be injected at 2-4 sites edging the tumor. A SPECT scan will be performed for visualization of the sentinel node(s).
16387367|NCT04068623||Triple negative breast cancer|
16387368|NCT04068610|Active Comparator|Control Arm (FOLFOX + Bevacuzimab)|Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only. Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle)
16387369|NCT04068610|Experimental|Exp. Arm (FOLFOX + Bevacuzimab + Durvalumab + Oleclumab)|"Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only.
~Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle) Durvalumab 1500 mg IV Q4W Oleclumab 3000mg IV Q2W x 4 then Q4W"
16387370|NCT04068597|Experimental|CCS1477 dose escalation NHL/MM|
16387371|NCT04068597|Experimental|CCS1477 dose escalation AML/High risk MDS|
16387372|NCT04068597|Experimental|CCS1477 expansion phase NHL|
16387373|NCT04068597|Experimental|CCS1477 expansion phase MM|
16387374|NCT04068597|Experimental|CCS1477 expansion phase AML/High risk MDS|
16387375|NCT04068584|Experimental|Complete Smart Angel|Smat Angel application with artificial intelligence
16387376|NCT04068584|Experimental|Basic Smart Angel|Smat Angel application without artificial intelligence
16387377|NCT04068584|No Intervention|Control|
16387378|NCT04068571|Active Comparator|I-PUSH intervention sites|Clusters with I-PUSH intervention
16387379|NCT04068571|No Intervention|No I-PUSH intervention sites|Clusters with no I-PUSH intervention
16387380|NCT04068558|Experimental|VNI-NAVA/sNIPPV|Ventilation of the child non-invasive ventilation (VNI) NAVA then sNIPPV
16387381|NCT04068558|Experimental|sNIPPV/VNI-NAVA|Ventilation of the child sNIPPV then non-invasive ventilation (VNI) NAVA
16387382|NCT04068532|Placebo Comparator|Placebo|Participants will receive matching placebo to BIIB104 on Days 1-4 in treatment periods 1 or 2.
16387383|NCT04068532|Experimental|BIIB104|Participants will receive BIIB104 on Days 1-4 in treatment periods 1 or 2.
16387384|NCT04068519|Experimental|Tislelizumab|Tislelizumab will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
16387385|NCT04068506|Experimental|Group A|Gabapentin 600 mg Tab
16387386|NCT04068506|Active Comparator|Group B|Paracetamol 1000 mg Tab
16387387|NCT04068493|Experimental|Dissonance-based obesity intervention|Participants in this arm will receive Enhanced Project Health.
16387388|NCT04068493|No Intervention|Assessment Only|Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
16387389|NCT04068480||Capsule endoscopy|Patient refered for small bowel capsule endoscopy in conventional indication.
16387390|NCT04068467|Experimental|Active|Instructed to download the app and use the app daily for 30 days.
16387391|NCT04068467|Active Comparator|Waitlist Control|Waitlist control.
16387392|NCT04068454|Active Comparator|classical rehabilitation group|
16387393|NCT04068454|Experimental|virtual reality group|
16387394|NCT04068441||Regular treatment|
16387395|NCT04068441||Treatment interruption|
16387396|NCT04068402|Experimental|Treatment|
16387397|NCT04068376|Active Comparator|Control group (C-GR)|Control group of an aerobic-balance-stretching exercise program led by a coach for 24 weeks (C-GR).
16387398|NCT04068376|Experimental|T1-GR training sessions by health professional|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health professional with a nursing background previously certified to coach SSE trainings by the Institute of Square-Stepping Exercise in Mie, Japan (Chief Tomohiro Okura and Overseas Director Professor Ryosuke Shigematsu).
16387399|NCT04068376|Experimental|T2-GR older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
16387400|NCT04068363||Matched group|Same sex of both donor and recipient
16387401|NCT04068363||Mismatched group|Sex mismatch between donor and recipient, subgroups might be added
16387402|NCT04068350||Single arm|The evaluation at 3 months of the postoperative pain will be carried out without the information collected in preoperative and immediate postoperative.
16387403|NCT04068337||Hemiarch|Patients with Freestyle aortic root implantation receiving a hemiarch replacement by open anastomosis technique with axillary cannulation and antegrade cerebral perfusion
16387404|NCT04068337||Non-Hemiarch|Patients with Freestyle aortic root implantation without hemiarch replacement with normal systemic perfusion
16387405|NCT04068324|No Intervention|8 hours fasting group|Routine preoperative fasting group undergoes 8 hours of fasting before the operation.
16387406|NCT04068324|Experimental|Clear liquid group|"30 pediatric patients drink 3ml/kg 1 hour before the surgery. Although clear liquid suggests any drinks that do not contain any solid ingredients, but in this study we define clear liquid as water."
16387407|NCT04068324|Experimental|Carbohydrate containing liquid group|"Other 30 pediatric patients drink 3ml/kg of carbohydrate containing fluid 1 hour before the surgery. The product name we have is NoNPO from NewCare (South Korean company). This fluid does not contain any solid ingredients, so consuming the fluid does not exceed Nil per Os time needed before the surgery."
16387408|NCT04068311|No Intervention|Pre Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
16388554|NCT04059653|Experimental|Electrical stimulation|Neuromuscular electrical stimulation treatment
16387409|NCT04068311|Active Comparator|Post Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
16387410|NCT04068285|Active Comparator|High intensity interval exercise|"Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
~exercise"
16387411|NCT04068285|Active Comparator|Moderate intensity continuous exercise|"Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
~exercise"
16387412|NCT04068285|No Intervention|No Intervention: Control group|The participants with type 2 Diabetes mellitus in the control group will make stretching exercise at home
16387413|NCT04068272|Experimental|Treatment|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
16387414|NCT04068272|Placebo Comparator|Placebo|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
16387415|NCT04068259|Experimental|Cohort 1, Dose 1 of PBI-4547 or Placebo|Dose 1 of PBI-4547 or matching Placebo tablets by mouth
16387416|NCT04068259|Experimental|Cohort 2, Dose 2 of PBI-4547 or Placebo|Dose 2 of PBI-4547 or matching Placebo tablets by mouth
16387417|NCT04068259|Experimental|Cohort 3, Dose 3 of PBI-4547 or Placebo|Dose 3 of PBI-4547 or matching Placebo tablets by mouth
16387418|NCT04068259|Experimental|Cohort 4, Dose 4 of PBI-4547 or Placebo|Dose 4 of PBI-4547 or matching Placebo tablets by mouth
16387419|NCT04068259|Experimental|Cohort 5, Dose 5 of PBI-4547 or Placebo|Dose 5 of PBI-4547 or matching Placebo tablets by mouth
16387420|NCT04068246|Placebo Comparator|Control group|patients will receive the standard therapy (methotrexate) plus placebo tablets
16387421|NCT04068246|Experimental|Metformin group|patients will receive the standard therapy plus 1 g metformin daily.
16387422|NCT04068233|Experimental|Eligible patients - pacing mode sequence 1|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-synchronous pacing mode first, then AV-dyssynchronous pacing mode.
16387423|NCT04068233|Experimental|Eligible patients - pacing mode sequence 2|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-dyssynchronous pacing mode first, then AV-synchronous pacing mode.
16387424|NCT04068220|Other|Intraoperative FVEPs monitoring|adult patients admitted to TOH - Civic Campus, for chiasmal or pre-chiasmal lesions undergoing a first time minimally invasive endoscopic skull base surgery.
16387425|NCT04068207|Experimental|Minocycline|Tablets Minocycline 100mg po per day for 24 weeks
16387426|NCT04068194|Active Comparator|Arm A (hypofractionated RT, avelumab)|Patients undergo 5 fractions of hypofractionated RT QOD on days -17 to -7. Patients also receive avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16387427|NCT04068194|Experimental|Arm B (hypofractionated RT, peposertib, avelumab)|Patients undergo 5 fractions of hypofractionated RT QOD on days -17 to -7. Patients also receive peposertib PO BID on days 1-28, and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16387428|NCT04068181|Experimental|Talimogene Laherparepvec and Pembrolizumab|To evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting.
16387429|NCT04068155|Experimental|DaRT Seeds Intratumoral Diffusing alpha-emitters|An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.
16387430|NCT04068142|No Intervention|Clinical Personnel Safety Planning|Patients will complete a traditional written suicide safety plan with clinical personnel.
16387431|NCT04068142|Experimental|Peer Supporter Safety Planning|Patients will complete a traditional written suicide safety plan with peer supporters.
16387432|NCT04068129||Burma|Patients from remote Burma clinic
16387433|NCT04068129||Alaska|Patients in pediatric ophthalmology clinic
16387434|NCT04068116|Experimental|Postconditioning in primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention with post-conditioning by making 4 cycles of repeated occlusion & re-perfusion 30-second each by inflation/deflation of an appropriately sized PTCA (per-cutaneous trans-luminal coronary angioplasty) balloon
16387435|NCT04068116|Active Comparator|Primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention without post-conditioning
16387436|NCT04068103|Active Comparator|Arm I (blood stored and tested for ctDNA later)|Patients undergo active surveillance.
16387437|NCT04068103|Experimental|Arm II (blood tested for ctDNA at baseline)|"Patients are assigned to 1 of 2 groups.
~GROUP I (ctDNA DETECTED): At the discretion of the investigator, patients receive either oxaliplatin IV over 2 hours on day 1, leucovorin IV over 2 hours on day 1, and fluorouracil IV bolus over 2-4 minutes on day 1 and then by continuous IV over 46-48 hours repeated every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14 repeated every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity at the discretion of the investigator.
~GROUP II (ctDNA NOT DETECTED): Patients undergo active surveillance."
16387438|NCT04068090||Patients with CIPN|Patients with peripheral neuropathy after treatment with taxanes
16387439|NCT04068090||Patients without CIPN|Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage
16387440|NCT04068077||Experimental|Patients with amyloidosis and other indistinguishable diseases
16387441|NCT04068064|Experimental|EABM training group|about 40 individuals with IGD will be randomly assigned to the EABM training group
16387632|NCT04066699||Localization|Electromagnetic navigation (EMN) guided percutaneous localization of suspicious lung lesion(s).
16387442|NCT04068064|Placebo Comparator|Control training group|about another 40 individuals with IGD will be randomly assigned to the control training group
16387443|NCT04068051|Experimental|AXS-07|
16387444|NCT04068025|No Intervention|No Intervention: Control group|Patients in the control group were given usual care by a health professional who was not involved in the study and who worked in the Department of Urology. After the end of the study, the patients in the control group were also given structured bladder training similar to the patients in the intervention group.
16387445|NCT04068025|Active Comparator|the IMB model|Structured bladder training was applied to the patients in the intervention group via the IMB model.
16387446|NCT04068012|Experimental|Intervention|Ventilator management using the proposed protocol in both acute and weaning phases
16387447|NCT04067999||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
16387448|NCT04067986|Other|Camrelizumab + Apatinib|Camrelizumab + Apatinib
16387449|NCT04067973||patients|"Premature subjects benefit from the examinations described in the protocol, namely automated refractometry, intraocular air pressure, biometrics (with axial length and pachymetry (corneal thickness) performed by the same machine at the same time), a photo of the fundus (retinophotography) and an OCT RNFL. These examinations are necessary for the follow-up of premature children.
~All children examined at Nantes University Hospital benefit systematically from: automated refractometry, intraocular pressure in the air and a photo of the fundus."
16387450|NCT04067973||control|"controls benefit from two additional tests: RNFL OCT and biometrics. The duration of the RNFL OCT is about 2 minutes, with a total of 10 seconds per eye, the rest being computer manipulation.
~The biometrics take about 2 minutes to complete, with a total of 30 seconds per eye, the rest being computer manipulation.
~These two reviews are conducted on the same day as the initial consultation and directly following the consultation."
16387451|NCT04067960||Ancillary-correlative (pharmacogenomics testing)|Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing.
16387452|NCT04067947|Experimental|XG005|XG005 in 4 dose levels
16387453|NCT04067947|Placebo Comparator|Placebo|Placebo in all cohort
16387454|NCT04067934|Experimental|Jumping exercise|High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
16387455|NCT04067908|Experimental|woman giving birth prematurely|Proteome: by liquid chromatography coupled with tandem mass spectrometry. Fibronectin: by vaginal sampling. Ultrasound of the cervix. Cytokines: ELISA kit of a panel of several cytokines.
16387456|NCT04067895||human bone graft screw|human bone graft screws will be used during the epiphysiodesis
16387457|NCT04067882||Cervix cancer|Women older than 18 years with histopathological diagnosis of cervical cancer clinical stage I2-IVA, candidates to receive standard treatment with chemotherapy followed by brachytherapy.
16387458|NCT04067869|Experimental|Single arm|Patient with confirmed HIV-1 infection
16387459|NCT04067856|Active Comparator|Bevacizumab|Intravitreal injection of 1.25mg/0.05cc bevacizumab
16387460|NCT04067856|Active Comparator|Dexamethasone implant|Intravitreal injection of 0.7mg dexamethasone implant
16387461|NCT04067843|Experimental|Photodynamic treatment|Skin microbiome after photodynamic treatment before and after skin antisepsis
16387462|NCT04067830|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
16387463|NCT04067830|Experimental|Arm II (RMT + usual care)|Patients use a power lung device to complete 3 sets of 15 RMT exercises over 30 minutes 6 days per week over 2-4 weeks for a minimum of 12 sessions prior to surgery. Patients also receive usual care consisting of attending physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
16387464|NCT04067817|Experimental|norepinephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, norepinephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered
16387465|NCT04067817|Experimental|phenylephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, phenylephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered.
16387466|NCT04067804|No Intervention|Usual Care|Standard school disciplinary practices.
16387467|NCT04067804|Experimental|Dynamic Adaptation Process|Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.
16387468|NCT04067791|Experimental|Prolonged-Release melatonin then Immediate-release melatonin|
16387469|NCT04067791|Experimental|Immediate-Release Melatonin then Prolonged-Release Melatonin|
16387505|NCT04067492|Experimental|RPH - 4 mg|Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
16387470|NCT04067778|Experimental|Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
16387471|NCT04067778|Other|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
16387472|NCT04067765|Experimental|Alcohol Cue|Alcohol cue exposure in scanner
16387473|NCT04067765|Active Comparator|Neutral Cue|Neutral cue exposure in scanner
16387474|NCT04067752|Experimental|High Dialysate Na|high dialysate sodium concentration (138 mEq/L)
16387475|NCT04067752|Active Comparator|Low Dialysate Na|Low dialysate sodium concentration (132 mEq/L)
16387476|NCT04067739||Readmission group|Readmission is defined as ICU readmission within ≤ 3 months of initial ICU discharge
16387477|NCT04067739||Non readmitted group|Non readmission is defined as no need for ICU readmission within ≤ 3 months of initial ICU discharge
16387478|NCT04067726|Experimental|Denosumab|"Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months
~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination.
~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur.
~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
16387479|NCT04067726|Placebo Comparator|Placebo|"Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months
~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination
~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur.
~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
16387480|NCT04067713||PARADIGM-D|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Docetaxel with androgen deprivation therapy (ADT).
16387481|NCT04067713||PARADIGM- A|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Abiraterone with androgen deprivation therapy (ADT).
16387482|NCT04067700|Other|Coronary perfusion PET/CT patients|
16387483|NCT04067687|No Intervention|Control|No palliative home visit intervention
16387484|NCT04067687|Experimental|Intervention|Palliative home visit intervention
16387485|NCT04067674||Septic shock patients|Patients included in this cohort will have blood sampling for measurement of immune related biomarkers (immunophenotyping, functional tests, messenger ribonucleic acid (mRNA), circulating markers) in circulating blood and their associations with relevant clinical outcomes
16387486|NCT04067661|Experimental|Intervention|Participants and their partners will complete four couples counseling sessions focused on developing and enhancing relationship skills to decrease HIV risk behaviors.
16387487|NCT04067661|Active Comparator|Control|Participants and their partners will receive information and referrals on HIV risk and prevention strategies.
16387488|NCT04067648|Experimental|S1 group|Sufentanil 0.3 μg/kg was intravenously given during anesthesia induction
16387489|NCT04067648|Experimental|S2 group|Sufentanil 0.4 μg/kg was intravenously given during anesthesia induction
16387490|NCT04067648|Experimental|S3 group|Sufentanil 0.5 μg/kg was intravenously given during anesthesia induction
16387491|NCT04067635||Conservative Arm|Participants are followed by the research team conservatively. Participants in this arm may choose to undergo any valvular intervention at the discretion of their treating clinical team.
16387492|NCT04067635||Surgical Arm|Participants have already elected upfront to undergo surgical repair (at least, mitral annuloplasty) with their treating clinical team, just prior to enrollment into this study.
16387493|NCT04067622|Other|Exersides restraints first|Patients in this arm will wear the novel Exersides restraint during hours 1-4 on Day 1, then switched to soft wrist restrains during hours 5-8. On Day 2, patients in this arm will will wear soft wrist restraints during hours 1-4, and Exersides during hours 5-8. They will then wear Exersides during study days 3-6.
16387494|NCT04067622|Other|Traditional restraints first|Patients in this arm will wear soft wrist restraints during hours 1-4 on Day 1; they will then be switched to the novel Exersides restraint during hours 5-8. On Day 2, patients in this arm will will wear Exersides during hours 1-4, and soft wrist restraints during hours 5-8. They will then wear soft wrist restraints during study days 3-6.
16387495|NCT04067609|Experimental|patients receiving dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
16387496|NCT04067609|Placebo Comparator|placebo|100mL of normal saline (placebo) immediately upon the subjects' arrival to the Post Anesthesia Care Unit (PACU) after leaving the operating room from their scheduled c-section
16387497|NCT04067596|Experimental|epiphysiodesis|The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).
16387498|NCT04067583||Physicians with recent aflibercept experience|Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
16387499|NCT04067570|Experimental|SBRT post operative|"Stereotactic Body Radiotherapy (SBRT) 30 Gy in 5 fractions, once weekly to prostate bed
~/ - 25 Gy in 5 fractions, once weekly simultaneously to pelvic lymph nodes
~/ - 6-24 months of androgen deprivation therapy (ADT)"
16387500|NCT04067544|Other|Acupuncture Treatment|All patients receive 10 acupuncture treatments over the course of 8 weeks.
16387501|NCT04067531|Other|treatment of BV|all patients be treated with first Deqularum then with clindamycin Cream,
16387502|NCT04067518|Experimental|Pegaspargase arm|
16387503|NCT04067505|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.
16387504|NCT04067505|Active Comparator|Warfarin/Nadroparin|Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.
16387626|NCT04066725|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 60 days.
16387506|NCT04067492|Experimental|RPH - 20 mg|Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
16387507|NCT04067492|Experimental|RPH - 40 mg|Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
16387508|NCT04067492|Experimental|RPH - 80 mg|Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
16387509|NCT04067492|Experimental|RPH - 160 mg|Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
16387510|NCT04067492|Active Comparator|Voltaren® (diclofenac)|Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
16387511|NCT04067479|Experimental|Young|
16387512|NCT04067479|Experimental|Older Adults|
16387513|NCT04067466|Experimental|Fiber product|Fiber product: Inulin, maltodextrin, gum guar, plum powder
16387514|NCT04067466|Placebo Comparator|Control product|Maltodextrin, plum powder
16387515|NCT04067453||Patients undergoing fatiguing protocol|patient consulting for anorectal manometry in order to explore anorectal disorders with a voluntary command on external anal sphincter
16387516|NCT04067440||Patients|Subjects to undergo surgery including opening of the jejunum with non-inflammative condition.
16387517|NCT04067427|Active Comparator|Mental training|AF ablation followed by 3 months of a daily app-based mental training for 10 to 15 minutes per session. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
16387518|NCT04067427|No Intervention|Control|AF ablation without subsequent mental training. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
16387519|NCT04067414|Experimental|BZ019 treatment|Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. A 3×3 dose escalation design of BZ019 will be adopted.
16387520|NCT04067401|Experimental|Wingman Connect|Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
16387521|NCT04067401|Active Comparator|Stress Management|The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.
16387522|NCT04067375||Pregnant women, HPA-1a positive|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a positive.
16387523|NCT04067375||Pregnant women, HPA-1a negative with HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and have formed anti-HPA-1a alloantibodies.
16387524|NCT04067375||Pregnant women, HPA-1a negative without HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and did not have formed anti-HPA-1a alloantibodies.
16387525|NCT04067362|Placebo Comparator|no fiber|Breakfast with hot chocolate with no fiber
16387526|NCT04067362|Experimental|chicory root flour|Breakfast with hot chocolate with chicory root flour
16387527|NCT04067362|Experimental|chicory root fiber supplement|Breakfast with hot chocolate with chicory root fiber supplement
16387528|NCT04067349|Active Comparator|laparoscopic liver resection|Patients undergoing laparoscopic liver resection
16387529|NCT04067349|Active Comparator|open liver resection|Patients undergoing open liver resection
16387531|NCT04067323|Placebo Comparator|LCT consumption|20g soy oil (containing mainly long chain triglycerides - LCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
16387532|NCT04067323|Experimental|MCT consumption|20g MCT oil (containing 100% MCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
16387533|NCT04067310|Experimental|Group Experimental|Participants who will use the spray skin protector
16387534|NCT04067310|Active Comparator|Group control|Participants who will use moisturizer containing in its composition calendula officinalis
16387535|NCT04067297|No Intervention|Control Arm|The 14 communities that are in the control arm of the trial will receive usual standard of care. The usual standard of care will follow clinical daily practice patterns provided by family physicians in Ontario for CVD prevention. This follows the periodic standard of care provided by Canadian cholesterol, hypertension, and diabetes best practice guideline recommendations utilized based on each physician's clinical judgement, physical assessment, and discretion. Patients also typically have access to existing cardiovascular prevention materials offered online through publicly available websites.
16387536|NCT04067297|Experimental|Intervention Arm|The 14 communities that are in the intervention arm of the trial will receive a multicomponent intervention that provides both physicians and patients with access to a 'toolbox' of lipid management resources. The components planned for the 'toolbox' are all evidence-based interventions and chosen after consultations with Canadian family physicians and implementation science experts based on their potential for scalability to the entire population, cost and practicality. Online tools will be used and the trial will leverage pre-existing implementation initiatives (e.g., newsletters, listservs) wherever possible to minimize study costs and increase accessibility.
16387537|NCT04067284|Active Comparator|Intervention 1|Nutrition education on dietary diversity.
16387538|NCT04067284|Experimental|Intervention 2|A combination of similar education plus daily supplementation of homemade yogurt.
16387539|NCT04067284|Active Comparator|Usual care|Control group.
16387540|NCT04067258||Beta-Thalassemia group|Patients suffering from beta thalassemia major or intermedia will be included in this group
16387541|NCT04067258||Control group|Healthy age and sex matched volunteers will be included in this group
16388555|NCT04059653|Active Comparator|Treatment As Usual|Usual GP treatment
16387542|NCT04067245|Other|Tetrasodium EDTA cathether lock solution|There is only one arm in this study where home parenteral nutrition patients who meet the inclusion criteria will receive tetrasodium EDTA catheter lock solution.
16387543|NCT04067232|Experimental|Patients with posttraumatic forearm impairment|All patients with a one-sided posttraumatic impairment of forearm pro- and/or supination at least 3 months after injury
16387544|NCT04067219|Experimental|Single arm|HIV-1 infected patients
16387545|NCT04067206|Experimental|Recorded mothers' voice group.|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
16387546|NCT04067206|Experimental|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
16387547|NCT04067206|Experimental|MiniMuffs|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
16387548|NCT04067206|No Intervention|Control Group|The control group who were administered standard care.
16387549|NCT04067193||old geriatric inpatients|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes)
16387550|NCT04067193||unformal caregivers|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes) by their relative
16387551|NCT04067193||professional caregivers|usability assessment after the possible use of the device (PARADE CONNECT shoes) by 40 hospitalzed old patients in the geriatrics ward
16387552|NCT04067180|Experimental|Haplo SCT|Allogeneic stem cell transplantation with a haplo-identical family donor graft.
16387553|NCT04067180|Active Comparator|URD SCT|Allogeneic stem cell transplantation with a matched unrelated donor graft.
16387554|NCT04067167|Sham Comparator|WB-EMS (Sham-intervention)|Low-theshold WB-EMS combined with nutritional therapy
16387555|NCT04067167|Experimental|WB-EMS|WB-EMS combined with nutritional therapy
16387556|NCT04067167|Experimental|Free WB-EMS|WB-EMS using a mobile System combined with nutritional therapy
16387557|NCT04067167|Experimental|Flexi Band Resistance Training|Flexi band resistance Training combined with nutritional therapy
16387558|NCT04067154|Experimental|ALPE-TAC|ARDS patients on mechanical ventilation. Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O to evaluate potential for recruitment and measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
16387559|NCT04067141|Experimental|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
16387560|NCT04067141|Experimental|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
16387561|NCT04067128|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach called patients three times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
16387562|NCT04067128|No Intervention|Usual care arm|Patients assigned to usual care had access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
16387563|NCT04067115|Experimental|Trabectedin and Irinotecan|Trabectedin will be delivered by infusion on day 1 followed by 2 doses on irinotecan delivered by infusion for one hour on day 2 and day 4 of 21 day cycles. Some patients will receive an 18F-FLT Imaging scan prior to the first administration of trabectedin and once after administration of trabectedin.
16387564|NCT04067102|Experimental|Nab-paclitaxel Based Regimens|
16387565|NCT04067102|Active Comparator|Paclitaxel Based Regimens|
16387566|NCT04067089|Experimental|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
16387567|NCT04067089|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
16387568|NCT04067076||Students of IEMS of Mexico City|Students currently enrolled in the academic year 2019-2020 from the 24 IEMS centers of Mexico City
16387569|NCT04067063||Milpa Alta inhabitants|Population among 15 and 70 years old
16387570|NCT04067050|Experimental|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
16387571|NCT04067050|Active Comparator|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
16387572|NCT04067037|Experimental|Camrelizumab Combined With AVD regimen|Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
16387573|NCT04067024|Active Comparator|Local anesthesia by the surgeon (LAS)|Local infiltration (ropivacaine 3,75 mg/ml) by surgeon
16387574|NCT04067024|Experimental|Regional anesthesia group (LRA):|By ultrasound, a pecs block I associated with a supraclavicular nerf block is performed. (Ropivacaine 3,75 mg/ml)
16387575|NCT04067011|Experimental|Group 1:Ciprofloxacin + AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
~Group 1 will concomitantly receive ciprofloxacin."
16387627|NCT04066725|Placebo Comparator|Placebo|Participants will be given a placebo orally once daily for a total of 60 days.
16387628|NCT04066712|Experimental|A: Normal (control) renal function|
16387576|NCT04067011|Experimental|Group 2: Doxycycline +AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
~Group 2 will concomitantly receive doxycycline."
16387577|NCT04067011|Experimental|Group 3: AV7909|Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
16387578|NCT04066998|Experimental|Conjunctivitis|Patients treated with Dupilumab with conjunctivitis
16387579|NCT04066998|Other|No conjunctivitis|Patients treated with Dupilumab and showing no signs of ocular involvement
16387580|NCT04066985|Experimental|Growth Mindset Intervention|"Includes one online, single-session program, the Growth Mindset Program. The 30-minute, self-administered youth program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
16387581|NCT04066985|Experimental|Self-Kindness Intervention|Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
16387582|NCT04066985|Active Comparator|Supportive Therapy Intervention|Includes one online, single-session active comparator program, the Supportive Therapy Intervention. The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. The 30-minute, self-administered control group program includes: vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family; the same number of reading and writing activities as the web-based growth mindset intervention. However, the only goals of the ST intervention are to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs.
16387583|NCT04066972|Experimental|Single arm|
16387584|NCT04066959|Experimental|Question Prompt List (QPL)|A QPL is a simple, inexpensive communication tool that is comprised of list of questions related to the physical and psychosocial aspects of an illness and treatment components about which patients may want to ask their diabetes care team during a routine diabetes clinic visit.
16387585|NCT04066959|Experimental|Motivation Enhancement System (MES)|MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
16387586|NCT04066959|Experimental|Text Message Reminders (TXT)|Participants will receive 30 days of one-way text messages targeting one of three key daily diabetes care behaviors: monitoring blood glucose, insulin administration, or carbohydrate counting. Participants will set a reminder schedule, i.e., frequency and timing of text message reminders.
16387587|NCT04066959|Experimental|QPL & MES|Participants will receive the QPL and MES interventions as described above.
16387588|NCT04066959|Experimental|QPL & TXT|Participants will receive the QPL and TXT interventions as described above.
16387589|NCT04066959|Experimental|MES & TXT|Participants will receive the MES and TXT interventions as described above.
16387590|NCT04066959|Experimental|MES, QPL & TXT|Participants will receive the MES, QPL, and TXT interventions as described above.
16387591|NCT04066959|No Intervention|Standard Medical Care|Participants will receive standard medical care at one of two participating clinical sites. Clinical practices at these sites are consistent with the standards of T1D care recommended by the American Diabetes Association and will include diabetes clinic visits every 3-4 months for routine diabetes medical care provided by an endocrinologist and/or nurse practitioner.
16387592|NCT04066946|Experimental|Group 1 = Intervention group|Standard of care (hydration + silicone gel sheet) + Microcurrent
16387593|NCT04066946|Active Comparator|Group 2 = Control Group|Standard of care (hydration + silicone gel sheet)
16387594|NCT04066920|Experimental|IBER treatment arm|This is the only arm in a single-arm phase II study.
16387595|NCT04066907|Experimental|Integrated Disease Management|Physicians randomized to intervention will attend a training session on the program standards and details of the IDM. Following the initial baseline interview a certified heart failure educator (CHFE) will meet with subjects to obtain a detailed history of their HF, provide education, self-care management strategies (medication adherence, symptoms monitoring, dietary adherence, fluid restriction, exercise, weight management, smoking cessation) and review immunization status. A self-management action plan will be developed with the study physician and CHFE to enable monitoring and management of HF by the participant. All participants will meet with a dietitian at all IDM appointments.
16387596|NCT04066907|No Intervention|Usual Care|Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months in person interviews will be conducted by the research assistant and the questionnaires will be completed.
16387629|NCT04066712|Experimental|B: Mild impairment renal function|
16387630|NCT04066712|Experimental|C: Moderate impairment renal function|
16387597|NCT04066894|Experimental|Supportive Care (sacral nerve stimulator)|Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
16387598|NCT04066881|Experimental|Group A|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm
~1 tab of Truvada (0-26 weeks)"
16387599|NCT04066881|Experimental|Group B|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm
~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm
~1 tab of Truvada (0-26 weeks)"
16387600|NCT04066881|Placebo Comparator|Group C:|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48
~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.
~1 tab of Truvada (0-26 weeks)"
16387601|NCT04066881|Active Comparator|Group D|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm
~1 tab of Descovy (0-26 weeks)"
16387602|NCT04066881|Experimental|Group E|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm
~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm
~1 tab of Descovy (0-26 weeks)"
16387603|NCT04066881|Placebo Comparator|Group G|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48
~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.
~1 tab of Descovy (0-26 weeks)"
16387604|NCT04066868|Experimental|PRO active|
16387605|NCT04066868|Active Comparator|PRO not active|
16387606|NCT04066855||Chronic Kidney Disease (CKD)|patients diagnosed as CKD
16387607|NCT04066855||Renal transplant|recipients of renal transplantation
16387608|NCT04066842||1 - Controls|Control Healthy controls
16387609|NCT04066842||2 - SSc|SSc Systemic Sclerosis
16387610|NCT04066842||3 - Cardiovascular|Cardiovascular Cardiovascular disease
16387611|NCT04066842||4 - SSc+Periodontitis|SSc+ Periodontitis Systemic Sclerosis with Periodontitis
16387612|NCT04066829|Experimental|Default setting intervention|The arm will include all patients undergoing tonsillectomy at C.S. Mott Hospital by a pediatric otolaryngology faculty member at the University of Michigan.
16387613|NCT04066829|No Intervention|Control (Usual Care)|The arm will include all patients undergoing tonsillectomy at University Hospital, Brighton Center for Specialty Care, or Livonia Center for Specialty Care by a general otolaryngology faculty member at the University of Michigan.
16387614|NCT04066816|Experimental|Walnut Consumption|After screening, participants will avoid foods high in ellagic acid. These foods include pomegranates, hazelnuts, pistachios, strawberries, raspberries, blackberries, oak-aged wines, spirits, and walnuts (besides the ones given by researchers); a complete list will be provided to the subjects. Participants will then return to research facility and provide urine and stool samples, as well as a set of 3-day dietary records. Then, they will start to consume 2 ounces of walnuts per day for 21 days with their usual diet. At the end, they will collect another urine and stool sample as well as another set of dietary records, and then come in for the scheduled colonoscopy where they will be asked to provide biopsy specimens. That completes the intervention and participation in the study.
16387615|NCT04066803|Experimental|MTX group with folic acid|the group with optimal MTX dose (gradually increased from 0 to 12weeks，appropriate folic acid，and stable original other DMARDs
16387616|NCT04066803|Active Comparator|control group without folic acid|the group with stable MTX 10mg/w dose and maximum DMARDs doses（graduallly increased from 0 to 12 weeks）without folic acid
16387617|NCT04066790|Experimental|Pyrotinib in combination with nab-paclitaxel|Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
16387618|NCT04066790|Active Comparator|Trastuzumab in combination with nab-paclitaxel|Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
16387619|NCT04066777|Other|Hypertrophic obstructive cardiomyopathy|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
16387620|NCT04066764|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg oral twice daily for 3 weeks after operation, later rivaroxaban 20mg oral once daily until 3 months after the filter is retrieved.
16387621|NCT04066764|Active Comparator|Warfarin/ Nadroparin|Participants will receive Nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 3 months after the filter is retrieved.
16387622|NCT04066751|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
16387623|NCT04066751|Placebo Comparator|Placebo|Placebo, 150 mg PO every 12 hrs for 84 days
16387624|NCT04066738|Other|Patients with myocardial scar|Patient with previous STEMI resulting in myocardial scar, elected to CRT implant
16387625|NCT04066725|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 60 days
16387633|NCT04066686||Young|Participants recruited into one of two groups on age stratification. Young cohort defined as aged 18-65yrs old
16387634|NCT04066686||Elderly|Participants recruited into one of two groups on age stratification. Elderly cohort defined as over 65yrs of age.
16387635|NCT04066660|Experimental|Treatment & Oligo Fucoidan|4.4 g Oligo Fucoidan powder by six months, BID
16387636|NCT04066660|Placebo Comparator|Treatment & Placebo|4.4 g Placebo powder by six months, BID
16387637|NCT04066647|Experimental|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
16387638|NCT04066634|Experimental|Assist in Diagnosis|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
16387639|NCT04066621|Experimental|CRO-SBT|Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)
16387640|NCT04066595|Experimental|Experimental (cohorts 1 and 2)|Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib). Both cohorts receive the same treatment.
16387641|NCT04066582||Experimental|Suspected skin inflammations or skin tumors
16387642|NCT04066569|Active Comparator|OGTT Tests and Placebo Test|Patients with acromegaly
16387643|NCT04066569|Active Comparator|OGTT Tests|age and sex matched healthy volunteers
16387644|NCT04066556||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
16387645|NCT04066543|Active Comparator|TACE group|Device: Transcatheter arterial chemoembolization(TACE)
16387646|NCT04066543|Experimental|TACE+Anlotinib group|Device: Transcatheter arterial chemoembolization Drug: Anlotinib Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
16387647|NCT04066530|Experimental|AD-203|
16387648|NCT04066530|Active Comparator|Mucosta tab.|
16387649|NCT04066517|Experimental|Open Label|Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
16387650|NCT04066504||Sonidegib|Patients with laBCC undergoing sonidegib treatment in routine clinical practice
16387651|NCT04066491|Experimental|Safety Run-In Part: Bintrafusp alfa + Gemcitabine + Cisplatin|
16387652|NCT04066491|Experimental|Double-blinded Part: Bintrafusp alfa + Gemcitabine + Cisplatin|
16387653|NCT04066491|Placebo Comparator|Double-blinded Part: Placebo + Gemcitabine + Cisplatin|
16387654|NCT04066478|Experimental|Teatment|75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
16387655|NCT04066478|Placebo Comparator|Comaprator|75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
16387656|NCT04066465||Proton Therapy|Patients receive proton Radio(chemo)therapy according to clinical standard. Proton Treatment is indicated BEFORE inclusion into the trial ans is not part of the trial. Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases. In addition to the treatment parameters of the radio(chemo)therapy protocol, further radiation doses to brain substructures and organs at risk are documented.
16387657|NCT04066465||No Radiotherapy - Surgical only group|"Patients are included AFTER surgery of their brain tumour and receive no radiotherapy due to their disease (i.e. according to clinical standard). This Treatment is not part of the trial, but stratifies the Patient in this second Group.
~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
16387658|NCT04066465||Control Group|"Healthy kids are recruited as Standard Group.
~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
16387659|NCT04066452||Single-group studies|"Patients will be informed about the study and their written informed consent will be requested.
~Once included in the study:
~A series of clinical, analytical and echocardiographic parameters will be collected and measured
~Will be performed:
~Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP)
~Analytical to rule out monoclonal protein:
~Proteinogram and serum immunoglobulins.
~Light chains free in serum -Freelite-
~Immunofixation in serum and urine.
~The number of readmissions, emergency visits and mortality in the following 12 months will be recorded to compare the readmission and mortality rates in one year of patients with and without CA.
~The prescribed pre- and post-diagnostic treatments will be described, according to clinical practice (without intervention).
~No intervention, whether diagnostic or follow-up, that is not the usual clinical practice will be applied to patients."
16387660|NCT04066426|Experimental|naproxen sodium+codeine phosphate|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Codeine phosphate is an opioid analgesic which has similar applications to those of morphine. However, it is significantly less potent as an analgesic and has only mild sedative effects. The drug's principal site of action is at the µ-opioid receptors (MOR) which are distributed in the central nervous system. Peak effect is reached within 2 hours and analgesic action continues for approximately 4 hours. Naproxen sodium (550 mg)+codeine phosphate (30 mg) was used twice daily in this study.
16387727|NCT04065971|Placebo Comparator|Placebo arm|Group N°1: Placebo treatment (6 months of treatment)
16387776|NCT04065581|Experimental|Treatment A-washout-treatment B|Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
16387661|NCT04066426|Experimental|naproxen sodium+dexamethasone|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
16387662|NCT04066426|Experimental|naproxen sodium|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily in this study.
16387663|NCT04066426|Active Comparator|paracetamol|Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea.
16387664|NCT04066413|No Intervention|Breastfed group|Non-randomized breastfed reference group
16387665|NCT04066413|Placebo Comparator|Control formula|Group receiving standard infant formula
16387666|NCT04066413|Active Comparator|Formula with HMO|Group receiving standard infant formula supplemented with HMO
16387667|NCT04066400|Placebo Comparator|wheat-based diet|The patients continue a wheat-based diet aiming at a reduction in bodyweight.
16387668|NCT04066400|Experimental|ATI reduced diet|Patients are counselled to reduce dietary gluten uptake.
16387669|NCT04066374|Experimental|Treatment Arm|Intrathoracic placement of neurostimulation device
16387670|NCT04066361|Experimental|Chatbot|"Participant is given a pamphlet introducing genetic testing
~Participant is given information utilized for clinical, standard of care testing.
~Will receive genetic information with a virtual interactive Chatbot prior to genetic testing. After the Chatbot education, participant is asked if they would like to proceed with genetic testing.
~Participant is asked to complete an electronic family history tool"
16387671|NCT04066361|Experimental|Video Education|"Participant is given a pamphlet introducing genetic testing
~Participant is given information utilized for clinical, standard of care testing.
~Participant will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing. After the video education, participant is asked if they would like to proceed with genetic testing.
~Participant is asked to complete an electronic family history tool"
16387672|NCT04066348|Experimental|Etanercept Injection Group|Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.
16387673|NCT04066348|Placebo Comparator|Placebo Injection Group|Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.
16387674|NCT04066322||system treatment|Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
16387675|NCT04066322||system treatment and Surgery|Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
16387676|NCT04066309|Experimental|Abutment removal|At the time of surgery, customizable healing abutments will be placed on implants. These will be replaced by Pro PEEK Abutments 21 days later to placement of temporary prostheses (loading). The final abutments (Titanium Bases) and final prostheses will be inserted 2 months after loading.
16387677|NCT04066309|Experimental|Final abutment|The final abutments (Titanium Bases) will be placed at the time of the implant placement surgery and will stay at mouth during all period of the study. Temporary and final prosthesis will be placed on Titanium Bases.
16387678|NCT04066296|Active Comparator|Liposomal Bupivicaine|Treatment with liposomal bupivicaine
16387679|NCT04066296|Active Comparator|Standard Local Anesthestic|Treatment with Standard Local Anesthestic
16387682|NCT04066270||study group|"candidates for cochlear implantation 18 years or older, who are eligible for implantation for the indication of bilateral severe hearing loss or single sided deafness.
~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
16387683|NCT04066270||control group|"Symptomatic DFNA9 patients carrying the p.P51S mutation in COCH, presenting the radiologic semicircular canal lesion(s) on CT and/or MR.
~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
16387684|NCT04066257|Active Comparator|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg twice daily for 7 days
16387685|NCT04066257|Active Comparator|Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
16387686|NCT04066257|Active Comparator|MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
16387687|NCT04066244|Other|Cohort 1|Dose 1 of BLZ945
16387688|NCT04066244|Other|Cohort 2|Dose 2 of BLZ945
16387689|NCT04066244|Other|Cohort 3|Dose 3 of BLZ945
16387690|NCT04066244|Other|Cohort 4|Dose 4 of BLZ945
16387691|NCT04066244|Other|Cohort 5|Dose 5 of BLZ945
16387692|NCT04066231|Experimental|VIPUN GMS|Single arm study.
16387693|NCT04066218||age 15-19|The investigators plan to complete 24 interviews with 12 in the age 15-19 cohort.The investigators will also ensure that at least 8 people from each sex are included in this study.
16387694|NCT04066218||age 20-24|The investigators plan to complete 24 interviews with 12 in the age 20-24 cohort. The investigators will also ensure that at least 8 people from each sex are included in this study.
16387771|NCT04065633|Experimental|Part A sequence 2|
16387772|NCT04065633|Experimental|Part B sequence 1|
16387773|NCT04065633|Experimental|Part B sequence 2|
16387774|NCT04065594|Experimental|PRP dressing|
16387696|NCT04066192|Placebo Comparator|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
16387697|NCT04066192|Active Comparator|BREX 2mg|The BREX 2mg group will start at the same dose at the BREX 4mg group and titrate up at the same rate, so the BREX 2mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, and 2mg on day 5, to reach its final 2mg dose for day 5-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
16387698|NCT04066192|Active Comparator|BREX 4mg|The BREX 4mg group will start at the same dose as the BREX 2mg group and titrate up at the same rate, so the BREX 4mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, 2mg on day 5-6, and 4mg on day 7 to reach its final 4mg dose for days 7-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
16387699|NCT04066179|Experimental|Prednisolone+G-CSF|Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days
16387700|NCT04066179|Active Comparator|Prednisolone|Prednisolone 40 mg/day for 7 days
16387701|NCT04066179|Experimental|Granulocytes-Colony Stimulating Factor|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
16387702|NCT04066166||Subjects|Healthy
16387703|NCT04066127|Experimental|Non-ischemic heart preservation (NIHP)|Non-ischemic hypothermic perfusion (NIHP): The donor heart is preserved using a portable heart-lung machine. The device perfuse the heart continuously with a a new preservation solution at a temperature of 8°C.
16387704|NCT04066127|Other|Standard cold storage (SCS)|Standard cold static storage (SCS): The donor heart is preserved using a standard crystalloid cardioplegia. The heart is in then storage i a transport box containing ice to keep the temperature around 4-8°C. The device does not perfuse the heart.
16387705|NCT04066114|Experimental|lulizumab pegol + novel ISR|lulizumab pegol + novel ISR: lulizumab pegol plus immunosuppressive regimen (anti-thymocyte globulin (rabbit), steroids,) belatacept, tocilizumab, and everolimus)
16387706|NCT04066101||high caries risk|100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
16387707|NCT04066101||low caries risk|100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
16387708|NCT04066088|Sham Comparator|Placebo|
16387709|NCT04066088|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
16387710|NCT04066075|Experimental|Telerehabilitation with low vision provider|
16387711|NCT04066075|Experimental|Telerehabilitation w/ low vision provider plus tele-extender|
16387712|NCT04066075|Active Comparator|Usual Care (active control)|
16387713|NCT04066062||Retrospective|A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.
16387714|NCT04066062||Prospective|A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months
16387717|NCT04066036||Study Population|The study will enroll a total of 1,000 ART-experienced participants from the study sites in Uganda and South Africa who are being transitioned to TLD from non-nucleoside reverse transcriptase-based antiretroviral therapy.
16387718|NCT04066023|Experimental|C213 1.9 mg|C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch
16387719|NCT04066023|Experimental|C213 3.8mg|C213 3.8 mg administered as two 1.9 mg patches
16387720|NCT04066023|Placebo Comparator|Placebo|Placebo microneedle system administered as two placebo patches
16387721|NCT04066010|No Intervention|Control|
16387722|NCT04066010|Other|Intervention|Mobile application intervention
16387723|NCT04065997||Patients implanted with HVAD System|Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.
16387726|NCT04065971|Experimental|2LHERP® arm|Group N°1: 2LHERP® treatment (6 months of treatment)
16387775|NCT04065594|Experimental|conventional ordinary dressing|
16387728|NCT04065958|Experimental|Yoga-mindfulness|Yoga-mindfulness program consisting of movements/postures (asanas), breathing practices, relaxation practices and meditation practices, together with brief talks on yoga-based coping strategies. The intervention starts with a introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks, with home assignments for about 30 minutes per day, four days per week.
16387729|NCT04065958|Active Comparator|Patient education and physiotherapy|Patient education program consisting of lectures on topics related to inflammatory arthritis and pain together with mild physiotherapy. The interventions starts with an introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks. Each session consists of a lecture and a program of instructed physiotherapy. Besides the weekly sessions, home assignments consisting of 30 minutes of walking, are performed four days per week.
16387730|NCT04065945||Couples undergoing ART treatment|Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
16387731|NCT04065945||Couples getting pregnant naturally|Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
16387732|NCT04065932|Experimental|BMS-985165-01 prototype formulation 1|
16387733|NCT04065932|Experimental|BMS-986165 Tablet|
16387734|NCT04065932|Experimental|BMS-985165-01 prototype formulation 2|
16387735|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3|
16387736|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3 or 4|
16387737|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3, 4 or 5|
16387738|NCT04065919|Active Comparator|Exparel|"administration of liposomal bupivacaine 266mg/20mL+ 40 mL bupivacaine 0.25% bupivacaine
~."
16387739|NCT04065919|Active Comparator|Standard of Therapy|administration of 0.25% bupivacaine with epinephrine at 1cc/kg total dose
16387740|NCT04065906|Experimental|NIRS group|Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.
16387741|NCT04065906|Other|Drug group|Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine
16387742|NCT04065906|Other|Control group|Healthy children, 12 sessions of NIRS feedback, for two sessions per week.
16387743|NCT04065893||Catheter ablation group|Patients with reduced biventricular pacing due to PVC or VT receiving catheter ablation of PVC/VT according to guidelines and clinical practices
16387744|NCT04065893||Medical treatment group|Patients with reduced biventricular pacing due to PVC or VT receiving intensified medical therapy (antiarrhythmics/betablocker) according to guidelines and clinical practices
16387745|NCT04065880|Active Comparator|TachoSil®|TachoSil® is a collagen sponge coated with the human coagulation factors fibrinogen and thrombin.
16387746|NCT04065880|Active Comparator|Neoveil®|Neoveil® sheet made of polyglycolic acid (PGA). It is a biodegradable, thermoplastic and non-antigenic polymer.
16387747|NCT04065854|No Intervention|Control|The control group will receive standard brief falls assessment and advice.
16387748|NCT04065854|Active Comparator|Intervention|Therapy intervention.
16387749|NCT04065841|Experimental|Arm A: combination therapy|tropifexor + licogliflozin
16387750|NCT04065841|Experimental|Arm B: tropifexor monotherapy|tropifexor (+ licogliflozin placebo)
16387751|NCT04065841|Experimental|Arm C: licogliflozin monotherapy|licogliflozin (+ tropifexor placebo)
16387752|NCT04065841|Placebo Comparator|Arm D: Placebo|licogliflozin placebo + tropifexor placebo
16387753|NCT04065815|Experimental|Resistance Training (RT)|Individualized, protein-rich nutritional therapy combined with resistance training
16387754|NCT04065815|Experimental|WB-EMS|Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
16387755|NCT04065815|Experimental|High-intensity interval training (HIIT)|Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
16387756|NCT04065815|Experimental|Combined HIIT and Resistance Training (Combi)|Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training
16387757|NCT04065802|Experimental|Radioablation Treatment|Patients will receive radioablation to scar regions of the heart responsible for ventricular tachycardia
16387758|NCT04065789|Experimental|Carfilzomib,Daratumumab,revlimid and dexamethasone|Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
16387759|NCT04065776|Experimental|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
16387760|NCT04065737|Experimental|Sintilimab|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
16387761|NCT04065724|Other|Physical training resistance and aerobic|Physical training as resistance and aerobic training
16387762|NCT04065711|Experimental|RAP Treatment|Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.
16387763|NCT04065698|Experimental|RV521|Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)
16387764|NCT04065685|Active Comparator|CG|control group receiving the usual care, the standardized information on anticipated directives
16387765|NCT04065685|Active Comparator|IG p+r|intervention group with patients and her/his relative
16387766|NCT04065685|Active Comparator|IG p|intervention group with patients without relative
16387767|NCT04065672|Experimental|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
16387768|NCT04065646|Experimental|Intervention|The intervention group will receive daily text messages with information on: (i) HMM stop locations and schedule; (ii) information on HMM weekly produce specials and sales; (iii) motivational messages encouraging use of the HMM; and (iv) links to produce coupons that they can exchange at HMM- $5 coupons received weekly for the four-week texting period.
16387769|NCT04065646|No Intervention|Control|The control group will receive the same dosage of daily text messages covering free activities taking place at the Hartford Public Library and other community locations. The control group will not receive incentive coupons.
16387770|NCT04065633|Experimental|Part A sequence 1|
16387777|NCT04065581|Experimental|Treatment B-washout-treatment A|Subject will receive a single oral dose of 50 mg acarbose and 500 mg metformin as loose combination (Treatment B) in period 1, followed by a single oral dose of acarbose/metformin FDC (Treatment A, 50mg acarbose/500 mg metformin) in period 2. Washout interval between 2 treatment periods was at least 7 days.
16387778|NCT04065568|Experimental|Intervention group|The patient will receive conventional out patient rehabilitation after discharge to the home after stroke. In addition an individualized training program with gamified excercises for motor function will be set and followed up by clincians using video communication, as part of the DISKO-tool. Patients are instructed to train self sufficiently 5 days a week and will be supervised by the treating physiotherapist. The intervention will last for 6 weeks.
16387779|NCT04065568|No Intervention|Control group|Conventional rehabilitation in primary care after discharge to the home after stroke.
16387780|NCT04065555|Experimental|CIVO Microdose Injection of TAK-981, Cetuximab, and Avelumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
16387781|NCT04065529|Experimental|Gelatin tannate (GT)|Gelatin tannate (GT)
16387782|NCT04065529|Placebo Comparator|Placebo|Placebo
16387783|NCT04065516|Experimental|Argon Plasma Coagulation of the gastroesophageal junction|Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
16387784|NCT04065503|Experimental|Healthy Adults|Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.
16387785|NCT04065490|Experimental|PBM Treatment|The Valeda™ Light Delivery System
16387786|NCT04065490|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System non-effective treatment
16387787|NCT04065477|Experimental|Experimental|The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.
16387788|NCT04065477|No Intervention|Control group|"The control group will receive no active treatment and will be treated as a no-contact control group."
16387789|NCT04065451|Experimental|Epinephrine|Epinephrine in the submucosal injection fluid (1:200,000)
16387790|NCT04065451|No Intervention|No epinephrine|Submucosal injection fluid without epinephrine
16387791|NCT04065438|Experimental|LIPOSORBER® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
16387792|NCT04065412|Active Comparator|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed to localize the cricothyroid membrane
16387793|NCT04065412|Experimental|Modified laryngeal handshake technique|The modified laryngeal handshake is performed to localize the cricothyroid membrane
16387794|NCT04065399|Experimental|Experimental: SNDX-5613|"Phase 1:
~Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D). Patients will be enrolled in one of three dose-escalation arms:
~Arm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/ inducers.
~Arm B: Patients receiving strong cytochrome P450 3A4 inhibitors for antifungal prophylaxis.
~Arm C: Patients receiving SNDX-5613 and cobicistat.
~Phase 2:
~Oral SNDX-5613; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows:
~Cohort 2A: Patients with MLLr acute lymphoblastic leukemia (ALL)/mixed phenotype acute leukemia (MPAL).
~Cohort 2B: Patients with MLLr AML.
~Cohort 2C: Patients with NPM1c AML."
16387797|NCT04065373|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored a common peripheral IV site over a 24 hour observation period.
16387798|NCT04065360|Experimental|Cognitive behavioural family intervention|
16387799|NCT04065360|Active Comparator|Usual group psychoeducation|
16387800|NCT04065347||Group 1|A total of 150 participants taking tenofovir alafenamide will be enrolled in this cohort.
16387801|NCT04065347||Group 2|A total of 30 participants initiating/re-initiating tenofovir alafenamide will be enrolled in this cohort.
16387802|NCT04065334|Experimental|low dose training|
16387803|NCT04065334|Active Comparator|high dose training|
16387804|NCT04065321||Control group|250 patients will be assigned into control group.
16387805|NCT04065321||Trial group|250 patients will be assigned into trial group.
16387843|NCT04065035|Active Comparator|Topical Firming Body Moisturizer|Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
16387844|NCT04065035|Placebo Comparator|Placebo Moisturizer|Oil-in-water emulsion base containing emollients.
16387878|NCT04064749|No Intervention|Control|Participants will receive screening (i.e. services as usual) provided by a national credit counseling program.
16388643|NCT04059003||Drug resistance group|100 patients will be assigned into drug resistance according to the actual situation of them.
16387806|NCT04065308|Experimental|Experimental arm|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).
~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)
~dexamethasone :40mg/day D1-4, intravenous
~cyclophosphamide: 400mg/m2 D1-4, intravenous
~etoposide: 40mg/m2 D1-4, intravenous
~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
16387807|NCT04065295|Experimental|Single Rising Dose Part|
16387808|NCT04065295|Experimental|Bioavailability Part|
16387809|NCT04065282|Experimental|neoadjuvant therapy with Sintilimab plus Xelox|3 cycles of neoadjuvant therapy: Sintilimab iv d1 Q3W, Oxaliplatin 130mg/m2 iv d1 Q3W, and Capecitabine 1000mg/m2 po Bid d1-14 Q3W
16387810|NCT04065269|Experimental|1A: AZD6738|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with single agent AZD6738.
16387811|NCT04065269|Experimental|1B: AZD6738 + olaparib|"In second stage of trial, opening of this cohort depends on response rate in cohort 1A during first stage of trial.
~Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with AZD6738 in combination with olaparib."
16387812|NCT04065269|Experimental|2: AZD6738 + olaparib|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with NO loss of ARID1A expression treated with AZD6738 in combination with olaparib.
16387813|NCT04065269|Experimental|3: AZD6738 + olaparib|Women with other rare relapsed gynaecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status, treated with AZD6738 in combination with olaparib.
16387814|NCT04065256|Experimental|Personalized music intervention group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. A total treatment dosage of 560 minutes is required.
16387815|NCT04065256|Experimental|Personalized music plus earplug group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. In addition, using earplug during night time sleep. The music intervention total treatment dosage of 560 minutes is required.
16387816|NCT04065256|No Intervention|Control group|The control group involves neither music intervention nor using earplug at night.
16387817|NCT04065243|Active Comparator|Control group|Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
16387818|NCT04065243|Experimental|Overfed group|Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
16387819|NCT04065230||TAF antiviral therapy group|
16387820|NCT04065217|Other|Iraqi patients with face hemangioma|Diode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.
16387821|NCT04065191|Experimental|High-intensity interval training|High-intensity interval training
16387822|NCT04065178||Level of Activity|Level of activity for all patients admitting to the inpatient neurological rehabilitation unit.
16387823|NCT04065165|Experimental|Experimental arm|Lanreotide 120 mg q4w Telotristat Ethyl 250 mg TID
16387824|NCT04065165|Placebo Comparator|Control arm|Lanreotide 120 mg q4w Placebo TID
16387825|NCT04065152|Experimental|oncolytic immunotherapy|Talimogene laherparepvec Dose: 10^6 pfu/ml at week 1 then 10^8/ml at week 4 and every 2 weeks (up to 4ml for each injection) Route: intralesional injection Duration of treatment: 6 months (12 cycles)
16387826|NCT04065139|Active Comparator|Control Arm|
16387827|NCT04065139|Experimental|Experimental Arm : PIPAC|
16387828|NCT04065126|Experimental|Physical activity Intervention|This arm receives ten two-hour group sessions with physical activity and psycho-educational components, held by a physiotherapist over a period of ten weeks.
16387829|NCT04065126|Active Comparator|Brief Psycho-education|This arm receives two brief lectures of psycho-education held by a physiotherapist.
16387830|NCT04065113|Experimental|Embolization Only|Medically managed patient receives middle meningeal artery embolization
16387831|NCT04065113|Experimental|Embolization + Evacuation|Participant receives standard of care evacuation and then undergoes MMA embolization
16387832|NCT04065113|No Intervention|Medical Management|Historical control of medically managed patients
16387833|NCT04065113|Active Comparator|Surgical Patients|Historical control of patients receiving standard surgery alone
16387834|NCT04065100|Experimental|Study group|Maternal PCOS
16387835|NCT04065100|Active Comparator|Comaprator|Non-PCOS pregnant women
16387836|NCT04065087|Experimental|GX-I7|GX-I7 administered until Progression of Disease
16387837|NCT04065087|Placebo Comparator|Placebo|Placebo administered until Progression of Disease
16387838|NCT04065074|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
16387839|NCT04065061|Experimental|Experimental|Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49.
16387840|NCT04065061|Placebo Comparator|Placebo|Placebo dietary supplement from week 0 to week 49.
16387948|NCT04064177||Preterm infants|Preterm infants with fetal growth restriction
16387845|NCT04065022|Experimental|Head stimulation|Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
16387846|NCT04065022|Experimental|Arm stimulation|Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
16387847|NCT04065009|Placebo Comparator|Placebo|Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
16387848|NCT04065009|Experimental|Experimental|Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
16387849|NCT04064996|Active Comparator|Group A|Routine rehabilitation program patient education
16387850|NCT04064996|Experimental|Group B|Routine rehabilitation program + foot exercise training
16387851|NCT04064970||PASS Cohort|
16387852|NCT04064944|Experimental|Immunoadsorption group|patients' blood purification treatment protocal is Protain A Immunoadsorption method.
16387853|NCT04064944|Experimental|Plasma exchange group|patients' blood purification treatment protocal is Plasma exchange method.
16387854|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
16387855|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
16387856|NCT04064931||general population|Women of childbearing age in general examination.
16387857|NCT04064918|Other|Netarsudil 0.02% QD|4 weeks of Netarsudil 0.02% QD, then a 4 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
16387858|NCT04064918|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 4 Week washout, followed by 4 weeks of Netarsudil 0.02% QD
16387859|NCT04064905|Experimental|mRNA-1893|
16387860|NCT04064905|Placebo Comparator|Placebo|0.9% sodium chloride
16387861|NCT04064892|Experimental|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
16387862|NCT04064879|Experimental|Deployment of AD-SVF|Administration of autologous adipose derived SVF
16387863|NCT04064866|Experimental|PRP/Hemocyte Autograft Intervention Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to active condition will have exactly 3 cc of hemocyte autograft placed in a 3 cc syringe. The syringe barrels and tubing were covered with opaque tape so that the injector was blinded to the contents. 1-2 cc of PRP was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
16387864|NCT04064866|Placebo Comparator|Placebo Control Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to placebo condition will have exactly 3 cc of saline placed in a 3 cc syringe. 1-2 cc of saline was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
16387865|NCT04064840|Active Comparator|IVF: dual trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
16387866|NCT04064840|Placebo Comparator|IVF: hCG trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
16387867|NCT04064840|Active Comparator|FET: agonist|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
16387868|NCT04064840|Placebo Comparator|FET: control|On the day of FET, normal saline will be injected subcutaneously.
16387869|NCT04064827|Experimental|Participants Receiving Paricalcitol|Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks
16387872|NCT04064788|Experimental|Consecutive mCIMT group|6 hours / day, 10 consecutive days, 60 hours mKZHT + 2 days 45 minutes / day traditional physiotherapy
16387873|NCT04064788|Experimental|Intermittent mCIMT group|6 hours / day 2 days a week 5 weeks, a total of 60 hours mKZHT + 2 days 45 min / day traditional physiotherapy
16387874|NCT04064788|Active Comparator|Traditional physiotherapy control group|45 min / day, 2 days a week traditional physiotherapy
16387875|NCT04064775|Experimental|Smart snacking intervention|In intervention 2 participants took part in a 4-week intervention on Instagram. Participants saw images of fictitious peers' snacks or beverages three times per week, and saw snack information images three times per week. Peer snack images were posted on days 2,4 and 6 of each week, and snack information images were posted on days 1,3 and 5 of each week. Images were posted between 10-11am each day. Participants also completed quizzes related to snacking at the end of weeks 1-3. Participants completed a survey at baseline and intervention end to assess their ideal portion sizes to allow for examination of the effectiveness of the intervention.
16387876|NCT04064775|No Intervention|Control|Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
16387877|NCT04064762|Experimental|Vagus Nerve Stimulation + Prolonged Exposure Therapy|Study treatment is vagus nerve stimulation (VNS) delivered during Prolonged Exposure Therapy.
16387879|NCT04064749|Experimental|Intervention|Participants will receive screening services provided by the credit counseling program plus added brief intervention services by University of Maryland School of Social Work (UMSSW). Added intervention services include: 1) feedback about the individual's gambling, and 2) text messages to support the individual.
16387880|NCT04064723|Active Comparator|Stem components|Randomization between two stem components. LCU or Corail stem.
16387881|NCT04064723|Active Comparator|Cup components|Randomization between two cup components. DeltaTT or Pinnacle cup.
16387882|NCT04064710|Other|Allograft Tissue|Allograft tissue product for patients with painful vertebral compression fractures
16387883|NCT04064697|No Intervention|Control group|Patient will be treated by vedolizumab the standard of care alone.
16387884|NCT04064697|Experimental|Experimental group|Patient will be treated by vedolizumab the standard of care associated at valganciclovir.
16387885|NCT04064684|Experimental|treatment with Budesonide|
16387886|NCT04064684|Placebo Comparator|Placebo|
16387887|NCT04064658|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.
~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in Sham RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.
~Procedure: Encephaloduroarteriosynangiosis"
16387888|NCT04064658|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.
~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.
~Procedure: Encephaloduroarteriosynangiosis"
16387889|NCT04064645|Experimental|Respiratory rate accuracy measurement|
16387890|NCT04064632|Experimental|RPV +DRV/cobi|The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.
16387891|NCT04064632|Active Comparator|baseline therapy (CAR)|The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).
16387892|NCT04064619|Active Comparator|sudden stopping|patients were followed up after 1 and 3 months from stopping the drug,
16387893|NCT04064619|Experimental|Weaning|patients were followed up after 1and 3 months from the end of gradual weaning
16387894|NCT04064593|Experimental|Polygraphy|
16387895|NCT04064567|Active Comparator|Enhanced Standard of Care|PrEP education and referral to a community-based PrEP provider (enhanced standard of care)
16387896|NCT04064567|Experimental|Community Health Worker Involved Enhanced Standard of Care|PrEP education, referral to a community-based PrEP provider, and referral to a CHW who will facilitate access to community-based PrEP and other healthcare and social-support services.
16387897|NCT04064554|Experimental|MicronJet600|BCG vaccination with MicronJet600
16387898|NCT04064554|Active Comparator|Conventional needle|BCG vaccination with conventional needle
16387899|NCT04064541|Other|Virtual Visit|"At the baseline visit patients will complete an in-clinic baseline visit consisting of Medical Hx review, NYHA assessment, Questionnaires (EQ-5D-5L, KCCQ, Frailty Index for Elders & Mini Cog) and Functional Assessments (Timed Up & Go and 6MWT). Patients will also receive virtual visit training and complete an in-clinic virtual visit consisting of the previously stated functional assessments.
~All follow-up visits will occur via virtual distance health visits. These f/u visits will occur at Day 7and Day 14 At the initiation of each distance health f/u visit the patient's current state of health will be assessed as well as NYHA. Patient Questionnaires(EQ-5D-5L, KCCQ & Frailty Index) and Functional Assessments(Timed Up & Go and 6MWT) will be completed."
16387900|NCT04064528|Active Comparator|Young|Young adults will be given a 10 g oral bolus of amino acids.
16387901|NCT04064528|Experimental|Older Adults|Older adults will be given a 10 g oral bolus of amino acids.
16387902|NCT04064515||Cervical Cancer|Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
16387903|NCT04064515||Control|Participants without a history of cervical cancer or high grade pre-cancer of the cervix
16387904|NCT04064502||volunteers|273 adult volunteers ranging from 18-78 years old
16387905|NCT04064489|No Intervention|neutral|No specific instructions for prescribing prophylaxis or not
16387906|NCT04064489|Active Comparator|TRIPscore|calculation of the TRIPcast score and prescription of prophylactic or not according to the result (score > or = 7 : treatment (low molecular weight heparin or fondaparinux); score < 7 : no treatment)
16387907|NCT04064463|Active Comparator|Control Group|Standard care
16387908|NCT04064463|Experimental|Experimental Group|Standard care plus contingency management
16387909|NCT04064450||Heart Failure|Individuals with asymptomatic or symptomatic heart failure
16387910|NCT04064450||Population Controls|Individuals free of heart failure and echocardiographic cardiac dysfunction
16387911|NCT04064437||Individuals with type 1 diabetes|
16387912|NCT04064437||Healthy controls|
16387913|NCT04064424|Experimental|Prevention Advertisement|Participants will be exposed to prevention videos and images through Facebook Advertising
16387914|NCT04064424|Active Comparator|No Advertisement|No prevention videos and images will be shown through Facebook Advertising
16387915|NCT04064411|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide
16387916|NCT04064411|Active Comparator|abaloparatide-SC|A combination product consisting of the drug abaloparatide in a single-patient-use prefilled pen that delivers 80 μg of abaloparatide as a SC injection
16387917|NCT04064398|Active Comparator|Routine aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
16387918|NCT04064398|No Intervention|No aspiration of gastric residuals|Infants will not have routine aspiration of gastric contents prior to each feeding.
16387919|NCT04064385|Experimental|Intervention|FES cycle training will be performed on the RT300 FES cycle ideally 3 times per week for 6 weeks, each session lasting up to 90 minutes. Electrical stimulation will be delivered through up to 12 independent channels each delivering up to 140 mA current on the following muscles (both on the right and left leg): quadriceps, femoral biceps and gluteus, gastrocnemius and tibialis anterior. Abdominal and back extensor muscles may also be stimulated if the participant presents with neurological trunk weakness (SCI above T6). The FES unit will stimulate the muscles that extend the hip (gluteals), flex the knee (hamstrings) and extend the knee (quadriceps) in the correct order to bring about a cycling motion. The feet and lower legs of the participants will be strapped into the pedals and the wheelchair will be coupled in a rigid manner with the training device.
16387920|NCT04064385|No Intervention|Control|Participants in the control group will receive usual care, consistent with standard NHS care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting approximately 90 minutes. Physiotherapists provide one to one function-oriented physiotherapy session to improve balance, muscle strength and transfer skills.
16387921|NCT04064372|Experimental|Mindful Response to Adversity|"The treatment condition will be trained in techniques designed to teach a mindful approach to adversity. These techniques will include: normalizing, attention, equanimity, non-judgment, de-centering, accepting of experiences, and impermanence. Participants will be instructed on the mindset, asked to write about an instance of non-judgment and share with a partner, and then guided through a short training designed to practice each skill."
16387922|NCT04064372|Active Comparator|Strength-based approach to adversity|The control condition will be trained in techniques designed to teach a typical narrative self-analysis / strengths-based approach to adversity. These techniques will include: choosing the best approach, minimizing stress, and identifying and enhancing personal strengths. Participants will be instructed on the mindset, asked to write about an instance of personal strength and share with a partner, and then guided through a short training designed to practice each skill.
16387923|NCT04064359|Experimental|OBT076 Dose Escalation and Expansion|OBT076 administered intravenously (IV) every 3 weeks in escalating dose cohorts during Part A and OBT076 administered at or below the MTD in the Part B expansion cohort.
16387926|NCT04064333|Experimental|Slow-Stream Expiratory Muscle Strength Training|The therapy protocol consists of 12 sets of five breaths through the EMST150 device per week, in sessions of three or four sets (15 or 20 breaths). A typical schedule might be one 15 breath session four days per week, or one 20 breath session three days per week.
16387927|NCT04064320|Experimental|Intervention group|Received lullaby intervention and usual care
16387928|NCT04064320|No Intervention|Control group|No intervention other than usual care
16387929|NCT04064294||Statin Before Levodopa|Historical use of a statin (simvastatin or lovastatin) BEFORE beginning levodopa
16387930|NCT04064294||Statin After Levodopa|Historical use of a statin (simvastatin or lovastatin) AFTER beginning levodopa
16387931|NCT04064294||No Statin|No historical use of a statin (simvastatin or lovastatin)
16387932|NCT04064281|Experimental|the healthy Cantonese diet|Based on the typical Cantonese diet, the healthy Cantonese diet is developed according to the DASH diet and the balanced dietary pattern of the Chinese Dietary Guidelines 2016. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set to achieve the healthy goal. Compared with the typical Cantonese diet, the healthy Cantonese diet is increased in fruit, vegetables, low-fat dairy products, whole grains, nuts and seeds, and reduced in salt, oil and sweets.
16387933|NCT04064281|Placebo Comparator|the typical Cantonese diet|The typical Cantonese diet is a diet of what many Cantonese eat. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set at the average dietary intake levels in Guangdong.
16387934|NCT04064268|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
16387935|NCT04064268|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
16387936|NCT04064268|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
16387937|NCT04064255|Active Comparator|Case: Practical Body Image + Treatment as Usual|"The Case arm involves Practical Body Image + treatment as usual.
~Practical Body Image is based on a cognitive behavioural model of body image addressing thoughts, feelings, behaviours and misperceptions. PBI is designed to be administered over 10 weeks (6 weekly sessions over 6 weeks, followed by 8 twice weekly sessions over 4 weeks).
~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
16387938|NCT04064255|No Intervention|Control: Treatment as Usual Only|"Control arm involves treatment as usual only.
~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
16387939|NCT04064242|Experimental|CMK389|CMK389
16387940|NCT04064242|Placebo Comparator|Placebo|Placebo
16387941|NCT04064229|Experimental|Infiltrated Tissue|The ivWatch Model 400 SmartTouch and fiber optic sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
16387942|NCT04064216||Robot assisted laparoscopic surgery|This group will be consisted of patients that will undergo robot assisted laparoscopic surgery for benign gynecologic disorders
16387943|NCT04064216||Conventional laparoscopic surgery|This group will be consisted of patients that will undergo conventional laparoscopic surgery for benign gynecologic disorders
16387944|NCT04064203|Experimental|Totally pancreatectomized patients|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
16387945|NCT04064203|Experimental|Healthy controls|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
16387946|NCT04064190|Experimental|Vactosertib+Durvalumab|Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
16387947|NCT04064177||Babies (24-42 weeks)|All babies born between 24 and 42 weeks
16387949|NCT04064164|Experimental|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
16387950|NCT04064164|No Intervention|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
16387951|NCT04064151|Experimental|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
16387952|NCT04064151|No Intervention|Standard Medical Care|Standard clinical care with no smartphone intervention.
16387953|NCT04064138|Active Comparator|Peritoneal block|patients will receive peritoneal block as an adjuvant analgesic technique.
16387954|NCT04064138|Active Comparator|Ultrasound guided erector spinae plane block|Patients will receive ultrasound guided erector spinae plane block
16387955|NCT04064125|Experimental|FMX-101|
16387956|NCT04064112|Experimental|S-BLR|For S-BLR, the lower horn of the LR is recessed based on near exodeviation and the upper horn is recessed based on distant exodeviation.
16387957|NCT04064112|Active Comparator|C-BLR|For C-BLR, the LR is recessed based on distant exodeviation.
16387958|NCT04064099|Experimental|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
16387959|NCT04064086|Active Comparator|Comprehensive Pre-ESRD Patient Education (CPE)|These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
16387960|NCT04064086|Active Comparator|Enhanced Usual Care|This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
16387961|NCT04064073|Experimental|1|
16387962|NCT04064073|Experimental|2|
16387963|NCT04064073|Experimental|3|
16387964|NCT04064060|Experimental|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to subjects by the study staff at the clinical site and administration will be documented in the subject's source record.
16387965|NCT04064047|Active Comparator|External Anal application - 5 minutes exposure|Anal application of lidocaine cream 5% for 5 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
16387966|NCT04064047|Active Comparator|External Anal application - 10 minutes exposure|Anal application of lidocaine cream 5% for 10 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
16387967|NCT04064047|Active Comparator|External Anal application - 20 minutes exposure|Anal application of lidocaine cream 5% for 20 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
16387968|NCT04064047|Active Comparator|External Anal plus intrarectal - 5 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 5 minutes before probe insertion.
~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
16387969|NCT04064047|Active Comparator|External Anal plus intrarectal - 10 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 10 minutes before probe insertion.
~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
16387970|NCT04064047|Active Comparator|External Anal plus intrarectal - 20 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 20 minutes before probe insertion.
~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
16387971|NCT04064047|Sham Comparator|Control group|No anal application of lidocaine cream prior to probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
16387972|NCT04064034|Experimental|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
16387973|NCT04064034|Experimental|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
16387974|NCT04064034|Experimental|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
16387975|NCT04064021|Experimental|Acupuncture|Acupuncture 12 sessions over 6 week to be given to pateints
16387976|NCT04064008||Primary Total Hip Arthroplasty|Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem
16387977|NCT04063995|Experimental|Excitatory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment with 10 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in excitation. Stimulation is planned for a total of 15 minutes and a total of 1500 beats in the form of a 5 seconds 10 Hz stimulation followed by a 25 seconds interval.
16387978|NCT04063995|Experimental|Inhibitory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in excitation. Stimulation is planned for a total of 25 minutes and a total of 1500 beats in the form of 1 Hz stimulation.
16387979|NCT04063995|Sham Comparator|Sham repetitive transcranial magnetic stimulation group|Single session of sham application for a total of 25 minutes. Sham application will be performed by holding the probe of the device vertically to the vertex. The device will be operated at the lowest operating power of 1 to produce the same stimulation sounds like the active application. The device operating at this power is not likely to give any stimulation due to the probe being held upright.
16387980|NCT04063969||Endovascular team members|"All vascular surgeons, surgical trainees, nurses active in the hybrid angiography suite at one of the participating centers will be invited to participate in the study.
~All participating team members complete an online questionnaire containing an assessment of their perceived radiation safety climate (28 items, 5 dimensions), radiation safety behaviors(2 items, 2 dimensions), radiation safety knowledge (single item) and radiation safety motivation (single item). All data will be stored pseudonymized."
16387981|NCT04063969||Vascular surgical patients|"In each center, five patients undergoing primary elective endovascular repair for an infrarenal abdominal aortic aneurysm (EVAR) will be enrolled in the study.
~For each participating patient, a set of demographical (BMI, case difficulty, ASA-grade,etc.), procedure-related (procedure duration, contrast use, etc.) and radiation dose parameters (DAP, cumulative air kerma) will be collected and stored in a pseudonymized way.
~Participation in this study has no effect on the interventional procedure, or the chosen approach."
16387982|NCT04063956|Experimental|Cognitive training group|Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 4 x 40 minutes per week, for 12 weeks.
16387983|NCT04063956|Active Comparator|Active-control group|Fixed, primary difficulty level tasks. 4 x 40 minutes per week, for 12 weeks.
16387984|NCT04063943|Experimental|Sidus Stem-Free Total Shoulder|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
16387985|NCT04063930|Active Comparator|Lokelma|"Sodium zirconium cyclosilicate Lokelma® 5 g, powder (Astra Zeneca)
~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.
~Duration: 12 weeks"
16387986|NCT04063930|Placebo Comparator|Placebo|"Matching placebo (indistinguishable from the active comparator)
~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.
~Duration: 12 weeks"
16387987|NCT04063917|Experimental|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
16387988|NCT04063917|Experimental|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
16387989|NCT04063904|Experimental|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
16387990|NCT04063891|Placebo Comparator|Placebo-Controlled|Placebo group will have placebo treatment by standing on the LMHFV platform for 20 minutes/day
16387991|NCT04063891|Experimental|Vibration Group|Vibration group is treated with LMHFV at 35Hz, 0.3g, for 20 minutes/day, 5 times/week
16387992|NCT04063878|Experimental|Single tooth restorations using Acuris conometric concept|
16387993|NCT04063865|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
16387994|NCT04063865|Experimental|Study Arm|Everolimus monotherapy maintenance immunosuppression
16387995|NCT04063826|Other|PET MRI Scan|Imaging scan of the liver
16387996|NCT04063813|Experimental|40 minute up trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree incline and at 75% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
16387997|NCT04063813|Experimental|40 minute down trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree decline and at 45% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
16387998|NCT04063813|Experimental|Two 20 minute up trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 75% of maximal effort, the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h..Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
16387999|NCT04063813|Experimental|Two 20 min down trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 45% of maximal effort , the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
16388000|NCT04063813|Active Comparator|Sedentary trial|No exercise day with isocaloric meals provided at 7:00, 13:00. and 19:00 h.
16388001|NCT04063787|Experimental|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.
~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
16388002|NCT04063774|Experimental|Dengue diagnostic algorithm|single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)
16388003|NCT04063761|Experimental|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
16388004|NCT04063748|Experimental|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
16388005|NCT04063748|Placebo Comparator|Placebo|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
16388006|NCT04063735|Experimental|Experimental group|supplement was given for 3 months.
16388007|NCT04063735|Placebo Comparator|Placebo group|Placebo was given for 3 months.
16388008|NCT04063722|Experimental|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
16388009|NCT04063722|Active Comparator|webester procedure|periareolar incision with excision of the breast tissue
16388010|NCT04063709|Experimental|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
16388011|NCT04063709|Experimental|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
16388012|NCT04063709|Experimental|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
16388013|NCT04063709|Experimental|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
16388014|NCT04063683|Experimental|Anlotinib with chemotherapy|
16388015|NCT04063670|Active Comparator|Control|Routine, standard-of-care treatment
16388016|NCT04063670|Experimental|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
16388017|NCT04063657|Active Comparator|External fixation|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
16388018|NCT04063657|Active Comparator|Splinting|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.
16388019|NCT04063644|Experimental|Vis Glyc Neo|"Vis glyc eye drops is administered.
~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
16388020|NCT04063644|Active Comparator|physiological saline solution|Physiological saline solution ALVITA is administered.
16388021|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
16388022|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
16388023|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
16388024|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
16388025|NCT04063618|Experimental|Osteopathic Manipulative Therapy (OMT) Treatment Group|Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
16388026|NCT04063618|Active Comparator|Standard of care concussion treatment group|Standard of care concussion treatment without OMT
16388027|NCT04063605|Experimental|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
16388028|NCT04063605|Active Comparator|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
16388029|NCT04063592|Experimental|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
16388030|NCT04063579|Experimental|Patients with heart failure with preserved ejection fraction|
16388031|NCT04063579|Experimental|Non-heart failure patients|
16388032|NCT04063579|Experimental|Normal Volunteers|
16388033|NCT04063566|Other|Total cohort|The study will consist of one group, one arm, all receiving the same screening procedures.
16388034|NCT04063553|Other|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
16388035|NCT04063553|Other|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
16388036|NCT04063540|Other|placebo-amiloride|Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
16388037|NCT04063540|Other|amiloride -placebo|Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
16388038|NCT04063527|Active Comparator|Standard therapy|combination of paclitaxel and carboplatin
16388039|NCT04063527|No Intervention|Observation|Observation
16388040|NCT04063514|Experimental|Focused Ultrasound|The ultrasound treatment will last either 1 hour or 20 minutes total time for the DWL device or Brainsonix Focused Ultrasound Device, respectively.
16388041|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
16388042|NCT04063475|Experimental|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
16388043|NCT04063462|Experimental|Cohort 1|Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC
16388044|NCT04063462|Experimental|Cohort 2|Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC
16388045|NCT04063449|Experimental|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
16388994|NCT04056377||White boys|239 white boys were included in the study (mean age 7.4 years)
16388046|NCT04063449|Active Comparator|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
16388047|NCT04063436|Experimental|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
16388048|NCT04063423||hemodialysis study session|"4h hemodialysis session using standard polysulphone dialyzer and Nikkiso dialysis monitors
~Minimal dose of unfractionated heparin (UFH) with loading dose 500IE and maintenance 500IE/h, stopped 60 minutes before session end in case of AVF use.
~Standard bicarbonate-based ultrapure dialysate. Na, K, Ca, bicarbonate concentrations according to the patient's routine dialysis prescription.
~The blood flow rate maximized as per routine nursing care.
~Dialysate flow rate fixed at 500 ml/min.
~Dialysate temperature between 35.5°C and 36.5°C.
~Ultrafiltration according to patient's dry weight and supported ultrafiltration rate.
~At the end of the dialysis session the blood will be returned (100ml/min) to the patient."
16388049|NCT04063410|Experimental|Screening (pPCA)|Patients undergo standard of care CTA and undergo pPCA MRI for up to 60 minutes before surgery.
16388050|NCT04063397||Preeclampsia|40 patients diagnosed with preeclampsia with or without severe features
16388051|NCT04063397||Control|20 Control group of patients without hypertensive disorders of pregnancy
16388052|NCT04063384|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
16388053|NCT04063384|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
16388054|NCT04063371||Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
16388055|NCT04063371||Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
16388056|NCT04063371||Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
16388057|NCT04063358|Experimental|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
16388058|NCT04063358|Active Comparator|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
16388059|NCT04063358|Experimental|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
16388060|NCT04063345|Experimental|IVUS-guided PCI|Percutaneous intervention under IVUS-guidance
16388061|NCT04063345|Active Comparator|Angiography-guided PCI|Percutaneous intervention under angiograhy-guidance only
16388062|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
16388063|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
16388064|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
16388065|NCT04063319|Experimental|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
16388066|NCT04063319|No Intervention|Control|The participants in the control group will not receive any instructional intervention
16388067|NCT04063293|Experimental|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
16388068|NCT04063267|Experimental|E cigarettes|
16388069|NCT04063267|Active Comparator|Nicotine Replacement Therapy|
16388070|NCT04063254|Experimental|High-Dose Stereotactic Radiotherapy|
16388071|NCT04063254|Active Comparator|Standard-Dose Stereotactic Radiotherapy|
16388072|NCT04063241|No Intervention|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
16388073|NCT04063241|Experimental|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
16388074|NCT04063241|Other|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
16388075|NCT04063228|Active Comparator|Standard of care|
16388076|NCT04063228|Active Comparator|Simple Skill Group|
16388077|NCT04063215|Experimental|HB-adMSC|HB-adMSCs will be infused three times over a six week period, spaced 14 days apart
16388078|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
16388079|NCT04063189|Experimental|First Relapsed Multiple Myeloma|
16388080|NCT04063163|Experimental|A|HLX 10+chemotherapy (Carboplatin-Etoposide)
16388081|NCT04063163|Placebo Comparator|B|Placebo+chemotherapy (Carboplatin-Etoposide)
16388082|NCT04063150|Active Comparator|IPV at 14 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 14 weeks and 9 months of age.
16388083|NCT04063150|Active Comparator|IPV at 6 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 6 weeks and 9 months of age.
16388084|NCT04063150|Active Comparator|fIPV ID at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
16388085|NCT04063150|Active Comparator|fIPV ID at 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
16388086|NCT04063150|Active Comparator|fIPV IM at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
16388087|NCT04063150|Active Comparator|fIPV 0.1mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
16388088|NCT04063150|Active Comparator|fIPV 0.2mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.2 mL) of IPV at 14 weeks and 9 months of age.
16388089|NCT04063137|Active Comparator|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
16388090|NCT04063137|Placebo Comparator|White bread|
16388091|NCT04063124|Experimental|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
16388092|NCT04063111|Active Comparator|group A|Group A will be treated with vacuum assistant closure
16388093|NCT04063111|Active Comparator|group B|Group B will be treated with conventional dressing
16388094|NCT04063098|Other|All participants|Participants scheduled for endoscopic sleeve gastroplasty
16388095|NCT04063085|Experimental|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
16388096|NCT04063085|Active Comparator|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
16388097|NCT04063085|Sham Comparator|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
16388098|NCT04063085|Active Comparator|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
16388099|NCT04063085|Active Comparator|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
16388100|NCT04063072|No Intervention|Usual care|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to current hospital clinical practice.
16388101|NCT04063072|Experimental|ERAS protocol|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to ERAS protocol.
16388102|NCT04063059|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
16388103|NCT04063059|No Intervention|Control|Usual care
16388104|NCT04063046|Active Comparator|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
16388105|NCT04063046|Experimental|peripheral nerve block|popliteal sciatic nerve block
16388106|NCT04063033|Experimental|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
16388107|NCT04063033|No Intervention|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
16388108|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
16388109|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
16388110|NCT04062994||Intervention Group|All patients scheduled for surgery at a UCLA site in the one year period after go-live
16388111|NCT04062981|Experimental|Cohort I|"Subjects ≥ 18 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
16388112|NCT04062981|Experimental|Cohort II|"Subjects 12 to <18 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
16388113|NCT04062981|Experimental|Cohort III|"Subjects 6 to <12 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
16388114|NCT04062981|Experimental|Cohort IV|"Subjects 2 to <6 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
16388115|NCT04062968|Experimental|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
16388116|NCT04062968|No Intervention|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
16388117|NCT04062955|Experimental|Prevention (dietary intervention)|"DIETARY INTERVENTION: Participants receive dietary counseling with a dietitian in person or via telephone to support adherence to a diet based on the AHEI guidelines once weekly for up to 12 weeks.
~DXA ONLY STUDY: Participants undergo DXA scan for breast density measurement at baseline and at 12 weeks."
16388118|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
16388213|NCT04062149|Experimental|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
16388119|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
16388120|NCT04062916||women with endometriosis|65 women whose main symptom was pain and who did not respond to medical treatment and underwent endometriosis surgery
16388121|NCT04062903|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
16388122|NCT04062903|Active Comparator|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
16388123|NCT04062890|Active Comparator|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
16388124|NCT04062890|Placebo Comparator|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
16388125|NCT04062851|No Intervention|GRV group|Gastric residuals will be checked prior to feeds
16388126|NCT04062851|Experimental|NO GRV group|Gastric residuals will not be checked prior to feeds
16388127|NCT04062838|Experimental|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
16388128|NCT04062825||VIH positive patients without lymphoma|200 VIH positive patients without lymphoma
16388129|NCT04062825||VIH positive patients with lymphoma|20 VIH positive patients with lymphoma
16388130|NCT04062825||healthy volunteers|20 healthy volunteers
16388131|NCT04062799||Study cohort|
16388132|NCT04062773|Experimental|TRF|Eating restricted to between midday and 6pm.
16388133|NCT04062773|Placebo Comparator|Normal timing of food intake.|Eating between 8am and 11pm.
16388134|NCT04062760|Active Comparator|Standard diuretic therapy (SDT)|Furosemide +/- spironolactone or potassium canrenoate
16388135|NCT04062760|Experimental|Early sequential nephron blockade (ESNB)|Furosemide + metolazone + acetazolamide +/- spironolactone or potassium canrenoate
16388136|NCT04062747|Active Comparator|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
16388137|NCT04062747|Active Comparator|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
16388138|NCT04062721|Experimental|Chemotherapy + RFA + in situ immunotherapy|Patients with non-resectable CRC liver-only metastases.
16388139|NCT04062708|Experimental|Treatment|Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.
16388140|NCT04062695|Active Comparator|Tofacitinib|5 mg oral BID
16388141|NCT04062695|Placebo Comparator|Placebo|matching Placebo BID
16388142|NCT04062682|No Intervention|Controls|No changes in dietary habits
16388143|NCT04062682|Experimental|Healthy Diet|Changes in dietary habits only
16388144|NCT04062669|Experimental|Low dose (Ld-) RG SAM (CNE) group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Days 1 and 61).
~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)"
16388145|NCT04062669|Experimental|Medium dose (Md-) RG SAM (CNE) group|Healthy adults,18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) medium dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Day 1.
16388146|NCT04062669|Experimental|Lower dose (Lrd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lower dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
16388147|NCT04062669|Experimental|Lowest dose (Ltd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lowest dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
16388148|NCT04062669|Placebo Comparator|Saline Placebo group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive two intramuscular injections of saline placebo, one in each arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).
~In Part 2 of the study, healthy adults, 18 to 40 years of age will receive one intramuscular injections of saline placebo in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
16388149|NCT04062669|Active Comparator|RabAvert group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm and one intramuscular injection of saline solution in the other arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).
~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
16388150|NCT04062656|Experimental|B - Nivolumab|"Responders
~6 preoperative cycles nivolumab (i.v., 240mg, q2w)
~4 postoperative cycles nivolumab (i.v., 240mg, q2w)
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)
~Non-responders
~2 preoperative cycles nivolumab (i.v., 240mg, q2w)
~4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative
~followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
16388209|NCT04062175|Active Comparator|cephalosporin +azithromycin arm|72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
16388151|NCT04062656|Experimental|D - Nivolumab + relatlimab|"Responders
~6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)
~4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)
~Non-responders
~2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)
~4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
16388152|NCT04062643||Patients with obesity|Obesity in those with BMI ≥30 kg/m2
16388153|NCT04062643||Patients without obesity|Normal weight was considered in the patients with BMI <30 kg/m2
16388154|NCT04062630|Active Comparator|Standard care|Multilevel Lumbar Fusion Surgery
16388155|NCT04062630|Experimental|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
16388156|NCT04062604||Femur fracture|Stabilization of femur fracture according to the AO fundation guidelines
16388157|NCT04062604||Hip alloplasty|Endoprothesis
16388158|NCT04062604||Knee alloplasty|Endoprothesis
16388159|NCT04062604||Knee arthroscopy|Resection of the meniscus lesion or anterior cruciatus ligamentum reconstruction
16388160|NCT04062591|Active Comparator|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
16388161|NCT04062591|Sham Comparator|placebo|saline IM in the same dose of piroxicam
16388162|NCT04062578|Experimental|CD Oliver|Female first team players of the club that plays in the National Second Division league.
16388163|NCT04062578|Active Comparator|SD Huesca|Female first team players who play in the Aragonese Territorial First league
16388164|NCT04062565|Experimental|Experimental|Treprostinil and Riociguat
16388165|NCT04062552|Experimental|Group I (ENABLE palliative care program, phone calls, VLC)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for 15 months.
16388166|NCT04062552|Experimental|Group II (ENABLE palliative care program, phone calls, TA)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for 15 months.
16388167|NCT04062526|Experimental|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.
~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
16388168|NCT04062526|Experimental|Healthy Control|Subject must be a Healthy.
16388169|NCT04062513|Experimental|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
16388170|NCT04062513|Experimental|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
16388171|NCT04062513|Other|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
16388172|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
16388173|NCT04062487|Experimental|Lumbar pedicle screws implantation of traditional procedure|traditional method of lumbar pedicle screws implantation
16388174|NCT04062474|Experimental|Epidural Intervention with Steroids|Epidural Intervention with Steroids
16388175|NCT04062461|Experimental|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.
~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).
~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
16388176|NCT04062461|Active Comparator|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
16388177|NCT04062448|Experimental|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
16388178|NCT04062435|Experimental|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX
~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
16388179|NCT04062435|Active Comparator|Control Group|"Peschke®TE 0.25 % application on the CORNEA
~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
16388180|NCT04062409||Sickle cell patients|
16388181|NCT04062409||Asmathic patients|
16388182|NCT04062396|Active Comparator|Eurosets REMOWELL 2 oxygenator|
16388183|NCT04062396|Active Comparator|LivaNova INSPIRE oxygenator|
16388184|NCT04062383|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
16388210|NCT04062162|Active Comparator|Interventional group|Walking football training
16388211|NCT04062162|No Intervention|Control group|Usual care
16388212|NCT04062149|Active Comparator|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
16388185|NCT04062370|Experimental|1+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 1 time ( month 1), and then IVR is required if central macular thickness (CMT) greater than 300 μm during the follow-up observation (Pro re nata, PRN, means if necessary).
~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.
~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.
~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
16388186|NCT04062370|Active Comparator|3+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 3 consecutive times ( months 1, 2 and 3 ),and then IVR is required if CMT greater than 300 μm during the follow-up observation (PRN).
~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.
~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.
~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
16388187|NCT04062357|Active Comparator|lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
16388188|NCT04062357|Placebo Comparator|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).
16388189|NCT04062344||Short oral drug provocation test|Minors performing a short (1-4 days) drug provocation test
16388190|NCT04062344||Prolonged oral drug provocation test|Minors performing a prolonged (5-8 days)drug provocation test
16388191|NCT04062331|Placebo Comparator|Placebo group|This group will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) without any frequency (device doesn't running; it means, device turned off) but the same duration of sessions.
16388192|NCT04062331|Experimental|Group under TMS 1 Hertz treatment|1 Hertz group (1 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 1 Hertz.
16388193|NCT04062331|Experimental|Group under TMS 5 Hertz treatment|5 Hertz group (5 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 5 Hertz .
16388194|NCT04062318|Experimental|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
16388195|NCT04062318|Active Comparator|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
16388196|NCT04062305|Experimental|Diagnostic (nTMS, sensory testing)|Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
16388197|NCT04062292||Obstructive lung diseases group|"Having been diagnosed with obstructive pulmonary disease,
~No acute exacerbation or infection in the past 1 week, Being between the ages of 18 and 65,"
16388198|NCT04062292||Healthy group|Age and sex matched healthy subjects without orthopedic and chronic diseases
16388199|NCT04062279||case group|patients diagnosed with idiopathic paaarkinson's disease according to the clinical criteria.
16388201|NCT04062253||HCV or HIV negative|Individuals who test negative for HCV or HIV are given information regarding ways of transmission.
16388202|NCT04062253||HCV and HIV positive|Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.
16388203|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
16388204|NCT04062214|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
16388205|NCT04062214|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
16388206|NCT04062201|Experimental|Study Strategy|
16388207|NCT04062201|Active Comparator|Control Strategy|
16388208|NCT04062175|Active Comparator|cephalosporin arm|72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision
16406117|NCT03936023||2nd Generation SUs|Reference Group
16388214|NCT04062136|Experimental|Stem cell transplantation|1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
16388215|NCT04062123|Experimental|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
16388216|NCT04062123|Experimental|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
16388217|NCT04062123|Experimental|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
16388218|NCT04062110|Active Comparator|Long plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with long plaster casts (above-elbow, Long plaster casts).
16388219|NCT04062110|Active Comparator|Short plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with short plaster casts (below-elbow, Short plaster casts)
16388220|NCT04062097||dabigatran-group|Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
16388221|NCT04062097||VKA-group|Patients under effective treatment with VKA and with intracranial hemorrhage.
16388222|NCT04062084|Experimental|Multifunctional Cataract-assisted Retractor|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
16388223|NCT04062084|Experimental|Capsule Retractor|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
16388224|NCT04062058|Experimental|Total Neoadjuvant Chemoradiotherapy|Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery
16388225|NCT04062045|Experimental|Group A - Local anesthetic group|Group A will receive a continuous infusion of ropivacaine 0,2% 5ml/h and intermittent boluses of the same local anesthetic 15ml/4h through the erector spinae catheter.
16388226|NCT04062045|Placebo Comparator|Group B - Placebo group|Group B will receive a continuous infusion of 0,9% saline 5ml/h and intermittent boluses of the same fluid 15ml/4h through the erector spinae catheter.
16388227|NCT04062032|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 7 days
16388228|NCT04062032|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 7 days.
16388229|NCT04062019|Experimental|interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 once every other day, for 3 months.
16388230|NCT04062006|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
16388231|NCT04061993|Experimental|Intervention Group OBV|Intervention Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
16388232|NCT04061993|Active Comparator|Control Group OBV|Control Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
16388233|NCT04061993|Experimental|Intervention Group SBNM|Intervention Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
16388234|NCT04061993|Active Comparator|Control Group SBNM|Control Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
16388235|NCT04061980|Experimental|Arm I (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16388236|NCT04061980|Experimental|Arm II (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD and binimetinib PO BID as in arm I. Patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16388237|NCT04061967|Other|HPV self sampling test ordered|An invitation to order a HPV self sampling test through an online application will be sent by SMS
16388238|NCT04061954|Experimental|Intervention group|"Families in the intervention group received:
~Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts
~Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children
~Trauma-focused therapies
~Parents receive training regarding agriculture and micro credit projects, and financial assistance
~One child per family receives a social skill training group preparing them for returning to school
~Access to schools and school material
~If needed medical assistance is provided
~If needed legal assistance is provided"
16388239|NCT04061954|No Intervention|No intervention group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
16388240|NCT04061941||Stimulant Users|Stimulant users that fulfill SCID-5 clinician version definition for assessment on stimulant use disorder under DSM-5
16388241|NCT04061928|Experimental|Combination of toripalimab with preoperative chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive toripalimab and combined with preoperative chemoradiotherapy and operation.
~generic name：PD-1 dosage form：Injection dosage：240mg (6ml) frequency：every 3 weeks duration：4 times before operation and 4 times after operation"
16388242|NCT04061915|Experimental|Infographic Intervention|Emerging adults randomized to the online intervention arm will review the self-testing infographic. Once participants finish reviewing, they will answer comprehension and preference questions about the self-testing infographic.
16388243|NCT04061915|Active Comparator|Control|Emerging adults randomized to the online control arm will read paper-based HIV self-testing information.
16388244|NCT04061876|Experimental|Ruxolitinib combined with Corticosteroids|Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
16388245|NCT04061876|Active Comparator|Corticosteroids|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
16388246|NCT04061863|Experimental|ER+/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
16388247|NCT04061863|Experimental|ER-/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
16388248|NCT04061837|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
16388249|NCT04061824|Experimental|Patients with fixed-dose combination of 2 drugs|Medication for hypertension and dyslipidemia in these group was fixed-dose combination of 2 drugs
16388250|NCT04061824|Active Comparator|Patients with 2 separated drugs|Medication for hypertension and dyslipidemia in these group was 2 separated drugs for each disease.
16388251|NCT04061811||HF (heart failure)|Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.
16388252|NCT04061811||Control|Patients with end stage renal disease requiring dialysis without HF.
16388253|NCT04061798|Experimental|ACT guided heparinization|Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
16388254|NCT04061798|Active Comparator|5 000 IU of heparin|A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.
16388255|NCT04061785|Active Comparator|Participants in 12 week Judo Inspired Exercise program|"The subjects will participate in a 12 week judo inspired training program (45 minute sessions once a week) with the specific aim to increase physical qualities related to falls and injuries during falls.
~The subjects will be tested before and after the 12 week period"
16388256|NCT04061785|No Intervention|Control Group|The subjects will go about their normal life for 12 weeks without any intervention. The persons will be tested before and after the 12 week period.
16388257|NCT04061772|Experimental|BCHEP|Bortezomib：1.3mg/m2, intravenous drip, d1,d8, every 3 weeks； Etoposide：100mg/m2,intravenous drip, d1-3, every 3 weeks； Cyclophosphamide：750mg/m2,intravenous drip, d1, every 3 weeks； Pharmorubicin：75mg/m2,intravenous drip, d1,every 3 weeks； Prednisone：100mg,tablet by mouth, d1-5, every 3 weeks.
16388258|NCT04061759|Active Comparator|Soft tissue mobilization&stabilization exercises|"The following manual therapy techniques will be applied:
~Soft Tissue Mobilization;
~Pretzel Maneuvers;
~Pelvis Backward-Distraction;
~Trunk Rotation;
~Multifidus Mobilization; and
~Piriformis Transverse Friction Massage"
16388259|NCT04061759|Active Comparator|Kinesiotape&stabilization exercises|The Kinesio® Taping muscle technique, with 10-25% of the stretch of the tape, will be applied to the sacrospinalis, quadratus lumborum, gluteus medius/maximus and piriformis muscles, based on the the weakness that patient's muscles had. Factors interfering with tape adhesion, such as sweat or hair, will be removed before the application. The tape can stay in place for 3-5 days due to its water resistant and breathable properties
16388260|NCT04061759|Active Comparator|Stabilization exercises|The core stabilization exercise treatment program consisted of the following exercises: a posterior pelvic tilt exercise, lower abdominal muscle isometric strengthening, hip adductor muscle isometric strengthening, lumbar stabilization exercises with a Swiss ball, upper and lower abdominal muscle strengthening exercises with a Swiss ball, oblique abdominal muscle strengthening exercises with a Swiss ball, quadratus lumborum muscle stretching with a Swiss ball, back extensor muscle strengthening exercises with a Swiss ball, a slump exercise (sciatic nerve stretching), lumbar lordosis exercises with a Swiss ball, bridge exercises with a Swiss ball, single leg bridge exercises on a Swiss ball, posture exercises, push-up exercises with a Swiss ball, and squat exercises with a Swiss ball
16388261|NCT04061759|Active Comparator|Reflex therapy&Stabilization exercises|Mobilization of each vertebra and pulls were applied from the medial side of the toe to the medial malleolus and to the heel by hand or with the help of an apparatus, including the cervical, thoracic and lumbar spine reflex zones. Finally, the procedure was finished by making a V-shaped maneuver with a thumb in the direction of spinal nerve exits.
16388262|NCT04061746|Experimental|Group A Treatment|2.5 x 10^6 MSC per kg will be infused intravenously on Day 1
16388263|NCT04061746|Placebo Comparator|Group B Placebo|Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1
16388264|NCT04061733|Experimental|Experimental|Subjects who will receive an injection of the hydrogel
16388265|NCT04061720|Experimental|Enhanced Chronic Care|Enhanced Chronic Care provides ongoing, phone-based motivational interventions and interpersonal support to promote readiness to quit, with facilitated access to evidence-based smoking treatment.
16388266|NCT04061720|Active Comparator|Standard Care|Standard Care provides phone-based brief advice to quit once per year.
16388267|NCT04061694|Experimental|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
16388268|NCT04061694|Other|Immediate loading|Historic cohort subjected to immediate loading
16388269|NCT04061681|Experimental|Behavioral Intervention (BIPAMS)|Participants will complete a 16-week behavioral intervention to increase physical activity levels.
16388270|NCT04061681|No Intervention|Waitlist Control|Participants will have 16-weeks of no intervention or interaction.
16388351|NCT04061096|Active Comparator|MIH-effected carious first permanent molar teeth|MIH-effected carious permanent first molar teeth were well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
16388271|NCT04061668|Other|single needle path PECS I and II block group(|The probe is placed inferior to the clavicle . A probe and needle is introduced with in-plane technique . The US is placed below outer third of the clavicle showing pectoralis major and minor muscles then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles is visualised . The US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle is inserted from caudal to cranial using an inclined manner, 15mL of bupivacaine 0.25% is put between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject 15 ml of bupivacaine in thel plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection will be visualized .
16388272|NCT04061668|Sham Comparator|double needle path PECS I and II block group|The probe will be placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles are visualised, then the needle is inserted in plane with probe and 15mL of bupivacaine are put into between pectoralis muscles. In the second puncture , the US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles are identified , the needle will be inserted in plane with the probe from caudal to cranial , 15mL of bupivacaine will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
16388273|NCT04061655|Active Comparator|iron therapy group|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
16388274|NCT04061655|Placebo Comparator|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
16388275|NCT04061642|Experimental|Clinical Decision Aid|
16388276|NCT04061629||Group C|Size of the cuffed ETT based on the Cole formula = (Age/4) + 4.
16388277|NCT04061629||Group D|size of the cuffed ETT based on the Duracher formula = (Age/4) + 3 + 0.5 mm.
16388278|NCT04061629||Group K|size of the cuffed ETT based on the Khine formula = (Age/4) + 3.
16388279|NCT04061616|Experimental|Participants|All the participants volunteer to participate to the study that were included.
16388280|NCT04061603|Experimental|iCLAS Ablation|Ablation of the left and right atrium with the Adagio Medical iCLAS System
16388281|NCT04061590|Experimental|Cohort A (pembrolizumab)|Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
16388282|NCT04061590|Experimental|Cohort B (pembrolizumab, cisplatin pemetrexed)|Patients receive 200mg pembrolizumab IV over 30 minutes and chemotherapy (cisplatin/pemetrexed) IV on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
16388283|NCT04061577|Experimental|Stimulation arm|"Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers:
~Tier 1 - 1 mA, and Tier 2- 2 mA: Consist of a single stimulation cycle (20min) after the endovascular procedure (EVT) in patients with TICI<2c,3 and negative immediate post-EVT CT scan for definitive evidence of ICH.
~Tier 3 - 1 mA and Tier 4- 2mA consist of 2 treatment cycles after the EVT in patients with TICI<2c and 3, and negative immediate post-EVT CT scan for definitive evidence of ICH.
~Tier 5 - 1 mA and tier 6- 2 mA consist of 3 treatment cycles. The first cycle will be up to 20 min cycle, after initial imaging and prior to arterial puncture, the second and third cycles after EVT in patients with TICI<2c and 3 and negative immediate post-EVT CT scan for definitive evidence of ICH."
16388284|NCT04061577|Sham Comparator|Sham arm|Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without delivery of electrical stimulation.
16388285|NCT04061564|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be administered vagal nerve stimulation to each ear (20 minutes in total)
16388286|NCT04061564|Sham Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be administered sham stimulation to each ear (20 minutes in total)
16388287|NCT04061551|Experimental|EC Clinic Support|Whole of practice interventions delivery through nurse-led model
16388288|NCT04061538|Experimental|Zinc sulfate|Zinc sulfate 20 mg by mouth, once a day for 10 days
16388289|NCT04061538|Placebo Comparator|Placebo|Placebo tablet, once a day for 10 days
16388290|NCT04061525||Patients with coronary bifurcation lesions|Patients from 18 to 90-years old with coronary bifurcation lesions with significant >50% diameter stenosis artery scheduled for intervention of the main vessel (Medina types: 1x1, x11, 111)
16388291|NCT04061512|Active Comparator|DRC Arm|The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.
16388292|NCT04061512|Experimental|RI Arm|The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.
16388293|NCT04061499||Hip OA|Individuals with diagnosed hip osteoarthritis
16388294|NCT04061499||Control|Individuals without diagnosed hip osteoarthritis
16388295|NCT04061486||Experimental arm|One half of the oocyte cohort is microinjected with sperm selected by the Fertile technique, while the other half of the patient's oocyte cohort is microinjected with sperm selected by the MACS technique.
16388296|NCT04061473|Placebo Comparator|Pancreatectomized + Placebo|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
~Before the meal (1 h and 12 h) 1+1 placebo tablets will be administered orally."
16388297|NCT04061473|Active Comparator|Pancreatectomized + DPP-4 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
~Before the meal (1 h and 12 h) 1+1 DPP4-inhibitor tablets will be administered orally."
16388779|NCT04058015||adult patients with thoracoabdominal injuries|adult patients with moderate to severe thoracoabdominal injuries
16388298|NCT04061473|Active Comparator|Pancreatectomized + SGLT-2 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
~Before the meal (1 h and 12 h) 1+1 SGLT-2 tablets will be administred orally."
16388299|NCT04061473|Placebo Comparator|Healthy + Placebo|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
16388300|NCT04061473|Active Comparator|Healthy + DPP-4 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
16388301|NCT04061473|Active Comparator|Healthy + SGLT-2 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
16388302|NCT04061460|Other|non smokers|patient who never smoked
16388303|NCT04061460|Other|former smoker|patient who smoked in the past
16388304|NCT04061460|Other|smoker|patient who still smoke
16388305|NCT04061447|Experimental|susceptibility-guided therapy|In the group of the empirical triple therapy, patients received rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
16388306|NCT04061447|Active Comparator|empirical clarithromycin-based triple therapy|In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
16388307|NCT04061434||Cardiac resynchronisation therapy recipients|
16388308|NCT04061434||Other cardiac implantable electronic devices recipients|
16388309|NCT04061421|Experimental|ASTX727 + itacitinib|ASTX727 and itacitinib will be taken by mouth
16388310|NCT04061408|Experimental|FSRT|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
16388311|NCT04061395|Experimental|Guselkumab|Guselkumab 200 mg Q4W; subcutaneous injections; duration of 16 weeks.
16388312|NCT04061382||Randomised selection of population - Group 1|Group 1 will be focusing on COVID-19, diphtheria and group C invasive meningococcal disease. The investigators are aiming to recruit around 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). PHE have generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visit. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history.The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
16388313|NCT04061382||Group 2|"Group two will focus on 0-19 year olds only. They will not be restricted to the post code sampling. Instead this will include standard recruitment methods such as social media advertisements within the normal recruiting regions for each site. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients. The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
~A proportion of participants from this group from selected sites will also provide up to a maximum of three blood samples for separation of peripheral blood mononuclear cells (PBMCs) to evaluate T cell responses. These participants can be either seronegative or seropositive at their Visit 1."
16388314|NCT04061382||Group 3|Group three will consist of up to 300 participants aged 0-19 from the Black, Asian and Minority ethnic population aged 0-19 years. They will not be restricted to the post code sampling and will be recruited at a sub-set of sites depending on capacity and the demographic profile of the local population. Recruitment will be by multiple approaches, including mail outs, radio and advertising in community (e.g. community centres, religious establishments) or Pharmacies and GP practices where we have ethics approval for them to act as PICs. These can vary according to each site's experience and their contacts within their local community on how is best to approach the BAME community. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients.
16388315|NCT04061369|Experimental|Meal 1|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
16388316|NCT04061369|Experimental|Meal 2|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
16388317|NCT04061369|Experimental|Meal 3|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
16388318|NCT04061369|Experimental|Meal 4|"A liquid meal, similar to a smoothie, that is high (60% of energy) in fat calories."
16388319|NCT04061330|Experimental|Ketamine Group|
16388320|NCT04061330|Active Comparator|Opioid group|
16388321|NCT04061304|Experimental|Active rTMS (Anorexia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).
~For the second session each day the patients in the anorexia group will receive low-frequency treatment (1 Hz, 60 second cycles, 30 second inter-train interval, 20 trains, 1200 total pulses) at 120% of the resting motor threshold to the orbitofrontal cortex"
16388322|NCT04061304|Experimental|Active rTMS (Bulimia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).
~For the second session each day the patients in the bulimia group will receive high-frequency (10 Hz, 5 second cycles, 50 pulses, 25 second inter-train interval, 60 trains, 3000 total) at 120% of the resting motor threshold treatment to the left dorsomedial prefrontal cortex"
16388323|NCT04061304|Sham Comparator|Sham rTMS (Anorexia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Anorexia Nervosa group however their will be no actual brain stimulation.
16388324|NCT04061304|Sham Comparator|Sham rTMS (Bulimia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Bulimia Nervosa group however their will be no actual brain stimulation.
16388325|NCT04061278|Experimental|4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy|Four cycles of neoadjuvant chemotherapy combined with radical radiotherapy
16388326|NCT04061278|Active Comparator|3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy
16388327|NCT04061265|Active Comparator|Lidocaine 2% group|lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd)
16388328|NCT04061265|Experimental|Articaine 4%|articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)
16388329|NCT04061252|Experimental|KHK4827 210mg Q2W SC|
16388330|NCT04061252|Placebo Comparator|Placebo Q2W SC|
16388331|NCT04061239|Experimental|CPX-351 Arm|"CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
~The treatment includes up to 2 cycles of induction as follows:
~1 x CPX-351 1st induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1, 3, and 5
~1 x CPX-351 2nd induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1 and 3
~Each induction cycle will last 28 days. Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy after induction or be discontinued from the treatment phase and transferred directly to alloHCT, if applicable. CPX-351 consolidation is with daunorubicin 29 mg/m² and cytarabine 65 mg/m² in liposomes on days 1 and 3. For patients < 60 years up to 3 consolidation cycles and for patients ≥ 60 years up to 2 consolidation cycles are allowed."
16388332|NCT04061239|Other|CCR Arm|"The conventional care regimens (CCR) arm has 2 options according to the discretion of the investigator:
~conventional 7+3 cytarabine/daunorubicin chemotherapy regimen
~treatment with s.c. Azacitidine"
16388335|NCT04061213||Patients with symptomatic severe aortic stenosis|Elderly patients referred for TAVR evaluation
16388336|NCT04061200|Active Comparator|Semaglutide 1,34 mg/ml|Semaglutide 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
16388337|NCT04061200|Placebo Comparator|Placebo 1,34 mg/ml|Placebo 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
16388338|NCT04061174|Experimental|Shoulder stabilization exercise and office exercise training|Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
16388339|NCT04061174|Experimental|Office exercise training|"Office-based stretching exercises will be given to other group 3 sets will be applied by waiting 15 seconds for increasing range of motion of back, shoulder and neck joints.
~In addition, isometric exercises and scapula stabilization exercises will be given to strengthen the shoulder muscles and participants will do these exercises 3 times a week and once a day in 10 repetitions (10-15 seconds) and 3 sets. Each set will be given a rest of 60-90 seconds. Total time will be 10-15 minutes.Office exercise training will last a total of 8 weeks."
16388340|NCT04061161|Active Comparator|Tiotropium respimat|Tiotropium respimat 2.5mcg two actuations once daily
16388341|NCT04061161|Placebo Comparator|Placebo respimat|Placebo respimat two actuations once daily
16388342|NCT04061148|Other|Non-Depressed Controls|"Volunteers who have screened by a clinical psychiatrist, to exclude depression and other major psychiatric and neurocognitive disorders.
~They will undergo NIRSIT testing to measure frontal blood oxygenation up to 3 times, with an interval of 3 weeks between each measurement."
16388343|NCT04061148|Active Comparator|Depressed Patients|Patients diagnosed with Major Depressive Disorder by a clinical psychiatrist. They will undergo NIRSIT testing to measure frontal blood oxygenation up to 5 times, with an interval of 3 weeks between each measurement, over the course of their clinical therapy for Major Depressive Disorder.
16388344|NCT04061135|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
16388345|NCT04061135|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
16388346|NCT04061122||EX + / ECTS +|Patients suffering COPD exacerbation in last 7 days; active tobacco smokers
16388347|NCT04061122||EX - / ECTS +|Patients without COPD exacerbation in last 6 months; active tobacco smokers
16388348|NCT04061122||EX + / ECTS -|Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier
16388349|NCT04061122||EX - / ECTS -|Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier
16388350|NCT04061109|Experimental|Prophylactic therapy|Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.
16388352|NCT04061096|Active Comparator|not MIH-effected carious first permanent molar teeth|The carious not MIH-effected teeth were only carious without any hypomineralize areas and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
16388353|NCT04061096|Placebo Comparator|MIH-effected non-carious first permanent molar teeth|MIH-effected teeth were carious permanent first molar teeth with well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and did not have any sign of caries.
16388354|NCT04061096|Placebo Comparator|not MIH-effected non-carious first permanent molar teeth|not any signs of being caries or hypomineralization.
16388355|NCT04061083|Experimental|Continuous Endotracheal Cuff Pressure Control|Continuous endotracheal cuff pressure control using smart cuff manager during the first 48 hours of intubation in the intensive care unit
16388356|NCT04061083|Experimental|Intermittent Endotracheal Cuff Pressure Control|Intermittent cuff pressure control through manual manometer measurement performed 3 times per day during the first 48 hours of intubation in the intensive care unit
16388357|NCT04061083|No Intervention|Standard Care|ET cuff pressure control will be provided with pilot balloon fingers during the first 48 hours of intubation in the intensive care unit
16388358|NCT04061070|Sham Comparator|No Intervention with the mix threalose plus polyphenols|The patients allocated in this arm will not treated with a mix of threalose plus polyphenols
16388359|NCT04061070|Active Comparator|Intervention with the mix threalose plus polyhenols|The patients allocated in this arm will treated with a mix of threalose plus polyphenols
16388360|NCT04061057|Experimental|IV lidocaine|Perioperative IV lidocaine infusion
16388361|NCT04061057|Placebo Comparator|Normal saline|Perioperative IV normal saline infusion
16388362|NCT04061044|Experimental|Treatment|
16388363|NCT04061031|Experimental|Parent-Child Interaction Therapy|
16388364|NCT04061031|Active Comparator|Child-Centered Therapy with Parent Education|
16388365|NCT04061018||High Cholesterol Efflux|Dallas Heart Study participants who are above the sex and ethnicity specific 90th % of cholesterol efflux
16388366|NCT04061018||Low Cholesterol Efflux|Dallas Heart Study participants who are below the sex and ethnicity specific 10th % of cholesterol efflux
16388367|NCT04061005|Active Comparator|Hot snare polypectomy (HSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). According to the randomized group, patients with HSP group were treated with HSP to excise 5-15 mm colorectal polyps. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopist carefully observed the edge of the resection to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
16388368|NCT04061005|Experimental|Cold snare polypectomy (CSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). After randomization, patients in the CSP group will be treated with CSP to remove colorectal polyps of 10-15 mm size. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopic surgeon carefully observed the resection margin to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
16388369|NCT04060992|Experimental|Early Follicular Phase|Women enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
16388370|NCT04060992|Active Comparator|Late Follicular Phase|Women enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
16388371|NCT04060992|Active Comparator|Luteal Phase|Women enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
16388372|NCT04060979|Experimental|Group 1- NO treatment- dose 1|Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
16388373|NCT04060979|Experimental|Group 2- NO treatment- dose 2|Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
16388374|NCT04060979|Other|Group 3- Control treatment|Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
16388375|NCT04060966|Experimental|Cold - Pressor Task|
16388376|NCT04060953|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report.
16388377|NCT04060953|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report following completion of the study.
16388378|NCT04060940|Experimental|Emotion Regulation Therapy: 8-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 8-session version of ERT will receive 8 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-5 will be 1 hour long, sessions 6 and 7 will be 1.5 hours long, and session 8 will be one hour long, resulting in a total required time commitment of 9 hours over the course of 8 weeks.
16388379|NCT04060940|Experimental|Emotion Regulation Therapy: 16-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 16-session version of ERT will receive 16 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-9 will be 1 hour long, sessions 10-13 will be 1.5 hours long, and sessions 14-16 will be 1 hour long, resulting in a total required time commitment of 18 hours over the course of 16 weeks.
16388380|NCT04060927|Experimental|Group 1|Freebreathing SBRT with SGRT
16388381|NCT04060927|Experimental|Group 2|Breath hold SBRT with SGRT
16388382|NCT04060927|Experimental|Group 3|Breath hold SBRT with SGRT in combination with implanted fiducials
16388383|NCT04060914|Experimental|Ticagrelor(90mg)|
16388384|NCT04060914|Experimental|Ticagrelor(90/60mg)|
16388385|NCT04060914|Active Comparator|Clopidogrel(75mg)|
16388386|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 1|Participants in the first cohort will receive the CCSH Interventions for Teams during the fall session (first intervention period).
16388387|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 2|Participants in the second cohort will receive the CCSH Interventions for Teams during the spring session (second intervention period).
16388388|NCT04060888|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
16388389|NCT04060888|Placebo Comparator|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
16388390|NCT04060875||Feasibility group|First phase group will involve piloting a novel virtual reality treatment for chronic pain to investigate feasibility and safety with a smaller number of patients
16388391|NCT04060862|Experimental|Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant|
16388392|NCT04060862|Placebo Comparator|Phase 3: Placebo + Palbociclib + Fulvestrant|
16388393|NCT04060849|Experimental|Arm I (Nozin)|Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
16388394|NCT04060849|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
16388395|NCT04060836|Experimental|group A|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.
16388396|NCT04060836|Experimental|group B|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.
16388397|NCT04060823|Experimental|Easy Breathing|Easy Breathing will be implemented in participating clinics. Asthma-related sick visits will be monitored for changes.
16388398|NCT04060810|Other|grey zone hydrocephalic patients|MR CSF flowmetry CT brain Ventriculoperitoneal shunt
16388399|NCT04060797|Experimental|endovascular denervation|endovascular denervation
16388400|NCT04060784|Experimental|Immediate implant placement and provisionalization|On the control group, Implant will be placed immediately after tooth extraction. The gap between the implant and buccal bone will be filled with bone graft. Temporary crown will be attached to implant fixture.
16388401|NCT04060784|Experimental|Socket shield technique|On the test group, Implant will be placed immediately after tooth extraction. A piece of root shield will be retained intentionally at facial side. Temporary crown will attached to implant fixture.
16388402|NCT04060771|Experimental|Group P|During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
16388403|NCT04060771|Active Comparator|Group D|During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
16388404|NCT04060758|Experimental|14.7 mcg|PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.
16388405|NCT04060758|Experimental|26.6 mcg|PA5108 Latanoprost FA SR Ocular Implant which releases 26.6 mcg.
16388406|NCT04060758|Experimental|35.5 mcg|PA5108 Latanoprost FA SR Ocular Implant which releases 35.5 mcg.
16388407|NCT04060745|Experimental|Cooling|Participants will be cooled using an individualized cooling protocol with a water-perfused vest for two hours while resting. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
16388408|NCT04060745|Experimental|Thermoneutrality|Participants will rest for one hours. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
16388409|NCT04060732||Flash Glucose Monitoring Device|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid used by Diabetes Mellitus type 1 patients."
16388410|NCT04060719|Experimental|Reference (Period 1) - BI 894416 alone|Reference (Period 1) followed by Test (Period 2)
16388411|NCT04060719|Experimental|Test (Period 2) - BI 894416 + Rifampicin|
16388412|NCT04060706||Prostate Cancer|Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.
16388413|NCT04060706||Head & Neck Cancer|Adults suitable for radical image-guided radiotherapy for their Head & Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 & Modified xerostomia questionnaires will be used.
16388414|NCT04060706||Central Nervous System Tumours|Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination & Generalised activites of daily living scale (G-ADL) questionnaires will be used.
16388415|NCT04060706||Lung Cancer|Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG & LENT SOM(A) questionnaires will be used.
16388416|NCT04060693|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 30 days of home-based measurement, scheduled within a 40 days' time frame. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed within 3 minutes after the BG measurement using the thenar of the right hand of the subject.
16388418|NCT04060667|Experimental|Intervention|
16388419|NCT04060667|No Intervention|control|
16388420|NCT04060654|Experimental|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator (either 100 mg or 300 mg) for up to 5 total injections
16388421|NCT04060641||RDN Patients|Patients who have received renal denervation with the Medtronic SymplicitySpyral device will have DNA collected in using a buccal swab.
16388422|NCT04060615|Other|Patients with chronic total occlusion of the coronary artery|In each patient before the PCI procedure, the investigators will assess myocardial viability, functional parameters of collateral blood vessels, and quality of life. 24h and 6 months after the procedure these parameters will be reevaluated as well as functional parameters of the treated coronary artery.
16388423|NCT04060602|Experimental|Personalized Feedback and Education|This arm is provided personalized feedback concerning their cannabis use in addition to educational materials about risky cannabis use.
16388424|NCT04060602|Active Comparator|Education|This arm is provided educational materials about risky cannabis use.
16388425|NCT04060589||Cohort Observation|This is a cohort study where participating men will be asked to donate blood, urine, tissue in addition to access to standard of care tissue and medical data (including imaging files). Men will also consent to longer term healthcare data linkage.
16388426|NCT04060576|Experimental|Group A treated with a 16-gauge needle|Group A is intervened on the gastrocnemius muscle with a 16-gauge needle.
16388427|NCT04060576|Experimental|Group B treated with a 25-gauge needle|Group B is intervened on the gastrocnemius muscle with a 25-gauge needle.
16388428|NCT04060576|Experimental|Group C treated with a 32-gauge needle|Group C is intervened on the gastrocnemius muscle with a 32-gauge needle.
16388429|NCT04060563|Sham Comparator|Sham (fake) microcurrent therapy|Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
16388430|NCT04060563|Experimental|Frequency specific microcurrent therapy|Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),
16388431|NCT04060550||Normal controls|No history of skin disease and atopy
16388432|NCT04060550||ADEH-|Atopic dermatitis without a history of eczema herpeticum
16388433|NCT04060550||ADEH+|Atopic dermatitis with a history of eczema herpeticum
16388434|NCT04060537||Research|Patients with Renal Cell Carcinoma who have had previous systemic treatment, with adequate tissue samples and radiological data
16388435|NCT04060511|Experimental|HS-10342|Each subject will receive a single dose(C0) of HS-10342 and then repeat doses(C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
16388436|NCT04060498|Experimental|Mindfulness intervention|This arm consists of seven weekly-session mindfulness-based intervention for psychosis (MBI-p). The MBI-p is a protocol-based, low intensity intervention developed to help patients achieve a greater sense of peace and calmness, and facilitates participants in handling everyday stress and conflicts.
16388437|NCT04060498|Placebo Comparator|Psychoeducation intervention|This arm consists of seven weekly-sessions of psychoeducation. Topics to be discussed in the sessions include the signs and symptoms of psychosis, aetiology of psychosis, as well as pharmacological and non-pharmacological interventions.
16388438|NCT04060472|Experimental|albumin-bound paclitaxel + oxaliplatin|
16388439|NCT04060459|Experimental|Treatment plan|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
16388440|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
16388441|NCT04060433|Experimental|ROCKETLAUNCH project|Intensive treatment program with focusing on the implementation of evidence based family therapy
16388442|NCT04060420|Experimental|Comprehensive sexual and reproductive health services|In clusters randomised to the Yathu Yathu intervention, the comprehensive, community-based and peer-led intervention is being delivered. In addition to delivery of sexual and reproductive health services through community-based hubs, the intervention includes the Yathu Yathu prevention points cards, with which adolescents and young people can accrue points for accessing services at the Yathu Yathu hub and local health facility, and redeem rewards using these points.
16388443|NCT04060420|No Intervention|Standard of care|In the comparison arm, adolescents and young people will have access to sexual and reproductive health services at the local health facility. They will also have a Yathu Yathu prevention points card, with which they can accrue points for accessing sexual and reproductive health services at the local health facility and redeem rewards using these points.
16388444|NCT04060407|Experimental|Advanced Melanoma|Patients with advanced melanoma.
16388445|NCT04060394|Experimental|Phase I Cohort 1|LAE001 (capsules) 75mg Twice Daily (BID) + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg Once Daily (QD) will be administered in Cycles of 28 days.
16388446|NCT04060394|Experimental|Phase I Cohort 2|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg QD will be administered in Cycles of 28 days.
16388447|NCT04060394|Experimental|Phase I Cohort 3|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 125mg QD will be administered in Cycles of 28 days.
16388448|NCT04060394|Experimental|Phase I Cohort 4|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 150mg QD will be administered in Cycles of 28 days.
16388449|NCT04060394|Experimental|Phase II Arm 1|LAE001 (capsules) + prednisone (tablet) +afuresertib at the Recommended Phase II Dose (RP2D)
16388450|NCT04060394|Experimental|Phase II Arm 2|Docetaxel/prednisone + afuresertib
16388451|NCT04060381||Fetuses of normal weight women|Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37
16388452|NCT04060381||Fetuses of severely obese women|Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37
16388453|NCT04060381||New-borns in need of blood transfusion|Neonates mainly receive blood due to blood loss, often because of repeated blood sampling
16388454|NCT04060381||New-borns in need for closure of the arterial duct|Neonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct.
16388455|NCT04060381||New-borns in need of treatment with catecholamines|Neonates are mainly treated with epinephrine, nor epinephrine or atropine due to compromised cardiovascular function or hypotension.
16388456|NCT04060368|Experimental|ESG Stitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
16388457|NCT04060368|Active Comparator|LSG + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
16388461|NCT04060342|Experimental|Phase 1: Regimen A - GB1275 monotherapy|GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
16388462|NCT04060342|Experimental|Phase 1: Regimen B - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab dose escalation and expansion:
~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
16388463|NCT04060342|Experimental|Phase 1: Regimen C - GB1275 with Standard of Care (SOC)|"GB1275 with SOC dose escalation:
~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)"
16388464|NCT04060342|Experimental|Phase 2: Cohort 1 - GB1275 with SOC|"GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:
~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI."
16388465|NCT04060342|Experimental|Phase 2: Cohort 2 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:
~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
16388466|NCT04060342|Experimental|Phase 2: Cohort 3 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:
~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
16388467|NCT04060329|No Intervention|Phase 1|Usual care
16388468|NCT04060329|Experimental|Phase 2|Usual care + coopeRATE Prompt intervention
16388469|NCT04060329|Other|Clinicians|After Phase 2, clinicians will be asked about their experiences with, and views about, the coopeRATE Prompt intervention.
16388470|NCT04060316|Experimental|GLS-1200|3 ml of GLS-1200 (1 mg/ml in 0.9% saline)
16388471|NCT04060316|Placebo Comparator|Sterile Saline|3 ml of 0.9% saline
16388472|NCT04060303|Active Comparator|ENRICH-US Implementation- early|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.
~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
16388473|NCT04060303|Active Comparator|ENRICH-US Implementation- mid|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.
~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
16388474|NCT04060303|Active Comparator|ENRICH-US Implementation- late|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.
~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
16388475|NCT04060277|Experimental|Arm I (letermovir, Triplex)|Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
16388476|NCT04060277|Active Comparator|Arm II (letermovir, placebo)|Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
16388477|NCT04060264|Experimental|BCD-148|"14 participants in BCD-148 group. During the main period (first 27 weeks), test product BCD-148 will be administered as 25- to 45-minute intravenous infusions.
~After Week 27 BCD-148 900 mg will be administered biweekly as maintenance therapy."
16388478|NCT04060264|Active Comparator|Soliris|"14 participants in Soliris group. During the main period (first 27 weeks), Soliris® will be administered as 25- to 45-minute intravenous infusions.
~After Week 27, patients be switched to BCD-148 900 mg biweekly as maintenance therapy."
16388517|NCT04059926||Patients with lumen metal apossing stent|
16388479|NCT04060251|Experimental|Group 1, iGetBetter Group|Use only iGetBetter for the 3 months preceding surgery. After surgery, you will be given a new, Post-Op program to use for 2-3 months. For the first 3 weeks, you will only use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks.
16388480|NCT04060251|Experimental|Group 2, E-vive Group|You will use iGetBetter starting 3 months out from surgery. You will receive CyMedica's electrical-stimulation garment during the preoperative appointment. In addition to iGetBetter, you will wear the conductive garment two times each day for the last 3 weeks before surgery. After surgery, for the first 3 weeks you will only use the conductive garment, and will not use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to wearing the brace, approximately twice per week for the next 6-8 weeks. You will not need to return the brace after this time is up, and you may keep the brace, if you so choose, at no cost.
16388481|NCT04060251|No Intervention|Group 3, Physical Therapy Group|You will receive only iGetBetter for the 3 months preceding surgery. After surgery, you will receive only home physical therapy, and will not use iGetBetter. After those three weeks, you will receive outpatient physical therapy approximately twice per week for the next 6-8 weeks.
16388482|NCT04060238||Normal colour vision|Normal trichromopsia
16388483|NCT04060238||Inherited red blindness|Protanopia
16388484|NCT04060225|Experimental|Participants|Participants will be asked to participate in a single arm study with three phases (washout phase, abstinence phase, and exposure phase). These participants will first be asked to abstain from drinking any caffeinated food or beverages for 72 hours (known as the washout phase). Following the first phase, participants will then wear a blood pressure cuff to collect diastolic and systolic blood pressure for 24 hours (abstinence phase) wherein they will be asked to refrain from caffeinated products. Participants will then drink the coffee intervention and collect blood pressure measurements for 24 hours (exposure phase).
16388485|NCT04060212|Experimental|All Participants|All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
16388486|NCT04060199|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
16388487|NCT04060199|Placebo Comparator|Placebo|Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
16388488|NCT04060186|Active Comparator|Balloninflation Group|Patient who will perform a balloninflation after operation
16388489|NCT04060186|Sham Comparator|Conservative Group|Patient without performing a balloninflation
16388490|NCT04060173|Experimental|Treatment with ABP-671|Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.
16388491|NCT04060173|Placebo Comparator|Treatment with placebo|Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.
16388492|NCT04060147|Experimental|CILO 30 mg|Participants will receive escalating doses of CILO 30 mg, 60 mg, and 100 mg.
16388493|NCT04060134||HADM|Patients who had human acellular dermal matrix used in their breast reconstruction procedure.
16388494|NCT04060108||MDMA Within Subject Cross-over|Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
16388495|NCT04060095||β1-adrenergic antagonists|Patients who have been treated for more than 3 months with β1-adrenergic antagonists
16388496|NCT04060082||Persons Diagnosed|Individuals with a diagnosis of bvFTD.
16388497|NCT04060082||Persons At Risk|Individuals with a known genetic risk factor for bvFTD: people with genetic testing that identified a disease-causing change in a gene that is known to cause bvFTD, such as in C9ORF72, MAPT, GRN, VCP, TARDBP, CHMP2B, or another gene that has been identified as causing FTD in the family
16388498|NCT04060069||Before pneumoperitoneum|Fluid administration
16388499|NCT04060043|Experimental|Goserelin acetate Injection|Pepti 10.8mg is a generic formulation of Zoladex® 10.8mg, with the same ingredients (active and excipients), the same formulation, the same dosage, the same size and route of administration.
16388500|NCT04060030|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
16388501|NCT04060030|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
16388502|NCT04060017|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
16388503|NCT04060017|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
16388504|NCT04060004|Other|Control group|Electrotherapy + therapeutic exercise
16388505|NCT04060004|Experimental|Experimental group 1|Electrotherapy + therapeutic exercise + dry needling
16388506|NCT04060004|Placebo Comparator|Experimental group 2|Electrotherapy + therapeutic exercise + sham dry needling
16388507|NCT04059978|Active Comparator|CBD + Remifentanil|CBD 1600 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min
16388508|NCT04059978|Placebo Comparator|Placebo + Remifentanil|Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min
16388509|NCT04059965|Experimental|Intervention Arm|This cohort of patients will receive panel management through a customize software that integrates with the electronic health record
16388510|NCT04059965|Active Comparator|Control Arm|This cohort of patients will receive usual care
16388511|NCT04059952||Unipolar Depression|Patients diagnosed with Major Depressive Disorder.
16388512|NCT04059952||Bipolar Depression|Patients diagnosed with Bipolar I or II.
16388513|NCT04059952||Healthy Control|Patients without psychiatric diagnoses.
16388514|NCT04059939|Experimental|Reading Plus Attention Control|
16388515|NCT04059939|Experimental|Reading Plus Anxiety|
16388516|NCT04059939|Active Comparator|BAU|
16388518|NCT04059913|Other|Part 1 (2 arms) and Part 2|The purpose of Part 1 is to evaluate difference between low and standard weight-based doses and Part 2 is to evaluate the difference among dosing frequencies
16388519|NCT04059913|Other|Part 1|"Part 1:
~Arm Type: Other
~Arm Title: Low weight-based dosing
~Arm 1: Low weight-based dosing
~Arm Description: Subjects in this arm will receive roxadustat 70 mg three times a week (TIW) for body weight < 60 kg or 100 mg TIW for body weight ≥ 60 kg
~Arm Type: Other
~Arm Title: Standard weight-based dosing
~Arm 2: Standard weight-based dosing
~Arm Description: Subjects in this arm will receive roxadustat 100 mg TIW for body weight < 60 kg or 120 mg TIW for body weight ≥ 60 kg"
16388520|NCT04059913|Other|Part 2|"Part 2:
~Arm Type: Other
~Arm Title: Roxadustat
~Arm Description: Subjects in this arm will receive roxadustat at different dose frequencies"
16388521|NCT04059900|Experimental|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
16388522|NCT04059900|Placebo Comparator|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
16388523|NCT04059887|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administrated every 3 week cycle
16388524|NCT04059874|Experimental|donafenib tablets 1|This is the dose group was given once a day. donafenib tablets 1 100mg qd dose group
16388525|NCT04059874|Experimental|donafenib tablets 2|This is the dose group was given twice a day. donafenib tablets 2 100mg bid dose group
16388526|NCT04059861|Other|ultrasound assisted resection|resection of tongue cancer will be done with assistance of ultrasound to visualise the deep margin.
16388527|NCT04059848|Experimental|tDCS combined with NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
16388528|NCT04059848|Active Comparator|tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
16388529|NCT04059848|Sham Comparator|sham tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional sham tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
16388530|NCT04059835|Active Comparator|standard|Standard bra, soft
16388531|NCT04059835|Experimental|compression bra|experimental bra, compression and stabile
16388532|NCT04059822|Experimental|Slow and deep breathing|Daily practice of slow and deep breathing for 10 minutes per day. Breathing frequency will be 6 breaths per minute, with participants accessing a video aid to help guide their breathing. Breathing exercises will be conducted from enrolment until birth (maximum ~20 weeks if enrolment at 20 weeks gestation until ~40 weeks gestation birth)
16388533|NCT04059809|No Intervention|Usual Care|The control group will have usual care according to the orientation of the radiation therapy faculty responsible for the radiotherapy treatment the PBM device will be switched off
16388534|NCT04059809|Experimental|Photobiomodulation (PBM)|Additionally to the usual care, the patients will receive the PBM. Treatment will be done twice a week.
16388535|NCT04059796|Experimental|Study Eye|Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
16388536|NCT04059796|Active Comparator|Control Eye|approved monofocal or toric IOL after cataract extraction
16388537|NCT04059770|Experimental|single dose of L-AmB|single IV dose of 10 mg/kg of L-AmB on day 1;
16388538|NCT04059770|Experimental|2 doses of L-AmB|IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
16388539|NCT04059770|Active Comparator|2 weeks of L-AmB|IV dose of 3 mg/kg of L-AmB for 2 weeks.
16388540|NCT04059757|Experimental|Fecal Microbiota Transplantation (FMT)|"One dose of FMT equal to 30 capsules will be administered on day 1 of a 28 day cycle. Steroids and routine GVHD prophylaxis medications and antibiotics may be administered concurrently with FMT therapy.
~Participants will be followed for 28 days following completion of the FMT dose or protocol defined outcome.
~aGVHD will be treated as per standard of care."
16388541|NCT04059744|Experimental|Experimental arm|"Device: Fun-Knee Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.
~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
16388542|NCT04059731|Experimental|Surmimed®OPD Drink|Normocaloric oligomeric-hyperprotein supplement
16388543|NCT04059731|Active Comparator|Atempero® or Impact®|Inmunonutrition
16388544|NCT04059718|Experimental|Treatment|Treatment arm will be enrolled in the SCI Thrive Peer-Led Online Self-Management program and will take part in the next available group session.
16388545|NCT04059718|No Intervention|Wait-list Control|Wait-list control arm will only complete assessments during the 6 week group period. Subjects will be offered a place in the SCI Thrive Peer-Led Online Self-Management program after 6 weeks and completing the assessments.
16388546|NCT04059705|Experimental|Dual-Task Intervention|This study arm will receive the dual-task training program.
16388547|NCT04059692|Experimental|Cervical manipulation intervention|"To perform the evaluation and detect the cervical vertebral level with mobility restriction, with the patient in supine position, a cervical examination is carried out to determine the mobility restriction, both in flexo-extension, as in inclination and rotation. To check the level of restriction, the post-anterior sliding test is performed.
~The manipulation is performed following the criteria of thrust manipulations. A maximum of 3 manipulations are applied in total per subject, one for each level (high level C1-C2, medium level C3-C6, and low level C7), if necessary."
16388548|NCT04059692|Placebo Comparator|Placebo intervention|This group will receive 15 minutes of sham techniques in a supine position over the stretcher. First, a series of short-time and no pressure contact with physiotherapist´s hands is performed in several points of head and shoulders for 10 minutes. Subsequently, light touch is applied on standardized anatomic areas, for 2 minutes each time.
16388549|NCT04059679|Active Comparator|EC aspirin (81mg qd)|
16388550|NCT04059679|Experimental|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)|
16388551|NCT04059666|Active Comparator|Control|
16388552|NCT04059666|Experimental|Investigational|
16388557|NCT04059627|Experimental|Experimental arm|"Participants were introduced to Heart-Track mobile app system and its navigational characteristics with standardised instructions. Each participant then performed a self-directed Cardiac rehabilitation session using the app."
16388558|NCT04059614|Active Comparator|"High flow nasal cannula (HFNC)"|"HFNC group: those who receive high-flow nasal cannula therapy"
16388559|NCT04059614|Experimental|conventional oxygen therapy (COT)|COT group: those who receive conventional oxygen therapy group
16388560|NCT04059601||Patients with acute cholecystitis|All patients with acute cholecystitis are included in the study cohort during year 2019. MRCP and IOC will be performed to all patients whenever feasible.
16388561|NCT04059588|Experimental|Injection of 2141-V11|Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.
16388562|NCT04059575|Experimental|PERFORMANCE PLUS|performance plus better than GOLD TEX
16388563|NCT04059575|Active Comparator|GOLD TEX|GOLD TEX better than performance plus
16388564|NCT04059562|Experimental|Treatment|Combination of Lonsurf® and Campto®
16388565|NCT04059549|Active Comparator|A-CHESS|Patients randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
16388566|NCT04059549|Experimental|PartnerCHESS|Patients randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
16388567|NCT04059536||Roxwood Anchoring Catheters|Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.
16388568|NCT04059523|Experimental|S6G5T-3|topical cream
16388569|NCT04059523|Active Comparator|Retin-A® 0.1% Cream|topical cream
16388570|NCT04059510||Screening for GBS|Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
16388571|NCT04059510||Sampling method optimisation|"If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).
~The sampling study will last for 12 weeks and samples collected include:
~A self-taken low vaginal swab
~A self-taken rectal swab
~Menstrual cup fluid
~Serum sample
~Urine pregnancy tests"
16388572|NCT04059510||Focus groups|"In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.
~Women may opt out of the focus groups at any time but remain in the sampling study if they choose.
~In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples."
16388573|NCT04059497|Experimental|Exercise group|The exercise group will receive a 10-minute exercise intervention.
16388574|NCT04059497|Experimental|Healthy diet group|The healthy diet group (control) will receive a 10-minute healthy-diet intervention.
16388575|NCT04059484|Experimental|Amcenestrant|Daily amcenestrant dose administered orally under fed or fast condition
16388576|NCT04059484|Active Comparator|Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator|"Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.
~Fulvestrant
~Aromatase inhibitors (anastrozole, letrozole, exemestane)
~Selective estrogen receptor modulator (Tamoxifen)"
16388577|NCT04059471|Active Comparator|Standard Dose|Yellow fever vaccine, Institut Pasteur, standard dose as release by manufacturer will be administered subcutaneously once.
16388578|NCT04059471|Experimental|Fractional dose (1000 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 1000IU/dose and administered subcutaneously once.
16388579|NCT04059471|Experimental|Fractional dose (500 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 500IU/dose and administered once.
16388580|NCT04059471|Experimental|Fractional dose (250 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 250IU/dose and administered once.
16388581|NCT04059458|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
16388582|NCT04059458|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
16388583|NCT04059445|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
16388584|NCT04059445|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
16388621|NCT04059146|Active Comparator|Standard Education + Exercise|"The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage.
~All participants will receive the same progressive Achilles tendon loading exercise program."
16388585|NCT04059419|Experimental|Experimental|30 Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
16388586|NCT04059419|Active Comparator|Control|Should remain under geriatric care after randomization.
16388587|NCT04059406|Experimental|IONIS TMPRSS6-LRx|A single injection of IONIS TMPRSS6-LRx at multiple dose levels, administered subcutaneously every 4 weeks
16388590|NCT04059380||Patients with Hypoparathyroidism|Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
16388591|NCT04059380||Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
16388592|NCT04059367|Experimental|NNC9204-1177 and cocktail of approved drugs|
16388593|NCT04059354|Experimental|Speech therapy|Direct speech therapy will be provided for a 12 week period with up to three one-hour sessions per week.
16388594|NCT04059341|Experimental|Active LI-ESWT|Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.
16388595|NCT04059341|Sham Comparator|Sham|Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.
16388596|NCT04059328||Physicians in Haiti|7 OBGYN physicians underwent a laparoscopic training and simulation course and then were proctored as they performed 3 in vivo cases using a check list to help the participants remember all the steps of laparoscopic set-up.
16388597|NCT04059315||Retrospective cross sectional study|"This is an Epidemiological observational analytic study where the subjects sustained with oral and maxillofacial trauma will be divided into the two-time-frame;
~1st, retrospective study between 1 June 2011 to 31 May 2019"
16388598|NCT04059315||Prospective cohort study|2nd prospective study on 1 June 2019 to 1 June 2021.
16388599|NCT04059302|Experimental|Online CBT-I|Fully-automated, internet-delivered cognitive behavioral therapy for insomnia program that consists of 6 therapy cores delivered weekly over 6 weeks.
16388600|NCT04059302|No Intervention|Wait-List Control|Wait-list control group will receive no intervention until after the trial period is completed. During the trial period they will complete all study assessments, but receive no active treatment.
16388601|NCT04059289||Intraocular lens type I|Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
16388602|NCT04059289||Intraocular lens type II|Clareon IOL (Alcon Pharma. Freiburg/FRG)
16388603|NCT04059276||Patients with stroke|
16388604|NCT04059276||Healthy subjects|
16388605|NCT04059250|Experimental|Nobio flange|On the Nobio flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it the Nobio composite.
16388606|NCT04059250|Placebo Comparator|Traditional composite flange|On the traditional composite flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it a traditional composite.
16388607|NCT04059237|Experimental|Online Decision Aid|web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.
16388608|NCT04059224|Experimental|Arm A: advanced BRAF V600 wild-type/NRAS-mutant melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
16388609|NCT04059224|Experimental|Arm B: advanced BRAF V600 wild-type/NRAS wild-type melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
16388610|NCT04059198|Experimental|Arm 1 - Inarigivir Soproxil Daily|Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks
16388611|NCT04059198|Experimental|Arm 2 - Inarigivir Soproxil 3 Times Weekly|400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks
16388612|NCT04059198|Experimental|Arm 3 - Inarigivir Soproxil and TAF Daily|400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks
16388613|NCT04059185|Experimental|Program 1|Triple P-Level 2 (TPL2), parenting education and consultation
16388614|NCT04059185|Experimental|Program 2|Play Nicely (PN), multimedia, computer-based parenting education
16388615|NCT04059185|Placebo Comparator|Control|"Our usual care control group participants receive a resource and referral list for local social services"
16388616|NCT04059172|Active Comparator|Ibuprofen|one 200 mg tablet of ibuprofen and 2 placebo tablets
16388617|NCT04059172|Experimental|Ibuprofen and acetaminophen|one 200 mg table of ibuprofen and two 325 mg tablets of acetaminophen
16388618|NCT04059172|Placebo Comparator|Placebo|3 tablets of tableting compounds with no active ingredients
16388619|NCT04059159|Experimental|Connected Catheter Users|
16388620|NCT04059146|Experimental|Pain Education + Exercise|"The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain.
~All participants will receive the same progressive Achilles tendon loading exercise program."
16388622|NCT04059133|Experimental|LiESWT arm|"For SUI: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.
~For OAB: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°, and the applicator was gently placed on suprapubic skin area over the bladder dome and bilateral bladder walls with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually."
16388623|NCT04059133|Sham Comparator|Sham arm|"For SUI: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.
~For OAB: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). The applicator was gently placed on the suprapubic skin area over the bladder dome (1000 pulses) and bilateral bladder walls (each side 1000 pulses). The probe was placed on the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°."
16388624|NCT04059120|Experimental|Experimental group|The physical load will be organized as follows: The experimental group (EG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with specific stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
16388625|NCT04059120|Active Comparator|Control group|The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with single or general stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
16388626|NCT04059107|Experimental|Prosthetic Device|3D Printed Myoelectric Prosthetic Device
16388627|NCT04059094|Placebo Comparator|Placebo|2 puffs ofmatching placebowere inhaledorally via theRespimat®inhaler twice dailyfor a treatmentperiod of 4 weeksin patients withcystic fibrosis.
16388628|NCT04059094|Experimental|BI 1265162 50 μg b.i.d.|2 puffs of 25micrograms (μg)BI 1265162(Total: 50μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:100μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
16388629|NCT04059094|Experimental|BI 1265162 100 μg b.i.d.|2 puffs of 50micrograms (μg)BI 1265162(Total: 100μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:200μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
16388630|NCT04059094|Experimental|BI 1265162 200 μg b.i.d.|2 puffs of 100micrograms (μg)BI 1265162(Total: 200μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:400μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
16388631|NCT04059094|Experimental|BI 1265162 20 μg b.i.d.|2 puffs of 10micrograms (μg)BI 1265162(Total: 20μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:40μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
16388632|NCT04059081|Experimental|GC chemotherapy|"Before administration of GC chemotherapy, all patients must undergo pretreatment bone marrow biopsy. The pretreatment BM biopsy must include at least 1 long core biopsy samples and 10 cc of aspirate.
~Obinutuzumab 1000mg fixed dose will be administered intravenously (Day 1,8,15 for cycle 1 and D1 for subsequent cycles). Chlorambucil 0.5mg/kg will be administered orally (D1,15 for all cycles).
~28 days are considered as one cycle, and cycles will be repeated every 4-weeks for a total of 6 cycles."
16388633|NCT04059068||NASH (non-alcoholic steatohepatitis)|Patients diagnosed with non-alcoholic steatohepatitis.
16388634|NCT04059068||NAFLD (non-alcoholic fatty liver disease)|Patients diagnosed with non-alcoholic fatty liver disease.
16388635|NCT04059068||Control|Patients with normal liver tissue.
16388636|NCT04059068||obese / high WAT inflammation and fibrosis|Patients who are obese with inflammed white adipose tissue and evidence of fibrosis.
16388637|NCT04059068||obese / low WAT inflammation and fibrosis|Patients who are obese with no evidence of inflammed white adipose tissue and no evidence of fibrosis.
16388638|NCT04059068||non- obese controls|Patients who are not obese.
16388639|NCT04059042|Experimental|Music|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music.
~The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (~60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level."
16388640|NCT04059042|Placebo Comparator|Nature Sounds|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds.
~Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level."
16388641|NCT04059029||Morbidly obese patients with NAFLD|Morbidly obese patient with Nonalcoholic fatty liver disease. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance. The diagnosis of NASH would be made histologically.
16388642|NCT04059003||Sensitivity group|100 patients will be assigned into sensitivity group according to the actual situation of them.
16388644|NCT04058990|Experimental|Agent Paclitaxel-Coated PTCA Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (Agent Paclitaxel-Coated PTCA Balloon Catheter with paclitaxel 2.0 μg/mm²)
16388645|NCT04058990|Active Comparator|SeQuent Please Drug Eluting Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (SeQuent Please Drug Eluting Balloon Catheter with paclitaxel 3.0 μg/mm²)
16388646|NCT04058977|Experimental|Power training|Randomized to early power training with standardized exercise progression plus standard of care
16388647|NCT04058977|No Intervention|Standard of Care|Standard of care
16388648|NCT04058964|Experimental|Treatment (pembrolizumab, PEGPH20)|Patients receive pembrolizumab IV over 10 minutes on day 1 and pegylated recombinant human hyaluronidase PH20 SC on days 1, 8, and 15. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16388649|NCT04058951|Placebo Comparator|High Animal Protein Diet (HAPD)|Consuming a diet high in protein primarily from animal origin.
16388650|NCT04058951|Experimental|High Plant Protein Diet (HPPD)|Consuming a diet high in protein exclusive from plant origin.
16388651|NCT04058938|Active Comparator|Control|The control group received standard of care, including standard patient counseling from the surgical teams.
16388652|NCT04058938|Experimental|Intervention|In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.
16388653|NCT04058912||PATİENCE GROUP|"To be in the range of 18-40 years
~Patients with an operation indication with >=5 cm endometrioma
~Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)
~Patients who will be followed for IVF cycle due to infertility"
16388654|NCT04058912||PATİENCE-CONTROL GROUP|"To be in the range of 18-40 years
~Patients with operation plan due to non-endometrioma ovarian pathologies
~Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)
~Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic"
16388655|NCT04058899|Active Comparator|, Dexmedetomidine group(DEX group)|dexmedetomidine group (DEX)group who will receive 0.5 µg/kg dexmedetomidine diluted in 50 ml of normal saline 0.9% to be given by IV infusion over 10 minutes after induction of anesthesa then 5ml of 0.9% normal saline IV ,
16388656|NCT04058899|Active Comparator|Nalbuphine group(NAL group)|nalbuphine group (NAL)group will receive IV infusion of 50 ml of 0,9%normal saline by IV infusion over 10 minutes then 0.1mg/kg nalbuphine diluted in 5ml of 0.9%normal saline IV after induction of anesthesia.
16388657|NCT04058886|Experimental|Telephone-delivered Mindfulness|Participating caregivers and care partners will receive mindfulness training in 8 weekly telephone sessions plus one 3.5-hour retreat. Respite care for the care recipient is provided for the retreat.
16388658|NCT04058860|Other|Study Patients|Patients undergoing open heart surgery with minimal invasive extracorporeal circulation (MiECC) according to accepted indications
16388659|NCT04058847|Experimental|Intervention|Use of Your Heart Forecast and an e-mail follow up-program.
16388660|NCT04058847|No Intervention|Control|The control group uses standard regime (business as usual).
16388661|NCT04058834|Experimental|NNC0385-0434|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo. Following safety observation, patients with hypercholesterolaemia will enter a fourth cohort. There will be 15 participants in this cohort.
16388662|NCT04058834|Placebo Comparator|Placebo (NNC0385-0434)|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo.
16388663|NCT04058821|Experimental|Adults with traumatic brachial plexus injuries|Participants will have two MRI scans before surgery (to find out the best time to scan), then two after surgery (at 6 and 12 months).
16388664|NCT04058808|Experimental|Participants with Atrial Fibrillation attending the clinic.|
16388665|NCT04058795|Experimental|Cancer Distress Coach (CaDC)|Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.
16388666|NCT04058795|Experimental|CaDC and mCoaching|Participants in this group will get both the CaDC app and weekly clinician support.
16388667|NCT04058795|Experimental|mCBT|Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).
16388668|NCT04058795|No Intervention|Control|Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.
16388669|NCT04058782||Patients with myocardial|
16388670|NCT04058769|Other|Software first|Patients that are pre-operatively assessed first software-guided and then traditional
16388671|NCT04058769|Other|Traditional|Patients that are first pre-operatively assessed in the traditional way and then with aid of the software
16388673|NCT04058743|Active Comparator|TKA with standard cobalt chromium components|Patients randomized to this group will receive the standard cobalt chromium components in their total knee arthroplasty
16388674|NCT04058743|Experimental|TKA with nickel free components|Patients randomized to this group will receive nickel free components in their total knee arthroplasty
16388675|NCT04058730|Experimental|LRYGBP|"Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.
~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge."
16388676|NCT04058730|Experimental|LSG|Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge
16388677|NCT04058730|Experimental|SMM|"Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.
~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult"
16388678|NCT04058717|Experimental|NNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
16388679|NCT04058717|Experimental|NNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.
16388680|NCT04058717|Experimental|VLNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
16388681|NCT04058717|Experimental|VLNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid
16388682|NCT04058704|Experimental|Early intervention|Icotinib is administered orally three times per day. Radiation therapy (SRS/ WBRT/ HA-WBRT/SMART) start in 1 month since take icotinib orally.
16388683|NCT04058704|Experimental|Late intervention|Icotinib is administered orally three times per day. Until emerge the progression of the disease, then is given radiation therapy (SRS/WBRT/HA-WBRT/SMART)
16388684|NCT04058678|Sham Comparator|CONTROL|"A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term normal ovarian reserve referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve."
16388685|NCT04058678|Experimental|EXPERIMENTAL|A group of women with diminished ovarian reserve that will take an inactive substance has been included to avoik biases and to set the fertility base line for women with compromised ovarian reserve.
16388686|NCT04058665||Observational group|No intervention performed. This is the overall group that will be retrospectively assessed for different variables pertaining to blood loss.
16388688|NCT04058639|Experimental|felt relief|"custom felt relief"
16388689|NCT04058639|Active Comparator|treatment as usual|standard treatment usually provided by the Surgical Outpatient Clinic
16388690|NCT04058613|Experimental|Albumin|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
16388691|NCT04058613|Placebo Comparator|Placebo|Placebo
16388692|NCT04058600|Experimental|Virtual Reality|The patients will be exposed to a virtual reality software that simulates the environment of the hospital, from admission to the operating room and the recovery room.
16388693|NCT04058600|No Intervention|Control|Patients in this group are not exposed preoperatively to the virtual reality software and are given the standard therapy and cares for their disease.
16388694|NCT04058587|Experimental|Simmitinib tablet|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.
~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.
~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
16388695|NCT04058574|Active Comparator|ACL|"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction"
16388696|NCT04058574|Placebo Comparator|Control|Control Group: 15 healthy volunteers, athletes.
16388697|NCT04058561|Experimental|6 weeks|6-week lengthening interval
16388698|NCT04058561|Active Comparator|16 weeks|16-week lengthening interval
16388699|NCT04058548|Experimental|6MWT and STS|All participates will receive 6MWT and STS test
16388700|NCT04058535|Experimental|ALT-L9|Intravitreal injection of ALT-L9 50 ul, every 4 weeks
16388701|NCT04058535|Active Comparator|Eylea|Intravitreal injection of Eylea 50 ul, every 4 weeks
16388702|NCT04058522|Experimental|Group Physiotherapy|1 class per week for 6 weeks (30 min length) aiming for 5-10 participants per class. Classes included advice on the nature of the condition and exercises for scapulo-humeral mobility, scapulo-humeral stability and specific rotator cuff rehabilitation exercises
16388703|NCT04058522|Active Comparator|Routine Physiotherapy|Individual physiotherapy sessions: 6 sessions weekly (30 min) for 6 weeks. Treatment was based on evidence-based guidelines for the treatment of shoulder impingement (CSP 2005) and consisted of mobilisation techniques, supervised exercises and stretches.
16388704|NCT04058509|Experimental|focused shockwave therapy|3 sessions of shock wave treatment.(Focused Shockwave Therapy).
16388705|NCT04058496||1|Coronary artery bypass surgery off-pump (n=20)
16388706|NCT04058496||2|Coronary artery bypass surgery on-pump (n=20)
16388707|NCT04058496||3|Coronary artery bypass surgery plus valve surgery (n=20)
16388995|NCT04056377||White girls|224 white girls were included in the study (mean age 7.4 years)
16388708|NCT04058483|Active Comparator|HIP First|Participants randomized to perform the in-person hypnotizability test first. This will be followed within 1 week with the by-phone rHIP test performed by a second, randomly-assigned investigator.
16388709|NCT04058483|Active Comparator|rHIP First|Participants randomized to perform the by-phone hypnotizability test first. This will be followed within 1 week with the in-peron HIP test performed by a second, randomly-assigned investigator.
16388710|NCT04058470|Experimental|TR-CHOP|TR-CHOP: Toripalimab,Rituximab,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone
16388711|NCT04058457||STN DBS|Patients planned to undergo deep brain stimulation of the subthalamic nucleus
16388712|NCT04058457||GPi DBS|Patients planned to undergo deep brain stimulation of the globus pallidus interna
16388713|NCT04058457||VIM DBS|Patients planned to undergo deep brain stimulation of the ventral intermediate nucleus of thalamus.
16388714|NCT04058444|Experimental|ERAS Group|Perioperative management follows the ERAS (Enhanced Recovery After Surgery) protocol
16388715|NCT04058444|Experimental|Control Group|Perioperative management follows the conventional program
16388716|NCT04058431|Experimental|Osteopathic group|Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
16388717|NCT04058418||Familial breast cancer risk assessment services in England|All familial breast cancer risk assessment services in England
16388718|NCT04058392|Experimental|Camu Camu|Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
16388719|NCT04058379|Experimental|CT scan|During this study each patient will have 3 CT scans : D0, D1 and D3. A daily follow up during first seven days in ICU, then a follow up at D28 if still in hospital, and a phone call at M6 for neurological outcome
16388720|NCT04058366|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
16388721|NCT04058353|Active Comparator|Control: IVA or TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
16388722|NCT04058353|Experimental|TC: ELX/TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.
16388723|NCT04058340|Active Comparator|lactizole-placebo|A group of patients who will receive 3ml lactizole solution (150ppm) in nebulization twice a day for 4 weeks , and then for the next 4 weeks they will receive 2 times a day 3ml 0.9% NaCl solution in nebulization
16388724|NCT04058340|Active Comparator|placebo-lactizole|A group of patients who will receive 2 times a day for 4 weeks (0.9% NaCl solution in nebulization) for 4 weeks and will receive 3ml of lactizole solution (150ppm) in nebulization 2 times a day for 4 weeks
16388725|NCT04058327||MHE group|Patients whose MHE test are positive
16388726|NCT04058327||no HE group|Patients whose MHE test are negative
16388727|NCT04058327||overt HE group|2/3/4 HE patients
16388728|NCT04058314|Experimental|Study Eye|Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
16388729|NCT04058314|Active Comparator|Control Eye|control eyes will received an approved monofocal or toric IOL after cataract extraction
16388730|NCT04058301|No Intervention|Handout|Participants receive a generic handout about resources in Boston
16388731|NCT04058301|Experimental|Text message|Participants receive a generic handout about resources in Boston and a text message with a geographically proximate resource
16388732|NCT04058288||Stroke|People suffering from upper-limb motor dysfunction due to stroke
16388733|NCT04058275||Control|Deployed to 1990-1991 Persian Gulf War Do not meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] Good general medical and psychiatric health
16388734|NCT04058275||Gulf War Illness|Deployed to 1990-1991 Persian Gulf War Meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] plus Center for Disease Control criteria for Chronic Multisymptom Illness (CMI) [Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, Noah DL, Barrett DH, Randall B, Herwaldt BL, Mawle AC, Reeves WC. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998 Sep 16;280(11):981-8. PubMed PMID: 9749480.]
16388735|NCT04058262|Experimental|Meditation presential|
16388736|NCT04058262|Experimental|Reiki|
16388737|NCT04058262|Experimental|Meditation (app)|
16388738|NCT04058262|Placebo Comparator|round of conversation|
16388739|NCT04058249|Experimental|Right DLPFC aiTBS stimulation|
16388740|NCT04058236|Experimental|human albumin 5%|10 patients with pancreatic cancer will receive human albumin 5% in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
16388741|NCT04058236|Active Comparator|gelofusine|10 patients with pancreatic cancer will receive gelofusine in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
16388742|NCT04058223||PPH/DST|Patients underwent hemorrhoidopexy by PPH or DST stapler.
16388743|NCT04058197|Experimental|Active|Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks
16388744|NCT04058197|Placebo Comparator|Placebo|Placebo
16388745|NCT04058184||Contact sports players|Athletes who engage in contact sports, football for example. Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
16406118|NCT03936023||Saxagliptin|Exposure Group
16388746|NCT04058184||Non-contact sports players|Athletes who engage in non-contact sports, swimming for example.Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
16388747|NCT04058171||LSS group|Participants with a diagnosis of lumbar spinal stenosis
16388748|NCT04058171||PAD group|Participants with a diagnosis of peripheral artery disease
16388749|NCT04058171||LBP group|Participants with a diagnosis of non specific low back pain
16388752|NCT04058145|Experimental|Pembrolizumab+AMD3100 q3w|"Pembrolizumab is administered intravenously on day 1 of each cycle
~AMD3 100 is administered via injection subcutaneously on day 1 of each cycle"
16388753|NCT04058145|Experimental|Pembrolizumab+AMD3100 weekly|"Pembrolizumab is administered intravenously on day 1 of each cycle
~AMD3 100 is administered via injection subcutaneously on a weekly basis"
16388754|NCT04058145|Experimental|Pembrolizumab+AMD3100|"Pembrolizumab is administered intravenously
~AMD3 100 is administered via injection subcutaneously"
16388755|NCT04058132|Other|Group 1: acute/subacute Traumatic Brain Injury|Any gender, age 18-55 years who have had a traumatic brain injury within 30 days
16388756|NCT04058132|Other|Group 2: Non-TBI healthy control (HC)|Any gender, age 18-55 years with no history of traumatic brain injury
16388757|NCT04058119|Experimental|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates)
16388758|NCT04058119|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the Functional Training Program after the experimental period (6 months).
16388759|NCT04058106||A patient who need the spine surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for spine surgery
16388760|NCT04058093|Experimental|Functional Training Program|"Functional training program (FTP) will last for 6 months and will include:
~Functional training sessions (each 45-minutes long, twice a week);
~Group nutrition counseling (each 90-minutes long, in three different moments throughout the intervention: week 1, 12 and 20)."
16388761|NCT04058093|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the FTP after the experimental period (6 months).
16388762|NCT04058080|Experimental|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6 degrees Celsius, 40% humidity). The class opened with a deep breathing exercise and continued with 50 minutes of standing asanas and 40 minutes of floor-based asanas, including a quick, forceful breathing exercise to finish. All but the last asana (i.e., spine-twisting) were performed twice. Savasana, which is a restorative and relaxation posture, was performed between asanas throughout the floor series and at the end of class. The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
16388763|NCT04058080|Active Comparator|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Selecting these classes was done in consultation with the general manager of the YMCA, who was familiar with each class type. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration.
16388764|NCT04058080|No Intervention|Waitlist|Waitlisted individuals were not able to access yoga or exercise classes throughout the intervention period but participated in the rest of the study protocol. Following the post-treatment assessment, they received access to the class type of their choosing.
16388765|NCT04058067|Experimental|Brolucizumab 6 mg|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
16388766|NCT04058067|Active Comparator|Aflibercept 2 mg|5 x every 4 weeks loading then every 8 weeks maintenance
16388767|NCT04058054|Experimental|KeraStat® Cream|KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
16388768|NCT04058054|Experimental|KeraStat® Gel|KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
16388769|NCT04058054|Experimental|Biafine|Wound dressing for management of partial and full thickness wounds.
16388770|NCT04058054|Active Comparator|Histamine|Histamine is provided as a solution of histamine base (6.0 mg/mL).
16388771|NCT04058054|Sham Comparator|Saline|Saline (sterile) is provided as a 0.9% NaCl solution.
16388772|NCT04058041|Experimental|Neural mobilization|passive mobilization of the median nerve by the therapist following by an active movement of the fingers of the pathology hand
16388773|NCT04058041|Active Comparator|Surgery|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will teach home exercises (no neural exercises) to the patients.
16388774|NCT04058041|Active Comparator|Surgery and Neural mobilization|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will perform mobilizations of the median nerve just like the experimental group.
16388775|NCT04058028|Experimental|Rozibafusp Alfa, Dose A|Investigational product solution in vial
16388776|NCT04058028|Experimental|Rozibafusp Alfa, Dose B|Investigational product solution in vial
16388777|NCT04058028|Experimental|Rozibafusp Alfa, Dose C|Investigational product solution in vial
16388778|NCT04058028|Placebo Comparator|Placebo for Rozibafusp Alfa|Placebo Investigational product solution in vial
16406119|NCT03936010||DPP4i|Reference group
16388780|NCT04058002|Experimental|Experimental|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
16388781|NCT04058002|Active Comparator|Control group|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
16388782|NCT04057989||Battlefield Injury with ketamine treatment|Patients who received ketamine infusions to treat pain from January 2007 to December 2013.
16388783|NCT04057976|Experimental|Patients having pre-operative DTT prior to surgery|All patients in this study will undergo DTT as part of a pre-operative MRI.
16388784|NCT04057963|Experimental|Conventional plus Functional Inspiratory Muscle Training Group|Conventional program plus functional inspiratory muscle training will be carried out three sessions per week during the six weeks. The content of the program will be the same as for the conventional group. Additional functional inspiratory muscle training will be began with 50% of the maximal inspiratory pressure value in a specific device and it will be progressed 5% every week according to the tolerance.
16388785|NCT04057963|Active Comparator|Conventional Physiotherapy Program|Conventional program will be carried out three sessions per week during the six weeks. Cervical mobilization techniques (glidings-grade 2) of cyriax will be applied in the direction of lateral flexion and rotation. Stretching exercises, craniovertebral flexion exercise and scapulothoracic strengthening exercises will be performed.
16388786|NCT04057950|Active Comparator|treating shampoo|treating shampoo (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo) 1144628 D cosmetic product
16388787|NCT04057950|Placebo Comparator|vehicle|1144781 cosmetic product
16388788|NCT04057937|Experimental|30 mg Apremilast twice daily (BID) from week 0 to 32|Subject will received Apremilast 30 mg BID from Week 0 to Week 32 weeks. Dose titration will be implemented in the first week of this study.
16388789|NCT04057937|Placebo Comparator|Placebo and Apremilast|Subject will receive Placebo BID from Week 0 to Week 16 and will receive 30 mg Apremilast BID from week 16 to 32. Dose titration will be implemented in the first week of subject switch to receive Apremilast.
16388790|NCT04057924||CIN 2 women|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
16388791|NCT04057911|Experimental|Real NIBS|In Real NIBS arm, active Noninvasive brain stimulation (NIBS) will be given for 20 mins.
16388792|NCT04057911|Sham Comparator|Sham NIBS|In Sham NIBS arm, sham Noninvasive brain stimulation (NIBS) will be given for 20 mins.
16388793|NCT04057898|Experimental|MN-166|Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day for 12 months.
16388794|NCT04057898|Placebo Comparator|placebo|Subjects will take up to 5 matching placebo capsules twice a day for 12 months.
16388795|NCT04057885|Experimental|Device Arm|A prospective series of 10 patients will receive sensor-guided TKA using the this special Orthosensor™ VERASENSE™ Knee System assisted surgery for optimization of soft tissue balance
16388796|NCT04057885|Active Comparator|Standard of Care|10 patients will receive standard of care. Prior to cementing final implants, VERASENSE will be utilized with the standard of care group with the surgeon blinded to the data.
16388797|NCT04057872|Active Comparator|TPE in Septic Shock|The patients in this arm will receive TPE
16388798|NCT04057872|No Intervention|Reference Population|The patients will receive the standard of care for septic shock treatment
16388799|NCT04057846|Active Comparator|Double pigtail|Plastic stent group EUS-guided drainage shall be performed as follows: a) Puncture of WON with a 19 GA Access needle (Cook Medical), b) aspiration of fluid in WON for microbiological assessment, c) insertion of guidewire (0.035 inch, 450 cm, Dreamwire (Boston Scientific), d) creation of transmural tract with needle knife over the guidewire, e) dilatation of tract to a diameter of 15 mm with dilation balloon (EZDilate, Olympus), f) insertion of two 7-Fr/6 cm double pigtail stents and a 7-Fr naso-cystic irrigation catheter.
16388800|NCT04057846|Experimental|Lumen apposing metal stent|LAMS shall be the Hot AXIOS stent with electrocautery-enhanced delivery system (Boston Scientific). The stent is a through-the-scope, fully covered, self-expandable metal stents with a diameter of 20 mm and a length of 10 mm. Before placement of the LAMS, the WON shall be punctured with a 19 GA Access needle (Cook Medical) and fluid in WON aspirated for microbiological assessment. Thereafter the LAMS shall be placed as follows: After directly puncturing the WON using the electrocautery tip (without the use of a guidewire to assist in stent insertion), the delivery catheter is advanced into the WON and the distal flange is deployed under EUS-guidance. The proximal flange is then released under EUS guidance or endoscopic view. After placement of the LAMS, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS.
16388801|NCT04057833|Experimental|E-CEL UVEC|"Patients will receive an injection of the Cell therapy vehicle into their supraspinatus muscle and tendon at the time of rotator cuff repair.
~E-CEL UVEC cells suspended in autologous plasma and combined with thrombin at the implantation site (tendon delivery).
~E-CEL UVEC cells suspended in 6.0% Dextran 40 and 10.0% human serum albumin (HSA) (infusion solution) (muscle delivery)."
16388802|NCT04057820|Active Comparator|Usual care, Finnegan Neonatal Abstinence Scoring Tool|Usual institutional care for infants with NOWS with the Finnegan Neonatal Abstinence Scoring Tool (FNAST)
16388803|NCT04057820|Active Comparator|Eat, Sleep, Console care tool|New treatment implemented at the site for infants with NOWS using the Eat, Sleep, Console (ESC) care tool
16388804|NCT04057807|Experimental|Patients receiving endotoxin|The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
16388805|NCT04057807|No Intervention|control|
16388806|NCT04057794|Active Comparator|Site-Based Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
16388807|NCT04057794|Active Comparator|Centralized Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.
16388808|NCT04057781|No Intervention|Control|
16388809|NCT04057781|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment every 2 weeks for 6 weeks (weeks 0, 2, 4, 6).
~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
16388842|NCT04057534|Experimental|CB-CRT TUD group|experimental group TUD: patients receive standard smoking cessation therapy and an add-on CB-CRT
16406120|NCT03936010||Canagliflozin|Exposure group
16388810|NCT04057781|Active Comparator|Dry Needling with Intramuscular ES (DNES)|"Subjects will receive dry needling treatment with electrical stimulation every 2 weeks for 6 weeks (week 0, 2, 4, 6)
~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
16388811|NCT04057768|Other|Intervention|Device: Venus Viva
16388812|NCT04057755|Experimental|Botulinum toxin A vs placebo|50 Allergan units (diluted in 0,5 ml sterile NaCl) or 0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
16388813|NCT04057755|Active Comparator|Botulinum toxin A|50 Allergan units (diluted in 0,5 ml sterile NaCl) will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
16388814|NCT04057755|Placebo Comparator|NaCl|0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance and volume will be repeated after 3 months.
16388815|NCT04057742||Group A|30 participants with a positive virtual crossmatch (VXM) at the time of transplant will be monitored for 24 months and undergo protocol biopsies on months 3, 12, and 24 to detect subclinical rejection. Participants may also undergo clinically indicated biopsies for suspicion of rejection. AlloSure, AlloMap, immune cell phenotypes, and inflammatory cytokines will be measured at baseline (within 48 hours of transplant), 3 weeks, 6 weeks, 3 months (Standard of Care (SOC) biopsy), 6 months, 12 months (SOC biopsy), 24 months (SOC biopsy) and additionally at the time of any indication biopsy (5-8 time points/participant). Participants in this group will be monitored for 24 months per SOC. Paticipants will be offered the option of donating either 22.5 mL of blood (Allosure+AlloMap+cytokines) or 52.5 mL of blood (Allosure+AlloMap+cytokines+immune cell phenotyping) at each visit. Participants may change their donation volume from 22.5 mL to 52.5 mL at any point during the study.
16388816|NCT04057742||Group B|35 participants with De novo donor specific antibodies (dnDSA) will undergo a SOC biopsy within approximately three months to determine the incidence of Active Antibody Mediated Rejection (AMR). Immune cell phenotyping, AlloSure, and AlloMap will be measured at the time of the SOC biopsy (1 timepoint/patient). This is a single-time point study, unless participants are diagnosed with AMR and require treatment. In this case, they would be enrolled in group C (see below).
16388817|NCT04057742||Group C|35 additional participants with the diagnosis of Chronic Active Antibody Mediated Rejection (cAMR) will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months. Immune cell phenotyping, AlloSure, and AlloMap will be used at baseline (prior to index biopsy) and 3 month (follow-up surveillance biopsy) (2 timepoints/participant). Participants in this group will be monitored per SOC for three months (time between the two biopsies).
16388818|NCT04057729|Experimental|Arm 1 （IMP4297 100mg, Fasted-Fed）|Period 1: Fasted control → Period 2: Fed control
16388819|NCT04057729|Experimental|Arm 2（IMP4297 100mg, Fed- Fasted）|Period 1: Fed control → Period 2: Fasted control
16388820|NCT04057716|Experimental|Sleep restriction followed by extension|Children will spend 1.5 hours less than usual in bed for one week, engage in one week of wash-out, and then spend 1.5 hours more than usual in bed for one week.
16388821|NCT04057716|Experimental|Sleep extension followed by restriction|Children will spend 1.5 hours more than usual in bed for one week, engage in one week of wash-out, and then spend 1.5 hours less than usual in bed for one week.
16388822|NCT04057690||MCA ischemia without malignant edema|MCA ischemia without malignant edema
16388823|NCT04057690||MCA ischemia with malignant edema|MCA ischemia without malignant edema w/o surgical treatment
16388824|NCT04057677|Experimental|Exercise Recovery|Older males and females with Type 2 diabetes. We are examining the effects of a recovery exercise program for older adults with type 2 diabetes. Following 10 days of bed rest and during the first 4 weeks of recovery, participants will perform a combination of aerobic and resistance exercise training.
16388825|NCT04057677|Experimental|Non-Exercise Recovery|Older males and females with Type 2 diabetes. Participants in the ambulatory recovery group will not receive any exercise intervention or advice on exercise following 10 days of bed rest. Rather these participants will return to their regular daily routine that they engaged in prior to the bed rest intervention.
16388826|NCT04057664||Multidisciplinary Group Therapy|Multidisciplinary group therapy for women with chronic pelvic or belly pain
16388827|NCT04057651||Hip osteoarthritis waiting for surgery|
16388828|NCT04057651||Knee osteoarthritis waiting for surgery|
16388829|NCT04057638|Experimental|Treatment group|There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
16388830|NCT04057625|Other|lung ultrasound|using lung ultrasound in diagnosis and follow up of vap measuring the largest area of consolidation according to intercostal space and the direction of the probe
16388831|NCT04057612||Pediatric participants|"Participants' temperature measured at 2 places at the same time
~Esophagus
~Skin near to carotid artery"
16388832|NCT04057586|Experimental|Nonintubated|Nonintubated thoracoscopic surgery
16388833|NCT04057586|Active Comparator|Intubated|Intubated thoracoscopic surgery
16388834|NCT04057573|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
16388835|NCT04057573|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
16388836|NCT04057560||SIBO Group|
16388837|NCT04057560||Control Group|
16388838|NCT04057547|Experimental|Experimental group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
16388839|NCT04057547|Active Comparator|Control group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
16388840|NCT04057534|Experimental|CB-CRT AUD group|experimental group AUD: patients receive standard clinical therapy and an add-on chess based - cognitive remediation treatment (CB-CRT)
16388841|NCT04057534|Active Comparator|Control group AUD|control group: patients with AUD receive standard clinical therapy
16388992|NCT04056377||Black boys|240 black boys were included in the study (mean age 7.5 years)
16388843|NCT04057534|Active Comparator|Control group TUD|control group: patients with TUD receive standard smoking cessation therapy
16388844|NCT04057521|Experimental|CHECK Program|Participants were offered enrollment into CHECK care coordination services.
16388845|NCT04057521|Active Comparator|Comparison Group|Participants were not offered enrollment into CHECK.
16388846|NCT04057508|Active Comparator|Stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order .
16388847|NCT04057508|Sham Comparator|Sham stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order.
16388848|NCT04057495|Placebo Comparator|no mango intake|No mango consumption on the study visit
16388849|NCT04057495|Experimental|white bread with same amount of calorie as mango|White bread consumption on the study visit
16388850|NCT04057495|Experimental|mango consumption|mango consumption on the study visit
16388851|NCT04057469|Experimental|Tulobuterol patch|
16388852|NCT04057469|Placebo Comparator|Placebo|
16388853|NCT04057456|Placebo Comparator|Placebo diet and placebo capsules|Participants taking the placebo diet and capsules
16388854|NCT04057456|Active Comparator|Placebo diet and Nabilone capsules|Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.
16388855|NCT04057456|Active Comparator|Anti-inflammatory diet and placebo capsules|This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc).
16388856|NCT04057456|Active Comparator|Anti-inflammatory diet and Nabilone capsules|"Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.
~This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc)."
16388857|NCT04057443|Experimental|Intervention group|Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.
16388858|NCT04057443|Active Comparator|Control group|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
16388859|NCT04057430|Active Comparator|String floss|
16388860|NCT04057430|Experimental|Gumchucks floss|
16388861|NCT04057417|Experimental|Urban Trail Expansion|Neighbourhoods within 400m to 800m of a neely built greenway, defined as a multi-use concrete/asphalt trail that was >4km in length)
16388862|NCT04057417|No Intervention|Control|Neighbourhoods that are located beyond 400 to 800m of a newly built greenway
16388863|NCT04057391||QT Scanner in comparison to mammography|Women who have experience with both technologies (QT Scanner/Breast mammography
16388864|NCT04057378|Active Comparator|0.5 ms pulse width stimulus|Electroconvulsive therapy initiated with 0.5 ms pulse width stimulus
16388865|NCT04057378|Active Comparator|1.0 ms pulse width stimulus|Electroconvulsive therapy initiated with 1.0 ms pulse width stimulus
16388866|NCT04057365|Experimental|DKN 01 and Nivolumab Safety Run in|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle
~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
16388867|NCT04057365|Experimental|DKN 01 and Nivolumab|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle
~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
16388868|NCT04057352|Other|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
16388869|NCT04057339|Placebo Comparator|SOC (Standard of Care)|Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
16388870|NCT04057339|Experimental|TRE + SOC|Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
16388871|NCT04057326|Active Comparator|Oryz-Aspergillus Enzyme and Pancreatin Tablet Arm|Oryz-Aspergillus Enzyme and Pancreatin Tablet ,2 tablets/time, 3 times daily. Study drug will be administered orally.
16388872|NCT04057326|Placebo Comparator|Placebo Arm|Placebo,2 tablets/time, 3 timesdaily. Study drug will be administered orally.
16388873|NCT04057313|Active Comparator|Group 1|Group 1 will receive 80 cc of coffee in the dialysis session
16388874|NCT04057313|Placebo Comparator|Group 2|Group 2 will receive 80 cc of decaffeinated coffee in the dialysis session
16388875|NCT04057300|Experimental|Ticagrelor 90mg|Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
16388876|NCT04057300|Active Comparator|Clopidogrel 75mg|Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
16388877|NCT04057287||NASH related Cirrhosis|
16388878|NCT04057287||Healthy Controls|
16388879|NCT04057287||First Degree Relatives of NASH related Cirrhosis|
16388880|NCT04057287||HBV Disease Control|
16388881|NCT04057274|Experimental|Exercise assessment|The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
16388993|NCT04056377||Black girls|339 black girls were included in the study (mean age 7.5 years)
16388882|NCT04057274|No Intervention|Resting assessment|The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
16388883|NCT04057261|Active Comparator|Liraglutide|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen.
16388884|NCT04057261|Placebo Comparator|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
16388885|NCT04057248|Experimental|Digital platform and CDE coaching intervention for patients with type 2 Diabetes|"Patients provided with digital platform and connected devices. They undergo digital and human (CDE) intervention based on patient captured clinical data.
~Clinical parameters (HbA1C, weight, lipids profile, etc.) before and after intervention is assessed."
16388886|NCT04057222||Patients included|"Patient with multiple sclerosis and anorectal symptoms, with indication to realize a anorectal manometry, age > 18
~A first record of rectal sensory function will be at strong desire to void. A second record will be after void. Rectal sensory function records consist on an anorectal manometry with 3 measures of external anal sphincter resting pressure, 5 measures of RAIR, 1 measure of perception, constant sensation to need to defecate and maximum tolerable threshold volumes."
16388887|NCT04057209|Active Comparator|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|Transoral CO2-Laser Microsurgical Cordectomy defined by European Laryngological Society (Remacle M, Eckel HE, Antonelli A, et al. Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol. 2000;257(4):227-231.)
16388888|NCT04057209|Experimental|Arm B: Single Vocal Cord Irradiation (SVCI)|Single Vocal Cord Irradiation defined by Kwa et al. and Al-Mamgani et al. (Kwa SLS, Al-Mamgani A, Osman SOS, Gangsaas A, Levendag PC, Heijmen BJM. Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. Int J Radiat Oncol Biol Phys. 2015;93(1):190-195. Al-Mamgani A, Kwa SLS, Tans L, et al. Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results. Int J Radiat Oncol Biol Phys. 2015;93(2):337-343.)
16388889|NCT04057196|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 12 weeks.
16388890|NCT04057170|Experimental|mulligan method|Mulligan mobilization with mowement method every three days for six weeks
16388891|NCT04057170|Experimental|accelerated protocol|accelerated rehabilitation protocol every three days for six weeks
16388892|NCT04057144|Experimental|ACT with mindfulness|4-hour weekly session of acceptance and commitment therapy (ACT) with mindfulness exercises during 8 weeks in groups of 8
16388893|NCT04057144|Experimental|ACT without mindfulness|4-hour weekly acceptance and commitment therapy (ACT) without mindfulness exercises during 8 weeks in groups of 8
16388894|NCT04057144|Active Comparator|Education program|Self-management education program during 8 weeks in groups of 8.
16388895|NCT04057131||Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
16388896|NCT04057118|Experimental|SKI-O-703 100 mg|
16388897|NCT04057118|Experimental|SKI-O-703 200 mg|
16388898|NCT04057118|Experimental|SKI-O-703 400 mg|
16388899|NCT04057118|Placebo Comparator|Placebo|
16388900|NCT04057092|Experimental|Intervention group|Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total.
16388901|NCT04057079|Experimental|Anugel|"In this arm, after the surgery a hydrogel impregnated sponge will be placed in the rectum.
~The patient is evaluated after the operation and the following day when the sponge is removed.
~A hydrogel impregnated foam pad is applied on the surface of the wound the following 5 days.
~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5
~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
16388902|NCT04057079|Active Comparator|Sponge|"Currently used treatment method i.e. insertion of gelatine sponge in to the rectum post operation.
~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5
~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
16388903|NCT04057066|Experimental|Intervention|Participants receive physical activity counseling as well as an individualized exercise plan.
16388904|NCT04057053|Experimental|Netarsudil use|Patient eye undergoes cataract surgery + DWEK, immediately after surgery Netarsudil 0.02% ophthalmic 1 drop daily is used in the operative eye until corneal clearance is documented.
16388905|NCT04057053|Active Comparator|Standard of care + possible rescue drop|Patient eye undergoes cataract surgery + DWEK, no Netarsudil is used after surgery, if cornea is not cleared in time for first eye Netarsudil 0.02% ophthalmic 1 drop dailyadded daily as possible rescue drop and time to corneal clearance is documented
16388906|NCT04057040|Experimental|Dose finding PTG-300 (Part 1); PTG-300 (Part 2); Open label extension PTG-300 (Part 3)|
16388907|NCT04057040|Experimental|Dose finding PTG-300 (Part 1); Placebo (Part 2); Open label extension PTG-300 (Part 3)|
16388908|NCT04057027|Experimental|Delayed Cord Clamping for 30 seconds|Infants whose umbilical cord clamping will be delayed for 30 secs.
16388909|NCT04057027|Experimental|Delayed Cord Clamping for 60 seconds|Infants whose umbilical cord clamping will be delayed for 60 secs.
16388910|NCT04057027|Experimental|Umbilical Cord Milking|Infants whose umbilical cord will be clamped after milking from the distance of 20 cm from mother's side to the baby for 3-4 times.
16388911|NCT04057014|Active Comparator|Extraction Only|Immediate extraction of infected tooth without antibiotic prescription.
16388912|NCT04057014|Experimental|Average Dose Antibiotic|Average dose antibiotic therapy(25 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 10 days and receive tooth extraction on day 10 (25 patients). (*given the average weight of a 12 year old is 45 kilos, we do not expect that we will reach the maximum dose in this group)
16406781|NCT03931161|Placebo Comparator|Placebo|Matching Placebo.
16388913|NCT04057014|Experimental|High Dose Antibiotic|High dose antibiotic therapy (45 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 5 days and receive tooth extraction on day 10 (25 patients)
16388914|NCT04057001||Patients who received a HCV+ liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
16388915|NCT04057001||Patients who received a HCV- liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.
16388916|NCT04056988|Experimental|Acute spinal cord injury patients to undergo contrast-enhanced|"Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
~A hand-held intraoperative ultrasound probe will be used to collect sagittal images of the spinal cord centered above the spinal cord injury. A bolus IV injection of DEFINITY® contrast agent (1.5ml DEFINITY®/8.5ml saline) will be given. Continuous imaging will be obtained to record contrast inflow and washout."
16388917|NCT04056975|Experimental|single arm|A-319 dosage: 0.05, 0.15, 0.03, 0.06, 0.12, 0.18, 0.24 μg/kg
16388918|NCT04056962|Experimental|patients treated with Tacrolimus ointment|
16388919|NCT04056949|Other|IBI308 + Paclitaxel/Albumin-Bound Paclitaxel|IBI308 Combined with Albumin-Bound Paclitaxe
16388920|NCT04056936||Infants diagnosed with a tongue-tie and a frenotomy|If a tongue-tie is present at the routine newborn examination, the infant can be included in the study. If the infant also has breastfeeding problems and there is a decreased tongue mobility and poor sucking ability, the pediatrician may find indication for frenotomy. If the frenotomy is performed before discharge the infant is included in this group. All Mother-infant dyads will get breastfeeding support.
16388921|NCT04056936||Infants diagnosed with a tongue-tie and no frenotomy|The infants that are recruited to the tongue-tie cohort that do not receive treatment before discharge. The pediatrician evaluates that the tongue tie does not cause any functional problems and no treatment is performed before discharge. All Mother-infant dyads will get breastfeeding support.
16388922|NCT04056936||All infants born in Telemark and Vestfold Counties|All the infants born in the study period that will contribute to the prevalence study.
16388923|NCT04056923|Experimental|3D-printed template-guided(3D-G)|Intraoperative 3D-G methylene blue dye marking in the operating room
16388924|NCT04056923|Active Comparator|CT-guided(CT-G)|Preoperative localization is performed by CT-G indocyanine green marking in the radiology department
16388925|NCT04056910|Experimental|Concurrent dosing of ivosidenib and nivolumab|Ivosidenib will be administered concurrently with nivolumab on a Q28 day schedule.
16388926|NCT04056897|Experimental|BCD-132, 125 mg|72 patients
16388927|NCT04056897|Experimental|BCD-132, 500 mg|72 patients
16388928|NCT04056897|Active Comparator|Teriflunomide|72 patients
16388929|NCT04056897|Placebo Comparator|Placebo|54 patients
16388930|NCT04056884|Active Comparator|SIBS intervention|SIBS intervention is a 5-session group intervention for siblings and parents of children with chronic illness. Sessions 1-3 are delivered in one day, and sessions 4-5 are delivered in one day one week later.
16388931|NCT04056884|No Intervention|Waitlist|Waitlist is 12 week of no intervention/usual care
16388932|NCT04056871||Fried Frailty Phenotype|This group of patients will be assess by using 5 characteristics of Frailty which are weight loss, weakness, exhaustion, low activity and physical fitness of the patients. Patients classify as frail will have more than 3 criteria, intermediate or pre-frail will be 1 or 2 criteria present and robust will not have criteria.
16388933|NCT04056871||Groningen Frailty Index|GFI is a simple questionnaire consisting of 15 items which are classified into 8 groups, consistent of 4 domains of functioning. A score of 4 or more indicates a higher risk for frailty and possible delirium.
16388934|NCT04056845|Experimental|Knee brace group|Patients in this group will receive a valgus knee brace (Medex K39-OA Corrector), to be worn for at least four hours a day, during the study period, on top of the presrciption of physiotherapy and oral analgesic (diclofenac and panadol).
16388935|NCT04056845|Active Comparator|Control Group|Patients in this group will receive physiotherapy and oral analgesic (diclofenac and panadol).
16388936|NCT04056832|Experimental|Single Strip Pericardium|Aortic Valve Replacement using single strip of patient's autologous pericardium
16388937|NCT04056832|Active Comparator|Mechanical Prosthetic Valve|Aortic Valve Replacement using mechanical prosthetic valve
16388938|NCT04056819|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack.
16388939|NCT04056806|Experimental|Group A|receiving terlipressin 2mg bolus on enrollment followed by 1mg per 6 hours. Both Terlipressin infusion and Ceftriaxone continue till 48 hours after endoscopic therapy
16388940|NCT04056806|Active Comparator|Gruoup B|receiving terlipressin 2mg bolus instituted on enrollment followed by 1mg per 6 hours. Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval. Both Terlipressin infusion and Ceftriaxone continue till 5 days after endoscopic therapy.
16388941|NCT04056793|Experimental|Parturients in situation of dystocia|Positioning of the parturients in an optimized birthing position
16388942|NCT04056780||Septic group|The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.
16388943|NCT04056780||Aseptic group|The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.
16388944|NCT04056767||Imaginal PE|
16388945|NCT04056767||Writing PE|
16388946|NCT04056754|Experimental|Abiraterone acetate group|Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
16388947|NCT04056754|Placebo Comparator|Placebo group|Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
16388948|NCT04056741|Experimental|Surfactant administered via supraglottic administration device|Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.
16388949|NCT04056728|Experimental|Eupenta Inj.|
16388950|NCT04056715||HCM Group|Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.
16388951|NCT04056702||Prescribed triple combination|A group of 60 people with CF who are clinically prescribed elexacaftor-tezacaftor-ivacaftor and have chronic sinusitis
16406837|NCT03930810||FIC1-deficiency and Bsep-deficiency|
16388952|NCT04056702||Not eligible for modulators|A group of 10 patients with two class I/II mutations who are ineligible for elexacaftor-tezacaftor-ivacaftor based on their genotype and have chronic sinusitis.
16388953|NCT04056689|Experimental|DNL151 Low Dose|
16388954|NCT04056689|Experimental|DNL151 Mid Dose|
16388955|NCT04056689|Experimental|DNL151 High Dose|
16388956|NCT04056689|Placebo Comparator|Placebo|
16388957|NCT04056676|Active Comparator|Intraoperative modified PEC block only|Intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
16388958|NCT04056676|Experimental|Adding preoperative thoracic paravertebral nerve block|Preoperative thoracic paravertebral nerve block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug and intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
16388959|NCT04056663|Experimental|Health-Circuit mobile application|"The intervention contemplates. (i) management of unexpected events; and, (ii) empowering the patient to improve self-efficacy.
~Users of the intervention arm will have the Health-Circuit mobile application, which will offer them the possibility of contacting the case managers to notify a health event at any time and that this can be resolved by their health professionals through Health -Circuit. The improvement of the patient's self-efficacy for the management of their health problems through the use of Health-Circuit is considered through the virtual visits of follow-up with the manager, the possibility of interacting with the manager and the consultation of the shared documents reminders of the action plan agreed with the patient."
16388960|NCT04056663|No Intervention|Conventional treatment|Patients assigned to this group will follow conventional treatment. Once the three months have passed, we will contact you again to ask the pertinent questions.
16388961|NCT04056650|Active Comparator|Single caffeinated beverage/supplement|
16388962|NCT04056650|Active Comparator|Combination caffeine and L-theanine|
16388963|NCT04056637|No Intervention|Group 1: Standard of Care|Participants will be asked to complete follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider.
16388964|NCT04056637|Experimental|Group 2: Flexible Follow-Up|Participants will be offered three follow-up options, including: 1) follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider; 2) repeat serum beta-hCG testing; 3) repeat multi-level pregnancy test strategy
16388965|NCT04056624|Experimental|Low dose|1 x 6 ounces of carotenoid-containing juice (6 mg carotenoids/6 oz)
16388966|NCT04056624|Experimental|High dose|2 x 6 ounces of carotenoid-containing juice (12 mg carotenoids/12 oz)
16388967|NCT04056624|Placebo Comparator|Placebo|12 ounces of apple juice (negligible carotenoids 0.06 mg/12 oz)
16388970|NCT04056598||Moderate to severe acne vulgaris|Determined by the acne severity grade of IGA 2 and above
16388971|NCT04056598||Mild acne vulgaris|Determined by the severity grade of IGA <2
16388972|NCT04056585|Experimental|Brachial plexus block with intermittent pneumatic compression|Hand and forearm surgery is performed after axillary brachial plexus block with intermittent pneumatic compression for 3 minutes.
16388973|NCT04056585|Placebo Comparator|Brachial plexus block|Hand and forearm surgery is performed after axillary brachial plexus block only.
16388974|NCT04056572|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally, twice daily.
16388975|NCT04056559|Experimental|SIngle arm|The research is based on a population of men and women practicing a sport at risk of oral trauma.
16388976|NCT04056533|Experimental|CMV CTLs|1x10^5 CMV-CTLs/kg
16388978|NCT04056507||ITP group|On frozen spleens of already splenectomized adult ITP patients.
16388979|NCT04056507||Control group|On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident.
16388980|NCT04056468|Experimental|Moderate HI (Child-Pugh B): Mobocertinib 40 mg|Mobocertinib 40 milligram (mg), capsule, orally, a single dose on Day 1.
16388981|NCT04056468|Experimental|Severe HI (Child-Pugh C): Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
16388982|NCT04056468|Experimental|Normal Hepatic Function: Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
16388983|NCT04056455|Experimental|Severe Renal Impairment (RI): Mobocertinib 80 mg|Mobocertinib 80 milligram (mg), capsule, orally, a single dose on Day 1.
16388984|NCT04056455|Experimental|Normal Renal Function: Mobocertinib 80 mg|Mobocertinib 80 mg, capsule, orally, a single dose on Day 1.
16388985|NCT04056442|Experimental|Cannabidiol|300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
16388986|NCT04056442|Placebo Comparator|Placebo|Olive Oil Solution
16388987|NCT04056429|Experimental|BHA|Subjects treated with BHA + standard of care
16388988|NCT04056429|No Intervention|Control|Subjects treated as per standard of care
16388989|NCT04056416|Experimental|HIIT Exercise Program|Exercise on a MedBIKE 3 times a week for 8 weeks with pre- and post-CPET testing, questionnaires and qualitative interviews.
16388990|NCT04056390|Active Comparator|Substrate Modification|After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) < 0.5mV.
16388991|NCT04056390|Active Comparator|LAA Isolation|Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.
16388996|NCT04056364||Asthma|Asthma patients will be diagnosed according to a clinical history of wheezing, cough, chest tightness or shortness of breath, as well as the presence of BHR (cumulative dose caus¬ing a 20% decrease in FEV1), based on the GINA guidelines. None of them had a history of COPD, or previous doctor-diagnosed ACO. All subjects had not used any oral or/and inhaled corticosteroid (ICS) in the previous 12 weeks. The included patients with asthma had initial diagnosis and were under uncontrolled stage.
16388997|NCT04056364||COPD|COPD patients were diagnosed according to the GOLD criterion, which included a post-bronchodilator spirometry to confirm airflow obstruction (FEV1 to forced vital capacity ratio [FEV1/FVC] ,70%), in a clinical context (dyspnea, chronic cough or sputum production, and a history of expo¬sure to risk factors for the disease). They had received a COPD diagnosis at least 1 year before the study. None of them had a history of asthma. All subjects had not used any oral or/and ICS in the previous 4 weeks. The included COPD patients had exacerbations. The GOLD stage of COPD was defined according to the 2019 recommendations of GOLD.
16388998|NCT04056364||ACO|ACO will be diagnosed by two steps: the first step is the identification of a history of chronic airway disease, i.e., chronic or recurrent cough, sputum production, wheezing, or repeated acute lower respiratory tract infections. In the second step, the features of asthma and those of COPD that best describe the patients
16388999|NCT04056351|Other|Cohort of 50 enrolled patients|The following visits will be performed: direct post-OP, 3 weeks, 6 weeks, 3 months and 6 months after surgery. Surgical details will be assessed from the surgical notes. Medical images will be collected according to the standard of care. A post-OP CT scan will also be acquired when the treating surgeon requests it as per standard of care, or additionally, as a study specific imaging procedure for the rest of the participants. Patient activity will be estimated based on various factors, including questionnaires on demographics, activity level, comorbidity score and contralateral grip strength. The actual post-OP shoulder activity will be measured by motion tracking by means of sensors attached to upper arm of the treated side and on the chest for 6 weeks and by grip strength assessed at the treated arm at week 6. Fixation failure status will be determined 6 months post-OP. Imaging and details regarding the fixation failure event will be sent to ARI.
16389000|NCT04056338||Delirium|Patients with delirium as assessed by the bedside nurse using Confusion Assessment Method for the ICU.
16389001|NCT04056338||Non-delirium|Patients without delirium.
16389002|NCT04056325|Experimental|Phase 2a - Arm A|2 mg Moxidectin at day 0 administered orally
16389003|NCT04056325|Experimental|Phase 2a - Arm B|4 mg Moxidectin at day 0 administered orally
16389004|NCT04056325|Experimental|Phase 2a - Arm C|6 mg Moxidectin at day 0 administered orally
16389005|NCT04056325|Experimental|Phase 2a - Arm D|8 mg Moxidectin at day 0 administered orally
16389006|NCT04056325|Experimental|Phase 2a - Arm E|10 mg Moxidectin at day 0 administered orally
16389007|NCT04056325|Experimental|Phase 2a - Arm F|12 mg Moxidectin at day 0 administered orally
16389008|NCT04056325|Placebo Comparator|Phase 2a - Arm G|matching Placebo tablet(s) at day 0 administered orally
16389009|NCT04056325|Experimental|Phase 2b - Arm A|the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) at day 0 administered orally
16389010|NCT04056325|Active Comparator|Phase 2b - Arm B|200 µg/kg ivermectin at day 0 administered orally
16389011|NCT04056325|Placebo Comparator|Phase 2b - Arm P|matching Placebo tablet(s) at day 0 administered orally
16389012|NCT04056312|Experimental|Group memory retraining|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
16389013|NCT04056312|Placebo Comparator|Placebo|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
16389014|NCT04056299|Active Comparator|AR201 powder (Hen Egg Allergen formulation)|Subjects will be randomized to active arm of AIME01 and will be administered IP (AR201) in escalating doses for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
16389015|NCT04056299|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of AIME01 and will be administered escalating doses of IP (placebo) for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
16389016|NCT04056286|Experimental|Healthy + Whey|Healthy (overnight fast)
16389017|NCT04056286|Experimental|Catabolic + Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
16389018|NCT04056286|Experimental|Catabolic + 3-OHB / Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
16389021|NCT04056260|Experimental|ICG injection|ICG 0.5mg/ml x 0.5ml x 4 sites
16389027|NCT04056234||Rheumatoid arthritis group|Patients with rheumatoid arthritis
16389028|NCT04056234||Control group|Patients with osteoarthritis / joint effusion.
16389029|NCT04056221|Experimental|acupuncture|Acupuncture at the selected points.
16389030|NCT04056221|Sham Comparator|Sham acupuncture|Similar appearance to conventional acupuncture, however, without needles skin penetration.
16389031|NCT04056208|Active Comparator|Evening Pistachio Consumption|Participants will consume two ounces per day (57 g) of pistachios as an evening snack (i.e., after dinner and before sleep).
16389032|NCT04056208|Active Comparator|Usual care|Advice to consume a snack that contains 1-2 exchanges (15-30 g of carbohydrate) as an evening snack - this is consistent with the current standard of care for people with impaired fasting glucose.
16389033|NCT04056195|Experimental|SKI-O-703 200 mg|2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks
16389034|NCT04056195|Experimental|SKI-O-703 400 mg|4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks
16389035|NCT04056195|Placebo Comparator|Placebo|4 capsules of placebo during 12 weeks
16389036|NCT04056182|Experimental|Lofexidine|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
16389037|NCT04056169|Active Comparator|Rosuvastatin|rosuvastatin 20 mg once a day for 6 months
16389038|NCT04056169|Experimental|ezetimibe/rosuvastatin|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
16389039|NCT04056156|No Intervention|Control|Standard of care (no specific intervention)
16389040|NCT04056156|Experimental|Level 1: Online dissemination of the HIV screening advice|General practitioners included at the first level receive the HIV-testing advice through a personal electronic mail by their local GP-organization coordinator containing an information message with the printer-friendly screening advice attached. The message also provides a link to the website of the Flemish umbrella organization for GPs (https://domusmedica.be), where the tool is available for download for all Flemish GPs. A reminder is sent out to all participants after 13 months.
16389041|NCT04056156|Experimental|Level 2: additional group-level training session|At the second intervention level, GPs first receive intervention condition 1 and additionally the face-to-face group-level training session. These sessions are organized as part of regular 'continuous medical education' provided by the GP organizations ('quality circles') at their usual venues and are organized a few months after receiving intervention level 1. A reminder of the advice is sent out 13 months after the initiation of intervention level 1.
16389042|NCT04056143||Dabigatran|Subjects who are receiving long-term Dabigatran for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
16389043|NCT04056143||Rivaroxaban|Subjects who are receiving long-term Rivaroxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
16389044|NCT04056143||Apixaban|Subjects who are receiving long-term Apixaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
16389045|NCT04056143||Edoxaban|Subjects who are receiving long-term Edoxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
16389046|NCT04056130|Experimental|Cohort SAD1|9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
16389047|NCT04056130|Experimental|Cohort SAD2|9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
16389048|NCT04056130|Experimental|Cohort MAD1|9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
16389049|NCT04056130|Experimental|Cohort MAD2|9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
16389050|NCT04056117|Experimental|NA (Non-adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the non-adjuvanted investigational product
16389051|NCT04056117|Experimental|A (adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the adjuvanted investigational product
16389052|NCT04056117|Experimental|NA (Non-adjuvanted) - low dose -infants|Infants receive 3 low doses of the non-adjuvanted investigational product
16389053|NCT04056117|Experimental|A (adjuvanted) - low dose - infants|Infants receive 3 low doses of the adjuvanted investigational product
16389054|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the non-adjuvanted investigational product
16389055|NCT04056117|Experimental|A (adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the adjuvanted investigational product
16389056|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - children|Children receive 3 medium doses of the non-adjuvanted investigational product
16389057|NCT04056117|Experimental|A (adjuvanted) - medium dose - children|Children receive 3 medium doses of the adjuvanted investigational product
16389058|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose-adults|Adults receive 2 medium doses of the non-adjuvanted investigational product
16389059|NCT04056117|Experimental|A (adjuvanted) - medium dose - adults|Adults receive 2 medium doses of the adjuvanted investigational product
16389060|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - infants|Infants receive 3 high doses of the non-adjuvanted investigational product
16389061|NCT04056117|Experimental|A (adjuvanted) - high dose - infants|Infants receive 3 high doses of the adjuvanted investigational product
16389062|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - children|Chilldren receive 3 high doses of the non-adjuvanted investigational product
16389063|NCT04056117|Experimental|A (adjuvanted) - high dose - children|Chilldren receive 3 high doses of the adjuvanted investigational product
16389064|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - adults|Adults receive 2 high doses of the non-adjuvanted investigational product
16389065|NCT04056117|Experimental|A (adjuvanted) - high dose - adults|Adults receive 2 high doses of the adjuvanted investigational product
16389066|NCT04056117|Experimental|MenACWY-Placebo|Adults receive one administration of MenACWY followed by one placebo administration
16389067|NCT04056117|Other|Rabies|Children receive three administrations of Rabies
16389068|NCT04056117|Other|MenACWY-DTaP|Infants receive two administrations of MenACWY followed by DTaP administration
16389069|NCT04056104|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters
16389070|NCT04056091|Experimental|Back rub stimulation|
16389071|NCT04056091|Active Comparator|Foot flicks stimulation|
16389072|NCT04056078||Team Handball Players Playing with Shoulder Pain|Team Elite Handball players playing with shoulder pain i their dominated shoulder for more than 3 months.
16389073|NCT04056078||Team Handball Players playing without shoulder pain|Team Elite Handball players who never have experience shoulder pain i their dominated shoulder.
16389074|NCT04056078||Team Handball Players playing with previous shoulder pain|Team Handball players who have had shoulder pain i their dominated shoulder, but currently have been playing without shoulder pain in the previous 6 months.
16389075|NCT04056065|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
16406965|NCT03929952|Experimental|Chronic low back pain|
16389076|NCT04056065|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
16389077|NCT04056052|Sham Comparator|Home Activity Only|Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
16389078|NCT04056052|Active Comparator|Home Activity + cooking Workshop|The 8-week cooking workshop condition incorporated all of the home activities previously described, however, this cohort also participated in two, two-hour cooking workshops held at a local cooking school.
16389079|NCT04056039|Active Comparator|"Atorvastatin"|"-Changes of troponin I in rheumatoid arthritis with atorvastatin 40 mg orally every 24 hours for four weeks"
16389080|NCT04056039|Active Comparator|"Colchicine"|"Changes of troponin I in rheumatoid arthritis with colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks"
16389081|NCT04056026|Experimental|Fecal Microbiota Transplant|The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
16389082|NCT04056013|Active Comparator|Absorbable|Wound repaired with Vicryl Rapide absorbable suture
16389083|NCT04056013|No Intervention|Nonabsorbable|Wound repaired with traditional nonabsorbable suture
16389084|NCT04056000|Experimental|Exercising following the ingestion of a high-carbohydrate br|60 minutes of cycling, with the ingestion of a high-carbohydrate breakfast and 200 mg of caffeine.
16389085|NCT04056000|Experimental|Exercising following the ingestion of caffeine only|60 minutes of cycling, with the ingestion of 200 mg of caffeine.
16389086|NCT04056000|Experimental|Exercising in the absence of breakfast or caffeine ingestion|60 minutes of cycling, without the ingestion of breakfast, or caffeine.
16389087|NCT04055987|Experimental|Congenitally deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of consonant-vowel-consonant (CVC) combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
16389088|NCT04055987|Experimental|Adventitiously deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of CVC combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
16389089|NCT04055974|Experimental|BeAMom|Low-risk (LR) women will receive a web-based intervention for the promotion of maternal mental health (the Be a Mom program). In addition, women will receive postpartum treatment as usually performed in primary care settings (TAU).
16389090|NCT04055974|No Intervention|Control|Low-risk (LR) women will receive postpartum treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
16389091|NCT04055948|No Intervention|Control - Standard of Care|- All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
16389092|NCT04055948|Experimental|Intervention|"All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
~Three in-person, one-on-one teaching sessions with the caregiver during radiation treatments, followed by a telephone booster contact 2 weeks post-treatment."
16389093|NCT04055935|Experimental|full thickness mucoperiosteal flap|A full thickness mucoperiosteal flap (FTMPF) was reflected on FTMPF side at the maxillary canine/premolar region by the same surgeon for all patients following the same procedures.
16389094|NCT04055935|Experimental|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length
16389095|NCT04055935|No Intervention|Control for Full thickness mucoperiosteal flap|Control for Full thickness mucoperiosteal flap, in which canine retraction was done in a conventional method
16389096|NCT04055935|No Intervention|control for Low level laser therapy group|Control for Low level laser therapy , in which canine retraction was done in a conventional method
16389097|NCT04055909|Experimental|nangibotide 1|
16389098|NCT04055909|Experimental|nangibotide 2|
16389099|NCT04055909|Placebo Comparator|Placebo|
16389100|NCT04055896|No Intervention|Control Group|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
16389101|NCT04055896|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:
~Medication reconciliation
~Identification of patient priorities for care
~Identification of medications that are potentially appropriate for discontinuation/dose reduction
~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
~Identification of medications for trial of discontinuation/dose reduction (shared decision making) Pause of medication and clinical monitoring"
16389102|NCT04055883|Experimental|DA-1229 5mg|Oral administration of DA-1229 5mg tablet once a day
16389103|NCT04055883|Experimental|DA-1229 10mg|Oral administration of DA-1229 10mg tablet once a day
16389104|NCT04055883|Placebo Comparator|DA-1229 Placebo|Oral administration of DA-1229 Placebo tablet once a day
16389105|NCT04055870||Undergone EUS-guided liver biopsy at MDMC|Undergone EUS-guided liver biopsy at MDMC
16389106|NCT04055857||NIID|NIID patients
16389107|NCT04055857||HC|healthy control
16389108|NCT04055844|Experimental|Decitabine + Ruxolitinib + DLI|Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
16389109|NCT04055831||GD1 subjects with no bone complications|1. GD1 subjects with no bone complications (n=10)
16389110|NCT04055831||GD1 patients with mild bone complication|2. GD1 subjects with mild bone complications
16389111|NCT04055831||GD1 with severe bone complications|3. GD1 subjects with severe bone complications
16389112|NCT04055831||No bone disease|Controls with no known bone disease (n=10)
16389113|NCT04055818|Experimental|Nicotinamide|Oral Nicotinamide 1000 mg twice daily
16389114|NCT04055818|Experimental|THU Decitabine|Oral 250 mg THU and 5 mg decitabine Once per week
16389115|NCT04055805||Fondazione Policlinico Universitario A. Gemelli, Roma|Polo Scienze della Salute della Donna e del Bambino
16389116|NCT04055805||Università degli Studi di Pavia|
16389117|NCT04055805||"Università di Napoli Federico II"|
16389118|NCT04055805||Università degli Studi di Siena|
16389119|NCT04055805||Azienda Ospedaliero-Universitaria Careggi Firenze|
16389120|NCT04055805||Fondazione Policlinico Universitario A. Gemelli Roma|U.O.C Chirurgia Senologica
16389121|NCT04055805||Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale|
16389122|NCT04055792|Experimental|Sintilimab combine with Anlotinib|Sintilimab 200mg intravenously on day 1 and Anlotinib 12mg per os on day 1-14 of each 3-week cycle
16389123|NCT04055792|Active Comparator|Anlotinib|Anlotinib 12mg per os on day 1-14 of each 3-week cycle
16389124|NCT04055779||Induced hypotension and arterial occlusion pressure|The patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
16389125|NCT04055779||induced hypotension and limb occlusion pressure|the patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
16389126|NCT04055766||Meningitis/Encephalitis|Patients with clinical signs and symptoms suspected of meningitis/encephalitis
16389127|NCT04055766||Stroke|Patients with clinical signs and symptoms suspected of stroke
16389128|NCT04055766||Headache|Patients with clinical signs and symptoms suspected of headache
16389129|NCT04055766||Vertigo|Patients with clinical signs and symptoms suspected of vertigo
16389130|NCT04055753||Doxorubicin|
16389131|NCT04055753||Doxil|
16389132|NCT04055740|Experimental|IVUS imaging|IVUS imaging will be used each patient undergoing transvenous lead extraction to visualize ILA
16389133|NCT04055714|Experimental|Treatment arm|Balloon dilation of the Eustachian Tube(s) with Acclarent Aera Balloon
16389134|NCT04055701|Other|dichorionic diamniotic twin pregnancy|rutin examination: the assesment of fetal thymus volume at all cases.
16389135|NCT04055688||Participants with known or suspected high grade gliomas|
16389136|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
16389137|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
16389138|NCT04055662||Cannabis users|
16389139|NCT04055662||Cannabis naive|
16389140|NCT04055649|Experimental|Treatment - ONC201 & Paclitaxel|Patients receive ONC201 PO on days 1, 8, 15, and 22 and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
16389145|NCT04055623|Experimental|Intravenous infusion of Treg cells + Interleukin-2 injections|For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.
16389146|NCT04055623|Placebo Comparator|Intravenous infusion w/Placebo + matching placebo injections|For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.
16389147|NCT04055623|Experimental|2nd 6-months Open Label: Treg Infusions + IL-2 injections|For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.
16389148|NCT04055610|Experimental|H-MEX|10 participants with paraplegia will participate in explorative gait training using H-MEX powered exoskeleton.
16389149|NCT04055597|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
16406966|NCT03929939|Experimental|Lifestyle Modification Group|
16389150|NCT04055597|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
16389151|NCT04055584||Sputum spot|
16389152|NCT04055545|Active Comparator|MICT|
16389153|NCT04055545|Active Comparator|HIIT|
16389154|NCT04055532||Mild Cognitive Impairment|
16389155|NCT04055532||Alzheimer's Disease|
16389156|NCT04055532||Dementia with Lewy Bodies|
16389157|NCT04055532||Frontotemporal Lobar Dementia|
16389158|NCT04055532||Parkinson's Disease with Dementia|
16389159|NCT04055532||Transient Epileptic Amnesia|
16389160|NCT04055532||Temporal Lobe Epilepsy|
16389161|NCT04055532||Spinocerebellar Ataxia|
16389162|NCT04055532||HIV-Associated Neurocognitive Disorder|
16389163|NCT04055532||Amyotrophic Lateral Sclerosis|
16389164|NCT04055532||Primary Lateral Sclerosis|
16389165|NCT04055519|Other|LID017569, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
16389166|NCT04055519|Other|Biofinity, then LID017569|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
16389167|NCT04055506|Experimental|Combination Therapy|
16389168|NCT04055493|Experimental|Ribociclib plus ET|Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice
16389169|NCT04055493|No Intervention|Standard-of-care chemotherapy|Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,
16389170|NCT04055480|Active Comparator|Closed-loop using standard rapid-acting insulin|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin
~The CamAPS FX closed-loop system comprises
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
16389171|NCT04055480|Experimental|Closed-loop using faster insulin aspart|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using faster insulin aspart
~The CamAPS FX closed-loop system comprises
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
16389172|NCT04055467|Other|[F18]-ASEM + Contingency Management|PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide with incentive payments.
16389173|NCT04055454|Experimental|MV-LASV low dose: treatment group A|In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.
16389174|NCT04055454|Experimental|MV-LASV high dose: treatment group B|In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.
16389175|NCT04055454|Placebo Comparator|Placebo: treatment group C|In total 12 participants will receive placebo treatment on day 0 and 28.
16389176|NCT04055428|Experimental|Sacubitril/Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
16389177|NCT04055428|Active Comparator|Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
16389178|NCT04055415|Experimental|Intervention group|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml . Once every week#a total of two times. The Conventional drug therapy（expectorant，bronchodilator） is used.
16389179|NCT04055415|Other|Control group|The Conventional drug therapy（expectorant，bronchodilator） is used with the control group
16389180|NCT04055402|Experimental|EMA group|Participate in the baseline survey, 2-week ecological momentary assessments and a 1-month follow-up survey
16389181|NCT04055402|Active Comparator|Control group|Participate in the baseline survey,and a 1-month follow-up survey
16389182|NCT04055389|Experimental|AT-III treatment|
16389183|NCT04055389|Placebo Comparator|Placebo|
16389184|NCT04055376|Experimental|Daily exposure to active stimulation|Subjects in this arm will receive daily exposure to active stimulation
16389185|NCT04055376|Sham Comparator|Daily exposure to control stimulation|Subjects in this arm will receive daily exposure to control stimulation
16389186|NCT04055363|Experimental|Formula-fed infants|Infants fed exclusively with experimental formula
16389187|NCT04055363|Experimental|Mixed-fed infants|Infants receiving breastmilk and experimental formula
16389188|NCT04055363|No Intervention|Breast-fed infants|Reference group of exclusively breastfed
16389189|NCT04055337|Experimental|Flap Sliding|"noninvasive flap sliding technique for managing flap striae following laser in situ keratomileusis (LASIK)."
16389190|NCT04055311|Active Comparator|Usual care enhanced|Bladder cancer patients & caregivers receive standard instructions about post-op care from nursing staff plus the NCI published Facing forward cancer survivorship manual.
16389191|NCT04055311|Experimental|Intervention|Bladder cancer patients & caregivers receive standard instructions about post-op care from nursing staff plus access to Internet based software program, specifically designed for this research study. Software program contains relevant bladder cancer care instructions through videos, text, and graphics.
16389223|NCT04055129||Birth Control|Hormone levels controlled with subject on birth control pill
16389224|NCT04055129||Non-Birth Control|Hormone (estrogen) levels not controlled but monitored for levels of estrogen at two points in menstrual cycle (Follicular and ovulatory phases)
16389319|NCT04054505|Active Comparator|Vitamin E|Rise or fall of Vitamin E after three months
16406967|NCT03929939|No Intervention|Control Group|
16389192|NCT04055298|Other|Patients|"The study will be performed at the Walk-in-Clinic (WIC) and Interdisciplinary Emergency Department (ED) of the cantonal hospital of Baden, Switzerland. During their stay at the WIC or ED the patients will be invited to use the triage-symptom-checker SMASS-Triage.
~In this study, the patient's self-triage using a symptom checker will be compared with the urgency assessments conducted by three interdisciplinary panels of physicians (panel A, B and C). In order to appropriately reflect the complex interaction in medical decision-making, which usually leads to a low inter-rater reliability, the cases assessed to be undertriaged by panel A, are subsequently assessed a second time by two panelist of panel B. Cases which are adjudged to be undertriaged by all panelist (panel A and B), are assessed for a risk to health or life by panel C. The risk assessments of panel C will be based on the structured reports generated by the symptom-checker and the discharge summaries of the WIC/ED."
16389193|NCT04055285|Experimental|Sympathetic Renal Denervation|Sympathetic Renal Denervation
16389194|NCT04055285|Active Comparator|Conventional treatment with drug therapy|Conventional drug therapy of resistant hypertension
16389195|NCT04055272|Experimental|Text messaging|Participants in the text messaging intervention arm receive mobile text messages communicating the risks of indoor tanning and motivating cessation on their mobile phones
16389196|NCT04055272|No Intervention|Control|Participants in the control arm receive no intervention
16389197|NCT04055259|Experimental|mobile Health and Wellness Coaching|
16389198|NCT04055259|Active Comparator|Usual Care|
16389199|NCT04055246|Experimental|Prebiotic|Participants receive prebiotics containing fiber bar to consume 2x daily for 1 week.
16389200|NCT04055246|Placebo Comparator|Placebo|Participants receive placebo bar containing no added prebiotics to consume 2x daily for 1 week.
16389201|NCT04055233|Experimental|Subcutaneous irrigation with 0.04% polyhexanide solution|"Intervention: after closure of abdominal fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml antiseptic solution (0.04% polyhexanide) will be done once for ten minutes.
~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
16389202|NCT04055233|Active Comparator|Subcutaneous irrigation with NaCl (saline)|"Intervention: after closure of fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml NaCl (saline) will be done once for one minute.
~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
16389203|NCT04055220|Experimental|Regorafenib|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib followed by a 7-day period of rest.
~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).
~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
16389204|NCT04055220|Placebo Comparator|Placebo|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo followed by a 7-day period of rest.
~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).
~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
16389205|NCT04055207|Experimental|VVC|Option to receive VA Video Connect (VVC) delivery of HIV care.
16389206|NCT04055207|No Intervention|Usual Care|All HIV care available at MEDVAMC will be delivered as usual.
16389207|NCT04055194|Active Comparator|Tranexamic acid group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
16389208|NCT04055194|Placebo Comparator|Placebo group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
16389209|NCT04055181|Active Comparator|rTMS in schizophrenia patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
16389210|NCT04055181|Sham Comparator|rTMS in schizophrenia Controls|In sham rTMS, all procedures were identical to 10Hz Schizophrenia group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
16389211|NCT04055181|Active Comparator|rTMS in major depressive disorders patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
16389212|NCT04055181|Sham Comparator|rTMS in major depressive disorders controls|In sham rTMS, all procedures were identical to 10Hz depression group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
16389213|NCT04055168|Experimental|Cohort 1 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
16389214|NCT04055168|Experimental|Cohort 2 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
16389215|NCT04055168|Experimental|Cohort 3 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 3 of AZD6615 (6 subjects) or matching placebo (2 subjects).
16389216|NCT04055168|Experimental|Cohort 1 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
16389217|NCT04055168|Experimental|Cohort 2 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
16389218|NCT04055155||Staff/Provider end-users|Testing usability of a technology-enabled behavioral intervention for depression among provider end-users in primary care.
16389219|NCT04055155||Patient participants|Testing acceptability, feasibility, and preliminary effectiveness of a technology-enabled behavioral intervention for depression among patients with depression in primary care.
16389220|NCT04055142|Active Comparator|Electrocoagulation|This procedure will be implemented following the Standard of Care (SoC) on weeks: 0, 8 and 16 calculated since the day the patient is included into the trial.
16389221|NCT04055142|Experimental|Sinecatechins (10%)|Topical ointment wich contains 2 grams of active principle (sinecatechins 10%) at each administration. It will be taken three times per week during 8 weeks of treatment.
16389222|NCT04055142|Experimental|cidofovir (1%)|Topical ointment wich contains 2 grams of active principle (cidofovir 1%) at each administration. It will be taken three times per week during 8 weeks of treatment.
16389225|NCT04055116|Experimental|Unbuffered Lidocaine, then Buffered Lidocaine|Subjects will receive an injection of non-buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
16389226|NCT04055116|Experimental|Buffered Lidocaine, then Unbuffered Lidocaine|"Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion.Subjects will receive an injection of this buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
~We will use 8.4% Sodium Bicarbonate manufactured by Hospira, Inc. Lake Forest, IL"
16389229|NCT04055090||Subjects who received VM202|
16389230|NCT04055090||Subjects who received Placebo|
16389231|NCT04055077|Active Comparator|ASA I/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16389232|NCT04055077|Active Comparator|ASA II/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16389233|NCT04055077|Active Comparator|ASA III/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16389234|NCT04055077|Experimental|ASA I/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16389235|NCT04055077|Experimental|ASA II/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16389236|NCT04055077|Experimental|ASA III/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16389237|NCT04055064|Experimental|Intervention|patients received nutrition education and nutritional supplements
16389238|NCT04055064|No Intervention|Control|patients did not receive any intervention
16389239|NCT04055051||Hemophilia A and B Cases|No intervention. Only patients that have undergone a liver transplant per study eligibility are in this cohort.
16389240|NCT04055051||Hemophilia A and B Controls|No intervention. Comparable patients to those in Case cohort will be put in this cohort.
16389241|NCT04055038|Experimental|Platinum-based chemotherapy|"This is an experimental arm of this study. Allowed therapeutic options:
~Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);
~Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;
~Doxorubicin 40-50 mg/m2 d 1 + carboplatin AUC5 or cisplatin 60-75 mg/m2 d 1 every 3 weeks;
~Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;
~Etoposide 100 mg once daily orally d 1-7 + cisplatin 60-75 mg/m2 d1 every 3 weeks.
~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
16389242|NCT04055038|Active Comparator|Non-platinum monochemotherapy|"This is a control arm of this study. Allowed therapeutic options:
~Paclitaxel 60-80 mg/m2 weekly (or day 1, 8, 15 every 4 weeks schedule);
~Gemcitabine 1000 mg/m2 d 1, 8, 15 every 4 weeks;
~Doxorubicin 50-60 mg/m2 d 1 every 3 weeks;
~Topotecan 1,2-1,5 mg/m2 d 1-5 every 3 weeks;
~Etoposide 100 mg once daily orally d 1-10 every 3 weeks.
~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
16389243|NCT04055025|Other|Sleeve gastrectomy operated patients|Five test days in a randomized, patient-blinded, cross-over design
16389244|NCT04055012|Experimental|High Dose Metformin|High Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1,000mg) for the first week then increase to 3 tabs per day (1,500mg) for the remaining 6 months.
16389245|NCT04055012|Experimental|Low Dose Metformin|Low Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1 metformin tab (500mg) and 1 placebo tab in pre-packaged blister pack) for the first week then increase to 3 tabs per day (1 metformin tab (500mg) and 2 placebo tabs (in pre-packaged blister pack) for the remaining 6 months.
16389246|NCT04055012|Placebo Comparator|Placebo|Placebo Group (n=100). Subjects will receive placebo and will be instructed to take 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months.
16389247|NCT04055012|Other|Wait-List Control|"Control Group (n=100). Subjects will be told that they are in the wait-list control group. They will have a 3 month waiting period before they will be randomized again to a treatment group. They will be randomized to one of the previous groups."
16389248|NCT04054999|Experimental|Cyanokit|Single dose intraoperatively of Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
16389249|NCT04054999|Active Comparator|Methylene Blue|Single dose intraoperatively of Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
16389250|NCT04054986|Experimental|Breast Cancer|Breast cancer
16389251|NCT04054973|Experimental|L-arginine and Kuvan|Open-label single arm study, all participants will be in this group
16389252|NCT04054960|Experimental|Real tPCS|Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
16389253|NCT04054960|Sham Comparator|Sham tPCS|Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
16389254|NCT04054960|Active Comparator|Levodopa|Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
16389255|NCT04054947|Experimental|Suicide Prevention Program|
16389256|NCT04054947|No Intervention|Usual Care|
16389257|NCT04054934||Normal Circardian rhythm|Regular night sleep, with at least 7 hours length of sleep.
16389258|NCT04054934||Reversed circadian rhythm|Night/day circadian clock is opposite, with at least 7 hours length of sleep
16389259|NCT04054921|Experimental|Interventions|PTG-300
16389260|NCT04054908||Cohort A|Patients treated with oral fluoropyrimidine (Capecitabine (CAP)) as part of standard of care (SOC) chemotherapy
16389261|NCT04054908||Cohort B|Patients treated with Trifluridine/Tipiracil (TAS-102) including those receiving it in combination with Y-90 radioembolization as part of a clinical trial
16389262|NCT04054908||Cohort C|Patients receiving CAP plus immunotherapy (pembrolizumab) and bevacizumab as part of a clinical trial.
16389315|NCT04054531|Experimental|KN046 + carboplatin/paclitaxel|KN046 5 mg/kg IV every three weeks (Q3W) +Carboplatin AUC5 IV Q3W x 4 cycles + Paclitaxel 500 mg/m2 IV Q3W x 4 cycles
16389263|NCT04054895|Experimental|Physiological pacing|"Pacing the his-purkinje system.
~Crossover to biventricular CRT will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria [Europace. 2019 Oct 9. doi: 10.1093/europace/euz275]."
16389264|NCT04054895|Active Comparator|Biventricular resynchronization therapy|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.
~Crossover from biventricular CRT to physiological pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
16389265|NCT04054882|Experimental|Sabin-IPV and DTaP|234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
16389266|NCT04054882|Active Comparator|Sabin-IPV only|234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
16389267|NCT04054882|Active Comparator|DTaP only|234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
16389268|NCT04054869|Experimental|Bio-mechanically correct manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
16389269|NCT04054869|Experimental|Bio-mechanically incorrect manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically incorrect direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
16389270|NCT04054856|Other|Patients with Morbus Parkinson|
16389271|NCT04054856|Other|Healthy Subjects|
16389272|NCT04054843||Gestational diabetes mellitus|First trimester pregnancies with gestational diabetes mellitus
16389273|NCT04054843||Control|First trimester healthy pregnancies
16389274|NCT04054830|Experimental|Topical, preservative-free NSAID|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
16389275|NCT04054830|Active Comparator|Topical, preservative-free steroid|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
16389276|NCT04054830|Experimental|Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee
16389277|NCT04054817|Experimental|Single Arm|
16389278|NCT04054778|Experimental|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
16389279|NCT04054778|Active Comparator|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
16389280|NCT04054765|Experimental|Teens in the Invite Only VR videogame|155 adolescents playing the Invite Only VR intervention
16389281|NCT04054765|Other|Teens receive treatment as usual|132 adolescents receive treatment as usual, which includes regular instruction in health class regarding the dangers of e-cigarettes
16389285|NCT04054739|Experimental|Robot-assisted gait training|experimental group that applied the end-effector robot-assisted gait training
16389286|NCT04054739|Active Comparator|Treadmill gait training|control group that applied the treadmill gait training
16389287|NCT04054726|Experimental|Real tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
16389288|NCT04054726|Sham Comparator|Sham tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
16389316|NCT04054531|Experimental|KN046 + carboplatin/pemetrexed|KN046 5 mg/kg IV Q3W +Carboplatin AUC5 IV Q3W x 4 cycles + Pemetrexed 500 mg/m2 IV Q3W x 4 cycles
16389317|NCT04054518|Experimental|Durvalumab|1500 mg durvalumab (MEDI4736) via IV infusion Q4W <<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48>> or <<until confirmed disease progression>> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
16389318|NCT04054505|Active Comparator|Vitamin A|Rise or fall of Vitamin A after three months
16389289|NCT04054713|Active Comparator|Chromoendoscopy with acetic acid and targeted biopsies|Acetic acid is prepared at a concentration of 2.5%, after initial cleaning is done, it will be applied with a 7 French spray catheter, starting the proximal application performing a uniform application on the area of intestinal metaplasia an then will be timed for mucous visualization in search of areas of loss of acetowhitening, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the esophageal face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal (glands evenly distributed with normal or abnormal crypt density (compact crypts with increased density; focal irregularity or disorganized crypts; absence of a cryptic pattern), once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
16389290|NCT04054713|Active Comparator|Seattle protocol|Take random biopsies by quadrants every 2 centimeters biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction begins, taking tissue every 2cm from the 4 quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
16389291|NCT04054700|Experimental|distal upper rehabilitation robot|experimental group that applied the distal upper rehabilitation robot
16389292|NCT04054700|Other|proximal upper rehabilitation robot|control group that applied the proximal upper rehabilitation robot
16389293|NCT04054687|Experimental|TXA|Research participants in the experimental group will receive one dose of 100mg/mL TXA soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
16389294|NCT04054687|Placebo Comparator|Saline|Research participants in the placebo group will receive one dose of normal saline (0.9%) soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
16389295|NCT04054674|Experimental|flat occlusal scheme restored by lithium disilicate crown|flat occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
16389296|NCT04054674|No Intervention|planar occlusal scheme restored by lithium disilcate crown|planar occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
16389297|NCT04054661|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.
~At the clinic site lab, study staff conducted the SD Biosensor STANDARD point-of-care G6PD test and the point-of-care HemoCue hemoglobin test on both finger stick blood and whole blood samples.
~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
16389298|NCT04054648|Active Comparator|Bedtime Antihypertensive Medications|The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.
16389299|NCT04054648|No Intervention|Morning Antihypertensive Medications|No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.
16389300|NCT04054635|Experimental|Regimen 1|Two applications of silver diamine fluoride (SDF) four months apart, which is the protocol frequency adopted by the Winnipeg Regional Health Authority's (WRHA) Clinical Guideline on SDF.
16389301|NCT04054635|Experimental|Regimen 2|Two applications of silver diamine fluoride (SDF) six months apart (American Dental Association recommendation)
16389302|NCT04054635|Experimental|Regimen 3|Two applications of silver diamine fluoride (SDF) one month apart, which is proposed in the American Academy of Pediatric Dentistry's clinical practice guidelines.
16389303|NCT04054609|Other|FAZA PET/MRI scan|PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside
16389304|NCT04054596|Experimental|STEM|The treatment group (TX) will complete 8 sessions of STEM (2 sessions per week for 4 weeks), Sessions are approximately 30-45 minutes long.
16389305|NCT04054596|No Intervention|Controlled|During weeks 2-5, one group will undergo a memory enhancement protocol, used to improve memory functioning in individuals with neurological injuries. The other group will serve as a control group and complete memory exercises with the researcher.
16389306|NCT04054583||Residents|Residents living on a special care unit in a long-term care facility. All 60 residents residing in the unit pre- and post-renovation will be eligible, and all will have intermediate or advanced dementia.
16389307|NCT04054583||Family Members|Family members are defined as the key person who supports the resident on a regular basis. This could include a spouse, adult child, adult grandchild, niece or nephew, close friend, former neighbour, or other significant person to the resident.
16389308|NCT04054583||Staff|Staff are the people who work on the special care unit. They may work only briefly or work on the design of the renovations. Types include: managers, nurses, health care aides, recreation facilitators, social worker, occupational therapist, physiotherapist, rehabilitation assistant, speech language pathologist, physicians, designers, and cleaning staff.
16389309|NCT04054570||Adaptive servo-ventilation patients|All patients under adaptive servo-ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
16389310|NCT04054570||Barometric and Volumetric patients|All patients under barometric and volumetric ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
16389311|NCT04054557|Active Comparator|Arm I (Standard of Care office Visits)|Participants receive standard of care office visits approximately every 3 months (± 2 weeks) for one year.
16389312|NCT04054557|Experimental|Arm II (Standard of Care Office Visits, survey, telehealth)|Patients receive standard of care as in Arm I and 4 automated electronic surveys every 3 weeks (+/- 1 weeks) for a total of 18 electronic surveys over one year. Patients who report severe or very severe side effects, or stopping or are thinking about stopping their ET will have a follow up encounter with a research coordinator.
16389313|NCT04054557|Experimental|Arm III (Smart Pill Bottle, messaging)|Patients receive a wireless smart pill bottle that performs daily time-specific reminders to open the pill bottle and take the medication. Additional messages are triggered by the pill bottle when non-adherence is indicated (lack of bottle opening or no change in remaining pills), as well as when medication is skipped.
16389314|NCT04054544|Experimental|Gluten challenge|Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
16407330|NCT03927443|Active Comparator|Reference|
16389320|NCT04054505|Active Comparator|Vitamin B1|Rise or fall of Vitamin B1 after three months
16389321|NCT04054505|Active Comparator|Vitamin B2|Rise or fall of Vitamin B2 after three months
16389322|NCT04054505|Active Comparator|Vitamin B6|Rise or fall of Vitamin B6 after three months
16389323|NCT04054505|Active Comparator|Vitamin B12|Rise or fall of Vitamin B12 after three months
16389324|NCT04054505|Active Comparator|Vitamin C|Rise or fall of Vitamin C after three months
16389325|NCT04054505|Active Comparator|Vitamin D|Rise or fall of Vitamin D after three months
16389326|NCT04054505|Active Comparator|Calcium|Rise or fall of Calcium after three months
16389327|NCT04054505|Active Comparator|Iron|Rise or fall of Iron after three months
16389328|NCT04054505|No Intervention|IGF1|Rise or fall of IGF1 after three months
16389329|NCT04054505|No Intervention|FT-3|Rise or fall of FT-3 after three months
16389330|NCT04054492|Experimental|sIPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
16389331|NCT04054492|Active Comparator|sIPV+sIPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
16389332|NCT04054492|Active Comparator|sIPV+sIPV+sIPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
16389333|NCT04054479|Experimental|Penehyclidine|Patients in this arm will receive penehyclidine after anesthesia intubation.
16389334|NCT04054479|Placebo Comparator|Normal Saline|Patients in this arm will receive normal saline after anesthesia intubation.
16389335|NCT04054466|Experimental|Experimental group|Intervention with counselling designed
16389336|NCT04054466|Other|Control group|Intervention with habitual counselling
16389337|NCT04054453|No Intervention|Pre-intervention|Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
16389338|NCT04054453|Experimental|Post-intervention|Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
16389339|NCT04054427|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF
16389340|NCT04054414|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
16389341|NCT04054414|Experimental|PMZ-1620|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
16389342|NCT04054388|Experimental|300 Randomized to re-education group|LINE re-education of colon preparation
16389343|NCT04054388|No Intervention|300 Randomized to control group|education of colon preparation 1 time in hospital
16389344|NCT04054375|Experimental|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
16389345|NCT04054362|Experimental|With Cisplatin|Paclitaxel Protein bound, Cisplatin, and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
16389346|NCT04054362|Experimental|Without Cisplatin|Paclitaxel Protein bound and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
16389347|NCT04054349|Experimental|Low FODMAP Diet Group|The parent/caregiver was given detailed nutrition education by the investigator concerning the low FODMAP diet and was asked to implement for 2 weeks.
16389348|NCT04054349|No Intervention|Control Group (Habitual Diet)|The parent/caregiver was asked to continue their child's usual dietary intake for 2 weeks.
16389349|NCT04054336|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures containing soft drinks by swiping/pulling them towards themselves, whereas pictures with alcoholic content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
16389350|NCT04054336|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon soft drinks by swiping/pulling towards themselves the picture. Pictures containing alcoholic content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
16389351|NCT04054336|Sham Comparator|Control group|This type of active control group receives the instructions to swipe alcohol pictures to the left and soft drink pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
16389352|NCT04054323|Experimental|Patient Physical Activity Arm|Patients only receive physical activity intervention.
16389353|NCT04054323|Experimental|Dyadic Physical Activity Arm|Patients and caregivers both receive physical activity intervention.
16389354|NCT04054310|Experimental|Study-gate|Single arm of biopsy naïve participants suspected of having NAFLD or NASH, who have been referred for a liver biopsy as part of routine clinical care
16389355|NCT04054297|Experimental|High GI/SFA diet|Subjects will adhere to a two-week high GI and high SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
16389356|NCT04054297|Experimental|Low GI/SFA diet|Subjects will adhere to a two-week low GI and low SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
16389357|NCT04054284|Experimental|Intervention|Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
16389358|NCT04054284|Active Comparator|Control|Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
16389414|NCT04053868|Experimental|Electronic Cigarette|The participants will participate in a standardized vaping session using a JUUL E-cigarette device with a JUUL e-liquid pod.
16389359|NCT04054258|Experimental|App support programme group|In addition to the usual care, the participant and one family member will receive a CHD app and a briefing from a trained research nurse (A). The reason to invite an additional family member to install the app is to ensure that he/she can be informed automatically when the patient presses an icon during a chest pain attack. The patient may be too stressed during an angina attack and may not be able to follow the 'Things to Do List' quickly. In addition, automatic reminders of the individual's medication times and follow-up times will be pre-set in the app for individual use.
16389360|NCT04054258|Active Comparator|Telephone support group|In addition to the above usual care, bi-weekly 20-minute telephone follow-ups will be provided by a trained research nurse (B) for up to 3 months. Patients can ask about related health problems if any. The nurse will address their problem by providing advice or referring them to the ED follow-up clinic. The team has set up a telephone advice guide to support the research nurse in giving phone advice.
16389361|NCT04054245|Experimental|Treatment (LOXL2 inhibitor PAT-1251)|Patients receive LOXL2 inhibitor PAT-1251 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16389362|NCT04054232|Experimental|EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to have their primary care physician receive an electronic health record message regarding their high risk of having PAD and a recommendation will be made to have the participant referred for non-invasive testing called Ankle Brachial Index (ABI) testing to confirm diagnosis. For individuals who undergo ABI testing and are confirmed to have PAD, they and their physicians will be provided with American Heart Association Guidelines for the management of PAD. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications.
16389363|NCT04054232|No Intervention|No EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to the control arm and they nor their physicians will be alerted of their status for 6 months. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications. At the end of 6 months of observation, the primary care physician's of control participants will receive the same alert as participants in the intervention arm.
16389364|NCT04054206|Active Comparator|Sequence 1|"Two participants will be randomly assigned to sequence 1 comprising 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart:
~Day 1-7: ER fasted; Day 8-15: ER fed Day 15-22: IR fasted"
16389365|NCT04054206|Active Comparator|Sequence 2|Two participants will be randomly assigned to sequence 2 comprising 3 treatments in a crossover design, administered one week apart: Day 1-7: ER fed; Day 8-15: IR fasted; Day 15-22: ER fasted
16389366|NCT04054206|Active Comparator|Sequence 3|"Two participants will be randomly assigned to sequence 3 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: IR fasted; Day 8-15: ER fasted; Day 15-22: ER fed"
16389367|NCT04054206|Active Comparator|Sequence 4|"Two participants will be randomly assigned to sequence 4 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: IR fasted; Day 8-15: ER fed; Day 15-22: ER fasted"
16389368|NCT04054206|Active Comparator|Sequence 5|"Two participants will be randomly assigned to sequence 5 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: ER fasted; Day 8-15: IR fasted; Day 15-22: ER fed"
16389369|NCT04054206|Active Comparator|Sequence 6|"Two participants will be randomly assigned to sequence 6 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: ER fed; Day 8-15: ER fasted; Day 15-22: IR fasted"
16389370|NCT04054193|Experimental|Fosaprepitant Treatment|Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine [5-HT3]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
16389371|NCT04054180|Experimental|CPAP S.Box associated with its 3 connected devices|S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.
16389372|NCT04054167|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
16389373|NCT04054154|Experimental|Device Feasibility (Millar Mikro-tip catheter, elastography)|Patients scheduled for an ultrasound-guided tumor biopsy undergo stiffness assessment of the tumor with shear wave elastography over 2 minutes and pressure measurements of the tumor using a Millar Mikro-tip catheter before and after the biopsy is collected.
16389374|NCT04054141|Experimental|rTMS arm|"Each patient's participation will last a maximum of 12 weeks and involves 2 sessions of neurophysiological testing (TMS) sessions and 15 neurophysiological treatment sessions (rTMS).
~Patients will have a neurophysiological testing session (TMS) at the screening visit (week 0). Patients will then return for 15 neurophysiological treatment sessions (rTMS) within 14 days of screening. Patients must complete three neurophysiological treatment sessions (rTMS) during weeks 1, 2, 3, 4 and 5. The second neurophysiological testing session will be done at the final visit (week 5). Follow-up visits will be scheduled at weeks 7 and 10 (+/- 3 days). That is, the follow-up visits will occur two and five weeks after the final rTMS session which occurs on day 15."
16389375|NCT04054128|Experimental|Sodium bicarbonate catheter lock group (SBCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with sodium bicarbonate 7.5% Injection.
16389376|NCT04054128|Active Comparator|Heparin catheter lock group (HCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with heparin, 1000 Units/mL injectable solution
16389415|NCT04053868|Experimental|Tobacco Cigarette|The participants will participate in a standardized smoking session using commercial tobacco cigarettes.
16408271|NCT03920839|Experimental|INCMGA00012 + pemetrexed/carboplatin|
16389377|NCT04054115|Experimental|Treatment Arm|"Baseline cardiac catheterization under GA. (Standard of Care, SOC)
~Transfer patient to MRI unit
~Baseline MRI
~Obtain ABG for pCO2 from existing femoral arterial access.
~Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.
~MRI phase contrast imaging for flow measurements(SOC).
~During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.
~Post alprostadil infusion
~1ml blood sample taken from existing femoral venous access for prostaglandin level.
~Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.
~Repeat MRI flow measurements
~7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC)."
16389378|NCT04054102|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
16389379|NCT04054102|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
16389380|NCT04054089|Experimental|A|B/F/TAF
16389381|NCT04054089|Active Comparator|B|DTG+3TC
16389382|NCT04054076|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
16389383|NCT04054076|Experimental|Custom-made insoles soft|Custom-made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate.
16389384|NCT04054076|Experimental|Custom-made hard|Custom-made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate.
16389385|NCT04054076|No Intervention|Control group|No intervention with therapeutic insoles and/or shoes.
16389386|NCT04054063|Experimental|HSK3486+etomidate|Cohort 1: HSK3486 0.324 mg/kg + etomidate 0.15 mg/kg Cohort 2: HSK3486 0.216 mg/kg + etomidate 0.2 mg/kg Cohort 3: HSK3486 0.432 mg/kg + etomidate 0.1 mg/kg There were an additional 2 cohorts (Cohorts 4 and 5) planned for dose escalation once the optimal ratio of the drug combination was identified from the first 3 cohorts. However, these 2 cohorts were not done as the results of Cohorts 1 to 3 suggested that dose increases would cause higher occurrence of drug-related adverse events (AEs).
16389387|NCT04054050|Experimental|Light therapy|Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
16389388|NCT04054037||HBV-ACLF Group|Patients with HBV related acute on chronic liver failure
16389389|NCT04054024|Active Comparator|Active drug|
16389390|NCT04054024|Placebo Comparator|Placebo|
16389391|NCT04054011|Experimental|deoxycholic acid|Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)
16389392|NCT04053985|Experimental|TAI+lenvatinib group|TAI combine lenvatinib
16389393|NCT04053985|Active Comparator|lenvatinib group|lenvatinib only
16389394|NCT04053972|Experimental|treatment group|adjuvant lenvatinib
16389395|NCT04053972|No Intervention|control group|no intervention
16389396|NCT04053959|Experimental|AI Group|Artificial intelligence assisted insulin titration system group
16389397|NCT04053959|Active Comparator|Control Group|Physicians decided insulin titration group
16389398|NCT04053946|Experimental|Next Science|Following amputation, SurgX™ will be applied directly to the surgical incision in the operating room under sterile conditions and covered with SOC dressing. The surgical dressing will not be removed until post-operative day 3, except if deemed necessary by the treating surgeon. At that time, direct application of the BlastX™ to the incision will be placed, then covered with a SOC dressing. BlastX™ will be applied every day and covered with SOC dressing.
16389399|NCT04053946|No Intervention|Control|Post-op SOC dressing as per treating research doctor to include dressing changes post-op day 3 and daily thereafter.
16389400|NCT04053933||Patients treated with ESA|
16389401|NCT04053933||Patients treated with 5'azacitidin|
16389402|NCT04053933||Patients treated with deferoxamine|
16389403|NCT04053933||Patients treated with deferasirox|
16389404|NCT04053933||Patients treated with transfusion only|
16389405|NCT04053933||Patients treated with lenalidomide|
16389406|NCT04053933||Patients treated with intensive chemotherapy|
16389407|NCT04053920|Experimental|Low load|Training at 30-40% one-repetition maximum (1RM)
16389408|NCT04053920|Experimental|High load|Training at 65-75% one-repetition maximum (1RM)
16389409|NCT04053907|No Intervention|CCM:Standard of Care|Community Case Management (CCM), with passively monitored malaria incidence by community health workers using standard RDTs and artemisinin-based combination therapy (ACT), artemether-lumefantrine (AL) according to national guidelines.
16389410|NCT04053907|Experimental|CCM plus weekly fever screening and treatment|CCM plus active case detection (ACD) by fever screening and treatment if positive. Trained VHW recruited for this study will carry out weekly visits of all residents and screen for fever using research-grade thermometers. A standard RDT will be performed in all individuals with a body temperature ≥37.5°C or with reported fever in the last 24 hours. RDT positive individuals will be treated with AL according to national guidelines.
16389411|NCT04053907|Experimental|CCM plus MSAT|CCM plus monthly screening for malaria infection and treatment of positive individuals, regardless of symptoms. Screening will be performed by research staff and timed to ensure a gap of 25-35 days between screening rounds; Positive individuals will be treated with AL, according to national guidelines.
16389412|NCT04053907|Experimental|CCM plus dry season MDA|CCM plus plus 3 monthly rounds of MDA with a long-acting ACT (dihydroartemisinin-piperaquine, DP) starting in the dry season (April, May, June) (tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight).
16389747|NCT04051476|Experimental|6-g footbath|Footbath with 6g ginger flour per liter of water
16389416|NCT04053855||Renal mass patients|"Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.
~They will have an urinary sample."
16389417|NCT04053855||Control patients|Control patients (without renal mass) will be included. They will have an urinary sample.
16389418|NCT04053842|Experimental|Multi-modality prostate cancer imaging|The study requires eligible patients to complete one imaging session at St. Joseph's Health Care to begin within 6 weeks of the scheduled Radical Prostatectomy. Imaging will consist of simultaneous multiparametric MRI (mpMRI), sodium MRI and positron emission tomography (PET) with a radio-labeled probe for prostate-specific membrane antigen (PSMA).
16389419|NCT04053829|Experimental|HOLOBalance|The experimental arm will use the HOLOBalance tele-rehabilitation system to provide the intervention. Participants will be required to use the HOLOBalance system on a daily basis for the duration of the 8 week study. Although participants will have daily interaction with the HOLOBalance system, they will be free to choose when to complete their exercises.
16389420|NCT04053829|Active Comparator|OTAGO Home Exercise Programme|The comparator for this study is the OTAGO home exercise programme. The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. The OTAGO is well-established and is widely used in clinical practice in the UK for the management of older adults who fall or have increased risk for falling. It has been shown to be well tolerated in older adults in community settings with good adherence rates, and reduces falls rate in older adults by 35%, with greatest effects observed in frailer older women
16389421|NCT04053816|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
16389422|NCT04053816|Active Comparator|Tight control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
16389423|NCT04053803|Experimental|Open Label|
16389424|NCT04053790|Placebo Comparator|placebo group|Patients in this group will receive placebo 1 tablet every 12 hours, during 4 weeks.
16389425|NCT04053790|Active Comparator|LB 10000|Patients in this group will receive placebo 1 tablet containing 5,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
16389426|NCT04053790|Active Comparator|LB 20000|Patients in this group will receive placebo 1 tablet containing 10,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
16389427|NCT04053777||NIV group|Patients receiving non-invasive ventilation in the hospital or at home
16389428|NCT04053764|Experimental|crizanlizumab + standard of care|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.
16389429|NCT04053764|Active Comparator|standard of care|Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.
16389430|NCT04053751|Experimental|closed suctioning system|Closed suctioning system will be compared with open suctioning system
16389431|NCT04053751|No Intervention|open suctioning system|The patient will be monitored with closed system for one day and open aspiration system on the other day.
16389432|NCT04053738|No Intervention|Baseline|Participants slept in the anti-snoring bed in the laboratory, but the bed did not provide any intervention
16389433|NCT04053738|Experimental|Anti-snoring Intervention|Participants slept in the anti-snoring bed in the laboratory, and the bed moved the trunk of the participant
16389434|NCT04053712|Placebo Comparator|Single-hormone|FiAsp (R) - Saline
16389435|NCT04053712|Active Comparator|Dual-hormone|FiAsp(R) - GlucaGen(R)
16389436|NCT04053699||Patients undergoing treatment with a VWF-containing product|Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months
16389437|NCT04053686|Experimental|Intervention|The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
16389439|NCT04053660|No Intervention|Control|Periodontally healthy group
16389440|NCT04053660|Experimental|Chronic Periodontitis|Patients with chronic periodontitis
16389441|NCT04053647||Hypoparathyroid patients|Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.
16389442|NCT04053647||Control patients, without hypoparathyroidism|
16389443|NCT04053634|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
16389444|NCT04053634|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
16389445|NCT04053621|Experimental|Experimental group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and thiamine pyrophosphate (weekly dose of 1 gram administered by IV: 25 ml of thiamine pyrophosphate + 250 ml saline solution at a 60-80 drops/minute rate).
~Total duration of 12 weeks."
16389446|NCT04053621|Placebo Comparator|Placebo group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and weekly administration of 275 ml of saline solution at a 60-80 drops/minute rate).
~Total duration of 12 weeks."
16389447|NCT04053595|Experimental|Estimated Oxygen Extraction|
16389448|NCT04053595|Active Comparator|Dynamic Parameters|
16389449|NCT04053582|Active Comparator|Augmented Mindfulness Training (AMT)|Participants will receive real-time neurofeedback from the PCC during mindfulness practice in the MRI
16389450|NCT04053582|Active Comparator|Sham|Participants will receive an artificial neurofeedback signal during mindfulness practice in the MRI
16389451|NCT04053569|Experimental|Diet with table grape|Table grape (5g/Kg) administered for four weeks with dietary recommendations. A strict restriction of fruits and the limitation of other foods containing polyphenols will be necessary.
16389452|NCT04053569|No Intervention|Specific dietary advice|Dietary recommendations (such as limitation of alcohol, caffeine), and low consumption of fruits.
16389453|NCT04053543|Experimental|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
16389454|NCT04053530|Experimental|3M™ Ketac™ Universal Aplicap™|"3M™ Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clean the cavity preparation with water. Rinse thoroughly and dry. Extrude the mixed ketac universal out of the capsule directly into the prepared cavity with a capsule gun. Please ensure that no air bubbles are included.
~It is recommended that the finishing and polishing can be continued after approximately 4 minutes after the start of the mixing or earlier if heat is applied for faster setting. The finishing and polishing can be done immediately after final setting with Extra-Fine, Friction Grip diamonds under water-cooling."
16389455|NCT04053530|Experimental|Filtek™ Bulk Fill Flowable composite|"Filtek™ Bulk Fill Flowable Restorative is the 3M ESPE choice in the bulk fill flowable category.
~Selective etching 15-20 s for enamel. The adhesive system (BISCO universal all bond) will be applied following the manufacturer's instructions (apply 2 coats 20 s before curing). Bulk fill flowable composite will be light cured for 40 s using a visible light curing unit."
16389456|NCT04053530|Active Comparator|ketac N100|"Ketac™ Nano Light Curing Glass Ionomer Restorative. Primer will be applied to both enamel and dentinal surfaces for 15 seconds. The prepared tooth surfaces will be wet with the primer for the full application time.
~Dispensing two clicks from the Clicker™ Dispenser will provide an adequate amount of material for most restorative filling applications.
~It will be placed with a syringe system then will be placed in 2mm increments or less, and light cured after each increment. An LED curing light will cure all shades with a 20 second light exposure.
~Finishing Ketac Nano restorative will be polished with conventional finishing and polishing instruments such as a diamond impregnated rubberized polishing system under water spray. A glaze such as Vitremer™ Finishing Gloss will be applied after polishing if desired."
16389457|NCT04053517||Observational (questionnaire administration)|Patients complete questionnaires about financial state and quality of life over 15 minutes. Patients' medical chart is also reviewed.
16389458|NCT04053504|Experimental|Intervention|Behavioral intervention delivered by parent peer leaders.
16389459|NCT04053504|No Intervention|Standard Care|Standard diabetes care
16389460|NCT04053491|Experimental|Axillary block group|Initial bolus will be given and then a perinervous catheter will be inserted by the axillary approach.
16389461|NCT04053491|Experimental|Infraclavicular block group|Initial bolus will be given and then a perinervous catheter will be inserted by the infraclavicular approach.
16389462|NCT04053478|Experimental|Myometrium + Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine (from 10 -10M to 10 -3M)
16389463|NCT04053478|Experimental|Myometrium + Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine(from 10 -10M to 10 -3M)
16389464|NCT04053478|Experimental|Myometrium + Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine(from 10 -10M to 10 -3M)
16389465|NCT04053478|Experimental|Umbilical artery + Ephedrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine (from 10 -10M to 10 -3M)
16389466|NCT04053478|Experimental|Umbilical artery + Phenylephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine(from 10 -10M to 10 -3M)
16389467|NCT04053478|Experimental|Umbilical artery + Norepinephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine(from 10 -10M to 10 -3M)
16389468|NCT04053465|Experimental|Exercise in heat group|Exercise in a hot environment
16389469|NCT04053465|Placebo Comparator|Exercise in cool group|Exercise in a cool environment
16389470|NCT04053452|Experimental|GBS Patients|
16389471|NCT04053452|Active Comparator|Controls|
16389472|NCT04053439||Lymphoma patients >=60 receiving cytotoxic chemotherapy|Lymphoma patients >=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.
16389473|NCT04053426||"Population before"|Patient included before implementation of care algorithm.
16389474|NCT04053426||"Population after"|Patients included after the implementation of care algorithm and training of health professionnals
16389475|NCT04053413|No Intervention|Usual care|Women in this group will undergo usual care and the complete the survey questions on knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean.
16389476|NCT04053413|Active Comparator|Decision Aid|Women in this group will receive a decision aid prior to undergoing counseling by their physician. Following completion of the decision aid and physician counseling, they will complete a series of survey questions to assess their perceptions of their knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean delivery.
16389477|NCT04053400||Ketamine Group|Active duty military service member injured in theater, AEROVAC-ED out, and received ketamine.
16389478|NCT04053400||Non-Ketamine Comparison Group|Active duty military service member injured in theater, AEROVAC-ED out, and did NOT receive ketamine treatment for pain.
16389479|NCT04053387|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
16389480|NCT04053374||DMD treatment naive CIS or RRMS patients|Newly presenting Clinically Isolated Syndrome (CIS) or Relapsing and Remitting Multiple Sclerosis (RRMS) patients not treated before with Disease Modifying Drugs (DMD) Additional analysis of CSF and CSF cells will be performed in this cohort on a voluntary basis.
16389481|NCT04053374||Secondary Progressive Multiple Sclerosis (SPMS)|People with confirmed diagnosis of SPMS
16389482|NCT04053374||Primary Progressive Multiple Sclerosis (PPMS)|People with confirmed diagnosis of PPMS
16389483|NCT04053374||DMD-treated with stable disease|People with Multiple Sclerosis (MS) who are treated with DMD who have had stable disease symptoms for at least 3 months
16389484|NCT04053374||Disease controls|People who undergo lumbar puncture due to clinical suspicion of neurological condition, but brain Magnetic Resonance Imaging (MRI) and CSF examination exclude MS diagnosis.
16389485|NCT04053374||Healthy donors|Age, sex and ethnicity matched healthy donors will also be recruited from university and hospital staff and patient friends after informed consent has been obtained. Healthy donors will be asked to provide a blood sample and demographic information but will NOT be asked to provide CSF samples.
16389583|NCT04052672|Active Comparator|Randomized Intervention|The intervention will consist of an exercise intervention, a combination of supervised exercise classes and in home exercises and open label nutritional supplement.
16389486|NCT04053361|Active Comparator|Group A: Clinical ablation|"Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.
~If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.
~If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.
~If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.
~If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.
~No induction protocols for other, on top of already ablated, arrhythmias will be attempted."
16389487|NCT04053361|Experimental|Group B: Clinical plus substrate-based ablation|"- The initial ablation steps will be identical to those in patients from Group A.
~Supplemental ablation will consist of:
~Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)
~AND
~Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage <0.5 mV in sinus rhythm or <0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (<20% of atrial surface) achievable to ablate.
~Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.
~Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (>5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol."
16389488|NCT04053348|Experimental|Intervention|Participants allocated to the intervention group will receive their home-based rehabilitation program using mobile app installed in the mobile device.
16389489|NCT04053348|Active Comparator|Control|Those assigned to the control group will receive the same home-based rehabilitation program but with information and instructions delivered through the use of paper-based handouts.
16389490|NCT04053335||Cohort 1: Multicomponent Physician Performance Peer-Comparison|Cohort 1 (2 groups): Runs July 2019 - December 2020 - Inova/Signature Parters and Sentara/Sentara Quality Care Network
16389491|NCT04053335||Cohort 2: Multicomponent Physician Performance Peer-Comparison|Cohort 2 (2 groups): Runs November 2019 - April 2021 - Ballad Health and Carilion Clinic
16389492|NCT04053335||Cohort 3: Multicomponent Physician Performance Peer-Comparison|Cohort 3 (2 groups): Runs March 2020 - August 2021 - Health Care Associates Virginia/Virginia Care Partners and Virginia and Commonwealth University Health System
16389493|NCT04053322|Experimental|Study Arm|
16389494|NCT04053309||Males undergoing TESE or microTESE|All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.
16389495|NCT04053296||The first pregnancy with PAH group|
16389496|NCT04053296||The second pregnancy with PAH group|
16389497|NCT04053283|Experimental|Intratumoural|In the IT cohort, patients will receive a single dose of NG-641 by IT injection on Day 1. The dose given to each patient will be dependent on the size of the tumour lesion to be injected.
16389498|NCT04053283|Experimental|Intravenous|In the IV cohort, patients will receive a single cycle of study treatment, with three single doses of NG-641 on Days 1, 3 and 5 by IV infusion.
16389499|NCT04053270|Experimental|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
16389500|NCT04053270|Placebo Comparator|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
16389501|NCT04053257|No Intervention|Before intervention|HH opportunities, compliant moments and HAIs recorded before the intervention
16389502|NCT04053257|Active Comparator|After intervention|HH opportunities, compliant moments and HAIs recorded after the intervention
16389503|NCT04053244|Experimental|treatment|all participants will be assigned to the treatment, consisting of therapist-assisted iCBT.
16389504|NCT04053218|Active Comparator|Exercise and supplement|Supervised aerobic exercise three times weekly and daily omega-3 supplements
16389505|NCT04053218|Placebo Comparator|Placebo|Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association
16389506|NCT04053205|Experimental|1 Gentuximab+ Paclitaxel|8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
16389507|NCT04053205|Experimental|2 Gentuximab+ Paclitaxel|12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
16389508|NCT04053192||High-Gradient Aortic Stenosis (HG-AS)|(Pmean >40mmHg, AVA <1cm^2, Vmax >4m/s)
16389509|NCT04053192||Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)|(Pmean <40mmHg, AVA <1cm^2, Vmax <4m/s, EF <50%)
16389510|NCT04053192||Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)|Pmean <40mmHg, AVA <1cm^2, Vmax < 4m/s, EF >50%)
16389511|NCT04053179|Experimental|Connected patch validation|
16389512|NCT04053166|Experimental|Individualized home-based physical activity|The subjects of this arm will have a daily goal in number of steps based on the initial 2 first week evaluation of daily number of steps. They will wear connected wrists, and will be contacted twice a month by phone call by the adapted physical activity trainer to revaluate these goals.
16389513|NCT04053166|Active Comparator|Control group|The subjects of this arm will not have evaluation of daily steps and recommendations regarding physical activity and sedentary behaviour. They will be asked to live as usual.
16389514|NCT04053153|Experimental|Use of musical instrument|
16389515|NCT04053153|Sham Comparator|Use of sham musical instrument|
16389516|NCT04053140|Experimental|Routine intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.
16389517|NCT04053140|Experimental|Closed-loop control of intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
16389518|NCT04053140|Experimental|Closed-loop control of continuous infusion|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
16389519|NCT04053127|Experimental|RAVANS|Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
16389520|NCT04053127|Sham Comparator|non-RAVANS|For sessions randomized to sham stimulation, the electrodes in the ear will remain as described above, but the leads will be disconnected from the stimulator. Subjects will be instructed that for this session they may or may not feel pulsing in their ear, and that the goal is to ensure that the stimulus was not painful.
16389521|NCT04053114||Retrospective cohort|Tissue samples
16389522|NCT04053088||SAVR patients|patients undergoing surgical aortic valve replacement (SAVR) by usage of the INSPIRIS RESILIA Aortic valve™
16389523|NCT04053075|Active Comparator|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
16389524|NCT04053075|Active Comparator|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
16389525|NCT04053062|Experimental|LIGHT-PSMA-CART|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -6 to -4. Patients receive LIGH-PSMA-CART IV at split doses from day 0 on.
16389526|NCT04053049|Active Comparator|High fat/ Semi-solid|Subject will receive a high fat/semi-solid meal.
16389527|NCT04053049|Active Comparator|High carbohydrate/ Semi-solid|Subject will receive a high carbohydrate/semi-solid meal.
16389528|NCT04053049|Active Comparator|High fat/ solid|Subject will receive a high fat/solid meal.
16389529|NCT04053049|Active Comparator|High carbohydrate/ solid|Subject will receive a high carbohydrate/solid meal.
16389530|NCT04053036|Experimental|Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)
16389531|NCT04053036|Experimental|MDMA Then Placebo|Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
16389532|NCT04053023|Experimental|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
16389533|NCT04053010|Experimental|group 1|234 subjects; simultaneously administration of Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
16389534|NCT04053010|Active Comparator|group 2|234 subjects; Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
16389535|NCT04053010|Active Comparator|group 3|234 subjects; DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
16389536|NCT04052997|Experimental|Camidanlumab Tesirine|Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
16389537|NCT04052984|Experimental|Intervention group|Twenty four pares of healthy mothers-newborns, with delayed clamping and immediate skin-to-skin contact after birth by caesarean section
16389538|NCT04052984|No Intervention|Control group|Twenty four pares of healthy mothers-newborns, with early clamping without skin-to-skin contact after birth by caesarean section and newborn attended in radiant warm table
16389539|NCT04052971|Experimental|Escalation phase|"Drug: ABN401
~Route of Administration: Oral
~The study will follow a single patient cohort approach for the first 3 regular dose levels followed by classic 3+3 design. The starting dose is 50mg QD."
16389540|NCT04052971|Experimental|Expansion phase|"Drug: ABN401
~Route of Administration: Oral
~Once the MTD or highest escalation cohort has been reached, or notable efficacy has been observed at a given dose level, a decision as to RP2D will be determined. Upon the establishment of RP2D, up to 4 expansion cohorts of 10-29 patients will be recruited representing various c-Met amplification or mutant tumor types of interest."
16389541|NCT04052958|Active Comparator|Group 1: Strength Training|Respiratory muscle strength training
16389542|NCT04052958|Active Comparator|Group 2: Endurance Training|Respiratory muscle endurance training
16389543|NCT04052958|No Intervention|Group 3: Control group|no training of respiratory muscles
16389544|NCT04052945|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
16389545|NCT04052945|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
16389546|NCT04052932|Placebo Comparator|Placebo|Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks
16389547|NCT04052932|Experimental|SHR4640 dose1|SHR4640 dose1 once a day, orally, for 36 weeks
16389548|NCT04052932|Experimental|SHR4640 dose2|SHR4640 dose2 once a day, orally, for 36 weeks
16389549|NCT04052932|Active Comparator|Allopurinol|Allopurinol 300mg (milligram) once a day, Orally, for 36 week
16389584|NCT04052672|No Intervention|Randomized - Control|The control will consist of a single group educational session which will include the discussion of general advice on health, exercise and nutrition as well as open label nutritional supplement
16389748|NCT04051476|Experimental|12-g footbath|Footbath with 12g ginger flour per liter of water
16389550|NCT04052919|Experimental|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.
~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.
~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
16389551|NCT04052906|Experimental|Intervention Group|Planned Inhaler Medication Training
16389552|NCT04052906|No Intervention|Control Group|usual care
16389553|NCT04052893|Experimental|Study group|100 patients will be assigned into a study group.
16389554|NCT04052893|Active Comparator|Control group|100 patients will be assigned into a control group.
16389555|NCT04052880|Experimental|Daratumumab with dose-attenuated VRd|SubQ Daratumumab with Dose-Attenuated VRd
16389556|NCT04052867|Experimental|Lignocaine group|20 patients undergoing elective laparoscopic donor nephrectomy will be given lignocaine infusion as part of the perioperative pain management.
16389557|NCT04052867|Active Comparator|Control group|20 patients undergoing elective laparoscopic donor nephrectomy will be receiving an equivalent volume of normal saline.
16389558|NCT04052841|Experimental|MGD-thermal pulsation group|Undergo a 15-minute Lipiflow treatment lid hygiene, then receive topical eye drops for 3 months.
16389559|NCT04052841|Experimental|MGD-IPL group|Undergo 3 times intense pulsed light therapies for each 3 weeks, then receive topical eye drops for 3 months.
16389560|NCT04052841|Experimental|MGD-manual meibomian gland expression|Warm compresses and lid hygiene per day, lid massage up to four times per day for 15 minutes for 3 months. Then receive topical eye drops for 3 months.
16389561|NCT04052841|No Intervention|Normal health subject group|Normal health subject without intervention.
16389562|NCT04052828|Experimental|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
16389563|NCT04052815|Experimental|Diabetes prevention program culturally tailored|Adult females with Hispanic background
16389564|NCT04052802|Experimental|Bioactive resin (Giomer)|"This group of patients will receive a bioactive resin Beautifil flow plus X (Shofu Dental) for treatment of their demineralized fissures"
16389565|NCT04052802|Experimental|Conventional resin|"This group of patients will receive a conventional resin Filtek Z350xt Flowable composite (3M ESPE) for treatment of their demineralized fissures"
16389566|NCT04052789|Active Comparator|Zirconia single posterior crowns veneered with ceramics|'In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
16389567|NCT04052789|Experimental|BioHpp PEEK single posterior crowns veneered with compos|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
16389568|NCT04052776|Active Comparator|Buspirone|40mg
16389569|NCT04052776|Active Comparator|Levodopa-Carbidopa|400mg/100mg
16389570|NCT04052776|Active Comparator|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
16389571|NCT04052776|Placebo Comparator|Placebo|Mannitol pill
16389572|NCT04052763||High-risk ACS patients|High-risk ACS patients admitted to the emergency departement witch chest pain.
16389573|NCT04052750|No Intervention|The control group|Patients in this group only received medications without daily text message reminder
16389574|NCT04052750|Experimental|The intervention group|Patients in this group received a daily short message service (SMS) reminder when medications were prescribed
16389575|NCT04052737|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
16389576|NCT04052737|Experimental|PMZ-1620 (sovateltide)|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1 (total dose/day: 0.9 µg/kg body weight), the same dosing regimen will be repeated every month for 6 months post randomization.
16389577|NCT04052724|Experimental|Intervention group LINGI|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
16389578|NCT04052724|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
16389579|NCT04052711|Experimental|FMX-101|
16389580|NCT04052698|Experimental|All patients|Patients with type 3, type 2 (except 2N), or severe type 1 VWD aged ≥6 years at screening receiving Wilate for prophylactic treatment.
16389581|NCT04052685|Experimental|Selective removal to soft dentin (SRSD)|The patients in SRSD group will be randomized into two subgroups as Group A and Group C. After caries removal to soft dentin calcium silicate based material (Biodentine) will be applied in Group A while will not be applied in Group C prior to placement of the resin composite restoration. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel.Carious tissue at the periphery of the cavity will be prepared to hard dentin using round tungsten carbide burs and/or an excavator, while soft carious dentin will remain in the pulpal aspect of the cavity to prevent pulp exposure. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration.
16389582|NCT04052685|Active Comparator|Selective removal to firm dentin (SRSD)|Procedures will be done using local anesthesia. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel. Caries tissue in the periphery including the enamel-dentinal junction will be removed using round tungsten carbide burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries tissue will be removed until hard or leathery dentin remains. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration. Restoration will be performed after caries removal to firm dentin and placement of calcium silicate based material (Biodentine).
16389718|NCT04051684|No Intervention|No intervention|General anesthesia
16389585|NCT04052659|Experimental|Treatment (sintilimab,chidamide and azacitidine)|"Sintilimab: 200 mg IV, Q3W, d1
~Chidamid: 30 mg PO, BIW, d1, d4
~Azacidine: 100 mg SC, Q3W, d1-7"
16389586|NCT04052633||Cholangiography success|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative success of cholangiography
16389587|NCT04052633||Cholangiography failure|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative failure of cholangiography
16389588|NCT04052620|Experimental|Diclofenac diethylamine (DDEA) 2.32%/ Placebo gel|Participants will receive 4 tubes, DDEA 2.32% gel and Placebo gel (2 each) and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2). DDEA 2.32% gel will be applied in morning and late afternoon and Placebo gel will be applied in noon and late evening for 7 days.
16389589|NCT04052620|Active Comparator|DDEA 1.16% gel|Participants will receive 4 tubes of DDEA 1.16% gel and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2) in morning, noon, late afternoon, and late evening for 7 days.
16389590|NCT04052607|Experimental|Dydrogesterone Suppression|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.
16389591|NCT04052607|Experimental|Dydrogesterone Suppression with minimal stimulation|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.
16389592|NCT04052607|Active Comparator|Antagonist Suppression|cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.
16389593|NCT04052594|Experimental|LY3475766 - IV|LY3475766 administered intravenously (IV) to participants with dyslipidemia
16389594|NCT04052594|Placebo Comparator|Placebo - IV|Placebo administered IV to participants with dyslipidemia
16389595|NCT04052594|Experimental|LY3475766 - SC|LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
16389596|NCT04052594|Placebo Comparator|Placebo - SC|Placebo administered SC to participants with dyslipidemia
16389597|NCT04052581||POEM-TIF|All participants will undergo the POEM-TIF in the same session.
16389599|NCT04052555|Experimental|Treatment (berzosertib, radiation therapy)|Patients receive berzosertib IV over 60 minutes BIW for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo RT 5 days a week for 5-6 weeks depending on the type of surgery undergone.
16389600|NCT04052542|Active Comparator|Traditional online continuing education|
16389601|NCT04052542|Active Comparator|Interprofessional education|
16389602|NCT04052542|Active Comparator|Just-in-time education|
16389603|NCT04052529|Experimental|Intervention|Participants are instructed to use a popular dietary self-monitoring application on their smartphone for one month.
16389604|NCT04052529|No Intervention|Control|Participants are not asked to use the smartphone application.
16389605|NCT04052516|Placebo Comparator|Placebo|Placebo oral capsules taken one daily for 52 weeks
16389606|NCT04052516|Experimental|Icosabutate 300mg|Icosabutate 300mg oral capsule taken once daily for 52 weeks
16389607|NCT04052516|Experimental|Icosabutate 600mg|Icosabutate 600mg oral capsules taken once daily for 52 weeks
16389608|NCT04052503|Experimental|Fully Supported Group|Meetings with knowledge broker 6 times over 10 months to design and implement knowledge translation intervention. Intervention consisted of audit and feedback, goal setting, education, reminders, documentation changes, and KB support.
16389609|NCT04052503|Active Comparator|Partially Supported Group|Meetings with knowledge broker 4 times over 10 months to design and partially implement knowledge translation intervention. Group meets 2 additional times without knowledge broker to self implement intervention. Intervention consisted of audit and feedback, goal setting and documentation changes. Group self implemented education and reminders.
16389610|NCT04052490|Experimental|flat occlusal reduction with feather edge finish|
16389611|NCT04052490|Experimental|flat occlusal reduction with shoulder finish line|
16389612|NCT04052490|No Intervention|planar occlusal reduction with shoulder finish line|
16389613|NCT04052464||endometrium biopsy only|In these cases, only endometrium biopsy is investigated for the selected biomarkers gene expression profile.
16389614|NCT04052464||endometrium lavage followed by endometrium tissue biopsy|In these cases before the endometrium tissue biopsy, an endometrial lavage is performed and from both samples, the selected biomarkers gene expression profile are investigated.
16389615|NCT04052464||serial endometrium lavage followed by endometrium biopsy|In these cases before the endometrium tissue biopsy, at different days endometrial lavage samples are taken. From all samples, the selected biomarkers gene expression profile are investigated.
16389616|NCT04052451|Experimental|Major Depression Disorder|MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
16389617|NCT04052451|Experimental|Generalized Anxiety Disorder|MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured
16389618|NCT04052438||Patients with recurrent abortion.|More than three idiopathic involuntary miscarriages.
16389619|NCT04052438||Patients with implantation failure.|More than three IVF abortions with good quality embryos or more than two abortions in oocyte donation cycles.
16389620|NCT04052425|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
16389621|NCT04052425|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
16389622|NCT04052412|Experimental|NSCLC with Immunotherapy without radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
16408272|NCT03920839|Experimental|INCMGA00012 + paclitaxel/carboplatin|
16389623|NCT04052412|Experimental|NSCLC with Immunotherapy with radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy
16389624|NCT04052399|Active Comparator|Anodal tDCS|Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
16389625|NCT04052399|Active Comparator|Cathodal tDCS|Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
16389626|NCT04052399|Placebo Comparator|Sham stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
16389627|NCT04052386|Experimental|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
16389628|NCT04052386|No Intervention|Control|Participants randomized to the control group did not receive any intervention. They were an assessment-only control group.
16389629|NCT04052373|Experimental|Peri-implantitis treatment with implantoplasty|Open flap debridement with implantoplasty treatment
16389630|NCT04052373|Active Comparator|Peri-implantitis treatment without implantoplasty|Open flap debridement withput implantoplasty treatment
16389631|NCT04052360|Experimental|Cenerimod / ACT-334441|
16389632|NCT04052360|Placebo Comparator|Matching Placebo|
16389633|NCT04052347|Experimental|Shared decision-making with a patient decision-aid|
16389634|NCT04052347|Active Comparator|routine shared decision-making|control group
16389635|NCT04052334|Experimental|Infusion of Tumor-infiltrating lymphocyte|"Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB). All participants will receive not less than 10^9, and up to 1x10^12 T cells in ≥250 mL NS as an inpatient by intravenously (IV).
~Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated."
16389636|NCT04052321|Experimental|3D scan arm|This is a single arm study. Patients in this arm will receive a 3D scan just prior to, 2 weeks after, as well as 6 and 12 months after Nuss bar removal.
16389637|NCT04052308|Active Comparator|Control group|"Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team.
~They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end fo the study; The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end fo the study; Answer EQ-5D-5L at baseline and at the end fo the study."
16389638|NCT04052308|Experimental|Continuous group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill at 60% of reserve heart rate), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
16389639|NCT04052308|Experimental|Interval group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill with alternating intensity between 50% and 80%) of HR, resulting in an average load of 60% ((50% 2) + 80% 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
16389640|NCT04052282||Mobile Health App - Healthy Individuals|"Mobile health App - Test
~Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants.
~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
16389641|NCT04052269|Experimental|eyes with glaucoma|patients with glaucoma will have imaging of retina post administration of Sildenafil or Tadalafil.
16389642|NCT04052269|Other|Healthy (unaffected) eyes|patients with healthy eyes who are already taking Sildenafil or Tadalafil have their imaging of retina post administration of Sildenafil or Tadalafil.
16389643|NCT04052256||Patients with intermediate coronary lesions|Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.
16389644|NCT04052243|Other|All patients|Exercise is added to resting right heart catheterization
16389645|NCT04052217|Other|Control Ring|"Normal intercourse with very thin (less than 0.5cm) ring randomised to either 3, 4 or 5 episodes of intercourse (Phase A)"
16389646|NCT04052217|Experimental|"1 RIng"|"Intercourse wearing a 1 ring. Randomised to either 3, 4, or 5 episodes of intercourse (Phase B)"
16389647|NCT04052217|Experimental|"1.5 Ring"|"Intercourse wearing a 1.5 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase C)"
16389648|NCT04052217|Experimental|"2 Ring"|"Intercourse with a 2 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase D)"
16389649|NCT04052204|Experimental|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
16389650|NCT04052204|Experimental|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
16389651|NCT04052204|Experimental|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
16389652|NCT04052191|Experimental|Low Dose|Low Dose of MCRcI® stem cells.
16389653|NCT04052191|Experimental|Intermediate Dose|Intermediate Dose of MCRcI® stem cells.
16389654|NCT04052191|Experimental|High Dose|High Dose of MCRcI® stem cells.
16389655|NCT04052178|Active Comparator|Repetitive transcranial magnetic stimulation (rtMS)|"Acute repetitive transcranial magnetic stimulation on the pharyngeal sensory cortex. Applied intensity 90% of the resting motor threshold, 1250 pulses at 5 Hz.
~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
16389656|NCT04052178|Active Comparator|Intrapharyngeal electrical stimulation (PES)|"Intrapharyngeal electrical stimulation applied to an intensity of 75% of the tolerance threshold with 0.2 ms pulses at 5 Hz during 10 min.
~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
16389657|NCT04052178|Active Comparator|Capsaicin|"100 mL of oral capsaicin solution at a concentration of 10-5M.
~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized"
16389658|NCT04052165|Experimental|Glaucoma drainage device in glaucoma patient|GDD is inserted in glaucoma patients
16389659|NCT04052152|Experimental|Group A|"Patients in the study group will receive the following treatment:
~21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be administered until disease progressioncor un-tolerable toxicity. Anlotinib will be administered until disease progression. If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again"
16389660|NCT04052139|Active Comparator|Low-dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
16389661|NCT04052139|Active Comparator|Gabapentin|Participants randomized to the gabapentin arm begin on a dose of 300 mg daily (300 mg qd). In week 2, participants will take 300 mg of gabapentin three times daily. In week 3 the dose will be titrated up to 1800 mg daily (300 mg+300 mg tid) will remain on the dose until week 8, when they will be tapered back down to 900 mg daily (300 mg tid). In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
16389662|NCT04052139|Placebo Comparator|Placebo|Participants will receive a placebo to be taken three times daily for 8 weeks.
16389663|NCT04052126|Experimental|Individualized physical activity program|
16389664|NCT04052100|Active Comparator|Usual care|Patients following the standard preoperative policies of opur institution
16389665|NCT04052100|Experimental|Prehabilitation|Patients following the standard preoperative policies of opur institution and the multimodal prehabilitation program
16389666|NCT04052074|Experimental|Intervention group. Music in palliative patient|Listening to pre-recorded and selected music preferred by the patient, half an hour for 7 days.
16389667|NCT04052074|Sham Comparator|Palliative patient.|Basic therapeutic education repetition performed to all patients through earphones, half, an hour for 7 days.
16389668|NCT04052074|Experimental|Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
16389669|NCT04052074|Sham Comparator|Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
16389670|NCT04052061|Experimental|CD19 t-haNK|CD19 t-haNK will be administered to patients with Diffuse Large B-Cell Lymphoma who have received 2 or more lines of therapy and are ineligible for transplant.
16389672|NCT04052009|Experimental|CT - Group|The conventional training consists of gait training during walking over ground. It includes the standard interventions therapists apply during training over ground. The aim is to achieve as many steps as possible. Three training sessions per week of intensive over ground therapy are planned, and twice a week a therapy with focus of attention isn't walking.
16389673|NCT04052009|Active Comparator|EET - Group|In the end-effector-based training participants undergo gait training in the end-effector device lyra (THERA-trainer). The principle of an end-effector is that the movement is induced at the level of participants feet. Furthermore, participants wear a harness attached to the end-effector lyra for safety purpose and for weight support. Three training sessions per week of intensive over lyra therapy are planned, and twice a week a therapy with focus of attention isn't walking
16389674|NCT04052009|Active Comparator|CETcomb:|The group with the combined training receives 5 sessions of CT and EET each. The pattern of series per week is always either two sessions of CT with one session of EET or vice versa.
16389675|NCT04051996|Experimental|DAC5|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
16389676|NCT04051996|Experimental|DAC10|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
16389677|NCT04051970|Experimental|Strategy TRI-BI|
16389678|NCT04051970|Active Comparator|Strategy Immediate BI|
16389679|NCT04051957|Experimental|Isosorbide Mononitrate|
16389680|NCT04051957|Placebo Comparator|Placebo|
16389681|NCT04051944|Experimental|Rozanolixizumab|Subjects in this arm will receive predefined subcutaneous doses of rozanolixizumab at a specified frequency.
16389682|NCT04051931||stable COPD group|include COPD patients with stable state
16389683|NCT04051931||AECOPD group|include COPD patients with acute exacerbation
16389684|NCT04051918|Experimental|Socially Assistive Robot Intervention|Piano training intervention led by a semi-autonomous socially assistive robot
16389685|NCT04051918|Active Comparator|Content Only Intervention|Piano training intervention using the same curriculum displayed on a computer monitor, without the socially assistive robot tutor.
16389686|NCT04051892|Experimental|Implantation of FixNip™ NRI|Female Patients Seeking Reconstructive Surgery of the Nipple
16389687|NCT04051879||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
16389688|NCT04051879||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype.
16389689|NCT04051879||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
16389690|NCT04051866|Other|Control|Usual care (provided in Primary Health Care Centres) Oral hygiene instructions
16389691|NCT04051866|Experimental|Intervention|Usual care (provided in Primary Health Care Centres) Non-surgical periodontal treatment: Scaling and root planing (SRP) Oral hygiene instructions
16389692|NCT04051853|Experimental|Sorafenib with midazolam clearance test|"Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
16389693|NCT04051853|Experimental|Sorafenib with CYP cocktail test|"In this subgroup of 15 patients (in the Academic Medical Center Amsterdam), the midazolam test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
16389694|NCT04051840|Experimental|ClinOleic group|Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
16389695|NCT04051827|Experimental|Part A: Midazolam + TAK-788|Midazolam 3 mg, solution, orally, once on Days 1 and 24 and midazolam 1 mg, infusion, intravenously, once on Days 2 and 25 along with TAK-788 160 mg, capsule, orally, once daily from Day 3 through 30 in Cycle 1.
16389696|NCT04051827|Experimental|Part B: TAK-788|TAK-788 160 mg, capsules, orally, once daily in a 28-day treatment cycle from Cycle 2 to Cycle 24, or until progressive disease (PD), intolerable toxicity, or another discontinuation criterion is met, whichever is sooner. Eligible participants from Part A may enter into Part B. Based on the investigator's opinion, if a participant continues to experience clinical benefit, treatment with TAK-788 may be continued after PD.
16389697|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 1|
16389698|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 1|
16389699|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 2|
16389700|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 2|
16389701|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 3|
16389702|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 3|
16389703|NCT04051788|Experimental|Step Aerobics|Step Aerobics Training (120 to 126 foot steps per min)
16389704|NCT04051788|Active Comparator|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling
16389705|NCT04051762||Preterm neonates on HFNC|neonates extubated to HFNC (High flow nasal cannula)
16389706|NCT04051762||Preterm neonates on NCPAP|neonates extubated to NCPAP ( nasal continuous positive airway pressure)
16389707|NCT04051749||Patients submitted to VS|
16389708|NCT04051736|Experimental|group 1|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
16389709|NCT04051736|Active Comparator|group 2|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV
16389710|NCT04051723|Experimental|The dexamethasone plus ropivacaine group|Patients in the dexamethasone plus ropivacaine group will receive a peri-incisional scalp infiltration with 0.025% dexamethasone and 0.2% ropivacaine and normal saline miscible liquids.
16389711|NCT04051723|Active Comparator|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 0.2% ropivacaine and normal saline miscible liquids.
16389712|NCT04051710|Experimental|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
16389713|NCT04051710|Active Comparator|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
16389714|NCT04051710|Placebo Comparator|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
16389715|NCT04051697|No Intervention|Usual Care arm|Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).
16389716|NCT04051697|Experimental|Intervention arm|Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.
16389717|NCT04051684|Experimental|TAP, Bupivacaine|This group will receive general anesthesia and at the end of the operation, but still in the operating room, a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
16389719|NCT04051671|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
16389720|NCT04051671|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins (sham mode) of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
16389721|NCT04051658|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the motor area (M1) of the affected hemisphere, Cathodal on the contralateral supraorbital area. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
16389722|NCT04051658|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the supraorbital area of the affected hemisphere, Cathodal on the primary motor area (M1) of the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
16389723|NCT04051658|Experimental|Dual-tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
16389724|NCT04051658|Sham Comparator|Sham-tDCS & PT|Dual transcranial direct current stimulation (tDCS) in sham mode will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
16389725|NCT04051645|Experimental|Breathing through a system with adjustable flow resistance|During the experiment, the volunteers will breathe through ten adjustable flow resistances and their work of breathing will be measured.
16389726|NCT04051632||Type 1 Diabetes patients treated with the Medtronic 670G|Type 1 Diabetes patients treated with the Medtronic 670G at Boston Childrens Hospital
16389727|NCT04051619|Experimental|oxytocin|The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
16389728|NCT04051619|Placebo Comparator|matching placebo|The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
16389729|NCT04051606|Experimental|Regorafenib|160 mg regorafenib 3 weeks on/ one week off in participants with Avastin refractory Glioblastoma, continued until progression or toxicity. Participants will receive an MRI every 8 weeks.
16389730|NCT04051593|Experimental|Treatment|Exercise
16389731|NCT04051580|Experimental|Lactated Ringer's solution|For patients randomized to lactated Ringer's solution (study group), lactated Ringer's solution is used as a base solution for del Nido cardioplegia.
16389732|NCT04051580|Active Comparator|PlasmaLyte-A|For patients randomized to PlasmaLyte-A (control group), PlasmaLyte-A (Baxter Healthcare Corporation, Deerfield, IL, USA) is used as a base solution for del Nido cardioplegia.
16389733|NCT04051567|Experimental|LDA group|
16389734|NCT04051567|No Intervention|NC group|
16389735|NCT04051554|Experimental|Neuromuscular and Proprioceptive Training|Myklebust's training program
16389736|NCT04051554|Active Comparator|Conventional Training|Running, Sprints, Agility training, and Dynamic stretching
16389737|NCT04051541|Other|Simulation arm|All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized.
16389738|NCT04051528|Experimental|combinatorial training group|Combinatorial training group will have the same procedure with the sequential training group in the first 8 sessions. After that the procedure for sessions from 9th to 16th will be 60 minutes of guiding training.
16389739|NCT04051528|Experimental|sequential training group.|Sequential training group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of computerized cognitive training. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
16389740|NCT04051515|Experimental|Intradialysis exercise guided by nursing staff|During 16 weeks subjects will exercise during the hemodialysis session, the exercise will include both aerobic and resistance training. Guidance will be provided by nursing staff
16389741|NCT04051515|Active Comparator|Home-based exercise program|During 16 weeks subjects will exercise on their own at home. A booklet will be provided, with a diary. Instructions to do resistance exercise with intervals of walking will be provided. Initial training will be provided by physiotherapy staff from the hospital.
16389742|NCT04051502||Group 1|First group of 10 participants enrolled
16389743|NCT04051502||Group 2|Second group of 10 participants enrolled
16389744|NCT04051502||Group 3|Third group of 10 participants enrolled
16389745|NCT04051489||Mobile App|Individuals with symptomatic knee osteoarthritis
16389746|NCT04051476|Experimental|3-g footbath|Footbath with 3g ginger flour per liter of water
16389749|NCT04051476|Placebo Comparator|Warm water footbath|Footbath with warm water only
16389752|NCT04051437|Experimental|Plasma exchange|The consented patients will receive standard medical management with sessions of single volume plasma exchange with fresh frozen plasma and 5% human albumin.Plasma exchange session will be done on an alternate day to a maximum of 5 procedures.
16389753|NCT04051437|Active Comparator|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections, entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
16389754|NCT04051424|Active Comparator|ConMed bite block|Standard bite block (Conmed Bite Block; Conmed Corp., Utica NY, USA)
16389755|NCT04051424|Active Comparator|Williams Airway|Williams Airway Intubator (Williams Airway Intubator Ltd, Calgary, Canada)
16389756|NCT04051424|Experimental|McKay airway|A new device that enables maintenance of jaw thrust. (US patent application 16/098,530)
16389757|NCT04051398|Experimental|Intervention Arm (BI)|The BI participants will initially undergo simple spirometry and a 6-minute walk test and Borg scale application upon admission to the thoracic surgery department. Immediately after the exams, they will undergo a TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes. Immediately after the TENS application, the participants will be submitted to a new spirometry, a new 6-minute walk test and again to the Borg scale.
16389758|NCT04051398|Placebo Comparator|Control Arm (BC)|The BC participants will undergo the same steps as BI, however when applying TENS to these participants investigators will place the electrodes over the points without turning on the device in order to obtain the effect of a placebo.
16389759|NCT04051385|Active Comparator|stage II grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage II grade B periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
16389760|NCT04051385|Active Comparator|stage III grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage III grade B periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
16389761|NCT04051385|Active Comparator|gingivitis|"GCF and serum samples were taken before and after treatment from gingivitis patients.
~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
16389762|NCT04051385|Placebo Comparator|periodontally healthy|GCF and serum samples were taken at baseline from periodontally healthy individuals.
16389763|NCT04051372||BAL group|"Adult patients with hematology disease under allo-HSCT at any phase of treatment are enrolled according to the following criteria:
~lung infiltration detection at computed tomography (CT) scan.
~Patients with fever, cough, respiratory symptoms. According to the investigators, the patients fulfilling these criteria undergo BAL as soon as possible"
16389764|NCT04051359|Active Comparator|Standard carbohydrate (200 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
16389765|NCT04051359|Experimental|Low carbohydrate (130 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the low carbohydrate (130 g) group.
16389766|NCT04051346|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
16389767|NCT04051346|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
16389768|NCT04051320|Experimental|Women with a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
16389769|NCT04051320|Experimental|Women without a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
16389770|NCT04051307|Experimental|intervention|"Vaccination with:
~PD-L1 peptide:
~PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL Dose: 100 µg PD-L1 long1 dissolved in DMSO/water - Total volume: 0,5 ml.
~Arginase1 peptide:
~ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL Dose: 200 µg ARGLong2 dissolved in DMSO/water - Total volume: 0,5 ml.
~Both vaccines are given at a treatment. Adjuvant Montanide ISA 51 0,5ml is mixed with the peptides before treatment To be administered every second week - a total of twelve times, with a possibility of additional six treatments."
16389771|NCT04051294|Experimental|Intervention group 1: commercial kombucha|8oz
16389772|NCT04051294|Experimental|Intervention group 2: brewed kombucha|8oz
16389773|NCT04051294|Active Comparator|Control group 1: tea|8oz
16389774|NCT04051294|Placebo Comparator|Control group 2: water|8oz
16389775|NCT04051281|No Intervention|Just under target control|Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.
16389797|NCT04051190|Experimental|Sleeve Gastrectomy group|Participants will undergo standard clinical practice prior to surgery.
16389776|NCT04051281|Experimental|Just under target letter|"Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
16389777|NCT04051281|No Intervention|Over target control|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent
~Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)
~Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)"
16389778|NCT04051281|Experimental|Over target letter|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
16389779|NCT04051281|Experimental|Over target letter with bar chart|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
16389780|NCT04051281|Active Comparator|Top 20% feedback letter control|"Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
16389781|NCT04051281|Experimental|Top 20% above target letter|"Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
16389782|NCT04051281|Experimental|Top 20% feedback letter with specific example of patient harm|"Targeting practices that are currently in the top 20% of prescribers
~• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
16389783|NCT04051268|Experimental|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
16389784|NCT04051268|Experimental|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
16389785|NCT04051268|Experimental|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
16389786|NCT04051268|Active Comparator|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
16389787|NCT04051268|Active Comparator|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
16389788|NCT04051255|Experimental|Smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgingival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients has prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
16389789|NCT04051255|Experimental|Non-smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
16389790|NCT04051242|Experimental|XenMatrix AB Surgical Graft|This study proposes to use XenMatrix™ AB Surgical Graft which has 510(k) approval [#K162193] intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue. This trial proposes to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after trauma
16389792|NCT04051216|Experimental|Supportive Care|Caregivers receive the Roadmap information system loaded on an Apple iPad® for use during the inpatient hospitalization of CART therapy. The Roadmap information system consists of 5 modules personalized to the CART patient: laboratory studies, medications, clinical trial enrollment, healthcare providers, and criteria for discharge. Patients wear an activity monitoring device on days 0-100. Patients wear the device as long as they can each day to monitor physical activity level, sleep/wake patterns, skin temperature, heart rate and respiratory rate.
16389793|NCT04051203|Experimental|Autologous Platelet Rich Plasma Injection|PRP contains high concentrations of platelets, growth factors, and anti-inflammatory molecules.
16389794|NCT04051203|Active Comparator|Standard Treatment|Steroid and anesthetic injection: the clinical standard.
16389795|NCT04051203|Placebo Comparator|Normal Saline|Placebo injection, with no known treatment effects.
16389796|NCT04051190|Experimental|VLED group|Participants will undergo a 10-week VLED.
16389798|NCT04051190|Experimental|Gatric Bypass group|Participants will undergo standard clinical practice prior to surgery.
16389799|NCT04051177|Experimental|parents living with HIV intervention group|Parents living with HIV in this group received five two-hour parent HIV disclosure intervention, delivered one session per week for five weeks in the clinics where the parents are recruited. The intervention curriculum is modeled after the TRACK program with supplemental materials from TALC.
16389800|NCT04051177|Other|Parents living with HIV control group|"Parents living with HIV in this group received five two-hour nutrition education curriculum in same delivery way. The nutrition curriculum is modeled after the Simply Good Eating: curriculum developed at University of Minnesota."
16389801|NCT04051164|Experimental|Progressive Muscle Relaxation Technique|Progressive muscle relaxation technique
16389802|NCT04051164|Active Comparator|Conventional treatment|Conventional Treatment: (Strengthening exercises of residual limb, Gait training, Deep Breathing exercise)
16389803|NCT04051151|Experimental|Gameification Arm|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game.
16389804|NCT04051151|No Intervention|Education Arm|Participants and partners that randomized to the control group will receive standard of care educational resources on the importance of physical activity in Parkinson's patients.
16389805|NCT04051112|Experimental|SCB-313|
16389806|NCT04051099|Experimental|bilateral cervical plexus block|bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 0.25% bupivacaine 16 mg)
16389807|NCT04051099|Experimental|General anesthesia|General anesthesia with endotracheal intubation under total intravenous anesthesia (TIVA)
16389808|NCT04051086|Other|Williams Beuren|Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
16389809|NCT04051086|Other|Micro-duplication 7q11.23|Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
16389810|NCT04051086|Other|Healthy Group|Subjects without cardiovascular and neurological medical history.
16389811|NCT04051073|Sham Comparator|Blinded|CNAP monitoring applied, but screen and information not visible to treating anaesthetist
16389812|NCT04051073|Active Comparator|Unblinded|CNAP monitoring applied and available in full to the treating anaesthetist
16389813|NCT04051060||Patients with Bronchial Asthma|
16389814|NCT04051060||Healthy individuals|
16389815|NCT04051047|Experimental|Gemcitabine|Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure. The surgical procedure is standard of care.
16389816|NCT04051034|Experimental|Omega 3 supplementation|12 weeks: Active: 1.25 g capsules/ [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
16389817|NCT04051034|Experimental|Placebo|12 weeks: Placebo: 1.25 g capsules/ [1.25-gram high oleic safflower oil capsule]with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
16389818|NCT04051021|Other|Usual Care|
16389819|NCT04051021|Experimental|Comfort Coach|
16389820|NCT04051008|No Intervention|Group 1 - Control|No intervention - participants will shop in-person as they usually would. Participants will receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
16389821|NCT04051008|Experimental|Group 2 - Online|Participants will utilize online grocery shopping (shopping at a local grocery store via an online platform). Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
16389822|NCT04051008|Experimental|Group 3 - Default|The default intervention will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make recipes from the provided recipe cards, and that they can modify it as they like. Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
16389823|NCT04050982|Experimental|AF CARE|Patients will interface with digital application.
16389824|NCT04050982|Active Comparator|Usual Care and Daily Weight|Usual care with daily weight entry
16389825|NCT04050969|Active Comparator|Atrial Fibrillation (AF) Catheter Ablation-Group A|Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
16389826|NCT04050969|Experimental|Bariatric surgery prior to AF Catheter Ablation-Group B|"Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.
~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation."
16389827|NCT04050956||Myocardial infarction|As it is an observational study, no intervention is planned. However, nested clinical interventional trials are planned for which a specific registration will be done
16389828|NCT04050943||CRD patients|Patients with chronic pulmonary disease like COPD, asthma, bronchiectasis, and etc.
16389829|NCT04050930|Experimental|Normal weight, normo-dented|healthy young male presenting a good oral health ad a normal weight
16389830|NCT04050930|Experimental|Obese, normo-dented|healthy young male presenting a first level of obesity, and a good oral health
16389831|NCT04050917|Experimental|Real stimulation|The smartwatch produces vibration stimulation.
16389832|NCT04050917|Sham Comparator|No stimulation|The smartwatch produces no vibration.
16389833|NCT04050904|Experimental|ExpHeart|The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
16389863|NCT04050696|Experimental|Treatment (with PT run-in)|Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
16390325|NCT04047537|Other|Placebo|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
16389834|NCT04050891|No Intervention|group GA (general anesthesia)|"After pre-oxygenation general anesthesia was induced using 2mg/kg propofol, 1μg/kg of fentanyl. After loss of consciousness 0.5 mg/kg of atracurium was injected. The endotracheal tube (ETT) was placed and inflated. The patient was mechanically ventilated to adjust end tidal CO2 between 35 and 40mmHg, anesthesia was maintained using 1.2 % isoflurane diluted in 3L of 50 % oxygen mixed with air. Increments of fentanyl (0.5 μg/kg ) and atracurium 10 mg were used whenever required and the hemodynamic values were maintained within 20% of the basal values.
~At the end of surgery, residual muscle relaxant was reversed with 50µg/kg neostigmine and 0.02 mg/kg atropine."
16389835|NCT04050891|Active Comparator|group RA (regional anesthesia)|received combined supraclavicular and interscalene block.The mixture of anesthetic suolution was prepared by 20 ml isobaric bupivacaine 0.5% plus 10ml lidocaine 2% plus 10ml normal saline, total volume was 40ml which is devided into 25ml for suraclavicular block and 15ml for intersalene block
16389836|NCT04050878|Experimental|Patient with or without dental prostheses|The patient will be submitted to two facial scans, one with and another without the dental prostheses and the obtained datasets will be compared to assess the differences. Marks will be made in the face to allow for measurements (digital and conventional)
16389837|NCT04050865|Experimental|OTX-DP|
16389838|NCT04050865|Placebo Comparator|Placebo|
16389839|NCT04050852|Experimental|SMA patients receiving nusinersen treatments|
16389840|NCT04050839|Experimental|Neuroscience pain education group|Pain neuroscience education in addition medical treatment
16389841|NCT04050839|Active Comparator|Control group|Medical treatment only
16389842|NCT04050826|Experimental|Dermal Pharmacokinetic study|"Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dOFM after topical application of three lidocaine/prilocaine products in 20 participants.
~After baseline sampling (1 hour pre-dose) the three lidocaine/prilocaine products will be applied and removed after 3 hours. ISF and blood sampling will be continued for a duration of 12 hours post-dose. Additionally different physical parameters (e.g. TEWL) will be measured."
16389843|NCT04050813|Experimental|Control|"The program is performed 2 times per week using resistance equipment in a physiotherapy clinic. Each session consists of on 2-legged loaded exercises for hamstring, quadriceps, gluteus maximun and core. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 4 exercises.
~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 set of 12-repetition maximum (12RM), in week 1 and 2; 3 set of 10 RM, in week 3 and 4; 4 set of 10RM, in weeks 5 and 6; and 4 set of 8RM, in weeks 7 to 8."
16389844|NCT04050813|Experimental|Intervention|Experimental: Inertial flywheel resistance training The program is performed 2 times per week using resistance equipment in a physiotherapy clinical. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 16 repetition maximum (RM) with moment inertia 0.05 m² from week 1-2, 24 repetition maximum (RM) with moment inertia = 0.10 m² from week 3 to 4. 32 repetition maximum (RM) with moment inertia = 0.10 m² from week 5 to 6 and 32 repetition maximum (RM) with moment inertia = 0.13 m² in a flywheel hamstring curl devise.
16389845|NCT04050800|Experimental|Healthy Controls|Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
16389846|NCT04050787|Experimental|D2 Lymphadenectomy including No. 10|lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
16389847|NCT04050787|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy but without No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
16389848|NCT04050774|Experimental|Age group 1|6-9 years old
16389849|NCT04050774|Experimental|Age group 2|15-17 years old
16389850|NCT04050774|Experimental|Age group 3|18 - 24 years old
16389851|NCT04050774|Experimental|Age group 4|65-80 years old
16389852|NCT04050761||Monotherapy|Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.
16389853|NCT04050748|Placebo Comparator|Early Rehabiliation|6 weeks of non-weight bearing in addition to basic stretching exercises.
16389854|NCT04050748|Active Comparator|Accelerated Rehabilitation|Patients will be non-weight bearing for 2 weeks. After 2 weeks patients were transitioned to a boot with two heel wedges and were weight bearing as tolerated. At 4 weeks, patients were transitioned to one wedge, and at 6 weeks patients were weight bearing as tolerated in a flat shoe. Each heel wedge was ¾ inch tall. After 6 weeks, patient's in both groups underwent identical rehab regimens per protocol
16389855|NCT04050735|Experimental|Alcohol, ethyl, moderate dose|0.6 gram ethyl alcohol per kilogram of body weight
16389856|NCT04050735|Placebo Comparator|Placebo|0 gram ethyl alcohol per kilogram of body weight
16389857|NCT04050722|Experimental|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent [%] of stannous fluoride] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
16389858|NCT04050722|Other|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
16389859|NCT04050709|Experimental|PD-L1 t-haNK Dose Level 1|PD-L1 t-haNK will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 1 is 3 to 6.
16389860|NCT04050709|Experimental|PD-L1 t-hanK Dose Level 2|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 2 is 3 to 6.
16389861|NCT04050709|Experimental|PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into RP2D is 4.
16389862|NCT04050709|Experimental|PD-L1 t-haNk Dose -1a (if needed)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level -1a is 3 to six, if needed.
16389864|NCT04050683|Experimental|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Right Atrial Pressure (RAP) ≥ 15mmHg or change in RAP ≥ 10 mmHg or Peak Systolic Right Ventricular (PSRV) Pressure ≥ 46 mmHg
16389865|NCT04050683|Active Comparator|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Normal hemodynamic parameters
16389866|NCT04050670|Experimental|Tirzepatide - Upper Arm|Tirzepatide administered subcutaneously (SC) to the upper arm of healthy participants in one of three study periods.
16389867|NCT04050670|Experimental|Tirzepatide - Thigh|Tirzepatide administered SC to the thigh of healthy participants in one of three study periods.
16389868|NCT04050670|Active Comparator|Tirzepatide - Abdomen|Tirzepatide administered SC to the abdomen of healthy participants in one of three study periods.
16389869|NCT04050657|Experimental|Two-week appointment interval group|Orthodontic patients who come to tighten their braces every 2-weeks.
16389870|NCT04050657|Other|Eight-week appointment interval group|Orthodontic patients who come to tighten their braces every every 8-weeks.
16389871|NCT04050644|Experimental|Preservative-free dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preservative-free dexamethasone 0.1% and diclofenac 0.1% eye drops.
16389872|NCT04050644|Active Comparator|Preserved dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preserved dexamethasone 0.1% and diclofenac 0.1% eye drops.
16389873|NCT04050631||L&D team|the first responders on L&D floor including : anesthesia, nurses and OBGYN
16389874|NCT04050618|Experimental|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
16389875|NCT04050618|Experimental|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
16389876|NCT04050605|Experimental|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
16389877|NCT04050592|Other|Group A, Abrupt Discontinuation|Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
16389878|NCT04050592|Other|Group B, Tapered Discontinuation|"Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows:
~weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days.
~weeks 10-20: placebo"
16389879|NCT04050592|Active Comparator|Group C, Control Group|Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.
16389880|NCT04050579|Other|OPIE in thin inverventricular septum|The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.
16389881|NCT04050566||Mothers|900 mothers recruited during pregnancy
16389882|NCT04050566||Children|900 children born to the recruited mothers
16389883|NCT04050553|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) in one of two study periods.
16389884|NCT04050553|Placebo Comparator|Placebo|Placebo administered SC in one of two study periods.
16389885|NCT04050540|Experimental|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
16389886|NCT04050540|No Intervention|Standard of Care Arm|Participants assigned to Standard of Care
16389887|NCT04050514|Experimental|H-MAD, hinge system according to Herbst|"Patients with snoring and OSAS. Therapy with MAD type H-MAD with lateral hinges according to Herbst.
~Bite elevation 2 mm interocclusal distance with a lower jaw advancement of 5 mm"
16389888|NCT04050514|Active Comparator|F-MAD, SomnoDent Fusion|Patients with snoring and OSAS,Fusion MAD with sliding side wings (F-MAD). Bite elevation 5 mm interocclusal distance with a lower jaw advancement of 5 mm
16389889|NCT04050501|Active Comparator|non-invasive Vagus Nerve Stimulation|non-invasive Vagus Nerve Stimulation on top of best medical practice
16389890|NCT04050501|No Intervention|Standard Care|Best medical practice alone
16389891|NCT04050488|Active Comparator|Treatment Group|Participants who receive the intervention.
16389892|NCT04050488|Placebo Comparator|Control Group|Participants who receive the placebo.
16389893|NCT04050475|Experimental|PSY-FMD|Subjects randomized in the PSY-FMD group carried out the Functional Therapy protocol over 20 individual sessions, which were scheduled twice a week for the first two months and once a week for the last month (three months total). The treatment program was specifically manualized for treating depression with the aim to increase mood, self-esteem and quality of life. Furthermore, patients followed a Fasting Mimicking Diet (FMD) protocol consisting of 3 cycles of 5 days a month each: the first day of the diet provided 1090 kcal (10% protein, 56% fat, 34% carbohydrate), the days 2-5 were identical in the formulation and provided 725 kcal (9-10% protein, 44-56% fat, 34-47% carbohydrate). Between cycles of FMD the subjects stuck to a free diet. At the end of the treatment all patients were re-tested through the same assessment protocol and the same things was realized at the follow-up (three months later the end of the treatment).
16389894|NCT04050475|No Intervention|PSY|Subjects randomized into the control group (PSY) completed the same Functional Therapy program without practicing any diet. Specifically, at the end of the nutritional consultation the nutritionist suggested them to keep a food diary without changing their habitual diet style.
16389895|NCT04050462|Active Comparator|Nivolumab Monotherapy|
16389896|NCT04050462|Experimental|Nivolumab/BMS-986253 combination|
16389897|NCT04050462|Experimental|Nivolumab/Cabiralizumab combination|
16389898|NCT04050449||Group 1: Switch to TLD from NNRTI first-line regimen|Participants switching to TLD from a first-line regimen containing a NNRTI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 1a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 1b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
16389939|NCT04050189|Active Comparator|postnatal probiotic|will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery
16389975|NCT04049916|Active Comparator|Pyronaridine-artesunate (PA)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days.
16389899|NCT04050449||Group 2: Switch to TLD from boosted PI second-line regimen|Participants switching to TLD from a second-line regimen containing a boosted PI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 2a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 2b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
16389900|NCT04050449||Group 3: Concomitant TLD and RIF-containing TB treatment|Participants initiating concomitant TLD and RIF-containing TB treatment, with an additional daily dose of dolutegravir (DTG) 50mg. For participants already on RIF-containing TB treatment when TLD treatment is started, TLD treatment must be started within 8 weeks (56 days) of the start of RIF-containing TB treatment. Group 1, 2, or 4 participants who start RIF-containing TB treatment after enrollment will have additional evaluations at the start and end of concomitant HIV and TB treatment but will not be co-enrolled in Group 3 (their additional evaluations will, however, be considered when analyzing data from Group 3).
16389901|NCT04050449||Group 4: ART-naive initiating TLD therapy|Antiretroviral therapy (ART)-naïve participants initiating therapy with TLD
16389904|NCT04050423||Breast Characterization|
16389905|NCT04050410|Experimental|Moxonidine|Patients will receive a single oral dose of moxonidine 0.4 mg.
16389906|NCT04050410|Placebo Comparator|Placebo|Patients will receive a single oral dose of placebo.
16389907|NCT04050397|Experimental|Supervised exercise arm|Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.
16389908|NCT04050397|Active Comparator|Non-supervised exercise arm|Informational initiation lecture and only non-supervised exercise
16389909|NCT04050384|No Intervention|No vibratory stimulus before or during heel lance|Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
16389910|NCT04050384|Experimental|Vibratory stimulus before and during heel lance|Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.
16389911|NCT04050371|Experimental|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
16389912|NCT04050358|Active Comparator|1X dose of NRPT|
16389913|NCT04050358|Placebo Comparator|Placebo|
16389914|NCT04050345||Colon|Patients who have a diagnosis of large bowel cancer (in the colon) and the cancer is not metastatic.
16389915|NCT04050345||Rectal|Patients who have a diagnosis of large bowel cancer (in the Rectum) and the cancer is not metastatic.
16389916|NCT04050332|Experimental|Stair Walking|Participants in this arm will engage in four minutes of stair walking while being tracked by radio frequency identification equipment.
16389917|NCT04050332|No Intervention|Control|Participants in this arm will stand in the stairwell for four minutes while being tracked by radio frequency identification equipment.
16389918|NCT04050306||Adolescents and young adults|Participants 12-19 years old without chronic diseases.
16389919|NCT04050293|Experimental|SPN-538|Patients will be treated with SPN-538 as a single dose once a day
16389920|NCT04050293|Placebo Comparator|Placebo|Patients will be treated with Placebo once a day
16389921|NCT04050280|Experimental|CLAG-GO|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
16389922|NCT04050267|Placebo Comparator|Control group - air|Breathing air with 21 % of oxygen (0% nitrous oxide). Performing cognitive tests as per protocol.
16389923|NCT04050267|Experimental|Intervention Group - 5% nitrous oxide|Breathing 5% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
16389924|NCT04050267|Experimental|Intervention Group - 7% nitrous oxide|Breathing 7% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
16389925|NCT04050267|Experimental|Intervention Group - 10% nitrous oxide|Breathing 10% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
16389926|NCT04050267|Experimental|Intervention Group - 12% nitrous oxide|Breathing 12% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
16389927|NCT04050267|Experimental|Intervention Group - 15% nitrous oxide|Breathing 15% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
16389928|NCT04050267|Experimental|Intervention Group - 20% nitrous oxide|Breathing 20% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
16389929|NCT04050254|Experimental|Real tDCS + exercise|Transcranial direct current stimulation combined with therapeutic exercise
16389930|NCT04050254|Sham Comparator|Sham tDCS + exercise|Sham transcranial direct current stimulation combined with therapeutic exercise
16389931|NCT04050254|No Intervention|Control|No treatment.
16389932|NCT04050241|Experimental|Videolaryngoscope|Anesthetists performing intubation with the Glidescope videolaryngoscope.
16389933|NCT04050241|Experimental|Direct laryngoscope|Anesthetists performing intubation with the Mcintosh laryngoscope.
16389934|NCT04050228|No Intervention|Standard Neoadjuvant Chemotherapy Monitoring|
16389935|NCT04050228|Experimental|Adaptive Chemotherapy Monitoring|
16389936|NCT04050215|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 3 hours. Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent management decision.
16389937|NCT04050202|Experimental|ABC|ABC delivers therapy through 10, home-based, in-person sessions led by a trained professional. Treatment content is based on attachment theory and an understanding of children's stress neurobiology. Components aim to improve parental sensitivity, nurturance, and responsivity, as well as children's biological and behavioral reactivity through dyadic interactions between parents and children.
16389938|NCT04050189|Active Comparator|prenatal probiotic|will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery
16389940|NCT04050176|Experimental|Blinded Hypnotic Medication Taper (BT)|Participants assigned to the Blinded Taper group will not know the medication dose they receive during the Structured Medication Taper (SMT) phase.
16389941|NCT04050176|Active Comparator|Open-Label Hypnotic Medication Taper (OLT)|Participants assigned to the Open-Label Hypnotic Medication Taper group will know the medication dose they receive during the SMT phase.
16389942|NCT04050163|Experimental|Low Dose|
16389943|NCT04050163|Experimental|Intermediate Dose|
16389944|NCT04050163|Experimental|High Dose|
16389945|NCT04050150|Experimental|Arm Training in Standing|Task-oriented, functional arm training completed in standing or during walking. All participants receive the same arm training intervention.
16389946|NCT04050137|Experimental|Exercise group|Exercise programme 3 times/week.
16389947|NCT04050124|Experimental|Promogran Prisma|Following standard of care split thickness skin grafting, patients randomized to the intervention group will receive Promogan Prisma as the primary contact dressing at the donor grafting site.
16389948|NCT04050124|Active Comparator|Standard of care (SOC) dressings|
16389949|NCT04050111|Experimental|SVF injection|"Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
~Interventions:
~Procedure: Liposuction Other: SVF isolation Other: Intraarticular administration of autologous SVF"
16389950|NCT04050098|Active Comparator|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
16389951|NCT04050098|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
16389952|NCT04050085|Experimental|Treatment (SD-101, radiation therapy, nivolumab)|Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
16389953|NCT04050072||Childhood Cancer Survivors (CCSS)|i. PRO-CTCAE-SCC ii.Quality of life assessment
16389954|NCT04050072||St. Jude Life (SJLIFE)|i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
16389955|NCT04050072||Community non-cancer control|i. PRO-CTCAE-SCC ii.Quality of life assessment
16389956|NCT04050059|Active Comparator|2% Lidocaine group|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited) skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal anesthesia induction.
16389957|NCT04050059|Active Comparator|EMLA cream group|In EMLA (Eutectic Mixture of Local Anesthesia- lidocaine 2.5% and prilocaine 2.5%) cream group, EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
16389958|NCT04050046|Active Comparator|Real tDCS + CBCT|20 minutes of 2.0mA of tDCS for 5 consecutive days
16389959|NCT04050046|Sham Comparator|Sham + CBCT|Sham stimulation closely imitates reals tDCS 30 second ramp-up / ramp-down
16389960|NCT04050033|Experimental|Treatment Arm|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).
16389961|NCT04050020|Active Comparator|Group A|
16389962|NCT04050020|Placebo Comparator|Group B|
16389963|NCT04050007|Experimental|1|Preventive initiation of fluid removal
16389964|NCT04050007|Other|2|Curative initiation of fluid removal
16389965|NCT04049994|Experimental|Immunomodulation|Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
16389966|NCT04049994|Placebo Comparator|Placebo|Oral placebo tablet once daily for 90 days.
16389967|NCT04049981|Experimental|Facial Engagement|This group will receive a version of Superpower Glass that targets specific areas of social deficits associated with autism.
16389968|NCT04049981|Experimental|Emotion Recognition|This group will receive a version of Superpower Glass that targets different areas of social deficits associated with autism.
16389969|NCT04049968|Experimental|Experimental group|Patients in the experimental group were individually assessed by a mobile health application (APP).
16389970|NCT04049968|Active Comparator|Control group|Patients in the control group were individually assessed by a traditional routine health care and instruction.
16389971|NCT04049955|Experimental|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
16389972|NCT04049942|Experimental|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
16389973|NCT04049942|Experimental|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
16389974|NCT04049929|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
16390241|NCT04048083|Active Comparator|Healthy-controls|9 Healthy, age and gender-matched subjects, without any kind of training
16389976|NCT04049916|Experimental|PA with single low dose primaquine (PQ)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
16389977|NCT04049916|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days.
16389978|NCT04049916|Active Comparator|DP with single low dose primaquine (PQ)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
16389979|NCT04049903|Experimental|MP0310 (AMG 506) Part A|Enrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD or unacceptable toxicity is reached. Up to 12 additional patients in total may be included at selected dose levels (up to 3).
16389980|NCT04049903|Experimental|MP0310 (AMG 506) Part B|weekly schedule, at least 3 and up to 24 patients evaluable for DLT assessment will be enrolled (1 to 4 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
16389981|NCT04049903|Experimental|MP0310 (AMG 506) Part C|q3w schedule implementing B-cell depletion, at least 3 and up to 12 patients evaluable for DLT assessment will be enrolled (1 to 2 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
16389982|NCT04049890||Parents of children with a chronic disease with no siblings|Parents of children suffering from a chronic disease who has no brother or sister over 3 years of age
16389983|NCT04049890||Parents of children with a chronic disease with siblings|Parents of children suffering from a chronic disease who one or more sibling over the age of 3 years old
16389984|NCT04049864|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
16389985|NCT04049851|Experimental|Moxidectin|
16389986|NCT04049851|Active Comparator|Ivermectin|
16389987|NCT04049838|Active Comparator|lateral transversus abdominis block|patients will take lateral transversus abdominis plan block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
16389988|NCT04049838|Active Comparator|posterior tansversus abodominis plane block|patients will take posterior transversus abdominis plane block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
16389989|NCT04049838|Active Comparator|convential analgesia|conventional analgesia in form of 1 micrograms. Kg-1 fentanyl and paracetamol 15 mg. Kg-1 suppositories
16389992|NCT04049812|Active Comparator|Pulsed electromagnetic field (PEMF) treatment Group|Group received routine hot pack, Transcutaneous electrical nerve stimulation (TENS) and PEMF treatment.
16389993|NCT04049812|Sham Comparator|Sham PEMF treatment Group|Group received routine hot pack, TENS and sham PEMF treatment.
16389994|NCT04049799||Medically-supervised withdrawal (MSW)|
16389995|NCT04049799||Opioid agonist treatment (OAT)|
16389996|NCT04049786|Experimental|Simvastatin Study|Adult patients (18-60 years old) with body mass index ≥ 35 kg/mˆ2 who have indication for bariatric surgery and do not use simvastatin are being recruited. All patients are being submitted to 3 steps: before, 4-6 months and 10-12 months after surgery. In all steps, patients are receiving oral single dose of simvastatin (40 mg). Serial blood sampling are being collected up to 24 hours after drug administration for pharmacokinetic study. The phenotype for cytochrome P450 (CYP) 3A4 phenotype is being evaluated using midazolam as probe. CYP3A4 and P-glycoprotein expression (mRNA) are being assessed in intestinal biopsies before (step 1), during and after surgery (step 3). Blood sample are being collected for DNA extraction (step 1). Patients are being genotyped for polymorphisms on genes SLCO1B1 (521 C>T) and ABCB1 (1236C>T, 2677nonG and 3435C>T).
16389997|NCT04049786|Experimental|Carvedilol Study|Adult patients (18-60 years old) with body mass index ≥ 35 kg/mˆ2 who have indication for bariatric surgery and do not use carvedilol are being recruited. All patients are being submitted to 3 steps: before, 4-6 months and 10-12 months after surgery. In all steps, patients are receiving oral single dose of carvedilol (25 mg). Serial blood sampling are being collected up to 24 hours after drug administration for pharmacokinetic study. Cytochrome P450 (CYP) 3A4 and CYP2D6 phenotypes are being evaluated using midazolam and metoprolol as probes. CYP3A4 and P-glycoprotein expression (mRNA) are being assessed in intestinal biopsies before (step 1), during and after surgery (step 3). Blood sample are being collected for DNA extraction (step 1). Patients are being genotyped for polymorphisms on genes CYP2C9 (432 C>T, 1075A>C) and ABCB1 (1236C>T, 2677nonG and 3435C>T ).
16389998|NCT04049760|Experimental|migalastat HCl 150 mg|One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
16389999|NCT04049747|Experimental|CHRONOS A - Arm 1 (Control)|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]). In patients undergoing radiotherapy a maximum of 6-months neo-adjuvant hormonal therapy will be allowed. In patients undergoing radical prostatectomy, cytoreduction of maximum 6 months with medication will be permissible, provided this is part of local practice.
16390000|NCT04049747|Experimental|CHRONOS A - Arm 2 (Intervention)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second focal therapy session in-field, or a first focal therapy session to an out-of-field progressive or de novo lesion will be allowed as part of the focal therapy intervention.
16390001|NCT04049747|Experimental|CHRONOS B - Arm 3 (Control)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second treatment in-field, or a first focal ablation to an out-of-field progressive or de novo lesion will be allowed but will be regarded as failure events for the purpose of CHRONOS-B.
16390002|NCT04049747|Experimental|CHRONOS B - Arm 4 (Intervention):|Neoadjuvant finasteride 5mg once daily for a minimum of 12 weeks followed by focal therapy (as per CHRONOS B control arm).
16390003|NCT04049747|Experimental|CHRONOS B - Arm 5 (Intervention)|Neoadjuvant bicalutamide 50mg once daily therapy for a minimum of 12 weeks followed by focal therapy (as per control arm).
16390004|NCT04049734|Active Comparator|patients received the oral losartan|50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
16390005|NCT04049734|No Intervention|patients didn't receive the oral losartan|50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs
16390006|NCT04049721|Active Comparator|Standard of Care without HBO|Intravenous access and fluid resuscitation (standard of care treatment)
16390007|NCT04049721|Experimental|HBO + Standard of Care|Ten daily treatment sessions of HBO at 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks
16390008|NCT04049695|Experimental|Exercise Intervention|This arm will receive a 12-month individually tailored phone and email-based exercise program.
16390009|NCT04049695|Active Comparator|Health & Wellness Intervention|This arm will receive a 12-month health and wellness program.
16390010|NCT04049682||Pre Time-change|Daily activity, sleep duration, subjective sleepiness, and response time before change in school start time
16390011|NCT04049682||Post Time-change|Daily activity, sleep duration, subjective sleepiness, and response time after change in school start time
16390012|NCT04049669|Experimental|Core Regimen, sub-cohort A|For patients not eligible for re-irradiation; Start with Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
16390013|NCT04049669|Experimental|Core Regimen, sub-cohort B|For patients who are eligible for partial re-irradiation; Start with indoximod plus up-front re-irradiation, using a palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
16390014|NCT04049669|Experimental|Core Regimen, sub-cohort C|For patients who are eligible for full-dose radiation; (All newly diagnosed DIPG patients and some relapsed ependymoma patients); Start with indoximod plus up-front radiation, using a palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
16390015|NCT04049669|Experimental|Salvage Regimen 1|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral metronomic cyclophosphamide and etoposide).
16390016|NCT04049669|Experimental|Salvage Regimen 2|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral lomustine and temozolomide).
16390017|NCT04049656|Experimental|HFVI intervention group|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
16390018|NCT04049656|No Intervention|Standard of Care Group|Subjects receiving a balanced maintenance anesthetic consisting primarily of a sevoflurane hypnotic (titrated to a BIS range of 40-60) and fentanyl analgesia. Subjects randomized to the control group (Standard Practice) will have analgesia administered as needed according to standard clinical monitoring and practice requirements based on the judgment of the clinician responsible for the case. The HFVI monitor will be applied, but the display will be masked in this control group population.
16390019|NCT04049643|Active Comparator|Audiologist-Based|In this group, the audiologist-based fitting will be used to provide hearing aids.
16390020|NCT04049643|Experimental|Service-Only|In this group, hearing aids that have minimum amplification will be fitted by audiologists.
16390021|NCT04049643|Experimental|Device-Only|In this group, hearing aids will be provided with minimum services from audiologists.
16390022|NCT04049630|Experimental|LEV 1 mg/kg|Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
16390023|NCT04049630|Experimental|LEV 1,5 mg/kg|Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
16390024|NCT04049630|Experimental|LEV 2,5 mg/kg|Tablet of LEV at 2,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
16390025|NCT04049630|Placebo Comparator|Placebo|Tablets of placebo will be administrated to the participant in single dose only one time.
16390026|NCT04049617|Experimental|GS-4224|"Dose Escalation (Phase 1b):
~Participants will be sequentially enrolled in a dose escalation design to receive GS-4224 starting at 400 mg once a day (QD). Subsequent doses of 700 mg QD, 1000 mg QD, 1500 mg QD, and 1000 mg twice a day (BID) are planned based on the safety and tolerability of each dose level.
~Dose Expansion (Phase 2):
~Dose expansion will begin when the RP2D has been determined."
16390027|NCT04049604||1/Cohort 1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
16390028|NCT04049604||2/Cohort 2|Women undergoing active treatment or surveillance for known malignancy
16390029|NCT04049591|Active Comparator|Higher Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
16390030|NCT04049591|Active Comparator|Lower Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
16390031|NCT04049578|Experimental|Balovaptan|
16390032|NCT04049565||Procalcitonin|septic patients who will receive Procalcitonin
16390033|NCT04049565||C-Reactive Protein|septic patients who will receive C-Reactive ptotein
16390034|NCT04049552|Experimental|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
16390035|NCT04049552|Placebo Comparator|Placebo|Placebo will be applied as a control on one keloid on the subject
16390036|NCT04049539|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|Within 14-26 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
16390037|NCT04049513|Experimental|WZTL002-1 (1928T2z CAR T-cells)|"A starting WZTL-002 dose of 5 × 10^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.
~Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level."
16390039|NCT04049487|Active Comparator|Generalized Exercise|General wellness/exercise program designed to replicate a generic wellness program that one would find in a gym setting. Will be led by an exercise instructor.
16390040|NCT04049487|Experimental|Diastasis Specific Exercise|Diastasis specific exercise program incorporating multiple muscle groups and based on research findings of exercises that are shown to be effective for reducing size and impact of diastasis rectus.
16390041|NCT04049474|Experimental|Bronchoscopic Cryo-Immunotherapy (BCI)|BCI is performed by advancing a flexible cryoprobe through a bronchoscope to reach a peripheral tumor. The cryoprobe is activated to freeze a portion of the tumor. The cryoprobe is allowed to thaw to prevent removal of lung or airway tissue. The tumor must be located by radial EBUS and a guide sheath placed prior to cryoablation.
16390042|NCT04049461||PDAC Group|Radical operations were performed through central abdominal incisions. The postoperative pathology was pancreatic ductal adenocarcinoma.
16390043|NCT04049461||Benign Group|The abdominal midline incision was performed and the postoperative pathology was benign.
16390044|NCT04049448|Experimental|ABX464 50 mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)
16390045|NCT04049435||horizontal deficiency anterior maxilla|Using the titanium sheet in augmentation of horizontally deficient anterior maxilla will be efficient, time saving, accurate reconstruction
16390046|NCT04049409|Experimental|CMAB809|
16390047|NCT04049409|Active Comparator|Trastuzumab|
16390048|NCT04049396|Experimental|Berberine|Berberine (6.25 g/day)
16390049|NCT04049396|No Intervention|Control|No intervention
16390052|NCT04049370||"Retrospective data collection of the actual state"|"Retrospective data collection of the actual state 6 months prior to August 2019."
16390053|NCT04049370||Prospective data collection|Prospective data collection after implementation of the quality assurance measure for another 6 months (SOP as clinical decision tool into the electronic database of the CPU).
16390054|NCT04049357|Experimental|The intervention group|"If the FIT test is returned and positive the individual can choose either Camera Capsule Endoscopy (CCE) or Optical colonoscopy (OC) as the primary bowel investigation. If OC is chosen, it is performed as standard and the participant outcomes remains analyzed in the intervention group as intention to treat.
~If CCE is chosen an out-clinic CCE will be done at one of four regional sites. Overall and segmental bowel preparation grade (Leighton-Rex 1-4) and all pathological findings are reported. If the anal verge is identified without video blackout in the colon the transit is considered complete. Any incomplete CCE investigation will be followed by standard optical endoscopy to the extent needed to investigate the proportion of the colon not visualized by the capsule and remove any detected polyps. If the CCE is complete with complete transit and adequate preparation, individuals with more than two polyps or one polyp over 9 mm will be referred for colonoscopy."
16390055|NCT04049357|No Intervention|The control group|The control group will be invited to screening as usual. The intervention group will be informed that if the fecal test is returned and positive they can either choose to have an initial colon capsule endoscopy, and only colonoscopy if significant findings are made or an initial colonoscopy as usual.
16390056|NCT04049344|Experimental|Combination of decitabine with oxaliplatin treatment|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
16390057|NCT04049331|Experimental|Testosterone|Testosterone undecanoate injection 750 MG/3 ML
16390058|NCT04049331|Placebo Comparator|Placebo|clinical grade saline 0.9% sodium chloride injection
16390059|NCT04049318||24 weeks|Subjects who participated in the intervention who have data available at week 24
16390060|NCT04049318||48 weeks|Subjects who participated in the intervention who have data available at week 48
16390061|NCT04049305|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
16390062|NCT04049305|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
16390063|NCT04049305|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
16390064|NCT04049292|Experimental|RTS and rehabilitation tool|Six months after ACLR, athletes will commence a standardized RTS assessment. The athlete will follow a standardized, sport-specific progression protocol designed to increase athletic confidence and trust in the knee during sports. Readiness to return to full, unrestricted practice will be determined based on 7 time-based, load-based, clinical and functional criteria. If the athlete fails any of the criteria, he or she will continue to participate in restricted practice. Depending on which of the specific criteria the athlete fails, a targeted treatment plan will be developed. Standardized protocols for effusion management, knee control and strength training will be triggered if the athlete fails the criteria for knee joint effusion, hopping and muscle strength, respectively. The RTS assessment and development of the targeted treatment plan will be repeated every 2 months until the athlete is cleared to RTS, up to a maximum of 12 months after ACLR.
16390065|NCT04049292|Active Comparator|Usual care|Athletes will receive usual care as determined by their treating health care professional
16390066|NCT04049279|Active Comparator|BiMobile standard cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
16390067|NCT04049279|Active Comparator|BiMobile larger cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
16390068|NCT04049279|Active Comparator|Avantage standard cement|25 patients will receive a cemented THA with an Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
16390069|NCT04049266|Experimental|KSI-301 5 mg|"Drug: KSI-301 5 mg. KSI-301 5 mg will be administered by intravitreal injection into the study eye at 12, 16, and 20 weeks intervals as specified in the study protocol.
~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
16390070|NCT04049266|Active Comparator|Aflibercept 2 mg|"Drug: Aflibercept 2 mg. Aflibercept 2 mg will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.
~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
16390071|NCT04049253|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
16390072|NCT04049253|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
16390073|NCT04049240|Active Comparator|Active Comparator: 18<BMI<30 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16390074|NCT04049240|Active Comparator|Active Comparator: 30≤BMI<35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16390075|NCT04049240|Active Comparator|Active Comparator: BMI≥35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16390076|NCT04049240|Active Comparator|Experimental: 18<BMI<30 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16390077|NCT04049240|Active Comparator|Experimental: 30≤BMI<35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16390078|NCT04049240|Active Comparator|Experimental: BMI≥35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16390079|NCT04049227|Experimental|Treatment (letrozole, abemaciclib)|Patients receive letrozole PO QD and abemaciclib PO BID on days 1-14. Patients then undergo standard of care hysterectomy on day 15.
16390080|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
16390081|NCT04049201|Experimental|Group tablet|group T will receive interactive Tablet containing many cartoon's videos 20 minutes before parental separation until the anesthesia induction
16390082|NCT04049201|Active Comparator|Group Midazolam|group Midazolam will receive oral midazolam 0.5 mg/kg (max 20 mg) 20 minutes before the parental separation
16390083|NCT04049188|Experimental|Single-Fraction Palliative RT|Single-Fraction Palliative Radiation Therapy Adminstration
16390088|NCT04049162|Experimental|Blueberry Plus Exercise (BB-EX)|BB-Ex participants will consume lyophilized blueberry powder, mixed with water (18 grams, equivalent to 3/4ths cup of blueberries) with 2 daily meals (36 g/d blueberry powder total; approx. 1.5 servings/d)
16390089|NCT04049162|Placebo Comparator|Blueberry Placebo Plus Exercise (P-EX)|Participants randomized to P-EX treatment will consume an indistinguishable placebo powder, matched for color, flavor, consistency, and caloric content, in the same manner.
16390090|NCT04049149|Other|JADE-PRISM group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
16390091|NCT04049149|Other|JADE group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
16390092|NCT04049136||Healthy pregnant women with BMI <30|
16390093|NCT04049136||Healthy pregnant women with BMI >=30|
16390094|NCT04049123|Active Comparator|Insulin Lispro (Humalog)|Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
16390095|NCT04049123|Experimental|LY900014|LY900014 administered once, SC, in two of three study periods.
16390096|NCT04049110|Experimental|Dapagliflozin first, placebo second|Dapagliflozin followed by placebo
16390097|NCT04049110|Experimental|Placebo first, Dapagliflozin second|Placebo followed by dapagliflozin
16390098|NCT04049097|Experimental|Arimoclomol|1200 mg/day arimoclomol citrate (400 mg t.i.d.)
16390099|NCT04049071||Case|Cases are patients that are prescribed tocilizumab as escalation therapy for relapsing/refractory GCA
16390100|NCT04049071||Control|Controls are those that are prescribed an alternative escalation therapy (not tocilizumab) for relapsing/refractory GCA.
16390101|NCT04049045|Active Comparator|Verum arm|25 mg tablet of empagliflozin once daily for five days
16390102|NCT04049045|Placebo Comparator|Placebo arm|one tablet of the matching Placebo once daily for five days
16390103|NCT04049032||In-Person Participants|This group received perinatal OUD treatment in-person.
16390104|NCT04049032||Telemedicine Participants|This group received perinatal OUD treatment via telemedicine.
16390105|NCT04049019|Experimental|Urine collection|"The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.
~The child will be asked to perform home recordings for seven days consisting of measurements of diaper weight and first morning voided volume and a two-day frequency-volume chart."
16390106|NCT04049006|Experimental|complex-treatment benefiting group|Participants in the intervention group will receive the complex treatment and the usual clinical practice.
16390107|NCT04049006|No Intervention|complex-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
16390108|NCT04048980|No Intervention|Control Group|Patients with dementia or cognitive impairment and femur fracture receiving the traditional care in traumatology units.
16390109|NCT04048980|Experimental|Experimental Group|Patients with dementia or cognitive impairment and femur fracture receiving an intervention in traumatology units.
16390110|NCT04048967|Experimental|Intervention|Preschool staffs will participate in 50 hours of professional development over 7 months focused on promotion of physical activity in the preschool setting. Staffs and investigators will work together to develop models to ensure children receive 60 minutes per day of moderate-to-vigorous physical activity, 90 minutes per week of motor challenging physical activity, 90 minutes per week of cognitively engaging games/play, and 90 minutes per week of physically active learning.
16390111|NCT04048967|No Intervention|Control|Staffs receive no professional development and children will receive standard care.
16390112|NCT04048954||APPLITABAC arm|Use of a smartphone application on screening for complications related to tabagism
16390113|NCT04048941|Experimental|Verum Acupuncture with Movement|Verum acupuncture along radial side of 2nd metacarpal, following by active movement of previously painful body part x 10 minutes.
16390114|NCT04048941|Active Comparator|Verum Acupuncture without Movement|Verum acupuncture along radial side of 2nd metacarpal, following by laying on examination table x 10 minutes.
16390115|NCT04048941|Sham Comparator|Control Acupuncture with Movement|Sham/control acupuncture at acupoint LI4, following by active movement of previously painful body part x 10 minutes.
16390116|NCT04048928|Experimental|Strength group|Receives maximal strength training
16390117|NCT04048928|No Intervention|Control group|receives no active treatment
16390118|NCT04048915|Experimental|Long live drama|Primary school students watched an interactive long live drama (90 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
16390119|NCT04048915|Experimental|Short live drama|Primary school students watched an interactive short live drama (60 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
16390120|NCT04048915|No Intervention|Waitlist control|Primary school students received no intervention during the 3-month study period. After the study finished, the students watched either short or long live drama, and DVD with worksheets were distributed to students and they were invited to share with their parents.
16390121|NCT04048902|Placebo Comparator|Pilates and Shortwave placebo|In this group the patients will receive 20 minutes of short wave placebo application. The equipment will keep the timer on and the intensity will remain at zero. The patient will be informed that the dose is subsensory and therefore there will be no perception of the passage of the short waves through the body.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
16390122|NCT04048902|Active Comparator|Pilates and Shortwave active|In this group the patients will receive 20 minutes of application of the Shortwave Active continuous mode (thermal effect), with vigorous local thermal sensation.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
16390123|NCT04048889|Experimental|Popliteal plexus block and continuous femoral nerve block|
16390124|NCT04048889|Active Comparator|continuous femoral nerve block|
16390129|NCT04048863|Active Comparator|Stage 1 Baseline|Study site to use standard of care PIVC device(s) and procedure(s) on patients.
16390130|NCT04048863|Other|Stage 2 Education|RN education and training in the use of B. Braun PIVC products, devices and procedures.
16390131|NCT04048863|Other|Stage 3 Run-In|Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.
16390132|NCT04048863|Other|Stage 4 Post-Education|Study site uses B. Braun PIVC device(s) and procedure(s) on patients.
16390133|NCT04048850||Patients living with HCV +/- HIV|HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.
16390134|NCT04048824|Experimental|Inhibitory Learning-Based Exposure|Participants will receive exposure therapy aimed at increasing inhibitory learning.
16390135|NCT04048824|Active Comparator|Habituation-Based Exposure|Participants will receive exposure therapy aimed at reducing fear responding.
16390136|NCT04048811|Experimental|HSK3486|HSK3486 induction + maintenance group
16390137|NCT04048811|Active Comparator|Propofol|Propofol induction + maintenance group
16390138|NCT04048811|Other|Propofol HSK3486|Propofol induction + HSK3486 maintenance group
16390139|NCT04048798|Active Comparator|Oxygen therapy via HFNC|Patients who will be applied high frequency nasal cannula before and after surgery
16390140|NCT04048798|Active Comparator|Oxygen therapy via face mask|Patients who will be applied O2 via face mask before and after surgery
16390141|NCT04048785|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
16390142|NCT04048785|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
16390143|NCT04048772|Experimental|Intervention|Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.
16390144|NCT04048772|Other|Control|Standard of care in vitro fertilization patients at our institution.
16390145|NCT04048759|Other|Remote Low|
16390146|NCT04048759|Other|Remote High|
16390147|NCT04048759|Other|Personal Coach|
16390492|NCT04046354|Experimental|Group A|The group will use microwave ablation equipment to treat benign thyroid nodules.
16390148|NCT04048746||ASTHMA|"The patient presents to the emergency department for an aggravation of his asthma. The patient later sees an emergency investigator for medical care for his aggravation of asthma. When the patient's condition is stabilized, the investigator checks his eligibility for study and offers to participate. If the patient agrees, the investigator gives him the questionnaire and possibly helps to fill it out.
~When the investigator returns to see the patient for a reassessment of his condition, he retrieves the completed questionnaire. He verifies that the patient has completed the questionnaire. Prescriptions and action plans are retrieved by the principal investigator either in digitized format from the patient's computerized medical record or in paper format. Each medication prescription and each action plan are read by the principal investigator and evaluated according to the grids."
16390149|NCT04048733|Experimental|Patchy type-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.
~Second and third 12 lead ECG will be taken using patchy-type 12-lead ECG device as a doctor's order. This device will be automatically record 12-lead ECG 3 times in 1 minutes at a time by its algorithm."
16390150|NCT04048733|No Intervention|Standard 12-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.
~Second and third 12 lead ECG will be taken using standard 12-lead ECG device as a doctor's order. Interns and ECG technicians will perform 12-lead ECG as they perform as usual."
16390151|NCT04048720|Experimental|Family Nurture Intervention (FNI)|FNI sessions will be held once a week in the afternoon for eight weeks. Participants will take part in FNI group therapy with their child alongside other mother-child pairs. One to two staff members will lead FNI sessions.
16390152|NCT04048707|Active Comparator|Midodrine/Octreotide|This arm will receive standard of care treatment of midodrine, octreotide, and albumin.
16390153|NCT04048707|Experimental|Angiotensin 2|This arm will receive the experimental treatment of angiotensin 2 infusion and albumin.
16390154|NCT04048681|Experimental|Diet Soda|12oz can of Diet Coke
16390155|NCT04048681|Active Comparator|Soda|12oz can of Coke
16390156|NCT04048681|Placebo Comparator|Carbonated Water|12oz can of carbonated (unflavored) water
16390157|NCT04048668|Active Comparator|Anodal tDCS|2mA for 20 minutes
16390158|NCT04048668|Sham Comparator|Sham tDCS|30 second ramp-up / ramp-down for 20 minutes
16390159|NCT04048655|Other|Study group|Single arm and everyone gets the same treatment according the protocol
16390160|NCT04048642|Experimental|DASH diet; plant-based diet; DASH diet|Food is provided: 7 days of an ad libitum DASH diet, followed immediately by 7 days of an ad libitum whole food, plant based diet, followed immediately by 7 days of an ad libitum DASH diet again.
16390161|NCT04048629|Experimental|Point-of-care (POC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At POC facilities, at the first antenatal visit (ANC1), all women enrolled in the intervention cohort will have a blood sample collected for VL which will be tested onsite using an existing POC device. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
16390162|NCT04048629|Active Comparator|Standard of care (SOC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At SOC facilities, at ANC1, all women enrolled in the intervention cohort will have a blood sample collected for VL which will be sent to centralized labs for testing. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
16390163|NCT04048616|Active Comparator|whey protein isolate + KHCO3|1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
16390164|NCT04048616|Active Comparator|whey protein isolate + microcrystalline cellulose|1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
16390165|NCT04048616|Active Comparator|maltodextrin powder + KHCO3|isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
16390166|NCT04048616|Placebo Comparator|maltodextrin powder + microcrystalline cellulose|isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
16390167|NCT04048603||idiopathic REM sleep behavior disorder|Subjects with the diagnosis of idiopathic REM sleep behavior disorder
16390168|NCT04048603||Controls without iRBD|Healthy controls without the diagnosis of idiopathic REM sleep behavior disorder
16390169|NCT04048590|No Intervention|Control|Control subjects will receive care at a skilled nursing facility.
16390170|NCT04048590|Active Comparator|Intervention|Intervention subjects will go home from the hospital and receive care from a specialized care team.
16390171|NCT04048577|Experimental|Dose Interruption|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
16390172|NCT04048577|No Intervention|Standard Treatment|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days).
16390173|NCT04048551|No Intervention|No S&D Reduction Training; PrEP and SRH only|Arm 1 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
16390174|NCT04048551|Experimental|No S&D Reduction Training; PrEP and SRH + YWHC|Arm 2 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
16390175|NCT04048551|Active Comparator|S&D Reduction Training; PrEP and SRH only|Arm 3 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
16390176|NCT04048551|Experimental|S&D Reduction Training; PrEP, SRH + YWHC|Arm 4 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
16390179|NCT04048525|Experimental|CVVHD with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
16390180|NCT04048525|Active Comparator|CVVH with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
16390183|NCT04048486||CAPA-IVM|Live babies born from CAPA-IVM
16390184|NCT04048486||IVF/ICSI|Live babies born from IVF/ICSI
16390185|NCT04048486||Natural conception|Live babies born from natural conception
16390186|NCT04048473||MUH (Mansoura University Hospital)|enrolled 127 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5). Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
16390187|NCT04048473||Ocmu (Oncology center Mansoura University)|enrolled132 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5).Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
16390188|NCT04048460|Experimental|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
16390189|NCT04048434|No Intervention|Standard of care (SOC)|
16390190|NCT04048434|Experimental|Cyotosorb|
16390191|NCT04048421|Experimental|hvNOTES group|Participants will undergo hvNOTES radical colectomy.
16390192|NCT04048408||Obstructive lung diseases group|
16390193|NCT04048408||Healthy group|
16390194|NCT04048395||Follicular lymphoma arm|The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
16390195|NCT04048382|Experimental|Patient Navigation (PN)|This intervention consists of standardized health educational materials and manualized sessions that can be implemented based on a participant's stage in the PrEP continuum. The intervention will utilize bilingual peer lay navigators and also consist of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP.
16390196|NCT04048382|Other|Usual Care (UC)|Participants in this condition will receive the CDC's 2-page PrEP Information Sheet in the participant's preferred language (either English or Spanish).
16390197|NCT04048369|Experimental|Point-of-care testing arm|for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.
16390198|NCT04048369|Active Comparator|Core Lab testing arm|for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)
16390199|NCT04048356|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
16390200|NCT04048356|Active Comparator|Povidone Iodine|Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
16390201|NCT04048343|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
16390202|NCT04048330||Women of reproductive age|Women 15 to 40 years of age who are not pregnant or lactating
16390203|NCT04048317|Experimental|drug eluting bead trans arterial chemo embolization|the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere
16390204|NCT04048317|Placebo Comparator|conventional trans arterial chemo embolization|the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol
16390205|NCT04048304|Experimental|short antibiotic therapy|3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
16390206|NCT04048304|Active Comparator|long antibiotic therapy|6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
16390207|NCT04048291|Experimental|Brisk walking and balance training|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session
~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session
~Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)"
16390208|NCT04048291|Active Comparator|Upper limb exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session
~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session
~Participants practice own upper limb exercise 2-3 times/week (to aim at 150 min of exercise per week)"
16390274|NCT04047888||Intervention Group|Mothers and children in this group will have measurements, questionnaire administration. The children will have routine child care at their health center and mothers will have a 60 minute nutrition-based and non-nutrition based educational message
16390209|NCT04048278|Experimental|Lidocaine Hydrochloride|The IV bolus and infusions of lidocaine to those patients assigned to the lidocaine group will be started in the operating room and will continue until 24 h later. The group receiving the lidocaine infusion will first be administered a 1.0 - 1.5 mg/kg loading infusion over 5 minutes followed by a 1.0 - 1.5 mg/kg/h infusion for 24 h
16390210|NCT04048278|Placebo Comparator|Saline Solution for Injection|The group receiving the saline infusion will be administered an equivalent volume of saline infused over 5 min followed by a saline infusion at the same flow rate as that used in the lidocaine group for 24 h (1.0 - 1.5 mg/kg/hr)
16390211|NCT04048265|Experimental|Pain in PD Arm one|This arm will receive a total 5 sessions of TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
16390212|NCT04048265|Sham Comparator|Pain in PD Arm two|This arm will receive a total 5 sessions of sham-TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
16390215|NCT04048226|Placebo Comparator|Control group|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
16390216|NCT04048226|Experimental|Dexmedetomidine-Ketamine group|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
16390217|NCT04048200|Other|Control group|Anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The patients in this group will be connected to a syringe pump before induction of anesthesia that was prepared by anesthesia resident not participating in the study and contain normal saline and adjusted at a rate of 1 ml/kg/hr till the end of the surgery.
16390218|NCT04048200|Experimental|Opioid free anesthesia group|A syringe 50 ml was prepared by anesthesia resident not participating in the study and contain 100 ug of dexmedetomidine (2 ug/ml) and 25 mg ketamine 90.5 mg/ml) and 200 mg lidocaine (4 mg/ml). The syringe will be connected to the patients before induction of anesthesia at a rate of 0.1 ml/kg/hr according to the ideal body weight. Anesthesia will be induced by propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The syringe infusion will be continued till the end of peritoneal manipulation. Patients in this group will receive magnesium sulphate preload at a dose of 40 mg/kg ideal body weight followed by maintenance infusion of 10 mg/kg/hr.
16390219|NCT04048187|Experimental|Phone Application|
16390220|NCT04048174|Sham Comparator|Saline irrigation|"Each participant performed nasal saline irrigation at 2 periods:
~Day -14 to Day 0
~Day 14 to Day 28"
16390221|NCT04048174|Experimental|Probiotic lactococcus lactis W136 irrigation|Each participant performed Probiotic lactococcus lactis W136 nasal irrigation from Day 0 to D14
16390222|NCT04048161|Experimental|Tacrolimus(Group A)|Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
16390223|NCT04048161|Experimental|Mycophenolate Mofetil(Group B)|Mycophenolate Mofetil: 250mg; Dispersible tablets; 20~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
16390224|NCT04048148|Other|Novel myopia control lenses|This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months and then test lenses for another 6 months
16390225|NCT04048148|Other|Single vision lenses|This group will be randomized to wear control lenses for 6 months followed by test lenses for 12 months
16390226|NCT04048135|Experimental|Dose 1|
16390227|NCT04048135|Experimental|Dose 2|
16390228|NCT04048135|Experimental|Dose 3|
16390229|NCT04048135|Experimental|Dose 4|
16390230|NCT04048135|Experimental|Dose 5|
16390231|NCT04048135|Experimental|Dose 6|
16390232|NCT04048135|Placebo Comparator|Placebo|
16390233|NCT04048135|Experimental|Dose 4 Open Label|
16390234|NCT04048122|Active Comparator|Standard of Care (Control Group)|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
16390235|NCT04048122|Experimental|MC4PD Strategy Training|This treatment focuses on improving functional performance by enhancing the generation and use of strategies-which can be internal (e.g., self-talk, planning) or external (e.g., checklist, alarm)-to circumvent cognitive processing limitations caused by PD. It uses a standardized approach across and within sessions for all clients while being tailored to each client's cognitive problems and goals.
16390236|NCT04048096|Placebo Comparator|Placebo|4g/day of mixed vegetable oil supplements
16390237|NCT04048096|Experimental|Krill|4g/day krill oil
16390238|NCT04048083|Experimental|Patients-MT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training (MT) of reaching to grasp movements
16390239|NCT04048083|Experimental|Patients-CAT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in computer-aided training (CAT) of reaching to grasp movements using virtual environment with visual-feedback.
16390240|NCT04048083|Experimental|Patients-CAMT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training of reaching to grasp movements supplemented by virtual environment (patients that received both types of training).
16390242|NCT04048070|Experimental|ERAS with postoperative intravenous Flubiprofen Axetil|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
16390243|NCT04048070|Experimental|ERAS with analgesia pump|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
16390244|NCT04048070|Experimental|Traditional care with Flubiprofen Axetil|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
16390245|NCT04048070|Experimental|Traditional care with analgesia pump|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
16390246|NCT04048070|Placebo Comparator|traditional care without postoperative intravenous analgesia.|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Intravenous saline with necessary oral analgesic for postoperative pain management.
16390247|NCT04048057|Experimental|Modarete Intensity Continous Training|
16390248|NCT04048057|Experimental|High Intensity Interval Training I|
16390249|NCT04048057|Experimental|High Intensity Interval Training II|
16390250|NCT04048044|Active Comparator|Telomere length, GigaHz exposure|Measurement of white blood cell telomeres before and yearly for 5 years
16390251|NCT04048031|Active Comparator|Nutrafol Supplement Capsules|"NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.
~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal."
16390252|NCT04048031|Placebo Comparator|Placebo Capsules|The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
16390253|NCT04048031|Other|Open Label 6 month Extension|"During the 6 month open label extension all 70 subjects will receive NUTRAFOL's Synergen Complex Plus® which is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.
~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for the six month extension with a substantial meal."
16390254|NCT04048018||Active Tuberculosis Patient|
16390255|NCT04048018||High risk for LTBI Participant|
16390256|NCT04048018||Low risk for prior TB infection Participant|
16390257|NCT04048018||NTM patient|
16390258|NCT04048018||Precision patient|
16390259|NCT04047992|Experimental|Exoskeleton Users|All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
16390260|NCT04047979|Experimental|Younger Group|Participants between the ages of 50 to 60 years will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
16390261|NCT04047979|Experimental|Older Group|Participants who are ≥70 year old will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
16390262|NCT04047966||Fetal growth restriction|63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile
16390263|NCT04047966||Control group|63 control fetuses with an estimated fetal weight about the 10th percentile
16390264|NCT04047953|Experimental|Conversion Therapy|Paclitaxel (albumin-bound) +S-1+Oxaliplatin
16390265|NCT04047940|Experimental|LY900020 Formulation 1|LY900020 Formulation 1 administered orally
16390266|NCT04047940|Experimental|LY900020 Formulation 2|LY900020 Formulation 2 administered orally
16390267|NCT04047940|Experimental|LY900020 Formulation 3|LY900020 Formulation 3 administered orally
16390268|NCT04047940|Active Comparator|Reference Drugs|Metformin XR, atorvastatin, and valsartan administered orally
16390269|NCT04047927|Experimental|EpiFinder|Eligible subjects will be included to this group to receive an epidural injection of steroids to treat their chronic back pain. The investigational device will be used in conjugation to the standard practice of epidural injections, to assist the investigator to identify the epidural space.
16390270|NCT04047914|Experimental|experimental PDT group|Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 1 minute pre-irradiation time. Irradiations will be performed with a red laser diode (wavelength = 660 nm), 240 seconds and 4-point nostril application (one point on each of the 4 walls).
16390271|NCT04047914|Active Comparator|control mupirocin group|A standard treatment will be performed conventionally with topical mupirocin. Will be performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
16390272|NCT04047901|No Intervention|control group|"A group of patients who will not be trained will be evaluated at baseline (pre) and after 16 weeks.
~They are oriented to maintain lifestyle changes"
16390273|NCT04047901|Experimental|Training group|Patients will complete 16 weeks of training including 40 minutes of aerobic training, 15 minutes of resistive exercise and 5 minutes of relaxation.
16390603|NCT04045509|Other|Group 'young age'|Group 'young age': 18 - 30 years of age; healthy eyes
16390275|NCT04047888||Control Group|Mothers and babies will have measurements and questionnaire administration and children will receive routine child care at their health centers. These mothers will receive a non-nutrition based educational message only.
16390276|NCT04047875|Experimental|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Primolut-Nor® per bleeding episode)
16390277|NCT04047875|Placebo Comparator|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Placebo per bleeding episode)
16390278|NCT04047862|Experimental|Phase 1|"Cycle 1 (28 Days): A flat dose of BGB-A1217 as a single agent on Day 1. In the first cycle, 200 mg tislelizumab will be administered on Day 8.
~If BGB-A1217 is tolerated in Cycle 1, participants will receive tislelizumab + BGB-A1217 sequentially on Day 29 and every 21 days for up to 8 months."
16390279|NCT04047862|Experimental|Phase 1b Cohort 1|Patients with metastatic squamous NSCLC will receive BGB-A1217 + tislelizumab + paclitaxel/nab-paclitaxel + Carbo once every 3 weeks (Q3W) for 4 to 6 cycles (21 days each) followed by BGB-A1217+tislelizumab Q3W)
16390280|NCT04047862|Experimental|Phase 1b Cohort 2|Patients with metastatic squamous NSCLC will receive BGB-A1217 + tislelizumab + pemetrexed + Cis/Carbo Q3W for 4 to 6 cycles (21 days each) followed by BGB-A1217+tislelizumab Q3W)
16390281|NCT04047862|Experimental|Phase 1b Cohort 3|Patients with metastatic NSCLC (PD-L1 positive, [TPS] ≥ 1%) will be treated with BGB-A1217 + tislelizumab
16390282|NCT04047862|Experimental|Phase 1b Cohort 4|Patients with extensive stage SCLC will be treated with BGB-A1217 + tislelizumab + etoposide + Cis/Carbo Q3W for up to 6 to 8 cycles followed by BGB-A1217+tislelizumab Q3W
16390283|NCT04047862|Experimental|Phase 1b Cohort 5|Checkpoint inhibitor (CPI)-experienced NSCLC patients will be treated with BGB-A1217 plus tislelizumab
16390284|NCT04047862|Experimental|Phase1b Cohort 6|Patients with metastatic ESCC will be treated with BGB-A1217 + tislelizumab + cisplatin + 5-fluorouracil /paclitaxel Q3W for 6 cycles followed by BGB-A1217+tislelizumab Q3W
16390285|NCT04047862|Experimental|Phase1b Cohort 7|Patients with metastatic EAC will be treated with BGB-A1217 + tislelizumab + cisplatin + 5-fluorouracil or paclitaxel Q3W for 6 cycles followed by BGB-A1217+tislelizumab Q3W
16390286|NCT04047862|Experimental|Phase1b Cohort 8|Patients with recurrent or metastatic HNSCC (PD-L1 positive, vCPS≥ 1%) will be treated with BGB-A1217 + tislelizumab Q3W
16390287|NCT04047862|Experimental|Phase1b Cohort 9|Patients with metastatic G/GEJ carcinoma will be treated with BGB-A1217 + tislelizumab + [oxalipatin + capecitabine] or [cisplatin + 5-fluorouracil] Q3W for 6 cycles followed by BGB-A1217+tislelizumab + capecitabine Q3W
16390288|NCT04047849|Experimental|Antibiotics|This will include those subjects randomized into the treatment arm, receiving the outpatient antibiotic course of azithromycin and amoxicillin prior to re-admission at viability (23 0/7 weeks gestation). They will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home).
16390289|NCT04047849|No Intervention|No antibiotics|This will include those subjects randomized into the control arm and will not receive outpatient antibiotics prior to re-admission at viability (23 0/7 weeks gestation).
16390290|NCT04047836|Other|Low Nicotine|Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
16390291|NCT04047836|Other|Medium or High Nicotine|The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
16390292|NCT04047810|Experimental|Subjects with Advanced Chronic Obstructive Pulmonary Disease|Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)
16390293|NCT04047797|Experimental|Treatment (ixazomib, rituximab)|Patients receive ixazomib by mouth on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of cycle 1. Beginning in cycle 3, patients receive rituximab Intravenous over 4-8 hours on day 1. Treatment repeats every 28 days up to cycle 12 in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue to receive ixazomib indefinitely in the absence of disease progression or unacceptable toxicity.
16390294|NCT04047784|Experimental|Critically Ill Patients|"Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.
~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
16390295|NCT04047784|Experimental|Patients undergoing standard of care clinical bronchoscopy|"Patients undergoing clinical bronchoscopy as a part of their standard of care.
~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
16390296|NCT04047784|No Intervention|Previously recorded patient media from standard of care clinical bronchoscopy with EBUS|"Patients who underwent a standard of care clinical bronchoscopy with EBUS previously.
~Information and media including images and videos that were previously recorded for patients who underwent a standard of care clinical bronchoscopy with EBUS will be available to the study team."
16390297|NCT04047771|Experimental|SCB-313|
16390298|NCT04047758|Experimental|Palbociclib + Letrozole group|210 patients will be randomly assigned to receive treatment with palbociclib and letrozole (palbociclib + letrozole group) .
16390299|NCT04047758|Placebo Comparator|Letrozole group|210 patients will be randomly assigned to receive treatment with letrozole (letrozole group).
16390300|NCT04047745|Active Comparator|liposomal bupivacaine|
16390301|NCT04047745|Active Comparator|ropivacaine|
16390302|NCT04047732|Experimental|Topical KB105|HSV1-TGM1 vector (KB105)
16390303|NCT04047719||Intent-to-Diagnose Population|All subjects enrolled in the study that have at least one Karius Test with a valid result
16390322|NCT04047563|Experimental|PMZ-1620 (sovateltide) + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
16390323|NCT04047537|Other|Experimental: WBF-0011|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
16390493|NCT04046354|Active Comparator|Group B|The group will use radiofrequency ablation equipment to treat benign thyroid nodules.
16390304|NCT04047706|Experimental|Cohort I (radiation, temozolomide, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT methylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive temozolomide PO QD, IDO1 inhibitor BMS-986205 PO QD, and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins.
~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Within 4 weeks of radiation therapy completion, patients also receive temozolomide PO QD on days 1-5 of cycles 2-6. Cycles repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
16390305|NCT04047706|Experimental|Cohort II (radiation, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT unmethylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive IDO1 inhibitor BMS-986205 PO QD and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Cycles repeats every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins."
16390306|NCT04047693|Experimental|ddMVAC|4 cycles of neoadjuvant chemotherapy using dose dense MVAC with G-CSF
16390307|NCT04047680||SOF-based DAAs|Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks
16390308|NCT04047680||SOF-free DAAs|Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks
16390309|NCT04047667||CBCT guided TBCB|Patients with ILD who met the following including criteria from September 2018 to July 2019 were suggested to receive TBCB under CBCT guidance: more than 18 years old, diffuse parenchymal lung diseases without a diagnosis after integration of clinical profile, laboratory tests and HRCT features, FVC more than 50%, DLCO more than 35%, patients without acute exacerbation within one month, patients without bleeding diathesis, anticoagulant therapy, using antiplatelet drugs, patients without pulmonary hypertension, respiratory failure, liver or kidney disfunction, or cardiac insufficiency, PLT more than 50 x 109/L. All included patients signed the informed consent.
16390310|NCT04047654||Non vitamin K oral anticoagulants (NOACs)|Patients who were prescribed with apixaban, dabigatran, edoxaban, or rivaroxaban for stroke secondary prevention.
16390311|NCT04047654||Warfarin|Patients who were prescribed with warfarin for stroke secondary prevention.
16390312|NCT04047641|Experimental|Treatment (idarubicin, cladribine, cytarabine, quizartinib)|"INDUCTION: Patients receive idarubicin Intravenous over 1 hours on days 1-3, cladribine intravenous over 1-2 hours on days 1-5, cytarabine Intravenous over 3 hours on days 1-5 (or days 1-3 for patients over age 60), and quizartinib by mouth daily on days 6-19. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR or CRp after Induction receive idarubicin Intravenous over 1 hours on days 1-2, cladribine Intravenous over 1-2 hours on days 1-3, cytarabine Intravenous over 3 hours on days 1-3, and quizartinib by mouth daily on days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients who achieve CR or CRi/CRh after Consolidation receive quizartinib by mouth daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16390315|NCT04047615|Experimental|Exercise effects on Behavior|An exercise intervention programme will be implemented 3 times a week for an 8 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will be fun for the students to participate in and will involve aspects of fundamental movement skills.
16390316|NCT04047602|Experimental|Reduced Dose Stereotactic Radiosugery|Subjects will receive one SRS treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment
16390317|NCT04047589||Subjects|Cancer patients with curable or previously treated malignancies
16390318|NCT04047589||Providers|Physicians seeing patients in the outpatient clinics at the IU Simon Cancer Center
16390319|NCT04047576|Experimental|sirolimus group|"Sirolimus: 2 mg/day for the first 3 days and 1 mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L.
~Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until discontinuation."
16390320|NCT04047576|Active Comparator|corticosteroid group|Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until 5-7.5 mg/d.
16390321|NCT04047563|Active Comparator|Normal Saline + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
16390324|NCT04047537|Other|Experimental: WBF-0011 (0.2X concentration)|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
16390604|NCT04045509|Other|Group 'advanced age'|Group 'advanced age': 50 - 70 years of age; healthy eyes
16390326|NCT04047524|Other|Prehabilitation|These participants will receive a home based prehabilitation programme for a period of 2-6 weeks prior to surgery and will be provided with a Fitbit Charge 2.
16390327|NCT04047524|Other|Control|These participants will receive a Fitbit Flex and told to continue with their every day activity levels for a period of 2-6 weeks prior to surgery
16390328|NCT04047511|Experimental|Virtual Reality|"Twice a week, for a 4 consecutive weeks:
~8 sessions of VRTierOne therapy ( 20 minutes each).
~8 sessions of general fitness training (40 minutes each)
~8 sessions of psychoeducation (20 minutes each"
16390329|NCT04047511|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:
~8 sessions of general fitness training (40 minutes each)
~8 sessions of psychoeducation (20 minutes each"
16390330|NCT04047498|Experimental|Within-subjects comparison of constant and alternating DBS|
16390331|NCT04047485||Elderly Female (A)|Female subjects between 65 and 85 years old
16390332|NCT04047485||Great Elderly Female (B)|Female subjects with more than 85 years old
16390333|NCT04047485||Elderly Male (C)|Male subjects between 65 and 81 years old
16390334|NCT04047485||Great Elderly Male (D)|Men subjects with more than 81 years old
16390335|NCT04047472|Experimental|Brolucizumab 6 mg|
16390336|NCT04047472|Active Comparator|Aflibercept 2 mg|
16390337|NCT04047459||Patient undergoing prosthetic surgery|Patients undergoing surgery for the insertion of a hip prosthesis or a cruciate ligament reconstruction will be included. On those patients tissue samples collection and cells isolation will be performed
16390338|NCT04047446|Experimental|Liposomal bupivacaine & standard bupivacaine|
16390339|NCT04047446|Active Comparator|Standard bupivacaine & dexamethasone|
16390340|NCT04047433|Experimental|women with external anal sphincter injury|The study cohort will be composed of women undergoing vaginal delivery and diagnosed with external anal sphincter injury after a vaginal delivery.
16390341|NCT04047433|Experimental|women without external anal sphincter injury|The control group will be women who had a vaginal delivery without any clinically apparent perineal laceration
16390343|NCT04047407||Fibromyalgia|
16390344|NCT04047407||Healthy volunteers|
16390345|NCT04047394|Experimental|PEGylated recombinant candida urate oxidase|Participants will be administered with 2mg, 3mg, 4.5mg, 6mg, 8mg, 10mg once by Intravenous injection. Subjects will be followed for 56 days.
16390346|NCT04047381||Atrial Fibrillation|Turkish patients diagnosed with atrial fibrillation
16390347|NCT04047368|Active Comparator|Rotablation|
16390348|NCT04047368|Experimental|Coronary Lithoplasty|
16390349|NCT04047355|Experimental|Group A: Propranolol first|"Participants randomly assigned to this group will receive Propranolol first. After the washout period, they will receive Placebo.
~Propranolol will be given in liquid or pill form."
16390350|NCT04047355|Placebo Comparator|Group B: Placebo first|"Participants randomly assigned to this group will receive Placebo first. After the washout period, they will receive Propranolol.
~Placebo will look identical to the study drug Propranolol."
16390351|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
16390352|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.
~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
16390353|NCT04047329||Without post-operative myocardial infarction|Patients without post-operative myocardial infarction after first admission for transurethral resection of the prostate
16390354|NCT04047329||With post-operative myocardial infarction|Patients with post-operative myocardial infarction after first admission for transurethral resection of the prostate
16390355|NCT04047303|Experimental|Administration of CC-90010|During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
16390356|NCT04047290|Experimental|AK112|AK112 IV every 2 weeks (q2w)
16390357|NCT04047277|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxztion, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
16390358|NCT04047277|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
16390359|NCT04047264|Experimental|Mutant or WT tumor|Patients with suspected or biopsy-proven IDH-mutant tumor. Patients with suspected or biopsy-proven IDH-WT tumor
16390360|NCT04047251|Experimental|Cohort 1: Treatment at Dose Level 1|FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16390361|NCT04047251|Experimental|Cohort 2: Treatment at Dose Level 2|FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16390362|NCT04047251|Experimental|Cohort 3: Treatment at Dose Level 3|FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16390363|NCT04047238|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving Reminiscence Therapy or to a control group receiving treatment as usual. Participants in the intervention group will participate in two Reminiscence Therapy sessions per week for 3 months besides their treatment as usual. The sessions will be based on the Book of Past and Present and they will follow the same protocol in every participant institution.
16390364|NCT04047238|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
16390365|NCT04047225|Experimental|Analgesia Nociceptive Index (ANI)|Using ANI for guiding intraoperative opioid administration.
16390366|NCT04047225|No Intervention|No Analgesia Nociceptive Index (ANI)|Do not use ANI
16390367|NCT04047212||Smokers|
16390368|NCT04047212||non-Smokers|
16390369|NCT04047186|Experimental|neoadjuvant PD-1 group|receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
16390370|NCT04047173|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
16390371|NCT04047173|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
16390372|NCT04047160|Experimental|OP-724|"Dose: 140, 280, 380 mg/m2/4 hrs
~Administration method:
~[Level 1] 140 mg/m2/4 hours [Level 2] 280 mg/m2/4 hours (starting dose) [Level 3] 380 mg/m2/4 hours Continuous intravenous administration will be done for 4 hours twice a week. This procedure will be as one cycle and 12 cycles (12 weeks in total) will be conducted. On 7 days prior to the first cycle administration, a dose scheduled in the first cycle will be administered with continuous intravenous for 4 hours and the safety and pharmacokinetics on the day of administration to the next day after administration will be evaluated."
16390373|NCT04047147||Enrollment in the Million Hearts CVD Risk Reduction Model|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to participate in the Million Hearts CVD Risk Reduction Model intervention.
16390374|NCT04047147||Enrollment in control provider organizations|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to the control group.
16390375|NCT04047134|Experimental|Experimental Group (EG)|The Experimental Group (EG) will observe and execute/repeat Activities of Daily Living (ADL) actions.
16390376|NCT04047134|Active Comparator|Control Group (CG)|The COntrol Group (CG) will observe landscapes and perform the same actions observed by their peers but after verbal instructions.
16390377|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
16390378|NCT04047095|Experimental|Intervention|"Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.
~8 a.m. - normal meal plus one sachet immune nutrients
~1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients"
16390379|NCT04047095|Active Comparator|Control|"Normal daily meals. 8 a.m. - normal meal
~1 p.m. - normal meal 6 p.m. - normal meal"
16390380|NCT04047069|Other|Control|Awareness Training
16390381|NCT04047069|Experimental|Intervention group|"Awareness Training
~Person-Centered Occupational Therapy Intervention"
16390382|NCT04047056|Placebo Comparator|Ergonomic Guidelines Manual|A manual of ergonomic occupational and daily living guidelines will be given to both control and labor kinesiotherapy groups, which is the only approach for the control group initially.
16390383|NCT04047056|Active Comparator|Labor Kinesiotherapy in group|The intervention will be performed by a physical therapist, which will consist of preparatory labor kinesiotherapy, which aims to prepare the workers' osteo-articular system for the beginning of the work activity, acting more specifically on those muscle groups that will be most required during the journey which will be identified in the evaluation. Labor kinesiotherapy will be performed in the workplace before the workday and will last 20 minutes, 3 times a week, for 12 weeks.
16390384|NCT04047043||Taurine > 30 μmol/L|serum taurine level
16390385|NCT04047043||Taurine 30-20 μmol/L|serum taurine level
16390386|NCT04047043||Taurine < 20 μmol/L|serum taurine level
16390387|NCT04047030||Injured Cohort|Approximately 300 participants treated for a fracture of the tibial plateau, pilon, ankle or calcaneus will be enrolled from METRC civilian trauma centers and military treatment facilities over an 18 month period. Participating centers treat large numbers of severe orthopaedic injuries and have a proven track record for successfully recruiting and retaining participants in prospective studies in orthopaedic trauma. Participants will be enrolled following definitive treatment of their injury.
16390388|NCT04047030||Non-Injured Volunteers|Non-injured adults of similar age and gender distribution will be enrolled at two participating centers (Carolinas Medical Center and Womack Military Medical Center). The sample of non-injured volunteers will exclude individuals with history of lower extremity injury, vascular disease, or who require use of ambulatory aides to walk.
16390389|NCT04047017|Experimental|Test group|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
16390390|NCT04047004|Experimental|High-risk gastric cancer patients|The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.
16390602|NCT04045535|Active Comparator|Usual care|Usual clinical care based on current clinical practice guidelines.
16390391|NCT04046991|Active Comparator|HD-tDCS+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
16390392|NCT04046991|Sham Comparator|Sham+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
16390393|NCT04046978|Experimental|Group F|Mos3.1 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
16390394|NCT04046978|Experimental|Group G|Mos3.2 100 ug at Month 0 Mos3.1 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
16390395|NCT04046978|Experimental|Group H|Mos3.3 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.1 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
16390396|NCT04046978|Experimental|Group I|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug at Months 0, 2 and 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
16390397|NCT04046965||Region XI Head Start children and families|children (800) parents (800) classrooms/teachers (80) program directors (22) center directors (37)
16390398|NCT04046952|Active Comparator|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
16390399|NCT04046952|Experimental|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
16390400|NCT04046939|Experimental|dexpramipexole 75 mg/day|dexpramipexole 37.5 mg tablets taken orally BID
16390401|NCT04046939|Experimental|dexpramipexole 150 mg/day|dexpramipexole 75 mg tablets taken orally BID
16390402|NCT04046939|Experimental|dexpramipexole 300 mg/day|dexpramipexole 150 mg tablets taken orally BID
16390403|NCT04046939|Placebo Comparator|placebo|matching placebo tablet taken orally BID
16390404|NCT04046913|Active Comparator|Low food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
16390405|NCT04046913|Placebo Comparator|Habitual food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
16390406|NCT04046900|Active Comparator|Vaginal microbiome transplant|Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor
16390407|NCT04046900|Placebo Comparator|Saline placebo|Women in this group will be randomized to receive two doses of sterile saline
16390408|NCT04046887|Experimental|Combination of lonsurf + gemcitabine + nab-paclitaxel|
16390409|NCT04046874|Other|Usual Care|All patients were referred for the study by their General Practitioner (GP). GPs were encouraged to assess and treat their patients as usual and make all the referrals they think are appropriate for their patients.
16390410|NCT04046874|Other|Stratified Model of Care|A subgrouping tool helps guide clinical decision-making about treatment and onward referral (Start Back Screening Tool). Patients in each subgroup (low, medium or high risk of chronicity) are then managed according to a targeted treatment system of increasing complexity.
16390411|NCT04046861|Active Comparator|Vitamin C|2g vitamin C (ascorbic acid) iv before cardiopulmonary bypass, 2 g vitamin C iv before removing the aortic clamp, 1g vitamin C iv 8 h after aortic clamp removal and every 8 h thereafter(2 times)
16390412|NCT04046861|Placebo Comparator|Placebo (saline)|placebo (saline) iv before cardiopulmonary bypass, placebo before removing the aortic clamp, placebo iv 8 h after aortic clamp removal and every 8 h (2 times)
16390413|NCT04046848|Experimental|Cohort 1|"50 IU/kg (n=4): single-period investigation with a single sc dose of 50 IU/kg OCTA101 profiled up to 72 hours after dosing in adult male patients with severe hemophilia A.
~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 2, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
16390414|NCT04046848|Experimental|Cohort 2|"100 IU/kg (n=4): single-period investigation with a single sc dose of 100 IU/kg OCTA101 profiled up to 96 hours after dosing in adult male patients with severe hemophilia A.
~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 3, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
16390415|NCT04046848|Experimental|Cohort 3|"50 IU/kg (n=8): two-period investigation of a single iv dose of 50 IU/kg Human-cl rhFVIII (Nuwiq) profiled for up to 72 hours after dosing followed by sc dose of 50 IU/kg OCTA101 profiled up to 72 hours in adult male patients with severe hemophilia A.
~Treatments will be administered in fixed sequence, with Human-cl rhFVIII first.
~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 4 and 5 alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
16390416|NCT04046848|Experimental|Cohort 5|(n=4): Three-period investigation of single sc doses of 20, 40, and 60 IU/kg OCTA101 profiled up to 72 hours after dosing. Treatments were to be administered in fixed dose-ascending sequence.
16390417|NCT04046848|Experimental|Cohort 6|(n≥16): Following an initial 4 to 6-week run-in period with Nuwiq iv prophylaxis, >3-6 months daily prophylactic treatment with 12.5 IU/kg OCTA101 sc, then 25 IU/kg OCTA101 sc for a further 6-7 months (exact dosing depends on available vial sizes). In case of two spontaneous bleeding episodes, after having completed at least 3 months with 12.5 IU/kg OCTA101 daily treatment the individual treatment dose will be increased from 12.5 to 25 IU/kg. Site of administration (abdomen or thigh) to be chosen by the patient. A further treatment phase with 40 IU/kg OCTA101 will be discussed with the DMC, once results of earlier dosing phases are available.
16390418|NCT04046822|Active Comparator|Active drug|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
16390419|NCT04046822|Placebo Comparator|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
16390420|NCT04046809|Experimental|Study Treatment|500 ml oral solution containing citicoline free acid 50 mg/ml.
16390421|NCT04046809|Placebo Comparator|Placebo|500 ml oral solution indistinguishable from active product in appearance and taste
16390422|NCT04046796||Healthy twin|
16390423|NCT04046796||Effected Twin|Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
16390424|NCT04046783||Group A included subjects without a history of C-section|Group A consisted of 47 women without a prior a history of C-section: 24 controls and 23 subjects who used patch. These latest 23 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
16390425|NCT04046783||group B subjects who had already undergone previous C-section|Group B consisted of 46 women already undergone previous C-section: 22 controls and 24 subjects who used patch. These latest 24 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
16390426|NCT04046770|Experimental|Double-Chamber Syringe|Intravenous administration of drugs and flushing with the Double-Chamber Syringe
16390427|NCT04046770|Active Comparator|Classical Syringes|Intravenous administration of drugs and flushing with the classical syringe
16390428|NCT04046744|Active Comparator|BAX|
16390429|NCT04046744|Experimental|BAX-Asso|
16390430|NCT04046731|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive NMBAs during surgery in order to determine Negative Predictive Values and Non-Irritant Concentrations.
16390431|NCT04046718|Experimental|electroacupuncture|the study group received electroacupuncture stimulation at different points
16390432|NCT04046718|No Intervention|control group|a control group with no intervention
16390433|NCT04046705|Experimental|HLA matched haematopoietic stem cell transplantation|Peripheral blood stem cell from matched HLA related donor.
16390434|NCT04046705|Other|Control arm|Best standard care : Patients will receive the best standard care according to their situation and their previous treatment: initiation of Hydroxyurea, continuation or optimization of the dose of Hydroxyurea, initiation or continuation of TP, initiation of a new drug proved to improve SCD and having authorization to use in France.
16390435|NCT04046692||children in hospital school in contact with outside school|children experience school's lesson with the hospital teacher in the school's room or into their bedrooms and the investigator give before/after the lesson 2 questionnaire (PANAS-C and PH-C) and the VAS to evaluate the aim's study. Then, the investigator asks the children to make 2 paintings: one about the hospital school experience (what is for him/her the hospital school) and one about the outside school (what he/she do/did outside during school).
16390436|NCT04046692||children in hospital school NOT in contact with outside school|"it's the same of the previous group (children experiencing hospital school still in contact with outside school); the only difference of this group is that children are not in contact with the outside school."
16390437|NCT04046692||hospital teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
16390438|NCT04046692||outside teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
16390439|NCT04046692||Parents|parents have to answer some questions (qualitative interview)
16390440|NCT04046679|Experimental|Bleomycin|Bleomycin Infusion By Tattoo Machine
16390441|NCT04046679|Placebo Comparator|Saline Solution|Saline Infusion by Tattoo Machine
16390442|NCT04046666|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
16390443|NCT04046666|Other|Healthy group|This group will include 40 healthy volunteers.
16390444|NCT04046666|Other|Healthy intervention group|This group will include 40 healthy volunteers, who will receive moxibustion intervention.
16390445|NCT04046653|Experimental|Study arm 1|Allin capsules (x2) and Sulforaphane capsules (x2) once daily for 4 weeks
16390446|NCT04046653|Experimental|Study arm 2|Allin capsules (x2) and placebo capsules (x2) once daily for 4 weeks
16390447|NCT04046653|Experimental|Study arm 3|Sulforaphane capsules (x2) and placebo capsules (x2) once daily for 4 weeks
16390448|NCT04046653|Placebo Comparator|Study arm 4|Placebo capsules (x4) once daily for 4 weeks
16390449|NCT04046640||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
16390450|NCT04046640||Healthy group|This group will include 40 healthy volunteers.
16390451|NCT04046614|Experimental|nintedanib nivolumab|nintedanib-nivolumab combination therapy
16390452|NCT04046601|Experimental|Impedance|every resected tissue will measured by an impedance probe
16390453|NCT04046588|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
16390454|NCT04046588|Other|Healthy control group|This group will include 40 healthy volunteers.
16390455|NCT04046588|Experimental|Healthy intervention group|This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
16390456|NCT04046575|Experimental|IMRT + Carboplatin + Paclitaxel|Concurrent chemoradiation will consist of hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) for 3 weeks with carboplatin and paclitaxel for 3 cycles every 7 days. Endoscopy and (optional) PET/CT within 6-8 weeks post-completion of chemoradiation.
16390494|NCT04046341|Experimental|Behavioral Sleep Intervention|Parents attend 1-3 one-hour sessions at their primary care office or via telemedicine, where they receive sleep education and work with interventionists to develop strategies to help their child at bedtime.
16390457|NCT04046562|Active Comparator|PAW plus standard of care|Each PAW session will include handouts and worksheets to assist with new strategies as well as homework. Strategies taught within PAW will be integrated with the skills taught in weight management. For example, pain diaries will be kept along with food and exercise logs to examine relationships among pain, eating and activity.
16390458|NCT04046562|Placebo Comparator|Pain education plus standard of care|For those randomized into the information-only group, sessions will be delivered in the same manner. Sessions will cover general pediatric pain management but no behavioral or cognitive skills training will be taught.
16390459|NCT04046549|Experimental|Belatacept+VIB4920|Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.
16390460|NCT04046536|Active Comparator|Active rTMS at the LDLPFC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left dorsolateral prefrontal cortex (LDLPFC).
16390461|NCT04046536|Sham Comparator|Sham rTMS at the LDLPFC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LDLPFC.
16390462|NCT04046536|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
16390463|NCT04046536|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
16390464|NCT04046523|Experimental|Healthy Controls|In the first phase of the experiment, 20 healthy controls will test the VO device to determine whether the camera with a CCD or CMOS lens is the most appropriate for use in ICP patients and to synchronize the VO, ECG, PPG, IOP and respiratory signals.
16390465|NCT04046523|Experimental|Transfer Function Estimation|Subjects in the second phase of the experiment (70 subjects total) will be randomized to either Group A or Group B. We anticipate that 25 adult and 10 pediatric (ages 4-17) patients will participate in each group. Individuals in Group A will have two inter-leaved examinations (1-14 days apart). Data from the first examination will serve for SVP-ICP transfer function estimation and data from the second examination will serve for the intra-group verification for the estimated transfer function.
16390466|NCT04046523|Experimental|Intra-Group Verification|Individuals in Group B will undergo one examination. Data from Group B participants will serve as the inter-group re-test verification of the estimated transfer function.
16390467|NCT04046510|Active Comparator|High doses|the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion
16390468|NCT04046510|Experimental|Intermediate doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion
16390469|NCT04046510|Experimental|Low doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion
16390470|NCT04046497|Experimental|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
16390471|NCT04046497|Active Comparator|Usual Care|Usual care provided at CSC clinic
16390472|NCT04046484|Active Comparator|Normal Saline (Dose: Equal volume) + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
16390473|NCT04046484|Experimental|PMZ-1620 + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
16390474|NCT04046471|Other|Individual In-Person|
16390475|NCT04046471|Other|Group Remote|
16390476|NCT04046458|Experimental|EHR Alert|Physician teams will observe the EHR alert as they perform their clinical duties in the EHR.
16390477|NCT04046458|Placebo Comparator|No Alert|Physician teams will perform their clinical duties in the EHR as usual, with no visible alert.
16390483|NCT04046432|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial 1. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101-LAB capsule II) containing 10 billion bacteria per capsule for clinical trial 2.
16390484|NCT04046432|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
16390485|NCT04046406|Experimental|Pelvic pain syndromes|Patients with pelvic pain syndromes who will undergo MR neurography-guided cryoanalgesia
16390486|NCT04046393|Experimental|Traditional Chinese Medicine(TCM) group|nasal irrigation with Traditional herbal medicine(licorice) extract-saline isotonic solution
16390487|NCT04046393|Placebo Comparator|Saline control group|nasal irrigation with saline isotonic solution
16390488|NCT04046380||normal lungs|
16390489|NCT04046380||Acute respiratory distress syndrome (ARDS) group|
16390490|NCT04046367|Experimental|Intervention|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, with specific training aimed at increasing physical activity, functional capacity and conditioning of the respiratory musculature (prehabilitation by a physiotherapist)
16390491|NCT04046367|Active Comparator|Control|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
16390495|NCT04046328|Experimental|"Low Dose ECC Regimen"|ECC at the 1.7 g daily dose, administered BID as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
16390496|NCT04046328|Experimental|"High Dose ECC Regimen"|ECC at the 4.25 g daily dose, administered BID as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
16390497|NCT04046302|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
16390498|NCT04046302|Placebo Comparator|placebo|one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
16390499|NCT04046289||Low Calcium|low calcium milk of 180 ml, twice daily for 24 weeks
16390500|NCT04046289||Regular Calcium|regular calcium milk of 180 ml, twice daily for 24 weeks
16390501|NCT04046289||Probiotic 1|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
16390502|NCT04046289||Probiotic 2|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
16390503|NCT04046276|Placebo Comparator|Conventional Physical Therapy|Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
16390504|NCT04046276|Sham Comparator|Medium Intensity Aerobic exercise (50% VO2 max)|Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
16390505|NCT04046276|Experimental|High Intensity Aerobic exercise|Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
16390506|NCT04046263|Experimental|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
16390507|NCT04046250|Experimental|TK112690|TK112690 treatment
16390508|NCT04046250|Placebo Comparator|Placebo|TK112690 formulation
16390509|NCT04046237|No Intervention|Usual treatment - Control group|"The patient is referred to his treating dentist with a diagnosis report of his oral state including his periodontal status.
~The usual care usually includes the extraction of non-preservable teeth, the dental prosthesis to replace them and at least one descaling session."
16390510|NCT04046237|Experimental|Periodontal treatment - Intervention group|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit at M9.
~Briefly, the intervention group includes initial therapy with information on oral hygiene techniques, scaling and surfacing of dental roots. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
16390511|NCT04046224|Experimental|Sequential dose escalation|ST-920 is administered as a single infusion
16390512|NCT04046211|Experimental|Hydrogen exposure|The first two patients will be exposed to 2.4% hydrogen gas in medical air via HFNC for 24 hours. The second two patients will be exposed to the same gas for 48 hours. The final 4 patients will be exposed to the same gas for 72 hours.
16390513|NCT04046198|Experimental|İntervention group|Nurses working at Akdeniz University Hospital became the intervention group. The nurses who accepted to participate in the study were divided into groups of 5-15 people. Pre-test was applied to nurses who accepted the research. Nurses were given 4-hour group trainings. A booklet on the subject prepared by the researchers was given. Three interim interviews were conducted in the subsequent 3-month period. Six separate posters were posted in the clinics. Weekly reminder messages were sent via WhatsApp. At the end of the third month, post-test data were collected from the nurses.
16390514|NCT04046198|Other|Control group|The nurses working in the University of Health Sciences Antalya Training and Research Hospital constituted the control group. Pre-test was applied to nurses who accepted the research. Post test applied 3 months later. A booklet on the subject prepared by the researchers was given after the post test. Group training was conducted to nurses.
16390515|NCT04046185|Experimental|pd-1 inhibitor and progesterone|Toripalimab. 240mg intravenous injection, every 3 weeks, 4 times. Megestrol Acetate Tablets, 160mg, po, once a day.
16390516|NCT04046185|Active Comparator|progesterone|Megestrol Acetate Tablets, 160mg, po, once a day.
16390517|NCT04046172|Experimental|test group|intensive periodontal treatment (IPT)
16390518|NCT04046172|Sham Comparator|control group|Control periodontal treatment (CPT)
16390519|NCT04046159|Active Comparator|Radiotherapy arm|Radiotherapy for ipsilateral whole breast with 50 Gy/25 fractions or 40.05 Gy/15 fractions
16390520|NCT04046159|Experimental|Tamoxifen arm|Tamoxifen 5 mg QD for 10 years
16390521|NCT04046146|Experimental|NIR-ICG MRL|We may ask healthy subjects to return for up to four injection sessions for the study. The first injection session will consist of intradermal injection of ICG into the webspaces of the hand as done in our previous studies followed by NIR camera imaging. The second session will consist of intradermal gadolinium injection and intravenous (IV) iron contrast agent followed by MRI imaging approximately 1 week after the first session. The third session will occur at minimum eight weeks later and entail intra-articular ICG injection in order to evaluate drainage via the lymphatics. The MCP joints will be identified in the non-dominant hand and injected with ICG. Approximately one week later, the fourth session will compromise of intra-articular gadolinium injection and IV iron contrast to confirm lymphatic drainage. The MCP joints of the non-dominant hand will again be identified and injected with gadolinium.
16390522|NCT04046133|Experimental|pembrolizumab|Patients with locally advanced (stage IIIA/B, T3/T4, any N, M0) anal cancer will receive pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT.
16390523|NCT04046120|No Intervention|Heel included|The bandage is made by including the heel as recommended in routine.
16390524|NCT04046120|Experimental|Heel not included|he bandage is made by leaving the heel uncovered.
16390525|NCT04046107|Experimental|Cohort 1: Cemiplimab (0.3 mg/kg)|Participants will receive cemiplimab 0.3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
16390526|NCT04046107|Experimental|Cohort 2: Cemiplimab (1 mg/kg)|Participants will receive cemiplimab 1 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
16390527|NCT04046107|Experimental|Cohort 3: Cemiplimab (3 mg/kg)|Participants will receive cemiplimab 3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
16390528|NCT04046094|Experimental|IV Ascorbic Acid|IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks
16390529|NCT04046081|Other|Dichloroacetate|Open label study
16390530|NCT04046055|Sham Comparator|Sham|50% of participants will have a unilateral cerebellar montage with the anode (active electrode) three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode (return electrode) on the ipsilateral cheek. 50% of participants will have a bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned (2 mA) on for the 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
16390531|NCT04046055|Experimental|Unilateral, 2 mA|A unilateral cerebellar montage with the anode three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode on the ipsilateral cheek. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
16390532|NCT04046055|Experimental|Bilateral, 2 mA|Bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
16390533|NCT04046055|Experimental|Unilateral, 4 mA|A unilateral cerebellar montage with the anode three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode on the ipsilateral cheek. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16390534|NCT04046055|Experimental|Bilateral, 4 mA|Bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
16390535|NCT04046042|Active Comparator|Conventional exercise time|During 12 months subjects will exercise during the first two hours of the hemodialysis session. A virtual reality exercise program will be implemented
16390536|NCT04046042|Experimental|Experimental group|During 12 months subjects will exercise during the last two hours of the hemodialysis session. A virtual reality exercise program will be implemented
16390537|NCT04046029|Experimental|Bivalirudin|
16390538|NCT04046029|Active Comparator|Heparin|
16390539|NCT04046016|Experimental|Subjects|A total of two subjects were enrolled. Those are breast cancer patients.
16390540|NCT04046003|Experimental|Tai Chi intervention|24-form Yang style Tai Chi
16390541|NCT04045990|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. rTMS will be administered in an excitatory pattern as 20Hz. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
16390542|NCT04045990|Sham Comparator|SHAM stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory or language performance, or whether practice effects or other non-specific effects are responsible for any changes in memory or language performance which may be observed.
16390543|NCT04045977|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
16390544|NCT04045977|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
16390545|NCT04045964|Experimental|Motivational advice and free NRT|
16390546|NCT04045964|Active Comparator|Quitline referral|
16390547|NCT04045951|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
16390548|NCT04045951|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
16390549|NCT04045925|Experimental|Taïso practice|6 months of biweekly practice Taïso
16390550|NCT04045912|Experimental|HIVST + AGYW-Friendly Services|"Drug shops in Arm 1 will implement AGYW-friendly services, including a sexual and reproductive health (SRH) product display, a tablet with SRH videos, and a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discretely request free SRH products. They will also provide HIV self-test (HIVST) kits to AGYW customers for free."
16390551|NCT04045912|Active Comparator|HIVST Only|Drug shops in Arm 2 will provide HIVST kits to AGYW customers for free.
16390552|NCT04045899|Active Comparator|ProSeal Laryngeal Mask Airway Group|ProSeal LMA was inserted in 50 patients
16390553|NCT04045899|Experimental|Air-Q LMA Group|Air-Q LMA was inserted in 50 patients
16390554|NCT04045899|Experimental|Ambu AuraGain LMA Group|Ambu AuraGain was inserted in 50 patients
16390555|NCT04045886|Experimental|Online Educational Modules group|anesthesia residents are randomized to watch educational videos which is the intervention.
16390556|NCT04045886|Active Comparator|Reading two research papers group|anesthesia residents are randomized to read 2 research papers which is the active comparator
16390557|NCT04045873|Experimental|ECMO plus IABP|
16390558|NCT04045873|Experimental|IABP|
16390559|NCT04045860|Experimental|CDT for head and neck lymphedema|Complete Decongestive Therapy
16390560|NCT04045860|Other|Standard of Care for head and neck lymphedema|Observation
16390561|NCT04045847|Experimental|CD147-CART|CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
16390562|NCT04045821|Placebo Comparator|Control|Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D&C procedure will be completed.
16390563|NCT04045821|Experimental|Intervention|Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D&C procedure will be completed.
16390564|NCT04045808||CAD(+) group|Participants were included in CAD (+) if they had more than 50% reduction in diameter in one or more major epicardial arteries,
16390565|NCT04045808||CAD(-) group|patients with less than 50% reduction in epicardial artery diameter were enrolled to CAD (-) group
16390566|NCT04045795|Experimental|Dose regimen 1|Isatuximab SC administration dose level 1 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
16390567|NCT04045795|Experimental|Dose regimen 2|Isatuximab SC administration dose level 2 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
16390568|NCT04045795|Experimental|Dose regimen 3|Isatuximab SC administration dose level 3 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
16390569|NCT04045795|Experimental|Dose regimen 4|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
16390570|NCT04045795|Experimental|Dose regimen 5|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
16390571|NCT04045782|Other|single arm|Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
16390572|NCT04045769|Experimental|Study Treatment 1|Saroglitazar magnesium 4 mg
16390573|NCT04045769|Experimental|Study treatment 2|Saroglitazar magnesium 20 mg
16390574|NCT04045769|Placebo Comparator|Placebo|Placebo
16390575|NCT04045769|Active Comparator|Active Control|Moxifloxacin 400 mg
16390576|NCT04045756|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
16390577|NCT04045743|Experimental|Bermekimab (MABp1)|
16390578|NCT04045743|Experimental|Placebo|
16390579|NCT04045730|Experimental|Patients with metastatic pancreatic ductal adenocarcinoma|Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma, and all patients must have at least 15 unstained slides of formalin fixed paraffin embedded (FFPE) tumor tissue available or a pre-treatment core needle biopsy will be required as outlined in section 7.1.2.7. All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab in 4-week cycles.
16390580|NCT04045717|Experimental|Hypo-FLAME 2.0|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
16390581|NCT04045678|Experimental|LY03003|
16390582|NCT04045678|Placebo Comparator|Placebo|
16390583|NCT04045665|Active Comparator|Antiplatelet Therapy|Antiplatelet-only strategy
16390584|NCT04045665|Active Comparator|Oral Anticoagulant|OAC-based strategy
16390585|NCT04045652||Kenyan women|Kenyan women, some HIV-infected and some HIV-uninfected, VIA negative at enrollment.
16390586|NCT04045639||Intervention arm|The AF risk prediction algorithm will be run on patient records within the Egton Medical Information Systems (EMIS) data base, in order to identify patients at risk of developing AF
16390587|NCT04045639||Control arm|Patients may be diagnosed with AF through routine clinical practice only
16390588|NCT04045626|Active Comparator|Transepithelial accelerated cross-linking|"Paracel is instilled 1 drop every 1.5 minutes for 4.5 minutes then vibex-xtra is instilled 4 drops at 5.5 minutes followed by 1 drop at 6.5 minutes for a total soak time of 11 minutes followed by ultraviolet-A UVA irradiation with intended irradiance of 45mW/cm2 for 2.4 minutes"
16390589|NCT04045626|Active Comparator|Epithelium-off accelerated cross-linking|"Vibex-rapid is instilled every 2 minutes for 10 minutes followed by ultraviolet-A UVA irradiation of 30 mW/cm2 for 4 minutes"
16390590|NCT04045613|Experimental|Derazantinib monotherapy [Substudy 1]|Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib dose level 1.
16390591|NCT04045613|Experimental|Derazantinib + atezolizumab: Dose finding [Substudy 2]|Dose finding and dose expansion in patients with solid tumor.
16390592|NCT04045613|Experimental|Derazantinib + atezolizumab: First line [Substudy 3]|Patients with urothelial cancer will be treated with a combination of derazantinib and atezolizumab.
16390593|NCT04045613|Experimental|Derazantinib +/- atezolizumab: Second line [Substudy 4]|Patients with urothelial cancer progressing after prior FGFR inhibitor treatment will be randomized to receive either derazantinib alone or a combination of derazantinib and atezolizumab.
16390594|NCT04045613|Experimental|Derazantinib monotherapy [Substudy 5]|Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib dose level 2.
16390595|NCT04045600|Experimental|Mult FCT/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
16390596|NCT04045600|Experimental|Mult FCT + Stimulus Fading/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
16390597|NCT04045587||Severe Asthma Participants|Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
16390598|NCT04045574|Experimental|DAMP1 :|Single arm trial comparing a conventional technique with an experimental one, within the same patient.
16390599|NCT04045548|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
16390600|NCT04045548|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
16390601|NCT04045535|Experimental|Intervention group|Intervention with nurse and patients
16390605|NCT04045496|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
16390606|NCT04045483|Experimental|VR based cognitive training|Participants perform the VR based cognitive training under the supervision of a research nurse or psychologist for 30 min per session, twice per week, over the 6-week intervention period.
16390607|NCT04045483|No Intervention|Usual care|Participants take some medication for risk factors and cognitive impairment and receive health advice as a usual care.
16390608|NCT04045470|Experimental|Initial Cohort|"Patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma
~Mandatory skin biopsy for corollary studies will be obtained
~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)"
16390609|NCT04045470|Experimental|Expansion Cohort|"Only patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma who plan to start systemic therapy as part of standard of care
~Mandatory skin biopsy for corollary studies will be obtained
~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)
~Participants will receive standard of care therapy and clinical course followed
~Participants will undergo standard of care therapy as previously determined by treating oncologist and/or dermatologist prior to enrollment to study
~Participants will not be assigned any treatment intervention"
16390610|NCT04045457|Other|SIngle arm|Single arm, intervention All recipients were treated with dry needling technique into active myofascial trigger points They received 1 treatment weekly for three weeks.
16390611|NCT04045444|Experimental|women non active young people|women between 18 and 30 years practice less than 1h of physical activity per week
16390612|NCT04045444|Experimental|men non active young people|men between 18 and 30 years practice less than 1h of physical activity per week
16390613|NCT04045444|Experimental|women non active old people|women between 60 and 85 years practice less than 1h of physical activity per week
16390614|NCT04045444|Experimental|men non active old people|men between 60 and 85 years practice less than 1h of physical activity per week
16390615|NCT04045444|Experimental|women active old people|women between 60 and 85 years practice at least 3h of physical activity per week
16390616|NCT04045444|Experimental|men active old people|men between 60 and 85 years practice at least 3h of physical activity per week
16390617|NCT04045444|Experimental|women with parkinson's disease|women between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
16390618|NCT04045444|Experimental|men with parkinson's disease|men between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
16390619|NCT04045431|Experimental|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
16390620|NCT04045431|Active Comparator|Synvisc-One|Intra-articular injection with Synvisc-One (hyaluronic acid)
16390621|NCT04045418||COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
16390622|NCT04045418||Healthy control group|This group will include 40 healthy volunteers.
16390623|NCT04045418||Healthy intervention group|This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
16390624|NCT04045405|Experimental|CDR132L|
16390625|NCT04045405|Placebo Comparator|Saline|
16390626|NCT04045392|Experimental|Mediterranean diet group|Mediterranean diet with calorie restriction below 1,500 kcal per day.
16390627|NCT04045392|No Intervention|Conventional diet group|Conventional diet with calorie restriction below 1,500 kcal per day.
16390628|NCT04045379|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
16390629|NCT04045379|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
16390630|NCT04045379|Active Comparator|Estriol|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
16390631|NCT04045353|No Intervention|Standard of care|Subjects will receive standard counseling on obesity as part of routine postpartum care.
16390632|NCT04045353|Active Comparator|Low carbohydrate diet education|Subjects will receive educational materials regarding a low carbohydrate diet in addition to the standard counseling on obesity as part of routine postpartum care.
16390633|NCT04045353|Active Comparator|Low carbohydrate diet education with behavioral component|Subjects will receive in person instruction regarding a low carbohydrate diet as part of a 12 week course, in addition to receiving educational materials regarding a low carbohydrate diet and the standard counseling on obesity as part of routine postpartum care.
16390634|NCT04045327|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
16390635|NCT04045327|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
16390636|NCT04045314|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the long-term effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study.
16390637|NCT04045301|Experimental|Omalizumab 16 mg/kg|"Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.
~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
16390696|NCT04044885|No Intervention|No nap|After each night with a 8-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead have free time.
16390697|NCT04044872|Experimental|Single Arm:Diagnosing Cardiotoxicity when on Radiation therapy|
16390638|NCT04045301|Experimental|Omalizumab 8 mg/kg|"Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.
~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
16390639|NCT04045301|Placebo Comparator|Placebo|"Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.
~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
16390640|NCT04045288|Active Comparator|Standard Implementation|All schools in SWITCH receive training through webinars and an in-person conference to learn about the defining elements and school wellness programming in general. Consistent with the standard implementation, schools were added to the online content management system (CMS) and were given access to an online community of practice (CoP) to interact with other schools / teachers in the study. Schools were provided with resources and program materials (i.e. educational modules, trinkets, posters, etc.) but were given autonomy with regard to how they were used within their school. Weekly updates through the online CMS, the CoP, and via direct email correspondence provided information about the weekly corresponding weekly themes, implementation tips, recommended module activities to incorporate, upcoming evaluation needs, important SWITCH dates, and other program reminders.
16390641|NCT04045288|Experimental|Enhanced Implementation|The 'Enhanced' implementation strategy provided schools with the same training, access and resources as the standard SWITCH implementation along with more personalized, web-based training based on motivational interviewing (MI) techniques and feedback throughout the implementation process. The supplemental support was provided through participation in two online 'checkpoint sessions' that helped schools self-assess their use of the recommended quality elements and setting-specific best practices. The sessions used principles of motivational interviewing (MI) to promote autonomy and motivation for school change through the process. Schools were also provided with information about how to capitalize on support from local 4H program leaders in their county.
16390642|NCT04045275|Experimental|Calm|"The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete 7 days of Calm meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails."
16390643|NCT04045275|No Intervention|Control|This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.
16390644|NCT04045249|No Intervention|1st Group|Children were treated as per standard CMAM protocols; provided RUTF until MUAC reaches 11.5 cm
16390645|NCT04045249|Experimental|2nd Group (1st Intervention group)|Children were initially provided RUTF until MUAC reach 11 cm then 50 % calories were provided from RUTF and 50% calories from home based food
16390646|NCT04045249|Experimental|3rd Group (2nd Intervention)|Children were initially provided RUTF until MUAC reach 11 cm then 100 % calories provided from home based food
16390647|NCT04045236||Non metastatic rectal cancer|Patients receiving the diagnosis of non metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The study population will consist of all the patients enrolled in the participating centres from the start of the rectal cancer registry on.
16390648|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
16390649|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
16390650|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
16390654|NCT04045197|Experimental|Intervention group|In the intervention group; informed consent forms, Relaxation Focused Nursing Care and routine nursing care in the hospital were performed. Then data collection tools were applied.
16390655|NCT04045197|No Intervention|Control group|Women in the control group received routine nursing care in the hospital and data collection tools were applied at the same hours as the intervention group.
16390656|NCT04045184||B-FED|Clients of the Birmingham AIDS Outreach Food and Education Delivery (B-FED) program who are also patients at the 1917 Clinic.
16390657|NCT04045184||non B-FED|Patients at the 1917 Clinic who have chosen not to participate in B-FED at this time.
16390658|NCT04045145|Experimental|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
16390659|NCT04045132|Active Comparator|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
16390660|NCT04045132|Experimental|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
16390661|NCT04045119|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the longterm effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study
16390692|NCT04044911|Active Comparator|Stepping followed by tea making|A control condition comprising five 1-hour weekly stepping training sessions is followed after a 3-week break by five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (COgWatch)
16390662|NCT04045106|Experimental|PNF pattern|"PNF patterns were performed using Dynamic of reversals technique which is characterized as active motion alternating from one direction (agonist) to the opposite (antagonist) without relaxing. The cervical patterns consisted of
~Cervical flexion with right rotation followed by extension with left rotation.
~Cervical flexion with left rotation followed by extension with right rotation."
16390663|NCT04045106|Experimental|PNF stretching|PNF stretching was done using contract-relax-antagonist contract (CRAC) technique for cervical flexors, extensors, right and left lateral flexors, right rotators and left rotators.
16390664|NCT04045106|Sham Comparator|control|Participants allocated to the control group received ineffective passive ROM.
16390665|NCT04045093|Experimental|Dabigatran etexilate|Subjects randomized into this group will be prescribed with either Dabigatran 150mg or Dabigatran 110mg (twice daily) according to creatinine clearance level, twice daily) for stroke prevention.
16390666|NCT04045093|Active Comparator|Warfarin|Subjects randomized into this group will be prescribed with Warfarin with dosage adjustment according to INR level (targeting to INR 2-3) for stroke prevention.
16390667|NCT04045080|Experimental|AMADEO Training|Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
16390668|NCT04045080|Active Comparator|OT training|"Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment.
~Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait."
16390669|NCT04045067||Group 1|A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
16390670|NCT04045067||Group 2|A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
16390671|NCT04045067||Group 3|A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
16390672|NCT04045054|Other|Intervention|The Link Team follows up with the participants for 6 months after they discharge from the hospital
16390673|NCT04045041|Experimental|Treatment group|10 week internet-based acceptance and commitment therapy
16390674|NCT04045041|No Intervention|Control group|Waiting-list control.
16390679|NCT04045015|Active Comparator|glycyrrhizic acid 1.5 mg/kg body weight|Liqourice corresponding to 1.5 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
16390680|NCT04045015|Active Comparator|glycyrrhizic acid 3.0 mg/kg body weight|Liqourice corresponding to 3.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
16390681|NCT04045015|Active Comparator|glycyrrhizic acid 6.0 mg/kg body weight|Liqourice corresponding to 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
16390682|NCT04045002|Experimental|Intervention|Intervention group receive 'MyPinkMom' educational intervention delivered through WhatsApp application for 2 weeks and routine antenatal care.
16390683|NCT04045002|No Intervention|Control|Control group receive information on anaemia in pregnancy placed at respondents' antenatal card and routine antenatal care
16390684|NCT04044989|Experimental|Root resorption (total)|The resorption cavities on the root surface were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
16390685|NCT04044989|Experimental|Root resorption (local)|The resorption cavities on the root surface (palatal, buccal, distal and mesial root surfaces) were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
16390686|NCT04044976|Experimental|Treated infants|Infants who will receive caffeine in the delivery room.
16390687|NCT04044963|Experimental|Exercise Group|All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The exercise intervention is prescribed based on the FITT principle: frequency, intensity, time and type. The 10-point Rating of Perceived Exertion (RPE) scale, which has been well correlated to target HR levels, will be used to monitor exercise intensity levels throughout the intervention, with participants instructed to maintain their intensity level at 3-5 during exercise sessions. Participant progression will be individualized and based on their subjective perceived intensity level using the RPE scale. In person instruction, from a member of the research team with standard first aid and CPR-C training, and an instructional handout and exercise log will be provided, as well as exercise resistance bands to perform resistance exercises.
16390688|NCT04044963|No Intervention|Control Group|This will consist of regular care, which is standard procedure.
16390689|NCT04044950|Experimental|Arm 1|Approximately 3x10^8 E7 TCR T cells (based on the number of disease sites the patient has) will be injected on day 0.
16390690|NCT04044937|Experimental|Diagnostic FET PET|All participants receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes. Repeat FET PET will be offered to adult patients.
16390691|NCT04044911|Active Comparator|Tea making followed by stepping|Five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (CogWatch) is followed after a 3-week break by a control condition in which participants receive five 1-hour weekly stepping training sessions.
16390693|NCT04044898|Experimental|Low dose|
16390694|NCT04044898|Experimental|High dose|
16390695|NCT04044885|Experimental|Nap|After each night with a 6.5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
16390698|NCT04044859|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
16390699|NCT04044846|Experimental|The recipients of the home-based physical activity program|Frail OAs will be asked to fill out the Vitality Plus Scale at the beginning of the implementation phase (baseline) by a research assistant over the telephone. At the end of the 6-month implementation phase, the research assistant will administer the survey again (post-intervention).
16390700|NCT04044833||intervention|(n=63)
16390701|NCT04044833||control|(n=65)
16390702|NCT04044820|Active Comparator|Standardized Discharge Prescription|Based on a previous study examining mean number of opioid pills used by patients undergoing elective, unilateral hand and forearm surgery
16390703|NCT04044820|No Intervention|Usual Discharge Prescription|Routine standard of care involves prescription for opioids at the discretion of the surgical team
16390704|NCT04044794|Active Comparator|Standard Care|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a monetary gift of $60 that can be used to purchase health-promoting supplies to support weight management.
16390705|NCT04044794|Experimental|Daily Self-Weighing|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a commercially available wireless scale. Participants will be instructed to weigh daily and view their weight on the scale's digital display.
16390706|NCT04044781|Experimental|Test Group|Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
16390707|NCT04044768|Experimental|Autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) SPEAR™ T cells|
16390708|NCT04044755|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
16390709|NCT04044755|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
16390710|NCT04044742|Experimental|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume is administered as a one-time dose, intra-articularly
16390711|NCT04044742|Placebo Comparator|Placebo|Placebo formulation in 5 mL volume administered intra-articularly
16390712|NCT04044729|Active Comparator|Cannabidiol|"Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
~Other Names:
~CBD"
16390713|NCT04044729|Placebo Comparator|Placebo|"Drug: Placebos An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
~Other Names:
~placebo"
16390716|NCT04044703|Experimental|Model-based vancomycin dosing|Participants will receive model-based intermittent intravenous vancomycin dosing as calculated by the dosing calculator available on a web application. Participants will then have routine therapeutic drug monitoring and linear dose adjustments.
16390717|NCT04044690|Experimental|IgPro20|human immunoglobulin G administered subcutaneously
16390718|NCT04044690|Placebo Comparator|Placebo|human albumin solution administered subcutaneously
16390719|NCT04044677|Experimental|tDSC-active|"The TDCS-active will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend) during the practice of VR games, TDCS-active will be performed with a current of 1 mA and 20 min of duration (20 seconds of ramp-up and ramp-down). The stimulation target will be the M1 area, choosing the more functional side of the participant (C3 or C4).
~This group will perform the tDCS-sham after one-month washout."
16390720|NCT04044677|Sham Comparator|tDCS-sham|"The TDCS-sham will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend). However, the electrodes will be positioned at the same sites of the tDCS-active and the device will be switched on for 20 seconds (with ramp-up and ramp-down), giving the children the initial sensation of the 1 mA current, but with no stimulation administered during the rest of the time. This sham protocol is already programmed in the device prior to data collection.
~This group will perform the tDCS-active after one-month washout."
16390721|NCT04044664|Placebo Comparator|Placebo|
16390722|NCT04044664|Experimental|NYX-783 Low Dose|
16390723|NCT04044664|Experimental|NYX-783 High Dose|
16390724|NCT04044651|Experimental|Lenvatinib plus nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w+ lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
16390725|NCT04044651|Active Comparator|Lenvatinib|Lenvatinib 12 mg (or 8 mg) Po once daily
16390726|NCT04044638|Experimental|Young Group|"Young women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.
~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
16390727|NCT04044638|Experimental|Middle-aged Group|"Middle-aged women women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.
~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
16390728|NCT04044625|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
16414203|NCT03880175|No Intervention|FCC control and no info|
16390729|NCT04044625|Active Comparator|Low-intensity NPPV|The patients will receive low-intensity noninvasive positive pressure ventilation.
16390730|NCT04044612|Experimental|Medial Unloader Brace|
16390731|NCT04044599|Experimental|Study|THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS
16390732|NCT04044599|No Intervention|Control|Control group
16390733|NCT04044573|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
16390734|NCT04044560|Experimental|Blinatumomab Treatment|Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
16390735|NCT04044547|Experimental|LY03003|
16390736|NCT04044547|Placebo Comparator|Placebo|
16390737|NCT04044534|Experimental|Intranasal insulin|Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).
16390738|NCT04044534|Experimental|Placebo|Subjects in this arm will receive placebo.
16390739|NCT04044521|Experimental|Academic detailing only|Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
16390740|NCT04044521|Experimental|Academic detailing+practice facilitation|"Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months.
~At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-6, then quarterly for months 7-18."
16390741|NCT04044521|Experimental|Academic detailing+practice facilitation+physician peer consul|Clinicians will receive academic detailing at month 0 and practice facilitation at month 3. At month 6, clinics will be randomized to receive physician peer consulting. Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
16390742|NCT04044521|Experimental|Academic detailing+physician peer consulting|"Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months.
~At month 6, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant."
16390743|NCT04044508|Active Comparator|Interventional diet|A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
16390744|NCT04044508|Placebo Comparator|Placebo diet|A placebo diet (over 100 g of carbohydrates per day)
16390745|NCT04044495|Experimental|Sample of 100 persons included in AMI / AMImage 2|Sample of 100 persons included in AMI / AMImage 2
16390746|NCT04044469|Experimental|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
16390747|NCT04044469|Experimental|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
16390748|NCT04044469|Experimental|Control group|This group does not receive additional information after the doctor's report.
16390749|NCT04044456|Experimental|GMT plus attention|GMT consists of 2-hour, 10 weekly sessions using an interactive Power Point presentations. Attention training consists of 2-hour computerized attention training using Attention Process Training III and Brain HQ.
16390750|NCT04044456|Placebo Comparator|BHW plus movies|Brain Health Workshop consists of 2-hour, 10 weekly sessions using Power Point presentations and national geographic movies (2-hour, 10 weekly sessions).
16390751|NCT04044430|Experimental|Treatment (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days for a maximum of 24 cycles of treatment in the absence of disease progression or unacceptable toxicity.
16390752|NCT04044417|Placebo Comparator|open flap debridement only|surgical treatment of periodontal defects
16390753|NCT04044417|Active Comparator|curcumin and simvastatin|open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
16390754|NCT04044417|Active Comparator|EDTA, curcumin and simvastatin|open flap debridement followed by 24% EDTA root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
16390755|NCT04044404||A on C group|Acute on Chronic Kidney Disease patients
16390756|NCT04044404||functional delayed graft function group|patients with functional delayed graft function(fDGF) after kidney transplantation
16390757|NCT04044404||Normal|without functional kidney injury
16390758|NCT04044391||Intention to Treat: Cardiac Catheterization|All patients meeting inclusion criteria and scheduled to undergo cardiac catheterization will undergo a CardioFlux magnetocardiogram (MCG) to determine presence of patterns which indicate myocardial ischemia.
16391123|NCT04041921||Chronic coronary occlusion patients|≥3 months chronic total occlusion on coronary angiography
16390759|NCT04044391||Post Percutaneous Coronary Intervention|All patients found to have significant coronary artery obstruction seen via angiography +/- fractional flow reserve (FFR) or instant wave-free ratio (iFR) and who receive a catheter based intervention will have a post-procedure CardioFlux MCG scan. Follow up over the next 30 and 180 days will be performed to determine if a persistent pattern suggesting residual ischemia will correlate with an increased incidence of major cardiac adverse events (MACE).
16390760|NCT04044378|Experimental|Arm A: famitinib and camrelizumab|"In the dose-defining phase I portion, camrelizumab was given at a fixed dose of 200mg Q2W, while the de-escalated 3+3 design was used to detect the recommended dose of famitinib from an initial level of 15mg orally taken daily. Recommended phase 2 dose (RP2D) was defined as the highest dose at which no more than 30% patients experience a DLT in the first two courses.
~In the phase II portion, famitinib will be orally taken daily with RP2D together with camrelizumab intravenous infusion at a dose of 200 mg over 30 minutes, once every two weeks (Q2W), 4 weeks (28 days) as one treatment cycle."
16390761|NCT04044378|Active Comparator|Arm B: famitinib alone|Only phase II portion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle.
16390762|NCT04044378|Experimental|Arm C: Famitinib and Ifofamide|Only phase II protion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle together with ifofamide 1800 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 and 15-17 of each 28-day cycle for a total of 5 cycles.
16390769|NCT04044352|Experimental|Group 1|2 mL (approximately 5x10^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
16390770|NCT04044339|Experimental|TD-5202 for SAD (Part A)|6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202
16390771|NCT04044339|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo
16390772|NCT04044339|Experimental|TD-5202 for MAD (Part B)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202
16390773|NCT04044339|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.
16390774|NCT04044326|Experimental|microwave ablation (MWA)|20 patients with liver cancer, considered for local treatment of liver tumors of size measuring <5 cm and without any signs of extra-hepatic metastasis, will be enrolled to be treated with microwave ablation (MWA)
16390775|NCT04044313|Experimental|HAIC plus Lenvatinib and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
16390776|NCT04044300|Experimental|Operative|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level.
16390777|NCT04044300|Experimental|Non-operative|Continued pain management and physical therapy
16390778|NCT04044287|Active Comparator|Intervention|200 micrograms of Misoprostol applied sublingually together with standard parenteral oxytocic therapy
16390779|NCT04044287|Placebo Comparator|Placebo|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy micrograms of misoprostol
16390780|NCT04044274|Experimental|IOPstim|
16390781|NCT04044261|Experimental|Study Arm|Single open-label study arm. All participants are enrolled into this arm.
16390782|NCT04044248||TIPS-obliteration|Patients undergoing combined transjugular intrahepatic portosystemic shunt (TIPS) creation plus transvenous obliteration for the treatment of gastric varices (GVs).
16390783|NCT04044235|Experimental|PrEP Cohort|AGYW HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.
16390784|NCT04044235|No Intervention|HIV Incidence|HIV Incidence Cohort: In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence.
16390785|NCT04044222|Experimental|Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)|Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
16390786|NCT04044222|Experimental|Treatment (placebo, etoposide, ifosfamide, carboplatin)|Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.
16390787|NCT04044209|Experimental|Patients receiving nivolumab and ivosidenib|"Patients who meet eligibility criteria will initiate therapy with the IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
~On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle. Patient will be treated until progression, transplant or unacceptable toxicity. The patient will be continually monitored on therapy and will undergo scheduled response assessments to evaluate response."
16390882|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)
~Placebo is a transdermal patch, applied weekly for 24 weeks"
16390788|NCT04044183|Experimental|Active Brains|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
16390789|NCT04044183|Placebo Comparator|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
16390790|NCT04044170|Experimental|Poziotinib|"Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC
~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"
16390791|NCT04044144|Experimental|Probiotic Dietary Supplement|Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days
16390792|NCT04044131|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
16390793|NCT04044131|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
16390794|NCT04044118|Experimental|Caloric Restriction|3-week low calorie diet
16390795|NCT04044105|No Intervention|No Education|Patients in this arm receive no education regarding how to dispose of their opiate medication
16390796|NCT04044105|Experimental|Pamphlet education|Patients receive an educational pamphlet only, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment.
16390797|NCT04044105|Experimental|Pamphlet education + texts|Patients receive an educational pamphlet, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment. In addition, 3 automated text messages sent at those same time points.
16390798|NCT04044092|Active Comparator|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization, Cervical Spine strengthening exercises
16390799|NCT04044092|Experimental|ELDOA stretching exercise|ELDOA stretching exercise protocol along with Conservative physical therapy
16390800|NCT04044079|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
16390801|NCT04044079|Active Comparator|misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
16390802|NCT04044079|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
16390803|NCT04044053|Experimental|Relative Bioavailability|Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state
16390804|NCT04044053|Experimental|Fasted State|Comparison of 400 mg MR in fed and fasted states
16390805|NCT04044040|Experimental|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
16390806|NCT04044027|No Intervention|Control Group|
16390807|NCT04044027|Experimental|Intervention Group|
16390808|NCT04044014|Active Comparator|Arm A|Left arm: Gellan sheet; Right arm: Mepitel One.
16390809|NCT04044014|Active Comparator|Arm B|Left arm: Mepitel One; Right arm: Gellan sheet.
16390810|NCT04044014|Active Comparator|Arm C|Left arm: Gellan fluid gel; Right arm: Mepitel One.
16390811|NCT04044014|Active Comparator|Arm D|Left arm: Mepitel One; Right arm: Gellan fluid gel.
16391124|NCT04041908|Experimental|Experimental Product|Drink mix powder
16390824|NCT04043975||Patients with metastatic RCC|Patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) with intermediate or poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, who will be treated with Nivolumab + Ipilimumab for the first time
16390825|NCT04043962|Experimental|Web-based CBT (Web-MAP)|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
16390826|NCT04043949||Normal|healthy subjects
16390827|NCT04043949||Dry eye group|patients with dry eye
16390828|NCT04043949||Dry eye after treatment|patients with dry eye after treatment
16390829|NCT04043936|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions."
16390830|NCT04043936|Sham Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a CBM task with a neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
16390831|NCT04043936|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
16390832|NCT04043923|Experimental|Norketotifen|Norketotifen oral capsules, once daily for 5 days
16390833|NCT04043923|Placebo Comparator|Placebo|Placebo oral capsules, once daily for 5 days
16390834|NCT04043910|Experimental|Single-sided deaf group|30 children will be included in this group
16390835|NCT04043910|Active Comparator|Normal hearing group|30 children will be included in this group
16390836|NCT04043897|Experimental|Drug|Patients will receive open-label rifaximin 550mg tid x 4 weeks.
16390837|NCT04043884|Experimental|sEmg Biofeedback training|8-week exercise program, twice a week, with emg biofeedback training.
16390838|NCT04043884|Active Comparator|Exercises|8-week exercise program, twice a week.
16390839|NCT04043871||Patients with renal insufficiency|
16390840|NCT04043858|Experimental|Midodrine daily|Midodrine hydrochloride 2.5 mg tab once per day
16390841|NCT04043845|Experimental|LY3214996+Ibrutinib|"LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle
~Ibrutinib will be administered by mouth once daily continuously throughout each treatment cycle."
16390842|NCT04043819|Experimental|PSC-01|All study participants will receive intraarticular injection of the investigational biological product, PSC-01.
16390843|NCT04043806|Experimental|Open-Label Triple Combination|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
16390844|NCT04043780|Experimental|Decompression prototype splint|The patients of this group will wear the decompression prototype splint.
16390845|NCT04043780|Active Comparator|standard splint|The patients of this group will wear a standard splint.
16390846|NCT04043767||Pediatric patients aged between 1-8 years|Pediatric patients aged between 1-8 years who scheduled for general anesthesia in elective surgery. Additional physical examinations which were including thyromental distances, hyomental distances and neck circumferences, was performed at one day prior surgery. Intubation was done by general anesthesiologist in order to grade the laryngoscopic view.
16390847|NCT04043754|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
16390848|NCT04043754|Active Comparator|GTR treated patients|"Periodontal surgery with MEMBRANE is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers ; then, ABG will be applied alternatively with MEMBRANE into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositioned and sutures completed by interrupted sutures."
16390849|NCT04043741|Experimental|Dry Needling|Dry needling (04 Sessions) and exercises
16390850|NCT04043741|Active Comparator|Sustain Pressure|sustained pressure and Exercises
16390851|NCT04043728|Experimental|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
16391125|NCT04041895||Alzheimer's Disease|Those individuals who possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
16390852|NCT04043728|Experimental|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
16390853|NCT04043728|Experimental|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
16390854|NCT04043715|Other|Comparison of transcutaneous & epidural stimulation|Comparison of transcutaneous vs epidural electrical stimulation
16390855|NCT04043702||on topiramate|"topiramate, conviban® group vs no treatment ( control group)."
16390856|NCT04043702||on empagliflozine|"empagliflozine, jardiance® vs no treatment ( control group)."
16390857|NCT04043702||on topiramate plus empagliflozine|all patients' vs no treatment ( control group).
16390858|NCT04043702||no treatment|all patients' vs no treatment ( control group).
16390859|NCT04043689|Active Comparator|tACS stimulation of the right frontal region|Active tACS stimulation of the right frontal region (around the right FEF, EEG electrode FC2) at a high-beta frequency (30 Hz) with the goal of visibly training EEG recordings, frontal oscillatory activity and right fronto-parietal synchrony (FEF-IPS, or between FC2 and P4 electrodes) in the high-beta band (~ 30 Hz) which facilitates attentional orientation and visual perception in the two visual hemi-fields, but more particularly the targets present on the blind field of vision.
16390860|NCT04043689|Active Comparator|tACS stimulation of the occipito-parietal region|Active tACS stimulation of the occipito-parietal posterior contralesional region(around the right IPS, EEG electrode P4), at an alpha frequency (10 Hz) which will induce on the EEG recordings an oscillatory drive in the alpha band ( ~ 10Hz) and an increase in synchrony at this frequency band on the stimulated posterior occipital and parietal lobe (EEG electrodes P4 and 02), but also, by transcallosal push-and-pull phenomena, a desynchronization effect of the contralateral posterior occipital and parietal area (EEG electrodes P3 and 01), which will facilitate attention orientation and target detection in the blind visual field of view.
16390861|NCT04043689|Sham Comparator|TACS stimulation of the right frontal (FEF)|. Condition TACS stimulation of the right frontal (FEF) at a high-beta frequency (30 Hz) for half of the patients and unilateral occipital cortex (right / left) at an alfa frequency (10 Hz) for the other half . This condition will control the possible placebo effects of tACS stimulation and the potential effects of visual field enhancement with repetition of perimetry tests. This condition will also verify the lack of changes in cerebral rhythm activity in the case of an application without effective electrical current.
16390862|NCT04043676|Experimental|Ponatinib Treatment|Patients will be treated with 15 mg/day of ponatinib during 48 weeks. If a patient maintains MR4 throughout the 48 weeks, he/she will be eligible to start the ponatinib TFR phase. If a patient has confirmed loss of MR4 (two consecutive BCR-ABL > 0.01% IS) or loss of MMR (no confirmation needed), he/she will not be eligible for the TFR phase. Instead, he/she will restart imatinib treatment.
16390863|NCT04043663|Experimental|Virtual reality program group|Virtual reality program based on a virtual reality guided tour registered in the investigator's pediatric OR setting before surgery.
16390864|NCT04043663|Active Comparator|control group|standard perioperative care without virtual reality program
16390865|NCT04043650|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
16390866|NCT04043624|Experimental|Lidocaine group|First group (lidocaine group) will include those who receive a intraoperative lidocaine infusion.Induction bolus dose of 1.5 mg/kg body weight ( 30 minutes before incision)followed by a continous lidocaine infusion of 2mg/kg/h，until 1 hours after skin closure.
16390867|NCT04043624|Placebo Comparator|Saline group|The second group（saline group） will include those who receive a intraoperative placebo.The same dosage of saline was given according to the same method of administration in the lidocaine group.
16390868|NCT04043611|Active Comparator|Conservative physical therapy management|Tens and hot pack , Soft tissue mobilization , Maitland's Lumbar segmental mobilization, Traction, Neurodynamics, Active Stretching, McKenzie Prone Extension Exercises
16390869|NCT04043611|Experimental|ELDOA|Conservative physical therapy management + ELDOA positions
16390870|NCT04043598|Active Comparator|high sodium infusion fluid|Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
16390871|NCT04043598|Active Comparator|low sodium infusion fluid|Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
16390872|NCT04043572||Participants with Epilepsy|This group comprises pregnant patients with epilepsy who are actively using anti-epileptic drugs
16390873|NCT04043572||Healthy Controls|Healthy volunteers
16390874|NCT04043559||patients with an acute symptomatic infarction|
16390875|NCT04043559||controls with cryptogenic stroke|
16390876|NCT04043546|Experimental|Exercise intervention|
16390877|NCT04043533|Experimental|Exercises Group|
16390878|NCT04043533|No Intervention|Control Group|
16390879|NCT04043520|Experimental|Premenopausal: GnRH antagonist + estradiol|"Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection
~Estradiol is a transdermal patch 0.075 mg, applied weekly for 12 weeks"
16390880|NCT04043520|Experimental|Premenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection
~Placebo is a transdermal patch, applied weekly for 12 weeks"
16390881|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + estradiol|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)
~Estradiol is a transdermal patch 0.075 mg, applied weekly for 24 weeks"
16390883|NCT04043520|Placebo Comparator|Postmenopausal: placebo + placebo|"Placebo (1) is normal saline, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)
~Placebo (2) is a transdermal patch, applied weekly for 24 weeks"
16390884|NCT04043494|Other|SR I/II: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~maintenance therapy"
16390885|NCT04043494|Experimental|SR I/II: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment Phase (protocol M)
~maintenance therapy"
16390886|NCT04043494|Other|SR: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
16390887|NCT04043494|Experimental|SR: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
16390888|NCT04043494|Other|"HR: R1 into Pred and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
16390889|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
16390890|NCT04043494|Experimental|"HR: R1 into Pred and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib*)
~HR extra-compartment phase (intensified protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
16390891|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib*)
~HR extra-compartment phase (intensified protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
16390892|NCT04043468|Experimental|Improved A&F intervention|Two feedback sessions and four structured focus groups
16390893|NCT04043468|Active Comparator|Standard A&F intervention|Two feedback sessions
16390894|NCT04043455|Experimental|Olorinab low dose (Main Study)|
16390895|NCT04043455|Experimental|Olorinab medium dose (Main Study)|
16390896|NCT04043455|Experimental|Olorinab high dose (Main Study)|
16390897|NCT04043455|Placebo Comparator|Placebo (Main Study)|
16390898|NCT04043455|Experimental|Olorinab (Long-Term Extension)|Participants will receive olorinab based on their treatment assignment in the Main Study.
16390899|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 1|Custom neural anatomical target 1 defined by neuroimaging data
16390900|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 2|Custom neural anatomical target 2 defined by neuroimaging data
16390901|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 3|Custom neural anatomical target 3 defined by neuroimaging data
16390902|NCT04043442|Active Comparator|Active + Placebo rTMS for Left DLPFC Neural Target|"Neural anatomical target will be the Left Dorsolateral Prefrontal Cortex identified using the 5cm from the motor hot spot rule."
16390903|NCT04043429|Experimental|Vision Restoration Training (VRT)|home-based rehabilitation program which applies intense light stimulation via a PC-monitor to areas of residual vision with a duration of 1 hour daily/six days a week, subjects are asked to respond via button press upon appearance of light stimuli without eye movements
16390904|NCT04043429|Active Comparator|Vision Exploration Training (VET)|home-based rehabilitation program to train eye movements upon visual stimuli presented via a PC-monitor with a duration of 1 hour daily/six days a week, subjects are asked to shift their gaze towards targets and respond via button press upon detection of targets
16390905|NCT04043416|Experimental|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.
~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
16390906|NCT04043416|Experimental|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program
~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
16390907|NCT04043390|Experimental|CRP and Xpert ULTRA MTB/RIF|Scheme 1 will screen all patients for HIV using rapid tests routinely used by the clinics and a rapid CRP. Patients with CRP >10 will be further tested using Xpert ULTRA. Individuals with HIV will undergo an HIV VL using Xpert HIV-1 VL.
16390973|NCT04042909|Experimental|Counter Attitudinal Advocacy|Participants in this arm will articulate ways to avoid alcohol-related consequences using self-generated protective strategies and publicly state those strategies.
16415624|NCT03870282|Experimental|"9h 15m Goal | Texts A&B"|
16390908|NCT04043390|Experimental|CRP and Molbio Truenat MTB|Scheme 2 will screen individuals for HIV and CRP (as in scheme 1) and patients with CRP >10 will be tested using Molbio Truenat MTB. Individuals with HIV will undergo an HIV VL using Molbio Truenat HIV-VL and individuals with Truenat MTB-positive samples wil be tested with Truenat MTB RIF.
16390909|NCT04043390|No Intervention|standard test Xpert|All patients receiving in scheme 1 and scheme 2 will be tested using the standard tests used in the study context. These are rapid HIV tests, Xpert MTB/RIF and culture.
16390911|NCT04043364|Experimental|LIVE|A multicomponent intervention focusing on Learning, Innovation, Volunteers and Empowerment organized by a local coordinator.
16390912|NCT04043364|No Intervention|Treatment as usual|Care coordination and facilitation as usual.
16390913|NCT04043338|Experimental|XC130-A10H|XC130-A10H (single dose)
16390914|NCT04043338|Placebo Comparator|Placebo|placebo (single dose)
16390915|NCT04043312|Sham Comparator|Control|Patients will receive one hour of sham stimulation.
16390916|NCT04043312|Experimental|Active|Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.
16390917|NCT04043299|Experimental|Intervention|This arm will receive 100% oxygen at a rate of 10L/min for 15 minutes
16390918|NCT04043299|Active Comparator|Control|This arm will receive medical air (21% oxygen) at a rate of 10 L/min for 15 minutes
16390919|NCT04043286|No Intervention|Control group|Healing abutments are connected on the implants on the day of surgery, which will be subjected to multiple disconnection and reconnection during the prosthetic phase
16390920|NCT04043286|Experimental|Test group|Definitive abutments connected to the implants on the day of surgery. No disconnection or reconnection during the prosthetic phase
16390921|NCT04043273||Whole cohort|The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
16390922|NCT04043260|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 3 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
16390923|NCT04043247|Sham Comparator|Control Group|Same as TEAS group but without electrical stimulation
16390924|NCT04043247|Experimental|TEAS Group|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
16390925|NCT04043208|Experimental|Biofeedback|
16390926|NCT04043208|Placebo Comparator|Placebo|
16390927|NCT04043195|Experimental|Nivolumab + Oxaliplatin|Cohort 1
16390928|NCT04043195|Experimental|Nivolumab + Oxaliplatin + Ipilimumab|Cohort 2
16390929|NCT04043182|No Intervention|group control|You will not receive any type of intervention
16390930|NCT04043182|Experimental|treatment group (ultrasound)|Will perform protocols of 10 sessions of ultrasound in the region of abdomen
16390931|NCT04043182|Placebo Comparator|placebo group|It will perform protocols of 10 sessions of ultrasound in the region of abdomen, but the apparatus will be with zero intensities
16390932|NCT04043156|Experimental|High-precision RT|Study Arm: 18 x 2.33 Gy of high-precision RT in 3.5 weeks.
16390935|NCT04043130|Experimental|Pulse Treatment App|The treatment app is a web-based mobile health app designed for Black & Latinx women ages 18-20. Through culturally and age-appropriate content, Pulse provides information on birth control, healthy relationships, sexual health, pregnancy, & utilization of clinical services to encourage users to choose effective birth control, seek reproductive health services, and prevent unplanned pregnancies. Users access Pulse autonomously and on their own terms. The app does not require users to follow a specific sequence of content viewed. Participants randomized to the intervention condition are given access to Pulse and receive Multimedia Messaging Service (MMS) messages related to sexual health several times a week for 6 weeks. Participants receive a baseline survey, 6-week follow-up survey, and 6-month follow-up survey via an electronic survey platform (6-month survey only administered to participants recruited between November 2018-March 2019).
16390936|NCT04043130|Active Comparator|Pulse Control App|The control app, also called Pulse, is a web-based mobile health app designed by the study team for young women ages 18-20. Although Pulse control and Pulse treatment apps look and feel similar aesthetically, they contain different content. Pulse control app provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Users access Pulse autonomously, on their own terms, and in their own time and place. The app does not require the user to follow a specific sequence of content viewed; however, all users receive a monetary incentive after completing a baseline survey and registering with the app. Control participants also receive MMS messages related to general health for six weeks. Participants receive a baseline survey and a six-week follow-up which are conducted online via an electronic survey platform.
16390937|NCT04043117||Clinical Group|Group is composed by 12-19 years adolescents with a tumor (excluding brain tumor). Every patient included in the group complete the assessment including: evaluation of self-esteem (TMA test) and body image (BUT test, I-BICI test and Human Figure Drawing).
16390938|NCT04043104|Experimental|1 x 1011 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
16390939|NCT04043104|Experimental|3 x 1011 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
16390940|NCT04043104|Experimental|1 x 1012 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
16390941|NCT04043104|Experimental|3 x 1012 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
16390942|NCT04043091|Experimental|percutaneous coronary intervention|stable obstructive coronary artery disease (coronary artery stenosis >70%) - percutaneous coronary intervention performed in all diseased segments until 300 mL of contrast reached; preferably with drug eluting stents; along with standard medical therapy
16390943|NCT04043091|No Intervention|standard of care|stable obstructive coronary artery disease (coronary artery stenosis >70%) - no intervention (revascularization), just standard medical therapy
16390944|NCT04043078|Other|Exercise|Exercise and respiratory muscle training before surgery
16390945|NCT04043065|Experimental|LEAP-2|Liver-enriched antimicrobial peptide 2
16390946|NCT04043065|Placebo Comparator|Placebo|Saline
16390947|NCT04043052|Active Comparator|Treatment As Usual (TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination
16390948|NCT04043052|Experimental|EMA intervention assocuated to Treatment As Usual (EMA-TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination in addition with Ecological Momentary Assessment (EMA) evaluation.
16390949|NCT04043039|Experimental|FULL THICKNESS PALATAL GRAFT|the full thickness palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
16390950|NCT04043039|Active Comparator|FREE GINGIVAL GRAFT|the Epithelialized Free Gingival Grafts palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
16390951|NCT04043026||WP1: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease
16390952|NCT04043026||WP1: AF + no CKD|Anticoagulated participants with atrial fibrillation and no chronic kidney disease
16390953|NCT04043026||WP1: no AF + CKD|Anticoagulated participants with chronic kidney disease and no atrial fibrillation
16390954|NCT04043026||WP1: no AF + no CKD|Anticoagulated participants without atrial fibrillation or chronic kidney disease
16390955|NCT04043026||WP2: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy
16390956|NCT04043013|Active Comparator|Mini-Taurus® (Rocky Mountain©) Brackets|"Brackets Mini-Taurus® (Rocky Mountain©) with:
~ORTHODONTIC BRACKET PRESCRIPTION Canines 0º First Premolar 0º Second Premolar 0º First Molar 0º"
16390957|NCT04043013|Active Comparator|Smart Clip® SL3 High Torque (3M Unitek©)|"Brackets Smart Clip® SL3 High Torque (3M Unitek©) with:
~ORTHODONTIC BRACKET PRESCRIPTION
~Canines +6º First Premolar -4º Second Premolar -4º First Molar -14º"
16390958|NCT04043013|Active Comparator|Tip-Edge Plus® (TP Orthodontics©)|"Brackets Tip-Edge Plus® (TP Orthodontics©) with:
~ORTHODONTIC BRACKET PRESCRIPTION
~Canines -4º First Premolar -7º Second Premolar -7º First Molar 0º -14º -11º -14º"
16390959|NCT04043013|Active Comparator|Victory® (3M Unitek©)|"Brackets Victory® (3M Unitek©) with:
~ORTHODONTIC BRACKET PRESCRIPTION
~Canines 0º First Premolar -7º Second Premolar -7º First Molar -14º"
16390960|NCT04043000|Experimental|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
16390961|NCT04043000|Placebo Comparator|Placebo|" The placebo without Super 13 Pro & Prebiotics was given three times a day for four weeks."
16390962|NCT04042987||Historical Control Group|Retrospective chart review
16390963|NCT04042987||Prospective QIP Group|Participants that meet eligibility criteria will be prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption.
16390964|NCT04042974|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
16390965|NCT04042974|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
16390966|NCT04042961|Experimental|Reactive balance training|
16390967|NCT04042961|Active Comparator|Aerobic and strength training|
16390968|NCT04042948|Experimental|Experimental Group|preventive use non-steroidal anti-inflammatory drugs to before the removal of drainage tube
16390969|NCT04042948|No Intervention|Control Group|without any intervention when remove the drainage tube
16390970|NCT04042935|Experimental|Alpha Lipoic Acid (ALA) during chemoradiation|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation as standard of care will receive ALA before, during, and after treatment. The drug will have dose escalation in a 3+3 design. The first group of 3 patients will receive 600 mg twice a day. If there are no DLTs, the next 3 patients will receive the highest dose of 600 mg three times a day. If one or more patients develop a DLT at any of the dosing levels, the group will either be expanded or dropped to a lower dose level.
16390971|NCT04042922|Experimental|Exposure to active stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of active stimulation
16390972|NCT04042922|Sham Comparator|Exposure to control stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of control stimulation
16390974|NCT04042909|Active Comparator|Personalized Normative Feedback|Participants in this arm will view personalized normative feedback regarding their 1) own drinking quantity and frequency of drinking, 2) perceptions of typical drinking by same-sex students' on campus (i.e., perceived descriptive norms), and 3) actual drinking rates by same-sex students' on campus (i.e., actual descriptive norms).
16390975|NCT04042909|No Intervention|Assessment-only Control|Participants in this arm will not receive any intervention.
16390976|NCT04042896|Experimental|exergame group|"The exergame group performed exercise using the Exer Heart device (D&J Humancare, Seoul, South Korea), which consisted of a running/jumping board and a screen connected to the board. The exercise program Alchemist's Treasure, a running-based exergame, moves the avatar according to the user's motions and was used for the exercise session. Alchemist's Treasure is a game in which the user listens to stimulating music, runs with the avatar, avoiding obstacles, and wins items using the front, back, left, and right sensors on the exercise board. The subject can control the speed of the avatar movement by adjusting the walking or running speed on the board.
~This study did not enforce exercise intensity in order to allow patients to enjoy the exergame. Thus, during the training period, the patients exercised at a self-selected pace for 40 minutes per day."
16390977|NCT04042896|Active Comparator|treadmill group|The treadmill group consisted of 40 minutes of walking or jogging at 60-80% of the heart rate (HR) reserve. The exercise intensity was determined using the Karvonen method target HR = [Exercise Intensity × (HRmax - resting HR)] + resting HR. The HR was recorded during each session using an HR monitor (Polar RS400sd; Madison Height, Michigan, USA). The control group was asked to maintain their regular physical activity level for 12 weeks.
16390978|NCT04042896|No Intervention|control group|The control group was asked to maintain their regular physical activity level for 12 weeks.
16390979|NCT04042883|Active Comparator|ANH|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
16390980|NCT04042883|No Intervention|Control|No intervention
16390981|NCT04042870|Experimental|Joint Loosening Yoga|Yoga Intervention. Dose: 15 minutes, M-F for 4-weeks.
16390982|NCT04042857|Experimental|Next Science|Patients will apply Next Science treatment to the study target hallux nail for 48 weeks daily.
16390983|NCT04042844|Experimental|Active Treatment- BRTX-100|BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.
16390984|NCT04042844|Placebo Comparator|Saline|Isotonic saline will be used as a control in this study. Drug: saline (0.9% sodium chloride).
16390985|NCT04042831|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16390986|NCT04042805|Experimental|Sintilimab Plus Lenvatinib|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16390987|NCT04042792||ADA for ≥12 weeks and concomitant MTX therapy|PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)
16390988|NCT04042792||ADA for ≥ 12 weeks without MTX|PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)
16390989|NCT04042779|Active Comparator|model-based WM training|In order to build the model-based WM training, existing tasks used to assess the different component of the Baddeley's model will be reviewed on their findings according to test-retest reliability and construct validity. For each component - phonological loop, visuospatial sketchpad, episodic buffer and central executive - the task with the highest reliability and validity will be chosen and then build the basis for the computerized training program. This procedure results in a model-based, adaptive, computerized training program for WM.
16390990|NCT04042779|Active Comparator|single-task WM training|"The basis for the single-task training administered to the second group will be the widely used dual-n-back training paradigm suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices."
16390991|NCT04042779|Active Comparator|multiple-task WM training|Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
16390992|NCT04042779|Sham Comparator|sham intervention|Active control group that as well performs a training, however not based on WM. To exclude the involvement of WM, a motor training will be administered to the control group.
16390993|NCT04042766|Active Comparator|laser treatment|
16390994|NCT04042766|Sham Comparator|sham treatment|
16390995|NCT04042753|Experimental|Pituitary Cancer|Participants will have a pituitary adenoma/carcinoma of any histology
16390996|NCT04042740|Experimental|Glecaprevir/Pibrentasvir (G/P)|"In Step 1, participants will receive G/P FDC tablets to be taken orally once daily for 4 weeks.
~Any participant who experiences viral re-infection, suspected relapse, virologic failure, or undefined post-treatment HCV viremia may enter Step 2. In Step 2, participants may receive G/P FDC tablets orally once daily for 8-16 weeks. Some participants may also receive ribavirin (RBV) tablets orally twice daily. Alternate regimens are allowed in Step 2."
16390997|NCT04042727|Experimental|Dexmedetomidine plus Standard of Care|Dexmedetomidine hydrochloride infusion will be prepared by the investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
16390998|NCT04042727|Placebo Comparator|Placebo plus Standard of Care|Normal Saline solution will be prepared by investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
16390999|NCT04042714|Experimental|TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
16391126|NCT04041895||Control|Those individuals who do not possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
16391000|NCT04042701|Experimental|Part 1 (Dose Escalation)|HER2-positive breast cancer, HER2-low expressing breast cancer, HER2-expressing NSCLC, and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.
16391001|NCT04042701|Experimental|HER2-positive breast cancer (Part 2 Dose Expansion)|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
16391002|NCT04042701|Experimental|HER2-low breast cancer (Part 2 Dose Expansion)|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
16391003|NCT04042701|Experimental|HER2-expressing NSCLC (Part 2 Dose Expansion)|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
16391004|NCT04042701|Experimental|HER2-mutant NSCLC (Part 2 Dose Expansion)|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
16391005|NCT04042688|Experimental|Treatment group|Patients were randomly allocated to one of two groups during preoperative preparation by computer-generated randomization. Treatment group; IA administration of TXA, control group; no TXA administration
16391006|NCT04042688|No Intervention|Control gorup|
16391007|NCT04042675||parkinson group|parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage.
16391008|NCT04042675||Control group|healthy individuals between the ages of 40-75 and without any neurological disorders.
16391009|NCT04042662||Meropenem Failure ( Treatment failure)|
16391010|NCT04042662||Meropenem Success ( Treatment Success)|
16391011|NCT04042649|No Intervention|pre-intervention|Critically ill patients didn't provide environmental intervention (help sleep cycle, provide comfortable environment)
16391012|NCT04042649|Experimental|post-intervention|After providing environmental intervention for critically ill patients
16391013|NCT04042636||1|Patients with Bacteremia after trauma
16391014|NCT04042636||2|Patients with non-bacteremia after trauma
16391015|NCT04042623|Experimental|Treatment with AVB-S6-500|Patients will receive AVB-S6-500 by intravenous infusion every 2 weeks for total of 6 doses.
16391016|NCT04042610|Experimental|Intervention: electronic prompt to interrupt sitting time|The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
16391017|NCT04042610|No Intervention|Control Group|The control group will be given an Amazfit BIP device to record their steps. They will submit their daily steps counts for weeks: 1,2,4, 6 and 8.
16391018|NCT04042597|Experimental|Arm A: anlotinib arm|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
16391019|NCT04042597|Active Comparator|Arm B: imatinib arm|Imatinib was given at dose of 400 mg twice daily continuously
16391020|NCT04042584|Experimental|Visio conference device evaluation|Neurological tele-evaluation by a neurologist
16391021|NCT04042571|Experimental|Cerebral oxymetry monitoring (NIRS)|Cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools
16391022|NCT04042558|Experimental|Cohort with Bevacizumab|"4 cycles of induction every 3 weeks with :
~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route
~Pemetrexed 500 mg/m² per IV route
~Atezolizumab 1200 mg per IV route
~Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles"
16391023|NCT04042558|Experimental|Cohort without Bevacizumab|"4 cycles of induction every 3 weeks with :
~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route
~Pemetrexed 500 mg/m² per IV route
~Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles"
16391024|NCT04042545|Experimental|inhaled THC/CBD (PPP001)|PPP001 (cannabis dosing capsule with THC/CBD) inhalation with a device
16391025|NCT04042545|Placebo Comparator|Placebo|Placebo inhalation with a device
16391026|NCT04042532|Active Comparator|Active group|Active group will receive active stimulation of standard intermittent TBS (iTBS) protocol.
16391027|NCT04042532|Sham Comparator|Sham group|Sham group will receive sham stimulation of the same iTBS protocol with the coil set at 90 to the skull.
16391028|NCT04042532|No Intervention|Cognitively normal control|Cognitively normal controls will be recruited for neuroimaging comparison.
16391029|NCT04042519||Healthy control|age - and sex-matched healthy individuals without lung disease
16391030|NCT04042519||Patients with mild and moderate COPD|Grading according to the GOLD guide standards
16391031|NCT04042519||Patients with severe and very severe COPD|Grading according to the GOLD guide standards
16391032|NCT04042519||The severe and very severe COPD group baseline|Severe and very severe COPD patients were in the baseline time group
16391033|NCT04042519||The severe and very severe COPD group six months|Patients with severe and very severe COPD were six months from baseline.
16391034|NCT04042519||The severe and very severe COPD group one year|Patients with severe and very severe COPD were one year from baseline.
16391067|NCT04042285|Placebo Comparator|Standard wound care|Patient with a diabetic foot wound who receive standard wound care, consisting of dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate.
16391127|NCT04041882|Experimental|68Ga-DOTATATE PET/CT|Inject 68Ga-DOTATATE and then perform PET/CT scan
16391128|NCT04041869|Experimental|MapTrek|
16391035|NCT04042506|Experimental|Extracranial SBRT and Nivolumab|"Stereotactic body radiation therapy (SBRT) will be given to a single extracranial metastatic site in combination with nivolumab.
~Patients will receive nivolumab 480mg intravenously (IV) every 4 weeks (1 cycle = 8 weeks), as well as SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
~Nivolumab will be continued until confirmed progression, unacceptable toxicity, or total of 6 Cycles (whichever occurs first)."
16391036|NCT04042493|Experimental|Connect for Health Program|
16391037|NCT04042480|Experimental|SGN-CD228A|SGN-CD228A administered intravenously
16391038|NCT04042467|Experimental|Greenlight Plus|"Families will receive the Greenlight intervention plus a health information technology (HIT) intervention aimed at supporting family goal-setting and behavior change.
~This design allows us to determine if HIT and the asynchronous support it provides between well-child visits can promote additional behavior change and obesity prevention."
16391039|NCT04042467|Active Comparator|Greenlight|During each of the recommended well child visits from 0-24 months, pediatric residents, trained in clear health communication skills and shared goal-setting, will use the Greenlight Toolkit of low literacy, age- specific, parent education booklets to promote healthy family behaviors and obesity prevention.
16391040|NCT04042454|Experimental|Test Product|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
16391041|NCT04042454|Active Comparator|Control Product|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
16391042|NCT04042441||Ryzodeg® as per local practice|Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.
16391043|NCT04042428|Experimental|Treatment group|Subjects receive a 14-day treatment. A 450 mL blood sample is extracted 6 hours after the last administration (day 14).
16391044|NCT04042428|No Intervention|Control group|Subjects do not receive any treatment. A 450 mL blood sample is extracted at baseline.
16391045|NCT04042415|No Intervention|Free diet controls|Patients on free diet
16391046|NCT04042415|Experimental|Caloric restriction|Patients will be treated with a mild caloric restriction (15-20% caloric restriction)
16391047|NCT04042415|Experimental|Caloric restriction without cow's milk and gluten|Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten
16391048|NCT04042402|Experimental|Open Label|Open label, monthly subcutaneous injection
16391049|NCT04042389|Experimental|WhatsApp|WhatsApp reminders
16391050|NCT04042389|Experimental|Email|Email reminders
16391051|NCT04042389|Other|Control|No reminder
16391052|NCT04042376|Experimental|Ibrutinib 420 milligram (mg)|Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.
16391053|NCT04042363|Experimental|Active Transorbital electrical stimulation|Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks
16391054|NCT04042363|Sham Comparator|Sham Transorbital stimulation|Sham stimulation - 10 sessions during 2 consecutive weeks
16391055|NCT04042350||CKD patients on dialysis|Data will be analyzed from CKD patients on dialysis that participated in the AURORA study.
16391056|NCT04042337|Experimental|PRT Telehealth|Participating parents will receive 12 weekly 60-minute parent training sessions via secure videoconference to learn Pivotal Response Treatment
16391057|NCT04042337|No Intervention|Waitlist|Participants will continue stable community-based treatments
16391058|NCT04042324|Experimental|Triferic post-dialyzer; UFH via continuous infusion|Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.
16391059|NCT04042324|Experimental|UFH and Triferic admixture|"Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer heparin line. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis."
16391060|NCT04042324|Experimental|UFH via continuous infusion pre-dialyzer|Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis
16391061|NCT04042311|Experimental|High-Intensity interval training|High-intensity interval training performed for 20 minutes, 3 times weekly for a period of 6 weeks at 85-100% of maximal heart rate.
16391062|NCT04042298||5-FU Chemotherapy (Experimental)|Comprised of newly diagnosed cancer patients 21 years or older who have received 5-FU chemotherapy within the past 30 days or are scheduled to receive 5-FU chemotherapy.
16391063|NCT04042298||Non-5-FU Chemotherapy (Sub-Control)|Comprised of newly diagnosed cancer patients 21 years or older who have received chemotherapy other than 5-FU within the past 30 days or are scheduled to receive chemotherapy other than 5-FU.
16391064|NCT04042298||Age/Sex matched Control (Control)|Age, biological sex, and prior health history (excluding cancer diagnosis) matched control for cancer patients
16391065|NCT04042298||5-FU Chemotherapy Cancer Survivor (Survivor)|Cancer survivors who have not received cancer therapy during the past year but previously received 5-Fluorouracil chemotherapy.
16391066|NCT04042285|Active Comparator|Extracorporeal shockwave therapy|The shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second (17). Participants will receive 3 sessions of shockwave therapy in a 7-day period. In addition to standard wound care (dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate).
16391122|NCT04041934|Experimental|cohort 3|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.04
16391198|NCT04041362|Active Comparator|Arm1 (Standard ART)|Standard ART
16391068|NCT04042272||Healthy volunteers|Healthy volunteers group; Kidney donor groups; Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
16391069|NCT04042272||Living kidney graft recipients|Kidney transplant group; Course of the research: Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
16391070|NCT04042259|Active Comparator|Negative Pressure Wound Therapy|Standardized wound closure with negative pressure therapy.
16391071|NCT04042259|Other|Historic Cohort|Historic cohort have undergone a midline laparotomy and managed with an open abdomen for at least one day and have contaminated or dirty wound classification.
16391072|NCT04042246|No Intervention|Control|No intervention is implemented among Control
16391073|NCT04042246|Experimental|Treatment (Educational Information on Vaccination)|Provide general and tailored information on vaccination and vaccination schedule at the end of the baseline survey
16391074|NCT04042233|Active Comparator|IV administration of vancomycin|Standard IV vancomycin administration protocol.
16391075|NCT04042233|Experimental|IO Vancomycin 500mg in 250 mL NS|Experimental Intraosseous administration protocol.
16391076|NCT04042220||GK + IT|Gamma Knife and immunotherapy
16391077|NCT04042220||GK + IT + GC|Gamma Knife, immunotherapy and glucocorticoids
16391078|NCT04042220||GK only|Gamma Knife without immunotherapy
16391079|NCT04042207|Active Comparator|Reference treatment (Open-Loop)|Sensor-augmented pump therapy (SAP) namely the Low Glucose Predictive Suspend system or LGPS and a blinded glucose sensor (Dexcom G6) followed by a 48-week extension period in closed-loop condition
16391080|NCT04042207|Experimental|DBLHU system (Closed-Loop)|DBLHU software (a Model Predictive Control [MPC]-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleido insulin pump followed by a 48-week extension period in closed-loop condition
16391081|NCT04042194|Experimental|Thickened with T-PRF|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and T-PRF was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
16391082|NCT04042194|Active Comparator|Thickened with CTG|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and CTG was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
16391083|NCT04042181|Placebo Comparator|Placebo|
16391084|NCT04042181|Active Comparator|Bifidobacterium longum|
16391085|NCT04042168|Experimental|Intervention|Inappropriate use of inhalers and medication change. Pre-post intervention data will be compared.
16391086|NCT04042142|Active Comparator|Healthy overweight subjects|MR spectroscopy verified no steatosis
16391087|NCT04042142|Active Comparator|Subjects with non-alcoholic fatty liver disease|MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy
16391088|NCT04042142|Active Comparator|Subjects with non-alcoholic steatohepatitis|MR spectroscopy verified steatosis, steatohepatitis on liver biopsy
16391089|NCT04042129||1|gynecologic operations with urologic complications
16391090|NCT04042116|Experimental|Phase 1b: Dose Escalation|- Up to 50 patients with advanced solid tumor
16391091|NCT04042116|Experimental|Phase 1b: Food Effect Cohort|- Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled
16391092|NCT04042116|Experimental|Phase 2: Expansion Cohort - Endometrial Cancer|"Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen
~Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll"
16391093|NCT04042116|Experimental|Phase 2: Expansion Cohort - Ovarian Cancer|"Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma
~At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy
~Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll"
16391094|NCT04042116|Experimental|Phase 2: Expansion Cohort - Clear Cell Cancer|"Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin
~At least 1 prior platinum- and taxane-based chemotherapy regimen"
16391095|NCT04042116|Experimental|Phase 2: Expansion Cohort - Cervical Cancer|"Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology
~At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease"
16391096|NCT04042103|Experimental|Tapinarof (DMVT-505) cream, 1%|Tapinarof (DMVT-505) cream, 1% applied topically once daily
16391097|NCT04042090|Experimental|Intervention group: use of therapeutic virtual reality|Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. Meanwhile, participant is placed on the waiting list to receive normal chronic pain treatment.
16391098|NCT04042090|No Intervention|Control group: no use of therapeutic virtual reality|Control group: no intervention, patient is waiting to receive normal chronic pain treatment.
16391101|NCT04042064||Inhalation|Patient anesthetised with Inhalation anesthetic agents.
16391102|NCT04042064||TIVA (total intravenous anesthesia)|Patient anesthetised with total total intravenous anesthesia.
16391103|NCT04042051|Other|Single Arm|This study is a phase Ib open label, single arm, adaptive multi-centre trial. Patients with unresectable locally advanced or metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, separately or in combination, will be treated with copanlisib (as assigned at registration according to the dose escalation scheme) plus trastuzumab emtansine 3.6mg/kg IV on day 1 of a 21-day cycle.
16391104|NCT04042038|Experimental|CBT|Intensive CBT (20 sessions in 1 month)
16391105|NCT04042038|No Intervention|Waiting-list|Waiting-list
16391106|NCT04042025|Other|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi|Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene
16391107|NCT04042012|Experimental|Eccentric group|The dancers of this group wil perform a soleus eccentric exercise
16391108|NCT04042012|Experimental|PNE group|"The dancers of this group will receive a PNE treatment, consisting of the application of galvanic current, by ultrasound.
~The approach will be performed with a transverse axis with a needle orientation that will depend on the location of the target tissue. The parameters will be 3 mA, 3 seconds, 3 impacts (3: 3: 3). The periodicity will be 1day/7day/21day"
16391109|NCT04042012|Experimental|Combined group|The dancers of this group will receive a combined treatment and will be carried out in the same way as the other two groups.
16391110|NCT04041999|Experimental|Daily Cognition Training Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.
~Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.
~Specifically we focus on tasks related to taking medication and adherence to treatment."
16391111|NCT04041999|Active Comparator|Traditional Cognitive Stimulation Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.
~Tasks are performed to work various cognitive functions."
16391112|NCT04041986|Experimental|Site-Finding|Each subject will receive anodal, cathodal, and sham stimulation to both the ipsilesional and contralesional hemispheres in a series of six sessions (one condition per session), each separated by at least two days. During anodal and cathodal tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 mA using a 5x5 cm electrode. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. The participant will complete pre/post language testing at each session in order to determine if the subject is a tDCS responder and if so, which site produces the best transient language improvement in that individual. Subjects who do not respond to tDCS will not be invited to move forward to the treatment phase.
16391113|NCT04041986|Active Comparator|Real tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
16391114|NCT04041986|Sham Comparator|Sham tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
16391115|NCT04041973|Experimental|ACT arm|Artemether-lumefantrine (AL) x 3 days followed by 1 day per week
16391116|NCT04041973|Active Comparator|Multivitamin arm|Multivitamin x 3 days followed by 1 day per week
16391117|NCT04041960|Experimental|SMG|Brain region targeted with transcranial magnetic stimulation: superamarginal gyrus
16391118|NCT04041960|Experimental|MTG|Brain region targeted with transcranial magnetic stimulation: middle temporal gyrus
16391119|NCT04041960|Active Comparator|Vertex|Brain region targeted with transcranial magnetic stimulation (none associated): Vertex
16391120|NCT04041934|Experimental|cohorte 1|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.11
16391121|NCT04041934|Experimental|cohorte 2|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.07
16391129|NCT04041856|Active Comparator|EKC patients|Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
16391130|NCT04041856|No Intervention|Control group|All patients will undergo observational treatments including artificial tear drop and improving hygiene level
16391131|NCT04041843|Experimental|Abixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
16391132|NCT04041830|Experimental|NW (Normal Weight)|20 to 55 years old lean adults
16391133|NCT04041830|Experimental|OBESE|20 to 55 years old adults with obesity
16391134|NCT04041817|Experimental|Trigger increasing steps|"Trigger variations will be performed following increasing steps of 2 L/min every 15 minutes. End expiratory lung volume and lung aeration will be conducted using elecrical impedance tomography. Diaphragmatic motion and thickening will be analyzed by ultrasonography. Work of breathing will be evaluated using gastric and oesophageal pressure measurements.
~Measurements will be conducted during the last minute of each step."
16391135|NCT04041804|Active Comparator|Every week RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every week until getting the require expansion needed
16391136|NCT04041804|Active Comparator|Every four days RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every four days until getting the require expansion needed
16391137|NCT04041791|Active Comparator|Benzyl penicillin/ampicillin + gentamicin & IV fluids|"Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.
~Maintenance fluids will be given as a continuous infusion for at least 24 hours."
16391138|NCT04041791|Experimental|Ceftriaxone and IV fluids|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days.
~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
16391139|NCT04041791|Experimental|Amoxicillin-clavulanate and IV fluids|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days.
~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
16391140|NCT04041791|Experimental|Benzyl penicillin/ampicillin + gentamicin & NG feeds|"Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.
~Nasogastric feeds will be given 3 hourly for at least 24 hours."
16391141|NCT04041791|Experimental|Ceftriaxone and NG feeds|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days.
~Nasogastric feeds will be given 3 hourly for at least 24 hours."
16391142|NCT04041791|Experimental|Amoxicillin-clavulanic acid and NG feeds|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days.
~Nasogastric feeds will be given 3 hourly for at least 24 hours."
16391143|NCT04041765|Experimental|Treatment Group|IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
16391144|NCT04041765|Placebo Comparator|Placebo Group|Antibiotics only
16391145|NCT04041752|Experimental|Normal weight|30 healthy normal weight adults will be involved and will realize the three conditions
16391146|NCT04041739||diabetic foot osteomyelitis|"Patients will be subjected to:
~1-History taking including duration of diabetes and ulcer . 2 Clinical examination of ulcer , including diagnosis of osteomyelitis 3- Venous blood will be withdrawn to do the following laboratory tests :
~HbA1c
~erythrocyte sedimentation rate(ESR)
~C reactive protein(CRP)
~Complete blood culture
~Serum urea and creatinine 4-culture and sensitivity test 5-Bone fragments and tissue biopsy from infected ulcers 6-Fundus examination"
16391147|NCT04041713|Active Comparator|Rett T|Rett T is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
16391148|NCT04041713|Placebo Comparator|Placebo|Placebo is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
16391149|NCT04041700|Experimental|Osia 2 system|
16391150|NCT04041674|Experimental|Group 1 (T1): DNA + MVA + Placebo (IM)|"Participants will receive 3 mg of GEO-D02 DNA by intramuscular (IM) injection at Months 0 and 2.
~Participants will also receive 1×10^8 50% tissue culture infective dose (TCID50) of MVA/HIV62B plus placebo for B63521^11 gp120 plus placebo for IHV01, each by IM injection at Months 4, 6, and 10."
16391151|NCT04041674|Experimental|Group 2 (T1): DNA + MVA + Placebo (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B by IM injection plus placebo for B63521^11 gp120 by subcutaneous (SC) injection plus placebo for IHV01 by SC injection at Months 4, 6, and 10."
16391152|NCT04041674|Experimental|Group 3 (T2): DNA + MVA + IHV01 + B63|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B plus 150 mcg of B63521^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
16391153|NCT04041674|Experimental|Group 4 (T3): DNA + MVA +IHV01 + Placebo|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B plus placebo for B63521^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
16391154|NCT04041674|Experimental|Group 5 (T4): DNA + MVA +IHV01 (SC)+ B63 (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 3.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B by IM injection plus 150 mcg of B63521^11 gp120 by SC injection plus 150 mcg of IHV01 by SC injection at Months 4, 6, and 10."
16391199|NCT04041362|Experimental|Arm 2 (ART plus UB-421)|ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks
16415625|NCT03870282|Experimental|"9h 15m Goal | Incentive B"|
16391155|NCT04041661|Experimental|Active tDCS plus gait training group|Participants in Active tDCS plus gait training group will execute Active tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
16391156|NCT04041661|Sham Comparator|Sham tDCS plus gait training group|Participants in Sham tDCS plus gait training group will executeSham tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
16391157|NCT04041648|Placebo Comparator|placebo|placebo group
16391158|NCT04041648|Experimental|L606 Liposomal inhalation solution|Liposomal inhalation solution
16391159|NCT04041635|Experimental|Stimuli Reduction|This group will receive reduced visual and auditory stimuli in addition to usual care during venipuncture. Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
16391160|NCT04041635|Active Comparator|Usual Care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
16391161|NCT04041622|Other|Endoscopy and biopsy|Participants of the HUNT study with a positive serological assay for celiac disease are invited to attain a diagnostic endoscopy with duodenal biopsies
16391162|NCT04041609|Active Comparator|LYR-210 (Low Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus
16391163|NCT04041609|Active Comparator|LYR-210 (High Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus
16391164|NCT04041609|Sham Comparator|Sham Procedure|In-office bilateral sham procedure
16391166|NCT04041570|Experimental|cAd3-EBO S at 1x10^10 PU dose|Twenty (20) subjects enrolled in Group 1 will receive a 1x10^10 PU dose of cAd3-EBO S vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
16391167|NCT04041570|Experimental|cAd3-EBO S at 1x10^11 PU dose|Twenty (20) subjects enrolled in Group 2 will receive a 1x10^11 PU dose of cAd3-EBO S vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
16391168|NCT04041557||adults with CHD|Adults with congenital heart disease 18-32 years of age
16391169|NCT04041557||controls|healthy peers
16391170|NCT04041544|Active Comparator|SN1011|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
16391171|NCT04041544|Placebo Comparator|SN1011 placebo|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
16391172|NCT04041518|Other|Intervention|Autotransplantation and intra-operative extraoral apicoectomy of a permanent tooth.
16391173|NCT04041505|Active Comparator|Breastfeeding|Infant consumes mother's milk directly from the breast.
16391174|NCT04041505|Experimental|Bottle-feeding|Infant consumes mother's expressed milk from a bottle.
16391175|NCT04041492|Experimental|Group 1|Vitamin D3 1000UI + Placebo (Calcined Magnesia).
16391176|NCT04041492|Experimental|Group 2|Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
16391177|NCT04041492|Active Comparator|Group 3|Vitamin D3 1000UI + Vitamin K2 100 mcg
16391178|NCT04041479|Active Comparator|Standard of Care|FDA-cleared, standard-of-care iTBS repetitive Transcranial Magnetic Stimulation targeting the left dorsolateral prefrontal cortex (DLPFC), regardless of the depression subtype (biotype) determined by a magnetic resonance imaging (MRI) scan.
16391179|NCT04041479|Experimental|Targeted Side Arm|iTBS rTMS targeting the area of the brain (DLPFC or dorsomedial prefrontal cortex DMPFC)) that we hypothesize will be most effective for that subject's biotype (confirmation arm).
16391180|NCT04041479|Active Comparator|Opposite Side Arm|iTBS rTMS targeting the opposite site (DLPFC or DMPFC) than the one we hypothesize will be most effective for that subject's biotype (disconfirmation arm).
16391181|NCT04041466|Experimental|Atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
16391182|NCT04041466|Experimental|Sinus Rhythm (SR)|Patients diagnosed with SR during reference ECG
16391183|NCT04041466|Experimental|Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
16391184|NCT04041453|Active Comparator|Albendazole 400mg|Albendazole 400mg in single dose
16391185|NCT04041453|Experimental|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
16391186|NCT04041453|Experimental|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
16391187|NCT04041453|Experimental|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
16391188|NCT04041440|Experimental|Auditory Training|Pre- and post assessments of auditory training intervention
16391189|NCT04041427|Experimental|Fasting|Albendazole 400mg will be ingested by study participants with an 8-hour fasting diet.
16391190|NCT04041427|Experimental|High fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with high fat content (40 grams of fat).
16391191|NCT04041427|Experimental|Moderate fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with moderate fat content (15 grams of fat).
16391192|NCT04041414|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
16391193|NCT04041414|Active Comparator|Control schools|Students in control schools will receive no intervention
16391194|NCT04041401||Children and their Caregivers|Children following discharge from PICU and their caregivers receiving a storybook intervention.
16391195|NCT04041388|Other|Tooth tipping|
16391196|NCT04041375|Experimental|iNSPiRED|Peer coaching intervention
16391197|NCT04041375|Active Comparator|Usual Care|Directory of resources and encouragement to follow-up with Primary Care Physician
16391200|NCT04041349|No Intervention|The standard treatment group|The standard treatment group is treated with conventional drugs and cholinesterase inhibitors
16391201|NCT04041349|Experimental|mouse nerve growth factor (mNGF)group|Conventional drugs and cholinesterase inhibitors + mouse nerve growth factor (mNGF) of 20 μg (9000 U)/day for 14 consecutive days by intramuscular injection.
16391202|NCT04041336|Experimental|All participants|All participants will have measurements taken. There are no comparators or controls in this feasibility study
16391203|NCT04041310|Experimental|Cohort A - Dose-escalation|"Phase I. Part 1. Dose escalation cohort. Subjects treated with low dose or with high dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D, in combination with pembrolizumab.
~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors."
16391204|NCT04041310|Experimental|Cohort B - Expansion Cohort Phase I|"Phase I. Part 1. Expansion cohort at RP2D. Subjects treated with RP2D dose of GAd20-209-FSP prime and MVA-209-FSP boosts, in combination with pembrolizumab.
~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic dMMR or MSI-H CRC, gastric, or G-E junction tumors."
16391205|NCT04041310|Experimental|Cohort C - Expansion cohort Phase IIa|Phase IIa. Expansion cohort at RP2D. Subjects treated with RP2D of GAd20-209-FSP prime and MVA-209-FSP, in combination with pembrolizumab. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who eligible for anti-PD-1 1st line treatment.
16391206|NCT04041284|Experimental|fremanezumab|monthly 225 mg. In the open-label extension phase starting at week 12, all patients will receive active treatment with a quarterly dose of 675 mg sc
16391207|NCT04041284|Placebo Comparator|Placebo|
16391208|NCT04041271||Nonspecific chronic neck pain (NCNP) group|Subjects with nonspecific chronic neck pain will be included to perform clinical test and assess their jaw kinematics and muscle activation.
16391209|NCT04041271||Control group|Healthy control subjects will be included to compare the differences in jaw kinematics, muscle activation and clinical tests between healthy subjects and subjects with nonspecific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
16391210|NCT04041245||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
16391211|NCT04041245||Healthy group|This group will include 40 healthy volunteers.
16391213|NCT04041219|Experimental|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
16391214|NCT04041206||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
16391215|NCT04041206||Healthy group|This group will include 40 healthy volunteers.
16391216|NCT04041193|Experimental|SIDERA^B|Behavioral: telerehabilitation activities Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) 5 sessions/week of an individualized telerehabilitation program at home. The sessions will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by the therapist weekly. Each patient's performed session will be reviewed by the therapist.
16391217|NCT04041193|Active Comparator|usual care|Behavioral: paper and pencil activities as usual rehabilitation at home Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) of a usual rehabilitation program.
16391218|NCT04041167|Active Comparator|Alpha lipoic acid|All patients will be assigned intravenous alpha lipoic acid 600mg within 24 hours of symptom onset. Patients will receive intravenous alpha lipoic acid 600mg/day for one week, followed by an oral pill of alpha lipoic acid 600mg/day for three months.
16391219|NCT04041167|Placebo Comparator|Normal saline|All patients will receive intravenous normal saline within 24 hours of symptom onset.
16391220|NCT04041154|Experimental|Cognitive Fatigue|We will use a behavioral intervention. Participants will perform a cognitively demanding task, repeatedly, to induce cognitive fatigue.
16391221|NCT04041154|Experimental|Physical Fatigue|We will use a behavioral intervention. Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
16391222|NCT04041154|Experimental|Rewarding Stimuli|We will use a behavioral intervention. Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
16391223|NCT04041141||Oral Cancer|Patients receiving curative radiation treatment for an oral cancer.
16391224|NCT04041128|Experimental|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
16391225|NCT04041115|Active Comparator|Control|personalized nutritional therapy + aerobic exercise
16391226|NCT04041115|Active Comparator|Non-alcoholic Beer|non-alcoholic beer + personalized nutritional therapy + aerobic exercise
16391227|NCT04041102||Infantile (Type 1) or Juvenile (Type 2) GM1 Gangliosidosis|This study observes one cohort: up to 40 Infantile GM1 (Type 1) or Juvenile GM1 (Type 2) subjects.
16391228|NCT04041089|Experimental|Recognition of objects|Patients will do the therapy in the following order: object location, object manipulation and object recognition
16391229|NCT04041089|Experimental|Location of objects|Patients will do the therapy in the following order: object recognition, object location, and object manipulation
16391230|NCT04041089|Experimental|Manipulation of objects|Patients will do the therapy in the following order: object manipulation, object recognition and object location
16391231|NCT04041076||Elective Surgical Patients in Tuen Mun Hospital|Patients who received elective surgical operation in Tuen Mun Hospital from 1July 2012 to 30June 2018
16392435|NCT04032652|Active Comparator|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
16391232|NCT04041063|Experimental|Nerve transfer + robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
16391233|NCT04041063|Active Comparator|Nerve transfer + delayed robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year + six weeks after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
16391234|NCT04041050|Experimental|Part 1: Navitoclax Monotherapy|Participants will receive various doses of navitoclax once daily (QD).
16391235|NCT04041050|Experimental|Part 2: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive various doses of navitoclax once daily (QD) in combination with ruxolitinib twice daily (BID).
16391236|NCT04041050|Experimental|Part 3: Navitoclax Monotherapy|Participants will receive navitoclax once daily (QD).
16391237|NCT04041050|Experimental|Part 4: Navitoclax + Celecoxib|Participants will receive navitoclax once daily (QD) starting on Day 3. Participants will also receive celecoxib single dose on Day 1 and Day 7.
16391238|NCT04041024|Experimental|bulimia nervosa group|Patients with Bulimia Nervosa according to DSM 5 criteria aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right handed.
16391239|NCT04041024|Other|Control group|healthy participants without any history of eating disorder aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right
16391240|NCT04041011|Experimental|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|
16391241|NCT04041011|Experimental|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|
16391242|NCT04041011|Experimental|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|
16391243|NCT04040998|Experimental|CCT+TAU group|The participants in CCT+TAU group received compensatory cognitive training plus treatment as usual. The CCT intervention consisted of two 50-minute sessions each week for 10 weeks
16391244|NCT04040998|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as CCT+TAU group.
16391245|NCT04040985|Other|Legion Primary|Legion Primary TKA
16391246|NCT04040972|Experimental|Rebalance - Group Compassion Focussed Therapy|
16391247|NCT04040959|Experimental|Nicotinamide Riboside|Each nicotinamide riboside capsule contains 250 mg of nicotinamide riboside chloride mixed with microcrystalline cellulose. Dosage: 500 mg by mouth twice a day for 3 months.
16391248|NCT04040959|Placebo Comparator|Placebo|Matched placebo capsules.
16391249|NCT04040946|Other|TEMP-TDM with MIBI|Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
16391250|NCT04040946|Other|F18-choline PET|Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
16391251|NCT04040933|Active Comparator|Marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391252|NCT04040933|Active Comparator|Marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391253|NCT04040933|Active Comparator|Non-marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391254|NCT04040933|Experimental|Non-marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391255|NCT04040933|Experimental|Non-marketed Adhesive Bandage #3|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391256|NCT04040933|Experimental|Non-marketed Adhesive Bandage #4|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391257|NCT04040933|Experimental|Non-marketed Adhesive Bandage #5|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
16391258|NCT04040933|No Intervention|No Treatment (Uncovered, Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
16391259|NCT04040920|Experimental|Ozone therapy|Ozone application before pits and fissure sealants
16391260|NCT04040920|Active Comparator|Pits and fissure sealants|
16391261|NCT04040907|Active Comparator|XNW3009|
16391262|NCT04040907|Placebo Comparator|XNW3009 placebo|
16391263|NCT04040881|Experimental|Remote monitoring using Smartphone|Patients will be provided with a Global System for Mobile communications (GSM) accelerometer-equipped Android smartphone (specific model to be decided) with an installed open source, freely available pedometer application (Google Fit, Google, CA, United States) which will record their daily steps. Patients will receive daily calls from a research assistant to document the presence of clinically significant chemotherapy-related toxicity.
16391264|NCT04040868|Other|robot-assisted technique|
16391265|NCT04040868|Other|conventional fluoroscopy-assisted technique|
16392436|NCT04032639||Prader-Willi Syndrome|24 children and adolescents (7-16 years) with diagnosed Prader-Willi Syndrome will be recruited
16391266|NCT04040855|Experimental|Intervention|Patients in the intervention groups received multi-professional medication reviews. A nurse performed a symptom evaluation, a pharmacist assessed the drug list and made adjustment suggestions and finally a physician took action and performed medication changes.
16391267|NCT04040855|No Intervention|Control|Patients were treated according to the usual routine.
16391268|NCT04040829|Active Comparator|SE + TAU|"Supported education (SE) includes a variety of services ranging from orientation, study strategies or homework help. This intervention is personalized to the need of each patient in terms of services and frequency. Previous to this randomized controlled trial, we conducted interviews with each site that will provide SE. In these interviews, we explored the fidelity of their services to the Individual Placement and Support adapted to education. Information regarding the dosage of SE (frequency, length of session, type of support) will be collected and used as covariates for each participant since intensity treatment can impact outcomes.
~Treatment as usual (TAU) consists of medication and routine contact with the clinical team. Patients will continue to receive their standard treatment, but we will collect information regarding the type of medication, the dosage, and all other relevant information and use it as covariate in our analyses."
16391269|NCT04040829|Experimental|CR + SE + TAU|"Cognitive remediation therapy (CR) will be conducted using CIRCuiTS, a computerized program designed to improve cognition (attention, memory, executive functioning) and metacognitive skills. CIRCuiTS has an integrated focus on the transfer of cognitive skills to daily living, using real-world goals and homework to facilitate in vivo use of new strategies, as well as a formulation-based approach, which takes into account the impact of cognitive strengths and difficulties with daily living skills. Each session includes about 4-8 tasks targeting a range of cognitive problems, which become more ecologically valid as the program progresses. The rate of delivery for CIRCuiTS will be two to three sessions per week, for a maximum of 40 sessions. The therapy will be provided entirely online with a therapist, using the platform Zoom.
~This arm will include our active control condition : supported education (SE) as well as Treatment as usual (TAU) as previously described."
16391270|NCT04040816|Experimental|Dose A|Dose A SAP-001 versus placebo
16391271|NCT04040816|Experimental|Dose B|Dose B SAP-001 versus placebo
16391272|NCT04040816|Experimental|Dose C|Dose C SAP-001 versus placebo
16391273|NCT04040816|Experimental|Dose D (allopurinol patients)|Dose D SAP-001 versus placebo in gout patients who remain on allopurinol
16391274|NCT04040803|Experimental|10 Hz tACS|"Stimulation will be applied at 10 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~10 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
16391275|NCT04040803|Experimental|20 Hz tACS|"Stimulation will be applied at 20 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~20 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
16391276|NCT04040803|Experimental|70Hz tACS|"Stimulation will be applied at 70 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~70 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
16391277|NCT04040803|Experimental|0.1-640Hz tRNS|"Stimulation will be applied at 0.1-640Hz tRNS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~0.1-640Hz tRNS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
16391278|NCT04040803|Sham Comparator|Sham|"Stimulation will be performed only for 10 s before the fade out, with 20 Hz tACS and an intensity of 1.5 mA (peak to peak).
~Sham condition will be applied over pseudo-stimulation of pharyngeal cortex region and contralateral supraorbital region."
16391279|NCT04040790|Experimental|Healthy volunteers|15 healthy volunteers for trials with passive artificial iris
16391280|NCT04040764|Experimental|Uncemented Tritanium Knee Replacement|30 participants will be randomly allocated to receive an uncemented Tritanium total knee replacement.
16391281|NCT04040764|Active Comparator|Cemented Triathlon Knee Replacement|30 participants will be randomly allocated to receive standard Triathlon cemented total knee replacements.
16391282|NCT04040751|Experimental|CARE-CITE Carepartner|This study arm consists of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
16391283|NCT04040751|Active Comparator|Control Carepartners|"Carepartners (CP) receiving customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The CP will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
16391284|NCT04040751|Experimental|CARE-CITE Stroke Survivor|This study arm consists of stroke survivors of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
16391285|NCT04040751|Active Comparator|Control Stroke Survivors|"Stroke survivors (SS) or carepartners receiving customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The CP will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
16391286|NCT04040738|Active Comparator|Upper extremity surgery under general anaesthesia|Fentanyl 2 mcg/kg iv, propofol 2 mg/kg iv induction, 1MAC sevoflurane maintenance
16391287|NCT04040738|Active Comparator|Upper extremity surgery under regional anaesthesia|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
16391288|NCT04040725|Experimental|Rogaratinib|"Rogaratinib is administered orally twice daily
~Rogaratinib is held for 72 hours before cystoscopy/TURBT and if no complications are seen, treatment is resumed 24 hours after the TURBT"
16391289|NCT04040712|Experimental|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
16391290|NCT04040712|Sham Comparator|Sham FMT|Sham fecal microbiota transplantation
16391291|NCT04040699|Experimental|KN026 combined with KN046|"KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.
~KN046 is a PD-L1 - CTLA-4 bispecific antibody."
16415626|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts B"|
16391292|NCT04040686|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection
16391293|NCT04040673||Normal benign|participants with normal benign nodules (no cancer)
16391294|NCT04040673||Follicular thyroid cancer|participants with follicular thyroid cancer
16391295|NCT04040673||Papillary thyroid cancer|participants with papillary thyroid cancer
16391296|NCT04040673||Anaplastic thyroid cancer|participants with anaplastic thyroid cancer
16391297|NCT04040673||Medullary thyroid cancer|participants with medullary thyroid cancer
16391298|NCT04040647||colorectal surgery|50 consecutive patients scheduled to colorectal surgery in an enhanced recovery programme
16391299|NCT04040647||bariatric surgery|50 consecutive patients scheduled to bariatric surgery (gastric by-pass, sleeve gastrectomy) in an enhanced recovery programme
16391302|NCT04040621|Experimental|Ceftazidime-avibactam|This arm includes 4 cohorts
16391303|NCT04040608||experimental group|differences in responses to visual analog scales depending on screen sizes
16391304|NCT04040595|Experimental|Adipocyte measurement|Abdominal fat biopsy
16391306|NCT04040556||anesthesia residence|anesthesia residences who currently study in the department of Anesthesia and voluntarily enrolled into the study
16391307|NCT04040543|Experimental|Daily|Daily supplementation with product containing markers
16391308|NCT04040543|Experimental|Intermittent|Daily supplementation with either the product containing markers or the product not containing markers
16391309|NCT04040543|Placebo Comparator|Control|Daily supplementation with product not containing markers
16391310|NCT04040530||Cryoablation|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with CT-guided cryoablation at Odense University Hospital in the period from 1/6-2019 to 1/6-2021.
16391311|NCT04040530||Partial nephrectomy|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with partial nephrectomy at Odense University Hospital or Zealand University Hospital in the period from 1/6-2019 to 1/6-2021.
16391312|NCT04040504|Experimental|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
16391313|NCT04040504|Active Comparator|Pentax ED-34i10T Duodenoscope|Pentax ED-34i10T Duodenoscope
16391314|NCT04040491|Experimental|Newly diagnosed PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
16391315|NCT04040491|Other|Relapse/refractory PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
16391316|NCT04040478||Abdominal|80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.
16391317|NCT04040478||Vascular|20 patients undergoing femoral endarterectomy.
16391318|NCT04040465|Active Comparator|Normal Weight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
16391319|NCT04040465|Active Comparator|Normal Weight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
16391320|NCT04040465|Active Comparator|Normal Weight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
16391321|NCT04040465|Active Comparator|Overweight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
16391322|NCT04040465|Active Comparator|Overweight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
16391323|NCT04040465|Active Comparator|Overweight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
16391324|NCT04040465|Active Comparator|Obese/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
16391325|NCT04040465|Active Comparator|Obese/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
16391326|NCT04040465|Active Comparator|Obese/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
16391327|NCT04040452|Experimental|Treatment|"Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte). To eliminate excess exposure and the associated side effects, all patients enrolled in the study will not be given any additional NSAIDs (except aspirin, which is standard of care in many post-operative cardiac surgery patients) during the study period.
~Dosage and Route of Administration:
~Continuous ketorolac 0.08mg/kg/hr, with a maximum of 5mg/hr for patients weighing greater than or equal to 60kg, administered intravenously by nursing staff. Study drug will infuse continuously for 48 hours.
~Intermittent Plasmalyte 0.033mL/kg (max 2mL) infusion every 6 hours for 48 hours."
16391328|NCT04040452|Placebo Comparator|Standard of care|"Description: Patients randomized to the standard of care arm of the study will receive a generically marked syringe of Plasmalyte to be infused at the same rate as the treatment medication, and will only receive intermittent dosing of ketorolac (current standard of care). As in the treatment group, no additional NSAIDs (except aspirin) are to be given during the 48 hour study period.
~Dosage and Route of Administration
~Continuous Plasmalyte infusion to match the aforementioned ketorolac dosing
~Intermittent ketorolac 0.5mg/kg IV infusion every 6 hours (max 30mg per dose)"
16391329|NCT04040439||Dexmedetomidine Hydrochloride|"Pediatric patients (45 weeks corrected gestational age to <18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation during and after mechanical ventilation in the intensive care setting"
16392510|NCT04032184|Experimental|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|
16391330|NCT04040426|Experimental|Human split thickness skin allograft (Theraskin™)|Theraskin™ is an all-human split thickness skin allograft with a native extracellular matrix that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing. Theraskin™ is an allograft tissue and will be used in compliance with homologous use by the FDA under section 361 of the PHS Act and 21 CFR Part 1271
16391331|NCT04040426|Active Comparator|Fibracol wound dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
16391332|NCT04040400|Experimental|Treatment Arm|intraoperative radiotherapy (IORT) arm
16391333|NCT04040387|Experimental|Treatment Arm|Intervention with NightWare Therapeutic System
16391334|NCT04040387|Sham Comparator|Sham Arm|NightWare system set to not provide any interventions
16391335|NCT04040374|Experimental|AI-based diagnosis|• AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
16391336|NCT04040374|Active Comparator|Expert endoscopist diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
16391337|NCT04040361|Experimental|Pembrolizumab+Ramucirumab+Surgery|Pembrolizumab and Ramucirumab will be administered simultaneously for non small cell lung cancer patients for 2 cycles before surgery.
16391338|NCT04040348|Experimental|hMSC Treatment group|Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period.
16391339|NCT04040322|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
16391340|NCT04040322|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
16391341|NCT04040309|Experimental|Plasma rich in growth factors group|Group of patients who will receive 1 ml of PRGF 2nd fractions injections into their trigger points in the masseter muscle.
16391342|NCT04040309|Active Comparator|Lidocaine group|Group of patients who will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle.
16391343|NCT04040296|No Intervention|Usual Care|Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.
16391344|NCT04040296|Experimental|Kidney Action Team Recommendations|Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.
16391345|NCT04040270|Experimental|Live drama+DVD+Worksheets|Primary school students watched an interactive live drama in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
16391346|NCT04040270|Experimental|DVD+Worksheets|Primary school students were given DVD and worksheets and they were asked to watch the DVD and finish the worksheets with their parents. After the study finished, the students watched the live drama.
16391347|NCT04040270|No Intervention|Waitlist control|Primary school students received no intervention during the 4-week study period. After the study finished, the students watched the live drama, and DVD with worksheets were distributed to students and they were encouraged to share with their parents.
16391348|NCT04040257|No Intervention|Individual Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
16391349|NCT04040257|Experimental|Group Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
16391350|NCT04040244|Experimental|Exhaled Breath Analysis|Exhaled breathe condensate will be collected using R-tube and ReCIVA device over 5-10 minutes.
16391351|NCT04040231|Experimental|Malignant Pleural Mesothelioma (MPM)|Participants with previously treated Malignant Pleural Mesothelioma/MPM
16391352|NCT04040205|Experimental|Abemaciclib|Subjects will be treated with abemaciclib 200 mg twice daily by mouth.
16391353|NCT04040192|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied once daily (QD)
16391354|NCT04040192|Placebo Comparator|Vehicle|Vehicle ointment applied once daily (QD)
16391355|NCT04040166|Other|PET/MRI scan with 68Ga DOTATATE|PET/MRI scan with 68Ga DOTATATE of carotid arteries in in patients following head and neck radiation therapy
16391356|NCT04040153|Experimental|Guiding Good Choices|Enrollment in the intervention, Guiding Good Choices, a substance use initiation prevention program, will be recommended by the pediatrician to parents of those adolescents empaneled with an intervention arm pediatrician
16391357|NCT04040153|No Intervention|Control|Parents of adolescents empaneled with a control arm pediatrician will not be offered Guiding Good Choices
16391358|NCT04040140|Experimental|APA Treatment|Oncology patients with a pain rating of four or greater will receive APA treatment for patients' cancer-related pain. The ear points will be determined by the corresponding body points related to the patient's specific pain. Pain data will be tracked by electronic surveys and Electronic Health Records.
16391359|NCT04040127|Experimental|Cord blood stem cells|cord blood stem cells from Invitrx
16391360|NCT04040127|Placebo Comparator|0.9% sodium chloride (saline)|canal will be rinsed by saline solution.
16391361|NCT04040114|No Intervention|Lead-in phase|During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).
16393258|NCT04026828||Periodontitis Group|Chronic periodontitis and aggressive periodontitis patients
16391362|NCT04040114|Active Comparator|Active phase|During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.
16391363|NCT04040101|No Intervention|Healthy Adult|balance assessment
16391364|NCT04040101|No Intervention|Stroke|balance assessment
16391365|NCT04040101|Experimental|Stroke smartphone training|smartphone balance training
16391366|NCT04040101|Active Comparator|Stroke traditional training|traditional physical therapy training
16391367|NCT04040088|Experimental|Cohort A (68Ga-DOTATATE, PET/CT)|Patients with newly diagnosed neuroendocrine cancer receive 68Ga-DOTATATE intravenously (IV) and undergo PET/CT over 20-30 minutes at diagnosis (before any treatment) and at the time of radiation treatment planning.
16391368|NCT04040088|Experimental|Cohort B (68Ga-DOTATATE, PET/CT)|Patients with previously diagnosed with neuroendocrine cancer receive 68Ga-DOTATATE IV and undergo PET/CT over 20-30 minutes at the time of radiation treatment planning.
16391369|NCT04040075|Other|Open label|Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation
16391370|NCT04040062|Experimental|SCC|Subjects will be treated according to their frequency response pattern which may show one or more distinct frequencies of stimulation that generated increased SCC
16391371|NCT04040049|Experimental|FLT190|FLT190 is a replication-incompetent adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
16391372|NCT04040036|Experimental|VR-Rollercoaster|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, individuals feel as if they are getting on and riding a rollercoaster. The rollercoaster speeds up and slows down.
16391373|NCT04040036|Experimental|VR-Ocean Rift|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
16391374|NCT04040036|No Intervention|Control|They would be monitored during the procedure if their informed consent was received. Control group children did not receive any distraction techniques.
16391375|NCT04040023|Other|I Group: PBMi|Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices
16391376|NCT04040023|Experimental|C Group: PBMc|"Patient Blood Management: full program
~PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)"
16391377|NCT04040010|Experimental|Postmenopausal women colostrum supplement|
16391378|NCT04040010|Experimental|Osteoporosis patients colostrum supplement|
16391379|NCT04040010|Experimental|Osteopenia patients colostrum supplement|
16391380|NCT04040010|Placebo Comparator|Postmenopausal women placebo|
16391381|NCT04040010|Placebo Comparator|Osteoporosis patients placebo|
16391382|NCT04040010|Placebo Comparator|Osteopenia patients placebo|
16391383|NCT04039997|Experimental|Chest compression without cpr feedback device|teaching resuscitation without application of cpr feedback device
16391384|NCT04039997|Experimental|Chest compression with cpr feedback device|teaching resuscitation with application of CPRMeter - cpr feedback device
16391385|NCT04039984|Experimental|Prime Cup|The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.
16391386|NCT04039971|Active Comparator|Tendon-Bone Graft|Participants receive the Quadriceps Tendon Tendon-Bone Graft technique during ACL reconstruction.
16391387|NCT04039971|Active Comparator|All-Soft-Tissue Graft|Participants receive the Quadriceps Tendon All-Soft-Tissue Graft technique during ACL reconstruction.
16391388|NCT04039958|Experimental|T test|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
16391389|NCT04039958|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
16391390|NCT04039958|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
16391393|NCT04039919|Experimental|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
16391394|NCT04039919|Placebo Comparator|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
16391395|NCT04039919|No Intervention|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
16391396|NCT04039919|No Intervention|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
16391397|NCT04039919|Experimental|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
16391398|NCT04039919|Placebo Comparator|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
16391399|NCT04039906|No Intervention|Removal of needle with existing method|Participants will remove needles from syringes with the existing method like they are already doing. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
16391400|NCT04039906|Experimental|Removal of needle with using ANDYs|Participants will remove needles from syringes with Andy. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
16391401|NCT04039893|Other|Node-positive breast cancer patients|All patients with positive lymph nodes for who an axillary node clearance is proposed as part of the surgical treatment
16391402|NCT04039880|Experimental|Cohort A (mass balance)|evaluation of mass balance and metabolite profiling
16391403|NCT04039880|Experimental|Cohort B (biliary evaluation)|evaluation of biliary elimination
16391404|NCT04039867|Experimental|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
16391405|NCT04039854|Active Comparator|Volatile anaesthetics arm|Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
16391406|NCT04039854|Active Comparator|Propofol anaesthetics arm|Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
16391407|NCT04039841|Other|Motor imagery evaluation|cohort study
16391408|NCT04039828|Experimental|Stratum|"Stratum 1: From 3 months to <18 months= 175 Stratum 2: From 18 months to 59 months= 175
~In total, 350 participants will be enrolled"
16391409|NCT04039815|Experimental|ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group|"patients in study group, so called ABC (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days"
16391410|NCT04039815|Placebo Comparator|normal saline group|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
16391411|NCT04039802||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery
16391412|NCT04039802||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures
16391413|NCT04039789|Active Comparator|Control|Usual Care: that consists of healing the wound (assessment, cleaning, disinfection, debridement and topical treatment) and compression therapy multilayer usual practice, according to the recommendations for the treatment of cutaneous ulcers of the Region of Madrid.
16391414|NCT04039789|Experimental|Intervention|"ACTIVE LEGS: The usual care plus experimental intervention. It is a structured educational intervention, directed by nurses and carried out in the health center consultations. The intervention Active Legs has been designed based on the available evidence. It incorporates a program of lower limb exercise at home and daily walking patterns.
~Home program of lower limb exercises. The nurse will instruct the patients in the performance of 4 exercises of lower limbs of progressive difficulty that must be performed at home 5 days a week, twice a day Daily walking program. In addition, patients must ambulate progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)) .
~At the start of the study, the Active Legs diary will be provided, showing the patterns of the exercise and walking program graphically and a pedometer."
16391415|NCT04039776|Experimental|Bone patellofemoral joint indices|Evaluation of the bone index values in patients affected by patellofemoral joint disorders, obtained from CT scans performed in both orthostatism and clinostatism
16391416|NCT04039763|Experimental|Real Time Continuous Glucose Monitoring|"Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via Dexcom clarity with the research/clinical team, who will support them making changes to their insulin regime in light of the data."
16391417|NCT04039763|Placebo Comparator|Standard care|Standard care - finger prick self monitoring of blood glucose.
16391418|NCT04039750|Experimental|Antibiotic irrigation with suction|Group A: You will receive antibiotic irrigation with suction if a PA is found during surgery
16391419|NCT04039750|Active Comparator|suction only|Group B: You will receive suction alone if a PA is found during surgery
16391420|NCT04039737|Experimental|Treatment Group|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
16391421|NCT04039737|No Intervention|Control Group|
16391422|NCT04039724|Experimental|Sequence A|"Period 1 : HCP0605+HGP0816
~Period 2 : HCP1305"
16391423|NCT04039724|Experimental|Sequence B|"Period 1 : HCP1305
~Period 2 : HCP0605+HGP0816"
16391424|NCT04039711|Other|Genital infections|Women with vaginal/cervical sampling indications
16391425|NCT04039698|Experimental|Telemedicine|Sofosbuvir 400mg and velpatasvir 100mg qd for 12 weeks Telemedicine support
16391426|NCT04039685|Experimental|Aerobic exercise group|
16391427|NCT04039685|Experimental|Resistance exercise group|
16391428|NCT04039685|Experimental|Combined (aerobic+resistance) exercise group|
16391429|NCT04039685|No Intervention|Non-exercise group|
16391430|NCT04039672|Experimental|Biopsy|Skin biopsy before BRAFi/MEKi treatment
16391431|NCT04039659|No Intervention|Control Group|Patients will be cured with dressings wound everyday or before if there are complications in surgical incisions.
16391432|NCT04039659|Active Comparator|PICO group|Patients will carry the device for 7 days uninterrupted until its withdrawal.
16391433|NCT04039646|Active Comparator|Standard postoperative care group|Patients received standard postoperative care as ususal.
16391434|NCT04039646|Experimental|ERAS group|Patients received postoperative ERAS treatment.
16391435|NCT04039633|Experimental|Burst spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
16391436|NCT04039633|Sham Comparator|sham spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
16391439|NCT04039594||ECMO|
16391467|NCT04039412|Active Comparator|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
16391468|NCT04039399|Experimental|Ischemic Conditioning|Study participants will receive one session of ischemic conditioning on their affected leg with cuff inflation to 225 mmHg.
16393163|NCT04027387|Experimental|TMB-365 400 mg- Group 1|Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
16391440|NCT04039581|Experimental|Group Kinesio Taping and TENS|"The number of participants in this group is anticipated to be 30. The treatment method for this group is the conventional treatment + KT (Kinesio Taping) relaxation technique (muscle inhibition technique). In KT technique, while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.
~In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises."
16391441|NCT04039581|Active Comparator|Group TENS|The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist. Therapeutic exercises will consist of active shoulder evolution, active cervical rotations, active cervical lateral flexion movement and active shoulder flexion and abduction exercises.
16391442|NCT04039581|Active Comparator|Group Kinesio Taping|The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.
16391443|NCT04039568|Active Comparator|Active Control Group|"Ten to fifteen participants in the HEP arm will participate in the program for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.
~The Health-Enhancement Program (HEP) was designed and used as a manualized active control in meditation-based intervention trials. HEP controls for several non-specific factors found in a meditation groups, including: group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is tailored to be structurally equivalent to SSM with similar-sized groups, meeting schedule, total contact hours, amount of home practice and encouragement to keep practice logs."
16391444|NCT04039568|Experimental|Intervention Group|"Ten to fifteen participants in the SSM arm will be trained for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.
~This standardized, manualized therapy will be delivered by certified meditation instructors. On day 1, participants will learn the nature of meditation, and then undergo personal guided meditation. Training on days 2-4 includes understanding the nature of the mind and the thoughts arising from it, guided meditations by the instructor, and a discussion of meditation processes. Weekly 75 min reinforcement sessions will include 20 minutes of guided meditation practice, and then focus on participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice. Participants will also be encouraged to practice twice daily at home for 20 minutes per session."
16391445|NCT04039555|Active Comparator|Active Arm - CO2 intimate|Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart
16391446|NCT04039555|Active Comparator|Active Arm - Erbium-yag|Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart
16391447|NCT04039555|Sham Comparator|Sham Arm|Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart
16391448|NCT04039542|Experimental|Compassion focused therapy (CFT)|A group programme of CFT running for 10 sessions lasting 90 minutes per session.
16391449|NCT04039529|No Intervention|CT-only guided biopsy|The current standard of care for biopsy at Temple University Hospital.
16391450|NCT04039529|Experimental|SCENERGY-guided Biopsy|The use of the SCENERGY to fuse CT and Ultrasound for biopsy
16391451|NCT04039516|Experimental|Lutathera Treatment Arm|• 4x cycles of 7.4 GBq (200mCi) of Lutathera therapy (177Lu-DOTA0-Tyr3-Octreotate) with concomitant amino acids for participants randomised onto the Lutathera therapy arm, every 8 weeks, plus long term somatostatin analogues (SSTA).
16391452|NCT04039516|No Intervention|Best Supportive Care|Somatostatin analogue treatment according to current standard, routine care
16391453|NCT04039503|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16391454|NCT04039503|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16391455|NCT04039503|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16391456|NCT04039503|Placebo Comparator|Placebo|Placebo administered SC once a week.
16391457|NCT04039490|No Intervention|Ultrasound-only Pediatric Vessel Cannulation|The standard of care for vessel cannulation currently employed at CNMC
16391458|NCT04039490|Experimental|SCENERGY-guided Pediatric Vessel Cannulation|The addition of the SCENERGY guidance combined with the ultrasound for pediatric vessel cannulations.
16391459|NCT04039477|Experimental|Arm A - KZR-616 30mg|KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks
16391460|NCT04039477|Experimental|Arm B - KZR-616 45mg|KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.
16391461|NCT04039464|Active Comparator|Monotherapy with Sildenafil Group|mono-therapy: first-line monotherapy (sildenafil alone) - in pediatric subjects with PAH.
16391462|NCT04039464|Active Comparator|Duo Therapy with Sildenafil + Bosentan Group|duo-therapy: compare two treatment strategies - first-line combination therapy (sildenafil and bosentan)
16391463|NCT04039451||people who live in rural areas in Assuit governorate|The study will performed on people who live in rural areas in Assuit governorate (all households) regardless of sex or age.
16391464|NCT04039425||cancer patient|"Recently diagnosed cancer stage 1, 2, or 3
~Assigned to receive immunosuppressive chemotherapy treatment
~Natural hair that has not been dyed or permed in the past 3 months"
16391465|NCT04039412|Active Comparator|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
16391466|NCT04039412|Active Comparator|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
16391469|NCT04039399|Sham Comparator|Sham Ischemic Conditioning|Study participants will receive one session of sham ischemic conditioning on their affected leg with cuff inflation to 10 mmHg.
16391470|NCT04039386|Experimental|Cell Phone Based Cognitive Based Therapy|Young adults with hip pain
16391471|NCT04039386|Placebo Comparator|Placebo|Young adults with hip pain
16391472|NCT04039373|Experimental|Treatment Arm|
16391473|NCT04039347|Experimental|L-CsA 5 mg plus Standard of Care|L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant
16391474|NCT04039347|Experimental|L-CsA 10 mg plus Standard of Care|L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant
16391475|NCT04039334|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 week. All exercise sessions will be performed at home.
16391476|NCT04039334|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
16391477|NCT04039321|Active Comparator|ESPB group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
16391478|NCT04039321|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
16391479|NCT04039282|Other|Patient Participant|Patients will be asked to complete an 3 days worth of an online dietary recall prior to their out patient appointment with the dietitian
16391480|NCT04039282|Other|Dietitian Participant|The Dietitian will be asked to review the patients completed dietary recalls prior to the patient attending their out patient appointment.
16391481|NCT04039269|Active Comparator|Multiple (watch > 3 times)|Preoperative video information
16391482|NCT04039269|Active Comparator|single (watch 1 time)|Preoperative video information
16391483|NCT04039269|No Intervention|conventional (do not watch)|Do not watch video
16391484|NCT04039256|Experimental|PVR implantation group|Patients enrolled receive PVR intervention
16391485|NCT04039243|Experimental|Active Treatment|Up to 12 sessions of Parent-Child CBT using an adaptation of the Being Brave protocol
16391486|NCT04039243|Active Comparator|Parent Education|Parents receive educational materials about how to help young children overcome shyness and anxiety
16391487|NCT04039243|No Intervention|Monitoring|
16391489|NCT04039217|Experimental|Group A|Group A will provide biological specimens 2, 48, and 96 hours after the in-clinic dose of TAF/FTC/BIC. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre- wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at 1 study timepoint.
16391490|NCT04039217|Experimental|Group B|Group B will provide biological specimens 4, 26, and 120 hours after the in-clinic dose of TAF/FTC/BIC. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre- wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at 1 study timepoint.
16391491|NCT04039217|Experimental|Group C|Group C will provide biological specimens 24, 28, and 72 hours after the in-clinic dose of TAF/FTC/BIC. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre- wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at 1 study timepoint.
16391492|NCT04039204|Experimental|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
16391493|NCT04039204|Active Comparator|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
16391494|NCT04039191|Placebo Comparator|SMS survey|Subject to receive SMS survey.
16391495|NCT04039191|Active Comparator|SMS survey with education|Subject to receive SMS survey with education.
16391496|NCT04039178|Active Comparator|Treatment group|Real BQ treatment, 40 treatments including 20 minutes of device guided functional motor tasks.
16391497|NCT04039178|Sham Comparator|Control group|Sham BQ treatment, (zero intensity) 40 treatments including 20 minutes of device guided functional motor tasks.
16391498|NCT04039165|Experimental|Intervention Group|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, and complete a group walk or indoor exercise during the group sessions. The investigators will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program. During times when in-person visits cannot happen (e.g., COVID-19), we will do virtual group sessions instead of meeting at the clinics, conducted via videoconference platform (i.e., Zoom), the group walks will not happen, and all exercise will be done individually to comply with social distancing measures.
16391499|NCT04039165|No Intervention|Wait-list Control Comparison Group|Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At Week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
16391500|NCT04039152||Pre- interventions group|Without clinical pharmacists recommendations to optimize antibiotics use
16391501|NCT04039152||Post - interventions group|interventions include clinical pharmacists recommendations to optimize antibiotics use
16391502|NCT04039139|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
16391503|NCT04039139|Active Comparator|Mind Body Intervention 1|Participants will receive a mind body educational-based intervention to learn the techniques comprising intervention 1.
16391504|NCT04039139|Experimental|Mind Body Intervention 2|Participants will receive a mind-body educational-based intervention to learn the techniques comprising intervention 2.
16391505|NCT04039126|Experimental|PATIENTS WITH MALIGNANT PLEURAL EFFUSION|PARTICIPANTS WITH MALIGNANT PLEURAL EFFUSIONS REQUIRING PLEURODESIS, COMBINATION OD POVIDONE IODOONE-TETRCYCLINE TO BE USED.
16391506|NCT04039126|Active Comparator|PATEINT WITH MALIGANT PLEURAL EFFUSION REQUIRNG PLEURODESIS|TO USE POVIDONE IODINE ALONE IN THIS GROUP
16391507|NCT04039113|Active Comparator|Tezepelumab|Tezepelumab, SC, Q4W
16391508|NCT04039113|Placebo Comparator|Matching Placebo|Matching placebo, SC, Q4W
16391509|NCT04039100|Experimental|Family Caregiver Ambassador Support|Intervention group: caregivers of newly diagnosed patients (n=30), former family caregivers as ambassadors (n=20)
16391510|NCT04039087|Active Comparator|Sildenafil|active sildenafil 40 mg p.o. three times per day
16391511|NCT04039087|Placebo Comparator|Placebo Arm|placebo three times per day
16391512|NCT04039074|Experimental|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
16391513|NCT04039074|Active Comparator|Iyengar yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
16391514|NCT04039074|Active Comparator|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
16391515|NCT04039061||ADPKD patients|Patients with a diagnosis, or suspected diagnosis, of ADPKD
16391516|NCT04039048|Experimental|ctDCS during Balance training|
16391517|NCT04039048|Sham Comparator|ctDCS sham during Balance training|
16391519|NCT04039009||Infertility patients|Infertility patients will be examined according to the pelvic organ prolapse quantification classification system during hysteroscopy.
16391520|NCT04038983||Observational|"ER2 is a simple and standardized clinical tool composed of two sequential components: an assessment followed by recommendations for intervention. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies (21-24). Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
16391521|NCT04038970|Experimental|KN019 5mg/kg|Intravenous (IV) solution, 5 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
16391522|NCT04038970|Experimental|KN019 10mg/kg|Intravenous (IV) solution, 10 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
16391523|NCT04038970|Placebo Comparator|Placebo|Intravenous (IV) solution, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
16391524|NCT04038957|Experimental|SEP-363856|SEP-363856 50mg, 75mg flexible dosing, dosed once daily
16391525|NCT04038944||Subjects with new onset atrial fibrillation|Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion
16391526|NCT04038918|Experimental|Progressive Muscle Relaxation Exercise Group|Standard postoperative physiotherapy program plus progressive muscle relaxation (PMR) exercise will be applied.
16391527|NCT04038918|Other|Control Group|Standard postoperative physiotherapy program will be applied.
16391528|NCT04038892|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. After the training given by the physiotherapist, all exercise sessions will be performed at home.
16391529|NCT04038892|Experimental|Nintendo Wii Fit Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive Nintendo Wii Fit based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
16391530|NCT04038892|Experimental|BreathingLabs Breathing Games Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
16391531|NCT04038879||Mitral/Aortic Regurgitation|Subjects identified with mitral or aortic regurgitation will be asked to undergo testing with trans thoracic echocardiogram, stress echocardiography, and cardiac MRI with and without contrast. In addition, patients will be asked to answer the KCC and EQ5DL questionnaires.
16391532|NCT04038866|Experimental|DUAL-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait with a dual-task program with secondary cognitive and upper limb motor tasks.
~In this group, the training of the tasks (walking and cognitive or motor) was performed separately and then they were trained at the same time under a progression system. Cognitive/motor secondary tasks were different from those used in the assessment of gait.
~Each training session consisted of three parts: the initial warm-up, dual-training, and back-to-calm."
16391533|NCT04038866|Active Comparator|SINGLE-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait without a dual-task program (physical and walking exercises without additional load of cognitive or upper limb motor tasks).
~Each training session consisted of three parts: initial warm-up, physical exercise in single-task condition, and back-to-calm.
~The objectives and walking exercises were the same as those performed in the experimental group."
16391534|NCT04038853|Experimental|Vitamin D|Intervention drug, containing 1,25-dihydroxy-vitamin D, comes in original packages as vials containing a total amount of 10 ml of clear solution. 5 drops accounting for 1000 IU of 1,25-dihydroxy-vitamin D will be administered orally on a daily basis.
16391535|NCT04038853|Placebo Comparator|Placebo|A placebo identical to the study intervention drug in all its characteristics (package, visual characteristics of the fluid, smell, and taste) will be administered in the same manner.
16391613|NCT04038398|Other|FiO2: 21% - 50% - 100%|see above
16415627|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A"|
16391536|NCT04038840|Experimental|Healthy Control (HC) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
16391537|NCT04038840|Experimental|Schizophrenia (SZ) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
16391538|NCT04038814||VAP1 - historical group|Routine prevention of VAP
16391539|NCT04038814||VAP2 - study group|Modified prevention of VAP
16391540|NCT04038801|Active Comparator|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed over four visits at 1-weekly intervals using an assortment of manual periodontal curettes.
16391541|NCT04038801|Experimental|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
16391542|NCT04038801|Experimental|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
16391543|NCT04038788|Active Comparator|Active tRNS|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
16391544|NCT04038788|Sham Comparator|Sham treatment|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham group were maintained on their antipsychotic medications throughout the study period.
16391545|NCT04038775|Experimental|Volunteering|"The experimental arm will receive a volunteer prescription from their provider and assistance from a study team member to find a volunteer job."
16391546|NCT04038775|No Intervention|Control|The control arm will not be recommended to volunteer or assisted in finding a volunteer activity. They will answer the same survey questions as the intervention subjects.
16391547|NCT04038762|Active Comparator|Conventional nasal intubation|Passage of an endotracheal tube via the nare followed by video laryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
16391548|NCT04038762|Experimental|Nasotracheal Intubation with cuff inflation-deflation method|Nasotracheal intubation placed with video laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
16391549|NCT04038749|Experimental|Pharmaceutical method- Bromocriptine|
16391550|NCT04038749|Experimental|Pharmaceutical method- Cabergoline|
16391551|NCT04038749|Other|Without medications that inhibit lactation|
16391552|NCT04038736|Experimental|Healthy subjects at averge risk for CRC|All subjects are healthy who didn't have any known polyps in past colonoscopy and who arw candidates for CRC screening
16391553|NCT04038736|Experimental|Healthy subjects at high risk for CRC|Subjects who had polyps in former colonoscopy, subjects who have family history of CRC or subjects who have positive stool blood test.
16391554|NCT04038723|Experimental|Pre- and Post-HIIT|Participants will be evaluated before and after exercise training.
16391555|NCT04038710||Patients with severe disease|Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
16391556|NCT04038697|Experimental|Ischemic Conditioning + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning and treadmill training.
16391557|NCT04038697|Placebo Comparator|Ischemic Conditioning Sham + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning sham and treadmill training.
16391558|NCT04038697|Active Comparator|Ischemic Conditioning Only|Study participants with prior history of stroke will receive only ischemic conditioning.
16391559|NCT04038697|Active Comparator|Healthy Control - Ischemic Conditioning + Treadmill Training|Healthy control participants will receive both ischemic conditioning and treadmill training.
16391560|NCT04038684|Experimental|Mindfulness-Based Weight Control|All participants will be randomly assigned to a 16-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 90 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
16391561|NCT04038684|Active Comparator|Standard Behavioral Weight Control|All participants will be randomly assigned to a 16-week group-based Mindfulness-Based Behavioral Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the SBWC intervention will receive the SBWC without mindfulness components. Each of the 16 group sessions will be approximately 90 minutes. Outside of group sessions, participants will be asked to practice dietary self-monitoring at home during the week.
16391562|NCT04038671|Experimental|Activated Carbon Dressing|A low-adherent, comprised of 100% pure activated carbon and also conforms to body contours to maintain contact with the incision surface. The dressing may be used either dry or moistened with sterilized water over dry or discharging, partial and full thickness wounds.
16391563|NCT04038671|Active Comparator|Knitted Cellulose Acetate Mesh|a non-adhering dressing, comprised of a knitted cellulose acetate mesh impregnated with a specially-formulated petrolatum emulsion.
16391564|NCT04038671|Active Comparator|Antimicrobial Alginate Dressing with Silver|a non-adherent antimicrobial alginate dressing with silver
16391565|NCT04038658|Experimental|Intervention Group (MoveIt)|10-minute Qigong exercise session (video demonstration via website) delivered twice a day at set break times during the working day for 12 consecutive weeks
16391566|NCT04038658|No Intervention|Wait-list control group|No intervention for 12 weeks. Then received the MoveIt Intervention for 12 weeks.
16393164|NCT04027387|Experimental|TMB-365 800 mg- Group 2|Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
16391567|NCT04038645|Active Comparator|Experimental Group (laser)|"The patients (n=18) will receive infrared LEDs in 6 points (3 on the right side and 3 on the left side) using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt (mW) . The LED light outputs will be positioned in direct contact with the skin. During application of the LED both patient and operator will wear goggles.
~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
16391568|NCT04038645|Placebo Comparator|Control group (Placebo)|The patients (n=18) will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days (by the same evaluator), as well as the evaluation of serum CRP.
16391569|NCT04038632|Experimental|District Hospital focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.
16391570|NCT04038632|Experimental|Primary Health Center focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.
16391571|NCT04038619|Experimental|Treatment (loperamide, colonoscopy, FMT)|Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
16391572|NCT04038606|Active Comparator|acceptance of mastectomy|Assess the determinants of acceptance of mastectomy based on personal background,Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
16391573|NCT04038606|Experimental|rejection of mastectomy|Assess the determinants of rejection of mastectomy based on personal background, Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
16391574|NCT04038593|No Intervention|Non interventional arm|Standard conditions of complex dressing cares, without experimental intervention. It will be a control intervention
16391575|NCT04038593|Active Comparator|Comparative arm with relaxation music from Youtube©|Standard conditions of complex dressing cares + use of non standardized music relaxation during complex dressing cares
16391576|NCT04038593|Experimental|Interventional arm with MUSIC CARE©|Standard conditions of complex dressing cares + administration of a specific music therapy program (U method) delivered through headphones from a tablet, under the direction of trained nurses.
16391577|NCT04038580|Sham Comparator|Prescribed Laminated Socket|In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
16391578|NCT04038580|Experimental|Adjustable Sockets|In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
16391579|NCT04038567|Experimental|High dose / therapist attention / introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and an introductory call from a therapist.
16391580|NCT04038567|Experimental|High dose / therapist attention / no introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and no introductory call from a therapist.
16391581|NCT04038567|Experimental|High dose / app attention / introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
16391582|NCT04038567|Experimental|High dose / app attention / no introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
16391583|NCT04038567|Experimental|Standard dose / therapist attention / introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and an introductory call from a therapist.
16391584|NCT04038567|Experimental|Standard dose / therapist attention / no introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and no introductory call from a therapist.
16391585|NCT04038567|Experimental|Standard dose / app attention / introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
16391586|NCT04038567|Experimental|Standard dose / app attention / no introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
16391587|NCT04038554||Acute Pancreatitis|Patients older than 18 years old diagnosed of acute pancreatitis according to Atlanta 2012.
16391588|NCT04038554||Healthy Control|Healthy people with a proximity relationship with case patients and similar age (+/- 5 years).
16391589|NCT04038541|Other|Prebiotic/ Probiotic|These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
16391590|NCT04038541|Other|Probiotic/ Prebiotic|These subjects will be assigned to first receive probiotics (Visbiome®) for 6 weeks. Then after a 6 week wash-out period, subjects will take (Prebiotin Prebiotic Fiber Stick) for 6 weeks (followed again by a 6 week washout period).
16391591|NCT04038528||Telemedicine Group|Patients in this group monitor blood sugar levels at home and upload their data through a telemedicine systems.
16391592|NCT04038528||Control Group|The control group will attend their routine appointments scheduled by their GPs and specialists in outpatient clinics and will record blood sugar levels according to the traditional method as per GP or specialist physician's indications.
16391686|NCT04037891|Placebo Comparator|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
16393165|NCT04027387|Experimental|TMB-365 1600 mg- Group 3|Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
16391593|NCT04038515|Experimental|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
16391594|NCT04038515|Experimental|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
16391595|NCT04038515|Experimental|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
16391596|NCT04038515|Experimental|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
16391597|NCT04038502|Active Comparator|Treatment Arm 1 - Carboplatin to Olaparib|Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.
16391598|NCT04038502|Active Comparator|Treatment Arm 2 - Olaparib to Carboplatin|Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.
16391599|NCT04038489|Experimental|Tamoxifen and Aspirin with AC-T Chemotherapy|AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor.
16391600|NCT04038476|Other|Standard monitoring|"When assigned to the group Standard monitoring:
~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. The examiner (doctor or physicians involved in the study) are blinded to the transcutaneous CO2 measurement. An adjustment of the sedation management therefore takes place on the basis of the monitoring measures mentioned above. Transcutaneous CO2 monitoring is recorded in the background (Excel table of all registered values) and also monitored by the sedation assisting nurse and integrated into the standard sedation protocol."
16391601|NCT04038476|Other|Standard monitoring + transcutaneous CO2 monitoring|"When assigned to the group Standard monitoring + transcutaneous CO2 monitoring:
~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. In this group, the values of transcutaneous, continuous CO2 monitoring, including an alarm sound, are accessible to the treating physicians. Moreover, sedation management is adjusted on the basis of transcutaneous CO2 measurement. The above-mentioned measurements of the standard monitoring are carried out as described, in addition there is the the transcutaneous CO2 monitoring."
16391602|NCT04038463|Experimental|Early Follicular Phase (EFP)|The group will engage in the Resistance Training intervention on the fourth day of their menstrual cycle, which will correlate with the middle of the early follicular phase (EFP).
16391603|NCT04038463|Experimental|Late Follicular Phase (LFP)|The group will engage in the Resistance Training intervention on the eleventh day of their menstrual cycle, which will correlate with the middle of the late follicular phase (LFP).
16391604|NCT04038463|Experimental|Early Luteal Phase (ELP)|The group will engage in the Resistance Training intervention on the eighteenth of their menstrual cycle, which will correlate with the middle of the early luteal phase (ELP).
16391605|NCT04038463|Experimental|Late Luteal Phase (LLP)|The group will engage in the Resistance Training intervention on the twenty-fifth day of their menstrual cycle, which will correlate with the middle of the late luteal phase (LLP).
16391606|NCT04038450||Practicing Physical Therapists|licensed physical therapists currently practicing
16391607|NCT04038450||Student Physical Therapists|students currently enrolled in DPT program
16391608|NCT04038437|Experimental|CPX-351 and Venetoclax|CPX-351 and Venetoclax will be administered over 28 day cycles
16391609|NCT04038424|Experimental|Study group|The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
16391610|NCT04038424|No Intervention|Control group|The control group (n = 30) will receive only the Routine Hospital Management (RHM) and the department conventional rehabilitation activity.
16391611|NCT04038411|Experimental|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 Antibody: 240mg, d1, Chidamide: 20mg, twice a week, Lenalidomide: 25mg, d1-14 Etoposide:100mg/m2, d1-3 and 21 days made one treatment cycle.
16391612|NCT04038398|Other|FiO2 : 100% - 50% - 21%|see above
16391614|NCT04038385|Experimental|Intervention|This group will receive routine services provided by WIC and an intervention that will combine behaviorally-focused nutrition education with 1) the establishment of a WIC-based farmers' market (implemented in 2019 during the WIC Farmers' Market Nutrition Program voucher issuance period [June 19 to August 19]), and 2) monthly trips to an area farmers' market and local supermarket (between September 1, 2019 and November 30, 2019 [the end of the local growing season]).
16391615|NCT04038385|No Intervention|Control|This group will receive routine services provided by WIC only.
16391616|NCT04038359|Experimental|Duvelisib, Continuous and Intermittent Dosing|Duvelisib 25 mg BID continuously for 10 weeks, followed by 25 mg BID dosed two weeks on and two weeks off of each subsequent 4-week cycles.
16391617|NCT04038359|Experimental|Duvelisib, Intermittent Dosing|Duvelisib 25 mg BID dosed two weeks on and two weeks off.
16391618|NCT04038346|Experimental|NSAID|Naproxen at weight based standard dose given bid daily until symptoms resolve
16391619|NCT04038346|Active Comparator|Acetaminophen|Acetaminophen at weight based standard dose given qid until symptoms resolve
16391620|NCT04038346|Experimental|NSAID first, then Acetaminophen|Naproxen at weight based standard dose given bid for one week, then acetaminophen at weight based standard dose given qid until symptoms resolve
16391621|NCT04038346|No Intervention|Standard Care|Symptom observation only
16391622|NCT04038333||Children|Interviewees are parents or grandparents of children aged between 6 to 59 months.
16391623|NCT04038333||Elderly|Interviewees are the elderly aged 60 years old or above.
16391624|NCT04038333||Chronic disease patients|Interviewees are adult patients with chronic diseases aged below 60 years old.
16391625|NCT04038333||Vaccination and health care personnel|Interviewees are vaccination and health care personnel in each study site.
16391626|NCT04038320||HCV infected patients|All HCV infected confirmed by HCV RNA,
16391627|NCT04038307|Placebo Comparator|control|will receive 100 ml of saline
16391628|NCT04038307|Experimental|paracetamol group|will receive 1gm paracetamol (100ml)
16391629|NCT04038294|Experimental|Protein Supplementation|The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
16391630|NCT04038294|Placebo Comparator|Placebo Supplementation|Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).
16391631|NCT04038268||Patients|Adults and children, males and females, with IgE mediated pollen, house dust mites, animal dander and moulds respiratory allergy who will initiate aeroallergen AIT, either SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice
16391632|NCT04038268||Prescribers|Doctors who are currently prescribing AIT as part of their regular clinical practice
16391633|NCT04038255|Active Comparator|Usual Care|Participants in this group will receive a brief advice to quit smoking, 6-week supplies of nicotine replacement therapy (NRT), and self-help materials to quit smoking.
16391634|NCT04038255|Experimental|Craving-to-Quit app|"Participants in this group will receive one in-person orientation session, 6-week supply of NRT, the Craving-to-Quit app, and two brief follow-up phone calls."
16391635|NCT04038255|Experimental|In-person Mindfulness Training|Participants in this group will receive twice weekly group sessions (eight total during 4 weeks) that were manualized and delivered by instructors experienced in Mindfulness Training (MT) (a single therapist with >4 years of training in MT).
16391636|NCT04038242|Experimental|Resilience promotion program|Subjects in the intervention group will participate in an eight-session resilience promotion program.
16391637|NCT04038242|No Intervention|Treatment as usual|Treatment as usual for subjects in the control group.
16391638|NCT04038229|No Intervention|Standard of care|Prospective derived data from children and adolescents undergoing spinal fusion due to idiopathic scoliosis
16391639|NCT04038229|Experimental|Enhanced recovery pathway|Children and adolescents undergoing spinal fusion due to idiopathic scoliosis using the pre -per and postoperative enhanced recovery protocol
16391640|NCT04038216||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
16391641|NCT04038216||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures.
16391642|NCT04038203||Neonates with UAC placement|Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
16391643|NCT04038190|Experimental|Behavioral Activation Course|Behavioral activation course condition administered in a college freshman orientation seminar
16391644|NCT04038190|No Intervention|Standard Orientation Course|Standard freshman orientation seminar course condition
16391645|NCT04038177|Experimental|Superset strength training|This is the experimental group that performs strength training with sets and rest intervals programmed in a superset manner
16391646|NCT04038177|Active Comparator|Traditional strength training|This is the comparator group that engages in strength training with sets and rest intervals programmed in accordance with the recommendations from The American College of Sports Medicine
16391647|NCT04038164|Experimental|Dog-Assisted Therapy (DAT) and pharmacological treatment|The DAT program comprised 12 manualized sessions and included two phases: 1) individual intervention (6 sessions) and 2) group activity (6 sessions). Patients participated in weekly sessions for about 3 months. Each session lasted 45 minutes. The groups were formed by 3-4 patients. Sessions included the participation of two certified therapy dogs, two technicians specialized in DAT and a psychologist. Participants in this group were visited by their psychiatrist in order to monitor their adherence to medications.
16391687|NCT04037878|Experimental|TAP block group|Patients in this arm will be given Transversus Abdominal Plane(TAP) block after the induction of anesthesia. They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
16415628|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A&B"|
16391648|NCT04038164|Active Comparator|Treatment as usual (TAU, pharmacological treatment)|Participants received their usual treatment. They were visited by their psychiatrist in order to monitor their adherence and continuation on medications as prescribed. Inclusion and exclusion criteria were the same as for the experimental group. Participants in the TAU group did not receive DAT sessions.
16391649|NCT04038151|Experimental|Condition A: Hybrid Leg|Subject will be trained on use of the experimental device, the Hybrid Leg.
16391650|NCT04038151|Other|Condition B: Passive Leg|Subject will use their currently prescribed home passive prosthesis
16391651|NCT04038138|Experimental|Patient with muscular dystrophy|
16391652|NCT04038125|Other|Ozurdex Implant|Intravitreal injection of Ozurdex implant
16391653|NCT04038112|Other|Method of Levels (MOL)|all participants will be offered intervention
16391654|NCT04038099|Placebo Comparator|Water Based Lubricating Jelly|5ml of Water Based Lubricating Jelly
16391655|NCT04038099|Active Comparator|Lidocaine 2% Jelly|5ml of Lidocaine 2% Jelly
16391656|NCT04038086|Experimental|oral glucose tolerance test|
16391657|NCT04038086|Other|circadian rhythm|
16391658|NCT04038086|Experimental|effect of insulin on peptide transport|
16391659|NCT04038073||ADHD|Attention Deficit/Hyperactivity Disorder
16391660|NCT04038060|Experimental|WhatsApp Group|Participants will be assigned to participate in a WhatsApp Group
16391661|NCT04038060|Experimental|2-way SMS|Participants will be assigned to receive weekly 2-way SMS initiated by the study team
16391662|NCT04038060|Experimental|2-way SMS and monthly counseling sessions|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions
16391663|NCT04038060|Experimental|2-way SMS and drug level feedback|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback
16391664|NCT04038060|Experimental|WhatsApp Group and monthly counseling sessions|Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions
16391665|NCT04038060|Experimental|WhatsApp Group and drug level feedback|Participants will be assigned to participate in a WhatsApp Group and drug level feedback
16391666|NCT04038047||Core|Cystic Fibrosis patients prescribed elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).
16391667|NCT04038034|Placebo Comparator|group A|35 patients treated with pressure lowering drugs and placebo
16391668|NCT04038034|Experimental|group B|35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
16391669|NCT04038021|Experimental|PEth-based CM|PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result. They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row. There is a cap at $100 for each negative result.
16391670|NCT04038021|Active Comparator|Non-contingent Control|Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol. Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
16391671|NCT04038008|Other|Sequence AB|13 subjects assigned to the sequence AB will receive a single 200 mg dose of test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 1 and a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
16391672|NCT04038008|Other|Sequence BA|13 subjects assigned to the sequence BA will receive a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in Period 1 and test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
16391673|NCT04037982|Experimental|LPD|In this group, patients will undergo laparoscopic pancreaticoduodenectomy.
16391674|NCT04037982|Active Comparator|OPD|In this group, patients will undergo open pancreaticoduodenectomy.
16391675|NCT04037969|Experimental|Nesofilcon A/Delefilcon A|Nesofilcon A was worn in right eye and delefilcon A worn in the left eye.
16391676|NCT04037969|Experimental|Delefilcon A/Nesofilcon A|Delefilcon A was worn in right eye and Nesofilcon A worn in the left eye.
16391677|NCT04037956|Experimental|Tubeless NOSES|Patients receive Tubeless NOSES.
16391678|NCT04037956|Active Comparator|traditional laparoscopic|Patients receive traditional laparoscopic radical resection.
16391679|NCT04037943|Experimental|Low-dose group|Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.
16391680|NCT04037943|Experimental|High-dose group|High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.
16391681|NCT04037943|No Intervention|Control group|Control group will received non-edible gifts during the study period of 6 months.
16391682|NCT04037917|Experimental|Synthetic Tissue Substitute|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
16391683|NCT04037904||H. pylori negative group|Subjects who have not have H. pylori infection, and had not receive H. pylori eradication
16391684|NCT04037904||H. pylorieradicated group|Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication
16391685|NCT04037891|Experimental|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
16391750|NCT04037514|Experimental|Paracetamol|Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days
16391688|NCT04037878|Experimental|Local infiltration|Patients in this arm will be given local and intraperitoneal infiltration of local anesthetic before closure.They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
16391689|NCT04037878|Other|Control group|These patients will be given post operative analgesia in the form of patient controlled intravenous analgesia(PCIA) using tramadol. Neither local infiltration nor TAP block will be administered
16391690|NCT04037865|Experimental|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
16391691|NCT04037865|Experimental|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
16391692|NCT04037865|Experimental|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
16391693|NCT04037865|Experimental|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
16391694|NCT04037852|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
16391695|NCT04037852|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
16391696|NCT04037852|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
16391697|NCT04037826|Experimental|L. reuteri Gastrus|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
16391698|NCT04037826|Placebo Comparator|Placebo|Placebo chewable tablets
16391699|NCT04037813||Laparoscopic tubal occlusion|54 patients will undergo laparoscopic tubal occlusion.
16391700|NCT04037813||Hysteroscopic tubal occlusion|54 patients will undergo hysteroscopic tubal occlusion.
16391701|NCT04037800|Experimental|SFUR-RARP|Patients in which RARP with sustainable functional urethral reconstruction (SFUR) is performed.
16391702|NCT04037800|Active Comparator|Standard RARP|Patients in which standard RARP is performed.
16391703|NCT04037787|No Intervention|Usual care|Perioperative care for colorectal cancer cancer is managed according to current hospital clinical practice.
16391704|NCT04037787|Experimental|ERAS protocol|Perioperative care for colorectal cancer surgery is managed according to ERAS protocol.
16391705|NCT04037774|Active Comparator|dex 5microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 5micrograms of dexmedetomidine.
16391706|NCT04037774|Active Comparator|dex 10microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 10micrograms of dexmedetomidine.
16391707|NCT04037774|Placebo Comparator|placebo|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of placebo.
16391708|NCT04037748|Experimental|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
16391709|NCT04037748|Experimental|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
16391710|NCT04037735|Experimental|ATTUNE|Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
16391711|NCT04037735|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
16391712|NCT04037722|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
16391713|NCT04037722|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
16391714|NCT04037722|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
16391715|NCT04037709|Placebo Comparator|scaling and root planing (SRP) + PDT placebo|"17 patients will receive periodontal treatment (scaling and root planing - SRP) with universal curettes and ultrasound depending on their needs. The SRP will be done in one session. Periodontal treatment will be performed by only one experienced researcher, who will not do the periodontal exams. Periodontal reassessment will be performed after 7 and 21 days.
~The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application."
16391716|NCT04037709|Experimental|scaling and root planing (SRP) + PDT|"17 patients will receive the same scaling and root planing treatment that placebo group.
~However the PDT will be done using methylene blue 0.005% - Chimiolux 5, DMC - purified water and methylene blue.The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pocket."
16391717|NCT04037696|Experimental|Experimental group|The experimental group will receive individual face-to-face brief MI (about 5 minutes) on a health-related lifestyle practice. The experimental group will then receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up.
16391751|NCT04037514|Active Comparator|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days
16391718|NCT04037696|Other|Control group|The control group will be given general brief advice and receive a self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
16391719|NCT04037683||MOLI participants pre IOL|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) after recruitment to MOLI RCT but prior to the start of the induction of labour (IOL) process
16391720|NCT04037683||MOLI participants post IOL (misoprostol/misoprostol)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/misoprostol Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
16391721|NCT04037683||MOLI participants post IOL (misoprostol/oxytocin)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
16391722|NCT04037683||Staff focus group pre and during MOLI recruitment|"A focus group in each of the 2 recruitment sites before the start of the MOLI trial (n=2) A focus group in each of the 2 recruitment sites and with each cadre of staff during the MOLI trial (n=8)
~Research assistants
~Residents
~Consultants
~Midwives"
16391723|NCT04037670|Experimental|SASI bypass|Patients with super obesity underwent SASI bypass
16391724|NCT04037657|Experimental|HSK3486|0.288 mg/kg ，0.432 mg/kg ，0.540 mg/kg ，0.648 mg/kg，0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
16391725|NCT04037657|Active Comparator|Propofol|2.5 mg propofol
16391726|NCT04037644|Experimental|Albumin|fluid loading with 200 mL of 4% albumin over a 10' interval
16391727|NCT04037644|Active Comparator|Ringer Lactate|fluid loading with 5 mL/kg actual body weight of Ringer Lactate over a 10' interval
16391728|NCT04037631||Patients without clinically significant age-related cataract|
16391729|NCT04037618|Experimental|[14C]-EYP001a|[14C]-EYP001a dose A containing 100 μCi radioactivity
16391730|NCT04037605|Experimental|Control Condition|"8 am - Saline Solution for Injection
~10 am - Placebo oral capsule
~1 pm - Saline Solution for Injection
~4 pm - Placebo oral capsule & start hourly blood sampling
~7 pm- Gonadorelin (GnRH) and Corticorelin (CRH) injections
~9 pm - Saline Solution for Injection & last blood sample"
16391731|NCT04037605|Experimental|Hypothalamic Condition|"8 am -Ganirelix
~10 am - Placebo oral capsule
~1 pm - Dexamethasone injection
~4 pm- Placebo oral capsule and start of hourly blood sampling
~7 pm - GnRH and CRH injections
~9 pm - Saline Solution for Injection and last sample blood sample"
16391732|NCT04037605|Experimental|Pituitary Condition|"8 am - Saline Solution for Injection
~10 am - Ketoconazole Pill
~1 pm - Saline Solution for Injection
~4 pm - Ketoconazole Pill & start of hourly blood sampling
~7 pm - GnRH and CRH
~9 pm - Hydrocortisone Injection and last blood sample"
16391733|NCT04037605|Experimental|Adrenal/Testis Condition|"10 pm - Ganirelix Injection & Dexamethasone Pills (night before)
~8 am - Start of hourly blood sampling
~10 am - Dexamethasone Pills
~11 am - Last hourly blood sample taken
~11:30 am - Start of blood sampling every 10 minutes
~1 pm - Recombinant Human Luteinizing Hormone (rhLH) Injection
~3 pm - rhLH Injection
~5 pm - rhLH Injection
~5 pm - Cosyntropin Injectable product
~7 pm - GnRH and CRH Injections
~9 pm - Last blood sample"
16391734|NCT04037592|Experimental|Active standardized iTBS-DMPFC|This active group will receive standardized dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
16391735|NCT04037592|Experimental|Active high-dosage iTBS-DMPFC|This active group will receive high dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
16391736|NCT04037592|Sham Comparator|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Patients in the sham group will receive the same standardized or high-dosage iTBS performing by a sham coil
16391737|NCT04037579||Down Syndrome Cordoba Association|The participant will answer a questionnaire related to social skills and physical activity
16391738|NCT04037579||Down Syndrome Granada Association|The participant will answer a questionnaire related to social skills and physical activity
16391739|NCT04037579||Down Syndrome Malaga Association|The participant will answer a questionnaire related to social skills and physical activity
16391740|NCT04037579||Observers in Cordoba|Observers from Cordoba, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
16391741|NCT04037579||Observers in Granada|Observers from Granada, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
16391742|NCT04037579||Observers in Malaga|Observers from Malaga, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
16391743|NCT04037566|Experimental|XYF19 CAR-T cell|"One arm study consisting of 3 + 3 dose escalation study design followed by dose expansion phase at determined MTD."
16391744|NCT04037553||Group 1|Patients underwent right ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the left) was applied to the patients and ICP values were documented following 3 respiration cycles.
16391745|NCT04037553||Group 2|Patients underwent left ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the right) was applied to the patients and ICP values were documented following 3 respiration cycles.
16391746|NCT04037553||Group 3|Patients underwent left head and neck surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, gel pillow with the height of 4,5 cm was placed under the shoulders of patients to extend the neck. Following 3 respiration cycles, the ICPs were noted. Then, right or left lateral neck rotation was applied depending on the operation side (approximately 60-70 degree to the opposite site). After 3 respiration cycles, ICPs were documented again.
16391747|NCT04037540|Experimental|Operational approach|The patients enrolled in this arm underwent surgical treatment of the Jones fracture.
16391748|NCT04037540|Experimental|Conservative approach|The patients enrolled in this arm were treated conservatively, using fixation of the injured extremity.
16391749|NCT04037527|Experimental|Neoadjuvant Chemotherapy Plus Radiation Therapy|Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.
16391754|NCT04037488||Cohort: ADT patients|"All enrolled patient data entered in single group cohort. All patient who started androgen deprivation therapy for prostate cancer can included this cohort by following inclusion and exclusion criteria. We do not planned any intervention on this cohort. We measuring changes of body composition by Inbody 320 in the planned follow-up period.
~We planned sub-group analysis for timing of intervention (Intervention 1) , ADT type(Intervention 2), LHRH agonist type(Intervention 3), patients age(Intervention 4), initial PSA level (Intervention 5) and Gleason Grade Group (Intervention 6)."
16391755|NCT04037475|Placebo Comparator|Control (placebo)|The patients will receive an agent with the same vehicle as methylene blue to mimic irrigation with the photosensitizer and the laser will be switched off at the time of application. The placebo PDT procedures will be performed on the lesion: Application of methylene blue placebo with a carpule syringe and needle (with stop and without bevel) inside the lesions; 1 minute of pre-irradiation will be expected. The irradiations will be performed with the same device positioned in the same way and at the same time of application, however, the laser will be turned off. The beep sound will be recorded and turned on during application to blind treatment to the patient. The patient will receive a catheter with acyclovir cream and will be advised to spread on the lesions four times a day for 7 days, which will be their return for reevaluation. It will be washed in abundance with saline (saline solution) until the total removal of the placebo from the photosensitizer.
16391756|NCT04037475|Experimental|experimental group|Patients will be treated with photodynamic therapy and will receive a placebo ointment simulating acyclovir cream. If the lesions are in the vesicle phase, they will be ruptured with a sterile needle. The methylene blue solution at 0.005% concentration will be gently placed on the lesions. Application of methylene blue on the lesions.1 minute of pre-irradiation will be expected. The irradiations will be performed with the Laser Duo® with a wavelength of 660 nm, with a power of 100 mW(milliwatts), the energy density of 300 J / cm², with the energy of 3 J (joules) in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each lesion with energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. Patients will receive a tube with a placebo cream simulating aciclovir and the same will be advised to spread the cream 4 times per day for 7 days.
16391757|NCT04037462|Experimental|Lead in Dexamethasone followed by immunotherapy|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
16391758|NCT04037449|Experimental|TAP block|Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
16391759|NCT04037449|Active Comparator|Conventional analgesia|Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
16391760|NCT04037436|Experimental|Intervention|"At regular intervals (the steps) one cluster (i.e., one site) is randomised to cross from the control to the intervention under evaluation. This process continues until all clusters have crossed over to be exposed to the intervention. At the end of the study there will be a period when all clusters are exposed. Four sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart."
16391761|NCT04037436|Other|Control|Each cluster contributes observations under both control and intervention observation periods.
16391762|NCT04037423||PE patients treated with CDT|Acute pulmonary embolism patients undergoing catheter-directed embolectomy.
16391763|NCT04037397|Active Comparator|Antiarrhythmic Medications|Patients randomized to the antiarrhythmic drug group are administered medications approved for treatment of AF by the regulatory bodies of each participating country. The selection of antiarrhythmic drugs and dosages is left to the discretion of the investigator, and will follow the AHA/ACC/HRS general guidelines
16391764|NCT04037397|Active Comparator|Radio Frequency Catheter Ablation|Patients randomized to radiofrequency catheter ablation will undergo isolation of the pulmonary veins with confirmation of entrance block into each vein. The CARTO TM(Biosense Webster, CA) system will be used to reconstruct the atrial geometry and assist for mapping and ablation. Ablation will be performed using approved ablation devices (Biosense Webster, CA).
16391765|NCT04037384|Active Comparator|Eye Yoga group|Eye yoga exercises
16391766|NCT04037384|Placebo Comparator|Reading Group|Passive reading
16391767|NCT04037358|Experimental|Radium-223 and SABR|First radium-223 infusion will be within two weeks of SABR
16391768|NCT04037358|Active Comparator|SABR|SABR(1-5 fractions) will be administered for all men
16391769|NCT04037345|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
16391770|NCT04037345|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
16391771|NCT04037345|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
16391772|NCT04037332||Pre-RAS roll-out . Group I|I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
16391773|NCT04037332||Post-RAS roll-out - Group II|II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
16391774|NCT04037332||Post-RAS roll-out - Group III|III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
16391775|NCT04037332||Post-RAS roll-out - Group IV|IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
16391776|NCT04037319||Main cohort|Will undergo surgery for colorectal cancer with curative intent as planned by local cancer multidisciplinary team.
16415629|NCT03870282|Experimental|"9h 15m Goal | Incentive A"|
16391777|NCT04037306|Active Comparator|Rapid Feedback|Participants received daily feedback on both fiber intake and stool butyrate measurements.
16391778|NCT04037306|Active Comparator|Delayed Feedback|Participants received daily feedback on fiber intake and one-time feedback on stool butyrate measurements at the end of the study period.
16391779|NCT04037280|Experimental|Isometric strenghtening 1|once a day (1RI): patients in this group will have to play 20 tonic contractions of Pelvic Floor Muscle with a duration of 5 seconds each, performed in supine position), in sitting position and in standing position.
16391780|NCT04037280|Experimental|Isometric strenghtening 2|twice a day (2RI): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
16391781|NCT04037280|Experimental|Functional strenghtening 1|once a day (1RF): patients in this group will have to play 10 times the postural passage from supine position to sitting position on a bed and 10 times the postural passage from sitting position to erect position (STS), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional act. In sequence, starting from erect position, they will have to play 10 trunk flexion bending their knees (as to pick up an object on the ground), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional movement.
16391782|NCT04037280|Experimental|Functional strenghtening 2|twice a day (2RF): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
16391783|NCT04037267|Experimental|Endoscopic Treatment|Endoscopy was performed using a rigid endoscope. The hematoma was removed by a technique using irrigation and aspiration. The ventricular drainage catheter was placed on the surgical side. Six hours after surgery, we administered 20,000 U urokinase with 5 ml saline every 8 hours through the catheter and the catheter was closed for 1 hour to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
16391784|NCT04037267|Active Comparator|EVD Treatment|The surgeons used a soft catheter to puncture in depth of about 5 cm. The next step was to fix the drainage catheter. Postoperative CT was done immediately to confirm positioning of the soft catheter and stability of the hematoma. Six hours or more after catheter placement, we administered 20,000 U urokinase with 5 ml saline every 8 hours and the catheter was closed for 1 h to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
16391785|NCT04037254|Experimental|Phase I (niraparib, GnRH, IMRT)|Patients receive niraparib PO QD and receive standard of care GnRH agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.
16391786|NCT04037254|Active Comparator|Phase II, Arm I (GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
16391787|NCT04037254|Experimental|Phase II, Arm II (niraparib, GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
16391788|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel|"Patients in the anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
16391789|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|"Patients in the anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
16391790|NCT04037241|Active Comparator|2nd Line: Gemcitabine /nab paclitaxel Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
16391791|NCT04037241|Active Comparator|2nd Line: NLIR + FU/FA Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
16391815|NCT04037046|Active Comparator|Screening HCV and CCR with FOT at primary care centers|Patients assigned to the strategy 2 will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
16391875|NCT04036630|Sham Comparator|sham tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391792|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
16391793|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
16391794|NCT04037241|Active Comparator|3rd Line: NLIR+FU/FA Alone|Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
16391795|NCT04037241|Active Comparator|3rd Line: Capecitabine Alone|Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
16391796|NCT04037228||KneeAlign 2|Those of the group will be adopt KneeAlign 2: accelerometer-based navigation system at total knee arthroplasty.
16391798|NCT04037202|Experimental|Study Group|"The first session of the foot massage was performed after mothers were taken to the postpartum service and after the effect of the first analgesia had elapsed (4-6 hours after birth).
~The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported."
16391799|NCT04037202|No Intervention|Control Group|Routine procedures were applied and VAS was repeated at the same time periodical as the study group mothers (0th, 20th and 50th minute) and after 20-24 hours (before discharge), at the same time intervals (0th, 20th and 50th minute) pain status was measured by using VAS and PCS was administered for the last time and analgesics administered were recorded on the DFC.
16391800|NCT04037176|Active Comparator|Omalizumab|"Omalizumab is a sterile solution in a prefilled syring for subcutaneous injection. The syrings contains 75 mg or 150 mg omalizumab.
~75 patients will have Omalizumab in doses depending of body weight and IgE every 2. or 4. week for 6 month Omalizumab is administered subcutaneously"
16391801|NCT04037176|Placebo Comparator|Placebo|"Placebo contains sodium chloride 0,9 % in a prefilled syring for subcutaneous injection.
~25 patients will have placebo depending of the body weight and IgE every 2. or 4. week in 3 month. They will subsequently get Omalizumab for 3 month if nonresponders.
~Placebo is administered subcutaneously"
16391802|NCT04037163||CCTA-FFR|Patients who underwent CCTA within 90 days before FFR measurement will be included in the present study.
16391803|NCT04037124||Cervical procedure abandoned|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is abandoned due to intraoperatively reported lymph node matestasis. Patient is referred for primary (chemo)radiation.
16391804|NCT04037124||Cervical procedure completed|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is completed. Patient is referred for adjuvant chemoradiation.
16391805|NCT04037111|Experimental|drug treatment and active VNS|At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
16391806|NCT04037111|Sham Comparator|drug treatment and sham VNS|It received oxacillin oxalate tablets and sham VNS for 2 months.
16391807|NCT04037111|Other|drug treatment|The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
16391808|NCT04037098|Experimental|Magnesium|Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
16391809|NCT04037098|Placebo Comparator|Control|2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
16391810|NCT04037085|Experimental|Ketamine|Ketamine - IV after cord clamping; IV infusion for 12 hours OR in the weaning population IV Ketamine infusion for 12 hours in the Montefiore CTRC
16391811|NCT04037072|Experimental|Mitomycin C|Cotton swab or strip of 2x2 cotton gauze soaked with 0.4mg/mL Mitomycin C
16391812|NCT04037072|Placebo Comparator|Control|Cotton swab or strip of 2x2 cotton gauze soaked with Normal saline
16391814|NCT04037046|Experimental|Screening HCV with DBS at primary care centers|Patients assigned to the strategy 1 will receive an invitation letter for HCV screening with DBS at the primary care center to be performed by the general practitioner
16393259|NCT04026828||Control Group|Both periodontal and medically healthy volunteers.
16391816|NCT04037046|Active Comparator|Self-testing at home for screening HCV and CCR|Patients assigned to the strategy 3 will receive an invitation letter for self-testing at home for HCV screening with DBS, and CCR screening with FOT
16391817|NCT04037020||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa.
16391818|NCT04037007|Active Comparator|Fistulotomy - High experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists.
16391819|NCT04037007|Active Comparator|Fistulotomy - Low experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists.
16391820|NCT04037007|Active Comparator|Conventional (guidewire) cannulation- High experience|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists.
16391821|NCT04037007|Active Comparator|Conventional (guidewire) cannulation - Low experienced.|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.
16391822|NCT04036994|Active Comparator|Experimental: Treatment group|
16391823|NCT04036994|Sham Comparator|Sham Comparator: Control group|
16391824|NCT04036981||Brachialis|Targeted muscle for BoNT A injection
16391825|NCT04036981||Biceps|Targeted muscle for BoNT A injection
16391826|NCT04036981||Brachialis plus Brachioradialis|Targeted muscles for BoNT A injection
16391827|NCT04036968|Experimental|5 outpatient sessions|This is a within-subject study so all session procedures will be identical, however the specific medications provided as part of the double-blinded study medications may change during each session. During each session, which will last up to 8 hours a day and will be conducted on an outpatient basis, participants will be asked to complete standardized pain testing procedures, as well as questionnaires about how participants are feeling and to complete cognitive tasks.
16391828|NCT04036955|Experimental|intervention group|"The INFOSA-DEM programme consists of five, 90-minute informational/training sessions delivered consecutively over one week. Morning or afternoon groups are offered depending on the caregiver's availability. Programme content was developed for use in small groups of 6-8 caregivers. Topics covered in the sessions include basic concepts in dementia and specific issues such as nutrition, rest, medication, physical and cognitive changes, management of behavioural symptoms, affective problems in the patient and informal caregiver, verbal and non-verbal communication techniques, caregiver self-care and information on available resources and community services.
~The sessions are conducted using audio-visual material to facilitate understanding of the content and to encourage active participation among caregivers when talking about their experiences."
16391829|NCT04036955|No Intervention|usual care|Caregivers in the Group control received usual care in the centres where the follow-up was carried out. This consisted of annual or quarterly consultations with a health professional (GP, geriatrician or neurologist) and, depending on the health centre, a nurse and social worker.Currently, there is no homogenous protocol for all care centres for the patient with high levels of cognitive impairment and dependency.
16391830|NCT04036942|Active Comparator|Hybrid argon plasma.|"After diagnostic endoscopy investigators will proceed to use argon plasma probe for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will use the jet included in the argon plasma probe with effect 20 to 40 system for the injection of the background submucosa in the marking area, applying 0.9% saline solution with methylene blue, to achieve adequate Submucosal elevation for application or argon plasma with high voltages (100 watts, 1.5 liters / min) using forced coagulation mode, applying plasma argon to 1cm above the Z line in the esophageal mucosa and 2cm below it towards the gastric mucosa, argon will be applied until a carbonization effect of the mucosa is achieved, once the application of the therapy is performed mucosal lavage and immersion technique to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications"
16391831|NCT04036942|Active Comparator|Band mucosectomy|After diagnostic endoscopy investigators will proceed to use the tip of a polypectomy snare for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will perform submucosal elevation with the injection of 0.9% saline with carmine indigo and adrenaline 1:10000, after adequate submucosal elevation investigators will proceed with the help of a band ligation cap to suction and release the elastic band in the previously marked and elevated tissue, proceeding to resect the previously ligated tissue with polypectomy loop below the elastic band with forced coagulation (Effect 2, 40 W), until the marked mucosa is completely resected (average used of 5 elastic bands, reviewing the work area for complications like bleeding or perforation.
16391834|NCT04036916|Experimental|Virtual Reality Training (Experimental)|Participants will receive multi-modal sensorimotor training interventions, including activities training the vestibular system, oculomotor control and visual perception, neuromotor control and strengthening of the cervical spine, postural control/ balance exercises, and exercises integrating the use of multiple types of sensory information for controlled motor output, including speed and accuracy. Novel headset virtual reality (VR) games/activities; compliant balance surfaces; resistance bands/weight; and biofeedback devices will be utilized to deliver the training intervention. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 12 sessions over 6 weeks.
16391835|NCT04036916|No Intervention|No Virtual Reality Training (Control)|True control.
16391836|NCT04036890|Experimental|2% minocycline hydrochloride controlled-delivery system (MHS)|Mechanical ultrasonic/ hand instrumentation and subsequent administration of MHS on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
16391837|NCT04036890|Placebo Comparator|Placebo|Mechanical ultrasonic/ hand instrumentation and subsequent administration of a placebo gel on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
16391838|NCT04036851|No Intervention|Local standard of care|Women receive integrated antenatal and HIV services during pregnancy and are referred to general adult HIV services after delivery; no standardized peer support groups exist for this patient population.
16391839|NCT04036851|Experimental|Peer support intervention|Women will be invited to attend monthly peer support groups during pregnancy and postpartum, separate from any routine health services.
16391840|NCT04036838|Experimental|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
16391841|NCT04036825|Experimental|Liquid Nutritional Supplement from Hospital Product|This group received liquid nutritional supplement from hospital product. The product is in a form of low lactose milk ready to drink with volume 200 ml and will be given 2 times daily for 14 days. This product is consist of 1.017 kcal/ml, 10 vitamin and 9 mineral
16391842|NCT04036825|Placebo Comparator|Placebo|This group received standard liquid nutritional supplement as a placebo. Placebo will be given 2 times daily for 14 days
16391843|NCT04036812|Experimental|Superficial cervical plexus block group|
16391844|NCT04036812|Sham Comparator|Control group|
16391845|NCT04036799||Hypertrophic Cardiomyopathy|
16391846|NCT04036786|Experimental|study gorup|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
16391847|NCT04036786|Other|control group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
16391848|NCT04036773|Experimental|Intervention Group|
16391849|NCT04036773|No Intervention|Control Group|
16391850|NCT04036760||Standard of Care transitional care coordination|
16391851|NCT04036760||Research transitional care coordination|
16391852|NCT04036734|Active Comparator|Transverse Ultrasound Orientation|Transverse placement of ultrasound to long axis of target lower limb vein
16391853|NCT04036734|Experimental|Longitudinal Ultrasound Orientation|Longitudinal placement of ultrasound to long axis of target lower limb vein
16391854|NCT04036721|Experimental|ARM A - PROLONGED|induction dose 1-4mg/kg of prednisone, prednisone 60mg q24h for 2-4wks, tapering not faster than 10mg each 14d, maintenance dose 10mg q24h for 8wks, withdraw of treatment during 4wks, summary of treatment time not shorter than 12-24wks.
16391855|NCT04036721|Active Comparator|ARM B - FAST REDUCTION|induction dose 1-4mg/kg of prednisone, prednisone 30-60 mg q24h, tapering not faster than 10mg each 7d, summary of treatment time 6-12wks.
16391856|NCT04036708|Experimental|MISC and WTM|Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
16391857|NCT04036708|Active Comparator|WTM only|WTM trainings only (recommended standard of care) bi-weekly for 12 months.
16391858|NCT04036695|Experimental|Reveal LINQ insertable cardiac monitoring system|In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
16391859|NCT04036682|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|CLN-081 BID in single patient dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations that either have received or never received prior EGFR TKIs.
16391860|NCT04036682|Experimental|Phase 1 Dose Escalation (Rolling Six)|CLN-081 QD or BID in Rolling Six dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations.
16391861|NCT04036682|Experimental|Phase 1 Dose Expansion(s)|CLN-081 BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Rolling Six cohorts.
16391862|NCT04036682|Experimental|Phase 2a Dose Expansion(s)|CLN-081 QD or BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Phase 1 Dose Escalation cohorts.
16391863|NCT04036669||RA patients|RA patients ( N=80; BMI= 26.4± 3.96 ) Eighty patients diagnosed with Rheumatoid arthritis according to American Rheumatology Association criteria and radiographic analysis for at least 10 years previously were randomly involved in this study
16391864|NCT04036669||Healthy control|A healthy control group ( N=80; BMI=22.3± 1.85) eighty age and sex-matched healthy controls were included in the study following the assignment of informed consent.
16391865|NCT04036656|Experimental|Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg|Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.
16391866|NCT04036656|Experimental|Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg|Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.
16391867|NCT04036656|Experimental|Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg|Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.
16391868|NCT04036656|Experimental|Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg|Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.
16391869|NCT04036656|Experimental|Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg|Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.
16391870|NCT04036656|Experimental|Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg|Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.
16391871|NCT04036656|Experimental|Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg|Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.
16391872|NCT04036656|Experimental|Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg|Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.
16391873|NCT04036643|Experimental|patient with rectal cancer|Patient with rectal cancer treated by neoadjuvant chemo-radiation therapy with clinical complete response
16391874|NCT04036630|Experimental|2kHz tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16393713|NCT04023552|Placebo Comparator|Placebo|Monthly subcutaneous injections.
16391876|NCT04036630|Experimental|2kHz tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391877|NCT04036630|Sham Comparator|sham tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391878|NCT04036630|Experimental|2kHz tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391879|NCT04036630|Sham Comparator|sham tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391880|NCT04036630|Experimental|env tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391881|NCT04036630|Active Comparator|time-reversed env-tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391882|NCT04036630|Sham Comparator|sham tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
16391883|NCT04036617|Experimental|NaQuinate|Initial SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150 mg
16391884|NCT04036617|Experimental|Placebo|Initial SAD cohorts will receive 1 placebo dose between 10-150 mg . MAD cohorts will receive 7 days placebo dosing between 70-150 mg
16391885|NCT04036604|Experimental|Group of pelvic floor exercise|Group of pelvic floor exercise include 47 elderly people which contains contraction and repetition of pelvic floor muscle exercises during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.
16391886|NCT04036604|No Intervention|Group of pelvic floor education|Group of pelvic floor education include 47 elderly people which contains anatomy of pelvic floor and dysfunction during once a week for 8 weeks performed by an expert pelvic health physiotherapist.
16391887|NCT04036591||Children under 24 months with ARIS|
16391888|NCT04036578|Other|Pelvic Floor Dysfunction With and Without POP|group 1(Pelvic Floor Dysfunction Without POP Stage I~II) and group 2(Pelvic Floor Dysfunction With POP Stage I~II)
16391889|NCT04036565||The experimental group|The first post-test measurements were taken right after the participants completed the sunlight therapy (two to four weeks after the start of the intervention), and the second post-test measurements were taken one month after the intervention was completed (six to eight weeks after the start of the intervention).
16391890|NCT04036565||The control group|Standard care.The first and second post-test measurements were taken two and six weeks, respectively, after they started receiving standard care.
16391891|NCT04036539|Placebo Comparator|Control (placebo)|Patients in Control will receive the photobiomodulation placebo,application, but with the laser off. Procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described: Simulations will be performed with the same laser.This will require 10 seconds of application simulation per point. As 10 points will be simulated, it will take 100 seconds for this simulation.5 points lingual and 5 points at vestibular
16391892|NCT04036539|Experimental|Experimental:|Experimental: Molar verticalization + PBM (n = 17 + 3) - patients will receive laser treatment (photobiomodulation) in order to modulate orthodontic movement and act on inflammation and pain. The procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described:The irradiations will be performed with the red diode laser ( = 660 nm) with 100 milliwatts output power The power of the device will be 100miliWatts and the wavelength used will be 808 nanometers (± 10nm). The optical fiber diameter of the device is 600 micrometer, therefore a spot (area) of 0.002826 centimeter2. The energy delivered per point will be 1Joule. This will require 10 seconds of application per point. As 10 points will be irradiated, the total application time will be 100 seconds and the total energy delivered will be 10Joule. The energy density will be 25 Joule / cm2 and the power density will be 35.38 Watt / cm2
16391893|NCT04036526|Experimental|Group 1 Drop method|Group 1 will receive vaccine/placebo by drop method.
16391894|NCT04036526|Experimental|Group 2 Nasal actuator|Group 2 will receive vaccine/placebo with nasal actuator.
16391895|NCT04036513|Experimental|MINST|"Usage of magnification loupes, specific thin and delicate tips together with piezoelectric device and specifically designed Hu-Friedy mini five, micro mini five, and after five Gracey curettes under local anaesthesia."
16391896|NCT04036513|Active Comparator|Conventional SRP|Conventional non-surgical mechanical treatment using piezoelectric device (PiezoLED, Kavo) and standard Gracey curettes under local anaesthesia.
16391897|NCT04036500|Experimental|Estradiol|Subjects will take estradiol 1 mg orally after time 0 blood draw. They will get 7 blood draws at hours 0,1,2,3,4,6,8. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. On day 2 of study, subject will take estradiol 1 mg sublingually after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1 of study.
16391898|NCT04036487|Experimental|IH group|Inhalation anesthesia will be given during transaxillary endoscopic breast augmentation.
16391899|NCT04036487|Active Comparator|TIVA group|Total intravenous anesthesia will be given during transaxillary endoscopic breast augmentation.
16391900|NCT04036474|Experimental|Smoking Prevention Education Program|In addition to the lecture on the hazards of smoking, students received the SPEP intervention. The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. The SPEP intervention was delivered to participants in their usual classroom setting, during school hours combined with relevant school subjects such as physical education class. The duration of SPEP intervention took approximately one month.
16391901|NCT04036474|No Intervention|Control|Immediately after the collection of baseline data, students received a one-time lecture on the hazards of smoking by the research assistant.
16391902|NCT04036461|Experimental|Arm 1 (CC-99712 monotherapy)|CC-99712 will be administered via intravenous (IV) infusion once per 21-days on a Once every three weeks (Q3W) schedule, and once per 28-days on a Once every four weeks (Q4W) schedule
16391903|NCT04036461|Experimental|Arm 2 (CC-99712 and BMS-986405 combination)|CC-99712 will be administered as indicated above. BMS-986405 will be administered orally TIW every week during a 21-day cycle (eg, Day 1, Day 3, Day 5, Day 8, Day 10, Day 12, Day 15, Day 17, and Day 19), with 48 hours between each dose with a week
16395125|NCT04013828||Relatives|Close relatives of patients with recurrent high-grade glioma
16391904|NCT04036448||Lenalidomide in IPSS Low-or intermediate-1-risk del population|For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
16391905|NCT04036448||Lenalidomide in Refractory/relapsed rrMC/ Follicular lymphoma population|For the Refractory/relapsed Mantle cell lymphoma (rrMCL), the recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. For the Follicular lymphoma (FL), the recommended starting dose of rituximab is 375 mg/m2 intravenously (IV) every week in Cycle 1 (days 1, 8, 15, and 22) and day 1 of every 28-day cycle for Cycles 2 through 5.
16391906|NCT04036435|Experimental|BMS-986165|
16391907|NCT04036422|Experimental|Computer based exercise group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week to a total of twenty hours over a four week period. In addition to this, these patients will receive half an hour of conventional occupational therapy and half an hour of Rejoyce computerized exercise seven days a week to a total of twenty eight hours over a four weeks period.
16391908|NCT04036422|Active Comparator|Conventional treatment group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week, to a total of twenty hours over a four week period. In addition to this, patients in this group will receive one hourly sessions of conventional occupational therapy seven days a week to a total of twenty eight hours over a four week period.
16391909|NCT04036409|Experimental|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP <120 mm Hg.
16391910|NCT04036409|Active Comparator|Standard Control of Systolic Blood Pressure|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg
16391911|NCT04036396|Active Comparator|Standard of Care|A client-centered assessment of priorities and needs and customized prevention and testing referrals.
16391912|NCT04036396|Experimental|Mobile Enhanced Prevention Support|Standard of Care in addition to a client-centered assessment of priorities and needs and customized prevention and testing referrals, and the Mobile Enhanced Prevention Support Program
16391913|NCT04036383|Active Comparator|vestibüler|vestibular exercise training
16391914|NCT04036383|Experimental|balance training|vestibular exercise training+ balance training with computerized balance system
16391915|NCT04036383|Experimental|square-step|vestibular exercise training+ square step exercise
16391916|NCT04036370|Active Comparator|PECS group|In addition to routine analgesic protocol; before anaesthesia induction; following the PECS I + II block, a continuous infusion catheter will be placed at the PECS II block level under the guidance of USG, and local anesthetic infusion will be started via the catheter at the end of the operation.
16391917|NCT04036370|Sham Comparator|Control group|Peroperative and postoperative routine analgesic protocol will be performed with no additional intervention (block).
16391918|NCT04036344|No Intervention|Control|Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
16391919|NCT04036344|Experimental|Mentee - Preoperative Consult|Mentees are enrolled at preoperative consultation visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
16391920|NCT04036344|Experimental|Mentee - Same Day Surgery|Mentees are enrolled at same day surgery visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
16391921|NCT04036331|Active Comparator|Adolescent Participants|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
16391922|NCT04036331|Experimental|Caregivers of Adolescent Participants|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
16391923|NCT04036331|Experimental|Co-enrollment|This condition is for dyads that are co-enrolled in This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.
16391924|NCT04036305||EDS Patients|Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome
16391925|NCT04036305||Healthy Volunteers|Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome
16391926|NCT04036292|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, 0.12 mg/ML
16391927|NCT04036292|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.6 mg/ML
16391928|NCT04036292|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
16391929|NCT04036253|Active Comparator|Eprex/Erypo|"Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.
~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
16391930|NCT04036253|Experimental|Hemax PFS|"receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.
~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
16391931|NCT04036240|Experimental|Finger feeder|HMF supplementation will be given by finger feeder
16391932|NCT04036240|No Intervention|Control|HMF supplementation will be given by mother preference such as cup, bottle.
16391933|NCT04036227|Experimental|GS-248|"Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses)
~Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I."
16391934|NCT04036227|Placebo Comparator|Placebo|Matching placebo oral solution
16391935|NCT04036201|Experimental|Group 1(22-24 mm)|Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.
16391936|NCT04036201|Experimental|Group 2(24.1-26 mm)|Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m
16391937|NCT04036188|Experimental|Triamcinolone Cream + Vitamin D3|This arm will continue to take Vitamin D3 at Week 16 to Week 28.
16391938|NCT04036188|Placebo Comparator|Triamcinolone Cream + Placebo|Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.
16391939|NCT04036175|Other|Group 1|Standard oxygen - High-Flow Nasal Oxygen - Non-invasive ventilation - Standard Oxygen (20 minutes for each condition)
16391940|NCT04036175|Other|Group 2|Standard oxygen - Non-invasive ventilation - High-Flow Nasal Oxygen - Standard Oxygen (20 minutes for each condition)
16391941|NCT04036162|Experimental|Young group|Young Right-handed healthy volunteers
16391942|NCT04036162|Experimental|Aged group|Aged Right-handed healthy volunteers
16391943|NCT04036149|Experimental|LUCIA|CT LUCIA 611P - Intraocular lens
16391944|NCT04036149|Active Comparator|ASPHINA|CT ASPHINA 409MP - Intraocular lens
16391945|NCT04036136|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
16391946|NCT04036136|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
16391947|NCT04036123|Experimental|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
16391948|NCT04036110|Experimental|Intervention 1|Vitamin C 500 mg taken daily for 3 months
16391949|NCT04036110|Experimental|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
16391950|NCT04036110|Placebo Comparator|Control|Placebo tablets taken daily for 3 months
16391951|NCT04036084||Patients|Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL
16391952|NCT04036084||Control|
16391953|NCT04036058|Experimental|Intervention|Enact universal gloving practices
16391954|NCT04036058|No Intervention|Control|Continue standard of care gloving practices
16391955|NCT04036019|Experimental|C-CAR066|Autologous C-CAR066 administered by intravenous (IV) infusion
16391956|NCT04036006|Experimental|Group-Based|
16391957|NCT04036006|Active Comparator|Self-Directed|
16391958|NCT04035993|Experimental|Intervention group|
16391959|NCT04035980|No Intervention|Conventional care|Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
16391960|NCT04035980|Active Comparator|Telemedicine care|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
16391961|NCT04035954|Active Comparator|Interventional|The control group will continue the routine physiotherapy program based on NDT: Neurodevelopmental Therapy twice a week, 2 days / 1 hour / day during 8 weeks.
16391962|NCT04035954|Experimental|Experimental|The treatment group will participate in clinical pilates exercises 2 days / 1 hour / day during 8 weeks.They will also continue their weekly routine physiotherapy programs.
16391963|NCT04035941|Experimental|Feasibility|The cycle training intervention group
16391964|NCT04035928|Experimental|3D digital scanning for maxillofacial prosthetics|
16391965|NCT04035915|Experimental|Limited driving pressure ventilation|
16391966|NCT04035915|Experimental|Conventional mechanical ventilation strategies|
16391967|NCT04035902|Experimental|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered during surgery
16391968|NCT04035902|Active Comparator|control|Ferric carboxymaltose is not administered
16391969|NCT04035889|Experimental|Group 1|Participants assigned to Group 1 will take 2 weeks of melatonin followed by 2 weeks of placebo
16391970|NCT04035889|Experimental|Group 2|Participants assigned to Group 2 will take 2 weeks of placebo followed by 2 weeks of melatonin.
16391971|NCT04035876|Experimental|Camrelizumab plus apatinib|
16391995|NCT04035681|Active Comparator|Stroke-Related Health Education|Participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. Each session will cover information about a different topic related to stroke.
16391996|NCT04035668|Experimental|LOU064 Dose 1|high orally
16391997|NCT04035668|Experimental|LOU064 Dose 2|high orally
16391972|NCT04035863|Experimental|PBM + physiotherapy exercises|"will be submitted to active PBM and physiotherapeutic exercises.
~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated at the lesion level with a wavelength of 808 nm, 25 J per point for 12 sessions. The same laser device (Laser DMC Therapy EC).
~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
16391973|NCT04035863|Sham Comparator|SHAM PBM + physiotherapy exercises|"will be submitted to sham PBM and physiotherapeutic exercises.
~For irradiation sham, the individuals will be positioned comfortably in lateral decubitus on the examining table. The same laser device (Laser DMC Therapy EC) will be used but the device will emit sound but not light.
~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
16391974|NCT04035850|Experimental|Participants|Vortioxetine PO tablets, 5-20mg Daily
16391975|NCT04035837|Experimental|short-course combination group|Nucleoside analogue is used during the first 3 months.
16391976|NCT04035837|Experimental|full-course combination group|Nucleoside analogue is used during all the course of study.
16391977|NCT04035824|Active Comparator|Gastrodia and Uncaria granule|Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
16391978|NCT04035824|Placebo Comparator|Placebo|Placebo of Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
16391979|NCT04035798|Experimental|memantine (MM)|The participants will receive memantine 5mg (1 capsule) per day for 12 weeks.
16391980|NCT04035798|Placebo Comparator|Placebo|The participants will receive one capsule of placebo per day for 12 weeks.
16391981|NCT04035785|Experimental|Kangfu anti-inflammatory suppository|"Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.
~One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.
~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
16391982|NCT04035785|Placebo Comparator|antibiotics alone group|"One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.
~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
16391983|NCT04035772|Experimental|Wiki101 and WikiTrauma|"Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.
~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care."
16391984|NCT04035759|Experimental|APPEAL Program|Participants receive the APPEAL program, consisting of three one-on-one sessions, each lasting approximately one hour, and spaced one month apart. Sessions are designed to promote positive affect. Participants receive optional weekly check-ins to support behavior change efforts. All participants continue to receive standard of care.
16391985|NCT04035759|No Intervention|Standard of care|Participants receive standard of care.
16391986|NCT04035746||Single-group study|Assessment of microcirculation, brain plasticity and clinical function
16391987|NCT04035733|Experimental|Open-label single arm study|
16391988|NCT04035720|Experimental|Quantitative risk estimation|Participants will be exposed to case-scenarios. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating the probability of risk progression (20%, 25%, 85%, 90%). This information may or may not be accurate to reflect potential errors of risk prediction tools.
16391989|NCT04035720|Active Comparator|Qualitative risk estimation|Participants will be exposed to the same case-scenarios as the intervention arm. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating a qualitative probability of risk progression (low, high). This information may or may not be accurate to reflect potential errors of risk prediction tools.
16391990|NCT04035707|Experimental|anaesthesia with rocuronium|rocuronium is used during anaesthesia
16391991|NCT04035707|Experimental|anaesthesia without rocuronium|during anaesthesia rocuronium is not used
16391992|NCT04035694|Experimental|Intervention|Participants will receive access to Media Aware.
16391993|NCT04035694|No Intervention|Delayed-Intervention Control|Participants will receive their regular health education programming not related to sexual health education or media literacy education.
16391994|NCT04035681|Experimental|Problem-Solving Therapy|Participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. During each session, participants will identify a problem (big or small) and create a plan to work on that problem.
16391998|NCT04035668|Experimental|LOU064 Dose 3|middle orally
16392001|NCT04035655|Experimental|Clinical and electrophysiological evaluation of tDCS session|"In this prospective case-control study, the investigator's main goal was to evaluate the impact of a single standard-care tDCS session on brain activity (EEG).
~The effect of a single 20 minutes 2 mA tDCS session with the anode placed over the left dorsolateral prefrontal cortex and the cathode over the right supraorbital cortex administered as routine care were evaluated by combined behavioral and electrophysiological assessments immediately before and after the stimulation.
~The study consisted of the following interventions, administered immediately before and after the stimulation session:
~detailed behavioral assessment by the Coma Recovery Scale-Revised (CRS-R)
~5 minutes resting state high-density EEG recordings and 6 minutes auditory oddball paradigm immediately.
~Additionally, clinical anatomical MRI (T1) acquired as routine care were used to model the estimated tDCS-induced electric fields in the entire head of patients, based on available T1-weighted MRI."
16392002|NCT04035642|Experimental|IGRT 24 Gy Single dose|Patients will be treated using image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with a single fraction at a prescription dose of 24 Gy.
16392003|NCT04035629|Experimental|Hyperpolarized 129Xe MRI for lung diagnosis|All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung.
16392004|NCT04035616|Placebo Comparator|Placebo|placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets with active comparator and labelled as A
16392005|NCT04035616|Active Comparator|Hexbio® MCP|The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120. The placebo sample was similar in appearance and taste, but contained no microbial cells.
16392006|NCT04035603|Experimental|D-Cycloserine Augmentation|D-cycloserine (DCS) augmentation of CET sessions
16392007|NCT04035603|Placebo Comparator|Placebo Augmentation|Placebo (PBO) augmentation of CET sessions
16392008|NCT04035590|Active Comparator|With drain|Patients undergo mastectomy with flap fixation and low vacuum drainage.
16392009|NCT04035590|Experimental|No drain|Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.
16392010|NCT04035577|Experimental|Extended usability of a mobile self-help intervention|Participants will have open access to the Intellicare Hub app for 8-weeks and be surveyed at Baseline, 4-weeks, and 8-weeks
16392011|NCT04035564|Active Comparator|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
16392012|NCT04035564|Experimental|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
16392013|NCT04035551||patients receiving home parenteral nutrition|Includes patients receiving home parenteral nutrition for any indication.
16392014|NCT04035538|Experimental|A group|
16392015|NCT04035538|Experimental|B group|
16392016|NCT04035525|Experimental|MaxSimil® fish oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g MaxSimil® fish oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
16392017|NCT04035525|Active Comparator|Rice bran oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
16392018|NCT04035525|Active Comparator|CoQ10 as powder form|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
16392019|NCT04035512|Experimental|Expressive writing|The expressive writing group will perform the writing task, for 3 consecutive days, 20 minutes each day
16392020|NCT04035512|No Intervention|Control group|Any intervention
16392021|NCT04035499|Experimental|Experimental Arm:single|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©® is a progressive walking and resistance exercise program
16392022|NCT04035486|Active Comparator|Osimertinib 80mg QD|"Osimertinib (AZD9291) 80mg QD.
~All patients randomized into this will only receive Osimertinib 80mg.
~Dose may be reduced to allow for the management of IP related toxicity."
16392023|NCT04035486|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
~Dose may be reduced to allow for the management of IP related toxicity."
16392024|NCT04035473|Active Comparator|Sequence A (Oraxol, IV paclitaxel)|"The treatment sequences will be:
~A Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2 B IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2"
16392025|NCT04035473|Active Comparator|Sequence B (IV paclitaxel, Oraxol)|"The treatment sequences will be:
~A IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2 B Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2"
16392026|NCT04035460|Active Comparator|Helmet oxygenation group|Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet
16392027|NCT04035460|Active Comparator|High Flow Nasal Oxygen|Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs
16392028|NCT04035447|Experimental|Behavioral Symptom Management for Young Adult Cancer Survivors|The proposed intervention will provide systematic training in cognitive and behavioral coping skills (e.g., activity-rest cycling, cognitive restructuring, relaxation training) delivered over the course of 8 sessions (10 therapy hours). By employing these strategies, participants learn to adjust their thoughts, behaviors, and emotions in the service of better managing symptoms.
16392029|NCT04035447|Active Comparator|Waitlist Control|Waitlist control participants will receive the intervention and receive systematic training in cognitive and behavioral coping skills approximately 6 months into their participation in the study.
16392030|NCT04035434|Experimental|CTX110|Administered by IV infusion following lymphodepleting chemotherapy.
16392031|NCT04035408||All subjects|All the enrolled subjects will be considered for the assessment of the primary and secondary outcomes.
16392032|NCT04035395|Experimental|Intervention|Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
16392033|NCT04035395|No Intervention|Control|Participants randomized to the usual care group will receive the SyV 1.0 program which includes community based program referrals (excluding intervention programs) and home-based visits from CHWs. These participants will also receive the standard follow-up from UTHealth staff such as a phone call, an information session as per their treatment plan, and /or a onetime mailing of information about the importance of following their treatment plan. Before implementation begins, additional details about standard care will be ascertained from partner organizations to better understand how these differ from the treatment conditions of the intervention group. Once the participant completes 12 months in the study, 2.0 services will be initiated.
16392034|NCT04035382|Experimental|Labor Induction|Induction of labor between 39 0/7 to 39 6/7 weeks. Cervical ripening and induction method will be left to the managing clinician. However, combination method of cervical ripening with prostaglandin or oxytocin and Foley catheter, followed by oxytocin infusion and amniotomy will be encouraged.
16392035|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - TAI|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to TAI
16392036|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - PPV|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to PPV
16392037|NCT04035356||HAART 300|HAART 300 Aortic Annuloplasty Device
16392038|NCT04035356||HAART 200|HAART 200 Aortic Annuloplasty Device
16392039|NCT04035343|Active Comparator|Conventional face down positioning|Patients in third arm will be treated with the current standard of care, that is, they will be kept supine in the ophthalmic surgery chair after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will transition to face down positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
16392040|NCT04035343|Experimental|Supine positioning|Patients in the second arm will be kept supine after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will maintain supine positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
16392041|NCT04035330|Experimental|etidronate in sodium hypochlorite|It comes in a capsule containing 0.9 g of etidronate powder, which should be mixed immediately with 10 mL of a NaOCl solution of choice directly before treatment, resulting in a combined irrigant containing both active chlorine and approximately 9% etidronate. Irrigation with a total volume of 25 ml for each case
16392042|NCT04035330|Active Comparator|sodium hypochlorite|irrigation with 2.5% NaOCl with a total volume of 25 ml for each case
16392043|NCT04035317|Experimental|Aesculus hippocastanum|Patients will receive extract of Aesculus hippocastanum
16392044|NCT04035317|Placebo Comparator|Placebo|Patients will receive placebo
16392045|NCT04035304|Experimental|Mindfulness Coach Mobile App|Participants in this condition will complete 3 assessments: initial, end of month two and end of month four. Each participant, following initial assessment will be provided with a link to download the Mindfulness Coach mobile app as well as with brief recommendations for how to use the app over the subsequent 16 weeks of the study. Mindfulness Coach is a mobile app for iPhone and Android, developed by the VA National Center for PTSD in collaboration with National Center for Telehealth and Technology (T2).
16392046|NCT04035304|No Intervention|No Treatment Control Group|Participants in this condition will initially be provided with links to resources for Veterans with PTSD (http://ptsd.va.gov) and will be told that they will be contacted again in 8 weeks (60 days) to complete a second assessment. Each participant will then be provided with a link to download the Mindfulness Coach mobile app and with brief recommendations for how to use the app over the subsequent 8 weeks of the study (see description above). Participants will participate in a final follow up survey 8 weeks after receiving the app.
16392047|NCT04035291|Active Comparator|Interventional|The first group (n = 25) will be asked to apply the physiotherapy program by the family at home that includes the principles of therapeutic handling-holding-positioning of NDT principles, starting at the third month for 8 weeks. And It will last for at least 45 minutes, 3 days a week. Family education will be evaluated after 4 weeks and improvements will be made in accordance with the motor development of the infant. The program will be implemented by families for 8 weeks.
16392048|NCT04035291|Experimental|Experimental|In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
16392049|NCT04035291|No Intervention|control|In the third study group, families who are out of town or who cannot participate in the treatment program for other reasons will be included in the evaluations.
16392050|NCT04035278|Experimental|Dengusiil|
16392051|NCT04035278|Placebo Comparator|Placebo|
16392052|NCT04035265|Active Comparator|pain+ / synovitis +|SLE patients with inflammatory pain and synovitis determined by the practitioner during physical examination of radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP. Defining synovitis as pain and inflammation and/or deformity (present or existing over the past year) included in the clinical history
16392053|NCT04035265|Active Comparator|pain + / synovitis -|SLE patients with inflammatory pain without determined synovitis. Current (or over the past year) pain in radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP, with no synovitis
16392054|NCT04035265|Active Comparator|pain - / synovitis -|SLE patients without inflammatory pain with normal physical examination currently or over the past year
16392055|NCT04035265|Placebo Comparator|healthy|control patients (healthy participants: no pain, no SLE, no family affected by systemic inflammatory disease, a blood test with no elevation APR or autoimmunity +)
16392056|NCT04035252||1. Young healthy group|Male or female between the age of 18 and 40 years old. No presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
16392057|NCT04035252||2. Patients with an AAA|Individuals (>60 years) with a small, stable, abdominal aortic aneurysm (i.e. AAA diameter of 30-50 mm)
16392058|NCT04035252||3. Healthy older group|Healthy age- and sex- matched with group 2 with no presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
16392059|NCT04035239|Experimental|BGS use|Use of BGS goggles for a 3-6 weeks period.
16392060|NCT04035226||Relapsed/refractory Multiple Myeloma|Patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody treatment will be observed.
16392061|NCT04035213|Experimental|Behavior of Sleep Course|A semester-long course focused on sleep improves college students' sleep patterns over one semester. The listed aims of this course are to: 1) provide students with a comprehensive understanding of sleep; 2) afford an overview of the multiple ways sleep impact health, performance and well-being; and 3) to assist students in discovering how their own sleep-wake patterns impact their day to day functioning.
16392062|NCT04035213|No Intervention|Control|Students from other upper level departmental courses with content that does not include a focus on or discussion of sleep
16392063|NCT04035200|Experimental|V117957 1 mg|V117957 tablets taken orally at bedtime
16392064|NCT04035200|Experimental|V117957 2 mg|V117957 tablets taken orally at bedtime
16392065|NCT04035200|Placebo Comparator|Placebo|Placebo to match V117957 tablets taken orally at bedtime
16392066|NCT04035187|Experimental|Sequence A (fast, medium, oral solution, then slow)|Participants first receive fast tablet, then medium tablet, then oral solution, and then slow tablet. Washout period is (at least) one week.
16392067|NCT04035187|Experimental|Sequence B (medium, slow, fast, then oral solution)|Participants first receive medium tablet, then slow tablet, then fast tablet, and then oral solution. Washout period is (at least) one week.
16392068|NCT04035187|Experimental|Sequence C (slow, oral solution, medium, then fast)|3, 4, 2, 1 Participants first receive slow tablet, then oral solution, then medium tablet, then fast tablet. Washout period is (at least) one week.
16392069|NCT04035187|Experimental|Sequence D (oral solution, fast, slow, then medium)|Participants first receive oral solution, fast tablet, then slow tablet, and then medium tablet. Washout period is (at least) one week.
16392070|NCT04035174|Experimental|LTS-2 DEC patch|This is a transdermal device with diethylcarbamazine (DEC) applied directly on the skin. The reading will be done 24 hours after.
16392071|NCT04035174|Active Comparator|Skin snip|A skin snip will be performed using a 2 mm Holth corneoscleral's punch. Once done, the microfilariae of Onchocerca volvulus will be counted with a microscope.
16392072|NCT04035161|Experimental|Investigational Product|Skin will be prepared with investigational product
16392073|NCT04035161|Other|Reference Standard|Skin will be prepared with reference standard
16392074|NCT04035161|Active Comparator|Active Control|Skin will be prepared with active comparator
16392075|NCT04035161|Other|Negative Control|Skin will be prepared with negative control
16392076|NCT04035135|Experimental|Open Label Treatment Arm|One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.
16392077|NCT04035122|Experimental|Robotic Treatment|The Lokomat is a robotic device. For treatment with the robotic system, the amount of body weight supported will initially set at 70% of every patient's weight, then decreasing in accordance with load tolerance, although not providing less than 20% support. The selected speed will be adapted to the patient's working comfort under the supervision of a trained physiotherapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
16392078|NCT04035122|Active Comparator|Conventional Treatment|The CG will perform traditional overgroung gait rehabilitation. Exercises in this program are designed with gradual increments to meet each patient's abilities and were supervised by a physical therapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
16392126|NCT04034771|Active Comparator|propofol and placebo|propofol iv infusion and a placebo tablets through a nasogastric tube once at admission
16393787|NCT04023058|Other|Control 2|massive IMR at rest with increasing during exercise - CABG+ mitral surgery
16392079|NCT04035109|Other|Anakinra (Period 1) then Placebo (Period 2)|Subjects randomized to this arm will receive a single injection of anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their first allergen challenge (Period 1), followed by the matching saline placebo after their second allergen challenge (Period 2).
16392080|NCT04035109|Other|Placebo (Period 1) then Anakinra (Period 2)|Subjects randomized to this arm will receive a single injection of saline placebo administered subcutaneously after their first allergen challenge (Period 1), followed by anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their second allergen challenge (Period 2).
16392081|NCT04035096|Experimental|The high-dose vitamin C with very low carbohydrate diet group|"Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.
~Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose
~Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.
~The Riordan IVC protocol (Taiwan)
~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks
~The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month
~VLCD intervention in the first 12 weeks"
16392082|NCT04035096|Active Comparator|The control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs
~Usual care"
16392083|NCT04035083|Experimental|Laser activated irrigation|Laser activated irrigation of sodium hypochlorite using a 980 nm diode laser device
16392084|NCT04035083|Active Comparator|Passive ultrasonic irrigation|passive ultrasonic irrigation of sodium hypochlorite using an ultrasonic laser device
16392085|NCT04035070|Experimental|Root canal irrigation with co-amoxiclav-clindamycin solution|Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
16392086|NCT04035070|Experimental|Root canal irrigation with MTAD|Irrigation with 5 mL MTAD irrigating solution for 5 minutes between each size instrument and the consequent one.
16392087|NCT04035070|Active Comparator|Root canal irrigation with 2.5% sodium hypochlorite|Irrigation with 5 mL 2.5% sodium hypochlorite irrigating solution between each size instrument and the consequent one.
16392088|NCT04035057|Experimental|Behaviorally Enhanced Training Strategies|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
16392089|NCT04035057|Active Comparator|Standard Didactic Training|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions.The two conditions will differ in their training focus during the subsequent half-day training. The Standard Didactic condition will involve additional didactic instruction related to common barriers and more advanced delivery concepts than will be presented in the half-day training for the Behaviorally Enhanced condition. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Standard Didactic condition will involve counseling on the implementation of exposure with therapists' patients without explicit focus on therapists' remaining reservations about exposure.
16392090|NCT04035031|Experimental|Forxiga first, placebo second|Forxiga followed by placebo
16392091|NCT04035031|Experimental|Placebo first, Forxiga second|Placebo followed by forxiga
16392092|NCT04035018|Experimental|pharmacopuncture therapy|The physicians will select one or more pharmacopuncture therapy for each participants. The physicians will also decide dosage and frequency of treatment according to the participant's status.
16392093|NCT04035018|Active Comparator|physical therapy|The physicians will select one or more physical therapy for each participants. The physicians will also decide intensity and frequency of treatment according to the participant's status.
16392094|NCT04035005|Experimental|Ocrelizumab|Participants will receive ocrelizumab by IV infusion every 24 weeks.
16392095|NCT04035005|Placebo Comparator|Placebo|Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
16392098|NCT04034979|No Intervention|Phase I-Baseline evaluation|The first two months of the investigator's project will be a baseline evaluation of the current decision making process about goals-of-care in a local ICU setting (Levis, Quebec). A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) dyads of physicians and newly admitted elderly patients discussing goals-of-care.
16392099|NCT04034979|Experimental|Phase II-Impact of the decision aid|The two following months will be an evaluation of the decision making process about goals-of-care in the same local ICU setting using only the decision aid without any training. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care, whether the physician chooses to use the context-adapted decision-aid or not.
16392100|NCT04034979|Experimental|Phase III- Impact of the decision aid and the|This phase will be an evaluation of the decision making process about goals-of-care in the same local ICU setting after intensivists complete the training program and using the DA. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care using the context-adapted decision aid and the new skills learned in the training program.
16392101|NCT04034966|Active Comparator|Claria|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) with the telemedicine module. The telemedicine module is the platform for storing patient information directly from the PD machine. Handling will be done according to the basic operating instructions established by the manufacturer.
16392102|NCT04034966|No Intervention|Control|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device. the device is used for automated peritoneal dialysis. Handling will be done according to the basic operating instructions established by the manufacturer.
16392103|NCT04034953|Other|Colorectal Cancer Screening|"Potential screening participants will firstly be briefed about the CRC screening pilot program launched by the Department of Health (DH).
~This project will offer screening referrals to the government pilot program or FIT screening tests for a total of 10,000 consecutive visitors."
16392104|NCT04034953|Other|Prostate Cancer Screening|A blood test for Prostate Specific Antigen (PSA) will then be performed. Subsequently, for subjects with serum PSA 4-10 ng/ml, additional blood tests for Prostate Health Index (PHI) will be performed for the further assessment of risk of prostate cancer. Subjects with serum PSA > 10 ng/ml; or PHI ≥ 35 will be referred for Trans-rectal Ultrasound-guided Prostatic Biopsy (TRUS+PB). Subjects with serum PSA < 4 ng/ml or with PHI level < 35 will be invited to repeat the prostate screening tests every 2-years. We aim to screen not more than 5,000 subjects. For all patients recruited for prostate cancer screening, the study team will continue follow the subjects, by phone or mail or other means, for the long term clinical outcome for up to 10 years.
16392105|NCT04034953|Other|Breast Cancer Screening|Up to 5,000 eligible female subjects will receive a mammography on a 2-yearly basis. Individuals with abnormal findings on mammography will be referred for subsequent follow-up by the Jockey Club Breast Health Centre (BHC) run by the Hong Kong Breast Cancer Foundation (HKBCF).
16392106|NCT04034940|Other|primary PCI STEMI patients|All Patients with AMI refered for primary PCI in single center
16392109|NCT04034914|Experimental|Yoga Therapy|
16392110|NCT04034901|Experimental|Monitoring of cardiorespiratory parameters|Monitoring of cardiorespiratory parameters with BORA Band
16392111|NCT04034888|Experimental|Home Exercise Program (HEX)|Customized home exercise program
16392112|NCT04034875|Experimental|Patients with acquired brain injury|
16392113|NCT04034862|Experimental|2DR|Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)
16392114|NCT04034862|No Intervention|3DR|Continued 3 drug regimen treatment (DTG+ABC+3TC)
16392115|NCT04034849|Experimental|Test group|Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
16392116|NCT04034849|Placebo Comparator|Placebo group|Low-Level Laser Therapy was applied in the placebo group with a Diode Laser Fox (A.R.C. Laser, Italy) turned off with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
16392117|NCT04034836|Experimental|The scalp blocks group|The scalp blocks group will receive scalp blocks with ropivacaine, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine (5 ug/mL) and i.v. saline 2ml;
16392118|NCT04034836|Active Comparator|The i.v. group|The i.v. group will receive scalp blocks with ropivacaine 20ml, plus saline 2ml with epinephrine (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously.
16392119|NCT04034836|Active Comparator|The control group|The control group will receive scalp blocks with ropivacaine, 20ml, plus saline 2ml with epinephrine (5 ug/mL) and i.v. saline 2ml;
16392120|NCT04034823|Experimental|KN035 in combination with trastuzumab and docetaxel|
16392121|NCT04034797|Experimental|Photo|
16392122|NCT04034797|Active Comparator|No photo|
16392123|NCT04034784|Experimental|Discrete(TM)|Intraperitoneal injection
16392124|NCT04034784|Sham Comparator|Control Lactated Ringer's Solution (Control LRS)|Intraperitoneal injection
16392125|NCT04034771|Experimental|propofol and melatonin|propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.
16392127|NCT04034758|Placebo Comparator|Placebo capsule arm|Oral administration of 30 placebo capsule containing edible pigmented starch together with full dose of oral 5-Aminosalicylic acid(5-ASA).
16392128|NCT04034758|Active Comparator|SQIMC-md FMT arm|Oral administration of 30 SQIMC-md capsules containing 2*10^13 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces together with full dose of oral 5-Aminosalicylic acid(5-ASA).
16392129|NCT04034745||Standard of Care telotristat ethyl (Xermelo) Treatment|Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
16392130|NCT04034732|Experimental|Mindfulness-based Relapses Prevention (MBRP)|The MBRP program will be delivered by an instructor with training in MBSR/MBCT who has more than two years of teaching experience in MBSR/MBCT. The MBRP programme will consist of 2.5 hour weekly sessions for 8 weeks. The mindfulness curriculum will include training in mindfulness through (1) a body scan, (2) sitting meditation and (3) mindful stretching exercises.
16392131|NCT04034732|Active Comparator|Usual Care Control Group (UCCG)|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
16392132|NCT04034719|Experimental|Experimental group|"Newborn hospitalized in the neonatal department with their parent will be included.
~They will have a portage scarf to help them to keep their child skin-to-skin"
16392133|NCT04034719|Active Comparator|Control group|"Newborn hospitalized in the neonatal department with their parent will be included.
~They wont have a portage scarf."
16392134|NCT04034706||PCOS females|Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.
16392135|NCT04034706||Non-PCOS control females|Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.
16392136|NCT04034693|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
16392137|NCT04034693|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
16392138|NCT04034680|Experimental|Home care services - Intervention group|Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
16392139|NCT04034680|Active Comparator|Home care services - Control group|Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
16392140|NCT04034641|Experimental|probiotics plus standard therapy|
16392141|NCT04034641|Placebo Comparator|placebo plus standard therapy|
16392142|NCT04034628||Laparoscopic insertion|Individuals who undergo laparoscopic PD catheter insertion
16392143|NCT04034628||Percutaneous insertion|Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.
16392144|NCT04034615|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
16392145|NCT04034615|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
16392146|NCT04034615|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
16392147|NCT04034602|Experimental|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
16392148|NCT04034602|Active Comparator|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
16392149|NCT04034589|Experimental|Pyrotinib plus fulvestrant|Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
16392153|NCT04034563|Other|Risk of advanced neoplasia at 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy at 3-years
16392154|NCT04034563|Other|Risk of advanced neoplasia beyond 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy beyond 3-years
16392155|NCT04034550|Experimental|hospitalized patients diagnosed with leptospirosis|hospitalized patients diagnosed with leptospirosis: 12 months of follow up with biological samples and data collection
16392272|NCT04033601|Experimental|non-pharmacological intervention group|
16392156|NCT04034537|Experimental|cPSTA GROUP|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
16392157|NCT04034524||New users of GLP1 receptor agonists (exposure)|
16392158|NCT04034524||New users of basal insulin (reference)|
16392159|NCT04034511|Experimental|Medically-tailored meal delivery and medical nutrition therapy|Participants assigned to this arm will receive home-delivered, medically-tailored meals for 3 months combined with monthly individual Medical Nutrition Therapy sessions for 6 months. Participants will also receive participants' usual case management services from participants' Medicaid insurance program.
16392160|NCT04034511|No Intervention|Usual care|Participants assigned to this arm of the study will receive usual care and case management services from participants' Medicaid insurance program.
16392161|NCT04034485|Experimental|LIB003 (lerodalcibep)|300 mg SC Q4W
16392162|NCT04034485|Active Comparator|evolocumab|420 mg SC Q4W
16392163|NCT04034472|Other|Cardiometabolic risk in women with obesity|The use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
16392164|NCT04034459|Active Comparator|FOLFOXIRI plus bevacizumab|"One cycle (cycle duration 14 days) consists of:
~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
~Oxaliplatin 85mg/m² day 1
~5-FU 3000 mg/m² iv over 48 h days 1-2
~Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1 *1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.
~Repeat administration every 2 weeks for a maximum of 12 cycles
~Dose adaptation at the treating physician's discretion.
~Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
16392165|NCT04034459|Experimental|FOLFOXIRI plus cetuximab|"One cycle (cycle duration 14 days) consists of:
~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
~Oxaliplatin 85mg/m² day 1
~5-FU 3000 mg/m² iv over 48 h days 1-2
~Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
~Repeat administration every two weeks up to a maximum of 12 cycles.
~Dose adaptation at the treating physician's discretion.
~Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
16392166|NCT04034446|Experimental|A|Single dose of CD19-CD22 CAR-T cells
16392167|NCT04034433|Experimental|Exercise|
16392168|NCT04034433|No Intervention|Control|
16392169|NCT04034420|Experimental|Online training|To receive self-paced online training and learning materials
16392170|NCT04034407|Experimental|Damage control surgery|In the damage control surgery (DCS) group the surgeon was asked to perform rapid source control by stapling the perforated segment leaving blind ends or suturing the perforation site if possible, doing a thorough lavage of the abdominal cavity and placing an intra-abdominal negative pressure system avoiding the retraction of the abdominal wall with dynamic sutures as published. The second-look operation was scheduled for a time 24-48 hours after primary surgery that would be during regular working hours with a colorectal surgeon on hand to make the decision for either anastomosis or ostomy.
16392171|NCT04034407|Active Comparator|Control group|In the conventional treatment group (Group C), the decision to reconstruct the colon or perform a Hartmann procedure was made by the surgeon during the emergency operation. After performing the anastomosis or the Hartmann procedure, patients with advanced peritonitis received an intraabdominal negative pressure system at the discretion of the operating surgeon.
16392172|NCT04034394|Experimental|Electromoxibustion|Participants in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside (Fort Mayer, Guangzhou, China).
16392173|NCT04034394|Active Comparator|Knee health education|Participants in this group will attend 2 sessions (120 minutes each, 1-week apart) of health education related to knee OA symptom management.
16392174|NCT04034381||Port-au-Prince metropolitan area|
16392175|NCT04034381||Other urban areas|
16392176|NCT04034381||Rural areas|
16392177|NCT04034368|Experimental|Experimental Arm|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
16392178|NCT04034355|Experimental|PledOx (5 µmol/kg)|Calmangafodipir 5 µmol/kg
16392179|NCT04034355|Placebo Comparator|Placebo|0.9% sodium chloride in 20 mL vials
16392180|NCT04034329||ASVAL - group|GSV diameter ≤ 6 mm
16392181|NCT04034329||EVLA-group|GSV diameter > 6 mm
16392182|NCT04034316|Experimental|MSC|"During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:
~25% reduction of the ongoing immunosuppressive treatment following the first administration;
~50% reduction of the ongoing immunosuppressive treatment following the second administration;
~interruption of the ongoing immunosuppressive treatment following the third administration.
~In the case that the hypothesis that P ≥ 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
16392183|NCT04034290|Experimental|Stage 1 (GamFluVac intranasal drip)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated by intranasal drip
16392184|NCT04034290|Experimental|Stage 1 (GamFluVac with the help of a spray dispenser)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated intranasally with the help of a spray dispenser
16392185|NCT04034290|Experimental|Stage 2 Vaccine|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
16392186|NCT04034290|Placebo Comparator|Stage 2 (Controll Group)|Placebo
16392273|NCT04033601|Experimental|control group|
16392187|NCT04034277|Experimental|Lee Silverman Voice Therapy|LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
16392188|NCT04034277|Active Comparator|Conventional Treatment|The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality
16392191|NCT04034251|Experimental|1/ Arm1|IP and IV paclitaxel administration with concomitant oral capecitabine
16392192|NCT04034238|Experimental|1. Dose escalation|LMB-100 at escalating doses plus tofacitinib
16392193|NCT04034238|Experimental|2. Dose expansion|LMB-100 at optimal dose plus tofacitinib
16392194|NCT04034225|Experimental|SNS-301 added to pembrolizumab|"SNS-301
~Pembrolizumab"
16392195|NCT04034212|Experimental|Singing for Lung Health group|Once weekly attendance at a Singing for Lung Health group for 12 weeks.
16392196|NCT04034212|No Intervention|Usual Care group|Usual care group, participants given advice on physical activity while continuing with usual care.
16392197|NCT04034199|Experimental|Denosumab group|Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
16392198|NCT04034199|Active Comparator|Zoledronic acid|Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.
16392199|NCT04034173|Other|RAS mutations frequency <= 7%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1
~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
~Followed by FOLFIRI regimen
~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
~5-FU 400 mg/m² BSA, bolus, D1
~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
~q day 14"
16392200|NCT04034173|Other|RAS mutation frequency >7% to <=14%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1
~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
~Followed by FOLFIRI regimen
~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
~5-FU 400 mg/m² BSA, bolus, D1
~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
~q day 14"
16392201|NCT04034173|Other|RAS mutation frequency >14% to <=20%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1
~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
~Followed by FOLFIRI regimen
~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
~5-FU 400 mg/m² BSA, bolus, D1
~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
~q day 14"
16392202|NCT04034160|Experimental|burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The beef patty (Beef Patty Chuck) will be 80% lean and 20% fat.
16392203|NCT04034160|Active Comparator|vegetarian burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The vegetarian patty (Impossible Burger) will be 18% fat.
16392204|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 50mg bid|Oral tablet for 24 weeks
16392205|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 150mg qd|Oral tablet for 24 weeks
16392206|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 200mg qd|Oral tablet for 24 weeks
16392207|NCT04034121|Other|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
16392208|NCT04034108|Experimental|Experiment group|All the patients were classified as AIS-A at the time of admission to the clinical center. The MRI was performed in all cases prior to and after the surgery. Surgeries were performed between 12 hours to 30 days after trauma. At 15 days after surgery, with protection of a tailored chest-waist cast made of polyurethane 8 foam for thoracic/lumbar injuries or a neck support for cervical injuries, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers.
16392209|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.
16392210|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
16392211|NCT04034082|Experimental|IHT group|Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
16392212|NCT04034082|Active Comparator|Conventional group|Conventional phase 2 in-hospital rehabilitation program
16392213|NCT04034069|Experimental|cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
16392214|NCT04034069|Active Comparator|Sham cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
16392215|NCT04034069|Sham Comparator|Sham cTBS + sham iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
16392216|NCT04034056||Obinutuzumab|
16395126|NCT04013815|Experimental|group E|patients receiving the ESP block
16392217|NCT04034030|Experimental|Treatment Group|This study will be conducted over one year in 10 focal CSWS patients ranging in age from 3 to 21 years. The patients will be recruited from the large patient population that is served by the Children's Mercy Comprehensive Epilepsy Monitoring Unit (EMU) in Overland Park, Kansas. Subjects will be identified from these EMU patient population. Those meeting inclusion criteria will be approached for possible enrollment. Inclusion criteria will be defined by patients that were diagnosed with focal CSWS in accordance with the ILAE classification with SWI >85% during NREM sleep on their previous or most recent EEG. Patients and their parents/guardians will provide assent/consent for participation in the study after being briefed on the nature of the study, by reading and signing assent and assent/consent forms, respectively
16392218|NCT04034004|Experimental|Meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
16392219|NCT04034004|Experimental|meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
16392220|NCT04033991||Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)
16392221|NCT04033978|Experimental|Cognitive remediation arm|Participants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
16392222|NCT04033978|Active Comparator|Control group|Participants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
16392223|NCT04033965||women <35 with early breast cancer|
16392224|NCT04033965||women>65 years old with early breast cancer|
16392225|NCT04033952|Experimental|Assigned Interventions|The OPASS program will be delivered to the intervention group. The intervention protocols of the OPASS program were developed based on the strategy training guidelines developed by Skidmore et al. and based on the findings identified from the feasibility study. Trained research therapists will take the responsibility for delivering the intervention to participants. The program consists of four critical ingredients: self-selected goals, self-evaluation of performance, strategy development, and implementation, and therapeutic guided discovery.
16392226|NCT04033952|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
16392227|NCT04033939|Experimental|HSK3486-01|Randomized to receive HSK3486 (0.016mg/kg,0.064mg/kg )as a single IV injection. HSK3486-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
16392228|NCT04033939|Placebo Comparator|Placebo-01|Randomized to receive placebo (0.016mg/kg,0.064mg/kg )as a single IV injection. placebo-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
16392229|NCT04033939|Experimental|HSK3486-02|Randomized to receive either HSK3486（0.128mg/kg,0.192mg/kg,0.288mg/kg,0.432mg/kg,0.540mg/kg,0.648mg/kg,0.810mg/kg) as a single IV injection. HSK3486-02 was open-label.(5 HSK3486-02: 1 propofol-02)
16392230|NCT04033939|Active Comparator|Propofol-02|Randomized to receive propofol (2.5mg/kg) as a single IV injection. Propofol-02 was open-label.(5 HSK3486-02: 1 propofol-02)
16392231|NCT04033926|Other|Arm A|"Treatment Period 1: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks
~Treatment Period 2: Placebo SC weekly for 16 weeks"
16392232|NCT04033926|Other|Arm B|"Treatment Period 1: Placebo SC weekly for 16 weeks
~Treatment Period 2: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks"
16392233|NCT04033913||Adult patient learning self-catheterization|Patients who have successfully perform self-catheterization during a day hospital in a neuro-urology department complete a questionnaire validated by experts on the different criteria that guided the final choice of the catheter
16392234|NCT04033900|Experimental|Prewarming|Active warming is allowed prior to surgery with forced-air warming devices
16392235|NCT04033900|No Intervention|No prewarming|Non active warming is allowed before surgery
16392236|NCT04033887||HCV-only infected|"Archived frozen plasma samples from individuals that were characterised to be HCV-antibody positive or HCV-antibody negative (HCV-only infected). These samples are characterised for their HIV status (negative)."
16392237|NCT04033887||HCV/HIV co-infected|"Archived frozen plasma samples from HCV-positive or HCV-negative individuals who are HIV infected (HCV/HIV co-infected)."
16392238|NCT04033874|Experimental|Kangaroo care|"Heel stick procedure will be performed during kangaroo care.
~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
16392239|NCT04033874|Experimental|Mother's lap|"Heel stick procedure will be performed during newborns who are holding on their mother's lap.
~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
16392274|NCT04033588|Other|Freedom® Total Knee System|A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in United Kingdom
16392275|NCT04033575|Sham Comparator|Fluoride Control|Colgate Cavity Protection 0.76% as Na MFP Toothpaste
16392276|NCT04033575|Active Comparator|Colgate Total SF|Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste
16393788|NCT04023045|Active Comparator|Habitual Prosthesis|Participant's prescribed prosthesis
16392240|NCT04033874|Experimental|White noise|"Heel stick procedure will be performed during newborns listened to white noise.
~For the white noise; the track named do not cry your baby, pt. 2 will be played in Orhan Osman's Colic album. The white noise level will be adjusted to an average of 55 decibels. During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
16392241|NCT04033874|Experimental|Ambient sound|"Heel stick procedure will be performed during newborns listened to ambient sound.
~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
16392242|NCT04033861|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
16392243|NCT04033861|Placebo Comparator|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
16392244|NCT04033835|Experimental|MBT-I|12 sessions of MBT
16392245|NCT04033835|Active Comparator|Waiting list control|Treatment as usual
16392246|NCT04033822|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the trial will not receive accelerated cholecystectomy surgery to correct cholecystitis. No services will be taken away but patients will continue with care as originally provided by the healthcare system.
16392247|NCT04033822|Experimental|FAST Intervention|Patients diagnosed with cholecystitis and randomized to the FAST intervention arm of the study will undergo surgery as soon as possible with a goal of surgery within 6 hours of diagnosis.
16392248|NCT04033809|Active Comparator|Multigrain powder (S)|Oral high fiber multigrain supplements
16392249|NCT04033809|No Intervention|Standard care (C)|Standard care without oral high fiber multigrain supplements
16392250|NCT04033796|Active Comparator|25,000 IU|
16392251|NCT04033796|Active Comparator|50,000 IU|
16392252|NCT04033796|Placebo Comparator|Placebo|
16392253|NCT04033783|Experimental|6MWT - assessor walks behind the patient|In this experimental condition, the assessor walks behind the patient to continuously measure oxygen saturation during the test (recommended procedure)
16392254|NCT04033783|Active Comparator|6MWT - assessor does not walk behind the patient|In this experimental condition, the assessor does not walk behind the patient. The patient carries the pulse oximeter to continuously measure oxygen saturation during the test.
16392255|NCT04033770|Active Comparator|Air-charged measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS but using an air-charged instead of a water-filled measurement system."
16392256|NCT04033770|Active Comparator|Water-perfused measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS."
16392257|NCT04033757||Sub-cohort 1|1,469 participants were enrolled in 2015. Two follow-ups have been completed in 2016 and 2017, and will be asked to participate in follow-up in 2020, 2023, and 2026.
16392258|NCT04033757||Sub-cohort 2|1,267 participants were enrolled in 2018. They will be asked to participate in follow-up in 2021, 2024, 2027, and 2030.
16392259|NCT04033757||Sub-cohort 3|Plan to recruit about 1300 participants in 2019. And they will be asked to participate in follow-up in 2022, 2025, 2028, and 2031.
16392260|NCT04033744|Experimental|PRF (platelet-rich fibrin)|PRF will be used after the extraction of the third molar to prevent periodontal defects to second molar
16392261|NCT04033744|Active Comparator|spontaneous healing|after the extraction of the third molar the socket will be left to heal spontaneously
16392262|NCT04033731||Controls|Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
16392263|NCT04033718|Experimental|Inpatient testing package|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA
16392264|NCT04033692||JuggerKnot Mini Soft Anchors|Patients who have been implanted with the JuggerKnot Mini Soft Anchor who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc
16392265|NCT04033679|Experimental|Active TDCS|In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
16392266|NCT04033679|Sham Comparator|Sham TDCS|In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
16392267|NCT04033666|Active Comparator|High Flow nasal cannula|It will be administered as part of the high-flow nasal cannula treatment to reduce the symptoms of acute asthma
16392268|NCT04033666|Active Comparator|NIV noninvasive ventilation|It will be administered as part of the Noninvasive ventilation treatment to reduce the symptoms of acute asthma
16392269|NCT04033640|Other|screening with STANDARD G6PD Test|all participants recruited in the study will be screened with an investigational IVD- STANDARD G6PD Test- in addition to routine case. The investigational test will not be used to determine any treatment or case-management
16392270|NCT04033627|Experimental|In Vitro T cell depletion|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
16392277|NCT04033562|Active Comparator|Lidoderm patch|Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
16392278|NCT04033562|Active Comparator|Infusion pump|Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.
16392279|NCT04033536|Active Comparator|Involved target SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined Involved Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
16392280|NCT04033536|Active Comparator|Elective target SSRS|SSRS with 16 Gy in single fraction to the defined Elective Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
16392281|NCT04033523|Experimental|High intensity-interval training (HIIT)|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
16392282|NCT04033523|No Intervention|normal counterparts|gender-matched normal counterparts (NC) did not receive any form of intervention
16392283|NCT04033510||AF/NR|Single cohort with a known or new diagnosis of atrial fibrillation, and intention attain/maintain normal rhythm. Subjects with be their own controls: Tablet-based cognitive testing to be performed while in atrial fibrillation (AF), and while they are in normal rhythm (NR). Results of both sets of cognitive testing will be compared.
16392284|NCT04033497|Experimental|TRAMs I|"Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs)
~Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs"
16392285|NCT04033484|Active Comparator|Biological Mesh|Using biological mesh to recnostruct the pelvic floor following ELAPE
16392286|NCT04033484|Experimental|Biological Mesh With Negative Pressure Wound Therapy|Using biological mesh compined with negative pressure wound therapy to recnostruct the pelvic floor following ELAPE
16392287|NCT04033471|Active Comparator|MI|Bupivacaine 0.25% + midazolam 5mg in total volume 10m1
16392288|NCT04033471|Active Comparator|MM|Bupivacaine 0.25% + midazolam 5mg and morphine 5mg in total volume 10ml
16392289|NCT04033471|Active Comparator|MO|bupivacaine 0.25% + morphine 5 mg in total volume 10 ml
16392290|NCT04033458|Experimental|Treatment Sequence ABECD|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B), then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and, then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392291|NCT04033458|Experimental|Treatment Sequence BCADE|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and, then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392292|NCT04033458|Experimental|Treatment Sequence CDBEA|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then, JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then, JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392293|NCT04033458|Experimental|Treatment Sequence DECAB|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regiment 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392294|NCT04033458|Experimental|Treatment Sequence EADBC|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then, JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392295|NCT04033458|Experimental|Treatment Sequence DCEBA|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392296|NCT04033458|Experimental|Treatment Sequence EDACB|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392297|NCT04033458|Experimental|Treatment Sequence AEBDC|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and then JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392342|NCT04033224||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
16393789|NCT04023045|Experimental|Assist-Knee|Experimental knee prosthesis
16392298|NCT04033458|Experimental|Treatment Sequence BACED|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392299|NCT04033458|Experimental|Treatment Sequence CBDAE|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
16392308|NCT04033432|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay >= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.
16392309|NCT04033419|Experimental|Memantine|
16392310|NCT04033406|Experimental|VIR-2482|VIR-2482
16392311|NCT04033406|Placebo Comparator|Placebo|Placebo
16392312|NCT04033393|Experimental|Game based dual-task training group|Participants in dual-task training group will execute game based dual-task training with treadmill, 3 times per week for 8 weeks
16392313|NCT04033393|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training, 3 times per week for 8 weeks
16392314|NCT04033380|Active Comparator|Resin bloc endocrown|composite-based blocs (Grandio Blocs, VOCO)
16392315|NCT04033380|Active Comparator|Ceramic endocrown|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
16392316|NCT04033367|Experimental|Dupilumab|Dupilumab 300mg q2w
16392317|NCT04033367|Placebo Comparator|Placebo|Matching placebo
16392318|NCT04033354|Experimental|A|HLX10 + chemotherapy (carboplatin nab paclitaxel)
16392319|NCT04033354|Placebo Comparator|B|Placebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
16392320|NCT04033341|Experimental|LY3214996 + [14C]-LY3214996|A single dose of LY3214996 and [14C]-LY3214996 administered orally.
16392321|NCT04033328|Experimental|Dose Escalation|ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
16392322|NCT04033328|Experimental|Dose Expansion|RP2D dose
16392323|NCT04033302|Experimental|Single arm|Multiple CAR T cells to treat CD7-positive hematological malignancies
16392324|NCT04033289|Experimental|experimental group|
16392325|NCT04033289|No Intervention|control group|
16392326|NCT04033276|Active Comparator|Rituximab|Inj Rituximab 375mg/m2 IV given on day 0
16392327|NCT04033276|Active Comparator|Combination of high-dose IVIG and Rituximab|IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0
16392328|NCT04033263|Placebo Comparator|Placebo mouth rinse|Placebo: Deionized water (serving as negative control)
16392329|NCT04033263|Active Comparator|Elmex mouth rinse|commercial mouth rinse used as gold standard in erosion studies: elmex® Erosion Protection solution (which contains 800 ppm Sn2+, as SnCl2, and 500 ppm F-, as NaF and AmF)
16392330|NCT04033263|Active Comparator|Fluoride mouth rinse|Fluoride solution similar to many other commercial mouth rinses containing sodium fluoride (NaF at 500 ppm F-)
16392331|NCT04033263|Experimental|Plant extract A|Plant Extract A
16392332|NCT04033263|Experimental|Plant extract A with fluoride|Plant Extract A + Fluoride
16392333|NCT04033263|Experimental|Plant extract B|Plant Extract B
16392334|NCT04033263|Experimental|Plant extract B with fluoride|Plant Extract B + Fluoride
16392335|NCT04033263|Experimental|Plant extract C|Plant Extract C
16392336|NCT04033263|Experimental|Plant extract C with fluoride|Plant Extract C + Fluoride
16392337|NCT04033250|Experimental|Interventional arm (group A)|"Patients with risk factors for IBP who will receive intensified bowel preparation"
16392338|NCT04033250|Active Comparator|Control arm (group B)|Patients with risk factors for IBP who will receive standard bowel preparation
16392339|NCT04033250|Active Comparator|Control arm (group c)|Patients without risk factors for IPB who will receive standard bowel preparation
16392340|NCT04033237|Experimental|Very low nicotine content cigarettes|
16392341|NCT04033237|No Intervention|Usual Brand|
16392343|NCT04033211||Novosyn® CHD|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using Novosyn® CHD suture for fascia and skin closure of trocar wounds.
16392344|NCT04033211||Novosyn®|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using either Novosyn® suture for fascia and skin closure of trocar wounds.
16392345|NCT04033198||fourth decade|appendectomy done , appendix send for histopathological examination
16392346|NCT04033198||fifth decade|appendectomy done , appendix send for histopathological examination
16392347|NCT04033198||sixth decade|appendectomy done , appendix send for histopathological examination
16392348|NCT04033198||older than 60 years|appendectomy done , appendix send for histopathological examination
16392349|NCT04033185|Active Comparator|study group|virtual reality, robot-assisted gait training, conventional treatment
16392350|NCT04033185|Other|control group|conventional treatment
16392351|NCT04033172|Experimental|Pyrotinib plus Fulvestrant|
16392352|NCT04033159|Experimental|cohort 1|DYN101 in a low dose (1.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
16392353|NCT04033159|Experimental|cohort 2|DYN101 in a middle dose (4.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
16392354|NCT04033159|Experimental|cohort 3|DYN101 in a high dose (9 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
16392355|NCT04033146|Experimental|Economical muscle dynamics|The investigators are trying to figure out how to optimize muscle contractile conditions for mobility. To do this, the investigators are systematically altering muscle contraction conditions for all participants.
16392356|NCT04033133|Experimental|Multiple Sclerosis|People with MS get tDCS with different intensities.
16392357|NCT04033133|Active Comparator|Healthy Subjects|Healthy subjects get tDCS with different intensities.
16392358|NCT04033120||Cohort 1|"Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:
~MycoF/lytic blood culture system
~Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis
~Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis
~Histoplasma antigen in urine (HAg) LFA for histoplasmosis
~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period"
16392359|NCT04033120||Cohort 2|"Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:
~CrAg LFA for cryptococcosis
~HAg LFA for histoplasmosis
~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period."
16392360|NCT04033107|Experimental|Treatment arm|Vitamin C combined with metformin
16392361|NCT04033094||MorphaBond ER|
16392362|NCT04033094||Comparator Group|
16392363|NCT04033081|Experimental|CivaSheet Treatment|Implanted with CivaSheet during tumor removal
16392364|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccinations (high dose)|14 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and day 28
16392365|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccination (low dose)|14 Participants will receive MV-ZIKA-RSP 2,5 x10E4 /dose on day 0 and day 28
16392366|NCT04033068|Experimental|One MV-ZIKA-RSP vaccination (high dose) and one placebo|12 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and placebo on day 28
16392367|NCT04033068|Placebo Comparator|Two placebo injection|8 Participants will receive placebo on day 0 and placebo on day 28
16392368|NCT04033055|Experimental|CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).
~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
16392369|NCT04033055|Active Comparator|CycloMesh™ soaked in saline solution 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).
~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
16392370|NCT04033042|Experimental|Protocol 1|RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
16392371|NCT04033042|Experimental|Protocol 2|"RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
~One group of subjects will receive training in the use of the device the other will not. Both groups will receive the instructions for use."
16392372|NCT04033029||Patients under CVVHDF with high adsorption membrane|Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
16392373|NCT04033016|Experimental|Facebook and motivational interviewing group|Women from this group were included in social media intervention and in two sessions of motivational interviewing.
16392374|NCT04033016|Experimental|Facebook only group|Women from this group were included in the social media intervention only.
16392375|NCT04033016|No Intervention|control group|women from this group only received the information on the benefits of physical activity during pregnancy.
16392376|NCT04033003|Experimental|Group ANC|Intervention groups consist of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
16392377|NCT04033003|No Intervention|Stand ANC|Individual standard antenatal care delivered at health facilities in Ghana
16392378|NCT04032990|Experimental|Transcutaneous spinal stimulation - Acute and Training|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while upper extremity function is assessed at 3 time points (acute) and/or in combination with activity-based upper extremity training (40 sessions, 1.5 hours/day, 5 days/week); stimulation will be applied intermittently for no more than 10 minutes at a time. Upper extremity training is based on usual care activities to challenge use of the hands and arms, e.g. reaching, grasping, manipulating objects.
16392379|NCT04032977|Experimental|PN40082|Test device: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w
16392380|NCT04032977|Active Comparator|Restylane Silk|Restylane Silk (manufactured by Q-Med AB for Medicis - A Division of Valeant Pharmaceuticals Corporation North America, LLC ) is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
16392381|NCT04032964|Experimental|Arm L19TNF + DOXO|"Patients will be treated with:
~doxorubicin 75 mg/m2 i.v. on day 1 of each 21-day cycle;
~L19TNF 13 µg/kg i.v. on day 1, 3 and 5 of each 21-day cycle"
16392382|NCT04032951|Experimental|Adominal neoplasms patients|Patients in whom EUS-FNTA is performed with a novel type of biopsy neede.
16392383|NCT04032938||the control group|30 healthy people as the control group.
16392384|NCT04032938||the case group|60 patients were admitted to intensive care unit (ICU) as the case group after cardiac surgery and extracorporeal circulation. This group should contain 30 patients with fever and/or hemodynamic instability and 30 patients with normothermia and normal hemodynamic.
16392385|NCT04032925|Experimental|PICSO therapy Group|"This will be the only treatment of the PICSO VIPER study. Within this group patients will be randomised to have cycles of 2 minutes of balloon-induced myocardial schema with PICSO device in ON vs OFF modality."
16392386|NCT04032899|Experimental|L. fermentum CECT5716 3x109 ufc|Volunteers will take 1 capsule per day with L. fermentum CECT5716 3x109 cfu mixed with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
16392387|NCT04032899|Placebo Comparator|Maltodextrin|Volunteers will take 1 capsule per day with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
16392388|NCT04032886|Experimental|classic kinesio tape|this group will receive mechanical correction tape with classic tape plus exercise.
16392389|NCT04032886|Experimental|performance kinesio tape|this group will receive mechanical correction tape with performance tape plus exercise.
16392390|NCT04032886|Other|control|this group will receive only exercise.
16392391|NCT04032873|Other|Provider Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by the orthopaedic surgeon before the decision for immobilization has been made.
16392392|NCT04032873|Other|Research Team Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by a member of the study team after the decision for immobilization has been made.
16392393|NCT04032860|Experimental|ETV group|group in which patients take ETV as antiviral therapy after curative treatment
16392394|NCT04032860|Experimental|TDF group|group in which patients take TDF as antiviral therapy after curative treatment
16392395|NCT04032847|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001.
16392396|NCT04032847|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor.
16392397|NCT04032834|Other|Part 1, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
16392398|NCT04032834|Other|Part 1, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
16392399|NCT04032834|Other|Part 1, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
16392400|NCT04032834|Other|Part 1, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
16392401|NCT04032834|Other|Part 1, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
16392402|NCT04032834|Other|Part 1, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
16392403|NCT04032834|Other|Part 2, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
16392404|NCT04032834|Other|Part 2, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
16392405|NCT04032834|Other|Part 2, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
16392406|NCT04032834|Other|Part 2, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
16392434|NCT04032652|Active Comparator|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
16392407|NCT04032834|Other|Part 2, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
16392408|NCT04032834|Other|Part 2, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
16392409|NCT04032834|Other|Part 3, Arm A of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask.
16392410|NCT04032834|Other|Part 3, Arm B of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece.
16392411|NCT04032834|Other|Part 3, Arm C of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask.
16392412|NCT04032834|Other|Part 3, Arm D of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece.
16392413|NCT04032821|Experimental|Alkotinib（300mg）First empty stomach, after the meal|Alkotinib（300mg），Subjects need to be fasting overnight for at least 10 hours before being warmed to 240 mL on an empty stomach Water service, lunch 4 hours later, dinner 10 hours later.
16392414|NCT04032821|Experimental|Alkotinib（300mg）After eating first, after fasting|Alkotinib（300mg），Subjects need to be fasting for at least 10 hours overnight, starting 30 min before taking the medication A standard meal (800-1000 CAL) can be taken before taking the medicine, and 240 mL warm water can be taken after the meal Lunch hours later, dinner 10 hours later.
16392415|NCT04032795|Experimental|Lycium barbarum polysaccharide (LBP)|Experimental group takes LBP tablet (300mg/day) for 6 weeks
16392416|NCT04032795|Placebo Comparator|Placebo|Placebo control group takes placebo 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
16392417|NCT04032782|Experimental|HM15136|
16392418|NCT04032782|Placebo Comparator|Placebo of HM15136|
16392419|NCT04032769|Experimental|Modified strategy MODS|"the threshold of D-dimer will depend on the YEARS rule (MODS strategy):
~If all the three items of YEARS are negative (i.e. No hemoptysis, No clinical sign of deep venous thrombosis and PE is not the most likely diagnosis), then the threshold of D-dimer will be raised at 1000 ng/ml.
~If at least one item of YEARS is positive, then the threshold will remain unchanged (>500 ng/ml for patients aged < 50 and > agex10 for patients aged 50 and over).
~A positive result of D-dimer and the absence of other obvious cause for PE will mandate a CTPA, or V/Q scan if CTPA is contra-indicated.
~A negative result of D-dimer will rule out PE."
16392420|NCT04032769|No Intervention|Control group|All included patients will be tested with D-Dimer, threshold for ordering a CTPA as usual
16392421|NCT04032756||Group 1|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
16392422|NCT04032756||Group 2|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.
16392423|NCT04032730|No Intervention|Control|Participants assigned to the control arm will undergo treatment and care for MDR/XDR-TB as per the South African Department of Health guidelines.
16392424|NCT04032730|Experimental|Intervention|Participants assigned to the intervention arm will undergo extensive counselling, participants will be provided with an electronic pillbox that monitors their adherence to one of their TB and one of their ART medication. Based on the recordings provided by the wisepill device we will determine if a participant is adherent to their medication and intervene with counselling, phone calls, home visits and relevant referrals.
16392425|NCT04032717|Experimental|Open-label Q-GRFT enema|Open-label Q-GRFT enema administered rectally once as a single dose (Arm 1)
16392426|NCT04032717|Experimental|Randomized, blinded Q-GRFT enema|Blinded Q-GRFT enema administered rectally once as a single dose (Arm 2)
16392427|NCT04032717|Placebo Comparator|Randomized, blinded placebo enema|Blinded placebo enema administered once as a single dose (Arm 3)
16392428|NCT04032704|Experimental|Ladiratuzumab Vedotin|SGN-LIV1A monotherapy
16392429|NCT04032691|Experimental|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
16392430|NCT04032678|Experimental|1 (DGT7)|"Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard Touch 7 - DGT7, Schiller Medical, France) with recommended by the manufacturer adult pads (FRED-PA1, Schiller) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.
~Other Name: DGT7"
16392431|NCT04032678|Active Comparator|2 (LP15)|"Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.
~Other Name: LP15"
16392432|NCT04032665||Stable coronary and peripheral artery disease (CAD/PAD)|Stable CAD/PAD patients with previous percutaneous coronary intervention and drug eluting stent-implantation treated with dual antiplatelet therapy (ASA+clopidogrel)
16392433|NCT04032665||Acute coronary artery disease (ACS)|Patients with troponin-positive ACS (NSTEMI/STEMI) with planned percutaneous coronary intervention and drug eluting stent-implantation treated with P2Y12 inhibitor (ticagrelor) and ASA
16392437|NCT04032639||Controls|24 children and adolescents (7-16 years) without diagnosed Prader-Willi Syndrome will be matched for age, sex, and BMI-percentile to the Prader-Willi group
16392438|NCT04032626|Experimental|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
16392439|NCT04032626|Placebo Comparator|Placebo|Placebo taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
16392440|NCT04032613|Experimental|Vascular access quality improvement program participants|All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.
16392441|NCT04032600|Other|Full paracentesis|All ascites is drained
16392442|NCT04032600|Other|Fractioned paracentesis|3 Liters are drained, then the drain is clamped and the rest of the ascites is drained on the next day
16392443|NCT04032587|Experimental|Non-treatment seeking subjects with Alcohol Use Disorder|AUD; mild vs. moderate to heavy
16392444|NCT04032587|Active Comparator|Healthy Controls|
16392445|NCT04032574|Experimental|Herbal medicinal product|three times daily two film coated tablets containing: extracts of restharrow root (Ononidis radix) 80mg,Java tea (Orthosiphonis folium) 90mg, goldenrod herb (Solidaginis herba) 180mg
16392446|NCT04032574|Placebo Comparator|Placebo|three times daily two film coated tablets
16392447|NCT04032548|Placebo Comparator|Placebo|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
16392448|NCT04032548|Experimental|Propolis|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
16392449|NCT04032548|Active Comparator|Chlorhexidine|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
16392450|NCT04032535|Experimental|SAD|"Single Ascending Dose of 2 cohorts:
~Cohort A will be administered three ascending dose levels: 0.2 mg (dose 1), 2 mg (anticipated dose 3), 8 mg (anticipated dose 5) or placebo; Cohort B will be administered three ascending dose levels: 1 mg (anticipated dose 2), 4 mg (anticipated dose 4), 14 mg (anticipated dose 6, maximum dose) or placebo."
16392451|NCT04032535|Experimental|MAD|"Multiple Ascending Dose of 4 cohorts:
~Cohort A will be administered with 2 mg (anticipated dose 1) or placebo; Cohort B will be administered with 4 mg (anticipated dose 2) or placebo; Cohort C will be administered with 8 mg (anticipated dose 3) or placebo; Cohort D will be administered with 12 mg (anticipated dose 4) or placebo;"
16392452|NCT04032535|Experimental|2way crossover|Two 28-day treatment periods (Period 1 and Period 2), separated each by 32 days (up to 40 days) wash-out period, in crossover design. The treatment period will consist in repeated administrations of CHF 6523 at one dose level or placebo.
16392453|NCT04032522||Intervention Arm (A)|Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA >1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
16392454|NCT04032522||Control Arm (B)|The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
16392455|NCT04032509||Mild TBI|Mild TBI (GCS 13-15 on admission) within 12 hours after injury
16392456|NCT04032496|Experimental|Mindfulness Intervention|Participants in this arm will participate in the Contemplative-Based Intervention for People Living with SLE intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
16392457|NCT04032496|Active Comparator|HEP Intervention|Participants in this arm will participate in the Health Enhancement Program (HEP) intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
16392458|NCT04032470||Essential Tremor|Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems
16392459|NCT04032457|Active Comparator|A1 - SiHyDD to Moist|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
16392460|NCT04032457|Active Comparator|A2 - Moist to SiHyDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
16392461|NCT04032457|Active Comparator|A3 - SiHyDD to OASDD|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of ACUVUE® OASYS 1-Day contact lenses.
16392462|NCT04032457|Active Comparator|A4 - OASDD to SiHyDD|1 week of ACUVUE® OASYS 1-Day contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
16392463|NCT04032457|Active Comparator|A5 - SiHyDD to DT1|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of Alcon DAILIES TOTAL 1® contact lenses.
16392464|NCT04032457|Active Comparator|A6 - DT1 to SiHyDD|1 week of Alcon DAILIES TOTAL 1® contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
16392465|NCT04032457|Active Comparator|B1 - HydDD to Moist|1 week of Test HydDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
16392466|NCT04032457|Active Comparator|B2 - Moist to HydDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
16392467|NCT04032457|Active Comparator|B3 - HydDD to BioTrue|1 week of Test HydDD contact lenses followed by cross over to 1 week of BIOTRUE ONEday® contact lenses.
16392468|NCT04032457|Active Comparator|B4 - BioTrue to HydDD|1 week of BIOTRUE ONEday® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
16392469|NCT04032457|Active Comparator|B5 - HydDD to AqCom+|1 week of Test HydDD contact lenses followed by cross over to 1 week of DAILIES® AquaComfort PLUS® contact lenses.
16392470|NCT04032457|Active Comparator|B6 - AqCom+ to HydDD|1 week of DAILIES® AquaComfort PLUS® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
16392471|NCT04032431|Experimental|Telerehab VR intervention|The telerehab VR intervention consists of a custom-made software running on a computer connected with a commercial VR device (i.e. Oculus Rift). PwMS will be requested to reproduce several ADLs from the three main areas of self-care, dressing and meal preparation. The user can physically see his/her hands within the virtual scenario and, during the exercise, the hand coordinates are continuously recorded. Thus, data on 3D trajectory, speed, accuracy on target placement and movement smoothness, will be accessible. They will be stored in the PC and also be remotely sent to the clinical center for further analysis/processing. Both target position and task complexity will define the exercise difficulty, which can be modified automatically, on the basis of the previous performance or manually modified by the user
16392472|NCT04032431|Active Comparator|Conventional therapy|Conventional therapy will focus on task-related upper-limb treatments while in a sitting or prone position, representing the standard care in MS. Several manual techniques, therapy tools and objects of ADL will be allowed during treatment. No restrictions will be placed on the material used (ie, ADL, reaching and grasping material). Use of additional electrical or mechanical therapy devices (ie, support arm systems, splints) will be avoided. The interventions will be conducted on a one-on-one basis in the physiotherapy or occupational therapy department of each participating center. Training and therapy content will be tailored to each participant's preferences, the agreed movement aims and the motor function level of each MS patient.
16392473|NCT04032418|Active Comparator|Arm I (200mg pembrolizumab 3 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16392474|NCT04032418|Experimental|Arm II (200mg pembrolizumab 12 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16392475|NCT04032405|Active Comparator|CAF+CTG|the combined connective tissue graft (CTG) with coronally advanced flap (CAF)
16392476|NCT04032405|Experimental|CAF+CTG+i-prf|the combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
16392477|NCT04032392|Experimental|Autologous γδT cells|"Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions.
~Dose escalation subjects will receive 6 infusions with dose of γδT cells escalation from 1×10e9 to 6×10e9.
~Constant dose subjects will have single infusion intravenously at a target dose of 1~2×10e9 γδT cells."
16392478|NCT04032379||Certain IIH or IIH-WOP|According to revised diagnostic criteria, Friedmann, 2013.
16392479|NCT04032379||Suspected IIH|IIH is suspected, does not fulfill diagnostic criteria.
16392480|NCT04032379||IIH ruled out|Patients in whom another diagnosis is made.
16392481|NCT04032366||PEEP 5|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, without inhaled nitric oxide
16392482|NCT04032366||PEEP 10|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, without inhaled nitric oxide
16392483|NCT04032366||PEEP 10 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, with inhaled nitric oxide
16392484|NCT04032366||PEEP 5 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, with inhaled nitric oxide
16392485|NCT04032353|Other|Medical Consortium|subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)
16392486|NCT04032340||Elderly with a companion dog|elderly living at home with a dog consulting his family doctor
16392487|NCT04032340||Elderly without a companion dog|elderly living at home without a dog consulting his family doctor
16392488|NCT04032327|Active Comparator|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
16392489|NCT04032327|Active Comparator|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
16392490|NCT04032314||Healthy controls - cross-sectional project design|
16392491|NCT04032314||Patients - cross-sectional project design|
16392492|NCT04032314||Patients - longitudinal project design|
16392493|NCT04032301|Experimental|Intravenous ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
16392494|NCT04032301|Placebo Comparator|Intravenous saline infusions|Six infusions of normal saline solution over 3 weeks.
16392495|NCT04032275||Untreated chronic HBV infected person group|Enrolled in the Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Department of Liver Histology, Department of Hepatology, Chronic HBV HBV infection.
16392496|NCT04032262|Other|Parkinson's Disease Relationship to the GI track|Patients with Parkinson's.
16392497|NCT04032249|Active Comparator|Control Group (CG)|Education and modifying diet
16392498|NCT04032249|Experimental|Intervention Group (IG)|Education, modifying diet and Indications to record self-weighing with a frequency of 2 times per week
16392499|NCT04032236|Other|smoking group|35 smoking case
16392500|NCT04032236|Other|nonsmoking group|35 nonsmoking case
16392501|NCT04032223|Experimental|3D printed metal copings|3D printed primary and secondary metal copings inderctly from 3D printed resin in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
16392502|NCT04032223|Active Comparator|Cast metal copings|Cast metal primary and secondary metal copings in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
16392503|NCT04032210|Experimental|Regimen using dual Zinc plus Arginine based toothpaste|
16392504|NCT04032210|Experimental|Regimen using Zinc based toothpaste (Crest complete)|
16392505|NCT04032210|Active Comparator|Fluoride based toothpaste (Signal)|
16392506|NCT04032197|Experimental|Semaglutide|Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.
16392507|NCT04032197|Placebo Comparator|Placebo|Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.
16392508|NCT04032184|Active Comparator|Fluoride toothpaste|
16392509|NCT04032184|Experimental|fluoride toothpaste and chlorhexidine mouthwash|
16392511|NCT04032171|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
16392512|NCT04032171|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
16392513|NCT04032158|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
16392514|NCT04032158|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
16392515|NCT04032145||Observational|All participants who go to the Montreal Museum of Fine Arts will fill out an online questionnaire called: CESAM ( Self Administered Questionnaire). This questionnaire will asse participant's health condition. Moreover, the goal of the questionnaire is to evaluate if art activities may change the participants' health conditions in time.
16392516|NCT04032132|Experimental|curcumin paste in conjunction with open flap debridement surge|curcumin paste (2% circumin) in conjunction with open flap debridement surgery
16392517|NCT04032132|Placebo Comparator|open flap debridement surgery only|surgical treatment for periodontal pocket
16392518|NCT04032119|Experimental|Epinephrine|0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection
16392519|NCT04032119|Active Comparator|Non-epinephrine|No epinephrine would be added into the solution
16392520|NCT04032106|Active Comparator|Group A (standard HPV information)|Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
16392521|NCT04032106|Experimental|Group B (Outsmart HPV, unidirectional vaccine reminders)|Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
16392522|NCT04032106|Experimental|Group C (Outsmart HPV, interactive vaccine reminders)|Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
16392523|NCT04032093|Experimental|RSV dose with aluminum hydroxide|RSV vaccine with aluminum hydroxide
16392524|NCT04032093|Experimental|RSV dose without aluminum hydroxide|RSV vaccine without aluminum hydroxide
16392525|NCT04032093|Experimental|Higher RSV dose with aluminum hydroxide|Higher dose level RSV vaccine with aluminum hydroxide
16392526|NCT04032093|Experimental|Higher RSV dose without aluminum hydroxide|Higher dose level RSV vaccine without aluminum hydroxide
16392527|NCT04032093|Placebo Comparator|Placebo dose|Normal saline solution for injection (0.9% sodium chloride injection)
16392528|NCT04032080|Experimental|LY3023414 + prexasertib|Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.
16392529|NCT04032067|Active Comparator|Control Group|"GV1001-Placebo ID injection administered every 2 weeks through Week 24
~+ Proscar PO administered once a day through Week 24"
16392530|NCT04032067|Experimental|Study Group 1|"GV1001 0.56 mg ID injection administered every 2 weeks through Week 24
~+ Proscar-placebo PO administered once a day through Week 24"
16392531|NCT04032067|Experimental|Study Group 2|"GV1001 1.12 mg ID injection administered every 2 weeks through Week 24
~+ Proscar-placebo PO administered once a day through Week 24"
16392532|NCT04032054||A|mono-axial
16392533|NCT04032054||B|poly-axial
16392534|NCT04032041||Group 1: Healthy Able-bodied Individuals (Completed)|Healthy able-bodied individuals with no history of lower extremity trauma.
16392535|NCT04032041||Group 2: Individuals Requiring AFO Use (Recruiting)|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
16392536|NCT04032015|Active Comparator|rTMS treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own MRI images. Daily treatment regiments will last 30 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
16392537|NCT04032015|Sham Comparator|Sham treatment|"Sham rTMS will be delivered for 20 sessions over 4 weeks. To maximize sham validity, both 1) a direction-sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity 10Hz electrical stimulation will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS treatment. Daily treatment regiments will last 30 minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS sessions for adverse events and/or side effects.
~Upon completing the 20 sham sessions, participants are unblinded and offered 20 treatments of active rTMS. The open-label treatment would follow the active rTMS treatment protocol."
16392538|NCT04032002|Other|Patients hereditary bradykinetic angioedema|
16392539|NCT04032002|Other|healthy volunteers|
16392540|NCT04031963||No treatment|Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.
16392541|NCT04031950||test group|Test group will wear PSG
16392542|NCT04031950||Novel wearable device|THis group will wear the novel device
16392543|NCT04031937|Active Comparator|major depressive disorder|psychometric scales psychomotor assessment
16392544|NCT04031937|Active Comparator|Control|psychometric scales psychomotor assessment
16393166|NCT04027374||Fetal surgery group|Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
16392545|NCT04031924||Liver Transplantation|Sixteen individuals with liver transplantation were included in the study, and their physical and demographic characteristics of the individuals recorded. The Senior Fitness Test (SFT) was used to evaluate to physical fitness. The Tampa Scale for Kinesiophobia (TSK) was used to assess kinesiophobia; the Fatigue Impact Scale (FIS) and Fatigue Severity Scale (FSS) to evaluate fatigue; the Berg Balance Scale (BBS) and the Timed Up and Go test (TUG) to evaluate the balance; the International Physical Activity Questionnaire (IPAQ) to determine the level of physical activity;and the Hospital Anxiety and Depression Scale (HADS) to evaluate psychological status.
16392546|NCT04031924||Healthy Subjects|Sixteen age- and sex-matched healthy subjects were included in the study.
16392547|NCT04031911|Other|Control group|Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).
16392548|NCT04031911|Experimental|Study group|"Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."
16392549|NCT04031898||full analysis set|All eligible patients who meet all inclusion criteria and none of the exclusion criteria
16392550|NCT04031885|Experimental|Abemaciclib + Fulvestrant|150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
16392551|NCT04031885|Active Comparator|Standard Chemotherapy|Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.
16392552|NCT04031872|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine
16392553|NCT04031859|Experimental|Group A|In this group a VTE risk stratification procedure will be used
16392554|NCT04031859|No Intervention|Group B|In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)
16392555|NCT04031846|Experimental|V114|Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
16392556|NCT04031846|Active Comparator|Prevenar 13™|Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
16392557|NCT04031833|Experimental|Phase 1a single ascending dose study|Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
16392558|NCT04031833|Experimental|Phase 1b multiple day dosing|9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
16392559|NCT04031833|Experimental|Phase 2 safety and tolerability|Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.
16392560|NCT04031820|Active Comparator|unipolar cup|550 patients will receive a total hip arthroplasty with a unipolar cup.
16392561|NCT04031820|Active Comparator|Dual Mobility cup|550 patients will receive a total hip arthroplasty with a dual mobility cup.
16392562|NCT04031794||Conventional ARDS treatment group|Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.
16392563|NCT04031794||ECMO group|Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support
16392564|NCT04031781|Active Comparator|Receiving repetitive transcranial magnetic stimulation (rTMS)|This group received 5 rTMS sessions, delivered over one week over the left dorsolateral prefrontal cortex (LDLPFC ) at 5-Hz frequency and 100% motor threshold intensity.
16392565|NCT04031781|Placebo Comparator|Group receiving placebo rTMS|This group received Placebo rTMS was given with the same stimulation frequency at a fixed intensity of 50% of the machine output
16392566|NCT04031768|Other|0-2-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~0 minutes 2 minutes 5 minutes 5 minutes"
16392567|NCT04031768|Other|0-5-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~0 minutes 5 minutes 2 minutes 5 minutes"
16392568|NCT04031768|Other|2-0-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~2 minutes 0 minutes 5 minutes 5 minutes"
16392569|NCT04031768|Other|5-0-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~5 minutes 0 minutes 2 minutes 5 minutes"
16392570|NCT04031768|Other|2-5-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~2 minutes 5 minutes 0 minutes 5 minutes"
16392571|NCT04031768|Other|5-2-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~5 minutes 2 minutes 0 minutes 5 minutes"
16392572|NCT04031755|Experimental|Minocycline versus Placebo|"Phase 1: 4 weeks of daily minocycline 100mg BID dosing
~2-week washout period
~Phase 2: 4 weeks of daily placebo dosing"
16392573|NCT04031755|Experimental|Placebo versus Minocycline|"Phase 1: 4 weeks of daily placebo dosing
~2-week washout period
~Phase 2: 4 weeks of daily minocycline 100mg BID dosing"
16392574|NCT04031742|Experimental|Part 1: IBI306|Participants received open-label IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
16392575|NCT04031742|Experimental|Part 2: IBI306|Participants received open-label 450mg Q4W subcutaneously for 12 weeks.
16392576|NCT04031729|Experimental|Aspirin|Low-dose (81mg) aspirin tablets
16392577|NCT04031729|Placebo Comparator|Placebo|Placebo tablets
16392621|NCT04031365|Experimental|Acupuncture and Cognitive Behavioral Therapy|Participants will receive four sessions of a brief acupuncture therapy in addition to a brief cognitive behavioral therapy.
16393790|NCT04023032|Experimental|multicomponent cognitive intervention|
16392580|NCT04031703|Experimental|6 cycles of PC adjuvant chemotherapy|6 cycles of PC (Paclitaxel 80 mg/m2 ivgtt d1,8,15+ Carboplatin Auc = 2 ivgtt d1,8,15, 28 days per cycle).
16392581|NCT04031703|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|3 cycles of FEC (epirubicin100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
16392582|NCT04031690||patient-caregiver dyads|
16392583|NCT04031677|Other|Standard arm|Surgery alone
16392584|NCT04031677|Experimental|Experimental arm|Preoperative chemotherapy and surgery
16392585|NCT04031664|Experimental|Qianjin Capsule of Gynaecology|"On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.
~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
16392586|NCT04031664|Placebo Comparator|Antibiotics alone group|"Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.
~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
16392587|NCT04031638||Radioactive Iodine treatment for thyroid cancer|
16392588|NCT04031625||Metastatic Colorectal Cancer|
16392589|NCT04031612||Neoadjuvant Breast Cancer|Patients undergoing neoadjuvant therapy for breast cancer
16392590|NCT04031599|Active Comparator|Carbohydrate counting|Rapid acting insulin analogue with carbohydrate counting
16392591|NCT04031599|Active Comparator|Simplified qualitative meal size estimation|Rapid acting insulin analogue with simplified qualitative meal size estimation
16392592|NCT04031586||Children diagnosed with Solid Tumors|Children diagnosed with solid tumors in Managua, Nicaragua in Central America
16392593|NCT04031573|Experimental|Ivabradine (Low)|
16392594|NCT04031573|Experimental|Ivabradine (High)|
16392595|NCT04031573|Placebo Comparator|Control|
16392596|NCT04031560|Experimental|Experimental|Integrative treatment
16392597|NCT04031560|No Intervention|Control|The control group (62 patients) will not receive any type of add-on psychotherapy.
16392598|NCT04031547|Active Comparator|Active tES-fMRI|
16392599|NCT04031547|Sham Comparator|Inactive/Sham tES-fMRI|
16392600|NCT04031534|Experimental|Measure of hypoxia by F-Miso PET scan and RMI|Patient will undergo F-Miso PET scan and MRI to detect hypoxia. Imaging will be correlated with immunohistochemistry on tumour biopsy
16392601|NCT04031521||Sickle cell pain crisis|
16392602|NCT04031521||Sickle cell steady-state|
16392603|NCT04031508|Experimental|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
16392604|NCT04031508|Sham Comparator|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
16392605|NCT04031482||Ongoing or incipient targeted therapies|Ongoing or incipient targeted therapies with biologics and/or other targeted therapies (e.g. Janus kinase inhibitors)
16392606|NCT04031469||General Population|The general population will have their microbiome sequenced from stool samples provided.
16392607|NCT04031456|Experimental|Participants receiving PRP treatment|Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion
16392608|NCT04031456|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP) treatment|Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion
16392609|NCT04031430|Experimental|telemonitoring group (TM)|
16392610|NCT04031430|Active Comparator|Patient self-monitoring group (PSM)|
16392611|NCT04031430|No Intervention|control group (CC)|
16392612|NCT04031417|Other|Placebo|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
16392613|NCT04031417|Other|soy isoflavones|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
16392614|NCT04031417|Other|soy isoflavones & cocoa polyphenols|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
16392615|NCT04031404|Experimental|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
16392616|NCT04031404|Experimental|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
16392617|NCT04031391|Experimental|physical activity group|
16392618|NCT04031391|No Intervention|Control group|
16392619|NCT04031378|Active Comparator|A|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation using PET/CT imaging studies every 6 months
16392620|NCT04031378|Experimental|B|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months stratified by whether disease is castrate-sensitive (mCS-PCa) or castrate-resistant (mCR-PCa)
16392622|NCT04031365|Active Comparator|Cognitive Behavioral Therapy|Participants in this group will receive a brief cognitive behavioral therapy in addition to four telephone follow-ups.
16392623|NCT04031339||Patients diagnosed with thyroid cancer|Patients with histologically-confirmed diagnoses of papillary, follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer
16392624|NCT04031326|Experimental|LENA Home|Home visitors assigned to the intervention group will be trained to use and administer LENA Home in addition to the standard ECS curriculum during designated home visits beginning when the child is between 6- and 9-months old.
16392625|NCT04031326|No Intervention|Standard Practice|Home visitors assigned to the control group will administer the standard ECS curriculum only
16392626|NCT04031300|Experimental|RSP-20|Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 48 days.
16392627|NCT04031274||TAVI no MR|Patients undergoing TAVI with MR up to moderate following the procedure
16392628|NCT04031274||TAVI + MR no further intervention|Patients undergoing TAVI with MR more than moderate following the procedure, no further mitral valve intervention
16392629|NCT04031274||TAVI + MR undergoing TMVR/r|Patients undergoing TAVI with MR more than moderate following the procedure, underwent transcatheter mitral valve intervention
16392630|NCT04031261||National Validation|All patients must have a diagnosis of severe asthma, be taking high dose inhaled corticosteroids (GINA step 4 & 5), and be aged 16 years or over.
16392631|NCT04031261||Sensitivity to Change|Patients commencing a biologic treatment for their severe asthma (GINA step 4 & 5), as per National Institute for Health and Care Excellence (NICE) guidelines.
16392632|NCT04031248|Experimental|WBV group (experimental)|"Participants in the experimental group will follow a program that will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work.
~The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience."
16392633|NCT04031248|Active Comparator|Exercise group (control)|Control subjects will perform the same exercise program without whole-body vibration.
16392634|NCT04031235|Experimental|Safe Sleep Education|Mothers in the intervention group will receive education on American Academy of Pediatrics safe sleep recommendations using a specially-designed children's book (Sleep Baby, Safe and Snug). In addition, they will receive information on the importance of reading with their infant using a brochure created by the AAP.
16392635|NCT04031235|Active Comparator|Infant Reading Education|Mothers in the control group will receive education on American Academy of Pediatrics recommendations on reading and talking to infants using a specially-designed children's book (Read Baby, Every Day). In addition, they will receive information on safe sleep using a brochure created by the AAP.
16392636|NCT04031209||G7 G7 Acetabular System|All patients will receive G7 G7 Acetabular System
16392637|NCT04031196|Active Comparator|QLB group, Quadratus Lumborum Block group|the patient placed in the lateral decubitus position, the low-frequency convex probe of Sonosite M Turbo ultrasonography was placed in the anterior axillary line midway between subcostal margin and iliac crest to identify the abdominal muscle layers, then the probe was moved to the posterior axillary line to visualize the quadratus lumborum muscle attached to the transverse process of the L4, With the psoas major muscle placed anteriorly, the erector spinae muscle posteriorly, a 22-gauge, 80 mm needle was inserted in-plane into the posterior aspect of QL muscle (between quadratus lumborum and erector spinae muscle), and then 0.5ml/kg of 0.25% levobupivacaine local anesthetic was injected behind the muscle as a bolus dose. The block was performed bilaterally.
16392638|NCT04031196|Active Comparator|TAP block group,Transversus Abdominis Plane Block group|patient placed in the supine position, a linear multifrequency 6-13 MHz probe of Sonosite M Turbo ultrasonography was placed posterior to the midaxillary line at the midpoint between the inferior costal margin and the iliac crest, a 22-gauge, 50 mm needle was placed using an in-plane technique between the internal oblique and transversus abdominis muscle then local anesthetic was injected in a bolus dose 0.5ml/kg of 0.25% levobupivacaine, the block was done bilaterally.. after ultrasound Identification of the plane between the internal oblique and transversus abdominis muscle,
16392639|NCT04031170|Experimental|Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic & Advanced Parent Training Program. It consists of twelve (12) 2-hour classes led by Dean Coffey, a senior psychologist and certified peer coach in the Incredible Years Parent Training Series.
16392640|NCT04031170|Other|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts. The control group is offered the Incredible Years® School Age Basic & Advanced Parent Training Program after a 3-month wait list period.
16392641|NCT04031157|Experimental|PGT arm|Predictix Antidepressant-guided treatment condition
16392642|NCT04031157|No Intervention|soc arm|Standard of Care condition
16392643|NCT04031144|Experimental|Ultrafiltration|Ultrafiltration is applied at the end of cardiopulmonary bypass. Maximal clot formation (MCF) of ROTEM-EXTEM tracing is reduced before applying the ultrafiltration.
16392644|NCT04031131|Active Comparator|Intervention Arm|topical anaesthetic gel and lubricating gel
16392645|NCT04031131|Placebo Comparator|Control Arm|lubricating gel alone
16392646|NCT04031105|Experimental|Condition 1|Priming sham TBS, followed by iTBS after an inter-stimulation-interval (ISI) of 0 minutes
16392647|NCT04031105|Experimental|Condition 2|Priming cTBS, followed by iTBS after an ISI of 0 minutes
16392648|NCT04031105|Experimental|Condition 3|Priming cTBS, followed by iTBS after an ISI of 10 minutes
16392649|NCT04031105|Experimental|Condition 4|Priming cTBS, followed by iTBS after an ISI of 20 minutes
16392650|NCT04031092|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for patients with chronic pain.
16393865|NCT04022525||leflunomide responsive vs non-responsive|
16392651|NCT04031092|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
16392652|NCT04031079|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program).
16392653|NCT04031079|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
16392654|NCT04031066|Experimental|Velmanase alfa|
16392655|NCT04031066|Placebo Comparator|placebo|
16392656|NCT04031053||Intensive Pharmacokinetic Group|After receiving the first dose of ITZ, a single blood sample will be collected 12-hours post-dose. On Day 7, the blood will be collected for intensive PK study. After 7 days of combined ITZ + EFV, a blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. An identical set of intensive PK blood samples will be drawn 2 weeks after initiating the EFV based regimen.
16392657|NCT04031053||Trough Level Group|On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.
16392658|NCT04031040|Experimental|Genio(TM) system therapy|Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.
16392659|NCT04031014|Experimental|Active treatment|Treatment with the active treatment protocol of the BTL EMSELLA device twice per week for six treatments total
16392660|NCT04031014|Sham Comparator|Sham treatment|Treatment with the sham protocol of the BTL EMSELLA device twice per week for six treatments total
16392661|NCT04030988|Active Comparator|Active|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
16392662|NCT04030988|Placebo Comparator|Placebo|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
16392663|NCT04030975||interview|emergency physicians
16392664|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1A|Administration of AGN-242428 ophthalmic solution
16392665|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1B|Administration of AGN-242428 ophthalmic solution
16392666|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1C|Administration of AGN-242428 ophthalmic solution
16392667|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1A|Administration of AGN-231868 ophthalmic solution
16392668|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1B|Administration of AGN-231868 ophthalmic solution
16392669|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1C|Administration of AGN-231868 ophthalmic solution
16392670|NCT04030962|Placebo Comparator|Stage 1: AGN-242428 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
16392671|NCT04030962|Placebo Comparator|Stage 1: AGN-231868 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
16392672|NCT04030962|Experimental|Stage 2: AGN-242428 Group 1|Administration of AGN-242428 ophthalmic solution
16392673|NCT04030962|Experimental|Stage 2: AGN-242428 Vehicle Group 2|Administration of matching placebo (vehicle) ophthalmic solution
16392674|NCT04030962|Experimental|Stage 2: AGN-231868 Group 3|Administration of AGN-231868 ophthalmic solution
16392675|NCT04030962|Experimental|Stage 2: AGN-231868 Vehicle Group 4|Administration of matching placebo (vehicle) ophthalmic solution
16392676|NCT04030962|Active Comparator|Comparator Ophthalmic Solution|Administration of comparator ophthalmic solution
16392677|NCT04030949||Ateendes STD clinics Östergötland physician appointment|"Attendees with an appointment to a physician (if she has symptoms or if she wishes a gynecological exam).
~The exam starts with an Abbot multi-collect swab taken from the anal verge, at the opening of the anal canal.
~A pediatric proctoscope (a proctoscope designed and manufactured to examine children) is used for sampling the rectal specimens using an Abbot multi-collect swab and a standard Sigma swab of Sigma virocult, followed by vaginal speculum exam. Firstly samples from the lateral fornix for wet smear are collected, secondly a swab for methylene-blue staining from the endocervical orifice followed by two Abbot multi-collect swabs for chlamydia/gonorrhoea and M.genitalium respectively from the orifice, the portio and the vaginal wall and one standard Sigma swab of Sigma virocult from the same areas. Lastly a sample is collected from the distal urethra and stained with methylene blue."
16392678|NCT04030949||Ateendes STD clinics Östergötland, nurse appointment|"The participant collects the rectal sample for chlamydia and gonorrhea (Abbot multi-collect swab) first and is instructed to try not to touch the perianal/perineal areas. Then the vaginal samples for chlamydia/gonorrhoea and M.genitalium are collected.
~There is a group of women who have been tested positive for chlamydia by self-collected vaginal swab which is sent to the patient by mail. Those are requested to attend the STD-clinic for partner tracing and are offered antibiotic treatment with doxycycline. Those accepting to participate in the study will answer the study questions and will be tested again and a nurse will collect firstly an Abbot multi-collect swab from the anal verge, at the opening of the anal canal and then two rectal swabs using a pediatric proctoscope (one Abbot multi-collect and one standard Sigma swab of Sigma virocult) and the participant will self-collect a new vaginal sample for chlamydia/gonorrhea and one for M.genitalium (two Abbot multi-collect swabs)"
16392702|NCT04030780|Placebo Comparator|Cohort 1FD (on-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks on-PPI+ placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
16392703|NCT04030780|Active Comparator|Cohort 2FD (off-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks of sporebiotics (2) followed by 8 weeks of sporebiotics (open label)
16392679|NCT04030949||Ateendes STD clinics Östergötland+Jönköping partner chlamydia|"Women attending the STD clinics because of a verified chlamydia infection of their current partner. This group of patients is examined and tested by a nurse or doctor before doxycycline treatment is offered.
~Those accepting to participate in the study answer the questions about the experience of receptive anal sex and fellatio (and condom use) during the last 12 months and even additional questions regarding fellatio and whether it happened that a male partner ejaculated in oral cavity of the participant.
~The first sample is an Abbot multi-collect swab taken from the anal verge and the anal canal and two more swabs are taken under the use of a pediatric proctoscope: one Abbot multi-collect and one standard Sigma swab of Sigma virocult and finally vaginal samples are collected (one Abbot multi-collect and one standard Sigma swab of Sigma virocult)"
16392680|NCT04030923|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses on the left DLPFC for 10 consecutive sessions totally over period of 10 days.
16392681|NCT04030923|Sham Comparator|sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses with coil perpendicular on scalp over the occipital cortex for 10 consecutive sessions totally over period of 10 days.
16392682|NCT04030910|Experimental|'LIFEView' intervention|"The 'LIFEView' session(s) involves the use of audiovisual software by Motitech AS (technology provided by and used with permission from Motitech AS). For its primary uses as Motiview, the audiovisual software was coupled to a mobile user-adapted cycle-trainer. Since a secondary benefit of the virtual cycle trip may include reminiscence which may in-turn facilitate conversation of past experiences, the audiovisual software is being adapted for use in reminiscence therapy for a palliative care population.
~As there is an extensive library available to participants and 'LIFEView' sessions could potentially be longer than feasible for research personnel to conduct, each 'LIFEView' session will be limited to up to 3 videos per session or up to 1 hour of videos per session, whichever is a shorter duration. Additional post-study 'LIFEView' sessions can be provided upon request from participants."
16392683|NCT04030897|Active Comparator|Online Programs + Information/Psychoeducation/Referral (IPR)|"Includes 2 online, one-session programs (one for youths; one for parents) and Primary Care-based IPR. The 30-min, self-administered YOUTH PROGRAM includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change. In the 15-min Qualtrics-based PARENT PROGRAM, parents read 2 scientific passages on (1) the notion that emotions are flexible in youth and adults, and (2) that failure promotes personal growth. After each passage, parents write a persuasive summary of its main arguments, directed to fellow parents who may benefit from the information."
16392684|NCT04030897|Placebo Comparator|Information/Psychoeducation/Referral (IPR; usual care control)|Information, Psychoeducation and Referral (IPR) represents usual care in the Stony Brook University Hospital's Pediatric Primary Care Division. Families of a youth with elevated MD symptoms during a PC visit receive a folder containing informational materials about the nature of depression and referrals to providers in their area. All families in this study will receive PC-based IPR.
16392685|NCT04030884|Experimental|Intervention Lap.Chol.|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a laparoscopic cholecystectomy.
16392686|NCT04030884|No Intervention|Control Lap.Chol.|The participants received standard care for their laparoscopic cholecystectomy.
16392687|NCT04030884|Experimental|Intervention Thyroidectomy|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a thyroidectomy.
16392688|NCT04030884|No Intervention|Control Thyroidectomy|The participants received standard care for their thyroidectomy.
16392689|NCT04030871|Active Comparator|Capsule Dome G-Tube|Capsule Dome G-Tube
16392690|NCT04030871|Active Comparator|Balloon Bolus feeding tube|Balloon Bolus feeding tube
16392691|NCT04030858|Experimental|Treatment group|The treatment group will eat a nutrient-dense plant-based diet and attend weekly nutrition education sessions.
16392692|NCT04030858|No Intervention|Control group|
16392693|NCT04030845||breast reconstruction|
16392694|NCT04030845||oncoplastic breast-conserving surgery|
16392695|NCT04030819|No Intervention|control group|no intervention
16392696|NCT04030819|Experimental|experimental group|schema therapy
16392697|NCT04030806|Experimental|Intervention group|"All patients will perform 60 minutes of intervention, twice a week, for six weeks. During the intervention, the patient will be positioned seated in a chair with a table in front of him and a mirror (50cm x 50cm) will be placed vertically between his upper extremity.
~The patient's paretic upper extremity will be positioned behind the mirror, allowing only the movements of his healthy upper extremity to be visualized. The reflective side of the mirror will be facing the healthy upper extremity , the patient will perform the exercises observing the movements of his healthy upper extremity through the reflection produced by the mirror, interpreting as the movement of his paretic member."
16392698|NCT04030806|Sham Comparator|Control group|All patients will perform 60 minutes of intervention, twice a week, for six weeks. The mirror will be placed in the same position as the intervention group. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm. In the control group, the patients will be submitted to the same bimanual activities of the intervention group, but without the reflecting side of the mirror. Thus, the nonreflective side of the mirror will be facing the healthy arm, the patient will perform the same exercises visualizing only the movement of the healthy member.
16392699|NCT04030793|Experimental|Individualized stimulation group|Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
16392700|NCT04030793|Active Comparator|Conventional stimulation group|Conventional stimulation on leg motor areas during 30 minutes.
16392701|NCT04030780|Active Comparator|Cohort 1FD (on-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks on-PPI+ sporebiotics (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
16393681|NCT04023786|Experimental|56 patients, one arm|All patients benefits of a passive leg raising test and a PEEP test to compare these two tests.
16392704|NCT04030780|Placebo Comparator|Cohort 2FD (off-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks of placebo (2) followed by 8 weeks of sporebiotics (open label)
16392705|NCT04030767|Experimental|lip repositioning technique with Botox injection.|"Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity (Binder et al., 1998).
~Therefore, the technique is a useful adjunct in the esthetic improvement of the smile and provides better results when combined with resective gingival surgery(Pedron & Mangano, 2018)."
16392706|NCT04030767|Active Comparator|lip repositioning technique.|Lip repositioning aims to limit the retraction of elevator smile muscles. Lip repositioning results in a shallow vestibuler restricting of the muscle pull; Thereby limiting the gingival display during smiling.(Makkiah, 2017) It is a less invasive, viable substitute for patients, has fewer post-operative complications and provides a faster recovery compared to orthognathic surgery(Grover, Gupta, & Luthra, 2014).
16392707|NCT04030754|Experimental|amniotic membrane group|amniotic dressing will be applied to these patients
16392708|NCT04030754|Experimental|duoderm group|duoderm dressing will be applied to these patients as intervention
16392709|NCT04030741|Active Comparator|Meronem and flagyl|Children in Non-operative treatment (group A) Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours. Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses) and metronidazole (20 mg/kg/day divided into 3 doses for another 8 days.
16392710|NCT04030741|Active Comparator|Surgery (appendectomy)|"Children in group B: appendectomy will b done and post operative single dose of antibiotics.
~discharge after 24hour and Follow up after 1 week."
16392711|NCT04030728||Group 1: Standardized coaching arm|Patients in this group receive a continuous standardized MOATT based patient education and coaching and optional eMBSR (electronic Mindfulness-Based Stress Reduction) within the first 24 weeks of Abemaciclib treatment.
16392712|NCT04030728||Group 2: Coaching according to local practice|Patients in this group receive a patient management according local routine.
16392713|NCT04030715|Other|the successful group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
16392714|NCT04030715|Other|the failure group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
16392715|NCT04030689||Axis 2|Each patient diagnosed HIV positive following VihTest test will be invited to participate to ALSO-Parcours; This program aimed to decribe the link to care for this population and to make a descriptive analysis of this HIV+ patients.
16392716|NCT04030676|Experimental|QuantiFERON Test|Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.
16392717|NCT04030663|Active Comparator|papaverine|
16392718|NCT04030663|Active Comparator|nitroglycerine|
16392719|NCT04030663|Placebo Comparator|xlyocaine|
16392720|NCT04030650||healthy volunteers|
16392721|NCT04030650||patients|patients with lower limb amputations
16392722|NCT04030637||CRC cases|samples will be collected from subjects with known diagnosis of colorectal cancer
16392723|NCT04030637||Healthy cases|samples will be collected from healthy subjects with normal colonoscopy findings
16392724|NCT04030637||Cases with pathologies|samples will be collected from subjects whose colonoscopies showed other pathologies (e.g. inflammatory polyps, adenomas, diverticular diseases)
16392725|NCT04030624|Experimental|Remote Electronic Patient Monitoring|"The Remote Electronic Patient Monitoring intervention will entail monitoring of vital sign data and patient reported assessments to address and manage any concerning issues identified.
~The Remote Patient Monitoring system uses algorithms that can indicate when patient vitals and patient-reported outcomes have changed.
~Automatic patient surveys are sent to the patient with results displayed on the clinician user interface (i.e., dashboard) on a computer located in the clinical area.
~Qualitative interviews with patient participants and their oncology clinicians using a semi-structured interview guide will be conducted."
16392726|NCT04030611||control group|Participants in the type 2 DM group were diagnosed with DM based on criteria recommended by the American Diabetes Association and required to have a fasting plasma glucose of ≥7mmol/L or an HbA1c of ≥6.5%, as measured on 2 separate occasions.
16392727|NCT04030611||diabetic retinopahty group|Participants in th ediabetic retinopahty group group were diagnosed according to the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales.
16392728|NCT04030598|Experimental|IONIS-PKK-LRx (Part A)|IONIS-PKK-LRx administered subcutaneously (SC) to participants with HAE-1/HAE-2 every 4 weeks for up to 12 weeks.
16392729|NCT04030598|Experimental|IONIS-PKK-LRx (Part B)|IONIS-PKK-LRx administered SC to participants with HAE-nC1-INH every 4 weeks for up to 12 weeks.
16392730|NCT04030598|Placebo Comparator|Placebo|Placebo will be administered SC to HAE-1/HAE-2 participants every 4 weeks for up to 12 weeks during Part A.
16392731|NCT04030585|Experimental|robot-assisted exercise|Robot-assisted exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
16392732|NCT04030585|Active Comparator|Home exercise|Home exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
16392733|NCT04030572|Experimental|Clonidine Pill|One week period of clonidine, 0.1 mg tabs, one by mouth daily at bedtime
16392734|NCT04030559|Experimental|Treatment (niraparib)|Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
16392735|NCT04030546|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session
16392736|NCT04030546|No Intervention|Usual care|Patient will receive usual care
16392737|NCT04030533|Experimental|Cohort 1: Guselkumab (SC): Dose 1|Participants will receive a single subcutaneous (SC) injection of guselkumab (dose 1), administered on Day 1.
16392738|NCT04030533|Experimental|Cohort 2: Guselkumab (SC): Dose 2|Participants will receive a single SC injection of guselkumab (dose 2), administered on Day 1.
16392739|NCT04030533|Experimental|Cohort 3: Guselkumab (IV): Dose 1|Participants will receive a single intravenous (IV) infusion of guselkumab (dose 1), administered on Day 1.
16392740|NCT04030533|Experimental|Cohort 4: Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2), administered on Day 1.
16392741|NCT04030533|Experimental|Cohort 5: Ustekinumab (IV): 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 milligrams per milliliter (mg/mL) solution on Day 1.
16392742|NCT04030520|Experimental|intervention|participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP
16392743|NCT04030520|Active Comparator|comparison|participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP
16392744|NCT04030507|Experimental|Inflammatory Breast Cancer Managed with Curative Intent|"Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain
~If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression."
16392745|NCT04030507|Experimental|HR+ or HER2+ Metastatic Breast Cancer - Screening Arm|"An initial MRI screening will be conducted
~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
16392746|NCT04030507|No Intervention|HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm|No initial MRI screening will be conducted
16392747|NCT04030507|Experimental|Triple Negative Breast Cancer|"An initial MRI screening will be conducted
~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
16392748|NCT04030494|Other|Blood pressure (BP)|Group for the validation of blood pressure measurement by the device
16392749|NCT04030494|Other|Atrial fibrillation (AF)|Group for the validation of detection of AF by the device
16392750|NCT04030494|Other|Valvular heart disease (VHD)|Group for the validation of detection of VHD by the device
16392751|NCT04030481||Group A: Sevoflurane, sufentanil and rocuronium|sevoflurane (1-3%)and sufentanil (0.5-2 mcg/kg/h) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
16392752|NCT04030481||Group B: Propofol, sufentanil and rocuronium|propofol (4-12 mg/kg/h) and sufentanil (0.5-2 mcg/kg/h/) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
16392753|NCT04030468|Experimental|General practitioners|Educational intervention
16392754|NCT04030468|Experimental|Patients|Informative intervention
16392755|NCT04030468|Experimental|General practitioners and patients|Combined strategy
16392756|NCT04030468|No Intervention|Control|No intervention
16392757|NCT04030455|Experimental|Treatment (cisplatin, docetaxel, pembrolizumab)|Patients receive cisplatin IV over 1 hour, docetaxel IV over 1 hour (patients who develop significant adverse events to cisplatin treatment may receive carboplatin IV over 1 hour instead), and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who completely respond to the study drugs (the disease appears to go away) then receive pembrolizumab IV over 30 minutes on day 1 for 4 additional cycles in the absence of disease progression or unacceptable toxicity.
16392758|NCT04030442|Placebo Comparator|Smoked cannabidiol 0%|
16392759|NCT04030442|Active Comparator|Smoked cannabidiol 3.4%|
16392760|NCT04030442|Active Comparator|Smoked cannabidiol 12.7%|
16392761|NCT04030429|Experimental|Crizotinib arm|Crizotinib 250 mg bid orally
16392762|NCT04030403||Microbial Keratitis participants|151 participants presenting with clinically suspected microbial keratitis will be recruited from St Paul's Eye Unit, Royal Liverpool University Hospital.
16392763|NCT04030403||Healthy control participants|20 participants with no history of microbial keratitis who use no eye drop medication will be recruited.
16392764|NCT04030403||Contact-lens wearers|20 participants with no history of microbial keratitis who are contact-lens wearers will be recruited.
16392765|NCT04030403||Glaucoma eye drop users|20 participants who have no history of microbial keratitis but are on eye drop treatment for glaucoma. This group has been included to assess for changes in the corneal microbiome that could be secondary to drop treatment.
16392766|NCT04030403||Keratoconus participants|30 participants with keratoconus who are undergoing cross-linking will be recruited. These participants as part of the routine cross-linking procedure will have their corneal epithelium removed. This removed epithelium from an otherwise healthy corneal surface will allow for a direct comparison between the corneal microbiome characterised from the corneal impression membrane and that characterised directly from the epithelium.
16392767|NCT04030390|Experimental|Physical Fatigue Condition|
16392768|NCT04030390|Placebo Comparator|Control Condition|
16392769|NCT04030364|Other|Self-referral to group exercise classes|"Structured, multi-component, supervised group exercise classes are the health related intervention proposed for this study. The group classes will occur at a local CrossFit gym facility.
~For the purposes of this project, all eligible Rosemount Clinic patients with type 2 diabetes mellitus will receive an email or letter mail invitation to self-refer to a structured, facility-based, supervised aerobic and resistance exercise program. Interested patients will be invited to attend a 1-hour information session at the exercise facility at the time of implementation start up where they will complete an initial baseline survey. This session will also serve as an initial meet and greet for participants to meet exercise trainers prior to starting exercise classes and to receive a tour of the facility."
16392770|NCT04030351|Experimental|dried fruit|100 g per day of dried fruit
16392771|NCT04030351|No Intervention|no dried fruit|no intervention to be given
16392772|NCT04030338||Prostate cancer|Participants with histologically confirmed prostate cancer, that is either newly diagnosed OR progressive as defined by standard PCWG3 criteria. Patients w ill remain on study until 30 days after their last PSMA imaging timepoint required by their companion therapeutic protocol.
16392773|NCT04030325|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
16392961|NCT04028999|Experimental|the EO31 shoulder sling|To develop and evaluate the effects of the EO31 shoulder sling for the prevention of pain, subluxation, spasticity, as well as effect on increasing functional use of the UL in activities of daily living.
16392774|NCT04030325|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
16392775|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
16392776|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
16392777|NCT04030325|No Intervention|Assessment Only Control|Participants complete baseline survey, longitudinal follow up assessments, and pre- and post- event surveys.
16392778|NCT04030312|Active Comparator|Standard Infant Formula|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of standard 20 calorie-per-ounce infant formula up to two times during the duration of the study to treat hypoglycemia.
16392779|NCT04030312|Experimental|Commercially-Sterilized Donor Human Milk|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of 20 calorie-per-ounce commercially-sterilized donor human milk up to two times during the duration of the study to treat hypoglycemia.
16392780|NCT04030299|Experimental|OTC Group|In this group, the over-the-counter fitting will be used to provide hearing aids.
16392781|NCT04030286||Control|Healthy patients
16392782|NCT04030286||Periodontitis|Patients with periodontal disease
16392783|NCT04030286||Cardiovascular|Patients with cardiovascular disease
16392784|NCT04030286||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
16392785|NCT04030273||Open (laparotomic) myomectomy|Women undergoing uterine myomectomy by open surgery (laparotomy).
16392786|NCT04030273||Laparoscopic myomectomy|Women undergoing uterine myomectomy by laparoscopy.
16392787|NCT04030273||Robotic myomectomy|Women undergoing uterine myomectomy by robotic surgery.
16392788|NCT04030260|Experimental|Regorafenib and Nivolumab in Combination with Radiotherapy|
16392789|NCT04030247|Experimental|Plant Sterol|South Asian participants with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.
16392790|NCT04030234|Experimental|Intensive treatment group|Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
16392791|NCT04030234|Active Comparator|Standard treatment group|Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
16392792|NCT04030208|Other|Sequence A|If patient is randomly assigned to Sequence A, they will be placed on a traditional ventilator for the first period. This period will be 1 hour in duration. Delivered tidal volume, respiratory rate (RR), and peak pressure will be recorded throughout the period using the ventilator. Heart rate (HR), Blood Pressure (BP), and oxygen (O2) saturation measurements will be recorded every 5 minutes. Arterial blood gas (ABG) data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing. Next, the study participant will be transitioned to the Umbulizer to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be taken every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour.
16392793|NCT04030208|Other|Sequence B|If patient is randomly assigned to Sequence B, they will be shifted to the Umbulizer for the first period. This period will be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour. Next, the study participant will be transitioned to a traditional ventilator to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using the ventilator. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing.
16392794|NCT04030195|Experimental|Dose Level 1 of PBCAR20A CAR T cells|"1 x 10^6 CAR T cells per kg body weight.
~In this study, PBCAR20A, allogeneic anti-CD20 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
~Route of Administration: Intravenous infusion.
~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16392795|NCT04030195|Experimental|Dose Level 2 of PBCAR20A CAR T cells|3 x 10^6 CAR T cells per kg body weight.
16392796|NCT04030195|Experimental|Dose Level 3 of PBCAR20A CAR T cells|6 x 10^6 CAR T cells per kg body weight.
16392797|NCT04030182||Level of vitamin D|Level in blood sample of vitamin D for each patient
16392798|NCT04030169|Experimental|Experimental: MDMA-assisted psychotherapy|Two sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
16392962|NCT04028986||Surgery group|patients treated by surgery before starting the IVF/ICSI treatment
16392799|NCT04030156||ultrasonographic tonsil volume|All measurements were done by the same radiologist with over 20 years of experience. GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) was used in USG examination. The patients were viewed using a 2-9 MHz linear probe from the submental region. The examination was done while the patient was in a supine position, with a neck support. Right tonsil measurement was done by turning the neck slightly to the upper left whereas left tonsil measurement was done by turning the neck slightly to the upper right. Tonsil volume was calculated with standard ultrasonography formula (height x length x thickness x 0.52) due to its ellipsoid shape.
16392800|NCT04030156||Actual tonsil volume|Excised tonsil volumes were calculated by water replacement method.
16392801|NCT04030143|Experimental|Aripiprazole 2M LAI|"2 Months (2M) Long-acting injection (LAI).
~Participants will receive a total of 4 injections of aripiprazole 2M LAI, administered every 56 days (+/- 2 days) from Day 1.
~Participants will continue to take their current oral antipsychotic or be given 10 to 20 mg oral aripiprazole for 7 days after the first administration."
16392802|NCT04030143|Active Comparator|Aripiprazole 1M depot injection|"1 Month (1M) depot injection.
~Participants will receive a total of 8 injections of aripiprazole 1M depot, administered every 28 days (+/- 2 days) from Day 1.
~Participants will continue to take their current oral antipsychotic or be given 10 to 20 mg oral aripiprazole for 14 days after the first administration."
16392803|NCT04030130|Experimental|NDURE|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system-(care coordination), interpersonal-(social support), and individual- (health belief model [HBM]; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, enhance HNSCC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE navigation sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit, time points chosen to facilitate case identification and coordination across key care transitions.
16392804|NCT04030130|No Intervention|Usual Care|UC consists of discussions about the indications, risks/benefits/alternative, Guidelines, timing, and logistical details of adjuvant therapy. These discussions will be administered according to practice patterns of the involved providers.
16392805|NCT04030117|Experimental|ACTIVA Test arm|Treatment of decay in Class II second primary molars using ACTIVA restorative material.
16392806|NCT04030117|Active Comparator|Compomer Comparator arm|Treatment of decay in Class II second primary molars using compomer restorative material.
16392807|NCT04030104|Active Comparator|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
16392808|NCT04030104|Experimental|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
16392809|NCT04030091|Experimental|3 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
16392810|NCT04030091|Experimental|2 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
16392811|NCT04030065|Experimental|Experimental Arm - omega 3 fatty acid|
16392812|NCT04030065|No Intervention|Control Arm - No intervention|
16392813|NCT04030052|Experimental|Untreated/minimally treated moderate HA no inhibitors|Previously untreated patients (PUPs) and minimally treated patients (MTPs) <3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.
16392814|NCT04030052|Experimental|Treated any moderate HA with existing inhibitors|Children <21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).
16392815|NCT04030039||chronic hepatitis B patients during the immune control period|Patients with chronic HBV infection during the immune control period do not have any clinical treatment intervention cohort
16392816|NCT04030039||Therapy group A|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with interferon
16392817|NCT04030039||Therapy group B|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they stopped to be treated with interferon
16392818|NCT04030039||Therapy group C|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential nucleoside analogues
16392819|NCT04030039||Therapy group D|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential interferon
16392820|NCT04030039||Therapy group E|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with the nucleoside analogues
16392821|NCT04030026|Active Comparator|Arm 1a: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 1
16392822|NCT04030026|Placebo Comparator|Arm 2a: Placebo|Placebo twice a day for Treatment Period 1
16392823|NCT04030026|Placebo Comparator|Arm 1b: Placebo|Placebo twice a day for Treatment Period 1
16392824|NCT04030026|Active Comparator|Arm 2b: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 2
16392825|NCT04030013|Active Comparator|Group education for 2 years|Patients who will receive structured diabetes education in groups , Group 1
16392826|NCT04030013|Active Comparator|One to one education for 2 years|Patients who will receive one to one structured diabetes education, Group 2
16392827|NCT04030013|No Intervention|Control group without structured education|Patients who will not receive structured diabetes education, Group 3
16392963|NCT04028986||Ulipristalacetate group|patients treated by ulipristalacetate before starting IVF/ICSI treatment
16392964|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 1)|
16392965|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 2)|
16392828|NCT04030000|Other|Paclitaxel/Carboplatin and radiation|"Paclitaxel 135 mg/m2 over 3 hrs on day 1 Carboplatin IP (AUC= 6.0) on day 1 Paclitaxel 60 mg/m2 IP on Day 8 Repeat q 21 days x 6 cycles
~Pelvic 6MV Photon Beam Energy, or IMRT where appropriate 1.8 Gy Dose/FX Total Dose 45 Gy
~High Dose Radiation (HDR) x 3, or IMRT where appropriate 5 Gy to 0.5cm Depth from the Vaginal Cylinder Surface Total Dose 15 Gy"
16392829|NCT04029987|Active Comparator|Trans Muscular Quadratus Lumborum fascial plane Block|"In group (Trans Muscular Quadratus Lumborum Block),will undergo ultrasound guided trans-muscular quadratus lamborum block as follows:
~A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoas Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
16392830|NCT04029987|Active Comparator|Intra Muscular Quadratus Lumborum fascial plane Block|"In group Intra Muscular Quadratus Lumborum Block ,will undergo ultrasound guided intra-muscular quadratus lamborum (QL) block as follows:
~A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
16392831|NCT04029987|Placebo Comparator|group c → control|group c → control ,will receive conventional analgesia in the form of paracetamol with 15 mg\ k.g every 6 hours, and naluphin 0.1 mg \kg on demands
16392832|NCT04029974|Experimental|Treatment|Progressive elevation (0 degrees, 25 degrees, 50 degrees, 75 degrees; x2 minutes in each position) while on robotic tilt-stepper at the cadence of 0, 40, and 80 steps/minute.
16392833|NCT04029961|Active Comparator|Video Education|Participants will receive video education on radiation therapy.
16392834|NCT04029961|Experimental|VR-based Education|Participants will receive VR-based education on radiation therapy.
16392835|NCT04029948|Active Comparator|laser ERBT|Laser En Bloc Resection Of bladder Tumor
16392836|NCT04029948|Active Comparator|electro-surgical ERBT|electro-surgical En Bloc Resection Of bladder Tumor
16392837|NCT04029935|Experimental|Physical Fatigue Condition|
16392838|NCT04029935|Placebo Comparator|Control Condition|
16392839|NCT04029922|Experimental|Arm 1- Dose Escalation|"The dose escalation part of the study is aimed at determining the Recommended Phase 2 Dose (RP2D) of MT-5111.
~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
16392840|NCT04029922|Experimental|Arm 1- Dose Expansion|"The dose expansion part of the study will begin after completion of the dose escalation phase to confirm the safety and tolerability of the RP2D.
~The RP2D dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
16392841|NCT04029909|Experimental|Gimatecan 0.6mg/m2/d|Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
16392842|NCT04029909|Experimental|Gimatecan 0.8mg/m2/d|Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
16392843|NCT04029909|Experimental|Gimatecan 0.4mg/m2/d|Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
16392844|NCT04029883|No Intervention|Control Group|The Control group will receive care as usual, as well as a MEMS-cap and a leaflet explaining the importance of pill-taking routines and how to establish them. The study coordinator will spend approximately ten minutes with them to go over the leaflet and answer questions. Control group participants also spend time with the study coordinator at each clinic visit where contact information is updated, and any MEMS-cap problems are resolved. These procedures, which we successfully applied in previous studies, minimize the possibility that results are confounded by differences in attention or other non-specific effects between groups.
16392845|NCT04029883|Active Comparator|Message Group|The Message group will receive the same brief information session as the Control group but also receive daily text messages reinforcing the information provided for 3 months. A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time. To keep the importance of routinizing pill- taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform. These messages will reinforce the information provided at recruitment, and remind participants of their personalized routinization strategy. Messages will be tailored and refreshed based on patient-specific factors including BP control, prior adherence, and current medication regimen.
16392846|NCT04029883|Experimental|Incentive Group|The Incentive group will receive the same information and text messages, but in addition have a chance of winning small, intermittent rewards for taking their medication at the time coinciding with their anchoring strategy. In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits. When the participants return for their monthly visit, the study coordinator will download their MEMS-cap data and check whether this eligibility criteria was satisfied. MEMS software can be easily customized to display this information. If the patient qualifies, s/he is invited to draw one of three laminated cards with numbers 0, 25, and 50 out of a bag. The client receives the corresponding amount in USD in the form of a gift card immediately after the drawing.
16392847|NCT04029857|Active Comparator|Group I (standard of care)|Patients receive standard of care nutritional supplementation.
16392848|NCT04029857|Experimental|Group II (Impact Advanced Recovery)|Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
16392849|NCT04029844|Experimental|Colibri Device|Treatment
16392850|NCT04029831|Experimental|K61|Patients in K61 group received propofol and ketamine in a ratio of 6:1. The 6:1 ketofol mixture was made by mixing 30 mL of 1% propofol (10 mg/mL) and 1 mL of ketamine (50 mg/ml), then 19 mL of 0.9% NaCl was added until the volume of the mixture was 50 mL. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
16392851|NCT04029831|Experimental|K41|Patients in K41 group received propofol and ketamine in a ratio of 4:1. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
16392852|NCT04029818|Experimental|Probiotic|Volunteers will take a capsule with Bifidobacterium BSL_PS404 (3x109 cfu) daily.
16392853|NCT04029818|Placebo Comparator|Placebo|Volunteers will take a capsule with maltodextrin daily.
16392854|NCT04029805|Experimental|Combination of a Plant Extract and a Probiotic|Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
16392855|NCT04029805|Placebo Comparator|Placebo|Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.
16392856|NCT04029792|Experimental|Combination of Plant Extracts (BSL_EP028)|Volunteers will take twice at day for 8 weeks a capsule containing the combination of a plant extracts (BSL_EP028)
16392857|NCT04029792|Placebo Comparator|Placebo|Volunteers will take twice at day for 8 weeks a capsule containing maltodextrin.
16392858|NCT04029779|Experimental|Immediate implant placement coated with I-PRF|The test group received implants coated with injectable platelet-rich fibrin and also the sockets were injected with injectable- platelet rich fibrin
16392859|NCT04029779|No Intervention|immediate implant only|The control group received immediate dental implants only after extraction of the teeth without any local coating.
16392860|NCT04029766|Experimental|HSK3486|0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)
16392861|NCT04029753|Experimental|Walk out from operating room|Patients will return to the ward after surgery by walking.
16392862|NCT04029753|No Intervention|Leave operating room by transporting bed|Patients will return to the ward after surgery by lying on the transporting bed.
16392863|NCT04029740|Other|Healthy controls|40 Healthy controls matched on gender and age with no current psychopathology will have exosomal microRNAs measured twice over a 3 month period.
16392864|NCT04029740|Experimental|panic disorder receiving CBT|40 adult patients diagnosed with primary panic disorder will have their exosomal microRNAs measured 2x over 3 months.
16392865|NCT04029727|Experimental|Combination of Plant Extracts (BSL_EP025)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP025)
16392866|NCT04029727|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
16392867|NCT04029714|Active Comparator|Arm 1: Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and initiation of curative treatment are performed according to the urologist's judgement.
16392868|NCT04029714|Experimental|Arm 2: Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
16392869|NCT04029701|Experimental|Research group|"Subjects who are recruited into this group are asked to take the Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.
~P.S. Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
16392870|NCT04029701|Placebo Comparator|Control group|"Subjects who are recruited into this group are asked to take the placebo of Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.
~P.S. Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
16392871|NCT04029688|Experimental|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
16392872|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Venetoclax|
16392873|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Cyclophosphamide + Topotecan|
16392874|NCT04029688|Experimental|AML: Idasanutlin + Venetoclax|
16392875|NCT04029688|Experimental|AML: Idasanutlin + Fludarabine + Cytarabine|
16392876|NCT04029688|Experimental|ALL: Idasanutlin + Venetoclax|
16392877|NCT04029675|Experimental|Study Group ( High dose vitamin C group )|They will receive 1.5 gm intravenous (IV) Vitamin C in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes every 6 hours daily for 4 days or until ICU discharge.
16392878|NCT04029675|Active Comparator|Control Group (Daily requirements vitamin C Group )|They will receive standard daily requirements of Vitamin C intravenously which is 75-90 mg in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes daily for 4 days or until ICU discharge
16392879|NCT04029662|Experimental|Group Valsalva Maneuver|Patients who undergo spinal anesthesia and perform Valsalva maneuver to reduce the pain intensity
16392880|NCT04029662|No Intervention|Group Control|Patients who undergo spinal anesthesia and perform nothing to reduce the pain intensity
16392881|NCT04029649|Experimental|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days
16392882|NCT04029649|Placebo Comparator|Placebo|This group received empty capsule with dose 3x1 capsule a day for 90 days
16392883|NCT04029636||Established LONIPC|The first cohort will comprise of patients with established LONIPCs and the investigative procedures in this study will provide data on the scope of abnormalities and pathology across the spectrum of these conditions.
16392884|NCT04029636||Trajectory of LONIPC|The second, prospectively followed, cohort will provide data on the sequence and temporal development of these abnormalities, and therefore provide information on the trajectory of LONIPCs
16393866|NCT04022499|Experimental|Pre-NDPP|Presessions + usual care NDPP
16392885|NCT04029623|Experimental|Partnered Rhythmic Rehabilitation (PRR)|Participants in this study are will receive the PRR intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
16392886|NCT04029623|Active Comparator|Group walking (WALK)|Participants in this study are will receive the WALK intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
16392887|NCT04029610|Active Comparator|Local anesthesia of lidocaine and arterial blockage on the arm|Local anesthesia of lidocaine and arterial blockage on the arm
16392888|NCT04029610|Experimental|Local anesthesia with lidocaine and adrenalin|Local anesthesia with lidocaine and adrenalin
16392889|NCT04029597|Experimental|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the Remote Patient Monitoring System.
16392890|NCT04029584|Experimental|Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.
~For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.
~Before starting hepatic induced period, subjects will have a washout for greater than one week.
~To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg."
16392891|NCT04029584|Experimental|Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone|"The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.
~For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.
~Before starting induction periods, subjects will have a washout greater than one week.
~To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg."
16392892|NCT04029571|Experimental|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
16392893|NCT04029571|Active Comparator|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
16392894|NCT04029571|No Intervention|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
16392895|NCT04029558|Experimental|Combination of plant extracts (BSL_EP024)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
16392896|NCT04029558|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
16392897|NCT04029545|Experimental|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
16392898|NCT04029545|Active Comparator|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
16392899|NCT04029545|Experimental|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
16392900|NCT04029532||Non-overweight/obese & normal weight|Body mass index (BMI) < 24.0 kg/m^2
16392901|NCT04029532||Overweight and obese|Body mass index (BMI) >= 24.0 kg/m^2
16392902|NCT04029519|Experimental|PN40082|All subjects in this study will receive one open-label treatment with PN40082.
16392903|NCT04029506||medical staff group|medical staff in Qilu Hospital who recieveing endoscopy for physical examination
16392904|NCT04029506||general population group|general population who recieveing endoscopy for physical examination in Qilu Hospital
16392905|NCT04029480|Experimental|Ertugliflozin 5 mg/5 mg|"All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.
~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
16392966|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 1)|
16392967|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 2)|
16392968|NCT04028960|Placebo Comparator|Placebo|No active drug
16392969|NCT04028960|Experimental|Humulin-R|Insulin
16392970|NCT04028947|No Intervention|Standard TKA|Subjects will have the standard procedure.
16392971|NCT04028947|Active Comparator|TKA with Neurectomy|Subjects will the nerve excised and protected with soft tissue.
16392906|NCT04029480|Experimental|Ertugliflozin 5 mg/15 mg|"All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.
~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
16392907|NCT04029480|Placebo Comparator|Placebo|At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.
16392908|NCT04029467|Active Comparator|Precedex|participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
16392909|NCT04029467|Experimental|Dexmedetomidine|participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
16392910|NCT04029454|Experimental|Intervention period|Intervention : birth dose vaccination against hepatitis B strategy Birth dose of vaccine against hepatitis B + routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
16392911|NCT04029454|No Intervention|Control period|Routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
16392912|NCT04029441||the successful eradication cohort|the subjects who eradicate the Hp successfully after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
16392913|NCT04029441||the failure eradication cohort|the subjects who fail to eradicate the Hp after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
16392914|NCT04029428|Active Comparator|90Y DOTATATE|Therapy 90Y DOTATATE, total activity 4x3.7GBq (14.8 GBq), i.v. infusion of 90Y DOTATATE administered for 20 min. via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
16392915|NCT04029428|Experimental|177Lu DOTATATE or mix 90Y and 177Lu DOTATATE (50% each)|Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
16392916|NCT04029402||Diabetic kidney disease|Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
16392917|NCT04029402||Healthy controls|Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
16392918|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Conservational|After ESWT therapy patients suffer from extreme pain will recieve only conservational therapy (26 patients)
16392919|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Local|After ESWT therapy patients suffer from extreme pain will receive local steroid injections
16392920|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Tibial nerve|After ESWT therapy patients suffer from extreme pain will receive tibial nerve block
16392921|NCT04029350|Experimental|Anlotinib Combined With Osimertinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
16392922|NCT04029324|Active Comparator|Immediate implant placement|Implants are placed immediately after extraction
16392923|NCT04029324|Placebo Comparator|Early implant placement|Implants are placed 4-8 weeks after extraction
16392924|NCT04029311|Experimental|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
16392925|NCT04029311|Experimental|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
16392926|NCT04029298|Experimental|HBDC Intervention Group|Immediate enrollment in the 16-week, HBDC education-based intervention, followed by a 12-month observation period
16392927|NCT04029298|Other|Control/Usual Care/Delayed Intervention Group|16-week, HBDC education-based intervention will be delayed by 12 months. Following the delayed intervention, this group will be observed for an additional 12-month period
16392928|NCT04029285|Other|Traditional Gym Based exercise - Control|Twice weekly sessions of TGB exercise for six weeks.
16392929|NCT04029285|Experimental|Exergaming|Twice weekly sessions of exergames for six weeks.
16392930|NCT04029272|Active Comparator|Metformin|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)
~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d."
16392931|NCT04029272|Experimental|Metformin+EQW|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)
~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d.
~EQW: Participants will receive long-acting Exenatide once a week for 12 weeks"
16392932|NCT04029246|No Intervention|Letter only|
16392933|NCT04029246|Active Comparator|Letter plus phone call|
16392934|NCT04029246|Active Comparator|Letter plus incentive|
16392972|NCT04028921||Normal weight, active|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, >=60 min/day of moderate/vigorous physical activity.
16393867|NCT04022499|Active Comparator|Usual care NDPP|Usual care NDPP only
16392935|NCT04029220|Experimental|Parent Peer Navigation (PPN) by Family Run Organization|In this arm, families receive PPN services from a trained provider with lived experience whose role is to effectively engage parents/caregivers in necessary treatment for their children by helping them connect with assessment, treatment and community-based resources and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support once the PPN is no longer involved. PPN providers use the foundational competencies and skills to educate, inform and support families who are just entering the child-serving systems due to emerging behavioral health issues of their child.
16392936|NCT04029220|Active Comparator|Resources provided by Family Support Organization|"The active comparator is service provided by Family Support Organizations (FSOs), which provide information and resources for families about disabilities, special education and other services as well as workshops and parent support groups. Unlike PPN services, FSO staff members are not veteran caregivers of a child with mental health challenges, do not provide personalized service delivery, do not provide a comprehensive assessment of family needs, and do not prepare families to make use of services through support for their initial and continued involvement in them. Finally, whereas PPNs participate in comprehensive training and coaching, training for FSO staff tends to be more general and consists primarily of being aware of local resources to which families may be referred."
16392937|NCT04029207||African Surgical OutcomeS-2 Trial|The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.
16392938|NCT04029194|Experimental|Treatment|
16392939|NCT04029194|No Intervention|Control|
16392940|NCT04029181|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval.
16392941|NCT04029181|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of the anti-CD8 imaging agent in patients before and during treatment with checkpoint inhibitors.
16392942|NCT04029168||Pelvic floor surgery|The group will consist of females with pelvic floor disorders (pelvic organ prolapse, stress urinary incontinence) qualified for pelvic floor surgery
16392943|NCT04029155|Active Comparator|TBNA with Conventional bronchoscope|patients in this arm will undergo bronchoscopy by a conventional probe
16392944|NCT04029155|Experimental|TBNA with a Ultrathin bronchoscope|Patients in this arm will undergo bronchoscopy by a ultra thin probe
16392945|NCT04029129|No Intervention|High exposure|Ambient air was allowed freely into the room.
16392946|NCT04029129|Experimental|Medium exposure|Limited air filtration was used to partially reduce levels of pollution in the room relative to outside.
16392947|NCT04029129|Experimental|Low exposure|Doors and windows were closed and sealed and full filtration was used to maximally reduce pollution in the room.
16392948|NCT04029116|Experimental|Ibrexafungerp|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
16392949|NCT04029116|Placebo Comparator|Placebo|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days
16392950|NCT04029103|Active Comparator|used m-DAKBAS|"m-DAKBAS application was downloaded to the mobile phones of the participants who met the research criteria and accepted to participate in the study; the participants were given a username and a password for the confidentiality. They were instructed how to use the application after a number of trials.
~The participants were asked to send their blood sugar levels each time they measured it and foot observations daily through the application. Using the admin panel, the researcher followed the participants' frequency of using the application and the data they sent throughout 24 weeks and tried to find solutions to the problems experienced (for example: hyperglycaemia, insulin dosage adjustments). The participants were provided with feedback in line with these data; SMS reminders were sent if the tasks were not completed."
16392951|NCT04029103|Experimental|not used m-DAKBAS|The participants who met the research criteria and accepted to participate in the study were given training via verbal instruction about the information in the content of m-DAKBAS (definition of Diabetic Foot, risk factors, protective precautions, daily foot care)
16392952|NCT04029090|Experimental|Sequence 1|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
16392953|NCT04029090|Experimental|Sequence 2|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
16392954|NCT04029090|Experimental|Sequence 3|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
16392955|NCT04029077||Vapor group|Bronchoscopic lung volume reduction treatment using Vapor
16392956|NCT04029038|Experimental|Treatment (CD19-CD22 CAR T cells)|Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
16392957|NCT04029025|Active Comparator|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
16392958|NCT04029025|Active Comparator|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
16392959|NCT04029025|Active Comparator|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C).
16392960|NCT04029012|Experimental|Penthrox|methoxyflurane inhaler (Penthrox)
16395127|NCT04013815|Active Comparator|group I|patients receiving the intercostal nerve block
16392973|NCT04028921||Normal weight, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, <60 min/day of moderate/vigorous physical activity.
16392974|NCT04028921||Overweight/obese, active|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, >=60 min/day of moderate/vigorous physical activity.
16392975|NCT04028921||Overweight/obese, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, <60 min/day of moderate/vigorous physical activity.
16392976|NCT04028895|Other|Experimental|
16392977|NCT04028882||Non viremic HIV patients under treatment|Patients with various immune activation profiles
16392978|NCT04028869||Glycyrrhizin preparation treatment group|Clinical effect of glycyrrhizic acid preparation for 144 weeks of autoimmune liver disease and safety during treatment
16392979|NCT04028856||Continuous interferon treatment group|Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
16392980|NCT04028856||Intermittent interferon treatment group|patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months
16392981|NCT04028843|No Intervention|WIC Nutrition|Participants will receive weight management advice and care through the standard Women, Infants, and Children program. They will also receive weekly health information related to pregnancy, birth, and infant health through a closed Facebook group.
16392982|NCT04028843|Experimental|Healthy Beginnings|Participants will receive the SmartMoms smartphone application, a wireless connected scale, and a Fitbit. The Healthy Beginnings program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the SmartMoms smartphone application, personalized feedback from counselors, and evidence-based behavioral intervention delivered throughout pregnancy.
16392983|NCT04028830|Experimental|Arm 1|Medical representative presentation with the help internet tool for decision ANTIBIOCLIC
16392984|NCT04028830|Experimental|Arm 2|Medical representative presentation without presentation of the internet tool for decision support
16392985|NCT04028830|No Intervention|Arm 3|Usual practice without intervention regarding the prescription of antibiotics
16392986|NCT04028817|Experimental|group treatment|This group will receive laser treatment combined with low intensity exercises
16392987|NCT04028817|Placebo Comparator|group control|This group will receive placebo laser treatment combined with low intensity exercises
16392988|NCT04028804||FDG PET|FDG PET imagaing
16392989|NCT04028804||FLT PET|FLT PET imaging
16392990|NCT04028791|Experimental|AS and AA|Participants will be submitted to 45 minutes of exercise on ergocycle.
16392991|NCT04028778|Experimental|Gefitinib + Anlotinib|Patients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
16392992|NCT04028778|Placebo Comparator|Gefitinib + Placebo|Patients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
16392993|NCT04028765|Active Comparator|Oral Misoprostol|Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated
16392994|NCT04028765|Active Comparator|Oxytocin|IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol
16392995|NCT04028752||Males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
16392996|NCT04028739|Experimental|Theracurmin CR-033P|1 Capsule with 150mL water, Single, curcumin 90mg/day
16392997|NCT04028739|Experimental|Theracurmin CR-031P|3 Capsule with 150mL water, Single, curcumin 90mg/day
16392998|NCT04028739|Experimental|Curcumin|1 Capsule with 150mL water, Single, curcumin 90mg/day
16392999|NCT04028726|Active Comparator|Cluster set Resistance Training Protocol|Cluster set configuration is the new training approach that it is being tested.
16393000|NCT04028726|Sham Comparator|Traditional Resistance Training Protocol|Traditional is commonly used in training sessions.
16393001|NCT04028713|Active Comparator|Standard dosing group|Patients will continue to receive adalimumab according to the standard dosing schedule.
16393002|NCT04028713|Experimental|Dose tapering group|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
16393003|NCT04028700|Experimental|G6PD Deficient Red Blood Cell Transfusion, then Non-G6PD deficient Red Blood Cell Transfusion|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity.
16393004|NCT04028700|Active Comparator|Non-G6PD deficient Red Blood Cell Transfusion, then G6PD Deficient Red Blood Cell Transfusion,|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity
16393005|NCT04028687||Taperloc Complete Stems|Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
16393006|NCT04028674|Experimental|Early Activation of Laryngeal Pacing device|Early Activation of the laryngeal pacing device (n=9) at one month post-implantation.
16393007|NCT04028674|Sham Comparator|Delayed Activation of Laryngeal Pacing device|Delayed activation of the laryngeal pacing device (n=3) at two months post-implantation.
16393008|NCT04028661|Experimental|Intervention group|use of 3D printed Modified Twin Block Appliance.
16393009|NCT04028661|No Intervention|Untreated control group|No treatment phase of 8 months.
16393010|NCT04028648||elderly|150 elderlies (>60 years): community dwelling or living in old
16393011|NCT04028635|Experimental|Cognitive-behavioral therapy plus VR-based body exposure|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, six sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which the they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions, until a healthy BMI value is reached.
16393012|NCT04028635|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the centre in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
16393013|NCT04028622|Experimental|TCAD (telemedicine anesthesia consultation)|Patients having a telemedicine anesthesia consultation
16393014|NCT04028609|Experimental|Intervention|Subjects receive an intervention with 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.
16393015|NCT04028609|Active Comparator|Services as Usual|Subjects receive medical services as usual.
16393016|NCT04028596|Active Comparator|Acetaminophen|Trade name: Paracetamol Pharmaceutical form: Tablet (oral use) Once 1000 mg 2h before the ECT-session. Total maximum of five times over the course of weeks
16393017|NCT04028596|Active Comparator|Nimodipine|Trade name: Nimotop Pharmaceutical form: Film-coated tablet (oral use) Once 60mg 2h before the ECT-session. Total maximum of five times over the course of weeks.
16393018|NCT04028596|No Intervention|Control|Glass of water (50cc) only. Once 2h before the ECT-session. Total maximum of five times over the course of weeks.
16393019|NCT04028583|Experimental|PIM-Check group|
16393020|NCT04028583|Active Comparator|STOPP/START group|
16393021|NCT04028570|Experimental|Radiation|This study involves a 3+3 design. The starting cohort (n=3) will receive a neoadjuvant Background dose to the affected hemithorax (starting at 0 cGy) as well as concomitant Boost dose (of at least 2100 cGy) to a part of the gross tumour volume (GTV). The radiation will be delivered over 3 alternate days over 5-7 calendar days followed by macroscopically complete extensive pleural resection (either extra-pleural pneumonectomy or extended pleurectomy decortication, at the surgeon's discretion) after 7 to 14 days. If no dose limiting toxicities (DLTs) seen, then the Background RT dose will be increased by 600 cGy (up to 1800 cGy) and the cohort (n=3) for the next dose level will be accrued. If only 1 DLT seen, then an additional 3 patients will be treated on this dose level. If 2 or more DLTs seen at any given dose level, then the previous dose level will be defined as the maximum tolerated dose (MTD). Patients will be stratified by type of resection.
16393022|NCT04028557|Experimental|Customized CDS|The customized CDS will be designed and implemented with comprehensive application of known best practice principles in CDS design. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
16393023|NCT04028557|Active Comparator|Commercial CDS|The commercial CDS is available to all institutions using the Epic electronic health record vendor, but violates some CDS design best practices, notably not being tailored to the end users of a given health system. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
16393024|NCT04028544|Experimental|The Treatment Group|standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
16393025|NCT04028544|Placebo Comparator|The Control Group|standard treatment + placebo (oral use, 1 bag each time, three times a day).
16393026|NCT04028531||Sample Collection|"Blood tests required for assessment
~Specimens and data will also be collected from outside sites
~Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute"
16393027|NCT04028518|Experimental|The high-dose group|"Experimental: r-PA Dose: stick 18 mg;
~Mode of admin:
~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
16393028|NCT04028518|Experimental|The low-dose group|"Experimental: r-PA Dose: stick 18 mg;
~Mode of admin:
~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
16393029|NCT04028518|Experimental|Active Comparator: Alteplase|"Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg
~Mode of admin:
~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours of medication.Subjects were monitored according to the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018."
16393030|NCT04028505|Experimental|Terlipressin Continuous Infusion|Standard of care being given at AKUH + Continuous infusion of Terlipressin (Terlipressin Injectable Product) at a rate of 0.5mg/hour for the first 24 hours
16393031|NCT04028505|Active Comparator|Terlipressin Bolus Infusion|Standard of care being given at AKUH + Bolus infusion of Terlipressin (Terlipressin Injectable Product) at a frequency of 2mg every six hourly for first 24 hours
16393032|NCT04028492|Experimental|Tradipitant|Oral Capsule
16393033|NCT04028492|Placebo Comparator|Placebo|Oral Capsule
16393034|NCT04028479||Validation Cohort|Patients enrolled into the study to allow validation of a specific element, process, or endpoint. Validation will be done showing concordance with traditional interventional trial standards.
16393035|NCT04028479||Analysis Cohorts|Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit. Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study. Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
16393036|NCT04028479||Retrospective Chart Review Cohorts|"This arm will use retrospective data obtained through systematic chart review on previously seen patients to compare, contrast, or enhance the efforts of the prospective arms. Because most RWD has been traditionally obtained through retrospective methods, this is also considered the control arm. Data in this arm will be collected without any patient identifiers. This arm is optional."
16393037|NCT04028466|Experimental|Vonoprazan|Patients will be randomized to receiving vonoprazan, which will be taken 30 minutes before the first meal of the day for 14 days
16393038|NCT04028466|Active Comparator|Omeprazole|Patients will be randomized to receiving omeprazole, which will be taken 30 minutes before the first meal of the day for 14 days
16393039|NCT04028453||Mother|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation questionnaire.
16393040|NCT04028440|Experimental|Autologous γδT cells|Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions, single infusion intravenously at a target dose of 1~2×10e9 γδT cells (constant dose).
16393041|NCT04028427|Experimental|Participants randomly assigned to VGI|
16393042|NCT04028427|Experimental|Participants randomly assigned to MBI|
16393043|NCT04028414|Experimental|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
16393044|NCT04028414|No Intervention|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
16393049|NCT04028362||Neuromuscular blockade|Patients who will receive neuromuscular blockade during their ICU length stay will be follow until day 28 or their hospital discharge.
16393050|NCT04028349|Experimental|Single Arm|Ad26.ZEBOV/ MVA-BN-Filo Vaccines
16393051|NCT04028336|Experimental|TITRATION|"All patients hospitalized in intensive care and meeting inclusion criteria and without criteria for non-inclusion will be included in this study. All patients will benefit from Lung ultrasound (LUS) and esophageal pressure measurement (Peso) according to the habits of the service. A PEP titration pulmonary opening (PEP-OP) test using a recruitment maneuver was then performed in all patients followed by a new LUS and Peso measurement."
16393052|NCT04028323|Experimental|Experimental group|Drug: Terlipressin. Terlipressin should be administrated with an initial dose of 1-2 mg intravenously and slowly injected (over 1 minute) while monitoring the heart rate and blood pressure. The maintenance dose should be administrated every 4-6 hours. Each dose of terlipressin is 1mg. The usual duration of therapy is 3-5 days.
16393053|NCT04028323|Active Comparator|Control group|Drug: Octreotide. Octreotide should be continuously and intravenously dripped at the speed of 0.025-0.05 mg/h and could be diluted with saline with the maximum duration of 5 days. The usual duration of therapy is 3-5 days.
16393054|NCT04028310|Experimental|Phonological group|
16393055|NCT04028310|Experimental|visual-attention group|
16393056|NCT04028284|Active Comparator|Group 1|In Group 1 (control), the staff anesthesiologist will follow the traditional technique for US-guided thoracic epidural insertion. Briefly, the anesthesiologist will use the US to identify and mark the appropriate spot for placement of the thoracic epidural catheter. The US probe is then placed at rest and the anesthesiologist will proceed with thoracic epidural needle insertion following standard techniques.
16393057|NCT04028284|Active Comparator|Group 2|In Group 2 (intervention), the staff anesthesiologist will use the HoloLens tool to assist with the traditional technique as described above for Group 1. In combination with the US, a hologram image of the trajectory towards the epidural space will be generated, thereby mitigating the need to walk off the lamina. The holographic system will mark the appropriate spot for placement of the thoracic epidural catheter. Then, the needle will be inserted following the holographic trajectory overlaid on the patient's back.
16393058|NCT04028271|Experimental|experimental|local anesthesia applyed with Comfort in system
16393059|NCT04028271|Active Comparator|conventional injection|local anesthesia applyed with conventional syringe
16393060|NCT04028258|Other|Group A: study+wash out+control|Study product (3 weeks) + wash out (2 weeks) + control product (3 weeks)
16393061|NCT04028258|Other|Group B: control+wash out+study|Control product (3 weeks) + wash out (2 weeks) + study product (3 weeks)
16393062|NCT04028245|Experimental|Spartalizumab and Canakinumab|Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.
16393063|NCT04028219||Transgender patients|Gender dysphoric patients undergoing hormone treatment
16393064|NCT04028206|No Intervention|Control Group|No intervention on sarcopenic subjects screened (based on the AWGS definition).
16393065|NCT04028206|Active Comparator|Exercise + HMB Group|Sarcopenic subjects on combined treatment of elastic-band exercise and HMB supplementation
16393066|NCT04028206|Active Comparator|Vibration Treatment + HMB Group|Sarcopenic subjects on combined treatment of vibration treatment and HMB supplementation
16393067|NCT04028193|Other|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
16393068|NCT04028193|Other|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
16393069|NCT04028180|Experimental|Midge Repellency|Treatment of forearm with insect repellent and exposure to midges every 1 hour for 12 hours
16393070|NCT04028167|Experimental|Sequential FLOT followed by chemoradiation|Sequential Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/Leucovorin followed by chemoradiation with concurrent carboplatin and paclitaxel
16393071|NCT04028154|Experimental|ESP Block|
16393072|NCT04028154|Active Comparator|TLIP Block|
16393073|NCT04028141||participants undergoing procedural sedation|"The study gathered observational data about participants who underwent procedural sedation according to the new standard protocol with ketofol in a 1 on 4 concentration.
~The participant was observed for complications or cardiorespiratory interventions by the sedating physician until he was fully awake. Thirty minutes after the awakening, the participant was questioned for his remembrance and perception of the sedation and procedure. He was observed for complications until discharge"
16393074|NCT04028128|Experimental|Cocoa group|The cocoa was provided in 5 g sachets. The intervention last 10 weeks. Cocoa was provided in a single daily dose of 5 g, which provided 425 mg of flavonoids
16393075|NCT04028128|Placebo Comparator|Placebo group|Maltodextrin (5 g) was supplied as placebo in sachets identical to those provided for cocoa.
16393076|NCT04028115|Experimental|Interventional|Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. In this, study no randomisation will occur. All patients will receive the same treatment.
16393077|NCT04028089|Experimental|Diet Modification Group|
16393078|NCT04028089|Other|Regular Diet Group|
16393079|NCT04028076|Experimental|Peers LEAD|8-week educational behavioral intervention
16393080|NCT04028063|Experimental|doxorubicin with AGEN1884 and AGEN2034|Doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. Doxorubicin dosing is standard at 75 mg/m2 via Bolus with prior Dexrazoxane. AGEN2034 - 300 mg IV over 60min with infusion pump. AGEN1884 - 1 mg/kg IV over 90 min (-10 /+20 min) with infusion pump, within 30 minutes (0 / +20) of completion of AGEN2034.
16393081|NCT04028050|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
16393082|NCT04028037|Experimental|FTPG treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. In Test group, the harvest of palatal graft was performed using FTPG technique. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
16393083|NCT04028037|Active Comparator|Sub-epithelial connective tissue graft (SCTG) treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. To ensure an effective randomization only at this stage the patients were assigned to the test and to the control group.In control group trap door technique was used to obtain connective palatal graft. SCTG was adapted to recipient site in way that the first mm upon cementoenamel junction (CEJ) was covered , the flap is stabilized with interrupted sutures. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
16393084|NCT04028024|Other|inhibiting systemic inflammatory response|Ulinastatin 5000U/kg in 20ml NS i.v. before occlusion of aorta
16393085|NCT04028011||PSG and novel wearable device|75 patients will wear polysomnography at the same time as the Novel wearable device
16393086|NCT04028011||PG and novel wearable device|75 patients will wear polygraphy at the same time as the novel wearable device
16393087|NCT04027998||Carpal tunnel syndrome|group of carpal tunnel syndrome patients
16393088|NCT04027998||Control group|group of healthy controls
16393089|NCT04027985|Experimental|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
16393090|NCT04027985|Sham Comparator|Control group|the patients will receive sham KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
16393091|NCT04027972|Experimental|Primary|6 Subjects will receive all 4 types of medication administration in random sequence
16393092|NCT04027959|Experimental|Epilation|Hair epilated prior to application of Vitamin B12 solution to skin
16393093|NCT04027959|Experimental|Oleic Acid|Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin
16393094|NCT04027959|Experimental|No Prep|Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin
16393095|NCT04027946|Experimental|Arm 1|LMB-100 administered in cycles 1 and 2. Pembrolizumab administered in subsequent cycles
16393096|NCT04027933|Active Comparator|Experimental|Education Based on Standard Patient Simulation was given to this group
16393097|NCT04027933|No Intervention|Control|Control group
16393098|NCT04027907||T2DM|
16393099|NCT04027907||healthy controls|
16393100|NCT04027894|Experimental|Rifamycin SV MMX plus ORT|Each tablet contains 200mg Rifamycin SV MMX for oral administration
16393101|NCT04027894|Placebo Comparator|Placebo tablets plus ORT|Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
16393102|NCT04027881|Experimental|STAR - immediate|Receive 15-week STAR intervention immediately after pretest.
16393103|NCT04027881|No Intervention|STAR - waitlist control|No intervention for the 15 weeks after pretest.
16393130|NCT04027634|Experimental|Baduanjin program|The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
16393104|NCT04027855|Other|collection of PBMC from healthy donors|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.
~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
16393105|NCT04027842|Experimental|Prewarming group|Participants in Prewarming group was warmed with forced air warming device (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) over the entire body for 10 minutes before anesthesia was induced in the operating theater. All participants received active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
16393106|NCT04027842|No Intervention|Non-prewarming group|In Non-prewarming group, no active warming was conducted before induction of anesthesia. Only standard care was provided with introperative active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
16393107|NCT04027829|Experimental|Dexmedetomidine|Intravenous infusion of dexmedetomidine for 50 min after surgery at intensive care unit
16393108|NCT04027803|Experimental|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
16393109|NCT04027803|Active Comparator|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
16393110|NCT04027790||Group 1 - Cancer Patients|Subjects with known colorectal cancer (i.e. AJCC/UICC stages 0, I, II, and III) who provide plasma at least 7 days after diagnosis by colonoscopy, but prior to surgery or treatment
16393111|NCT04027790||Group 2 - Screening Subjects|Prospectively enrolled subjects reporting for screening colonoscopy who provide a blood sample up to 2 weeks prior to bowel prep and prior to colonoscopy. We accept all subjects who meet the institutional criteria as average risk subjects referred for a screening colonoscopy for colorectal cancer, including subjects undergoing a colonoscopy as a follow-up to a positive (non-colonoscopic) test
16393112|NCT04027777|Experimental|Aktiia.product-P0|Main study arm including 85 subjects
16393113|NCT04027777|Experimental|Aktiia.product-P0 Diabetics|Second study arm including 40 diabetic patients
16393114|NCT04027777|Experimental|Aktiia.product-P0 Aged|Thirs study arm including 40 patients aged 65+
16393115|NCT04027764|Experimental|Toripalimab Combined With S1 and Albumin Paclitaxel|
16393116|NCT04027751|Experimental|Tropisetron|Patients allocated to this arm will receive single dose of intravenous Tropisetron (5mg) before anesthesia induction.
16393117|NCT04027751|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of saline solution before anesthesia induction.
16393118|NCT04027738|Experimental|PRP injection|The patients received a single 3-ml injection of PRP.
16393119|NCT04027725|Experimental|Sensorimotor neurofeedback training group|"Three interventions will be administered :
~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours.
~The third intervention is the neurofeedback training sensorimotor that will be recorded at channel Cz according to the international 10-20 system."
16393120|NCT04027725|No Intervention|Control Group|"Three interventions will be administered :
~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours
~The psychopedagogical care: each session will be organized using the same video material"
16393121|NCT04027699|Experimental|Mini-bolus|"First injection of 2ml/kg (saline solution)
~Second injection of 18ml/kg (saline solution)"
16393122|NCT04027686|Experimental|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
16393123|NCT04027686|Active Comparator|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
16393124|NCT04027673|Experimental|Treatment|Participants in the treatment group complete interactive modules. They will be asked to complete one module per week, for a total of eight weeks.
16393125|NCT04027673|No Intervention|Control|Participants in the control group will have no active study requirements for the eight weeks following Survey Session 1.
16393126|NCT04027660||Exposed Immediate Zirconia Implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications to be enrolled in an immediate implant.
~No Active Infection
~No loss of buccal plate
~ASA 1 or ASA 2 Patient
~Extraction of the tooth will be performed and in the same clinical act, a zirconia dental implant will be placed toghether with a provisional or an individualized customs healing abutment. The jumping gap will be filled with a xenograft biomaterial.
~Final Zirconia Crown delivered 3 month after healing.
~3 STL files will be generated - Before extraction, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion
~Measure 1,2 and 3 will be at the gingival margin(measure 1), at 2mm (measure 2) and 4 mm (measure 3) apical to gingival margin. Both palatal and buccal references are joined by a line that gives a distance.Difference on the dimensions of each line with different time of evaluation represent ridge loss."
16393127|NCT04027660||Non-exposed delayed Zirconia implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications not to be enrolled in an immediate implant.
~Active Infection
~Loss of the buccal plate.
~Extraction will be performed but a classical implant approach will be made, that include a waiting period of 3 month before implant placement and 3 month after osseointegration period before place final crown.
~Implant placement with Guided bone regeneration (xenograft), if needed. Final Zirconia Crown 3 month after implant placement.
~4 STL files will be generated - Before extraction, before implant placement, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion
~Measure 1,2 and 3 the same has the other group"
16393128|NCT04027647|Experimental|Treatment|Daily administration of oral Dacomitinib
16393129|NCT04027634|No Intervention|Control group|The control group (CG) received routine care and was required to walk during 6-7 pm.
16393131|NCT04027621|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
16393132|NCT04027621|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
16393133|NCT04027582|Active Comparator|Low Fidelity Simulator - Wooden block|This simulator consists of a simple series of wooden panels with holes. The resident learns how to manipulate the fiberoptic bronchoscope through the holes.
16393134|NCT04027582|Active Comparator|High fidelity Simulator - ORSIM|The ORSIM® bronchoscopy is a virtual reality simulator (Airway Simulation Limited, Auckland, New Zealand). It consists of hardware and software components that interact to create a high-fidelity virtual reality simulation. A replica fiberoptic scope is advanced by the resident through a desktop sensor, which is connected to a laptop computer. The laptop software program provides a virtual airway in which the user must navigate the probe.
16393135|NCT04027569|Active Comparator|PSFS group|Patients in this arm will complete the patient specific functional scale (PSFS) during their visits
16393136|NCT04027569|Experimental|PROMIS PF group|Patients in this arm will complete the PROMIS Physical Function during their visits
16393137|NCT04027556|Experimental|Low dose - lean body weight|Low CT contrast media dose calculated based on lean body weight
16393138|NCT04027556|Active Comparator|Standard dose|Standard CT contrast media dose calculated based on total body weight
16393139|NCT04027543||Neoadjuvant chemoradiotherapy|Patients who had chemoradiotherapy before surgery.
16393140|NCT04027543||Neoadjuvant chemotherapy|Patients who had chemotherapy before surgery.
16393141|NCT04027543||Surgery alone|Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
16393142|NCT04027530|Experimental|Ertugliflozin 15mg once daily|Once daily treatment with oral ertugliflozin (steglatro) 15mg for 4 consecutive weeks.
16393143|NCT04027530|Placebo Comparator|Placebo|Once daily treatment with a placebo pill for 4 consecutive weeks.
16393144|NCT04027517|Experimental|JTZ-951|Oral doses once daily
16393145|NCT04027517|Active Comparator|Darbepoetin Alfa|Intravenous doses of Darbepoetin Alfa administered once weekly
16393146|NCT04027504|Experimental|Fitabisc|Participants receiving fitabisc preoperatively
16393147|NCT04027491|Experimental|Virtual reality intervention|"Participant undergo 12 treatment sessions, during a 4-week period (3 sessions per week).
~Each intervention session lasts 45 minutes."
16393148|NCT04027491|No Intervention|Observational|Participant undergo a 4 weeks observational period. No intervention are performed.
16393149|NCT04027478|Active Comparator|FMD (fasting-mimicking diet)|Over the course of three rounds of chemotherapy, patients in the FMD will consume a diet that consists of 10 cal/kg/day and includes 50% fat, 40% carbohydrates, and no more than 10% protein. The diet includes nuts, olives, vegetable broth, broccoli/cauliflower, white rice/puffed rice cake, onion, tea/coffee, almond milk. The diet prohibits meat products, dairy, alcohol, sugar, and artificial sweeteners. Patients will be instructed to drink 2 cups of water each morning, take their usual medications and limit exercise to walking.
16393150|NCT04027478|No Intervention|regular diet|Diet not influenced by a fast-mimicking diet.
16393151|NCT04027465|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
16393152|NCT04027465|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses of egg protein, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
16393153|NCT04027452|Experimental|Traumatic memory reactivation|Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
16393154|NCT04027452|Placebo Comparator|Neutral memory reactivation|Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
16393155|NCT04027439|Active Comparator|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
16393156|NCT04027439|Active Comparator|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
16393157|NCT04027426|Active Comparator|FBT (family-based behavioral treatment)|This condition will be prescribed the Traffic Light Diet (1000-1500 kcal/day, < 2 servings/day of RED [non-nutrient-dense, energy-dense] foods) and a > 60 min/day of MVPA prescription for children and > 30 min/day of MVPA for adults at least 5 days/week. FBT will receive a family-based, behavioral intervention to assist the targeted child and a participating adult caregiver with making changes in energy balance behaviors.
16393158|NCT04027426|Experimental|FBT+Variety|The FBT+Variety condition will receive FBT along with a limited variety prescription. In this prescription families will identify two RED foods, a dinner entree and snack food, and develop meal plans that reduce variety of RED foods by regularly consuming these foods and limiting consumption of other RED entrees and snack foods.
16393159|NCT04027413|Placebo Comparator|Placebo/ Control|participants in this group will receive carbohydrate product which does not include protein at all
16393160|NCT04027413|Experimental|Intervention group|Participants in this group will receive high protein product
16393161|NCT04027400|Active Comparator|Primarily visual computer exercises|Participant performs visual computer exercises 30 minutes a day, five days a week for one month.
16393162|NCT04027400|Experimental|Visual+Audio|Participant performs audio computer exercises and some visual computer exercises 30 minutes a day, five days a week for one month
16415630|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts B"|
16393167|NCT04027374||Glucocorticoid control group|Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
16393168|NCT04027374||Healthy controls|Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
16393169|NCT04027361|Active Comparator|Amphetamine ER Tablets, 20 mg|Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline
16393170|NCT04027361|Placebo Comparator|Placebo|Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline
16393171|NCT04027348|Experimental|Treatment (octreotide, dexamethasone, metoclopramide)|IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.
16393172|NCT04027335|Experimental|Leva Arm|Subjects will undergo training in the use of a vaginal device and its associated app, to be used twice daily to perform pelvic floor muscle exercises guided by the device/app for 10 weeks.
16393173|NCT04027322|Active Comparator|Budesonide|"Drug Name: budesonide Dose: 2000mcg (2mg) of budesonide nebulizer solution is mixed with normal saline solution to make a total volume of 8mL.
~Frequency: Stat Dose Route: Nebulization"
16393174|NCT04027322|Active Comparator|Dexamethasone|"Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.
~Frequency: Stat Dose Route: Nebulization"
16393175|NCT04027322|Placebo Comparator|Control|Drug Name: Normal Saline Dose: 8ml. Frequency: Stat Dose Route: Nebulization
16393176|NCT04027309|Active Comparator|Arm A (Midostaurin)|Midostaurin (50 mg BID PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
16393177|NCT04027309|Experimental|Arm B (Gilteritinib)|Gilteritinib (120 mg QD PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
16393179|NCT04027283|Active Comparator|Erythritol|18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
16393180|NCT04027283|Active Comparator|Erythritol + lactisole|18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
16393181|NCT04027283|Active Comparator|D-allulose|18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
16393182|NCT04027283|Active Comparator|D-allulose + lactisole|18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
16393183|NCT04027283|Placebo Comparator|Tap water|18 volunteers receive 300mL tap water via a nasogastric tube
16393184|NCT04027283|Placebo Comparator|Tap water + lactisole|18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
16393185|NCT04027270|No Intervention|Standard of Care|These individuals will receive standard of care for post operative recovery following a prostatectomy.
16393186|NCT04027270|Experimental|Physical Therapy|These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.
16393187|NCT04027257|Experimental|STAR|Receive 15-week STAR intervention immediately after pretest.
16393188|NCT04027257|No Intervention|Waitlist Control|No intervention for the 15 weeks after pretest.
16393189|NCT04027244||Primary cohort|Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
16393190|NCT04027244||Frailty & cognitive additional assessments|Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
16393191|NCT04027244||Cardiac MRI additional assessments|Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
16393192|NCT04027244||Biomarkers additional assessments|Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
16393193|NCT04027244||Historical cohort|Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
16393194|NCT04027231||Ahlback I|
16393195|NCT04027231||Ahlback II|
16393196|NCT04027231||Ahlback III|
16393197|NCT04027231||1 year following TKA|
16393198|NCT04027231||TKA revision|
16393199|NCT04027218|Active Comparator|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.
~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
16393200|NCT04027218|Active Comparator|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.
~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
16393201|NCT04027218|Active Comparator|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.
~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
16393202|NCT04027205|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
16393203|NCT04027205|Active Comparator|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation.
16393204|NCT04027192|Experimental|Bridging part: intervention sequence ABC or BAC|10 healthy male participants will be randomly allocated to this arm. The study interventions will follow the sequence ABC or BAC: A: single dose of 50 mg BAY2328065 given as LSF in fasted state B: single dose of 50 mg BAY2328065 given as tablet in fasted state C: single dose of 50 mg BAY2328065 given as tablet in fed state (i.e. after a high caloric and high fat meal)
16393205|NCT04027192|Experimental|Multiple dose escalation part: dose 1|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day"
16393206|NCT04027192|Experimental|Multiple dose escalation part: dose 2|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
16393207|NCT04027192|Experimental|Multiple dose escalation part: dose 3|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
16393208|NCT04027192|Experimental|Multiple dose escalation part: dose 4|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
16393209|NCT04027192|Experimental|Multiple dose escalation part: dose 5|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by a treatment pause of 2 days followed by twice daily doses for 1 day followed by three times daily doses for 9 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
16393210|NCT04027179|Experimental|FMS chlorhexidine mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
16393211|NCT04027179|Placebo Comparator|FMS placebo mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
16393212|NCT04027179|Active Comparator|FMS no mouthwash|Full-mouth scaling and root planning with manual curettes.
16393213|NCT04027166|Experimental|administration immediate|Methadone will be administered prior to study procedures
16393214|NCT04027166|Experimental|administration delayed|Methadone will be held for four hours until the end of all study procedures.
16393215|NCT04027153|Experimental|Fee Arm|Participants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice.
16393216|NCT04027153|Active Comparator|Standard of Care Arm|Participants in this arm will pick up their medication refill at the local clinic
16393217|NCT04027127|Active Comparator|ACS GRUP|"Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared.
~GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared."
16393218|NCT04027127|Active Comparator|plasebo grup|It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.
16393219|NCT04027114|Experimental|Behavioural Physical Activity (PA) intervention|
16393220|NCT04027114|No Intervention|Wait list control|
16393221|NCT04027101|Experimental|Experimental group|Oral baricitinib 4mg/day for 12 weeks. Then, at week 12, if PMR-AS≤10, patients will receive baricitinib 2 mg for 12 weeks. If PMR-AS ≤10, the patients will not receive any treatment until W24 At W24, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1 mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) according to investigator's opinion.
16393222|NCT04027101|Placebo Comparator|Control group|Oral placebo every day during 3 months (W12). Then, at week 12, if PMR-AS ≤10, placebo for 12 weeks. If PMR-AS ≤10, the patients do not receive any treatment until a flare. If PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) and according to investigator's opinion.
16393223|NCT04027088|Experimental|Immunonutrition|Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
16393224|NCT04027088|Placebo Comparator|Standard|Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
16393225|NCT04027075|Experimental|Intervention|This group will be asked to use the Rewire app daily in the month following the baseline assessment. This group will also receive services as usual from the Department of Youth Services.
16393226|NCT04027075|No Intervention|Services as usual|This group will receive services as usual from the Department of Youth Services.
16393227|NCT04027062|Other|Diabetes Continuing Education Program|"the physicians will be assessed before and after intervention
~the intervention group will be enrolled to the intervention program proposed to be (lecture + interactive workshop + group discussion + role play)"
16393256|NCT04026854||Psychiatric nurses|Nurse with a degree in the state or psychiatric sector. Work in a psychiatric ward that offers full hospitalization, a day hospital (HdJ) or a medico-psychological center (CMP).
16415631|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A"|
16393228|NCT04027049|Experimental|Supine cycle ergometry of the lower extremities|Patients will receive two 20 minute cycle ergometry sessions separated by at least 4 hours in addition to usual care. The cycle will be set to a gear of zero and will begin in passive mode, the patient will be able to actively cycle if patients are able.
16393229|NCT04027049|No Intervention|Control|Patients will receive usual care only.
16393230|NCT04027036|Active Comparator|fIPV Intramuscular|180 children will receive 0,1 ml of inactivated poliovirus vaccine intramuscularly
16393231|NCT04027036|Active Comparator|fIPV Intradermal|180 children will receive 0,1ml of inactivated poliovirus vaccine intradermally
16393232|NCT04027010|Experimental|"Healthy U tablet application"|Healthy U is a self-administered intervention implemented through a tablet app with interactive learning experiences, including videos, digital games, quizzes, and role-plays. Healthy U takes youth 3-4 hours to complete. The goals of Healthy U are to: 1) Increase male youth's perception of vulnerability to unplanned fatherhood, STDs and HIV; 2) Increase male youth's self-efficacy for negotiating condom use with their partners; 3) Increase male youth's self-efficacy for using condoms correctly and consistently every time they have sex; and 4) Increase male youth's engagement with goals and dreams for their future.
16393233|NCT04027010|No Intervention|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition. OYA does not provide much programming to youth in its facilities related to sexual health and pregnancy prevention.
16393234|NCT04026997|Experimental|Cohort 1|CIN-102 tablets by mouth twice daily for 14 days
16393235|NCT04026997|Placebo Comparator|Cohort 1 - Placebo|Placebo tablets by mouth twice daily for 14 days
16393236|NCT04026997|Experimental|Cohort 2|CIN-102 tablets by mouth twice daily for 14 days
16393237|NCT04026997|Placebo Comparator|Cohort 2- Placebo|Placebo tablets by mouth twice daily for 14 days
16393238|NCT04026997|Experimental|Cohort 3|CIN-102 tablets by mouth twice daily for 14 days
16393239|NCT04026997|Active Comparator|Cohort 3- Placebo|Placebo tablets by mouth twice daily for 14 days
16393240|NCT04026984|Experimental|Rifamycin SV MMX plus ORT|One tablet contains 50 mg Rifamycin SV-MMX® plus standard of care Oral Rehydration Therapy (ORT). Two 50mg tablets will be administered twice daily.
16393241|NCT04026984|Placebo Comparator|Placebo tablets plus ORT|Matching placebo tablets plus standard of care Oral Rehydration Therapy (ORT)
16393242|NCT04026971|Experimental|Phone Application Supported Nutrition Education|Classic nutrition training and diet list is provided. Then notification was sent to obese patients for 3 months by phone application named 'MotiVe'
16393243|NCT04026971|Other|Classical Nutrition Education|Classic nutrition training and diet list is provided.
16393244|NCT04026958|Experimental|Clarithromycin|Participants in this study arm will receive clarithromycin for 14 days.
16393245|NCT04026958|Placebo Comparator|Placebo|Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
16393246|NCT04026945|Other|Active Treatment (ST-CP) Group|"This study uses a dose-escalating approach in the active treatment arm. There is no comparator product. All qualifying patients receive the active treatment ST-CP as an injection in the region around the spermatic cord. The following dosing cohorts will be used:
~I: 1 x 2 mL of 140 mg/mL ST-CP (= 280 mg lidocaine) II: 1 x 3 mL of 140 mg/mL ST-CP (= 420 mg lidocaine) III: 1 x 4 mL of 140 mg/mL ST-CP (= 560 mg lidocaine)"
16393247|NCT04026932|Placebo Comparator|Unmodified music group|34 participants in Group 1 will listen to the music without any modification for at least two hours a day in total.
16393248|NCT04026932|Experimental|Modified tinnitus relieving sound group|34 participants in Group 2 will listen to the music modified according to the matched dominant tinnitus pitch for at least two hours a day in total.
16393249|NCT04026919|Experimental|to analyze the effectiveness of Ok en Casa Zaindoo|The multicomponent online programme is composed of the components explained in the detailed study description:
16393250|NCT04026906|Experimental|Skin Glue|Patients in the intervention group will receive standard peripheral intravenous catheter (PIVC) securement (with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape). In addition they will receive a drop of cyanoacrylate glue (Dermabond® topical skin adhesive) at both the PIVC insertion site and under the hub of the catheter.
16393251|NCT04026906|Placebo Comparator|Standard Care|Patients in the control group will receive standard PIVC placement with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape.
16393252|NCT04026880|Active Comparator|Treatment Arm|weekly IM administration of 25 mg Testosterone Enanthate for 12 weeks
16393253|NCT04026880|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks
16393254|NCT04026867|Active Comparator|Clinician Referral Only|"The Clinician Referral arm will serve as an active control and baseline standard of care. All individuals who test positive for HCV antibodies or are identified with untreated, active HCV will be informed of their result and receive the following information from their clinical care teams in the ED: (a) explanation of process and rationale for follow-up RNA testing; (b) delivery of simple posttest counseling (e.g., risk for liver disease, risks of transmission); and (c) provision of a list of insurance enrollment resources, as needed, along with (d) a list of HCV treatment providers and their contact information as provided in aftercare instructions. For new HCV diagnoses, patients will be instructed to access their electronic patient portal (MyChart) for their RNA test results or to call a designated results line. Post-testing counseling messages and follow-up instructions will be included on the patient discharge papers."
16393255|NCT04026867|Experimental|Clinician Referral + Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS). Individuals randomized to this intervention will be contacted by a linkage navigator either during the ED visit (if during business hours) or the following business day (if during non-business hours). If the navigator does not contact the patient at the time of ED visit, they will offer to meet with the patient in person or over the phone. For all individuals in this arm, a structured linkage navigation process will include motivational interviewing and (a) reiteration of posttest counseling messages, (b) assessment of the patient's needs for medical insurance and substance abuse treatment, c) assistance scheduling and/or rescheduling appointments for HCV treatment, and d) follow-up phone call after the first HCV treatment appointment and thereafter as needed up to 6 months after ED visit.
16393257|NCT04026841|Experimental|PD-1 Antibody Sintilimab|Patients receive the treatment of PD-1 antibody Sintilimab
16393260|NCT04026815||60 - 65 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393261|NCT04026815||65 - 69 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393262|NCT04026815||70 - 74 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393263|NCT04026815||75 - 79 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393264|NCT04026815||80 - 84 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393265|NCT04026815||85 - 89 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393266|NCT04026815||≥90 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
16393267|NCT04026802|Experimental|In--Bed Resistance Training Device|The present invention provides full body resistance training devices that attach to a planar edge, such as a footboard, headboard, or sideboard of a bed. The devices employ resistance bands for resistance training in both the incursion (force applying) and excursion (force releasing) phase of exercise.
16393268|NCT04026802|Active Comparator|Standard of Care|No resistance training device
16393269|NCT04026789|Active Comparator|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
16393270|NCT04026789|Active Comparator|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
16393271|NCT04026776|Experimental|Preterm Group|Subjects with very low birth weight (<37 completed weeks' gestation and birth weight <1500 g) will receive a dietary intervention (high/low salt diet) and FDA approved drug, Allopurinol
16393272|NCT04026776|Active Comparator|Term-born control group|Subjects with birth weight ≥2500 g will receive a dietary intervention (high/low salt diet)
16393273|NCT04026763|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as a US guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy guided prostate biopsy.
16393274|NCT04026750|Experimental|Pitolisant|
16393275|NCT04026750|Placebo Comparator|Matching placebo|
16393276|NCT04026724||Exposed group|Chinese patent medicine combined with western medicine routine treatment
16393277|NCT04026724||Non-exposed group|Western medicine routine treatment
16393278|NCT04026711|Active Comparator|MitoQ|MitoQ 40 mg per day for 12 weeks
16393279|NCT04026711|Placebo Comparator|Placebo|placebo daily for 12 weeks
16393280|NCT04026698|Experimental|Resident and Family Engagement Intervention.|The intervention has three components: leadership coaching for managers, administrators/ directors of care in long-term care settings; a one-day in-person training session for staff and managers; and resident and family led huddles (brief, 15 minute meetings) with staff.
16393281|NCT04026685|Active Comparator|Phenylephrine infusion only|Phenylephrine infusion only
16393282|NCT04026685|Active Comparator|Phenylephrine infusion and Ringer-Acetate bolus|Phenylephrine infusion and Ringer-Acetate bolus
16393283|NCT04026659|Experimental|Multi-modal exercise programme|The 10-week multi-modal exercise programme will comprise of twice weekly supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
16393284|NCT04026646|Experimental|Proprioceptive Neuromuscular Facilitation stretching exercises|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
16393285|NCT04026646|Experimental|Static stretching exercises|Passive Static Stretching exercises will be performed 2 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
16393286|NCT04026633|Experimental|Experimental: Enhanced Intervention|Participants assigned to this arm will complete a personal writing task about alcohol use.
16393287|NCT04026633|Placebo Comparator|Placebo Comparator|Participants assigned to this arm will complete a personal writing task about eating behaviors.
16393288|NCT04026620|Other|Pamphlet-only|Pamphlet-only women will be provided with two (2) informational pamphlet(s) (both in Afrikaans).
16393289|NCT04026620|Other|MET Group|MET women will be provided with a one (1) hour and 30 minute session of Motivational Enhancement Therapy (MET) and informational pamphlet(s) (both in Afrikaans).
16393290|NCT04026607|Experimental|Whey Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
16393291|NCT04026607|Experimental|Pea Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
16393292|NCT04026607|Experimental|Collagen Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
16393293|NCT04026594|Experimental|Mindfulness Based Stress Reduction (MBSR)|"306 participants will be randomized in the MBSR program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a MBSR recall session will be offered six month after intervention.
~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability.."
16393335|NCT04026295|Experimental|Short burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
16393294|NCT04026594|Active Comparator|Progressive Muscle Relaxation Training (PMRT)|"306 participants will be randomized in a relaxation program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a relaxation recall session will be offered six month after intervention.
~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability"
16393295|NCT04026581||Assessment|A comprehensive AAC assessment collecting clinical and personal data required to select a speech-generating device (SGD) is conducted along with a trial of three AAC technology solutions, followed by a trial for BCI access to an AAC system.
16393296|NCT04026581||Training and Treatment|AAC training and treatment services will be provided and communication performance outcomes monitored over the course of studying clinical treatment services. At monthly home visits the SLP gathers clinical and personal data on communication performance outcomes and user satisfaction of their AAC system and any alternative access methods.
16393297|NCT04026568|Experimental|Single dose 4AP|15mm opaque capsule containing 10mg of 4-AP
16393298|NCT04026568|Placebo Comparator|Placebo|Opaque capsule identical looking to the 4AP placebo pill
16393299|NCT04026555|Active Comparator|MEWS++ Monitoring|This consists of all the patients that will be receiving MEWS++ escalation monitoring and provider alerting.
16393300|NCT04026555|Placebo Comparator|Standard of Care Monitoring|Patients in the control arm will have a score calculated but no alert will be sent.
16393301|NCT04026529|Experimental|walking at incline|Subjects will walk on treadmill at slope and speed to equal 60% of their peak work rate as determined on baseline cardiopulmonary exercise test.
16393302|NCT04026516|Experimental|CAVA Dizziness Trial Arm|All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
16393303|NCT04026503|Experimental|Live Long Walk Strong|8 week rehabilitation program
16393304|NCT04026503|Active Comparator|8 week wait list control|8 week wait list then followed by 8 weeks of the Live Long Walk Strong rehabilitation program
16393305|NCT04026490|Experimental|Immediate intervention group|The student will have a conversation with an Interventionist.
16393306|NCT04026490|Active Comparator|Waitlist control group|These students will be approached for intervention for the months following the implementation of the immediate intervention group using the same procedures.
16393307|NCT04026477|Experimental|Immediate intervention group|Universal Trauma-Informed Care and Cultural Humility Training. After video and workshop training, staff will have ability to recognize trauma and racism and its impact on school procedures, practices, and children themselves. Staff will be able to apply core principles of cultural humility. Staff will examine their own cultural identity and how it influences their interactions and relationships with students of diverse cultural backgrounds (Principle 1). Staff will learn ways that privilege and oppression relate to their cultural identity and identify ways to flatten power hierarchies between themselves and students, including handling misbehavior from a trauma-informed, culturally humble perspective (Principle 2). Staff will problem-solve ways for their schools to be accountable for equitable discipline practices (Principle 3).
16393308|NCT04026477|Active Comparator|Waitlist control group|All staff from waitlisted schools will receive Universal Trauma-Informed Care and Cultural Humility Training at the end of the waitlist period.
16393309|NCT04026464|Active Comparator|Ibuprofen+Acetaminophen Group|Infants with PDA randomized to the combined treatment group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) and oral acetaminophen (15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses).
16393310|NCT04026464|Placebo Comparator|Ibuprofen Group|Infants with PDA randomized to the control mono therapy group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) alone.
16393311|NCT04026451|Experimental|Intervention|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.
16393312|NCT04026451|Active Comparator|Control|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SAS (1-2). SedLine® monitor will be also used in these patients but the screen will be covered.
16393313|NCT04026438|Experimental|Intervention Arm - potassium phosphate injection|
16393314|NCT04026438|No Intervention|Control Arm|
16393315|NCT04026425|Experimental|ME/CFS|Adults with ME/CFS
16393316|NCT04026425|Active Comparator|Healthy controls|Healthy, low-active adults
16393317|NCT04026412|Experimental|Arm A: nivolumab + CCRT + ipilimumab|Concurrent chemoradiotherapy (CCRT)
16393318|NCT04026412|Experimental|Arm B: nivolumab + CCRT|Concurrent chemoradiotherapy (CCRT)
16393319|NCT04026412|Experimental|Arm C: CCRT + durvalumab|Concurrent chemoradiotherapy (CCRT)
16393320|NCT04026399|Experimental|stimulation + therapy|The participant receives stimulation and home therapy.
16393321|NCT04026399|Sham Comparator|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
16393322|NCT04026386|Experimental|Center Based Early Intervention Program|
16393323|NCT04026373|Experimental|modified Prolonged Exposure|
16393324|NCT04026373|Active Comparator|Treatment as usual|
16393325|NCT04026347|Experimental|Vesair|Subjects are treated with Vesair Balloon at enrollment (day 0)
16393326|NCT04026347|Sham Comparator|Sham|Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
16393327|NCT04026334|Experimental|V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline|
16393328|NCT04026321|Experimental|SQ-001 125mL/day|
16393329|NCT04026321|Experimental|SQ-001 250mL/day|
16393330|NCT04026321|Experimental|SQ-001 500mL/day|
16393331|NCT04026321|Experimental|SQ-001 625mL/day|
16393332|NCT04026321|Placebo Comparator|saline(0.9% NaCl injection)|
16393333|NCT04026308|No Intervention|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
16393334|NCT04026308|Experimental|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
16393336|NCT04026295|Active Comparator|Traditional Locomotor Treadmill Training (TLTT)|TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
16393337|NCT04026282|Experimental|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
16393338|NCT04026282|Active Comparator|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
16393339|NCT04026269|Experimental|MOAP treatment|Chlormethine Hydrochloride Injection 10mg d1,8 iv Vindesine Sulfate for Injection 4mg d1,8 iv Doxorubicin Hydrochloride Injection 25mg/m2 d1,8 iv Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po 28 days/Cycle
16393340|NCT04026256|Active Comparator|Teriparatide only|daily subcutaneous injection teriparatide for 3 months
16393341|NCT04026256|Active Comparator|Denosumab only|one dose of subcutaneous injection denosumab
16393342|NCT04026256|Active Comparator|Denosumab and teriparatide|daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
16393343|NCT04026243|Active Comparator|QL group (n = 25)|After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
16393344|NCT04026243|Active Comparator|TF group (n = 25)|After GA, patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in midaxillary line just cephalad to the iliac crest. Scanning anteriorly will identify the three muscles of the anterior abdominal wall. The transversus abdominis typically tapers to form a hyper echoic aponeurosis that passes posterior to quadratus lumborum. Scan will be continued posteriorly to visualize solid organs or viscera deep to the transversus abdominis. The needle will be positioned such that it enters the skin anterior to the ultrasound probe and passes in-plane posterolateral through the three lateral abdominal muscles. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the transversus abdominis muscle and the transversalis fascia anterolateral to quadratus lumborum.
16393345|NCT04026230|Experimental|Atorvastatin|Capsules of atorvastatin. Daily dose of 80 mg for max. 5 years or until development of castration resistance.
16393346|NCT04026230|Placebo Comparator|Placebo|Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 5 years or until development of castration resistance
16393347|NCT04026204||Coronary cannulation after TAVR|Coronary ostia cannulation after TAVR
16393348|NCT04026191|Other|Orthovisc-T|
16393349|NCT04026178|Experimental|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients > 40 kg: 2.5mg Female patients > 40 kg: 5mg
16393350|NCT04026165|Experimental|Selonsertib|"Run-in Period (5 Weeks): Participants will receive placebo for at least one week and then SEL 18 mg for at least 4 weeks.
~Double-Blind Treatment: Participants will be randomized to receive SEL 18 mg until death, study drug discontinuation, kidney failure, or the global study end date."
16393351|NCT04026165|Placebo Comparator|Placebo|"Run-in Period (5 Weeks): Participants will receive placebo for at least one week and then SEL 18 mg for at least 4 weeks.
~Double-Blind Treatment: Participants will be randomized to receive placebo until death, study drug discontinuation, kidney failure, or the global study end date."
16393352|NCT04026152|Experimental|Resistance training + Unified Protocol|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will also receive four weekly hour-long sessions with a therapist to learn cognitive-behavioural strategies to assist them with managing their anxiety when exercising. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
16393353|NCT04026152|Active Comparator|Resistance training|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
16393354|NCT04026152|No Intervention|Waitlist|Participants randomly assigned to this condition will maintain their usual physical activity and exercise routine and not engage in any additional exercise than they were prior to the study. These participants will fill out questionnaires (~20 minutes each time) following randomization into this condition, once per week for four weeks, and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up. After completing the last follow-up, participants in the waitlist condition will be re-randomized into either the resistance training only or resistance training + Unified Protocol conditions.
16393386|NCT04025957|Experimental|SHR-1501 dose expansion|SHR-1501 given subcutaneously
16393714|NCT04023539|Active Comparator|Intervention group|Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
16393355|NCT04026139|Experimental|experimental group|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
16393356|NCT04026139|Active Comparator|control group|The control group underwent active joint range-of-motion exercises and isometric contraction exercises.
16393357|NCT04026126|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline hemodynamic assessments as well as VO2max measurements. Subjects will complete 10 heat therapy treatments over the course of 14 days. Hemodynamics will be assessed with the use of the Clearsight© fingertip blood pressure cuff. Within 24-48 hours after the last heat therapy experience, hemodynamic assessments and VO2max will be performed. Blood samples will be collected pre- and post intervention and analyzed for levels of nitric oxide mediators, heat shock protein levels and pro-anti-inflammatory markers.
16393362|NCT04026100|Experimental|CTA101|
16393363|NCT04026087||patient with kidney transplant|Blood sample will be took from subjects during this research
16393364|NCT04026074|Experimental|Fentanyl i.v. (intravenously)|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
16393365|NCT04026074|Experimental|Remifentanil i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
16393366|NCT04026074|Experimental|Clonidine i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
16393367|NCT04026074|Experimental|EMLA salve|Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo
16393368|NCT04026074|Placebo Comparator|Placebo|Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)
16393369|NCT04026061|Experimental|FMA group|Receiving the FMA training and tool
16393370|NCT04026061|Placebo Comparator|control group|Receiving a simple tablet training and some websites
16393371|NCT04026048|Experimental|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
16393372|NCT04026048|Experimental|Waitlist Control Group|Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
16393373|NCT04026022|Placebo Comparator|Standard pain management|Besides the standard pain management a placebo TTS (normal wound plaster) will be administered in the Emergency Room (ER) or Post Anaesthesia Care Unit (PACU)
16393374|NCT04026022|Experimental|Modified pain management|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial i.v. treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day
16393375|NCT04026009|Experimental|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
16393376|NCT04026009|Placebo Comparator|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
16393377|NCT04026009|Experimental|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
16393378|NCT04026009|Experimental|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag + AS01B adjuvant vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
16393379|NCT04026009|Placebo Comparator|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
16393380|NCT04025996||Diseased Group|Patients with type 2 diabetic retinopathy and known cardiac dysfunction.
16393383|NCT04025970||Cancer of Unknown Primary (CUP)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for possible cancer of unknown primary (CUP).
~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
16393384|NCT04025970||Suspected CANcer (SCAN)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for suspected cancer (SCAN) based on serious non-specific symptoms and signs of cancer.
~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
16393385|NCT04025957|Experimental|SHR-1501 dose escalation|SHR-1501 given subcutaneously
16393387|NCT04025944||chronic hepatitis B|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
16393388|NCT04025944||chronic hepatitis C|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
16393389|NCT04025931|Experimental|chidamide combined with Toripalimab|"chidamide 30mg orally twice a week;
~240 mg of toripalimab (fixed dose) every three weeks.
~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
16393390|NCT04025918|Experimental|vasopressor delivery automated system|vasopressor delivery automated system that administered phenylephrine and ephedrine based on data from continuous non-invasive hemodynamic monitor
16393391|NCT04025918|Active Comparator|manual vasopressor delivery|manual bolus that delivered phenylephrine and ephedrine based on data from non-invasive intermitted blood pressure monitor
16393392|NCT04025905|Experimental|Social Cognition Training Program|This program is taken from two validated cognitive remediation programs: the SCIT program and the RC2S program : perception of social situations - emotional processes and social perception;interpretation of social situations - theory of mind and attributions;acting in social situations - social skills training
16393393|NCT04025905|Sham Comparator|Informations program|Educational team Information will be given to participants about work environment, social environment, stress management, sleep management, treatments. It will also include socialization sessions with board games or cultural activities.
16393394|NCT04025892|Experimental|Tracking group|Participants will be asked to track weight daily for six weeks
16393395|NCT04025879|Experimental|Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo|
16393396|NCT04025879|Placebo Comparator|Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.|
16393397|NCT04025866|Active Comparator|Conventional rehabilitation|Conventional rehabilitation treatment for inpatients with femur fracture
16393398|NCT04025866|Active Comparator|Aerobic exercise|Addition of cycle ergometer for upper limb to conventional rehabilitation treatment for femur fracture
16393399|NCT04025840|No Intervention|Control|Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.
16393400|NCT04025840|Experimental|Epidural block|Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.
16393401|NCT04025840|Experimental|Dexamethasone|Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
16393402|NCT04025840|Experimental|Epidural block+Dexamethasone|Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.
16393403|NCT04025814|Experimental|CaregiverAssist|Parents and School Mental Health Providers (SMHPs) will participate in focus groups and discussions to facilitate the build, design, and use of a digital Health (dHealth) tool to improve parent adherence sustained use of evidence-based parenting strategies. Parents will participate in a 2-month trial during which time they will use the dHealth tool in daily life contexts.
16393404|NCT04025775|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days
~The CamAPS HX closed-loop system comprises
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump
~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
16393405|NCT04025775|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.
16393406|NCT04025762|Experimental|Day and night hybrid closed loop control|"The day and night hybrid closed-loop system (CamAPS FX) will consist of:
~Dana RS insulin pump (Sooil)
~G6 real-time CGM sensor (Dexcom)
~An unlocked android smartphone hosting the CamAPS FX app with Cambridge control algorithm"
16393407|NCT04025762|Active Comparator|Sensor augmented pump therapy|The comparator will consist of Dana RS insulin pump (Sooil) and G6 real-time CGM sensor (Dexcom)
16393408|NCT04025749|Experimental|Immediate intervention group|Thirty children with CP aged 8 to 12 years (or fifteen with neuroimage data) will participate in a computerized executive training program from home (12 weeks, 5 days a week, 30 min a day).
16393409|NCT04025749|Other|Wait-list delayed intervention|Thirty children with CP (or fifteen with neuroimage data) matched by age, sex, motor and cognitive impairment severity.
16393410|NCT04025736|Experimental|Patients received Tranexamic acid|The patient was assigned as intervention group, TXA will be aspirated into a syringe. In TXA group, TXA 1000 mg (20 mL) was given intravenously 10 minutes before surgery.
16393411|NCT04025736|Placebo Comparator|Patients received same volume of saline|In the control group, the patient received 20ml saline intravenous also 10 min before surgery.
16393412|NCT04025723|Active Comparator|Young|men aged between 18 to 30 years old
16393413|NCT04025723|Active Comparator|Middle-aged|men aged between 35 to 50 years old
16393415|NCT04025697|Placebo Comparator|Conventional CD|A conventional Complete denture will be constructed and the amount of denture tooth movement will be measured
16393416|NCT04025697|Active Comparator|Rapid Prototyped Denture|A digital light processed denture will be constructed and the amount of tooth movement will be measured
16393417|NCT04025684|Other|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million [ppm] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
16393418|NCT04025684|Other|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
16393419|NCT04025684|Other|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
16393420|NCT04025684|Other|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
16393421|NCT04025671|Experimental|Nasal Spray Naloxone|This arm will be randomized to administer a nasal spray naloxone device in a simulated overdose setting.
16393422|NCT04025671|Active Comparator|Intramuscular|This arm will be randomized to administer a intramuscular naloxone device in a simulated overdose setting.
16393423|NCT04025671|Active Comparator|Improvised Nasal Atomizer|This arm will be randomized to administer an improvised nasal atomizer naloxone device in a simulated overdose setting.
16393424|NCT04025658|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16393425|NCT04025658|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16393426|NCT04025658|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16393427|NCT04025658|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16393428|NCT04025658|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16393429|NCT04025658|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16393430|NCT04025645||PATIENTS WITH CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITH CHOLELITHIASIS
16393431|NCT04025645||PATIENTS WITHOUT CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITHOUT CHOLELITHIASIS
16393432|NCT04025632|Experimental|0.3 mg/kg zilucoplan|Daily subcutaneous (SC) injection
16393433|NCT04025632|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection
16393434|NCT04025619|Experimental|treatment group|the data is collected from the same participant after the intervention.
16393435|NCT04025619|No Intervention|Control group|The Collect the data from the same participant before the intervention as control
16393436|NCT04025606|Active Comparator|Thoracic epidural analgesia|Standard thoracic epidurals preoperatively at the dag of surgery.
16393437|NCT04025606|Experimental|Paravertebral block|Paravertebral block inserted at the end of the operation by the surgeons
16393438|NCT04025593|Active Comparator|RCHOP|
16393439|NCT04025593|Experimental|RCHOPX|
16393440|NCT04025580|Experimental|Flucelvax, Fluvirin, or Fluzone High Dose|Healthy Volunteer between ages 18-65 receiving Flucelvax
16393441|NCT04025567|Experimental|1/Arm 1|Oral vancomycin
16393443|NCT04025541|Other|COHORT 1 BREAST TUMOR/PALBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib
~BLOOD SAMPLING"
16393444|NCT04025541|Other|COHORT 2 BREAST TUMOR / RIBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib
~BLOOD SAMPLING"
16393445|NCT04025528||Hypercapnic|Obese patients with daytime hypercapnia
16393446|NCT04025528||Eucapnic|Obese patients with normal daytime carbon dioxide levels
16393447|NCT04025502||Healthy Volunteer Subjects (HV)|"Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.
~Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
16393448|NCT04025502||Subjects with Schizophrenia (SZ)|"Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.
~Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
16393449|NCT04025489|Experimental|Vitamin D and Placebo|Doses of cholecalciferol (commercial name, Calcirol) 60,000IU (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose Granules) to the placebo group according to the random numbers generated by the computer.
16393450|NCT04025476||VKH patients|acute VKH patients
16393451|NCT04025476||control|health people age/sex match to the VKH patients
16393452|NCT04025463|Other|Intervention|Hybrid type II effectiveness/implementation study design - pre-post design with each participant serving as his or her own control.
16393453|NCT04025450|Experimental|Chidamide plus VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
16393454|NCT04025450|Active Comparator|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
16393455|NCT04025437|Experimental|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
16393456|NCT04025437|Active Comparator|Neoadjuvant radiotherapy plus hepatectomy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
16393457|NCT04025424||Skin melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary lesion;
~2) The availability of basic clinical information about the patient and the course of his illness;"
16393553|NCT04024722|Experimental|Dual ovary treatment|
16393458|NCT04025424||Hodgkin disease, retrospective|"1) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);
~2) The availability of basic clinical information about the patient and the course of his illness;"
16393459|NCT04025424||Uveal melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);
~2) The availability of basic clinical information about the patient and the course of his il"
16393460|NCT04025424||Skin melanoma, proscpective|"1) Clinically and morphologically verified diagnosis of metastatic melanoma;
~2) The availability of basic clinical information about the patient and the course of his illness;"
16393461|NCT04025424||Lung cancer, procpective|"1) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;
~2) The availability of basic clinical information about the patient and the course of his illness;
~3) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;"
16393462|NCT04025411|Experimental|Experimental group|Patient with stroke ischemic or hemorrhagic will be included. They will have visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device and electroencephalography (EEG).
16393463|NCT04025411|Active Comparator|Control group|Patient with stroke ischemic or hemorrhagic will be included. They will have simulation with the traditional Mirror Therapy (TM) and electroencephalography (EEG).
16393464|NCT04025398|Experimental|REHABILITUS|Réhabilitus is a cognitive remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among adults with intellectual disabilities.
16393465|NCT04025398|Active Comparator|CONTROL GROUP|The control group involves manual activities and research computer information.
16393466|NCT04025385|No Intervention|Control Group|Patients will participate in regular training units
16393467|NCT04025385|Active Comparator|HIIT Group|Patients will participate in high intensity interval training
16393468|NCT04025372|Experimental|Bicalutamide+GnRH Agonist+Radiation Therapy|"Bicalutamide is administered orally on a daily basis
~GnRH Agonist as prescribed
~Radiation therapy is administered starting 4-12 weeks after ADT"
16393469|NCT04025372|Experimental|Darolutamide+Radiation Therapy|"Darolutamide is administered orally twice daily
~Radiation therapy is administered starting 4-12 weeks after ADT"
16393470|NCT04025359|Active Comparator|Dronabinol 10mg|Dronabinol 10mg
16393471|NCT04025359|Active Comparator|Dronabinol 20mg|Dronabinol 20mg
16393472|NCT04025359|Placebo Comparator|Placebo|Placebo
16393473|NCT04025346|Active Comparator|Capsimax|
16393474|NCT04025346|Placebo Comparator|Placebo|
16393475|NCT04025320|Experimental|Group 1|"Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received.
~9 total treatment visits, 3 visits per week
~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
16393476|NCT04025320|Sham Comparator|Group 2|"SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week
~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
16393477|NCT04025307|Experimental|bacTRL-IL-12|single-dose, 1 mL IV infusion of bacTRL-IL-12
16393478|NCT04025294|Experimental|Students playing videogame|The experimental group will consist of our videogame intervention including the five mini-games.
16393479|NCT04025294|Active Comparator|Students receiving school climate assessment|The control group differs from the experimental group as it includes the school climate assessment tool but excludes the mini-games
16393480|NCT04025281|Active Comparator|Extra virgin olive oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
16393481|NCT04025281|Active Comparator|Refined olive oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
16393482|NCT04025268|Active Comparator|pregnant women receiving group prenatal care (GPNC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to receive the 10-session GPNC intervention.
16393483|NCT04025268|Active Comparator|pregnant women receiving standard of care (SOC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to continue with standard of care (SOC) prenatal care visits.
16393484|NCT04025255|Experimental|Braini|28-day oral capsules of Braini
16393485|NCT04025255|Placebo Comparator|Placebo|28-day oral capsule of placebo comparator
16393486|NCT04025229|Experimental|HIIT exercise|Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery
16393487|NCT04025216|Experimental|Dose Escalation Arm1: Solid Tumors|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
16393488|NCT04025216|Experimental|Dose Escalation Arm 2: Multiple Myeloma|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
16393489|NCT04025203|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
16393490|NCT04025203|Active Comparator|Ibuprofen arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
16393491|NCT04025203|Active Comparator|Gabapentin|Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
16393492|NCT04025203|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
16393493|NCT04025190||Allogeneic Transplant|All patients seen in the UNC Bone Marrow Transplant clinic who are candidates for allogeneic transplantation attending their pre-admission visit were approached to offer study participation. Study participation included completion of surveys over a time period up to 60 days after their transplant.
16393494|NCT04025177|Experimental|Neonates with an open PDA|Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.
16393495|NCT04025164|Experimental|Hypofractionated Radiotherapy|"40 Gy/15 fractions irradiation is delivered to the whole breast, 2.67 Gy per fraction, 5 fractions weekly.
~Tumor bed is boosted to 48 Gy simultaneously, 3.2 Gy per fraction, 5 fractions weekly."
16393496|NCT04025164|Active Comparator|Conventional Irradiation|"50 Gy/25 fractions irradiation is delivered to the whole breast, 2 Gy per fraction, 5 fractions weekly.
~Additional 10 Gy/5 fractions is boosted to tumor bed sequentially, 2 Gy per fraction, 5 fractions weekly."
16393497|NCT04025151|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
16393498|NCT04025151|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through SMS
16393499|NCT04025138|Experimental|female subjects involved in races over 100 km (F>100)|Female subjects involved in races over 100 km (F>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
16393500|NCT04025138|Experimental|female subjects involved in races less than 60 km (F<60)|Female subjects involved in races less than 60 km (F<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
16393501|NCT04025138|Experimental|male subjects involved in races over 100 km (H>100)|Male subjects involved in races over 100 km (H>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
16393502|NCT04025138|Experimental|male subjects involved in races less than 60 km (H<60)|Male subjects involved in races less than 60 km (H<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
16393503|NCT04025112|Experimental|Armeo|Patients group (54 patients) for robotic therapy.
16393504|NCT04025112|Active Comparator|Conventional|Patients group (54 patients) for conventional rehabilitation protocol.
16393505|NCT04025099|Experimental|Internal Cues|"Over 10 weeks, participants will be asked to participate in the following:
~Classes (held in STAR Tower 419/420 IPE Space and Conference Room 413)
~One ~60-minute Intuitive Eating class per week (total = 10 classes);
~Two ~60-minute yoga classes per week (total = 20 classes);
~Repeat one of the ~60-minute yoga classes each week on the participants' own, in a space participants feel comfortable, using a video recording (total = 10 classes).
~Assessments (held in STAR tower)
~Three ~60-minute assessments* which will include:
~Height & weight measurements (taken privately)
~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors
~Collection of participants' heart rate overnight (on their own)
~Collection of participants' saliva three times in one day (on their own)"
16393506|NCT04025099|Active Comparator|External Cues|"Over the next 10 weeks, participants will be asked to participate in the following:
~Classes (held in STAR Tower 419/420 IPE Space)
~One ~60-minute Healthy Eating class per week (total = 10 classes);
~Participants will be provided with a UD group fitness membership. Using this membership, participants will be asked to attend at least 2 cardio fitness classes per week and do an additional 30 minutes of heart-raising activity on participants' own (total = 3 exercise sessions/week).
~Assessments (held in STAR tower)
~Three ~60-minute assessments* which will include:
~Height & weight measurements (taken privately)
~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors
~Collection of participants' heart rate overnight (on their own)
~Collection of participants' saliva three times in one day (on their own)"
16393507|NCT04025099|No Intervention|Assessment Only|"Over the next 10 weeks, participants will be asked to participate in the following:
~a. Assessments (held in STAR tower)
~•Three ~60-minute assessments* which will include:
~Height & weight measurements (taken privately)
~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors
~Collection of participants' heart rate overnight (on their own)
~Collection of participants' saliva three times in one day (on their own)"
16393508|NCT04025086||Study group|"44 patient undergoing spinal surgery in prone position at Gaspare Rodolico Presidium, in which the new Perioperative Goal Directed Therapy protocol has been used"
16393509|NCT04025086||Control group|44 patients who underwent spinal surgery in the period January 2016 - December 2017, in which was not used a Perioperative Goal Directed Therapy approach but a classical hemodynamic monitoring, according to the recommendations of good clinical practice and the international guidelines.
16393510|NCT04025073|Experimental|Intervention Group|The intervention group will be assigned to the DASH diet with moderately reduced caloric intake and will participate in a nutrition education program.
16393511|NCT04025073|Experimental|Control Group|The control group will continue to follow the standard hospital diet and will participate in the same nutrition education program as the intervention group.
16393512|NCT04025060|Experimental|Caffeine-free Soda|Consumption of caffeine-free soda daily for two weeks
16393513|NCT04025060|Experimental|Carbonated Water|Consumption of unsweetened, carbonated water daily for two weeks
16393514|NCT04025060|Active Comparator|Regular Soda|Consumption of regular soda daily for two weeks
16393515|NCT04025047||Transvaginal mesh|Patients who undergo pelvic reconstruction surgery using trans-vaginal mesh (commercial mesh kits or self-cut synthesized mesh).
16393516|NCT04025034|Experimental|Study Group|Use of SONOPET(R) to orbital surgery.
16393710|NCT04023578|Experimental|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
16393517|NCT04025021|No Intervention|Control group (standard fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:
~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines."
16393518|NCT04025021|Experimental|Intervention group (targeted fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:
~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study."
16393519|NCT04024982|Other|Lecture followed by Simulation|Subjects will undergo the lecture on TEE first followed by the simulation session.
16393520|NCT04024982|Other|Simulation followed by Lecture|Subjects will undergo the TEE simulation first followed by the lecture.
16393521|NCT04024969||Clinically isolated syndrome|Those presenting for diagnositic evaluation of multiple sclerosis, not currently meeting the 2017 McDonald criteria.
16393522|NCT04024956|Experimental|Sealing Device|Sealing Device applied in hepatic resection or distal pancreatectomy
16393523|NCT04024917|Experimental|Coherence cardiac|
16393524|NCT04024917|Active Comparator|Standard care|
16393525|NCT04024904|No Intervention|control group|In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
16393526|NCT04024904|Experimental|VRHD1|In the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
16393527|NCT04024904|Experimental|VRHD2|In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
16393528|NCT04024891|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye, 1 hour post medically-induced mydriasis
16393529|NCT04024891|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye, 1 hour post medically-induced mydriasis
16393530|NCT04024878|Experimental|Stanfard Platinum|"A total of 5 NeoVax immunizations will be administered over a 3-week period
~Two booster vaccinations will be given at Week 12
~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks."
16393531|NCT04024878|Experimental|Stanfard Platinum with Surgical or Core Needle Biopsy|"A total of 5 NeoVax immunizations will be administered over a 3-week period
~Two booster vaccinations will be given at Week 12
~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.
~Will undergo required surgical or core needle biopsy at first recurrence with progression free interval"
16393532|NCT04024865||Treated with domperidone|Women who received a prescription for domperidone during the six months following delivery.
16393533|NCT04024865||Unexposed group (reference)|Women with no prescription for domperidone during the six months following delivery.
16393534|NCT04024852|No Intervention|Control group|The control group did daily mild exercise (walking) outdoors for 30 minutes, for maximum 70 days.
16393535|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes. Total study period lasted for maximum 70 days.
16393536|NCT04024839|Active Comparator|Post Isometric Relaxation|Post Isometric Relaxation was applied three times a week for the duration of three weeks.
16393537|NCT04024839|Experimental|Active Isolated stretch|Active Isolated stretch was was applied three times a week for the duration of three weeks.
16393538|NCT04024826|Experimental|Early Follicular Phase (EFP)|This group is comprised of participants at the Early Follicular Phase (EFP) of the menstrual cycle.
16393539|NCT04024826|Experimental|Late Follicular Phase|This group is comprised of participants at the Late Follicular Phase (LFP) of the menstrual cycle.
16393540|NCT04024826|Experimental|Early Luteal Phase|This group is comprised of participants at the Early Luteal Phase (ELP) of the menstrual cycle.
16393541|NCT04024826|Experimental|Late Luteal Phase|This group is comprised of participants at the Late Luteal Phase(LLP) of the menstrual cycle.
16393542|NCT04024813|Placebo Comparator|Placebo (N=25)|Placebo for the remainder of the study
16393543|NCT04024813|Experimental|Seladelpar 5 mg (N=25)|5 mg seladelpar daily for the remainder of the study
16393544|NCT04024813|Experimental|Seladelpar 10 mg (N=25)|10 mg seladelpar for the remainder of the study
16393545|NCT04024813|Experimental|Seladepar 25 mg (N=25)|25 mg seladelpar for the remainder of the study
16393546|NCT04024800|Experimental|Arm 1|AE37 peptide vaccine every 21 days for 5 doses + Pembrolizumab every 21 days for 2 years (Maximum 35 cycles)
16393547|NCT04024787|Experimental|Immediate intervention|
16393548|NCT04024787|No Intervention|Waitlist|
16393549|NCT04024774||index cases and their parents|
16393550|NCT04024761|Experimental|CIML NK|"CIML NK will be administered intavenously on day 0
~Fludarabine will be administered as one-hour IV infusion once daily for 3 doses beginning on day -5.
~Cyclophosphamide will be administered as 2-hour IV infusion on days -5 and -4."
16393551|NCT04024748||Patients already scheduled for a FDG test|Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
16393552|NCT04024722|Experimental|Single ovary treatment|
16393554|NCT04024696|Experimental|Dosing Cohorts|Three (3) dose cohorts are pre-set to include 40 mg BID, 60 mg BID and 80 mg BID,respectively.The pre-set dose group is subject to change during the study and the actual dosage increment is determined by the Data safety Monitoring Committee (DSMC).
16393555|NCT04024683||Serratus block group|Realization of a serratus block and para-vertebral catheter
16393556|NCT04024683||Control group|Realization of a para-vertebral catheter
16393561|NCT04024631|Other|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.
~They will also undergo a whole body DXA (intervention) during the study day."
16393562|NCT04024618|Active Comparator|Parenteral Nutrition|Patients who have been randomized to receive PN will be started on day 5 post AHSCT. This will be if patient intake is < 80% of usual oral intake at that time. The central venous catheter required for PN administration will be already in place for AHSCT treatment, prior to admission and pre-transplant evaluation. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
16393563|NCT04024618|Experimental|Enteral Nutrition|Patients who have been randomized to receive EN will have a Nasogastric tube (NGT) inserted on day 5 post AHSCT, prior to start of Enteral feeds. This would be a polyurethane tube, 8-10 French, which will be inserted by physician or Nurse Practitioner with position confirmed by radiological examination. This will be if patient intake is < 80% of usual oral intake at that time. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
16393564|NCT04024605|Experimental|Sunflower|Biscuits containing sunflower isolate intrinsically labelled with 15N and 2H
16393565|NCT04024605|Experimental|Rapeseed|Biscuits containing rapeseed isolate intrinsically labelled with 15N and 2H
16393566|NCT04024605|Experimental|Flaxseed|Biscuits containing flaxseed isolate intrinsically labelled with 15N and 2H
16393567|NCT04024605|Experimental|Lupin|Biscuits containing lupin flour intrinsically labelled with 15N and 2H
16393568|NCT04024592|Experimental|children|
16393569|NCT04024553||bipolar disorder family|Screening priori BD-I/BD-II patients， their relatives with mental illness (including but not limited to BD) and their healthy families.
16393570|NCT04024553||health control|Group-matched non-psychiatric family history health subjects were enrolled, DSM-IV-TR is used for demographic assessment.
16393571|NCT04024540|Experimental|isocaloric dietary restriction|Very low caloric diet 400 kcal/d for a week, 600 kcal/d for another week and 800 kcal/d for 2 weeks and 1000 kcal/d for 2 months.
16393572|NCT04024540|Active Comparator|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
16393573|NCT04024527|Active Comparator|Dual therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
16393574|NCT04024527|Experimental|Metronidazole plus dual therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
16393575|NCT04024514|Experimental|Low dose|Low CT contrast media dose
16393576|NCT04024514|Active Comparator|Standard dose|Standard CT contrast media dose
16393577|NCT04024501|Experimental|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
16393578|NCT04024501|Experimental|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
16393579|NCT04024501|Experimental|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
16393580|NCT04024501|Experimental|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
16393581|NCT04024501|Experimental|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
16393582|NCT04024488|Experimental|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
16393583|NCT04024488|Active Comparator|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
16393584|NCT04024475||A: Opportunistic screening & benign prostate syndrome (BPS)|Asymptomatic men offered screening (PSA testing) with prostate biopsy (A1). Or patients with lower urinary tract symptoms from benign prostatic hyperplasia undergoing: no treatment (A2), medical therapy (A3), or transurethral resection of the prostate (A4)
16393585|NCT04024475||B: Localized/locally advanced PCa with curative intent|B0: Patients under active surveillance (B0, closed group); B1: radical prostatectomy (RP) or RP followed by (adjuvant) external beam radiation; B2: external beam radiation therapy (EBRT) without androgen deprivation therapy (ADT); B3: external beam radiation therapy with ADT
16393586|NCT04024475||C: Biochemical relapse|Patients with PSA progression after RP with or without systemic therapy
16393587|NCT04024475||D: Metastatic PCa but hormone sensitive|Metastatic PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical), with or without additive treatments. Oligometastatic PCa.
16393588|NCT04024475||E: Metastatic castration resistant prostate cancer (mCRPC)|Metastatic castration resistant prostate cancer (mCRPC). Oligometastatic PCa.
16395802|NCT04008992|Experimental|Part C JMAD - C3 Cohort|Japanese Multiple Ascending Dose
16393589|NCT04024462|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
16393590|NCT04024462|Experimental|Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) of will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.
16393591|NCT04024449||Celiac Disease|"Celiac disease with the following criteria;
~13 ≤ Age ≤20
~At least one year after menarche
~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia."
16393592|NCT04024449||Control|"The adolescent with the following criteria;
~13 ≤ Age ≤20
~At least one year after menarche
~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia.
~Control group; with normal menstrual period, Non-chronic diseases"
16393593|NCT04024436|Experimental|Futibatinib|"Group/Cohort 1 Description HR+ HER2- Measurable Disease w/ FGFR2 Amplification
~Group/Cohort 2 Description TNBC Measurable Disease w/ FGFR2 Amplification
~Group/Cohort 3 Description HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification"
16393594|NCT04024436|Experimental|Futibatinib plus Fulvestrant|Group/Cohort 4 Description HR+ HER2- Measurable Disease w/ FGFR1 Amplification
16393595|NCT04024423||Related M. abscess isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
16393596|NCT04024423||Unrelated M. abscessus isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
16393597|NCT04024423||Related M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
16393598|NCT04024423||Unrelated M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
16393599|NCT04024423||Related M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
16393600|NCT04024423||Unrelated M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
16393601|NCT04024384|Experimental|Daratumumab|Daratumumab as maintenance after peripheral blood stem cell transplantation from HLA-identical or haploidentical family donor in the treatment of refractory or relapsed multiple myeloma
16393602|NCT04024371||HV|Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.
16393603|NCT04024371||SZ|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.
16393604|NCT04024371||MDD|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.
16393605|NCT04024345|Experimental|Psychometric assessment group|Arms to whom the psychometric assessment will be administered
16393606|NCT04024332|Experimental|Group A (healthy)|On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
16393607|NCT04024332|Experimental|Group B (severe renal function impairment)|On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
16393608|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
16393609|NCT04024319||Local Infiltration Analgesia|Retrospectively, the data of the patients belonging to the control group (LIA) were collected through the electronic file in the SAPP program of the internal network of the Barcelona Clinic Hospital in chronological order until completing 35 cases. To include them in the control group, the patients had to meet the same criteria as those belonging to the intervention group (GNB), therefore, the surgery should have been performed under spinal anesthesia and subsequently followed with an oral analgesia schedule meeting criteria of fast track hospitalization. The same data were obtained as in the GNBG, demographic data (age, sex, weight, height, hematocrit, hemoglobin, ASA), duration of the surgery and ischemia time, PACU VAS, AM VAS, PM VAS and finally some data of the post-operative period (hematocrit, hemoglobin, transfusion, hospital stay)
16393610|NCT04024306||ULTRAFILTRATION|
16393611|NCT04024306||DIURETICS|
16393612|NCT04024293|Experimental|All participants|All patients will be follow the same procedures and be placed the investigational device
16393613|NCT04024280|Experimental|Intervention arm|Patients will perform a supervised physical exercise program specifically developed for breast cancer patients, based on the guidelines of the American College of Sports Medicine. The physical exercise program comprises 3 weekly sessions of 60 minutes each. Each session will involve an initial warm-up with light mobility exercises, followed by resistance and aerobic training and ending with a return to calm phase of light stretching exercises.
16393614|NCT04024280|No Intervention|Control arm|Patients should maintain the usual physical activity
16393711|NCT04023565|Experimental|perindopril + moxonidine|perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
16393712|NCT04023552|Experimental|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
16393615|NCT04024267|Experimental|Eurythmy therapy (ERYT)|"Eurythmy therapy (ERYT) is a standardized movement therapy and for each medical condition standardized ERYT exercise (series) exist. In such, in the present study, the cancer series O-E-M-L-I-B-D that is specific and standardized for breast cancer patients will be applied. Patients can perform and maintain the postures without stress and tension. Patients are instructed by ERYT therapists in sessions with 1 to 4 patients."
16393616|NCT04024267|Active Comparator|CoordiFit|The CoordiFit program consists of standardized exercises that address physical coordination, stability, balance and dexterity. These exercises serve as a control intervention and are non-specific with respect of cancer-related fatigue and breast cancer. They mimic those of ERYT but have no mindfulness features. Patients are instructed by physical therapists in session with 1 to 4 patients.
16393617|NCT04024254|Experimental|Folic Acid|Folic Acid supplement 1 mg by mouth daily
16393618|NCT04024254|No Intervention|No Supplementation|
16393619|NCT04024241||high dose of cytarabine|high dose of cytarabine
16393620|NCT04024241||HAM|medium dose of cytarabine and mitoxantrone
16393621|NCT04024228|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
16393622|NCT04024228|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
16393623|NCT04024202||Patients|"Patients with a positive DAT, a positive eluate and signs of hemolysis
~Patients with a positive DAT with complement only, negative eluate, but with hemolysis"
16393624|NCT04024202||Blood donors|Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies
16393625|NCT04024176|Experimental|Moderate hemophiliac patients|Each participant will perform a gait analysis and clinical examination
16393626|NCT04024163|Experimental|Benznidazole|Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days
16393627|NCT04024150||Newborns exposed|Newborns exposed in-utero to raltegravir
16393628|NCT04024150||Newborns controls|Newborns exposed to antiretroviral therapy without anti-integrase
16393629|NCT04024137|Experimental|ZSP1273-200 mg BID|Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
16393630|NCT04024137|Experimental|ZSP1273-400 mg BID|Subjects will receive 10 doses of ZSP1273 400mg（200mg*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
16393631|NCT04024137|Experimental|ZSP1273-600 mg QD|Subjects will receive 5 doses of ZSP1273 600mg （200mg *3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
16393632|NCT04024137|Placebo Comparator|Placebo|Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
16393633|NCT04024111|Experimental|KONTAKT(c)|A social skills group training
16393634|NCT04024111|Active Comparator|Art group|A social Art group
16393635|NCT04024085||Participants|adult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) < 7, consulting in a neuro-urology department
16393636|NCT04024072|Experimental|Perrigo active|Test product
16393637|NCT04024072|Active Comparator|Reference active|Azopt ophthalmic suspension
16393638|NCT04024059|Experimental|Buprenorphine Adherence and Opiate Abstinence|Participants will receive financial incentives for buprenorphine use and opiate abstinence.
16393639|NCT04024059|Experimental|Buprenorphine Adherence Only|Participants will receive financial incentives for buprenorphine use.
16393640|NCT04024059|No Intervention|Control|Participants will not receive any intervention.
16393641|NCT04024046||Control - Placebo|"Placebo Drink-Mix Daily for 180 days
~Placebo Capsules Daily for 180 days"
16393642|NCT04024046||Group 1|"Uqora Drink-Mix Daily for 180 days
~Placebo Capsules Daily for 180 days"
16393643|NCT04024046||Group 2|"Uqora Drink-Mix Daily for 180 days
~Uqora Capsules Daily for 180 days"
16393644|NCT04024033|Active Comparator|capsule|patinets receiveing pine cone extract tablets
16393645|NCT04024033|Placebo Comparator|placebo capsule|patinets receiving placebo
16393646|NCT04024020||Individuals with insomnia|Men and women with chronic insomnia (>5 years duration)
16393647|NCT04024020||Good sleepers|Men and women with a longstanding pattern of good sleep
16393648|NCT04024007||Dialysis patients|Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Dialysis performed according to the standard indications of the service. Patients are dialysed with the prismaflex system on AN69ST membranes.
16393649|NCT04023994|Placebo Comparator|Placebo|In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
16393650|NCT04023994|Experimental|RO7126209 (0.1 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
16393651|NCT04023994|Experimental|RO7126209 (0.4 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
16393652|NCT04023994|Experimental|RO7126209 (1.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
16393653|NCT04023994|Experimental|RO7126209 (3.6 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
16393654|NCT04023994|Experimental|RO7126209 (7.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
16393655|NCT04023981|No Intervention|Standard care alone|Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
16393676|NCT04023838|Active Comparator|Left distal radial approach|After local anesthesia on left anatomical snuffbox area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
16393656|NCT04023981|Experimental|Parafricta bootees plus standard care|Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.
16393657|NCT04023968|Experimental|YESplus workshop|Your Enlightened Side, plus more (YESplus) is an four-day, 15-hour integrative life skills workshop with a strong emphasis on breathing techniques and social connectedness. In addition to specific contemplative techniques such as yoga, mindfulness meditation, and compassion meditation that help cultivate inner peace, YESplus incorporates discussions and other activities to facilitate social connectedness, leadership, and community service. During the workshop, participants have ample time to learn and practice the Sudarshan Kriya Yoga (SKY) technique, as well as to ask questions. SKY has four sequential, form- and rhythm-specific breathing components interspersed with normal breathing while sitting in a relaxed position with eyes closed, followed by Yoga Nidra. A certified instructor with a minimum of 1,000 hours of SKY instruction training will lead each workshop.
16393658|NCT04023968|Active Comparator|WOW! workshop|"A comparison workshop titled Wisdom On Wellness (WOW!) will be implemented to control for potential expectancy effects, time commitment, group-based interactions, and wisdom/knowledge of YESplus that is anticipated to have beneficial effects on stress management and well-being, allowing for more rigorous evaluation of the contemplative practices and other activities unique to the YESplus workshop. This workshop differs from YESplus due to the increased focus on cognitive approaches to conceptualizing and managing stress (e.g. thoughts about the past and future versus present moment), and absence of physical or somatic activities."
16393659|NCT04023955||Intervention|Twitter messages delivered over 1 month period
16393660|NCT04023942|Active Comparator|Low carb - App-based group|Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
16393661|NCT04023942|Active Comparator|Low carb - Newsletter-based group|"Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
16393662|NCT04023942|Active Comparator|Low fat - App-based group|Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
16393663|NCT04023942|Active Comparator|Low fat - Newsletter-based group|"Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
16393664|NCT04023929||Term babies|Babies who are born at or after 37 gestational weeks.
16393665|NCT04023929||Preterm babies|Babies who are born between 32 and 36+6 gestational weeks.
16393666|NCT04023929||Very preterm babies|Babies who are born before 32 gestational weeks.
16393667|NCT04023916|Experimental|Sintilimab-R-CHOP|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and Sintilimab, rituximab, and CHOP during Cycles 2-6 (21-day cycle) ,Sintilimab and rituximab during Cycles 6-8 (21-day cycle) , followed by Sintilimab from Cycles 9-14 (8-week cycle) during consolidation treatment.
16393668|NCT04023903|Experimental|RTA 402 5mg 3cap at fasting|
16393669|NCT04023903|Experimental|RTA 402 5mg 3cap after meal|
16393670|NCT04023877|Experimental|E2027|Participants will receive approximately 130 microcurie (μCi) of [14C]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
16393671|NCT04023864|Experimental|Platycodon Grandiflorus Extract(GCWB107) group|Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
16393672|NCT04023864|Placebo Comparator|Placebo group|Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
16393673|NCT04023851||Adolescent patient|"Participant between the ages of 15-18
~Participants who are taking antiepileptic drug for seizure control"
16393674|NCT04023851||Parents with epilepsy children|"Participants who have child with epilepsy (ages of 1-15)
~Participants' child who are taking antiepileptic drug for seizure control"
16393675|NCT04023838|Placebo Comparator|Right conventional radial approach|After local anesthesia on right wrist area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
16393677|NCT04023825|Experimental|experimental group|Patients will receive loco regional anesthesia
16393678|NCT04023825|No Intervention|control group|Patients will not receive loco regional anesthesia
16393679|NCT04023812||Cohort 1|Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
16393680|NCT04023812||Cohort 2|Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
16393682|NCT04023773|Experimental|Liver perfusion|"Device: Liver Machine Perfusion (MP) Device
~The liver grafts will be preserved at hypothermic and normothermic temperature on the institutional-developed Liver MP Device, and have continuous perfusion with oxygen supply in the ex vivo organ preservation phase."
16393683|NCT04023760|Experimental|Treatment group A: Cyclosporine in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on cyclosporine as part of their immunosuppressive regimen
16393684|NCT04023760|Active Comparator|Cyclosporine in healthy subjects|"Results from Treatment group A will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of cyclosporine at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)
~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
16393685|NCT04023760|Experimental|Treatment group B: Tacrolimus in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on tacrolimus as part of their immunosuppressive regimen
16393686|NCT04023760|Active Comparator|Tacrolimus in healthy subjects|"Results from Treatment group B will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of tacrolimus at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)
~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
16393687|NCT04023747||Cohort 1|Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
16393688|NCT04023747||Cohort 2|Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
16393689|NCT04023747||Cohort 3|Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma
16393690|NCT04023734|Experimental|Intervention|A targeted and tailored pharmacist intervention at baseline and at 1-month follow-up.
16393691|NCT04023734|Active Comparator|Control group|Usual care based on the Indonesian guideline at baseline and 1-month follow-up.
16393692|NCT04023721|Experimental|Cohort 1 - Inarigivir Soproxil Alone|Cohort 1, 400 mg Inarigivir daily for 24 weeks and after treatment discontinuation will be followed for a further 18 months.
16393693|NCT04023721|Experimental|Cohort 2 Arm A - Inarigivir Soproxil and NUC|Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
16393694|NCT04023721|Experimental|Cohort 2 Arm B - Inarigivir Soproxil and NUC|Cohort 2, Arm B, 400 mg Inarigivir daily plus prestudy nucleoside/nucleotide (NUC) analogue inhibitors for at least 24 weeks and up to 48 weeks. After treatment discontinuation of both inarigivir and the NUC, subjects will be followed off treatment up to Week 96.
16393695|NCT04023708||Cohort I: CYD-TDV exposed pregnant women and offspring|Pregnant women of any age and their offspring who were inadvertently exposed to CYD-TDV anytime during the pregnancy or in the 30 days preceding their LMP
16393696|NCT04023695|Active Comparator|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
16393697|NCT04023695|Experimental|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
16393698|NCT04023682|Other|Anesthesia Provider hands|"Each provider will serve as their own control.
~Control phase is at baseline using standard hygiene practices.
~Intervention phase will include the addition of Provodine hand sanitizer"
16393699|NCT04023669|Experimental|A: prexasertib + cyclophosphamide|"Stratum A: Participants receive combination treatment with cyclophosphamide given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.
~Note: Only if absolutely necessary, cyclophosphamide may be given on day 16 and prexasertib may be given on day 17."
16393700|NCT04023669|Experimental|B: prexasertib + gemcitabine|"Stratum B: Participants receive combination treatment with gemcitabine given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.
~Note: Only if absolutely necessary, gemcitabine may be given on day 16 and prexasertib may be given on day 17."
16393701|NCT04023643|Experimental|CPAP + PS|Weaning from mechanical ventilation using CPAP + PS
16393702|NCT04023643|Active Comparator|SIMV + PS|Weaning from mechanical ventilation using SIMV+PS
16393703|NCT04023630|Experimental|rivaroxaban plus ticagrelor|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months
16393704|NCT04023630|Active Comparator|rivaroxaban plus clopidogrel|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months
16393705|NCT04023617|Experimental|Nivolumab + Docetaxel|"Nivolumab was administered at a dose of 300 mg on the first day of the 21-day cycle (every 3 weeks; q3w) when combined with docetaxel, and administered at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w) after stopping docetaxel treatment.
~On the first day of each cycle (21 days), docetaxel 75 mg/m2 was infused by IV on Day 1 of each 21-day cycle for 4-6 cycles (judged by investigator)."
16393706|NCT04023617|Active Comparator|Nivolumab|Nivolumab was administered in the monotherapy group at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w).
16393709|NCT04023591||Surgery|Surgery/ Occupational Therapy
16393715|NCT04023539|Placebo Comparator|Control group|Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
16393716|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg|Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
16393717|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg|Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
16393718|NCT04023513|Experimental|Strength Training and Protein high|6 weeks of high protein intake (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
16393719|NCT04023513|Experimental|Strength Training and Protein low|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
16393720|NCT04023513|Other|Control|No Intervention.
16393721|NCT04023500|Active Comparator|Motivational interview|The MI-intervention is used as a part of normal dental hygienist appointment. Dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients. Dental hygienist support patients in decision making although patients were addressed as an active agent.
16393722|NCT04023500|Active Comparator|Prevailing education|In control group prevailing, more professional-centered education is used. Dental hygienist define patients educational needs and give direct instructions how to change behaviour and self-care.
16393723|NCT04023487|Experimental|Lifestyle Intervention|Resilient, Empowered, Active Living-Telehealth (REAL-T)
16393724|NCT04023487|No Intervention|Usual Care|Participants will continue to have access to routine diabetes care from the provider of their choosing; they will not receive any study-related intervention.
16393725|NCT04023474|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft in clinic at the time any pertinent post-operative complication is identified.
16393726|NCT04023474|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
16393727|NCT04023461|No Intervention|Clinical Treatment Group|
16393728|NCT04023461|Experimental|Interventional Ablation Group|
16393729|NCT04023448|Experimental|coloplasty(CP)|After purse-string suture and ligation of the head of the stapler at the colonic end, 5cm away from the colonic end, 5cm longitudinal incision was made to the proximal end of the teniae coli in the anterior wall of the colon, transverse suture was performed, and the plasmomuscular layer was embedded, then end to end colon-rectum (or anal canal) anastomosis was performed
16393730|NCT04023448|No Intervention|straight colorectal anastomosis (SCA)|End to end colon-rectum (or anal canal) anastomosis was performed routinely
16393731|NCT04023435|Experimental|PNE education|All subjects will be tested before and after receiving PNE education
16393732|NCT04023422|Active Comparator|Clinical intervention|Clinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit.
16393733|NCT04023422|Experimental|Clinical intervention AND Home Visit|Patient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics.
16393734|NCT04023422|Experimental|Clinical intervention AND Feedback|
16393735|NCT04023422|Experimental|Clinical intervention AND Home Visit AND Feedback|
16393736|NCT04023409||Severe COPD patients|Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
16393737|NCT04023396|Experimental|ABX464 50mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
16393738|NCT04023383|Placebo Comparator|Control|The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
16393739|NCT04023383|Experimental|HyaRegen NCH gel group|In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
16393740|NCT04023370|Experimental|BeGraft Peripheral Stent Graft System|Covered stent
16393741|NCT04023370|Active Comparator|Bare metal stent system|bare metal stent
16393742|NCT04023357|Experimental|PEEK|"PEEKs (polyetheretherketones) are presented as alternative materials to metal and glass ceramics,1 Their elastic modulus comparable to those of cortical bone and dentin so the polymer could exhibit good stress distribution. Also they have high fracture resistance, and low abrasion to the antagonist enamel.
~Yet clinical studies are needed to evaluate their clinical performance."
16393743|NCT04023357|Active Comparator|Emax|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for Endocrowns
16393744|NCT04023344|Active Comparator|Humalog® Mix 25|Insulin Humalog® Mix 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
16393745|NCT04023344|Experimental|Insulin Lispro Biphasic 25|Insulin Lispro Biphasic 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
16393746|NCT04023331|Experimental|67Cu-SARTATE|"64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.
~67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as a slow IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion."
16393747|NCT04023318|Experimental|Integrated Lifestyle Intervention|
16393748|NCT04023305|Experimental|Nonfocal ARDS|ARDS patient with nonfocal lung imaging phenotype
16393749|NCT04023305|Experimental|Focal ARDS|ARDS patient with focal lung imaging phenotype
16393750|NCT04023292|Experimental|Arm I (2 weeks preoperative endocrine therapy))|Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
16393751|NCT04023292|Active Comparator|Arm II (4 weeks preoperative endocrine therapy)|Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
16393752|NCT04023279|Experimental|TENS|Conventional TENS of 100 Hz and 100 usec for 20 minutes
16393753|NCT04023279|Experimental|Myofascial Therapy|Conventional TENS of 100 Hz and 100 usec for 20 minutes plus myofascial release therapy in the brachial biceps; Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding
16393754|NCT04023266|Experimental|Intravenous N-Acetylcysteine arm|On arrival at the recruiting hospital, eligible and consenting STEMI patients randomly allocated to the experimental arm would be administered an intravenous N-Acetylcysteine bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours.
16393755|NCT04023266|No Intervention|Control arm|Patients randomized to this arm would receive no experimental therapies and would continue to receive all standard guideline recommended medical therapies and interventions.
16393756|NCT04023253|Experimental|mirabegron|Receive mirabegron 2 mg treatment per day
16393757|NCT04023253|Experimental|solifenacin|Receive solifenacin 5 mg treatment per day
16393758|NCT04023240|Experimental|68Ga-FAPI PET/CT|Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
16393759|NCT04023227|Experimental|Sacubitril/valsartan|"Sacubitril/valsartan 200 mg b.i.d.
~Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).
~Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug
~Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively"
16393760|NCT04023227|Active Comparator|Enalapril|"Enalapril 10 mg b.i.d.
~Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily)."
16393761|NCT04023214||ADPKD|ADPKD patients
16393762|NCT04023214||Controls|Healthy volunteers
16393763|NCT04023201||Parkinson's disease patients|Parkinson's disease patients with or without nocturnal symptoms
16393764|NCT04023175|Active Comparator|In office|Patients will undergo our standard in office preoperative counseling.
16393765|NCT04023175|Experimental|Virtual visit|Patients will undergo preoperative counseling using telemedicine virtual visits.
16393766|NCT04023162|Experimental|Biomedical group|Therapy Exercises and Back School by month, 2 times a week for 60 minutes.
16393767|NCT04023162|Experimental|Biopsychosocial group|Operant Conditioning implement in physiotherapy, Therapy Exercises and Back School by month, 2 times a week for 60 minutes.
16393768|NCT04023162|No Intervention|Usual care|Usual care and written instructions on Therapeutic Exercises and Back School for home work.
16393769|NCT04023149|Experimental|experimental group|Patients will receive rhIL-2 solution oral gargle twice per day (2 million units of rhIL-2 dissolved in 5ml normal saline for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
16393770|NCT04023149|Placebo Comparator|control group|Patients will receive placebo solution oral gargle twice per day (5ml for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
16393771|NCT04023136|Other|only one arm (resected patients)|liver resection group
16393772|NCT04023123||Anterior Cornea Striae|Eyes with anterior cornea striae present
16393773|NCT04023123||Hypotony Maculopathy|Eyes with hypotony maculopathy present
16393774|NCT04023123||Hypotony only|Eyes with intraocular pressure less than 10 without cornea striae and/or maculopathy
16393775|NCT04023110|Experimental|Carvedilol|"Carvedilol will be initiated at 3.125mg twice daily and uptitrated as tolerated in a stepwise fashion to a maximum dose of 25mg twice daily or to a systolic blood pressure (SBP) of 110-120mmHg or heart rate (HR) of 50-55 beats per minute (bpm). Patients will start carvedilol in the evening after first dose of chemotherapy and will continue on medication for 12 months.
~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months."
16393776|NCT04023110|No Intervention|Usual Care|Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months.
16393777|NCT04023097|Experimental|Toothwave contraindicated subject|"the Toothwave toothbrush is contraindicated for people in certain conditions, e.g. pregnant or nursing women, people with pacemaker and more.
~This arm is assembled from contraindicated subject, who should exclude themselves from use of the device, based on the user manual and box sleeve."
16393778|NCT04023097|Active Comparator|potential users of the Toothwave device|The control arm is assembled from people who can use the toothbrush and should recognize themselves as potential users.
16393779|NCT04023084|Experimental|Atopic Dermatitis Group|Receive crisaborole intervention
16393780|NCT04023071|Experimental|FT516 Monotherapy|FT516 monotherapy in adult subjects with r/r AML.
16393781|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies|FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
16393782|NCT04023058|No Intervention|CABG/increasing MR|non-massive IMR with increasing IMR during exercise - CABG only
16393783|NCT04023058|Experimental|CABG+mitral surgery (MS)/increasing MR|non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
16393784|NCT04023058|No Intervention|CABG/non-increasing MR|non-massive IMR non-increasing IMR during exercise - CABG only
16393785|NCT04023058|Experimental|CABG+MS/non-increasing MR|non-massive IMR non-increasing IMR - CABG+ mitral surgery
16393786|NCT04023058|Other|Control 1|massive IMR at rest without increasing during exercise - CABG+ mitral surgery
16395803|NCT04008979|Experimental|PL-ASA 325 mg|Novel aspirin formulation being tested
16393791|NCT04023019||Group 1: ITI with Nuwiq, octanate, or wilate|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery and for prophylaxis.
16393792|NCT04023019||Group 2: ITI with Nuwiq, octanate, or wilate with emicizumab|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate, in combination with emicizumab prophylaxis. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery.
16393793|NCT04023019||Group 3: Prophylaxis with emicizumab, aPCC, or rFVIIa|Participants receiving routine prophylaxis with emicizumab, aPCC, or rFVIIa without immune tolerance induction. On-demand aPCC/rFVIIa can be used as needed to treat bleeding episodes or during surgery.
16393794|NCT04023006||Edentulous Patients|The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
16393795|NCT04022993|Active Comparator|Lantus® SoloStar®|Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
16393796|NCT04022993|Experimental|Insulin RinGlar®|Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
16393799|NCT04022967|Experimental|Arm 1 : Dual maintenance therapy DTG+3TC|
16393800|NCT04022967|Experimental|Arm 2 : Dual maintenance therapy ATV/r+3TC|
16393801|NCT04022967|Active Comparator|Arm 3 : Reference triple therapy TDF+3TC+EFV|
16393802|NCT04022954||Inquiry™ AFocusII™ Double Loop|The Inquiry™ AFocus™ catheters are for recording intracardiac signals and cardiac stimulation during diagnostic electrophysiological studies. The Inquiry™ AFocus™ catheters are for use in mapping atrial regions of the heart.
16393803|NCT04022954||Advisor™ HD Grid, Sensor Enabled™|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart with recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
16393804|NCT04022941|Experimental|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
16393805|NCT04022941|Placebo Comparator|Placebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
16393806|NCT04022928|Experimental|PRP injection|Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
16393807|NCT04022915|Experimental|Acute pulmonary embolism|Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
16393808|NCT04022889|Experimental|Stage 1|Stage 1 is a randomized, 2-period crossover design. Test platelets stored for 7 days will be radiolabeled using either the BEST or Variant 1 methods (depending on the period and randomization scheme for the Test platelets) for 12 healthy subjects. The recovery and survival for Test platelets prepared with the BEST and Variant 1 methods will be compared with each other and against the fresh platelet Control.
16393809|NCT04022889|Experimental|Stage 2|Stage 2 is a single arm study in which all Test platelets will be prepared for radiolabeling using the Variant 1 methodology. The recovery and survival for Test platelets will be compared against the fresh platelet Control. Recovery and survival of INTERCEPT platelets will be assessed after Day 7, 6 or 5 days of storage for up to 24 evaluable subjects. The storage duration of the Test platelet components will be determined by Cerus based on the outcome of Stage 1.
16393810|NCT04022876|Experimental|Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed|
16393811|NCT04022876|Experimental|Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed|
16393812|NCT04022876|Experimental|Part 1 SCLC: ALRN-6924+Topotecan|
16393813|NCT04022863||ovarian tumor benign|all pathological proven benign ovarian tumors
16393814|NCT04022863||ovarian tumor borderline|all pathological proven borderline ovarian tumors
16393815|NCT04022863||ovarian tumor malignant|all pathological proven malignant ovarian tumors
16393816|NCT04022850|Active Comparator|Passive dissemination|Passive dissemination strategies focused on the distribution of materials, support tools and training
16393817|NCT04022850|Experimental|Intuitive de-implementation|Mindless externally imposed de-implementation strategies to discourage the non-desired behavior and to encourage the preferred/desired behavior
16393818|NCT04022850|Experimental|Reflexive de-implementation|Active de-implementation strategies targeting conscious cognition processes to discourage the non-desired behavior and to encourage the preferred/desired behavior
16393819|NCT04022837|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
16393820|NCT04022837|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
16393821|NCT04022824||OSA|
16393822|NCT04022824||Non-OSA|
16393823|NCT04022811|Experimental|Artificial tears|0.1% bromfenac VS Artificial tears
16393824|NCT04022798|Experimental|Experimental group|Neural mobilization (NM), lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
16393825|NCT04022798|Active Comparator|Control group|lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
16393826|NCT04022785|Experimental|Treatment (BRD4 Inhibitor PLX51107, azacitidine)|Patients receive PLX51107 PO QD on days 1-21 and azacitidine SC or IV over 15 minutes on days 8-14 and 22-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16393827|NCT04022772|Experimental|GROUP I (PACK Health program)|Patients participate in PACK Health program consisting of weekly contact with an assigned health coach via text message, phone call, and email for 3 months. After 3 months, patients continue to be contacted by the health coach at least once monthly for an additional 3 months.
16393828|NCT04022772|Active Comparator|GROUP II (standard of care)|Patients receive standard of care support services over 6 months.
16393829|NCT04022759|Active Comparator|Treatment as Usual|Participants randomised to the 'treatment as usual' group will receive behavioural activation guided-self help intervention as routinely delivered in the service.
16393830|NCT04022759|Experimental|Treatment with Security Prime|Participants randomised to the experimental group will receive behavioural activation guided self-help intervention as is routinely delivered in the service with additional attachment security priming intervention.
16393831|NCT04022746|Experimental|Diagnostic (MRI/MRE)|Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
16393832|NCT04022733|Placebo Comparator|Moderate NMB group|
16393833|NCT04022733|Experimental|Deep NMB group|
16393834|NCT04022720|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft.
16393835|NCT04022720|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
16393836|NCT04022707|Experimental|High-Velocity Resistance Circuttraining (HVRCT)|The participants will perform three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three weeks from 1 to 3 circuits.
16393837|NCT04022707|Experimental|Educational Control (CON)|A supervised program will be provided to the participants that includes lectures on health and fitness.
16393838|NCT04022694|Active Comparator|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
16393839|NCT04022694|Experimental|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
16393840|NCT04022694|No Intervention|Baseline for Calorie/Control Poster|We will collect baseline data from a group of students before posting the Calorie/Control Poster in the control school.
16393841|NCT04022694|No Intervention|Baseline for SSB Warning and Non-SSB Promotion Poster|We will collect baseline data from a group of students before posting the SSB Warning and Non-SSB Promotion Poster in the intervention school.
16393842|NCT04022681||Non-specific liver disease|Patients who were categorised as having a non-specific liver disease in the original BALLETS study.
16393843|NCT04022668||STEMI|Current international ECG criteria (New ST-segment elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV millivolts (mV) in all leads other than leads V2-V3; for leads V2-V3: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age) with troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia.
16393844|NCT04022668||NSTEMI|Troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia without abovementioned criteria.
16393845|NCT04022668||Normal|Emergency department admission with a clinical picture compatible with acute coronary syndrome, but no change in serial ECGs and no rise in cardiac biomarkers
16393846|NCT04022655||ANCA-associated Vasculitis|Patients with ANCA-associated vasculitis admitted to the ICU
16393847|NCT04022642|Experimental|HIIT Group|Two HIIT sessions delivered at the beginning of Physical education classes
16393848|NCT04022642|No Intervention|Control Group|Usual programmed Physical education classes
16393849|NCT04022629|Active Comparator|Treatment Group 1|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
16393850|NCT04022629|Active Comparator|Treatment Group 2|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
16393851|NCT04022616||Immediate Surgery|Adult patients with breast malignancy.
16393852|NCT04022616||Neo-adjuvant Chemotherapy|Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.
16393853|NCT04022616||Lymph Node Tissue|Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.
16393854|NCT04022616||Metastatic Breast Cancer|Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).
16393855|NCT04022603|Experimental|Optiflow nasal googles|Oxygen provided by means of high throughput nasal googles (Optiflow, Fisher&Paykel- New Zealand).
16393856|NCT04022603|Active Comparator|Venturi mask|Oxygen provided by means of a Venturi mask.
16393857|NCT04022590|Experimental|E-clothes|The participants with E-clothes do aerobic training at home
16393858|NCT04022590|Active Comparator|Home exercise|The participants with healthy consultation do aerobic training at home.
16393859|NCT04022577|Experimental|experimental group|The experimental group will participate in a eight session course of Adherence Therapy
16393860|NCT04022577|Placebo Comparator|control group|The control group received routine care
16393861|NCT04022564||The subjects are diagnosed as MS patient|The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.
16393862|NCT04022551||Observational|"At Emergency nurses will carry out a test called: Emergency Room Evaluation and Recommendation which contents the following statements:
~Being 85 years older and over (Yes/No)
~Male (Yes/No)
~Home services (Yes/No)
~Taking 5 different medication daily (Yes/No)
~Use of walking aid (Yes/No)
~Disoriented (Yes/No)"
16393863|NCT04022538|Experimental|Sandwich osteotomy with simultaneous implant placement|This group will undergo Sandwich osteotomy procedure and segment will be fixed using the dental implants placed simultaneously during the same surgical procedure. The remaining gap will be filled using xenograft.
16393864|NCT04022538|Active Comparator|Sandwich osteotomy using micro-plates fixation|This group will undergo Sandwich osteotomy procedure and segment will be fixed using micro-plates and screws, and the gap will be filled using xenograft.
16393868|NCT04022486||Children admitted in the PICU for severe bronchiolitis|Children admitted in the Pediatric Intensive Care Unit (PICU) for severe bronchiolitis between January 1st, 2010 and April 30th, 2018
16393869|NCT04022473|Experimental|Bafiertam|oral capsules administered twice daily
16393870|NCT04022473|Active Comparator|Tecfidera|oral capsules administered twice daily
16393871|NCT04022434|Placebo Comparator|Placebo|"Psyllium powder is used as the placebo. A member of the research staff will package and dispense L-alanine and placebo in similar containers. A standard measuring spoon will be provided to the subject for preparing the placebo solution. Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
~Meal Placebo Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
16393872|NCT04022434|Experimental|Experimental Alanine|"L-alanine, USP (Spectrum® Chemicals and Laboratory Products, Gardena, CA) will be packaged and dispensed by one member of the research staff who will have no other role in the study. A one-month supply will be dispensed to the subjects.
~Meal L-Alanine Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
16393873|NCT04022421|Experimental|hydroxychloroquine arm|
16393874|NCT04022408|Experimental|Liquid based cytology|.Liquid-based cytology (LBC), enables cells to be suspended in a monolayer. LBC makes better cytological assessment possible with improved sensitivity and specificity, since fixation is better and nuclear details are well preserved in the technique. Preneoplasticand neoplastic cells are not obscured by other cells, such as normal epithelial and inflammatory cells. LBC techniques are currently applied to cytological samples from several tissues or fluids. They include uterine cervix , endometrium, aspirates from breast , thyroid tumors, ascites and pleural effusion, and urine , LBC technology is suggested as an appropriate diagnostic method for metastatic tumors in cerebrospinal fluid .
16393875|NCT04022408|Active Comparator|Conventional cytology|It is a gold standard for histopathological diagnosis of pancreatobiliary malignancies till date
16393876|NCT04022395|Experimental|stress cardiac MRI|"To optimize the scan protocol and the sequence parameters
~To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients
~To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features"
16393877|NCT04022382|Experimental|Restylane Defyne recipient|
16393878|NCT04022369|Experimental|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. Education program based on Empowerment model. Weekly motivational telephone interviews were conducted with the patients, and the home visits and telephone interviews were repeated when belived necessary. The purpose of the study were explained to all individuals involved in the study. Body movements, balance levels, exercise durations, and strengths of individuals before exercise program and after exercise program were evaluated. A booklet demonstrating the exercises was given to the patients to enhance their understanding, and they were allowed to ask questions about the exercise program during the training.
16393879|NCT04022369|No Intervention|Control Group|The patients in the control group continued their standard treatment and care. Data collection forms were applied to the patients in the control group at the first month and 12 weeks after discharge. After the study was completed, all patients in the control group were provided with home-based exercise training booklets.
16393880|NCT04022356|Experimental|Connected soles|Number of steps recorded by the soles (activation per smartphone)
16393881|NCT04022356|Active Comparator|Gold Standard|Number of steps counted by two observers viewing the film
16393882|NCT04022343|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
16393883|NCT04022330|Other|Blood sampling|
16393884|NCT04022317|Experimental|Biocon Insulin R|0.3 IU/kg Dose per administration, subcutaneous Route of administration
16393885|NCT04022317|Active Comparator|Humulin® R (regular insulin human)|0.3 IU/kg Dose per administration, subcutaneous Route of administration
16393886|NCT04022304|Experimental|Sequence: Humulin® N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
16393887|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
16393888|NCT04022304|Experimental|Sequence: Humulin® N- Humulin® N-Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
16393889|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
16393890|NCT04022304|Experimental|Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
16393891|NCT04022304|Experimental|Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
16395804|NCT04008979|Active Comparator|IR 325 mg|Immediate release aspirin
16393892|NCT04022291|Experimental|Biocon Insulin 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
16393893|NCT04022291|Active Comparator|Humulin® 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
16393894|NCT04022265|Active Comparator|Control Site -Drill site|The control sites (Drills) will be prepared with a lanceolate drill (FS 230, Sweden / Martina), with a maximum diameter of 2.3 mm,
16393895|NCT04022265|Experimental|Test site -sonic site|test sites will be prepared with conical diamond inserts of increasing diameter (SFS99.000.014 to SFS99.000.024, Komet-Brasseler-GmbH, Germany) mounted on a sonic-air surgical instrument
16393896|NCT04022252|Experimental|Tooth Movement|Canine distalization on premolar extracted patients
16393897|NCT04022252|Experimental|Biochemistry measurements|biochemistry analysis of IL-8, OPG, RANKL
16393898|NCT04022252|Experimental|periodontal measurements|gingival and plaque index, blooding on probing, pocket depth
16393899|NCT04022239|Experimental|Schedule I (non-lymphoma)|Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
16393900|NCT04022239|Experimental|Schedule II (lymphoid malignancies)|Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.
16393901|NCT04022226|Active Comparator|Methohexital|Standard of care anesthesia that does not affect slow wave characteristics
16393902|NCT04022226|Experimental|Ketamine|Standard of care anesthesia that suppresses slow wave characteristics
16393906|NCT04022200||Paclitaxel DCB for De Novo Coronary Lesions|we define de novo coronary artery lesions as the lesions never been treated with any interventional device, such as POBA, stent, rota ablation, laser etc.
16393907|NCT04022187||Bulbocavernosus reflex assessment|Patients over 18 years old, consulting in neuro-urology department for urinary, anorectal or genito-sexual disorders.
16393908|NCT04022174|Experimental|Moderate dosage training|
16393909|NCT04022174|Experimental|Intensive dosage training|
16393910|NCT04022161|Placebo Comparator|Nitrogen|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
16393911|NCT04022161|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled nitric oxide (iNO) will be weaned and discontinued.
16393912|NCT04022135|Active Comparator|Folic acid|0.6 mg/day
16393913|NCT04022135|Experimental|(6S)-5-methyltetrahydrofolic acid (Metafolin)|0.625 mg/d (an equimolar dose to folic acid)
16393914|NCT04022122||Heart Failure patients|The study does not imply any specific therapeutic intervention, and will not imply any change in the management of the participating patients, who will follow the usual clinical controls and will receive the medical and invasive treatments usually provided to patients with HF in our health area; as well as the different modalities of specific health education for this disease. At the time of hospital discharge, patients will be handled according to the usual protocols of the center established for outpatient follow-up of HF patients.
16393915|NCT04022109||Gastric cancer patients undergoing surgery|Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
16393916|NCT04022109||Gastric cancer patients|Patients with histologically confirmed gastric cancer (adenocarcinoma)
16393917|NCT04022109||Control group patients without gastric cancer|Patients without gastric malignant disease according to data obtained in upper endoscopy
16393918|NCT04022109||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
16393919|NCT04022109||Patients with dyspeptic symptoms|Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
16393920|NCT04022096|Experimental|Tegoprazan 25mg QD|Tegoprazan 25mg tablet, once daily, oral administration
16393921|NCT04022096|Active Comparator|Lansoprazole 15mg QD|Lansoprazole 15mg capsule, once daily, oral administration
16393922|NCT04022070|Other|Dynamic Tape|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of subjects affected by plantar fasciitis.
16393923|NCT04022057|Active Comparator|Pre-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
16393924|NCT04022057|Sham Comparator|Post-GA|10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
16393925|NCT04022031||Exposed group|Chinese patent medicine combined with western medicine routine
16393926|NCT04022031||Non-exposed group|Western medicine routine treatment
16393927|NCT04022018|Experimental|Adaptive radiotherapy group|Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of adaptive radiotherapy group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
16393928|NCT04022018|Active Comparator|Control group|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.
16393929|NCT04022005|Experimental|Chidamide combined with R-GemOx|Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
16393930|NCT04021992|Experimental|GVD with or without R|Gemcitabine 1000mg/m2, d1,d8, intravenous drip; Vinorelbine 50mg/m2, d1,d8, oral; Doxorubicin liposomes 30mg/m2, d1,intravenous drip; With or without rituximab 375 mg/m2, d0,intravenous drip; All patients received up to 6 treatment cycles of 21 days.
16393931|NCT04021979|Experimental|Enteral Nutritional+PEG|Enteral Nutritional Powder with low volume 1.5L PEG
16393932|NCT04021979|Placebo Comparator|Self-controlled diet+PEG|Self-controlled diet with normal amount of 2L PEG
16393933|NCT04021966|Experimental|Laser|In this arm, participants will have 3 real laser treatments first, followed by 3 consecutive sham treatments.
16393934|NCT04021966|Sham Comparator|Sham|In this arm, participants will have 3 sham treatments first, followed by 3 consecutive real laser treatments.
16393935|NCT04021953|Experimental|Intervention Group|"The online intervention comprises a series of six videos, each about 10-minutes in length, entitled the People Like Us series. The intervention was developed by gayhealth.sg and Action for AIDS Singapore in 2018. The series follow the love and sex lives of four ethnically-diverse GBQ men of varying socioeconomic backgrounds, as they negotiate issues of sexual health, mental health, and relationships throughout the six-part miniseries.
~The intervention group will also be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention."
16393936|NCT04021953|Active Comparator|Control Group|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
16393937|NCT04021940|Experimental|Dose adjusted ULOD|dose adjusted ULOD using 60J/cm3 applied to the larger ovary. The number of punctures (Np) per ovary will be calculated according to the following formula: Np = 60 J/cm3 divided by 30 W x 4 s.
16393938|NCT04021940|Active Comparator|Fixed dose ULOD|600 J for the larger ovary will be delivered through four punctures, each for 4 s and 40 W
16393939|NCT04021927|Experimental|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
16393940|NCT04021914|Experimental|EnChroma glasses|EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.
16393941|NCT04021901||F21|balloon diameter F21
16393942|NCT04021901||F24|balloon diameter F24
16393943|NCT04021888|Experimental|Exercise Group|
16393944|NCT04021888|Active Comparator|Control|
16393945|NCT04021862|Experimental|Treatment Arm 1 (bermekimab every week)|"Loading Dose: 400 mg subcutaneous (SC) injection of bermekimab and a SC injection of placebo at week 0 (Baseline)
~Treatment Dose: 400 mg subcutaneous injection of bermekimab administered weekly (qw) from week 1 to week 15."
16393946|NCT04021862|Experimental|Treatment Arm 2 (bermekimab every other week)|"Loading Dose: Two 400 mg SC injections of bermekimab at week 0 (Baseline)
~Treatment Dose: 400 mg SC injection of bermekimab administered every other week (q2w) alternating with placebo q2w from week 1 to week 15"
16393947|NCT04021862|Placebo Comparator|Placebo|"Loading Dose: Two SC injections of placebo at week 0 (Baseline)
~Treatment Dose: Subcutaneous injection of placebo administered once weekly (qw) from week 1 to week 15."
16393948|NCT04021849|Experimental|Intervention|Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
16393949|NCT04021849|Sham Comparator|Control|Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
16393950|NCT04021836|Other|3d evaluation of naso labial changes using alar cinch suture|
16393951|NCT04021836|Other|3d evaluation of nasolabial change without Alar cinch|
16415632|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A&B"|
16393952|NCT04021823||DBS patients|Patients with treatment resistant major depression participating in the FORESEE III study.
16393953|NCT04021823||Healthy controls|Age- and sex-matched healthy controls undergoing analyses of neurodegenerative markers (neurofilament light protein) in blood and metabolomic analyses in blood and urine.
16393954|NCT04021810|Active Comparator|CPAP only|Obstructive sleep apnea patients with CPAP treatment only
16393955|NCT04021810|Active Comparator|Mandibular Advancement Device only|Obstructive sleep apnea patients with Mandibular Advancement Device only
16393956|NCT04021810|Experimental|CPAP + Mandibular Advancement Device|Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device
16393957|NCT04021797|Sham Comparator|Sham|For the sham condition, the electrodes will be attached to an ear location that has not been shown to engage the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the active tVNS condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
16393958|NCT04021797|Experimental|Active|For the active condition, the electrodes will be attached to the ear at a place previously demonstrated to stimulate the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the sham condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
16393959|NCT04021784|Experimental|Spring Distraction System (SDS)|The SDS will be placed and fits around a standard rod of 4.5 or 5.5mm.
16393960|NCT04021784|Experimental|Necker Enfants Malade OSTeosynthesis (NEMOST)|The NEMOST is a one-way-rod that uses a ratchet type of locking mechanism. Both NEMOST devices should be placed in parallel, on the two fixator rods that are connected with a cross connector
16393961|NCT04021771|Other|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
16393962|NCT04021771|Other|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
16393963|NCT04021758|Experimental|Peer to peer program intervention|The experimental condition for the proposed project is the Airman's Edge program, a peer to peer program in which peer mentors will be trained to provide a series of interventions aimed at reducing risk for suicidal behaviors both directly and indirectly through the targeting of emotion dysregulation, cognitive rigidity, and contextual risk factors (e.g., insomnia, meaning in life, social support, firearm availability).
16393964|NCT04021758|No Intervention|Wait list|
16393965|NCT04021745|Experimental|App-based mindful eating|The intervention will be delivered through a mindful eating smartphone application using the latest evidence-based mindful eating methods and behavior change theory.
16393966|NCT04021719||OnTrackNY LHS Participants and Stakeholders|OnTrackNY participants and stakeholders, including past participants, family members, clinicians, administrators, payors, and state leadership
16393967|NCT04021706|Active Comparator|anamorelin|one 100 mg tablet daily, taken one hour before breakfast
16393968|NCT04021706|Placebo Comparator|microcrystaline cellulose|one identical appearing tablet daily, taken one hour before breakfast
16393969|NCT04021693|Experimental|Handheld Ultrasound Devices|
16393970|NCT04021693|No Intervention|No Handheld Ultrasound Devices|
16393971|NCT04021667|Experimental|INDIVIDUAL BREASTFEEDING TRAINING|"Individual Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.
~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates."
16393972|NCT04021667|Experimental|GROUP BREASTFEEDING TRAINING|"Group Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.
~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates.The groups were composed of five pairs of parents."
16393973|NCT04021667|No Intervention|Control Group|Control Group: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates. Routine procedures were applied to the mother and father candidates.
16393974|NCT04021641||Participants with Typical Hearing|From 5 age groups from their 6 years of age to adulthood
16393975|NCT04021641||Participants with Hearing Impairment|Participants with various degree of hearing impairment
16393976|NCT04021615|Experimental|Group A (study group)|Twenty five patients will receive comprehensive rehabilitation program combined with inspiratory muscle training.
16393977|NCT04021615|Active Comparator|Group B (Control group)|Twenty five patients will receive traditional chest physical therapy combined with inspiratory muscle training.
16394014|NCT04021355|Experimental|Late Sodium|Late sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for the next 9 days and in addition will take 2 g of sodium with dinner each day.
16394092|NCT04020796|Placebo Comparator|Mineral water|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of mineral water in a single moment.
16394093|NCT04020783||Observation group|sequential
16415633|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B"|
16393978|NCT04021602|Active Comparator|Intervention 1 (Tx1) - DPP + Breastfeeding + Usual Care|Patients randomized to Tx1 will receive education in both the Diabetes Prevention Program (DPP) and in Breastfeeding. At baseline, this includes 16 DPP sessions (core curriculum), one 2-hour breastfeeding session, and participation in a professional peer support group. The 2-hour breastfeeding session is pre-recorded into four (4) 30-minute sessions and archived on a secure, private Facebook group. Participants will have access to all four breastfeeding sessions by week 24 of pregnancy and they need to complete all sessions by week 30 of pregnancy. At delivery, the patient will receive usual lactation support in the hospital, additional breastfeeding assessment and support (at day 3, day 10, week 3 and week 6), followed by 6 DPP sessions (post-core curriculum).
16393979|NCT04021602|Active Comparator|Intervention 2 (Tx2) - DPP Only + Usual Care|Patients randomized to Tx2 will receive education in only the Diabetes Prevention Program. At baseline, this includes 16 DPP sessions (core curriculum). At delivery, the patient will receive usual lactation support in the hospital, followed by 6 DPP sessions (post-core curriculum).
16393980|NCT04021602|Placebo Comparator|Intervention 3 (Tx3) - Usual Care Only|Patients randomized to Tx3 will receive only usual standard of care. At baseline, the patient will receive only regular prenatal care provided by their physician. At delivery, the patient will receive standard of care breastfeeding support provided by the hospital.
16393981|NCT04021589|Experimental|WLS-intervention group|chemotherapy + WLS
16393982|NCT04021589|Active Comparator|the control group|chemotherapy
16393983|NCT04021576|Experimental|intervention|preventative training program
16393984|NCT04021576|No Intervention|control|no such training
16393985|NCT04021563|Experimental|SR419|Ascending single and multiple doses of SR419 orally
16393986|NCT04021563|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
16393987|NCT04021550|Experimental|Combined Treatment|Subjects will be given 80 mg/day Telmisartan + 600 mg/day Alpha-Lipoic Acid. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
16393988|NCT04021550|Placebo Comparator|Placebo Control|Subjects will be given placebo capsules. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
16393989|NCT04021537|Experimental|non-invasive nerve stimulation a|Electrical stimulation will be delivered to a location at the ear.
16393990|NCT04021537|Active Comparator|non-invasive nerve stimulation b|Electrical stimulation will be delivered to a location at the ear.
16393991|NCT04021524|Active Comparator|Hibiclens Soap|
16393992|NCT04021524|Experimental|BPO Soap|
16393993|NCT04021511|No Intervention|Phase A|The first one (Phase A) will occur in the emergency department with the application of OAR only by the physicians (without changing the standard of care) during 4 weeks
16393994|NCT04021511|Experimental|Phase B|The second one (Phase B) will occur after the Phase A. Nurses will apply OAR according to the protocol. This phase will also lasts 4 weeks.
16393995|NCT04021498|Placebo Comparator|Placebo|"placebo
~1 year"
16393996|NCT04021498|Experimental|Simvastatin|"40 mg
~1 year"
16393997|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 3 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.
~Interventions will include:
~Standardized neurological exam
~Morphometric measurements including height, weight, head circumference
~Blood pressure measurement
~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY subtests and KABC-II (Kaufman Assessment Battery for Children II) subtests,
~Social Relativeness, using Social Relativeness Scale parental questionnaire,
~Parental stress using PSI questionnaire"
16393998|NCT04021472|Experimental|Text message|Participants receive text messages about healthy eating or physical activity.
16393999|NCT04021459|Other|women with endometrial cancer|
16394000|NCT04021446|Active Comparator|Exercise|Will receive the exercise intervention
16394001|NCT04021446|No Intervention|Attention Control|Will not receive the exercise intervention
16394002|NCT04021433|Experimental|MDD|Treatment resistant patients will be treated with multiple doses of IM/SC ketamine [dose range 0.3-1.5mg/kg]
16394003|NCT04021420|Experimental|low intensity pulsed UltraSound|SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
16394004|NCT04021407|Active Comparator|LMA|36 patients were ventilated with LMA during dacryocystorhinostomy surgery
16394005|NCT04021407|Active Comparator|AirQ|36 patients each were ventilated with air Q airway during dacryocystorhinostomy surgery
16394006|NCT04021394||Non-metastatic, high-risk hormone sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
16394007|NCT04021394||Low-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
16394008|NCT04021394||High-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
16394009|NCT04021394||Metastatic castrate-resistant prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
16394012|NCT04021368|Experimental|RVU120(SEL120)|The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.
16394013|NCT04021355|Experimental|Early Sodium|Early sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for 9 days and in addition will take 2 g of sodium in the form of salt tablets with breakfast each day.
16394044|NCT04021173|Placebo Comparator|Placebo|
16394155|NCT04020367|Other|patients with biopsy|
16394015|NCT04021342|Active Comparator|Montmorency tart cherry concentrate|Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to ~180 cherries per day).
16394016|NCT04021342|Placebo Comparator|Isocaloric cherry flavoured placebo|The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.
16394017|NCT04021329|Other|EMDR Therapy|One arm will be a group subjected to EMDR Therapy
16394018|NCT04021329|Other|CBT Therapy|other arm will be a group subjected to CBT Therapy
16394019|NCT04021316|Active Comparator|Standard care arm|Compression bandaging therapy as per standard care
16394020|NCT04021316|Experimental|DCD Arm|DCD graft plus compression bandaging therapy as per standard care
16394021|NCT04021303|Experimental|Experimental Cereal|Experimental cereal with probiotics, prebiotic fiber and low carbohydrates through all the duration of the study.
16394022|NCT04021303|Active Comparator|Conventional cereal|Conventional gluten free cereal between 4 and 6 months old, and conventional gluten cereal between 7 and 12 months old.
16394023|NCT04021290|Experimental|Participants receiving DTG/3TC FDC|Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
16394024|NCT04021290|Active Comparator|Participants receiving CAR|Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
16394025|NCT04021277|Experimental|ACT with chemotherapy in metastatic solid tumours|Part 1: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with solid tumours
16394026|NCT04021277|Experimental|ACT with chemotherapy in metastatic CRC|Part 2: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with metastatic colorectal cancer
16394027|NCT04021277|Experimental|ACT with chemotherapy in metastatic PDAC|Part 2: PS101 administered together with standard of care chemotherapy (Gemcitabine and nab-paclitaxel) and US insonation over the targeted liver metastasis in patients with metastatic Pancreatic Duct Adenocarcinoma (PDAC)
16394028|NCT04021264|Active Comparator|PRE-GA|14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
16394029|NCT04021264|Sham Comparator|POST-GA|14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
16394030|NCT04021251|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.
16394031|NCT04021251|Experimental|Medium term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements.
16394032|NCT04021251|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 90 days distributed over a time period of 6 months. Spectral data will be compared to standard BG measurements.
16394033|NCT04021251|Experimental|Medium term collection of IMD data, increased # of sessions|Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
16394034|NCT04021238|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
16394035|NCT04021225|Active Comparator|Ectoin® Allergy Eye Drops 2%|"20 Patients:
~- Ectoin® Allergy Eye Drops 2% (bitop AG)"
16394036|NCT04021225|Active Comparator|Ectoin® Eye Spray Colloidal|"20 Patients:
~-Ectoin® Eye Spray Colloidal (bitop AG)"
16394037|NCT04021225|Active Comparator|Tears Again® Eye Spray|"20 Patients:
~- Tears Again® Eye Spray (Optima Pharmazeutische GmbH)"
16394038|NCT04021212||Patients with pituitary adenomas resection|Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once
16394039|NCT04021199|Active Comparator|T1D Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.
~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.
~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
16394040|NCT04021199|Experimental|MODY Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.
~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.
~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
16394041|NCT04021186|Experimental|Intervention|Insulin treatment using standard measurements.
16394042|NCT04021186|No Intervention|Control|Standard care.
16394043|NCT04021173|Experimental|Anfibatide|
16394045|NCT04021160|Active Comparator|Active Group|A total of 16, every other day sessions of rTMS at 10 Hz frequency will be applied to 4 locations along the perilesional area (see target selection). Intensity will be 100% of motor threshold, 25 trains - 40 pulses per train with 20 seconds intertrain interval and a total of 1000 pulses per session. The coil handle will be directed downwards at 45º of the sagittal plain to ensure that the induced electric field be perpendicular to the underlying gyrus.
16394046|NCT04021160|Sham Comparator|Sham Group|Sham group will receive the same sessions as above with the exact same parameters yet a sham coil identical in shape and size to the active coil will be used instead. The sham coil produces sounds and sensations very similar to the active one.
16394047|NCT04021147|Experimental|Action Observation|
16394048|NCT04021147|Experimental|Motor Imagery|
16394049|NCT04021147|Experimental|Visual mirror feedback|
16394050|NCT04021147|Active Comparator|Orofacial exercise|
16394051|NCT04021121|Experimental|High Dose RIF with LZD|Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.
16394052|NCT04021121|Experimental|Standard dose RIF with LZD|Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.
16394053|NCT04021121|Experimental|High Dose RIF|Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.
16394054|NCT04021121|Active Comparator|Standard Dose RIF|Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.
16394055|NCT04021108|Other|Cohort 1|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.
~Subjects in Cohort 1 will receive Nivolumab alone (every 2 weeks for two doses, and then every 4 weeks)"
16394056|NCT04021108|Experimental|Cohort 2|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.
~Subjects in Cohort 2 will receive Nivolumab (every 2 weeks for two doses, and then every 4 weeks) plus radiation therapy (total 5 sessions)"
16394057|NCT04021095|Experimental|Decompressive craniectomy|3D printed skull replacement piece will be fitted to subject.
16394058|NCT04021082|Experimental|Cohort A|Cerdulatinib dosing of patients with Peripherial T-Cell Lymphoma (PTCL) not otherwise specified (NOS); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
16394059|NCT04021082|Experimental|Cohort B|Cerdulatinb dosing of patients with nodal lymphomas of T follicular helper (TFH) phenotype origin, including angioimmunoblastic T cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype; Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
16394060|NCT04021082|Experimental|Cohort C|Cerdulatinb dosing of patients with Anaplastic large cell lymphoma (ALCL) (anaplastic lymphoma kinase positive [ALK+] and negative [ALK-]); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
16394061|NCT04021082|Experimental|Cohort D|Other rare types of extranodal non-cutaneous aggressive PTCL, including hepatosplenic T-cell lymphoma (HSTCL), enteropathy-associated T-cell lymphoma (EATL type I), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, EATL type II), and extranodal NK/T-cell lymphoma (nasal type); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
16394062|NCT04021043|Experimental|Group I (ipilimumab, BMS-986156, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16394063|NCT04021043|Experimental|Group II (ipilimumab, BMS-986156, SBRT, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16394064|NCT04021043|Experimental|Group III (nivolumab, BMS-986156, SBRT)|Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
16394065|NCT04021030|Experimental|Cognitive Behavioral Therapy (CBT)|
16394066|NCT04021017|Experimental|Treatment|"Participants randomized to the treatment arm will be divided by maturational status:
~Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months.
~o These participants will also receive progesterone (Provera 10 mg tablet) orally every 4 weeks, for 7 days during the second half of the planned menstrual cycle, in order to induce a menstrual period.
~Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches:
~3.1 mcg/day (1/8 patch) for first six-months,
~6.2 mcg/day (1/4 patch) for second six-months,
~12.5 mcg/day (1/2 patch) for third six-months, and
~25 mcg/day (full patch) for final six-months."
16394067|NCT04021017|No Intervention|No Treatment|The participants in this group will not receive the estrogen patch nor the oral progesterone.
16394068|NCT04020991||Doctors working in a tertiary hospital|Doctors working in a tertiary hospital
16394091|NCT04020796|Active Comparator|Beetroot juice|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of beetroot juice in a single moment.
16394069|NCT04020978|Other|Patients with GUC|Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
16394070|NCT04020965|No Intervention|Control arm|This arm includes all households in villages randomized to the active control arm (double-sized) or passive control arm of the original trial. Village-level promoter visited households enrolled in the WASH Benefits Kenya study active control arm and strictly engaged in recording the child's MUAC and referring children identified as malnourished (MUAC<11.5 cm) to health clinics, for two years. These visits were also conducted in all active comparator arms. Households in active control and active comparator villages which were not enrolled in the original study did not receive such visits.
16394071|NCT04020965|Experimental|Water Treatment|This arm includes all households in villages randomized in the original WASH Benefits trial to the water treatment arm, combined water treatment with handwashing and sanitation (WASH) arm, and combined WASH + nutrition arm. Village-level promoter visited households enrolled in the original trial to promote the interventions for approximately two years.
16394072|NCT04020952|Active Comparator|"st.st 0.019×0.025 wire"|
16394073|NCT04020952|Experimental|"st.st 0.016×0.022 wire"|
16394074|NCT04020952|Experimental|"st.st 0.017×0.025 wire"|
16394075|NCT04020939|Experimental|Patients undergoing intestinal resections|"Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence
~Drug:
~Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only"
16394076|NCT04020913||Short Stature Boys|Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (defined as peak GH responses to pharmacologic stimuli <10ng/ml) or idiopathic short stature (i.e., no identifiable pathology) will be studied pre and post 12 months of GH therapy.
16394077|NCT04020913||Normally Statured Boys|A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on Growth Hormone replacement, preferably siblings (although not exclusively), will be recruited to serve as healthy controls.
16394078|NCT04020900||Children <18 years, admitted for a general anesthesia.|Children <18 years, admitted for a general anesthesia.
16394079|NCT04020887|No Intervention|Observation Phase|In the first three months of this proof-of-concept study, a telemedicine center for the PACU will monitor patients assigned to PACU bays. Both telemedicine center clinicians and nurses caring for patients in these PACU bays will independently record information on patient physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness (based on the modified Aldrete scale). During this phase of the study, clinicians in the telemedicine center will not communicate with clinicians in the PACU (nurses or physicians), unless there was a patient safety event.
16394080|NCT04020887|Experimental|Interaction Phase|In the three months following the observation phase, clinicians in the telemedicine center will interact with clinicians and patients in the two designated PACU bays using audio-visual technology. The clinicians in the telemedicine center will continue to document information on physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness.
16394081|NCT04020874|No Intervention|Baseline|Year 1, no intervention to generate baseline, comparative data for subsequent years
16394082|NCT04020874|Experimental|HuTT-2x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 2 times each week throughout the regular season.
16394083|NCT04020874|Experimental|HuTT-4x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 4 times each week throughout the regular season.
16394084|NCT04020861|Active Comparator|PBM + TENS|The patients will be submitted to the active PBM and active TENS
16394085|NCT04020861|Active Comparator|PBM|The patients will be submitted to the active PBMT and placebo TENS
16394086|NCT04020861|Active Comparator|TENS|The patients will be submitted to the placebo PBMT and active TENS
16394087|NCT04020861|Placebo Comparator|Placebo|The patients will be submitted to the placebo PBMT and placebo TENS.
16394088|NCT04020848||Patients with Alternating Hemiplegia of Childhood (AHC)|"Patients who fit the Aicardi Alternating Hemiplegia of Childhood clinical criteria of any age. The Aicardi Criteria are six (Heinzen et al 2015). (1) Paroxysmal hemiplegia episodes. (2) Bilateral hemiplegia or quadriplegia episodes. (3) Other paroxysmal manifestations, such as abnormal eye movements, nystagmus, strabismus, ataxia, dystonia, choreoathetosis, tonic spells, or autonomic disturbances. (4) Evidence of permanent neurological dysfunction, which can manifest as cognitive impairment, developmental delay, and/or persistent motor deficits such as spastic diplegia/quadriplegia, hypotonia, ataxia, choreoathetosis, or dystonia. (5) Sleep relieves symptoms, although attacks may resume soon after awakening. (6) First signs of dysfunction occur prior to the age of 18 months.
~Patients having some but not all the above criteria and have the mutation in ATP1A3 gene can be included."
16394089|NCT04020822|Experimental|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
16394090|NCT04020809|Experimental|Atezolizumab|Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.
16395122|NCT04013841|Experimental|Oral preparation|The bowel preparation prior to colorectal resection will be conducted using oral-agents
16394094|NCT04020770|Experimental|Vibrating Ball|Vibrating ball is held in both hands. Participants complete 5 30-second bouts of 68 Hz vibration with a 1 minute rest in between each bout.
16394095|NCT04020757|Other|Bicarb Variation|Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3
16394096|NCT04020744|Active Comparator|healthy elderly participants receiving feedback from the hippocampus|This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.
16394097|NCT04020744|Sham Comparator|healthy elderly participants receiving feedback from another area|This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.
16394098|NCT04020744|Experimental|patients with MCI receiving feedback from the hippocampus|This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.
16394099|NCT04020744|Sham Comparator|patients with MCI receiving feedback from another brain area|This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.
16394100|NCT04020731|Experimental|Right-handed healthy volunteers|Magnetoencephalography (MEG) records
16394101|NCT04020718|Experimental|Early assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 4 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
16394102|NCT04020718|Experimental|Late assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 8 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
16394103|NCT04020705|Experimental|Citicoline eye drops (OMK1)|45 patients will be treated with active treatment (OMK1)
16394104|NCT04020705|Placebo Comparator|hypromellose based ocular lubricant|45 patients will be treated with placebo (lubricant eye drops)
16394105|NCT04020692|Experimental|"intervention  group"|"Patient At D0, the patient receives his discharge drugs prescription and benefits from a pharmaceutical counselling.
~At D+3, he benefits from a telephone follow-up (good understanding of the methods of taking drugs, collection of difficulties).
~Community pharmacist At D0, he receives the discharge drugs prescription. At D+3, he is contacted to collect information relating to drugs 'dispensation.
~The attending physician At D0, he is informed of the patient's discharge and his drugs treatment
~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].
~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
16394106|NCT04020692|No Intervention|Control group|"At D0, the patient receives his discharge drugs prescription.
~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].
~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
16394107|NCT04020679|No Intervention|Control arm|Participants will not receive GOCI materials
16394108|NCT04020679|Experimental|Intervention|Participants will receive GOCI materials and clinicians will receive training.
16394109|NCT04020666||HUK group|On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.
16394110|NCT04020666||control group|The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.
16394111|NCT04020653|Placebo Comparator|Placebo + ACT|Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
16394112|NCT04020653|Experimental|5 ALA/SFC+placebo+ACT BID|"5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
~Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14)."
16394113|NCT04020653|Experimental|5-ALA/SFC+placebo+ACT QD|5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
16394114|NCT04020640||Exclusive breastfeeding (EBF)|provision of breast milk only, allowing only receiving oral rehydration salts (ORS), drops and syrups (vitamins, minerals, medicines) as necessary
16394115|NCT04020640||Predominant breastfeeding (PBF)|providing breast milk plus other liquids (water and water-based drinks, fruit juice) and ORS, drops and syrups (vitamins, minerals, medicines)
16394116|NCT04020640||Partial breastfeeding (PartBF)|provision of breast milk plus infant formula or cow milk or other solid/semi-solid complementary foods
16394117|NCT04020627|Experimental|BiPAP Group|Bilevel Positive Airway Pressure
16394118|NCT04020627|Experimental|CPAP Group|Continuous Positive Airway Pressure
16394119|NCT04020614||Survey|All of the patients that enrolled in this study will be in this group.
16394120|NCT04020601|Active Comparator|PRE-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through the interscalene catheter
16394121|NCT04020601|Sham Comparator|POST-GA|10 ml of 5% dextrose injection before the start of surgery and 1% ropivacaine injection at the end of surgery through the interscalene catheter
16394122|NCT04020588|Active Comparator|Celecoxib|Celecoxib 200 mg twice a day
16394123|NCT04020588|Active Comparator|Minocycline|Minocycline 100 mg twice a day
16394124|NCT04020588|Placebo Comparator|Placebo|Placebo capsules twice a day
16394125|NCT04020575|Experimental|Dose Escalation|"Dose escalation or de-escalation is tested in cohorts of 3 patients each using standard 3+3 dose-finding."
16394126|NCT04020575|Experimental|Luminal|Dose Expansion - 15 patients will be enrolled with luminal (hormone receptor positive, HER2 negative) metastatic breast cancer.
16394127|NCT04020575|Experimental|HER2+|Dose Expansion - 15 patients will be enrolled with HER2+ metastatic breast cancer.
16394128|NCT04020575|Experimental|Triple Negative|Dose Expansion - 15 patients will be enrolled with triple negative metastatic breast cancer.
16394129|NCT04020562|Experimental|Mild Resistive Expiratory Technique|Mild resistive Expiratory Technique from EMST150- five-week training protocol.
16394130|NCT04020562|Active Comparator|Conventional Training|Breathing exercise, Assistive Coughing, ROM Exercises, Sustained stretching, Splinting, Bracing, Functional Mobility, Tilt table standing
16394131|NCT04020549|Experimental|Intervention|
16394132|NCT04020549|Sham Comparator|Study Skills Control|
16394133|NCT04020536||kala-azar group|
16394134|NCT04020536||epidemic hemorrhagic fever group|
16394135|NCT04020536||brucellosis group|
16394137|NCT04020510|Active Comparator|Standard Injections|For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 30mL of injectable saline injected in 30 sites with 1mL per injection along the posterior wall of the bladder above the trigone.
16394138|NCT04020510|Experimental|Reduced Injections|"For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone."
16394139|NCT04020497|Experimental|Ensemble + SAU (Support as usual)|The five-session Ensemble program provided to informal caregivers targeted support + SAU
16394140|NCT04020497|Active Comparator|SAU (Support as usual)|SAU alone which was chosen as a control condition.
16394141|NCT04020484|Experimental|Intervention Group|Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
16394142|NCT04020484|Other|Waitlist Control|Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete the Baseline and Immediate Follow-up questionnaire at comparable times to families in the intervention arm; they will not complete the Extended Follow-up questionnaire. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.
16394143|NCT04020471||Experimental|All subjects who have completed their standard of care total knee arthroplasty will undergo pharmacogenomics testing and will complete a daily pain and medication diary for 30 days post discharge from the hospital. Subjects will be offered a consultation visit with a member of the Pharmacogenomics Team to discuss results.
16394144|NCT04020458|Active Comparator|Periodontitis, no kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)
~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)
~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).
~iv. Single visit intensive scaling and root planning (SRP) (full mouth)
~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)
~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations
~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
16394145|NCT04020458|Active Comparator|Experimental- chronic kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)
~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)
~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).
~iv. Single visit intensive scaling and root planning (SRP) (full mouth)
~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)
~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations
~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
16394146|NCT04020458|No Intervention|Control- no Periodontitis or kidney disease.|Only regular dental cleaning
16394147|NCT04020432||pregnant women|"Pregnant women are coming to their monthly consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.
~Pregnant women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
16394148|NCT04020432||childbearing age women|"Women of childbearing age, who are coming for a gynecological consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.
~Childbearing age women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
16394149|NCT04020419|Experimental|Pediaberry group|PediaBerry™ is a proprietary blend powdered berry extracts
16394150|NCT04020419|Placebo Comparator|Placebo|Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).
16394151|NCT04020406||Antibacterial Activity of Urea|Activity of Urea Solution against Ocular Bacterial Isolates
16394152|NCT04020393||Block group|The patients that had received Sphenopalatine ganglion block(SPGB) before the surgery
16394153|NCT04020393||Control Group|The patients that had not received SPBG before the surgery
16394154|NCT04020380|Experimental|Azithromycin 250 mg|Azithromycin, 250 mg capsules once a day for a total of 3 months
16394156|NCT04020354|Experimental|HABIT-ILE|Early HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
16394157|NCT04020354|Active Comparator|Usual Care|A two weeks period of usual customary care
16394158|NCT04020341|Active Comparator|Gepotidacin|Subjects will be administered oral doses of 1500 mg gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days
16394159|NCT04020341|Active Comparator|Nitrofurantoin|Subjects will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
16394160|NCT04020328|Experimental|leflunomide + low dose glucocorticoids therapy group|the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
16394161|NCT04020328|No Intervention|Basic conservative treatment group|the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy
16394162|NCT04020315|Experimental|Generalized aggressive periodontitis|Non-surgically performed scaling and root planing.
16394163|NCT04020302|Experimental|Shopping group|Participants will receive an 8-week intervention which will include weekly sessions that are delivered in an alternating group-individual format. Sessions will provide participants the opportunity to practice and apply self-monitoring techniques across a variety of shopping tasks and settings to promote generalization and transfer of learning (Phase B).
16394164|NCT04020289|Experimental|"BalancingMySwing"|"Psychoeducational Program BalancingMySwing for bipolar disorder"
16394165|NCT04020289|Other|treatment as usual (TAU)|Patients received treatment as usual
16394167|NCT04020263|Experimental|Levosimendan|Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
16394168|NCT04020263|Placebo Comparator|Placebo|Control group: Patients with cardiogenic shock treated with placebo for levosimendan in addition to the conventional strategy.
16394169|NCT04020237|No Intervention|Observational arm|General counselling to particulate matter practice score.
16394170|NCT04020237|Other|Interventional arm|Active education and feedback on the particulate matter practice score that affects real life.
16394171|NCT04020224|Experimental|Treatment with pathogen reduced whole blood|Subjects will receive one amustaline/GSH treated whole blood product.
16394172|NCT04020224|Active Comparator|Treatment with Standard of Care|Subjects will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product
16394173|NCT04020211||HF10|SCS stimulation with HF10 therapy
16394174|NCT04020198||Parkinson's Disease|Subjects who have a PD diagnosis
16394175|NCT04020198||Multiple System Atrophy|Subjects who have an MSA diagnosis
16394176|NCT04020198||Age-matched controls|Subjects who do not have a diagnosed parkinsonian disorder
16394177|NCT04020198||Rapid Eye Movement Sleep Behavior Disorder (RBD)|Subjects who have a diagnosis of RBD
16394178|NCT04020198||Normal Pressure Hydrocephalus|Subjects who are prescribed a lumbar puncture to treat normal pressure hydrocephalus
16394179|NCT04020185|Experimental|Ph I Monotherapy|"Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified.
~The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients.
~Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose [HNSTD] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg."
16394180|NCT04020185|Experimental|Ph I Combination Therapy|"Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria:
~A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).
~The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).
~The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints.
~Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related.
~Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation."
16394181|NCT04020185|Experimental|Ph II Monotherapy (Arm A)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy
~Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment."
16394182|NCT04020185|Experimental|Ph II Combination Therapy (Arm B)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors.
~This arm shall include a safety run-in of 5-10 patients.
~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment."
16394183|NCT04020185|Experimental|Ph II Combination Therapy (Arm C)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA.
~This arm shall include a safety run-in of 5-10 patients.
~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.."
16394253|NCT04019691|Active Comparator|EDOF group|Cataract surgery and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
16394254|NCT04019691|Active Comparator|Trifocal group|Cataract surgery and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
16394184|NCT04020172|Experimental|Dobutamine+fluid therapy|All patients will receive a baseline infusion of Ringer's lactate at 3ml/kg/hr to satisfy maintenance fluid requirements. The intervention will commence at anesthesia induction and continue for up to 4 hours postoperatively. In addition to maintenance fluids, patients will receive 250ml fluid challenges with crystalloid as required until they are no longer fluid responsive. The absence of fluid responsiveness will be defined as the absence of a sustained rise in stroke volume of at least 10% for 20 minutes or more, at which point, the patient will be considered fluid optimized. At this point, a low-dose dobutamine infusion at a fixed rate (2.5 μg/kg/min) will be commenced and maintained until 4h postoperatively. The infusion rate will be halved and/or discontinued if the patient develops a tachycardia (heart rate ≥ 100bpm) for more than 30 minutes despite adequate anesthesia/analgesia and fluid status.
16394185|NCT04020172|No Intervention|Standard of care|Patients in the control group will also receive a baseline infusion of Ringer's lactate at 3ml/kg/hr to satisfy maintenance fluid requirements, which will be commenced upon admission to the operating room. The anesthetic management will otherwise be according to standard practice. No specific cardiac output monitoring device will be used to guide fluid therapy. Likewise, perioperative dobutamine will not be used unless clinically indicated to improve cardiac function.
16394186|NCT04020159||Participants with COL6-related dystrophy|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
16394187|NCT04020146||group 1;|healthy controls (C, n=15),
16394188|NCT04020146||group 2|periodontitis patients with stage 3 grade B; (P, n=15)
16394189|NCT04020146||group 3|peri-implantitis patients (PI, n=15).
16394190|NCT04020133|Active Comparator|the control group|this group will receive post-operative saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
16394191|NCT04020133|Active Comparator|the intervention group|this group will receive popliteal plexus block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg in addition to standard saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
16394192|NCT04020120||ADHD in professional activity|Adult ADHD patients in active employment at the time of inclusion or who were in employment within 3 months prior to inclusion
16394193|NCT04020107|Active Comparator|Compressive garment associated with physical therapy|
16394194|NCT04020107|Placebo Comparator|Low compressive garment associated with physical therapy|
16394195|NCT04020094|Experimental|Treatment: all patients|
16394196|NCT04020081|Experimental|Effect of yoga exercises in COPD patients after 12 weeks.|Yoga group
16394197|NCT04020081|No Intervention|COPD patients lung functions without yoga excercises.|Control group
16394198|NCT04020055|Experimental|migalastat HCl 150 mg|All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
16394199|NCT04020042|Experimental|Ultrasound imaging guidance|Determination of epidural needle site by using ultrasound guidance
16394200|NCT04020042|Active Comparator|Traditional landmark palpation|Depermination of epidural needle site by using traditional landmark method
16394201|NCT04020029|Experimental|Mindset Intervention|Mindset Intervention will include watching three brief ~10-25 minute films and respond to a number of short reflection activities after viewing the films.
16394202|NCT04020029|Active Comparator|Treatment As Usual (TAU)|TAU Control Arm will complete the same assessments as those participants in the Mindset Intervention Arm, but will not view the short films or complete the corresponding response activities.
16394203|NCT04020016|Experimental|Part 1 Single Ascending Dose|Impaired liver function subjects and healthy liver subjects single ascending dosing up to 162 mg BID of Nalbuphine ER
16394204|NCT04020016|Experimental|Part 2 Multiple Ascending Dose|Impaired liver function subjects will receive multiple ascending dosing up to 162 mg BID of Nalbuphine ER
16394205|NCT04020003|Other|Routine treatment|Routine treatment group: control infection, remove or control the primary disease; mechanical ventilation with low tidal volume and high PEEP mechanical ventilation strategy; strictly control volume, strengthen airway management, timely nutritional support and severe rehabilitation treatment.
16394206|NCT04019990|Other|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
16394207|NCT04019977|Experimental|Nurse Home Visiting Group|This group will be offered services from the nurse home visiting program.
16394208|NCT04019977|No Intervention|Non-intervention Group|This group will not be offered services from the nurse home visiting program.
16394209|NCT04019964|Experimental|Nivolumab in biochemically recurrent prostate cancer|"Participants with previous prostatectomy or radiation therapy who subsequently developed detectable prostate specific antigen (PSA) levels (biochemically recurrent prostate cancer)."
16394210|NCT04019951|Experimental|Propionate (1 g)|Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
16394211|NCT04019951|Experimental|Propionate (3 g)|Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
16394212|NCT04019951|Placebo Comparator|Placebo|Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
16394213|NCT04019938||Diabetic adults|
16394214|NCT04019925|Other|ADM/MDM hip prosthesis|Type of prosthesis participant received.
16394255|NCT04019678|Experimental|Group 1: experimental|patients with micro metastatic sentinel lymph node and/or parasentinella lymph node (ypN1mi). Axillary dissection is not performed.
16394256|NCT04019678|Active Comparator|Group 2: standard|patients with negative sentinel lymph node (ypN0) or with ITC finding (ypN0 / YpN0 (i +)). Axillary dissection is not performed as standard treatment.
16394257|NCT04019665|Other|SAGE and MMSE score|
16394215|NCT04019912|Experimental|Gait Training plus music|Patients will be randomly assigned to the rehabilitation group through gait trainer3 with Rhythmic Auditory Stimulation (RAS). All patients will undergo a complete clinical and neurophysiological evaluation at baseline. The training program consist of 45 minutes of treadmill training with RAS. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists with 2 years of RAS training.
16394216|NCT04019912|Active Comparator|Traditional Gait Training|Patients will be randomly assigned to the non-Rhythmic Auditory Stimulation (RAS) treadmill walking group. All patients will undergo a complete clinical and neurophysiological evaluation at baseline.The daily training program consist of 45 minutes of conventional gait training using a non-RAS treadmill. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. Non-RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists.
16394217|NCT04019899|Active Comparator|Control group|
16394218|NCT04019899|Experimental|Study group|
16394219|NCT04019886|Experimental|Experimental Group|"It consists following techniques-
~Peri-oral stimulation
~Vertebral pressure
~Anterior stretch -lifting posterior basal area
~Co-contraction -abdomen
~Intercoastal stretch
~Moderate manual pressure"
16394220|NCT04019886|No Intervention|Control Group|Outcome measure will be measured at baseline on first day prior to the intervention and on 5th day after the treatment.
16394221|NCT04019873||Subjects receiving 2DR treatment|Data will be collected from HIV positive male or female adult subjects who have started 2DR with an integrase inhibitor plus a reverse transcriptase inhibitor from 2014.
16394222|NCT04019860|Experimental|High Intensity Interval Training|High intensity interval training for seven weeks. Three weekly, supervised training sessions.
16394223|NCT04019860|Experimental|Time-Restricted Eating|Time-restricted eating for seven weeks. Maximal daily eating window of 10 hours.
16394224|NCT04019860|Experimental|High Intensity Interval Training & Time-Restricted Eating|
16394225|NCT04019860|No Intervention|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
16394226|NCT04019847|Experimental|STAK Tool|The STAK Tool enables patients to apply a high intensity stretch to their knee independently. Patients are asked to do this for a maximum of 60 mins per day.
16394227|NCT04019847|Active Comparator|Standard treatment|Patients are treated as per their Clinician's prescription. Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain ROM and function.
16394228|NCT04019834|Experimental|regional nerve block with local anesthesia|Treatment Arm (n=55) will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes and perform regional nerve blocks. A block needle will be passed into the fascial plane an injectate will be deposited . The injectate in the active arm will contain a local anesthestic and dexamethasone.
16394229|NCT04019834|Placebo Comparator|regional nerve block with normal saline|Placebo Comparator Arm (n=55). Patients will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue.
16394230|NCT04019821|Active Comparator|Normal Bolus|Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).
16394231|NCT04019821|Experimental|Super Bolus|Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.
16394232|NCT04019795|Sham Comparator|Non-Active REVIAN (Sham) Cap 100|Sham (Control) Group
16394233|NCT04019795|Experimental|Active REVIAN Cap 101|(625 nm and 660 nm)
16394234|NCT04019795|Experimental|Active REVIAN Cap 102|(425 nm)
16394235|NCT04019795|Experimental|Active REVIAN Cap 103|(425 nm, 625 nm and 660 nm)
16394236|NCT04019782|Experimental|Collagen-PVP|Collagen-polyvinyl pyrrolidone (collagen-PVP).
16394237|NCT04019782|Active Comparator|Hylan G-F 20|Hylan G-F 20.
16394238|NCT04019769|Experimental|1|All patients will receive L-glutamine 10-30mg daily based on weight for 3 months
16394239|NCT04019756||Patients with cancer|50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)
16394240|NCT04019743|Experimental|Group 1|"Period 1: Treatment A
~Period 2: Treatment B
~Period 3: Treatment C"
16394241|NCT04019743|Experimental|Group 2|"Period 1: Treatment C
~Period 2: Treatment A
~Period 3: Treatment B"
16394242|NCT04019743|Experimental|Group 3|"Period 1: Treatment B
~Period 2: Treatment C
~Period 3: Treatment A"
16394243|NCT04019743|Experimental|Group 4|"Period 1: Treatment C
~Period 2: Treatment B
~Period 3: Treatment A"
16394244|NCT04019743|Experimental|Group 5|"Period 1: Treatment B
~Period 2: Treatment A
~Period 3: Treatment C"
16394245|NCT04019743|Experimental|Group 6|"Period 1: Treatment A
~Period 2: Treatment C
~Period 3: Treatment B"
16394246|NCT04019730|Experimental|low carbohydrate diet|less than 10 En% carbohydrates
16394247|NCT04019730|Experimental|high carbohydrate diet|more than 50 En%carbohydrates
16394248|NCT04019717|Experimental|8 weeks|
16394249|NCT04019717|Experimental|12 weeks|
16394250|NCT04019704|Experimental|AXS-05|AXS-05 (bupropion and dextromethorphan) oral tablets
16394251|NCT04019704|Placebo Comparator|Placebo|Placebo oral tablets to match AXS-05
16394252|NCT04019691|Active Comparator|Mix-and-Match group|Cataract surgery and implantation of a Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
16394258|NCT04019652|Experimental|10 mg CS-3150 (Treatment Sequence 1)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 10-mg dose of CS-3150, a 40-mg dose of CS-3150, a 400-mg dose of moxifloxacin, followed by placebo.
16394259|NCT04019652|Experimental|40 mg CS-3150 (Treatment Sequence 2)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 40-mg dose of CS-3150, placebo, a 10-mg dose of CS-3150, followed by a 400-mg dose of moxifloxacin.
16394260|NCT04019652|Experimental|Moxifloxacin (Treatment Sequence 3)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 400-mg dose of moxifloxacin, 10-mg dose of CS-3150, placebo, 40-mg dose of CS-3150.
16394261|NCT04019652|Experimental|Placebo (Treatment Sequence 4)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral dose of placebo, 400-mg dose of moxifloxacin, 40-mg dose CS-3150, 10-mg dose of CS-3150.
16394262|NCT04019639|Experimental|CG Paste+EasyFoam|"The subjects assigned to the test group through random assignment will receive the wound treatment by applying CG Paste and EasyFoam. CG Paste is a medical device currently marketed in CGBio.It is a free-flowing, acellular allogeneic dermis processed from human tissue skin, and then granulated and homogenized. This increases the water content and viscosity of the micronized ADM particles mixed with the gelatin sol carrier to protect the wound area and maintain the wet environment by applying to the desired wound area.It contains collagen, elastin and various growth factors in the dermis and has excellent tissue compatibility compared to the heterogeneous or synthetic material, so that the immune rejection is hardly observed in the graft site.
~It also contains collagen, elastin, fibronectin, laminin, and proteoglycans, which are components of the human skin, to help the interaction between normal cells and extracellular matrix."
16394263|NCT04019639|Active Comparator|EasyFoam|"Subjects randomly assigned to the control group receive EasyFoam treatment for wound healing.
~The foam has excellent moisture permeability, absorbs a large amount of exudates, and prevents scar formation to minimize scar formation."
16394264|NCT04019626|Active Comparator|Continue-smoking|The subject's usual brand of combustible cigarette
16394265|NCT04019626|Experimental|myblu Tobacco 2.5%|myblu e-cigarette system with Tobacco flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
16394266|NCT04019626|Experimental|myblu Tobacco 4.0%|myblu e-cigarette system with Tobacco flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
16394267|NCT04019626|Experimental|myblu Honeymoon 2.5%|myblu e-cigarette system with Honeymoon flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
16394268|NCT04019626|Experimental|myblu Honeymoon 4.0%|myblu e-cigarette system with Honeymoon flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
16394269|NCT04019626|Active Comparator|JUUL 5%|JUUL® system with Virginia Tobacco Flavor JUULpod, 5.0% nicotine. This arm is only included in the PK sub-study.
16394270|NCT04019613|Experimental|Subjects undergoing clinical invasive hemodynamic stress test|Subjects scheduled for standard-of-care, clinically indicated, invasive hemodynamic stress test will undergo lung ultrasound and assessment of extravascular lung water by pulmonary thermodilution technique.
16394271|NCT04019587||Test of reliability and validity|
16394272|NCT04019574|Experimental|CR845 0.5 mcg/kg IV (Therapeutic Dose)|
16394273|NCT04019574|Experimental|CR845 3 mcg/kg IV (Supratherapeutic Dose)|
16394274|NCT04019574|Placebo Comparator|Placebo IV|
16394275|NCT04019574|Active Comparator|Moxifloxacin 400 mg|
16394276|NCT04019561|Experimental|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
16394277|NCT04019561|Placebo Comparator|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
16394278|NCT04019561|Experimental|MEDI0382 low dose|MEDI0382 low dose administered subcutaneoously
16394279|NCT04019561|Placebo Comparator|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
16394280|NCT04019548|Experimental|Prophylactic PEG|Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.
16394281|NCT04019548|Experimental|Reactive PEG|Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).
16394282|NCT04019522|Experimental|Hypoxia|During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position. AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position. Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
16394283|NCT04019509|Active Comparator|Tg AB positive, TPO AB negative|Includes patients with only anti-thyroglobuline autoantibodies present and no anti-thyreoperoxydase antibodies at start of fertility treatment.
16394284|NCT04019509|Active Comparator|Tg AB negative, TPO AB negative|Includes patients without thyroid autoantibodies at start of fertility treatment
16394285|NCT04019509|Active Comparator|Tg AB positive, TPO AB positive|Includes patients with anti-thyroglobuline autoantibodies and anti-thyreoperoxydase antibodies at start of fertility treatment.
16394286|NCT04019496||Episodic Migraine|
16394287|NCT04019496||Healthy controls|equal to or less than 1 headache day/month
16394288|NCT04019457|Experimental|Dietary fiber 1|Participants receive cereal flakes 1 to include it in their normal diet.
16394289|NCT04019457|Experimental|Dietary fiber 2|Participants receive cereal flakes 2 to include it in their normal diet.
16395805|NCT04008979|Experimental|PL-ASA-650|Novel aspirin formulation being tested
16394294|NCT04019431|Experimental|Whey protein|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
16394295|NCT04019431|Active Comparator|Vegetable proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
16394296|NCT04019431|Active Comparator|Animal proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
16394297|NCT04019418|Placebo Comparator|No Carbohydrate Drink + Rest|Participants will consume the no carbohydrate drink (300ml water) followed by a rest session
16394298|NCT04019418|Active Comparator|No Carbohydrate Drink + Exercise|Participants will consume the no carbohydrate drink (300ml water) followed by an exercise session (75% VO2 max on a cycle ergometer)
16394299|NCT04019418|Active Comparator|Carbohydrate Drink + Rest|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by a rest session
16394300|NCT04019418|Experimental|Carbohydrate Drink + Exercise|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by an exercise session (75% VO2 max on a cycle ergometer)
16394301|NCT04019405||Frailty status|Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.
16394302|NCT04019392|Active Comparator|Wetted ice with elastic wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied to each participants' lower leg for 30 minutes using an elastic wrap. The elastic wrap will be applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half. The elastic wrap application will consist of pulling the wrap to its full tension, measuring the length of the wrap, and calculating 75% of the total length to apply to the body part.
16394303|NCT04019392|Active Comparator|Game Ready|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
16394304|NCT04019379|Experimental|Sequence A|Low Ca/High Phos crossover to Low Ca/Low Phos
16394305|NCT04019379|Experimental|Sequence B|Low Ca/Low Phos crossover to Low Ca/High Phos
16394306|NCT04019366|Experimental|Group I|The experimental group was treated with Balance Training on Biodex Stability System along with traditional exercises.
16394307|NCT04019366|Active Comparator|Group II|The Control group was treated with Traditional exercises only for Symptomatic knee osteoarthritis.
16394308|NCT04019353||cf-DNA Collection|All patients undergoing kidney allograft biopsy for suspicion of an acute rejection episode will be approached for consent into the study. Patients who consent to the study will have the cf-DNA test drawn at time of biopsy to determine levels of cf-DNA. All consented patients will be followed for biopsy outcomes. Those whose biopsy shows acute rejection leading to treatment will have cf-DNA determination at 2, 4, 6, and 8 weeks post biopsy. Recipients with persistent high cf-DNA levels will undergo repeat biopsy at ~6 weeks after end of treatment per standard of care (this is not performed for purpose of the study, but for clinical care).
16394309|NCT04019340|No Intervention|Control|Usual care for patients in the CG is defined as visiting the outpatient wound clinic as prescribed by the physician. Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses.
16394310|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient wound clinic as prescribed by the physician). Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a pluridisciplinary educational program
16394311|NCT04019327|Experimental|Metastatic Castration Resistant Prostate Cancer|Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
16394312|NCT04019314|Experimental|Subjects with know chronic systolic heart failure|Subjects with know chronic systolic heart failure (LVEF<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis
16394313|NCT04019301|Experimental|Community-based Qigong Group|Participants randomized into this group follow one, 75 minutes class per week supplemented by home practice for 20 minutes on 3 additional days.
16394314|NCT04019301|Experimental|Internet-based Qigong Group|Participants randomized into this group follow two online sessions for 40 minutes each, also supplemented by home practice for 20 minutes on 3 additional days.
16394315|NCT04019301|No Intervention|Self-Care Control Group|The Self-care control group, will be requested not to practice any Qigong during the study. Participants will be provided with an educational book on caregiving that includes self-guided activities related to caregiving and caregiver health (The Caregiver Helpbook: Powerful Tools for Caregiving). The book's evidence-based program is designed to provide caregivers the tools to increase their self-care and their confidence to handle difficult situations, emotions, and decisions. In addition, study staff will call participants in the self-care control group once a month.
16394343|NCT04019093|Experimental|Jaw pain patients|Individuals seeking care for jaw pain, including temporomandibular joint and muscle disorder (TMD).
16394344|NCT04019093|Experimental|Healthy controls|Healthy social drinkers without jaw pain recruited as a comparison group.
16394316|NCT04019288|Experimental|Arm I (batiraxcept, durvalumab)|Patients receive batiraxcept IV over 60 minutes on days 1, 15, and 29 of cycle 0, and on days 1 and 15 of subsequent cycles. Beginning cycle 1, patients also receive durvalumab IV over 60 minutes on day 1. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16394317|NCT04019288|Experimental|Arm II (durvalumab, batiraxcept)|Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive batiraxcept IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16394318|NCT04019275|Experimental|ENGAGE|The intervention blends social learning, guided discovery, and skill training to promote community participation after stroke. The intervention is delivered in a group format and comprises group learning activities and individual action planning activities that address barriers to community participation after stroke.
16394319|NCT04019262|Active Comparator|40 Gy in 15 fractions|Patients randomized to 40 Gy in 15 fractions will receive 75 mg/m^2 temozolomide per day for 15 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
16394320|NCT04019262|Active Comparator|25 Gy in 5 fractions|Patients randomized to 25 Gy in 5 fractions will receive 150 mg/m^2 temozolomide per day for 5 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
16394321|NCT04019249|Experimental|Experimental: Healthy Weight Coaching|Intervention: Healthy Weight Coaching.
16394322|NCT04019236|Other|" interventional "|New other than Routine nursing care will be used.
16394323|NCT04019236|No Intervention|" Control group "|Routine care only will be done for this group
16394324|NCT04019223||anti-tissue transglutaminase group|serum IgA-tissue transglutaminase antibody (tTG) was analyzed in serum using a quantitative automated ELISA method by means of a commercially available detection kit using recombinant human tTG as antigen recommended cut-off by the manufacturer > 8 U/mL).
16394325|NCT04019223||biopsy group|upper gastrointestinal endoscopic examination will be done and the jejunal histopathological examinations will be done at the Histopathology Laboratory. The features consistent with CD included: hyperplasia of crypts, atrophy of villous, and increase of intraepithelial lymphocytes.Duodenal samples will be processed using haematoxylin/eosin staining and CD3 immunophenotyping. The number of intra-epithelial lymphocytes (IEL), the architecture of villi, and the inflammatory cell infiltration of the lamina propria will be assessed. Histopathological changes will be classified according to the Marsh-Oberhuber criteria.Lymphocytic enteropathy (Marsh 1 lesion) was defined as 25 or more IEL per 100 epithelial nuclei, and normal villous architecture.
16394326|NCT04019210|Experimental|MODIFIED TRABECULECTOMY|"Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane.
~Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm."
16394327|NCT04019197|Experimental|Participants with HIV and lipohypertrophy: semaglutide arm|Participants with HIV/lipohypertrophy will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
16394328|NCT04019197|Placebo Comparator|Participants with HIV and lipohypertrophy: placebo arm|Participants with HIV/Lipohypertrophy will receive placebo x32 weeks, then no placebo for 24 weeks.
16394329|NCT04019184|Experimental|Glutamine group|Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization
16394330|NCT04019184|Placebo Comparator|Control group|Intravenous infusion of 2.5 ml/kg body weight sodium chloride 0.9 % over 12 h after randomization
16394331|NCT04019171|Experimental|interval exercise training|
16394332|NCT04019171|No Intervention|waiting list|
16394333|NCT04019158|Experimental|Parkinson's Disease patients|Parkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality
16394334|NCT04019145|Experimental|Fiber Reinforced bulk fill resin composite|Fiber reinforced bulk fill resin composite dentine substitute, capped occlusally and proximally (closed centripetal technique) by nanohybrid resin composite.
16394335|NCT04019145|Active Comparator|nanohybrid resin composite incrementation|Nanohybrid resin composite layering to fill the whole cavity, using closed centripetal technique.
16394336|NCT04019132||Older adults|Older adults aged >65 years
16394337|NCT04019132||Young group|Younger adults between the age of 20 and 35 years
16394338|NCT04019119|Experimental|Intervention: digital intervention Behaviour Change Technique|The assigned participants will receive an intervention based on gamification and the use of behavior change techniques to reduce sedentary lifestyle. Thus, a new mobile application will be used for 12 weeks that proposes to the user the realization of activities with the aim of reducing their sedentary behavior. The development of the application is based on previous analyzes that propose 6 clusters that encompass 33 factors that influence sedentary behavior. In this way, the application is designed to act on the two accessible: social support and behavior. On the social support, he proposes to the user to share his achievements in social networks or in an internal network of game users. In terms of habit modification, behavior modification strategies proposed in the Michie et al. (2013) taxonomy are applied, such as the following: establishment of personalized goals, rewards and reminders, awareness of achievements achieved, among others
16394339|NCT04019119|No Intervention|Control Group|The control group will receive the usual indications about the harms of sedentary lifestyle and the benefits of physical activity, not receiving specific intervention. In case the use of the intervention applied in the experimental group is beneficial, the participants assigned to the control group will be offered the opportunity to receive the intervention outside the study to allow the benefit to be used.
16394340|NCT04019106|Experimental|Dosing Level 1|0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
16394341|NCT04019106|Experimental|Dosing Level 2|0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
16394342|NCT04019106|Experimental|Dosing Level 3|0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
16395806|NCT04008979|Active Comparator|IR 650|Immediate release aspirin
16394345|NCT04019067|Experimental|MCE first group|"Patients randomized to the MCE first group will have a MCE deployed as the first detection method."
16394346|NCT04019067|No Intervention|standard of care group|For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.
16394347|NCT04019054|Experimental|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.
~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
16394348|NCT04019054|Placebo Comparator|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.
~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
16394349|NCT04019041|Experimental|bermekimab ew|2 800 mg bermekimab loading dose subcutaneous injections, followed by weekly 400 mg bermekimab injections
16394350|NCT04019041|Experimental|bermekimab eow|2 800 mg loading dose subcutaneous injections, followed by alternating weekly 400 mg bermekimab injections with matching placebo injections
16394351|NCT04019041|Placebo Comparator|placebo ew|2 800 mg placebo loading dose subcutaneous injections, followed by weekly placebo subcutaneous injections
16394352|NCT04019028|Experimental|Navigated low frequency rTMS|"Application of 1Hz low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere using a navigation system.
~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image."
16394353|NCT04019028|Experimental|only low frequency rTMS(not using Navigation System)|"Application of low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere not using a navigation system.
~TMS coil is fixed on the target area based on MEP hotspot."
16394354|NCT04019028|Sham Comparator|Navigated Sham rTMS|"Application of repetitive transcranial magnetic stimulation with sham mode(no stimulation) to the primary motor area of the dominant hemisphere using a navigation system.
~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image.
~Sham stimulation is stimulated by the same frequency, intensity and time as the actual stimulus in such a way that the 8-shaped coil is placed at a 90 degree angle to the scalp in the same manner as rTMS and sounds are heard but the magnetic stimulus is not transmitted to the cerebrum"
16394355|NCT04019015|Experimental|Kcentra|"A single dose of Kcentra based on estimated body weight
~2000 U for patients with an estimated body weight ≤ 75kg
~3000 U for patients with an estimated body weight > 75kg"
16394356|NCT04019015|Placebo Comparator|Placebo|A single infusion of volume matched placebo solution (Normal Saline)
16394357|NCT04019002|Experimental|Cohort 1: Newly Diagnosed- Standard Treatment|"This arm is for patients with histologically proven newly diagnosed glioblastoma who will undergo standard treatment with radiation therapy (RT) and temozolomide (TMZ).
~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (8 weeks later)."
16394358|NCT04019002|Experimental|Cohort 2: Recurrent- Standard Surgical Resection|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence.
~Patients will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery."
16394359|NCT04019002|Experimental|Cohort 3: Recurrent- Standard Treatment|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will undergo standard treatment for the recurrence.
~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment."
16394360|NCT04018976|Experimental|Heat and Vacuum|AVACEN 100 applies heat and vacuum to hand
16394361|NCT04018976|Active Comparator|Heat Only|AVACEN 100 applies heat only
16394362|NCT04018976|Sham Comparator|Sham|AVACEN 100 applies neither heat nor vacuum
16394363|NCT04018963||Uninostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the single nostril approach.
16394364|NCT04018963||Binostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the bilateral nostril approach.
16394365|NCT04018950|Experimental|ETX2514 and 14C-ETX2514|Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.
16394366|NCT04018937|Experimental|Reduced Intensity Conditioning with FAM|Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
16394367|NCT04018924|Experimental|T - Treated|After standard cleansing or debridement of all wounds, on wound or portion of wound selected for treatment is treated with EmoLED device. Then covered with hydro fibre medication and dressing or compressive dressing when needed on the whole wound (SOC). Treatment is repeated once a week.
16394368|NCT04018911|Active Comparator|Hearing Aid standard NR_1|Hearing Aid with standard Noise Reduction (NR) serves as reference condition.
16394369|NCT04018911|Experimental|Hearing Aid with NR_2|NR_2: Noise Reduction principle 2
16394370|NCT04018911|Experimental|Hearing Aid with NR_3|NR_3: Noise Reduction principle 3
16394371|NCT04018911|Experimental|Hearing Aid with NR_4|NR_4: Noise Reduction principle 4
16394418|NCT04018625|Active Comparator|Treatment as usual|Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
16394419|NCT04018612|Active Comparator|High Dose IV Acetaminophen|High Dose IV Acetaminophen Post Op
16394420|NCT04018612|Active Comparator|Low Dose IV Acetaminophen|Low Dose IV Acetaminophen Post Op
16394372|NCT04018898||Observational|Each participant will be evaluated at Emergency Department based on ER2 screening tool (Emergency Room Evaluation and Recommendation Form). Six closed-ended format questions (i.e., yes versus no) composed ER2 assessment: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless its type, and temporal disorientation (inability to give the current month and/or year).
16394373|NCT04018885|Experimental|ALA 2.5% 0.5h|Topical application of 2.5% ALA for 0.5 hour
16394374|NCT04018885|Experimental|ALA 2.5% 1.5h|Topical application of 2.5% ALA for 1.5 hours
16394375|NCT04018885|Experimental|ALA 2.5% 3h|Topical application of 2.5% ALA for 3 hours
16394376|NCT04018885|Experimental|ALA 5% 0.5h|Topical application of 5% ALA for 0.5 hour
16394377|NCT04018885|Experimental|ALA 5% 1.5h|Topical application of 5% ALA for 1.5 hours
16394378|NCT04018885|Experimental|ALA 5% 3h|Topical application of 5% ALA for 3 hours
16394379|NCT04018885|Experimental|ALA 10% 0.5h|Topical application of 10% ALA for 0.5 hour
16394380|NCT04018885|Experimental|ALA 10% 1.5h|Topical application of 10% ALA for 1.5 hours
16394381|NCT04018885|Experimental|ALA 10% 3h|Topical application of 10% ALA for 3 hours
16394382|NCT04018872|Experimental|Itraconazole|Itraconazole capsule 300mg twice daily for 6-8 weeks following chemoradation.
16394383|NCT04018859|Experimental|Platelet-Rich Plasma|Participants will receive intradermal injections of 2-3mL autologous PRP to eyebrows.Three treatments will be performed 1 month apart.
16394384|NCT04018859|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of 2-3mL sterile saline to eyebrows.Three treatments will be performed 1 month apart.
16394385|NCT04018833||ranibizumab|Patients nonresponsive to bevacizumab that were switched to ranibizumab
16394386|NCT04018833||aflibercept|Patients nonresponsive to bevacizumab that were switched to aflibercept
16394387|NCT04018820|Experimental|Training program|
16394388|NCT04018807|Other|Resource Pamphlet|Participants will receive a pamphlet detailing mental health and social service providers at the local, state, and national level.
16394389|NCT04018807|Experimental|Remote Therapy|Participants will receive eight 30-minute remote therapy sessions over the course of twelve weeks.
16394390|NCT04018794|Experimental|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
16394391|NCT04018781||MR group|Patients who benefit from a full process of medication reconciliation (entrance and discharge) before being discharged to home.
16394392|NCT04018781||Control group|Patients who benefitted from a medication reconciliation at entrance only before being discharged to home.
16394393|NCT04018768||Ibuprofen + Percocet|
16394394|NCT04018768||Percocet|
16394395|NCT04018755|Experimental|treatment|anakinra 100 mg subcutaneous once daily
16394396|NCT04018742||Patients with an abscess|Patient diagnosed with a cerebral abscess at admission; and to benefit from an abscess puncture as part of routine care.
16394397|NCT04018729|Experimental|Endobronchial valve + marrow-derived mesenchymal stromal cell|
16394398|NCT04018729|Active Comparator|Endobronchial valve|
16394399|NCT04018716|Experimental|MTA|mineral trioxide aggregate
16394400|NCT04018716|Active Comparator|Dycal|calcium hydroxide cement
16394401|NCT04018703|Experimental|Dexmedetomidine|Dexmedetomidine will be used for perioperative sedation.
16394402|NCT04018703|Experimental|Midazolam|Midazolam will be used for perioperative sedation.
16394403|NCT04018690|Experimental|Experimental|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.
16394404|NCT04018690|Active Comparator|Control Group|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine
16394406|NCT04018664|Placebo Comparator|Placebo|"Placebo
~150 mL flavored beverage"
16394407|NCT04018664|Experimental|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution
~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
16394408|NCT04018664|Experimental|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution
~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
16394409|NCT04018664|Experimental|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution
~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
16394410|NCT04018664|Experimental|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution
~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
16394411|NCT04018664|Experimental|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution
~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
16394412|NCT04018664|Experimental|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution
~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
16394413|NCT04018664|Experimental|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution
~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
16394414|NCT04018651|Experimental|PrEP Master Adherence Intervention|The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
16394415|NCT04018638|Experimental|Adults with TKR Perform Home Exercise Program|Participants that have a total knee replacement will complete a home-based exercise program
16394416|NCT04018638|No Intervention|Healthy Controls Only|Participants that have no history of knee joint dysfunction will serve as age-matched uninjured controls
16394417|NCT04018625|Experimental|Intervention|Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
16394421|NCT04018612|Placebo Comparator|Placebo|IV Placebo Post Op
16394422|NCT04018599|Experimental|40 mg MSB11022 via Auto-injector|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
16394423|NCT04018599|Experimental|40 mg MSB11022 via Pre-filled Syringe|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
16394424|NCT04018586|Experimental|Heat and Vacuum|AVACEN 100 device applies heat and vacuum to hand
16394425|NCT04018586|Active Comparator|Heat Only|AVACEN 100 device with heat only
16394426|NCT04018586|Sham Comparator|Sham|AVACEN 100 device with neither heat nor vacuum
16394427|NCT04018573|Active Comparator|Parent Support Film|Parents will watch Lead with Love, a 35-minute documentary style film designed to provide support, information, and behavioral guidance to parents with a lesbian, gay, or bisexual child. One month later, parents will look over material that reviews the major points of the film. All of this material is presented online via our webapp.
16394428|NCT04018573|Experimental|Parent Support Film + PATHS Sexual Communication Toolkit|Parents in this arm will have the option of watching Lead with Love, and then will engage with our parent toolkit, designed to increase the frequency and quality of parent-child communication about HIV and condoms. One month later, parents will engage with booster content, customized to address their self-reported barriers to communicating with their sons. All of this material is presented online via our webapp.
16394429|NCT04018560|Experimental|Intervention|
16394430|NCT04018560|No Intervention|Usual care|
16394431|NCT04018534|Experimental|Control group|The patients in control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society(BOS) educational goals.
16394432|NCT04018534|Experimental|Video assisted education group|The patients in one of the study groups received a video assisted education
16394433|NCT04018534|Experimental|Hands-on training group|The patients in other study group received a hands-on training.
16394434|NCT04018521|Active Comparator|Parent Connectors|trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newlyenrolled youth or young adults (Y/YA) in FEP services
16394435|NCT04018521|Active Comparator|Usual Care|Coordinated Specialty Care (CSC)
16394436|NCT04018508|Experimental|Massages|During routine clinic visits, subjects will receive a total of six 30-minute massages (one massage per week for 4 weeks, then one massage every two weeks for 4 weeks).
16394437|NCT04018508|No Intervention|Control|Subjects randomized to the control arm will also attend routine clinic visits at the same pre-prescribed intervals (one clinic visit per for 4 weeks, then one visit every two weeks for 4 weeks).
16394438|NCT04018495|Experimental|Interventional - Fitbit tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
16394439|NCT04018482|Experimental|Open label test arm|Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
16394440|NCT04018456|Experimental|Biodentine|Intervention group: application of biodentine as pulp space barrier during regenerative endodontic treatment.
16394441|NCT04018456|Active Comparator|White MTA|Control group: application of White MTA as pulp space barrier during regenerative endodontic treatment.
16394442|NCT04018443||patients admitted ti surgical ICU after major surgery|patient admitted to surgical ICU after major surgery for post-operative close monitoring, assessment and resuscitation of the intravascular volume status
16394443|NCT04018417|Experimental|Amphotericin B|The eye bank will add amphotericin B 0.255 μg/mL to the Optisol-GS donor cornea storage solution.
16394444|NCT04018417|No Intervention|Control|The donor cornea will be stored in Optisol-GS per the eye bank's standard procedure.
16394445|NCT04018404|No Intervention|Control|Subjects will be approached for enrollment prior to or following clinic visit with physician. Only children present with a biological mother will be considered for enrollment. Charts of controls will be flagged so that they will not be able to be enrolled in the FRI clinical program if they present to a morning clinic where the program is offered.
16394446|NCT04018404|Experimental|Subject|Mothers and children will be approached by study personnel (separate from Outreach Coordinators who will obtain consent for use of information to evaluate the FRI Clinical Program) for enrollment in the FRI Research Program following completion of all FRI Clinical Program activities for that day. Both mother and child will be enrolled and contribute data and samples to the FRI Research Program.
16394447|NCT04018391|Experimental|Stepped care for non-adherence and depression|Participants will be randomized approximately two weeks post-baseline. Those randomized to the experimental condition will receive the Intervention and Stepped Care Treatment Protocol
16394448|NCT04018391|Active Comparator|Enhanced Usual Care|Participants will be randomized two weeks post-baseline. Those randomized to the control condition will receive Enhanced Usual Care.
16394449|NCT04018378|Experimental|RT|"period 1: HGP1604 1mg (reference drug, R) will be administered once orally.
~period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period."
16394450|NCT04018378|Experimental|TR|"period 1: HIP1502 1mg (test drug, T) will be administered once orally.
~period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period."
16394451|NCT04018365|Experimental|Treatment of empagliflozin|Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of <7.0%, 10 mg will be continued: in case of >=7.0%, it will be increased to 25 mg.
16394452|NCT04018339|Experimental|RTA 402 5mg or 10mg oral administration|
16394453|NCT04018339|Placebo Comparator|Placebo|
16415634|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts B"|
16394454|NCT04018326||Compliant patients|The compliant patient was defined as a patient who did not miss any follow-up visit until the end of the study period.
16394455|NCT04018326||Loss to follow-up (LTFU)|LTFU was defined as missing any follow-up visit for any interval exceeding 6 months provided that patients eventually resumed care before the end of the study period (time zero was defined as the date of the missed follow-up visit).
16394456|NCT04018313|Experimental|CT-P39 (Part 1)|150 mg/mL, Solution for injection in PFS
16394457|NCT04018313|Active Comparator|EU-approved Xolair (Part 1)|150 mg/mL, Solution for injection in PFS
16394458|NCT04018313|Experimental|CT-P39 (Part 2)|150 mg/mL, Solution for injection in PFS
16394459|NCT04018313|Active Comparator|EU-approved Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
16394460|NCT04018313|Active Comparator|US-licensed Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
16394461|NCT04018300|Experimental|Ferrous sulfate|Subjects will take a 65 mg Fe capsule of ferrous sulfate, once daily for 21 consecutive days. The first treatment capsule will be consumed with a semi-purified meal (egg albumin, sugar, vanilla, maltodextrose and corn oil) and will have blood drawn hours 0, 1, 2, 3, 4, 6 and 8 post consumption. Serum will be used to determine non-transerrin bound iron, serum iron and percent saturation. Throughout the treatment period, subjects are informed to consume the capsule with food and report symptoms in an online questionnaire. Following three weeks treatment, participants return for a blood draw and oxidative stress indicators are measured. A three week washout period with placebo treatment takes place between treatment crossover.
16394462|NCT04018300|Experimental|Aspiron|AspironTM which is an iron-enriched supplement will follow the same guidelines and protocol as ferrous sulfate arm. Equivalent 65 mg Fe per capsule will be administered to participants.
16394463|NCT04018300|Placebo Comparator|Placebo|Participants will follow the same description for the other two experimental treatment groups. Capsules will be given to subjects in opaque formation, therefore will be unable to differentiate the iron supplements.
16394464|NCT04018287||HPP-Group|"genetical verified hypophosphatasia
~age >18 years
~written informed consent
~complete serological and radiological examinations"
16394465|NCT04018287||Control-Group|"healthy men and women without any history of musculoskeletal diseases
~Alkaline phosphatase (AP) in reference range
~written informed consent
~complete serological and radiological examinations"
16394466|NCT04018274|Experimental|Sequence 1|In Treatment Sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into Period 2 where they will receive PF-06651600 PO for 9 days followed by administration of a single dose of OC on the morning of Day 10.
16394467|NCT04018274|Experimental|Sequence 2|In Treatment Sequence 2, Period 1, participants will be dosed with PF-06651600 PO QD for 9 days and administered a single dose of OC on the morning of Day 10. After a washout period of at least 10 days, participants will continue into Period 2 and will receive an additional single dose of OC.
16394468|NCT04018261|Experimental|Activated T-Lymphocytes|Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.
16394469|NCT04018248|Experimental|Treatment ( BR101801):Phase Ia (dose escalation)|Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
16394470|NCT04018248|Experimental|Treatment ( BR101801):Phase Ib (dose expansion)|"Group A: Patients with diffuse large B-cell lymphoma (DLBCL) including MYC-altered DLBCL
~Group B: Patients with follicular lymphoma.
~Group C: Patients with chronic lymphocytic leukemia/small lymphocytic leukemia, other B-cell lymphoma such as, but not limited to mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, or PTCL"
16394471|NCT04018235||localized disease or locally advanced disease|"Subgroups:
~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy"
16394472|NCT04018235||metastatic disease|"Subgroups:
~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
16394473|NCT04018235||follow up disease|"Subgroups:
~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
16394474|NCT04018222||Lupus Cases|This cohort of patients will involve individuals with a confirmed medical history of Systemic Lupus Erythematosus. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
16394475|NCT04018222||Healthy Controls|This cohort of patients will involve individuals whom do not have a diagnosis of Systemic Lupus Erythematosus or any other rheumatological or auto-immune diseases. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
16394476|NCT04018196|Experimental|Experimental group|Patient aged over 80 years old will be included. They will have motor imagery training of manual task and motor imagery training of motor task.
16394477|NCT04018196|Active Comparator|Control group|Patient aged over 80 years old will be included. They will have emotionally neutral film as training of manual task and emotionally neutral film as training of motor task.
16394478|NCT04018170|Experimental|JW1601|tablet formulation
16394479|NCT04018170|Placebo Comparator|Placebo|tablet formulation identified with JW1601
16394480|NCT04018157|Active Comparator|ketodex|ketamine dexmedetomidine mixture
16394481|NCT04018157|Active Comparator|ketofol|ketamine propofol mixture
16394482|NCT04018157|Placebo Comparator|placebo|normal saline
16394483|NCT04018144||Group-1|Healthy individuals
16394484|NCT04018144||Group-2|Periodontitis patients-stage 3-grade B
16394485|NCT04018144||Group-3|Periodontitis patients-stage 3-grade C
16394486|NCT04018131|Active Comparator|Cimetidine|
16394487|NCT04018131|Placebo Comparator|Placebo|
16394488|NCT04018118||Eosinophilia/Hypereosinophilic syndrome|patient with eosinophilia and/or hypereosinophilic syndrome
16394489|NCT04018105|Experimental|taking metformin 30 or 60 minutes before the OGTT|
16394490|NCT04018105|Placebo Comparator|No metformin before OGTT|
16394491|NCT04018092|Experimental|Active NIR-PBM|"For transcranial stimulation, the study team will use two MedX units (1116 Rehab Console, MedX Health), whereas intranasal stimulation is delivered using the 810 Intranasal device (Vielight Inc). During each lab session, six transcranial LED clusters will be placed on the scalp in two distinct configurations guided by 10-20 EEG system. Total transcranial stimulation time is 40 minutes, 20 min per cluster. Concurrently, two 810 intranasal devices will be placed in each nostril for 25 min of total dose per nostril. For at home sessions, participants will use the standalone 810 Intranasal device only.
~Total amount of sessions:
~16 sessions of stimulation will occur in the laboratory. Each session will last approximately 90 minutes and will include two 20-minute segments of NIR stimulation.
~AND
~44 sessions of intranasal stimulation in the home. Each session will last 25 minutes and will occur on weekdays when there is no in-lab session."
16394492|NCT04018092|Sham Comparator|Sham NIR-PBM|"Participants randomized to the Sham control group will undergo identical procedures as the Active group. The only difference is that the sham NIR devices are modified not to deliver stimulation. Because NIR is invisible, participants are unable to detect whether NIR is being delivered."
16394493|NCT04018066|Experimental|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
16394494|NCT04018053|Experimental|18F-fluciclovine|"18F-fluciclovine will be administered via slow push over 10 seconds through a peripheral intravenous line
~Immediately after the injection of the radiopharmaceutical, dynamic PET/CT images of the pelvis will be obtained for 15 minutes
~Subsequently, PET/CT images will be obtained from the pelvis to the base of skull."
16394495|NCT04018040|No Intervention|Control Group|Patients will be asked to continue their usual diet patterns over an 8 week period
16394496|NCT04018040|Experimental|Intervention Group|Patients will follow a lacto-ovo vegetarian diet for an 8 week period. patients will be provided with a lacto-ovo vegetarian food box delivery service with fresh ingredients and recipes to cover four dinners per week.
16394497|NCT04018027|Active Comparator|Difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablet administered twice daily
16394498|NCT04018027|Active Comparator|Difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablet administered twice daily
16394499|NCT04018027|Active Comparator|Difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg tablet administered twice daily
16394500|NCT04018027|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
16394501|NCT04018014||< 30 kg/m2|patients with BMI < 30/kg/m2
16394502|NCT04018014||>30 kg/m2|patients with BMI > 30 kg/m2
16394503|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
16394504|NCT04017988|Experimental|Ethanol Extracts of Porphyra Tenera(PTE10) group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 2.5 g/day)
16394505|NCT04017988|Placebo Comparator|Placebo group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 0 g/day)
16394506|NCT04017975|No Intervention|Non-imaging cohort|There will be no intervention for the non-imaging group. Subjects will receive standard of care for cardiac surgery.
16394507|NCT04017975|Experimental|Imaging cohort|Up to 5mL of 1:1000 dilute fluorescite will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes. The system will be used to assist the investigator with the operative course.
16394509|NCT04017936|Experimental|Anakinra|100 mg/0.67 mL daily subcutaneous injection for 4 weeks
16394510|NCT04017936|No Intervention|Standard of Care|Continue standard of care treatment
16394511|NCT04017923||20-29 age group|
16394512|NCT04017923||30-39 age group|
16394513|NCT04017923||40-64 age group|
16394514|NCT04017923||65 and older age group|
16394515|NCT04017897|Experimental|Experimental|
16394516|NCT04017884|Experimental|Remin Pro Forte.|intervention
16394517|NCT04017884|Active Comparator|Remin pro.|comparator
16394518|NCT04017871|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
16394519|NCT04017871|Placebo Comparator|Control|10 days of care and classic activities
16394520|NCT04017858|Experimental|Experimental|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
16394521|NCT04017858|Active Comparator|Control|Patients will be submitted to total knee replacement.
16394522|NCT04017845|Active Comparator|Household-Open Invitation (HOI)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
16394523|NCT04017845|Active Comparator|Recommendation By Physician (RBP)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
16394528|NCT04017819|Active Comparator|Healthy volunteers (Group 1)|Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
16394529|NCT04017819|Experimental|Patients with newly diagnosed lung cancer (Group 2)|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
16394530|NCT04017819|Experimental|Patients with lung cancer undergoing non-surgical tx (Group 3)|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of [18F]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a [18F]-C-SNAT4 PET/CT scan)
16394531|NCT04017793|Active Comparator|Mindfulness Based Stress Reduction Program|
16394532|NCT04017793|Active Comparator|Relaxation Group|
16394533|NCT04017780|Experimental|Single-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
16394534|NCT04017780|Experimental|Double-limb circuit with Intensive Care Unit ventilator|Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
16394535|NCT04017780|Experimental|Double-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
16394536|NCT04017767|Experimental|Moderate to Severe Obstructive Sleep Apnea (OSA)|Individuals with moderate to severe OSA defined as having an Apnea-hypopnea Index (AHI) that is greater than or equal to 15.
16394537|NCT04017767|Active Comparator|Without OSA|Individuals without OSA defined as having AHI less than 5.
16394538|NCT04017754||Study sample|"In total, 267 women with unexplained recurrent pregnancy loss was included.
~Only patients with a history of 3 or more consecutive spontaneous pregnancy losses are included. Both biochemical and clinical losses documented in hospital records are accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social reasons are not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (<22 and >35 days interval), and/or no MBL measurement."
16394539|NCT04017754||Reference Group|The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information. After informed approval, all controls had an extra blood sample taken, which was analysed for p-MBL.
16394540|NCT04017741|Active Comparator|Active group|The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
16394541|NCT04017741|Placebo Comparator|Placebo group|The placebo group will be administered 4mls of 0.9% saline.
16394542|NCT04017728|Active Comparator|Conventional Percutaneous Vertebroplasty|The cement is injected after the successful puncture.
16394543|NCT04017728|Experimental|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied to destroy the metastatic lesion before coment injection.
16394544|NCT04017715|Experimental|warm up|warm up exercises
16394545|NCT04017715|Experimental|cool down|cool down exercises
16394546|NCT04017715|Active Comparator|control|Following conventional protocol
16394547|NCT04017702||Pregnant women with gestational age between 32-40 weeks.|100 patients scheduled for cesarean section under neuraxial anesthesia with 150 mcg intrathecal or 3-mg epidural morphine.
16394548|NCT04017702||Patients post anesthesia care units (PACU) and surgical floor.|100 patients scheduled to receive General Anesthesia (GA) and planned to receive opioid intravenously (boluses/patient controlled analgesia (PCA).
16394549|NCT04017702||Patients in step down/ICU.|50 patients suffered from rib fracture and 50 patients after weaning from mechanical ventilation and extubation.The Expiron will provide continuous information about the respiratory status (tidal volume, respiratory rate and minute ventilation) of non-intubated patients specifically: sleeping or awake; with the use of incentive spirometry; the response to medications and other interventions (such as paravertebral/epidural block); the need for endotracheal re-intubation.
16394550|NCT04017689||Verbal Information Group|Verbal Information
16394551|NCT04017689||Photo Group|Information by photos
16394552|NCT04017689||Video Group|Information by video
16394553|NCT04017676|No Intervention|Control group|The first group will be under the usual treatment conditions (TAU)
16394554|NCT04017676|Experimental|Experimental group|The second group will be exposed to a multidisciplinary therapeutic program that has a monitoring component and after two months an intervening component will be.
16394555|NCT04017663||Public group|patients who performed cardiovascular rehabilitation in a public center
16394556|NCT04017663||Private group|patients who performed cardiovascular rehabilitation in a private center
16394557|NCT04017650|Experimental|Treatment (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV over 1 hour on days 1 and 15, and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16394558|NCT04017637|No Intervention|Usual Care (UC)|Those randomized to the UC group will complete baseline and post-intervention assessments only. No intervention will be administered.
16394559|NCT04017637|Experimental|Resistance Training Intervention (RT)|Those randomized to the RT group will complete baseline and post-intervention assessments at weeks 0 and 12. For the intervention, they will complete resistance training for approximately 12 minutes 2x per week for 12 weeks.
16394560|NCT04017624|Experimental|Fresh Truck with stipend|Referral to Fresh Truck mobile market
16394561|NCT04017624|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
16394562|NCT04017611|Experimental|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
16394563|NCT04017598|Active Comparator|Ferrous Sulfate|Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.
16394564|NCT04017598|Experimental|Ferrous Bisglycinate|Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.
16394565|NCT04017598|Placebo Comparator|Placebo|Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.
16394566|NCT04017585|Active Comparator|patients with IBS treated with gluten|patients receiving gluten
16394567|NCT04017585|Placebo Comparator|patients with IBS treated with placebo|patients receiving placebo
16394568|NCT04017572|Active Comparator|Standard treatment|APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.
16394569|NCT04017572|Active Comparator|Optimized treatment|APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.
16394570|NCT04017559|Experimental|Intervention cohort|All participants were entered into the intervention cohort to receive the Motivational Interviewing intervention
16394571|NCT04017546|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15. Venetoclax will be taken daily on Day 1 through Day 15. One cycle will be 28 days or 4 weeks.
16394572|NCT04017533|Experimental|GMK Sphere|Patients receive a cementless GMK Sphere Total Knee Replacement
16394573|NCT04017520||Mother-infant dyads|"200 mother-infant dyads enrolled at delivery and followed longitudinally at regularly scheduled well child checks (4, 16, 24, and 48- weeks) at a primary care outpatient pediatric clinic affiliated with an academic medical center. Eligible mothers will be those who plan to breast feed for 16 weeks and infants born at term (37-42 weeks). The cohort will be divided post-hoc into atopic and non-atopic groups based on the primary outcome measure (described below).
~No intervention will be administered."
16394574|NCT04017507||Oscillating-rotating electric toothbrush|Twice daily brushing
16394575|NCT04017507||Side-to-side electric toothbrush|Twice daily brushing
16394576|NCT04017507||Manual toothbrush|Twice daily brushing
16394577|NCT04017494||Single ventricle|Patients with single ventricle lesions
16394578|NCT04017481|Experimental|Repetitive stimulating transcranial stimulation (rTMS)|Subjects receive 8 sessions M1 Neuromodulation using rTMS according to the protocol ( 80% resting motor threshold, 10 Hertz; 1000 pulses; 25 trains de 4 seconds con 25 seconds intertrain.
16394579|NCT04017481|Experimental|EEG guided Neurofeedback (NFB)|Subjects receive 8 sessions M1 EEG guided NFB with virtual reality goggles in order to modify the beta rhythm. The sessions have a duration of 20min
16394580|NCT04017481|Experimental|rTMS + NFB|Subjects receive both interventions sequentially
16394581|NCT04017481|No Intervention|No intervention|No interventions, the patient just comes to be evaluated sequentially according to the timing of experimental groups.
16394582|NCT04017468|Active Comparator|Treatment Arm|The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
16394583|NCT04017468|No Intervention|Control Arm|The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.
16394584|NCT04017455|Experimental|bevacizumab and atezolizumab|1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy
16394585|NCT04017442|Experimental|Morphine|2mg preservative free morphine
16394586|NCT04017442|Placebo Comparator|Saline|4 mL preservative free saline
16394587|NCT04017429|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
16394588|NCT04017429|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
16394589|NCT04017416||Standard Care|Audiologists in the standard care group were instructed to manage the patients in the same way as they would do in their routine clinics which were in accordance with national practice guidelines and were typical of National Healthcare Services (NHS) audiology departments across the UK.
16394590|NCT04017416||I-PLAN|Audiologists were instructed to deliver the I-PLAN in addition to standard care at the hearing aid fitting consultation.
16394591|NCT04017403|Experimental|Probiotic group|The probiotic group was treated with Bifidobacterium tripleis,one day before surgery to the sixth day after surgerythe drug is taken orally, 4 capsules at a time, 2 times a day.
16394592|NCT04017403|Placebo Comparator|Placebo group|The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
16394593|NCT04017390|Experimental|Arm 1: Theraworx Foam alone|Theraworx foam only
16394594|NCT04017390|Active Comparator|Arm 2: Theraworx Foam and night splint|Theraworx foam with a night time splint
16394595|NCT04017390|Placebo Comparator|Arm 3: Placebo foam alone|Placebo foam alone
16394596|NCT04017390|Other|Arm 4: Placebo foam and night splint|Placebo foam with a night time splint
16394597|NCT04017377|Experimental|Chemotherapy+ Radiation therapy|"Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2, Patients secondly receive weekly cisplatin (40 mg/m^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.
~Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days."
16394598|NCT04017364|Active Comparator|PTCA of coronary de novo lesion PCB|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
16394599|NCT04017364|Experimental|PTCA of coronary de novo lesion SCB|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
16395123|NCT04013841|Experimental|Enema preparation|The bowel preparation prior to colorectal resection will be conducted using rectal enema
16394600|NCT04017351|Experimental|Subjects with virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery will have access to artificial intelligence virtual assistance (AIVA)
16394601|NCT04017351|No Intervention|Subjects without virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery
16394602|NCT04017338|Experimental|Non Randomized Intervention|"Intervention description: recipients on the wait-list for lung, heart, kidney, and/or pancreas transplants will all receive antiviral treatment in the form of 8 total doses of oral tablets. Lung recipients will also receive donor lungs that are treated with normothermic EVLP (details of both described below).
~Drug: All recipients will receive glecaprevir (300mg)/pibrentasvir (120mg) supplied as three tablets per dose 6-12 hours prior to transplant, and for 7 days post-transplant. Other Names: Maviret. Patients will also receive ezetimibe (10mg), supplied as one tablet per dose to be taken at the same time as Maviret tablets (6-12 hours prior to transplant in addition to 7 daily doses post-transplant).
~Ex Vivo Lung Perfusion (EVLP): Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions. Other names: Normothermic EVLP."
16394603|NCT04017325||TOOKAD VTP TREATMENT|Subjects randomized in the treatment arm (TOOKAD VTP treatment) in the initial period of the study.
16394604|NCT04017325||Active surveillance|Subjects randomized in the control group (active surveillance) in the initial period of the study.
16394605|NCT04017312|Active Comparator|HFCWO group|Subjects in this arm of treatment will use The Vest® as their primary airway clearance modality for the duration of the study.
16394606|NCT04017312|Active Comparator|OPEP group|Subjects in this arm of treatment will use the Acapella® as their primary airway clearance modality for the duration of the study.
16394607|NCT04017299|Active Comparator|Virtual reality with computer graphics|Use of Virtual reality with computer graphics
16394608|NCT04017299|Active Comparator|Virtual reality with real movies|Use of Virtual reality with real movies
16394609|NCT04017299|Active Comparator|Music therapy (dedicated device and music scores)|Use of music therapy (dedicated device and music scores)
16394610|NCT04017299|Other|Usual device (TV radio)|usual distraction : watching TV
16394611|NCT04017286||depressive disorder group|At 21 weeks of pregnancy, women diagnosed with depressive disorder by the Hamilton depression scale and Beck depression rating scale and their offspring were enrolled.
16394612|NCT04017286||Nutrient-deficient group|Nutrients (Vitamin A,D,E) were tested at 21 weeks of pregnancy, and pregnant women with one or more nutrient deficiencies or insufficiency and their offspring were enrolled.
16394613|NCT04017286||depressive disorder and nutrient deficiency group|At 21 weeks of pregnancy, pregnant women with depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
16394614|NCT04017286||Neither group|At 21 weeks of pregnancy, pregnant women without depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
16394615|NCT04017273||Observational|The participants of this study will be seen at Emergency Department, and a nurse will perform a test called ER2 ( Emergency Room Evaluation and Recommendation).
16394616|NCT04017260|Experimental|open and closed technique|treatment of pilonidal sinus by open and closed approach
16394617|NCT04017260|Experimental|Rhomboid flap technique|treatment of pilonidal sinus by Rhomboid flap
16394618|NCT04017260|Experimental|karydakis technique|treatment of pilonidal sinus by Karydakis
16394619|NCT04017260|Experimental|open technique|treatment of pilonidal sinus by open approach
16394620|NCT04017247|Active Comparator|Intermittent treatment|Infusion of oxytocin for 6 hours at a time until patient delivers.
16394621|NCT04017247|Active Comparator|Continous treatment|Infusion of oxytocin continuously from patient admission until patient delivers.
16394622|NCT04017234|Experimental|PMP group|children received health education for eye and the intervention(which included frequency following response, eye exercise, and transcutaneous electrical nerve stimulation) a 30 minute three times per week for four weeks.
16394623|NCT04017234|No Intervention|control group|children just received health education for eye
16394624|NCT04017221||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current use of a SGLT2 inhibitor alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
16394625|NCT04017221||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current use of a DPP-4 inhibitor alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
16394626|NCT04017221||Other treatment combinations|Current use of other antidiabetic drugs, current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
16394627|NCT04017208|Experimental|ASP2713|Participants will receive a single dose of ASP2713. Up to 8 dose levels will be administered in the study.
16394628|NCT04017208|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
16394629|NCT04017195|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
16394630|NCT04017195|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
16394631|NCT04017195|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
16394632|NCT04017195|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
16394798|NCT04015986|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
16394633|NCT04017169||No reflow phenomenon|"Those that during procedure experience no reflow phenomenon
~To define no reflow requires:
~• Angiographic evidence of reopening of occluded coronary artery and successful stent placement with no evidence of flow-limiting residual stenosis (<50%), dissection, vessel spasm, or thrombus burden
~and
~Angiographic documentation of a TIMI flow grade ≤II, or
~A TIMI flow grade III with a myocardial perfusion grade 0 or I, at least 10 min after the end of PCI procedure."
16394634|NCT04017169||No NRP|Normal angiographic coronary flow/blush post patent culprit vessel.
16394635|NCT04017156|Experimental|Test site (torque of <10 Ncm)|The test sites (<10 Ncm) will be over-prepared with drills of larger diameter
16394636|NCT04017156|Other|Control site (torque of ~30 Ncm)|the standard sites (~30 Ncm)will be prepared with the corresponding drills suggested by the manufacturer
16394637|NCT04017143|Experimental|HPV App group|Participants will be assigned to receive an HPV app.
16394638|NCT04017143|No Intervention|Usual Care|This is a usual care group that receives a brochure that is usually distributed by a clinic.
16394645|NCT04017117|Experimental|Custom Made Poly Ether Ether Ketone Mesh|Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
16394646|NCT04017117|Active Comparator|Conventional Titanium mesh|Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
16394647|NCT04017104||18F-FDG PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-FDG PET/CT procedure.
~18FFDG is considered standard care and has been approved by Health Canada."
16394648|NCT04017104||68Ga-DOTATOC PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 68Ga-DOTATOC PET/CT procedure.
~The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
16394649|NCT04017104||18F-DCFPyL PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-DCFPyL PET/CT procedure.
~The 18F-DCFPyL radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
16394650|NCT04017091|Experimental|VR Group|ABI Patients Twenty-one patients with ABI participated in this pilot study (Figure 1): 9 diagnosed with stroke (43%), 6 with TBI (29%), 2 with anoxic injury (10%), 3 with brain tumor (14%), and 1 with amyloid angiopathy (5%).
16394651|NCT04017091|No Intervention|Control Group (Standard Care)|The 12 Controls were age- and gender-matched (and etiology when possible) patients who had previously received traditional neurorehabilitation and completed the same measures as the VR group prior to onset of the study, but they did not receive VR treatment.
16394652|NCT04017078||Patients who referred for periodontal therapy|Patients who referred to Baskent University, Faculty of Dentistry, Department of Periodontology, during 2016-2018
16394653|NCT04017065||Patients treated with the MAXFRAMETM system|Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system
16394654|NCT04017052|Other|Booster vaccination|Intervention = one i. m. TBE booster vaccination (FSME-Immun) at visit 1.
16394655|NCT04017039|No Intervention|Phase 1|Phase I is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 6.5 hr/night (short sleep)
16394656|NCT04017039|Experimental|Phase 2|Phase II is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep less than 6.5 hr/night (Specific Aims 3).
16394657|NCT04017026||6 mm implants|Patients were treated with 6mm short implants (Straumann, SLA, SLActive, 4.1 or 4.8 mm in diameter).
16394799|NCT04015973|No Intervention|Group A: Control|Standard Care
16395124|NCT04013828||Patients|Patients with recurrent high-grade glioma
16394658|NCT04017013|Active Comparator|Epidural Analgesia|"The placement of the thoracic epidural catheter will be located depending on surgical incision as follows:
~Surgery of the upper abdomen: T7-T8.
~Surgery of lower abdomen: T8-T9. The epidural catheter placement technique will be determined by the treating anesthesiologist. However, once the epidural space is located and the respective catheter is inserted, the correct location of the catheter should be tested with lidocaine at 2% CE 5 cc and a sensitivity test with temperature should be performed on the target dermatomes. A negative test for an adequate location of the catheter indicates that the procedure should be repeated until the epidural space is correctly located. Once this is achieved, the catheter will be left 4 cm away from the skin. The catheter will be fixed according to the institutional protocol."
16394659|NCT04017013|Experimental|Lidocaine Infussion|Intravenous lidocaine
16394660|NCT04017000|Active Comparator|BlaST study|"Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.
~The participants Urodynamic clinic will run according to routine care."
16394661|NCT04017000|Other|Calibration Sub Study|"Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.
~Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.
~Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change."
16394662|NCT04016987|Experimental|Automated, Individualized Education|Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
16394663|NCT04016987|No Intervention|Routine care|Subjects only receive the education provided by health-care professionals in the outpatient department
16394664|NCT04016974|Experimental|Oral semaglutide|
16394665|NCT04016974|Placebo Comparator|Placebo|
16394666|NCT04016961|Experimental|Animal Assisted Therapy - Dog Session|Therapy dog added to PT and OT session
16394667|NCT04016961|Active Comparator|Treatment as usual - No Dog session|No dog added to PT and OT session - PT and OT session as usual standard of care
16394668|NCT04016948|Experimental|Probe-based confocal laser endomicroscopy(pCLE)|Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group
16394669|NCT04016948|Active Comparator|Intra-operative frozen section(IFS)|Intra-operative frozen section will be performed for patients assigned to this group
16394670|NCT04016935||Patients with primary invasive ER+ HER2- breast cancer|Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
16394671|NCT04016922||Group A|Patients with mild anemia (Hb concentration: 9.0-10.9 g\dl).
16394672|NCT04016922||Group B|Patients with moderate anemia (Hb concentration: 7.0-8.9 g\dl).
16394673|NCT04016922||Group C|Patients with severe anemia (Hb concentration: >7.0 g\dl).
16394674|NCT04016909|Experimental|aerobic exercise plus calorie restriction|"The experimental intervention: both exercise and calorie restriction, as described below:
~Exercise intervention. 6 months, 72 supervised aerobic exercise training sessions on cycle ergometers, including 3 sessions of training per week. A warm-up procedure consisting of 5 min of low-intensity stretching was completed by all women before the aerobic training. Subsequently, a 50 min aerobic training at an intensity between 60% and 70% of the maximum heart rate (HR) was performed. Thereafter, a cool-down consisting of 5 min of low-intensity stretching and breathing exercises was completed. HR was recorded continuously throughout the training sessions using an HR monitor (S625X, Polar Electro, Kempele, Finland).
~Calorie restriction intervention. The CR intervention was designed to create a 12.5% energy deficit, with the goal of reducing body weight by 5%-10% over 6 months."
16394675|NCT04016909|No Intervention|Control|No intervention and participants were instructed to maintain their regular physical activity and diet regime for 6 months; they were also prohibited from participating in any weight-loss or exercise program.
16394676|NCT04016896|Experimental|Widowed Elders' Lifestyle after Loss (WELL)|digital monitoring of sleep, meals, physical activity; motivational health coaching; personalized feedback
16394677|NCT04016896|Active Comparator|Enhanced Usual Care|enhanced usual care
16394678|NCT04016883|Sham Comparator|Conventional web platform|Participants asked to review the web platform for 4 weeks.
16394679|NCT04016883|Experimental|Problem Solving Therapy offered through a web platform|4 sessions with cognitive behavioral therapy, offered through a web platform. Each session will be offered per week.
16394680|NCT04016870|Active Comparator|New Device|New pacemakers will be sourced from pacemaker manufacturers.
16394681|NCT04016870|Experimental|Reconditioned Device|Donated devices are inspected according to specific protocols that evaluate physical and electrical (battery longevity) suitability for future use. Devices deemed to be acceptable are shipped to a third-party vendor (NEScientific) for disassembly, cleaning and re-sterilization.
16394682|NCT04016857|Experimental|RIPC Group|Remote ischemic preconditioning
16394683|NCT04016857|Sham Comparator|Control Group|Sham remote ischemic preconditioning
16394684|NCT04016844|Active Comparator|tDCS effects on glucose uptake in leg muscles|tDCS Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time tDCS will be applied to the motor cortex (M1) corresponding to the more-affected leg.
16394685|NCT04016844|Placebo Comparator|Sham effects on glucose uptake in leg muscles|Sham Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time SHAM will be applied to the motor cortex (M1) corresponding to the more-affected leg.
16394686|NCT04016831|Other|Mapping Enhanced Counseling (MEC) only|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
16394687|NCT04016831|Experimental|Mapping Approaches to Prepare for Implementation Transfer|an implementation intervention to explore and address agency preparation needs in order to promote implementation success (includes MEC training)
16394688|NCT04016818|Experimental|18-F FDG Study using Breast-Dedicated PET Camera|Breast-Dedicated PET Camera will be used with standard PET 18-F FDG tracer dose
16394689|NCT04016805|Experimental|ublituximab + umbralisib + ibrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
~umbralisib: 800 mg; to be administered daily
~ibrutinib: dose tolerated by subject; to be administered daily"
16394690|NCT04016805|Experimental|ublituximab + umbralisib + venetoclax|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
~umbralisib: 800 mg; to be administered daily
~venetoclax: dose tolerated by subject; to be administered daily"
16394691|NCT04016805|Experimental|ublituximab + umbralisib + acalabrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
~umbralisib: 800 mg; to be administered daily
~acalabrutinib: previously tolerated dose; to be administered every 12 hours"
16394692|NCT04016792|Placebo Comparator|Placebo|Placebo qd
16394693|NCT04016792|Experimental|SPN-812|200 mg SPN-812
16394694|NCT04016779|Placebo Comparator|Placebo|Placebo qd
16394695|NCT04016779|Experimental|SPN-812|SPN-812 qd
16394696|NCT04016766|Experimental|Prepartying mobile app intervention|Mobile app intervention
16394697|NCT04016766|No Intervention|Control|Control participants receive a personalized attention control task (i.e., listing and ranking favorite movies, music, and books), which controls for the time needed by the intervention group to view the intervention material.
16394698|NCT04016753|Experimental|Monotherapy|
16394699|NCT04016740|Experimental|Multimodal General Anesthesia|"Intraoperative
~The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.
~Routine anesthetic induction
~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision
~Ketamine (0.06 to 0.12 mg.kg/hr)
~Remifentanil (0.05-0.2 mcg/kg/min)
~Dexmedetomidine (0.2-1.0 mcg/kg/hr)
~Rocuronium intermittent bolus (TOF)
~Propofol infusion ± Sevoflurane titrated based on EEG monitoring
~Postoperative
~Standard pain management protocol
~Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)
~Infusion continued till extubation
~Propofol infusion may be added/used for sedation based on the treating physician's discretion"
16394700|NCT04016740|Other|Standard Practice with EEG monitoring|The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
16394701|NCT04016727|Experimental|PRP group|patients in which 60 units of prp was injected
16394702|NCT04016727|No Intervention|Control group|patients not given any intervention
16394703|NCT04016714|Experimental|V114|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2 and 4 (approximately 3, 5, and 12 months of age).
16394704|NCT04016714|Active Comparator|Prevnar 13®|Infant participants will receive a single 0.5 mL IM injection of Prevnar 13® at Visit 1, 2 and 4 (approximately 3, 5, and 12 months of age).
16394705|NCT04016701|Experimental|VR Intervention|Eight weeks of training with Floreo's VR Joint Attention Module with two sessions per week
16394706|NCT04016701|Active Comparator|Treatment as Usual|Regularly scheduled therapy
16394707|NCT04016688|Active Comparator|ES Erector Spinae Plane Block|"bilateral ESP block at the level of T9 by a linear ultrasound (US) transducer (Phillips Saronno Italy) placed vertically 3cm lateral to the midline to visualize the back muscles superior to the transverse process.
~A 22-G short bevel needle (spinocan, B.Braun, melsungen AG, Germany) will be inserted in cranial-caudal direction until it make contact with the transverse process. Confirmation of the correct position of the tip of the needle is by injection of 1 ml saline causing hydrodisscetion between the erector spinae muscle and the transverse process. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected.The same procedure is done on the other side of the back."
16394708|NCT04016688|Active Comparator|TAP Transversus Abdominis Plane Block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.
~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
16394709|NCT04016675|Experimental|Study Group|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
16394710|NCT04016675|Active Comparator|Control Group|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
16394711|NCT04016662|Active Comparator|Hybrid Closed Loop Control (HCL)|The HCL intervention arm will utilize the Tandom t:slim X2 with Control-IQ Technology and Dexcom G6 CGM
16394712|NCT04016662|Active Comparator|Predictive Low-Glucose Insulin Suspension (PLGS)|The PLGS intervention arm will utilize the Tandom t:slim X2 with Basal-IQ Technology and Dexcom G6 CGM
16394713|NCT04016662|No Intervention|Sensor-Augmented Pump (SAP)|The SAP arm will utilize the Tandem t:slim X2 without HCL or PLGS features turned on and Dexcom G6 CGM
16394800|NCT04015973|Experimental|Group B: High energy diet|High energy diet for 8-12 weeks pre-surgery
16415635|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts A"|
16394715|NCT04016623|Experimental|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
16394716|NCT04016623|Active Comparator|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
16394717|NCT04016610|Experimental|ASR Treatment|Single and/or multi-treatment ASR device applied to the keloid scar for a period of 2 minutes for each 3 cm.
16394718|NCT04016597||Lung diffusing capacity measurements|Participants perform single-breath lung diffusing capacity measurements in random order during one study visit.
16394719|NCT04016584|Experimental|Latino adults with type 2 diabetes|"Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -
~hemoglobin A1c > 8% at or prior to enrollment, or
~hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):
~Fasting plasma glucose > 130 mg/dL
~2-hour post-prandial or random blood glucose > 180 mg/dL
~> 1 hypoglycemic event (blood glucose < 70 mg/dL) , or
~adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider."
16394720|NCT04016571||Adults with Cystic Fibrosis|"All Adults with a confirmed diagnosis of Cystic Fibrosis being admitted for Intra-Venous Antibiotic Treatment of a Pulmonary Exacerbation
~This study is observational so no intervention will be carried out."
16394721|NCT04016558|Experimental|StreamLine|Diabetes education, behavioral management
16394722|NCT04016558|Experimental|TunedIn|Diabetes distress reduction, emotion regulation techniques.
16394723|NCT04016558|Experimental|FixIt|Unified program combining diabetes education, behavioral management, diabetes distress reduction, and emotion regulation techniques.
16394724|NCT04016545||Treated patients|
16394725|NCT04016532|Other|Patient malnourished or at risk of undernutrition|Dietary follow-up at home: 4 visits (D15, D30, D60, D90)
16394726|NCT04016532|Other|Not undernourished patients|Dietary follow-up at home: 3 visits ( D30,D60, D90)
16394727|NCT04016519||Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.
~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
16394728|NCT04016506||Pancreas injury|children with Pancreas trauma
16394729|NCT04016493||Control group (CAF+CTG; N=20)|
16394730|NCT04016493||Test group (TUN+CTG; N=20)|
16394731|NCT04016480|Active Comparator|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
16394732|NCT04016480|Active Comparator|Conventional Oxygen Therapy|Conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
16394733|NCT04016467|Experimental|Thoracic Manipulation (ThM)|Will undergo spinal manipulation between pain assessment pre and post.
16394734|NCT04016467|Sham Comparator|Sham thoracic treatment (ThS)|Sham manipulation between pain assessment pre and post
16394735|NCT04016454|Experimental|Intervention group|No handover of anesthesia care
16394736|NCT04016454|No Intervention|Control group|Complete handover of anesthesia care
16394737|NCT04016441||Subjects|Subjects who are capable of completing an online, English survey.
16394738|NCT04016428|Experimental|OPTIMISM Intervention|Participants will receive online delivery of a mindfulness-based program for improving sleep in pregnancy, along with the usual care they would receive from their provider.
16394739|NCT04016428|Active Comparator|Sleep Education|Participants will receive online delivery of an education program on sleep in pregnancy, along with the usual care they would receive from their provider.
16394740|NCT04016415|Experimental|Mindfulness Based Stress Reduction|
16394741|NCT04016415|Active Comparator|Stress Management Education|
16394742|NCT04016402||Study Group|All participants enrolled in the study
16394743|NCT04016389|Experimental|Neo-Adjuvant Chemotherapy, Surgery, and Adjuvant Chemotherapy|"Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles.
~After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done.
~Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done."
16394744|NCT04016376|Experimental|PVB|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
16394745|NCT04016376|Experimental|PVB + PECS-1|"Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
~For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor."
16394746|NCT04016376|Experimental|Serratus + PECS-1|"For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor.
~For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior."
16394747|NCT04016363|Experimental|ProbeFix arm|The echocardiography probe is fixated on the patient's thorax using the ProbeFix
16394748|NCT04016363|Active Comparator|Controll arm|The sonographer manually holds the probe on the patient's thorax
16394749|NCT04016350|Experimental|Exercise Training with Inulin Propionate Ester|Study participants underwent 4 week supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation at doses of 10g / day.
16394750|NCT04016350|Experimental|Exercise Training with Placebo|Study participants underwent 4 week supervised moderate intensity exercise training combined with cellulose as placebo at doses of 10g / day.
16394751|NCT04016337|Experimental|Intervention with beverage added with sucralose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with sucralose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.
~Concentrations of lemon and maqui extract are under industrial secret. The sweetener sucralose was added within the ranges established by law as maximums.
~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.
~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
16394752|NCT04016337|Experimental|Intervention with beverage added with saccharose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with saccharose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.
~Concentrations of lemon and maqui extract are under industrial secret. The sweetener saccharose was added within the ranges established by law as maximums.
~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.
~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
16394753|NCT04016337|Experimental|Intervention with beverage added with stevia|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with stevia extract was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.
~Concentrations of lemon and maqui extract are under industrial secret. The sweetener stevia was added within the ranges established by law as maximums.
~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.
~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
16394754|NCT04016324|Other|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
16394755|NCT04016311|Experimental|Mindful Drinking/Eating Group|Behavioral: Mindful Drinking/Eating Intervention Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
16394756|NCT04016311|No Intervention|Wait list control|Usual care. Offered intervention after post-test data collected.
16394757|NCT04016285|Experimental|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
16394758|NCT04016285|Active Comparator|Standard of Care: Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
16394759|NCT04016272|Experimental|Active tDCS|
16394760|NCT04016272|Placebo Comparator|Sham tDCS|
16394761|NCT04016259|Experimental|Self-CES|
16394762|NCT04016259|Placebo Comparator|Sham-CES|
16394763|NCT04016246|Experimental|Propofol|"Propofol (Propofol LIPURO 1% 100mL), Pharmacologic form: 10mg/ml. Considering the birthweight of most preterm babies, Propofol will be diluted to a final concentration of 1mg/ml by the nurse.
~Treatment initiation: the 1st dose will be injected following usual management of LISA procedure included the installation of the newborn and the atropine and caffeine injections and sugar solution administration Dose per administration: 0.5mg/kg per dose of Propofol. Number of administrations: Several administrations of 0.5 mg/kg are possible, according the level of sedation achieved, as evaluated by the FANS score. If the FANS score is ≥6, a new dose will be injected up to a total of two (before 28 wGA) or 3 (between 28 - 31 wGA) administrations of the drug. (See paragraph 5.3)"
16394764|NCT04016246|Placebo Comparator|medialipide|"Name of treatment for placebo: Medialipide® (B. BRAUN) Pharmacological form: 20g/100ml Medialipide 20% will be used as the placebo. This is an emulsion of medium and long triglycerides based on soya oil and having same appearance organoleptic characteristics as Propofol.
~Dose per administration: Same volume as for the Propofol administration
~Number of administrations: according the same protocol that for the Propofol administration.
~Modalities of preparation : The same dilution procedure as Propofol lipuro 1% SPC (Summary of Product Characteristics):1 part of Medialipide 20% with 9 parts of 5% w/v glucose solution or 0.9% w/v sodium chloride solution as shown in parenteral nutrition which is in accordance with medialipide 20% SPC"
16394765|NCT04016233|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, each with 3 douches. Sequence A will be 3 sequential doses of TFV douche; Sequence B will be one dose of TFV douche followed by 2 sequential non-medicated douches; Sequence C will be 2 sequential non-medicated douches followed by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by various specimen collections over 8 days according to individual sampling schedule assigned to each participant. Specimens will be collected on Days 1, 2, 4, and 8 post sequence administration.
16394801|NCT04015947|Experimental|Active treatment|This is an open label, single-institution pilot study to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.
16394766|NCT04016220|Experimental|Budesonide group|The experimental group received a first nebulization of 5 mg of terbutaline(solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
16394767|NCT04016220|Placebo Comparator|normal saline|The control group received a nebulization of 2 ml normal saline at baseline, 20, 40, 60 and 120 min as placebo comparator in association with nebulized terbutaline . All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
16394768|NCT04016207||Guanfacin regular treatment|
16394769|NCT04016168||Patients with DILD|Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
16394770|NCT04016155|Active Comparator|SMBG|Patients use their own glucometers as control
16394771|NCT04016155|Experimental|Flash CGMS|
16394772|NCT04016142|Experimental|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients
~will be registered in the first part of the study at diagnosis and will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).
~will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage (no progression during Part 1 of the study and no medical contra-indication to the study treatment)."
16394773|NCT04016129|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
16394774|NCT04016116|Experimental|Pembrolizumab (Cohort 1)|Pembrolizumab IV every 3 weeks (Cohort 1: Advanced progressive MPNs)
16394775|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 1: Advanced progressive MPNs)
16394776|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib (Cohort 2)|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 2, unresponsive to PD-1)
16394777|NCT04016103|Experimental|MY01 Device|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
16394778|NCT04016090|Placebo Comparator|Placebo treatment|Participant will be asked to ingest a placebo capsule.
16394779|NCT04016090|Experimental|Folic Acid|Participant will be asked to ingest a capsule containing 5 mg of folic acid.
16394780|NCT04016077|Experimental|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
16394781|NCT04016077|Experimental|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
16394782|NCT04016077|Experimental|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.
~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
16394783|NCT04016064|Other|group 1;|Er:YAG laser
16394784|NCT04016064|Other|group 2|Nd:YAG laser
16394785|NCT04016064|Other|group 3|Electrosurgery
16394786|NCT04016051|Experimental|Clarithromycin DST|"Participants received oral administration of Clarithromycin DST twice a day:
~125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).
~187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).
~250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).
~For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw."
16394787|NCT04016051|Active Comparator|Clarithromycin Syrup|"Participants received oral administration of Clarithromycin Syrup twice a day:
~2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).
~3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).
~5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years)."
16394788|NCT04016038||QualiPas Observational|Prospective qualitative study through a participant observation procedure with 8 care teams practicing within Palliative Care Units, Palliative Care Mobile Team or Territorial Palliative Care Team.
16394789|NCT04016038||QualiPas clinical interview|Qualitative study retrospective research interviews with the doctor and another carer involved in the care of the patient, and close relatives of patients who had sedated before their death. The interviews will be based on 50 cases of patients who have been sedated.
16394790|NCT04016038||QualiPas Focus|Qualitative study by group focus group interviews with clinical teams participating in the project.
16394791|NCT04016025|Active Comparator|cream|Treatment with topical Methylprednisolone aceponate 0,1% cream (Advantan®) plus Basic care (Bepanthen® Sensiderm)
16394792|NCT04016025|Active Comparator|fatty ointment|Treatment with topical Methylprednisolone aceponate 0,1% fatty ointment (Advantan®) plus Basic care (Bepanthen® Sensiderm)
16394793|NCT04016012|Experimental|Intervention arm|Participants in the intervention group will receive local zambian foods and standard health care for eight (8) weeks.
16394794|NCT04016012|No Intervention|Control arm|The control group will have their usual (standard) diet in their home and receive standard health care for eight (8) weeks.
16394795|NCT04015999|Experimental|Intervention arm|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
16394796|NCT04015999|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
16394797|NCT04015986|Experimental|Intervention arm|MDCF-2 prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth).
16394802|NCT04015921||Inpatients|Patients admitted with various psychiatric disorders
16394803|NCT04015921||Age-matched control group|
16394804|NCT04015908|Experimental|multi-modal|"3 Different Non-opioid pain medication taken every 6 hours
~Celecoxib 100mg
~Acetaminophen 325mg
~Pregabalin 50 mg
~Plus, for breakthrough pain
~oxycodone 5-10 mg will be taken every 4 hours as needed for pain."
16394805|NCT04015908|Active Comparator|Control|7 day supply of Percocet (oxycodone 5mg/acetaminophen 325 mg) to be taken 1-2 by mouth every 4 hours as needed for pain.
16394806|NCT04015895||Patient with cancer|Patient with cancer will be included. They will have to answer at DEFCO tool.
16394807|NCT04015882|Active Comparator|exercise|the exercise group will applied virtual reality exercises by Nintendo Wii Fit Plus System Game Console.
16394808|NCT04015882|No Intervention|control|No exercise applied the control group.
16394809|NCT04015869|Active Comparator|allopregnanolone|allopregnanolone
16394810|NCT04015869|Placebo Comparator|placebo|placebo
16394811|NCT04015856|Experimental|Full TP intervention including emphasized social norms change|Participants in this study arm will receive the full TP intervention, including emphasized social norms change, for 18 months.
16394812|NCT04015856|Active Comparator|Light TP intervention without emphasized social norms change|Participants in this study arm will receive the light TP intervention, without emphasized social norms change, for 18 months
16394813|NCT04015856|No Intervention|Control|The control group will not have any study interventions.
16394814|NCT04015830|Experimental|Older Adults with HIV (N = 60)|African Americans and Whites age 50 and older
16394815|NCT04015817|Experimental|Etude longitudinale|Work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, support from the mobile palliative care team
16394816|NCT04015804|Experimental|Clinical database|
16394817|NCT04015791||Match Group|Surgery conducted at the disc level corresponding with the highest level of NOCISCORE value in the subject and that is classified as either NOCI + or NOCI mild
16394818|NCT04015791||Miss Group|Surgery conducted at a disc that: (a) corresponds with a low relative NOCISCORE value in the subject and that is classifies as NOCI - or (b) excludes the disc level with the highest NOCISCORE value in the subject and that is classifies as NOCI+ or NOCI mild
16394819|NCT04015778|Experimental|Nivolumab Mono|In arm A, 24 participants will be enrolled into this arm according to PD-L1 expressing level (≥50%).Arm A consists of 3 cycles of neoadjuvant nivolumab (240mg every 2 weeks), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
16394820|NCT04015778|Experimental|Nivolumab Plus Chemo|In arm B, up to 12 participants will be enrolled into each subgroup according to PD-L1 expressing level (<1% and 1%-49%).arm B consists of 3 cycles of neoadjuvant nivolumab (360mg every 3 weeks) with nab-paclitaxel and carboplatin(nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every three weeks ), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
16394821|NCT04015765|Experimental|Group treatment h-APC and EMR|Standard endoscopic mucosal resection (EMR) technique will be used for primary removal of all polyps. Submucosal injection will be used to lift the polyp from the muscularis propria. Injection is used as per the current standard of care using a contrast agent and a lifting agent (e.g. NaCl 0.9% or Voluven). Snare electrocautery resection will be facilitated until complete visible removal of the complete polyp. Electrocautery snare technique is facilitated using standard microprocessor controlled electrocautery (e.g. ERBE VIO Endocut 3-1-6). Ablation of the margin after visibly complete removal of the polyp is routinely applied. For thermal ablation hybrid APC (Erbe Hybrid APC) will be applied using standard settings on the margin and resection base. Once resection and thermal ablation is considered complete the mucosal defect can be closed with clips or another preventative measure applied to reduce the risk for post-polypectomy bleeding.
16394822|NCT04015752||diabetics|"Full history with special attention to:
~Causes of admission to ICU . Duration of DM when present, medication used, controlled or not.
~Complete physical examination with special attention to :
~Vital signs ( MAP, pulse, temp, RR). Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).
~Laboratory investigations includes :
~CBC , Liver and kidney functions → baseline and follow up. Arterial Blood Gases (ABG). Lactic acid level. HBA1C. ESR, CRP →baseline and follow up.
~Culture :
~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
16394823|NCT04015752||non diabetics|"Full history with special attention to:
~Causes of admission to ICU . Duration of DM when present medication used, controlled or not.
~Complete physical examination with special attention to :
~Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).
~Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.
~Culture :
~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
16394824|NCT04015752||patients devoloped hyperglycemia in ICU only|"Full history with special attention to:
~Causes of admission to ICU . Duration of DM when present medication used, controlled or not. 2. Complete physical examination with special attention to : Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, CVP,..). 3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.
~Culture :
~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
16394825|NCT04015739|Experimental|Bevacizumab, Olaparib and Durvalumab|Single arm study
16394826|NCT04015713||TB HIV-negative|"Patients will receive standard TB treatment and will be followed according to the national procedures.
~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.
~All participants will be followed 24 weeks."
16394827|NCT04015713||TB HIV-positive|"Patients will receive standard TB treatment and will be followed according to the national procedures.
~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.
~All participants will be followed 24 weeks."
16394856|NCT04015544|Experimental|Watermelon|Watermelon puree 710 mL per day for six weeks
16394857|NCT04015544|No Intervention|Control|No intervention
16394828|NCT04015700|Experimental|Vaccine (GNOS-PV01 + INO-9012)|"Standard radiation therapy will be administered per standard of care and is outside the scope of this study.
~GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2 for a total of 6 cycles or until intolerance or progression"
16394829|NCT04015687|Experimental|AG-881 (Group 1)|On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.
16394830|NCT04015687|Experimental|AG-881 (Group 2)|Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
16394831|NCT04015687|Experimental|AG-881 (Group 3)|Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
16394832|NCT04015674|Experimental|Exercise group|Patients will remain in supine position for 5 minutes to measure their vascular caliber of the AVF by echography. After, will be instructed to perform 30 minutes on stationary bicycle (Model Monark). The AVF vascular caliber will be measured during aerobic exercise. Because it is a cross-over trial, participants will perform the other arm after 7 days.
16394833|NCT04015674|Active Comparator|Control group|The patients will perform 30 minutes of rest in a chair and the measurements will be performed in the same moments established by the exercise group. Because it is a cross-over trial, participants will perform the other arm after 7 days.
16394834|NCT04015661|Experimental|Nab-paclitaxel+Nedaplatin|induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
16394835|NCT04015661|Active Comparator|Paclitaxel+Nedaplatin|induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
16394836|NCT04015648|Experimental|Group 1|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^9 vp vaccination intramuscularly.
16394837|NCT04015648|Experimental|Group 2|Volunteers will receive standalone dose of ChAdOx1 Zika 2.5 x 10^10 vp vaccination intramuscularly.
16394838|NCT04015648|Experimental|Group 3|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^10 vp vaccination intramuscularly.
16394839|NCT04015648|Experimental|Group 4|Volunteers will receive co-administration dose of ChAdOx1 Zika 5 x 10^9 vp vaccination and ChAdOx1 Chik 5 x 10^9 vp intramuscularly.
16394840|NCT04015648|Experimental|Group 5|Volunteers will receive co-administration dose of ChAdOx1 Zika 2.5 x 10^10 vp vaccination and ChAdOx1 Chik 2.5 x 10^10 vp intramuscularly.
16394841|NCT04015648|Experimental|Group 6|Volunteers will receive co-administration dose of ChAdOx1 Zika 5 x 10^10 vp vaccination and ChAdOx1 Chik 5 x 10^10 vp intramuscularly.
16394842|NCT04015635||Study group|"80 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.
~Clinical and laboratory assessment. NO intervention."
16394843|NCT04015635||Control|"80 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.
~Clinical and laboratory assessment. NO intervention."
16394844|NCT04015622|Experimental|A: Biomarker directed Therapy (BT)|ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
16394845|NCT04015622|Active Comparator|B: Clinician's Choice (CC)|Enzalutamide or docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
16394848|NCT04015596|Experimental|Intervention|Participants receive Naproxen Sodium.
16394849|NCT04015596|Placebo Comparator|Placebo|Participants receive placebo.
16394850|NCT04015583|Experimental|exergaming group|"The exergaming group (EXG) performed exercise using Exerheart® devices (D&J Humancare, Busan, South Korea) composed of a running/jumping mat [730(W) × 730(D) × 130(H)] and a tablet PC on a stand (can be adjusted to any height between 70 and 155 cm) (Supplemental Figure 1A). Exerheart® is an exergaming developed for in-situ running along with the video game called Alchemist's Treasure (D&J Humancare, Busan, South Korea). To play this game, the subject has to run or jump on a spot on the mat to move a virtual avatar on the screen of the tablet PC to the front, back, left, and right along with music. The subject can control the speed of avatar movement by running or jumping speed on the mat."
16394851|NCT04015583|Active Comparator|treadmill exercise group|The treadmill exercise group (TEG) performed exercise using commercial treadmills (MOTUS, Gyeonggi-do, South Korea). Each subject walked or ran on the treadmill at a comfortable speed.
16394852|NCT04015570|Experimental|High Volume Plasma Exchange with SMT|"PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity.
~Standard Medical Treatment (Albumin + High Caloric Diet)"
16394853|NCT04015570|Active Comparator|Standard Medical Treatment|Standard Medical Treatment (Albumin + High Caloric Diet)
16394854|NCT04015557|Experimental|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
16394855|NCT04015557|Experimental|Acetaminophen + N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
16415636|NCT03870282|Experimental|"9h 15m Goal | Incentives A&B | Texts A&B"|
16394858|NCT04015531|Active Comparator|Conventional radiotherapy|"50 Gy in 25 fractions to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla), followed by tumor bed boost of 10 Gy in 5 fractions in case of breast conserving surgery.
~Total time: 5-6 weeks."
16394859|NCT04015531|Experimental|Hypofractionated radiotherapy|"40 Gy in 15 fractions (2.67 Gy each) to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla).
~Patients undergoing breast conserving surgery will receive concomitant boost with total dose of 48 Gy in 15 fractions (3.20 Gy each) to tumor bed.
~Total time: 3 weeks."
16394860|NCT04015518|Experimental|Dose group 1|
16394861|NCT04015518|Experimental|Dose group 2|
16394862|NCT04015518|Experimental|Dose group 3|
16394863|NCT04015518|Experimental|Dose group 4|
16394864|NCT04015518|Placebo Comparator|Placebo only|
16394865|NCT04015505|Experimental|Intervention|Participants will receive 5 sessions of a psychological (talking therapy) intervention based on the wisdom enhancement 'timeline technique' within cognitive behavioural therapy for older adults.
16394866|NCT04015492|Experimental|BAY94-9027 / Adynovi|Treatment sequence A-B with washout before each treatment
16394867|NCT04015492|Experimental|Adynovi / BAY94-9027|Treatment sequence B-A with washout before each treatment
16394868|NCT04015479|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
16394869|NCT04015479|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
16394870|NCT04015466||Cases|Patients with high diagnostic suspicion of advanced GC diagnosis
16394871|NCT04015466||Control|Patients with confirmed absent of GC
16394872|NCT04015440|Experimental|HBMT|
16394873|NCT04015440|Placebo Comparator|Placebo|
16394874|NCT04015427|Active Comparator|screw-retained|Patients in group A will receive a screw-retained implant crown. Following this first period of 16 weeks, the screw-retained implant crown will be replaced by a new intraorally cemented implant crown. Cement removal will be preformed according to best clinical procedure. These implant crowns will again be left for another period of 16 weeks and followed up for the harvesting of microbiological samples every 8 weeks. After the second 16-week the implant crowns will be removed to evaluate any excess cement. All patients will be fitted with the original screw-retained implant crown. Clinical parameters for inflammation and probing depths will be obtained after each 16 week-period.
16394875|NCT04015427|Active Comparator|cement-retained|In group B the implant crowns will be incorporated in a reverse pattern. During the first 16 weeks a cemented implant crown will be inserted and any possible cement residues will be removed according to best clinical procedure, while for the second period of 16 weeks patients will be fitted with a screw-retained single implant crown. Again, microbiological and clinical parameters will be obtained at the same intervals as in Group A.
16394876|NCT04015414|Active Comparator|Varenicline (Champix)|Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
16394877|NCT04015414|Active Comparator|Cytisine (Tabex)|Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
16394878|NCT04015388||Diabetes Mellitus / Hyperglycemia|iPro Continuous Glucose Monitoring on subjects with blood sugar value >140 mg/dL upon admission to the intensive care unit or who have been diagnosed with type 1 or type 2 diabetes or have glycosylated hemoglobin A1C (HbA1C) values > 6.5% prior to admission.
16394879|NCT04015375|Experimental|Dapsone gel, 7.5% (Torrent Pharmaceuticals Ltd.)|Topical, once daily for 84 days
16394880|NCT04015375|Active Comparator|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical, once daily for 84 days
16394881|NCT04015375|Placebo Comparator|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical, once daily for 84 days
16394882|NCT04015362|Experimental|Pulsed magnetic stimulation of the spinal cord|Sub-threshold intermittent pulsed magnetic stimulation of spinal cord
16394883|NCT04015362|Sham Comparator|Sham magnetic stimulation|Sham - patient and machinery placed in same position as intervention arm but no magnetic stimulation delivered
16394884|NCT04015336|Experimental|Arm 1|Up to 3x1010 E7 TCR T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
16394885|NCT04015323|Experimental|IFC Therapy 2 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 2 kHz
16394886|NCT04015323|Experimental|IFC Therapy 4 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 4 kHz
16394887|NCT04015323|Experimental|IFC Therapy 8 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 8 kHz
16394888|NCT04015310||PSC patients attending outpatient|Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
16394889|NCT04015297|Experimental|control|healthy controls
16394890|NCT04015297|Experimental|patient|patients diagnosed with endometriosis
16394891|NCT04015284|Experimental|SSNB + PCB|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL ropivacaine 0.5%, then single shot US-guided posterior cord block (PCB) with 10 ml ropivacaine 0.5%.
16394892|NCT04015284|Active Comparator|ISBPB|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL ropivacaine 0.5%.
16395042|NCT04014361|Experimental|LY3154885 + Itraconazole - Part B|LY3154885 administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. LY3154885 co-administered with itraconazole, orally, once.
16394893|NCT04015271|Experimental|Action Observation + Repetitive Task Practice|Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
16394894|NCT04015271|Placebo Comparator|Placebo Video + Repetitive Task Practice|The control placebo videos (PV) will be 6 minutes, and will include a series of changing static images without animals, human beings, or sound (i.e. pictures of buildings, trees, cruise ships, mountains, beach umbrellas, beds, and tables). A Repetitive Task Practice (RTP) therapy regimen will be completed immediately after observing the PV, which emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task. These tasks include putting on a shirt, picking up a sandwich and bringing it to mouth, eating food with a spoon, or cutting meat with knife and fork. The PV + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
16394895|NCT04015258|Experimental|Blueberries|Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day
16394896|NCT04015258|Experimental|Blueberry powder|Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries
16394897|NCT04015258|Placebo Comparator|Blueberry components capsules|Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption
16394898|NCT04015245|Experimental|SNMC|
16394899|NCT04015245|No Intervention|non-SNMC|
16394900|NCT04015232|Experimental|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
16394901|NCT04015232|Active Comparator|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
16394902|NCT04015219|Experimental|Treatment Arm|PROKERA SLIM + Standard of Care
16394903|NCT04015219|Active Comparator|Control Arm|Standard of Care
16394904|NCT04015206|Experimental|IPT-G+UCT|10 sessions of Group Interpersonal therapy added to pharmacotherapy + clinical management plus one individual session pre-group and one session pos-group
16394905|NCT04015206|Active Comparator|Usual treatment (UCT)|Pharmacotherapy + Clinical management once a month
16394906|NCT04015193||Full responders|Full responders: no signs or symptoms of Raynaud's phenomenon (RP) in Raynaud condition score, no RP during cooling-recovery experiment.
16394907|NCT04015193||Partial responders|Partial responders: at least 25% reduction in Raynaud condition score and finger ischemia time during cooling and recovery.
16394908|NCT04015193||Non-responders|Non-responders: no or less than 25% reduction in Raynaud condition score and/or finger ischemia time during cooling and recovery.
16394909|NCT04015180|Experimental|Aflibercept arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
16394910|NCT04015180|Active Comparator|Laser photocoagulation arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
16394911|NCT04015167||T2 Alpha Tibia|Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.
16394912|NCT04015154||T2 Alpha Femoral Nail PF|Subjects in the clinical investigation will undergo placement of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the piriformis fossa, according to the Instructions for Use and Operative Technique Manual
16394913|NCT04015141|Experimental|Perampanel|Participants age 1 month to less than 18 years with pediatric epileptic syndrome (Cohort 1) or age 1 month to less than 2 years with POS with or without secondary generalization (Cohort 2) will receive perampanel oral suspension or perampanel tablets, once daily up to 56 weeks.
16394914|NCT04015128||T2 Alpha Femoral Nail GT|Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.
16394915|NCT04015115|Experimental|Youth Opioid Recovery Support service model|The components of the Youth Opioid Recovery Support service model includes 1) home-delivery of standard-of-care medication and individual/family counseling services; 2) assertive outreach efforts by the treatment team; and 3) contingency management incentives upon receipt of medication treatment.
16394916|NCT04015089|Experimental|Partially hydrolyzed formula (pHF)|Infants fed exclusively with a infant formula based on partially hydrolyzed serum cow's milk proteins.
16394917|NCT04015089|Active Comparator|Standard formula (SF)|Infants fed exclusively with a standard formula based on intact cow's milk proteins
16394918|NCT04015076|Experimental|Single Ascending Dose|Inzomelid or Placebo
16394919|NCT04015076|Experimental|Multiple Ascending Dose|Inzomelid or Placebo
16394920|NCT04015076|Experimental|Patients with CAPS|Inzomelid Open Label
16394921|NCT04015063|Other|Primary Subjects|Women subjects 40-65 years of age that meet the specified inclusion/exclusion criteria taking P29429-01 as a skin care product per the protocol.
16394922|NCT04015050|Experimental|Test product|Cow's milk based infant formula containing prebiotics and postbiotics
16394923|NCT04015050|Active Comparator|Control product|Cow's milk based infant formula without prebiotics and postbiotics
16394924|NCT04015037|Experimental|Group A|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
16394925|NCT04015037|Experimental|Group B|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
16394926|NCT04015024|Experimental|SKLB1028 150mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs.
16394927|NCT04015024|Experimental|SKLB1028 200mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
16394928|NCT04015024|Experimental|SKLB1028 300mg qd|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
16394929|NCT04015011|Experimental|Low Calorie Diet (LCD) diet intervention|In person or video conference
16394930|NCT04014998|Experimental|Virtual Reality|Virtual Reality + Exercise
16394931|NCT04014998|Other|Exercise|Exercise Only
16394932|NCT04014985|Other|Girls with RETT syndrome|100 girls over 18 years old with RETT syndrome
16394933|NCT04014972||Patients with Myocardial Infarction|
16394934|NCT04014959|Experimental|All Participants|All participants follow the same procedures.
16394935|NCT04014946|Other|ICD implantation|Implantation of a Lumax 540 single/dual chamber ICD or successor according to local practice within 3 months after enrolment. The patient will be implanted with a single or dual chamber device according to ESC guidelines.
16394936|NCT04014933||open-angle glaucoma|patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP >21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
16394937|NCT04014933||normal tension glaucoma|patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP </=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
16394938|NCT04014933||healthy controls|individuals with normal optic disc and IOP </21mmHg and normal visual fields
16394939|NCT04014920|Active Comparator|Oxygen Group|Patient will receive standard oxygenotherapy
16394940|NCT04014920|Experimental|NIV Group|Patient will receive non invasive ventilation
16394941|NCT04014894|Experimental|ET019003-T Cells|The trial will enroll 9 patients with leukemia and 9 patients with lymphoma. Each disease has 3 dose-levels.
16394942|NCT04014881|Experimental|CD123+ Acute Myeloid Leukemia|Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial. Each dose group has 3 patients and the the maximum dose can be extended.
16394943|NCT04014868|Experimental|Nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with active nasal high-flow :
~Flow : 30 L/min; Temperature : 34°C;
~The device will be out of sight of the patient. The device allow for oxygen supplementation (fitting on the back of the device). Usual oxygen prescription (if any) will be adjusted to reach a transcutaneous oxygen saturation superior to 90%. A second fitting will be placed just before the nasal canula to allow for oxygen supplementation during the sham nasal high-flow (device turned OFF) test.
~Due to the cross-over design of the study, all patients will perform both interventions."
16394944|NCT04014868|Sham Comparator|Sham nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with a sham nasal high-flow :
~The procedure will be exactly the same but the device (out of sight of the patient) will be turned OFF. Oxygen supplementation will be possible through the fitting placed just before the nasal canula.
~Due to the cross-over design of the study, all patients will perform both interventions."
16394945|NCT04014855|Active Comparator|obese children 1|iron supplementation
16394946|NCT04014855|Active Comparator|obese children 2|lactoferrin supplementation
16394947|NCT04014842|Other|RapidShock|
16394948|NCT04014829||Control|Preoperative assessment with questionnaires, Mechanical Temporal Summation, and Pain-Pressure Threshold. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 4 and 6 months.
16394949|NCT04014829||Chronic Post-Hysterectomy Pain (CPHP)|Preoperative assessment with questionnaires, Mechanical Temporal Summation, and Pain-Pressure Threshold. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 4 and 6 months.
16394950|NCT04014816||Group I|Patients who had GI dysfunction (Group I) for one or more occasions.
16394951|NCT04014816||Group II|Patients who had normal GI function (Group II) for one or more occasions.
16394952|NCT04014803|Active Comparator|Prasugrel plus Aspirin arm|"Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily* will be given for one year.
~* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement."
16394953|NCT04014803|Active Comparator|Clopidogrel plus Aspirin arm|Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.
16394954|NCT04014790|Experimental|RGI-2001|Subjects will be administered RGI 2001 in combination with standard of care treatment
16394955|NCT04014777|Experimental|NGM621 Cohort 1 Single Ascending Dose|NGM621 single IVT injection Cohort-Dose 1
16394956|NCT04014777|Experimental|NGM621 Cohort 2 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 2
16394957|NCT04014777|Experimental|NGM621 Cohort 3 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 3
16394958|NCT04014777|Experimental|NGM621 Cohort 4 Multiple Dose|NGM621 multiple IVT injection Cohort--Dose 4
16394959|NCT04014764||Single group|"Documented hematologic malignancy in need of starting an active anti-cancer therapy.
~This is a non-interventional study."
16415637|NCT03870282|Experimental|Personal Goal|
16394960|NCT04014751||Symptom Monitoring Cohort|This cohort will include up to1,050 cancer patients being seen at regional Northwestern Medicine (NM) cancer centers for their cancer care. Patients who have recently completed an on-line, EHR-integrated patient-reported symptom and needs assessment as part of their regular care will be invited to complete a survey at baseline, 6- and 12-months targeting the assessment of their symptoms, healthcare experiences and utilization. Patients may also be invited to participate in a one-time interview or focus group designed to help study investigators better understand the value of the symptom and needs assessment from the patient perspective.
16394961|NCT04014725|Experimental|Eligible patients for AI test|
16394962|NCT04014712|Experimental|acute BH4/Tetrahydrobiopterin treatment|Oral supplement, Pill, 10 mg/kg of body weight
16394963|NCT04014712|Placebo Comparator|Placebo|Oral supplement, Pill, Placebo pill with inert excipient
16394964|NCT04014699|Experimental|modified 2.2mm micoincision|
16394965|NCT04014699|Active Comparator|conventional 2.2mm microincision|
16394966|NCT04014686|Sham Comparator|Control group|No exercise intervention
16394967|NCT04014686|Experimental|Exercise intervention group|Exercise intervention group (resistance band exercise training for 12 weeks, 3x per week, for 60 minutes per day).
16394968|NCT04014673|Other|Patients with a PGRN gene mutation|Symptomatic patients with a PGRN gene mutation
16394969|NCT04014673|Other|Presymptomatic individuals|Asymptomatic 'At-risk' individuals with a PGRN gene mutation
16394970|NCT04014673|Other|healthy volunteers|'At-risk' individuals without a PGRN gene mutation
16394971|NCT04014660|Active Comparator|Probiotic group|The participants in this group are provided with a dietary supplement (capsules) containing freeze dried bacteria (active lactobacilli culture) mixed with corn starch, for daily intake (1 capsule per day).
16394972|NCT04014660|Placebo Comparator|Placebo group|The participants in this group are provided with a dietary supplement (capsules) containing corn starch only, for daily intake (1 capsule per day).
16394973|NCT04014647||Event-free|Patients who have had no negative events (as described in group 2)
16394974|NCT04014647||Negative event|"Group 2 - patients with one or more of the following negative events post-operatively:
~Whether the patient has been prescribed inotropic support
~Wound infection by assessing use of antibiotics.
~Length of stay in hospital >1 week
~Reduced renal function assessed by having any AKI alert during hospital stay
~Cardiac event within 31 days following surgery
~Death within 31 days following surgery"
16394975|NCT04014634|Placebo Comparator|Placebo|Injection of NaCl
16394976|NCT04014634|Experimental|Verum|
16394977|NCT04014621|Active Comparator|Treated|Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
16394978|NCT04014621|Sham Comparator|Control|Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
16394979|NCT04014608||Baseline Control|Standard Practice before the intervention was introduced
16394980|NCT04014608||Intervention initiative|Standard Practice plus Admission Surveillance for toxigenic C. difficile.
16394981|NCT04014595||Rotational atherectomy + Cutting Balloon|Rotational atherectomy in combination with cutting balloon in severely calcified coronary lesions
16394982|NCT04014582|Experimental|Communal Coping Intervention|This group will participate in diabetes education + a communal coping based intervention.
16394983|NCT04014582|Active Comparator|Control|This group will participate in diabetes education and an individual intervention.
16394984|NCT04014569|Experimental|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA algorithm
16394985|NCT04014556|Active Comparator|Aflibercept plus micropulse laser (group A)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
16394986|NCT04014556|Active Comparator|Aflibercept monotherapy (group B)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
16394987|NCT04014543|Experimental|Gastrostomy|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.
~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
16394988|NCT04014530|Experimental|Phase I dMMR and pMMR|2-4 groups of 3 patients treatment with 200mg i.v. Pembrolizumab q3w and dose escalation of Ataluren in order to determine the Ataluren MTD. These patients can either be pMMR/dMMR CRC and dMMR EC patients.
16394989|NCT04014530|Experimental|Phase II dMMR|Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
16394990|NCT04014530|Experimental|Phase II pMMR|Mismatch repair proficient CRC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
16394991|NCT04014517|Active Comparator|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
16394992|NCT04014517|Experimental|Immunonutrition|Impact
16394993|NCT04014504||study group|The results of the hearing screening test of the beats of the patients who have undergone pethidine in the active phase of labor will be examined. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at.
16394994|NCT04014504||control group|In the active phase of labor, hearing screening test results of beats of pediatric patients will be evaluated. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at. control group.
16394995|NCT04014491|Experimental|Scapula control exercise|Subjects will perform three exercises with EMG biofeedback and verbal cues. Three exercises are elevation in scapular plane, sidelying external rotation and dynamic hug plus
16394996|NCT04014491|Experimental|Scapula strengthening exercise|The subjects in the scapular strengthening group will be asked to perform the three exercises the same as scapula control exercise group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
16394997|NCT04014491|Other|Healthy subject group|Healthy subjects will be included to compare the differences in corticospinal system between healthy subjects and subjects with shoulder impingement syndrome, so this group will not receive any treatment.
16394998|NCT04014478|Experimental|Endovascular Denervation|
16394999|NCT04014465||patients with radiotherapy|The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
16395000|NCT04014452|Experimental|Microwave ablation group|Microwave ablation is used for the treatment of Complicated Monochorionic Pregnancies
16395001|NCT04014452|Active Comparator|Radiofrequency ablation group|Radiofrequency ablation is used for the treatment of Complicated Monochorionic Pregnancies
16395002|NCT04014439||Normal Diaphragm|Diaphragm thickness is 2 mm or more
16395003|NCT04014439||Thinning Diaphragm|Diaphragm thickness is less than 2 mm
16395004|NCT04014426|Other|Exposed|Healthcare workers participating at two PIPAC
16395005|NCT04014426|Other|Non-exposed|Healthy volunteers unexposed to chemotherapy
16395006|NCT04014413|Experimental|Crohn's disease|Fecal Microbiota Transplant will be performed.
16395007|NCT04014413|Experimental|Ulcerative colitis|Fecal Microbiota Transplant will be performed.
16395008|NCT04014413|Experimental|Celiac disease|Fecal Microbiota Transplant will be performed.
16395009|NCT04014413|Experimental|Irritable bowel syndrome|Fecal Microbiota Transplant will be performed.
16395010|NCT04014413|Experimental|Functional dyspepsia|Fecal Microbiota Transplant will be performed.
16395011|NCT04014413|Experimental|Constipation|Fecal Microbiota Transplant will be performed.
16395012|NCT04014413|Experimental|Metabolic disease (diabetes mellitus or obesity)|Fecal Microbiota Transplant will be performed.
16395013|NCT04014413|Experimental|Multidrug-resistant infection|Fecal Microbiota Transplant will be performed.
16395014|NCT04014413|Experimental|Hepatic encephalopathy|Fecal Microbiota Transplant will be performed.
16395015|NCT04014413|Experimental|Multiple sclerosis|Fecal Microbiota Transplant will be performed.
16395016|NCT04014413|Experimental|Pseudo-obstruction|Fecal Microbiota Transplant will be performed.
16395017|NCT04014413|Experimental|CRE infection|Fecal Microbiota Transplant will be performed.
16395018|NCT04014413|Experimental|VRE infection|Fecal Microbiota Transplant will be performed.
16395019|NCT04014413|Experimental|Multiple organ dysfunction|Fecal Microbiota Transplant will be performed.
16395020|NCT04014413|Experimental|Dysbiotic bowel syndrome|Fecal Microbiota Transplant will be performed.
16395021|NCT04014413|Experimental|MRSA enteritis|Fecal Microbiota Transplant will be performed.
16395022|NCT04014413|Experimental|Pseudomembranous enteritis|Fecal Microbiota Transplant will be performed.
16395023|NCT04014413|Experimental|Alopecia|Fecal Microbiota Transplant will be performed.
16395024|NCT04014413|Experimental|Autism|Fecal Microbiota Transplant will be performed.
16395025|NCT04014413|Experimental|Graft-versus-host disease|Fecal Microbiota Transplant will be performed.
16395026|NCT04014413|Experimental|Idiopathic thrombocytopenic purpura|Fecal Microbiota Transplant will be performed.
16395027|NCT04014413|Experimental|Atopy or allergy|Fecal Microbiota Transplant will be performed.
16395028|NCT04014413|Experimental|Liver disease|Fecal Microbiota Transplant will be performed.
16395029|NCT04014413|Experimental|Alcohol dependence|Fecal Microbiota Transplant will be performed.
16395030|NCT04014413|Experimental|Antibiotic-associated diarrhea|Fecal Microbiota Transplant will be performed.
16395031|NCT04014400|Experimental|Suprathel|Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
16395032|NCT04014400|Active Comparator|Xeroform|After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.
16395033|NCT04014387|Active Comparator|Zolpidem Arm|Participants will be given one week of Zolpidem.
16395034|NCT04014387|Active Comparator|Suvorexant Arm|Participants will be given one week of Suvorexant.
16395035|NCT04014387|Placebo Comparator|Placebo Arm|Participants will be given one week of a placebo pill.
16395036|NCT04014374||Transplant Arm|Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT
16395037|NCT04014374||Control Arm|Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT
16395038|NCT04014361|Experimental|LY3154885 - Part A|LY3154885 administered orally in two of three study periods.
16395039|NCT04014361|Placebo Comparator|Placebo - Part A|Placebo administered orally in one of three study periods.
16395040|NCT04014361|Experimental|LY3154885 - Part B|LY3154885 administered orally alone.
16395041|NCT04014361|Placebo Comparator|Placebo - Part B|Placebo administered orally alone.
16395119|NCT04013854|Active Comparator|Arm A: Adjuvant Nivolumab (Complete Pathological Response)|480 mg IV for up to one year
16395043|NCT04014361|Placebo Comparator|Placebo + Itraconazole - Part B|Placebo administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. Placebo co-administered with itraconazole, orally, once.
16395044|NCT04014361|Experimental|LY3154885 - Part C|LY3154885 administered orally on consecutive days.
16395045|NCT04014361|Placebo Comparator|Placebo - Part C|Placebo administered orally on consecutive days.
16395046|NCT04014361|Experimental|LY3154885 - Part D|LY3154885 administered orally once in each of three study periods.
16395048|NCT04014335|Experimental|IONIS-FB-LRx|
16395049|NCT04014322|Experimental|E-cigarette|All participants will be instructed to switch completely from combustible cigarettes to e-cigarettes for the next 8weeks. They will be assessed at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.
16395050|NCT04014309|Experimental|Supportive and survivorship care program|Routine distress screening will be conducted using the Distress Thermometer (DT) and an accompanying problem list. Participants will complete the screening tool before their consults with oncologists and the results will be stored in their medical records. During the consult, oncologists will review the DT scores and problem list with each participant to provide the corresponding educational materials, advice or referrals. Highly distressed participants may be referred by oncologists to the supportive care nurses (SCN) for further triage and review.
16395051|NCT04014309|Placebo Comparator|Usual care|No routine distress screening will be performed.
16395052|NCT04014296|Experimental|High Protein Diet|Enrollment in State of Slim (SOS) weight loss program with a high protein diet.
16395053|NCT04014296|Experimental|Resistance Training|Enrollment in State of Slim (SOS) weight loss program with resistance training counseling sessions.
16395054|NCT04014283|Active Comparator|BRCA(+) Selenium deficiency|Placebo: 100 Supplement: 100
16395055|NCT04014283|Active Comparator|BRCA(+) Selenium excess|Diet modification: 500 Observation: 500
16395056|NCT04014283|Active Comparator|BRCA(-) Selenium deficiency|Placebo: 900 Supplement: 900 Diet modification: 900 Observation: 900
16395057|NCT04014283|Active Comparator|BRCA(-) Selenium excess|Diet modification: 1100 Observation: 1100
16395058|NCT04014283|Active Comparator|BRCA(+) Selenium excess, age > 50|Diet modification: 200 Observation: 200
16395059|NCT04014270|Experimental|Self modulated functional electrical stimulation (SM-FES)|Patients will receive self-modulated functional electrical stimulation SM-FES
16395060|NCT04014270|Active Comparator|Standard care (SC)|Patients will receive standard care, dose matched to the experimental group therapy
16395061|NCT04014257|Experimental|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
16395062|NCT04014244|Experimental|Corticosteroids vs. Dextrose|In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance.
16395063|NCT04014244|Experimental|Corticosteroids or Dextrose vs. Surgery|In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. Surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
16395064|NCT04014231||Observational (single wave assessment)|Patients undergo placement of a single wave application near the carotid region of the neck.
16395065|NCT04014218|Experimental|Inhalation sedation|
16395066|NCT04014218|Active Comparator|Propofol|
16395069|NCT04014192|Experimental|Dapagliflozin Group|10mg/d for one week
16395070|NCT04014192|Experimental|Empagliflozin Group|10mg/d for one week
16395071|NCT04014192|Experimental|Canagliflozin Group|100mg/d for one week
16395072|NCT04014192|No Intervention|Normal Glucose Tolerance Group|
16395073|NCT04014179|Experimental|Immediate Intervention (Dried Blood Spot)|Blood samples will be tested for HCV RNA from dried blood spot cards.
16395074|NCT04014179|Experimental|Immediate intervention (Point-of-care testing)|Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.
16395075|NCT04014179|Active Comparator|Delayed intervention (Dried Blood Spot)|There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing from dried blood spots.
16395076|NCT04014179|Active Comparator|Delayed intervention (Point-of-care testing)|There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing using the point-of-care assay.
16395077|NCT04014166|Experimental|15 refractory ITP patients|15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose.
16395078|NCT04014153||Group 1 (5-year prognosis)|
16395079|NCT04014153||Group 2 (1-year prognosis)|
16395080|NCT04014140||Patients with multi-vessel coronary artery disease (MVCAD)|iFR measurements will be taken pre-operatively during the invasive coronary angiography.
16395081|NCT04014127||Controls|25 controls with preserved renal function
16395082|NCT04014127||Kidney Donors|25 living kidney donors who have donated a kidney at least 12 months prior to enrollment in the study.
16395083|NCT04014127||Pre-dialysis|25 patients with pre-dialysis chronic kidney disease stage 5
16395084|NCT04014127||Peritoneal dialysis|25 patients with chronic kidney disease stage 5 undergoing peritoneal dialysis
16395120|NCT04013854|Active Comparator|Arm B: Adjuvant Nivolumab (Less than Complete Response)|480 mg IV for up to one year
16395121|NCT04013854|Experimental|Arm C: Adjuvant Combination (Less than Complete Response)|ipilimumab (1mg/kg) plus nivolumab (3mg/kg) for 4 doses and then nivolumab (480 mg) alone for a total of one year
16395085|NCT04014101|Experimental|SHR-1210+ apatinib|SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
16395086|NCT04014088|Active Comparator|helmet CPAP|helmet CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
16395087|NCT04014088|Active Comparator|facemask CPAP|facemask CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
16395088|NCT04014075|Experimental|All participants|Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer will be treated with trastuzumab deruxtecan by intravenous (IV) infusion every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.
16395089|NCT04014062|Experimental|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
16395090|NCT04014062|Active Comparator|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
16395091|NCT04014036|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
16395092|NCT04014036|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
16395093|NCT04014023|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
16395094|NCT04014023|Experimental|DWP16001 Bmg|DWP16001 Bmg, Tablets, Orally, Once daily
16395095|NCT04014023|Experimental|DWP16001 Cmg|DWP16001 Cmg, Tablets, Orally, Once daily
16395096|NCT04014023|Placebo Comparator|Placebo|Placebo, Tablets, Orally, Once daily
16395097|NCT04014010||Cohort|Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
16395098|NCT04013997|Experimental|Exoskeletal-assisted walking training group|Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study.
16395099|NCT04013997|No Intervention|Matched control group|"Twenty inpatients with SCI were identified as the matched control group through reviewing an acute inpatient rehabilitation database of Uniform Data System for Medical Rehabilitation by a person blinded to the study.
~The control group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. The control groups received the same amount of acute rehabilitation time per week as the intervention group."
16395100|NCT04013984|Experimental|Accupuncture|"Acupuncture twice a week during the preceding cycle and the ovarian stimulation by GnRH agonist stopped protocol."
16395101|NCT04013984|No Intervention|Non-accupuncture|"Ovarian stimulation by GnRH agonist stopped protocol without intervention."
16395102|NCT04013971|Other|Game without AR, Game with AR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without AR, game with AR, traditional interface
16395103|NCT04013971|Other|Game without AR, Traditional Interface, Game with AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without AR, traditional interface, game with AR
16395104|NCT04013971|Other|Game with AR, Game without AR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with AR, game without AR, traditional interface
16395105|NCT04013971|Other|Game with AR, Traditional Interface, Game without AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with AR, traditional interface, game without AR
16395106|NCT04013971|Other|Traditional Interface, Game without AR, Game with AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game without AR, game with AR
16395107|NCT04013971|Other|Traditional Interface, Game with AR, Game without AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game with AR, game without AR
16395108|NCT04013958|Active Comparator|IV Ketamine|IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
16395109|NCT04013958|Experimental|IM Ketamine|IM Ketamine group will receive IM Ketamine with IV morphine.
16395110|NCT04013945|Active Comparator|Superba Boost capsules|1000 mg krill oil concentrate per capsule
16395111|NCT04013945|Placebo Comparator|Placebo capsules|1000 mg capsule composed of mixed vegetable oil.
16395112|NCT04013932|Experimental|KUPAA Intervention + Standard of Care|Patient/caregiver dyads will be assigned to a KUPAA group composed of approximately 6 patients and 6 matched caregivers. The dyads will first participate in 1-2 joining sessions with a provider, followed by a 1-day group educational workshop. Participants will then attend weekly family psychoeducation group sessions (~1.5-2 hours) for 12 weeks.
16395113|NCT04013932|No Intervention|Control - Standard of Care|Patients will receive the standard of care.
16395114|NCT04013919||Type 1 Diabetes|
16395115|NCT04013919||Type 2 Diabetes|
16395116|NCT04013906|Experimental|Rotational atherectomy|Patients will undergo rotational atherectomy
16395117|NCT04013906|Experimental|Intravascular lithotripsy|Patients will undergo intravascular lithotripsy
16395118|NCT04013880|Experimental|Treatment (ASTX727, FT-2102)|Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16395128|NCT04013802|Experimental|HLA-matched VSTs|"Partially HLA-matched VSTs will be thawed and given by intravenous injection. Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused with agreement of the principal investigator, patient and/or guardian and the treatment team
~Additional doses may be from the same donor or a different donor based on available cell lines and patient/disease factors. Decision to switch to a different donor can be made by the principal investigator based on factors that include sequential treatment of different viral infections, concerns for immune escape of the targeted virus and/or availability of a better matched or otherwise superior VST line. Additional treatments will only be given following the agreement of the patient, treating physician, and investigator. This process can be repeated as needed."
16395129|NCT04013789|Other|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
16395130|NCT04013789|Other|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
16395131|NCT04013776|Active Comparator|Phosphate supplemented diet|All participants will undergo phosphate testing after following a phosphate supplemented diet for 5 days
16395132|NCT04013776|No Intervention|Low phosphate diet|All participants will undergo phosphate testing after following a low phosphate diet for 5 days
16395133|NCT04013763|Experimental|Atopic dermatitis with stop using product|case wheat allergy with atopic dermatitis and stop using wheat containing skin care products
16395134|NCT04013763|Experimental|Atopic dermatitis with containing using product|case wheat allergy with atopic dermatitis and continue using wheat containing skin care products
16395135|NCT04013763|Experimental|Non atopic dermatitis with stop using product|case wheat allergy with normal skin and stop using wheat containing skin care products
16395136|NCT04013763|Experimental|Non atopic dermatitis with continue using product|case wheat allergy with normal skin and continue using wheat containing skin care products
16395137|NCT04013763|No Intervention|Atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis
16395138|NCT04013763|No Intervention|Non atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis
16395139|NCT04013750|Experimental|left hemiplegia|Patients in the left hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
16395140|NCT04013750|Experimental|right hemiplegia|Patients in the right hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
16395141|NCT04013750|No Intervention|control|10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme.
16395142|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Prospective evaluation of a co-designed intervention to support enhanced knowledge and understanding of infections and their management.
16395143|NCT04013737||Prescribers|Quantitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
16395144|NCT04013724|Experimental|Intervention group|"The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' Supporting Smoking Cessation Guide for Health Professionals17 and the World Health Organization's Strengthening Health Systems for Treating Tobacco Dependence in Primary Care training package.18
~The topics that were explored during the group sessions include:
~Introduction to the Program and Reasons to Quit
~Benefits of Quitting and Understanding Why We Smoke and Ways of Quitting
~Withdrawal Symptoms and Social Support
~Dealing with Stress and Anxiety and Coping with Depression
~Assertiveness Training and Anger Management
~Tobacco-Free Lifestyle and Dealing with High Risk Situations"
16395145|NCT04013724|No Intervention|Control|The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT.
16395146|NCT04013711|Experimental|Thermal Imaging|Patients will undergo non-invasive, thermal imaging of their whole breast or head and neck cancer site, during the course of the radiotherapy treatment, at weekly time intervals.
16395147|NCT04013698|Experimental|PEEP level 5 cmH2O to 15 cmH2O|
16395148|NCT04013698|Experimental|PEEP level 15 cmH2O to 5 cmH2O|
16395149|NCT04013685|Experimental|Subjects with Acute Leukemia or Myelodysplasic Syndrome|"This is a non-randomized, single-arm study. Patients will be grouped based on their underlying disease:
~Group 1 will enroll subjects planning to undergo myeloablative allogeneic hematopoietic cell transplantation (MA-alloHCT) for the treatment of either acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi), and with no known minimal residual disease positivity.
~Group 2 will enroll subjects Subjects planning to undergo MA-alloHCT for acute myeloid, lymphoid or mixed phenotype leukemia that is either:
~not in morphologic CR with bone marrow infiltration by leukemic blasts of <= 10%, or
~in morphologic CR with evidence of minimal residual positivity by either multiparameter flow cytometric analysis or by a nucleic acid-based technique.
~Group 3 will enroll subjects planning to MA-alloHCT for high or very high risk myelodysplasic syndrome (MDS) myelodysplastic syndromes."
16395150|NCT04013672|Experimental|Arm A - Have not received immunotherapy|Arm A is patients with first recurrence of glioblastoma who have failed prior chemotherapy and radiation but have not received any immunotherapy.
16395151|NCT04013672|Experimental|Arm B - Have failed prior anti-PD1 therapy|Arm B is an exploratory arm of 10 patients who have failed prior anti-PD1 therapy.
16395225|NCT04013191|Experimental|Adult study participants|Participants will receive assigned single and multiple doses of padsevonil.
16395152|NCT04013659|Experimental|G1 - Permanence of the Whitening Gel|Permanence of the Whitening Gel (Biological Product: 35% Hydrogen Peroxide) on the tooth enamel during the 15 minutes of dental-bleaching
16395153|NCT04013659|Experimental|G2 - Renewal of the Whitening Gel|3 Whitening Gel (Biological Product: 35% Hydrogen Peroxide) renewal every 5 minutes during the 15 minutes of dental-bleaching
16395154|NCT04013646|Experimental|UCB infusion and EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
16395155|NCT04013646|Experimental|UCB infusion and placebo EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
16395156|NCT04013646|Placebo Comparator|Placebo UCB infusion and placebo EPO injection group|Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
16395157|NCT04013633|Experimental|Lifesaver virtual reality (VR) training|Training using the Lifesaver VR application. Lifesaver VR is an interactive game that can be played on smartphones allowing users to 'resuscitate' a victim of cardiac arrest, while wearing VR-goggles showing a filmed CPR-scenario
16395158|NCT04013633|Active Comparator|Face-to-face training|A short face-to-face CPR training based on international guidelines provided by certified instructors
16395159|NCT04013620|Experimental|transient belatacept|
16395160|NCT04013607|Experimental|Fiber drink|A drink high in fructo- and galacto-oligosaccharides.
16395161|NCT04013594|Experimental|carbohydrate group(CHO group)|
16395162|NCT04013594|No Intervention|control group|
16395163|NCT04013581|Experimental|TZD group|Pioglitazone added to Metformin, DPP-4 inhibitors, Sulfonylurea
16395164|NCT04013581|Active Comparator|SGLT-2 inhibitor group|Empagliflozin added to Metformin, DPP-4 inhibitors, Sulfonylurea
16395165|NCT04013568|Active Comparator|Group 1 - Agree to Exercise Program|12-week exercise program
16395166|NCT04013568|No Intervention|Group 2 - Declines Exercise Program|Same biometric and biomarker assessment at as Group 1 (at baseline, after 12 weeks and annually) however they will not participate in the exercise sessions
16395167|NCT04013555|Experimental|N-acetylcysteine & Tryptophan|N-acetylcysteine 140 mg/kg up to a maximum of 15 g. Thirty minutes after N-acetylcysteine administration participants will receive Tryptophan, 6 grams.
16395168|NCT04013555|Placebo Comparator|Placebo & Tryptophan|Placebo 140 mg/kg up to a maximum of 15 g. Thirty minutes after placebo administration participants will receive Tryptophan, 6 grams.
16395169|NCT04013542|Experimental|Treatment (nivolumab, ipilimumab, radiation therapy)|"CONCURRENT THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 8 cycles, and treatment with ipilimumab repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 1 day of starting nivolumab and ipilimumab, patients also undergo radiation therapy 5 days a week (Monday-Friday) over 6-7 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
16395172|NCT04013516|No Intervention|Pure Control|Respondents received New Incentives' normal program.
16395173|NCT04013516|Placebo Comparator|Reminder Call|Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives.
16395174|NCT04013516|Experimental|Small Additional Incentive|Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
16395175|NCT04013516|Experimental|Large Additional Incentive|Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
16395176|NCT04013490|Placebo Comparator|Placebo capsule|Subject receive the Placebo product for 4 weeks.
16395177|NCT04013490|Active Comparator|Cassava dietary fiber capsule 1.5 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
16395178|NCT04013490|Active Comparator|Cassava dietary fiber capsule 3 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
16395179|NCT04013477|Experimental|Cohort1|"drug : DA-5207 80mg/40cm²
~placebo : 40cm²"
16395180|NCT04013477|Experimental|Cohort2|"drug : DA-5207 120mg/60cm²
~placebo : 60cm²"
16395181|NCT04013477|Experimental|Cohort3|"drug : DA-5207 160mg/80cm²
~placebo : 80cm²"
16395182|NCT04013477|Active Comparator|Cohort4|drug : Aricept
16395183|NCT04013464|Experimental|MDD and Health Control|MDD in open label
16395184|NCT04013451|Experimental|Intervention Group|Participants allocated to the intervention group will participate in the intervention (acts of kindness).
16395185|NCT04013451|No Intervention|Control Group|Participants allocated to the control group will not participate in the intervention and will act as the comparison condition.
16395186|NCT04013438|Experimental|FET cycle, discontinue estradiol after 6 gestational weeks|In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
16395187|NCT04013438|Active Comparator|FET cycle, continue estradiol till 12 gestational weeks|Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.
16395188|NCT04013425|Experimental|Ice Cream Cone Technique|Atraumatic extraction followed by addition of barrier membrane and xenograft in the socket.
16395189|NCT04013425|No Intervention|Spontaneous Healing|Spontaneous Healing after Atraumatic Extraction
16396090|NCT04006912|Experimental|Minimal residual theoretical astigmatism group|
16395190|NCT04013412|Experimental|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
16395191|NCT04013412|No Intervention|Control|Ad libitum diet for four days immediately before surgery
16395192|NCT04013399|Experimental|Continuous Positive Airway Pressure|Women will receive Continuous Positive Airway Pressure (CPAP) for one month.
16395193|NCT04013399|No Intervention|Control|Women will receive standard prenatal care.
16395194|NCT04013386|Active Comparator|Aprepitant/Dexamethasone Group|
16395195|NCT04013386|Active Comparator|Mertazepine /Dexamethasone Group|
16395196|NCT04013386|Active Comparator|Dexamethasone Group|
16395197|NCT04013373||BIS home-based monitoring|
16395198|NCT04013360|Active Comparator|Breath Stacking|Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes.
16395199|NCT04013360|Active Comparator|Expiratory Positive Airway Pressure|Therapeutic technique consisting of a face mask, a one-way valve and an expiratory resistor, responsible for resistance to expiratory flow, which will determine the level of pressure in the airway.
16395200|NCT04013347||Early Surgery|Surgery after ≤ 42 days from the end of neoadjuvant radio-chemotherapy
16395201|NCT04013347||Late Surgery|Surgery after 43-56 days from the end of neoadjuvant radio-chemotherapy
16395202|NCT04013347||Very Late Surgery|Surgery after 57 or more days from the end of neoadjuvant radio-chemotherapy
16395203|NCT04013334|Experimental|MTG201 plus Nivolumab|Single arm, open-label, patients receive both MTG201 and nivolumab
16395204|NCT04013321|Experimental|Test intervention group|Chronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
16395205|NCT04013321|Active Comparator|Active control|Chronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
16395206|NCT04013321|No Intervention|Passive control|Chronic insomniacs in the passive control group will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
16395207|NCT04013321|No Intervention|Healthy control|Healthy sleepers will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
16395208|NCT04013308|Experimental|10 iontophoresis treatments with potassium iodide|
16395209|NCT04013308|No Intervention|10 iontophoresis treatments with placebo|
16395210|NCT04013295|Experimental|Prize-linked savings intervention|Participants in the intervention group will be assisted with opening bank accounts at the partner bank and will be eligible for monetary rewards linked to the amount they save in these project accounts. During the intervention period, information about participants' savings activities will be shared with the study team at regular intervals by the bank. Winners will learn of their prize via text message and will have their prize money deposited into their accounts. Respondents who did not win the lottery will also receive a text message, which will remind them to save.
16395211|NCT04013295|No Intervention|Control|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.
~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
16395212|NCT04013269|Active Comparator|CytoSorb-Therapy|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber
16395213|NCT04013269|No Intervention|Standard of care|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy
16395214|NCT04013256|Experimental|Dermal Exposure to Thirdhand Cigarette Smoke|Participants will wear clothing that has been exposed to cigarette smoke, for 3 hours while breathing filtered, temperature and humidity controlled air.
16395215|NCT04013256|Active Comparator|Inhalational Exposure to Thirdhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 22 hours, for 3 hours while wearing clean clothing.
16395216|NCT04013256|Active Comparator|Inhalational Exposure to Secondhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 30 minutes, for 3 hours while wearing clean clothing.
16395217|NCT04013256|Sham Comparator|Clean Air Exposure|Participants will breathe filtered, temperature and humidity controlled air while wearing clean clothing for 3 hours.
16395218|NCT04013243|Active Comparator|Magnesium Sulfate group|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
16395219|NCT04013243|Placebo Comparator|Placebo group|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
16395220|NCT04013230|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic.
16395221|NCT04013230|Active Comparator|Web-COP|Usual care plus group sessions and a web-based treatment program
16395222|NCT04013217|Experimental|Eribulin ORA|To determine the MTD of Eribulin ORA (oral eribulin mesylate and HM30181A) when administered on Day 1 and Day 8 of a 3 weeks cycle.
16395223|NCT04013204|Experimental|Intervention group|Intervention group: Before the patient returns to the doctor and the prescription is issued, the EDCM system will feed back the EndoPAT test results to the responsible doctor through the automatically generated information on the doctor's mobile phone, but will not let the patient know the endothelium test results (blinded to the patient).
16395224|NCT04013204|No Intervention|Control group|Control group: The EDCM system will not report the EndoPAT test results to the responsible doctor (the doctor cannot see the final EFT results), nor can the patients know the EFT results.
16395226|NCT04013191|Experimental|Elderly study participants|Participants will receive assigned single and multiple doses of padsevonil.
16395227|NCT04013178|Experimental|Accentuated eccentric loading + electromyostimulation|This group will undertake a supervised 12-week intervention involving accentuated eccentric loading and electromyostimulation of the knee extensors, dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
16395228|NCT04013178|Active Comparator|Traditional resistance training|This group with undertake a supervised 12-week intervention involving volume matched dynamic resistance training of the knee extensors, and dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
16395229|NCT04013165|Active Comparator|Active control|Usual care of the Community Mental Health Service
16395230|NCT04013165|Experimental|Village-based intervention|Individual-based case management + group-based program
16395231|NCT04013152|Experimental|clinical database|
16395232|NCT04013139||CKD Stage 3|CKD patients with GFR between 30-60cc/min
16395233|NCT04013139||CKD Stage 4|CKD Patients with GFR 15-30 cc/min
16395234|NCT04013126|Experimental|endometriosis|Women who undergoing surgery for removal of endometriosis implants
16395235|NCT04013126|Active Comparator|non-endometriosis|Women who undergoing surgery for removal of benign masses in the pelvis
16395236|NCT04013113|Active Comparator|Standard Medical Treatment|Group A will be given standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
16395237|NCT04013113|Experimental|Hemoadsorption plus standard medical therapy|
16395238|NCT04013113|Experimental|Plasma Exchange plus standard medical therapy|
16395239|NCT04013087|Experimental|Test Formula|Feihe Stage 1 infant formula
16395240|NCT04013087|Active Comparator|Control formula|A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used)
16395241|NCT04013087|Other|Breast feeding|Breast fed of human milk
16395242|NCT04013074|Experimental|TIPS+Standard Medical Treatment|TIPS along with standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
16395243|NCT04013074|Active Comparator|Standard Medical Treatment|standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
16395244|NCT04013061||Standard consultation|
16395245|NCT04013061||Pharmacist-anesthesiologist consultation|
16395246|NCT04013048|Experimental|[14C]-Fluzoparib|Patients will receive single dose of [14C]- Fluzoparib.
16395247|NCT04013022||Young|Healthy young subjects (age 18 - 30 )
16395248|NCT04013022||Old Sedentary|Healthy and sedentary old subjects (age 65 - 75)
16395249|NCT04013022||Old Endurance Trained|Healthy old subjects ( age 65 - 75) who participated in endurance sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
16395250|NCT04013022||Old Strength Trained|Healthy old subjects ( age 65 - 75) who participated in resistance training/sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
16395253|NCT04012983||diabetic patients with periodontitis|
16395254|NCT04012983||periodontitis patients|
16395255|NCT04012983||healthy control|
16395256|NCT04012970|Experimental|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
16395257|NCT04012970|Experimental|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
16395258|NCT04012957|Experimental|Darbepoetin Alfa Injection|Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.
16395259|NCT04012957|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
16395260|NCT04012944|Experimental|Cordella™ Pulmonary Artery Sensor System|The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
16395262|NCT04012918|Experimental|A.I. + Capeciabine|Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
16395263|NCT04012918|Active Comparator|A.I|Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.
16395264|NCT04012905|Experimental|Short tapering corticosteroids|Corticosteroid taper over 28 weeks
16395265|NCT04012905|Active Comparator|Long tapering corticosteroids|Corticosteroid taper over 52 weeks
16395266|NCT04012892|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
16395267|NCT04012879|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
16395268|NCT04012866|Experimental|SEQ (sequential training group)|The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
16396091|NCT04006912|Active Comparator|Steep meridian incision design group|
16395269|NCT04012866|Experimental|DUAL (dual training group)|The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
16395270|NCT04012866|Active Comparator|CI (control intervention group)|The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
16395271|NCT04012853|Experimental|treatment arm|tDCS treatment group
16395272|NCT04012853|No Intervention|control arm|Sham tDCS
16395273|NCT04012827|Experimental|Apatinib Mesylate Combined With Doxorubicin and Ifosfamide|A course of treatment every 21 days. For patients with disease control (CR+ PR+SD) and tolerable adverse reactions after 6 courses of treatment, continuous drug use was considered by the researchers as inappropriate for patients to continue drug use or when the efficacy was assessed as disease progression (PD).No other antitumor treatment can be given during the treatment.
16395274|NCT04012814|Experimental|Subject treatment group|Treatment group receiving up to 4 diode treatments and up to 8 RF treatments.
16395275|NCT04012788|Active Comparator|probiotic arm|inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
16395276|NCT04012788|Placebo Comparator|placebo arm|placebo powder, 15 g
16395277|NCT04012775|Active Comparator|Insulin Humulin® NPH|Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
16395278|NCT04012775|Experimental|Insulin Rinsulin® NPH|Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
16395279|NCT04012762|Active Comparator|Moderate-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 25 Hz for training frequency in moderate-intensity group.
16395280|NCT04012762|Active Comparator|Vigorous-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 40 Hz for training frequency in vigorous-intensity group.
16395281|NCT04012749|Active Comparator|Advance directive|Messaging and advance directive distribution. All arms receive physician advance care planning education at the clinic level.
16395282|NCT04012749|Active Comparator|Advance directive and Prepare|Messaging and advance directive distribution plus introduction to the Prepare For Your Care website. All arms receive physician advance care planning education at the clinic level.
16395283|NCT04012749|Active Comparator|Advance directive, Prepare and Facilitator|Messaging and advance directive distribution, introduction to the Prepare For Your Care website, plus patient engagement from a trained facilitator who also can interact with the primary care physician. All arms receive physician advance care planning education at the clinic level.
16395284|NCT04012736||Celiac disease|Celiac disease subjects enrolled after diagnosis and before gluten free diet initiation
16395285|NCT04012736||Control|Healthy controls with no chronic condition
16395286|NCT04012723|Experimental|MY01 Device|"Device: MY01 Device
~Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure"
16395287|NCT04012710|Active Comparator|Laparoscopy|Abdominal conventional laparoscopy for salpingo-oophorectomy
16395288|NCT04012710|Active Comparator|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
16395289|NCT04012697|Experimental|Peer Support|Peer support services from a peer support worker in the emergency department.
16395290|NCT04012697|No Intervention|Usual care|Usual care in the emergency department.
16395291|NCT04012684|Experimental|rTMS: left first|One-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
16395292|NCT04012684|Experimental|rTMS: right first|"One-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
~After at least two weeks, stimulations of the same parameters are given over left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well."
16395293|NCT04012684|Sham Comparator|Sham: left first|One-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
16395294|NCT04012684|Sham Comparator|Sham: right first|One-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
16395295|NCT04012658||Patients with the genetic diagnosis of Wilson's Disease|
16395296|NCT04012658||Asymptomatic Wilson's Disease carriers|
16395297|NCT04012658||Relatives of Wilson's Disease patients or carriers|
16395298|NCT04012658||Unrelated healthy controls|
16395299|NCT04012645|Experimental|experimental group|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used during the surgeries.
16395300|NCT04012645|Active Comparator|control group|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
16395301|NCT04012632||cases|Early puberty cases of Han Chinese
16395302|NCT04012632||controls|Controls were matched to cases at 1:1 by age (± 3 months)
16395303|NCT04012619|Experimental|Anlotinib Hydrochloride Combined With AP|Patients receive pemetrexed (500mg/m2) with cisplatin (75mg/m2)/carboplatin (area under the curve 5) once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14 of a 21-day cycle. Anlotinib with AP will be administrated up to 4 cycles followed by maintenance treatment with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.
16395304|NCT04012606|Experimental|TORIPALIMAB|
16395305|NCT04012606|Active Comparator|Chemotherapy|
16395306|NCT04012593||premenopausal women|diary
16395431|NCT04011618|Experimental|Ellagic acid|16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
16395307|NCT04012580|Experimental|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the program, participants will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact provided on a weekly basis.
16395308|NCT04012580|No Intervention|Treatment as usual control|Participants will not receive access to the transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) program for 12-weeks. Participants will be permitted to access community resources (e.g., support groups). After 12-weeks, participants will be offered the program although their treatment data will not be included in the current study.
16395309|NCT04012567|Experimental|The Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
16395310|NCT04012567|Active Comparator|The BIOSURE HA Interference Screw|The Biosure HA Interference Screw, an absorbable screw made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
16395311|NCT04012554|Experimental|avoiding chest drainage tube placement after resection of lung|This group of patients underwent avoiding chest drainage tube placement after VATS of the lung.
16395312|NCT04012554|Other|indewlling chest drainage tube after resection of lung|This group of patients underwent indewlling chest drainage tube after VATS of the lung.
16395313|NCT04012541|Experimental|treatment group|"post-myocardial infarction management
~basic periodontal examinations
~active dental procedure"
16395314|NCT04012541|Active Comparator|control group|"post-myocardial infarction management
~basic periodontal examinations"
16395315|NCT04012528||"the before group"|75 teenagers after scoliosis surgery before ERAS program implementation
16395316|NCT04012528||"the after group"|75 teenagers after scoliosis surgery after ERAS program implementation
16395317|NCT04012515|Experimental|CAVA Electrode Pad Appraisal Trial Arm|All trial participants are within this arm. All participants will wear the same selection of electrode pads and follow the same replacement schedules.
16395318|NCT04012502|Active Comparator|conventional treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
16395319|NCT04012502|Experimental|Toxicities reduced treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
16395320|NCT04012489|Active Comparator|Breath Stacking|Breath stacking: patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
16395321|NCT04012489|Experimental|Air Stacking|Air stacking: the same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
16395322|NCT04012476|Experimental|ICG|Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green
16395323|NCT04012450|Active Comparator|Epidural Anesthesia|Women in labor receiving epidural anesthesia
16395324|NCT04012450|Active Comparator|Spinal-epidural|Women in labor receiving spinal-epidural anesthesia
16395325|NCT04012437|Experimental|Experimental|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a mobile app and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter. The groups use of a masturbation aid device called Myhixel I from the spanish company New Wellness Concept SL.
16395326|NCT04012437|Active Comparator|Control|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a video tutorial and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter.
16395327|NCT04012424|Experimental|Drug (400mg Curcumin) Curcumin is apice|"Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .
~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .
~patients will take 400mg capsule curcumin one hour before endodontic treatment and study its effect on post endodontic pain immediately and after 8,12,24,48 hours after completion of endodontic treatment"
16395328|NCT04012424|Placebo Comparator|Starch(400mg starch) starch is sometype of carbohydrates|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
16395329|NCT04012411|Active Comparator|Patient with LP|Huntington's disease patients who agreed to have LP
16395330|NCT04012411|Active Comparator|Patient without LP|Huntington's disease patient with contraindication to LP or refusal to have LP
16395331|NCT04012411|No Intervention|Control Group|Retrospective study with biologic samples of patients without Huntington's disease
16395332|NCT04012385|No Intervention|Control|Subjects assigned to control group receives only a booklet including the recommendations for a correct diet by the Italian National Institute for Research on Food and Nutrition (INRAN), presently called (CRA-NUT) .
16395363|NCT04012138|Active Comparator|Insuline + dextrose|Patients in the experimental group will receive : 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period
16395333|NCT04012385|Experimental|Intervention|"Subjects assigned to the intervention group will follow a nutritional pathway based on a Mediterranean diet pattern for 4 months and receive suggestions on the regular practice of physical activity, under the guide of some nutritionists, who will propose individualized diets for each subject.
~All subjects of both groups will undergo urologic examination, measurement of weight, height and abdominal circumference, an interview on demographic data and lifestyle variables, and will provide blood and semen samples in fasting conditions, at the enrollment (baseline), at the end of the intervention phase (after 4 months) and at the end of follow-up (after 8 months)."
16395334|NCT04012372|Experimental|ROSA water|Ad libitum hydration with ROSA oligomineral water
16395335|NCT04012372|Active Comparator|Control water|Ad libitum hydration with other waters
16395336|NCT04012359||Bullous emphysema|Participants with known bullous emphysema will undergo lung ultrasound according to standard of care clinical practice during a regular follow-up consultation or scheduled hospitalization.
16395337|NCT04012359||Pneumothorax|Participants hospitalized in pulmonary medicine units for the treatment of a pneumothorax will undergo lung ultrasound according to standard of care clinical practice.
16395338|NCT04012346|Active Comparator|Active Comparator: MCI patients with real iTBS|Patients will receive real iTBS in a week-long sessions.
16395339|NCT04012346|Sham Comparator|Sham Comparator: MCI patients with sham iTBS|Patients will receive sham iTBS in a week-long sessions.
16395340|NCT04012333|Experimental|Intervention|Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: >2.2g/kg/day
16395341|NCT04012333|No Intervention|Standard Care|Patients will receive standard care (enteral nutrition only) to stay below the protein level: <1.2g/kg/day
16395342|NCT04012320||Pamidronate therapy|
16395343|NCT04012320||Zoledronate therapy|
16395344|NCT04012307|Other|Sequence AB|20 subjects assigned to the sequence AB will receive a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in Period 1 and a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16395345|NCT04012307|Other|Sequence BA|20 subjects assigned to the sequence BA will receive a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in Period 1 and a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16395346|NCT04012294|Experimental|allopurinol|150 mg daily for a month then 300 mg daily for the rest of the study (5 months)
16395347|NCT04012281||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured fractional flow reserve after PCI
16395348|NCT04012268|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs. They will also accept medication treatment by professional neurologists.
16395349|NCT04012268|Other|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists.
16395350|NCT04012255|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
16395351|NCT04012255|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
16395352|NCT04012242||NAFLD patients who are scheduled for liver biopsy|
16395353|NCT04012229||Patients treated by chemotherapy for an early breast cancer|Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
16395354|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
16395355|NCT04012203||Healthy subjects|Participants free from any pain specific to the upper limb during the past 3 months, chronic pain or other disease.
16395360|NCT04012164|Experimental|Microbiological, anthropological and historical study|"30 adult participants will be recruited to self-report daily activities and contacts with domesticated and wild animals for a five month period. Following the five months of data collection, we will collect 5ml blood and 2g stool from each participant.
~From the fifth month of investigation, an additional 30 adult participants will participate in oral anthropological, historical interviews to develop the socio-historical context of their changing activities and relations with selected domesticated and wild animals. No other intervention will be performed."
16395361|NCT04012151||Pregnant cohort|Parturients of gestational age >= 32 weeks will have measurements of arm length, MAC, proximal arm circumference, distal arm circumference, finger circumference to generate the conicity index.
16395362|NCT04012138|Experimental|Salbutamol|Patients in this experimental group will receive : 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air);
16415638|NCT03870282|Experimental|"Personal Goal | Texts B"|
16395364|NCT04012138|Experimental|Insuline + Dextrose + Salbutamol|"Patients in the experimental group will receive either:
~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR
~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
16395365|NCT04012125|Experimental|Prospective, single-arm trial|
16395366|NCT04012112|Experimental|single-arm trials|longitudial study of the thoracolumbar brace in the neuromuscular scoliosis for 6 months
16395367|NCT04012099|Experimental|BMT101|BMT101 injection (treatment)
16395368|NCT04012099|No Intervention|control|Un-treated control
16395369|NCT04012086|Experimental|physical therapy (PT)|The physical therapy program consisted of 6 individual sessions/week, each lasting 60 minutes for 4 weeks in addition to their usual pharmacological therapy
16395370|NCT04012086|No Intervention|No physical therapy (CT)|Subjects in CT group received only standard medication.
16395371|NCT04012073|Experimental|IPERPEEP|"End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial.
~Set PEEP will be ≥5 cmH2O and chosen to ensure the maximum recruitment, with a maximum plateau pressure of 30 cmH2O. Recruitment across two adjacent PEEP levels will be normalized to the changes in applied PEEP: Recruitment/cmH2O (Rec) will be computed as the ratio of recruitment and PEEP difference.
~Rec ≥ 19 ml/cmH2O will lead to the higher PEEP value.
~Rec< 7 ml/cmH2O will lead to lower PEEP value.
~19 ml/cmH2O >Rec≥7ml/cmH2O: the choice among two adjacent PEEP levels will be left to the attending physician.
~In patients with airway closure, no PEEP lower than airway opening pressure will be tested or used (due to interferences with EELV measurement) for the whole duration of treatment. A 5-step PEEP trial will re-assess EELV at different PEEP levels every 12-24 hours,after body position or ventilator settings changes."
16395372|NCT04012073|Active Comparator|EXPRESS|PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O
16395373|NCT04012060|Active Comparator|Conventional group|All patients undergoing aortic valve replacement through full sternotomy.
16395374|NCT04012060|Experimental|Limited access group|All patients undergoing aortic valve replacement through partial upper hemisternotomy.
16395375|NCT04012060|Other|Registry group|"All patients unwilling or unable to participate in the randomized part of the trial.
~All patients will undergo aortic valve replacement through median full sternotomy."
16395376|NCT04012047|Active Comparator|Levcromakalim|
16395377|NCT04012047|Placebo Comparator|Saline|
16395378|NCT04012034|Experimental|Radiofrequency A|Treatment with radiofrequency
16395379|NCT04012034|Placebo Comparator|Placebo|Treatment with radiofrequency without energy
16395380|NCT04012021|Experimental|EX-VIVO SPECIMENS|"Three groups of ex-vivo surgical specimen:
~Group A: native livers in transplant recipients Group B: liver grafts excluded for donation Group C: primary pancreatic cancer"
16395381|NCT04012008|Active Comparator|Standard care|"Regular follow-up by internists every 3 month
~May consult nephrologists case-by-case"
16395382|NCT04012008|Experimental|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month
~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
16395383|NCT04011995|Experimental|Intermittent caloric restriction|
16395384|NCT04011995|Active Comparator|Low carbohydrate diet|
16395385|NCT04011969||Colorectal cancer suspects|Patients suspected with colorectal cancer who come to our hospital to conduct colonoscopy procedure will be recruited for this study and will undergo a series of examinations.
16395386|NCT04011956||Retrospective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures from 2002 to Feb 28th 2019 were recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
16395387|NCT04011956||Perspective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures after Mar. 1st 2019 will be recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
16395388|NCT04011943|Experimental|Participants with bowel diseases|Treatment by transplantation of fecal microbiota
16395389|NCT04011943|Experimental|autologous transplantation of fecal microbiota - healthy|Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)
16395390|NCT04011943|Experimental|Both autologous and heterologous transplantation - healthy|Healthy volunteers will receive both autologous and heterologous transplantation (capsules)
16395391|NCT04011943|Placebo Comparator|placebo capsules - healthy|Healthy volunteers will receive placebo capsules
16395392|NCT04011930|Active Comparator|Experimental study|"vitamin D Generic name -cholecalciferol (40,000IU)Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks.
~Drug cholecalciferol- ingredients -cholecalciferol (40,000 IU) Microcrystalline cellulose(58.1 gm),hydroxy toluene (.2mg),magnesium stearate(3mg0,gelatin capsule shell(1mg)
~other name D-rise"
16395393|NCT04011930|Placebo Comparator|Experimental control|"Placebo oral capsule Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks
~placebo oral capsule-ingredients-microcrystalline cellulose,butylated hydroxy toluene
~,magnesium stearate
~other name D-rise"
16395394|NCT04011917||Caseload group|
16395395|NCT04011917||Prediction group|
16395396|NCT04011904|Experimental|Traditional Inuit Diet|This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%).
16395397|NCT04011904|Placebo Comparator|Westernized Diet|This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
16395398|NCT04011891|Active Comparator|Robotic Partial Nephrectomy|Partial nephrectomy performed using the DaVinci robotic surgical system.
16395399|NCT04011891|Active Comparator|Open Partial Nephrectomy|Partial nephrectomy performed using the open approach.
16395400|NCT04011878|Experimental|isolated trabeculodysgensis|etiology of primary congenital glaucoma
16395401|NCT04011865|Active Comparator|Robotic-assisted surgery|
16395402|NCT04011865|Sham Comparator|Laparoscopic surgery|
16395403|NCT04011826|Experimental|Experimental: Experimental trial nasal mask|Experimental trial nasal mask: Participants will be placed on this arm for a total of 14±3 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm. Participants on the extension will use this trial mask for a further six months after Visit 3.
16395404|NCT04011813||"Control arm, H-"|semen treated without hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
16395405|NCT04011813||"Experimental arm, H+"|semen treated with a 50mM hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
16395406|NCT04011800|Active Comparator|Catheter ablation|Patients will undergo catheter ablation of atrial fibrillation.
16395407|NCT04011800|Experimental|Risk factor modification|Patiemt will undergo risk factor intervention and antiarrhythmic drugs
16395408|NCT04011787|Active Comparator|Intervention|bolus NGT feeding
16395409|NCT04011787|Other|Control|Continuous NGT feeding (standard care)
16395410|NCT04011774|Experimental|PLANI-REV|Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program
16395411|NCT04011774|Active Comparator|RELAXATION|Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.
16395412|NCT04011761|Active Comparator|Experimental Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
16395413|NCT04011761|No Intervention|Control Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the control arm will receive treatment prescribed by pediatricians.
16395414|NCT04011748|Experimental|Haire regrowth by SCE|AA subjects will receive Stem Cell Educator therapy combined with oral minoxidil. Hair regrowth will be evaluated during one-year follow-up studies.
16395415|NCT04011748|Experimental|Minoxidil therapy|Control subjects will receive treatment with topical 5% minoxidil
16395416|NCT04011735||Respimat SMI-experienced: Switching to re-usable Respimat|patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry.
16395417|NCT04011735||Respimat SMI-naïve|patients who have not previously used a Respimat SMI product and receive their first prescription at study entry
16395418|NCT04011735||Respimat SMI-experienced: Maintenance treatment|patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry.
16395419|NCT04011722|Experimental|Portico™ NG valve, FlexNav™ Delivery System|Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)
16395420|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2A|Subjects who carried out 3 attempts at Visit 1, failed to achieve nebulization success and subsequently were included in Test Arm 2A for Visit 2
16395421|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2B|Subjects who carried out 3 attempts at Visit 1, achieved nebulization success and were subsequently included in Test Arm 2B for Visit 2
16395422|NCT04011670|Active Comparator|Caffeine group|Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
16395423|NCT04011670|Placebo Comparator|Placebo group|Participants will receive a placebo tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
16395424|NCT04011657|Experimental|Voluntary CDSS|Voluntary use of computerized decision support with prospective review and feedback
16395425|NCT04011657|No Intervention|Compulsory CDSS|Compulsory use of computerized decision support with prospective review and feedback
16395426|NCT04011644|Active Comparator|Self monitored|"Patients of this group will continue receiving regular care from their physician with no interference from the two experimental groups. Patient subjects will download the app on their Android or Apple smart phone that will direct them to external information hosted on the internet that may help reduce their drinking (e.g., NIAAA resources). For the first 12 weeks, once a week patients can set a weekly goal related to their alcohol use or other health related behaviors (e.g., I will only drink on Friday this week.). At the end of the week subjects will be prompted to take a weekly survey, which will include questions such as a variation of the brief alcohol monitor (BAM) and timeline followback. Patients will then receive feedback on the amount of drinks they had compared to their goal. Then the patient will set a new goal for the following week. Patients will complete quarterly surveys on the A-CHESS app to assess study outcomes."
16395427|NCT04011644|Experimental|Peer supported|Patients will be asked to take the same surveys and have the access to the same information as the self-monitoring group. Patient subjects in this group will have access to discussion boards where they can talk to one another and have the ability to share and see stories of other patients. The only involvement of someone other than patients themselves in the peer-supported group will be by a sponsor (i.e., a dedicated user from the area with a sustained history of successful alcohol reduction). The sponsor will participate in discussion groups and encourage use of the system. Patient-reported feedback will be presented directly to the patient.
16395428|NCT04011644|Experimental|Clinically integrated|Patients in the clinically integrated group will receive the same intervention as the peer-supported group aside from three differences: 1) patients have the option to share selected elements of their app data with the University of Wisconsin (UW) Health health coach, 2) the health coach will replace the role of the sponsor in the peer-support group, and 3) patients will have the option to attend an initial 60- to 90-minute and two 30-minute follow-up consultations with the health coach in-person, via phone, or via video chat.
16395429|NCT04011631|Experimental|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
16395430|NCT04011618|Placebo Comparator|Placebo|16 patients to receive 1 homologated placebo capsule (calcinated magnesia 500 mg) every 12 hours along 12 weeks
16395434|NCT04011579|Experimental|MSFIT|The MSFIT group will self-manage Pilates exercises at-home through a tool based on XBox Kinect for 12 weeks, performing at least 3 sessions/week for a total of 30 minutes of exercises for each session(also distributed during the day with a minimum slot of 10 minutes). No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
16395435|NCT04011579|No Intervention|CTRL|No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
16395436|NCT04011566||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
16395437|NCT04011553|Experimental|Virtual group|This virtual realtiy was implemented with MarVAJED® (Marmara Visual Auditory Joint Education Device) system which was developed by Marmara University, Department of Physiotherapy and Rehabilitation, Istanbul,Turkey. MarVAJED® is a system that evaulates the range of motion of the joints, analyzes the sensation of joint position, provides biofeedback support to increase joint control and the same time allows exercises to be controlled. This device analyzes the joint motion with the help of small sensors (Figure 2). The obtained data transfers to your mobile phone, to the tablet or to your personal computer. It stores the data by downloading it to the central server via internet for storage.
16395438|NCT04011553|Active Comparator|Control group|Conventional physiotherapy consists of electrotherapy and exercise programs. Hotpack or coldpack, therapeutic ultrasound (US) and conventional TENS were applied as electrotherapy program.
16395439|NCT04011540|Experimental|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
16395440|NCT04011540|No Intervention|Usual Care|Usual care
16395441|NCT04011527||Patients with Coronary Artery Disease|Patients with Coronary Artery Disease undergoing a Rotational Atherectomy in Coronary Lesion/s
16395442|NCT04011514||Baseline period|Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
16395443|NCT04011514||Intervention period|Intervention: 2 month implementation period of specialized stroke nurses allocated to ED for nurse specific treatment of stroke patients specific observations and care
16395444|NCT04011501|Experimental|Continuous unilateral ESP block|Erector spine block and catheter placement will be performed for continuous analgesia on this group of patients undergoing minimally invasive cardiac surgery. Initially a volume of 20 ml of Levobupivacaine 0.25% will be administered and subsequently a 22G catheter will be introduced and fixed 10-12 cm from the skin. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
16395445|NCT04011488|No Intervention|Standard patient information data sheet|
16395446|NCT04011488|Experimental|SDM Tool|A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).
16395447|NCT04011475||Subjects with Tiotropium and Olodaterol|
16395448|NCT04011475||Subjects treated with other LABA/LAMA therapy|
16395449|NCT04011475||Subjects treated with LAMA therapy|
16395450|NCT04011462|Experimental|Prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
16395451|NCT04011462|Experimental|Prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
16395452|NCT04011462|No Intervention|Standard care|warming with cotton sheet and blanket for 20 minutes.
16395453|NCT04011449|Experimental|Device Implantation|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
16395454|NCT04011436|Experimental|Core, Hip and knee.|Physical Exercises to strengthen the core, hip and knee.
16395455|NCT04011436|Sham Comparator|Hip and Knee|Physical Exercises to strengthen the hip and knee.
16395456|NCT04011423|Experimental|Unstable shoes|Wearing unstable shoes during the whole-body vibration training
16395457|NCT04011423|Active Comparator|Stable shoes|Wearing stable shoes during the whole-body vibration training
16395458|NCT04011410|Experimental|Hydroxychloroquine|"Hydroxychloroquine (HCQ)
~DOSAGE FORM: 200 mg tablet, oral route
~DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg
~FREQUENCY: HCQ is taken twice daily (morning and night) with food.
~DURACTION OF HCQ: 90-days"
16395459|NCT04011397|Experimental|Intervention group|Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment. [low recruitment prohibited control arm]
16395460|NCT04011384|No Intervention|Control Group|Participants in this arm will view the typical web-based ordering system platform (usual care group).
16395461|NCT04011384|Experimental|Behavioral Economic Intervention Group|Participants in this arm will be exposed to the web-based ordering system with multiple behavioral economic interventions applied, including healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
16395462|NCT04011371|Experimental|Cyanoacrylate closure|Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
16395465|NCT04011345|Other|Folic Acid Supplement [Phase 1]|Phase 1: Folic acid supplement (1 mg per day) for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Placebo for 12 weeks
16395557|NCT04010669|Active Comparator|Study group|The study group includes participants who will receive somatostatin postoperatively (after liver resection).
16395466|NCT04011345|Other|Placebo [Phase 1]|Phase 1: Placebo for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Folic acid supplement (1 mg per day) for 12 weeks
16395467|NCT04011332|Experimental|Intervention Group|
16395468|NCT04011332|No Intervention|Control Group|
16395469|NCT04011319|No Intervention|convention culture|Each droplet separate culturing an individual embryo.
16395470|NCT04011319|Experimental|group culture|Embryos were cultured in the same droplet.
16395471|NCT04011306|Experimental|Lumina24 BLU|Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.
16395472|NCT04011293|Experimental|A|Single dose of CNCT19
16395473|NCT04011280|Experimental|Low Dose Varenicline|0.5 mg twice daily with 0.5 mg daily titration over one full week
16395474|NCT04011280|Active Comparator|Standard Dose Varenicline|1.0 mg twice daily with standard titration
16395475|NCT04011267|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in the SOPeD software three times/week at home via web-software. In the follow-up period, patients will follow the same schedule set by the project till the end of the study.
16395476|NCT04011267|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
16395477|NCT04011254||Healthy Control|Healthy control
16395478|NCT04011254||Haemodialysis %IDWG >4%|Patient on regular haemodialysis with average IDWG >4%
16395479|NCT04011254||Haemodialysis %IDWG <4%|Patient on regular haemodialysis with average IDWG <4%
16395480|NCT04011241|Experimental|Reference - BI 1323495 alone|Reference followed by Test
16395481|NCT04011241|Experimental|Test - BI 1323495 + Itraconazole|
16395482|NCT04011228||Type 2 diabetic patients|
16395483|NCT04011228||Prediabetic patients|
16395484|NCT04011228||Women with gestational diabetes|
16395485|NCT04011228||Healthy control subjects|
16395486|NCT04011228||Pregnant women without gestational diabetes|
16395487|NCT04011215|Experimental|wool-first (wool X standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing
16395488|NCT04011215|Active Comparator|standard-first (standard X wool)|standard clothing to be worn for 6 weeks followed by 6 weeks of superfine merino wool clothing
16395489|NCT04011202|Experimental|VR Group|Receives the VR protocol
16395490|NCT04011202|No Intervention|Control Group|Receives regular care
16395491|NCT04011189|Experimental|Videotaping|"Upon successful recruitment of the study, patients will be asked to complete 2 questionnaires and rate their pre-surgical pain on the numerical rating scale in the pre-anaesthetic evaluation clinic. Their face and body pose from a frontal view will be videotaped.
~The general anaesthesia technique and type of analgesia administered intra-operatively will be according to standard practice and is at the discretion of the attending anaesthesiologist. After surgery, patients will be reviewed at 12-36 hrs, 36 hrs till before discharge post-operatively in the ward. They will be asked to rate their pain scores and videotaping will be done from a frontal view."
16395492|NCT04011176|Placebo Comparator|Standard treatment + placebo|Placing the microcurrent pads on the patient but not turning on the microcurrent box for 30 minutes once a week for 6 weeks
16395493|NCT04011176|Experimental|Standard treatment + Microcurrent Therapy|100-300µA microcurrent delivered for 20-300 minutes, once a week for 6 weeks
16395494|NCT04011163|Experimental|VPIA analgesia|VPIA pump will be connected to patients after surgery for up to three days. The vital signs (oxygen saturation, respiratory rate, heart rate) will be closely monitored when patients are using VPIA pump. Intravenous medication (morphine) will be given intravenously.
16395495|NCT04011150|Experimental|Variable volume Automated Mandatory Bolus (VVAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
16395496|NCT04011150|Active Comparator|Automated mandatory bolus (AMB) of variable-frequency (VAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
16395497|NCT04011137|No Intervention|Control|No exercise - 30-min of rest
16395498|NCT04011137|Experimental|High-intensity interval training|8 x 60 s intervals at 70% peak power output (intersperesed with 60 s recovery intervals at 10% peak power output)
16395499|NCT04011137|Experimental|Moderate-intensity continous training|25 min at 45% peak power output
16395500|NCT04011124|Experimental|Rifampicin + Fluzoparib|
16395501|NCT04011098|Active Comparator|Control Group (No Additional Epidural Fentanyl Bolus)|The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
16395502|NCT04011098|Experimental|Fentanyl bolus group|The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
16395503|NCT04011085||Group1|Patients currently undergoing treatment for early breast cancer (either targeted HER2 therapy and chemotherapy OR targeted HER therapy alone)
16395504|NCT04011085||Group2|Patients with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving locoregional treatment, chemotherapy or targeted HER2 therapy; patients may still be receiving hormone therapy)
16395505|NCT04011085||Group3|Patients receiving treatment for metastatic breast cancer
16395506|NCT04011072|Active Comparator|Infrared treatment arm|Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year
16395507|NCT04011072|No Intervention|Control arm|The control group will not receive any intervention, but will be followed with the same data as the treatment group
16395508|NCT04011059|Placebo Comparator|Comparison/control group|Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.
16395509|NCT04011059|Active Comparator|Experimental group|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed.
16395510|NCT04011033|Experimental|TACE+iNKT for unresectable HCC|TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TACE will be performed at 0th and 4th week. 5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
16395511|NCT04011033|Other|TACE for unresectable HCC|TACE will be conducted at 0th week and 4th week.
16395512|NCT04011020|Experimental|Treatment of T1D with Stem Cell Educator therapy|Recruited T1D subjects will receive one treatment with SCE therapy.
16395513|NCT04011020|Experimental|Conventional insulin therapy|Control group will receive conventional insulin therapy.
16395514|NCT04011007|Active Comparator|vitrectomy without ILM peeling|vitrectomy without ILM peeling
16395515|NCT04011007|Active Comparator|vitrectomy with inverted ILM flap technique|vitrectomy with inverted ILM flap technique
16395516|NCT04010994|Other|rtACS|repetitive transorbital ACS
16395517|NCT04010981|Experimental|study grup-Virtual reality- Nintendo Wii Fit exercise group|in this group patients will complete 12 sessions of virtual reality exercise - Nintendo Wii Fit Plus, 30-minute training sessions with strengthening exercises for the lower extremities and upper extremities, aerobic and balance exercises, two days a week. They will do 5 minute warm-up exercises before stretching, stretching exercises and 5 minute cooling exercises at the end of the session, as well as breathing exercises and will attend a total of 50 minutes of treatment.
16395518|NCT04010981|Active Comparator|control group-home based video exercise group|Patients will be join home based exercises two days a week during 12 sessions .we will prepare for the lower and upper extremity features similar to Nintendo Wii Fit exercises 30 minutes of video game exercise practices, 5 minutes warm-up exercises, 5 minutes cooling exercises and complete the 50-minute training session with the breathing exercises we will teach them. In addition to exercise sessions, patients will record their activities (walking, cycling, swimming ına) in daily life schedules with their pedometers. Thus, changes in physical activity levels will be monitored.
16395519|NCT04010968|Active Comparator|FCR|"FCR :
~rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.
~fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.
~cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6."
16395520|NCT04010968|Experimental|venetoclax and ibrutinib (I+VEN)|"ibrutinib: 420 mg/d orally, continuously from Month 1 to the end of treatment, either Month 15 or Month 27
~venetoclax: stepwise weekly dose ramp-up beginning at Month 4 from a starting dose of 20 mg/d to the final dose of 400 mg/d (20, 50, 100, 200 and then 400 mg) over a 5 weeks, and then 400 mg/d continuously from Month 5 to the end of treatment, either Month 15 or Month 27."
16395521|NCT04010955||Edoxaban Monotherapy|"edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.
~However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians."
16395522|NCT04010955||Edoxaban and antiplatelet combination|edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.
16395523|NCT04010942|Active Comparator|Vitamin D|"Group V : number of 60 women will receive 100000 IU Cholecalciferol Intramuscular every month + 2000 mg Metformin (oral: 2 tablets 1000 per day) for 5 months .
~-after two months from the start:
~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day,from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
16395524|NCT04010942|Placebo Comparator|Control|"Group C: number of 60 patients will receive Metformin 2000mg (oral: 2 tablets1000 mg per day) for months .
~-after two months from the start:
~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day, from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
16395525|NCT04010929|Experimental|Laser+MTA group|before the MTA condensation, Er, Cr: YSGG laser was applied to the exposure area
16395526|NCT04010929|Active Comparator|MTA group|MTA was applied to the exposed area
16395527|NCT04010916|Active Comparator|Group Pre = preoperatively before inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
16395528|NCT04010916|Active Comparator|Group Pre-T = preoperatively after inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
16395529|NCT04010916|Active Comparator|Group Post = Postoperatively group|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
16395530|NCT04010903|Experimental|HEALTHY SUBJECTS|SUBJECTS WITH BMI<27 and HOMA<4
16395531|NCT04010903|Experimental|OVERWEIGHT NON INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA<4
16395532|NCT04010903|Experimental|OVERWEIGHT INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA>4
16395533|NCT04010890|Experimental|Culturally adapted CBT|Ca_CBT will be delivered to the experimental group using the newly developed manual . The intervention will be delivered over 8-12 sessions. The Control group will receive standard CBT
16395534|NCT04010890|Active Comparator|Standard CBT|Participants in this group will receive standard CBT
16395535|NCT04010877|Experimental|Multiple CAR T cells to treat AML|Multiple CAR T cells to treat AML
16395536|NCT04010864||SHARP-2|ShangHai At Risk for Psychosis-Phase 2
16395558|NCT04010669|Placebo Comparator|Control group|The control group includes participants who will receive placebo (a 24 hours infusion of 1000ml Normal Saline solution 0.9%) postoperatively (after liver resection).
16395537|NCT04010851|Experimental|Peer co-led educational group|The intervention delivered in a group format is added to treatment as usual. After the parents participate in the one day-intervention, they can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence.
16395538|NCT04010851|Other|Control group|The control goup will receive treatment as usual.
16395539|NCT04010838|No Intervention|Conventional treatment|
16395540|NCT04010838|Experimental|Spinal cord stimulation and conventional treatment|
16395541|NCT04010825|Experimental|Hypnosis Arm|"In parallel with an inpatient pulmonary rehabilitation program, nine visits will be carried out :
~V0 : an inclusion visit
~V1 : a randomization visit
~V2 to V6 : five visits with hypnosis sessions
~V7 : a end-stay visit
~V8 : a 6-month post-rehabilitation visit ( by phone call)
~The five hypnosis sessions (V2 to V6) will be spread over three weeks of rehabilitation program (1 to 2 hypnosis sessions per week).
~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
16395542|NCT04010825|No Intervention|Control Arm|"In parallel with an inpatient pulmonary rehabilitation program, no additional intervention will be carry out and four visits will be carried out :
~V0 : an inclusion visit
~V1 : a randomization visit
~V7 : a end-stay visit
~V8 : a 6-month post-rehabilitation visit ( by phone call)
~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
16395543|NCT04010799|Experimental|CHF6333|"CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).
~CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days."
16395544|NCT04010799|Placebo Comparator|CHF6333 Placebo|"Part I (SAD): Single dose of placebo matching CHF6333 at each period
~Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days"
16395545|NCT04010786|Experimental|Active treatment NNC0247-0829|Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
16395546|NCT04010786|Placebo Comparator|Placebo|In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
16395547|NCT04010760||PE confirmed|Patients admitted with confirmed pulmonary embolism.
16395548|NCT04010760||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
16395549|NCT04010760||Controls|Healthy controls same gender and age (within af range of 10 years) as PE patients
16395550|NCT04010747|Experimental|Motivational Interviewing for Loved Ones (MILO)|"MILO consists of four sessions of coaching in communication skills called motivational interviewing. Participants meet with a trainer/therapist for each session. At the first session, participants learn about the ideas behind motivational interviewing. In the second session, participants practice motivational interviewing skills. In the third and fourth sessions, the participant and therapist discuss the participant's efforts to communicate with their loved one using MI skills. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one."
16395551|NCT04010747|Active Comparator|Mental Health Services Consultation and Waitlist|This consultation will consist of a 30 minute appointment in which participants can speak with a clinician knowledgeable about psychosis treatment resources. He/she can recommend specific programs, educational websites, and/or support groups that might be relevant for the participant's family. Participants will then be placed on a 6-week waitlist, after which they will have the opportunity to participate in the active intervention (four sessions of MILO).
16395552|NCT04010734|Active Comparator|peroral Cholangioscopy examination|"Patient with suspected malignant biliary stricture (SMBS) is allowed:
~to the peroral Cholangioscopy examination with both visual and tissue diagnosis. The visual diagnosis is based on morphological and vascular patterns (presence or not of nodular or papilary masses, irregularity of the surface, morphology of the vessels and the fragility of mucosa). The tissue diagnosis consists on cytopathological evaluation after tissue sampling using minuature biopsy forceps (SpyBite). During this, 5-8 samples are taken under visual control, from different parts of the lesion."
16395553|NCT04010734|Active Comparator|ERCP examination with sampling|"Patient with suspected malignant biliary stricture (SMBS) is allowed:
~to ERCP examination with both sampling by brushing and forceps biopsy, with subsequent pathological evaluation and an additional fluorescence in situ hybridization(FISH) examination of the specimens.
~ERCP (Endoscopic retrograde cholangiopancreatography) is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Brushing and endocanal forceps biopsies were the most used techniques, both with different specificity and sensitivity. It was demonstrated that Fluorescence in Situ Hybridization (FISH) improved the diagnostic yield of routine cytology. That is the reason why the investigators will combine FISH with the sampling methods to maximize the chance to make early diagnosis of the biliary stenosis."
16395555|NCT04010708||IOMUM|Pregnant women
16395556|NCT04010695|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.
~At the clinic site lab, study staff conducted the SD Biosensor point-of-care G6PD test and the point-of-care HemoCue Hb test on both finger stick blood and whole blood samples.
~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
16395559|NCT04010656|Experimental|PVR-based home self-catheterization|Patients will learn to self-catheterize preoperatively prior to urogynecology surgery requiring trial of void. First post-operative void will be used to collect basic information about voiding function. All participants will leave the hospital and self-catheterize until they achieve two sequential voids with post-void residual (PVR) less than half the volume voided. The cases of urinary retention captured with abnormal PVR will be used to compare the diagnostic accuracy of several commonly-used, pre-defined parameters for trial of void.
16395560|NCT04010643|Active Comparator|online cognitive behavioural therapy (oCBT)|"20 hours of online engagement with the oCBT programme over 5 weeks, distributed as follows.
~Each week, the participants complete 1 hour of of the MoodGym program, followed by 2 hours of practical online CBT homework. To equate time and type of engagement spent in doing oCBT and oCBT+NCRT, 1 final hour per week is dedicated to completing online puzzles."
16395561|NCT04010643|Experimental|online neurocognitively-enhanced CBT (oCBT+oNCRT)|"20 hours of online engagement with the oCBT+oNCRT programme over 5 weeks, distributed as follows.
~Each week, the participants complete 1 hour of the MoodGym program, followed by 1 hour of practical online CBT homework & 3 hours of the online NCRT programme Cognifit targeting attention, memory, and planning ability."
16395562|NCT04010630|No Intervention|control group|The physicians will resuscitate the patients according to the current critical care medicine guidelines.
16395563|NCT04010630|Experimental|Sodium bicarbonate group|Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion
16395564|NCT04010617|Experimental|Pharyngeal Electrical Stimulation|Orotracheal intubated patients at high risk of extubation failure will receive open-label PES
16395565|NCT04010604||SMA type I|
16395566|NCT04010604||SMA type II|
16395567|NCT04010604||SMA type III|
16395568|NCT04010604||Asymptomatic carriers of SMA|
16395569|NCT04010604||Relatives of SMA patients and carriers|
16395570|NCT04010604||Unrelated healthy controls|
16395571|NCT04010591||UDS group|All enrolled patients with urodynamic study
16395572|NCT04010578|Experimental|MK-7 and vitamin D3 supplementation|Patients will receive a daily MK-7 and vitamin D3 supplementation for 3 months.
16395573|NCT04010578|Placebo Comparator|Placebo|Patients will receive a daily placebo for 3 months.
16395574|NCT04010565|Experimental|Extract of aged black garlic|Participants will consume a tablet of 550 mg daily with 250 mg of aged black garlic extract and 300 mg of excipients (microcrystaline cellulose 90 mg; dicalcium phosphate 157 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg) .
16395575|NCT04010565|Placebo Comparator|Placebo|Participants will consume a tablet of 550 mg daily with 550 mg of excipients (microcrystaline cellulose 342.5 mg; dicalcium phosphate 154.5 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg).
16395576|NCT04010552|Experimental|NALIRINOX treatment|Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.
16395579|NCT04010526|Experimental|treatment|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
16395580|NCT04010526|Placebo Comparator|placebo|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
16395581|NCT04010513|Experimental|Hypnosis|
16395582|NCT04010513|Active Comparator|Standard of Care|
16395583|NCT04010500|Experimental|Rugby Players|
16395584|NCT04010487||Endometrial carcinoma arising in adenomyosis|Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
16395585|NCT04010487||Adenomyosis without malignancy|Patients pathologically diagnosed with adenomyosis
16395589|NCT04010448|Experimental|TV P2-VP8|
16395590|NCT04010448|Active Comparator|Rotarix®|
16395591|NCT04010435|Active Comparator|Group A (r TMS group)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.
16395592|NCT04010435|Active Comparator|Group B (Galvanic stimulation)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo galvanic vestibular stimulation; in addition to designed vestibular rehabilitation exercises.
16395593|NCT04010435|No Intervention|Control (Group C)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo designed vestibular rehabilitation exercises.
16395800|NCT04008992|Experimental|Part C JMAD - C1 Cohort|Japanese Multiple Ascending Dose
16395594|NCT04010422||ASD group|"Inclusion Criteria:
~Having a clinical diagnosis of autism spectrum disorder
~Aged over 20 years; able to read and sign an informed consent form.
~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.
~Exclusion Criteria:
~Unable to cooperate with the examinations.
~Younger than 20 years old"
16395595|NCT04010422||TD Group|"Inclusion Criteria:
~Aged over 20 years; able to read and sign an informed consent form.
~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.
~Exclusion Criteria:
~Unable to cooperate with the examinations.
~Younger than 20 years old.
~Having a clinical diagnosis of autism spectrum disorder"
16395596|NCT04010409||ASD Group|Autism spectrum disorder participants, no intervention
16395597|NCT04010409||TD Group|Typically developmental controls,no intervention
16395598|NCT04010396||Recipients of Bovine Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
16395599|NCT04010396||Recipients of Mechanical Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
16395600|NCT04010383||normal visual field subjects|"Cataract yes or no
~Age range 40 - 80 years
~normal visual field (MD: < +2 dB)
~Refractive error within ±5 dpt. spherical equivalent
~Astigmatism of < -3 dpt.
~Visual acuity of ≥0.3 logMar (decimal ≥0.5)
~Experience in perimetry (history of at least one perimetry examination)
~False positive or negative errors each less than 20% in each examination"
16395601|NCT04010383||Glaucomatous subjects|"Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma
~Early to moderate visual field loss (MD: +2 to +12 dB)
~Refractive error within ±5 dpt. spherical equivalent
~Astigmatism of < -3 dpt.
~Visual acuity of ≥0.3 logMar (decimal ≥0.5)
~Experience in perimetry (history of at least one perimetry examination)
~False positive or negative errors each less than 20% in each examination
~Cataract yes or no
~Age range 40 - 80 years"
16395602|NCT04010370||Healthy individuals|Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara
16395603|NCT04010357|Experimental|Abemaciclib|"Subjects will receive Abemaciclib (200 mg), orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.
~Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment."
16395604|NCT04010344|Experimental|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
16395605|NCT04010344|Active Comparator|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
16395606|NCT04010331|Experimental|Nokyong Mixture Extract(CME-PI) group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
16395607|NCT04010331|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
16395608|NCT04010318||Corrected group|The patients in which the PVI will corrected by fluid to level below 15
16395609|NCT04010318||Uncorrected group|Patients in which intravenous fluid administration didn't result any change in PVI or changed but still higher than 15
16395610|NCT04010305|Placebo Comparator|Placebo|Sublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
16395611|NCT04010305|Experimental|20 micrograms|Sublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
16395612|NCT04010305|Experimental|60 micrograms|Sublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
16395613|NCT04010305|Experimental|120 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
16395614|NCT04010305|Experimental|180 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501.
16395615|NCT04010292|Experimental|Patient education card|
16395616|NCT04010292|No Intervention|Control|
16395617|NCT04010279|Active Comparator|spontaneous breathing|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the spontaneous position.
16395618|NCT04010279|Active Comparator|spontaneous breathing with APL 5 cmH2O|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the 5 cmH2O position.
16395619|NCT04010279|Active Comparator|CPAP 5cmH2O PEEP|volunteers will breath via an anesthesia face mask spontaneously on the CPAP mode of the anesthesia workstation with 5 cmH2O PEEP.
16395620|NCT04010266|Active Comparator|Standard of care group|Receive standard of care for pain management, do not receive RelieVRx headset
16395621|NCT04010266|Experimental|Standard of care + RelieVRx group|Receive standard of care for pain management, plus RelieVRx headset
16395622|NCT04010253|Experimental|SIMEOX|
16395623|NCT04010253|Active Comparator|Autogenic Drainage|
16395624|NCT04010240||Retrospective cohort|For eligible subject, tumor material will be tested by immunohistochemistry (Pan-Trk ICH testing with mAb EPR17341).
16395625|NCT04010227|Experimental|Acceptance and Commitment Therapy|Patients and caregivers in the ACT arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
16395626|NCT04010227|Active Comparator|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
16395627|NCT04010175|Active Comparator|Control group|
16395628|NCT04010175|Experimental|Experimental group 1|Moderate frequency cognitive distance training
16395629|NCT04010175|Experimental|Experimental group 2|High frequency cognitive distance training
16395630|NCT04010162||Group-1: King's College Hospital|Doctors in King's College Hospital, London, The United Kingdom (Excluding Urology and Gynecology)
16395631|NCT04010162||Group-2: Uludag University Hospital|Doctors in Uludag University Hospital, Bursa, Turkey (Excluding Urology and Gynecology)
16395632|NCT04010162||Group-3: The United States|Doctors from The United States (Excluding Urology and Gynecology)
16395633|NCT04010162||Group-4: The World|Doctors from all over the world (Excluding Urology and Gynecology)
16395634|NCT04010149|Experimental|Active tDCS|During cognitive training in the first 2 weeks, participants will also received brain stimulation. The investigators will use a total current intensity of 2mA for 20 minutes, preceded by 30 seconds ramping up and followed by 30 seconds ramping down (total stimulation time = 21s).
16395635|NCT04010149|Sham Comparator|SHAM tDCS|During sham stimulation, concurrent with the cognitive training, The investigators will use the same setup as in the active condition but after ramping up, the current will be brought back to zero and the process repeated 30 seconds before the end of the 21 minutes time interval (total sham stimulation time = 21s).
16395636|NCT04010136|No Intervention|Control group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will be given no intervention
16395637|NCT04010136|Experimental|Identification tool group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive access to the Identification tool Supportive and Palliative Care Indicators Tool (SPICT-PT) with a brief training on how to use it.
16395638|NCT04010136|Experimental|Standard Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training according to the Center Healthcare Administrative Region standard model of training.
16395639|NCT04010136|Experimental|Clinical cases based Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training using a clinical cases based model.
16395640|NCT04010110||Patients on hydroxychloroquine|A data collection sheet was used to collect patient's information. All patients underwent a complete ophthalmic examination including assessment of visual acuity, anterior segment examination looking for corneal verticillata and a dilated fundus examination looking for retinal pigment epithelium (RPE) depigmentation either in a para-foveal or extra-macular distribution within the retina. Ancillary tests were done which included: visual field testing (10-2), spectral domain ocular coherence tomography (SDOCT). Fundus auto-fluorescence and mf-ERG were done if further ancillary testing was needed in doubtful cases or to confirm findings.
16395641|NCT04010097|Experimental|Horton group|The test involves chewing a chewing gum for 4 minutes plus a standard Horton disease diagnostic
16395642|NCT04010097|Active Comparator|N Horton Group|The test involves chewing a chewing gum for 4 minutes
16395643|NCT04010084|Placebo Comparator|Control group|
16395644|NCT04010084|Active Comparator|Laser group|
16395645|NCT04010071|Experimental|axitinib plus toripalimab|"Axitinib (Inlyta, Pfizer Inc.) is a novel oral angiogenesis inhibitor that selectively targets vascular endothelial growth factor (VEGFR) 1, 2 and 3.
~Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody."
16395646|NCT04010032|Experimental|PIEB (Programmed intermittent epidural bolus)|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)
16395647|NCT04010032|Active Comparator|CEI (Continuous epidural infusion)|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device
16395648|NCT04010019|Experimental|Enhanced Facebook Condition|The enhanced Facebook group will be moderated by clinicians and offer psychosocial pain management techniques.
16395649|NCT04010019|Active Comparator|Control Facebook Condition|In the control condition, there will be no outside intervention; rather, the investigators will instruct participants to offer mutual support for the duration of the group and will not comment further.
16395650|NCT04010006|Experimental|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
16395651|NCT04010006|Active Comparator|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
16395652|NCT04009993|Experimental|A-BIRTHPERFORM digital tool|interactive partogram that maternity care professionals of the experimental group use, in interactive and device will guide the professional thought the NICE guidelines on labour care
16395653|NCT04009993|No Intervention|control group with conventional partogram use|Conventional care in each participant hospital, with conventional partogram in each centre
16395654|NCT04009980|Experimental|OMK2 group|Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day
16395655|NCT04009980|Placebo Comparator|Placebo group|Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day
16395656|NCT04009967|Experimental|Prostate Cancer|Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
16395657|NCT04009954||Delayed transit|CRC patients with delayed gut transit recovery( first time defecation >3 day )
16395658|NCT04009954||Normal transit|CRC patients with normal gut transit recovery( first time defecation <=3 day )
16395659|NCT04009941|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
16395660|NCT04009928|Experimental|Active followed by sham stimulation|2 weeks of active stimulation of the medial forebrain bundle or subcallosal cingulate at the optimized stimulation settings derived during the open-label phase. After 1 week of washout period (with no stimulation), subjects undergo 2 weeks of sham stimulation
16395661|NCT04009928|Sham Comparator|Sham followed by active stimulation|"2 weeks of sham-stimulation, followed by 2 weeks of active stimulation, separated with 1 week washout period.
~This is a crossover study, patients will undergo both arms, the order of which they do is randomized."
16395662|NCT04009915|Experimental|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer
16395663|NCT04009915|Active Comparator|open surgery|Patients undergo a standard open operation for stage II-III lung cancer
16395664|NCT04009889|Active Comparator|verum|probiotic bland with 5 different lactobacilli
16395665|NCT04009889|Placebo Comparator|placebo|Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
16395666|NCT04009876|Experimental|Chemotherapy + Surgery|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection
16395667|NCT04009876|Experimental|Chemotherapy + Watch-and-wait|"Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and watch-and-wait surveillance protocol."
16395668|NCT04009863|Active Comparator|HIFU on NMNG|The patients with non-toxic multinodular goiter are assigned to have high intensity focused ultrasound treatment.
16395669|NCT04009863|Active Comparator|RAI on NMNG|The patients with non-toxic multinodular goiter are assigned to have radioactive iodine (i131) treatment.
16395670|NCT04009850|Experimental|Menthol e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a menthol flavored e-cigarette
16395671|NCT04009850|Experimental|Tobacco e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a tobacco flavored e-cigarette
16395672|NCT04009837|Experimental|Hip-focused|Hip-focused rehabilitation intervention
16395673|NCT04009837|Active Comparator|Spine-focused|Spine-focused rehabilitation intervention
16395674|NCT04009824|Placebo Comparator|Group 1: Saline Placebo|Participants will receive placebo on Days 1 and 22.
16395675|NCT04009824|Experimental|Group 2: AGS-v PLUS Non-Adjuvanted|Participants will receive 1012 µg of unadjuvanted AGS-v PLUS vaccine on Days 1 and 22.
16395676|NCT04009824|Experimental|Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo|Participants will receive 1012 µg of AGS-v PLUS + Montanide ISA-51 on Day 1 and placebo on Day 22.
16395677|NCT04009824|Experimental|Group 4: AGS-v PLUS + Montanide ISA-51|Participants will receive 1012 µg of AGS-v PLUS + Montanide ISA-51 on Days 1 and 22.
16395678|NCT04009824|Experimental|Group 5: AGS-v PLUS + Alhydrogel® Adjuvant|Participants will receive 1012 µg of AGS-v PLUS + Alhydrogel® on Days 1 and 22.
16395679|NCT04009811|Experimental|Suersen obturator then membraneous obturator|
16395680|NCT04009811|Experimental|Membraneous obturator then Suersen obturator|
16395681|NCT04009772|Active Comparator|"Cefepime , Maxipime® 1 gm"|"Patient will receive Cefepime ,Maxipime® 1 gm IV during cesarean section just before skin incision"
16395682|NCT04009772|Active Comparator|"Cefuroxime, Zinnat® 1gm plus metronidazoleFlagyl® 500"|"Patient will receive Cefuroxime, Zinnat® 1gm ,and metronidazoleFlagyl® 500 IV; just before skin incision for emergency cesarean section"
16395683|NCT04009759|Active Comparator|Morphine|"Morphine group (M) (n=80), where patients will be treated with i.v. injection of Morphine 2 mg/ml - 5 ml - 10 mg Epidural. The treatment will be given during CPR as soon as possible."
16395684|NCT04009759|Active Comparator|Ketamine|"Ketamine (K) group (n=80), where patients will be treated with i.v. injection of S-Ketamine 10 mg/ml - 5 ml - 50 mg Ketamin Abcur. The treatment will be given during CPR as soon as possible."
16395685|NCT04009759|Placebo Comparator|Saline|"Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% B. Braun. The treatment will be given during CPR as soon as possible."
16395686|NCT04009733|Experimental|Osteogenesis imperfecta type 1|Patients with OI type 1
16395687|NCT04009733|Experimental|Osteogenesis imperfecta type 3|Patients with OI type 3
16395688|NCT04009733|Active Comparator|Control population|The control population corresponds to a pre-existing serum collection of osteoarthritis cohorts (OFELY and MODAM for women, STRAMBO for men).
16395689|NCT04009707||patients with alcool use desorders|Patient cared for in the addictology department of the University Hospital of Nîmes
16395690|NCT04009694|Experimental|Pelvic Floor Muscle Training|"Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist.
~Participants will be assessed at weeks 0 / 4 / 10 & 16 and the outcome measures will be recorded at week 0 & week 16.
~During each assessment, participants will be educated regarding the anatomy of pelvic organ prolapses and the pelvic floor muscles. They will be taught how to contract their pelvic floor, offered a vaginal examination, given a personalised pelvic floor muscle training programme (including the Knack) - up to a ten second hold long contractions (x 10 repitations) and up to 10 quick contractions. They will also be taught a sub max contraction for up to 30 seconds, offered lifestyle management advice including avoiding heavy lifting or straining. A leaflet explaining the aforementioned information will also be provided at the initial assessment."
16395691|NCT04009681|Experimental|THOR-707 Monotherapy, Q2W|Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.
16395692|NCT04009681|Experimental|THOR-707 Monotherapy, Q3W|Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
16395693|NCT04009681|Experimental|THOR-707 in combination with a checkpoint inhibitor, Q3W|Dose Escalation: THOR-707 will be administered in sequential ascending doses in combination with a checkpoint inhibitor via IV administration Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
16395694|NCT04009681|Experimental|THOR-707 in combination with an anti-EGFR antibody, Q3W/QW|Dose Escalation: THOR-707 will be administered in sequential ascending doses in combination with an anti-EGFR antibody via IV administration Q3W/QW (respectively) until unacceptable toxicity, disease progression, or withdrawal of consent.
16395695|NCT04009668|Experimental|adalimumab|Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously
16395696|NCT04009655|Experimental|music therapy|The infant will receive music therapy over 3 consecutive days and will obtain standard care as usual
16395801|NCT04008992|Experimental|Part C JMAD - C2 Cohort|Japanese Multiple Ascending Dose
16395697|NCT04009655|No Intervention|control|The infant does not receive any sound emission because the headphone will be turned off and will obtain standard care as experimental
16395698|NCT04009642||Type 2 Diabetes|
16395699|NCT04009642||Non Diabetic|
16395700|NCT04009629|Experimental|Exercise|A single 15 minute bout of moderate intensity aerobic exercise.
16395701|NCT04009616|Experimental|Aloe Vera mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving aloe vera mouthwash by studying plaque, gingival and bleeding indices.
~the plaque will be accumulated for 3 days accumulation phase before applying aloe vera mouthwash for 5 days rinsing phase."
16395702|NCT04009616|Experimental|Chlorhexidine mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving chlorhexidine mouthwash by studying plaque, gingival and bleeding indices.
~the plaque will be accumulated for 3 days accumulation phase before applying chlorhexidine mouthwash for 5 days rinsing phase."
16395703|NCT04009616|Placebo Comparator|Placebo mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving placebo mouthwash by studying plaque, gingival and bleeding indices.
~the plaque will be accumulated for 3 days accumulation phase before applying placebo mouthwash for 5 days rinsing phase."
16395704|NCT04009603|Active Comparator|Metformin|Group no 1(26 patients) Metformin tablets at a dose of 500mg BD for 12 weeks
16395705|NCT04009603|Experimental|Probiotic|Group no 2(26 patients): will be given probiotics alone at a dose of 180mg B.D for 12 weeks
16395706|NCT04009603|Experimental|Metformin and Probiotic|Group no 3(26 patients): will be given metformin 500mg B.D and probiotics 180mgram O.D. for 12 week
16395707|NCT04009590|Experimental|GROUP I (Quit4Health)|Participants utilize Quit4Health intervention that includes interactive features, coping strategies and games related to cigarettes and other tobacco products for 1 month.
16395708|NCT04009590|Active Comparator|Group II (educational booklet)|Participants read an educational booklet about cigarettes and other tobacco products for 1 month.
16395709|NCT04009577|Experimental|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
16395710|NCT04009577|Experimental|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
16395711|NCT04009577|Experimental|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
16395712|NCT04009564|Experimental|Date seeds filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 45 g of date seeds coffee in 280 ml of boiled water, coffee flavour and brown food colouring ( made using a filter coffee machine). it will be served in a paper cup with lid
16395713|NCT04009564|Experimental|Normal filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 6 g of coffee in 280 ml of boiled water (made using a filter coffee machine) it will be served in a paper cup with lid
16395714|NCT04009564|Placebo Comparator|Placebo|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 280 of boiled water, coffee flavour and brown food colouring it will be served in a paper cup with lid
16395715|NCT04009538|Experimental|COPD patients participated PR program|COPD patients participated first and second PR program
16395716|NCT04009525|Experimental|MSD-HSCT|matched sibling donors hematopoietic stem cell transplantation
16395717|NCT04009525|Experimental|URD-HSCT|unrelated donor hematopoietic stem cell transplantation
16395718|NCT04009525|Experimental|haplo-HSCT|haplo-identical hematopoietic stem cell transplantation
16395719|NCT04009512|Experimental|Primary Study Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
16395720|NCT04009512|Experimental|Expanded Use Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments. The expanded use arm provides broaden inclusion criteria to include select patients excluded from the primary study arm.
16395722|NCT04009486|Experimental|Obstructive Sleep Apnea|Subjects will undergo 6 weeks of whole body vibration.
16395723|NCT04009473|Experimental|SEGOVA Intervention Group|Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.
16395724|NCT04009460|Experimental|Part A dose escalation|ES101 will be escalated in patients with advanced solid tumors.
16395725|NCT04009460|Experimental|Part B expansion|Subjects with solid tumors will be treated with single-agent ES101 at either specified dose levels or RP2D.
16395726|NCT04009447|Other|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) 6 sessions of Cognitive Behavioral Training for Insomnia (1 hour each).
16395727|NCT04009434|Other|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy
16395728|NCT04009434|Experimental|TAVI/MitraClip|Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.
16395729|NCT04009421||High and low coronary artery plaque burden|Patients with high plaque burden defined as plaque in >=4 segments of the coronary tree and low plaque burden as plaque in <4 segments of the coronary tree assessed by postprocessing of CT coronary angiography images and cardiovascular events and mortality.
16395730|NCT04009408|Experimental|EMST therapy|Participants use the EMST device as per study protocol, set to 50% of the patient's maximal expiratory pressure, as measured by handheld manometer.
16395731|NCT04009408|Sham Comparator|Sham EMST therapy|Participants use a sham EMST device that has the spring removed as per study protocol, with no significant airflow resistance.
16395732|NCT04009395||Pregnant women|One-on-one in-depth interviewing
16395733|NCT04009395||Midwives|One-on-one in-depth interviewing or focus group discussions
16395734|NCT04009382|Experimental|Baduanjin|This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
16395735|NCT04009382|Active Comparator|Cognitive Fitness Program|This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
16395736|NCT04009369|No Intervention|Emergency Physician Group|Usual care by the EP without the intervention of the ED PT.
16395737|NCT04009369|Experimental|Physical Therapist Group|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
16395738|NCT04009343|Active Comparator|Artemether-lumefantrine|Standard 6-dose regimen
16395739|NCT04009343|Experimental|Dihydroartemisinin-piperaquine|Standard 3-dose regimen
16395740|NCT04009330||Adults in the Intensive Care Setting|Adults in the Intensive Care Setting
16395741|NCT04009317|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.
16395742|NCT04009317|Active Comparator|Crizotinib|Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.
16395743|NCT04009304|Experimental|In-person|OSNAP intervention delivered to afterschool sites using an in-person train-the-trainer model implementation strategy
16395744|NCT04009304|Experimental|Online|OSNAP intervention delivered to afterschool sites using an online training model implementation strategy
16395745|NCT04009304|No Intervention|Control|
16395746|NCT04009291|Experimental|TransCon PTH 15 mcg|TransCon PTH 15 mcg delivered once daily by subcutaneous injection
16395747|NCT04009291|Experimental|TransCon PTH 18 mcg|TransCon PTH 18 mcg delivered once daily by subcutaneous injection
16395748|NCT04009291|Experimental|TransCon PTH 21 mcg|TransCon PTH 21 mcg delivered once daily by subcutaneous injection
16395749|NCT04009291|Placebo Comparator|Placebo|Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
16395750|NCT04009278|Experimental|1. Self-compression arm|Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
16395751|NCT04009278|No Intervention|2. Control arm|The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.
16395752|NCT04009265|Experimental|Chemotherapy|Docetaxel 75mg/m2, 3w, 2cycles. DDP 75mg/m2, 3wl, 2cycles.
16395753|NCT04009265|Experimental|Chemoradiotherapy|5040cGy, 180cGy/d, 28F Concurrent Docetaxel 60mg/m2, 3w, 2cycles DDP 60mg/m2, 3w, 2cycles
16395754|NCT04009265|No Intervention|Surgery alone|Surgery alone, no adjuvant treatment.
16395755|NCT04009252|Experimental|Intervention Group|3D model to be printed and used as teaching tool to discuss injury with patient as well as its associated long-term outcomes and potential complications. The operative plan will also be reviewed with the patient using the model as well as post-operative course (ie rehabilitation)
16395756|NCT04009252|No Intervention|Control Group|The CT image will be shown to the patients along with teaching
16395757|NCT04009239|Experimental|Early Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 1 hour after habitual wake time.
16395758|NCT04009239|Experimental|Mid-day Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 6 hours after habitual wake time.
16395759|NCT04009226||Participants with GNE|
16395760|NCT04009213|Experimental|LiquiBand FIX8®|LiquiBand FIX8® is an n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
16395761|NCT04009213|Active Comparator|AbsorbaTack™|AbsorbaTack™ is an absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2
16395762|NCT04009200||circumcision|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.
~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
16395763|NCT04009200||inguinal hernia|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.
~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
16395764|NCT04009187|Active Comparator|Training group|Training group will first receive 30 minutes of education about biomechanically efficient propulsion techniques. They will be tested on this knowledge to make sure participants understand the material. The participant then will be asked to come into the lab for 6 sessions of training, two times per week for three weeks. The training is an hour of the proper wheelchair propulsion techniques broken into 5 parts, 7 minutes each with breaks. Based on the motor learning principles, we gradually increase the components of the training by focusing either hand reaching toward the back of the wheel or hands reaching down toward the axle.
16395765|NCT04009187|Active Comparator|Control group|Control group will first receive 30 minutes of education about the biomechanically efficient propulsion. They will be tested on this knowledge to make sure participants understand the material. No further training will be implemented with this group.
16395766|NCT04009174|Experimental|Imaging Panel|Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.
16395767|NCT04009148||Successful Cascade Testing|Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
16395768|NCT04009148||Relative Declines Genetic Testing|Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.
16395769|NCT04009135|Experimental|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
16395770|NCT04009135|Experimental|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind & acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
16395771|NCT04009135|Placebo Comparator|Attention Control (AC)|Patients in the control condition will be given access online psychoeducation about depression and chronic pain. They will be provided weekly phone calls to query symptoms and well-being.
16395772|NCT04009122|Experimental|IGEN-0206|a sachet after each meal, preferably (3 sachets per day)
16395773|NCT04009122|Placebo Comparator|Placebo|a sachet after each meal, preferably (3 sachets per day)
16395774|NCT04009122|No Intervention|group C|standard treatment
16395775|NCT04009109|Experimental|Lenalidomide|12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
16395776|NCT04009109|Experimental|Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone|12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
16395777|NCT04009096|Experimental|Group 1|3 volunteers receiving 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later.
16395778|NCT04009096|Experimental|Group 2|Up to 10 volunteers receiving one dose of 5 x 10^10 vp ChAd63 PvDBP, 12-18 months later receiving a second dose of 5 x 10^10 vp ChAd63 PvDBP and 8 weeks later 2 x 10^8 pfu MVA PvDBP, followed by blood-stage CHMI 2-4 weeks later.
16395779|NCT04009096|Experimental|Group 3|"If fewer than 6 volunteers complete the study in Group 2, then new volunteers will be recruited into Group 3, to make up a total of 6 volunteers between Groups 2 and 3 who complete all vaccinations and CHMI.
~Volunteers in Group 3 will receive 5 x 10^10 vp ChAd63 PvDBP and 2 x10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later."
16395780|NCT04009083|Other|Standard of Care|
16395781|NCT04009083|Experimental|18F-Fluciclovine PET Scan|
16395782|NCT04009070|Active Comparator|Acupuncture|"Group A: Acupuncture group:Group A: Acupunctur will be applied to the Acupunctur group 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally on the tibia) . The tape (Needle Press) will stay for 24 hours.
~Needle Press: Pres Needle: 0.22x1.5 mm needle"
16395783|NCT04009070|No Intervention|Control Group|Group C: Control group
16395784|NCT04009057||B/F/TAF|HIV-1 infected adults who initiate B/F/TAF therapy
16395785|NCT04009044|Experimental|Treatment (afimoxifene)|Patients apply afimoxifene gel topically QD to both breasts for 4 weeks and then undergo core needle biopsies of both breasts.
16395786|NCT04009031|Experimental|Bootle Blast|"Bootle Blast is a series of 13 mini-games targeting different upper limb motor therapy goals. Bootle Blast is designed with many of the features of mainstream video games known to be appealing to young people. Game rewards are linked to meeting therapeutic objectives, such as daily play targets that are customizable to each child. Bootle Blast is played through movements of the upper limbs tracked via a low-cost camera/sensor (Microsoft Kinect, no hand-held controls needed). The movements required to play are customizable to each child's range of motion. Some of the mini-games are mixed reality, where children interact and manipulate real-life objects (e.g. musical instruments, coloured building blocks) to play the game. The use of skeletal tracking and mixed reality enables both gross and fine motor skills to be practiced in line with each child's therapy goals and motor abilities."
16395787|NCT04009018|Other|Psycometric analyses|It will be a validation study of the Perioperative Satisfaction Scale in Regional Anesthesia. This study is not experimental research. This is a psychometric assessment study of a questionnaire and data will collect pencil-paper survey and face to face from the patients who will get regional anesthesia in the postoperative second day.
16395788|NCT04009005|No Intervention|Usual care|Participants will receive usual care from their treating neurologist
16395789|NCT04009005|Experimental|Therapeutic Lifestyle|Participants will be trained via videos from a three day in-person seminar that teaches the public about the use of a therapeutic diet and lifestyle to reduce multiple sclerosis related fatigue and improve quality of life.
16395790|NCT04008992|Experimental|Part A SAD - A1 Cohort|Single Ascending Dose
16395791|NCT04008992|Experimental|Part A SAD - A2 Cohort|Single Ascending dose
16395792|NCT04008992|Experimental|Part A SAD- A3 Cohort|Single Ascending dose
16395793|NCT04008992|Experimental|Part A SAD- A4 Cohort|Single Ascending dose
16395794|NCT04008992|Experimental|Part A SAD - A5 Cohort|Single Ascending dose
16395795|NCT04008992|Experimental|Part A SAD- A6 Cohort|Single Ascending dose
16395796|NCT04008992|Experimental|Part B MAD- B1 Cohort|Multiple Ascending Dose
16395797|NCT04008992|Experimental|Part B MAD - B2 Cohort|Multiple Ascending Dose
16395798|NCT04008992|Experimental|Part B MAD - B3 Cohort|Multiple Ascending Dose
16395799|NCT04008992|Experimental|Part B MAD - B4 Cohort|Multiple Ascending Dose
16395807|NCT04008966|Active Comparator|single trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
16395808|NCT04008966|Active Comparator|Dual trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously
16395809|NCT04008953||Sixteen patients having end stage renal disease|Intravascular volume assessment in 16 pediatric patients under going renal transplant surgery using ultrasonography, CVP and echocardiography
16395810|NCT04008927|Other|All patients|All participants recruited during the RDS survey.
16395811|NCT04008927|Other|HCV infected patients|HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL)
16395812|NCT04008927|Other|Patients with hepatitis C|Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.
16395813|NCT04008914||readmission at 30 days|
16395814|NCT04008914||readmission at 90 days|
16395815|NCT04008901|Active Comparator|Treatment group|The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
16395816|NCT04008901|Placebo Comparator|Placebo group|The randomly assigned target was given a placebo for eight weeks.
16395817|NCT04008888|Experimental|A:Allogeneic Stem Cell Transplant Group|Fludarabine+Melphalan followed by Allogeneic SCT.
16395818|NCT04008888|Experimental|B:Autologous Stem Cell Transplant|Melphalan followed by Autologous SCT.
16395819|NCT04008888|Experimental|C:Non-Transplant|Consolidated Chemotherapy for Patients Unable to Receive Transplantation
16395820|NCT04008875||Successful weaning/extubation|"Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.
~Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation."
16395821|NCT04008875||Failed weaning/extubation|"Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.
~Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy."
16395822|NCT04008862|Experimental|Partnership-based care|Each patient will serve as his/her own control
16395823|NCT04008849||Subjects treated with MGTA-456|MGTA-456 is an investigational expanded CD34+ cell therapy
16395824|NCT04008797|Experimental|HCC: E7386 QD Part|Participants with HCC will receive E7386 tablets, orally, QD for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386 tablets, orally, QD in combination with lenvatinib capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
16395825|NCT04008797|Experimental|HCC: E7386: BID Part|Participants with HCC will receive E7386 tablets, orally, BID for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386 tablets, orally, BID in combination with lenvatinib capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
16395826|NCT04008797|Experimental|Other ST: E7386 QD Part|Participants with ST (except for HCC) will receive E7386 tablets, alone orally, QD for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386 tablets, orally, QD in combination with lenvatinib capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 and lenvatinib will be based on the available safety data from the previous cohorts.
16395827|NCT04008797|Experimental|Other ST: E7386 BID Part|Participants with ST (except for HCC) will receive E7386 tablets, alone orally, BID for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386 tablets, orally, BID in combination with lenvatinib capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 and lenvatinib will be based on the available safety data from the previous cohorts.
16395828|NCT04008784||Crisaborole 2% Topical Application Ointment [EUCRISA]|Crisaborole 2% Topical Application Ointment [EUCRISA] applied twice a day for 8 weeks
16395829|NCT04008784||Crisaborole 2% plus Triamcinolone Acetonide 0.1%Ointment|Crisaborole 2% plus Triamcinolone Acetonide 0.1% Ointment applied twice a day for the first 2 weeks, followed by Crisaborole 2% alone applied twice a day for the following 6 weeks
16395830|NCT04008771|Experimental|Severe Disease|Subjects with baseline BCVA between 20/16000 and hand motion (HM). Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
16395831|NCT04008771|Experimental|Moderate to Severe Disease|Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten [10]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
16395832|NCT04008758|Experimental|sono group|Evaluate the participant's lung condition using ultrasound and do recruitment maneuver if it is necessary
16395833|NCT04008758|No Intervention|control group|If participants need recruitment maneuver (decreasing saturation, peak airway pressure > 35 mmHg) by clinical judgement, do recruitment maneuver not using lung ultrasound
16395834|NCT04008745|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in an educational booklet three times/week at home. In the follow-up period, patients will follow the same schedule set by the project till the end of the study (16-weeks).
16395871|NCT04008550|Other|Pulmonary Arterial Hypertension before TAVI|In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).
16395835|NCT04008745|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
16395836|NCT04008732|Experimental|MED2005 (0.6 mg)|MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study
16395837|NCT04008732|Experimental|MED2005 (1.2 mg)|MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study
16395838|NCT04008732|Experimental|MED2005 (1.8 mg)|MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study
16395839|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 1|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
16395840|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 2|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
16395841|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 1|MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study
16395842|NCT04008732|Active Comparator|Intravenous (I.V.) dose of GTN (0.3 mg)|GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study
16395843|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 2|MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study
16395844|NCT04008719|Other|Patients|Assessments are made by a psychiatrist
16395845|NCT04008706|Experimental|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive (TN) cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory (R/R) cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior Bruton tyrosine kinase inhibitor (BTKi) therapy cohort, up to 70 to 100 participants with Prior BTKi therapy will be enrolled.
16395846|NCT04008693|Active Comparator|Kyolic® Hi-Po Formula - Kyolic|Aged garlic extract
16395847|NCT04008693|Placebo Comparator|Placebo|Maltodextrin
16395848|NCT04008680|Other|Low response burden|Participants will be assigned to complete only the EQ-5D-5L questionnaire.
16395849|NCT04008680|Other|Low to medium response burden|Participants will be assigned to complete the General Anxiety Disorder-7 (GAD-7) questionnaire first, followed by the EQ-5D-5L questionnaire.
16395850|NCT04008680|Other|Medium to high response burden|Participants will be assigned to complete the Pain Catastrophizing Scale (PCS) questionnaire first, followed by the GAD-7, and lastly the EQ-5D-5L questionnaire.
16395851|NCT04008680|Other|High response burden|Participants will be assigned to complete the Brief Pain Inventory (BPI) questionnaire first, followed by the PCS secondly, the GAD-7 third, and lastly the EQ-5D-5L questionnaire.
16395852|NCT04008667|Experimental|Intervention arm|"Receiving the acupoint application and optimal supports.
~The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
16395853|NCT04008667|Placebo Comparator|Placebo arm|"Receiving the fake acupoint application and optimal supports.
~The fake acupoint is
~The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
16395854|NCT04008667|No Intervention|Control arm|"Receiving the optimal supports.
~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
16395855|NCT04008654|Active Comparator|ERAS group|This groups will receive ERAS protocol
16395856|NCT04008654|Placebo Comparator|Conventional care|This group will not receive the ERAS protocol.
16395857|NCT04008641||Parents after pediatric antenatal consultation|Survey after pediatric antenatal consultation, for both members of couple if possible
16395858|NCT04008628|Active Comparator|Nitrous oxide|Inhalation of a 50%/50% mixture of nitrous oxide and oxygen. Reassurance of the child during procedure
16395859|NCT04008628|No Intervention|Standard care|Infants will be reassured as currently performed in routine clinical practice
16395860|NCT04008615||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.
~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test.
~For the purpose of this study, patients will be offered to participate in an additional exercise session in which they will repeat the same procedure (two 6-minute stepper test) but but monitoring cardiopulmonary parameters and gaz exchanges using a face mask, a pneumotachograph and a gaz analyser (indirect calorimetry)."
16395861|NCT04008602|Active Comparator|Experimental: Quick Icing|Group receiving the application of cold on the ventral side of the thigh (bilaterally) for 30 seconds, using the technique of ice beakers dynamically.
16395862|NCT04008602|Active Comparator|Experimental: Prolonged Cold|"Group receiving the intervention of ice bag for a period of eight minutes n the ventral side of the thigh (bilaterally)."
16395863|NCT04008602|No Intervention|Control:|Group that does not receive intervention and that will rest for ten minutes.
16395864|NCT04008589|Experimental|rtACS|repetitive transorbital ACS
16395865|NCT04008589|Experimental|tDCS/rtACS|Sequential tDCS - tACS
16395866|NCT04008589|Sham Comparator|Sham stimulation|
16395868|NCT04008563|Experimental|Bariatric Surgery and Progestin Intrauterine Device|This group will receive a progestin intrauterine device and be offered to undergo bariatric surgery.
16395869|NCT04008563|No Intervention|Progestin Intrauterine Device Alone|This group will receive a progestin intrauterine device alone.
16395870|NCT04008550|No Intervention|No Pulmonary Arterial Hypertension before TAVI|No intervention has been done in this group of patients.
16415639|NCT03870282|Experimental|"Personal Goal | Texts A"|
16395873|NCT04008511|Experimental|Phase Ib: Regorafenib plus XELOX|"Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:
~Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)"
16395874|NCT04008511|Experimental|Phase II: Regorafenib plus XELOX|Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
16395875|NCT04008511|Active Comparator|Phase II: XELOX|Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
16395876|NCT04008498|Experimental|AEEG monitoring|"Babies whose families consent to involvement will have their head cleaned, EEG leads attached, the monitor set up, and observations.
~Babies will be recorded continuously for the entire duration of their time on the intensive care unit.
~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.
~Before being discharged home, the babies will have additional follow-up. They will receive magnetic resonance imaging (MRI) of the brain on a 1.5T scanner at the University of Sheffield. They will also have a standardised examination of their neurological system performed by a physiotherapist (The Hammersmith Neonatal Neurological Examination)."
16395877|NCT04008485|Experimental|Asymptomatic high-risk women|Women will be scheduled to attend for MIS measurement at 20-22 weeks, to be repeated at 26-28 weeks. This measurement will be taken at the same time as the routine examination which they receive when they attend the prematurity clinic. At each study visit the patient will undergo a vaginal examination. Triple high vaginal swabs will then be taken for bacteriology and fetal fibronectin. The sterile magnetic impedance probe will then be introduced, data being captured automatically by pressing the data capture button on the handle of the device. A transvaginal scan will also be performed to measure CL.
16395878|NCT04008485|Experimental|Symptomatic pregnant women|These women (≥ 16 years of age) will be approached when they attend the labour delivery room or triage with symptoms of preterm labour as detailed above. As a matter of clinical routine these women receive a speculum examination, triple vaginal swabs taken, and fetal fibronectin and cervical length scans as indicated. The study will be explained to them and study materials provided. They will be asked to contact research staff by telephone or through their clinical midwife if they wish to participate. They will be given time to decide. If they agree to take part, written informed consent will then be obtained by research staff who will also conduct the MIS study. If clinical assessments have not already been performed by the time of obtaining consent they will be carried out at the same time
16395879|NCT04008472|Experimental|Telemedecine|Patients benefiting from telemedicine
16395880|NCT04008472|No Intervention|Control|routine care without telemedecine
16395881|NCT04008459||Degenerative musculoskeletal spinal conditions|Participants are included who are enrolled in a 6-week physiotherapy exercise class aimed at improving function in people with degenerative spinal conditions.
16395882|NCT04008433|Experimental|Lidocaine pre-intravenous injection|The initial dose of lidocaine for pre-injection was set at 0.5mg /kg according to previous literature and preliminary test results. The dose of lidocaine was according to the patients' pain level. If there is no pain (negative reaction), the dose of lidocaine in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of lidocaine will be increased in the next patient until the patient is painless.
16395883|NCT04008420||Adults who are scheduled to undergo robotic esophagectomy|Adults who are scheduled to undergo robotic esophagectomy
16395884|NCT04008407|Active Comparator|ESD|Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
16395885|NCT04008407|Active Comparator|EMR|Lesion with no overt or a low risk for (<10%) for covert SMIC
16395886|NCT04008394|Experimental|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
16395887|NCT04008381|Experimental|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
16395888|NCT04008368|Other|1|patients with HLA-matched sibling donors
16395889|NCT04008368|Other|2|patients with haploidentical donors
16395890|NCT04008355|Experimental|60mg/day/84 days|Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
16395891|NCT04008355|Experimental|80mg/day/10 days followed by 50mg/day/74 days|Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
16395892|NCT04008355|Placebo Comparator|Placebo/84 days|Patients randomized in this arm will receive placebo solution once daily during 84 days.
16395893|NCT04008342|Experimental|Intervention group|The intervention group (IG) was submitted to 16 multisensory sessions that followed the protocol.
16395894|NCT04008342|No Intervention|Control group|The control group (CG) received usual care with routine interventions and services in the LTC, such as bath, hygiene care, watching TV and so on.
16395895|NCT04008316|Experimental|colchicine 1mg/day|Colchicine per os: 1 tablet (1mg) / day during 6 months
16395896|NCT04008316|Placebo Comparator|placebo|placebo 1 tablet / day during 6 months
16395935|NCT04008043|Active Comparator|Vicodin|Participants in this arm will take a vicodin tablet every 4-6 hrs as needed to a maximum of 8 tablets after surgery. Each tablet has 300 mg acetaminophen and 5 mg hydrocodone. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
16415640|NCT03870282|Experimental|"Personal Goal | Texts A&B"|
16395897|NCT04008303||Patients with migraines|"Patients seen in clinic and assessed with Migraine Headache Diagnostic Criteria to ensure diagnosis.
~Patients track the characteristics of migraine headaches for one month before surgery.
~After this month, patients receive surgery in the operating room for migraine.
~After surgery, patients track the characteristics of migraine headaches for 3 months.
~Patients will then be asked to track the characteristics migraine headaches again at 1 year and 2 years and 5 years after surgery. For these time periods, patients only have to keep track of the characteristics for 1 month intervals."
16395898|NCT04008290|Experimental|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl containing 0.6 mg liraglutide.
16395899|NCT04008290|Placebo Comparator|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl saline (0.9%) solution.
16395900|NCT04008264||Standard post operative pain regimen|There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
16395901|NCT04008264||Scopolomine group|During the observational phase, patients will be on scopolamine for a total 6 day course (one patch applied at time of surgery, prescription for one patch), and patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery. The patients who incorporate scopolamine into their post operative analgesia regimen will be eligible for inclusion in the study.
16395902|NCT04008251|Experimental|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
16395903|NCT04008238|Experimental|Biomarker analysis|This study is a single arm study with biomarker analysis
16395904|NCT04008225||ARDS group|Inpatients hospitalized in medical intensive care with a table of ARDS defined according to the Berlin criteria and requiring an BAL for a diagnostic purpose under a suspicion of pneumopathy acquired under mechanical ventilation.
16395905|NCT04008225||Control group|The control group will be made up of patients with an BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: < 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (< 20%), neutrophils: < 5%, eosinophils: < 2%.
16395906|NCT04008212||EVAR aneurysm|
16395907|NCT04008212||Stenosis|
16395908|NCT04008199|No Intervention|Control|Control group will not receive any intervention. Households in this group will only be surveyed.
16395909|NCT04008199|Experimental|Treatment|Treatment group will receive an invitation to join Super Abbu in addition to identical surveys to those in the control group.
16395910|NCT04008186|Experimental|Omaveloxolone and Multiple Drugs (Part 1)|Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27
16395911|NCT04008186|Experimental|Omaveloxolone & Gemfibrozil (Part 2)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
16395912|NCT04008186|Experimental|Omaveloxolone and Itraconazole (Part 3)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
16395913|NCT04008186|Experimental|Omaveloxolone and Verapamil (Part 4)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.
16395914|NCT04008173||Male|Non-interventional patient registry
16395915|NCT04008173||Female|Non-interventional patient registry
16395916|NCT04008173||Kidney Disease|Non-interventional patient registry
16395917|NCT04008173||Diabetes|Non-interventional patient registry
16395918|NCT04008173||Elderly|Non-interventional patient registry
16395919|NCT04008160||healthy persons|
16395920|NCT04008160||individuals with paraplegia|
16395921|NCT04008147|Active Comparator|No GDM, non-anemic|12 women with no gestational diabetes who are not anemic
16395922|NCT04008147|Active Comparator|No GDM, anemic|12 women with no gestational diabetes who are anemic
16395923|NCT04008147|Experimental|GDM, non anemic|12 women with gestational diabetes who are not anemic
16395924|NCT04008147|Experimental|GDM, anemic|12 women with gestational diabetes who are anemic
16395925|NCT04008134|No Intervention|Standard recommendation (ORS)|Participants received the standard recommendation on oral rehydration solution use
16395926|NCT04008134|Experimental|mHealth with no home visits|Participants received the health facility delivery of CHoBI7, plus bi-weekly mHealth (voice and text) reminders for 12 months
16395927|NCT04008134|Experimental|mHealth with home visits|Participants received the health facility delivery of CHoBI7, plus two home visits and bi-weekly mHealth (voice and text) reminders for 12 months
16395928|NCT04008121|Experimental|Adult participants with normal or diseased eyes|500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography
16395929|NCT04008108|Experimental|Patient with urinary incontinence|Patient with urinary incontinence
16395930|NCT04008082||Lenvatinib|Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (<) 60 kg, orally, once daily as per routine clinical practice.
16395931|NCT04008069|Experimental|Study drug|sarilumab 200 mg subcutaneously every two weeks
16395932|NCT04008069|Placebo Comparator|placebo|placebo subcutaneously every two weeks
16395933|NCT04008056||Patients undergoing chemotherapy|
16395934|NCT04008043|Experimental|Dexamethasone|Participants in this arm will take a 6mg dexamethasone tablet the day before surgery, a 6 mg tablet the day of surgery, a 4mg tablet the day after surgery and a 2mg tablet the second day after surgery. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
16395936|NCT04008030|Experimental|Arm A: Nivolumab Monotherapy|Specified dose on specified days
16395937|NCT04008030|Experimental|Arm B: Nivolumab + Ipilimumab Combination|Specified dose on specified days
16395938|NCT04008030|Active Comparator|Arm C: Investigator's Choice Chemotherapy|Specified dose on specified days. Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress
16395939|NCT04008017||stable Chronic obstructive pulmonary disease|clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
16395940|NCT04008017||acute exacerbation of Chronic obstructive pulmonary disease|patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
16395941|NCT04008004|Experimental|EDP-514 HV SAD Cohorts|EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
16395942|NCT04008004|Experimental|EDP-514 HV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
16395943|NCT04008004|Placebo Comparator|EDP-514 HV SAD Placebo Cohort|Matching placebo, orally, once daily in one single administration
16395944|NCT04008004|Placebo Comparator|EDP-514 HV MAD Placebo Cohort|Matching placebo, orally, once daily for 14 days
16395945|NCT04008004|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
16395946|NCT04008004|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days
16395947|NCT04007991|Experimental|Ecopipam 2 mg/kg/day|Ecopipam HCl 12.5-, 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings
16395948|NCT04007991|Placebo Comparator|Placebo|Matching Placebo tablets taken orally in the evening
16395949|NCT04007978|Experimental|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
16395950|NCT04007965|Experimental|Opacified posterior capsule|PCO
16395951|NCT04007965|Active Comparator|Clear posterior capsule|CPC
16395952|NCT04007952|No Intervention|Intervention 1 (Control)|No anterior gastropexy will be performed.
16395953|NCT04007952|Experimental|Intervention 2 (Treatment)|Anterior gastropexy will be performed.
16395954|NCT04007939||Employee population|Subject comprised of employees of Metagenics but later will be expanded to those recruited from practitioner practices
16395955|NCT04007926|No Intervention|Control Group|Participants assigned to the control arm of the study will be asked to maintain their normal dietary and exercise habits.
16395956|NCT04007926|Experimental|Aerobic exercise group|Participants randomised to the aerobic exercise intervention will undertake a 12-week aerobic exercise training programme.
16395957|NCT04007926|Experimental|Resistance exercise group|Participants randomised to the resistance exercise intervention will undertake a 12-week aerobic exercise training programme.
16395958|NCT04007913|Experimental|teleCBIT|Patient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
16395959|NCT04007900|Experimental|Positive Affect Treatment|Individuals randomized to the intervention will participate in 20 therapy visits. Before each therapy visit, the participant will meet briefly with a member of the research staff, who will measure weight (blind to the participant) and administer the CHEDS, PANAS, and a pre-session feedback form that will assess how helpful the skills learned in the prior session had been over the past week. After the session, the participant will complete the post-session feedback form, which will assess how helpful the skills he or she perceived the skills from this session to be. These procedures will take approximately 10 minutes. Each intervention session will take approximately 50 minutes to complete. Therefore, each intervention visit will be approximately 1 hour long. Therapy sessions will take place either in the private office of a study therapist or in a consultation room of the Ambulatory Research Center.
16395960|NCT04007900|No Intervention|Waitlist|For participants randomized to the waitlist control, the opportunity will be offered to participate in the intervention following the second assessment (20 weeks following their Baseline assessment).
16395961|NCT04007887|Experimental|Intervention|Post-MI patients attending an adult education program designed to inform and motivate them on how to best control cardiovascular risk factors as a means to offer optimized secondary prevention of cardiovascular events
16395962|NCT04007887|No Intervention|Controls|Usual care for post-MI patients
16395963|NCT04007874|Experimental|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
16395964|NCT04007874|Active Comparator|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
16395965|NCT04007861||Patients with pain|"This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.
~Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included."
16395966|NCT04007861||Patients without pain|"This will be the group of patients in whom pain is deemed not to be a significant problem.
~Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the patients with pain will be identified using records of hospital operating lists by the peri-operative medicine team.
~Patients will be matched based upon the following details:
~Age (within 5 years of matched case)
~Surgical procedure (matched for the following elements:
~Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)
~+/- Sentinal lymph node biopsy or axillary dissection
~+/- Reconstruction
~Surgical procedure within 3-months of matched case.
~Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls."
16395967|NCT04007848|Experimental|Cobimetinib|Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
16395968|NCT04007848|Placebo Comparator|Placebo|Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
16396052|NCT04007224|Experimental|Autologous umbilical cord blood|Intravenous administration of autologous umbilical cord blood
16396053|NCT04007211|Experimental|ABT13107|
16396054|NCT04007211|Active Comparator|Hyalobarrier|
16395969|NCT04007835|Experimental|Anlotinib Hydrochloride combined with EGFR-TKI|Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
16395970|NCT04007822||Physiotherapists|Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
16395971|NCT04007809|Experimental|New-onset Type 1 diabetes|
16395972|NCT04007796|Experimental|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
16395973|NCT04007796|Active Comparator|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
16395974|NCT04007770|Experimental|Acupuncture|
16395975|NCT04007770|Sham Comparator|Sham Acupuncture (SA)|
16395976|NCT04007770|Other|Wait-List Control|This arm is Closed to accrual.
16395977|NCT04007757||1|Participants who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study who live in the area of University of Cincinnati, Massachusetts General Hospital, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of participant or legal representative to provide informed consent. Racial/ethnic category of Caucasian, African American or Hispanic.
16395978|NCT04007744|Experimental|Treatment (sonidegib, pembrolizumab)|Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16395979|NCT04007731|Experimental|High protein, high fibre and creatine load bar (DrRip)|1 new protein bar (260 kcal) after training every day
16395980|NCT04007731|Active Comparator|Voltage energy bar|1 control commercially available protein bar (260 kcal) after training every day
16395981|NCT04007718|Experimental|Active|
16395982|NCT04007718|Sham Comparator|Control|
16395983|NCT04007705|Experimental|Anti-inflammatory and low FODMAPs diet|The anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy and processed food, for three months. During the first month, a low FODMAPs diet will be implemented, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Additionally, some potentially anti-inflammatory foods will be promoted: Omega-3 through specific fish (tuna fish, salmon, sardine, horse mackerel) and nuts, antioxidant rich foods, such as fruit and vegetables, and the maintenance of glycemic index.
16395984|NCT04007705|Active Comparator|Control|Dietary counselling based on general recommendations for healthy eating according to the World Health Organization
16395985|NCT04007692||Simple interrupted suture group|Participants will have a simple interrupted suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
16395986|NCT04007692||Triangular suture group|Participants will have a triangular suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
16395987|NCT04007679|Experimental|Pain education group|Pain education was conducted in physical conditions similar to the university classrooms where the study was performed for all participants.
16395988|NCT04007666|Experimental|Cognitive Processing Therapy (CPT)|CPT is a gold-standard evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms. It can be delivered in group and individual formats, but will be delivered in a group format in this project due to feasibility in the setting. Structure will be based on feedback obtained during completion of Aim 2 while remaining within the range evaluated in prior research (i.e., 8-12 sessions, 1-2x per week, each lasting 1.5-2 hours).
16395989|NCT04007666|Active Comparator|Coping Skills Group|The Coping Skills Group will match for attention and dose, without adding any cost to the system. Exact content will be determined during completion of Aim 2; however, project sites already provide coping-focused programming and coping-skill approaches to trauma treatment are a common alternative to evidence-based therapies for PTSD, such as CPT, that deal more directly with the index trauma. To provide an enhanced standard of care, the investigator will review treatment materials (workbooks, handouts) already used in prison settings and arrange a curriculum of skills similar to those in coping-focused trauma-informed interventions (e.g., psychoeducation, assertiveness).
16395990|NCT04007653||Patients treated with heparin+edoxaban for VTE|Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
16395991|NCT04007653||Patients treated with heparin+VKA for VTE|Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
16395992|NCT04007640|Other|Volunteer patient|1st stage: To adjust the transducer, test and validate pancreatic MRI sequences on volunteers without history of known pancreatic disorders. Adjustment of MRI parameters is needed to optimize data acquisition, especially in obese patients. Moreover, an external material (transducer) has to be applied on the abdomen. The right position has to be tested and specified before stages 2 and 3 of the study. We aim to include volunteers without history of known pancreatic disorders for the Stage 1, meaning volunteers without personal history or symptoms suggesting pancreatic disorders.
16396092|NCT04006899||subj 1|Three commercially available BIA devices vs SBIS device
16395993|NCT04007640|Other|Obese volunteers with indication for hepatic MRI|2nd stage: To validate and assess pancreatic MRI sequences on obese volunteers with indication for hepatic MRI , in relation with acceptable resolution and field of view criteria applicable to the typical anteroposterior diameters found in obese persons. For Magnetic Resonance Elastography (MRE), the amplitude setting of the MRE transducer will be adapted to the size of obese patients, in addition to the aforementioned adjustments to spatial resolution and field of view sizes. The effect of frequency on MRE data quality will be investigated. The effects of respiratory motion will be investigated; indeed in obese patients respiration amplitude is typically low and this enables to acquire data in free breathing mode over long periods of time, which offers more possibilities (notably in terms of averaging, spatial resolution, mechanical wave sampling rate) than when constraining acquisition parameters with a maximum breath hold time of less than 20s.
16395994|NCT04007640|Other|Obese patient|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
16395995|NCT04007640|Other|Non obese patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
16395996|NCT04007640|Other|Overweight patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
16395997|NCT04007614||Patients|Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
16396000|NCT04007588|Experimental|Nivolumab+BMS-986205|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
~BMS-986205 will be administered orally on a daily basis"
16396001|NCT04007588|Experimental|Nivolumab|-Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
16396002|NCT04007588|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
~Ipilimumab will be administered intravenously every 6 weeks"
16396003|NCT04007562||Lipin-1 deficiency|Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
16396004|NCT04007549|Experimental|Individual brief motivational intervention|Individual brief motivational intervention (IBMI) on tobacco/alcohol risk reduction for the breast cancer patient; the partner receive e-mail or postal brief advices.
16396005|NCT04007549|Active Comparator|Couple-based brief motivational intervention|Couple-based brief motivational intervention (CBMI) on tobacco/alcohol risk reduction.
16396006|NCT04007536||Part 1|Patients from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
16396007|NCT04007536||Part 2|Patients from 2 through 30 years of age who have MPS II will be enrolled; Part 2 will entail a single collection of CSF, urine, and blood. Clinical assessments are optional in Part 2.
16396008|NCT04007523|No Intervention|Usual Care Group|Usual care per surgical ward standards
16396009|NCT04007523|Experimental|HELP Support System|This arm will receive the HELP Support System intervention only
16396010|NCT04007523|Experimental|Family Support System|This arm will receive the Family Support system intervention only
16396011|NCT04007523|Experimental|Combined Support Systems|Participants randomized to this arm will receive both HELP- and family-based support system interventions
16396012|NCT04007510|Experimental|EPI-CAL mHealth data network|"This arm of the study involves the use of the mobile health technology (app) to measure outcomes within an early psychosis (EP) program."
16396013|NCT04007510|Experimental|DUP Evaluation|A subset of individuals will participate in interviews to validate a tool to determine the duration of untreated psychosis in community settings
16396014|NCT04007484|Experimental|HP+CPB/DHCA group|For patients randomized into the intervention group, a hemoperfusion device will be connected in series to the extracorporeal circulation machine in advance to ensure that every single patient will undergo continuous hemoperfusion from the beginning to the end of CPB.
16396015|NCT04007484|No Intervention|CPB/DHCA group|For patients randomized into the CPB/DHCA group, no hemoperfusion device will be connect to the extracorporeal circulation machine. Patients will undergo CPB and DHCA without continuous hemoperfusion.
16396016|NCT04007458|Active Comparator|Letter|Patients will receive a letter reminding them that they are overdue for repeat annual screening.
16396017|NCT04007458|Experimental|Community Health Worker phone call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
16396018|NCT04007445|Active Comparator|Formally Directed Group (Exercise Group)|A group performing a 12 - week guided exercise program at an accessible Community Health and Wellness Center
16396019|NCT04007445|Placebo Comparator|Self-Directed Group (Control Group)|A group receiving educational information about physical activity and exercise at home and then self-directing a 12 - week exercise program on their own.
16396020|NCT04007432|Experimental|Older patients with hip fracture|Older patients admitted for hip fracture surgery
16396055|NCT04007198|Experimental|EQ001|EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
16396056|NCT04007198|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
16396057|NCT04007185||Control group|30 patients undergoing biopsy for brain tumour. They have the effect of the tumour but not the impact of surgery. Changes in QoL will inform the RCI measures planned
16396058|NCT04007185||Surgery Group|The main test group. This group have been determined by their treating surgeon to undergo a resection of the tumour so will be different from the control arm by undergoing a safe, maximal resection of their tumour
16396021|NCT04007419|Experimental|Single Arm|The Promotoras de Donación eLearning module will be launched and 40 participating lay health educators trained. Access to the module will be provided via a link to the website embedded in an announcement email. To assess the impact of the Promotoras de Donación eLearning module on lay health educators' knowledge of organ donation and the need for Hispanic donors, and confidence communicating about donation and promoting the act of donor registration, participating lay health educators will complete a brief online survey upon enrollment (pre) and after completing the module (post). Then, trained lay health educators will hold at least 2 small group sessions with mature Latina (6-8 per session); in all, 80 sessions are anticipated with 480 to 640 mature Latina. Participating mature Latina will complete anonymous paper-pencil surveys before and after each session to assess changes in attitudes toward organ donation and donor registration and intent to register as posthumous organ donors.
16396022|NCT04007406|Experimental|DP13 low|DP13 for 8 weeks
16396023|NCT04007406|Experimental|DP13 middle|DP13 for 8 weeks
16396024|NCT04007406|Experimental|DP13 high|DP13 for 8 weeks
16396025|NCT04007393|Other|LSMT x 12 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks. At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
16396026|NCT04007393|Other|LSMT x 24 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
16396027|NCT04007380|Other|CPAP-therapy arm|This single-arm clinical trial will examine the effects of 4-month period CPAP therapy in individuals living with SCI. The CPAP will be adjusted according to the results of the auto-titrating CPAP testing for each participant.
16396030|NCT04007354|No Intervention|Intubated|The patient was intubated with a left-sided double-lumen endobronchial tube. The protective ventilation was performed as follows: a tidal volume of 6 mL/kg predicted body weight, I:E ratio of 1:2, a respiratory rate to maintain PaCO2 within 35 to 45 mmHg, and positive end-expiratory pressure at 5 cmH2O. If the airway pressure exceeded 25 cmH2O, tidal volume was adjusted.
16396031|NCT04007354|Experimental|Non-intubated|The patients were oxygenated via facial mask with O2 5~10 L/min during the whole procedure. The end-tidal carbon dioxide (EtCO2) was measured by insertion of a detector inside one of the nostrils. Respiration rate was maintained between 12 and 20 breaths/min with adjustment of anesthetics.
16396032|NCT04007341|No Intervention|Saline group|Patients in the saline group were infused with an identical volume of normal saline.
16396033|NCT04007341|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.
16396034|NCT04007328|Experimental|methylprednisolone|20 mg of methylprednisolone IV Q12H for 5 days
16396035|NCT04007328|Placebo Comparator|Placebo|normal saline IV Q12H for 5 days
16396036|NCT04007315|Experimental|SaeboGlove Therapy + usual care|Use for 6 weeks - given an individualised self-management training programme involving repetitive grasping and releasing movements.
16396037|NCT04007315|Active Comparator|Usual care|Usual NHS rehabilitation care based on National Clinical Guidelines for 6 weeks + 2 study visits and one study phone call
16396038|NCT04007302|Experimental|walking with distraction|the patient walks in front of a screen with virtual reality simulation
16396039|NCT04007302|Active Comparator|Walking without distraction|the patient walks on a treadmill without virtual reality simulation
16396040|NCT04007289|Active Comparator|APIXABAN|Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.
16396041|NCT04007289|Placebo Comparator|PLACEBO|Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.
16396042|NCT04007276|Experimental|Lumify Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
16396043|NCT04007276|Sham Comparator|Control Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
16396044|NCT04007263|Placebo Comparator|Placebo|Placebo intravenous infusion over 30 minutes, five days of once daily dosing
16396045|NCT04007263|Experimental|NP10679 25 mg|NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
16396046|NCT04007263|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
16396047|NCT04007263|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing
16396048|NCT04007250||FENIX participants|Individuals being treated with the FENIX™ Continence Restoration System.
16396049|NCT04007237|Experimental|Selsun Shampoo (SeS2 shampoo)|Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
16396050|NCT04007237|Active Comparator|Ketoconazole shampoo|Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
16396051|NCT04007224|Active Comparator|Oxytocin|Intranasal Oxytocin
16415641|NCT03870282|Experimental|"Personal Goal | Incentive B"|
16396059|NCT04007172|Experimental|Neural Therapy & home exercise program|"Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
16396060|NCT04007172|Experimental|Physical Therapy & home exercise program|"Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
16396061|NCT04007159|Experimental|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
16396062|NCT04007159|Experimental|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
16396063|NCT04007159|Experimental|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
16396064|NCT04007159|Placebo Comparator|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
16396065|NCT04007146|Experimental|Cardiac Output Measurement|Subject will have a usual cardiac output
16396066|NCT04007133||Diabetic patients|Patients with non-insulin-dependent diabetes, taking statins for at least 1 month
16396067|NCT04007120|Experimental|RVT-1601 Low Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
16396068|NCT04007120|Experimental|RVT-1601 Mid Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
16396069|NCT04007107|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
16396070|NCT04007107|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
16396071|NCT04007094|Experimental|Study Arm|Participants will be entered into the single armed study in which one side of the fusion will be coated with milled local autograft bone and the opposite fusion side will be supplemented with an equal volume of Depuy Synthes ViviGen.
16396072|NCT04007081|Experimental|Participants with Xerostomia|Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration
16396073|NCT04007055|Experimental|Experimental: screening/treating for HPR|Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
16396074|NCT04007055|No Intervention|Control: guideline based therapy|Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
16396075|NCT04007029|Experimental|Treatment (fludarabine, cyclophosphamide, CD19/CD20 T-cells)|"CONDITIONING CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes 5, 4, and 3 days before cell infusion.
~T-CELL INFUSION: Patients receive CD19/CD20 CAR-T cells IV on day 0. Patients with cytokine release syndrome may also receive tocilizumab IV on day 2 at the discretion of the clinical investigator."
16396076|NCT04007016||Pemberton osteotomy （PO）|PO group received Pemberton osteotomy
16396077|NCT04007016||"inner L shaped iliac osteotomy (ILSO)"|"ILSO group received inner L shaped iliac osteotomy"
16396078|NCT04007003|Experimental|optimal injection technique|Subjects will be trained on site regarding optimal insulin injection technique, including avoiding injections in lipohypertrophy areas and proper rotation. Furthermore subjects are provided with access codes to watch online training modules on the Becton Dickinson (BD) and Me(TM) platform
16396079|NCT04006990|Experimental|Intervention|Subjects are given recliner chairs and education on the dangers of bedrest
16396080|NCT04006990|No Intervention|Control|Subjects are treated with standard care
16396081|NCT04006977|Placebo Comparator|Arm 1: placebo plus standard therapy|placebo plus standard therapy
16396082|NCT04006977|Experimental|Arm 2: DSF plus standard therapy|DSF (4 sachets/day) plus standard therapy
16396083|NCT04006964||Identification Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
16396084|NCT04006964||Validation Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
16396085|NCT04006951|Experimental|Biological collection|"For all the patients include in the study :
~Paraffin tissue samples (if applicable) collected during pre-therapeutic rectal biopsy
~Blood samples collected at different times : Before any treatment and Before surgery if the patient received pre-operative radiochemotherapy
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16396086|NCT04006938|Experimental|Single Bout ('S') - 30 minutes of moderate intensity cycling|Subjects will perform a single 30-minute bout of moderate intensity cycling before breakfast
16396087|NCT04006938|Experimental|Multiple Bout ('M')|Subjects will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
16396088|NCT04006925|Active Comparator|Sodium Oxybate (SXB) arm|Sodium Oxybate (SXB) will be dispensed to the participants.
16396089|NCT04006925|Placebo Comparator|Placebo (PBO) arm|Placebo will be dispensed to the participants.
16396093|NCT04006873|Active Comparator|Tezacaftor/Ivacaftor in combination with Ivacaftor|"A film-coated tablet containing 100mg tezacaftor and 150mg ivacaftor will be taken in the morning.
~A film-coated tablet containing 150mg ivacaftor will be taken in the evening.
~Participants will take these tablets for 28 days.
~All tablets are licensed for use in the EU."
16396094|NCT04006873|Placebo Comparator|Placebo|A visually matched placebo to the active drugs will be taken in the morning and in the evening for 28 days.
16396095|NCT04006860|Experimental|SHC014748M: Fast + Fed|Participants will receive a single oral dose of SHC014748M capsules in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fed condition on Day 8 of treatment period 2.
16396096|NCT04006860|Experimental|SHC014748M: Fed + Fast|Participants will receive a single oral dose of SHC014748M capsules in fed condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fasted condition on Day 8 of treatment period 2.
16396097|NCT04006847|Experimental|Eicosapentaenoic Acid (EPA)|"Phase I: TKI with escalating/de-escalating doses of EPA to determine MTD.
~Phase I dose levels: Dose Level 1 = EPA 1500 mg orally once per day; Dose Level 2 = EPA 2000 mg orally once per day; Dose Level 3 = EPA 3000 mg orally once per day; Dose Level -1 = EPA 1000 mg orally once per day; Dose Level -2 = EPA 500 mg orally once per day.
~Phase II: TKI administered in combination with the recommended Phase II dose of EPA"
16396098|NCT04006834||MDD with hypersomnia|Patient with a history of MDD and ESS >10
16396099|NCT04006834||MDD without hypersomnia|Patient with a history of MDD and ESS <=10
16396100|NCT04006821|Experimental|PD-1 antibody + Apatinib mesylate|Every patient will receive PD-1 antibody 200mg iv every 2 weeks and apatinib 250mg or 500mg (according to the patient's tolerance) orally every day. PD-1 antibody will be administered until disease progression or lasts for two years. Apatinib mesylate will be administered until disease progression.
16396101|NCT04006808|Experimental|PED-HZ/su 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)
16396102|NCT04006808|No Intervention|Control 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care
16396103|NCT04006808|Experimental|PED-HZ/su 1-11 Group|"Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su).
~Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin."
16396104|NCT04006808|No Intervention|Control 1-11 Group|Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care
16396105|NCT04006795|Experimental|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
16396106|NCT04006795|Experimental|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
16396107|NCT04006795|Experimental|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
16396108|NCT04006795|Placebo Comparator|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
16396109|NCT04006782|Other|Narrow dental implants in multiple fixed prosthesis|
16396110|NCT04006769|Experimental|Entacapone & Imatinib mesylate|"Entacapone 200mg tablet by mouth, three times a day and then increasing to 400mg tablet by mouth, three times a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.
~And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first."
16396111|NCT04006756|Experimental|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
16396112|NCT04006756|Active Comparator|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
16396113|NCT04006743|No Intervention|The routine care group|In the routine care group, while a neonatal nurse performed the OGT insertion procedure, physiological measurements of the highest value of heart rate and the lowest value of oxygen saturation were recorded by one researcher (the first author) 1 min before the procedure, during the process and after the process in 1st and 2nd minutes acquired for each infant in the unit with an individual monitor.
16396114|NCT04006743|Experimental|The swaddling group|In this group, preterm infants were given swaddling method.
16396115|NCT04006743|Experimental|The expressed breast milk group|In this group, preterm infants were given expressed breast milk method.
16396116|NCT04006743|Experimental|The facilitated tucking group|In this group, preterm infants were given facilitated tucking method.
16396117|NCT04006743|Experimental|The swaddling and expressed breast milk group|In this group, preterm infants were given combined swaddling and expressed breast milk method.
16396118|NCT04006743|Experimental|The facilitated tucking and expressed breast milk group|In this group, preterm infants were given combined facilitated tucking and expressed breast milk method.
16396119|NCT04006717|No Intervention|Control|Routine root canal treatment
16396120|NCT04006717|Placebo Comparator|Low-Level Laser Placebo|Patient informed that laser will be applied but device won't be turned on
16396121|NCT04006717|Experimental|Low-Level Laser Therapy|Low-Level Laser Therapy following root canal treatment
16396122|NCT04006717|Experimental|Intracanal Cryotherapy|Cold saline irrigation before obturation
16396123|NCT04006717|Experimental|Combination of LLLT and ICCT|Both cold saline irrigation before obturation and Low-level laser Therapy after root canal treatment
16396124|NCT04006704|Experimental|D/C/F/TAF (Whole Placebo Tablet then Split Placebo Tablet)|Participants will receive scored film-coated 10 milligram (mg) FDC matching placebo tablets (Intake period 1) swallowed whole followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed as a split tablet on Day 1. Both the intakes will be separated by at least 15 minutes.
16396125|NCT04006704|Experimental|D/C/F/TAF (Split Placebo Tablet then Whole Placebo Tablet)|Participants will receive scored film-coated 10 mg FDC matching placebo tablets (Intake period 1) swallowed as a split tablet followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed whole on Day 1. Both the intakes will be separated by at least 15 minutes.
16396126|NCT04006691|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml. 3-6 once weekly intravesical instillations for the ablation treatment.
16396127|NCT04006678|Experimental|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
16396128|NCT04006678|Active Comparator|conventional sandwich osteotomy|:conventional segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla.
16396129|NCT04006665||Lung Ultrasonography prior to docking Robotic arms|Base line Lung ultrasonography will be performed in three basal zones for Right and Left lung -Post intubation and prior to docking robotic arms .
16396130|NCT04006665||Lung Ultrasonography after removal of robotic arms|Lung Ultrasonography will be performed to assess degree of atelectasis after removal of robotic arms and before extubation in three basal zones for Right and Left lung .
16396131|NCT04006652|Experimental|Recipient|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician
~Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines"
16396132|NCT04006652|No Intervention|Donor|-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)
16396133|NCT04006639|Active Comparator|Bilateral superficial cervical plexus block with Bupiv|Patients, who will have tracheostomy procedure, might receive bilateral superficial cervical plexus block with 10 mL of Bupivacaine 0.5% (20 mL spuit with 25 G 1.5 inch needle) on each side before tracheostomy procedure.
16396134|NCT04006639|Active Comparator|Local infiltration of Lidocaine 2%|Patients, who will have tracheostomy procedure, might receive local infiltration of Lidocaine 2% (5 mL spuit with 25 G 1.5 inch needle) before tracheostomy procedure.
16396135|NCT04006626||PET group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT
16396136|NCT04006626||FES group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT
16396137|NCT04006613|Experimental|Circuit Training|Structured intervention to improve aerobic capacity, balance and strength
16396138|NCT04006613|Active Comparator|Usual Care|Unstructured intervention to improve mobility and balance
16396139|NCT04006587|Experimental|IS intervention|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
16396140|NCT04006587|No Intervention|control|standard care without IS intervention
16396141|NCT04006574|Experimental|core stabilization training|Patient with hip dysplasia aged between 20-60, non-operated
16396142|NCT04006574|Active Comparator|traditional physiotherapy and core stabilization|Patient with hip dysplasia aged between 20-60, non-operated
16396143|NCT04006561||newly-diagnosed patients with primary CNS lymphoma|
16396144|NCT04006522|Experimental|Cohort 1|Patients with Localized RCC prior to nephrectomy.
16396145|NCT04006522|Experimental|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
16396146|NCT04006509|Experimental|Antenatal Education Group|Patients will receive a prenatally delivered lactation educational program.
16396147|NCT04006509|No Intervention|Standard of Care Group|Patients will receive standard of care and not a prenatally delivered lactation educational program.
16396232|NCT04005807|Experimental|Cohort 2 (fasted condition)|25 mg BPN-14967 or placebo
16396148|NCT04006496|Experimental|Experimental: Intervention|In-patient, Chemotherapy patients in this arm will receive the expressive writing intervention twice each week for two weeks. These writing samples will be reviewed and analyzed. These patients will receive coaching from an expert expressive writing coach and will be allowed to ask questions and receive guidance. All patients will receive standard of care treatment in addition to the intervention.
16396149|NCT04006496|No Intervention|Control|Patients in the control group will not interface with the expressive writing coach for guidance nor have their writing samples reviewed and analyzed. All patients in the control arm will still receive standard care
16396150|NCT04006483||Stannous Fluoride Dentifrice|Twice daily brushing
16396151|NCT04006483||Positive control dentifrice|Twice daily brushing
16396152|NCT04006483||Negative control dentifrice|Twice daily brushing
16396153|NCT04006470||Stannous Fluoride Dentifrice|Twice daily use
16396154|NCT04006470||Positive control dentifrice|Twice daily use
16396155|NCT04006470||Negative control dentifrice|Twice daily use
16396156|NCT04006457|Experimental|Treatment sequence 1|"Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 given QD for 35 months.
~Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 32 visit of the main B7981032 study."
16396157|NCT04006457|Experimental|Treatment sequence 2|"Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 given QD for 36 months.
~Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 32 visit of the main B7981032 study."
16396158|NCT04006405||Cohort 1|140 patients with a minimum follow-up of 12 months
16396159|NCT04006405||Cohort 2|up to 140 patients with a minimum follow-up of 12 months
16396160|NCT04006392|Experimental|Erchonia FX-635|The Erchonia FX-635 is administered to the foot 12 times over 6 weeks (2 times each week) for 15 minutes per foot.
16396161|NCT04006392|Sham Comparator|Placebo Laser|Noise and appearance of output is the same but no active therapy applied. Treatment administration procedure is the same as with the experimental arm.
16396162|NCT04006366|Other|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
16396163|NCT04006353|Experimental|Group 1: ABT|Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.
16396164|NCT04006353|Experimental|Group 2: ABT+RIF|600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.
16396165|NCT04006340|Placebo Comparator|Empirical group|Patients receive conventional triple therapy containing esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days
16396166|NCT04006340|Active Comparator|Genotypic resistance-guided tailored group|"Patients receive triple or quadruple therapy by resistance-associated mutations in 23S ribosomal RNA which are identified by polymerase chain reaction (PCR).
~Triple therapy contains esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days and quadruple therapy contains esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days."
16396167|NCT04006327||Palliative care patients and their family caregivers|The present study is a cross-sectional study with single group study design. Only palliative care patients and their family caregivers will be recruited.
16396168|NCT04006314|Other|Receiving PRP injections or PRP plus neural prolotherapy|PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
16396169|NCT04006301|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
16396170|NCT04006301|Experimental|Part 2: Dose Expansion|Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1.
16396177|NCT04006275|Experimental|Sonovue and Sonazoid Group|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.
~Contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
16396178|NCT04006275|Experimental|Sonazoid and Sonovue Group|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.
~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
16396179|NCT04006262|Experimental|Experimental arm|"Neo-adjuvant treatment (6 cycles - 12 weeks)
~Surgery
~Adjuvant treatment (9 cycles - 9 months)"
16396180|NCT04006249|Other|diagnostic test|
16396181|NCT04006236|Experimental|Experimental Infant Formula|extensively hydrolyzed casein protein
16396182|NCT04006236|Active Comparator|Control Infant Formula|extensively hydrolyzed casein protein
16415642|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts B"|
16396184|NCT04006210|Experimental|Group A|ND0612 SC infusion + placebo IR-LD/CD + active IR-LD/CD (Carbidopa Levodopa USP tabs 25mg/100mg), for 24 hours.
16396185|NCT04006210|Active Comparator|Group B|Placebo for ND0612 SC infusion + placebo IR-LD/CD + active IR-LD/CD (Carbidopa Levodopa USP tabs 25mg/100mg), for 24 hours.
16396186|NCT04006184||Endovenous Thermal Ablation|Limbs treated with either radiofrequency ablation or endovenous laser ablation
16396187|NCT04006184||Cyanoacrylate Closure|Limbs treated with cyanoacrylate closure system
16396188|NCT04006171|Active Comparator|women with polycystic ovary syndrome|30 patients with PCOS
16396189|NCT04006171|Active Comparator|Healthy women of reproductive age|30 patients with regular normal menstrual cycle
16396190|NCT04006158|Experimental|LightStim LED Bed|Full body LED bed device.
16396191|NCT04006145|Experimental|Elobixibat|Elobixibat 5 mg once daily
16396192|NCT04006145|Placebo Comparator|Placebo|Placebo
16396193|NCT04006132|Experimental|Ponto 3 SuperPower sound processor|All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.
16396194|NCT04006119|Experimental|Ad-RTS-hIL-12 + veledimex in combination with cemiplimab-rwlc|Intratumoral Ad-RTS-hIL-12 and oral veledimex (activator ligand, 20mg) given in combination with cemiplimab-rwlc via infusion.
16396195|NCT04006093|Experimental|participants with normal renal function|
16396196|NCT04006093|Experimental|participants with end-stage renal disease|
16396197|NCT04006080|Experimental|Vedolizumab|
16396198|NCT04006067|Experimental|Group A|
16396199|NCT04006067|No Intervention|Group B|
16396200|NCT04006054|Experimental|Dexmedetomidine treatment group|Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
16396201|NCT04006054|Active Comparator|Midazolam treatment group|Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
16396202|NCT04006041|Experimental|Toripalimab group|All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.
16396203|NCT04006015||Main study group|31 people with COPD and 31 controls in the main study group.
16396204|NCT04006015||six-minute walk substudy|We will aim to have 40 participants participating in the 6 minute walk sub-study.
16396205|NCT04006015||Qualitative dance substudy|We will aim for 20 participants.
16396206|NCT04006002||Endoscopic Sleeve Gastrectomy|This group includes all patient who undergo Endoscopic Sleeve Gastrectomy for weight loss
16396207|NCT04006002||Laproscopic Sleeve Gastrectomy|This group includes all patient who undergo Laproscopic Sleeve Gastrectomy for weight loss
16396208|NCT04005989|Placebo Comparator|PLACEBO GROUP|injection of saline solution
16396209|NCT04005989|Active Comparator|Low dose group|hASC injection (1x10e6 / kg body weight)
16396210|NCT04005989|Active Comparator|Intermediate Dose|injection of hASC (2x10e6 / kg of body weight)
16396211|NCT04005989|Active Comparator|High dose group|injection of hASC (4x10e6 / kg body weight)
16396212|NCT04005976||Patients with heritable thoracic aortic disease (H-TAD)|Patients with heritable thoracic aortic disease (H-TAD) with causal mutations in the known H-TAD genes.
16396213|NCT04005950||medical doctors|
16396214|NCT04005950||paramedics|
16396215|NCT04005937|Experimental|H-reflex|H-reflex with different interstimulus interval of the plegic side soleus muscle were tested
16396216|NCT04005924|No Intervention|Control|Bread and sugar-free blackberry jam breakfast
16396217|NCT04005924|Experimental|Low dose|Bread and sugar-free blackberry jam breakfast with 6 g arabinogalactan
16396218|NCT04005924|Experimental|High dose|Bread and sugar-free blackberry jam breakfast with 21 g arabinogalactan
16396219|NCT04005911||Post-Surgical|Patients who underwent surgery and were admitted to the PACU
16396220|NCT04005898|Experimental|Experimental: near-infrared cholangiography|Each subject included in the study will be subjected to a fluorescence cholangiography. The control group will be the same patient. The study consists of knowing if fluorescence is able to visualize structures that are not seen with the naked eye. For this purpose the structures are visualized with normal light and then with infrared light of the same patient. During laparoscopic cholecystectomy it will change between normal and infrared light.
16396221|NCT04005885|Experimental|somofilcon A then stenfilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear somofilcon A daily disposable test lens for 1 week of daily wear and stenfilcon A daily disposable test lens for 1 week of daily wear.
16396222|NCT04005885|Experimental|stenfilcon A then somofilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear stenfilcon A daily disposable test lens for 1 week of daily wear and somofilcon A daily disposable test lens for 1 week of daily wear.
16396223|NCT04005872|Experimental|Nano Silver Fluoride|2 drops of nano silver fluoride (NSF) applied on the last soft carious layer using micro brush
16396224|NCT04005872|Active Comparator|Calcium Hydroxide|Calcium hydroxide placed on the last soft carious layer approaching the pulp
16396227|NCT04005846|Other|Active tDCS first / Sham tDCS second|Receiving active tDCS during the first visit followed by sham tDCS on the next visit
16396228|NCT04005846|Other|Sham tDCS first / Active tDCS second|Receiving sham tDCS during the first visit followed by active tDCS on the next visit
16396229|NCT04005833||COPD exacerbation|COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)
16396230|NCT04005820|Experimental|children and young adults supported in one of SFCE's centers|
16396231|NCT04005807|Experimental|Cohort 1 (fasted condition)|10 mg BPN-14967 or placebo
16396233|NCT04005807|Experimental|Cohort 3 (fasted condition)|50 mg BPN-14967 or placebo
16396234|NCT04005807|Experimental|Cohort 4 (fed condition)|10 mg BPN-14967 or placebo
16396235|NCT04005807|Experimental|Cohort 5 (high-fat fed condition)|10 mg BPN-14967 or placebo
16396236|NCT04005794|Active Comparator|VR Social Skills Training|Participants will undergo a virtual reality social skills training program for 10 sessions. Each session takes about an hour. Participants visit the lab twice a week. Therefore, the training duration is 5 weeks.
16396237|NCT04005794|Other|Cognitive training game|If there is a significant improvement in social skills for the active treatment condition, the reason might be that the participants were exposed to social environment by coming to the lab and interacting with the research staff twice a week for 5 weeks and/or they used a computerized training tool twice a week for 5 weeks. In order to control for these potential confounds, we included a cognitive training arm. Participants will undergo a commercially available brain fitness program (Posit Science) for ten 1-hour sessions (twice a week for 5 weeks).
16396238|NCT04005794|No Intervention|Healthy Controls|Healthy controls are recruited to yield comparison data. They do not undergo training.
16396239|NCT04005781|Experimental|Hydroxychloroquine sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
16396240|NCT04005781|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
16396241|NCT04005768|Experimental|Hydroxychloroquine Sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
16396242|NCT04005768|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
16396243|NCT04005755|Experimental|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
16396244|NCT04005742||Healthy|Participants recruited to the healthy arm of the BORICC Study (BORICC1) at baseline.
16396245|NCT04005742||Polyp|Participants recruited to the polyp arm of the BORICC Study (BORICC2) at baseline, with a prior history of polyps.
16396246|NCT04005729|Experimental|Cangrelor + Ticagrelor|Bolus of cangrelor (30 mcg/kg) and immediately afterwards a continuous intravenous infusion of 4 mcg/kg/min at the start of the primary percutaneous coronary intervention. Crushed and dissolved ticagrelor tablets (180 mg) will be given via inserted enteral tube.
16396247|NCT04005729|No Intervention|Ticagrelor|Crushed and dissolved ticagrelor tablets (180 mg) will be given via enteral tube (standard care).
16396248|NCT04005716|Experimental|tislelizumab plus etoposide and platinum|
16396249|NCT04005716|Active Comparator|Placebo plus etoposide and platinum|
16396250|NCT04005703||Pediatric Hodgkin's lymphoma|Children with newly diagnosed Hodgkin's lymphoma
16396251|NCT04005690|Experimental|Arm I (cobimetinib)|Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
16396252|NCT04005690|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
16396253|NCT04005677||lung cancer|
16396254|NCT04005677||benign lung nodule|
16396255|NCT04005677||lung nodule|
16396256|NCT04005664|No Intervention|Bolus group|Hypotension occurring under spinal anaesthesia (SBP < 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
16396257|NCT04005664|Active Comparator|Phenylephrine coload group|Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
16396258|NCT04005651|Experimental|POD L GF|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
16396259|NCT04005651|Active Comparator|Symfony®|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
16396260|NCT04005651|Active Comparator|AcrySof®|Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
16396261|NCT04005638||Autoimmune Cytopenia|
16396262|NCT04005612|Experimental|vitamin d3 group|weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks
16396263|NCT04005612|Experimental|omega3-Fatty Acid group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
16396264|NCT04005612|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily
16396265|NCT04005612|No Intervention|Control group|NO INTERVENTION
16396266|NCT04005599|Active Comparator|Remifentanil group|Intravenous anesthesia with propofol and remifentanil
16396267|NCT04005599|Experimental|Magnesium group|Intravenous anesthesia with propofol and magnesium sulfate
16396268|NCT04005586|Experimental|Light Delivery Device (LDD)|Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.
16396269|NCT04005573|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
16396270|NCT04005573|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
16396271|NCT04005573|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
16396272|NCT04005573|Other|control group|no intervention was given
16396273|NCT04005560|Other|patient|Score of PedSQL who is the Pediatric Quality of Life Questionnaire
16396274|NCT04005547|Experimental|Program+survey|
16396275|NCT04005547|No Intervention|Survey-only|
16396276|NCT04005534|Placebo Comparator|Regular group|Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 0.5% levobupivacaine with adrenaline 1:200,000 plus 5 ml 2% lidocaine with adrenaline 1:200,000) and sedation ( midazolam 3 mg, fentanyl 50 µg and dexmedetomidine 1 µg/kg (infusion lasting 10 min) followed by 0.5 µg/kg/min).
16396277|NCT04005534|Experimental|Preemptive group|Patients from this group will undergo ultrasound-guided brachial plexus blockade, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 0.5% levobupivacaine with adrenaline 1:200,000 plus 5 ml 2% lidocaine with adrenaline 1:200,000) and sedation ( midazolam 3 mg, fentanyl 50 µg and dexmedetomidine 1 µg/kg (infusion lasting 10 min) followed by 0.5 µg/kg/min).
16396278|NCT04005521|Experimental|Preventive intervention|Patient will perform daily exercise: jaw and swallwing exercises, as well as are encouraged to eat and drink for as long as possible during treatment
16396279|NCT04005521|No Intervention|Control group|No intervention, only encouragement to eat and drink for as long as possible during treatment
16396280|NCT04005508||OSA (Watch PAT AHI >/= 15 events per hour)|Patients found to have OSA by an overnight sleep study
16396281|NCT04005508||Non-OSA (Watch PAT AHI < 15 events per hour)|Patients found NOT to have OSA by an overnight sleep study
16396283|NCT04005469|Experimental|Trepostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
16396284|NCT04005456|Other|N of 1 Tent|Personalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
16396285|NCT04005456|Other|Wellness Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
16396286|NCT04005456|Other|Elevated Homocysteine Bucket|Personalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
16396287|NCT04005456|Other|Dental Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
16396288|NCT04005456|Other|Immune Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
16396289|NCT04005456|Other|Elevated Anti-Nuclear Antibodies (ANA) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
16396290|NCT04005456|Other|Autoimmune Conditions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
16396291|NCT04005456|Other|Symptomatic Fatigue/Myalgias Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
16396292|NCT04005456|Other|Gastrointestinal Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
16396293|NCT04005456|Other|Irritable Bowel Syndrome (IBS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
16396294|NCT04005456|Other|Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
16396295|NCT04005456|Other|Wellness Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
16396296|NCT04005456|Other|Metabolic Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
16396297|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket C/S Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
16396298|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket R/I Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
16396299|NCT04005456|Other|Ketogenic Product Development Exploratory Group|Subgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
16396300|NCT04005456|Other|Reproductive Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
16396301|NCT04005456|Other|Perimenopausal and Menopausal Transitions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
16396302|NCT04005456|Other|Premenstrual Syndrome Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
16396303|NCT04005456|Other|Polycystic Ovary Syndrome (PCOS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
16396304|NCT04005456|Other|Andropause/Late Onset Hypogonadism Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
16396305|NCT04005443|Other|PET at 68Ga-NODAGA-RGD|The first PET scan will be performed within a maximum of one month following the initial ophthalmologic assessment including OCT and measurement of visual acuity (M0);
16396306|NCT04005430|Experimental|Phase 1|Phase I open label study
16396307|NCT04005417||Stannous fluoride dentifrice|Twice daily brushing
16396308|NCT04005417||Positive control dentifrice|Twice daily brushing
16396309|NCT04005417||Negative control dentifrice|Twice daily brushing
16396310|NCT04005404|Experimental|intertrochanteric femoral fractures|geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
16396311|NCT04005404|Experimental|neck femur fractures|geriatric patients with neck of femur fracture who have consented to the study intervention
16396312|NCT04005404|Experimental|subtrochanteric femoral fractures|geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
16396313|NCT04005391|Experimental|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
16396314|NCT04005391|No Intervention|Routine Care offered to Control Clusters|Women will receive routine postpartum care
16396315|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
16396316|NCT04005378|Other|Usual Care|Usual care provided by CSC center
16396317|NCT04005365|Experimental|Prop+neochemo|
16396320|NCT04005339|Experimental|Single Arm|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.
16396321|NCT04005326|Experimental|QLB Group|this group will receive ultrasound-guided transmuscular quadratus lumborum block; (Anterior QLB or QLB III)
16396322|NCT04005326|Experimental|FIB Group|this group will receive suprainguinal fascia iliaca block
16396323|NCT04005313|Experimental|Comparison between unisensory and multisensory stimulation|The same person receive unisensory and multisensory stimulation on separate day.
16396324|NCT04005313|Experimental|The treatment effect of multisensory stimulation|The persons living in long-term care facility would receive multisensory stimulation for one month.
16396325|NCT04005313|Experimental|Multisensory stimulation and virtual reality.|The subjects would receive vibroacoustic therapy or virtual reality.
16396326|NCT04005313|Experimental|Vibroacustic therapy on neck pain.|The subjects would receive either vibroacustic therapy or music therapy.
16396327|NCT04005300|Experimental|low calorie feeding group|Enteral nutrition was fed at 10-20kcal/kg/d for the first three days before identifying the refeeding syndrome
16396328|NCT04005300|Active Comparator|standard calorie feeding group|Enteral nutrition was fed at 500-750kcal/d for the first three days before identifying the refeeding syndrome
16396363|NCT04005014|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SE and presence of high myopia in the subsequent 10 years.
16396364|NCT04005014|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
16396365|NCT04005001|Experimental|Experimental|The experimental arm will involve patients monitored by HindSight.
16396366|NCT04005001|Active Comparator|Control|The control arm will involve patients monitored by InSight.
16396329|NCT04005300|No Intervention|RFS group|The definition of RFS is that serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded. And it is divided into three sub-group that is Group 1 that a drop of >0.16 mmol/L from any previous measurement, to below 0.65 mmol/L within 72 h after starting nutritional support, Group 2 that their serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded, and Group 3 that their serum phosphate concentration decreased to below 0•32 mmol/L within 72 h after starting nutritional support.
16396330|NCT04005300|No Intervention|nRFS group|It is not up to the RFS definition
16396331|NCT04005287|Placebo Comparator|Placebo Low Dose|WST-057 Matching placebo 2 mL volume
16396332|NCT04005287|Placebo Comparator|Placebo High Dose|WST-057 Matching placebo 4mL volume
16396333|NCT04005287|Experimental|Active Low Dose|WST-057 2mL volume
16396334|NCT04005287|Experimental|Active High Dose|WST-057 4mL volume
16396335|NCT04005261||patients with type 2 diabetes treated with insulin|"Patients with type 2 diabetes who have been using insulin for at least six months.
~They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital"
16396336|NCT04005248|Other|Testing for HCV|HCV IgG test and questionnaire; both at visit to the sexual health clinic
16396337|NCT04005222|Other|SELENIUM|The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
16396338|NCT04005222|Other|MELATONIN|The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
16396339|NCT04005209|Active Comparator|Pain management without ketamine infusion|Pain management without ketamine infusion. No other restrictions on pain management or medications.
16396340|NCT04005209|Experimental|Pain management with ketamine infusion|Pain management that includes a ketamine infusion. No other restrictions on pain management or medications.
16396341|NCT04005183||All patients|Patients undergoing nephrectomy at the University Health Network are eligible for enrolment. All histological subtypes and stages are eligible. Tumor, blood and urine samples are acquired at the time of nephrectomy.
16396342|NCT04005170|Experimental|PD-1 group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50.4 Gy in 28 fractions over 5-6 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 and 2 cycles of toripalimab 240 mg on days 1, 22 followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
16396343|NCT04005157|Experimental|Patients undergoing bronchoscopic MWA|Patients meeting the inclusion criteria will be enrolled in the study and undergo ENB guided MWA. Chest CT will be performed at 1 day after the procedure to confirm the complications and then at 1 month, every 3 months for 2 years, and every 6 months for 3 years thereafter after the procedure. PET/CT will be performed 3 months after MWA to assess the treatment response.
16396344|NCT04005144|Experimental|Treatment (brigatinib, binimetinib)|Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16396345|NCT04005131|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 10 weeks
16396346|NCT04005131|Active Comparator|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 weeks
16396347|NCT04005118||preoperative preparation on microbiome composition|Mechanical Bowel Preparation + oral antibiotics group: receiving mechanical bowel preparation only MBP will be prepared with 4 liters of Polyethylene glycol (PEG) solution to be started 24 hours before the planned surgery. 500mg of Metronidazole will be administrated 3 times one day before the surgery at 2 pm, 3 pm and 10 pm.
16396348|NCT04005105|Active Comparator|Intensive management|"Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure. Intra-surgical values of ± 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group
~1 based on cardiac index and MPP will be followed for 24 hours."
16396349|NCT04005105|No Intervention|Standard management|MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.
16396350|NCT04005092|Active Comparator|Helmet Continuous Positive Airway Pressure(hCPAP)|Helmet CPAP produce a better physiological outcomes after 1-hour intervention
16396351|NCT04005092|Active Comparator|High Flow Nasal Cannula(HFNC)|HFNC produce a better physiological outcomes after 1-hour intervention
16396352|NCT04005079|Experimental|Treatment Group|2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)
16396353|NCT04005079|Active Comparator|Control Group|Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine
16396354|NCT04005066|Other|Cohort 1|metastatic colorectal cancer patients who are accordance with Elunate® package insert
16396355|NCT04005066|Other|Cohort 2|other patients suitable for according to investigator's judgement
16396356|NCT04005053|Experimental|Low-Dose NAC|3600 NAC mg/day
16396357|NCT04005053|Experimental|High-Dose NAC|5400 NAC mg/day
16396358|NCT04005053|Placebo Comparator|Placebo|Placebo
16396359|NCT04005040|Active Comparator|Mobile X-ray|Intervention: X-ray examination in the patients own home
16396360|NCT04005040|Placebo Comparator|X-ray at the Hospital|Control: X-ray at the hospital
16396361|NCT04005027|Experimental|Intermittent graded exercise (INT)|The intermittent graded exercise test (INT) increase treadmill speed incrementally using three minute stage duration on a motorised treadmill. However, the speed within each three minute exercise bout will vary every 30 s between the target speed, and a complete pause for 30 s. The acceleration of the treadmill belt will be set to its maximum capability.
16396362|NCT04005027|Active Comparator|Continuous graded exercise (CONT)|The continuous graded exercise test (CONT) will increase treadmill speed incrementally using three minute stage duration on a motorised treadmill
16396367|NCT04004988|Experimental|Tirzepatide Test|Tirzepatide administered subcutaneously (SC) to healthy participants via an autoinjector (AI) in one of two study periods.
16396368|NCT04004988|Experimental|Tirzepatide Reference|Tirzepatide administered SC to healthy participants via a prefilled syringe (PFS) in one of two study periods.
16396369|NCT04004975|Experimental|anlotinib|12 mg daily from day 1 to 14 of a 21-day cycle
16396370|NCT04004949||study group (high scapular dyskinesia )|group A (30 patients): with high scapular dyskinesia scores
16396371|NCT04004949||control group (low or no scapular dyskinesia )|group B (30 patients): with low or no scapular dyskinesia scores. (30 patients): with low or no scapular dyskinesia scores.
16396372|NCT04004936|Active Comparator|Active Feedback|EQUIPPED with active provider feedback, implementing one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
16396373|NCT04004936|Active Comparator|Passive Feedback|EQUIPPED with passive provider feedback, implementing monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
16396374|NCT04004923|Active Comparator|Monopolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
16396375|NCT04004923|Active Comparator|Bipolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
16396376|NCT04004910|Experimental|Immunopheresis - Arm 1|All patients will receive up to 16 weeks of initial treatment as per study arm assignment, which will include up to 48 LW-02 column-based immunopheresis treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient assigned to the treatment with LW-02 column-based immunopheresis will require central vascular access for the procedure.
16396377|NCT04004910|Experimental|Immunopheresis combined with weekly chemotherapy - Arm 2|All patients will receive up to 16 weeks of treatment as per study arm assignment, which will include up to 48 LW-02 column-based immunopheresis treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient will require central vascular access for the procedure. Patients also will receive a chemotherapy regimen administered iv on a weekly basis (every 7 days) in predefined doses that will be administered before immunopheresis. Patients treated with combination will be administered their chemotherapy following the first LW-02 column-based immunopheresis procedure of each week starting from week 2, assuming first week of study treatment serves as a run-in period confirming good tolerance of immunopheresis alone.
16396378|NCT04004910|Active Comparator|Chemotherapy - Arm 3|Patients who are assigned chemotherapy arm of the study will be treated with paclitaxel+carboplatin chemotherapy alone. The chemotherapy regimen will be administered intravenously on a weekly basis (every 7 days) in doses: 80 mg/m2 of paclitaxel and carboplatin AUC2 (Calvert formula).
16396379|NCT04004897|Other|Preeclampsia group|Patients with preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
16396380|NCT04004897|Other|Pregnants without preeclampsia|Pregnant women without preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
16396381|NCT04004884||UPA Treatment|Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018
16396382|NCT04004871|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.
16396383|NCT04004858|Active Comparator|Standard margin|Patient cohort planned with the current standard PTV margin
16396384|NCT04004858|Experimental|Reduced margin|Patient cohort planned with the reduced margin validated from the retrospective study
16396385|NCT04004845||Pregnant women|We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.
16396386|NCT04004819|Experimental|Rituximab group|Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
16396387|NCT04004819|No Intervention|Control group|Patients will receive usual care and drug use.
16396388|NCT04004806|No Intervention|Pre-Intervention|Phase 1 (Observational phase): All residents and staff physicians rotating through the inpatient medicine services during the first three (3) months, who agreed to be a part of the study, will be provided with Hill Rom tracking devices to quantify the time spent at the patient's bedside by each member as part of the daily practice.
16396389|NCT04004806|Experimental|Intervention|Phase 2 (Intervention phase): The interventional phase will be six (6) months duration. During this period, the recorded time spent by the individual study participants at the patient's bedside will be compared to their respective peers, and percentile scores will be generated. Based on these percentile scores, the study participants will receive emails notifying them of the results. Participants whose scores fall in the lower 50th percentile will be encouraged to increase patient interaction times. Participants with scores in the top 50th percentile will receive congratulatory emails to encourage them to keep up the performance.
16396390|NCT04004806|No Intervention|Post-Intervention|Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
16396391|NCT04004793|Experimental|Dapagliflozin plus intensive lifestyle intervention|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
16396392|NCT04004793|Placebo Comparator|Placebo plus intensive lifestyle intervention|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
16396393|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
16415643|NCT03870282|Experimental|"Personal Goal | Incentive B | Text A"|
16396394|NCT04004754||Complicated CL in Gondar|Patients treated with miltefosine in Gondar will be followed up to see outcomes of treatment
16396395|NCT04004754||Complicated CL in Boru Meda|Patients treated with miltefosine in Boru Meda hospital will be followed up to see outcomes of treatment
16396396|NCT04004741|Experimental|Osteopathic Manipulative Treatment|Group A will receive osteopathic treatment by NMM/OMM board certified attending physicians. The protocol for the OMT intervention group is based on the guidelines set forth previously in textbooks. The protocol will last 25 minutes total, with 10 minutes for the evaluation and 15 minutes for treatment. The protocol will start in ribs so as to not exacerbate any tachyarrhythmias with rib raising, thoracic myofascial release, and a pectoralis lift. The investigator will then proceed with opening the thoracic inlet, cervical myofascial release, suboccipital release, and then end by checking for and treating Chapman's points. The physician will submit their osteopathic evaluation and fill out a form in order to determine if certain arrhythmias have an associated trigger point.
16396397|NCT04004741|Sham Comparator|Light Touch Treatment|Group B will receive a light touch treatment, based on previous research done studying heart rate variability and OMM, where sham treatment was utilized. The protocol consisted of contacting the right ankle, left knee, right hip, diaphragm, right shoulder, neck, and cranium for precisely two minutes each, with the goal of preventing placebo autonomic nervous system stimulation. The protocol is 25 minutes long, with 10 minutes for the evaluation and 15 minutes for treatment.
16396398|NCT04004728|Other|laser, leg veins, sclerotherapy|to compare laser and sclerotherapy on treating leg veins
16396399|NCT04004715|Experimental|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
16396400|NCT04004715|Active Comparator|Whey Protein|commercially available whey protein isolate
16396401|NCT04004715|Active Comparator|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
16396402|NCT04004702|Experimental|Levetiracetam|All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
16396403|NCT04004689||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join the rehabilitation program.
~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
16396404|NCT04004676|Active Comparator|Placebo|isocaloric carbohydrate - only containing drink will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
16396405|NCT04004676|Experimental|Ketone_CHO|Ketone - Carbohydrate supplementation will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
16396406|NCT04004663|Experimental|Treatment Sequence 1|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D).
16396407|NCT04004663|Experimental|Treatment Sequence 2|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment D); Period 3 (Treatment A); Period 4 (Treatment C).
16396408|NCT04004663|Experimental|Treatment Sequence 3|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment C); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment B).
16396409|NCT04004663|Experimental|Treatment Sequence 4|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment D); Period 2 (Treatment C); Period 3 (Treatment B); Period 4 (Treatment A).
16396410|NCT04004650|No Intervention|Primary closure|Primary perineal closure after extralevator abdomino perineal resection
16396411|NCT04004650|Experimental|Gluteal turnover flap|Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
16396412|NCT04004637|Experimental|CD7 CAR-T cells Infusion|
16396413|NCT04004624|Active Comparator|Study Arm|The left ventricle is mapped during atrial and right or left ventricular pacing (site close to the infarct) at a similar cycle length of 600ms. Radio-frequency ablation is performed selectively in areas of activation slowing (defined as ≤40ms per 5mm while voltage abnormalities and late potentials were not specifically targeted.
16396414|NCT04004624|No Intervention|Control|Patient who underwent ablation using similar technology and irrigated catheters guided by standard substrate mapping techniques.
16396415|NCT04004611|Experimental|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) and Subcutaneously (SC). Participants >40 kilograms (kg)
16396416|NCT04004611|Experimental|Mirikizumab Dose 2|Mirikizumab administered IV and SC. Participants ≤40 kg
16396417|NCT04004611|Experimental|Mirikizumab Dose 3|Mirikizumab administered IV and SC. Participants ≤40 kg
16396418|NCT04004598|Experimental|golf training|12-week golf training program
16396419|NCT04004585|Experimental|Intervention|This was a single arm study with all participants receiving the same intervention. Participants will receive a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour.
16396420|NCT04004572|Experimental|LEAP Regimen|Pegaspargase, 2500IU/m2, im, day 1 Sintilimab, 200mg, iv day1 Anlotinib, 8mg, oral, day 1-14 The LEAP regimen will be repeated every 3 weeks.
16396421|NCT04004559||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|Cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the training cohort.
16396422|NCT04004559||Sun Yat-sen University Cancer Center|Cohort of Sun Yat-sen University Cancer Center is validation cohort 1.
16396423|NCT04004559||Tungwah Hospital of Sun Yat-Sen University|Cohort of Tungwah Hospital of Sun Yat-Sen University is validation cohort 2.
16396424|NCT04004546|Experimental|Intervention group|At baseline: video and education booklet. 2-weeks after enrollment: telephone call by nurse.
16396425|NCT04004546|No Intervention|Control group|Usual care
16396458|NCT04004273|No Intervention|Control|Participants randomised to control will receive no interventions and will be requested to maintain their habitual lifestyle during the six week intervention phase
16396459|NCT04004260|Experimental|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
16396426|NCT04004533||Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
16396427|NCT04004520|Experimental|Virtual Reality with Meditation|Participants will receive a virtual reality and audio guided mindfulness meditation program available at (https://guidedmeditationvr.com/)
16396428|NCT04004520|Other|Virtual Reality Control|Participants will receive a virtual reality of historic photographs and written narratives program (https://lookingglassvr.com/)
16396429|NCT04004520|Other|Audio Control|Participants will receive an online audio-only guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations).
16396430|NCT04004507|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye (QD) for one day.
16396431|NCT04004507|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye (QD) for one day.
16396432|NCT04004494|Experimental|3D Reconstruction|Chest contrast-enhanced computed tomography will be performed preoperatively, and 3-dimensional reconstruction will be formed based on the data of chest CT. Video-assisted segmentectomy will be performed guided by the image of 3-dimensional CT. IPS-lung software (Shenzhen Yorktal Digital Medical Imaging Technology Company, Shenzhen, China) will be used preoperatively to construct a 3D-image to ascertain the position and structure of targeted segmental blood vessels and bronchi.
16396433|NCT04004494|No Intervention|Chest computed tomography|Chest contrast-enhanced computed tomography will be performed preoperatively. Video-assisted segmentectomy will be performed based on the image of preoperative chest CT
16396434|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
16396435|NCT04004468|Active Comparator|Standard Periodization Training|Utilization of traditional periodization strength training model
16396436|NCT04004468|Active Comparator|Conjugate Training|Utilization of conjugate strength model
16396437|NCT04004455||Childhood cancer|Children with an established cancer diagnosis (any type) between 8-18 years old that are currently being treated for cancer (not necessarily hospitalized) in the University Hospital Brussels or Ghent.
16396438|NCT04004455||Healthy controls|Healthy children between 8-12 years old, selected based on age and sex.
16396440|NCT04004429|Experimental|50 mg AP1189|50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
16396441|NCT04004429|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
16396442|NCT04004429|Placebo Comparator|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
16396443|NCT04004416|Placebo Comparator|Healthy Controls|
16396444|NCT04004416|Experimental|Early Psychosis patients|
16396445|NCT04004416|Experimental|Schizophrenia or Schizoaffective disorder patients|
16396446|NCT04004416|Experimental|Bipolar disorder patients|
16396447|NCT04004403|Experimental|Alternate day fasting|"These participants will consume 25% of their baseline energy needs on the fast day and eat ad libitum at home on alternating feed days."
16396448|NCT04004403|Experimental|Exercise|These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session.
16396449|NCT04004403|Experimental|Combination alternate day fasting plus exercise|"These participants will consume 25% of their baseline energy needs on the fast day and eat ad libitum at home on alternating feed days. They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session."
16396450|NCT04004403|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.
16396451|NCT04004377||acoustic neuroma monitored radiologically|patient with an acoustic neuroma (vestibular schwannoma) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, monitoring by radiology
16396452|NCT04004377||acoustic neuroma whose treatment is surgical|patient with an acoustic neuroma (vestibular schwannoma or) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, resection surgery planified
16396453|NCT04004325|Experimental|Cohort A|
16396454|NCT04004325|Experimental|Cohort B|
16396455|NCT04004312|Experimental|Single Fraction SBRT in the treatment of prostate cancer|Prior to treatment, a hydrogel spacer will be inserted between the recutm and prostate. A urinary catheter will also be inserted in the bladder. A single dose of 19Gy will be delivered with an IMRT technique. The treatment should last approximately 30 minutes. After the treatment, the urinary catheter will be removed.
16396456|NCT04004299|Other|HCV self-test intervention|Diagnostic intervention: participant performs capillary blood sampling at home in between outpatient clinic visits (3 months after) and sends the sample to the investigator's laboratory by regular post mail for HCV RNA analysis. This is on top of standard of care ALT measurement at every 6-monthly outpatient clinic visit, followed by HCV RNA testing if ALT is elevated. Follow-up period is 2 years, in which participants will perform and send in 4 self-tests, in combination with filling out 4 questionnaires into sexual risk behavior.
16396457|NCT04004273|Experimental|Exercise|Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; ~50 min per session). Each week, three exercise training sessions will be supervised by the research team (visits three to 20), whilst one session will be unsupervised but monitored objectively using a heart rate monitor.
16415644|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts A&B"|
16396460|NCT04004260|Other|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
16396461|NCT04004247|Experimental|Experimental group|"10-12 young healthy volunteers. Placed on semi-sitting position on the bed (40 deg.elevation). Calibration of electrical impedance tomography (EIT) on defined tidal volume 500ml, done with 500ml syringe connected to closed breathing circuit using full face mask as an interface.
~Insertion an esophageal and nasopharyngeal catheter for pressures measurement. In the first phase - spontaneous breathing with full face mask at 0, 5 and 10 cm H20 levels of PEEP.
~In the second phase - high flow oxygenation through nasal cannula, start with flow rate 10 L/min with gradual increase up to 60 L/min.
~Spirometry to determine functional residual capacity (FRC) before and after procedure is planed."
16396462|NCT04004234|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
16396463|NCT04004221|Experimental|Tislelizumab|200mg intravenously (IV) every 3 weeks(Q3W)
16396464|NCT04004208|Experimental|Aflibercept arm|Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
16396465|NCT04004208|Active Comparator|Laser photocoagulation arm|Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
16396466|NCT04004195|Experimental|Healthy participants|
16396467|NCT04004195|Experimental|Participants with mild renal impairment|
16396468|NCT04004195|Experimental|Participants with moderate renal impairment|
16396469|NCT04004195|Experimental|Participants with severe renal impairment|
16396470|NCT04004182|Active Comparator|OGTT session|Oral Glucose Tolerance test (OGTT)
16396471|NCT04004182|Active Comparator|Fruit bar|Fruit bar Plus Oral Glucose Tolerance test (OGTT)
16396472|NCT04004182|Experimental|Fruit bar with bilberry|Fruit bar with addition of 600 mg bilberry anthocyanins Plus Oral Glucose Tolerance test (OGTT)
16396473|NCT04004182|Experimental|Fruit bar with bilberry and apple|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols Plus Oral Glucose Tolerance test (OGTT)
16396474|NCT04004169|Experimental|Arm 1: Intervention (stimulation ON)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
16396475|NCT04004169|Sham Comparator|Arm 2: Control (stimulation OFF)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
16396476|NCT04004156|Experimental|Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
16396477|NCT04004143||Cross-sectional|a cross-sectional study.
16396478|NCT04004117|Experimental|Fentanyl s/l|Sublingual fentanyl will consist in liquid fentanyl at a concentration of 25 mcg/mL, with preparation by the pharmacist of pre-dosed syringes of 12,5 mcg (0,5 mL).
16396479|NCT04004117|Placebo Comparator|Placebo|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
16396480|NCT04004104|Active Comparator|Control - Upright Exercise|Participants will perform upright exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
16396481|NCT04004104|Experimental|Intervention - Supine Exercise|Participants will perform supine exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
16396482|NCT04004091|Experimental|24-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
16396483|NCT04004091|Experimental|26-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
16396484|NCT04004091|Experimental|28-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
16396485|NCT04004091|No Intervention|24-Day Non Spermine Group|Subjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
16396486|NCT04004091|No Intervention|26-Day Non Spermine Group|Subjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
16396487|NCT04004091|No Intervention|28-Day Non Spermine Group|Subjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
16396488|NCT04004078||Group A|Non-gene directed group：Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）. Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）.
16396489|NCT04004078||Group B|Gene directed group（UMs and EMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs，EMs.
16396490|NCT04004078||Group C|Gene directed group（IMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with IMs.
16396491|NCT04004078||Group D|Gene directed group（PMs）： Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 100mg . Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
16415645|NCT03870282|Experimental|"Personal Goal | Incentive A"|
16396492|NCT04004065|Experimental|Part A: SRP-5051|Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051, monthly, via intravenous (IV) infusion for at least 12 weeks during Part A. Once the maximum tolerated dose (MTD) has been determined in Part A, all patients who have completed Part A will transition to Part B.
16396493|NCT04004065|Experimental|Part B: SRP-5051|Patients will receive SRP-5051 at the MTD determined in Part A, or if applicable, at a second dose introduced in Part B, monthly, via IV infusion, for 24 weeks. This includes the patients who roll over from Part A, as well as expansion cohort patients who will enroll in the study at the beginning of Part B.
16396494|NCT04004052|Active Comparator|Group 1|Blockade of the LFCN is performed for therapeutic management of MP in group 1.
16396495|NCT04004052|Active Comparator|Group 2|Ten sessions of conventional TENS were applied to the group 2 daily 20 minutes per session, 5 days per week, for 2 weeks.
16396496|NCT04004052|Sham Comparator|Group 3|Sham TENS was applied to the group 3 with the same protocol.
16396497|NCT04004026||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform 3 m backwards walk test.
16396498|NCT04004013|Active Comparator|Lifenol|50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
16396499|NCT04004013|Placebo Comparator|Placebo|50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
16396500|NCT04004000|Experimental|Treatment|FSHD1 subjects with genetic confirmation with receive 15 mg of losmapimod twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for for up to approximately 1 year.
16396501|NCT04003987|Active Comparator|ESP Block|For the ESP block the ultrasound is positioned in a parasagittal fashion, 2-3 inches lateral to the spinous process. This approach visualizes the transverse process. The needle is inserted cranial-to-caudal to make contact with the shadow of the transverse process, with the needle tip deep to the fascial plane of the erector spinae muscle. Injection of saline confirms the location of the needle, and the anesthetic is injected (40 ml into each side; 20 ml injected at T8 and 20 ml injected at T12)
16396502|NCT04003987|Active Comparator|TAP Block|For the TAP block, the ultrasound probe is placed transverse to the abdominal wall, between the iliac crest and the costal margin. The needle is placed in the plane of the probe and advanced until it is between the internal oblique and the transversus abdominis muscles. Once in the plane, 2 mL of saline is injected to confirm needle position, then the local anesthetic solution is injected (40 ml into each side; 20 ml injected for subcostal TAP and 20 ml injected for posterior TAP).
16396503|NCT04003974|Experimental|Treatment|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
16396504|NCT04003974|Placebo Comparator|Placebo|FSHD1 patients with genetic confirmation will receive a Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
16396505|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
16396506|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
16396507|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
16396508|NCT04003948|Experimental|Fixed dose|Ibogaine Hydrochloride 100 mg on each administration.
16396509|NCT04003948|Experimental|Ascending dose|Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).
16396510|NCT04003935||Control|Continuing habitual diet and lifestyle.
16396511|NCT04003935||Active 1|Ingestion of a macro- and micro-nutrient rich shake, otherwise continuing habitual diet and lifestyle.
16396512|NCT04003935||Active 2|Ingestion of an encapsulated vitamin and phytonutrient supplement, otherwise continuing habitual diet and lifestyle.
16396513|NCT04003909|Experimental|ESP group|patients will have ultrasound guided ESP block before spinal anesthesia.
16396514|NCT04003909|Experimental|Control group|patients will have spinal Anesthesia without ESP block
16396515|NCT04003896|Experimental|Abemaciclib|Abemaciclib will be given as a single oral agent Approximately up to 27 subjects may be enrolled to attain at least 24 evaluable participants. The starting dose will be 200 mg twice daily. Dosing will continue daily for 28 days, this being one cycle. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.
16396516|NCT04003883||Emergency physicians|Emergency physicians doing shifts at the Medical University of Vienna's emergency response car will recieve a thorough cardiac pretesting. During shifts they will be attached to a Holter-ECG to detect changes in ST-T Segment and other ECG changes. Furthermore surrogate parameters of stress will be measured
16396517|NCT04003870|Experimental|Runner|Subject will undergo an assessment wearingeither the CASO or the HL. Sequence of CASO of HL will be randomly allocated.
16396518|NCT04003857|Experimental|PNEUMOSTEM®|A single intratracheal administration of Pneumostem® (10.0 x 10^6 cells/kg)
16396519|NCT04003857|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
16396520|NCT04003844|Experimental|Experimental|Investigational product (IP)
16396521|NCT04003831|Other|Optical Coherence Tomographer|
16396522|NCT04003818|Experimental|Teicoplanin|teicoplanin, administered orally 100-200 mg, twice a day
16396523|NCT04003805|Experimental|Switching from Smoking Cigarettes to SREC|
16396524|NCT04003805|Experimental|Switching from Smoking Cigarettes to Nicotine Mini-Lozenge|
16396525|NCT04003805|No Intervention|Usual Brand Cigarettes|
16396526|NCT04003792|Experimental|single arm prospective trial|
16396612|NCT04003259|Experimental|Overweight and obese subjects|1-year lifestyle programme
16396613|NCT04003246|Experimental|Single Arm: Therapeutic Intervention|
16396614|NCT04003233|Experimental|Spring Distraction System|The SDS device will be implanted during a scoliosis correction operation.
16415646|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts B"|
16396528|NCT04003766|Active Comparator|Percutaneous Biopsy|"The subject would undergo the standard of care procedure for a percutaneous biopsy of the liver.
~All percutaneous biopsies will be performed after administration of local anesthetic. No pre-procedure antibiotics will be administered. Subcostal or subxyphoid area will be cleaned and draped in the standard manner. 2% lidocaine solution will be injected subcutaneously using a 25-gauge needle and then administered into the subcutaneous tissue up to the liver capsule. A 16-gauge biopsy needle is inserted into the liver parenchyma under US or CT-guidance, with the location of needle placement left to the discretion of the performing radiologist. One or two core biopsy samples will be obtained. All procured specimens will be placed in a single specimen container of 10% formalin for tissue processing. When biopsy samples have been obtained, the patient will be taken to the recovery area for post-procedure monitoring."
16396529|NCT04003766|Active Comparator|Endoscopic-guided Ultrasound Biopsy|"The subject would undergo the standard of care procedure for an endoscopic-guided biopsy of the liver.
~The left lobe of the liver is identified from the gastric lumen, EUS-guided fine needle biopsy (FNB) will be performed using a 19-gauge FNB needle, with the choice of needle type at the discretion of the performing endoscopist. Stylet will only be used to puncture the liver at the time of the first pass and then subsequently removed. No suction will be used. Fanning technique will not be used. A total of 10 to-and-fro needle movements will be performed during each pass. A total of two passes will be performed.All tissue specimens procured will be placed in a single specimen container of 10% formalin for tissue processing. When two passes are complete under EUS-guidance, the echoendoscope will be withdrawn from the patient and the patient will be taken to the recovery area for post-procedure monitoring."
16396530|NCT04003753|Experimental|Exposure|"Study phase 1: The experimental intervention in the experimental group consists of three 20-minutes VR exposures (total duration in VR: 60 minutes).
~Study phase 2: The experimental intervention in the experimental group consists of six 30-minutes VR exposures as home training (total duration in VR: 3 hours) within two weeks."
16396531|NCT04003753|No Intervention|Control|"Study phase 1: The control group will not receive any active treatment. Instead they will use an App to make virtual tours (three times 20 minutes, total duration in VR: 60 minutes).
~Study phase 2: The control group will not receive any active treatment (untreated comparison group)."
16396532|NCT04003740|Experimental|Active tDCS|The anode will be placed over the right dorsolateral prefrontal cortex (DLPFC) and the cathode over the left DLPFC. Stimulation will be performed for 30 minutes with a current intensity of 2 mA. A ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero will be used.
16396533|NCT04003740|Sham Comparator|Sham tDCS|The same montage will be used. Sham stimulation will have the same ramp-up and ramp-down time in three different moments (beginning, middle and at the end of the session).
16396534|NCT04003727|Active Comparator|Neutral Position|Head and neck will be on neutral position.
16396535|NCT04003727|Active Comparator|Sniffing Position|Head and neck will be on sniffing position
16396536|NCT04003727|Active Comparator|Head Extension position|Head will be on simple extension position
16396537|NCT04003714|Experimental|Repetitive Transcranial Magnetic Stimulation Group|Patients in r-TMS group received r-TMS 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions.
16396538|NCT04003714|Sham Comparator|Sham Group|Control group received sham r-TMS with the same protocol.
16396539|NCT04003701|Active Comparator|Usual care group (control group)|Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head or stretched out and lying down along the body, with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.
16396540|NCT04003701|Experimental|Robot-assisted puncture procedure (experimental group)|During the experimental intervention, the child, a nurse, one of the parents/guardians, a researcher and the humanoid robot NAO (H25 Academic Edition, Aldebaran Robotics, Paris, France) will be present in the same room. The child will sit down in the same position as with the usual care. Next to the patient a humanoid robot of three-foot tall will sit on eye level on a slanted reading table, at the non-puncture side. The nurse will carry out the puncture procedure as performed as usual. The robot is programmed to distract the child during the entire procedure (before, during and after the puncture) by playing a game with the child based on his/her interests. The child can therefore choose between a number of games in different themes. In the end the robot tells the child that he/she did very well. During the whole intervention, the robot will be re-activated for each phase only when the child and the nurse are ready.
16396541|NCT04003688|Placebo Comparator|Placebo group|Patient will be administered saline solution followed by venous general anesthesia.
16396542|NCT04003688|Experimental|Magnesium sulfate through real weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's actual weight followed by venous general anesthesia.
16396543|NCT04003688|Experimental|Magnesium sulfate through ideal corrected weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's ideal corrected weight followed by venous general anesthesia.
16396544|NCT04003675||Adolescent elite athletes|Adolescent boys and girls elite athletes over 16 years of age studying at elite sport high schools in Norway.
16396545|NCT04003675||Adolescent controls|Adolescent boys and girls over 16 years of age studying at regular high schools in Norway.
16396546|NCT04003675||Trainers and leaders|Trainers (with more than 20 percent employment status) at elite sport high schools, and leaders/principals at elite sport high schools and regular high schools.
16396547|NCT04003662||inpatients|Vital signs measurement - standard of care and prototype
16396548|NCT04003662||outpatients|Vital signs measurement - standard of care and prototype
16396549|NCT04003662||Healthy controls|Vital signs measurement - standard of care and prototype
16396615|NCT04003233|Experimental|Minimal Invasive Deformity Correction system|The MID-C device will be implanted during a scoliosis correction operation.
16396616|NCT04003220||MyeloDysplastic Syndrome|platelets <150 G/l and diagnosis of myelodysplasia according to the WHO classification (abnormal bone marrow features).
16415647|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A"|
16396550|NCT04003649|Experimental|Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)|Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
16396551|NCT04003649|Experimental|Arm II (nivolumab, IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
16396552|NCT04003636|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
16396553|NCT04003636|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
16396554|NCT04003623|Experimental|Pemigatinib|
16396555|NCT04003610|Experimental|Pemigatinib + Pembrolizumab|Combination of pemigatinib plus pembrolizumab.
16396556|NCT04003610|Experimental|Pemigatinib|Pemigatinib alone.
16396557|NCT04003610|Active Comparator|Standard of Care|Chemotherapy or pembrolizumab.
16396558|NCT04003597|Placebo Comparator|Usual-salt diet|Usual-salt diet followed for 5 weeks
16396559|NCT04003597|Active Comparator|Reduced-salt diet|Reduced-salt diet followed for 5 weeks
16396560|NCT04003584||Minimally Invasive Cardiac Bypass patients|
16396561|NCT04003584||Traditional Sternotomy Cardiac Bypass patients|
16396562|NCT04003571|Experimental|Augmented reality with functional electrical stimulation group|Ten participants in group A will undergo 30 minutes interactive augmented reality with functional electrical stimulation intervention and 30 minutes traditional physiotherapy per day, 3 days a week for 8 weeks.
16396563|NCT04003571|Active Comparator|Traditional physiotherapy group|Ten participants in group B will undergo 30 minutes treadmill and balance training as well as 30 minutes traditional conventional physiotherapy a day, 3 days a week, for 8 weeks.
16396564|NCT04003558||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is a training cohort.
16396565|NCT04003558||Sun Yat-sen University Cancer Center|The cohort of Sun Yat-sen University Cancer Center is a validation cohort.
16396566|NCT04003558||Tungwah Hospital of Sun Yat-Sen University|The cohort of Tungwah Hospital of Sun Yat-Sen University is a validation cohort.
16396567|NCT04003558||Shunde hospital of southern medical university|The cohort of Shunde hospital of southern medical university is a validation cohort.
16396568|NCT04003545|Active Comparator|Active group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
16396569|NCT04003545|Placebo Comparator|Placebo group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
16396572|NCT04003493|Experimental|Intervention group of nutrition|On the basis of a blood test, Mini Nutritional Assessment, food diary and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the caregivers. If the caregivers seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
16396573|NCT04003493|No Intervention|Control group of nutrition|The control group has the same examinations as the intervention group, they do not get dietary counseling.
16396574|NCT04003493|Experimental|Intervention group of oral health|After the dental hygienist interview and oral health examination, the caregivers in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
16396575|NCT04003493|No Intervention|Control group of oral health|The control group has the same examinations as the intervention group, they do not get oral health counseling.
16396576|NCT04003480|Experimental|FRAME|Vein graft to be treated with FRAME
16396577|NCT04003467|Experimental|EBP05 1.5mg|subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
16396578|NCT04003467|Experimental|Placebo for EBP05 0.5mg (1, 2, 3 or 5)|subjects will be randomly assigned to receive 3 or 5 tablets of matching EBP05 placebo orally each day for 6 months
16396579|NCT04003467|Experimental|EBP05 2.5mg|subjects will be randomly assigned to receive 5 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
16396580|NCT04003467|Experimental|EBP05 0.5mg|subjects will be randomly assigned to receive 1 tablet of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
16396581|NCT04003467|Experimental|EBP05 1.0mg|subjects will be randomly assigned to receive 2 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
16396582|NCT04003454|Other|Nontargeted Screening|The nontargeted HCV screening arm will consist of implementing non-risk-based rapid opt-out HCV screening.
16396617|NCT04003220||Idiopathic Chronic Thrombocytopenia of Unknown Significance|Acquired thrombocytopenia lasting>6 months, without feature of dysimmunity (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. All ICTUS patients included in the study will thus have a bone marrow aspiration.
16396583|NCT04003454|Other|Targeted Screening|"The targeted HCV screening arm will consist of implementation of risk-based rapid opt-out HCV screening using current recommendations for HCV screening by the CDC, USPSTF, and AASLD-IDSA. Targeted HCV screening will consist of offering HCV testing to those identified with the following specific risk characteristics, adapted from the above recommendations: born between 1945 - 1965 (birth cohort); injection drug use (IDU); intranasal drug use;tattoo or piercing in an unregulated setting; or blood transfusion or organ recipient before 1992."
16396584|NCT04003441|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
16396585|NCT04003441|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
16396586|NCT04003428|Experimental|Per-caesarean HIFU shots|Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
16396587|NCT04003415|Experimental|Investigational Device Arm|Once consented for the study, participants will undergo testing with the investigational device for a one hour period. Testing will entail the participant wearing an EKG monitor, a respiratory rate monitor, a pulse oximeter, and being positioned next to the investigational device. The investigational device is contactless and captures chest movement of participants which allows it to estimate real time heart rate and respiratory rate. Additional data collected with the EKG monitor, respiratory rate monitor, and the pulse oximeter will be used to validate the vital sign data collected by the investigational device. After data collection is complete, participant involvement will then be over. Participants will have the option to return on a later date for additional testing (up to a maximum of three sessions total), within the six month window of the study. Participants will continue their standard of care therapies for their respiratory condition.
16396588|NCT04003402|Experimental|Sequence 1: Participants receiving treatment sequence A,B,C,D|"Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol"
16396589|NCT04003402|Experimental|Sequence 2: Participants receiving treatment sequence B,D,A,C|"Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol"
16396590|NCT04003402|Experimental|Sequence 3: Participants receiving treatment sequence C,A,D,B|"Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol"
16396591|NCT04003402|Experimental|Sequence 4: Participants receiving treatment sequence D,C,B,A|"Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol"
16396592|NCT04003389|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
16396593|NCT04003389|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
16396594|NCT04003389|Placebo Comparator|placebo|Participants will receive placebo for 52 weeks.
16396595|NCT04003376|Active Comparator|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata
16396596|NCT04003376|Experimental|fractional carbon dioxide laser and triamcinolone acetonide|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide (10mg/ml)
16396597|NCT04003376|Experimental|fractional carbon dioxide laser and platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
16396598|NCT04003376|Experimental|fractional carbon dioxide laser and vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
16396599|NCT04003363||Participants with Myotonic Dystrophy|
16396600|NCT04003350|Active Comparator|Opioid Regimen|"Weeks 1-4
~Oxycodone 5 mg PRN q4h (30 tablets)
~Tramadol 50 mg PRN q6h (30 tablets)"
16396601|NCT04003350|Experimental|Multimodal pain regimen with PRN opioids|"Weeks 1-4
~Tylenol 1000 mg q8h (standing)
~Meloxicam 15 mg qD (standing).
~Gabapentin 200 mg BID (with morning and evening Tylenol dose)
~Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)
~Esomeprazole 20mg daily if not already on another H2 blocker or PPI
~Oxycodone 5 mg PRN q4h (30 tablets)
~Tramadol 50 mg PRN q6h (30 tablets)"
16396602|NCT04003337|No Intervention|GROUP A: Morphological embryo selection|Patients enrolled in group A will receive an embryo transfer according to classical morphological criteria.
16396603|NCT04003337|Active Comparator|GROUP B: Morpho-kinetics embryo selection|Patients enrolled in group B will receive an embryo transfer according to new morphokinetics criteria.
16396604|NCT04003324|Experimental|Intervention group|Self-monitoring tool (Activator) and general information
16396605|NCT04003311||Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
16396606|NCT04003298|Experimental|Electric toothbrush and power interdental device|Electric toothbrush and power interdental device
16396607|NCT04003298|Active Comparator|Electric toothbrush|Electric toothbrush
16396608|NCT04003285|Experimental|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
16396609|NCT04003285|Experimental|ALLO 50 nM|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
16396610|NCT04003285|Experimental|ALLO 150 nM|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
16396611|NCT04003272||Comprehensive Reverse Versa-Dial Titanium Glenosphere|Patients who have an allergy to typical cobalt chrome or other metal allergies had surgery to repair shoulder malfunction/disease.
16396618|NCT04003220||Immune Thrombocytopenic Purpura|Diagnosis of Immune Thrombocytopenic Purpura (ITP) is made according to the international ITP consensus (diagnostic criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia
16396619|NCT04003220||healthy volunteers undergoing cardiac surgery|patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors
16396620|NCT04003207|Experimental|Phelan-McDermid syndrome|Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy
16396621|NCT04003194|Experimental|Pinto beans|1/2 cup pinto beans eaten daily by free-living individuals for 12 consecutive weeks.
16396622|NCT04003194|Active Comparator|Green beans|1/2 cup green beans eaten daily by free-living individuals for 12 consecutive weeks.
16396623|NCT04003181|Active Comparator|Positive breath test|Patients with a positive breath test are treated with antibiotics.
16396624|NCT04003181|Active Comparator|Positive SeHCAT scan|Patients with a positive SeHCAT scan are treated with a bile acid binder.
16396625|NCT04003181|No Intervention|No intervention|Patients with a normal breath test and a normal SeHCAT scan receive no intervention.
16396626|NCT04003168|Experimental|Human BCMA targeted T Cells Injection|"A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10^6 CAR T +cells/kg. The classic 3+3 dose escalation will be applied."
16396627|NCT04003155|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
16396628|NCT04003155|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
16396629|NCT04003155|Placebo Comparator|placebo|Participants will receive placebo for 12 weeks, after 12 weeks participants will be re-assigned to either low dose or high dose fezolinetant for 40 weeks.
16396630|NCT04003142|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
16396631|NCT04003142|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
16396632|NCT04003142|Placebo Comparator|placebo|Participants will receive placebo for 12 weeks, after 12 weeks participants will be re-assigned to either low dose or high dose fezolinetant for 40 weeks.
16396633|NCT04003116|Experimental|Supplementary oxygen|Supplementary oxygen added to conventional anticoagulant treatment.
16396634|NCT04003116|No Intervention|Standard medical therapy|Standard management.
16396635|NCT04003103|Experimental|Islatravir 60 mg|60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
16396636|NCT04003103|Experimental|Islatravir 120 mg|120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
16396637|NCT04003103|Placebo Comparator|Placebo|Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
16396638|NCT04003090|Experimental|Citicoline eyes|Patients had to administer 3 drops/day of an ophthalmic solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride for 14 days before surgery and 2 hours prior to surgery.
16396639|NCT04003077|Experimental|Laser meridian massage|They are treated with laser meridian massage on the back including Bladder meridian and Governor vessel three times a week for 4 weeks.
16396640|NCT04003077|No Intervention|Control|A control group of participants without laser meridian massage treatment are matched by age.
16396641|NCT04003051|Experimental|Supportive Care (Project Prepare website)|Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
16396642|NCT04003038|Active Comparator|Group I (wound care with a standard dressing)|Patients receive wound care with a standard dressing (bandage) after surgery for 7 days.
16396643|NCT04003038|Experimental|Group II (NPWT)|Patients receive NPWT after surgery for 7 days.
16396644|NCT04003012|Active Comparator|EMLA|The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
16396645|NCT04003012|Active Comparator|Lidocaine|The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
16396646|NCT04002999|Active Comparator|Ceramic braces, directly placed|Patients in this group will be treated with directly-bonded traditional tooth-colored ceramic brackets
16396647|NCT04002999|Experimental|Ceramic braces, indirectly placed|Patients will be treated with the same brackets from treatment group 1 but using the indirect bonding technique
16396648|NCT04002999|Experimental|3D printed customized ceramic braces|Patients will be treated using indirectly bonded 3D-printed ceramic (tooth-closed) brackets
16396649|NCT04002986|Experimental|Women at intermediate/high risk of breast cancer|Women age 35 years old identified at intermediate/high risk of breast cancer will receive genetic testing
16396650|NCT04002973|Experimental|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
16396651|NCT04002960|Experimental|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
16396653|NCT04002934|Experimental|Group A|"Group A is the early-start group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA"
16396654|NCT04002934|Experimental|Group B|"Group B is the delayed-start group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA"
16396655|NCT04002921||Right colectomy|Patient with scheduled right colectomy and with a documented preoperative scan.
16396656|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
16396657|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
16396658|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain & milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.
~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
16396659|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
16396660|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.
~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
16396661|NCT04002895|Experimental|Foliglurax|
16396662|NCT04002882||Subjects with Cystic Fibrosis|n=60 patients with CF ages 16-30
16396663|NCT04002882||Healthy Controls|n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
16396664|NCT04002869||Active TB suspicion|This study will include both adults and children with suspicion of different degrees of severity of active TB (pulmonary and extrapulmonary) to bring the investigator's study population into line with the routine clinical practice and to avoid the spectrum bias
16396665|NCT04002869||Latent TB infection|Individuals with latent TB infection (adults and children), with positive TST and/or IGRAs; without any sign or radiological evidence of TB disease or any clinical picture compatible with the criteria defined in the section TB cases.
16396666|NCT04002869||NTM infection|Adult and pediatric patients with lymphadenopathies caused by NTMs or individuals with chronic respiratory diseases with a NTM microbiologically confirmed by culture isolation.
16396667|NCT04002869||Uninfected control|Both adult and children without active TB and no immunologic evidence of M. tuberculosis infection, with negative TST and/or IGRAs
16396668|NCT04002869||Other respiratory diseases|Subjects with ARIs, and subjects with lung cancer; without any clinical picture compatible with the criteria defined in TB cases section. Patients with ARIs will be identified as individuals with clinical signs, symptoms and radiology of respiratory infections, and microbiological confirmation of non-TB origin. Patients with lung cancer will be identified as those with a high clinical suspicion, a suggestive chest X-ray/computed tomography scan, and a confirmed histopathological/cytological diagnosis
16396669|NCT04002856|Experimental|Profhilo®|"The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated after 1 month (T1).
~2 mL of Profhilo® was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 vertical-lines (3-4-3 ). The amount of product injected was 0.2 ml for each injection point."
16396670|NCT04002843|Experimental|- Virgin patients with Botulinum Toxin, first injection|"Experimental: - Virgin patients with Botulinum Toxin, first injection
~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.
~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)
~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of the elbow flexor muscle chosen (biceps brachialis, anterior brachialis), located ultrasonographically.
~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
16396671|NCT04002843|Experimental|- Injected group: Patients already injected|"- Injected group: Patients already injected
~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.
~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)
~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of in one elbow flexor muscle (biceps brachialis, anterior brachialis), located ultrasonographically.
~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
16396672|NCT04002843|Other|Control|healthy patient matched in age and sex to included patients
16396673|NCT04002830|Experimental|Taliglucerase Alpha|Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
16396674|NCT04002804|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
16396675|NCT04002791|Placebo Comparator|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
16415648|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A&B"|
16396676|NCT04002791|Active Comparator|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
16396677|NCT04002778|Active Comparator|ROSE by endosonographer|Submitted to fine-needle aspiration. Endosonographer's on-site evaluation of sample adequacy and categorization
16396678|NCT04002778|Other|non-ROSE|Submitted to fine-needle aspiration.
16396679|NCT04002765|Other|New RA patients|"Adults aged 18 to 90 years-old
~Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria
~Onset of disease duration at least 1 year and at most 10 years prior to inclusion"
16396680|NCT04002752|Experimental|Panel A: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 1) or matching placebo as single subcutaneous injection.
16396681|NCT04002752|Experimental|Panel B: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 2) or matching placebo as single subcutaneous injection.
16396682|NCT04002752|Experimental|Panel C: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 3) or matching placebo as single subcutaneous injection.
16396683|NCT04002739|Experimental|Patients with Acute Coronary Syndrome (ACS)|Patients admitted to a Coronary Care Unit (CCU) with a new diagnosis of ST Elevation Myocardial Infarction (STEMI) or Non ST Elevation Myocardial Infarction (NSTEMI). Patients are eligible within 72 hours from the admission in CCU. All patients admitted to CCU are going to perform the following procedures/exams as standard clinical practice: coronary angiogram, blood samples, echocardiogram, 24-hour Holter EKG Monitoring. The experimental arm will also perform a polygraphy during CCU stay, a bioelectrical impedance and will complete baseline questionnaires assessing daytime sleepiness such as Epworth Sleepiness Scale (ESS), STOP-BANG and Mallampati score. After the discharge from CCU, patients that had a diagnosis of Obstructive Sleep Apnea Syndrome are going to complete a follow up visit in 90 days undergoing a new polygraphy, bioelectrical impedance, questionnaires (ESS, STOP-BANG and Mallampati Score), echocardiogram.
16396684|NCT04002726|Active Comparator|Group Aa|Allocated to do the app-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
16396685|NCT04002726|Active Comparator|Group As|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
16396686|NCT04002726|Active Comparator|Group Sa|Allocated to do the slide-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
16396687|NCT04002726|Active Comparator|Group Ss|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
16396688|NCT04002713||ALT&AMT free flap reconstruction|Patients who underwent ALT or AMT free flap reconstruction after head and neck cancer surgery between March 1, 2008 and February 28, 2017
16396689|NCT04002700||Target Cohort 1|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.
16396690|NCT04002700||Target Cohort 2|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.
16396691|NCT04002700||Target Cohort 3|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (>=) 65 years.
16396692|NCT04002700||Target Cohort 4|Participants will be analyzed for stroke-risk who are new users of haloperidol aged >= 65 year.
16396693|NCT04002700||Target Cohort 5|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.
16396694|NCT04002700||Target Cohort 6|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.
16396695|NCT04002700||Comparator Cohort 7|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.
16396696|NCT04002700||Comparator Cohort 8|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged >= 65 years.
16396697|NCT04002700||Comparator Cohort 9|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.
16396698|NCT04002687|Experimental|ATV-PG 1000-400 mg + AQ 612 mg|T1 (n=16) - Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.
16396699|NCT04002687|Active Comparator|ATV-PG 1000-400 mg + AQ unmatched placebo|T 2 (n=12) - Atovaquone (ATV)-Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) unmatched placebo on days 1,2, 3.
16396700|NCT04002687|Active Comparator|ATV-PG unmatched placebo + AQ 612 mg|T 3 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + Amodiaquine (AQ) 612 mg on days 1,2, 3.
16396701|NCT04002687|Placebo Comparator|ATV-PG unmatched placebo + AQ unmatched placebo|T 4 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + AQ unmatched placebo on days 1,2, 3.
16396702|NCT04002674|Placebo Comparator|Placebo|"Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
16396703|NCT04002674|Active Comparator|200 mg Nilotinib|Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
16396704|NCT04002661|Active Comparator|Arm 1 - Active|Participants will take flibanserin 100mg orally every night for approximately 3 months.
16396705|NCT04002661|Placebo Comparator|Arm 2 - Placebo|Participants will take a placebo orally every night for approximately 3 months.
16396706|NCT04002648||MT-Right|
16396707|NCT04002648||Sternotomy|
16396708|NCT04002635|Active Comparator|Hormonal Replacement Therapy|Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.
16396709|NCT04002635|Experimental|Letrozole|Using letrozole for ovulation induction before planning the frozen embryo transfer
16396710|NCT04002622|Experimental|TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
16396745|NCT04002349|Experimental|B: Budesonide Nasal Spray (Rhinocort)|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning
16396711|NCT04002609||Group A, Active comparator|Patients in this group did not receive any rountine oxygen supplementation during the procedure. Rescue supplemental oxygen through nasal cannual was provided if clinically significant desaturation could be observed during bronchoscopy. This significant desaturation was defined as systemic oxygen saturation ≤90% on pulsoxymetry or a relative change of ≥ 4% lasting for 1 minute. N=31 patients
16396712|NCT04002609||Group B, Active comparator|Supplemental oxygen was provided for the patients through nasal cannula by a flow rate of 2 l/minutes throughout the procedure. N= 31 patients
16396713|NCT04002609||Group C, Active comparator|Supplemental oxygen administration through nasal cannula by a flow rate of 4 l/minutes throughout the procedure. N= 30 patients
16396714|NCT04002596|Experimental|ExAblate MRgFUS treatment|Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
16396715|NCT04002583|Experimental|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
16396716|NCT04002570||GROUP I/GROUP I bis|20 breast cancer patients who performed radiotherapy treatment
16396717|NCT04002570||GROUP II|maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.
16396718|NCT04002570||CONTROLS GROUP|healthy women with +/- 5 years compared to breast cancer patients age
16396719|NCT04002557||Focus group|"This is a qualitative study using focus group discussions with young people aged 12-18 who are receiving consultation summaries.
~Patients attending a single diabetes service will be invited to enrol. This service serves a population from a wide geographic area and socio-economic backgrounds.
~Interviews will be conducted by a qualitative researcher with relevant experience. They will be held on the day of a participant's clinic appointment within the same hospital or on the day agreed with the participant."
16396720|NCT04002544|Active Comparator|NTG group|In this group, nitroglycerin patch will be applied near the radial artery pulsation covered with a gauze.
16396721|NCT04002544|Placebo Comparator|Control group|In this group, no patch as applied to the patient. However, a gauze will be applied to confirm blinding
16396722|NCT04002531|Other|Single Visit|"General and neurological examination
~Vital signs including height, weight, blood pressure, pulse, temperature
~12 lead ECG
~2 hour Holter monitor for heart rate variability
~Echocardiogram
~Renal function will be assessed by the eGFR. The eGFR will be calculated from serum creatinine using CKD-EPI equation.
~CBC with differential
~Complete metabolic panel
~Urinalysis
~Urine Albumin/creatinine ratio.
~Urine and plasma samples for biomarkers (Gb3, lyso-Gb3) that will be stored in -80 freezer and assayed in our lab.
~Brief Pain Inventory questionnaire.
~Quality of Life Questionnaires (SF36)"
16396723|NCT04002518||3.0mm and 4.0mm|Patients who have surgically been treated with a 3.0mm or 4.0mm screw.
16396724|NCT04002518||5.0mm|Patients who have surgically been treated with a 5.0mm screw.
16396725|NCT04002518||6.5mm and 8.0mm|Patients who have surgically been treated with a 6.5mm or 8.0mm screw.
16396726|NCT04002505|Experimental|Head Injury Subject|Subjects that present to the Emergency Department with a blunt head injury within the past 24 hours, determined to be low risk by the Canadian CT Head Rules (CCHR), and are being considered for a head CT by the treating provider will use the shared decision making tool Concussion and Brain Bleed app (CBC) with their clinician
16396727|NCT04002492|Experimental|Addition of bodyweight training|All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
16396728|NCT04002479|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16396729|NCT04002466||Children (6-59 months)|
16396730|NCT04002466||Women of Reproductive Age (15-49 years)|
16396731|NCT04002466||Adult Men (15-49 years)|
16396732|NCT04002453||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
16396733|NCT04002440|Active Comparator|AMIA with SHARESOURCE|For this arm, dialysis nurses will review those patients using the AMIA with SHARESOURCE connectivity platform twice a week and will contact patients who meet certain triggers. They will then offer patients interventions, ie. a change in the preset AMIA ultrafiltration program, in order to achieve prescribed dry weight.
16396734|NCT04002440|Placebo Comparator|HomeChoice PRO|For this arm, routine standard of care for peritoneal dialysis patients will continue using the HomeChoice PRO device. Data regarding treatments will be captured on a chip to be analyzed at the end of 6 months to evaluate compliance with treatments.
16396735|NCT04002427|Experimental|Only one study arm|"[14C]AZD7594 Solution for Infusion 5 µg/mL (1.1 kBq/mL)
~AZD7594 Inhalation Powder, SD3FL Inhaler"
16396736|NCT04002414|Active Comparator|Usually Active- Decrease|Participants who usually meet or exceed recommended levels of physical activity who will be asked to minimize activity during stimulation.
16396737|NCT04002414|Experimental|Usually Active- Maintenance|Participants who usually meet or exceed recommended levels of physical activity who will be asked to maintain usual level of activity during stimulation.
16396738|NCT04002414|Experimental|Usually Insufficiently Inactive- Increase|Participants who are usually inactive who will be asked to try to increase activity to the recommended level during stimulation.
16396739|NCT04002414|Active Comparator|Usually Insufficiently Inactive- Maintenance|Participants who are usually inactive who will be asked to maintain inactivity during stimulation.
16396740|NCT04002401|Experimental|Axicabtagene Ciloleucel and Rituximab Combination|Participants will receive rituximab, and fludarabine and cyclophosphamide conditioning chemotherapy, followed by axicabtagene ciloleucel and additional rituximab.
16396741|NCT04002388|Experimental|Activity Monitor Group|This arm will receive a FitBit and will be asked to wear this for one year
16396742|NCT04002388|Active Comparator|Usual Care Group|The usual care group will NOT receive a FitBit
16396743|NCT04002362|Experimental|Children receiving triamcinolone acetonide|Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks.
16396744|NCT04002349|Placebo Comparator|A: Placebo group|Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning
16396746|NCT04002349|Experimental|C: Levocabastine Nasal Spray (Livostine)|Treated by Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
16396747|NCT04002349|Experimental|D: Combined Treatment|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
16396748|NCT04002336|Active Comparator|Traditional Voice Therapy|Standard of care (traditional) voice therapy.
16396749|NCT04002336|Experimental|App Group|Voice therapy using a smartphone app.
16396750|NCT04002323||HIV-1 ART-Naive|Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)
16396751|NCT04002310|Experimental|BI 754132|Single Rising Dose (SRD) part followed by a Multiple Dosing (MD) part
16396752|NCT04002297|Experimental|zanubrutinib plus rituximab|
16396753|NCT04002297|Active Comparator|bendamustine plus rituximab|
16396754|NCT04002284|Experimental|anlotinib|anlotinib 12mg qd p.o. d1-14/21day/cycle
16396755|NCT04002271|Active Comparator|Group SA|Patients in Group SA will undergo spinal anaesthesia.
16396756|NCT04002271|Active Comparator|Group GAS|Patients in Group GAS will undergo general inhalational anaesthesia using sevoflurane.
16396757|NCT04002271|Experimental|Group TIVA|Patients in Group TIVA will undergo general anaesthesia using propofol total intravenous anaesthesia.
16396758|NCT04002245|Experimental|Go back|Application of a compress impregnated with alcoholic Betadine® by movement of return
16396759|NCT04002245|Experimental|Technique of snail|Application of a compress impregnated with alcoholic Betadine into a single movement from the center towards the periphery and covering the end surface of followed by spontaneous drying time 30 seconds.
16396760|NCT04002232|Experimental|CPP-ACP-NaF|Dental varnish that contains calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
16396761|NCT04002232|Placebo Comparator|Placebo|Dental varnish base that does not contain calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
16396762|NCT04002219|Experimental|Active arm|Subjects will receive treatment with active beverage containing the active ingredient
16396763|NCT04002219|Placebo Comparator|Placebo arm|Subjects will receive treatment with placebo beverage not containing the active ingredient
16396764|NCT04002206|Experimental|Muscle Energy Technique|Post isometric relaxation technique was used in experimental group
16396765|NCT04002206|Active Comparator|Static Stretch|Static stretching was given in control group
16396766|NCT04002180||Vedolizumab 300 mg|Vedolizumab (Genetical Recombination) 300 mg, IV infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
16396767|NCT04002167|Experimental|Neurofeedback|The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
16396768|NCT04002167|Active Comparator|Cognitive Training|The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
16396769|NCT04002167|No Intervention|Waitlist|Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
16396770|NCT04002154|Experimental|A - papilocare alternative days|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
16396771|NCT04002154|Experimental|B - papilocare semiintensive|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
16396772|NCT04002154|No Intervention|C - standard of care|Arm C: usual clinical practice: no treatment
16396773|NCT04002141|Experimental|Endometriosis Letrozole|Participants will be asked to take 5mg letrozole daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to letrozole. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
16396774|NCT04002141|Placebo Comparator|Endometriosis Placebo|Participants will be asked to take one tablet placebo daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to placebo. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
16396775|NCT04002141|No Intervention|No Endometriosis Control|Participants will be asked to complete surveys during their ovarian stimulation and up to 12 weeks following retrieval to evaluate symptoms of pelvic pain. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
16396776|NCT04002128|Placebo Comparator|Group air|"Group air was mechanically ventilated using 35% oxygen in 65% air during the whole surgical procedure.
~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
16396828|NCT04001777|Experimental|APG-1252 plus Osimertinib (AZD9291)|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase; Dose of osimertinib will be fixed at 80mg QD based on approved label.
16396829|NCT04001764|Active Comparator|The first group|The radial artery catheterization with ultrasound-guided short axis out of plane intervention will be performed over 2 cm of the wrist for this group.
16396777|NCT04002128|Active Comparator|Group nitrous oxyde (N2O)|"Group N2O was mechanically ventilated using 35 % oxygen and 65 % of nitrous oxyde during the surgical procedure.
~Nitrous oxyde may increase cuff pressure during the general endotracheal anesthesia and result in the respiratory symptoms like sore throat, hoarseness and postoperative cough.
~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
16396778|NCT04002115|Experimental|Clofarabine 30 mg/m^2|Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.
16396779|NCT04002102|Experimental|OLP treatment|Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.
16396780|NCT04002102|Other|Usual care|Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.
16396781|NCT04002102|Active Comparator|Expectancy Group|Participants receive educational materials and positive expectancy orientation via Zoom or telephone
16396782|NCT04002089|Experimental|Cohort 1 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.
16396783|NCT04002089|Experimental|Cohort 2 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.
16396784|NCT04002089|Experimental|Cohort 3 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only
16396785|NCT04002089|Active Comparator|Cohort 4 - bupivacaine|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.
16396786|NCT04002076|Experimental|Robot-assisted hand combined with occupational therapy|Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
16396787|NCT04002076|Active Comparator|Traditional occupational therapy|Another 10 participants allocated to the group B will receive 60 minutes a day and 3 days a week traditional occupational therapy for six weeks.
16396788|NCT04002063|Experimental|CBT-D augmented with CBT MobileWork-V|Patients randomized to this condition will receive CBT-D as usual plus access to CBT MobileWork-V, a comprehensive tailored smartphone app for CBT skills practice for OEF/OIF Veterans.
16396789|NCT04002063|Active Comparator|CBT-D|Patients randomized to CBT-D will receive CBT-D as usual only.
16396790|NCT04002050|Active Comparator|CBTm Course Intervention|Participants placed in the intervention group will receive the CBTm Course. The CBTm Course consists of 5 classes, 90 minutes each, and held in-person on a weekly basis.
16396791|NCT04002050|No Intervention|Comparison Group|Participants in the comparison group will not receive the intervention during the study, but will be offered intervention once the study has been completed (i.e. 3 month waiting-period). However, in the event that a stressful situation arises while a participant is placed in the comparison group, the participant may seek assistance from the usual mental health supports offered through their respective occupational organizations, EAP programs, and other programs in the community. Following completion of the study, participants in the comparison group will be invited to attend the CBTm Course.
16396792|NCT04002037|Active Comparator|Triamcinolone 40mg/mL|A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
16396793|NCT04002037|Active Comparator|Triamcinolone 10mg/mL|A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
16396794|NCT04002037|Active Comparator|Soluble dexamethasone 4mg/mL|A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.
16396795|NCT04002024|Active Comparator|Placebo and Treatment Arm A|The patients in treatment arm A group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the right side of their face and placebo which is moisturizer without those active ingredients on the left side of their face.
16396796|NCT04002024|Active Comparator|Treatment and Placebo Arm B|The patients in treatment arm B group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the left side of their face and placebo which is moisturizer without those active ingredients on the right side of their face.
16396797|NCT04002011|Active Comparator|Group VKA|"103 patients. First intake at postoperative day 1 or later when anticoagulation is secondary indicated.
~Dosage adapted to INR = [2.0-3.0], parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) until INR > or = 2.0.
~Daily INR during hospital stay, then management by familial doctor. Duration: 3 months"
16396798|NCT04002011|Active Comparator|Group DOAC|"103 patients - One drug among the 4 DOAC according the morbidity of each patient (preoperative DOAC, oral nutrition recovery).
~First intake at hospital discharge - parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) during hospital stay.
~Regular daily dosages according the drug, its indication (atrial fibrillation/flutter or biological mitral replacement/repair or biological tricuspid replacement versus venous thromboembolism) and the morbidity of each patient (age, weight, creatinine ou its clearance).
~Validation by one referent pharmacist. No biological monitoring. Duration: 3 months"
16396799|NCT04001998|Experimental|Tablet vs Capsule Formulation|Single oral dose of BLD-2660 capsule or tablet formulation
16396800|NCT04001998|Experimental|Dose Proportionality|Single oral dose of BLD-2660 tablet formulation
16396801|NCT04001985|Active Comparator|Immediate NG tube removal|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
16396802|NCT04001985|Active Comparator|NG tube clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
16396803|NCT04001972|Experimental|Intervention group|Brief advice (AWARD model) + NRT-S + IM Apps and Chatbot
16396804|NCT04001972|Active Comparator|Control group|Brief advice (AWARD model) + regular SMS
16396805|NCT04001959|Active Comparator|Silver Diamine Fluoride|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Next, dry the tooth for 30 seconds with air jet followed by a drop of 30% Diamino Fluoride Silver with a disposable applicator brush for 3 minutes and after that time washing for 1 minute.
16396806|NCT04001959|Experimental|Silver Diamine Fluoride with Potassium Iodide|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Then the tooth is dried for 30 seconds with an air jet and applied one drop of the Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the surface treated with Diamino , until the formed creamy white color becomes transparent. After these steps have been completed, rinse with water for 1 minute.
16396807|NCT04001946|Other|G-button Securement Device|Subjects will be provided instructions and a 12-week supply of test devices, sufficient to change the gauze dressing at least once per day.
16396808|NCT04001946|No Intervention|Standard Dressing|Subjects will be provided instructions and a 12-week supply of tape and gauze (current standard of care), sufficient to change the gauze dressing at least once per day.
16396809|NCT04001933|Experimental|Intervention Arm|CPOP Intervention (see below).
16396810|NCT04001933|No Intervention|Control Arm|Usual care.
16396811|NCT04001920|Experimental|Training program|12-week strength and endurance training program
16396812|NCT04001907|Experimental|exercise combined with β-hydroxy-β-methylbutyrate (HMB)|Resistance Exercise ( 3d/week) and HMB: 3g/d as three 1g capsules orally, for 9 weeks
16396813|NCT04001907|Placebo Comparator|exercise combined with placebo|Resistance exercise ( 3d/week) and placebo as 3g/d maltodextrin as three 1g capsules orally, for 9 weeks
16396814|NCT04001894|Experimental|Ticagrelor|To observe the safety and efficacy of standard-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
16396815|NCT04001894|Active Comparator|Clopidogrel|To observe the safety and efficacy of standard-dose clopidogrel in Chinese patients with Stable Coronary Artery Disease
16396816|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
16396817|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
16396818|NCT04001868|Experimental|Experimental Group|Application of the sub occipital inhibition technique.
16396819|NCT04001868|Placebo Comparator|Placebo Group|Hand contact in the sub occipital region without executing any technique.
16396820|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach bath|Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.
16396821|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach gauze soaks|Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.
16396822|NCT04001842|Experimental|Axially vascularized constructs|Reconstructing a mandibular defect using an axially vascularized bone substitute using the arteriovenous loop (AVL)
16396825|NCT04001803|Experimental|Subjects with HIV infection|HIV-infected subjects receiving CAB LA+RPV LA will be included in this arm.
16396826|NCT04001790|Experimental|Project Search + ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center where they rotate through three 10-12 week internships within the business learning marketable skills, social communication, and adaptive behavior in the business setting. In order to meet the unique needs of youth with ASD, Wehman, et al. (2014) enhanced the Project SEARCH model by adding autism supports to the original model. Those added supports were: 1) on-site, intensive, systematic instruction using the principles of applied behavior analysis, 2) on-site support and consultation from a behavior/autism specialist, and 3) intensive staff training in ASD and the Project SEARCH Model.
16396827|NCT04001790|No Intervention|Business as Usual|Business as Usual means these youth remain in their high school programs as determined on their individualized education plans
16396885|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 610|
16396830|NCT04001764|Experimental|The second group|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
16396831|NCT04001764|Experimental|The third group|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
16396832|NCT04001751|Experimental|Therapeutic educational postural yoga program|Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
16396833|NCT04001738|Active Comparator|Direct Transfer to Angio Suite|After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
16396834|NCT04001738|No Intervention|Direct Transfer to CT Scan|After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
16396835|NCT04001725|Active Comparator|A (Dexamethasone)|Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route (control arm). The total dose can either administered once a day or through a refracted schedule
16396836|NCT04001725|Experimental|B (Dexamethasone and Metformin)|"Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route.The total dose can either administered once a day or through a refracted schedule.
~The same patients subjected at a metformin. Metformin initial dosage will be 850 mg per day, and will be escalated based on patient tolerability up to a maximum of 2550 mg daily (experimental arm)."
16396837|NCT04001712|Experimental|early caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support
16396838|NCT04001712|Active Comparator|late caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support
16396839|NCT04001699|Experimental|Intervention|Preoperative assessment conducted by an interprofessional team
16396840|NCT04001699|Active Comparator|Usual care|Usual care
16396841|NCT04001673|Active Comparator|Pharmacist's intervention|Evaluation of knowledge and adherence of patients treated by bDMARDs before and after the intervention of a pharmacist that will give information concerning bDMARDs management.
16396842|NCT04001673|No Intervention|Control|Evaluation of knowledge and adherence of patients treated by bDMARDs who did not receive pharmacist's intervention.
16396843|NCT04001660|Experimental|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
16396844|NCT04001647|Experimental|TUDCA|Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
16396845|NCT04001647|Placebo Comparator|Placebo|Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
16396846|NCT04001634||Dual anti-HER2 group|Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy
16396847|NCT04001621|Experimental|Pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
16396848|NCT04001608|Experimental|Seraprevir and sofosbuvir|Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
16396849|NCT04001595||Participants with FKRP genetic mutation|
16396850|NCT04001582||Participants with FSHD|
16396851|NCT04001569|Experimental|AZD8186 in combination with paclitaxel|
16396852|NCT04001556|Experimental|Patients reporting subjective sicca symptoms|HAQ(Health Assessment Questionnaire) Score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
16396853|NCT04001556|Experimental|Patients without subjective sicca symptoms|HAQ(Health Assessment Questionnaire) score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
16396886|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
16396887|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 430|
16396888|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 520|
16396854|NCT04001543|Experimental|Immunomodulating oral supplementation|"The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3.
~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
16396855|NCT04001543|Active Comparator|Sip feed control|"The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control.
~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
16396856|NCT04001530|Experimental|Half-normal saline|Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters
16396857|NCT04001530|Active Comparator|Normal saline|Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters
16396858|NCT04001517|Experimental|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
16396859|NCT04001517|Placebo Comparator|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
16396862|NCT04001478||Control group|Patients who are attending hospital for a gastroscopy as part of their routine clinical care as a 2 week wait rule referral and those on Barrett's surveillance , will be asked to give a sample of their breath prior to the procedure.
16396863|NCT04001478||Early oesophageal cancer (T1)/ Barrett's high grade dysplasia|Patients who have known pre-diagnosed T1 oesophageal adenocarcinoma or HGD attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation. Patients will be sampled upon return for follow up endoscopy to assess breath profile changes and correlation with endoscopy findings.
16396864|NCT04001478||Advanced Oesophageal cancer (T2/3/4)|Patients who have been diagnosed with oesophageal adenocarcinoma attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation.
16396865|NCT04001465|Active Comparator|Volumetric methacholine challenge|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer
16396866|NCT04001465|Active Comparator|Methacholine challenge with spirometer|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer fitted with an ultrasonic spirometer
16396867|NCT04001452||Level of experience in interventional cardiology|"Total cohort will be grouped according to experience in interventional cardiology, as defined by a single choice questionnaire:
~Yearly personal PCI volume Less than 75 / Between 75 and 150 / Between 151 and 250 / More than 250"
16396868|NCT04001452||Level of experience with intravascular ultrasound|"Total cohort will be grouped according to experience with intravascular ultrasound, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
16396869|NCT04001452||Level of experience with optical coherence tomography|"Total cohort will be grouped according to experience with optical coherence tomography, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
16396870|NCT04001452||Level of experience with fractional flow reserve|"Total cohort will be grouped according to experience with fractional flow reserve, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
16396871|NCT04001452||Level of experience with non-hyperaemic pressure ratios|"Total cohort will be grouped according to experience with non-hyperaemic pressure ratios, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
16396872|NCT04001439|Other|Clinical trial|the study design is an open-label, single-arm propective clinical trial. In this proof-of-concept study we will assess feasibility safety and potential efficacy of an intervention of FMT in SZ subjects with MD.
16396873|NCT04001426|Experimental|Monitoring during activation of the FemPulse System|Subjects will undergo non-invasive monitoring during activation of the FemPulse System.
16396874|NCT04001413|No Intervention|Arm A: Observational|No intervention, observational arm.
16396875|NCT04001413|Experimental|Arm B: Durvalumab Alone|Durvalumab will be administered as an IV Infusion.
16396876|NCT04001413|Experimental|Arm C: MEDI0457 and Durvalumab|MEDI0457 is an injection. Durvalumab will be administered as an IV Infusion.
16396877|NCT04001400|Experimental|High-dose rabeprazole|Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
16396878|NCT04001400|Active Comparator|Standard-dose rabeprazole|Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks
16396879|NCT04001387||Spinal anesthesia|
16396880|NCT04001374||Ticagrelor|Ticagrelor 90mg tablet bid for 12 months
16396881|NCT04001374||Ticagrelor + ASA|Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months
16396882|NCT04001361|Sham Comparator|Sham|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser inserted into knee joint but not turned on.
16396883|NCT04001361|Experimental|Laser Only|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser fiber is inserted into knee over an 18 gauge needle and micro-channels are made into the damaged cartilage.
16396884|NCT04001361|Experimental|Laser plus Marrow|Under conscience sedation, a 10mL marrow aspiration is performed. Laser fiber is inserted into the knee over an 18 gauge needle and micro-channels are made into the damaged cartilage. After the channels are made, marrow aspirate is injected over the same 18 gauge needle.
16396889|NCT04001335||CL suspicion|Patients with skin lesions suspected to be cutaneous leishmaniasis
16396890|NCT04001322|Experimental|14 Intervention LGAs|Various target beneficiaries will receive broadcast, targeted and individualized SMS messages on immunization.
16396891|NCT04001322|Other|7 Control LGAs|This arm will not receive any SMS messages on immunization
16396892|NCT04001309|Experimental|Infectious diseases physician led|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly
~Also including standard of care
~infectious disease consultant on demand
~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
16396893|NCT04001309|Experimental|Multiprofessional team|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention
~Also including standard of care
~infectious disease consultant on demand
~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
16396894|NCT04001296|Experimental|21 day Brush Day and Night intervention|The 21 day Brush Day and Night programme aims to instruct on and encourage twice a day brushing with a fluoridated toothpaste.
16396895|NCT04001296|No Intervention|Control schools|Schools / children who receive only toothpaste / toothbrushes, no 21 day Brush Day and Night intervention
16396896|NCT04001283|Experimental|sodium nitrite 24hours before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
16396897|NCT04001283|Experimental|sodium nitrite 30minutes before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
16396898|NCT04001283|Placebo Comparator|0.9% sodium chloride|Intravenous normal (0.9%) sodium chloride infused at 1ml/min
16396899|NCT04001270||Patients anti leucine rich glioma inactivated-1 encephalitis|Biomarkers from patients with anti-leucine rich glioma inactivated 1 encephalitis (anti LGI1-E) will be studied. This is a non-interventional study involving biological samples (CSF biomarkers) already stored in biobank repositories. All stored samples were collected as part of the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population.
16396900|NCT04001244||Endometriosis (EAP)|Surgical diagnosis of endometriosis (aim equal distribution of stage I/II and stage III/IV disease); at least one pelvic pain >3/10; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
16396901|NCT04001244||Bladder Pain Syndrome (BPS)|Bladder pain syndrome (as defined by ESSIC criteria: pelvic pain, pressure or discomfort for greater than 6 months, perceived to be related to the urinary bladder accompanied by at least one other urinary symptom like persistent urge to void or frequency); no history of endometriosis
16396902|NCT04001244||Endometriosis and Bladder Pain (EABP)|Surgical diagnosis of endometriosis; at least one pelvic pain >3/10; pain perceived by the patient as arising from the bladder AND from other area(s) of the pelvis; at least one urinary symptom (e.g. urge, frequency)
16396903|NCT04001244||Controls|No endometriosis; No pelvic pain (or dysmenorrhea; NRS <3/10)
16396904|NCT04001244||Pelvic Pain (PP)|At least one pelvic pain >3/10; no endometriosis; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
16396905|NCT04001231|Experimental|Single arm of exenatide once-weekly suspension|Exenatide once-weekly suspension via subcutaneous (SC) injection
16396906|NCT04001218|Experimental|Painful condition|Participants will be injected with 0.5ml hypertonic saline (5.8%) into a neck muscle
16396907|NCT04001218|Experimental|Control condition|Participants will be injected with 0.5ml Isotonic saline (0.9%) into a neck muscle
16396908|NCT04001205||No oral anticoagulation|Patients without oral anticoagulation for AF
16396909|NCT04001205||Oral anticoagulation|Patients with long term oral anticoagulation
16396910|NCT04001192|Experimental|exercise|exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
16396911|NCT04001179||Presence of pulmonary embolism|≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
16396912|NCT04001179||No pulmonary embolism|Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
16396913|NCT04001153||Upper primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
16396914|NCT04001153||Lower primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
16396915|NCT04001153||Upper primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
16396916|NCT04001153||Lower primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
16396917|NCT04001140|Active Comparator|Intervention group|The intervention group will take part in the sessions of the intervention, in which they learn different skills for the purpose of emotion regulation. All participants will complete the questionnaires and take part in the experiment again. This group prevention program, which is short-term, entailing 7 sessions, synthesizes techniques from three therapeutic models: Cognitive-Behavioral Therapy, Dialectical-Behavioral Therapy and Acceptance and Commitment Therapy.
16396918|NCT04001140|No Intervention|Waiting-list group|The waiting-list group will receive the intervention 7 weeks after the intervention group finishes. The intervention group will finish the research in week 7, while the waiting-list group will start to attend the intervention. They will complete the questionnaires and the experiment.
16396919|NCT04001127|Experimental|High Intensity Functional Training|Intervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
16415649|NCT03870282|Experimental|"Personal Goal | Incentive A&B"|
16396920|NCT04001114|Other|Smokers with schizophrenia|This is a diagnostic group, defined independently from this study.
16396921|NCT04001114|Other|Smokers without schizophrenia|This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
16396922|NCT04001101|Active Comparator|RT and Anti-PD-1|"In the pembrolizumab + RT arm, pembrolizumab will be started on study within 7 days (+/- 7 days) of start of RT.
~Pembrolizumab will be given as standard of care in both arms"
16396923|NCT04001101|Placebo Comparator|Anti-PD-1|anti-PD-1 therapy alone Pembrolizumab will be given as standard of care in both arms
16396924|NCT04001088|Experimental|Probiotic|Probiotics in a capsule.
16396925|NCT04001088|Placebo Comparator|Placebo|Non active ingredients in a capsule.
16396927|NCT04001062|Active Comparator|Non-operatively|"Adults 18 and older
~Native English-speaker
~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
16396928|NCT04001062|Active Comparator|Surgical|"Adults 18 and older
~Native English-speaker
~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
16396929|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX15|Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
16396930|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX07|Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
16396931|NCT04001023|Experimental|PDS|18F-EF5 PET/CT and 18F-FDG PET/CT scan prior to primary cytoreductive surgery and targeted sample collection during primary cytoreductive surgery
16396932|NCT04001023|Experimental|IDS|"18F-EF5 PET/CT and 18F-FDG PET/CT scans prior to diagnostic laparoscopy and after neoadjuvant chemotherapy before interval cytoreductive surgery .
~Targeted sample collection during diagnostic laparoscopy and interval cytoreductive surgery"
16396933|NCT04001010|Experimental|inhaled THC/CBD (PPP011)|PPP011 (synthetic THC/CBD) inhalation with mighty medic device
16396934|NCT04001010|Placebo Comparator|Placebo|Placebo inhalation with mighty medic device
16396935|NCT04000997||Failure group|Patients with a failure endotracheal extubation
16396936|NCT04000997||Success group|Patients with a successful endotracheal extubation
16396937|NCT04000984|Experimental|Mindfulness-Based Intervention|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.
16396938|NCT04000984|Active Comparator|Cognitive Rehabilitation Training|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
16396939|NCT04000984|No Intervention|Treatment As Usual|Participants in the Treatment As Usual group were only required to attend baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. Participants in this group will not receive an intervention for the duration of the study. They received treatment as usual which is 6 months to 1-year follow up visits with their attending neurologist of psychologist.
16396940|NCT04000971|Active Comparator|Integrated Stroke Practice Unit (ISPU)|ISPU personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge. This will be supplemented by a more integrated model designed to increase coordination through team-based initiatives across the continuum of care for stroke - from acute and in-hospital care through 12 months post-discharge. Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, increase understanding, and build positive behavior change for patients and caregivers. Primary outcomes will be assessed by phone at 3, 6, 12, and 24 months; secondary outcomes will be assessed at 3, 6, and 12 months.
16396941|NCT04000971|Active Comparator|Comprehensive or Primary Stroke Center (CSC/PSC)|CSC/PSC personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge, follow-up clinic visits as recommended by their outpatient provider, and other clinic visits initiated by the patient when issues arise. Primary outcomes will be assessed by phone at 3, 6, 12, and 24 months; secondary outcomes will be assessed at 3, 6, and 12 months.
16396942|NCT04000958|Experimental|PIFR group|
16396943|NCT04000958|Active Comparator|control group|
16396944|NCT04000945|Experimental|BTL-899 Therapy Arm|
16396945|NCT04000945|Sham Comparator|Sham Arm|
16396946|NCT04000932|Experimental|Platelet rich plasma (PRP) -T lab PRP kit|A single 1ml PRP extract injection will be will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel. performed once into the carpal tunnel in the wrist . PRP will be obtained by centrifugation of autologous anticoagulated whole blood.
16396947|NCT04000932|Active Comparator|Diprospan ®, Schering Plough|A single steroid injection (1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel.
16396948|NCT04000919|Sham Comparator|Effects of single-dose of carbidopa (50mg) on CNS excitability|Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
16396949|NCT04000919|Placebo Comparator|Effects of single-dose placebo on CNS Excitability|Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
16397012|NCT04000503|Experimental|Community Health Meeting Self-Collection|Community health meeting recruitment of women for self-collected HPV testing
16396950|NCT04000919|Active Comparator|Effects of single-dose 5HTP/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
16396951|NCT04000919|Active Comparator|Effects of single-dose L-DOPA/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
16396952|NCT04000906|Experimental|Experimental Arm|Pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration of Nab paclitaxel and cisplatin
16396953|NCT04000893|Experimental|Resistance exercise session|Acute isometric session, about 20 minutes.
16396954|NCT04000893|Active Comparator|Aerobic exercise session|Acute aerobic session, about 20 minutes.
16396958|NCT04000867|Active Comparator|real TCMS treatment|Subjects with DN located in their bilateral feet that have been previously identified and have a graded average baseline score of at least 5 in each foot will receive either TCMS treatment or Sham treatment on clinic day-1 according to the contents of a sealed opaque envelope corresponding to the subject's number in the series and opened immediately before treatment on day 1. (Our statistician will have generated these envelopes and their contents in advance.) Subjects and staff evaluating the subject's response will remain blinded to treatment assignment; only the staff member setting the treatment mode will know whether it is active or sham.
16396959|NCT04000867|Sham Comparator|Sham TCMS treatment|Patients in the sham treatment group, will use the same device. The device will be switched into sham mode by the clinician by pressing a small, non-descript button on the backside of the pulse generator. The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
16396960|NCT04000854|Active Comparator|Calcium hydroxide|Root canal dressing with Ca(OH)2 (Calasept)
16396961|NCT04000854|Active Comparator|Chlorhexidine|Root canal dressing with clorhexidine digluconate 2 % gel
16396962|NCT04000841|Experimental|Intervention|Intervention participants receive access to the Mindful You app for 12 weeks. They will use the app to listen to guided meditations and to receive notifications, messages, and reminders that they select and ones sent to all participants by the app.
16396963|NCT04000841|No Intervention|Waitlist Control|Waitlist control participants will continue business as usual with regards to stress-management and reduction.
16396964|NCT04000828|Other|single Arm|all patients receive the measurement with Sensimed Triggerfish
16396965|NCT04000815|Active Comparator|Reproductive age women|The healthy women between 18-40 years old.
16396966|NCT04000815|Active Comparator|Perimenopausal women|The healthy women between 40-49 years old.
16396967|NCT04000815|Active Comparator|Postmenopausal women|The healthy women that has been in to menopause more than a year
16396968|NCT04000789|Experimental|NPDR|
16396969|NCT04000789|Active Comparator|NPDR Comparator|
16396970|NCT04000789|Experimental|PDR|
16396971|NCT04000789|Active Comparator|PDR Comparator|
16396972|NCT04000763|Experimental|Transcutaneous Nerve Stimulator(TENS)|Adult females who have difficulty emptying their bladder due to non-obstructive urinary retention or because of an under-active bladder will be given transcutaneous nerve stimulation (TENS) therapy.
16396973|NCT04000750|Experimental|Time Restricted Eating (16:8)|Participants will consume all calories within an 8 hour window each day.
16396974|NCT04000750|Active Comparator|Control|Participants will consume all calories within a ~12 hour window each day (4 separate meals + needed snacks).
16396975|NCT04000737|Experimental|Sorafenib + YIV-906|Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
16396976|NCT04000737|Active Comparator|Sorafenib + Placebo|Patients in the placebo arm will be given sorafenib with placebo
16396977|NCT04000724|Experimental|Text+Step|The TechStep Text+Step messaging intervention is a six-month technology-based culturally competent theory-based text messaging intervention that sends three automated text messages to participants daily to reduce HIV risk and increase PrEP uptake and adherence.
16396978|NCT04000724|Experimental|WebApp+Step|The TechStep WebApp+Step website intervention is a six-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV sexual risk reduction and PrEP uptake and adherence.
16396979|NCT04000724|Experimental|Information|The Information/No Step intervention includes nothing more than access to a website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
16396980|NCT04000711|Experimental|Outpatient oral antibiotic treatment group.|After randomization, participants assigned to receive outpatient treatment with oral cefixime at a dose of 8 mg/kg/day were discharged. Treatment was provided by the researchers. Subjects were evaluated daily at the outpatient clinic of the hospital. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed in the outpatient group, they were re-admitted to the hospital to receive intravenous antibiotics. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
16396981|NCT04000711|Active Comparator|Inpatient intravenous antibiotic treatment group.|After randomization, participants continued intravenous inpatient antibiotic with cefepime 150 mg/kg/day according to local standard of care guidelines. Subjects were evaluated daily. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed, treatment was changed according to clinical guidelines. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
16396982|NCT04000698|Experimental|intervention/treatment|"Preparative chemotherapy before allogeneic HSCT
~Fludarabin
~Cytarabine
~Venetoclax
~Daratumomab
~Vecanoid
~treosulfan
~fludarabine
~thiophosphomide
~Venetoclax
~Plerixafor
~abatacept
~tocilizumab
~rituximab
~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
16396983|NCT04000685|Active Comparator|Yoga exercise group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing, warm up and relaxation exercises.
16396984|NCT04000685|Active Comparator|Spinal stabilization exercise group|Spinal stabilization exercise with three different progressive phases were applied all patients in this group accompanied by physiotherapist.
16396985|NCT04000685|Active Comparator|aerobic walking exercise group|Aerobic walking exercise program applied all patients in this group accompanied by physiotherapist.
16396986|NCT04000672|Active Comparator|HTO with navigation|High Tibial Osteotomy is offered to patients with symptomatic medial compartment knee osteoarthritis (OA)
16396987|NCT04000672|Experimental|HTO with navigation + PSI jig|"3D printed patient specific metal jigs (PSI jig) are created based on the pre-operative CT image. After that, calibrated osteotome is used to achieve the desired correction with the use of navigation for overall lower limb alignment, which is the same as the Active Comparator group."
16396988|NCT04000659|Experimental|Episealer Knee System|The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.
16396989|NCT04000659|Placebo Comparator|Microfracture|The control arm will comprise of subjects that will receive a Microfracture surgery.
16396990|NCT04000646|Other|standard care|Standard care non-pharmacologic interventions during anesthesia induction
16396991|NCT04000646|Experimental|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
16396992|NCT04000633|Active Comparator|lidocaine group|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
16396993|NCT04000633|Placebo Comparator|Placebo group|the patients of this group will recieve nebulization of 5 ml of normal saline prior to induction of general anesthesia
16396994|NCT04000620||cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as positive for cancer cell involvement by imaging based deep learning.
16396995|NCT04000620||no cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as negative for cancer cell involvement by imaging based deep learning.
16396996|NCT04000607|Experimental|Edwards Transcatheter Atrial Shunt System|
16396997|NCT04000594|Experimental|Dose level 1 of RO7234292 (RG6042)|Participants will receive dose level 1 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
16396998|NCT04000594|Experimental|Dose level 2 of RO7234292 (RG6042)|Participants will receive dose level 2 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
16396999|NCT04000594|Experimental|Dose level 3 of RO7234292 (RG6042)|Participants will receive dose level 3 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
16397000|NCT04000581|Active Comparator|Arm I (usual care)|Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
16397001|NCT04000581|Experimental|Arm II (additional mobility)|Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
16397002|NCT04000568||Study Population|All the infants enrolled in the study will receive 1 h of NAVA-NIV and 1h PC-NIV in a cross-over study design
16397003|NCT04000555|Experimental|Study drug|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
16397004|NCT04000555|Placebo Comparator|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
16397005|NCT04000542|Experimental|Eligible Participants|Eligible Participants that consent will receive the pharmacist intervention.
16397006|NCT04000529|Experimental|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
16397007|NCT04000529|Experimental|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
16397008|NCT04000516|No Intervention|Control|The control group was asked to continue their usual eating schedule and pattern.
16397009|NCT04000516|Experimental|Evening Fasters (EF)|Evening fasters were asked to not consume food after 3 pm until the next morning.
16397010|NCT04000516|Experimental|Morning Fasters (MF)|Morning fasters were asked to not consume food from the time they woke until 11 am.
16397011|NCT04000503|Experimental|Community Health Worker Self-Collection|Door-to-door recruitment of women for self-collected HPV testing
16397013|NCT04000490||patient with a chest pain|adult patient with a chest pain calling for urgency center
16397016|NCT04000464|Experimental|Single Arm|24 Week Lifestyle Modification intervention
16397017|NCT04000451|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
16397018|NCT04000451|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
16397019|NCT04000438|Experimental|Experimental DF01 high dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
16397020|NCT04000438|Experimental|Experimental: DF01 medium dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
16397021|NCT04000438|Experimental|Experimental: DF01 low dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
16397022|NCT04000438|Placebo Comparator|Placebo comparator: PL1|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
16397023|NCT04000425||ctDNA detection|The blood samples for ctDNA and other tumor markers (such as CEA, et al.) will be first collected within 7 days before surgery, and then be tested after radical gastrectomy in scheduled interval.
16397024|NCT04000412||CASE GROUP|patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias
16397025|NCT04000399|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinician trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.
~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE.; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
16397026|NCT04000386|Experimental|zinc oxide nanoparticles coated socks|62 patients with zinc oxide nanoparticles coated socks
16397027|NCT04000386|Placebo Comparator|placebo|62 patients with placebo socks
16397028|NCT04000373|Other|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
16397029|NCT04000360|Experimental|High-Intensity Exercise Group|Mild to moderate Parkinson's disease patients: The exercise group will be asked to cycle 3x/week for 12 months on a Peloton bicycle which will be delivered to their home.
16397030|NCT04000360|No Intervention|Usual and Customary Care Group|Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
16397031|NCT04000347|Active Comparator|2.5% benzoyl peroxide|43 patients with 2.5% benzoyl peroxide gel
16397032|NCT04000347|Active Comparator|5% benzoyl peroxide|43 patients with 5% benzoyl peroxide gel
16397033|NCT04000334|Experimental|Cerebral hypoperfusion (group A)|Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4.
16397034|NCT04000334|Active Comparator|Normal cerebral perfusion (group B)|Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm > 30 cm/s, Vd > 20 cm/s, PI < 1.4.
16397035|NCT04000321|Experimental|Windmill group 30 Mins|In the Windmill Group, the Windmill technique is carried out after 30 minutes. The windmill technique of the umbilical cord for placental development is performed by a trained obstetrician or midwife with a doctor presence. In a frustrated attempt to develop placenta using the Windmill technique, a manual removal is performed according to the clinic standard.
16397036|NCT04000321|Active Comparator|Control Group|In the control group, after a total of 45 minutes of unsuccessful application of the traditional and customary measures, the Windmill technique is used. If unsuccessful, a manual placenta removal is performed according to hospital Standards.
16397037|NCT04000308|Experimental|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
16397038|NCT04000308|Active Comparator|Wound Infiltration|Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
16397039|NCT04000295|Experimental|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
16397040|NCT04000295|Active Comparator|Weekly Paclitaxel|Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
16397041|NCT04000282|Experimental|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
16397042|NCT04000282|Experimental|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
16397043|NCT04000269|Experimental|Treatment Group|Treatment with 'Soterix MxN Neuromodulation device (high definition transcranial direct current stimulator) using HD-Targets for optimal neural targeting will be provided to participants and will include 20 minutes of stimulation coupled with conventional OT treatment during and after the intervention. There will be a total of 10 sessions over about a 2 week period.
16397044|NCT04000269|Sham Comparator|Sham group|Sham stimulation will consist of using the devices auto-sham feature. The exact same setup/device will be used during both groups. This is considered a control for the experiment. Both groups will receive similar physical occupational and speech therapy
16397125|NCT03999697|Experimental|CAR-CD22 Cell immunotherapy|Enrolled patients will receive CAR-CD22 cell immunotherapy with a novel specific chimeric antigen receptor targeting CD22 antigen by infusion.
16397045|NCT04000256||Spinal Cord Injury|The data during the first visit involves questionnaires, performance and observational measures for baseline evaluation. The 2nd to 8th visit involves feedback survey and interview data collection based on experiences of participants undergoing activity-based training using upper extremity rehabilitation equipment.
16397046|NCT04000230|Experimental|TCIT|Teachers in the intervention group receive TCIT in the first half of the school year and booster coaching is provided throughout the second half of the school year as the Waitlist Control group is trained.
16397047|NCT04000230|Active Comparator|Waitlist Control|Waitlist Control teachers do not receive any intervention for the first half of the school year. They then receive the same TCIT training as the intervention group in the second half of the school year.
16397048|NCT04000217|Active Comparator|Written Exposure Therapy|Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA & DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
16397049|NCT04000217|Active Comparator|Imaginal Exposure Therapy|Imaginal exposure therapy will involve verbal recounting of trauma memories for 30 minutes with therapist instruction and feedback before and after each recounting exercise.
16397050|NCT04000204|Experimental|HYAJOINT Plus|
16397051|NCT04000204|Active Comparator|Durolane|
16397052|NCT04000191|Active Comparator|Usual monitored anesthesia care (MAC)|Monitored anesthesia care (MAC) administered by anesthesiology and injection of local anesthesia by the operating surgeon.
16397053|NCT04000191|Experimental|MAC and perianal ice|Monitored anesthesia care (MAC) administered by anesthesiology, application of ice to the perianal area after it is prepared with betadine, and injection of local anesthesia by the operating surgeon.
16397054|NCT04000178|Other|group A|patients who received polyurethane stents
16397055|NCT04000178|Experimental|group B|patients who received silicone stents
16397056|NCT04000165|Experimental|SC|subjects with SCD
16397057|NCT04000152|Active Comparator|Control group (group 1)|Deferred single blastocyst transfer with blastocyst selection according to morphology.
16397058|NCT04000152|Experimental|Intervention group (group 2)|Deferred single blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).
16397059|NCT04000139|Active Comparator|Standardized anthocyanin rich extract|3 doses of 2x 500mg in capsules daily
16397060|NCT04000139|Placebo Comparator|Placebo|3 doses of 2x 500mg in capsules daily
16397061|NCT04000126|Active Comparator|Control C|This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)
16397062|NCT04000126|Experimental|Lignocaine group L|This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
16397063|NCT04000126|Placebo Comparator|Placebo P|This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation
16397064|NCT04000113|Experimental|laser acupuncture treatment|Subjects accept low-dose near-infrared laser acupuncture (10mWx10) treatment for 5 minutes in each trial.
16397065|NCT04000113|Sham Comparator|Sham laser acupuncture treatment|Subjects accept the sham (blank) laser acupuncture treatment for 5 minutes in each trial.
16397066|NCT04000100|Placebo Comparator|Control group|This group received supraclavicular block using 25mL of 0. 5% bupivacaine and 1 mL normal saline
16397067|NCT04000100|Active Comparator|Neostigmine group|This group received 25 mL 0. 5% bupivacaine and 1 mL neostigmine (0.5 mg)
16397068|NCT04000087|Experimental|Intervention|Care teams randomized to intervention will have access to the screening tool.
16397069|NCT04000087|No Intervention|Control|Care teams randomized to control will continue routine practice.
16397070|NCT04000074|Experimental|Telephonic Services - Intervention|Persons in this group are linked with a telephonic case manager to help address their social needs.
16397071|NCT04000074|No Intervention|Telephonic Services - Control|Persons in this group are similar in risk to those in the 'Telephonic Services - Intervention' arm, but are not linked with a case manager.
16397072|NCT04000074|Experimental|In-Person Services - Intervention|Persons in this group are linked with an in-person case manager who makes home visits to help address their social needs.
16397073|NCT04000074|No Intervention|In-Person Services - Control|Persons in this group are similar in risk to those in the In-Person Services - Intervention' arm, but are not linked with a case manager.
16397074|NCT04000061||acute coronary syndrome (ACS)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed.
16397075|NCT04000061||acute heart failure (AHF)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed.
16397076|NCT04000035|Experimental|Health in work|The interdisciplinary Health in work intervention consists of three information sessions over the course of one year, with work place processes in between. In the meetings, structured health information about musculoskeletal- and mental disorders is given and put in the context of working and the specific workplace. It is an integrated intervention where information is given together by both healthcare- and NAV-personnel.
16397077|NCT04000035|Active Comparator|Regular work place measures|Regular work place measures offered by NAV workplace service. Those are interventions given by NAV personnel without healthcare involvement and can be varying.
16397078|NCT04000022||Non-Treatment Resistant Patients|
16397079|NCT04000022||Treatment-Resistant Patients|The group of patients from NCT03944213
16397080|NCT04000009|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
16397081|NCT03999996|Experimental|Takeda's Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once at Month 15.
16397082|NCT03999996|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once at Month 15.
16397083|NCT03999970|Active Comparator|Phlebotomus papatasi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus papatasi fed on blood twice in the laboratory prior to human exposure.
16397126|NCT03999684|Experimental|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
16397084|NCT03999970|Active Comparator|Phlebotomus duboscqi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus duboscqi fed on blood twice in the laboratory prior to human exposure.
16397085|NCT03999957|Other|Interventional Arm|Telehealth conferencing
16397086|NCT03999944|Other|Sequence 1|"FRESCA Airbox Flow Generator set to fixed pressure first, then FRESCA Airbox Generator set to auto-adjusting pressure.
~Second intervention within 1 - 10 days of first intervention."
16397087|NCT03999944|Other|Sequence 2|"FRESCA Airbox Flow Generator set to auto-adjusting pressure first, then FRESCA Airbox Generator set to fixed pressure.
~Second intervention within 1 - 10 days of first intervention."
16397088|NCT03999931||schizophrenia with positive symptoms|schizophrenia with positive symptoms
16397089|NCT03999931||schizophrenia with negative symptoms|schizophrenia with negative symptoms
16397090|NCT03999931||bipolar disorder|bipolar disorder
16397091|NCT03999931||depression|depression
16397092|NCT03999931||panic disorder|panic disorder
16397093|NCT03999931||obsessive-compulsive disorder|obsessive-compulsive disorder
16397094|NCT03999931||control|
16397097|NCT03999905|Experimental|Intervention Arm|Online training on Oral anticoagulant counseling.
16397098|NCT03999905|No Intervention|Control Arm|No counseling training
16397099|NCT03999892|Experimental|Consumers with SMI|Consumers with serious mental illness who attend a psychiatric rehabilitation program (PRP) will participate in a group-based diet and physical activity program.
16397100|NCT03999892|Other|Staff at PRP|Staff and peer leaders who work at a psychiatric rehabilitation program (PRP) will observe sessions of a group-based diet and physical activity program for consumers with SMI.
16397101|NCT03999879||Cognitively Normal|having 30 participants with normal cognition
16397102|NCT03999879||Amnesic MCI|aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.
16397103|NCT03999866|Active Comparator|satisfaction of instructor|visual analogy scale of the satisfaction of the instructor was recorded
16397104|NCT03999866|Active Comparator|satisfaction of the patient|visual analogy scale of the satisfaction of the patient was recorded
16397105|NCT03999866|Active Comparator|duration of view|duration of the visualization the vocal cords was recorded
16397106|NCT03999853|Experimental|Conventional Therapy / Butyrate|This arm will be receiving usual therapy for the first study period then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) after washout and cross-over
16397107|NCT03999853|Experimental|Butyrate / Usual Therapy|This arm will be receiving 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) placebo for the first study period then usual therapy after washout and cross-over
16397108|NCT03999840|Experimental|IMP|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
16397109|NCT03999840|Placebo Comparator|Placebo|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
16397110|NCT03999827|Experimental|Immediate Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning immediately after randomisation.
16397111|NCT03999827|Active Comparator|Delayed Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning 12 weeks after randomisation.
16397112|NCT03999801||All|All subjects that previously received RGX-314 in a parent study are enrolled into this arm.
16397113|NCT03999788|Experimental|multiple sclerosis patients|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
16397114|NCT03999788|Experimental|control subjects|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
16397115|NCT03999788|Experimental|multiple sclerosis patients with spasticity and selected SNPs|iTBS therapeutic protocol
16397116|NCT03999775|Active Comparator|Calcium, vitamin D and bioactive collagen peptides supplement|In this arm, all patients received a sachet containing 5mg bioactive collagen peptides, 500 mg calcium lactate and 400 IU vitamin D3 per day.
16397117|NCT03999775|Active Comparator|Calcium and vitamin D supplement|In this arm, all patients received a chewable tablet containing 500 mg calcium carbonate and 400 IU vitamin D3 per day.
16397118|NCT03999762|Active Comparator|Density gradient sample prep|Standard density gradient sample preparation
16397119|NCT03999762|Experimental|Automated sample prep|Automated experimental sample preparation
16397120|NCT03999749|Experimental|Induction Phase, Maintenance Phase|"Induction Phase: 2 induction treatment cycles of 42 days (6 weeks) each, of which the first cycle of 6 weeks is the DLT period.
~Maintenance Phase: Consists of treatment cycles of 84 days (12 weeks) each, and may extend up to 1 year."
16397121|NCT03999736|Experimental|Treatment|"14 sessions x 30 minutes of 2mA transcranial direct current stimulation to the dorsolateral prefrontal cortex.
~10 x sessions over the course of the initial two weeks (e.g. 5 x per week with flexibility).
~4 x sessions over the course of a two week maintenance treatment."
16397122|NCT03999723|Experimental|Vitamin C|Oral vitamin C (ascorbic acid) will be given in a dose of 1000 mg daily (two capsules of 500 mg once daily) starting day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier.
16397123|NCT03999723|Placebo Comparator|Placebo|Placebo will be administered orally as two capsules once daily that look and taste identical to the capsules containing vitamin C. Treatment will start day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier. The content of the placebo capsules is glucose monohydrate, potato starch, gelatin, magnesium stearate and talc.
16397124|NCT03999710|Experimental|Non-Small Cell Lung Cancer|All participants have locally-advanced non-small cell lung cancer, Stage II-III. Treatment will consist of durvalumab administered concurrently with thoracic radiation consisting of 60 Gy in 30 fractions. Patients will be monitored weekly during on-treatment visits. Durvalumab will then be continued up to 1 year as maintenance or until disease progression or unacceptable toxicity. Optional Research MRIs (Does not apply to the Alliance Sites. Research MRIs will only be done at MSKCC)
16397127|NCT03999671|Experimental|INSTRUMENT SF 36|Instrument SF36 Spanish version, validated in Spain, translated in several languages and applied to multiple studios in Mexico. The 36 items explore 8 dimensions: the state of physical health, physical function, physical role, body pain, general health, vitality, social function, emotional role and mental health: considering depression, anxiety, self-control, and general well-being.
16397128|NCT03999671|Active Comparator|Checklist|Verify that the interventions of both groups were carried out
16397129|NCT03999658|Experimental|Extranodal NK/T-cell lymphoma (ENKTL)|Intravenous STI-3031 (anti-PD-L1 antibody)
16397130|NCT03999658|Experimental|Peripheral T-cell lymphomas (PTCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
16397131|NCT03999658|Experimental|Diffuse large B-cell lymphoma (DLBCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
16397132|NCT03999658|Experimental|Biliary tract cancers (BTC)|Intravenous STI-3031 (anti-PD-L1 antibody)
16397133|NCT03999645|Active Comparator|Group E: Early LC (n=60)|Early laparoscopic cholecystectomy (within 72h from symptom onset)
16397134|NCT03999645|Active Comparator|Group L: Late LC (n=60)|Late laparoscopic cholecystectomy (after 72h up to seven days from symptom onset)
16397135|NCT03999632|Experimental|Mankai Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group A (Wolffia Globosa) will be allowed to have two meals a day and one protein shake (Wolffia Globosa) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Wolffia Globosa) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
16397136|NCT03999632|No Intervention|Control Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group B (Control) will be allowed to have two meals a day and one protein shake (Control) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Control) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
16397137|NCT03999619|Experimental|Experimental|Children will enter into the Move 2 Learn program immediately following their first assessment (between week 0 to 10)
16397138|NCT03999619|Other|Wait-list Control|Children will not participate in the program until after their second assessment (between week 11 to 21). Their control period will take place between week 0 and 10.
16397139|NCT03999606|Active Comparator|Mindfulness Training|Participants in the control group will be assigned to a online based mindfulness training.
16397140|NCT03999606|Experimental|Music Training|Participants in the experimental group will be assigned to a online based choir program.
16397141|NCT03999580|Experimental|Experimental Arm:|"Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day
~3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks.
~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)."
16397142|NCT03999580|Active Comparator|Control Arm:|"Active Comparator: Vitamin D3 600 UI/day then 600 UI/day
~600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks.
~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
16397143|NCT03999567|Experimental|Pen and Paper vs. Mobile Digit Symbol Substitution Test|This validation study will assess the convergent validity of the mobile DSST application with the pencil version of the DSST. Correlations between performance on app-based version of the DSST and paper-based version of DSST will be measured.
16397144|NCT03999554|Experimental|Low dose Sing2016 M2SR|Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
16397145|NCT03999554|Experimental|Medium dose Sing2016 M2SR|Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
16397146|NCT03999554|Experimental|High dose Sing2016 M2SR|High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
16397147|NCT03999554|Active Comparator|Low dose Bris10 M2SR|Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
16397148|NCT03999554|Placebo Comparator|Placebo|Saline will be administered intranasally on days 1 and 29
16397149|NCT03999541|Experimental|Freeze-all|Good quality embryos (either day 3 or 5) will be frozen and subsequent frozen embryo transfer will be arranged within three months of the egg retrival.
16397150|NCT03999541|No Intervention|Fresh embryo transfer|Women will undergo fresh embryo transfer at the cleavage (day 3) or blastocyst stage (day 5).
16397151|NCT03999528||study group|RA Patients
16397152|NCT03999528||control group|normal control
16397153|NCT03999515|Experimental|Treatment (abiraterone acetate, enzalutamide, erdafitinib)|Patients receive abiraterone acetate orally PO QD or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16397154|NCT03999502|Experimental|Intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
16397155|NCT03999476|Experimental|ambu scope2|intubation of cancer tongue patients with ambu scope2 device
16397156|NCT03999476|Active Comparator|fiberoptic|intubation of cancer tongue patients with fiberoptic device
16397157|NCT03999450|Experimental|Behavioral intervention|Patients admitted to Strong Hospital with opioid use will be given 1 to 3 brief motivational interventions and computer based cognitive behavioral therapy
16397158|NCT03999437|Experimental|Treatment # 1|
16397159|NCT03999437|Experimental|Treatment # 2|
16397160|NCT03999437|Placebo Comparator|Placebo Control|
16397161|NCT03999424|Experimental|Autologous human Schwann cells|All participants will receive autologous human Schwann cells harvested from their own sural nerve.
16397162|NCT03999411|Placebo Comparator|Usual Care|Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.
16397163|NCT03999411|Active Comparator|Smoking cessation only intervention|"Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the Crave-to-Quit app, and two brief follow-up phone calls."
16397164|NCT03999411|Experimental|Combined smoking cessation and HIV intervention|Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.
16397165|NCT03999398||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
16397166|NCT03999398||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
16397167|NCT03999385|Experimental|Immediate Training Group|8 weeks of training in Mindful Self-Compassion.
16397168|NCT03999385|Other|Waitlist Control Group|No intervention for approximately 12 weeks. After this waiting period, participants will complete 8 weeks of training in Mindful Self-Compassion.
16397169|NCT03999372|Experimental|PICSI procedure|PICSI procedure: PICSI dishes are conventional plastic culture dishes pre-prepared with 3 microdots of powdered. The powdered HA is re-hydrated by adding 5 μL droplets of fresh culture medium to each of the three microdots. A 2 μL droplet with suspension of treated spermatozoa is then connected with a pipette tip to these culture medium droplets. The PICSI dish is incubated under oil; within 5 minutes the bound spermatozoa are attached by their head to the surface of the HA-microdots and are spinning around their head. An ICSI injecting pipette is used to pick the best motile HA-bound sperm up and inject them one by one into an oocyte. The ICSI injecting pipette can be previously loaded with viscous medium (PVP or Sperm Slow) to facilitate sperm micromanipulation.
16397170|NCT03999372|Active Comparator|ICSI procedure|ICSI procedure: following sperm preparation as described before, samples were incubated until time of injection. Each oocyte was injected with a single morphologically abnormal and immobilized in polyvinyl Pyrolidone (PVP) spermatozoon. Individual sperm subjected to ICSI was examined and evaluated. The injection procedure was carried out in a sterilized dish using holding pipette and injection needle. Intra cytoplasmic sperm injection was performed according to the protocol of Van Steirteghem.
16397171|NCT03999359|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
16397172|NCT03999359|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
16397173|NCT03999333|Experimental|Virtual Reality|Every participant is provided with a VR headset
16397174|NCT03999320|Experimental|Sophrology group|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
16397175|NCT03999320|Other|Control group|usual care
16397176|NCT03999307|Experimental|Low-Level Laser Therapy (LLLT)|In the LLLT group, a low-level laser with wavelength of 808 nm, output of 250 mW, energy of 4 Joules per point and application time of 16 seconds per point will be applied on each tooth of the six maxillary anterior teeth according to this protocol: the root will be divided theoretically into 2 halves; gingival and cervical, and laser will be applied in the center of each half from both buccal and palatal sides which means 4 application points and a total energy of 16 Joules per tooth.
16397177|NCT03999307|Experimental|Flapless Corticopuncture|In the flapless corticopuncture group, 3 interdental punctures located between the roots of the six maxillary anterior teeth from both the buccal and palatal sides, will be done using a 1-mm diameter round surgical Tungsten bur with 1 mm depth and 1.5 mm space between each puncture. These punctures start 2 mm from the free gingiva. Besides, an additional 2 parallel set of punctures with the same dimensions of the interdental ones will be done in the extraction sockets from both the buccal and palatal sides.
16397178|NCT03999307|Experimental|Control|Patients in control group will undergo typical orthodontic treatment only with no LLLT or flapless corticopuncture application.
16397179|NCT03999294|No Intervention|Control Group|
16397180|NCT03999294|Experimental|Experimental Group|
16397181|NCT03999281||Diabetic Foot Ulcers (DFU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
16397182|NCT03999281||Venous Leg Ulcer (VLU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
16397183|NCT03999268|Experimental|Intervention|Participants assigned to the intervention group will receive insulin administration education according to standard procedures plus have access to the I-START app. Over the course of the study period, participants will be able to use I-START as much or as little as they prefer.
16397184|NCT03999268|Active Comparator|Usual Care|Participants in the usual care group will receive insulin administration education according to standard procedures. They will not have access to the I-START app.
16397185|NCT03999255|Experimental|Patients undergoing intrarenal surgery|
16397186|NCT03999229|Active Comparator|Blood transfusion with SNO agent|"Autologous blood transfusion packed red blood cells (RBCs) while inhaling S-nitrosylating agent (SNO)
~A single intra venous blood transfusion of one unit of packed Red Blood Cells (RBCs) will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.
~Inhalation of SNO agent, 20-40 parts per million will occur during the transfusion."
16397187|NCT03999229|Placebo Comparator|Normal Saline with SNO agent|"Normal Saline Transfusion while inhaling S-nitrosylating agent (SNO)
~A single intra venous infusion of one unit of normal saline, will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.
~Inhalation of the SNO agent at 20-40 parts per million, will occur during the transfusion."
16397188|NCT03999216|Active Comparator|Loop only|Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.
16397189|NCT03999216|Active Comparator|Loop + Thiazide|Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.
16397225|NCT03998969|Experimental|Pantoprazole and DA-5204|Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks
16397190|NCT03999203||A - T2 High Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL and consistently high FeNO levels ≥30 ppb.
~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
16397191|NCT03999203||B - T2 Low Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≤ 0.2x10^9/mL and consistently low FeNO levels <30 ppb.
~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
16397192|NCT03999203||C - Mild/Moderate Asthmatics|mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
16397193|NCT03999203||D - T2 Intermediate|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL OR consistently high FeNO levels ≥30 ppb.
~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
16397194|NCT03999190||30 subjects with schizophrenia|
16397195|NCT03999190||30 healthy controls|
16397196|NCT03999177|Experimental|Kinect-TOLF prototype|
16397197|NCT03999164|Experimental|Moderate to Severe Traumatic Brain Injury|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
16397198|NCT03999151|Active Comparator|Arm A: Reference Group|Arm A will receive print educational materials about the benefits of exercise and diet for men with prostate cancer, with recommendations geared at men living with prostate cancer, mailed around the date of surgery. They also receive a 9-week text messaging program focused on recovery after radical prostatectomy surgery.
16397199|NCT03999151|Experimental|Arm B (Arm A + Exercise)|Arm B receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise habits and various tools, such as the ability to track exercise; additional educational print materials on exercise; additional text messages over 2 years that supports healthy exercise habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years.
16397200|NCT03999151|Experimental|Arm C (Arm A + Diet)|Arm C receives the following: Arm A material plus access to an online portal with additional educational materials to help improve diet habits and various tools, such as the ability to track diet; additional educational print materials on diet; additional text messages over 2 years that supports healthy diet habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
16397201|NCT03999151|Experimental|Arm D (Arm A + Exercise + Diet)|Arm D receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise and diet habits and various tools, such as the ability to track exercise and diet; additional educational print materials on exercise and diet; additional text messages over 2 years that supports healthy exercise and diet habits; a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
16397202|NCT03999138||Single Arm|
16397203|NCT03999125|Active Comparator|Group 1|Aflibercept intravitreal injection for CSME
16397204|NCT03999125|Other|Group 2|Ranibizumab Intravitreal Injection for CSME
16397205|NCT03999125|Experimental|Group 3|Dexamethasone Implant for CSME
16397206|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 4 week|Standard MERIT + 4 week baseline period
16397207|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 6 week|Standard MERIT + 6 week baseline period
16397208|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 8 week|Standard MERIT + 8 week baseline period
16397209|NCT03999099|Placebo Comparator|Placebo|
16397210|NCT03999099|Experimental|Suvorexant 10mg|Suvorexant 10mg oral dose
16397211|NCT03999099|Experimental|Suvorexant 20mg|Suvorexant 20mg oral dose
16397212|NCT03999086||Control Group|Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.
16397213|NCT03999086||Intervention arm|Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.
16397214|NCT03999073||Subjects with coarctation|
16397215|NCT03999073||Controls|
16397216|NCT03999060|Experimental|Electric Stimulation|
16397217|NCT03999034|Experimental|Patients|experimental, cognitive test, no treatment investigated. 140 patients (90 relasping remitting and 50 progressive multiple sclerosis)
16397218|NCT03999034|Experimental|Healthy controls|experimental, cognitive test, no treatment investigated. 400 healthy controls divided into 20 groups, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not).
16397219|NCT03999021|Experimental|Experimental Arm|All participants to receive study intervention.
16397220|NCT03999008|Active Comparator|Budesonide|"Oral viscous budesonide will be given in apple sauce according to body weight at inclusion:
~< 10 kg: 250 mcg BID in 5 ml apple sauce 10 kg to <15 kg: 500 mcg BID in 5 ml apple sauce >15 kg: 1000 mcg BID in 5 ml apple sauce"
16397221|NCT03999008|Placebo Comparator|Placebo|Placebo: 5 ml apple sauce BID plus 1 mL saline
16397222|NCT03998995|Experimental|IVR rehabilitation game intervention|Clinical trial patients' use the IVR rehabilitation game for two 15 minute sessions during one physical therapy session with their usual practitioner, with support from the physiotherapist and the game expert on the team.
16397223|NCT03998982|Active Comparator|glycyrrhetinic acid Combining HD-DXM|Compound glycyrrhizin tablets 75mg three times per day, 1 month, and HD-DXM (orally at 40 mg daily for 4d )
16397224|NCT03998982|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
16415650|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts B"|
16397226|NCT03998969|Active Comparator|Pantoprazole and placebo|Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks
16397227|NCT03998956|Active Comparator|Circumferential PV isolation|Circumferential PV isolation only
16397228|NCT03998956|Experimental|Circumferential PV and BOX isolation|Circumferential PV and BOX isolation
16397229|NCT03998956|Experimental|circumferential PV and BOX isolation with substrate ablation|Atrial substrate ablation apart from circumferential PV and BOX isolation
16397230|NCT03998930|Experimental|brain injuried patients|"Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R),
~15-minute break between the two evaluations.
~Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task (imagine moving the right or left wrist)."
16397231|NCT03998917||Chronic Kidney Disease (CKD) Patients|Patients with chronic kidney disease and a glomerular filtration rate less than 60 ml/min of creatinine. Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
16397232|NCT03998917||Control cohort|The control cohort will consist of a group of people from the same age group as the CKD group but without chronic kidney disease. The exclusion criteria apply to this group. They will be selected from the spouses and other volunteers. This group will also perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
16397233|NCT03998904|Experimental|Muscle preservation|Muscle preservation for hamsting graft
16397234|NCT03998904|Active Comparator|None preservation|No muscle preservation for hamstring graft
16397235|NCT03998891||salt restricted diet|In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
16397236|NCT03998891||normal salt diet|In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
16397237|NCT03998878|Experimental|Low-Carbohydrate Diet|Participants will be instructed to consume less than 30 grams of carbohydrates per day.
16397238|NCT03998878|Experimental|Intermittent Energy Restriction|Participants choose 2 non-consecutive days per week in which they will consume 500-650 calories.
16397239|NCT03998878|Experimental|Hunger Training|Participants monitor their hunger symptoms and blood glucose, and eat only when blood glucose is below a certain threshold level.
16397240|NCT03998865|Experimental|PEEK Provisional Abutment|The provisional crown will be fixed onto a PEEK abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
16397241|NCT03998865|Active Comparator|Titanium Provisional Abutment|The provisional crown will be fixed onto a titanium abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
16397242|NCT03998852|Experimental|Molecular imaging|Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
16397243|NCT03998839||Intervention|Children tested will live within an area targeted for community IPTp distribution for pregnant women.
16397244|NCT03998839||Control|Children tested will live within an area NOT targeted for C-IPTp, but will live in an area nearby.
16397245|NCT03998826|Experimental|Piroxicam drug|20 mg piroxicam
16397246|NCT03998826|Placebo Comparator|Placebo|placebo
16397247|NCT03998813|Experimental|Locoregional analgesia by femoral triangle catheterization|
16397248|NCT03998813|Active Comparator|Tissue infiltration|
16397249|NCT03998800|Experimental|L-arginine and L-citrulline|10 days of supplementation with 1.5 g of L-arginine and 1.5 g of L-citrulline per day
16397250|NCT03998800|Experimental|L-arginine|10 days of supplementation with 3 g of L-arginine per day
16397251|NCT03998800|Placebo Comparator|Placebo (corn-starch)|10 days of supplementation with corn-starch
16397252|NCT03998787||Patients with Parkinson's disease|Patients with Parkinson's disease
16397253|NCT03998787||Healthy Subjects|Healthy subjects
16397254|NCT03998761|Active Comparator|Micronized progesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening).
16397255|NCT03998761|Active Comparator|Micronized progesterone plus dydrogesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening).
16397256|NCT03998748|Experimental|Experimental|This group of participants will receive the feedback that they have a genetic vulnerability to depression.
16397257|NCT03998748|Active Comparator|Control|This group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
16397262|NCT03998722|Experimental|Vagivital|Vagivital once Daily for 12 weeks
16397263|NCT03998709|Other|Elevation of fasting FFA and Glucose|People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
16397297|NCT03998514|Experimental|Group B1 multiple ascending dose (MAD)|CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
16397298|NCT03998514|Experimental|Group B2 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
16397299|NCT03998514|Experimental|Group B3 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
16415651|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts A"|
16397264|NCT03998709|Other|Lowering of fasting FFA and glucose|People with elevated fasting glucose and elevated fasting FFA (Impaired fasting glucose / impaired glucose tolerance - IFG / IGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive insulin to lower fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
16397265|NCT03998696|Active Comparator|Weekly Cisplatin|Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
16397266|NCT03998696|Experimental|Three weekly Cisplatin|Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
16397267|NCT03998683|Experimental|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
16397268|NCT03998683|Placebo Comparator|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
16397269|NCT03998670|Experimental|Prism Group|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by prism and alternate cover test (PACT) at distance or near) equally divided between the 2 lenses will be prescribed to the participant
16397270|NCT03998670|Placebo Comparator|Non-Prism Group|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism will be prescribed to the participant
16397271|NCT03998657|Experimental|Exablate Treated Arm|Treatment with Exablate Prostate 2100 Type-3 System
16397272|NCT03998644||healthy|Subjects without colorectal disorders.
16397273|NCT03998644||precancerous|Subjects with risk factors that may contribute to the carcinogenesis.
16397274|NCT03998644||colorectal cancer|Patients who were identified by standard procedures to suffer with colorectal cancer.
16397275|NCT03998631|Placebo Comparator|Saline Flush|This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
16397276|NCT03998631|Experimental|Carbon Dioxide and Saline Flush|Carbon dioxide flush of the TEVAR or TAVI device followed by saline flush.
16397277|NCT03998618|Experimental|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
16397278|NCT03998618|Active Comparator|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
16397279|NCT03998605|Experimental|Abuse Prevention Program Condition|"The abuse prevention program will address: (1) BEFORE -- (a) Learning about problem of abuse and what abuse is; (b) Knowing about types of abuse, who the abusers are and where abuse happens; (c) Planning ahead and identifying safe people; (2) DURING -- (a) Rejecting abuse by saying no; (b) Getting away if possible/staying safe and paying attention, (c) Staying calm and getting home; and (3) AFTER -- (a) Telling your safe person, (b) Knowing what to do and what not to do, and (c) Reporting the abuse and getting help to cope with the event."
16397280|NCT03998605|Active Comparator|Control condition|During the study the control group will receive 12 activity sheets from the ESCAPE-NOW curriculum. Six activity sheets will be given at the initial meeting and half way through the study the remaining activity sheets will be mailed to the dyads. We chose these activity sheets because they provide abuse information that was designed for individuals with ID.
16397281|NCT03998592|Experimental|Low-dose vaccine|
16397282|NCT03998592|Experimental|Mid-dose vaccine|
16397283|NCT03998592|Experimental|High-dose vaccine|
16397284|NCT03998592|Placebo Comparator|Placebo|
16397285|NCT03998579|Experimental|Individualized exercise|The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.
16397286|NCT03998579|Active Comparator|Active control group|Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity
16397287|NCT03998566|Experimental|TraceIT Tissue Spacer|
16397288|NCT03998540||Patients with myopathy suspected of titinopathy|Patients with myopathy in which one or more potentially pathogenic TTN variants have been previously identified (index cases and related cases affected). Muscle biopsy performed previously
16397289|NCT03998527|Experimental|Non-Disabled (ND) and Spinal Cord Injured (SCI) controls|The ND Control group (n=6) and SCI Control group (n=6) will be used to assess related values as acute effects of transcutaneous electrical spinal cord stimulation (TcESCS) itself and will not receive any training intervention. The ND group will receive baseline assessments, then up to 12 (4-Respiratory function, 4-Arm function, and 4-Trunk function) TcESCS mapping experiments, followed by repeating the assessments in the presence of TcESCS. The investigators will decide which stimulation type should be used for the post-mapping assessments.
16397290|NCT03998527|Experimental|Spinal Cord Injured (SCI) intervention groups|The respiratory training (RT) group (n=6) will receive the respiratory training intervention only); the transcutaneous electrical spinal cord stimulation (TcESCS) group (n=6) will receive transcutaneous spinal cord stimulation only; TcESCS + RT group (n=6) will receive TcESCS combined with RT; TcESCS + Arm Training (AT) group (n=6) will receive TcESCS combined with AT; and TcESCS + Trunk Training (TT) group (n=6) will receive TcESCS combined with TT.
16397291|NCT03998514|Experimental|Group A1 single ascending dose (SAD)|CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
16397292|NCT03998514|Experimental|Group A2 SAD|CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
16397293|NCT03998514|Experimental|Group A3 SAD|CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
16397294|NCT03998514|Experimental|Group A4 SAD|CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
16397295|NCT03998514|Experimental|Group A5 SAD|CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
16397296|NCT03998514|Experimental|Group A6 SAD|CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
16397300|NCT03998514|Experimental|Part C|CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
16397301|NCT03998501|Experimental|Active|5-week CBTm
16397302|NCT03998501|No Intervention|Waitlisted|Waitlisted (will receive 5-week CBTm 3 months after).
16397303|NCT03998488|Experimental|Investigational FMT|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy.
~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
16397304|NCT03998488|Active Comparator|Investigational FMT + psyllium fiber|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy. They will also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.
~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
16397305|NCT03998488|Placebo Comparator|Placebo FMT +/- psyllium fiber|"Participants will be blindly randomized to receive a single dose of placebo FMT during the week 0 colonoscopy. They may or may not also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.
~Additionally, participants will blindly receive a single dose of investigational FMT during the week 8 by flexible sigmoidoscopy."
16397306|NCT03998475|Experimental|Transition preparation program|Transition preparation intervention for young adults with type 1 diabetes (T1D)
16397307|NCT03998462|Active Comparator|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
16397308|NCT03998462|Placebo Comparator|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
16397309|NCT03998449|Experimental|Cholera vaccination|Two doses of the vaccine against cholera
16397310|NCT03998436|Active Comparator|Galnobax® 14% gel plus SoC|Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
16397311|NCT03998436|Sham Comparator|SoC Only|Only Standard of Care will be administered twice daily (150 subjects)
16397312|NCT03998436|Placebo Comparator|Vehicle plus SoC|Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)
16397313|NCT03998423|Experimental|1 dose fecal microbiota transplant|This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
16397314|NCT03998423|Experimental|2 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
16397315|NCT03998423|Experimental|3 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
16397316|NCT03998397|Experimental|patients with alcohol use disorders|
16397317|NCT03998397|Experimental|patients without alcohol use disorders|
16397318|NCT03998384|Active Comparator|group of autoserum|One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
16397319|NCT03998384|Placebo Comparator|group of placebo|The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
16397320|NCT03998371||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology and FISH.
16397321|NCT03998371||Non-cancer participants group|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
16397322|NCT03998358||High Fatigue|TBI patients with significant fatigue as calculated by a score of >= 5.5 on the Fatigue Severity Scale
16397323|NCT03998358||Low Fatigue|TBI patients without significant fatigue as calculated by a score of < 5.5 on the Fatigue Severity Scale
16397324|NCT03998345|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance
16397328|NCT03998306|Experimental|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive probiotic lozenge before falling asleep for12 weeks. They will receive hygienic and dietetic instructions. examination will be conducted before study and after 12 weeks.
16397329|NCT03998306|Sham Comparator|CONTROL|no intervention
16397330|NCT03998293|Other|proinsulin clearance|all participants will be studied once where somatostatin will be used to block endogenous insulin secretion
16397331|NCT03998267|Active Comparator|Intervention arm|"For the subjects using the app (intervention group): The mobile app team shall do the following:
~Educate/train patients on app usage
~Patients will be subscribed to the app and their profile on the app will be created
~Subjects will log in their blood sugar readings and communicate with the mobile app team (educators and physician) via the app
~Additionally patients will be placed on a diet and lifestyle plan as agreed upon by the patient and health care provider team, best suited towards the patient's needs
~Throughout the study, patient will receive notifications and advice on how to follow diet and lifestyle changes
~Throughout the study; patient interaction and app usage will be tracked
~Patients will additionally be interviewed by the research team together with Droobi to capture app experience at 3 months and 6 months"
16397518|NCT03996902|Experimental|Control|Intervention consistent with standard clinical practice (Control)
16397332|NCT03998267|Placebo Comparator|Standard of care arm|"For the subjects not using the app (the standard of care group):
~At time 0, will be seen by the dietician and diabetes educators at HGH endocrine clinics as part of standards of care
~The educators contact number and diabetes hotline number will be provided to the patients
~o The diabetes hotline number #16099 is a new service provided to diabetes patients at the national diabetes center to help communicate with the diabetes educators with questions relating to their diabetes management, medication adjustment such as dose titrations etc.
~Appointments thereafter with the educator and/or dietician will be decided and scheduled according to the individual patient needs, with a minimum visit every 3 months during the study period"
16397333|NCT03998254|Experimental|V503|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
16397334|NCT03998254|Active Comparator|Gardasil|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
16397335|NCT03998215|Experimental|Diphtheria booster vaccination|One booster dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
16397336|NCT03998202||Adults 60-74 years|
16397337|NCT03998202||Adults >= 75 years|
16397338|NCT03998189|Experimental|Female Participants|45 female patients will be screened to participate.
16397339|NCT03998189|Experimental|Male Participants|45 male patients will be screened to participate
16397340|NCT03998176|Experimental|B/F/TAF|Participants will receive B/F/TAF for 48 weeks
16397341|NCT03998163|Experimental|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
16397342|NCT03998150|Active Comparator|HoLEP holmium laser enucleation of the prostate|holmium laser enucleation of the prostate
16397343|NCT03998150|Active Comparator|BPEP bipolar plasmakinetic enucleation of the prostate|bipolar plasmakinetic enucleation of the prostate
16397344|NCT03998137||Autograft|Standard Rigid Fixation plus autograft
16397345|NCT03998137||AUGMENT® Injectable|Standard rigid fixation plus AUGMENT® Injectable Bone Graft
16397346|NCT03998124|Experimental|Peer-led intervention|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
16397347|NCT03998124|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
16397348|NCT03998111|Experimental|Trial|Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
16397349|NCT03998098||Oxygen Saturation (Oximetry)|Arm to determine the performance of the Oxygen Saturation measurement in LifeLight First
16397350|NCT03998098||Heart Rate (Pulse)|Arm to determine the performance of the Heart Rate measurement in LifeLight First
16397351|NCT03998098||Respiratory Rate|Arm to determine the performance of the Respiratory Rate measurement in LifeLight First
16397352|NCT03998098||Blood Pressure|Arm to determine the performance of the Blood Pressure measurement in LifeLight First
16397353|NCT03998085|Experimental|anlotinib|
16397354|NCT03998072|Experimental|Intervention|
16397355|NCT03998072|No Intervention|Treatment as usual (waiting list control)|
16397356|NCT03998059||30 immune thrombocytopenia(ITP) patients|A total of 30 cases. The investigators plan to take 20ml of peripheral blood (PB) of these 30 ITP patients at 6 time points, including 1 day before surgery, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery
16397357|NCT03998059||20 normal controls|A total of 20 cases.18 age- and gender- matched healthy donor will also be enrolled as controls and taken 20ml of peripheral blood.
16397358|NCT03998059||Spleens of the 30 cases patients(ITP)|These 30 ITP patients agree to have splenectomy.The investigators will take a small amount of spleen tissue during surgery.
16397359|NCT03998059||Spleens of the 10 cases patients(normal controls)|The investigators also plan to take splenic tissue from 10 patients who have splenectomy due to hereditary spherocytosis or trauma.
16397360|NCT03998046|Active Comparator|Basic Resources and Services|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, and information about linkages to extant intensive lifestyle interventions in the community
16397361|NCT03998046|Experimental|Coordinated Primary Care Population Management (C3PO)|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, information about linkages to extant intensive lifestyle interventions, and outreach MyChart messages that are tailored to each individual's pattern of self-weighing and progress towards their weight goal, and more intensive support from a primary care nurse based on self-weighing behavior and weight loss success.
16397362|NCT03998033|Experimental|ET140202 T cells|ET140202 Receptor (+) T Cells
16397363|NCT03998020|Other|chronic sleep disorders|Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
16397364|NCT03997994|Experimental|Experimental: DCB Treatment|Stricture patients treated by DCB
16397365|NCT03997981||Breast cancer patients with weekly/biweekly paclitaxel regimen|
16397366|NCT03997981||Breast cancer patients receiving docetaxel regimen|
16397367|NCT03997981||Lymphoma patients receiving vincristine regimen|
16397368|NCT03997968|Experimental|Experimental: Active treatment|This is an open label study. All patients will receive single agent CYT-0851 administered orally or CYT-0851 in combination with chemotherapy.
16397369|NCT03997955|Experimental|Experimental group|Myofascial induction
16397370|NCT03997955|Sham Comparator|Control group|Sham myofascial induction
16397371|NCT03997942||proprioceptive neuromuscular facilitation|PNF will be applied to randomly selected patients.
16397372|NCT03997942||Mirror therapy|Mirror therapy will be applied to randomly selected patients.
16397373|NCT03997942||Standart therapy|Standard treatment will be applied to randomly selected patients.
16397374|NCT03997929||CASE (intra abdominal candidiasis)|Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection
16397375|NCT03997929||CONTROL (bacterial intra abdominal infection)|Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)
16397376|NCT03997916|Other|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient. There will be no separate arm to test a different device.
16397377|NCT03997903|Experimental|Imatinib Intervention|
16397378|NCT03997890|Experimental|Symfony group|The subjects who underwent cataract surgery with binocular implantation of either Symfony or Symfony toric IOLs
16397379|NCT03997877|Active Comparator|Control|"The usual physical activity valued by the YPAS questionnaire (Yale Physical Activity Survey) will be maintained. The questionnaire allows to calculate the time in physical activity expressed in hours / week, the energy expenditure expressed in MET-h / week and the summary index of physical activity that takes into account the frequency and duration of physical activity and oscillates from 0 to 137. A value below 51 identifies sedentary patients. Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.
~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
16397380|NCT03997877|Experimental|Intervention|"It is intended that the exercise program have a duration of 6 months and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule and without the need for instruments or special facilities. In this sense the walk is adjusted to these assumptions and the goal of 10.000 steps / day can encourage compliance.
~The subjects assigned to the intervention group will be supervised and trained by a physiotherapist who will explain the training program and resolve the doubts raised by the patient.
~Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.
~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
16397381|NCT03997864|Active Comparator|Treatment - prazosin|Participants randomized to this group will receive the medication prazosin.
16397382|NCT03997864|Placebo Comparator|Control - placebo|Participants randomized to this group will receive placebo .
16397383|NCT03997851|Experimental|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
16397384|NCT03997851|Experimental|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
16397385|NCT03997851|Experimental|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
16397386|NCT03997851|Placebo Comparator|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
16397387|NCT03997838|Experimental|VVZ-149 Injections|
16397388|NCT03997838|Placebo Comparator|Placebo|
16397389|NCT03997812|Experimental|VVZ-149 Injections|
16397390|NCT03997812|Placebo Comparator|Placebo|
16397391|NCT03997799|Experimental|uniportal transcervical approache|Uniportal lobectomy with complete lymphadenectomy - transcervical approach with elevation of the sternum
16397392|NCT03997799|Experimental|uniportal intercostal approache|Uniportal lobectomy with complete lymphadenectomy - intercostal approache
16397393|NCT03997786|Placebo Comparator|Part B - Placebo|
16397394|NCT03997786|Active Comparator|Part B - Etanercept|
16397395|NCT03997786|Experimental|Tildrakizumab|
16397396|NCT03997773|Experimental|Intervention|Will receive the intervention
16397397|NCT03997773|No Intervention|Usual care|Will receive usual care - will be the control group
16397398|NCT03997760|Experimental|SHP655|Participants with baseline SCD will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner for 14 days.
16397399|NCT03997760|Placebo Comparator|Placebo|Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion for 14 days.
16397400|NCT03997747||comprehensive genomic analysis group|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. The therapy patients received would not be based on the results of the genomic analysis.
16397401|NCT03997734|Experimental|Treatment A-AB001|Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
16397402|NCT03997734|Experimental|Treatment B-AB001|Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
16397403|NCT03997734|Active Comparator|Treatment C|Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
16397404|NCT03997734|Placebo Comparator|Treatment A-Placebo|Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
16397405|NCT03997734|Placebo Comparator|Treatment B-Placebo|Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
16397406|NCT03997721||Perforation|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal perforation or ( small intestine, large intestine), perforated ventricular or duodenal ulcer
16397407|NCT03997721||Obstruction|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal obstruction
16397408|NCT03997721||Anasomotic leak|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of anastomotic leak following elective surgery.
16397411|NCT03997695|Active Comparator|Core stabilization exercise group|"Core stabilization exercise (CSE):
~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional."
16397412|NCT03997695|Experimental|Core stabilization exercise plus kinesio taping group|"Core stabilization exercise (CSE):
~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
~Kinesio Taping:
~The Kinesio Taping was carried out 2 days a week for 6 weeks (12 sessions) by experienced and certificated physiotherapist. Kinesio taping was applied to spinal region."
16397413|NCT03997682|Experimental|Hands-Up Program|Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
16397414|NCT03997682|No Intervention|Standard Care|The control group will receive usual care after a distal radius fracture. The standard care for a distal radius fracture will receive an assessment related to whether casting or surgery is necessary. The participant may be in a cast for 6 weeks with routine check up and x-rays to monitor the healing, at 3 months, 6 months and 12 months. The participant should receive some physical therapy related to restoring function of the hand and wrist.
16397415|NCT03997669||experimental group|patients with malignant pleural effusion
16397416|NCT03997669||control group|patients with benign pleural effusion
16397417|NCT03997656|Experimental|MyDipp|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program. Each lesson will take 30 to 60 minutes to complete. The lesson will be considered complete if the participants clicked through all of the pages and answered multiple choice questions to indicate engagement and understanding.
16397418|NCT03997656|Other|Control|Participants in the control group (usual care) will receive standard health education from primary care providers in the clinic. In addition, they also will be provided with pamphlets and booklets about various health topics. They will be given a diary to record their weights, diet, physical activities and blood test result.
16397419|NCT03997643|Active Comparator|Standard Radiotherapy|Radiotherapy to all dissected areas
16397420|NCT03997643|Experimental|Radiotherapy to smaller treatment area|Omit radiation to pN0 neck
16397421|NCT03997630|Experimental|Interventional group|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
16397422|NCT03997630|Active Comparator|Control group|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
16397423|NCT03997617|Other|Personalized Functional Profiling|
16397424|NCT03997591||Conventional therapy|Group doing conventional rehabilitation was assessed at T0 and then after 6 weeks of conventional therapy (occupational therapy, physical therapy, aquatic therapy, musicotherapy, others)
16397425|NCT03997591||Ready2E.A.T. therapy|Group doing Ready2E.A.T. program received a mean of 1 hour per week and was assessed at T0 and then after 6 weeks of this program implementation.
16397426|NCT03997578|Active Comparator|NIPSA|Patients will be treated with only NIPSA technique.
16397427|NCT03997578|Experimental|NIPSA plus Connective tissue graft|Patients will be treated with NIPSA technique associated to a connective tissue graft.
16397428|NCT03997565||Patients TKR|
16397429|NCT03997565||Healthy subjects|
16397454|NCT03997396||the DGM group|The subject recruitment was implemented in the obstetrics department of the First People's Hospital of Chongqing Liangjiang New Area, China. 255 pregnant women diagnosed with GDM by IADPSG2010 standard and their children will be enrolled into the GDM group.
16397455|NCT03997396||the Non-GDM group|In the obstetrics department of Chongqing First People's Hospital of Liangjiang New Area,China,the healthy pregnant women and delivery children in the same period were enrolled into the non-GDM group in a 1:1 ratio.
16415652|NCT03870282|Experimental|"Personal Goal | Incentives A&B | Texts A&B"|
16397430|NCT03997552|Experimental|Non-incised papillae surgical approach (NIPSA)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
16397431|NCT03997552|Active Comparator|marginal approach by palatal incision|A small incision in the palatal aspect and a limited papila elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
16397432|NCT03997552|Active Comparator|Minimally invasive surgical technique (MIST)|The incision of the defect-associated papilla will be performed according to the principles of the papilla preservation techniques. Enamel matrix derivates will be applied on the debrided root surfaces. Stable primary closure of the flaps will be obtained with internal modified mattress sutures.
16397433|NCT03997539|Experimental|pyrotinib 320mg + vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
16397434|NCT03997539|Experimental|pyrotinib 400mg + vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
16397435|NCT03997539|Experimental|Pyrotinib + vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
16397436|NCT03997539|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
16397437|NCT03997526||3C Patch treatment|Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)
16397438|NCT03997513|Experimental|Pulmonary Telerehabilitation Intervention Group|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
16397439|NCT03997513|No Intervention|Usual Care Group|Participants randomized to the usual care arm will also be enrolled in our institution's telehealth program, will receive an automatic blood pressure monitor, portable pulse oximeter, and scale and will be in regular contact with a telehealth provider. A study team member will meet with participants randomized to the usual care arm to discuss the importance of exercise and will encourage exercise (strength training, light aerobic activity such as walking or cycling) a minimum of 20-40 minutes three times per week at discharge.
16397440|NCT03997500|Placebo Comparator|Normal saline|Simultaneous with subarachnoid block, a bolus of normal saline was given followed by normal saline infusion
16397441|NCT03997500|Experimental|Norepinephrine|Simultaneous with subarachnoid block, a bolus of norepinephrine was given followed by norepinephrine infusion
16397442|NCT03997487|Experimental|Children examined|All children examined for clinical signs of trachoma will be invited to participate to have photos of conjunctivae taken with the TOFTEE smartphone app and a DSLR camera.
16397443|NCT03997474|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
16397444|NCT03997474|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.
16397445|NCT03997474|Experimental|Cohort C|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
16397446|NCT03997461|Experimental|BPro vs Oscar 2|Blood pressure measurement with BPro and Oscar 2 simultaneously during 24 hours under ambulatory conditions
16397447|NCT03997448|Experimental|Abemaciclib and Pembrolizumab|Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
16397450|NCT03997422|Experimental|Vertical Sleeve Gastrectomy (VSG)|Bariatric surgical procedure
16397517|NCT03996902|Experimental|Tailored intervention|Brief Motivational Smoking Intervention
16397458|NCT03997370|Experimental|Treatment (iohexol, standard care carboplatin, blood samples)|Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
16397459|NCT03997344|Experimental|Nature hiking|Group hikes in a natural setting (e.g., park, wilderness area)
16397460|NCT03997344|Active Comparator|Urban hikes|Group hikes in a urban setting (e.g., downtown area)
16397461|NCT03997331|Experimental|Intervention|"Subjects in the Intervention arm will receive the following:
~Automated in-app messages containing behavioral and educational content that is tailored to each subject based on an assessment of their entry survey results and on their adherence and glucose data. (Behavioral Support Engine).
~Targeted in-app messages and phone calls from clinicians or as designated by the Investigator (through the CRx Care app) based on the subject's adherence and glucose data.
~Push notifications that alert the subject that it is time to complete a regimen event (ie take medication or take a fasting blood glucose reading).
~Push notifications that alert the subject that they have missed a scheduled regimen event.
~In-app messages containing adjustments to the subject's insulin glargine dose when the Investigator(s) approves an adjustment in the CRx Care App. (Treatment Support Engine)."
16397462|NCT03997331|Active Comparator|Control|Subjects in the Control arm will receive the CRx Health solution for self-management of chronic conditions.
16397463|NCT03997318|Experimental|AMDC-USR|AMDC-USR is the study product (Autologous Muscle Derived Cells for Urinary Sphincter Repair).
16397464|NCT03997318|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
16397465|NCT03997292||Alteplase group|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion
16397466|NCT03997292||Urokinase group|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End
16397467|NCT03997279|Experimental|S.boulardi|Quadruple eradication therapy with S. boulardi
16397468|NCT03997279|Placebo Comparator|Placebo|Quadruple eradication therapy without S. boulardi
16397469|NCT03997266|Active Comparator|Empiric antibiotics|Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
16397470|NCT03997266|Placebo Comparator|Placebo|Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.
16397471|NCT03997253|Experimental|blood and urine samples|blood and urine samples at D0, D7, D14, M1, M3, M6 and M12
16397474|NCT03997227|Active Comparator|Block group|
16397475|NCT03997227|No Intervention|control group|
16397476|NCT03997214|No Intervention|Control group|as usual care
16397477|NCT03997214|Experimental|experimental group|The intervention of inspiratory muscle strength training
16397478|NCT03997201|Other|Ripple Mapping guided ischaemic VT ablation|Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.
16397479|NCT03997188|Experimental|Hepilor arm|patients received ZLC solution. The prescribed dose was 10 ml, in the morning and evening, between meals.
16397480|NCT03997188|Placebo Comparator|Placebo arm|Patients received a placebo solution. The prescribed dose was 10 ml, in the morning and evening, between meals
16397481|NCT03997175|Experimental|Intervention|The children were in daily contact with biodiversity sand 5 days a week for two weeks.
16397482|NCT03997175|Placebo Comparator|Placebo|Children were in contact with normal but colored sand that looked as it were the biodiversity sand. All the other details were as above.
16397483|NCT03997162||Observational (ERAS protocol)|Participants complete standard of care early recovery after surgery protocol beginning the day before surgery to day 6 after surgery.
16397484|NCT03997149|Experimental|Stress Condition|The stress condition involved the Trier Social Stress Test (TSST), a standardized laboratory stressor designed to elicit psychological stress and cortisol responses. Following the TSST, participants were brought to a separate room, instructed to rest and given the option to eat at their leisure. Books and magazines were included in the room for the participant to utilize.
16397485|NCT03997149|Placebo Comparator|Rest Condition|Participants completed a control condition on a separate day. This condition followed the same sequence of events as the stress condition with the exception that the 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
16397486|NCT03997123|Experimental|Capivasertib + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.
~Capivasertib: Oral tablets. 400 mg of Capivasertib (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
16397487|NCT03997123|Placebo Comparator|Placebo + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.
~Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
16397488|NCT03997110|Active Comparator|Arm A Or Control Arm- Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
16415914|NCT03868631|Active Comparator|Whey protein group|
16397489|NCT03997110|Experimental|Arm B or Experimental Arm-Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
16397490|NCT03997097|Experimental|sildenafil|• Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent and adult patients, and for a period of 6 months.
16397491|NCT03997097|Placebo Comparator|placebo|• Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6 months. To guarantee the double blind, capsules will be similar in size and colour and will be differentiated only by a vial number regarding to the randomization list
16397492|NCT03997058|No Intervention|Control group|
16397493|NCT03997058|Experimental|Auricular acupoint pressing group|
16397494|NCT03997058|Active Comparator|Oral estazolam group|
16397495|NCT03997058|Active Comparator|Combined treatment group|
16397496|NCT03997045|Experimental|Intervention group|Pregnant women receiving usual care and participating in supervised physical exercise program.
16397497|NCT03997045|No Intervention|Control group|Pregnant women that are receiving usual care but are not participating in supervised physical exercise program.
16397498|NCT03997032|Experimental|Patients with Diabetes|Patients with Type 1 or Type 2 Diabetes
16397499|NCT03997019|Active Comparator|group A|opioid analgesia
16397500|NCT03997019|Active Comparator|group B|ESP block
16397501|NCT03997006|Active Comparator|Group A (n=30)|Aminophylline group
16397502|NCT03997006|Active Comparator|Group NA (n=30)|Neostigmine/Atropine group
16397503|NCT03996993||Hormone Therapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.
16397504|NCT03996993||Salvage Radiotherapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.
16397505|NCT03996980|Experimental|Custom-made foot orthoses|treatment intervention custom-made polypropylene foot orthoses for a period of 4 weeks
16397506|NCT03996980|Placebo Comparator|Placebo|a flat insole for a period of 4 weeks
16397507|NCT03996967||BA Group|The bacterial group: Patients will be assorted to this group if he/she has a bacterial pathogen culture of fluid from a normally sterile site (e.g. blood, pleural fluid)
16397508|NCT03996967||VI Group|"The viral group: Patients will be assigned to this group if they have negative bacteria microbiological tests, negative malaria blood slides, X-rays without endpoint pneumonia, no evidence of fungal infection, and positive PCR for a viral pathogen from nasopharyngeal swabs."
16397509|NCT03996967||MA Group|The malarial group: Patients will be assigned to this group if they have normal X-rays, no bacterial infection and >0 asexual P. falciparum parasites if they are aged < 1 year, or > 2,500 asexual parasites/µl of blood if they are aged > 1 year
16397510|NCT03996954|Active Comparator|Normal ECGs|Patients with normal ECGs
16397511|NCT03996954|Active Comparator|Abnormal ECGs|Patients with different kinds of abnormal heart rhythms will be enrolled in order to compare whether Alivecor can accurately differentiate between these abnormal heart rhythms and normal sinus rhythm/sinus tachycardia. Also, Alivecor diagnostic accuracy in differentiating between different kinds of arrhythmias will be assessed.
16397512|NCT03996941||seguiPrEP|MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
16397513|NCT03996928|Experimental|Eccentric exercise by physiotherapist|"A physiotherapist will apply (in this order) a plan of stretching exercises, warm-up exercises and eccentric exercises of epicondylar muscle,according to a program of 10 sessions of 20 minutes each, during two weeks.
~Before exercise, ultrasounds will be applied at intensity of 0.1 wat/cm2, which is considered as a placebo, in order to achieve greater adherence and monitor the treatment."
16397514|NCT03996928|Active Comparator|Illustrated booklet|A physiotherapist will train the patient an exercise plan equivalent to the one above explained with the help of illustrations. Now, in order to achieve palmar flexion at the same time the patients will contract their epicondylar muscles (the eccentric effect), and elastic band is used.
16397515|NCT03996915|Experimental|experimental PDT group|G1-20 patients Photodynamic therapy with methylene blue as photosensitizer device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point (6 points) and radiant 90 seconds. Photosensitiser (PS) will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.Six points with the distances of 1 cm between them will be irradiated.
16397516|NCT03996915|Active Comparator|control tongue scrapper group|G2-20 patients Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum in order to promote the mechanical removal of tongue coating
16397519|NCT03996889||Popliteal aneurysm patients with GORE VIABAHN®|The study population will include all popliteal aneurysm patients treated with GORE VIABAHN® stent graft in scheduled elective surgery, whether symptomatic or asymptomatic.
16397520|NCT03996876|Active Comparator|Threat ABM Training|Attention Bias Modification Training with threatening words
16397521|NCT03996876|Placebo Comparator|Neutral Attention Training|Non-active version of ABM Training
16397522|NCT03996863|Experimental|Otoband efficacy on CINV|"Participants will wear the Otoband during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.
~The Otoband will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the OtoBand is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the OtoBand 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
16397523|NCT03996863|Placebo Comparator|Placebo device efficacy on CINV|"Participants will wear the placebo device during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.
~The placebo device will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the device is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the device 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
16397524|NCT03996850||Health service research (MIBI SPECT/CT, questionnaire)|Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
16397525|NCT03996837|Experimental|Fresh embryo transfer with intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
16397526|NCT03996837|No Intervention|Fresh embryo transfer without intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
16397527|NCT03996837|Experimental|Freeze embryo transfer with intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
16397528|NCT03996837|No Intervention|Freeze embryo transfer without intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
16397529|NCT03996824||AAV viral transduction|Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
16397530|NCT03996811|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity for 40 min, three times a week on non-dialysis days. We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the target heart rate, as determined by the Karvonen method, and 12-13 on the RPE.
16397531|NCT03996811|No Intervention|usual-care group|Hospital routine care
16397532|NCT03996798|Experimental|Jessa Hospital, Herk-de-Stad|"Back to Work methodology: a revalidation trajectory with standard revalidation therapy in combination with an early focus on back to work, using a Disability Case Manager"
16397533|NCT03996798|No Intervention|Revalidation and MS Clinic Overpelt|"Standard revalidation therapy without explicit focus on back to work"
16397534|NCT03996785|Active Comparator|Urban|"Patients will go for a silent 60-minute walk in an urban setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.
~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology). The urban walk will be located on Boulevard de la Vérendrye with large arteries with three to four lanes."
16397590|NCT03996421|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
16416692|NCT03863223|Experimental|A|Pyrotinib Plus trastuzumab and docetaxel
16397535|NCT03996785|Experimental|Nature|"Patients will go for a silent 60-minute walk in a nature park setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.
~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology).
~The nature walk will take place at Parc Angrignon, an area of 96 hectares, one of Montreal's largest green and biodiverse spaces with a forest of 20 000 trees and a pond surrounded by willow trees."
16397536|NCT03996772|Experimental|Direct Oral Anticoagulant|"If the patient is randomized in this arm, a direct oral anticoagulant (DOAC) included:
~Direct thrombin inhibitor: Dabigatran
~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban will be prescribed to the patient. Choice and dose of DOAC treatment as well as the use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the spectrum of licensed doses labelled for stroke prevention in atrial fibrillation patients in Europe following the Summary of Product Characteristics."
16397537|NCT03996772|No Intervention|No Anticoagulant|If the patient is randomized in this arm investigators will use their best judgment to decide upon the prescription of an antiplatelet drug of their choice or no such therapy
16397538|NCT03996759||Critically ill patients|Patients admitted in ICU
16397539|NCT03996746||Non-dialysis Group|non-dialysis patients with CKD 2-5
16397540|NCT03996746||Hemodialysis Group|patients with CKD 5 under hemodialysis for more than 3 months
16397541|NCT03996733|Active Comparator|GControl|Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
16397542|NCT03996733|Experimental|GModel|"Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
~Participants in this group will also practice jugular vein puncture on our homemade jugular central venous catheterization training model."
16397543|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
16397544|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
16397545|NCT03996707|Other|Immediate protected weight-bearing|Immediate protected weight-bearing
16397546|NCT03996707|Other|Traditional non weight bearing|Strict non-weight-bearing
16397547|NCT03996694|Experimental|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
16397548|NCT03996694|Experimental|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
16397549|NCT03996694|Experimental|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
16397550|NCT03996694|Active Comparator|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
16397551|NCT03996694|Active Comparator|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
16397552|NCT03996694|Placebo Comparator|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
16397553|NCT03996681|Experimental|TACE plus methylcantharidimide tablets|Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
16397554|NCT03996668|No Intervention|Control|Subjects received standard operating room dress including sequential compression devices.
16397555|NCT03996668|Experimental|Experimental|Subjects wore thigh high compression stockings in addition to standard operating room dress including sequential compression devices.
16397556|NCT03996655|Experimental|Group S|Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
16397557|NCT03996655|Active Comparator|Group N|Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
16397558|NCT03996642|Other|Patients with Active Cancer|Eligible participants will undergo an unknown number of Avatar-life review sessions depending on acceptability of the intervention to subjects and the capacity of the team to provide the intervention.
16397559|NCT03996629|Experimental|Pharmacist-managed anticoagulation service|
16397560|NCT03996629|No Intervention|Usual medical care|
16397561|NCT03996616|No Intervention|Control Group|"During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.
~The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor."
16397562|NCT03996616|Active Comparator|Assigned Intervention|During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
16397563|NCT03996603|Experimental|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
16397564|NCT03996603|No Intervention|Control Cohort|No intervention will be given.
16397565|NCT03996577|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
16397566|NCT03996577|Experimental|Experimental: lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
16397591|NCT03996408|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16397592|NCT03996395||Infants|Infants, 4-4.5 months of age at enrollment
16417209|NCT03859583|Placebo Comparator|Control|60 g omelette
16397567|NCT03996564|Active Comparator|Acupuncture Group|"Battlefield Acupuncture (BFA) has a structured administration sequence that was utilized to limit any variability between investigators administering the treatment. The BFA technique has been suggested that the needles are placed not just in an acupoint but actually acupoint zones. BFA utilizes one to ten (maximum five points per ear) ASP semi-permanent gold needles® placed in one or both ears. The ASP Gold needle® is a sterile device which inserts a small 2 mm needle into the auricle. It is comprised in single-needle applicator ensuring ease of insertion combined with excellent precision. The needles remain in the ear and fall out spontaneously as early as two hours and up to seven days. After administration of the BFA, if subjects felt that their pain was not controlled based on verbal response, rescue medication could be administered to control pain to a tolerable level for discharge."
16397568|NCT03996564|Active Comparator|Standard Care Group|Participants randomized to the standard care group were treated with one, or a combination of selected medications to include oral Acetaminophen 500mg-1000mg, Diclofenac 50mg-75 mg orally, Diazepam 5mg-10 mg intravenous or oral, Hydrocodone 5mg/325mg-10mg/650mg mg oral, or intramuscular Ketorolac 30mg-60 mg, as deemed appropriate by the treating investigator (medical provider). Standard treatment was administered by the investigators based on the patient's presentation and driving status as many of the medications cannot be administered if the subject would operate a vehicle. No standardized algorithm was specified and the route and dose of medications was administered at the provider's discretion. After administration of the traditional standard care medications, if subjects felt their pain was not controlled based on verbal responses, rescue medication would be given to control pain to a more tolerable level for discharge.
16397569|NCT03996551|Experimental|Intervention Group|This group will receive access to the 12-week kidney transplant specific weight gain prevention online resource (ExeRTiOn online resource). After the 12 weeks, they will be offered the option to continue using the website up until the completion of the study (12 months)
16397570|NCT03996551|No Intervention|Control group|This group will not receive the online resource. They will receive the standard encouragement to follow a healthy diet and perform physical activity during routine transplant follow up appointments.
16397571|NCT03996538|Experimental|Metformin Hydrochloride Extended Release Tablets|Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
16397572|NCT03996538|Placebo Comparator|Placebo|Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
16397573|NCT03996525|Experimental|Electrical Stimulation|"Electrical Stimulation
~The patient will receive active electrical stimulation."
16397574|NCT03996525|Placebo Comparator|Sham Treatment|"No Electrical Stimulation
~The patient will receive sham electrical stimulation."
16397575|NCT03996512|Experimental|Post scaphoid fracture with screw fixation|Post surgical rehabilitation using an early active controlled wrist motion rehab protocol that limits the amount of proximal carpal row loading forces
16397576|NCT03996499|Experimental|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).
~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.
~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
16397577|NCT03996486|Experimental|Hemophilia|Dose escalation starting with 200 mg of BAY1093884
16397582|NCT03996460|Placebo Comparator|Placebo powder|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1). Fifteen (15) patients in arm 1 (group 1) will receive the matching placebo powder orally once daily for 12 weeks (90 days).
16397583|NCT03996460|Active Comparator|192 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 2 (group 2) will receive the 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally once daily for 12 weeks (90 days).
16397584|NCT03996460|Active Comparator|384 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 3 (group 3) will receive the 384 mg powder of K0706 (equivalent to 192 mg capsule of K0706) orally once daily for 12 weeks(90 days).
16397585|NCT03996447|Other|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
16397586|NCT03996447|Other|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI
16397587|NCT03996434|Experimental|Coasting group|Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
16397588|NCT03996434|Active Comparator|Antagonist group|"Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration.
~GnRH agonist will be discontinued at the start of antagonist administration.
~E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given."
16397589|NCT03996421|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
16397748|NCT03995212|Active Comparator|CR845 1.0 mg|Oral CR845 1.0 mg tablet administered twice daily
16397593|NCT03996382|Other|Suspicion of cardiac amyloidosis|Patients who display signs of cardiac amyloidosis will be referred for further diagnosis.
16397594|NCT03996369|Experimental|Etrasimod 2 mg|
16397595|NCT03996369|Placebo Comparator|Placebo|
16397596|NCT03996343|Experimental|Endotracheal intubation|
16397597|NCT03996343|Experimental|Laryngeal mask airway|
16397598|NCT03996317|No Intervention|Standard care|Standard practice where 10L/min O2 is delivered to patient by mask when any fetal tracing abnormalities are identified.
16397599|NCT03996317|Experimental|Room air|O2 will be withheld at times when fetal tracing abnormalities are identified. Patient will continue to breath room air.
16397600|NCT03996291|Experimental|SAR442168|"SAR442168 : Experimental - Part A: Double-blind period of continued treatment with the respective SAR442168 dose administered in the DRI15928 study until selection of Phase 3 dose.
~Part B: Open-label period of a single-group treatment with SAR442168 selected Phase 3 dose of 60 mg. All participants will be switched to this 60 mg dose."
16397601|NCT03996278||Patients in the Grafalon group|Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database
16397602|NCT03996278||Patients in the Thymoglobulin group|Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database
16397603|NCT03996265|Experimental|Arm I (bupropion hydrochloride controlled-release)|Patients receive bupropion hydrochloride controlled-release PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
16397604|NCT03996265|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
16397605|NCT03996252|Experimental|Combination treatment arm|Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.
16397606|NCT03996239|Experimental|patients with clonal hematopoiesis|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
16397607|NCT03996239|Experimental|post treatment patients with breast or colorectal cancer|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
16397608|NCT03996239|Experimental|men with localized prostate cancer undergoing active surveillance|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
16397609|NCT03996226|Experimental|E7386: Fed + Fast|Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
16397610|NCT03996226|Experimental|E7386: Fast + Fed|Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
16397611|NCT03996213|No Intervention|supine group|induction of anesthesia will be initiated while patient in supine position
16397612|NCT03996213|Active Comparator|head down|induction of anesthesia will be initiated while patient in head down position
16397613|NCT03996213|Active Comparator|leg elevation|induction of anesthesia will be initiated while patient in leg elevation position
16397614|NCT03996200|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
16397615|NCT03996161|Active Comparator|Supine position|After the induction of anesthesia, mask ventilation is performed in the supine position.
16397616|NCT03996161|Experimental|Semi-sitting position|After the induction of anesthesia, mask ventilation is performed in the semi-sitting position.
16397617|NCT03996148|Active Comparator|Remifentanil, Propofol, and Desflurane|Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
16397618|NCT03996148|Active Comparator|Remifentanil, Dexmedetomidine, and Desflurane|Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
16397619|NCT03996148|Active Comparator|Remifentanil and Desflurane|Study group C (control group): no midazolam given; maintenance drugs started immediately after induction and airway is secured.
16397620|NCT03996135|Experimental|Experimental : Cannulation with AccuVein AV400|Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
16397621|NCT03996135|No Intervention|Control|Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
16397622|NCT03996122||resistant patients with schizophrenia|Age 18 - 60 years No MRI contraindication
16397623|NCT03996109|Experimental|Aim2Be|Youth-parent dyads randomized to Aim2Be
16397624|NCT03996109|Active Comparator|BnLt|Youth-parent dyads randomized to BnLt
16397625|NCT03996096||Group with the TKI withdrawal syndrome|There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.
16397626|NCT03996096||Group without the TKI withdrawal syndrome|As abovementioned.
16397651|NCT03995901|No Intervention|Control|"Standard induction therapy followed by a maintenance regimen of tacrolimus, mycophenolate, and corticosteroids after kidney transplant.
~Control donors are not followed beyond randomization."
16397652|NCT03995888|Experimental|Healthy Volunteers|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
16397627|NCT03996083|Experimental|Multicomponent exercise intervention|The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
16397628|NCT03996083|Experimental|Walking intervention|Participants assigned to the walking group walked with the research staff two days per week; additionally, they walked partially supervised by LTNH staff, family members or caregivers the rest of the week. Daily walking goals were set follows: walking between 5 to 10 minutes on the first month, up to 15 minutes on the second, and finally 20 minutes per day on the third month. The final goal was to get as close as possible to the recommendations of engaging in 150 minutes of aerobic exercise per week from the World Health Organization (WHO). Participants were asked to walk as fast as they could and rest was allowed whenever needed. Walking goals were achieved in one or multiple sessions, depending on each participant´s capacities. Those participants that met the walking goals without any rest were encouraged to walk at a faster pace.
16397629|NCT03996070|Active Comparator|Treatment arm|Therapeutic dose regime
16397630|NCT03996070|Placebo Comparator|Sham arm|Sub-therapeutic dose regime
16397631|NCT03996057|Experimental|Methenamine augmentation|2g methenamine hippurate twice daily for 90 days added to a baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
16397632|NCT03996057|Active Comparator|No methenamine augmentation|Baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
16397633|NCT03996044|Experimental|Group 1|Thirteen patients who will receive treatment with teeth brushing, dental floss and tongue scraper.
16397634|NCT03996044|Experimental|Group 2|Thirteen patients who will receive treatment with teeth brushing, dental floss and antimicrobial photodynamic therapy applied to the back and middle third of the tongue.
16397635|NCT03996044|Experimental|Group 3|Thirteen patients who will receive treatment with teeth brushing, dental floss and probiotics.
16397636|NCT03996044|Experimental|Group 4|Thirteen patients who will receive treatment with teeth brushing, dental floss, antimicrobial photodynamic therapy applied to the back and middle third of the tongue and probiotics..
16397637|NCT03996031||Study Sample|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests. Following the baseline assessment, participants will engage with the Plan to Thrive app for a 90-day period.
16397638|NCT03996018||group 1(HIV Uninfected)|Participant is HIV negative per antibody screen conducted on premises and participant is enrolled on HPTN 083 study
16397639|NCT03996018||group 2 (HIV Infected)|Participant has initiated ART therapy as a patient at St Jude Children's Research Hospital, newly diagnosed HIV and prolonged HIV
16397640|NCT03996005|Experimental|MRI Guided Transurethral Ultrasound|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
16397641|NCT03995992|Active Comparator|multi sport|During 10 days, each morning, from 9 am to 12 pm, participants had sporting activities: mountain walking, mountain biking, climbing, canyoning and collective orienteering running. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
16397642|NCT03995992|Experimental|diving|During 10 days, each morning, from 9 am to 12 pm, participants had diving activities. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
16397643|NCT03995979|Experimental|Protein Restriction Group|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided.
16397644|NCT03995966|Active Comparator|Subtype 2 Automatically Maintained SIB|
16397645|NCT03995966|Active Comparator|Subtype 3 Automatically Maintained SIB|
16397646|NCT03995953|No Intervention|Control|2 control zones with no intervention at the clinic or community level
16397647|NCT03995953|Experimental|SHIELD: Community-based behavioral intervention|2 clinic zones where participants attend modules designed to educate and empower adolescent girls and young women (AGYWs) and their families, along with attendance at community-based youth clubs to foster peer support.
16397648|NCT03995953|Experimental|SHIELD: Community- based behavioral intervention & IWC Clinic|2 clinic zones where participants receive the Support for HIV Integrated Education, Linkages to care, and Destigmatization (SHIELD) intervention along with the coupled benefits of having an integrated wellness care (IWC) clinic within health facilities where adolescent girls and young women (AGYWs) can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and human papilloma virus (HPV) vaccination.
16397649|NCT03995927||Data collection/questionnaire|Data collection for patient medical charts and patient fill out questionnaires first visit and post-treatment visits
16397650|NCT03995901|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
16397653|NCT03995888|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
16397654|NCT03995862||Patients in care, at high risk of HIV infection|Patients in care, at high risk of HIV infection, according to the criteria defined by the French Ministry Of Health for the use of FTC / TDF in PreP (men who have sex with men, transgender, heterosexual women migrants or not, sex workers (sexual intercourse in exchange for money, drugs, housing, food), intravenous drug users) HIV-negative, exposed by their sexual practices to a high risk of HIV infection.
16397655|NCT03995836||Obstructive Sleep Apnea|
16397656|NCT03995836||Non Obstructive Sleep Apnea|
16397657|NCT03995810|Experimental|Carnosine|Carnosine, capsulle, 2 g/day, 8 weeks
16397658|NCT03995797|Active Comparator|Treatment arm|Treatment with erbium YAG laser
16397659|NCT03995797|Placebo Comparator|Sham arm|Sub therapeutic procedure with erbium YAG laser
16397660|NCT03995784|Experimental|Intravenous Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
16397661|NCT03995784|Experimental|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
16397662|NCT03995771||Children and adolescents with knee pain|Children and adolescents (8-19 years old) presenting to general practice for knee pain
16397663|NCT03995758|Active Comparator|Standard laser lithotripsy|standard of care for stone fragmentation in ureteroscopy
16397664|NCT03995758|Active Comparator|MOSES laser lithotripsy|MOSES technology used for stone fragmentation in ureteroscopy
16397665|NCT03995745|Experimental|adherence based financial incentives|Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
16397666|NCT03995745|No Intervention|control|Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
16397667|NCT03995732|Experimental|40 mg treatment group|PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
16397668|NCT03995732|Experimental|80 mg treatment group|PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
16397669|NCT03995732|Experimental|160 mg treatment group|PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
16397670|NCT03995732|Placebo Comparator|placebo control group|placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
16397671|NCT03995719|Other|Preoperative education|Each patient had individual consultation several days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
16397672|NCT03995719|Other|Postoperative education|Each patient had individual consultationseveral days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
16397673|NCT03995706|Experimental|Breast Brain Metastasis and Glioblastoma|Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.
16397674|NCT03995693|Experimental|Concentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of CONCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
16397675|NCT03995693|Experimental|Concentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of concentric cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
16397676|NCT03995693|Experimental|Eccentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
16397677|NCT03995693|Experimental|Eccentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
16397678|NCT03995680|Experimental|Chewable tablet of mebendazole|"3-5 year olds allocated to the swallowable tablet arm will be given the crushed tablet on a spoon mixed with a small amount of clean water;
~6-12 year olds allocated to the swallowable tablet arm will be given the whole tablet to swallow with a glass of clean water;"
16397679|NCT03995680|Active Comparator|Swallowable tablet of mebendazole|"3-5 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and swallow it without water; if they cannot chew it then a small amount of water will be added to the tablet in a spoon;
~6-12 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and then swallow it without water."
16397680|NCT03995667|Experimental|Prevention (TTFields therapy, questionnaire)|Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
16397681|NCT03995641|No Intervention|Surgery Alone|Patient will receive sacrospinous ligament suspension surgery without any additional interventions
16397682|NCT03995641|Experimental|Surgery Plus Trigger Point Injection|Patient will have sacrospinous ligament suspension procedure with addition of a trigger point injection (9cc of 0.5% marcaine and 1 cc kenalog) over area of suture placement
16397683|NCT03995628|Experimental|Steroid Group|Participants will receive a one-time dose of oral dexamethasone at 0.5 mg/kg on the third post-operative day
16397684|NCT03995628|No Intervention|No Steroid Group|Participants will not receive dexamethasone
16397685|NCT03995615|No Intervention|Group I (Control)|• Group I (Control) - 15 periodontally healthy patient with probing depth< 3mm and ≤ 10% sites with bleeding on probing.
16397686|NCT03995615|No Intervention|• Group II|• Group II - 15 systemically healthy chronic periodontitis patient who had presented >25% of sites with gingival bleeding ,surface demonstrating supra-gingival plaque accumulation and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm
16397687|NCT03995615|No Intervention|• Group III|• Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1with out scaling and root planing
16397688|NCT03995615|Active Comparator|• Group IV|• Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed
16397689|NCT03995602|Experimental|Dragon fruit first then placebo|2 weeks of dragon fruit juice intake or placebo with crossover to the other
16397690|NCT03995602|Experimental|Placebo first then dragon fruit|2 weeks of dragon fruit juice intake or placebo with crossover to the other
16397691|NCT03995589|Experimental|Walking Group|
16397692|NCT03995589|Active Comparator|Control|
16397693|NCT03995563|Active Comparator|D group|0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
16397694|NCT03995563|Placebo Comparator|N group|0.19% Ropivacaine 8mL only every other day injection during 10 days
16397695|NCT03995550|Experimental|Single ascending dose Cohort A|Single dose of LEO 142397 or placebo.
16397696|NCT03995550|Experimental|Single ascending dose Cohort B|Single dose of LEO 142397 or placebo.
16397697|NCT03995550|Experimental|Single ascending dose Cohort C|2 single doses, separated by a washout of ≥7 days.
16397698|NCT03995550|Experimental|Single ascending dose Cohort D|2 single doses, separated by a washout of ≥7 days.
16397699|NCT03995550|Experimental|Single ascending dose Cohort E|Single dose of LEO 142397 or placebo.
16397700|NCT03995550|Experimental|Single ascending dose Cohort F|Single dose of LEO 142397 or placebo.
16397701|NCT03995550|Experimental|Single ascending dose Cohort G|Single dose of LEO 142397 or placebo.
16397702|NCT03995550|Experimental|Single ascending dose Cohort H|Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.
16397703|NCT03995550|Experimental|Multiple ascending dose Cohort K|Multiple doses of LEO 142397 or placebo.
16397704|NCT03995550|Experimental|Multiple ascending dose Cohort L|Multiple doses of LEO 142397 or placebo.
16397705|NCT03995550|Experimental|Multiple ascending dose Cohort M|Multiple doses of LEO 142397 or placebo.
16397706|NCT03995550|Experimental|Multiple ascending dose Cohort N|Multiple doses of LEO 142397 or placebo.
16397707|NCT03995550|Experimental|Multiple ascending dose Cohort O|Multiple doses of LEO 142397 or placebo.
16397708|NCT03995550|Experimental|Multiple ascending dose Cohort P|Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.
16397709|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
16397710|NCT03995511|Experimental|Bilateral sagittal split|
16397711|NCT03995498|Active Comparator|Individualized carbohydrate intake|"Based on glucose sensor level, carbohydrate (orange juice, Oasis classic) will then be given as follow:
~If sensor glucose level is under < 4.5 mmol/L, the camp staff will treat hypoglycemia according to the camp procedure, If sensor glucose level is between 4.5 and 7.0 mol/L, 0.5g of CHO/kg body weight will be given, If sensor glucose level is between 7.1 and 10.0 mmol/L, 0.25g of CHO/kg body weight will be given, If sensor glucose level is between 10.1 and 15.0 mmol/L, no CHO will be given, If sensor glucose level is > 15.1 mmol/L, the camp staff will treat hyperglycemia according to the camp procedure."
16397712|NCT03995498|Active Comparator|Usual camp protocol|As per camp routine care, there will be no mandatory glucose level measurement before the start of physical activity if no symptoms of hypoglycemia or hyperglycemia appear.
16397713|NCT03995485|Experimental|KW-136+SOF|Treatment-naive and experienced subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
16397714|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose escalation|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
16397715|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose expansion|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
16397716|NCT03995472|Experimental|SHR-1501 and SHR-1316 Indication expansion|SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.
16397717|NCT03995446|Experimental|low-level laser therapy|808nM wavelength, power density of 300mW
16397718|NCT03995446|Sham Comparator|Sham laser acupuncture treatment|received the same manner except for joule.
16397719|NCT03995420|Experimental|Virtual Reality Therapy (V-NeST)|Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
16397720|NCT03995420|Other|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) only.
16397721|NCT03995407|Active Comparator|Control|"Participants in the control arm will receive usual care."
16418558|NCT03850379|Experimental|Levo|Levofloxacin 500 mg once daily
16397722|NCT03995407|Experimental|100% Whey Protein|Participants will receive 100% Whey Protein oral nutritional supplements.
16397723|NCT03995394|Experimental|Positive Reinforcement Group|"In the intervention group, participants will receive two text messages weekly. The first text message will ask if participants completed the recommended activity. If the participants respond yes, the participant will receive a positive reinforcement response. If the participants respond no, the participant will receive a text message stating, Thank you for your response."
16397724|NCT03995394|No Intervention|Control Group|"For the control group, participants will receive two text messages weekly. The first text message will ask if the participants completed the recommended activity. When the participant responds, the participant will receive a second text message stating, Thanks for your response."
16397725|NCT03995381|Experimental|DAs group|Shared decision making using decision aids
16397726|NCT03995381|No Intervention|Control group|Standard oral explanation guided with booklets
16397727|NCT03995368|Experimental|People with Schizophrenia|People who have been diagnosed with schizophrenia and meet the investigators' research criteria for symptoms indicative of schizophrenia within their lifetime.
16397728|NCT03995368|Experimental|People with TBI|People who have been diagnosed with a mild or moderate traumatic brain injury (TBI) and meet research criteria indicative of TBI within their lifetime.
16397729|NCT03995368|Experimental|Healthy Controls|People without a history of psychiatric illness or TBI and who do not meet research criteria for a psychiatric illness or TBI.
16397730|NCT03995342|Experimental|exprimental: Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
16397731|NCT03995342|Placebo Comparator|Active comparator: maltodextrin|Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.
16397732|NCT03995329|Other|healthy non smokers|"Healthy non smokers males, aged 18-55years,receiving no medications
~Intervention: the use of an IQOS Examination of pulmonary function, exhaled CO, blood pressure, heart rate and O2 saturation immediatly after IQOS"
16397733|NCT03995316|Other|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
16397734|NCT03995316|Other|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
16397735|NCT03995303|Active Comparator|NCP and home-delivered meals|Preventing malnutrition with NCP by a registered dietician and home-delivered meals
16397736|NCT03995303|No Intervention|Current practice|Current practice after discharge from the University Hospital of Iceland.
16397737|NCT03995277|Other|Healthy cohort - high dose|Apparently healthy subjects, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
16397738|NCT03995277|Other|Hypothyroid cohort|Subjects under thyroid medication, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
16397739|NCT03995277|Other|Healthy cohort - low dose|Apparently healthy subjects, who take 50 µg/d of biotin at the same time each morning for 20 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), after 20 days of biotin supplementation (day 20), and 10 days after participants stopped taking biotin (day 30).
16397742|NCT03995251|Experimental|Standard Medical Treatment +Intramuscular Testosterone + Exerc|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
16397743|NCT03995251|Active Comparator|Standard Medical Treatment+Exercise|Standard Medical Treatment +Exercise
16397744|NCT03995238|Experimental|Error-augmentation training|A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
16397745|NCT03995238|Experimental|Error-correction training|A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
16397746|NCT03995238|Active Comparator|Supervised waking|A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
16397747|NCT03995225|Experimental|Smokers|This study involves wearing a smartband to monitor, record and notify smokers of smoking events and deliver real-time brief mindfulness exercises by smartphone app.
16397749|NCT03995212|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
16397750|NCT03995199||Furlow group|All cleft palate patients surgically treated with a modified Furlow technique since January 2012
16397751|NCT03995199||Furlow + Sommerlad group|All cleft palate patients surgically treated with a modified Furlow technique in combination with an intravelar veloplasty by Sommerlad
16397752|NCT03995186|Experimental|Behavioural activation group|
16397753|NCT03995186|Active Comparator|Activity monitoring group|
16397754|NCT03995186|No Intervention|Waiting list control group|
16397755|NCT03995173|Active Comparator|active|active rTMS
16397756|NCT03995173|Placebo Comparator|placebo|placebo rTMS
16397757|NCT03995160|Active Comparator|Total knee replacement with use of closed suction drainage|Use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
16397758|NCT03995160|Active Comparator|Total knee replacement without use of closed suction drainage|Without the use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
16397759|NCT03995147|Experimental|Treatment Arm|
16397760|NCT03995134||Propofol and Remifentanil|Procedural sedation in Dentistry provided by a Target Controlled Infusion pump using propofol as the sedative/hypnotic agent and Remifentanil as the opioid analgesic agent.
16397761|NCT03995121||Schizophrenia and other psychotic disorders|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
16397762|NCT03995121||Cannabis Use Disorder|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
16397763|NCT03995121||Healthy Control|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
16397764|NCT03995108|Experimental|Mavorixafor|Participants (adults and adolescents [12 to 17 years of age weighing >50 kilograms [kg]) will receive mavorixafor 400 milligrams (mg) once daily (QD) orally for 52 weeks in the Randomized Period. Adolescents weighing ≤50 kg will receive mavorixafor 200 mg QD. Participants who complete the Randomized Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent adjudication committee (AC), will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
16397765|NCT03995108|Placebo Comparator|Placebo|Participants will receive placebo matching to mavorixafor QD orally for 52 weeks in the Randomized Period. Participants who complete the Randomized Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent AC, will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
16397766|NCT03995095|No Intervention|Control group|Group of participants that received usual psychological attention.
16397767|NCT03995095|Experimental|Experimental group|Group of participants that received usual psychological attention plus attention of spiritual needs following the Kibo protocol (intervention).
16397768|NCT03995082|Experimental|Experimental Group|Patients will receive the results from the PROM survey in graphical form each time they complete a survey.
16397769|NCT03995082|No Intervention|Normative Control|These patients will complete the PROM surveys, but will not be presented with the results of the survey.
16397770|NCT03995069|Experimental|3D|The participant's voluntary grip forces in all 3 dimensions will be shown to the participant via computer screen.
16397771|NCT03995069|Active Comparator|1D|The participant's voluntary grip force in 1 dimension will be shown to the participant via computer screen.
16397772|NCT03995056|No Intervention|Control-group|Subjects diagnosed with NAFLD and a sedentary lifestyle will have no changes in their habits and diets.
16397773|NCT03995056|Experimental|Exercise-group|This group with diagnosed NAFLD patients will perform a high-intensity aerobic interval exercise training without changing their diets.
16397774|NCT03995043|Experimental|Control Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.
~Personal Support from community peer mentor to access counselling services through SRH"
16397775|NCT03995043|Experimental|Case Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.
~Personal Support from community peer mentor to access counselling services through SRH
~Access to Contraception and counselling and service provision will be provided by the mobile reproductive health team at contraceptive access points."
16397776|NCT03995017|Experimental|Safety Lead In|"Rucaparib 600 milligrams twice daily
~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
~Nivolumab 480 milligrams intravenous every 4 weeks
~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
~One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients
~1 cycle= 28 days"
16397777|NCT03995017|Experimental|Cohort A|"Rucaparib 600 milligrams twice daily
~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
~Nivolumab 480 milligrams intravenous every 4 weeks
~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
~1 cycle= 28 days"
16397778|NCT03995017|Active Comparator|Cohort B|"Rucaparib 600 milligrams twice daily
~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
~1 cycle= 28 days"
16397779|NCT03995004|Experimental|Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.
~IV Normal Saline (1mL) on induction and continued q12h for 4 more doses."
16397780|NCT03995004|Active Comparator|Dexamethasone|"Placebo capsules at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.
~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
16397781|NCT03995004|Experimental|Dexa_Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.
~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
16418559|NCT03850379|Active Comparator|Cipro|Ciprofloxacin 500 mg BID
16397782|NCT03994991|Experimental|Active TMS|Patients in the active TMS group will receive active TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
16397783|NCT03994991|Sham Comparator|Sham TMS|Patients in the shamTMS group will receive sham TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
16397784|NCT03994978||Surgical group|Patients with uncomplicated recurrent diverticulitis undergoing elective sigmoid resection
16397785|NCT03994978||Conservative group|Patients with uncomplicated recurrent diverticulitis with conservative treatment
16397786|NCT03994965|Experimental|Patients|"40 antipsychotic-free, first-episode schizophrenia spectrum patients will receive 6 weeks of treatment with a selective serotonin 2A Receptor (2AR) blockade.
~Before initiation of treatment patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR binding potential using the radioligand [¹¹C]Cimbi-36; magnetic resonance spectroscopy (MRS) of cerebral glutamate levels; structural Magnetic Resonance Imaging (MRI), including diffusion tensor imaging (DTI); cognitive and psychopathological examinations; Electrocardiography (ECG), and blood sampling for genetic- and metabolic analyses.
~(Full description will be updated on approval)."
16397787|NCT03994952||Uninjured Physically Active Young Adults|"This is a group of physically active, and currently uninjured young adults. They will complete a single balance assessment, the modified balance error scoring system protocol, as outlined by the Sway Balance application.
~There is no comparison group for this investigation."
16397788|NCT03994939|Experimental|Intervention|Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
16397789|NCT03994939|No Intervention|Control|Parents randomized to the control group did not receive any intervention sessions and only completed assessment questionnaires.
16397790|NCT03994926|Experimental|Experimental|Directed smoking of about 3.6% THC cannabis cigarette
16397791|NCT03994913|Experimental|CAR-CD19-T Cells|The subjects are enrolled into 3 dose levels cohorts in sequence.
16397792|NCT03994900|Experimental|Blood sampling for HbNO assessment|
16397793|NCT03994887|Experimental|Experimental group|Patients under general anesthesia will be included.
16397794|NCT03994874|Experimental|PolyCore PUF|PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.
16397795|NCT03994874|Active Comparator|Control|Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.
16397796|NCT03994861|Active Comparator|Patients with musculoskeletal disorders|Patients with either shoulder pain, knee pain, hip pain, low back pain, pelvic pain or neck pain as their primary pain complaint, lasting for 6 weeks or longer
16397797|NCT03994861|Sham Comparator|Healthy controls|Age- and gender-matched healthy controls (without musculoskeletal pain)
16397798|NCT03994848|No Intervention|Control|
16397799|NCT03994848|Experimental|Spirometry Group|
16397800|NCT03994822|Experimental|pRESET Thrombectomy Device|Mechanical Thrombectomy using the pRESET Thrombectomy Device
16397801|NCT03994822|Active Comparator|Solitaire Revascularization Device|Mechanical Thrombectomy using the Solitaire Revascularization Device
16397802|NCT03994796|Experimental|Arm I (CDK gene mutation)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16397803|NCT03994796|Experimental|Arm II (PI3K gene mutation)|Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16397804|NCT03994796|Experimental|Arm III (NTRK/ROS1 gene mutation)|Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16397805|NCT03994783|Active Comparator|Standard of Care (SOC)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants)
16397806|NCT03994783|Experimental|Standard of Care plus Rituximab (SOCR)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants) Rituximab (375 mg/m2 max 1 g (no dose adjustment for paediatric participants), n=2 14 days +/- 2 days apart)
16397807|NCT03994770|Other|STR|Older people who have suffered a stroke
16397808|NCT03994757|Experimental|MRBI group|
16397809|NCT03994757|Sham Comparator|Control group|
16397810|NCT03994744|Experimental|Sintilimab and Metformin|"Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).
~The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up."
16397811|NCT03994731|Experimental|Pegloticase with methotrexate (MTX)|Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period and Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 52 weeks
16397812|NCT03994731|Placebo Comparator|Pegloticase with placebo for methotrexate (MTX)|Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period, placebo for MTX (weekly) in the Run-in Period, then pegloticase (every 2 weeks) with placebo for MTX (weekly) for 52 weeks
16397843|NCT03994458|Placebo Comparator|Placebo|Participants get the placebo program for 6 weeks.
16397844|NCT03994445|Experimental|Intervention group|Intervention group will be enrolled to the intervention program proposed to be (pharmacotherapy + counseling+ motivator phone messages).
16397813|NCT03994718|Experimental|Music|The musician will either offer music that can either be played for the participant or an instrument so they can experience playing themselves. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. The outpatient music intervention will consist of providing a recording of similar music for the participant to listen to for at least 30 minutes per week, along a with telephone call session with the music therapist.
16397814|NCT03994718|Experimental|Visual art|The creative visual artist will assess interest in spending time using the materials provided. Participants will be offered watercolor painting, drawing, or adult coloring. There will be a guided activity based on their art making preference. A standardized prompt will be utilized for both writing and visual art sessions. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For remote follow-up sessions, participants will be supplied with a small art kit to use at home.
16397815|NCT03994718|Experimental|Creative writing|The writer will ask the participant about their interests and experiences in writing or storytelling. The following options are offered; introduction to journaling, storytelling or writing exercises with prompts to get started, interactive writing or storytelling activities. For participants who are unable to write or prefer not to, the writer can scribe their words on a laptop and print them out. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For follow-up sessions, participants will be supplied with a journal.
16397816|NCT03994705|Experimental|Dose-Escalation|
16397817|NCT03994692|Experimental|PEEK eminoplasty|"CT scan with bony window for facial bones and DICOM files on CD .then, Using cad cam software (mimics 15) , the virtual design and surgery will be done.
~under general anathesia The TMJ will be exposed using the endural incision line and the articular eminence will be identified then blunt dissection so that the front wall of the articular capsule can be exposed completely.
~The patient specific PEEK eminence will be inserted and secured with two to three pre-planed screws .
~Functional mandibular movements were reproduced to confirm absence of subluxation and then closure"
16397818|NCT03994692|Active Comparator|autogenous onlay grafting eminoplasty|"under general anesthesia , chin graft was taken Layered Endural approach to TMJ making wedge in eminence by mallet & chisel (green stick fracture), then wedging piece of chin graft to increase the height of the eminence creating an obstacle to treat dislocation by manipulation of patient mandible intra operative.
~- Functional mandibular movements were reproduced to confirm absence of subluxation then closure"
16397819|NCT03994679||cleft patient requiring bone graft|Patients presenting at the division of maxillofacial surgery at the AZ Sint-Jan Brugge-Oostende av (Belgium) or the 1st department of pediatrics at the USemmelweis (Hungary) for bone graft surgery of the unilateral cleft receive a complete routine work-up, including a cone-beam CT (CBCT).
16397820|NCT03994666|Experimental|simple dose|
16397821|NCT03994666|Experimental|double dose|
16397822|NCT03994666|Placebo Comparator|placebo|
16397823|NCT03994653||Cases|Participants diagnosed with ovarian cancer
16397824|NCT03994653||Controls|Participants without ovarian cancer
16397825|NCT03994640|Experimental|Cannabis cream|Cannabis cream topical skin application in experimental group
16397826|NCT03994640|Placebo Comparator|Placebo cream|Placebo cream topical skin application in control group
16397827|NCT03994614|Experimental|the Acupuncture intervention group|Patients in this group will be given acupuncture treatment for 12 weeks prior to COS.
16397828|NCT03994614|No Intervention|No intervention group|Patients in this group will not be given any intervention for 12 weeks prior to COS.
16397829|NCT03994601|Experimental|Arm A BMS-986288|Specified dose on specified days
16397830|NCT03994601|Experimental|Arm B BMS-986288 in combination with Nivolumab|Specified dose on specified days
16397831|NCT03994588|Active Comparator|study arm|In this arm a light weight, wide pore, soft polypropylene mesh will be used for intraperitoneal hernia repair
16397832|NCT03994588|Active Comparator|control|in this arm a double mesh (vicryl + polypropylene mesh) will be used for intraperitoneal hernia repair.
16397833|NCT03994549|Active Comparator|ZP7570|Single subcutaneous injection
16397834|NCT03994549|Placebo Comparator|Placebo|Single subcutaneous injection
16397835|NCT03994536|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
16397836|NCT03994536|Experimental|Comparison group: Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
16397837|NCT03994510|Other|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
16397838|NCT03994497|Other|Patient in need of a kidney transplant|
16397839|NCT03994484|Experimental|HA121-28 tables|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
16397840|NCT03994471|Experimental|XyloCore peritoneal dialysis solution|Patients will receive 2 to 3 daily (short-dwell) exchanges with XyloCore of an osmotic strength comparable to their pre-randomization prescription of glucose peritoneal dialysis solution (XyloCore Low, Medium and High Strenght have an osmotic strength comparable to Physioneal, Fixioneal or Dianeal 1.36%, 2.27%, 3.86% glucose, respectively, and Balance, Bicavera, Bicanova or Equibalance with 1.5%, 2.5%, 4.25% glucose, respectively). All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
16397841|NCT03994471|Active Comparator|Glucose peritoneal dialysis solution|Patients randomized to glucose solution will continue the 2 to 3 daily (short-dwell) exchanges of Physioneal 40 or 35, Fixioneal 40 or 35 or Dianeal (1.36%, 2.27%, 3.86% glucose), Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.5%, 4.25% glucose) with the same osmotic strength of their pre-randomization prescription. All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
16397842|NCT03994458|Experimental|Experimental|Participants get the full program for 6 weeks.
16418560|NCT03850366|Experimental|Bortezomib|
16397845|NCT03994445|No Intervention|Control group|Control group will receive the standard treatment of the Ministry of the Health program (pharmacotherapy + counseling) only.
16397846|NCT03994432|Experimental|Intervention group|"patients with symptomatic endometriosis in therapy with estro-progestins or progestins, who will be asked to follow a mediterranean diet and to practice an aerobic physical exercise according to the 7-minutes workout model"
16397847|NCT03994432|No Intervention|Control group|patients with symptomatic endometriosis in therapy with estro-progestins or progestins.
16397848|NCT03994406|Experimental|CLM2 Topical Gel|CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
16397849|NCT03994406|Placebo Comparator|Placebo Topical Gel|Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
16397850|NCT03994393|Active Comparator|Cohort 1|Participants with no evidence of T790M
16397851|NCT03994393|Active Comparator|Cohort 2|Participants with evidence of T790M
16397852|NCT03994380|Experimental|Intervention|rhDNAse 2.5 mg nebulizer daily for 4 weeks
16397853|NCT03994367|No Intervention|Standard protein (control)|
16397854|NCT03994367|Experimental|High animal protein isolate|
16397855|NCT03994367|Experimental|High animal protein whole food|
16397856|NCT03994367|Experimental|High plant protein isolate|
16397857|NCT03994367|Experimental|High plant protein whole food|
16397858|NCT03994354||1,2|"J-P drain group
~Penrose drain group"
16397859|NCT03994341||NEC Group|Infrared images of the abdomen, timed at handling. A FLIR Thermovision a320M thermal IR camera bound with an Microsoft Kinect RGB-D sensor system connected to a laptop will be used. Both imaging technologies are non-invasive and represent no risk to the subject. The thermal images record the temperature distribution, the Kinect sensor will acquire color image and depth image that will be used to segment the subject from the background bedding surface. All three sets of images will be collected in synchronization. Thermography requires period of slight cooling of the skin surface to stabilize the body surface temperature. The room temperature will be maintained slightly below thermoneutrality. Thermographic camera will be positioned about 60-70 cm above the baby.
16397860|NCT03994341||Normal Group|Same procedure for both experimental and active comparator.
16397861|NCT03994328||Group 1|500 patients already receiving safinamide (50 or 100 mg/day) as add-on to L-dopa for no more than 2 months.
16397862|NCT03994328||Group 2|500 patients receiving rasagiline 1 mg/day as add-on to L-dopa for no more than 2 months.
16397863|NCT03994328||Group 3|235 patients receiving other SoC drugs as add-on to L-dopa for no more than 2 months.
16397864|NCT03994315|Experimental|B. infantis EVC001 + LNT (3 g/L then 8 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 1 [B. infantis + LNT (3 g/L then 8 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 3 g/L for 2 weeks followed by 8 g/L for the next 2 weeks, without a washout period in between.
16397865|NCT03994315|Experimental|B. infantis EVC001 + LNT (6 g/L then 12 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 2 [B. infantis + LNT (6 g/L then 12 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 6 g/L for 2 weeks followed by 12 g/L for the next 2 weeks, without a washout period in between.
16397866|NCT03994315|Active Comparator|B. infantis EVC001 alone|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days.
16397867|NCT03994302||Immune toxicity induced by drugs and chemotherapies|Immune toxicity induced by drugs and chemotherapies Case reported in the World Health Organization (WHO) of immune toxicities(such as Antiphospholipid syndrome) of patient treated by a drug, with a chronology compatible with the drug toxicity
16397868|NCT03994289|No Intervention|Control|Participants remain seated for 2 hours after the intake of a standardized breakfast.
16397869|NCT03994289|Experimental|Motor-assisted cycling|Participants will perform 3 bouts of motor-assisted cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
16397870|NCT03994289|Experimental|FES cycling|Participants will perform 3 bouts of FES cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
16397871|NCT03994276|Placebo Comparator|Phase 1: Control|oral glucose tolerance test (OGTT): 58g Dextrose in 330ml water
16397872|NCT03994276|Active Comparator|Phase1: Chickpea Control|"sub-cellular Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring"
16397873|NCT03994276|Experimental|Phase1: Chickpea Powder|Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring
16397874|NCT03994276|Active Comparator|Phase 2: Control|Wheat bread: breakfast consisting of a 100% wheat bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
16397875|NCT03994276|Experimental|Phase 2: 30%Chickpea Powder|Wheat bread: breakfast consisting of a 70% wheat / 30% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
16397876|NCT03994276|Experimental|Phase 2: 60%Chickpea Powder|Wheat bread: breakfast consisting of a 40% wheat / 60% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
16397877|NCT03994263|Experimental|iTind arm|ITind device implant
16397878|NCT03994250|Active Comparator|Kinematic Arm|Kinematic Alignment for TKR surgery
16397879|NCT03994250|Placebo Comparator|Control Arm|Mechanical alignment for TKR surgery
16397880|NCT03994237||ALZHEIMER CAREGIVER|Caregiver available to accompany the patient to the consultation, helping calling for the first time the memory center, aidant who noticed a cognitive disorder help, having a family link identified with the patient
16397881|NCT03994211|Experimental|Arm A (core phase)|
16397882|NCT03994211|Experimental|Arm B (core phase)|
16397883|NCT03994211|Experimental|Extension phase|
16397884|NCT03994198|Experimental|Alpha-lactalbumin|Participants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
16397885|NCT03994198|Active Comparator|Collagen peptides|Participants will consume 60 g of collagen peptides for 3 training days.
16397886|NCT03994185|Experimental|Group Treated with stent graft|This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
16397887|NCT03994172|Experimental|teriparatide (TPTD) + the calcimimetic cinacalcet|Combination arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a 30-mg tablet of cinacalcet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
16397888|NCT03994172|Placebo Comparator|teriparatide (TPTD) + placebo|Monotherapy arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a placebo tablet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
16397889|NCT03994159|Experimental|PARO emotional robot|"Quasi-experimental before after study of the impact of the PARO robot on team dynamics among caregivers in geriatric wards caring for patients with dementia.
~Pre intervention period: no PARO robot. Post-intervention period: with the PARO robot."
16397890|NCT03994146|Experimental|Remifentanil tapering / Placebo abrupt cessation|Syringe one contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1 and Syringe two contains 40 ml NaCl 9 mg.ml-1 at an identical infusion rate. According to randomisation syringe one will then be tapered towards the end of surgery and syringe two abruptly stopped.
16397891|NCT03994146|Placebo Comparator|Placebo tapering / Remifentanil abrupt cessation.|Syringe one contains 40 ml NaCl 9 mg.ml-1 and Syringe two contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1. According to randomization syringe one will be tapered towards the end of surgery and syringe two abruptly stopped.
16397892|NCT03994133||Daily Home Dialysis patients|Daily Home Dialysis patients with low-flow dialisate for more than 3 months in France
16397893|NCT03994120|Active Comparator|Motor Cortex rTMS|Motor Cortex rTMS
16397894|NCT03994120|Active Comparator|PPC rTMS|PPC rTMS
16397895|NCT03994120|Placebo Comparator|vertex rTMS|vertex rTMS
16397896|NCT03994107|Experimental|PLD/albumin-bound paclitaxel/Trastuzumab|"First phase
~PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.
~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
~Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.
~Second phase
~PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.
~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
~Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6."
16397897|NCT03994081|Experimental|transcranial alternating current stimulation (tACS) at alpha|10 Hz tACS with an amplitude of 1 mA for 40 minutes. Uses tACS device.
16397898|NCT03994081|Sham Comparator|sham stimulation|Will include 20 seconds of ramp-up, 40 seconds of 10 Hz tACS at 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation. Uses sham tACS device.
16397899|NCT03994068|Experimental|VIVO mapping pre-procedure|15 patients with structurally normal heart and indication for PVC/VT catheter ablation, who will undergo pre-procedural non invasive mapping with VIVO mapping system.
16397900|NCT03994055|Experimental|Anti-inflammatory Diet|"Dietary intervention providing:
~Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).
~This group will include the consumption of foods that contain immune modulating nutrients:
~Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area."
16397901|NCT03994055|Active Comparator|Low residue Diet|"Dietary intervention providing:
~Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction."
16397902|NCT03994042|Experimental|Mental imagery neurofeedback training|Complete intervention with mental imagery neurofeedback training. Patients recruited by physioterapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
16397903|NCT03994029|Experimental|Polyphenol supplementation|120mg per day of powder polyphenol for 60 days
16397904|NCT03994029|Placebo Comparator|Placebo|1 tab PO QD per day of placebo for 60 days
16397905|NCT03994016|Experimental|WiseGuyz Participant|Individuals in this arm will receive the WiseGuyz program in their grade 9 year.
16397906|NCT03994016|No Intervention|Comparison Participant|Individuals in this arm will not receive any intervention in their grade 9 year, and will be used to create a matched comparison group for individuals in Arm 1 (WiseGuyz Participants).
16397907|NCT03993990|Experimental|Experimental group|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation).
16397908|NCT03993990|No Intervention|Control group|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
16397909|NCT03993977|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
16397910|NCT03993977|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
16397911|NCT03993964|Experimental|Experimental: Pyrotinib + SHR6390|Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd
16397912|NCT03993938|Experimental|Patients for TMVR|Patients with severe mitral regurgitation scheduled for TMVR procedure at Henry Ford Hospital - main campus.
16397913|NCT03993912|Experimental|Arm 1: Experimental group|"Daratumumab SC 1800 mg
~once every week for 8 weeks
~then once every other week for 16 weeks
~thereafter once every 4 weeks, until progression Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of a 28-day cycle, for the first 2 cycles, then discontinued"
16397914|NCT03993912|Sham Comparator|Arm 2: Control group|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
16397915|NCT03993899|Active Comparator|Cochlear implant (CI) with FineHearing Strategy then HDCIS|cochlear implant with FineHearing strategy first during 15 days then with HDCIS strategy during 15 days
16397916|NCT03993899|Active Comparator|CI with HDCIS Strategy then FS4|cochlear implant with HDCIS strategy first during 15 days then with FS4 strategy during 15 days
16397917|NCT03993886|Other|Arm 1|Adult (≥ 18 years of age) ambulatory patients diagnosed with heart failure and/or undergoing cardiac management.
16397918|NCT03993886|Other|Arm 2|Adult (≥ 18 years of age) patients undergoing chronic hemodialysis.
16397919|NCT03993886|Other|Arm 3|Adult (≥ 18 years of age) patients (i) implanted with the CardioMEMS HF device and (ii) diagnosed with heart failure and/or undergoing cardiac management.
16397920|NCT03993886|Other|Arm 4|Adult (≥ 18 years of age) patients diagnosed with heart failure and/or undergoing cardiac management.
16397921|NCT03993873|Experimental|Phase 1 TPX-0022|"The dose-escalation part of the study will determine the safety, tolerability, MTD, and RP2D of TPX-0022.
~A food-effect sub-study will be conducted once the RP2D has been determined.
~The dose-expansion part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.
~Dose expansion cohorts: Cohort I (NSCLC, METΔex14, MET Target Therapy Naive), Cohort II (NSCLC, METΔex14, MET Target Therapy Pre-treated), Cohort III (MET-amplified NSCLC, Hepatocellular Carcinoma (HCC), Gastric Cancer, or GEJ, Cohort IV (MET KD Mutations or MET Fusions)"
16397922|NCT03993860|Experimental|Intervention arm|Infants will be given fish powder called Chisense (Potamothrissa acutirostris) for a period of 6 months from the time they are 6 months up to the time they are 12 months.
16397923|NCT03993860|Placebo Comparator|Control arm|Infants will be given fish powder called sorghum powder for a period of 6 months from the time they are 6 months up to the time they are 12 months.
16397925|NCT03993834||Normal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test ≤ 15 seconds
16397926|NCT03993834||Abnormal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test > 15 seconds
16397927|NCT03993821|Experimental|Burosumab|Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
16397928|NCT03993808|Experimental|Educational/behavioral support for hypertension self efficacy|On-site monitoring of pulse, blood pressure, weight, and surveys, at Months 0,1,3,6; Four educational sessions to address: 1) basics about blood pressure (BP); 2) training in home BP monitoring with personal Omron 10 device; 3) information about Dietary Intervention to lower Systemic Blood Pressure (DASH) eating plan, recipes and cooking demonstrations; 4) education about BP medication adherence. Interventions occur on the background of Carter Burden Network's implementation of a DASH-congruent menus for congregant meals for all seniors attending the sites, including those not enrolled in the protocol.
16397929|NCT03993795|Experimental|A19010-W, B19010-F Use Group|Use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
16397930|NCT03993795|Experimental|B19010-F, A19010-W Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
16397931|NCT03993782|Experimental|A19010-R, B19010-O Use Group|Use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
16397932|NCT03993782|Experimental|B19010-O, A19010-R Use Group|Use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
16397933|NCT03993769|Experimental|A19010-F, B19010-F Use Group|Use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
16397934|NCT03993769|Experimental|B19010-F, A19010-F Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
16397935|NCT03993743|Experimental|CD147-CART|Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
16397936|NCT03993730|Other|Device Implantation|A prospective, blocked, randomised, controlled trial of primary prophylaxis ICD therapy or ILR insertion in patients with LVEF <45% and LGE on CMR.
16397937|NCT03993730|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF <45% and no LGE on CMR.
16397938|NCT03993717|Experimental|Three to six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine three to six months after kidney transplant
16397939|NCT03993717|Experimental|Twelve to thirty-six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine twelve to thirty-six months after kidney transplant
16397940|NCT03993704|Experimental|Active|450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days
16397941|NCT03993704|Placebo Comparator|Placebo|Placebo to match LHF-535 given once daily for 14 days
16397942|NCT03993691|Experimental|All Participants|Participants that have undergone standard of care, conventional 2D radiographic imaging of wrist for presumed or known scaphoid, wrist or distal radius fractures will receive the Tomo-E scans within two weeks.
16397943|NCT03993678|Experimental|Ablation + IP-001|"Ablation + IP-001 will be administered every 4 weeks for up to 6 treatment visits.
~Trial treatment will stop in case of tumor progression according to RECIST 1.1 or iRECIST or unacceptable toxicity.
~In all cases, toxicity assessment will continue for at least 100 days after discontinuing the last treatment of Ablation + IP-001 or until resolution of Ablation + IP-001-associated toxicity."
16397944|NCT03993665||affected|All patients with a histologically confirmed squamous cell carcinoma in the head and neck region
16397945|NCT03993665||control|Whartin tumour or pleomorphic adenoma of the parotid gland without malignant transformation
16397946|NCT03993652|Experimental|Screen-time and Snacking|Aim: to reduce both screen-time and unhealthy snacking
16397947|NCT03993652|Experimental|Screen-time only|Aim: to reduce screen-time only
16397948|NCT03993652|Experimental|Snacking only|Aim: to reduce unhealthy snacking only
16397949|NCT03993652|No Intervention|Control|Control
16397950|NCT03993639|Experimental|KRN125|Single SC administration
16397951|NCT03993626|Experimental|CXD101 and Nivolumab combination|"CXD101 will be presented as 10mg HPMC capsules and will be taken orally for 5 consecutive days repeated every three weeks on an outpatient basis.
~Nivolumab will be presented as a 10 mg/mL solution in a single-dose vial, administered as iv infusion over 60 mins, repeated every two weeks.
~CXD101 in combination with nivolumab will be administered in the Phase II component of the trial at doses determined in the Phase Ib component."
16397952|NCT03993613|Experimental|human apotransferrin|Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.
16397953|NCT03993600|Sham Comparator|Healthy volunteers|sweat test and skin biopsy
16397954|NCT03993600|Experimental|Patients with Cystic fibrosis|sweat test and skin biopsy
16397955|NCT03993600|Experimental|Heterozygotes subjects|sweat test and skin biopsy
16397956|NCT03993574|Other|Standard Care|The standard care group will receive baseline testing #1, standard care, baseline testing #2 and follow up testing approximately 8 weeks later.
16397957|NCT03993574|Experimental|Experimental|Experimental group will baseline testing #1, standard care, baseline testing #2 however then participate in a 6-week self-management intervention (either generic or vision specific self-management based) and then get 8 week follow up testing.
16397958|NCT03993561|Experimental|TSSP Group|A one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists will be provided
16397959|NCT03993548|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
16397960|NCT03993535|Other|SSRI or cognitive behavioral therapy|selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine) or cognitive-behavioral therapy, depending on availability and patient preference
16397961|NCT03993522|Experimental|CTO Exerciser|"2x Symptom limited cardiopulmonary exercise tests
~1x Sub-maximal cardiopulmonary exercise test (20 minutes)"
16397962|NCT03993509|Experimental|1 Hz Arm|Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered. Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
16397963|NCT03993509|Experimental|10 Hz Arm|Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI. Stimulation will occur while subjects are doing the Sternberg WM paradigm. The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
16397964|NCT03993496||EVAR Patients|Patients with infrarenal abdominal aortic aneurysm scheduled for elective endovascular aneurysm repair (EVAR) surgery will undergo intraoperative assessments of aneurysm wall pulsatility using ultrasound M-Mode.
16397965|NCT03993483|Experimental|Higher Load|One arm and one leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
16397966|NCT03993483|Experimental|Lower Load|The other arm and leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
16397967|NCT03993470|Experimental|experimental|The short foot exercise daily for 4 weeks
16397968|NCT03993470|Placebo Comparator|Control|A placebo excercise daily for 4 weeks
16397969|NCT03993457|Other|CRP<1, CRP consistent antidepressant selection|Participants with CRP<1 will be prescribed escitalopram
16397970|NCT03993457|Other|CRP> or equal to 1, CRP consistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed bupropion XL
16397971|NCT03993457|Other|CRP<1, CRP inconsistent antidepressant selection|Participants with CRP< 1 will be prescribed bupropion XL
16397972|NCT03993457|Other|CRP> or equal to 1, CRP inconsistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed escitalopram
16397973|NCT03993444|Experimental|communication and problem solving|Three smal group sessions (separate for employees (length 2 hours each) and for supervisors (length 2,5 hours each)) focused on training communication and problem solving skills.
16397974|NCT03993444|Active Comparator|psychoeducation|Two, 1 hour, lectures, one on the topic of pain and one on the topic of stress (for employees and supervisors combined).
16397975|NCT03993431|Experimental|Bio-active cement|Bio-active cement dispensed into the crown, and the crown was properly positioned over the tooth, cement was allowed to self-set for 20 seconds while maintaining gentle pressure on the crown, then flash cured using a light curing unit to remove excess cement, buccal and lingual surfaces were light cured for extra 10 seconds each.
16398011|NCT03993197|Experimental|Patients suffering from severe endometriosis and chronic pain|Patients suffering from severe endometriosis and chronic pain that have been identified during a gynecological consultation (individual or during a multidisciplinary team meetings) or during a pain consultation on the same site of the Croix-Rousse Hospital and having signed a consent form
16397976|NCT03993431|Active Comparator|Packable glass ionomer|Dentin conditioner was applied to the prepared crown surfaces for 20 sec, then rinsed, and dried. Capsule was activated, mixed for 10 seconds in an amalgamator, then loaded into the capsule applier to extrude cement directly into the crown, the crown was properly positioned over the tooth, cement was allowed to self-set for 2 minutes while maintaining gentle pressure on the crown, excess cement was removed before complete setting of cement.
16397977|NCT03993418|Experimental|Stevia arm|stevia drops
16397978|NCT03993418|No Intervention|Control arm|No change in diet
16397979|NCT03993405|Active Comparator|Control group:young|Sixty older subjects will be evaluated in this study.
16397980|NCT03993405|Active Comparator|Control Group:Middle-aged|Sixty middle-aged subjects will be evaluated in this study.
16397981|NCT03993405|Experimental|Experimental group:older|Sixty older subjects will be evaluated in this study.
16397982|NCT03993392|Experimental|TM buprenorphine followed by SUBLOCADE 300 mg|Participants with a diagnosis of OUD stopped use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, participants were administered 4 mg transmucosal (TM) buprenorphine. If tolerated without sensitivity, clinical signs of sedation, or precipitated withdrawal, 300 mg SUBLOCADE was administered. Following SUBLOCADE administration, participants remained in the clinic for approximately 48 hours and were assessed for safety and tolerability, as well as for any signs of precipitated withdrawal. Participants returned to the clinic weekly, until the end-of-treatment (EOT) visit (28 days after SUBLOCADE administration).
16397983|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-front line|histologically or cytologically confirmed solid tumor who have received no prior treatment
16397984|NCT03993379|Experimental|CX-072 in combination with ipilimumab|histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
16397985|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Progressed|histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
16397986|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Neoadjuvant|neo-adjuvant study in subjects with histologically confirmed solid tumor
16397987|NCT03993366|Experimental|Simple Meal Announcement|Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.
16397988|NCT03993366|Active Comparator|Full Carbohydrate counting|The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.
16397989|NCT03993353|Experimental|Tadalafil and Pembrolizumab|Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
16397990|NCT03993340||1|Rescue stenting group
16397991|NCT03993327|Experimental|Diagnostic (iodine I 124 monoclonal antibody M5A, PET scan)|Patients receive iodine I 124 monoclonal antibody M5A IV on day 0 and undergo PET scan on days 2 and 6.
16397992|NCT03993314|Active Comparator|Bupivacaine|
16397993|NCT03993314|Experimental|Chloroprocaine|
16397994|NCT03993301|Experimental|Probiotic A formula|Infant Formula with Lactobacillus salivarius AP-32.
16397995|NCT03993301|Experimental|Probiotic B formula|Infant Formula with Bifidobacterium lactis CP-9.
16397996|NCT03993301|Placebo Comparator|Regular formula|The infant formula without any probiotic.
16397997|NCT03993288|Experimental|Ferrum Lek|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
16397998|NCT03993288|Active Comparator|MALTOFER|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
16397999|NCT03993275||Patients with Stroke|30 Patients suffering a stroke will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 4 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
16398000|NCT03993275||Patients with Multiple Sclerosis|50 Patients suffering multiple sclerosis will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 3 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
16398001|NCT03993262|Experimental|Interventional|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
16398002|NCT03993262|Placebo Comparator|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
16398003|NCT03993249|Other|Chemoradiotherapy|standard of care chemo-radiotherapy
16398004|NCT03993249|Experimental|Combination|standard of care chemo-radiotherapy + Nivolumab
16398005|NCT03993236|Experimental|Rosuvastatin/Ezetimibe 10/10mg|The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
16398006|NCT03993236|Active Comparator|Rosuvastatin 20mg|The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days
16398007|NCT03993223||MTrP group|Healthy overhead athletes with upper trapezius myofascial trigger point
16398008|NCT03993223||Control group|Healthy overhead athletes without upper trapezius myofascial trigger point
16398009|NCT03993210|Experimental|GYN Cancer Cases|"Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.
~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
16398010|NCT03993210|Active Comparator|GYN Benign Controls|"Benign gynecological (GYN) fibroids.
~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
16398012|NCT03993184|Experimental|90-minute Hot Yoga Classes|This group will complete 3, 90-minute hot yoga classes weekly for 12 weeks.
16398013|NCT03993184|Experimental|60-minute Hot Yoga Classes|This group will complete 3, 60-minute hot yoga classes weekly for 12 weeks.
16398014|NCT03993184|No Intervention|Control|This group will maintain their current physical activity for 12 weeks.
16398015|NCT03993171|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16398016|NCT03993171|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16398017|NCT03993171|Experimental|Second dose determined by results of Cohort 1 of CNM-Au8|Second dose determined by results of Cohort 1 of CNMAu8 suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16398018|NCT03993171|Experimental|Dose determined by results of Cohort 1 of CNM-Au8|Dose determined by results of Cohort 1 of CNMAu8 suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16398019|NCT03993145|Experimental|Web-based lifestyle intervention|participants will be provided access to web-based lifestyle intervention program with personalized coaching from a clinical dietician
16398020|NCT03993132||Patients with type 2 diabetes|
16398021|NCT03993119||patients with NVAF|
16398022|NCT03993106|Experimental|Study Drug|All study participants will receive sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. All study participants will receive two doses of study drug on Days 1 and 15 of each 4 week cycle.
16398023|NCT03993093||HIV with OIs|Treatment naive HIV patients with OIs
16398024|NCT03993080|Experimental|Virtual reality relaxation|Virtual reality relaxation using virtual landscape and audio features and sound
16398025|NCT03993080|No Intervention|Treatment as usual|Seated in similar environment as experimental group for same time
16398026|NCT03993067|Active Comparator|Standard Treatment|Fibrin glue and Tabotamp on cut surface
16398027|NCT03993067|Experimental|Hemopatch|Hemopatch on cut surface
16398028|NCT03993054|Active Comparator|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
16398029|NCT03993054|Experimental|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
16398030|NCT03993041|Experimental|Cognitive-behavioral therapy (CBT)|Individuals in the CBT arm are expected to participate in a phone screen + baseline phase (one assessment) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
16398031|NCT03993041|Active Comparator|Waitlist Control|Individuals in the Waitlist Control arm are expected to participate in a phone screen + baseline phase (two assessments, 12 weeks apart) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
16398032|NCT03993015||Patients attending the Obstetrical Emergency Unit|Patients attending the Obstetrical Emergency Unit of CHU Montpellier during 2018
16398033|NCT03993002|Active Comparator|Normoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40"
16398034|NCT03993002|Active Comparator|Normoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60"
16398035|NCT03993002|Active Comparator|Hyperoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40"
16398036|NCT03993002|Active Comparator|Hyperoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60"
16398037|NCT03992989|Experimental|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
16398038|NCT03992989|Active Comparator|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
16398039|NCT03992976||Teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
16398040|NCT03992976||Parents of teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
16398041|NCT03992963|Active Comparator|Hearing Aid without frequency lowering enabled|
16398042|NCT03992963|Experimental|Hearing Aid with frequency lowering enabled|
16398043|NCT03992950|Experimental|Cricoid pressure|Cricoid pressure is applied during direct and video laryngoscopies
16398044|NCT03992950|Experimental|Paratracheal pressure|Cricoid pressure is applied during direct and video laryngoscopies
16398045|NCT03992937|Experimental|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
16398046|NCT03992937|Active Comparator|LNG-IUS|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.
16398047|NCT03992924|Active Comparator|angiography-guided PCI|
16398048|NCT03992924|Experimental|FFR-guided PCI|
16398049|NCT03992924|Experimental|OCT-guided PCI|
16398050|NCT03992911|Experimental|FOLFSIM Plus Teripalimab|Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab
16398051|NCT03992911|Active Comparator|EP/EC|Etoposide plus Cisplatin or Carboplatin
16398052|NCT03992898||Chronic hepatitis cohort|In this cohort, patients were defined as type A acute-on-chronic liver failure (ACLF) patients who have chronic liver disease but without cirrhosis.
16398053|NCT03992898||Cirrhosis cohort|In this cohort, patients were defined as type B and type C ACLF patients with cirrhosis.
16398054|NCT03992885|Experimental|combination therapy with ectiecinib, pemetrexed and platinum|ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally;Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle, a total of 6 cycles.Maintenance therapy: ectinib: ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally, pemetrexed 500mg/m2,d intravenous infusion, day 1,21 days for a cycle
16398055|NCT03992872|Experimental|PXVX0317, a purified CHIKV VLP vaccine in Alhydrogel adjuvant|All study participants will receive the same Investigational Product according to the same schedule. The alphavirus vaccine naïve subjects will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity.
16398056|NCT03992859|Experimental|serratus catheter|Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine
16398057|NCT03992859|No Intervention|standard treatment|Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine
16398058|NCT03992846|Experimental|Linzagolix 75 mg|
16398059|NCT03992846|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
16398060|NCT03992846|Placebo Comparator|Placebo|
16398061|NCT03992833|Experimental|lung cancer screening|"Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.
~At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected."
16398062|NCT03992820|Experimental|TENS arm (trial arm)|The trial group will have the TENS (transcutaneous electrical nerve stimulator) to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.
16398063|NCT03992820|Other|EMLA arm (Control arm)|The control group will have EMLA (Eutatic mixture of local anaesthetic) applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution.
16398064|NCT03992807|Experimental|A patient decision aid|A patient decision aid that includes not only the standard general information, but also the quantitative risk information on the possible outcomes of cataract surgery as well as value clarification exercise.
16398065|NCT03992807|Active Comparator|A usual education booklet|A traditional booklet with standard general information developed by the National Eye Institute (NEI) to help patients understand cataract.
16398066|NCT03992794||Total patients|Consecutive patients presenting to the ED with either a suspected or documented infection in which blood samples were taken during routine. An extra blood sample was taken to measure PCT & MR-proADM using the Samsung IB10 point of care assay.
16398067|NCT03992781||Newly prescribed tofacitinib|patients who were newly prescribed tofacitinib at baseline and who scored at least 11 points on CUDOS scale
16398068|NCT03992755|Experimental|LIQ861 Inhaled Treprostinil|LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg. LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients. Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
16398069|NCT03992742|Experimental|Intervention Group (subgroup A+B+C)|Personalized instant messaging (PIM) + optional cocktail interventions (OCI) + AWARD advice + referral card + warning leaflet+ COSH booklet
16398070|NCT03992742|Experimental|Control Group (subgroup D+E+F)|Regular instant messaging (RIM) + personalized instant messaging (PIM) + AWARD advice + referral card + warning leaflet+ COSH booklet
16398071|NCT03992729||Tildrakizumab-Exposed Cohort|Exposure to tildrakizumab for the treatment of an approved indication
16398072|NCT03992729||Disease-Matched Comparison Cohort|No exposure to tildrakizumab at any time in the current pregnancy
16398073|NCT03992716|Experimental|SmofKabiven® extra Nitrogen|Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
16398074|NCT03992716|Active Comparator|Olimel N9E|Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
16398075|NCT03992703||Standard strategy|This group has been treated with antibiotic susceptibility testing on a conventional Mueller-Hinton medium with reading after 24 hours of incubation (Period 1: from July 1, 2015 to December 31, 2016)
16398076|NCT03992703||Rapid strategy|This group has been treated with antibiotic susceptibility testing on a rapid Mueller-Hinton medium after 8 hours of incubation (period 2: January 1, 2017 to June 30, 2018)
16398077|NCT03992690|Experimental|WANR protocol|Including training with Brain-machine interfaces, visuo-tactile feedback and assisted locomotion
16398078|NCT03992690|Active Comparator|Classical physiotherapy protocol|Training with classical physiotherapy protocol
16398079|NCT03992677||Brugada VF|Confirmed Brugada Syndrome by either Spontaneous or drug induced Type 1 ECG, confirmed cardiac arrest or appropriate ICD therapy for potentially lethal arrhythmia.
16398080|NCT03992677||Brugada relative|Relatives of Brugada syndrome patients with proven no pathology by Ajmaline challenge
16398081|NCT03992677||Ventricular ectopy|Patients undergoing ablation with ECGi system for other arrhythmias -these patients will be similar to our original controls and provide a repeat set of controls.
16398082|NCT03992677||AF|Patients with AF undergoing ablation with ECGi system (n=10). These patients will be older and have varying RR intervals which may cause a falsely low V-CoS.
16398083|NCT03992677||Ischaemic VF|Out-of-hospital cardiac arrest primary PCI with full recovery of left ventricular function and full revascularisation (n=10) - the purpose of this group is to confirm that the changes detected in our SCD group are not secondary to the SCD event. These are patients who have had a cardiac arrest secondary to coronary occlusion, but have made a full recovery with normal LGE-MRI and no indication for ICD.
16398084|NCT03992677||Athletes|Athletic Hypertrophy (n=10) - Elite athletes often have physiological LVH and abnormal ECGs at rest. It is unclear if these variations in activation will lead to a decrease in V-CoS.
16398085|NCT03992664|Experimental|EDUCATION|If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
16398086|NCT03992664|No Intervention|NON-INTERVENTION|The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
16398087|NCT03992651|Experimental|Experimental group|One single group of healthy subjects
16398088|NCT03992638|Experimental|L-PRF membrane|Periodontal plastic surgical procedures (coronally advanced flap, CAF) in combination with a double layer autologous leucocyte and platelet-rich fibrin (L-PRF) membrane.
16398089|NCT03992638|Active Comparator|Control|CAF
16398090|NCT03992612|Experimental|CBT for chronic pain|"Cognitive-behavioral treatment with twelve group sessions (6-8 subjects) with a duration of between 90 and 120 minutes and a weekly periodicity (total hours1080).
~components of the intervention are: reducing pain and emotional discomfort, increasing adaptive behaviors, changing irrational thoughts associated with pain, increasing self-efficacy, reducing anxiety, decreasing catastrophic thoughts and increasing healthy habits"
16398091|NCT03992612|Experimental|MBPM- Minfulness- Based Pain Management|"Psychological intervention with 8 group sessions ( 8 -10 subjects) with a duration of 2 and a half hours per session and a weekly periodicity (total hours 1080).
~It is centered on training on the awareness of physical, cognitive and emotional sensations, and the attentional processes to become an observer of one's own thoughts and emotions. With the aim to provide greater flexibility to manage pain"
16398092|NCT03992599||Laparoscopic modified central mesocolic excision|Patients receiving laparoscopic colectomy with the concept of modified complete mesocolic excision for right-sided colon cancer
16398093|NCT03992586|Experimental|Pink lenses|Pink-colored lenses
16398094|NCT03992586|Placebo Comparator|Clear lenses|Clear lenses
16398095|NCT03992573|Experimental|Study group|
16398096|NCT03992573|No Intervention|Control group|
16398097|NCT03992560|No Intervention|Standard CRT implantation|
16398098|NCT03992560|Experimental|MRI guided CRT implantation|
16398099|NCT03992547|Experimental|robot assisted gait traing|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks.
16398100|NCT03992534|Experimental|LACTIN-V|"Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)
~Dosage: LACTINV is a powder formulation of Lactobacillus crispatus CTV-05 provided in a prefilled vaginal applicator at a dose of 2 x 10^9 CFU of L. crispatus CTV-05. Route of Administration: LACTIN-V powder is administered vaginally using a specially designed applicator.
~Formulation: LACTIN-V is supplied as a pre-filled, single-use applicator. Each applicator contains LACTIN-V powder at a dose of 2 x 10^9 CFU. The LACTIN-V powder formulation contains L. crispatus CTV-05 and a preservation matrix containing inactive excipients of non-animal origin."
16398101|NCT03992508|Other|complex decongestive treatment|In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
16398102|NCT03992508|Experimental|intermittent pneumatic compression|In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
16398103|NCT03992495||Neck pain|People suffering from neck pain at the time of recruitment
16398104|NCT03992495||Healthy|Participants with no significant past neck pain, chronic pain or other relevant medical disorders.
16398105|NCT03992482|Experimental|IVIG-Eye Drop|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
16398106|NCT03992482|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl)
16398107|NCT03992469|Experimental|BFAHF-2|Low dose BFAHF-2 (29 mg/kg/d divided two times a day) for 2 weeks followed by a full dose (71mg/kg/d divided two times a day) for 6 weeks
16398108|NCT03992469|Placebo Comparator|Placebo|tablets are identical in appearance to BFAHF-2 tablets
16398109|NCT03992456|Experimental|Arm A (panitumumab)|Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
16398144|NCT03992209|Other|Standard handwashing by anesthesia provider|Anesthesia provider will conduct patient care per their usual standard practice in the operating room.
16419896|NCT03840993|Placebo Comparator|Placebo|Placebo, IV, over 16 weeks
16398110|NCT03992456|Active Comparator|Arm B (regorafenib, trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12, or regorafenib PO QD on days 1-21, at the discretion of the treating physician. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
16398111|NCT03992443|Experimental|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 milligrams (mg) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose, if needed, at min 90. Assessments were performed at min 30, 60, 90, 120, 150, and 180.
16398112|NCT03992430|Experimental|Part 1: Eteplirsen|Patients will receive high dose level 1 of eteplirsen once weekly for at least 4 weeks, followed by high dose level 2 of eteplirsen once weekly for at least 4 weeks. Patients will continue treatment with the selected high dose as a distinct cohort for up to a maximum of 144 weeks.
16398113|NCT03992430|Active Comparator|Part 2: Eteplirsen 30 mg/kg|Patients will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
16398114|NCT03992430|Experimental|Part 2: Eteplirsen-High Dose Level 1|Patients will receive high dose level 1 of eteplirsen once weekly before the selection of high dose occurs and then the selected high dose once weekly for up to 144 weeks.
16398115|NCT03992430|Experimental|Part 2: Eteplirsen-High Dose Level 2|Patients will receive high dose level 2 of eteplirsen once weekly before the selection of high dose occurs and then the selected high dose once weekly for up to 144 weeks.
16398116|NCT03992417||Participants with AD|Adult and adolescent participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician
16398119|NCT03992391|No Intervention|Qualitative Interviews|Qualitative Interviews with adolescents, their parents and clinicians.
16398120|NCT03992391|Experimental|Open Pilot|Open-label pilot group of adolescents (n=10) in a suicide prevention intensive outpatient program
16398121|NCT03992391|Experimental|Open-label trial|Open-label trial of adolescents (n=40) in a suicide prevention intensive outpatient program
16398122|NCT03992378|Experimental|Active Treatment|Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
16398123|NCT03992378|Sham Comparator|Sham Control|Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
16398124|NCT03992365|Experimental|Quiklean®|Quiklean® (32 tablets)
16398125|NCT03992365|Active Comparator|GroKlean-Prep with Dulcolax®|2 sachets of Klean-Prep with 1 tablet of Dulcolax®
16398126|NCT03992352||Age 60+ with planned HCT for Hematologic Malignancy|Subjects 60 years or older with a planned allogeneic transplantation for a hematologic malignancy.
16398127|NCT03992339|Experimental|ATG-010|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.
16398128|NCT03992326|Experimental|TIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
16398129|NCT03992313|Experimental|Facility-based testing intervention|Community Health Workers (CHWs) will provide information inside their groups on the possibility to be tested in health centers for HCV infection. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center that will be in charge to give result to the participant and to refer to care in case of active infection.
16398130|NCT03992313|Experimental|Community-based testing intervention|After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the village of participants. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS and sent to Phnom Penh for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center of each cluster and CHWs will be in charge to give result to the participant and to refer to care in case of active infection.
16398131|NCT03992300|Experimental|Intraoral scanning|An intraoral scanning is taken. An auxiliary device is used to achieve better accuracy. A zirconia framework is produced
16398132|NCT03992300|Active Comparator|Conventional scanning|A conventional elastomeric impression is taken and a zirconia framework is produced
16398133|NCT03992287|Experimental|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
16398134|NCT03992287|Placebo Comparator|Placebo|Placebo for 12 weeks
16398135|NCT03992274|Active Comparator|Standard implementation|During Standard Implementation, sites will use standard Yunnan Center for Disease Control and Prevention strategies to introduce HIV prevention innovations.
16398136|NCT03992274|Experimental|Enhanced implementation|During Enhanced Implementation, sites will transition to receive enhanced Implementation Support to plan and implement PrEP.
16398137|NCT03992261|Experimental|Halobetasol Propionate Foam|2 weeks of application, 2 times daily
16398138|NCT03992248|Experimental|Time Restricted Feeding|Participants are instructed to eat within a limited time frame during the day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
16398139|NCT03992248|Other|Control|Participants are instructed to spread their habitual food intake over at least 14hrs per day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
16398140|NCT03992235|Experimental|Study Group|Chest physiotherapy + educational material
16398141|NCT03992235|Other|Control group|Chest physiotherapy
16398142|NCT03992222|Experimental|administration of a physical exercise programme|administration of a Physical exercise program for 24 weeks.
16398143|NCT03992222|No Intervention|control|
16398145|NCT03992209|Active Comparator|Protocolized hand washing by anesthesia provider|Anesthesia provider will conduct patient care using a personal hand washing device to optimize hand washing and captures hand washing events in real time.
16398146|NCT03992196|Experimental|Rotigotine|Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
16398147|NCT03992170|Experimental|Single Arm|"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).
~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."
16398148|NCT03992157|Experimental|holter-ECG|Implementation of an ECG Holter during hospitalisation patient.
16398149|NCT03992157|No Intervention|Crontrole|No implementation of an ECG Holter
16398150|NCT03992144|Experimental|amoxicillin|single preoperative oral 500 mg dose of Amoxicillin before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
16398151|NCT03992144|Experimental|metronidazole|single preoperative oral 400 mg dose of metronidazol before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
16398152|NCT03992144|Active Comparator|conventional group|conventional therapy for prevention of dry socket post operative; 400mg metrinidazol 3 times a day for 5 days 500mg of amooxicillin 2 times a day for 5 days painkiller 48 hours after extraction then sos
16398153|NCT03992131|Experimental|Arm A: Oral rucaparib and oral lucitanib|"Phase 1b (Dose escalation): Up to 55 patients with advanced or metastatic solid tumors.
~Phase 2 (Dose expansion): Up to 80 patients with High Grade Ovarian Cancer."
16398154|NCT03992131|Experimental|Arm B: Oral rucaparib and IV sacituzumab govitecan|"Phase 1b (Dose escalation): Up to 55 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, platinum resistant Ovarian Cancer, or a tumor with a BRCA1, BRCA2, PALB2, RAD51C, or RAD5/1D mutation
~Phase 2 (Dose expansion): Up to 139 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, or platinum resistant Ovarian Cancer"
16398155|NCT03992118|Experimental|Feeding Challenges|Parents will be coached to implement strategies to address factors contributing to feeding challenges based on a multidisciplinary assessment using the medico-oral-behaviour-sensory-environment (MOBSE) approach.
16398156|NCT03992105|Other|historical cohort|150 homeless patients in crisis, identified from an extraction of the database of psychiatric emergencies of the same territory, and matched for age, sex, and main diagnosis.
16398157|NCT03992092|Experimental|C-Mac VS|Intubation using the C-MAC Video Stylet
16398158|NCT03992092|Active Comparator|FB|Intubation using the Flexible Bronchoscope
16398159|NCT03992079|No Intervention|Control|The control group will receive standard preoperative and postoperative directions, with the anesthesiologist and surgeon's preferences for analgesia during and after surgery.
16398160|NCT03992079|Experimental|Experimental|The experimental group will receive routine directions for surgery and a ReCOVER patient education document on the Enhanced Recovery protocol, with instructions on preoperative preparation, postoperative wound care, pain management, preventing and managing constipation, activity limitations, and return precautions. The information sheet will be provided to patients in clinic and reviewed with a member of the healthcare team to ensure an understanding of the plan.
16398161|NCT03992066|Experimental|Vadadustat 600 mg|Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
16398162|NCT03992066|Experimental|Vadadustat 750 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
16398163|NCT03992066|Experimental|Vadadustat 900 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
16398164|NCT03992066|Other|Erythropoiesis-stimulating agent|Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
16398165|NCT03992053|Active Comparator|Group 1|conventional 2-D fluoroscopy guidance as the first choice of guidance
16398166|NCT03992053|Active Comparator|Group 2|3-D CT guidance as the first choice of guidance
16398167|NCT03992040||Reinforced SSIAD (SSIADR arm )|"Reinforced Home Nursing Care Services: Patients with a score between 11 and 21 on the regional public health authorities (ARS) score.
~This arm will benefit from better coordination and delivery of care, which can reduce hospitalizations and visits to emergency departments"
16398168|NCT03992040||Classic SSIAD (Control arm)|Classic Home Nursing Care Services. For this arm, no direct benefit is expected since taking care, even for the heaviest patients, corresponds to current practice.
16398169|NCT03992027|Experimental|Immediate CF-CBT Intervention|This group will enter immediately into the 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT).
16398170|NCT03992027|Other|Waitlist control|This group will enter into the same 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT) 3 months after enrollment.
16398171|NCT03992014|Experimental|Linerixibat + [14C]-linerixibat|Subjects will receive a single oral dose of linerixibat 90 milligram (mg) (2*45 mg) tablets concomitantly with [14C]-linerixibat 100 microgram (approximately 9.25 kilobecquerel; 250 nano curie) IV infusion for 3 hours, after an overnight fast that continues for 2 hours after the oral dose/start of IV infusion, small standard high-fat meal will be given on Day 1 in treatment Period 1; followed by a single oral dose of [14C]-linerixibat 90 mg (approximately 4.96 megabecquerel; 134.1 micro curie) solution on Day 1 in treatment Period 2. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
16398172|NCT03992001|Experimental|Sequence A-B|Patients in this arm will receive blood component A for 6 months and blood component B for the next 6 months
16398173|NCT03992001|Experimental|Sequence B-A|Patients in this arm will receive blood component B for 6 months and blood component A for the next 6 months
16398174|NCT03991988|Experimental|Montelukast Group|Montelukast (10, 20, or 40 mg)
16398175|NCT03991988|Placebo Comparator|Placebo Group|Matched placebo pill
16398176|NCT03991975|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16398177|NCT03991962|Experimental|mFOLFIRINOX followed by SBRT|Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
16398178|NCT03991949|Experimental|Experimental Infant Formula|Ready-to-feed, milk-based formula
16398179|NCT03991936|Placebo Comparator|Placebo|Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
16398180|NCT03991936|Experimental|Triamcinolone Acetonide 2.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
16398181|NCT03991936|Experimental|Triamcinolone Acetonide 5.0 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
16398182|NCT03991936|Experimental|Triamcinolone Acetonide 7.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
16398183|NCT03991936|Experimental|Triamcinolone Acetonide 10 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
16398184|NCT03991923|Experimental|Non-ischemic heart preservation (NIHP)|Continous cold cardioplegic perfusion of hearts
16398185|NCT03991923|Active Comparator|Ischemic cold static storage (ICSS)|Standard preservation technique
16398186|NCT03991910|Placebo Comparator|control|control patients will be given a placebo
16398187|NCT03991910|Experimental|treatment|Ramipril 5 mg treatment group
16398188|NCT03991897|Experimental|Ketogenic diet|"the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.
~Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not."
16398189|NCT03991897|Active Comparator|Isocaloric diet|During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
16398190|NCT03991884|Experimental|Dose -1 (0.3 mg/m^2)|Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16398191|NCT03991884|Experimental|Dose 1 (0.3 mg/m^2)|Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16398192|NCT03991884|Experimental|Dose 2 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16398193|NCT03991884|Experimental|Dose 3 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16398194|NCT03991871|Placebo Comparator|Control Group|35 hours ECP treatment, initial treatment pressure is 75 mmHg
16398195|NCT03991871|Experimental|Intervention Group|35 hours ECP treatment, initial treatment pressure is 300 mmHg
16398196|NCT03991858|Other|Phone follow-up|Phone follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
16398197|NCT03991858|Experimental|Telerehabilitation follow-up|Telerehabilitation follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
16398198|NCT03991845|Experimental|Low dose Vit D|All Patients belonging to arm 1 will be treated with low dose oral Vit D (2000 IU/day) for 12 weeks
16398199|NCT03991845|Active Comparator|High dose Vit D|All patients in this group will be treated with high dose oral Vit D (60,000 IU/week) for 12 weeks
16398200|NCT03991845|No Intervention|Placebo|No Vit D supplementation will be given to patients in this group
16398201|NCT03991832|Experimental|Cohort A: IDH mutated glioma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
16398202|NCT03991832|Experimental|Cohort B: IDH mutated cholangiocarcinoma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
16398203|NCT03991832|Experimental|Cohort C: Other IDH mutated solid tumors|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
16398204|NCT03991819|Experimental|Phase 1|"Cycle 1 = 28 days and Cycle 2 and Future Cycles = 21 days
~Binimetinib, by mouth (orally): Level 1: 45 mg, twice a day, continuously; Level -1: 30 mg, twice a day, continuously; Level -2: 30 mg, twice a day, for Days 1-14 of each cycle only
~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 8 of Cycle 1, then Day 1 of Cycle 2 and future cycles."
16398205|NCT03991819|Experimental|Phase 1b|"All Cycles = 21 days
~Binimetinib, by mouth (orally), at the best dose found in Phase 1 of the study, twice a day, continuously.
~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 1 of every cycle."
16398206|NCT03991793||Sepsis|Severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
16398207|NCT03991793||Control|Absence of severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
16398208|NCT03991780|Experimental|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib (tablet taken orally) twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
16398209|NCT03991767|Experimental|period 1|"Period 1: Retrospective period:
~Collection of data from the 12 months preceding the start of the research of hospitalized patients:
~number of hospitalizations,
~number of HIV serologies performed,
~number of patients with socio-demographic criteria justifying HIV screening.
~Start of research: Implementation of the POP-UP electronic alert
~Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.
~Six possibility to answer:
~Patient accept to participate: patient is include and receive HIV serology during their hospitalization.
~Not time to answer to the alert
~Patient already has a serology less than 3 months old
~Patient followed for a known HIV infection.
~Patient who refused the test
~Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization."
16398210|NCT03991754|Experimental|Amiodarone|Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
16398211|NCT03991754|Placebo Comparator|Control|Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
16398212|NCT03991741|Experimental|melanoma|
16398213|NCT03991741|Experimental|head and neck cancer|
16398215|NCT03991715|Experimental|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
16398216|NCT03991689|Experimental|the six weeks solution-focused pain management groups|
16398217|NCT03991676|Experimental|Values-Based Behavioral Treatment|
16398218|NCT03991650||Control|"n=30 healthy participants will be recruited using social networks and leaflets of information distributed by the research team at the Hospital Cliníc de Barcelona.
~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants' data will also be monitored with a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
16398219|NCT03991650||Experimental|"The recruitment process will be carried out in patients of external consultations and the day hospital of the Addictions Unit at the Hospital Clinic of Barcelona.
~n=30 patients with Anxiety and Alcohol Use Disorder.
~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants will also be monitored using a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
16398220|NCT03991637|Experimental|NICMP Spectral Reading|Non-invasive spectral data is collected from this arm to function as the intervention of interest.
16398221|NCT03991637|Active Comparator|Venipuncture CMP|"A standard CMP blood draw is performed to function as the gold standard reference value.
~Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method."
16398222|NCT03991624|Other|Alzheimer's patients (lack of executive functions)|
16398223|NCT03991624|Other|control (lack of executive functions)|
16398224|NCT03991624|Other|Alzheimer's patients (lack of working memory)|
16398225|NCT03991624|Other|control (lack of working memory)|
16398226|NCT03991624|Other|Alzheimer's patients (lack of episodic memory)|
16398227|NCT03991624|Other|control (lack of episodic memory)|
16398228|NCT03991611|Experimental|IPREA3 program|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for at least 5 months
16398229|NCT03991611|Other|Intermediate group|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for less than 5 months
16398230|NCT03991611|Active Comparator|Standard care|Standard care
16398231|NCT03991598|Experimental|intervention|EDs 1 to 7 will then be randomly phased-in INT every 3 months.
16398232|NCT03991598|No Intervention|control|During the first 6 months and throughout CTRL time
16398233|NCT03991585|Experimental|Three times a week MCRF|Participants in this arm will participate in the MCRF intervention sessions three times a week for 12 consecutive weeks.
16398234|NCT03991585|Experimental|One time a week MCRF|Participants in this arm will participate in the MCRF intervention sessions one time a week for 12 consecutive weeks.
16398235|NCT03991572|Active Comparator|Real Stimulation|The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
16398236|NCT03991572|Sham Comparator|Sham Stimulation|The procedure of Sham Stimulation protocol was performed by a placebo coil,lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
16398237|NCT03991559|Active Comparator|Dose-Escalation, intranasally|With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
16398238|NCT03991559|Active Comparator|Dose-Escalation, inhalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
16398239|NCT03991546|Experimental|Acceptance and Commitment Therapy|Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy.
16398240|NCT03991546|No Intervention|Control group|Subjects randomizing into this arm did not receive the text message study intervention.
16398241|NCT03991533||affected|patients with a histologically confirmed head and neck tumour
16398242|NCT03991533||control|histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation
16398243|NCT03991520|Experimental|Active Treatment with Anakinra|10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
16398244|NCT03991520|Placebo Comparator|Standard Comparison|10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
16398245|NCT03991494|Experimental|Pamiparib|
16398246|NCT03991481|Experimental|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
16398247|NCT03991481|Active Comparator|Liquid-stored platelets|Platelets that have been liquid stored, with an expiry of 5 days.
16398248|NCT03991455|Other|Apyx device treatment|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.
16398249|NCT03991442|Experimental|BR1010 and Fimasartan/Amlodipine placebo|BR1010 or Fimasartan/Amlodipine
16398250|NCT03991442|Active Comparator|BR1010 placebo and Fimasartan/Amlodipine|BR1010 or Fimasartan/Amlodipine
16398251|NCT03991429||Group 1|Patients with BPH and significant improvement in storage symptoms after BOO procedures
16398252|NCT03991429||Group 2|Patients with BPH who have persistent storage symptoms after BOO procedures
16398253|NCT03991429||Group 3 (Control group)|Men without LUTS who are planning to undergo radical prostatectomy
16398254|NCT03991416|Experimental|Understanding Your Baby|Understanding Your Baby plus postnatal care as usual
16398255|NCT03991416|Active Comparator|Care As Usual|Postnatal care as usual
16398256|NCT03991403|Experimental|Atezolizumab group|
16398257|NCT03991403|Active Comparator|Control group|
16398258|NCT03991390|Experimental|Core stability and feedback visual laser exercises|"Two complementary protocols for the treatment of balance after stroke in patients with pusher syndrome were designed, including multidimensional physiotherapy exercises. Both protocols differentiate 3 levels of difficulty: Second level requires maintenance of balance sitting 5, if the patient does not succeed, stays in level 1. To move to L3 patients must stay seated 10''. Each exercise is repeated 5 times, always considering patients' levels of fatigue and safety.
~Visual feedback with laser (Motion Guidance Clinical Kit, approved for therapeutic use): Through visual aid, patients' verticality is achieved by encouraging their active participation in correcting the imbalance while performing the exercises.
~Core stability: The exercises have to be adapted for the pusher patient avoiding overuse of the less affected side of the body, and strengthening the muscles that stabilize the trunk."
16398259|NCT03991390|Active Comparator|Control stroke|Rehabilitation program is based on a comprehensive approach, where the patient follows a personalized plan of exercises according to the deficits, the previous situation and personal concerns.
16398260|NCT03991377|Experimental|EMDR therapy|Patients in the psychotherapy intervention will receive up to 20 individual sessions of EMDR, weekly sessions, of 60 minutes each, using the standard EMDR therapy protocol developed by Shapiro to treat both current and past trauma-related symptom.
16398261|NCT03991377|Active Comparator|Treatment as usual|Multidisciplinary approach that includes pharmacological treatment and psychological support.
16398262|NCT03991364|Experimental|Constant gait speed group|experimental group that applied the speed of the robot-assisted gait training constantly
16398263|NCT03991364|Other|Increasing gait speed group|control group that applied the gradual increase of the speed of the robot-assisted gait training
16398264|NCT03991351||Men aged 18-34|Participants will be males aged 18-34. Each individual will be exposed to images of men with either a muscular, skinny or overweight physique or the control images of landscapes.
16398265|NCT03991325||difficult laryngoscopy|group of patients with Cormack and Lehane grade III or IV
16398266|NCT03991325||easy laryngoscopy|group of patients with Cormack and Lehane grade I or II
16398267|NCT03991312|Experimental|Part 1|"Period 1: Day 1, participants will receive 20 milligrams (mg) of mitapivat sulfate.
~Period 2: Day 1 to Day 9, participants will receive 200 mg of itraconazole, once daily and 20 mg of mitapivat sulfate on Day 5."
16398268|NCT03991312|Experimental|Part 2|"Period 1: Day 1, participants will receive 50 milligrams (mg) of mitapivat sulfate.
~Period 2: Day 1 to Day 12, participants will receive 600 mg of rifampin, once daily and 50 mg of mitapivat sulfate on Day 8."
16398269|NCT03991299|Experimental|Botox Arm|Botox will be injected into duodenums of subjects via endoscopy.
16398270|NCT03991286|Placebo Comparator|Placebo|"Drug: Placebo
~Ovulatory Agent:
~Clomiphene Citrate"
16398271|NCT03991286|Experimental|experimental|"Drug: Astaxanthin 8mg
~Drug: Ovulatory Agent Clomiphene Citrate"
16398272|NCT03991273|Experimental|Y-M2M©|a group-based M2M© program conducted onsite at a local YMCA
16398273|NCT03991273|Experimental|B-M2M©|a blended program that provides Y-M2M© and a home-based M2M© via videoconferencing
16398274|NCT03991260||The tested injected doses of 99mTc- ADAPT6 500 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 500 µg. Subjects withdrawn from the study for any reason will be replaced.
16398275|NCT03991260||The tested injected doses of 99mTc- ADAPT6 1000 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 1000 µg. Subjects withdrawn from the study for any reason will be replaced.
16398276|NCT03991247|Experimental|Internet Behavioral therapy program + spa therapy|Patient following a program of computerized behavioral therapy for insomnia management during a 3 weeks spa treatment.
16398277|NCT03991247|Active Comparator|Internet Behavioral therapy program at home|Patient following a program of computerized behavioral therapy for insomnia management during 3 weeks at home.
16398278|NCT03991234|Experimental|Coordinated Reading and Math Intervention|Coordinated intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction addressing similar skills as those addressed in the reading intervention arm & similar skills as the math intervention arm.
16398279|NCT03991234|Active Comparator|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction designed to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
16398280|NCT03991234|Active Comparator|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge, counting strategies, and arithmetic skill.
16398281|NCT03991234|No Intervention|Business-as-usual Control|Participation in the school's typical reading and math classroom instruction and, if designated by the school, its supplemental program.
16398282|NCT03991221|Other|Dental exam by orthodontic non-specialists|Detection of the presence of at least one malocclusion by orthodontic non-specialists with the graphic chart
16398283|NCT03991221|Other|Dental exam by orthodontic experts|Detection of the presence of at least one malocclusion by orthodontic experts
16398284|NCT03991208|Experimental|Rest|Pharmacokinetics of Single Dose Malarone at Rest
16398285|NCT03991208|Experimental|Exercise|Pharmacokinetics of Single Dose Malarone under exercise in a heat chamber
16398286|NCT03991195|Experimental|Probiotic supplemented group with aMCI|Thirty participants in this group will take Bifidobacterium for three months.
16398287|NCT03991195|Placebo Comparator|Placebo group with aMCI|Thirty participants in this group will take placebo for three months.
16398288|NCT03991182|Experimental|Community-based parenting group|The community-based parenting group will include 39 health zones and 585 caregiver-child dyads
16398289|NCT03991182|Active Comparator|Control group|The control group will include 39 health zones and 585 caregiver-child dyads
16398293|NCT03991143|Experimental|ATH3G10|Phosphorylcholine human monoclonal antibody (ATH3G10)
16398294|NCT03991143|Placebo Comparator|Placebo|Placebo to ATH3G10, 0.9% sodium chloride
16398295|NCT03991130|Experimental|High Dose IL-2 and Nivolumab|
16398296|NCT03991117|Experimental|80 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
16398297|NCT03991117|Experimental|80 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
16398298|NCT03991117|Experimental|30 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
16398299|NCT03991117|Experimental|30 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
16398300|NCT03991104|Experimental|SOX-based Chemoradiotherapy|IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
16398301|NCT03991091|Experimental|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm
16398302|NCT03991091|Active Comparator|continuation of oxytocin administration|Standard care in France, i.e. when oxytocin is started during the latent phase of the 1st stage, administration of oxytocin is continued during the active 1st stage and during the 2nd stage if the fetal heart rate is reassuring.
16398303|NCT03991065|Experimental|with endoscopy|high digestive endoscopy
16398304|NCT03991065|No Intervention|without endoscopy|no endoscopy
16398305|NCT03991052|Active Comparator|EV1000 monitor|MAP management will be done as usual (adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
16398306|NCT03991052|Experimental|EV1000 monitor + closed-loop system|Fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
16398307|NCT03991039|Active Comparator|Gamma knife group|Patients selected to be treated with gamma knife radiosurgery
16398308|NCT03991039|Active Comparator|MVD Group|Patients treated with microvascular decompression
16398337|NCT03990844|Placebo Comparator|0% Okra seed noodle|In this arm, subjects will consume noodles made with 0% okra seed. This serves as a control arm for the study.
16398338|NCT03990844|Experimental|10% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
16398339|NCT03990844|Experimental|20% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
16398340|NCT03990831|Other|burn injury and normal patient|HbO2 PFC perfusion using fNIRS
16398341|NCT03990805|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
16398342|NCT03990805|Placebo Comparator|saline|saline
16398533|NCT03989544|Experimental|Tezepelumab via AI|Participants will be randomized to a single dose of tezepelumab via SC administration with AI
16420090|NCT03839693|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
16398309|NCT03991026|Experimental|Healthy food and Education/Cooking Classes|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, healthy eating attitudes, and demographics. Every week for 6 weeks, participants will pick-up a healthy food bag (e.g. fresh vegetables) for a $3 co-pay and attend an hour-long education classes at East Baltimore Medical Center. All participants will complete a survey at healthy food bag pick-up or an education class. Surveys at bag pick-up will ascertain outcomes like vegetable consumption. Surveys at education classes will ascertain outcomes like healthy eating attitudes. At 6 weeks, all participants will complete a follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again at 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
16398310|NCT03991026|No Intervention|Control Group|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, cooking habits, food security, healthy eating attitudes, and demographics. As a control group, participants will not partake in the healthy food bag pick-ups or cooking classes therefore they will not fill out those associated surveys. After the 6 weeks of the intervention, control participants will be given the follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again after 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
16398311|NCT03991013|Active Comparator|Supplementary dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.
16398312|NCT03991013|Placebo Comparator|Placebo dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.
16398313|NCT03991000|Experimental|Intravenous iron|Intravenous iron administration in the form of ferric carboxymaltose will be carried out according to summary of product characteristics. Bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks (up to a total of 2000 mg which is in-label) according to approved dosing rules, followed by administration of 500 mg ferric carboxymaltose at months 4 and 8, except when haemoglobin is > 16.0 g/dL or ferritin is > 600 µg/L. To avoid unblinding in these patients a saline infusion will be administered.
16398314|NCT03991000|Placebo Comparator|Placebo|Administration of i.v. NaCl according to the dosing rules for intravenous iron.
16398315|NCT03990987||Day group|patients in Day group accept operation from 8：00～12：00
16398316|NCT03990987||Night group|patients in Night group accept operation from 18：00～22：00
16398317|NCT03990974|Experimental|Postoperative antimicrobial prophylaxis|Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.
16398318|NCT03990974|Sham Comparator|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.
16398319|NCT03990961|Experimental|Pembrolizumab Treatment|
16398320|NCT03990948||Patients with obesity|In 100 patients with obesity, blood samples will be collected.
16398321|NCT03990948||Patients with a Sleeve Gastrectomy|In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
16398322|NCT03990948||Patients with a Roux-en-Y Gastric Bypass|In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
16398323|NCT03990935|Active Comparator|sodium fluoride varnish|"The fluoride varnish will be bifluorid 10 single use by voco (Germany). It Contains 5 % sodium fluoride (equal to 22,600 ppm fluoride).
~A thin coat will be applied on the tooth surface by using a brush. 10-20 s are sufficient for the varnish to be absorbed and then dry with air. Participants will be informed that they should not brush their teeth for 12-24 hours after the application and not to eat, or drink for at least 30 minutes after use to get the best results."
16398324|NCT03990935|Experimental|Ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
16398325|NCT03990922|Experimental|CTPVB with ropivocaine|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
16398326|NCT03990922|Placebo Comparator|CTPVB with saline|Continuous Paravertebral block with saline and Patient-controlled analgesia with morphine
16398327|NCT03990909|Experimental|BCAAs|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
16398328|NCT03990909|Placebo Comparator|Rice Protein|Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
16398329|NCT03990909|Placebo Comparator|Microcrystalline Cellulose|Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
16398330|NCT03990896|Experimental|Talazoparib|-Talazoparib will be provided as capsules for oral administration daily
16398331|NCT03990883|Other|Treatment of device 1 on left side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
16398332|NCT03990883|Other|Treatment of device 1 on right side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF
16398333|NCT03990870|Experimental|Experimental Treatment|dCBGT + WASABI
16398334|NCT03990870|Active Comparator|Active Comparator|dCBGT Only
16398335|NCT03990857|Experimental|Intervention|Group of participants with a recent DM2 debut (less than 5 months) treated according to the comprehensive care protocol in DM2 with comorbidities attended in Primary care nurse office
16398336|NCT03990857|No Intervention|comparison group|Participants in the study that do not receive the intervention. usual care.
16398368|NCT03990636|Placebo Comparator|Placebo arm|Placebo (without metil 5-aminolevulinate) arm with photo activation.
16398343|NCT03990792|Experimental|e-predictD intervention|In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).
16398344|NCT03990792|Active Comparator|m-Health control|In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.
16398345|NCT03990779||Children with congenital cardiac disease|Children with congenital cardiac disease who undergoing surgery
16398346|NCT03990766|Experimental|Theophylline saline irrigation|Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
16398347|NCT03990766|Placebo Comparator|Placebo saline irrigation|Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
16398348|NCT03990753||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.
16398349|NCT03990740||Cases|Patients suffering from keratoconus and requiring a first optical corneal transplant
16398350|NCT03990740||Controls|Patients with an indication of orbital exenteration operation due to an orbital tumor
16398351|NCT03990727||Retinitis pigmentosa|Any type of retina dystrophy with pigment / retinitis pigmentosa
16398352|NCT03990727||Usher Syndrome|Retina dystrophy or retinitis pigmentosa associated with audition problems
16398353|NCT03990727||Cone>rod syndromes|Retina dystrophy diagnosed or started in central vision.
16398354|NCT03990727||Retinitis pigmentosa sx|Retinitis pigmentosa with any type of other features
16398355|NCT03990714|Experimental|Intracorporeal anastomosis|The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
16398356|NCT03990714|Experimental|Extracorporeal anastomosis|The mobilized colon was externalized preferentially via a transverse or midline incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed.The incision for the extraction of the right colon and the realization of the anastomosis is sutured in two layers by absorbable suture. Drains were not used routinely.
16398357|NCT03990701|Experimental|Single Arm|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 150 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease.
16398358|NCT03990688|Experimental|AK3280 (Cohort 1)|Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.
16398359|NCT03990688|Experimental|AK3280 (Cohort 2)|Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.
16398360|NCT03990688|Experimental|AK3280 (Cohort 3)|Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
16398361|NCT03990688|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.
16398362|NCT03990675|Experimental|FNA, FNB|
16398363|NCT03990662||TMD|Patients (aged ≥18 years) with a diagnosis of Temporomandibular Disorders
16398364|NCT03990649|Placebo Comparator|Double-Blind Treatment Period - Part A: Placebo|Soticlestat matching placebo tablets, orally, twice daily (BID) for Weeks 1, 2 and 3 in Double blind Titration Period. Soticlestat matching placebo tablets, orally BID for 12 weeks in Double blind Maintenance Period. Taper period (if participant did not continue to Part B): Dose of soticlestat matching placebo tablets was reduced to next lower dose every 3 days (maximum 6 days) until discontinuation.
16398365|NCT03990649|Experimental|Double-Blind Treatment Period - Part A: Soticlestat|Soticlestat, tablet, orally, 100 mg BID for Week 1, followed by 2×100 mg tablets, soticlestat, orally BID for Week 2, further followed by 3×100 mg tablets, soticlestat, orally BID for Week 3. Dose was uptitrated every week based on safety and tolerability. Part A (Double blind Maintenance Period): 3×100 mg tablets, soticlestat, orally BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period (if participant did not continue to Part B): Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
16398366|NCT03990649|Experimental|Open-Label Extension Period - Part B: Soticlestat|Soticlestat, 2×100 mg tablets, orally, BID for Week 1, followed by 3×100 mg tablets, soticlestat, orally, BID for Week 2. Dose was uptitrated every week based on safety and tolerability. Part B (Open label extension: Maintenance Period): 3×100 mg tablets, soticlestat, orally, BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period: Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
16398367|NCT03990636|Experimental|Metil 5-aminolevulinate arm|Metil 5-aminolevulinate arm with photo activation.
16420091|NCT03839693|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
16398369|NCT03990623|Experimental|Diagnostic (CT perfusion scans, liver biopsy)|Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.
16398370|NCT03990610|Experimental|Treatment (vascularized lymph node transfer)|Patients undergo vascularized lymph node transfer during standard of care breast reconstructive surgery.
16398371|NCT03990597|Experimental|Supportive care (StrataXRT, placebo)|Beginning first day of CSI proton radiation therapy, caregivers apply StrataXRT gel to half of the patient's forehead and one ear and placebo to the other half of the forehead and the other ear BID until the last day of radiation therapy.
16398372|NCT03990584|Experimental|three irrigation activation methods|"Manual dynamic irrigation was performed using a well-fitting gutta-percha cone inserted to WL with in-and-out vertical strokes of 5 mm at a rate of approximately 100 strokes per minute in order to hydrodynamically displace the irrigant.
~Passive ultrasonic irrigation was performed using a non-cutting size 25 file attached to a piezoelectric ultrasonic unit.
~Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm."
16398373|NCT03990584|Active Comparator|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
16398374|NCT03990571|Experimental|Treatment (axitinib, avelumab)|Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16398375|NCT03990558||Primary ICH|Subject with acute brain injury will have data collected, including EEG, behavioral, clinical, and outcome measures.
16398376|NCT03990545||Cases with stroke|
16398377|NCT03990545||Controls without stroke|
16398378|NCT03990532|Experimental|treatment group|
16398379|NCT03990519|Experimental|Cohort1: JNJ-2636682/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
16398380|NCT03990519|Experimental|Cohort 2: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
16398381|NCT03990519|Experimental|Cohort 3: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.
16398384|NCT03990493|Experimental|PV-001-DV in Combination with PV-001-DC|Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
16398385|NCT03990480|Active Comparator|valsartan|Group I treated with valsartan (160 mg/d, n = 100)
16398386|NCT03990480|Active Comparator|amlodipine|Group II amlodipine (10 mg/d, n = 100).
16398387|NCT03990480|No Intervention|Control|30 healthy subjects are enrolled as control group (Group III).
16398388|NCT03990467|Experimental|Patients treated by amikacin and piperacillin|ICU patient with a sepsis treated by amikacin and piperacillin/tazobactam
16398389|NCT03990454|Experimental|Dose escalation|"The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented.
~A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met."
16398390|NCT03990441|Experimental|Intervention|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
16398391|NCT03990441|Placebo Comparator|Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
16398392|NCT03990428||Caregivers of Patients|This is an observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other histiocytic diseases. That will collect data cross-sectionally, at a single time point. Caregiver-reported data will be completed in the form of online surveys by the participants themselves using the Research Electronic Data Capture Platform [RedCAP] platform.
16398393|NCT03990415|Experimental|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
16398394|NCT03990415|Active Comparator|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
16398395|NCT03990415|No Intervention|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
16398396|NCT03990402||Malawi group|500 young people with asthma symptoms in Malawi
16398397|NCT03990402||South Africa group|500 young people with asthma symptoms in South Africa
16398398|NCT03990402||Uganda group|500 young people with asthma symptoms in Uganda
16398399|NCT03990402||Nigeria|500 young people with asthma symptoms in Nigeria
16398400|NCT03990402||Zimbabwe group|500 young people with asthma symptoms in Zimbabwe
16398401|NCT03990402||Ghana group|500 young people with asthma symptoms in Ghana
16399485|NCT03982706||MRI-US Fusion|patients undergoing MRI targeted prostate biopsy
16398402|NCT03990389|No Intervention|Usual Care Group|"Subjects will undergo screening including Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Edinburgh Postnatal Depression Scale (EPDS) and a few additional questions.
~Eligible subjects randomized to usual care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.
~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
16398403|NCT03990389|Experimental|Chabot Care Group|"Subjects will undergo screening including REALM-R and EPDS and a few additional questions.
~Eligible subjects randomized to chatbot care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.
~In addition to the above procedures, eligible subjects randomized to chatbot care will receive weekly messages from the chatbot asking them to complete a depression severity measure and side-effect burden assessments. Within week 1 subjects will receive a check-in call from a study coordinator to answer any questions regarding use of the chatbot.
~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
16398404|NCT03990389|No Intervention|Provider Subject Cohort|20 provider subjects from each study site will be enrolled to ensure they understand the study and consent to have their patients enrolled in the study
16398405|NCT03990376|Other|Blood volume assessment with Blood Volume Analyzer|Injections of 1 mL of I-131-labeled serum albumin based on each patient's height and weight - 1 pre-surgical and 1 post-surgical
16398406|NCT03990363|Experimental|High Dose|High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
16398407|NCT03990363|Experimental|Intermediate Dose|Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
16398408|NCT03990363|Experimental|Low Dose|Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.
16398409|NCT03990363|Experimental|Allopurinol alone (0/300 mg)|Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
16398410|NCT03990363|Placebo Comparator|Placebo (0/0 mg)|Placebo (mg) in 3 steps_0/0
16398411|NCT03990350||Hispanic children with obesity|
16398412|NCT03990350||Hispanic children without obesity|
16398413|NCT03990350||Caucasian non-Hispanic children with obesity|
16398414|NCT03990350||Caucasian non-Hispanic children without obesity|
16398415|NCT03990337|No Intervention|Control group (CPG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage using finger palpation without ultrasonography
16398416|NCT03990337|Active Comparator|Ultrasound group (USG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage after localization with ultrasonography
16398417|NCT03990324|No Intervention|Control group|The control group did not received intervention and sat on a table for approximately 5 minutes
16398418|NCT03990324|Experimental|Stretching group|The stretching group received a standardized manual stretching protocol
16398419|NCT03990311|Experimental|Intervention|The experimental arm receives 2 months of sodium restricted prepared meals plus dietary counseling followed by 3 months of counseling alone.
16398420|NCT03990311|Placebo Comparator|Control|The control arm receives 5 months of usual care followed by 2 months of receipt of sodium restricted prepared meals.
16398421|NCT03990298|Other|All subjects|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.
16398422|NCT03990285|Other|[18F]Fluciclovine in glioblastoma|Axumin is a positron emitting radiopharmaceutical that has been studied in vivo in humans in a number of tumor types with positron emission tomography (PET/CT). 18F-Fluciclovine is a fluorine-18 labeled synthetic amino acid analog that is FDA approved as a PET imaging agent for prostate cancer recurrence, however, it has also been tested in other tumors. Investigators will use a typical dose of 18F-fluciclovine that is used for clinical studies in glioblastoma. This will be 5 mCi (approximate range for most studies is anticipated to be 5 mCi +/- 20%), but a lesser dose may be injected if, in the opinion of a Nuclear Medicine Authorized User, complete imaging data could be generated.
16398423|NCT03990272|Experimental|artemisia annua allergen extract drops|
16398424|NCT03990272|Placebo Comparator|Placebo drops|
16398425|NCT03990259||Male|The male individuals of the study population
16398426|NCT03990259||Female|The female individuals of the study population
16398427|NCT03990246|Experimental|Acid stable emulsion with solid droplets|Acid stable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
16398428|NCT03990246|Experimental|Acid stable emulsion with liquid droplets|Acid stable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
16398429|NCT03990246|Experimental|Acid unstable emulsion with solid droplets|Acid unstable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
16398430|NCT03990246|Experimental|Acid unstable emulsion with liquid droplets|Acid unstable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
16398431|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts A|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
16398432|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts B|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
16398433|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C1|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous patients with selected advanced solid tumours (e.g. Non-small Cell Lung Carcinoma, Triple Negative Breast cancer, Pancreatic cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Renal cell carcinoma, Urothelial Carcinoma, Small Cell Lung Cancer, Gastric cancer, Colorectal Cancer and Ovarian cancer)
16398532|NCT03989544|Experimental|Tezepelumab via APFS|Participants will be randomized to a single dose of tezepelumab via SC administration with APFS
16398434|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C2|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with selected advanced solid tumours (e.g. Non-small Cell Lung Carcinoma, Triple Negative Breast cancer, Pancreatic cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Renal cell carcinoma, Urothelial Carcinoma, Small Cell Lung Cancer, Gastric cancer, Colorectal Cancer and Ovarian cancer)
16398435|NCT03990220||Treatment|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of yoghurt containing Lactobacillus rhamnosus, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
16398436|NCT03990220||Control|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of milk, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
16398437|NCT03990207|Experimental|PowerSpiral Enteroscopy System|Subjects who have a medical indication for antegrade enteroscopy
16398438|NCT03990181|Experimental|Meal & natural polyphenol supplement (NPPS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
16398439|NCT03990181|Experimental|Drink & natural polyphenol supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
16398440|NCT03990181|Placebo Comparator|Meal & control supplement (CS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
16398441|NCT03990181|Placebo Comparator|Drink & control supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
16398442|NCT03990168|Experimental|Experimental|Participants will receive one anodal tDCS at 1 mA intensity over the left superior temporal gyrus (T3 in 10-20 international system) and the cathode tDCS over the right orbitofrontal area (Fp2 in 10-20 international system). tDCS will be delivered for 20 minutes during fluency intervention for six consecutive days.
16398443|NCT03990168|Sham Comparator|Sham Comparator|Participants will receive sham tDCS while the one anode electrode will be positioned over the left superior temporal gyrus and the cathode will be placed over the right orbitofrontal similar to the active mode. The sham stimulation will break down after 30 seconds at the beginning of 20 minutes of fluency intervention for six consecutive days.
16398444|NCT03990155|Experimental|HFNCOT+ECCO2R|Patients on NIV+ECCO2R who have reached at least for 4 consecutive hours, a RR <25 bpm + pH >7.35 + absence of clinical signs of respiratory distress after treatment with NIV+ECCO2R
16398445|NCT03990142|Experimental|Group 1: patients without intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
16398446|NCT03990142|Experimental|Group 2: patients with intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
16398447|NCT03990129|Other|Study population|All participants
16398448|NCT03990116|Experimental|Lateral kangaroo|Placing the infant in lateral on the parents chest, keeping the head neutral and limbs flexed towards body midline
16398449|NCT03990116|Active Comparator|Prone Kangaroo|placing the baby in upright and ventral position between mother's breasts or over the father chest, in skin-to skin contact with no clothes in between and with lower limbs flexed
16398450|NCT03990103|Experimental|Experimental arm|S1+Paclitaxel (IV&IP)+Bevacizumab (IP)
16398451|NCT03990103|Active Comparator|Control arm|S1+Oxaliplatin (IV)
16398452|NCT03990090|Experimental|TG103|Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.
16398453|NCT03990090|Placebo Comparator|Placebo|Placebo administered SC once in healthy participants.
16398454|NCT03990077|Experimental|dose escalation of HL-085 plus Docetaxel|"HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).
~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects."
16398455|NCT03990064|Experimental|musicotherapy|daily sessions of music listening during 2 months, associated with their standard treatment,
16398456|NCT03990064|No Intervention|waiting list|waiting list
16398457|NCT03990051|Experimental|Pro-ocular™|Pro-ocular™ 1% topical gel applied dermally to forehead twice daily, morning and before bedtime.
16398458|NCT03990051|Placebo Comparator|Placebo|Vehicle topical gel without active ingredient applied dermally to forehead twice daily, morning and before bedtime.
16398459|NCT03990038|Active Comparator|Group C|"Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter.
~They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery"
16398460|NCT03990038|Active Comparator|Group U|"Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down.
~They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total"
16398461|NCT03990025|Other|Linked Color Imaging - White Light Imaging|Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging
16398462|NCT03990025|Other|White Light Imaging - Linked Color Imaging|Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging
16398463|NCT03990012|Experimental|Patients referred for breast biopsy|Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.
16398464|NCT03989999|Experimental|TCD Group|Transcranial Doppler within 8 hours of traumatic injury
16398465|NCT03989999|No Intervention|CONTROL Group|Mild TBI management with SFMU recommandations
16398466|NCT03989986|Experimental|iPeer2Peer Mentorship|In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
16398467|NCT03989986|No Intervention|Waitlist Control Group|The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.
16398468|NCT03989973||Cirrhosis patients|Patients were diagnosed by liver biopsy, CT or ultrasound
16398469|NCT03989960|Experimental|LISA+SNIPPV group|receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation
16398470|NCT03989960|Active Comparator|InSurE group|receives intubation-surfactant- extubation technique and selects CPAP ventilation
16398471|NCT03989947|Experimental|Active BMN 111|Age-appropriate daily subcutaneous injections of BMN 111 as determined by the 111-206 study
16398472|NCT03989934|Experimental|The Mind in Action|The Mind in Action is a mindfulness intervention developed by the Holistic Life Foundation (HLF), a Baltimore-based non-profit organization. The curriculum will be delivered over approximately 40 sessions and will follow HLF's typical program modifications for high school students (i.e., sustained focus on breath work and meditation). Each program session will include an initial exercise of focusing on the breath to center oneself, followed by the introduction and practice of different breathing techniques (e.g., rhythmic breathing) that enhance calmness and reduce physiological arousal, and concluding with a brief guided meditation. Instructors will describe benefits of the practices for health and stress management. Participants are given assignments between sessions to reinforce lessons (e.g., breathing exercises or periods of meditation).
16398473|NCT03989934|Active Comparator|Healthy Topics|Adapted from the Glencoe Health Curriculum (McGraw Hill), Healthy Topics is designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
16398474|NCT03989921||normo responders|that have an AMH dosage greater than or equal to 1.2 ng/mL
16398475|NCT03989921||poor responders|with a dosage of less than 1.2 ng/mL
16398476|NCT03989908|Experimental|Co-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the same direction in the production of the microfluidic noodle.
16398477|NCT03989908|Experimental|Counter-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the opposite direction in the production of the microfluidic noodle.
16398478|NCT03989908|Placebo Comparator|Mee Sua|Mee Sua is used as a control to compare the outcome due to its similarity in textural properties
16398479|NCT03989895|Experimental|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
16398480|NCT03989882|Experimental|Wheat germ|Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
16398481|NCT03989882|Placebo Comparator|Control|Control energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
16398482|NCT03989869|Experimental|VEMA|Immediate medical abortion treatment
16398483|NCT03989869|No Intervention|Standard of Care|Delayed care until an intrauterine pregnancy has been confirmed with ultrasound.
16398484|NCT03989856|Experimental|Suturing group|"The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
~The running suture starting from central area, around the ovarian hilus to peripheral tissue, will be performed with intraovarian knots to re-approximate the edges to achieve satisfying hemostasis. Knots will not be detectable on the ovarian surface for prevention of adhesion. Mean time for hemostasis of ovary was recorded in a form. The cyst wall will be removed from the abdomen by means of an endobag. All resected cyst walls will be sent to the pathology laboratory, to confirm the histopathology of endometriosis."
16398485|NCT03989856|Active Comparator|Bipolar group|In bipolar coagulation group, after stripping the ovarian cyst wall, bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). In laparoscopic suturing group, no bipolar coagulation will be performed during or after stripping the ovarian cyst wall.
16398486|NCT03989843||Frozen embryo transfer|Frozen embryo transfer
16398487|NCT03989843||Fresh embryo transfer|Fresh embryo transfer
16398488|NCT03989830|Experimental|Second-line chemotherapy combined with Endostar|Second-line chemotherapy+Endostar
16398489|NCT03989817|Active Comparator|VIP|To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.
16398490|NCT03989817|Placebo Comparator|Saline|To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.
16398491|NCT03989804|Experimental|Targeted follow-up|
16398492|NCT03989804|No Intervention|Usual practice|Usual practice at the fitness center is self-directed use
16398493|NCT03989791|Active Comparator|Absolute diet|
16398494|NCT03989791|Experimental|Normal diet|
16398495|NCT03989778|Experimental|Vitamin D supplement|he intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas
16398496|NCT03989778|No Intervention|Control|control group will receive Metformin treatment during the study period.
16398497|NCT03989765|Experimental|Intervention arm|Municipalities in the intervention arm will, in Stage 1, be part of developing the intervention to reduce the rate of compulsion. In Stage 2 they will implement the intervention through their services.
16398498|NCT03989765|No Intervention|Control municipality|As all outcome measures will be collected from the National Patient Register, there will be treatment as usual.
16398828|NCT03987516|No Intervention|Control group|Patients in the control group will not receive any intervention
16398499|NCT03989752|Experimental|Wearable robotic exoskeleton-assisted walking program|Total of 34 training sessions (60 min/session) during 16 weeks (1-3 session/week). Session intensity will be individualized and safely progressed thereafter (standing time, number of steps) to maintain a moderate-to-vigorous intensity (Borg rate of perceived exertion ≥12/20).
16398500|NCT03989739||robotic distal pancreatectomy|
16398501|NCT03989739||laparoscopic distal pancreatectomy|
16398502|NCT03989726|Experimental|High density voltage and fractionation map guided group|"Complex fractionated atrial electrogram (CFAE), voltage and fractionation map will be performed with a multielectrode mapping catheter.
~The mapping should be performed in AF.
~First, low-voltage zone is defined as an area with bipolar peak-to-peak voltage amplitudes < 0.5mV.
~A voltage-map guided segmental PV isolation is performed. Radiofrequency energy is applied in the antral regions of the PVs. High voltage zone over 0.5mV in the antral region is targeted. IF PV isolation in not achieved by voltage-guided segmental ablation, additional Lasso catheter guided segmental antral ablation is performed.
~Radiofrequency energy is delivered at target sites for 15-30 sec guided by contact force, lesion size index (LSI) and local electrogram elimination.
~If the patient is still in AF after PV isolation, additional fractionation map guided ablation is performed. The fractionation area within low voltage area (<0.5mV) should be targeted."
16398503|NCT03989726|Active Comparator|Circumferential PV isolation|A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
16398504|NCT03989713|Experimental|MRD-triggered arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.
~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)
~Consolidation therapy: Patients receive one cycle of HAM and are further allocated based on the MRD-results assessed by flow cytometry with a cut of level of 0.1%: if the MRD is negative they remain in the MRD-triggered arm, whereas MRD positive patients cross over to the prophylactic arm.
~(Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)
~Observation: No treatment will be given in the MRD-triggered arm. (Duration: 48 weeks in total.)
~Safety follow-up and observational follow-up"
16398505|NCT03989713|Experimental|Prophylactic Arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.
~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)
~Consolidation therapy: Patients may receive up to two cycle of Q-HAM. (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)
~Maintenance therapy: Quizartinib will be given as single-agent therapy. The dose of quizartinib is aimed to be increased during maintenance therapy. (Up to 12 cycles. Duration: four times three cycles á 28 days, 48 weeks in total.)
~Safety follow-up and observational follow-up"
16398506|NCT03989700|Experimental|Low dose|Low dose of thiamin supplementation
16398507|NCT03989700|Experimental|High dose|High dose of thiamin supplementation
16398508|NCT03989700|Placebo Comparator|Placebo|placebo supplementation
16398509|NCT03989687|Experimental|glass ionomer sealant|glass ionomer sealant
16398510|NCT03989687|Experimental|isolation|isolation type either rubber dam or cotton roll isolation
16398511|NCT03989674|No Intervention|White bread|
16398512|NCT03989674|Experimental|Anthocyanin-fortified bread (2% w/w)|
16398513|NCT03989674|Experimental|Anthocyanin-fortified bread (4% w/w)|
16398514|NCT03989661||Test group|This group corresponds to patients who had undergone preoperative embolization (with resorbable material) before myomectomy.
16398515|NCT03989661||Control group|This group corresponds to patients with myomectomy without embolization.
16398516|NCT03989648|Active Comparator|Esmarch bandages|
16398517|NCT03989648|Active Comparator|simple leg elevation|
16398518|NCT03989635|Experimental|QAW039|QAW039 450mg
16398519|NCT03989635|Placebo Comparator|Placebo|Placebo to QAW039
16398520|NCT03989622|Experimental|evaluation of the visual field on the ground|evaluation of the visual field on the ground followed by 10 reeducation sessions
16398521|NCT03989622|No Intervention|usual care|control session followed by 10 re-education sessions
16398522|NCT03989609|Experimental|Dexmedetomidine Group|patients will receive dexmedetomidine as sedative
16398523|NCT03989609|Active Comparator|Midazolam|patients will receive midazolam as sedative
16398524|NCT03989596|Experimental|Radiotherapy with hyperthermia|10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)
16398525|NCT03989583||Children's feet temperature|The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
16398526|NCT03989570|Experimental|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
16398527|NCT03989570|Active Comparator|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
16398528|NCT03989570|Placebo Comparator|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
16398529|NCT03989557|Experimental|Monitoring Arm|Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
16398530|NCT03989557|Experimental|Conventional Arm|Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.
16398531|NCT03989544|Experimental|Tezepelumab via Vial-and-syringe|Participants will be randomized to a single dose of tezepelumab via SC administration with Vial-and-syringe
16398534|NCT03989531|Experimental|Adrecizumab on top of standard of care|8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion
16398535|NCT03989531|Placebo Comparator|Placebo on top of standard of care|100 mL saline as single dose infusion
16398536|NCT03989518|Experimental|Simple stimuli|Two perceptually simple stimuli are used during all experimental phases (geometrical figures).
16398537|NCT03989518|Experimental|Complex stimuli|Two complex stimuli are used in all experimental phases. Stimuli consist of photographs of real objects of the same size and shape as the simple stimuli, but include perceptually more complex patterns, details and colors.
16398538|NCT03989505||Cohort|214 consecutive patients undergoing contrast-enhanced diagnostic and/ or therapeutical intervention in the cath lab of the University Heart Center Hamburg
16398539|NCT03989492|Experimental|Autonomic responses to stressors|Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
16398540|NCT03989479|Active Comparator|Conventional Toothbrush|Brushing with conventional Kid's Soft Toothbrush, Colgate (5-9-year-old)
16398541|NCT03989479|Experimental|T-shaped Toothbrush|Brushing with T-shaped toothbrush (Denson™, Malaysia)
16398542|NCT03989466|Experimental|Treatment (itacitinib, alemtuzumab)|"CYCLE 1: Patients receive itacitinib PO QD on days 1-28 and alemtuzumab IV over 2 hours on days 15, 17, 19, 21, 23, 25, and 27 in the absence of disease progression of unacceptable toxicity.
~CYCLE 2 AND BEYOND: Patients receive itacitinib PO QD on day 1-28 and alemtuzumab IV over 2 hours on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients who achieve a response (CR/CRi or PR) may receive itacitinib for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity."
16398543|NCT03989453|Experimental|Chi Kung group|This group receives physical training based on Chi Kung.
16398544|NCT03989453|No Intervention|Control Group|This group does not receive any treatment.
16398547|NCT03989427|Experimental|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
16398548|NCT03989427|Experimental|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
16398549|NCT03989414|Experimental|Cohort A: CC-92480 with bortezomib and dexamethasone|"Oral CC-92480 at specified cohort A dose administered over a 21-day cycle
~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle
~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8"
16398550|NCT03989414|Experimental|Cohort C: CC-92480 with carfilzomib and dexamethasone|"Oral CC-92480 at specified cohort C dose administered over a 28-day cycle
~Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle
~Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) administered over a 28-day cycle"
16398551|NCT03989414|Experimental|Cohort H: CC-92480 with elotuzumab and dexamathasone|"Oral CC-92480 at specified cohort H dose administered over a 28-day cycle
~Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle
~Oral (28 mg) and IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg] and IV [8 mg] dexamethasone for total 16 mg/day for subjects > 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) on non-ELO dosing days, administered over a 28-day cycle"
16398552|NCT03989414|Experimental|Cohort I: CC-92480 with isatuximab and dexamathasone|"Oral CC-92480 at specified cohort I dose administered over a 28-day cycle
~Intravenous ISA 10 mg/kg administered over a 28-day cycle
~Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects > 75 years old)"
16398553|NCT03989414|Experimental|Cohort D: CC-92480 with bortezomib and dexamethasone|"Oral CC-92480 at RP2D administered over a 21-day cycle
~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle
~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8"
16398554|NCT03989414|Experimental|Cohort F: CC-92480 with carfilzomib and dexamethasone|"Oral CC-92480 at RP2D administered over a 28-day cycle
~Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle
~Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) administered over a 28-day cycle"
16398555|NCT03989414|Experimental|Cohort J: CC-92480 with elotuzumab and dexamathasone|"Oral CC-92480 at RP2D administered over a 28-day cycle
~Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle
~Oral (28 mg)/IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg]/IV [8 mg] dexamethasone for total 16 mg/day for subjects > 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) on non-ELO dosing days, administered over a 28-day cycle"
16398556|NCT03989414|Experimental|Cohort K: CC-92480 with isatuximab and dexamathasone|"Oral CC-92480 at RP2D administered over a 28-day cycle
~Intravenous ISA 10 mg/kg administered over a 28-day cycle
~Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects > 75 years old)"
16398557|NCT03989414|Experimental|Cohort G: CC-92480 with bortezomib and dexamethasone|"Oral CC-92480 at RP2D administered over a 21-day cycle
~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle up to Cycle 6
~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle up to Cycle 6"
16398588|NCT03989284|Experimental|Combination group|Senior citizens in this group underwent both peer counseling and social engagement interventions mentioned above.
16421390|NCT03830684|Placebo Comparator|placebo group|control group
16398558|NCT03989414|Experimental|Subcohort B1: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at specified cohort dose administered over a 28-day cycle
~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
16398559|NCT03989414|Experimental|Subcohort B2: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at specified cohort dose administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards
~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards"
16398560|NCT03989414|Experimental|Subcohort B3: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at specified cohort B dose administered over a 28-day cycle
~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
16398561|NCT03989414|Experimental|Subcohort E1: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at RP2D administered over a 28-day cycle
~Either IV DARA administered at a dose of 16 mg/kg or SC DARA administered at a dose of 1800 mg over 3 to 5 minutes
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
16398562|NCT03989414|Experimental|Subcohort E2: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at RP2D administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards
~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards"
16398563|NCT03989414|Experimental|Subcohort E3: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at RP2D administered over a 28-day cycle
~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
16398564|NCT03989401|Experimental|Multimedia video education|The experimental group conducted multimedia video education while admission.
16398565|NCT03989401|No Intervention|None multimedia video education|The control group conducted usual nursing of oral face-to-face education on admission.
16398566|NCT03989388|Experimental|Intervention Group|Occupational Self-Analysis Programme
16398567|NCT03989388|Active Comparator|Control group|Vocational guidance or usual rehabilitation (in the case of ABI participants)
16398568|NCT03989375|Experimental|experiment group|
16398569|NCT03989375|No Intervention|control group|
16398570|NCT03989362|Experimental|LM1|Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC
16398571|NCT03989362|Experimental|LT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC
16398572|NCT03989362|Experimental|UM1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
16398573|NCT03989362|Experimental|UT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
16398574|NCT03989362|Experimental|LM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
16398575|NCT03989362|Experimental|LT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
16398576|NCT03989362|Experimental|UM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
16398577|NCT03989362|Experimental|UT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
16398578|NCT03989349|Placebo Comparator|Placebo|Placebo administered via subcutaneous injection
16398579|NCT03989349|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
16398580|NCT03989336|Experimental|Manganese primed Sintilimab plus nPP chemotherapy|Subject received Manganese primed Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
16398581|NCT03989336|Active Comparator|Sintilimab plus nPP chemotherapy|Subject received Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
16398582|NCT03989323||Patients treated with immunotherapy|Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4…). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.
16398583|NCT03989310|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
16398584|NCT03989310|Experimental|anti-PD-1 antibody plus nPG chemotherapy|Subject received anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
16398585|NCT03989297||NPC patients|Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
16398586|NCT03989284|Experimental|Peer counseling group|Peer counselors performed 1-hour home visits weekly to their assigned clients for three months.
16398587|NCT03989284|Experimental|Social engagement group|Senior citizens joined 3-hour weekly social events held at the OSCA Center for three months.
16398589|NCT03989284|No Intervention|Control group|Senior citizens in this group had access to usual or standard care from health and aged care services that were usually available.
16398590|NCT03989271|Active Comparator|Quercetin|Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.
16398591|NCT03989271|Placebo Comparator|Placebo|"Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.
~Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months."
16398592|NCT03989258|Active Comparator|Cohort 1|High monogenic breast cancer risk
16398593|NCT03989258|Active Comparator|Cohort 2|High polygenic breast cancer risk
16398594|NCT03989258|No Intervention|Cohort StMG|Standard mammography screening in age 50-69
16398595|NCT03989245||Target arm: UCC (Cognitive Behavioural Unit)|Patients receiving care in Cognitive Behavioural Unit (UCC )
16398596|NCT03989245||Control arm: SSR (Geriatric Follow-up and Rehabilitation Unit)|Patients receiving care in Geriatric Follow-up and Rehabilitation Care Unit (SSR)
16398599|NCT03989219|Experimental|lung nodules were found by CT scanning|Plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
16398601|NCT03989193|Experimental|Computer guided alveolar ridge splitting technique|Computer guided alveolar ridge splitting using piezo electric device and a 3D printed surgical guide. An L shaped splitting pattern with one crestal and one distal cut will be performed.
16398602|NCT03989167|Experimental|Intervention group|Group receiving the Clinical decision support
16398603|NCT03989167|No Intervention|Control group|
16398604|NCT03989141|Experimental|Repeated cannulation Buttonhole|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
16398605|NCT03989141|Active Comparator|Single cannulation Buttonhole|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
16398606|NCT03989128||Observational (survey)|Participants complete a survey over 5-10 minutes
16398607|NCT03989115|Experimental|RMC-4630 and Cobimetinib|RMC-4630 and Cobimetinib for oral administration
16398608|NCT03989115|Experimental|RMC-4630 and Osimertinib|RMC-4630 and Osimertinib for oral administration
16398609|NCT03989102|Experimental|Arm 1|Arm 1: (n= 100) will receive 3 doses of PfSPZ Vaccine (9 x10(5)) via direct venous inoculation (DVI) at 1, 8, 29 days.
16398610|NCT03989102|Experimental|Arm 2|Arm 2: (n= 100) will receive 3 doses of PfSPZ Vaccine (1.8 x10(6)) via DVI at 1, 8, 29 days.
16398611|NCT03989102|Placebo Comparator|Arm 3|Arm 3: (n=100): will receive 3 doses of normal saline (placebo) injection via DVI at 1, 8, 29 days.
16398612|NCT03989089|Experimental|Pembrolizumab single agent|Pembrolizumab 200 mg will be given intravenously every 3 weeks , on Day 1 on each 3 week cycle. Pembrolizumab can be given up to 35 adminstration (2 years).
16398613|NCT03989063|Experimental|Amputees (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
16398614|NCT03989063|Active Comparator|Amputees (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
16398615|NCT03989063|Experimental|Diabetes (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
16398616|NCT03989063|Active Comparator|Diabetes (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
16398617|NCT03989050||Melanoma patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for melanoma
16398618|NCT03989050||Non-small cell lung cancer (NSCLC) patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for NSCLC
16398619|NCT03989050||other malignancy patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for other malignancy
16398620|NCT03989037|Experimental|SIBP-01 & Docetaxel & Carboplatin|SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
16398621|NCT03989037|Active Comparator|Herceptin & Docetaxel & Carboplatin|Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
16398622|NCT03989024|Experimental|Pulsatile Gonadotropin-releasing Hormone|Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
16398623|NCT03989024|Experimental|Clomiphene|Use Clomiphene for 3 months to treat PCOS
16398624|NCT03988998|Experimental|Radiofrequency ablation with radiotherapy|Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.
16398625|NCT03988998|Active Comparator|Radiofrequency ablation alone|Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.
16398626|NCT03988985|Experimental|PATIENT-GP-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
16398627|NCT03988985|Active Comparator|GP-FEEDBACK|Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
16398628|NCT03988985|No Intervention|NO-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.
16398629|NCT03988972|Experimental|diathermy group|"Diathermy incisions will be carried out using monopolar blade pen electrode, set on cutting mode and delivering a 35 continuous current. Electrosurgical cutting was performed without pressure or mechanical displacement.
~'Bleeders' will be controlled by using diathermy, on coagulating mode, and will be applied to a hemostat on the vessels"
16398630|NCT03988972|Active Comparator|scalpel group|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
16398631|NCT03988959|Other|Control|Standard resection
16398632|NCT03988946|Experimental|Transcatheter Mitral Valve Replacement|Replacement valve delivered through a transfemoral access and transseptal approach
16398633|NCT03988933|Experimental|Intervention Arm 1|Two months of daily self-administered rifampin at 20 mg/kg (maximum 1200 mg/day).
16398634|NCT03988933|Experimental|Intervention Arm 2|Two months of daily self-administered rifampin at 30 mg/Kg (maximum 1800 mg/day).
16398635|NCT03988933|Active Comparator|Control Arm|Four months of daily self-administered rifampin at a dose of 10mg per kg per day (maximum 600mg per day).
16398636|NCT03988920|Experimental|Tenapanor w/Sevelamer|Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
16398637|NCT03988920|Experimental|Sevelamer w/Tenapanor|Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed
16398638|NCT03988907|Experimental|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
16398639|NCT03988907|Experimental|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
16398640|NCT03988894|No Intervention|Control: Usual Care|All participants will (a) receive a general hypertension health education booklet from the Heart and Stroke Foundation of Ontario;(b) be encouraged to see their family physicians or primary health care providers regarding their blood pressure status; those who do not have a primary health care provider will be referred to a walk-in clinic or a community health centre; and (c) have access to family physicians, tele-health, emergency care, hospital and other health care facilities in the Greater Toronto Area as required.
16398641|NCT03988894|Active Comparator|Intervention: mDASHNa-CC app use|In addition to usual care, those participants randomized to the intervention group will be offered use of the app.Then, they will load the app in their smartphones and be requested to review educational contents, conduct dietary self-assessment, and monitor blood pressure for 8 weeks.By the end of eight weeks post randomization, seniors will be prompted by phone using an audible alert to complete the app Evaluation Questionnaire on the smartphone, which ascertains likes and dislikes with the app.
16398642|NCT03988881||1 PCI Group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with positive dobutamine stress echocardiography and positive Fractional Flow Reserve recieving revascularization (PCI or CABG) Drug: Standard of care after acute myocardial infarction
16398643|NCT03988881||Group 2 OMT group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with negative dobutamine stress echocardiography and negative Fractional Flow Reserve or the mismatching cases Standard of care after acute myocardial infarction
16398644|NCT03988855|Experimental|Part 1|10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days.
16398645|NCT03988855|Experimental|Part 2|30 subjects with severe CDI will be enrolled and randomized in a 2:1 ratio to receive DNV3837 or standard of care. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days
16398646|NCT03988842|Experimental|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
16398647|NCT03988842|Active Comparator|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
16423176|NCT03818126|Active Comparator|cold blood cardioplegia|
16398648|NCT03988829|Active Comparator|Low-C|In an experimenter-designed simulation game, participants will be trained on predictable low attentional control shifts during working memory.
16398649|NCT03988829|Experimental|High-C|In an experimenter-designed simulation game, participants will be trained on unpredictable high attentional control shifts during working memory.
16398650|NCT03988829|Experimental|High-C+|In this commercially-available video game, in addition to unpredictable shifts of attentional control in working memory, task switching and resource planning will be trained.
16398651|NCT03988816|Experimental|Roflumilast|Roflumilast tablets will be supplied at a concentration of 500 mcg. Each tablet contains 500mcg of the active ingredient in addition to the excipients: lactose monohydrate, corn starch, povidone and magnesium stearate. The coating contains hypromellose, macrogol, titanium dioxide, yellow iron oxide. Patients should take 1 tablet once daily, before, during or after meals, at the same time each day.
16398652|NCT03988816|Placebo Comparator|Placebo (control)|Roflumilast placebo-containing tablets will look similar to active roflumilast tablets and will be supplied to patients in packs identical to those of the active drug.
16398653|NCT03988803|Experimental|All subjects|
16398654|NCT03988790|Experimental|VOC analysis|VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
16398655|NCT03988777||Prospective Magseed|This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.
16398656|NCT03988777||Retrospective hooked-wire|This cohort includes patients with an impalpable breast lesion that were scheduled for breast conserving surgery with hooked-wire before September 2018. Their data will be retrospectively collected and analysed.
16398657|NCT03988764||Antibody-negative|"Patient has been found negative for at least three T1D antibodies.
~The investigators will proceed with whole exome sequencing"
16398658|NCT03988764||Antibody-positive|"Patient has been found to be positive for at least one T1D autoantibody.
~No further studies will be performed as part of the main study."
16398659|NCT03988751|Active Comparator|Continuous Ambulation|The total distance will be 40 meters. Study team members will walk, support, and coach the subject to walk as slow as he/she wants
16398660|NCT03988751|Active Comparator|Interval Ambulation|The subject will walk a total distance of 40 meters. This distance will be divided into four intervals of 10 meters to equal the same measured distance as the continuous group. The subject will receive two minutes of rest between each interval and will be supported and coached to walk as fast as they can.
16398661|NCT03988738|Experimental|Intervention|Participants will receive messages regarding blood donation promotion and campaigns through social media once or twice a week for six months.
16398662|NCT03988738|Sham Comparator|Control|Participants will receive a message regarding blood donation at the beginning of the study through social media. After four months they will receive another message including information about upcoming blood donation campaigns.
16398663|NCT03988725|Experimental|Vitamin E intervention|All study participants receive Vitamin E 800 IU once daily for 6 months
16398664|NCT03988712||Iron deficiency anaemia with bowel symptoms|Patients with IDA presenting with bowel symptoms like change in bowel habits, weight loss and abdominal mass other than rectal bleed
16398665|NCT03988712||Iron deficiency anaemia with no bowel symptoms|Patients with IDA with no bowel symptoms
16398666|NCT03988712||Iron deficiency anaemia with rectal bleeding|Patients with IDA and rectal bleeding
16398667|NCT03988699|Experimental|Subject with severe tinnitus|Subjects diagnosed with severe tinnitus for at least six months, and it has not responded to conventional management will have surgical implantation of the device Tinnitus Implant System.
16398668|NCT03988686|Experimental|Intervention Group|Radical prostatectomy plus standard care
16398669|NCT03988686|Active Comparator|Comparator Group|Standard care, currently ADT +/- other systemic therapies.
16398670|NCT03988673|No Intervention|decision aid with information only (control)|decision aid with information only, without values clarification method (VCM)
16398671|NCT03988673|Active Comparator|decision aid with implicit VCM|decision aid with information plus an implicit VCM
16398672|NCT03988673|Active Comparator|decision aid with explicit VCM|decision aid with information plus an explicit VCM
16398673|NCT03988660||Healthy controls|Healthy individuals
16398674|NCT03988660||Histologically confirmed appendicitis|Patients who have diagnosis of appendicitis on histology
16398675|NCT03988660||Histologically normal appendix|Patients who have diagnosis of a normal appendix on histology
16398676|NCT03988660||Alternative diagnosis group|Patients who diagnosed with a condition other than appendicitis
16398677|NCT03988647|Experimental|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
16398678|NCT03988634|Experimental|sacubitril/valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.
~Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by patient's previous dose of ACEi/ARB immediately prior to hospital admission for acute decompensated heart failure. Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).
~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril/valsartan and one tablet of valsartan matching placebo pack)."
16398679|NCT03988634|Active Comparator|valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.
~Initial dose at randomization will be based on patient's previous dose of or lack of ACEi/ARB immediately prior to current hospital admission for ADHF, or at the time of out-of-hospital randomization.
~Study treatment will be titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).
~Patients will be required to take a total of two tablets twice daily (one tablet of active valsartan and one tablet of sacubitril/valsartan (LCZ696) matching placebo pack)."
16398730|NCT03988322|Experimental|Quantitative assessment of imaging biomarkers|This is the intervention arm. In this arm, the participants will be scanned with low-dose CT with pre-defined scanning parameters for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the volume of the nodule. The quantitative assessment of imaging biomarkers of lung cancer, COPD and cardiovascular disease will be recorded.
16398682|NCT03988608|Experimental|Eltrombopag|Subjects will start eltrombopag treatment at 25 mg/day since Day 1.
16398683|NCT03988595|Experimental|aerobic training 90 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
16398684|NCT03988595|Experimental|aerobic training 150 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
16398685|NCT03988595|Experimental|aerobic training 225 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
16398686|NCT03988595|Experimental|aerobic training 300 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
16398687|NCT03988582|Experimental|HCT (hematopoietic cell transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
16398688|NCT03988582|Experimental|SOT (solid organ transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
16398689|NCT03988582|Experimental|Other immune competent or immune compromised patients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
16398690|NCT03988569|Experimental|Intervention Group|Will view audiovisual decision aid (AVDA) and then have opportunity for questions with physician before signing consent forms
16398691|NCT03988569|No Intervention|Control Group|Will undergo standard verbal informed consent with physician before signing consent forms
16398692|NCT03988556|Experimental|Cohort A1 - Head & neck cancer - Prophylactic intent|"Patients with head & neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent).
~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.
~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis.
~."
16398693|NCT03988556|Experimental|Cohort A2 - Head & neck cancer - Curative intent|"Patients with head & neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent).
~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).
~The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions."
16398731|NCT03988322|Active Comparator|Visual assessment of imaging biomarkers|This is the control arm. In this arm, the participants will be scanned with low-dose CT with routine scanning parameters used for lung cancer screening in the hospital for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the diameter of the nodule. The imaging biomarkers related to lung cancer, COPD and cardiovascular disease will be visually assessed.
16398694|NCT03988556|Experimental|Cohort B1 - Breast cancer - Prophylactic intent|"Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent).
~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.
~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis."
16398695|NCT03988556|Experimental|Cohort B2 - Breast cancer - Curative intent|"Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent).
~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).
~The device will be used on each lesion. All existing lesions will be treated."
16398696|NCT03988543|No Intervention|Usual Care|Patients will receive current standard care of EHR-integrated symptom monitoring.
16398697|NCT03988543|Experimental|Enhanced Care|Patient will receive current standard care of EHR-integrated symptom monitoring, plus patient self-management intervention.
16398698|NCT03988530|Active Comparator|DPI-386 Nasal Gel|DPI-386 Nasal Gel (0.2 mg / 0.12 g)
16398699|NCT03988530|Placebo Comparator|Placebo Nasal Gel|placebo nasal gel (0.12 g)
16398700|NCT03988517|Active Comparator|levothyroxine at Iftar|Patients took levothyroxine 30 minutes before breaking the fast at sunset (iftar)
16398701|NCT03988517|Active Comparator|Levothyroxine at Suhour|Patients took levothyroxine 30 minutes before an early morning meal before sunrise (suhour)
16398702|NCT03988491||End stage renal disease on maintanance hemodialysis|End-stage renal disease due to any etiology on maintenance hemodialysis and consented to participate in the study.
16398703|NCT03988478|Experimental|Behavioral, detoxificaiton & psychotherapy|Providing treatment as usual (detoxificaion) & psychotherapy
16398704|NCT03988465||Cardiac Surgery Patients|Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.
16398705|NCT03988452|Active Comparator|Darunavir/r Zidovudine Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
16398706|NCT03988452|Experimental|Darunavir/r Tenofovir Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
16398707|NCT03988452|Experimental|Dolutegravir Zidovudine Lamivudine|Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
16398708|NCT03988452|Experimental|Dolutegravir Tenofovir Lamivudine|Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
16398709|NCT03988439|Experimental|IDP-118 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 4 to 11 years 11 months) will apply IDP-118 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
16398710|NCT03988426|Experimental|Octanorm|Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center [during first training sessions and then for every 4th administration] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
16398711|NCT03988413|Experimental|25mg|Tablets, Oral, 25mg, single dose
16398712|NCT03988413|Experimental|50mg|Tablets, Oral, 50mg, single dose
16398713|NCT03988413|Experimental|100mg|Tablets, Oral, 100mg, single dose
16398714|NCT03988413|Experimental|200mg|Tablets, Oral, 200mg, single dose
16398715|NCT03988413|Experimental|400mg|Tablets, Oral, 400mg, single dose
16398716|NCT03988413|Experimental|800mg|Tablets, Oral, 800mg, single dose
16398717|NCT03988400|Experimental|Sensory augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
16398718|NCT03988400|Active Comparator|Random vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
16398719|NCT03988387|Experimental|Peer Support PS)|Participants randomized to the PS arm will be assigned a trained peer supporter (PSr) to enhance adherence to PrEP.
16398720|NCT03988387|Experimental|Reminders and Resource Transfer (RRT)|Participants randomized to the RRT arm will receive weekly SMS text messages and resource transfers to enhance adherence to PrEP.
16398721|NCT03988374|Active Comparator|0% Baking Soda Dentifrice|
16398722|NCT03988374|Active Comparator|20% Baking Soda Dentifrice|
16398723|NCT03988374|Active Comparator|35% Baking Soda Dentifrice|
16398724|NCT03988361||Control group|Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
16398725|NCT03988361||Study group|"Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS.
~The sperm used in this group is considered to be enriched in non apoptotic cells."
16398726|NCT03988348|Experimental|study group|infraumbilical transverse incision will be done
16398727|NCT03988348|Active Comparator|control group|Direct intraumbilical transverse incision will be done
16398728|NCT03988335|Experimental|RIST4721|RIST4721 as once-daily 300mg oral solution for 28 days.
16398729|NCT03988335|Placebo Comparator|Placebo|Placebo as once-daily 300mg oral solution for 28 days.
16398794|NCT03987763|Experimental|IDP-122 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 6 to 11 years 11 months) will apply IDP-122 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
16398732|NCT03988309|Active Comparator|"Test, subjects categorised as low risk or Not low risk"|"A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either low risk or not low risk categories. Low risk subjects satisfy all conditions and not low risk satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as not low risk will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects."
16398733|NCT03988309|No Intervention|Control|Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
16398734|NCT03988283|Experimental|Personalized neoantigen DNA vaccine|Patients will receive the vaccine on a 28-day cycle. It will be given weekly (+/- 3 days) during Cycle 1 (i.e., C1D1, C1D8, C1D15, C1D22) as a priming phase followed by booster injections on Day 1 (+/- 7 days) of each subsequent cycle (i.e., C2D1, C3D1, etc.). Vaccine administration will continue indefinitely until development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression.
16398735|NCT03988270|Experimental|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
16398736|NCT03988270|No Intervention|Control|Participants in the control group will not receive any pre-surgical instructions for exercise in the access arm
16398737|NCT03988257|Experimental|Experimental group|Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day.
16398738|NCT03988257|Placebo Comparator|Control group|A vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight.
16398739|NCT03988244|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
16398740|NCT03988231|Active Comparator|Enoxaparin 40mg once daily|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
16398741|NCT03988231|Placebo Comparator|Placebo|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
16398742|NCT03988218|Experimental|Anorexia|Subjects with anorexia nervosa
16398743|NCT03988218|Active Comparator|Control|Subjects without eating disorders
16398744|NCT03988205|Experimental|Intervention|The study intervention is the application of a prescribed outpatient care model including a nurse teacher educational program and quality of life surveys for both subjects and caregivers. Induction therapy and medical follow up are performed without prophylactic admission to an inpatient facility. Subjects will also receive CPX-351 according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
16398745|NCT03988192|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.
16398746|NCT03988166|Other|Chronic Total Occlusion Percutaneous Coronary Intervention|CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
16398747|NCT03988153|Experimental|Probiotic Milk Formula (PMF)|Twenty subjects should drink 200 mL of PMF (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
16398748|NCT03988153|Placebo Comparator|Skimmed Milk Formula|Twenty subjects should drink 200 mL of skimmed milk drink (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
16398749|NCT03988140|Experimental|Implant placed at supra crestal level (SL)|Implants were placed at supra crestal level (SL)
16398750|NCT03988140|Other|Implant placed at crestal level (CL).|Implants were placed at crestal level (CL)
16398751|NCT03988114|Experimental|Abemaciclib + NSAI|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.
16398752|NCT03988101|Experimental|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
16398753|NCT03988101|Placebo Comparator|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
16398754|NCT03988088|Experimental|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
16398755|NCT03988075|Active Comparator|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
16398756|NCT03988075|Experimental|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
16398757|NCT03988062|Experimental|TrelliX Embolic Coil System|
16398758|NCT03988049|Active Comparator|1,550 laser|This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.
16398759|NCT03988049|Active Comparator|755 laser|This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.
16398853|NCT03987295|Experimental|AL001|AL001 every 4 weeks for up to 96-weeks
16398760|NCT03988036|Experimental|HER2-enriched|"Trial treatment is defined as neoadjuvant therapy only. The Investigational Medicinal Products (IMPs) are pembrolizumab, trastuzumab biosimilar and pertuzumab.
~Trastuzumab Biosimilar (Trazimera®) - Investigational Medicinal Product
~Loading dose: 8 mg/kg bodyweight at initial administration infusion over 90 min; monitor patient for at least 6 h afterwards.
~Maintenance dose: 6 mg/kg bodyweight, over 30-90 min; monitor patient for 2 h afterwards.
~Route: Intravenous infusion.
~Schedule: Every 3 weeks during the neoadjuvant phase.
~Pertuzumab (Perjeta®) - Investigational Medicinal Product
~Loading dose: 840 mg, initial administration.
~Maintenance dose: 420 mg.
~Route: Intravenous infusion.
~Schedule: Every 3 weeks during the neoadjuvant phase.
~Pembrolizumab (Keytruda®) - Investigational Medicinal Product
~Dose: 200 mg.
~Route: Intravenous infusion.
~Schedule: Every 3 weeks during the neoadjuvant phase."
16398761|NCT03988023|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
16398762|NCT03988023|Placebo Comparator|Saline|Saline solution, 4 mL, single intra-articular injection
16398763|NCT03988010|Experimental|Amantadine Sulphate|200 mg ıv Amantadine Sulphate in 500 cc solution
16398764|NCT03988010|Placebo Comparator|Placebo group|iv 500 cc %0.9 sodium chloride
16398765|NCT03987997|Active Comparator|Association electrical muscle stimulation with cyclo-ergometer|Randomized leg with receive electrical muscle stimulation of the quadriceps in addition to early mobilization of lower limbs with cyclo-ergometer.
16398766|NCT03987997|Other|Cyclo-ergometer only|This control group correspond to the leg which don't receive electrical muscle stimulation (as usually supported)
16398767|NCT03987971|Experimental|Deep acupuncture on GB26|
16398768|NCT03987971|Sham Comparator|Superficial acupuncture on GB26|
16398769|NCT03987971|No Intervention|waiting list|
16398770|NCT03987958||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for AML.
~The decision to treat with venetoclax has been made independently from this observational study before participants are offered the opportunity to participate in this study."
16398771|NCT03987945||Left atrial appendage occlusion|Patients with non-valvular atrial fibrillation who have received left atrial appendage occlusion procedure.
16398772|NCT03987932|Experimental|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
16398773|NCT03987932|Experimental|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
16398774|NCT03987932|Other|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
16398775|NCT03987919|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16398776|NCT03987919|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16398777|NCT03987919|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16398778|NCT03987919|Active Comparator|Semaglutide|Semaglutide administered SC once a week.
16398779|NCT03987906|Experimental|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
16398780|NCT03987906|No Intervention|Standard Oncology Care|The control arm receives standard oncology care, which includes routine symptom screening at every outpatient visit.
16398781|NCT03987893|Experimental|PEG+Lactulose|this arm will recieve PEG3350 in addition to standard of care
16398782|NCT03987893|Active Comparator|Lactulose alone|this arm will recieve only standard of care for management of hepatic encephlaopathy with ACLF
16398783|NCT03987880|Active Comparator|4.0 mm zone|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
16398784|NCT03987880|Experimental|3.5 mm zone|PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
16398785|NCT03987867|Experimental|Arm: CIK+PD-1 inhibitor+chemotherapy|"CIK cell, IBI308, Pemetrexed, Liposome paclitaxel, Carboplatin
~IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Liposome paclitaxel intravenous infusion 135mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
16398786|NCT03987854|Experimental|complete diet and lifestyle program|
16398788|NCT03987815|Experimental|Study Arm|Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
16398789|NCT03987802||Fiasp®|Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.
16398790|NCT03987789|Active Comparator|Low PEEP group|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
16398791|NCT03987789|Experimental|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers
16398792|NCT03987776|Experimental|Anti-inflammatory diet|energy-reduced diet with the use of low glycemic foods, wholegrain products, legumes, colorful vegetables and fruit, nuts, seeds, marine fish, olive oil, green/black tea, and multiple spices and herbs
16398793|NCT03987776|Experimental|Control energy-resticted diet|isocaloric to anti-inflammatory diet, energy restricted diet (55-60% carbohydrates, 25% fat, 15-20% protein) used in a standard obesity management
16398995|NCT03986255|Experimental|Lumbar Puncture|Participants will undergo Lumbar puncture procedure
16398795|NCT03987750|Experimental|Safinamide 100mg|Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
16398796|NCT03987750|Experimental|Safinamide 150mg|Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
16398797|NCT03987750|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
16398798|NCT03987737|Experimental|small catheter|In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ.
16398799|NCT03987737|No Intervention|control group|In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet without small catheter in situ.
16398800|NCT03987724|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
16398801|NCT03987711|Experimental|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
16398802|NCT03987711|Active Comparator|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
16398803|NCT03987711|Active Comparator|No oral anticoagulation|Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.
16398804|NCT03987698|Experimental|Arm 1: CIK+PD-1i|"SHR-1210 & CIK cells
~SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
16398805|NCT03987698|Active Comparator|Arm 2: Control|SHR-1210,200mg/d,intravenous infusion,d1; Q3W.
16398806|NCT03987685|Experimental|Oratopo|To determine the Maximum Tolerated Dose (MTD) of oral topotecan with HM30181A administered once daily for 5 consecutive days every 21 days.
16398807|NCT03987672|Other|Assess Nutritional Effects of Nutritional Formula|Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.
16398808|NCT03987659|Active Comparator|Root Canal Treatment without dECMs release|Two visit non-surgical root canal therapy with conventional irrigation protocols
16398809|NCT03987659|Experimental|Root Canal Treatment with dECMs release|Two visit non-surgical root canal treatment with irrigation protocols that optimise release of soluble dentine extracellular matrix components (dEMCs)
16398810|NCT03987646|Experimental|xenograft cortical flexible sheet|a-traumatic tooth removal , socket lavage and curettage, performing a vestibular access horizontal incision corresponding to the socket 3-4 mm apically from the muccogingival junction , a tunnel is then created from the socket office and extended apically till it connects with the vestibular access incision, a computer guided surgical template is then used to deliver the implant in its optimal position, a slowly resorbable membrane shield is then introduced through the tunnel and stabilized with a membrane tac , it is a sturdy fixable membrane barrier placed above the labial plate
16398811|NCT03987633||Displaying trait of interest|There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.
16398812|NCT03987633||Not displaying trait of interest|Please see above.
16398813|NCT03987620|Experimental|Ibrexafungerp (SCY-078)|300 mg BID for one day
16398814|NCT03987620|Placebo Comparator|Placebo|Matching Placebo
16398815|NCT03987607||Patients scheduled for elective surgery|Patients scheduled for elective surgery requiring neuromuscular blockade
16398816|NCT03987594|Placebo Comparator|TUF|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
16398817|NCT03987594|Experimental|TUF+HD|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
16398818|NCT03987581|Experimental|CBT + mCM + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.
16398819|NCT03987581|Experimental|CBT + mCM + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.
16398820|NCT03987581|Experimental|CBT alone + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
16398821|NCT03987581|Active Comparator|CBT alone + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
16398822|NCT03987568|Experimental|Diagnostic (MRI biospecimen collection)|Patients undergo MRI over 15 minutes before standard of care surgery. Patients also undergo collection of blood samples during MRI and at the time of surgery.
16398823|NCT03987542||Exposed|Patients who had their asparaginase treatment truncated or had no asparaginase enzyme activity.
16398824|NCT03987542||Unexposed|Patients who did not have their asparaginase treatment truncated and had measurable asparaginase enzyme activity
16398825|NCT03987529||Sevoflurane+Remifentanil|Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil
16398826|NCT03987529||Propofol+Remifentanil|Using continuous infusion of Propofol and Remifentanil
16398827|NCT03987516|Experimental|Active intervention|Patients will be included in an active intervention.
16423471|NCT03816189||Limited SSc|Recruitment of 20 patients with limited SSc
16398829|NCT03987503|Experimental|at Point-of-Diagnosis HCV treatment|At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
16398830|NCT03987503|Active Comparator|Passive observation|Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
16398831|NCT03987490|Experimental|Parents of Girls|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
16398832|NCT03987490|Experimental|Parents of Boys|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
16398833|NCT03987477|Experimental|Experimental group|The experimental group will be exposed to a brief online program aimed at the modification of negative emotional cognitive biases. The program consists of an introduction and four 1-hour sessions, in video format. In each session, participants are required to complete some open questions and scales about the type of cognitive bias addressed in each session. All sessions are structured in four parts: 1) description and examples of some specific cognitive biases; 2) information about negative consequences of each bias; 3) explanation of adaptive strategies to modify cognitive biases (i.e., the four-questions approach used in standard Cognitive behavioral therapy); and 4) use of some practices to familiarize participants with the use of those strategies.
16398834|NCT03987477|Other|Waiting list group|The control group will be composed of individuals waiting for the treatment. Participants will not be exposed to the experimental program or any other between the pre-evaluation and the post-evaluation sessions. Participants in this group will have access to the potential benefits of the intervention after the post-evaluation of both groups.
16398835|NCT03987464|Experimental|Patients with MCI|Participants diagnosed with mild cognitive impairment (MCI) and their study partners
16398836|NCT03987451|Experimental|Semaglutide|Dose escalation to 2.4 mg of semaglutide once-weekly
16398837|NCT03987451|Placebo Comparator|Placebo|Semaglutide placebo once-weekly
16398838|NCT03987438|Experimental|Behavioral intervention|Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
16398839|NCT03987438|No Intervention|Control group|Participants randomized to the control group have regular care in their local hospitals. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
16398840|NCT03987425|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
16398841|NCT03987425|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
16398842|NCT03987412|Experimental|Behavioral intervention|Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
16398843|NCT03987412|No Intervention|Control group|Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
16398844|NCT03987399|Experimental|Tailored educational intervention|The intervention will be based on previous research and results from baseline (T1). The intervention will be a one-day educational day and includes lectures and workshops with main focus on the lowest competence in pediatric postoperative pain management. Healthcare providers at the included surgical wards will be invited to participate on this educational day. As a supplement, there will be provided clinical supervision in pediatric postoperative pain management and reminders (such as lectures and posters) over a period of six months after educational day.
16398845|NCT03987386|Active Comparator|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy daily over 6.5 weeks after standard of care surgery.
16398846|NCT03987386|Experimental|Arm II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 4.5 weeks after standard of care surgery.
16398847|NCT03987334|Experimental|Experimental Group (VRT)|Subjects in the experimental group (VRT) will undergo 30 minutes of motor control exercises using a virtual reality-based sensorimotor rehabilitation provided using the Virtual Reality Rehabilitation System (VRRS) of Khymeia Group. The equipment includes a computer workstation connected to a 6 degrees of freedom (DOF) motion-tracking system (Polhemus G4, Vermont, US), a high-resolution LCD displaying the virtual scenarios on a large screen and a software processing the motion data coming: from the receiver of the sensors end-effectors placed on the sternum and on the head through a helmet. The system has been found to reliably record head position and cervical range of motion among asymptomatic people as well as persistent neck pain patients. The VRRS allows the participant to perform the requested motor tasks, while the movement of the system's end-effector is simultaneously represented in a virtual scenario.
16398848|NCT03987334|Active Comparator|Control Group (CT)|Control group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
16398849|NCT03987321|Experimental|Denali Group|Those who received Denali filter placement
16398850|NCT03987321|Experimental|Celect Group|Those who received Celect filter placement
16398851|NCT03987308|Experimental|Beinaglutide|Five-week Beinaglutide pump treatment group
16398852|NCT03987308|Experimental|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
16398854|NCT03987282|Active Comparator|Enhanced usual care (EUC)|The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
16398855|NCT03987282|Experimental|Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model|The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
16398856|NCT03987269|Active Comparator|Intervention, Virtual Reality Group|The intervention group to experience the virtual reality embodied narrative experience.
16398857|NCT03987269|Placebo Comparator|Control, Narrative Video Group|The control group to watch the same narrative video content that has been formatted for standard television
16398858|NCT03987256|Experimental|ECRB needling with adjuvant PRP infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy
~Second step: one single tendon needling with PRP"
16398859|NCT03987256|Active Comparator|ECRB needling with adjuvant NaCl 0.9% infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy
~Second step: one single tendon needling with Saline solution"
16398860|NCT03987243|Other|Intervention|Two interventions will be provided. The first intervention is a structured education regarding pressure ulcer prevention through weight shifts at start of study. The second intervention is the use of a mobile seat interface pressure map (IPM), which will occur during two intervention phases.
16398861|NCT03987230|Active Comparator|Oust™ Demodex® Wipes™|Participant cleans eyelids with Oust™ Demodex® Wipes™
16398862|NCT03987230|Active Comparator|I-LID N LASH PLUS® Eyelid Cleanser|Participant cleans eyelids with I-LID N LASH PLUS® Eyelid Cleanser
16398863|NCT03987230|Active Comparator|Blephadex Lid Wipes|Participant cleans eyelids with Blephadex Lid Wipes
16398864|NCT03987230|Active Comparator|Eye Cleanse Lid Wipes|Participant cleans eyelids with Eye Cleanse Lid Wipes
16398865|NCT03987230|Active Comparator|Blephademodex|Participant cleans eyelids with Blephademodex
16398866|NCT03987230|Placebo Comparator|Sensitive Eyes® Plus Saline Solution|Participant cleans eyelids with Sensitive Eyes® Plus Saline Solution
16398867|NCT03987217|Experimental|Group I (resistance training)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minute each for 12 weeks.
16398868|NCT03987217|Experimental|Group II (resistance training, creatine supplementation)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minutes each for 12 weeks and receive creatine monohydrate supplementation given orally 4 times daily during week 1, and then QD (once per day) during weeks 2-12.
16398869|NCT03987204|Experimental|Ivabradine|Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.
16398870|NCT03987191|Active Comparator|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
16398871|NCT03987191|Experimental|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
16398872|NCT03987178|Experimental|Head Dunk|Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
16398873|NCT03987178|Placebo Comparator|No Head Dunk|Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
16398874|NCT03987165|Experimental|Music Therapy|Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
16398875|NCT03987165|No Intervention|Control|
16398876|NCT03987152|Other|Sirolimus|Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
16398878|NCT03987126|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.
~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)"
16398879|NCT03987126|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.
~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
16398880|NCT03987087|Experimental|Radiotherapy group|Thoracic intensity modulated radiation therapy (IMRT) concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.Cisplatin Thoracenteral infusion chemotherapy。 Thoracic intensity modulated radiation therapy (IMRT) concomitant with Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations.
16398881|NCT03987087|Active Comparator|Chemotherapy group|"EGFR-TKI on paticipants with known sensitive EGFR mutations,Cisplatin Thoracenteral infusion chemotherapy.
~Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations."
16398882|NCT03987074|Experimental|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
16398883|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
16398884|NCT03987074|Experimental|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
16399487|NCT03982693|Active Comparator|Active|edetate disodium (EDTA)dff active infusion
16398885|NCT03987074|Experimental|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
16398886|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
16398887|NCT03987061|Experimental|MOTIV bioresorbable vascular scaffold|MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
16398888|NCT03987048||Cirrhotic patients with septic shock|All consecutive adult cirrhotic patients admitted to the ICU with septic shock from 2002 to 2013.
16398889|NCT03987035|Experimental|BGP Stent Graft System|BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms
16398890|NCT03987022|Experimental|"ICE-T"|"Regimen #1 ICE-T Opioid Sparing Regimen At the end of surgery patients will receive 30mg of intravenous (IV) toradol. Once out of the post anesthesia care unit (PACU) patients will receive
~ICE PACKS applied to the surgical sites every hour for 20 minutes Around the clock (ATC) until discharge.
~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.
~Once out of the PACU will receive 1 gram of Tylenol per os (PO) every 6 hours for a total of 4 grams daily ATC until discharge
~Patients will receive dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain.
~Patients will be discharged home with (PO) Tylenol and PO toradol as needed (PRN)."
16398891|NCT03987022|Active Comparator|Standard of care|"Regimen #2 STANDARD Postoperative Regimen
~Once out of the PACU patients will receive Standard postoperative regimen
~Motrin 600mg PO every 4 hours PRN pain scale 1-3 pain
~Percocet 1 tab PO every 4-6 hours PRN pain scale 4-6 pain
~Percocet 2 tabs PO every 7-10 hours PRN pain scale 7-10 pain
~Patients will receive dilaudid 0.2mg IV every 3 hours PRN for breakthrough pain.
~Patients will be discharged home with Motrin and Percocet for pain PRN."
16398892|NCT03987009|Experimental|Without RAMP and without video|Sniffing position and a standard Macintosh laryngoscope
16398893|NCT03987009|Experimental|With RAMP and with video|Ramped position and a McGrath Mac videolaryngoscope
16398894|NCT03987009|Experimental|Without RAMP and with video|Sniffing position and a McGrath Mac videolaryngoscope
16398895|NCT03987009|Experimental|With RAMP and without video|Ramped position and a standard Macintosh laryngoscope
16398896|NCT03986996|Active Comparator|Group 1 -Amoxycillin Doxycyclin and metronidazole|triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.
16398897|NCT03986996|Experimental|Group 2 -Amoxycillin and Doxycyclin|double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.
16398898|NCT03986983|Experimental|Experimental group of Aerobic exercise|The participants perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
16398899|NCT03986983|Experimental|Experimental group of Shockwave therapy and Aerobic Exercise|"The participants do the Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position.
~In addition, the participants also perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch."
16398900|NCT03986983|No Intervention|Control group|The participants do not perform any type of intervention.
16398901|NCT03986970|No Intervention|Arm 1: Control|No PrEP.
16398902|NCT03986970|Experimental|Arm 2: FTC-TDF|FTC-TDF one day, 5 hours before circumcision.
16398903|NCT03986970|Experimental|Arm 3: FTC-TDF|FTC-TDF one day, 21 hours before circumcision.
16398904|NCT03986970|Experimental|Arm 4: FTC-TDF|FTC-TDF two days, 5 hours before circumcision.
16398905|NCT03986970|Experimental|Arm 5: FTC-TDF|FTC-TDF two days, 21 hours before circumcision.
16398906|NCT03986970|Experimental|Arm 6: FTC-TAF|FTC-TAF one day, 5 hours before circumcision.
16398907|NCT03986970|Experimental|Arm 7: FTC-TAF|FTC-TAF one day, 21 hours before circumcision.
16398908|NCT03986970|Experimental|Arm 8: FTC-TAF|FTC-TAF two days, 5 hours before circumcision.
16398909|NCT03986970|Experimental|Arm 9: FTC-TAF|FTC-TAF two days, 21 hours before circumcision.
16398910|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
16398911|NCT03986944|Experimental|Linzagolix 75 mg|
16398912|NCT03986944|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
16398913|NCT03986944|Placebo Comparator|Placebo|
16398914|NCT03986931|Experimental|Pharmacist-Bidirectional Texting Group|Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
16398915|NCT03986931|Active Comparator|Control Group|Patients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.
16398916|NCT03986918||Ovation and Ovation Tribute|All patients having undergone a total hip arthroplasty that received the Ovation® or Ovation Tribute® (Ortho Development, Draper, Utah) Hip system will be sent the survey.
16398917|NCT03986905|Experimental|Scopolamine Nasal Gel|DPI-386 Nasal Gel + placebo patch
16398918|NCT03986905|Placebo Comparator|Placebo|placebo nasal gel + placebo patch
16398919|NCT03986905|Active Comparator|TDS Patch|placebo nasal gel + TDS patch
16398920|NCT03986892||COmPLETE-Health|No intervention
16398921|NCT03986892||COmPLETE-Heart|No intervention
16398922|NCT03986866|No Intervention|No Video|Patients are not shown the informational video on the safe usage of opioids.
16398923|NCT03986866|Experimental|Video|Patients are shown an informational video on the safe usage of opioids.
16398924|NCT03986853|Experimental|Blood sample|Blood sampling Under general anesthesia
16399488|NCT03982693|Placebo Comparator|Placebo|Placebo infusion
16398925|NCT03986840|Experimental|Exercise program|The exercise program was applied for 6 weeks. A total of 18 sessions were distributed in 3 weekly sessions. The participants performed a resistance exercises: leg press at an intensity of 40%-60% with 10 repetitions, 12 repetitions of steps with their bodyweight and a plantar flexion followed by a cardiovascular HIIT exercise walking on a treadmill.
16398926|NCT03986840|Active Comparator|Daily activities|The patients who belongs to this group will continue to perform their daily routines.
16398927|NCT03986827|Experimental|Cool Kids Anxiety Program - Social Enhanced (CK-E)|CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
16398928|NCT03986827|Active Comparator|Cool Kids Anxiety Program (CK)|"The standard Cool Kids Anxiety Program is a treatment program based on generic CBT techniques such as cognitive restructuring and gradual exposure.
~The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session."
16398929|NCT03986801|Experimental|PASS pharmaceutical interview|
16398930|NCT03986801|No Intervention|Usual management out of hospital|
16398931|NCT03986788|Other|Weightlessness|Weightlessness measurements during flight
16398932|NCT03986775|Active Comparator|citrus drink with isomaltulose|
16398933|NCT03986775|Placebo Comparator|citrus drink with sucrose|
16398934|NCT03986762|Experimental|Open Label Clav|
16398935|NCT03986749|Experimental|ARCR-BursaSeries|Tendon healing in the reconstruction of the rotator cuff, taking advantage of augmentation potential of the subacromial bursa.
16398936|NCT03986736||Patients with major trauma|Patients with major trauma will be included in the study.
16398937|NCT03986697|Active Comparator|Bictarvy|Intervention group: those randomised to switch antiretroviral therapy to Bictegravir, Emtricitabine and Tenofovir Alafenamide fixed dose combination.
16398938|NCT03986697|No Intervention|Usual therapy|Control group: those randomised to continue their usual antiretroviral regime
16398939|NCT03986684||Non-NAFLD|
16398940|NCT03986684||NAFLD|
16398941|NCT03986671|Experimental|EMG Testing|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
16398942|NCT03986658|Experimental|Adolescents|Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
16398943|NCT03986645|Experimental|4DFLOW|Acquire MR 4DFLow data.
16398944|NCT03986632|Experimental|Tundra gifts program|
16398945|NCT03986632|No Intervention|Comparison|
16398946|NCT03986606|Experimental|Open-label Dose Escalation and Expansion Study of PSB205|"Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.
~Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts."
16398947|NCT03986593|Other|Cryoablation +- cementoplasty treated patients|cone beam computed tomography guided cryoablation +- cementoplasty
16398948|NCT03986580|Other|Annular closure device|Single arm study; all patients treated with an annular closure device
16398949|NCT03986567|Active Comparator|control|Providing with a paper notification card to the STI diagnosed young person
16398950|NCT03986567|Experimental|intervention web app|providing to the STI diagnosed young person, with a code number to enter into the app to notify sexual partners
16398951|NCT03986567|Experimental|intervention game|providing to the STI diagnosed young person, with a code number to enter into the app and play a game to get motivated to notify sexual partners
16398952|NCT03986554|Other|Randomization Visit A|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Each sequence will be use VFSS to visualize swallows.
16398953|NCT03986554|Other|Randomization Visit B|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Sequences 1 and 3 will use videofluoroscopy only, while sequence 2 will use VFSS with simultaneous pharyngeal high resolution manometry in order to visualize swallows.
16398954|NCT03986541||Retrospective cohort|Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
16398955|NCT03986541||Prospective cohort|Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
16398956|NCT03986528|Experimental|Kanglaite Injection + Chemotherapy|Participants receive Kanglaite Injection PLUS first-line chemotherapy.
16398957|NCT03986528|Active Comparator|Chemotherapy|first-line chemotherapy.
16398958|NCT03986515|Experimental|treatment group|"apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.
~SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.
~(the first dose of SHR-1210 is set on the 3-5 days after apatinib"
16398959|NCT03986502|Experimental|Arm I (financial navigation program)|Patients and caregivers watch a web-based financial literacy video and receive information about financial counseling, direct medical cost and healthcare coverage assistance, and indirect and non-medical cost assistance.
16398960|NCT03986502|Active Comparator|Arm II (usual care)|Patients and caregivers participate in usual clinic procedures and utilize any available clinic or community-based financial resources. Patients and caregivers will also be provided the financial navigation videos and worksheets from the intervention.
16398961|NCT03986489|Experimental|Mindfulness-based dance/movement therapy|Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered online by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.
16398962|NCT03986489|Active Comparator|Chronic pain social support group|Participants assigned to the control condition will participate in a 12-session (90-minute session/week) online social support group.
16398963|NCT03986476|Experimental|Lactobacillus reuteri strain 1|Probiotic compound
16398964|NCT03986476|Experimental|Lactobacillus reuteri strain 2|Probiotic compound
16398965|NCT03986476|Placebo Comparator|Placebo|Placebo
16398966|NCT03986463||Cohort 1|"Stage III NSCLC as per the American Joint Committee on Cancer 8th edition (AJCC 8th ed.)
~Appropriate to undergo concurrent chemotherapy and radiation
~Planned radiation dose must be between 54 and 66 Gy
~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine
~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2
~No prior system chemotherapy (induction) for their stage III NSCLC, any adjuvant chemotherapy given for resected disease must have been at least 100 days prior to enrollment"
16398967|NCT03986463||Cohort 2|"Stage IV NSCLC or stage III NSCLC, as per the AJCC 8th ed.
~Planning to start systemic cytotoxic chemotherapy, without concurrent radiation
~Previous treatment with tyrosine kinase inhibitors or immunotherapy (PD-1, PD-L1, CTLA4 directed antibodies) is allowed as long as no cytotoxic chemotherapy was given concurrently
~Previous palliative radiation is permitted, but must have been completed at least at least 21 days prior to the initiation of treatment
~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine
~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2
~If cytotoxic chemotherapy was previously given for adjuvant or stage III NSCLC it must have been at least 100 days prior to enrollment"
16398968|NCT03986463||Cohort 3|"Patients with advanced NSCLC set to undergo palliative radiation to the primary or regional or distant metastatic lesion(s), including intracranial lesions
~Radiation dose scheduling must be 2.5 to 4.0 Gy on days 1 through 3 for extracranial treatment, ideally 40 Gy in 15 fractions, 20 Gy in 5 fractions, or 30 Gy in 10 fractions.
~Radiation dose for brain lesions must be 6 to 9 Gy per dose, ideally 30 to 35 Gy in 5 daily fractions or 27 Gy in 3 fractions on alternating days
~No plans for concurrent chemotherapy to be given
~Five patients in cohort 3 will receive radiation to the primary tumor and five patients will receive radiation to brain lesions"
16398969|NCT03986450|Active Comparator|ERAS group|Patients in this group will receive ERAS protocol preoperatively, perioperatively and postoperatively.
16398970|NCT03986450|No Intervention|Control|This group of patients will not receive ERAS care and will undergo a standard laparoscopic hysterectomy.
16398973|NCT03986411|Other|Feasibility study of physiotherapy for UI in athletic women|A mixed methods study with 3 distinct but related phases to explore the feasibility of conducting an RCT of physiotherapy as management of urinary incontinence in athletic women
16398974|NCT03986398|Experimental|Prophylactic efficacy of Urell®|Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty
16398975|NCT03986385|Experimental|A(apatinib Xelox)|Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
16398976|NCT03986385|Active Comparator|B(Xelox)|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles
16398977|NCT03986372|Experimental|PRP injection, once|PRP injection, once
16398978|NCT03986372|Experimental|PRP injection, twice|PRP injection, twice, 2 weeks apart
16398979|NCT03986372|Experimental|PRP injection, 3 times|PRP injection, 3 times, 2 weeks apart
16398980|NCT03986359|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
16398981|NCT03986359|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
16398982|NCT03986346|Experimental|Laser group|Participants in this group receive pulsed dye laser to treat the scar.
16398983|NCT03986346|Active Comparator|Control group|Participants in this group receive standardized care.
16398984|NCT03986333||Control|Children whose drooling was expected to remain relatively stable over 1 month
16398985|NCT03986333||Intervention|Children receiving a treatment to reduce their drooling
16398986|NCT03986320|Experimental|Keeogo™ Dermoskeleton|Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
16398987|NCT03986307|Experimental|Omega-3|Elderly supplemented with omega-3.
16398988|NCT03986307|Placebo Comparator|Placebo|Elderly supplemented with corn oil.
16398989|NCT03986294|Experimental|S1 and liposomal irinotecan|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
16398990|NCT03986294|Experimental|Liposomal irinotecan, Leucovorin and 5-fluoracil|Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
16398991|NCT03986281|Active Comparator|Omron HeartGuide Smartwatch|Readings from the Omron HeartGuide Smartwatch
16398992|NCT03986281|Active Comparator|Arterial Line|Readings from the arterial line
16398993|NCT03986268|Active Comparator|study group|The patients measured a total of 25 OH vitamin D3 levels, initial, 3'th month and 6'th month of neoadjuvant therapy with replacement treatment with vitamin D3 at least weekly 50000 IU for eight weeks.
16398994|NCT03986268|Other|control group|The patients had measured a total of 25 OH vitamin D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamin D3.
16398996|NCT03986242|Experimental|static stretchin|Static extremity muscles of the lower extremities, including: gluteal muscles (major muscle group: gluteus maximus), anterior thigh muscles (strand rectus, medial femoral muscle, lateral femoral muscle, medial femoral muscle), posterior thigh muscles (main muscle) Group: semimembranosus, semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). 4 groups per muscle group, 30 seconds/group
16398997|NCT03986242|Experimental|non- vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each leg of each pair performs 30 seconds/group for a total of 4 groups for a total time of 20 minutes.
16398998|NCT03986242|Experimental|Vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each muscle group of each foot performs 30 seconds/group, a total of 4 groups, the vibration frequency is 28 Hz, and the total time is 20 minutes.
16398999|NCT03986229|Active Comparator|With compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
16399000|NCT03986229|Active Comparator|Without compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
16399001|NCT03986216|Experimental|Home based group|This group will involve 2-4 randomly selected participants who have already completed the lab based sessions. They will use the developed ReIn-Hand device to assist them to practice 'reach-grasp-retrieve-release' movements at home, 1 hours per day (20 trials), 7 days per week for 12 weeks.
16399002|NCT03986203|Experimental|Active|Subjects in this group will receive the active treatment for each daily treatment session.
16399003|NCT03986203|Sham Comparator|Sham|Subjects in this group will receive the sham treatment for each daily treatment session.
16399004|NCT03986190|Experimental|Healthy Juntos Intervention Condition|Parent-adolescent dyads randomized to the Healthy Juntos intervention condition will access a program that includes didactic, behavioral, and positive parenting content from their smartphones for 8 weeks.
16399005|NCT03986190|No Intervention|Control Group|This group will receive a digital standard of care - a list of publicly available lifestyle apps and websites which they may access at their discretion.
16399006|NCT03986177|Experimental|Intervention|The intervention arm will receive a multi-faceted self-management intervention package.
16399007|NCT03986177|No Intervention|Enhanced care|The control arm will receive usual care plus basic asthma education from a trained nurse educator.
16399008|NCT03986164|Active Comparator|Guided surgery (GS)|Installation of dental implant with the aid of the virtually planned guide by means of specific software
16399009|NCT03986164|Active Comparator|Conventional surgery (CS)|Installation of dental implant performed freehand using a conventional surgical guide made by study models
16399010|NCT03986151|Active Comparator|Conventional radial access|
16399011|NCT03986151|Experimental|Distal radial access|
16399012|NCT03986138|Experimental|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
16399013|NCT03986138|Experimental|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
16399014|NCT03986125|Experimental|Emotional Awareness & Expression Therapy|Participants will attend three individual sessions focused on becoming aware of and expressing avoided or conflicted emotions.
16399015|NCT03986125|Experimental|Mindfulness Meditation Training|Participants will attend three individual sessions focused on increasing equanimity and compassion and reducing self-judgement.
16399016|NCT03986125|No Intervention|Wait-List Control|Participants will receive the intervention of their choice following assessment at four and eight weeks after randomization.
16399017|NCT03986112||hypertensive group|Evaluation of the ability of carotid sonography and inferior vena cava sonography for the post-induction hypotension in hypertensive patients undergoing general anesthesia
16399018|NCT03986099|No Intervention|Standard of care|SOC viral load
16399019|NCT03986099|Active Comparator|Near point of care|POC viral load
16399020|NCT03986086|Experimental|MPH966|Participants receive MPH966 at RP2D tablet orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
16399021|NCT03986086|Placebo Comparator|Placebo|Participants receive MPH placebo tablet matching MPH966 orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
16399022|NCT03986073|Experimental|Low dose group|Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
16399023|NCT03986073|Experimental|High dose group|Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
16399024|NCT03986073|Active Comparator|Positive drug control group|Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.
16399025|NCT03986073|Placebo Comparator|Placebo group|Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
16399026|NCT03986047|Experimental|Thermal care|Participants will be asked to wear a heat wrap over the lower lumbar spine, during the day for 8 hours on 7 consecutive days. The Thermal care group will also receive education by a physiotherapist on acute low back pain management.
16399027|NCT03986047|Experimental|Thermal care + exercises|In addition to heat wrap and pain management education as for Thermal care group, participants of this group will be asked to perform exercises at home over 7 days, targeted on functional capacity, lumbar mobility, and slight contraction of trunk muscle (posture and/or cognitive).
16399028|NCT03986047|Sham Comparator|Control|Participants in the control group will receive the same education program as those of the two other groups. A sham non-heating wrap will be used to control for potential supportive and sensory influence of the heat wrap.
16399029|NCT03986034|Experimental|Relapsed/Refractory CLL pts|Ages 18 and older
16399031|NCT03986008|Experimental|Benaglutide|Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
16399032|NCT03986008|Active Comparator|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
16399033|NCT03985995|Active Comparator|CBD 800 mg p.o.|The study Investigational Medical Product (IMP) is a cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration.
16399034|NCT03985995|Placebo Comparator|Placebo p.o.|Participants in the control arm will be receiving a single dose of oral placebo solution 8 ml matched to the active comparator.
16399035|NCT03985982|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
16399036|NCT03985982|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
16399037|NCT03985969|Experimental|DDI|Period 1: study of elafibranor's pharmacokinetics Period 2: study of elafibranor's pharmacokinetics under CHRONO-INDOCID® (indomethacin) at steady state
16399038|NCT03985943|Placebo Comparator|Placebo|Placebo
16399039|NCT03985943|Experimental|Nemolizumab|Nemolizumab Active
16399040|NCT03985930|Experimental|Distraction Group|Children between the ages of 3 and 6 years will be distracted using virtual reality content delivered through goggles. Since exposure to video screens has been previously discouraged by various scientific and professional medical organizations in children under 3 years of age, these children will be distracted using video projections of the same content.
16399041|NCT03985930|Active Comparator|Treatment as Usual|Children randomized to this group will receive the usual medical care.
16399042|NCT03985917|Experimental|Intervention Singing Group Program|Singing group intervention program that includes six components: (1) vocal warm-up exercises; (2) vocal technique; (3) rehearsal of repertoire; (4) break for socialization; (5) creation and presentation of a show; (6) assessment of participants performance (vocal tuning).
16399043|NCT03985917|Active Comparator|Alternative Social and Leisure Activities|While the experimental group is participating in the intervention program, the control group will participate in the other activities proposed by the day care centers, which will be registered.
16399044|NCT03985904|Experimental|Art Therapy|Participants will attend art therapy group sessions for three months in a designated museum.
16399045|NCT03985904|No Intervention|Control|Participants will NOT attend art therapy group sessions but will continue with usual care during the three months
16399046|NCT03985891|Experimental|JS001 in combination with Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks) in combination with JS001 (3mg/kg, Q2W). Patients will receive 6 cycles treatment in pre-operation and same cycles after operation.
16399047|NCT03985891|Active Comparator|Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks). Patients need to receive 6 cycles treatment in pre-operation and same cycles after operation.
16399048|NCT03985878|Experimental|Eteplirsen|Patients will receive eteplirsen via intravenous (IV) infusions, once weekly, for up to 284 weeks.
16399049|NCT03985865|Experimental|Intragastric quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
16399050|NCT03985865|Experimental|intragastric denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
16399051|NCT03985865|Placebo Comparator|Intragastric placebo|0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
16399052|NCT03985865|Experimental|Intraduodenal quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
16399053|NCT03985865|Experimental|Intraduodenal denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
16399054|NCT03985865|Placebo Comparator|Intraduodenal placebo|0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
16399055|NCT03985852|Active Comparator|Patient Directed Standard of Care|Patients receive pre-test genetic counseling and, if relevant, post-test counseling for a negative result from an automated genetics education assistant.
16399056|NCT03985852|No Intervention|Enhanced Standard of Care|Patients receive standard counseling from a genetic counselor.
16399060|NCT03985826||Childhood ALL survivors|The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
16399061|NCT03985826||Comparison cohort|A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
16399062|NCT03985813|Experimental|Screening Wizard|Youth and parents receiving Screening Wizard will be screened for depression and suicidal risk within their pediatric primary care provider's office. Screening will be analyzed in real-time to produce a decision support tool meant to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
16399063|NCT03985800|Active Comparator|TEAM-care as usual approach|Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
16399064|NCT03985800|Active Comparator|TECH-telehealth approach|Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
16399065|NCT03985787|Experimental|All Participants|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
16399066|NCT03985774||Patients requiring carotid revascularization|Symptomatic patients, male or female, with atherosclerotic extracranial internal carotid stenosis (ICA) with or without involvement of the contiguous common artery (CCA), that require carotid revascularization.
16399067|NCT03985761|Experimental|Home Telerehabilitation_Motivation Enhanced HTme|The Home Telerehabilitation Motivation Enhanced (HTme) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTme group will use three simulations that will provide the user with eight to twelve levels of gradually increasing difficulty and complexity. A screen announces each level change and the graphics for each new level change substantially. Scoring opportunities increase at each new level.
16399068|NCT03985761|Active Comparator|Home Telerehabilitation_Unenhanced (HTu)|The Home Telerehabilitation Motivation Enhanced (HTu) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTu group will use three simulations. Difficulty will be increased utilizing an adaptive control algorithm that increases difficulty based on performance. Difficulty changes are extremely incremental making them imperceptible for most subjects. Graphics and scoring do not change as difficulty level changes.
16399069|NCT03985748|Experimental|Breath Actuated Nebulizers (BAN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
16399070|NCT03985748|Active Comparator|Standard Nebulizer (SN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
16399071|NCT03985735||Group good sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).
~Sleeping time are more than six hours."
16399072|NCT03985735||Group poor sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).
~Sleeping time are less than two hours."
16399073|NCT03985722|Experimental|Unlimited cycles of Olaratumab and Trabectedin|"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label,.
~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."
16399074|NCT03985709|Experimental|Probiotcal group|Probiotic (Lactobacillus casei) once daily taken by 3 months
16399075|NCT03985696|Experimental|patients with DLBCL|
16399076|NCT03985696|Active Comparator|Healthy volunteers|
16399077|NCT03985683|Active Comparator|Control group|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
16399078|NCT03985683|Experimental|Experimental (Nutritional Interventional)|In experimental group athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively. Average carbohydrates required for athletes are 6 to 10 gram per kilogram per day. T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test will use as baseline assessment and after 6 days of intervention.
16399079|NCT03985670|Experimental|treatment group|teripalimab 240mg d1 paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1
16399080|NCT03985670|Active Comparator|chemotherapy followed by immunotherapy|paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1 teripalimab 240mg d3
16399081|NCT03985657|Active Comparator|Baseline Sleep Study|Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
16399082|NCT03985657|Experimental|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
16399083|NCT03985644||Fulfilling Hangzhou criteria|"Patients flfilling Hangzhou critieria:
~Without macrovascular invasion Tumor burden <=8 cm Preoperative AFP level <=400 ng/mL Histopathologic grades I, II"
16399084|NCT03985644||Exceeding Hangzhou criteria|Patients exceeding Hangzhou critieria
16399085|NCT03985631|Experimental|Telerehabilitation|Tai Chi intervention by telerehabilitation (3-month intervention, three sessions per week: two supervised session and one unsupervised session).
16399086|NCT03985618|Active Comparator|Randomized Caesarean section|Randomized to planned pre-labour Caesarean section
16425191|NCT03804775||control group|inpatients with no history of gallstones
16399087|NCT03985618|Active Comparator|Randomized Induction of Labour|Randomized to planned induction of labour
16399088|NCT03985618|Active Comparator|Preference Caesarean section|Preference for planned pre-labour Caesarean section
16399089|NCT03985618|Active Comparator|Preference Induction of Labour|Preference for planned Induction of Labour
16399090|NCT03985592|Other|Educational Intervention for ICU-Based Clinicians|ICU-based clinicians (e.g. physicians, RNs, and social workers) will be provided with educational modules related to bereavement support for family members. Following the modules a survey will be provided to participants to assess their perceived usefulness of the modules.
16399091|NCT03985592|Experimental|Educational material and personalized card of condolence|Members of the ICU team who cared for deceased ICU patients will be asked to send a letter of condolence to family members listed as the patient's primary contact and provide them with educational modules related to bereavement support for family members.
16399092|NCT03985592|Experimental|Virtual meeting with the care team to address unmet needs|At 8-12 weeks post-death, we will contact FMs and invite them to meet virtually with the care team. Our observational studies indicated that the most common need reported by bereaved FMs was the desire to meet with the care team to review events during the ICU stay and particularly the events that led to death, and that this was the type of support that ICU clinicians were most comfortable providing.
16399093|NCT03985592|Experimental|Offering a facilitated storytelling intervention session|At six months post-death, we will contact FMs and administer the Inventory of Complicated Grief-Revised (ICG-r), Brief Grief Questionnaire (BGQ), Impact of Events Scale - Revised (IES-r), Patient Health Questionnaire-9 (PHQ-9), and the Bereavement Dependency Scale (BDS). FMs who complete all questionnaires will be invited to participate in a 1-2-hour narrative exploration of their grief and bereavement experience, regardless of the severity of their symptoms. Those with severe symptoms will be notified of symptom severity, with a suggestion to participate in the narrative exploration of their grief and bereavement experience. Storytelling interventions require specialized resources but the results of Barnato et al., as well as the response to our qualitative interviews, suggest that this intervention may only be helpful for selected FMs. Storytelling interventions have been shown to reduce healthcare utilization and improve subjective health following a traumatic experience.
16399094|NCT03985579|Experimental|Standard care and Kinesiology taping Group|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders.
16399095|NCT03985579|No Intervention|Standard care Group|Assistance in baby feeding, manual of device-assisted (lactator) milk expression, cold compress, ibuprofen, gentle breast massage, breathing and shoulder girdle exercise.
16399096|NCT03985566|Experimental|Fibre Grains|Fibre grains were used to partially replaced Jasmine white rice in this arm.
16399097|NCT03985566|Placebo Comparator|Jasmine white rice|Jasmine white rice is used as a control to compare the outcome.
16399098|NCT03985553|Other|Parenting Self-Management Program|Participants were provided a Parenting Self -Management Program booklet with the twenty-four fact sheets at the beginning of the four-week program on topics such as adaptive babycare techniques, advocacy in the courts, emergency planning, safety in the community, talking to children about disability, managing pain/fatigue, connecting to other parents with SCI/D, and wheelchair adjustment/management during and after pregnancy. Sessions included topic introduction, participant interaction, goal setting, resource utilization, and program evaluation. Participants were allowed to choose which resources they wanted and what tips to incorporate into their parenting roles. Participants were asked to develop a weekly goal to encourage achievement, allowing individuals to identify what they wanted or decided to do that could be related to parenting directly or indirectly, such as health and wellness goals that gave them more energy or strength to complete parenting tasks.
16399099|NCT03985540|Experimental|memory experimental group|Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
16399100|NCT03985540|Placebo Comparator|Placebo comparator memory|Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
16399101|NCT03985540|Experimental|Processing speed|Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
16399102|NCT03985540|Placebo Comparator|Processing speed placebo|Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
16399103|NCT03985527|Experimental|Transvenous nerve stimulation|
16399104|NCT03985514|Active Comparator|Antibiotic treatment|Patients will receive in-hospital intravenous antibiotics (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3). Surgery if no symptom relif occur.
16399105|NCT03985514|Other|Clinical observation|"Patients are followed by in-hospital Active observation (watchful waiting) according to clinical routine. Patients are observed until either, recovery and dismissal from hospital, or decision for intervention (surgery) is taken."
16399107|NCT03985488||Eview Fluoroscopy Machine|The Eview Fluoroscopy Machine is the standard of care fluoro machine used in endoscopy.
16399108|NCT03985488||Fluoroshield Device|The FluoroShield technology (Omega Medical Imaging) has been developed in an effort to further reduce the degree of radiation exposure to patients and provides. This technology is an additional component that can be fitted to the preexisting Eview fluoroscopy machines, in order to further filter radiation that has passed through the pre-existing machine.
16399109|NCT03985475||Person with a skin infection|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
16399110|NCT03985462|Experimental|VSEL Max|A total of 300,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a high dose group
16399111|NCT03985462|Experimental|VSEL Medium|A total of 200,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a middle dose group
16399112|NCT03985462|Experimental|VSEL Mini|A total of 100,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a low dose group
16401475|NCT03968991|Experimental|Subjects with congenital visual impairment|Visual congenital disability
16399113|NCT03985462|No Intervention|Control|5 mL plate-rich plasma with no cells inside were injected into the bilateral fallopian tubes as a control group
16399114|NCT03985449|Other|Active Implementation phase|See the 'detailed description' section to read about the intervention(s) clinicians will use during the active implementation phase of the randomized stepped-wedge design.
16399115|NCT03985436|Experimental|Trek for Surgical Success|Cognitive behavioral therapy for pain
16399116|NCT03985423|Experimental|Emapalumab|
16399117|NCT03985410|Experimental|Treatment Sequence ABC|Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
16399118|NCT03985410|Experimental|Treatment Sequence ACB|Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
16399119|NCT03985410|Experimental|Treatment Sequence BAC|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
16399120|NCT03985410|Experimental|Treatment Sequence BCA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
16399121|NCT03985410|Experimental|Treatment Sequence CAB|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
16399122|NCT03985410|Experimental|Treatment Sequence CBA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
16399123|NCT03985397|Experimental|Experimental group (EG)|At the first interview, after the application of the scales to the intervention group patients, planned discharge training and the manual prepared by the researcher were given. The second interview was performed 4 weeks later and the same scales were reapplied.
16399124|NCT03985397|No Intervention|Control group|In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
16399125|NCT03985384|Active Comparator|Semaglutide|Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
16399126|NCT03985384|Placebo Comparator|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
16399127|NCT03985371|Experimental|Drops Used|
16399128|NCT03985358|No Intervention|Control Group|Patients randomized to the Control Group will not receive opioid counseling and will only receive their standard of care instructions for preoperative and postoperative care.
16399129|NCT03985358|Experimental|Treatment Group|Patients randomized to the Treatment Group will have opioid counseling plus standard of care instructions given by the same counselor (investigator on the study) using the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher).
16399130|NCT03985345|Experimental|EMY Probe|
16399131|NCT03985319|Experimental|YYD601 20mg|Esomeprazole IR 10mg + esomeprazole SR 10mg
16399132|NCT03985319|Active Comparator|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca
16399133|NCT03985306|Experimental|Feasibility trial group|Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
16399134|NCT03985293|Placebo Comparator|Placebo|
16399135|NCT03985293|Experimental|PF-06882961 2.5 milligrams (mg)|
16399136|NCT03985293|Experimental|PF-06882961 10 mg|
16399137|NCT03985293|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
16399138|NCT03985293|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
16399139|NCT03985293|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
16399140|NCT03985280|Experimental|Cooled radiofrequency|The procedure will be performed under regimen of major ambulatory surgery, it will be done under guidance of combined X-ray and ultrasound. . The nerves will be located b, after applying AL (Lidocaine 1%), a RF needle will be placed in the objective position.After verifying the positive sensitive and negative motor responses the cooled radiofrequency will proceed (previous application of local anesthesia (lidocaine 2%)). Cooled RF will be performed for 2:30 minutes at 60 degrees.
16399141|NCT03985280|Active Comparator|Intraarticular local anesthetic and steroids injections|An intraarticular injection will be done in ambulatory surgery regimen with a 22 Gauge needle. Intraarticular injection will be done under Fluoroscopic guidance (X-rays) with intra articular position confirmation by infusion of iodine contrast (Omnipaque 240). Once the needle position has been verified we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.
16399144|NCT03985254|Active Comparator|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).
~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
16399145|NCT03985254|Experimental|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
16399146|NCT03985241|Experimental|Functional Assessment of Myocardial Ischemia by icECG|Evaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
16399147|NCT03985228|Experimental|Fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks.
16399148|NCT03985228|Placebo Comparator|Placebo milk|The subjects assumed daily 250 ml of placebo milk for 12 weeks.
16399149|NCT03985202|Experimental|Structured Exercise Programme|"An initial 45 min exercise counselling incorporating behaviour modification techniques.
~Participants will be offered three sessions per week of aerobic interval exercise on a cycle ergometer over nine weeks. Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
~Following this:
~Participants will be encouraged to comply with current physical activity recommendations: 150 min of moderate intensity aerobic exercise per week (brisk walking / cycling). They will also be sign posted to local exercise facilities."
16399150|NCT03985189|Experimental|ME-401|ME-401 administered orally
16399151|NCT03985176||Aneurysmal SAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
16399152|NCT03985137||HIV-infected patients|Male patient presenting at a follow-up consultation for HIV infection or following a Sexual Viral Exposure (EVA) accident, pre-exposure prophylaxis (PrEP) or screening for a Sexually Transmitted Infection (IST).
16399153|NCT03985124|Experimental|Intervention TIK-T|24 kindergartens will receive the full intervention. Dosage: 1 3 hour implementation session for kindergarten leaders; 1 x 2-day training workshop for kindergarten leaders and a lead resource person in each kindergarten who will support teachers in learning and implementing Emotion Coaching with children; 2 full training days for all teachers/childcare workers in Emotion Coaching; 2 x booster sessions for all teachers with the resource person in their kindergarten to assist them in using Emotion Coaching with children in their kindergartens.
16399154|NCT03985124|No Intervention|wait list control|24 kindergartens will be in the 12-month wait list condition
16399155|NCT03985111||No CVC inserted|Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
16399156|NCT03985111||CVC inserted|Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
16399157|NCT03985098|Experimental|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
16399158|NCT03985098|No Intervention|Control|usual care
16399160|NCT03985072|Experimental|Andes-1537|There will be 4 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, gastric cancer, and pancreatic cancer). All patients will receive a dose of 400 mg of Andes-1537 five days per week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression without any noted clinical benefit as assessed by the investigator.
16399161|NCT03985059||Cases|Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
16399162|NCT03985059||Controls|Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
16399163|NCT03985046|Experimental|Sintilimab plus chemotherapy|
16399164|NCT03985033|Experimental|L-PRF|Post-extraction sockets will be filled with autologous leucocyte and platelet-rich fibrin (L-PRF) clot.
16399165|NCT03985033|No Intervention|Control|Post-extraction sockets will be left to heal spontaneously with natural blood clot.
16399166|NCT03985020|No Intervention|Standard of Care|The control group will receive standard of care dietary advice for their solid food and beverage intake.
16399167|NCT03985020|Active Comparator|Water Intervention|We will order and deliver bottled water to the homes of subjects in the treatment group. We will provide each participant with a weekly supply of about 36 16.9 fl oz single-serving containers. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously.
16401579|NCT03968146|Other|Group C|Control group will receive only intravenous fentanyl.
16399168|NCT03985020|Experimental|Stevia Intervention|We will order and deliver a commercially-available stevia-sweetened soft drink Zevia (Los Angeles, CA) to each participant in the treatment group. We will provide each participant with a weekly supply of 24 12 fl oz single-serving containers. Zevia will be provided in an assortment of flavors for the first week, then catered to the preference of the participant for the remainder of the study. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously. Participants will also be asked to keep track of how many containers they consume using a sticker chart, and we will also phone parents weekly to verify the sticker charts
16399169|NCT03985007|Experimental|CDIAG|Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.
16399170|NCT03984994|Experimental|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
16399171|NCT03984994|Active Comparator|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
16399172|NCT03984968|Experimental|CAR-T infusion|CAR-T cells and feeding T cells were infused into remission patients sequentially,with 5*10e6/kg and 1*10e7/kg respectively for each cycle. Each patient underwent 3 cyles of CAR-T consolidation therapies and was followed up for 2 years.
16399173|NCT03984955|Active Comparator|Group A PRP injection|"Platelet-Rich Plasma injection Single therapeutic injection of Platelet-Rich Plasma performed under ultrasound guidance.
~This group will also undergo a class-based physiotherapy intervention. This outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and those receiving the sham injection."
16399174|NCT03984955|Active Comparator|Group B Ostenil Tendon|Sodium hyaluronate with mannitol (Ostenil Tendon) Single therapeutic injection of sodium hyaluronate with mannitol (marketed under the device name Ostenil Tendon) under ultrasound guidance. This group will also undergo a class-based physiotherapy intervention.
16399175|NCT03984955|Sham Comparator|Group C control group|Subcutaneous sham injection. This group will also undergo a class-based physiotherapy intervention. The outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and to those receiving PRP injection.
16399176|NCT03984929|Experimental|Localized Information Resource Intervention|
16399177|NCT03984929|Active Comparator|Generic Information Resource Intervention|
16399178|NCT03984916|Active Comparator|Hesperidin Pharma|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The approximate particle size is less than 100 µm for the 90% of the extract, and of 10 µm for 10% of the extract.
16399179|NCT03984916|Active Comparator|Hesperidin Pharma_M|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The size of 90% of particles is less than 10 µm.
16399180|NCT03984916|Experimental|Cardiose|500 mg of sweet orange extract with more than 90% of the isomer -S. The size of the 90% of particles is less than 10 µm.
16399181|NCT03984903|Active Comparator|Face-to-face Learning Group|
16399182|NCT03984903|Experimental|Multimedia Learning Group|
16399183|NCT03984890|Experimental|Vitamin D Group|Vitamin D3 Supplementation plus traditional treatment of CGD and TB
16399184|NCT03984890|Other|Control Group|Traditional treatment of CGD and TB without Vitamin D Supplementation
16399185|NCT03984877||Amyloidosis|TAVI patients with diagnosis of amyloidosis
16399186|NCT03984877||Non-Amyloidosis|TAVI patients without diagnosis of amyloidosis
16399187|NCT03984864|Experimental|Exercise therapy Chosen|
16399188|NCT03984864|Active Comparator|Exercise therapy no Chosen|
16399189|NCT03984851||Group A: Surgicel Group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
16399190|NCT03984851||Group B: Bipolar Cautery group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
16399191|NCT03984838|Experimental|Subjects receiving Dolutegravir and Rilpivirine FDC|Subjects will receive Dolutegravir/Rilpivirine 50mg/25mg fixed dose combination (FDC) tablet as a single oral dose in a fed state.
16399192|NCT03984825|Experimental|Portia followed by Portia co-administered with GSK3640254|Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
16399223|NCT03984656|Active Comparator|AL group|patients will receive a local infiltration of 10 mL Lidocaine without epinephrine 20 mg/mL
16399202|NCT03984799|Experimental|Bronchoscopy|Research bronchoscopy
16399203|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.
~Participants randomized to this arm will then receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
16399204|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/No Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.
~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
16399205|NCT03984786|Experimental|ICBT alcohol misuse: No Assessment Interview/Guidance|"The client will not receive any assessment interview during the telephone screen.
~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
16399206|NCT03984786|Experimental|ICBT for alcohol misuse: No Assessment Interview/No Guidance|"The client will not receive any assessment interview during the telephone screen.
~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
16399207|NCT03984773|No Intervention|Control|Clinicians will receive current standard communications regarding serious illness performance.
16399208|NCT03984773|Experimental|Mortality Estimates and Nudges|Clinicians will receive a weekly email with upcoming patients that have high mortality estimates to consider for a serious illness conversation. Clinicians will have the opportunity to review the list and pre-commit (using an opt-out design) to patients appropriate for a conversation. They will receive a nudge on the day of the patient visit through a text message reminding them of their pre-commitment to conduct a serious illness conversation
16399209|NCT03984760|Experimental|Ferric Citrate Capsule|Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion & BF Biotech Inc.
16399210|NCT03984760|Active Comparator|Sevelamer Carbonate Tablet|Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited
16399211|NCT03984747||Adult Transplant Patients|Adult subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
16399212|NCT03984747||Pediatric Transplant Patients|Pediatric subjects between ages 2-17 who have undergone at least one organ transplant prior to enrollment and are willing to provide assent/LAR is willing to provide consent.
16399213|NCT03984747||Pregnant Transplant Patients|Pregnant subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
16399214|NCT03984734|Active Comparator|Control group|Patients undergoing pancreatoduodenectomy with antrectomy
16399215|NCT03984734|Experimental|Study group|Patients undergoing pancreatoduodenectomy with pylorus-preserving pancreatoduodenectomy
16399216|NCT03984721|Experimental|Amylose typing|Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed
16399217|NCT03984708|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
16399218|NCT03984708|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
16399219|NCT03984695|No Intervention|Control|"15 minute discharge planning session with health educator
~Health education booklet containing SHE-Women intervention content in print form(N~100)
~access to health educator via text message"
16399220|NCT03984695|Experimental|Intervention|"Deliver text-Web intervention to (N ~100) women
~Researchers will deliver the integrated, multimedia electronic women's health literacy intervention arm of SHEWomen in text-Web format for individuals recently released from jail. Two health educators will be responsible for delivering content to participants, with an estimated contact time of ~10 hours pushed to participants over approximately a 5-day period."
16399221|NCT03984682|Experimental|Experimental group|Patients will benefit from regular care + Joint Crisis Plan
16399222|NCT03984682|No Intervention|Control group|Patients will benefit from regular care
16399309|NCT03984019|Other|A|Radiotherapy; SBRT Additional cardiac diagnostics
16399224|NCT03984656|Experimental|Serratus group|patients will receive ultrasound guided serratus plane block injection of 30 mL Ropivacaine 4.75 mg/mL
16399225|NCT03984643|Experimental|Deep Brain Stimulation|Subjects in this study will have been implanted with a DBS lead in the VIM as part of their routine clinical care and have an existing set of brain MRI's.
16399226|NCT03984630|No Intervention|Control Arm|Participants were informed to continue to receive usual care by their Obstetrician and were asked to send in body weights weekly.
16399227|NCT03984630|Experimental|Intervention Arm|Received snacks high in fiber, attended weekly phone calls, recorded daily food intake and reported weekly body weight for 12 weeks.
16399228|NCT03984604|Active Comparator|CHI-921|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (CHI-921) for 3 weeks, followed by another 3 weeks of treatment at 1.0 mL for and another 3 weeks of treatment at 2.0 mL.
16399229|NCT03984604|Placebo Comparator|Placebo|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (placebo) for 3 weeks, followed by another 3 weeks of placebo treatment at 1.0 mL for and another 3 weeks of placebo treatment at 2.0 mL.
16399230|NCT03984591|Active Comparator|Spironolactone|Spironolactone used according to heart failure guidelines
16399231|NCT03984591|Active Comparator|Eplerenone|Eplerenone used according to heart failure guidelines
16399232|NCT03984578|Experimental|Colon cancers|Pre-operative CAPEOX 1 cycle Pre-operative Pembrolizumab 2 cycles with cycle 1 on Day 1 (concurrent with start of CAPEOX) and cycle 2 on Day 22
16399233|NCT03984578|Experimental|Rectal Cancers|Following completion of neo-adjuvant chemo-radiotherapy, 2 cycles of pre-operative Pembrolizumab administered 3 weeks apart.
16399234|NCT03984565|Experimental|Cannabidiol Treatment Arm|20mg/ml CBD sublingual product administered twice daily for 6 weeks
16399235|NCT03984565|Placebo Comparator|Placebo Treatment Arm|Placebo sublingual product administered twice daily for 6 weeks
16399236|NCT03984539|Active Comparator|CBT-E|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). CBT-E will occur over the course of 25 weeks and be delivered as it typically is in the clinic setting of the investigators.
16399237|NCT03984539|Experimental|CBT-T|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). Participants who agree to participate will receive 10 weeks of CBT-T.
16399238|NCT03984526|Placebo Comparator|Control group|intravenous normal saline pretreatment
16399239|NCT03984526|Experimental|Atropine group|intravenous atropine 0.5mg pretreatment
16399240|NCT03984526|Experimental|Ephedrine group|intravenous ephedrine 8mg pretreatment
16399241|NCT03984513|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
16399242|NCT03984513|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
16399243|NCT03984500|Other|Education|"During phase 1 of this study parents who attend in person education sessions will be recruited to have their standard sessions video-taped, timed, and reviewed by the SCTaware Team. Subjects will complete before and after education questionnaires that will then be reviewed to see how much participants learned about SCT, how education was not clear and/or appropriate (too much medical jargon). The SCTaware education will then be created based on review of these videos and participants' survey responses.
~For phase 2 of the study, the same recruitment strategy will be utilized. Participants will receive SCTaware and complete before and after questionnaires for evaluation. Participants in this phase will also complete follow-up questionnaires at 1 and 6 months."
16399244|NCT03984487|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
16399245|NCT03984487|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
16399246|NCT03984474||Single bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
16399247|NCT03984474||Double bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
16399248|NCT03984461|Active Comparator|Group A - PRP plus Lipoaspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate). Total Volume varies by joint.
16399249|NCT03984461|Active Comparator|Group B - PRP plus Bone Marrow Aspirate|Equal proportions of PRP plus bone marrow aspirate. Total Volume varies by joint.
16399250|NCT03984461|Active Comparator|Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate) plus bone marrow aspirate. Total Volume varies by joint.
16399253|NCT03984435||Patients|Patients with a diagnosed malignancy who have been referred for radiotherapy with extended treatment time (>10 minutes)
16399254|NCT03984435||Radiographers|Radiographers from radiotherapy departments in the UK who deliver radiotherapy
16399255|NCT03984422||Raynaud phenomenon|Use of smartphone application
16399486|NCT03982706||Focal|patients undergoing focal treatment for localized prostate cancer (HIFU, NanoKnife, Cryotherapy)
16399256|NCT03984409|Active Comparator|Group 1|Potassium citrate x 7days Off therapy x 7 days 500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Return to potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
16399257|NCT03984409|Active Comparator|Group 2|500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Off therapy x 7 days Potassium citrate x 7days Continue on potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
16399258|NCT03984396|Experimental|Intervention - Patient and Clinician|Intervention educational materials provided to patient and family and clinician
16399259|NCT03984396|No Intervention|Delayed Intervention|Usual care
16399260|NCT03984383||Lung-derived endothelial cells|Every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.
16399261|NCT03984383||Umbilical cord-derived endothelial cells|Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.
16399262|NCT03984370|Experimental|80 ug of sc dasiglucagon|80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
16399263|NCT03984370|Experimental|200 ug of sc dasiglucagon|200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
16399264|NCT03984370|Placebo Comparator|0.4 mL of sc saline (placebo)|0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
16399265|NCT03984357|Experimental|PD-1 blocking antibody combined with IC+IMRT|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blocking antibody (360 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of PD-1 blocking antibody are administrated concurrently with IC and IMRT, respectively. After 4 weeks of the completion of IMRT, adjuvant PD-1 blocking antibody (480 mg per cycle) will begin every 4 weeks for 6 cycles.
16399266|NCT03984344|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
16399267|NCT03984344|Experimental|Active cTBS|Continuous TBS will be delivered at 80% of RMT and will be applied as 600 pulses in a 40-second train of uninterrupted 50Hz bursts to the right dorsolateral prefrontal cortex.
16399268|NCT03984344|Sham Comparator|Sham TBS|Sham stimulation will be given at the right or left dorsolateral prefrontal cortex (counterbalanced) for 40 seconds or 3 minutes and 9 seconds (counterbalanced), at the same frequency as active TBS (50Hz), however a sham coil will be used.
16399269|NCT03984331|Experimental|Fish skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
16399270|NCT03984331|Active Comparator|Cadaver skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
16399271|NCT03984318|Experimental|patient treated with immune checkpoint targeted monoclonal AB|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
16399272|NCT03984305|Experimental|PKG+ Group|"For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is controlled or uncontrolled based on scores provided by the PKG."
16399273|NCT03984305|Placebo Comparator|PKG- Group|For subjects in the PKG- Group (SOC control group), participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
16399274|NCT03984292|Experimental|Mass Learning|Single teaching session of 3 hours shall be provided
16399275|NCT03984292|Experimental|Distributed Learning|Three teaching sessions of 1 hour each shall be provided.
16399276|NCT03984279||Sequentiel group (SEQ)|
16399277|NCT03984279||Siral group (SPI)|
16399278|NCT03984253||Severe Asthma|All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.
16399279|NCT03984240|Experimental|Brain eloquent area glioma group|The brain eloquent area glioma will be diagnosed by MRI scan.
16399280|NCT03984240|Active Comparator|control group|Healthy volunteers without intracranial diseases.
16399281|NCT03984227||SLE patient group|SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
16399282|NCT03984227||control group|The control group will include age and sex matched healthy volunteers
16399283|NCT03984214|Active Comparator|Dronabinol|BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)
16399284|NCT03984214|Placebo Comparator|Placebo|Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets
16399285|NCT03984201|Active Comparator|iTBS over L-DLPFC to dACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the dorsal anterior cingulate cortex (dACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.
~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
16399365|NCT03983655|Sham Comparator|Sham High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
16399286|NCT03984201|Active Comparator|iTBS over L-DLPFC to sgACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the subgenual cingulate cortex (sgACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.
~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
16399287|NCT03984201|Sham Comparator|Sham iTBS over L-DLPFC|"Participants will receive sham iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system.
~Sham stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
16399288|NCT03984188|Experimental|Low-dose Theophylline Group|Participant in this group will receive low-dose theophylline in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment, over a one year period.
16399289|NCT03984188|Placebo Comparator|Placebo Group|Participant in this group will receive a placebo in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment.
16399290|NCT03984175|Experimental|Patients with ARDS at three Intermountain tertiary hospitals|
16399291|NCT03984149||FH pediatric patients|1000 clinically diagnosed FH pediatric patients (age <18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
16399292|NCT03984136|Experimental|Intervention group|Men will be required to exchange the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends conditionally.
16399293|NCT03984136|Active Comparator|Control group|Men will share the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends freely without conditional exchange requirement.
16399294|NCT03984123|Other|Double cuff inflation|The first arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end-diastolic volume of left ventricle
16399295|NCT03984123|Other|Single cuff inflation|The second arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
16399296|NCT03984123|No Intervention|Standard treatment|The third arm utilizes no cuff inflation to cause remote conditioning and serves as control group. Follow up echocardiography is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
16399297|NCT03984110|Experimental|Combination of Ozurdex and Eylea|Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
16399298|NCT03984110|Active Comparator|Eylea Monotherapy|Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
16399299|NCT03984097|Experimental|Treatment Phase: TAK-079 and LenDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are greater than (>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
16399300|NCT03984097|Experimental|Treatment Phase: TAK-079 and VRd|TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are >75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
16399301|NCT03984097|Experimental|Safety Extension Phase: TAK-079 and, if applicable, backbone therapy (LenDex, VRd, or PomDex)|TAK-079 dosing and, if applicable, backbone therapy will be administered as per the schedule outlined in the parent study.
16399302|NCT03984084||externally recruited participants|Self-referred affected and non-affected participants responding to advertisements
16399303|NCT03984084||In-house patients|Patients seeking treatment in the outpatient clinic of the Max-Planck-institute of Psychiatry
16399305|NCT03984045|Experimental|SPG block|SPG block performed by using qtip applicator soaked in 2% lidocaine and placed posteriorly into nasal cavity where it dwells for up to 30 min
16399306|NCT03984045|Active Comparator|Control|Delivered through IV access obtained in all patients.
16399307|NCT03984032|Experimental|LMA Protector Cuff Pilot|
16399308|NCT03984032|Active Comparator|LMA Supreme|
16399310|NCT03983993|Experimental|Treatment (niraparib, panitumumab)|Patients receive 200 or 300 mg niraparib orally once daily on days 1-28 and 6 mg/kg panitumumab intravenously over 60-90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16399311|NCT03983980|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
16399312|NCT03983980|Placebo Comparator|Vehicle Cream Group|Vehicle cream applied once daily
16399313|NCT03983967|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Cytokine-Induced Killer cells; Immuncell-LC) 3 times(3 treatments at a frequency of once per week) or 6 times(3 treatments at a frequency of once per week followed by 3 treatments every 2 weeks)
16399314|NCT03983954|Experimental|Naptumomab estafenatox 2 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 2 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399315|NCT03983954|Experimental|Naptumomab estafenatox 5 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 5 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399316|NCT03983954|Experimental|Naptumomab estafenatox 10 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399317|NCT03983954|Experimental|Naptumomab estafenatox 15 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399318|NCT03983954|Experimental|Naptumomab estafenatox 20 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399319|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 10 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399320|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 15 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399321|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at MTD and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399322|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP, at the previous dose level, and durvalumab|NAP, at the previous dose level, and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
16399323|NCT03983941|Active Comparator|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
16399324|NCT03983941|Experimental|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
16399325|NCT03983928|Experimental|TQB2450 Combined with Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16399326|NCT03983915|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
16399327|NCT03983915|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
16399328|NCT03983902|Active Comparator|Delayed cord clamping|Delayed cord clamping
16399329|NCT03983902|Active Comparator|Umbilical cord milking|Umbilical cord clamping
16399330|NCT03983902|Active Comparator|Immediate cord clamping|Immediate cord clamping
16399331|NCT03983889|Experimental|F|Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
16399332|NCT03983889|Experimental|DR|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
16401908|NCT03965767|Active Comparator|local group|
16399333|NCT03983889|Experimental|DF|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
16399334|NCT03983889|Experimental|PR|Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
16399335|NCT03983876|Experimental|AVT02 100mg/mL in PFS|Prefilled Syringe Arm
16399336|NCT03983876|Experimental|AVT02 100mg/mL in Autoinjector|Autoinjector Arm
16399337|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
16399342|NCT03983837|Experimental|1|Participants will be on this diet for 4 weeks. The amount per serving will be determined on the basis of the participant s weight and caloric needs, as determined by a staff dietician.
16399343|NCT03983824|Experimental|Treatment (M3814, mitoxantrone, etoposide, cytarabine)|Patients receive M3814 PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity.
16399344|NCT03983811|Experimental|Chemotherapy+Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
16399345|NCT03983811|Placebo Comparator|Chemotherapy+Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
16399346|NCT03983798||Simulation training in psychiatry|Convenient sample of 72 voluntary medical students, allocated among 6 groups of around 12 students, will be recruited at Paris Descartes, Paris Diderot and Brest Universities between september of 2018 and June of 2019.
16399347|NCT03983785|Experimental|Pilates|
16399348|NCT03983785|Experimental|Elastic Taping|
16399349|NCT03983785|No Intervention|Wait List Control|
16399350|NCT03983772|Experimental|RS10-10-10|First 2 weeks is for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 10 g RS blend. Fourth 2 weeks is 10 g RS blend.
16399351|NCT03983772|Experimental|RS10-20-20|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 20 g RS blend.
16399352|NCT03983772|Experimental|RS10-20-30|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 30 g RS blend.
16399353|NCT03983772|Placebo Comparator|Placebo10-10-10|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g placebo. Third 2 weeks is 10 g placebo. Fourth 2 weeks is 10 g placebo.
16399354|NCT03983759|Experimental|treatment group|"phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events.
~the dose of sintilimab is fixed dose of 200mg every three weeks"
16399355|NCT03983746|Experimental|traditional physical therapy program (control group)|fifteen children with DS received a traditional exercises program with instructions to the children for 60 minutes aiming to improve posture control and balance
16399356|NCT03983733|Experimental|Dietary Intervention|Dietary intervention using standardised test meals, on up to 8 days within the study period.
16399357|NCT03983720|Experimental|Patient with multiple sclerosis and lowly fatigued|"Patient with multiple sclerosis and lowly fatigued will be included.
~They will have:
~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
16399358|NCT03983720|Experimental|Patient with multiple sclerosis and highly fatigued|"Patient with multiple sclerosis and highly fatigued will be included. They will have:
~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
16399359|NCT03983720|Active Comparator|Healthy subjects|"Healthy subjects will be included. They will have:
~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
16399360|NCT03983694||BabyLux device|Cerebral haemodynamics of neonates undergoing erythrocyte transfusion according to the local clinical guidelines are monitored with BabyLux device before and after transfusion and with traditional NIRS during itself.
16399361|NCT03983681|Experimental|Experimental|The experimental group will receive memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
16399362|NCT03983681|Placebo Comparator|Control group|The control group will receive placebo memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
16399363|NCT03983668|Experimental|CMP-001 plus pembrolizumab|Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab
16399364|NCT03983655|Experimental|Real High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.
16399366|NCT03983642|Experimental|Intervention group|The intervention group received a session of 40min for an 8 weeks' period. Both games requested the participants to stand on a balance board in front of the television, without shoes, while trying to control their avatars by shifting their body weights.
16399367|NCT03983642|No Intervention|Control group|Participants in the control group were followed-up by an assessor, who made sure that they will not get involved in any type of training program during the eight weeks' period of the trial.
16399368|NCT03983629||CDA patients|
16399369|NCT03983603|Experimental|Plant stanol group|This arm receives soft chews containing 0.5g of plant stanols (delivered as plant stanol esters).
16399370|NCT03983603|Placebo Comparator|Placebo group|This arm receives soft chews that do not contain 0.5g of plant stanols (delivered as plant stanol esters).
16399371|NCT03983577|Experimental|Point of service delivery model|After the informed consent is signed, the participant will watch a standardized video on the principles of genetic testing. At the end of the video, the provider will return to answer any remaining questions. The participant will receive pre- and post- surveys for evaluation of the delivery model.
16399372|NCT03983564||All patients|Patients in this group will serve to validate the cutoff of the combination of the DES-OSA and BOSTON scores derived in the retrospective group.
16399373|NCT03983551|Experimental|Dipeptidyl peptidase 4 inhibitors|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
16399374|NCT03983551|Active Comparator|Sulfonylureas|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
16399375|NCT03983538||Patients receiving chemotherapy|Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference.
16399376|NCT03983525|Experimental|Goji berry|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
16399377|NCT03983525|Active Comparator|Lutein + zeaxanthin supplementation|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
16399378|NCT03983512|Experimental|PULSTA TPV|PULSTA Transcatheter Pulmonary Valve (TPV) System
16399379|NCT03983499|Experimental|Special Intervention|The special intervention (SI) arm addresses glycemic control, medication adherence, control of modifiable CVD risk factors, health behavior change, and psychosocial and cultural barriers to self-management. The SI arm consists of a collaborative care team approach with four main elements including: 1) Specialized clinical care by a medical provider; 2) Specialized behavioral health care by a behavioral health provider; 3) Group-based chronic disease self-management education by peer-leaders; 4) Intensive, proactive care coordination facilitated by a patient registry and electronic health records.
16399380|NCT03983499|No Intervention|Usual Care|Participants randomized to the Usual Care (UC) arm continue to see their primary care provider and receive referrals to health education. At the discretion of the provider, UC patients are screened and referred to behavioral health (BH) care.
16399381|NCT03983473|Other|Crohn's disease|Patients suffering from established Crohn 's disease without spondyloarthritis
16399382|NCT03983473|Other|Spondyloarthritis|Patients with established spondyloarthritis without Crohn 's disease
16399383|NCT03983473|Other|Crohn + spondyloarthritis|Patients suffering from both spondyloarthritis and Crohn 's disease
16399384|NCT03983473|Other|healthy controls|Patients without spondyloarthritis and Crohn 's disease
16399385|NCT03983460|Experimental|Dupimulab arm|"At Day 0, patients will receive Dupilumab treatment. The recommended dose of Dupilumab for adult patients is an initial dose of 600mg followed by 300mg given every two weeks administered as subcutaneous injection. Dupilumab could be self-administered by subcutaneous injection into thigh or abdomen or injected in the upper arm in case of administration by the patient's caregiver. It is recommended to rotate the injection site with each injection.
~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
16399386|NCT03983460|Active Comparator|Optimized TCS treatment arm|"At Day 0, patients will receive topical corticosteroid treatment (TCS) adapted to the AD severity (potent and very potent TCS) with a personal therapeutic education for treatment optimization. It will be asked to perform, every day, an application of topical corticosteroid (TCS) (betamethasone valerate cream 0.1%, and if not active, clobetasol propionate cream 0.05%) on active lesions. Once the AD lesion is cleared, the patients will continue to apply TCS on healed lesions, twice a week until the end of the treatment period to prevent relapse.
~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
16399387|NCT03983447|Experimental|School-based intervention to promote Physical Activity (PA)|"This intervention included :
~Physical (Environmental) adaptation of playground
~Time adaptation of lunch breaks
~Curriculum-based program of children
~Workshops and newsletters for parents
~Meetings for teachers"
16399388|NCT03983447|No Intervention|Control|Nothing has changed in the school.
16399389|NCT03983434|Experimental|Healthy volunteers|Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
16399390|NCT03983434|Experimental|Irritable Bowel Syndrome Patients with Diarrhea|Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
16399483|NCT03982719|Experimental|Brief protocol|4 intervention sessions with the occupational therapist of 30 minutes duration.
16399391|NCT03983434|Experimental|Irritable Bowel Syndrome Patients with Constipation|Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
16399392|NCT03983421|No Intervention|Treatment as Usual|Treatment as usual enhanced with a brief psychosis literacy training (45-60 minutes) for the counselors at the university's student health and counseling center
16399393|NCT03983421|Other|Screening|Implementation of the Prodromal Questionnaire - Brief, which is a screening tool to detect risk of psychosis.
16399394|NCT03983421|Other|Screening Plus Warm Hand-Off|Addition of a warm hand-off to coordinated specialty care (CSC) for those determined eligible on the screening tool.
16399395|NCT03983408|Active Comparator|KRG group|"Enrollment: 60 patients
~Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)"
16399396|NCT03983408|Placebo Comparator|Placebo group|"Enrollment: 60 patients
~Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks"
16399397|NCT03983395|Experimental|Part 1: Cohort 101 - ISB 1302 250 ng/kg|Cohort 101, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
16399398|NCT03983395|Experimental|Part 1: Cohort 201 - ISB 1302 325 ng/kg|Cohort 201, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
16399399|NCT03983395|Experimental|Part 1:Cohort 301- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Cohort 301, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
16399400|NCT03983395|Experimental|Part 1:Cohort 401- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Cohort 401, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
16399401|NCT03983395|Experimental|Part1Cohort501-ISB1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Cohort 501, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
16399402|NCT03983395|Experimental|Part1Cohort601-ISB1302 325ng/kgD1;550 ng/kg D8;900 ng/kgD15,22|Cohort 601, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
16399403|NCT03983395|Experimental|Part 1 Cohort 701- ISB 1302 escalating doses,1200 ng/kg D15,22|Cohort 701, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
16399404|NCT03983395|Experimental|Part 2 (Dose Expansion) -ISB 1302 at the MTD and/or RP2D dose|Subjects treated with ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
16399405|NCT03983382||HER2-Positive Breast Cancer|
16399406|NCT03983369|Experimental|"preventive treatment with LLLT (Laser group)"|
16399407|NCT03983369|Placebo Comparator|control group with a placebo intervention|
16399408|NCT03983356|Experimental|Group of GPs receiving training|GPs, psychologists and social workers in the intervention regions will receive a training program.
16399409|NCT03983356|No Intervention|Group of GPs receiving no attention|GPs, psychologists and social workers in the control regions will not receive information about the intervention.
16399410|NCT03983343|No Intervention|control group|Standard technique: Suturing the perineal skin with fast-absorbable running sutures (Vicryl Rapide 3-0).
16399411|NCT03983343|Active Comparator|intervention group|Closing the perineal skin using adhesive glue- Derma+flex®QSTM (Octyl-2-cyanoacrylate)
16399412|NCT03983330|Experimental|Intervention group|"The trained RA will deliver brief MI to each subject individually via WeChat or WhatsApp in the smart phones throughout the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once per 2-3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering message through WeChat or WhatsApp will be interactive, depended on subjects' actions and responses.
~Start from 6 months, minimal messages by merely following the subjects' progress and responding to their questions to maintain contact will be provided to subjects till one-year follow-up.
~The readiness of quitting smoking will be assessed at 3-month follow-up. For those who are willing to take further actions to promote their health, i.e. with an intention to quit smoking, health advice on smoking will be given with more emphasis on the health benefits of quitting. The whole intervention will be given through WeChat/WhatsApp."
16399413|NCT03983330|Other|Control group|Subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months
16399414|NCT03983317|No Intervention|Baseline|For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
16399415|NCT03983317|Experimental|Active treatment|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
16399416|NCT03983304|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
16399417|NCT03983291|Experimental|FaReWell Depression|Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily
16399418|NCT03983291|Placebo Comparator|Resting exercise|Resting 15 minutes daily
16399419|NCT03983278|Experimental|School Model|School Model (n=47 schools): Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.
16399484|NCT03982719|Active Comparator|Intense Protocol|6 intervention sessions with the occupational therapist of 60 minutes duration.
16399420|NCT03983278|Experimental|Referral Model|Referral Model (47 schools): Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary.
16399421|NCT03983278|Experimental|Referral Model + Cost Recovery|"Referral Model + Cost Recovery (47 schools): Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles (which was shown to be appealing to families in the recent PRICE study. These spectacles have scratch-proof coatings and designs selected to appeal to local children. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary."
16399422|NCT03983265|Other|computer guided condylar reposition device|surgical procedure : under general anesthesia after BSSO condyle will be repositioned by computer guided repostioning device
16399423|NCT03983252|Experimental|Relapsing Remitting Multiple Sclerosis starting Alemtuzumab|"Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (defined by International Panel Criteria), age 18-60 years, enrolled to start treatment with alemtuzumab.
~Subjects will undergo [F-18]PBR06 PET scans at baseline, 6 months and 18 months."
16399424|NCT03983239|Experimental|Fedratinib plus Rifampin|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of rifampin. On Day 17, a single dose of fedratinib will be concomitantly administered with rifampin.
16399425|NCT03983239|Experimental|Fedratinib plus Efavirenz|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of efavirenz. On Day 17, a single dose of fedratinib will be concomitantly administered with efavirenz.
16399426|NCT03983226|Experimental|Surgery|"Intervention:
~Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib"
16399427|NCT03983226|Active Comparator|No surgery|Intervention: Drug: Platinum-based chemotherapy and Niraparib
16399428|NCT03983213||Pat. after mpfl reconstruction|All 45 subjects operated with mpfl reconstruction included to chek-up after follow-up.
16399429|NCT03983200|Sham Comparator|Control group|Mecobalamine 0.5mg, tid
16399430|NCT03983200|Experimental|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid
16399431|NCT03983187|No Intervention|Control|
16399432|NCT03983187|Experimental|Rotating Magnetic Therapy group|
16399433|NCT03983174|Experimental|Drainage seton with flap|Drainage seton will be put around the external anal sphincter with mucosal advancement flap
16399434|NCT03983174|Experimental|EAS sparing seton|Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done
16399435|NCT03983161|Experimental|Fedratinib in moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to subjects with moderate hepatic impairment
16399436|NCT03983161|Experimental|Fedratinib in severe hepatic impairment subjects|A single dose of 200 mg of fedratinib will be given to subjects with severe hepatic impairment
16399437|NCT03983161|Experimental|Fedratinib in healthy vs moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to healthy subjects with normal hepatic function.
16399438|NCT03983161|Experimental|Fedratinib in healthy vs severe hepatic impairment subjects|A single oral dose of 200 mg of fedratinib will be given to healthy subjects with normal hepatic function.
16399439|NCT03983148|Experimental|Motivational interviewing|Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
16399440|NCT03983148|Placebo Comparator|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.
~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
16399441|NCT03983135|Experimental|Study group|Patients who undergo revisional bariatric surgery
16399442|NCT03983122|Experimental|Study group|Patients who undergo laparoscopic sleeve gastrectomy
16399443|NCT03983109|Experimental|Detection by EpiFaith syringe with air|
16399444|NCT03983109|Experimental|Detection by EpiFaith syringe with saline|
16399445|NCT03983096||test group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
16399446|NCT03983096||control group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
16399447|NCT03983083|Experimental|Intervention|Aspects of the HEALED intervention are based on various components of successful interventions for breast cancer survivors and older adults, NCI funding priorities, CPS-3 survivor preferences discussed in prior focus groups and survivorship research from other cohorts. As such, HEALED participants will receive monthly motivational e-mails, based on prior studies of the most effective delivery time intervals for interventions involving cancer survivors, with links to a web-based platform which will provide: physical activity information (largely consisting of publicly available evidence-based resources), at-home exercise demonstrations/videos for survivors of all fitness levels, personal survivor stories, physical activity/sitting recommendations (based on National Guidelines and ACS guidelines for survivors), positive messaging, a space for SMART goal setting, a platform for physical activity tracking, a discussion board, etc.
16399448|NCT03983083|No Intervention|Wait-list control|"Wait-listed control group will be instructed to continue behavior as-usual. They will receive access to the HEALED website at the end of the 12-week intervention period."
16399449|NCT03983070|Active Comparator|Control Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
16399450|NCT03983070|Experimental|Blood Flow Restriction and Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include the application of blood flow restriction during two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 40% maximal Watts, and deadlifts at 30% of one-repetition maximum. Blow flow restriction will be applied at 80% occlusion during both exercise modalities.
16399451|NCT03983057|No Intervention|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
16399452|NCT03983057|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 3mg/kg
16399453|NCT03983005||Patients with suspected lung cancer|Patients with pulmonary parenchymal lesions suspected for malignancy in contact or adjacent to the esophagus which can be sampled by EUS-B-FNA
16399454|NCT03982992|Experimental|DLI-TARGET|"14d screening period: methotrexate, cytarabine, dexamethasone infusion i.th.
~Cycle 1 (all patients): d1-28: blinatumomab continuous infusion i.v., d4: allogeneic donor lymphocyte single infusion i.v., d29: methotrexate, cytarabine, dexamethasone infusion i.th.
~Cycle 2 (only patients with toxicity ≤ grade 2 CTCAE in cycle 1): d43-d70: blinatumomab continuous infusion i.v., d46: allogeneic donor lymphocyte single infusion i.v., d71: methotrexate, cytarabine, dexamethasone infusion i.th."
16399455|NCT03982966|Experimental|Omega 3|Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)
16399456|NCT03982966|No Intervention|Control|20 patients will not take omega 3 fatty acids.
16399457|NCT03982953||PD patients with STN-DBS|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus
16399458|NCT03982953||Controls - PD patients with medical treatment|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.
16399459|NCT03982940|Experimental|BGP+ Stent Graft System|Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms
16399460|NCT03982901|Experimental|women with chest pain|women with chest pain and coronary artery stenosis less than 50%
16399461|NCT03982901|Sham Comparator|healthy women|women without chest pain and coronary artery stenosis less than 50%
16399462|NCT03982888|Experimental|DBS Treatment|Deep brain stimulation of both limbic and dysfunctional reward processing circuits for treatment of repetitive self injurious behaviours in children with ASD
16399463|NCT03982875|Experimental|SmartBag arm|"The Alfred SmartBag System will be placed on the ostomy site during surgery. The system will be used to wirelessly monitor ostomy function in the hospital setting and the patient will otherwise receive the standard of care. At discharge the patient will continue to use the Alfred SmartBag System and ostomy function will be monitored by the research and clinical teams remotely.
~If participant's output is (i) less than 50mL or greater than 1500mL per day or (ii) greater than 1200mL in two days; the mobile app will alert not only the participant but also the clinical staff (nurse).
~Participants will also receive support from a 'Patient Coach', a trained health coach who is also an ostomy patient to provide quality of life support."
16399464|NCT03982862|Active Comparator|control group|0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume
16399465|NCT03982862|Experimental|botox group|4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume
16399466|NCT03982849|Active Comparator|Hydroquinone group|Hydroquinone 4% cream Cream applied once daily at night on affected areas for 3 months.
16399467|NCT03982849|Experimental|Silymarin group|Silymarin 0.7% cream Cream applied twice daily on affecectec areas for 3 months.
16399468|NCT03982836|Experimental|Fructooligosaccharide|All the 25 volunteers received the sandwich containing 20 grams of fructooligosaccharide
16399469|NCT03982836|Experimental|Partially hydrolyzed guar gum|All the 25 volunteers received the sandwich containing 20 grams of partially hydrolyzed guar gum
16399470|NCT03982836|Placebo Comparator|Maltodextrin|All the 25 volunteers received the sandwich containing 20 grams of Maltodextrin
16399471|NCT03982823|Experimental|Hand-Sewn Sleeve Gastrectomy|
16399472|NCT03982823|Active Comparator|Stapled Sleeve Gastrectomy|
16399473|NCT03982810||Surgical Site Infections|Patients equal or greater than 18 years of age undergoing non-emergent non-cardiac surgical procedures involving a skin incision will be included in the study.
16399474|NCT03982797|Experimental|treated with IMUNO BCG Moreau RJ adjuvant.|
16399475|NCT03982784|Experimental|single-injection TQLB(transmuscular quadratus lumborum block)|Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
16399476|NCT03982784|Active Comparator|Control|postoperative IPCA is given alone
16399477|NCT03982771|Experimental|BCD regimen|Bortezomib, cyclophosphamide and dexamethasone (the BCD regimen) would be utilized in newly diagnosed iMCD (idiopathic Multicentric Castleman's disease) patients
16399478|NCT03982758|Experimental|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
16399479|NCT03982758|Experimental|isometric of lower limbs|Isometric session for lower limbs: 4 series with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute.
16399480|NCT03982732||Women vaccinated at less than 24 weeks|Women receiving a pertussis containing vaccine at less than 24 weeks
16399481|NCT03982732||Women vaccinated at 24-27+6 weeks|Women receiving a pertussis containing vaccine at 24-27+6 weeks
16399482|NCT03982732||Women vaccinated at 28-31+6 weeks|Women receiving a pertussis containing vaccine at 28-31+6 weeks
16399489|NCT03982680|Experimental|Toripalimab combined with Gem/5-FU|All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.
16399490|NCT03982667|Experimental|PCT group|For patients randomly assigned to the PCT-guided group, measurements of serum PCT concentrations (Day 1, 3, 7, and 9) will be taken and made available to the attending physicians. This means 3 ml of whole blood will be sampled from the arterial line of the patients for each measurement the serum PCT in plain tubes. The samples will be immediately assayed for the PCT measurement using the available device and the results will be ready in next 30 minutes after running the system.
16399491|NCT03982667|No Intervention|Standard-of-care group|
16399492|NCT03982654|Experimental|Bloomlife|
16399493|NCT03982641||Colon surgery|patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
16399494|NCT03982641||Rectal surgery|patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
16399495|NCT03982628||Sepsis|Adults admitted to a mixed medical/surgical ICU for sepsis with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
16399496|NCT03982628||Trauma|Adults admitted to a mixed medical/surgical ICU for trauma (without sepsis) with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
16399497|NCT03982615|Experimental|Laser-Lok abutment|Laser-etched abutment
16399498|NCT03982615|Active Comparator|Standard Healing abutment|Standard abutment which is not laser-etched
16399499|NCT03982602|Experimental|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 [fat]: [protein + carbohydrate] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
16399500|NCT03982576|Experimental|CS Relapse Prevention|"Participants will receive 4 group sessions of a novel culturally specific, CBT-based intervention. They will also receive Path2Quit, a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Notably, CS relapse prevention will incorporate surface and deep structure elements,17 including race-matched interventionists, religion/spirituality, discussion of race-related stress, traditional values (e.g., collectivism), culturally specific recipes, etc.
~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
16399501|NCT03982576|Active Comparator|Standard Relapse Prevention|"Participants will receive 4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov. Participants will also receive SmokefreeTXT, the NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7.
~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
16399502|NCT03982563|Experimental|Growth Mindset|
16399503|NCT03982563|Experimental|Gratitude|
16399504|NCT03982563|Experimental|Behavioral Activation|
16399505|NCT03982563|Sham Comparator|Study Skills|
16399506|NCT03982550|No Intervention|Control Period|Participants will serve as their own controls. All 12-week control periods will take place before the RT intervention to ensure that results are not confounded by detraining effects or long-term cognitive benefits of RT. In addition, a control period equal in duration to the intervention allows direct within-subjects statistical comparisons, accounting for each participants' baseline and rate of aging - i.e. age-associated cognitive decline and arterial stiffening. Participants will not be monitored, but may be contacted for scheduling.
16399507|NCT03982550|Experimental|Intervention Period|Participants will perform a periodized and progressive total-body RT program emphasizing development of lower and upper body strength. All 36 training sessions (3 days per week for 12 weeks) will be performed at the CERC, supervised by an exercise specialist. Participants will be encouraged to continue normal activities of daily living and eating routines outside the RT program of the present study. Because this is a proof-of concept study on normal aging, participants may be contacted for scheduling, but will not be monitored outside of training.
16399508|NCT03982537|Experimental|Nature's Blend N-Acetyl-L-Cysteine 600 mg with Chemotherapy|The treatment with NAC will be given twice daily for at least 10 days with the goal to cover the window of opportunity time between the treatment decision for CRT and the beginning of treatment (usually 14-21 days).
16399509|NCT03982537|Other|Standard of Care Chemotherapy (CONTROL)|Patients will receive definitive or adjuvant concurrent chemotherapy and radiotherapy as per standard of care
16399510|NCT03982524|Experimental|CBT complemented with emotion regulation training|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
16399511|NCT03982524|Active Comparator|Cognitive behavior therapy (CBT)|"This arm is based on conventional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
16399512|NCT03982511|Experimental|PCIT-Health|Participants assigned to the PCIT-Health arm will receive the intervention.
16399513|NCT03982511|No Intervention|Wait list control|Participants in the wait list control will receive an invitation to participate in the intervention 10 months after baseline data collection.
16399514|NCT03982485|Experimental|Arm I|Apatinib+Paclitaxel+Cisplatin
16399515|NCT03982485|Active Comparator|Arm II|Paclitaxel+Cisplatin
16399516|NCT03982472|Experimental|TENS right side|TENS stimulation at the right side
16399517|NCT03982472|Experimental|TENS left side|TENS stimulation at the left side
16399518|NCT03982472|No Intervention|sham stimulation|Sham stimulation
16399519|NCT03982459|Experimental|Decision support tool|Patients in this single-arm study all receive training in use of a decision support tool by a trained coordinator.
16399520|NCT03982446||Patients with germline mutations|This group will comprise of patients with pancreatic cancer who carry pathogenic mutations in genes associated with a predisposition to cancer.
16399521|NCT03982446||Patients without germline mutations|This group will comprise of patients with pancreatic cancer who did not carry pathogenic mutations in any of the genes tested, that have been previously shown to be associated with a predisposition to cancer.
16399522|NCT03982433|Experimental|Intervention|participants all receive the intervention
16399523|NCT03982407|Experimental|Ga68 PSMA PET-MR|68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan
16399526|NCT03982381|Active Comparator|Metformin|Metformin 1000-3000 mg per day according to clinical guidelines. Split into 2-3 doses per day.
16399527|NCT03982381|Experimental|Dapagliflozin|Dapagliflozin 10 mg once daily
16399528|NCT03982368|Experimental|rhNGF 20 μg/ml TID|One drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
16399529|NCT03982368|Experimental|rhNGF 20 μg/ml BID + vehicle OD|One drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily (BID) plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (OD) (every 6-8 hours)
16399530|NCT03982368|Placebo Comparator|Vehicle TID|Vehicle eye one drop will be instilled in both eyes three times daily (every 6-8 hours)
16399531|NCT03982355||Breast Cancer|Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
16399532|NCT03982355||Rectal Cancer|Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
16399533|NCT03982342|Active Comparator|Catheter-closure of PDA|Infants randomized to this group will undergo a catheter procedure to close hemodynamically-significant patent ductus arteriosus (HSPDA).
16399534|NCT03982342|Active Comparator|Conservative management of PDA|"Infants randomized to this group will be treated to reduce the symptoms of a hemodynamically-significant patent ductus arteriosus (HSPDA), in the hopes that over time the HSPDA will become reduced in size (to the point of no longer meeting criteria for being hemodynamically significant) or close naturally. Infants in this group with declining health status attributable to a PDA which meet qualifying criteria may receive catheter closure (intervention) if deemed medically necessary."
16399535|NCT03982329|Active Comparator|nrTMS group|15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days
16399536|NCT03982329|Sham Comparator|sham group|15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days
16399537|NCT03982316|Experimental|Telehealth Behavioral Migraine Management|Participants will receive weekly online education sessions in the following categories: Relaxation, Early Warning Signs, Triggers, Medication Adherence, Reducing Migraine Impact, Stress Management, Biofeedback, and Relapse Prevention. Participants will receive four monthly 50-minute telehealth sessions with a doctoral psychology student in a clinical health psychology program covering these topics, and three check-ins to enhance adherence to behavior change strategies. Participants will complete a daily headache diary throughout the course of treatment.
16399538|NCT03982303|Experimental|Hemay102 at the dosage of 5mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 5mg/m2.
16399539|NCT03982303|Experimental|Hemay102 at the dosage of 10mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 10mg/m2.
16399540|NCT03982303|Experimental|Hemay102 at the dosage of 20mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 20mg/m2.
16399541|NCT03982303|Experimental|Hemay102 at the dosage of 40mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 40mg/m2.
16399542|NCT03982303|Experimental|Hemay102 at the dosage of 60mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
16399543|NCT03982303|Experimental|Hemay102 at the dosage of 90mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 90mg/m2.
16399544|NCT03982303|Experimental|Hemay102 at the dosage of 120mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 120mg/m2.
16399545|NCT03982290|Active Comparator|Lactobacillus plantarum PS128 (PS128)|Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks.
16399546|NCT03982290|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks.
16399547|NCT03982290|No Intervention|Normal Control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
16399548|NCT03982277|Experimental|High dose Rifampin + DTG|High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
16399549|NCT03982277|No Intervention|Standard dose Rifampin + DTG|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
16399550|NCT03982277|Experimental|High dose Rifampin + EFV|High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
16399551|NCT03982277|No Intervention|Standard dose Rifampin + EFV|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
16399552|NCT03982264|Active Comparator|ESD group|In ESD group, enrolled patients will receive the treatment modality of ESD to remove the rectal NET
16401909|NCT03965767|Active Comparator|systemic group|
16399553|NCT03982264|Experimental|EMR-C group|In EMR-C group, enrolled patients will receive the treatment modality of EMR-C to remove the rectal NET
16399554|NCT03982251|Experimental|High frequency whole body vibration|This group will receive a single 8-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
16399555|NCT03982251|Active Comparator|low frequency whole body vibration|This group will receive a single 12-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
16399556|NCT03982238|Active Comparator|Control group|continuous subcutaneous insulin infusion therapy
16399557|NCT03982238|Experimental|Metformin|metformin therapy
16399558|NCT03982238|Experimental|Dapagliflozin|Dapagliflozin
16399559|NCT03982225|Experimental|2.5% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 2.5% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
16399560|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
16399561|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.4 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.4 mL injections, 1.0 cm apart, up to 20.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
16399562|NCT03982225|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants receive placebo administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
16399563|NCT03982212|Experimental|Intratumoral Copaxone|Eligible subjects receive at least 1 and up to 3 doses of Copaxone® 40 milligrams (mg) intratumorally prior to standard of care surgery. The doses will be administered at least 48 hours apart. The last dose will be given within 96 hours of standard of care surgery.
16399572|NCT03982173|Experimental|previously treated patients with solid tumors|previously treated patients with solid tumors harboring a high mutational load.
16399573|NCT03982160|Experimental|L-arginine|Intravenous infusion of L-arginine (250-350 mg/kg) will be performed for 30 minutes.
16399574|NCT03982160|Placebo Comparator|Saline|Saline will be infused for 30 minutes
16399575|NCT03982147||Stroke patients|Patients with recent ischaemic stroke
16399576|NCT03982134|Experimental|PDR001 with Panobinostat|All enrolled patients will be treated with a combination of PDR001 at 400mg every 4 weeks and panobinostat. Dose and frequency of Panobinostat will vary depending upon the dose-level cohort of the study participants. Each participant will be assigned to a particular dose-level cohort.
16399577|NCT03982121|Experimental|A|FOLFOX IV + NIVOLUMAB IV
16399578|NCT03982121|Experimental|B|FOLFOX IV + GLA IT
16399579|NCT03982121|Experimental|C|FOLFOX IV + IPILIMUMAB IT
16399580|NCT03982121|Experimental|D|FOLFOX IV + NIVOLUMAB IV + GLA IT
16399581|NCT03982121|Experimental|E|FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT
16399582|NCT03982121|Experimental|F|LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT
16399583|NCT03982108|Experimental|Knotless suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knotless suture-bridge technique.
16399584|NCT03982108|Active Comparator|Knot-tying suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knot-tying suture-bridge technique.
16399585|NCT03982082|Experimental|Device feasibility (MuscleSound technology)|Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.
16399586|NCT03982069|Active Comparator|FluMist live attenuated influenza vaccine|Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
16399587|NCT03982069|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
16399588|NCT03982056||Main study group|"Assessments performed:
~Height
~Mass
~Body fat density
~Bone density
~Lean muscle density
~Lung volume measurements
~Floating technique
~Buoyancy"
16401910|NCT03965767|Active Comparator|combined local and systemic|
16399589|NCT03982056||Validation group|"Assessments performed:
~Height
~Mass
~Body fat density
~Bone density
~Lean muscle density
~Lung volume measurements
~Floating technique
~Buoyancy"
16399591|NCT03982030|Experimental|Dalbavancin|Participants with susceptible gram-positive infections requiring prolonged parenteral antibiotic therapy will be treated with dalbavancin.
16399592|NCT03982017|Active Comparator|Usual care|Consists of routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
16399593|NCT03982017|Experimental|Application|Participants will be provided a special link to navigate to the online content and resources.
16399594|NCT03982004|Experimental|Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF|"Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-15 (every 2 weeks for the first 2 treatments, then every 3 weeks until week 15)
~Topical imiquimod will be applied 5 days per week (5 days on, 2 days off from weeks 1-15)
~Pembrolizumab will be given every 3 weeks for a minimum of 4 cycles starting at Week 3 until disease progression or unacceptable toxicity.
~Intra-lesional GM-CSF 250 mcg every 2 weeks x 2 doses then every 3 weeks for 3 doses"
16399595|NCT03981965|Experimental|Focus guidelines|"Participants enrolled in a 2-phase physical activity program divided in 2 phases as described above. Briefly, The activity consisted in a 1-h set of exercises twice per week. The first 12-week phase was performed in group under the direct supervision of a health monitor. The second 12-week phase was autonomous, and consisted of the same physical performance while maintaining virtual link through a social network based on the mobile phone.
~The FOCUS guidelines provided 2 features, the participation in monthly health talks provided by the principal investigator and the availability of a virtual mailbox to transmit any comment or suggestion."
16399596|NCT03981965|Active Comparator|Active group|Participants enrolled in a 2-phase physical activity program divided into 2 phases as described above. This group lacked the monthly talks and did not have access to the virtual mailbox.
16399597|NCT03981965|No Intervention|Inactive|Women of similar clinical characteristic who did not participate in the PA program.
16399602|NCT03981939||CD Participants with CPAF - The Ottawa Hospital (TOH)|Participants diagnosed with Complex Perianal Fistula (CPAF) from the Ottawa Hospital (TOH) were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
16399603|NCT03981939||CD Participants without CPAF (ICES database)|Participants diagnosed with CD and without CPAF from Institute for Clinical Evaluative Sciences (ICES) database who did not meet the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
16399604|NCT03981939||CD Participants with CPAF (ICES database)|Participants with CD and CPAF from ICES database who met the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
16399605|NCT03981926|No Intervention|In-Person|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek atopic dermatitis care from primary care practitioners or dermatologists, just as they would in the real world.
16399606|NCT03981926|Experimental|Team-Based Connected Health (TCH)|The intervention arm is the team-based connected health (TCH) model, which purports to increase access to specialists and improve outcomes. Specifically, TCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. TCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
16399607|NCT03981913||Healthy control (HC)|Participants without neurological or psychiatric disturbance (n= 30)
16399608|NCT03981913||Parkinson's disease (PD)|Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
16399609|NCT03981900||Rheumatoid arthritis|All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib
16399610|NCT03981887|Experimental|Nafithromycin 200 mg as IV infusion|Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
16399611|NCT03981887|Placebo Comparator|placebo administered as IV infusion|Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
16399612|NCT03981874|Experimental|Telephonic interview|Parents or patients will be contacted by phone in order to precise whether there are persistent sequelae or not
16399613|NCT03981861|Experimental|Overall Study|Treatment with Metformin and Spironolactone
16399614|NCT03981848||Relapse|Relapse of tumor within two years after liver transplantation
16399615|NCT03981848||Non-relapse|Non-relapse of tumor within two years after liver transplantation
16399616|NCT03981835||Post -PCI Patients scheduled for Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Cardiac Surgery. No intervention will be administered.
16399617|NCT03981835||Post -PCI Patients scheduled for Non- Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Non-Cardiac Surgery. No intervention will be administered.
16399618|NCT03981822|Active Comparator|Part A: VP-102 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
16399619|NCT03981822|Active Comparator|Part A: VP-102 6-hour Active|For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
16399620|NCT03981822|Active Comparator|Part A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
16399621|NCT03981822|Placebo Comparator|Part A: Placebo|For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.
16399622|NCT03981822|Active Comparator|Part B & A: VP-102 6 hour-Active|Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
16399623|NCT03981822|Placebo Comparator|Part B & A: 6-hour-Placebo|Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
16399624|NCT03981822|Active Comparator|Part B & A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
16399625|NCT03981822|Placebo Comparator|Part B & A: 24-hour-Placebo|Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
16399626|NCT03981796|Active Comparator|Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab|
16399627|NCT03981796|Placebo Comparator|Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
16399628|NCT03981796|Active Comparator|Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib|
16399629|NCT03981796|Placebo Comparator|Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
16399630|NCT03981783|Active Comparator|Best available care (BAC)|
16399631|NCT03981783|Experimental|Telerehabilitation (TH)|
16399632|NCT03981770||Group good sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are more than four hours.
16399633|NCT03981770||Group poor sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are less than four hours.
16399634|NCT03981757|Experimental|NeurOS Group|Apply the single use NeurOS cerebral oximetry sensor adhesive onto patients' head who are going to have CEA surgery in the operating room before anesthesia induction.
16399637|NCT03981731|Experimental|Cardiac coherence|
16399638|NCT03981718|Active Comparator|Group: Standard|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive fat grafting procedure per standard of care during their 2nd stage breast reconstruction.
16399639|NCT03981718|Experimental|Group: Experimental|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive their fat grafting procedure until 6 months after their 2nd stage breast reconstruction.
16399640|NCT03981692|Active Comparator|Consecutive Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. Immediately after these trainings, they should expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week etc. Attention, memory and arithmetic training will be given the ability to run.
16399641|NCT03981692|Active Comparator|Integrated Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
16399642|NCT03981679|Experimental|Biological collection|"For all the patients include in the study :
~- Blood samples collected before the colonoscopy In parallel to this biological collection, standardized clinical data will be entered into a database"
16399643|NCT03981666|Experimental|Patients with insomnia|adult outpatients with a localized or metastatic breast, colorectal, pulmonary or urological cancer
16399644|NCT03981640|Experimental|Black Adults|Black adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
16399645|NCT03981640|Experimental|White Adults|White adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
16399646|NCT03981627|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation
16399647|NCT03981627|Active Comparator|NovoRapid®|Subcutaneous injection of insulin aspart
16399648|NCT03981614|Experimental|Arm A (binimetinib, palbociclib)|Patients receive binimetinib PO BID on days 1-28 and palbociclib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16399649|NCT03981614|Experimental|Arm B (trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may optionally crossover to Arm A.
16399650|NCT03981601|Active Comparator|lovastatin 40 mg with bone graft|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
16399651|NCT03981601|Active Comparator|without drug with bone graft|after tooth extraction, put the bone graft wifin tooth socket
16399652|NCT03981575||Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months
16399653|NCT03981562|Experimental|1000 IU Vitamin D|
16399654|NCT03981562|Experimental|4000 IU Vitamin D|
16399655|NCT03981562|Placebo Comparator|Placebo|
16399656|NCT03981549|Active Comparator|Immediate Cellular Therapy / Deferred Sham Therapy|"At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.
~At 6 months: Sham bone marrow aspiration and sham intravitreal injection."
16399657|NCT03981549|Sham Comparator|Immediate Sham Therapy / Deferred Cellular Therapy|"At baseline: Sham bone marrow aspiration followed by sham intravitreal injection.
~At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells."
16399658|NCT03981536|Experimental|AP-101: Dose Level 1|Single dose of AP-101
16399659|NCT03981536|Experimental|AP-101: Dose Level 2|Single dose of AP-101
16399660|NCT03981536|Experimental|AP-101: Dose Level 3|Single dose of AP-101
16399661|NCT03981523|Experimental|BZN-60|150 mg twice a day for 60 days.
16399662|NCT03981523|Experimental|BZN-30|150 mg once a day for 30 days.
16399663|NCT03981523|Experimental|BZN-90|150 mg once a day for 90 days.
16399664|NCT03981523|Experimental|NFX-60|240 mg twice a day for 60 days.
16399665|NCT03981523|Experimental|NFX-30|240 mg twice a day for 30 days.
16399666|NCT03981523|Experimental|NFX-90|240 mg once a day for 90 days.
16399667|NCT03981510|Experimental|Children being investigated with 3D-transit|"4 groups of each 20 children will be investigated with respectively one or two capsules:
~Healthy children (1)
~Children with chronic constipation (2)
~Children with neurofibromatosis type 1 (2)
~Children with cancer receiving treatment with Vincristine (1)"
16399668|NCT03981497||Small Renal Tumors|Subjects with small renal tumors (SRT) ad described by current ESMO (European Society for Medical Oncology) guidelines who are candidates for MWA
16399669|NCT03981497||Primary and Secondary Liver cancer|Primary liver tumors: subjects who are candidates for MWA with nodules ≤ 3 cm Liver metastases: subjects who are candidates for MWA with nodules less than ≤ 3 cm
16399670|NCT03981484|Experimental|PCC|single dose of 4-Factor PCC in addition to standard resuscitation methods
16399671|NCT03981484|Active Comparator|Standard of Care|standard resuscitation methods only
16399672|NCT03981471|Other|Elderly without fall history|Elderly people in the community who have no fall history
16399673|NCT03981471|Other|Elderly with fall history|Elderly people in the community who have fall history
16399674|NCT03981458|Active Comparator|Hyalofemme|Hyalofemme is a cream/gel containing hyaluronic acid, designed to be applied vaginally. This is primarily used in treatment of atrophic vaginitis and is applied by the patient once every three days. We intend treatment to continue for 6 months.
16399675|NCT03981458|Active Comparator|Ialuril|Ialuril is a bladder instillation designed to be delivered to the bladder via catheter. This is primarily used in patients suffering from recurrent UTI and acts to help rebuild the lining of the bladder, reducing irritation. Ialuril is applied weekly for 6 weeks, followed by every 2 weeks for 6 weeks, then once monthly for maintenance. Treatment will be continued for 6 months.
16399676|NCT03981445|Experimental|On-site Integrated Care with Adherence Counseling|Participants randomized to the on-site integrated care with adherence counselling arm will be prescribed pre-exposure prophylaxis (PrEP) (Truvada®) and, if indicated, Hepatitic C (HCV) treatment (Epclusa®) at the OAT clinic or SAP from which they were recruited. In addition to PrEP and, if indicated, HCV care, participants in the on-site integrated care arm will receive any required health care services as per local standard of care. Addiction treatment, OAT, and mental health services will be provided, if necessary and available. Participants recruited at syringe access programs (SAP) will be offered addiction counseling and treatment, including OAT when in the integrated care arm in addition to site standard of care.
16399677|NCT03981445|Experimental|Off-site Referral to Specialized Care with Patient Navigation|Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
16399678|NCT03981432|Experimental|Constitutional leanness|Constitutional leanness
16399679|NCT03981432|Experimental|Normal weight|Normal weight women
16399680|NCT03981432|Experimental|Anorexia nevrosa|women presenting Anorexia nevrosa
16399681|NCT03981419|Experimental|GRF6021|"Subjects will receive GRF6021 per the following schedule:
~On the day before surgery
~On the day of surgery within 4 hours before surgery start (first incision)
~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)
~On the day after surgery"
16399682|NCT03981419|Placebo Comparator|Placebo|"Subjects will receive Placebo per the following schedule:
~On the day before surgery
~On the day of surgery within 4 hours before surgery start (first incision)
~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)
~On the day after surgery"
16399683|NCT03981406|Experimental|Palliative Care|Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings.
16399684|NCT03981406|Placebo Comparator|Standard of Care|Standard of care for idiopathic pulmonary fibrosis
16399685|NCT03981393||'Less severe hypoxaemia'|PaO2/FiO2 ratio > 68 mmHg (9.1kPa) at decision-to-cannulate
16399686|NCT03981393||'Very severe hypoxaemia'|PaO2/FiO2 ratio ≤ 68 mmHg (9.1kPa) at decision-to-cannulate
16399687|NCT03981380|Experimental|MESA study participants|Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
16399688|NCT03981341|Experimental|Post menopausal sleep apnea|Post menopausal women with severe sleep apnea
16399689|NCT03981341|Experimental|Post menopausal non sleep apnea|Post menopausal women without sleep apnea
16399690|NCT03981328|Active Comparator|self-monitored blood glucose|The control group participants will perform self-monitored blood glucose testing with a study-provided blood glucose meter, including testing supplies. They will perform capillary blood glucose monitoring as routinely used for patients with GDM i.e. at least four capillary blood glucose values daily including measurements at fasting as well as 1h after starting each meal by using a routinely available blood glucose measurement device.
16399691|NCT03981328|Experimental|Continuous glucose monitoring|Patients randomized to the intervention group will be equipped with a real-time CGM sensor (Dexcom G6 sensor, a small flexible device that records interstitial glucose levels every five minutes). The sensor will be inserted into the subcutaneous tissue of the anterior abdomen wall. Additionally, patients will be advised to record capillary blood glucose values if glucose alerts or readings do not match with symptoms or expectations. Participants will be educated how to exchange the sensor (has to be exchanged every ten days) and will be equipped with a real-time CGM monitor and instructed in its use. The monitor provides the user with information about current glucose levels and notifies the patient before she reaches her upper or lower glucose threshold and when glucose levels change rapidly. All patients in the intervention group will specifically trained how to use the system.
16399692|NCT03981315||Lithogenic bile in symptomatic patient|Patients who are performed a cholecystectomy as a treatment of their gallbladder disease
16399693|NCT03981315||Lithogenic bile in asymptomatic patient|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found
16399694|NCT03981315||Non-lithogenic bile|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones
16399695|NCT03981302|Experimental|Family nursing conversations|The intervention will consist of structured family nursing conversations between a nurse, the patient and their selected family members. The patients will receive the intervention and usual treatment.
16399696|NCT03981302|No Intervention|Usual treatment|The patients will receive usual treatment.
16399697|NCT03981289||CAPN3 (LGMD2A)|Clinical Assessments, Biomarkers
16399698|NCT03981289||DYSF (LGMD2B)|Clinical Assessments, Biomarkers
16399699|NCT03981289||ANO5 (LGMD2L)|Clinical Assessments, Biomarkers
16399700|NCT03981289||DNAJB6 (LGMD1D)|Clinical Assessments, Biomarkers
16399701|NCT03981289||Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)|Clinical assessments
16399702|NCT03981276||Primary participant:|"Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.
~Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques."
16399703|NCT03981276||Secondary participant/ First or second-degree|First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.
16399704|NCT03981276||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.
16399705|NCT03981263|Other|MEAVANTI + Standard protheses|The patients will benefit from the experimental prothesis (MEAVANTI), after a wash-out period of 15 days, they will benefit from the standard non-adherent prothesis.
16399706|NCT03981263|Other|Standard + MEAVANTI protheses|The patients will benefit from the standard non-adherent prothesis, after a wash-out period of 15 days, they will benefit from the experimental prothesis (MEAVANTI).
16399707|NCT03981250|No Intervention|Control Group|The control group will be asked to keep their lifestyle behaviour and not increase their physical activity levels during the study period.
16399708|NCT03981250|Experimental|Exercise Group|The exercise group will engage in a home-based resistance exercise intervention for 12 weeks. They will perform 6 exercises, one each day for one minute, for 6 days a week.
16399709|NCT03981237|Experimental|Root canal treatment with laser-activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of a pulsed erbium laser. The canals are then dried and obturated.
16399710|NCT03981237|Active Comparator|Root canal treatment with ultrasonically activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of an ultrasonically driven instrument. The canals are then dried and obturated.
16399711|NCT03981224||plasma EBV DNA detectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
16399712|NCT03981224||plasma EBV DNA undetectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
16399713|NCT03981211|Experimental|Cohort A: 8 weeks G/P standard therapy|8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).
16399714|NCT03981211|Experimental|Cohort B: 4 weeks SOF/G/P shortened therapy|4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).
16399715|NCT03981198|Other|RAP treatment|Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.
16399716|NCT03981185|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
16399717|NCT03981172||Non-obese/HED|Non-obese women given 60 gram portions of high energy density snack foods to consume daily for two weeks.
16399718|NCT03981172||Non-Obese/LED|Non-obese participants that were given 60 gram portions of low energy density foods to consume daily for two weeks.
16399719|NCT03981172||Obese/LED|Obese participants that were given 60 gram portions of low energy density snack foods to consume daily for two weeks.
16399720|NCT03981172||Obese/HED|Obese participants that were given 60 gram portions of high energy density snack foods to consume daily for two weeks.
16399721|NCT03981159|Experimental|Active group (under physical training)|Subjects belonging to this arm underwent physical training for three months, twice per week (60 minutes per session).
16399722|NCT03981159|No Intervention|Passive group (no physical training)|Subjects served as controls.
16399723|NCT03981146|Experimental|Nivolumab|Patients will receive 480mg of Nivolumab on a four weekly cycle for a maximum of two years.
16399724|NCT03981133|Experimental|A: unrestricted pacifier|recommendation to offer a pacifier at the facility providing maternity and newborn services the first days of life
16399725|NCT03981133|Active Comparator|restricted pacifierr|recommendation not to offer a pacifier to normal new born infant at the maternity thre first days of live
16399726|NCT03981120|No Intervention|Standard Care Group|Patients in the control arm will not undergo laser and acupuncture treatment. The treatment and control group will be compared to the baseline pregnancy rate of women meeting the same inclusion and exclusion criteria from the clinic through a chart review over the two years prior to initiation of the study.
16399727|NCT03981120|Experimental|Laser and Acupuncture Group|"The patients in the treatment arm will have 7 treatments before transfer (2-4 sessions a week), for the 3 weeks from starting estrace leading to the day before embryo transfer, then one (before and after transfer) on the day of transfer (total 8 sessions). Each treatment leading up to transfer day treatment consists of:
~Traditional Acupuncture at points Sp9 to SP6 EA2Hz Milliamp (Pantheon device), ST-36 B, LI4 unilateral, LV3 unilateral and/or LU7 unilateral, K6 unilateral.
~Bioflex Array (Photobiomodulation) - simultaneously array placements with each treatment over the sacrum (points BL-31, BL 32, BL 33 BL 34, DU2, DU3) and lower Abdomen above uterus (Ren 2 to Ren 6)
~Laser acupuncture over ST-9, ST10, SJ 17, ST-11. Ren 3 and Ren 4. 6.75 J per point at ST 9, ST10 (over carotid) and SJ17 (vertebral artery).
~On the day of FET on site at IVF clinic there will be a before and after traditional and laser acupuncture treatment."
16399728|NCT03981107|Experimental|Chest Compression Only CPR (CO-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform CO-CPR with chest compressions only.
16399729|NCT03981107|Active Comparator|Standard CPR (S-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform S-CPR with chest compressions and rescue breaths in a 30:2 ratio.
16399730|NCT03981094|Experimental|BMS-986278|
16399731|NCT03981094|Experimental|Pirfenidone|
16399732|NCT03981094|Experimental|BMS-986278 + Pirfenidone|
16399733|NCT03981081|Experimental|eosinophil-guided group|patients will receive prednisone at a dose of 1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days, only if the eosinophil count is> 2%
16399734|NCT03981081|Active Comparator|control group|a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days
16399735|NCT03981068|Experimental|Re-Irradiation with protons|60 Gy in 50 fraktions, 10 weekly with protons
16399736|NCT03981055|Experimental|Active tDCS and Active TUS|Active tDCS and Active TUS for 20 min
16399737|NCT03981055|Sham Comparator|Sham TDCS and Sham TUS|Sham TDCS and Sham TUS for 20 min
16399738|NCT03981042|No Intervention|Control group|waiting for a 3-minute delay after injection of the atracurium before laryngoscopy
16399739|NCT03981042|Experimental|Monitoring group|waiting for the TOF ratio at 0 at the corrugator supercilli before laryngoscopy
16399740|NCT03981029||FACT High-dose folic acid treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily high-dose folic acid supplementation during pregnancy.
16399741|NCT03981029||FACT Placebo treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily placebo supplementation during pregnancy.
16399742|NCT03981016|Experimental|Biological collection|"For the patients include in the study :
~blood samples collected at different times : Before surgery and during the post-operative visit and
~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
16399743|NCT03981003||MS Patients|
16399744|NCT03980990|Experimental|Metformin Continuation|Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.
16399745|NCT03980990|No Intervention|Metformin Interruption|Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.
16399746|NCT03980977|Other|skin and/or tumor Biopsy and blood sample|
16399747|NCT03980964|Experimental|Active NMES|Treatment arm receives an active NMES therapy including a conductive garment with NMES therapy, electrodes, and mobile app.
16399748|NCT03980964|Sham Comparator|Inactive NMES|Control arm receives inactive NMES therapy including a conductive garment (no NMES and no electrodes), and mobile app.
16399749|NCT03980951|Active Comparator|combined spinal epidural group|Bupivacaine 2.5 mg
16399750|NCT03980951|Active Comparator|dura puncture epidural group|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
16399751|NCT03980951|Active Comparator|epidural|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
16399752|NCT03980938|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
16399753|NCT03980938|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
16399754|NCT03980925|Experimental|Nivolumab + platinum-doublet chemotherapy|"Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.
~Order of administration: Nivolumab, Carboplatin, Etoposide
~Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years."
16399755|NCT03980899||Patients with PPI|
16404272|NCT03949010|Experimental|Kinesiotaping with muscle inhibition technique|
16399756|NCT03980873|Experimental|Experimental|An experimental group. The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
16399757|NCT03980873|No Intervention|Control|Three-month waitlist
16399758|NCT03980860|Active Comparator|HIIT (High Intensity Interval Training)|Subjects are undergoing high intensity interval training
16399759|NCT03980860|Active Comparator|Low intensity training long duration|Subjects are undergoing a lower intensity training program for a long duration
16399760|NCT03980860|No Intervention|Control|No exercise program intervention (usual care)
16399761|NCT03980847|Active Comparator|Alendronate 20 mg with bone graft|after tooth extraction, put teh Alendronate 20mg with bone graft within teh tooth socket
16399762|NCT03980847|Active Comparator|bone graft alone|after tooth extraction, put the bone graft within the tooth socket
16399763|NCT03980834|Active Comparator|Professional Learning, Program Training and Coaching|
16399764|NCT03980834|Active Comparator|Program for Parents of Pre-K Students|
16399765|NCT03980834|Active Comparator|Program for Pre-K Students|
16399766|NCT03980821|Experimental|AZD4635 monotherapy|Dose escalation of AZD4635 monotherapy for patients with advanced solid malignancies
16399767|NCT03980808|Experimental|ASL-ADE Intervention Arm|One-half of enrolled participants will view the ASL-ADE video intervention.
16399768|NCT03980808|Sham Comparator|Control Arm|One-half of enrolled participants will view a non-health related video approximately the same length as the video intervention.
16399769|NCT03980795|Experimental|Intervention|The intervention (I) group received monthly exercise physiologist consultations, exercise prescription (resistance and aerobic exercise program using exercise bands) and weekly phone calls over 12 weeks.
16399770|NCT03980795|No Intervention|Control|Usual care
16399771|NCT03980782|Experimental|Music Intervention|Each participant will receive a 30 minute individual music intervention twice daily.
16399772|NCT03980782|No Intervention|Care as usual|Each participant will receive care as usual.
16399773|NCT03980769|Experimental|Treatment (chemotherapy, transplant)|Patients receive thiotepa IV BID on days -7, treosulfan IV on days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.
16399774|NCT03980756|Experimental|Group A1|Period 1: Test Drug(AD-206 20mg) Period 2: Reference Drug(Esomeprazole 20mg)
16399775|NCT03980756|Experimental|Group A2|Period 1: Reference Drug(Esomeprazole 20mg) Period 2: Test Drug(AD-206 20mg)
16399776|NCT03980756|Experimental|Group B1|Period 1: Test Drug(AD-206 40mg) Period 2: Reference Drug(Esomeprazole 40mg)
16399777|NCT03980756|Experimental|Group B2|Period 1: Reference Drug(Esomeprazole 40mg) Period 2: Test Drug(AD-206 40mg)
16399778|NCT03980743|Active Comparator|iOTA text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly meetings with a study health coach to develop reasonable health goals and interactive text messaging to provide daily support and self-monitoring of behavior change goals between in-person visits. Participants may receive phone calls between visits from their health coach for additional support if needed. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
16399779|NCT03980743|Placebo Comparator|Health Education text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly in-person visits with a health coach to learn about healthy eating and activity behaviors, including developing readiness for health behavior change. Participants will not set specific health goals, but will receive weekly text messages about general health tips related to their in-person visits. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
16399780|NCT03980730|Experimental|Azeliragon|Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
16399781|NCT03980730|Placebo Comparator|Placebo|Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
16399782|NCT03980717|Experimental|Fetal Endotracheal Occlusion (FETO)|Placement and retrieval of the GoldBAL4 or GoldBAL2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
16399783|NCT03980717|No Intervention|non-FETO|The control group will consist of patients who did not undergo the FETO procedure who fit the same fetal inclusion/exclusion criteria as our FETO subjects and will be matched by variables including maternal age, body mass index, gestational age, severity of CDH and site of CDH (left- or right-sided).
16399784|NCT03980704|Active Comparator|High Protein|Provision of 400 ml per day of high protein oral nutritional supplements
16399785|NCT03980704|Experimental|Immuno ONS|Provision of 400 ml per day of immunostimulating oral nutritional supplements
16399786|NCT03980691|Experimental|Chidamide combined with CAR-T or TCR-T cell therapy|Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
16399787|NCT03980691|No Intervention|without intervention|Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
16399788|NCT03980678|Active Comparator|Mineral Rich Algae with orange flavoring|Participants will consume the Aquamin Soluble (Mineral Rich Algae) equivalent of 1000mg Calcium in 250 ml of orange flavoured water.
16399789|NCT03980678|Placebo Comparator|Water with orange flavoring|Participants will consume a placebo of maltodextrin in 250 ml of orange flavoured water (40mg Calcium).
16399790|NCT03980665|Experimental|Arsenic trioxide combined with cART|Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
16399791|NCT03980665|No Intervention|Without arsenic trioxide therapy|Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
16399792|NCT03980652|Other|Intervention|Change of gloves and use of separate, sterile instruments before closing the abdominal wall
16399793|NCT03980652|No Intervention|Current routine hospital practice|No change of gloves or use of separate, sterile instruments before closing the abdominal wall
16399794|NCT03980639||abatacept|patients with abatacept prescription
16399795|NCT03980639||others bDMARDs|patients with at least one bDMARD prescriptions
16399796|NCT03980626|Experimental|Walking Intervention|Walking participants will engage in the 3-times weekly walking program for 12 weeks.
16399797|NCT03980626|No Intervention|Usual Care|Usual care participants will be offered two personalized exercise sessions with a trained exercise specialist after all post-intervention data have been collected.
16399798|NCT03980613||Spontaneous subarachnoid haemorrhage|Patients with verified spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
16399799|NCT03980613||Controls|Patients without spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
16399800|NCT03980600|Experimental|Donor site treatment with NFC dressing/FibDex®|"Patients requiring skin graft donor site treatment were enrolled in the investigation. Patients were selected based on clinical evaluation by a plastic surgeon.
~Of the total 33 patients enrolled in the study, nine patients were treated during the optimization phase with experimental NFC dressing Types 1-3. The remaining 24 patients were treated with the final product Type 4 (FibDex®). The mean age of patients treated with NFC dressing/FibDex® was 50 ± 18 years, in the range of 21-74 years.
~Suprathel® was used to treat donor sites in the same patients as a reference material. During the optimization phase, Suprathel was intra-individually compared with NFC dressing types 1-3 in five patients out of nine. From the remaining 24 patients, Suprathel was intra-individually compared with FibDex® in 17 patients."
16399803|NCT03980561|Experimental|Varenicline|2 mg daily
16399804|NCT03980561|Placebo Comparator|Placebo|2 mg daily
16399805|NCT03980548||CABG patients|
16399806|NCT03980548||PAD patients|
16399807|NCT03980548||Healthy volunteers|
16399808|NCT03980548||Patients with CAD|
16399809|NCT03980535|Experimental|Device Feasibility (MRI, MRSI)|Patients undergo an additional investigational MRI or MRSI sequence along with the standard MRI or MRSI. Healthy volunteers undergo an investigational MRI or MRSI sequence. Healthy volunteers may also undergo an additional standard sequence if there is one that can be compared to the investigational sequence. All MRI or MRSI procedures, including the standard MRI or MRSI, are no longer than 60 minutes.
16399810|NCT03980522|Experimental|KPL-914: Part 1 Participants|Part 1 enrolls symptomatic participants with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein [CRP] > 1mg/dL).
16399811|NCT03980522|Experimental|KPL-914: Part 2 Participants|Part 2 enrolls symptomatic participants with RIP with CRP ≤1 mg/dL which, in the opinion of the Investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
16399812|NCT03980522|Experimental|KPL-914: Part 3 Participants|Part 3 enrolls participants with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
16399813|NCT03980522|Experimental|KPL-914: Part 4 Participants|Part 4 enrolls symptomatic participants with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP > 1mg/dL).
16399814|NCT03980522|Experimental|KPL-914: Part 5 Participants|Part 5 enrolls participants with corticosteroid-dependent recurrent PPS not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
16399815|NCT03980509|Experimental|Curcumin|Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.
16399816|NCT03980496|Active Comparator|omeprazole infusion (OI) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
16399817|NCT03980496|Active Comparator|omeprazole bolus (OB) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.
16399818|NCT03980483|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and more than or equal to (>=)5 mg/week folic (or folinic) acid as standard of care (SoC).
16399819|NCT03980483|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
16399820|NCT03980483|Active Comparator|Tofacitinib|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
16399821|NCT03980483|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
16399868|NCT03980106|Experimental|Experimental RI-PI|They receive the Reciprocal Inhibition (RI) technique in the first stage and then the Post-isometric Inhibition (PI) technique in the second stage.
16399822|NCT03980483|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
16399823|NCT03980483|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
16399824|NCT03980470|Experimental|Low-dose|The experimental intervention is an additional CT scan with a lower dose (about 20 to 50% decrease) and a similar contrast agent administration that is reconstructed with a deep-learning image reconstruction immediately after the clinical CT scan. The additional time required is about 5 minutes.
16399825|NCT03980470|No Intervention|Normal-dose|The control intervention consists of the routinely performed cardiac CT datasets reconstructed with a standard iterative reconstruction algorithm (ASIR-V). Median radiation dose is about 0.5 mSv, range between about 0.2 and 1.2 mSv; median contrast agent administration about 45 mL, range between 35 and 55 mL.
16399826|NCT03980457|Experimental|Exo-group|Standard rehabilitation plus use of Exoskeleton
16399827|NCT03980457|Placebo Comparator|Control-Group|Standard rehabilitation
16399828|NCT03980444|Experimental|control group, no basket of wire|"The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.
~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.
~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
16399829|NCT03980444|Sham Comparator|using a basket of wires|In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
16399830|NCT03980431|Experimental|FBY in suspected malignant brain tumor|This arm investigates the metabolic characteristics of FBY in suspected malignant brain tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after FBY PET scan.
16399831|NCT03980431|Experimental|FBY in suspected recurrent glioma|This arm investigates the value of FBY to differentiate tumor progression from pseudoprogression. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operation, MRI follow up or change of treatment strategy, according to specific conditions, will be recommended for the definitive diagnosis as well as the management of patients.
16399832|NCT03980418|Experimental|all included patients will have the same procedure|After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
16399833|NCT03980405|Experimental|Group 1|Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
16399834|NCT03980405|Experimental|Group 2|6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
16399835|NCT03980392|Experimental|Facility-based Intervention|A group will consist of 5 or 10 persons depending on the size of the study center. Exercise training will be guided by study exercise therapists at a gym and consist of programs for progressive muscle strength training, aerobic exercise, and exercises to improve postural balance and flexibility using elastic bands, floor plate and chairs (three times per week, 60 min per session).The cognitive training program is a program including tasks to be effective in episodic memory, executive function, attention, working memory, calculation, and visuospatial function (twice per week, 60 min per session). The nutritional intervention is conducted by study nutritionists (three individual sessions and seven group sessions). Management of metabolic and vascular risk factors will include additional meetings with the study nurse (at 0, 4, 8, 16, and 20 weeks), and the study physician (at 0 and 12 weeks). Motivational training is conducted by psychologist (four group session).
16399836|NCT03980392|Experimental|Home-based Intervention|The nutritional intervention, management of metabolic and vascular risk factors, social activity, and motivational training in the home-based intervention are similar to the facility-based intervention. The physical exercise programs consist of one group session (60 min) and two home-based sessions (60 min per session) per week in the first 2 months of the trial. During the remaining months of the 6-month study, participants in the home-based intervention attend a 1-h physical exercise group session per two weeks and two or three exercise sessions (60 min per session) alone at home per week. The cognitive training programs consist of one group session (60 min) and one home-based sessions (60 min per session) per week in the first 2 months of the trial. For the remainder of the 6-month study, participants in the home-based intervention attend a 1-h group cognitive training session per two weeks and one or two cognitive training sessions (60 min per session) alone at home per week.
16399837|NCT03980392|No Intervention|Controls|They are waiting list controls. They will receive the multi-domain intervention after this study.
16399838|NCT03980379|Experimental|experimental group|304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL
16399839|NCT03980379|Active Comparator|control group|Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.
16399840|NCT03980366|Experimental|ECT to treat self-injurious behaviors in adults with ASD|After initial exams and pre-screening, participants will receive bilateral Electroconvulsive Therapy (ECT) for 12 treatments sessions over the course of 4 weeks, plus non-ECT follow-up sessions at 1, 2, 6, and 12 months post-ECT treatment.
16399841|NCT03980353||Children before entrance in primary school|Children with type 1 diabetes, who are too young to go to primary school at the start of the school year 2018-2019, followed in the Diabetology Department of Lyon Pediatric Hospital.
16399842|NCT03980327|Experimental|probiotic|Lactobacillus rhamnosus (5 billion colony forming units per day) and Lactobacillus johnsonii (200 million colony forming units per day) given orally or through a gastrostomy tube daily for 3 months
16399843|NCT03980327|Placebo Comparator|control|1 mL of pure medium chain triglyceride oil given orally or through a gastrostomy tube daily for 3 months
16399844|NCT03980314|Experimental|Arm A (Process C)|"Participants will receive nivolumab specified dose on specified days"
16399845|NCT03980314|Experimental|Arm B (Process D)|"Participants will receive nivolumab specified dose on specified days"
16399846|NCT03980288|Experimental|CAR-GPC3 T Cells|The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
16399847|NCT03980262|Experimental|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
16399848|NCT03980262|Active Comparator|MoneySmart|A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.
16399849|NCT03980249|Experimental|Carvedilol + Standard Treatment|Subjects will receive carvedilol starting at 6.25 mg orally (PO) twice daily for 1-2 weeks and if tolerated will then be increased to 12.5 mg PO twice daily starting on day 1 of concurrent chemoradiotherapy and continue daily until the end of adjuvant cycle 6 of temozolomide and Tumor Treated Fields.
16399850|NCT03980236|Experimental|Livongo-Insulia Study App Arm|Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
16399851|NCT03980223|Experimental|Doxy PEP|Doxycycline 200mg in addition to standard of care STI testing and treatment
16399852|NCT03980223|No Intervention|Control|The control arm will consist of standard of care STI testing and treatment
16399853|NCT03980210|Experimental|Hyperbaric oxygen therapy|"Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)
~Five successive steps:
~FiO2 0.21 - 1 ATA
~FiO2 1 - 1 ATA
~FiO2 1 - 2.5 ATA
~FiO2 0.21 - 2.5 ATA
~FiO2 0.21 - 1 ATA"
16399854|NCT03980197|Experimental|Intervention|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
16399855|NCT03980197|Active Comparator|Control|No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.
16399856|NCT03980184|Experimental|Study Medication|guanfacine 3mg/day (GUA)
16399857|NCT03980184|Placebo Comparator|placebo|placebo (PBO)
16399858|NCT03980171|Experimental|Obinutuzumab+venetoclax+lenalidomide|Patients in both dose escalation and dose expansion will receive 6 cycles of induction treatment consisting of obinutuzumab (flat dose of 1000mg) and protocol defined dose levels of venetoclax and lenalidomide.
16399859|NCT03980158||Upper airway stimulation group|
16399860|NCT03980158||OSA group with conservative / no treatment|
16399861|NCT03980158||Test group without OSA|
16399862|NCT03980145|Active Comparator|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training.40-43 Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
16399863|NCT03980145|Experimental|End-Effector Robotic Training|G-EO training: Using the G-EO System, participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system, with feet secured to pressure sensitive footplates. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence ~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking and stair climbing for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.
16399864|NCT03980132|Experimental|Preoperative Lugol Solution preparation|Patients will receive Lugol Solution preparation for 10 days before thyroidectomy
16399865|NCT03980132|No Intervention|No preparation|Patients will not receive preparation before thyroidectomy
16399866|NCT03980119|Experimental|HITSystem 3.0 Intervention|All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
16399867|NCT03980119|No Intervention|Control|All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
16400050|NCT03978611|Experimental|Part 1: Dose Escalation Phase|
16399869|NCT03980106|Experimental|Experimental PI-RI|They receive the Post-isometric Inhibition (PI) technique in the first stage and then the Reciprocal Inhibition (RI) technique in the second stage.
16399870|NCT03980093|Experimental|Education plus Values|
16399871|NCT03980093|Active Comparator|Education|
16399872|NCT03980080|Experimental|OSE-127: Part 1 (SAD), Cohort A & Cohort B|
16399873|NCT03980080|Placebo Comparator|Placebo: Part 1 (SAD), Cohort A & Cohort B|
16399874|NCT03980080|Experimental|OSE-127: Part 2 (MAD)|
16399875|NCT03980080|Placebo Comparator|Placebo: Part 2 (MAD)|
16399876|NCT03980067|Experimental|Virtual Reality Group|The children in the experimental group will receive the standard of care (access to in room activity including television (TV) distraction if desired, parent support and distraction at bedside, and quiet time) in addition to our intervention, an interactive virtual reality game, played for a minimum of 5 minutes prior to procedural sedation.
16399877|NCT03980067|No Intervention|Standard of Care|The children in the control group receiving standard of care will have access to in room activity including TV distraction if desired, parent support and distraction at bedside, and quiet time.
16399878|NCT03980054|Experimental|Arm Pyrotinib|Intervention: Drug: Pyrotinib
16399879|NCT03980054|Placebo Comparator|Arm Placebo|Intervention: Drug: Placebo
16399880|NCT03980041|Experimental|IPI-549 + Nivolumab|Participants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
16399881|NCT03980041|Active Comparator|Placebo + Nivolumab|Participants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
16399882|NCT03980015||erythema migrans|patients with erythema migrans
16399883|NCT03980002|Experimental|FCR/BR alternating with ibrutinib|FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
16399884|NCT03979989|Experimental|Tapentadol IR|A single oral dose of tapentadol IR was administered in a fasted state (Treatment A).
16399885|NCT03979989|Experimental|Omeprazole, Tapentadol IR|Oral doses of omeprazole were administered once daily in a fasted state on 4 consecutive days (Days -3 to 1), plus 1 capsule of CG5503 IR administered 2 hours after the administration of omeprazole on Day 1 (Treatment B).
16399886|NCT03979976|Active Comparator|ramipril group|Use of ramipril 10mg/day per 12 weeks
16399887|NCT03979976|No Intervention|Control Group|Without ramipril
16399888|NCT03979924|Other|Interventional Step|The interventional step will comprise the same follow-up as the observational step, except for the addition of an early and preventive care, conducted by a specialized physiotherapist using an active exercise handbook elaborated with the patient's therapeutic education transversal Unit (Utep). This aims at increasing the patient's adhesion to the program and to limit the reduction of mouth opening and its consequences ( Trismus rehabilitation)
16399889|NCT03979898|Experimental|Astrostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells
16399890|NCT03979885|Other|Goal-Directed Incentives|
16399891|NCT03979885|Other|Outcome-Based Incentives|
16399892|NCT03979885|Other|Enhanced Usual Care|
16399893|NCT03979872|Active Comparator|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
16399894|NCT03979872|Experimental|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
16399895|NCT03979872|Experimental|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
16399896|NCT03979872|Experimental|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
16399897|NCT03979859|Experimental|WCK 4873|200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study
16399898|NCT03979859|Placebo Comparator|Placebo|Visually matching placebo
16399899|NCT03979846|Experimental|Arm I (usual care, computer-based symptom reporting)|Participants receive usual care for 3 weeks, then use a computer based symptom reporting system for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
16399900|NCT03979846|Experimental|Arm II (computer-based symptom reporting, usual care)|Participants use a computer based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
16399901|NCT03979833||1|Individuals currently living, over the age of 18 years and known carriers of a pathogenic variant in the VHL gene.
16399902|NCT03979820|Experimental|10 mg BI 1467335/10 mg BI 1467335 + Tyramine|
16399903|NCT03979820|Experimental|15 mg BI 1467335/15 mg BI 1467335 + Tyramine|
16399904|NCT03979820|Active Comparator|Phenelzine/Phenelzine + Tyramine|
16399905|NCT03979820|Placebo Comparator|Placebo/Placebo + Tyramine|
16399906|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
16399907|NCT03979794|Experimental|Be-WEL Intervention|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
16399908|NCT03979794|No Intervention|Standard Care|Standard Care consists of the standard care patients typically receive from their medical team.
16399909|NCT03979781|Experimental|Treatment Group|Intervention group
16399910|NCT03979781|Active Comparator|Control Group|Standard of Care group
16399911|NCT03979768|Experimental|Risk Assessment Only pharmacies (RTO-group)|Offered a diabetes risk assessment service without any blood sample testing.
16399912|NCT03979768|Experimental|HbA1c-group /pharmacies|Offered a diabetes risk assessment service including a measurement of Haemoglobin A1c (HbA1c) to the people with a high risk of developing type 2 diabetes on the risk assessment form (The Finnish Diabetes Risc Score (FINDRISC) to those with a western background, and Leicester Risk Assessment (LRA) form for those with a non-western background.
16399913|NCT03979755||Study Group|Women cancer survivors living in Campo Belo, Minas Gerais.
16399914|NCT03979755||Control Group|Women in routine follow-up in the public health system in Campo Belo, Minas Gerais.
16399918|NCT03979729||3D + 2D-Mammogram Recipients (Patient Group A)|Women presenting for mammographic screening who selected 3D + 2D- mammogram. These women will undergo in-person or telephone interviews.
16399919|NCT03979729||2D-Mammogram Recipients (Patient Group B)|Women presenting for mammographic screening who selected 2D- mammogram alone (declined 3D + 2D- mammogram). These women will undergo in-person or telephone interviews.
16399920|NCT03979729||Women Who Have Never Received a Mammogram (Patient Group C)|Women who have never undergone recommended mammographic screening. These women will participate in a onetime facilitated focus group.
16399921|NCT03979729||Providers|Primary care providers (physicians, physicians assistants, and advanced nurse practitioners) working in clinics providing primary care for underserved patient populations in New Mexico, including primary care providers at a RIOSNET-affiliated and UNM-affiliated clinics
16399922|NCT03979716|Experimental|Anosmic patients|
16399923|NCT03979716|Experimental|Hyposmic patients|
16399924|NCT03979716|Experimental|Normosmic patients|
16399925|NCT03979703|Experimental|Intervention group|Intervention will be a 12 week yoga class
16399926|NCT03979703|No Intervention|Control group|Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.
16399927|NCT03979690|Experimental|Subjects Receiving Colonoscopy|Subjects receiving tandem colonoscopies using the NISInspire-C System followed by a Conventional Colonoscopy
16399928|NCT03979677|Experimental|Intervention Group|All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.
16399929|NCT03979664|Active Comparator|Active Iontophoresis|One active iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
16399930|NCT03979664|Sham Comparator|Inactive Iontophoresis|One inactive iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
16399931|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 1)|Patients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
16399932|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 2)|Patients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
16399933|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 3)|Patients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
16399934|NCT03979638|Experimental|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
16399935|NCT03979638|Placebo Comparator|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
16399936|NCT03979599|Active Comparator|magnesium sulphate& levobupivacaine|Levobupivacaine add to magnisum sulphate
16399937|NCT03979599|Placebo Comparator|levobupivacaine|levobupivacaine
16399938|NCT03979586|Experimental|Patient phototype I to IV|The study will be conducted in the Laser Dermatological and Plastic Center of the Conception Hospital in Marseille. It will be a prospective, controlled, hemiface, single-blind, independent-evaluator pilot study of 20 patients, 30 to 70 years old, with phototype I to IV (Fitzpatrick scale). By this study in hemiface, each patient will be his own witness. Neither the patient nor the examining doctor will know the choice of the hemiface of application of hyaluronic acid. This will be a single-blind study with independent evaluator. Patients will be included for 3 months, and followed for a period of 3 months.
16399939|NCT03979573|Other|Intervention Arm|"PSA testing
~Multiparametric MRI (mp-MRI)
~Radiomics
~MR-guided biopsy (MR-guided and systematic US-guided)
~Molecular Markers (Histological analysis of biopsy cores)"
16399940|NCT03979560|No Intervention|Control|"The control group will benefit from the usual support (depending on the practices of the department, prescription or not of oral nutritional supplements and physiotherapy at home, but without home intervention of adapted physical activity professionals or dieticians).
~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
16399941|NCT03979560|Experimental|Nutrition intervention with appropriate physical activity|"Intervention at home of professionals:
~Patients in this arm will benefit from 14 home interventions
~7 home nutrition support (NS) sessions in 3 months or 1 session every 10 days (+/-4 days). These sessions will be conducted by a dietician from the company Saveurs et Vie.
~7 home sessions of adaptive physical activity (APA) in 3 months, one session every 10 days (+/-4 days). These sessions will be conducted by professionals from association group Siel Bleu.
~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
16399942|NCT03979547|Experimental|Exercise intervention|The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
16399943|NCT03979547|No Intervention|Standard of Care|Subjects are instructed to maintain their current activity level.
16399944|NCT03979534|Experimental|Diet group|"Diet follow-up to personalize a low-protein diet for each patient. All patients following a low protein diet one month or more compose the diet group."
16399945|NCT03979534|No Intervention|Control group|Patients who accepted to take part of the study but refused the low protein diet and patients who discontinued the diet on the first month compose the control group.
16399946|NCT03979508|Experimental|Group 1 (surgery)|Patients undergo standard of care surgical resection.
16399947|NCT03979508|Experimental|Group 2 (abemaciclib, surgery)|Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.
16399948|NCT03979495|No Intervention|Standard of care|standard of care
16399949|NCT03979495|Active Comparator|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
16399950|NCT03979495|Active Comparator|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
16399951|NCT03979495|Active Comparator|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
16399952|NCT03979482||PAH patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
16399953|NCT03979482||Sedentary healthy patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.
16399954|NCT03979469|Experimental|opiod free general anesthesia|In group A opioid free anesthesia is administered. Anesthesia and analgesia were achieved with ketamine(1mg/kg, bolus), dexmedetomidine(1mcg/kg, over 10 minutes), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg). Anesthesia induction with ketamine(1mg/kg), propofol 1% 2-3mg/kg, rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
16399955|NCT03979469|Active Comparator|opioid based general anesthesia|In group B opioid based anesthesia is administered.Anesthesia and analgesia were achieved with remifentanil(0.3mcg/kg/minute), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg).Anesthesia induction with propofol 1% 2-3mg/kg,fentanyl(2mcg/kg), rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
16399956|NCT03979456|Active Comparator|6-month dosing interval|This arm is receiving standard dose rituximab 500 mg every 6 months
16399957|NCT03979456|Experimental|12-month dosing interval|This arm is receiving the comparator dose rituximab 500 mg every 12 months
16399958|NCT03979443|No Intervention|Inpatient|patients staying in the hospital for 1-3 nights after surgery
16399959|NCT03979443|Active Comparator|Outpatient|discharge on the day of the surgery, usually within 6-8 hours after procedure
16399961|NCT03979417||Liver fibrosis F0-F1|Blood draw and liver resection at the liver surgery
16399962|NCT03979417||Liver fibrosis F2-F3|Blood draw and liver resection at the liver surgery
16399963|NCT03979417||Liver Fibrosis F4|Blood draw and liver resection at the liver surgery
16399964|NCT03979404|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
16399965|NCT03979391|Experimental|Children with CIS or RIS|The detection of supernumerary oligoclonal bands (OCBs) in tears will be performed
16399966|NCT03979365|Active Comparator|Tacrolimus twice-daily|Subjects assigned to this arm will take tacrolimus two times daily by mouth, at the clinically prescribed dose.
16399967|NCT03979365|Active Comparator|Envarsus XR|Subjects assigned to this arm will take Envarsus XR one time daily by mouth, at the clinically prescribed dose.
16399968|NCT03979352|Active Comparator|Empagliflozin arm|"Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.
~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.
~Participant and research staff is blinded to arm assignment."
16399969|NCT03979352|Placebo Comparator|Placebo arm|"Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.
~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.
~Participant and research staff is blinded to arm assignment."
16399970|NCT03979339|Experimental|blood sample collection|For all participants whatever the group Groups 0 and 4: Healthy volunteers Group1: Metastatic HER2-positive breast cancer Group 2: Advanced CA-125 positive ovarian cancer Group 3: Metastatic PSA-positive castrate-resistant prostate cancer Participants will receive the following interventions because they are enrolled in the study: blood sample collection of 32mL (4x8mL in EDTA tubes)
16399971|NCT03979326|Experimental|Young women during various of phases of menstrual cycle.|The group of 40 young women will have their hamstring muscle stretched in different phases of the menstrual cycle: follicular, ovulatory and luteal. Static stretching will last 3x 45 seconds with a 15 second break between repetitions. Before and after the intervention a series of tests will be performed.
16399972|NCT03979313|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
16399973|NCT03979313|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline
16399974|NCT03979287|Experimental|IFC and Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour. Participants will receive treatment with Interferential current therapy plus a program of therapeutic exercise focused on the neck region
16399975|NCT03979287|Active Comparator|Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour.This group will only receive the same therapeutic exercise program.
16399976|NCT03979274|Experimental|Reference Eutirox®, then Test Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (mcg) (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
16399977|NCT03979274|Experimental|Test Eutirox®, then Reference Eutirox®|Participants received single oral dose of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Reference Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
16399978|NCT03979261||sex ratio evaluation|Valvular surgery is performed in 30-40% of cases. The Cardiology and Cardiac Surgery De la Timone services 1000 patients as part of their valvulopathy and 450 benefit from cardiac surgery. On the other hand, transcriptomic analysis by microarray will only be done on 40 patients because the analysis costs 150 € / patients.
16399979|NCT03979248|Experimental|BMS-986165 + Rabeprazole|
16399980|NCT03979235||Heahlthy people|perform motor function assessment by using scales, sEMG, and inertia sensors
16399981|NCT03979235||People with motor deficits|perform motor function assessment by using scales, sEMG, and inertia sensors
16399982|NCT03979235||Patients with dysphagia|perform motor function assessment by using scales, sEMG, and inertia sensors
16399983|NCT03979209|Experimental|Mometasone 1mg|1mg capsule dissolved in 240mg saline solution nasal irrigation
16399984|NCT03979209|Experimental|Mometasone 2mg|2mg capsule dissolved in 240mg saline solution nasal irrigation
16399985|NCT03979209|Experimental|Mometasone 4mg|4mg capsule dissolved in 240mg saline solution nasal irrigation
16399986|NCT03979196|Active Comparator|Inpatient Management|Women in this arm will follow the standard of care for admission to high-risk units at Sunnybrook Health Sciences Centre or North York General Hospital.
16399987|NCT03979196|Active Comparator|Outpatient Management|Women in this arm will be encouraged to follow the standard of care established in the high-risk clinics at Sunnybrook Health Sciences Centre or North York General Hospital.
16399988|NCT03979183|Experimental|Intervention|Therapeutic exercise
16399989|NCT03979183|No Intervention|Control|Usual care
16399990|NCT03979157|Experimental|Healthy Volunteers|Multispectral Optoacoustic Tomography (MSOT) of proximal and distal leg muscles (total of 12 sites: left and right, 3 measurement points of Musculus quadriceps, and 3 measurement points of Musculus triceps surae) before and after the 6-Minute-Walk-Test by to independent investigators. Repetition of the same protocol after 14 days.
16399991|NCT03979131|Experimental|Resectable GC and GEJC+avelumab+FLOT preoperative treatment|Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.
16399992|NCT03979105||Ketamine infusion|Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.
16399993|NCT03979092|Experimental|IP-ACLS|
16399994|NCT03979092|Other|Waitlist|
16399995|NCT03979066|Active Comparator|Atezolizumab|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
16399996|NCT03979066|Experimental|Atezolizumab in combination with PEGPH20|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery in combination with PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
16399997|NCT03979053||Patients with AIH|60 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at KCH NHS FT and are either being investigated for AIH or have confirmed AIH
16399998|NCT03979040|Experimental|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
16399999|NCT03979040|Active Comparator|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant?s principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
16400000|NCT03979027|No Intervention|No Breakfast|Fasting. Ad libitum water intake permitted.
16400001|NCT03979027|Experimental|Breakfast|Ad libitum intake of ready-to-eat-cereal with milk. Participants were given a choice of four commercially available RTECs with 1.8% fat cow's milk. Ad libitum water intake was also permitted. The four ready-to-eat-cereals were corn flakes, toasted rice, shredded whole wheat pieces with a sugar topping, and wheat, corn and oat shapes.
16400002|NCT03979014|Experimental|Vaccinated Arm|Add vaccine
16400003|NCT03979014|No Intervention|Control|No intervention
16400004|NCT03979001||Patients|Patients referred for polysomnography diagnosis of obstructive sleep apnea syndrome
16400005|NCT03979001||Controls|Person without obstructive sleep apnea syndrome
16400006|NCT03978988|Experimental|Thrombectomy + Carotid Stenting|"Intravenous thrombolysis will be administered if possible. Standard mechanical thrombectomy(MT) will be performed with a balloon Guide Catheter. MT technique will be left at the discretion of the operators.
~Concerning the cervical disease, emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion. An intravenous bolus of 250mg of Aspirin (up to Imaging 24H) will be given at the end of the procedure in case of absence of complication.
~Intravenous sedation or general anesthesia will be permitted.A second antiplatelet agent is used if a thrombus is formed : IV or nasogastric tube (choice by operator) A dual antiplatelet therapy is administered after 24H imaging follow-up excluding intracranial hemorrhagic complications (discretion of the local practice)"
16400007|NCT03978988|No Intervention|Thrombectomy alone|"Endovascular procedure:
~Intracranial thrombectomy alone (carotid angioplasty may be performed)"
16400008|NCT03978975|Active Comparator|normal weight women|20 women with a body mass index ranging between 18,5 and 24,9 kg.m2
16400009|NCT03978975|Experimental|overweight women|20 women with a body mass index ranging between 25 and 29,9 kg.m2
16400010|NCT03978962||Study population|Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure
16400011|NCT03978949|Experimental|Probiotics|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
16400012|NCT03978949|Placebo Comparator|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
16400051|NCT03978611|Experimental|Part 2: Dose Expansion Phase|
16400013|NCT03978936|Experimental|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
16400014|NCT03978936|Active Comparator|EAM only|Electronic Adherence Self-Management [EAM] only
16400015|NCT03978923||the drill-inserted implants (G1)|
16400016|NCT03978923||the ultrasonic device- inserted implants (G2)|
16400017|NCT03978910|Experimental|Weigthlessness|during a flight
16400018|NCT03978897|Experimental|Blood flow restriction with physical/occupational therapy|physical/occupational therapy including use of blood flow restriction tourniquet over 6 visits (within a twelve week period).
16400019|NCT03978897|Active Comparator|Evidence based physical/occupational therapy|evidence based physical/occupational therapy program over 6 visits (within a twelve week period) without use of blood flow restriction tourniquet
16400020|NCT03978884|Experimental|Mild Hypertensive|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg
16400021|NCT03978884|Experimental|Mild Hypertensive with Diabetes|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg and diabetes.
16400022|NCT03978884|Experimental|Severe Hypertension|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg
16400023|NCT03978884|Experimental|Severe Hypertension with Diabetes|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg with diabetes
16400024|NCT03978871|Experimental|Growth Mindset|Persuasive education about emotions, brain development, and teenagers' ability to learn how to manage emotions
16400025|NCT03978871|Active Comparator|Brain Education|Neutral education about functions of different parts of the brain
16400026|NCT03978845|Experimental|Phrenic Nerve Blockade|All patients will be submitted to bilateral phrenic nerve block on its cervical portion.
16400027|NCT03978832|Experimental|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
16400028|NCT03978819||Patients with large CPA tumors|Patients with large cerebellopontine angle tumors (>2 x 2cm) undergoing elective surgery
16400029|NCT03978806|Active Comparator|peer navigator|The first PN visit will take place within 1-2 weeks of consent. Each of the 5 subsequent PN visits will take place every 1-2 weeks. We expect patients to complete the intervention within 2-3 months of consent. The function of the initial visit is to establish trust and ensure a more personal approach with participants. The community-based PN intervention is grounded in core Latino values (e.g. trust, personalized relationships). The core elements of the PN intervention include patient motivational interviewing as well as patient activation, empowerment (e.g. help with scheduling of healthcare appointments and re-scheduling of missed HD sessions), education (e.g. education of ESKD and need for renal replacement therapy), and social challenges (e.g. access to resources for transportation, benefits, immigration issues). The duration, individuals present during the visit, and content discussed will be documented in the visit form.
16400030|NCT03978806|Placebo Comparator|Control Arm (standard of care)|Standard of care
16400031|NCT03978793||MyTPill|Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill.
16400034|NCT03978767|Experimental|NSAID Analgesic bundle|Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery
16400035|NCT03978767|Active Comparator|NSAID free analgesic bundle|Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.
16400036|NCT03978754||patients with lymphedema|
16400037|NCT03978741|Experimental|Test Device|Yōni.Fit Test Device
16400038|NCT03978741|Active Comparator|Comparator Device|Yōni.Fit Comparator Device
16400039|NCT03978728||ECMO patients|Patients with ECMO support
16400040|NCT03978702|Experimental|Indication for pancreatectomy|Blood sampling at different time points before and after pancreatectomy
16400041|NCT03978689|Experimental|CUE-101 dose escalation and expansion|Part A&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)
16400042|NCT03978689|Other|Pembrolizumab and CUE-101|Part C&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
16400043|NCT03978663|Experimental|Neoadjuvant radiotherapy|3 doses of stereotactic radiotherapy administered prior to neoadjuvant chemotherapy in high-risk breast cancers.
16400044|NCT03978637|Experimental|Itacitinib 300 mg|Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
16400045|NCT03978637|Experimental|Itacitinib 400 mg|Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
16400046|NCT03978637|Experimental|Itacitinib 600 mg|Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
16400047|NCT03978637|Experimental|Itacitinib|Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
16400048|NCT03978624|Experimental|A: Pembrolizumab alone|Subjects will be administered pembrolizumab alone 200 mg IV on day 1 and day 22
16400049|NCT03978624|Experimental|B: Pembrolizumab plus Entinostat|Subjects will be administered pembrolizumab on day 1 and day 22 and entinostat 5 mg given orally on day 1, day 8 and day 15
16400052|NCT03978598|Experimental|Immediate insertion group|Immediate insertion in the first 24 hours after delivery ENG implant insertion Intervention.
16400053|NCT03978598|Active Comparator|Standard Postpartum Insertion Group|Insertion of the Etonogestrel implant 4-6 weeks postpartum Intervention.
16400054|NCT03978585|Experimental|HTEMS Arm|High tone therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
16400055|NCT03978585|Active Comparator|TENS Arm|TENS therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
16400056|NCT03978572|Active Comparator|Resistance Training|12 weeks of whole-body progressive resistance training, three days per week, lower-extremity focused (60% of exercises targeting lower extremities)
16400057|NCT03978572|Active Comparator|Moderate-intensity continuous cycling|12 weeks of progressive endurance cycling on a stationary bicycle at a target heart rate, three days per week.
16400058|NCT03978572|Experimental|High-intensity interval cycling|12 weeks of progressive high-intensity interval cycling on a stationary bicycle, three days per week.
16400059|NCT03978559|Experimental|CAS with TMP/SMZ|
16400060|NCT03978559|Active Comparator|TMP/SMZ|
16400061|NCT03978546|Experimental|Non-Glaucoma Patient Arm|All participants will complete the same assessments
16400062|NCT03978546|Experimental|Glaucoma Patient Arm|All participants will complete the same assessments
16400063|NCT03978533|Experimental|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
16400064|NCT03978520|Experimental|Group 1: Upadacitinib and Elsubrutinib|Participants will be administered with elsubrutinib dose A and upadacitinib dose A.
16400065|NCT03978520|Experimental|Group 2: Upadacitinib and Elsubrutinib|Participants will be administered with elsubrutinib dose A and upadacitinib dose B.
16400066|NCT03978520|Experimental|Group 3: Elsubrutinib and Placebo for Updadacitinib|Participants will be administered with elsubrutinib dose A and placebo for upadacitinib.
16400067|NCT03978520|Experimental|Group 4: Upadacitinib and Placebo for Elsubrutinib|Participants will be administered with placebo for elsubrutinib and upadacitinib dose A.
16400068|NCT03978520|Experimental|Group 5: Placebo for Elsubrutinib and Placebo for Upadacitinib|Participants will be administered with placebo for elsubrutinib and placebo for upadacitinib.
16400069|NCT03978507|Experimental|DeFOG group|feedback number of steps + cueing
16400070|NCT03978507|Active Comparator|Control group|feedback number of steps
16400071|NCT03978494|Experimental|Period 1: Advagraf®; Period 2: Generic tacrolimus|In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
16400072|NCT03978494|Experimental|Period 1: Generic tacrolimus; Period 2: Advagraf®|In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
16400073|NCT03978481||Eradicated group|Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication
16400074|NCT03978481||Negative group|Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative
16400075|NCT03978468|Active Comparator|Usual Care Group|Children will receive usual care.
16400076|NCT03978468|Experimental|Interagency Collaboration (ICollab Group)|Subjects of this arm will receive ICollab intervention in addition to usual care which consists of communication with Home Health Nurse (HHN) , Collaborative meetings, and communication with Primary Care Physician (PCP)
16400077|NCT03978455||Patients Who Smoke|"This group will consist of up to 100 English-speaking adult smokers recruited from their primary care clinic who are willing to complete a brief phone-based interview about their experience in using the Learn, Connect, and Quit (LCQ) tablet-based mobile application. The LCQ app presents smoking and cessation-related educational and motivational content in an easily accessible manner (i.e., via videos) and provides avenues for smokers to connect to evidence-based treatment."
16400078|NCT03978455||Clinic Staff|"Rooming staff and physicians from the primary care clinic (where Patients Who Smoke group participants are recruited) will be asked to participate in interviews about the feasibility of implementing the LCQ app including implementation burden, impact on clinical workload, and clinical utility of the app (i.e., Did patients ask more questions about smoking treatment? How challenging was it to try to give all smokers the app to explore?)."
16400079|NCT03978442|Experimental|CPT-SMART|COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) - an intervention that combines evidence-based PTSD treatment with guideline-concordant cognitive-behavioral smoking cessation counseling, bupropion, and intensive behavioral therapy through CM.
16400080|NCT03978442|Active Comparator|Combined Contact Yoked Control|COMBINED CONTACT YOKED CONTROL (CCYC) - an intervention that is identical to CPT-SMART for PTSD and smoking treatment, except for using non-contingent payment (i.e., yoked CM) to control for compensation and monitoring.
16400081|NCT03978429|Experimental|Intervention Arm|"Community-based Pre-eclampsia/Eclampsia Detection and Management
~Strengthened Referral Network from Community to Referral hospital levels
~Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.
~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.
~Antenatal Care Nurses will receive bluetooth blood pressure monitors.
~Community Health Workers within the intervention arm facilities will receive training in pre-eclampsia features and will be provided with smart phones and access to a smart phone application that will prompt them to initiate follow ups with pregnant women within the community and they will receive SMS/text messages reminders about pregnant women within the community who require follow up."
16400116|NCT03978169||General anaesthesia with orotracheal intubation|surgery patients under general anaesthesia with orotracheal intubation
16404273|NCT03949010|Active Comparator|Home exercise program|
16400082|NCT03978429|No Intervention|Enhanced Usual Care|"Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.
~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.
~Antenatal Care Nurses will receive bluetooth blood pressure monitors."
16400083|NCT03978416|No Intervention|Focus groups|"Information on practical and cultural barriers and promoters of successful weight management will be collected through focus groups. This will include include food access, dietary patterns, physical activity, time and financial constraints, and additional psychosocial and cultural factors.
~A total of 30 participants will be recruited for the focus groups."
16400084|NCT03978416|Experimental|Pilot behavioral intervention|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests with 5 participants per test (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery.
16400085|NCT03978403|Experimental|M207 3.8 mg (two 1.9 mg Patches in foil pouches, Treatment A)|M207 3.8 mg (Zolmitriptan Microneedle System) administered as two 1.9 mg disposable titanium microneedle patches packaged in a foil pouch (Treatment A)
16400086|NCT03978403|Experimental|M207 3.8 mg (two 1.9 mg Patches in cups, treatment B)|M207 3.8 mg (Zolmitriptan Microneedle System) administered as two 1.9 mg disposable titanium microneedle patches packaged in cups (Treatment B)
16400087|NCT03978403|Experimental|M207 3.9 mg (two 1.9 mg Patches in cups (Treatment C)|M207 3.8 mg (Zolmitriptan Microneedle System) administered as two 1.9 mg disposable titanium microneedle patches packaged in cups (Treatment C)
16400088|NCT03978403|Active Comparator|Zolmitriptan Nasal Spray (Treatment D)|Zolmitriptan 2.5 mg/0.1 ml nasal spray (Zomig® Nasal Spray)
16400089|NCT03978390|Experimental|Superhero images, Reward at the beginning,|Also, Showing superhero images for 5 minutes before starting the dental procedure. Also, providing the children with reward before begging the dental procedure and telling them that they can only keep it if they cooperate during the treatment procedure.
16400090|NCT03978390|Experimental|Superhero images, Reward at the end|Universally-accepted positive reinforcement to increase children cooperation in dental settings
16400091|NCT03978390|Experimental|No Superhero Images, Reward at the beginning|Showing superhero images for 5 minutes before starting the dental procedure
16400092|NCT03978390|Active Comparator|No Superhero Images, Reward at the end|Showing no picture before starting the dental procedure
16400093|NCT03978364|Experimental|azacitidine|"azacitidine
~azacitidine 75mg/m2，iH，qd， d1-7"
16400094|NCT03978364|Active Comparator|azacitidine combined HHT|azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3
16400095|NCT03978338|Experimental|Intervention group|The experimental group will take the brain polypeptide solution .
16400096|NCT03978338|Placebo Comparator|Control group|The control group was treated with the same package of placebo .
16400097|NCT03978325|Active Comparator|Control|This arm will complete a standard prehabilitation intervention.
16400098|NCT03978325|Experimental|HIIT Intervention|This group will complete a pre-operative high intensity interval training programme.
16400099|NCT03978299||Positive PSA result|"Men with a positive PSA test defined as:
~Serum total PSA concentration is over 10 ng/ml.
~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is under 25%, in at least in two determinations."
16400100|NCT03978299||Negative PSA result|"Men with a negative PSA test defined as:
~Serum total PSA concentration is under 10 ng/ml.
~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is over 25%."
16400101|NCT03978286|Experimental|Vortioxetine therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
16400102|NCT03978286|Experimental|Sertraline therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
16400103|NCT03978273|Experimental|Night-time brace + virtual-brace|Patients are conventionally treated with night-time brace. Additionally, they use the new developped virtual-brace (MD).
16400104|NCT03978273|Active Comparator|Night-time brace only|Patients are conventionally treated with night-time brace only.
16400105|NCT03978247|Experimental|NASHMIR group|Validation of the NASHMIR Test
16400106|NCT03978234|Experimental|Single group|Single group
16400107|NCT03978221|Experimental|diaphragmatic tissue doppler evaluation|A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
16400108|NCT03978208|Active Comparator|Placebo Comparator|ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days
16400109|NCT03978208|Active Comparator|ATB-346 mid-dose|ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days
16400110|NCT03978208|Active Comparator|ATB-346 standard dose|ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days
16400111|NCT03978208|Placebo Comparator|Active Comparator|Overencapsulated placebo tablet taken by mouth once daily for 14 days
16400112|NCT03978195|Experimental|Treatment|
16400113|NCT03978195|No Intervention|Control|
16400114|NCT03978182|Active Comparator|active accelerated deep rTMS|Stimulation: We will use a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil, which includes a sham option. In analogy to our former accelerated rTMS studies (2, 3), all patients will receive 20 dTMS sessions (5 sessions per day; 4 consecutive days) with a stimulation intensity of 120% of the subject's resting MT, as reported by Levkovitz et al.(4). Furthermore, we selected these FDA approved dTMS parameters, so that for one session each dTMS repetition includes 2-sec pulse trains separated by 20-sec inter-train intervals. Patients will receive 55 trains in each treatment session, for a total of 1980 pulses per session. This makes 9900 pulses/day, and in total 39600 pulses per treatment.
16400115|NCT03978182|Sham Comparator|sham|Built-in sham in the H1 Helmet (same device as active treatment)
16400117|NCT03978169||General anaesthesia with laryngeal mask|surgery patient under general anaesthesia with laryngeal mask
16400118|NCT03978169||Spinal anaesthesia|surgery's patients under Spinal anaesthesia
16400119|NCT03978156|Experimental|Dronabinol, Then Placebo|Participants will take 2.5 mg of Dronabinol for 2 weeks, 1 week washout and then take 2 weeks of placebo (microcrystalline cellulos). Subjects will take up to 8 capsules daily of the treatment daily during each phase.
16400120|NCT03978156|Experimental|Placebo, Then Dronabinol|Participants will take placebo (microcrystalline cellulos) for 2 weeks, 1 week washout and then take 2.5 mg of Dronabinol for 2 weeks. Subjects will take up to 8 capsules daily of the treatment daily during each phase.
16400121|NCT03978143|Other|Sequence 1|Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G
16400122|NCT03978143|Other|Sequence 2|Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G
16400123|NCT03978143|Other|Sequence 3|Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G
16400124|NCT03978143|Other|Sequence 4|Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H
16400125|NCT03978143|Other|Sequence 5|Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H
16400126|NCT03978143|Other|Sequence 6|Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H
16400127|NCT03978130|Experimental|mHealth-CR|
16400128|NCT03978130|No Intervention|Usual Care|
16400129|NCT03978117|Experimental|Freeze Dried Powder Preparation|
16400130|NCT03978117|Placebo Comparator|Placebo|
16400134|NCT03978091|Experimental|Arm 1|2.5g dose of ceftazidime-avibactam (AVYCAZ) administered intravenously as a 2-hour infusion, every 8 hours for 7 days. N=8
16400135|NCT03978091|Experimental|Arm 2|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion once, then 0.32g dose per hour daily as a continuous infusion (7.5 g/day) for 7 days. N=8
16400136|NCT03978091|Experimental|Arm 3|2g dose of aztreonam (ATM) administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
16400137|NCT03978091|Experimental|Arm 4|2g of ATM administered intravenously as a 2-hour infusion once, then 0.33g dose administered intravenously per hour, daily as a continuous infusion (8 g/day) for 7 days. N=8
16400138|NCT03978091|Experimental|Arm 5|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion, every 8 hours for 7 days, and a 1.5g dose of ATM administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
16400139|NCT03978091|Experimental|Arm 6|2.5 g dose of AVYCAZ administered intravenously as a 2-hour infusion every 8 hours for 7 days, and a 2g dose of ATM as a 2-hour infusion every 6 hours for 7 days. N=8
16400140|NCT03978078|Experimental|Biological collection|"For all the patients include in the study :
~- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16400141|NCT03978052|Experimental|1|"EGCG + multimodal intervention (n=50) Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~+ personalized intervention"
16400142|NCT03978052|Active Comparator|2|"Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~non personalized intervention"
16400143|NCT03978052|Placebo Comparator|3|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~+ personalized intervention"
16400144|NCT03978052|Sham Comparator|4|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~non personalized intervention"
16400145|NCT03978026|Experimental|nap in a bed|the participants take a nap of 30 min in a bed in a bedroom
16400146|NCT03978026|Experimental|nap in an armchair|the participants take a nap of 30 min in a car sit in a bedroom
16400147|NCT03978026|Experimental|nap in teh Sombox|the participants take a nap of 30 min in the micro-hotel Sombox
16400148|NCT03978026|Sham Comparator|no nap in a bed|the participant stay awaked for 30 min in a bed in a bedroom
16400149|NCT03978013|Experimental|Pomegranate|
16400150|NCT03978013|Active Comparator|Apple|
16400151|NCT03978000|Active Comparator|IBP-9414|
16400152|NCT03978000|Placebo Comparator|Placebo|
16400153|NCT03977987||The treatment group|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
16400154|NCT03977987||The control group with high HBV DNA level|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
16400155|NCT03977987||The control group with low HBV DNA level|Pregnant women with high HBV DNA level < 2*10^6 IU/ml
16400156|NCT03977974|Experimental|LY3526318 - Part A|LY3526318 administered orally once.
16400157|NCT03977974|Placebo Comparator|Placebo - Part A|Placebo administered orally once.
16400158|NCT03977974|Experimental|LY3526318 - Part B|LY3526318 administered once orally on consecutive days.
16400159|NCT03977974|Placebo Comparator|Placebo - Part B|Placebo administered once orally on consecutive days.
16400160|NCT03977961||DDD Patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) with a diagnosed DDD fulfilling the inclusion criteria and scheduled for surgery will be considered for this study.
16400185|NCT03977727|Experimental|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
16400186|NCT03977727|Experimental|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
16400161|NCT03977935|No Intervention|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
16400162|NCT03977935|Experimental|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
16400163|NCT03977922|Experimental|Diet group|"The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:
~Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet previously studied in Allison and Ditor (2015).
~10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.
~At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier.
~Once per month, we will be offering a live cooking class."
16400164|NCT03977922|No Intervention|Control group|The control group will eat their usual diet for the 12-week period.
16400165|NCT03977896|Experimental|11C-MET PET/MRI|
16400166|NCT03977870||patients with Venous thromboembolism (VTE)|
16400167|NCT03977857||28-day nonsurvival or transplantation|patients who died or underwent liver transplantation within 28 days since admission
16400168|NCT03977857||28-day transplantation-free survival|patients who survived without liver transplantation at 28 days since admission
16400169|NCT03977844|Active Comparator|Technical Assistance|Technical Assistance. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security.
16400170|NCT03977844|Experimental|Community Engagement and Planning|Community Engagement and Planning. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security. In addition, community agencies will be invited to meet with one another to develop novel and investigator supported coalitions using principles of community partnered participatory research that will adapt toolkits and other local assets to seek to enhance community resilience related to threats of disaster risk, financial insecurity, housing insecurity, mental health, or other coalition-determined domains.
16400171|NCT03977844|Active Comparator|Community Resources (CR)|Community Resources (CR). At the Individual level of randomization, individuals in the Community Resources (CR) arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security.
16400172|NCT03977844|Experimental|Community Resources (CR) + eBT|Community Resources + eBT. At the Individual level of randomization, individuals in the CR+eBT arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security, along with an interactive component to support CBT-informed coping with mood and stressors at the individual level.
16400173|NCT03977831|Active Comparator|Open Radical Cystectomy (ORC)|Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.
16400174|NCT03977831|Active Comparator|Robot-assisted Radical Cystectomy (iRARC)|Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.
16400175|NCT03977818||patients with metastatic softtissue sarcomas diagnosed between 1990 and 2013|
16400176|NCT03977805|Experimental|Hetrombopag Olamine|Hetrombopag Olamine (5 mg, 100 uCi)
16400177|NCT03977792|Experimental|Experimental treatment|"Subjects treated with BOR15001L7.
~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
16400178|NCT03977792|Active Comparator|Comparator treatment|"Subjects treated with Docosanol 10%.
~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
16400179|NCT03977779|Experimental|Prophylactic biodegradable pancreatic stent placement|
16400180|NCT03977766|Experimental|nurse then patient digital prevalidation of chemotherapy|"Outpatient Chemotherapy prevalidation will done
~with the help of a nurse, using the digital application, for cycle 2 and 3.
~by the patient alone, using the digital application, for cycle 4 and 5."
16400181|NCT03977753|Experimental|2LVERU®/2LVERU® JUNIOR|Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)
16400182|NCT03977753|Placebo Comparator|Placebo|Group N°2: Placebo treatment (6 months of treatment)
16400183|NCT03977740|Experimental|chest PNF|"participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.
~Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow."
16400184|NCT03977740|Active Comparator|Conventional|participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
16400187|NCT03977714|Experimental|Group A - test implant and abutment|Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
16400188|NCT03977714|Experimental|Group B - test implant and control abutment|"Zirconia implant and control abutment (test implant, negative control abutment).
~Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons."
16400189|NCT03977714|Experimental|Group C - control implant and test abutment|Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
16400190|NCT03977714|Active Comparator|Group D - control implant and abutment|Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
16400191|NCT03977714|Experimental|Group E - test and control implants|"Zirconia implant and titanium implant for histological and histomorphometric evaluation.
~This study will be performed in the area of the wisdom teeth (a non useful site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction."
16400192|NCT03977701|Experimental|Mono-morphemic Singleton PD|Speech sound treatment on mono-morphemic singleton consonants for children with PD.
16400193|NCT03977701|Experimental|Mono-morphemic Singleton PD-SLI|Speech sound treatment on mono-morphemic singleton consonants for children with PD-SLI.
16400194|NCT03977701|Experimental|Mono-morphemic Cluster PD|Speech sound treatment on mono-morphemic consonant clusters for children with PD.
16400195|NCT03977701|Experimental|Mono-morphemic Cluster PD-SLI|Speech sound treatment on mono-morphemic consonant clusters for children with PD-SLI.
16400196|NCT03977701|Experimental|Bi-morphemic Singleton PD|Treatment on singletons in bi-morphemic contexts for children with PD.
16400197|NCT03977701|Experimental|Bi-morphemic Singleton PD-SLI|Treatment on singletons in bi-morphemic contexts for children with PD-SLI.
16400198|NCT03977701|Experimental|Bi-morphemic Cluster PD|Treatment on bi-morphemic consonant clusters for children with PD.
16400199|NCT03977701|Experimental|Bi-morphemic Cluster PD-SLI|Treatment on bi-morphemic consonant clusters for children with PD-SLI.
16400200|NCT03977701|Experimental|Bi-morphemic Singleton SLI|Treatment on singletons in bi-morphemic contexts for children with SLI.
16400201|NCT03977701|Experimental|Bi-morphemic Cluster SLI|Treatment on bi-morphemic consonant clusters for children with SLI.
16400202|NCT03977688||none Cyto|septic shock, refractory, without Cytokin-adsorption therapy
16400203|NCT03977688||cyto|septic shock, refractory, treated with Cytokin-adsorption therapy
16400204|NCT03977675|Experimental|Ketamine 0.3 mg/kg|Subjects are assigned to receive a dose of 0.3 mg/kg of Ketamine.
16400205|NCT03977675|Experimental|Ketamine 0.5 mg/kg|Subjects are assigned to receive a dose of 0.5 mg/kg of Ketamine.
16400206|NCT03977675|Experimental|Ketamine 0.7 mg/kg|Subjects are assigned to receive a dose of 0.7 mg/kg of Ketamine.
16400207|NCT03977662|Experimental|PTG with adult pancreatic islet co-transplantation|People with Type 1 (c-peptide negative) diabetes with stable kidney or liver allografts on chronic immunosuppression who receive study intervention, which is co-transplantation of allogeneic parathyroid (PTG) with adult pancreatic islets in people with Type 1 diabetes in the intramuscular (IM) site
16400208|NCT03977649|Experimental|erenumab|monthly subcutaneous erenumab 140 mg for 12 weeks
16400209|NCT03977649|Placebo Comparator|placebo|monthly subcutaneous masked placebo for 12 weeks.
16400210|NCT03977610|Experimental|Ga68-PSMA ligand|Glass vial with 4~20 mCi(148-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), more than 0.33 mCi/mL @ EOS; One time dose of 2-5 mCi (74-185 MBq) for PET Imaging ; i.v. injection
16400211|NCT03977584|Experimental|[^18F]GTP1 in Mutation Carriers: Crenezumab|Mutation-carrying participants receiving crenezumab in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
16400212|NCT03977584|Placebo Comparator|[^18F]GTP1 in Mutation Carriers: Placebo|Mutation-carrying participants receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
16400213|NCT03977584|Placebo Comparator|[^18F]GTP1 in Non-carriers of Mutation: Placebo|Non-carriers of the mutation receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
16400214|NCT03977571|Experimental|Deferred nephrectomy|Surgery after induction therapy (Nivo + Ipi), followed by maintenance therapy (Nivo)
16400215|NCT03977571|Active Comparator|No surgery|Induction therapy (Nivo + Ipi), followed by maintenance therapy alone (Nivo).
16400216|NCT03977558|Experimental|Intervention group|Isocaloric diet, based on individual energy requirements calculated from indirect calorimetry and physical activity adjustment Participants will be asked to eat daily ~50g canola oil
16400217|NCT03977558|Active Comparator|Control group|Standard dietary advice that is used as current best practice in the treatment of lipid disturbances of European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias)
16400218|NCT03977545|Other|Newborn with risk of neonatal opioid abstinence syndrome|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days
16400219|NCT03977545|Other|Eutrophic term newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
16400220|NCT03977545|Other|Term newborn with low birth weight|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
16400221|NCT03977545|Other|Eutrophic premature newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
16400222|NCT03977532|Experimental|patients with sickle cell disease|
16400223|NCT03977519|Experimental|MA group|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used at EX-B8,BL32,SP8,and SP6.
16400224|NCT03977519|Active Comparator|TENS group|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used to stimulate the area along the lower borders of the ribs and the upper borders of the hip crests on both sides.The parameters of the electric acupuncture apparatus：Continuous wave,the frequency is 100Hz, the current intensity is 2.5mA-5mA.
16400225|NCT03977506|Experimental|Behavoiral|The evaluation will be realized on two different assessment grids during the test on the road
16400226|NCT03977493|Active Comparator|Xeomin®|Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).
16400227|NCT03977493|Placebo Comparator|Placebo concentrate|Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).
16400228|NCT03977480|Active Comparator|Hemay007 400 mg BID group|Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.
16400229|NCT03977480|Active Comparator|Hemay007 800 mg QD group|Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.
16400230|NCT03977480|Active Comparator|Hemay007 600 mg BID group|Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.
16400231|NCT03977480|Placebo Comparator|placebo group|Patients will orally take placebo tablets for 12 weeks.
16400232|NCT03977467|Experimental|Arm A (Chemo + Atezolizumab)|Arm A consists of patients with advanced NSCLC who received first-line PD-1-monotherapy, who have subsequent disease progression. In Arm A, patients with NSCLC will be randomized 1:1 to either chemotherapy plus atezolizumab at a flat dose of 1200 mg IV every 3 weeks or chemotherapy alone until progression or unacceptable toxicity. Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
16400233|NCT03977467|Experimental|Arm B (Atezolizumab Only)|Arm B consists of approximately 10-15 patients per disease type (renal cell carcinoma [RCC], triple negative breast cancer [TNBC], small cell lung cancer [SCLC], squamous cell carcinoma of the head and neck [SCCHN], melanoma, microsatellite instability-high [MSI-high] solid tumors {as determined by local testing for MSI/mismatch repair (MMR)}), as well as patients with NSCLC who were treated with a PD-1 antibody in ≥ second-line setting and who have had subsequent disease progression and NSCLC patients who have progressed after pembrolizumab plus chemotherapy in the first-line setting. In Arm B, patients with advanced solid tumors will be treated with an atezolizumab flat dose of 1200 mg IV every 3 weeks until progression or unacceptable toxicity.
16400234|NCT03977454|Experimental|Group 1 patients will receive nerve block per standard of care|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.
~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and
~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI."
16400235|NCT03977454|Active Comparator|Group 2 will NOT receive any nerve blocks.|Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
16400236|NCT03977441|Placebo Comparator|control group|treated with Pramipexole 0.75mg/d（0.25mg tid)+placebo 25mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+placebo 50mg qn * 10 weeks
16400237|NCT03977441|Experimental|experimental group|treated with Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine25 mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine 50mg qn * 10weeks
16400238|NCT03977415||RA with no ILD|"Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.
~Study Assessments Include:
~Medical history and Physical exams
~Quality of Life Questionnaires
~Collection of Sputum and Blood
~Radiology (HRCT)
~Lung Function Test"
16400239|NCT03977415||RA with ILD|"Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.
~Study Assessments Include:
~Medical history and Physical exams
~Quality of Life Questionnaires
~Collection of Sputum and Blood
~Radiology (HRCT)
~Lung Function Test
~Spirometry"
16400240|NCT03977389||Population of the study|"Patient undergoing total wrist denervation between January 1995 and December 2013 at Brest CHRU, performed by the same senior surgeon.
~Total wrist denervation is a routine procedure in orthopedic surgery for wrist arthritis."
16400241|NCT03977376|Experimental|Intervention|Valuation instruments were two validated scales: ESAS y HADS. Experimental nursing instrument: Guide of hosting.
16400242|NCT03977376|No Intervention|Control|Valuation instruments were two validated scales: ESAS y HADS. Without Guide of hosting.
16400243|NCT03977363||Anticoagulated patients|Patients receiving anticoagulation treatment
16400244|NCT03977350||Patients over 65 years undergoing heart surgery|Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored
16400245|NCT03977324|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
16400246|NCT03977324|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
16400247|NCT03977311|Experimental|MR-HIFU|-The study team will determine the tumor volume to be treated per standard-of-care diagnostic MRI or CT imaging. An array of scans will be used to align the participant with the HIFU system, optimize heat delivery to the patients, and/or monitor aspects related to the participant such as motion. Vendor-provided software will be used with the participant in each position to create a customized treatment plan for heat delivery. The HIFU device will then be used to apply clinical levels (41-42°C) of heat to the tumor volume. Regions will be heated to the 41-42°C for up to 60 minutes in one session (either before or after radiation) on one day per five to ten standard radiation therapy fractions, with a maximum of 6 days of hyperthermia over the course of their standard, indicated radiation therapy treatment.
16400248|NCT03977298|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine
16400249|NCT03977298|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
16400250|NCT03977285|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
16400251|NCT03977285|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
16400252|NCT03977285|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
16400253|NCT03977272|Active Comparator|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
16400254|NCT03977272|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 200mg.
16400255|NCT03977259|No Intervention|Standard fortification|Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.
16400256|NCT03977259|Experimental|Individually targeted fortification|"Standard of care fortification plus extra protein and/or calories to ensure that base milk has protein 1 g/dL and calories 67/dL."
16400257|NCT03977246|Experimental|Open-placebo|The open-placebo intervention session
16400258|NCT03977246|Placebo Comparator|Control|The control session
16400259|NCT03977233|Experimental|SingleArm: FOLFIRINOX|Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.
16400260|NCT03977220|Experimental|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
16400261|NCT03977207|Experimental|Levothyroxine|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.
~The intervention period is 24 weeks. Patients will undergo up to two subsequent dose titrations after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points. Patients whose TSH levels are higher or lower than the therapeutic TSH target of 0.5-3.0mIU/L will undergo a dose adjustment (+/- 25mcg), while those whose TSH levels are in target range will continue the prior dose."
16400262|NCT03977207|Placebo Comparator|Placebo|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.
~The intervention period is 24 weeks. Patients in the placebo arm will undergo an equivalent titration in placebo pills (as that of the experimental arm) after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points."
16400263|NCT03977194|Active Comparator|Arm A : standard treatment|Carboplatine + paclitaxel (4 cycles of 28 days)
16400264|NCT03977194|Experimental|Arm B : standard treatment + immunotherapy|Carboplatine + paclitaxel (4 cycles of 28 days) + atezolizumab (every 21 days) until progression or toxicity
16400265|NCT03977181|Experimental|Health Club|A group-based community health club akin to an ART adherence club
16400266|NCT03977181|Experimental|One-on-one|One-on-one adherence counselling and support
16400267|NCT03977181|No Intervention|Medication pick-up|Community-based medication dispensary
16400268|NCT03977155|Experimental|High dose of BOS-589|Participants will receive a high dose of BOS-589 orally twice a day (BID).
16400269|NCT03977155|Experimental|Low dose of BOS-589|Participants will receive a low dose of BOS-589 orally BID.
16400270|NCT03977155|Placebo Comparator|Placebo|Participants will receive matching placebo orally BID.
16400271|NCT03977129|Experimental|QFR group|
16400272|NCT03977129|Active Comparator|CAG group|
16400273|NCT03977116|Experimental|heart failure patients with diabetes treated by SGLT2 drugs|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
16400274|NCT03977116|Placebo Comparator|heart failure patients with diabetes treated by placebo|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
16400275|NCT03977103|Experimental|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
16400276|NCT03977090|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
16400277|NCT03977077|Experimental|Albumin binding taxol|
16400278|NCT03977064|Experimental|Intensive treatment group|The intensive treatment group will pass a life-style intervention program including consequent escalation of measures to reach sustained reduction of 10% of initial body weight at minimum.
16400279|NCT03977064|No Intervention|Standard treatment group|Patients will be taken care of by general physician without lifestyle program.
16400280|NCT03977051||Focus group|Focus group to explore immunosuppressant medication adherence in kidney transplant patients
16400281|NCT03977038||TRD sample|Individuals in the treatment resistant depression (TRD) sample suffer from the condition called TRD. The intervention that will be administered to this group is the standardized rTMS treatment using High Frequency dTMS (HF-dTMS) stimulation over L-DLPFC, at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks.
16400282|NCT03977038||Healthy Controls (HC) sample|Individuals in the HC sample are age-, sex-, education-matched to the individuals in the TRD sample. HC sample does not receive any therapeutic treatment and are solely examined as a comparative measure of normal cognitive capabilities.
16400283|NCT03977012||Patients with CRPS Type I|"Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.
~-drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks"
16400284|NCT03976999|Experimental|Biological collection|"For all the patients include in the studie :
~Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)
~Tissue samples (tumor tissue and healthy tissue) collected during the surgery
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16400285|NCT03976986|Experimental|cPOC - pPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
16400286|NCT03976986|Experimental|pPOC - cPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by pPOC (pulsed-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by cPOC (continuous-flow).
16400287|NCT03976973|Experimental|Intervention|Patients with inoperable pseudomyxoma peritonei or peritoneal mucinous tumour that meet the entry criteria and consent to the intervention will receive intratumoural or intraperitoneal treatment/s with the combination experimental drug treatment BromAc. The drug will be injected directly into the tumour or free intraperitoneally via a percutaneously radiologically placed drain.
16400288|NCT03976960|Experimental|Biological collection|"For all the patients include in the study :
~samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16400289|NCT03976947||Before group|"The before group is the control group. We collect retrospective data in consecutive patients operated before the implementation of lung recruitment maneuvers protocol"
16400290|NCT03976947||After group|We collect data in consecutive patients operated after the implementation of lung recruitment maneuvers protocol. This lung recruitment maneuvers will be realised along the surgery, (After tracheal intubation, per-CPB, post-CPB). Each recruitment maneuver consisted of applying a continuous positive airway pressure of 30 cm of water for 30 seconds
16400291|NCT03976934|Active Comparator|Tamsulosin group|administration of 0,4mg of tamsulosin 24 hours before surgery and 0,4mg 6 hours before surgery
16400292|NCT03976934|Placebo Comparator|Placebo group|administration of placebo 24 and 6 hours before surgery
16400293|NCT03976921|Experimental|CCTA Strategy|CCTA will be performed with one of the latest generation scanners. A stenosis > 50% will be considered as significant from an anatomical point of view. For coronary stents, degree of intrastent restenosis will be evaluated by visual assessment of intraluminal contrast density. ISR > 50% will be considered as significant from an anatomical point of view. For CABG, each graft will be visually evaluated and scored as patent, non-significant stenosis ≤ 50%, significant stenosis > 50%, or occluded. For patients with positive CCTA results, additional stress CTP will be performed subsequently. If indicated, vasodilatation will be induced with i.v. adenosine injection or regadenoson. Static or dynamic CTP will be performed according to local practice and scanner technology available. For all patients with previous history of MI the presence of reversible ischemia will be obtained by the comparison between rest and stress perfusion.
16400294|NCT03976921|Active Comparator|Standard of care Strategy|Patients randomized to this group will be evaluated according to current clinical guidelines with the following approaches: (a) stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET; (b) direct referral to ICA.
16400295|NCT03976908|Experimental|ON-OFF|Patients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
16400296|NCT03976908|Experimental|OFF-ON|Patients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
16400299|NCT03976882|Experimental|Hetrombopag treatment|Study is 2:1 randomization ratio (hetrombopag to placebo).
16400300|NCT03976882|Placebo Comparator|Placebo treatment|Study is 2:1 randomization ratio (hetrombopag to placebo).
16400301|NCT03976869|Experimental|Cohort 1|The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
16400302|NCT03976856|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
16400303|NCT03976843|Experimental|1/18F-DCFPyL PET/CT + radical prostatectomy|18F-DCFPyL PET/CT with radical prostatectomy andlymphadenectomy
16400304|NCT03976830||Children diagnosed with cancer|Patients diagnosed with childhood cancer in participating sites in Central American countries
16400305|NCT03976817||SA-AVR group|Patients who underwent the supra-annular aortic valve replacement (SA-AVR) technique in our institution between December 2010 and December 2017 were retrospectively reviewed.
16400306|NCT03976804|Experimental|atherosclerotic cardiovascular event associated with tobacco|
16400307|NCT03976791|Experimental|Enlarged internal incision|enlarged the internal incision about 0.4mm
16400308|NCT03976791|Placebo Comparator|Regular 2.2mm incision|regular 2.2mm corneal incision for microincision coaxial phacoemulsification
16400309|NCT03976778|Other|a pre-post interventional study|intervention consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
16400310|NCT03976765||Hospital discharge at day 7|
16400311|NCT03976752|No Intervention|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
16400312|NCT03976752|Experimental|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
16400313|NCT03976752|Experimental|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
16400314|NCT03976752|Experimental|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
16400315|NCT03976752|Experimental|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
16400316|NCT03976739||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
16400317|NCT03976739||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
16400318|NCT03976739||gastric cancer|patients with gastric cancer according to histopathological results
16400319|NCT03976726||i-gel size #3|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
16400320|NCT03976726||i-gel size #4|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
16400321|NCT03976726||i-gel size #5|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
16400322|NCT03976713|Experimental|Bufei Yishen granule plus Western medicine|Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
16400323|NCT03976713|Placebo Comparator|Placebo Bufei Yishen granule plus Western medicine|Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
16400324|NCT03976700|Experimental|Bufei Jianpi granule|Patients in this arm will receive Bufei Jianpi granule.
16400325|NCT03976700|Placebo Comparator|Placebo Bufei Jianpi granule|Patients in this arm will receive placebo Bufei Jianpi granule.
16400326|NCT03976687|Experimental|1: EYP001a Dose A|Dose A once daily morning dose
16400327|NCT03976687|Experimental|2: EYP001a Dose B|Dose B once daily morning dose
16400328|NCT03976687|Experimental|3: EYP001a Dose C|Dose C twice daily - first dose morning dose and second dose 3 hours post first dose
16400329|NCT03976674|Experimental|Patients in preparation for bariatric surgery|Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy
16400330|NCT03976674|No Intervention|Control group|Standard practice
16400331|NCT03976661||DIAPASON 92 arm|Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
16400332|NCT03976661||Control arm|Arm will be constituted by people residing at the EHPAD (retirement home)
16400333|NCT03976648|Experimental|GLPG1690|
16400334|NCT03976635|Active Comparator|Removable Mandibular Retractor|Patients in this group will be treated by the Removable Mandibular Retractor (RMR) in order to get rid of the anterior cross bite. This appliance is removable.
16400335|NCT03976635|Experimental|Bone-anchored intermaxillary Traction|Patients will be treated using bone-anchored intermaxillary traction. Class III elastics will be extended from the Adam's clasps placed in the upper removable appliance towards the heads of mini-implants placed between the permanent canine and lateral incisors on either side of the lower dental arch.
16400336|NCT03976622||vitiligo|Patients aged 18 to 75 years with non-segmental vitiligo;
16400337|NCT03976622||psoriasis|Patients aged 18 to 75 years with plaque psoriasis;
16400338|NCT03976622||atopic dermatitis|Patients aged 18 to 75 years with atopic dermatitis;
16400339|NCT03976622||alopecia areata|Patients aged 18 to 75 years with alopecia areata sclerosis;
16400340|NCT03976583|Active Comparator|Cpp-acp|MI paste Self-administration of the product by the patient once in the evening. A pea-size amount of the product should be applied per arch, using a dry finger or cotton pellet to distribute it evenly across all teeth and to work it into the interdental spaces. The product was then retained in the mouth for 1-3 min, and manipulated around the teeth using the tongue, before being expectorated and patient should not rinse it until 30 min.
16404945|NCT03944343|Experimental|Test product D|Specific designed cereals D and yogurt
16400341|NCT03976583|Experimental|Pearl powder|Pure pearl powder in the form of gel Self-administration of the product should be used once daily (in the evening), after a 2 min manual tooth brushing. .Participants were explicitly instructed to apply the gel by his finger allover the teeth and not to rinse their mouths after application and not to eat or drink for at least 30 min.
16400342|NCT03976570|Experimental|Occupational Therapy|Occupational Therapy
16400343|NCT03976557|Experimental|BIP CVC|Polyurethane CVC with noble metal coating
16400344|NCT03976557|Active Comparator|Standard CVC|Standard CVC made of polyurethane
16400345|NCT03976544|No Intervention|Natural cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.
~The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.
~Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge."
16400346|NCT03976544|Experimental|Hormone replacement therapy cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.
~In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation."
16400347|NCT03976531||Elderly cancer patients included in randomized controlled trials|
16400348|NCT03976518|Experimental|ATEZOLIZUMAB|Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 [± 3] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
16400349|NCT03976505|Active Comparator|textual prescription healthy volunteers|
16400350|NCT03976505|Active Comparator|table prescription healthy volunteers|
16400351|NCT03976505|Experimental|textual prescription Parkinson's disease patients|
16400352|NCT03976505|Experimental|table prescription Parkinson's disease patient|
16400353|NCT03976492||Normal group|normal population
16400354|NCT03976492||Brain injury group|patients with traumatic brain injury within 24 hours
16400355|NCT03976492||Non-brain injury group|Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
16400356|NCT03976466|Experimental|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
16400357|NCT03976466|Active Comparator|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
16400358|NCT03976453||Group A|Women who underwent caesarean hysterectomy
16400359|NCT03976453||Group B|Women who underwent lower segment caesarean section
16400360|NCT03976453||Group C|Women who underwent spontaneous Vaginal delivery
16400361|NCT03976427|Experimental|Guided Imagery|Participants will listen to a guided imagery recording
16400362|NCT03976414||eMOM website users|"Any woman who visits the research tab on the eMOM website will see an invitation to participate in a research study about the impact of the website on her bladder and bowel symptoms. Women may use the intervention (the website) regardless of whether they opt to participate in the research study.
~The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence."
16400363|NCT03976401|Experimental|EFX Dose 1|Main Study
16400364|NCT03976401|Experimental|EFX Dose 2|Main Study
16400365|NCT03976401|Experimental|EFX Dose 3|Main Study
16400366|NCT03976401|Placebo Comparator|Placebo|Main Study
16400367|NCT03976401|Experimental|EFX Dose (Cohort C)|
16400368|NCT03976401|Placebo Comparator|Placebo (Cohort C)|
16400369|NCT03976388|Experimental|Clinical virtual simulator|A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
16400370|NCT03976388|Active Comparator|Standard educational session|A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
16400376|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 during Part A [Single Ascending Dose (SAD)].
16400377|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 2|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
16400378|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 3|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
16400379|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 4|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
16400380|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 5|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
16400381|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 6|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
16400382|NCT03976349|Experimental|Part B (MAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 on multiple days during Part B [Multiple Ascending Dose (MAD)].
16400383|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 2|Participants [Non leucine-rich repeat kinase 2 (Non LRRK2)] will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
16400384|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 2|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
16400385|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 3|Participants (Non LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
16400386|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 3|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
16400387|NCT03976349|Placebo Comparator|Part A (SAD): Matching Placebo|Participants will receive matching placebo during Part A [Single Ascending Dose (SAD)].
16400388|NCT03976349|Placebo Comparator|Part B (MAD): Matching Placebo|Participants will receive matching placebo on multiple days during Part B (MAD).
16400389|NCT03976336|Experimental|Berberine|
16400390|NCT03976336|Placebo Comparator|Identical Placebo|
16400391|NCT03976323|Experimental|Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib|"For the Induction Phase, participants receive 4 cycles:
~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4).
~If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.
~For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21-day cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
16400392|NCT03976323|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed|"For the Induction Phase, participants receive 4 cycles:
~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy. For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21 day-cycle for up to 31 cycles PLUS maintenance pemetrexed IV 500 mg/m^2 on Day 1 of each 21-day cycle. In the Maintenance Phase, the participant continues to receive maintenance pemetrexed until progressive disease, physician decision or intolerable toxicity."
16400393|NCT03976310|Other|The study population|The study population corresponds to severe eosinophilic asthma patients (see eligibility criteria).
16400394|NCT03976297|Experimental|Control Tower Intervention|For participants in the intervention arm, the results of the prediction model will be presented through a GUI interface hereby known as the Control Tower. Participants receive scores from Control Tower (0-100; higher score indicating increased need) for palliative care and are subsequently ranked from highest to lowest. Red (7 or greater) is considered high risk. The intervention will include a Control Tower operator who will interact with the inpatient palliative care consult service. The operator will monitor the Control Tower during weekday normal business hours and select daily a cohort of participants in the intervention units with the highest need of palliative care review. The final list of participants will then be sent to palliative care. The palliative care team who is on service will also assess the need for each participants, and those participants which they agree could benefit they will approach the attending clinical team to suggest a palliative care referral.
16400471|NCT03975894|No Intervention|Control|Symptom directed blood transfusion during pregnancy.
16400472|NCT03975881|Experimental|Open Label|Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).
16425192|NCT03804762|Experimental|patients received treatment of TS-RECS|
16400395|NCT03976297|No Intervention|Standard of Care|For participants who are not in an intervention period they will receive the standard of care commensurate with their clinical unit. This is feasible given that this is a pragmatic clinical trial where the investigators can easily control the communication between the control tower operator and palliative care team to prevent any contamination between clusters. In addition to the usual source of care control the investigators intentionally have calibrated the prediction model and the Control Tower review to match the average capacity of the palliative care service, knowing that that the team will still receive palliative care consults through the traditional pathway i.e. the attending care team consulting palliative care directly.
16400396|NCT03976284|Experimental|Garden-fresh produce and exercise (GFPE)|Participants are encouraged to double their consumption of minimally processed fiber-rich plant foods, especially garden-fresh produce from the church community garden. Participants are also encouraged to limit pro-inflammatory foods rich in saturated fat, sodium and added sugar. Participants are also encouraged to engage in 150 minutes of moderate to vigorous physical activity per week, most likely in the form of brisk walking.
16400397|NCT03976271|Active Comparator|T1DM poor glycaemic control|patients with type 1 diabetes and poor glycaemic control (HbA1c >8% / >64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
16400398|NCT03976271|Active Comparator|T1DM impaired awareness|patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
16400399|NCT03976271|Active Comparator|T1DM Normal awareness|patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
16400400|NCT03976271|Active Comparator|T2DM + Insulin|patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
16400401|NCT03976271|Active Comparator|Healthy control T2DM|healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
16400402|NCT03976271|Active Comparator|Healthy control T1DM|Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
16400403|NCT03976258||HIV-infected adults actively using heroin|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.
16400404|NCT03976258||HIV-infected adults never having used heroin|HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.
16400405|NCT03976258||HIV-infected adults initiating buprenorphine/naloxone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
16400406|NCT03976258||HIV-uninfected adults initiating buprenorphine/naloxone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
16400407|NCT03976258||HIV-infected adults initiating methadone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone
16400408|NCT03976258||HIV-infected adults initiating Vivitrol|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
16400409|NCT03976258||HIV-uninfected adults initiating methadone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.
16400410|NCT03976258||HIV-uninfected adults initiating Vivitrol|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
16400411|NCT03976245|Active Comparator|etanercept|etanercept 50 mg subcutaneously injected per week
16400412|NCT03976245|Active Comparator|tofacitinib|tofacitinib 5 mg orally daily
16400413|NCT03976232|Experimental|tDCS-Group|Participants of this arm will receive tDCS and Conventional therapy for 2 weeks.
16400414|NCT03976232|Experimental|CST- Group|Participants of this arm will receive CST and Conventional therapy for 2 weeks.
16400415|NCT03976232|Active Comparator|combination of tDCS and CST|Participants of this arm will receive CST+ tDCS and Conventional therapy for 2 weeks.
16400416|NCT03976219|Experimental|Evoked potentials of ECAPs and SSEPs|Patients implanted with a spinal cord stimulator. In this arm, we are measuring the evoked potentials of electric compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs).
16400417|NCT03976206|Experimental|VSEL Max|We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
16400418|NCT03976206|Experimental|VSEL Medium|We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
16400419|NCT03976206|Experimental|VSEL Mini|We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
16400420|NCT03976206|No Intervention|Control|Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group
16400421|NCT03976193|Placebo Comparator|BfitBwell program|BfitBwell is a 3-month supervised exercise program for cancer survivors delivered at the Anschutz Health and Wellness Center. This program has demonstrated effectiveness for improving physical fitness, fatigue, and depression among participants
16400473|NCT03975855||Suspicious axillary lymph nodes|All patients with histologically confirmed breast cancer or highly suspicious breast lesions presenting with suspicious axillary lymph nodes
16400787|NCT03973489|Experimental|Wild Type (WT) MUD Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
16425485|NCT03802617|Experimental|MR13A9 high dose|
16400422|NCT03976193|Active Comparator|BfitBwell + 6, bi-weekly PA Behavior Change counseling session|Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
16400423|NCT03976180|Active Comparator|standard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
16400424|NCT03976180|Experimental|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
16400425|NCT03976180|Experimental|HFNO with intermediate FiO2 (50%)|HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
16400426|NCT03976180|Experimental|HFNO with high FiO2 (100%)|HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
16400427|NCT03976167|Active Comparator|Common nasal cannula|Oxygen administration up to 4 liters according defined protocol
16400428|NCT03976167|Experimental|High flow nasal cannula|Oxygen administered with high flow nasal cannula according child weight and protocol designed for this study
16400429|NCT03976154|Experimental|Dermabond|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
16400430|NCT03976154|Active Comparator|Mastisol|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Mastisol spray. The investigator performing the epidural placement will distribute Mastisol spray both in close proximity to the catheter insertion site as well as around the insertion site. Once the Mastisol is allowed to dry, a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team with a goal rate of 6ml/hr.
16400431|NCT03976154|Active Comparator|Grip-lock|Catheter fixation will be performed after appropriate placement of a thoracic epidural with a Grip-Lok fixation bandage. The investigator performing the epidural placement will place the fixation bandage one centimeter caudal from the insertion site. Mastisol will be applied to the surrounding skin and a clear Tegaderm will then be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team in the operating room with a goal rate of 6ml/hr.
16400432|NCT03976141||a|
16400433|NCT03976128|Experimental|Nordic Walking training|20 sessions of 45 minutes x 2 times/week x 10 weeks using NW
16400434|NCT03976128|Active Comparator|Conventional endurance training|20 sessions of 45 minutes x 2 times/week x 10 weeks using treadmill and cycloergometer training.
16400435|NCT03976115|Experimental|1. healthy volunteers|3x single dose of DDO-3055 and placebo
16400436|NCT03976115|Experimental|2. Patients with chronic kidney disease|3x single dose of DDO-3055 and placebo
16400437|NCT03976102|Experimental|Arm A: DRL_RI|DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36
16400438|NCT03976102|Active Comparator|Arm B: MabThera®|MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36.
16400439|NCT03976089|Experimental|Recipe 4 Success intervention|10 lessons delivered across 10 successive weeks within Early Head Start infrastructure by families' regular Early Head Start home visitors. Lessons involved active coaching in which parents and children prepared healthy snacks or meals. Lessons also included information on children's self-regulation skills and healthy eating habits.
16400440|NCT03976089|Active Comparator|Treatment as usual Early Head Start|Regular Early Head Start home visitors continued to implement evidence-informed developmentally appropriate curriculum designed to promote children's physical health, cognitive skills, and social-emotional functioning as well as parents' capacities to support their children's development.
16400441|NCT03976076|Experimental|JBPOS0101 (investigational product)|
16400442|NCT03976063|Active Comparator|Nifedipine|
16400443|NCT03976063|Placebo Comparator|Placebo|
16400444|NCT03976050|Experimental|Dose escalation|Subjects in the dose escalation cohorts will receive ascending doses of HL-085 until the MTD is determined. The first three subjects will receive twice-daily doses (BID) of HL-085 6 mg. Additional cohorts may receive doses of HL-085 9, 12 or 18 mg BID respectively and sequentially. If DLTs are observed in <33.3% of subjects at the 18 mg dose.
16400445|NCT03976037|Active Comparator|Vaginal Misoprostol in combination with foley bulb|"Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.
~Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
16400446|NCT03976037|Active Comparator|Buccal Misoprostol in combination with foley bulb|"misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.
~Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
16400447|NCT03976024|Experimental|DHBN-FN arm|"Recruitment is planned in traditional hospitalization for DHBN-FN patients. Evaluation of streptococcal carriage by swab, pharyngeal, anal and perineal in patients hospitalized for a DHBN-FN at the end of hospitalization and 1 month after discharge from hospital during the reassessment consultation. Swabs made by the dermatologist.
~The carriage of streptococcus in patients living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index"
16400448|NCT03976024|Active Comparator|Control arm (Erysipelas)|"Recruitment is planned in traditional hospitalization for patients with erysipelas.
~The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission)."
16400449|NCT03976011|Experimental|Transcutaneous Laryngeal Ultrasonography|All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
16400450|NCT03975998||Aymptomatic patients with severe mitral regurgitation|Watchful waiting Early Surgery
16400451|NCT03975985|Experimental|Core stability exercises|This group will be divided in two: core stability exercises (CSE) plus conventional therapy (CP) and CSE with transcutaneous electrical nerve stimulation (TENS) plus CP.
16400452|NCT03975985|Active Comparator|Conventional physiotherapy (CP)|CP consists in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
16400453|NCT03975972|Experimental|Occupational Therapy Based Literacy Intervention|For the intervention group, the results from the Inventory of Reading Occupations will be utilized to determine a prescriptive weekly intervention for each participant in the intervention group that will be provided to teachers based on student interest and literacy need. For the intervention group, each participant will be provided with a list of 12 questions that will be used to inform the intervention plan based on the interests of each participant within the intervention group. Collectively, the information from the 12 questions and the results of the Inventory of Reading Occupations will be used to determine a 9-week intervention plan for each participant within the intervention group. The researchers will work with the subjects twice per week, 30 minutes per session in the classroom using the prescriptive intervention that was determined from the assessments utilized.
16400454|NCT03975972|No Intervention|Standard Classroom Based Literacy Intervention|The control group will receive the standard reading instruction provided within the school. With the control group, the researchers will provide occupational therapy support to classroom teachers. But, will provide this support using the materials that are standardly provided within the classroom for literacy instruction. The researchers will provide support to the classroom teachers to students in the control group twice per week for 30 mintues per session in the classroom.
16400455|NCT03975959|Other|GLIOBLASTOMA|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
16400456|NCT03975959|Other|glioma|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
16400457|NCT03975959|Other|breast cancer|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
16400458|NCT03975959|Other|healthy|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
16400459|NCT03975946|Active Comparator|the rheopheresis group|
16400460|NCT03975946|Placebo Comparator|the shamapheresis group|
16400461|NCT03975933|Experimental|Free pregnancy tests at baseline but not for the future|We offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
16400462|NCT03975933|Experimental|Free pregnancy tests at baseline and for the future|We offer free pregnancy test service at baseline and a free pregnancy test for future use.
16400463|NCT03975933|Experimental|Free pregnancy tests at baseline and future use (random price)|We offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
16400464|NCT03975933|No Intervention|Control Group|Control group. No intervention is implemented.
16400465|NCT03975933|Experimental|Pregnancy test for the future use|No free pregnancy tests at baseline, but receive a free pregnancy test for the future.
16400466|NCT03975933|Experimental|Pregnancy test for the future with random price|No free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
16400467|NCT03975920|No Intervention|Usual Care (UC)|The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.
16400468|NCT03975920|Experimental|Experimental Care (EC)|The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block.
16400469|NCT03975907|Experimental|CAR-BCMA T Cells|Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm
16400470|NCT03975894|Experimental|Intervention|Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of <30%.
16400474|NCT03975829|Experimental|Dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:
~Patients who received monotherapy of either of dabrafenib or trametinib
~Patients who received combination of dabrafenib and trametinib
~Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up"
16400475|NCT03975790||Truven Health MarketScan Research Database|Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX
16400476|NCT03975777|Experimental|low-intensity exercise - high-intensity exercise|low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
16400477|NCT03975777|Experimental|high-intensity exercise - low-intensity exercise|high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
16400478|NCT03975764||Preterm birth|Delivery between 24-32 weeks of gestation
16400479|NCT03975764||Term delivery|Delivery between 37-41 weeks of gastation
16400480|NCT03975738||A GP Surgery|A selection of healthcare workers from a GP Surgery to be recruited
16400481|NCT03975738||A Patient and Public Involvement and Engagement Group|A selection of healthcare workers from a Patient and Public Involvement and Engagement Group to be recruited
16400482|NCT03975738||Young Person's Steering Group|A selection of patients from a Young Person's Steering Group to be recruited
16400483|NCT03975738||An Acute Trust|A selection of healthcare workers from an Acute Trust to be recruited
16400484|NCT03975738||Hayward Hospital Social Care Team|A selection of healthcare workers from the Hayward Hospital Social Care Team to be recruited
16400485|NCT03975738||A Hospice|A selection of healthcare workers from a Hospice to be recruited
16400486|NCT03975738||West Midlands Cares|A selection of healthcare workers from a the West Midlands Cares Group to be recruited
16400487|NCT03975738||CRN Clinical Research Speciality Leads (CRSL)|A selection of healthcare workers from a group of CRN (Clinical Research Network) Clinical Research Speciality Leads (CRSL) to be recruited
16400488|NCT03975738||CRN Sub Speciality Leads (SSL)|A selection of healthcare workers from a CRN Sub Speciality Leads (SSL) to be recruited
16400489|NCT03975738||A District General Hospital|A selection of healthcare workers from a A District General Hospital to be recruited
16400490|NCT03975725|Experimental|witcard|
16400491|NCT03975699||Patients in centre 1: Louis-Mourier Hospital|All SCD follow-up consultations were conducted jointly by a paediatrician and a clinical psychologist.
16400492|NCT03975699||Patients in centre 2: Evry hospital|All SCD follow-up consultations were conducted by a paediatrician alone. The unit had close links with the local psycho-medical paediatric care centre when specialized referrals were necessary.
16400493|NCT03975699||Patients in centre 3: Clamart hospital|All SCD follow-up consultations were conducted by a paediatrician alone.
16400494|NCT03975686|Experimental|intervention|
16400495|NCT03975686|No Intervention|control|
16400496|NCT03975673|Active Comparator|Conventional Total Hip Replacement (cTHR )|"Osteoarthritic patient undergoing the conventional technique
~medializing the hip center of rotation
~obtain a standing acetabular cup position fitting the Lewinneck recommendations (inclination 40°±10°, version 15°±10°)"
16400497|NCT03975673|Experimental|Kinematically Aligned Total Hip Replacement (KATHR )|"Osteoarthritic patient undergoing the kinematically aligned technique
~restoring the acetabular center of rotation
~restoring the constitutional acetabular anteversion by using the transverse acetabular ligament (TAL) as a reference landmark.
~making personalized choice for the hip component design
~considering additional spine surgery based on the assessment of the individual spine-hip relation."
16400498|NCT03975660|Experimental|Dural puncture epidural (DPE)|Patients will receive dural puncture epidural (DPE) and will have pain levels monitored by ROPA System (CereVu Medical, Inc. San Francisco, CA) during labor.
16400499|NCT03975660|Experimental|Combined spinal-epidural (CSE)|Patients will receive combined spinal-epidural (CSE) and will have pain levels monitored by ROPA System (CereVu Medical, Inc. San Francisco, CA) during labor.
16400502|NCT03975634|Experimental|Transcutaneous spinal stimulation|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while trunk control is assessed at 3 time points (acute) and/or while transcutaneous stimulation is applied in combination with activity-based locomotor training (40 sessions, 1.5 hours/day, 5 days/week; stimulation will be applied intermittently for no more than 10 minutes at a time during training)
16400503|NCT03975621|Experimental|Immediate Intervention|The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months. Patients will receive the tablet, a pedometer and an exercise band. Patients will use Nurse AMIE while receiving weekly phone calls from a patient navigator. After 90 days of the intervention observation will take place for 90 days, the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
16400504|NCT03975621|Experimental|Delayed Intervention|The delayed intervention group will receive the intervention 3 months after consent (6 months of intervention with 3 months delay total of 9 months); the patient will then follow the same pattern as listed above. The only difference is we will ask the delayed intervention group to wear a FitBit device for 1 week following consent in order to gain baseline data as to their activity/movement.
16400505|NCT03975608|Experimental|"Adaptation of CALM"|"This is the patient group that receives the intervention (IG), i.e., the psychotherapeutic treatment, i.e., the adapted version of the psychotherapeutic program Managing Cancer and Living Meaningfully (CALM) which was originally designed for patients with cancer."
16400506|NCT03975595|Active Comparator|Meditation Group A|A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).
16400507|NCT03975595|Active Comparator|Meditation Group B|A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).
16400508|NCT03975569|Experimental|vulvovaginitis patients- lactobacillus gel|Daily use of vaginal gel containing lactobacilli by patients. Probiotic vaginal gel.
16400786|NCT03973502|Experimental|18F-DOPA PET|PET/CT
16400509|NCT03975556|Experimental|Intervention|Intervention group consisting of culturally-appropriate foods and diet advice in an initial individual session followed by daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
16400510|NCT03975556|Active Comparator|Control|Control arm of standard portion-control general nutritional and cooking advice at the initial individual session, followed by text messages for 2 months. A reinforcement phase of 2-months will follow to repeat the education and text messages.
16400511|NCT03975530|Experimental|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it. At 6 months postpartum, and upon completion of the intervention, participants in the treatment group will be asked to participate in brief semi-structured phone interviews.
16400512|NCT03975530|Active Comparator|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
16400513|NCT03975504|Other|LDCT Screening|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
16400514|NCT03975491|Experimental|Aerobic Exercise|Moderate-intensity aerobic exercise
16400515|NCT03975491|Sham Comparator|Control|Wait-list control
16400516|NCT03975478|Active Comparator|Gastric bypass|Bariatric surgery by gastric bypass (GB)
16400517|NCT03975478|Experimental|Sleeve gastrectomy|Bariatric surgery by sleeve gastrectomy (SG)
16400518|NCT03975465|Experimental|Expiratory Muscle Strength Training|Patients randomized to the EMST arm will use the EMST150 device as packaged, i.e. following package instructions
16400519|NCT03975465|Active Comparator|Pharyngeal Muscle Strengthening Exercises|Patients randomized to Standard Care will receive swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion
16400520|NCT03975452|Experimental|Primary resectable cT2-low lying-T3, N0-N1 rectal tumour|Primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes.
16400521|NCT03975426||conservative group|received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture.
16400522|NCT03975426||absorbable screws|received open reduction and internal fixation with fixation by absorbable screws.
16400523|NCT03975413||N=1 MS patient|"Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention.
~Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development."
16400524|NCT03975400|No Intervention|Pre-Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States prior to campaign initiation.
16400525|NCT03975400|Active Comparator|Active Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States during the active campaign initiation.
16400526|NCT03975387|Experimental|ASTX295|
16400527|NCT03975374|Experimental|Tobramycin/Dexamethasone opthamic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
16400528|NCT03975374|Active Comparator|Tobradex Opthalmic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
16400529|NCT03975361|Other|Bliss-Believe|Patients included in the BLISS-BELIEVE study (NCT03312907).
16400530|NCT03975348|Other|Baseline conventional facemask|The patients will receive oxygen therapy through conventional facemask for 10 minutes
16400531|NCT03975348|Experimental|HFNC 40 L/min up|The patients will receive oxygen/air mixture through high flow nasal cannula at incremental, then decremental flows, starting at 40 L/min for 10 minutes
16400532|NCT03975348|Experimental|HFNC 60 L/min up|High flow nasal cannula at 60 L/min for 10 minutes
16400533|NCT03975348|Experimental|HFNC 80 L/min up|High flow nasal cannula at 80 L/min for 10 minutes
16400534|NCT03975348|Experimental|HFNC 100 L/min|High flow nasal cannula at 100 L/min for 10 minutes
16400535|NCT03975348|Experimental|HFNC 80 L/min down|High flow nasal cannula at 80 L/min for 10 minutes
16400536|NCT03975348|Experimental|HFNC 60 L/min down|High flow nasal cannula at 60 L/min for 10 minutes
16400537|NCT03975348|Experimental|HFNC 40 L/min down|High flow nasal cannula at 40 L/min for 10 minutes
16400538|NCT03975348|Other|Washout conventional facemask|Again, the patients will receive oxygen therapy through conventional facemask for 10 minutes, to reduce the influence of HFNC on CPAP therapy
16400539|NCT03975348|Active Comparator|CPAP|The patients will receive CPAP at 10 cmH2O for 10 minutes
16400540|NCT03975335|Experimental|Intervention group|Health education on NCDs and behavioral risk factors was delivered through motivation and observational learning session.
16400541|NCT03975335|Placebo Comparator|Control group|Control group received session on carrier guidance.
16400542|NCT03975309||Previous DHS Participants|Observational
16400543|NCT03975296|Experimental|TMQLB group|
16400544|NCT03975296|Active Comparator|TPVB group|
16425486|NCT03802617|Placebo Comparator|Placebo|
16400545|NCT03975283|Experimental|Exparel (Liposomal Bupivicaine)|20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
16400546|NCT03975283|Active Comparator|0.25% Bupivicaine HCL|Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.
16400547|NCT03975270|Experimental|Sintilimab in Combination With Nab-paclitaxe|Sintilimab 200 mg intravenous drip, first day Nab-paclitaxe120 mg/m2, intravenous drip, first day and eighth day
16400548|NCT03975257|Experimental|Preventive application of EHT02|application of one Ectoin Lozenge before SLIT-initiation
16400549|NCT03975257|Experimental|Therapeutic application of EHT02|application of one Ectoine Lozenge after SLIT-initiation
16400550|NCT03975257|No Intervention|No application of EHT02|SLIT-Initiation without Ectoin Lozenge
16400551|NCT03975244|Experimental|Exercise group|Three months of semi-supervised exercise program in patients awaiting bariatric surgery. Body composition, cardiovascular risk factors, physical fitness, physical activity levels and quality of life will be assessed before and at the end of the study. In addition, surgery time, hospital length of stay and operative complications also will be evaluated.
16400552|NCT03975244|No Intervention|Control group|The control group only will perform the evaluations of the study.
16400553|NCT03975231|Experimental|Treatment (dabrafenib, trametinib, IMRT)|See Detailed Description
16400554|NCT03975218||Patients with stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
16400555|NCT03975205|Active Comparator|Doxil|This group of patients will receive Intravenous Doxil of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
16400556|NCT03975205|Experimental|doxorubicin|This group of patients will receive Intravenous Doxorubicin of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
16400557|NCT03975192|Experimental|Intervention Group|50% of subjects will be randomized to the Intervention group and will receive percutaneous electric nerve field stimulation (PENFS) through the BRIDGE Device for 120 hours to treat withdrawal symptoms in patients following opiate exposure in the PICU.
16400558|NCT03975192|No Intervention|Standard of Care Group|50% of subjects will be randomized to the Standard of Care group and will receive be started on the standardized PICU Methadone wean for patients following opiate exposure in the PICU.
16400561|NCT03975166|Experimental|Test Product|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16400562|NCT03975166|Active Comparator|Reference Product|ADVAIR DISKUS® 100/50
16400563|NCT03975153|Experimental|guselkumab treatment|Treatment with guselkumab for 20 weeks
16400564|NCT03975140|Experimental|Hypersensitive acupoint group|
16400565|NCT03975140|Active Comparator|Hyposensitive acupoint group|
16400566|NCT03975127|No Intervention|Routine|women will routinely be invited to attend for cervical screening via the SCCRS application.
16400567|NCT03975127|Experimental|SMS|Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast
16400568|NCT03975114|Active Comparator|Chemo first|Standard chemotherapy followed at progression by durvalumab
16400569|NCT03975114|Experimental|Immuno Monotherapy first|Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
16400570|NCT03975114|Experimental|Immuno Combination Therapy first|experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
16400571|NCT03975101|Experimental|VSEL Max|A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient
16400572|NCT03975101|Experimental|VSEL Medium|A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient
16400573|NCT03975101|Experimental|VSEL Mini|A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient
16400574|NCT03975101|No Intervention|Control|A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient
16400575|NCT03975088|Other|Persistent Diabetic macular edema|Authors defined refractory DME as eyes with persistent DME despite receiving at least 6 monthly Ranibizumab injections of anti VEGF, and then switched to Aflibercept, receiving at least three monthly injections.
16400576|NCT03975075|Experimental|Biofeedback|Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). The biofeedback training session will be conducted using the eSense Pulse smartphone application. Participants will receive further instruction explaining how physiological information will be displayed and used as a means of training to induce a relaxed state while receiving real time feedback. Participants will be instructed on using controlled breathing to assist with reaching this relaxed state. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone.
16400577|NCT03975075|Active Comparator|Control Group|"Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). Participants will be provided with the following instructions: You will be monitored with this equipment for 30 minutes. During this time frame, please try to limit movement and conversation as much as possible. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone."
16400578|NCT03975062|Experimental|Abbreviated course group (ACG)|The patients receiving 3-days course of dabigatran etexilate during pre-cardioversion period. After cardioversion has been performed the patients continue with dabigatran etexilate until 30 days after cardioversion
16400579|NCT03975062|Active Comparator|Conventional course group (CCG)|The patients receiving 3-weeks course of dabigatran etexilate before cardioversion of AF. After cardioversion has been performed the patients will continue with dabigatran etexilate until 30 days after cardioversion
16400580|NCT03975049|Active Comparator|5-Fu + RT|5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX * 6-8
16400581|NCT03975049|Experimental|mFOLFOXIRI|mFOLFOXIRI * 4 --- TME --- mFOLFOXIRI * 4
16400582|NCT03975049|Experimental|mFOLFOX|mFOLFOX * 9 --- TME --- mFOLFOX * 3
16400583|NCT03975036|Experimental|Anlotinib&pd-1 antibody|Anlotinib 10mg/d,q.d.,p.o.&pd-1 antibody 200mg/d.q.3w.d.l.v
16400584|NCT03975023||hockey players|"During each study visit, the participants will undergo the following procedures:
~NeuroCatch Platform (NCP) assessment (only if participant meets NCP-specific criteria)
~RightEye's eye-tracking battery
~Highmark Interactive's EQ application
~Cambridge Brain Science's neuropsychological tests"
16400585|NCT03975010|Experimental|BUP TDS 20 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.
16400586|NCT03975010|Experimental|BUP TDS 40 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.
16400587|NCT03975010|Experimental|BUP TDS 40 mg for 4 day|Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.
16400588|NCT03974997|Other|serum concentration changes in cytokine TWEAK|We will perform a prospective study in which 50 patients with multiple sclerosis in the isolated clinical syndrome stage will be included over a 12-month period. Mental Cerebral MRIs will be performed for each patient at baseline (T0), month 6, and month 12. Serum dosages of TWEAK will be performed each month for each patient for one year. Patients will also be treated with soluble TNF, the leader in the TNF family of ligands, anti-TWEAK antibodies (which may interfere with the activity and dosage of TWEAK) as well as C-reactive Protein C ( search for intercurrent infectious episode). These dosages will be correlated with the clinical evolution (appearance or not of an inflammatory flare) as well as the data of the imagery (number of lesions raised or not by the gadolinium).
16400589|NCT03974984||"The Hvidovre population:"|We will include patients undergoing laparoscopic hemicolectomy for cancer scheduled for anesthesia with total intravenous anesthesia combined with epidural anesthesia and perioperative NSAID on Hvidovre Hospital.
16400590|NCT03974984||"The Zealand University Hospital population"|"The immunological and oxidative stress in relation to abdominal surgery (IMOX) study is ongoing at Zealand University Hospital, Roskilde. It is a prospective explorative study cohort that consists of 60 patients undergoing laparoscopic colorectal cancer surgery.
~The population has been anesthetized according to the standard operating procedure with either total intravenous anesthesia with propofol and remifentanil or volatile anesthesia with sevoflurane combined with a fast acting opioid (remifentanil or sufentanil). Patients anaesthetized with other techniques including epidural or other regional blocks will be excluded from the analysis."
16400591|NCT03974971||BPDCN diagnosis group|By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018
16400592|NCT03974958|Experimental|AAA patients|Patients with abdominal aortic aneurysm (AAA)
16400593|NCT03974958|Experimental|PAOD patients|patients with peripheral arterial obstructive disease (PAOD)
16400594|NCT03974945||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-60 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
16400595|NCT03974932|Experimental|Cohort 1|HTX-011 + MMA
16400596|NCT03974932|Experimental|Cohort 2|HTX-011 + MMA
16400597|NCT03974932|Experimental|Cohort 3|HTX-011 + MMA
16400598|NCT03974932|Experimental|Cohort 4|HTX-011 + MMA
16400599|NCT03974906|Experimental|GDT group|The fluid in GDT group (Goal-directed fluid therapy) will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the LiDCO monitoring system.
16400600|NCT03974906|No Intervention|Control group|Patients in the control group received conventional fluid therapy, decided by the attending anesthesiologists based on the patient's hemodynamic condition and responses, to maintain MAP >65 mm Hg, heart rate 50-100 bpm, and urine output >0.5 ml/kg/h.
16400601|NCT03974893||Vegetarian Diet|Includes children following a vegetarian diet.
16400602|NCT03974893||Non-Vegetarian Diet|Includes children following a non-vegetarian diet.
16400603|NCT03974880||patency group|Freedom from restenosis or clinically driven re-intervention in the treated lesion at 1,3,6,12 months after procedures
16400604|NCT03974880||restenosis group|Restenosis was defined as a reduction in the luminal diameter of more than 50 percent according to any imaging examinations such as duplex ultrasound, CTA, MRI or DSA Re-intervention in the treated segment for the clinical progression at 1,3,6,12 months after procedures
16400605|NCT03974880||the second adverse events group|a composite of all-cause death, myocardial infarction, and stroke and any amputation at 1,3,6,12 months after procedures
16400606|NCT03974867|Experimental|Oral Prednisone Group|36 participants in Group 1 will receive oral prednisone 1mg/kg/d (maximum daily dosage is no more than 60mg) for 7 days, followed by a 7-day taper.
16400607|NCT03974867|Experimental|Intratympanic Methylprednisolone Group|36 participants in Group 2 will receive 7 intratympanic 40mg/ml methylprednisolone injections in 14 days, one injection every other day.
16400608|NCT03974854|Experimental|Arm A: XELOXIRI-3|capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days
16400609|NCT03974854|Active Comparator|Arm B: Gemcitabine|1000 mg / m2 on D1, D8 and D15, every 28 days
16400610|NCT03974828|No Intervention|Non-Contact|Participants in the non-contact group will be monitored by anesthesia control tower clinicians who will utilize AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes predictions, but who will not contact the postoperative provider unless it is clinically necessary for patient safety purposes.
16400611|NCT03974828|Experimental|Brief contact|PACU and ward providers caring for participants in the brief contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a brief summary of the patient's forecast risk of major adverse events.
16400612|NCT03974828|Experimental|Full contact|PACU and ward providers caring for participants in the full contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.
16400613|NCT03974815|Experimental|ACTIVE|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
16400614|NCT03974815|Sham Comparator|SHAM|Sham stimulation (tDCS) will be used in the dose of 0mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
16400615|NCT03974802|Experimental|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
16400616|NCT03974789||Suspected Cushing Disease|
16400617|NCT03974776|Experimental|PF-06946860|Single subcutaneous administration of PF-06946860
16400618|NCT03974776|Placebo Comparator|Placebo|Single subcutaneous administration of placebo
16400619|NCT03974763||Test Group|Patients with acute, unilateral, facial paralysis (Bell's Palsy)
16400620|NCT03974763||Control Group|A group of age- and sex-frequency matched 'normal' controls. Based on past research, gender and age are possible confounders of facial movement/function. Thus, the control group will be frequency-matched to the patient group on gender and age.
16400622|NCT03974737||Adolescents with POTS|"Adolescents with Postural Orthostatic Tachycardia Syndrome (POTS) who meet diagnostic criteria for an orthostatic heart rate increase of >30, between ages 12-21 are eligible for this group. They will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.
~Interventions performed:
~Urine specific gravity measurement
~CRI measurements, orthostatic vitals measurements
~Survey administration"
16400623|NCT03974737||Adolescents without POTS, Control Group|"Adolescents without Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21 are eligible for this group. This group of subjects will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and their urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.
~Interventions performed:
~Urine specific gravity measurement
~CRI measurements, orthostatic vitals measurements
~Survey administration"
16400624|NCT03974737||Adolescents diagnosed with POTS who do not meet HR|"Adolescents diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21, who do not meet diagnostic heart rate criteria, are eligible for this group. This group of subjects will have a urine specific gravity conducted at beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.
~Interventions performed:
~Urine specific gravity measurement
~CRI measurements, orthostatic vitals measurements
~Survey administration"
16400625|NCT03974711||All study subjects|"Note: No interventions are administered under this evaluation.
~This is a real-world population. The determination to undergo a lateral lumbar interbody fusion procedure is made outside of this evaluation and is a standard of care, on-label procedure."
16400626|NCT03974698|Active Comparator|Anterolateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
16400627|NCT03974698|Active Comparator|Lateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
16400628|NCT03974685|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
16400629|NCT03974672||T drain|Patients treated with a T drain approach
16400630|NCT03974672||Stoma|Patients treated with a stoma
16400631|NCT03974659|Active Comparator|Theta Burst Stimulation|"Intervention group: ten consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation.
~Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
~The stimulation intensity was 80% Rest Motor Threshold.According to the patients' condition, age and tolerance,the intensity should be adjusted."
16400632|NCT03974659|Sham Comparator|sham Theta Burst Stimulation|sham group: we flip coil to make fake stimulation, the stimulation will also make sounds, but no magnetic field effect, the stimulation mode is the same as the intervention group.
16400633|NCT03974646|Experimental|intervention group|Participants assigned to the intervention group will receive both will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up , and a 12- weeks self-management intervention delivered by two dedicated and trained renal nurse educators. The intervention will involve three group-based sessions, CKD booklet and three follow-up phone calls.
16400634|NCT03974646|No Intervention|control group|Participants randomized to the control group in this study will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up. Usual care consisted of brief verbal information (2-5 minutes) about taking medications, reducing salt, smoking cessation and reducing alcohol consumption. There will no structured program but only the provision of written material to patients.
16400635|NCT03974633|Placebo Comparator|Control|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, without administering any type of non-invasive analgesic
16400636|NCT03974633|Experimental|Vibration|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, while applicating a vibrating device on the skin below the injection site, before and during injection.
16400637|NCT03974633|Experimental|Cold|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a bag of 50mL of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds
16400638|NCT03974633|Experimental|Anesthetic cream|subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a uniform thickness of 2mm of the anesthetic cream EMLA covered with an adhesive transparent plastic dressing for 30 minutes
16400639|NCT03974620|Experimental|Individual Placement and Support (IPS)|IPS is a vocational support program to facilitate return to employment in individuals with severe and enduring mental illnesses.
16400640|NCT03974620|Experimental|Cognitive Remediation Therapy (CRT)|CRT will be delivered twice weekly individual computerised CRT with therapist input. This therapy will be delivered by a CRT trained assistant psychologist.
16400641|NCT03974620|Experimental|IPS and CRT|A combination of IPS and CRT will be provided to participants in this arm.
16400642|NCT03974620|No Intervention|Treatment as usual|Continued input as normal with treating psychiatrist.
16400643|NCT03974607|Experimental|Physical Activity|Physical Activity Programme (PAP) was planned for the promotion of PA and other healthy habits in inactive adolescents as an agent of change intervention, in which a trained staff actively disseminates effective practices to improve the PA's habits of adolescents.
16400644|NCT03974607|No Intervention|No Physical Activity|The control group will be selected in a targeted manner according to the availability of the center. You will not be given any information about healthy habits nor will any physical training program be applied to you, so that you do not give indications that may produce a variation of your habitual behavior.
16400645|NCT03974594|Experimental|Trifluridine and Tipiracil Tablets|
16400646|NCT03974594|Active Comparator|TAS-102|
16400647|NCT03974581||Pharmacoinvasive strategy|Patients whom received pharmacoinvasive strategy (fibrinolysis and subsequently PCI) as reperfusion treatment.
16400648|NCT03974581||Primary PCI|Patients whom primary PCI as reperfusion treatment.
16400649|NCT03974542|Experimental|telephone outreach|
16400650|NCT03974542|No Intervention|control|
16400651|NCT03974529|Experimental|Intensive running arm|20 patients will be assigned randomly to intensive running arm (intervention arm). They will be required to complete a designed training protocol.
16400652|NCT03974529|Active Comparator|Physiotherapy arm|10 patients will be assigned randomly to physiotherapy arm. They will be required to complete a designed training protocol.
16400653|NCT03974516|Experimental|Careseng 1370|"Four dose cohorts are employed for Careseng 1370 oral administration in healthy volunteers:
~Level A (1 sachet): 1 sachet before breakfast;
~Level B (2 sachets): 1 sachet before breakfast, 1 sachet before lunch;
~Level C (3 sachets): 1 sachet before breakfast, 2 sachets before lunch;
~Level D (4 sachets): 2 sachets before breakfast, 2 sachets before lunch"
16400654|NCT03974503|Experimental|Exposure, Relaxation, and Rescripting Therapy (ERRT)|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
16400655|NCT03974503|Active Comparator|Sleep and Nightmare Management|This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
16400656|NCT03974490|Experimental|Intervention Group|"2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
~3 Times a week, intervention: Start with global body warming, 15 minutes, following the rhythm marked by the metronome. Central part of the session, 60 minutes, with rhythmic auditory stimulation exercises and music. Closure of the session, 15 minutes, round of impressions."
16400657|NCT03974490|No Intervention|Historical control group|2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
16400658|NCT03974477|Experimental|Intervention|"The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about The new Food Wheel, a guide to the daily food choice!."
16400659|NCT03974477|No Intervention|Control|"No intervention will be carried out except the provision of a leaflet on The new Food Wheel, a guide to the daily food choice! to the participants."
16400660|NCT03974451|Experimental|IOL implantation experimental|Implantation of the PhysIOL FineVision POD F® IOL
16400661|NCT03974451|Active Comparator|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL.
16400662|NCT03974438|Experimental|Intervention - Acupunture (SDN)|Patients allocated to the intervention arm will receive SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain.
16400663|NCT03974438|Sham Comparator|Control - Sham acupunture|Patients allocated to the control arm will receive sham-SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain. The sham procedure consists of a blunted needle, that does not penetrate the skin.
16400664|NCT03974425|Other|Diabetic macular edema resistant to Bevacizumab|Patients resistant to 6 monthly Bevacizumab injection were switched to Aflibercept.
16400665|NCT03974412|Experimental|All eligible participants|All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.
16400666|NCT03974399|Other|study enrollment|all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months
16400667|NCT03974386|Experimental|Blood Purification|Patients will receive resuscitation and treatment according to current guidelines for septic shock. In addition to standard care, the patients will receive continuous venovenous hemofiltration and adsorption with oXiris blood purification set.
16400668|NCT03974386|No Intervention|Conventional Treatment|Patients will receive standard care, including resuscitation and treatment according to current guidelines for septic shock.
16400669|NCT03974373|Experimental|BFP removal|this will be the group evaluated in this study, individuals who performed the BFP removal procedure.
16400670|NCT03974360|Experimental|Erenumab|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
16400671|NCT03974347||Acute kidney injury, no acute kidney injury|Acute kidney injury after cardiac surgery will be defined by KDIGO criteria, Creatinine rise from baseline and or urine production.
16400672|NCT03974347||No Acute Kidney Injury|No Acute kidney Injury after Cardiac surgery, according to KDIGO AKI definition
16400673|NCT03974334|Experimental|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
16400674|NCT03974308|Experimental|Study group 1|Patients with spine osteoarthritis who will be treated in polish spas in Subcarpathian Region. Comprehensive physiotherapy including balneotherapy will be applied.
16400675|NCT03974308|Active Comparator|Study group 2|Patients with spine osteoarthritis who will be treated in outpatient treatment. Comprehensive physiotherapy without balneotherapy will be applied.
16400676|NCT03974308|Other|Control group|Patients with spine osteoarthritis who will not have applied physiotherapy nor balneotherapy.
16400677|NCT03974295|Experimental|Intercourse Group|unlimited unprotected vaginal intercourse starting 24 hours after the frozen embryo transfer
16400678|NCT03974295|No Intervention|Pelvic Rest Group|pelvic rest after frozen embryo transfer until positive pregnancy test
16400679|NCT03974282|Other|Virginia Commonwealth University|Enrolled at VCU
16400680|NCT03974269|Active Comparator|Hypnosis arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
16400681|NCT03974269|Placebo Comparator|Sedation arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
16400682|NCT03974256|No Intervention|Group standard method|Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
16400683|NCT03974256|Experimental|Group automated method|Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
16400684|NCT03974243|Experimental|treatment group|"In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.
~Intervention: Drug: Chiauranib and Chidamide"
16400685|NCT03974230||Patients with Fuchs Endothelial Corneal Dystrophy (FECD)|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of datas and a blood sample.
16400686|NCT03974230||Control group|Witness will be included in control group. They will have a blood sample and slit lamp examination.
16400687|NCT03974217|Experimental|Talazoparib|"Talazoparib is administered orally on a daily basis
~Hydroxyurea is allowed for up to two cycles per institutional guidelines"
16400688|NCT03974204|Experimental|Cerebrospinal fluid and Blood sample collection|"Collection of cerebrospinal fluid and blood samples:
~At initial diagnostic assessment;
~1 month and 3 months after initial diagnostic assessment, for patients classified possible, probable or confirmed according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;
~In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified lack of evidence according to EANO-ESMO classification."
16400689|NCT03974191||131 participants with chronic low back pain|All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
16400690|NCT03974178|Experimental|Fexinidazole|"Patients with a body weight ≥ 35 kg:
~1800 mg (3 tablets) from day 1 to 4
~1200 mg (2 tablets) from day 5 to 10
~Patients with a body weight ≥ 20 and < 35 kg:
~1200 mg (2 tablets) from day 1 to 4
~600 mg (1 tablet) from day 5 to 10"
16400691|NCT03974165|Experimental|Cereal-legume product 1|Treatment with cereal-legume product-1
16400692|NCT03974165|Experimental|Cereal-legume product 2|Treatment with cereal-legume product-2
16400693|NCT03974165|Experimental|Cereal product|Treatment with cereal product
16400694|NCT03974165|Active Comparator|Reference food|Treatment with reference food
16400695|NCT03974152|Active Comparator|Own brand cigarette|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
16400696|NCT03974152|Experimental|ENDS: Subox Mini C with 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
16400697|NCT03974152|Experimental|ENDS: Subox Mini C with 18 mg nicotine regular (unprotonated)|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
16400698|NCT03974139|Experimental|Obese patients|Patients with body mass index >30
16400699|NCT03974126|Experimental|40 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
16400700|NCT03974126|Experimental|80 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
16400701|NCT03974113|Experimental|Fitusiran|Participants will receive a selected dose of fitusiran on regular intervals, as per study protocol
16400702|NCT03974100|Experimental|GP2411|60 mg /mL subcutaneous injection every 6 months
16400703|NCT03974100|Active Comparator|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
16400704|NCT03974087|Active Comparator|MCI patients with real transcranial direct current stimulation|Patients will receive 2mA stimulation in 10 consecutive sessions.
16400705|NCT03974087|Sham Comparator|MCI patients with sham transcranial direct current stimulation|Patients will receive sham stimulation in 10 consecutive sessions.
16400706|NCT03974074|Experimental|Albumin infusion group|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
16400707|NCT03974074|No Intervention|Empty control|Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
16400708|NCT03974061|Experimental|Brief Acceptance and Commitment Therapy|Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
16400709|NCT03974061|Active Comparator|Brief Alcohol Intervention|Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.
16400710|NCT03974048||Trauma patients|All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
16400711|NCT03974048||Patients admitted for elective orthopedic surgery|The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
16400712|NCT03974035|No Intervention|Control Group|Patients undergoing elective bimaxillary osteotomy who receive a preincisional infiltration of lidocaine and adrenaline.
16400713|NCT03974035|Experimental|Study Group|Patients undergoing elective bimaxillary osteotomy who receive two infiltrations (firstly pre-incision with lidocaine and adrenaline, secondly pre-extubation with ropivacaine).
16400714|NCT03974022|Experimental|DZD9008|
16400715|NCT03974009|Experimental|Calcaneal taping and Conventional therapy|Calcaneal Taping Technique along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
16400716|NCT03974009|Active Comparator|Sham taping and Conventional therapy|Sham taping along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
16400717|NCT03973996|Experimental|Green Tea|Participants consuming gummy confections with catechin-rich green tea extract daily for 4 weeks
16400718|NCT03973996|Placebo Comparator|Placebo|Participants consuming matched gummy confections formulated without green tea extract daily for 4 weeks
16400719|NCT03973983|Experimental|Ultrasound-guided pudendal nerve injection group|Patients who received Ultrasound-guided pudendal nerve injections
16400720|NCT03973983|Experimental|Finger-guided pudendal nerve injection group|Patients who received Finger-guided pudendal nerve injections
16400721|NCT03973970||Test Arm 1- T-SPOT.TB assay|Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
16400722|NCT03973970||Test Arm 2-QuantiFERON-TB Gold Plus assay|Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
16400723|NCT03973957|Active Comparator|Control Arm|If undergoing talc slurry in the control arm, the patient will undergo IPC placement in the pulmonary procedure unit on day one of admission. The IPC will then be connected to a pleur-evac as standard of care protocol for chest tube drainage. At 1-2 hours post-IPC placement a chest x-ray will be obtained to assess for full lung re-expansion. If the lung does not fully expand the patient will be excluded from the study. Once full lung re-expansion has occurred, talc slurry will be ordered and the patient will be given 25 mcg of IV fentanyl. Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will be administered via the IPC. The patient will remain in the hospital, with continuous drainage measured daily for 2-5 days, depending on drainage of the effusion.
16400724|NCT03973957|Active Comparator|Intervention Arm|"An indwelling pleural catheter (IPC) will be placed during this visit. After complete drainage of the effusion, a chest x-ray will be done to determine if full lung reexpansion occurs. If there is lack of full lung re-expansion the patient will be excluded from the study at this time. If full lung re-expansion is present, the patient will receive an intravenous line (IV) by our nursing staff for analgesia prior to talc administration and will be pre-treated with 25 mcg of IV fentanyl.
~Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will then be administered through the IPC. The IPC will then be connected to a circuit that will consist of the IPC connected to a 4-liter fluid drainage collection bag via a one-way Heimlich valve (picture of set up included in additional documents)."
16400725|NCT03973944|Other|Cardiac resynchronization therapy|AV coupling by atrio-biventricular pacing
16400726|NCT03973931|No Intervention|Usual Care|This group will not receive an intervention. We have included a usual care group to demonstrate the impact of the text messaging interventions above and beyond usual care given that many prior medication adherence interventions have demonstrated small to negligible effects.
16400727|NCT03973931|Experimental|Generic Nudge|A generic reminder text will be delivered to patients to refill their medication at days 1, 3, 5, 7 and 10 after they been labeled as non-adherent.
16400728|NCT03973931|Experimental|Optimized nudge|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1, 3, 5, 7 and 10 after they have been labeled as non-adherent.
16400729|NCT03973931|Experimental|Optimized nudge plus AI Chat Bot|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1 and 3 after they have been labeled as non-adherent. If the patient has not filled their medication on days 5 and 7, in addition to receiving an optimized nudge text, an AI will conduct interactive chat via a chat bot to assess barriers filling the medication as described in Aim 1 above. If they still have not filled the medication, they will receive another message on day 10.
16400730|NCT03973918|Experimental|Treatment Cohort 1 AA & GBM|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
~Research Bloods"
16400731|NCT03973918|Experimental|Treatment Cohort 2 anaplastic PXAs|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
~Research Bloods"
16400732|NCT03973918|Experimental|Surgical Arm|"Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery
~Tumor; research blood; CSF samples
~post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle"
16400733|NCT03973918|Experimental|Treatment Cohort 3 Other Tumors|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
~Research Bloods"
16400734|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).
~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
16400735|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).
~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
16400736|NCT03973879|Experimental|PVSRIPO + Atezolizumab|Single PVSRIPO infusion at a dose of 5x10^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
16400737|NCT03973866|Experimental|Alfapump|Implantation of Alfapump
16400738|NCT03973853|Experimental|Active group with virtual reality stimulation|The subjects in this arm will undertake 14 sessions of virtual reality stimulation. The program will be delivered by a nurse, trained to the use of such a tool, and familiar with cognitive remediation techniques. Before and after these 14 sessions, social autonomy, daily life skills, cognitive domains and self-esteem will be measured
16400739|NCT03973853|Placebo Comparator|Treatment as Usual group (TAU)|Patients in this group will carry on benefiting from their usual care with no additional program. They will be assessed before and after a 3 month period for social autonomy, daily life skills, cognitive domains and self-esteem.
16400740|NCT03973840|Experimental|healthy men treatment arm|Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.
16400741|NCT03973827|Experimental|ProTrans-Repeat|"Patients 1-3: 25 x10e6 cells Patients 4-6:100 x10e6 cells Patients 7-9:200 x10e6 cells
~Control group 9 patients= non treated"
16400742|NCT03973814|Active Comparator|Prior to Thermax Warming|Baseline temperature
16400743|NCT03973814|Active Comparator|During warming|Temperature during Thermax warming
16400744|NCT03973814|Active Comparator|Post warming|Temperature after cessation of Thermax warming
16400745|NCT03973801|Experimental|Auricular acupressure|
16400746|NCT03973788|Experimental|Intervention|repetitive transcranial magnetic stimulation
16400747|NCT03973775|Experimental|Test Drug Treatment Arm|Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC
16400748|NCT03973775|Active Comparator|Reference Drug Treatment Arm|Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.
16400749|NCT03973762|Experimental|DR Grading with CAD|DR Grading with CAD
16400750|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
16400751|NCT03973749|Experimental|Group 1|Low salycilate diet on day one and High salycilate diet on day 7
16400752|NCT03973749|Experimental|Group 2|High salycilate diet on day one and Low salycilate diet on day 7
16400753|NCT03973736||PDAC patients diagnosed in 2008-2011|
16400754|NCT03973736||PDAC patients diagnosed in 2013-2016|
16400755|NCT03973723||Patients with NPC after treatment|All patients with NPC without distant metastases who receiving adequate RT dose
16400756|NCT03973710|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
16400757|NCT03973710|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
16400758|NCT03973697|Experimental|Single dose of PMT|
16400759|NCT03973697|Experimental|Two doses of PMT|Administered within 24 hours
16400760|NCT03973684|Active Comparator|aPDT group|G1- 40 patient 40 patients will be included in this group. One section of Pdt will be performed with the photosensitizer (PS). PS will be applied in sufficience quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated. The apparatus shall be precalibrated at wavelength 660nm for 90 seconds per point.
16400761|NCT03973684|Experimental|experimental tongue scrapper group|40 patients will be included in this group. Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
16400762|NCT03973671||UC patients|"Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer.
~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.
~The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way."
16400763|NCT03973658||First time users of hearing aids|Hearing aid fitting and usage
16400764|NCT03973632|Experimental|Group A|Fasting at last 10h before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
16400765|NCT03973632|Experimental|Group B|Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Fasting at last 10h before taking 200mg（two pills） of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
16400766|NCT03973619|Active Comparator|Labial|Patients who received a labial graft as replacement of urethral tissue
16400767|NCT03973619|Active Comparator|Jugal|Patients who received a jugal (inner cheek) graft as replacement of urethral tissue
16400768|NCT03973606|No Intervention|Arab Women health literacy focus groups|Arab women in East Jerusalem will be part of focus groups. During the focus groups, a set of pre-prepared questions will be presented to the participants. The focus groups will be recorded and analyzed verbatim.
16400769|NCT03973606|Experimental|Health literacy workshop|Women from East-Jerusalem and other Arab communities in Israel will be invited to participate in a 4-sessions workshop designed to improve health literacy, self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
16400770|NCT03973580|Active Comparator|Attentional Bias Modification (ABM) group|Participants in this arm will participate in a six-session ABM task, one session per week.
16400771|NCT03973580|Placebo Comparator|Control group|Participants in this arm will participate in a six-session control task, one session per week.
16400772|NCT03973567|Experimental|refractory FD patients using antidepressants|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori（HP） treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
16400773|NCT03973567|Placebo Comparator|refractory FD patienTS using conventional treatment|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
16400774|NCT03973567|No Intervention|normal control|Age, sex and education matched, right-handed 30 normal people.
16400775|NCT03973554|Experimental|pearl powder|natural product, support bone and joint health
16400776|NCT03973554|Active Comparator|CPP-ACP|product for professional use containing the active ingredient (CPP-ACP), a special milk-derived protein that has a unique ability to release bio-available calcium and phosphate to tooth surfaces.
16400777|NCT03973541|Experimental|Virtual Reality Exposure Therapy|VRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
16400778|NCT03973541|Active Comparator|In Vivo Exposure Therapy|In vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
16400779|NCT03973541|Placebo Comparator|Virtual Reality Relaxation Therapy|VR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
16400780|NCT03973528|Experimental|traditional Chinese medicine|The experimental group use traditional Chinese medicine
16400781|NCT03973528|No Intervention|non- traditional Chinese medicine|The no intervention group no use traditional Chinese medicine.
16400782|NCT03973515|Experimental|PB-201 50/50mg by mouth,every morning and noon for 7 days|
16400783|NCT03973515|Experimental|PB-201 100/50mg by mouth,every morning and noon for 7 days|
16400784|NCT03973515|Experimental|PB-201 100/100mg by mouth,every morning and noon for 7 days|
16400785|NCT03973515|Placebo Comparator|placebo|
16400788|NCT03973489|Experimental|Common Variant (CV) MUD Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
16400789|NCT03973489|Experimental|Wild Type (WT) Healthy Control Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
16400790|NCT03973489|Experimental|Common Variant (CV) Healthy Control Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
16400791|NCT03973476|Experimental|Intervention group|Mothers received a phone support service with their midwife during the 8 weeks after childbirth.
16400792|NCT03973476|No Intervention|Control group|Mothers received standard postpartum care
16400793|NCT03973463|Sham Comparator|Low fat diet,12 weeks low oil balance 1200 kcal / day|12 weeks low oil balance 1200 kcal / day
16400794|NCT03973463|Experimental|12-week resistance exercise 3 times a week|12-week stretch with resistance exercise, 3 times a week
16400795|NCT03973463|Experimental|12 weeks low oil balance and resistance exercise|12 weeks low oil balance 1200 kcal / day and 12-week stretch with resistance exercise, 3 times a week
16400796|NCT03973450||Pituitary tumours|Patients affected by pituitary tumours and followed-up at the Neuroendocrinology Unit over a 5 yrs period (2014-2018)
16400797|NCT03973437|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
16400798|NCT03973437|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
16400799|NCT03973424|Experimental|Simple|This arm uses a simplified form of dietary tracking that involves tracking only high-calorie, high-fat foods, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
16400800|NCT03973424|Experimental|Standard|This arm uses standard calorie tracking, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
16400801|NCT03973411|Active Comparator|Ondansetron group|Patients will receive intravenous ondansetron before spinal anesthesia
16400802|NCT03973411|Placebo Comparator|Control group|Patients will receive intravenous saline before spinal anesthesia
16400803|NCT03973398|Active Comparator|Quadratus Lumborum Block anterior subcostal (QLa)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
16400804|NCT03973398|Active Comparator|Quadratus Lumborum Block posterior (QLp)|Patients in this group will receive Posterior Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
16400805|NCT03973398|Placebo Comparator|Quadratus Lumborum Block anterior subcostal control (QLca)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
16400806|NCT03973398|Placebo Comparator|Quadratus Lumborum Block posterior control (QLcp)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
16400807|NCT03973385|Experimental|cryotherapy group|cryotherapy by vapocoolant spray is applied on skin for 4 to 10 seconds ( or up to skin whitening) to 15 centimeters distance with sweeping action before ABG
16400808|NCT03973385|Placebo Comparator|control group|water spray is applied on skin for 4 to 10 seconds to centimeters distance with sweeping action before ABG
16400809|NCT03973359|No Intervention|Epidemiology|HCMV-seropositive pregnant women receiving standard care
16400810|NCT03973359|Experimental|Prevention|HCMV-seropositive pregnant women receiving hygienic information
16400811|NCT03973346|Experimental|Intervention group|Encounters at primary care clinics with the risk screening tool
16400812|NCT03973346|No Intervention|Comparison group|Propensity score matched comparison encounters
16400813|NCT03973333|Experimental|IMC-C103C - Arm A1|n= approximately 28 patients to establish the MTD/RP2D
16400814|NCT03973333|Experimental|IMC-C103C and atezolizumab Arm A2|n=approximately 12 patients to establish the MTD/RP2D
16400815|NCT03973333|Experimental|IMC-C103C - Arm B1|Patients will be enrolled n=9-24 metastatic/unresectable tumors of interest patients treated at the RP2D of IMC-C103C to assess preliminary anti-tumor efficacy
16400816|NCT03973333|Experimental|IMC-C103C and atezolizumab Arm B2|Patients will be enrolled n=9-24 metastatic/unresectable tumors of interest patients treated at the RP2D of IMC-C103C to assess preliminary anti-tumor efficacy
16400817|NCT03973320||Primary Total Hip Arthroplasty|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty
16400818|NCT03973307||Participants with bladder cancer|50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
16400819|NCT03973307||Participants without bladder cancer|50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
16400820|NCT03973294|Active Comparator|Supraglottic jet ventilation|Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
16400821|NCT03973294|Active Comparator|Subglottic jet ventilation|"Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an auto-PEEP."
16400822|NCT03973281|Active Comparator|Materna Prep Device|Materna Prep Device
16400823|NCT03973281|Other|Standard of Care (SOC)|Standard of Care (SOC)
16400824|NCT03973268|Experimental|1|Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.
16400825|NCT03973268|Experimental|2|Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.
16404983|NCT03944018|Experimental|Intervention with rehabilitation coordinator|
16400826|NCT03973268|Experimental|3|Individuals in Arm 3 will receive doubleblinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.
16400827|NCT03973255|Placebo Comparator|Home based vestibular rehabilitation program|Home-based vestibular rehabilitation program including vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises was given to each group in the form of a booklet. All exercises were demonstrated and performed first time at hospital under supervision. Booklet with descriptions and pictures of each exercise were given to patients in order to enable them to perform exercises at home. Vestibular rehabilitation exercises were prescribed as once daily with 10 repetitions at home for one month and wanted to mark a chart if the exercises were performed daily. A diary was used to monitor adherence with the program.
16400828|NCT03973255|Active Comparator|Biofeedback training|"Biofeedback training was performed five days a week during a month for 20 minutes for a total of 20 sessions with Tetrax ® (Sunlight Medical Ltd) static posture analysis device. Biofeedback training including catch, speedball, sky ball, gotcha exercises which requires following a visual target during weight transfer movements, capturing fast-moving objects by changing the center of gravity or quickly escaping from incoming objects, were applied to the patients in biofeedback training. There is a 30 seconds pause between each exercise."
16400829|NCT03973255|Active Comparator|Whole body vibration|Whole body vibration training was also performed five days a week during a month for 20 minutes for a total of 20 sessions with Power Plate Pro 5 (MDD CE 0086). In whole body vibration, single leg, squat and deep squat positions were applied respectively with 35 Hz frequency, including rest periods of 30 seconds between each application.
16400830|NCT03973242|Active Comparator|DF-NBI|Initially, gastric mucosa is observed by conventional wight light endoscopy. Then, converting to dual-focus mode with narrow band imaging is done. Gastric mucosa is observed once again by DF-NBI mode.
16400831|NCT03973242|Placebo Comparator|WL|Conventional white light endoscopy use It is routine practice for the upper gastrointestinal endoscopy.
16400832|NCT03973229|Experimental|Cohort 1: PTSD Receiving Estradiol then Placebo|Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
16400833|NCT03973229|Experimental|Cohort 1: PTSD Receiving Placebo then Estradiol|Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
16400834|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
16400835|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
16400836|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
16400837|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
16400838|NCT03973229|Experimental|Cohort 2: PTSD Receiving Estradiol then Placebo|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
16400839|NCT03973229|Experimental|Cohort 2: PTSD Receiving Placebo then Estradiol|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
16400840|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Estradiol, then Placebo|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
16400841|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Placebo then Estradiol|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
16400842|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
16400843|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
16400844|NCT03973216|Experimental|A primary care group-based therapeutic yoga program|A primary care care group-based therapeutic yoga program that consists of 9 sessions.
16400845|NCT03973203|Experimental|Niacin in controls|The arm includes healthy controls supplemented with niacin.
16404984|NCT03944018|No Intervention|Control|
16400846|NCT03973203|Experimental|Niacin in mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
16400847|NCT03973190|Placebo Comparator|RET Group|Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).
16400848|NCT03973190|Active Comparator|SBC Group|Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).
16400849|NCT03973190|Active Comparator|PRO Group|Alveolus sealing by a temporary ovoid pony of acrylic resin.
16400850|NCT03973177|Experimental|Treatment Group: Phenol injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites
16400851|NCT03973177|Other|Control Group: Methylprednisolone injection|Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site
16400852|NCT03973151|Experimental|HL-085|HL-085 will be administered as BID with specified dose.
16400853|NCT03973138|Experimental|Treatment group|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab under the pro re nata (PRN) treatment regimen.
16400854|NCT03973125|Experimental|Treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
16400855|NCT03973112|Experimental|HLX10+HLX04|
16400856|NCT03973099|Experimental|Placebo|Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
16400857|NCT03973099|Experimental|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
16400858|NCT03973086|Experimental|Citrus flavonone-O-glycosides (Low dose)|
16400859|NCT03973086|Experimental|Citrus flavonone-O-glycosides (High dose)|
16400860|NCT03973086|Placebo Comparator|Microcrystaline Cellulose- 400mg|
16400861|NCT03973073|Experimental|camouflage group|Topical applications and/or NB-UVB plus Capulin TM on-demand treatment period
16400862|NCT03973073|Other|blank group|Topical applications and/or NB-UVB on-demand treatment
16400863|NCT03973060|Experimental|Concentric muscular work|4 series of 12 repetitions of concentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
16400864|NCT03973060|Experimental|Eccentric muscular work|4 series of 12 repetitions of eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
16400865|NCT03973060|Experimental|Concentric-eccentric muscular work|4 series of 12 repetitions of concentric-eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
16400866|NCT03973060|Experimental|Isometric muscular work|6 seconds of contraction, with 20 seconds of rest with 24 repetitions, for a total working time of 12 minutes.
16400867|NCT03973047|Placebo Comparator|Group 1: BMT plus placebo|1 dose of BMT 1.75 mg via autoinjector plus placebo (dosed 30±5 minutes prior to BMT dosing) on Day 1.
16400868|NCT03973047|Active Comparator|Group 2: BMT plus Zofran|1 dose of BMT 1.75 mg via autoinjector plus Zofran 8 mg (dosed 30±5 minutes prior to BMT dosing) on Day 1.
16400869|NCT03973034||Normal people|
16400870|NCT03973034||Benign breast disease patients|
16400871|NCT03973034||Breast cancer patients in early stage|
16400872|NCT03973021|Experimental|VSEL Max|Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
16400873|NCT03973021|Experimental|VSEL Medium|Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
16400874|NCT03973021|Experimental|VSEL Mini|Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
16400875|NCT03973021|No Intervention|Control|In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.
16400876|NCT03973008|Experimental|Adujvant CT+CRT|Four to six weeks after D2 radical surgery, adjuvant chemotherapy was initiated with SOX regimen , repeated every three weeks, and adjuvant radiotherapy was started at the end of two cycles of adjuvant chemotherapy , with synchronous tegiol single drug chemotherapy. And the original SOX regimen was continued for 4 cycles after 3-4 weeks of radiotherapy.
16400877|NCT03973008|Active Comparator|Adujvant CT|The adjuvant chemotherapy was started 4-6 weeks after D2 radical operation. The SOX regimen was repeated every 3 weeks for 8 cycles.
16400878|NCT03972982|Experimental|Simplified regimen group|Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
16400879|NCT03972982|Active Comparator|Routine group|Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.
16400880|NCT03972969|Experimental|In-person exercise group|facility-based structured exercise program
16400881|NCT03972969|Experimental|Remote exercise group|home-based structured exercise program
16400882|NCT03972969|Active Comparator|Control group|health education
16400883|NCT03972956||Colorectal cancer or gastric cancer patient|Patients suffering from CRC or gastric cancer scheduled to have surgical resection of colon/rectum or stomach.
16400884|NCT03972956||Non-malignant disease patient|Patients suffering from non-malignant disease scheduled to have surgery.
16400885|NCT03972943|Active Comparator|Cohort I (observation)|Patients not diagnosed with OSA undergo observation for 6 months.
16400886|NCT03972943|Experimental|Cohort II: (CPAP treatment)|Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.
16400887|NCT03972930|Experimental|Hypofractionated Radiotherapy for Soft Tissue Sarcoma|Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
16400888|NCT03972917||ulipristal acetate based therapy|Fertile women under ulipristal acetate treatment
16400889|NCT03972904|Experimental|Intervention group|The Light-Fat Rice® group
16400890|NCT03972904|Placebo Comparator|Control group|The comparable energy staple food group
16400891|NCT03972891|Experimental|12-weeks intervention break|The intervention break starts as soon as 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy. The intervention break will last for 12 weeks.
16400892|NCT03972891|No Intervention|traditional therapy|After 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy, the children will maintain their traditional therapy until more than 90% of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations (max. 12 weeks).
16400893|NCT03972878|Active Comparator|control snack|control snack
16400894|NCT03972878|Experimental|control cream|control spreadable cream
16400895|NCT03972878|Experimental|cream version 1|control spreadable cream, version 1
16400896|NCT03972878|Experimental|cream version 2|control spreadable cream, version 2
16400897|NCT03972878|Experimental|cream version 3|control spreadable cream, version 3
16400898|NCT03972878|Experimental|control chocolate bar|control chocolate bar
16400899|NCT03972878|Experimental|chocolate bar version 1|control chocolate bar version 1
16400900|NCT03972865|Experimental|Participants of the race|Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
16400901|NCT03972839||D-Dimers patients|population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)
16400902|NCT03972826|Other|1|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
16400903|NCT03972813|Experimental|cervical cancer - sexually transmitted (STD) - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
16400904|NCT03972813|Experimental|cervical cancer - STD - 12 years old (y.o.)|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
16400905|NCT03972813|Experimental|cervical cancer - STD - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
16400906|NCT03972813|Experimental|cervical cancer - infectious - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
16400907|NCT03972813|Experimental|cervical cancer - infectious - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
16400908|NCT03972813|Experimental|cervical cancer - infectious - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
16400909|NCT03972813|Experimental|cervical cancer - blank - standard|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
16400910|NCT03972813|Experimental|cervical cancer - blank - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
16400911|NCT03972813|Experimental|cervical cancer - blank - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
16400912|NCT03972813|Experimental|many cancers - STD - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
16400913|NCT03972813|Experimental|many cancers - STD - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
16400914|NCT03972813|Experimental|many cancers - STD - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
16400915|NCT03972813|Experimental|many cancers - infectious - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
16400939|NCT03972657|Experimental|Dose Expansion Cohorts|In a series of dose expansion cohorts, patients will receive 3-week monotherapy and then combination therapy of REGN5678 at the recommended phase 2 dose (RP2D) and cemiplimab
16400916|NCT03972813|Experimental|many cancers - infectious - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
16400917|NCT03972813|Experimental|many cancers - infectious - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
16400918|NCT03972813|Experimental|many cancers - blank - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
16400919|NCT03972813|Experimental|many cancers - blank - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
16400920|NCT03972813|Experimental|many cancers - blank - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
16400921|NCT03972787|Experimental|Proactive Social Robot (Intervention)|Participants will have the opportunity to use ElliQ for a total of 8 weeks to determine the impacts of the system on participants' loneliness, mood, technology use, and quality of life.
16400922|NCT03972787|No Intervention|Waitlist Control|Participants will not receive any intervention for a total of 8 weeks to determine whether any impacts noted for participants' loneliness, mood, technology use, and quality of life are unique to ElliQ or are influenced by other factors.
16400923|NCT03972774|Other|Cardiac PET stress testing and test-dependent management|Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not).
16400924|NCT03972774|Other|Management without stress-imaging|Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up.
16400925|NCT03972761|Active Comparator|Group exposed to cognitive remediation|Computerized cognitive remediation program. Program performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
16400926|NCT03972761|Placebo Comparator|Group not exposed to cognitive remediation|Standard remediation performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
16400927|NCT03972748|Experimental|Itraconazole|Oral Itraconazole capsules, 200 mg
16400928|NCT03972735|Experimental|NECT + follow up|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.
16400929|NCT03972735|Placebo Comparator|TAU|"Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder
~Support in day-care hospital
~No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)"
16400930|NCT03972722|Experimental|GLS-010|Full-human anti-pd-1 monoclonal antibodies
16400931|NCT03972709|Experimental|RG6147 Q4W|Participants will receive RG6147 every 4 weeks (Q4W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label RG6147 injections.
16400932|NCT03972709|Sham Comparator|Sham Control Q4W|Participants will receive Sham-control Q4W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label RG6147 injections.
16400933|NCT03972709|Experimental|RG6147 Q8W|Participants will receive RG6147 every 8 weeks (Q8W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label RG6147 injections.
16400934|NCT03972709|Sham Comparator|Sham Control Q8W|Participants will receive Sham-control Q8W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label RG6147 injections.
16400935|NCT03972696|Active Comparator|BA3S|Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
16400936|NCT03972696|Experimental|BA2|RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
16400937|NCT03972683|Experimental|Handgrip Exercise Training Intervention|"Participants will visit the lab for baseline measurements designed to evaluate signaling mechanisms that regulate blood flow. A physician will place a catheter in the brachial artery for pharmacological infusions. The following drugs will be administered to each participant: acetylcholine, adenosine triphosphate, atropine, phenylephrine, and sodium nitroprusside (see Interventions for further details regarding each drug). The order of infusions will be randomized and blood flow will be allowed to return to baseline between each infusion (~15 min) with the exception of atropine, which will be administered last owing to its longer half-life.
~Following baseline measurements, participants will complete a 7 week handgrip exercise training intervention, then they will return to the laboratory for post-training measurements. The post-training assessments will be performed in the same manner as the baseline visit; thus, the same drugs will be infused as described above."
16400938|NCT03972657|Experimental|Dose Escalation Cohorts|In a series of dose escalation cohorts, patients will receive a 3-week monotherapy lead-in of 3 weekly doses of REGN5678 followed by REGN5678 and cemiplimab in combination.
16400940|NCT03972644|Active Comparator|Early intervention|Patients will undergo aortic valve replacement immediately
16400941|NCT03972644|No Intervention|Watchfull waiting|Patients will be followed and treated as recommended by guidelines.
16400942|NCT03972631|Placebo Comparator|Lifestyle education|The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
16400943|NCT03972631|Experimental|Intensive Lifestyle Intervention|The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
16400944|NCT03972618|Experimental|School and village|Simultaneous installation of filters in schools and the village
16400945|NCT03972618|Experimental|School only|Initial installation in school only
16400946|NCT03972618|Experimental|Village only|Initial installation in village only
16400947|NCT03972618|No Intervention|Control|Control group. No filter installation initially.
16400948|NCT03972592|Experimental|Topical sirolimus|The experimental group will consist in one area of the CMLM (almost half of it) that will receive 0.1% sirolimus preparation. This product will be applied 1/day on the randomly allocated area, by a nurse at home, during 12 weeks.
16400949|NCT03972592|Placebo Comparator|Vehicle|The control group will consist in the other half area of the CMLM, that will receive the same vehicle than the one used in the topical 0.1% sirolimus preparation. It will be applied 1/day in the corresponding area by a nurse, at home, during 12 weeks.
16400950|NCT03972579|Active Comparator|Graded exposure therapy|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
16400951|NCT03972579|Active Comparator|Pacing + mindfulness|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
16400952|NCT03972566||CREST with Calcinosis cutis|
16400953|NCT03972566||CREST without Calcinosis cutis|
16400954|NCT03972553|Other|Sugarbaker|For the Sugarbaker group, the bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
16400955|NCT03972553|Other|Keyhole|For the Keyhole group the stoma will be taken down and rematured through a cruciate incision (keyhole)
16400956|NCT03972540|Experimental|Mindful eating intervention|The mindful eating intervention was taught by a mindfulness-based stress reduction instructor certified by the Center of Mindfulness at the University of Massachusetts Medical School.
16400957|NCT03972527|Active Comparator|Active Device Treatment Cohort|The MuReva Phototherapy System consists of Light Control Unit and a Mouthpiece Cable Assembly. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly.
16400958|NCT03972527|Sham Comparator|Sham Device Treatment Cohort|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a Mouthpiece Cable Assembly. The sham control Mouthpiece Cable Assembly will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly.
16400959|NCT03972501|Placebo Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
16400960|NCT03972501|Experimental|AZR-MD-001 Active Dose|AZR-MD-001 Active Dose will be dosed up to once daily.
16400963|NCT03972462|Experimental|NPC-12G Gel 0.2% (Period 1)|A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.
16400964|NCT03972462|Active Comparator|Rapamune Tablet (Period 2)|Rapamune® (sirolimus) 2 mg tablet for oral dosing.
16400965|NCT03972449|Experimental|Beatboxing: BEAT-Speech|
16400966|NCT03972449|Experimental|Traditional Articulation Approach|
16400967|NCT03972423||IRCTC group|- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
16400968|NCT03972423||CONTROL group|- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
16400969|NCT03972410|Experimental|Eye Movement Desensitization and Reprocessing (EMDR)|The EMDR treatment will follow the EMDR Recent Birth Trauma Protocol. This protocol was recently developed by some of the colleagues collaborating in this research project (Catteneo et al., 2018). This EMDR protocol can be used to intervene immediately after birth, or at later times. The main purposes of early intervention is to prevent the onset and development of PTSD and Post-partum Depression in the mother during the months following childbirth and to facilitate mother-newborn bonding.
16400970|NCT03972410|Active Comparator|Supportive Expressive Dynamic Psychotherapy (SEDP)|The SEDP treatment (Luborsky 1984; Book, 1998) is one of the most widespread treatments and can be considered the treatment as usual in Italian maternity wards. This intervention includes both supportive techniques (to create a positive, helpful and empathic relationship with the patient) and expressive techniques (aimed at helping the patient to express and to understand and change problems).
16400971|NCT03972397|Experimental|Intercostal Nerve Cryoablation plus SOC Pain Control|Standard of Care (SOC)
16400972|NCT03972397|Active Comparator|Standard of Care (SOC) Pain Control|
16400995|NCT03972254|Experimental|Intervention|Caregivers and their child will interact for 10 minutes while being observed and videotaped. Psychoeducation will be provided and goal setting will occur to ensure dyad specific relationship gains are made.
16400973|NCT03972384|Experimental|Post-ICU Problem Solving|The PIC-UPS intervention focuses on self-regulation activities and environmental cues to overcome problems with memory, planning and decision-making. The interventionist uses guided discovery, reviews progress, and emphasizes generalization and transfer to other patient-identified problems. This approach may be more acceptable to participants because they can see the relevance of tasks to everyday life. Activities such as goal-setting, self-evaluation and reflective thinking behaviors enhance self-efficacy and increase the likelihood that the individual will engage in self-management behaviors. The first session of PIC-UPS will be delivered after enrollment to those participants randomized to the intervention group. Weekly intervention sessions will be conducted by a trained interventionist and supplemented by telephone reminders to complete daily homework. Follow-up data collection will be conducted in the home by a blinded data collector three months post-enrollment.
16400974|NCT03972384|No Intervention|Control Group|Participants in the control group will complete several surveys upon enrollment and randomization. Follow-up data collection will be conducted in the home for all participants control group by a blinded data collector three months post-enrollment.
16400975|NCT03972371|Experimental|Treatment Group|The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms
16400976|NCT03972358|Experimental|Medical menstrual regulation|"Mifepristone 200 mg orally on day 1.
~Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone)."
16400977|NCT03972345||Paediatric patients with iGHD or SGA|Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)
16400978|NCT03972332||Sensitised|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
16400979|NCT03972332||Non-sensitised|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
16400980|NCT03972319|Experimental|Omega-3 Supplementation|Proof of Concept and Safety Study of 4 weeks of Omega-3 supplementation pre- Bariatric Surgery
16400981|NCT03972306|Experimental|Group A: Cohorts A1-A4|"Participants (participants pretreated with ocrelizumab) will receive a single injection of subcutaneous (SC) ocrelizumab co-mixed with rHuPH20 in the abdomen. For every new dose level, recruitment will be staggered by enrolling 1 participant in each cohort followed by a 48-hour waiting period to review safety and tolerability data by the Safety Monitoring Committee (SMC) prior to enrolling subsequent participants in the same cohort. Currently, the planned dose escalation steps for patients who enroll in Group A are as follows:
~Cohort A1: 40 mg of SC ocrelizumab
~Cohort A2: 200 mg of SC ocrelizumab
~Cohort A3: 600 mg of SC ocrelizumab
~Cohort A4: 1200 mg of SC ocrelizumab"
16400982|NCT03972306|Experimental|Group A: Cohort A5|In the non-randomized subphase, participants will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
16400983|NCT03972306|Experimental|Group A: Cohort AA|Participants will receive a single 600-mg dose ocrelizumab by intravenous (IV) infusion
16400984|NCT03972306|Experimental|Group B: Cohorts B1-B4|"Ocrelizumab treatment- naive participants will receive a minimum of 3 patients in Cohort B will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
~Cohort B1: 40 mg of SC ocrelizumab
~Cohort B2: 200 mg of SC ocrelizumab
~Cohort B3: 600 mg of SC ocrelizumab
~Cohort B4: 1200 mg of SC ocrelizumab"
16400985|NCT03972293|Experimental|Within-participant Micro-randomization|"Each week in the study, with probability .25 for each, a participant is randomized to receive either a week of mood notifications, activity notifications, sleep notifications, or no notifications.
~If the participant is assigned to receive mood, activity, or sleep notifications on a given week, then, for every day of that week the participant is randomized to: send notification on that day (with probability .5), or to not send a notification on that day (with probability .5)."
16400986|NCT03972293|Experimental|No intervention|Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
16400987|NCT03972280|Experimental|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
16400988|NCT03972280|Experimental|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
16400989|NCT03972280|Experimental|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
16400990|NCT03972280|Experimental|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
16400991|NCT03972280|Experimental|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
16400992|NCT03972280|Experimental|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
16400993|NCT03972267|Sham Comparator|Control Group - Free Gingival Graft|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the Control Group will not receive any kind of treatment in the palatal region.
16400994|NCT03972267|Experimental|Test Group - Free Gingival Graft + EMD|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. EMD will be applied immediately after the graft removal surgical procedure on the palatal donor area, leaving it in contact with the wound for 5 min. In sequence, it will be covered with an individualized acetate plate that will extend throughout the palatal area and be in position for 2 hours after the procedure
16400996|NCT03972241|Experimental|Intervention|different interventions including foot insole or kinetic training
16400997|NCT03972241|No Intervention|control|No intervention
16400998|NCT03972228|Experimental|Microdevice Intervention|The intervention to be administered is the placement of the microdevice containing 19 FDA-approved drugs into the lung lesion and the device's subsequent surgical resection. All study subjects will receive this same intervention; there is only one arm.
16400999|NCT03972215|Experimental|Berberine treatment|
16401000|NCT03972215|Placebo Comparator|Placebo control|
16401001|NCT03972202|Experimental|Patients with cerebellar ataxia (CA)|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
16401002|NCT03972202|Active Comparator|Matched controls|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
16401003|NCT03972202|Experimental|Additional healthy volunteers|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI) Transcranial magnetic stimulation (TMS)
16401004|NCT03972189|Experimental|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
16401005|NCT03972163|Experimental|SPECTORx Educational Intervention|The program intervention is based on a combination of 3 existing, complementary, educational programs that, together, equip hospice staff to create a comprehensive, patient-centered, medication management care plan.
16401006|NCT03972163|Active Comparator|Attention Control|"As the attention control, we will refer staff in control offices to the National Institute of Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
16401007|NCT03972150|Experimental|Part I: BI 836880 alone|Part I followed by Part II
16401008|NCT03972150|Experimental|Part II: BI 836880 and BI 754091|
16401009|NCT03972137|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
16401010|NCT03972124|Active Comparator|CBD 100 mg OD|The lower dose CBD group will start with CBD capsules 10 mg OD, then increase the dose every 4 days until on the target dose of 100 mg OD.
16401011|NCT03972124|Experimental|CBD 200 mg OD|The higher dose CBD group will start with CBD capsules 10 mg OD and will increase every 4 days until on a target dose of 200 mg OD.
16401012|NCT03972124|Placebo Comparator|Placebo|
16401013|NCT03972098||ra patients|The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young.
16401014|NCT03972098||healthy control|healthy person, similar population
16401015|NCT03972085|Experimental|Group 1|Patient received neural gliding exercises in addition electrotehrapy sessions.
16401016|NCT03972085|Active Comparator|Group 2|Patient received only electrotherapy sessions
16401017|NCT03972072|Experimental|Single Intervention Arm|daily imaging for MR-IGRT once weekly offline plan adaptation subjective/objective LENT-SOMA xerostomia-evaluation including flow measurements at baseline, 6 month-, 12 month- and 24 month-follow up EORTC-QoL questionnaires at baseline, 6 month-, 12 month- and 24 month-follow up
16401018|NCT03972059|Experimental|Experimental group|A 12-week high intensity interval circuit training program for weight management in overweight adults.
16401019|NCT03972059|No Intervention|Control group|No intervention for 12 weeks, participants perform all tests.
16401020|NCT03972046|Experimental|T-Vec + BRAF/MEK|"Participants will begin taking the following 3 medications:
~BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10^6 PFU/mL; Dose #2: 10^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10^8 PFU/mL every 14 (+/-3) days).
~Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.
~May stop earlier than 3 months at physician discretion depending on side effects and response.
~Ultrasound of tumor nodal basin(s) monthly.
~Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.
~PET CT or brain MRI as needed at discretion of the investigator.
~Manual tumor measurement in office prior to each injection."
16401021|NCT03972033|Experimental|Eye Movement Desensitization and Reprocessing|EMDR manualized protocol is DEPRend (Hofmann, Ostacoli, et al., 2015), based on the eight-phase protocol by Shapiro (2001) adapted for the treatment of Depression by the European Depression EMDR Network and used in previous studies (Hase et al., 2015; Hofmann et al., 2014). EMDR targets were selected following the Adaptive Information Processing model that looks for stressful events linked with the depression and for specific developments of resources.
16401022|NCT03972033|Active Comparator|Cognitive Behavioral Therapy|CBT is based on the principles described by Beck (Beck et al., 1979) and included behavioral activation and cognitive restructuring according to a session-by- session protocol with homework assignments.
16401023|NCT03972020|Experimental|Mindfulness Based Intervention|8 group sessions lasting 2.5 hours each, on a weekly basis.
16401024|NCT03972020|Active Comparator|Cognitive Behavioral Therapy|8 group sessions lasting 2.5 hours each, on a weekly basis.
16401025|NCT03972007|Experimental|Immediate LEDT Group|The 940nm LED blanket will be positioned across the full length of the biceps brachii muscle in the dominant limb immediately before the muscle fatigue protocol.
16401026|NCT03972007|Experimental|LEDT Group 15Min|The 940nm LED blanket will be positioned across the length of the biceps brachii muscle in the dominant limb 15 minutes before the muscle fatigue protocol.
16401027|NCT03972007|Sham Comparator|Immediate Sham Group|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, immediately prior to the muscle fatigue protocol.
16401028|NCT03972007|Sham Comparator|Sham Group 15Min|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, 15 minutes before the protocol of muscle fatigue.
16401029|NCT03971994|Active Comparator|Young adults|Participants aged between 18 and 40 years old.
16401030|NCT03971994|Active Comparator|Healthy old adults|Participants aged between 65 and 95 years old.
16401031|NCT03971994|Experimental|Patients with Alzheimer's Disease|Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.
16401032|NCT03971981|Experimental|100% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
16401033|NCT03971981|Experimental|22% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
16401034|NCT03971968||Group 1 = Intervention group|Group 1 suffered from third degree full thickness burns in the face/neck and received a surgical procedure with Integra Artificial Skin in the past
16401035|NCT03971968||Group 2 = Control Group|Group 2 is the healthy skin of a comparable and/or contralateral skin-site of the face/neck
16401036|NCT03971955||Adult Onset Autoimmune Diabetes/Latent Autoimmune Diabetes|
16401037|NCT03971955||Type 2 Diabetes|
16401038|NCT03971955||Type 1 Diabetes|
16401039|NCT03971955||Healthy Normal Volunteers (HNV)|
16401040|NCT03971942|Experimental|Neutral ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
16401041|NCT03971942|Experimental|Positive ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
16401045|NCT03971916|Experimental|HBM9161 340mg|
16401046|NCT03971916|Experimental|HBM9161 510mg|
16401047|NCT03971916|Experimental|HBM9161 680mg|
16401048|NCT03971916|Placebo Comparator|Placebo|
16401049|NCT03971903|Experimental|Attention bias modification treatment|12-session of ABMT
16401050|NCT03971903|Placebo Comparator|Placebo controls|12-session of placebo(i.e.,sham) training
16401051|NCT03971890|Experimental|DanceTherapy Group|The experimental group will receive a dance treatment.
16401052|NCT03971890|Experimental|Control Group|The control group will be subjected to a educational treatment.
16401053|NCT03971877||Patients admitted in ICU or oncohaematology ward|
16401054|NCT03971851||Low frailty|Frailty risk score less than 5
16401055|NCT03971851||Intermediate Frailty|Frailty risk score 5-15
16401056|NCT03971851||High frailty|Frailty risk score 15 and above
16401057|NCT03971838|Experimental|Intervention Arm|Women with a history of gestational diabetes will be offered 4-6 months of a diabetes prevention program.
16401058|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Healthy Subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
16401059|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Psoriasis subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.
16401060|NCT03971812||Patient with high grade astrocytoma|Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
16401061|NCT03971799|Experimental|CD33CART|All patients who receive CD33CART cell infusion
16401062|NCT03971773|Experimental|Patient ongoing hypnosis sessions|
16401063|NCT03971760|Active Comparator|Group 1: 30cc/24h|This group represents the currently used value of drain output used to determine the timing of drain removal
16401064|NCT03971760|Experimental|Group 2: 50cc/24h|This group represents the experimental value of drain output used to determine the timing of drain removal
16401065|NCT03971747|Experimental|C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
16401066|NCT03971734|Experimental|Arm 1 regadenoson 0.05mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose.
~Regadenoson 0.05mg"
16401067|NCT03971734|Experimental|Arm 2 regadenoson 0.1mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
16401068|NCT03971734|Experimental|Arm 3 regadenoson 0.2mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
16405062|NCT03943459|No Intervention|Atorvastatin|20 patients treated with atorvastatin 80 mg/day
16401069|NCT03971734|Experimental|Arm 4 regadenoson 0.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
16401070|NCT03971734|Experimental|Arm 5 regadenoson 0.7mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
16401071|NCT03971734|Experimental|Arm 6 regadenoson 1.0mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
16401072|NCT03971734|Experimental|Arm 7 regadenoson 1.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
16401073|NCT03971721|Experimental|Wave Mattress Support|The mattress support will be delivered at the subject's home by professional staff of the sponsor (Hill-Rom) in the presence of the research coordinator or investigator. The subject will sleep on mattress support for the duration of study participation.
16401074|NCT03971708|Other|Ropivacaine|This is the control where patients will receive ropivacaine via the TAP block infusion post-operatively.
16401075|NCT03971708|Active Comparator|Lidocaine|This is the study arm where patients will receive lidocaine via the TAP block infusion post-operatively.
16401076|NCT03971695|Experimental|BI 706321|
16401077|NCT03971695|Placebo Comparator|Placebo|
16401078|NCT03971682|Experimental|Experimental - PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP is a structured individual program for detained youth. This program is based on Compassion Focused Therapy (CFT), which conceptualizes antisocial behavior and psychopathic traits as evolutionary rooted responses to deal with harsh rearing scenarios. The ultimate goal of the PSYCHOPATHY.COMP is to develop a compassionate motivation in these youth.
~PSYCHOPATHY.COMP consists of 20 individual sessions, each lasting about 60 minutes, which run on a weekly basis. Sessions must be carried out by therapists skillful in CFT. Sessions are grouped into four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse prevention, and finalization.
~The treatment group attended the PSYCHOPATHY.COMP program in addition to the Treatment As Usual (TAU) delivered at Portuguese juvenile detention facilities."
16401079|NCT03971682|Active Comparator|Treatment As Usual - TAU|"Treatment As Usual:
~Subjects in this group received Treatment As Usual in Portuguese juvenile detention facilities (school frequency, token economy system for behavior control, frequency of a structured cognitive-behavioral group program, as well as individualized counseling sessions delivered by psychologists from the juvenile justice system) and did not attend the PSYCHOPATHY.COMP program."
16401080|NCT03971669|Experimental|Vaccination with Oral Typhoid Vaccine (Vivotif)|Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.
16401081|NCT03971656|No Intervention|Control|Standard care
16401082|NCT03971656|Experimental|Intervention|Three-Fold Nutritional Intervention
16401083|NCT03971643|Experimental|IFX-1|Exploratory, Proof of Concept with a total of 15 doses of IFX-1.
16401084|NCT03971630|No Intervention|Standard care group|These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.
16401085|NCT03971630|Experimental|MyVENT group|These patients will be followed up using the telemedicine (MyVENT System and APP)
16401086|NCT03971617|Experimental|Hydrogen tablets|The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
16401087|NCT03971617|Placebo Comparator|Placebo tablets|effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water
16401088|NCT03971604|Experimental|group 1|treated with VA
16401089|NCT03971604|Experimental|group 2|treated with VE
16401090|NCT03971604|Experimental|group 3|treated with VA+VE
16401091|NCT03971604|No Intervention|group 4|No intervention
16401119|NCT03971409|Experimental|Arm A (avelumab, binimetinib, liposomal doxorubicin)|Patients will receive a 15-day lead-in of binimetinib taken twice daily (PO BID), followed by binimetinib PO BID, and liposomal doxorubicin once every 28 days starting on Day 1 of Cycle 1, and 10mg/kg avelumab over 60 minutes every 2 weeks starting on Day 1 of Cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16401230|NCT03970720|Placebo Comparator|T1DM - Unaware: Placebo|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
16401092|NCT03971591|Experimental|Guided Lifestyle program|The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
16401093|NCT03971591|Active Comparator|Self-Guided Lifestyle program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
16401094|NCT03971578||Autism Spectrum Disorders Group|Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old
16401095|NCT03971578||Normal Control Group|Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old
16401096|NCT03971565||Patients with chronic lymphocytic leukemia|Patient with a minimum period of 90 days without treatment
16401097|NCT03971539|Experimental|Single Rising Dose|
16401098|NCT03971539|Experimental|Multiple Rising Dose|
16401099|NCT03971513|No Intervention|usual practice|Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations
16401100|NCT03971513|Experimental|TAP block|In addition of usual practice, patients receiving a TAP block at the beginning of the surgery
16401101|NCT03971500|Experimental|IVUS-guidance|In the IVUS-guided DES implantation group, optimal stent deployment criteria included: 1) the MLA in the stented segment is >5.0 mm^2, or 90% of the MLA at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is <55%; and 3) absence of >=Type B edge dissection. Further treatment will be required if any of those 3 criteria was not met.
16401102|NCT03971500|Active Comparator|Angiography-guidance|In the Angiography-guided DES implantation group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of >Type B dissection.
16401103|NCT03971500|Experimental|SAPT group|Ticagrelor + aspirin for 1 month followed by ticagrelor plus matching placebo for an additional 11 months.
16401104|NCT03971500|Active Comparator|DAPT group|Ticagrelor + aspirin for 12 month.
16401105|NCT03971487|Active Comparator|Ocrelizumab|Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.
16401106|NCT03971487|Placebo Comparator|Placebo|Two placebo intravenous infusions will be administered two weeks apart.
16401107|NCT03971474|Active Comparator|Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed)|Patients receive docetaxel IV over 10-30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 or ramucirumab IV over 60 minutes and docetaxel IV over 10-30 minutes on day 1. Patients with non-squamous NSCLC receiving docetaxel and gemcitabine hydrochloride, also receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16401108|NCT03971474|Experimental|Arm B (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16401109|NCT03971461|Experimental|Lutathera|
16401110|NCT03971448|Active Comparator|Fiberglass above-knee walking cast (AKWC)|The standard treatment arm will be a posterior splint placed in the ED by the ED clinical team (nurse/physician) and then a fiberglass AKWC to be placed ideally within 72 hours in the fracture clinic. This AKWC will be in place for 3 weeks, which is currently the most common strategy to manage TF.
16401111|NCT03971448|Experimental|Landmark Pediatric Walker Boot (LPWB)|The Landmark Pediatric Walker Boot (LPWB) will be placed in the ED and will be kept on for a minimum of one week, and then for a duration dictated by the patient's comfort.
16401112|NCT03971435||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360)
16401116|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm I (binimetinib, avelumab)|Patients will receive a 15-day lead-in of binimetinib, followed by binimetinib PO BID and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16401117|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm II (anti-OX40 antibody PF-04518600, avelumab)|Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16401118|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm III (utomilumab, avelumab)|Patients will receive a 15-day lead-in of utomilumab, followed by utomilumab IV over 60 minutes every 4 weeks and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16401159|NCT03971097|Active Comparator|Control Group (TAU)|Participants of the study who will receive the normal programming schedule or treatment as usual (TAU).
16401321|NCT03970109|Active Comparator|ANS-6637 - 600mg|600 mg ANS-6637 (given as 2 x 300 mg tablet) once a day
16401120|NCT03971409|Experimental|Arm B (avelumab, sacituzumab govitecan)|Patients will receive a 15-day lead-in of sacituzumab govitecan, followed by sacituzumab govitecan on Days 1 and 8 of every 21 day cycle and 10mg/kg avelumab over 60 minutes every 2 weeks. Cycles repeat in the absence of disease progression or unacceptable toxicity.
16401121|NCT03971409|Experimental|Arm C (avelumab, liposomal doxorubicin)|Patients will receive a 15-day lead-in of liposomal doxorubicin, followed by liposomal doxorubicin once every 28 days and 10mg/kg avelumab over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16401122|NCT03971383|Experimental|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
16401123|NCT03971383|Placebo Comparator|Placebo|3 tablets one time, 3 times a day(tid)
16401124|NCT03971370|Experimental|Experimental 1|
16401125|NCT03971370|Experimental|Experimental 2|
16401126|NCT03971370|Active Comparator|Positive Control|
16401127|NCT03971357|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
16401128|NCT03971357|Placebo Comparator|Placebo|Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
16401129|NCT03971344||Family members of newborns extremely premature|Parents and siblings (if any) of infants born at 30 weeks gestational age or less, or with a birthweight less than 1500 grams.
16401130|NCT03971344||Family members of new pediatric oncology patients|Parents and siblings (if any) of patients with new onset (not relapses) pediatric oncologic diagnoses including liquid, solid, and brain cancer.
16401131|NCT03971344||Family members of critical congenital heart defect patients|Parents and siblings (if any) of newborns with critical congenital heart defects who typically undergo surgery by 12 months of life.
16401132|NCT03971344||Family members of children with severe neurological impairment|Parents and siblings (if any) of patients with severe neurologic impairments, associated with substantial functional impairment, relentless progressive deterioration, or substantially shortened life-spans.
16401133|NCT03971331|No Intervention|control group|Patients in control group received usual care that was decided by attending.
16401134|NCT03971331|Experimental|study group|Patients in study group who had been placed the PAC were performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately.
16401135|NCT03971292||Validation phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
16401136|NCT03971292||Prospective phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
16401137|NCT03971266|Experimental|Prevention (Fitbit, PRO diary)|Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.
16401138|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
16401139|NCT03971240|Experimental|outcome of surgically evacuated traumatic ASDH|we will operate patients with traumatic acute subdural hematoma with some criteria and evaluate the outcome of surgery
16401140|NCT03971227|Experimental|Acuity 200 contact lens|Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
16401141|NCT03971227|Active Comparator|Acuity 100 contact lens|Rigid gas permeable contact lens for daily wear, hexafocon A
16401142|NCT03971214|Experimental|PD-1 inhibitor JS-001 consolidation for SCLC|The extensive-stage SCLC patients will receive PD-1 inhibitor JS-001 treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
16401143|NCT03971201|Experimental|Surgery plus sorafenib|surgical resection followed by adjuvant sorafenib
16401144|NCT03971201|Active Comparator|sorafenib only|sorafenib only
16401145|NCT03971188|Experimental|Internal Brace|Patients will undergo Internal Brace procedure for thumb CMC OA.
16401146|NCT03971188|Active Comparator|LRTI|Patients will undergo ligament reconstruction tendon interposition (most commonly performed surgery for thumb CMC OA) and serve as control group.
16401147|NCT03971175|Active Comparator|Forceps group|
16401148|NCT03971175|Experimental|Cryobiopsy group|
16401149|NCT03971162|Experimental|Group A|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 3 months. Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
16401150|NCT03971162|Experimental|Group B|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 6 months.Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
16401151|NCT03971149|Experimental|Behavorial intervention|
16401152|NCT03971136|Other|Children with sickle cell disease|Child from 12 months to 18 years old admitted for vaso-occlusive crisis
16401153|NCT03971123|Experimental|AC-SD-03 (for Part 1)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
16401154|NCT03971123|Experimental|AC-LMP-01 (for Part 1)|Tricaprilin LMP formulation, single dose (20g tricaprilin). Administered orally.
16401155|NCT03971123|Experimental|AC-SD-03P (for Part 1)|Placebo formulation, single dose. Administered orally
16401156|NCT03971123|Experimental|AC-1202 (for Part 2)|Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
16401157|NCT03971123|Experimental|AC-SD-03 (for Part 2)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
16401158|NCT03971110|Experimental|Zoladex and Casodex|Subjects who are diagnosed with advanced prostate cancer at clinical stage of T3 and T4 (N0 or N1, M0 or M1 with five or fewer extra-pelvic lesions) are the target population of this study. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
16401322|NCT03970109|Placebo Comparator|Matched Placebo|2 placebo tablets once a day
16401160|NCT03971097|Experimental|Experimental Group (TAU plus self-forgiveness model)|Participants of the study who will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Everett L. Worthington.
16401163|NCT03971071|Placebo Comparator|Placebo|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
16401164|NCT03971071|Active Comparator|Erenumab 70 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
16401165|NCT03971071|Active Comparator|Erenumab 140 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
16401166|NCT03971058|Active Comparator|young individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
16401167|NCT03971058|Active Comparator|elderly individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
16401168|NCT03971045|Experimental|Pembrolizumab and metronomic cyclophosphamide|.Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
16401169|NCT03971032|Other|Women undergoing hysteroscopy|Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
16401170|NCT03971019|Experimental|Statin therapy (experimental group)|"On the basis of guiding patients to control their diet and improve their lifestyle, etc.
~Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)"
16401171|NCT03971019|Other|Dietary intervention group (control group)|Guiding patients to control diet, improve lifestyle, etc.
16401172|NCT03971006||Immunocompetent ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
16401173|NCT03971006||Immunosuppressed ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above). These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
16401174|NCT03971006||Controls|(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression. These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
16401175|NCT03970993|Experimental|Group 1a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart and an optional booster vaccination 12 months after the third dose
16401176|NCT03970993|Experimental|Group 2a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
16401177|NCT03970993|Experimental|Group 3a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
16401178|NCT03970993|Experimental|Group 4a|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
16401179|NCT03970993|Experimental|Group 5|Volunteers will receive 2 doses of 10μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 2μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
16401180|NCT03970993|No Intervention|Group 6|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
16401181|NCT03970993|No Intervention|Group 7|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
16401182|NCT03970993|Experimental|Group 1b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M, 4 weeks apart followed by an optional vaccination booster 12 months after the third dose.
16401183|NCT03970993|Experimental|Group 2b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks.
16401184|NCT03970993|Experimental|Group 3b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart.
16401185|NCT03970993|Experimental|Group 4b|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks.
16401186|NCT03970980|Experimental|FIO2 >90% group|This group receives FIO2 >90% during the surgery.
16401187|NCT03970980|Active Comparator|FIO2 <70% group|This group receives FIO2 <70% during the surgery.
16401188|NCT03970967|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16401189|NCT03970954|Experimental|1|Low-dose IL-2
16401190|NCT03970941||CERAMENT|Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.
16401191|NCT03970941||NO CERAMENT COMPARATIVE COHORT|Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.
16401229|NCT03970720|Experimental|T1DM - Unaware: Metoclopramide|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
16401291|NCT03970330|Experimental|Low-Dose Naltrexone|12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
16401192|NCT03970928|Active Comparator|goal-directed fluid management (GDFM)|A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
16401193|NCT03970928|No Intervention|Conventional fluid management group (CFMG)|This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
16401194|NCT03970915|Experimental|ON (standard warming process + body warmer)|Patients included during the ON periods will constitute the experimental group. Warming will be provided by the body warmer in addition to the standard warming procedure (survival blanket and heating in the emergency vehicle).
16401195|NCT03970915|Sham Comparator|OFF / Control group (standard warming process )|Patients included during the OFF periods will constitute the control group. Warming will be provided by the standard warming procedure : survival blanket and heating in the emergency vehicle.
16401196|NCT03970902||Integrated Osteoporosis Care|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis in whom a complex patient-tailored intervention is provided.
16401197|NCT03970902||Care As Usual|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis receiving care as usual for the management of osteoporosis.
16401198|NCT03970889|No Intervention|Standard Care|Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
16401199|NCT03970889|Experimental|Klue|Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
16401200|NCT03970876|Experimental|ATGC-100 (Phase I/II)|ATGC-100 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
16401201|NCT03970876|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
16401202|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Males|Arm 1 - Urine from males subjects
16401203|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Females|Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects
16401204|NCT03970850|Active Comparator|Multi-arm - FDA cleared NAATs (Comparator)|Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)
16401205|NCT03970837|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
16401206|NCT03970837|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
16401207|NCT03970837|Active Comparator|Tofacitinib 5 mg|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
16401208|NCT03970837|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
16401209|NCT03970837|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
16401210|NCT03970837|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
16401211|NCT03970824|Experimental|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
16401212|NCT03970824|Active Comparator|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
16401213|NCT03970824|Active Comparator|EU-approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
16401214|NCT03970811|Experimental|Immediate implants with immediate temporization|Immediate implants with simultaneous immediate placement of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
16401215|NCT03970811|Active Comparator|Immediate implants without temporization|Immediate implants without the use of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
16401216|NCT03970798|Experimental|KW-6356/Healthy Japanese adult male subjects|Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
16401217|NCT03970772|Experimental|Glucagon injection|Dilute Glucagon (1 mg/ml)
16401218|NCT03970772|Active Comparator|Glucose tablets|Dextrose glucose tablets
16401219|NCT03970759||Stannous Fluoride Dentifrice|Twice daily brushing
16401220|NCT03970759||Positive Control Dentifrice|Twice daily brushing
16401221|NCT03970759||Negative Control Dentifrice|Twice daily brushing
16401222|NCT03970746|Experimental|Cohort A1|PDC*lung01 Low Dose
16401223|NCT03970746|Experimental|Cohort A2|PDC*lung01 High Dose
16401224|NCT03970746|Experimental|Cohort B1|PDC*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment
16401225|NCT03970746|Experimental|Cohort B2|PDC*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment
16401226|NCT03970733|Experimental|VLA15 with Alum lower dose|Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
16401227|NCT03970733|Experimental|VLA15 with Alum higher dose|Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
16401228|NCT03970733|Placebo Comparator|Placebo|Main Study Phase: placebo - Booster Phase: arm discontinued
16401231|NCT03970720|Placebo Comparator|T1DM - Aware: Placebo|T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
16401232|NCT03970707|Experimental|Small Number of Players training protocol A|Small Sided Game: 4 vs 4
16401233|NCT03970707|Experimental|Large Number of Players training protocol B|Small Sided Game: 8 vs 8
16401234|NCT03970707|No Intervention|Control|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
16401235|NCT03970694|Experimental|Neoadjuvant chemoradiotherapy group|Neoadjuvant chemoradiotherapy（XELOX * 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
16401236|NCT03970694|Other|Neoadjuvant chemotherapy group|Arm Type: control. Neoadjuvant chemotherapy（XELOX * 4）→ Surgery (if possible) → post-surgery chemotherapy.
16401237|NCT03970668||Linagliptin plus insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment with linagliptin plus insulin
16401238|NCT03970668||Insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment only with insulin
16401239|NCT03970655|Experimental|Group 1|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine with epinephrine 1:200.000 with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa fo 4 milliliters of 0.5% Bupivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side)
16401240|NCT03970655|Experimental|Group 2|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine with epinephrine 1:200.00 with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side).
16401241|NCT03970642|Experimental|Intervention group|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will receive the video directly observed therapy smartphone app. Research staff will be able to monitor these medication adherence video on a password protected server linked to the app. Upto 50 patients will be randomly assigned to this group.
16401242|NCT03970642|No Intervention|Control|The control group will receive current standard of care. Upto 50 patients will be randomly assigned to this group.
16401243|NCT03970629|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA via ROSA Robot
16401244|NCT03970629|Active Comparator|Conventional TKA|Conventional TKA
16401245|NCT03970616|Experimental|Tivozanib in Combination with Durvalumab|Tivozanib in Combination with Durvalumab
16401246|NCT03970603|Active Comparator|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
16401247|NCT03970603|Active Comparator|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
16401248|NCT03970590|Experimental|CTC|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
16401249|NCT03970590|Active Comparator|Control|6-month HTN management assessment text messages without narrative component
16401250|NCT03970577|Experimental|Rituximab treatment|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
16401251|NCT03970577|Active Comparator|Oral steroid treatment|"The patients will continue exclusive oral steroid treatment, that will be progressively tapered, for a total of 24 weeks (by taking into account the initial oral steroid therapy administered during 8 weeks and the oral steroid treatment given after randomization).
~Each patient will be followed up until 18 months after randomization. The patient will have study visits at inclusion, 4 weeks and 8 weeks after inclusion. At the time of randomization, patients who will have reached CR of MCNS will be allocated in test or control group and will be followed up similarly: visits at 1, 4, 16, 24 weeks, 12 and 18 months after randomization."
16401252|NCT03970564||Suspected lung cancer|Suspected and later on confirmed lung cancer with evidence of mediastinal lymphadenopathy on computerised tomography
16401253|NCT03970551|No Intervention|No Physical Intervention|The participant will actively stand up from a seated position without performing any physical counter-maneuvers either prior to or following the stand.
16401254|NCT03970551|Experimental|Supine Knee Raises|The participant will perform 30 seconds of raising their knees to their chest while sitting down before actively standing.
16401255|NCT03970551|Experimental|Leg Crossing|The participant will actively stand and then immediately cross their legs and tense their leg muscles for 60 seconds.
16401256|NCT03970551|Experimental|Cold Pressor Test|The participant will submerge their hands in ice water for approximately 45 seconds.
16401257|NCT03970551|Experimental|Serial 7's Stress Test|The participant will perform a mental arithmetic stress test for 30 seconds prior to standing.
16401258|NCT03970551|Experimental|Functional Electrical Stimulation|The participant will have their quadriceps passively contracted using mild electrical stimulation for approximately 30 seconds prior to standing.
16401260|NCT03970525||Venturi pump|This cohort will receive femtosecond laser cataract surgery with Venturi pump.
16401261|NCT03970525||Peristaltic vacuum pump|This cohort will receive femtosecond laser cataract surgery with peristaltic pump.
16401262|NCT03970499|Experimental|glial cerebral tumor|patient with an indication of glial cerebral tumor surgery
16401263|NCT03970486|Active Comparator|Needle Manipulation|Participant will receive dry needling intervention with manipulation.
16401264|NCT03970486|Active Comparator|In Situ|Participant will receive dry needling intervention without manipulation.
16401265|NCT03970473|Active Comparator|PRM 30 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 30 cm H2O in the semi-fowler position.
16425595|NCT03801889|Experimental|Cohort 3|SP-420 initially at 84 mg/kg
16401266|NCT03970473|Active Comparator|PRM 15 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 15 cm H2O in the semi-fowler position.
16401267|NCT03970460|Active Comparator|45-54 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
16401268|NCT03970460|Active Comparator|55-59 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
16401269|NCT03970460|Experimental|45-54 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
16401270|NCT03970460|Experimental|55-59 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
16401271|NCT03970447|Active Comparator|Control Arm|"Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.
~Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles."
16401272|NCT03970447|Experimental|Regorafenib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
~Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)."
16401273|NCT03970447|Experimental|Paxalisib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles.
~Recurrent GBM: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 21 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 21 days for all subsequent cycles."
16401274|NCT03970447|Experimental|VAL-083 Treatment Arm|"Newly Diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle.
~Recurrent GBM: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle."
16401275|NCT03970434|Experimental|Metformin|
16401276|NCT03970421||patients without anticoagulant and / or antiplatelet treatment|Patients older than 16yo with no anticoagulant or antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
16401277|NCT03970421||patients on antiplatelet therapy (ASA and / or clopidogrel|Patients older than 16yo on antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
16401278|NCT03970421||patients on treatment with acenocoumarol and INR <2|Patients older than 16yo on acenocumarol and with INR <2 attended at ED because of Head Injury and with a Head CT performed.
16401279|NCT03970421||Others|patients on anticoagulant therapy with acenocoumarol and INR> = 2 or patients on treatment with direct thrombin inhibitors (dabigatran), or inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or patients on treatment with low molecular weight heparins (LMWH) attended at ED because of Head Injury and with a Head CT performed.
16401280|NCT03970408||Carpal tunnel syndrome|"Patients with CTS who fulfill the following eligibility criteria:
~Inclusion criteria
~Females and male patients referred with a CTS diagnosis confirmed by nerve conduction studies and positive Tinel and Phalen tests.
~Age ranging from 30-50 years old.
~The selected patient will be able to tolerate the entire standard neurodynamic technique.
~Exclusion criteria
~Symptoms referred to the neck.
~Sever CTS
~More than 10% limitation of neck flexion, rotation, and side bending ranges.
~History of disease, trauma, or surgery to neck, thorax, or upper limbs.
~Presence of peripheral neuropathy or cervical radiculopathy.
~History of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity."
16401281|NCT03970408||Healthy control|Asymptomatic healthy age-matched control with no symptoms or history of upper quadrant disease, dysfunction, trauma or surgery.
16401282|NCT03970395|Experimental|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).
~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
16401283|NCT03970395|Sham Comparator|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)
~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
16401284|NCT03970382|Experimental|NeoTCR-P1|Single dose of NeoTCR-P1
16401285|NCT03970382|Experimental|NeoTCR-P1 plus nivolumab|Single dose of NeoTCR-P1 plus nivolumab 480mg IV every four weeks for up to 6 doses.
16401286|NCT03970382|Experimental|NeoTCR-P1 plus IL-2|Single dose of NeoTCR-P1 plus IL-2 500,000 IU/m2 SC twice daily (BID) for 7 days.
16401287|NCT03970369|Experimental|Monitor|Activity monitoring with feedback. Participants in the Monitor group will wear a step counter to track if the activity prescription is being met.
16401288|NCT03970369|Active Comparator|Usual care|All children will receive the usual care, which includes personalized goals and an activity prescription. Participants in the usual care group will not receive a step counter.
16401289|NCT03970356|Experimental|intervention|The antibiotic stewardship intervention will encourage to prescribe according to the latest relevant UTI guidelines which promote more restrictive use of antibiotics in case of non-specific symptoms.
16401290|NCT03970356|No Intervention|control|Usual care
16401292|NCT03970330|Placebo Comparator|Placebo|12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
16401293|NCT03970317|Experimental|Broad Band Light|Broad Band Light (BBL) motion treatment
16401297|NCT03970291|Experimental|Nociceptive-Level (NOL)|Analgesic component of anesthesia (fentanyl) will be guided using NOL
16401298|NCT03970291|No Intervention|Standard Clinical Care (SCC)|Standard Clinical Care guided fentanyl administration
16401299|NCT03970278||All Participants|All participants enrolled in study 401GSDIA02 will have received a single IV dose of DTX401 during their participation in study 401GSDIA01 (NCT03517085).
16401300|NCT03970252|Experimental|Treatment (nivolumab, mFOLFIRINOX)|Patients receive nivolumab IV over 60 minutes on day 1. Patients also receive fluorouracil IV over 10 minutes and over 46 hours, irinotecan hydrochloride IV over 90-120 minutes, leucovorin calcium IV over 120 minutes, and oxaliplatin IV over 120 minutes on days 1 and 15. Treatments repeat every 28 days for 3-6 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients with resectable disease undergo surgery. Within 8-12 weeks after surgery, patients with successful resection may receive 6 additional cycles of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in the absence of disease progression or unacceptable toxicity.
16401301|NCT03970239|Experimental|Parkinson's Disease patients|"All study participants undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). [11C] -DASB is a highly specific PET radiotracer which binds to the serotonin transporter (SERT).
~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
16401302|NCT03970239|Experimental|Imaging of healthy volunteers|"All healthy volunteers undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [18F]-altanserin.
~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
16401303|NCT03970226|Experimental|Tocilizumab Administration: Phase 0|In Phase 0, patients will receive one dose of tocilizumab prior to surgery.
16401304|NCT03970226|Experimental|Tocilizumab Administration: Feasibility Phase|During the Feasibility Phase, patients will receive tocilizumab every 2 weeks for up to 13 cycles (approximately 1 year). Patients will be followed for up to 5 years.
16401305|NCT03970213|Placebo Comparator|Control Group|Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
16401306|NCT03970213|Experimental|TXA Group|One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
16401307|NCT03970200|Active Comparator|No investigational product|Participants who receive the antibiotics usually prescribed for C diff infection.
16401308|NCT03970200|Experimental|Upper gastrointestinal FMT|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor
16401309|NCT03970200|Experimental|Lower gastrointestinal FMT|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).
16401310|NCT03970187|Experimental|Exposure|Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks
16401311|NCT03970187|No Intervention|Control|"Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention.
~Phase 2 (home training): waitlist"
16401312|NCT03970174|Experimental|Intervention|Two of the 4 Medicine wards will have implemented the care transition module of Care Connector
16401313|NCT03970174|No Intervention|Control|Remaining 2 of 4 Medicine wards will use all other aspects of Care Connector (except for care transition module)
16401314|NCT03970161|Experimental|T2DM Patients|Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
16401315|NCT03970161|Experimental|healthy control subjects|All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
16401316|NCT03970148|Experimental|Nd: YAG laser treatment|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
16401317|NCT03970135|Experimental|Fasting|
16401318|NCT03970122|Experimental|GFB-887 SAD active|GFB-887 single dose active
16401319|NCT03970122|Placebo Comparator|GFB-887 SAD placebo|GFB-887 single dose placebo
16401320|NCT03970109|Active Comparator|ANS-6637 - 200mg|200 mg ANS-6637 (given as 2 x 100 mg tablet) once a day
16401323|NCT03970096|Experimental|Arm A1 (TBI, TnD)|Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
16401324|NCT03970096|Experimental|Arm A2 (busulfan, TnD)|Patients receive fludarabine IV over 30 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
16401325|NCT03970096|Experimental|Arm C1 (TBI, PTCy, tacrolimus)|Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
16401326|NCT03970096|Experimental|Arm C2 (busulfan, PTCy, tacrolimus)|Patients receive fludarabine IV over 30 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
16401327|NCT03970096|Experimental|Arm D1 (TBI, tacrolimus, methotrexate)|Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
16401328|NCT03970096|Experimental|Arm D2 (busulfan, tacrolimus, methotrexate)|Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
16401329|NCT03970083||Oxygen Levels in Tumors|-Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences
16401330|NCT03970070|Experimental|Health service research (Periop-OSMT)|Patients and/or support persons/family caregivers complete Periop-OSMT session in-person or via telephone over 20-40 minutes before surgery and before hospital discharge and group telehealth session over 1.5-2 hours at weeks 1-3, 4, 5, 6, and 7 post discharge
16401331|NCT03970057|Experimental|MoodUP|
16401332|NCT03970057|Placebo Comparator|HealthyMUM|
16401333|NCT03970044|Experimental|Exenatide 2 mg plus Dapagaliflozin 10 mg|Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
16401334|NCT03970044|Active Comparator|Exenatide 2 mg|Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment
16401335|NCT03970044|Active Comparator|Dapagaliflozin 10 mg|Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
16401336|NCT03970031|Active Comparator|MSDC-0602K|MSDC-0602K one tablet per day taken orally
16401337|NCT03970031|Placebo Comparator|Placebo|Placebo one tablet per day taken orally
16401338|NCT03970018||Autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease (ADPKD) patients starting peritoneal dialysis for end stage renal failure will be included in this study.
16401339|NCT03969992|Other|nCPAP alone|Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary
16401340|NCT03969992|Experimental|Drug: Low Dose AeroFact|AeroFact-low dose SF-RI 1
16401341|NCT03969992|Experimental|Drug: High Dose AeroFact|AeroFact-high dose SF-RI 1
16401342|NCT03969979||testis with epididymo-orchitis|The patients' previously inflamed testis with epididymo-orchitis
16401343|NCT03969979||healthy testis|The patients' non inflamed testis
16401344|NCT03969953|Experimental|Rivaroxaban|Rivaroxaban 2.5mg, twice daily.
16401345|NCT03969953|Placebo Comparator|Placebo|Matched placebo, twice daily.
16401346|NCT03969940||Thermo|Buruli ulcer patients receiving thermotherapy
16401347|NCT03969940||Chemo|Buruli ulcer patients receiving chemotherapy
16401348|NCT03969927|Experimental|Low-Fidelity PDS Training|Individuals with stroke, PD, or MS
16401349|NCT03969927|Active Comparator|High Fidelity Fixed-Base Simulator Training|Individuals with stroke, PD, or MS
16401350|NCT03969914||Critically ill ventilated patients|Patients admitted to ICU with expected mechanical ventilation >48h
16401351|NCT03969901|Experimental|IMI/REL|Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
16401352|NCT03969901|Active Comparator|Active Control|Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.
16401357|NCT03969862||Patient with an allergen-mediated IgE allergy|Patients with a clinical history consistent with an allergen-mediated IgE allergy & with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
16401358|NCT03969862||Patient without an allergen-mediated IgE allergy|Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
16401359|NCT03969849|Experimental|Part A: Cohort 1|Part A: Cohort 1 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
16401360|NCT03969849|Experimental|Part A: Cohort 2|Part A: Cohort 2 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
16401361|NCT03969849|Experimental|Part A: Cohort 3|Part A: Cohort 3 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
16401362|NCT03969849|Experimental|Part A: Cohort 4|Part A: Cohort 4 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
16401363|NCT03969849|Experimental|Part B|Part B: Randomized 1:1 will receive REGN5713-5714-5715 or matching placebo in Healthy Participants with birch pollen allergy
16401364|NCT03969836|Experimental|NeurOS Group|All patients will have both INVOS and NeurOS systems placed before and during cardiac surgery for monitoring cerebral oxygenation and brain blood volume.
16401365|NCT03969823|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
16401366|NCT03969810|Experimental|Rounding Summary|"Surrogates who are assigned to the intervention group will receive a written rounding summary every day or every other day that the patient is in the ICU. The summary will be organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
~For patients assigned to the intervention group, the investigators will forward the previous day's summary to the ICU nurse at the beginning of each day shift. After participating in morning rounds, ICU nurses will be asked to modify the summary based on the plan for the day. Nurses will be asked to use the written summary to guide communication with surrogates that day."
16401367|NCT03969810|No Intervention|Usual Care|Usual ICU care
16401368|NCT03969784|Experimental|colorectal cancer patient with peritoneal carcinosis|
16401369|NCT03969784|Active Comparator|colorectal cancer patient without metastasis|
16401370|NCT03969771|Experimental|Frequently Absent|8 weeks of training in Mindfulness-Based Stress Reduction
16401371|NCT03969771|Active Comparator|Normal Attendees (Controls)|8 weeks of training in Mindfulness-Based Stress Reduction
16401372|NCT03969758|Active Comparator|Ciprofloxacin plus Metronidazole therapy|Will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks. Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
16401373|NCT03969758|Active Comparator|Cefixime plus Metronidazole Therapy|Will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks.Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
16401374|NCT03969745|Experimental|Time restricted feeding (TRF)|Participants restricted their daily energy intake window to between 8 am and 4 pm for two weeks. They were encouraged to not alter the quantity and composition of their diet or alter physical activity patterns.
16401375|NCT03969745|Active Comparator|Caloric deficit|The investigators observed significant weight loss in the TRF group with participants reporting to consume ~400 kilocalories less per day. Therefore the investigators added a caloric deficit group to control for the effects of weight loss on metabolism. Total energy expenditure was measured for one week and was used to prescribe a 400 kilocalories/day energy deficit diet to follow for two weeks.
16401376|NCT03969732|Experimental|amyloid PET、T807 PET|PET/CT
16401377|NCT03969719|Placebo Comparator|Placebo|Palacebo
16401378|NCT03969719|Experimental|Low Dose|150 mg
16401379|NCT03969719|Experimental|High Dose|300 mg
16401380|NCT03969706|Experimental|Single Arm|Abemaciclib 200mg tablet PO twice daily administered on 28-day cycles Subjects remain on treatment until tumor progression or unacceptable toxicity.
16401381|NCT03969693||The patients with mediastinal malignant lymphoma|Patients whose radiation therapy field essentially encompasses anterior mediastinum; namely, the majority of malignant lymphoma patients with mediastinal involvement.
16401382|NCT03969680|Experimental|BMSCs plus PRP group|Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
16401383|NCT03969680|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
16401384|NCT03969667||healthy young adults|healthy young adults
16401385|NCT03969654|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA
16401386|NCT03969654|Active Comparator|Conventional TKA|Conventional TKA
16401443|NCT03969186|No Intervention|Standard of care follow-up|Standard of care
16401387|NCT03969641|Experimental|RIV4|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
16401388|NCT03969641|Active Comparator|IIV4|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
16401389|NCT03969628|Experimental|Multivariate risk assessment group (ICCMS®)|Multivariate risk assessment group (ICCMS®): multivariate caries risk assessment based on International Caries Classification and Management System (ICCMS™) guide
16401390|NCT03969628|Experimental|Simplified risk assessment group (dental caries experience)|Simplified risk assessment group (dental caries experience): simplified caries risk assessment based on dental caries experience (WHO criteria)
16401391|NCT03969615|Active Comparator|Supplemental oxygen|5lpm of supplemental oxygen via a nasal cannula or face mask
16401392|NCT03969615|Experimental|SuperNO2VA nasal positive airway pressure device|Intervention arm will receive the SuperNO2VA nasal positive pressure device at 10lpm
16401393|NCT03969602|Experimental|Experimental Group|Participants randomized will receive six individual 1-hour sessions of CBT: two sessions before the operation and four after, delivered by a psychologist trained in CBT for chronic pain. The CBT intervention is tailored to reduce pain catastrophizing. Main techniques are: pain education and the influence of cognitions, emotions and behavior on pain and pain disability; identification of catastrophizing cognitions and replacing them with more adaptive cognitions; stress/anxiety reduction by diaphragmatic breathing and progressive muscle relaxation; emotion regulation skills training; cognitive restructuring; coping skills training to combat helplessness and foster a sense of control and self-efficacy for dealing with acute post-operative pain. The four postoperative sessions build on and further extend the skills learned preoperatively. Each session ends with specific homework assignments. All patients receive a homework book and an individually tailored instruction manual.
16401394|NCT03969602|Active Comparator|Control Group|Participants will have six meetings with members of the research team (in person or through telephone). In a first preoperative meeting a member of the team provides verbal information on the preparation for surgery, surgery itself and recovery from surgery, stressing the importance of postoperative exercise. Any questions raised by the patient are discussed. A booklet is provided with information about: structure of the spinal column and spinal diseases; examinations before surgery; the operative environment; surgical procedures; anesthetic procedures; postoperative care and postoperative pain reduction. A second preoperative (telephone) meeting is scheduled to answer any remaining questions. During the postoperative phase, instructions and an exercise manual are provided, Patients keep a diary to record their training activity. Three, six and eight months after discharge patients are contacted by telephone and their training progress is discussed.
16401395|NCT03969602|No Intervention|Observational Group (low catastrophizing)|Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
16401396|NCT03969589|Experimental|Reproductive Life Planning-Mental Health Intervention|Reproductive Life Planning-Mental Health (RLP-MH) intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
16401397|NCT03969589|Other|Written materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
16401398|NCT03969576|Experimental|DEB-TACE|172 subjects in this study group will be receive the treatment of drug-eluting bead TACE
16401399|NCT03969576|Active Comparator|cTACE|172 subjects in this study group will be receive the treatment of conventional TACE
16401400|NCT03969563|Experimental|MBSR|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
16401401|NCT03969563|Active Comparator|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
16401402|NCT03969537||Telemedicine|The patients selected to participate in the study are cervical dystonia (CD) patients who receive treatment at Vanderbilt University Medical Center, where the study takes place.
16401403|NCT03969511|Experimental|Direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is then performed as well as intravenous thrombolysis when contraindications are excluded.
16401404|NCT03969511|Active Comparator|Standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
16401405|NCT03969498||1- Obstetric APS women (oAPS)|No intervention, pure observational study.
16401406|NCT03969498||2-Women positive for F5rs6025 or F2rs1799963 polymorphis|No intervention, pure observational study.
16401407|NCT03969498||3-Women with negative thrombophilia screening (Control group|No intervention, pure observational study.
16401408|NCT03969485|Experimental|Hybrid Fractional Laser|Hybrid Fractional Laser Treatment
16401409|NCT03969472|Experimental|probiotic group|apply probiotic after surgery
16401410|NCT03969472|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery without probiotic
16401411|NCT03969472|No Intervention|control|without electrophysiologic therapy and probiotic after surgery
16401444|NCT03969173|Active Comparator|PEEP3|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
16401412|NCT03969446|Experimental|Cohort I (pembrolizumab, decitabine)|Patients with AML receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10. Patients who achieve a CR receive decitabine on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
16401413|NCT03969446|Experimental|Cohort II (pembrolizumab, decitabine)|Patients with MDS receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine over 1 hour on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
16401414|NCT03969433|Experimental|Phase I|Data collections are performed with TMSi Porti system and CTG (reference)
16401415|NCT03969433|Experimental|Phases II-III-IV|Data collections are performed with the Bloomlife sensor and CTG (reference)
16401416|NCT03969420|Experimental|Stage 1: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
16401417|NCT03969420|Experimental|Stage 1: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
16401418|NCT03969394|Experimental|Heart Failure Patients|Patients with Heart Failure
16401419|NCT03969381||1 lymphoma patients|pre therapy and post therapy of lymphoma patients
16401420|NCT03969368|Experimental|Treatment Group|Treatment with the investigational device - rPMS
16401421|NCT03969368|Active Comparator|Control Group|Control group
16401422|NCT03969355||Paediatric patients 2008-2012|Paediatric patients admitted to intensive care in 2008-2012 who died during PICU stay
16401423|NCT03969355||Paediatric patients 2013-2017|Paediatric patients admitted to intensive care in 2013-2017 who died during PICU stay
16401424|NCT03969342|Experimental|Trainees|Local mid-level providers who undergo five day training on point of care ultrasound for diagnosing pediatric pneumonia
16401425|NCT03969329|Experimental|Etelcalcetide|Patients will receive etelcalcetide in addition to standard of care
16401426|NCT03969316|Active Comparator|Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
16401427|NCT03969316|Active Comparator|Transversus Abdominis Plane Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound between internal oblique and transversus abdominis muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
16401428|NCT03969303||NOTAL OCT v.2.5 and Commercial OCT on AMD Patients|OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).
16401429|NCT03969290|Experimental|Sequence 1|Verofilcon A contact lens in the right eye (OD), with etafilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
16401430|NCT03969290|Active Comparator|Sequence 2|Etafilcon A contact lens in the right eye (OD), with verofilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
16401431|NCT03969277|Experimental|Graded Motor Imagery|Each subject in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, and home exercises.
16401432|NCT03969277|Active Comparator|Standard Rehabilitation|Each subject in the Standard Rehabilitation group will receive a treatment protocol consisting of stretching and strengthening exercises, cold therapy, and home exercises.
16401433|NCT03969264|Active Comparator|Carb Snacks|Will follow study diet based on the Dietary Guidelines and consume study carbohydrate snacks between meals.
16401434|NCT03969264|Experimental|Tree Nut Snacks|Will follow study diet based on the Dietary Guidelines and consume study tree nut snacks between meals.
16401435|NCT03969251|Experimental|Transcranial Magnetic Stimulation (rTMS)|repetitive transcranial magnetic stimulation
16401436|NCT03969251|Sham Comparator|Sham (SS)|repetitive sham rTMS
16401437|NCT03969238||Patients/Providers|Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
16401438|NCT03969212|Experimental|Baloxavir Marboxil|Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.
16401439|NCT03969212|Placebo Comparator|Placebo|Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.
16401440|NCT03969199|Experimental|MANNA Food Delivery Service|MANNA will deliver meals to patients randomized to the intervention arm of the study every week on the same day for 90 days. Each delivery will include: 7 breakfast meals, 7 lunch meals, 7 dinner entrees, health desserts, and fresh fruit. Meals will be delivered frozen and can be stored in a freezer until ready to eat. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
16401441|NCT03969199|No Intervention|Standard of Care Counseling|Patients randomized to the control arm will receive standard or care dietary counseling from either their physician or a dietician. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
16401442|NCT03969186|Experimental|Daily telehealth follow-up|The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
16401445|NCT03969173|Active Comparator|PEEP6|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
16401446|NCT03969173|Active Comparator|PEEP9|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
16401447|NCT03969160|Experimental|Imaginal exposure|The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
16401448|NCT03969147|Active Comparator|MRI Comparison|MRI images will be obtained of the airways of healthy volunteers both with the ManMaxAirway oropharyngeal airway adjunct and with no airway adjunct in place in order to observe any changes to the airway anatomy caused by placement of the airway adjunct. The order of the scans (with and without airway adjunct) will be determined by randomization software in advance.
16401449|NCT03969147|Experimental|Tolerability Comparison|Healthy volunteers will self-place either the ManMaxAirway oropharyngeal airway adjunct or the Guedel Oropharyngeal airway adjunct, which will be left in place for an interval of one minute, while supervised by research staff. After completing a questionnaire and resting for a timed interval, they will then self-place the other airway adjunct, which will be left in place for the same length of time as the first, before completing another questionnaire. The order in which the devices are placed by each subject will be determined in advance via computer randomization.
16401450|NCT03969147|Active Comparator|Forced Oscillation|Volunteers from the tolerability comparison arm will also be invited as a subset of subjects to participate in a measurement of resistance to forced oscillation. The volunteers will be subject to forced oscillations in a pulmonary function lab with the ManMaxAirway oropharyngeal airway adjunct in place and with no airway adjunct in order to observe changes in resistance to oscillatory airflow
16401451|NCT03969134|Active Comparator|Vaccine arm|ChAd63 KH 7.5x1010 vp, single dose, by IM injection
16401452|NCT03969134|Placebo Comparator|Placebo|Normal Saline, single dose, by IM injection
16401453|NCT03969121|Active Comparator|Placebo + Endocrine therapy|Endocrine therapy for 16 weeks plus placebo
16401454|NCT03969121|Active Comparator|Palbociclib + Endocrine therapy|Endocrine therapy for 16 weeks plus Palbociclib
16401455|NCT03969108|Experimental|Indocyanine Green|
16401456|NCT03969095|Experimental|Immediate|Participants in the immediate intervention arm will begin a 4-week intervention tongue pressure resistance training protocol within 10 days of their baseline Videofluoroscopic Swallowing Evaluation assessment, with 2 face-to-face 1-hour visits per week under direct supervision of a speech-language pathologist. These treatment sessions will be supplemented by daily home practice of the intervention.
16401457|NCT03969095|Active Comparator|Delayed|Participants in the delayed intervention arm will begin their involvement with a 4-week waiting period after the baseline Videofluoroscopic Swallowing Evaluation. Treatment will commence after the second Videofluoroscopic Swallowing Evaluation and will follow the same schedule for the tongue pressure resistance training, supplemented by daily home practice.
16401458|NCT03969082|Experimental|Bibliotherapy|"Students will read to patients receiving active treatment using the read aloud method. This will be performed in a 1: 1 relationship for half an hour for 8-10 times during a period of six months."
16401459|NCT03969069||Fistula/chronic perianal conditions|Participants symptomatic of FI with chronic perianal disease
16401460|NCT03969069||Obstetric injury <12 months|Participants symptomatic of FI < 12 months following obstetric injury.
16401461|NCT03969069||Obstetric injury >12 months|Participants symptomatic of FI >12 months following obstetric injury.
16401462|NCT03969069||Neurogenic|Participants symptomatic of FI with evidence/history of neurological condition.
16401463|NCT03969056|Experimental|Artificial Intelligence (AI) Activity group|Participants in this group receive an AI based intervention (automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning and message)
16401464|NCT03969056|Active Comparator|Control group|Participants in this group receive a standardized and fixed 10,000 daily steps goal intervention.
16401465|NCT03969043|Experimental|Young volunteers|"Volunteers between 18 ans 45 years old
~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
16401466|NCT03969043|Experimental|Older Volunteers|"Volunteers between 60 ans 85 years old
~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
16401467|NCT03969030|Experimental|Intervention|"Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:
~ART Refill
~SMS notifications
~Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery."
16401468|NCT03969030|No Intervention|Control|Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club).
16401469|NCT03969017|Experimental|NAs+Peg IFN Group|NAs+Peg IFN Group will receive the treatment of NAs (patients previously treated with telbivudine will be changed to entecavir) plus pegylated interferon (Peg IFN)α-2b.
16401470|NCT03969017|Other|NAs Group|NAs Group will be treated with NAs as before enrollment.
16401471|NCT03969004|Experimental|Cemiplimab|
16401472|NCT03969004|Placebo Comparator|Placebo|
16401473|NCT03968991|Active Comparator|Healthy volunteer group|male or female healthy volunteers
16401474|NCT03968991|Experimental|Subjects with acquired visual impairment|visual acquired disability
16401476|NCT03968978|Experimental|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
16401477|NCT03968978|Experimental|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
16401478|NCT03968965|Experimental|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
16401479|NCT03968965|Other|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
16401480|NCT03968952|Active Comparator|SMARThealth Pregnancy|"The components of the SMARThealth Pregnancy intervention include:
~Educational and Training component on high-risk pregnancy conditions, focusing on; Anaemia, Hypertensive Disorders of Pregnancy (HDPs) and Gestational diabetes mellitus (GDM).
~An mHealth platform providing clinical decision support, lifestyle advice, recall and reminder system for Community Health Workers (CHWs) and Primary Care Physicians (PCPs).
~Pregnant women in the intervention group will receive 3 visits at home by their CHW, in addition to their standard antenatal and postnatal care. One visit during the third trimester of pregnancy; one during Week 1 postpartum and; one visit during Week 6 postpartum."
16401481|NCT03968952|No Intervention|Enhanced Standard Care|"The control group will receive enhanced standard antenatal and postnatal care, involving:
~An awareness programme for pregnant women, Community Health Workers (CHWs) and Primary Care Physicians (PCPs), held at the villages within the control group Primary Health Centre (PHC) cluster (Enhanced Standard Care). The community and health professionals will receive information on the high-risk conditions of anaemia in pregnancy, HDPs and GDM as part of the awareness programme.
~Standard antenatal and postnatal care (consisting of free monthly antenatal care, and up to 7 postnatal visits), delivered by CHWs in partnership with their PHC doctor."
16401485|NCT03968926||Vasoplegic ECMO|All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2
16401486|NCT03968913|Placebo Comparator|Control|Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
16401487|NCT03968913|Active Comparator|One dose Anakinra, one dose placebo|Subjects will receive one injection of sterile saline and one injection of anakinra after ACL injury, prior to surgery
16401488|NCT03968913|Active Comparator|Two doses Anakinra|Subjects will receive two injections of anakinra after ACL injury, prior to surgery
16401489|NCT03968900|Experimental|Sleep Restriction|4 hours time in bed (1 am to 5 am)
16401490|NCT03968900|Experimental|Sleep Extension|10 hours time in bed (10 pm to 8 am)
16401491|NCT03968887||Case group|Patients with postoperative delirium.
16401492|NCT03968887||Control group|Patients who have not had postoperative delirium.
16401493|NCT03968874|Experimental|Light box|Commercially available lightbox emitting 10,000 lux of light. Subjects asked to use lightbox everyday for an hour for 4 weeks upon waking.
16401494|NCT03968874|Sham Comparator|Negative Ion Generator|Commercially available negative ion generator. Subjects asked to use everyday for an hour for 4 weeks upon waking.
16401495|NCT03968861||Standard care with moderate hypothermia|Surviving children allocated to standard care with moderate hypothermia in the TOBY-Xe trial
16401496|NCT03968861||30% Xenon for 24 hours combined with moderate hypothermia|Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial
16401497|NCT03968848|Experimental|Subjects with Severe Hepatic Impairment|Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
16401498|NCT03968848|Experimental|Matched-Control Subjects|Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
16401499|NCT03968835||Biological Dressings|Bacitracin will be applied and covered with xeroform and gauze
16401500|NCT03968835||Artificial Dressings|the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft
16401501|NCT03968822|Experimental|Intralipid 20% IV Bolus|
16401502|NCT03968822|Placebo Comparator|Saline|
16401503|NCT03968809||Standard Coronary Artery Disease Screening|All patients presenting for standard coronary artery disease screening will undergo additional imaging with CardioFlux MCG. These patients will be followed longitudinally for short and long term MACE.
16401504|NCT03968796|Active Comparator|Group 1|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.
~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
16401505|NCT03968796|Active Comparator|Group 2|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.
~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
16401506|NCT03968796|Active Comparator|Group 3|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.
~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
16401507|NCT03968796|Placebo Comparator|Group 4|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.
~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
16401508|NCT03968783|Experimental|Monofilament suture|continuous double-layer unlocked suturing with 1.0 monofilament synthetic absorbable suture
16401509|NCT03968783|Active Comparator|Multifilament suture|continuous double-layer unlocked suturing with 1.0 multifilament synthetic absorbable suture
16401510|NCT03968770|Experimental|Experimental group|Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
16401511|NCT03968770|Placebo Comparator|Control group|Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
16401512|NCT03968757||Obese patients eligible for laparoscopic RYGB surgery.|
16401513|NCT03968744|Experimental|Safinamide|PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day
16401514|NCT03968731|Experimental|ZEST treatment|The study subjects will receive the ZEST treatment protocol (Zocular Eyelid System treatment) to treat Meibomian Gland Dysfunction causing Contact Lens discomfort symptoms.
16401515|NCT03968718|Experimental|Systematic ePROMs Assessment|"Intervention: The intervention is constituted by a Systematic ePROMs Assessment in routine cancer care in a comprehensive cancer centre.
~This will involve preliminary sensitization and training of both clinicians and patients towards the use of ePROMs.
~Data filled in by patients through electronic devices will be prompt made available to the clinician during the patient examination."
16401516|NCT03968679|Experimental|Unilateral elective nodal irradiation|Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.
16401517|NCT03968666||Gynecological surgery with ERAS protocol|Patients scheduled for benign gynecological surgery under ERAS protocol
16401519|NCT03968640|Active Comparator|CoQ10 group|The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
16401520|NCT03968640|Placebo Comparator|Placebo|Allocation-concealed placebo will be used as an appropriate control.
16401521|NCT03968627||Protocol application|The study describes the method and the criteria used in the development of the protocol, the steps followed in its implementation in two Don Gnocchi Foundation Pilot Hospitals
16401522|NCT03968614|Experimental|Electrical Dry Needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
16401523|NCT03968614|Active Comparator|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
16401524|NCT03968601||cohorte 1|Severe primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
16401525|NCT03968588|Experimental|reduced-dose tacrolimus + standard-dose MMF|Tacrolimus dose was individually adjusted with a target trough blood level of between 3ng/mL and 8ng/mL throughout the study period (6 months after transplantation). MMF started within 72 hours after transplantation and the dose of MMF was 1.5~2.0g per day.
16401526|NCT03968588|Active Comparator|standard-dose tacrolimus + reduced-dose MMF|Control group, target trough blood level was between 5ng/mL and 15ng/mL throughout the study period. MMF dose was 0.5~1g per day and MMF started within 72 hours after transplantation.
16401527|NCT03968575|Experimental|Laser|
16401528|NCT03968562|Active Comparator|2% Doxycycline Cream in Generic Aquaphor|2% Doxycycline Cream in Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Placebo Comparator
16401529|NCT03968562|Placebo Comparator|Generic Aquaphor|Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Active Comparator.
16401530|NCT03968549|Placebo Comparator|Placebo|These patients will receive capsules containing vegetable oil and corn starch
16401531|NCT03968549|Active Comparator|Probiotic|These patients will receive capsules containing Lactobacillus acidophilus
16401532|NCT03968523|Active Comparator|TAP block|TAP block technique.
16401533|NCT03968523|Experimental|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
16401534|NCT03968510||parathyroidectomy cases|patients who will be operated for primary hyperparathyroidism
16401535|NCT03968497|Other|Postoperative pain assessment|Postoperative pain evaluation by a female and a male investigator, respectively at approximately 15-minute intervals.
16401536|NCT03968484|Experimental|<50.000/µl|Transfusion of platelets starting with a platelet count <50.000/µl
16401537|NCT03968484|Experimental|<20.000/µl|Transfusion of platelets starting with a platelet count <20.000/µl
16401538|NCT03968458|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions.
16401539|NCT03968445|Experimental|Recent Myocardial Infarction|
16401540|NCT03968445|Experimental|undergoing elective percutaneous coronary intervention|
16401541|NCT03968432|Sham Comparator|Standard Care|Be Sweet to Babies Videos and Pamphlet. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of the sweet solution during vaccination will be used.
16401542|NCT03968432|Active Comparator|Intervention|Be Sweet to Babies Videos, pamphlet, and MIAS&Q. MIAS&Q includes five questions and statements based on MI approach which was developed by the researcher and was reviewed further by a panel of parent representatives and HCPs representatives and the research team consisting of the supervisor and two Ph.D. committee members. This MIAS&Q intervention consists of four scaled questions and two open-ended questions and presents brief informative and affirmative questions and statements. This aims to help the parents reflect on their own thoughts, and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
16401543|NCT03968419|Experimental|canakinumab monotherapy|All patients will receive canakinumab (ACZ885) prior to surgery
16401544|NCT03968419|Experimental|canakinumab + pembrolizumab|All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery
16401545|NCT03968419|Experimental|pembrolizumab monotherapy|All patients will receive 2 doses of pembrolizumab prior to surgery
16401546|NCT03968406|Experimental|Treatment (talazoparib, radiation therapy)|Patients receive talazoparib PO QD beginning on days -10 to -7 and continuing for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy 5 days a week (Monday-Friday) for up to 7 weeks.
16401547|NCT03968393|Experimental|Non-vitamin K oral anticoagulant (NOAC)|
16401548|NCT03968393|No Intervention|No anticoagulation|Patients allocated to the no anticoagulation arm are not allowed to receive oral anticoagulation, unless the patient develops an indication for its use during follow-up.
16401549|NCT03968380||Population in Quito|720 randomly chosen people living in District 17D06, Quito (Ecuador)
16401550|NCT03968380||Population in Esmeraldas|720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador)
16401551|NCT03968367|Experimental|Magnetic activated sperm cell sorting for infertile man|A 0.5 mL aliquot of spermatozoa suspended in HTF-modified HEPES buffer, obtained either after sperm wash to remove the seminal plasma or after DGC, was centrifuged and the pellet (maximum of 107 cells) was resuspended in 80 uL of binding buffer with 20 uL of Annexin V-conjugated microspheres, both from the Annexin V microbead kit (Miltenyi Biotec, Huburn, CA, USA), for 15 min at room temperature. After addition of 400 lL of binding solution, the suspension was placed in the separation column (MiniMACS, Miltenyi Biotec). Labeled (apoptotic) cells were retained on the column and non-labeled (viable) cells passed through the column.
16401552|NCT03968354||Steatosis group - Experimental1|Steatosis group
16401553|NCT03968354||NASH group without fibrosis - Experimental 2|NASH group without fibrosis
16401554|NCT03968354||Moderate fibrosis - Experimental 3|Moderate fibrosis
16401555|NCT03968354||Advanced fibrosis - Experimental 4|Advanced fibrosis
16401556|NCT03968354||Control group - Active Comparator|Control group
16401557|NCT03968341|Experimental|intraocular antibiotic concentrations determination|"In the event that the patient develops unfavourably, the ophthalmologist include the patient in the trial.
~The patient is reviewed at 48 hours after the introduction of probabilistic antibiotic therapy for clinical reassessment and the return of microbiological test results. Following this inclusion, the new samples will be taken when the patient passes through the operating room for the treatment of his pathology as part of the care. Ophthalmologists may have to adapt the patient's management (i.e. adjustment of antibiotic therapy) as part of their usual care routine. An anterior chamber puncture and a vitrectomy are performed. Eye fluids collected as part of the treatment are sent for analysis."
16401558|NCT03968328||Observational (interview, survey)|Patients respond to a survey and participate in an interview with study staff about their fever and when they started feeling unwell.
16401559|NCT03968315|Experimental|Diagnostic (MRI, diaphragm fluoroscopy)|Patients undergo an MRI scan over 45-60 minutes and a diaphragm fluoroscopy 30 days before surgery.
16401560|NCT03968302|Experimental|ARM A|The triple regimen, amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole 40 mg twice a day
16401561|NCT03968302|Experimental|ARM B|The quadruple regimen,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day, omeprazole 40 mg twice a day dose and colloidal bismuth subcitrate 240 mg twice daily
16401562|NCT03968276|Experimental|use of digital tablet|"if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.
~The first connection to the tablet and then to the My medication protects my vessels application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.
~After discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study."
16401563|NCT03968263|Active Comparator|Hycon device(Routine protocol)|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions.
16401564|NCT03968263|Active Comparator|Hycon device(Modified protocol)|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise.
16401565|NCT03968263|Active Comparator|Hycon device(Routine protocol) and Vibration|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
16401566|NCT03968263|Active Comparator|Hycon device(Modified protocol) and Vibration|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
16401567|NCT03968250|Experimental|Cognitive Behavioral Therapy for Treating Fatigue|This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
16401568|NCT03968224|Experimental|Metformin/Dapagliflozin|Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.
16401569|NCT03968224|Active Comparator|Metformin|Metformin 1,700 mg/day
16401570|NCT03968211|Experimental|Vaccine|Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine
16401571|NCT03968198|Experimental|ASC (Adipose-derived Stem/Stroma Cells)|Patients administrated with autologous ASC in their ischemic inferiors limbs
16401572|NCT03968185||Interfascial infiltration|Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.
16401573|NCT03968185||Standard medical treatment|Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.
16401574|NCT03968172|Experimental|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
16401575|NCT03968172|Active Comparator|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
16401576|NCT03968159|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
16401577|NCT03968159|Placebo Comparator|Placebo|Placebo tablets
16401578|NCT03968146|Active Comparator|Group E|patients will receive Erector Spinae plane block in addition to intravenous fentanyl
16401580|NCT03968133|Experimental|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5*10^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10^9 CFU/gram) per day.
16401581|NCT03968133|Placebo Comparator|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
16401582|NCT03968120|No Intervention|Group Fix:One-lung ventilation with constant PEEP|Controll group: lung protective one-lung ventilation with fix positive end-expiratory pressure (PEEP)
16401583|NCT03968120|Active Comparator|Group Variable:One-lung ventilation with variable PEEP|Variable group: lung protective one-lung ventilation with variable positive end-expiratory pressure (PEEP)
16401584|NCT03968107||Women with a singleton pregnancy over 28 weeks|All pregnant women with a singleton pregnancy over 28 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures , will be proposed inclusion in the study.
16401585|NCT03968081|Experimental|Social exclusion|Participating at the cyberball game in exclusion condition in wich they will receive 2 time the ball in the 10 first throw then none of them in the last 20 throw.
16401586|NCT03968081|Active Comparator|Social inclusion|Participating at the cyberball game in inclusion condition in wich they will receive 33% of the throw : 10 in a total of 30
16401587|NCT03968068|Experimental|Exercise|
16401588|NCT03968068|Experimental|Remote Ischaemic Conditioning|
16401589|NCT03968042|Placebo Comparator|Regular treatment (RT)|Combination of vitamin B1, B6, C, E and mecobalamine
16401590|NCT03968042|Experimental|RT with NGF|Nerve growth factor adding to regular treatment
16401591|NCT03968042|Experimental|RT with EDV|Edaravone adding to regular treatment
16401592|NCT03968029|Experimental|Suturing meniscal augmented|Non-vascularised area meniscus tear was sutured and bone marrow was injected under a protective collagen membrane (ChondroGide)
16401593|NCT03968029|Active Comparator|Suturing meniscal|Non-vascularised area meniscus tear was only sutured
16401594|NCT03968016|Placebo Comparator|Healthy|Control group
16401595|NCT03968016|Active Comparator|Stable heart disease|Stable heart disease and non-hospitalized
16401596|NCT03968003|Experimental|Inulin|Group A (intervention group) will receive inulin 10 g.
16401597|NCT03968003|Placebo Comparator|Maltodextrin|Group B will receive placebo of isocaloric maltodextrin.
16401598|NCT03968003|Active Comparator|Dietary fiber|Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.
16401599|NCT03967990|Experimental|refined-50/50-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
16401600|NCT03967990|Experimental|50/50-whole-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
16401601|NCT03967990|Experimental|whole-refined-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
16401602|NCT03967990|Experimental|refined-whole-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
16401603|NCT03967990|Experimental|50/50-refined-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
16401604|NCT03967990|Experimental|whole-50/50-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
16401605|NCT03967977|Active Comparator|Tislelizumab in combination with chemotherapy|Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
16401606|NCT03967977|Placebo Comparator|Placebo in combination with chemotherapy|Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
16401607|NCT03967964|Experimental|Group 1: AVD|Vaginal ring with 2.2 grams dehydroepiandrosterone (DHEA), wearing time 72 hours
16401608|NCT03967964|Experimental|Group 2: AVT|Vaginal ring with 35 mg testosterone, wearing time 72 hours.
16401609|NCT03967964|Experimental|Group 3: AVD+T|Vaginal ring with 1.5 grams DHEA and 25 mg testosterone, wearing time 72 hours.
16401610|NCT03967964|Active Comparator|Group 4: DHEA capsule|Capsules with 25 mg DHEA, oral administration every 8 hours for a 72-hour period.
16401611|NCT03967964|Active Comparator|Group 5: Testosterone transdermal gel|Testosterone transdermal gel with dosing valve (pump): administration of 3 pump actuations (equivalent to 5 mg of testosterone each) per day (total daily dose 15 mg), on 3 consecutive days (72 hours).
16401612|NCT03967938|Experimental|Olaparib|tablets of 300mg twice daily until disease progression
16401613|NCT03967925|Active Comparator|Belimumab|Weekly 200mg SC injections of belimumab for 12 months
16401614|NCT03967925|Placebo Comparator|Belimumab placebo|Weekly SC injections of belimumab placebo for 12 months
16401615|NCT03967912|Experimental|MOVE UP for Caregivers|12-week lifestyle intervention focusing on diet and activity
16401616|NCT03967886|Experimental|YYD601 20mg|Esomeprazole magnesium Dihydrate.
16401617|NCT03967886|Active Comparator|Nexium 20mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
16401618|NCT03967847|No Intervention|Control|
16401619|NCT03967847|Experimental|Ketorolac|
16401620|NCT03967834|Other|Patient with Soft Tissue Sarcoma (Prospective cohort)|
16401621|NCT03967821||Intervention|
16401622|NCT03967795|Other|All patients|"Citrulline genration test before starting enteral nutrition
~At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration"
16401623|NCT03967782|Experimental|cohorte 1|18 adolescents with obesity are involved and will perform the three conditions.
16401624|NCT03967769|No Intervention|Standard Practice|Infants will have high Flow nasal cannulae placed into the nares before induction. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
16401625|NCT03967769|Experimental|Low Flow oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 0,2L/kg/min of oxygen flowing through the cannulae in this group during the study.
16401626|NCT03967769|Experimental|High Flow Oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 1L/kg/min of oxygen flowing through the cannulae in this group during the study.
16401627|NCT03967756|Experimental|AI-assisted withdrawal group|A deep learning-based automatic polyp detection system was used to assist the endoscopist.
16401628|NCT03967756|No Intervention|Routine withdrawal group|Routine withdrawal without any assist.
16401629|NCT03967743||Infants with rare genetic disorders|This is a prospective, registry study of infants with genetic disorders being seen clinically in the NICU GraDS program.
16401630|NCT03967730|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
16401631|NCT03967717||Patients with edematous states|Patients with edematous states receive standard of care diuretic.
16401632|NCT03967704|Experimental|Life quality evaluation|"Patients consulting the Emergency Department (SAU) or the rheumatology department of the GHPSJ (referred by a colleague orthopaedic surgeon, rheumatologist, radiologist or other) for a recent symptomatic osteoporotic dorsal or lumbar vertebral fracture, are called for a rheumatology consultation, vertebral fracture consultation.
~Patients consulting in the rheumatology department during a spinal fracture consultation at the GHPSJ as well as patients hospitalized in the rheumatology department at the GHPSJ are selected consecutively.
~- Arm 1 (intervention): two additional consultations with the rheumatology"
16401633|NCT03967691|Placebo Comparator|Saline infusion|Subjects will be infused with saline (placebo) on study day 1
16401634|NCT03967691|Active Comparator|Tocilizumab infusion|Subjects will be infused with tocilizumab on study day 2
16401635|NCT03967691|Other|Saline infusion under tocilizumab influence|Subjects will be infused withsaline (but still under the influence of tocilizumab) on study day 3
16401636|NCT03967678|Placebo Comparator|Beef from standard supply|
16401637|NCT03967678|Experimental|n-3 enriched beef from dietary supplement finished cattle|
16401638|NCT03967678|Active Comparator|n-3 enriched beef from grass finished cattle|
16401639|NCT03967665|Experimental|Treatment arm|NAC 400 mg three times per day from -14D pre-HSCT to +2 months
16401640|NCT03967665|No Intervention|Control arm|No-NAC concurrent control according to a 2:1 schedule.
16401641|NCT03967652||cancer|Patients with definitively diagnosed of solid tumors
16401642|NCT03967652||Benign disease|Patients with definitively diagnosed of benign disease or precancerous lesion
16401643|NCT03967652||Normal|Healthy volunteers
16401644|NCT03967639||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
16401645|NCT03967639||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
16401646|NCT03967626|Experimental|Cerebral temperature target|CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)
16401647|NCT03967626|Active Comparator|Systemic temperature target|CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).
16401648|NCT03967613|Experimental|FES|Functional Eletrical Stimulation
16401649|NCT03967600||Hidradenitis Suppurativa Patients|Patients with physician diagnosed Hidradenitis Suppurativa
16401650|NCT03967600||Healthy Volunteers|Healthy volunteers without any skin conditions or recent history of antibiotic use.
16401651|NCT03967587|Experimental|Neosense Umbilical Catheter|
16401652|NCT03967574|Experimental|Real tDCS|Participants received the full tDCS intervention for a total of 20 minutes, one time, two weeks following the CSI
16401653|NCT03967574|Sham Comparator|Sham tDCS|The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
16401654|NCT03967574|No Intervention|Control|Participants received no further intervention two weeks following their CSI
16401655|NCT03967561|Experimental|Progressive aerobic training|Water-based aerobic training performed with progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
16401656|NCT03967561|Experimental|Non-progressive aerobic training|Water-based aerobic training performed without progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
16401657|NCT03967548|Experimental|0.004% single-dose|96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).
16401658|NCT03967535||Control|Individuals between 45-85 years old with no diagnosis of dementia. No intervention used
16401659|NCT03967535||Dementia|Individuals between 45-85 years old with a diagnosis of dementia. No intervention used
16401660|NCT03967522|Experimental|Cabozantinib treatment|All participants will be treated by 60 mg of cabozantinib once daily.
16401661|NCT03967509|Experimental|Behavioral teacher training|Behavioral preschool teacher training (BPTT) delivered in an educational group format during nine 2,5-hour biweekly sessions with training at sessions and in between followed by supervisor's feedback on the practice and two optional coaching occasions on the spot.
16401662|NCT03967509|No Intervention|Waiting list control group|Preschool teachers worked with children as usual.
16401663|NCT03967496||No Delirium|No Delirium: CAM-ICU score of less than 3 throughout Post-Anesthesia Care Unit stay
16401664|NCT03967496||Initial Delirium|Initial Delirium: CAM-ICU score of 3 or more at 15 minutes following end of anesthesia and/or at 30 minutes following end of anesthesia
16401665|NCT03967496||Delirium|Delirium: CAM-ICU score of 3 or more immediately prior to discharge from Post-Anesthesia Care Unit
16401666|NCT03967470|Placebo Comparator|Placebo arm|Placebo spray used during one month
16401667|NCT03967470|Active Comparator|Treatment arm|Bacteria spray used during one month
16401668|NCT03967444|Other|Restylane Kysse|Hyaluronic acid
16401669|NCT03967444|Other|Restylane Kysse with other HA|Hyaluronic acid
16401670|NCT03967431|Experimental|Narrative Enhancement and Cognitive Therapy group|The patients in the experimental group received narrative enhancement and cognitive therapy which contains 20 times group meetings.
16401671|NCT03967431|No Intervention|Control group|The patients in the control group received routine care.
16401672|NCT03967418|Other|Patients with behavioral addictions|Patients suffering from behavioural addiction (sexual addiction, excessive use of video games and eating disorders with bulimia episodes) will be recruited
16401673|NCT03967418|Other|Healthy volunteers|Healthy volunteers will be matched on gender, age and education level to patients
16401674|NCT03967392|Active Comparator|GROUP X(xylocaine)|20 ml bupivacaine 0.5% + 20 ml normal saline.
16401675|NCT03967392|Active Comparator|GROUPX(Dxylocaine and dexamethasone)|20 ml bupivacaine 0.5% + 18 ml normal saline + 8 mg dexamethasone 2 ml
16401676|NCT03967379|Experimental|Mobile app plus enhanced standard care|"Patients will received enhanced standard care in addition to access to the sexual health mobile app.
~The app will also prompt patients to engage their partners with specific exercises."
16401677|NCT03967379|Other|Enhanced Standard Care|"Patients will receive Enhanced Standard Care
~Patients will meet with a transplant clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or vulvovaginal GVHD
~Patients will not have access to the sexual health mobile app"
16401678|NCT03967366||plasma melatonin 1|Quartile 1 of plasma melatonin
16401679|NCT03967366||plasma melatonin 2|Quartile 2 of plasma melatonin
16401680|NCT03967366||plasma melatonin 3|Quartile 3 of plasma melatonin
16401681|NCT03967366||plasma melatonin 4|Quartile 4 of plasma melatonin
16401682|NCT03967353|No Intervention|Routine Treatment Group|Routine treatment group(6 months treatment regimen-2HRZE/4HR); Routine health education; Dose-taken supervised by family members
16401683|NCT03967353|Experimental|Intervention Group|Using mobile technology management means to manage newly treated smear-positive tuberculosis patients, to guide patients'treatment, infection control, doctor-patient communication, and to strengthen health education on infection control of patients.
16401685|NCT03967327|Active Comparator|MOR SR|"This arm includes MOR SR and placebo for BUP TDS, detailed information is as below:
~Treatment dosage form dosage frequency duration MOR SR Tablet 10,30,60mg q12h 8 weeks
~Placebo for Patch -- every 3-4 days 8 weeks BUP TDS"
16401686|NCT03967327|Experimental|BUP TDS|"This arm includes BUP TDS and placebo for MOR SR, detailed information is as below:
~Treatment dosage form dosage frequency duration Placebo for Tablet -- q12h 8 weeks MOR SR
~BUP TDS Patch 20/30/40mg every 3-4 days 8 weeks"
16401687|NCT03967314|Active Comparator|Group T = TLIP block group|After the induction of anesthesia and placement of the patient in a prone position, US-guided mTLIP block was performed via the lateral approach in group T. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
16401688|NCT03967314|Active Comparator|Group W = Wound infiltration group|After the induction of anesthesia and placement of the patient in a prone position wound infiltration was performed in group W. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
16401689|NCT03967301|Experimental|Probiotic isolated intestinal bacteria (active)|Patients randomized to active arm, will consume 5ml every 12 hours per day of a suspension of probiotics (Bioflora ® Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis y Bifidobacterium brevis) for 14 days.The content of each bottle is reconstituted up to 50 ml (10 doses) with drinking water The prescription of the intervention will be carried out and monitored through the electronic medical record. In the hospital setting, the probiotic is reconstituted by the nursing staff. If the patient is discharged before this period the patient and family will be instructed to perform the reconstitution at home.
16401690|NCT03967301|Placebo Comparator|Placebo|Patients randomized to the placebo arm, will consume 5ml every 12 hours per day of a suspension of placebo for 14 days. The prescription of the intervention will be carried out and monitored through the electronic medical record.
16401691|NCT03967288|Experimental|Chloroprocaine|50 mg of 1% spinal chloroprocaine (5 mL) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
16401692|NCT03967288|Active Comparator|Bupivacaine|10.5 mg of spinal hyperbaric bupivacaine (1.4 mL of 0.75% bupivacaine hydrochloride in 8.25% dextrose) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
16401693|NCT03967262|Experimental|Intervention|
16401694|NCT03967262|No Intervention|Control|
16401695|NCT03967249|Experimental|IONIS GHR-LRx + SRL|IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.
16401696|NCT03967223|Experimental|Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
16401911|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
16401697|NCT03967223|Experimental|Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
16401698|NCT03967197|Experimental|Lidocaine|Patients randomized to the lidocaine intervention will receive 2 sprays of lidocaine hydrochloride 10% in each nostril 3-5 minutes before their test.
16401699|NCT03967197|Placebo Comparator|Placebo (Saline)|Patients randomized to placebo will receive 2 sprays of physiological saline in each nostril 3-5 minutes before their test.
16401700|NCT03967171|Experimental|before uterine incision oxytocin group|IV infusion of 20 IU of oxytocin started before uterine incision
16401701|NCT03967171|Active Comparator|after clamping the umbilical cord oxytocin group|IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord
16401702|NCT03967158||Consecutive percutaneous coronary intervention|
16401703|NCT03967132|Active Comparator|Control Infant Formula|Milk-based infant formula
16401704|NCT03967132|Experimental|Experimental Infant Formula|Milk-based Infant Formula with oligosaccharides
16401705|NCT03967132|Other|Reference Group|Human-milk fed
16401706|NCT03967119||Laparoscopic surgery|"The following parameters are assessed and recorded at the following time points in all participants.
~The parameters assessed: mean arterial pressure, heart rate, pulse oxygen saturation, SVV, PPV, PWV, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, respiratory rate (all dynamic variables are assessed at two levels of tidal volume- 6 ml/kg and 12 ml/kg).
~The time points: T0, before anesthetic induction; T1, immediately after anesthetic induction; T2, immediately after pneumoperitoneum; T3, 10 min before desufflation; T4, immediately after desufflation.
~The desufflation-induced hypotension is defined as more than 20 % decrease in MAP at T4 from MAP at T3."
16401707|NCT03967106|Experimental|Remote Ischaemic preconditioning|Remote IPC (RIPC) intervention daily for six weeks.
16401708|NCT03967106|Sham Comparator|Sham|Remote sham intervention daily for six weeks.
16401709|NCT03967093|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
16401710|NCT03967093|Experimental|Part 2: Ependymoma Patients|Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
16401711|NCT03967093|Experimental|Part 2: Brain Tumor Patients|Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
16401712|NCT03967093|Experimental|Part 2: DIPG Patients|Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
16401713|NCT03967093|Experimental|Part 2: Other Solid Tumor Patients|Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
16401714|NCT03967054|Experimental|Ivermectin mass drug administration|Ivermectin given monthly from July-October (4 times) as a 3-day course of 300 µg/kg/day to all eligible persons per exclusion/inclusion criteria. Per package insert, dosing of IVM will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
16401715|NCT03967054|Placebo Comparator|Placebo mass administration|Placebo given monthly from July-October (4 times) as a 3-day course to all eligible persons per exclusion/inclusion criteria. Dosing of placebo will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
16401716|NCT03967041||Sarcopenic patients|
16401717|NCT03967041||Non-sarcopenic patients|
16401718|NCT03967028||Study group|primigravida scheduled for cesarean section
16401719|NCT03967015|Experimental|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will receive MUAC training and nutritional education at enrollment. A short message service (SMS) message will be sent at 7 days following enrollment asking them to measure and send their child's MUAC. Weekly SMS messages asking for the child's MUAC measurement will be sent every 7 days until the last study visit at 180 days following enrollment.
16401720|NCT03967015|No Intervention|Standard of care (SOC)|Participants randomized to the standard of care (SOC) arm will receive the same MUAC training and nutritional education as mothers in the MAMMS arm. To accurately simulate community malnutrition outreach programs, no SMS message will be sent to participants in this arm.
16401721|NCT03967002|Experimental|Test group with corticotomy surgery|Orthodontic treatment and minimally invasive corticotomy surgery with piezoelectric device and surgical guide
16401722|NCT03967002|No Intervention|Control group without corticotomy surgery|Standard orthodontic treatment without surgery
16401723|NCT03966989|Experimental|Performance Feedback|Feedback offline either via email or text
16401724|NCT03966989|No Intervention|Control|Standard practice control
16401725|NCT03966976|Experimental|Vitaphone Arm|Follow-up via VITAPHONE in addition to conventional monitoring.
16401726|NCT03966976|Active Comparator|Conventional Arm|Conventional follow-up
16401727|NCT03966963|Experimental|Eye Movement Desensitization Reprocessing (EMDR)|Subjects with trauma-related symptomology resultant from CSA will undertake EMDR; they will be systematically observed through use of their quantitative treatment outcome measures at both pre- and post- treatment alongside one-month follow-up interview data to determine outcomes of interest (namely emotional, behavioural and neuropsychological functioning).
16401728|NCT03966950|Experimental|melatonin group|for the melatonin group, 10 mg of melatonin will be taken per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
16401729|NCT03966950|Placebo Comparator|placebo group|For the placebo group, placebo will be administered per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
16401730|NCT03966937|Experimental|Dry needling|The experimental group will receive dry needling over trigger points of Quadriceps muscles along with therapeutic exercises.
16401731|NCT03966937|Active Comparator|Control|The control group will only receive standardized therapeutic exercises for Patellofemoral pain syndrome.
16401732|NCT03966924|Experimental|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
16401733|NCT03966911|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
16401734|NCT03966898|Experimental|SHR6390, Letrozole or Anastrozole|SHR6390, Letrozole or Anastrozole
16401735|NCT03966898|Placebo Comparator|Placebo, Letrozole or Anastrozole|Placebo, Letrozole or Anastrozole
16401736|NCT03966885|Experimental|Brief Intervention (BI)|30 minute alcohol brief intervention delivered by lay provider during HIV clinic visit.
16401737|NCT03966885|Experimental|Brief Intervention + CETA|30 minute alcohol brief intervention delivered by lay provider during clinic visit followed by 6-12 weekly sessions of CETA.
16401738|NCT03966872|Experimental|Integrated Illness Management and Recovery (I-IMR):|Participants assigned to I-IMR will receive 2 individual sessions to discuss principles of recovery and set personally meaningful goals, with the remainder of the 14 I-IMR sessions delivered in groups of 8-10 (to enable individual tailoring)
16401739|NCT03966872|Experimental|Stanford Chronic Disease Self-Management Program (CDSMP):|Participants randomly assigned get a 6-session group-based educational program co-delivered by two peers (lay people who have successfully managed a chronic illness) or a peer and a professional
16401740|NCT03966859|Placebo Comparator|Placebo|Participants will receive lactose placebo tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
16401741|NCT03966859|Experimental|Atorvastatin|Participants will receive 20mg atorvastatin tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
16401742|NCT03966846|Experimental|Kefir Group|Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
16401743|NCT03966846|Placebo Comparator|Control Group|Control group received one bottle of milk (180 ml) daily for 12 weeks.
16401744|NCT03966833|Experimental|group-based interpersonal therapy (IPT-G)|14 weeks of group-based interpersonal therapy (IPT-G): StrongMinds is focused on treating depression in Uganda by training community members (in this case ELA club mentors) to act as mentors in IPT-G techniques. This intervention will be offered to 13-19 year old young women who score a 10 or higher on the PHQ-8. These adolescents who take up the offer will then be enrolled in the 14 weeks of therapy. Group therapy sessions build bonds between young women and encourage them to actively engage in the healing process and to support each other in the exploration of their depression triggers. With new healthier patterns and skills, women can learn to manage their current depression and ensure future depressive episodes can be quickly identified and resolved before the onset of any long-term consequences.
16401745|NCT03966833|Experimental|IPT-G + Unconditional Cash Transfer:|A one time lump sum of 200,000 UGX (~$54) be provided to all study participants in a random sub-set of intervention (IPT-G) clusters near or at the conclusion of the 14-week therapy. This treatment variation will allow for determination of whether complimentary income support enhances the effects of IPT-G on psychological wellbeing and other outcomes of interest.
16401746|NCT03966833|No Intervention|control|ELA clubs function as normal
16401749|NCT03966794|Experimental|Epidural Electrical Stimulation|
16401750|NCT03966794|Experimental|Functional scaffold & Epidural Electrical Stimulation|
16401751|NCT03966781|Active Comparator|ESWL followed by ERCP|Patients enrolled in the active treatment group will be subjected to ESWL followed by ERCP and pancreatic duct stenting.
16401752|NCT03966781|Sham Comparator|Sham ESWL followed by sham ERCP|Patients enrolled in the sham treatment group will be subjected to sham ESWL followed by sham ERCP with no pancreatic duct intervention.
16401753|NCT03966768|Experimental|Duramesh suturable mesh for laparotomy closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be closed with Duramesh suturable mesh.
16401754|NCT03966768|Experimental|Conventional suture closure for laparotomy closure|Patients randomized to conventional laparotomy closure will be closed using size 1 slowly-absorbing polydiaxonone (PDS) single strand or looped suture, based on surgeon preference.
16401755|NCT03966768|Experimental|Open abdomen group closed in delayed fashion with Duramesh|Patients undergoing delayed primary closure of an open abdomen will also be studied. 20 study patients undergoing delayed primary closure of an open abdomen will be closed with Number 1 or Number 2 Duramesh
16401756|NCT03966755|Experimental|UFA dietary recommendations|Dietary intervention aimed at increasing UFA consumption.
16401757|NCT03966755|No Intervention|Standard dietary recommendations|Standard of care dietary recommendations as currently performed in the clinic (2015-2020 United States Department of Agriculture (USDA) Dietary Guidelines for Americans)
16401758|NCT03966742|Experimental|Treatment|Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
16401759|NCT03966729||HFrEF|"HFrEF (Heart failure with reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF < 40%.
~LVEF = Left ventricular ejection fraction"
16401760|NCT03966729||HFmrEF|"HFmrEF (Heart failure with mid-range reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF 40-49%.
~LVEF = Left ventricular ejection fraction"
16401761|NCT03966729||HFpEF|"HFmrEF (Heart failure with preserved ejection fraction): ESC Guideline heart failure 2016: patients with LVEF > 50%.
~LVEF = Left ventricular ejection fraction"
16401762|NCT03966716|Experimental|Arthroplasty|Arthroplasty, hemi or total depending on patient characteristics and surgeon's choice
16401938|NCT03965585||Primary Infertility|Women with a diagnosed primary infertility undergoing hysteroscopy before IVF.
16401763|NCT03966716|Active Comparator|Internal Fixation|Internal fixation with 2-3 screws or pins, or sliding hip screw device, depending on each hospital's routine
16401764|NCT03966703|Experimental|conventional denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
16401765|NCT03966703|Experimental|implant fixed denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
16401766|NCT03966690|Experimental|leg curl device starters|Group A randomly assigned to start with legcurl device
16401767|NCT03966690|Experimental|legpress device starters|Group A randomly assigned to start with legpress device
16401768|NCT03966677||P-GHR|Patients with persistent severe pain after groin hernia repair.
16401769|NCT03966677||NP-GHR|Patients without pain after groin hernia repair.
16401770|NCT03966677||NP|Healthy non-operated controls
16401771|NCT03966664||Septic patients|Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
16401772|NCT03966664||Healthy controls|Age and sex matched healthy volunteers.
16401773|NCT03966664||Non septic patients|Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
16401774|NCT03966651|Experimental|PRRT with 177Lu-DOTATATE|
16401775|NCT03966638||Patients receiving platelet rich plasma|The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.
16401776|NCT03966599|Active Comparator|Lateral position|The patient position was changed to lateral during surgery
16401777|NCT03966599|Active Comparator|prone position|The patient position was changed to prone during surgery
16401778|NCT03966586|Experimental|Enhanced Care|Usual clinical care + intervention components
16401779|NCT03966586|Active Comparator|Usual Care|Usual clinical care and counseling
16401780|NCT03966573|Other|Evaluating function, Radiographic imaging, Forms|"Tests for lower extremity function
~Evaluating arthritis of hip and knee, leg length discrepancy and axis deviation radiographically
~Evaluating quality of life, function and pain by forms"
16401781|NCT03966560|Experimental|Primary open-angle glaucoma|"Participants over 40 years of age and diagnosed with primary open-angle glaucoma.
~Medical treatment was initiated for the diagnosed participants."
16401782|NCT03966560|No Intervention|Healthy|Healthy volunteers who do not have systemic disease that may affect the choroidal thickness and have no ocular features that may affect test measurements.
16401783|NCT03966547|Experimental|Local anesthetic|
16401784|NCT03966547|Placebo Comparator|Isotonic NaCl|
16401785|NCT03966534|No Intervention|Control Group|Blood culture obtained as first test after venipuncture and prior to biochemistry test
16401786|NCT03966534|Experimental|Diversion Group|Biochemistry test obtained as first test after venepuncture and prior to blood culture
16401787|NCT03966508|Experimental|hyperalgesia measurement|
16401788|NCT03966495||PRisM program|"Pluriprofessional primary care offices with the PRiSM RM program:
~Nine of the pluriprofessional primary care offices which implemented the RM program tested in the PRiSM study (2015-2017). The program consisted in: 1) Training on RM in the context of primary care; 2) The appointment of a RM referent in the office; 3) The conduct of six incident review meetings.
~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.
~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
16401789|NCT03966495||Control|"Pluriprofessional primary care offices without the PRiSM RM program:
~Nine of the offices pluriprofessional primary care offices which didn't implement the RM program tested in the PRiSM study (2015-2017). They belonged to the PRisM study control group.
~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.
~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
16401790|NCT03966482|Experimental|Group before-after|Speech therapy with Semiocluded vocal tract exercise.
16401791|NCT03966469||Support Person Present|Participants who bring a support person with them to their preoperative appointment.
16401792|NCT03966469||Patient Present Only|Participants who present by themselves to their preoperative appointment.
16401793|NCT03966456||nivolumab|Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
16401794|NCT03966456||pembrolizumab|Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
16401795|NCT03966456||toripalimab|Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
16401796|NCT03966456||sintilimab|Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
16401797|NCT03966430|Experimental|damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the damage control surgery group.
16401798|NCT03966430|Sham Comparator|non-damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the non-damage control surgery group.
16401799|NCT03966417|Active Comparator|Exercise training group|"Patient to be randomized to exercise training group will have exercise training sessions 2 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 75% of Vo2max."
16401800|NCT03966417|No Intervention|Usual care group|"Patient to be randomized to usual care group will undergo standard care fo 12 weeks."
16401801|NCT03966391|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/ fear/fainting mitigation interventions from CARD during vaccination)
16401802|NCT03966391|No Intervention|Control (standard care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
16401939|NCT03965585||Secondary Infertility|Women with a diagnosed secondary infertility undergoing hysteroscopy before IVF.
16401803|NCT03966378|Experimental|Grape seeds extract|Every week the grape seeds extract (gel) put into the tray and apply it to the upper teeth of the participant.
16401804|NCT03966378|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste apply to the teeth twice daily.
16401805|NCT03966365|Experimental|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
16401806|NCT03966365|Active Comparator|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
16401807|NCT03966339|Experimental|GH group|Growth Hormone adding to controlled ovarian hyperstimulation
16401808|NCT03966339|No Intervention|control group|regular controlled ovarian hyperstimulation
16401809|NCT03966326|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
16401810|NCT03966326|Active Comparator|PECS II group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
16401811|NCT03966300|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination)
16401812|NCT03966300|No Intervention|Control (standard/usual care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
16401813|NCT03966274||Delirium positive|
16401814|NCT03966274||Delirium negative|
16401815|NCT03966248|Experimental|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
16401816|NCT03966248|Active Comparator|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
16401817|NCT03966235|Experimental|Melatonin group|drug: melatonin tablets (Sigma-Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.
16401818|NCT03966235|Placebo Comparator|Control group|drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.
16401819|NCT03966222|Active Comparator|Open vein harvest|For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.
16401820|NCT03966222|Experimental|Endoscopic vein harvest|We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.
16401821|NCT03966209|Experimental|treatment|JS001（PD-1 inhibitor）, 240mg I.V. Q3W,
16401822|NCT03966196|Other|Healthy Volunteers|oxymetry and finger pressure in Healthy subjects
16401823|NCT03966196|Experimental|COPD patients|oxymetry and finger pressure in COPD patients
16401824|NCT03966183||UVFP patients post thyroplasty|Patients in this group are adults who have undergone type I medialization thyroplasty (with Montgomery implant, silicone implant, follow-up of more than 3 months) as a definitive procedure following unilateral vocal fold paralysis.
16401825|NCT03966183||Control participants|The people in this group are control subjects of the same age, sex and manual laterality as the patients.
16401826|NCT03966170|Experimental|Citicoline|Citicoline as neuroprotector
16401827|NCT03966170|Placebo Comparator|Placebo drug|Placebo
16401828|NCT03966157|Experimental|Nasal Bridle|Patients randomized to have nasal bridle.
16401829|NCT03966157|No Intervention|Standard|Patients randomized with adhesive tape.
16401830|NCT03966144|Experimental|RoboHear Device|Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words.
16401831|NCT03966131|Experimental|patients with complete denture for the first time|Arm that allows to follow the adaptation of this population to the new complete denture during the tasks of speech production and swallowing.
16401832|NCT03966131|Experimental|patients with complete denture used to their complete denture.|Arm that allows a descriptive cross-sectional study of tongue pressure measurements during the tasks of speech production and swallowing
16401833|NCT03966118|Experimental|Ramucirumab + Avelumab + Paclitaxel|Single-Arm
16401834|NCT03966105||Patients with CTS surgery indication|
16401835|NCT03966105||Patients with LSS surgery indication|
16401836|NCT03966092|No Intervention|Usual practice|Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations
16401837|NCT03966092|Experimental|QLB block|"Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.
~In addition, patients receiving a bilateral QLB at the end of the surgery"
16401838|NCT03966079|Experimental|Intervention arm|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
16401839|NCT03966066|Experimental|low dose erythromycin group|Erythromycin 3-5mg/kg.d orally for 6 months
16401840|NCT03966066|No Intervention|Non-erythromycin treatment group|systemic treatment
16401845|NCT03966040|Experimental|Immunization schedule of day 0-3-7|Three doses of schedule given at day 0, 3 and 7.
16401846|NCT03966040|Experimental|Immunization schedule of day 0/0-3-7|Four doses of schedule given at day 0/0, 3 and 7.
16401847|NCT03966040|Experimental|Immunization schedule of day 0/0-7|Three doses of schedule given at day 0/0 and 7.
16401848|NCT03966040|Experimental|Immunization schedule of day 0/0-7-14|Four doses of schedule given at day 0/0, 7 and 14.
16401849|NCT03966027|Experimental|Hindfoot Offloading Braces / Immediate Weight-bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
16401850|NCT03966027|Placebo Comparator|No Hindfoot Offloading Braces / Delayed Weight-Bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
16401851|NCT03966014|Active Comparator|EM-amoxicillin 3 x 10 days|
16401852|NCT03966014|Active Comparator|EM-amoxicillin 3 x 14 days|
16401853|NCT03966014|Active Comparator|EM-amoxicillin 2 x 14 days|
16401854|NCT03966014|Other|Controls|
16401855|NCT03966001||Planned Cesarean Group|Pregnant women undergoing a planned cesarean section at 38-42 gestational week.
16401856|NCT03966001||Emergency Cesarean Group|Pregnant women who are planning to give normal birth between 38-42 weeks of gestation but have to been performed an urgent cesarean section due to an emergency such as acute fetal distress, cephalo-pelvic disproportion or another obstetrical condition.
16401857|NCT03965988|Experimental|Docosahexaenoic Acid|Docosahexaenoic acid
16401858|NCT03965988|Placebo Comparator|Placebo drug|Placebo
16401859|NCT03965975|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated urine cups. The urine sample was then sent the Lab and tested sequentially; first by the golden standard techniques used by the Lab (first intervention) and by the S-There device (comparative device - second intervention).
16401860|NCT03965962|Experimental|Group 1: VRVg-2 + HRIG|VRVg-2 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28 + Human Rabies Immunoglobulins (HRIG) single injection at Day 0
16401861|NCT03965962|Active Comparator|Group 2: Verorab + HRIG|Verorab 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28 + HRIG single injection at Day 0
16401862|NCT03965962|Active Comparator|Group 3: Imovax Rabies + HRIG|Imovax Rabies 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28 + HRIG single injection at Day 0
16401863|NCT03965962|Experimental|Group 4: VRVg-2|VRVg-2 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28
16401864|NCT03965949||Group 1|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support
16401865|NCT03965949||Group 2|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)
16401866|NCT03965949||Group 3|Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)
16401867|NCT03965949||Group 4|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
16401868|NCT03965936|Placebo Comparator|lipofilling|subcutaneous injection of lipoaspiate (microfat) in one temporal region
16401869|NCT03965936|Active Comparator|lipofilling enriched with adipose tissue derived stem cells|subcutaneous injection of lipoaspiate enriched with adipose tissue derived stem cells in one temporal region
16401870|NCT03965923|Experimental|Cohort 1: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401871|NCT03965923|Experimental|Cohort 1: Truvada Tablet|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401872|NCT03965923|Experimental|Cohort 2: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401873|NCT03965923|Experimental|Cohort 2: Truvada Tablet|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401874|NCT03965923|Experimental|Cohort 3: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 3 (20 0/7 weeks - 29 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401940|NCT03965585||Recurrent miscarriages|Women with recurrent miscarriages undergoing hysteroscopy before IVF.
16405063|NCT03943459|Experimental|Quercetin|20 patients treated with quercetin 500 mg/day
16401875|NCT03965923|Experimental|Cohort 3: Truvada Tablet|Participants in Cohort 3 (20 0/7 weeks - 29 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401876|NCT03965923|Experimental|Cohort 4: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 4 (12 0/7 weeks - 19 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401877|NCT03965923|Experimental|Cohort 4: Truvada Tablet|Participants in Cohort 4 (12 0/7 weeks - 19 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
16401878|NCT03965910|Other|group 1|Group 1:Early rehabilitation
16401879|NCT03965910|Other|group 2|Group 2:Late rehabilitation
16401882|NCT03965884|Experimental|lumbal stabilization exercise group|
16401883|NCT03965884|Experimental|connective tissue massage group|
16401884|NCT03965884|No Intervention|control group|
16401885|NCT03965871|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401886|NCT03965871|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401887|NCT03965871|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401888|NCT03965871|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401889|NCT03965858|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401890|NCT03965858|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401891|NCT03965858|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401892|NCT03965858|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
16401898|NCT03965832|Experimental|HFNT|Patients who meet the eligibility criteria will be randomized to receive HFNT and then crossover to other device during the study procedures.
16401899|NCT03965832|Experimental|Standard oxygen|Patients who meet the eligibility criteria will be randomized to receive Standard oxygen and then crossover to HFNT during the study procedures.
16401900|NCT03965819|Experimental|Randomized to consume Pain Bloc-R, Acetaminophen, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Investigational Natural Health Product in Study Period 1, Comparator in Study Period 2, and Placebo in Study Period 3.
16401901|NCT03965819|Experimental|Randomized to consume Acetaminophen, Placebo, then Pain Bloc-R|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Comparator in Study Period 1, Placebo in Study Period 2, and the Investigational Product in Study Period 3.
16401902|NCT03965819|Experimental|Randomized to consume Placebo, Pain Bloc-R, then Acetaminophen|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Investigational Product in Study Period 2, and Comparator in Study Period 3.
16401903|NCT03965793|Active Comparator|Manual management of hypotension|Fluid and vasopressor will be managed as standard practice ( manually infusion of both fluid and vasopressors) following the investigators manual individualized hemodynamic protocol.(objective being to keep both stroke volume and MAP within 90 % of the target values)
16401904|NCT03965793|Experimental|Automated management of hypotension|Fluid and vasopressor will be managed with a novel active clinical decision support system to guide fluid administration and automated closed-loop system to maintain MAP within 90% of patient' baseline.
16401905|NCT03965780|Experimental|Training group|Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.
16401906|NCT03965780|No Intervention|Wait-list control group|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above.
16401907|NCT03965767|Placebo Comparator|control|
16401912|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
16401913|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
16401914|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
16401915|NCT03965741||Men with Prostate Cancer (PCa)|
16401916|NCT03965741||Men without PCa|
16401917|NCT03965728|Experimental|BAY1830839 arm|Period 1: Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, single dose. Period 2: Dose 1, Dose 2 and Dose 3, once daily over 10 days. Dose 4 and Dose 5, twice daily over 10 days. Dose 6, single dose on Day 1, three times daily (TID) for 9 days (Days 2-10).
16401918|NCT03965728|Placebo Comparator|Placebo arm|Placebo tablets matching BAY1830839
16401919|NCT03965715|No Intervention|Gait analysis with barefoot|Participants walk without assistance under gait detection.
16401920|NCT03965715|Experimental|Gait analysis with AFOs|Participants walk with AFOs under gait detection.
16401921|NCT03965715|Experimental|Satisfaction questionnaire|User feedback from the participants was obtained by questionnaire, the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and SF-36, to compare the satisfaction of AFOs
16401922|NCT03965702|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
16401923|NCT03965702|Experimental|EV1000 monitoring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
16401924|NCT03965689|Experimental|Treatment (paclitaxel, carboplatin, pevonedistat)|Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30-60 minutes on day 1, and pevonedistat IV over 1 hour on days 1, 3, and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
16401925|NCT03965676|Other|Adult patients with a tophaceous gout|Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia < 360µmol/L).
16401926|NCT03965663|Experimental|Trans-tibial Amputees|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living
16401927|NCT03965663|Experimental|Trans-tibial Amputees with TSR|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living. The subjects underwent a functional nerv-transfer surgery prior to participation, where the proximal part of the sural nerv was to the distal part of the saphenous nerv.
16401928|NCT03965650|Experimental|Intervention group: video coaching exercises|Video coaching exercises group: patients will perform physical exercises according to a video coaching program 3 times weekly during 6 months. The on-line program has been designed especially for this study.
16401929|NCT03965650|Active Comparator|Control group: routine exercises|Routine method advising and encouraging patients to perform physical activities according to the WHO recommendations during 3 months then to follow the video coaching physical exercises program during 3 months.
16401930|NCT03965637|Experimental|vitamin C|Intervention patients will be received double dose of Ascorbic acid via intravenous injection
16401931|NCT03965637|No Intervention|Control|Control patients will not be received any intervention
16401932|NCT03965624|Experimental|Ixazomib|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see below) or de-escalation in case of response and severe adverse events.
16401933|NCT03965611||Patients with isolated severe traumatic brain injury (TBI)|TBI with initial Glasgow Coma Scale (GCS) ≤ 8 and AISextrahead score ≤3. Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
16401934|NCT03965611||Patients with severe trauma without TBI|Patients with severe trauma without TBI (AISextrahead score > 3). Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
16401935|NCT03965611||Healthy Controls|"Persons who have not had the conditions being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements.
~Oropharyngeal and rectal swabs will be taken only once, at inclusion, after that the participation of the control individual in the trial will be completed."
16401936|NCT03965598||Ultra-high risk for psychosis (UHP)|"Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia.
~Inclusion Criteria: age of 13-30 years; meet the diagnostic criteria of COPS prodromal syndrome by SIPS clinical interviews; have not received any psychiatric medication; be in good health, without major mental illness or physical illness; normal intelligence, can be operated on a clinical scale; volunteer to participate in the study and sign the written consent form.
~Exclusion criteria: exclusion of current or previous psychiatric disorders by SCID interview; meet the diagnostic criteria for substance abuse and substance dependence in DSM-IV; contraindications for MRI; pregnant or lactating women."
16401937|NCT03965598||Healthy controls|"Inclusion Criteria: the gender, age, and education level of the group are matched with the Ultra-high risk group; 13 to 30 years old; right-handed; no history of mental illness; no mental disorder consistent with DSM-IV diagnostic criteria within two or three generations; No contraindications for MRI; volunteer to participate in the study and sign the written consent form.
~Exclusion criteria: history of disturbance of consciousness over 5 minutes; history of brain organic disease or head injury; history of alcohol and drug dependence; history of coma; history of endocrine disease; abnormity in examination of blood, heart, liver, or renal function; pregnant or lactating women."
16401941|NCT03965572||Postpartum women who requested cabergoline|A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression.
16401942|NCT03965572||Control group|An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression.
16401943|NCT03965559||plasmapheresis group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the plasmapheresis during January 2006 to October 2015
16401944|NCT03965559||double filtration plasmapheresis (DFPP) group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the double filtration plasmapheresis (DFPP) during January 2006 to October 2015
16401945|NCT03965546|Experimental|ET140202-T cell combine with Sorafenib|Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion
16401946|NCT03965546|Experimental|ET140202-T cell combine with TAE|TAE treatment ahead every two times of autologous ET140202-T cell administered by intravenous (IV) infusion
16401947|NCT03965546|Experimental|solo ET140202-T cell|autologous ET140202-T cell administered by intravenous (IV) infusion
16401948|NCT03965533|Placebo Comparator|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
16401949|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
16401950|NCT03965533|Placebo Comparator|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
16401951|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
16401952|NCT03965533|Placebo Comparator|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
16401953|NCT03965533|Experimental|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
16401954|NCT03965533|Experimental|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
16401955|NCT03965520|Active Comparator|usual training|exercise intensity arranged by cardiopulmonary exercise test results
16401956|NCT03965520|Experimental|Novel exercise training|exercise intensity monitor by near-infrared spectrometer
16401957|NCT03965507||The group with sacroiliac joint dysfunction|The patient with sacroiliac joint dysfunction in lumbar disc hernia
16401958|NCT03965507||The group without sacroiliac joint dysfunction|The patient without sacroiliac joint dysfunction in lumbar disc hernia
16401959|NCT03965494|Experimental|AXL inhibitor BGB324 then surgery|Participants receive AXL inhibitor BGB324 PO QD on days 1-5, then undergo surgery 3-6 hours after last dose. Within 45 days, participants receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16401960|NCT03965494|Experimental|Surgery then AXL inhibitor BGB324|Participants undergo surgery, then within 45 days receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16401961|NCT03965481|Experimental|Diagnostic (CECT, PET-MRI)|Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.
16401962|NCT03965468|Experimental|Immunotherapy, chemotherapy, radiotherapy and surgery|"Durvalumab 1500 mg administered intravenously every 3 weeks for the first 4-6 cycles (during chemotherapy);
~4-6 cycles of chemotherapy, carboplatin AUC5 every 3 weeks plus paclitaxel 175 mg/m2, every 3 weeks;
~Stereotactic body radiotherapy (SBRT) of all oligo-metastatic lesions, in a maximum of 10 treatment fractions over 2 weeks, starting after week one of chemotherapy cycle 1 and completed within four weeks after start of durvalumab treatment;
~Restaging at 3 months; if no disease progression, proceed to definitive local treatment (surgical resection of primary tumour or radiotherapy at a minimum dose of 60-66Gy to the primary tumour). Durvalumab continues at 1500 mg intravenously every 4 weeks until progression of disease or for a maximum of 1 year from start of treatment."
16401963|NCT03965455||conventional group|
16401964|NCT03965455||diode laser group|
16401965|NCT03965442||Control|"Patients who underwent mastectomy under standard general anesthesia
~Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump."
16401966|NCT03965442||Esmolol|Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
16401967|NCT03965429||Donor|In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.
16401968|NCT03965429||Receiver|Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used
16401969|NCT03965416|Experimental|Doctor with white coat|Doctor during consultation is wearing a white coat
16401970|NCT03965416|Experimental|Doctor without white coat|Doctor during consultation is not wearing a white coat
16401971|NCT03965403|Experimental|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
16401972|NCT03965390|No Intervention|Classical care pathway|"Patients are following classical care pathway. Before brain surgery patients will be included after oral, medical and life quality evaluation.
~After randomization in the control group, patients will be evaluated at 6, 12 and 24 months after surgery, during classical follow up visits."
16406782|NCT03931161|Active Comparator|Evolocumab|Evolocumab Auto-Injector [Repatha]
16401973|NCT03965390|Experimental|Oral education|"Patients are following classical care pathway but combined at each visit with an oral education Before brain surgery patients will be included after oral, medical and life quality evaluation.
~After randomization in the experimental group, patients will be evaluated at 6, 12 and 24 months after surgery, during classical follow up visits. At each timepoint an oral education will be realized in parallel."
16401974|NCT03965377|Experimental|Home Safety Hero game play|Home Safety Hero is parental psychoeducational computer game to prevent childhood injuries
16401975|NCT03965364||INCRAFT|Endovascular abdominal aortic aneurysm repair
16401976|NCT03965351|Experimental|Probenecid|the study medication (probenecid) as well as a placebo.
16401977|NCT03965351|Placebo Comparator|Placebo|placebo compared to probenecid
16401978|NCT03965338|Other|fMRI brain activity|screening
16401979|NCT03965312|Experimental|Temperature monitoring (1) and incubator test (2) groups|"In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.
~In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator."
16401980|NCT03965299|Experimental|VERUM transcutaneous tibial nerve stimulation (TTNS)|
16401981|NCT03965299|Sham Comparator|SHAM transcutaneous tibial nerve stimulation (TTNS)|
16401982|NCT03965286||Patients with chronic HCV will be on direct antiviral drugs|is defined as the presence of detectable viral replication for at least six months diagnosed by quantitative HCV RNA polymerase chain reaction (PCR)
16401983|NCT03965273|Experimental|Full TP|Full TP intervention including emphasized social norms change
16401984|NCT03965273|Experimental|Light TP|Light TP intervention without emphasized social norms change
16401985|NCT03965273|No Intervention|Pure control|Pure control
16401986|NCT03965260||Bacteria-infected cirrhotic patients|All kind of etiologies for cirrhosis and all kind of bacterial infections (spontaneous bacterial peritonitis, urinary tract infections, pneumonia, skin and soft tissue infections and spontaneous bacteremia)
16401987|NCT03965247|Experimental|Lithium|Increasing amounts of lithium for 11 plus or minus 1 day. Day 1: 400 mg at night Day 2: 600 mg at night Day 3-11: 800 mg at night. The lithium intervention was prepared from 200mg Priadel prolonged release tablets. The intervention was provided in blue and white gelatine capsules to be taken orally.
16401988|NCT03965247|Placebo Comparator|Rayotabs|The placebo intervention was 200mg Rayotabs. The intervention was provided in blue and white gelatine capsules to be taken orally - same as the lithium intervention to maintain blinding.
16401989|NCT03965234|Experimental|Prevention (cisplatin, metastasectomy)|Patients undergo pulmonary suffusion consisting of cisplatin via infusion. Patients the undergo metastasectomy. Beginning 4-8 weeks, patients with unresectable sarcoma may receive chemotherapy.
16401990|NCT03965221|Experimental|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
16401991|NCT03965221|Experimental|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
16401992|NCT03965221|No Intervention|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
16401993|NCT03965208|Active Comparator|Unfractionated heparin|Patients randomized to this group will receive anticoagulation with unfractionated heparin
16401994|NCT03965208|Experimental|Bivalirudin|Patients randomized to this group will receive anticoagulation with bivalirudin
16401995|NCT03965195|Experimental|RIV4|Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff
16401996|NCT03965195|Active Comparator|IV4|Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff
16401997|NCT03965182|Active Comparator|PEG group|Patients in the PEG group were instructed to take the first sachet of PEG at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
16401998|NCT03965182|Active Comparator|PEG plus SPMC group|Patients in the PEG plus SPMC group will be instructed to take the SPMC sachet at 19:00 hours the day before colonoscopy and the PEG sachet at 6:00 hours on the morning of the day of colonoscopy.
16401999|NCT03965182|Active Comparator|SPMC group|Patients in the SPMC group were instructed to take the first sachet of SPMC at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
16402000|NCT03965169|Experimental|Patients undergoing prone spinal surgery|Patients undergoing elective spinal surgery in prone position under general anesthesia, which is performed by neurosurgeons in Seoul National University Hospital
16402001|NCT03965156|Active Comparator|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
16402002|NCT03965156|Active Comparator|transversus abdominis plane block|Ultrasound guided transversus abdominis plane block
16402003|NCT03965143||3D talar group|Patients that will undergo a 3D custom talar augment
16402004|NCT03965130|Experimental|Glucagon|Participants will receive glucagon or saline during the PINTA study
16402005|NCT03965117|Experimental|norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect.
16402006|NCT03965104|Experimental|Intervention pharmacists|Will receive the HC-PCP prior to starting enrollment, and then will provide care to their patients, which will include risk assessment, prescribing of antihypertensive medications, and follow-up monthly according to the Hypertension Canada Guidelines.
16402117|NCT03964259|Experimental|Reduced hydration regimen|The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.
16402007|NCT03965104|No Intervention|Control pharmacists|Will provide usual pharmacist care. All patients with blood pressure above target will be entered into the study database and serve as the control group. No specific interventions or follow-up will be mandated other than usual pharmacist care, although all patients will be assessed at 3 months to determine change in BP since enrollment (the primary outcome).
16402008|NCT03965091|Experimental|Fremanezumab - Dose A|
16402009|NCT03965091|Experimental|Fremanezumab - Dose B|
16402010|NCT03965091|Placebo Comparator|Placebo|
16402011|NCT03965078||CMO without epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery without evidence of epiretinal membrane at the time of diagnosis.
16402012|NCT03965078||CMO with epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery with evidence of epiretinal membrane at the time of diagnosis.
16402013|NCT03965065|Experimental|Sutureless Aortic Valve Prosthesis|Patients receiving sutureless aortic valve prostheses
16402014|NCT03965065|Active Comparator|Conventional Aortic Valve Prosthesis|Patients receiving conventional biological aortic prostheses
16402015|NCT03965052|Experimental|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
16402016|NCT03965052|Active Comparator|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
16402017|NCT03965039|Active Comparator|Marketed stannous fluoride toothpaste|Brush twice daily
16402018|NCT03965039|Active Comparator|Marketed potassium nitrate toothpaste|Brush Twice Daily
16402019|NCT03965039|Placebo Comparator|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
16402020|NCT03965039|Experimental|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
16402021|NCT03965013|Experimental|Part 1 (healthy): NNC0268-0965|A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)
16402022|NCT03965013|Placebo Comparator|Part 1 (healthy): placebo|A single dose of placebo (NNC0268-0965) given s.c.
16402023|NCT03965013|Experimental|Part 2 (type 1 diabetes): NNC0268-0965|A single dose of NNC0268-0965 given s.c.
16402024|NCT03965013|Active Comparator|Part 2 (type 1 diabetes): insulin glargine|A single dose of insulin glargine given s.c.
16402025|NCT03965000||Patients|Patients carrying one or both mutations.
16402026|NCT03965000||Controls|Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.
16402027|NCT03964987||Control group|Women with normoevolutionary gestation.
16402028|NCT03964987||Problem group|Patients with GDM.
16402029|NCT03964974|Experimental|CBTi-CB|Cognitive Behavioral Therapy for Insomnia in Cannabis Users
16402030|NCT03964974|Placebo Comparator|Sleep Education|Psycho-education on sleep and sleep hygiene
16402031|NCT03964961|Experimental|Functional massage|
16402032|NCT03964961|Active Comparator|Conventional massage|
16402033|NCT03964948|Other|Healthy Volunteers|20 healthy volunteers will be recruited and will receive a kidney MRI and the same blood and urine labs that are collected for the other arms. Results will be compared to the disease groups.
16402034|NCT03964948|Other|Kidney Transplant|20 subjects that have received a kidney transplant that have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
16402035|NCT03964948|Other|Stage 2-5 CKD|20 subjects that have been diagnosed with stage 2-5 CKD and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
16402036|NCT03964948|Other|Lupus nephritis|"20 subjects that have that have active lupus nephritis and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
~Subjects that are post-lupus treatment will receive an additional MRI at the time of the next biopsy."
16402037|NCT03964935|Experimental|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.
~After scaling, root planing, and polishing (SRP), the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
16402038|NCT03964935|Active Comparator|Minocycline HCL|Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
16402039|NCT03964935|Placebo Comparator|Distilled water|Used to irrigate periodontal pockets after SRP
16402040|NCT03964922|Experimental|immune escape mecanims|Cohort study with a representative sample of patients
16402041|NCT03964909|Experimental|Diagnostic (fMRI, CVR MRI, rs-fMRI)|Patients undergo standard of care fMRI, CVR MRI over 3 minutes, and rs-fMRI over 6 minutes 1 month before and within 6 weeks after standard of care surgery.
16402042|NCT03964896|Experimental|Supportive Care (telephone intervention)|During standard of care chemotherapy, patients receive up to 18 telephone calls from a nurse using a standardized triage call script over 20 minutes.
16402043|NCT03964857|Other|Refined olive oil (ROO)|Control
16402044|NCT03964857|Experimental|Blended Oil 1|BO1, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 2
16402045|NCT03964857|Experimental|Blended Oil 2|BO2, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 1
16402046|NCT03964844||CASE|Patients who had an episode of diarrhoea caused by C. difficile in an hematological unit (2003-2018)
16402047|NCT03964844||CONTROL|Patients who have had an episode of diarrhoea not caused by C. difficile in an hematological unit (2003-2018)
16402048|NCT03964844||PROSPECTIVE COHORT|All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019.
16402049|NCT03964805|Active Comparator|group A|Embryo culture at 20% O2
16402050|NCT03964805|Active Comparator|group B|Embryo culture at 5% O2
16402051|NCT03964805|Active Comparator|group C|Embryo culture at 5% O2 and at 20% O2
16402159|NCT03963934|Experimental|Women with uncontrolled hypertension|Women with uncontrolled hypertension and unsatisfactory medication adherence
16402246|NCT03963362|Experimental|Administration of GLA5PR 150 mg as 60~89 mL/min|Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)
16402052|NCT03964792|Experimental|DREPAGLOBE drug product|The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.
16402053|NCT03964779||Anovulatory women|40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility
16402054|NCT03964779||Tubal factor women|40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility
16402055|NCT03964779||male factor couple|40 women with exclusive male factor of infertility and will be used as a control group
16402056|NCT03964766|Experimental|rotary instrumentation|endodontic treatment will be performed with the use of pedo rotary files that will be activated by engine
16402057|NCT03964766|Active Comparator|hand istrumentation|endodontic treatment will be performed with the use of conventional hand files
16402058|NCT03964753|Experimental|Neo-adjuvant chemotherapy group|"cisplatin and nab-paclitaxel: Nab-paclitaxel, 125mg/m(2), d1,d8, Cisplatin, 75mg/m(2), d1, 3 week, 2 cycles.
~Surgery:
~4-6weeks after Neo-adjuvant chemotherapy"
16402059|NCT03964753|Active Comparator|Surgery alone|Surgery alone
16402060|NCT03964740|Experimental|Intervention|Mobile App intervention group
16402061|NCT03964740|No Intervention|Control Group|No intervention group
16402063|NCT03964688|Experimental|Vitamin C|vitamin C intravenous during hospitalization, followed with vitamin C oral
16402064|NCT03964688|Experimental|Placebo|placebo intravenous during hospitalization, followed with placebo oral
16402065|NCT03964675|Experimental|Respiratory rate measurement|Simultaneous measurement of respiratory rate using SenseGuard and Capnography
16402066|NCT03964662|Experimental|Patients with stroke|Rehabilitation of patients with stroke using a new technological device: WeReha
16402067|NCT03964649||Truven Health MarketScan Research Database|To compare RA-related costs among patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs (individually, as well as to TNFi and to non-TNFi each combined as groups).
16402068|NCT03964636||no contraceptive intake|
16402069|NCT03964636||combined 1st/2nd generation oral contraceptives intake|
16402070|NCT03964636||3rd/4th generation combined oral contraceptives intake|
16402071|NCT03964623||smokers|
16402072|NCT03964623||vapers|
16402073|NCT03964623||non smokers/non vapers|
16402074|NCT03964571|Experimental|Diabetic foot patients|
16402075|NCT03964558|Other|100 mg [14C]-acebilustat|a single oral dose of 100 mg [14C]-acebilustat
16402076|NCT03964545|Experimental|EFP neurofeedback|Ten sessions of EFP neurofeedback training. EEG is picked up with scalp electrodes, processed in real-time and returned to patients. One session lasts 30 min.
16402077|NCT03964545|No Intervention|Treatment as usual|Like patients from the treatment arm, these patients are on current residential treatment.
16402078|NCT03964532|Experimental|Phase I/Phase II|Talazoparib (1mg by mouth [PO] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously [IV] D1 every 2 weeks) will be added to talazoparib.
16402079|NCT03964519|Experimental|20% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
16402080|NCT03964519|Experimental|40% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 40% less compared to the first repetition.
16402081|NCT03964519|Placebo Comparator|Control group|This group will be just tested as a control group.
16402082|NCT03964506|Experimental|Hyperbaric Oxygen Therapy|Patients will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
16402083|NCT03964493|Experimental|TNP-2092|TNP-2092 300 mg intravenous every 12 hours
16402084|NCT03964493|Active Comparator|Vancomycin|vancomycin 1 g intravenous every 12 hours
16402085|NCT03964467|Experimental|Experimental|Transcranial Direct Current Stimulation.1) Scalp measurements of the scalp will be taken using the 10-20 EEG measurement system to determine anode and cathode placement. 2) One 1x1 Bicarbon electrode with wires attached will be placed in the center of each 5 cm x 7 cm sponge electrode dampened with 8 ml of saline. 3) One sponge electrode will be placed over the ipsilesional PMd (F3) and the other sponge electrode over the contralesional supraorbital region(Fp2). 4) Each sponge electrode will be secured under the plastic EZ strap 5) The current from the Actividose II will be turned up to 2 MA. The current will ramp up/down in 15 seconds. We will observe for adverse effects and hit the pause button, then turn the machine off, if a participant does not tolerate the stimulation. Individuals in this arm will have the stimulation stay in current until the full dose is delivered. Each participant will then engage in the UE TRT as outlined below.
16402118|NCT03964246|Experimental|Compassion Meditation (CM) intervention group|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
16402086|NCT03964467|Sham Comparator|Control|Individuals in this arm will have the stimulation cycled off after 2-3 minutes. All will be part of the Circuit-Based, UE Task Related Training. Each participant will engage in the training program for 1.5 hours; rotating through 5 stations at about 15 minute intervals, participating in standing as tolerated, but stations can be adapted to sitting. The goal is for each participant perform > 225 movements with the affected arm per session, at the highest functional level. Rest breaks given as needed. Examples of stations are: Reach-to-grasp tasks to objects of various weight, texture and dimension at different distances and table heights. Practice opening simulated locks and containers. Shoulder wheel involving grasping plastic plates with varied grip patterns and sliding them up and over the wheel from the unaffected to the affected side encouraging shoulder abduction, external rotation and supination. Bimanual/unimanual ball toss: catching, releasing.
16402087|NCT03964454|Experimental|SC + BFI|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives contingent on observed breastfeeding.
16402088|NCT03964454|Active Comparator|SC|Participants randomized into Standard Care (SC) will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
16402089|NCT03964441||control|fetus with at least 2 ultrasound abnormalities and both parents
16402090|NCT03964441||comparison|fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
16402091|NCT03964441||professional|obstetrician, midwife, geneticist, biologist
16402092|NCT03964428||periodontitis|
16402093|NCT03964428||periodontitis with T2DM|
16402094|NCT03964428||control|
16402097|NCT03964402||Control|Control arm, i.e., as per standard procedures
16402098|NCT03964402||Experimental|Experimental arm, i.e. investigational product
16402099|NCT03964389|Experimental|Intervetion group|"A sessions of Therapeutic Neuroscience Education (TNE) joint a physical exercises programs"
16402100|NCT03964389|No Intervention|Control group|Only a therapeutic physical exercises programs
16402101|NCT03964376|Experimental|Nasal High Flow Group|Nasal High-Flow oxygen delivery will be applied starting at airflow of minimum 20 Litre/minute. It will be titrated in 15Litre/minute increments to 35 Litre/minute and a maximum 50 Litre/minute as determined by patient comfort. O2 supplementation will be managed by the anesthesia and surgical health care team to maintain the oxygen saturation level in the blood between 92-95%. In the Nasal High-Flow group, when SPO2 is in the range of 92-95%, air will be given instead of oxygen for the 1st 3 nights and during the day, if required, till discharge, whichever is earlier.
16402102|NCT03964376|Other|Usual Care Group|In the usual care, patients will receive oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via facemask titrated to keep SpO2 level in the range of 92-95%. When SpO2 level reaches in the range of 92-95%, oxygen delivery will be discontinued.
16402103|NCT03964363|Experimental|Prehabilitation|Participants are scheduled for elective surgery and follow the home-based prehabilitation for 11-17 days
16402104|NCT03964363|Experimental|Prehabilitation + TAVI|Study participants who will undergo a TAVI form a subgroup with a modified enrolment procedure and longer duration of the intervention. The prehabilitation period is extended to 30 days.
16402105|NCT03964363|No Intervention|Control|Participants are initially evaluated for frailty prior to scheduled surgery but subsequently receive regular care without a prehabilitation program. All pre- and postsurgical evaluations will be identical to the prehabilitation group.
16402106|NCT03964363|No Intervention|Control+TAVI|The subgroup of participants who undergo a TAVI will be compared to a group of patients who will have had the same procedure. Hence the control group will also receive a screening via phone but then receive regular care. Follow-up after surgery will be identical in all groups.
16402107|NCT03964350|Experimental|Ethanol|Subjects will receive ethanol (0.4 or 0.8 g/kg) which will be administered in a gelatin vehicle.
16402108|NCT03964350|Placebo Comparator|Placebo (gelatin vehicle)|Subjects will receive placebo of black cherry sugar-free jello.
16402109|NCT03964337|Experimental|Cabozantinib Followed by Prostatectomy (Arm A)|Experimental group will received cabozantinib for 4 weeks, followed by a 2 week drug washout before a prostatectomy.
16402110|NCT03964337|Active Comparator|Immediate Prostatectomy (Arm B)|Control group will receive an immediate prostatectomy.
16402111|NCT03964324|Experimental|Severe snorers|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are noninvasive.
16402112|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2).
16402113|NCT03964285|Active Comparator|Rumination group|The patients will receive rumination induction. Rumination induction will follow a relevant activity for our patients: climbing steps. Rumination induction will be done right after climbing the steps.
16402114|NCT03964285|Experimental|distraction group|Distraction will follow a relevant activity for our patients: climbing steps. Distraction induction will be done right after climbing the steps.
16402115|NCT03964272|Experimental|ExAblate 4000 System|Exablate bilateral treatment for Parkinson's Disease Motor Features
16402116|NCT03964259|Active Comparator|Standard Hydration Regimen|In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).
16402158|NCT03963960|Active Comparator|Conventional triweekly high-flow hemodialysis|
16402119|NCT03964246|Active Comparator|Psychoeducational healthy aging group|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
16402120|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091|All neoplasms
16402121|NCT03964233|Experimental|Dose Expansion - Cohort 1-Arm A -BI 907828+BI 754091|NSCLC
16402122|NCT03964233|Experimental|Dose Expansion - Cohort 1 - Arm B - BI 907828|NSCLC
16402123|NCT03964233|Experimental|Dose Expansion - Cohort 2 - BI 907828 + BI 754091|Melanoma
16402124|NCT03964233|Experimental|Dose Expansion - Cohort 3 - BI 907828 + BI 754091|Liposarcoma
16402125|NCT03964233|Experimental|Dose Expansion - Cohort 4 - BI 907828 + BI 754091|Hepatocellular carcinoma
16402126|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091 + BI 754111|All neoplasms
16402127|NCT03964220||Patients with Asthma|
16402130|NCT03964181||Students Grades 3-12|
16402131|NCT03964181||Parents of Students Grades K-12|
16402132|NCT03964181||School Based Teachers and Staff Grades K-12|
16402133|NCT03964168||Biologic Therapy|Patient's who received and discontinued a biologic therapy
16402134|NCT03964155|Experimental|Patients with SDRA|Patients within 24 hours from meeting the Berlin criteria for moderate or severe ARDS and receiving inhaled sedation with sevoflurane
16402135|NCT03964142|Experimental|Cardiac Rehabilitation|Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
16402136|NCT03964142|No Intervention|Conventional management|Patients with conventional management and physical activity recommendation
16402137|NCT03964129|Experimental|Avance Nerve Graft with autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.
16402138|NCT03964116|Other|AYA|Questionnaires set all 3 months and psychological interviews if needed
16402139|NCT03964103|Experimental|gQ-lab daily|
16402140|NCT03964103|Placebo Comparator|Placebo|
16402141|NCT03964090|Experimental|1|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
16402142|NCT03964090|Experimental|2|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib Days 1-10 (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
16402143|NCT03964064|Experimental|I125 Seed Implantation|3D-printing Template-assisted CT-guided I125 Seed Implantation Prescription dose: gtv140-160gy ctv100-140gy Particle activity: 0.4-0.5mCi
16402144|NCT03964064|Experimental|Stereotactic Radiotherapy|According to the tumor volume, location, organ function and other factors, the dosage of stereotactic directional radiotherapy was determined. The range of BED value of radiotherapy was 80-100 for tumors above 5 mm from gastrointestinal tract and 60-80 for tumors below 5 mm from gastrointestinal tract.
16402145|NCT03964051|Experimental|Omalizumab 300 mg for s.c.injection|Omalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
16402146|NCT03964038|Active Comparator|gilteritinib|Participants will receive a single dose of gilteritinib under fasting conditions.
16402147|NCT03964038|Experimental|gilteritinib mini-tablet oral suspension|Participants will receive a single dose of gilteritinib oral suspension with water under fasting conditions.
16402148|NCT03964038|Experimental|gilteritinib mini-tablet|Participants will receive a single dose of gilteritinib mini-tablets under fasting conditions.
16402149|NCT03964025|Experimental|Cardioskin™ and 3-lead Holter recorder|This is single-arm study. All subjects will receive the investigational device (Cardioskin™) and comparator device (3-lead Holter recorder).The subject will be wearing both the Cardioskin™ and 3-lead Holter recorder for a period of 24 hours, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
16402150|NCT03964012|Experimental|NmCV-5|"Subjects in this arm will receive polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.
~A single dose of 0.5 mL will be administered intramuscularly."
16402151|NCT03964012|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.
~A single dose of 0.5 mL will be administered intramuscularly."
16402152|NCT03963999|Experimental|Patients Undergoing HCT|All patients enrolled will undergo grayscale US, Doppler US, US SWE and CEUS at specific time points as outlined in the protocol based on disease course.
16402153|NCT03963986|Active Comparator|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
16402154|NCT03963986|No Intervention|STANDARD group|The STANDARD group participants dont receive an access to an online digital platform but they receive an adapted advice sheet.
16402155|NCT03963973|Experimental|RDN-929|low, medium and high dose of RDN-929 capsules
16402156|NCT03963973|Placebo Comparator|Placebo|Matching placebo capsules
16402157|NCT03963960|Experimental|Hemodialysis with low dialysate flow|
16402160|NCT03963921|Experimental|F4 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
16402161|NCT03963921|Experimental|F3 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
16402162|NCT03963908|Experimental|Intervention|AtEase is a mobile app designed to promote pain self-management, healthy sleep habits, and effective stress management. It includes a tailored Newsfeed that updates regularly with articles, activities, videos, and quizzes chosen for the user; a chat feature that asks questions and provide tailored feedback; a Message Center; and a Pain Tracker. Users can interact with AtEase as often as they like for six months.
16402163|NCT03963908|Active Comparator|Comparison|Chronic Pain Education for Veterans is a VA-endorsed pain management online educational curriculum that provides CBT pain self-management materials. Users randomized to the comparison condition will have unlimited access for 6 months.
16402164|NCT03963895|Experimental|AB002 (E-WE-thrombin)|
16402165|NCT03963895|Placebo Comparator|placebo|
16402166|NCT03963882|Experimental|Group A|Patients in group A don't receive neoadjuvant chemotherapy
16402167|NCT03963882|Experimental|Group B|Patients in group B receive neoadjuvant chemotherapy and achieve imaging response
16402168|NCT03963882|Experimental|Group C|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy
16402169|NCT03963882|Experimental|Group D|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy
16402170|NCT03963869|Experimental|Arm A: New Malaria Camp (MC) village|"Receives MC intervention in year 1 and year 2.
~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
16402171|NCT03963869|Active Comparator|Arm B: No Malaria Camp (MC) village|"Receives Standard Malaria Control in Year 1 and MC intervention in Year 2.
~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
16402172|NCT03963869|Active Comparator|Arm C: Old Malaria Camp (MC) village|"Villages already in receipt of MCs prior to study initiation to study longer term effects.
~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual)) in the 2 year time frame of phase 1."
16402173|NCT03963843|Experimental|SCI internet delivered cognitive behavioural therapy|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
16402174|NCT03963843|Active Comparator|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
16402175|NCT03963830|Experimental|MOVE UP-Sustainability|12-week lifestyle intervention focusing on diet and activity
16402176|NCT03963817||Normals|Imaging normal subjects for equipment refinement
16402177|NCT03963817||Subjects with AMD|Imaging subjects with AMD
16402178|NCT03963804||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
16402179|NCT03963804||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
16402180|NCT03963791|Experimental|Eggshell powder gel|prepared from eggshell powder. applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
16402181|NCT03963791|Active Comparator|CPP-ACP crème|CPP-ACP crème (GC Tooth Mousse). applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
16402182|NCT03963765|Active Comparator|Group I (Standard DL-PDT)|"Superficial skin curettage all face with a dermatological curette
~All exposed skin was covered with pure chemical sunscreen
~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
16402183|NCT03963765|Experimental|Group II (DL-PDT with microneedles)|"Superficial skin curettage all face with a dermatological curette
~All exposed skin was covered with pure chemical sunscreen
~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
~A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding
~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
16402184|NCT03963765|Experimental|Group III (DL-PDT with CO2 laser)|"Superficial skin curettage all face with a dermatological curette
~All exposed skin was covered with pure chemical sunscreen
~After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
~A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
16402185|NCT03963765|Experimental|Group IV (DL-PDT with microdermabrasion)|"Superficial skin curettage all face with a dermatological curette
~Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied
~All exposed skin was covered with pure chemical sunscreen
~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
16402186|NCT03963752|Experimental|Ziyinxiehuo Granules and Megestrol Acetate|Experimental：Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.
16402187|NCT03963752|Active Comparator|Gonadotrophin|Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
16402188|NCT03963739||Race: Non-Hispanic African American|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
16402189|NCT03963739||Race: Non-Hispanic White|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
16402190|NCT03963739||Income: Low Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
16402191|NCT03963739||Income: Moderate to High Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
16402192|NCT03963726|Experimental|Stereotactic radiotherapy|In this study, the liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
16402193|NCT03963726|Experimental|Microwave ablation therapy|In this study, 3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
16402194|NCT03963713|Experimental|Stereotactic radiotherapy|"In this study, the metastases were treated with Stereotactic radiotherapy（SBRT）.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
~Stereotactic radiotherapy"
16402195|NCT03963713|Experimental|Conventionally-fractionated image- guided Intensity modulated|In this study, the metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
16402196|NCT03963700||Cancer patients with Paraneoplastic neurological syndromes|"Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies:
~Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer
~anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration
~anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis
~anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors
~anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors
~anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
~without antibodies (50 patients)."
16402197|NCT03963687|Active Comparator|Control Group|Participants will receive the Standard Nursing Education Intervention first
16402198|NCT03963687|Experimental|Intervention Group|Participants will receive the New Nursing Education Intervention first
16402199|NCT03963674|Experimental|Diacutaneous fibrolysis|
16402200|NCT03963674|No Intervention|Control|
16402201|NCT03963661|Experimental|c-SIGHT|SIGHT requires participants to grasp and lift rods with their less impaired arm.
16402202|NCT03963648|Experimental|CRSwNP|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are non-invasive.
16402203|NCT03963635||Lyme Infected|Subjects presenting with suspected Lyme Disease
16402204|NCT03963635||Controls|Subjects with no known Lyme Disease, past or present
16402205|NCT03963622|Active Comparator|Control|Standard ventilation strategy.
16402206|NCT03963622|Experimental|Respiratory Mechanics|The goal of this arm is to individualize tidal volume (VT) and PEEP according to respiratory mechanics.
16402207|NCT03963596|Active Comparator|Ranibizumab|Arm 1
16402208|NCT03963596|Active Comparator|Aflibercept|Arm 2
16402209|NCT03963583|Experimental|HEROIC Intervention Group|This group will receive the HEROIC intervention.
16402245|NCT03963362|Experimental|Administration of GLA5PR 75 mg over 90 mL/min|Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
16402210|NCT03963583|Experimental|Waitlist Control Group|The waitlisted group will receive usual care for caregivers for the first 16 weeks, which is normally limited to inclusion in some clinical assessment and teaching during patient visits. Waitlisted participants will receive monthly study postcards to encourage retention. After 16 weeks, they will begin the intervention.
16402211|NCT03963570|Experimental|Safe Step - digital exercise program|Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
16402212|NCT03963570|Other|Control group|During 1 year, the participants randomized to the control group will receive an email every month with general falls prevention information in a short video.
16402213|NCT03963557||Healthy participants|BMI 5th percentile to less than the 85th percentile
16402214|NCT03963557||Overweight/Obese participants|BMI 85th percentile or more
16402215|NCT03963518||Control|chemotherapy
16402216|NCT03963518||Experimental|immune-checkpoint inhibitor
16402217|NCT03963492|Active Comparator|Continuous Walking|Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
16402218|NCT03963492|Experimental|Interval Walking|Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
16402219|NCT03963479|Active Comparator|Magnesium-Vitamin B6|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
16402220|NCT03963479|Placebo Comparator|Placebo|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
16402221|NCT03963466|Experimental|group 1|(left side of cheek) 1064-nm Q-Switched fractional laser+drug Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
16402222|NCT03963466|Experimental|group 2|(right side of cheek) 1064-nm Q-Switched laser+drug Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
16402223|NCT03963466|Experimental|group 3|(left side of cheek) 1064-nm Q-Switched fractional laser Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24
16402224|NCT03963466|Experimental|group 4|(right side of cheek) 1064-nm Q-Switched laser Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24
16402225|NCT03963453||Interventional|Regular physical exercise group
16402226|NCT03963453||Control|Standards of care treatment
16402227|NCT03963440|Experimental|Cohorte 1|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).
~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.
~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
16402228|NCT03963427|Other|Irradiated women|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap.
16402229|NCT03963427|Other|Non-irradiated women|Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
16402230|NCT03963414|Experimental|Cohort 1|Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
16402231|NCT03963414|Experimental|Cohort 2|Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.
16402232|NCT03963401|Experimental|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
16402233|NCT03963401|Experimental|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
16402234|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
16402235|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
16402236|NCT03963401|Placebo Comparator|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
16402237|NCT03963401|Placebo Comparator|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
16402238|NCT03963388|Experimental|Intervention group|Speech therapy, right after T0 (baseline measurement).
16402239|NCT03963388|No Intervention|Control group|Patients will be on a waiting list for 8 weeks. After the primary endpoint (T1), patients will receive speech therapy.
16402240|NCT03963375|Other|Group 1: LP at Baseline and Week 5|Group 1: LP at Baseline and end of Week 5. Week 5 is the optimal time point for assessing cladribine concentrations in CSF
16402241|NCT03963375|Other|Group 2: LP at Baseline and Week 10|"Group 2: LP at Baseline and end of Week 10. Week 10 is the expected nadir time for lymphocyte and monocyte levels in CSF"
16402242|NCT03963375|Other|Group 3: LP at Baseline and End of Year 1|Group 3: LP at Baseline and end of Year 1. To assess if cladribine effects on CSF markers are maintained at the end of the first treatment cycle
16402243|NCT03963375|Other|Group 4: LP at Baseline and End of Year 2|Group 4: LP at Baseline and end of Year 2. To assess if cladribine effects on CSF markers are maintained at the end of the last treatment cycle
16402244|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 60~89 mL/min|Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)
16425689|NCT03801161|No Intervention|Healthy infants|
16402247|NCT03963362|Experimental|Administration of GLA5PR 150 mg over 90 mL/min|Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
16402248|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 30~59 mL/min|Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)
16402249|NCT03963336|Active Comparator|Group A|12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
16402250|NCT03963336|Active Comparator|Group B|12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
16402251|NCT03963336|No Intervention|Control group|24 healthy subjects for whom serum D-dimer was assessed by ELISA.
16402252|NCT03963323|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
16402253|NCT03963323|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
16402254|NCT03963271||Patients with unexplained polymorphic VT and/or VF|"Unexplained polymorphic VT and/or VF patients.
~Patients with VF and the DPP6 risk haplotype, reported by the AUMC team.
~The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+"
16402255|NCT03963271||Family members|Family members of index patients of group(s) mentioned above
16402256|NCT03963271||Control group|Control subjects with structurally normal hearts with an indication for a cardiac CT,
16402257|NCT03963258|Active Comparator|control group|Over a 3-week period, the subjects in the control group received 1 hour daily of conventional upper limb training 5 times a week,including compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
16402258|NCT03963258|Experimental|whole-body vibration group|Subjects in the whole-body vibration group received half an hour of daily conventional upper limb training, followed by whole-body vibration training for an additional half hour per day,5 days per week during a 3-week period
16402259|NCT03963245|Experimental|Intervention group|MA&R - an eight months rehabilitation intervention in addition to standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
16402260|NCT03963245|Active Comparator|Control group|Standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
16402261|NCT03963232|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
16402262|NCT03963232|Placebo Comparator|Placebo|Placebo administered SC.
16402263|NCT03963219|Experimental|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
16402264|NCT03963219|Active Comparator|Standard Bolus Calculator|Standard bolus calculator
16402265|NCT03963206|Other|Cabozantinib group|patients will receive Cabozantinib (within the framework of its MA) (an ECG is added)
16402266|NCT03963193|Experimental|Etoposide plus Cisplatin|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
16402267|NCT03963193|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
16402268|NCT03963180|No Intervention|control group|the control group received 3 cups hot water on the 6th, 12th and 18th hours after the operation
16402269|NCT03963180|Experimental|study group|drank 3 cups of caffeinated coffee on the 6th, 12th and 18th hours after the operation.
16402270|NCT03963167||Patient in treatment with BDP/FF/G fixed combination|
16402271|NCT03963154|Experimental|Implantation of a therapeutical patch|All the patients will receive a single central subretinal implantation in one eye of a monolayer of Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE). The implanted eye will be the one with the worst visual acuity.
16402272|NCT03963128|Active Comparator|Supplemented Vitamin D3|
16402273|NCT03963128|Placebo Comparator|Placebo|
16402274|NCT03963115|Active Comparator|Coated syringe with epinephrine|Epinephrine was coated syinge before drawing the allergen to filled in.
16402275|NCT03963115|Placebo Comparator|placebo|Normal saline was coated syinge before drawing the allergen to filled in.
16402276|NCT03963102|Active Comparator|Control Group 3 hours|Application of Ameluz for 3 hours.
16402277|NCT03963102|Experimental|Trial Group 4 hours|Application of Ameluz for 4 hours.
16402278|NCT03963089|Experimental|Study group|"Measure pulse pressure variation and systolic pressure variation after each set of tidal volume to 6mL/kg, 10mL/kg and 14mL/kg. Measure respiratory variation of aortic blood flow peak velocity via transesophageal echocardiography at tidal volume of 10mL/kg.
~Measure stroke volume index via transesophageal echocardiography before and 5 min after fluid loading with 10mL/kg of crystalloid."
16402279|NCT03963076|Experimental|allergic rhinitis|administration of a nasal hypertonic spray twice a day for one month
16402280|NCT03963063|Active Comparator|Non Goal-directed Care Group|
16402281|NCT03963063|Experimental|Goal-directed Care Group|
16402282|NCT03963050|Experimental|CF|30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
16402761|NCT03959527|Experimental|zoliflodacin|Participant in this arm will receive a single dose of zoliflodacin.
16402283|NCT03963050|Experimental|PF|30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
16402284|NCT03963037||Patients|The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.
16402285|NCT03963037||Controls|The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.
16402286|NCT03963024|Experimental|Single Arm Treatment|"Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;"
16402287|NCT03963011|No Intervention|Arm A: AXR Only|Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
16402288|NCT03963011|Active Comparator|Arm B: AXR + Bowel US|Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention
16402289|NCT03962998|Active Comparator|Lactulose/Rhamnose|1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
16402290|NCT03962998|Experimental|MB-102|4 μmol of MB-102/kg body weight administered orally as a solution
16402291|NCT03962985|Other|Intervention|The 41 participants will attend the guided tours at the Montreal Museum of Fine Arts.
16402292|NCT03962959|Active Comparator|Healthy Controls|"Healthy Controls: Participants who are matched for age and gender. No cognitive impairment supported by the following measures of general cognitive function: (a) Mini-Mental State Exam (MMSE) > 27; (b) Montreal Cognitive Assessment (MoCA) > 26; and (c) Clinical Dementia Rating Scale score of 0.
~This group will undergo the Transcranial Magnetic Stimulation (TMS) protocol. Intervention: Device: TMS"
16402293|NCT03962959|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment (MCI) clinical criteria: (a) self- or informant-reported cognitive complaint; (b) preserved independence in functional abilities; and (c) absence of dementia.
~Objective cognitive impairment supported by the following measures of general cognitive function: (a) Mini-Mental State Exam (MMSE) 24-27 (inclusive); (b) Montreal Cognitive Assessment (MoCA) 18-26 (inclusive); or (c) Clinical Dementia Rating Scale score of 0.5. Intervention: Device: TMS"
16402294|NCT03962933|No Intervention|Flexcystoscopy|Control cystoscopy every 3 months as a standard procedure
16402295|NCT03962933|Active Comparator|Uine biomarker|Urine test every 3 months
16402296|NCT03962920|Active Comparator|Surgical treatment + antibiotics|Use antibiotic
16402297|NCT03962920|Placebo Comparator|surgical treatment + placebo|Use placebo
16402298|NCT03962907|Experimental|Carrier group - intervention|BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
16402299|NCT03962907|No Intervention|Carrier group - control|
16402300|NCT03962907|Experimental|Non - carrier group - intervention|Lifo-Scrub sol 4%®, 500ml, B. Braun
16402301|NCT03962907|No Intervention|Non - carrier group - control|
16402302|NCT03962894|Experimental|Early Prehospital Systemic Corticosteroids|Children with asthma attacks who receive systemic corticosteroids in the prehospital environment by emergency medical services
16402303|NCT03962894|No Intervention|Usual Care|Children with asthma attacks treated by emergency medical services who receive usual care en route to emergency departments, where in the ED they then receive systemic corticosteroids
16402304|NCT03962881|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16402305|NCT03962881|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
16402306|NCT03962881|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
16402307|NCT03962868|Experimental|Endoscopic submucosal dissection (ESD)|
16402308|NCT03962868|Active Comparator|Endoscopic Mucosal Resection (WF-piece meal EMR)|
16402309|NCT03962855|Active Comparator|Ifetroban|Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.
16402310|NCT03962855|Placebo Comparator|Placebo|Matching placebo administered once daily for a minimum of 4 weeks.
16402311|NCT03962842|Experimental|Pilates group|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
16402312|NCT03962842|No Intervention|Control group|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
16402313|NCT03962829|Placebo Comparator|Placebo condition|Participants receive placebo capsule
16402314|NCT03962829|Active Comparator|mCPP condition|Participants receive active (mCPP) capsule
16402315|NCT03962816|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16402316|NCT03962816|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
16402317|NCT03962816|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
16402318|NCT03962803|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16402319|NCT03962803|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
16402320|NCT03962803|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
16402321|NCT03962790|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
16402322|NCT03962790|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
16402323|NCT03962777|Experimental|oil pulling|patients used oil pulling therapy for 4 days
16402324|NCT03962777|Active Comparator|chlorhexidine|patients used chlorhexidine digluconate for 4 days
16402325|NCT03962764||Incarcerated|Incarcerated fathers include fathers recruited in re-entry centers, detention facilitation and in county jails.
16402326|NCT03962764||Community|Community fathers include fathers who are recruited through community partners and self-referrals.
16402762|NCT03959527|Active Comparator|ceftriaxone and azithromycin combination|Participant in this arm will receive a single dose of comparators combination (ceftriaxone and azithromycin).
16402327|NCT03962751|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
16402328|NCT03962751|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
16402329|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
16402330|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
16402331|NCT03962751|No Intervention|Baseline Assessment Only|Participants complete baseline survey and conclude participation.
16402332|NCT03962738|Experimental|50 milligram (mg) Lasmiditan|50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
16402333|NCT03962738|Experimental|100 mg Lasmiditan|100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
16402334|NCT03962738|Experimental|200 mg Lasmiditan|200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
16402335|NCT03962738|Placebo Comparator|Placebo|Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
16402336|NCT03962725|Active Comparator|Control Group (C)|Endotracheal intubation would be facilitated by either Rocuronium (0.6-1mg kg-1) or Succinylcholine (1-1.5mg kg-1) and further dosing of Rocuronium would be left at the discretion of the anesthesia team members. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Neuromuscular blockade would be reversed with either Sugammadex or Neostigmine (based on institutional availability) and trachea would be extubated once patient meets criteria per attending anesthesiologist.
16402337|NCT03962725|Experimental|No Relaxant Group (NR)|Endotracheal intubation would be facilitated by Succinylcholine (1-1.5mg/kg) or Remifentanil (1-2mcg kg-1) if Succinylcholine use is contraindicated. No non-depolarizing NMBA would be administered to the patients randomized to the NR group. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine) either as boluses or infusion would be recommended in case of sustained high peak airway pressures (>35mm Hg), high intra-abdominal pressure, involuntary patient/diaphragmatic movement hindering surgical exposure and dissection. Choice and dose of adjunct/s to optimize operating conditions would be left to the discretion of the anesthesia team.
16402338|NCT03962712||Low-Wage Workers from Minneapolis, MN|Low-wage workers from Minneapolis, MN, where the minimum wage will be increased to $15-an-hour over the study period.
16402339|NCT03962712||Low-Wage Workers from Raleigh, NC|Low-wage workers from Raleigh, NC, where the minimum wage will not be significantly changed over the study period.
16402340|NCT03962699||Obese patients selected for bariatric surgery|Normospermic obese patients ((BMI>40), aged 20-50 years) who will undergo Bariatric surgery.
16402341|NCT03962699||Control Group: Non obese volunteers|Normospermic obese patients ((BMI>40), aged 20-50 years
16402342|NCT03962686||normoglycemics|In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
16402343|NCT03962686||patients with diabetes mellitus (DM) treated with metformin|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
16402344|NCT03962686||patients with diabetes mellitus (DM) treated with metformin plus SLGT2i|In this cohort will be enrolled 20 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by metformin 1000 mg daily (n 20) added to SLGT2i, 100 mg daily (n 30).
16402345|NCT03962673|Experimental|UVB- exposure|Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.
16402346|NCT03962660|Experimental|HaRTS-TRENDS|See description below.
16402347|NCT03962660|Active Comparator|Standard Care (SC)|See description below.
16402348|NCT03962647|Experimental|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
16402349|NCT03962647|Active Comparator|Letrozole Control|
16402350|NCT03962634|Experimental|Kovanaze Nasal Spray (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
16402351|NCT03962634|Active Comparator|Articaine Injections (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
16402763|NCT03959514|Experimental|AT247|Single subcutaneous injection 0.3 U/Kg
16402352|NCT03962621|Active Comparator|2940 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
16402353|NCT03962621|Active Comparator|1064 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 1064 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
16402354|NCT03962621|Experimental|Combined treatment group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm or 1064 nm laser (Fotona, Slovenia, EU) alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
16402355|NCT03962608|Experimental|Yaq-001|Standard medical treatment + Yaq-001 (8 g/ day)
16402356|NCT03962608|Placebo Comparator|Placebo|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
16402357|NCT03962582|Experimental|Supportive Back Comparison|Motion Concepts matrx back to be attached to individual's wheelchair in place of the individual's back. It will be adjusted for size and to support the spinal curves as compared to a fabric back
16402358|NCT03962556||Non-Trigger Point|
16402359|NCT03962556||Trigger Point|
16402361|NCT03962517|Experimental|Training with GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.
~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with the device."
16402362|NCT03962517|Active Comparator|Training without GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.
~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without the device."
16402363|NCT03962504|Experimental|written exposure therapy|The WET condition consists of 5 weekly treatment sessions, with the first session lasting 1 hour and each subsequent session lasting approximately 40 minutes. The first session consists of education about common trauma reactions and the WET rationale. The participant is then given general instructions for completing the trauma narratives and specific instructions for completing the first 30-minute narrative writing session. All WET sessions begin with the therapist reading the specific writing instructions, clarifying any questions the person has, and leaving the instructions with the participant during the 30-minute writing session. Writing instructions begin with a focus on the details of the trauma and then shift to the meaning of the trauma event. After 30 minutes of writing, the therapist stops the writing and conducts a 5-10 minute check-in regarding how the writing session went for the participant.
16402364|NCT03962504|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a 8-15, 90 minute trauma-focused treatment which consists of imaginal and in vivo exposures
16402365|NCT03962491|Other|Daily Self-Monitoring Surveys|Asked to complete daily self-monitoring surveys.
16402366|NCT03962491|Experimental|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete daily self-monitoring surveys, with opportunity for monetary rewards.
16402367|NCT03962478|Experimental|Stent with high-intensity focused ultrasound ablation|Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.
16402368|NCT03962478|Active Comparator|Stent without high-intensity focused ultrasound ablation|Patients undergo stent insertion on day 1.
16402369|NCT03962465|Experimental|3-drug re-induction regimen with inotuzumab|"One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.
~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.
~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
16402370|NCT03962465|Experimental|4-drug re-induction regimen with inotuzumab|"One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.
~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.
~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
16402371|NCT03962452|Other|Mitochondrial disease|Unresolved index patients with suspected mitochondrial disease
16402372|NCT03962439|Experimental|High-Demand Photography|A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
16402373|NCT03962439|Active Comparator|Moderate-Demand Photography|A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
16402374|NCT03962439|Placebo Comparator|At-Home Engagement Group|Participation, alone at home, in tasks that are relatively low in intellectual engagement.
16402375|NCT03962426|Active Comparator|Social Cognitive Training (SCT)|10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week
16402376|NCT03962426|No Intervention|Treatment as usual (TAU)|This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy
16402377|NCT03962413|Active Comparator|The middle meatal antrostomy approach.|"The middle turbinate will be gently moved medially. Then uncinectomy is the next step which will be performed in numerous ways. Once the natural ostium will be identified, an ostium seeker will be placed through the ostium and then carefully will be pushed posteriorly to widen the ostium.
~Using a through-cutting forceps, the ostium will be enlarged."
16402378|NCT03962413|Active Comparator|The endoscopic prelacrimal recess approach|A curved incision will be made between the anterior aspect of the IT and the posterior end of the nasal vestibule.the mucoperiosteum will be lifted posteriorly.Bone removal will be achieved. the anterior bony portion of the medial wall of the MS will be removed, .then the IT-NLD flap will be formed.The prelacrimal recess will be opened
16402454|NCT03961854|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
16402455|NCT03961841|Active Comparator|Chemoradiation|weekly 5-Fu and oxaliplatin
16402379|NCT03962413|Active Comparator|The canine fossa approach.|"It will be done either transnasally or transorally:
~** The transoral approach through a sublabial incision : CFA consist in a trocar placed in the canine fossa.After removal of the trocar a 4-mm microdebrider blade will be placed through the passage created by the trocar.
~** The transnasal approach: A curved incision will be made between the anterior aspect of the Inferior Turbinate and the posterior end of the nasal vestibule,the mucoperiosteum will be lifted posteriorly Then the investigators will reach the anterior wall of the maxillary sinus through bone removal which will be achieved using a gauch and hammer and a high-speed electric drill."
16402380|NCT03962400|Active Comparator|Control|Subjects will have warfarin dose determined in the usual fashion by a health care provider.
16402381|NCT03962400|Experimental|Treatment|Subjects will have warfarin dose determined using a reinforcement learning computer model.
16402382|NCT03962387||Atopic Dermatitis|
16402383|NCT03962374|Experimental|Frova|Frova will be used to facilitate the endotracheal intubation.
16402384|NCT03962374|Active Comparator|Stylet|Stylet will be used to facilitate the endotracheal intubation.
16402385|NCT03962361||Sudden cardiac death of ischemic cause|Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS < 8 points).
16402386|NCT03962348|Experimental|Targeted Educational Campaign (TEC) for Correction Officers|The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails at New York City's Rikers Island. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
16402387|NCT03962348|Experimental|Specialized Early Engagement Team|The investigators will implement a Specialized Early Engagement Team (SEET) in the same three jails. The SEET will increase the likelihood that referred individuals found to have first-episode psychosis enroll in Coordinated Specialty Care upon release.
16402388|NCT03962335|Experimental|VD group|Group that starts with Vegetarian diet (VD)
16402389|NCT03962335|Experimental|MD+Bt group|Group that starts with Mediterranean diet with oral supplementation with butyrate (MD+Bt)
16402390|NCT03962335|Active Comparator|MD group|Group that starts with Mediterranean diet (MD)
16402391|NCT03962322|Experimental|Weaning TDI|A tissue doppler evaluation, using a sector transducer, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration in the modality of ventilation which precedes the trial, during the SBT and after extubation.
16402392|NCT03962309||Patients in charge of the participating GPs|In the study will be included patients in charge of the participating GPs aged 40-70 years
16402393|NCT03962296|Experimental|Entelon|Three daily oral doses of 50mg tablets were administered to patients
16402394|NCT03962296|Active Comparator|Doxium|Three daily oral doses of 250mg tablets were administered to patients
16402395|NCT03962296|Placebo Comparator|Placebo|Three masking tablets were administered to patients
16402396|NCT03962283|Active Comparator|Rifaximin|ASA daily + misoprostol + Rifaximin (Rifaximin group)
16402397|NCT03962283|Placebo Comparator|Rifaximin Placebo|ASA daily + misoprostol + Placebo Rifaximin (Placebo group)
16402398|NCT03962270|Experimental|Treatment group|
16402399|NCT03962270|Sham Comparator|Control group|
16402400|NCT03962257|No Intervention|Conventional|This group will have standard of care infertility counseling and consent processes.
16402401|NCT03962257|Experimental|Engaged MD|This group will have standard of care infertility counseling and access to online teaching modules and the ability to sign consents online.
16402402|NCT03962244||SEMS Group|The outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy
16402403|NCT03962244||EVT Group|The outcome of using endoscopic vacuum therapy (EVT) in the treatment of postoperative leakage after esophagogastrostomy
16402404|NCT03962231|Active Comparator|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid re-education exercises, assisted arm elevation and scapula control exercises.
16402405|NCT03962231|Active Comparator|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises with focus on lateral rotation, medial rotation and arm elevation.
16402406|NCT03962218|Experimental|Early Aquatic Therapy (EAT)|Aquatic physiotherapy treatment at time 1 (week 1)
16402407|NCT03962218|Other|Late Aquatic Therapy (LAT)|Control for Group 1 for the 5 first weeks of Group 1 treatment. Aquatic physiotherapy treatment at time 2 (week 6).
16402408|NCT03962205|Experimental|Cognitive Behavioral life-style and well-being intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification and then 4 group-based 2-hour weekly sessions of the well-being intervention in addition to the treatment as usual.
16402409|NCT03962205|Placebo Comparator|Cognitive Behavioral life-style intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification in addition to the treatment as usual.
16402410|NCT03962192|Experimental|Survey tools|Survey instruments are shared with reviewers.
16402411|NCT03962179|Experimental|VACStent Group|Patient s who received a VACStent
16402412|NCT03962166||Cohort|consecutive adult patients undergoing first-time elective open-heart surgery
16402413|NCT03962127||First time ischemic stroke|Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
16402414|NCT03962114|Experimental|Intervention group|treatment with vitamin B3
16402415|NCT03962101|Experimental|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
16402456|NCT03961841|Experimental|FLOT|Eight perioperative chemotherapy cycles
16402457|NCT03961841|Experimental|FOLFOX|Twelve perioperative chemotherapy cycles
16402458|NCT03961828|Experimental|Thalassemia with HCV|The study was carried out upon 50 β-thalassaemic children infected with hepatitis C virus who attended for a medical check-up at the Hematology Unit, Pediatric Department, Tanta University Hospital. Hepatitis C virus infection was diagnosed by serological detection of HCV-Ab, and quantitative detection of serum HCV RNA by polymerase chain reaction (PCR).
16402459|NCT03961815|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
16402764|NCT03959514|Active Comparator|NovoRapid|Single subcutaneous injection 0.3 U/Kg
16402416|NCT03962075|Other|laparoscopic paravaginal repair|"patient enrolled in this arm were offered laparoscopic paravaginal repair by Using a 10mm laparoscope, video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique All cases received diclofenac potassium 100 mg and meperidine hydrochloride 50 mg intramuscular with anesthesia recovery and 12 hours later second dose of diclofenac potassium was given. Also 40-60 mg Enoxaparin was given 6-12 hours postoperatively as subcutaneous injection.
~Foley's catheter was removed 6 hours postoperative"
16402417|NCT03962062|Experimental|Cohort 1: 12-17 years|Moxidectin 8mg per oral, single dose
16402418|NCT03962062|Experimental|Cohort 2: 8-11 years|Moxidectin 8mg (or lower dose) per oral, single dose
16402419|NCT03962062|Experimental|Cohort 3: 4-7 years|Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2
16402420|NCT03962049|Experimental|Normal Hepatic Function|Healthy participants with Normal Hepatic Function
16402421|NCT03962049|Experimental|Mild Hepatic Impairment|Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)
16402422|NCT03962049|Experimental|Moderate Hepatic Impairment|Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)
16402423|NCT03962049|Experimental|Severe Hepatic Impairment|Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)
16402424|NCT03962023||Patient cohort|Routine follow-up of patients in the Cardiological Functional Explorations department - Valve Disease Centre for their primary mitral insufficiency by prolapse
16402425|NCT03962010|Experimental|Dose level 1|
16402426|NCT03962010|Experimental|Dose level 2|
16402427|NCT03962010|Experimental|Dose level 3|
16402428|NCT03962010|Experimental|Dose level 4|
16402429|NCT03962010|Placebo Comparator|Placebo|
16402430|NCT03962010|Active Comparator|Dulaglutide|
16402431|NCT03961997|Other|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
16402432|NCT03961997|Other|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
16402433|NCT03961997|Other|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
16402434|NCT03961984||Complex anal fistula|Patients with complex transsphincteric anal fistulas were treated with Biodesign® plug.
16402435|NCT03961971|Experimental|Treatment (MBG453, spartalizumab, stereotactic radiosurgery)|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16402436|NCT03961958|No Intervention|No protocolled propofol reduction|In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.
16402437|NCT03961958|Experimental|Two protocolled propofol reductions|In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness-reduction calculated using a predefined formula, and (2) before positioning-reduction equal to the average percentage decrease in CO after knee-chest position in phase
16402438|NCT03961945|Other|Screening Population|Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
16402439|NCT03961945|Other|Upper endoscopy - Barrett's Esophagus|Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
16402440|NCT03961945|Other|Upper endoscopy - No Barrett's Esophagus|Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
16402441|NCT03961932|Experimental|Normal Renal Function|Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m^2)
16402442|NCT03961932|Experimental|Mild Renal Impairment|Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m^2)
16402443|NCT03961932|Experimental|Moderate Renal Impairment|Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m^2)
16402444|NCT03961932|Experimental|Severe Renal Impairment|Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m^2), not on hemodialysis
16402445|NCT03961932|Experimental|End-Stage Renal Disease|Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis
16402446|NCT03961919|Experimental|FLAT-Auto|Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT
16402447|NCT03961906|Active Comparator|Tübingen physiotherapy concept|Will receive our therapy concept and perform self-trainings on a regular basis.
16402448|NCT03961906|No Intervention|controls|Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.
16402449|NCT03961893|Experimental|Arm A: Standard colonoscopy then colonoscopy with G-EYE|Arm A: Standard colonoscopy then colonoscopy with G-EYE
16402450|NCT03961893|Experimental|Arm B: G-EYE colonoscopy then standard colonoscopy|Arm B: G-EYE colonoscopy then standard colonoscopy
16402451|NCT03961867|Experimental|DS|D2 resection -- S1 * 1 cycle + DS * 6 cycles + S1 * 9 cycles
16402452|NCT03961867|Active Comparator|SOX|D2 resection -- SOX * 8 cycles + S1 * 8 cycles
16402453|NCT03961854|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
16402765|NCT03959514|Active Comparator|Fiasp|Single subcutaneous injection 0.3 U/Kg
16402460|NCT03961815|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
16402461|NCT03961802|Experimental|systematic early rehabilitation|systematic early rehabilitation
16402462|NCT03961802|No Intervention|without systematic rehabilitation|without systematic rehabilitation
16402463|NCT03961789||cohorte 1|patients undergoing opioid replacement therapy
16402464|NCT03961776||non-metastatic rectal adenocarcinoma nRCT indicated|Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.
16402465|NCT03961763|Active Comparator|omega-3 supplement|This group will receive a daily dose of 4g EPA+DHA (which is the recommended safe tolerable upper intake level of omega-3 supplements for healthy individuals) for eight weeks.
16402466|NCT03961763|Placebo Comparator|Placebo|This group will receive a daily dose of 4g olive oil placebo for eight weeks.
16402467|NCT03961750|Experimental|Intervention|A feasibility study examining a single patient group undertaking a 12 week, student-led, OTAGO exercise class for community dwelling older adults at Glasgow Caledonian University. OTAGO consists of progressive strength and balance exercises.
16402468|NCT03961737|Experimental|prostatic explants|A first series of biopsies will be performed during the procedure to place the gold grains prior to radiotherapy. Explants will be performed from these biopsies. Half of these explants will be irradiated with a research irradiator at a dose of 2 Gy then placed for 24 hours in an appropriate culture medium. The other half will be directly cultured for 24 hours. After 24 hours of incubation, half of the irradiated explants and half of the explants will be used to study the transcriptome. The tissues will be stored in RNAlater solution and then frozen at -80°C. The remaining half explants will be used for immunohistochemical analysis. Two years after the end of radiotherapy, a new series of biopsies will be performed for research, in order to verify histologically the effectiveness of radiotherapy.
16402469|NCT03961724||ESRD group|
16402470|NCT03961724||Control group|
16402471|NCT03961711|Experimental|Telemedicine encounter|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
16402472|NCT03961711|Active Comparator|In-person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
16402473|NCT03961698|Experimental|Cohort A (TNBC)|"IPI-549 in combination with front-line treatment. Cohort A will include two sub-cohorts: Cohorts A1 and A2.
~Cohort A1: Approximately 30 patients with locally advanced and/or metastatic TNBC with programmed death-ligand 1 (PDL1) positive disease based on immunohistochemistry (IHC) defined as IC1/2/3.
~Cohort A2: Approximately 30 patients with locally advanced and/or metastatic TNBC with PDL1 negative disease based on IHC defined as IC0."
16402474|NCT03961698|Experimental|Cohort B (RCC)|"IPI-549 in combination with front-line treatment. Cohort B will include two sub-cohorts: Cohorts B1 and B2.
~Cohort B1: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 positive disease based on IHC defined as IC1/2/3.
~Cohort B2: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 negative disease based on IHC defined as IC0."
16402475|NCT03961672|Experimental|Treatment (duvelisib)|"INDUCTION: Patients receive duvelisib PO BID on days 1-28. Cycles repeat every 28 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive duvelisib PO BID on days 1-2, 8-9, 15-16, and 22-23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16402476|NCT03961659|Active Comparator|Liraglutid|Liraglutid will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutid could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
16402477|NCT03961659|Active Comparator|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but dapagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
16402478|NCT03961659|Active Comparator|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to100mg three times daily if appropriate. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but acarbose could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
16402479|NCT03961633|Experimental|AWARE intervention|"This arm is the treatment group, which receives the intervention, and is the only arm in the study. See the intervention column for more descriptions."
16402480|NCT03961607|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
16402481|NCT03961607|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 50 J/cm2) after applying 5% 5-aminolevulinic acid cream for 1.5h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
16402517|NCT03961373|Experimental|Experimental Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
16402518|NCT03961360|Experimental|162 mg/day Aspirin|
16402519|NCT03961360|Active Comparator|81 mg/day Aspirin|
16402520|NCT03961347|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
16402766|NCT03959501|Experimental|Dapagliflozin|Dapagliflozin 10mg daily PO for 24 weeks
16402482|NCT03961594|Other|volume expansion in the ventilated patient|Including 51 patients, ventilated, under vasopressors suffering from septic shock. GLS, cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders. Patients with a 15% increase in cardiac output 20minutes after the end of volume expansion will be classified as persistent responders.
16402485|NCT03961568|Experimental|Core Study Placebo|Subjects who did not receive Cenobamate in the Core Study will receive Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks.
16402486|NCT03961568|Experimental|Core Study Active|Subjects who received cenobamate in the Core study will continue to receive the same daily dose (150 mg or 200mg).
16402487|NCT03961555|Experimental|SYN023+Rabies vaccine|"SYN023:
~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
~SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.
~Dosage form: 6mg/2mL, liquid,
~Dosage: 0.3 mg/kg of SYN023
~Frequency/duration: at Day 1
~Rabies vaccine (RabAvert/Rabipur):
~Interventions: should be administered in deltoid muscle
~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use
~Dosage: 1 mL after reconstitution
~Frequency/duration: at Day 1, 4, 8, 15, 29"
16402488|NCT03961555|Active Comparator|HRIG+Rabies vaccine|"HRIG:
~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
~Dosage form: 150 IU/mL or 300 IU/mL, liquid,
~Dosage: 20 IU/kg of HyperRab (HRIG)
~Frequency/duration: at Day 1
~Rabies vaccine (RabAvert/Rabipur):
~Interventions: should be administered in deltoid muscle
~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use
~Dosage: 1 mL after reconstitution
~Frequency/duration: at Day 1, 4, 8, 15, 29"
16402489|NCT03961542|Experimental|Intervention Group|"This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.
~Differences in fasting glucose and longitudinal changes over the study period should be additionally examined."
16402490|NCT03961542|No Intervention|Control Group|Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).
16402491|NCT03961529|Experimental|0.3% OPA-15406 ointment|Twice daily
16402492|NCT03961529|Experimental|1% OPA-15406 ointment|Twice daily
16402493|NCT03961516||Cystic Fibrosis, Pancreatic Sufficient|CF patients with exocrine pancreatic sufficiency
16402494|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, No Insulin|CF patients with exocrine pancreatic insufficiency but not treated with insulin therapy
16402495|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin|CF patients with exocrine pancreatic insufficiency who are treated with insulin therapy for CFRD
16402496|NCT03961503||Daptomycin (DAP)|DAP : Cohort of patients who received daptomycin as the first line treatment for at least 48 hours for the defined indication
16402497|NCT03961503||Vancomycin (VAN)|VAN : Cohort of patients who received vancomycin as the first line treatment for at least 48 hours for the defined indication
16402498|NCT03961477|Active Comparator|IF group|Interferential therpapy
16402499|NCT03961477|No Intervention|Placebo|No intervention
16402500|NCT03961464|Experimental|d-cycloserine|oral, capsule, 250 mg
16402501|NCT03961464|Experimental|Placebo|oral, capsule, lactose
16402502|NCT03961451||Group With Recommendations (GAR)|Patients in the GAR group will receive several recommendations and will have access to an online tool to increase motivation to engage in physical activity.
16402503|NCT03961451||Control Group (GC)|No recommendation given
16402504|NCT03961438|Active Comparator|Group A|HIV-uninfected participants
16402505|NCT03961438|Active Comparator|Group B|HIV-uninfected participants
16402506|NCT03961425|Active Comparator|NO CO2|Traditional De Airing maneuver
16402507|NCT03961425|Active Comparator|CO2 Cannula|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by non specific needle cannula
16402508|NCT03961425|Active Comparator|CO2 Cardia|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by commercial diffuser Cardia
16402509|NCT03961412|Experimental|family-based intervention + education materials|The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
16402510|NCT03961412|Active Comparator|women only intervention + education materials|Only the participants will attend the 1.5-2 hour face-to-face intervention on cervical cancer and screening.
16402511|NCT03961399|Active Comparator|biventricular stimulation (BiV) group|patients with Abbott Medical® CRT implanted with only biventricular stimulation (BiV).
16402512|NCT03961399|Experimental|SyncAVTM stimulation group|patients with Abbott Medical® CRT implanted and SyncAVTM stimulation activated
16402513|NCT03961386|Experimental|FallsTalk-C|FallsTalk CG intervention
16402514|NCT03961386|Active Comparator|FallsTalk|FallsTalk intervention
16402515|NCT03961386|No Intervention|PostCardOnly|Postcard only- Control group
16402516|NCT03961373|Active Comparator|Standard Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
16402521|NCT03961347|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
16402522|NCT03961334|Experimental|DOACs|Direct oral anticoagulants
16402523|NCT03961334|Active Comparator|Antiplatelets|Antiplatelets
16402524|NCT03961308|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
16402525|NCT03961308|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
16402526|NCT03961295|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
16402527|NCT03961295|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
16402528|NCT03961282|Experimental|Parkinson Disease Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
16402529|NCT03961282|Experimental|Healthy Participant Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
16402530|NCT03961256|Experimental|Exenatide SR Intervention Group|Subjects will receive, in addition to standard care, Exenatide SR 2 mg subcutaneous (SQ) weekly for 24 months.
16402531|NCT03961256|No Intervention|Standard of Care|Subjects will receive standard post-transplant care as per Mayo Clinic usual practice.
16402532|NCT03961243|Experimental|YUVA-GT-F901|Gene transfer to treat Hemophilia B
16402533|NCT03961230|Experimental|Oral Chinese medicine|Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.
16402534|NCT03961230|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.
16402535|NCT03961217||Gynecological Cases|"Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy at
~Radiumhemmat, Karolinska University Hospital and
~Jubileumskliniken at Sahlgrenska University Hospital in Sweden."
16402536|NCT03961217||Prostate Cases|Prostate Cancer survivors treated with radiotherapy for localized prostate cancer at Sahlgrenska University Hospital, Gothenburg, Sweden
16402537|NCT03961217||Gynecological Rehab Cases|Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy
16402538|NCT03961204|Experimental|Cladribine|
16402539|NCT03961191||Benign group|Patients with benign cervical histology, including normal findings, inflammation and LSIL
16402540|NCT03961191||HSIL group|Patients with cervical histology of HSIL
16402541|NCT03961191||Cancer group|Patients with cervical histology of cancer
16402542|NCT03961165|Experimental|Treatment arm|1mL 20 mg/mL butylscopolamine bromide i.v.
16402543|NCT03961165|Placebo Comparator|Placebo|1mL 9mg/mL NaCl
16402544|NCT03961152|Experimental|PainCoach-app group|In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
16402545|NCT03961152|No Intervention|Control group|The control group received usual care.
16402546|NCT03961139|Experimental|Continuous feeding (CF)|"Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.
~Feed volume increment per day is as per departmental protocol and same as comparator arm."
16402547|NCT03961139|Active Comparator|Bolus feeding (BF)|"Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.
~Feed volume increment per day is as per departmental protocol and same as experimental arm."
16402548|NCT03961126|Experimental|Group autologous platelet-rich plasma injection|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
16402549|NCT03961126|Active Comparator|Group Control|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
16402550|NCT03961113||assessment by questionnaire|
16402551|NCT03961100|Experimental|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
16402552|NCT03961100|Experimental|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
16402553|NCT03961087|Active Comparator|case group|patients with liver cirrhosis and frequent hepatic encephalopathy received coenzyme Q10 and Meclofenoxate in addition to usual hepatic support
16402554|NCT03961087|No Intervention|control group|patients with liver cirrhosis and frequent hepatic encephalopathy received usual hepatic support only
16402555|NCT03961074||Exposure group|Chinese women with iron deficiency anemia (IDA) during pregnancy.
16402556|NCT03961074||Control group|Chinese women without iron deficiency anemia (IDA) during pregnancy.
16402767|NCT03959501|Active Comparator|Sitagliptin|Sitagliptin 100mg daily PO for 24 weeks
16402557|NCT03961061|Active Comparator|Brenner FIT (Standard Care)|Adolescents will participate in Brenner Families in Training along with their caregiver. They will receive all components of standard Brenner FIT treatments.
16402558|NCT03961061|Experimental|Brenner mFIT (standard care plus mobile health components)|"Adolescents will participate in Brenner Families in Training along with their caregiver.
~Brenner mFIT (Families in Training + mobile health) includes all components of the standard Brenner FIT"
16402559|NCT03961048|Experimental|Bilateral catheters|patients receiving bilateral catheters (such as for patients undergoing sternotomies/midline incisions or with planned bilateral thoracotomy incisions)
16402560|NCT03961048|Experimental|Single catheter|patients who only have one catheter in place (such as in patients who have unilateral thoracotomies and not midline sternotomies)
16402561|NCT03961035||25% cycle ratio|Patients group treated with CPCTSI at a 25% cycle ratio
16402562|NCT03961035||31.3% cycle ratio|Patients group treated with CPCTSI at a 31.3% cycle ratio
16402563|NCT03961022|Active Comparator|ReWin(d)|Subjects have to take ReWin(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
16402564|NCT03961022|Placebo Comparator|placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
16402565|NCT03961009|Experimental|Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
16402566|NCT03960996|Experimental|Dacryocystorinostomy with bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy with bicanalicular intubation.
16402567|NCT03960996|Experimental|Dacryocystorinostomy without bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy without bicanalicular intubation.
16402568|NCT03960983|Experimental|Elderly pacients with complete dentures and Tongue Scraper|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of repeated before these steps
16402569|NCT03960983|Active Comparator|Elderly pacients with complete dentures and PDT|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
16402570|NCT03960970|Active Comparator|One-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once
16402571|NCT03960970|Experimental|Two-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once
16402572|NCT03960957|Experimental|Experimental|AbobotulinumtoxinA
16402573|NCT03960957|Placebo Comparator|Placebo|
16402574|NCT03960944|Experimental|Yoga in School Group|30-mins yoga sessions were conducted in schools for 8-weeks
16402575|NCT03960944|No Intervention|Control Group|Usual Activities in school
16402576|NCT03960931|Experimental|Aquatic rehabilitation|
16402577|NCT03960931|Experimental|Land based physical activities|
16402578|NCT03960931|Other|Conventional rehabilitation|
16402579|NCT03960918|No Intervention|usual neuro-rehab training|stroke patient under usual neuro-rehab training
16402580|NCT03960918|Experimental|Novel exercise training|stroke patient under aerobic exercise training
16402581|NCT03960905||Children with the usage of anti-infective drugs|in conformity with the clinical practice
16402582|NCT03960892|Experimental|E-CAU with Group Problem Management Plus (PM+)|"190 participants will be randomly assigned to E-CAU with Group PM+. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
~The participants in the experimental arm will receive Group PM+ by trained, non-specialist peer-refugees in addition to E-CAU."
16402583|NCT03960892|No Intervention|Enhanced care as usual (E-CAU) only|190 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a leaflet which will include information on the services that they can get from RASASA and other public services. ), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
16402584|NCT03960866|Experimental|Nyxol Ophthalmic Solution 1%|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
16402585|NCT03960866|Placebo Comparator|Nyxol Ophthalmic Solution Vehicle|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
16402586|NCT03960853|Experimental|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
16402587|NCT03960853|Placebo Comparator|volume controlled ventilation|patients will be allocated to volume controlled ventilation in operation
16402588|NCT03960840|Experimental|CLL/SLL|Dose escalation and expansion of YTB323 in combination with ibrutinib
16402589|NCT03960840|Experimental|DLBCL|Dose escalation and expansion of YTB323 single agent in DLBCL
16402590|NCT03960840|Experimental|Adult ALL|Dose escalation and expansion of YTB323 single agent in adult ALL
16402591|NCT03960827|No Intervention|Sedentary control|The control group does not engage in any acute exercise testing protocol.
16402592|NCT03960827|Active Comparator|Sedentary EE|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
16402593|NCT03960827|Active Comparator|Sedentary RE|Participants randomized to RT first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
16402594|NCT03960827|No Intervention|Highly Active EE|A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
16426636|NCT03794648|Experimental|Intervention Group|
16402595|NCT03960827|No Intervention|Highly Active RE|A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
16402596|NCT03960814||Cohort 1|New users of basal insulins glargine and detemir
16402597|NCT03960801|Experimental|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
16402598|NCT03960801|Active Comparator|Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
16402599|NCT03960788|Experimental|MRI with Gadoxetate Sodium|Subjects will receive Gadoxetate Sodium during MRI.
16402600|NCT03960775|Experimental|Group A (dexmedetomidine)|dexmedetomidine infusion group
16402601|NCT03960775|Placebo Comparator|Group B (saline)|normal saline infusion group
16402602|NCT03960762|Active Comparator|Group A = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
16402603|NCT03960762|Active Comparator|Group B = SAP group|SAP block (Group SAP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
16402604|NCT03960749|Experimental|Sprotte 25G needle, stylet reinserted|
16402605|NCT03960749|Experimental|Sprotte 25G needle, stylet not reinserted|
16402606|NCT03960749|Experimental|Sprotte 22G needle, stylet reinserted|
16402607|NCT03960749|Experimental|Sprotte 22G needle, stylet not reinserted|
16402608|NCT03960749|Experimental|Spinocan 25G needle, stylet reinserted|
16402609|NCT03960749|Experimental|Spinocan 25G needle, stylet not reinserted|
16402610|NCT03960736|Active Comparator|Group ESPB = Erector spinae plane block group|ESP block (Group ESP) will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
16402611|NCT03960736|Active Comparator|Group TEA = Thoracic epidural analgesia group|TEA will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
16402612|NCT03960710||Neuronal network Training group|"The following radiological variables, related to each CT examinations, will be collected for each patient:
~Injection modalities (without injection, injected)
~Major hepatectomy surgery
~Importance of hepatic dysmorphia
~Presence of intraperitoneal fluid effusion
~Presence of renal polycystosis (especially on the right side)."
16402613|NCT03960710||Neuronal network Validation group|"The following radiological variables, related to each CT examinations, will be collected for each patient:
~Injection modalities (without injection, injected)
~Major hepatectomy surgery
~Importance of hepatic dysmorphia
~Presence of intraperitoneal fluid effusion
~Presence of renal polycystosis (especially on the right side)."
16402614|NCT03960697|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
16402615|NCT03960697|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
16402616|NCT03960684|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System
16402617|NCT03960671|Experimental|Anxiolytics|Pediatric patients treated with sedation using anxiolytics
16402618|NCT03960658|Experimental|Ketamine and PE|ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.
16402620|NCT03960619|Experimental|in-person & mHealth coping skills training|hybrid in-person and mHealth coping skills training and activity coaching intervention is to reduce physical disability and decrease pain, fatigue and stress while enhancing patients' abilities to cope with symptoms that interfere with activity.
16402621|NCT03960606|Experimental|10 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
16402622|NCT03960606|Experimental|20 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
16402623|NCT03960606|Experimental|35 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
16402624|NCT03960606|Placebo Comparator|Placebo|Placebo
16402625|NCT03960593||Patients with cancer and / or hematological|The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.
16402626|NCT03960580|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
16402627|NCT03960580|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
16402628|NCT03960580|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
16402629|NCT03960554|Active Comparator|Active drug|Denosumab 60 mg subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
16402630|NCT03960554|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
16402631|NCT03960541|Experimental|CD24Fc Treatment|Participants with HIV on antiretroviral therapy will be administered 3 doses of CD24Fc (240mg IV infusion) q2w during a 4-week window, followed by a 24-week follow-up window to assess safety and changes in LDL.
16402632|NCT03960541|Placebo Comparator|Placebo|Patients with HIV on antiretroviral therapy will be administered 3 doses of normal saline solution (100 ml, IV infusion) q2w during a 4-week window, followed by a 24-week follow-up window to assess safety and changes in LDL.
16402658|NCT03960333||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
16402633|NCT03960528|Active Comparator|Under direct vision erector spinae plane block|"20 ml bupivacaine 0,25%+ lidocaine 1% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
16402634|NCT03960528|Sham Comparator|Control group|"20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
16402635|NCT03960502|Experimental|AG881|On Day 1, after fasting for 10 hours participants, will receive an oral capsule of [14C]AG-881 followed 2 hours later by a single intravenous (IV) infusion of [13C315N3]AG-881.
16402636|NCT03960489|Experimental|Treatment Sequence 1 (ABCD)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
16402637|NCT03960489|Experimental|Treatment Sequence 2 (BDAC)|Participants will receive 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 1 followed by single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
16402638|NCT03960489|Experimental|Treatment Sequence 3 (CADB)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 2 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
16402639|NCT03960489|Experimental|Treatment Sequence 4 (DCBA)|Participants will receive single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 3 followed by 100 mg of roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
16402640|NCT03960476|Experimental|Access to Web-Based Intervention|All study participants will be given access to the web-based study intervention, PlanYourLifespan.org.
16402641|NCT03960463|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
16402642|NCT03960463|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
16402643|NCT03960450|Experimental|Part A: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
16402644|NCT03960450|Placebo Comparator|Part A: Vehicle cream|Daily application of vehicle cream
16402645|NCT03960450|Experimental|Part B: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
16402646|NCT03960450|Placebo Comparator|Part B: Vehicle cream|Daily application of vehicle cream
16402647|NCT03960437|Other|Study Participant|Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.
16402648|NCT03960424|Experimental|Diabetes Telemonitoring (DTM)|"Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for Type 2 Diabetes (T2D), uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time virtual visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and teach back quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability."
16402649|NCT03960424|Active Comparator|Comprehensive Outpatient Management (COM)|"Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 American Diabetes Association (ADA) Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or well visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study Registered Nurse (RN) to collect data."
16402650|NCT03960411|Experimental|Doxycycline|Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI
16402651|NCT03960411|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI
16402652|NCT03960398||Patients concerned by iatrogenic diseases|Patients living in the South-East of France and consulting in the emergency department of Toulon La Seyne sur Mer hospital for iatrogenic diseases
16402653|NCT03960385||Hospitalized and controls|Age-matched case of hospitalized dengue and non-dengue control
16402654|NCT03960385||Outpatient and controls|Age-matched dengue case and non-dengue control
16402655|NCT03960359||Episodic viral wheezers (EVW)|EVW: Wheezing during discrete time periods (exacerbations), absence of symptoms between exacerbations Among which SIW: EVW with ≥ 2 exacerbations over the last 6 months Clinical, microbiological and inflammatory phenotype
16402656|NCT03960359||Multiple trigger wheezers (MTW)|MTW : wheezing during exacerbations but also symptoms between episodes. Clinical, microbiological and inflammatory phenotype
16402657|NCT03960346|Other|Esophageal Effects|To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
16402695|NCT03960008|Other|Trans-Arterial Chemoembolization (TACE)|Procedure/Surgery - Chemoembolization Drug: Doxorubin
16402696|NCT03959995|Experimental|exercise|Exercise group
16402659|NCT03960333||Overweight/Obese|Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
16402660|NCT03960333||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
16402661|NCT03960307||Septic patients|ICU patients with resuscitated sepsis, based on the sepsis-3 criteria. (n=30)
16402662|NCT03960307||Healthy controls|Apparently healthy controls (n=10)
16402663|NCT03960294|Experimental|DOZE Users|Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
16402664|NCT03960281||Single implant crowns in the anterior maxilla|No drugs to be administered. Patients who have had a single implant crown placed since more than one year in the anterior maxilla (second premolar to second premolar) will be invited for a review session for dental examination and to fill the Oral Health Impact Profile (OHIP) questionnaire.
16402665|NCT03960268|Experimental|Intervention|Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks
16402666|NCT03960255||Normal adiposity group|Body fat < 25% and <32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
16402667|NCT03960255||High adiposity group|Body fat ≥ 25% and ≥32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
16402668|NCT03960229|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips (for ICSI) will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
16402669|NCT03960229|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
16402670|NCT03960216|Sham Comparator|Minimal Periodontal Treatment (MPT)|Once the hopeless teeth have been extracted, randomized patients will receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and, after the last session, placebo capsules (one every 24 h for three days).
16402671|NCT03960216|Experimental|Intensive Periodontal Treatment (IPT)|Once the hopeless teeth have been extracted, randomized patients will receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and after the last session, systemic antibiotics (azithromycin 500 mgrs, every 24 h for three days).
16402672|NCT03960203|Experimental|Comparator|The comparator arm will involve patients monitored by InSight.
16402673|NCT03960190|Experimental|1K expression kit|Subjects will be using the breastpump with the with 1K expression kit.
16402674|NCT03960190|Experimental|2K expression kit|Subjects will be using the breastpump with the with 2K expression kit.
16402675|NCT03960177|Experimental|Treatment (glucarpidase)|Patients receive standard of care HDMTX IV over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.
16402676|NCT03960164|Experimental|Patient group|The group of patients included in the study following inclusion criteria with local (wound) and systemic test values prior and after to the application of the DRPM.
16402677|NCT03960151|Experimental|Rolapitant|Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone
16402678|NCT03960138|Experimental|Intermittent Theta-burst stimulation (iTBS)|Cross-over design - participants will receive both experimental treatments.
16402679|NCT03960138|Experimental|Continuous Theta-burst stimulation (cTBS)|Cross-over design - participants will receive both experimental treatments.
16402680|NCT03960125|Experimental|4% Imipramine Cream on Upper Forearm Site|Base cream will be applied to the lower forearm site.
16402681|NCT03960125|Experimental|4% Imipramine Cream on Lower Forearm Site|Base cream will be applied to the upper forearm site.
16402682|NCT03960112|Experimental|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
16402683|NCT03960099|Active Comparator|Pictograph in Banner and Verification Alert|Patient Pictograph displayed in the banner (at the top of the screen) AND Pictograph displayed in a verification alert when placing electronic orders.
16402684|NCT03960099|No Intervention|No Pictograph|No patient Pictographs displayed in the electronic health record.
16402685|NCT03960086|Experimental|Custom-made foot orthoses|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.
~Treatment period of 12 weeks"
16402686|NCT03960086|Active Comparator|Heel Lifts|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.
~Treatment period of 12 weeks"
16402687|NCT03960073|Experimental|MitoQ|20mg daily oral dose of MitoQ
16402688|NCT03960073|Placebo Comparator|Placebo|Oral TTP placebo
16402690|NCT03960047|Experimental|Intervention: Virtual Reality Training|Uses virtual reality to train children to cross streets
16402691|NCT03960047|Experimental|Intervention: Streetside Training|Train children to cross streets using real traffic in curbside locations
16402692|NCT03960047|No Intervention|Control|Receives no intervention
16402693|NCT03960021|Experimental|Single arm|Each patient is treated with 2 RFA interventions.
16402694|NCT03960008|Other|Stereotactic Body Radiation Therapy (SBRT)|Radiation Therapy
16402698|NCT03959982|Experimental|HHHFA Randomized Group|Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
16402699|NCT03959982|Active Comparator|Control Group|Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
16402700|NCT03959969|Experimental|Educational Video Recipients|Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
16402701|NCT03959969|Active Comparator|Standard of Care Recipients|Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
16402702|NCT03959943||Innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction with additional sensory nerve coaptation.
16402703|NCT03959943||Non-innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction without sensory nerve coaptation.
16402704|NCT03959930|Experimental|Interventional arm|Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
16402705|NCT03959904|Active Comparator|Small Stitch|Small stitch for wound closure
16402706|NCT03959904|Active Comparator|Large Stitch|Large Stitch for wound closure
16402710|NCT03959878|Experimental|Gastrostomy Tube|Non-hospitalized outpatients undergoing placement of a gastrointestinal gastrostomy tube (GIG tube) or GI jejunostomy tube (GIJ tube) will receive the usual Standards of Care related to the placement of a GIG or GIJ tube and the Constant Pressure Skin Disk.
16402711|NCT03959865||Long-acting GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
16402712|NCT03959865||Short-acting GLP-1RA|Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
16402713|NCT03959865||Human GLP-1 based GLP-1RA|Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
16402714|NCT03959865||Exendin-based GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
16402715|NCT03959865||Fixed ratio combination of BI/GLP-1RA|Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
16402716|NCT03959865||Flexible combination of BI/GLP-1RA|Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
16402717|NCT03959852|Active Comparator|Sub-Dissociative Ketamine alone|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
16402718|NCT03959852|Active Comparator|Fentanyl alone|1 mg/kg of Fentanyl IV administered over at least 1 minute
16402719|NCT03959852|Experimental|Sub-dissociative Ketamine and Fentanyl|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
16402720|NCT03959839|Experimental|Endoscopic Treatment|Rectal Endoscopic Submucosal Dissection
16402721|NCT03959839|Experimental|Minimally Invasive Laparoscopic Local Surgical Treatment|Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
16402722|NCT03959826|Active Comparator|Job activity contracting|Standard services plus job activity contracting
16402723|NCT03959826|Experimental|Reinforcement for completing activities|Standard services plus job activity contracting plus reinforcement for completing job-related activities
16402726|NCT03959774|Experimental|breast or colorectal or lung cancer, age 70 or older|breast or colorectal or lung cancer, age 70 or older
16402727|NCT03959761|Experimental|Treatment Group|Intraperitoneal (IP) nivolumab treatment, after extensive debulking surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
16402728|NCT03959748||PAH adults|Patients with pulmonary arterial hypertension who are at least 18 years old at study entry
16402729|NCT03959748||PAH children|Patients with pulmonary arterial hypertension who are at least 3 months old and are less than 18 years old at study entry
16402730|NCT03959748||CTEPH|Patients with chronic thromboembolic pulmonary hypertension who are at least 18 years old at study entry
16402768|NCT03959488|Experimental|MEDI8897|anti-RSV monoclonal antibody with an extended half-life
16402769|NCT03959488|Active Comparator|Palivizumab|anti-RSV monoclonal antibody
16402770|NCT03959475||Saint-Etienne Hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16406968|NCT03929926|Active Comparator|Group 1 (usual care)|receive usual care
16402731|NCT03959735|Experimental|High Intensity Interval Training (HIIT)|"50% of participants (inpatients with a diagnosis of severe mental illness) will be randomised to HIIT. HIIT will be conducted twice a week for 12 weeks using a stationary bike. Each session will have the following structure: 4-minute warm-up, followed by 5X1 minute intervals at 85-95% of maximum heart rate, interspersed with active pauses of 90 seconds cycling at approximately 60-70% of maximum heart rate, and a 4-minute cool-down. Each exercise session will take 19 minutes to complete (11 minutes of HIIT + warm-up and cool-down). However, the amount of HIIT will be adapted for people who may be unable to complete the above target and gradually build up until they can complete the recommended amount.
~All exercise sessions will be conducted in a 1:1 environment with a participant and a member of the research team who will supervise the exercise session."
16402732|NCT03959735|No Intervention|Treatment As Usual (TAU)|50% of participants will be randomised to TAU. They will be provided with details of the local hospital gym availability and instructed to maintain their usual dietary habits
16402733|NCT03959722|Experimental|Probiotics:Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a multispecies probiotics: Ecologic® PERFORMANCE ( 1*1010 CFU(Colony forming units)/daily dose, Winclove Probiotics B.V., Amsterdam).
16402734|NCT03959722|Placebo Comparator|Placebo: Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a placebo comparator (Winclove Probiotics B.V., Amsterdam)
16402735|NCT03959709|Experimental|Prepectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
16402736|NCT03959709|Active Comparator|Subpectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
16402737|NCT03959696|Active Comparator|Notification only arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening.
16402738|NCT03959696|Experimental|Training and Notification arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening and will complete a two-hour shared decision making communication skills training course that includes case studies, interactive exercises, and lecture content.
16402739|NCT03959683|Active Comparator|Trilogy device|Trilogy Lithotrite to fragment urinary tract calculi in the kidney, ureter and bladder
16402740|NCT03959683|Active Comparator|ShockPulse-SE|ShockPulse-SE Lithotripsy System to fragment urinary calculi in the kidney, ureter and bladder
16402741|NCT03959670||extensive TAAA|including Crawford extent I and II TAAA
16402742|NCT03959670||Crawford extent III TAAA|
16402743|NCT03959670||supra-renal aortic aneurysms|Crawford extent IV TAAA and para-renal abdominal aortic aneurysms.
16402744|NCT03959631|Experimental|Intervention group|The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
16402745|NCT03959631|No Intervention|Control group|The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
16402746|NCT03959618||dietary supplements group|dietary supplements questionary
16402747|NCT03959592|Active Comparator|Lutein, zeaxanthin and mesozeaxanthin|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
16402748|NCT03959592|Placebo Comparator|Placebo|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).
16402749|NCT03959579||"1st cohort = derivation cohort:"|"1st cohort = derivation cohort: 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy"
16402750|NCT03959579||"2nd cohort = validation cohort"|"2nd cohort = validation cohort: 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)"
16402751|NCT03959566|Active Comparator|Arm 1 (U0)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily"
16402752|NCT03959566|Experimental|Arm 2 (U600)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~600 mg Sutezolid orally once daily"
16402753|NCT03959566|Experimental|Arm 3 (U1200)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~1200 mg Sutezolid orally once daily"
16402754|NCT03959566|Experimental|Arm 4 (U600BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~600 mg Sutezolid orally twice daily"
16402755|NCT03959566|Experimental|Arm 5 (U800BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~800 mg Sutezolid orally twice daily
~2 mg Midazolam orally once per day on day-1 and day 14"
16402756|NCT03959553|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
16402757|NCT03959553|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
16402758|NCT03959553|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
16402759|NCT03959540||Cohort 1|Standard of care (including L-DOPA) + starting opicapone
16402760|NCT03959540||Cohort 2|Standard of care (including L-DOPA)
16402907|NCT03958526|Active Comparator|Active|Active stimulation over M1
16402771|NCT03959475||Firminy hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16402772|NCT03959475||South Lyon hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16402773|NCT03959475||Bordeaux hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16402774|NCT03959475||Saint-Chamond hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16402775|NCT03959475||Angers hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16402776|NCT03959475||Clermont Ferrand hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
16402777|NCT03959462|Experimental|Real tDCS|20 min of 1 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
16402778|NCT03959462|Sham Comparator|Sham tDCS|30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
16402779|NCT03959449|Experimental|Action Observation and Motor imagery|
16402780|NCT03959449|Active Comparator|Motor Imagery|
16402781|NCT03959449|Experimental|Exercise plus motor imagery and action observation|
16402782|NCT03959423|Experimental|Subjects 7-75 years of age|Subjects who have been diagnosed with type 1 diabetes
16402783|NCT03959410||HPV-positive patients|Patients who are positive for HPV DNA test
16402784|NCT03959397|Experimental|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
16402785|NCT03959384|Experimental|Surfactant replacement (Curosurf)|"Broncho-alveolar lavage (BAL) with 25 mg / kg of Curosurf, diluted 1:10 with physiological solution, divided in two aliquots administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).
~Following supplementation of a dose of 25 mg / kg of Curosurf, diluted with physiological solution 1: 2 (1 ml = 40 mg of surfactant), given in two aliquots with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
16402786|NCT03959384|Placebo Comparator|Ambient Air|"Broncho-alveolar lavage (BAL) with air, administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).
~Following supplementation of air given with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
16402787|NCT03959358|Experimental|Lenalidomide|"Participants will only receive lenalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.
~Participants will first be given a low dose of lenalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.
~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with lenalidomide at."
16402788|NCT03959358|Experimental|Pomalidomide|"Participants will only receive pomalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.
~Participants will first be given a low dose of pomalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.
~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with pomalidomide at."
16402789|NCT03959345|Experimental|Combination therapy group|intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
16402790|NCT03959345|Active Comparator|Standard therapy group|intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
16402791|NCT03959332|Experimental|Baloxavir Marboxil 40 mg|
16402792|NCT03959332|Experimental|Baloxavir Marboxil 80 mg|
16402793|NCT03959319|Experimental|Movement Pattern Training|Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
16402794|NCT03959319|Active Comparator|Manual Therapy (Joint Mobilization)|Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
16402795|NCT03959306|Experimental|Group I|this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months
16402796|NCT03959306|Active Comparator|Group II|this group of patients will receive their standard anti-diabetic treatment only
16402797|NCT03959293|Experimental|FOLFIRI plus durvalumab|"Durvalumab: 1500 mg by 1-hour IV infusion. Every 4 weeks until progression
~FOLFIRI (1 course every 2 weeks, until progression):
~Irinotecan: 180 mg/m² by 2-hour IV infusion,
~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,
~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,
~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
16402798|NCT03959293|Experimental|FOLFIRI plus durvalumab plus tremelimumab|"Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.
~Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).
~FOLFIRI (1 course every 2 weeks, until progression):
~Irinotecan: 180 mg/m² by 2-hour IV infusion
~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion
~5-FU bolus: 400 mg/m² by 10-minutes IV bolus
~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
16402799|NCT03959280|Experimental|Tailored intervention|"In this group, participants will receive a comprehensive lifestyle program in addition to CPAP therapy which will include a supervised exercise program, diet interventions and behavioural counselling during 12 weeks.
~Then, participants will follow a real-world maintenance program from weeks 12 to 24. It will include one telephone-based contact per month with the study coordinator. Participants will be encouraged to maintain their lifestyle modification during this phase."
16402800|NCT03959280|Active Comparator|Control|Participant in this group will benefit from routine CPAP therapy management from week 0 to 24.
16402801|NCT03959267|No Intervention|Usual Care|Participants will continue with their usual medical care. Usual care may vary at different sites. Based on the investigator's preliminary data usual care can result in not GCRA referral, referral directly to testing, or referral to genetic counseling with an interpreter. The investigators will document usual care for participants from the sites randomized to usual care.
16402802|NCT03959267|Other|Telephone Genetic Counseling|Participants will receive telephone genetic counseling with the culturally adapted protocol and booklet
16402803|NCT03959254|Experimental|Intervention Group|Application of a protocol of active exercises for recovery after arthroscopic hip surgery, adapted to the femoroacetabular shock characteristics.
16402804|NCT03959254|Active Comparator|Control Group|Usual post-surgical general guidelines for hip interventions described by Gocen et al
16402807|NCT03959228|No Intervention|referencial diet|0.8 g/kg/day of protein
16402808|NCT03959228|Experimental|protein very poor diet with additional keto-analogs|0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.
16402809|NCT03959215|Experimental|Usual care + Back in the Game|Smartphone-delivered cognitive behavioural therapy to support confidence to return to sport + usual post-operative physiotherapy rehabilitation
16402810|NCT03959215|Active Comparator|Usual care|Usual post-operative physiotherapy rehabilitation
16402811|NCT03959202|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
16402812|NCT03959202|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants in this group will also receive a Go4Life program book from the National Institute on Aging.
16402813|NCT03959189|Experimental|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
16402814|NCT03959189|Experimental|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
16402815|NCT03959176|Experimental|Group 1|"The right eye will receive a sham drop followed by 1 drop of Tropicamide 1%/Phenylephrine 2.5% five minutes after the sham drop is administered. A one minute wait will occur followed by a second drop of Tropicamide 1%/Phenylephrine 2.5%.
~The left eye will receive 2 drops of Brimonidine 0.2% followed by a five minute wait time. One drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a one minute wait time. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered."
16402816|NCT03959176|Experimental|Group 2|"The right eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered followed by a 15 second wait after which a sham drop will be administered.
~The left eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a 15 second wait after which 2 drops of Brimonidine will be administered."
16402817|NCT03959163|Other|DMSA/Quick MRI|All participants will go through DMSA and Quick MRI scan to help determine the validity of the Quick Renal MRI in pediatric kidney disease.
16402818|NCT03959150|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 po qd
16402819|NCT03959150|No Intervention|Observation|Observation
16402820|NCT03959137||Primary study group|Stage IV untreated NSCLC
16402821|NCT03959124|Experimental|AD with DBS|Alzheimer's disease subjects with optimal medication therapy and with DBS treatment
16402822|NCT03959124|Active Comparator|AD without DBS|Alzheimer's disease subjects with optimal medication therapy and without DBS treatment
16402823|NCT03959124|No Intervention|Normal control|Matched aged and demographics subjects
16402824|NCT03959111|Experimental|Ear stimulation (Location 1)|
16402825|NCT03959111|Experimental|Ear stimulation (Location 2)|
16402826|NCT03959085|Experimental|Arm I (HR-FAV B-ALL)|See detailed description for Arm I
16402827|NCT03959085|Active Comparator|Arm II (HR B-ALL CONTROL)|See detailed description for Arm II.
16402828|NCT03959085|Experimental|Arm III (HR B-ALL EXPERIMENTAL)|See detailed description for Arm III.
16402829|NCT03959085|Experimental|Arm IV (MPAL)|See detailed description for Arm IV.
16402830|NCT03959085|Experimental|ARM V (B-LLY)|See detailed description for Arm V.
16402908|NCT03958526|Placebo Comparator|Sham|Sham stimulation over M1
16402831|NCT03959072||Robotic Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
16402832|NCT03959072||Conventional (manual) Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
16402833|NCT03959059|Experimental|PKP of traditional procedure|traditional method of PKP
16402834|NCT03959046|Experimental|GIST|"GIST is an alternative way of speaking to patients. In order for patients to get the gist, Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved."
16402835|NCT03959046|No Intervention|Usual Care|These are physician and patient participants that will communicate in their normal, unchanged way.
16402836|NCT03959020||Patients, undergoing anti-reflux surgery|Patients having undergone anti-reflux surgery at the Department of Surgery, Kolding Hospital, a part of Hospital Lillebaelt, from 1th January 2002 - 31th December 2013
16402837|NCT03959007|Active Comparator|Control|Usual therapy and complete 3 questionnaire at 3 times during hospitalization : Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status
16402838|NCT03959007|Experimental|Experimental|9 consultations (3 x 3 sessions during hospitalization) of aesthetic care will be provided to patient include in experimental arm and 3 times questionnaires (Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status)
16402839|NCT03958981|Experimental|castor oil group|60 mL of castor oil in 140 mL of orange juice
16402840|NCT03958981|Placebo Comparator|placebo group|Patients will receive sunflower oil as a placebo
16402841|NCT03958955|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
16402842|NCT03958955|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
16402843|NCT03958942|Active Comparator|quadratus lumborum block|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
16402844|NCT03958942|Active Comparator|lumbar epideural block|received pre-emptive lumbar epidural block with 15 mL of 0.25% bupivacaine before induction of GA.
16402845|NCT03958929|Experimental|Education group|Subjects will be asked to watch a 5-10 min education film two times (pre-op one day and post-op one day).
16402846|NCT03958929|No Intervention|Control group|Standard patient procedure that includes a pre-operative discussion with an ophthalmologist about glaucoma surgery, during which the surgeon gains the patient's informed consent. Subjects will not be asked to watch education film..
16402847|NCT03958903|Experimental|Neurophysiological recording and stimulation of amygdala|Recording and stimulation of amygdala using Neuropace RNS devices at certain points through out the behavioral tasks.
16402848|NCT03958890|Experimental|HLX10|
16402849|NCT03958890|Placebo Comparator|placebo|
16402850|NCT03958877|Experimental|BIIB017 (peginterferon beta-1a)|Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
16402851|NCT03958877|Active Comparator|Avonex|Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
16402852|NCT03958864|Experimental|CC-90001 100 mg|100 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
16402853|NCT03958864|Experimental|CC-90001 200 mg|200 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
16402854|NCT03958864|Experimental|CC-90001 400 mg|400 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
16402855|NCT03958851||patients with lupus nephritis|Lupus nephritis is diagnosed by either the presence of proteinuria (>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.
16402856|NCT03958851||systemic lupus patients without lupus nephritis|The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group
16402857|NCT03958851||healthy individuals|a group of age and sex matched healthy individuals will be taken as a control group.
16402858|NCT03958838|Experimental|Intervention Group|"Subjects will receive usual care from community health center staff. In addition, they will also receive a variety of community-level and individual-level interventions, categorized broadly into three levels.
~At the community level, subjects will receive the 5 Key Diabetes Messages that Everyone Should Know and the 6 Modules of Basic Diabetes Education. At the individual level, subjects and their families will be invited to participate in group activities, co-organized by community health staff, CHC staff, and CSMG peer leaders. Subjects will receive in-person peer support through these group activities, with follow up through telephone calls and text messaging. For subjects that have poorly controlled diabetes or are experiencing emotional distress related to their diabetes, CSMG peer leaders will work closely with them to help them solve problems around their diabetes."
16402859|NCT03958838|No Intervention|Control Group|Subjects in the control group will receive usual care from community health center staff.
16402860|NCT03958825|Active Comparator|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
16402861|NCT03958825|Experimental|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
16402862|NCT03958812||Gastric cancer|patients with definitive diagnosis of gastric cancer by pathology
16402863|NCT03958812||Breast cancer|patients with definitive diagnosis of breast cancer by pathology
16402864|NCT03958812||Benign gastric diseases|Gastritis or gastric ulcer
16402865|NCT03958812||Benign breast diseases|Hyperplasia of mammary glands or mastitis
16402866|NCT03958812||Normal|healthy volunteers
16402867|NCT03958799|Experimental|Group 1: Investigational Product (IP) Formulation A|IP Formulation A administration, participation in Stage 1 and Stage 2
16402868|NCT03958799|Experimental|Group 2: IP Formulation A|IP Formulation A administration, participation in Stage 1
16402869|NCT03958799|Experimental|Group 3: IP Formulation B|IP Formulation B administration, participation in Stage 1 and Stage 2
16402870|NCT03958799|Experimental|Group 4: IP Formulation B|IP Formulation B administration, participation in Stage 1
16402871|NCT03958799|Experimental|Group 5: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
16402872|NCT03958799|Experimental|Group 6: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
16402873|NCT03958799|Experimental|Group 7: IP Formulation D|IP Formulation D administration, participation in Stage 1 and Stage 2
16402874|NCT03958799|Active Comparator|Group 8: Tdap|TdaP administration, participation in Stage 1 and Stage 2
16402875|NCT03958799|Active Comparator|Group 9: Tdap|TdaP administration, participation in Stage 1
16402876|NCT03958786|Experimental|single arm|500 HIV-1 infected patients, aged 70 years and older
16402877|NCT03958773|Experimental|Cardiovalve treatment|Patients that implanted with the Cardiovalve device
16402878|NCT03958760||Diabetic patients with CVD, CKD or at risk|The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
16402879|NCT03958760||Diabetic patients without CVD, CKD or at risk|The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
16402880|NCT03958760||Non-diabetic patients with CVD, CKD or at risk|The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
16402881|NCT03958760||Health controls|The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk.
16402882|NCT03958747|Experimental|Ultrasound|Undergo peripheral nerve ultrasound
16402883|NCT03958734|Other|Low physical activity/fitness|Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
16402884|NCT03958734|Other|High physical activity/fitness|Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
16402885|NCT03958721|Experimental|Concurrent Adjuvant Capecitabine and Radiotherapy|
16402886|NCT03958708|Experimental|Treatment Arm|
16402887|NCT03958695|Active Comparator|Tunable-tension transobturator tape (TTT)|
16402888|NCT03958695|Active Comparator|Transobturator mid-urethral tape (TOT)|
16402889|NCT03958682|Experimental|experimental group|During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.Patients can receive timely diagnosis and appropriate treatment
16402890|NCT03958669||Sorafenib treated HCC patients|No intervention is performed. This is an observational study.
16402891|NCT03958656|Experimental|1/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Dose Escalation|Patients will receive escalating doses (up to 4 planned) of Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
16402892|NCT03958656|Experimental|2/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Expansion Phase|Maximum tolerated dose (MTD) dose of Anti-Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)- CAR T Cells + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
16402893|NCT03958643||1|In a population of adult patients with SCD we will comprehensively evaluate renal function
16402895|NCT03958617|Active Comparator|On condition|Ongoing thalamic deep brain stimulation
16402896|NCT03958617|Sham Comparator|Off condition|Switched off thalamic deep brain stimulation, sham stimulation
16402897|NCT03958604|Experimental|Burst Spinal Cord Neurostimulation|Burst spinal cord stimulation. When this fails, tonic stimulation targeting the DRG wil be applied
16402898|NCT03958591|Experimental|Intensive-de-escalation group with intelligent management|
16402899|NCT03958591|Experimental|Intensive-de-escalation group without intelligent management|
16402900|NCT03958591|Active Comparator|Traditionally upgrading group|
16402901|NCT03958565||Actionable driver oncogene|One group will have an actionable driver oncogene and initiate treatment in any line with a TKI as standard of care and concurrent to participation to this study; expected to have an objective response rate in ≥40% who have not previously seen anti-bone resorptive therapy.
16402902|NCT03958565||No Actionable Mutations|The other group will not have actionable mutations and initiate treatment with chemotherapy/immunotherapy along with new onset therapy with IV zoledronic acid 4mg Q4 weeks or subcutaneous denosumab 120 mg Q12 weeks for bone disease, which is standard of care and would be concurrent to participation in this study.
16402903|NCT03958552|No Intervention|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
16402904|NCT03958552|Experimental|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
16402905|NCT03958539|Active Comparator|Intervention arm|6 sites out of a total of 12 will act as the intervention sites. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to be provided with bespoke 3-D printed insoles.
16402906|NCT03958539|No Intervention|Control|6 sites out of a total of 12 will act as the control sites providing standard care. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to standard care
16402909|NCT03958513|Placebo Comparator|Placebo|0.9% normal saline, 1.5 ml for 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
16402910|NCT03958513|Experimental|Intervention|0.25% Bupivacaine, 1.5 ml per 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
16402911|NCT03958500|Experimental|Comprehensive anastomotic testing|"All patients undergo:
~Indocyanine green fluorescent angiography intraluminally and intraperitoneally
~Air leak test
~Methylene blue test"
16402912|NCT03958487|Experimental|executive/monitoring training|All participants will be part of the same group and their performance after treatment will be compared to their own performance prior to treatment (baseline)
16402913|NCT03958474|Experimental|Active treatment followed by placebo treatment|Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
16402914|NCT03958474|Experimental|Placebo treatment followed by active treatment|Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
16402915|NCT03958461|Other|Calculus removement|Anti-infective treatment of teeth
16402916|NCT03958448|Experimental|Short Group|In each side of the posterior region of the maxilla, one tissue level implant, 4 mm long and 4.1 mm in diameter, will be installed
16402917|NCT03958448|Experimental|Standard group|sinus floor elevation with will be performed using natural bovine bone graft as filler material and porcine dermis collagen membrane to cover the antrostomy. After 4 months of healing, one bone level implant, 10 mm long and 4.1 mm in diameter, will be installed into each augmented sinus.
16402918|NCT03958422|Experimental|Myocardin test group|Patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI.
16402919|NCT03958422|No Intervention|Blank test group|Patients in blank test group aren't given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) .
16402920|NCT03958409|Experimental|Rigorous evaluation|Participants will be evaluated for the rigorous evaluation received.
16402921|NCT03958409|Active Comparator|Standard care|The participants will be evaluated for the standard of care received.
16402922|NCT03958396|Active Comparator|OSA Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea
16402923|NCT03958396|Active Comparator|Control (non-OSA) Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic
16402924|NCT03958383|Experimental|Experimental Groups|"PHASE IA: As described above. Participants receive hu14.18-IL2 fusion protein intratumorally (IT).
~PHASE IB: As described above. Participants undergo palliative RT and hu14.18-IL2 fusion protein IT as in phase IA.
~PHASE IC: As described above. Participants undergo palliative RT, receive nivolumab, and hu14.18-IL2 fusion protein IT as in phase IA.
~PHASE ID: As described above. Participants undergo palliative RT, receive nivolumab in combination with ipilimumab, and hu14.18-IL2 fusion protein IT as in phase IA."
16402925|NCT03958370||Fitbit|
16402926|NCT03958357||Treatment arm|Single arm study, 40 participants will undergo brachytherapy with the Advanced Gynecological Applicator Venezia Configuration
16402927|NCT03958344|Experimental|Intraorbital injection of steroid|"2 mL of steroid will be ready for each injection session:
~1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL
~For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.
~For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.
~For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection."
16402928|NCT03958344|Active Comparator|Oral Steroid|"Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).
~Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications."
16402929|NCT03958331|Active Comparator|Control Group|Automated reminders and individualized adherence feedback reports
16402930|NCT03958331|Experimental|Treatment Group|Automated reminders and individualized adherence feedback reports with social norms comparisons
16402931|NCT03958318|Experimental|Exercise|Multi-modal exercise program
16402932|NCT03958318|Experimental|Exercise plus nutritional suplementation|Multi-modal exercise program plus nutritional suplementation
16402933|NCT03958318|No Intervention|Control|No interventions
16402934|NCT03958305||LAPAROTOMY|Radical hysterectomy by laparotomy
16402935|NCT03958305||MINIMALLY INVASIVE SURGERY|Radical hysterectomy by minimally invasive surgery (Laparoscopy or Robotics)
16402936|NCT03958292|Experimental|Patients undergoing routine cataract surgery|"Two eye drops containing PVP-Iodine instillation in the eye undergoing cataract surgery three times for three days before surgery.
~Each patient was evaluated for conjunctival flora variation by means of two conjunctival swabs before starting the treatment and at the end of the treatment before the surgery."
16402937|NCT03958279||primipara giving birth|"The investigators involve every primipara giving birth in a period of two years.
~Exclusion criteria:
~a) Unwilling to participate
~b) Minors (under 18 years old)
~c) Foetus mortus or perinatal death of the newborn
~d) Admission of the newborn to the ICU
~e) Unfamiliar with slovak language
~f) Multiple pregnancy"
16402938|NCT03958266||MyIBD Care - Study Group|Will have traditional face to face outpatient contacts replaced with a novel mobile phone application supported via a digital clinician portal
16402939|NCT03958253|Experimental|Lung Cancer Screening Toolbox|"WU Staff will train local screening staff using a train-the-trainer model three months prior to the intervention and will provide technical assistance on an ongoing basis.
~During the 3 hour train-the-trainer session, the selected staff from the referral sites will learn about the program, receive an orientation to the toolbox elements, and discuss how to adapt the elements of the toolbox to their referral sites."
16407477|NCT03926416|Placebo Comparator|Placebo|Leibovitz's L-15 medium (IN) or saline (IM)
16402940|NCT03958240|Other|Patient with local and/or metastatic solid malignant tumor|Patient receiving an anticancer treatment in the context of their standard care.
16402941|NCT03958227|Experimental|''Manuel Therapy group''|This treatment group will be received Manuel Therapy techniques and exercise interventions.
16402942|NCT03958227|Experimental|''Exercise group''|This treatment group will be received only exercise interventions.
16402943|NCT03958214|Experimental|Recipe 4 Success|For 12 weeks, home visitors will stop delivering the usual practice Early Head Start home visits and deliver the Recipe 4 Success curriculum instead. At the end of 12 weeks, home visitors will resume usual practice Early Head Start home visits.
16402944|NCT03958214|Active Comparator|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
16402945|NCT03958201|Other|Protocol|Patients will have perioperative neuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed objectively at adductor pollicis with quantitative neuromuscular monitoring.
16402946|NCT03958188||Patients|"Patients who have undergone pre-operated computerized tomography (CT) imaging for a subsequently operated Neuro-endocrine tumor (NET).
~Clinical data collected for each patients:
~Age
~Sex
~Symptomatology (abdominal pain, diarrhea, carcinoid flush, digestive bleeding, weight loss, occlusive syndrome)
~Blood Chromogranine A and urinary 5-hydroxyindoleacetic acid (5-HIAA)
~Carcinoid valvulopathy"
16402947|NCT03958175||Patients with Parkinson's Disease|Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
16402948|NCT03958175||Patients without Parkinson's Disease = control group|Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
16402949|NCT03958162|Experimental|uniportal and tubeless video assisted thoracic surgery|lung biospy by the uniportal and tubeless video assisted thoracic surgery
16402950|NCT03958162|Experimental|transbronchial lung cryobiopsy|transbronchial lung cryobiopsy
16402951|NCT03958149|Other|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
16402952|NCT03958136|Experimental|Patients HR + and HER2-|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
16402953|NCT03958136|Experimental|Patients HER2 + with or without HR+|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
16402954|NCT03958136|Experimental|Patients triple negative (HR- and HER2-)|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
16402955|NCT03958123|Experimental|Treatment Group 1: Cebranopadol|"Supratherapeutic dose (1600 μg) of cebranopadol:
~Participants received placebo once a day for 2 days (Days -3 and -1); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 3 days; 900 μg once a day for 3 days; 1300 μg once a day for 3 days; 1600 μg once a day for 14 days; and placebo once a day on the last dosing day.
~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
16402956|NCT03958123|Experimental|Treatment Group 2: Cebranopadol|"Therapeutic dose (600 μg) of cebranopadol:
~Participants received placebo once a day for the first 11 days (Days -3, -1 and 1-9); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 14 days; and placebo once a day on the last dosing day.
~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
16402957|NCT03958123|Experimental|Treatment Group 3A: Placebo and Moxifloxacin|"Placebo / Moxifloxacin:
~Participants received placebo once a day for 31 days (Days -3, -1 and 1-29) and moxifloxacin 400 mg once on the last dosing day. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.
~Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
16402958|NCT03958123|Experimental|Treatment Group 3B: Moxifloxacin and Placebo|"Moxifloxacin / Placebo:
~Participants received placebo once a day for 2 days (Days -3 and -1); moxifloxacin 400 mg once for 1 day; and placebo once a day for the following 29 days. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.
~Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
16402959|NCT03958097|Experimental|NK cell combined with PD-L1 antibody|"Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16), total NK cells infused at least 3×10^9 .
~200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.
~NK cells and PD-L1 antibody will be infused every 21 days until disease progression or unacceptable adverse events."
16402960|NCT03958084|Experimental|Massage group|The deep massage will be applied for three minutes in the ischiotíbial muscles, only in the left limb, towards the muscular fibers. The volunteers will be placed in a ventral decubitus position on the stretcher.
16402961|NCT03958084|Experimental|Ventosa therapy group|The negative pressure ventosa therapy slide winds will be applied for three minutes in the oval direction in the posterior region of the thigh to contemplate the full extent of the ischiotíbial muscles, only in the left limb. The volunteers will be placed in a ventral decubitus position on the stretcher.
16403049|NCT03957486|Placebo Comparator|Different group|arterial cannulation on different arm of continuous hemoglobin monitoring
16402962|NCT03958084|Experimental|Foam roller group|The foam roller is a self-applied intervention for three minutes where the volunteers will be positioned on bench press on the floor of the room, with the left thigh posteriorly on the foam roller and the leg extended, the right lower limb will be in flexion of hip and knee, only the right foot and the right and left hands will touch the ground. Volunteers will be instructed to move so that they move forward and backward, causing the roller to travel the full length of the hamstring muscles.
16402963|NCT03958084|Experimental|Lumbar mobilization group|Unilateral lumbar mobilization of grade III at the frequency of 2Hz at the joint L4 / L5 of the ipsilateral side of the limb tested. The frequency was guaranteed by a metronome set at 120 beats per minute. Three sets of 1 minute of mobilization were performed with a 30 second interval, totaling a time of 4 minutes and 30 seconds of intervention. The technique was performed with the patient in the ventral decubitus position.
16402964|NCT03958084|Experimental|Proprioceptive neuromuscular facilitation group|Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
16402965|NCT03958084|No Intervention|Control group|The patient remained lying down in the ventral position for 4 minutes. the patient remained lying down in the ventral position for 4 minutes.
16402966|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
16402967|NCT03958058||Anti-borrelial antibiotic therapy|
16402968|NCT03958058||No antibiotics|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
16402969|NCT03958045|Experimental|Patients with Stage IV SCLC|Patients with extensive stage (IV) SCLC (small cell lung cancer)
16402970|NCT03958032||Participants with gastric cancer|All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
16402971|NCT03958019|Experimental|Intervention Group|12 week multidisciplinary program consisting of; i) supervised and home-based aerobic and resistance training, ii) 1:1 dietary counselling, and iii) group education sessions.
16402972|NCT03958019|No Intervention|Control|Usual care control group
16402973|NCT03958006|Experimental|Cochlear implantation|Simultaneous cochlear implantation with tumor resection
16402974|NCT03957993|Experimental|Occupational Therapy via Telehealth|Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
16402975|NCT03957993|Active Comparator|Standard of Care Occupational Therapy|Participants in the standard of care model will undergo occupational therapy treatment via traditional in- person encounters in an outpatient clinic setting for the entire episode of care (generally 10-12 weeks). These children will receive routine occupational treatment via in-person sessions with an occupational therapist conducted in an outpatient clinic setting.
16402976|NCT03957980|Other|Telehealth Intervention First|The participants in this arm of the study received occupational therapy via telehealth in the first 12 weeks of enrollment, then received no other intervention for the duration of the study.
16402977|NCT03957980|Other|No Intervention First|The participants in this arm of the study did not receive an intervention in the first 12 weeks of enrollment, but received occupational therapy via telehealth during the second 12 weeks of enrollment.
16402978|NCT03957967||acute pain|Patient with acute pain
16402979|NCT03957954|Experimental|Cultivated Limbal Stem-Cells (cLSC)|One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.
16402980|NCT03957954|Active Comparator|Scleral Contact Lens Device (SCL)|Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.
16402981|NCT03957941|Experimental|FamilyLink Pumping|Pump three times while away from infant, while watching baby via FamilyLink.
16402982|NCT03957941|Active Comparator|Standard Pumping|Pump three times while away from infant, not watching baby via FamilyLink.
16402983|NCT03957928|Active Comparator|Low fat cookies|Subjects consume 100 kcal of low fat cookies daily for 12 weeks.
16402984|NCT03957928|Experimental|Mango fruit|Subjects consume 100 kcal of mango fruit daily for 12 weeks.
16402985|NCT03957915|Experimental|INA03|INA03 administration
16402986|NCT03957902|Experimental|Arm 1 (100 mg/24h)|
16402987|NCT03957902|Experimental|Arm 2 (300 mg/24h)|
16402988|NCT03957902|Experimental|Arm 3 (100 mg/12h)|
16402989|NCT03957889||Student|
16402990|NCT03957889||Trainers|
16402991|NCT03957876|Experimental|intravenous CPX-351 with potential maintenance therapy|Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
16402992|NCT03957850|Experimental|Cognitive Reappraisal Training Group|Cognitive Reappraisal Training group will perform 4 training sessions in Cognitive Reappraisal during which, behavioral responses, event-related potentials (ERPs) and eye-tracking data are collected.
16402993|NCT03957850|Active Comparator|Control Training Group|Control Training Group will perform 4 control sessions without Cognitive Reappraisal Training during which behavioral responses, ERP and eye-tracking data are collected.
16402994|NCT03957837||Steep Trendelenburg|Patients undergoing elective laparoscopic prostatectomy in steep Trendelenburg position (25 degrees head down position)
16402995|NCT03957837||Healthy controls|Healthy awake volunteers undergoing steep Trendelenburg position (25 degrees head down position)
16402996|NCT03957811|No Intervention|Controls|Subjects under treatment for diabetes will receive the standard treatment for their condition.
16403081|NCT03957265|Experimental|Syncone|Tapered abutment connection
16402997|NCT03957811|Experimental|Intervention|Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.
16402998|NCT03957798|No Intervention|Control (Treatment as Usual)|TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment. For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center. For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service. For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service. For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
16402999|NCT03957798|Experimental|Intervention (Treatment as usual + game)|
16403000|NCT03957785|Experimental|Alter G treatment|All participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.
16403001|NCT03957785|Active Comparator|Traditional Gait Training|All participants practiced one session a day TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using FAC-tailored physiotherapist assistance, to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). Physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions.
16403002|NCT03957785|Active Comparator|Healthy Control|ll participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.The HC initially practiced the device at the same BWS and S administered to the patients. BWS and S were reduced progressively and increased, respectively, across the AlterG sessions in keeping with patients progresses.
16403003|NCT03957772|Active Comparator|Extrafascial injection|"Extrafascial injection of local anesthetic
~Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic"
16403004|NCT03957772|Experimental|Intrafascial injection|"Intrafascial injection of local anesthetic
~Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic"
16403005|NCT03957759||COPD patients|
16403006|NCT03957746|Experimental|3 sets of resistance exercise|
16403007|NCT03957746|Experimental|6 sets of resistance exercise|
16403008|NCT03957746|Experimental|9 sets of resistance exercise|
16403009|NCT03957746|No Intervention|Rest|
16403010|NCT03957733|Experimental|Experimental arm|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
16403011|NCT03957733|No Intervention|Standard arm|Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
16403012|NCT03957720|Experimental|homo-R778L|When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
16403013|NCT03957720|Experimental|R778L+truncation mutation|"When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment.
~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
16403014|NCT03957720|Experimental|Homo-P992L|"When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment.
~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
16403015|NCT03957720|Experimental|P992L+truncation mutation|"When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment.
~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
16403016|NCT03957720|Experimental|T935M+other point mutations|When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
16403114|NCT03957044|Experimental|sensory integration group|This group was given the education of sensory integration with vestibular education.
16403017|NCT03957720|Experimental|Presymptomatic patients with Wilson's disease|"According to different age group, they receive various dosage of Zinc Gluconate treatment.
~Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;"
16403018|NCT03957707|Experimental|stereotactic surgery with drugs treatment|
16403019|NCT03957707|Sham Comparator|drugs treatment alone|
16403020|NCT03957694|Experimental|AMG531|
16403021|NCT03957681|Experimental|KHK4827|
16403022|NCT03957681|Placebo Comparator|Placebo|
16403023|NCT03957668|Experimental|PEG 3350|The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.
16403024|NCT03957668|Active Comparator|Lactulax|15 ml of Lactulax syrup (containing 10 g of lactulose) is drunk with 240 ml of water once daily at bedtime, for a duration of 14 days
16403025|NCT03957655|Experimental|SHED group|SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.
16403026|NCT03957655|No Intervention|Control|Standard medication for viral hepatitis and cirrhosis
16403027|NCT03957629|Active Comparator|TDF group|93 patients would receive treatment of oral medication of tenofovir disoproxil fumarate (TDF) 300mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
16403028|NCT03957629|Active Comparator|Combination group|93 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg once per week and meanwhile oral medication of tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
16403029|NCT03957616||Paraneoplastic neurological syndromes patients|Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
16403030|NCT03957603|Experimental|TPF-DM Combined with Medical Nutrition Therapy Intervention|Participants in the experimental group will be provided with an individualized dietary, nutrition recommendation and the additional Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml). Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
16403031|NCT03957603|Active Comparator|Medical Nutrition Therapy Intervention|Based on the standard care, Participants will receive an individualized dietary, nutrition recommendations with the application of food exchange porting. Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
16403032|NCT03957590|Experimental|Tislelizumab + chemoradiotherapy|Tislelizumab once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
16403033|NCT03957590|Placebo Comparator|Placebo combined + chemoradiotherapy|Placebo once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
16403034|NCT03957577||All participants|Participants with COPD or Asthma-COPD overlap syndrome (ACOS)
16403035|NCT03957564|Experimental|Patients receiving neoadjuvant chemotherapy.|"Compare the monitoring of CTC, ctDNA and cfDNA with the results of CT scan and the blood level of CEA ,CA19-9 and CA72-4 tumor markers to explore the clinical value of dynamic detection of CTC, ctDNA and cfDNA in neoadjuvant chemotherapy and operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer.
~Explore the clinical value of different types of CTC in neoadjuvant chemotherapy and Operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer. CTC can be classified into three types: epithelial CTC, mesenchymal CTC, hybrids CTC.
~Explore the consistency between plasma ctDNA and tumor related DNA in pathological tissues after operation.
~To explore the relationship between the dynamic changes of plasma CTC, ctDNA and cfDNA levels and the prognosis of patients after operation."
16403036|NCT03957551|Experimental|Cabozantinib and pembrolizumab|Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
16403037|NCT03957538|No Intervention|Standard care|Standard consent and explanation
16403038|NCT03957538|Experimental|Virtual reality|Addition of VR headset
16403039|NCT03957525|Experimental|Orthopaedic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
16403040|NCT03957525|No Intervention|Orthopaedic Control group|Gets written and oral preparation for surgery
16403041|NCT03957525|Experimental|Urologic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
16403042|NCT03957525|No Intervention|Urologic Control group|Gets written and oral preparation for surgery
16403043|NCT03957525|Experimental|General Paediatric Surgery Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
16403044|NCT03957525|No Intervention|General Paediatric Surgery Control group|Gets written and oral preparation for surgery
16403045|NCT03957499|Placebo Comparator|the control group|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
16403046|NCT03957499|Active Comparator|Group dexamethasone/Bupivacaine:|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml).(
16403047|NCT03957499|Active Comparator|Group Magnesium sulphate/Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
16403048|NCT03957486|Experimental|Same group|arterial cannulation on same arm of continuous hemoglobin monitoring
16403050|NCT03957473||Single Arm|Single Arm - Use of Indigo Aspiration System with CAT RX Aspiration Catheter (mechanical thrombectomy) in high thrombus burden acute coronary vessel occlusions
16403051|NCT03957460||continuous and noninvasive hemoglobin monitoring|Group receive the continuous and noninvasive hemoglobin monitoring during laparoscopic gastrectomy.
16403052|NCT03957447||patients exhibiting skin wounds|Within the framework of Taabo HDSS Cross-sectional community and health services surveys are performed before wound management intervention (main study and substudy 1) is implemented (baseline) and are continued at 6 monthly intervals thereafter. Surveys are done door-to-door. All patients with skin lesions (broken skin barrier) are enrolled, lesions are documented with help of a questionnaire and photographic documentation.
16403053|NCT03957447||patients identified in the survey and willing to participate|Each patient with a wound will be enrolled. Presumptive clinical diagnosis and empirical treatment, as well wound assessment, will be recorded at enrollment and at each follow-up visit. Additional laboratory testing done within the framework of the local health system will also be recorded.
16403054|NCT03957447||patients exhibiting Buruli ulcers < 2cm|Buruli ulcer patients fulfilling inclusion criteria will be offered thermotherapy instead of standard antibiotic treatment. Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
16403055|NCT03957434|Experimental|Physiotherapy|12-weekly physiotherapy treatment sessions.
16403056|NCT03957434|No Intervention|Standard usual care|Participants will be asked to continue the usual care established during the regular follow-up with their medical doctor for 12 weeks.
16403057|NCT03957421|Experimental|Aquatic exercise is more beneficial than land based exercise|use of aquatic exercise will be evaluated for individuals with stroke
16403058|NCT03957408|Experimental|Visual Stimuli|Participants will be presented various visual stimuli in which accommodative response is measured.
16403059|NCT03957395|Experimental|scs high-frequency|high-frequency stimulation
16403060|NCT03957395|Experimental|scs tonic|tonic stimulation
16403061|NCT03957395|Experimental|scs burst|burst stimulation
16403062|NCT03957395|Placebo Comparator|scs off|off stimulation
16403063|NCT03957369||Adult naive HIV positive individuals|HIV-diagnosed subjects, older than 18 years, with no prior exposure to any antiretroviral drug.
16403064|NCT03957356|Experimental|HLBLS-200|HLBLS-200, absorbent hemostactic powder, will be applied intraoperatively to stop blood oozing during hepatic resection.
16403065|NCT03957343|Experimental|Pacing and Planning App|The Pacing and Planning Program is a points system to aid individuals with an acquired brain injury/concussion in planning daily activities and managing symptoms. Activities are allotted various points, depending on the energy the task requires and the symptoms they create. Activities can include anything from grocery shopping to driving or watching TV, etc. Patients are allotted a number of points for a day, and therefore learn to sparingly perform activities. This results in a reduction of symptoms and improved recovery time.
16403066|NCT03957330|Experimental|Community Mental Health Clinic|In this arm, clients will be assigned to therapists working in a community mental health clinic in Saskatchewan where the focus of the setting is primarily on face-to-face treatment and ICBT makes up a small component of the workload in the clinic.
16403067|NCT03957330|Experimental|Once a week therapist contact|In once a week treatment, therapists will email their clients once a week on a pre-determined day.
16403068|NCT03957330|Experimental|Reflection Questionnaire|"In the reflection questionnaire, patients will be asked to complete the following questions five times during the treatment period (beginning lesson 2-5 and then at the point they complete post-questionnaires):
~How much of the lesson were you able to review?
~How much effort were you able to put into the lesson?
~How difficult was the lesson?
~Please share any difficulties you had with the lesson.
~How understandable was the lesson?
~How helpful did you find the lesson?
~Please describe an example of what you learned.
~To what extent have you continued to use strategies from previous lessons
~If applicable, please provide an example of what you are working on from previous lessons
~Please indicate which Additional Resources you reviewed this week.
~If applicable, please share any skills you are working on from the Additional Resources."
16403069|NCT03957330|Experimental|Specialized Internet Therapy Clinic|In this arm, clients will be assigned to therapists working in a specialized internet therapy clinic where the therapists only deliver ICBT.
16403070|NCT03957330|Experimental|Twice a week therapist contact|In twice a week treatment, therapists will email their clients twice a week on pre-determined days.
16403071|NCT03957330|Experimental|No Reflection Questionnaire|In this arm, no reflection questions will be asked of clients receiving ICBT.
16403072|NCT03957317|No Intervention|Control|Subjects in this group do not receive an eye mask or ear plugs, and receive standard of care (including pain control modalities). The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
16403073|NCT03957317|Experimental|Intervention|Subjects in this group receive an eye mask and ear plugs in addition to standard of care for pain control. The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
16403074|NCT03957304|Experimental|Dexmedetomidine 1 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 1 mcg/kg (max 100 mcg or 1 mL).
16403075|NCT03957304|Active Comparator|Dexmedetomidine 2 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 2 mcg/kg (max 100 mcg or 1 mL).
16403076|NCT03957304|Active Comparator|Dexmedetomidine 3 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 3 mcg/kg (max 100 mcg or 1 mL).
16403077|NCT03957304|Active Comparator|Dexmedetomidine 4 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 4 mcg/kg (max 100 mcg or 1 mL).
16403078|NCT03957291|Active Comparator|Povidine-Iodine|patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye before operation
16403079|NCT03957291|Active Comparator|chlorhexidine|patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye before operation
16403080|NCT03957278|Experimental|DAISe System|The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.
16403082|NCT03957252||Training Cohort|1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than 3 ng/mL and no greater than 10ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
16403083|NCT03957252||Validation Cohort|Up to 1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than 3 ng/mL and no greater than 10ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
16403084|NCT03957239|Experimental|Cranberry Beverage|Four prepackaged juice boxes (4.23 oz each) containing a whole milled cranberry beverage for 2 weeks
16403085|NCT03957239|Placebo Comparator|Placebo Group|Four prepackaged juice boxes (4.23 oz each) containing a cranberry-flavored beverage for 2 weeks
16403086|NCT03957226|Experimental|Trasnhumeral e-OPRA Implant|This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.
16403087|NCT03957213|Experimental|Active IH + CT|Acute intermittent hypoxia will be provided to the subject by delivering 15 brief exposures (~60 seconds) of hypoxic air alternated with 15 brief exposures (~60 seconds) of room air. The amount of oxygen delivered during hypoxic exposures may range from 15%-9% fraction of inspired oxygen, compared to 21% oxygen in normal atmospheric air. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training.
16403088|NCT03957213|Sham Comparator|Sham IH + CT|A sham protocol will be administered in which 21% fraction of inspired oxygen will be delivered by the hypoxicator during hypoxic intervals, and room air will be delivered through the four-way valve during room air intervals. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training (Posit; Brain HQ).
16403089|NCT03957174|Experimental|Reboxetine|Single dose of 4mg
16403090|NCT03957174|Experimental|Rivastigmine|Single dose of 3mg
16403091|NCT03957174|Placebo Comparator|Placebo|Single dose of placebo
16403092|NCT03957161|Experimental|ACEi/ARB continuation|Intervention group will continue or start to take ACEi and/or ARBs
16403093|NCT03957161|No Intervention|ACEi/ARB withdrawal|The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
16403094|NCT03957148|Experimental|SSB Education|The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
16403095|NCT03957148|Sham Comparator|Food Safety Education|The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
16403096|NCT03957135|Experimental|Laparoscopic distal pancreatectomy|Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
16403097|NCT03957135|Active Comparator|open distal pancreatectomy|Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
16403098|NCT03957122|Experimental|individualized rTMS|Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
16403099|NCT03957122|Active Comparator|standard rTMS in responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
16403100|NCT03957122|Active Comparator|standard rTMS in non-responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
16403101|NCT03957109|Other|general anesthesia|general anesthesia
16403102|NCT03957109|Other|spinal anesthesia|spinal anesthesia
16403103|NCT03957096|Experimental|SGN-CD47M|
16403104|NCT03957083|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16403105|NCT03957083|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16403106|NCT03957083|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16403107|NCT03957083|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16403108|NCT03957083|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16403109|NCT03957083|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16403110|NCT03957070|Experimental|Liver Incyte|Patients with successfully treated HCV, or NASH Healthy volunteers with no history of liver disease. Patients and Volunteers will be scanned with FibroScan and Liver Incyte.
16403111|NCT03957057|Experimental|Iron carboxymaltose group|Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight > 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
16403112|NCT03957057|Experimental|Iron isomaltoside group|Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight > 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
16403113|NCT03957057|Active Comparator|Iron sulphate group|Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.
16403115|NCT03957044|No Intervention|Control group|The control group was given the education of sensory integration without vestibular education.
16403116|NCT03957031||Cases|Patients with a pathological confirmation of GC diagnosis
16403117|NCT03957031||Control|Patients with confirmed absent of GC
16403118|NCT03956992|Experimental|Mouth gel|A mouth gel with hydroxyapatite
16403119|NCT03956979|Experimental|JM-010 group A|As JM-010 4/0.8mg dose fixed combination drug(tablet) +Placebo 2
16403120|NCT03956979|Experimental|JM-010 group B|As JM-010 8/0.8mg dose fixed combination drug(tablet) + Placebo 1
16403121|NCT03956979|Placebo Comparator|Placebo|Double-dummy - 2 tablets = Placebo 1 +Placebo 2
16403122|NCT03956966|Placebo Comparator|saline|bilateral quadratus lumborum block using 0.9% normal saline
16403123|NCT03956966|Active Comparator|Bupivacaine|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25%
16403124|NCT03956966|Active Comparator|Bupivacaine and dexamethasone|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25% and dexamethasone
16403125|NCT03956953|Experimental|Group 1: BMS-986165 Dose 1|Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
16403126|NCT03956953|Experimental|Group 2: BMS-986165 Dose 2|Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
16403127|NCT03956953|Placebo Comparator|Group 1: Placebo Dose 1|Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
16403128|NCT03956953|Placebo Comparator|Group 2: Placebo Dose 2|Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
16403129|NCT03956940|Experimental|Intplex test|In vitro diagnostic device
16403130|NCT03956927||patients|Insulin-dependent diabetic patients who have participated in a full TPE program (3 sessions)
16403131|NCT03956914|Experimental|DSW (deep sea water) group|DSW, 440 ml/day for 8 weeks
16403132|NCT03956914|Placebo Comparator|Placebo group|Placebo, 440 ml/day for 8 weeks
16403133|NCT03956901|Experimental|Liberal Fluid Management|liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
16403134|NCT03956901|Experimental|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after
~2 ml \ kg crystalloid infusion to be started
~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.
~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.
~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
16403135|NCT03956888|Experimental|N-acetylcysteine treatment|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
16403136|NCT03956875|Active Comparator|yoga|Yoga treatment
16403137|NCT03956875|Placebo Comparator|massage|massage
16403138|NCT03956862|Experimental|GB001|GB001 40 mg once per day (QD) for 16 weeks
16403139|NCT03956862|Placebo Comparator|Placebo|Placebo QD for 16 weeks
16403140|NCT03956849||Professionals working with children|The studypopulation for this mixed-methods study is consisting of healthcareprofessionals working with children (with overweight or obesity), such as pediatric residents, paediatricians and youth health care professionals. Also other professionals working with children, not working in the field of healthcare, such as teachers, can be included in the study population.
16403141|NCT03956823|Experimental|Telmisartan|generic name：telmisartan；dosage form：80 mg；dosage：80 mg；frequency：once a day；duration：June , 2019-June , 2021
16403142|NCT03956823|Active Comparator|Amlodipine|generic name： amlodipine；dosage form：5mg；dosage：5mg；frequency：once a day；duration：June , 2019-June , 2021
16403143|NCT03956810|Experimental|On-demand transportation|Women randomized to the intervention group will be able to contact the transportation broker via telephone, web portal, or the broker's mobile application. In addition to the current trips provided by their Medicaid managed care organization , women assigned to the intervention group will be provided with extra trips to the pharmacy and grocery store or food bank.
16403144|NCT03956810|Active Comparator|Usual transportation|Women assigned to the usual care group will receive the usual transportation services from their Medicaid managed care organization.
16403145|NCT03956797|Experimental|-15 degrees Celsius for 10 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds.
16403146|NCT03956797|Experimental|-15 degrees Celsius for 15 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds.
16403147|NCT03956784|Experimental|E-assessed follow up|Patients undergoing colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric, for whom an early discharge has been programmed, and followed by a connected application and a nursing logistics platform at home.
16403148|NCT03956784|Other|Standard home follow-up care|Patients undergoing surgery for colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric surgery, for whom an early discharge has been programmed, and followed by usual way.
16403149|NCT03956771|Experimental|Real neurofeedback|Two sessions of neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
16403150|NCT03956771|Sham Comparator|Sham neurofeedback|Two sessions of placebo/control neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
16403151|NCT03956732|Experimental|High protein yoghurt and vitamin D supplement|Subjects will receive high protein yoghurt and vitamin D tablets.
16403152|NCT03956732|Experimental|High protein yoghurt and placebo supplement|Subjects will receive high protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
16403153|NCT03956732|Experimental|Medium protein yoghurt and vitamin D supplement|Subjects will receive medium protein yoghurt and vitamin D tablets.
16403154|NCT03956732|Placebo Comparator|Medium protein yoghurt and placebo supplement|Subjects will receive medium protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
16403421|NCT03954873|Experimental|Hyperglycaemia + GLP-2|Glucose + GLP-2
16403155|NCT03956719|Experimental|Autologous adipose-derived mesenchymal stem cells|Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells
16403156|NCT03956706|Experimental|Dose Escalation (18Gy)|Receive additional dose of 18Gy to the subventricular zone
16403157|NCT03956706|Experimental|Dose Escalation (20Gy)|Receive additional dose of 20Gy to the subventricular zone
16403158|NCT03956706|Experimental|Dose Escalation (22Gy)|Receive additional dose of 22Gy to the subventricular zone
16403159|NCT03956693|Experimental|HEADS: UP|HEADS: UP is group-based mindfulness intervention based on the original mindfulness based stress reduction course, but adapted for people affected by stroke.
16403160|NCT03956680|Experimental|Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)|
16403161|NCT03956680|Experimental|Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study|
16403162|NCT03956680|Experimental|Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study|
16403163|NCT03956680|Experimental|Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab|
16403164|NCT03956680|Experimental|Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab|
16403165|NCT03956667|Experimental|Experimental: Live Music|Live Music will be played during the required Emergency Department procedure.
16403166|NCT03956667|No Intervention|Control: No Live Music|There will be no music played during the required Emergency Department procedure.
16403167|NCT03956641|Experimental|experimental: observational cohort|Evaluation of the physical condition and the quality of life
16403168|NCT03956628|Experimental|experimental group|participants in experimental group receive intervention and experimental group consists of two sub groups, teachers and students.
16403169|NCT03956628|No Intervention|control group|participants in control group does not receive intervention and control group consists of two sub groups, teachers and students.
16403170|NCT03956602|Active Comparator|Pretzels|Subjects consume pretzels to examine postprandial response
16403171|NCT03956602|Experimental|Brazil nuts|Subjects consume Brazil nuts to examine postprandial response
16403172|NCT03956602|Active Comparator|Potato chips|Subjects consume potato chips to examine postprandial response
16403173|NCT03956602|Experimental|Mixed nuts|Subjects consume mixed nuts to examine postprandial response
16403174|NCT03956589|Experimental|Orkambi open-label arm|Open-label study: all subjects will receive Orkambi during 3 months.
16403175|NCT03956576|Active Comparator|Chronic Kidney Disease patients|"Forearm blood flow studies
~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.
~Renal clearance studies
~Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.
~Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.
~[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.
~Crossover design, so patients will receive both apelin and placebo infusion."
16403176|NCT03956576|Active Comparator|Healthy volunteers|"Forearm blood flow studies
~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.
~Renal clearance studies
~Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.
~Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.
~[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.
~Crossover design, so patients will receive both apelin and placebo infusion."
16403177|NCT03956563|Active Comparator|Active treatment arm|Youlaser MT: sequential 10600+1540 nm with vaginal (2 passes) and intritus (1 pass) treatment
16403178|NCT03956563|Sham Comparator|Control arm|Youlaser MT: no laser emission with vaginal (2 passes) and intritus (1 pass) treatment
16403179|NCT03956550|Experimental|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
16403180|NCT03956550|Experimental|REGN5069 High Dose|Randomized in a 1:1:1 ratio
16403181|NCT03956550|Experimental|Matching Placebo|Randomized in a 1:1:1 ratio
16403182|NCT03956537||Pedicle screw system alone|
16403183|NCT03956537||Pedicle screw system with cages|
16403184|NCT03956524|Experimental|Test group|Single dose of EuTCV will be administered intramuscularly
16403185|NCT03956524|Active Comparator|Comparator group 1|Single dose of Typbar-TCV™ will be administered intramuscularly
16403186|NCT03956524|Active Comparator|Comparator group 2|Single dose of Typhim Vi® will be administered intramuscularly
16403187|NCT03956498|Other|Patients with cervix or vaginal cancer|
16403188|NCT03956472|Experimental|Osteopathic group|LCS Drainage before altitude exposure
16403189|NCT03956472|Experimental|PEEP 10 cmH2O|10 min at rest
16403190|NCT03956472|Sham Comparator|Control group|Sham PEEP and fake osteopathic protocol
16403191|NCT03956459|Other|Patients with a cancer|
16403192|NCT03956446|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
16403193|NCT03956446|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
16403194|NCT03956446|Other|Healthy controls|Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
16403195|NCT03956433|Experimental|Docosahexaenoic Acid enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) to be consumed daily for 4 weeks.
16403196|NCT03956433|Experimental|Beta-glucan enriched pancakes|One portion of pancakes enriched with 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
16403197|NCT03956433|Experimental|Anthocyanin enriched pancakes|One portion of pancakes enriched with 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
16426637|NCT03794648|No Intervention|Control Group|
16403198|NCT03956433|Experimental|DHA+BG enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
16403199|NCT03956433|Experimental|DHA+AC enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
16403200|NCT03956420||Study group|Implemented ERAS (Early Recovery After Surgery) elements
16403201|NCT03956420||Control group|The control group will consist of patients treated during the study in accordance with the current standards used in the Department
16403202|NCT03956407|Active Comparator|Active, subacute stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
16403203|NCT03956407|Sham Comparator|Sham, subacute stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
16403204|NCT03956407|Active Comparator|Active, chronic stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
16403205|NCT03956407|Sham Comparator|Sham, chronic stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
16403206|NCT03956394|Other|Active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
16403207|NCT03956394|Other|Non-active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
16403208|NCT03956381||THR with OPS system-TriFit TS/Trinity combination|Hip prosthesis combination: TriFit TS stem/ Trinity cup implanted by Surgeon 1 via a posterolateral approach according to their standard of practice.
16403209|NCT03956381||THR with OPS system-MetaFix/Trinity combination|Hip prosthesis combination: MetaFix stem/ Trinity cup implanted by Surgeon 2 via a direct anterior approach according to their standard of practice.
16403210|NCT03956368|Experimental|Treatment Group|Randomised on the day of admission to receive oral Atorvastatin 20mg daily for 8 weeks.
16403211|NCT03956368|Placebo Comparator|Control Group|Randomised on the day of admission to receive placebo 20mg daily for 8 weeks.
16403212|NCT03956355|Experimental|Tapinarof (DMVT-505)|Tapinarof (DMVT-505) Cream Group
16403213|NCT03956355|Placebo Comparator|Vehicle Cream|Vehicle Cream Group
16403214|NCT03956342||Pediatric Clinicians - Group 1|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.
~This cohort will complete a first round of interviews to assess measure content."
16403215|NCT03956342||Pediatric Clinicians - Group 2|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.
~This smaller cohort will be a randomized subset of the original cohort and will complete interviews to assess changes made based on the feedback from the first cohort."
16403216|NCT03956329|No Intervention|Usual care, control arm|Usual care in which participants will not see a video intervention. This group will attend their influenza vaccination appointment as usual, without intervention. Participants will receive Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
16403217|NCT03956329|Experimental|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
16403218|NCT03956329|Experimental|Individualised Digital Intervention|Similar to the standardised digital intervention, however participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
16403219|NCT03956303|Active Comparator|Plain Levobupivacaine (Chirocaine (% 0.5)|Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain
16403220|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 40|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40
16403221|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 60|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60
16403222|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 80|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80
16403223|NCT03956290|Experimental|TREAT pilot study|Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.
16403224|NCT03956277|Experimental|Observational PUG|Patients receive gastrostomy via percutaneous ultrasound gastrostomy.
16403225|NCT03956264|Experimental|VR|"VR Installation 5 min before the drain removal and stop 10 min after the procedure.
~If Pain assessed by numerical rating scale (NRS) > 4, administration of morphine."
16403226|NCT03956264|Active Comparator|Kalinox®|"Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.
~If Pain NRS > 4, administration of morphine."
16403227|NCT03956251|Experimental|Combined Mineralized/Demineralized Putty Allograft|Ridge preservation with a Mineralized/Demineralized Putty allograft
16403228|NCT03956251|Active Comparator|Demineralized Putty Allograft|Ridge preservation with Demineralized Putty allograft
16403229|NCT03956238|Experimental|Males and Alcohol Intoxication|Men assigned to alcohol intoxication arm (target BAC .08%)
16403230|NCT03956238|Placebo Comparator|Males and Placebo Control|Men assigned to placebo control arm
16403231|NCT03956238|Experimental|Females and Alcohol Intoxication and Objectifying Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and objectifying gazes arm
16403232|NCT03956238|Experimental|Females and Alcohol Intoxication and Eye Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and eye gazes arm
16403233|NCT03956238|Experimental|Females and Placebo Control and Objectifying Gazes|Women assigned to placebo control arm and objectifying gazes arm
16403234|NCT03956238|Placebo Comparator|Females and Placebo Control and Eye Gazes|Women assigned to placebo control arm and eye gazes arm
16403235|NCT03956225|Experimental|iLux|Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.
16403236|NCT03956225|Active Comparator|LipiFlow|Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.
16403237|NCT03956212|Experimental|erythema migrans patients treated with doxycycline|adult patients with erythema migrans will be treated with oral doxycycline
16403238|NCT03956199|Experimental|experimental pulpotomy|
16403239|NCT03956199|Active Comparator|Root canal treatment|
16403240|NCT03956186||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
16403241|NCT03956186||Non-hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
16403242|NCT03956173||Clamp group|24 patients with type 1 diabetes.
16403243|NCT03956160|Experimental|Intervention group|"For 12 months from the return home, patients in the intervention group will benefit from telephone support by a trained case-manager (number and frequency of contacts defined according to the patient's needs) and access to an Internet platform.
~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon return home, including identifying and requesting the necessary health or social resources."
16403244|NCT03956160|No Intervention|Control group|"Patients randomized to the control group will receive the usual practices. As part of the study, they will be contacted for data collection upon their return home, at 6 months and 12 months by a clinical research associate.
~Access to the internet platform and an interview with the case-manager will be offered at the end of the study to patients in the control group."
16403245|NCT03956134|Experimental|Tapentadol Test Product 1 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
16403246|NCT03956134|Experimental|Tapentadol Test Product 2 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
16403247|NCT03956134|Experimental|Tapentadol Test Product 1 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
16403248|NCT03956134|Experimental|Tapentadol Test Product 2 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
16403249|NCT03956134|Active Comparator|Tapentadol PR Reference Product|Tapentadol PR tablet formulation given as single oral dose with 240 mL of still mineral water under fasting condition.
16403250|NCT03956121||Exposed group|Exposed group( with magnesium sulfate): fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for neuroprotective purposes, with decision of extraction or spontaneous or induced labour
16403251|NCT03956121||Control group|Control group (without magnesium sulfate) : fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision or spontaneous or induced labour
16403252|NCT03956108|Experimental|MRI/Fusion biopsies|Stockholm3+MRI+targeted biopsies
16403253|NCT03956108|Active Comparator|Systematic biopsies|PSA+systematic biopsies
16403254|NCT03956095||Ensure Surgery Immunonutrition Shake supplements|Participants will be provided with and instructed to drink three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
16403255|NCT03956082|Other|This is a prospective single arm study|"The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. Surgical smoke refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments."
16403256|NCT03956056|Experimental|Neoantigen Peptide Vaccine|The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.
16403257|NCT03956043||Patients with suspected sepsis in Emergency Department|Patients with suspected sepsis treated by the sepsis emergency team or the medical emergency team in the Emergency Department of Oslo University Hospital Oslo are included prospectively.
16403258|NCT03956030|Experimental|Intervention|Intervention group will receive educational handout on contraception.
16403259|NCT03956030|Experimental|Control|Control group will receive educational handout on nutrition.
16403260|NCT03956017|Experimental|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
16403261|NCT03956017|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
16403262|NCT03956004|Experimental|Experimental|Full decision aid, consisting of education on osteoarthritis and treatment options, preferences and values elicitation, and personalized risk/benefit estimates based on patient's response to patient-reported outcome measures.
16403263|NCT03956004|Active Comparator|Control|Education component of the decision aid only.
16403264|NCT03955991|Experimental|R-CBSM|10 weeks of group intervention convene by a broadband connection for approximately 75-90 minutes. Intervention given prior to Influenza Vaccine.
16403265|NCT03955991|Active Comparator|Wait List Condition (WLC)|Persons assigned to this group will receive R-CBSM approximately 28 days after receiving the Influenza Vaccine.
16403266|NCT03955978|Experimental|TSR-042 and Brachytherapy|"Patients will receive four doses of TSR-042. The first dose is given 21 days prior to the first brachytherapy fraction. The second dose is given at the time of fraction #1. The third dose is given at the time of fraction #4. The final dose is given 1 week after fraction #6.
~Brachytherapy will consist of 6 weekly fractions of 6 Gy per fraction (total 36Gy)"
16403267|NCT03955965||Emergency patients with medication reconciliation|All patients who beneficiated from medication reconciliation in the emergency department between November 2017 and April 2018
16403268|NCT03955952||Bariatric Surgery|Patients with type 2 diabetes with BMI >=30 that underwent bariatric surgery
16403269|NCT03955952||Non-Surgical Control|Matched non-surgical controls with type 2 diabetes and BMI >=30
16403270|NCT03955939|Experimental|LY3295668 Erbumine Part A|"LY3295668 erbumine administered orally (Part I).
~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
16403271|NCT03955939|Experimental|LY3295668 Erbumine Part B|"LY3295668 erbumine administered orally (Part I).
~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
16403272|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Cohort 1|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).
16403273|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Continuation Part C|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
16403274|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Switch Part D|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
16403275|NCT03955926|No Intervention|Control group|kept fasted from midnight until surgery
16403276|NCT03955926|Experimental|NO-NPO group|drink carbohydrate beverage until 2 h before surgery
16403277|NCT03955913||Participants with Urothelial Cancer,selected FGFR aberrations|Participants with urothelial cancer (UC) will be evaluated for the prevalence of positive results of selected fibroblast growth factor receptor (FGFR) aberrations and will be assessed for eligibility status for erdafitinib studies. The primary data source for this study will be the medical records of each participant.
16403278|NCT03955900||Participants with Multiple Myeloma (MM)|Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
16403279|NCT03955887||Experimental|Patients with severe acute lung disease requiring mechanical ventilation
16403280|NCT03955887||Control|Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection
16403281|NCT03955874||INITIAL SBT|Patients who underwent an Spontaneous Breathing Trial prior to extubation. This cohort will be further subdivided into initial patients who initially pass an SBT successes and those who initially fail an SBT.
16403282|NCT03955874||DIRECT EXTUBATION|Patients that were directly extubated without conduct of a prior SBT or tracheostomy
16403283|NCT03955874||DIRECT TRACHEOSTOMY|Patients who underwent a direct tracheostomy without conduct of a prior SBT or extubation
16403284|NCT03955874||No attempt at mechanical ventilation discontinuation|Patients who died without conduct of a prior SBT, extubation or tracheostomy
16403285|NCT03955848|Experimental|ARM 1|NK cell infusion
16403286|NCT03955848|No Intervention|ARM 2|Follow up without treatment
16403288|NCT03955809|Active Comparator|Ketamine 0.5 mg/kg|ketamin 0.5 mg/kg intraarticular
16403289|NCT03955809|Active Comparator|Ketamine 1 mg/kg|ketamin 1 mg/kg intraarticular injection
16403290|NCT03955809|Sham Comparator|% 0.9 Saline|% 0.9 NaCL intraarticular injection
16403291|NCT03955796|Experimental|RayOne Hydrophobic Aspheric|Patient will receive the hydrophobic IOL during cataract surgery
16403292|NCT03955796|Experimental|RayOne Aspheric|Patient will receive the non-hydrophobic IOL during cataract surgery
16403293|NCT03955783|Experimental|Treatment (venetoclax, selinexor)|Patients receive venetoclax PO QD on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Venetoclax naïve AML patients receive selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax refractory AML patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16403294|NCT03955770|Experimental|HFOT first then LFOT|
16403295|NCT03955770|Experimental|LFOT first then HFOT|
16403296|NCT03955757|Experimental|Boot Camp Translation|Intervention communities will undergo the Boot Camp Translation process.
16403297|NCT03955757|Active Comparator|Control|Control communities will behave as usual
16403298|NCT03955744|Experimental|3D translabial ultrasound|3D translabial ultrasound with concurrent vaginal manometry
16403299|NCT03955731|Other|Single study arm|STEMI Patients treated with Magmaris resorbable magnesium scaffold
16403300|NCT03955718|Experimental|Motherly App|A smartphone app with an automated intervention that provides strategies to prevent maternal depression and to promote child development: (1) behavioral activation, (2) sleep hygiene, (3) physical activity, (4) social support, (5) nutrition, (6) prenatal care schedule, and (7) educational content.
16403301|NCT03955718|Active Comparator|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
16403302|NCT03955705|Experimental|Nefopam|Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day
16403303|NCT03955705|Placebo Comparator|Normal saline solution|Normal saline or 0.9% Sodium Chloride (NaCl) or NSS
16403304|NCT03955692|Active Comparator|Active tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
16403305|NCT03955692|Sham Comparator|Sham tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
16403306|NCT03955666|Experimental|Cohort A (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
16403307|NCT03955666|Experimental|Cohort B (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
16403308|NCT03955653|Active Comparator|RAO projection|Patients will be randomized to right anterior oblique (RAO) projection by fluoroscopy for the access to the femoral artery
16403309|NCT03955653|Active Comparator|AP projection|Patients will be randomized to anterior-posterior projection by fluoroscopy for the access to the femoral artery
16403311|NCT03955627|No Intervention|Enhanced Standard Care|Participants will receive standard care, plus a brochure about hormonal therapy use.
16403312|NCT03955627|Experimental|Treatment (Education plus Exercise)|Participants will receive the same materials as the standard care group, plus participate in group exercise and group discussion sessions.
16403313|NCT03955614|Experimental|St Marys Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
16403314|NCT03955614|Experimental|University College Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
16403315|NCT03955614|Experimental|Chelsea and Westminster Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
16403316|NCT03955601|Experimental|TBI free Haploidentical HSCT|Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.
16403317|NCT03955588||Women undergoing invasive prenatal diagnostic procedures|For women requiring invasive prenatal diagnosis by chorionic villus sampling or amniocentesis, they will be offered the options of having either conventional cytogenetics or aCGH.
16403318|NCT03955575|Active Comparator|Liraglutide/placebo-colesevelam|Liraglutide as active and colesevelam as placebo
16403319|NCT03955575|Active Comparator|Placebo-Liraglutide/colesevelam|Liraglutide as placebo and colesevelam as placebo
16403320|NCT03955562|Experimental|Intervention|Communities that receive a pedestrian footbridge.
16403321|NCT03955562|Experimental|Comparison|Communities that do not receive a pedestrian footbridge.
16403322|NCT03955549|Experimental|Insight Enhancement Program (IEP)|The insight enhancement program is a dynamo-cognitive therapeutic modality with the main target of improving insight in psychotic patients as a means of improving their overall outcome.
16403323|NCT03955549|Experimental|Metacognitive Training for Psychosis (MCT)|The metacognitive training program, developed by Moritz et al. (Moritz & Woodward, 2007) targets cognitive biases putatively involved in the formation and maintenance of psychotic symptoms.
16403324|NCT03955549|Active Comparator|Treatment As Usual (TAU)|"Treatment as usual will be used as a control condition to assure ethicality of our procedure.
~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
16403325|NCT03955536|Active Comparator|Group A|Routine cardiac rehabilitation program (RCRP)atient education
16403326|NCT03955536|Experimental|Group B|routine cardiac rehabilitation program + virtual reality
16403327|NCT03955536|Experimental|Group C|RCRP + inspiratory muscle training
16403328|NCT03955523|Experimental|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
16403329|NCT03955523|Experimental|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
16403330|NCT03955523|No Intervention|Control (doing nothing)|Non-exercise trial day The protocol of the non-exercise trial day is identical to that of the exercise trial day, except that exercise is substituted by 30 min of quiet sitting in a lounge area (e.g. reading, working or watching a movie on an electronic device) without further engagement with other people.
16403331|NCT03955510|Other|"Right-time eating / no alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will be asked to not drink alcohol for 1 week. Subjects will randomly be assigned to each eating pattern during the study period."
16403332|NCT03955510|Other|"Right-time eating / with alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
16403333|NCT03955510|Other|"Delayed-eating / no alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Subjects will be asked to not drink alcohol for 1 week."
16403422|NCT03954873|Active Comparator|Hyperglycaemia + Placebo|Glucose + saline
16403423|NCT03954873|Experimental|Hypoglycaemia + GLP-2|Insulin + glucose + GLP-2
16403334|NCT03955510|Other|"Delayed-eating / with alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
16403335|NCT03955497|Experimental|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
16403336|NCT03955497|Placebo Comparator|sodium hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
16403337|NCT03955484||Patients who had benign prostatic hyperplasia|"Male patients presenting with lower urinary tract symptoms to urology outpatient clinic
~According to the European Association of Urology Guidelines:
~International prostate symptom score> 8 Prostate volume> 40 ml Q max <15 ml /sn Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time Patients who have not undergone lower urinary tract surgery"
16403338|NCT03955471|Experimental|Niraparib+TSR-042|Participants will receive both Niraparib and TSR-042 to evaluate the efficacy and safety of the combination of both drugs. Niraparib will be administered once daily (QD) continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) will be administered via a 30-minute intravenous (IV) infusion on Day 1 every 3 weeks (Q3W) during Cycles 1 through 4. Beginning at Cycle 5, dostarlimab (TSR-042) will be administered via a 30-minute IV infusion on Day 1 of each 6-week cycle until PD or toxicity, for a maximum of 3 years.
16403339|NCT03955458|Experimental|FICB with EXPAREL|Group 1: Suprainguinal Fascia Iliaca Compartment Block (FICB) with EXPAREL and bupivacaine HCl
16403340|NCT03955458|Active Comparator|FICB with Standard of Care: ropivacaine|Suprainguinal FICB with continuous infusion of local anesthetic (ropivacaine) via catheter placed in the FIC.
16403341|NCT03955445|Experimental|Open Label LNP023|LNP023 capsules formulation
16403342|NCT03955432|Experimental|LINQ ICM|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.
16403343|NCT03955419|No Intervention|Control group|Participants in the control group will be fasted from midnight until surgery.
16403344|NCT03955419|Experimental|Study group|Participants will receive 800 mL of carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg). They will drink this beverage freely, starting from the evening before surgery until 2 hours before surgery.
16403345|NCT03955406|Active Comparator|Conventional group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min.
16403346|NCT03955406|Active Comparator|Fixed Fresh Gas Flow Rate group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC.
16403347|NCT03955393||LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter>10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.
16403348|NCT03955380|Active Comparator|Active Comparator: Contraloid 160 mg|160 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
16403349|NCT03955380|Active Comparator|Active Comparator: Contralod 320mg|320 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
16403350|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 160 mg|160 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
16403351|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 320 mg|320 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
16403352|NCT03955367|Active Comparator|Pelvic Irradiation|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.
16403353|NCT03955367|Experimental|Prophylactic EFI|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.
16403354|NCT03955354|Experimental|experimental arm|SHR1210 plus apatinib
16403355|NCT03955341|No Intervention|conventional selective caries removal without disinfection|After collecting the first sample of dentin, the cavity will be restored
16403424|NCT03954873|Active Comparator|Hypoglycaemia + Saline|Insulin + glucose
16403425|NCT03954873|Experimental|Euglycaemia + GLP-2|GLP-2
16403426|NCT03954873|Active Comparator|Euglycaemia + Placebo|
16403356|NCT03955341|Other|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
16403357|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
16403358|NCT03955328|Experimental|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
16403359|NCT03955315|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells)
16403360|NCT03955315|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
16403361|NCT03955315|Sham Comparator|Sham|Sham needle puncture (outside disc)
16403362|NCT03955302|Experimental|Exercise|Patients in this group will perform the water exercise protocol, 3 times a week, for 12 weeks.
16403363|NCT03955302|No Intervention|Control|Patients in this group will not perform any type of exercise during the 12 weeks of the treatment.
16403364|NCT03955276||Matched Therapy|Targeted therapy matched to each patient's genomic/immunophenotypic tumor profile (whereby oncogenic alterations are matched with targeted agents)
16403365|NCT03955276||Unmatched Therapy|General, unmatched therapy (standard of care)
16403366|NCT03955250|Experimental|Mobile After-Care Support (MACS) app|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and intervention.
16403367|NCT03955250|Active Comparator|Mobile app attention control|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and psychoeducation about illness.
16403368|NCT03955237|Active Comparator|non glucose infusion group|Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.
16403369|NCT03955237|Active Comparator|Drug:1% Dextrose infusion group|Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,
16403370|NCT03955237|Active Comparator|2% Dextrose infusion group|Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,
16403371|NCT03955224|Active Comparator|Basic Oral Care + active LLLT (experimental arm)|
16403372|NCT03955224|Placebo Comparator|Basic oral Care + inactive LLLT (control arm)|
16403373|NCT03955224|Other|Basic Oral Care (control arm)|
16403374|NCT03955211|Experimental|Treatment Group 1|A single dose of HTX-011 administered via instillation into the surgical site.
16403375|NCT03955211|Experimental|Treatment Group 2|A single dose of HTX-011 administered via instillation into the surgical site and a scheduled non-opioid multimodal analgesic (MMA) regimen.
16403377|NCT03955185|Experimental|Minimally invasive surgery|The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
16403378|NCT03955185|Active Comparator|Open abdominal surgery|The patients will receive traditional radical hysterectomy.After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
16403379|NCT03955172|Experimental|Everolimus|
16403380|NCT03955159|Experimental|Experimental: Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
16403381|NCT03955159|Placebo Comparator|Placebo comparator|The placebo that will be used in the present study is maltodextrin, which is a food supplement based on carbohydrate powder.
16403382|NCT03955146|Experimental|Pamrevlumab|
16403383|NCT03955146|Experimental|Placebo|
16403384|NCT03955133|Experimental|intervention|This is a single arm before and after study with data collection at 4 time points.
16403385|NCT03955120|Experimental|Sleep Apnea- Dayzz|The intervention group is also provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the adherence to CPAP. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device. The intervention group meets a CPAP technician at the sleep clinic, as detailed below in the Sleep Apnea TAU group
16403386|NCT03955120|Active Comparator|Sleep Apnea- Treatment as Usual|"The treatment as usual [TAU] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial."
16403387|NCT03955120|Experimental|Insomnia - Dayzz|The intervention group is provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the insomnia concerns, sleep symptoms, and achieve sleep goals. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device.
16403526|NCT03954288||control|patients scheduled to operation with diagnosis of other causes
16403388|NCT03955120|Active Comparator|Insomnia - Treatment as Usual|"The treatment as usual [TAU] group, will receive standard treatment recommendations for their insomnia, including sleep hygiene suggestions, referral for supportive/non-medical treatments [e.g. relaxation therapies], and if needed hypnotics or other medications prescribed by the sleep clinic physician."
16403389|NCT03955107|Other|Continuous Glucose Monitoring System|
16403390|NCT03955094|Experimental|AMBU® AURAGAIN™ device|Assess feasibility of AMBU® AURAGAIN™ as an intubating device in paediatrics
16403391|NCT03955068|Other|Strict Classic Ketogenic Diet Arm|The classic ketogenic diet is individually calculated for each patient based on age, weight, and nutritional needs. The diet is typically administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates. The basis of calculations is first on the amount of required protein needed to meet RDA to insure adequate growth. Fine tuning of ketogenic diet therapy is based on serum beta-hydroxybutyrate levels (target levels of 3.5-6.5 mmol/L), tolerance of the diet, and response to treatment.
16403392|NCT03955055|Experimental|Early Capsule Group|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the clinical decision unit. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
16403393|NCT03955055|No Intervention|Standard of Care Work-up|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
16403394|NCT03955042|Experimental|Pemetrexed|Pemetrexed
16403395|NCT03955029|Experimental|Conventional Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow conventional Interval Training
16403396|NCT03955029|Experimental|Progressive Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow progressive Interval Training
16403397|NCT03955016|Experimental|Rehabilitation group|15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
16403398|NCT03955016|No Intervention|Control group|Usual care
16403399|NCT03955003|Experimental|Group Drumming|6 week one hour/week drumming sessions. The detailed intervention protocol was created in collaboration with board-certified music therapists. The music used in the intervention will include both recorded percussion music and the use of percussion instruments.
16403400|NCT03955003|Other|Attention Control Entertaining Educational Series|6 week one hour/week educational series. The educational group is largely intended to create an attention group control so group effect and time of the drumming intervention can be controlled.
16403401|NCT03954990|Placebo Comparator|Control Arm|Placebo tablets oral, 4 tablets once.
16403402|NCT03954990|Active Comparator|Treatment Arm|Will receive 4 tablets (2g) of metronidazole oral once.
16403403|NCT03954977|Experimental|Ultrasound vs Radiograph|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
16403404|NCT03954964|No Intervention|Control Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement.
16403405|NCT03954964|Experimental|Intervention Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement will receive additional education about the disposal of opioids.
16403406|NCT03954951|No Intervention|Control group|The clinicians in the control group will continue usual care without intervention. They will not receive the online course or performance feedback reports.
16403407|NCT03954951|Active Comparator|Intervention group|The primary care physicians will receive access to an online course on hypertension management based on the ACC/AHA and ESC guidelines. They will also receive feedback reports on their performance on hypertension management for 16 weeks.
16403408|NCT03954938|Sham Comparator|Neutral-Look|Subjects will be instructed to look at cocaine associated images and respond naturally.
16403409|NCT03954938|Experimental|Positive|Subjects will be instructed to look at cocaine associated images and anticipate the positive aspects of engaging with the items shown.
16403410|NCT03954938|Active Comparator|Negative|Subjects will be instructed to look at cocaine associated images and anticipate the negative aspects of engaging with the items shown.
16403411|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with short hamstring|Anatomic anterior cruciate ligament with short hamstring graft
16403412|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with standard hamstring|Anatomic anterior cruciate ligament with standard hamstring graft
16403413|NCT03954912|Active Comparator|MAKO robotic assisted UKA|image base (MAKO) robotic assisted UKA
16403414|NCT03954912|Active Comparator|NAVIO robotic assisted UKA|imageless (NAVIO) robotic assisted UKA
16403415|NCT03954899|Experimental|MCI+ Melatonin 5mg|MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months
16403416|NCT03954899|Placebo Comparator|MCI+ placebo|MCI+ individuals receiving placebo for a period of 9 months
16403417|NCT03954899|Experimental|MCI- Melatonin 5mg|MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months
16403418|NCT03954899|Placebo Comparator|MCI- placebo|MCI- individuals receiving placebo for a period of 9 months
16403419|NCT03954886|Experimental|Induced myopic defocus|Subjects will view a television through a lens that induces blur to the retina for one hour. Images of the eye will be captured every 10 minutes
16403420|NCT03954886|No Intervention|No defocus|Subjects will view a television through a lens that induces no blur to the retina for one hour. Images of the eye will be captured every 10 minutes
16403427|NCT03954860|Experimental|No Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
16403428|NCT03954860|Active Comparator|Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
16403429|NCT03954847||Lung cancer patients|Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment
16403434|NCT03954821||control group|control group in which all of them present pronated foot without tratment
16403435|NCT03954821||experimental group|Group in which they have been treated with prefabricated plantar insoles to stop pronation
16403436|NCT03954808|Experimental|Motor imagery training group|Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
16403437|NCT03954808|Active Comparator|Cerebral Palsy control group|Children with Cerebral Palsy. Traditional physiotherapy control group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
16403438|NCT03954808|No Intervention|Typically developing control group|Age matched healthy individuals, with no treatment.
16403439|NCT03954795|Active Comparator|Group 1: TAP Block|TAP Block performed from the petit triangle ( anterior axillary line and iliac crest.)
16403440|NCT03954795|Active Comparator|Group 2: OSTAP Block|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
16403441|NCT03954795|No Intervention|No Block|No interventions
16403444|NCT03954769||Inpatients|Patients admitted to Stanford Hospital and Clinics medical and surgical units
16403445|NCT03954756|Experimental|apatinib and PD-1|Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
16403446|NCT03954743|Experimental|HRV PCV-free Liq Group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in liquid formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
16403447|NCT03954743|Active Comparator|HRV Lyo group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries.
16403448|NCT03954730|Experimental|Eccentric Training Group|Eccentric training will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
16403449|NCT03954730|Active Comparator|Active Release Technique Group|Active release technique will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
16403450|NCT03954717||Participants in the Shepherd CAN DO Program|24 people with MS enrolled into the Shepherd CAN DO Program.
16403451|NCT03954717||Control Group-Shepherd (CG-S)|24 people with MS who are current patients of the MS Institute at the Shepherd Center.
16403452|NCT03954717||Control Group-iConquerMS (CG-iCMS)|24 iConquerMS members
16403453|NCT03954717||Support partners of CAN DO|24 support partners of the participants in the Shepherd CAN DO Program group
16403454|NCT03954717||CG-S support partners|24 support partners of the people with MS in the CG-S group.
16403455|NCT03954717||CG-iCMS|24 support partners of the people with MS in the CG-iCMS group
16403456|NCT03954704|Experimental|Phase 1a, Part A - Dose Escalation|Part A will consist of dose escalation by an accelerated dosing design and a 3+3 dose escalation scheme. Participants will receive escalating dose levels GS-1423 of up to 45 mg/kg on Day 1 of each 2-week cycle (Q2W) until the participants meets study treatment discontinuation criteria or for up to 1 year.
16403457|NCT03954704|Experimental|Phase 1a, Part B - Flat Dose Regimen|Part B will consist of 3 adaptive cohorts. Based on PK, pharmacodynamics, and safety results from the Part A study, participants will be administered a flat dose of GS-1423 on Day 1 of each cycle QW, Q2W and/or every 3 weeks (Q3W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
16403527|NCT03954275||Critically ill patients with a CrCl24h|Patients admitted to any intensive care unit (surgical, medical or cardiac) and having at least one 24h creatinine clearance measurement available.
16403528|NCT03954262||TCI group|Group I received TCI at 5-6 ug/ml target effect concentration (Ce)
16403529|NCT03954262||bolus group|groups II received an induction bolus of propofol (2-2.5mg/kg).
16403530|NCT03954249|Experimental|Erector Spinae nerve block group|Receive multimodal analgesia and in addition erector spinae plane block
16403531|NCT03954249|Active Comparator|Multimodal Analgesia group|Receive standard multimodal analgesia
16426638|NCT03794635|Experimental|Patients|Latino/a advanced cancer patients
16403458|NCT03954704|Experimental|Phase 1b, Cohort 1 (Gastric Cancer)|"Safety run-in: A standard 3+3 dose escalation design will be used to determine the DLT and MTD or RP2D of GS-1423 in combination with mFOLFOX6. The planned starting dose of GS-1423 will be targeted to achieve the exposure at -1 dose of RP2D monotherapy (Q2W) determined from Phase 1a. GS-1423 will be administered in combination with mFOLFOX6.
~Post safety run-in: Approximately 70 participants will be enrolled to receive GS-1423 at the dose level determined from the safety run-in period, in combination with mFOLFOX6 regimen.
~Participants will receive GS-1423 on Day 1 of each 14-day cycle up to 2 years until PD, or unacceptable toxicity, substantial noncompliance with study procedures or study drug, study discontinuation or withdrawal from study. Participants will also receive mFOLFOX6 regimen Q2W for up to 12 cycles."
16403459|NCT03954704|Experimental|Phase 1b, Cohort 2 (Paired Biopsy)|Participants will receive GS-1423 at the dose level determined from Phase 1a Q2W until the participants meets study treatment discontinuation criteria or for up to 1 year.
16403460|NCT03954678|Experimental|Exercise Group|Participants randomized to the activity intervention will aim for taking 10,000 steps per day and completing strength training exercises three times per week.
16403461|NCT03954678|Active Comparator|Nutrition Group|Participants randomized to the nutrition intervention will consume a liquid over-the-counter nutrition supplement two times per day.
16403462|NCT03954665|Active Comparator|Baseline Testing|Baseline testing for a 10km cycle time trial and a 30s Wingate cycle test.
16403463|NCT03954665|Experimental|Dietary Supplement: Exogenous Ketone Salt|Ketone salt supplementation (0.6-0.8g•kg-1•d-1) 7-days. Participants will perform two exercise performance tests (a 10km cycle time trial and a 30s Wingate cycle test on separate days) after supplementation.
16403464|NCT03954652|Other|Cohort 1: Intellectual disability|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
16403465|NCT03954652|Other|Cohort 2 Retinal diseases|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
16403466|NCT03954652|Other|Cohort 3: Rare tumors in childhood|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
16403467|NCT03954639|Experimental|Cohort 1, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.
~EXPAREL will be mixed with Bupivacaine
~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
16403468|NCT03954639|Active Comparator|Cohort 1, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.
~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
16403469|NCT03954639|Experimental|Cohort 2, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.
~EXPAREL will be mixed with Bupivacaine
~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
16403470|NCT03954639|Active Comparator|Cohort 2, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.
~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
16403471|NCT03954626|Experimental|RTH258|Intravitreal injection
16403472|NCT03954613|Experimental|Group A|Donepezil/Memantin Combination
16403473|NCT03954613|Experimental|Group B|Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
16403474|NCT03954613|Active Comparator|Group C|Donepezil Mono
16403475|NCT03954613|Active Comparator|Group D|Donepezil Mono + Cognitive Exercises (BEYNEX Software)
16403476|NCT03954613|Active Comparator|Group E|Memantine Mono
16403477|NCT03954613|Active Comparator|Group F|Memantine Mono + Cognitive Exercises (BEYNEX Software)
16403478|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Unfed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
16403479|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Fed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Fed.
16403480|NCT03954600|Other|NPT520-34 - SAD Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT520-34: 250 mg OR Single dose of orally administered placebo capsule(s) to match dose.
16403481|NCT03954600|Other|NPT520-34 - SAD Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT520-34: 500 mg OR Single dose of orally administered placebo capsule(s) to match dose.
16403482|NCT03954600|Other|NPT520-34 - SAD Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT520-34: 1000 mg OR Single dose of orally administered placebo capsule(s) to match dose.
16403483|NCT03954600|Other|NPT520-34 - MAD Cohort 1, Dose 1|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
16403484|NCT03954600|Other|NPT520-34 - MAD Cohort 2, Dose 2|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
16403485|NCT03954600|Other|NPT520-34 - MAD Cohort 3, Dose 3|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
16403486|NCT03954587||Artificial (HRT) Cycles|"Commence estradiol valerate (E2) 4mg from day 2 or 3 of period for 3 days
~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.
~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.
~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.
~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.
~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily).
~Embryo transfer is scheduled on the 5th full day of progesterone administration."
16403532|NCT03954236|Experimental|topical ruxolitinib BID to left side of face/body|And topical moisturizer BID to right side of face/body.
16403533|NCT03954236|Experimental|topical ruxolitinib BID to right side of face/body|And topical moisturizer BID to left side of face/body.
16403534|NCT03954223|Experimental|LSC + blinded CGM|Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
16403487|NCT03954587||Spontaneous natural cycles:|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.
~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.
~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).
~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/mL confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
16403490|NCT03954561|Experimental|endoscopist group|endoscopist-administered abdominal compression group
16403491|NCT03954561|Active Comparator|assistant group|assistant-administered abdominal compression group
16403492|NCT03954548|Experimental|With CB-17-08 CADe|
16403493|NCT03954548|No Intervention|Without CB-17-08 CADe|
16403494|NCT03954535|Experimental|Intervention|9 sessions and website with entertainment features and resources
16403495|NCT03954535|Placebo Comparator|Control|website with entertainment features and resources
16403496|NCT03954522|Experimental|Expérimental|psychologist interview and psychometrics scales
16403497|NCT03954509||semi-structured interview|"Screening and inclusion of patients hospitalized or seen in day hospital to conduct semi-structured interviews according to the interview grid. This interview schedule was established after review of the literature and identification of primary and secondary objectives.
~Identification of key ideas through content analysis of the interviews conducted and based of the anchored theory.
~This step is performed until the results are saturated (approximately 15 patients). The principle of saturation is based on the fact that from a threshold, the diversity of the elements collected decreases. Much more than an end signal, this principle is a methodological guarantee since it allows the possibility of comparing divergent or contradictory data and thus validating the data."
16403498|NCT03954509||questionnaires|"From the previous results: elaboration of a written questionnaire built according to the results obtained thanks to the previous interviews. In order to apply the simple correspondence factor analysis method, this questionnaire will be constructed on a Likert scale. The objective is twofold:
~to reduce the observer's bias by considering both the literature reviews but also the points of view of patients to develop the questionnaire;
~reach a larger patient population (more than 100 patients) compared to the previous qualitative analysis (15 patients planned), in order to generalize the results. This methodology combines both qualitative and quantitative study to minimize bias induced by both types of study.
~Dissemination of the questionnaire and filling by the patient independently. The health professional who submitted the questionnaire will remain available to answer any questions the patient may have."
16403499|NCT03954496|Experimental|Active tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2.5mA, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
16403500|NCT03954496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
16403501|NCT03954483|Experimental|Buspirone|Participants will receive buspirone 10 mg prior to experiments.
16403502|NCT03954483|Experimental|Triazolam|Participants will receive triazolam 0.25 mg prior to experiments.
16403503|NCT03954483|Placebo Comparator|Placebo|Participants will receive a placebo prior to experiments.
16403504|NCT03954457|Experimental|A-CWS Intervention|Participants received A-CWS Intervention.
16403505|NCT03954457|Active Comparator|Standard Care Control|Participants received standard care.
16403506|NCT03954444|Active Comparator|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
16403507|NCT03954444|Active Comparator|RHOFADE Cream, 1%|RHOFADE Cream, 1%
16403508|NCT03954444|Placebo Comparator|Vehicle Cream|Vehicle cream
16403509|NCT03954431|Experimental|CE-BCT|All subjects will undergo contrast-enhanced breast CT (CE-BCT)
16403510|NCT03954418|Experimental|Intervention group|Participants will drink an artificially sweetened drink 2-4 hours before elective caesarean section.
16403511|NCT03954418|No Intervention|Control group|Participants in the control group will refrain from intake of artificial sweeteners.
16403512|NCT03954392|Experimental|CBT+SCT|Cognitive behavioral therapy plus social cognitive skills training (SCT)
16403513|NCT03954392|Active Comparator|CBT-only|Cognitive behavioral therapy only (without SCT)
16403514|NCT03954379|Active Comparator|Group C ( Comparator Group )|Standard of care: Adductor Canal Block(ACB), Spinal Anesthesia (SA) and Peri-op Pain management
16403515|NCT03954379|Experimental|Group S ( Study Group )|iPACK and multi-modal analgesic regimen
16403516|NCT03954366|Other|Arm A - rucaparib and oral rosuvastatin|
16403517|NCT03954366|Other|Arm B - rucaparib and oral contraceptives|
16403518|NCT03954340|Active Comparator|1 iRemember Treatment|Subjects randomized to this arm of the study will undergo 20 EEG NFB treatments with the iRemember System for the treatment of MCI
16403519|NCT03954340|Sham Comparator|2 Sham Treatment|Subjects randomized to this arm of the study will undergo 20 SHAM treatments
16403520|NCT03954327|Experimental|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir|one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
16403521|NCT03954327|Placebo Comparator|Placebo|Identical tablets resembling one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
16403522|NCT03954314|Active Comparator|Topical Tranexamic Acid/Placebo|Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
16403523|NCT03954314|Active Comparator|Intravenous Tranexamic Acid/Placebo|Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
16403524|NCT03954288||chronic otitis media|patients with chronic otitis media without cholesteatoma
16403525|NCT03954288||cholesteatoma|patients with chronic otitis media whose cholesteatoma
16403535|NCT03954223|Experimental|LSC+TLE + blinded CGM|Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
16403536|NCT03954223|Experimental|LSC+TLE+ real time feedback via CGM|Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
16403537|NCT03954210|Experimental|Six-Week CBT-I Program|"CBT-I, six sessions, forty-five to sixty minutes in duration.
~Session 1: set up sleep restriction and stimulus control, discuss strategies for how to stay awake to a prescribed hour and what to do with wake after onset sleep time, provide sleep hygiene education.
~Session 2: determine if upward titration of total sleep time is warranted, review sleep hygiene.
~Session 3: continue upward titration of total sleep time, cognitive therapy for negative sleep beliefs if indicated.
~Session 4: continue upward titration of total sleep time, follow-up regarding negative sleep beliefs.
~Session 5: continue upward titration of total sleep time, discuss relapse prevention.
~Session 6: assess global treatment gains, discuss questions regarding relapse prevention."
16403538|NCT03954210|Active Comparator|Six-Week Sleep and Lifestyle Education Program|"Sleep and Lifestyle Education, six sessions, forty-five to sixty minutes in duration.
~Session 1: Sleep education, Instruction/demonstration on stretching exercises.
~Session 2: Education on environmental factors & sleeping positions that impact sleep.
~Session 3: Education on lifestyle factors that impact sleep.
~Session 4: Education on diet and sleep.
~Session 5: Education on exercises and sleep.
~Session 6: Discus maintaining achievements & preventing relapses."
16403539|NCT03954197|Experimental|Without injection group|no injection used as priming
16403540|NCT03954197|Active Comparator|hCG group|hCG used as priming
16403541|NCT03954197|Active Comparator|GnRHa group|GnRH agonist used as priming
16403542|NCT03954184|No Intervention|TAU/Control|Sites in the Treatment as Usual (TAU)/Control Arm will receive product training/online support. Sites in the TAU/Control Arm will participate in a one-day product implementation or training session.
16403543|NCT03954184|Experimental|NIATx-TI Framework|Sites in the NIATx-TI Arm will receive product training/online support, and training in the NIATx-TI framework. The NIATx-TI framework will include a pre-implementation (planning) phase, and post-implementation (problem-solving) phase, with training delivered by a NIATx-TI coach.
16403544|NCT03954171|Other|Patients treated with platinum based-chemotherapy|
16403545|NCT03954158|Experimental|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
16403546|NCT03954158|Experimental|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
16403547|NCT03954145|Active Comparator|PUMICING GROUP|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.
~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle.Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors"
16403548|NCT03954145|Experimental|SANDBLASTING GROUP|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.
~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
16403550|NCT03954106|Experimental|Defibrotide|"Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.
~After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose."
16403551|NCT03954093|Sham Comparator|Sham stimulation|
16403552|NCT03954093|Active Comparator|Motor cortex stimulation|
16403553|NCT03954093|Experimental|MEG-localized stimulation|
16403554|NCT03954080|Experimental|ISS|
16403559|NCT03954054||Former therapeutic education participants|Semi-structured interviews with people who already completed the TPE programme
16403560|NCT03954054||Intervention group (current therapeutic education participants)|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)
~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
16403561|NCT03954054||Control AUD (Alcohol Use Disorder) patients|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)
~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
16403562|NCT03954041|Experimental|BIIB093 3 mg|Participants will be administered BIIB093 3 mg/day as a bolus followed by rapid and slow intravenous (IV) infusions for 96 hours.
16403563|NCT03954041|Experimental|BIIB093 5 mg|Participants will be administered BIIB093 5 mg/day as a bolus followed by rapid and slow IV infusions for 96 hours.
16403564|NCT03954041|Placebo Comparator|Placebo 3 mg|Participants will be administered matching placebo to BIIB093 as a bolus followed by rapid and slow IV infusions for 96 hours.
16403565|NCT03954041|Placebo Comparator|Placebo 5 mg|Participants will be administered matching placebo to BIIB093 as a bolus followed by rapid and slow IV infusions for 96 hours.
16403566|NCT03954028|Active Comparator|CTG Group|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the autogenous connective tissue graft (CTG) material will be randomized to transplant to one side of the arch.
16403567|NCT03954028|Active Comparator|ADM Group|The patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the commercial acellular dermal matrix (ADM) materials will be transplanted to the opposite side of the arch with CTG transplants.
16403568|NCT03954015|Other|patients over age 30 with suspicious BIRADS 4/5 Lesions|Patients who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with CEDM, CEMR and CEUS.
16403570|NCT03953989|Experimental|Patients with hypertrophic cardiomyopathy|"Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid).
~V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply.
~V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety.
~Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die"
16403572|NCT03953963|Experimental|Intra-Abdominal Mesenteric Fat Extraction Group|All enrolled patients will undergo the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery.
16403573|NCT03953950|Experimental|Combination of spironolactone and losartan|
16403574|NCT03953950|Active Comparator|Losartan Alone|
16403575|NCT03953937||ICP cohort|Patients with idiopathic pancreatitis
16403576|NCT03953924|No Intervention|Control group|No interventions were performed for the control patients during the study. While those in the control group were given conventional care ( nursing procedure, education about diet, exercise and so on)
16403577|NCT03953924|Experimental|Intervention group|The patients in intervention group received conventional care, transtheoretical model-based (TTM-based) intervention and motivational interviewing (MI).
16403578|NCT03953911|Active Comparator|Control: Mobile Clinic Only|The middle school assigned to the control arm will receive a visit by a mobile clinic every 6 months only. The school will follow normal protocol for HPV vaccination awareness. Parents will be made aware of the mobile clinic per normal school newsletters and mailers.
16403579|NCT03953911|Experimental|Mobile Clinic plus Educational Sessions|The middle school assigned to the Mobile Clinic every 6-mos or month plus Educational Sessions arm will receive visitation of a mobile clinic providing free HPV vaccination among other school-related vaccines once every 6-months or once a month. Parents will be made aware of the mobile clinic per normal school newsletters and mailers. In addition, parents will be provided with free weekly educational sessions about the HPV Vaccine as a cancer-prevention effort.
16403581|NCT03953885|Experimental|Fire needle group|Participants in experimental group will receive Fire needle therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
16403582|NCT03953885|Placebo Comparator|Fire needle placebo group|Participants in experimental group will receive Fire needle placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
16403583|NCT03953872||ARB|Group of angiotensin receptor blockers(ARB) monotherapy users. A subject was considered as an ARB user when the total prescription days of ARB monotherapy was at least 30.
16403584|NCT03953872||combination of CCB and ARB|Group of calcium channel blockers(CCB) and angiotensin receptor blockers(ARB) combination users. A subject was considered as a CCB and ARB combination user when the total prescription days of CCB and ARB combination therapy was at least 30.
16403585|NCT03953872||CCB|Group of calcium channel blockers(CCB) monotherapy users. A subject was considered as a CCB user when the total prescription days of CCB monotherapy was at least 30.
16403586|NCT03953872||No treatment|Group of nonusers of antihypertensives. A subject was considered as a nonuser never received regular antihypertensive treatment or total prescription days of antihypertensives was less than 30.
16403587|NCT03953859||Gamete donors|healthy male and female game donors to undergo routine gamete donation process
16403588|NCT03953859||Infertile Couple|Couples undergoing routine IVF to treat their infertility
16403589|NCT03953833|Experimental|recombinant anti-HER2 humanized monoclonal antibody conjugate|Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R & D code: B003 Drug Type : Biological Products
16403590|NCT03953820|Experimental|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
16403591|NCT03953820|Experimental|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
16403592|NCT03953820|Experimental|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
16403593|NCT03953807|Experimental|Ozurdex|OZURDEX implant 700 μg
16403594|NCT03953794||Patients with inflammatory bowel disease|"Patients who have...
~a diagnosis of ulcerative colitis or Crohn's disease as confirmed by a clinician
~experienced a flare within the past 24 months as determined by a clinician
~had quiescent disease for at least 3 months as determined by a clinician"
16403595|NCT03953781||group 1|25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years
16403596|NCT03953781||group 2|25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
16403597|NCT03953768|Experimental|Patients undergoing device implantation|Patients undergoing device implantation with vagal nerve stimulator (VNS) for epilepsy
16403598|NCT03953755|No Intervention|Control 1|no/mild tricuspid regurgitation - left-side surgery alone
16403599|NCT03953755|No Intervention|moderate TR - left-side surgery|moderate tricuspid regurgitation - left-side surgery alone
16403600|NCT03953755|Experimental|moderate TR - left-side surgery+TVS|moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery
16403601|NCT03953755|No Intervention|Control 2|tricuspid regurgitation - left-side surgery +tricuspid valve surgery
16403602|NCT03953742|Experimental|CPI-200|"Dose Escalation Group: CPI-200 will be administered via intravenous infusion once every 3 weeks for up to 7 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
16403603|NCT03953729|Experimental|Group 1:Ibuprofeno|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
16403604|NCT03953729|Placebo Comparator|Group 2: Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
16403605|NCT03953716|Experimental|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
16403606|NCT03953716|Placebo Comparator|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
16403607|NCT03953716|Experimental|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
16403608|NCT03953716|Active Comparator|Marvelon|1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
16403609|NCT03953703|Experimental|Experimental: Levocarnitine, Placebo|990 mg of levocarnitine twice per day for four weeks, a two week washout period, 990mg of placebo twice per day for 4 weeks
16403610|NCT03953703|Experimental|Experimental: Placebo, Levocarnitine|990 mg of placebo twice per day for four weeks, a two week washout period, 990mg of levocarnitine twice per day for 4 weeks
16403611|NCT03953677|Experimental|Dexmedetomidine|
16403612|NCT03953677|Placebo Comparator|Placebo|
16403613|NCT03953664|Experimental|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
16403614|NCT03953664|Experimental|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
16403615|NCT03953664|Experimental|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
16403616|NCT03953651||Patients|Patients admitted in the emergency department presenting a myocardial oxygenation imbalance and are therefore at risk for Myocardial Infarction (MI) type 2.
16403617|NCT03953625|No Intervention|no delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.
~if the patient is included and depending on the week of inclusion, he will then be randomized to either the no booklet or the booklet group.
~If it is randomized to the arm 1 no booklet group, the patient will have classic management.
~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
16403650|NCT03953352|Other|Radiotherapy treatment|
16427453|NCT03788915|Placebo Comparator|Usual care|Usual care
16403618|NCT03953625|Experimental|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.
~If the patient is included and depending on the week of inclusion, the patient will then be randomized to either the no booklet or the booklet group.
~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.
~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
16403619|NCT03953612|Experimental|patients receiving PREG|Eligible participants will then be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) and randomly assigned to 2 doses of PREG (300/500 mg/day)over 8 weeks.
16403620|NCT03953612|Placebo Comparator|patients receiving placebo|Eligible participants will then be admitted to the Clinical Neuroscience Research Unit (CNRU) at the CMHC and randomly assigned to a placebo (PLA) treatment (N=20/group) over 8 weeks.
16403621|NCT03953599|Experimental|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
16403622|NCT03953586||bubble suction test and peristalsis in hydrosalpnix|. Group A: Women with unilateral or bilateral blockage of the distal end of the fallopian tubes with tubal distension.
16403623|NCT03953586||bubble suction test and peristalsis in normal tubes|Group B: Women with normal appearance of the fallopian tubes by HSG.
16403624|NCT03953573||Women post-delivery|
16403625|NCT03953560|Experimental|Screening|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.
~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.
~In all patients, the following tests will be performed:
~Pulsioximetry.
~Electrocardiogram.
~Blood sample with determination of NT-ProBNP.
~Echocardiography. Only an echocardiography indicative of PH warrants further evaluation
~V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.
~Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis"
16403626|NCT03953547||search for antiplatelet resistance|Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.
16403627|NCT03953521|Experimental|navigated|Positioning of the coil according to neuronavigation (Mylius et al., 2013, Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: Inter-rater reliability, accuracy, and influence of gender and Age, NeuroImage 78, 224-232).
16403628|NCT03953521|Active Comparator|F3|Positioning of the coil according to EEG (electroencephalography) electrode Position F3 (marking this Position on a head cap).
16403629|NCT03953508|Other|Menthol|Participants will smoke and rate several puffs of a menthol Camel Crush cigarette
16403630|NCT03953508|Other|Non-menthol|Participants will smoke and rate several puffs of a non-menthol Camel Crush cigarette
16403631|NCT03953495|Experimental|Better Together|Participants will be recruited with e-mail, print, and social media announcements and advertisements distributed through the professional contacts and networks of the investigators. The experimental group will consist of randomly assigned volunteers who meet the eligibility requirements (i.e., same-sex female couple over the age of 18 who lives in Central Appalachia).
16403632|NCT03953469|No Intervention|Placebo Group|"(a) Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating, or caffeine consumption.
~b) will be given 1/4 tsp of blackstrap molasses placebo. Subjects may not consume caffeine or eat food during this time.
~(c) blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
16403633|NCT03953469|Active Comparator|Group II|"Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating food, or caffeine consumption.
~15 minutes after examination - will be given 1/8 tsp (900mg) of Passiflora incarnata solid extract by Wise Woman Herbals mixed with 1/8 tsp of blackstrap molasses to mask the taste.
~blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
16403634|NCT03953456|Experimental|elafibranor 120mg followed by placebo|Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
16403635|NCT03953456|Placebo Comparator|placebo followed by elafibranor 120mg|Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
16403636|NCT03953430||study group|Patients with clubfoot recurrence undergoing Tibialis Anterior tendon transfer with a minimum age of three years from a prospective, consecutive database of patients with clubfoot treated with the Ponseti method.
16403637|NCT03953430||control group|healthy children of employees of our hospital
16403638|NCT03953417|Experimental|Bilateral accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
16403639|NCT03953404||septic shock|
16403640|NCT03953404||severe sepsis|
16403641|NCT03953404||sepsis|
16403642|NCT03953404||sirs positive, not septic|
16403643|NCT03953391|Experimental|Tea-water|Tea before water
16403644|NCT03953391|Experimental|Water-tea|Water before tea
16403645|NCT03953378||"Group RA patients"|Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.
16403646|NCT03953378||"Group PsA patients"|Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.
16403647|NCT03953378||"Group Healthy donors"|Anonymous healthy donors from the Etablissement Français du Sang.
16403648|NCT03953365|No Intervention|without mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh
16403649|NCT03953365|Other|with mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh
16403651|NCT03953339|Active Comparator|no release|no release of the suprascapular nerve during arthroscopic repair of a rotator cuff tendon repair
16403652|NCT03953339|Experimental|release|arthroscopic release of the suprascapular nerve according to the established, standard technique during arthroscopic repair of a rotator cuff tendon repair
16403653|NCT03953326|Experimental|HeartPhone Intervention|Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.
16403654|NCT03953300|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
16403655|NCT03953300|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
16403656|NCT03953287|Experimental|Pharmacokinetic Study of Paracetamol.|"Detailed Description:
~Twelve healthy young volunteers are recruited, and the experiments begin at 07:45 after an overnight fast. BMI and blod pressure are recorded and a catheter is inserted in an antecubital vein for blood samples.
~At 08.00 participants take 500 mg paracetamol as a tablet with 200 ml tap water or a Paracetamol1523 capsule in random order. Subsequently, blood samples are taken every minute for 3 minutes the first hour, then every 10 minutes the following two hours. In addition, blood pressure and puls rate are measured every 20 minute the first hour, and then every 30 minutes.Side effects and time to the participants registrate any effect of the drugs are assessed in a prefabricated scheme.
~The disadvantages associated with the experiment are sought monitored by adverse event registration which ends at the end of the trial. The trial day lasts 2 hours in which blood samples are taken as described above, and blood pressure and records are stored ."
16403657|NCT03953261|Experimental|Curcumin|
16403658|NCT03953261|Placebo Comparator|Placebo|
16403659|NCT03953248|No Intervention|Non L-Carnitine|Subjects in this arm will receive standard treatment only (without LC). It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment
16403660|NCT03953248|Active Comparator|L-Carnitine|Subjects in this arm will receive standard treatment in addition to LC IV, as a dose of 1 g/8 hours
16403661|NCT03953235|Experimental|Phase 1|"GRT-C903
~GRT-R904
~nivolumab
~ipilimumab"
16403662|NCT03953235|Experimental|Phase 2|"GRT-C903
~GRT-R904
~nivolumab
~ipilimumab"
16403663|NCT03953222|Experimental|Experimental|A single group of people with Parkinson's disease will undergo real-time feedback intervention.
16403664|NCT03953209|Experimental|spironolactone 50 mg|Oral administration of spironolactone 50 mg once daily for 12 weeks
16403665|NCT03953209|Experimental|spironolactone 100 mg|Oral administration of spironolactone 100 mg once daily for 12 weeks
16403666|NCT03953209|Experimental|spironolactone 200 mg|Oral administration of spironolactone 200 mg once daily for 12 weeks
16403667|NCT03953196|Experimental|Cohort 1: Vaccine Challenge Imvanex|Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
16403668|NCT03953196|Experimental|Cohort 2: Vaccine Challenge Shingrix|Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
16403669|NCT03953196|Experimental|Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)|Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
16403670|NCT03953196|Experimental|Cohort 4: Antigen Challenge Candin|Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
16403671|NCT03953196|Experimental|Cohort 5: Skin Wounding Challenge|3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
16403672|NCT03953183|Other|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
16403673|NCT03953183|Other|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
16403674|NCT03953170|Active Comparator|Teduglutide|Teduglutide 0.05 g/kg/day
16403675|NCT03953170|Placebo Comparator|Placebo|Placebo
16403676|NCT03953157|Experimental|Arm I (dietary intervention)|Patients receive a controlled anti-inflammatory diet over 12 weeks.
16403677|NCT03953157|Experimental|Arm II (exercise intervention)|Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
16403678|NCT03953144|Experimental|VisiblePatient™ 3D Lung Modelling + IC-GREEN Segmentectomy|Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Visible Patient™ to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
16403679|NCT03953131|Experimental|Diagnostic (gallium Ga 68-DOTATATE PET/CT)|Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.
16403680|NCT03953118|Placebo Comparator|Placebo|
16403681|NCT03953118|Active Comparator|Azithromycin|
16403682|NCT03953105||Resusci Baby|Resusci Baby used for the simulated emergency scenario
16403683|NCT03953105||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
16403684|NCT03953092|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
16403685|NCT03953092|Experimental|SAD Cohort 2|10 mg YG1699 or placebo
16403686|NCT03953092|Experimental|SAD Cohort 3|25 mg YG1699 or placebo
16403687|NCT03953092|Experimental|SAD Cohort 4|50 mg YG1699 or placebo
16403688|NCT03953092|Experimental|SAD Cohort 5|100 mg YG1699 or placebo
16403692|NCT03953079|Experimental|GB-102 Dose 2 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
16403693|NCT03953079|Experimental|GB-102 Dose 3 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline, intravitreal (IVT) GB-102 (1 mg) at Month 6 and sham at Months 2, 4, 8 and 10.
16403694|NCT03953079|Active Comparator|Aflibercept 2 mg Dose|Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
16403695|NCT03953066|Active Comparator|women with vaginal delivery|30 women with spontaneous vaginal delivery will be included in group 1 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
16403696|NCT03953066|Active Comparator|women with emergency cesarean section|30 women with emergency cesarean section will be included in group 2 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
16403697|NCT03953066|Active Comparator|women with elective cesarean section|30 women with elective cesarean section will be included in group 3serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
16403698|NCT03953053|Experimental|FLACS Group|Femto Laser treated (anterior Capsulotomy and Fragmentation of lens body before phaco emulification)
16403699|NCT03953053|Active Comparator|Manual Group|Gold Standard Method with manual rhexis with pinzette and phaco emulsification
16403700|NCT03953027||Health Services Research (surveys about drug shortages)|At baseline, practice sites complete a Baseline Drug Shortage Survey and Pharmacy Baseline Survey; Drug Shortage Incident Reports are completed in real time as cancer care delivery problems occur; and the Quarterly Follow-Up Survey Number Treated Report every 3 months for one year (4 total).
16403701|NCT03953001|Experimental|Buzzy|Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
16403702|NCT03953001|Active Comparator|Control|Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.
16403703|NCT03952988|Experimental|Probiotic|
16403704|NCT03952988|Placebo Comparator|Placebo|
16403705|NCT03952975|Other|follicular phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as <15 adjusted days, group A).
16403706|NCT03952975|Other|luteal phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) [14]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).
16403707|NCT03952962|Experimental|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
16403708|NCT03952962|Experimental|Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
16403709|NCT03952949|Experimental|Default|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
16403710|NCT03952949|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read a brief education brochure before online grocery shopping.
16403711|NCT03952936|Other|Mobility|Self comparison of data from pre-post intervention.
16403712|NCT03952923|Experimental|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
16403713|NCT03952910|Experimental|Experimental group|Online pain education program will be accessible by the intervention group
16403714|NCT03952910|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
16403715|NCT03952897||Group 1|Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.
16403716|NCT03952884|Active Comparator|Leucine|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
16403717|NCT03952884|Experimental|Leucine Peptide (Dileucine)|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
16403718|NCT03952871||Intensive care patient with hemodynamic instability|The study group is composed of intensive care patients which already need an invasive monitoring of the cardiac output because of a shock state.
16403719|NCT03952858|Experimental|Telerehabilitation Group|Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
16403749|NCT03952650|Placebo Comparator|4a|Receiving normal saline with 75 mg pyrimethamine day 0 post injection
16403750|NCT03952650|Placebo Comparator|4b|Receiving normal saline with 75 mg pyrimethamine days 2&amp;3 post injection
16427719|NCT03787004|Placebo Comparator|Part 2 Placebo|Placebo oral tablet
16403720|NCT03952858|Active Comparator|Community Center group|"The Community Center Group will receive the traditional exercise programs offered in a Community Center for older people. The exercise program can vary dependent on the offer in the individual community center. Often the training consists of exercises carried out in a range of different training equipments such as exercise bikes, steppers, rowing machines etc. often supervised by a physiotherapist. At some community centers the training will be performed in groups on appointed times. Some citizens are offered one or two times instruction and hereafter they have to train on their own. Some times the citizens are offered few times of training in their own home and hereafter follow the offer at the community center for older people. Before discharge, at the hospital, their plan for rehabilitation will be completed.
~Participants in the Community Center Group will be tested by the same instruments at baseline and after 4 and 8 weeks and at 6 months of follow-up."
16403721|NCT03952845|Experimental|Intranasal Capsaicin|Separate patients will be given escalating doses of intranasal capsaicinoid spray
16403722|NCT03952832|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16403723|NCT03952819||Diabetic group,|The study was designed with 28 chronic hemodialysis patients (17 men, 11 women) receiving treatment at our hospital. Of the 28 hemodialysis patients, 14 had Type 2 diabetes mellitus. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
16403724|NCT03952819||Non-Diabetic group,|Of the 28 hemodialysis patients, the other 14 were not diabetic. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
16403725|NCT03952819||Control group,|The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
16403726|NCT03952806|Experimental|Arm 1: BHV-3241- Experimental|
16403727|NCT03952806|Placebo Comparator|Arm 2: Placebo Comparator|
16403728|NCT03952793|Experimental|Experimental|Extended biopsy
16403730|NCT03952754|Experimental|Group 2: Hip Hop Nutrition-Math Curriculum|The intervention group will receive an tailored program for ten weeks, meeting twice a week.
16403731|NCT03952754|Active Comparator|Group 1: Food Explorers Program|The control group will receive the usual care for nutrition program provided by the schools, called Food Explorers. The group will also be conducted ten weeks, meeting twice a week.
16403732|NCT03952741|Experimental|Cognitive Functional Therapy|The intervention is a targeted cognitive functional therapy and will be based on examination findings. It is behaviorally directed with a focus on normalizing mal-adaptive pain, cognitive and movement behaviors in a graduated manner. In the evaluation process it is considered whether the patient has adjusted to the back complaints in a positive way (confrontation, active coping, minimal avoidance behavior) or in a negative way (passive coping, fear and avoidance behavior). Work related issues will be a particular focus, with the aim of achieving close co-operation between the worker, the workplace and the worker's responsible health care provider.
16403733|NCT03952741|Active Comparator|Cognitive Patient Education and PT|The intervention in the second group will receive much training in cognitive coping techniques after the COPE LBP trial principles (Werner et al. 2010). The educational part of the COPE for new instructors with a PT background takes 2 days supervised by Werner and his group, with regular follow-up meeting with the project leaders, together with a psychologist trained in cognitive therapy
16403734|NCT03952728||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention, consented to administrative data linkages, and were successfully linked to Medicare databases.
16403735|NCT03952728||Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education control arm, consented to administrative data linkages, and were successfully linked to Medicare databases.
16403736|NCT03952715|Experimental|Evoked pain training|
16403737|NCT03952715|Experimental|Control|
16403738|NCT03952689|Experimental|Post cardiac surgery patients|For all patients, readings of the urine output from both the Serenno system and the collection bag (urinometer) (by camera) will be recorder every 10 minutes, for the duration of 24 hours.
16403739|NCT03952676|Experimental|Moving cupping intervention|Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
16403740|NCT03952676|Placebo Comparator|Moving cupping placebo control|Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
16403741|NCT03952663|Experimental|Group I|inferior alveolar nerve lateralization for dental implant placement ,and platelet rich fibrin membrane is placed around the nerve.
16403742|NCT03952663|Active Comparator|Group II|inferior alveolar nerve lateralization for dental implant placement without placement of platelet rich fibrin membrane around the nerve.
16403743|NCT03952650|Experimental|1a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
16403744|NCT03952650|Experimental|1b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
16403745|NCT03952650|Experimental|2a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
16403746|NCT03952650|Experimental|2b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
16403747|NCT03952650|Experimental|3a|Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
16403748|NCT03952650|Experimental|3b|Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
16403751|NCT03952650|Placebo Comparator|4c|Receiving normal saline with weekly chloroquineibuprofen (if necessary)
16403752|NCT03952650|Experimental|5a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
16403753|NCT03952650|Experimental|5b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
16403754|NCT03952650|Experimental|6a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
16403755|NCT03952650|Experimental|6b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
16403756|NCT03952637|Experimental|1|In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg /kg of the gene transfer agent, and asentinel Type II subject will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transferagent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
16403757|NCT03952637|Experimental|2|Following the last Stage 1 subject s 6 months visit, data will be reviewed, and Stage 2 dosing andassessments will be determined. If Stage 2 dosing is toproceed, it will be reflected in a protocol amendment.
16403758|NCT03952624||Control|FNS <= 3
16403759|NCT03952624||Fatigued|FNS >= 4
16403760|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
16403761|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Reveal®|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
16403762|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Endocuff Vision|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
16403763|NCT03952598|Experimental|1/Arm 1|Monitoring of quantitative levels of 2-hydroxyglutarate (2- HG) via proton magnetic resonance spectroscopy (1H-MRS)
16403767|NCT03952572|Experimental|CDOP regimen|cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
16403768|NCT03952572|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
16403774|NCT03952546|Experimental|Treatment Arm|Saline-coupled bipolar sealer
16403775|NCT03952546|Active Comparator|Control Arm|Unipolar electrocautery
16403776|NCT03952533|Experimental|ALA|"ALA Group will be composed of women allocated to the Treatment Group. These women will receive 2 tablets of Alpha lipoic Acid (ALA) as Dav® food supplement 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy) daily until delivery."
16403777|NCT03952533|No Intervention|Control|"Control Group will be composed by women allocated in the Control Group and will not receive any supplementation but the standard care."
16403778|NCT03952520|Active Comparator|Standard Approach (SA)|The Standard Approach is a one-size-fits-all multifaceted implementation strategy that was systematically developed using Intervention Mapping.
16403779|NCT03952520|Experimental|Tailored Approach (TA)|The Tailored Approach includes an implementation strategy that will be tailored to match site-specific barriers to implementation of SNaP at that site.
16403780|NCT03952507|Experimental|Group 1: JNJ-64417184|Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16403781|NCT03952507|Experimental|Group 2: JNJ-64417184|Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16403782|NCT03952507|Experimental|Group 3: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16403783|NCT03952507|Experimental|Group 4: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16403845|NCT03952143|Experimental|LY900014|LY900014 given subcutaneously (SC) with either insulin glargine given SC or insulin degludec given SC.
16403846|NCT03952143|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) given SC with either insulin glargine given SC or insulin degludec given SC.
16403784|NCT03952507|Experimental|Group 5: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16403785|NCT03952507|Experimental|Group 6: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16403786|NCT03952494|Experimental|Intervention group|Intervention group will have the PGx test results available via Epic, three days after the biospecimen is received.
16403787|NCT03952494|Experimental|Control group|"The control group will be considered in TAU(treatment as usual) group but will have the PGx test results available after 24 weeks.
~Note: Patient in both the groups will be followed for 24 weeks and will take questionnaires every other week."
16403788|NCT03952481|Experimental|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
16403789|NCT03952468|Active Comparator|TMS + Brief Cognitive Behavioral Therapy|Combined transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
16403790|NCT03952468|Sham Comparator|Sham TMS + Brief cognitive behavioral therapy|Sham Transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
16403791|NCT03952455|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
16403792|NCT03952442|Active Comparator|control group|
16403793|NCT03952442|Experimental|experimental group|
16403794|NCT03952429|Active Comparator|Active Cognitive Bias App|Participants will receive the Anti-Alcohol App with the Active Cognitive Bias modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
16403795|NCT03952429|Placebo Comparator|Inactive Cognitive Bias Modification|Participants will receive the Anti-Alcohol App with the Inactive Cognitive Bias Modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
16403796|NCT03952416|No Intervention|Standard of Care (SOC)|The control group for this study will receive rehabilitation therapy that is recommended and provided by the current healthcare structure. The SOC group will receive therapy only from four therapists who are not trained and supervised in EMR. These therapists will be monitored (videotaped or observed) but will not be not asked to do anything differently with their patients. The investigators recognize that spillover of therapist EMR training to untrained therapists is a concern. Thus, the investigators will ask therapists in the EMR group to agree not to share any of the training with non-trained therapists over the course of the study, and the investigators will provide free EMR training to the non-trained therapists once the treatment phase of the study is complete.
16403797|NCT03952416|Experimental|Enhanced Medical Rehabilitation (EMR)|Patients in the EMR group will also receive the recommended rehabilitation therapy, but they will receive therapy only from four therapists who are trained and supervised in EMR. The therapy sessions will follow EMR protocol. EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation.
16403798|NCT03952403|Experimental|Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
16403799|NCT03952403|Experimental|Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
16403800|NCT03952403|Experimental|Part 2-Arm B (HLX10+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
16403801|NCT03952403|Active Comparator|Part 2-Arm C (Carboplatin+Pemetrexed)|Participants will receive IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
16403802|NCT03952390||control|healthy volunteers
16403803|NCT03952390||sepsis|patients with sepsis
16403804|NCT03952377|Placebo Comparator|0.9% Sodium Chloride for Injection|
16403805|NCT03952377|Experimental|12.5 mg SX600|Low Dose
16403806|NCT03952377|Experimental|25.0 mg SX600|High Dose
16403807|NCT03952351|Experimental|CTCA with standard care|Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
16403808|NCT03952351|No Intervention|Standard care|
16403847|NCT03952130|Experimental|LY900014|LY900014 given subcutaneously (SC) with either insulin glargine given SC or insulin degludec given SC.
16403848|NCT03952130|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) given SC with either insulin glargine given SC or insulin degludec given SC.
16403849|NCT03952117|Active Comparator|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
16403809|NCT03952338|Experimental|Nutrition Coupons|Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
16403810|NCT03952338|No Intervention|Control|No intervention provided. Participants will be eligible to participate in the BC Farmers' Market Nutrition Coupon Program during the next farmers' market season (i.e. one year following the current intervention).
16403811|NCT03952325|Experimental|Cohort 1, Arm A: Tesetaxel plus nivolumab|
16403812|NCT03952325|Experimental|Cohort 1, Arm B: Tesetaxel plus pembrolizumab|
16403813|NCT03952325|Experimental|Cohort 1, Arm C: Tesetaxel plus atezolizumab|
16403814|NCT03952325|Experimental|Cohort 2: Tesetaxel|
16403815|NCT03952325|Experimental|Cohort 3: Tesetaxel|
16403816|NCT03952312|Experimental|"OncoTool Intervention"|
16403817|NCT03952312|Active Comparator|"Oncotool Control"|
16403818|NCT03952299|Active Comparator|Oral administration|"Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.
~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital."
16403819|NCT03952299|Experimental|Transdermal administration|Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.
16403820|NCT03952286|Experimental|Intervention|ED-Dispensing with home and school supervision
16403821|NCT03952286|No Intervention|Control|ED-Dispensing with home supervision
16403822|NCT03952273|Active Comparator|Combo|PCI with COMBO stent
16403823|NCT03952273|Active Comparator|BioMatrix Alpha|PCI with BioMatrix Alpha stent
16403824|NCT03952260|Active Comparator|Fasting clear fluid for 1 hour prior to anaesthesia|Fasting clear fluid for 1 hour prior to anaesthesia
16403825|NCT03952260|No Intervention|Fasting clear fluid for 2 hours prior to anaesthesia|Fasting clear fluid for 2 hours prior to anaesthesia
16403826|NCT03952247|Experimental|Single Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
16403827|NCT03952247|Active Comparator|Conventional Multi Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
16403828|NCT03952234|Other|Dose finding safety study|In this study, the highest acceptable dose of an amino acid called citrulline will be established in people who have a mitochondrial disorder. Previous research conducted by several groups including our center at Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in people affected with MELAS.
16403829|NCT03952221|Active Comparator|Usual physiotherapy and continuous ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and continuous ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
16403830|NCT03952221|Active Comparator|Usual physiotherapy and pulsed ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and pulsed ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle) every working day for two weeks (10 occasions).
16403831|NCT03952221|Active Comparator|Usual physiotherapy and sonotens therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sonotens therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 0,5 W/cm2 SATA intensity, transcutanous electrical nerve stimulation) every working day for two weeks (10 occasions).
16403832|NCT03952221|Placebo Comparator|Usual physiotherapy and sham ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sham ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 0 MHz frequency, 0 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
16403833|NCT03952208|Experimental|Concussion Group|Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
16403834|NCT03952208|Experimental|Matched Subjects Group|Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
16403835|NCT03952182|Active Comparator|Spinal Orthosis (LSO, TLSO, etc)|Patient's in this arm will be given an orthosis for the treatment of their injury (TLSO for thoracic or upper lumbar injury, LSO for lumbar injury)
16403836|NCT03952182|Experimental|No Spinal Orthosis|the patient's in this arm will not be given an orthotic. They will be given a bending restriction and otherwise remain activities as tolerated.
16403837|NCT03952169|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
16403838|NCT03952169|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
16403839|NCT03952156|Experimental|Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
16403840|NCT03952156|Experimental|Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
16403841|NCT03952156|Experimental|Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
16403842|NCT03952156|Experimental|Delayed Treatment Control|Delayed Treatment Control Arm
16403843|NCT03952156|Experimental|Expansion Phase First Dose level|Expansion Phase First Dose Level of HMI-102 delivered intravenously one time
16403844|NCT03952156|Experimental|Expansion Phase Second Dose level|Expansion Phase Second Dose Level of HMI-102 delivered intravenously one time
16407787|NCT03924180|Active Comparator|Control -Amino acids mixtures|Mixtures of conventional amino acids.
16403850|NCT03952117|Sham Comparator|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
16403851|NCT03952104|Experimental|Experimental-Low Intensity Strength Training|Strength training (low intensity)
16403852|NCT03952104|Experimental|Experimental-Moderate Intensity Strength Training|Strength training (moderate intensity)
16403853|NCT03952104|Experimental|Experimental-High Intensity Strength Training|Strength training (high intensity)
16403854|NCT03952104|No Intervention|Control|No intervention
16403857|NCT03952078|Experimental|CPI-818 Dose Escalation|Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for >2 months or if dose determined to be unsafe.
16403858|NCT03952078|Experimental|CPI-818 Dose Expansion phase|"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.
~CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for > 2 months."
16403859|NCT03952065|Experimental|PD1/PDL1 inhibitor infusion via neck artery|Interventional technique is used to localize neck artery to infuse the inhibitors directly into tumor.
16403860|NCT03952065|Experimental|PD1/PDL1 inhibitor infusion via peripheral vein|Routine peripheral vein infusion of PD1/PDL1 inhibitor is performed as control.
16403861|NCT03952052|Other|Patient enrolled|Recurrent mutations determination
16403862|NCT03952039|Experimental|Fedratinib 400mg/day|Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
16403863|NCT03952039|Active Comparator|Best Available Therapy (BAT)|Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.
16403864|NCT03952026||isolated pelvic fracture|Patients with an isolated pelvic fracture
16403865|NCT03952026||combined abodominal/pelvic injury|Patients with a combined injury of a pelvic fracture and an abdominal injury.
16403866|NCT03952013||Study group|"All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE
~LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),
~HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)
~HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)"
16403867|NCT03952000|Experimental|Experimental: Exercise|Exercise: Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1.
16403868|NCT03952000|No Intervention|No Intervention: Control|Participants will rest on day 1.
16403869|NCT03951987|Experimental|Treatment A: 4 ml CG5503|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) was administered as a 2 minutes infusion.
16403870|NCT03951987|Experimental|Treatment B: 4 ml CG5503; 5 g charcoal powder|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) with oral co-administration of charcoal (5 g charcoal were co-administered orally at 1, 0.5 hours and 10 minutes before the start of CG5503 infusion and 0.5, 1, 1.5, 2 and 4 hours thereafter)
16403871|NCT03951974|Experimental|Experimental|Participants in the experimental group will receive training in utilizing social regulation of emotion strategies in an individualized format. They will meet with an interventionist for 5 weeks (1 in-person session and 4 telephone sessions) for 1-1.5 hours each week, and keep a journal documenting their emotion challenges and regulation strategy use.
16403872|NCT03951974|Other|Control|Participants in the control group will not receive training in utilizing social regulation of emotion strategies. While they will still meet with the interventionist on the same schedule and for approximately the same length of time, they will simply be asked to report the emotion regulation strategies that they naturally employ. They will also keep a journal documenting their emotion challenges and regulation strategy use.
16403873|NCT03951961|Experimental|Midostaurin|50 mg Midostaurin bid for 12 months
16403874|NCT03951935||sLSS|patients diagnosed with sLSS scheduled for decompression surgery
16403875|NCT03951935||control subjects|healthy, age-matched control subjects
16403876|NCT03951922|Experimental|Therapeutic Horticulture Group|The therapeutic horticulture group will participate in a 6-week horticulture program meeting twice a week for an hour led by an occupational therapist incorporating plant-based activities and education on pain management techniques at a community farm.
16403877|NCT03951909|Experimental|Active intervention|Either Physiotherapy activity and awareness intervention (PAAI) or Teaching recovery techniques (TRT)
16403878|NCT03951909|Experimental|Waiting list|The same interventions as above will be hold for waiting lists participants, but after 6 to 8 weeks
16403879|NCT03951896|Experimental|PRP|"Interventions:
~A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects."
16403880|NCT03951896|Placebo Comparator|Placebo|For the control group, same amount of blood was sampled and they were given a same amount of waiting time with the other group, with the resulting injection preparate being 2 ml's of 0,9% saline instead.
16403881|NCT03951883|Active Comparator|Typical Diet (TD)|Participants will be instructed to continue habitual dietary intake.
16403882|NCT03951883|Experimental|Increased Egg Consumption (IE)|Participants will be prescribed an additional 2 eggs per day to their diet.
16404028|NCT03950843|Placebo Comparator|Placebo Group|"Patients assigned to this group are treated with 3 placebo capsules (the placebo of CKD-825)
~The necessity of a dose titration is adjudicated every 2 weeks"
16403883|NCT03951870|Experimental|Mesolimbic Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects will participate in four fMRI-NF sessions, up-regulating activation of three mesolimbic reward nodes:
~ventral tegmental area, and bilateral ventral striatum. ROIs are 5 mm spheres around peak activations in funcitonal localizer task (Monetary Incentive delay, reward anticipation contrast), within a predifned meta-analytic anatomical masks of the three regions.
~anatomical masks: VTA (Midbrain): -4 -24 -10 Right Nac: 12 10 -4 Left Nac: -10 10 -6 Oldham, Stuart, et al. Human brain mapping (2018).
~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
16403884|NCT03951870|Active Comparator|Control Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects will participate in four fMRI-NF sessions, up-regulating activation of regions comprising one of 4 control networks (5mm spheres around MNI coordinates):
~Motor Imagery (Hétu, Sébastien, et al. Neurosci. & Biobehav Rev (2013)) R. Cerebellum: 32 -62 -28 L. Cerebellum: -32 -56 -30 L. Precentral Gyrus: -26 -2 58; Auditory imagery (McNorgan, Chris.Front in Human Neurosci 6 (2012)) R STG:64 -30 9 L IFG:-48 24 -5 L precentral Gyrus: -52 1 47; Arithmetic processing (Arsalidou, Marie, and Margot J. Taylor. Nuroimage (2011)) R. SPL: 29 -66 49 L. MFG (dlpfc): -45 32 29 L. precuneus: -28 -71 33; Spatial Navigation (Kühn, Simone, and Jürgen Gallinat. Human Brain Map. (2014)) R. hippocampus 26 -35 -11 L. hippocampus -26 -47 -9 L. Post. cingulate -15 -59 19
~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
16403885|NCT03951870|Other|Natural history|"No brain manipulation (Assesment of natural history immune response).
~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
16403886|NCT03951857|No Intervention|Young men|Range of age is 20-35 years, young men (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
16403887|NCT03951857|No Intervention|Young women|Range of age is 20-35 years, young women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
16403888|NCT03951857|Experimental|Elderly women (control)|Range of age is 65-80 years, Elderly women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
16403889|NCT03951857|Experimental|Elderly obese women|Range of age is 65-80 years,Elderly obese women (BMI ≥25 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
16403890|NCT03951844|Experimental|Experimental group|Each participant is evaluated while wearing or not wearing the device.
16403891|NCT03951831|Experimental|ADT Followed by Chemoimmunotherapy|"REGN2810 followed by chemoimmunotherapy:
~Initiate degarelix 240mg SC once, followed by leuprolide acetate 22.5mg SC every 3 months.
~Week 4 start cemiplimab (REGN 2810) 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
~Week 10 start docetaxel 75 mg/m2 every 21 days for up to 6 cycles."
16403892|NCT03951805|Experimental|Insulin 287 algorithm A|Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
16403893|NCT03951805|Experimental|Insulin 287 algorithm B|Controlled on metformin with or without DPP4i and with or without SGLT2i.
16403894|NCT03951805|Experimental|Insulin 287 algorithm C|Controlled on metformin with or without DPP4i and with or without SGLT2i.
16403895|NCT03951805|Active Comparator|Insulin Glargine algorithm D|Controlled on metformin with or without DPP4i and with or without SGLT2i.
16403896|NCT03951792||Colorectal Cancer Subjects|Subjects under going colorectal resection with colorectal cancer will have tissue and stool collected
16403897|NCT03951792||Benign Colon Resection Subjects|Subjects under going colorectal resection without colorectal cancer will have tissue and stool collected
16403898|NCT03951779|Experimental|Subjects with unexplained but suspected cardiac dyspnea|Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR).
16403899|NCT03951766|Other|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
16403900|NCT03951753|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
16403901|NCT03951753|Active Comparator|Semaglutide|Semaglutide administered SC
16403902|NCT03951753|Placebo Comparator|Placebo|Placebo administered SC
16403903|NCT03951740|Experimental|Group of cardiac patients|All patients completed the study wearing two wrist-worn activity trackers and the Oxycon mobile as reference method during a laboratory activity protocol.
16403904|NCT03951727|Other|Endovascular treatment for PAD|Single group study (1 arm)
16403905|NCT03951714|Other|Reference|Control experience using marketed application to record medication intake without reminders from the app
16403906|NCT03951714|Experimental|Intervention|Full experience using marketed application, with all functionalities enabled
16403907|NCT03951701|Experimental|observation cohort|Questionnaire to assess the supportive care needs
16403908|NCT03951688|Experimental|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.
~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
16403909|NCT03951688|No Intervention|Control Group|No intervention
16403910|NCT03951675||Individuals Living with DMD|90 patients/parents
16403911|NCT03951675||Healthcare Providers to Patients with DMD|40 healthcare providers
16403912|NCT03951662||With alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.
16403913|NCT03951662||Without alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.
16404029|NCT03950830|Experimental|Treatment arm|Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously
16404092|NCT03950336|Other|"Placebo + Low n-6 PUFA Diet"|A combination of maltodextrin (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
16403914|NCT03951649|Experimental|Occipital Nerve block|"Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.
~Site of injection will be cleaned with an alcohol swab.
~5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.
~After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved."
16403915|NCT03951649|Active Comparator|Oral Acetaminophen/Caffeine Group|Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)
16403916|NCT03951636|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant/abutment surface will be cleaned by copious irrigation with Chlorhexidine
16403917|NCT03951636|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant/abutment surface.
16403918|NCT03951636|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant/abutment surface.
16403919|NCT03951623|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks and 16 weeks open-label treatment.
16403920|NCT03951623|Placebo Comparator|placebo arm|Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks and 16 weeks open-label treatment.
16403921|NCT03951610|Experimental|Test lens|Subjects wearing the test lens for one week, either randomized as the first or second pair.
16403922|NCT03951610|Active Comparator|Control lens|Subjects wearing the control lens for one week, either randomized as the first or second pair.
16403923|NCT03951597|Experimental|Combined therapy using Gemox, Lenvatinib and PD1|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.
~Lenvatinib (8mg/d), continuous use for 1 year.
~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
16403924|NCT03951584||ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study cohort. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset, to evaluate the damage and prognosis of vestibular function.
16403925|NCT03951571|Experimental|Anlotinib Gruop|
16403926|NCT03951571|Placebo Comparator|Placebo Group|
16403927|NCT03951558|Experimental|Diet for calciuria prevention|placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.
16403928|NCT03951558|Placebo Comparator|hydrochlorothiazide for calciuria prevention|recommendations for water intake and decrease in salt intake will be given.
16403929|NCT03951545|Active Comparator|Mechanical group|Group of patients whose tibial sections will be performed using extramedullary mechanical sighting
16403930|NCT03951545|Experimental|Gyroscopic group|Group whose tibial sections will be performed using gyroscopic and accelerometric navigation (I-Assist) will be randomized
16403931|NCT03951532||children with hyperthyroidism|children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
16403932|NCT03951519|Experimental|Water|
16403933|NCT03951519|Active Comparator|Physiological serum|
16403934|NCT03951506|Experimental|Experimental-Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
16403935|NCT03951506|Experimental|Experimental-conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
16403936|NCT03951493|Experimental|RSHF + zoledronic acid|Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).
16403937|NCT03951493|Active Comparator|RSHF|Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.
16403938|NCT03951480|Experimental|Manual medicine|
16403939|NCT03951480|Active Comparator|Corticosteroids infiltration|
16403940|NCT03951467|Experimental|Interventional arm|
16403941|NCT03951467|No Intervention|Controlled arm|Patients within this arm will be follow as usual care of the cardiologic unit
16403942|NCT03951454|Experimental|Conexiones|5 telephone sessions of Conexiones, with each session delivered 2 weeks apart across a total period of 8 weeks
16403943|NCT03951454|Other|Taking Time|1 telephone session consisting of a scripted protocol guiding participants through the NCI's Taking Time Booklet.
16403944|NCT03951428||All Participants|
16403945|NCT03951415|Experimental|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
16403946|NCT03951402|Experimental|CG5503 PR 100 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 100 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 1 tablet CG5503 PR and 1 placebo-tablet, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin 400 mg.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
16403947|NCT03951402|Experimental|CG5503 PR 200 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 200 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
16403948|NCT03951402|Placebo Comparator|Placebo|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
16403949|NCT03951402|Active Comparator|Moxifloxacin 800 mg single dose|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); and 2 placebo-capsules, matching moxifloxacin on days 1 and 2; In the morning of Day 3, each participant received additionally 2 capsules each containing 1 tablet moxifloxacin.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
16403950|NCT03951376|Experimental|Intervention|"The schools in this arm will implement the UPRIGHT programme (18 skills related to Mindfulness, Coping, Efficacy and Social and emotional learning) during a minimum of 18 sessions and a maximum of 24 in a period of 6 months, which will be conducted by teachers to adolescents of 1st grade (12-14 years of age).
~Teachers will be trained by the UPRIGHT team at the beginning of the school year (3 months) and families will have a combination of face to face training and online training throughout the UPRIGHT platform."
16403951|NCT03951376|No Intervention|Control|Schools in the control arm have their usual curricula and are not provided of any intervention resources or support, apart from those in the common daily activities.
16403952|NCT03951363|No Intervention|Qualitative Interview|Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
16403953|NCT03951363|Other|Pilot Testing|Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
16403954|NCT03951350|No Intervention|Control (TAU)|Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
16403955|NCT03951350|Experimental|Lifestyle Modification Program (LMP)|It will consist of 6 weekly group sessions (lasting 90 minutes each).
16403956|NCT03951350|Experimental|Lifestyle Modification Program (LMP) + ICTs|It will consist of 6 weekly group sessions (lasting 90 minutes each).
16403957|NCT03951337|Experimental|64Cu ATSM|pretherapeutic 64Cu-ATSM PET/CT scan
16403958|NCT03951324||Expert Endoscopists|Experienced Endoscopists with significant user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
16403959|NCT03951324||None-Expert Endoscopists|Experienced Endoscopists with non-significant or beignner user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
16403960|NCT03951298||Wolfram Syndrome Patients|Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
16403961|NCT03951298||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
16403962|NCT03951285|Experimental|NR|"One intervention includes healthy BMI-discordant monozygotic twin pairs, which both are treated with NR. With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background.
~The final dose for NR will be 1 g/day. The daily NR dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full NR dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
16403963|NCT03951285|Placebo Comparator|Placebo|"The second intervention includes monozygotic twins concordant for body weight. It's randomized which member of the twin pair is treated with NR while the other co-twin gets placebo.
~The final dose for placebo will be 1 g/day. The daily placebo dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full placebo dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
16403964|NCT03951272|Experimental|Lyoplant® Onlay|All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
16403965|NCT03951272|Active Comparator|DURAFORM™ Dural Graft Implant|All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
16403966|NCT03951259|Experimental|SM934 10mg|SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids
16403967|NCT03951259|Experimental|SM934 30mg|SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids
16403968|NCT03951259|Experimental|SM934 50mg|SM934 10mg（5 tablet）p.o. qd in combination with steroids
16403969|NCT03951259|Placebo Comparator|Placebo|Placebo（5 tablets）p.o. qd in combination with steroids
16403970|NCT03951246|Experimental|Training Group|"Training Group recieved cognitive and Motor training included 6 sessions using the following training devices.
~Dynavision D2 ® (USA) (https://products.dynavisioninternational.com/products/d2) presents a panel with 64 bulbs which take the form of five circles. The task of a participant is to press the bulb that is glowing as quick as possible. In the trial 8 modes will be used; they have different instructions which are aimed at visual-motor co-ordination, processing speed, inhibition, and shifting.
~Fitlight Trainer ® (Canada) (https://www.fitlighttraining.com) consists of 7 clickers, and the tasks are similar to Dynavision ones.
~NeuroTracker ® (Canada) (https://neurotracker.net) includes a task of multiple object training for working memory and attention enhancement."
16403971|NCT03951246|No Intervention|Control Group|Control Group didn't recieved any cognitive and motor training. They visited swimming pool and physical therapy.
16403972|NCT03951233||K-RAS and EGFR mutated|
16403973|NCT03951233||Wild type|
16403974|NCT03951220||Group 1- Myeloma|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.
~This will be repeated at 6 months."
16404091|NCT03950336|Other|"Prebiotics + Control Diet"|A combination of beta-fructans (12g/day) and a control diet following the guidelines of Canada's Food Guide.
16403975|NCT03951220||Group 2- MGUS|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.
~This will be repeated at 6 months."
16403976|NCT03951220||Group 3- Healthy Volunteers|Participants will have the experimental combined MR imaging.
16403977|NCT03951207|Experimental|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
16403978|NCT03951207|Experimental|Rosuampin 20/5mg|Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
16403979|NCT03951207|Active Comparator|Amlodipine/Atorvastatin 5/20mg|Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks
16403980|NCT03951194|Experimental|Participants receiving PRP treatment|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
16403981|NCT03951194|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP)|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
16403982|NCT03951181|Experimental|LEAP-MS Intervention|This is a single arm study.
16403983|NCT03951168|Other|Routine Management|The patients were divided into routine diabetic health education management model group. Patients who meet the criteria for admission and discharge.
16403984|NCT03951168|Experimental|Standardized Management|The patients were divided into standardized diabetes health education management model group. Patients who meet the criteria for admission and discharge.
16403985|NCT03951155|Experimental|ADHD Group|Muscle Relaxation technique for behavioral management
16403986|NCT03951155|No Intervention|Tell Show Do Group|Tell Show Do Technique for behavioral management
16403987|NCT03951142|Experimental|Study A: Recurrent glioblastoma (denoted 'AR')|"Patients with recurrent glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 12 cycles will be administered for a total of 6 weeks (42 days) to 24 weeks (168 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.
~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy (temozolomide or lomustine tablets)."
16403988|NCT03951142|Experimental|Study A: Newly diagnosed glioblastoma (denoted 'AN')|"Patients with newly diagnosed glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 17 cycles will be administered for a total of 6 weeks (42 days) to 34 weeks (238 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.
~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving adjuvant chemotherapy (Temozolomide tablets)."
16403989|NCT03951142|Experimental|Study B: Brain metastases (denoted 'BM')|"Patients with brain cancer from non-small cell lung cancer (N=45) with all receive a dose of 50mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 3 months (90 consecutive days) defined as a treatment cycle. A minimum of one cycle and a maximum of three cycles will be administered for a total of 3 months (90 days) to 9 months (270 days), respectively.
~A stepped-wedge randomized design (ratio 1:1:1 over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy alone (carboplatin in combination with vinorelbin or pemetrexed or equivalent analogs) or in combination with pembrolizumab (2mg/kg/3rd week)."
16403990|NCT03951129||verbal group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal informing before hemodialysis catheter insertion
16403991|NCT03951129||verbal and video group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal and video informing before hemodialysis catheter insertion
16403992|NCT03951116|Experimental|Dose escalation cohort of FCN-437c|"The dose-escalation cohort:
~Participants will receive FCN-437c monotherapy once daily (QD) for 21 days followed by a 7 day rest period (28-day cycle).
~FCN-437c will be administered orally.
~Participants with histologically or cytologically confirmed advanced unresectable/metastatic solid tumor will participate in this cohort."
16403993|NCT03951103||Hemophili A patients|Patients treated with rFVIIIFc for ITI
16403994|NCT03951090|Experimental|GARRT Arm|Participants in this arm complete an brief geriatric assessment, and the results of these assessments are given to providers with recommendations to address deficits identified by the geriatric assessment
16403995|NCT03951090|Active Comparator|Control Arm|Providers of participants of this group will not receive the results of the brief geriatric assessments. These participants will receive standard of care treatment
16403996|NCT03951077|Experimental|Various doses of Elagolix plus matching placebo|Various dosing regimens for Elagolix taken orally plus matching placebo taken orally depending on arm assignment.
16403997|NCT03951077|Placebo Comparator|Placebo|Placebo taken orally twice a day (BID)
16403998|NCT03951064|Experimental|Optimal PEEP|The waveforms of airway pressure (Paw), esophageal pressure (Pes), and transpulmonary pressure (Ptp) will be visualized on the ventilator. Ptp is obtained from Paw - Pes. PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP). Measurements will be obtained daily and adjustments to PEEP will occur daily. PEEP will be reduced below Optimal PEEP in the setting of hemodynamic compromise (requiring increasing vasoactive medications for blood pressure support).
16404027|NCT03950843|Experimental|Experimental Group|"Patients assigned to this group are treated with 1 capsule of CKD-825 and 2 placebo capsules(the placebo of CKD-825)
~The necessity of a dose titration is adjudicated every 2 weeks.
~After unblinding at the end of Administration Period, only patients in experimental group are treated with 1 capsule of CKD-825 for additional 4 weeks of Extension Period."
16407914|NCT03923218||Smoker patients with chronic periodontitis|Smoker patients with chronic periodontitis
16403999|NCT03951064|Active Comparator|ARDSNet High PEEP|PEEP in the control group will be determined by High PEEP ARDSnet PEEP/FiO2 table. Titration of PEEP will occur when clinically indicated by partial pressure of oxygen (PaO2) or oxygen saturation (SpO2), and FiO2. The investigators chose the High PEEP table based on the clinical suspicion that obese patients may require higher PEEP levels on average than non-obese patients to balance the additional pressure of their chest wall. In addition, EPVent2, a study of esophageal balloon PEEP titration in patients with ARDS utilized the High PEEP table. Patients with moderate and severe ARDS benefit from higher levels of PEEP.
16404000|NCT03951051|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16404001|NCT03951051|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16404002|NCT03951038|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with saline added up to a volume of 80ml in total ) and the equal volume of 0.9% normal saline will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
16404003|NCT03951038|Experimental|Lateral TLIPB group|Participants in this group will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine, and combined with PCIA post-operatively. The regimen of the Lateral TLIPB is 0.2% 20 ml ropivacaine respectively and the regimen of PCIA is same with PCIA group.
16404004|NCT03951025|Active Comparator|Melatonin oral administration|Consumption of one tablet with 1 mg of melatonin orally
16404005|NCT03951025|Experimental|Melatonin sublingual administration|Consumption of one tablet with 1 mg of melatonin sublingually
16404006|NCT03950999|Experimental|Study arm|Each subject underwent baseline assessment of pain reporting accuracy (FAST). Thereafter, the placebo response was assessed using tonic heat stimuli delivered at fixed temperature of 44, 46.5, and 48°C which evoke mild, moderate and severe pain sensations (in accordance). The stimuli were given in a pseudo-random order twice, once before receiving the placebo pill (a sugar pill) and once after, maintaining the same order as before.
16404007|NCT03950986|No Intervention|Control|Providers assigned to the control group will receive unmodified vaccine reminders (as they already appear in the VA EHR system). Separate reminders will appear for the different vaccines of interest.
16404008|NCT03950986|Experimental|Treatment|Providers in the treatment group will receive modified clinical reminders for the vaccines of interest. Reminders for the different vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
16404009|NCT03950973|Experimental|CareAvenue|Participants receive access to CareAvenue, an e-health tool, and receive one weekly automated telephone call and 4-5 text messages per week for 52 weeks.
16404010|NCT03950973|Active Comparator|Guest Assistance Program|Participants receive information about the Guest Assistance Program (GAP) and receive 3-4 text messages per week related to diabetes management and resources for 52 weeks.
16404011|NCT03950960|Experimental|BMS-986256 +Itraconazole|
16404012|NCT03950947|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis and randomization to the intervention group, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug, CE0086).
16404013|NCT03950947|Sham Comparator|Sham-Control|In the presence of a significant right coronary artery stenosis, and randomization to the sham-procedure: right IMA will be selectively intubated using an appropriate catheter. Angiography of the RIMA and the pericardiacophrenic branch will be performed.
16404014|NCT03950921|Experimental|Patient Safety Display Arm|Patient Safety Display in patient room
16404015|NCT03950921|No Intervention|Control Arm|Usual Care
16404016|NCT03950908|Other|Single bite|The single bite technique involved removing the forceps with its specimen after each individual biopsy.
16404017|NCT03950908|Other|Double bite|The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
16404018|NCT03950882|Experimental|PXL770|PXL770 500 mg once daily (QD) for 4 weeks
16404019|NCT03950882|Placebo Comparator|Placebo|placebo once daily (QD) for 4 weeks
16404020|NCT03950869|Experimental|Negative Expectations|Expectations on the severity and frequency of intrusions are increased while expectations on the controllability of intrusions are decreased.
16404021|NCT03950869|Experimental|Positive Expectations|Expectations on the severity and frequency of intrusions are decreased while expectations on the controllability of intrusions are increased.
16404022|NCT03950869|No Intervention|No Expectation Manipulation|Expectations on the severity and frequency of intrusions and on the controllability are neither increased nor decreased.
16404023|NCT03950856|Experimental|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)
16404024|NCT03950856|Experimental|V114 Lot 2|Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)
16404025|NCT03950856|Experimental|V114 Lot 3|Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)
16404026|NCT03950856|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
16408078|NCT03922113||Healthy subjects|Healthy volunteers
16404030|NCT03950817|Active Comparator|0.75 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 0.75 mg/kg sub-dissociative dose ketamine (SDK) to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
16404031|NCT03950817|Active Comparator|SDK: 1 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses 1 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
16404032|NCT03950817|Active Comparator|SDK: 1.5 mg/kg.|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 1.5 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
16404033|NCT03950804||CHAPLE patients, without eculizumab treatment|Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
16404034|NCT03950804||Control subjects- no intervention|Healthy subjects with no history of any chronic disease. All investigational analyses are performed on both the case and the control subjects. Therefore, the same type of biological specimens collected from the case group are collected from the control group simultaneously.
16404035|NCT03950804||Non-CHAPLE PILs|PIL patients with intact CD55 on flow-cytometry assesment undergo genetic testing to exclude a potential missense mutation in the CD55 gene that impairs its function while retaining protein expression. Overall, patients and their parents undergo exome sequencing as trios, and examined for potential gene mutations underlying their disease. Non-CHAPLE PILs are also examined by high-throughput investigation similarly to CHAPLE patients.
16404036|NCT03950804||CHAPLE patients on eculizumab|Among CHAPLE patients, there is a subgroup who receive eculizumab treatment. These patients are prospectively followed and biological samples collected at baseline as well as periodically under therapy. Eculizumab (Soliris) is being provided for CHAPLE patients on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to manufacturer's recommendations based on the weight of the patients.
16404037|NCT03950791|Experimental|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials.
16404038|NCT03950791|Placebo Comparator|Health Education|A 2-hour in-person informational session about general health education. Participants receive a list of resources in the community.
16404039|NCT03950778|Active Comparator|Septic patients receiving albumin replacement|Septic patients receiving albumin replacement 20 ml Inj Human Albumin 20% -3x100 ml- 3 day
16404040|NCT03950778|No Intervention|Septic patients not receiving albumin replacement|
16404041|NCT03950765|Experimental|Ecological Momentary Intervention|This group will receive three intervention prompts and three assessment prompts on their smartphone each day.
16404042|NCT03950752|Experimental|Bagels with optimized composition in fatty acids|Participants will consume three bagels with an optimized composition in fatty acids and without oil palm in only one day.
16404043|NCT03950752|Active Comparator|Bagels with conventional composition in fatty acids|Participants will consume three bagels with a conventional composition in fatty acids in only one day.
16404044|NCT03950739|Experimental|Tyvaso to TreT|Each subject will receive a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
16404045|NCT03950726||Study Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection through the same incision
16404046|NCT03950726||Control Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection who underwent standard laparoscopic resection
16404047|NCT03950713|Experimental|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|Participants in the intervention group received the MBSR-T in addition to routine care.
16404048|NCT03950713|No Intervention|Routine care|The control group received the routine care provided in facilities, including routine check-ups at diabetes clinics as necessary.
16404049|NCT03950700|Experimental|Bupivacaine solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
16404050|NCT03950700|Placebo Comparator|Saline solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
16404051|NCT03950687|Active Comparator|Control group A|intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
16404052|NCT03950687|Experimental|Experimental group B|intravenous administration, 0.5μg/kg, once a week, for 32 weeks
16404053|NCT03950687|Experimental|Experimental group C|"intravenous administration,
~1μg/kg, once every two weeks, for 32 weeks"
16404054|NCT03950674|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression (up to 35 treatment administrations; up to approximately 2 years).
16434144|NCT03742986|Experimental|HER2-positive, independent of HR status|
16404055|NCT03950674|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression (up to 35 treatment administrations; up to approximately 2 years).
16404056|NCT03950661|Experimental|Forest|"Each subject is exposed to a 50 minute walk in a green location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
16404057|NCT03950661|Experimental|Urban|"Each subject is exposed to a 50 minute walk in a gray location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
16404058|NCT03950648|Experimental|Spatial Cognitive Training|map reading and route-learning skills
16404059|NCT03950635|Experimental|Group I (fiber-rich diet)|Patients consume a whole-foods, fiber-rich diet for 6 weeks.
16404060|NCT03950635|Experimental|Group II (ketogenic diet)|Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
16404061|NCT03950622|Experimental|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
16404062|NCT03950622|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
16404064|NCT03950596|Active Comparator|One acute resistance load exercise|One hundred volunteers will participate in one acute resistance load exercises to their quadriceps
16404065|NCT03950596|Active Comparator|Three acute resistance load exercises|One hundred volunteers will participate in three acute resistance load exercises to their quadriceps
16404066|NCT03950596|Active Comparator|Control Group|One hundred volunteers will participate in study as a control group
16404067|NCT03950570|Experimental|Phase 1: Dose Escalation|"Advanced solid tumors or metastatic breast cancer: Treatment with a single oral agent, ORIN1001.
~Relapsed, refractory metastatic breast cancer: Treatment with a combination of ORIN1001 and Abraxane."
16404068|NCT03950570|Experimental|Phase 2: Dose Expansion|Relapsed refractory metastatic breast cancer that are Triple negative, ER+ or HER2- and treated with a single agent (ORIN1001) or in combination with ORIN1001 and Abraxane.
16404069|NCT03950544|Experimental|only meropenem therapy,|this group is only meropenem therapy as a single antibiotic treatment
16404070|NCT03950531||COPD exacerbation without Bronchiectasis|COPD patients who have been in exacerbation period and have no bronchiectasis
16404071|NCT03950531||COPD exacerbation with Bronchiectasis|COPD patients who have been in exacerbation period and have bronchiectasis
16404072|NCT03950518|Experimental|One-drug Regimes|Drug: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
16404073|NCT03950518|Experimental|Two-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride
16404074|NCT03950518|Experimental|Three-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride Levamisole Hydrochloride
16404075|NCT03950505|Experimental|1|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
16404076|NCT03950492|Experimental|OUD DBS|This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.
16404077|NCT03950479||primiparous group|women who will give birth to their first baby
16404078|NCT03950453|Experimental|Parenting Mindfully for Health Nutrition (PMH)|Parenting Mindfully for Health (PMH) + nutrition and physical activity counseling to promote healthy eating and physical activity in parent and child.
16404079|NCT03950453|Active Comparator|Contact Control Nutrition (C+N)|Contact control intervention (C) + nutrition and physical activity counseling (N).
16404080|NCT03950427|Active Comparator|Videogame-based Physical Activity Group|"The videogame-based physical activity group, will play active videogames using the Kinect for Xbox 360 game system. Each videogame group will be facilitated by the study coordinator, the principal investigator or other study staff.
~Participants in this group will also receive bupropion and counseling for smoking cessation."
16404081|NCT03950427|Placebo Comparator|Sedentary Videogame Group|"The sedentary videogame group will play videogames while seated using the Xbox 360 game system (without the Kinect sensor). Each sedentary videogame group will be facilitated by study staff.
~Participants in this group will also receive bupropion and counseling for smoking cessation."
16404082|NCT03950414|Experimental|Tier 1|3 participants enrolled at dose level 5x10^3 cells/kg of CMV viral specific T-cells
16404083|NCT03950401|Active Comparator|Monocryl|Closure of the skin at the completion of surgery by interrupted subcuticular technique with absorbable Monocryl suture.
16404084|NCT03950401|Active Comparator|Nylon|Closure of the skin at the completion of surgery by interrupted technique on top of the skin with non-absorbable Nylon suture. These will be removed at the first postoperative visit.
16404085|NCT03950388|No Intervention|Treatment as Usual|
16404086|NCT03950388|Experimental|Intervention|
16404087|NCT03950375||cochlear implantation|"cochlear implantation group : patients undergoing cochlear implantation between December 2018 and June 2019 in the ENT service of Reims universitary hospital."
16404088|NCT03950362|Experimental|Radiotherapy associated to immunotherapy|"Radiotherapy: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
~Concomitant administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)"
16404089|NCT03950349||"Anterior cervical discectomy group"|
16404090|NCT03950336|Other|"Prebiotics + Low n-6 PUFA Diet"|A combination of beta-fructans (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
16404093|NCT03950336|Other|"Placebo + Control Diet."|A combination of maltodextrin (12g/day) and a control diet following the guidelines of Canada's Food Guide.
16404094|NCT03950323|Experimental|patients operated on for parotid tumor|All consecutive patients operated on for parotid tumor.
16404095|NCT03950310|Experimental|ELCA|On the antegrade delivery of the laser catheter after wiring, we used safe laser techniques and injected saline before and during the laser procedure at a 0.5 mm/sec catheter advancement rate. Whether to perform a retrograde laser method depended on each operator. After ablation by ELCA, patients undergo balloon dilation via standard techniques, and as appropriate, receive drug-eluting stent deployment.
16404096|NCT03950310|No Intervention|non ELCA|In non ELCA group, the conventional PCI procedure, including thrombus aspiration, POBA, and stent implantation was performed. The indication for aspiration was at the discretion of the physician based on angiographic, intravascular ultrasound, or optical coherence tomography/Optical Frequency-Domain Imaging.
16404097|NCT03950297|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6;
16404098|NCT03950284|Experimental|immediate loading with all on four technique in FFF|immediately loaded dental implants with the all-on-four technique in free vascularized fibular grafts
16404099|NCT03950271|Experimental|SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine|trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.
16404100|NCT03950258|Experimental|endovascular embolization|patients under the age of 18 years with arteriovenous shunts manifested by systemic or neurological manifestations will undergo endovascular embolization
16404101|NCT03950245|Other|Gastric bypass operated patients|Four test days in a randomized, patient-blinded, cross-over design
16404102|NCT03950245|Other|Sleeve gastrectomy operated patients|Four test days in a randomized, patient-blinded cross-over, design
16404103|NCT03950245|Other|Un-operated controls|Four test days in a randomized, patient-blinded cross-over, design
16404105|NCT03950219||Intervention, Centre for Diabetes or local setting|Group-based course in diabetes education including 6 sessions of approximately 3 hours. Sessions are constructed around themes such as; diabetes knowledge and complication, mental health, diet, physical activity, Ramadan, medicine and include practical exercises such as blood sugar measurements, walking etc.
16404106|NCT03950219||Usual care|Usual care in 5 municipalities in the west area of Copenhagen
16404107|NCT03950206|Other|Women with endometriosis|Women undergoing laparoscopic surgery for endometriosis
16404108|NCT03950193||premature child|Premature children evaluated during their 24 months follow up consultation
16404109|NCT03950180|Active Comparator|PCCI group|In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.
16404110|NCT03950180|No Intervention|Standard care|Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.
16404111|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
16404112|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
16404113|NCT03950154|Experimental|Arm 1:CIK|"Bevacizumab & Oxaliplatin & Capecitabine & PD1-T cells
~Bevacizumab,7.5mg/kg,intravenousinfusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; PD1-T cells, 1x10^10 (10 billion),intravenous infusion,17; Q3W,after 6 cycles; Bevacizumab, 7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2;Oral administration,d1-14; PD1-T cells,1x10^10(10 billion),intravenous infusion,d17; Q3W, maintenance treatment."
16404114|NCT03950154|Active Comparator|Arm 2: Control|"Bevacizumab & Oxaliplatin & Capecitabine
~Bevacizumab,7.5mg/kg,intravenous infusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; Q3W,after 6 cycles; Bevacizumab,7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2, Oral administration,d1-14; Q3W, maintenance treatment."
16404115|NCT03950141|Experimental|Apatinib and S1 group|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
16404116|NCT03950128|Experimental|Mindfulness-Based Skills Training|This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.
16404117|NCT03950128|Active Comparator|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions.
16404118|NCT03950115|Active Comparator|Group 1|
16404119|NCT03950115|Active Comparator|Group 2|
16404120|NCT03950102|Experimental|SBRT|SBRT will be used as the primary bridging therapy for HCC patients on waitlist
16404121|NCT03950089||Patients with Central Serous Chorioretinopathy|
16404122|NCT03950089||Healthy patients|
16404123|NCT03950076|Experimental|Edoxaban 60/30mg daily|Edoxaban 60/30 mg daily (lower dose depending on clinical criteria)
16404124|NCT03950076|Active Comparator|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy: no antithrombotic therapy or antiplatelet monotherapy (at discretion of local investigator)
16404125|NCT03950063||Patients with Cutibacterium acnes bone infections|Patients with Cutibacterium acnes orthopedic material infections
16404126|NCT03950050|Experimental|Ambroxol|"Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.
~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
16404237|NCT03949270|No Intervention|Usual Care|Patients in the usual care arm will not receive any text messages.
16404127|NCT03950037|Experimental|Medical intervention|Participants are hospitalized for 15-30 days while they receive the antiparasitic drug albendazole along with supportive drugs including dexamethasone and omeprazole.
16404128|NCT03950024|Experimental|with arthrogenic Muscle Inhibition|
16404129|NCT03950024|Active Comparator|without arthrogenic Muscle Inhibition|
16404130|NCT03950011||ERP|Any patient requiring oncologic surgery, including hysterectomy or curettage, posterior pelvectomy, conventional laparoscopic or assisted robotic surgery, or laparotomy for cervical or cervical cancer or ovarian cancer, body or cervix uterus and ovaries as well as benign pathologies or borderline malignancy.
16404131|NCT03949998|Experimental|Dry Needling|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals.
16404132|NCT03949998|Active Comparator|Dry Needling + Manual Therapy|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals IN ADDITION TO manual therapy of the above muscles and/or cervical joint traction and/or mobilization as indicated.
16404133|NCT03949998|Active Comparator|Manual Therapy|Participants will receive manual therapy of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals and/or cervical joint traction and/or mobilization as indicated.
16404134|NCT03949985||Estrogenic contraceptive users|
16404135|NCT03949985||Non-estrogenic contraceptive users|
16404136|NCT03949972||A - Pediatric Cohort|Pediatric patients until 18 years of age presenting with or diagnosed with idiopathic nephrotic syndrome or a biopsy-proven diagnosis of MCD or FSGS.
16404137|NCT03949972||B -Adult Cohort|Adult patients 18 years and above with a biopsy-proven diagnosis of primary or secondary FSGS or MCD.
16404138|NCT03949959|Experimental|Physiotherapy (PRPt)|The 6-week exercise program (2 sessions in each of weeks 1-4 and 1 session in each of weeks 5 and 6) will comprise specific individually-tailored exercises to improve the movement and control of the neck and shoulder girdle. The exercises will be of a low load nature and designed to be pain free. At the same time, the physiotherapist will provide pragmatic multimodal physiotherapy to facilitate ability to pursue exercises and guide the participant's return to normal activities. This specific treatment program has been described in detail (Jull et al., 2008; Ritchie et al., 2015b) and focuses on activating and improving the coordination and endurance capacity of the neck flexor, extensor and scapular muscles in specific exercises and functional tasks. Participants will also perform the exercises at home, once per day. Written and illustrated exercise instructions will be provided. The exercise program follows Australian guidelines for the management of chronic whiplash (TRACsa, 2008).
16404139|NCT03949959|No Intervention|Wait and See (PRPu)|"Individuals randomized to usual care will be provided with an advice booklet Whiplash Injury Recovery: A Self Help Guide (MAIC, Qld, 2nd edition). It provides information about whiplash; assurance about prognosis; advice to stay active and resume working as well as information on correct posture; pictorial descriptions of specific exercises for the neck and upper limbs and information on resuming functional daily activities. The booklet is based on the recommendations of the current Australian Guidelines for Whiplash Management (SIRA, 2014).
~Usual care involves a 'wait and see' approach (in combination with provision of home exercises) and will include weekly review appointments with a medical doctor, primarily to review the information in the booklet and progress the 'general' exercises and activity recommendations within the booklet. No hands-on physiotherapy will be provided. Education regarding PRP and associated healing cycles will also be provided during this time period."
16404140|NCT03949946||High-risk|Female participants confirmed to be BRCA1/2 or TP53 gene carriers
16404141|NCT03949946||Patients|Female participants confirmed to have invasive ductal carcinoma of the breast
16404142|NCT03949933|Experimental|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
16404143|NCT03949907|Other|Nutritional counseling alone|Nutritional counseling consists of a personalized dietary prescription with regular consultation by a registered dietitian and telephone interviews, as well as of the use of oral nutritional supplements, when necessary.
16404144|NCT03949907|Experimental|Supplemental parenteral nutrition plus nutritional counseling|Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.
16404145|NCT03949894|Experimental|tolvaptan|
16404146|NCT03949881|Experimental|FEMJA transplatation|"FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing.
~The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation."
16404150|NCT03949855|Experimental|Part A: Low Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.
~Ten participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
16404271|NCT03949010|Experimental|Kinesiotaping with space correction technique|
16404151|NCT03949855|Experimental|Part A :High Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.
~Ten participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~An adjustment (increase) in prescribed weekly dose may occur, per protocol, if indicated by pharmacokinetics (PK) assay results.
~High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
16404152|NCT03949855|Experimental|Part B: Low Proteinuria Group - Belimumab and Rituximab|Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
16404153|NCT03949855|Placebo Comparator|Part B: Low Proteinuria Group - Placebo and Rituximab|Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
16404154|NCT03949855|Experimental|Part B :High Proteinuria Group - Belimumab and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~A higher dose of belimumab, per protocol, will be prescribed in high proteinuria participants, if indicated in Part A."
16404155|NCT03949855|Placebo Comparator|Part A :High Proteinuria Group - Placebo and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~A higher dose of belimumab placebo, per protocol, will be prescribed in high proteinuria participants, if indicated in Part A."
16404156|NCT03949842|Experimental|Subjects who inhaled non-ELLIPTA MITT|Subjects with moderate or severe exacerbation in the past year and history of use of inhaled non-ELLIPTA MITT of ICS/LABA/LAMA within a routine clinical practice setting in the 52-week retrospective pre-switch period.
16404157|NCT03949842|Experimental|Subjects receiving TRELEGY ELLIPTA SITT|Subjects will receive FF/UMEC/VI (100 microgram [mcg]/62.5 mcg/25 mcg), inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) in the 52-week prospective post-switch period.
16404158|NCT03949816|Experimental|patient-centered communication style|The patient-centered style is characterized by features such as empathetic communication, open questions, and uses an easily understandable language.
16404159|NCT03949816|Experimental|doctor-centered communication style|The doctor-centered style is defined by an authoritarian and goal-oriented communication. The doctor uses medical terms instead of lay language.
16404160|NCT03949816|Active Comparator|information letter|In the active control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
16404161|NCT03949803|Experimental|Morning Chocolate|Test the if Chocolate Timing in the morning changes the metabolism
16404162|NCT03949803|Experimental|Evening Chocolate|Test the if Chocolate Timing before bedtime changes the metabolism
16404163|NCT03949803|Experimental|No Chocolate (Control)|Test the if no Chocolate Timing may affect the metabolism
16404164|NCT03949790|Active Comparator|Intercostal block with ESPB|Performed ESPB in VATs with intercostal nerve block
16404165|NCT03949790|Active Comparator|Intercostal block without ESPB|Not Performed ESPB in VATs with intercostal nerve block
16404166|NCT03949777|Experimental|Study Cohort|61 subjects will undergo colonoscopy
16404167|NCT03949764|Experimental|HCV Positive Study Participants|Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
16404168|NCT03949764|No Intervention|Control (Pike County)|After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
16404169|NCT03949751|No Intervention|Control group|The participants of the control group will not get the local therapy in the investigator's preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.
16404170|NCT03949751|Experimental|Therapy group|30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae.
16404172|NCT03949725|Experimental|Hans Kai program|
16404173|NCT03949725|No Intervention|Wait list control|
16404174|NCT03949712|Experimental|Right motor cortex (M1) tSMS|tSMS will be applied to the right motor cortex for 30 minutes.
16404175|NCT03949712|Experimental|Left motor cortex (M1) tSMS|tSMS will be applied to the left motor cortex for 30 minutes.
16404176|NCT03949712|Sham Comparator|Sham tSMS|Sham tSMS will be applied to the left or right motor cortex (randomized) for 30 minutes.
16404177|NCT03949699|Other|Resistance Training|. Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down. Performance during exercise sessions will be monitored by study staff who will progress the participant to exercises of greater intensity (increasing number of repetitions, sets, or resistance load; on an individual basis over the 8-week intervention period according to the participant's level of readiness). This progression will also be guided by a strength training protocol. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise
16404178|NCT03949686|Sham Comparator|Saline + Placebo|Ultrasound guided 0.5 ml/kg saline injection to erector spinae plane
16434879|NCT03738020|Active Comparator|Restylane|
16404179|NCT03949686|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection to erector spinae plane
16404180|NCT03949673|Other|Knee or Hip Joint Arthroplasty|Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study
16404181|NCT03949660|Experimental|Epidural stimulation for blood pressure without stand|To assess whether epidural stimulation, used for regulating blood pressure without standing, is neuromodulatory for bowel motility after motor complete SCI
16404182|NCT03949660|Experimental|Epidural stimulation for blood pressure with stand|To assess whether epidural stimulation, used for regulating blood pressure with standing, is neuromodulatory for bowel motility after motor complete SCI
16404183|NCT03949660|Experimental|Epidural stimulation for trunk and core without stand|To assess whether epidural stimulation, used for activating the trunk and core musculature without standing, is neuromodulatory for bowel evacuation after motor complete SCI
16404184|NCT03949660|Experimental|Epidural stimulation for trunk and core with stand|To assess whether epidural stimulation, used for activating the trunk and core musculature with standing, is neuromodulatory for bowel evacuation after motor complete SCI
16404186|NCT03949634|Experimental|PLD plus CTX sequential docetaxel or PTX|pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
16404187|NCT03949634|Active Comparator|DOX plus CTX sequential docetaxel or PTX|doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
16404188|NCT03949621|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
16404189|NCT03949621|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
16404190|NCT03949608|Experimental|BASIC|"mon cœur, mon BASIC video viewing and installation in the own smartphone or tablet of the patient"
16404191|NCT03949608|No Intervention|Control|Usual care
16404192|NCT03949595||cases|women suffering from severe/massive obesity
16404193|NCT03949582|Experimental|Mycoprotein as in Soup|24 will be randomised to soup (12 caucasian and 12 south asian) in order to test raw mycoprotein. Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
16404194|NCT03949582|Experimental|Mycoprotein as in Mince|24 will be randomised to mince (12 caucasian and 12 south asian) in order to test processed mycoprotein (Quorn). Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
16404195|NCT03949569|Experimental|Arm 1|In this condition, children will interact with the therapy dog prior to the psychosocial stress task and with the stuffed toy dog prior to the prosocial behavior tests.
16404196|NCT03949569|Experimental|Arm 2|In this condition, children will interact with the stuffed toy prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
16404197|NCT03949556|Experimental|Intervention program - stress management program|This intervention program on stress management is developed to prevent suicidal ideation in medical students and residents.
16404198|NCT03949556|Active Comparator|Intervention program - health promotion program|This intervention program on health promotion is developed to prevent suicidal ideation in medical students and residents.
16404199|NCT03949556|Placebo Comparator|Control condition - general information|Participants will receive weekly emails and SMSs, over the same periods of time, with general information about health except mental health, e.g. prevention of melanoma, dental care….
16404200|NCT03949543|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with large lunch intervention
16404201|NCT03949543|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with large dinner intervention
16404202|NCT03949530|Experimental|IDL-2965 Oral Capsule|IDL-2965 oral capsule, single and multiple doses
16404203|NCT03949530|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single and multiple doses
16404204|NCT03949517|Experimental|68-Ga RM2+68-Ga PSMA11|68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
16404205|NCT03949517|Experimental|68-Ga PSMA11+68-Ga RM2|68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
16404206|NCT03949504||General population|Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
16404207|NCT03949504||Patients with type 2 Diabetes|Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed
16404208|NCT03949491|Experimental|3-D virtual planning and medical modeling of breast|"3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction.
~Preoperative CT-Angiogram of the abdominal wall
~Volumetric analysis preformed
~3D printed models made
~Pre operative BREAST-Questionnaires given
~Free tissue transfer performed: Operative/Dissection Time Recorded
~Flap/Abdominal donor site complications recorded
~Standard Digital Photography and Harris Scoring
~BREAST-Questionnaires given at 3, 6 months"
16404209|NCT03949478|Placebo Comparator|Placebo|Patients will receive placebo for at least five days prior to the first blood flow study. They will continue to receive placebo until the baseline study is obtained after the postictal study has been completed.
16404210|NCT03949478|Experimental|Ibuprofen|Patients will receive ibuprofen 400 mg by mouth three times a day (po tid) for at least five days prior to the first blood flow study. They will continue to receive ibuprofen until the baseline study is obtained after the postictal study has been completed.
16404211|NCT03949478|Experimental|Nifedipine|Patients will receive nifedipine 10 mg po tid for 2 days, then 20 mg po tid, thereafter for at least five days prior to the first blood flow study. They will continue to receive nifedipine until the baseline study is obtained after the postictal study has been completed.
16404212|NCT03949465|Experimental|Open label iTBS rTMS|Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
16404213|NCT03949452|Active Comparator|Subcostal Transversus Abdominis Plane catheter|This group includes patients who will receive subcostal Transversus abdominis plane block analgesia
16404214|NCT03949452|Placebo Comparator|Epidural catheter|This group includes patients who will receive epidural analgesia using a catheter technique
16404215|NCT03949439||Non-Frail|non-frail (frailty score 1~3) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
16404216|NCT03949439||Pre-Frail|Pre-frail (frailty score 4) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
16404217|NCT03949426|Experimental|KPG-818|Dose escalation
16404218|NCT03949426|No Intervention|Placebo|Matching placebo
16404219|NCT03949413|Experimental|Pediatric balance scale|The Pediatric Balance Scale (PBS) includes fourteen items. Each item of subsets scored as 4, 3, 2, 1 or 0. Finally, the total test score was calculated
16404220|NCT03949400||Patients diagnosed with knee OA|Patients diagnosed with knee OA and assigned to undergo exercise therapy and education.
16404221|NCT03949387|Experimental|FES Cycling Exercise|FES cycling will involve systematic, transcutaneous electrical stimulation of the leg muscles to produce leg-cycling movement. The intensity and duration of training will be prescribed based on guidelines for aerobic exercise training for persons with MS and from the American College of Sports Medicine, and will progressively increase across 24 weeks. Participants will be encouraged to actively cycle at a minimum cadence of ~40-50 rpm, at 40-60% VO2peak for between 10-50 minutes. The intensity of stimulation will be adjusted per leg muscle group based on sensory tolerance with the goal of maintaining pedaling action and target heart rate over the entire session. At each session, we will record the distance traveled, energy expended, power output, resistance, heart rate and rating of perceived exertion (RPE).
16404222|NCT03949387|Placebo Comparator|Passive Leg Cycling|Passive leg cycling will involve movement of the participant's legs by the cycle ergometer motor without electrical stimulation. The duration of training will follow the same schedule as the FES cycling condition and the same data will be recorded at each session. The passive cycling condition will include the same exposure with the training facility, the exercise equipment (i.e. RT300 cycles), and the research staff (i.e. social contact and attention) as with the FES cycling condition.
16404223|NCT03949374|Active Comparator|10mg of the generic formulation (rosuvastatin, ROVASRO®)|Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
16404224|NCT03949374|Active Comparator|10mg of the reference formulation (rosuvastatin, CRESTOR®)|Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)
16404225|NCT03949361||Patients starting glucocorticoids|Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.
16404226|NCT03949361||Patients stopping glucocorticoids|Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.
16404227|NCT03949348|Active Comparator|autologous fascia|Patients who underwent a transobturator sling placement using autologous rectus fascia
16404228|NCT03949348|Active Comparator|synthetic mesh|Patients who underwent a transobturator sling placement using synthetic mesh
16404229|NCT03949335|Experimental|Investigational|Bilateral implantation with investigational IOL Model ZFR00V
16404230|NCT03949335|Active Comparator|Control|Bilateral implantation with control IOL Model ZCB00
16404231|NCT03949322|Experimental|Adapted Physical Activity Program|Patients in the experimental group take part in a program of Adapted Physical Activity lasting 6 weeks, with 2 sessions per week.
16404232|NCT03949309||Eligible patients|All eligible patients discharged from hospital for Acute Myocardial Infarction (AMI) or acute decompensation of Chronic Heart Failure (CHF)
16404233|NCT03949296|Active Comparator|Mindfulness Intervention|Mindfulness-Based Treatment for Insomnia intervention led by a certified instructor. It is adapted from the Mindfulness-Based Stress Reduction Curriculum developed by the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School. It introduces the concept of mindfulness and provides the opportunity to practice it within sessions and during home practice. Participants learn about stress, and explore habitual behavioral, physical, emotional and cognitive patterns, as well as more effective responses to challenges and demands of everyday life. Each class includes mindfulness practice, group discussions, and practices and exercises related to the class topics. Participants receive home assignments with guided meditation and yoga practices.
16404234|NCT03949296|Placebo Comparator|Sleep Hygiene|Control group participants attend a 30-minute group counseling session on sleep hygiene. The session includes a handout from the Centre for Clinical Intervention in Australia that provides 15 sleep hygiene tips.
16404238|NCT03949270|Experimental|BETA-Text Intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
16404239|NCT03949257|Experimental|colonic TET and FMT|gut microbiota will be collected through the colonic TET after FMT
16404240|NCT03949244|Active Comparator|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
16404241|NCT03949244|Experimental|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
16404242|NCT03949244|Placebo Comparator|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
16404243|NCT03949231|Experimental|PD1/PDL1 inhibitor hepatic artery infusion|Interventional technique to place microcatheter in hepatic artery to infuse PD1/PDL1 inhibitor in 30 minutes.
16404244|NCT03949231|Experimental|PD1/PDL1 inhibitor vein infusion|Regular IV infusion of PD1/PDL1 inhibitor in 30 minutes.
16404245|NCT03949218||bipolar disorder(BD)|hospitalized patients BD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F31 bipolar disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
16404246|NCT03949218||major depressive disorder（MDD）|hospitalized patients MDD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F32 depressive disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
16404247|NCT03949205|Experimental|Leg Extension Isometric Training|Experimental group will perform leg extension isometric exercise.
16404248|NCT03949205|No Intervention|Control Group|Control group will be advised to maintain their work habits and not to change their routine activities, especially diet and physical activities.
16404249|NCT03949179||Pain and Disability Drivers Management model|Participating clinicians will use the PDDM model to guide assessment and treatment of their patients for a 6-weeks period.
16404250|NCT03949166|No Intervention|Fasting|After completion of an epidural block patients that agreed to participate in the study and were randomised to the fasting arm will be allowed to drink water and clear fluids during labor and delivery as accepted by the institute protocol.
16404251|NCT03949166|Experimental|Eating|After completion of an epidural block patients that agreed to participate in the study and were randomized to the eating arm will be allowed to eat during their labor and delivery. They will be provided with the list of food that was approved and accepted by the anesthesia team. They will be asked to try eating every 2 hours but if they feel lack of need to eat or any side effects preventing them to eat they can choose not to eat. When reaching full dilatation of 10cm they will ber asked to stop eating.
16404252|NCT03949153|Experimental|Experimental arm|Single Nivolumab 240 mg infusion at D0, followed by cryotherapy using interventional radiology of metastatic lymphadenopathy at D1 and in situ injection with ipilimumab at D2.
16404254|NCT03949127|Experimental|Exercise Group|The group who will exercise to manage pain.
16404255|NCT03949127|No Intervention|Control Group|The group who will not take part in any exercises and only have to do assessments.
16404256|NCT03949114|Experimental|test group|"1) Performing a weak debilitating phenotype screening on the patients before surgery;
~(2) Do the early rehabilitation intervention process:"
16404257|NCT03949114|Active Comparator|Control group|1) Performing a weak debilitating phenotype screening on the patients before surgery; (2) Patients in the control group were treated according to the general nursing routine after neurosurgery;
16404258|NCT03949101|Experimental|combined use of 1% atropine and 0.01% atropine|first week, use atropine sulfate 1% ophthalmic ointment every night before sleep; then use atropine sulfate 1% ophthalmic ointment once every week(Friday night before sleep is recommended) for half a year; then use atropine sulfate 0.01% eye drop every night before sleep for one year and a half.
16404259|NCT03949101|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years.
16404260|NCT03949088|Experimental|Linear descending UF profile|2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)
16404261|NCT03949088|Experimental|Run-in & washout phases|constant Na concentration, constant UF rate 3 weeks (6+3 sessions)
16404262|NCT03949088|Experimental|Ascending/descending UF profile|2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)
16404263|NCT03949075|Experimental|Enalapril treatment|
16404264|NCT03949075|Placebo Comparator|Placebo treatment|
16404265|NCT03949062|Experimental|iR2|Participants received six 21-day cycles of ibrutinib, lenalidomide, and rituximab (iR2) treatment (21-day cycles).
16404266|NCT03949049|Experimental|Citacoline|Citacoline as neuroprotector
16404267|NCT03949049|Placebo Comparator|Placebo|Placebo
16404270|NCT03949023||Standard of Care Cerebral Angiogram Group|Participants undergoing a standard of care cerebral angiogram.
16404274|NCT03948997|Experimental|Treatment group|Patients with port wine stains receive PDL (1.5-10ms, 11-12.5J/cm2) with a treatment range of approximately 10*10cm2
16404275|NCT03948997|No Intervention|No treatment group|Patients with port wine stains have not been treated with PDL treatment
16404276|NCT03948984|Experimental|Therapeutic Music Session|
16404277|NCT03948971|Other|Venogram Group|Participants in this group have a scheduled clinically indicated a cerebral angiogram procedure and will undergo a Venogram.
16404278|NCT03948958|Experimental|TIVAD evaluation|TIVAD evaluation at port removal evaluation of catheter function, visualization of catheter tip, presence of thrombus material and sleeve and any device damage during linogram (contrast injection via TIVAD), tip and chamber content microbiological culture, macroscopic catheter and port chamber evaluation PROM: patient reported outcome measurements regarding TIVAD insertion, presence and removal
16404279|NCT03948945|No Intervention|before treatment|The patient with facial and neck photoaging did not receive laser treatment.
16404280|NCT03948945|Experimental|after treatment|The patient with facial and neck photoaging received Profile HaloTM mixed fractional laser treatment
16404281|NCT03948919|Active Comparator|FMT Treatment|Fecal microbiota - 1.0-3.0 x 10^11 CFU / day (2 capsules per day for 8 weeks).
16404282|NCT03948919|Placebo Comparator|Placebo|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
16404283|NCT03948893|Experimental|MORE|
16404284|NCT03948893|Active Comparator|CBT|
16404285|NCT03948867|Experimental|Elevated Initial Screening TCD|Those who have an elevated initial screening TCD (either conditional or abnormal TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule.
16404286|NCT03948867|Experimental|Normal Initial Screening TCD|Those who are found to have a normal TCD at enrolment are a part of the observation/control cohort and will undergo repeat TCD every 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant will be reassigned to the elevated initial screening TCD arm and can begin study treatment (hydroxyurea), but will not be included in the primary endpoint analysis.
16404287|NCT03948854|Experimental|Registered dietitian education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in person by a registered dietitian
16404288|NCT03948854|Experimental|On-line video program education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet using an on-line video program
16404289|NCT03948854|Experimental|Handout education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet by a printed handout
16404290|NCT03948854|Experimental|Dietitian-led group education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in a dietitian-led group setting
16404291|NCT03948841||Neuroendocrine tumor|Patients with liver metastasis from neuroendocrine tumor
16404292|NCT03948828|Other|Conventional treatment group|GnRHa combained with reverse addition therapy
16404293|NCT03948828|Experimental|Conventional treatment and Autologous NK cells therapy|GnRHa combained with reverse addition therapy and NK cell combined treatment group
16404294|NCT03948815|Experimental|Intervention room|An adaptable, person-centered, birthing room that is specially designed.
16404295|NCT03948815|Other|Control room|A regular standard birthing room
16404296|NCT03948802||STROKE GROUP|Cerebral ischemic stroke patients treated.
16404297|NCT03948802||CONTROL GROUP|Ambulatory healthy patients
16404298|NCT03948789|Active Comparator|A Myomectomy|Removement of uterine fibroids by myomectomy
16404299|NCT03948789|Experimental|B MRgFUS-TUF|Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)
16404300|NCT03948776||Healthy volunteers|Adults without HF or prior heart transplantation
16404301|NCT03948776||Participants in our existing LVAD body composition study|Currently-enrolled LVAD body composition participants, who chose to participate in this study on the same day as a DXA scan already scheduled for study #12026
16404302|NCT03948776||Patients with heart failure, an LVAD or heart transplantation|Any patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation
16404303|NCT03948776||Inpatients with heart failure, LVAD, heart transplantation|Patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation, currently admitted as inpatients at Tufts Medical Center. The 6/20/2019 protocol update includes these patients who will participate without a DXA scan (which can only be performed as an outpatient).
16404306|NCT03948750||Patients with Ocular Toxoplasmosis|
16404307|NCT03948750||Patients without Ocular Toxoplasmosis|
16404308|NCT03948737|Active Comparator|Alpha-Tocopgerol|"Alpha-Tocopherol supplementation will be given orally for 4 weeks with doses adjusted by age.
~5-8 years old: 200 mg daily, 9-13 years old: 400 mg daily and 14-18 years old 600 mg daily."
16404309|NCT03948737|Placebo Comparator|Control|Placebo is the drug with the same shape and color as the alpha-tocopherol supplementation.
16404310|NCT03948724|Experimental|Therapeutic patient education|Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize
16404311|NCT03948724|Active Comparator|Standard Care|Patient receive usual informations
16404312|NCT03948685|Experimental|Carvedilol SR|Carvedilol SR 8mg, 16mg, 32mg
16404313|NCT03948685|Placebo Comparator|Placebo|Placebo
16404339|NCT03948490|No Intervention|Arm 2 Cohort 4: Longitudinal arm/Upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
16434880|NCT03738007|Experimental|HA IDF II|
16404314|NCT03948672|Active Comparator|Control-then-Intervention|In each intensive care unit assigned to the Control-then-Intervention arm, all participants who regularly access the ICUs will wear the wristband while at work for 5 months. The functionality of the wristband will not be disclosed to the healthcare providers. Handwashing compliance data will be automatically collected, but data will not be shared with the healthcare providers or hospital management teams. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from the sensor system. Then, all healthcare providers will be educated on the functionalities of the CleanHands system with real time reminders now turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection reduction. This phase will last for 5 months.
16404315|NCT03948672|Active Comparator|Intervention-then-Control|In each intensive care unit assigned to the Intervention-then-Control arm, all participants who regularly access to the ICUs will be educated on the functionalities of the CleanHands system with real time reminders turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection control. This phase will last for 5 months. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from sensor system installation and implementation. Then, the real-time reminder functionality of the wristband will be turned off and no more education will be provided. Handwashing compliance data will be automatically collected but will not be shared with the healthcare providers. This process will last for 5 months.
16404316|NCT03948659||Cirrhotic patients in intensive care unit|
16404317|NCT03948646|Experimental|Active|Sofpironium bromide, 15% gel, once per day
16404318|NCT03948646|Placebo Comparator|Vehicle|Vehicle gel, once per day
16404319|NCT03948633|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination).
16404320|NCT03948633|No Intervention|Control|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting).
16404321|NCT03948620||Children whose mother prescribed antibiotics during pregnancy|"Children whose mother were prescribed an only monotherapy of macrolides or penicillins from 5 gestational weeks (GW) to delivery. A monotherapy is defined as one or more consecutive prescriptions for a single antibiotic (i.e. same drug substance) separated by no more than 30 days and uninterrupted by prescriptions for other antibiotic drug substances.
~The investigators will also build a negative control cohort which includes children whose mother were prescribed an only monotherapy of macrolides or penicillins from 50 to 10 weeks before conception."
16404322|NCT03948607||Adult ADHD|Adult ADHD patients without current comorbidity and treatment.
16404323|NCT03948607||Healthy controls|Healthy controls without ADH, paired in age and gender.
16404324|NCT03948594|Placebo Comparator|plain water|subject drink 250cc plain water
16404325|NCT03948594|Active Comparator|resource|subject drink 1 packet resource(237ml)
16404326|NCT03948581|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
16404327|NCT03948581|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
16404328|NCT03948568|Active Comparator|Concurrent Endocrine Therapy and Radiotherapy|Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
16404329|NCT03948568|Active Comparator|Sequential Endocrine Therapy after Radiotherapy|Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
16404330|NCT03948555||Acute aortic dissection|stable patients with confirmed diagnosis of acute AD.
16404331|NCT03948555||Chronic aortic dissection|patients with diagnosis of chronic AD, being followed up in outpatient aortic clinic.
16404332|NCT03948542||Outcome|Nerve conduction studies (NCV) Functional assessment according to Daniels and Worthingham
16404333|NCT03948529|Experimental|eltrombopag|Eligible patients will receive the investigational drug eltrombopag
16404334|NCT03948503|Experimental|Mobilization with movement (MWM) group|Application of the Mulligan concept
16404335|NCT03948503|Placebo Comparator|Sham group|Sham treatment
16404336|NCT03948490|Other|Arm 1 Cohort 1: Interventional arm/In-person rehab|"The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
~n = 20 patients"
16404337|NCT03948490|Experimental|Arm 1 Cohort 2: Interventional arm/ReMind iPad app|"The ReMind iPad-based cognitive rehabilitation was developed with collaborators at Tilburg University, The Netherlands, and is an evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors. Brain plasticity-based computerized cognitive training is a newly developing field of therapeutics for neurological and psychiatric disorders that uses frequent game-like training sessions to drive improvements in cognitive functions.
~n = 20 patients"
16404338|NCT03948490|Experimental|Arm 1 Cohort 3: Interventional arm/Healthy SMS texting|"The mobile phone texting intervention was developed with collaborators at Zuckerberg San Francisco General Hospital and is currently being studied in individuals with depression and traumatic brain injury. Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
~n = 20 patients"
16404340|NCT03948490|No Intervention|Arm 1 Cohort 5: Longitudinal arm/No upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
16404341|NCT03948490|Other|Arm 1 Cohort 1A: Telehealth Cognitive Rehabilitation|"The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning. During treatment implementation, patients acquire, apply, and adapt evidenced based strategies based on neuropsychological testing and conjointly developed treatment planning goals.
~N=20"
16404342|NCT03948477|Other|Pantoprazole/Placebo|Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
16404343|NCT03948477|Other|Placebo/Pantoprazole|Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
16404344|NCT03948464|Experimental|Slow release oral morphine (SROM)|Daily witnessed ingestion of SROM (24-hour formulation) for 24 weeks as per provincial and national guidelines for opioid use disorder.
16404345|NCT03948464|Active Comparator|Methadone|Daily witnessed ingestion of methadone for 24 weeks as per provincial and national guidelines for opioid use disorder.
16404346|NCT03948451|Experimental|[14C]AZD5718 Oral Suspension|One 200 mg dose of [14C]AZD5718 Oral Suspension
16404347|NCT03948425|Experimental|Stroke|Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms):Intervention 'spectral CT'
16404348|NCT03948412|Experimental|Closed Incision Negative Pressure Wound Therapy (Prevena)|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
16404349|NCT03948412|Active Comparator|Standard Dressings|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. Standard care wound dressings are applied for patients in this arm. These are changed as clinically appropriate whilst in hospital.
16404350|NCT03948399||STROKE GROUP|150 patients admitted to Stroke Unit with a diagnosis of acute ischemic stroke (IS) or transient ischemic attack (TIA)
16404351|NCT03948399||CONTROL GROUP|50 individuals admitted to hospital without diagnosis of acute cerebrovascular disease; with diagnosis of dizziness, epilepsy, sclerosis multiplex.
16404352|NCT03948386|Active Comparator|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for > 74 height"
16404353|NCT03948386|Active Comparator|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for > 74 height"
16404354|NCT03948386|Active Comparator|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for > 74 height"
16404355|NCT03948373|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
16404356|NCT03948373|No Intervention|Conservative measures|Patients who will receive conservative treatment based on hygienic-dietetic measures
16404357|NCT03948360|Experimental|LIMB Phototherapy with SOC|Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
16404358|NCT03948360|Experimental|LIMB Phototherapy without SOC|Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
16404359|NCT03948347|Active Comparator|active|Active patients will receive liraglutide injections
16404360|NCT03948347|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
16404361|NCT03948334|Experimental|ZPL389 30mg|30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
16404362|NCT03948334|Experimental|ZPL389 50mg|50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
16404363|NCT03948321|Experimental|Painless Photodynamic Therapy（P-PDT）|The painless photodynamic therapy（P-PDT）group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 400 J/cm2) after applying 20% 5-aminolevulinic acid（ALA）cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
16404364|NCT03948321|Active Comparator|Conventional Photodynamic Therapy（C-PDT）|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 100 J/cm2) after applying 20% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
16404365|NCT03948308|Experimental|Interventional arm|blood sample before, during and after treatment for infection
16404366|NCT03948295|Experimental|Lipid Challenge Intervention|Participants of all weights will receive the lipid challenge intervention.
16404367|NCT03948269|Experimental|Internet- and mobile-based group treatment|the therapy consists of 10 modules (15 hours in total) in groups of 8 participants each over a period of 10 weeks and one follow-up meeting (2 hours) 12 weeks after the 10th module (week 22). Each module is adapted from the previous literature on CBT rationale and will be conducted online on WeChat, a mobile social networking software with 1 billion users in 2018. First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging.
16404368|NCT03948269|Active Comparator|Face-to-face group treatment|10 modules will be conducted every weekend in the psychological counseling room of The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University.
16404369|NCT03948256|Active Comparator|Control intervention|Prompt closure, based on best available scientific data
16404370|NCT03948256|Experimental|Experimental intervention|Gradual weaning, based on best available scientific data
16404372|NCT03948230|Active Comparator|Sodium chloride / Water|300mg sodium chloride consumed in a capsule on two occasions with 300ml water
16404373|NCT03948230|Active Comparator|Sodium chloride / no water|300 mg sodium chloride consumed
16404374|NCT03948230|Active Comparator|Sodium chloride / colored water|300mg sodium chloride consumed in a capsule on two occasions with 300ml coloured water
16404375|NCT03948230|Placebo Comparator|Placebo / water|Placebo consumed in a capsule on two occasions with 300ml water
16404376|NCT03948230|Placebo Comparator|Placebo / no water|Placebo capsule consumed
16404377|NCT03948230|Placebo Comparator|Placebo / coloured water|Placebo consumed in a capsule on two occasions with 300ml colored water
16404378|NCT03948217|Active Comparator|L1|regimen L1 has overall higher intensity, higher color temperature and less light fluctuations
16404379|NCT03948217|Active Comparator|L2|regimen L2 has lower intensity, lower color temperature and more light fluctuations.
16404380|NCT03948204||Prostate cancer|Men diagnosed with prostate cancer
16404381|NCT03948204||Men without prostate cancer|Men without prostate cancer matched for age and county
16404382|NCT03948191|Active Comparator|Methylprednisolone(ivMP)|Methylprednisolone(ivMP) 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
16404383|NCT03948191|Experimental|99Tc-MDP|99Tc-MDP 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
16404384|NCT03948178|Experimental|Levosimendan|Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
16404385|NCT03948165||Distal Radial Approach|Distal transradial access will be performed on patients above 18 years of age, undergoing diagnostic and/or therapeutic coronary angiography, with palpable pulse at the level of the radial fossa, and these patients will be also subjected to the following tests: Allen maneuver and Barbeau maneuver; a positive Allen test was indication to perform the transradial access, while a type D Barbeau test will be a contraindication for it.
16404386|NCT03948152|Active Comparator|Standard of Care|
16404387|NCT03948152|Experimental|Mask Advice Tool|
16404388|NCT03948139|Other|Functional Bracing Group|In a presented abstract, the functional brace group has been to shown equivalent outcomes to the hip spica cast. Subject will be administered the functional brace without going to the operating room to be put under full anesthesia. Most cases will not require any sedation in this group (in some cases, light sedation may be needed). Brace will be used for up to 8 weeks post-administration, until adequate callous formation is confirmed.
16404389|NCT03948139|Other|Spica Cast Group|If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
16404390|NCT03948126||travel medicine|Healthy adults originating from Sub-Saharan Africa, South America and the Caribbean and attending a travel medicine and international vaccination consultation in France.
16404391|NCT03948100|Experimental|Group I (dyadic yoga)|Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions.
16404392|NCT03948100|Active Comparator|Group II (dyadic education)|Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions.
16404393|NCT03948087|Experimental|Vacuum Removable Rigid Dressing (VRRD)|Application of a Vacuum Removable Rigid Dressing (VRRD)
16404394|NCT03948087|No Intervention|Soft Dressing Control Group|Application of standard of care soft dressing (SD) intra-operatively.
16404395|NCT03948074|Experimental|High THC/Low CBD Cannabis Oil|THC+THCa ≥ 500 mg CBD+CBDA≤ 5 mg Total cannabinoids = 505 mg (0.83mg/drop) Dried marijuana equivalent = 2.5g
16404396|NCT03948074|Experimental|Low THC/High CBD Cannabis Oil|THC+THCa ≤25 mg CBD+CBDA≥ 500 mg (0.83mg/drop) Total cannabinoids = 525 mg Dried marijuana equivalent = 2.5g
16404397|NCT03948074|Experimental|Equal amounts of THC/CBD Cannabis Oil|THC+THCa ~ 250 mg (0.415mg/drop) CBD+CBDA~ 250 mg (0.415mg/drop) Total cannabinoids ~ 500 mg (0.83mg/drop) Dried marijuana equivalent = 2.5g
16404398|NCT03948074|Placebo Comparator|Placebo Oil|A 2:1 mixture of Rosemary oil + Unrefined Coconut oil
16404399|NCT03948061|Experimental|Cherry juice followed by placebo|Sweet cherry juice concentrate will be consumed twice daily for 6 weeks, followed by consumption of placebo beverage twice daily for 6 weeks.
16404400|NCT03948061|Experimental|Placebo beverage followed by cherry juice|Placebo beverage will be consumed twice daily for 6 weeks, followed by consumption of sweet cherry juice concentrate twice daily for 6 weeks.
16404401|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
16404402|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
16404403|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
16404404|NCT03948035|Experimental|E-KRd/ Arm A|Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
16404405|NCT03948035|Active Comparator|KRd/ Arm B|Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
16404406|NCT03948022|Active Comparator|intramuscular progesterone|progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.
16404407|NCT03948022|Active Comparator|vaginal progesterone|crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.
16404408|NCT03948022|Experimental|oral dydrogesterone|oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)
16404409|NCT03947996|Experimental|Stretching|Stretching
16404410|NCT03947996|Experimental|Walking|Walking
16404411|NCT03947983|Experimental|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
16404412|NCT03947983|Active Comparator|Control group|The control group will receive only the weight monitoring and physical activity sensors
16404413|NCT03947970|Experimental|[14C] CR845|Subjects will receive a single dose of [14C] CR845 IV solution administered as an IV bolus on Day 1.
16404415|NCT03947944|Active Comparator|manifest refraction planning group|The subjects underwent SMILE using manifest refraction planning.
16404416|NCT03947944|Active Comparator|vector planning group|The subjects underwent SMILE using vector planning.
16404417|NCT03947931||General group|Patient with extremely severe ulcerative colitis
16404420|NCT03947905|Experimental|Type of visit|Single arm, non-randomized crossover design. All patients will receive both types of visits virtual and physical, and after assessments are made, participants will be classified by physicians into low, moderate or high risk for intervention.
16404421|NCT03947879|Experimental|L-glutamine|Treatment with L-glutamine for 3 months.
16404422|NCT03947879|Experimental|No L-glutamine|No L-glutamine for 3 months.
16404423|NCT03947827|Active Comparator|Active|Minocycline will start at an oral dose of 100mg daily and will be increased after one week to 100mg twice daily.
16404424|NCT03947827|Placebo Comparator|Placebo|Placebo capsules will start at one capsule daily, and will be increased after one week to one capsule twice daily
16404425|NCT03947814|Experimental|Part A: Normal renal function (control group)|Participants with normal renal function (glomerular filtration rate [GFR] greater than or equal to [>=] 90 milliliters per minute [mL/min]) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
16404426|NCT03947814|Experimental|Part A: Severe renal impairment or ESRD|Participants with severe renal impairment (GFR >=15 to less than [<]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR <15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
16404427|NCT03947814|Experimental|Part B (Optional): Mild renal impairment|Participants with mild renal impairment (GFR >=60 mL/min to <90 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
16404428|NCT03947814|Experimental|Part B (Optional): Moderate renal impairment|Participants with moderate renal impairment (GFR >=30 to <60 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
16404429|NCT03947801|Experimental|Greek Yogurt condition|3x 160g of 0% Plain Greek yogurt (~115 kcals, 17 g protein, ~11.5 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
16404430|NCT03947801|Placebo Comparator|Isoenergetic condition - Carbohydrate|3x 30g of isoenergetic CHO supplement (~115 kcal, 0.04 g protein, ~28.6 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
16404431|NCT03947788|Experimental|Interventional Practices|These clinics, including physicians, clinical and administrative staff, will receive the One Key Question training program, delivered by Power to Decide, via an in-person group training session.
16404432|NCT03947788|No Intervention|Control Practices|These clinics will not receive the OKQ training program during the study period. They will have the opportunity to receive the training after the study period is over.
16404433|NCT03947775|Experimental|Immediate Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
16404434|NCT03947775|Active Comparator|Delayed Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at month 24, dose #2 at month 26, and dose #3 at month 30.
16404435|NCT03947749||Patients with HICMP|Patients with PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized into this group.
16404436|NCT03947749||Patients without HICMP|Patients without PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized will be categorized into this group.
16404437|NCT03947749||Patients at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
16404438|NCT03947749||Patients not at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
16404439|NCT03947736||patients with positive HER2 amplification|
16404440|NCT03947736||patients with negative HER2 amplification|
16404441|NCT03947723|Experimental|Low power|"These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of low."
16404442|NCT03947723|Experimental|1 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
16404443|NCT03947723|Experimental|1.5 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
16404444|NCT03947723|Experimental|2 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
16404445|NCT03947710|Experimental|High-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume high protein meals during their dialysis sessions for one week.
16404446|NCT03947710|Experimental|Low-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume low protein meals during their dialysis sessions for one week
16404447|NCT03947710|Experimental|No meals|Patients with End Stage Renal disease on maintenance hemodialysis will not consume meals during their dialysis sessions for one week
16404448|NCT03947697|Placebo Comparator|Control|Participants will receive stimulation only up to sensory level.
16404449|NCT03947697|Experimental|NMES|Participants will receive stimulation up to maximum tolerable level.
16404450|NCT03947697|Placebo Comparator|Resistance Training|Participants will receive exercise training with stimulation up to sensory level.
16404451|NCT03947697|Experimental|Resistance Training + NMES|Participants will receive exercise training with stimulation up to maximum tolerable intensity.
16404452|NCT03947684|Experimental|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
16404453|NCT03947671|Experimental|Body wrap|This group will receive the body wraps post surgery to maintain normothermia.
16404454|NCT03947671|Active Comparator|Tylenol|This group will receive the standard of care of monitoring temperature and administering Tylenol if a fever develops.
16410161|NCT03907696|No Intervention|control|regular curriculum with no addition educational contents
16404455|NCT03947671|Experimental|Tylenol with body wrap|This group will receive the standard of care of monitoring temperature but will be administered Tylenol and body wraps if a fever develops.
16404456|NCT03947658|Experimental|Six weeks group|Prosthetic restoration started 6 weeks after surgical crown lengthening
16404457|NCT03947658|Experimental|Fourteen weeks group|Prosthetic restoration started 14 weeks after surgical crown lengthening
16404458|NCT03947645|Experimental|Ipsilesional stimulation|Ipsilesional stimulation
16404459|NCT03947645|Experimental|Contralesional stimulation|Contralesional stimulation
16404462|NCT03947606|Experimental|Basic social support + communication + Ottawa guide|3 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
16404463|NCT03947606|Experimental|Basic social support + communication|2 in-person/telephone weekly sessions on providing decision social support and tips for good communication
16404464|NCT03947606|Experimental|Basic social support + Ottawa guide|2 in-person/telephone weekly sessions on providing decision social support and decision support tools
16404465|NCT03947606|Experimental|Basic social support only|1 in-person/telephone weekly session on providing decision social support
16404466|NCT03947606|Experimental|Advanced social support + communication + Ottawa guide|5 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
16404467|NCT03947606|Experimental|Advanced social support + communication|4 in-person/telephone weekly sessions on providing decision social support and tips for good communication
16404468|NCT03947606|Experimental|Advanced social support + Ottawa guide|4 in-person/telephone weekly sessions on providing decision social support and decision support tools
16404469|NCT03947606|Experimental|Advanced social support only|3 in-person/telephone weekly sessions on providing decision social support
16404470|NCT03947593||Households with children under 13|Interviews conducted with the parent or guardian of a child or children under age 13.
16404471|NCT03947593||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
16404472|NCT03947593||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
16404473|NCT03947593||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
16404474|NCT03947580|Experimental|Use of the Dvectis Single pad|The Dvectis Single Dynamic-directional pad is a basic model of the Dvectis product range that provides full functionality based on the dynamic-directional seating principle. The Dvectis Single pad is designed to steer muscle tension during sitting in deep-seated muscles. The Dvectis Single pad is intended to eliminate chronic lumbar spine pain by strengthening the stabilizing muscles.
16404475|NCT03947580|Experimental|Use of the Dvectis Double pad|The Dvectis Double Dynamic-directional pad is based on the Dvectis Single model, but in addition to its dual-chamber design, it provides seating with a more balanced load and a higher dynamic-directional effect. The Dvectis Double pad is designed to create and route muscle tension during sitting in deep-seated muscles. The Dvectis Double is also suitable for soft substrates (sofa, soft chair, etc.). The Dvectis Double Pad is intended to remove chronic lumbar spine pain by strengthening the stabilizing muscles.
16404476|NCT03947580|No Intervention|Use of no pad|Description is not needed
16404477|NCT03947567|Experimental|Recombinant Human Coagulation FVIII|
16404478|NCT03947554|Experimental|HRG80 Panax ginseng|Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
16404479|NCT03947554|Active Comparator|Panax ginseng|Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
16404480|NCT03947554|Placebo Comparator|Placebo|Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
16404483|NCT03947528|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
16404484|NCT03947528|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
16404485|NCT03947515|Experimental|cancer group|
16404486|NCT03947515|Experimental|control group|
16404487|NCT03947502|Experimental|Intervention Group with|Educational intervention in neurobiology of pain
16404488|NCT03947502|No Intervention|Control group|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
16404489|NCT03947489|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
16404490|NCT03947489|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
16404491|NCT03947463|Experimental|PECS block group|20ml of 0.25% bupivacaine was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualised on the ultrasound screen. similarly, in Serratus plane block, ultrasound probe was placed over the mid-axillary region of the thoracic cage in a sagittal plane. Ribs were identified inferiorly and laterally, until the identification of the 3rd rib in the mid axillary line. 10 ml of 0.25% bupivacaine was infiltrated in between Serratus anterior muscle and Latissimus Dorsi muscle
16404492|NCT03947463|No Intervention|Control group|Patient were given multimodal analgesia without the regional block
16404691|NCT03946046|Experimental|Clinical targeting|Clinical localization method (observation and palpation of target muscles)
16404493|NCT03947450|Experimental|Autologous skin fibroblasts|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives autologous skin fibroblast whole stump injections.
~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives autologous skin fibroblasts."
16404494|NCT03947450|Placebo Comparator|Control|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives vehicle (placebo) whole stump injections.
~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives a placebo."
16404495|NCT03947437|Experimental|Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
16404496|NCT03947437|Experimental|High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
16404497|NCT03947437|Experimental|TBD dose in patients|TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.
16404498|NCT03947437|Placebo Comparator|Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
16404499|NCT03947424|Experimental|Experimental 1|Long-pulse (LP) Er:YAG laser snoring treatment.
16404500|NCT03947424|Experimental|Experimental 2|Fotona SMOOTH mode Er:YAG laser snoring treatment.
16404501|NCT03947424|Sham Comparator|Control|Sham laser snoring treatment with no energy applied.
16404502|NCT03947411|Experimental|Oseltamivir Phosphate+Xiyanping injection|Oseltamivir Phosphate+Xiyanping injection treatment for 7-10 days
16404503|NCT03947411|Active Comparator|Oseltamivir Phosphate treatment only|Oseltamivir Phosphate treatment for 7-10 days
16404504|NCT03947398|Experimental|Treatment with BLIMP first|
16404505|NCT03947398|Active Comparator|Treatment with low-profile balloon first|
16404506|NCT03947385|Experimental|Dose Escalation Monotherapy|IDE196 dosed orally, twice daily (BID) for each 28-day cycle
16404507|NCT03947385|Experimental|Dose Expansion Monotherapy|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)
16404508|NCT03947385|Experimental|Dose Escalation Binimetinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle
16404509|NCT03947385|Experimental|Dose Expansion Binimetinib Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
16404510|NCT03947385|Experimental|Dose Escalation Crizotinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
16404511|NCT03947385|Experimental|Dose Expansion Crizotinib Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
16404512|NCT03947385|Experimental|Tablet PK Substudy|IDE196 dosed orally, once on Cycle 1 Day 1; thereafter, twice daily (BID) for each 28-day cycle
16404513|NCT03947372|Active Comparator|OA (open Appendectomy)|Open Appendectomy
16404514|NCT03947372|Experimental|LA (Laparoscopic Appendectomy)|Laparoscopic Appendectomy
16404515|NCT03947359|Other|Participants with a thoracic diameter < 75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
16404516|NCT03947359|Other|Participants with a thoracic diameter >75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
16404517|NCT03947346||survivors of neuroblastoma treated with nephrotoxic therapy|Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
16404518|NCT03947333|Experimental|Intervention|Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the My Diabetes Care.
16404519|NCT03947333|No Intervention|Control|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the My Diabetes Care (i.e., usual care).
16404520|NCT03947320|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
16404521|NCT03947307|Experimental|Experimental Intervention (treatment / medical device)|Patients in the experimental group will receive lymphtaping using Easytape® according to common practice on day 1 after surgery by specifically trained physiotherapists. The tape has an elasticity of 150%. The material is moisture- and air-permeable with a hypoallergenic adhesive coating that is activated by body temperature to increase durability of contact. If possible the taping will be left for 7 days, in case of insufficient adhesion taping will be repeated.
16404522|NCT03947307|Active Comparator|Control Intervention (compression treatment )|Patients in the control group will be treated with manual lymphatic drainage followed by compression treatment using compressive stockings if accepted or compressive bandaging in cases with pronounced swelling depending on medical necessity.
16404523|NCT03947307|Sham Comparator|Control Intervention (sham taping)|Patients in the control group will be treated by sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
16404524|NCT03947281|Experimental|Almond snack|The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
16404525|NCT03947281|Experimental|Cereal-based snack|The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
16404526|NCT03947268|Experimental|Short-course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.
16404527|NCT03947255|Experimental|Brentuximab vedotin|
16404528|NCT03947242|Experimental|Pyrotinib + trastuzumab +Vinorelbine|Pyrotinib in Combination With Trastuzumab Plus Vinorelbine
16404529|NCT03947229|Active Comparator|Clopidogrel mono-therapy|After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.
16404530|NCT03947229|Active Comparator|Dual-antiplatelet therapy|Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.
16404531|NCT03947216|Experimental|PIMAVANSERIN|In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.
16404532|NCT03947216|Placebo Comparator|PLACEBO|In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.
16404533|NCT03947203|No Intervention|Pamphlet|Provided with only a pamphlet containing educational material about oral health
16404534|NCT03947203|Experimental|Social media|Provided pamphlet containing educational material about oral health and will have access to a private Facebook group, where we will share informational messages and content relating to oral health
16404535|NCT03947190|Experimental|Group 1|Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
16404536|NCT03947190|Experimental|Group 2|Group 2 adults (n=20) will be receiving 5x10^10 vp ChAd63 ME-TRAP and 2x10^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
16404537|NCT03947190|Experimental|Group 3|Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
16404538|NCT03947190|Experimental|Group 4|Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
16404539|NCT03947177|Placebo Comparator|Control|GMIT
16404540|NCT03947177|Experimental|Intervention|Modified GMIT + Parenting support groups
16404541|NCT03947164|Other|Case group|"Case :
~- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.
~POPs will be classified in stages 2-4 using the ICS classification;
~Without urinary incontinence associated effort (eliminated by the interrogation);
~Registered to a health insurance system;
~Having received information on the protocol and giving informed written consent."
16404542|NCT03947164|Other|Control group|"Control:
~Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.
~No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.
~Registered to a health insurance system;
~Having received information on the protocol and giving informed written consent."
16404543|NCT03947151|Other|one arm|one arm
16404544|NCT03947138|Experimental|GC3107_Part1|Part 1 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
16404545|NCT03947138|Experimental|GC3107_Part2|Part 2 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
16404546|NCT03947138|Active Comparator|BCG SSI_Part1|Part 1 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
16404547|NCT03947138|Active Comparator|BCG SSI_Part2|Part 2 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
16404548|NCT03947125||knee applied group|the patients with buprenorphine patch applied to painful knee joint in knee osteoarthritic patients
16404549|NCT03947125||chest applied group|the patients with buprenorphine patch applied to anterior chest wall in knee osteoarthritic patients
16404550|NCT03947112||Norwegian population with Duchenne Muscular Dystrophy (DMD)|Boys with DMD.
16404551|NCT03947086|Active Comparator|Active TDCS Group|Participants will receive active Transcranial Direct Current Stimulation (TDCS) (1.5 mA). Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
16404552|NCT03947086|Sham Comparator|Sham tDCS Group|Participants will receive sham TDCS. The protocol is identical for placebo stimulation, but the current will stop after 30 seconds from the start of stimulation. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
16404553|NCT03947073|No Intervention|Standard of Care|Subjects with newly diagnosed gestational diabetes are randomized to standard of care diabetes education.
16404554|NCT03947073|Experimental|Interactive Educational Application|Subjects with newly diagnosed gestational diabetes are randomized to standard of care plus an interactive educational application.
16404555|NCT03947060||Nasal & Frontal sensor position|One group of participants with two modes of measurement. First mode is standard frontal placement of the SedLine® sensor. Second mode is alternative nasal placement of the SedLine® sensor.
16404556|NCT03947047||Placenta Accreta|Women found to have abnormal placentation (any degree of placenta accreta) during the cesarean section.
16404557|NCT03947047||No Placenta Accreta|Women found to have normal placenta separation during the cesarean section.
16404558|NCT03947034||Metabolic toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
16404559|NCT03947021|Experimental|BSPM-only group|Participants will only receive body-surface potential mapping (BSPM) with an extensive electrode set (256 electrodes).
16404560|NCT03947021|Experimental|CT+BSPM group|Participants will receive body-surface potential measurements (BSPM) and a CT scan. These data will allow for non-invasive reconstruction of electrical potentials at the heart surface.
16404561|NCT03947008|Experimental|First Intuitive Eating Group (IE1)|IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
16404622|NCT03946540||L-FED sample|All young people treated in Maudsley Child and Adolescent Eating Disorder Service between 1/8/2009 and 31/1/2014.
16404692|NCT03946046|Experimental|Ultrasonography targeting|Ultrason-guided method
16434881|NCT03738007|Active Comparator|Perlane|
16404562|NCT03947008|Experimental|Second Intuitive Eating Group (IE2)|IE2 will be the second group to will participate in an intuitive eating program and will be required to attend 5 intuitive eating classes. The classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted on the same day as IE1 but they will take the 5 week course once the first group completes the class. This group will have an additional initial assessment on the day they begin their curriculum. The initial assessment will occur during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. During assessments, they will complete a questionnaire that will ask about body satisfaction and eating attitudes, and have their height and weight measured.
16404563|NCT03946995|Experimental|Dry needling|Dry needling will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
16404564|NCT03946995|Active Comparator|Graston|Graston Technique will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
16404565|NCT03946982|Experimental|Low thoracic patient controlled epidural analgesia|
16404566|NCT03946982|Active Comparator|Lumbar epidural patient controlled epidural analgesia|
16404567|NCT03946982|Active Comparator|Low thoracic epidural morphine|
16404568|NCT03946982|Active Comparator|Lumbar epidural morphine|
16404569|NCT03946969|Experimental|Sintilimab + Liposome Paclitaxel + Cis-Platinum + S-1|Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
16404570|NCT03946956|Active Comparator|Prebooking|Participants randomised to this arm receives a prebooked appointment to screening
16404571|NCT03946956|Placebo Comparator|Web based booking|Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
16404572|NCT03946956|Active Comparator|Pictured invitation|Participants randomised to this arm receives a pictured invitation to screening
16404573|NCT03946956|Placebo Comparator|Texted invitation|Participants randomised to this arm receives a classical texted invitation to screening
16404574|NCT03946943|Experimental|anlotinib + Toripalimab|Concurrent anlotinib and Toripalimab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies
16404575|NCT03946917|Experimental|JS001/regorafenib|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with regorafenib tablet
16404576|NCT03946904|Experimental|preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. The lesion in this case was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
16404577|NCT03946904|Experimental|no preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG.the lesion in this case was prepared with high power laser setting first to ablate the enamel, dentin, and caries.
16404578|NCT03946891|Experimental|Arm A|
16404579|NCT03946891|Experimental|Arm B|
16404580|NCT03946878|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16404581|NCT03946865|Experimental|Hospitalized hematology/oncology cancer subjects|Hospitalized hematology/oncology cancer will participate in Reiki Therapy
16404582|NCT03946852|Experimental|ARP arm|Patients will receive DCD after therapy after the abdominal reperfusion protocol.
16404583|NCT03946839||ICU Survivors|Patients with high risk of cognitive impairment who discharge from ICU
16404584|NCT03946839||Healthy Control|The control group have to be medically and cognitively healthy(MMSE ≥ 28). These individuals are recruited from the community and all attempts will be made to match them on age,sex and education to individuals recruited for groups of ICU Survivors.
16404585|NCT03946826|Experimental|PDL+ Halometasone Cream group|PDL+ Halometasone Cream Halometasone Cream, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
16404586|NCT03946826|Experimental|PDL+Vaseline group|PDL+Vaseline Vaseline, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
16404587|NCT03946826|Active Comparator|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
16404588|NCT03946826|Placebo Comparator|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
16404589|NCT03946813|Experimental|Poor ovarian reserve|Infertile women with poor ovarian reserve
16404592|NCT03946787|Active Comparator|EMDR Therapy + TAU|"Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU).
~It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life.
~Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma."
16404623|NCT03946527|Experimental|lanreotide arm|Patients with a histopathologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability who meet the inclusion/exclusion criteria. Approximately 40 patients will be enrolled.
16404624|NCT03946514|Experimental|losartan/hydrochlorothiazide group|
16404625|NCT03946514|Active Comparator|amlodipine/hydrochlorothiazide group|
16404626|NCT03946501||clinical research visit|
16435037|NCT03736967|Experimental|Combo|
16404593|NCT03946787|Placebo Comparator|TAU (Treatment as Usual)|"Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months.
~Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses."
16404594|NCT03946774|Active Comparator|High protein|Subjects getting high protein shake
16404595|NCT03946774|Active Comparator|Low protein|Subjects getting low protein shake
16404596|NCT03946761|Experimental|Cancer goggle system|"The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG & visualization of biliary/liver anatomy using the cancer goggles system
~The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG & will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.
~Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles."
16404597|NCT03946748|Experimental|REGN3918|"Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A.
~Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B."
16404598|NCT03946735|Experimental|Intervention study|Cognitive Behavioural Therapy for social anxiety
16404599|NCT03946735|Experimental|Social anxiety|
16404600|NCT03946722|Other|Standard downregulation with GnRH analogue|"Participants in this arm will be assigned to the routine IVF protocol currently being used in the investigators' IVF unit, as outlined below, with one week of downregulation. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.
~Start progesterone (Norethisterone 5mg twice daily orally) on day 14 of downregulation cycle and continue for 11 days. Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed. Baseline scan on day 1 - 5 of bleed and start oestrogen (Progynova 2mg three times daily orally). Serial scanning from day 10 until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
16404601|NCT03946722|Experimental|Prolonged downregulation with GnRH analogue|"Participants in this arm will be exposed to an additional five weeks of downregulation using a GnRH analogue. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.
~Baseline scan on day 1-5 of bleed and administer GnRH analogue (Leuprorelin acetate 3.75 mg subcutaneously single injection). 28 days later administer second dose of GnRH analogue (Leuprorelin acetate 1.875 mg subcutaneously), and 21 days later start oestrogen (Progynova 2 mg three times daily orally). Serial scanning from day 10 of oestrogen until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
16404602|NCT03946709|Other|Muscle strength condition|
16404603|NCT03946709|Other|Muscle weakness condition|
16404604|NCT03946709|No Intervention|Control|
16404605|NCT03946696||Dementia|Observations of communication and interactions between people with dementia living in a care home and therapy-animals.
16404606|NCT03946683|Experimental|Cyberknife for Early Stage Breast Cancer|Cyberknife Robotic Radiosurgery will be utilized as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer.
16404607|NCT03946670|Experimental|MBG453 + hypomethylating agents|Patients will take MBG453 plus hypomethylating agents
16404608|NCT03946670|Placebo Comparator|Placebo + hypomethylating agents|Patients will take placebo plus hypomethylating agents
16404609|NCT03946657|Active Comparator|The Inhalation Group|Sevoflurane (1 minimum alveolar concentration [MAC]) were used in the Inhalation group for the maintenance of anesthesia.
16404610|NCT03946657|Active Comparator|The TIVA (total intravenous anesthesia) Group|Propofol infusion (4-8 mg/kg of total body weight/h) were used in the TIVA group.
16404611|NCT03946644|Active Comparator|EVLA with keeping of security distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
16404612|NCT03946644|Experimental|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
16404613|NCT03946631|Other|Blood Glucose Test - 2hour GTT|Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.
16404614|NCT03946618|Experimental|Epilepsy|Patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy
16404615|NCT03946592|Placebo Comparator|Placebo group|Inject the Drug into submental fat via subcutaneous
16404616|NCT03946592|Experimental|DWJ211 group|Inject the Drug into submental fat via subcutaneous
16404617|NCT03946579|Other|Patient treated by adjuvant therapy|Self questionnaires of sexual health and quality of life (FSFI, QLQ-C30, BR23, ELD 15, HADS, GDS 15, BIS, FACIT)
16404618|NCT03946566||Acupuncture group|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
16404619|NCT03946566||Basic treatment group|Use basic treatments, such as western medicine.
16404620|NCT03946553||Allergic Rhinitis Group|Individuals with allergic rhinitis
16404621|NCT03946553||Control Group|Individuals without allergic rhinitis
16404627|NCT03946488|No Intervention|Inactive neuroprosthesis|
16404629|NCT03946475|Other|Intervention group|4 schools in 4 subdistrict which are divided into north and south Malang District. North area (Lawang and Singosari) and South area (Kepanjen and Gondanglegi).
16404630|NCT03946475|No Intervention|Control group|4 schools in 4 subdistrict which are divided into north (Sumberpucung), south (Lawang and Singosari), and east (Tumpang) Malang District.
16404631|NCT03946462|Experimental|NO Group|
16404632|NCT03946462|Placebo Comparator|Placebo Group|
16404633|NCT03946449|Experimental|ARO-AAT Cohort 1|"Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.
~Treatment Extension (optional enrollment): Administered every 12 weeks for 8 additional doses."
16404634|NCT03946449|Experimental|ARO-AAT Cohort 1b|"Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.
~Treatment Extension (optional enrollment): Administered every 12 weeks for 8 additional doses."
16404635|NCT03946449|Experimental|ARO-AAT Cohort 2|"Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.
~Treatment Extension (optional enrollment): Administered every 12 weeks for 8 additional doses."
16404636|NCT03946436|Experimental|I-AVI|The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
16404637|NCT03946436|Active Comparator|NO-AVI|The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
16404638|NCT03946423|Experimental|Sleeve Gastrectomy & Lifestyle Intervention|
16404639|NCT03946423|Active Comparator|Lifestyle Intervention|
16404640|NCT03946410|Active Comparator|Screening|Invitation to cardiovascular screening
16404641|NCT03946410|Placebo Comparator|Control|No invitation to cardiovascular screening
16404642|NCT03946397|Experimental|Multisensory massage|
16404643|NCT03946397|No Intervention|Control|
16404644|NCT03946384||patients|Hemophilia B with p.Ile112Thr mutation on factor IX gene
16404645|NCT03946371||Extubation Success|Patients who do not require re-intubation, upto 48 hours after a planned extubation in the adult intensive care unit.
16404646|NCT03946371||Extubation failure|Patients who required re-intubation within 48 hours after a planned extubation in adult intensive care unit.
16404647|NCT03946358|Experimental|Atezolizumab and UCPVax|"Induction phase:
~Atezolizumab 1200 mg intravenous (IV) every 3 weeks since day 1
~UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).
~Boost phase:
~UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)
~Atezolizumab 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
16404648|NCT03946332|Experimental|Physical exercise arm|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice
16404649|NCT03946332|Active Comparator|controlled arm|patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.
16404650|NCT03946319|Experimental|Personalized, Transdiagnostic Assessments|One or more times per day, participants in the Experimental Arm will be presented with a variable-length assessment based on the personalization algorithm. The assessment will include a dynamic number of questions based on personalized relevancy, engagement level, and assessment completion metrics. Questions are scored immediately upon submission, regardless of how many questions are answered. As questions are scored, the personalization algorithm takes the previous responses and response times into consideration when determining what and when to ask additional questions.
16404651|NCT03946319|Active Comparator|Monotopic Assessments|Once daily, participants in the Control Arm will be presented with the standard of care mental health surveillance assessments identified as relevant upon intake. The assessments will be scored in totality or not at all and have a fixed, predefined number of questions. No personalization of assessment will take place.
16404652|NCT03946306|Active Comparator|Group 1|5,25% NaOCl with syringe needle irrigation alone
16404653|NCT03946306|Active Comparator|Group 2|5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)
16404654|NCT03946293|Active Comparator|White bread|White bread 3 x 30 g, single serving
16404655|NCT03946293|Active Comparator|Wholegrain|Standard wholegrain, 3 x 30 g, single serving
16404656|NCT03946293|Experimental|Wholegrain Enzyme|Enzyme-treated wholegrain, 3 x 30 g, single serving
16404657|NCT03946280|Other|Fluoroscopy Group|Patient undergoing common flutter (AFL) ablation procedure using conventional X-ray based fluoroscopy for for catheter tracking
16404658|NCT03946280|Experimental|3D Group|Patient undergoing common flutter (AFL) ablation procedure using the low X-ray 3D navigation technique for for catheter tracking
16404659|NCT03946267|Experimental|IFCG = Infracyanine Green stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 ml of low-concentration (0.5 mg/mL, 0.05%) IFCG injected over the macular area with the infusion line closed.
16404660|NCT03946267|Experimental|BBG = Brilliant Peel stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 mL BBG at a concentration of 0.25 mg/mL (0.025%) injected over the macular area with the infusion line closed.
16404661|NCT03946254|Experimental|Intervention|THE EXPERIMENTAL GROUP WILL DEVELOP 20 WEEKS OF TRAINING TO IMPROVE THE MUSCLE CAPACITY. FOR THIS, FORCE EXERCISES WILL BE DEVELOPED IN GUIDED MACHINES.
16404662|NCT03946254|Experimental|Control|THE CONTROL GROUP WILL DEVELOP 20 WEEKS OF BALANCE AND BREATHING EXERCISES.
16404731|NCT03945747||Hybrid closed-loop artificial pancreas system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
16404663|NCT03946241||Pre-reform study populations|Children from 1st to 9th grade (n ~ 2,600) from four different school-based studies collecting objective physical activity data. The four studies are 1) The European Youth Heart Study (EYHS) conducted in 1997-98, 2003-04 and 2009-10, 2) When Cities Move Children (WCMC) conducted in 2010 and 2012, 3) Childhood Health, Activity, and Motor Performance School Study Denmark (CHAMPS-DK) conducted in 2009, 2010 and 2012, and 4) School site, Play Spot, Active transport, Club fitness and Environment (SPACE) conducted in 2010 and 2012. A total of 44 schools where included in the studies.
16404664|NCT03946241||Post-reform study population|Children from 1st to 9th grade in 2017-18 from the same schools as included in the pre-reform research studies (n ~ 2,600). Two of the pre-reform research studies (CHAMPS-DK and SPACE) introduced PA promoting initiatives as part of the study. To minimize any influence from participation in these interventions we chose only to include and recruit participants from control schools from these studies. A total of 36 schools where invited and 31 subsequently accepted to participate. Parents and teachers of the children were included as well.
16404665|NCT03946228|Experimental|Behavioral Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
16404666|NCT03946228|No Intervention|Control Condition|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
16404667|NCT03946215|Experimental|well-trained athletes|A cardiorespiratory stress test
16404668|NCT03946202|Experimental|Radiotherapy + radiation sensitiser|Patients randomised to the test group will receive standard radiotherapy for breast cancer + a radiation sensitiser
16404669|NCT03946202|No Intervention|Radiotherapy alone|Patients randomised to the control group will receive standard radiotherapy for breast cancer alone
16404670|NCT03946189||P/F less than 100|Patients receiving mechanical ventilation with paO2/FiO2 less than 100
16404671|NCT03946189||P/F between 100 and 200|Patients receiving mechanical ventilation with paO2/FiO2 between 100 and 200
16404672|NCT03946189||P/F between 200-300|Patients receiving mechanical ventilation with paO2/FiO2 between 200 and 300
16404673|NCT03946176|Experimental|Symbiotic|HD patients with 7 weeks symbiotic administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
16404674|NCT03946176|Placebo Comparator|Placebo|HD patients with 7 weeks placebo administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
16404675|NCT03946163|Experimental|first group|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
16404676|NCT03946163|Placebo Comparator|second group|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
16404677|NCT03946150||P/FP Ratio|P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
16404678|NCT03946150||P/F ratio|P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
16404679|NCT03946137|Experimental|Sample|"30 patients of both sexes aged between 0 and 6 years with chronic neurological involvement with respiratory complications.
~Individual sessions of chest therapy every fifteen days for three months, in total 6 respiratory physiotherapy sessions of 30 minutes each were performed. And the postural hygiene workshops were given to the parents, this educational intervention was carried out at the beginning of the study, at 3 months and at 6 months from the beginning. Each intervention lasted 4 hours with theoretical and practical part."
16404680|NCT03946124|Other|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
16404681|NCT03946111|Experimental|Naltrexone/Bupropion|
16404682|NCT03946111|Placebo Comparator|Placebo|
16404683|NCT03946098|Experimental|iCBT for Gambling Disorder|Treatment will consist of a 1+10 module internet delivered CBT program targeting problem gambling, newly developed. A bottom-up procedure was used to develop the treatment protocol, inspired by Clark's (2004) method for developing novel CBT treatments. We developed a clinical model delineating what factors contribute to the persistence of problem gambling behavior, and aligned these with targeted treatment interventions; based on behavioral upon research on the learning and maintenance processes of gambling behavior (Ramnerö et al, in press), theoretical models of gambling and comorbidity (Blaszczynski & Nower, 2002); as well as qualitative interviews with treatment seeking gamblers with or without comorbidity.
16404684|NCT03946085|Experimental|Lumega-Z group|Participants assigned the study supplement Lumega-Z.
16404685|NCT03946085|Active Comparator|AREDS2 group|Participants assigned the AREDS2 supplement
16404686|NCT03946085|No Intervention|Control|Participants are determined ocular normal after clinical examination and do not have retinal drusen.
16404687|NCT03946072|Active Comparator|Transseptal Group|Transseptal Aortic Approach Catheter Ablation Procedure
16404688|NCT03946072|Active Comparator|Retrograde Group|Retrograde Aortic Approach Catheter Ablation Procedure
16404689|NCT03946059|Experimental|iTBS then cTBS|"Participants in this arm first receive the iTBS brain stimulation in week 1, then have a one-week washout period and then receive cTBS brain stimulation in week 2.
~intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.
~continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered."
16404690|NCT03946059|Experimental|cTBS then iTBS|Participants in this arm first receive the cTBS brain stimulation in week 1, then have a one-week washout period and then receive iTBS brain stimulation in week 2.
16435038|NCT03736967|Experimental|Placebo|
16404693|NCT03946033|Other|Single arm|All participants are included in the same arm. Immunoscore Colon Test is applied on a tumor sample and the result is kept secret. In the Multidisciplinary Meeting evaluating the adjuvant therapy of the participant, a first therapeutic decision is taken, then Immunoscore result will be disclosed and the Multidisciplinary Meeting will take a second decision.
16404694|NCT03946020|Active Comparator|Augmentation with autologous bone + DBBM|A layer of autogenous bone chips was placed on the implant surface. On top of this a layer of DBBM (Bio-Oss™, Geistlich®, Wolhusen, Switserland) was placed, thereafter covered with a collagen membrane.
16404695|NCT03946020|Experimental|Augmentation with DBBM|A layer of DBBM was placed on the implant surface and thereafter covered with a collagen membrane. Care was taken to make both augmentations as comparable as possible by weighting the used amount of graft material.
16404696|NCT03946007||Patients with melanoma or NSCLC|Patients (age ≥18 years) with melanoma or NSCLC ≥2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.
16404697|NCT03945994|No Intervention|Connecting People Control Group|CMHTs (Community Mental Health Teams) will continue to support people with mental health problems using their standard care.
16404698|NCT03945994|Experimental|Connecting People Intervention Group|CMHTs will receive training on how to implement Connecting People programme. They will receive implementation toolkit to improve their practice in contrast to standard care.
16404700|NCT03945955|Experimental|Melatonin|
16404701|NCT03945955|Placebo Comparator|Placebo|
16404702|NCT03945942|Other|Pediatric liver transplant patients|Using somatic and cerebral Near infrared spectroscopy devices
16404703|NCT03945929|Experimental|Distraction1 group|Distraction-1 Group (Cards containing optical illusion pictures)
16404704|NCT03945929|No Intervention|Control|Control
16404705|NCT03945929|Experimental|Distraction 2 group|Distraction-2 Group
16404706|NCT03945916|Experimental|Dark chocolate|180g/d dark chocolate
16404707|NCT03945916|Placebo Comparator|Placebo|180g/d of artificial dark chocolate
16404708|NCT03945877||English-speaking Community Members|Survey respondents
16404709|NCT03945877||Spanish-speaking Community Members|Survey respondents
16404710|NCT03945877||Arabic-speaking Community Members|Survey respondents
16404711|NCT03945864|Experimental|antimicrobial synthetic bone graft|This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
16404712|NCT03945864|Active Comparator|parenteral antibiotics with pure synthetic bone graft|This group will have parenteral antibiotics and pure synthetic bone graft
16404713|NCT03945851|Experimental|VNS + Rehabilitation|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The experimental arm for that study includes subjects whose stroke treatment via Vagal Nerve Stimulation (VNS) delivered during rehabilitation.
16404714|NCT03945851|Active Comparator|Control VNS|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The active control arm for that study included subject whose stroke treatment is rehabilitation (standard-of-care) with only a minimal amount of VNS at the start of each rehabilitation session.
16404715|NCT03945838||Breast cancer related lymphedema|All patients were included in the complete decongestive therapy programme. This therapy includes patient education, skin care, exercises, manual lymphatic drainage (self), and compression bandage therapy.
16404716|NCT03945825|Experimental|Group 1|0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
16404717|NCT03945825|Experimental|Group 2|0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
16404718|NCT03945825|Experimental|Group 3|0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
16404719|NCT03945825|Experimental|Group 4|0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
16404720|NCT03945825|Experimental|Group 5|0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
16404721|NCT03945825|Experimental|Group 6|0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
16404722|NCT03945812||Granulocyte Colony Stimulating Factor Arm|"Women in this group will receive G-CSF with conventional hormonal therapy:
~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
16404723|NCT03945812||Platelet Rich Plasma Arm|"Women in this group will receive PRP with conventional hormonal therapy:
~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
16404724|NCT03945812||Saline|"Women in this group will receive saline with conventional hormonal therapy:
~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
16404725|NCT03945799|Experimental|Anlotinib|Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
16404726|NCT03945773|Experimental|Cohort A|Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.
16404727|NCT03945773|Experimental|Cohort B|Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.
16404728|NCT03945760|Experimental|Subjects Taking Baricitinib 2 mg|Subjects will be taking Baricitinib 2mg
16404729|NCT03945760|Placebo Comparator|Subjects Taking Placebo|Subjects will be taking placebo
16404730|NCT03945747||Control group|Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
16404732|NCT03945747||Predictive low glucose suspend system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
16404733|NCT03945734|Experimental|Expressive Helping|Participants complete four 20-minute writing/voice-recording sessions spaced one week apart. During the first week, the instructions will explain that cancer patients and survivors benefit from learning about other cancer survivors' experiences. They are told that the first three weeks of writing/voice-recording (writing/talking about their stress and coping at Week 1, deepest emotions about cancer at Week 2, self-affirmation and benefit finding at Week 3) are exercises designed to help them think about their cancer experiences and to prepare them to write/record the narrative they would share on Week 4. During Week 4, they are asked to write/record a narrative as if they are speaking to another Chinese person with cancer, adding advice and encouragements, and reminded that their writing/recording would be shared with other Chinese American cancer patients and survivors.
16404735|NCT03945708|Experimental|Treatment|Addition of whole blood adsorber to CPB circuit
16404736|NCT03945708|No Intervention|Control|Standard treatment
16404737|NCT03945695|Experimental|Pneumatic Vitreolysis|All included eyes will receive one intravitreal injection of filtered sulfur hexafluoride gas (SF6).
16404738|NCT03945682|Experimental|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
16404739|NCT03945682|No Intervention|Usual Standard of Care|Participants continue with usual care and existing therapy recorded in study diary
16404740|NCT03945669|Active Comparator|Intramedullary Nail|Intramedullary Nailing: Alignment will be obtained by closed or limited open reduction of the fracture. A standard reamed intramedullary nail is inserted. Access above the patella, through the patella tendon or parapatellar access is used according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. Patients are administered preoperative antibiotics (Dicloxacillin) 15 minutes before surgery commences. Postoperative antibiotics is administered by discretion of the surgeon based on individual patient considerations.
16404741|NCT03945669|Experimental|External Ring fixator|External Ring fixation: Closed or limited open reduction of the fracture is performed. A circular frame is attached on both sides of the fracture. Connection to the bone is obtained by hydroxyapatite coated half pins and/or k-wires with olives as needed according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. After applying the ring fixator alignment is assessed radiologically and corrected both peri- and postoperatively. Patients are administered preoperative antibiotics (Dicloxacillin) preoperatively 15 minutes before surgery commences. Following surgery antibiotics are continued until wounds, pin- and wire perforations are dry.
16404742|NCT03945656|Experimental|Insulin 287 followed by insulin glargine|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.
~After run-in, participants will receive insulin 287 once a week (OW) for 6 weeks.
~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 12 days."
16404743|NCT03945656|Active Comparator|Insulin glargine followed by insulin 287|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.
~After run-in, participants will receive insulin glargine U100 OD for 12 days.
~After insulin glargine treatment, participants will receive insulin 287 OW for 6 weeks."
16404744|NCT03945643|Active Comparator|Sildenafil administration|Administration of 50mg sildenafil one time, one hour prior to measurements
16404745|NCT03945643|Placebo Comparator|Placebo administration|Administration of 50mg placebo one time, one hour prior to measurements
16404746|NCT03945630|Experimental|anterior Quadratus Lumborum Block (QLB)|"Anterior QLB will be performed in the sitting position. This block is also known as TQL- Transmuscular QLB or QLB 3. A convex transducer will be placed in a transverse position, in the posterior axillary line and tilted caudad until the 'shamrock sign' at L4 level will be obtained. An 80-110 mm SonoTAP (PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the needle tip will be inside the interfascial plane between the Quadratus Lumborum and the Psoas muscles. The successful needle placement will be confirmed by observing the spread of 5 mls 0,9%NaCl. Subsequently, 30 ml 0.5% ropivacaine with 100 mcg dexmedetomidine and adrenaline 1:200,000 will be injected. Satisfactory interfascial spread will be assessed by longitudinal probe orientation.
~Following QLB, a spinal anaesthetic will be sited and a THA via posterior approach will be performed."
16404747|NCT03945630|Active Comparator|Standard of Care (no QLB)|A spinal anaesthetic will be sited and a THA via posterior approach will be performed.
16404748|NCT03945617|Experimental|Unified treatment protocol|This intervention group receives 16 sessions of CBT-based, individual psychotherapy using to the Unified Treatment Protocol for the treatment of emotional disorders by Barlow et al. (2011).
16404749|NCT03945617|No Intervention|Waitlist Control Group|Participants in the waitlist control group gain access to the Unified Treatment after a waiting period of 16 weeks
16404750|NCT03945604|Experimental|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity
16404751|NCT03945591|Experimental|Cyclophosphamide and Bortezomib|
16404752|NCT03945578|Active Comparator|Control Group|"This group performed a supervised Pelvic Floor Muscle Training (PFMT) protocol associated with a manual sham therapy (MST) sessions.
~The PFMT protocol consisted of 20 sessions of 45-60 minutes each, twice a week, totalizing a five weeks treatment.
~The MST protocol was performed once a week, during five weeks lasting approximately 15 minutes."
16404753|NCT03945578|Experimental|Experimental Group|"The experimental group performed the same PFMT protocol as the CG, but associated with a Visceral Manual Therapy (VMT) protocol.
~The VMT sessions were held once a week, for five weeks. Each session lasted approximately 20 minutes."
16404754|NCT03945565|Active Comparator|FiO2 0.3|Patients allocated to this group are going to receiving FiO2 of 0.3 during surgery
16404755|NCT03945565|Active Comparator|FiO2 0.8|Patients allocated to this group are going to receiving FiO2 of 0.8 during surgery
16404756|NCT03945552|No Intervention|Control|Care as usual
16410805|NCT03903549|Experimental|Brain uptake and kinetics in Parkinson patients|
16404757|NCT03945552|Experimental|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
16404758|NCT03945539|Experimental|JNJ-56136379 and Itraconazole|Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single dose of JNJ 56136379 on Day 38 in Treatment Period 2. JNJ-56136379 intake in Treatment Period 1 and the first intake of itraconazole in Treatment Period 2 will be separated by a washout period of at least 33 days. Study drug (JNJ-56136379 and itraconazole) intakes will be taken orally and under fed conditions.
16404759|NCT03945526|Active Comparator|Astaxanthin|Astaxanthin supplementation will be given at 2 x 8mg for 7 days.
16404760|NCT03945526|Placebo Comparator|Control|A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation
16404761|NCT03945513|Experimental|LPRI424|
16404762|NCT03945500|Experimental|Standardized Home Spirometry (SHS) Method|"The Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded in an Android Tablet & FDA approved spirometer & pulse oximeter.
~Participants will be trained with the SHS method, perform an initial home spirometry test session & a lab-based spirometry test (if practicable).
~Pre-surveillance Phase:Daily SHS Testing for 4 to 10 weeks to enable the Mobile Medical application to generate volunteer specific normal range.
~Surveillance Phase: At least weekly SHS Testing. During approximately two months of the surveillance phase, the volunteer will test one to four times per week to assess the SHS neural pathways as directed by the study team. Test sessions will be documented on a test log. Subjects may be asked to perform additional SHS pathway test logs, continue at least weekly testing, pause testing or end participation following completion of the initial SHS neural pathway test log."
16404763|NCT03945487|Experimental|Comprehensive treatment plus UC-MSC treatment|
16404764|NCT03945487|Other|Comprehensive treatment|
16404765|NCT03945474|Experimental|OMT|Patients will receive a standardized protocol of: condylar decompression, Still's technique for the sternocleidomastoid, hyoid rebalancing and thoracic inlet myofascial release.
16404766|NCT03945474|Sham Comparator|Sham|Patient will be treated in the supine position, with hands gently applied without pressure to the four areas: occiput, lateral cervical spine, hyoid area and thoracic inlet.
16404767|NCT03945461|Experimental|Gum chewing|Chew xylitol based, peppermint flavored gum for 30 minutes every two hours during the hours of 7 am to 9 pm, for the first 24 hours after your surgery
16404768|NCT03945461|No Intervention|Standard Care|Standard hospital management with no deviations from usual care
16404769|NCT03945448|Experimental|Single dose liposomal Amphotericin and fluconazole|"Experimental:
~Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)"
16404770|NCT03945448|Active Comparator|fluconazole (standard of care)|Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months
16404771|NCT03945435||Normal Glucose Tolerance|Blood glucose level of less than 140 mg/dL at the 2 hour timepoint.
16404772|NCT03945435||Impaired Glucose Tolerance|Blood glucose level of greater or equal to 140 mg/dL at the 2 hour timepoint.
16404773|NCT03945422|Experimental|Treatment Arm|Subject will receive AccuTite/FaceTite and Morpheus8 treatment
16404774|NCT03945396|Experimental|Multidisciplinary intervention + homeopathic medication|"Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c.
~A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation."
16404775|NCT03945396|Active Comparator|Multidisciplinary intervention + homeopathic placebo|"Multidisciplinary intervention (diet, exercise program, motivational support) and placebo.
~Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation."
16404776|NCT03945383|Experimental|Treatment with IPL device|The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
16404777|NCT03945370|Active Comparator|Intervention sequence 1|Ketone drink first - Placebo drink secondly
16404778|NCT03945370|Placebo Comparator|Intervention sequence 2|Placebo drink first - Ketone drink secondly
16404779|NCT03945357|Active Comparator|Saline Irrigation|Normal saline is to be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional saline irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure.
16404780|NCT03945357|Active Comparator|Antibiotic Irrigation|Antibiotic solution is prepared consisting of 240 mg gentamicin and 600 mg clindamycin in 500 ml saline to ensure proper concentration. This solution should be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional antibiotic irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure. This second irrigation is not timed.
16404781|NCT03945344|Experimental|Treatment A|Tiotropium with concomitant charcoal
16404782|NCT03945344|Experimental|Treatment B|Tiotropium without concomitant charcoal.
16404783|NCT03945331|Experimental|TESS|Transcutaneous Electrical Spinal Stimulation (TESS), used during all training sessions.
16404784|NCT03945331|Experimental|EES|TESS, used during the initial 6-month training period, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
16404785|NCT03945318|Experimental|Part 1: BION-1301|Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
16404786|NCT03945318|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of placebo administered by IV infusion.
16404787|NCT03945318|Experimental|Part 2: BION-1301|Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
16404788|NCT03945318|Placebo Comparator|Part 2: Placebo|Subjects will receive placebo by IV infusion.
16404789|NCT03945318|Experimental|Part 3: BION-1301|Up to 2 cohorts of subjects will receive multiple doses of BION-1301 at a dose and frequency to be determined by IV infusion.
16404790|NCT03945305|Experimental|RIC+ antihypertensive treatment|Baseline blood pressure and heart rate are measured 2 times a day for 3 days. And then the blood pressure and heart rate are measured before and after remote ischemic conditioning. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 30±2 days.
16404791|NCT03945292|Experimental|ARO-AAT|"Participants with no fibrosis: Administered on Day 1 and Week 4
~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 15 total doses."
16404792|NCT03945292|Placebo Comparator|Placebo|"Participants with no fibrosis: Administered on Day 1 and Week 4
~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 15 total doses."
16404793|NCT03945279|Experimental|Cohort 1: BIIB100 Dose 1|Participants will receive single oral dose of BIIB100 on Day 1.
16404794|NCT03945279|Experimental|Cohort 2: BIIB100 Dose 2|Participants will receive single oral dose of BIIB100 on Day 1.
16404795|NCT03945279|Experimental|Cohort 3: BIIB100 Dose 3|Participants will receive single oral dose of BIIB100 on Day 1.
16404796|NCT03945279|Experimental|Cohort 4: BIIB100 Dose 4|Participants will receive single oral dose of BIIB100 on Day 1.
16404797|NCT03945279|Experimental|Cohort 5: BIIB100 Dose 5|Participants will receive single oral dose of BIIB100 on Day 1.
16404798|NCT03945279|Experimental|Cohort 6: BIIB100 Dose 6|Participants will receive single oral dose of BIIB100 on Day 1.
16404799|NCT03945279|Placebo Comparator|Cohort 1-6: Matching Placebo|Participants will receive single oral dose of matching placebo on Day 1.
16404800|NCT03945266|Experimental|Intervention group|Participants receive the allocated intervention to help manage gestational weight gain that includes education on weight regulation, healthy eating, physical activity, and goal setting.
16404801|NCT03945266|Active Comparator|Control group|Participants do not receive the allocated intervention but self-monitor their behaviors, complete study tasks and receive prenatal care as normal.
16404802|NCT03945253|Experimental|ASP8374-dose A|Participants will receive dose A of ASP8374 solution intravenously on day 1 of every 3-week cycle.
16404803|NCT03945253|Experimental|ASP8374-dose B|Participants will receive dose B of ASP8374 solution intravenously on day 1 of every 3-week cycle.
16404804|NCT03945240|Experimental|Group 1 (Pinnacle, lower dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
16404805|NCT03945240|Experimental|Group 2 (Pinnacle, higher dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
16404806|NCT03945240|Experimental|Group 3 (Phoenix)|Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
16404807|NCT03945227|Placebo Comparator|Arm A (consolidation only arm)|Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
16404808|NCT03945227|Experimental|Arm B (concurrent arm)|Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
16404809|NCT03945214|Experimental|Meditation group|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
16404810|NCT03945214|Experimental|Healthy eating group|Participants in the healthy eating group will be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
16404811|NCT03945214|Experimental|Mediation + Healthy eating group|Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
16404812|NCT03945214|No Intervention|Waitlist control condition|Waitlist control group participants will continue their normal activities and not add any form of mediation during the study period.
16404813|NCT03945201|Active Comparator|Standard of care|"Participants receive normal cardiac rehabilitation according to approved standard of care. They use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session."
16438229|NCT03715114|Experimental|GV-971 1500 mg|1500 mg oral
16404814|NCT03945201|Experimental|Virtual walking trails|"Participants use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session. The treadmill is positioned in front of a vertically oriented high definition television screen showing Bionautica Trails, virtual walking trails created by Plas.md."
16404815|NCT03945188|Experimental|Etrasimod 2 mg|
16404816|NCT03945188|Placebo Comparator|Placebo|
16404817|NCT03945175|Experimental|Treatment|During the first two week lead-in, if the subject has a ≥30% decrease in the AISRS, they will not move into the 4-week treatment period of the study.
16404818|NCT03945162|Experimental|0.7 mg/cm^2 TLD-1433 Bladder infusion and Photodynamic Therapy|A single instillation of TLD-1433 (at the therapeutic dose of 0.7 mg/cm^2) will be infused intravesically into the bladder for approximately 60 minutes. Photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. Two treatment procedures will be performed, a primary treatment at Day 0 and a secondary treatment at Day 180 post primary treatment.
16404819|NCT03945149|Active Comparator|Turmipure Gold™|30 subjects will be randomized under active arm and will receive Active Product at V1 and until V2 (5 weeks of treatment).
16404820|NCT03945149|Placebo Comparator|Placebo|30 subjects will be randomized under Placebo arm and will receive placebo Product at V1 and until V2 (5 weeks of treatment).
16404821|NCT03945123|Experimental|Ginseng trial|compare experimental group to controlled group
16404822|NCT03945110|Experimental|Arm A|Patients in this Arm will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later.
16404823|NCT03945110|No Intervention|Arm B|Patients in this Arm will receive usual bladder care only.
16404824|NCT03945110|Experimental|Arm C|Patients in this Arm will be Spinal Urology Outpatients or Inpatients who are eligible for inclusion and experiencing significant urinary tract infection recurrence and/or complications. Patients will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later. Patients will be encouraged and supervised to self-administer iAluRil® intravesical instillations.
16404825|NCT03945097||Letters|Education program focuses on learning letters.
16404826|NCT03945097||Language|Education program focuses on language comprehension.
16404827|NCT03945084|Experimental|Experimental Arm|Patients assigned to experimental arm will receive Niraparib 300 mg or 200 mg daily (based on weight and platelet count) plus best supportive care (BSC), in 28-day cycles, until disease progression or unacceptable toxicity or death.
16404828|NCT03945084|Other|Control Arm|Patients assigned to control arm will receive best supportive care alone, until disease progression or death.
16404829|NCT03945071|Active Comparator|Puntal plug|Subjects will receive temporary punctal plug after intravitreal injection
16404830|NCT03945071|No Intervention|Non-Punctual plug|Subjects will not receive temporary punctal plug after intravitreal injection
16404831|NCT03945058|Experimental|Experimental|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
16404832|NCT03945058|Sham Comparator|CONTROL|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.
16404833|NCT03945045|Experimental|SCV|TIVAD implanted through subclavian vein under real-time ultrasound guidance
16404834|NCT03945045|Experimental|IJV|TIVAD implanted through internal jugular vein under real-time ultrasound guidance
16404835|NCT03945032|Experimental|8 parents of a childhood cancer survivor|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
16404836|NCT03945019|Experimental|CT-P13 SC|
16404837|NCT03945019|Placebo Comparator|Placebo SC|
16404838|NCT03945006||Multiple Sclerosis Patients with Incontinence|Multiple Sclerosis with incontinence 24-58 years of age and being volunteered.
16404839|NCT03945006||Multiple Sclerosis Patients without incontinence|Multiple Sclerosis without incontinence 24-58 years of age and being volunteered.
16404840|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on dominant leg.
16404841|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Non-dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on non-dominant leg.
16404842|NCT03944993|Sham Comparator|Sham Therapy (Control)|Inactive Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes.
16404843|NCT03944980|Experimental|Arm 1: CIK|"Docetaxel & PD1-T cells
~Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
16404844|NCT03944980|Active Comparator|Arm 2: Control|"Docetaxel
~Docetaxel,60mg/m2,intravenous infusion,d1; Q3W."
16404845|NCT03944954|Experimental|Excitatory TMS|Combinations of THC and excitatory TMS.
16404846|NCT03944954|Experimental|Inhibitory TMS|Combinations of THC and inhibitory TMS.
16404847|NCT03944941|Active Comparator|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
16404848|NCT03944941|Experimental|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
16404849|NCT03944915|Experimental|ARM 1|Induction Therapy
16404850|NCT03944915|Experimental|ARM 2|Radiation therapy with chemotherapy
16438230|NCT03715114|Placebo Comparator|Placebo|Oral placebo
16404854|NCT03944889|Placebo Comparator|Placebo Topical|Placebo Cream, applied topically to trapezius muscle
16404855|NCT03944889|Active Comparator|Low Dose, Topical|Capsaicin Cream- low dosage, applied topically to trapezius
16404856|NCT03944889|Active Comparator|High Dose, Topical|Capsaicin Cream- higher dosage, applied topically to trapezius
16404857|NCT03944889|Placebo Comparator|Placebo, Intrafascial|Injection placebo(saline)- injected intrafascially into trapezius
16404858|NCT03944889|Active Comparator|Low Dose, Intrafacial|Injection Capsaicin formulation low dose- injected intrafascially into trapezius
16404859|NCT03944889|Active Comparator|High Dose, Intrafascial|Injection Capsaicin formulation higher dose- injected intrafascially into trapezius
16404860|NCT03944889|Placebo Comparator|Placebo, Intramuscular|Injection placebo (saline) - injected intramuscularly into trapezius
16404861|NCT03944889|Active Comparator|Low Dose, Intramuscular|Injection Capsaicin formulation low dose - injected intramuscularly into trapezius
16404862|NCT03944889|Active Comparator|High Dose, Intramuscular|Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius
16404863|NCT03944876|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
16404864|NCT03944876|Placebo Comparator|Controls|placebo injections
16404865|NCT03944863||POEM + Antibiotic prophylaxis|Cefazolin: 2g or Amoxicillin - clavulanic acid: 1g x 3 during 7 days
16404866|NCT03944863||POEM + No antibiotic prophylaxis|
16404867|NCT03944850|Experimental|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
16404868|NCT03944837|Experimental|Severe fetal congenital heart disease (CHD)|Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
16404869|NCT03944824|Experimental|Exercise (Intervention) Arm|The 25 patients in this arm will receive an interventional exercise plan using resistance bands and once weekly visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
16404870|NCT03944824|Placebo Comparator|Control|The 25 patients in the control arm will not receive an interventional exercise plan or visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
16404871|NCT03944811|Active Comparator|Transcrestal sinus floor elevation using Summers technique|
16404872|NCT03944811|Experimental|Transcrestal sinus floor elevation using piezoelectric surgery|
16404873|NCT03944798|Active Comparator|Surveillance Arm I|Clinical assessment and chest radiograph (CXR) every six months for two years
16404874|NCT03944798|Experimental|Surveillance Arm II|Clinical assessment and CXR every three months for two years
16404875|NCT03944798|Experimental|Surveillance Arm III|Clinical assessment and chest computed tomography (CT) every six months for two years
16404876|NCT03944798|Experimental|Surveillance Arm IV|Clinical assessment and chest CT every three months for two years
16404877|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
16404878|NCT03944772|Experimental|Module 1: Osimertinib + Savolitinib|The patients in this group will receive osimertinib taken in combination with savolitinib
16404879|NCT03944772|Experimental|Module 2: Osimertinib + Gefitinib|The patients in this group will receive osimertinib taken in combination with gefitinib
16404880|NCT03944772|Experimental|Module 3: Osimertinib + Necitumumab|The patients in this group will receive osimertinib taken in combination with necitumumab
16404881|NCT03944772|Experimental|Module 4: Carboplatin + Pemetrexed + Durvalumab)|The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
16404882|NCT03944772|No Intervention|Observational Cohort: No study drug|"Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.
~With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib."
16404883|NCT03944772|Experimental|Module 5: Osimertinib + Alectinib|The patients in this group will receive osimertinib taken in combination with alectinib
16404884|NCT03944772|Experimental|Module 6: Osimertinib + Selpercatinib|The patients in this group will receive osimertinib taken in combination with selpercatinib
16404885|NCT03944759|Active Comparator|GBM:( bupivacaine/magnesium sulphate)|"serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.
~GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate"
16404886|NCT03944759|Active Comparator|GBN: ( bupivacaine/nalpuphin)|serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg.
16404887|NCT03944746||SAMMC Emergency Medicine Residents|Emergency Medicine Residents from San Antonio Military Medical Center in San Antonio, Texas.
16404888|NCT03944746||University Hospital Emergency Medicine Residents|Emergency Medicine Residents from University Hospital in San Antonio, Texas.
16404889|NCT03944733|Active Comparator|Iron Intervention|IDA mothers will receive a 65 mg of iron (ferrous sulfate) daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
16404943|NCT03944343|Experimental|Test product B|Specific designed cereals B and yogurt
16404890|NCT03944733|Placebo Comparator|Placebo|IS mothers will receive 600 mg of gelatin daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
16404891|NCT03944707|Experimental|LOU064|LOU064 100 mg once daily orally
16404892|NCT03944707|Placebo Comparator|Placebo|Placebo once daily orally
16404893|NCT03944694||Delirious|Patients were delirious if CAM-ICU was positive within 24 hours from admission due to acute ischemic stroke.
16404894|NCT03944694||Non-delirious|Patients were delirious if CAM-ICU was negative within 24 hours from admission due to acute ischemic stroke.
16404895|NCT03944681|Other|Droperidol group|Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus
16404896|NCT03944668|Experimental|Intervention|Exercise intervention
16404897|NCT03944655|Active Comparator|Strepsils|
16404898|NCT03944655|Placebo Comparator|Placebo|
16404899|NCT03944642|Experimental|Intervention|Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
16404900|NCT03944642|No Intervention|Standard Care|This group will receive the standard pre and postnatal regular care, for mother and child. Professionals who provide direct care will maintain their usual attention.
16404901|NCT03944616|Active Comparator|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
16404902|NCT03944616|Experimental|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
16404903|NCT03944577|Experimental|Treatment Arm|Patients who will receive the study drug.
16404904|NCT03944564|Active Comparator|Condition 1: sitting|Four hours of sitting condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
16404905|NCT03944564|Active Comparator|Condition 2: static standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
16404906|NCT03944564|Active Comparator|Condition 3: dynamic standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
16404907|NCT03944551|Experimental|Bubble CPAP|
16404908|NCT03944551|Other|Standard Therapy|
16404909|NCT03944538|Experimental|Lifestyle Physical Activity|"The primary content of the website will be delivered through interactive video courses. The courses will be released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.
~The website Tracker feature will allow for tracking of daily step counts as well as setting goals and monitoring progress.
~The one-on-one video chats will be conducted face to face through Zoom and will be semi-scripted. The chats will consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral changes based on social cognitive theory and current website content. The chats will occur at the same frequency as the video course release. For the second 6 months of the study, participants will be asked to maintain their usual activities."
16404910|NCT03944538|Active Comparator|General Wellness|The general wellness condition will focus on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the National Multiple Sclerosis Society. The delivery of the Internet materials and chat sessions will occur on the same schedule and frequency as the intervention condition, and will have a comparable time commitment. This condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. For the second 6 months of the study, participants will be asked to maintain their usual activities.
16404911|NCT03944525|Active Comparator|Intervention|Intervention consists of HFA using standard equipment at the department. A gas flow of 60L/min and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the pati ent or indication for intubation.
16404912|NCT03944525|Active Comparator|Control|Control consists of non-invasive CPAP ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine. A positive airway pressure of 5cm H2O and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.
16404913|NCT03944512|Experimental|Pravastatin|20 mg pravastatin daily
16404914|NCT03944512|Placebo Comparator|Placebo|Identical appearing daily placebo
16404915|NCT03944499|Experimental|FS-1502|"Phase Ia:
~Patients enrolled on the 1.2 and 2.0 regimens: FS-1502 monotherapy every 4 weeks with intravenous drip, 28 days as a cycle; Patients enrolled on the 3.0 regimens: starting from the 1.0mg/kg dose group, FS-1502 monotherapy every 3 weeks with intravenous drip, 21 days as a cycle;
~Phase Ib:
~FS-1502 monotherapy, the dose and frequency of administration for Stage Ib will be obtained according to Phase Ia (RP2D). All patients will continue treatment until no clinical benefit occurs, or intolerable toxicity occurs, or death occurs, or the investigator decides, or patients voluntarily withdraw from the study.
~Study end is defined as the last patient's treatment ended or 2 years after the last patient's treatment began(depending on which happens earlier)."
16404916|NCT03944486|Other|On-Track|One arm feasibility study
16404917|NCT03944473|Active Comparator|neostigmine|Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers [8]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
16404944|NCT03944343|Experimental|Test product C|Specific designed cereals C and yogurt
16404918|NCT03944473|Experimental|sugammadex|Sugammadex is a modified gamma-cyclodextrin, the first of a new class of drugs called selective relaxant binding agents, with an unusually high affinity for rocuronium. This medication offers an alternate mechanism of action to antagonize the effects of steroidal neuromuscular blockade agents.
16404919|NCT03944460|Active Comparator|Contraloid 4 mg|4 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404920|NCT03944460|Active Comparator|Contraloid 12 mg|12 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404921|NCT03944460|Active Comparator|Contraloid 36 mg|36 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404922|NCT03944460|Active Comparator|Contraloid 108 mg|108 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404923|NCT03944460|Active Comparator|Contraloid 320 mg|320 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404924|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 4 mg|4 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404925|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 12 mg|12 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404926|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 36 mg|36 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404927|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 108 mg|108 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404928|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 320 mg|320 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
16404929|NCT03944447|Experimental|Cannabis users|"Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is cannabis-naïve, defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution."
16404930|NCT03944447|Experimental|Cancer prevention|Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance.
16404931|NCT03944447|Experimental|Life-Threatening Conditions|"Opioids are a class of drugs naturally found in the opium poppy plant. Opioids are often used as medicines because they contain chemicals that relax the body and can relieve pain. Prescription opioids are used mostly to treat moderate to severe pain. Opioids can also make people feel very relaxed and high - which is why they are sometimes used for non-medical reasons. This can be dangerous because opioids can be highly addictive, and overdoses and death are common.
~From 1999 to 2017, more than 700,000 people have died from a drug overdose. Around 68% of the more than 70,200 drug overdose deaths in 2017 involved an opioid.
~In 2017, the number of overdose deaths involving opioids was 6 times higher than in 1999.
~On average, 130 Americans die every day from an opioid overdose.
~This study will focus on examining outcomes of patients that have been treated with cannabis as a replacement or alternative to life-threatening opioids or other prescription drugs."
16404932|NCT03944447|Experimental|COVID-19 / SARS-CoV-2|Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted through respiratory droplets, with potential for aerosol and contact spread. It uses receptor-mediated entry into the human host via angiotensin-converting enzyme II (ACE2) that is expressed in lung tissue, as well as oral and nasal mucosa. Modulation of ACE2 levels in these gateway tissues may prove a plausible strategy for decreasing disease susceptibility. Cannabis sativa, especially one high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been proposed to modulate gene expression and inflammation and possess anti-cancer and anti-inflammatory properties. Covid-19 infection rates in cannabis users will be compared to rates in the general population. Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population.
16404933|NCT03944434|Experimental|single arm|"patients will receive anastrozole tablets (1 mg once daily) or letrozole tablets (2.5 mg once daily) + ribociclib tablets (600 mg day 1 to 21 in a 28 day cycle). Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, physician's decision, patient's refusal/consent withdrawal, or lost to follow-up.
~A LHRH agonist (triptorelin 3,75 mg or leuprolide 3,75 mg or goserelin 3,6 mg, as injectable intramuscular (i.m.) or subcutaneous (s.c.) implant every 28 days) will be used in men."
16404934|NCT03944421|Experimental|Red and Processed Meat|240 grams (raw weight) of red and processed meat every day for 2 weeks
16404935|NCT03944421|Experimental|Quorn|240 grams (uncooked weight) of Quorn every day for 2 weeks
16404936|NCT03944408|Experimental|A metal bare stent with 125I seeds|125I seeds fixed on the metal bare stent, then stent implantation
16404937|NCT03944408|Other|A metal bare stent|A metal bare stent implantation
16404938|NCT03944395|Other|Assisted Partner notification services|Voluntary assisted partner notification (VAPN) services will be offered at facilities according to a stepped wedge design. Once VAPN services are activated at a facility, HIV positive individuals will be offered four options (3 voluntary assisted partner notification options and 1 standard of care option) for inviting their contacts, which they can choose to accept or decline.
16404939|NCT03944369|Other|Observational Control|The observational control arm is an observational control group.
16404940|NCT03944369|Other|KB109|KB109 is a novel glycan.
16404941|NCT03944343|Sham Comparator|Reference product|Commercial cereals and a commercial yogurt
16404942|NCT03944343|Experimental|Test product A|Specific designed cereals A and yogurt
16404946|NCT03944330|Active Comparator|a treatment group|All study participants were provided with a standard hospital diet that provided B25-30 kcal/kg/day
16404947|NCT03944330|No Intervention|control group|All study participants were not intervened with diet
16404948|NCT03944317|Active Comparator|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
16404949|NCT03944317|Active Comparator|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
16404950|NCT03944304|Experimental|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
16404951|NCT03944291|Active Comparator|Unilateral PNB|Unilateral Pudendal Nerve Block
16404952|NCT03944291|Active Comparator|Bilateral PNB|Bilateral Pudendal Nerve Block
16404953|NCT03944278|Experimental|Thulium Device|1927 Laser Treatment
16404954|NCT03944265|Experimental|Supportive care (treatment decision counseling session)|Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
16404955|NCT03944252|Experimental|A (avelumab)|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
16404956|NCT03944252|Experimental|B (cetuximab + avelumab)|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
16404957|NCT03944239|Experimental|retinal pigment epitheliums transplantation|Transplant clinical-grade hESC derived retinal pigment epitheliums into subretinal of patients with retinitis pigmentosa.The dosage is 150000.
16404958|NCT03944226|Experimental|Beetroot|16 patients confirmed with a diagnosis of invasive ductal carcinoma who will undergo wide local excision surgery or mastectomy. All patients in the single arm will undergo a 5 day intervention drinking concentrated beetroot juice and 2 magnetic resonance imaging scan sessions pre and post intervention. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
16404959|NCT03944213||MDD patients|
16404960|NCT03944213||Healthy controls|
16404961|NCT03944200|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
16404962|NCT03944200|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
16404963|NCT03944174||Single Trans-sacral Screw|
16404964|NCT03944174||Two Iliosacral Screws|
16404965|NCT03944161|Experimental|Intervention group|Participants in the intervention group will receive an oral nutrition supplement bottle (200/220 ml) with >20 % of protein and 1.5 Kcal/ml without fibre twice a day during 12 weeks and nutritional advice.
16404966|NCT03944161|Active Comparator|Control group|Participants in the control group will receive nutrition advice
16404967|NCT03944135|Experimental|Experimental group|The sample consisted of 40 people: 20 in an experimental group. There were 5 men and 15 women.
16404968|NCT03944135|Active Comparator|Control group|The sample consisted of 40 people: 20 in a control group. There were 5 men and 15 women.
16404969|NCT03944122|Experimental|continuous ultrasound|continuous ultrasound were applied to the patients
16404970|NCT03944122|Experimental|pulsed ultrasound|pulsed ultrasound were applied to the patients
16404971|NCT03944122|Experimental|placebo|placebo (sham) ultrasound were applied to the patients
16404972|NCT03944109|Experimental|SHR-1209|Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
16404973|NCT03944109|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
16404974|NCT03944096|Experimental|FMT+MTX|"FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient.
~Drug: Methotrexate (MTX) Weekly methotrexate"
16404975|NCT03944096|Placebo Comparator|autologous FMT+MTX|"autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself.
~Drug: Methotrexate (MTX) Weekly methotrexate"
16404976|NCT03944083||ADHD with and without DMDD|ADHD with DMDD versus ADHD without DMDD. Observational study at referral and after 6 and 12 months.
16404977|NCT03944070|Active Comparator|Intensive Treatment|The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
16404978|NCT03944070|Active Comparator|Standard Treatment|The participants will continue their preoperative treat and extend protocol .
16404979|NCT03944057|Experimental|ATG-010 + Dexamethasone|Open-label ATG-010 80mg plus Dexamethasone 20 mg
16404980|NCT03944044|Other|Subcutaneous route first|The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
16404981|NCT03944044|Other|Intravenous route first|The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.
16404982|NCT03944031|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.
16404985|NCT03944005|Active Comparator|Study Group|Spinal Anesthesia + ACB continuous catheter+ iPACK + Sham LIA
16404986|NCT03944005|Sham Comparator|Comparator Group|Spinal Anesthesia + LIA + Sham Blocks
16404987|NCT03943992|Experimental|YYD601 40mg|Esomeprazole magnesium Dihydrate.
16404988|NCT03943992|Active Comparator|Nexium 40mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
16404989|NCT03943979|Sham Comparator|Active Control group|This group will receive CT and sham tDCS each day, for four days.
16404990|NCT03943979|Active Comparator|Active group|This group will receive both CT and tDCS, each day, for four days.
16404991|NCT03943966|Experimental|Myocardial Infarction|
16404992|NCT03943966|Active Comparator|Stable coronary disease with intracoronary stent insertion|
16404993|NCT03943966|Active Comparator|Deep vein thrombosis and Pulmonary embolus|
16404994|NCT03943966|Active Comparator|Surgical and Transcatheter Aortic valve replacement|
16404995|NCT03943966|Active Comparator|Transient ischaemic attack and stroke|
16404996|NCT03943953|Experimental|Facial Palsy - Trial of ITG|In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
16404997|NCT03943953|Experimental|Friends or relatives - Trial of ITG|In this arm of the trial friends or relatives of individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
16404998|NCT03943940|Experimental|BM-MNC and UC-MSC|30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.
16404999|NCT03943940|Other|Stand medicines|30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines.
16405000|NCT03943927|Experimental|Pharmacogenetic-guided metoprolol management|
16405001|NCT03943914|Experimental|"An early NIV strategy associated with HFNC-O2"|
16405002|NCT03943914|Active Comparator|"A late NIV strategy associated with COT"|
16405003|NCT03943901|Experimental|Split Dose R-CHOP|"Each cycle is 28 days and consists of one A treatment on Day 1 and one B treatment on Day 15 for 6 cycles
~Day 1 (A part of cycle)
~Rituximab 375 mg/m2 IV (or biosimilars Ruxience or Truxima)
~Cyclophosphamide 375 mg/m2 IV
~Doxorubicin 25 mg/m2 IV
~Vincristine 1 mg IV
~Prednisone 50 mg (Days 1-5) PO
~Pegfilgrastim 6 mg on Day 2 (24 hours after completion of chemotherapy) or filgrastim daily as indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor.
~Day 15 (B part of cycle)
~Cyclophosphamide 375 mg/m2 IV
~Doxorubicin 25 mg/m2 IV
~Vincristine 1 mg IV
~Prednisone 50 mg (Days 15-19) PO
~Pegfilgrastim 6 mg on Day 16 (24 hours after completion of chemotherapy) or filgrastim daily as indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor."
16405004|NCT03943888|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex 15 minutes after rocuronium administration
16405005|NCT03943888|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex 15 minutes after rocuronium administration
16405006|NCT03943888|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex 15 minutes after rocuronium administration
16405007|NCT03943888|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) 15 minutes after rocuronium administration
16405012|NCT03943862|Experimental|Intervention (2Share) + treatment as usual|"Study participants randomized to the experimental group receive the intervention (2Share) while maintaining their current treatment (treatment as usual). 2Share is a peer-led group intervention containing three two-hour sessions within two weeks plus an additional booster session four weeks later.
~Fidelity to manual is rated in each session by study staff."
16405013|NCT03943862|No Intervention|Treatment as usual|Participants randomized to the control group do not receive the group program but maintain their current treatment (treatment as usual).
16405016|NCT03943836|Experimental|Music Group|
16405017|NCT03943836|No Intervention|No Music group|
16405018|NCT03943823|Active Comparator|Estrogen vaginal cream|
16405019|NCT03943823|Active Comparator|Trimo-San vaginal gel|
16405020|NCT03943797|Experimental|Cultivated oral mucosal epithelial cell transplantation|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
16405021|NCT03943784||Endoscopic Variceal Ligation|From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
16405022|NCT03943784||Propranolol Group|Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.
16405023|NCT03943771|Experimental|Virtual modelization group|Patients having their kidney modelized in three dimensions on a software
16405024|NCT03943771|Experimental|Printed modelization group|Patients having their kidney modelized and printed in three dimensions
16405025|NCT03943771|Sham Comparator|Control group|No kidney model
16405026|NCT03943758|Experimental|prepackaged Low-residue diet group|The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
16405027|NCT03943758|Active Comparator|self-prepared Low-residue group|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
16405028|NCT03943732|No Intervention|control|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays
16405029|NCT03943732|Experimental|Intervention|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
16405030|NCT03943706||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
16405031|NCT03943706||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
16405034|NCT03943680|Experimental|PRGF|Post-extraction socket grafted with PRGF-Endoret
16405035|NCT03943680|Active Comparator|ABB|Post-extraction socket grafted with anorganic bovine bone (ABB)
16405036|NCT03943667|Experimental|GEMPAX|Gemcitabine + Paclitaxel until progression
16405037|NCT03943667|Active Comparator|Control|Gemcitabine alone until progression
16405038|NCT03943654||Children living within study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live within the mobile pharmacy delivery area will receive illness assessments and treatment recommendations over the phone. Immediately following calls a nurse will conduct household visits to complete in-person assessments of the children. Illness progression will be tracked with a 8-12 day follow up call. The phone and in-person assessments will be compared to evaluate safety and accuracy of the healthline.
16405039|NCT03943654||Children living outside study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live outside the delivery area will receive illness assessments and treatment recommendations over the phone. Illness progression will be tracked with a 8-12 day follow up call.
16405040|NCT03943654||Children who are identified as having danger signs|Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
16405041|NCT03943641||Population-based|Population-based cohort of participants registered with a SAIL-contributing practice.
16405042|NCT03943628|Experimental|Familias Unidas|Consists of eight parent group sessions and four family sessions with the adolescent.
16405043|NCT03943628|Other|Community Practice|Consists of community practice.
16405044|NCT03943602|Experimental|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
16405045|NCT03943589|Experimental|Imlifidase|"One (1) dose of imlifidase, 0.25 mg/kg, will be administered IV over 30 minutes, Day 1.
~IVIg, 0.4 g/kg, will be administered for 5 consecutive Days, starting on Day 3 at least 48 h after imlifidase administration."
16405046|NCT03943576|Experimental|GXCPC1|GXCPC1 contains 6.7×10^6 or 4×10^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL
16405047|NCT03943576|Active Comparator|hyaluronic acid|Hya Joint Plus synovial fluid supplement 3mL
16405048|NCT03943563|Other|single cohort|"There is only one cohort where each patient experiment the classic sequences as the standard of care and the DIXON sequences for the study."
16405051|NCT03943537|Experimental|Intranasal Insulin (40 IU)|40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.
16405052|NCT03943524|No Intervention|DrApp Without Interax-AI|There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
16405053|NCT03943524|Experimental|DrApp With Interax-AI|"There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (Interax-AI).
~Intervention: Device: Medication Interaction System of Dr App (Interax-AI)"
16405057|NCT03943485|Active Comparator|Uterien Manipulator Arm|Patients in this group will receive a uterine manipulator during abdominal hysterectomy.
16405058|NCT03943485|No Intervention|Control|Patients in this group will receive standard abdominal hysterectomy without adoption of a uterine manipulator.
16405059|NCT03943472|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA CAR-T cells to patients with multiple myeloma
16405060|NCT03943472|Experimental|anti-BCMA CAR-T+ Immune inhibitors|Administration of anti-BCMA CAR-T cells + Immune inhibitors to patients with multiple myeloma
16405061|NCT03943459|No Intervention|Control|20 Patients on placebo
16405064|NCT03943446|Experimental|TAK-018 0.30 g Low Dose|TAK-018 3*0.10 gram (g), tablets, orally, twice daily (BID) for up to 26 weeks.
16405065|NCT03943446|Experimental|TAK-018 1.5 g High Dose|TAK-018 3*0.50 g, tablets, orally, BID for up to 26 weeks.
16405066|NCT03943446|Placebo Comparator|Placebo|TAK-018 placebo-matching 3*0 g tablets, orally, BID for up to 26 weeks.
16405067|NCT03943433|Active Comparator|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration at specific time points.
16405068|NCT03943433|Experimental|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration at specific time points.
16405069|NCT03943420||Experimental Group|Therapy A : Basic treatment + Qianyang Yuyin Granules
16405070|NCT03943420||Negative Control Group|Therapy B : Basic treatment
16405071|NCT03943420||Positive Control Group|Therapy C : Basic treatment + Donepezil
16405072|NCT03943407|Experimental|Zyclara/vehicle|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.
16405073|NCT03943407|Experimental|Zyclara/Doxepin|All subjects will be treated with the topical antihistamine cream (Prudoxin, containing 5% doxepin hydrochloride, Healthpoint, San Antonio, TX) or a placebo cream. After removal, subjects will be treated with Zyclara cream
16405074|NCT03943407|Experimental|Zyclara/Histamine/Cowage|All subjects will be treated with Zyclara cream, vehicle cream, histamine and cowhage
16405075|NCT03943407|Experimental|Zyclara/L-menthol/trans-cinnamaldehyde|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle. After removal, subjects will be treated with L/menthol and trans-cinnamaldehyde
16405076|NCT03943394||Denovo MDS/ AML|"Patients with de-novo myeloid neoplasm either myelodysplastic syndrome and/ or acute myeloid leukemia which are diagnosed by complete blood count , blood film, bone marrow aspirate, bone marrow biopsy , immunophenotyping and bone marrow biopsy with these inclusion criteria • Myelodysplastic syndromes: the diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy : blast count must be < 20%;
~• Acute myeloid leukemia with multilineage dysplasia: the diagnosis of AML-TLD must be confirmed by a bone marrow aspirate and/or biopsy NOTE: there must be evidence of >= 20% blasts on the review of the bone marrow aspirate and/or biopsy;"
16405077|NCT03943394||therapy related MDS/ AML|PCM1-JAK2 fusion gene detection in patients with therapy related Myelodysplastic syndrome / Acute myeloid leukemia patients
16405078|NCT03943368|Experimental|Experimental: Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
16405079|NCT03943368|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
16405080|NCT03943355||Nonoperative management protocol with angioembolization|The nonoperative management (NOM) protocol with angioembolization (AE) presents a trend in dealing with trauma patients with blunt splenic injury (BSI). This study was designed to explore the adverse events and associated risk factors before and after protocol-based NOM of BSI over a 12-year period.
16405081|NCT03943342|Experimental|Treatment (venetoclax, ibrutinib)|"OBSERVATION COHORT: Patients who are taking ibrutinib enter observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort.
~INTERVENTION COHORT: Patients receive venetoclax PO daily and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve MRD negative CR after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity."
16405082|NCT03943329|Active Comparator|Standard of Care|
16405083|NCT03943329|Experimental|Distal Targeting Treatment|
16405086|NCT03943290|Experimental|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
16405087|NCT03943290|Experimental|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
16405088|NCT03943290|Experimental|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
16405089|NCT03943290|Experimental|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
16405090|NCT03943290|Experimental|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
16405091|NCT03943290|Experimental|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
16405092|NCT03943290|Experimental|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
16405093|NCT03943290|Experimental|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
16405094|NCT03943290|Experimental|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
16405124|NCT03943082|Active Comparator|Cohort A : Usual Care (FRP Only)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent.
16405125|NCT03943082|Experimental|Cohort A: Usual Care + Intervention (FRP + Follow-up)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent and a follow-up phone call on day 3 after iMPACT consent.
16441084|NCT03696186|Experimental|Atypical type-2|Experimental treatment
16405095|NCT03943277||patient with infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:
~A group with an inflammatory syndrome and infection; infection being defined as:
~Viral infection confirmed by nasopharynx swab for: influenza, RSV, parainfluenza, rhinovirusses, coronavirusses.
~Bacterial infection confirmed with positive blood culture, positive articular punction, positive expectorations, pneumonia on chest radiograph, or infection documented by abdominal imagery (CT or echo), a positive urine culture with a confirmed pyelonephritis with a renal echography or a DMSA scintigraphy or specific clinical symptoms for pyelonephritis and positive hemoculture. A positive urine culture alone is not considered as urine infection because of the high prevalence of asymptomatic bacteriuria in geriatric patients."
16405096|NCT03943277||patient without infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:
~=> B) A group with inflammatory syndrome and inflammatory diseases without infection: defined as:
~Confirmed pulmonary embolism (PE) by CT or ventilation-perfusion scintigraphy
~Microcrystalline arthritis diagnosed by articular punction
~Crush syndrome or rhabdomyolyses defined by history of a fall and raised creatine kinase in blood sample."
16405097|NCT03943264|Experimental|0.3 mg/kg XPro1595|0.3 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
16405098|NCT03943264|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
16405099|NCT03943264|Experimental|3.0 mg/kg XPro1595|3.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
16405100|NCT03943251|Experimental|HEC113995PA•H2O tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
16405101|NCT03943251|Placebo Comparator|placebo tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
16405102|NCT03943238|Experimental|Combined kidney/stem cell transplants and recipient's Tregs|Preparatory regimen including TLI, ATG after kidney transplantation followed by infusion of donor CD34+, T cell and recipient Tregs
16405103|NCT03943212|Experimental|Blood Flow Rate Reduction|Participants will have their hemodialysis blood flow rate reduced on their regular schedule.
16405104|NCT03943212|Sham Comparator|Control|Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.
16405105|NCT03943199|Active Comparator|Metamizole sodium|1 gram intravenous, will be diluted in 0.9% physiological solution of 100 ml, applied for 30 minutes
16405106|NCT03943199|Active Comparator|Ketorolac|60 milligrams intravenously, it will be added to 20 ml with 0.9% physiological solution, it will be applied for 5 minutes
16405107|NCT03943199|Active Comparator|Lysine Clonixinate|100 milligram intravenously, diluted in 5% glucose solution of 100 ml, applied for 30 minutes
16405108|NCT03943199|Placebo Comparator|Placebo|20 milliliters of 0.9% physiological solution, will be applied for 5 minutes.
16405109|NCT03943186||Ectoin Lozenges Honey Lemon|application of 1 Lozenge every three hours or as often as required, not more than 10 lozenges per day
16405110|NCT03943186||Hyaluronic acid/Icelandic moss Lozenges|application as often as required, not more than 6 lozenges per day
16405111|NCT03943173|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After treatment, patients either undergo surgery then receive standard chemotherapy for up to 4 cycles or receive standard chemotherapy within 14 days for up to 4 cycles then undergo surgery in the absence of disease progression or unacceptable toxicity at the discretion of the treating physician.
16405112|NCT03943147|Experimental|Dose 1|Specified Dose on Specified Days
16405113|NCT03943147|Experimental|Dose 2|Specified Dose on Specified Days
16405114|NCT03943147|Placebo Comparator|Placebo|Specified Dose on Specified Days
16405115|NCT03943134||Avive® Soft Tissue Membrane|Subjects with utilization of Avive® Soft Tissue Membrane on an impacted but intact nerve during a surgical procedure for one of the following targeted acute upper extremity traumas (selected injuries): Spaghetti Wrist, Distal Radius Fracture, Medial Epicondyle Fracture, Flexor Tenolysis at Wrist, and Ballistic Injuries in the Forearm and/or Hand.
16405116|NCT03943134||Standard Surgical Procedures - Control Arm|Subjects who have undergone surgical procedures for the same selected injuries, but without placement of a surgical implant on an impacted but intact nerve.
16405117|NCT03943121|Experimental|Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. Steroid-eluting stent were implanted in one side of ethmoid sinus and frontal sinus randomly.
16405118|NCT03943121|Sham Comparator|Without Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. The side without the stent is defined as the control side.
16405119|NCT03943108||Obese teenagers within the PAIDOS clinic|Obese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
16405120|NCT03943108||Healthy children|Healthy children living in Mexico City, Mexico.
16405121|NCT03943108||Children with Type 2 Diabetes|Chjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
16405122|NCT03943095|Experimental|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million [ppm] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
16405123|NCT03943095|Active Comparator|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
16410806|NCT03903549|Experimental|Brain uptake and kinetics in healthy volunteers|
16405126|NCT03943082|Experimental|Cohort B: Non-Randomized|Patients or parents/legal guardians of patients currently enrolled in a cancer therapeutic clinical trial (TCT) or who recently completed a TCT within 90 days, and were offered, received, or are receiving benefits from the Lazarex FRP will be asked to complete assessments for exploratory endpoints.
16405127|NCT03943082|Active Comparator|Cohort C: Control Cohort|Patients with a cancer diagnosis, irrespective of TCT participation and access to FRP from the Lazarex Foundation, will be approached for the longitudinal follow-up portion of the study.
16405128|NCT03943069|Experimental|Patient with PSP|Patient who will be admitted with primary spontaneous pneumothorax.
16405129|NCT03943056|Experimental|Single Ascending Dose (SAD): Cohort 1A|Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
16405130|NCT03943056|Experimental|(SAD): Cohort 2A|Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
16405131|NCT03943056|Experimental|(SAD): Cohort 3A|Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
16405132|NCT03943056|Experimental|(SAD): Cohort 4A|Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
16405133|NCT03943056|Experimental|(SAD): Cohort 5A|Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
16405134|NCT03943056|Experimental|Multiple Ascending Dose (MAD): Cohort 1B|Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
16405135|NCT03943056|Experimental|(MAD): Cohort 2B|Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
16405136|NCT03943056|Experimental|(MAD): Cohort 3B|Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
16405137|NCT03943043|Experimental|gemcitabine oxaliplatin nab-paclitaxel|combination at different dose of gemcitabine, oxaliplatin and nab-paclitaxel
16405138|NCT03943030|Experimental|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
16405139|NCT03943030|No Intervention|Group control|The group will not receive pulmonary rehabilitation intervention. Patients will be guided and maintain their daily and routine lives normally during the evaluation process. However, a baseline evaluation will be performed, which will be repeated after 9 weeks: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes commonly used in the assistance to assess PR will also be measured.
16405140|NCT03943004|Experimental|DFP-14927|DFP-14927: weekly IV infusion, 28 day treatment cycle
16405141|NCT03942991|Active Comparator|2% Mepecaine-L|infiltration injection of 2% Mepivacaine
16405142|NCT03942991|Experimental|4% Artpharmadent|infiltration injection of 4% Articaine
16405143|NCT03942978|Active Comparator|Longitudinal Equity Action Plan (LEAP)|Heart failure patients admitted with a principal diagnosis of heart failure to general medicine service and admitted to a general medicine pod that is randomized to the intervention arm.
16405144|NCT03942978|No Intervention|Standard Care|Heart Failure patients admitted to a general medicine pod at our institution, which is not randomized to intervention arm. Patients will be treated for their heart failure as per standard of care while admitted to the hospital.
16405145|NCT03942952||CNS demyelinating diagnosis|"Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody.
~3T and 7T MRI
~Neuropsychological testing
~Optical Coherence Tomography
~Questionnaires: Quality of Life and Behavior scales
~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year later"
16405146|NCT03942952||Healthy Control|"3T and 7T MRI
~Neuropsychological testing
~Optical Coherence Tomography
~Questionnaires: Quality of Life and Behavior scales
~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year later"
16405147|NCT03942939|Experimental|A - TKA with short tourniquet time|50 arms: subjects will receive a tourniquet with a short tourniquet time during TKA surgery. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
16405148|NCT03942939|Active Comparator|B - TKA with tourniquet|50 arms: subjects will receive a tourniquet during TKA surgery.
16405149|NCT03942926|Experimental|Sirolimus|Patients in sirolimus group will receive sirolimus for 6 months.
16405150|NCT03942913||dual therapy|including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC.
16405151|NCT03942913||triple therapy|"including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC.
~In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran."
16405152|NCT03942900||Cohort LAND|Patients enrolled in OPTIMANAL clinical trial
16405153|NCT03942887|Active Comparator|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg.
16405154|NCT03942887|Active Comparator|Rituximab plus low-dose cyclophosphamide|5.1.2. Cyclophosphamide Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
16405155|NCT03942874|Experimental|Treatment|Participants will complete baseline sessions and then complete treatment right away.
16405156|NCT03942874|Experimental|Waitlist Control|Participants will complete a baseline session and then wait for 10 weeks before starting treatment.
16405157|NCT03942861||Severe Ulcerative Colitis|Consecutive patients admitted as in-patients to the Department of Gastroenterology at four University Hospitals in Denmark, with acute severe UC defined as an affirmed diagnosis of UC according to well established criteria, combined with a Mayo score of 8 or more (i.e. severe disease activity) and the need for intravenous corticosteroid treatment will be screened for participation in the study after informed consent.
16405158|NCT03942848|Experimental|intrathecal Ziconotide followed by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
16405159|NCT03942848|Placebo Comparator|intrathecal Ziconotide preceded by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
16405160|NCT03942835|Experimental|Healthy participants aged from 6 to 90 year-old|
16405161|NCT03942835|Experimental|patients with ADHD with no treatment|patients with ADHD aged from 6 to 90 year-old with no treatment
16405162|NCT03942835|Experimental|patients with ADHD with treatment|patients with ADHD aged from 6 to 90 year-old with psychostimulant treatment (Methylphenidate)
16405163|NCT03942822|Experimental|Chia supplemented group|8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
16405164|NCT03942809|Experimental|Effectiveness|Evaluate the Effectiveness in insertion success, insertion times, influence of respiratory, cardiac and cerebral circulation
16405165|NCT03942796|Active Comparator|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin
16405166|NCT03942796|Active Comparator|pulsed radiofrequency ablation of the dorsal root ganglion und|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion
16405167|NCT03942783|Active Comparator|Control Group|"The control group will receive a written work self-help information pack plus usual care. The pack includes published arthritis patient information booklets about work; a decision-tree flowchart; information about the UK Equality Act. The self-help information pack is mailed to the participants by the CTU following randomisation.
~Usual care consists of: prescribed medication; attending Rheumatology clinics; referral to rehabilitation, as and when deemed necessary from the Rheumatology clinic, but not including work advice. Any rehabilitation required will be provided as normal, e.g. provision of exercise, self-management education, activities of daily living advice, psychosocial support."
16405168|NCT03942783|Experimental|WORKWELL Group|The same as the Control Group (i.e. self-help information pack, plus usual care) PLUS the WORKWELL intervention. This consists of, on average, 4.5 hours contact, including: a structured work assessment; identification of work-related barriers and priority problems; collaborative treatment planning with the participant; a range of self-management, work advice and job modifications appropriate to the individual participant's problems; goal setting and action planning; and a 30 minute telephone review to identify progress with goals at the end of treatment.
16405169|NCT03942770|Active Comparator|Active Comparator: Group A (Intensive incentives)|"Group A will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will also have the opportunity to earn more incentives for providing negative results. For the first 3 weeks, these additional incentives will scale based on the number of consecutive days of sustained negative samples. For the remaining weeks incentives will be based on a randomized prize drawing."
16405170|NCT03942770|Active Comparator|Active Comparator: Group B (Prize-based incentives)|"Group B will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will only have the opportunity to earn more incentives based on a randomized prize drawing if they submit a negative sample."
16405171|NCT03942770|Sham Comparator|Sham Comparator: Group C (Intensive incentives)|Group C serves as a direct control group to Group A and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
16405172|NCT03942770|Sham Comparator|Sham Comparator: Group D (Price-based incentives)|Group D serves as a direct control group to Group B and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
16405173|NCT03942770|No Intervention|No Intervention: Group E (no incentives)|Group E will have no monitoring intervention, they will only complete assessment sessions.
16405174|NCT03942757||observation before educational program|100 preterm infant medical records will be studied in a first part of this observational study
16405175|NCT03942757||Observation after educational program|An educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
16405176|NCT03942744|No Intervention|high-flux hemodialysis|high-flux hemodialysis cut-off membrane above 50
16405177|NCT03942744|Active Comparator|on-line hemodiafiltration|postdilutional on-line hemodiafiltration with a convective transport above 21 liters
16405178|NCT03942731||Experimental|83 adult outpatients at CHR Metz-Thionville with penicillin allergy label
16405179|NCT03942718|No Intervention|Control group|Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.
16405180|NCT03942718|Experimental|Aerobic exercise group|Participants will obtain aerobic exercise only.
16405181|NCT03942718|Experimental|Anaerobic exercise group|Participants will obtain aerobic and anaerobic exercise respectively
16405182|NCT03942705||Kenyan Women|Women living in western Kenya will be asked to complete a self collected vaginal sample for HPV DNA screening and asked to undergo a second screening by VIA. As per Kenyan standard of care, vaccination against HPV will be offered to children/grandchildren (boys and girls) of women, and to the women themselves if age 26 or younger. The second vaccine dose (for children ages 9 through 14) and third doses (for children and adult women ages 15 through 26) will be administered at subsequent visits. There will be no requirement for HPV vaccination (of children or mothers up to 26 years of age) for participation in the study. Results of the screening will be returned to participants and they will be referred to receive standard care as applicable.
16405183|NCT03942692||Children with anaphylactic reaction|Children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in Paediatric Emergency Department of Femme-Mère-Enfant Hospital in Lyon in France.
16405184|NCT03942679|Other|PRPinjection group|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 201
16405185|NCT03942679|Other|physiotherapy group|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks
16405186|NCT03942666|Experimental|Treatment A|Single administration of CHF 6532 Dose #1
16405187|NCT03942666|Experimental|Treatment B|Single administration of CHF 6532 Dose #2
16405188|NCT03942666|Experimental|Treatment C|Single administration of CHF 6532 Dose #3
16405189|NCT03942666|Experimental|Treatment D|Single administration of CHF 6532 Dose #4
16405190|NCT03942666|Placebo Comparator|Treatment E|Single administration of CHF 6532 Placebo
16405191|NCT03942666|Other|Treatment F|Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.
16405193|NCT03942640|Other|perineural injection group|"perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years
~Buffered glucose preparation :
~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.
~Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :
~Suprascapular nerve.."
16405194|NCT03942640|Other|deepprolotherapy group|Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
16405197|NCT03942614|Experimental|Nordic pole walking|walking with a pair of poles customized to an individual's height and stride length
16405198|NCT03942614|No Intervention|Control|usual daily routine and activities of daily living
16405199|NCT03942601|Active Comparator|Group 1 - temsirolimus injection|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
16405200|NCT03942601|Active Comparator|Group 2 - temsirolimus and dexamethasone injection|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
16405201|NCT03942588|Experimental|High-intensity interval training|Twice-weekly supervised high-intensity interval treadmill training in a laboratory setting for 10 weeks.
16405202|NCT03942588|No Intervention|Control|Usual activities for 10 weeks
16405203|NCT03942575|No Intervention|No negative pressure wound therapy|Historical cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage and where negative wound pressure therapy has been omitted
16405204|NCT03942575|Experimental|Negative pressure wound therapy|Prospective cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage with negative wound pressure therapy
16405205|NCT03942549||MUS Cohort|This cohort will undergo midurethral sling placement.
16405206|NCT03942536||MNH Emergency Cohort|Participants will be either patients who have experienced a critical pregnancy-related, obstetric, or neonatal health emergency.
16405207|NCT03942536||Birth Planning cohort|Pregnant women who complete an initial Birth Plan through the HN program within Mfangano Island East and South Sub-locations.
16405208|NCT03942523|Experimental|School Children|School children will be administered with behavioral change communication sessions as an intervention
16405209|NCT03942510|Experimental|High intensity eccentric training|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
16405210|NCT03942510|Experimental|High intensity eccentric training with blood flow restriction|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week.
16405211|NCT03942510|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
16405212|NCT03942510|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week.
16405213|NCT03942484|Experimental|Treatment Group|Treatment with the investigational device - rPMS
16405214|NCT03942471|Other|Intervention Mindfulness Based Stress Reduction|Six Modules each delivering an important principle of Mindfulness Based Stress Reduction
16405215|NCT03942471|No Intervention|Control Group|Wait Group - received no mindfulness teaching
16405216|NCT03942458|Experimental|Vicagrel|Vicagrel 24mg loading followed by 6mg/day for 6 days
16405217|NCT03942458|Active Comparator|Clopidogrel|Clopidogrel 300mg loading followed by 75mg/day for 6 days
16405218|NCT03942445|Experimental|Control patients|
16405219|NCT03942445|Experimental|Chronic ischemia|
16405220|NCT03942445|Experimental|Acute ischemia|
16405221|NCT03942432|Experimental|Patients with dysmetabolic iron overload syndrome|
16410807|NCT03903549|Experimental|Dosimetry in healthy volunteers|
16405222|NCT03942419|Experimental|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
16405223|NCT03942419|Experimental|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
16405224|NCT03942419|Placebo Comparator|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
16405225|NCT03942406|Experimental|BPZE1 Intranasal Prime, BPZE1 Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
16405226|NCT03942406|Experimental|BPZE1 Intranasal Prime, Placebo Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
16405227|NCT03942406|Experimental|Boostrix IM Prime, BPZE1 Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
16405228|NCT03942406|Active Comparator|Boostrix IM Prime, Placebo Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
16405229|NCT03942380|Other|Cell-free tumor DNA|The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
16405230|NCT03942380|Other|Identifying recurrence|The aim is to identify recurrence through serial monitoring patients with blood samples.
16405231|NCT03942367|Experimental|Group A (Active Device Group)|Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient.
16405232|NCT03942367|Sham Comparator|Group B (Sham Device Group)|Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient.
16405233|NCT03942354|Experimental|Intervention arm|A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.
16405234|NCT03942354|Active Comparator|Standard therapy|72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.
16405235|NCT03942341||Adult subjects with Down syndrome and Alzheimer Disease|"Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS.
~All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity."
16405236|NCT03942328|Experimental|Treatment (EBRT, autologous dendritic cells, Prevnar)|Patients undergo standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8, and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
16405237|NCT03942315||Liver transplant in Hereditary Hemorrhagic Telangiectasia|Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
16405238|NCT03942289|Experimental|Healthy controls|
16405239|NCT03942289|Experimental|Parkinson disease|
16405240|NCT03942276|Placebo Comparator|Control|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
16405241|NCT03942276|Experimental|Alternative training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
16405242|NCT03942276|Experimental|Conventional training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training
16405243|NCT03942263||Newly Diagnosed and RR cHL Participants|Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
16405244|NCT03942263||Newly Diagnosed and RR sALCL Participants|Participants diagnosed with RR sALCL at the time of enrollment and RR sALCL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed sALCL, or RR sALCL at the time of enrolment, or RR sALCL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
16405245|NCT03942250|Experimental|Treated|Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks
16405246|NCT03942237|Experimental|single-injection QLB (quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
16405247|NCT03942237|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
16405369|NCT03941431|Experimental|Western medicine treatment group|Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks.
16405248|NCT03942224|Experimental|Arm I (DId)|"INDUCTION: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2 and on days 1 and 15 of cycles 3-8, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.
~MAINTENANCE: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
16405249|NCT03942224|Experimental|Arm II (DVd, DId)|"INDUCTION CYCLES 1-3: Patients receive dexamethasone IV and PO on days 1, 8, and 15, daratumumab IV on days 1, 8, and 15, and bortezomib subcutaneously (SC) on days 1, 4, 8, and 11. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
~INDUCTION CYCLES 4-8: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1 and 15, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.
~MAINTENANCE: Patients receive dexamethasone IV on day 1, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
16405252|NCT03942198|Experimental|Oral Chinese medicine|Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
16405253|NCT03942198|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
16405254|NCT03942185|Experimental|Psoriasis with Blood heat syndrome group|Participants in Psoriasis with Blood heat syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Clearing heat and Cooling blood, such as Cool blood detoxification Decoction I，Cool blood and activating blood prescription compound, Cool blood detoxification Decoction II, Cool blood activating blood Decoction, Tufu drink, Xiaoyin Decoction and etc., two times per day for 8 weeks.
16405255|NCT03942185|Experimental|Psoriasis with Blood stasis syndrome group|Participants in Psoriasis with Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Promoting blood circulation and Removing blood stasis, such as Huoxue Sanyu Xiaoyin Decoction, Cool blood detoxification Decoction III and etc., two times per day for 8 weeks.
16405256|NCT03942185|Experimental|Psoriasis with Non-Blood heat or Blood stasis syndrome group|Participants in Psoriasis with Non-Blood heat or Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of syndrome differentiation therapy two times per day for 8 weeks.
16405257|NCT03942185|No Intervention|Healthy control group|No Intervention.
16405258|NCT03942172|Experimental|SpotOn Balance|SpotOn Balance Glasses
16405259|NCT03942159||Donors|HLA-matched or haploidentical nursing relative donors
16405260|NCT03942159||Patients|recipients of allogeneic HSCT
16405261|NCT03942146|No Intervention|Control group|No information on smoking cessation
16405262|NCT03942146|Active Comparator|Written information, GynOp|"When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
16405263|NCT03942146|Active Comparator|Doctor informed|"The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation"
16405264|NCT03942146|Active Comparator|Written information, GynOp + doctor informed|A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
16405265|NCT03942133|Experimental|entrance placement of adductor canal catheter|
16405266|NCT03942133|Experimental|middle point placement of adductor canal catheter|
16405268|NCT03942107|Active Comparator|Group 1: RCT+post+core in 1 visit|the root canal treatment will be completed with 2Shape NiTi system as well as post and core application in the same visit prior to postoperative pain evaluation.
16405269|NCT03942107|Active Comparator|Group 2: after RCT, post and core in 2nd visit|after root canal treatment conducted with 2Shape NiTi system, the postoperative pain evaluation will be completed prior applying post and core for coronal restoration.
16405270|NCT03942094|Experimental|Nilotinib|
16405271|NCT03942081|Experimental|Ulcer Measurement and Photo Group|Diabetic patients with foot ulcers being seen in clinic.
16405272|NCT03942081|No Intervention|Healthy Control Group|Patients without foot ulcers being seen in the clinic.
16405273|NCT03942068|Experimental|albumin-bound paclitaxel+apatinib|albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po
16405371|NCT03941418|Experimental|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
16405274|NCT03942055||B-line score ≥7|"Patients with B-line score ≥7 at the end of the surgical procedure.
~The Sonosite Edge II Ultrasound device will be used.
~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
16405275|NCT03942055||B-line score <7|"Patients with B-line score <7 at the end of the surgical procedure.
~The Sonosite Edge II Ultrasound device will be used.
~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
16405276|NCT03942042|Experimental|Ixekizumab|"Induction Dosing Period:
~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.
~Maintenance Dosing Period:
~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.
~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1."
16405277|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Capsule|LY3154207 capsule (reference) administered orally, once.
16405278|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Tablet|LY3154207 tablet (test) administered orally, once.
16405279|NCT03942029|Experimental|Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole|LY3154207 (dose 1) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
16405280|NCT03942029|Experimental|Cohort 1 Part B - Placebo + Fluconazole|Placebo administered alone, orally, once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
16405281|NCT03942029|Experimental|Cohort 2 - LY3154207 (Dose 2) + Fluconazole|LY3154207 (dose 2) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
16405282|NCT03942029|Experimental|Cohort 2 - Placebo + Fluconazole|Placebo administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
16405283|NCT03942029|Experimental|Cohort 3 - LY3154207 + Fluconazole|LY3154207 (dose 2) administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
16405284|NCT03942029|Experimental|Cohort 3 - Placebo + Fluconazole|Placebo administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
16405285|NCT03942003|Experimental|Rhomboid|When applying the Rhomboid nerve block, the patient is tilted to the side position so that the corresponding breast is at the top. After T7 up to T10 sterile preparation of the C7 spinous projection, the convex probe shows a rhomboid muscle at the level of T5 and block is applied with 0.25% bupivacaine (20 cc), 2% lidocaine (10 cc) and 10 cc SF mixture.
16405286|NCT03942003|Experimental|Pectoral|The PEC I field block is performed by administering 10 cc of local anesthetic between the pectoralis minor and the major at the 2nd costal position. PEC II field block is performed using linear USG probe visibly in 3rd and 4th ribs while the patient is in supine position. In this block, a total of 20 cc 0.25% bupivacaine (10 cc), 2% lidocaine (5 cc) and 5 cc SF mixture were used to block the area between the pectoralis minor muscle and the serratus muscle
16405287|NCT03942003|Sham Comparator|Control|Infiltration analgesia was performed.
16405288|NCT03941990|Experimental|Nitrous oxyde|will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)
16405289|NCT03941990|Placebo Comparator|Placebo|will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)
16405290|NCT03941977|Experimental|Surgery|Group evaluated with MRI and submitted to the percutaneous introduction of cannula for bone grafting
16405291|NCT03941964|Experimental|Ventoclax + azacitidine or decitabine|Venetoclax (daily for 28 days), in combination with azacitidine or decitabine, beginning on Cycle 1 Day 1. Depending on investigator's choice, participants will receive either azacitidine for 7 days beginning on Day 1 of each 28-day cycle or decitabine for 5 days beginning on Day 1 of each 28-day cycle, as per institutional practice.
16405292|NCT03941951|No Intervention|Pre-intervention Cohort|Cohort of patients who have received either empirical or targeted treatment with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2016 to December 2019 will be included.
16405293|NCT03941951|Other|Intervention cohort|Cohort of patients with complex infections treated with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2010 to June 2021.
16405294|NCT03941951|No Intervention|Safety cohort|Cohort of patients with bacteremia due to carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, carbapenem-resistant enterobacteria, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus occurred in participating hospitals from 2017 to 2021 will be collected.
16405295|NCT03941938|Experimental|Cyanoacrylate|the anastomotic reinforcement with nebulized cyanoacrylate glue using the special short catheter device for open surgery or the laparoscopic catheter.
16405296|NCT03941938|Active Comparator|No reinforcement|No reinforcement will be applied on the anastomosis line
16405297|NCT03941925|Experimental|Prebiotic fructans|Prebiotic fructans. Prebiotic will be mixed into foods or drinks and consumed twice daily.
16405298|NCT03941925|Placebo Comparator|Maltodextrin|Maltodextrin. Maltodextrin will be mixed into foods or drinks and consumed twice daily.
16405299|NCT03941912|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm dual-diode laser application
16405300|NCT03941899|Other|QLB II|Quadratus Lomborum Blocck II type will be performed before robot-assisted laparoscopic radical prostatectomy
16405301|NCT03941886|No Intervention|Non-intervention group|Participants receive routine prenatal care
16405302|NCT03941886|Experimental|Intervention group|Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.
16405303|NCT03941873|Experimental|Sitravatinib monotherapy|Two dose levels of sitravatinib as monotherapy, 80 mg once daily and 120 mg once daily, will be evaluated in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer. A modified 3+3 design will be used in the dose escalation to confirm recommended Phase 2 dose (RP2D)
16405304|NCT03941873|Experimental|Sitravatinib plus Tislelizumab|The combination dose escalation of sitravatinib (80 mg once daily and 120 mg once daily; modified 3+3 design) with tislelizumab (200 mg every 3 weeks, in both cohorts) will be evaluated in unresectable locally advanced or metastatic HCC or G/GEJ cancer participants . If the combination dose of 80 mg sitravatinib and 200 mg tislelizumab has been declared tolerable, the dose of sitravatinib will be escalated to 120 mg and tislelizumab will remain fixed at 200 mg. Approximately 12 to 24 evaluable participants will be treated. The dose of tislelizumab during dose escalation for the combination will be kept fixed at 200 mg
16405305|NCT03941873|Experimental|Anti-PD-1/PD-L1 Antibody Naïve or R/R HCC (Monotherapy)|
16405306|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive HCC(Combination)|
16405307|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant HCC|
16405308|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive G/GEJ cancer|
16405311|NCT03941847|Experimental|music|The experimental group will benefit from musical listening during a classic period of induction of anesthesia
16405312|NCT03941847|No Intervention|silence|The control group will have a usual care.
16405313|NCT03941834|Active Comparator|BHV3000|
16405314|NCT03941834|Placebo Comparator|Placebo|
16405315|NCT03941821||G/P treatment|Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment
16405316|NCT03941808|Experimental|Drug|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
16405317|NCT03941808|Placebo Comparator|Placebo|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
16405318|NCT03941795|Experimental|JS001(Toripalimab Injection) Combined With Axitinib|
16405319|NCT03941795|Experimental|JS001 alone|
16405320|NCT03941795|Active Comparator|Axitinib alone|
16405321|NCT03941769|Experimental|Supportive care (recombinant interleukin-7)|Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.
16405322|NCT03941756|Experimental|Group I (LVB)|Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.
16405323|NCT03941756|No Intervention|Group II (no intervention)|Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.
16405325|NCT03941730|Experimental|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16405326|NCT03941717|Experimental|Mindfulness-Based Condition|Parents and children in the mindfulness intervention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of a mindfulness activity. There is a parent and child version of the mindfulness intervention. Both scripts were developed by Siegel and Bryson (2011), and include a parent and child version of a mindfulness activity targeting worries and anxiety. Adjustments to the child script were informed by the work of Petter and colleagues (2013). Adjustments to the parent script were informed by the work of Garland and colleagues (2015). This activity will last 5-minutes.
16405327|NCT03941717|Sham Comparator|Unfocused attention Condition|Parents and children in the unfocused attention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of an unfocused attention activity. There is a parent and child version of this activity. The parent version has been validated in other research with healthy adults as a control for a mindfulness intervention (Garland, Hanley, Farb, & Froeliger, 2015). This script was condensed in time from the original reading. The child version of the activity was developed for the current study, and was adapted from a mind-wandering script used for children aged 7-12 in past research (Spann, 2016). It was also informed by the unfocused attention script used for parents (Garland, Hanley, Farb, & Froeliger, 2015), and work by Cahn and Polich (2009). This activity will last 5-mintues.
16405330|NCT03941691|Experimental|Treatment Group|Experimental group is allocated to use novel fully degradable ventricular septal defect closure system manufactured by Shanghai shape memory alloy materials co. LTD.
16405331|NCT03941691|Active Comparator|Control Group|Control Group is allocated to use Interposition conveying device for ventricular septal defect closure produced by Shanghai shape memory alloy material co. LTD.
16405332|NCT03941678|Experimental|Creatine|0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
16405333|NCT03941678|Placebo Comparator|Placebo|0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
16405334|NCT03941665|Experimental|Gelronate|Tested new medical device
16405335|NCT03941665|Active Comparator|Aloevera|Current product used by the medical center
16405336|NCT03941652||Women with gestational diabetes without a prior GDM|The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview.
16405337|NCT03941652||Women with gestational diabetes with or without a prior GDM|The investigators define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. GDM women (n=up to 12) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview.
16405370|NCT03941431|Experimental|Integrated Chinese and Western Medicine Treatment Group|Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks.
16405338|NCT03941652||General pregnant women|The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week.
16405339|NCT03941626|Experimental|CAR-T/TCR-T cells immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
16405340|NCT03941613|Experimental|Anterior temporal lobectomy|surgical treatment for mTLE
16405341|NCT03941613|Active Comparator|SEEG guided RF-TC|SEEG recording and minimal invasive treatment for mTLE
16405344|NCT03941587|Active Comparator|Aflibercept + RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection + RF-PDT ( 6mg/m2 intravenous infusion of Verteporfin followed by laser light at a dose rate of 25 Joules/cm2) at baseline.
~Aflibercept- 1st treatment (baseline) followed by minimum retreatment interval of 4 weeks (from Baseline to week 8) and then retreatment at intervals of 4 weeks pro re nata (PRN) retreatment( week 12-48). Primary endpoint at week 52.
~RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.
~At each visit, subjects will be assessed based on BCVA, ophthalmic examination and Optical Coherence Tomography (OCT)"
16405345|NCT03941587|Active Comparator|Aflibercept + sham RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection, at baseline. A minimum of 1 injection(baseline) followed by minimum pro re nata (PRN) retreatment interval of 4 weeks ( from baseline to week 8) and then a minimum of 4 weeks retreatment thereafter (week 12-48). Primary endpoint at week 52.
~Sham RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.
~At each visit, subjects will be assessed based on Best Corrected Visual Acuity (BCVA), ophthalmic examination and Optical Coherence Tomography (OCT)"
16405346|NCT03941574|Experimental|HLX10|
16405347|NCT03941561|Experimental|S-1 for 9 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 9 months after D2 resection
16405348|NCT03941561|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
16405349|NCT03941548|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
16405350|NCT03941548|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
16405351|NCT03941535|Experimental|Decreasing Daily Dose of Vitamin K|"This group of patients will receive a decreasing dose of Vitamin K IV:
~Days 1-2 = 10mg/day (standard of care) Days 3-4 = 5mg/day Days 5-90 (or date of discharge, death, etc) = 2mg/day"
16405352|NCT03941535|Active Comparator|Standard of Care Dose of Vitamin K|This group of patients will be reviewed retrospectively and would have received Vitamin K IV at 10mg/day during their entire hospital course
16405353|NCT03941522|Experimental|Intervention group (23-hour stay)|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
16405354|NCT03941522|No Intervention|Control group (conventional hospitalization)|Patients randomized to the group conventional hospitalization will be hospitalized as per the current conventional care after ileostomy closure.
16405355|NCT03941509|No Intervention|Control|All facilities will receive usual care during the control phase of the trial.
16405356|NCT03941509|Experimental|Antimicrobial stewardship|Implementation of the nurse-led bundled antimicrobial stewardship intervention
16405357|NCT03941496|Experimental|AZA Treatment|"In Phase Ib dose escalation stage, participants will receive subcutaneous (SQ) AZA once daily x 5 days. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.
~Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:
~5 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals
~15 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals
~30 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals
~50 mg/m^2 SQ once daily x 5 days for 8 individuals
~75 mg/m^2 once daily x 5 days for 8 individuals"
16405361|NCT03941470||unexplained recurrent pregnancy loss|peripheral blood sample examined by flowcytometry
16405362|NCT03941470||control fertile multipara|peripheral blood sample examined by flowcytometry
16405363|NCT03941457|Experimental|anti-tumor response of BiCAR-NK cells (ROBO1 CAR-NK cells)|Patients with relapsed and refractory pancreatic cancer of ROBO1 expression will be treated with BiCAR-NK cells (ROBO1 CAR-NK cells).
16405364|NCT03941444|Experimental|Active arm|ANAVEX2-73 liquid oral solution
16405365|NCT03941444|Placebo Comparator|Placebo arm|Placebo liquid oral solution
16405366|NCT03941431|Experimental|Chinese medicine internal treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks.
16405367|NCT03941431|Experimental|Chinese medicine external treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks.
16405368|NCT03941431|Experimental|Chinese medicine treatment group|Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks.
16441085|NCT03696173||Participants taking abatacept|
16405372|NCT03941418|Placebo Comparator|Placebo|Patients will be administered with placebo as an addition to their standard therapy.
16405373|NCT03941405|No Intervention|No treatment|No treatment.
16405374|NCT03941405|Experimental|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days.
16405375|NCT03941392||Healthy children between 1 and 9 years old|A sample of 1500 apparently healthy children between 1 to 9 years old from urban areas from different regions of Spain.
16405376|NCT03941379||Patients previously participated in an Aura Biosciences study|Patients with Choroidal Melanoma or Indeterminate Lesions.
16405377|NCT03941366|Other|Neoadjuvant Chemotherapy and Follow-up Surgery|All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
16405378|NCT03941340|Experimental|[14C]-AST2818 80mg (oral solution)|Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.
16405379|NCT03941327|Placebo Comparator|Control|Patients who provide consent for implant placement but do not receive the implant.
16405380|NCT03941327|Experimental|Interventional|Patients who provide consent for implant placement and do receive the implant.
16405381|NCT03941314|Experimental|Supera® Peripheral Stent System|Femoro-popliteal arterial stenting with Supera® Peripheral Stent System as CE-marked by the manufacturer Abbott
16405382|NCT03941314|Active Comparator|EverFlex™ Self-Expanding Peripheral Stent System|Femoro-popliteal arterial stenting with EverFlex™ Self-Expanding Peripheral Stent System with Entrust™ Delivery System or as Protégé™ EverFlex™
16405383|NCT03941301|Active Comparator|Bright treatment light|
16405384|NCT03941301|Placebo Comparator|Red light|
16405385|NCT03941288|Active Comparator|Pharmacodynamics and clinical effects of cannabidiol|"Cannabidiol will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.
~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
16405386|NCT03941288|Placebo Comparator|pharmacodynamics and clinical effects of placebo|"Placebo will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.
~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
16405387|NCT03941275||Subjects undergoing bi-plane fluoroscopy|
16405388|NCT03941262|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once a week for five weeks.
16405389|NCT03941262|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered once a week for five weeks.
16405390|NCT03941262|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered once a week for five weeks.
16405391|NCT03941262|Experimental|Cohort 4 - SNK01 with avelumab|SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
16405392|NCT03941262|Experimental|Cohort 4 - SNK01 with pembrolizumab|SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
16405393|NCT03941236|Experimental|Dasiglucagon open-label|Dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
16405394|NCT03941223|Experimental|pectoral PECS II block|Ultrasound-guided PECS II block with ropivacaine 0.75% 20 ml (patients N = 75) + Parasternal ultrasound-guided block at T2, T4 levels with ropivacaine 0.375% 10 ml
16405395|NCT03941223|Active Comparator|Paravertebral nerve block|Ultrasound-guided paravertebral block with ropivacaine 0.75% 20 ml at T1-T2 and T3-T4 levels (10 ml each) (patients N = 75)
16405396|NCT03941210||HIV+/TB+|"Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm
~All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation"
16405397|NCT03941210||HIV+/TB-|"Participants included in this study arm will be HIV+ and TB-
~One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis"
16405398|NCT03941210||HIV-/TB+|"Participants included in this study arm will be HIV- and TB+
~Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment"
16405399|NCT03941210||HIV-/TB-|"Participants included in this study arm will be HIV- and TB-
~Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB."
16405400|NCT03941197|Experimental|Ready and Healthy for Kindergarten Family Literacy Program|Ready and Healthy for Kindergarten Family Literacy Program- 8 weekly parent child workshops with text message reminders
16405401|NCT03941184||SCAD cases|SCAD cases will be identified based on presence of at least one diagnosis code for SCAD followed by manual verification by a trained individual, OR, inclusion in the previously validated SCAD cohort (Tweet 2012).
16405402|NCT03941184||Controls without SCAD|Potential controls will be identified based on absence of any SCAD diagnosis codes.
16405403|NCT03941171|Experimental|Group 1|PAO+usual+PRT
16405404|NCT03941171|Active Comparator|Group 2|PRT
16405405|NCT03941145|Experimental|Exercise|Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
16405406|NCT03941145|No Intervention|Control|The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
16405407|NCT03941132|Experimental|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.
~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.
~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.
~Total of 11 visits"
16405585|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment without MSM|
16405408|NCT03941132|Placebo Comparator|Saline Solution - Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.
~Week 0: Loading dose of 6mg/kg saline intravenously.
~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.
~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.
~Total of 11 visits"
16405409|NCT03941119|Experimental|Intervention|The intervention arm will receive a VR-therapy session every 24-72 hours of their stay in the hospital. Participants will view specially designed 360-degree VR films using a Virtual Reality head mounted display for a maximum of 20 minutes per session.
16405410|NCT03941119|No Intervention|Control|The control arm will not receive any VR-therapy sessions during their hospital stay.
16405411|NCT03941106|Experimental|Left aTMS|
16405412|NCT03941106|Experimental|Right aTMS|
16405413|NCT03941093|Experimental|Arm A|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
16405414|NCT03941093|Placebo Comparator|Arm B|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
16405415|NCT03941080||GIMICC|Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.
16405416|NCT03941067|Experimental|Pre-event massage|
16405417|NCT03941067|No Intervention|Control|
16405418|NCT03941054|No Intervention|Control arm|No intervention
16405419|NCT03941054|Experimental|Pressure Release|Digitopressure treatment of the Myosfascial Trigger Points
16405420|NCT03941041|Experimental|Prenatal Yoga Practice|Pregnant women participating in a yoga course at least 12 session, each session in duration of 90 minutes.
16405421|NCT03941041|No Intervention|Regular Prenatal Care|Pregnant women being treated according to national guidelines
16405422|NCT03941028|Experimental|bone defects caused by trauma|Large bone defects (>6cm) caused by trauma
16405423|NCT03941028|Experimental|bone defects caused by infection|Large bone defects caused by chronic osteomyelitis
16405424|NCT03941028|Experimental|bone defects caused by tumor|Large bone defects caused by benign tumor
16405425|NCT03941015||patients with renal desaturation|Patients who underwent a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
16405426|NCT03941015||patients without renal desaturation|Patients who didn't undergo a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
16405427|NCT03941002|Placebo Comparator|Clinical pressure support|The level of inspiratory pressure support will be selected by the attending physician
16405428|NCT03941002|Active Comparator|Reduced pressure support|The level of inspiratory pressure support will be reduced by 25%
16405429|NCT03941002|Active Comparator|Lowest pressure support|The level of inspiratory pressure support will be reduced by 50%
16405432|NCT03940976|Experimental|Afatinib|
16405433|NCT03940963|Active Comparator|AxoGuard® Nerve Cap|"Porcine derived extracellular matrix (ECM) based Nerve Termination Device
~Implantation of appropriate diameter of AxoGuard® Nerve Cap at the time of surgery"
16405434|NCT03940963|Active Comparator|Standard Neurectomy|Standard surgical treatment for symptomatic neuroma entailing neuroma excision.
16405435|NCT03940950|Experimental|SVF (Stromal Vascular Fraction) Group|Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
16405436|NCT03940950|Placebo Comparator|Placebo Group|Subjects with knee osteoarthritis (OA) will be treated with a placebo
16405437|NCT03940924|Experimental|High Intensity Interval Training (HIIT) + Resistance Training|Subjects perform three sessions of training during 12 weeks. Session are composed of 20min HIIT program : 60 cycles of speeding up for 8s and pedaling slowly for 12s. (Intensity between 85 and 90% HRmax) + a single set circuits including 10 exercises with a load of 8-12 repetition at around 80% of maximal repetition (1RM)
16405438|NCT03940924|No Intervention|Control Group|Subjects don't have training program. They keep their life style.
16405439|NCT03940911|Other|anti-TNFα treatment and severe fatigue (FSS)|"See bellow (section Interventions) the full description for
~Measurement of aerobic exercise on cycloergometer
~Measurement of muscle mass by two-photon absorptiometry: specific study
~Measurement of Isometric Muscle Strength
~Blood sampling for measurement of cytokine levels in the blood
~Measurement of sedentarity
~Psychological impact
~Fatigue mesurement
~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
16405440|NCT03940911|Other|anti-TNFα treatment and with mild fatigue (FSS <4)|"See bellow (section Interventions) the full description for
~Measurement of aerobic exercise on cycloergometer
~Measurement of muscle mass by two-photon absorptiometry: specific study
~Measurement of Isometric Muscle Strength
~Blood sampling for measurement of cytokine levels in the blood
~Measurement of sedentarity
~Psychological impact
~Fatigue measurement
~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
16405441|NCT03940898|Active Comparator|study group-active rTMS|Participants in the study group received 100%MT(motor threshold) repetitive transcranial magnetic stimulation with the intermittent theta burst stimulation paradigm.
16405442|NCT03940898|Sham Comparator|control group-shame rTMS|Participants in the control group received rTMS pseudo-stimulation intervention. The stimulation head was inverted by 180 degrees or 90 degrees according to the model of the stimulation device to achieve pseudo-stimulation and the remaining stimulation parameters were consistent with the study group.
16405443|NCT03940885|Active Comparator|Erector spinea plane block group|this group is planned for ultrasound-guided Transversus abdominis plane block
16405444|NCT03940885|Active Comparator|Transversus abdominis plane block|this group is planned for ultrasound-guided Transversus abdominis plane block
16405445|NCT03940885|Placebo Comparator|Control group|standard general anesthesia
16405446|NCT03940872|Experimental|3PDQ self-questionnaire validation|200 patients will be included for this step in 10 French Parkinson expert centers.
16405447|NCT03940859||DEMAT|Patients with intramural hematoma in intracranial dissecting aneurysm treated by endovascular treatment will be recruited.
16405586|NCT03939884|Active Comparator|Voltaren Emulgel|
16405448|NCT03940846||Maastro (Lung1)|Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
16405449|NCT03940846||UCSF|A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
16405450|NCT03940846||Radboud|A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
16405451|NCT03940846||Stanford|Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
16405452|NCT03940833|Experimental|anti-tumor response of BCMA CAR-NK-92|Patients with relapsed and refractory MM of BCMA expression will be treated with BCMA CAR-NK 92 cells.
16405453|NCT03940820|Experimental|anti-tumor response of ROBO1 CAR-NK cells|Patients will receive a single dose of ROBO1 CAR-NK cells without any conditioning chemotherapeutic regimen.
16405454|NCT03940807|Experimental|Ultra-long protocol group|All women will receive one intra-muscular administration of 11.25 mg Gonadotropin Releasing Hormone (GnRH) agonist (triptorelin acetate) on luteal phase of their menstrual cycle. Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period. Ovarian stimulation will be started after 90 days desensitization.
16405455|NCT03940807|Active Comparator|Long protocol group|All women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous application of 0.1mg of GnRH agonist (triptorelin acetate) started on luteal phase of their menstrual cycle. Ovarian stimulation will begin after 15 days desensitization.
16405456|NCT03940794|Experimental|Verbal instruction|"The participants will be instructed to contract the pelvic floor muscle with the following verbal instruction: (1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.Those who will not be able to contract will be taught by the ultrasound as biofeedback."
16405457|NCT03940781|Experimental|intervention group|We conducted a twice a week, 12-week-intervention of 'comprehensive rehabilitation'
16405458|NCT03940781|No Intervention|control group|We kept the patients for the waiting list until after completing baseline and 12-week measurement
16405459|NCT03940768|Experimental|Lactobacillus plantarum 299v receivers|Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
16405460|NCT03940768|Placebo Comparator|Placebo receivers|Sanprobi IBS placebo 2 capsules per day for 4 weeks.
16405461|NCT03940755||Critical Illness Survivors|Those intensive care unit(ICU) patients who survive from critical illness.
16405462|NCT03940742|Experimental|Tirzepatide Control|Tirzepatide administered subcutaneously (SC) to participants with normal hepatic function
16405463|NCT03940742|Experimental|Tirzepatide Mild|Tirzepatide administered SC to participants with mild hepatic impairment
16405464|NCT03940742|Experimental|Tirzepatide Moderate|Tirzepatide administered SC to participants with moderate hepatic impairment
16405465|NCT03940742|Experimental|Tirzepatide Severe|Tirzepatide administered SC to participants with severe hepatic impairment
16405466|NCT03940729|Other|PWID colonized with S aureus|Repeated chlorhexidin showers for PWID colonized with S aureus
16405467|NCT03940716|Experimental|IntERact|"Participants randomized to this condition will receive behavioral therapy comprised of motivational interviewing, cognitive behavioral skills therapy, and care management. Youth will receive a total of six sessions, one delivered in the emergency department at the time of recruitment and five delivered over the five subsequent weeks after the ED visit (i.e., baseline). Participants will also receive a smartphone APP that will deliver intervention content between therapy sessions, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
16405468|NCT03940716|No Intervention|Enhanced Usual Care Condition|Participants randomized to this condition will receive a pamphlet with violence, mental health, and substance use resources.
16405469|NCT03940703|Experimental|Tepotinib and Osimertinib|Participants will receive a combination of tepotinib and osimertinib. The combination will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
16405470|NCT03940703|Experimental|Tepotinib Mono-therapy|Participants will receive once daily dose of tepotinib. The mono therapy will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
16405471|NCT03940690|Experimental|Anti-VEGF injections (bevacizumab)|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9
16405472|NCT03940690|Active Comparator|Arm : laser only|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
16405473|NCT03940677|Other|Parkinson's disease patient|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms
16405474|NCT03940677|Other|Healthy controls|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination
16405475|NCT03940664||neovascular group|patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
16405476|NCT03940664||non-neovascular group|patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
16405477|NCT03940651|Experimental|Knee Arthroplasty|Surgery to replace the knee joint with prothetic joint
16405478|NCT03940651|Experimental|Hip Arthroplasty|Surgery to replace the hip joint with prothetic joint
16405479|NCT03940638||Patients with septic non-union of the tibia|
16405480|NCT03940612|Experimental|STP4 (product with probiotics)|Dietary Supplement: STP4
16405481|NCT03940612|Experimental|Placebo (product without probiotics)|Dietary Supplement: Placebo
16405482|NCT03940599|Experimental|Fitbit with visible screen|The first group will receive a FitBit with the screen visible, displaying their daily step count (the Step-Counter group).
16405483|NCT03940599|Experimental|Scale group|The second will receive a BodyTrace scale that will display and record their weight in kilograms and a FitBit with the screen covered as it was for the run-in period so their physical activity can be measured, but the only feedback they will receive is from the scale (the Scale group).
16405484|NCT03940599|Experimental|Step counter and scale|The third group will receive a BodyTrace scale and a FitBit with the screen visible (the Step-Counter and Scale group).
16405485|NCT03940599|Sham Comparator|Fitbit with screen covered|The remaining 5 participants will serve as normal controls and continue wearing the FitBit with the screen covered as it was during the run in period for the duration of follow up.
16405486|NCT03940586|Experimental|Letermovir|Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
16405487|NCT03940573|Experimental|Treatment|All patients fitted with the device.
16405488|NCT03940560|Experimental|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
16405489|NCT03940547|Experimental|Experimental - provision of flour|This arm will receive infant and young child feeding education performed by community health workers and very-low aflatoxin (AF) pre-blended porridge flour, ratio 4:1 maize to groundnut. Provision of this pre-blended flour will be 50 grams/day for 6-8 month olds, 60/day grams for 9-11 months and 75 grams/day for 12-18 month olds (with 10-15 grams added per day to account for any loss). Participants will also receive 1 kg of low-AF groundnut flour each month for 6-18 month olds. Finally, participants will receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
16405490|NCT03940547|Active Comparator|Control - promotion of flour|This arm will receive infant and young child feeding education performed by community health workers and promotion of porridge made from maize and groundnut to match what is provided to the intervention arm. Participants will also receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
16405491|NCT03940534|Active Comparator|Start with Mobile Device|
16405492|NCT03940534|Active Comparator|Start without Mobile Device|
16405493|NCT03940521||HIV-A infected patients|
16405494|NCT03940508|Experimental|MCI + IPT-A|Participants will receive the Making Connections Intervention (MCI) in addition to IPT-A for depression.
16405495|NCT03940508|Active Comparator|IPT-A Only|Participants will receive IPT-A for depression.
16405496|NCT03940482|Experimental|Single Arm|Subjects will act as their own controls
16405497|NCT03940469|Placebo Comparator|Control group|received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block.
16405498|NCT03940469|Active Comparator|Dexamethasone group|received 35ml levobupivacaine+8mg dexamethasone
16405499|NCT03940469|Active Comparator|Dexmeteomidine group|received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.
16405500|NCT03940456||Inception cohort, former Elsinore pupils|640 former Elsinore pupils (330 female, 310 male). Aged 14 in 1965. Two earlier cross-sectional studies have been done in this group (in 1990 and 2000).
16405501|NCT03940443||Ground Emergency Medical Services|Patients suffering TBI or acute MI and has been treated by GEMS dispatched by an emergency dispatch centre.
16405502|NCT03940430|Active Comparator|Lactoferrin in iron deficiency anemia|lactoferrin ( pravotin) 100mg twice daily
16405503|NCT03940430|Active Comparator|Ferrous sulfate in iron deficiency anemia|ferrous sulphate (hemojet)
16405504|NCT03940430|Active Comparator|Lactoferrin and ferrous sulfate in iron deficiency anemia|Lactoferrin 100 mg twice daily and ferrous sulfate
16405505|NCT03940404||experiment|The patients whose treatment strategy containing anlotinib.
16405506|NCT03940391|Experimental|antihistamine combination|Participants in this group will get combination chlorpheniramine and midazolam injection for sedative endoscopy.
16405507|NCT03940391|Placebo Comparator|midazolam|Participants in this group will get only midazolam injection for sedative endoscopy
16405508|NCT03940378|Experimental|One-drug Regimes|Basic drug : Anlotinib Hydrochloride Capsules
16405509|NCT03940378|Experimental|Two-Drug Regimens|Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
16405510|NCT03940365|Experimental|Study Group|As detailed above, a single group will be used for the study to compare the output of the study device with the output of the standard device in each patient.
16405511|NCT03940352|Experimental|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
16405512|NCT03940352|Experimental|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
16405513|NCT03940339|Experimental|Suboccipital myofascial release|Treatment will be given for 3 minutes, 3 days per week for 4 weeks.
16405514|NCT03940339|Active Comparator|Coventional Physiotherapy|Treatment will be given for 3 days per week for 4 weeks
16405515|NCT03940326|Experimental|Levetiracetam|
16405516|NCT03940326|Active Comparator|Valproate|
16405517|NCT03940313||Subjects|Participants >18 years old who meet inclusion and exclusion criteria, and have findings on physical exam and ultrasound that suggest potential benefit from prolotherapy.
16405518|NCT03940313||Controls|Participants >or =18 years old who do not complain of lower back pain, but consent to have physical examination testing and musculoskeletal ultrasound of the lower back to evaluate these areas.
16405519|NCT03940300|Experimental|Adults with or risk for Type 2 Diabetes|All adult individuals with (non-insulin treated) or at risk for type 2 diabetes are in the treatment group and will receive prescriptions of fresh organic vegetables on a weekly basis for 10 weeks.
16405520|NCT03940287|Experimental|Muscle Energy Technique and Conventional Physiotherapy|Muscle Energy Technique will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks, where each session of Muscle Energy Technique will be repeated for 3-5 repetitions.
16405521|NCT03940287|Experimental|Kinesiotaping and Conventional Physiotherapy|Kinesiotape application will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks
16405522|NCT03940274|Experimental|Intervention|Participants will undergo a walking program using a treadmill, a body-weight support system, and an assistive device.
16405523|NCT03940261|Experimental|High Intensity Interval Training|
16405524|NCT03940261|Active Comparator|Continuous Moderate Intensity Training|
16405525|NCT03940248|Experimental|Early Stage Breast Cancer|Patients to be treated with Accelerated Partial Breast Irradiation utilizing pencil beam scanning proton therapy. Treatment will be delivered twice a day, at least 6 hours apart, over 5 treatment days.
16405587|NCT03939884|Placebo Comparator|Non-medicinal Placebo|
16405526|NCT03940235|Experimental|Stereotactic body Radiotherapy (SBRT) only|ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.
16405527|NCT03940235|Active Comparator|Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)|ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.
16405528|NCT03940222|Experimental|I-BiT group|Amblyopic patients will play I-BiT games without patching.
16405529|NCT03940222|Placebo Comparator|Placebo group|Amblyopic patients will patch their dominant eye and they will play placebo I-BiT games.
16405530|NCT03940209|No Intervention|Usual care|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.
16405531|NCT03940209|Experimental|Basic needs navigation|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
16405532|NCT03940196|Experimental|NovoTTF-100L(O)|Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
16405533|NCT03940196|Active Comparator|Best Standard of Care|Patients receive best standard of care with weekly Paclitaxel
16405534|NCT03940183|Experimental|Trelagliptin succinate 100 mg|Tablets,100mg per tablet,oral, once a week, 100mg each time, continuous medication for a total of 24 weeks
16405535|NCT03940183|Placebo Comparator|Placebo Oral Tablet|Tablets,N/A,oral, once a week, one tablet each time, continuous medication for a total of 24 weeks
16405536|NCT03940170||vistacam|
16405537|NCT03940170||ICDAS II|
16405538|NCT03940170||Fissurotomy|
16405539|NCT03940157|Experimental|Oh Happy Day Class - Still I Rise|The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
16405540|NCT03940144|Experimental|goal-directed fluid therapy|Stroke Volume variation (SVV)-guided fluid therapy
16405541|NCT03940144|Active Comparator|Conventional fluid therapy|Conventional fluid therapy such as CVP, MAP and urine-output guided fluid therapy
16405542|NCT03940131|Experimental|Single Arm|Panitumumab with FOLFOX6/FOLFIRI
16405543|NCT03940118|Active Comparator|Catheter secretion suctioning|Secretions are aspirated with a catheter at -120 to -150 mBar
16405544|NCT03940118|Experimental|Secretion suctioning + hypertonic saline|Hypertonic saline is nebulized prior to aspiration of secretions.
16405545|NCT03940118|Experimental|Ins-exsufflation|Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg
16405546|NCT03940118|Experimental|Ins-exsufflation + Hypertonic Saline|Mechanical insufflation-exsufflation and hypertonic saline
16405547|NCT03940105|No Intervention|Control|For 3 days during the control snack pattern, the participants will be asked to complete dietary recalls concerning their afternoon and evening snacking behavior. The participants will use the Automated Self-Administered 24-hour Recall (ASA24) system which was developed by the National Cancer Institute.
16405548|NCT03940105|Active Comparator|Standard Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch.
16405549|NCT03940105|Active Comparator|Large Package Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that the package sizes of all the foods are larger (though food amount remains the same).
16405550|NCT03940105|Active Comparator|Variety Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that there is about twice as much snack variety (though food amount remains the same).
16405551|NCT03940092||Healthy Volunteers|Healthy volunteers will be scheduled for an 23Na-MR examination
16405552|NCT03940092||Breast cancer patients (primary surgery)|Patients scheduled for primary surgery will undergo a single MR examination, involving 23Na-imaging prior to their planned surgery.
16405553|NCT03940092||Breast cancer patients (neoadjuvant chemotherapy)|Patients undergoing neo-adjuvant therapy will undertake up to two (2) combined PET/MR examinations with FDG. Examinations will be conducted at baseline and after 3-4 cycles of chemotherapy.
16405554|NCT03940079|Experimental|gross-motor group (GMG)|"The participants of GMG received motor-cognitive dual-task training. The sensors used by the participants were four different colored buttons. The participants wear a suit with two buttons on the shoulders and the other two fasten on the knees by velcros. To accomplish the tasks, the participants had to slap the correct colored buttons. The stretching of upper or lower limbs was demanding while slapping, so the participants of GMG received a training which required cognitive and motor functions at the same time.
~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
16405555|NCT03940079|Active Comparator|fine-motor group (FMG)|"The participants of FMG received cognitive training only. Four colored sensors used by the participants were the keys on the keyboard of the laptop. The participants simply pressed correct colored keys by fingers to complete the tasks.
~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
16405556|NCT03940066|Other|Monitoring group|
16405557|NCT03940066|Other|Standard Care|
16405558|NCT03940053|No Intervention|Observation|Subjects only accept the routine treatment for underlying diseases.
16441086|NCT03696173||Participants taking abatacept with methotrexate|
16405559|NCT03940053|Experimental|Intervention|Based on the routine treatment for underlying diseases, subjects were administrated by arginine.
16405560|NCT03940040|Active Comparator|Usual Care|Patients will under go usual care ( pulmonary rehabilitation on room air or with nasal oxygen supplementation)
16405561|NCT03940040|Experimental|High flow nasal oxygen|Patients will undergo pulmonary rehabilitation with high flow nasal oxygen
16405562|NCT03940027|Experimental|ropivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% ropivacaine with 10ml anhydrous alcohol
16405563|NCT03940027|Active Comparator|bupivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% bupivacaine with 10ml anhydrous alcohol
16405564|NCT03940014||Pulmonary arteriovenous malformations|"Patients with hereditary haemorrhagic telangiectasia (HHT)-related Pulmonary Arteriovenous Malformations (PAVMs). For all patients, the final diagnosis of certain HHT the diagnosis can be made depending on the presence of four criteria known as the Curaçao criteria: 1) Spontaneous recurrent epistaxis 2) Multiple telangiectasias in typical locations 3) Proven visceral Arteriovenous Malformations (AVM) (lung, liver, brain, spine) 4) First-degree family member with HHT. If conditions three or four are met, a patient has definite HHT, while condition two is considered as possible HHT. All patients had a molecular diagnosis and all follow-up clinical assessments were available in the database."
16405565|NCT03940001|Experimental|arm|"Biological: Sintilimab For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
~Drug: Paclitaxel 50 mg/m^2 IV Q3W day 1, day 8 and day 15
~Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15
~Radiotherapy:
~1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy"
16405566|NCT03939988|Active Comparator|Experimental group|In this study, immediately after the installation of the separators, the subjects of the experimental group will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
16405567|NCT03939988|Placebo Comparator|Placebo group|In the placebo group, the same procedures will be made, but the laser will be switched off.
16405568|NCT03939975|Experimental|Study arm|"Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely.
~Others with complete or partial responses would keep on going with mono-ICIs therapy."
16405569|NCT03939962|Experimental|treatment group|"Neoadjuvant therapy:SHR1210 combined with FOLFOX repeat every 14 days for a total of 4 cycles.
~Adjuvant therapy:SHR1210 combined with mFOLFOX6 repeat every 14 days for a total of 4 cycles,After that,SHR1210 monotherapy was followed up to 1 year (from the first SHR1210 treatment)."
16405573|NCT03939936|Active Comparator|Test Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.
~Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
16405574|NCT03939936|Placebo Comparator|Control Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.
~Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
16405575|NCT03939923|Active Comparator|Group One|Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).
16405576|NCT03939923|Active Comparator|Group Two|Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).
16405577|NCT03939910|Active Comparator|Control arm|bupivacaine 0.25% for pudendal block
16405578|NCT03939910|Experimental|Intervention arm|ropivacaine 0.2 % for the pudendal block
16405579|NCT03939897|Experimental|Phase I (FAC) (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level) and abemaciclib PO BID on days 2-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16405580|NCT03939897|Experimental|Phase II, Arm I (FAC) (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride as in phase I. Patients also receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16405581|NCT03939897|Active Comparator|Phase II, Arm II (FA) (abemaciclib, fulvestrant)|Patients receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16405582|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on with MSM|
16405583|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on without MSM|
16405584|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment with MSM|
16405588|NCT03939871|Experimental|Single arm|Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
16405589|NCT03939858||Cognitive Function Analysis|Cognitive function will be evaluated using a customized cognitive battery designed for brain tumor patients. Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
16405590|NCT03939845|Active Comparator|TACE|
16405591|NCT03939845|Experimental|TACE+RT|
16405592|NCT03939832|Active Comparator|FiO2 0.5|
16405593|NCT03939832|Active Comparator|FiO2 1.0|
16405594|NCT03939819|Experimental|ViSiGi® 3D suction calibration device|"The ViSiGi® 3D is the first calibration system specifically intended for use during sleeve gastrectomy.ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
~Advantages of ViSiGi® 3D device include simplification of sleeve calibration in addition to suctioning the stomach and performing leak tests all with one device making operative steps simpler for both the anesthesiology team and surgeons. Since it is single patient use it does not require reprocessing."
16405595|NCT03939819|Active Comparator|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope, similar to The ViSiGi device, have suction, calibration, and leak testing capabilities.
16405596|NCT03939806||Oxytocin|This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
16405597|NCT03939806||Carbetocin|This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
16405598|NCT03939793|Placebo Comparator|Usual Clinical Support|Participants will continue with their usual diabetes care provided by their clinic. Participants will receive a free wireless glucometer on the day of enrollment if they do not already have one.
16405599|NCT03939793|Active Comparator|DFI Alone|Participants will receive a free wireless glucometer on the day of enrollment if they don't already have one. To encourage habit formation, for the first 6 weeks of the trial, participants will be eligible for a daily lottery incentive for every day that they use their glucometer. Investigators will use an approach similar to what we have used in prior DFI trials: the lottery will provide infrequent large payoffs (a 1 in 100 chance of a US$50 reward) and more frequent small payoffs (an 18 in 100 chance of a US $5 reward). Participants who draw the winning lottery number, but did not check their glucose the day prior will receive an automated text or e-mail message informing them what earnings they would have won had they used their glucometer. After 6 weeks, investigators will terminate the lottery but continue to monitor patients' adherence to glucose self-monitoring.
16405600|NCT03939793|Experimental|Hybrid DFI CHW|Participants in the hybrid intervention will receive a wireless glucometer if they don't already have one and financial incentives just as in the DFI intervention. However, any individuals who have low adherence (no self-monitoring) or elevated glucose readings (>300 mg/dL) for >30% of days over any 2 week period in the first 12 weeks of the study will be assigned to receive ongoing community health worker (CHW) support for the duration of the 24-week study period.
16405601|NCT03939780|Experimental|Cohort 1|Subjects will be scanned twice (once with each of the tracers [18F]RO-948 and [18F]MK-6240)
16405602|NCT03939780|No Intervention|Cohort 2A|No PET scans will be done. Previous [18F]AV-1451 scans of selected aged matched older cognitively healthy controls (OC) subjects from the Baltimore Longitudinal Study of Aging (BLSA) study (IRB00047185) will be reanalyzed.
16405603|NCT03939780|Experimental|Cohort 2B1 - AD [18F]RO-948 and [18F]AV-1451|Alzheimer's Disease (AD) subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
16405604|NCT03939780|Experimental|Cohort 2B2 - AD [18F]MK-6240 and [18F]AV-1451|AD subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
16405605|NCT03939780|Experimental|Cohort 2B3 - OC [18F]RO-948 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
16405606|NCT03939780|Experimental|Cohort 2B4 - OC [18F]MK-6240 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
16405607|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
16405608|NCT03939754||Adult attendance to Dedalo activities|Adult attended one Dedalo's activity
16405609|NCT03939754||Adult living in Vercelli|Adult aged 40-75
16405610|NCT03939741|Experimental|Group A|"Participants having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) more than 1 x 10^6.
~Genetic: SVF containing Autologous Non Expanded ADSC."
16405611|NCT03939728||Chest radiography and lung ultrasound|All patients will be enrolled, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
16405612|NCT03939715|Active Comparator|DermaPure|
16405613|NCT03939715|Active Comparator|Native Tissue|
16405671|NCT03939299|Experimental|OCT group|Patients, whose coronary chronic total occlusion lesion was successfully implanted stent, received optical coherence tomography imaging immediately and at 9-12 months after index procedure.
16443275|NCT03681067|Experimental|GSK10708060|Humanised antibody GSK1070806
16405614|NCT03939702|Active Comparator|Non-Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
16405615|NCT03939702|Active Comparator|Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
16405616|NCT03939689|Active Comparator|Enzalutamide|
16405617|NCT03939689|Experimental|I-131-1095 in combination with enzalutamide|
16405618|NCT03939676||Major Depressive Disorder or Bipolar Disorder|All eligible participants will be included in this single study arm.
16405619|NCT03939663|Placebo Comparator|placebo group|2 tablets vaginally
16405620|NCT03939663|Experimental|misoprostol group|400 mcg vaginally
16405621|NCT03939650|Experimental|Diaana|"The patient fulfill Diaana
~The resident physician reads the Diaana summary
~The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)
~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
16405622|NCT03939650|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)
~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
16405623|NCT03939637|Experimental|Eltrombopag|Patients randomized to eltrombopag will be treated for 12 weeks, with the possibility to continue therapy for up to 1 year depending on response.
16405624|NCT03939637|Active Comparator|Standard first-line therapy|"Subjects randomized to the standard therapy arm will receive one of three treatments at the discretion of the treating physician. Patients who previously failed standard management prior to study entry must be treated with a different agent than their original failed agent. e.g. Patient who failed steroids could receive either IVIg or anti-D if randomized to the standard treatment arm.
~Standard therapy will be administered as commercially available drug.
~Investigator may choose amongst the following:
~IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
~Steroids: Prednisone/Prednisolone 4 mg/kg/day (Max 120 mg/day) x 4 days
~Rho(D) Immune Globulin: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)"
16405625|NCT03939624||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
16405626|NCT03939624||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
16405627|NCT03939611|Experimental|Foot Reflexology Group|Foot reflexology was performed to the reflexology group infants. Foot reflexology application (FRA) involved relaxation for the first 3-5 minutes and the last 2 minutes; the remaining 12-15 minutes included stimulation of the brain and digestive system organs. To ensure relaxation, rotation was performed by using the thumbs of the hand under the feet, cephalocaudally. The session of FRA included stimulating the brain and medulla spinalis (2 min), the solar plexus (1min), the stomach (2min), the liver (2min), the pancreas (2min), the gallbladder (1min), and the ileocecal valve and intestine (5min) reflex points. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
16405628|NCT03939611|Placebo Comparator|Placebo Foot Reflexology Group|Placebo foot reflexology was performed to the placebo group infants. Placebo foot reflexology application (PFRA) was constrained to ineffective touch without any stimulation and pressure. The aim of the PFRA was to create only a touch effect. It was applied by patted the foot by using the thumbs of the hand, for 20 minutes with the same rotation and to the same points as FRA. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
16405629|NCT03939585|Experimental|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.
~27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).
~Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.
~Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.
~Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
16405630|NCT03939572|Active Comparator|Accurate step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will simply display their accurate step count."
16405672|NCT03939286|Other|movement group|intensified training (equipment, coordination, balance)
16405673|NCT03939286|Other|control group|continuation of physical activity as usual
16405674|NCT03939273|Active Comparator|Active group|A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
16443276|NCT03681067|Placebo Comparator|Placebo - sodium chloride|Placebo
16405631|NCT03939572|Experimental|Deflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will display a deflated step count."
16405632|NCT03939572|Experimental|Inflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will display an inflated step count."
16405633|NCT03939572|Experimental|Accurate feedback + mindset intervention|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will display their accurate step count. Additionally, participants in this arm will receive a meta-mindset intervention."
16405634|NCT03939559|Experimental|Balance Exercises Group|Balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session
16405635|NCT03939559|Experimental|Dual Task Based Balance Exercises Group|Dual task based balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
16405636|NCT03939546|No Intervention|Control|The Control Arm will not receive any study intervention or placebo. The infants in this arm will receive standard NICU care.
16405637|NCT03939546|Active Comparator|B. infantis EVC001|Infants in the B. infantis arm will receive a once daily enteral feed of Evivo with MCT oil (8B CFU B. infantis EVC001) from Study Day 0 (by Day 10 of life) to hospital discharge, except on days when the infant is NPO.
16405638|NCT03939533|Experimental|Increased Volume Cohort - Cohort 1|Increased volume at each infusion site - patients will receive CUTAQUIG weekly and increase infusion volumes every 4 weeks
16405639|NCT03939533|Experimental|Increased Infusion Rate Cohort - Cohort 2|Increased infusion rate - patients will receive CUTAQUIG weekly and increase infusion rates every 4 weeks
16405640|NCT03939533|Experimental|Every Other Week Dosing Cohort - Cohort 3|Every other week dosing - patients will receive CUTAQUIG every other week at the equivalent of twice their body-weight dependent [mg/kg] weekly dose
16405641|NCT03939520|Experimental|Combined therapy|
16405642|NCT03939520|Active Comparator|Switch monotherapy|
16405643|NCT03939520|Other|Control group|
16405644|NCT03939507|Experimental|Intervention group|AEP score results were made available to the treating physician at each assessment visit.
16405645|NCT03939507|No Intervention|Control group|AEP scores were only made available at the end of follow-up.
16405646|NCT03939494|Experimental|Telehealth Intervention|This arm receives 26 hours of telehealth encounters with a registered dietitian in conjunction with their normal clinic/program care.
16405647|NCT03939494|No Intervention|Standard of Care Control|This arm will participate in their normal clinic/program routine.
16405648|NCT03939481||Observational (non-study chemo, questionnaire, assessments)|Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
16405649|NCT03939468||Observational Cohort|Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)
16405650|NCT03939455|Experimental|Experimental|Participants will complete a brief tablet-based intervention, which includes watching a 5 minute educational video on the importance of HIV testing, and respond via tablet computer to the offer of an HIV test.
16405651|NCT03939455|No Intervention|Treatment as usual|Participants will be offered an HIV test by hospital staff, and will respond face-to-face.
16405652|NCT03939429|Experimental|QPX2015|QPX2015, antibiotic
16405653|NCT03939429|Placebo Comparator|Placebo|Matched placebo
16405654|NCT03939416|Experimental|POLD concept treatment|Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment
16405655|NCT03939416|Active Comparator|CONTROL|Patients treated with the standart treatment
16405656|NCT03939403|Experimental|7-days pill free interval|
16405657|NCT03939403|No Intervention|5-days pill free interval|
16405658|NCT03939390|No Intervention|follicular phase stimulation|
16405659|NCT03939390|Experimental|luteal phase stimulation|
16405660|NCT03939377|Experimental|Osteopathy|Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.
16405661|NCT03939377|Placebo Comparator|Simulate|The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.
16405666|NCT03939338||Participates|
16405667|NCT03939325||first group|patient who exposed to frequency 60 shock wave per min
16405668|NCT03939325||second group|patient who exposed to frequency 80 shock wave per min
16405669|NCT03939325||third group|patient who exposed to frequency 100 shock wave per min
16405670|NCT03939312|Other|Atogepant 60mg|Taken orally once daily
16405737|NCT03938779|No Intervention|perineometer|Both groups will perform perineometry at baseline and 4 months after
16405675|NCT03939273|Placebo Comparator|Control group|A preoperative seven day course of placebo, consisting of pills and capsules identical in appearance and number to the active group
16405676|NCT03939247|Other|"Conventional PT treatment (CPT)"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching;
16405677|NCT03939247|Experimental|"CPT + Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an active Tecaretherapy is also provided during the sessions
16405678|NCT03939247|Sham Comparator|"CPT + Placebo Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an inactive Tecaretherapy is also provided during the sessions
16405679|NCT03939234|Experimental|Vaccination|Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC).
16405680|NCT03939221|Experimental|intervention of infrared lamp and acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6(neiguan) and ST36(zusanli) for one minutes) for our patient for the cold limbs, pain control and constipation problems.
16405681|NCT03939208|Experimental|Intervention (BRISC) Group|Clinicians randomly assigned to BRISC will implement a flexible intervention that, over four sessions, aims to assess and engage student clients, and identify and address student identified difficulties that are distressing and impacting academic performance/behavior, social, and overall functioning. BRISC uses an explicit, problem-solving structure and a range of techniques common to evidence-based practices (EBP) tailored to the identified needs of the student.
16405682|NCT03939208|Active Comparator|Services as Usual (SAU) Group|"Clinicians in the SAU condition will use a diverse array of treatment as usual strategies over four sessions that may include some directive, skill-building techniques common in EBPs, but, given findings from pilot studies and studies of mental health services as usual in community and school settings, are likely to be provided at an overall lower rate, and at lower intensity, than in BRISC or other EBP."
16405683|NCT03939182|Experimental|Abexinostat and Ibrutinib|The investigational agents to be used in this study are ibrutinib and abexinostat. Ibrutinib will be administered once daily on a 28-day cycle. Abexinostat will be administered orally twice daily (approximately 4-6 hours apart) for 7 days a week given every other week on a 28-day cycle.
16405684|NCT03939169|Other|Skin-to-skin support|The newborn is dressed in one layer of clothing with a hat, he is placed in the ventral position directly on the mother's chest, covered with a warm blanket and held in place with a band during the insertion of the naso-gastric feeding tube.
16405685|NCT03939169|Other|Holding|The newborn is held in his mother's arms during insertion of the naso-gastric feeding tube.
16405686|NCT03939169|Other|Four hands care|Carried out by two professionals: one health-care professional supports the child and helps stabilize the newborn whilst the other professional inserts the naso-gastric feeding tube.
16405687|NCT03939169|Other|Containing support with equipment|Carried out by one healthcare Professional, who places the newborn in such a manner that he will be held in the optimum position (using a soft sheet) during the insertion of the naso-gastric feeding tube.
16405688|NCT03939156||Group 1 - before starting ET|women candidate to receive ET and interviewed before starting treatment
16405689|NCT03939156||Group 2 - within 1 year of ET|women interviewed within 1 years from beginning of ET
16405690|NCT03939156||Group 3 - between 4 and 6 years of ET|women interviewed after more than 4 years but no more than 6 years of ET
16405691|NCT03939143|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
16405692|NCT03939143|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
16405693|NCT03939130|Experimental|Fructose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
16405694|NCT03939130|Active Comparator|Glucose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive glucose based beverage, prepared as a solution with 10% glucose, water and flavoring powder, totaling 1.0g / kg of body mass / day of glucose.
16405695|NCT03939130|Experimental|Fructose-rich diet and exercise|The subjects will perform the same protocol described in the intervention Fructose-rich diet, except for the inclusion of the physical exercise. During the 4-week intervention, participants will perform three sessions a week of 60 minutes of aerobic exercise at 60% of VO2 peak on cycle ergometer.
16405696|NCT03939104|Active Comparator|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
16405697|NCT03939104|Active Comparator|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|Triple ACTs
16405698|NCT03939104|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
16405699|NCT03939104|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs.
16405700|NCT03939091|Other|Ultrasonography|Renal Ultrasonography
16405701|NCT03939078||Vaginal Laser Intervention|Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.
16405702|NCT03939065|Experimental|Insulin Pump and CGM|
16405703|NCT03939065|Other|Standard of Care and CGM|
16405704|NCT03939052|Experimental|Protein intake|Free amino acids vs. Glycomacropeptide (GMP)
16405705|NCT03939039||Dyslipidemia|Genotype/phenotype correlation in patients with dyslipidemia
16405706|NCT03939026|Experimental|ALLO-647, ALLO-501|
16405738|NCT03938766|Other|PSMA PET/CT|Repeat PSMA PET/CT after ADT
16410808|NCT03903536||Thrombectomy|Patients with thrombosed external hemorrhoids undergoing thrombectomy
16405707|NCT03939013|Experimental|Xpert HCV VL, sof/dac (local standard of care therapy)|Use of Cepheid GeneXpert HCV VL device as diagnostic tool to test for HCV RNA for diagnosis of chronic hepatitis C infection, for assessment of sustained virological response at 12 weeks post treatment completion
16405708|NCT03938987|Experimental|CAR T cells|Patients with relapsed/refractory B-cell ALL or NHL.
16405709|NCT03938948|Experimental|Treatment Arm|62 participants shall be enrolled
16405710|NCT03938922|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
16405711|NCT03938909||Patients with Multiple Sclerosis|200 patients and 200 control
16405712|NCT03938909||Patients with dementia|100 patients and 100 control
16405713|NCT03938909||Patients with Parkinson's disease|50 patients and 50 control
16405714|NCT03938896|Other|platelet rich plasma|It started with puncture of the vein and taking specific amount of autologous blood from the participantnearly a sample of 20 ml of venous blood (Co AY, 2012).The blood sample was put in a sterile tube containing an anticoagulant as sodium citrate.Then the blood sample wascentrifuged for 15 minutes at 1800 rpmwhich leads to separation of the plasma at the top layer from the packed RBCs at the bottom layer. The RBCs layer is removedthenanother centrifugationwas done at 3500 rpm for 10 minuteswhich leads to formation of a more concentratedplatelet layer after removal of PPP(Anitua et al., 2012).Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area.
16405715|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle.
16405716|NCT03938883|Experimental|Ocular Bandage Gel (OBG)|Cross-linked Hyaluronic Acid 0.75%, regulated through CDRH (device). EyeGate Ocular Bandage Gel will be applied topically to both eyes (OU) four times a day. Ocular Bandage Gel use is discontinued once complete re-epithelialization has occurred in that eye.
16405717|NCT03938883|Other|Bandage Contact Lens (BCL)|standard-of-care post-operative intervention following PRK. BCL (Acuvue® Oasys plano lens) applied OU. Bandage contact lens use is discontinued once complete re-epithelialization has occurred in that eye.
16405718|NCT03938870||Experimental: Group 1|30 Young Normal Controls(YNC) ages 18 & Older will enroll to evaluate leucine infusion methods of labeling, vs. the oral method. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
16405719|NCT03938870||Experimental: Group 2|Group 30 CDR > 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
16405720|NCT03938870||Experimental: Group 3|Group of 40 CDR = 0 Age Matched. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
16405721|NCT03938857|Placebo Comparator|Fen. SOC+saline placebo (bolus+infusion)|Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
16405722|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
16405723|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
16405724|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
16405725|NCT03938844||TLH with BURCH Colposuspension|the patients who underwent simultaneous burch copying with TLH was evaluated. In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
16405726|NCT03938844||TLH with Transobturatuar Tape (TOT)|In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
16405727|NCT03938831|Experimental|dexmedetomidine group|dexmedetomidine mixture with fentanyl-based PCA infusion for 2 days
16405728|NCT03938831|Placebo Comparator|control group|Fentanyl-based PCA infusion for 2 days
16405729|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures
16405730|NCT03938818|Experimental|Tu'Washindi intervention|"Standard of care will include PrEP delivery according to the usual DREAMS procedures. The Tu'Washindi intervention includes the following components:
~PrEP sensitization for men (community level).
~Buddy Days (partner level).
~Adherence support clubs (individual and peer levels)."
16405731|NCT03938805|Experimental|I-CBT|Internet-based cognitive behavioral therapy program including 1-week introduction, 2 weeks psycho education on Cardiovascular disease/insomnia, 6 weeks of sleep hygiene, stimulus control and sleep restriction
16405732|NCT03938805|Active Comparator|Control group|3 weeks internet-based sleep hygiene education
16405733|NCT03938792|Experimental|PF-06741086|Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
16405734|NCT03938779|Experimental|Pelvic Floor Muscle Training (PFMT)|Experimental group will perform for 4 months a PFMT
16405735|NCT03938779|Experimental|Pad test|The experimental and control group will perform the pad test twice. At the beginning of the evaluation and 4 months after the PFMT. The modified pad test, has the durability of a workout (2h30min)
16405736|NCT03938779|No Intervention|Kings Health Questionnaire|Kings Health Questionnaire to assess the impact of urinary incontinence on quality of life of women. Both groups will complete the questionnaire.
16405739|NCT03938753|Experimental|Phonak Audéo M90-T|The Phonak Audéo M90-T is a Receiver-in-the-canal Hearing aid with direct connectivity functionality and a T-Coil from Phonak which will be fitted to the participants individual Hearing loss.
16405740|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
16405741|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
16405742|NCT03938714|Active Comparator|CH( Conventional Hemorrhoidectomy)|Closed Conventional Hemorrhoidectomy
16405743|NCT03938714|Experimental|HS( Harmonic Scalpel)|Harmonic Scalpel Hemorrhoidectomy
16405744|NCT03938701|Experimental|Fluorescence imaging with OTL38|"Fluorescence imaging with OTL38 in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) patients. A non-randomised, non-blinded, prospective, feasibility study.
~- Administration of 0.0125 mg/kg OTL38 to a total of 30 patients: 10 with Crohn's disease, 10 with ulcerative colitis and 10 with rheumatoid arthritis."
16405745|NCT03938688|Other|Transfascial sutures for mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. Full thickness transfascial sutures will be placed circumferentially to secure the mesh using slowly absorbable no. 1 sutures. A total of at least six transfascial sutures will be placed universally for all patients with additional sutures allowed according to each surgeon's discretion. Additional bone or ligament sutures for mesh fixation will be allowed according to each surgeon's discretion.
16405746|NCT03938688|No Intervention|No mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. No fixation method will be used. Bone or ligament sutures for mesh fixation will not be allowed.
16405747|NCT03938675||Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
16405748|NCT03938675||No Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
16405749|NCT03938662|Experimental|S-Adenosyl methionine and choline|Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.
16405750|NCT03938662|Placebo Comparator|Placebo|Patients in will be administered with placebo once daily for 24 weeks.
16405751|NCT03938649|Experimental|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).
~38 fractions of daily treatment, Monday to Friday"
16405752|NCT03938649|Experimental|SBRT|"RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)
~5 fractions of weekly treatment. Once fraction per week."
16405753|NCT03938636|Experimental|Subjects Free of Inflammatory Disease|The first arms is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
16405754|NCT03938636|Experimental|RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
16405755|NCT03938636|Experimental|Candidates for Initiation of, or Change to,|The third arm is designed to assess the efficacy of TUV global in clinically diagnosed subjects with active RA who are candidates for initiation of, or change to, a new anti-TNFα bDMARD therapy.
16405756|NCT03938623||Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
16405757|NCT03938623||Control|General Practitioners not using the patient-centered approach
16405758|NCT03938584|Experimental|Vitamin C|
16405759|NCT03938584|Placebo Comparator|Placebo|
16405760|NCT03938571|Experimental|Standard DS|"Standard duodenal switch:
~Sleeve gastrectomy over a 35 Fr bougie
~Division of the duodenum 2-3 cm distally of the pylorus
~Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.
~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.
~Entero-entero-anastomosis linear stapled and handsewn.
~Division between the two anastomosis.
~Closure of the mesenteric defects."
16405761|NCT03938571|Active Comparator|SADI-DS|"Duodenal switch with Single anastomosis duodeno-ileostomy:
~Sleeve gastrectomy over a 35 Fr bougie
~Division of the duodenum 2-3 cm distally of the pylorus
~Measurement of the small bowel. 250 cm alimentary limb/common channel.
~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.
~Closure of the mesenteric defects."
16405762|NCT03938558|Experimental|Dance intervention group|"Dancers at beginners level
~Dancers at advanced level"
16405763|NCT03938558|Active Comparator|Art intervention group|"Paint artists
~Word artists
~Film artists
~Photographers"
16405764|NCT03938545|Experimental|Regimen A-RVT-1401|Regimen A= RVT-1401 680 mg weekly for 12 weeks
16405765|NCT03938545|Experimental|Regimen B-RVT-1401|Regimen B= RVT-1401 340 mg weekly for 12 weeks
16405766|NCT03938545|Experimental|Regimen C-RVT-1401|Regimen C= RVT-1401 255 mg weekly for 12 weeks
16405767|NCT03938545|Placebo Comparator|Placebo|for 12 weeks
16405768|NCT03938532|Active Comparator|Control Arm|Infant will receive pressure regulated breaths, 40-60 breaths/min, PiP of 20-24cm of water as recommended by 2017 Neonatal Resuscitation Program (NRP) guidelines. Reading of the TV will be blinded from the providers as in routine clinical situations
16405769|NCT03938532|Experimental|Intervention Arm|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
16405770|NCT03938506||intubation using the endotracheal tube size of 6.0 or 8.0|Adult male patients who require endotracheal intubation using the endotracheal tube size of 6.0 or 8.0
16406362|NCT03934177|Placebo Comparator|Placebo powder|4 weeks of supplementation of 24 g placebo powder (maltodextrin)
16405771|NCT03938493||endotracheal intubation under general anesthesia|Adults who require endotracheal intubation for head and neck surgery under general anesthesia
16405772|NCT03938467|Experimental|Antiseptic Cleanser|Standard prophylaxis will be administered by Irrisept patients as would individuals in the control group. In addition, these Irrisept study subjects will be supplemented with the use of Irrisept irrigation by the study surgeon during the patient's surgical procedure. Standard times for irrigation will include immediately after incision through the dermal layer, and immediately prior to implantation of any prosthetic components. Final irrigation will be performed just prior to closure of the deltopectoral interval.
16405773|NCT03938467|No Intervention|Standard of Care Prophylaxis|Standard prophylaxis includes use of chlorhexidine wipes (Sage cloth) the night before and morning of surgery on the surgical site over the anterior shoulder.
16405774|NCT03938454|Experimental|Crizanlizumab|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51
16405775|NCT03938441|Experimental|Intermittent Fasting|Modified 5:2 intermittent fasting
16405776|NCT03938415|Experimental|Acupuncture|Acupuncture
16405777|NCT03938415|Active Comparator|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone
16405778|NCT03938402|Experimental|PEEP 5|
16405779|NCT03938402|Experimental|PEEP 10|
16405780|NCT03938402|Experimental|PEEP 15|
16405781|NCT03938389|Active Comparator|Valsartan|Valsartan 160 mg twice daily for 26 weeks
16405782|NCT03938389|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks
16405783|NCT03938389|Placebo Comparator|Placebo|placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)
16405784|NCT03938376||Potential Prostate Cancer|Biopsy naïve patients with rising Prostate Specific Antigen (PSA) results referred by their Urologist for a standard of care (SOC) biopsy.
16405785|NCT03938363|Experimental|Cervical Dystonia (CD)|Patients with cervical dystonia
16405786|NCT03938363|Placebo Comparator|Healthy Control CD|CD age- and sex-matched healthy control subjects
16405787|NCT03938363|Experimental|Blepharospasm (BS)|Patients with blepharospasm
16405788|NCT03938363|Placebo Comparator|Healthy Control BS|BS age- and sex-matched healthy control subjects
16405791|NCT03938337|Experimental|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
16405792|NCT03938337|Experimental|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
16405793|NCT03938324|Experimental|PiCASO Intervention Group|Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
16405794|NCT03938324|Sham Comparator|Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
16405795|NCT03938311|Experimental|very early rehabilitation|early mobilization initiates within 24h from the onset of the disease
16405796|NCT03938311|Experimental|relative early rehabilitation|early mobilization initiates between 24-72h from the onset of the disease
16405797|NCT03938311|Experimental|late mobilization group|early mobilization initiates after 72h from the onset of the disease
16405798|NCT03938298|Experimental|Intervention group|
16405799|NCT03938298|Active Comparator|Control group|
16405800|NCT03938285|Active Comparator|High Flux Hemodialysis|High Flux Hemodialysis with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment.
16405801|NCT03938285|Active Comparator|Extended Hemodialysis|Extended Hemodialysis with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment.
16405802|NCT03938285|Active Comparator|On Line Hemodiafiltration|On Line Hemodiafiltration with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
16405803|NCT03938285|Active Comparator|On Line Hemodiafiltration with an MCO membrane|On Line Hemodiafiltration with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
16405804|NCT03938272|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes Strain HC-1
16405805|NCT03938259||Control group; patients without obstructive sleep apnea|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
16405806|NCT03938259||Patients with known obstructive sleep apnea|Children with OSA having adenotonsillectomy for obstructive apnea will receive opioids with evaluation of respiratory changes
16405810|NCT03938233|Active Comparator|DSME program delivered by community health volunteers|Randomisation will happen in 21 primary care units to offer DSME delivered by lay health workers to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
16405811|NCT03938233|Active Comparator|DSME program delivered by nurses|Randomisation will happen in 21 primary care units to offer DSME delivered by nurses (for comparative effectiveness) to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
16405812|NCT03938233|No Intervention|Usual care(no DSME program)|Randomisation will happen in 21 primary care units where no DSME will be offered to those newly diagnosed with diabetes and/or those having difficulties with self-managing their diabetes.These patients will continue with usual care and will be assessed as the control group.
16405813|NCT03938220||fluid responders|fluid responder if stroke volume increases by > 10% after the fluid challenge
16405814|NCT03938220||fluid non responders|fluid responder if stroke volume increases by <= 10% after the fluid challenge
16405815|NCT03938207||Dry eye syndrome|Dry eye syndrome patients were extracted from Taiwan Biobank.
16405816|NCT03938207||Health subjects|Health subjects were extracted from Taiwan Biobank.
16405817|NCT03938207||Sjögren's syndrome|Sjogren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
16405818|NCT03938194|Experimental|Aquablation|Surgery of benign prostatic hyperplasia by waterjet ablation
16405819|NCT03938168||Pain patients|30 patients eligible for adhesiolysis because of chronic adhesion-related pain. Patients are recruited at the RadboudUMC, MUMC+ and Pantein hospital departments of surgery. These are patients with chronic pain after previous abdominal surgery who have been selected for operative treatment after evaluated with CineMRI. CineMRI is used to map adhesions. This technique has been established to provide insight in localization of adhesions in relation to the pain, and risk of bowel injury based on extensiveness of adhesions.
16405820|NCT03938168||Control group|The control group will comprise of 30 patients undergoing an abdominal reoperation during which adhesiolysis has to be performed for reasons other than chronic adhesion-related pain.
16405821|NCT03938142||patients with chronic pain|
16405822|NCT03938129||Group 1|Pregnant women and their baby
16405823|NCT03938116|Experimental|Healing Hearts Together|
16405824|NCT03938116|No Intervention|Usual Care|
16405827|NCT03938090|Placebo Comparator|Standard biventricular pacing|Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings
16405828|NCT03938090|Active Comparator|Optimised MultiSite Pacing (MSP)|Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.
16405829|NCT03938077|Experimental|S4E App intervention|"Youth will receive the S4E intervention via provided iPads. The intervention will last approximately 60. Content includes: (a) storytelling scenarios, (b) drug use and HIV/STI knowledge, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual and drug use risk behaviors and increase HIV self-testing, (e) Near Peer-youth communication, and (f) highlighting prevention principles. The youth will participate in a Near Peer-initiated prevention and risk reduction encounter which includes (a) reinforcement of HIV solutions that youth learned in the S4E app, (b) promotion of HIV self-tests, and (c) linkage to care and prevention services.
~Youth have the option to take a HIV self-test. We will determine the acceptability of youth disclosing their results to their Near Peer and linkage to resources.
~The research staff will also conduct in-depth qualitative interviews with both youth and Near Peer participants to assess feasibility and acceptability of S4E."
16405830|NCT03938064|Active Comparator|Group Early start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries from the day of ovum retrieval (OR).
16405831|NCT03938064|Placebo Comparator|Group Late start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries 2 days after OR.
16405832|NCT03938051|Experimental|Experimental group|Multi-component intervention
16405833|NCT03938051|Experimental|Control group|treadmill walk
16405834|NCT03938038|Active Comparator|Serial ultrasound assessments for GDT|
16405835|NCT03938038|Active Comparator|Usual care|
16405836|NCT03938012||Lung and head and neck tumours|"Age 18 years or older
~Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region
~No other active malignancy within the past 24 months
~Refractory disease"
16405837|NCT03937999|Experimental|Bezlotoxumab Arm|Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0
16405838|NCT03937999|No Intervention|No Bezlotoxumab|Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .
16405839|NCT03937986|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16405840|NCT03937986|Experimental|Suvorexant Dose 1|Subjects will be maintained on oral suvorexant dose 1. Cocaine will be administered acutely during suvorexant dose 1 maintenance. Placebo will be administered acutely during suvorexant dose 1 maintenance.
16405841|NCT03937986|Experimental|Suvorexant Dose 2|Subjects will be maintained on oral suvorexant dose 2. Cocaine will be administered acutely during suvorexant dose 2 maintenance. Placebo will be administered acutely during suvorexant dose 2 maintenance.
16405842|NCT03937986|Experimental|Suvorexant Dose 3|Subjects will be maintained on oral suvorexant dose 3. Cocaine will be administered acutely during suvorexant dose 3 maintenance. Placebo will be administered acutely during suvorexant dose 3 maintenance.
16405843|NCT03937973|Experimental|Social rejection by in-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone of their own race/ethnicity (e.g., African American rejected by another African American).
16405844|NCT03937973|Experimental|Social rejection by out-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone not of their own race/ethnicity (e.g., Caucasian American rejected by another African American).
16405847|NCT03937934|Experimental|Subjects with long term health condition|Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton
16405848|NCT03937921||Group 1 - Dotarem|Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study
16405849|NCT03937921||Group 2 - Gadavist|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.
16405850|NCT03937908|Experimental|2g CAP|Single administration of 2g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
16405851|NCT03937908|Experimental|4g CAP|Single administration of 4g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
16405852|NCT03937895|Experimental|Experimental: single arm|"Biological: 'SMT-NK' Inj. (allogeneic Natural Killer cell) weekly administration for 2 weeks. After that, 1 week is a withdrawal period. (Phase 1: up to *cycle 3, Phase 2a: up to cycle 9)
~Drug: Pembrolizumab administration of Pembrolizumab 200mg/m2 at first week during cycle.
~Cycle: 1 cycle is 3 weeks in total.'SMT-NK' Inj is administered at first and second week, and Pembrolizumab is administered at first week. The third week is a withdrawal period."
16405853|NCT03937882|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
16405854|NCT03937882|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
16405855|NCT03937869|Other|Single dose Solosec (secnidazole) 2g oral|Solosec 2 grams, oral
16405856|NCT03937856|Experimental|Intervention group|Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
16405857|NCT03937856|No Intervention|Control group|Usual care participants.
16405858|NCT03937843|Experimental|Arm with 2 cohorts|"Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:
~Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday.
~Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:
~Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday."
16405859|NCT03937830|Experimental|1/ Arm 1|Durvalumab, bevacizumab and tremelimumab
16405860|NCT03937830|Experimental|2/ Arm 2|Durvalumab, bevacizumab, tremelimumab and TACE
16405864|NCT03937791|Experimental|Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells|1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
16405865|NCT03937778|Experimental|Tourniquet block to left upper arm|Participants underwent ~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
16405866|NCT03937765|Experimental|PRP|Intervention group will receive PRP instead of the standard of care for skin grafts. PRP Group-will remove surgical dressing post operative day 5. Donor site will be cleaned with soap and water daily and dressed with gauze daily until drainage stops.
16405867|NCT03937765|No Intervention|Control|Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.
16405868|NCT03937752||Anal fistula|Patients with anal fistulas, no previous fistula procedures. Ultrasound investigation done as a part of surgical treatment, such as loose seton or fistulotomy.
16406468|NCT03933358||Euthyroid|
16405869|NCT03937739||Group 1: Case group,|The patients who admitted to the general surgery for operation with inguinal hernia were the case group of this study.
16405870|NCT03937739||Group 2: Control group,|The patients who were admitted to the same hospital with such as eye, ear/nose/throat, dermatologic diseases or elective surgeries and did not have any inguinal hernia complaints, constipation and other chronic disease which could increase the intra abdominal pressure selected as control group.
16405871|NCT03937726|Experimental|Boiled peanut Oral Immunotherapy|Desensitisation using boiled peanut
16405872|NCT03937726|Active Comparator|Conventional Oral immunotherapy|Desensitisation using defatted peanut flour
16405873|NCT03937713|Experimental|BBTI plus eszopiclone|participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.
16405874|NCT03937713|Active Comparator|BBTI|participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.
16405875|NCT03937700|Experimental|CPWalker Robotic-Assisted Gait Training|Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
16405876|NCT03937687|Placebo Comparator|Placebo|300 mg cellulose
16405877|NCT03937687|Experimental|Caffeine|300 mg caffeine
16405878|NCT03937687|Experimental|Caffeine Combination|150 mg caffeine with 100 mg Dynamine and 50 mg TeaCrine
16405879|NCT03937674|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
16405880|NCT03937661|Experimental|Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.
16405881|NCT03937661|Placebo Comparator|Control Group: participants receiving Platelet Free Plasma|Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period
16405882|NCT03937648|Experimental|COL-144 50mg|
16405883|NCT03937648|Experimental|COL-144 100mg|
16405884|NCT03937648|Experimental|COL-144 200mg|
16405885|NCT03937648|Experimental|COL-144 400mg|
16405886|NCT03937648|Placebo Comparator|Placebo|
16405887|NCT03937635|Experimental|Arm I (daratumumab, lenalidomide, dexamethasone)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16405888|NCT03937635|Experimental|Arm II (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16405889|NCT03937609|Other|Standard dosing|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The control group will continue with 5 mg/kg IFX at week 2 and 6, followed by every 8 weeks.
16405890|NCT03937609|Experimental|Intervention group|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The intervention group will receive model based dosing of infliximab with 5mg/kg at various timepoints based on the dashboard model.
16405891|NCT03937596|Experimental|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
16405892|NCT03937596|Placebo Comparator|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
16405893|NCT03937583|No Intervention|Limited screening|Complete clinical history, along with routine physical, analytical examination (creatinine, sodium, potassium, red series, white series, liver and calcium profile) and chest x-ray.
16405894|NCT03937583|Experimental|Extended screening|Limited screening plus positron emission tomography / computed tomography with 18 FDG (18FDG PET-CT).
16405895|NCT03937570|Experimental|EO GROUP|Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.
16405896|NCT03937570|No Intervention|CONTROL GROUP|Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.
16405897|NCT03937557|Active Comparator|men's hair count|
16405898|NCT03937557|Placebo Comparator|women's hair count|
16405899|NCT03937544|Experimental|CD19 CAR-T CELLS|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
16405900|NCT03937531|Experimental|Retrograde-fill void trial (RVT)|Subjects will leave the operating room with a urinary catheter inserted. Subjects should be recovered from anesthesia effects (2-3 hours after surgery) before voiding trial. First, the bladder will be completely drained into the Foley bag then the bag will be detached from the catheter. The bladder will be back-filled with sterile water (300 mL). After the catheter is removed, subjects are expected to void at least 2/3 (200 mL) of the total instilled amount within 30 minutes of filling. Post-void residual (PVR) will be measured by both subtraction of the voided volume from 300cc and by using a bladder scanner.
16405901|NCT03937531|Active Comparator|Spontaneous void trial (SVT)|"Subjects will leave the operating room without a urinary catheter. Participants are allowed up to 6 hours after surgery for spontaneous voiding. After voiding, the voided volume will be noted. PVR will be measured using a bladder scanner.
~In both groups, if PVR >=100 mL on a bladder scanner, an indwelling urinary catheter will be placed and the actual PVR will be documented. Subjects who failed voiding trial will be instructed to return to clinic within 2-4 days for the second void trial. Prophylactic antibiotics will NOT be given. The time to discharge will be measured for each subject. This will be determined by calculating the time between arrival to the PACU and the time of discharge using documentation from EPIC."
16405902|NCT03937518|Other|strontium ranelate|included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years,
16405903|NCT03937518|Other|physiotherapy|included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years
16405904|NCT03937505|Experimental|Dose-escalation|Dose-cohort escalation of single intravenous injection of IS-001 starting with 20 mg (n=8), escalating in 20 mg increments until optimal dose is determined.
16405905|NCT03937505|Experimental|Optimal dose-characterization|Single intravenous injection of IS-001 at the optimal dose will be administered to subjects assigned to the treatment group. Safety control subjects will not receive any study drug but will undergo robotic surgery and all associated safety assessment clinical trial procedures.
16405906|NCT03937492|Experimental|A group|In this group patients follow standard treatment after radius fracture plus GMI procol
16405907|NCT03937492|Active Comparator|B group|In this group patients follow standard treatment after radius fracture
16405908|NCT03937479|Experimental|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
16405909|NCT03937479|Experimental|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
16405910|NCT03937479|Experimental|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
16405911|NCT03937479|Experimental|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
16405912|NCT03937479|Placebo Comparator|Placebo twice daily|Placebo twice daily
16405913|NCT03937466|Experimental|Experimental Cooling Mattress Pad|Subjects will use a cooling mattress pad nightly for approximately 8 weeks
16405914|NCT03937453||New-Onset Diabetes Mellitus|Diabetes Mellitus diagnosed within the past 12 months
16405915|NCT03937440|Experimental|Deep neuromuscular block group|
16405916|NCT03937440|Experimental|Moderate neuromuscular block group|
16405917|NCT03937427||CRS with Asthma|
16405918|NCT03937427||CRS without Asthma|
16405919|NCT03937414|Experimental|SLNs were tested by the OSNA assay Intraoperatively|SLNs were tested by the OSNA assay Intraoperatively
16405920|NCT03937401|Experimental|Patients treated with oxytocin during MRI-HIFU|
16405921|NCT03937388|Experimental|Cochlear implant recipients|
16405922|NCT03937375||High PEEP|Use of high levels of PEEP with recruitment maneuvers
16405923|NCT03937375||Low PEEP|Use of low levels of PEEP without recruitment maneuvers
16405924|NCT03937362||Clinical Response Evaluation|"Patients with operable esophageal squamous cell carcinoma who are planned to undergo neoadjuvant chemoradiotherapy according to the CROSS regimen (intravenous carboplatin AUC 2 mg/mL/min and intravenous paclitaxel 50 mg/m2 on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery.
~Patients will undergo a first clinical response evaluation (CRE-1) 4-6 week after completion of nCRT. In patients without histological evidence of residual tumor surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy."
16405925|NCT03937349||sPTx group|Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism
16405926|NCT03937349||TPTx+AT group|Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism
16405927|NCT03937349||Control group|Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months
16405928|NCT03937336|No Intervention|Control Group|
16405929|NCT03937336|Experimental|Bike Intervention Group|A 1-month bike-based program (1 session/week)
16405930|NCT03937323||Group 1: Pancreatitis group|Patients with biliary pancreatitis
16405931|NCT03937323||Group 2: Control group,|Healthy volunteers
16405932|NCT03937310||Surgical intervention for non-union|The investigation group will consist of cases undergoing surgical intervention for non-union
16405933|NCT03937310||Acute fracture fixation|The control group will consist of cases undergoing acute fracture fixation
16405934|NCT03937297|Experimental|Arm 1|Six Arts intervention
16405935|NCT03937297|Experimental|Arm 2|Cognitive Stimulation Therapy (CST)
16405936|NCT03937297|Active Comparator|Arm 3|Usual care (control group)
16405937|NCT03937284||Parkinson's patients|Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
16405938|NCT03937284||Control group|Subject matched for sex, age and BMI
16405939|NCT03937271||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
16405940|NCT03937271||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 revised Systemic lupus erythematosus criteria
16405941|NCT03937271||Rheumatoid Arthritis|Rheumatoid Arthritis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria
16405942|NCT03937271||Systemic Sclerosis|Systemic Sclerosis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1980 ACR eSystemic Sclerosis criteria
16405943|NCT03937271||Ankylosing spondylitis|Ankylosing spondylitis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1984 Ankylosing spondylitis Modified New York criteria
16405944|NCT03937271||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min
16405945|NCT03937258|Other|PF-04965842 single dose|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
16405946|NCT03937258|Other|PF-04965842 multiple doses|In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions.
16405947|NCT03937258|Other|Probenecid and PF-04965842|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
16405948|NCT03937245||HA-BSI|Patients with HA-BSI treated in an ICU
16405949|NCT03937232|Active Comparator|Cross-Education|Cross education has been defined as the unilateral training of a limb with resisted exercise for the benefit of transferring strength to the contralateral (often injured or immobilized) limb. Participants randomized to cross-education will be provided with a hand-grip strengthener, adjusted to provide resistance at 70-80% of their maximum grip strength. They will be given written, illustrated instructions for performing grip strengthening exercises for their uninjured hand in a seated position with both forearms comfortably supported; this will be demonstrated during the teaching session. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
16405950|NCT03937232|Active Comparator|Mirror Visual Feedback|Mirror visual feedback is the performance of movements with an uninjured hand in front of a mirror hiding the injured hand, thus creating the illusion of bilateral movement. Participants randomized to mirror visual feedback will be provided with a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization of exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete a three sets of 10 repetitions for finger flexion and extension (mimicking the fisting motion of the grip strengthening exercises) twice daily. A diary for tracking exercise completion and attendance for usual care will also be provided.
16405951|NCT03937232|Experimental|Cross-education + Mirror Visual Feedback|In this group, participants will perform the cross-education resistance exercise in front of the mirror, visualizing the performance of the resistance exercises. Participants randomized to cross education with mirror visual feedback will be provided with both a hand-grip strengthener and a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization hand grip strengthening exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
16405952|NCT03937232|Active Comparator|Usual Care|Participants randomized to usual care will be encouraged to attend the recommended rehabilitation, and provided with a diary for frequency of rehab attendance, and tracking any exercises completed at home.
16405953|NCT03937219|Experimental|Experimental Arm|Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
16405954|NCT03937219|Active Comparator|Control Arm|Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
16405955|NCT03937206|Experimental|Low Dose|Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
16405956|NCT03937206|Experimental|Mid Dose|Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
16405957|NCT03937206|Experimental|High Dose|High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
16405958|NCT03937206|Placebo Comparator|Placebo|Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
16405959|NCT03937193||Non-SMAS group|subjects in this group are not clinically diagnosed as superior mesenteric artery syndrome(SMAS).
16405960|NCT03937193||SMAS group|subjects in this group are clinically diagnosed as superior mesenteric artery syndrome(SMAS).
16405961|NCT03937180|Other|Usual care|Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
16405962|NCT03937180|Experimental|Blended care|Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
16405963|NCT03937167|No Intervention|Control|Standard treatment at Hospital Infanta Leonor with Endocrinology and Psyquiatry
16405964|NCT03937167|Experimental|Completers|Randomized to treatment AND complete treatment 14 sessions are needed
16405965|NCT03937167|No Intervention|Drop-out|Randomized to treatment BUT do not assist or do not complete treatment Less than 14 sessions
16405966|NCT03937154|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
16405967|NCT03937154|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
16405968|NCT03937141|Experimental|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
16405969|NCT03937128|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
16405970|NCT03937128|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
16405971|NCT03937115|Experimental|Group S1|High level jump practice : more 4000 hours of practice during the last five years
16405972|NCT03937115|Experimental|Group S2|Amateur jump practice : less 4000 hours of practice during the last five years
16405973|NCT03937115|Experimental|Group C1|High level cycling practice: more 4000 hours of practice during the last five years
16405974|NCT03937115|Experimental|Group C2|Amateur cycling practice: less 4000 hours of practice during the last five years
16405975|NCT03937115|Experimental|Group T|Sedentary : less two hours of recreationally practice of sport by week
16405976|NCT03937089||Patients|Patients with persistent AF, who underwent a CA procedure in the Nancy hospital between January 2011 and April 2017, will be included in this retrospective study.
16405977|NCT03937076|No Intervention|intercostal block|patients will get intercostal block at the end of the surgery, control group
16405978|NCT03937076|Experimental|PECS II block|patients with get PECS II block at the end of the surgery, research group
16405979|NCT03937050|Experimental|Intervention|A package of three interconnected educational/behavioural film-based interventions will developed for delivery at the cluster (clinic) level. The aim of the three components will be as follows: a) improving knowledge of GDM guidelines and skills among health providers involved in GDM management, b) raising awareness of GDM and the importance of screening among pregnant women and their family members, and c) improving confidence and skills in self-management of GDM among women diagnosed.
16405980|NCT03937050|No Intervention|Control|Usual care practices.
16405981|NCT03937037|Experimental|Saline irrigation|CBD stone removal after routine ERCP procedure,100ml saline irrigation after a balloon occlusion cholangiogram confirming the absence of stones.
16405982|NCT03937037|No Intervention|None saline irrigation|CBD stone removal after routine ERCP procedure, a balloon occlusion cholangiogram confirms the absence of stones.
16405983|NCT03937011||Stratafix Arm|The single study arm would comprise of two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure).
16405984|NCT03936998|Experimental|vancomycin plus VE416 before PNOIT|active vancomycin plus VE416 before PNOIT
16405985|NCT03936998|Experimental|Vancomycin plus VE416 with PNOIT|active vancomycin plus active VE416 with active PNOIT
16405986|NCT03936998|Experimental|Placebo plus VE416 with PNOIT|placebo vancomycin plus active VE416 with active VE416
16405987|NCT03936998|Active Comparator|Placebo plus placebo with PNOIT|placebo vancomycin and placebo VE416 with active peanut oral immunotherapy
16405988|NCT03936972||ilizarov circular frame|46 participants with open tibia fracture Gustillo type III only
16405989|NCT03936972||Ex. Fix|47 participants with open tibia fracture Gustillo type III only
16405990|NCT03936959|Experimental|LY3434172|LY3434172 administered IV
16405991|NCT03936946|Experimental|Group 1--October Start Audio Content 1|This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention
16405992|NCT03936946|Other|Group 2--November Start Audio Content 1|This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.
16405993|NCT03936946|Sham Comparator|Group 3--October Start Audio Content 2|This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.
16405994|NCT03936933|Experimental|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
16405995|NCT03936933|Active Comparator|ZOLADEX® 3.6mg Injection.|3.6 mg, Subcutaneously at every 28 days
16405996|NCT03936907|Experimental|Orally Disintegrating MGC-ODT Tablet|Administration of a single tablet of Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5mg THC and 5 mg CBD
16405997|NCT03936907|Active Comparator|Sativex®|Sativex® spray X 2 actuations (1 under the tongue and 1 inside the cheek administered within 2 min) - Reference Product [Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 5.4 mg THC and 5.0 mg CBD]
16405998|NCT03936894|Experimental|Treatment|Canakinumab treatment
16405999|NCT03936868||Tendon transfer for irreversible radial nerve palsy patient|Tendon transfer for irreversible radial nerve palsy patient who had irreversible damage to radial nerve due to trauma with different mechanism especially gun shot injury
16406000|NCT03936855|Active Comparator|Incremental filling technique|Glass ionomer in the pulp chamber and incremental filling technique using composite resin
16406001|NCT03936855|Experimental|Bulk Fill|Bulk fill composite resin filling all the cavity
16406002|NCT03936842|Experimental|Single Arm|"Eligible patients who are referred to the one-stop diagnostic clinic with breast pain alone and have completed a clinical assessment will be given a patient information sheet inviting them to participate in the study. They will be met by the interviewing clinician at the same visit."
16406004|NCT03936816||GBS screened positive|150 patients that were screened positive by culture at 35-37 weeks gestational age.
16406005|NCT03936816||GBS unknown with risk factors|150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
16406038|NCT03936595|Other|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
16406469|NCT03933358||Low T3|low triiodothyronine syndrome
16406006|NCT03936803|Active Comparator|exercise group|Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD) and taking their standard medications in addition to aerobic interval training exercise .Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with heart rate (HR) at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum heart rate HR. The exercise session was terminated by 5 minutes cool-down
16406007|NCT03936803|Active Comparator|electro-acupuncture group|"Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD), and taking their standard medications In addition to electro acupuncture (EA) of (2 Hz, 4 mA) was applied at points of: liver 3 (LR3) ,liver 14 (LR14), gall bladder 34 (GB 34) and stomach 36 (ST36) .
~Duration of the session was 15 min / each, three sessions per week for six weeks"
16406008|NCT03936790|Other|Ropi_dosing|The dose of ropivacaine for each parturient is determined by the response of the previous participant to a higher or lower dose according to the sequential distribution algorithm (up-down sequential allocation).
16406009|NCT03936777|Experimental|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
16406010|NCT03936764|Other|Group 1|5 Preoperative Pulmonary Rehabilitation sessions / week during 3 weeks.
16406011|NCT03936764|Other|Group 2|3 Preoperative Pulmonary Rehabilitation sessions / week during 5 weeks.
16406012|NCT03936751|Active Comparator|CPAP|Continuous positive airway pressure
16406013|NCT03936751|Sham Comparator|Nasal strips|Nasal Strips
16406014|NCT03936725||Chronic and non specific low back pain patients|Chronic and non specific low back pain patients
16406015|NCT03936712|Experimental|Red Bull drink (RB)|Over the study, three participants were unable to complete all test sessions due to muscle pain or injury . Thus, 19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg) completed all test sessions
16406016|NCT03936712|Placebo Comparator|Placebo drink|19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg)
16406017|NCT03936699|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
16406018|NCT03936699|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
16406019|NCT03936686|Active Comparator|Children in grades 4 or 5|This group was comprised of participants that were in grades 4 or 5 in school.
16406020|NCT03936686|Active Comparator|Adolescents in grades 10 or 11|This group was comprised of participants that were in grades 10 or 11 in school.
16406021|NCT03936686|Active Comparator|College Age Participants|This group was comprised of participants that were sophomores or juniors in college/university that were non-health career majors.
16406022|NCT03936686|Active Comparator|Cardiac Rehab Adults|This group was comprised of participants that were adults over the age of 40 that had completed a phase II cardiac rehabilitation program.
16406023|NCT03936686|Active Comparator|General Adults|This group was comprised of participants that were adults over the age of 40 that had never attended an outpatient cardiac rehabilitation program before.
16406024|NCT03936673|Experimental|atrophic kidney|Patients diagnosed with unilateral obstructed kidney with RRF 10% or less underwent application of percutaneous nephrostomy tube on affected side.
16406025|NCT03936660|No Intervention|Control|Clinics in the control arm will be encouraged to follow guideline-based care.
16406026|NCT03936660|Active Comparator|Intervention|The cardiology clinics in the intensive educational intervention arm will receive guidance to develop an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
16406027|NCT03936647|Active Comparator|Standard conventional treatment (surgical or endovascular)|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
16406028|NCT03936647|Experimental|WEB embolization device|Endovascular treatment with WEB, including standard management of thrombo-embolic risk
16406029|NCT03936634||Newly Diagnosed (ND)|Recruited within 6 weeks of type 1 diabetes diagnosis. Age between 1 and <45 years
16406030|NCT03936634||Unaffected Family members (UFM)|"Participants who are not diabetic but have a first degree relative with type 1 diabetes diagnosed < 45 years of age.
~Age between 1 and <45 years"
16406031|NCT03936621|Active Comparator|Group 1: Omega 3 Fatty Acid|Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. In the first 6 months, you will be asked to take one capsule of Omega 3 fatty acids with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks. In the next 6 months (Months 7 to 12), you will have a blood test for markers of inflammation at the end of Month 7 and at Month 9 and 12 to determine if the anti-inflammatory effects of Omega 3 acids are still there after you have stopped taking it.
16406032|NCT03936621|Placebo Comparator|Group 2: Control Arm|No Omega 3 fatty acids for the first 6 months followed by Omega 3 fatty acids for the next 6 months. You will be asked to have a blood test for markers of inflammation at Month 1, 3 and 6 for markers of inflammation to determine the natural variation of the levels of these markers without Omega 3 fatty acid supplements. In Month 7, you will be asked to take one capsule of Omega 3 with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks.
16406033|NCT03936608|Experimental|Individualized RV-LV Pacing Offset|
16406034|NCT03936608|Active Comparator|No RV-LV Pacing Offset|
16406035|NCT03936595|Experimental|Core exercises protocol|Participants will perform 4 core exercises
16406036|NCT03936595|Experimental|Structural exercises protocol|Participants will perform 4 structural (Olympic lifting) exercises
16406037|NCT03936595|Experimental|Accentuated eccentric load exercises protocol|Participants will perform 4 exercises with eccentric loading
16406039|NCT03936582|Experimental|Treatment|All owners/managers of small businesses in 10 treatment neighborhoods will receive a request to support youth physical activity. The owners/managers will be able to direct support to specific programs, get recognized for their support, receive added information on the benefits of supporting such programs, have the oversight of an advisory board and interface with a local program representative
16406040|NCT03936582|Active Comparator|control|All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
16406041|NCT03936569|Experimental|Marketed Stannous Fluoride Toothpaste|Brush twice daily
16406042|NCT03936569|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
16406043|NCT03936556|Experimental|Marketed Stannous Fluoride Paste|Brush twice daily
16406044|NCT03936556|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
16406045|NCT03936543|Experimental|Extended axillary midline|Operator stands at the bedside on extended midline of the patient's lt. axilla during lt. internal jugular vein catheterization
16406046|NCT03936543|Active Comparator|Extended head midline|Operator stands at the bedside on extended midline of the patient's head during lt. internal jugular vein catheterization.
16406047|NCT03936517|Other|Prednisolone first; hydrocortisone second|Participant will receive 4 months of prednisolone in the first study period and 4 months of hydrocortisone in the second study period.
16406048|NCT03936517|Other|Hydrocortisone first; prednisolone second|Participant will receive 4 months of hydrocortisone in the first study period and 4 months of prednisolone in the second study period.
16406049|NCT03936504|Active Comparator|Control Group|Group received conventional exercise rehabilitation programs (CERP).
16406050|NCT03936504|Experimental|Experimental Group|Group received Tai Chi cardiac rehabilitation program(TCCRP).
16406051|NCT03936491|Experimental|Methylphenidate|The subjects will receive methylphenidate according to their clinical symptoms
16406052|NCT03936491|Active Comparator|Atomoxetine|The subjects will receive atomoxetine according to their clinical symptoms
16406054|NCT03936465|Experimental|Cohort A|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
~Patients with unselected relapsed or refractory solid tumors or lymphoma"
16406055|NCT03936465|Experimental|Cohort B|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
~Patients with relapsed or refractory solid tumors, lymphoma, or CNS tumors that have defined molecular features predicted to increase sensitivity to BET inhibition"
16406056|NCT03936452|Experimental|Treatment arm|Sintilimab 200mg ivdrip D1 Peg-aspargase 2500U/m2 im D1 Anlotinib 12 mg po D1-14 repeat every three weeks
16406057|NCT03936439||Consecutive stroke patient|All consecutive stroke patients from five time points, i.e. 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018 are selected for analysis.
16406058|NCT03936426|Experimental|SARTATE|All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
16406059|NCT03936413|Experimental|Bay Labs EchoGPS group|In this arm, medical residents will use the Bay Labs EchoGPS system to perform an echocardiogram.
16406060|NCT03936413|Active Comparator|Native Terason group|In this arm, medical residents will use the native Terason machine to perform an echocardiogram.
16406061|NCT03936400|Experimental|Randomized controlled trial|Experimental group receiving a couple-based intervention
16406062|NCT03936400|Active Comparator|Active comparator: control group|A control group that receives same but delayed couple-based intervention
16406063|NCT03936387|Experimental|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
16406064|NCT03936374|Experimental|BMS-986205 + Omeprazole|
16406065|NCT03936361|Active Comparator|Statin|The same statin agent and dose that subjects were using at the time of ICH onset.
16406066|NCT03936361|No Intervention|No-statin|Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects.
16406067|NCT03936348|Experimental|FB group|Participants who performed an exercise training program for 8 weeks using a nasal restriction device for inspiratory muscle training, called Feelbreathe®
16406068|NCT03936348|Experimental|ONB group|Participants who performed an exercise training program for 8 weeks with oronasal breathing without FB
16406069|NCT03936348|No Intervention|control group (CG)|Participants who received the standard medical recommendations for patients with COPD, but not participated in the exercise intervention program
16406070|NCT03936335||Dupilumab cohort|"Exposed to dupilumab during the relevant exposure window:
~First trimester
~Pregnancy"
16406071|NCT03936335||Other systemic therapy or phototherapy cohort|"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:
~First trimester
~Pregnancy"
16406072|NCT03936335||Unexposed cohort|"Not exposed to systemic medications (including dupilumab) or phototherapy; and
~Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:
~First trimester
~Pregnancy"
16406073|NCT03936322|Experimental|Pregnant women diagnosed with fetal myelomeningocele|Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.
16406074|NCT03936309|Experimental|Scar Deactivation Surface Release|Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
16406075|NCT03936309|Experimental|Scar Infiltration with 0.25-1% Lidocaine|Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
16406076|NCT03936309|Experimental|Physical Therapy|Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
16406077|NCT03936296|Active Comparator|fusion arm|Patients in this arm will be undertaken standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy
16406078|NCT03936296|Other|Standard arm|Patients in this arm will be undertaken only standard transrectal prostate biopsy
16406079|NCT03936283|Experimental|Lifestyle Intervention|
16406080|NCT03936283|No Intervention|Usual Care|
16406081|NCT03936270|Experimental|Palbociclib 125mg + Letrozole 2.5mg|Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment).
16406082|NCT03936257|Placebo Comparator|Breast milk|group receiving breastfeeding
16406083|NCT03936257|Active Comparator|infant formula conventional BIO|infant formula with conventional whey BIO
16406084|NCT03936257|Active Comparator|infant formula BIO TrueGreen|infant formula with whey BIO TrueGreen
16406085|NCT03936244|Active Comparator|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
16406086|NCT03936244|Experimental|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
16406087|NCT03936218|Experimental|Inj. Goserelin (Test) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
16406088|NCT03936218|Active Comparator|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
16406089|NCT03936205|No Intervention|Control|
16406090|NCT03936205|Experimental|Dexmedetomidine|
16406091|NCT03936192|Experimental|glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)|glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
16406092|NCT03936192|Active Comparator|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.
16406093|NCT03936192|Placebo Comparator|Placebo|Placebo administered once daily for 12 weeks
16406094|NCT03936179|Experimental|high dose radiochemotherapy|A total dose of 86 Gy to residual metabolic disease with concurrent chemotherapy
16406095|NCT03936166|Experimental|Single Ascending Dose (Part 1)|
16406096|NCT03936166|Experimental|Multiple Ascending Dose (Part 2)|
16406097|NCT03936166|Placebo Comparator|Elderly Cohort (Part 3)|
16406098|NCT03936153|Experimental|Abexinostat 80 mg bis in die (BID)|Abexinostat 80 mg BID
16406099|NCT03936140|Experimental|Iloprost 10|"Iloprost 10μg of inhaled iloprost (Ventavis®)
~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
16406100|NCT03936140|Experimental|Iloprost 20|"Iloprost 20μg of inhaled iloprost (Ventavis®)
~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
16406101|NCT03936140|Placebo Comparator|Distilled water|"Distilled water
~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
16406102|NCT03936127|Experimental|Transperineal (TP) Ultrasound (US) Targeted Fusion Biopsy|Transperineal (TP) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
16406103|NCT03936127|Active Comparator|Transrectal (TR) Ultrasound (US) Targeted Fusion Biopsies|Transrectal (TR) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
16406104|NCT03936114|Experimental|SMART|
16406105|NCT03936101||Prenatally Sequenced Group|750 trios with fetal structural anomalies who receive prenatal sequencing from the study
16406106|NCT03936101||No Prenatal Sequencing (Unsequenced) Group|350 trios with fetal structural anomalies who do not have prenatal sequencing
16406107|NCT03936088|Experimental|Intervention with Mindfulness App (Headspace)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the mindfulness (intervention) app.
16406108|NCT03936088|Active Comparator|Control with Water App (My Water Balance)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the My Water Balance (control) app and provided an in-person demonstration on how to use it.
16406109|NCT03936075|Experimental|intervention|treatment with the provision of 6 individual sessions of the Guided Imagery and Music method as a psychological supportive intervention, and psychometric questionnaires collection
16406110|NCT03936075|Placebo Comparator|control|standard care treatment with psychometric questionnaires collection and two individual counselling sessions, at baseline (week 1) and at the end (week 6)
16406111|NCT03936062||2nd Generation SUs|Reference group
16406112|NCT03936062||Sitagliptin|Exposure group
16406113|NCT03936049||DPP-4 inhibitor|Reference group
16406114|NCT03936049||Liraglutide|Exposure group
16406115|NCT03936036||2nd generation sulfonylureas|Reference group
16406121|NCT03935997|Experimental|Step 1|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
16406122|NCT03935997|Experimental|Step 2|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
16406123|NCT03935997|Experimental|Step 3|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
16406124|NCT03935984|Experimental|Treatment Group|All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging
16406125|NCT03935971|Experimental|Subjects with Allergic Contact Dermatitis|Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks
16406126|NCT03935958|Experimental|Curcumin Arm (Arm 1)|20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood and urine samples and questionnaires.
16406127|NCT03935958|Placebo Comparator|Placebo Arm (Arm 2)|20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood and urine samples and questionnaires.
16406128|NCT03935945|Experimental|Personalized Feedback Intervention (PFI)|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes.
16406129|NCT03935945|No Intervention|Attention-Control|Attention control information will be comparable in focus on health-related behaviors (e.g., nutrition, exercise). We will use behaviors in the attention control feedback that are not associated with study outcomes. Attention control feedback will have text and graphs that are similar in appearance and length (i.e., 20-30 minutes) to intervention feedback.
16406130|NCT03935932|Experimental|baseline followed by intervention|Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
16406131|NCT03935932|Experimental|intervention followed by baseline|Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
16406132|NCT03935906|Experimental|Reach Pathway|Community pharmacist will explain the risks of contracting HCV from current or historical intravenous drug use. OST patients will then meet with an outreach hepatology nurse specialist who will perform a diagnostic point-of-care (PoC) HCV test along with venepuncture for safety blood tests and confirmatory HCV RNA on the pharmacy premises. The nurse will return for a subsequent visit to prescribe (in the UK; in Australia prescribing is undertaken by qualified medic) and deliver HCV medication for participants who test positive, which will be dispensed alongside their OST schedule by their community pharmacist. The outreach nurse will return after approximately 14 days to confirm negative results, dispense medication for new patients with positive results (PCR positive but below limit of detection of POC test) and confirm follow up appointments where required. The RNA and PoC test will also be administered for sustained viral response at 12 weeks post treatment (SVR12).
16406133|NCT03935906|Experimental|Education-only Pathway|The community pharmacist will discuss the risks of contracting HCV through current or historical intravenous drug use. The community pharmacist will then advise participants on the nearest centre for HCV testing and treatment, as is standard of care for the countries included in this study. If they are referred from a REACH pharmacy, they will present a reply slip and/or the Patient Information Sheet to the nurse who will then consent the participant, perform HCV and safety blood tests, and complete the study paperwork. The participant's medication will be delivered to, and dispensed from, their community pharmacy alongside their OST. Participants will return to the local BBV clinic for an SVR12 test after completing treatment.
16406134|NCT03935893|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic gastric/esophagogastric, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal squamous cell, Merkel cell, cancers refractory to systemic therapy, and those with deficient mismatch repair and/or microsatellite instability cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused through a central vein catheter and administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
16406135|NCT03935880|Active Comparator|Cartiva Hemiarthroplasty|Cartiva implant
16406136|NCT03935880|Active Comparator|Cheilectomy|Bone spur removal
16406137|NCT03935867|Experimental|C-PROFET group|Community-dwelling, older adults participating in a home-based program -- C-PROFET, our adaptation of Prevention Of Falls in the Elderly Trial (PROFET).
16406138|NCT03935854|Experimental|Ketogenic Diet 16 Week Group|
16406139|NCT03935841|Experimental|3-OHB orally|36 gram 3-OHB salt consumed orally
16406140|NCT03935841|Active Comparator|3-OHB intravenously|Variable amounts of 3-OHB salt given i order to replicate the same individual plasma concentrations measured during the experimental arm.
16406141|NCT03935828|Experimental|Topical Sinonasal Antibiotics|For topical antibiotics, the compounding pharmacy will use pre-determined doses using data extrapolated from oral and intravenous doses and data that has detailed the effect of the medication on solubility, pH, and particle properties. Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml, all to be prescribed for 21 days, applied twice a day. Although the dosing schedule for these topical antibiotics has not been definitively studied, the majority of the data supports a range from two to three times daily for three to four weeks. Patients will be instructed by the pharmacist how to dissolve the cream, powder, or vial of antibiotic in saline, and to irrigate each nostril with 120 ml total. Doses will not be varied during the study period.
16406142|NCT03935828|Active Comparator|Oral Antibiotics|Oral antibiotics will be prescribed for 21 days, as available (albeit limited) evidence recommends antimicrobial therapy in CRS for at least 3 weeks. For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours, Levofloxacin 500 mg once daily, or Clindamycin 300 mg every 6 hours, as these are standard of care for treatment of Chronic Rhinosinusitis.
16406498|NCT03933137||Prolonged length of stay|Living donor patients who had > 6 days length of stay after laparoscopic nephrectomy procedure
16406143|NCT03935815|Active Comparator|Intervention|"Standard of care pain management plus quadratus lumborum nerve block.
~Ropivicaine 0.25% 60 mL will be injected in the fascial plane between the quadratus lumborum muscle and transverses abdominus muscle."
16406144|NCT03935815|Sham Comparator|Control|Standard of care pain management plus a sham procedure.
16406145|NCT03935802||primary non-metastatic breast cancer|primary non-metastatic breast cancer
16406146|NCT03935789|Experimental|BLAST|All participants in this study will be assigned to this group to participate in the BLAST intervention. The intervention will be a self-guided web-based platform using a self-management model to help support better engagement in everyday life activity
16406147|NCT03935776|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend a 12-week intensive lifestyle programme.
~The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.
~Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes."
16406148|NCT03935776|Active Comparator|Standard Healthcare|The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
16406149|NCT03935750|Experimental|BPTB + LET|Patients will undergo anterior cruciate ligament reconstruction (ACLR) using a bone patellar bone tendon (BPTB) autograft with lateral extra-articular tenodesis (LET).
16406150|NCT03935750|Active Comparator|BPTB alone|Patients will undergo ACLR using a BPTB autograft without LET.
16406151|NCT03935750|Experimental|QT + LET|Patients will undergo ACLR using a quadriceps tendon (QT) autograft with LET.
16406152|NCT03935750|Active Comparator|QT alone|Patients will undergo ACLR using a QT autograft without LET.
16406153|NCT03935737||Full dose Chest X-Ray|Subjects will receive a full (standard) dose chest X-ray at Day 1.
16406154|NCT03935737||Low dose Chest X-Ray|Subjects will receive a follow up X-ray at at a lower dose within 3 months after the first dose.
16406155|NCT03935724|Experimental|1A Intervention group 8 patients|Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident). N=8
16406156|NCT03935724|Placebo Comparator|1B Placebo group 8 patients|Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=8
16406157|NCT03935724|Experimental|2A Intervention group 27 patients|Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident) N=27
16406158|NCT03935724|Placebo Comparator|2B Placebo group 27 patients|Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=27
16406159|NCT03935698|Experimental|Physiotherapy|12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises.
16406160|NCT03935685|Experimental|mirtazapine in glioma patients treated with Temozolomide|Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
16406161|NCT03935672|Other|All trial participants|"Baseline plasma and saliva tests for future translational analysis
~Baseline planning FDG PET CT scan
~Patients will start their 6 weeks of CCRT within two to three weeks following the planning scans. Cisplatin chemotherapy will be administered. 33 daily fractions of radiotherapy will be delivered over 6 weeks.
~A second FDG-PET-CT scan (iPET) and repeat plasma and saliva tests will be carried out after 2 weeks of CCRT (on RT days 9 - 12) and the iPET assessed for residual FDG-avid disease. The biological GTV will be re-outlined based on the residual avid region of the tumour on the second PET-CT (bGTV_iP)
~At the end of treatment, plasma and saliva tests will be carried out at 4 weeks post treatment and again at the 3 month post-treatment PET-CT
~Swallowing and QoL assessments will be repeated 4 weeks (+/- 2 weeks) after treatment and will be repeated at 6, 12 and 24 months post-treatment. The plasma and saliva samples will be repeated at 12 and 24 months"
16406162|NCT03935659|Active Comparator|Standard gauze therapy|The control group will receive a standard sterile gauge dressing over the groin incision. The dressing will be removed on post-operative day #2 and the wound will be inspected for any complications, followed by daily dressing changes and wound inspections until discharge.
16406163|NCT03935659|Experimental|Negative Pressure wound therapy|The intervention group will receive a negative pressure dressing which will be applied in the operating room under sterile conditions. The brand of negative pressure dressing will be based on surgeon preference or center availability. The NPWT dressing will be removed on day 5 postoperatively or at discharge, whichever occurs first, and the groin wound inspected for any evidence of infection or dehiscence, and daily thereafter until discharge.
16406164|NCT03935646|Experimental|Stimulant Medication|Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
16406165|NCT03935633|Experimental|First Dosage|The dose of CN128 is 20 mg/kg bw， bid.
16406166|NCT03935633|Experimental|Second Dosage|The dose of CN128 is 15 mg/kg bw， bid.
16406167|NCT03935620|Experimental|EMT|After a period of stable baseline performance (3 to 5 sessions) for parents and children the interventionists will apply the EMT Language Intervention.
16406168|NCT03935607||Normal amniotic fluid index|Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
16406169|NCT03935607||Oligohydramnios|Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
16406198|NCT03935412|Active Comparator|ES Erector Spinae Plane Block|By the end of surgery parturient in the ESPB underwent bilateral ESPB at the level of T9 using a linear ultrasound (US) transducer (Phillips Saronno Italy) the transducer was placed vertically3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine 22-G short bevel needle (spinocan, B.Braun melsungen AG, Germany) was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml 0.5% bupivacaine was done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
16406170|NCT03935594|Experimental|PRP injection right half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.
~After finishing the VSS and POSAS, the area inside the control half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL normal saline into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.
~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
16406171|NCT03935594|Experimental|PRP injection left half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.
~After finishing the VSS and POSAS, the area inside the experimental half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL PRP into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.
~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
16406172|NCT03935581|Experimental|ExAblate 4000 System|ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
16406173|NCT03935568|Experimental|Single Dose Placebo|Patients randomized to receive Placebo
16406174|NCT03935568|Experimental|Single Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
16406175|NCT03935568|Experimental|Multiple Dose (Placebo)|Patients randomized to receive Placebo
16406176|NCT03935568|Experimental|Multiple Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
16406177|NCT03935555|Experimental|Oral - 50mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
16406178|NCT03935555|Experimental|Oral -100 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
16406179|NCT03935555|Experimental|Oral - 200 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
16406180|NCT03935555|Experimental|Oral - 300 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
16406181|NCT03935542||MPI arm|For the MPI arm, patients with severe jailed diagonal branch disease with available MPI in 3 months were selected from the Seoul National University Hospital Cardiac Catheterization and MPI database.
16406182|NCT03935542||CCTA arm|For the CCTA arm, patients from a previous multicenter prospective CCTA registry were retrospectively reviewed for a post-hoc analysis.
16406183|NCT03935529|Experimental|Behavioural Acitivation|Behavioural Activation. Originally a component of cognitive behavioural therapy, Behavioural Activation is a structured psychotherapeutic approach which aims to (a) increase engagement in activities associated with pleasure or mastery, (b) decrease engagement in activities that maintain depression, and (c) problem solve barriers limiting access to reward or maintain aversive control. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
16406184|NCT03935516|Experimental|Flexed Elbow|The first group will be placed in a cast with the elbow bent.
16406185|NCT03935516|Experimental|Extended Elbow|The second will be placed in a cast with the elbow straight.
16406186|NCT03935503||Total Extraperitoneal Repair|Laparoscopic Total Extraperitoneal (TEP) method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
16406187|NCT03935503||Lichtenstein repair|Lichtenstein method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
16406188|NCT03935490||e-TREPP|Patients with strangulated inguinal hernia treated with e-TREPP
16406189|NCT03935477||High risk surgery|those undergoing elective and emergency, high-risk surgery receiving arterial cannulation and urethral catheterisation as standard
16406190|NCT03935477||Critical Care|Emergency admissions to UCLH critical care unit receiving arterial cannulation and urethral catheterisation as standard
16406191|NCT03935464|Experimental|Intervention Arm|POC adherence testing by a urine TFV assay with feedback
16406192|NCT03935464|No Intervention|Standard of Care|Follow Kenya's PrEP guidelines on standard adherence counselling
16406193|NCT03935451|Placebo Comparator|Placebo|The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.
16406194|NCT03935451|Experimental|Experimental|The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.
16406195|NCT03935438|Experimental|Patients after ACS|Patients after acute coronary syndrome undergoing cardiac rehabilitation.
16406196|NCT03935425|Experimental|FitMi Plus|"Participants will perform targeted movement exercises by interacting with the FitMi Plus Functional modules at least 50% of the time they spend exercising.
~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
16406197|NCT03935425|Active Comparator|FitMi Basic|"Participants will perform targeted movement exercises by interacting with the FitMi Basic pucks, as described and monitored on a computer.
~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
16406306|NCT03934541|Placebo Comparator|Group 2 (Control 2): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
16406199|NCT03935412|Sham Comparator|intrathecal morphine ITM|participant in the ITM group intrathecal injection of 10mg of hyperbaric bupivacaine 0.5 % in addition to 100 mcg of preservative-free morphine. Then, the parturient immediately placed in the supine position with 15° left tilt, and an oxygen mask was applied at 2 l.min-1. After ensuring sufficient anesthesia level, the surgical procedure was done with continuous hemodynamics monitoring and recording. While participants in the ITM group underwent sham blocks; Sham blocks consisted of a non-invasive ultrasound scan, while a blunt needle was gently pressed on both sides.
16406200|NCT03935399|Other|Oxytocin first, then saline placebo|Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day
16406201|NCT03935399|Placebo Comparator|Saline placebo first, then oxytocin|Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day
16406202|NCT03935386|Active Comparator|Standard Compression|Standard multi-layer compression dressing with no graft or biologic material added
16406203|NCT03935386|Active Comparator|Standard Compression with application of human allograft|standard compression with application of a cryopreserved skin allograft (TheraSkin)
16406204|NCT03935373||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) primary or secondary SS; (2) aged between 20 and 75 years; (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG); (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; or (3) steroid pulse therapy within three months prior to the commencement of our study.
16406205|NCT03935373||Health subjects|Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 41 and 63 years (which the age could match the SS patients enrolling in the SS-1 trial); (2) had no chronic inflammatory illness. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; (3) abnormal findings of immune, liver, kidney, or blood function evaluations; (4) total sleeping time insufficiency less than 6 hours before one day of enrollment; (5) ever took the conventional medicine or hormone within one month; (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
16406206|NCT03935347|Experimental|Treatment (cyclophosphamide, fludarabine, pembrolizumab)|Patients receive cyclophosphamide IV over 2 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -2, and pembrolizumab IV over 30 minutes on day -1. At least 24 hours later, patients receive autologous tumor infiltrating lymphocytes LN-145 IV on day 0, and receive aldesleukin IV over 30 minutes for up to 6 doses on days 1-4. Patients then continue receiving pembrolizumab IV over 30 minutes beginning on day 21. Cycles of pembrolizumab repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity.
16406207|NCT03935334|Experimental|Eptacog alfa, biosimilar (AryoSeven)|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
16406208|NCT03935334|Active Comparator|Novoseven|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
16406211|NCT03935308|Experimental|MR-guided SBRT With SIB to the DILs to Prostate Cancer|Dose escalation to the DIL(s) will be performed in the traditional Phase I 3+3 design. Patients will be treated in four cohorts (three patients per dose level) starting with a dose of 9 Gy to the DIL(s). If no dose limiting toxicity (DLT), defined below, is observed after 90 days, then an additional three patients will be entered at the next dose level. Dose to the DIL(s) will be escalated at 1 Gy increments until DLT is observed or if maximum dose level (60 Gy in 5 fractions of 12 Gy) is reached with no observed DLT. If one of the three patients experience a DLT at a particular dose level an additional three patients will be enrolled at that level. If two or more patients experience a DLT a lower dose level will be explored to define the maximum tolerated dose (MTD). The three patients within any cohort can be enrolled simultaneously or sequentially without any waiting period among them.
16406212|NCT03935295|Experimental|Botulinum Toxin|"The investigators plan to administer approximately 1000 U Dysport ® in the concave-sided paraspinal musculature of the major curve, based on an estimated total dose of 1000 U, the maximum allowable dose. The total dose per treatment session will not exceed 15 units/kilogram or 1000 units, whichever is lower. If two curves are equivalent within 3˚, both will be treated, however, the dosing (described above) will be divided equally across both curves.
~There will be two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
16406213|NCT03935295|Placebo Comparator|Placebo|"Control patients will receive an injection of placebo specifically prepared as a control for this study. The same volumes as indicated in the experimental arm description will be injected.
~These will be administered during two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
16406214|NCT03935282|Experimental|Intervention - AH-HA tool|With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
16406215|NCT03935282|No Intervention|Usual Care|Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.
16406216|NCT03935269|Experimental|Intervention with Ambulatory Therapy|Caregivers of participants with high-grade glioma will undergo standard Cereset Research Office (CRO) in-office treatment for a total of five (5) treatments. Ambulatory therapy with the Cereset Research Wearable (CRW) will be available to caregivers while they are attending routine radiation therapy with glioma patients.
16406307|NCT03934528|Experimental|Pilot Study|
16411259|NCT03900338||PWV<10|Patients with PWV < 10 (SphygmoCor) in two different measurements
16406217|NCT03935256|Experimental|Full Dose Chemo, Reduced Dose Chemo + RT, Full Dose Chemo|Week 1 : Cycle 1: Full Dose Carboplatin and Paclitaxel Week 4: Pelvic Radiotherapy Begins Cycle 2: Dose reduced Carboplatin and Paclitaxel Week 7 : Cycle 3: Dose reduced Carboplatin and Paclitaxel Weeks 10,13,16: Cycle 4-6: Full Dose Carboplatin and Paclitaxel
16406218|NCT03935243|Experimental|equine assisted therapy|In the active intervention phase, patients participate twice a week in a equine assisted group therapy, while during the control phase they participate twice a week in a group that includes a non-specific and general activity program. After 15 therapy units in a study phase, the subjects will complete the 15 units of the other study phase (within-subject-design). All participants complete both study phases, with the order being randomized.
16406219|NCT03935243|Active Comparator|activating control phase|"In the present study, the interventions in the control phase are based on the sub-program Social Skills of the Integrated Psychological Treatment Program (IPT) for schizophrenic patients (Brenner et al., 1994, Roder et al., 1988, 2002)."
16406220|NCT03935217|Experimental|Solosec (containing 2 grams of secnidazole)|Orally administered as a single dose with applesauce. Upon completion of primary phase patients will receive the opposite treatment (placebo)
16406221|NCT03935217|Placebo Comparator|Placebo|Orally administered as a single dose with applesauce. Upon completion of primary phase patients will receive the opposite treatment (Solosec (containing 2 grams of secnidazole)
16406222|NCT03935204|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
16406223|NCT03935204|Placebo Comparator|Placebo|Participants in this arm would receive 1.0ml aluminium adjuvant.
16406224|NCT03935191||Group|Device: Dexcom CGM System
16406225|NCT03935165|Experimental|Indocyanine Green arm|"All the patients to be enrolled have to meet the inclusion criteria. All enrolled patient is subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions are described.
~Subsequently, 0.25 mg /(kg BW) Indocyanine Green is administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision is made, in order to identify the fluorescent lesions. All the lesions are described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged."
16406226|NCT03935152|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 8 hours until delivery
16406227|NCT03935152|Placebo Comparator|Placebo|placebo by mouth every 8 hours until delivery
16406228|NCT03935126||All patients|
16406229|NCT03935113|Experimental|KT group|The paretic upper limb is a common consequence of stroke that increases activity limitation.
16406230|NCT03935100|Experimental|Treatment Group|All visible diverticula clipped during index colonoscopy
16406231|NCT03935100|Placebo Comparator|Control Group|5 clips fired at random into colon lumen. No diverticula closed.
16406232|NCT03935074||group 1|Patients who received intra-arterial chemotherapy as a first line treatment
16406233|NCT03935074||group 2|Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
16406234|NCT03935061|Experimental|Mulberry juice|Two bottles (600 ml/bottle) of sanitized mulberry juice are delivered to the patients of the experimental group 20 days before the next clinic visit, with instruction to consume 50 ml of juice diluted with drinking water at room temperature. A reminder of the next clinic visit for continuous treatment is attached.
16406235|NCT03935061|No Intervention|Controlled|Patients of the controlled group are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
16406236|NCT03935048|Experimental|Higher Protein, Low Glycemic Load with Potatoes|Higher Protein, Low Glycemic Load with Potatoes (HPLG-P): low- to moderate- glycemic load meals containing white potatoes. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
16406237|NCT03935048|Active Comparator|Higher Protein, Low Glycemic Load with Processed Potatoes|Higher Protein, Low Glycemic Load with Processed Potatoes (HPLG-PP): low- to moderate- glycemic load meals containing processed white potato products. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
16406238|NCT03935048|Placebo Comparator|Higher Protein, Low Glycemic Load - Control|Higher Protein, Low Glycemic Load (HPLG-C): low- to moderate- glycemic load meals containing control carbohydrate (e.g. rice, pasta). Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing control carbohydrate sources.
16406239|NCT03935035|Experimental|internet-Cognitive Therapy for PTSD|This is a single-arm study. All participants will receive the same therapist supported, internet-delivered intervention.
16406240|NCT03935022|Experimental|Black rice Venere|Healthy volunteers will receive the black rice Venere in a cross-over randomized clinical trial (after 7 days wash-out).
16406241|NCT03935022|Experimental|Black rice Artemide|Healthy volunteers will receive the black rice Artemide in a cross-over randomized clinical trial (after 7 days wash-out).
16406242|NCT03935022|Sham Comparator|Complete white rice|Healthy volunteers will receive the complete white rice in a cross-over randomized clinical trial (after 7 days wash-out).
16406243|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°1|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and will be instructed to use them for six weeks.
16406244|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°2|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
16406271|NCT03934814|Experimental|Part 2 - Dose Expansion|30 participants (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 participants with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.
16406329|NCT03934411|Placebo Comparator|Placebo treatment|
16406245|NCT03935009|Active Comparator|Electric toothbrush N°1 with electric toothbrush N°2|Participants will receive an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
16406246|NCT03934996|No Intervention|Assesment Runners|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week.
16406247|NCT03934996|Experimental|Runners with educational training|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week with educational training about pelvic floor muscles.
16406248|NCT03934983||Trauma patients|Subject experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
16406249|NCT03934970||Diabetic Neuropathy|Thirty Egyptian patients with type 2 diabetes mellitus complaining of symptoms suggestive of peripheral neuropathy including 12 males and 18 females with a mean of 50.90 ± 9.18.
16406250|NCT03934970||Healthy Control Subjects|Fifteen normal healthy Egyptian volunteers including10 males and 5 females with a mean age of 45.67±7.77 years.
16406251|NCT03934944|Experimental|Phone application arm|Participants will have access to a educational video and foot alerts at weekly intervals to supplement usual Podiatry care and education.
16406252|NCT03934944|Other|Usual care|Participants will have Podiatry care and education.
16406253|NCT03934931|Experimental|Facilitated Directly Observed Therapy (DOT)|Facilitated DOT arm participants will attend the Mulago Immune Suppression Syndrome (ISS) clinic on a weekly basis to ingest 3HP medication under direct observation. DOT will be defined as a designated clinic staff member observing ingestion of each dose of 3HP. Additionally, participants randomized to facilitated DOT will receive: 1) DOT cards with instructions to present directly to the pharmacy for a pharmacy-only visit, without the need to wait in the general queue; 2) Automated short message service (SMS) or phone call reminders at no cost to participants the day before each appointment, 3) A fixed level of reimbursement (~$5/visit) for each weekly visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
16406254|NCT03934931|Experimental|Facilitated Self-Administered Therapy (SAT)|Facilitated SAT participants will take their 1st dose of medication under direct observation and be given a 4-week 3HP supply to take weekly via self-administration. Participants will return to the Mulago ISS clinic after completing their 5th dose to review adherence data with the clinic pharmacy technician and receive 5 additional 3HP doses (doses 7-11). At the scheduled refill visit (dose 6) and end-of-treatment visit (dose 12) participants will ingest 3HP via direct observation. Participants will also receive: 1) Free automated SMS reminders or phone call reminders before each scheduled dose; 2) Weekly check-ins inquiring about side effects via two-way SMS with a follow-up phone call depending on participant response, 3) Fixed level of reimbursement (~$5/visit) for the refill/end-of-treatment visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
16406255|NCT03934931|Experimental|Patient Choice between facilitated DOT and facilitated SAT|Participants randomized to the Patient Choice between facilitated DOT and facilitated SAT arm will be offered a choice between arms 1 and 2. A research nurse will review each section of the decision aid with participants, discuss values and preferences, and, after addressing any questions, ask participants to select facilitated DOT or facilitated SAT. Participants will have the option to switch between DOT and SAT at any time. The reason for switching and time spent under each strategy will be recorded.
16406256|NCT03934918|Experimental|Treatment|Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
16406257|NCT03934918|No Intervention|Control|Patients for IOL admitted to Labor and Delivery
16406260|NCT03934892||lactate during CPB|check lactate levels routinely during cardiac operations with cardiopulmonary bypass, choose the peak lactate data
16406261|NCT03934879|Experimental|Gateway Academy|For this study, Gateway Academy students will participate in the FitClub intervention. They will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
16406262|NCT03934879|Active Comparator|Control School|Other comparable school will be added as a control school, in which regular school activities will be provided.
16406263|NCT03934866||Group A (LDCT)|"25,000 individuals who are at high-risk for lung cancer due to a significant smoking history.
~Participants will receive at least 1 LDCT scan at baseline."
16406264|NCT03934853|Other|No arm|There is no arm for this study.
16406265|NCT03934840|Experimental|Carboplatin, Cabazitaxel and Abiraterone|
16406266|NCT03934827|Experimental|Part A|"Open label, preliminary phase
~20 participants"
16406267|NCT03934827|Experimental|Part B|"Randomised, double blinded phase
~100 participants"
16406268|NCT03934814|Experimental|Part 1A - TJ011133 Monotherapy|TJ011133 alone will be administered at up to 7 dose levels (0.3, 1, 3, 10, 20, 30, 45 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level).
16406269|NCT03934814|Experimental|Part 1B - Combination therapy of TJ011133 with pembrolizumab|TJ011133 will be administered Q1W, starting at 20 mg/ kg, in combination with pembrolizumab.
16406270|NCT03934814|Experimental|Part 1C - Combination therapy of TJ011133 with rituximab|TJ011133 will be administered Q1W, starting at 20 mg/kg, in combination with rituximab.
16406272|NCT03934801||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.
~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
16406273|NCT03934788|Experimental|Oxysoft|olifilcon C, daily disposable soft contact lens, 1 month
16406274|NCT03934788|Active Comparator|SiHy|olifilcon B, dialy disposable soft contact lens, 1 month
16406275|NCT03934775||Patients with acute illness|Patients admitted to the acute medical/emergency department and/or Cardiology department at Bispebjerg Hospital.
16406276|NCT03934762|Active Comparator|Placebo|A placebo solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
16406277|NCT03934762|Experimental|Natural aloe vera|A natural aloe vera solution (peel and leaf) will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
16406278|NCT03934762|Experimental|Aloe vera soup|An aloe vera soup solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
16406279|NCT03934749||standard mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
16406280|NCT03934749||Lowenstein mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
16406281|NCT03934736|Experimental|HEPLISAV-B®|A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).
16406282|NCT03934723|Active Comparator|Control|This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms.
16406283|NCT03934723|Experimental|Antidpressants|This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year.
16406284|NCT03934710|Placebo Comparator|Placebo|Placebo
16406285|NCT03934710|Experimental|Serotonin agonist|13ug of serotonin agonist
16406286|NCT03934697|Experimental|Imaginal Exposure Session|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
16406287|NCT03934684|Experimental|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone
~Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.
~Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
16406288|NCT03934684|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone
~Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.
~Lenalidomide 25 mg is taken orally on days 1 to 21.
~Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
16406289|NCT03934671|Experimental|Antioxidant dressing (active product)|
16406290|NCT03934671|Active Comparator|Usual care dressing (standard clinical practice)|
16406291|NCT03934658|Experimental|Active Treatment Arm|Intervention with the NightWare Therapeutic System every night.
16406292|NCT03934658|Sham Comparator|Sham Arm|NightWare Therapeutic System every night with interventions not-enabled.
16406293|NCT03934645||Not In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)=0
16406294|NCT03934645||In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)≥4
16406295|NCT03934632|Active Comparator|Postabsorptive|Saline infusion to mimic postabsorptive circulating amino acid concentrations
16406296|NCT03934632|Active Comparator|Postprandial|Amino acid infusion to mimic postprandial circulating amino acid concentrations
16406297|NCT03934619|Experimental|Intervention|Convenient cohort, non-randomized group will be enrolled to examine the effects of the Dolores One on improving the ease of communication and intelligibility
16406298|NCT03934593|Experimental|Faith-Based (FB, BHT DSMS)|The BHT DSMD intervention strategies adapted Stanford DSMP in a spiritual context is used in this group. Participants in the FB group will participate in BHT DSMS, which includes a Health Sermon, a 6-session Health Bible Study with cooking demonstrations, the Stanford DSMP and a Diabetes Resource Seminar delivered by two trained church lay leaders.
16406299|NCT03934593|Active Comparator|Faith-Placed (FP, Stanford DSMP)|The traditional Stanford DSMP is conducted in this control group. Participants in the FP group will first attend a 7-session community health and safety curriculum as a partial attention control intervention, followed by the Stanford DSMP and Diabetes Resource Seminar facilitated by the local public health department.
16406300|NCT03934580|Experimental|hallucinated meal|A breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated under hypnosis by participants for 15 minutes
16406301|NCT03934580|Active Comparator|real meal|A real meal (white bread plus ham and cheese with 250 ml still water) is consumed by participants in 15 minutes
16406302|NCT03934567|Experimental|Abexinostat 80 mg bis in die (BID)|Experimental: Abexinostat 80 mg BID
16406303|NCT03934541|Experimental|Group 1 (Treatment 1): MPER-656 Liposome Vaccine|Participants will receive 500 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
16406304|NCT03934541|Placebo Comparator|Group 1 (Control 1): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
16406305|NCT03934541|Experimental|Group 2 (Treatment 2): MPER-656 Liposome Vaccine|Participants will receive 2000 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
16406308|NCT03934515||Group A - etCO2|"At the end of the anaesthesia , as usual, the secretions are aspirated with a suction tube of 18 Fr of caliber (diameter 6 mm). When the tube is inserted into the endotracheal tube, before proceeding with the aspiration of the secretions, a capnometer is attached to its outer end, measuring the etCO2 value for 10-15 seconds. At the end of the measurement, authors proceed with the aspiration of the secretions as usual.
~Authors then proceed with the laying of a NGT according to local protocols. Also in this case, once the NGT has been inserted, the etCO2 is measured at the end of the probe for 10-15 seconds. At the end of the measurement, the capnometer can be detached, as a standard procedure, and the NGT can be used as usual.
~At the end of the procedure, therefore, for each patient, two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values recorded at the endotracheal level and the one recorded at the oesophageal level."
16406309|NCT03934515||Group B - pH|"At the end of the anaesthesia , once the NGT is inserted, the pH is measured by aspirating the gastric contents and measuring on specific litmus paper the pH values, both at a distance of 25 cm from the mouth (oesophageal site) and at a distance of 40 cm (gastric site).
~At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at oesophageal level and a value at the gastric level."
16406310|NCT03934502|Experimental|Evobrutinib: Treatment Sequence A, B, C, D|Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.
16406311|NCT03934502|Experimental|Evobrutinib: Treatment Sequence B, D, A, C|Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
16406312|NCT03934502|Experimental|Evobrutinib: Treatment Sequence C, A, D, B|Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.
16406313|NCT03934502|Experimental|Evobrutinib: Treatment Sequence D, C, B, A|Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.
16406314|NCT03934489|Experimental|PERSIST|Participants will receive Partnered Emotion Regulation Skills Intervention and Support.
16406315|NCT03934489|Active Comparator|Facilitated Peer Support|Participants will undergo a 12-week group intervention, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
16406316|NCT03934476|Experimental|Ketogenic diet|"Ketogenic diet:
~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)
~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.
~fat type intake recommendation:
~natural fats
~trans-FA reduction"
16406317|NCT03934476|Experimental|Exercise HIIT (High-Intensity Interval Training)|"Exercise intervention:
~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:
~Cycle 1
~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)
~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)
~Cycle 2
~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)
~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)
~Cycle 3
~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)
~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
16406318|NCT03934476|Experimental|Ketogenic diet + Exercise HIIT|"Ketogenic diet:
~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)
~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.
~fat type intake recommendation:
~natural fats
~trans-FA reduction
~Exercise intervention:
~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:
~Cycle 1
~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)
~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)
~Cycle 2
~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)
~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)
~Cycle 3
~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)
~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
16406319|NCT03934476|No Intervention|Control Group|The study subjects in this arm will undergo no dietary changes and no exercise intervention.
16406320|NCT03934450|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days
16406321|NCT03934450|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days
16406322|NCT03934450|Active Comparator|Primaquine Phosphate|Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days
16406323|NCT03934450|Placebo Comparator|Placebo|Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days
16406324|NCT03934437|Experimental|mLTCR|The mLTCR intervention consists of two smartphone applications (app), one for patients and one for patient supporters, to help facilitate communication.
16406325|NCT03934437|Active Comparator|LTC|Existing linkage to care and retention (LTCR) services which are standard-of-care
16406326|NCT03934424|Experimental|Weight Stigma|Weight stigma, read a weight stigma article for 5-10 minutes on one day
16406327|NCT03934424|Other|Ethnic stigma|Ethnic stigma, read an ethnic stigma article for 5-10 minutes on one day
16406328|NCT03934411|Experimental|Tramadol treatment|
16406330|NCT03934398||ReNEW Clinical Cohort|Individuals evaluated in the ReNEW Clinic at Johns Hopkins University who join the ReNEW Clinic Cohort Study are eligible for this cross-sectional study. Tests will be done for all participants which includes Cardiovascular Assessments, Actigraphy and Laboratory assessments.
16406331|NCT03934385|Experimental|Mental Rehearsal|Between-session rehearsal/retrieval exercises focused upon consolidating non-fear learning gained from exposures by prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditioned stimulus (i.e., spider) and unconditioned stimulus (e.g., bite/attack).
16406332|NCT03934385|Active Comparator|Control Rehearsal|Between-session rehearsal/retrieval exercises focused upon an unrelated, recent academic experience.
16406333|NCT03934372|Experimental|Ponatinib|Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.
16406334|NCT03934346|Other|Zinc transport kinetics|Three different amounts of dietary zinc are used in the creation of a standard curve for determining zinc absorption kinetics: 4 mg, 7 mg, and 15 mg of zinc.
16406335|NCT03934333|Experimental|A/B (BDA MDI/Pulmicort)|For each participant, the BDA MDI/Pulmicort Flexhaler DPI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP will be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
16406336|NCT03934333|Experimental|B/A (Pulmicort/ BDA MDI)|For each participant, the Pulmicort Flexhaler DPI / BDA MDI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP should be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
16406337|NCT03934320|Other|FAMCAT|
16406338|NCT03934307|Experimental|Part A: SAD: ALN-AGT01|Participants will be administered a single dose of ALN-AGT01.
16406339|NCT03934307|Placebo Comparator|Part A: SAD: ALN-AGT01-Matching Placebo|Participants will be administered a single dose of ALN-AGT01-matching placebo.
16406340|NCT03934307|Experimental|Part B: SD: ALN-AGT01|Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
16406341|NCT03934307|Placebo Comparator|Part B: SD: ALN-AGT01-Matching Placebo|Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
16406342|NCT03934307|Experimental|Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo|Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
16406343|NCT03934307|Active Comparator|Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan|Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
16406344|NCT03934307|Experimental|Part E: Open Label: ALN-AGT01 + Irbesartan|Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
16406345|NCT03934294|Experimental|Treatment group: specific acupuncture group(Acu)|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.
~Acupuncture doctor will disinfect the acupoints with alcohol and will perform acupuncture on the marked points with needle Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor."
16406346|NCT03934294|Placebo Comparator|Control group: non-specific acupuncture group (Con-Acu)|"Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related pathologies, and are not reported to improve digestive function.
~Acupuncture doctor 1 will disinfect the marked acupoints with alcohol and will perform acupuncture on the marked points. Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor"
16406347|NCT03934281|Active Comparator|HAS dressing|"Patients included in the HAS dressing arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) ."
16406348|NCT03934281|Experimental|Honey dressing|"the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%).
~The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months)."
16406349|NCT03934268||infants with seizure with KCNQ2 gene mutation.|Infants who met the inclusion criteria were enrolled in this study. The infants will get their own DNA sequencing results by WES technology. The researchers found that some of them carried mutations in the KCNQ2 gene. so they wanted to compare whether there were differences with or without KCNQ2 gene mutations in the efficacy of anticonvulsants or long-term neurodevelopment in different exposure groups.
16406350|NCT03934255|Experimental|Constant Routine Protocol|Participants will be kept in constant conditions for 30 hours to observe circadian physiology in the absence of light, physical activity, and meals.
16406351|NCT03934242||New born group 1|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, before nurses formation on the newborn's bedding
16406352|NCT03934242||New born group 2|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, after nurses formation on the newborn's bedding
16406353|NCT03934229|Experimental|Group Active|Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day
16406354|NCT03934229|Placebo Comparator|Group Placebo|Placebo
16406355|NCT03934216|Experimental|BMS-986165|
16406356|NCT03934216|Placebo Comparator|Placebo|
16406357|NCT03934203|Experimental|Treatment 1|
16406358|NCT03934203|Experimental|Treatment 2|
16406359|NCT03934203|Experimental|Treatment 3|
16406360|NCT03934203|Experimental|Treatment 4|
16406361|NCT03934177|Experimental|Blueberry powder|4 weeks of supplementation of 24 g whole blueberry powder
16406363|NCT03934151||intracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with intracorporeal technique
16406364|NCT03934151||extracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with extracorporeal technique
16406365|NCT03934138|Active Comparator|Educated open label placebo|These subjects will undergo all the same procedures as in the control group. But before the placebo CTP, they will watch a short movie explaining placebo mechanisms. While applying the placebo cream, they will be told that the cream is inert (placebo), efficient to decrease pain caused by cold and the mechanisms seen in the movie will take place.
16406366|NCT03934138|Placebo Comparator|Conventional placebo|These subjects will watch a video on hand washing. While applying the placebo cream, they will be told that this cream is effective to decreased pain caused by cold.
16406367|NCT03934099|Experimental|LC350189 50mg|LC350189 50mg, QD
16406368|NCT03934099|Experimental|LC350189 100mg|LC350189 100mg, QD
16406369|NCT03934099|Experimental|LC350189 200mg|LC350189 200mg, QD
16406370|NCT03934099|Placebo Comparator|Placebo|Placebo, QD
16406371|NCT03934073|Experimental|DEXTRAIN|The DexTrain group sessions will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting dexterity components.
16406372|NCT03934073|Active Comparator|CONVENTIONNELLE|Conventional training involving stretching of the spastic muscles as well as a set of exercises conventionally used in the protocols of post-stroke rehabilitation (repeated movements, manipulation of objects).
16406373|NCT03934073|Other|CONTROLE|To compare the results of SMT and functional MRI.
16406374|NCT03934060|Experimental|Intervention|Supervised exercise training including specific strength training tools and general exercise contents (standard care), 2-3 times per week, 30 minutes per session
16406375|NCT03934060|No Intervention|Control|Supervised exercise training regarding general exercise contents (standard care), 2-3 times per week, 30 min per session
16406376|NCT03934047|Experimental|Group A|Group A: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
16406377|NCT03934047|No Intervention|Group B|Group B: No Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
16406378|NCT03934021||Acute stroke patient group|"Consecutive patients diagnosed with acute ischaemic stroke during hospitalization in Prince of Wales Hospital will be recruited.
~After an informed consent, stool will be collected from enrolled patients in their first bowel opening after hospitalization and stored in a freezer (-80 degree Celsius) within 24 hours for analysis. If a subject develops constipation, stool sampling will be facilitated by stool softener or laxatives. Stools samples will be stored at -80 degrees Celsius within 24 hours once it is collected.
~Subjects will be followed up at 3 and 6 months after trial entry. NIHSS and mRS will be performed at each visit. Stool sample collection will be repeated in 6 months visit only."
16406379|NCT03934021||Control group|Age and disease matched subjects will be invited to join the study as the control. Stool will also be collected for the comparison of gut microbiota with acute stroke patients to look for evidence of gut dysbiosis in acute stroke. We shall match the control cohort with the stroke cohort in terms of age, gender, smoking status, medical co-morbidities including hypertension, hyperlipidaemia, diabetes, (atrial fibrillation), use of medications in particular metformin, proton pump inhibitors and aspirin.
16406380|NCT03934008||Historical Control Group|All pediatric patients 0-6 years of age seen in the clinic within one year prior to the start of the intervention period
16406381|NCT03934008||Post-Intervention Group|All pediatric patients 0-6 years of age seen in the clinic for one year following the implementation of the motivational interviewed based tool
16406382|NCT03933995||Mesenchymal stem cell|Long-term follow up of Mesenchymal stem cell group
16406383|NCT03933982|Experimental|Pyrotinib plus Vinorelbine|
16406384|NCT03933956|Experimental|Empagliflozin-treated|Oral empagliflozin tablets 10mg daily, taken for 30 days.
16406385|NCT03933943|Experimental|LY3361237|LY3361237 administered subcutaneously (SC)
16406386|NCT03933943|Placebo Comparator|Placebo|Placebo administered SC
16406387|NCT03933930|Experimental|Lactate-directed therapy|
16406388|NCT03933930|Experimental|Goal-directed therapy|
16406389|NCT03933917|Experimental|Large Volume Acute Normovolemic Hemodilution|All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
16406390|NCT03933904|Experimental|Sirolimus|Oral sirolimus: loading dose of 7.5 mg/m^2, rounded to the nearest mg, on day 1. Starting on day 2, oral sirolimus daily at 2.5 mg/m^2/day (rounded to the nearest mg), target trough level 5-15 ng/mL by HPLC, for 12 months.
16406391|NCT03933891||Decompensated liver cirrhosis with TIPS|
16406392|NCT03933878||Post-transplant recipient BAL samples|No intervention will be administered
16406393|NCT03933878||Donor BAL samples|No intervention will be administered
16406394|NCT03933865|Other|Buprenorphine Maintained Patients|All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
16406395|NCT03933839|Experimental|PainCOACH|This group will take part in an 8-week pain coping skills training (PCST) intervention.
16406396|NCT03933839|No Intervention|Wait List Control|The other group will be the wait list group and will receive the pain CST program after completing all study measures.
16406397|NCT03933826||Patients who have selected radical cystectomy|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected radical cystectomy as their second-line treatment
16406398|NCT03933826||Patients who have selected medical management|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected medical management as their second-line treatment
16406399|NCT03933813|Experimental|IV Iron Sucrose|Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period
16406400|NCT03933800|Experimental|High flow nasal cannula (HFNC)|High flow nasal cannula therapy
16406401|NCT03933800|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure therapy
16406402|NCT03933787|Placebo Comparator|mannitol in a tablet|two tablets containing mannitol in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
16406403|NCT03933787|Active Comparator|Saxagliptin in a tablet|two tablets containing each 5 mg of Saxagliptin in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
16406404|NCT03933774|Experimental|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
16406405|NCT03933774|Placebo Comparator|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
16406406|NCT03933761|Experimental|Pamiparib (BGB-290)|Drug: Pamiparib Oral capsules 60mg twice daily continuously Although treatment is continuous, a cycle is defined as 4 weeks or 28 days.
16406407|NCT03933735|Experimental|Arm A: Dose Escalation|Up to 15 cohorts of subjects receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
16406408|NCT03933735|Experimental|Arm B: Dose Expansion|An expansion cohort will be enrolled after maximum tolerated dose or recommended phase 2 dose is established.
16406409|NCT03933722||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
16406410|NCT03933709|No Intervention|Follow-up Group (FG)|dietary surveillance and conventional therapy
16406411|NCT03933709|Active Comparator|Control Group (CG)|deworming and WHO diet
16406412|NCT03933709|Experimental|Intervention Group (IG)|deworming and the Nutritional Support System (NSS)
16406413|NCT03933696|Active Comparator|Active Lighting Intervention|"The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater).
~The lighting intervention will be in place for 24 weeks"
16406414|NCT03933696|Placebo Comparator|Placebo Lighting Intervention|The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.
16406415|NCT03933683||Pathologic Group|Patients affected by Fecal Incontinence
16406416|NCT03933683||Control Group|Healty volunteers cohort
16406417|NCT03933670|Experimental|Diagnostic (HP C-13 MRI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.
16406418|NCT03933657|Experimental|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System-Peripheral is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions via atherectomy.
16406419|NCT03933644|Other|Ambu Aura Gain TM with gastric tube|
16406420|NCT03933644|Other|Ambu Aura Gain TM without gastric tube|
16406421|NCT03933631|Experimental|Pilocarpine, Prednisolone acetate and Ofloxacin|This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
16406422|NCT03933631|Active Comparator|Prednisolone acetate and Ofloxacin (standard of care)|This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.
16406423|NCT03933618|Other|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
16406424|NCT03933618|Other|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
16406425|NCT03933618|Other|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
16406426|NCT03933618|Other|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
16406427|NCT03933618|Other|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
16406428|NCT03933618|Other|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
16406429|NCT03933605|Active Comparator|midazolam and palonosetron|0.05 mg/kg of midazolam i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
16406430|NCT03933605|Active Comparator|palonosetron|the same volume (0.05 mg/kg) of normal saline i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
16406431|NCT03933592|Active Comparator|Thoracic epidural|thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
16406432|NCT03933592|Experimental|Serratus plane block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
16406433|NCT03933566||Ultrasound-Guided|Ultrasound-Guided Superficial Cervical Plexus Block
16406434|NCT03933566||Landmark-Based|Landmark-Based Superficial Cervical Plexus Block
16406435|NCT03933553|Experimental|Easy sleep complex essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
16406436|NCT03933553|Active Comparator|Lavender essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
16411260|NCT03900325|Experimental|Nimacimab|2.5 mg/kg
16406437|NCT03933540||Pediatric Asthma Patients|"Participants are ages 8 years through 17 years and have partially controlled or uncontrolled asthma.
~No intervention is included in this study."
16406438|NCT03933527|No Intervention|control group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).
16406439|NCT03933527|Experimental|coffee group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make coffee rinses for 30 seconds, four times daily.
16406440|NCT03933527|Experimental|tea group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make tea rinses for 30 seconds, four times daily.
16406441|NCT03933514||GAgP parents|Parents diagnosed with Generalized Aggressive Periodontitis
16406442|NCT03933514||GAgP children|Children from parents diagnosed with Generalized Aggressive Periodontitis
16406443|NCT03933514||Health parents|Parents diagnosed as periodontally healthy
16406444|NCT03933514||Health children|children from parents diagnosed as periodontally healthy
16406445|NCT03933501|Experimental|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
16406446|NCT03933501|Placebo Comparator|FMUD|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
16406447|NCT03933501|Experimental|SRP + AM|Four sessions (1/week) of scaling and root planning, plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the last session of treatment and taken every 8 hours for 7 days.
16406448|NCT03933501|Placebo Comparator|SRP|Four sessions (1/week) of scaling and root planning, plus two distinct placebo pills prescribed on the last session of treatment and taken every 8 hours for 7 days.
16406449|NCT03933488|Experimental|TAK-994: Part A|TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
16406450|NCT03933488|Experimental|TAK-994: Part B|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
16406451|NCT03933488|Experimental|TAK-994: Part C|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
16406452|NCT03933488|Experimental|TAK-994: Part D|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
16406453|NCT03933488|Experimental|TAK-994: Part E|TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
16406454|NCT03933475|Experimental|Intendu Active Brain Trainer Telerehabilitation Games|Use of telerehabilitation Games within the home environment
16406455|NCT03933462|Experimental|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
16406456|NCT03933462|Active Comparator|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
16406457|NCT03933449|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 2 years).
16406458|NCT03933449|Active Comparator|Chemotherapy|Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 2 years).
16406459|NCT03933436|Experimental|Iodine|Iodine swabs.
16406460|NCT03933436|Active Comparator|Normal Saline|Saline flush.
16406461|NCT03933423|Active Comparator|Intervention|Educational session of pregnant mothers, blood grouping of parents and identifying risk factors for developing jaundice, screening newborns for neonatal jaundice, glucose 6-phosphate dehydrogenase deficiency and illness, Home based phototherapy and referral.
16406462|NCT03933423|No Intervention|Control|No intervention will be deliver
16406463|NCT03933410|Experimental|KB195|KB195 is a novel glycan
16406464|NCT03933397|Experimental|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home, what was needed during their past hospital and emergency department visits to treat pain and doses that have been effective and safe in the past.
16406465|NCT03933397|Experimental|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight.
16406466|NCT03933384|Active Comparator|Tenofovir alafenamide group|Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).
16406467|NCT03933384|Active Comparator|Entecavir group|Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).
16406470|NCT03933345||People who use illicit opioids|The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.
16406471|NCT03933332||Ventilator length of use|measured in days
16406472|NCT03933319|Experimental|PLD in combination with trastuzumab|"Trastuzumab: administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
~pegylated liposomal doxorubicin(PLD):administered at dose of 35mg/m2 IV once every 21 days."
16406473|NCT03933306|Placebo Comparator|Placebo+routine blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is managed according to routine practice.
16406474|NCT03933306|Experimental|Dexmedetomidine+routine blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is managed according to routine practice.
16406475|NCT03933306|Experimental|Placebo+goal-directed blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
16406476|NCT03933306|Experimental|Dexmedetomidine+goal-directed blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
16406477|NCT03933293|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection
16406478|NCT03933293|Placebo Comparator|placebo|Placebo, Q4W, subcutaneous injection
16406479|NCT03933280|Active Comparator|Group P|nalbuphine/propofol group
16406480|NCT03933280|Active Comparator|Droup D|Nalbuphine/dexmedetomidine group
16406481|NCT03933267|Experimental|Group I|This group of participant will receive Cervical sensorimotor control training exercises. In addition to it conventional physical therapy protocol will be given.
16406482|NCT03933267|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol.
16406483|NCT03933241|Experimental|experiment group|nasal irrigation after transsphenoidal surgery for pituitary tumor
16406484|NCT03933241|No Intervention|matched group|without nasal irrigation after transsphenoidal surgery for pituitary tumor
16406485|NCT03933228||Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
16406486|NCT03933228||Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
16406489|NCT03933189|Active Comparator|Biomedical (BIOM) physical therapy|Six 60 minute PT sessions consisting of 15 minutes of education on topics such as ideal postural alignment (sitting, sleeping), maintenance of normal spinal curves, body mechanics, proper lifting techniques, home pain control via anti-inflammatory modalities such as ice; 15 minutes of manual therapy to region of pain (soft tissue and/or joint mobilization); 30 minutes of region specific exercises to address identified muscle imbalances -stretching and strengthening of the muscles local to the area of pain.
16406490|NCT03933189|Active Comparator|Biopsychosocial (BPS) physical therapy|"Six 60 minute PT sessions consisting of 15 minutes of pain neuro-science education, 15 minutes of Graded Motor Imagery (GMI) techniques, (a progressive program of visual and mental exercises consisting of laterality exercises, motor imagery and mirror therapy); 30 minutes of a general conditioning exercise program individualized for each participant based on initial examination findings and participant presentation consisting of:
~A cardiovascular component which may include walking on a treadmill, stationary cycling, or a seated stepping machine.
~A muscle strengthening component for extremities and trunk. A flexibility component for upper and lower extremity musculature."
16406491|NCT03933176|Experimental|Simplified restorative procedure|After selective carious tissue removal, the universal adhesive (Adper Universal; 3M ESPE, St. Paul, MN, EUA) will be applied on the cavity walls. The cavity will be restored using a single increment of Filtek One Bulk Fill (3M ESPE, St. Paul, MN, EUA).
16406492|NCT03933176|Active Comparator|Control|A thin layer of resin-modified glass ionomer (Ionoseal (Voco America Inc., Briarcliff Manor, NY, EUA) will be placed on the pulpal floor of the cavity. Then, the adhesive and composite will be used following the same directions defined for the experimental condition.
16406493|NCT03933163|Other|Resveratrol followed by placebo|1g micronised resveratrol twice daily for 24 weeks, a wash-out period of 4 weeks, followed by twice daily placebo for 24 weeks.
16406494|NCT03933163|Other|Placebo followed by Resveratrol|Twice daily placebo for 24 weeks, a wash-out period of 4 weeks, followed by 1g micronised resveratrol twice daily for 24 weeks
16406495|NCT03933150|Other|ultrasoun guided caudal epidural injection|A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.
16406496|NCT03933150|Other|fluoroscopy guided caudal epidural injection|B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
16406497|NCT03933137||Not prolonged length of stay|Living donor patients who had ≤ 6 days length of stay after laparoscopic nephrectomy procedure
16406499|NCT03933124|Experimental|Virtual Reality Intervention group|"The intervention group includes 60 patients who will use Virtual Reality for postoperative pain. Participants will use Virtual Reality minimal 10 minutes, minimal 3 times a day on the second, third and fourth day after surgery, on the general ward.
~20 participants will receive an Oculus Go immersive 3D nature videos, games, meditation videos, google earth experiences and sports games.
~20 participants will receive a Relaxmaker with 2D nature videos
~20 participants will receive CareVRx with 3D nature videos and meditation videos."
16406500|NCT03933124|No Intervention|Control group|The control group receives standard postoperative care.
16406501|NCT03933111|Experimental|patients with pancreatic solid neoplasms|Patients with pancreatic solid neoplasms are enrolled in this study and accept the test.
16406502|NCT03933098|Experimental|Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
16406503|NCT03933098|Experimental|Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
16406504|NCT03933098|Experimental|Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
16406505|NCT03933098|Active Comparator|Test group D: Typbar TCV|"One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
16406506|NCT03933085|Experimental|MCI Group|A within-subject, multiple baseline design, with each subject serving as their own control,4 will be implemented to get the maximum number of participants trained in the use of the MSS during the proposed funding period. This 2-year study will involve four phases: a 4-month translation and cultural adaptation development phase, a 12-month recruitment and treatment implementation phase, a 6-month post data collection only phase, and a 2-month data analysis and result writing phase. Data analyses will be conducted using the Statistical Package for the Social Sciences (SPSS) program.
16406507|NCT03933072|Experimental|patients with complete spinal cord injury|the planned interventions have been described in the section below
16406508|NCT03933059|Active Comparator|R&R Park City, Utah|This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
16406509|NCT03933059|Active Comparator|R&R Salt Lake City, Utah|This group will receive 12 daily individual sessions of CPT at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
16406510|NCT03933059|Active Comparator|Weekly Treatment Salt Lake City, Utah|This group will receive 12 individual sessions of CPT on a weekly basis at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
16406511|NCT03933046|Experimental|children referred to PSG due to suspected SDB|
16406512|NCT03933033|Active Comparator|Group A|treated with platelet rich plasma
16406513|NCT03933033|Active Comparator|Group B|treated with Erbium Yag Laser
16406514|NCT03933033|Active Comparator|Group C|treated with both line of treatments
16406515|NCT03933020|Experimental|Exercise Group|
16406516|NCT03933020|Active Comparator|Control Group|
16406517|NCT03933007|Other|Pharmacokinetic study|all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)
16406518|NCT03932994|Experimental|ACT on Health Intervention|Those assigned to ACT on Health will use the program over the next 8 weeks, completing weekly modules and coaching calls.
16406519|NCT03932994|No Intervention|Waitlist|Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
16406520|NCT03932981|Experimental|Temozolomide|Chemotherapy by temozolomide
16406521|NCT03932968||Symptomatic pain|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry during 24 hours will be performed.
16406522|NCT03932968||Control|patients after a sleeve gastrectomy without symptomatic pain
16406523|NCT03932955|Experimental|MC-19PD1 CAR-T Cells|
16406524|NCT03932942|Experimental|Point-of-care testing of respiratory pathogens on admission|Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
16406525|NCT03932942|No Intervention|Routine ED protocol|Diagnostic tests for respiratory pathogens will be obtained according to clinical judgement and tested on microbiological laboratory. The results are ready on the next office day.
16406526|NCT03932929|Experimental|Scotchbond universal adhesive (etch-and-rinse)|Acid etch (enamel&dentin)+adhesive agent Intervention: Device: Adhesive agent
16406527|NCT03932929|Experimental|Scotchbond universal adhesive (selective-etch)|Acid etch (only enamel)+adhesive agent Intervention: Device: Adhesive agent
16406528|NCT03932929|Experimental|Scotchbond universal adhesive (self-etch)|Adhesive agent Intervention: Device: Adhesive agent
16406529|NCT03932916|Experimental|experimental group 1|HHT201 17mg injection
16406530|NCT03932916|Experimental|experimental group 2|HHT201 34mg injection
16406531|NCT03932916|Active Comparator|experimental group 3|Donepezil Hydrochloride oral tablet 5mg
16406532|NCT03932903|Experimental|Contextually-tailored Mobile Messages for Adherence|All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
16406533|NCT03932903|No Intervention|No messages|All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
16406559|NCT03932760|Active Comparator|Pregnancy Skills Group|Weekly one-hour group sessions for 10 weeks facilitated by a registered nurse.
16406560|NCT03932747|Placebo Comparator|Placebo Creams|Measuring the skin before the application of the cream without urea (placebo), wait 3 hours and re-measure the hydration
16406561|NCT03932747|Active Comparator|Urea 5%|Measuring the skin before the application of the cream with urea (5%), wait 3 hours and re-measure the hydration
16411261|NCT03900325|Placebo Comparator|Placebo|0.9% sodium chloride
16406534|NCT03932890|Active Comparator|Lower Volume fluid bolus arm|The 'lower volume' (LV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the LV arm, the trigger will deliver 50mls over 10 mins at a rate of 300ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
16406535|NCT03932890|Experimental|Higher Volume fluid bolus arm|The 'higher volume' (HV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the HV arm, the trigger will deliver 200mls over 10 mins at a rate of 1200ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
16406536|NCT03932877||late-onset preeclampsia, group1|30 late-onset preeclampsia patients as group1 (gestational age≥34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
16406537|NCT03932877||Control, group 2|33 patients with normal pregnancies as group2 (gestational age≥34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
16406538|NCT03932877||early-onset preeclampsia, group 3|31 early-onset preeclampsia patients as group3 (gestational age<34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg considered mild, and higher values considered to being severe.
16406539|NCT03932877||Control, group 4|31 patients with normal pregnancies as group 4 (gestational age<34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
16406540|NCT03932864|Placebo Comparator|Single Ascending Dose of MGTA-145 or placebo|MGTA-145 or placebo dose escalation as single agent, single dose
16406541|NCT03932864|Placebo Comparator|Single Dose MGTA-145 or placebo plus plerixafor|MGTA-145 or placebo in combination with plerixafor, single dose
16406542|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor for 2 sequential d|MGTA-145 in combination with plerixafor on two consecutive days; single dose per day
16406543|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis
16406544|NCT03932851||HBsAg(+) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). The newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact of HBV mother-to-child transmission.
16406545|NCT03932851||HBsAg(-) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA).
16406546|NCT03932838|Experimental|clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
16406547|NCT03932825|Placebo Comparator|Air oxygen mixture|participants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%).
16406548|NCT03932825|Experimental|Nitrous oxide|Participants in this group inhale mixed 50% nitrous oxide and 50% oxygen.
16406549|NCT03932812|Experimental|Options Counselor Health Educator Intervention Group|These individuals will receive the Options Counselor Health Educator Intervention
16406550|NCT03932812|No Intervention|Control|These individuals will receive the typical standard of care treatment from clinics
16406551|NCT03932799||Washington|Workers in the Washington Department of Labor and Industries state fund insurance system.
16406552|NCT03932799||Ohio|Workers in the Ohio Bureau of Workers' Compensation state fund insurance system.
16406553|NCT03932786||Retrospective(biospecimens, vision assessment, questionnaires)|
16406554|NCT03932786||Prospective (biospecimens, vision assessment, questionnaires)|
16406555|NCT03932773|Sham Comparator|Sham rTMS + CPT|30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session
16406556|NCT03932773|Active Comparator|Active rTMS + CPT|30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
16406557|NCT03932773|Active Comparator|Active rTMS Alone|30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks
16406558|NCT03932760|Experimental|UPLIFT Program|Weekly one-hour group sessions for 10 weeks facilitated by a mental health professional.
16444476|NCT03673111|Experimental|9.0 mg|Y14 single dose, subcutaneous
16406562|NCT03932747|Active Comparator|Urea 20%|Measuring the skin before the application of the cream with urea (20%), wait 3 hours and re-measure the hydration
16406563|NCT03932734||survey|
16406564|NCT03932721|Active Comparator|Evolocumabe|Patients with T2DM treated with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure) AND evolocumab (anti-PCsk9).
16406565|NCT03932721|No Intervention|Control|Patients with T2DM treated exclusive with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure).
16406566|NCT03932708|Experimental|Urgent Care Antibiotic Stewardship Intervention|All 38 urgent care clinics will implement CDC Core Elements of outpatient antibiotic stewardship as described above.
16406567|NCT03932695|Active Comparator|High dose Milk peptides|2800mg of whey protein hydrolysates single dose
16406568|NCT03932695|Active Comparator|Low dose Milk peptides|1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
16406569|NCT03932695|Placebo Comparator|Placebo|maltodextrin
16406572|NCT03932669|Experimental|Nilotinib group|Patients with SCA and taking nilotinib treatment
16406573|NCT03932656||Females with borderline personality disorder|
16406574|NCT03932643|Experimental|ONC201 treatment|A 3+3 dose escalation design will be followed. Given the safety profile in prior trials, A dose of 250 mg weekly will be the starting dose. The first 12-15 patients are expected to receive escalating doses of ONC 201, the remaining patients will go on the expansion cohort.
16406575|NCT03932630|Experimental|Study intervention|
16406576|NCT03932630|Active Comparator|Control intervention|
16406577|NCT03932617||fluid responders|
16406578|NCT03932617||fluid non responders|
16406579|NCT03932604|No Intervention|Atrial sensing OFF mode|VDD-ICD programmed as atrial sensing Off mode
16406580|NCT03932604|Active Comparator|Atrial sensing ON mode|VDD-ICD programmed as atrial sensing ON mode
16406581|NCT03932591|Experimental|intervention|Inhibitory kinesio taping method will be used for intervention group. Y shaped, 34-40 cm length, 5 cm width, skin color kinesio tape will be applied on spastic gastrocsoleus muscle. The base of Y shaped tape will be strapped on calcaneus ( no stretch for first 5 cm) and the both legs of Y shaped tape will be strapped on gastrocnemius muscle medial and lateral head with 15% stretch.
16406582|NCT03932591|Sham Comparator|Control|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be applied on achilles tendon without stretch.
16406583|NCT03932578|Active Comparator|Atropine group|Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
16406584|NCT03932578|Active Comparator|Metoclopramide group|Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
16406585|NCT03932565|Experimental|The fourth-generation CAR-T therapy|Clinical trial study of Interventional therapy sequential with the fourth-generation CAR-T cells (IL7 and CCL19 or / and IL12) targeting Nectin4/FAP in the treatment of advanced malignant solid tumors with Nectin4-positive .
16406586|NCT03932552|Active Comparator|Control|Personalized nutritional therapy
16406587|NCT03932552|Experimental|Exercise|Aerobic exercise + Personalized nutritional therapy
16406588|NCT03932539||Twenty-five de-novo heart transplant recipients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs, either Everolimus or Sirolimus.
16406589|NCT03932526|Active Comparator|Vinorelbine + placebo group|92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
16406590|NCT03932526|Experimental|Vinorelbine + Apatinib group|92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
16406591|NCT03932513|Experimental|Treatment A: inarigivir soproxil|Inarigivir 400 mg once per day for 6 weeks (2800mg/week).
16406592|NCT03932513|Experimental|Treatment B: inarigivir soproxil|Inarigivir 400 mg three times per week for 6 weeks (1200mg/week).
16406593|NCT03932487||AITD group|Thyroid antibody positive and hypothyroidism
16406594|NCT03932487||normal group|Thyroid antibody negative and hypothyroidism
16406595|NCT03932474|Experimental|SAMEUp|SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
16406596|NCT03932474|Placebo Comparator|Placebo|Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
16406597|NCT03932461|Active Comparator|Vacuum assisted closure|At the index operation after the source of fecal or diffuse peritonitis has been treated there will be placed a Vacuum assisted closure system VAC® (San Antonio, TX) to temporarily close the abdomen. After 48-hours the system will be changed and potential complications will be treated. The process will be repeated until the peritonitis condition is under control, whereafter the abdomen can be closed according to Isrealsson's principles. The process will be repeated 8 days after the index operation with extension if needed. If needed the system can be changed earlier than 48-hours. All patients are routinely observed by clinical examination and SOFA-score.
16406598|NCT03932461|Active Comparator|"Relaparotomy on-demand"|At the index operation after the source of fecal or diffuse peritonitis has been treated the abdomen will be closed according to Isrealsson's principles. Patients will be reevaluated for potential relaparatomy every 48-hours based on clinical and paraclinical parameters by a surgeon. The process will be repeated continue 8 days after the index operation with extension if needed. If needed relaparotomy can be done earlier than 48-hours. All patients are routinely observed by clinical examination and SOFA-score.
16406599|NCT03932435|Experimental|TWLO_C → TWLO|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
16406600|NCT03932435|Experimental|TWLO → TWLO_C|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
16406601|NCT03932422||Controlled Hypertensive Patients (CHP)|Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
16406602|NCT03932422||Resistant Hypertensive Patients (RHP)|Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
16406603|NCT03932409|Experimental|Pembrolizumab + Radiation Therapy + Pembrolizumab/Chemotherapy|Pembrolizumab given 7 days prior to radiation therapy (e.g., vaginal cuff brachytherapy) followed by three cycles pembrolizumab combined with Carboplatin/Paclitaxel chemotherapy
16406604|NCT03932396||Single group of subjects who fulfill the inclusion criteria|All the population condemned to a non-custodial sentence that is presented in the Service of Management of Penalties and Alternative Measures of the Center of Social Insertion (CIS) José Hierro CP Dueso during the study period (March 2019 and March 2021) , with ages between 18 and 79 years (approximately 1000 people / year) and willing to participate (signs the IC).
16406605|NCT03932383|Experimental|Modified CPAP|Single arm cohort study of modified mask
16406606|NCT03932370||f-URS|
16406607|NCT03932370||mini-PCNL|
16406608|NCT03932344||SJIA patients on Kineret treatment|SJIA patients on Kineret treatment enrolled in the Pharmachild JIA registry
16406609|NCT03932331|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
16406610|NCT03932318|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).
~Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles.
~Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles.
~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
16406611|NCT03932305|Placebo Comparator|Control|Patients taking inactive placebo tablets
16406612|NCT03932305|Experimental|Lutein|Patients taking lutein supplement
16406613|NCT03932292|Active Comparator|Ectoin Mouth Wash|30 patients obtaining EML03 treatment
16406614|NCT03932292|Active Comparator|Supersaturated solution of calcium and phosphate ions|20 patients taking standard treatment (calcium phosphate mouth wash)
16406615|NCT03932279||Stage IA-IIA cutaneous T cell lymphoma|
16406616|NCT03932279||Stage IIB and above cutaneous T cell lymphoma|
16406617|NCT03932279||CD30+ lymphoproliferative disorders|
16406618|NCT03932279||Plaque psoriasis with BSA>5% on routine phototherapy|
16406619|NCT03932279||Moderate to severe atopic dermatitis on routine bleach bath|
16406620|NCT03932279||Healthy controls|
16406621|NCT03932266|Experimental|Experimental group|Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
16406622|NCT03932266|Other|Control group|Drug: Cisplatin Drug: Docetaxel Radiation
16406623|NCT03932253|Experimental|FCN-159|Preset 6 dose groups during the dose-escalation phase, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, and 6 mg, orally, continuous once a day for 21 days, followed by a 7-day break, 28 days is a cycle.
16406624|NCT03932240|Experimental|Fibrinogen Concentrate (FC)|"After separation from bypass, patients will receive platelets and FC. The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
16406625|NCT03932240|Active Comparator|Cryoprecipitate|"After separation from bypass, patients will receive platelets and cryoprecipitate. Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL.
~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
16406626|NCT03932227|Other|Cardioskin-Holter|Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.
16406627|NCT03932227|Other|Holter-Cardioskin|Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.
16406628|NCT03932214|Experimental|Infrared illumination group|The nurse uses the Accuvein® device to identify the veins before puncture.
16406629|NCT03932214|No Intervention|Control group|The nurse proceeds as usual (visual identification in the light of the room and palpation)
16406630|NCT03932201||Previously treated patient (PTPs) with hemophilia A|Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
16406631|NCT03932188||Control|Individuals between 13-25 years old that do not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or Cluster A personality disorder diagnosis
16406632|NCT03932188||Prodromal/Early psychosis|Individuals between 13-25 years old that meet diagnostic criteria for a prodromal syndrome or early psychosis
16406633|NCT03932175|Experimental|Intervention group|The multicomponent intervention will comprise three aspects on-top of usual care: i) Motivational interview to assess patient's adherence profile and to raise the compromise with the behaviour change towards NIV, physical activity and nutritional habits; ii) Bi-directional interaction between the study participants and clinical staff delivered by the MyPathway app, where specific clinical problems regarding NIV will be addressed as they arise; and iii) Motivational messages and educational material delivered via the MyPathway app regarding changes in physical activity and/or nutritional habits. As part of the behavioural intervention, goal setting for NIV adherence and life-style changes will be introduced to the MyPathway app in order for the participants to follow the advice.
16406634|NCT03932175|No Intervention|Control group|Patients will receive usual care according to guidelines on management of chronically ventilated patients, without any mHealth tool or behavioural intervention
16406635|NCT03932162|Placebo Comparator|Young Adult|One small area of skin will undergo treatment with a small amount of UVB.
16406636|NCT03932162|Active Comparator|Geriatric Adult|Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injectiosn with saline. Then the injected areas will be treated with a small amount of UVB.
16406637|NCT03932149|Experimental|Experimental Group|Real stimulation
16406638|NCT03932149|Sham Comparator|Control Group|Sham stimulation
16406639|NCT03932136|Active Comparator|SFN group|The intervention duration with SFN tablet is 52 consecutive weeks. The dosage is six active tablets (411 μmol GR) per day.
16406640|NCT03932136|Placebo Comparator|Placebo group|The intervention duration with placebo tablet is 52 consecutive weeks. The placebo group will be given six placebo tablets per day.
16406641|NCT03932110|Other|psoriasis vulgaris,|patients who have only psoriasis vulgaris
16406642|NCT03932110|Other|psoriatic arthritis|patients who have psoriatic arthritis
16406643|NCT03932110|Other|healthy control|healthy people
16406644|NCT03932097|Experimental|Parenting Now|Preventive Parenting Now digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
16406645|NCT03932097|Active Comparator|Active Control Materials|SAMHSA alcohol prevention materials for parents
16406646|NCT03932084|Experimental|Control group|"During hospitalization:
~Monitor subjects' blood glucose;
~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;
~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.
~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.
~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
16406647|NCT03932084|Experimental|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
16406648|NCT03932071|Experimental|experimental group|
16406649|NCT03932071|No Intervention|control group|
16406650|NCT03932058||osteosarcoma|
16406651|NCT03932058||chondrosarcoma|
16406652|NCT03932058||enchondroma|
16406653|NCT03932045|Experimental|SYB Filler (SF-01)|
16406654|NCT03932045|Active Comparator|Ellansé M|
16406655|NCT03932032|Experimental|Attention Bias Modification Treatment|Attention Bias Modification Treatment is a computer-based attention training program.
16406656|NCT03932032|Sham Comparator|Neutral Control Task|Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
16406657|NCT03932019|Experimental|High dose group|Jitongning tablet,3tablets,bid,po
16406658|NCT03932019|Experimental|Low dose group|Jitongning tablet,2tablets,bid,po Jitongning tablet placebo,1tablet,bid,po
16406659|NCT03932019|Placebo Comparator|Placebo Comparator controlled group|Placebo Comparator: Jitongning tablet placebo,3tablets,bid,po
16406660|NCT03932006|Experimental|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
16406661|NCT03932006|Experimental|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
16406662|NCT03932006|Active Comparator|Imrecoxib|Imrecoxib 0.1g twice a day,orally
16406663|NCT03931993|Placebo Comparator|Treatment Group 1|Six 1.0mL placebo injections (2% w/v L-tyrosine)
16406664|NCT03931993|Experimental|Treatment Group 2|Six 1.0mL injections of Grass MATA MPL 900, 2700, 8000, 8000, 8000, and 8000 SU
16406665|NCT03931980|Experimental|Robotic surgery|Patients undergoing robotic surgery for removal of rectal cancer.
16406666|NCT03931980|Experimental|Laparoscopic surgery|Patients undergoing laparoscopic for removal of rectal cancer
16406667|NCT03931967||MR-proADM|
16406668|NCT03931954||Study population|Patients completing the inclusión criteria
16406669|NCT03931941|Experimental|Active|RBX2660 is an enema of a microbiota suspension
16406670|NCT03931928|No Intervention|Control group (Group 1)|All patients receive Placebo
16406671|NCT03931928|Experimental|Group 2|"Patients will receive (Z)-endoxifen dosed according to CYP2D6 genotype"
16406672|NCT03931928|Experimental|Group 3|Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening
16406673|NCT03931915|Experimental|TAK-385|TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks
16406674|NCT03931915|Active Comparator|Leuprorelin acetate|TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks
16406675|NCT03931902|Experimental|Laryngeal Mask Airway (LMA)|Using laryngeal mask airway as the airway device during general anesthesia
16406676|NCT03931902|Active Comparator|Endotracheal Tube (ETT)|Using endotracheal tube as the airway device during general anesthesia
16406677|NCT03931889|Active Comparator|Vitamin D3|Cholecalciferol 80,000 IU (2 capsules of 40,000 IU) per oral per week for consecutive 26 weeks.
16406678|NCT03931889|Placebo Comparator|Vitamin D3 placebo|Placebo (2 capsules) per oral per week for consecutive 26 weeks.
16406679|NCT03931876|Placebo Comparator|Placebo|placebo
16406680|NCT03931876|Active Comparator|Active|AV-006
16407357|NCT03927235|Experimental|the freezing time of 6s|Transbronchial cryobiopsy in the freezing time of 6s
16406681|NCT03931863|Active Comparator|Group A|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
16406682|NCT03931863|Active Comparator|Group B|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
16406683|NCT03931863|Placebo Comparator|Group C|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
16406684|NCT03931850|Experimental|Dual guidance (ultrasound and neurostimulation)|This arm : patients will be received pudendal nerve block by dual guidance technique ( ultrasound and neurostimulation)
16406685|NCT03931850|Active Comparator|ultrasound-guided only|This arm : patients will be received pudendal nerve block by ultrasound-guided only.
16406686|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 75 mmHg|Before skin incision
16406687|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 100 mmHg|Before skin incision
16406688|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 150 mmHg|Before skin incision
16406689|NCT03931824|Experimental|PRP group|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).
~Injections were done every two weeks, for a total of 3 times."
16406690|NCT03931824|Sham Comparator|Placebo group|Injections containing saline were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used. To provide blindness, all injections were done using injectors coated with non transparent tape. All of the PRP injections were done by the same physician each time, with compliance to preventive measures against complications such as infections. Patients and the physician who applied the injection were blinded to the groups, and the solution was prepared by another researcher who was not blind to the groups.
16406691|NCT03931811|Experimental|Short wave diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.
~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.
~SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device). Both groups took injections in the beginning of the therapy, 3rd week and 6th week, a total of 3 times. SWD or sham SWD therapy was given right after the injections, also for a total of 3 times."
16406692|NCT03931811|Sham Comparator|Sham diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.
~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.
~Sham SWD group took 20 minutes of SWD therapy with device not working(Enraf-Nonius, Curapuls 970 Short wave diathermy device)."
16406693|NCT03931798|Experimental|Treatment|Healthy participants were administered the Visual Scanning Test
16406694|NCT03931785|Experimental|MD-7246 300 μg|1 MD-7246 300-μg oral tablet and 3 matching placebo oral tablets
16406695|NCT03931785|Experimental|MD-7246 600 μg|2 MD-7246 300-μg oral tablets and 2 matching placebo oral tablets
16406696|NCT03931785|Experimental|MD-7246 1200 μg|4 MD-7246 300-μg oral tablets
16406697|NCT03931785|Placebo Comparator|Placebo|4 matching placebo oral tablets
16406698|NCT03931772|Other|Automated Self-Hypnosis Intervention|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health. Participants will be provided the Amazon Alexa device to take home (necessary for using the program). After the lab visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they feel the urge to smoke). Furthermore, participants will be taking an at-home 15 minute survey at baseline, and then 1, 3, 6, 12 and 24 month follow-ups.
16406699|NCT03931759|Active Comparator|Diabetes mellitus|patients with diabetes mellitus
16406700|NCT03931759|No Intervention|non-Diabetes mellitus|patients without diabetes mellitus
16406701|NCT03931746|Experimental|Porcine Xenograft placement|Porcine xenograft will be placed on the wound.
16406702|NCT03931746|No Intervention|No porcine xenograft|The wound will be allowed to heal via second intention.
16406703|NCT03931733|Active Comparator|Music Therapy Intervention|Receiving one thirty minute music therapy intervention.
16406704|NCT03931733|No Intervention|Usual Care|Receiving usual care for a patient in the ICU during a 30 minute intervention.
16406705|NCT03931720|Experimental|anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
16406706|NCT03931707||Sick Neonatal Cohort, Sequencing|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
16406707|NCT03931694||All patients with chronic pain follow in pain clinic|
16406739|NCT03931512|Sham Comparator|sham transcrial direct current stimulation|20 minutes positioning the electrodes on the scalp. Whith an initial increasing of the current intensity by 10 seconds, until 1mA and a ramp down from 20 seconds to reach zero.
16406740|NCT03931499||Study cohort|Patients undergoing surgery under cardiopulmonary bypass
16406708|NCT03931681|Experimental|Experimental: Phase 1 - Dose Escalation|Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose and allows for additional cohorts enrolling subjects with an alternative dosing schedule such as OKI-179 orally (PO) daily on Days 1 - 5, 8 - 12 and 15 - 19 per 21-day cycles or Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
16406709|NCT03931668|Experimental|0.125mg single dose|single dose of TPN-672 0.125mg, 2 subjects
16406710|NCT03931668|Experimental|0.25mg single dose|single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
16406711|NCT03931668|Experimental|0.5mg single dose|single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
16406712|NCT03931668|Experimental|1mg single dose|single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
16406713|NCT03931668|Experimental|2mg single dose|single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
16406714|NCT03931668|Experimental|3mg single dose|single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
16406715|NCT03931668|Experimental|4mg single dose|single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
16406716|NCT03931655|Experimental|Spectroscopic photoacoustic imaging|Any suspicious lymph nodes identified through ultrasound will be imaged with spectroscopic photoacoustic imaging, which is a diagnostic test to measure saturated oxygen in the nodes.
16406717|NCT03931642|Experimental|R-CHOP- blinatumomab|"Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.
~At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.
~From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.
~Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28."
16406718|NCT03931629|Active Comparator|CONVENTIONAL PHACO|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
16406719|NCT03931629|Active Comparator|FEMTOSECONDLASER (FLACS)|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
16406720|NCT03931616|Experimental|STEMO deployment|STEMOs are specialized stroke ambulances providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
16406721|NCT03931616|Active Comparator|Regular care|Regular prehospital care consists of normal ambulance care. In suspected life-threatening cases, an emergency physician is sent to the emergency scene in parallel.
16406722|NCT03931590|Experimental|Healthy Male Subjects|Single oral dose of 150 mg of [14C] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.
16406723|NCT03931577|Experimental|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the use of C-reactive protein rapid testing.
16406724|NCT03931577|Experimental|Enhancement of communication skills|Continuous (on-site and monthly online training) illness-focused intervention with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
16406725|NCT03931577|Experimental|C-reactive protein + communication skills|Continuous (workshop and monthly web-based training) disease-focused intervention with C-reactive protein rapid testing and on-site and continuous (monthly online training illness-focused intervention) with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
16406726|NCT03931577|No Intervention|Usual care|Usual care.
16406727|NCT03931564|Active Comparator|PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS))|The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS).
16406728|NCT03931564|Active Comparator|Trabeculectomy|The usual care/control group will undergo a standard trabeculectomy.
16406729|NCT03931551|Experimental|Interventional Arm|Olaparib tablet 300mg bd po + Herceptin (IV 4 mg/kg body followed by weekly doses of 2 mg/kg, or SC 600 mg every 3 weeks) until progression or unacceptable toxicity.
16406730|NCT03931538|Active Comparator|Culture Only|Physician receives only culture result
16406731|NCT03931538|Active Comparator|Guidance 4.0 PCR test only|Physician receives Guidance report only
16406732|NCT03931538|Active Comparator|Culture and Guidance 4.0 PCR test Group|Physician receives both results, gets Culture report immediately before Guidance
16406733|NCT03931538|Active Comparator|Guidance 4.0 PCR test and culture group|Physician receives both results, gets Guidance report immediately before culture
16406734|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
16406735|NCT03931525|Active Comparator|Radiofrequency Therapy without drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
16406736|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 15 days|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
16406737|NCT03931525|Active Comparator|Radiofrequency therapy without drug delivery 15 days|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
16406738|NCT03931512|Experimental|transcranial direct current stimulation|"20 minutes of transcranial direct current stimulation
~1 mA on bi-hemispheric colocation with cathode on the left M1 and anode on the right M1"
16406741|NCT03931486||Operatively treated patients with Achilles tendon rupture|Cohort of operatively treated patients with acute Achilles tendon rupture.
16406742|NCT03931473|Experimental|Interceptor G2|Chlorfenapyr/alpha-cypermethrin
16406743|NCT03931473|Experimental|Royal Guard|Pyriproxyfen/alpha-cypermethrin
16406744|NCT03931473|Active Comparator|Interceptor|Alpha-cypermethrin
16406745|NCT03931447|Experimental|Cohort 1: JNJ-72537634 Dose 1 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a single day (SD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1.
16406746|NCT03931447|Experimental|Cohort 2: JNJ-72537634 Dose 2 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a SD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1.
16406747|NCT03931447|Experimental|Cohort 3: JNJ-72537634 Dose 1 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a multiple day (MD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1 for 14 consecutive days.
16406748|NCT03931447|Experimental|Cohort 4: JNJ-72537634 Dose 2 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a MD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1 for 14 consecutive days.
16406749|NCT03931434|Active Comparator|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
16406750|NCT03931434|Placebo Comparator|Placebo|The Placebo does not contain any Aged Garlic Extract (AGE)
16406751|NCT03931421|Experimental|experiment group|In this arm, patients are treated with B Cell Maturation Antigen (BMCA)-targeted CAR-T cells and the safety and efficacy will be observed.
16406752|NCT03931408|Experimental|Gentamicin|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of gentamicin mixed with saline, 2 times per day. A formulation derived from 480 mg gentamicin sulfate diluted in 1 L normal saline will be used for instillation. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
16406753|NCT03931408|Placebo Comparator|Placebo instillation (saline alone)|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of saline alone. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
16406754|NCT03931408|Other|No instillation|Participants will be randomized into one of three groups. In this arm participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
16406755|NCT03931395|Experimental|Honey Plus Standard of Care|The Honey standard of care group will receive treatment as usual, alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic, plus 1 tsp of honey with every dose of acetaminophen. The Honey standard of care group will receive the first dose of honey in the recovery room with the administration of acetaminophen and will be provided with honey upon discharge.
16406756|NCT03931395|Active Comparator|Standard of Care|The standard of care group will receive treatment as usual (alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
16406757|NCT03931382|Experimental|Virtual Reality|In this arm, participants will receive 45 minutes of preparation using a simulated virtual reality experience designed in collaboration with Medical Imaging and Child Life Specialists.
16406758|NCT03931382|Active Comparator|Mock MRI|In this arm, participants will receive 45 minutes of preparation using the standard of care simulator, conducted by a Child Life Specialist
16406759|NCT03931382|Active Comparator|Booklet|In this arm, participants will receive 45 minutes of preparation using the standard of care MRI Preparation Booklet for non-sedated MRIs.
16406760|NCT03931369|Experimental|Tolvaptan test|15 MG pill administered tolvatan once, one day
16406761|NCT03931343|Experimental|Thoracolumbar interfascial plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
16406762|NCT03931343|Active Comparator|Erectro spinae plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
16406763|NCT03931330|Experimental|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
16406764|NCT03931317|Other|Latanoprostene bunod 0.024% QD|4 weeks of Latanoprostene bunod 0.024% QD, then a 2 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
16406765|NCT03931317|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 2 Week washout, followed by 4 weeks of Latanoprostene bunod 0.024% QD
16406766|NCT03931304||Cases group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
16406767|NCT03931304||Control group|Cytoreductive surgery alone
16406768|NCT03931291|Experimental|Experimental arm: APR-246 + azacitidine|APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 cycles
16406769|NCT03931278|Other|persons with Multiple Sclerosis (MS)|
16406770|NCT03931278|Other|Healthy controls|
16406771|NCT03931252|Experimental|High fat|Boost VHC (Very High Calorie), Nestle, 8 ounce can
16406772|NCT03931252|Experimental|High protein|Ensure High Protein 8 ounce can
16406773|NCT03931239|Experimental|Vaccination|DTPw-HB-Hib vaccine
16406774|NCT03931226||Departmental cohort|Department level of the Haute-Garonne through the use of the 'POMME' cohort (PrescriptiOns Medicines Mother Children)
16406775|NCT03931226||National cohort|"National level through the use of the EGB database (General Sample of Beneficiaries)"
16406776|NCT03931187|Experimental|Women intervention arm|Intervention will be applied to the women within the couple.
16406777|NCT03931187|Experimental|Couple intervention arm|Intervention will be applied to the couple, both men and women.
16406778|NCT03931187|No Intervention|Control arm|The couple will receive the normal nursing care.
16406779|NCT03931174|Active Comparator|Addiction Technology Transfer Center (ATTC) Training|Half of the opioid treatment centers will receive the ATTC training strategy.
16406780|NCT03931174|Experimental|Enhanced ATTC (E-ATTC) Training Strategy|Half of the opioid treatment centers will receive the E-ATTC training strategy.
16406783|NCT03931148|Experimental|Intervention|"After first consultation for diagnosis of neurodegenerative disorder :
~Geriatric Assessment with specific neuropsychologic tests of decision making
~fRMI
~EEG High Resolution
~Qualitative interview"
16406784|NCT03931135|Active Comparator|Dexamethasone|
16406785|NCT03931135|Active Comparator|Cyclizine|
16406786|NCT03931122|No Intervention|Group A - Weight Based Method|"Body Weight Based method: This is the conventional method for LMA size selection. The patient will be weighed and LMA size corresponding to their weight will be used as follows.
~(LMA Size - 1 for up to 5 kg of body weight) (LMA Size - 1.5 for 5 to 10 kg of body weight) (LMA Size - 2 for 10 to 20 kg of body weight) (LMA Size - 2.5 for 20 to 30 kg of body weight) (LMA Size - 3 for 30 to 50 kg of body weight)"
16406787|NCT03931122|Experimental|Group B - Ear Size Based Method|"Ear Size Based method: External ear size will be measured by using a paper ruler and will be recorded in cm as follows:
~Vertical length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.
~Horizontal length (width): from the tragus to the furthest part of the helix horizontally.
~Dimension(cm2): Vertical length (L) × Horizontal length (width-W )
~Based on these ear measurements, nearest smaller LMA size will be selected."
16406788|NCT03931109||PHPT w/ Osteoporosis|Primary hyperparathyroidism patients with osteoporosis undergoing parathyroidectomy
16406789|NCT03931109||PHPT w/o Osteoporosis|Primary hyperparathyroidism patients without osteoporosis undergoing parathyroidectomy
16406790|NCT03931109||Thyroid w/ Osteoporosis|Thyroid disease patients with osteoporosis undergoing thyroidectomy
16406791|NCT03931096||children with congenital heart disease|Groupe 1: case: children with congenital heart disease aged 5 to 7 years.
16406792|NCT03931096||control children|Groupe 2: control children recruited in schools aged 5 to 7 years.
16406793|NCT03931083||Portable magnification device (Gynocular™)|The Gynocular™ examination will be performed following the steps involved in colposcopy as described in the IARC colposcopy manual. These steps include: visualization of the vagina, vulva and cervix following insertion of a speculum, magnified assessment after application of normal saline, examination of cervical vessel patterns using the red-free mode (or green filter), application of 5% acetic acid for 1 minute and finally assessment following application with Lugol's iodine. The findings of the live examination will be documented using the parameters of the Swede score. Each parameter is scored between zero and two. Treatment will be based on the results found at histopathology, unless the woman is also VIA positive in which case, after biopsy she will undergo routine treatment as per local guidelines. The results will be used to determine the optimal threshold for treatment in WLHIV.
16406794|NCT03931083||Testing for high risk HPV (HRHPV)|To reduce the number of examinations undergone by the study participant during the same day, HRHPV testing will be carried out at the time of the first gynecological examination by the VIA nurse (see next arm). Using specific single-use cervical cytobrush provided by GeneXpert, a specimen will be collected immediately prior to VIA examination. Cervical cytobrush specimens will be placed into ThinPrep PreservCyt (Cepheid, Sunnyvale, CA) immediately after collection. The HR-HPV testing of cervical specimens will be conducted by a GeneXpert™ machine (Cepheid, Sunnyvale, CA), which will be placed at the health facility and will be operated by a trained nurse in accordance with the manufacturer's instructions. Additionally, as part of the baseline clinical characteristics of the study participant, the study participant will undergo an STI test at the same time. The sample will be collected and tested using the same GeneXpertTM platform.
16406795|NCT03931083||Visual inspection with acetic acid (VIA)|VIA, which is standard of care for cervical cancer screening in Zambia, will be carried out using the methodology described by IARC. This is summarized as follows: visualization of the vagina, vulva and cervix following insertion of a speculum; assessment with the naked eye after application of normal saline; and further assessment after application of 5% acetic acid for 1 minute. This will be recorded as normal or abnormal by the assessor.
16406796|NCT03931083||Histopathological examination of tissue biopsies|All acetowhite lesions will be biopsied. When no lesion is seen, one biopsy is taken from each quadrant at the squamocolumnar junction. Biopsies will be sent and examined in a South African based lab. All histological slides will also be verified independently by an IARC trained pathologist at the end of the study. Histological endpoints are defined by the CIN classification system: CIN 1 affects only the lower third of the epithelium (mild dysplasia), CIN 2 involves two thirds of the epithelium and CIN 3 involves the full thickness (severe dysplasia and carcinoma in situ). These findings can be dichotomized by the Lower Anogenital Squamous Terminology into low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). All patients with CIN grade 2 that stained diffusely positive for p16 are considered as HSIL, all patients with CIN 3 are considered as HSIL. Expression of p16 will be visually assessed by immunohistochemistry.
16406797|NCT03931070|Experimental|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
16406798|NCT03931070|Placebo Comparator|Placebo|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
16406799|NCT03931057|Experimental|ADV6209|ADV6209 (= gamma-cyclodextrin-Midazolam) 0.25 mg/kg p.o. once 30 min. before anesthesia
16406800|NCT03931057|Active Comparator|Midazolam|Midazolam (in orange flavored syrup) 0.25 mg/kg p.o. once 30 min. before anesthesia
16406801|NCT03931044|Experimental|Image-Guided Robotic Gastrectomy|"The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).
~A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.
~The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.
~Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence."
16406802|NCT03931044|No Intervention|Robotic Gastrectomy|Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.
16406803|NCT03931031||Cardiac Surgery Patients|Patients taking antiplatelet medication who are scheduled for elective cardiac surgery.
16406835|NCT03930836|Experimental|interface group|high/low dosage intensive intervention using the interactive interface (motor function rehabilitation)
16407470|NCT03926442|Experimental|Active2|Cinnamon in active breakfast meal
16406804|NCT03931018|Experimental|70 grams alcohol|"Males and Females: Alcohol 70 grams (220 ml Vodka Absolut®), single dose, oral administration
~- 70 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
16406805|NCT03931018|Experimental|100 grams alcohol|"Males: Alcohol 100 grams (312 ml Vodka Absolut®), single dose, oral administration
~- 100 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
16406806|NCT03931005|Experimental|Decision-Support|An electronic copy of a collaboration decision-support guide.
16406807|NCT03931005|Active Comparator|General Support|An electronic copy of general collaboration supports (a list of collaborative implementation strategies and their definitions)
16406808|NCT03930992|Experimental|1 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
16406809|NCT03930992|Active Comparator|2 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
16406810|NCT03930992|Experimental|3 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
16406811|NCT03930992|Active Comparator|4 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
16406812|NCT03930979||Clearsight measurements|All patients presenting to the ED who have a painful condition for which procedural sedation is required will undergo Clearsight measurements
16406813|NCT03930966|Experimental|PDEQ, PCL-5 and demographic survey|State of the patient evaluated with questionnaires to make the connection between peri-traumatic dissociation and the occurrence of post-traumatic stress disorder
16406814|NCT03930953|Experimental|Administration of CC-99282|Escalating doses of CC-99282 administered orally once daily on intermittent schedules up to 2 years.
16406815|NCT03930953|Experimental|CC-99282 + rituximab|CC-99282 administered orally once daily on intermittent schedule with rituximab intravenously (IV) 375 mg/m2 weekly in Cycle 1, every 28 days in C2-6, then every 8 weeks through 2 years.
16406816|NCT03930940|Experimental|RIC group|RIC treatment and regular treatment.
16406817|NCT03930940|Other|Control group|Regular treatment alone.
16406818|NCT03930927|Experimental|Self Assembling peptide|intervention
16406819|NCT03930927|Experimental|Fluoride|Comparator
16406820|NCT03930914|Other|Active Treatment to Sham|Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the Parasym (TM) TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as sham treatment for the second phase of the study.
16406821|NCT03930914|Other|Sham to Active Treatment|Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the Parasym (TM) TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as active treatment for the second phase of the study.
16406822|NCT03930901|Other|Intervention|Children in this group were examined for intestinal parasites and then treated accordingly. Then, health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), & nail clipper).
16406823|NCT03930901|No Intervention|Control|Children in this group were examined for intestinal parasites and then treated accordingly. They were follow up for 6 months.
16406824|NCT03930888||Patients with nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients nutritionally supported by nutritional supplements.
16406825|NCT03930888||Patients without nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients without special nutritional supplements.
16406826|NCT03930875||Control - No Obstructive Sleep Apnea with Aspirin|"The control group consist of patients with a negative diagnosis of OSA (based on a negative home sleep apnea test (REI) < 5 and attended sleep study, AHI < 5; or attended NPSG with an AHI < 5) and the patient is taking aspirin at a dose of 81 mg/day for at least a week prior to inclusion.
~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
16406827|NCT03930875||Arm 1- Obstructive Sleep Apnea with CPAP therapy and Aspirin|"Arm 1 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old, CPAP has been started within the last 2 years, and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.
~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
16406828|NCT03930875||Arm 2 -Obstructive Sleep Apnea with no CPAP & Aspirin|"Arm 2 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.
~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
16406829|NCT03930862|Active Comparator|ball and socket|It is an attachment retaining implant overdentures to increase retention and stability of the denture
16406830|NCT03930862|Experimental|Locator attachment|attachment retaining implant overdentures
16406831|NCT03930849|Experimental|AIMS Intervention|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol.
16406832|NCT03930849|No Intervention|No Intervention|Participants randomized to the no intervention arm will not be enrolled in the Annie text messaging program.
16406833|NCT03930849|Experimental|AIMS Intervention Plus|Participants randomized to the AIMS Intervention Plus arm will be enrolled in VA's Annie text messaging program/study protocol and receive a weekly phone call.
16406834|NCT03930836|Active Comparator|control group|high/low dosage intervention, intensive or not (motor function rehabilitation)
16406836|NCT03930823|Other|Interview|One to one interviews with older people from Turkish origin in Belgium
16406838|NCT03930797|Experimental|Intimacy Enhancement|Participants attend four sessions (60-75 minutes) consisting of education and skills training to enhance physical and emotional intimacy.
16406839|NCT03930797|Active Comparator|Living Healthy Together|Participants attend four sessions (60-75 minutes) consisting of information and support across a range of breast cancer-related topics.
16406840|NCT03930784||Participants|Divided for analysis as having suffered post-operative complications or not
16406841|NCT03930771|Experimental|All Patients|"All subjects will receive:
~Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
~Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14.
~After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity)."
16406842|NCT03930758|Experimental|Uphill exercise before the meals|40 minutes of uphill treadmill exercise at +6o slope completed 1 hour before eating the meal
16406843|NCT03930758|Experimental|Uphill exercise after the meals|40 minutes of uphill treadmill exercise at +6o slope started 1 hour after eating the meal
16406844|NCT03930758|Experimental|Downhill exercise before the meals|40 minutes of downhill treadmill exercise at -6o slope completed 1 hour before eating the meal
16406845|NCT03930758|Experimental|Downhill exercise after the meals|40 minutes of downhill treadmill exercise at -6o slope started 1 hour after eating the meal
16406846|NCT03930758|Sham Comparator|Sedentary trial|A trial with no exercise
16406851|NCT03930719||PSD|Patients fulfilling DSM-5 criteria of PSD within 7 days of admission.
16406852|NCT03930719||No PSD|Patients NOT fulfilling DSM-5 criteria of PSD within 7 days of admission.
16406853|NCT03930706|Experimental|Group A|Group A will include all the patient that will start with progesterone ((P), Utrogestan®) supplementation after 7 days of E2 (Progynova®) intake and that will perform the FET (after 13 days of E2 and 6 days of P).
16406854|NCT03930706|Active Comparator|Group B|Group B will include the patients that will perform 14 days of E2 intake (Progynova®, 6 mg per day (2 mg every 8 hours) those patients will be asked to perform a supplementary blood test and ultrasound on day 14 of E2 intake, afterwards, they will start with P supplementation (Utrogestan®, 800 mg per day, 400 mg every 12 hours) from day 15 of E2 for 6 days and they will get their FET day 20 of the cycle (after 14 days of E2 and 6 days of P)
16406855|NCT03930693|Experimental|Normotensive pregnant women|Normotensive pregnant women
16406856|NCT03930693|Experimental|Hypertensive pregnant women|Hypertensive pregnant women
16406857|NCT03930693|Experimental|Normotensive non-pregnant women|Normotensive non-pregnant women
16406858|NCT03930693|Experimental|Hypertensive non-pregnant women|Hypertensive non-pregnant women
16406859|NCT03930680|Experimental|Dexrazoxane 100mg/m2|one dose of 100mg/m2 dexrazoxane
16406860|NCT03930680|Experimental|Dexrazoxane 200mg/m2|one dose of 200mg/m2 dexrazoxane
16406861|NCT03930680|Experimental|Dexrazoxane 300mg/m2|one dose of 300mg/m2 dexrazoxane
16406862|NCT03930680|Experimental|Dexrazoxane 400mg/m2|one dose of 400mg/m2 dexrazoxane
16406863|NCT03930680|Experimental|Dexrazoxane 500mg/m2|one dose of 500 mg/m2
16406864|NCT03930667|Active Comparator|clips|Closure of the appendix stump with hem-o-lok clips
16406865|NCT03930667|Experimental|knotting|Closure of the appendix stump with intracorporal knotting.
16406866|NCT03930654|Experimental|iPrEP Intervention|"iPrEP Intervention:
~Women will receive the iPrEP intervention on an iPAD Air tablet device
~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument
~iPrEP uses qualitative themes
~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence
~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument
~Scales were modified (in some cases) for cultural competency and tailoring to women"
16406867|NCT03930654|Active Comparator|Usual Care|"Control Intervention:
~Women will receive usual care
~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use
~Social worker will offer a list of substance abuse treatment referral agencies"
16406868|NCT03930641|Experimental|RTH258|brolucizumab 6 mg in a prefilled syringe
16406869|NCT03930615|Experimental|Letermovir|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.
16406870|NCT03930615|Placebo Comparator|Placebo|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.
16406871|NCT03930602|Experimental|BMS-986165+Fluvoxamine|
16406872|NCT03930602|Experimental|BMS-986165 only|
16406873|NCT03930602|Experimental|Fluvoxamine only|
16406874|NCT03930589|Placebo Comparator|Standard of care|no intervention will occur in the standard of care arm
16406875|NCT03930589|Active Comparator|Remote Ischemic Conditioning|Remote ischemic conditioning using BP cuff on left arm
16406876|NCT03930576||Early Legal Terminations|Participants who receive a legal termination at <10 weeks gestation at a recruiting facility.
16406877|NCT03930576||Late Legal Terminations|Participants who receive a legal termination at 10+ weeks gestation at a recruiting facility.
16406878|NCT03930576||Turn-aways: Termination outside Legal Setting|Participants who receive a termination at another facility or outside the formal healthcare sector.
16406879|NCT03930576||Turn-aways: Birth|Participants who ultimately carry the pregnancy to term
16407471|NCT03926442|Experimental|Active3|Pumpkin Spice Mix in active breakfast meal
16407472|NCT03926442|Placebo Comparator|Placebo Comparator|Placebo Breakfast
16406880|NCT03930563|Experimental|Beetroot Juice Low|Subjects will consume beetroot juice containing 250mg inorganic nitrate and 20mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
16406881|NCT03930563|Experimental|Beetroot Juice High|Subjects will consume beetroot juice containing 500mg inorganic nitrate and 40mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
16406882|NCT03930563|Active Comparator|Beetroot Juice Placebo|Subjects will consume beetroot juice devoid of inorganic nitrate and nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
16406883|NCT03930550|Experimental|Infrared guidance first|"In this arm the infra red guidance is applied to the first passage of the flexible scope to the trachea.
~The second passage of the flexible scope is without the infrared light"
16406884|NCT03930550|Active Comparator|Infrared guidance last|"In this arm NO infra red guidance is applied to the first passage of the flexible scope to the trachea.
~The second passage of the flexible scope is with the infrared light as guide"
16406885|NCT03930537|Active Comparator|Hip replacement with cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of cemented femoral component of hip prothesis.
16406886|NCT03930537|Active Comparator|Hip replacement with non-cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of non-cemented femoral component of hip prothesis.
16406887|NCT03930524|No Intervention|Assessment Only|Control
16406888|NCT03930524|Experimental|Early-college Universal|Prior to beginning their first semester of college, incoming students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
16406889|NCT03930524|Experimental|Early-college No Coach (automated email)|Students from the early-college universal arm, who flag on one of the self monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
16406890|NCT03930524|Experimental|Early-college Coach|Students from the early-college universal arm, who flag on one of the self monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
16406891|NCT03930524|Experimental|Later-college Universal|After beginning their first semester of college, students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
16406892|NCT03930524|Experimental|Later-college No Coach (automated email)|Students from the later-college universal arm, who flag on one of the self monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
16406893|NCT03930524|Experimental|Later-college Coach|Students from the later-college universal arm, who flag on one of the self monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
16406894|NCT03930511|No Intervention|PADL at the beginning of PR|First assessment of patients starting Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
16406895|NCT03930511|Experimental|PADL at discharge of PR|Assessment of patients at discharge of Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
16406896|NCT03930511|No Intervention|PADL at 6 months follow-up|Half-a-year reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
16406897|NCT03930511|No Intervention|PADL at 1 year follow-up|Yearly reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
16406898|NCT03930498|Experimental|PD-1 antibody plus chemoradiotherapy|
16406899|NCT03930472|Experimental|Voucher intervention F&V|Receiving $20 in vouchers at each of up to 4 markets ($80 total) that are good for F&V only
16406900|NCT03930472|Experimental|Voucher intervention SNAP|Receiving $20 vouchers at each of up to 4 markets that are good for any foods that SNAP/EBT benefits can be used for
16406901|NCT03930472|No Intervention|Waitlist control|Delayed intervention/waitlist control (who, at the final data gathering, will receive 5 x $20 in vouchers good at the WFfT 2019 and 2020 markets).
16406902|NCT03930459|Experimental|Static cold storage (SCS)|Traditional method of organ preservation which involves flushing of cold preservation solution following complete dissection and interruption of blood supply to the donor organ. Although cold preservation slows metabolism by 10- to 12-fold, substantial anaerobic activity continues even at ice temperature. This lead to the generation of reactive oxygen species that are the basis of ischaemia-reperfusion injury, when the organ is re-exposed to oxygenated blood at the time of transplantation. This damage, exacerbated by any prior injury, limits the maximum safe preservation time of the donor organ.
16406962|NCT03929991||Case|"All women admitted or already hospitalized with suspected or confirmed infection after C/S will be screened for inclusion in the study as a case. Case confirmation will be clinically established by an infectious disease expert.SSI post C/S will be classified as:
~Superficial incisional surgical site infection,
~Deep incisional surgical site infection,
~Organ/space surgical site infection."
16406903|NCT03930459|Experimental|Normothermic machine perfusion (NMP)|The main goal of NMP is to optimize graft preservation by mimicking physiological conditions. The perfused organ is supplied with nutrients and oxygen to maintain metabolic hemostasis. Under these conditions, ATP and glycogen reserves can be maintained or actively restored. At the same time, toxic products from the cellular milieu are continuously eliminated, so the cell-mediated injury phase of reperfusion injury can be minimized. Thus, ischemic injury is avoided and the activation of cell death cascades is prevented. This allows both hepatocellular and biliary protection.
16406904|NCT03930446|Experimental|Ethanol|Subjects will receive 4 color-coded beverages in green or blue cups, containing ethanol (0.2 g/kg per dose, total dose 0.8 g/kg).
16406905|NCT03930446|Placebo Comparator|Placebo (Juice)|Subjects will receive 4 color-coded beverages in green or blue cups, containing placebo (Juice).
16406906|NCT03930433|Active Comparator|Nebivolol group|Oral Nebivolol 5mg / day (2 weeks) -> 10mg / day (10 weeks)
16406907|NCT03930433|Placebo Comparator|Diltiazem group|Oral Diltiazem 90mg / day (2 weeks) -> 180mg / day (10 weeks)
16406908|NCT03930433|Placebo Comparator|Nebivolol+Diltiazem group|Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
16406909|NCT03930420|Active Comparator|Standard|Local health department staff in the standard arm will receive Connect to Wellness intervention materials, multiple real-time training sessions delivered via webinar, access to a web-based platform that includes all intervention and training materials and has features allowing them to communicate with each other and with research staff, and a monthly group technical assistance call.
16406910|NCT03930420|Experimental|Enhanced|Local health department staff in the enhanced arm will receive all the Connect to Wellness intervention materials, training, and support as described for the standard arm. In addition, the participants in the enhanced arm can telephone research staff at will to receive additional technical assistance. Research staff will also contact participants monthly, if they do not request assistance proactively.
16406911|NCT03930407||Hayman group|Who had undergone cesarean section within the last 6 months and received a The Hayman uterine compression suture for uterine atony.
16406912|NCT03930407||Control|Who had undergone cesarean section within the last 6 months and did not experience neither any complication nor any additional intervention
16406913|NCT03930381|Experimental|Intervention Arm|This group will download the ASTHMAXcel application and use it for the duration of the study
16406914|NCT03930381|No Intervention|Usual Care Arm|This group will just receive normal provider care
16406915|NCT03930368|Experimental|Intervened arm|as in a single-arm before-and after study, the only one arm will receive intervention of low GI diet with supplementation of RCS.
16406916|NCT03930355||Transfused|Patients who received blood transfusion in the perioperative period
16406917|NCT03930355||Non transfused|Patients who did not receive blood transfusion in the perioperative period
16406918|NCT03930342|Experimental|Native CHOICES Intervention|Native-CHOICES will comprise usual care plus 2 MI sessions delivered over 4 weeks; a contraception counseling session at a local clinic; and 3 months of electronic messaging to boost the effects of MI and counseling by increasing perceptions of social connection and social support for behavior change. Contraception counseling will be completed within 2 weeks after the second MI session, so the maximum duration of MI and counseling for each participant will be 6 weeks. Electronic messaging will include positive motivational content consistent with alcohol and contraception use goals set in the MI sessions.
16406919|NCT03930342|No Intervention|Wait-list Control Group|The control condition will comprise usual care for the 6-month study period, with a wait-list design that offers women the Native- CHOICES program after they have completed the 6-month data collection.
16406920|NCT03930329|Experimental|MBRP group|The mindfulness-based relapse prevention program consists of eight weekly 2-hour sessions. It combines mindfulness with evidence-based cognitive behavioural techniques that help participants to recognize internal and external triggers of their substance abuse, including smoking. Each session consists of mindful practices with cognitive exercises. The standardized treatment manual was published
16406921|NCT03930329|No Intervention|usual care|All participants in this trial will receive usual care, which consists of 8-12 weeks of counselling and drug treatment to help smokers quit. Data from the centre shows that approximately 50% of smokers are successfully abstinent from smoking at end of the program, as confirmed by the carbon monoxide breath test. This trial will only recruit those who successfully quitted smoking. During this 8-12 week program, written information about relapse prevention is given, including information for maintaining healthy lifestyles (e.g. diet/sleep/exercise/emotional control). Participants will receive follow-up phone interviews by trained smoking cessation counsellors at end of the program (week 8-12)
16406922|NCT03930303|Active Comparator|Multimedia Arm|
16406923|NCT03930303|No Intervention|Control|
16406924|NCT03930290||Pregnant patients|Pregnant patients in their 2nd trimester.
16406925|NCT03930277||Pregnant women in labor.|Pregnant women in labor during the 2nd stage of labor.
16406926|NCT03930264|Active Comparator|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
16406927|NCT03930264|Experimental|Jayempi™|"Generic name : Azathioprine
~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
16406928|NCT03930251|No Intervention|Treatment as Usual|This is the standard coordinated specialty care treatment (without cognitive remediation) that is provided to OnTrackNY clients. This treatment involves psychiatric treatment, employment and educational support, substance abuse treatment, family education and support, CBT-informed individual psychotherapy, and cognitive health support services as needed.
16406929|NCT03930251|Experimental|Clinic-Based Cognitive Remediation|Clinic-based cognitive remediation consists of twice weekly group-based and clinician-led sessions.
16406930|NCT03930251|Experimental|Partial-Remote Cognitive Remediation|Partial-Remote cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
16407473|NCT03926429||Patient with reactive arthritis|
16406931|NCT03930238|Experimental|VA MapTrek|Veterans in the intervention group receive a Fitbit and access to VA MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required to enroll). Each week, Veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. Throughout each race, participants will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
16406932|NCT03930238|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to VA MapTrek or simply by giving the Veterans a Fitbit.
16406933|NCT03930225|Experimental|study group|"In the study group, both patients and their family members will be required to attend a weekly 1 hour long psycho-educational sessions. Moreover assessment sessions will be attended also.
~The stigma directed intervention program"
16406934|NCT03930225|Other|control group|"In the control group, only Patients will attend the psycho-educational sessions.
~Family members and patients will be required to attend the assessment sessions."
16406935|NCT03930212|Experimental|Progesterone|received rectal progesterone suppositories 400 mg once daily
16406936|NCT03930212|Placebo Comparator|Control group|received placebo suppositories rectally once daily.
16406937|NCT03930199|Experimental|Not Meeting Mobility Goals|After the first three months of sensor monitoring, participants not meeting goals will receive an intervention (others will be removed from the study). The intervention assigned is not pre-determined, but will be assigned by an expert panel based on the individual needs determined from the assessment results and monitoring data. The intervention may include prosthetic care, physical therapy, motivational interviewing or other related psychological interventions, or a combination thereof. After three months of intervention, assessments are performed again and if improvement in prosthesis use is determined, participants are monitored for another three months to assess maintenance of prosthesis use (participants showing no improvement are removed from the study before these final three months of monitoring).
16406938|NCT03930186|Experimental|Administration of Apremilast|Apremilast tablets will be taken orally twice daily (BID), approximately 12 hours apart, through the last treatment visit.
16406939|NCT03930173|Experimental|18F-fluciclovine PET/CT of the brain|"Arm includes participants with a known diagnosis of brain metastases who have undergone prior intracranial SRS and whose MRI brain scan is equivocal for radiation necrosis versus tumor progression.
~Participants will undergo 18F-fluciclovine PET/CT of the brain. Qualitative and quantitative metrics will be documented at the time of image acquisition. Qualitative image assessment will be performed independently by 3 separate physicians."
16406940|NCT03930160||Mortality outcome|
16406941|NCT03930147|Experimental|Passive phase, Pressure-Control Ventilation / ASV order|90 minutes of Pressure-Control Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Control Ventilation mode at the end of the intervention.
16406942|NCT03930147|Experimental|Passive phase, ASV / Pressure-Control Ventilation order|90 minutes of ASV, change to Pressure-Control Ventilation mode with 15 to 30 minutes of washout, 90 minutes of Pressure-Control Ventilation.
16406943|NCT03930147|Experimental|Active phase, Pressure-Support / ASV order|90 minutes of Pressure-Support Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Support Ventilation at the end of the intervention.
16406944|NCT03930147|Experimental|Active phase, ASV / Pressure-Support order|90 minutes of ASV, change to Pressure-Support Ventilation with 15 to 30 minutes of washout, 90 minutes of Pressure-Support Ventilation.
16406945|NCT03930134|Experimental|sparse uterine suture|women who had a french ambulatory casarean section including a sparse uterine closure
16406946|NCT03930134|Active Comparator|one layer uterine closure|women who had a misgav ladach caesarean section section, including a one layer classical uterine closure
16406947|NCT03930121|Experimental|Experimental group|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
16406948|NCT03930121|Sham Comparator|Control group|Placebo stimulation (using sham-tDCS) combined with SLT
16406949|NCT03930108||Mortality outcome|
16406950|NCT03930095|Experimental|Acceptance-Based Behavior Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
16406951|NCT03930095|Active Comparator|Non-directive Supportive Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
16406952|NCT03930069|Active Comparator|misoprostol group|20 cases received 400 microgram prostaglandin E1 analogue, misoprostol, (Misotac®, 200 microgram, by SIGMA pharmaceutical industries, Alexandria, Egypt), intra-vaginally, 2 hr before operation.
16406953|NCT03930069|Active Comparator|vasopressin group|20 patients who had hysteroscopic guided intralesional vasopressin injection before hysteroscopic myomectomy
16406954|NCT03930056|Experimental|C-Brace II Group|Subjects will be assigned a C-Brace II orthotic for use.
16406955|NCT03930056|Active Comparator|Traditional Group|Subjects will continue with their own KAFO (non C-Brace II) use.
16406956|NCT03930043||Health Control|
16406957|NCT03930043||Non-gastrointestinal Lymphoma|
16406958|NCT03930043||Gastric Lymphoma|
16406959|NCT03930043||Intestinal Lymphoma|
16406960|NCT03930004||Type 1 diabetic patients|"Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease.
~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
16406961|NCT03930004||Control - Healthy subjects|"Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease.
~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
16406963|NCT03929991||Control|For each case, 3 patients undergoing the C/S on the same day and admitted to the same ward but not presenting Surgical Site Infection
16406964|NCT03929965|Experimental|advanced solid tumors with FGFR alteration|
16406969|NCT03929926|Experimental|Group II (outreach contact)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Eligible and interested patients receive an office visit at the JLCSP for shared decision-making and possible lung cancer screening.
16406970|NCT03929926|Experimental|Group III (outreach + Decision Counseling Program)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Patients then undergo a decision counseling session through a semi-structured Decision Counseling Program that includes a review of the mailed educational materials and completion of an interactive exercise intended to clarify personal preference related to screening options (to have LDCT or not to have LDCT). Patients interested in screening schedule an office visit at JLCSP for possible screening or are referred to their primary care physician for consultation.
16406971|NCT03929913|Experimental|Study arm #1|The Transcatheter Mitral Cerclage Annuloplasty implant is attached to a guidewire and pulled through the internal jugular sheath, along the coronary sinus, through the basal septum, through the tricuspidvalve, and back out of the internal jugular sheath. The position of the TMCA implant is adjusted so that the coronary protection element lies directly over any underlying branc of the left coronary artery.
16406972|NCT03929887||KORNERSTONE|"Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)
~Participants enrolled in KORNERSTONE with a biopsy proven GN.
~Eligible participants must be scheduled for a clinically indicated renal biopsy."
16406973|NCT03929874||18 ≤ age ≤ 40|18 ≤ age ≤ 40
16406974|NCT03929874||age ≥ 60|age ≥ 60
16406975|NCT03929861|Experimental|Fluconazole, period 1|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
16406976|NCT03929861|Experimental|Fluconazole, period 2|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours
16406977|NCT03929848||female|female patient who is scheduled for laryngomicrosurgery
16406978|NCT03929848||male|male patient who is scheduled for laryngomicrosurgery
16406979|NCT03929835|Experimental|Avidekel Oil|The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
16406980|NCT03929835|Placebo Comparator|Placebo|Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.
16406981|NCT03929822||Contrast-Enhanced Spectral Mammography (CESM)|Women called back from an abnormal screening mammogram/tomosynthesis exam will be offered CESM as part of their diagnostic work up. The radiologist will interpret the low energy images and record their findings.
16406982|NCT03929809||Adult Single-sided deafness|Adult subjects with unilateral single-sided deafness at least 6 months (to ensure stability of hearing loss), but no greater than 10 years will be implanted with a MED-EL Synchrony Cochlear Implant.
16406983|NCT03929783|Experimental|Diagnostic (CEM)|Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
16406984|NCT03929770|Active Comparator|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
16406985|NCT03929770|Experimental|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
16406986|NCT03929757|Experimental|Arm 1: Ad26.ZEBOV, MVA-BN-Filo|Participants will be administered 0.5 mL of Ad26.ZEBOV vaccine (5*10^10 viral particles [vp]) on Day 1 by intramuscular (IM) injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 infectious units [Inf U]) vaccine by IM injection on Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
16406987|NCT03929757|Active Comparator|Arm 2: MenACWY|Participants will be administered 0.5 mL of MenACWY vaccine by IM injection on Day 1 and Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
16406988|NCT03929744|Experimental|LY3502970 (Part A)|Single dose of LY3502970 administered orally.
16406989|NCT03929744|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally.
16406990|NCT03929744|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
16406991|NCT03929744|Placebo Comparator|Placebo (Part B)|Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
16406992|NCT03929744|Experimental|LY3502970 (Part C)|Single dose of LY3502970 administered orally in each of two study periods.
16406993|NCT03929744|Experimental|LY3502970 (Part D)|Single dose of LY3502970 administered orally.
16406994|NCT03929744|Placebo Comparator|Placebo (Part D)|Single dose of placebo administered orally.
16406995|NCT03929744|Experimental|LY3502970 Formulation 1 (Part E)|Multiple doses of LY3502970 - formulation 1 administered orally.
16406996|NCT03929744|Experimental|LY3502970 Formulation 2 (Part E)|Multiple doses of LY3502970 - formulation 2 administered orally.
16406997|NCT03929731||Polypoidal Choroidal Vasculopathy RCT|Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T&E studies
16406998|NCT03929718|Active Comparator|Standard Therapy|subjects undergoing CTI ablation
16406999|NCT03929718|Experimental|Interventional Therapy|subjects treated with an aldosterone antagonist after CTI ablation
16407000|NCT03929705||Test Arm 1- T-SPOT.TB assay|T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
16407001|NCT03929705||Test Arm 2 -QuantiFERON-TB Gold Plus assay|QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
16407002|NCT03929692|Other|Intervention Group|Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
16407003|NCT03929692|Other|Control Group|Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
16407004|NCT03929679||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
16407005|NCT03929666|Experimental|ZW25 + FP|ZW25 plus fluorouracil (5-FU) and cisplatin
16407006|NCT03929666|Experimental|ZW25 + mFOLFOX6|ZW25 plus 5-FU, leucovorin, and oxaliplatin
16407007|NCT03929666|Experimental|ZW25 + XELOX|ZW25 plus capecitabine and oxaliplatin
16407008|NCT03929666|Experimental|ZW25 + mFOLFOX6 with bevacizumab|ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
16407009|NCT03929666|Experimental|ZW25 + CisGem|ZW25 plus cisplatin and gemcitabine
16407010|NCT03929653||Advanced Refractory Solid Tumors|Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).
16407011|NCT03929640|Placebo Comparator|Ibuprofen and placebo|Oral administration of ibuprofen 600 mg tablet and placebo tablet every 6 hours
16407012|NCT03929640|Active Comparator|Ibuprofen and acetaminophen|Oral administration of ibuprofen 600 mg tablet and acetaminophen 650 mg tablet every 6 hours
16407013|NCT03929627||Group 1 - Medical personnell|Group 1 consists of 70 participants belonging to medical staff of the Medical University of Vienna/University Hospital of Vienna and is divided into subgroups consisting of medical technical assistants, nurses, assistant physicians and physicians.
16407014|NCT03929627||Group 2 - Control|Group 2 consists of 70 participants and is recruited from the General non-medical staff of the Austrian Federal Ministry of Defence and Sports, Austrian Armed Forces.
16407015|NCT03929601|Experimental|Rituximab followed by Abatacept|"Rituximab will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 1 of the study.
~Abatacept will be given by a subcutaneous formulation weekly for 2 years, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL)."
16407016|NCT03929588|Experimental|Refraction with a Hand-held Device Supported by Mobile App.|BCVA with handheld device with app.
16407017|NCT03929588|Active Comparator|Manual Refraction|BCVA with phoropter
16407018|NCT03929588|Active Comparator|Automated Refraction|BCVA with autorefractoer
16407019|NCT03929575|Placebo Comparator|Placebo of calcium|Participants will consume 250 mg of calcium
16407020|NCT03929575|Experimental|Rhodiola|Participants will consume 250 mg of Rhodiola
16407021|NCT03929575|Experimental|Rhodiola and Cordyceps|Participants will consume a combination of 250 mg of Rhodiola and 225 mg of Cordyceps
16407022|NCT03929562|Active Comparator|Brief advice|One brief advice session, resource brochure, standard of care, and an infographic about alcohol and surgical health at patient's pre-existing pre-operative clinical visit.
16407023|NCT03929562|Experimental|Health coaching|Two health coaching sessions, resource brochure, standard of care
16407024|NCT03929549|Experimental|RCMP titration|Remotely Controlled Mandibular Positioner
16407025|NCT03929523|Experimental|HOPE group|hypothermic oxygenated perfusion
16407026|NCT03929523|Active Comparator|Control group|classic static cold storage
16407027|NCT03929510|Experimental|Period A|Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
16407028|NCT03929510|Experimental|Period B|Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
16407029|NCT03929497|Experimental|Lu AF11167|
16407030|NCT03929484|Experimental|Group A|Each patient will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula alone (Period 2).
16407031|NCT03929484|Experimental|Group B|Each patient will receive oxygen for 1 hour using a standard nasal cannula alone (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).
16407032|NCT03929471|Experimental|Intervention group|Patients to be subjected to a fluid overload correction protocol.
16407033|NCT03929471|No Intervention|Control group|Patient will be followed but no fluid overload correction protocol will be applied.
16407034|NCT03929445|Active Comparator|AIR-Q group|the group which selected randomly to try AIR-Q device
16407035|NCT03929445|Active Comparator|I-LMA group|the group which selected randomly to try I-LMA device
16407036|NCT03929432|Active Comparator|Active tDCS (with Speech-Language Treatment)|tDCS Stimulation Dose: 1.5 mA for 20-mins
16407037|NCT03929432|Sham Comparator|Sham tDCS (with Speech-Language Treatment)|No tDCS stimulation
16407038|NCT03929419|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
16407039|NCT03929419|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
16407040|NCT03929406|Experimental|Brain Tissue Imprint|Evaluation and validation of the samples collected during the brain tissue imprint procedure using a CE marked Medical Device in patients presenting one of the following five disorders: Parkinson's disease (PD), essential tremor (ET), dystonia (DYS), Obsessive compulsive disorder (OCD) and Tourette Syndrome (TS).
16407041|NCT03929393|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
16407042|NCT03929393|Active Comparator|Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
16407043|NCT03929380|Experimental|10x10 squat protocol|
16407044|NCT03929380|Experimental|As Fast As Possible 100 squat protocol|
16407045|NCT03929367|Other|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
16411334|NCT03899779|Active Comparator|Online psychoeducation|12 weeks treatment with online psychoeducation
16407046|NCT03929354|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend the 12-week intensive lifestyle programme which includes healthy lifestyle change such as smoking cessation, healthy food choices and increasing physical activity levels, as well as management of cholesterol, diabetes, and blood pressure.
~The 12-week programme will consist of 12 sessions of 2.5 hours each per week.
~Each of the weekly sessions will incorporate an individualised meeting between the multidisciplinary healthcare team and each patient to review the progress and health goals.
~The weekly sessions will also include a one-hour group exercise programme and an educational workshop."
16407047|NCT03929354|Active Comparator|Standard Care|Standard care is defined as giving information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
16407048|NCT03929341|Experimental|CCTA first approach with Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
16407049|NCT03929341|Experimental|CCTA first approach without Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
16407050|NCT03929341|Active Comparator|Usual Care with Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
16407051|NCT03929341|Active Comparator|Usual Care without Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
16407052|NCT03929328|No Intervention|Spontaneous breathing trial with T-piece|Patients were randomized to undergo a spontaneous breathing trial with T-piece that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
16407053|NCT03929328|Experimental|Spontaneous breathing trial with high flow oxygen therapy|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
16407054|NCT03929315||Non-spaced learning|Learning/testing sessions will take place within 30 minutes of one another
16407055|NCT03929315||Spaced learning|Learning/testing sessions will take place 1 week after one another
16407056|NCT03929302|No Intervention|Brain Energy Metabolism and Sleep on cognition|In the phase-1 of the study, the investigator will be investigating the basic science of the relationship of sleep abnormalities, genes, brain energy metabolites variables with cognitive performance in three cohorts: cognitively normal adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
16407057|NCT03929302|Experimental|Dental Intervention to improve sleep and cognition|To investigate if MyTAP oral airway management with mouth shield will improve sleep and cognition in three cohorts: cognitively healthy adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
16407058|NCT03929289|Experimental|Social Facilitation|Cognitive tasks during the 2 functional Magnetic Resonance Imaging (fMRI) observed or not by a subject's known peer.
16407059|NCT03929276|Experimental|high-intensity laser therapy & exercises|High-intensity laser therapy application with iLux Laser device + exercise program
16407060|NCT03929276|Placebo Comparator|Shame laser & exercises|Sham high-intensity laser therapy application with iLux Laser device + exercise program
16407061|NCT03929276|Active Comparator|control - exercises only group|exercise program
16407062|NCT03929263|Experimental|Real-time fMRI neurofeedback|All participants will receive neurofeedback from the target region (no sham condition).
16407063|NCT03929250|Experimental|2g CAW Dose|2g of Centella asiatica water extract in a standardized product.
16407064|NCT03929250|Experimental|4g CAW Dose|4g of Centella asiatica water extract in a standardized product.
16407065|NCT03929224|Active Comparator|Bacitracin|Standard care: BAHA abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
16407066|NCT03929224|Experimental|Medicinal honey and bacitracin|Standard care + MediHoney: Medi-Honey will be applied to the abutment site immediately after surgery in addition to the bacitracin. The healing cap will be placed on the BAHA site. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment and MediHoney daily to the area for 2 weeks.
16407067|NCT03929211|Experimental|CPI-613 and hydroxychloroquine|The initial phase of the study will be a dose escalation of hydroxychloroquine from 600 mg to 1,200 mg orally flat dose given 2 hours before the CPI-613 infusion on days 1-5 of every 28 days. CPI-dose will be 2,000 mg/m² and will not be escalated.
16407068|NCT03929198|Experimental|Intervention|The intervention group participated in a 6-week Pritikin diet, exercise program, and behavioral modification.
16407069|NCT03929198|No Intervention|Control|This group did not receive any intervention.
16407070|NCT03929185||Tumor affected|Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
16407071|NCT03929185||Control|Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
16407072|NCT03929172|Experimental|AAVLP-HPV Vaccine Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
16407073|NCT03929172|Placebo Comparator|Placebo Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
16407074|NCT03929159||Group A (biospecimen collection)|Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
16407075|NCT03929159||Group B (biospecimen collection)|Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
16407076|NCT03929146|Experimental|Liposomal Bupivacaine|Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
16407077|NCT03929146|Other|Interscalene Nerve Block|Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
16407078|NCT03929120|Experimental|Interstitial Lung Disease with Connective Tissue Disorder|Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
16407079|NCT03929107|Experimental|Intervention group|In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.
16407080|NCT03929094|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
16407081|NCT03929081|Experimental|Inference Based Approach (IBA)|The IBA treatment, a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly. The IBA model is based on the assumption that patients with OCD feel the need to perform compulsive acts because they misjudge the actual state of affairs, for example fearing that an appliance is on when it is visibly off. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the patient's attention from observable reality. IBA teaches patients how to defend themselves against the absorbing and confusing effect of obsessive reasoning processes and how to stay in touch with reality by actively relying on the sensory information of the very moment. As a consequence, the patient realizes that any compulsive act is superfluous and feels able to omit it.
16407082|NCT03929081|Active Comparator|Cognitive Behavior Therapy (CBT)|In the control condition, the patients will receive twenty 45-minutes sessions of CBT consisting of self-guided exposure in vivo with response prevention (ERP) and cognitive therapy (CT), both standardized according to evidence-based session-by-session protocols, containing standardized forms for exercises and homework assignments.
16407083|NCT03929081|No Intervention|No intervention (healthy controls)|The healthy control group will receive no intervention.
16407084|NCT03929068|Active Comparator|carbidopa-levodopa|Each tablet of carbidopa-levodopa in this study will be equivalent to half of a standard carbidopa-levodopa 25/100mg tablet. Participants will take one tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
16407085|NCT03929068|Placebo Comparator|Placebo|Participants will take one placebo tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
16407086|NCT03929055|Active Comparator|venturi mask|oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92%
16407087|NCT03929055|Active Comparator|HFNC|HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min
16407088|NCT03929055|Active Comparator|CPAP|Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step
16407089|NCT03929042|Experimental|Posture Correction Girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
16407090|NCT03929029|Experimental|Nivolumab+Ipilimumab+NeoVax plus Montanide|"Run in period will begin within 2 weeks of metastatic tissue biopsy, once the following criteria
~Patients will receive Nivolumab at a flat dose I.V. infusion every 4 weeks (28 days)
~Patients will receive Ipilimumab injection on weeks 12, 15, 18, and 21
~Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21"
16407091|NCT03929016|Experimental|Active DNDI-0690 male 10mg fasting|Single dose 10mg male fasting
16407092|NCT03929016|Placebo Comparator|Placebo male fasting|Single dose placebo male fasting
16407093|NCT03929016|Experimental|Active DNDI-0690 male 30mg fasting|Single dose 30mg male fasting
16407094|NCT03929016|Experimental|Active DNDI-0690 male 150mg fasting|Single dose 150mg male fasting
16407095|NCT03929016|Experimental|Active DNDI-0690 male 400mg fasting|Single dose 400mg male fasting
16407096|NCT03929016|Experimental|Active DNDI-0690 male 1200mg fasting|Single dose 1200mg male fasting
16407097|NCT03929016|Experimental|Active DNDI-0690 male 3600mg fasting|Single dose 3600mg male fasting
16407098|NCT03929016|Placebo Comparator|Placebo male fed|Placebo male fed
16407099|NCT03929016|Experimental|Active DNDI-0690 400mg male fed|Single dose 400mg male fed
16407100|NCT03929016|Placebo Comparator|Placebo female fasting|Placebo female fasting
16407101|NCT03929016|Experimental|Active DNDI-0690 1200mg female fasting|Single dose 1200mg female fasting
16407102|NCT03929003|Experimental|Contingent|Participants in this arm will be required to meet CO goals in order to earn game-based rewards.
16407103|NCT03929003|Active Comparator|Non-contingent|Participants in this arm will submit CO verifications but will earn game-based rewards independent of meeting CO goals.
16407104|NCT03928990|Experimental|Experimental arm|
16407105|NCT03928977|Other|Confirmed TIA|Confirmed TIA at 3 months with standardized neurological expertise
16407106|NCT03928977|Other|Confirmed non-TIA|Not-confirmed TIA at 3 months with standardized neurological expertise
16407107|NCT03928951||Patients suffering from urinary infection|Patients consulting in one of Toulon - La Seyne sur Mer hospital emergency departments because of urinary infection
16407108|NCT03928938|Experimental|Electronic follow-up|Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
16407109|NCT03928925|Active Comparator|BOUGIE|"For patients randomized to use of a bougie, the operator will use a bougie on the first attempt at intubation. If successful, an assistant will load an endotracheal tube over the bougie, and the operator (without removing the laryngoscope from the mouth) will guide the tube through the vocal cords to the desired depth in the trachea.
~If the bougie is not successfully placed in the trachea or the endotracheal tube cannot be successfully advanced over the bougie on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
16407133|NCT03928756|Experimental|Within-participant randomization|Each day, each available participant will be randomly assigned to receive either: a push notification with tailored intervention content; a push notification with engaging, nontherapeutic content; or no push notification.
16407134|NCT03928743|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
16407110|NCT03928925|Active Comparator|Endotracheal Tube with Stylet|"For patients randomized to use of an endotracheal tube with stylet, the operator will use an endotracheal tube containing a removeable, malleable stylet, on the first attempt at intubation.
~Manipulation of the shape/curve of the endotracheal tube with stylet is at the discretion of the operator, however a straight-to-cuff shape and a bend angle of 25° to 35° is encouraged. The stylet will be left in place until the tube is advanced to the trachea.
~If the endotracheal tube with stylet is not successfully placed in the trachea on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
16407111|NCT03928912||without fracture nonunion|The patients who undergone surgery after tibial shaft fracture did not exist fracture nonunion
16407112|NCT03928912||with fracture nonunion|The patients who undergone surgery after tibial shaft fracture existed fracture nonunion
16407113|NCT03928899|No Intervention|old guideline group|"Women randomized to the old guideline group will be followed up once-weekly by electronic fetal heart rate monitoring and biophysical profile until 40 weeks 0 days (unless a medical indication arises), when induction of labor was then offered."
16407114|NCT03928899|Experimental|new procedure group|"Women randomized to new procedure group will first undergo fetal weight ultrasound estimation at 38 weeks 0 days to 38 weeks 6 days of gestation, if the fetus is estimated to be LGA/macrosomia by ultrasound, women should have an elective induction of labor immediately (at 38 weeks 0 days to 38 weeks 6 days of gestation). On the contrary, if the fetus is estimated to be normal size, the pregnant women were then given a cervical assessment. If the Bishop score ≥6, women will have at least weekly follow-up visits with their doctors and unless a medical indication is present, continue pregnancy and have selective induction at 40 weeks 0 days of gestation. Whereas, if the Bishop score <6, women will be followed up until 41 weeks 0 days of gestation with a close assessment of fetal wellbeing through the cardiotocographic trace. And women who will not deliver by this gestational age will be admitted for labor induction. Certainly, medical indication should warrant delivery without delay."
16407115|NCT03928886|Experimental|Senographe Pristina patient-assisted compression model|Senographe Pristina is a commercial mammography medical device consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). Senographe Pristina includes the hardware and software components required for multi-modality functioning and is designed to improve patient experience, patient throughput, and radiographer experience. The system offers two compression modes - standard mode and the optional patient-assisted compression. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
16407116|NCT03928886|Active Comparator|Senographe Pristina standard compression mode (usual care)|Senographe Pristina standard mode
16407117|NCT03928873|Experimental|Low energy ESWT|"Low energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks)"
16407118|NCT03928873|Experimental|High energy ESWT|"High energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks)"
16407119|NCT03928873|Sham Comparator|Sham treatment|All participants will receive sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks.
16407120|NCT03928860|Experimental|OMT Session and Doppler Ultrasonography|"OMT Session Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
~Doppler Ultrasonography Femoral artery diameter and flow evaluated by radiologist.
~In the evaluation, the wall contour characteristics of the vessel to be examined were evaluated and the diameter was measured. Color doppler examination was performed to determine whether the vessel contained color filling, patency, flow direction and turbulence.
~Peak systolic and end diastolic flow rates and flow pattern and flow rate were measured by spectral examination"
16407121|NCT03928847|Experimental|EGCG treatment|"Healthy volunteers: 450 mg, 600 mg, or 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
~Patients: 600 mg EGCG capsules once daily by mouth for two weeks"
16407122|NCT03928834|Experimental|Adapted Nzira Itsva Intervention|Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
16407123|NCT03928834|No Intervention|Standard of Care( SOC)|Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents
16407124|NCT03928821|Experimental|Group 1: PGT121 + VRC07-523LS|Participants will receive PGT121 and VRC07-523LS administered sequentially in this order at Day 0.
16407125|NCT03928821|Experimental|Group 2: PGDM1400 + VRC07-523LS|Participants will receive PGDM1400 and VRC07-523LS administered sequentially in this order at Day 0.
16407126|NCT03928821|Experimental|Group 3: 10-1074 + VRC07-523LS|Participants will receive 10-1074 and VRC07-523LS administered sequentially in this order at Day 0.
16407127|NCT03928821|Experimental|Group 4: PGDM1400 + PGT121 + VRC07-523LS|Participants will receive PGDM1400, PGT121, and VRC07-523LS administered sequentially in this order at Day 0 and Month 4.
16407128|NCT03928808|Experimental|FMT for SE-AN|Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
16407129|NCT03928795||neonates with acute acidosis|neonates with Cord blood gases measured immediately after birth inferior to 7.15
16407130|NCT03928795||neonates with a normal ph|neonates with Cord blood gases measured immediately after birth of at least 7.15
16407131|NCT03928769||Control Group|Patients with traumatic vascular injury, ultimately corresponding to control patients
16407132|NCT03928769||Atheroma Group|"Patients will be included either in the atheromatous group (patients with atheromatous pathology) or in the control group (patients without atheromatous pathology), according to the clinical evaluation.
~In the atheromatous group, subjects must have a clinically significant atheromatous pathology.
~The investigator must specify the site (s) affected by the atheroma: carotid artery, coronary artery, aorta, renal artery, mesenteric artery or lower limb artery."
16444477|NCT03673111|Experimental|18.0 mg|Y14 single dose, subcutaneous
16407135|NCT03928743|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
16407136|NCT03928730|Other|Group I|Inflammatory swellings
16407137|NCT03928730|Other|Group II|Cystic swellings
16407138|NCT03928730|Other|Group III|Lymph node swellings
16407139|NCT03928730|Other|Group IV|Benign swellings
16407140|NCT03928730|Other|Group V|Malignant swellings
16407141|NCT03928717|Experimental|Text-Based Adherence Game|Participants in the experimental condition will receive the Text Based Adherence Game. They will receive semi-automated text messages sent by study staff throughout the trial period.
16407142|NCT03928717|Active Comparator|Standard of Care (SOC)|SOC participants will receive the Standard of Care Intervention which includes receiving a brief adherence counseling session and access to clinic resources, including counseling services, throughout the trial period.
16407145|NCT03928691||Study group|pregnant women admitted to Women's Health Hospital , Assiut university during 2019-2020 will be counseled to participate in the study
16407146|NCT03928678|Active Comparator|thefast track (FTS group)|
16407147|NCT03928678|Placebo Comparator|Thecontrolgroup|
16407148|NCT03928665||Control group|
16407149|NCT03928665||Sleep apnea using CEPAP|
16407150|NCT03928665||Sleep apnea not using CEPAP|
16407151|NCT03928665||Glaucoma control group|
16407153|NCT03928626|Active Comparator|CRAVING REGULATION|"In the CRAVING REGULATION condition, participants will first read a brief essay about the adverse consequences of drinking alcohol. Then, participants may complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will be trained to use the information to inform the strategy they will use in the regulation of craving training (ROC-T). A single trial in the regulation of craving training will have two possible instructions: (a) STRATEGY: implement the strategy (bring to mind the negative facts from the essay) and (b) LOOK: to merely observe the image and allow natural responses to come. Participants will follow the instructions; followed by an alcohol-related picture, a brief delay, and will then rate their craving. Participants will then be instructed to use this strategy in daily life situations when they might drink."
16407154|NCT03928626|Placebo Comparator|CONTROL (NO REGULATION)|In the CONTROL condition, participants will first read a brief essay about a non-alcohol-related topic (e.g., color perception). Then, participants will complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will view images of objects that are unrelated to alcohol. Furthermore, participants in the control condition will not practice any strategy in the regulation of craving task (ROC-T). That is, in the CONTROL condition, participants would merely observe the image and allow natural responses to come (i.e., LOOK instruction) and rate how colorful is each item (this controls for task time and experiment setting).
16407155|NCT03928613|Experimental|Mild Cognitive Impairment|"Clinical dementia rating 0 or 0.5
~Diagnosed by physicians as mild cognitive impairment according to the criteria of International Working Group on Mild Cognitive Impairment"
16407156|NCT03928600|Experimental|Combined method induction group|"25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)
~After 4 hours of last misoprostol initiate oxytocin.
~Cervical Foley will be removed after 12h of placement or when fails out."
16407157|NCT03928600|Placebo Comparator|Current department guidelines group|"Following current department guidelines, as usual, with the method considered more suitable.
~If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.
~If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place."
16407158|NCT03928587|Experimental|Active|A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
16407159|NCT03928587|Placebo Comparator|Placebo|An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
16407160|NCT03928574||Ultrasound-Guided|Ultrasound-Guided Plane Block
16407161|NCT03928574||Conventional|Conventional Block
16407162|NCT03928561|Experimental|1 - Active air cleaner then Placebo|Exposure to cat allergen in the presence of active air cleaners then placebo. 3-week wash-out period between the two exposures.
16407163|NCT03928561|Experimental|2 - Placebo then active air cleaner|Exposure to cat allergen in the presence of placebo then active air cleaners. 3-week wash-out period between the two exposures.
16407164|NCT03928548||Low Risk Malnutrition|Participants who are determined to be at low risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
16407165|NCT03928548||High Risk Malnutrition|Participants who are determined to be at high risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
16407166|NCT03928535|Other|High-Flow Nasal Cannula|High-flow oxygen was applied immediately after extubation through specific nasal cannula.
16407167|NCT03928535|Other|Noninvasive Ventilation|Noninvasive Ventilation was applied immediately after extubation.
16407168|NCT03928522|Active Comparator|Pre-mixed tobramycin|patients will receive pre-mixed tobramycin cement
16407169|NCT03928522|Active Comparator|hand mixed tobramycin|patients will receive hand mixed tobramycin cement
16407170|NCT03928522|Active Comparator|hand mixed vancomycin|patients will receive hand mixed vancomycin cement
16407171|NCT03928522|Experimental|hand-mixed vancomycin and tobramycin|patients will receive hand mixed vancomycin and tobramycin
16407172|NCT03928509||Estrie CIUSSS|Subjects from the Estrie's Integrated Health and Social Services Centre
16407173|NCT03928509||Saguenay-Lac-Saint-Jean CIUSSS|Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres
16407174|NCT03928496|Experimental|Abobotulinumtoxina|300 units of abobotulinumtoxinA was reconstituted with 2.4 ml of 0.9% preservative free sterile saline so that each 0.1 ml contained 12.5 units of Abobotulinumtoxina 0.1 ml were injected into 31 sites of the head and neck
16407175|NCT03928496|Placebo Comparator|Placebo|0.9% preservative free sterile saline. 0.1 ml were injected into 31 sites of the head and neck
16407176|NCT03928483|Experimental|Modified WW Food program|Participants will be assigned to a SmartPoints budget and number and types of ZeroPoint foods.
16407177|NCT03928470|Experimental|EsoDuo Tab. 20/800mg|EsoDuo Tab. 20/800mg
16407178|NCT03928470|Active Comparator|Nexium Tab. 20mg|Nexium Tab. 20mg
16407179|NCT03928444|Experimental|stem cells|one side of the face to be treated with intradermal stem cells
16407180|NCT03928444|Placebo Comparator|control|one side of face treated with intradermal saline
16407181|NCT03928431|No Intervention|vaginally delivered|A non-randomized reference group of vaginally delivered infants.
16407182|NCT03928431|Active Comparator|CS intervention|"A piece of gauze soaked with saline (0.9%) will be placed in the birth canal 2 hours before the CS by the study midwife, using sterile glows. Before the CS procedure begins, the gauze will be removed from the vagina and then immediately contaminated by a swab carrying maternal fecal microbiota. The swab is contaminated by introducing it 3 cm into the anal canal and by rotating it for 10-20 s.
~Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding."
16407183|NCT03928431|Placebo Comparator|CS placebo|See above - the gauze will be exchanged to a clean gauze (soaked with saline). Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding.
16407184|NCT03928418|Experimental|Live Phone Call Booster Arm|The live phone call arm will include in-person counseling during 2 quarterly clinic visits plus live booster phone calls every three weeks in the interim.
16407185|NCT03928418|Experimental|Technology Booster Arm|The technology booster arm will include in-person counseling during 2 quarterly clinic visits plus tech (choice of SMS or IVR) boosters once to twice weekly in the interim.
16407186|NCT03928418|No Intervention|Standard of Care (SOC) Arm|The standard of care (SOC) control (brief unstructured advice, with a wait-listed intervention).
16407187|NCT03928405|Experimental|Virtual reality group|The subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT). The virtual reality group was trained with games selected from different categories such as balance and aerobic exercises with Nintendo Wii virtual reality device for 6 weeks, 1 session 30 min, 2 times a week. In the control group, no treatment was performed during this period and routine medical treatments were continued. In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control.
16407188|NCT03928405|No Intervention|Control Group|The sociodemographic characteristics of the subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT).the control group was reevaluated at the end of the 6th week after the initial evaluation. After the study was completed, training was given to the volunteers from the control group.
16407189|NCT03928392|Experimental|SCUBA Dive with OT|Two SCUBA dives in conjunction with occupational therapy intervention. The occupational therapy intervention will take place on the beach or on the boat before/after the SCUBA dive. The intervention will consist of learning 3 different breathing techniques. Participants will also be educated about mindfulness principals. Additionally, participants will complete journaling activities between dives.
16407190|NCT03928392|Active Comparator|SCUBA Dive without OT|The group will engage in two SCUBA dives.
16407191|NCT03928379|Experimental|LY3305677|LY3305677 administered SC
16407192|NCT03928379|Placebo Comparator|Placebo|Placebo administered SC
16407193|NCT03928366|Experimental|Volunteers recibing propofol and remifentanil|Volunteers receive propofol to the loss of consciousness. Then they receive remifentanil during 12 min (pain stimuli in their finger also)
16407194|NCT03928353|Experimental|1: 18 g PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
16407195|NCT03928353|Experimental|2: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
16407196|NCT03928353|Experimental|3: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
16407197|NCT03928353|Experimental|4: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
16407198|NCT03928353|Experimental|5: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
16407199|NCT03928340|Active Comparator|combined metformin and insulin|
16407200|NCT03928340|Other|Insulin only|
16407201|NCT03928327|Experimental|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
16407202|NCT03928327|Experimental|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
16407782|NCT03924206||Open surgery without SES|open surgical procedures during which no smoke evacuation device is used
16407203|NCT03928314|Experimental|Dose Escalation (Part I)|ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
16407204|NCT03928314|Experimental|Dose Expansion (Part II)|RP2D dose
16407205|NCT03928301|Active Comparator|Wholetones Intervention|"Wholetones music to help participants sleep. Data collected after listening to the Wholetones music was compared to that collected both at Baseline, and after listening to the other music condition (i.e. Classical music).
~Wholetones® 2Sleep is music that is designed to lull the listener into a deep, delta sleep, using frequency-enhanced music and precise tempos. Wholetones® differs from other musical genres in that it employs a proprietary method of tuning and layering the music with a unique frequency underlayment."
16407206|NCT03928301|Active Comparator|Classical Intervention|"Classical music was the additional music condition used to compare to both Baseline data and Wholetones data.
~The classical music was selected based on the Mayo Clinic and NIH music recommendations for better sleep. More specifically, the classical music consisted of the following six pieces: Beethoven (i.e., Moonlight Sonata, first movement), Marconi Union (i.e., Weightless), Chopin (i.e., Nocturne No.2, Op.9), Ravel (i.e., Piano Concerto in G major, 2nd movement), and J.S. Bach (i.e., Prelude No.1)."
16407207|NCT03928288|Experimental|Intervention|Cabergoline 0.5 mg PO twice weekly for 6 months
16407208|NCT03928288|Placebo Comparator|Placebo|Placebo capsule PO twice weekly for 6 months
16407209|NCT03928275|Experimental|Intralesional IL-2 Treatment|CMM patients will received 4 treatments of intralesional Interleukin-2 two weeks apart over an eight week period.
16407210|NCT03928275|Experimental|Combination therapy: Intralesional IL-2 and BCG Treatment|CMM patients will receive 4 treatments of combination therapy intralesional Interleukin-2 and Bacillus Calmette Guerin two weeks apart over an eight week period.
16407211|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 1|Benralizumab single dose administration subcutaneously
16407212|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 2|Benralizumab single dose administration subcutaneously
16407213|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 3|Benralizumab single dose administration subcutaneously
16407214|NCT03928249|Active Comparator|Grupo A|Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks
16407215|NCT03928249|Placebo Comparator|GRUPO B|group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks
16407216|NCT03928236|Experimental|Limited Benzodiazepine Policy|Policy of no routine use of any intraoperative benzodiazepines.
16407217|NCT03928236|Active Comparator|Liberal Benzodiazepine Policy|Policy for the administration of benzodiazepine as per clinical guidelines but no lower than 0.03 mg/kg (ideal body weight midazolam equivalent) to all patients undergoing cardiac surgery. Any benzodiazepine may be used.
16407218|NCT03928210|Experimental|Digoxin|
16407219|NCT03928197|Other|Healthy Volunteers|
16407220|NCT03928197|Other|Volunteers with Venous Insuficiency|
16407221|NCT03928184|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
16407222|NCT03928184|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
16407223|NCT03928171|Experimental|Intra-abdominal pressure of 8 mmHg|The laparoscopy insufflator is set to a pressure of 8 mmHg
16407224|NCT03928171|Experimental|Intra-abdominal pressure of 12 mmHg|The laparoscopy insufflator is set to a pressure of 12 mmHg
16407225|NCT03928171|Experimental|Intra-abdominal pressure of 16 mmHg|The laparoscopy insufflator is set to a pressure of 16 mmHg
16407226|NCT03928158|Experimental|LCZ 696|Initial dose - 50 mg twice daily, up-titration to 200 mg twice daily. Patients will also receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
16407227|NCT03928158|Active Comparator|Valsatran|Initial dose - 40 mg twice daily, up-titration to 160 mg twice daily. Patients also will receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
16407228|NCT03928145|Experimental|Chlorthalidone 25 mg + amiloride 20 mg|Chlorthalidone 25 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
16407229|NCT03928145|Active Comparator|Chlorthalidone 25 mg + amiloride 10 mg|Chlorthalidone 25 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
16407230|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 20 mg|Hydrochlorothiazide 50 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
16407231|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 10 mg|Hydrochlorothiazide 50 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
16407232|NCT03928132|Experimental|CPD Workshop on Depression and Diabetes|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
16407233|NCT03928132|Sham Comparator|CPD Workshop on Depression and Diabetes II|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
16407234|NCT03928119|Experimental|public education and network construction|"Public education was conducted to evaluate the effectiveness on patients delay of ST-Segment Elevation Myocardial Infarction treatment.
~Network construction was conducted to evaluate the effectiveness to minimize the medical delay of ST-Segment Elevation Myocardial Infarction treatment."
16407235|NCT03928106|Other|intervention|pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
16407236|NCT03928106|Other|control|pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
16407237|NCT03928093|Experimental|Pregabalin followed by placebo|The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.
16407238|NCT03928093|Experimental|Placebo followed by Pregabalin|Participants will receive placebo during the first treatment period of the study(10 weeks) followed by 10 weeks of pregabalin treatment . The dose will depend on the participant's weight and phase of the treatment period . Each treatment period consists of 3 phases: 4 weeks of escalating dose until the desired maximum, 4 weeks of active treatment and 2 weeks of titrating down.
16407239|NCT03928080||Experimental cohort|Primary study to assess diagnostic accuracy
16407240|NCT03928080||Confirmation cohort|Second cohort to confirm results from the first study on independent population
16407241|NCT03928067|Experimental|TREK Study Abroad Program|On-screen personalized normative feedback (PNF) will contain information on the drinking behavior and attitudes about gender- and country-specific study abroad peers. Participants will view text-based tips and strategies and watch clips of prior student abroad students discussing how they met their cultural engagement goals while abroad (Sojourner Adjustment Feedback or SAF). Content focuses around the four aspects of positive sojourner adjustment (social interaction with host nationals, cultural understanding and participation, language development and use, host culture identification) and the two negative sojourner adjustment factors while abroad (i.e., social interaction with co-nationals, homesickness/feeling out of place). The intervention will also contain text- and video-based tips and strategies for protective strategies used abroad to limit experience of risk sex and sexual violence victimization.
16407242|NCT03928067|No Intervention|Control|"Control participants will receive a link to a general website offering study abroad advice (www.studyabroad.com) and will be asked to spend at least 20 to 30 minutes reviewing their institution's study abroad website content, including policies for drinking abroad. This control condition was selected as a form of treatment as usual as our conversations with study abroad personnel indicate this is the extent of typical information students receive about alcohol use abroad."
16407243|NCT03928054|Experimental|"group 1 Kinesio Taping® KT"|Kinesio Taping® KT
16407244|NCT03928054|Experimental|" Kinesio Taping® with therapeutic alliance KT+AT"|Kinesio Taping® with therapeutic alliance
16407245|NCT03928041|Other|single prospective study|All subjects who are entered into this trial will receive the EVOS Lumbar Interbody System (EVOS- HA).
16407246|NCT03928028|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
16407247|NCT03928028|Experimental|FBT w/ Parent-focused Cognitive Remediation Therapy|Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
16407248|NCT03928028|Experimental|FBT w/Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.
16407249|NCT03928015|Experimental|Adjunctive dronabinol|Dronabinol 5mg BID and adjusting within the range of 2.5mg - 10mg BID, as an adjunct to systemic analgesics
16407250|NCT03928015|Active Comparator|Systemic analgesics|Systemic analgesics only
16407251|NCT03928002|Experimental|4DFlow magnetic resonance imagery|2D MRI, essential for diagnosis and monitoring of PAH, with an additional 8 minutes for 4D flow
16407252|NCT03928002|Active Comparator|Cardiac catheterization|cardiac catheterization procedure using the Fick method; gold standard
16407253|NCT03927989|Experimental|Treatment Arm|Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients
16407254|NCT03927989|Active Comparator|Standard Care|Advice to quit and brief discussion of tobacco use
16407255|NCT03927976|Experimental|Path2Quit|After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
16407256|NCT03927963|Placebo Comparator|propofol|
16407257|NCT03927963|Active Comparator|dexmedetomidine|
16407258|NCT03927950|Experimental|Escitalopram bupropion open-label|No comparator
16407259|NCT03927937|Experimental|AUTOTRANSPLANTATION TOOTH|
16407260|NCT03927924|Experimental|High-intensity focused ultrasound|
16407261|NCT03927911|Active Comparator|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
16407262|NCT03927911|Active Comparator|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
16407263|NCT03927911|Active Comparator|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
16407264|NCT03927898|Experimental|SBRT+Toripalimab|Participants received SBRT (BED>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.
16407265|NCT03927885|Experimental|Arm I (open labeled placebo)|Patients receive open labeled placebo PO BID for 4 weeks in the absence of disease progression.
16407266|NCT03927885|Active Comparator|Arm II (waiting list, open labeled placebo)|Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.
16407267|NCT03927872||cardioembolic stroke|
16407268|NCT03927872||non cardioembolic stroke|
16407269|NCT03927859|Active Comparator|Mailing Letter|Patients assigned to this arm, in which a letter is mailed out will receive 2 pamphlets in the mail. One pamphlet described the teleophthalmology program and the other pamphlet was designed by the Canadian Association of Ophthalmologists and describes what DR is and why screening is important. The letter will also contain contact information about the closest TOP to the area of the PCP practice.
16407302|NCT03927625|Experimental|Cohort 1|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.16 g/min for 60 minutes.
16407474|NCT03926416|Experimental|CodaVax-H1N1, low dose|Participants will receive a single dose of either CodaVax (5 x 10^3 PFU in 200 uL) and an intramuscular injection of placebo
16407783|NCT03924193|Active Comparator|LDX|
16407270|NCT03927859|Active Comparator|Phone call|"Administrative staff on site of each practice will contact all patients assigned to this arm by a phone call.
~The patient will be informed that they are calling from the family health practice that the patient belongs to. The reason for the call will be that the patient has been identified as somebody who is likely overdue for a screening test. Patients will be asked if they have had a screening test done recently, and if not, they will be offered an appointment. Patients that refuse an appointment, will be politely probed for reasons and attempts will be made to provide them with information on potential solutions to these barriers (e.g. patients working 9-5 on weekdays will be informed that they can access TOP on evenings). The call will also be used as an opportunity to inform patients about the importance of screening.Three attempts will be made to reach each patient. Only a single voicemail message will be left, when the possibility is available."
16407271|NCT03927859|Active Comparator|Mail + Phone call|Patients assigned to this arm will first have letters mailed out to them (identical to the ones mailed out in the letter only arm). A week later, the letter will be followed up by a phone call as per the phone only arm. Patients will be asked if they have already booked, and if not, will be provided with information about the program as per the phone call script in the phone only arm.
16407272|NCT03927859|No Intervention|Control|No intervention will be offered to patients in this arm.
16407273|NCT03927846|Active Comparator|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
16407274|NCT03927846|Active Comparator|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
16407275|NCT03927833|Active Comparator|Continuous Phototherapy|Continuous phototherapy
16407276|NCT03927833|Experimental|Cycled Phototherapy|Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels.
16407277|NCT03927820||Patients Using Inhalers|Adult patient admitted to Vanderbilt University Medical Center (excluding surgery services) on a long acting inhaler or prescribed a long acting inhaler during admission.
16407278|NCT03927807|Experimental|repetitive hourly dose of oral misoprostol|The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.
16407279|NCT03927807|Experimental|two hourly dose of oral misoprostol|The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.
16407280|NCT03927794|Experimental|Self-Assembling Peptide P11-4|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed at baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.
~Then they will receive the intervention by the self-Assembling Peptide P11-4 at Day 0 and will be followed up at 3 months, 6 months and 1 year."
16407281|NCT03927794|Active Comparator|5% Fluoride Varnish|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed as baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.
~Then they will receive Topical Fluoride Varnish at Day 0 and will be followed up at 3 months, 6 months and 1 year."
16407282|NCT03927781|Experimental|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
16407283|NCT03927768||200 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
16407284|NCT03927768||50 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
16407285|NCT03927755||Sub-xyphoid|Ultrasound views of the heart obtained using the sub-typhoid approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
16407286|NCT03927755||Para-sternal Long|Ultrasound views of the heart obtained using the parasternal long approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
16407287|NCT03927742|Experimental|Shade and application with UV message activated|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging activated
16407288|NCT03927742|Active Comparator|Shade and application without UV messaging|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging not activated
16407289|NCT03927729|Experimental|Penthrox|Patients with moderate to severe post-traumatic acute pain will be included in the emergency room.
16407290|NCT03927716|Experimental|SB206 12%|SB206 12% topically once daily
16407291|NCT03927716|Placebo Comparator|Placebo|Placebo topically once daily
16407292|NCT03927703|Experimental|SB206 12%|SB206 12% topically once daily
16407293|NCT03927703|Placebo Comparator|Placebo Comparator|Placebo topically once daily
16407297|NCT03927677|Experimental|Cohort|Period 1: LC350189 200mg Day 1~ Day 4 qd, Period 2: Colchicine 0.6 mg Day 8 ~ Day 15 bid, Period 3 : LC350189 200mg (qd) + Colchicine 0.6 mg (bid) Day 16~ 19
16407298|NCT03927664||Peritoneal Tuberculosis|Patients diagnosed with peritoneal tuberculosis and who have undergone a computed tomographic examination
16407299|NCT03927651|Experimental|Administration of ICG|ICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software. ICG will be stored at the NM Investigational Pharmacy and administered intravenously by the anesthesiologist at the direction of the surgeon during surgical procedure.
16407300|NCT03927638||Normal Weight|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
16407301|NCT03927638||Overweight/Obese|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
16407327|NCT03927456|Experimental|SHR6390 + Fulvestrant|Intervention Drug: SHR6390, Fulvestrant
16407328|NCT03927456|Placebo Comparator|Placebo + Fulvestrant|Intervention Drug: Placebo, Fulvestrant
16407303|NCT03927625|Experimental|Cohort 2|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.31 g/min for 60 minutes.
16407304|NCT03927625|Experimental|Cohort 3|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The second cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.63 g/min for 60 minutes.
16407305|NCT03927625|Experimental|Cohort 4|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The third cohort of patients will receive ascorbate-meglumine at a dose administration rate of 1.25 g/min for 60 minutes.
16407306|NCT03927612|Experimental|Alternate Perspective|After experiencing VR scenarios, participants will experience the interactions again from the virtual counterpart's perspective within the VR system.
16407307|NCT03927612|Placebo Comparator|Control Perspective|After experiencing VR scenarios, participants will experience the interactions again from the same perspective in the VR system.
16407308|NCT03927599||Advanced refractory tumor solid tumors patients|Patients with advanced refractory solid tumors carrying TP53 mutations and receive PARP-inhibitors in combination with the VEGFR-inhibitors therapy
16407309|NCT03927586|Experimental|cognitive training (COG group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each cognitive intervention session will last for 90 minutes. The COG group received computerized cognitive based training which include memory, executive function, visuospatial , language and attention trainings.
16407310|NCT03927586|Experimental|physical exercise training (PE group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each physical exercise intervention session will last for 90 minutes. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The PE group received multimodal exercise program which includes aerobic exercise, balance and muscle strength training.
16407311|NCT03927586|Experimental|sequential training (SEQ group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the SEQ group will first undergo physical exercise training for 45 minutes followed by 45 minutes of cognitive-based training. The participants will first perform 10 minutes of warm-up followed by 25 minutes of physical exercise, and end with 10 minutes of cool-down. The exercise intensity will be similar to the PE group. Following the physical exercise, the participants will take part in 45 minutes of cognitive training. The same tasks used in the COG group will be practiced.
16407312|NCT03927586|Experimental|dual-task training (Dual group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the DUAL group will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance. The 90 minutes of training session will be break up into 2 to 3 parts, and the participants can rest as needed.
16407313|NCT03927573|Experimental|GEM3PSCA|Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells
16407314|NCT03927560|Experimental|Robotic Assisted Percutaneous Coronary Intervention|
16407315|NCT03927547|Experimental|Inclined Sleep|Inclined mattress at 15 degrees
16407316|NCT03927547|No Intervention|Flat Sleep|Plane mattress
16407317|NCT03927534|Experimental|Experimental|Mindful Eating program is apply face to face 7 sessions of 120 minutes/session. ME is apply in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
16407318|NCT03927534|No Intervention|Control|Treatment As Usual (TAU) in Primary Care (PC) is any kind of treatment administered by the GP to the patient with overweight and obesity. According to nutritional status, overweight or obesity, as well as the presence of co-morbidity, different actions can comprise the treatment offered at a PC level. For individuals presenting with overweight (BMI 25-29.9 kg/m2) but with no co-morbidities, PC teams organise care plans to enable them to achieve a normal BMI range (BMI 18.5-24.9 kg/m2). In case of suicide risk, severe social dysfunction or worsening of symptoms, it is recommended that patients are referred to mental health facilities.
16407319|NCT03927521|Experimental|Focal HIFU guided by PET-MRI/68Ga-PSMA imaging|Patient with local/focal prostate cancer recurrence after radiotherapy and no distant metastasis (negative PET-Choline imaging confirmed by PET-MRI/68Ga-PSMA) will be treated by Focal-HIFU
16407320|NCT03927508|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
16407321|NCT03927495|Experimental|Concurrent chemoradiotherapy and KN046|Participants in the Arm I will receive chemoradiotherapy and concurrent KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
16407322|NCT03927495|Experimental|chemoradiotherapy and sequential KN046|Participants in the Arm II will receive chemoradiotherapy and sequential KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
16407323|NCT03927482|Experimental|CARES mobile app|Participants in this arm will receive 12 weeks of text messages and use of the smart phone mobile app that provides support for alcohol risk reduction.
16407324|NCT03927482|Active Comparator|Alcohol Education|Those randomized to the control arm will be given access to an online alcohol education intervention; Check Your Drinking (CYD: www.CheckYourDrinking.net). CYD provides normative feedback on the user's drinking habits relative to his/her peers.
16407325|NCT03927469||Hospitalisation group|The patients who were hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
16407326|NCT03927469||Re-hospitalisation group.|The patients who were re-hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
16407331|NCT03927404|Experimental|Adaptive Vacuum test Prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
16407332|NCT03927391|Active Comparator|reference (normal) dose|Normal dose of enzalutamide (160mg once daily)
16407333|NCT03927391|Experimental|test (reduced) dose|Reduced dose of enzalutamide (120mg once daily)
16407334|NCT03927378|Experimental|S-katamine group|Low-dose s-ketamine (0.2 mg/kg in 20 ml normal saline) is intravenously infused in 40 minutes after childbirth.
16407335|NCT03927378|Placebo Comparator|Placebo group|Placebo (20 ml normal saline) is intravenously infused in 40 minutes after childbirth.
16407336|NCT03927365|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
16407337|NCT03927365|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
16407338|NCT03927352|Experimental|SCT630|"Participants received 80 mg SCT630 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~Participants with a PASI 50 response at week 16 continued to receive 40 mg SCT630 until week 48."
16407339|NCT03927352|Active Comparator|adalimumab-EU source|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to SCT630 until week 48"
16407340|NCT03927339||pre and post excercise group|
16407341|NCT03927326|Experimental|Local infiltration|Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
16407342|NCT03927326|Experimental|Transversus abdominis plane block|Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
16407343|NCT03927313|Active Comparator|Standard of care anti-tubercular therapy|Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
16407344|NCT03927313|Experimental|Intensified anti-tubercular therapy|"Standard of care anti-TB therapy as described in Arm 1,
~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days)."
16407345|NCT03927313|Experimental|Intensified anti-tubercular therapy plus aspirin|"Standard of care anti-TB therapy as described in Arm 1,
~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),
~Plus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)"
16407346|NCT03927300||Patients without Telemonitoring with ApTelecare Software|
16407347|NCT03927300||Patients with implementation of Telemonitoring with ApTelecare|
16407348|NCT03927287||Radical prostatectomy (RP cohort)|Our institutional prostate cancer database was queried for all patients between 2000-2017 who had a biochemical recurrence (BCR) after radical prostatectomy (RP) (Total PSA>=0.2 ng/ml) and had at least one post-BCR free PSA ratio (FPSAR) blood test (RP cohort). FPSAR ascertainments were performed incidentally or reflexively (e.g. PSA in the range of 4-10 ng/ml, as per Institutional policy). If multiple FPSAR tests were performed, only the first FPSAR test was analyzed. otal PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
16407349|NCT03927287||Radiotherapy cohort|Our institutional database was queried or all patients between 2000-2017 who had a rising PSA after radiotherapy (RT) for intermediate- and high-risk prostate cancer, and at least one post-treatment free PSA ratio (FPSAR) blood test (RT cohort). As in the RP cohort, FPSAR was performed either incidentally or reflexively, and the first FPSAR test was used for the analyses. Total PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
16407350|NCT03927287||Biobank surgical cohort|To validate our findings in the two retrospective cohorts (RP and RT), we analyzed a third cohort of prospectively collected biobank specimens of patients who underwent RP and developed biochemical recurrence(Biobank cohort). The retrieved samples were batched and tested for FPSAR levels to determine the results in lower PSA ranges and also to account for intrinsic analyte measurements variability in the retrospective cohorts. For his cohort we used the Roche Elecsys analytical platform, according to the instructions of the manufacturer.
16407351|NCT03927274|Experimental|Cleveland Multiport Catheter (CMC) + Topotecan|For predominantly enhanced tumors with volume of 8 cc or less, only 1 Cleveland Multiport Catheter (CMC) will be placed and convection-enhanced delivery (CED) will be performed over a 4-hour period within an MRI scanner, with the goal of complete tumor coverage (as evidenced by tracer distribution on MRI). The initial rate will be 1.20 ml/hour (5.0 microliters/minute/microcatheter) and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 5 microliters/minute/microcatheter based upon the tumor coverage and safety characteristics of the previously treated patients.
16407353|NCT03927248|Experimental|Nivolumab and PAC-1|Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.
16407354|NCT03927235|Sham Comparator|the freezing time of 3s|Transbronchial cryobiopsy in the freezing time of 3s
16407355|NCT03927235|Experimental|the freezing time of 4s|Transbronchial cryobiopsy in the freezing time of 4s
16407356|NCT03927235|Experimental|the freezing time of 5s|Transbronchial cryobiopsy in the freezing time of 5s
16407358|NCT03927222|Experimental|DC vaccination with Td preconditioning and GM CSF|This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant GM-CSF on overall survival of newly diagnosed GBM patients who have undergone definitive resection, are unmethylated, and completed standard temozolomide and radiation treatment. All enrolled patients will undergo a leukapheresis for the generation of DCs. Patients will then receive approximately 6 weeks of standard of care radiation therapy (RT) and concurrent TMZ. A single post-RT cycle of dose intensified TMZ (100 mg/m2/day for 21 days) will then be given. On day 23 (± 2 days) of the cycle, patients will receive the first of 3 pp65 DC vaccines every 2 weeks. All patients will receive up to a total of 10 DC vaccines
16407359|NCT03927209|Experimental|BI 1467335 (low dose)|
16407360|NCT03927209|Experimental|BI 1467335 (high dose)|
16407361|NCT03927196|Experimental|extended statin counseling group|Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.
16407362|NCT03927196|No Intervention|convetional statin counseling group|Сounseling on the prevention of cardiovascular diseases and the use of drugs for this purpose
16407363|NCT03927183|Other|Person-centred practice|Person-centred care
16407364|NCT03927170|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
16407365|NCT03927170|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
16407366|NCT03927157|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
16407367|NCT03927157|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
16407370|NCT03927131|Experimental|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
16407371|NCT03927131|Active Comparator|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
16407372|NCT03927131|Active Comparator|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
16407373|NCT03927131|Experimental|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
16407374|NCT03927131|Experimental|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
16407375|NCT03927131|Experimental|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
16407376|NCT03927105|Experimental|Nivolumab + Cabiralizumab|Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.
16407377|NCT03927092||Multiple Sclerosis patients|Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
16407378|NCT03927066|Experimental|Healthy Volunteer|All Volunteers will be studied at rest and during experimental condition (lower body negative pressure)
16407379|NCT03927053||HIV infected youth who use marijuana only|
16407380|NCT03927053||HIV infected youth who use tobacco only|
16407381|NCT03927053||HIV infected youth who use tobacco and marijuana|
16407382|NCT03927053||HIV infected youth with no substance use|
16407383|NCT03927040|Experimental|TEMT Administration|Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
16407384|NCT03927027|Active Comparator|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
16407385|NCT03927027|Experimental|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
16407386|NCT03927014||Preeclampsia|The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
16407387|NCT03927014||Control|The control groups' samples will obtain during the routine obstetrical care examination in the third trimester of pregnancy.
16407388|NCT03927001|Other|Intervention|NeVa Stent Retrievers
16407389|NCT03926988|Other|Intervention|NeVa Stent Retriever
16407390|NCT03926975|Experimental|Experimental: Scleral Lens|One eye will be randomly selected to wear a scleral lens for a 6-hour testing period.
16407391|NCT03926975|Active Comparator|Control: no lens|The contralateral eye will not wear a lens.
16407392|NCT03926962|Experimental|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
16407393|NCT03926962|Placebo Comparator|Placebo|Visually matching placebo
16407394|NCT03926949|Active Comparator|Intervention group|Participants will receive parenteral nutrition (Olimel 7.6% E 1000 ml), infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
16407395|NCT03926949|Other|Control group|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively
16407396|NCT03926936|Experimental|Low-grade uterine sarcoma|
16407397|NCT03926936|Experimental|low-grade endometrial carcinoma|
16407398|NCT03926936|Experimental|sex cord stromal tumors|
16407399|NCT03926936|Experimental|low-grade serous ovarian cancer|
16407400|NCT03926910|Experimental|VESAP|patient receiving stimulation test to detect hypovolemia
16407401|NCT03926884|Experimental|Tea1 group|"This is the treatment group. This group will be taking 2 grams of the three-seeds mixture twice a day for three weeks."
16407402|NCT03926884|Placebo Comparator|Tea2 group|"This is the control group. This group will be taking 0.02 grams of the three-seeds mixture once a day for three weeks."
16407476|NCT03926416|Experimental|CodaVax-H1N1, high dose|Participants will receive a single intranasal (IN) dose of CodaVax-H1N1 (1 x 10^5 PFU in 500 uL)
16407403|NCT03926871|Experimental|Novices|They received ergonomic training after 1-2 days of hiring to do the work in the cutting room, and packaging sectors. They did not have experience in the refrigerator or butchers, so they had the minimum of information about tasks and risks.
16407404|NCT03926871|Experimental|Experienced|They received the same ergonomic training as the newbies, and should have been hired for more than 6 months in the company. In this period they had already acquired patterns of movement and self-protection to accomplish the tasks.
16407405|NCT03926845|Active Comparator|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|The cream contains 0.2% Isobutylamido-thiazolyl-resorcinol.
16407406|NCT03926845|Placebo Comparator|Vehicle|The cream contains no active ingredients.
16407407|NCT03926832|Experimental|Patients with Sarcoidosis|Participants with Sarcoidosis. This arm will complete baseline questionnaires assessing daytime sleepiness (Epworth Sleepiness Scale - ESS) and fatigue (Fatigue Assessment Scale - FAS). All participants will perform home polygraphy and will be treated with CPAP for three months if moderate-to-severe OSA has been diagnosed and re-assessed with the same questionnaires along with a complete analysis of CPAP adherence by analyzing the compliance report of the device.
16407408|NCT03926819|Active Comparator|Single Ascending Dose|
16407409|NCT03926819|Active Comparator|Multiple Ascending Dose|
16407410|NCT03926806|Active Comparator|Plain yoghurt|2x200g plain yoghurt/day for 12 weeks
16407411|NCT03926806|Experimental|Vitamin B yoghurt|2x200g yoghurt enriched with vitamins B for 12 weeks
16407412|NCT03926793|Experimental|Cohort 1|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
16407413|NCT03926793|Experimental|Cohort 2|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
16407414|NCT03926793|Experimental|Open Label Extension|Eligible subjects may participate in the Open Label Extension (OLE) study for a period of 24 weeks.
16407415|NCT03926780|Active Comparator|Warfarin|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin by the regular starting dose with follow up of the INR to target (2-3)
16407416|NCT03926780|Experimental|Rivaroxaban|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban in a dose of 20 mg per day
16407417|NCT03926767|Experimental|Pain Neuroscience Education + orofacial and neck exercises|All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
16407418|NCT03926767|Active Comparator|Orofacial and neck exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
16407419|NCT03926754|Active Comparator|Mirabegron|Active treatment arm (mirabegron)
16407420|NCT03926754|Placebo Comparator|Placebo|Placebo
16407421|NCT03926741|Experimental|GSNOR Challenge testing|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
16407422|NCT03926728|Experimental|Cohort A - 85µg CTH522-CAF01|Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01. This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
16407423|NCT03926728|Experimental|Cohort B - 85µg CTH522-CAF01+ TO CTH522|Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional doses TO CTH522 (12µg) is administered in each eye. The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
16407424|NCT03926728|Experimental|Cohort C - 85µg CTH522-CAF01+ID CTH522|Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140. The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID. The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
16407425|NCT03926728|Experimental|Cohort D - 15µg CTH522-CAF01|Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
16407426|NCT03926728|Experimental|Cohort E - 85µg CTH522-CAF09b|Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01. The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
16407427|NCT03926728|Placebo Comparator|Cohort F - Placebo|Cohort F will receive only placebo in form of 0.9% NaCl saline.
16407428|NCT03926702|Experimental|Radiopharmaceutical administration|All participants receive radiopharmaceutical for positron-emission tomography (PET) study.
16407429|NCT03926689|Experimental|Suaahara II Standard + SMS|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.) Suaahara II monthly SMS campaign targeting all adult household members of households in the 1000-day period between conception and a child's second birthday
16407430|NCT03926689|Active Comparator|Suaahara II Standard|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.)
16407431|NCT03926676|Experimental|Grandio blocks|Nano hybrid composite blocks
16407432|NCT03926676|Active Comparator|E max|ceramic blocks
16407475|NCT03926416|Active Comparator|Fluzone|Participants will receive an intranasal (IN) dose of placebo and an intramuscular (IM) dose of QuadriFlu- Tetravalent Influenza Vaccine (TIV) (Fluzone®)
16407433|NCT03926663|Experimental|group Bupivacaine|Group B; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) as preincisional local infiltration of the nasal mucosa of the nasal septum ,injected once before surgical intervention
16407434|NCT03926663|Active Comparator|group Bupivacaine +Dexmedetomidine|group B+D; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa of the nasal septum,injected once before surgical intervention.
16407435|NCT03926637||Study Participants|Participants with MS, including CIS will complete the MSPT at their standard of care visits.
16407436|NCT03926624|Experimental|Experimental|DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles
16407437|NCT03926624|Active Comparator|Control|"Non-Intensive:
~LoDAC: 20 mg SC BID 10 days
~Azacitidine: 75 mg/m²/day SC 7 days(or 5+2)
~Decitabine: CIV 20 mg/m²x5 days
~Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10.
~Intensive:
~High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m²
~FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 & G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida)
~MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr & cytarabine 1g/m² IV 6hr.
~CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3.
~Intermediate DAC: cytarabine 20 mg/m² IV dailyx5"
16407438|NCT03926611|Experimental|LOU064 Arm 1|Participants will be asked to take LOU064 low dose once daily
16407439|NCT03926611|Experimental|LOU064 Arm 2|Participants will be asked to take LOU064 medium dose once daily
16407440|NCT03926611|Experimental|LOU064 Arm 3|Participants will be asked to take LOU064 high dose once daily
16407441|NCT03926611|Experimental|LOU064 Arm 4|Participants will be asked to take LOU064 low dose twice daily
16407442|NCT03926611|Experimental|LOU064 Arm 5|Participants will be asked to take LOU064 medium dose twice daily
16407443|NCT03926611|Experimental|LOU064 Arm 6|Participants will be asked to take LOU064 high dose twice daily
16407444|NCT03926611|Placebo Comparator|Placebo Arm|Participants will be asked to take matching placebo twice daily
16407445|NCT03926598||Patients/Caretakers Group|Patients with Type II Diabetes and caretakers of patients with Type II Diabetes.
16407446|NCT03926598||Certified Diabetes Educators Group|Diabetes educators who help patients manage their Type II Diabetes.
16407447|NCT03926598||Physician Group|Physicians who help patients manage their Type II Diabetes.
16407448|NCT03926598||Front Desk Staff|Front desk staff who work with physicians that treat Type II Diabetes.
16407449|NCT03926598||Nurses|Nurses who help patients manage their Type II Diabetes.
16407450|NCT03926585||Responders|Patients in combination therapy due to persistent symptoms on L-thyroxin mono-therapy who experience a longtime effect of triiodothyronine treatment.
16407451|NCT03926585||Non-responders|Patients who have tried combination therapy due to persistent symptoms on L-thyroxin mono-therapy, but did not experience a longtime effect.
16407452|NCT03926572|Other|Patients with Pulmonary arterial hypertension|Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
16407453|NCT03926559|Experimental|Duramorph (Morphine)|2mg of Neuraxial Morphine given through epidural once after the patient has delivered.
16407454|NCT03926559|No Intervention|No intervention|Patient does not get any intervention.
16407455|NCT03926546|Experimental|Individual ERP|Individual Exposure and Response Prevention for OCD
16407456|NCT03926546|Experimental|Group ERP|Group Exposure and Response Prevention for OCD
16407457|NCT03926533|Experimental|Telehealth ICU Recovery Program|Components of the ICU RC telehealth visit will be structured parallel to what is done during a typical in-person clinic visit. The telehealth intervention consists of 5 chronological components conducted during two 1.5 hour telehealth clinic visits (the same time required for an in-person visit). Upon completion of the pre-intervention baseline assessment, the study coordinator will contact patients randomized to the intervention arm to schedule the first telehealth visit. Study visits will occur at 3 weeks and 3 months following hospital discharge.
16407458|NCT03926533|No Intervention|Standard Recovery Conditions|participants assigned to the standard of care control group will be contacted by the study coordinator to ensure the patient has a primary care and/or specialist appointment scheduled. At this time, patients will also receive an electronic PICS guide for ICU survivors created by the Society of Critical Care Medicine. Patients will be directed to use the information provided in the PICS guide for ICU survivors to connect with resources.
16407459|NCT03926520|Experimental|ECT+UC group|
16407460|NCT03926520|Sham Comparator|S-ECT+UC group|
16407461|NCT03926507|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
16407462|NCT03926481|Experimental|Obesity Only|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity who are 65 years and older.
16407463|NCT03926481|Experimental|Sarcopenia and Obesity|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity and sarcopenia who are 65 years and older.
16407464|NCT03926455|Experimental|Typhax 0.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
16407465|NCT03926455|Experimental|Typhax 2.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
16407466|NCT03926455|Experimental|Typhax 10 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
16407467|NCT03926455|Active Comparator|Typhim Vi 25 mcg|Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
16407468|NCT03926455|Placebo Comparator|Placebo (saline)|Placebo control was administered IM Days 0 and 28 ( n=9)
16407469|NCT03926442|Experimental|Active1|Italian Herb in active breakfast meal
16407478|NCT03926403|Experimental|Hypnosis|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
16407479|NCT03926403|Active Comparator|conventional management|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
16407480|NCT03926390|No Intervention|Non bovine colostrun|Preterm received preterm formula
16407481|NCT03926390|Active Comparator|Bovine colostrum group|Preterm received bovine colostrum as trophic feeding
16407482|NCT03926377|Other|Clobetasol propionate treatment|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
16407483|NCT03926364||Patients|Referred pain
16407484|NCT03926351|Placebo Comparator|Arm 1a; Placebo|Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
16407485|NCT03926351|Experimental|Arm 2a; Omega-3 capsules|Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
16407486|NCT03926338|Experimental|PD-1 inhibitor plus COX inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab) plus COX inhibitor (Celecoxib)
16407487|NCT03926338|Experimental|PD-1 inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)
16407488|NCT03926312|Experimental|Smart device-based rehabilitation|One month after myocardial infarction, patients will receive a smart band and a cellphone in order to transmit data on physical activity to electronic health record. A study nurse will periodically check compliance with recommended physical activity and intervene in the case of non-compliance.
16407489|NCT03926312|No Intervention|Control group|Patients will receive a guideline directed recommendation to increase physical activity to 30 minutes of moderate physical activity a week.
16407490|NCT03926299|Experimental|Laser|dual Fotona laser treatment (Nd:YAG and Er:YAG)
16407491|NCT03926299|Active Comparator|Topical steroid|clobetasol propionate 0.05% cream
16407492|NCT03926286|Experimental|FMT for Sjogrens|FMT- active ingredient coming from participant's screening stool
16407493|NCT03926273||group 1|Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
16407494|NCT03926273||group 2|Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
16407495|NCT03926260|Experimental|ctDNA analysis|additional blood sample of 20 ml
16407496|NCT03926247|Other|Immigrant Well-being Project Intervention|Intervention
16407497|NCT03926234||emergency triage patients|triage Level I triage Level II triage Level III triage Level IV
16407498|NCT03926221|Experimental|PBC_I plus TranS-C|The Parent Behavior Change Intervention (PBC-I) is a behavioral intervention intended to teach parent behavior change techniques to better support their adolescents to improve sleep health behavior. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
16407499|NCT03926208|Active Comparator|Control|Subjects in this group will receive the standard chlorhexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
16407500|NCT03926208|Experimental|Soak and Scrub|In addition to the standard chlorhexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
16407501|NCT03926195|Experimental|Double-Blind Phase: Filgotinib|Filgotinib up to Week 13
16407502|NCT03926195|Placebo Comparator|Double-Blind Phase: Placebo|Placebo up to Week 13
16407503|NCT03926195|Experimental|Extension Phase: Open-Label Filgotinib|Participants who received double-blind filgotinib and did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) and were arthritis responders at Week 13 will enter the Extension Phase and receive open-label filgotinib up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
16407504|NCT03926195|Other|Extension Phase: Standard of Care|Participants who received double-blind placebo and participants who received double-blind filgotinib and were arthritis non-responders who did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) at Week 13 will enter the Extension Phase and receive standard of care up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
16407505|NCT03926195|Other|Monitoring Phase: Standard of Care|Participants with a prespecified decrease in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) anytime at/after Week 13 will receive standard-of-care therapy as per investigator discretion in the Monitoring Phase for up to 52 weeks or until reversibility in semen parameters is met, whichever occurs first.
16407506|NCT03926182|Experimental|Fasted AST2818 tablets following a period of fasting|
16407507|NCT03926182|Experimental|High-fat meal AST2818 tablets following a high-fat meal|
16407508|NCT03926169|Experimental|Risankizumab: Dose A|Participants randomized to receive risankizumab dose A in treatment period A and placebo followed by risankizumab dose B in treatment period B
16407509|NCT03926169|Experimental|Risankizumab: Dose B|Participants randomized to receive risankizumab dose B in treatment period A and placebo followed by risankizumab dose B in treatment period B
16407510|NCT03926169|Placebo Comparator|Placebo|Participants randomized to receive Placebo in treatment period A and risankizumab dose B in treatment period B
16407511|NCT03926156|Experimental|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
16407724|NCT03924648||premature ovarian insufficiency|Idiopatic premature ovarian insufficiency (POI), defined as loss of ovarian function and subsequent amenorrhea before the age of 40.
16407512|NCT03926156|Active Comparator|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
16407513|NCT03926143|Experimental|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
16407517|NCT03926117|Placebo Comparator|Placebo|Matching placebo
16407518|NCT03926117|Experimental|Ziltivekimab 7.5 mg|
16407519|NCT03926117|Experimental|Ziltivekimab 15 mg|
16407520|NCT03926117|Experimental|Ziltivekimab 30 mg|
16407521|NCT03926091|Experimental|4 cycles of TC adjuvant chemotherapy|4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
16407522|NCT03926091|Active Comparator|6 cycles of TC adjuvant chemotherapy|6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
16407523|NCT03926078|Other|Patients under 18 years of age|Group A consists of patients that receive a chest radiography in the current work-up of PE.
16407524|NCT03926078|Other|Patients aged 18 years or older|Group B consists of patients that receive a CT scan in the current work-up of PE.
16407525|NCT03926065|Experimental|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
16407526|NCT03926065|Experimental|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
16407527|NCT03926065|Experimental|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
16407528|NCT03926065|Experimental|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
16407529|NCT03926052|Active Comparator|LDX|
16407530|NCT03926052|Placebo Comparator|Placebo|
16407533|NCT03926026|Experimental|NCX 4251 QD|NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
16407534|NCT03926026|Placebo Comparator|Placebo QD|Placebo once daily for 14 days
16407535|NCT03926026|Experimental|NCX 4251 BID|NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
16407536|NCT03926026|Placebo Comparator|Placebo BID|Placebo twice daily for 14 days
16407537|NCT03926013|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-63898081. Ascending dose levels will be sequentially tested.
16407538|NCT03926013|Experimental|Part 2: Dose Expansion|Participants with mCRPC or renal cell carcinoma (RCC) will receive JNJ-63898081 at the recommended Phase 2 dose (RP2D) determined in Part 1.
16407539|NCT03926000|Active Comparator|Pregabalin (PG)|Patients will receive 150 mg pregabalin one hour before the procedure.
16407540|NCT03926000|Placebo Comparator|Control placebo (C)|Patients will receive placebo tablet one hour before surgery.
16407541|NCT03925987|Experimental|Exposure therapy|Participants complete 10 weekly sessions of a group-based exposure therapy class for anxiety disorders.
16407542|NCT03925974|Experimental|HER2 overexpression|HER2 IHC 3+ or IHC2+ and ISH+
16407543|NCT03925974|Experimental|HER2 expression|HER2 IHC 2+ISH- or IHC 1+ and ISH+
16407547|NCT03925948|Experimental|Intervention|This is a one arm study with all participants enrolled into this arm.
16407548|NCT03925935|Experimental|Experimental|Up to 3 sequential dose escalation cohorts of AB-205
16407549|NCT03925909|Experimental|Eriomin 200 mg|The volunteers will receive one capsule containing 200 mg eriocitrin
16407550|NCT03925909|Experimental|Eriomin 400 mg|The volunteers will receive one capsule containing 400 mg eriocitrin
16407551|NCT03925909|Experimental|Eriomin 800 mg|The volunteers will receive one capsule containing 800 mg eriocitrin
16407552|NCT03925909|No Intervention|Placebo|The volunteers will receive a capsule containing corn starch (placebo)
16407553|NCT03925896|Experimental|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
16407554|NCT03925883|Active Comparator|Patient Navigation|Patients randomized to this arm will receive patient navigation with the goal of completing a follow-up colonoscopy within 12 months of a positive FIT result.
16407555|NCT03925883|No Intervention|Usual Care|Patients will receive usual care screening opportunities
16407556|NCT03925870|Experimental|KN046 monotherapy|Eligible subjects will be enrolled and receive KN046 monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first.
16407557|NCT03925857|Experimental|Allocetra-OTS|Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
16407558|NCT03925857|Experimental|Allocetra-OTS Two doses|Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg
16407559|NCT03925818|Experimental|B.I.D. TMPPI + Lactobacillus-10|pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
16407560|NCT03925818|Active Comparator|B.I.D. Bismuth|pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days
16407561|NCT03925805||Chronic disease|Cardiovascular disease (including diabetes), mental disease, musculoskeletal disease
16407562|NCT03925792|Experimental|Treatment Group|Lifestyle Medicine Group 1
16407563|NCT03925792|Experimental|Waitlist Control Group|Lifestyle Medicine Group 2
16407564|NCT03925779|Active Comparator|(Dexmedetomidine)Dex group|The patients will be administered a loading dose of i.v. dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h, titrated according to the sedation score, till the end of the procedure
16407565|NCT03925779|Active Comparator|Propofol-Remifentanil (P-R) group|Propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute then and 0.01-0.1 μg kg/min.
16407566|NCT03925740|Experimental|MI Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
16407567|NCT03925740|Experimental|PreviDent Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
16407568|NCT03925740|Active Comparator|1.23% APF Control Group|Regular application of APF for 4 minutes with high volume suction to the whole mouth.
16407572|NCT03925714|Other|life style|life style control only
16407573|NCT03925714|Active Comparator|Metformin|Metformin 500 mg twice daily
16407574|NCT03925714|Experimental|Nigetella salivata|NS 450 mg twice daily
16407575|NCT03925701|Experimental|vildagliptin|vildagliptin 50 mg twice daily
16407576|NCT03925701|Active Comparator|vildagliptin\metformin|vildagliptin\metformin twice daily
16407577|NCT03925688||without heterotopic ossification|There had not existed radiographic evidences of heterotopic ossification.
16407578|NCT03925688||with heterotopic ossification|There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.
16407579|NCT03925675|Experimental|Axumin (fluciclovine-F18) PET/CT scan|Axumin (fluciclovine-F18) PET/CT scan to evaluate possible glioma recurrence to help differentiate scar (fake recurrence) from true tumor recurrence
16407580|NCT03925662|Active Comparator|Folfox with avastin|Folfox with avastin only
16407581|NCT03925662|Experimental|Mebendazole|Folfox with avastin with mebendazole
16407582|NCT03925636|Experimental|Dietary therapy for C. difficile colonization|Dietary therapy intervention for this arm is the Specific Carbohydrate Diet.
16407583|NCT03925623||Commercial closure system|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with a standard two piece push and turn cap and asked to open this during 2 five minute trials.
16407584|NCT03925623||Physically based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped a novel closure that was designed using anthropometric data such that it disallows children from engaging the system and enables adults. Children will be asked to open this during 2 five minute trials.
16407585|NCT03925623||Cognitively based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with the design feature that was introduced as part of the physical intervention (above); however, this treatment is sized such that children should be able to engage it (if they understand how). In having these three treatments, we began to evaluate the paradigm which enables the design to work. (Do they fail to understand how?- Cognitive treatment fail- and or Can they not effectively manipulate the closure? --- Physical failure).
16407586|NCT03925610||Morbidly obese patients with moderate-to-severe OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.
~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.
~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).
~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
16407616|NCT03925337|Experimental|Arm-2 AI-Assisted Combined Colonoscopy/Standard Colonoscopy|Normal scope insertion but first withdrawal with the research software running on a separate screen, followed by a second withdrawal without the research software running.
16407587|NCT03925610||Morbidly obese patients with no or mild OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.
~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.
~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).
~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
16407588|NCT03925584|Experimental|Music Therapy|Implement standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.
16407589|NCT03925571|Experimental|music-listening group|patient will listen to music during the dental surgery (1 to 1h30 hours).
16407590|NCT03925571|No Intervention|non music-listening group|patient will receive their dental intervention without music-listening.
16407591|NCT03925558|Active Comparator|Probiotic formula|Lactobacillus strains
16407592|NCT03925558|Placebo Comparator|Placebo formula|Placebo
16407593|NCT03925545|Experimental|Unilateral|Implantation with the FluidVision AIOL in one eye during cataract surgery. Only one eye was treated.
16407594|NCT03925545|Experimental|Contralateral|Implantation with the FluidVision AIOL in the first eye during cataract surgery, followed by implantation with the AcrySof IQ monofocal IOL in the fellow eye during a subsequent cataract surgery
16407595|NCT03925532|Experimental|Supportive Care (denosumab)|Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
16407596|NCT03925519||non-obese|non-obese diabetic patients (n= 25, BMI ≤ 30 kg/m2) were subjected to supervised aerobic exercise
16407597|NCT03925519||obese group|obese diabetic group (n= 25, BMI ≥ 30 kg/m2)
16407598|NCT03925493|No Intervention|Control Group Procedures (RPE based exercise)|Patients in the control group will follow standard exercise prescription protocols in CR. Exercise intensity will be guided by the patient's reported rating of perceived exertion (RPE). The modified Borg scale will be used by the patients to determine their RPE. Therefore, a scale of 1-10 will be used. The general goal will be to exercise between intensity level 3 or 4 (i.e. moderate intensity), per current program standards. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise as appropriate. Exercise progression will be guided by RPE and clinical assessment.
16407599|NCT03925493|Experimental|Exercise Test and Heart Rate Range|Patients randomly assigned to this group will complete a graded exercise test (GXT) per standard protocols. The researchers will obtain the patients peak heart rate from this stress test. Obtaining an accurate peak heart rate will allow for the calculation of a target heart rate range (THRR) using the Karvonen formula. Based upon the Karvonen formula, the THRR will be between 60-80% of the patient's heart rate reserve. The Karvonen formula can be calculated as follows ((peak heart rate - resting heart rate) X % intensity (0.6 or 0.8) + resting heart rate)). An example would be: (155 -75) X (.6) + 75) = 123; ((155 - 75) X (.8) + 75 = 139) THRR: 123 - 139. Patients will then adjust their exercise intensity to match this target heart rate range for the duration of their time in cardiac rehabilitation. Cardiac rehabilitation staff will provide feedback about heart rate when they are able.
16407600|NCT03925493|Experimental|Exercise Test, Heart Rate Range, and Heart Rate Monitor|"Patients randomly assigned to this group will also undergo a stress test (GXT) and exercise within a target heart rate range (THRR) during cardiac rehabilitation comparable to second arm of the trial. Additionally, they will receive a personal heart rate monitor (HRM). This monitor will consist of a polar heart rate chest strap and polar watch. Patients will be asked to wear this during cardiac rehabilitation and adjust their own exercise intensity. This will provide continuous feedback to the patient about their heart rate. Cardiac rehabilitation staff will also provide feedback when available.
~The investigators are using the heart rate monitors because cardiac rehab staff are not always able to adjust exercise intensity for all patients, and telemetry is not always used."
16407601|NCT03925480|Experimental|Azithromycin|A single 2g dose of Azithromycin
16407602|NCT03925480|Placebo Comparator|Placebo|Matching Placebo
16407603|NCT03925467|Experimental|proximal acupoints|Acupuncture needles will be administered at proximal acupoints
16407604|NCT03925467|Experimental|distal acupoints|Acupuncture needles will be administered at distal acupoints
16407605|NCT03925467|Placebo Comparator|sham acupoints|Sham acupuncture needles will be administered in the abdominal sham acupoints.
16407606|NCT03925454||In-Centre Haemodiafiltration (ICHDF) Group|Participants undergoing ICHDF treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
16407607|NCT03925454||Home HaemoDialysis (HHD) Group|Participants undergoing HHD treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
16407608|NCT03925441||Pediatric participants with chronic severe plaque psoriasis|Participants with chronic severe plaque psoriasis receiving adalimumab in routine clinical practice
16407609|NCT03925428|Experimental|Treatment (entinostat, molibresib)|Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16407610|NCT03925402||Ertapenem|Patients who received ertapenem as an empirical antibiotic
16407611|NCT03925402||Other carbapenems|Patients who received carbapenems other than ertapenem as an empirical antibiotic
16407612|NCT03925363|Active Comparator|Active|Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
16407613|NCT03925363|Sham Comparator|Control|Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
16407615|NCT03925337|Experimental|Arm-1 Standard Colonoscopy/AI-Assisted Combined Colonoscopy|Normal scope insertion and withdrawal first, followed by a second withdrawal with the research software running on a separate screen to catch any additional polyps missed during the first withdrawal.
16407617|NCT03925324|Experimental|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.
16407618|NCT03925324|Placebo Comparator|Placebo|Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.
16407619|NCT03925298||group 1|participants with elevated serum troponin level (≥0.01μg/L)
16407620|NCT03925298||group 2|those with normal serum troponin level (<0.01μg/L)
16407621|NCT03925285|Experimental|IV fluorescent tracer bevacizumab-800CW|Patients will be administered with 10 or 25 bevacizumab-800CW.
16407622|NCT03925272|Experimental|Patients with Suppurated Hidradenitis|"Human biological samples :
~Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.
~bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)"
16407623|NCT03925272|Experimental|Patients with Alzheimer disease|"Human biological samples :
~stool, blood (20 ml), nasal swab, oro-pharyngeal swab, nasopharyngeal swab.
~bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test"
16407624|NCT03925272|Experimental|Patients with familial adenomatous polyposis|"Human biological samples :
~whole blood (30 to 100 mL), optional stool collection
~bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation"
16407625|NCT03925272|Experimental|Patients with chronic inflammatory diseases (SPA, Crohn, ...)|"Human biological samples :
~whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears
~Bio-clinical data :
~Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress."
16407626|NCT03925272|Experimental|Healthy cases|"Human biological samples :
~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.
~Bio-clinical data :
~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
16407627|NCT03925272|Experimental|Healthy cases relatives|"Human biological samples :
~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.
~Bio-clinical data :
~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
16407628|NCT03925272|Experimental|Subjects vaccinated against COVID-19|"Human biological samples :
~whole blood and derived products: serum, DNA, PBMCs, saliva, nasopharyngeal swab
~Bio-clinical data :
~ethno-geographical origin, family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases, specific history of otorhinolaryngology and broncho-pulmonary and treatments, specific COVID-19 history, risk factor for a severe form of COVID-19, symptoms of COVID-19 or positive test for SarsCov-2 positive"
16407629|NCT03925259|Active Comparator|Full-ACT|Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of eight modules in the Full-ACT arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all eight mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; self-as-context; values; and committed action.
16407630|NCT03925259|Experimental|ACT-SAC|"Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of seven modules in the ACT-SAC arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; values; and committed action.
~The ACT-SAC condition removed the self-as-context module; therapists were instructed to avoid any reference to self-as-context or to support discussions regarding this process."
16407631|NCT03925246|Experimental|Nivolumab|Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 weeks for 8 doses (4 months), followed by a 60 minutes intravenous infusion at dose of 480 mg every 4 weeks for 8 doses (8 months) or until progression, death , unacceptable toxicity or end of the research.
16407632|NCT03925233||HER2+ Breast Cancer|
16407633|NCT03925233||ER+ Breast Cancer|
16407634|NCT03925233||Triple Negative Breast Cancer|
16407662|NCT03925038|Active Comparator|Treatment as Usual|Participants will receive psychotherapy (treatment as usual).
16407663|NCT03925038|Experimental|Augmented Care|Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
16407664|NCT03925025|No Intervention|Control|Standard therapy
16407665|NCT03925025|Active Comparator|Magnesium sulfate|Standard therapy plus magnesium sulfate
16407666|NCT03925025|Active Comparator|Nimodipine|Standard therapy plus nimodipine
16407779|NCT03924206||Minimally invasive surgery with smoke evacuation system (SES)|minimally invasive surgical procedures during which a smoke evacuation device is used
16407635|NCT03925220|Experimental|Substance Use Prevention Intervention|Parents will be given a handbook specific to the gender of their child that provides information and advice communication and substance use prevention. Parents will then participate in a one-hour session with an interventionist where the main points in the handbook will be reviewed and they will fill out an action plan on how to make changes in communication about substances with their child. The interventionist will also provide parents with a referral packet. Two weeks after the live session, participants will have a half-hour follow-up phone call with the same study interventionist. For the home-based component, parents will receive two messages each week with reminders and tips that reinforce the information covered in the handbook. Finally, participants will receive a magnet about the importance of family meals that they will be instructed to put on their refrigerators.
16407636|NCT03925220|Active Comparator|Nutrition, Physical Activity, and Weight Talk Comparison|"For the comparison condition, after the baseline assessment, parents will receive a handbook on nutrition and physical activity entitled: Healthy Eating & Physical Activity Across Your Lifespan: Helping your Child - Tips for Parents. This handbook, which is adapted from the handbook developed by the National Institute of Diabetes and Digestive and Kidney Diseases and the Weight Control Information Network, is approximately the same length as the intervention handbook and is available in English and Spanish. It is given with an insert on reducing weight talk and weight teasing in the family. Parents will also receive a magnet with a message about nutrition and exercise. To control for contact time, these participants will meet live with a study staff member two weeks after receiving the handbook, complete an action plan, and have the 30-minute call, as well as receive two text messages twice per week for 13 weeks with tips and reminders from the comparison handbook and insert."
16407637|NCT03925194|Experimental|Anakinra|
16407638|NCT03925194|Placebo Comparator|Placebo|
16407639|NCT03925181|Experimental|Intervention|Recovery counselling group.
16407640|NCT03925181|No Intervention|Waitlist control|Waitlist control group. Will receive intervention after arm one is complete.
16407641|NCT03925168|Experimental|Experimental|Music therapy
16407642|NCT03925168|No Intervention|Control|No music therapy
16407643|NCT03925155|Experimental|Chlorhexidine gluconate vaginal scrub|Use of chlorhexidine 4% vaginal scrub instead of current standard of care 10% povidone iodine vaginal scrub for cesarean sections
16407644|NCT03925155|Active Comparator|Povidone-iodine vaginal scrub|Current standard of care 10% povidone iodine vaginal scrub for cesarean sections
16407647|NCT03925129|Experimental|TENS|
16407648|NCT03925129|Sham Comparator|Sham TENS|
16407649|NCT03925116|No Intervention|usual care|"women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.
~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
16407650|NCT03925116|Experimental|Contraceptive pathway|"Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:
~collect relevant medical history
~provide educational material on birth control options
~provide a link to bedsider.com for further information
~They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.
~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
16407651|NCT03925103|Experimental|3D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a three-dimensional display system
16407652|NCT03925103|Active Comparator|2D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a two-dimensional display system
16407653|NCT03925090|Experimental|Neoadjuvant and Adjuvant Toripalimab+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT Other Names:anti-PD-1 antibody, JS001
16407654|NCT03925090|Placebo Comparator|Neoadjuvant and Adjuvant Placebo+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: placebo placebo 240mg every 2 weeks with a total of 2 cycles as neoadjuvant treatment; placebo 240mg every 3 weeks with a total of 8 cycles as adjuvant treatment 2 weeks after CCRT.
16407655|NCT03925077|Active Comparator|Movement to Music (M2M)|All M2M sessions are delivered using videos uploaded to a secure study website (the SCIPE website). Participants in M2M will have access to the website and attend three 60-minute M2M sessions per week for a total of 8 weeks. Each session provides rhythmic-based exercises that are choreographed to music to target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
16407656|NCT03925077|Active Comparator|Standardised Exercise Training (SET)|All M2M sessions are delivered using videos uploaded to the SCIPE website. Participants in SET will have access to the website and attend three 60-minute SET sessions per week for a total of 8 weeks. Each session provides traditional exercises that target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
16407657|NCT03925077|No Intervention|Attention Control (AC)|Participants in AC will not have access to any exercise videos. They will have access to the weekly educational articles on health and fitness, same as the ones received by the M2M and SET groups, through the SCIPE website.
16407658|NCT03925064||Diabetic pregnancies|Pregnant women with pregestational or gestational diabetes mellitus
16407659|NCT03925064||non-diabetic pregnancies|Pregnant women without pregestational or gestational diabetes mellitus
16407660|NCT03925051|Experimental|CMAB807|60mg by subcutaneous injection once on the first day.
16407661|NCT03925051|Active Comparator|Prolia®|60mg by subcutaneous injection once on the first day.
16407784|NCT03924193|Active Comparator|Cognitive-Behavioral Therapy|
16407667|NCT03925012|Experimental|Intervention|Child participants will attend the healthy lifestyle summer program for 4 weeks, five days per week. The summer intervention will include daily one-hour nutrition education, one-hour behavioral counseling, and 3 one-hour exercise sessions. These physical activities include flexibility, games, traditional fitness, and dancing. Counseling and school psychology students, registered dietitian/nutrition educators, and fitness specialists will lead the respective sessions. Parental guardians will participate in a two-hour weekly parental sessions that involve: 1)nutrition education with cooking demonstrations of healthy recipes; 2)behavioral counseling to learn effective parenting strategies on how to support their child's healthy nutrition and exercise habits and goals; and 3)exercise sessions where parents will engage in different physical activities and will receive fitness tips on how to promote an active lifestyle for the entire family.
16407668|NCT03924999|Experimental|Combined decongestive treatment & Combined exercise|"Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 5 days a week, for 6 weeks (totally, 30 sessions).
~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
16407669|NCT03924999|Experimental|Intermittent pneumatic compression & Combined exercise|"Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
16407670|NCT03924999|Active Comparator|Combined exercise|All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
16407673|NCT03924973|Experimental|Experimental group|"Children below the age of 3 in this group received 2 years of ESDM intervention for 12 hours per week, and then treatment as usual for the 3 following years.
~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.
~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.
~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community."
16407674|NCT03924973|Other|Control group|"Children in this group received treatment as usual delivered in the community for the 2 years of IDEA.
~Participants will still receive treatment as usual delivered in the community during IDEA-2, in the 3 years following IDEA."
16407675|NCT03924960|Experimental|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
16407676|NCT03924960|Active Comparator|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
16407677|NCT03924960|Other|Control|Usual care control group
16407682|NCT03924934||Possible CA-HRE|Patients with suspected CA-HRE, discharged home after a previous hospitalization or outpatient visit during which CA-HRE was isolated from a clinical culture (approximately 210 patients)
16407683|NCT03924934||HA-HRE|Hospitalized patients with healthcare-associated HRE, who are not discharged home (HA-HRE) (210 selected control patients)
16407684|NCT03924934||HA-HRE discharged home|Patients eventually discharged home, either directly or through another facility, after a hospitalization during which HA-HRE was isolated from a clinical culture (100)
16407685|NCT03924934||Community contacts|Contacts of patients with HRE (approximately 1,500)
16407686|NCT03924921|Experimental|autogenic training|Autogenic training
16407687|NCT03924921|Experimental|wait list|usual care for 6 months Autogenic training after 6 months
16407688|NCT03924908|Experimental|VRH|Virtual reality hypnosis
16407689|NCT03924908|Active Comparator|VR|Virtual reality
16407785|NCT03924193|Active Comparator|LDX and Cognitive Behavioral Therapy|
16407697|NCT03924830|Active Comparator|Bulk without Surface Sealant|53 teeth will receive restorations using Bulk fill restoration without surface sealant
16407698|NCT03924830|Experimental|Bulk with Biscover|53 teeth will receive restorations using Bulk fill restoration with Biscover surface sealant
16407699|NCT03924830|Experimental|Bulk with Permaseal|53 teeth will receive restorations using Bulk fill restoration with Permaseal surface sealant
16407700|NCT03924804|Experimental|Group A: 2 ml/kg group|
16407701|NCT03924804|Experimental|Group B: 8 ml/kg group|
16407702|NCT03924804|Experimental|Group C: 16 ml/kg group|
16407703|NCT03924791|Experimental|Transforaminal Epidural Injection|Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
16407704|NCT03924791|No Intervention|Oral pain medication|Patients will receive oral pain medication according to general practitioner guidelines.
16407705|NCT03924778|Experimental|DASH diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber
16407706|NCT03924778|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber
16407707|NCT03924765|Experimental|Healthy individuals using powered exoskeleton|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
16407708|NCT03924752|Experimental|Healthy individuals using powered exoskeleton|This study will be conducted on a sample population of able-bodied subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
16407709|NCT03924739|Experimental|Intervention group|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model.
16407710|NCT03924739|No Intervention|Control group|The control group will receive the conventional care provided by the study hospital.
16407711|NCT03924726|Other|Control and experimental (4 weeks MOP)|This is a split mouth study. At the experimental site in group 1, three Micro-osteoperforation (MOP) were made directly at the buccal cortical bone of extracted first premolars sites, at equidistance from the canine and second premolar under local anaesthesia. This group received four sessions of MOPs at an interval of 4 weeks.
16407712|NCT03924726|Other|Control and experimental ( 8 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.
16407713|NCT03924726|Other|Control and experimental (12 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 12 weeks.
16407714|NCT03924713||Community Health Worker|"initial comprehensive health, behavioral, and social needs assessment;
~development of an individualized 'action plan' to address identified needs;
~linkage to necessary services and work with neighborhood-based health care and social services organization to address each individual's unique needs; and 4) provide follow-up support as needed."
16407715|NCT03924713||Usual Health Plan Services|1) receipt of other plan services besides the CHW program for which they are eligible.
16407716|NCT03924700|Experimental|Biportal endoscopic discectomy|Biportal endoscopic discectomy for lumbar herniated intervertebral disc
16407717|NCT03924700|Active Comparator|Microdiscectomy|Microdiscectomy for lumbar herniated intervertebral disc
16407718|NCT03924687|Experimental|ACT group|ACT group: participants receiving the 8-week bibliotherapy intervention based on Acceptance and Commitment Therapy
16407719|NCT03924687|No Intervention|control group|Wait-list control condition: participants placed on a wait-list (and receiving the intervention following the 9 week duration of the intervention)
16407720|NCT03924674|Active Comparator|Stepped Wedge Group 1: Sept. 2019 Launch|"Interventions will include:
~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF
~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;
~Tools to promote discussion about timing and necessity of routine lab draws
~Education and feedback for physicians regarding costs and harms of routine lab testing"
16407721|NCT03924674|Active Comparator|Stepped Wedge Group 2: Nov. 2019 Launch|"Interventions will include:
~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF
~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;
~Tools to promote discussion about timing and necessity of routine lab draws
~Education and feedback for physicians regarding costs and harms of routine lab testing"
16407722|NCT03924674|Active Comparator|Stepped Wedge Group 3: Jan. 2020 Launch|"Interventions will include:
~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF
~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;
~Tools to promote discussion about timing and necessity of routine lab draws
~Education and feedback for physicians regarding costs and harms of routine lab testing"
16407723|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
16407786|NCT03924180|Experimental|GMP - Dietary Supplement for PKU patients|Glycomacropeptides -GMP Glytactin
16407725|NCT03924648||Control|The investigators compared patients with POI to a cohort of age matched healthy controls recruited among women who visited the gynecology clinic for routine examination or from hospital workers. All volunteers for the control group had regular menstrual cycles and no concomitant health problems.
16407726|NCT03924635|Active Comparator|SYMBICORT as maintenance and reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
16407727|NCT03924635|Active Comparator|SYMBICORT as maintenance, salbutamol as reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
16407728|NCT03924622|Experimental|Group 1: Mepilex on Litter + AE Mattress + 30 degree backrest|Intervention: Mepilex
16407729|NCT03924622|No Intervention|Group 2: Without Mepilex on Litter + AE mattress + backrest|Intervention: Control (no Mepilex)
16407730|NCT03924622|Experimental|Group 3: Mepilex on VSB on AE mattress|Intervention: Mepilex
16407731|NCT03924622|No Intervention|Group 4: Without Mepilex on VSB on AE mattress|Intervention: Control (no Mepilex)
16407732|NCT03924622|Experimental|Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon litter|Intervention: LiquiCell mat
16407733|NCT03924622|No Intervention|Group 6: PFC Without LiquiCell on Talon Litter|Intervention: Control (no LiquiCell)
16407734|NCT03924609||Bone metastasis screening|The information about bone metastasis screening is retrospectively collected.
16407735|NCT03924596|Experimental|Luban Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
16407736|NCT03924596|Active Comparator|Uralyt-U Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)
16407737|NCT03924596|Experimental|Luban Uric acid|25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
16407738|NCT03924596|Active Comparator|Uralyt-U Uric acid|25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2
16407739|NCT03924570|Experimental|Intervention|This arm will receive training in the use of the IPASS package to improve communications during hands off.
16407740|NCT03924570|No Intervention|Control|Until randomization this arm will continue running hands offs per usual care.
16407741|NCT03924557|Active Comparator|Genotyping Intervention Supportive Care|For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
16407742|NCT03924557|No Intervention|Delayed Genotyping Intervention Supportive Care|For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
16407743|NCT03924544|Experimental|Decorin Group|26 patients will receive subconjunctival injection of 100 µg decorin 15 minutes before surgery, 1, 3, and 7postoperatively. A30-gauge needle was used to inject 100 µL of decorin. The needle was placed at the nasal margin of the superior rectus muscle
16407744|NCT03924544|Active Comparator|Mitomycin Group|MMC will then be applied in 26 patients to the sclera at a concentration of 0.3 mg/ml using cellulose sponges, which will be removed after 3 minutes followed by copious irrigation with balanced saline solution (BSS).
16407745|NCT03924531|Experimental|Mindful Awareness Program|The group that received mindfulness training.
16407746|NCT03924531|Active Comparator|Health Promotion Program|The group that received the health information.
16407747|NCT03924518|Experimental|granisetron group|3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
16407748|NCT03924518|Placebo Comparator|placebo group|Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
16407749|NCT03924505|Experimental|Implementation Manual and External Facilitation|This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.
16407750|NCT03924505|Active Comparator|Implementation Manual - only|This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.
16407751|NCT03924479|Experimental|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
16407752|NCT03924479|Sham Comparator|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
16407780|NCT03924206||Minimally invasive surgery without SES|minimally invasive surgical procedures during which no smoke evacuation device is used
16444478|NCT03673111|Experimental|36.0 mg|Y14 single dose, subcutaneous
16407753|NCT03924453||Pearl Powered by Proov|Participants are given hormone tests strips and a digital app and all instructions for use, collectively called the Pearl Power by Proov kit. The app will analyze hormonal test strip information to predict and confirm ovulation
16407754|NCT03924440||PDG Test strip Users|"Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).
~Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip."
16407755|NCT03924427|Experimental|BMS-986165|Given daily
16407756|NCT03924414|Active Comparator|Zoledronic acid (ZA)|A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes
16407757|NCT03924414|Placebo Comparator|Placebo|A single intravenous infusion of placebo infused over 45 minutes
16407758|NCT03924401|Experimental|Participants Receiving Abatacept|Pediatric participants who are undergoing URD HSCT for serious NMHD will receive 8 doses of abatacept in addition to conventional GVHD prophylaxis.
16407759|NCT03924388|Experimental|Short-term transcutaneous spinal cord stimulation|"In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function.
~In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and ~ 70° upright (adjusted by tilt-up table)."
16407760|NCT03924388|Experimental|Long-term transcutaneous spinal cord stimulation|"In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function.
~The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and ~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly."
16407761|NCT03924388|Experimental|Project 3|For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
16407762|NCT03924362|Active Comparator|Simultaneous Bilateral PCNL|Patients undergo simultaneous bilateral PCNL.
16407763|NCT03924362|Active Comparator|Unilateral PCNL|Patients undergoing unilateral staged PCNL.
16407764|NCT03924349|Experimental|ICG clip|Three clips are fixed in three directions (120 degrees apart) at the distal of the lesion (just distal) before surgery
16407765|NCT03924336|Experimental|Advanced- platelets rich fibrin with open flap debridement|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, , one PRF of the required size will be filled into the intraosseous defect, and the other will be used to prepare the membrane that will be used to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using 4-0 silk sutures
16407766|NCT03924336|Active Comparator|Open flap debridement (OFD)|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, The interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
16407767|NCT03924323|Experimental|Escitalopram 10 mg/day|Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion
16407768|NCT03924323|Placebo Comparator|Placebo|Matching oral administration of placebo once daily
16407769|NCT03924310|Experimental|Arm amputees|This single arm conducts all experiments. In three out of four experiments both interventions (with feedback & without feedback) are used, the fourth experiment does not allow the intervention without feedback.
16407770|NCT03924297|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
16407771|NCT03924284||NPA positive|NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
16407772|NCT03924284||NPA negative|NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
16407773|NCT03924284||Saliva positive|Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
16407774|NCT03924284||Saliva negative|Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
16407775|NCT03924271|Experimental|ONCOLOGY|Patient with a cancer
16407776|NCT03924258|Experimental|HEART FAILURE|Patients with Heart Failure diagnosis
16407777|NCT03924245|Experimental|Treatment (entinostat, olaparib)|Patients receive entinostat PO 1 week before starting combination therapy (day -7). Patients then receive entinostat PO on days 1, 8, 15, and 22, olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity
16407778|NCT03924219||Pediatric Solid Organ Transplant (SOT) Recipients|Pediatric patients (<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
16407781|NCT03924206||Open surgery with SES|open surgical procedures during which a smoke evacuation device is used
16407788|NCT03924167|Experimental|Families Receiving Weaving Healthy Families Intervention|The Weaving Healthy Families curriculum is a cognitive-behavioral, support group model for high-risk families related to alcohol, tobacco, or other drugs (ATOD) and/or or domestic violence, child abuse, or neglect. This curriculum is tailored for all ages (i.e., (a) parents/caregivers; (b) early childhood (4-7); (c) children (8-10); and (d) adolescent (11-18) and is aimed at reducing alcohol and other drug (AOD) abuse, promote unity, address mental health problems, strengthen parenting skills, and bolster wellness and resilience.
16407789|NCT03924167|No Intervention|Families who have not yet receive the Weaving Healthy Families|Baseline group --data will be collected prior to receiving the intervention in this stepped-wedge trial design.
16407790|NCT03924154|Experimental|RVT-1201|RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 [Anticipated])
16407791|NCT03924154|Placebo Comparator|Placebo|Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 [Anticipated])
16407792|NCT03924141|Experimental|Third year nursing students - intervention|Third year nursing students will receive the intervention in de-escalation training
16407793|NCT03924141|No Intervention|Third year nursing students - control|Third year nursing students will receive no training in de-escalation
16407794|NCT03924115|Experimental|Group Total|This group of patients was chosen at random. They are patients who receive the full PST as intervention, that is, they receive a Smartphone with the AFAM-Health application with all the contents of the PST and data plan for 1 year.
16407795|NCT03924115|Experimental|Group Partial|This group of patients was chosen at random under the criteria of parity with group A. They are patients who receive partial PST as intervention, that is, they only receive video capsules reproduced in the CESFAM waiting room as educational content.
16407796|NCT03924115|No Intervention|Group Control|This group of patients is the control group, that is, they do not receive any type of intervention additional to the one they already receive from their CESFAM.
16407797|NCT03924102|Experimental|patients with acute decompensated systolic and diastolic heart|
16407798|NCT03924089|Experimental|Oral nutritional supplement with probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics.
~Physical activity recommendations."
16407799|NCT03924089|Experimental|Oral nutritional supplement without probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics.
~Physical activity recommendations."
16407800|NCT03924089|Active Comparator|Individualized dietary recommendations|Individualized dietary recommendations. Physical activity recommendations.
16407801|NCT03924076|Experimental|Treatment Group|Received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL) for 90 days
16407802|NCT03924076|Placebo Comparator|Placebo Group|Received UHT milk (125 mL) for 90 days
16407803|NCT03924063|Other|conservative treatment|conservative treatment with physical therapy and non steroidal anti-inflammatory drugs
16407804|NCT03924050|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
16407805|NCT03924050|Placebo Comparator|Group Placebo combined with standard chemotherapy|
16407806|NCT03924037|Active Comparator|Zero Suicide|Participants randomly assigned to the Zero Suicide arm will also participate in a weekly support group until the final follow-up time point when they will be crossed-over into the intergenerational knowledge sharing group.
16407807|NCT03924037|Experimental|Zero Suicide plus KICKS|Participants randomly assigned to the Zero Suicide plus KICKS arm will participate in a weekly intergenerational knowledge sharing group.
16407808|NCT03924024|Experimental|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
16407809|NCT03924011|Sham Comparator|Control group|Receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
16407810|NCT03924011|Experimental|Treatment group|Receives PBMT (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
16407811|NCT03923998|Experimental|Neoadjuvant chemoradiotherapy followed by surgery|Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
16407812|NCT03923985|Active Comparator|Active Arm|1 tablet / day of probiotic containing 10 Mld L. crispatus during two months
16407813|NCT03923985|No Intervention|Control Arm|No treatment
16407814|NCT03923972||Patients with chronic kidney disease|Patients with non dialysis dependent chronic kidney disease stages 4-5, patients on renal replacement therapy treated with peritoneal dialysis or hemodialysis, patients after renal transplantation
16407815|NCT03923972||Nephrologists|physicians treating patients with chronic kidney disease
16407816|NCT03923972||Nephrology nurses|nurses caring for patients with chronic kidney disease
16407817|NCT03923972||heads of Nephrology departments|Medical and/or administrative directors of e nephrology department with knowledge of the healthcare system in their country
16407818|NCT03923959|Active Comparator|Intervention|100 cc normal saline with 1g of tranexamic acid in solution
16407819|NCT03923959|Placebo Comparator|Placebo|100 cc normal saline
16407820|NCT03923946|Experimental|Intervention|Compassionate Imagery Intervention- up to three 1:1 sessions, up to one hour each with the primary researcher
16407821|NCT03923946|No Intervention|Control|Treatment as usual arm
16407822|NCT03923933|Placebo Comparator|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
16407823|NCT03923933|Experimental|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
16407824|NCT03923920||Spinal Stenosis Biopsy|Biopsy of ligamentum flavum tissue during spinal stenosis surgery sent to pathology for amyloid-specific analysis
16412206|NCT03893981|Experimental|Strengthening Training|Strengthening Program
16407825|NCT03923907|Experimental|EIM group|patients with Hypertension (HT) will be recruited by a trained nurse when the patient attends the yearly to bi-yearly complication screening program called the risk assessment and management program (RAMP) program. This program is provided to all patients with HT, who are seen in the Government-funded primary care clinics in Hong Kong. The nurse will encourage the patient by motivational interviewing techniques and prescribe exercise. Combined exercise skills will be taught in the 12-week weekly exercise classes by certified physical trainers. Peer support is encouraged during and after the 12-week program. Regular feedback, prompting and problem solving will be provided by the nurse at 3m, 6m, and 12m. Exercise level will be monitored by validated wrist trackers to feedback participants, nurse and physical trainer by mobile apps and website. Resources to exercise will be made known to patients by apps, website and healthcare professionals.
16407826|NCT03923907|No Intervention|usual care|There is no extra intervention to patients allocated in this arm, except that they receive information and advice on lifestyle changes including benefits from exercise from the nurse at recruitment as stated above. Participants in both arms will have no changes in medication within the first 12-week to determine the BP difference between the two groups. In Hong Kong, patients have unlimited access to emergency department and general outpatient services. All patients with HT receive RAMP program counselling and screening every 1-2 years. These are not limited by the current trial.
16407827|NCT03923894|Experimental|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
16407828|NCT03923894|Placebo Comparator|Placebo|Placebo 2.07 g/day for 8 weeks.
16407829|NCT03923881|Experimental|Study group|Patients with oral squamous cell carcinoma that have been included in ICON-study and are scheduled for treatment of neck
16407830|NCT03923868|Experimental|dose escalation in healthy subjects|
16407831|NCT03923868|Experimental|dose escalation in hyperuricemia patients|
16407832|NCT03923855|Experimental|BTL-899 Therapy Arm|
16407833|NCT03923842|Experimental|ARM A: Denosumab Treatment|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
16407834|NCT03923842|Active Comparator|ARM B Control Arm|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for 12 months
16407835|NCT03923829|Experimental|Zinc administration with scaling and root planing|systemic administration of Zinc cap of 50 mg elemental zinc as zinc sulphate, once a day for 12 weeks in addition to scaling and root planing
16407836|NCT03923829|Active Comparator|scaling and root planing|scaling and root planing
16407837|NCT03923816|Experimental|Group (R)|Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
16407838|NCT03923816|Experimental|Group (C)|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).
16407839|NCT03923803||Chronic obstructive pulmonary disease|patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
16407840|NCT03923790|Experimental|STOP model|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet and a blue tooth enabled BP monitor with an iPad. A video telehealth visit occurs 7 days after discharge attended by a nurse practitioner (NP) or MD , social worker (SW), and pharmacist. The NP and pharmacist review the BP data to determine the need for medication adjustment. The SW assesses the need for resources. BP is reviewed via an online portal every 2 weeks until average BP is < 130/80mmHg, then monthly. Uncontrolled BP prompts a call from the pharmacist to discuss medication adherence and titration. Subsequent video telehealth visits occur 1 month, 3 months, and 5 months after enrollment.
16407841|NCT03923790|Active Comparator|Usual Care|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet.
16407842|NCT03923777|Other|Active Surveillance|Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.
16407843|NCT03923764|Experimental|Intervention group|1.3 g protein per kg bodyweight per day for 8 weeks
16407844|NCT03923764|Active Comparator|Kontrol group|habitual diet
16407845|NCT03923751||Polish Hospitals|Hospitals with anesthesia or intensive care practices
16407846|NCT03923738|Experimental|Tocilizumab|Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.
16407847|NCT03923725|Experimental|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
16407848|NCT03923725|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
16407849|NCT03923725|Experimental|Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)|Triple ACTs
16407850|NCT03923725|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs
16407851|NCT03923712|No Intervention|Control Group|Participants randomly assigned to control group will be instructed to maintain their normal life habits with respect to physical activity and diet. During the 5 months of intervention participants from this group will receive at least one call from the researchers to be interested in their health status and inform them about the next evaluation appointment, as well as, an objectively evaluation of the main behaviours in the middle of intervention. Investigators will inform about the relevance of attending the full process and respecting the condition and rule as control. Participants from the control group will be freely offered the possibility to get involve in a similar intervention protocol at the end of the study in order to benefit from the potential positive effect of exercise.
16407881|NCT03923465|Active Comparator|EPP with EMD+BS|Using minimally invasive surgery, entire papilla preservation technique with the adjunctive use of amelogenins and bone substitutes
16407882|NCT03923465|Other|EPP without EMD+BS|Using minimally invasive surgery, entire papilla preservation technique without the adjunctive use of amelogenins and bone substitutes
16407883|NCT03923452|Experimental|MBSR: Mindfulness-based stress reduction|Participants will be exposed to the 9-week MBSR program, facilitated by a trained MBSR facilitator.
16444479|NCT03673111|Placebo Comparator|Placebo|0.9% saline
16407852|NCT03923712|Experimental|Supervised exercise programme|5 months of supervised physical exercise program. The individualized and progressive Health periodization model will be applied establishing an initial individualizing period, as well as identifying any need or adaptation to apply during the exercise program. The physical exercise program will be applied in a period of progressive increase whose initial objective will be to reach the volume and intensity established by the international recommendations of physical activity (http://www.health.gov/paguidelines/) for this population. Briefly, a volume of 150 min/week of moderate-vigorous physical activity (60% -85% reserve heart rate) spread over a maximum of 5 days and including force work 2-3 days/week. The training load will progressively increase with a wave and flexible periodization.
16407853|NCT03923699|No Intervention|Standard of care arm|Operating rooms in the standard of care group will be monitored but, the ACT clinicians will not contact the operating room unless it is clinically necessary for patient safety purposes.
16407854|NCT03923699|Experimental|Anesthesia Control Tower monitoring|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room using AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes.
16407855|NCT03923686|Experimental|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
16407856|NCT03923686|Active Comparator|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
16407857|NCT03923673|Experimental|Subjects with Heart Failure with Preserved Ejection Fraction|Subjects with Heart Failure with Preserved Ejection Fraction (HFpEF) will receive a minimally invasive treatment called a pericardiotomy.
16407858|NCT03923660|Experimental|Concentric-eccentric|Concentric-eccentric
16407859|NCT03923660|Experimental|Eccentric-concentric|Eccentric-concentric
16407860|NCT03923647||Laparoscopy and CT scan|Usage of laparoscopy after inflation of co2 infra umbilical
16407861|NCT03923634|Experimental|Princess® RICH|"Eligible subjects will be injected with Princess® RICH (this is an open-label study).
~Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids."
16407862|NCT03923621|Experimental|Experimental - EPSiT|Endoscopic Pilonidal Sinus Treatment
16407863|NCT03923621|Active Comparator|Control - excision|Excision treatment
16407864|NCT03923608||strength test|The maximum strength test of external shoulder rotators will be performed on 5 different tools with specific protocols.
16407865|NCT03923608||Endurance test|"Test designed by the Laboratory of Sports Physical Therapy (LAFIDE) of FCT / UNESP - Presidente Prudente, used in the prescription of training for gain of localized muscular endurance. Will be realized in the tools: Isokinetic dynamometer, elastic bands, pulley and halter.
~The test will consist of the maximum possible repetitions (until fatigue) with loads of 70%, 80% and 90% of the maximum force (in different sessions)."
16407866|NCT03923582|No Intervention|Ecological needs assessment|To conduct a needs assessment of sexual health care delivery in Tanzania. To determine whether midwifery, nursing, medical and allied health science students would benefit from one curriculum or separate curricula tailored by discipline. We will conduct focus groups and key informant interviews of all three groups.
16407867|NCT03923582|No Intervention|Develop a sexual health training curriculum|We will further adapt a sexual health training curriculum tailored to Tanzanian/East African/Sub-Saharan context and pilot test it and train local faculty to implement it.
16407868|NCT03923582|Placebo Comparator|To evaluate the effectiveness of the sexual health curriculum|We will conduct a randomized, controlled, single blinded trial of the curriculum against a waitlist control assessing effects on sexual health knowledge, attitudes and sexual history and counseling skills.
16407869|NCT03923569|Other|Alzheimer's Disease patients group|This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease
16407870|NCT03923569|Other|Healthy control group|This group contains the 31 (anticipated) age and sex -matched healthy controls
16407871|NCT03923556|Experimental|Sugammadex|Sugammadex
16407872|NCT03923556|Active Comparator|Neostigmine|Neostigmine
16407873|NCT03923530|Experimental|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
16407874|NCT03923517|Experimental|YOD caregiver|The participants will be encouraged to use RHAPSODY for four weeks. After that they will have two individual MEET sessions with experts (social worker and psychologist).
16407875|NCT03923504|Active Comparator|Physical Activity Intervention (PAI)|Tailored multi-level physical activity intervention (PAI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
16407876|NCT03923504|Active Comparator|Healthy Living Control Group|Healthy living intervention (HLI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
16407877|NCT03923491|Experimental|Healthy Feeding, Healthy Eating|The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
16407878|NCT03923491|Active Comparator|Reading and Readiness|The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.
16407879|NCT03923478|Experimental|ABI-M201|"Cohort A: 1 capsule one time a day
~Cohort B: 1- 5 capsules one time a day"
16407880|NCT03923478|Placebo Comparator|Placebo|"Cohort A: 1 capsule one time a day
~Cohort B: 1-5 capsules one time a day"
16407884|NCT03923452|No Intervention|WLC: Wait list Control|Participants will be asked to log their self-care activities every week.
16407885|NCT03923439|Experimental|MRI protocol|For stroke patients, the follow-up MRI (named MRI-2) after successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously, will be performed between 24h and 72h after recanalization on our new Canon 3T research magnet with high gradient system. Patients will be explored for a follow-up evaluation at 3 months with a final MRI (named MRI-3) that will be performed on the Canon 3T research magnet.
16407886|NCT03923413||patients with chronic heart failure without LVAD support|patients with chronic heart failure without LVAD support
16407887|NCT03923413||patients with end-stage heart failure with LVAD support|patients with end-stage heart failure with LVAD support
16407888|NCT03923400||JI-GIST|The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
16407889|NCT03923400||G-GIST|The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
16407890|NCT03923387|Experimental|MynxGrip|MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
16407891|NCT03923387|Active Comparator|Manual compression|Manual compression hemostasis
16407892|NCT03923374||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 200 pregnant (<16weeks) mothers who have opioid use disorder and are taking buprenorphine
16407893|NCT03923374||Pregnant Mothers|Planned recruitment of 100 pregnant (>16weeks) mothers who do not have any history of opioid use disorder.
16407894|NCT03923361|Experimental|Propofol|
16407895|NCT03923348|Experimental|Leva Users|Subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.
16407896|NCT03923335||high-risk group|patients with any of the four genes hypermethylated
16407897|NCT03923335||low-risk group|patients with none of the four genes hypermethylated
16407898|NCT03923322|Experimental|Botanical Tincture|The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
16407899|NCT03923322|Placebo Comparator|Placebo|Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
16407900|NCT03923309||Intended rectal preservation|When rectal preservation (non-operative management or local excision) was agreed by their surgeon.
16407901|NCT03923309||Unintended rectal preservation|When rectal preservation (non-operative management or local excision) was disagreed by their surgeon.
16407902|NCT03923270|No Intervention|Thoracic Radiotherapy plus Durvalumab|This Arm is a standard of care Arm. Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 13 doses
16407903|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 4 doses and 75mg intravenously of Tremelimumab every 4 weeks for up to 4 doses
16407904|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and Olaparib|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg orally of Olaparib twice a day
16407905|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg Tremelimumab IV x 1 (single dose)
16407906|NCT03923257|Experimental|PRRT with 177Lu-DOTA-tyr3-OCTREOTATE|"177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.
~This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE."
16407907|NCT03923244|Experimental|cohorte 1|"Normal patient consultation schedule for cataract surgery with:
~Preoperative appointment scheduled for the patient
~Post-operative appointment 1 month before surgery No additional appointments.
~After geting consent and during the two consultations:
~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.
~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.
~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
16407908|NCT03923231||Children <5 years|Children under the age of 5 years who are receiving atazanavir as part of clinical care
16407909|NCT03923231||Children 6-11|Children aged 6-11 years who are receiving atazanavir as part of clinical care
16407910|NCT03923231||Adolescents 12-17|Adolescents aged 12-17 years who are receiving atazanavir as part of clinical care
16407911|NCT03923231||Pregnant women|Women who are at least 20 weeks gestation, who are receiving atazanavir as part of clinical care
16407912|NCT03923231||BMI < 18.5|Adults with a BMI of <18.5 kg/m2 who are receiving atazanavir as part of clinical care
16407913|NCT03923231||BMI >30|Adults with a BMI of >30 kg/m2 who are receiving atazanavir as part of clinical care
16407915|NCT03923218||non-smoker patients with chronic periodontitis|non-smoker patients with chronic periodontitis
16407916|NCT03923218||periodontally healthy patients|periodontally healthy patients
16407917|NCT03923205|Active Comparator|Control meal|The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
16407918|NCT03923205|Active Comparator|The test meal|The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
16407919|NCT03923192|Other|ICDAS II|Visual tactile examination based on ICDASII scoring system
16407920|NCT03923179|Experimental|pyrotinib+Etoposide|
16407921|NCT03923166|Experimental|pyrotinib+ capecitabine|
16407922|NCT03923153|Active Comparator|Inspiratory muscle training group|Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
16407923|NCT03923153|Sham Comparator|Sham group|Sham group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
16407924|NCT03923140|Experimental|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
16407925|NCT03923127|Experimental|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
16407926|NCT03923114|Other|Patient group with treatment response|PET/CT imaging of patients with response to GLP-1 receptor agonist treatment
16407927|NCT03923114|Other|Patient group without treatment response|PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment
16407928|NCT03923101||Patients with Keratoconus|Aim is to include as many Keratoconus patients as possible with the intention to elucidate how the disease begins and develops during lifetime.
16407929|NCT03923088|Experimental|jacobson's progressive muscle relaxation technique|
16407930|NCT03923088|Experimental|audiovisual distraction technique|
16407931|NCT03923088|No Intervention|conventional|
16407932|NCT03923075|Active Comparator|Dexmedetomidine|"Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type body weight (Kg)/4 or body weight (Kg) X 0.25.
~THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
16407933|NCT03923075|Placebo Comparator|0.9 % saline|"Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: body weight (Kg)/4 or body weight (Kg) X 0.25 THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
16407934|NCT03923062|Experimental|G I A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
16407935|NCT03923062|Experimental|G I B(left side):will be treated by cryopeeling|left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
16407936|NCT03923062|Experimental|G II A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
16407937|NCT03923062|Experimental|G II B (left side):will be treated by tranexemic acid|left side of patient's face will be treated by tranexemic acid(cyclokapron)
16407938|NCT03923049|Other|PET/MRI|Diagnostic testing with simultaneous PET/MRI for cardiac sarcoidosis diagnosis
16407939|NCT03923036||Metastatic colorectal cancer|"The French county Calvados registry of digestive cancers will allow to identify patients with a metastatic colorectal cancer diagnosed between 2004 and 2014.
~Patients will be included if the cancer was diagnosed at the metastatic stage between 2004 and 2014 or non-metastatic before 2004 that became metastatic between 2004 and 2014 (synchronous and metachronous tumors)"
16407940|NCT03923010|Experimental|Itraconazole|Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
16407941|NCT03922997|Experimental|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
16407942|NCT03922984|Experimental|Glioblastoma Patients|Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.
16407943|NCT03922971|Other|National comparison|Ability to view center's rate compared with all others
16407944|NCT03922971|Other|National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1
16407945|NCT03922945|Experimental|VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-56: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily
16407946|NCT03922945|Experimental|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-12: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Weeks 13-14: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 15-56: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
16407947|NCT03922945|Placebo Comparator|Placebo|Subjects will receive placebo oral capsule, once daily for up to 56 weeks
16407948|NCT03922932||Group A: PDR|This group will consist of 25 subjects with active proliferative diabetic retinopathy (PDR) and 25 subjects with treated PDR.
16407949|NCT03922932||Group B: NPDR|This group will consist of 50 subjects with severe non-proliferative diabetic retinopathy (NPDR), 50 subjects with moderate NPDR, and 50 subjects with mild NPDR.
16407950|NCT03922932||Group ME: Macular Edema|This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.
16407951|NCT03922932||Group C: DM without Retinopathy|This group will consist of 50 subjects with diabetes mellitus (DM) who do not have retinopathy.
16407952|NCT03922932||Group D: Healthy Controls|This group will consist of 40 subjects with healthy eyes who do not have diabetes.
16407953|NCT03922919|Active Comparator|Cefotaxime or ceftriaxone group|free use of cefotaxime or ceftriaxone by the investigator
16407954|NCT03922919|Experimental|Cefotaxim group|Systematic use of cefotaxime
16407955|NCT03922906|Experimental|Motus Pure-Vu System|The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
16407956|NCT03922893||Proband|First individual in a family to consent to this protocol
16407957|NCT03922893||Family Member Participants|Family members of the proband will be approached to consent to this protocol
16407958|NCT03922880|Experimental|Advanced Uveal Melanoma|
16407959|NCT03922867|No Intervention|Control Group|Subjects with receive standard of care for management of insomnia in subjects with fibromyalgia
16407960|NCT03922867|Active Comparator|Intervention Group|Subjects will receive standard of care and additionally complete the online cognitive behavior therapy program
16407961|NCT03922854||Mobile Monitor Group|Participants are recruited to this study if they have been monitored during their labour with a monica AN 24 monitor
16407962|NCT03922841||Subjects with pleural disease|"The subject must meet all of the following inclusion criteria to participate in this study.
~Evidence of pleural disease on chest radiograph or bedside ultrasound or Computed Tomography regardless of underlying aetiology
~No age or gender restrictions
~Ability to provide informed consent"
16407963|NCT03922815|Experimental|haemodynamic parametres-guided deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to disappearance of cilliary reflex; in the case of heart rate and/or arterial blood pressure increase by 20% a rescue dose of fentanyl 0,5 mcg per kilogram of body weight will be administered
16407964|NCT03922815|Experimental|SE-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weight of fentanyl in the case of heart rate and/or arterial blood pressure increase by 20%
16407965|NCT03922815|Experimental|AoA-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weightof fentanyl in the case of increase of SPI value > delta 15
16407966|NCT03922802|Experimental|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|"May receive up to 45 minutes of AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
~Intervention: Device: AIH prior to Noninvasive spinal stimulation during gait training"
16407967|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
16407968|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with sham transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
16407969|NCT03922776|Experimental|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection
~at diagnosis, before chemotherapy (pre-CT)
~after chemotherapy (post-ct)
~Intervention : Collection of two blood samples (5mL)
~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment
~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
16407970|NCT03922763|Active Comparator|Anatomically-matched cut|
16407971|NCT03922763|Active Comparator|Cutting guide|
16407972|NCT03922750|Experimental|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
16407973|NCT03922750|Experimental|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
16407974|NCT03922750|Active Comparator|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
16407975|NCT03922737|Active Comparator|In-person office visit|
16407976|NCT03922737|Active Comparator|Telehealth visit with provider|
16407982|NCT03922711|Experimental|Pridopidine Dose 1|Dose 1 (oral capsule) for 12 weeks following 4 week dosage regimen titration period
16407983|NCT03922711|Experimental|Pridopidine Dose 2|Dose 2 for (oral capsule) for 12 weeks following 4 week dosage regimen titration period
16407984|NCT03922711|Placebo Comparator|Placebo|Matching placebo (oral capsule) for 16 weeks
16407985|NCT03922698||Case Group|Patients who undergo surgical intervention of carotid trombo-endo-arterectomy at the Department of Vascular Surgery of the IRCCS Neuromed, with specific inclusion/exclusion criteria
16407986|NCT03922685|Active Comparator|Morning sedentary arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 11:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
16407987|NCT03922685|Active Comparator|Morning exercise arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 7:20 and 11:20, 3-ml blood samples were collected at 10-min intervals.After the 11:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
16407988|NCT03922685|Active Comparator|Evening sedentary arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 23:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
16407989|NCT03922685|Active Comparator|Evening exercise arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 19:20 and 23:20, 3-ml blood samples were collected at 10-min intervals.After the 23:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
16407990|NCT03922672|Experimental|Piano group|This group will consist of the adult with Parkinson's disease and their caregiver for a total of 14 pairs.
16407991|NCT03922659|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
16407992|NCT03922659|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
16407993|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
16407994|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
16407995|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
16407996|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
16407997|NCT03922646|Experimental|NEAT Active Experimental Group|People in the active group will receive NEAT intervention
16407998|NCT03922646|Active Comparator|Control Group|People in the control group will receive non-essential regularly-scheduled programming (active control) coinciding with the same timeframe
16407999|NCT03922633|Experimental|Cohort 1 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408000|NCT03922633|Experimental|Cohort 1 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408001|NCT03922633|Experimental|Cohort 2 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408002|NCT03922633|Experimental|Cohort 2 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408003|NCT03922633|Experimental|Cohort 3 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408004|NCT03922633|Experimental|Cohort 3 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408005|NCT03922633|Experimental|Cohort 4 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408006|NCT03922633|Experimental|Cohort 4 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
16408009|NCT03922607|Experimental|Substudy 2: Group 2|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28
16408010|NCT03922607|Experimental|Substudy 2: Group 1|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28
16408011|NCT03922607|Experimental|Substudy 1: Group 3|Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14
16408012|NCT03922607|Experimental|Substudy 1: Group 2|Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14
16408013|NCT03922607|Experimental|Substudy 1: Group 1|Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14
16408014|NCT03922594||Cameroon|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
16408015|NCT03922594||China|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
16408016|NCT03922594||Ivory Coast|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex and severely disproportionate length or weight according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
16408017|NCT03922594||Sri Lanka|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
16408018|NCT03922594||Vietnam|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
16408019|NCT03922581|Experimental|Mindfulness-Based Cognitive Therapy|Participants randomized to this study arm will receive Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks.
16408020|NCT03922581|No Intervention|Wait-list Control Group|Participants randomized to the wait-list control study arm will be administered the study assessments while not receiving active treatment. Participants will be given the opportunity to participate in the MBCT intervention following completion of the study assessments.
16408021|NCT03922568||Density Gradient Centrifugation (DGC)|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
16408022|NCT03922568||Physiological ICSI (PICSI)|Semen processing is done by double layer DGC method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
16408023|NCT03922568||Magnetic Activated Cell Sorting (MACS)|Semen processing is done by double layer DGC method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
16408024|NCT03922555|Experimental|ASTX727 (Cedazuridine + Cytidine Antimetabolite Decitabine)|-ASTX727 administered orally for 5 or 6 consecutive days every 28d cycle and will de-escalate to 4 consecutive days every 28 d cycle.
16408025|NCT03922555|Experimental|Expansion Cohort|"Oral ASTX727 will be administered daily for 4, 5 or 6 consecutive days
~Surgical resection will take place 12 days (+/- 1 day) after initiation of treatment"
16408026|NCT03922542|Active Comparator|Accelerated|Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
16408027|NCT03922542|Active Comparator|Standard|Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
16408028|NCT03922529|Active Comparator|Standard of Care|Care after an acute heart event will be at the discretion of the participants clinical providers.
16408029|NCT03922529|Experimental|MACRO|Research staff will provided personalized engagement, de-prescribing, and explicitly facilitate enrollment into Cardiac Rehabilitation.
16408030|NCT03922516|Other|Reporting order: Plain Film - ULDCT|"The plain film of half the participants (randomized) will be submitted for reporting by a radiologist as a first imaging method. After finishing this report, the same radiologist will assess the ULDCT of this participant. In this second report, the findings of both examinations will be summarized, and a second report will be filed.
~Emergency physicians will first receive the report for the plain film of the chest and will be asked for the diagnosis and its probability. Next, the report for ULDCT will be presented to them. Again, diagnosis and probabilities will be documented."
16408031|NCT03922516|Other|Reporting order: ULDCT - Plain Film|"For half the participants (randomized) radiologists will first receive the data from ULDCT of the chest and write a report. Subsequently, they will receive the data from the plain film of the chest and may expand their report (explicitly separated).
~Emergency physicians will first receive the report for the ULDCT of the chest and will be asked for probabilities of the nine most frequent diagnoses in chest-imaging plus other. Next, they will be presented with the report for the plain film and will again be asked to give an estimation of the probabilities for the same diagnoses as before."
16408032|NCT03922503|Experimental|Advanced- platelets rich fibrin with DFDBA|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
16408033|NCT03922503|Active Comparator|Collagen membrane and DFDBA|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
16408034|NCT03922490|Experimental|Knee Arthroscopy + Adipose Derived Stem Cells (ADSC)|Experimental Group: will undergo diagnostic knee arthroscopy with injection of adipose derived stem cells. Will also carry out all procedures associated with study (Physical Exam, Magnetic Resonance Imaging (MRIs), X-rays, Questionnaires).
16408035|NCT03922490|Other|Observation Cohort: Knee Arthroscopy|Observational Group: will undergo diagnostic knee arthscropy (No injection of adipose derived stem cells). Will also carry out all procedures associated with study (Physical Exam, MRIs, X-rays, Questionnaires).
16408036|NCT03922477|Experimental|Atezolizumab + Hu5F9-G4|An initial safety evaluation will be performed in participants with relapsed AML. If atezolizumab in combination with Hu5F9-G4 is initially safe and tolerable in participants an additional cohort with R/R AML will be evaluated to further test the safety and anti-tumor activity. If dose-limiting toxicities (DLT) are observed in >=33% of participants in this initial cohort, a dose de-escalation cohort will be enrolled. If less than 33% of enrolled and dosed participants in any given cohort experience a DLT, an expansion cohort of 15 participants will be enrolled at the highest tolerated dose for this combination. If a dose de-escalation cohort is needed, an expansion cohort will be enrolled at the lower tolerated dose for this combination.
16408037|NCT03922451||Pediatric patients supported on ECMO|
16408038|NCT03922438|Experimental|Cleft margin flap with anterior palatal closure|Usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
16408117|NCT03921892|Active Comparator|On-line parenting education|Participants will complete on-line parenting education at the times and locations of their choice over a two-week period.
16408039|NCT03922425|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
16408040|NCT03922425|No Intervention|Standard care|
16408041|NCT03922412|Active Comparator|plantar block|Short lasting sciatic nerve block (mepivacaine 1% 200mg) and long lasting plantar block (ropivacaine 0,5% 25mg + 2mg dexamethasone) with distal deep peroneal block (ropivacaine 0,5% 2ml).
16408042|NCT03922412|Active Comparator|Sciatic popliteal block|Long lasting sciatic nerve block (ropivacaine 0,5% 100mg + 2mg dexamethasone)
16408043|NCT03922399|Other|Laser and Surgery in patients with major burn scars|Evaluating patients with major burn scar after laser and surgical treatments Multiple-directions evaluation, including senior plastic resident, young resident, professional burn surgeons, senior nurse with burn scar, one non-medical patients(usually patients' family and friends)
16408044|NCT03922386|Other|JX model|Subjects implanted with an RA XFINE lead (JX model)
16408045|NCT03922386|Other|TX model|Subjects implanted with an RV XFINE lead (TX model)
16408046|NCT03922373|Experimental|Benzonatate|
16408047|NCT03922360|Active Comparator|Best Practices|
16408048|NCT03922360|Experimental|Best Practices + Financial Incentives|
16408049|NCT03922347|No Intervention|routine care|
16408050|NCT03922347|Active Comparator|Screening program including 2 consecutive tests|
16408051|NCT03922347|Active Comparator|Screening program with mobile health|
16408052|NCT03922334|Experimental|Navigation Group|Women who are randomized into NNM2 will be assigned to a patient navigator. The patient navigator will meet with the patient after delivery occurs for introductions and education. The patient navigator will offer support and resources (transportation, community referrals, support for your mental health, connection to your doctors, etc.). The navigator will also help to schedule postpartum medical appointments, and will remind the patients of these appointments via text, email, or phone calls. The navigator will continue to provide psychosocial support and continued linkage to resources through one-year postpartum.
16408053|NCT03922334|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
16408054|NCT03922321|Experimental|Open Label RVT-1401|Open Label RVT-1401 weekly 680 mg for two weeks followed by weekly 340 mg for four weeks
16408058|NCT03922295|Active Comparator|endoscopic double flap group|
16408059|NCT03922295|Active Comparator|endoscopic single flap group|
16408060|NCT03922282|Experimental|Gasless BABA|BABA robotic-thyroidectomy that do not using carbon dioxide but using elevation of flap.
16408061|NCT03922282|Active Comparator|Classic BABA|BABA robotic-thyroidectomy using carbon dioxide.
16408062|NCT03922269||Transgender individual with a diagnosis of HIV|The participant self-identifies as transgender and/or has a current gender identity which differs from gender assigned at birth, is 18 years old or above, has a diagnosis of HIV infection and has been prescribed antiretroviral therapy.
16408063|NCT03922230||Early esophageal cancer group|Pathological examination diagnosed as Early esophageal cancer.The ratio of male to female is 3:1, and the age is between 50 and 70 years old.
16408064|NCT03922230||Middle and advanced ES group|Pathological examination diagnosed as Middle and advanced esophageal cancer.
16408065|NCT03922230||Normal group|Confirmed as the normal by health checkups.
16408066|NCT03922217|Experimental|Mindfulness|This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
16408067|NCT03922204|Experimental|MCLA-145|In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days
16408068|NCT03922191||Pediatric population|Infants diagnosed with cardiac post-surgery mediastinitis within the HUDERF Hospital within the last 20 years.
16408069|NCT03922191||Adult population|Adults diagnosed with cardiac post-surgery mediastinitis within the CHU Brugmann Hospital within the last 20 years.
16408070|NCT03922178|Experimental|Elective coronary surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and anesthesiology wards. Subjects referred for elective coronary surgery will be prospectively included during the length of the study.
16408071|NCT03922165||DS peds eligible for Adenotonsillectomy|Dyads of caregivers and children with DS aged 3-13 years diagnosed with SDB and referred for treatment with adenotonsillectomy.
16408072|NCT03922152|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
16408073|NCT03922139|Experimental|Botox|"Ultrasound guided 1 mg/1 mL injection.
~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
16408074|NCT03922126|Experimental|Listos peer intervention|Listos intervention (peer counseling, PrEP information, and HIV/STI testing kits)
16408075|NCT03922126|Active Comparator|Peer only group|Peer only group (peer counseling, PrEP information)
16408076|NCT03922113||Critically ill patients|Patients who spent a minimum of 48h in ICU
16408077|NCT03922113||Surgical patients|Patients who were scheduled for elective colorectal surgery
16408079|NCT03922100|Experimental|Dose Escalation and Expansion (Phase I)|Dose escalation will be applied until one patient experiences first cycle DLT (Dose Limiting Toxicity) or 2 patients at any dose level experience non-DLT NCI CTCAE Grade ≥2 drug-related toxicity during the first cycle. Once the Maximum Tolerated Dose (MTD) is identified, a maximum of 10 additional patients will be enrolled (dose expansion).
16408080|NCT03922100|Experimental|AML FLT3 mutated (Phase II)|Cohort of AML FLT3 mutated patients. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
16408081|NCT03922100|Experimental|CMML (Phase II)|Cohort of patients with CMML. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
16408082|NCT03922087||Control Group|The pregnancy women without any diseases.
16408083|NCT03922087||Disease Group|The pregnancy women with cardio-metabolic and endocrinic disorders such as gestational diabetes, obesity, hypertension, thyroid diseases, anemia and other cardio-metabolic diseases.
16408084|NCT03922074|Experimental|Non-anesthesiologist administered propofol|Sedation directed by an endoscopist in which the intravenous drugs are propofol and fentanyl . Target level sedation: moderate - deep.
16408085|NCT03922074|Active Comparator|Monitored anesthesia care|Sedation directed by an anesthesiologist in which the used intravenous drugs and target level sedation are chosen by the anesthesiologist.
16408086|NCT03922061|Experimental|fIPV-dmLT|fractional-dose inactivated polio vaccine (fIPV) given intradermally with double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant
16408087|NCT03922061|Active Comparator|fIPV|fractional-dose inactivated polio vaccine (fIPV) given intradermally
16408088|NCT03922048|Experimental|Cohort 1 Part A: HTX-011|Adolescents ≥12 to <17 years of age. A single dose of HTX-011 via instillation into the surgical site.
16408089|NCT03922048|Active Comparator|Cohort 1 Part A: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.
16408090|NCT03922048|Experimental|Cohort 1 Part B: HTX-011|Adolescents ≥12 to <17 years of age. Dose to be determined from Cohort 1 Part A.
16408091|NCT03922048|Active Comparator|Cohort 1 Part B: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
16408092|NCT03922048|Experimental|Cohort 2 Part A: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
16408093|NCT03922048|Active Comparator|Cohort 2 Part A: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
16408094|NCT03922048|Experimental|Cohort 2 Part B: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
16408095|NCT03922048|Active Comparator|Cohort 2 Part B: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
16408096|NCT03922048|Experimental|Cohort 3: HTX-011|Children ≥3 to <6 years of age. Dose to be determined from Cohorts 1 and 2.
16408097|NCT03922048|Active Comparator|Cohort 3: bupivacaine HCl|Children ≥3 to <6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
16408098|NCT03922035|Experimental|Arm I (CBM588)|Patients receive standard peri-/post-transplant supportive care and CBM588 PO BID from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.
16408099|NCT03922035|Active Comparator|Arm II (standard of care)|Patients receive standard peri-/post-transplant supportive care.
16408100|NCT03922022|Experimental|EIM group|patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study
16408101|NCT03922009|Experimental|Virtual Reality group|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
16408102|NCT03922009|No Intervention|control group|General routine care
16408103|NCT03921996|Experimental|arm A: ePLND|Radical prostatectomy with extended pelvic lymph node dissection
16408104|NCT03921996|Active Comparator|arm B: no PLND|Radical prostatectomy only
16408105|NCT03921983|Experimental|LTOT +|COPD patients with long term oxygenotherapy
16408106|NCT03921983|Active Comparator|LTOT -|COPD patients without chronic hypoxemia (no LTOT)
16408107|NCT03921970|Active Comparator|Group ESP = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. From superior to inferior; trapezius (upper), rhomboideus major (middle), erector spinae (lower) muscles will be visualized on the hyperechoic transverse process. The 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be inserted in a cranio caudal direction and then for correction of the needle 5 ml normal saline solution will be enjected into the erector spina muscle fascia (figure). Following confirmation of the correct position of the needle, a dose of 20 ml %0.25 bupivacaine was administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine).
16408108|NCT03921970|No Intervention|Group C = Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
16408109|NCT03921957|Experimental|stereotactic|
16408110|NCT03921944|Other|one year post total shoulder surgery|
16408111|NCT03921931|Experimental|healthy volunteers|light stimulation
16408112|NCT03921931|Experimental|primary open angle glaucoma patients|light stimulation
16408113|NCT03921931|Experimental|age-related macular degeneration patients|light stimulation
16408114|NCT03921918|Other|Evaluation of Fluid Expression Technology|This study aims to provide important insights with respect to the safety, performance, and real-life usability of pumping technology
16408115|NCT03921905||Patients with CAD|In this study will be included patients with stable CAD
16408116|NCT03921892|Other|In-person parenting education|Participants will complete two six-hour in-person parenting education sessions on two consecutive Saturdays
16412207|NCT03893968|Experimental|Informed by a doctor|Information by a doctor
16408118|NCT03921879|Experimental|Stage 1 Dose Escalation|The dose escalation arm will use a modified 3+3 design to determine the maximum tolerated dose. or maximum tested dose.
16408119|NCT03921879|Experimental|Stage 2 Dose Expansion|The dose expansion arm will use the maximum tolerated dose to determine preliminary efficacy.
16408120|NCT03921853|Active Comparator|Active comparator|Control group with obesity under Resistant Training
16408121|NCT03921853|Experimental|Experimental group with morbid obesity|Experimental group with morbid obesity under Resistant Training
16408122|NCT03921840|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
16408123|NCT03921840|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
16408124|NCT03921827|Experimental|EECP therapy|Half of the study sample will be allocated to EECP therapy (35 sessions) of 1-hour each. Acetazolamide challenged HMPAO-SPECT will be performed before randomization and repeated 2-months after the completion of EECP therapy. MRI of the brain would be performed after completion of EECP therapy to document any silent stroke.
16408125|NCT03921827|No Intervention|Best Medical Therapy|This group will receive the best medical therapy according to our institutional practice and as per the recommendations of American Stroke Association.
16408126|NCT03921814|Experimental|Treatment with IPL device|This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual [5]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
16408127|NCT03921801|No Intervention|Control|14-week control period.
16408128|NCT03921801|Experimental|Intervention|14-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback and home-based strength training session for plantarflexor muscles three times per week.
16408129|NCT03921801|No Intervention|Young adults - control|Outcome measures obtained at a single time point. The data is used to compare outcome measured between older and young adults.
16408130|NCT03921788||Group 1|Patients with venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
16408131|NCT03921788||Group 2|Patients without venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
16408132|NCT03921788||Group 3|Volunteers without pain syndromes of any location. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
16408133|NCT03921775|Experimental|Treatment group A|IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance
16408134|NCT03921775|Active Comparator|Treatment B|IV pumping of propofol at 120~150mg/kg/h for anesthesia induction and 3~12mg/kg/h for anesthesia maintenance
16408135|NCT03921762|Experimental|Artis Active IOL|Artis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
16408136|NCT03921762|Experimental|AT Lara IOL|AT Lara IOLs will be implanted in patients eyes during cataract surgery
16408137|NCT03921749|Experimental|Focused shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be focused shock wave therapy (0.20 mJ/mm 2 )
16408138|NCT03921749|Experimental|Raidal shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be radial shock wave therapy (3 bar)
16408139|NCT03921736|No Intervention|Control Group|Control group consisted of 40 postmenopausal women with normal blood pressure.
16408140|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide|Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
16408141|NCT03921736|Experimental|Hypertensive women group receiving perindopril.|Patients received perindopril 4 mg/day p.o for 1 year.
16408142|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide and EPT|Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
16408143|NCT03921736|Experimental|Hypertensive women group receiving perindopril and EPT.|Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
16408144|NCT03921736|Experimental|Hipotensive women group receiving EPT.|Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.
16408145|NCT03921723|Experimental|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of >= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
16408146|NCT03921710|Active Comparator|CAPA-IVM|Immature oocytes are culture in the new capacitation-IVM system.
16408147|NCT03921710|Active Comparator|Standard-IVM|Immature oocytes are cultured in the standard IVM system.
16408213|NCT03921281|Other|control group|The control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks.
16408214|NCT03921268|Experimental|Treatment A|Dose A estimated delivered single dose of AZD1402 nebuliser solution administered via a nebuliser.
16408148|NCT03921697||Parkinson Disease Patients|"Patients with PD will be recruited at Fondazione Policlinico Universitario Gemelli and Fondazione Don Gnocchi ONLUS in Rome. All included patients will be affected by idiopathic PD. Clinical data will be acquired by a trained neurologist.
~We will remotely monitor 300 patients through wearable sensors. Subjects will be instructed to wear the sensor for 14 consecutive days."
16408149|NCT03921684|Experimental|Neoadjuvant Treatment|All subjects will receive chemoradiation followed by chemotherapy and nivolumab as neoadjuvant treatment
16408150|NCT03921671|Experimental|Ramucirumab +carboplatin+ paclitaxel|All patient will receive the combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with recurrent and / or metastatic thymic carcinoma or thymoma B3 with area of carcinoma, in the first line.
16408151|NCT03921658||Cohort 1 - Cross-sectional (within 2 years of diagnosis)|Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
16408152|NCT03921658||Cohort 2- Prospective (from diagnosis)|Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)
16408153|NCT03921645|Experimental|aerosol combined group|aerosol combined intravenous antibiotics group，amikacin 15mg/kg, qd
16408154|NCT03921645|No Intervention|No intervention group|this group follow the usual treatment without any intervention
16408155|NCT03921632|Experimental|Education Program Effectiveness|Outpatients and inpatients from UNC Center of Excellence for Eating Disorders clinic
16408156|NCT03921619|No Intervention|No Sling|Participants will perform the balance tests without any added equipment.
16408157|NCT03921619|Experimental|Sling (Dominant)|Participants will perform the balance tests with a sling on the dominant arm.
16408158|NCT03921606|Experimental|Experimental group|The experimental group will receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. However, the total time spent by the interventionist will not be more than that for a traditional MI with several long sessions. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up. The total time spent will be recorded and analysed.
16408159|NCT03921606|Other|Control group|The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
16408160|NCT03921593||Simultaneous Pancreas Kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Simultaneous Pancreas Kidney Transplant (SPK)
16408161|NCT03921593||Pancreas after kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Pancreas after kidney Transplant (PAK)
16408162|NCT03921593||Pancreas Transplant Alone Recipients|Patient affected by Insulin Dependent Diabetes Mellitus with hypoglycemia unawareness undergoing Pancreas Transplant Alone (PTA)
16408163|NCT03921580|Placebo Comparator|Control Canned Tuna|Control Canned Tuna
16408164|NCT03921580|Experimental|Enriched Canned Tuna Variety 1|Enriched Canned Tuna Variety 1: Wakame fiber
16408165|NCT03921580|Experimental|Enriched Canned Tuna Variety 2|Enriched Canned Tuna Variety 2: Polyphenols
16408166|NCT03921567|Experimental|Group I|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
16408167|NCT03921567|Active Comparator|Group II|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
16408168|NCT03921567|Placebo Comparator|The control group|will be given opioids during surgery, opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
16408169|NCT03921554|Experimental|Aicardi Goutières Syndrome patients receiving Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
16408170|NCT03921541|Experimental|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
16408171|NCT03921541|Placebo Comparator|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
16408172|NCT03921541|Experimental|Pegzilarginase Long Term Extension|After completion of 24 weeks DB treatment, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
16408173|NCT03921528|Experimental|Cohort 1|Ambulatory Type 3 SMA
16408174|NCT03921528|Experimental|Cohort 2|Type 2 SMA / Non-Ambulatory Type 3 SMA
16408175|NCT03921528|Experimental|Cohort 3|Type 2 SMA
16408215|NCT03921268|Experimental|Treatment B|Dose B estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
16408216|NCT03921268|Experimental|Treatment C|Dose C estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
16408250|NCT03921047||Ancillary-correlative (next generation sequencing)|Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.
16408178|NCT03921502|Experimental|ERCP with sphincterotomy + gall bladder drainage with LAMS|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist. After this, transmural drainage of the gallbladder will be performed by placing a LAMS Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL will be placed on it to generate the anastomosis between the aforementioned structures.
16408179|NCT03921502|Active Comparator|ERCP with sphincterotomy|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist.
16408180|NCT03921489||Subchondroplasty in treating bone marrow edema|These patients will have calcium phosphate mineral compound injected into the bone marrow lesions.
16408181|NCT03921476||Subjects on spironolactone for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
16408182|NCT03921476||Subjects on oral antibiotics for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
16408183|NCT03921463||caesarean section|
16408184|NCT03921463||vaginal delivery|
16408185|NCT03921450|Experimental|Inhibitory repetitive transcranial magnetic stimulation (rTMS)|1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
16408186|NCT03921450|Active Comparator|Facilitatory intermittent theta burst stimulation (iTBS)|"Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.
~total of 15 sessions in 3 weeks"
16408187|NCT03921450|Placebo Comparator|Placebo|1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
16408188|NCT03921450|No Intervention|Waiting group|This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm
16408189|NCT03921437|Experimental|decision support intervention|The intervention measures in this study were discussed with the nephrologist and CKD health teachers. Based on theoretical considerations, the experimental group provides decision support. Measures, including CKD Guardian as a decision-maker, and the use of e-book software to develop medical decision-assist tools, and the application and decision-making mode complemented by introduction and selection, including team discussions, option discussions, and decision-making conversations. The control group is introduced with traditional care instructions for routine care. The experimental group and the control group were referred to the CKD health teacher for the introduction of renal replacement therapy by the physician. The experimental group was guided by CKD Health Education to guide the patients to participate in the discussion, discuss the advantages and disadvantages of each treatment and guide patients to explore preferences. And value, supplemented by discussion and final decision.
16408190|NCT03921437|No Intervention|routine care|According to the nursing routine provide paper education.
16408191|NCT03921424|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of Pneumovax™23 at Week 8 (Vaccination 2)
16408192|NCT03921424|Experimental|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of Pneumovax™23 at Week 8 (Vaccination 2)
16408193|NCT03921411|Experimental|Nemolizumab|Nemolizumab
16408194|NCT03921398||Patients with ESRD|Patients with history of biopsy-proven lupus nephritis (all classes of lupus nephritis)
16408195|NCT03921398||Patients with active lupus prior to treatment and no ESRD|Patients with biopsy-proven ACTIVE lupus nephritis
16408196|NCT03921398||Healthy individuals|Healthy individuals
16408197|NCT03921385||Single cohort - navigated cranial and spine surgery|
16408198|NCT03921372|Experimental|Normal Tension Glaucoma (NTG)|Patients with diagnosed NTG
16408199|NCT03921372|Experimental|Healthy Control Subjects|Subjects with no sign of glaucoma, Age and sex matched
16408200|NCT03921359|Experimental|Conventional physical training|Participants assigned to this arm will receive the conventional physical training.
16408201|NCT03921359|Experimental|SMARTfit training|Participants assigned to this arm will receive the SMARTfit training.
16408202|NCT03921346|Experimental|Arm A (mobile device app)|"Paramedics preparing drugs with the help of the mobile device app PedAMINES™.
~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of the mobile device app PedAMINES™."
16408203|NCT03921346|Active Comparator|Arm B (conventional preparation method)|"Paramedics preparing drugs with the help of conventional method.
~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of conventional method"
16408204|NCT03921333|Active Comparator|Low dose plant extract|300 mg
16408205|NCT03921333|Active Comparator|Middle dose plant extract|500 mg
16408206|NCT03921333|Active Comparator|High Dose plant extract|700 mg
16408207|NCT03921333|Placebo Comparator|Placebo control|Cellulose microcrystalline
16408208|NCT03921320|Active Comparator|Bilateral sympathectomy|Bilateral sequential (one surgical procedure) videothoracoscopic R4 sympathectomy
16408209|NCT03921320|Experimental|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the right (dominant) side
16408210|NCT03921320|Experimental|Contralateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the left (contralateral) side
16408211|NCT03921294|Experimental|Single Arm|Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.
16408212|NCT03921281|Experimental|treatment group|The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks.
16408217|NCT03921255|Active Comparator|TAF Incongruent (TAF-INC)|Active condition (TAF-INC) cognitive bias modification for interpretations (CBM-I), incorporates an obsessional thought meant to elicit either moral or likelihood TAF, followed by a sentence incongruent to TAF bias and meant to reduce the impact of the previous statement. Before moving on, participants must fill-in and correctly solve a key word important in the interpretation of the sentence. Participants then must correctly solve a short yes/no comprehension question to ensure understanding of the scenario.
16408218|NCT03921255|Placebo Comparator|TAF Congruent (TAF-CON)|Maintenance/Control condition (TAF-CON) CBM-I, differs in that participants are provided with a sentence congruent with TAF bias. Again, participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
16408219|NCT03921255|Placebo Comparator|Stress Management Psychoeducation|In the stress management psychoeducation (SMP) psychoeducation about stress and stress management are provided, similar in length to the obsessional thought and interpretations presented in the TAF-INC and TAF-CON. Like the other conditions there is a key word to solve, and participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
16408225|NCT03921229|Experimental|Intervention|6-months of 11 web-based intervention (tele-coaching) sessions (9 biweekly sessions and 2 monthly sessions) of approximately 30 minutes each; continued use of eTrack nebulizer and vest monitor photo capture as measures of adherence.
16408226|NCT03921216||Diabetic nephropathy, on hemodialysis|
16408227|NCT03921216||Chronic kidney disease, on hemodialysis|Chronic kidney disease of other causes than Diabetes.
16408228|NCT03921216||Chronic kidney disease, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
16408229|NCT03921216||Diabetic nephropathy, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
16408230|NCT03921203||Type 2 diabetes patients|
16408231|NCT03921203||Healthy controls|
16408232|NCT03921190|Active Comparator|Open-mouth|Patients receiving maxillary buccal infiltration anesthesia (MBIA) with their mouth wide open
16408233|NCT03921190|Experimental|Closed-mouth|Patients receiving MBIA using a closed-mouth technique
16408234|NCT03921177|Experimental|Multiple micronutrient supplement|Daily micronutrient supplement
16408235|NCT03921177|Placebo Comparator|Placebo|Daily identifcal placebo tablet
16408236|NCT03921164||Patients scheduled for a neuroradiology procedure|Interventional neuroradiology procedure under general anesthesia requiring a continuous monitoring of mean arterial pressure and cardiac output, including electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and monitoring of neuromuscular function. In addition, for all patients, data from trans-oesophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.
16408237|NCT03921151|Other|Cocaine-dependent|Participants who use and are dependent on cocaine
16408238|NCT03921151|Other|Non-drug using Healthy Controls|Participants who are not drug users
16408239|NCT03921138||Benign laparoscopic hysterectomy|Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy
16408240|NCT03921125||Responders|
16408241|NCT03921125||Non responders|
16408242|NCT03921112|Active Comparator|lung ultrasound|
16408243|NCT03921112|Active Comparator|x-ray, ABG, RSBI, Vetilator parameters|
16408244|NCT03921099|No Intervention|Vancomycin only|Vancomycin 15-20mg/kg intravenous every 8-12 hours.
16408245|NCT03921099|Experimental|Vancomycin +Ascorbic acid|Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.
16408246|NCT03921086|Other|Hypertensive patients|Newly diagnosed or poorly controlled hypertensive patients will be initiated on appropriate therapy as per a specific algorithm.
16408247|NCT03921073|Experimental|Intralesional injection of T-VEC|Participants will undergo intralesional injections of up to 4 cc of 10^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.
16408248|NCT03921060|No Intervention|Main Study|Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan (if not completed as standard of care within 6 months prior to research visit), micro CT, and blood collection.
16408249|NCT03921060|Experimental|Denosomab Sub-study|Approximately 10 subjects with CF that have completed the main study and have results which indicate bone disease are eligible to participate in the sub study. Subjects who consent will receive treatment with denosumab (60 mg/ml via subcutaneous injection in the upper arm, upper thigh, or abdomen every 6 months) for up to 5 years. These subjects will be asked to return every 6 months for injections and annually (+/- 6 months) for up to 5 years for a DEXA scan, micro CT, and blood collection.
16408270|NCT03920839|Experimental|INCMGA00012 + pemetrexed/cisplatin|
16408251|NCT03921034|Active Comparator|continuous ACB with IPACK block|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and IPACK block with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine
16408252|NCT03921034|Sham Comparator|continuous ACB with sham subcutaneous saline injection|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and a sham IPACK block with subcutaneous saline injection along the medial thigh
16408253|NCT03921021|Experimental|Telomelysin (OBP-301)|All patients will receive Telomelysin (OBP-301) at 2x10^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
16408254|NCT03921008|Experimental|Paclitaxel and Radiation|"All patients will receive standard of care induction chemotherapy with 6 weekly cycles of paclitaxel at 80 mg/m^2. They will then receive 6 weekly cycles of paclitaxel at 80 mg/m^2 concurrently with radiation therapy. Patients will be receiving paclitaxel as part of their routine care, but in order to participate in this study, their induction chemotherapy regimen must be paclitaxel. Radiation therapy is 50.4 Gy in 28 fractions delivered within 7 weeks.
~Standard of care surgery ideally within 6 weeks after completing concurrent chemotherapy and radiation therapy"
16408255|NCT03920956|Experimental|Experimental: 24-hour ABPM by Pharmacists|Patients will meet with the pharmacist to be equipped with a 24-hour ambulatory blood pressure monitor (ABPM). Patients will return the monitor for the pharmacists to download the results to send to their medical provider.
16408256|NCT03920943|Other|Core and TAT measurements|As part of the standard of care, flight paramedics will insert an esophageal or rectal temperature probe in patients meeting including criteria to enable continuous temperature monitoring. Paramedics will measure core temperature on at least two occasions, the first measurements made at least 5 minutes after insertion of the temperature probe, and also prior to departure from the sending facility.
16408257|NCT03920930|Experimental|Early-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached."
16408258|NCT03920930|Active Comparator|Late-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied after the preparation of the femur and tibia bone shortly before the prosthesis is inserted and during the retreat from the knee joint."
16408259|NCT03920917|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.
~Esophageal temperature will be monitored to prevent esophageal injury.
~A 28mm second or third cryoballoon catheter will be used.
~Esophageal temperature will be monitored to prevent esophageal injury.
~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.
~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.
~The procedure and cryoablation times will be evaluated.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16408260|NCT03920917|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.
~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.
~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.
~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.
~Evaluated the procedure and radiofrequency ablation time.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16408261|NCT03920904||Bupivacaine dosage in PIFB block|The pharmacokinetics of bupivacaine 0.25% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following a PIFB block will be determined by the collection of blood samples at predetermined time points.
16408262|NCT03920891|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.
~Esophageal temperature will be monitored to prevent esophageal injury.
~A 28mm second or third cryoballoon catheter will be used.
~Esophageal temperature will be monitored to prevent esophageal injury.
~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.
~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.
~The procedure and cryoablation times will be evaluated.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16408263|NCT03920891|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.
~Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.
~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.
~Evaluated the procedure and radiofrequency ablation time.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16408264|NCT03920878|Experimental|Aflibercept injected Pre- and Post-operatively|Pre- and Post-operative time of Aflibercept injections
16408265|NCT03920878|Active Comparator|Aflibercept injected intraoperatively|Intraoperative time of Aflibercept injection
16408266|NCT03920865|Experimental|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
16408267|NCT03920865|Experimental|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
16408268|NCT03920852|Experimental|Ruxolitinib cream|
16408269|NCT03920839|Experimental|INCMGA00012 + gemcitabine/cisplatin|
16408273|NCT03920826|Experimental|tACS stimulation group|NEXALIN ADI transcranial alternating current stimulator
16408274|NCT03920826|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
16408275|NCT03920813|Experimental|Antitumor drugs|Mercaptopurine administered at standard dose for children with hematological neoplasms.
16408276|NCT03920800||Conservative management - progression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
16408277|NCT03920800||Conisation|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
16408278|NCT03920800||Conservative management - spontaneous regression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
16408279|NCT03920787|Experimental|Inositol|Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
16408280|NCT03920787|Placebo Comparator|Placebo|Administration of placebo. 2 capsules every day for 1 month
16408281|NCT03920774||Familial Dysautonomia|Patients diagnosed with familial dysautonomia, a genetic disorder that affects the development and survival of nerve cells in the autonomic nervous system. It primarily affects neurons that control involuntary actions like regulation of blood pressure and breathing. It also affects the sensory nervous system and the perception of pain, heat and cold.
16408282|NCT03920748||Difficult laryngoscopy (Group D)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 3-4 are classified as difficult laryngoscopy ( Group D).
16408283|NCT03920748||Easy laryngoscopy (Group E)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 1-2 are classified as easy laryngoscopy ( Group E).
16408284|NCT03920735||Opportunistic infection|Immunocompromised or frail patients with an opportunistic infection
16408285|NCT03920735||Control group|Immunocompromised or frail patients with no opportunistic infection
16408286|NCT03920722|Experimental|Rituximab|Experimental regimen: One year Glucocorticoid treatment and Rituximab IV 1 gram on Day 1 and 15
16408287|NCT03920722|Placebo Comparator|Rituximab-Placebo|Standard regimen: One-year Glucocorticoid treatment and Placebo-Rituximab IV on Day 1 and 15
16408288|NCT03920709||Chronic HIV-1 infected subjects : 50 Viremic subjects|plasma HIV RNA > 500 copies/mL, treatment-naive or treated (failing) regardless of the cause of persistent viremia
16408289|NCT03920709||Chronic HIV-1 infected subjects : 50 Treated Aviremic subjects|< 50 copies/mL under treatment for at least 12 months
16408290|NCT03920709||Chronic HIV-1 infected subjects :10 Spontaneous Controllers|from the ANRS CO21 CODEX Cohort or not (5 last viral loads < 400 copies /ml)
16408291|NCT03920683||Diabete type 1 and 2|Data collection from patients treated in the diabetes department, in Pitié-Salpêtrière hospital, and adressed for a one-day hospitalization to assess cardiovascular comorbidities.
16408292|NCT03920670|Experimental|Tetragraph (TG)|TetraGraph placed on dominant hand, ToFscan placed on non-dominant hand
16408293|NCT03920670|Active Comparator|ToFscan (TS)|ToFscan placed on dominant hand, TetraGraph (TG) placed on non-dominant hand
16408294|NCT03920657|Experimental|Deferasirox|patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.
16408295|NCT03920644|Experimental|DPI-386 Nasal Gel|Receives Active Nasal Gel 2 times per treatment day
16408296|NCT03920644|Placebo Comparator|Placebo nasal gel|Receives Nasal Gel 2 times per treatment day
16408297|NCT03920644|Active Comparator|TDS Patch|Receives one patch per treatment.
16408298|NCT03920631|Experimental|Cohort 1: Microtransplantation (MST)|MST:Infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
16408299|NCT03920631|Experimental|Cohort 2/2b: MST + Nivolumab|"2: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day+14)
~2b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day+14)."
16408300|NCT03920631|Experimental|Cohort 3/3b: MST + Nivolumab|"3: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day-1).
~3b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day-1)."
16408301|NCT03920631|Experimental|Cohort 4: Expansion|Microtransplantation (Day 0) + nivolumab (at RP2D)
16408302|NCT03920618|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
16408303|NCT03920618|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
16408304|NCT03920618|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
16408305|NCT03920605|Active Comparator|Peginterferon alfa group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
16408306|NCT03920605|Active Comparator|Combination group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week and meanwhile oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive treatment of oral TDF 300 mg once per day from 49 to 144 weeks.
16408307|NCT03920592|Experimental|Video watching|"All participants will watch 4 videos of potential everyday school situations, adapted for boys and girls.
~Videos contain different levels of bullying (presence/absence) and virtual reality (presence/absence).
~Every pupil will watch the 4 types of video content randomly."
16408308|NCT03920579|Experimental|Sequence 1|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: D326, D337, D013(3 tabs, once)
16408309|NCT03920579|Experimental|Sequence 2|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 2(1 tab, once)
16412208|NCT03893968|Experimental|Informed by an assistant nurse|Information by an assistant nurse
16408310|NCT03920579|Experimental|Sequence 3|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 1(1 tab, once)
16408311|NCT03920579|Experimental|Sequence 4|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: D326, D337, D013
16408312|NCT03920579|Experimental|Sequence 5|Period 1: D326, D337, D013(3 tabs, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: CKD-386 formulation 2(1 tab, once)
16408313|NCT03920579|Experimental|Sequence 6|Period 1: D326, D337, D013 (3 tabs, once)/ Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: CKD-386 formulation 1(1 tab, once)
16408314|NCT03920553|Experimental|Test Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it. No bleeding was observed after the frenectomy performed with laser. Then, commercially available Hiyaluronic acid was topically applied to the relevant area to completely cover the surgical field to the test group. Following the frenectomy performed with laser, no application was made to the control group patients.
16408315|NCT03920553|No Intervention|Control Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it.
16408316|NCT03920540|Experimental|GC1111|All subjects should receive the GC1111 for 52 weeks.
16408317|NCT03920540|Active Comparator|Comparator|All subjects should receive the comparator for 52 weeks.
16408318|NCT03920527|Active Comparator|Six months|Six months of itraconazole
16408319|NCT03920527|Experimental|12 months|12-months of itraconazole
16408320|NCT03920514|Active Comparator|GROUP 1|IUI 24 hours after hCGadminstration
16408321|NCT03920514|Active Comparator|GROUP 2|IUI 36 hours after hCG adminstration
16408322|NCT03920514|Active Comparator|GROUP 3|IUI 48 hours after hCG adminstration
16408323|NCT03920514|Active Comparator|GROUP 4|IUI at time of hCG adminstration
16408324|NCT03920501|Experimental|Tele-Critical Care|Tele-Critical Care + Audit & Feedback.
16408325|NCT03920501|No Intervention|Usual Care|Usual Care.
16408326|NCT03920475||TAU (treatment as usual) group|Patients with depression, meeting inclusion criteria, who needed antidepressant treatment and received either sertraline or venlafaxine.
16408327|NCT03920462|Other|Programme of intelligent electric bike for health (single arm)|All volunteers will realise the programme of intelligent electric bike for health with connected vests.
16408328|NCT03920449|Active Comparator|Botulinum toxin injection|
16408329|NCT03920449|Active Comparator|Posterolateral internal sphincterotomy|
16408330|NCT03920436|Experimental|Infrared water group|This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.
16408331|NCT03920436|Sham Comparator|sham group|This group takes drinking water using a tumbler at room temperature for 8 weeks.
16408332|NCT03920423|No Intervention|shallow depth|Radial arterial deth is shallow than the cutoff point that relative to results.
16408333|NCT03920423|Experimental|improved depth|Radial arterial deth is shallow than the cutoff point that relative to results, and increased by injection of saline to more than deep cutoff point.
16408334|NCT03920410|Experimental|stimulated serotonergic activity|
16408335|NCT03920410|Experimental|unstimulated serotonergic activity|
16408336|NCT03920397|Experimental|Adipose tissue-derived stem/stromal cells|Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
16408337|NCT03920397|Experimental|Daily 2000 UI of daily oral cholecalciferol|To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.
16408338|NCT03920384|Experimental|Experimental therapy arm|16 (minimum 4, maximum 20) sessions of therapy for psychosis including new therapeutic ingredients
16408339|NCT03920384|Active Comparator|Standard Psychological Therapy for Psychosis|16 (minimum 4 maximum 20) sessions of standard psychological therapy for psychosis.
16408340|NCT03920371|Experimental|gamma camera imaging|hand held camera
16408341|NCT03920345|Experimental|Treatment: Endoscopic ET on SI joint|New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.
16408342|NCT03920319|Experimental|Bupropion|Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
16408343|NCT03920319|Placebo Comparator|Placebo|Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
16408344|NCT03920306|Experimental|Intervention|"Drug administration for the experimental arm includes:
~AgNO3 applied to the fistula tract.
~A topical adhesive of either 2-Octylcyanoacrylate glue (Dermabond), or Fibrin glue, or Histoacryl glue (Tissue Seal), will be applied over the fistula's aperture.
~Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous fistula tract closure, whichever comes first."
16408345|NCT03920293|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
16408346|NCT03920293|Placebo Comparator|Placebo|Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.
16446945|NCT03656718|Experimental|Part B, Group 4: nivolumab (dose 2)|
16408350|NCT03920254|Experimental|Active Treatment TD-1473 with Dose A|Oral daily dose of TD-1473 for up to 156 weeks
16408351|NCT03920254|Experimental|Active Treatment TD-1473 with Dose B|Oral daily dose of TD-1473 for up to 156 weeks
16408352|NCT03920254|Experimental|Active Treatment TD-1473 with Dose C|Oral daily dose of TD-1473 for up to 156 weeks
16408353|NCT03920241||MBSR group|Attendants to Mindfulness-Based Stres Reduction programs offered to the community by Complutense University
16408354|NCT03920241||CCT group|Attendants to Compassion Cultivation Training programs offered to the community by Complutense University
16408355|NCT03920241||Control group|Control group matched by age, gender, and meditation experience.
16408356|NCT03920228|Experimental|Open label period|
16408357|NCT03920228|Placebo Comparator|Randomized period - Dosing A|
16408358|NCT03920228|Experimental|Randomized period - Dosing B|
16408359|NCT03920228|Experimental|Randomized period - Dosing C|
16408360|NCT03920215|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, 0.12 mg/mL
16408361|NCT03920215|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.62 mg/mL
16408362|NCT03920215|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
16408363|NCT03920215|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
16408364|NCT03920176|Active Comparator|Computed tomography coronary angiography|
16408365|NCT03920176|Sham Comparator|Assign Score only|
16408366|NCT03920163|Active Comparator|Control|Stable , penetrating trauma patients undergoing laparotomy who receive standard post operative care
16408367|NCT03920163|Experimental|ERATS|Stable penetrating trauma patients undergoing laparotomy who receive enhanced recovery measures post operatively .
16408368|NCT03920150|Active Comparator|Control|5 ml alcoholic solution containing 24'000 IU vitamin D for 3 months
16408369|NCT03920150|Active Comparator|IMP|Vitamin D oily capsules containing 24'000 IU vitamin D for 3 months
16408370|NCT03920150|Active Comparator|IMP + loading dose|Vitamin D oily capsules containing 24'000 IU vitamin D for an individual number of weeks calculated with the formula: 40 x (100 - actual value [nmol/l] x body weight [kg] / 24'000 IU.
16408371|NCT03920137|Active Comparator|Active- UP-ST|The intervention will be the UP-ST therapy sessions. Treatment will be delivered using the new UP-ST protocol that will be developed in Phase I by integrating components of smoking cessation treatments (e.g. using the nicotine patch) with the theoretical model and treatment components of the existing UP treatment protocol, which includes both a therapist14 and patient12 manual. The UP-ST will maintain the same focus on transdiagnostic mechanisms of change as in the original UP, but will be adapted to integrate the smoking cessation focus and concurrent use of NRT. Thus, the investigators can successfully adapt and develop the new UP-ST to be delivered in eight 90-minute sessions and will be able to incorporate content from each of the 8 modules of the UP in the new UP-ST protocol.
16408372|NCT03920137|Experimental|Control- Standard|The Intervention will be the standard therapy sessions. Participants will receive a standard smoking cessation treatment based on the most recent clinical practice guideline from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence19. The investigative team has considerable expertise in developing and evaluating behavioral and pharmacological treatments for smoking cessation. Treatment will be delivered in eight, 90-minute sessions over an eight-week period.
16408373|NCT03920124|Experimental|High intensity interval exercise|Completion of four separate step and walk-based high intensity interval exercise sessions, followed by completion of six week unsupervised (at home) high intensity interval exercise intervention
16408374|NCT03920111|Other|Group 1 - Any status|Up to 3-4 healthy adults
16408375|NCT03920111|Other|Group 2 - FlaviPrime Naive|Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
16408376|NCT03920111|Other|Group 3 - Flavivirus Exposed|Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
16408377|NCT03920098||Primipara pregnant women|Primipara pregnant women
16408378|NCT03920085|Experimental|LifeScan BGMSs|OneTouch Verio, OneTouch Select Plus and OneTouch Ultra Blood Glucose Monitoring Systems (BGMSs) tested using subject capillary blood and compared to a reference instrument (YSI 2900).
16408379|NCT03920072|Other|Open label|All subjects will be administered subcutaneously burosumab every 4 weeks at the dosage defined in study UX023-CL303 or UX023-CL304 until December 2021 or when the drug becomes commercially available.
16408380|NCT03920059|Placebo Comparator|FD arm|MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
16408381|NCT03920059|Active Comparator|CC Arm|MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48
16408382|NCT03920046||Effects of passive smoking on children|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents smoking.
16408383|NCT03920033|Experimental|Hypofractionated|65 Gy/ 26 fractions (fraction size 2.5 Gy)
16408384|NCT03920033|Active Comparator|Standard|66 Gy/ 33 fractions (fraction size 2 Gy)
16408385|NCT03920020|Other|the concentric isokinetic exercise group|the concentric isokinetic exercise group will perform quadriceps and hamstring concentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
16408386|NCT03920020|Other|the eccentric isokinetic exercise group|the eccentric isokinetic exercise group will perform quadriceps and hamstring eccentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
16408387|NCT03920020|Other|the control group|the control group will perform the standard exercise program predetermined by us consisting of stretching exercises and isometric strengthening (these exercises will be done at home, too) and the conventional physiotherapy program will be applied 3 times a week during 6 weeks.
16408388|NCT03920007|Experimental|SAR439483|SAR439483 single dose according to an ascending dose design (dose escalation phase) or SAR439483 single dose (dose expansion phase)
16408393|NCT03919981||nephropathic cystinosis patients receiving cysteamine|nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.
16408394|NCT03919968|Experimental|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
16408395|NCT03919968|Active Comparator|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
16408396|NCT03919955|Experimental|Atomoxetine and Oxybutynin|Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.
16408397|NCT03919955|Placebo Comparator|Placebo|Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.
16408398|NCT03919942|Experimental|OxyFlower gel|pericoronitis treatment with oxyflower gel.
16408399|NCT03919942|Experimental|Chlorhexidine gel|pericoronitis treatment with chlorhexidine gel.
16408400|NCT03919942|Placebo Comparator|Placebo gel|pericoronitis treatment with placebo gel.
16408401|NCT03919929|Active Comparator|Diet Intervention|Weight loss with dietary intervention
16408402|NCT03919929|Experimental|GLP-1 Intervention|Participants will take a daily oral tablet of semaglutide for 4 months.
16408403|NCT03919916|Experimental|Serratus plane block and patient controlled analgesia|"Initial local anaesthetic bolus of 0.4 ml/kg of 0.25% levobupivacaine. Subsequent continuous local anaesthetic infusion of 0.125% levobupivacaine
~Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes"
16408404|NCT03919916|Active Comparator|Patient controlled analgesia only|Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes
16408405|NCT03919890|Experimental|ONO-7684 Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
16408406|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
16408407|NCT03919890|Experimental|ONO-7684 Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
16408408|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
16408409|NCT03919890|Experimental|ONO-7684 Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
16408410|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
16408411|NCT03919877|Other|Optimizing Diet for Glycemic Control|"All individuals will go through all the phases of the study.
~Phase 1: Metabolic testing to determine insulin resistance status.
~Phase 2: Participants follow their own diet while using the CGM (continuous glucose monitor). Participants are provided with 5-10 standardized foods to test during this phase.
~Phase 3: Participants are provided with additional standardized foods and counseled to continue their own diet during this phase.
~Phase 4: Participants are counseled on reducing or limiting the foods that caused glucose spikes and they are also counseled on macronutrient composition of their diet based on lipid profile. Participants use the CGM for another cycle of 2-3 weeks to assess effectiveness of the recommendations. Blood is drawn for analyses before and after this cycle."
16408412|NCT03919864|Other|CONNECT Intervention Group|CONNECT includes a multi-component e-tool with the following: (1) a brief educational video that seeks to empower and educate caregivers about the importance of self-care and benefits of supportive care resource use; (2) an assessment of multidimensional supportive care needs (e.g., psychological, behavioral, social, financial, educational, spiritual); (3) a tailored resource list that includes local and national resources corresponding to caregivers needs (Table1); and (4) an optional automated referral to a caregiver navigator to facilitate connection to resources.
16408413|NCT03919864|Other|CONTROL Group|Control arm participants will receive a generic (i.e., not tailored) printed list of hospital, community, and national supportive care resources. Control participants will not receive the educational video, complete the E-tool Preference survey, or have an option for an automated referral to a caregiver navigator
16408414|NCT03919838|Active Comparator|Probiotics|Participants will receive two lozenges containing probiotic bacteria and cranberry.
16408415|NCT03919838|Placebo Comparator|Placebo - No probiotics|Participants will receive a control two lozenges containing no probiotic bacteria.
16408416|NCT03919812|Experimental|Vitamin D supplementation according to baseline Vitamin D|The intervention provided according to the participants' state of vitamin D sufficiency. vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance was systematically monitored using drug monitoring diary evaluated by researchers. Blood samples for the study objectives were taken at enrollment and after eight weeks of cholecalciferol supplementation during routinely scheduled visits to the clinic.
16408445|NCT03919643||Healthy controls (blood donors)|No intervention. Peripheral blood and urine samples will be obtained
16408420|NCT03919786|Experimental|intervention group|"Durg：0.375% Ropivacaine and 1% lidocaine
~topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation.
~Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex"
16408421|NCT03919786|Placebo Comparator|normal saline group|Same volume of normal saline will be administrated
16408422|NCT03919773|Active Comparator|Treatment IVIG Arm|IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
16408423|NCT03919773|Placebo Comparator|Treatment Albumin Arm|albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
16408424|NCT03919760||NAVIGATE EPI|"This group of first episode psychosis patients is receiving NAVIGATE early psychosis intervention (EPI) as their regular clinical standard of care.
~The project team is implementing NAVIGATE at several early psychosis intervention (EPI) programs in different geographic regions of Ontario. The team will recruit consecutive referrals to these programs in order to determine longitudinal change in functioning and symptoms (hypothesis #3).
~Additionally, the primary data collected for these patients will be linked deterministically to data sources held at the Institute for Clinical Evaluative Sciences (ICES) via their unique health card number. Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
16408425|NCT03919760||Non-NAVIGATE EPI|"This group of first episode psychosis patients received early psychosis intervention other than NAVIGATE as their regular clinical standard of care.
~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
16408426|NCT03919760||Non-EPI|"This group of first episode psychosis patients did not receive early psychosis intervention as their regular clinical standard of care.
~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
16408427|NCT03919734||AI ACS/possible ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression equal to or above 50 nmol/l. The patients should not have clinical signs of Cushing Syndrome, such as catabolic skin and muscle changes.
16408428|NCT03919734||AI non-ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression below 50 nmol/l.
16408429|NCT03919734||Treatment with Inhalation Steroids|Patients treated with inhalation steroids with and without ACS/possible ACS but not operated with adrenalectomy.
16408430|NCT03919734||Adrenalectomy|Patients with unilateral AI operated with adrenalectomy
16408431|NCT03919734||Controls|"A Group of Controls matched for sex and age, achieved by the government agency Statistics Sweden (SCB)."
16408432|NCT03919721|Experimental|Learners receiving Applied Behavior Analysis therapy|All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.
16408433|NCT03919708||Enriched Population|Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
16408434|NCT03919708||Unenriched Population|Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
16408435|NCT03919695|Experimental|structural and behavioral intervention|The KISOBOKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component changes the mode of work payment from cash to mobile money.
16408436|NCT03919695|Active Comparator|Screening and Referral|Brief feedback on AUDIT-C score, referral for alcohol counseling, and briefly discussion of the importance of HIV care engagement and adherence.
16408437|NCT03919682|Experimental|Training, Phase 1|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in April-May 2015
16408438|NCT03919682|Experimental|Training, Phase 2|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in November-December 2015
16408439|NCT03919682|No Intervention|Control|6 health centers served as controls and did not receive training during the study period
16408440|NCT03919669|Experimental|All Subjects|"All subjects will complete PET imaging sessions evaluating the tau PET radioligand [18F]MK-6240 at baseline, as well as at 6, 12 and 24 months post-baseline.
~If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points."
16408441|NCT03919656|Experimental|Dapagliflozin|Dapagliflozin 10 mg daily (orally)
16408442|NCT03919656|Placebo Comparator|Placebo|Matching placebo for dapagliflozin daily (orally). Does not contain active ingredient
16408443|NCT03919643||SLE patients with nephritis|No intervention. Peripheral blood and urine samples will be obtained
16408444|NCT03919643||SLE patients with without nephritis|No intervention. Peripheral blood and urine samples will be obtained
16408446|NCT03919630|Experimental|Cervical Thrust Mobilizations|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine.
16408447|NCT03919630|Active Comparator|Cervical Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
16408448|NCT03919617|Experimental|Open-Label REMD-477|
16408449|NCT03919604||ECLS group|Patients with CF undergoing LUTX. Need for intraoperative extracorporeal life support
16408450|NCT03919604||Non-ECLS group|Patients with CF undergoing LUTX. No need for intraoperative extracorporeal life support
16408451|NCT03919591|Other|Open Label Pilot|Open Label Pilot Study. All subjects will receive the viral challenge inoculum.
16408452|NCT03919578|Experimental|Hep B Batch 1|1 dose of 1 mL Hepatitis B Batch 1
16408453|NCT03919578|Experimental|Hep B Batch 2|1 dose of 1 mL Hepatitis B Batch 2
16408454|NCT03919578|Experimental|Hep B Batch 3|1 dose of 1 mL Hepatitis B Batch 3
16408455|NCT03919578|Active Comparator|Hep B (Bio Farma)|1 dose of 1 mL Hepatitis B (Bio Farma)
16408456|NCT03919565|Active Comparator|TDF group|80 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 144 weeks.
16408457|NCT03919565|Experimental|Peginterferon alfa group|40 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
16408458|NCT03919552|Experimental|Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and carboplatin (AUC 5 on day 1) every three weeks for three cycles during radiotherapy.
16408459|NCT03919552|Active Comparator|Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during radiotherapy.
16408460|NCT03919526|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/ CD22 CAR-T cells in the MRD-positive ALL patients.
16408461|NCT03919513|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
16408462|NCT03919513|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
16408463|NCT03919500|Experimental|Erythropoietin|Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
16408464|NCT03919500|Placebo Comparator|Normal saline|Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.
16408465|NCT03919487||Back-to-back colonoscopy group|As I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy.
16408466|NCT03919461|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows. Etodolac:400mg PO bid for the entire intervention period, Propranolol (slow release): 20 mg PO b.i.d. for 5 preoperative days; 80 mg PO b.i.d. on the day of surgery; 40 mg PO b.i.d. for the first post-operative week and 20 mg PO b.i.d. for the second post-operative week.
16408467|NCT03919461|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
16408468|NCT03919448|Active Comparator|Zutrab® (Bevacizumab Richmond)|a single 1 mg/kg IV dose of Bevacizumab
16408469|NCT03919448|Active Comparator|Avastin®|a single 1 mg/kg IV dose of Bevacizumab
16408470|NCT03919448|Active Comparator|Cizumab®|a single 1 mg/kg IV dose of Bevacizumab
16408471|NCT03919435|Experimental|On Drug|
16408472|NCT03919422|Active Comparator|IC group|Interscalene brachial plexus-Cervical plexus
16408473|NCT03919422|Experimental|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
16408474|NCT03919409|Experimental|Part A: Cohort 1: TS-161 15 mg|Single dose of TS-161 15 mg or placebo in a fasted condition.
16408475|NCT03919409|Experimental|Part A: Cohort 2: TS-161 50 mg|Single dose of TS-161 50 mg or placebo which will be dosed first in a fasted condition, and then in a fed condition, with a washout period in between 2 dosing. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
16408476|NCT03919409|Experimental|Part A: Cohort 3: TS-161 100 mg|Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
16408477|NCT03919409|Experimental|Part A: Cohort 4: TS-161 200 mg|Single dose of TS-161 200 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
16408478|NCT03919409|Experimental|Part A: Cohort 5: TS-161 400 mg|Single dose of TS-161 400 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
16408479|NCT03919409|Experimental|Part B: Cohort 6: TS-161 TBD|Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.
16408480|NCT03919409|Experimental|Part C: Cohort 7: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
16408786|NCT03917394||control group|Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.
16408481|NCT03919409|Experimental|Part C: Cohort 8: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
16408482|NCT03919409|Experimental|Part C: Cohort 9: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
16408483|NCT03919396|Experimental|OrthoK|Group wearing Breath-O corrected orthokeratology lenses for 2 years
16408484|NCT03919396|No Intervention|SV Lenses|Group wearing spectacle with single vision lenses for 2 years
16408485|NCT03919383|Experimental|Lenvatinib Plus Toripalimab|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 21-day treatment cycles, and received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16408486|NCT03919370||Cerebral ischemia|Patients undergoing planned surgery for carotid stenosis
16408487|NCT03919370||Reperfusion|Patients undergoing cerebral trombectomy.
16408488|NCT03919357||Verbal|Passing of a specialized questionnaire on verbal disorders
16408489|NCT03919357||Non-verbal|Passing of a specialized questionnaire on non verbal disorders
16408490|NCT03919357||Attention|Passing of a specialized questionnaire on attention disorders
16408491|NCT03919357||Complaint about learning|Passing of a specialized questionnaire on learning disorders
16408492|NCT03919344|Other|Central SAS cases|Patients with central apnea
16408493|NCT03919344|Other|Obstructive SAS controls|Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
16408494|NCT03919344|Other|Snorers controls|Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas <15 / h)
16408495|NCT03919331|Experimental|Experimental|Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
16408496|NCT03919318|Experimental|AH-Plus|
16408497|NCT03919318|Experimental|EndoSeal MTA|
16408498|NCT03919318|Experimental|Endosequence BC Sealer|
16408505|NCT03919279|Experimental|active arm with active tVNS for 1 month|
16408506|NCT03919266|Other|Control|usual antibiotic treatment
16408507|NCT03919266|Experimental|Intervention|targeted antibiotic treatment according to the results of PCR multiplex
16408508|NCT03919253|Experimental|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously; nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
16408509|NCT03919240|Experimental|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells
16408510|NCT03919227|Experimental|Group 1: empty bladder|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS.
16408511|NCT03919227|Active Comparator|Group 2: natural state of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS.
16408512|NCT03919214|Other|QardioArm and Messaging System|Participants will self-monitor their blood pressure using the Qardio Bluetooth device and obtain 3 separate blood pressure measurements per week (2 morning, 1 evening) for 12 weeks. An automated messaging system for blood pressure management will be triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg. This automated message will be sent to the participant's primary care provider, with copies to the participant and the primary medical oncologist.
16408513|NCT03919201|Sham Comparator|Control group|No exercise intervention
16408514|NCT03919201|Experimental|Resistance band exercise intervention|Exercise intervention group (resistance band exercise training for 12 weeks, 5x per week, for 60 minutes per day).
16408515|NCT03919188|Experimental|body heat loss (BHL) air control|Incubator control using BHL air control method
16408516|NCT03919188|Active Comparator|air temperature control (ATC)|Incubator control using air temperature control (ATC) method
16408517|NCT03919188|Active Comparator|skin servocontrol (SSC)|Incubator control using skin servocontrol method
16408518|NCT03919175|Experimental|Umbralisib+Rituximab|"A treatment cycle is defined as 28 consecutive days.
~Umbralisib will be administered at 800 mg by mouth once daily on days 1-28 of cycles 1-24.
~Rituximab will be administered at 375 mg/m2 by intravenous infusion on Cycle 1 Day 1 and may be administered at 375 mg/m2 by intravenous infusion or at 1400 mg by subcutaneous injection on days 8, 15, 22 of cycle 1, day 1 of cycles 2 to 6, then every 8 weeks starting on day 1 of cycle 7 until completion of 24 cycles of umbralisib (i.e. every other cycle for 18 cycles or 9 doses, for a total of 15 doses of rituximab), or until progression or intolerance."
16408519|NCT03919162|Experimental|600 mg|First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID
16408520|NCT03919162|Experimental|300 mg|First 4 weeks 150 mg BID, week 5-24 300 mg BID
16408521|NCT03919162|Experimental|150 mg|24 weeks on 150 mg BID
16408522|NCT03919162|Placebo Comparator|Placebo|
16408523|NCT03919136||Primary Objective|Evaluation of the devices accuracy referenced to interventional (A-line) measurement.
16408524|NCT03919110||Genetically Undiagnosed SAID Patients (guSAID)|"adults and children, with different SAID of unknown pathogenesis, for which no specific mutations is identified and whose pathogenic mechanism remains unknown:
~Still Disease,
~Recurrent pericarditis,
~Neutrophilic dermatosis,
~Schnitzler,
~Vasculitis (Kawasaki disease, Behçet disease, Takayasu arteritis),
~Inflammation of unknown origin,
~Chronic/recurrent osteitis."
16413284|NCT03886597|Experimental|60 Table Olives|Table Olives Nutritional Intervention
16408525|NCT03919110||Parents of guSAID patients|Enrollment of parents of guSAID patients is justified by the TRIO genomic analysis (patient plus two parents) of the guSAID patients without known mutations. Indeed, the TRIO based whole-exome sequencing helps to facilitate the interpretation of genotypes and improve genetic explorations
16408526|NCT03919110||Monogenic SAID patients (mSAID)|This group of patients will serve as positive control to classify other diseases and encompass the following diseases: FMF, TRAPS, HIDS, and CAPS. Investigators aim at recruiting 50 patients per disease entity.
16408527|NCT03919110||Patient Free of inflammatory disorders control subjects|In order to set a reference / baseline for the identification of biomarkers the study will need non-inflammatory samples.
16408528|NCT03919097||Control|No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
16408529|NCT03919097||Atrial fibrillation post ablation|Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
16408530|NCT03919097||Flutter recidive|Recidive of the flutter after ablation.
16408531|NCT03919097||Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
16408532|NCT03919097||No Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
16408533|NCT03919084|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
16408534|NCT03919084|Experimental|THRIVE+|Enhanced screening-and-referral with motivational interviewing and patient navigation services
16408536|NCT03919058|Active Comparator|Regime 1: control regime|All participants start with the control regime, where baseline activity will be measured.
16408537|NCT03919058|Experimental|Regime 2: Sit regime/sit less regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
16408538|NCT03919058|Experimental|Regime 3: Sit less regime/sit regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
16408539|NCT03919058|Experimental|Regime 4: Exercise regime|The exercise regime is the final regime for all participants. This is comparable with the sit regime, but 1h of sitting is replaced with 1 exercise bout.
16408540|NCT03919045|Experimental|Sodium chloride injection|Sodium chloride 9mg/ml by injection
16408541|NCT03919045|Placebo Comparator|Needle sting|Brief needle stings without injection
16408542|NCT03919019|Experimental|Macuprev Group|patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months
16408543|NCT03919019|Placebo Comparator|Placebo Group|patients taking oral placebo 2 capsules per day for 6 months
16408544|NCT03919006|Active Comparator|Periodontitis|"GCF, saliva and serum samples were taken before and after treatment from periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
16408545|NCT03919006|Active Comparator|Gingivitis|"GCF, saliva and serum samples were taken before and after treatment from gingivitis patients.
~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
16408546|NCT03919006|Placebo Comparator|Periodontally healthy|GCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
16408547|NCT03918993||Group T|31 Patients with ED who receiving 5 mg/day of Tadalafil for 8 weeks.
16408548|NCT03918993||Group C|Thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up
16408549|NCT03918980|Experimental|Part 1 Dose A|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408550|NCT03918980|Experimental|Part 1 Dose B|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408551|NCT03918980|Experimental|Part 1 Dose C|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408552|NCT03918980|Experimental|Part 1 Dose D|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408553|NCT03918980|Experimental|Part 1 Dose E|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408554|NCT03918980|Experimental|Part 1 Dose F|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408555|NCT03918980|Experimental|Part 1 Dose G|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408556|NCT03918980|Experimental|Part 1 Dose H|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408557|NCT03918980|Experimental|Part 1 Dose I|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408558|NCT03918980|Experimental|Part 1 Dose J|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
16408559|NCT03918980|Placebo Comparator|Part 1 Placebo|(Single Ascending Dose) Healthy volunteers will receive a single dose of placebo.
16408560|NCT03918980|Experimental|Part 2 Dose K|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
16408561|NCT03918980|Experimental|Part 2 Dose L|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
16408562|NCT03918980|Experimental|Part 2 Dose M|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
16408563|NCT03918980|Experimental|Part 2 Dose N|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
16408564|NCT03918980|Experimental|Part 2 Dose O|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
16408922|NCT03916445||chronic gynecological disease|all patients having a consultation doctor during the recruiting time
16408565|NCT03918980|Experimental|Part 2 Dose P|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
16408566|NCT03918980|Placebo Comparator|Part 2 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo once daily for 12 days
16408567|NCT03918980|Experimental|Part 3 Dose Fasted|Healthy volunteers will receive a single dose of LOU064 given under fasting conditions followed by a single dose of LOU064 given after a high fat meal (cross-over design).
16408568|NCT03918980|Experimental|Part 3 Dose Fed|Healthy volunteers will receive a single dose of LOU064 given after a high fat meal followed by a single dose of LOU064 given under fasting conditions (cross-over design).
16408569|NCT03918980|Experimental|Part 4 Dose R|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
16408570|NCT03918980|Experimental|Part 4 Dose S|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
16408571|NCT03918980|Placebo Comparator|Part 4 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo twice daily for 12 days
16408572|NCT03918980|Experimental|Part 5 Formulation A|Healthy Volunteers will receive a single dose of LOU064 formulation A followed by a single dose of LOU064 formulation B (cross-over design).
16408573|NCT03918980|Experimental|Part 5 Formulation B|Healthy Volunteers will receive a single dose of LOU064 formulation B followed by a single dose of LOU064 formulation A (cross-over design).
16408574|NCT03918980|Experimental|Part 6 Dose T|Subjects with atopic dermatitis will receive a twice daily dose of LOU064 for 4 weeks
16408575|NCT03918980|Placebo Comparator|Part 6 Placebo|Subjects with atopic dermatitis will receive a twice daily dose of placebo for 4 weeks
16408576|NCT03918967|Experimental|CT-G11|CT-G11 Experimental Drug
16408577|NCT03918967|Experimental|CT-G20|CT-G20 Experimental Drug
16408578|NCT03918967|Placebo Comparator|CT-G11 Placebo|
16408579|NCT03918967|Placebo Comparator|CT-G20 Placebo|
16408580|NCT03918954|Active Comparator|Physical sensory room|In the inpatient ward there is a specifically designed room for calming down which a patient can request access to. In the room there is calming music, soft mats, nature themed wallpaper and calming visual lighting.
16408581|NCT03918954|Experimental|Virtual sensory room|The patients will have access to wireless virtual reality glasses during a session. The glasses will have a specially made protection that will be disinfected between each user, all users will also have the opportunity to choose a disposable cover for the glasses. The VR glasses are adjustable and adaptable to all types of head sizes and can be used with regular glasses. The application accessable in the VR glasses is called Calm Place, a virtual natural environment with day and night cycles, dynamic weather and associated soundscapes.
16408582|NCT03918941|Experimental|Carey|
16408583|NCT03918941|Active Comparator|conventional information|
16408584|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1|1 drop in each eye at bedtime.
16408585|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: Vehicle|1 drop in each eye at bedtime.
16408586|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
16408587|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: Vehicle|1 drop in each eye at bedtime.
16408588|NCT03918915|Placebo Comparator|Part 1: Vehicle; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
16408589|NCT03918889|Experimental|dexmedetomidine|patients receive dexmedetomidine infusion
16408590|NCT03918889|Experimental|midazolam|patients receive midazolam infusion
16408591|NCT03918876||Healty Dancers|Healthy adult dancers
16408592|NCT03918876||Injured Dancers|Injured adult dancers
16408593|NCT03918863|Experimental|Neuromuscular electrical stimulation|8-week exercise program, twice a week, with neuromuscular eletrical stimulation on vastus medialis and gluteus medius.
16408594|NCT03918863|Active Comparator|Exercise|8-week exercise program, twice a week.
16408595|NCT03918850|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.
~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
16408596|NCT03918850|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.
~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
16408597|NCT03918837|Sham Comparator|Sham rTMS|"The investigators will perform sham rTMS at 30% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days. The coil will have a 180° rotation compared to the active coil position, thus making the magnetic field ineffective on the patient's cortex.
~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment.
~All participants of this group will have the opportunity to undergo an active rTMS treatment right after the end of each one's participation in the study."
16408598|NCT03918837|Active Comparator|Active rTMS|"The investigators will perform active rTMS at 120% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days.
~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment"
16408599|NCT03918811|Experimental|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
16408600|NCT03918811|Active Comparator|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
16408601|NCT03918798|Experimental|Chloroprocaine 1%|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
16408923|NCT03916432|Experimental|Interventional group|HELIOS biodegradable polymer sirolimus-eluting stents
16408602|NCT03918798|Experimental|Chloroprocaine 2%|All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
16408603|NCT03918785|Experimental|Rice Germ|"The Rice Germ was supplied in vacuum jars of a weight of 130 grams. These jars once opened, were stored in the refrigerator (-3-4°C). Together with cans, small containers were provided to act as dosers and served to determine the correct dose to be taken (25 grams, twice a day). The rice germ or placebo were continually taken every day twice a day (25 grams in the morning with breakfast and 25 grams in the afternoon as snacks) for 5 weeks. The rice germ was supplied by the company Acquerello (TenutaColombara, Livorno Ferraris, Vercelli, Italy)."
16408604|NCT03918785|Active Comparator|Control group|Active comparator, which consisted of an isocaloric wheat germ-based supplement. Characteristics of supplementation are the same of experimental group.
16408605|NCT03918772||Perioperative immediate hypersensitivity|Patients having experienced perioperative immediate hypersensitivity
16408606|NCT03918746|Experimental|internet Attachment-Based Compassion Therapy (iABCT)|"The intervention will consist of an internet version of Attachment-Based Compassion Therapy (iABCT).
~The length of the intervention will depend on the pace of each participant that will be advised to carry out one module per week, taking days between sessions to complete homework assignments. It is estimated that the online intervention can be completed in eight weeks, with a maximum period of ten weeks. However, each participant will be free to advance at his/her own pace. Formal telephone support will be not systematically provided, but participants will contact for technical assistance (i.e., web accessibility problems or forgotten password) if necessary."
16408607|NCT03918733|Experimental|surgical treatment|surgical treatment of failed root canal treated teeth following secondary root canal treatment.
16408608|NCT03918733|Experimental|Non surgical retreatment|Non surgical retreatment of failed root canal treated teeth
16408609|NCT03918720|Experimental|Trekkers|
16408610|NCT03918720|No Intervention|Controls|
16408611|NCT03918707||Prospective|The prospective group will consist of approximately 15 evaluable patients who will undergo rWGS sequencing in addition to standard of care genetic testing. Subjects in this study will be drawn from children admitted to the NICU at OSF HealthCare Children's Hospital of Illinois who meet inclusion criteria.
16408612|NCT03918707||Historical Control|The historical control group will consist of patients admitted to the NICU between January 1, 2016 and December 31, 2018 who received genetic testing at less than 4 months of age and fulfil eligibility criteria.
16408613|NCT03918694|Active Comparator|Experimental|Participants will receive Vit C tablets
16408614|NCT03918694|Placebo Comparator|Placebo|Participants will receive placebo tablets
16408615|NCT03918681|Experimental|Intervention Group|The experimental group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups experimental group participants will receive gait retraining cues to transition to a NRFS running pattern.
16408616|NCT03918681|No Intervention|Control Group|The control group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups control group participants will not receive any gait retraining cues and will only be instructed on standard of care return to run metrics to include volume, load, and duration of running.
16408617|NCT03918655||Patient newly diagnosed with AML (prospectively)|Patient newly diagnosed with AML in Saint Antoine hospital or Tours University hospital in 2018 to 2020.
16408618|NCT03918655||Patient diagnosed with AML (retrospectively)|Patient diagnosed with AML in Saint Antoine hospital in 2015 to 2018
16408619|NCT03918642|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
16408620|NCT03918642|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
16408621|NCT03918629|Experimental|Clostridium difficile vaccine - 3 dose|All 3 doses are the Clostridium difficile vaccine
16408622|NCT03918629|Experimental|Clostridium difficile vaccine - 2 dose|2 of the 3 doses are the Clostridium difficile vaccine with the other being placebo
16408623|NCT03918616||PD + AD|Patients with newly-diagnosed (onset of suggestive symptoms not later than 3 months) Parkinson disease (PD) or Alzheimer disease (AD) with no previous specific treatment, no anti-inflammatory drugs assumed in the three months preceding the enrolment and no chronic inflammatory diseases or cancer.
16408624|NCT03918616||Control group|An age and gender matched control group (n=50) was formed, on a volunteer basis, by the spouse of the probands participating in the study.
16408625|NCT03918603|Experimental|ultra-protective multimodal ventilation group|Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48
16408626|NCT03918603|No Intervention|protective ventilation group|Patient will received usual care
16408627|NCT03918590|Active Comparator|A single drop of nepafenac 0.3% suspension|A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
16408628|NCT03918590|Other|Patching|A light pressure patch applied for two hours
16408629|NCT03918590|Placebo Comparator|A single drop of preservative-free Artificial Tears|A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
16408630|NCT03918577|Experimental|right cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their right external ear canal, with before and after measures of OCRD symptom severity and insight.
16408747|NCT03917654|Active Comparator|Arm 3f|Arm 3f (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
16408631|NCT03918577|Experimental|left cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their left external ear canal, with before and after measures of OCRD symptom severity and insight.
16408632|NCT03918551|Other|Sequence AB|25 subjects assigned to the sequence AB will receive a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16408633|NCT03918551|Other|Sequence BA|25 subjects assigned to the sequence BA will receive a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16408634|NCT03918538|Experimental|The intervention group|"After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual.
~The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers."
16408635|NCT03918538|No Intervention|The control group|Participants in the control group received regular medication education.
16408636|NCT03918499|Experimental|Treatment (pembrolizumab, cyclophosphamide, and IRX-2)|Participants receive pembrolizumab IV over 30 minutes on day 1. Participants also receive cyclophosphamide IV on day 1 and IRX-2 SC for 10 days starting on day 4 during cycles 1, 5, 9, 13, 17, 21, 25, 29, and 33. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease or unacceptable toxicity.
16408637|NCT03918486||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
16408638|NCT03918473|Experimental|Mobilization with Movement|A weight- bearing mobilization directed to the talocrural joint in a standing position.
16408639|NCT03918473|Experimental|Thrust Mobilization|A high velocity, low amplitude thrust mobilization directed to the talocrural joint with the participant in a non-weight bearing position.
16408640|NCT03918460|Experimental|Intervention|All patients enrolled are intended to be treated
16408641|NCT03918447|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.
~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100.
~Patients will be assessed at an in-person follow-up visit at Week 104."
16408642|NCT03918447|Experimental|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.
~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100.
~Patients will be assessed at an in-person follow-up visit at Week 104."
16408643|NCT03918447|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.
~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive placebo during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 and will continue treatment through Week 100.
~Patients will be assessed at an in-person follow-up visit at Week 104"
16408644|NCT03918421||Immunogloblin M-anti myelin-associated-glycoprotein neuropathy|Patient group (25 subjects) presenting with an Immunogloblin M-anti myelin-associated-glycoprotein peripheral neuropathy
16408645|NCT03918408|Experimental|Pulsed, accelerated|30 mW, 5 sec, 5 sec off, 10 minutes of illumination
16408646|NCT03918408|Active Comparator|Conventional|9 mW, continuous 10 minutes of illumination
16408647|NCT03918395|Placebo Comparator|Placebo|Placebo beverage
16408648|NCT03918395|Active Comparator|Protein-Polyphenol supplement|Protein-polyphenol beverage
16408649|NCT03918382|No Intervention|Control group|First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
16408650|NCT03918382|Experimental|PRO group|Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
16408651|NCT03918369|Experimental|Laparoscopic Intracorporeal anastomosis|Laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis.
16408652|NCT03918369|Active Comparator|Laparoscopic extracorporeal anastomosis|Laparoscopic right hemicolectomy with extracorporeal anastomosis.
16408748|NCT03917654|No Intervention|Arm 4a|Receipt of AL on day 154
16408749|NCT03917654|No Intervention|Arm 4b|Receipt of AL on day 154
16408653|NCT03918356|Experimental|Inclusion Body Myositis patients|Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
16408654|NCT03918356|Experimental|Idiopathic Inflammatory Myopathies patients|Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
16408655|NCT03918356|Placebo Comparator|control|Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
16408656|NCT03918343|Other|All patients|
16408657|NCT03918317|Experimental|AirXpanders AeroFormtissue expander + Radiation therapy|AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
16408658|NCT03918291|Experimental|Addition of whole-body vibration to squat training|The addition of whole-body vibration to squat training (for 12 weeks, 3x/week). The mechanical stimulation parameters of the vibration consisted of the following: frequency of 35 to 40 Hz, amplitude of 4 mm and acceleration that ranged from 2.78 to 3.26 G
16408659|NCT03918291|Other|Squat training|Squatting exercises for 12 weeks, 3x/week
16408667|NCT03918265|Experimental|Efficiency of tacrolimus on autoimmune cytopenia|"A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.
~Medication time should last at least 6 months."
16408668|NCT03918252|Experimental|Arm A Nivolumab Only|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
16408669|NCT03918252|Experimental|Arm B Nivolumab + Ipilimumab|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
16408670|NCT03918239|Experimental|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
16408671|NCT03918239|Experimental|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
16408672|NCT03918226|Other|Exploratory Laparotomy|Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis
16408673|NCT03918213|Experimental|healthy subjects examined with solid-state catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
16408674|NCT03918200||Study|Women with unexplained infertility
16408675|NCT03918200||Control|Fertile women who had normal physical and pelvic examination, regular menstrual cycles, don't use hormonal contraceptive, had one child at least.
16408676|NCT03918187|Experimental|bupivacaine|12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
16408677|NCT03918187|Active Comparator|nalbuphine|12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
16408678|NCT03918187|Active Comparator|midazolam|12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
16408784|NCT03917394||iron sucrose monotherapy group|Iron sucrose was administrated during hospitalization period.
16408785|NCT03917394||rHuEPO combined with iron sucrose group|rHuEPO combined with iron sucrose was administrated during hospitalization period.
16446946|NCT03656718|Experimental|Part C: nivolumab (dose 3) + rHuPH20|
16408679|NCT03918174|Experimental|Dart Splint orthosis|The Dart-Splint orthosis allows oblique wrist motion along the Dart Throwing Motion (DTM) plane, thus inhibiting movement of the healing structures following surgery around the distal radius. This is a hinged orthosis that permits selective midcarpal mobilization along the plane of the DTM is a novel orthotic device that was developed in order to facilitate protected midcarpal motion.
16408680|NCT03918174|Experimental|The conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions.
16408681|NCT03918161|Experimental|MRE exam|Magnetic Resonance Elastography (MRE) exam associated with standard T1-weighted and T2-weighted sequences
16408682|NCT03918148||SGLT-2i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:
~dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily"
16408683|NCT03918148||DPP-4i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:
~sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily"
16408684|NCT03918135|Experimental|Paracetamol|Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 100 patients
16408685|NCT03918135|Experimental|İbuprofen|İbuprofen 400mg of ibuprofen (intrafen 400mg/4ml solution Gen ilaç sanayi,Turkey ) intravenous (IV) was given 100 patients
16408686|NCT03918109|Experimental|OTO-313|
16408687|NCT03918109|Placebo Comparator|Placebo|
16408688|NCT03918083|Other|5-pronged wellness approach|30-day assessment of daily exercise, mindfulness, sleep, social connectedness, and nutrition
16408689|NCT03918057|Experimental|Cognitive-Behavioural Therapy Group|Participants receive 5 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
16408690|NCT03918057|Active Comparator|Treatment as Usual Group|Participants receive usual obstetric care and are placed on a wait-list until six months postpartum. All activities or efforts participants make to treat or improve their sleep on their own is recorded and coded. After the final assessment six months postpartum, participants have the option of receiving 1.5-hour sessions (for a total of 5 session) of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
16408691|NCT03918031|Active Comparator|PFI for Smoking & Distress Tolerance|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking and distress tolerance.
16408692|NCT03918031|Active Comparator|PFI for Smoking Only|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking only (no distress tolerance component).
16408693|NCT03918005|Experimental|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
16408694|NCT03918005|Active Comparator|High glycemic load diet|Foods with high glycemic index or glycemic load (white rice, white bread, corn flakes, mashed potatoes, orange juice, banana, persimmon, grape, raisins, honey, sugar)
16408695|NCT03917979|Experimental|Individual GIM|Participants are provided with a series of individual GIM sessions.
16408696|NCT03917979|Other|Waitlist Control|Participants complete an initial wait list period, then are provided with a series of Group GIM sessions.
16408697|NCT03917966|Experimental|SHR-1210+Docetaxel+nedaplatin|SHR-1210+Docetaxel+nedaplatin
16408698|NCT03917953|Experimental|Arm I|Patients receive transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
16408699|NCT03917953|Sham Comparator|Arm II|Patients receive sham transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
16408700|NCT03917940|Experimental|Omega 3 + glimepiride|group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.
16408701|NCT03917940|Placebo Comparator|Control|group 2: 35 patients treated with glimepiride 2mg or 3mg /day.
16408702|NCT03917927|Experimental|Eztetic dental implant|Eztetic 3.1mm diameter, lengths 8, 10, 11.5, 13, 16 mm
16408703|NCT03917914|Active Comparator|Bisoprolol|1.25, 2.5 or 5mg of bisoprolol daily
16408704|NCT03917914|Placebo Comparator|Placebo|1.25, 2.5 or 5mg of matched placebo daily
16408705|NCT03917901|Experimental|Anxiety Sensitivity Training|The Anxiety Sensitivity training (AST) will provide: (1) psychoeducation on anxiety sensitivity and its consequences, (2) psychoeducation on the relationship between anxiety sensitivity and obesity-related health behavior correlates, and (3) concrete, evidenced-based strategies to reduce anxiety sensitivity.
16408706|NCT03917901|Placebo Comparator|Health Control|The Health Control (HC) will cover general health care, such as information on wearing sunscreen and regular attendance to doctor appointments. The HC will not provide any recommendations or education on mood, dietary, or physical habits.
16408707|NCT03917888|Experimental|Lung ultrasound|Patients will be monitored for ventilator associated pneumonia using lung ultrasound combined with clinical features
16408708|NCT03917888|No Intervention|Chest x-ray|Patients will be monitored for ventilator associated pneumonia using chest x-ray and clinical features.
16408709|NCT03917875|No Intervention|Control|
16408710|NCT03917875|Experimental|PFI|
16408711|NCT03917862|No Intervention|Control|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques.
16408712|NCT03917862|Active Comparator|TDM-621|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques and will receive the TDM-621 for complementary hemostasis.
16408713|NCT03917849|Experimental|Heavy slow resistance training|"The program is performed 3 times per week using resistance equipment in a fitness center. Each session consists of three 2-legged loaded quadriceps and lower limb kinetic chain exercises. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 3 exercises.
~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 times, 15-repetition maximum (15RM ), in week 1; 3 times, 12RM , in weeks 2 to 3; 4 times, 10RM , in weeks 4 to 5; 4 times, 8RM , in weeks 6 to 8; and 4 times, 6RM , in weeks 9 to 12."
16408714|NCT03917849|Experimental|Inertial flywheel resistance training|The program is performed 3 times per week using resistance equipment in a fitness center. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 12 repetition máximum (RM) with moment inertia 0.05 m² from week 1-6 and 8 repetition máximum (RM) with moment inertia = 0.10 m² from week 6-12.
16408715|NCT03917823|Experimental|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
16408716|NCT03917823|Sham Comparator|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
16408717|NCT03917810|Active Comparator|MODSUG|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
16408718|NCT03917810|Experimental|LOWSUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
16408719|NCT03917810|Experimental|LOWCHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
16408720|NCT03917797|Experimental|MSC treatment|Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
16408721|NCT03917797|Placebo Comparator|Placebo|Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
16408722|NCT03917784|Experimental|Curcumin and bioperine|This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months
16408723|NCT03917784|Placebo Comparator|Placebo|This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months
16408724|NCT03917771|Experimental|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery. Lower Limb measurement and care education
16408725|NCT03917771|Active Comparator|Usual follow-up|The usual follow-up will be carried out in GO consultation (0,1,6,12 months)
16408726|NCT03917758|Experimental|Diabetic patients|30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.
16408727|NCT03917745|Experimental|eHealth mindfulness intervention group|8 weeks of internet mindfulness training
16408728|NCT03917745|No Intervention|Control group|Care as usual
16408729|NCT03917732|Experimental|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.
~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
16408730|NCT03917732|Active Comparator|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.
~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
16408731|NCT03917719|Experimental|Dose 1|Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.
16408732|NCT03917706||Congenital Heart Disease|Adults suffering from congenital heart disease, followed within the CHU Brugmann hospital, operated during childhood.
16408733|NCT03917693|Active Comparator|Phytin capsules|2.4 g phytin to be consumed daily for a period of 2 weeks. Participants will consume 2 test capsules containing phytin, 3 times a day with a meal for a period of 2 weeks.
16408734|NCT03917693|Placebo Comparator|Microcrystalline cellulose (MCC) capsules|2.4 g MCC to be consumed daily for a period of 2 weeks. Participants will consume 2 placebo capsules, each containing microcrystalline cellulose, 3 times a day with a meal for a period of 2 weeks.
16408735|NCT03917680|Experimental|Type III angioedema|White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
16408736|NCT03917680|Experimental|Idiopathic angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
16408737|NCT03917680|Experimental|Type I or II angioedema|White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.
16408738|NCT03917680|Experimental|Post IEC (conversion enzyme inhibitors) angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.
16408739|NCT03917680|Experimental|Histaminic angioedema|Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
16408740|NCT03917680|Other|Control|Healthy individuals, no angioedema.
16408741|NCT03917667||Geriatric patients|Patients aged 70 years and older who are admitted to the acute care geriatric units.
16408742|NCT03917654|Experimental|Arm 1a/3c|Arm 1a (pilot) + Arm 3c (main) to receive 40 microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of artemether/lumefantrine (AL) on day -7
16408743|NCT03917654|Active Comparator|Arm 1b/3d|Arm 1b (pilot) + Arm 3d (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
16408744|NCT03917654|Experimental|Arm 2a/3a|Arm 2a (pilot) + Arm 3a (main) to receive 40 microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7 and 154
16408745|NCT03917654|Active Comparator|Arm 2b/3b|Arm 2b (pilot) + Arm 3b (main) to receive HAVRIX day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 and 154
16408746|NCT03917654|Experimental|Arm 3e|Arm 3e (main) to receive 40 microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7
16413285|NCT03886597|No Intervention|Control|Control of Table Olives Nutritional Intervention
16408750|NCT03917641|Experimental|Patients after Oculoplastic surgery|"Each participant will use one compression with Khat leaves and another standard compression and will decide on which eye to use which compression.
~The compressions will be used for 10 minutes per every waking hour in the first 2 days post-op.
~The patient will take pictures of both his eyes in days 1,3 and 7 post operative days."
16408751|NCT03917628|Experimental|SCT630|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing SCT630
16408752|NCT03917628|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
16408753|NCT03917615|Experimental|"after women health course"|The participants will be instructed to contract the pelvic floor muscle
16408754|NCT03917615|Active Comparator|"before women health course"|The participants will be instructed to contract the pelvic floor muscle
16408755|NCT03917602|Experimental|Patients with large macular holes|Patients suffering from large macular holes as documented by spectral domain OCT will undergo pars plan vitrectomy with human amniotic membrane insertion into the macular hole.
16408756|NCT03917589||Patients with corticosteroids|Patients who have systematically been treated by high-dose corticosteroids after the delivery
16408757|NCT03917589||Patients without corticosteroids|Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.
16408758|NCT03917576|Active Comparator|Normoglicamic group|Control normoglycaemic participants
16408759|NCT03917576|Active Comparator|Hyperglicaemic group|Control hyperglicaemic group
16408760|NCT03917576|Experimental|Experimental group|Experimental Type 2 Diabetes Mellitus Group
16408761|NCT03917563|Experimental|Intervention group|WATCHMAN LAA occluder treatment
16408762|NCT03917550|Experimental|Recovery (Transdiagnostic & self)|A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.
16408763|NCT03917550|Active Comparator|Transdiagnostic|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
16408764|NCT03917537||HNSCC patients have used Nivolumab|Retrospectively analyze WGS information from cancer tissues from HNSCC patients have used Nivolumab
16408765|NCT03917524||no need for any adjuvant therapy|Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy
16408766|NCT03917524||with risk factors|Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status
16408767|NCT03917511|Experimental|Robotic training with mirror therapy|20 minutes mirror therapy followed by 40 minutes robotic-assisted training
16408768|NCT03917511|Sham Comparator|Robotic-assisted training|20 minutes sham mirror therapy followed by 40 minutes robotic-assisted training
16408769|NCT03917498|Experimental|Single Pre-Operative Radiation Therapy with Delayed Surgery|Single Pre-Operative Radiation Therapy with Delayed Surgery
16408770|NCT03917472|Experimental|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
16408771|NCT03917472|Active Comparator|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
16408772|NCT03917459|Experimental|LCZ696|
16408773|NCT03917459|Active Comparator|Enalapril|
16408774|NCT03917446||Euvolaemic|
16408775|NCT03917446||Hypovolaemic|
16408776|NCT03917433|Experimental|Exposure with Tactile Feedback|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
16408777|NCT03917433|Experimental|Exposure with Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. The participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
16408778|NCT03917433|Experimental|Exposure with Tactile Feedback and Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world. Also, the participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
16408779|NCT03917433|Other|Virtual Reality Exposure Therapy Alone|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
16408780|NCT03917420|Experimental|Tenofovir/Emtricitabine|Participants will take 5 once daily doses above noted combination tab at 200mg/300mg before each sampling visit
16408781|NCT03917407|Active Comparator|Arm1: DUR-928 treatment for moderate alcoholic hepatitis|Enrolled alcoholic hepatitis patients would have MELD of 11-20; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with moderate alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
16408782|NCT03917407|Active Comparator|Arm 2: DUR-928 treatment for severe alcoholic hepatitis.|Enrolled alcoholic hepatitis patients would have MELD of 21-30; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with severe alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
16408783|NCT03917394||rHuEPO monotherapy group|rHuEPO was administrated during hospitalization period.
16413750|NCT03883269|Experimental|Clindamycin 1%|Clindamycin 1% topical lotion formulation, BID, 4 weeks
16408788|NCT03917368|Experimental|Ultrasound scan of the internal jugular veins|Hospitalised adult patients, requiring a scheduled central venous catheterisation and measurement of the central venous pressure as part of their usual care, will undergo a non-invasive ultrasound scan of the internal jugular veins (both side of the neck) synchronized with an ECG trace, to assess the jugular venous pulse. This procedure will be performed once throughout the study.
16408789|NCT03917342|Active Comparator|Control Group|EEG measure in 15 healthy women undergoing elective hysteroscopy under single shot spinal anesthesia. Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
16408790|NCT03917342|Active Comparator|Healthy parturients|EEG measure in 15 healthy parturients undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
16408791|NCT03917342|Active Comparator|Preeclamptic parturients|EEG measure in 15 parturients with preeclampsia undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
16408792|NCT03917329|Other|ACT and PBS group workshop|The intervention in this study is an Acceptance and Commitment Therapy (ACT) and Positive Behaviour Support (PBS) group workshop for parents and education staff of children with intellectual disabilities.
16408793|NCT03917316||ADHD|
16408794|NCT03917316||Control|
16408795|NCT03917303|Active Comparator|Adalimumab|Episodic adalimumab monotherapy as first line treatment for 6 months
16408796|NCT03917303|Active Comparator|Standard step-up care|Step-up care as first line treatment, starting with corticosteroids.
16408797|NCT03917290|Experimental|Intervention|Upon clearance to RTP after concussion, participants randomized to NMT will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency for 8 weeks.
16408798|NCT03917290|No Intervention|Usual Care|Participants cleared to RTP in the usual care arm will return to sports and not undergo any intervention.
16408799|NCT03917277|Experimental|Musculoskeletal ultrasound of the ankle|"see Intervention description"
16408800|NCT03917264|Active Comparator|Tooth-borne treatment|Titanium curettes
16408801|NCT03917264|Experimental|Implant-specific treatment|Implant brush
16408802|NCT03917251|Other|Right ventricular Pacemaker|Patients with right ventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
16408803|NCT03917251|Other|Biventricular Pacemaker|Patients with Biventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
16408804|NCT03917238|Other|Patients with T1D|gallium-68-exendin followed by a PET/CT scan (twice)
16408805|NCT03917225|Active Comparator|Active|
16408806|NCT03917225|Placebo Comparator|Placebo|
16408807|NCT03917212||Patients|Patients with propionic acidemia, isovaleric acidemia, methylmalonic acidemia
16408808|NCT03917212||Controls|Healthy humans
16408809|NCT03917186|Active Comparator|Group sevoflurane|Administration under labelling conditions
16408810|NCT03917186|Experimental|Group desflurane|Administration under labelling conditions
16408811|NCT03917173|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin
16408812|NCT03917173|Active Comparator|Comparator|Standard surgery
16408813|NCT03917160|Experimental|EMS treatment|Subjects will undergo treatment with EMS and measurements
16408814|NCT03917160|No Intervention|Control|Subjects will undergo measurements only
16408815|NCT03917147||AUB in Post-Menopause|Abnormal Uterine Bleeding (AUB) in Post-Menopause
16408816|NCT03917147||Endometrial Thickening in post-menopause|Ultrasonographic detection of Thickened Endometrium in post-menopause
16408817|NCT03917147||Endometrial Thickening in pre-menopause|Ultrasonographic detection of Thickened Endometrium in pre-menopause
16408818|NCT03917147||Pharmacological history of Tamoxifen-related therapy regimens|Patients who had been treated with Tamoxifen
16408819|NCT03917134|Experimental|cephalosporin + Metronidazole|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
16408820|NCT03917134|Placebo Comparator|cephalosporin + placebo|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
16408821|NCT03917121|Experimental|Jet anesthesia|Local infiltration anesthesia delivered using Madajet XL® (MADA Medical Products, Inc., Carlstadt, NJ, USA) needle-free jet injector
16408822|NCT03917121|Active Comparator|Conventional infiltration anesthesia|Local infiltration anesthesia delivered using 25 gauged short needle attached, 1.8 ml carpule loaded standard metal dental syringe
16408823|NCT03917108|Active Comparator|retraction cord|
16408824|NCT03917108|Other|subgingival clamp|
16408825|NCT03917095|Active Comparator|Mesalazine conventional enema|Participants undergo the conventional enema of Mesalazine Enemas (4g) for one week.
16408826|NCT03917095|Experimental|Mesalazine TET enema|Participants undergo the TET enema of Mesalazine Enemas (4g) for one week.
16408827|NCT03917095|Active Comparator|Compound Glutamine conventional enema|Participants undergo the conventional enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
16408828|NCT03917095|Experimental|Compound Glutamine TET enema|Participants undergo the TET enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
16408829|NCT03917095|Experimental|Compound Glutamine and Mesalazine TET enema|Participants undergo the TET enema of Mesalazine(4g) and Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
16449030|NCT03642795||Patients with rheumatoid polyarthritis|
16408830|NCT03917082|Experimental|standard of care endocrine therapy for two years|Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
16408831|NCT03917069|Experimental|nab-paclitaxel + endostatin+ carboplatin|nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d
16408832|NCT03917069|Active Comparator|paclitaxel+carboplatin|paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
16408833|NCT03917056|Experimental|Long needle group|Participants were treated with CAES using long needle.
16408834|NCT03917056|Experimental|Short needle group|Participants were treated with CAES using short needle.
16408835|NCT03917043|Experimental|APG-2449|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 30-40 patient at the MTD/RP2D dose level.
16408836|NCT03917030|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
16408837|NCT03917030|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
16408838|NCT03917017|Experimental|Radiomics and Watson artificial intelligence|
16408839|NCT03917004|Experimental|hypotension group (group H )|particcipants in hypotension group are received controlled hypertension in the operation.
16408840|NCT03917004|No Intervention|control group (group C )|participants in cotrol group are received no controlled hypertension in the operation
16408841|NCT03916991|Experimental|Neuromuscular Exercise|Neuromuscular Exercise
16408842|NCT03916991|No Intervention|Control|No intervention
16408843|NCT03916991|Sham Comparator|Sham Exercise|Sham Exercise
16408844|NCT03916978|Experimental|Participants receiving PRP treatment|Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.
16408845|NCT03916978|Placebo Comparator|Control Group: Participants receiving Platelet Free Plasma|Women in menopause, 45-55 years old, treated with autologous PFP intra ovarian infusion.
16408846|NCT03916952||Healthy younger|All participants between 18 and 65 years of age that completed the test
16408847|NCT03916952||Healthy older|All participants > 65 years of age that completed the test
16408848|NCT03916939|Experimental|Osteopathy|osteopathic treatment
16408849|NCT03916939|Placebo Comparator|simulated osteopathy|simulated osteopathic treatment
16408850|NCT03916926|Experimental|"A simple medical strategy consisting of SDF"|The treatment will be bi-annual application (at baseline and 26 weeks) of topical 38% silver diamine fluoride (Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL) following manufacturer's instructions and guidelines published by UCSF (2016).
16408851|NCT03916926|Active Comparator|"A typical dental strategy consisting of ART + FV"|Atraumatic Restorative Treatment (ART) will be a modification of the approach used by Lo and colleagues (2006), and the cavity restored at baseline with resin reinforced glass-ionomer cement (GIC) (GC Corporation, Japan). Participants in this arm will also receive biannual topical fluoride varnish application (FluoriMax, Elevate) according to manufacturer's instructions.
16408852|NCT03916913|Experimental|Local therapy|Consolidation local radiotherapy
16408853|NCT03916900|Experimental|Pulpotomy|"Group A (Experimental group) Pulpotomy:
~The teeth will be anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain) by inferior alveolar nerve block.Under rubber dam isolation, pulpotomy will be performed with a large sterile round end bur in a high speed hand piece with copious irrigation; pulp tissue will be removed by a sharp spoon excavator to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet moistened with 2.5% NaOCL for 2 min and repeated if needed.
~After hemostasis, Biodentine (Septodont, Saint Maur des Fausses, France) will be mixed according to the manufacturer's instructions and gently placed over the pulp to thickness of 2-3 mm.Biodentine will be covered by resin modified glass-ionomer and teeth will be restored using composite resin.A postoperative radiograph will be taken by parallel technique."
16408854|NCT03916900|Active Comparator|Root canal treatment|"Group B (control group) Root canal treatment:
~The teeth were anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain).Under rubber dam isolation, root canal treatment will be performed in single visit.Working length will be determined using stainless steel k-files (Mani, Inc.) keeping 0.5 to 1.0 mm short of the apex using a RootZX apex locator (J. Morita, Irvine, CA) and confirmed radiographically. Mechanical preparation will be achieved by a crown-down technique using using the M-PRO system (IMD, Shanghai, China) and irrigation with 5 mL 2.5% NaOCl between instruments.Obturation will be done with gutta-percha (Meta Biomed Co. Ltd, Cheongwongun, Chungbuk, Korea) and resin sealer ADseal (Meta Biomed CO., LTD, Korea) using cold lateral condensation technique and restored with composite resin with a base of glass-ionomer cement. A postoperative radiograph will be taken by parallel technique."
16408855|NCT03916887|Experimental|golf training|10-week golf training program
16408856|NCT03916874||Pregnant females and her newborn.|A longitudinal study of one cohort of 250 pregnant females less than 22 weeks gestation and her newborn. Swabs and samples (low vaginal, skin, urine, blood and stool) will be requested at one time point during each trimester from the participant. In addition, there are three different questionnaires at trimester 2.
16408857|NCT03916861|Experimental|Bioelectrical Impedance|The first group will be monitored by Inbody S20 analysis to measure fluid status. The Bioimpedance will be measured each time prior to hemodialysis session . The value of BIA measurement of more than 0.4 will be considered as edema.
16408858|NCT03916861|Active Comparator|Physicain-guided group|The fluid monitoring will be managed by physician-adjustment by physical examination and fluid balance record . The fluid balance (FB) is the total fluid administered minus the total fluids eliminated over a period of time.
16408859|NCT03916848|Experimental|Combined Micro-Macro SEEG Electrodes|Implanting SEEG electrodes with combined micro-macro electrodes capable of recording clinical data and experimental micro electrode single unit data
16408860|NCT03916835|Other|Music Therapy during cleaning care 1|"This group receives music therapy during cleaning care 1 and not during the cleaning care 2.
~Each patient will act as their own control"
16450937|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
16408861|NCT03916835|Other|Music Therapy during cleaning care 2|"This group receives music therapy during cleaning care 2 and not during the cleaning care 1.
~Each patient will act as their own control"
16408862|NCT03916822||ABMR|Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies
16408863|NCT03916822||TCMR|Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3
16408864|NCT03916822||No Rejection|Biopsy-proven, or clinical criteria
16408865|NCT03916809|Experimental|Active EMST + Standard Care|Patients randomized to the Active EMST + Standard Care arm (ACTIVE) will use the EMST150 device as packaged, i.e. following package instructions with a device that has its valve spring maintained.
16408866|NCT03916809|Sham Comparator|Sham EMST + Standard Care|Those randomized to the Sham EMST + Standard Care arm (SHAM) will use an EMST150 device that has been modified by removing the internal spring, which allows the valve to open in response to airflow through the device regardless of the amount of pressure generated.
16408867|NCT03916796|Experimental|Pre-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel|"Patients must be treated using daily image-guided radiotherapy
~Dietary counseling at baseline
~Exercise intervention throughout cancer rehabilitation protocol
~Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
16408868|NCT03916796|Experimental|Post-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel|"Patients must be treated using daily image-guided radiotherapy
~Dietary counseling at baseline
~Exercise intervention throughout cancer rehabilitation protocol
~Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
16408869|NCT03916783|Experimental|Combination intervention|"Selected families will be assigned to the treatment condition (delivered over 9 months) to receive BSC plus a family EE intervention comprising of a matched family development account (FDA) for health-related expenses, including transport to UCI, food/nutrition, and health insurance. Combined with the Family EE will be four sessions of Financial Literacy and Management (FL&M) and two sessions of cancer education. The sessions will be conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.
~*Due to insufficient sample size, the open clinical trial is not being conducted."
16408870|NCT03916770|Active Comparator|whole body vibration|WBV(whole body vibration) will be applied to interventional group for 4 weeks, 2 days a week, a total of 8 sessions while standing upright with the WBV powerplate pro5 device.(Vibration frequency: 30Hz, amplitude: 2.2 mm and duration 1x10 seconds (starting period) + 3x30 seconds).
16408871|NCT03916770|Sham Comparator|Sham whole body vibration|The sham WBV will be applied to the Control group. A WBV device with 99.5% weakened amplitude will be used for sham WBV. (Application duration of the sham WBV will be 1x10 seconds (starting period) + 3x30 seconds).
16408872|NCT03916757|Experimental|V-Boost recipients|In this open label study all eligible participants will receive daily tablet of V-Boost
16408873|NCT03916744|Experimental|Giredestrant Dose Level 1|
16408874|NCT03916744|Experimental|Giredestrant Dose Level 2|
16408875|NCT03916744|Experimental|Giredestrant Dose Level 3|
16408876|NCT03916731|Experimental|STARgraft AV|Participants will be implanted with 6mm diameter STARgraft AV grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
16408877|NCT03916731|Active Comparator|Control (ePTFE)|Participants will be implanted in the same upper arm location with standard 6mm diameter ePTFE dialysis access grafts. All other aspects of this study arm are identical to the Experimental one.
16408878|NCT03916718||Dementia|The target population includes patients seen at Ochsner Clinic Foundation, >=55 years old, diagnosed with dementia, and meeting other inclusion/exclusion criteria. this study will recruit subjects identified as high utilizers of the Ochsner System. This will be defined by >= 2 ED visits, >= 2 Hospitalizations, or some combination prior to baseline. We will co-variate by insurance plan.
16408879|NCT03916705|Other|single study arm|All enrolled participants will undergo ultrasound evaluation and chiropractic low back spinal manipulation treatment.
16408880|NCT03916692|Experimental|Standard Process - glucose balance|Standard Process - glucose balance formula (200 kcal)
16408881|NCT03916692|Experimental|Energy smart Carbohydrate blend|Energy smart carbohydrate blend (50 grams, 200 kcal)
16408882|NCT03916692|Active Comparator|Liquid Dextrose Control|Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
16408883|NCT03916679|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
16408884|NCT03916653|Experimental|Test group|Osseous resection using piezoelectric device
16408885|NCT03916653|Active Comparator|Control group|Osseous resection using conventional rotary instruments
16408886|NCT03916640|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.
16408887|NCT03916640|Active Comparator|Humulin® + Symlin®|Simultaneous, separate subcutaneous injections of human insulin and pramlintide.
16408888|NCT03916640|Active Comparator|Humalog®|Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.
16408889|NCT03916627|Experimental|Cohort A1|Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
16408890|NCT03916627|Experimental|Cohort A2|Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
16408891|NCT03916627|Experimental|Cohort A3|Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
16408892|NCT03916627|Experimental|Cohort B|Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
16408893|NCT03916627|Experimental|Cohort C|Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC)
16408894|NCT03916614|Experimental|START treatment|Participants randomized into the treatment arm will receive the START intervention as described above alongside usual care from the VPOP staff
16408921|NCT03916445||gynecological cancer|all patients having a consultation doctor during the recruiting time
16450938|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
16408895|NCT03916614|Active Comparator|standard of care|Those randomized to the control arm will receive the usual screening for PTSD and referral for outpatient services if warranted as well as usual care from VPOP staff.
16408896|NCT03916601|Experimental|Test (T)|SAR341402 Mix 70/30: single dose injection
16408897|NCT03916601|Active Comparator|Reference 1 (R1)|NovoLog Mix 70/30: single dose injection
16408898|NCT03916601|Active Comparator|Reference 2 (R2)|NovoMix30: single dose injection
16408899|NCT03916601|Experimental|Reference 3 (R3)|SAR341402 rapid-acting solution: single dose injection
16408900|NCT03916588||Memory Care Unit Residents|Residents on a locked memory care unit in southeastern Louisiana will be enrolled. Engaged family members and staff will also consent to provide qualitative information on the resident.
16408901|NCT03916562|Experimental|Healthy Participants|The investigators will determine how asymmetric walking constraints influence spatiotemporal coordination, energetic cost, and dynamic balance in healthy individuals. The investigators will manipulate spatiotemporal coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
16408902|NCT03916562|Experimental|Post-stroke Participants|The investigators will determine how different patterns of coordination during walking influence energetic cost and dynamic balance in people post-stroke. The investigators will manipulate coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
16408903|NCT03916549|Experimental|Group 1|The patients with bowel dysfunction following low anterior resection performed at least 1 year ago will undergo acupuncture. The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
16408904|NCT03916536|Active Comparator|Holmium Laser|holmium laser enucleation of the prosteate
16408905|NCT03916536|Active Comparator|Thulium Laser|Thulium laser enucleation of the prosteate
16408906|NCT03916536|Active Comparator|Bipolar Enucleation|Bipolar enucleation of the prosteate
16408907|NCT03916523|Experimental|Group A|Infants in the group receive CPAP for respiratory support in the delivery room. In addition, they receive a total of 15 sustained lung inflations in the first 96 hours of life; 6 in the first day, 3 in the second day, 3 in the third day and 3 in the forth day of life.
16408908|NCT03916523|Experimental|Group B|Infants in the group receive CPAP for respiratory support in the delivery room. No sustained lung inflation will be applied.
16408909|NCT03916523|Active Comparator|Group C|Infants in this group are intubated in the delivery room and supported with mechanical ventilation.
16408910|NCT03916510|Experimental|Dosing schedules 1 to 6|"Dosing Group 1:
~- Loading dose pre chemoradiation (CRT) - 1x10^12 viral particles (vp)
~Dosing Group 2:
~Loading dose pre CRT - 1x10^12 vp
~Maintenance dose post CRT - 1x10^12vp
~Dosing Group 3:
~Loading dose pre CRT - 1x10^12vp
~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 1x10^12vp
~Maintenance dose post CRT - 1x10^12vp
~Dosing Group 4:
~- Loading dose pre CRT - 3x10^12vp
~Dosing Group 5:
~Loading doses pre CRT - 3x10^12vp
~Maintenance dose post CRT - 3x10^12vp
~Dosing Group 6:
~Loading dose pre CRT - 3x10^12vp
~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 3x10^12vp
~Maintenance post CRT - 3x10^12vp"
16408911|NCT03916497||Group 1 : kidney transplant recipients (KTR)|
16408912|NCT03916497||Group 2 : hemodialysis patients|
16408913|NCT03916497||Group 3 : Control patients|
16408914|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention|AQ: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). The participant may or may not stay solely on AQ throughout the study.
16408915|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention + NSC|AQ+NSC: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). NSC sessions are scheduled approximately every other week (frequency) and last approximately 30 minutes per session (dose). The participant may or may not stay on AQ+NSC throughout the study.
16408916|NCT03916484|Experimental|AQ followed by AQ+NSC|At 3 months, those who were initially randomized to AQ who meet protocol defined definition for intervention non-responsiveness, are reassigned to AQ+NSC to complete months 4 - 6 of the trial.
16408917|NCT03916484|Experimental|AQ+NSC followed by AQ|At 3 months, those who were initially randomized to AQ+NSC who meet protocol defined definition for intervention responsiveness, may get re-randomized to AQ alone to complete months 4 - 6 of the trial.
16408918|NCT03916471|Experimental|S (SOLYX)|The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.
16408919|NCT03916471|Experimental|O (OBTRYX II)|The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.
16408920|NCT03916458||Subjects with reported metastatic renal cell carcinoma|The subjects have been treatment with sunitinib and they reached complete remission
16451417|NCT03626155|Experimental|Afternoon Exercise (walking)|
16408924|NCT03916419|Experimental|Safety lead-in: Chemoradiation + Durvalumab|"The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.
~Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every two weeks for up to 12 months."
16408925|NCT03916419|Experimental|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every two weeks for up to 12 months.
16408926|NCT03916406|Experimental|Sequence 1|midazolam alone followed by combination of PF 06835919 and midazolam
16408927|NCT03916406|Experimental|Sequence 2|PF 06835919 in combination with midazolam followed by midazolam alone
16408928|NCT03916393|Experimental|PF-06651600 Treatment A|Active pharmaceutical ingredient (API)solution in water
16408929|NCT03916393|Experimental|PF-06651600 Treatment B|API in sweetened solution
16408930|NCT03916393|Experimental|PF-06651600 Treatment C|API blend suspension in water
16408931|NCT03916393|Experimental|PF-06651600 Treatment D|API blend suspension in apple sauce
16408932|NCT03916393|Other|Bitrex (Registered) Treatment E|Positive control for bitterness
16408933|NCT03916380|No Intervention|Group A|Tacrolimus Extended Release + Midazolam
16408934|NCT03916380|Active Comparator|Group B|Tacrolimus Extended Release + Midazolam + Grapefruit Juice
16408935|NCT03916367||Early Stage Lung Cancer|The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
16408936|NCT03916354||appropriate GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is in the recommended normal range is in this group.
16408937|NCT03916354||excess GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is over the upper limit of the recommended normal range is in this group.
16408938|NCT03916354||insufficient GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is below the lower limit of the recommended normal range is in this group.
16408939|NCT03916341|Experimental|Non-user|Non- users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
16408940|NCT03916341|Experimental|Chronic EC user|Chronic EC users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
16408941|NCT03916341|Experimental|Chronic TC smoker|Chronic TC smokers will use, in a randomized, crossover fashion with a 4 week washout, a 1) TC with nicotine (own brand), 2) research TC with very low level nicotine, and 3) a straw (control)
16408942|NCT03916328|Active Comparator|DMPA+ and TDF+|HIV-infected women on DMPA, and TDF containing ART.
16408943|NCT03916328|Experimental|DMPA+ and B/F/TAF+|HIV-infected women on DMPA, and B/F/TAF.
16408944|NCT03916328|Experimental|DMPA- and B/F/TAF+|HIV-infected women on non hormonal contraception, and B/F/TAF.
16408945|NCT03916315|Experimental|Transdiagnostic Treatment|Participants in this group will receive from 11 to 17 sessions of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
16408946|NCT03916315|No Intervention|Control group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 11-12 sessions will take place in the intervention group.
16408947|NCT03916302||Complicated outcome|"The patients meet at least one of the following criteria:
~systolic blood pressure < 90 mmHg for at least 15 minutes
~need for catecholamine administration because of persistant arterial hypotension or shock
~need for mechanical ventilation
~need for cardiopulmonary resuscitation
~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
16408948|NCT03916302||Non-complicated outcome|"The patients meet none of the following criteria:
~systolic blood pressure < 90 mmHg for at least 15 minutes
~need for catecholamine administration because of persistant arterial hypotension or shock
~need for mechanical ventilation
~need for cardiopulmonary resuscitation
~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
16408949|NCT03916276|Active Comparator|Cognitive Therapy (CT) Condition|Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain.
16408950|NCT03916276|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
16408951|NCT03916276|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
16408955|NCT03916250|Experimental|PF-06700841 cream 0%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
16408956|NCT03916250|Experimental|PF-06700841 cream 0.1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
16408957|NCT03916250|Experimental|PF-06700841 cream 0.3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
16408958|NCT03916250|Experimental|PF-06700841 cream 1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
16408959|NCT03916250|Experimental|PF-06700841 cream 3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
16408960|NCT03916250|Experimental|White petrolatum|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
16408961|NCT03916237|No Intervention|CONTROL|Control group
16408962|NCT03916237|Experimental|GROUP A no referral|Screener does not document need for home visit or medical legal partnership referral.
16408963|NCT03916237|Experimental|GROUP B1 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener does not document need for medical legal partnership.
16408964|NCT03916237|Experimental|GROUP B2 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener documents need for medical legal partnership.
16408965|NCT03916237|Experimental|GROUP C1 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener does not document need for medical legal partnership.
16408966|NCT03916237|Experimental|GROUP C2 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener documents need for medical legal partnership.
16408967|NCT03916237|Experimental|D medical legal partnership only|Screener does not document need for home assessment. Screener does not document need for medical legal partnership.
16408968|NCT03916224||Intubated critically ill patients|Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
16408969|NCT03916211|No Intervention|routine treatment|Diabetic foot routine treatment without intervention
16408970|NCT03916211|Experimental|MSCs treatment|On the basis of routine treatment of diabetic foot, adipose stem cells will be added to treat diabetic foot
16408971|NCT03916198|Experimental|PDRN(polydeoxyribonucleotide)|polydeoxyribonucleotide 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
16408972|NCT03916198|Placebo Comparator|CONTROL(normal saline)|normal saline 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
16408973|NCT03916185|Experimental|RSV ΔNS2/Δ1313/I1314L Vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
16408974|NCT03916185|Experimental|RSV 6120/ΔNS2/1030s Vaccine|Participants will receive a single dose of the RSV 6120/ΔNS2/1030s vaccine at study entry (Day 0).
16408975|NCT03916185|Experimental|RSV 276 Vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
16408976|NCT03916185|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16408977|NCT03916172|Experimental|APT Treatment|Participants in this arm will receive the Open Door Approach to Parenting Teenagers (APT). It offers 6 weekly 50-minute appointments with an optional 7th review session.
16408978|NCT03916172|No Intervention|Waiting List|Participants in this group will be placed on a waiting list and will receive APT treatment after no longer than 25 weeks.
16408979|NCT03916159|Experimental|Extrauterine Placental Transfusion EPT|Intervention group
16408980|NCT03916159|Active Comparator|Delayed cord clamping DCC|Control group
16408981|NCT03916146|Experimental|Behavioral Parent Training|
16408982|NCT03916146|No Intervention|Control|
16408983|NCT03916133|Other|Intervention group|Included patients will undergo angiographic FDCT perfusion imaging.The study will be embedded in the standard procedure of pre-operative diagnostics and angiographic control after EC-IC bypass treatment of steno-occlusive disease and during pre-embolization mapping and embolization procedure. An informed consent will be acquired during consultations in the preparatory process of the different examinations and treatments
16408984|NCT03916120||Postoperative Analgesic Failure|
16408985|NCT03916120||Postoperative Analgesic Success|
16408986|NCT03916107|Experimental|Levator muscle and tarsus resection|
16408987|NCT03916107|Active Comparator|Frontal muscle flap|
16408988|NCT03916094|Experimental|HLX22 group|HLX22, at four dose levels (1, 3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
16408989|NCT03916081|Active Comparator|ARQ-151 cream 0.05%|
16408990|NCT03916081|Active Comparator|ARQ-151 cream 0.15%|
16408991|NCT03916081|Placebo Comparator|ARQ-151 cream Vehicle|
16408992|NCT03916068|Experimental|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO2) - 100% oxygen at 2.4 atmospheres ATA for 90 minutes, Monday-Friday for 30 sessions (six weeks)
16408993|NCT03916068|Active Comparator|Trental and Vitamin E|Trental (pentoxifylline), 400 milligrams three times a day in combination with Vitamin E, 400 international units orally twice daily for six months
16408994|NCT03916055|Experimental|Exposure and response prevention (ERP)|Therapist-guided and parent-guided internet-delivered exposure and response prevention (ERP)
16408995|NCT03916055|Active Comparator|Education on tics|Therapist-guided and parent-guided internet-delivered education on tics
16408996|NCT03916042|Experimental|Reproxalap (0.25% Novel Formulation) QID to BID|
16408997|NCT03916042|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
16451418|NCT03626155|Experimental|Evening Exercise (walking)|
16408998|NCT03916029|Active Comparator|Facilitator|120 hours training for local community members delivered on-country face-to-face during 6 4-day weeks and over a 3-6 month period. Certificate II modules in Aboriginal Primary Health Care, ear and hearing health skills development (otoscopy, tympanometry, and hearScreen) and employment as Ear Health Facilitators to the end of the trial.
16408999|NCT03916029|No Intervention|Control|No Facilitator. Brief 6-monthly 2 to 3 hour in-service training via zoom for health professionals.
16409000|NCT03916016|Experimental|Intervention Group|The intervention group received enhanced integrated behavioral health care.
16409001|NCT03916016|Active Comparator|Control Group|The control group received care as usual only.
16409002|NCT03916003|Experimental|PQ7|high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
16409003|NCT03916003|No Intervention|standard care|As per national guidelines for P. falciparum treatment
16409004|NCT03915990|Other|control group|60 healthy pregnant women will be included
16409005|NCT03915990|Active Comparator|controlled diabetics|30 diabetic pregnant women with controlled Diabetes (i.e. HbA1C less than 6.5 %)
16409006|NCT03915990|Active Comparator|uncontrolled diabetics|30 diabetic pregnant women with uncontrolled Diabetes (i.e. HbA1C equal or more to 6.5 %)
16409007|NCT03915964|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
16409008|NCT03915964|Experimental|Baricitinib High Dose|Baricitinib administered orally.
16409009|NCT03915964|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
16409010|NCT03915951|Experimental|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.
~Patients will receive the following per 28-day (± 3 days) cycle:
~Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)
~Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
16409011|NCT03915938|Experimental|Group S-Ketamine|S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
16409012|NCT03915938|Placebo Comparator|Group Placebo|A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.
16409013|NCT03915912|Experimental|Mindfulness meditation|Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and ~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.
16409014|NCT03915899|Experimental|WIN Intervention|WIN Intervention
16409015|NCT03915899|No Intervention|Standard of Care|No WIN intervention.
16409016|NCT03915886|Experimental|JNJ-0440 (Low Dose) or Placebo|Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
16409017|NCT03915886|Experimental|JNJ-0440 (Medium Dose) or Placebo|Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
16409018|NCT03915886|Experimental|JNJ-0440 (High Dose) or Placebo|Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.
16409019|NCT03915873||vWB patients|
16409020|NCT03915873||control|
16409021|NCT03915860|Experimental|Trifarotene|Open label, CD5789 (trifarotene) 50μg/g Cream
16409022|NCT03915847|Active Comparator|Single layer closure|
16409023|NCT03915847|Active Comparator|Double layer closure|
16409024|NCT03915847|Active Comparator|Doble layer closure with trimming|
16409025|NCT03915834||endovascular treatment group|
16409026|NCT03915821|Experimental|Patients diagnosed as major depression according to DSM V|"All patients presented with major depression disorder not received ECT previously within 6 monthes, admitted to the study site ( Psychiatry department, in Assiut University Hospital, Assiut, Egypt). They Fulifilled will be recruited within 6 monthes duration .
~The patients classified into group A comprised that will be treated with Unipolar ECT, and group B comprised that will be treated Biploar ECT."
16409027|NCT03915808|Experimental|Conjugated linoleic acid plus lifestyle counselling|supplementation of 3.2 g/day conjugated linoleic acid and receive education sessions regularly
16409028|NCT03915808|Placebo Comparator|Sunflower oil plus lifestyle counselling|supplementation of equivalent sunflower oil, and receive education sessions regularly
16409029|NCT03915782|Experimental|Remote Ischemic Conditioning (RIC) positive|Patients with remote ischemic conditioning
16409030|NCT03915782|Sham Comparator|Control group|The control group will receive a sham procedure (same procedure than Remote Ischemic Conditioning (RIC) with brachial cuff inflation to 30 millimeters (mm) of mercury (Hg) during 40 minutes).
16409031|NCT03915769|Experimental|0.46 mg ozanimod oral capsule once daily (QD)|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.46 mg ozanimod.
16409032|NCT03915769|Experimental|0.92 mg ozanimod oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.92 mg ozanimod.
16409033|NCT03915769|Placebo Comparator|Placebo oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with a placebo capsule, followed by 3 days of treatment with two placebo capsules, followed by two placebo capsules.
16409034|NCT03915756|Experimental|With drain|Participants who received a drain during surgery
16409035|NCT03915756|No Intervention|Without drain|Participants who did not receive a drain during surgery
16409036|NCT03915743|Experimental|Palliative care|Specialized palliative care arm in a newly formed COPD outpatient clinic
16409037|NCT03915743|No Intervention|Usual care|Usual care in a standard pulmonary out-patient clinic. Treatment as described in national standards.
16409038|NCT03915730|Experimental|Smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
16409039|NCT03915730|Experimental|Non-smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Never smoked patients were included into the nonsmoker group
16409040|NCT03915730|No Intervention|Smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
16409041|NCT03915730|No Intervention|Non-smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Never smoked patients were included into the nonsmoker group
16409042|NCT03915704|Experimental|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
16409043|NCT03915704|Experimental|Shotblocker|ShotBlocker is a small, flat, yellow horseshoe-shaped plastic tool that is non-invasive, appropriate for every age group, does not have the characteristics of medication or adverse effects. ShotBlocker has short, blunt points that provide contact with skin on one side, and a hole that exposes the injection site in the middle of the tool. It is used by being held on the skin surface during injection. The pointed surface of the tool is placed on the administration area right before the injection
16409044|NCT03915704|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
16409045|NCT03915691|Active Comparator|Ripple Mapping|Intervention: Ripple Mapping guided catheter ablation of atrial tachycardia.
16409046|NCT03915691|Active Comparator|Conventional Mapping|Intervention: conventional catheter ablation of atrial tachycardia.
16409047|NCT03915678|Experimental|Population 1: Pancreatic cancer|Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
16409048|NCT03915678|Experimental|Population 2: Virus-associated tumors|Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.
16409049|NCT03915678|Experimental|Population 3: anti-PD-1/L1 refractory non-small lung cancer|Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
16409050|NCT03915678|Experimental|Population 4: Soft-tissue sarcoma|Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.
16409051|NCT03915678|Experimental|Population 5: anti-PD-1/L1 refractory bladder cancer|Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
16409052|NCT03915678|Experimental|Population 6: Triple negative breast cancer|Participants with triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
16409053|NCT03915665|Active Comparator|Standard treatment|Manual treatment One application of Chlorhexidine 1% gel
16409054|NCT03915665|Experimental|Comprehensive treatment|Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
16409055|NCT03915652|Experimental|Rheum iCMP Wave 1|20 patients enrolled immediately in Rheum iCMP
16409056|NCT03915652|Experimental|Rheum iCMP Wave 2|20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months
16409057|NCT03915652|Experimental|BWH iCMP to Rheum iCMP|70 lupus patients within the Partners system who are already enrolled in BWH iCMP will have their iCMP nurse trained in lupus-specific care
16409058|NCT03915639|Experimental|Cocktail|Participants in Group Cocktail are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with the multimodal cocktail.
16409059|NCT03915639|Active Comparator|Ropivacaine|Participants in Group Ropivacaine are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with ropivacaine.
16409060|NCT03915626|Experimental|RLD patch|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
16409061|NCT03915626|Experimental|generic patch|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
16409062|NCT03915626|Experimental|RLD patch with heat|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
16409063|NCT03915626|Experimental|generic patch with heat|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
16409064|NCT03915613|Experimental|Insulin|"Intranasal insulin will be made prepared from Humulin® R [insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly]. Each mL contains: 100 units of insulin injection, human biosynthetic (rDNA Origin) REGULAR. Nonmedicinal ingredients contain: glycerol, hydrochloric acid, m-cresol, sodium hydroxide and water for injection.
~Unopened vials should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials should be stored at room temperature <25°C (<77°F) and discarded after 28 days.
~To obtain a dose Humulin R 160 U / placebo
~16 sprays (0.1 mL/spray) are to be given per dose
~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.
~The sprays will be administered between alternating nostrils"
16409095|NCT03915418|Experimental|Connected tools|3 nights at home with connected tools only and 1 night at hospital with connected tools and PSG.
16409096|NCT03915405|Experimental|KHK2455 in Combination with Avelumab|
16410082|NCT03908281|Active Comparator|Postprandial Exercise|Exercise will be performed in the postprandial period (i.e., after breakfast)
16409065|NCT03915613|Placebo Comparator|Sterile Diluent|"Intranasal placebo will be prepared from Eli Lilly's sterile diluent used with Humulin® R (10 mL/vial, manufactured by Eli Lilly). Nonmedicinal ingredients contain: dibasic sodium phosphate, glycerin, liquefied phenol, metacresol, hydrochloric acid, sodium hydroxide and water for injection.
~Unused sterile diluent should be kept at controlled room temperature until the expiration date. The USP defines controlled room temperature as (20° to 25°C [68° to 77°F]), with excursions permitted (15° to 30°C [59° to 86°F]). Once in-use, the sterile diluent vial should be used within 28 days.
~Participants will follow the same dosage, frequency, and administration as Humulin:
~16 sprays (0.1 mL/spray) are to be given per dose
~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.
~The sprays will be administered between alternating nostrils"
16409066|NCT03915600|Experimental|Quinoa|Personalized diet added with quinoa
16409067|NCT03915600|Experimental|Flaxseed|Personalized diet added with Flaxseed
16409068|NCT03915600|Experimental|Quinoa and Flaxseed|Personalized diet added with quinoa and flaxseed
16409069|NCT03915600|No Intervention|Normal diet|Personalized diet without dietary supplement
16409070|NCT03915587|Other|Fluid Challenge|After defining fluid responders from non-responders in this single arm prospective trial, we will compare the predictive utility of non-invasive devices such as the CipherOx-CRI and IVC CI to currently employed indices (heart rate, systolic blood pressure, urine output and pulse pressure variability) to gauge the need for additional fluid and ongoing resuscitation.
16409071|NCT03915574|Experimental|Dural Puncture Epidural|Participants will receive a dural puncture epidural block with a 25 gauge spinal needle followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
16409072|NCT03915574|Active Comparator|Standard Epidural|Participants will have standard epidural infusion followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
16409073|NCT03915561|Active Comparator|Study group|This group will be received intravenous injection with 10ml transparent mixture solution with 40mg Dynastat and 0.9% saline twice
16409074|NCT03915561|Placebo Comparator|Placebo|This group will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice
16409075|NCT03915548|Experimental|The Behavioral Activation/ Problem Solving Intervention|BA/PS teaches survivors to a) systematically examine the reasons an activity is challenging, b) set achievable short-term goals that have the potential to improve participation, c) brainstorm solutions including activity adaptations and environmental modifications, d) construct and implement a detailed action plan, and e) evaluate the results and level of goal attainment. The structured process gives participants repeated practice in goal reengagement that leads them progressively closer to their long-term functional goals. The BA/PS framework integrates the cognitive-behavioral therapies of Behavioral Activation and Problem-solving Treatment and incorporates concepts from an occupational therapy theory called the Person-Environment-Occupational Performance Model.
16409076|NCT03915548|Active Comparator|Attention Control Condition|"Investigators provide education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts. The control condition will match the intervention in terms of the number of sessions, the delivery by telephone, use of an occupational therapist, and the use of homework between sessions (i.e., reading the education materials for the control condition versus executing the action plan for the BA/PS condition)."
16409077|NCT03915535|Active Comparator|MaxSimil|Subjects of group A will receive a constant daily dose of 4.3g of MaxSimil, a combination of EPA + DHA in proportions of 500/200, for a period of 90 days.
16409078|NCT03915535|Experimental|MAG-EPA|Subjects of group B will receive a constant daily dose of 4.4g of MAG-EPA, a purified formulation of EPA with traces of DHA (730/050), for a period of 90 days.
16409079|NCT03915522|Experimental|Adductor Canal Block|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a single adductor canal block wiht 20cc of 0.5% Ropivacaine using ultrasound guidance .
16409080|NCT03915522|Placebo Comparator|Placebo Comparator|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a sham adductor canal block with 2ml of 1% subcutaneous lidocaine at the level of the adductor canal using ultrasound guidance.
16409081|NCT03915509|Experimental|Bioactive group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
16409082|NCT03915509|Active Comparator|Sandblasted group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
16409086|NCT03915483|Experimental|tDCS group|one session of computerized change detection attentional filter exercise (selective attention) combined with real tDCS
16409087|NCT03915483|Sham Comparator|sham group|one session of computerized change detection attentional filter exercise (selective attention) combined with sham tDCS
16409088|NCT03915470|Experimental|XF-73|0.3 mL applications in each naris of 0.2% w/w XF-73 nasal gel for a cumulative dose of 6.0 mg of XF-73.
16409089|NCT03915470|Placebo Comparator|Placebo|0.3 mL applications in each naris of placebo to match XF-73 nasal gel.
16409090|NCT03915457|Experimental|Dry immersion Control Group|5 days of dry-immersion
16409091|NCT03915457|Experimental|Thigh Cuffs intervention|5 days of dry-immersion with thigh cuffs
16409092|NCT03915444|Experimental|NabCG|nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
16409093|NCT03915431|Experimental|NCS-01|human bone marrow derived cells
16409094|NCT03915431|Placebo Comparator|Placebo|placebo
16413751|NCT03883269|Placebo Comparator|ethanol solution|70% topical ethanol solution, BID, 4 weeks
16409097|NCT03915379|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-67571244. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
16409098|NCT03915379|Experimental|Part 2: Dose Expansion|Participants in 2 expansion cohorts of acute myeloid leukemia (AML) or either high-risk myelodysplastic syndromes (MDS) or very high-risk MDS will receive JNJ-67571244 at the RP2D determined in Part 1.
16409099|NCT03915366|No Intervention|Standard of Care (SoC)|"Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:
~Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days"
16409100|NCT03915366|Experimental|Valganciclovir plus SoC|Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group
16409101|NCT03915366|Experimental|Tuberculosis Treatment plus SoC|"Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group
~Doses of tuberculosis treatment:
~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.
~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.
~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
16409102|NCT03915366|Experimental|Tuberculosis Treatment plus Valganciclovir plus SoC|"Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group
~Doses of tuberculosis treatment:
~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.
~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.
~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
16409103|NCT03915353||Experiment|No interventions
16409104|NCT03915353||Control|No interventions
16409105|NCT03915340|Other|Sequence ABAB|16 subjects assigned to the sequence ABAB will receive a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in Periods 1 and 3 and a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16409106|NCT03915340|Other|Sequence BABA|16 subjects assigned to the sequence BABA will receive a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in Periods 1 and 3 and a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16409107|NCT03915327|Experimental|Intravenous iron group|Enrolled subjects would receive intravenous iron dextran within 24 hours of the subject's inclusion.
16409108|NCT03915327|No Intervention|Control group|Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.
16409109|NCT03915314||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
16409110|NCT03915314||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
16409111|NCT03915301||ESPB|Erector spinae plane block group
16409112|NCT03915301||Opioids|Opioid group
16409113|NCT03915288|Experimental|Group continuous training at moderate intensity|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity - MICT (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).
~Regarding the MICT training, this was done with fast walk or jog in endless band with the floor tilted to reach the desired intensity. Also by bicycle, rowing and elliptical. During the entire intervention the participants was monitored by a Polar Multisport RS800CX, oximetry and with the Borg scale to avoid exceeding the training intensity (60-80% FCM, 6 to 8 Borg)."
16409114|NCT03915288|Experimental|Group high Intensity Interval Training|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).
~Concerning the HIIT training, it consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group, which we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%)."
16409115|NCT03915288|Active Comparator|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities. It is highlighted that in the institutions where the patients of the 3 groups attended, there is not a physical training area supervised by a professional. Therefore, the intervention protocol was not excluded or denied to the participants of the control group, but continuity and supervision was given for investigative purposes to its process and treatment. In addition, none of the 3 groups stopped their medical treatment or that of the other professionals that make up the interdisciplinary team.
16409116|NCT03915262||Crohn's Disease|
16409888|NCT03909737|Placebo Comparator|No intervention to pregnant women and Placebo to infants|No intervention to pregnant women and placebo to infants at 6 and 14 week EPI visits
16409117|NCT03915249||Allogeneic-HSCT candidates|Physical activity, pulmonary functions (FEV1, FVC, FEV1/FVC, FEF25-75%, PEF), exercise capacity, respiratory (maximal inspiratory and expiratory pressures (MIP, MEP)) and peripheral muscle strength were evaluated in allogeneic-HSCT candidates.
16409118|NCT03915236|Experimental|Group 1: MON4STRAT Strategy|
16409119|NCT03915236|Active Comparator|Group 2: Conventional treatment|
16409120|NCT03915223|Experimental|"Arm Injection corticosteroids"|Single dose of Solumedrol 2 mg/kg
16409121|NCT03915223|Placebo Comparator|"Arm  injection physiological serum"|Single dose of physilogical serum
16409122|NCT03915210||Candidates of HSCT|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
16409123|NCT03915210||Healthy individuals|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
16409124|NCT03915197|Experimental|group 1|cohorts of infants with acute bronchiolitis
16409125|NCT03915184|Experimental|CAR-BCMA T Cells|Phase 1b will include two parts, a dose escalation part to determine the recommended dose for the expansion part. During expansion patients will be treated with the recommended dose determined in the expansion part.
16409126|NCT03915171|Experimental|MSI-H|IHC/PCR tested as dMMR/ MSI-H
16409127|NCT03915171|Experimental|MSS|IHC/PCR tested as pMMR/ MSS
16409128|NCT03915145|Experimental|Kinesio tape group|Kinesio tape application has been applied
16409129|NCT03915145|Sham Comparator|Sham group|Sham kinesio tape application has been applied
16409130|NCT03915145|Other|Control group|No intervention has been applied
16409131|NCT03915132|Experimental|VMAT plus Nimotuzumab|Patients receive Nimotuzumab weekly during radiotherapy .
16409132|NCT03915119|Experimental|VR Obstacle group|"Initial Visit: navigates a cluttered array of fixed and moving virtual obstacles to reach a way-point (goal) as fast and efficiently (avoiding obstacles) as possible. In each block, task difficulty (i.e., complexity) will increase linearly, regardless of success or failure (≥ 1 collision before reaching the goal).
~Second (Training) Visit (randomized into two groups):"
16409133|NCT03915119|Experimental|Agility Group|"Initial Visit: Completes a soccer ball dribbling agility task in which they must dribble a soccer ball toward an artificial way-point, while avoiding artificial obstacles overlaid onto the real world via a Microsoft Hololens augmented reality display.
~Second (Training) Visit"
16409134|NCT03915106||Bracing|AIS patients undergoing bracing to control the spinal curve progression
16409135|NCT03915106||Surgical|Severe AIS patients requiring surgical intervention to correct the spinal curve
16409136|NCT03915093|Experimental|study group|receive educational nursing protocol
16409137|NCT03915093|Active Comparator|control group|receive routine hospital care
16409138|NCT03915080|Other|Oktokog alpha (Advate)|Personalized treatment according to individual PK using intravenous injection of oktokog alpha with dose and dose interval according to MyPKFIT and phenotypic evaluation.
16409139|NCT03915067|Active Comparator|BOTOX High Dose|BOTOX High Dose will be injected into the platysma muscle on Day 1.
16409140|NCT03915067|Active Comparator|BOTOX Low Dose|BOTOX Low Dose will be injected into the platysma muscle on Day 1.
16409141|NCT03915067|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1.
16409142|NCT03915054|Active Comparator|AREG-TRIGGER|"Per case (6mL) 5940 µL Basal Medium
~60 µL IVM MIX Do not need to filtrate media."
16409143|NCT03915054|Active Comparator|CONTROL-TRIGGER|Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
16409144|NCT03915041|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
16409145|NCT03915041|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
16409146|NCT03915028|Experimental|Treated group by thermal cure|Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
16409147|NCT03915028|No Intervention|Control group|Control group will receive a thermal cure after the end of the study
16409148|NCT03915015|Other|the study|Patients with a PPM or ICD getting a clinically indicated MRI
16409149|NCT03915002||Patients|"Steatohepatitis:
~Alcoholic Steatohepatitis and Alcoholic liver disease
~Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)"
16409150|NCT03915002||Disease control|Patients 18 years or older with a diagnosis of cholestatic liver diseases (primary biliary cholangitis or primary sclerosing cholangitis) or hepatotropic virus (hepatitis C or B virus), according to the current international guidelines.
16409151|NCT03915002||Control subjects|"Patients over 18 years old without a diagnosis of liver disease that for any other reason (i.e candidate to liver donor, patients with liver metastasis that require surgery, patients with any type of benign liver tumor or HCC in a healthy liver).
~Patient over 18 years old with a documented alcoholic used disorder in their clinical records and without any evidence of liver disease."
16409152|NCT03914989|Experimental|Experimental group|Individuals in this group receive exposure to a higher concentration of essential oil fragrances nightly.
16409153|NCT03914989|Placebo Comparator|Active control group|Individuals in this group receive exposure to a lower concentration of essential oil fragrances nightly.
16409154|NCT03914976||patient who will have a high risk digestive surgery|patient who will have a high risk digestive surgery: esophagectomy, major hepatectomy> 3 segments, duodeno cephalic pancreatectomy
16409155|NCT03914963|Experimental|Fibrin sealant treatment hemipelvis|•Drug: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis).
16409156|NCT03914963|Placebo Comparator|Control hemipelvis|Other hemipelvis
16409194|NCT03914690|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
16414234|NCT03879928|Experimental|FM101 600 mg for SAD|Single ascending doses of FM101
16409157|NCT03914950|Other|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen < 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x
~Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range
~1 x 500 ml water oral, 1 x
~Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
16409158|NCT03914937||Intervention Group: Virtual Reality|Patients will wear a virtual reality device in addition to standard lidocaine/novocaine numbing agent
16409159|NCT03914937||Control Group: Music|Patients will listen to music in addition to standard lidocaine/novocaine numbing agent
16409160|NCT03914924|Active Comparator|Exercise Program|Ex: The participants will be submitted to only exercise sessions for 12 weeks.
16409161|NCT03914924|Experimental|Exercise and Lifestyle Education Program|ExLE: The participants will be submitted to exercise sessions and education classes for 12 weeks.
16409162|NCT03914911|Experimental|Study Arm|The radiologist will perform a routine ultrasonic guided biopsy procedure using the Smart Biopsy Device, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
16409163|NCT03914898|Experimental|Nurse led intervention group|"The program was four sessions; It took about 1.5-2 hours. The intervention group was divided into two groups. The author who administered the intervention previously led nurse support groups, is also an active educator in psychiatry and mental health nursing, and has training in cognitive behavioral therapy.
~The group sessions were based on cognitive restructuring techniques."
16409164|NCT03914898|No Intervention|Control Group|No intervention was applied to the control group during the study.
16409165|NCT03914859|Other|Exposed|Urinary level of 1-hydroxypyrene, the most sensitive biomarker of PAH exposure greater than 0.1 μmol / mol creatinine
16409166|NCT03914859|Other|Not exposed|Urinary level of 1-hydroxypyrene, the most sensitive marker of PAH exposure below 0.1 μmol / mol creatinine
16409167|NCT03914846|Experimental|Cohort I (ultrasound)|Patients with skin lesions undergo at least 1 ultrasound during the consultation. Patients may undergo at most 2 additional scans after the standard of care approach for non-malignant lesions at the discretion of the radiation oncologist and/or dermatologist.
16409168|NCT03914846|Experimental|Cohort II (ultrasound)|Skin cancer patients who undergo surgery or radiation undergo 2-5 ultrasounds over a 1 year period (a baseline ultrasound scan may be performed prior to treatment, followed by 1 scan during and/or after radiation, and additional ultrasounds may be conducted [at the discretion of the treating physician] upon completion of radiation and/or surgery, at approximately 1, 6, and 12 month follow-up examinations).
16409169|NCT03914846|Experimental|Cohort III (ultrasound)|Participants with inflammatory skin disorders (psoriasis, eczema, alopecia, acne) undergo ultrasound at baseline and follow-up visits.
16409170|NCT03914833||Patients|Patients aged 13 to 25 years old with a concussion in sports practice less than 72 hours previously
16409171|NCT03914833||Control - High-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
16409172|NCT03914833||Control - Non-high-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
16409173|NCT03914820|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
16409174|NCT03914820|Active Comparator|Comparator|Standard surgey without HIPEC CO2
16409175|NCT03914807|Active Comparator|Whole (3.25%) milk|
16409176|NCT03914807|Active Comparator|Reduced fat (1%) milk|
16409178|NCT03914781|Experimental|SPIN-SELF program|Offered access to the online SPIN-SELF program in addition to usual care
16409179|NCT03914781|No Intervention|Not Offered the SPIN-SELF program|Usual care
16409180|NCT03914768|Experimental|Immunomodulatory DC vaccine to target DIPG and GBM|Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.
16409181|NCT03914755|Experimental|Cohort 1|50 mg twice daily on Days 1-13 and once daily on Day 14
16409182|NCT03914755|Experimental|Cohort 2|150 mg twice daily on Days 1-13 and once daily on Day 14
16409183|NCT03914755|Experimental|Cohort 3|300 mg twice daily on Days 1-13 and once daily on Day 14
16409184|NCT03914742|Experimental|Phase 1: Dose Finding|"Recurrent IDH1/2-mutant grade II-III glioma: BGB290: Days 1-28, 60 mg PO BID TMZ: Days 1-28, 20 QD starting dose
~TMZ de-escalated treatment schedule if necessary (days 1-21; days 1-14; days 1-7) BGG held constant at 60mg PO BID"
16409185|NCT03914742|Experimental|Phase 2: Arm A Alkylator-resistant|"Grade II-III: Recurrent IDH1/2-mutant glioma (WHO grades II/III) who have failed TMZ AND another alkylator
~BGB290 + TMZ at dose combination established in Phase 1"
16409186|NCT03914742|Experimental|Phase 2: Arm B NOT Alkylator-resistant|"Grade II-III:Recurrent IDH1/2-mutant glioma (WHO grades II/III) Failed TMZ OR another alkylator;
~>/=12 months since last treatment
~BGB290 + TMZ at dose combination established in Phase 1"
16409187|NCT03914742|Experimental|GBM Arm|Exploratory grade IV patients only BGB290 at Ph II dose for 7 days pre-surgery Progressed following RT + Chemo
16409188|NCT03914742|Experimental|Surgical Arm|Recurrent IDH1/2-mutant glioma (WHO grade II-IV) eligible for re-resection BGB-290: 60mg PO BID for 6 days AND day once day of surgery (day 7)
16409189|NCT03914729|Active Comparator|Primary Closure|After pilonidal sinus is excised, subcutaneous fat and skin are closed in midline with a running suture
16409190|NCT03914729|Active Comparator|Gluteus Maximus Plasty Flap|After pilonidal sinus is excised, gluteus maximus fascia flaps will be mobilised, approximated in the midline and fixed with a running suture. Subcutaneous fat and skin are closed in midline with a running suture.
16409191|NCT03914703||EZ Pass Suture Passer|Patients who have surgery using the EZ Pass Suture Passer Instrument either in rotator cuff or soft tissue repair
16409192|NCT03914703||Precision Flexible Reamer|Patients who have surgery using the Precision Flexible Reamer Instrument in ACL repair
16409193|NCT03914690|Experimental|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
16414235|NCT03879928|Experimental|FM101 1200 mg for SAD|Single ascending doses of FM101
16409195|NCT03914677|Experimental|Mecamylamine Oral Tablet|Initial dose - mecamylamine 2.5 mg tablet po 3 hours prior to provocative testing; subsequent dose escalations as needed, to 5 mg and then 7.5 mg, using the same testing methodology.
16409196|NCT03914664||Tourette Syndrome|Adults (>18 years of age) with diagnosis of Tourette syndrome
16409197|NCT03914664||Healthy Control|Adults who are generally healthy with no known neurologic or psychiatric diagnoses
16409198|NCT03914651|Active Comparator|300IU rFSH stimulation group|300IU rFSH stimulation group is defined as patients using gonadotropin-releasing hormone（GnRH）antagonist protocol with a 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation.
16409199|NCT03914651|Experimental|150IU rFSH stimulation group|150IU rFSH Gonal-F® stimulation group is defined as patients using GnRH antagonist protocol with a 150IU rFSH starting dose during controlled ovarian stimulation.
16409200|NCT03914638|Experimental|Active|Active intervention arm. Treatment for 8 weeks per treatment period.
16409201|NCT03914638|Placebo Comparator|Placebo|Placebo arm. Treatment for 8 weeks per treatment period.
16409211|NCT03914599||Neurological Disorder|For all neurological disorder participants an electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy. For participants with a diagnosis of Charcot Marie Tooth (CMT) disease, they will have an additional Neuropathy Score to assess disease severity.
16409212|NCT03914599||Healthy Control|An electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy.
16409213|NCT03914586||Septic patients with AKI|Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.
16409214|NCT03914547|Experimental|REDCHiP|REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.
16409215|NCT03914547|Active Comparator|ATTN|ATTN uses 10- video-based telemedicine sessions to deliver general patient education specific to young children. Similar to REDCHiP, all ATTN sessions last 45-60 minutes.
16409216|NCT03914534|Experimental|Test Formulation of Valproic Acid|Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2
16409217|NCT03914534|Active Comparator|Reference Formulation of Valproic Acid|Valcote tablets 500 mg Single dose administered in dosing period 1 or 2
16409218|NCT03914508|Experimental|Memory + Behavioral Weight Loss (M+BWL)|The M+BWL program will integrate memory interventions to the BWL program. The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
16409219|NCT03914495|Placebo Comparator|Placebo|Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
16409220|NCT03914495|Active Comparator|Inulin|Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
16409221|NCT03914482|Other|Patients at risk of FLD|Patients who choose to participate in the study that meet the inclusion criteria
16409222|NCT03914469|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
16409223|NCT03914469|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
16409224|NCT03914456|Experimental|Body Weight Supported Treadmill Training|"The rehabilitation program consisted of five hours per day of the treatment, five times a week for two months (40 sessions). The treatment protocol included kinesiotherapy (passive and active mobilizations, muscle lengthening), BWSTT, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training. The duration of each event was approximately one hour.
~The initial time of the treatment on the BWSTT was 20 minutes, and the modification of the time depended on the endurance and capability of each patient. Training charge began at 40% body weight supported and at treadmill speeds of at least 1.5 km per hour. The treadmill speed was increased progressively to 2.5 km per hour, and the level of weight supported was adjusted within sessions to achieve knee extension."
16409225|NCT03914443|Experimental|Cohort A|"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
16409226|NCT03914443|Experimental|Cohort B|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
16409227|NCT03914443|Experimental|Cohort C|"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
16409228|NCT03914443|Experimental|Cohort D|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
16409229|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured dairy|
16409230|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured non-dairy|
16409231|NCT03914430|Experimental|Water|Energy-free control
16409232|NCT03914417|Experimental|Imiquimod 3.75% cream|applied topically
16409233|NCT03914404|Experimental|Test group|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.
~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
16409234|NCT03914404|Experimental|Control Group|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.
~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
16409235|NCT03914378||Discovery Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
16409236|NCT03914378||Discovery Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
16409237|NCT03914378||Validation Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
16409238|NCT03914378||Validation Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
16409239|NCT03914365|Active Comparator|Ultrasound-guided pudendal nerve block (PNB)|"Standard circumcision under general anaesthesia with ultrasound-guided pudendal nerve block.Pudendal nerve block patients will be positioned dorsally with the legs in the  frog  position (hips in abduction, knees flexed, sole of the feet together). An ultrasound-guided technique will be used as described previously. A linear probe will be positioned horizontally between the ischiatic tuberosity and the rectum. The ischiorectal fossa is then located between these two landmarks. Using a sterile tech-nique, an echogenic 22 gauge, 50 mm block needle will be inserted out of plane on the superior edge of the probe, midline between the ischiatic tuberosity and the rectum. After feeling two distinct fascial  clics  and confirmation of correct needle posi-tioning in the ischiorectal fossa under ultrasound, 0,2 mL/kg (max 10mL) of ropiva-caine 0,25% will be injected under real-time ultrasound-guidance after negative aspiration. The same technique will be repeated on the contralateral side."
16409240|NCT03914365|Active Comparator|Ultrasound-guided penile nerve block (DPNB)|Standard circumcision under general anaes-thesia with ultrasound-guided penile nerve block.Penile nerve block patients will be positioned in the supine position. An ultrasound-guided technique will be used as described previously. A linear probe will be placed transversely at the base of the penis while an assistant applies caudal traction to the penis. The penile neurovascular sheath is then located just above the corpus cavernosum. The dorsal penile nerve, dorsal penile artery and penile deep dorsal vein are visualized deep to Buck's fascia. Using a sterile technique, a 25 gauge, 1,5 inch needle will be inserted in-plane from lateral to medial so that the needle tip is placed into the penile neurovascular sheath, 0,1 mL/kg (max 4 mL) of ropivacaine 0,25% will be injected under real-time ultrasound guidance while retracting the needle so that the local anaesthetic solution spreads bilaterally filling the neurovascular space.
16409241|NCT03914352|Experimental|PD-1 antibody group|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
16409242|NCT03914352|Active Comparator|Controlled group|In this group entrolled patients were treated with TACE in the 30 days after hepatic resection.
16409243|NCT03914339|Experimental|Test group|Eighteen periodontally compromised patients who will be given both orthodontic and periodontal treatment .
16409244|NCT03914339|Active Comparator|control group|Eighteen periodontally compromised patients will receive periodontal treatment alone .
16409245|NCT03914326|Experimental|Oral semaglutide|One tablet daily for 3.5 to 5 years
16409246|NCT03914326|Placebo Comparator|Placebo|One tablet daily for 3.5 to 5 years
16409247|NCT03914313|Experimental|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat Pro, in which the exoskeleton device is equipped with a VR screen. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Lokomat will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
16409248|NCT03914313|Active Comparator|Robotic treatment without VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Nanos, in which the exoskeleton device is equipped with a screen with a visual feedback (but not virtual reality). The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Nanos will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
16409315|NCT03913832|Active Comparator|paclitaxel releasing coronary balloon catheter.|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter
16409249|NCT03914313|Active Comparator|Conventional treatment|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a conventional gait rehabilitation. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Beside conventional overground training for gait, motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
16409251|NCT03914287|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
16409252|NCT03914287|No Intervention|Control|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
16409253|NCT03914274|No Intervention|"Thermometer FTN Medisana, precision 0.18º C),"|"Temperatures were taken with an infrared thermometer FTN Medisana, precision 0.18º C.
~The temperature will be taken into account to see if it will vary according to the socket used as the temperature is a favoring element of dermic injuries on the feet."
16409254|NCT03914274|No Intervention|Non-elastic tape measure|"Perimeter was measured with a flexible, non-elastic tape measure Lawton 18-0160, precision 1 mm.
~The measurement of the feet perimeters will be taken into account to see if it will vary according to the socket used and related to injuries in the feet."
16409255|NCT03914274|No Intervention|Bascule|"Weight was measured using scales (Tanita UM-076, precision 0.1kg). The scale is used to control the weight of the participants in order to find out their body mass index since the weight can influence the appearance of lesions on the feet."
16409256|NCT03914274|No Intervention|Altimeter|"Height was measured using the weight rod of different scales SECA 704, precision 1 mm) The altimeter is used to measure the participants in order to find out their body mass index."
16409257|NCT03914274|Experimental|Socks|"Socks were of two types: technical socks, designed for high performance sports use Lurbel brand, models Tierra and Set, and non-technical socks for everyday use. The socks had different composition: Tierra:50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra; Set:75% cotton, 17% polyamide, 8% lycra and cotton: 98% cotton, 2% elastane.
~Different socks were given to the participants to see if the different compositions influenced the appearance of injuries in a short route route and little difficulty"
16409258|NCT03914274|No Intervention|"Geographical Position System Garmin ETREX 20"|"The height range and the pace hikers were controlled with a Garmin ETREX 20X Geographical Position System"
16409259|NCT03914248||Active large vessel vasculitis|PET/MR scan
16409260|NCT03914235|Experimental|Tumescent anesthesia|A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
16409261|NCT03914235|Active Comparator|Local anesthesia with tourniquet.|"Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
~At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery."
16409262|NCT03914222|Other|CardioSpire Device|Patients blows into Respirix device or uses BIPAP machine for a few breaths solely to obtain signal.
16409263|NCT03914209||EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
16409264|NCT03914183|Other|Control|Standard of care arm - using insulin pen needles as previously prescribed
16409265|NCT03914183|Active Comparator|mCPN intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:
~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles."
16409316|NCT03913819||substance abuse group|Patients with voiding dysfunction secondary to substance abuse in a special clinic
16409266|NCT03914157|Active Comparator|15 patients with ARAS randomized to SWT|We will study 15 patients with ARAS randomized to SWT twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography [MDCT]), oxygenation, and fibrosis (magnetic resonance imaging [MRI]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
16409267|NCT03914157|Sham Comparator|15 patients with ARAS sham|we will study 15 patients with ARAS randomized to or sham twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography [MDCT]), oxygenation, and fibrosis (magnetic resonance imaging [MRI]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
16409268|NCT03914144||Normal Vaginal Delivery|The group of patients who achieved a normal delivery will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
16409269|NCT03914144||Insturmental Vaginal Delivery|The group of patients who underwent instrumental delivery (ventouse or forceps) will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
16409270|NCT03914144||Emergency Caesarean Section|Each patient will be recorded how many catheter episodes occurred during their labour and delivery.
16409271|NCT03914144||Elective Caesarean Section|We expect all patients in this group to have an indwelling catheter sited before their elective caesarean sections, however we will assess each patient individually to confirm whether they had a catheter for their delivery.
16409272|NCT03914131|Experimental|study group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.
~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.
~Dosage form:Capsule"
16409273|NCT03914131|Placebo Comparator|control group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.
~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.
~Dosage form:Capsule"
16409274|NCT03914118|Active Comparator|Preoperative modafinil + postoperative placebo|
16409275|NCT03914118|Active Comparator|Preoperative modafinil + postoperative modafinil|
16409276|NCT03914118|Placebo Comparator|Preoperative placebo + postoperative placebo|
16409277|NCT03914118|No Intervention|Control group|
16409278|NCT03914105|Active Comparator|Without music|Test without music
16409279|NCT03914105|Experimental|With music|
16409280|NCT03914092|Experimental|study group|female patients with vocal fold nodules undergoing intralesional steroid injection
16409281|NCT03914092|Active Comparator|control group|female patients with vocal fold nodules undergoing Smith Accent voice therapy
16409282|NCT03914066|Experimental|Group treatment in primary care|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
16409283|NCT03914040|Experimental|IPSE program|IPSE is conceptually divided in two phases: 1) pre-immersion preparation, 2) immersion.
16409284|NCT03914040|No Intervention|Traditional course|Participants in the control group will receive the current face-to-face course.
16409285|NCT03914027|No Intervention|Control|Patients allocated to the control group will follow the same procedure except for not using tele-rehabilitation.
16409286|NCT03914027|Experimental|Intervention|The intervention is the use of a tele-rehabilitation program during 12 weeks. The patient's training time will be registered automatically. The control group will receive standard treatment only.
16409287|NCT03914014|Active Comparator|intervention|connective tissue manipulation
16409288|NCT03914014|Placebo Comparator|placebo ultrasound|placebo ultrasound
16409289|NCT03914014|No Intervention|control|control group
16409290|NCT03914001|Other|NMIBC patients|eligible patients will undergo initial mpMRI before initial TURBT, then followed by second mpMRI and second resection TURBT after 4 weeks
16409291|NCT03913988|Active Comparator|LUCID DREAMING, STRESS REDUCTION, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:
~Psychoeducation regarding lucid dreaming, stress reduction, and sleep hygiene
~Practice of lucid dreaming induction techniques
~Guided visualization
~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
16409292|NCT03913988|Active Comparator|LUCID DREAMING, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:
~Psychoeducation regarding lucid dreaming and sleep hygiene
~Practice of lucid dreaming induction techniques
~Guided visualization
~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
16409317|NCT03913806|Experimental|Treatment group|Bevacizumab-IRDye800CW
16409318|NCT03913793|Active Comparator|Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction with peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
16409293|NCT03913988|Active Comparator|SLEEP HYGIENE|"This group will meet for 2 online group sessions and 4 email communications. The 2 online group sessions will each last 1 hour and occur in weeks 1 and 12. The 4 email communications will occur in weeks 3, 5, 7, and 9 and consist of individual communication between each participant and the PI or co-investigator. Each email communication will require 10 minutes of participants' time.
~The control group will be asked to engage in Sleep Hygiene techniques in which they adhere to a recommended protocol and record their adherence in a Sleep Hygiene Tracking Log, requiring 5 minutes per day.
~Through the 2 online sessions and the individual email with the investigators, participants will have the opportunity to discuss their experience with adherence to the sleep hygiene program and tracking log. Investigators will help participants trouble shoot problems adhering to the sleep hygiene protocol."
16409294|NCT03913962|Experimental|Patient|Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
16409295|NCT03913962|Active Comparator|Control|healthy children sex- and age-matched
16409296|NCT03913949|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
16409297|NCT03913936|Experimental|NEWLY DIAGNOSED|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.
~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
16409298|NCT03913936|Experimental|SURVIVOR|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.
~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
16409299|NCT03913936|Experimental|LIVING WITH ADVANCED DISEASE|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.
~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
16409300|NCT03913923|Experimental|BCD-217 and BCD-100|Patients will receive 4 blinded infusions of BCD-217 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
16409301|NCT03913923|Active Comparator|BCD-100 monotherapy|Patients will receive 4 blinded infusions of BCD-100 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
16409302|NCT03913910||Lipogems|Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice.
16409303|NCT03913897|Experimental|virtual reality group|The children in the groups were distracted by virtual reality goggles 2 minutes before venipuncture, until the process was over.
16409304|NCT03913897|Experimental|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
16409305|NCT03913897|No Intervention|control group|No intervention was made to children in the control group
16409306|NCT03913884|Experimental|Concentrated growth factor Group|Group I (test); in which CGF fibrin matrix was applied to the extraction socket
16409307|NCT03913884|Experimental|Non-Concentrated growth factor Group|Group II (control); in which CGF was not applied to the extraction socket
16409308|NCT03913871|Experimental|Telephone (text messages) support for healthy eating|Participants will receive average of 1-2 text messages per day for 4 weeks focused on health eating with the aim increasing consumption of fruits, vegetables and water; and a reduce intake of sugar sweetened beverages.
16409309|NCT03913871|Active Comparator|Telephone (text messages) support for physical activity|Participants will receive an average of 1-2 text messages per day for 4 weeks that offer physical activity and general health/wellbeing advice.
16409310|NCT03913858|Other|high-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
16409311|NCT03913858|Other|low-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
16409312|NCT03913845|Experimental|0.5% lidocaine with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
16409313|NCT03913845|Active Comparator|Normal saline with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
16409314|NCT03913832|Experimental|sirolimus drug coated balloon (SCB)|Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)
16453555|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
16409319|NCT03913793|Active Comparator|Non-Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction without peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
16409320|NCT03913793|No Intervention|Control group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction, not enrolled into exercise program.
16409321|NCT03913780|Active Comparator|Group 1 (Medical record)|For group 1, participants do not have intervention as groups 2 and 3. This group consists of reviewing the medical history of the year 2000 to determine the variables of the study and then compare them with groups 2 and 3. This group of participants they were from the year 2000 and whose information will be strictly taken from their medical history was based on initial training with warm-up and walking, after that, aerobic training was performed from 50 to 70% of their maximum heart rate and they finished their session training with breathing exercises, coordination, balance and walking.
16409322|NCT03913780|Experimental|Group 2: Aerobic exercise + Strength training in MMSS|"For group 2, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more strength exercises for upper limbs with dumbbells, multi-strength equipment and Theraband.
~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
16409323|NCT03913780|Experimental|Group 3: Aerobic exercise + Strength training in MMII|"For group 3, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more the strength training for lower limbs with theraband, multi-strength equipment and exercises for activation of the sole-twin pump.
~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
16409324|NCT03913754||Lupus Patients with kidneys failure|Assessment of quality of life on everydays life trough questionnare
16409325|NCT03913754||Lupus Patients without kidneys failure|Assessment of quality of life on everydays life trough questionnare
16409326|NCT03913741|Experimental|Experimental tisotumab vedotin|Open label, single arm trial where tisotumab vedotin will be administered
16409327|NCT03913728|Experimental|Outcome of blood test provided|These patients are given the results of their drug level blood tests and treatment can be altered/ further advice can be provided as a result of this.
16409328|NCT03913728|No Intervention|Outcome of blood test not provided|The blood results for these people are not fed back to the patient or the clinical site.
16409329|NCT03913728|Experimental|Patients have a telephone interview|All patients are randomised for a second time; 20% (10) of them will have a semi-structured phone interview
16409330|NCT03913728|No Intervention|No telephone interview|All patients are randomised for a second time; 80% won't have a phone call and this will be as per standard care.
16409331|NCT03913715|Active Comparator|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
16409332|NCT03913715|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient.
16409333|NCT03913702|Active Comparator|Ketorolac|Assigned patients will receive a subacromial injection of ketorolac 60mg (2ml + 8ml lidocaine 1%)
16409334|NCT03913702|Active Comparator|Methylprednisolone|Assigned patients will receive a subacromial injection of methylprednisolone 80mg (1ml + 9ml lidocaine 1%)
16409335|NCT03913689|Other|StimRouter Neuromodulation System|Implant of the Bioness StimRouter Neuromodulation System in subjects with chronic pain of peripheral nerve origin
16409336|NCT03913676|Experimental|Velibra|All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).
16409337|NCT03913663|Active Comparator|study group|20 patient with hemineglect, minimum 6 months post stroke
16409338|NCT03913663|Active Comparator|control group|20 patient with hemineglect, minimum 6 months post stroke
16409339|NCT03913650|Active Comparator|Nerve block(+)|patient accept nerve block for post-op pain control
16409340|NCT03913650|Sham Comparator|Morphine|patient received morphine for post-op pain control
16409341|NCT03913637|Experimental|Strategy Training|In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
16409342|NCT03913637|Active Comparator|Enhanced Usual Care|Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
16409373|NCT03913364|Experimental|Experimental Obese mothers|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
16409343|NCT03913624|Experimental|50 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 50 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
16409344|NCT03913624|Experimental|35 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
16409345|NCT03913624|No Intervention|Control group|Conventional treatment
16409346|NCT03913611|Other|Traditional Rehabilitation|In this arm, patients will undergo the standard rehabilitation protocol, with sling use for 6 weeks.
16409347|NCT03913611|Experimental|Accelerated Rehabilitation|In this arm, patients will undergo the accelerated rehabilitation protocol, with no sling use outside the immediate postoperative period.
16409348|NCT03913585|Experimental|Lifestyle intervention|The intervention group comprises ~4800 patients born 1959-1988, living in the municipalities of Haderslev or Middelfart, and affiliated to one of the participating GPs. No control group is included.
16409349|NCT03913572||REVOLVE|Patients that have agreed to be prospectively enrolled in the study and undergo Injection of adipose-derived stem cells into perianal fistula with the REVOLVE system
16409350|NCT03913572||Retrospective cohort|Patients that have undergone treatment of perianal disease without use of adipose-derived stem cell injection.
16409351|NCT03913559|Experimental|Inotuzumab ozogamicin|"Experimental:Inotuzumab Ozogamicin (InO) Patients with B cell acute lymphoblastic leukemia (B-ALL) that is showing early signs of relapsing (coming back) or is not responding to treatment (refractory).
~Interventions:methotrexate, hydrocortisone and cytarabine into the central nervous system (called triple intrathecal chemotherapy or IT chemotherapy) during this study.
~Premedication: diphenhydramine, acetaminophen and methylprednisolone"
16409352|NCT03913546|Sham Comparator|Sham spinal manipulation|Participants in the 'sham' group will receive a sham mechanical thrust (force set at level 0) instead of an actual one. In the force level 0, no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition. Therefore, the subject does not distinguish between intervention or placebo.
16409353|NCT03913546|Experimental|Actual spinal manipulation|Participants in the actual actual spinal manipulative therapy (SMT) group will be assessed through the Activator basic method. SMT will be performed with the Activator IV Adjusting Instrument (Activator Methods International, Phoenix, AZ) varying the force level depending on the adjusted segment.
16409354|NCT03913533|Active Comparator|Control group|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
16409355|NCT03913533|Experimental|Intervention group|Heart rate assessment using Tap-based smartphone application At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
16409356|NCT03913520|Other|Congenital Heart Disease|Undergoing evaluation at 30 days
16409357|NCT03913507|Experimental|one group : patients with suspicion of cystic fibrosis|
16409358|NCT03913494|Experimental|4 Week Snoozeal Use|Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
16409359|NCT03913481|Experimental|ANH|Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
16409360|NCT03913481|Other|Standard care|No ANH
16409361|NCT03913468||Received Ascorbic Acid IV|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who were treated within the first 24 hours of admission with the combination of IV ascorbic acid, IV thiamine, and IV hydrocortisone, with a duration of 4 days or until patient leaves the ICU.
16409362|NCT03913468||Control Group|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who did not receive any treatment with IV ascorbic acid.
16409363|NCT03913455|Other|Guadecitabine and Carboplatin|Each cycle = 28 days; Subjects receive 4 cycles
16409364|NCT03913442|Placebo Comparator|Placebo|Placebo in capsule identical to study drug
16409365|NCT03913442|Experimental|Colchicine|"0.6 or 0.8 mg orally once daily.
~Because recent studies suggest that a dose of 0.6mg may be sufficient for chronic inflammatory suppression and may reduce the already low risk of toxicity of 0.8mg, for the remainder (second half) of the study the dosage will be switched from 0.8mg to a 0.6mg dose to allow comparison of the two doses."
16409366|NCT03913429|Active Comparator|Control Group|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.
~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml."
16409367|NCT03913429|Experimental|Study Group|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.
~A total of 5ml of Ropivacaine 0.37% infiltrated on each side."
16409368|NCT03913416|Experimental|3D|Surgery with surgeon trained using a 3D printed model of the pulmonary malformation.
16409369|NCT03913416|Other|Control group|Conventional surgery without training using a 3D printed model of the pulmonary malformation.
16409370|NCT03913403||Intervention|Participants will receive 2 ECHO's and 2 Blood Draws
16409371|NCT03913377|Experimental|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
16409372|NCT03913377|Experimental|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
16409374|NCT03913364|Placebo Comparator|Placebo Obese mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
16409375|NCT03913364|Experimental|Experimental normal weight mothers|One portion (50g) of an ice-cream containing B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
16409376|NCT03913364|Placebo Comparator|Placebo normal weight mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
16409377|NCT03913351|Experimental|Lifestyle modification program|The dietary intervention program will be scheduled for 12 months, and conducted by a dietitian.The program aims to increase energy expenditure and reduce caloric intake, with an emphasis on long-term lifestyle and behavioural change. An exercise instructor will provide advice on physical activity. A mobile tracking device to monitor calories expenditure will be provided to each participant during they study period to encourage physical activity.
16409378|NCT03913351|No Intervention|Control|standard care of treatment, as in routine clinical practice
16409379|NCT03913338|Other|Study group|LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.
16409380|NCT03913338|Other|Control group|LASIK only
16409381|NCT03913325|Experimental|PREVSAM model|
16409382|NCT03913325|Active Comparator|Treatment as usual|
16409383|NCT03913312|Experimental|DAC combined with unrelated cord blood transplantation|Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC>1.5*107/kg), d0.
16409384|NCT03913286|Experimental|Intervention|The participant will be implanted with the Blackrock Microsystems MultiPort system.
16409385|NCT03913273|Experimental|Intervention group|Intervention: AMI transtibial amputation
16409386|NCT03913273|Active Comparator|Control group|Intervention: Standard transtibial amputation
16409387|NCT03913260|Experimental|Part A: LY3375880 Formulation A|LY3375880 Formulation A administered subcutaneously (SC).
16409388|NCT03913260|Experimental|Part A: LY3375880 Formulation B|LY3375880 Formulation B administered subcutaneously SC.
16409389|NCT03913260|Experimental|Part A: LY3375880 Formulation C|LY3375880 Formulation C administered SC.
16409390|NCT03913260|Placebo Comparator|Part A: Positive Control|Positive Control (buffer matrix, only) administered SC.
16409391|NCT03913260|Experimental|Part B: LY3375880 Test 1|LY3375880 Test 1 Formulation administered SC.
16409392|NCT03913260|Experimental|Part B: LY3375880 Test 2|LY3375880 Test 2 Formulation administered SC.
16409393|NCT03913260|Experimental|Part B: LY3375880 Test 3|LY3375880 Test 3 Formulation administered SC.
16409394|NCT03913247||Group with different size measures|Each patient included in the study will have different measure of size.
16409395|NCT03913234|Experimental|Combination of Letrozole, Trastuzumab with Ribociclib|Phase IB (dose escalation of ribociclib with fixed dose of letrozole and Ribociclib) Phase II (ribociclib of RPIID with fixed dose of letrozole and ribociclib)
16409396|NCT03913221|Active Comparator|Low Dose Caffeine (5 mg/kg)|Within 24 hours of delivery, participants will receive low dose administration of Caffeine citrate.
16409397|NCT03913221|Active Comparator|High Dose Caffeine (10 mg/kg)|Within 24 hours of delivery, participants will receive high dose administration of Caffeine citrate.
16409398|NCT03913208|Experimental|Study group|Will be subjected to priority to freeze
16409399|NCT03913208|Active Comparator|Control group|Will receive fresh embryo transfere
16409400|NCT03913195|Experimental|Sentinel Group|Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
16409401|NCT03913195|Experimental|Core Group|Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
16409402|NCT03913182|Experimental|apatinib group|apatinib：500mg po Qd
16409403|NCT03913169|Other|Students in Interprofessional Education Curriculum|The interprofessional intervention for the students to be employed in this study will include five modalities in a scaffolded structure progressing from low- to high-fidelity experiences over a two-year period: (1) classroom didactic sessions; (2) simulation laboratory sessions; (3) standardized patient sessions; (4) community-based clinical case conferences; and, (5) community-based interprofessional rotations.
16409404|NCT03913169|Other|Patients Experience with Interprofessional Care|For patients and their families, those who receive care from an Interprofessional team will receive the usual health care they normally receive at the participating clinics. In many cases patients already receive this care, but are unaware of it. Most of what occurs in Interprofessional practice happens outside of the patient encounter. For patients the process is generally invisible, but its affects are felt in terms of better communications with the patient. In this study, patients will be informed as usual about the presence of students as learners and will have the opportunity to decline student involvement in their care. The only difference for the patients and their families will be a request to fill out a survey form on paper indicating their perception of the experience in terms of quality of care and its potential impact on their access to care.
16409405|NCT03913169|Other|Clinician (Preceptor) Interprofessional Education Curriculum|Clinicians will experience many of the same learning experiences as the students, but will differ in the level of education and its focus. Clinicians and faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
16409406|NCT03913169|Other|Faculty in Interprofessional Education Curriculum|Doctor of Osteopathic Medicine and Physician Assistant Faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
16409407|NCT03913156|Other|Part 1|Part 1 of the study will recruit subjects who are about to be introduced to a concentrated phe-free protein substitute (i.e. second stage protein substitute) for the first time.
16409408|NCT03913156|Other|Part 2|Part 2 of the study will recruit subjects who have already been introduced to a concentrated phe-free protein substitute (i.e. have already transferred from phe-free infant formula onto a second stage protein substitute). This group will be included to evaluate the acceptability of the study product in patients who have already moved onto a second stage protein substitute.
16410552|NCT03905122||hemodialysis|to measure the fluid changes by using bioreactance method in hemodialysis group
16409409|NCT03913143|Experimental|Group 1: Dose 1 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
16409410|NCT03913143|Active Comparator|Group 2: Dose 2 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
16409411|NCT03913143|Sham Comparator|Group 3: Sham|Sham Intravitreal Injection (no experimental drug administered), at month 0, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated
16409412|NCT03913130|Experimental|Drug QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
16409413|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 0.3mg dose|Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
16409414|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 1 mg dose|Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
16409415|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 3 mg dose|High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
16409416|NCT03913117|Experimental|PVX-6|Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.
16409417|NCT03913104|Experimental|Medication Abortion Patients|Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
16409418|NCT03913091|Experimental|20 mL 0.5% Bupivacaine HCL|
16409419|NCT03913091|Experimental|Interscalene nerve block with Liposomal + Bupivacaine 0.5%|Administered in an Interscalene block for TSA
16409420|NCT03913078|Active Comparator|Group Fitness|Subjects will be offered several sessions per week of a traditional group fitness program led by a trained group leader.
16409421|NCT03913078|Active Comparator|PlayFit|Subjects will be offered several sessions per week of a modified sports fitness program, led by a trained group leader.
16409422|NCT03913065||Included patients|Cardiac arrest patients from sites participating in the TTM-2 CT-substudy still unconscious 48 hours after cardiac arrest are routinely examined with head computed tomography as soon as possible after inclusion.
16409423|NCT03913052|Experimental|Injection|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine was performed once when the knee joint was in the supine position and the knee was in the extension.
16409424|NCT03913039||transperineal protocol|"Transperineal biopsy approach with avoidance of rectal flora
~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated
~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria
~Multi-antibiotic prophylaxis
~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
16409425|NCT03913039||Traditional biopsy|"Transrectal approach
~Standard 12-core template
~Surgeon-specific antibiotic prophylaxis
~Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
16409426|NCT03913026|Experimental|Main intervention|Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
16409427|NCT03913013|Experimental|FFT with MCC App (FFT-MCC)|Youth in this study arm will receive 12 sessions of FFT (psychoeducation, communication skills training, and problem-solving skills training) with their parents and siblings. They and their parents will make regular mobile app ratings of mood, sleep, family functioning, stress, and perceived criticism. Children and parents will call into a voice-activated phone system and be asked to speak freely for 3-5 minutes about their health and family functioning. They will be guided through 12 lesson plans in which they practice skills such as active listening or identifying prodromal signs of episodes, paralleling what they are learning in sessions. The clinician will be able to set a weekly skill training assignment and observe the family's practice of the skill between sessions. They will adapt session content accordingly.
16409428|NCT03913013|Active Comparator|FFT with App Assessments only (FFT-Assess)|Youth in this condition will receive the same 12 sessions of FFT, but the app will be limited to daily and weekly assessments of their mood, sleep, stress, and family functioning. The app will not provide the skill training offered in the FFT-MCC condition.
16409429|NCT03913000|Experimental|ID-085 single dose|Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
16409432|NCT03912974|Active Comparator|Pretreatment with escitalopram|Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
16409433|NCT03912974|Placebo Comparator|Pretreatment with placebo oral capsule|Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
16409434|NCT03912935|No Intervention|Sniffing position|Subject will be maintained in standard intubation position which is supine position with head elevation with head rest (foam donut).
16409435|NCT03912935|Experimental|Bed up head elevation position|Subject will be maintained at bed up 20-30 degree aiming alignment between the external auditory meatus with sternal notch
16409436|NCT03912922|Experimental|Sit regime|Subjects will follow the sit regime during four days. Each day consists of 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
16409437|NCT03912922|Experimental|Sit less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
16409471|NCT03912636|Active Comparator|Diaphragmatic breathing in healthy volunteers in study1|Healthy volunteers will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
16410553|NCT03905109|Experimental|ABX464|50 mg
16409438|NCT03912922|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours sitting, 1 hour walking, 1 hour standing, 1 hour exercise and 8 hours sleeping. The cycle session will be at approximately 60% maximal power. Exact cycling intensity and duration will be calculated to ensure equal total energy expenditure between the sitting less and the exercise regime.
16409439|NCT03912909|Active Comparator|Phase 1|Empagliflozin 10mg daily or placebo
16409440|NCT03912909|Placebo Comparator|Phase2|Empagliflozin 10mg daily or placebo
16409441|NCT03912896|Experimental|Children with autism spectrum disorder|
16409442|NCT03912857|Experimental|test group|"Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
~Apatinib :250 mg or 375 mg, qd"
16409443|NCT03912844||Liver resection/liver transplantation after SIRT|The cohort consist of patients that have after decision of a multidisciplinary tumorboard received a SIRT tor made them later eligible for following liver resection or liver transplantation.
16409444|NCT03912831|Experimental|KITE-439|"Phase 1A (Dose Escalation): Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-439.
~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-439, at a dose selected based on Phase 1A."
16409445|NCT03912818|Experimental|Cohort II (durvalumab, cis-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Cisplatin 70 mg/m2 on Cycle Day 2, and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
16409446|NCT03912818|Experimental|Cohort III (Durvalumab, carbo-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Carboplatin: AUC 5 on Cycle Day 1 and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
16409447|NCT03912818|Experimental|Cohort I (durvalumab, DD MVAC)|Durvalumab (MEDI4736), at1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Dose Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin (DD MVAC), in 14 day cycles (2 weeks), Methotrexate 30 mg/m2 on Cycle Day 1, Vinblastine 3 mg/m2 on Cycle Day 2, Doxorubicin 30 mg/m2 on Cycle Day 2 and Cisplatin 70 mg/m2 on Cycle Day 2. Patients undergo cystectomy within 6 weeks.
16409448|NCT03912805|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
16409449|NCT03912805|Experimental|ET-01|botulinum toxin, Type A, topical liniment, administered once at baseline
16409450|NCT03912792||XLHED Patients|
16409451|NCT03912792||Healthy Controls|
16409452|NCT03912779|Experimental|C2Hear RLOs|C2Hear RLOs (https://www.youtube.com/C2HearOnline): nine (custom earmould) or eight (open fit hearing aid) multi-media learning clips covering practical and psychosocial components of owning a hearing aid, alongside user testimonials (n= 7). Participants asked to watch all relevant to their prospective hearing aid coupling (custom earmould or open fit), with no limit on number of views. A paper diary documented usage during the study duration.
16409453|NCT03912779|Placebo Comparator|Printed hearing aid booklet|A 32-page printed A5 colour booklet, designed and written by local Audiology staff, supplied to all prospective hearing aid owners at the study centre as standard care. Same booklet supplied irrespective of hearing aid style (custom/open fit). All content conveyed via text and supporting pictures only. Participants assigned to the placebo comparator were asked to read the booklet once. A paper diary documented usage during the study duration.
16409454|NCT03912766||Transurethral Prostatectomy|male patients undergoing transurethral prostatectomy (TURP) for benign prostatic hyperplasia, routine surgical removal using resectoscope
16409455|NCT03912753|Experimental|Comunică|Comunică is delivered over eight 60-min live chat sessions, delivered by trained psychologists, on our mHealth study platform compatible with any mobile device (laptops, smartphones).
16409456|NCT03912753|Active Comparator|Education Attention Control (EAC)|"The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.Topics include 1) GBM identity, 2) HIV 101, 3) HIV/STI testing, 4) alcohol and the body, 5) the role of alcohol in HIV risk, 6) HIV-status disclosure and sexual health communication, 7) finding social supports, and 8) summary. EAC participants will receive five quiz questions after each module, with correct answers in a following screen."
16409457|NCT03912740|Active Comparator|Remifentanil Analgesia|Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
16409458|NCT03912740|Active Comparator|Remifentanil and Dexmedetomidine Analgesia|Continuous intraoperative analgesia with remifenanil + dexmedetomidine
16409459|NCT03912727|Experimental|Alpha-lipoic acid|18 patients will receive alpha lipoic acid (thiotacidR) product with their standard therapy.
16409460|NCT03912727|Placebo Comparator|Control|18 patients will receive their standard therapy only.
16409461|NCT03912714|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy in therapy refractory ulcerative colitis patients after pre-operative endoscopic biopsies of the appendix
16409462|NCT03912714|Active Comparator|Non-active UC|Patients with non-active ulcerative colitis planned for surveillance colonoscopy will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
16409463|NCT03912714|Active Comparator|Healthy control|'Healthy control' patients (i.e. patients planned for colonoscopy for polyps) will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
16409464|NCT03912688|Experimental|single acupoint stimulation|
16409465|NCT03912688|Experimental|dual acupoints stimulation|
16409466|NCT03912688|No Intervention|no stimulation|
16409467|NCT03912675|Experimental|RigeneraTM protocol|Teatment with Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol.
16409468|NCT03912675|Experimental|Control|Treatment with Integra® dermal substitute only.
16409469|NCT03912662|Other|Hernia prevention cohort|
16409470|NCT03912649|Experimental|RemovAid arm|"RemovAid arm -
~All subjects have their implant removed by the RemovAid device"
16409579|NCT03911947|Active Comparator|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
16409472|NCT03912636|Active Comparator|Diaphragmatic breathing in rumination patients in study1|Rumination patients will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
16409473|NCT03912636|Active Comparator|Deep slow breathing in healthy volunteers in study1|Healthy volunteers will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
16409474|NCT03912636|Active Comparator|Deep slow breathing in rumination patients in study1|Rumination patients will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
16409475|NCT03912636|Placebo Comparator|Normal breathing in healthy volunteers in study1|healthy volunteers will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
16409476|NCT03912636|Placebo Comparator|Normal breathing in rumination patients in study1|rumination patients will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
16409477|NCT03912636|Active Comparator|Diaphragmatic breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
16409478|NCT03912636|Active Comparator|Deep slow breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
16409479|NCT03912623|Active Comparator|3 weeks SPA Treatment|"3-week thermal cure:
~Spa treatment harmonized in the different stations
~Therapeutic education workshops and conferences common to all stations in the form of practical workshops during supervised lunches
~Adapted physical activity, workshops are common to all spas and use an electric bike suitable for health (VELIS) with briefing and debriefing. An APA (Adapted Physical Activity) coaching consultation at the end of the cure for personalized post-cure programs and objectives is planned as well as a telephone or internet coaching during the 5 months post-cure (objectives and adaptation, motivation)
~Maintenance of the usual treatment within 6 months post randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by the software Diascope and / or HAS
~Information booklet for inclusion (French Association of Diabetics)"
16409480|NCT03912623|Sham Comparator|Discovery week end|"Maintenance of usual treatment within 6 months post-randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by Diascope and HAS software In addition, a discovery access to the baths of 2-3 days will be offered to patients. Finally, the information booklet on diabetes will be given at the inclusion (French Federation of Diabetics)."
16409481|NCT03912610||Health control group|5 health volunteer are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
16409482|NCT03912610||Knee osteoarthritis group|5 patients of knee osteoarthritis accompanied with depression or anxiety are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
16409483|NCT03912597|Experimental|Virtual Reality [A]|Participants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
16409484|NCT03912597|Active Comparator|Brochure Waitlist Control [A]|Participants read an informational brochure about depression, then answer post-intervention questionnaires. After that, they will be given a chance to watch the VR video at the end of their participation session.
16409485|NCT03912597|Active Comparator|Standard Video Control [B]|Participants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
16409486|NCT03912597|Experimental|Virtual Reality [B]|Participants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
16409487|NCT03912584|Other|Optical Coherence Tomographer|
16409488|NCT03912571||Mild Cognitive Impairment (MCI)|Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
16409489|NCT03912571||Normal Cognition (NL)|Clinical Dementia Rating [CDR] of 0 or Global Deterioration Scale [GDS] of 1-2
16409490|NCT03912558|Experimental|Butterfly device implantation|"Butterfly device implantation will be performed following initial cystoscopy to evaluate prostate condition and rule out other pathologies.
~Following implant size selection, the Butterfly implant will be deployed and positioned through the cystoscope over-sheath. After deployment the cystoscope (with its optics) will be re-introduced into the urethra to examine the Butterfly device position."
16409491|NCT03912545||Trauma patients|Subjects experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
16409492|NCT03912545||Obstetric hemorrhage patients|Subjects experiencing obstetric hemorrhage such that viscoelastic testing is performed as standard of care is performed to assess coagulopathy.
16409493|NCT03912532|Experimental|NGM282 Dose 1|Administered by subcutaneous injection
16409494|NCT03912532|Experimental|NGM282 Dose 2|Administered by subcutaneous injection
16409495|NCT03912532|Experimental|NGM282 Dose 3|Administered by subcutaneous injection
16409496|NCT03912532|Placebo Comparator|Placebo|Administered by subcutaneous injection
16409497|NCT03912519|Active Comparator|Parallel placement of 16 gauge electrodes|Parallel Group will undergo radiofrequency ablation via the approach described in Spine Intervention Practice Guidelines via 16 gauge electrodes. Specifically, the target nerve will be targeted with a parallel approach so as the electrode lay parallel to the nerves location within the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
16409498|NCT03912519|Active Comparator|Perpendicular placement with 22 gauge electrodes|Perpendicular Group will undergo radiofrequency ablation via the approach described in Spine Intervention Society Practice Guidelines for medial branch blocks, using a 22 gauge electrode. Specifically, the target nerve will be targeted with a perpendicular approach so as the tip of electrode contact the nerve at some point of it course along the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
16409499|NCT03912506||Patient admitted in the ICU for leptospirosis|Patient admitted in the ICU for leptospirosis None intervention was performed according to retrospective design
16409500|NCT03912493|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. The conventional program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
16409501|NCT03912493|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
16409502|NCT03912480|Experimental|Stem cells from human exfoliated teeth|"Basic treatment:
~The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).
~Stem cell therapy:
~Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .
~Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment.
~Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed."
16409503|NCT03912454|Experimental|BMAC Injection|
16409504|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 1|
16409505|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 2|
16409506|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 3|
16409507|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 4|
16409508|NCT03912428|Other|Single arm|all groups get the same studies
16409509|NCT03912415|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
16409510|NCT03912415|Placebo Comparator|Placebo|
16409511|NCT03912402|Experimental|BCD-100|BCD-100 mg/kg Q3W
16409512|NCT03912389|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
16409513|NCT03912389|Placebo Comparator|Placebo|
16409514|NCT03912376||Healthy Volunteer|Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history.
16409515|NCT03912363|Active Comparator|Rotating fluids|Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
16409516|NCT03912363|Active Comparator|Insulin infusion|Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.
16409519|NCT03912337|Placebo Comparator|Placebo|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
16409520|NCT03912337|Experimental|Erenumab|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
16409521|NCT03912324|Experimental|Unipolar voltage subtraction map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter
~Esophageal temperature will be monitored to prevent esophageal injury
~Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture
~the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)
~Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map
~Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map
~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection
~Evaluate time to complete isolation after additional ablation
~Evaluation of Procedure and Ablation time, and perfusion saline dose
~Rhythm follow-up after the procedure in accordance with the study design."
16409522|NCT03912324|Experimental|CT myocardial thickness map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter
~Esophageal temperature will be monitored to prevent esophageal injury.
~Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.
~Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map
~Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map
~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection
~Evaluate time to complete isolation after additional ablation
~Evaluation of Procedure time, Ablation time, and perfusion saline dose
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16409523|NCT03912324|Active Comparator|Empirical PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter
~Esophageal temperature will be monitored to prevent esophageal injury.
~The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.
~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection
~Evaluate time to complete isolation after additional ablation
~Evaluation of Procedure time, Ablation time, and perfusion saline dose
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16409524|NCT03912285|Experimental|Amlodipine, losartan, and amlodipine plus losartan|"Period 1:
~amlodipine 10mg will be administered orally once a day for 9 days.
~Period 2:
~losartan 100mg will be administered orally once a day for 9 days after 13 days of the washout period.
~Period 3:
~amlodipine 10mg once a day plus losartan 100mg once a day will be administered orally for 9 days after 6 days of the washout period."
16409525|NCT03912272|Placebo Comparator|Usual Care Control|Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend >70% of the classes.
16409580|NCT03911947|Active Comparator|AB (actual bicarbonat level)|Measurment 4 times per day, ABA (acid-bases analyses)
16409581|NCT03911934|Active Comparator|Usual care|Usual care in the geriatric outpatient clinic.
16409526|NCT03912272|Experimental|High-intensity Interval Training Group|HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend >70% of the classes.
16409527|NCT03912259|Experimental|Placebo Q2W|Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (Q2W) for 16 weeks.
16409528|NCT03912259|Placebo Comparator|Dupilumab 300 mg Q2W|Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks.
16409529|NCT03912246|Experimental|Healthy volunteers|"Human biological samples:
~whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.
~Bio-clinical data :
~adjusted to the purpose of the searches will be collected"
16409530|NCT03912246|Experimental|Patients with neuro-meningeal infection|"Human biological samples:
~Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.
~Extended collection of CSF
~Bio-clinical data :
~adjusted to the purpose of the searches will be collected"
16409531|NCT03912233|Experimental|Part 1: F/MF genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive multiple dose levels of VX-121 in TC with TEZ/VX-561.
16409532|NCT03912233|Placebo Comparator|Part 1: Placebo|
16409533|NCT03912233|Experimental|Part 2: F/F genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive VX-121 in TC with TEZ/VX-561
16409534|NCT03912233|Active Comparator|Part 2: Placebo + TEZ/IVA|
16409535|NCT03912220|Experimental|Nicotinamide Riboside|Experimental group of participants will receive Nicotinamide riboside at a dose of 900 mg twice a day orally.
16409536|NCT03912220|Placebo Comparator|Placebo|Study participants in the placebo arm will receive placebo pills that are similar in size and shape to the experimental group drug.
16409537|NCT03912207|Experimental|Group 1, 2 Day Bronchoscopy|Group 1: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 1 volunteers will have a bronchoscopy 2 days post challenge
16409538|NCT03912207|Experimental|Group 2, 7 Day Bronchoscopy|Group 2: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 2 volunteers will have a bronchoscopy 7 days post challenge
16409539|NCT03912207|Experimental|Group 3, 14 Day Bronchoscopy|Group 3: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG (Arm A) and 3 volunteers will receive aerosol inhaled normal saline placebo (Arm B). All Group 3 volunteers will have a bronchoscopy 14 days post challenge Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted. For group 3 volunteers this will be offered after unblinding.
16409540|NCT03912207|Experimental|Group 4, 28 Day Bronchoscopy|Group 4: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 4 volunteers will have a bronchoscopy 28 days post challenge
16409541|NCT03912207|Experimental|Group 5, 56 Day Bronchoscopy|Group 5: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 5 volunteers will have a bronchoscopy 56 days post challenge
16409542|NCT03912207|Experimental|Group 6, Intradermal injection, 14 Day Bronchoscopy|Group 6: 6 volunteers will receive 1 x 10^6 cfu intradermal injection BCG + aerosol saline and will have a bronchoscopy 14 days post challenge All volunteers in group 6 will be offered an optional follow up at 12 months
16409543|NCT03912207|Experimental|Group 7, 14 Day Bronchoscopy|"Group 7: 10 volunteers will receive 1 x 107cfu aerosol inhaled BCG. All Group 7 volunteers will have a bronchoscopy 14 days post challenge.
~Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted"
16409544|NCT03912194|Experimental|Early Withdrawal Exposure plus NAW Regulation Training|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) across the first 4 hours of abstinence over 4 separate sessions.
16409545|NCT03912194|Active Comparator|Early Withdrawal Exposure plus Relaxation Control Training|The development, application, modification, and repeated practice of relaxation strategies across the first 4 hours of abstinence over 4 separate sessions.
16409546|NCT03912194|Active Comparator|NAW Regulation Training Only|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) over 4 separate sessions involving smoking as usual.
16409547|NCT03912194|Active Comparator|Relaxation Control Training Only|The development, application, modification, and repeated practice of relaxation strategies over 4 separate sessions involving smoking as usual.
16409548|NCT03912181||Familial chylomicronaemia syndrome (FCS)|"Patient homozygous or compound heterozygous mutation in lipoprotein lipase (LPL) gene
~Patient homozygous or compound heterozygous mutation in any Apolipoprotein A5 (Apo A5), glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2), genes and heterozygous (het) mutation in LPL gene"
16409549|NCT03912181||Multifactorial chylomicronemia syndrome|"Patient with heterozygous mutation in lipoprotein lipase (LPL) , Apolipoprotein A5 (Apo AV), GPI HBP1, LMF1, ApoC2 genes and any additional combination of functional variant
~Patient with any additional combination of functional variant in LPL gene Apo AV, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2) genes"
16409550|NCT03912168|Experimental|Question Prompt List|
16409551|NCT03912168|Active Comparator|3 questions list|
16409552|NCT03912155||Patients|20 patients per presumed location of the epileptogenic zone (see experimental plan) for a total of 120 patients, including 30 minors. For patients, a MEG-EEG-SEEG examination during the SEEG exploration period.
16409553|NCT03912155||Controles|For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.
16410554|NCT03905109|Placebo Comparator|Placebo|50 mg matching placebo
16409554|NCT03912142||Three dimensional transperineal ultrasound|"This is a single arm study. All women who delivered vaginally will be included in the study .
~The planned interventions are:
~Clinical vaginal and rectal examination Three dimensional transperineal ultrasound."
16409555|NCT03912129|Other|pediatric Evans Syndrome|Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
16409556|NCT03912116|Experimental|Amniotic Umbilical Cord Particulate Injection|100mg Amniotic Umbilical Cord Particulate in 8cc saline
16409557|NCT03912116|Placebo Comparator|Saline Injection|8cc saline
16409558|NCT03912103|Active Comparator|Interdiciplinary medication review intervention|The clinical pharmacist perform medication review and presents medication interventions orally and written to the physician. The physician perform the changes and inform the patient about the changes. 7 days after intervention the patient receives a follow up phone call from the pharmacist about the medication interventions. If the pharmacist during the follow up phone call identify any complications due to compliance/add on/deprescribing the pharmacist uses motivational conversation to come to a solution.14 days after the beginning of the intervention the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire and measured on a Likert scale (1-5). 30 days after the beginning of the intervention the pharmacist collect an updated medication history. Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group.
16409559|NCT03912103|No Intervention|Control group|Standard treatment without a medication review and follow up related to medication changes (standard treatment).14 days after the enrollment the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire measured on a Likert scale (1-5). 30 days after the enrollment the pharmacist collect an updated medication history.Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group
16409560|NCT03912077|Experimental|Culturally Adapted Cognitive Behavioural Therapy|"Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) is an evidence-based psychological intervention manual developed by Devon Hinton, MD from Harvard University and Baland Jalal from University of Cambridge. It is a group therapy protocol that consists of 7 sessions.
~It is a brief, feasible and culturally sensitive intervention that has a transdiagnostical approach. Detailed information about Syrian culture, idioms of stress, cultural differences, and psychological problems that Syrian refugee women have been facing and their needs, expectations and sensitivities are considered in the adaptation process. Examples, cultural metaphors and imageries that take part in the manual are adapted according to Syrian culture."
16409561|NCT03912077|No Intervention|Treatment as Usual|Control arm participants will receive routine social support and/or care according to ordinary practice of the non-governmental organization (treatment as usual). Also, they will receive baseline and post assessments according to the study schedule.
16409562|NCT03912064|Experimental|CD25/Treg-depleted DLI + Ipilimumab|"Ipilimumab is administered intravenously every 12 weeks
~Patients will receive a defined dose of CD25hi Treg depleted DLI intravenoudsly"
16409563|NCT03912051|Experimental|asymmetric balloon|Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon
16409564|NCT03912038||Null or low consumption|No-intervention. The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
16409565|NCT03912038||Moderate consumption|No-intervention. The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
16409566|NCT03912038||High consumption|No-intervention. The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
16409567|NCT03912025||Mild hemodynamic CHD|"Mild severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses, as outlined in the European Society of Cardiology Section on Sports Cardiology consensus guidelines (Budts W, Borjesson M, Chessa M, van Buuren F, Trindade PT, Corrado D, Heidbuchel H, Web G, Holm J, Papadakis M. 2013).
~They define functional parameters such as systolic function, oxygen saturation, rhythm disorders, elevated pressure or volume load, etc. to divide patients into 3 hemodynamic groups. Based on their model, we define mild CHD as ones falling into the group that can train at High Intensity exercise levels."
16409568|NCT03912025||Moderate hemodynamic CHD|"Moderate severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses. Based on their model, we define moderate CHD as those that can train at Moderate Intensity."
16409569|NCT03912012|Other|Children and adolescent with a history of type 1 diabetes|Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
16409570|NCT03911999||Non-prostate cancer subjects|No clinical evidence of prostate cancer
16409571|NCT03911999||Subjects with pathologically insignificant prostate cancer|Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score < 7.
16409572|NCT03911999||Subjects with pathologically significant prostate cancer|Significant cancers are those with either Gleason score > 7, evidences of extra-prostatic extension with positive margins, or seminal vesicles / lymph nodes involvement.
16409573|NCT03911986|Other|Immediate External Loop Recorder|Participants randomized to the Immediate External Loop Recorder group will be monitored for the duration of the first week of the study using the Novacor R-Test 4.
16409574|NCT03911986|Other|Delayed External Loop Recorder|Participants randomized to the Delayed External Loop Recorder group will be monitored for the duration of the second week of the study using the Novacor R-Test 4.
16409575|NCT03911973|Experimental|Talazoparib + Gedatolisib|"Talazoparib + Gedatolisib
~Dose Level -1: Gedatolisib 150mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 1: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 2: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 1.00 mg/orally qd, Days 1-28"
16409576|NCT03911960|Experimental|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
16409577|NCT03911960|Active Comparator|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
16409578|NCT03911947|Active Comparator|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
16410555|NCT03905096|Experimental|Part 1|
16409582|NCT03911934|Experimental|Usual care plus polypharmacy intervention|Usual care in the geriatric outpatient clinic plus polypharmacy intervention. Polypharmacy intervention consists of a medication review by a physician from the Department of Clinical Pharmacology plus additional communication with patients' GPs before and after the visit in the outpatient clinic.
16409583|NCT03911921|Experimental|RSYYT decoction|RSYYT decoction Compound granules of traditional Chinese medicine
16409584|NCT03911921|Experimental|Astragalus membranaceus|one herb decoction Compound granules of one herb (Astragalus membranaceus)
16409585|NCT03911908|Active Comparator|ERC guided CPR (intervention/NIRS group)|CPR protocol according to current ERC guidelines (2015)
16409586|NCT03911908|No Intervention|ERC-based CPR (control group)|modified CPR protocol based on current ERC guidelines (2015), extended by evaluation of NIRS readings and interventions to optimize CPR quality
16409587|NCT03911895||patients with coronary artery diseas undergoing PCI|Effect of stent length on patients with coronary artery undergoing PCI
16409588|NCT03911882||Celergen Administration|The food supplement Celergen was administered to fibromyalgia patients following a protocol of a daily intake for the period of a total of 3 months (90 days)
16409589|NCT03911869|Experimental|Standard Dose Arm|"Patients in the standard-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.
~450 mg encorafenib orally once a day (QD)
~45 mg binimetinib orally twice a day (BID)
~Patients who are able to tolerate the standard dose during the first 4 weeks of treatment (Cycle 1) should be dose-escalated to 600 mg encorafenib QD plus 45 mg binimetinib BID provided they meet protocol-defined criteria."
16409590|NCT03911869|Experimental|High Dose Arm|"Patients in the high-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.
~300 mg encorafenib orally twice a day (BID)
~45 mg binimetinib orally twice a day (BID)"
16409591|NCT03911856|Experimental|Non-invasive assesment techniques|We hypothesize that non-invasive indices of right ventricular RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction pulmonary arterial hypertension and heart failure with preserved ejection fraction(PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
16409592|NCT03911856|Experimental|Efficacy of acute-oxygen therapy during exercise|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing pulse volume recording PVR, increasing RV functional reserve, increasing gas diffusion).
16409593|NCT03911843|Experimental|CASES|Of eligible subjects, 26/64 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
16409594|NCT03911843|Active Comparator|CONTROLS|Others 38/64 subjects joined to the study as data contributors, and were entered as controls (CONTR).
16409595|NCT03911830|Experimental|Exercise followed cold water immersion|Exercise program on cycloergometer and its submerged recovery
16409596|NCT03911817|No Intervention|IV vasopressor|Will receive IV vasopressor infusion only
16409597|NCT03911817|Active Comparator|Midodrine|Will receive midodrine in addition to IV vasopressor infusion
16409598|NCT03911804|Experimental|Bolus group|
16409599|NCT03911804|Active Comparator|Infusion group|
16409600|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
16409601|NCT03911765|Experimental|Executive Function cognitive training|20 hours of digital cognitive training targeting executive function.
16409602|NCT03911765|Active Comparator|Games|10 hours of computer games c available online which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc), followed by 10 hours of of digital cognitive training targeting executive function.
16409603|NCT03911752||People with Acquired Brain Injury|People with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=8).
16409604|NCT03911752||Partners of people with Acquired Brain Injury|Partners of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
16409605|NCT03911752||Relatives of people with Acquired Brain Injury|Relatives of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
16409606|NCT03911739|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.
~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
16409607|NCT03911739|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.
~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
16409608|NCT03911726|Other|Healthy subjects|30 healthy subjects will undergo a single PET/MR-measurement.
16409609|NCT03911726|Experimental|First-episode, drug-naive patients with schizophrenia|20 first-episode, drug-naive patients with schizophrenia will undergo a single PET/MR-measurement.
16409610|NCT03911726|Experimental|Pretreated chronically ill patients with schizophrenia|90 pretreated chronically ill patients with schizophrenia will undergo a single PET/MR-measurement.
16409611|NCT03911713|Experimental|VX-561|Subjects will be randomized to receive 1 of 4 dose levels of VX-561.
16409612|NCT03911713|Active Comparator|IVA|
16409613|NCT03911687|No Intervention|Control Group|"Control data will be collected in the CONCERN CDS system that will be live in the EHR, but in silent release mode (e.g., not providing notification to clinicians)."
16409716|NCT03910972|Active Comparator|Part B, Group I (HBV)|Hepatitis B Vaccine
16410556|NCT03905096|Experimental|Part 2|
16409614|NCT03911687|Experimental|Intervention Group|"Experimental data will be collected in the CONCERN CDS system that will be live in the EHR in active release mode (e.g., providing CONCERN CDS system notification to clinicians)."
16409615|NCT03911674|Experimental|Oral stimulation|Oral stimulation protocol: manual stimulation of the oral sucking
16409616|NCT03911674|No Intervention|Control|No intervention
16409617|NCT03911661|Active Comparator|Standard Management|The standard management phase will be historical and consist of warfarin management during the 12-months prior to signing informed consent.
16409618|NCT03911661|Experimental|Fearon Algorithm (FA) Anticoagulation Management Service|Once study patients have received an approved FA report, the FA AMS phase of the study will commence. An investigator will communicate the new warfarin tablet size, if necessary, and use the FA report to determine warfarin doses for the patient.
16409619|NCT03911661|Experimental|Fearon Algorithm (FA) Patient Self Management|At the conclusion of the six-month FA anticoagulation management service phase, patients will be trained to use the FA for patient self management (PSM) and after successfully demonstrating the ability to engage in PSM the FA PSM phase of the study will commence.
16409620|NCT03911648||Group B;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
16409621|NCT03911648||Group L;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44
16409622|NCT03911635|Experimental|Hypospadias in children|Distal shaft hypospadias at age of 12 years or less
16409623|NCT03911609|Experimental|Isometric (Static) Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
16409624|NCT03911609|Experimental|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
16409625|NCT03911583|Active Comparator|Control Group (CG)|Education, modifying diet and light physical activity (LPA)
16409626|NCT03911583|Active Comparator|Moderate physical activity group (MPA)|Education, modifying diet and moderate physical activity (MPA)
16409627|NCT03911583|Active Comparator|Intense physical activity group (IPA)|Education, modifying diet and intense physical activity (IPA)
16409628|NCT03911570||Glucosamine Sulfate Group (GS Group)|GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
16409629|NCT03911570||Control Group|Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).
16409630|NCT03911557|Experimental|Patients with moderate to high tumor mutational burden|Patients with recurrent or refractory disease in solid tumors naïve to anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy and have moderate to high tumor mutational burden (TMB)
16409631|NCT03911544|Active Comparator|TIVA anesthesia with BIS monitoring|The depth of anesthesia will be adjusted with the help of BIS monitoring.
16409632|NCT03911544|No Intervention|TIVA anesthesia without BIS monitoring|The depth of anesthesia will adjusted as in standard practice (clinical signs of poor anesthesia such as increase in blood pressure and/or heart rate, tearing and profuse sweating)
16409633|NCT03911531||Fetuses|DNA obtained from amniotic fluid samples
16409634|NCT03911531||Neonates|DNA obtained from neonatal blood samples
16409635|NCT03911518|Active Comparator|Control|Incision and drainage.
16409636|NCT03911518|Experimental|Intervention|Loop drainage.
16409638|NCT03911492|Other|SCP Pressure Management|Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg.
16409639|NCT03911479|Experimental|Bariatric Surgery Group|
16409640|NCT03911479|Other|Clinical Threatment|Convencional treatment in a public tertiary outpatients care unit
16409641|NCT03911466|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.
~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
16409642|NCT03911466|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.
~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
16409643|NCT03911453|Experimental|Treatment (rucaparib)|"Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of programmed cell death-1 with ligand (PD-L1) by immunohistochemistry (IHC)
~. Starting Dose 600 mg twice daily Dose Level -1 500 mg twice daily Dose Level -2 400 mg twice daily Dose Level -3 300 mg twice daily"
16409644|NCT03911440|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
16409645|NCT03911440|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
16409646|NCT03911427|Experimental|Powder Mix 1|Oat powder product, mixed with water
16409647|NCT03911427|Placebo Comparator|Powder Mix 2|Brown rice milk powder product, mixed with water
16409717|NCT03910959|Experimental|Animal-assisted therapy|Patients receive three weeks of two AAT sessions, each lasting ca 30 minutes.
16409648|NCT03911414|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
16409649|NCT03911414|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700mg QD) based on age .
16409650|NCT03911401|Experimental|0.3% OPA-15406|Twice daily
16409651|NCT03911401|Experimental|1% OPA-15406|Twice daily
16409652|NCT03911401|Placebo Comparator|Placebo|Twice daily
16409653|NCT03911388|Experimental|HSV G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
16409654|NCT03911375|Experimental|Mindfulness Based Stress Reduction (MBSR)|Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.
16409655|NCT03911375|No Intervention|Control|Participants assigned to the control group will follow the usual treatment, according to their diagnosis.
16409656|NCT03911362|Active Comparator|Lumbopelvic Stabilisation Exercises|Starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction
16409657|NCT03911362|Active Comparator|Pelvic Floor Exercises|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres and for slowly contracting muscle fibres,slow contraction by counting to ten hold for a count of ten, then gradually relax by counting to ten.
16409658|NCT03911336|Experimental|Group A - test|Group A (Test) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
16409659|NCT03911336|Active Comparator|Group B - Control 1|Group B (Control 1) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3- day period, starting the regime at 2 PM on the day of the extraction.
16409660|NCT03911336|Active Comparator|Group C - Control 2|Group C (Control 2) - Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
16409661|NCT03911310|Experimental|PET/CT 1: [18F]PSMA-11, PET/CT 2: [68Ga]PSMA-11|Patients in this arm will first receive the experimental radiotracer [18F]PSMA-11 PET/CT followed by the [68Ga]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
16409662|NCT03911310|Active Comparator|PET/CT 1: [68Ga]PSMA-11, PET/CT 2: [18F]PSMA-11|Patients in this arm will first receive the experimental radiotracer [68Ga]PSMA-11 PET/CT followed by the [18F]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
16409663|NCT03911271|Experimental|Loading dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
16409664|NCT03911271|Experimental|Low dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
16409665|NCT03911271|Placebo Comparator|Placebo|"In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
16409666|NCT03911258|Experimental|Nasal flora in CF patient|
16409667|NCT03911245||Patients with age equal or older than 40 years|
16409668|NCT03911245||Patients with age less than 40 years|
16409669|NCT03911232|Experimental|Enhanced recovery|rocuronium 2 effective dose at anesthesia induction sugammadex after skin incision and before extubation (total 2 mg/kg iv)
16409670|NCT03911232|No Intervention|Conventional anesthesia|standard general anesthesia protocol (1 effective dose of rocuronium at anesthesia induction)
16409671|NCT03911219||CANKADO (Arm A)|CANKADO application as eHealth support system: Patients use CANKADO for regular symptom self-reporting in addition to standard of care symptom management.
16409672|NCT03911219||Control (Arm B)|Control arm without eHealth support: Patients recieve standard of care symptom management.
16409673|NCT03911206|Experimental|Arm 1 : Inspirtory muscle training (IMT)|IMT exercises at home will gradually ramp up.
16409674|NCT03911206|Experimental|Arm 2: Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
16409675|NCT03911206|Experimental|Arm 3: IMT and Exercise|a combination of arm 1 and arm 3
16409676|NCT03911206|No Intervention|Arm 4: Routine care|no interventions will occur in this group besides testing procedures and offering access to the study team in case asthma-related questions come up.
16409677|NCT03911193|Experimental|Cabozantinib|Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days.
16409678|NCT03911180|Experimental|PFN straight parallel blade|All patients with pertrochanteric fracture that is eligible will undergo PFNA with straight parallel blade.
16409679|NCT03911167||RG|RG: robotic group
16409680|NCT03911167||LG|LG:laparoscopic group,
16409681|NCT03911167||OG|OG：open group
16409682|NCT03911154|Experimental|SmartSleep Modality Assignment|This study uses within subject comparison. For each subject, the order of SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 4 stimulation modalities.
16409683|NCT03911141|No Intervention|Control|Participants receive a daily text message stating whether or not they achieved their step goal on the prior day during the 12 months of intervention and 6 months of follow-up.
16409718|NCT03910959|Active Comparator|treatment as usual|Patients receive three weeks of two control sessions, each lasting ca 30 minutes.
16409684|NCT03911141|Experimental|Gamification Intervention|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.
~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.
~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.
~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
16409685|NCT03911141|Experimental|Financial Incentive Intervention|"Participants are informed that each week that money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.
~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
16409686|NCT03911141|Experimental|Gamification and Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
16409687|NCT03911128||Participants with newly diagnosed ALL|
16409688|NCT03911115||Bariatric surgery|Individuals that have undergone a gastric bypass (RYGB) or a sleeve gastrectomy (SG)
16409689|NCT03911102|Experimental|Cohort 1: DaxibotulinumtoxinA Dose A|Subjects will receive Dose A of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
16409690|NCT03911102|Experimental|Cohort 2: DaxibotulinumtoxinA Dose B|Subjects will receive Dose B of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
16409691|NCT03911102|Experimental|Cohort 3: DaxibotulinumtoxinA Dose C|Subjects will receive Dose C of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
16409692|NCT03911102|Experimental|Cohort 4: DaxibotulinumtoxinA Dose D|Subjects will receive Dose D of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
16409693|NCT03911089|Other|Open label|UCD Anamix Infant
16409694|NCT03911076|Experimental|PVX-2|Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein
16409695|NCT03911076|Placebo Comparator|Placebo|Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)
16409696|NCT03911063|Experimental|Cognitive behavioral therapy (CBT)|
16409697|NCT03911063|Active Comparator|Placebo Talking Sessions|
16409698|NCT03911050|Experimental|Apple consumption|Each subject took apple blends 600 g (made from two apples with seed removal) in a single dose, and samples (urine and blood and feces) at different timepoints were collected following administration of apple blends.
16409699|NCT03911050|Placebo Comparator|Control group|Each subject took breakfast without any apple-related products in a single dose, and samples (urine and blood and feces) at different timepoints were collected following breakfast.
16409700|NCT03911037|Active Comparator|Standard Medical Therapy + G CSF Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required). G-CSF ( prefilled syringe) at the dosage of 5 μg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
16409701|NCT03911037|Placebo Comparator|Standard Medical Therapy + Placebo|"Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required).
~Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered."
16409702|NCT03911024|Active Comparator|HIV|
16409703|NCT03911024|Placebo Comparator|General Health|
16409704|NCT03911011|Active Comparator|Fresh air|2 litres of fresh air
16409705|NCT03911011|No Intervention|no fresh air|no supply of fresh air
16409706|NCT03910998|Active Comparator|"Group M for Moderate muscle relaxation, low doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.
~Rocuronium IV bolus guided by TOF that must remain between 1-3 / 4 during surgery."
16409707|NCT03910998|Experimental|"Group D for Deep muscle relaxation, high doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.
~Bolus of rocuronium 0.1 mg/kg IV will be given during surgery to keep the TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes)."
16409708|NCT03910972|Experimental|Part A, Group A (Sm-TSP-2/Alhydrogel 10 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
16409709|NCT03910972|Experimental|Part A, Group B (Sm-TSP-2/Alhydrogel 10 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
16409710|NCT03910972|Experimental|Part A, Group C (Sm-TSP-2/Alhydrogel 30 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
16409711|NCT03910972|Experimental|Part A, Group D (Sm-TSP-2/Alhydrogel 30 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
16409712|NCT03910972|Experimental|Part A, Group E (Sm-TSP-2/Alhydrogel 100 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
16409713|NCT03910972|Experimental|Part A, Group F (Sm-TSP-2/Alhydrogel 100 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
16409714|NCT03910972|Active Comparator|Part A, Group G (HBV)|Hepatitis B Vaccine
16409715|NCT03910972|Experimental|Part B, Group H (Sm-TSP-2/Alhydrogel +/- AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, with or without AP 10-701, dose and formulation determined in Part A
16409719|NCT03910946||diabetic and renal|all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection
16409720|NCT03910920||Cystic fibrosis patients with PA|All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.
16409721|NCT03910907||Standard of care|Men treated for mycoplasma according to standard of care
16409722|NCT03910907||Standard of care plus|Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers
16409723|NCT03910881|Experimental|open-platform patient support system|Proof of concept testing of app
16409724|NCT03910855|Experimental|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
16409725|NCT03910855|Active Comparator|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
16409726|NCT03910842|Experimental|CD19-TriCAR-T/NK（SILK）|CD19-TriCAR-T/SILK cells will be administered intravenously
16409727|NCT03910829|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
16409728|NCT03910829|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
16409729|NCT03910829|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
16409730|NCT03910803|Other|Brodalumab - Open Label|"Randomized subjects will be receiving Brodalumab (210 mg) administered by subcutaneous injection at the following visits: Baseline, week 1, week 2 and every two weeks thereafter, until Week 24.
~Investigational Product not to be administer into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by Hidradenitis Suppurativa."
16409731|NCT03910790|Experimental|19 Gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle
16409734|NCT03910725||Obesity|Patients with BMI >40 awaiting stapled bariatric surgery, without a history of or concomitant ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be recruited prospectively from the bariatric surgery preoperative assessment clinics.
16409735|NCT03910725||Rheumatoid arthritis|Patients with RA without diagnosed or known ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication will be recruited prospectively from rheumatology clinics, prior to initiation of biologic or diseased modifying anti-rheumatic drugs.
16409736|NCT03910725||Dilated cardiomyopathy|TTNtv-positive and -negative DCM patients from the Royal Brompton Hospital biobank have provided informed consent to be contacted for research
16409737|NCT03910712|Experimental|Pyrotinib and trastuzumab plus aromatase inhibitor|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16409738|NCT03910712|Active Comparator|Trastuzumab plus aromatase inhibitor|Participants will receive trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16409739|NCT03910699|Active Comparator|Two-row anastomosis|Colorectal anastomosis is created with a two-row circular surgical stapler
16409740|NCT03910699|Experimental|Three-row anastomosis|Colorectal anastomosis is created with a three-row circular surgical stapler
16409741|NCT03910686|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
16409742|NCT03910686|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
16409743|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
16409744|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
16409745|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
16409746|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
16409747|NCT03910673|Experimental|2-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 2 hours after start of third infusion dose. n = 6
16409748|NCT03910673|Experimental|30-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 30 minutes after start of third infusion dose. n = 6
16409749|NCT03910673|Experimental|5-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 5 hours after start of third infusion dose. n = 6
16409750|NCT03910673|Experimental|75-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 75 minutes after start of third infusion dose. n = 6
16409751|NCT03910673|Experimental|8-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 8 hours after start of third infusion dose. n = 6
16409754|NCT03910647|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
16409755|NCT03910647|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
16409756|NCT03910634|Experimental|IMRT combined with carboplatin|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
16409757|NCT03910634|Placebo Comparator|IMRT combined with carboplatin and fluorouracil|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
16409759|NCT03910608|Experimental|DLPFC+10 IPL|Stimulation of dorsolateral prefrontal cortex (DLPFC) 10 ms before inferior parietal lobule (IPL) presumes that the DLPFC to IPL input facilitates insula postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
16409760|NCT03910608|Experimental|IPL+10 DLPFC|Stimulation of IPL 10 ms before DLPFC presumes that the IPL to DLPFC input inhibits insula postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
16409761|NCT03910608|Experimental|IPL+4 DPLFC|Stimulation of IPL 4 ms before DLPFC is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula inhibits insula postsynaptic output by weakening the IPL to insula input, thereby impairing cognition response.
16409762|NCT03910608|Experimental|DLPFC+4 IPL|Stimulation of DLPFC 4 ms before IPL is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula potentiates insula postsynaptic output by strengthening the IPL to insula input, thereby improving cognition response.
16409763|NCT03910608|Experimental|DLPFC+4 MPFC|Stimulation of DLPFC 4 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
16409764|NCT03910608|Experimental|MPFC+4 DLPFC|Stimulation of MPFC 4 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
16409765|NCT03910608|Experimental|DLPFC+10 MPFC|Stimulation of DLPFC 10 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
16409766|NCT03910608|Experimental|MPFC+10 DLPFC|Stimulation of MPFC 10 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
16409767|NCT03910595|Experimental|Mepitel Film Arm|This is a single arm trial where all patients will receive the intervention of Mepitel Film.
16409768|NCT03910582|Experimental|Experimental group|Subjects in this group will be treated with personalized frozen-thawed embryo transfer. The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
16409769|NCT03910582|Active Comparator|Control group|Subjects in this group will be treated with routine frozen-thawed embryo transfer.The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
16409770|NCT03910556||no complication|the patients who did not develop any kind of complication and no re-craniotomy
16409771|NCT03910556||with complication (s)|the patients who developed at least one of non-neurological complication or required re-craniotomy
16409772|NCT03910543|Experimental|Patients with Cutaneous Sarcoidosis|Patients with cutaneous sarcoidosis that may also have also have internal organ sarcoidosis
16409773|NCT03910543|Experimental|Patients with Granuloma Annulare|Patients with granuloma annulare that is long-standing and/or widespread
16409774|NCT03910530|Experimental|INCMGA00012|Single-agent INCMGA00012.
16409775|NCT03910530|Experimental|INCB001158 75 mg|Single-agent INCB001158.
16409776|NCT03910530|Experimental|INCB001158 100 mg|Single-agent INCB001158.
16409777|NCT03910530|Experimental|INCMGA00012 + INCB001158|Combination of INCMGA00012 and INCB001158.
16409778|NCT03910517||E-sport athletes|People aged 15-35 who engage in structured E-sport (e.g. community-based, pro team or educational setting).
16409810|NCT03910231|Placebo Comparator|Placebo|Placebo
16409811|NCT03910231|Experimental|15mg Tolvaptan|15mg Tolvaptan
16409812|NCT03910231|Experimental|30mg Tolvaptan|30mg Tolvaptan
16409887|NCT03909737|Experimental|No intervention to pregnant women and azithromycin to infants|No intervention to pregnant women and 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
16409779|NCT03910504|Active Comparator|Rocuronium 0,3 mg/kg|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.
~Patients, who have been randomized to this group, will be obtained single reduced dose of rocuronium (0,3 mg/kg) once intravenous bolus. The dose of rocuronium will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment. The drug will be diluited in a syringe with 20 ml of solution."
16409780|NCT03910504|Experimental|No rocuronium|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.
~Patients, who have been randomized to this group, will not receive rocuronium, but normal saline will be administered by the anesthesiologist in charge of the patients. The dose of normal saline (20 ml in one syringe) will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment."
16409781|NCT03910491|Experimental|Intervention|All participants who enroll in the study will be assigned to a PriCARE group program that will adhere to the approximately 9 hour PriCARE curriculum.The trainings are administered to groups of approximately 4-12 caregivers at a time and are led by 2 mental health providers trained in the PriCARE curriculum. The curriculum will be delivered in 2-6 sessions over a 2-20 week period.
16409782|NCT03910478|Experimental|Self-collected Dried Blood Spot (DBS) monitoring|N=100 Subject collected DBS CMV monitoring with mobile technology support
16409783|NCT03910478|Active Comparator|Standard Monitoring Control|N=50 Standard care with office based testing
16409784|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma.
16409785|NCT03910452|Experimental|1|This is a single arm open-label pilot study.
16409786|NCT03910439|Experimental|1/Avelumab 800 mg intravenous (IV) every two weeks in combination with radiation therapy|Avelumab 800 mg IV every two weeks in combination with radiation therapy
16409788|NCT03910400|Experimental|MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
16409789|NCT03910400|Experimental|Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
16409792|NCT03910374|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
16409793|NCT03910374|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
16409794|NCT03910361|Experimental|Evogliptin|evogliptin 5mg
16409795|NCT03910361|Active Comparator|Pioglitazone|pioglitazone 15mg
16409796|NCT03910348|Experimental|Whole body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting (2-4mm peak to peak) on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Each patient received the vibrations under supervision using five different static positions: squat, deep squat, widestep squat, lunge, and hands-front lunge. The exercise programs for each experimental groups consisted of 20 to 60-minute sessions on three days per week for 24 weeks, and they were performed under the supervision.
16409797|NCT03910348|Experimental|High-impact exercise|Depending on their individual calcium and vitamin D intakes, each patient advised to receive supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D.
16409798|NCT03910348|No Intervention|Control|Depending on their individual calcium and vitamin D intakes, each patient received supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D. The demographic characteristics of the participants were obtained at the baseline assessment.
16409799|NCT03910335||LSS patients|"Case/control study: Patients from surgical departments awaiting surgery for LSS will will out the questionnaire.
~Cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)"
16409800|NCT03910335||Non-LSS patients|Case/control study and cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)
16409801|NCT03910322|Placebo Comparator|Placebo|Placebo arm. Similar trial product, but without Bif195 bacteria
16409802|NCT03910322|Experimental|Low-dose Bif195|Active trial product with minimum 15 billion CFU daily dose
16409803|NCT03910322|Experimental|High-dose Bif195|Active trial product with minimum 50 billion CFU daily dose
16409804|NCT03910309||1 or 2 level TLIF candidates|Any subject determined to ALREADY be a candidate for 1 or 2 level transforaminal interbody fusion surgery
16409805|NCT03910296||Acceptance & Commitment Therapy|"Acceptance & Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.
~Each subject will participate for 6 sessions of Acceptance & Commitment Therapy (ACT).
~ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values."
16409806|NCT03910257|Experimental|nutrition education module|12 activities of the nutrition education module pre and post test
16409807|NCT03910257|No Intervention|control group|no intervention pre and post test
16409808|NCT03910244|Experimental|Pomalidomide|Oral Pomalidomide will be provided as a capsule at 4 mg/day dose. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
16409809|NCT03910244|Placebo Comparator|Placebo|A placebo matching the study drug will be provided as a capsule. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
16409813|NCT03910218|Experimental|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
16409814|NCT03910218|Placebo Comparator|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
16409815|NCT03910205||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
16409816|NCT03910205||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
16409817|NCT03910205||Healthy patients with gingivitis|Systemically healthy patients with gingivitis
16409818|NCT03910205||Healthy patients with healthy gingiva|Systemically healthy patients with healthy gingiva
16409819|NCT03910192|Experimental|Mindfulness meditation coaching|Mindfulness-based coaching - participants will receive instructions on (a) mindfulness meditation and gentle mindful movement through home-based and in-class participation at the Southlake Cardiovascular Rehabilitation Clinic and (b) personal coaching support. The health coach will further assist participants through either face-to-face or telephone-based discussions. They will meet with the health coach at mutually-agreed upon on times for designated time periods.
16409820|NCT03910192|Active Comparator|dietary cardiovascular risk reduction coaching|Cardiovascular risk reduction education - No change to standard of care where participants will receive instructions (in person or by phone call) on how to integrate exercise and dietary changes in your lifestyle to reduce your risk of future cardiovascular events. These instructions will be centered around the DASH dietary practices.
16409821|NCT03910166|Experimental|DCB group|use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
16409822|NCT03910166|Active Comparator|BMS group|use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
16409823|NCT03910153|Placebo Comparator|Placebo - (Age 30-50 years)|
16409824|NCT03910153|Experimental|MSPrebiotic - (Age 30-50 years)|
16409825|NCT03910153|Placebo Comparator|Placebo - (Aged 70 years and above)|
16409826|NCT03910153|Experimental|MSPrebiotic - (Aged 70 years and above)|
16409827|NCT03910140|Experimental|TILA-TACE group|
16409828|NCT03910127|Experimental|TQB2450 + Anlotinib (10 mg)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 10 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16409829|NCT03910127|Experimental|TQB2450 + Anlotinib (12 mg)|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16409830|NCT03910127|Placebo Comparator|TQB2450 + Placebo|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Placebo for Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16409831|NCT03910114||Dotarem Enhancement Group|
16409832|NCT03910114||Gadovist Enhancement Group|
16409833|NCT03910114||Magnevist Enhancement Group|
16409834|NCT03910101|Active Comparator|Hand surgery and intensive rehabilitation|"The surgical treatment for reducing spasticity comprises lengthening of tendons, muscle release and occasionally correction of deformities. Lengthening of a tendon or releasing a muscle from its insertion, results in relaxation of the whole muscle-tendon unit. Hence, the spasticity is not gone, but reduced in strength.
~The tendon lengthening procedures is performed by a stair-step incision technique followed by reattachment in the lengthened position using a side-to-side, cross-stich technique. The load to failure of the sutured tendon is approximately 200Newton, which gives a sufficient safety margin for early active mobilization of the tendons involved. This suture technique thus enables active training directly after surgery.
~Postoperative rehabilitation includes wrapping and a custom-made splint, for day and night use, muscle activation and passive stretching 2-4 times per day without the splint."
16409835|NCT03910101|Active Comparator|Botulinum toxin injections|Botulinum toxin injections are given in spastic muscles of the upper extremity. Dosage and number of injections per muscle vary depending on the degree and extent of spasticity. For optimal effect on hand function, botulinum toxin is accompanied by the treatment of individualized exercise and splinting when needed.
16409836|NCT03910088|Placebo Comparator|control group|received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
16409837|NCT03910088|Active Comparator|Pregabalin|received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
16409838|NCT03910088|Active Comparator|Hydrocortisone|received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
16409839|NCT03910075|Experimental|I-ACQUIRE High Dose|High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)
16409840|NCT03910075|Experimental|I-ACQUIRE Moderate Dose|Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)
16409841|NCT03910075|Active Comparator|Usual & Customary Treatment|Usual & Customary Treatment
16409842|NCT03910062||VA ECMO|Patients under VA-ECMO with a femoral reperfusion cannula.
16409843|NCT03910049||Study group|The group will include all adult patients that will sign ICF and will be operated for total thyroidectomy regardless of the undelying disease
16409844|NCT03910036|Experimental|PRP group|15 patients to constitute the PRP-group was injected intra-articularly with about 5 ml of PRP in the operated knee joint
16409845|NCT03910036|No Intervention|control group|The other fifteen patients were not injected and constituted control group.
16409846|NCT03910023|Active Comparator|Control group|The control group will perform home exercises alone
16409847|NCT03910023|Experimental|Spa group|The spa group will be proposed an additional spa treatment
16409848|NCT03910010|Experimental|Experimental: placebos|Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
16409849|NCT03910010|No Intervention|Waitlist|Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
16409850|NCT03910010|No Intervention|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
16409851|NCT03909984|Other|Intervention|All participants will be monitored for 2 months.
16409853|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|42 patients will receive both electroacupuncture（HANS100A）therapy and routine rehabilitation training.
16409854|NCT03909958|Other|Routine rehabilitation training Group|42 patients will receive simple routine rehabilitation training.
16409855|NCT03909945|Experimental|Interventional arm|The intervention consisted in the daily administration, during 60 days, of a 796 mg tablet of aqueous extracts of leaves of Annona muricata between 08:00 AM and 09:00 AM.
16409856|NCT03909932||Patients enrolled in the cross-sectional study|Patients over 18 years old, consulting in neuro-urology department.
16409857|NCT03909919|Experimental|Heart Failure|Heart Failure patients Subjects diagnosed with heart faikure, who will receive the best treatment of clinical practice, will be recruited. They must be more than 70 years old.
16409858|NCT03909919|Active Comparator|Healthy Subjects|Healthy Subjects/ Match control Healthy subjects of the same age as people with heart failure.
16409859|NCT03909906|Active Comparator|Euphytose®|Euphytose® 2 tablets 3 times per day for 14 days
16409860|NCT03909906|Placebo Comparator|Placebo|Matched placebo 2 tablets, 3 times per day for 14 days
16409862|NCT03909880|No Intervention|Control|Without kinesio tape on the forearm of subjects
16409863|NCT03909880|Placebo Comparator|kinesio taping with neutral tension|Kinesio tape with neutral tension on the forearm of subjects
16409864|NCT03909880|Experimental|kinesio taping with additional 20% tension|Kinesio tape with 20% additional tension on the forearm of subjects
16409865|NCT03909854|Active Comparator|Adaptive Pressure Control|The Adaptive Pressure Control arm is the baseline mode/protocol for medical intensive care unit mechanical ventilation
16409866|NCT03909854|Active Comparator|Assist Volume Control|The assist volume control arm is the new protocol that will be implemented and tested for feasibility
16409867|NCT03909841||DM|DM without DPN (Diabetic Peripheral Neuropathy)
16409868|NCT03909841||DPN|DM with DPN (Diabetic Peripheral Neuropathy)
16409869|NCT03909841||DPN-P|DM with DPN-P (Diabetic Peripheral Neuropathic Pain)
16409870|NCT03909828||Parkinson's disease patients|patients with Idiopathic Parkinsonism
16409871|NCT03909815|Experimental|Intervention|Insertion of dual mobility cup
16409872|NCT03909815|Active Comparator|Control|Insertion of standard cup
16409873|NCT03909802|Experimental|Experimental group|This arm will receive interventions consisting of self-management combined with family management programs.
16409874|NCT03909802|Placebo Comparator|Control group|Usual care refers to incorporating wound assessment, wound irrigation using NaCl, debridement, wound dressing, evaluation, and health education unmet with the self-and-family management of DFU program criteria in this study. All of the usual care will be performed and evaluated by the wound care nurses working at the selected clinics for this study.
16409875|NCT03909789|Active Comparator|plant based bioequivalent dietary nitrate supplement|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
16409876|NCT03909789|Placebo Comparator|placebo|The Placebo does not contain any nitric oxide supplement.
16409877|NCT03909776|Active Comparator|IA group|Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
16409878|NCT03909776|Sham Comparator|IV group|Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
16409879|NCT03909763|Experimental|Berberine plus danazol|Berberine plus danazol group
16409880|NCT03909750|Experimental|Lipoaspiration Microcannula ARM 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
16409881|NCT03909750|Experimental|Isolation-Concentration Adipose cSVF ARM 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
16409882|NCT03909750|Experimental|Normal Saline IV ARM 3|Sterile Normal Saline IV with cSVF
16409883|NCT03909737|Experimental|Azithromycin to pregnant women and azithromycin to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week Expanded Programme on Immunization (EPI) visits
16409884|NCT03909737|Experimental|Azithromycin to pregnant women and placebo to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
16409885|NCT03909737|Experimental|Placebo to pregnant women and azithromycin to infants|Oral placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
16409886|NCT03909737|Placebo Comparator|Placebo to pregnant women and placebo to infants|Placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
16410204|NCT03907423|Experimental|Rosuvastatin|DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients)
16409889|NCT03909724|Active Comparator|TAS-102 (Lonsurf)|35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
16409890|NCT03909724|Experimental|High Dose Intermittent Sunitinib|700 mg once every 2 weeks.
16409891|NCT03909698||Hemodialysis patients on amoxicillin-clavulanic acid|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for amoxicillin-clavulanic acid."
16409892|NCT03909698||Hemodialysis patients on ceftazidim|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for ceftazidim."
16409893|NCT03909698||Hemodialysis patients on piperacillin-tazobactam|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for piperacillin-tazobactam."
16409894|NCT03909698||Hemodialysis patients on vancomycin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for vancomycin."
16409895|NCT03909698||Hemodialysis patients on teicoplanin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for teicoplanin."
16409896|NCT03909685|Experimental|the intervention arm|During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy
16409897|NCT03909685|No Intervention|a waitlist control arm|The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm
16409898|NCT03909672|Experimental|Cupping therapy with 2 suctions|Participants in the intervention group will receive the application of cupping therapy with two acrylic type 1 cups with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally. This group will consist of the application of windsheets with 2 suctions for 10 minutes, once a week, for 10 weeks. The cups shall be secured by means of elastic bands.
16409899|NCT03909672|Placebo Comparator|Cupping Therapy sham|"The placebo group will receive the application of cupping therapy with 2 cups of acrylic type size 1 with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of applying the sham winds for 10 minutes, once a week for 10 weeks.
~However, the cups will be made with small holes <2 mm in diameter to release the negative pressure in seconds. The cups will also be fixed by means of elastic bands."
16409900|NCT03909659|No Intervention|Control|Normal salt
16409901|NCT03909659|Experimental|Reduced-sodium added-potassium salt substitute|salt substitute
16409902|NCT03909646|Active Comparator|Surgical excision|Standard surgical excision with 5 mm safety margin
16409903|NCT03909646|Active Comparator|Photodynamic therapy|PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval
16409904|NCT03909646|Active Comparator|5% 5-Fluorouracil|5FU cream, which has to be applied by the patient twice daily for 4 weeks.
16409905|NCT03909633||A: anesthesia group|Patients accepting endoscopy check under anesthesia will be included in this group as group A,will doing a series of tests
16409906|NCT03909633||B:Non-anesthesia group|patients undergoing endoscopy check without anesthesia will be included in this group as controls voluntarily,namely group B,will doing a series of tests
16409907|NCT03909620|Experimental|LDCT arm|All eligible participants will undergo screening with LDCT
16409908|NCT03909607|Active Comparator|SDK 0.75 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 0.75mg/k
16409909|NCT03909607|Active Comparator|SDK 1.0 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.0mg/k
16409910|NCT03909607|Active Comparator|SDK 1.5 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.5mg/k
16409911|NCT03909594|Experimental|Nerve Block with Bupivacaine an|Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
16409912|NCT03909594|Active Comparator|Nerve Block with Bupivacaine al|Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
16409913|NCT03909581|Active Comparator|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization
16409914|NCT03909581|Active Comparator|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator
16409915|NCT03909568|Experimental|Third molar surgery|Split mouth comparison of effect of complete third molar removal vs coronectomy of contralateral third molar
16409916|NCT03909555||Short-term intensive insulin therapy|Patients who used to participated in short-term intensive insulin therapy for 14 days when diabetes was newly diagnosed
16409917|NCT03909555||Routine diabetic therapy|Received routine diabetic therapy
16409918|NCT03909542||Ileostomy Closure|Patients who have undergone an ileostomy closure procedure.
16409919|NCT03909529|Experimental|Digoxin 250 micrograms (MCG) Oral Tablet|Administration of 20 mL of 25 mg / 5 mL singe dose Day 1 to Day 9 randomized to digoxin and Spironolactone treatment. On day 6, after overnight fasting of at least 10.00 hours, either digoxin or spironolactone will be administered orally for drug drug interaction evaluation
16409920|NCT03909529|Experimental|Spironolactone 25 mg/ 5 mL S/F Suspension|Crossover administration of 20 mL of 25 mg / 5 mL Day 1 to Day 9 randomized to Spironolactone or digoxin treatment. On day 6, after overnight fasting of at least 10.00 hours, either spironolactone or digoxin will be administered orally for drug drug interaction evaluation
16409921|NCT03909516|No Intervention|Standard of Care|"Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded."
16409922|NCT03909516|Active Comparator|Standard of Care + iovera° Treatment|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded.
~Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events.
~Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.
~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
16409924|NCT03909490|Active Comparator|Control|
16409925|NCT03909490|Experimental|intervention- tool|
16409926|NCT03909477||Cannabis Smoker|Participants in this group will be current or former cannabis smokers
16409927|NCT03909464||Patients receiving neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving known neurotoxic agents. Common neurotoxic agents include vinca alkaloids (ie. vincristine), taxanes (ie. Taxol), platins (ie. Oxaliplatin) and some other drugs beyond these categories (ie. Bortezomib).
~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:
~EORTC-QLQ CIPN20 Questionnaire
~Michigan Neuropathy Screening Instrument Questionnaire"
16409928|NCT03909464||Patients receiving non-neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving agents with negligible or doubtful risk of neurotoxicity.
~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:
~EORTC-QLQ CIPN20 Questionnaire
~Michigan Neuropathy Screening Instrument Questionnaire"
16409929|NCT03909451|Experimental|Dose 1|Sotagliflozin dose 1, once daily for 8 days
16409930|NCT03909451|Experimental|Dose 2|Sotagliflozin dose 2, once daily for 8 days
16409931|NCT03909451|Placebo Comparator|Placebo|Placebo, once daily for 8 days
16409932|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 0|"Carfilzomib at 20mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
16409933|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 1|"Carfilzomib at 27mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
16409934|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 2|"Carfilzomib at 36mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
16409935|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 3|"Carfilzomib at 45mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
16409936|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 4|"Carfilzomib at 56mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
16409973|NCT03909152|Experimental|PR+ Granulosa cell ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart and anastrozole 1mg po QD in AM beginning Day 1 of Cycle 1. A Cycle is 28 days.
16409937|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 5|"Carfilzomib at 70mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
16409938|NCT03909373||Cohort|patients with carpal tunnel syndrome
16409939|NCT03909360|Experimental|drainage|Placement of subhepatic drainage tube for laparoscopic cholecytetomy
16409940|NCT03909360|No Intervention|no drainage|no placement of subhepatic drainage tube for laparoscopic cholecytetomy
16409941|NCT03909347|Experimental|PLAN (intervention)|Group 1 will receive the study intervention during the 6 months of the study, after the first baseline questionnaire. The intervention is as follows: participants will be asked to take part in a one-time, one-hour education in participants' home or any community location that is most convenient for the participants by a trained community health worker. An educational resource that participants can read at home will be provided at the end of education session. Participants' community health worker will call the participants monthly to identify barriers to dementia care and help participants and participants' elder with making an appointment or transportation to the health care facility, when participants request for assistance.
16409942|NCT03909347|Active Comparator|Standard of care (control)|Group 2 will receive a signs and treatment of dementia pamphlet by the Alzheimer's Association and will be referred to the elder's primary physician.
16409943|NCT03909334|Active Comparator|Arm A (Osimertinib and Ramucirumab)|Osimertinib and Ramucirumab
16409944|NCT03909334|Active Comparator|Arm B (Osimertinib)|Osimertinib
16409945|NCT03909321|No Intervention|Control group|The Control group will not be submitted to intervention and will be instructed not to engage in any kind of structured physical exercise training and to keep the life activities identified at baseline.
16409946|NCT03909321|Experimental|Beach tennis training group|The Beach Tennis (BT) group will perform two sessions per week of the Beach Tennis training. This intervention will last 12 weeks.
16409947|NCT03909308|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 45 min.
16409948|NCT03909308|Experimental|Beach Tennis session|The participants performed a beach tennis training session throughout 45 min.The session started with a standardized 5-minute warm-up consisting of basic techniques (i.e., serve, volley, forehand, and backhand) followed by three 12-minute beach tennis matches with 2-minute intervals between the games. We used regular beach tennis rules in the game, which was played on a regular beach tennis court (i.e., 16 m long by 8 m wide and net 1.70 m high).
16409949|NCT03909295|Experimental|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
16409950|NCT03909282|Active Comparator|Surgery|
16409951|NCT03909282|Experimental|Neoadjuvant partial breast irradiation|Partial breast irradiation will be delivered once a day for 5 days before surgery. The planned daily dose is 6 Gy.
16409952|NCT03909269||Haemodialysis and type 2 diabetes|On chronic haemodialysis and type 2 diabetes
16409953|NCT03909269||Control group|Type 2 diabetes and with eGFR above 60ml/min
16409954|NCT03909256|Experimental|NUTRI-HAB|"The intervention group participates in a targeted rehabilitation program 'NUTRI-HAB' with a focus on eating problem after treatment for head and neck cancer. The program comprises:
~a five day residential stay with patient education
~a two day follow-up residential stay after 3 months
~two telephone consultations with clinical dietitian between the two residential stays."
16409955|NCT03909256|No Intervention|Control group|"The control group receives no intervention other than usual care in the study period.
~After 3 months, the control group will be offered participation in the same residential rehabilitation program as the intervention group parcitipated in."
16409956|NCT03909230||Day 2 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
16409957|NCT03909230||Day 4 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
16409958|NCT03909217|Experimental|TECAS|Patients will receive transcutaneous electrical cranial-auricular acupoint stimulation (TECAS) daily.
16409959|NCT03909217|Active Comparator|Anti-depressants|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by a clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
16409960|NCT03909204|Other|LAPEC|Patients with cecal percutaneous catheter placement.
16409961|NCT03909191||treatment-naïve|treatment-naïve patients with chronic HBV infection
16409962|NCT03909191||NAs treated CHB patients|CHB patients undergoing long-term NAs treatment
16409970|NCT03909152|Experimental|PR+ Granulosa cell tumor (This Arm is closed)|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days. This Arm is closed.
16409971|NCT03909152|Experimental|PR+ Low grade serous ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
16409972|NCT03909152|Experimental|PR+ Endometrioid endometrial cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
16409975|NCT03909126|Experimental|Montreal Region of Quebec|Vaccination with Boostrix at time of gestational diabetes screening in a hospital setting
16409976|NCT03909126|No Intervention|Montérégie|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
16409977|NCT03909126|Experimental|Maurice Region|Vaccination with Boostrix of pregnant women receiving routine care at high volume clinic
16409978|NCT03909126|No Intervention|National Capital|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
16409979|NCT03909113|Experimental|amino acid based formula|amino acid based formula
16409980|NCT03909100|Experimental|CoolSculpting® System|Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
16409981|NCT03909074|Experimental|Experimental group|36-71 months old children-experimental EV71 vaccine.
16409982|NCT03909074|Active Comparator|Vaccine-controlled group|36-71 months old children-control EV71 vaccine.
16409983|NCT03909074|Active Comparator|Age-controlled group|6-35 months old children-experimental EV71 vaccine.
16409984|NCT03909061|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent maintenance training materials. They will complete data collection measures embedded in the maintenance training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Assistive Technology Module Questionnaire (ATM-Q), and the Wheelchair Maintenance Training Questionnaire (WMT-Q).
16409985|NCT03909061|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the wheelchair maintenance training. Participants may also be asked to complete a user satisfaction survey.
16409986|NCT03909061|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the wheelchair maintenance training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent maintenance training program.
16409987|NCT03909048|Experimental|Interactive Psycho-education|Interactive psycho-education using interactive dashboard.
16409988|NCT03909048|Placebo Comparator|Psycho-education|Non-interactive psycho-education not using interactive dashboard.
16409989|NCT03909035|Experimental|Medication therapy management|Medication therapy management by the community pharmacist in collaboration with the General Practitioners to the Optimizations of Prescriptions
16409990|NCT03909035|No Intervention|Usual pharmaceutical care|Usual pharmaceutical care provided by the community pharmacist (first level pharmaceutical analysis of the prescriptions)
16409991|NCT03909009|Active Comparator|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
16409992|NCT03909009|Sham Comparator|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
16409993|NCT03908996|Experimental|Profile by Sanford|All enrolled subjects are assigned to participate in the Profile by Sanford weight management program for a period of 12 months..Subjects will follow the Profile program and will be provided a nutritional plan which includes consuming Profile nutritional supplements and other food items. Subjects will work with a Profile lifestyle coach to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior. Subjects on this research study will follow the Profile by Sanford weight loss and management plan as all Profile members. All enrolled subjects will collect and return a fecal specimen prior to beginning the Profile by Sanford weight management plan and again after 6 months of participation.
16409994|NCT03908983|Experimental|Implanted Patients|Implantation of Kalios Device
16409995|NCT03908970|Experimental|1% OPA-15406|Twice daily
16409996|NCT03908970|Placebo Comparator|Placebo|Twice daily
16409997|NCT03908957|Experimental|Ga68-Dolacga Injection|The healthy volunteer was injected with Ga68-Dolacga Injection iv and performed PET imaging for liver reserve evaluation.
16409998|NCT03908944|Active Comparator|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
16409999|NCT03908944|Experimental|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
16410000|NCT03908931|Experimental|MRI|
16410001|NCT03908918|Experimental|Active group|Mobile-app delivered mindfulness intervention. Dosage: 4 times per week for 4 weeks
16410002|NCT03908918|Other|Waitlist control|Waitlist control - receiving the app after 6 months
16410003|NCT03908905||Intervention|
16410004|NCT03908892|Experimental|Combination group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, plus local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day, till paronychia relief or progression.
16410005|NCT03908892|Active Comparator|Control group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, till paronychia relief or progression.
16410040|NCT03908619|Experimental|TTP (Group D)|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
16410205|NCT03907423|Placebo Comparator|Control|DM-type 2 patient who will receive glimepiride-metformin combination (20 patients).
16410006|NCT03908879|Experimental|Intraosseous (IO) catheter placement confirmation methods|All patients will undergo all three confirmation methods/procedures. Method 1 is a triage test and an index test. Method 2 is an index test. Method 3 is a reference standard. None of the procedures being performed in this study are regulated by the United States Food and Drug Administration.
16410007|NCT03908866|Experimental|PICC(Peripherally inserted central catheter)|Patients randomly assigned to receive a peripherally inserted central catheter(PICC).
16410008|NCT03908866|Active Comparator|CVC(Central venous catheter )|Patients randomly assigned to receive a centrally inserted central venous catheter(CVC).
16410009|NCT03908853||Patients|Subjects with painful bone metastases caused by primary breast cancer.
16410010|NCT03908853||Controls|Gender and age matched healthy volunteers.
16410011|NCT03908840|Experimental|TBI 302 Safety, Tolerability|5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).
16410012|NCT03908827|Experimental|Active BMAC treatment|60 mL of bone marrow will be aspirated from the iliac crest of each subject in the active treatment group. The bone marrow aspirate (BMA) will be centrifuged using a single spin protocol such that the red blood cells are minimized and the total nucleated and platelet cells are concentrated into a 12 mL volume of bone marrow aspirate concentrate (BMAC).
16410013|NCT03908827|No Intervention|Wait List Control|Participants will continue with their usual treatment, inclusive of medications or conservative treatments and will continue with activity guidelines as previously provided by clinical staff whilst awaiting joint arthroplasty
16410014|NCT03908814|Experimental|Drug: LDP|"This is a dose-escalation trial, all participants will receive treatment with LDP. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.
~Cohort 1: 0.1 mg/kg Cohort 2: 0.3 mg/kg Cohort 3: 1 mg/kg Cohort 4: 3 mg/kg Cohort 5: 10 mg/kg Cohort 6: 10 mg/kg"
16410015|NCT03908801|Experimental|Intervention|Specialized water dance intervention
16410016|NCT03908801|No Intervention|Control|No intervention
16410017|NCT03908788|Experimental|Intplex test|In vitro diagnostic device
16410018|NCT03908775|Active Comparator|Group VL|C-MAC Videolaryngoscope Patients intubated with C-MAC Videolaryngoscope
16410019|NCT03908775|Active Comparator|Group DL|Direct Laryngoscope Patients intubated with Direct laryngoscope
16410020|NCT03908762|Experimental|iSage|The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose <70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
16410021|NCT03908762|Active Comparator|Conventional Management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured <70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.
16410022|NCT03908736|Other|Single-arm cohort|Baseline experimental measurements will be collected for each individual participant twice prior to zinc supplementation (0 month and 3 month time points). After zinc supplementation, experimental measurements will be collected for each individual participant at the 6 month and 9 month time points. The zinc intervention is zinc picolinate 15 mg once per day for 6 months.
16410023|NCT03908723|Experimental|all patients in the study|
16410024|NCT03908710|Other|home Home blood pressure levels in hypertensive participants|Only one arm. No control group.
16410025|NCT03908697|Experimental|Single cohort|All 20 participants will use ClearBlue and Mira monitors on first morning urine
16410026|NCT03908684||Head and Neck|
16410027|NCT03908684||Prostate|
16410028|NCT03908684||Rectum|
16410029|NCT03908684||Prostate Characterization|
16410030|NCT03908671|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers
16410031|NCT03908658|Active Comparator|Inspiratory Muscle Training and Nasal High Flow|Inspiratory Muscle Training will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Nasal High Flow will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
16410032|NCT03908658|Active Comparator|Inspiratory Muscle Training and Venturi mask|IMT will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Venturi mask will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
16410033|NCT03908645|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
16410034|NCT03908645|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
16410037|NCT03908619|Active Comparator|TTP (Group A)|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
16410038|NCT03908619|Active Comparator|TTP (Group B)|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
16410039|NCT03908619|Active Comparator|TTP (Group C)|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
16410041|NCT03908606|Experimental|Periodontitis patients with diabetes type 2|scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment
16410042|NCT03908606|Experimental|Periodontitis patients|scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels.
16410043|NCT03908606|No Intervention|Healthy control group|We measured serum levels of hs-CRP in all healthy control subjects
16410044|NCT03908593|Active Comparator|One month of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month
16410045|NCT03908593|Experimental|Twelve months of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months
16410046|NCT03908580|Experimental|Meditoxin®|Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.
16410047|NCT03908567|Placebo Comparator|Placebo|Nasal spray solution without active ingredient
16410048|NCT03908567|Experimental|1 mg AM-125|Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.
16410049|NCT03908567|Experimental|10 mg AM-125|Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.
16410050|NCT03908567|Experimental|20 mg AM-125|Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.
16410051|NCT03908567|Experimental|Oral 16 mg betahistine|Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.
16410052|NCT03908554|Experimental|intervention|The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home).
16410053|NCT03908554|No Intervention|Control|Participants of the control group rested in a room for 40 minutes and were told that they could read every session.
16410054|NCT03908528|Experimental|Chemotherapy plus Placebo for six Months|• Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus Placebo.
16410055|NCT03908528|Experimental|Chemotherapy plus alpha lipoic acid for six Months|• Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks in addition to oral 600 mg alpha lipoic acid (ALA) once daily.
16410056|NCT03908489|Experimental|intervention we want to test vital pulpotomy using garlic oil|interventional group as garlic oil pulpotomy dressed in zinc oxide powder
16410057|NCT03908489|Active Comparator|control or comparator as mta vital pulpotomy in primary molars|mta vital pulpotomy in primary molars
16410058|NCT03908476|Experimental|Subjects using BurstDR SCS systems|Spinal cord stimulation with a Burst waveform.
16410059|NCT03908476|Experimental|Subjects using DRG systems|Dorsal root ganglion stimulation.
16410060|NCT03908463||The patients who undergo percutaneous coronary intervention|The patients who undergo percutaneous coronary intervention will be enrolled.
16410061|NCT03908450|Active Comparator|Control intervention|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
16410062|NCT03908450|Experimental|Experimental intervention|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
16410063|NCT03908437|Experimental|Rapid initiation|Rapid initiation of buprenorphine/naloxone, counseling, peer support and case management
16410064|NCT03908437|Active Comparator|Treatment as usual|Seeking treatment from the BAC/CRC (treatment as usual)
16410065|NCT03908424||CONTROL|Parturients who gave birth to a normal birth and did not receive epidural anesthesia.
16410066|NCT03908424||Normal Epidural|Parturients who gave birth to a normal birth with epidural anesthesia without an unintentional dural puncture.
16410067|NCT03908424||PDPH conservative treatment|Parturients who gave birth to a normal birth with epidural anesthesia and had an unintentional dural puncture, these women were treated conservatively.
16410068|NCT03908424||PDPH treated with Blood Patch|. Parturients who had a normal birth with epidural anesthesia and had an unintentional dural puncture and were treated with a blood patch following PDPH.
16410069|NCT03908411|Active Comparator|Paratracheal pressure|Left Paratracheal pressure is applied by ultrasound transducer after confirmation of the location of the esophagus.
16410070|NCT03908411|Active Comparator|Sellick's maneuver|Conventional Sellick's maneuver is applied.
16410071|NCT03908372|Experimental|Induction chemotherapy(IC)+IMRT|Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm
16410072|NCT03908372|Active Comparator|Concurrent chemoradiotherapy(CCRT)|cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy
16410073|NCT03908359|Active Comparator|traditional cataract surgery|
16410074|NCT03908359|Experimental|minimal invasive lens surgery|
16410075|NCT03908346|Other|Decision Aid for Surrogate Decision Makers|In this pilot trial all participants will be presented with the decision aid and queried as to the feasibility, acceptability and knowledge translation that is gained by exposure to the decision aid
16410076|NCT03908333|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
16410077|NCT03908320|Experimental|Menstrual Cycle Timing|
16410078|NCT03908320|Active Comparator|Menstrual Cycle Monitoring|
16410079|NCT03908307|Experimental|Study Eye|OZURDEX implant 700 μg
16410080|NCT03908294||Chronic hepatitis C under antiviral treatment with DAA|Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.
16410081|NCT03908281|Experimental|Fasted Exercise|Exercise training will be performed in the fasted state (i.e., before breakfast).
16410083|NCT03908268|Active Comparator|CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Standard Children's Learning Center Program group.
16410084|NCT03908268|Experimental|FNI plus CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Family Nurture Intervention plus Standard CLC Program group.
16410085|NCT03908255|Placebo Comparator|Control Group|The control group will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
16410086|NCT03908255|Experimental|Intervention Group|In the intervention group, patients will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
16410087|NCT03908242|Experimental|Salvianolic Acid A|2 anticipated doses are 90 mg and 180 mg.
16410088|NCT03908242|Placebo Comparator|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
16410089|NCT03908229|Experimental|Trainee colonoscopy|"In the investigation arm colonoscopy will be performed by gastroenterology fellows. The fellows will always start the case and proceed generally until they are unable to make further progress despite coaching from the staff attending.
~During the procedures with fellows, the staff attending will always actively participate in the entire procedure and assess for the presence of any lesions."
16410090|NCT03908229|Active Comparator|Experienced physician colonoscopy|In the control arm all colonoscopy will be performed by full-time board-certified gastroenterologists who have each done more than 5000 colonoscopy examinations.
16410091|NCT03908203|Other|Treatment Arm|
16410092|NCT03908190|No Intervention|Treatment As Usual|Participants will receive treatment as usual within the VHA Women's Wellness Clinic including any appropriate treatment or treatments for their medical and psychosocial concerns as determined by their primary care teams.
16410093|NCT03908190|Experimental|Treatment As Usual Plus Personalized Support for Progress|In addition to treatment as usual, women will receive the Personalized Support for Progress intervention.
16410094|NCT03908177|Experimental|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
16410095|NCT03908177|Active Comparator|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
16410096|NCT03908164|Experimental|Vaccination at <23+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW). Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
16410097|NCT03908164|Experimental|Vaccination at 24-27+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
16410098|NCT03908164|Experimental|Vaccination at 28-31+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
16410099|NCT03908138|Active Comparator|RDD group|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
16410100|NCT03908138|Active Comparator|VDD group|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
16410101|NCT03908125|Other|Continuous Glucose Monitoring Device|
16410102|NCT03908112|Active Comparator|Standard Community Concussion Care (SC)|Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.
16410103|NCT03908112|Experimental|SC plus Simple Convergence Procedures (SC+)|In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.
16410104|NCT03908112|Experimental|SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)|Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.
16410105|NCT03908099|Experimental|Fit-For-Fertility program|The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
16410106|NCT03908099|Active Comparator|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months.
16410107|NCT03908086||RA patients|Incident patients with rheumatoid arthritis as identified by the Danish National Patient Registry and the rheumatology registry, DANBIO.
16410108|NCT03908086||General population|All other adults, as Identified by the Civil Registration System. Patients who develop RA contribute person-years in the general population cohort until RA diagnosis
16410109|NCT03908073|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
16410110|NCT03908073|Placebo Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
16410111|NCT03908060|Experimental|Intravenous single-dose methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
16410343|NCT03906500|No Intervention|control group|Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020
16410112|NCT03908060|Active Comparator|Intravenous single-dose morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
16410113|NCT03908047||healthy volunteers|
16410114|NCT03908034|No Intervention|Uncontrollable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
16410115|NCT03908034|Experimental|Uncontrollable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
16410116|NCT03908034|Experimental|Uncontrollable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
16410117|NCT03908034|Experimental|Uncontrollable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
16410118|NCT03908021||children with type 1 diabetes mellitus|Saliva from 50 children ages 5 to 15 years old who had been diagnosed with type 1 diabetes mellitus and are followed at the Pediatric Endocrinology Clinic, Hadassah University Hospital Mt. Scopus and Ein Kerem, Jerusalem, Isreal,
16410119|NCT03908021||Control|50 healthy children, preferably their siblings, matched in age and gender.
16410120|NCT03908008|Active Comparator|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
16410121|NCT03908008|Experimental|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
16410122|NCT03907995|Experimental|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
16410123|NCT03907982|Experimental|DCCV + PVI|"DC cardioversion (DCCV) plus Pulmonary Vein Isolation (Cryoablation)
~At end of pulmonary vein isolation, DCCV performed (if patient still in AF). An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure."
16410124|NCT03907982|Active Comparator|DC cardioversion (DCCV)|Acute treatment of heart rhythm by cardioversion. An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure.
16410127|NCT03907956|Experimental|INTERVENTION|The subjects included in the intervention group will be treated with Dry Needling with Fascial Winding Technique according to the original Four-Pole Carpal Dry Needling approach, which has already been validated recently by means of a first ultrasound study.
16410128|NCT03907956|No Intervention|CONTROL|The individuals of the control group will remain within the normal course of their waiting list status for CTS surgery, without receiving any extraordinary treatment to what is normally practiced in this situation.
16410129|NCT03907943|Other|Surgical treatment of carotid endarterectomy|The change in the cognitive function will be assessed in all patient undergoing carotid endarterectomy.
16410130|NCT03907930|Active Comparator|conventional|this arm will have both nephrostomy tube and ureteric catheter after completing the operation
16410131|NCT03907930|Active Comparator|tubeless|the arm will have only ureteric catheter rafter completing the operation
16410132|NCT03907917|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
16410133|NCT03907917|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
16410157|NCT03907735||After term pregnancy (3rd trimester)|Third trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained at the time of cesarean delivery.
16410158|NCT03907722||Genotypic variants|AA, AG and GG genotype
16410159|NCT03907709||First Responders in In-Home Addiction Treatment Program|- First responders (individual who does or has worked as a police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer)
16410160|NCT03907696|Other|Intervention|The intervention arm participate in an educational program that aimed at reducing stigma
16454674|NCT03603340|Active Comparator|Control group|
16410134|NCT03907891|Experimental|Motivational social support (MSS) from a nurse alone|Participants will receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse. The nurse will apply motivational interviewing techniques to explore the patient's thoughts about making a behavior change to attain adequate physical activity (PA). Patients will be encouraged to exercise based on instructions provided by the hospital staff. The patient's ability to take their radial pulse before and after PA will be assessed, and patients will be provided written instructions on the correct manner to take a radial pulse. Patients will receive daily motivational text messages from the nurse for 6 weeks. The texts will be sent via the REDCap automated system. The automated system confirms that texts were sent. The motivational interviewer nurse will confirm by phone that the patient receives her/his first text from the REDCap system.
16410135|NCT03907891|Experimental|MSS from nurse with additional significant other support (SOS)|Participants will also receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse and text messages from a nurse for 6 weeks, as described in arm 1. In addition, patients will receive daily text messages from their significant other for 6 weeks. Researchers developed the 42 significant other text messages. The motivational interviewing nurse will provide the text messages to the significant other in writing. The order of texts sent from the significant other will be randomized so that we can determine their effectiveness in general. The significant other will be asked to type and send the text message listed for each date to the patient. Study staff will confirm by phone that the patient received the first text from the significant other. Patients will be asked to track the number of text messages from the significant other that they read over the 6-week period using the log provided.
16410136|NCT03907891|Active Comparator|Attention control (AC)|Participants in the AC group will receive a 60-minutes session with a nurse via videoconference or telephone (at participant discretion) viewing of American Heart Association educational videos and and documents regarding IHD. The nurse will additionally provide a written copy of the hospital physical activity instructions, will assess the patient's ability to take their pulse, and provide written instructions on the correct manner to take a radial pulse.
16410137|NCT03907878|Experimental|Ligelizumab|Ligelizumab q4w
16410138|NCT03907865|Experimental|intense|Patients have been randomized to receive Softacort eye drops for 12 days 4 times daily followed by 2 days twice daily treatment resulting in a total time of 14 days
16410139|NCT03907865|Experimental|standard|Patients have been randomized to receive Softacort eye drops for 8 days 3 times daily followed by 3 days twice daily treatment resulting in a treatment time of 11 days total
16410140|NCT03907852|Experimental|gavo-cel|gavo-cel
16410141|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by TC-210 T Cells
16410142|NCT03907852|Experimental|Phase 2 Dose|MPM, cholangiocarcinoma, and ovarian cancer will receive gavo-cel at the RP2D; NSCLC patients will receive gavo-cel at the RP2D or gavo-cel at the RP2D followed by anti-PD1
16410143|NCT03907839|Active Comparator|Endurance Training (ET)|endurance training for control group
16410144|NCT03907839|Experimental|ET+cognitive training(CT)|endurance training added to cognitive training for exprimental COPD group
16410145|NCT03907826|Experimental|PD-1 antibody plus IMRT|Patients randomized to this arm will receive PD-1 antibody (JS001) 240mg every three weeks during IMRT and as adjuvant therapy.
16410146|NCT03907826|Active Comparator|IMRT|Patients randomized to this arm will receive IMRT alone.
16410147|NCT03907813|Experimental|liposomal bupivacaine infiltration|Local infiltration of all wound layers with liposomal bupivacaine (Exparel(R)) 20 ml diluted with 70 ml of normal saline to 90 ml for patient with a BMI of 39 and under. If BMI is 40 or more the 20 ml of liposomal bupivicaine will be diluted to 150 ml by adding 130 ml of normal saline
16410148|NCT03907813|Placebo Comparator|Saline infiltration|Local infiltration of all wound layers with saline, using to match the amount. The amount of total fluid is divided into 4 and instilled with 1-2 ml at a time in between fascial layers after fascial closure. Each 1/4 will be instilled laterally (2) and on each side of the incision(2)- extra fluid is placed subcutaneously.
16410149|NCT03907800|Experimental|Nab-paclitaxel + Carboplatin ± Herceptin|
16410150|NCT03907787|Other|One-group pretest-posttest quasi-experimental design|50 subjects with moderate knee osteoarthritis were supplied for four weeks with two tablets/day, each containing 350 mg of standardized extracts of Zingiber officinale and Acmella oleracea.
16410151|NCT03907748|Experimental|Music Intervention|The music intervention will be provided to participant dyads (people with dementia and their cohabiting family caregivers) allocated to the first intervention. Caregivers will be trained to use the music intervention in three 2-hour training sessions with an intervention trainer (a music therapist). Training will take place at the dyad's home. The caregiver will then be asked to deliver the music intervention to the person with dementia at least 5x per week for 30 minutes.
16410152|NCT03907748|Active Comparator|Reading Intervention|The reading intervention will be provided to participant dyads (people with dementia and their cohabiting caregivers) allocated to the second intervention. Caregivers will be trained to use the reading intervention in three 2-hour training sessions with an intervention trainer. Training will take place at the dyad's home. The caregiver will then be asked to deliver the reading intervention to the person with dementia at least 5x per week for 30 minutes.
16410153|NCT03907748|No Intervention|Standard Care|Participant dyads (people with dementia and their cohabiting caregivers) allocated to the standard care group will not receive any training or be asked to deliver an intervention.
16410154|NCT03907735||2nd trimester|Second trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained primarily after second trimester surgical abortions or Dilation and Evacuation (D&E) procedures as well as after rare gravid hysterectomies or after late second trimester cesarean deliveries.
16410155|NCT03907735||Non-pregnant|Myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in non-pregnant women undergoing gynecologic surgery under anesthesia for laparoscopic tubal ligation.
16410156|NCT03907735||1st trimester|First trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained after first trimester surgical abortions or suction dilation and curettage (D&C).
16456153|NCT03592862|Placebo Comparator|Placebo|oral capsule, once daily
16410162|NCT03907683|Experimental|Random Messaging|Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.
16410163|NCT03907670||CML patients who will receive imatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment (imatinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
16410164|NCT03907670||CML patients who will receive nilotinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(nilotinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
16410165|NCT03907670||CML patients who will receive dasatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(dasatinib) measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
16410166|NCT03907657|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with Von-Hippel Lindau disease will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
16410167|NCT03907644|Experimental|Active FPS|We use Starstim AC (alternative current) -Stimulator R32. FPS protocol will be used with 20 minutes 2mAmp 6 Hz tACS to the middle frontal gyrus (DLPFC, F4 in EEG electrodes with 10-20 system measurement) and inferior parietal cortex (IPC, P4), as the main nodes of the frontoparietal network, in synchronous oscillation. The 4 return electrodes will receive 0.5 mAmp each around each active electrode (High Definition Montage). The electrodes are silver/silver chloride that are wet with conductive gel. We will use surface landmarks and EEG caps on the head to place the electrodes, which are held in place by head caps with holes indicating places for electrode positioning.
16410168|NCT03907644|Sham Comparator|Sham FPS|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
16410169|NCT03907631||Acute Severe Ulcerative Colitis|Patients hospitalised for acute severe ulcerative colitis will be invited to participate. Participants will be treated at the discretion of their treating physicians as per standard of care. We expect some participants will undergo an endoscopic assessment, some participants will be treated with standard versus accelerated infliximab dosing, permitting comparisons, in addition to other treatment strategies.
16410170|NCT03907618||Group 1 diagnosed with Diabetes Mellitus|Patients with Type 1 Diabetes Mellitus aged 18-40 years who had ovarian reserve with gynecological examination
16410171|NCT03907618||group 2 control group|Healthy volunteer patients aged 18-40 years who have no diagnosis of Type 1 Diabetes Mellitus and whose ovarian reserve is evaluated by gynecological examination
16410172|NCT03907592|Experimental|L-carnitine Group|Group participated in the training protocol and supplemented by 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout 24 weeks.
16410173|NCT03907592|Experimental|Leucine Group|Group participated in the training protocol and supplemented by 4000mg of L-leucine per day throughout 24 weeks.
16410174|NCT03907592|Experimental|Control Group|Group participated in the training protocol without any supplementation throughout 24 weeks.
16410175|NCT03907579|Experimental|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
16410176|NCT03907566||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals, and Turkish version of the Eating Assessment Tool.
16410177|NCT03907553||Health and Anemia|"individuals belonging to the Health and Anemia'' prospective population-based observational study (2003-2013) of all elderly residents (>65 years) in the municipality of Biella"
16410178|NCT03907553||Monzino|"individuals belonging to the Monzino Over 80 trial"
16410182|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells) IP Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy.
16410183|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells) IV Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy.
16410184|NCT03907514|Experimental|Intervention Group (IG)|"The adolescents in this group will use the FALE application through a smartphone in the waiting room before the dental appointment. When starting to answer the application, the adolescent will report his/her level of dental anxiety through the question, How do you feel about coming to see your dentist today?, and record his/her answer on a seven-point face scale. Then the participant will continue to answer the 12 other questions, and finally registers his/her anxiety level once more through the same question."
16410185|NCT03907514|No Intervention|Control Group (CG)|"Similarly to IG, the adolescents in this group will use the FALE application through a smartphone, but only to record their level of anxiety by answering the question How do you feel about coming to see your dentist today? using a seven-point face scale. Instead of continuing to answer the other questions, the application will guide him to wait for the one-minute interval (expected time to answer the questionnaire) and, once more, ask the same question regarding his/her feeling about the experience with the dentist."
16410803|NCT03903575|Active Comparator|Two-Step Retraction|Group treated by retracting the canines incisors in two different steps.
16410186|NCT03907501|Experimental|Synbiotic|Two grams of organic Triphala powder (Banyan Botanicals, Inc.) with 1 capsule VSL#3® (VSL Pharmaceuticals, Inc.) probiotic taken with a few ounces of room temperature water in the morning and at bedtime for 8 weeks. Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.) and VSL#3® (VSL Pharmaceuticals, Inc.) capsules.
16410187|NCT03907501|Active Comparator|Probiotic|Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
16410188|NCT03907501|Placebo Comparator|Placebo|Subjects will be provided both written and verbal instructions and given a kit containing placebo capsules. Subjects will be instructed to take 2 (inert) capsules with room temperature water in the morning and at bedtime.
16410191|NCT03907475|Active Comparator|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16410192|NCT03907475|Experimental|Arm II (gemcitabine hydrochloride, durvalumab)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16410193|NCT03907475|Experimental|Arm III (pegylated liposomal doxorubicin, durvalumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16410194|NCT03907475|Experimental|Arm IV (capecitabine, durvalumab)|Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, and durvalumab IV over 60 minutes on days 8 of cycle 1, day 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16410195|NCT03907475|Experimental|Arm V (carboplatin, durvalumab)|Patients receive carboplatin IV over 30-60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16410196|NCT03907475|Experimental|Arm VI (paclitaxel, durvalumab)|Patients receive paclitaxel IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16410197|NCT03907475|Experimental|Arm VII (nab-paclitaxel, durvalumab)|Patients receive nab-paclitaxel IV over 30 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16410198|NCT03907462|Experimental|Treatment One|Participants assigned to the SMART 2.0 with technology and personal health coaching treatment group (i.e., treatment one) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total, and 4) technology-mediated, real-time individual health coaching. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; be asked to interact with their online group via social media as frequently as possible; and speak with their health coach at a predetermined session schedule.
16410199|NCT03907462|Experimental|Treatment Two|Participants assigned to the SMART 2.0 technology alone treatment group (i.e., treatment two) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, and 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; and be asked to interact with their online group via social media as frequently as possible.
16410200|NCT03907462|No Intervention|Control|Participants assigned to the control group will receive a consumer-level wearable and scale with a corresponding app to use at their discretion.
16410201|NCT03907449||Symptoms of Strep Throat|"Any patient presenting with symptoms of pharyngitis
~Fever
~Sore throat
~Swollen lymph nodes in neck
~Redness of throat/tonsils
~White/yellow patches on tonsils
~Not currently on antibiotics"
16410202|NCT03907436|Sham Comparator|USDA diet arm|Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.
16410203|NCT03907436|Experimental|Mediterranean diet arm|Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.
16410206|NCT03907410|Experimental|Arm 1: Incentives, plus reminders & feedback (IRF)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).
~During the Experiment period (Months 1-3), Arm 1 will receive the IRF intervention.
~During the Observation period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
16410207|NCT03907410|Active Comparator|Arm 2: Reminders & feedback ONLY|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).
~During the Experiment period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives.
~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
16410208|NCT03907410|No Intervention|Arm 3 (Control)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).
~During the Experiment period (Months 1-3), Arm 3 will not receive any component of the IRF intervention.
~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
16410209|NCT03907397|Active Comparator|Treatment|Ingests peanut - . Depending upon reaction threshold, participants may begin with different starting amounts of store bought peanut butter measured with study-supplied kitchen measuring spoons.
16410210|NCT03907397|No Intervention|Avoidance|Avoids peanut, standard care
16410211|NCT03907384|Experimental|Mat Pilates training|The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
16410212|NCT03907384|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
16410213|NCT03907371|Experimental|Donepezil|Patients receive donepezil with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
16410214|NCT03907371|Placebo Comparator|Control|Patients receive placebo with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
16410215|NCT03907358||cataract in old age|
16410216|NCT03907358||cataract in young age|
16410217|NCT03907345|Experimental|Exposure|Participants of this arm receive one 120-minute session of exposure treatment for spider fear.
16410218|NCT03907345|No Intervention|No Exposure|Participants of this arm receive no exposure or other adequate treatment.
16410219|NCT03907332|Experimental|Intervention Arm|"Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).
~Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:
~One visit during the second trimester of the pregnancy
~Two visits during the third trimester of pregnancy"
16410220|NCT03907332|No Intervention|Control Arm|Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.
16410221|NCT03907306|Experimental|Patients after open hemorrhoidectomy (study group)|Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.
16410222|NCT03907306|Active Comparator|Patients after open hemorrhoidectomy (control group)|Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.
16410223|NCT03907293||Phase-III Cardiac Rehabilitation|Eight weeks of supervised exercise sessions (one session per week).
16410224|NCT03907293||Phase-III and Phase IV Cardiac Rehabilitation|Twenty weeks of supervised exercise sessions (one session per week for first eight weeks [phase-III], session frequency determined by participant for remaining twelve weeks [phase-IV].
16410225|NCT03907293||No Cardiac Rehabilitation|Participants who declined to take part in a cardiac rehabilitation programme.
16410226|NCT03907280|Experimental|T1-T2-R-T3|
16410227|NCT03907280|Experimental|R-T1-T2-T3|
16410228|NCT03907280|Experimental|T2-R-T1-T3|
16410229|NCT03907267|Experimental|Taurine|
16410230|NCT03907267|Placebo Comparator|Saline|
16410231|NCT03907254|Experimental|National Capital Region (NCR)|10-week longitudinal pre-post study, in which each participant will serve as their own control. Each participant will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up, and at a three-month post-training follow-up. The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
16410232|NCT03907241|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
16410233|NCT03907228|Experimental|RHT-3201|Lactobacillus rhamnosus IDCC 3201, Tyndallization (RHT-3201) (100 billion Colony Forming Units/sachet)
16410234|NCT03907228|Placebo Comparator|Placebo|Dextrose Anhydrous
16410235|NCT03907215|Other|Treatment A and B|"On Day 1 and Day 2, subjects will EITHER receive:
~a single dose of 50 mg ACT-541468 (Treatment A) on Day 1 and a single dose of ACT- 541468 placebo (Treatment B) on Day 2 OR
~a single dose of ACT-541468 placebo (Treatment B) on Day 1 and a single dose of 50 mg ACT-541468 (Treatment A) on Day 2."
16414236|NCT03879928|Experimental|FM101 2400 mg for SAD|Single ascending doses of FM101
16410236|NCT03907215|Other|Treatment C, D, E, and F|"From Day 3 to Day 10, subjects will on each day receive:
~• a single dose of 20 mg citalopram and EITHER a single dose of ACT-541468 placebo OR a single dose of 50 mg ACT-541468."
16410237|NCT03907202|Active Comparator|KBP-089|"Three cohorts:
~Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg
~Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg
~Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg"
16410238|NCT03907202|Placebo Comparator|Placebo|For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.
16410239|NCT03907189||Emergent Inflammation|Subjects with emergent inflammation detected by Podimetrics RTM Mat within the last week.
16410240|NCT03907189||No Inflammation|Subjects with no emergent inflammation detected by Podimetrics RTM Mat within the last week.
16410241|NCT03907176|Experimental|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (regimen 1)
16410242|NCT03907176|Experimental|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (regimen 2)
16410243|NCT03907163|Experimental|healthy subjects|
16410244|NCT03907163|Placebo Comparator|healthy volunteers|
16410245|NCT03907150||Pneumothorax|Pneumothorax
16410246|NCT03907150||Normal|Normal lung
16410247|NCT03907124|Experimental|Genetically-guided treatment arm|The active arm - where patients will receive genetically-guided treatment
16410248|NCT03907124|No Intervention|Treatment as usual (TAU) control arm|TAU is the control arm - where patients will continue to receive their usual treatment as before.
16410249|NCT03907111|Experimental|Chitosan gauze|100cm^2 Gauze made by chitosan material. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
16410250|NCT03907111|Placebo Comparator|Traditional gauze|100cm^2 Gauze made by traditional cotton yarn. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
16410251|NCT03907098|Experimental|endostar + chemotherapy|"Endostar 15 mg per square of BSA, continuous intravenous infusion 24 hours a day, continuous administration for 7 days, every three weeks.
~Chemotherapy regimens are selected by physicians based on regular clinical decision."
16410252|NCT03907085|Active Comparator|High intensity laser therapy (HILT) + exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
16410253|NCT03907085|Placebo Comparator|Placebo HILT + exercise|Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
16410254|NCT03907072|Experimental|WVE-210201 (3 mg/kg)|Weekly IV administrations of WVE-210210 at 3 mg/kg
16410255|NCT03907072|Experimental|WVE-210201 (4.5 mg/kg)|Weekly IV administrations of WVE-210210 at 4.5 mg/kg
16410256|NCT03907072|Placebo Comparator|Placebo|Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021
16410257|NCT03907059|Active Comparator|Omnivorous|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (whey) + 12 weeks of resistance training
16410258|NCT03907059|Experimental|Vegan|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (soy) + 12 weeks of resistance training
16410261|NCT03907033|Active Comparator|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
16410262|NCT03907033|Experimental|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
16410263|NCT03907020|Experimental|Meabolic Availabiliy of Barley|Healthy adult men
16410264|NCT03907007|No Intervention|Sole Medication|Monitoring under current prescribed medication
16410265|NCT03907007|Active Comparator|Combined stimulation & medication|Concurrent usage of stimulation with the prescribed medication
16410266|NCT03907007|Active Comparator|Sole Stimulation|Alternating usage of stimulation to the prescribed medication
16410267|NCT03906994|Experimental|Subjects with Amblyopia|Adult amblyopia subjects will play the video game Mario Kart Wii
16410268|NCT03906981||Caries free|6-9 year old caries free children
16410269|NCT03906981||Caries active|6-9 year-old caries active (>5 dmft/DMFT) children
16410270|NCT03906968|Experimental|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
16410271|NCT03906955|Experimental|Efficacy for Lifestyle PA|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for lifestyle physical activity.
16410272|NCT03906955|Active Comparator|Efficacy for Work-life Balance|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for work-life balance.
16410344|NCT03906487|Experimental|Intimate partner violence|The women in this arm must have suffered at least two physical aggressions. They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.
16410273|NCT03906942|Experimental|Fun For Wellness (FFW)|Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
16410274|NCT03906942|No Intervention|Usual Care (UC)|Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center.
16410275|NCT03906929|Experimental|Pediatric forearm fracture|
16410276|NCT03906916|Experimental|Patients with suspicion of invasive candidiasis|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
16410277|NCT03906903|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, three per weekday, with a final result of 30 sessions in this modality with a 30 minutes Cognitive Stimulation after session.
16410278|NCT03906903|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 30 sessions, three per weekday with a 30 minutes Cognitive Stimulation afterwards.
16410279|NCT03906877|Experimental|Injection laryngoplasty group (IL)|The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.
16410280|NCT03906877|Experimental|Voice therapy group (VT)|Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).
16410281|NCT03906877|Sham Comparator|Sham group|The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.
16410282|NCT03906864|No Intervention|Control group|Usual care consisted of 2 half hourly therapy sessions per day from Monday to Friday and medical ward rounds 3 times a week. Multidisciplinary rounds were conducted every 2 weeks. Any specific goals or interventions were at the discretion of the managing team.
16410283|NCT03906864|Experimental|Intervention group|Intervention group had structured assessments and checklists (as part of the integrated care pathway) in addition to usual care.
16410284|NCT03906851|Experimental|Activity and diet|"Multi-component, holistic model with a) physical activity, b) nutrition, and c) psychosocial work.
~A: physical activity will be provided as a pedagogical tool in subjects Mathematics, Norwegian and English B: Focus on school meals and menus in school cafeteria C: Psychosocial work with focus on the associations between physical activity, nutrition and psychosocial health. Collaboration between schools and school health services"
16410285|NCT03906851|No Intervention|Control|Schools are required to perform teaching activities, school meals and school cafeteria menus as usual
16410286|NCT03906838|Experimental|Regional Nerve Block|Subjects in the regional anesthesia cohort will have a regional anesthesia block and/or catheter placement administered according to current hospital policies and our established standard of care.
16410287|NCT03906838|No Intervention|No Regional Nerve Block|Subjects in the no regional anesthesia cohort will not get pre-operative regional anesthesia, and their surgery and anesthesia will be performed according to normal policies and standard of care in our hospital.
16410288|NCT03906825|Active Comparator|dietary supplement CEAG|The dietary supplements consists of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG).
16410289|NCT03906825|Placebo Comparator|Placebo|The Placebo does not contain any CEAG.
16410290|NCT03906812|Active Comparator|Unmonitored floor admission|Participants in this arm will be admitted to an unmonitored floor bed.
16410291|NCT03906812|Active Comparator|Floor admission with telemetry|Participants in this arm will be admitted to a telemetry bed.
16410292|NCT03906799|Experimental|Low OMT-28|Verum, low OMT-28
16410293|NCT03906799|Experimental|Middle OMT-28|Verum, middle OMT-28
16410294|NCT03906799|Experimental|High OMT-28|Verum, high OMT-28
16410295|NCT03906799|Placebo Comparator|Placebo|Placebo
16410296|NCT03906786|Experimental|motivacional interviewing group|
16410297|NCT03906786|No Intervention|control group|
16410298|NCT03906773||Intervention|The investigators seek to conduct a pragmatic trial including 2 sister clinical sites to test an innovation using a patient portal framework for Advance Care Planning. The intervention site implemented the intervention (secure patient portal delivered pre-visit planning framework for Advance Care Planning communication). The presence of ACP and the quality of documentation will be assessed through post-intervention chart review. Practice level enrollment was sought for the trial, and the framework will be delivered to all patients during a period of roll out. About 250 patients will receive the intervention.
16410299|NCT03906773||control|The control site delivered usual care during the same period of roll out.
16410300|NCT03906747||Patients|Patients at their end-of-life (EOL) phase attending the emergency department
16410301|NCT03906747||Family members and next-of-kin of (EOL) patients|Family members and next-of-kin of EOL patients in the emergency department
16410302|NCT03906747||Healthcare workers|Comprised of doctors in the emergency department, nurses and general practitioners
16410303|NCT03906734|Experimental|alfieri technique + Septal myectomy|Septal myectomy plus mitral valve repair using alfieri stich
16410304|NCT03906734|Active Comparator|Subvalvular intervention + Septal myectomy|Septal myectomy plus subvalvular mitral valve intervention
16410547|NCT03905148|Experimental|Part B: Group 2|Endometrial cancer with confirmed K-RAS mutations, approximately 15 participants
16410305|NCT03906721|Experimental|Conditioning & Open-Label Placebo (COLP)|Days 1 to 3 will include the acquisition phase where oxycodone will be prescribed on a schedule of 3-4 times per day and paired with open-placebo and smelling the essential oil. Days 4 to 6 will be the evoked phase, and patients will receive full oxycodone dosage on alternating days with open placebo and smelling the essential oil.
16410306|NCT03906721|Other|Treatment-as-usual|For the duration of the study, days 1 to 6, oxycodone will be prescribed on a schedule of 3-4 times per day.
16410307|NCT03906708||Premature Infants|Premature infants born between 24+0 and 36+6 weeks of gestation.
16410308|NCT03906695|Experimental|10-Day Schedule|"10-Day Schedule
~Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle."
16410309|NCT03906695|Experimental|5-Day Schedule A|"5-Day Schedule A
~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
16410310|NCT03906695|Experimental|5-Day Schedule B|"5-Day Schedule B
~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
16410311|NCT03906695|Experimental|5-Day Schedule C|"5-Day Schedule C
~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
16410312|NCT03906695|Experimental|7-Day Schedule|"7-Day Schedule
~IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle."
16410313|NCT03906682|Experimental|RAP Club program|RAP Club is a 12-session universal prevention program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
16410314|NCT03906682|Active Comparator|Healthy Topics program|Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
16410315|NCT03906669|Active Comparator|Letrozole|Letrozole 2.5mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
16410316|NCT03906669|Experimental|Letrozole and Prometrium|Letrozole 2.5mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
16410317|NCT03906669|Experimental|Tamoxifen and Prometrium|Tamoxifen 20mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
16410318|NCT03906656|Active Comparator|KAFO/SCO|Home use of 3 months with existing knee ankle foot orthosis (KAFO) or existing stance control orthosis (SCO)
16410319|NCT03906656|Experimental|C-Brace|Home use of 3 months with newly fitted C-Brace microprocessor-controlled stance and swing control orthosis.
16410320|NCT03906643|Experimental|HS-201|HS-201 will be administered intravenously as a single dose
16410321|NCT03906630||Shoulder patients|
16410322|NCT03906617|Experimental|Bupivacaine/epinephrine + dexamethasone|
16410323|NCT03906617|Active Comparator|Liposomal bupivacaine|
16410324|NCT03906604|Other|Dominant hand-open Carpal Tunnel Release|Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
16410325|NCT03906604|Other|Dominant hand-Incisionless thread carpal tunnel release|Incisionless thread carpal tunnel release on the dominant hand.
16410326|NCT03906591|Experimental|allogenic bone ring|
16410327|NCT03906591|Active Comparator|autogenous bone ring|
16410328|NCT03906578|Active Comparator|Probiotic|Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10^11 CFU) in the evening for 8 weeks
16410329|NCT03906578|Placebo Comparator|Placebo|Two sachets placebo in the evening for 8 weeks
16410330|NCT03906565|Experimental|utidelone|Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC
16410331|NCT03906552|Experimental|acupressure group|"2 neonates did not calm down before heel lancing; oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well.
~Acupressure was performed when the mother was holding the neonate on her arm. For two minutes, acupressure was performed in the acupressure points (Kun Lun (UB60) and Taixi (K3). Each point was applied acupressure for 60 seconds, and heel lancing was performed right after this procedure. The acupuncture points that Kun Lun (UB60) and Taixi (K3) are on the side of the ankle."
16410332|NCT03906552|Experimental|masssage group|"oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).
~Foot massage was performed when the mother was holding the neonate on her arm. Each neonate was given foot massage for two minutes, and heel lancing was performed right after the massage."
16410333|NCT03906552|No Intervention|control group|"oxygen saturation and heart rate values of 1 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).
~No application was made to theneonates in the control group before heel lancing procedure"
16410334|NCT03906539|Placebo Comparator|Control Group|The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
16410335|NCT03906539|Experimental|VCO Group|The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
16410340|NCT03906513|Active Comparator|Active treatment|20 patients will be treated with active treatment (OMK2)
16410341|NCT03906513|Placebo Comparator|Placebo|10 patients will be treated with placebo (lubricant eye drops)
16410342|NCT03906500|Experimental|Intervention|"The intervention consist of three main components.
~School environmental component
~The component targeting the high school environment consisted of two separate elements:
~Revision of school alcohol policy
~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.
~Student components
~The Student components consisted of three main elements:
~Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee
~Pocket movie campaign
~Social norms campaign
~Parent components
~The parent component consisted of three separate elements:
~Parent Information Meeting
~Parent Information Folder
~Parent Information Website"
16410345|NCT03906487|Active Comparator|Control group|The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event. These women will be recruited by a call for volunteers.
16410346|NCT03906474|Experimental|Group 1|A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
16410347|NCT03906474|Experimental|Group 2|A second blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to one blood-stage challenge in the VAC063 trial. Group 2 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 3 (malaria-naïve controls).
16410348|NCT03906474|Experimental|Group 3|Malaria-naïve controls will receive a primary blood-stage controlled human P. falciparum malaria infection. Group 3 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 2 (undergoing a second challenge).
16410349|NCT03906448|Experimental|Astrocytoma Patients|Patients newly diagnosed with Grade II and III astrocytoma.
16410350|NCT03906448|No Intervention|Control Arm|Data collection from medical record only
16410351|NCT03906435|No Intervention|Control Arm|Standard of care information given by NICU staff and Follow up Clinic staff, including information about health care, diagnosis, medications, daily cares, anticipatory guidance, and discharge prep information.
16410352|NCT03906435|Experimental|Intervention CBT Arm|In addition to Standard of care information that the control arm receives, this arm will also receive 5 CBT sessions focusing on past NICU trauma, emotional coping, parental perceptions of child vulnerability, and helpful parenting and emotional coping skills.
16410353|NCT03906422|Experimental|"A: 0.016 Nitinol"|"0.016 Nitinol (3M Unitek, Monrovia, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
16410354|NCT03906422|Experimental|"B: 0.016 Ormco 27oC NiTi"|"0.016 Ormco 27oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
16410355|NCT03906422|Experimental|"C: 0.016 Ormco 35oC NiTi"|"0.016 Ormco 35oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
16410356|NCT03906409|Active Comparator|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
16410357|NCT03906409|Experimental|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
16410358|NCT03906396|Experimental|Intervention Group|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant for 6 weeks, 3 times per week. Games use for the activity are Sports Kinect and Sports Kinect 2. The activity can be performed in solo or in pairs with another participant. The game activity will be played only at the site chosen for this study.
16410359|NCT03906396|No Intervention|Control Group|No standard activity is provided for the participants. The participants will continue with their normal daily life activities.
16410360|NCT03906383|Experimental|Remote Ischemic Conditioning|
16410361|NCT03906370||MS patients/cases|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
16410362|NCT03906370||Healthy subjects/controls|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
16410363|NCT03906305|Experimental|Dry needling in a myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into trigger point spastic muscle of the shoulder.
16410364|NCT03906305|Active Comparator|Dry needling in a non myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into a non trigger point spastic muscle of the shoulder.
16410365|NCT03906292|Experimental|Asciminib 60mg QD|Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
16410366|NCT03906292|Experimental|Asciminb 20 mg BID|Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
16410367|NCT03906292|Experimental|Asciminib 40 mg QD|Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
16410368|NCT03906292|Experimental|Asciminib 80 mg QD|Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
16410369|NCT03906292|Experimental|Asciminib 80 mg QD monotherapy|Asciminib 80 mg QD as a single agent
16410370|NCT03906279||Myopic participants|
16410371|NCT03906279||Emmetropic participants|
16410372|NCT03906279||Hyperopic participants|
16410373|NCT03906266|Active Comparator|nutric score|> 5 indicates high risk for malnutrition < 4 indicates low risk for malnutrition
16410374|NCT03906266|Placebo Comparator|adductor pollicis|< 20 mm indicates high high risk for malnutrition > 20 mm indicates low risk for malnutrition
16410375|NCT03906266|Placebo Comparator|SGA score|SGA 1 indicates no malnutrition SGA 2 indicates good diet SGA 3 indicates high risk for malnutrition
16410376|NCT03906266|Placebo Comparator|NRS 2002 score|> 3 indicates high risk for malnutrition
16410377|NCT03906253|Experimental|Factionated Laser Resurfacing - Right Arm|Right forearm treatment of fractionated laser resurfacing.
16410378|NCT03906253|Experimental|Factionated Laser Resurfacing - Left Arm|Left forearm treatment of fractionated laser resurfacing.
16410379|NCT03906240|No Intervention|No intervention|Veterans will access the online portal and complete session measures, but will not be presented with any intervention content (i.e., videos, journaling exercise, and goal setting exercise)
16410380|NCT03906240|Experimental|Moral Elevation Intervention|Moral Elevation Intervention (described in intervention section).
16410381|NCT03906227|Active Comparator|low CD5+ /on maintenance|Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
16459033|NCT03572972||Patients prescribed rivaroxaban|
16410382|NCT03906227|Active Comparator|high CD5/ on maintenance|Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
16410383|NCT03906227|Experimental|high CD5 / NO maintenance|Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
16410384|NCT03906201|Experimental|Control Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment
16410385|NCT03906201|Experimental|Ecdysterone Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment
16410386|NCT03906188|Experimental|LitEmotion group|This group will play to LitEmotion video game.
16410387|NCT03906188|No Intervention|Control group|This group will no do receive any intervention with the video game
16410388|NCT03906175|Experimental|Whole-body hyperthermia|Whole-body hyperthermia will be applied 2 times during 4 weeks. At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
16410389|NCT03906175|No Intervention|Wait list|Participants will wait for 6 weeks (primary outcome assessment point). They will then receive the same treatment procedure as the experimental group. They will also be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
16410390|NCT03906162|Experimental|Motivational interviewing|Experimental content + base intervention
16410391|NCT03906162|Active Comparator|Control intervention|Base intervention
16410392|NCT03906149|Experimental|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
16410393|NCT03906149|Active Comparator|Standard medical care|Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.
16410394|NCT03906136|Experimental|TREAT-TO-TARGET (T2T)|"Participants will receive secukinumab at a dose of 150 milligrams (mg) as subcutaneous (s.c.) injection at 150 mg dose at Baseline, Week 1, 2, 3, 4 and 8. From Week 12, only responders will continue to receive 4-weekly doses until Week 32 if they maintain the response. In case these patients experience a loss of response from week 24 they will be escalated to secukinumab 300 mg s.c. every 4 weeks until Week 32.
~Patients who are non-responders at Week 12 will receive 4-weekly secukinumab 300 mg s.c. until Week 24. From Week 24, only responders will continue to receive 4-weekly secukinumab 300 mg s.c. until Week 32. Patients who are non-responders to secukinumab 300 mg at Week 24 will receive biweekly of adalimumab biosimilar 40 mg s.c. until Week 34"
16410395|NCT03906136|Active Comparator|Standard-of-care (SOC)|SOC treatment up to the maximum recommended dose at the discretion of the investigator as according to current recommendation for treatment of axSpA
16410396|NCT03906123|Experimental|NBP|DL-3-n-butylphthalide (NBP), soft capsule, 200mg Tid, po, for 48 weeks.
16410397|NCT03906123|Placebo Comparator|Placebos|Placebo, soft capsule, 200mg Tid, po, for 48 weeks.
16410398|NCT03906110||C-Cares|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) Materials and FIT kits.
16410399|NCT03906110||C-Cares Plus|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) materials, FIT kids, and personalized one-on-one education and coaching.
16410400|NCT03906097|Experimental|intervention|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
16410401|NCT03906097|No Intervention|control|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
16410402|NCT03906084|Active Comparator|Corticotomy facilitated orthodontics.|Corticotomy is carried out under local anesthesia in right side.
16410403|NCT03906084|Experimental|Corticotomy and low level laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
16410404|NCT03906071|Experimental|Nivolumab and Sitravatinib|Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.
16410405|NCT03906071|Active Comparator|Docetaxel|Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.
16410406|NCT03906058|Experimental|Anlotinib|
16410407|NCT03906045|Experimental|All patients|10 patients with moderate COPD and 10 patients with severe/very severe COPD inhale BGF followed by a breath hold of up to 10 seconds.
16410408|NCT03906032|Experimental|Intra-medullary hip Nail|Surgery
16410409|NCT03906032|Active Comparator|Sliding hip screw|Surgery
16410410|NCT03906006|Experimental|ABP-671, Cohort 1-|ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
16410411|NCT03906006|Experimental|ABP-671, Cohort 2-|ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
16410412|NCT03906006|Experimental|ABP-671, Cohort 3-|ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
16410413|NCT03906006|Experimental|ABP-671, Cohort 4-|ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
16410548|NCT03905148|Experimental|Part B: Group 3|Tumor type of interest based on preliminary anti-tumor clinical activities observed in Part A, approximately 15 participants
16410414|NCT03905993||Experimental: unique group.|At V0: 1238 subjects were screened At V1: 1012 subjects (12 later withdrew) gave the following samples: blood, nasal swab,stool. 323 subjects among 1000 gave one additional sample (Skin Biopsy) At V2: 504 subjects came at V2 to perform blood, nasal swab and stool samples
16410415|NCT03905980||Vaginal delivery|woman who terminate their pregnancy by vaginal delivery
16410416|NCT03905980||Cesarean delivery|woman who terminate their pregnancy by cesarean delivery
16410417|NCT03905967|Experimental|Lenvatinib + TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib.
16410418|NCT03905967|Active Comparator|Lenvatinib|Lenvatinib alone
16410419|NCT03905954||Parkinson's Diagnosis|Usual care
16410420|NCT03905941|Experimental|Metformin then oral combined hormonal contraceptives|Subjects will take metformin 2000 mg/day for the first 6 months, followed by 6 months of oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg.
16410421|NCT03905941|Active Comparator|Oral combined hormonal contraceptives then metformin|Subjects will take oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg for the first 6 months, followed by 6 months of metformin 2000 mg/day.
16410422|NCT03905928|Experimental|18mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a tobacco flavor.
16410423|NCT03905928|Placebo Comparator|0mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a tobacco flavor.
16410424|NCT03905928|Experimental|18mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a strawberry vanilla flavor.
16410425|NCT03905928|Placebo Comparator|0mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a strawberry vanilla flavor.
16410426|NCT03905915|Other|Preoperative virtual reality session|Amsterdam Anxiety score recorded before VR session is followed by a 15 min VR session and finally Amsterdam Anxiety score is recorded after VR session
16410427|NCT03905902|Experimental|DCVAC/OvCa with standard of care|"Induction period: DCVAC/OvCa with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and pegylated liposomal doxorubicin, with or without bevacizumab
~Maintenance period: DCVAC/OvCa with bevacizumab, best supportive care or a PARPi"
16410428|NCT03905902|Placebo Comparator|Placebo with standard of care|"Induction period: DCVAC Placebo with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and doxorubicin, with or without bevacizumab
~Maintenance Period:DCVAC placebo with bevacizumab, best supportive care or a PARPi carboplatin and gemcitabine or carboplatin and paclitaxel with or without bevacizumab, best supportive care or a PARPi"
16410429|NCT03905889|Experimental|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
16410430|NCT03905876|Other|assessment of psychological experience|Questionnaire
16410431|NCT03905863|No Intervention|Standard of care arm|Patients in the standard of care arm will receive the standard care for their type of wound from their wound care centre.
16410432|NCT03905863|Active Comparator|Intervention arm|Patients in the intervention arm will receive standard of care plus Natrox® Oxygen Wound Therapy as treatment for their wound.
16410433|NCT03905850|Experimental|Somapacitan 5/10/10 mg|One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.
16410434|NCT03905850|Experimental|Somapacitan 10/5/10 mg|One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
16410435|NCT03905850|Experimental|Somapacitan 10/10/5 mg|Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
16410436|NCT03905837|Experimental|Lidocaine IV|Group 1: intravenous lidocaine and paravertebral saline (SF). In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
16410437|NCT03905837|Experimental|Lidocaine PV|Group 2: intravenous SF and paravertebral lidocaine. During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
16410438|NCT03905837|Active Comparator|no lidocaine|Group 3: intravenous remifentanil and paravertebral SF. During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.
16410439|NCT03905824|Experimental|Debridement and microfracture in LOC + Cells|Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.
16410440|NCT03905824|Active Comparator|Debridement and microfracture in LOC|Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus.
16410441|NCT03905811|Experimental|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
16410442|NCT03905811|Placebo Comparator|Placebo|Placebo administered once daily p.o. for 12 weeks
16410443|NCT03905798||Lorazepam|Patients administered Lorazepam in accordance with the indication (for Status Epilepticus, SE) and have no history of using this drug
16410590|NCT03904862|Experimental|Phase I - Skeletally-immature|Skeletally-immature children with refractory or recurrent medulloblastoma of the SHH group
16410444|NCT03905785|Experimental|Parenting Intervention Group(Samarthan)|Parenting intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
16410445|NCT03905785|No Intervention|Wait list Control group|wait list control group was given no intervention for the trial period. They were offered sam intervention after the intervention was completed in experimental group.
16410446|NCT03905772|Experimental|Voluntary exercise|The participants will perform 36 voluntary contractions of 20% of maximal voluntary isometrical contraction, 3 times per week for 8 weeks.
16410447|NCT03905772|Experimental|Wide pulse responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
~This group will classified in responder in the acute fase."
16410448|NCT03905772|Experimental|Wide pulse non responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
~This group will classified in non responder in the acute fase."
16410449|NCT03905772|Experimental|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
16410450|NCT03905759|Active Comparator|colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
16410451|NCT03905759|Active Comparator|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
16410452|NCT03905759|Active Comparator|amiodarone|amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
16410453|NCT03905746||acute decompensation group|patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis
16410454|NCT03905746||Pathological control group|patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event
16410455|NCT03905733||general anesthesia with rigid bronchoscopy|Patients 7 years or younger who undergo general anesthesia with rigid bronchoscopy
16410463|NCT03905681|Active Comparator|"Active TENS Group Group A"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. While the device is off, it will be set at the following settings: The selector switch will be set to 'Milli' or milliamperes, and the frequency dial will be rotated to 100 Hertz. The participant will be instructed to rotate both dials in a clockwise direction if more intensity is desired, or counter-clockwise if less intensity is desired. The participant will wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
16410464|NCT03905681|Placebo Comparator|"Placebo TENS Group Group B"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. However, no electrical stimulation will be provided. The participant will also wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
16410465|NCT03905668||ICU Patients|Adults in admitted to an ICU at University of Florida Health Gainesville with an expected length of stay greater than 24 hours which are not on any form of contact precaution or isolation. Patients will have continuous video, accelerometer, and electromyographic monitoring for up to seven days while in the ICU.
16410466|NCT03905668||ICU Patient Friends/Family Members|Adult visitors of participating ICU patients that are willing to provide feedback to the learning algorithms.
16410467|NCT03905655|Placebo Comparator|Group 1|Three placebo tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
16410468|NCT03905655|Active Comparator|Group 2|Two 300 mg NTZ tablets and one placebo tablet administered orally in the morning and three placebo tablets in the evening in addition to continuing TDF, TAF or ETV therapy
16410469|NCT03905655|Active Comparator|Group 3|Two 300 mg NTZ tablets and one placebo tablet administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
16410470|NCT03905655|Active Comparator|Group 4|Three 300 mg NTZ tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
16410471|NCT03905642|Experimental|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
16410472|NCT03905629||Patients aged 75 years and older hospitalized as an emergency|Patients considered will be all patients aged 75 years and older (on the day of the index admission) hospitalized as an emergency (i.e. after visit to ED) between january 2017 and december 2017.
16459034|NCT03572972||Patients prescribed warfarin|
16410473|NCT03905616|Experimental|healthy subjects|25 healthy subjects with a normal/corrected vision fitting to all of the inclusion/exclusion criteria. All the subjects will be tested on the same visual stimuli, leading to intrasubject comparison analyses of functional magnetic resonance imaging (fMRI) activity between conditions.
16410474|NCT03905603|Experimental|ACTH (Cosyntropin), rhCG (Ovidrel)|ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
16410475|NCT03905590|Experimental|periapical surgery with amniotic membrane|periapical surgery will be done and amniotic membrane will be placed over the defect before closure of flap
16410476|NCT03905590|Active Comparator|periapical surgery without amniotic membrane|periapical surgery will be done without the placement of amniotic membrane over the defect before closure of flap
16410477|NCT03905577|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
16410478|NCT03905577|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
16410479|NCT03905577|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
16410480|NCT03905564|Experimental|Doxylamine succinate/pyridoxine hydrochloride|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.
16410481|NCT03905564|Active Comparator|Diclegis (Registered Trademark)|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.
16410482|NCT03905551|Placebo Comparator|Standard Dialysis|Patients participated in a 7 months exercise trials receiving standard dialysis (at 37oC)
16410483|NCT03905551|Experimental|Cold Dialysis|Patients participated in a 7 months exercise trials receiving cold dialysis (at 35oC)
16410484|NCT03905538|Experimental|[18F]FLT-PET/CT Arm|The experimental [18F]FLT-PET/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
16410493|NCT03905512|Experimental|SEL-212|IV infusion of SEL-212 every 28 days for a total of up to 6 infusions of SEL-212.
16410494|NCT03905512|Active Comparator|KRYSTEXXA|IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for a total of up to 12 infusions of KRYSTEXXA®.
16410495|NCT03905499|Experimental|Robotic mediated therapy|Robotic mediated therapy with MJS (multi joint system) Tecnobody
16410496|NCT03905486|Active Comparator|G1: patients will receive pregabalin|pregabalin as a mono-therapy will be administered in increment doses for 3 months
16410497|NCT03905486|Active Comparator|G2: patients will receive pregabalin and milnacipran|pregabalin and milancipran as a combination therapy will be administered in increment doses for 3 months
16410498|NCT03905447|Experimental|PC945|
16410499|NCT03905447|Other|Standard of Care|Standard of care anti-fungal medication
16410502|NCT03905421||usual care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. They will not be randomized to palliative care.
16410503|NCT03905421||palliative care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. Based on the patients in Group 1 and 3 PH and a high SYMPACT score> 1.0 in any domain they will be randomized to receive standard care or a palliative care initial consult.
16410504|NCT03905408|Experimental|50 mL Dextrose|50 mL of 50% dextrose
16410505|NCT03905408|Experimental|100 mL Dextrose|100 mL of 50% dextrose
16410506|NCT03905408|Experimental|150 mL Dextrose|150 mL of 50% dextrose
16410507|NCT03905408|Experimental|200 mL Dextrose|200 mL of 50% dextrose
16410508|NCT03905395|Active Comparator|Meditation and mindfulness intervention|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
16410509|NCT03905395|No Intervention|Control group|Women in the no intervention arm will receive no introduction to meditation and mindfulness - only questionnaires at the same time as the intervention group receives questionnaires.
16410510|NCT03905382|Other|Qualitaitve|Qualitaitve
16410511|NCT03905369|Experimental|Decision aid, SDM booster and deliberation training|In the first arm, patients have COMBO, consisting of the decision aid, the SDM-booster, and the values deliberation training for physicians
16410512|NCT03905369|Active Comparator|Deliberation training|In the second arm, patients have the values deliberation training for physicians alone.
16410549|NCT03905135|Experimental|1- Experimental Treatment: Dose Escalation|IL-15 by civ infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by IV infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine MTD
16410550|NCT03905135|Experimental|2- Experimental Treatment: Dose Expansion|IL-15 by civ infusion at the MTD on days 1-5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 of each cycle
16410551|NCT03905122||continous veno-venous hemodialysis|to measure the fluid changes by using bioreactance method in continous veno-venous hemodialysis group
16414237|NCT03879928|Placebo Comparator|Placebo for MAD|Placebo comparator for MAD
16410513|NCT03905356|Experimental|Exercise|"The exercise intervention will utilize the Moving Through Cancer: A Guide to Exercise for Cancer Survivors framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises)."
16410514|NCT03905343|Experimental|A: endocrine therapy + ribociclib|
16410515|NCT03905343|Active Comparator|B: mono-chemotherapy|
16410516|NCT03905330|Experimental|Maralixibat|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
16410517|NCT03905330|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
16410518|NCT03905317|Experimental|Bevacizumab|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
16410519|NCT03905304|Experimental|Meditoxin|Meditoxin administered 200U~300U, single-dose administration.
16410520|NCT03905304|Active Comparator|Botox|Botox administered 200-300U, single-dose administration.
16410521|NCT03905291|Experimental|MT921 60mg Group|MT921 60 mg
16410522|NCT03905291|Experimental|MT921 120mg Group|MT921 120 mg
16410523|NCT03905291|Experimental|MT921 150mg Group|MT921 150 mg
16410524|NCT03905291|Placebo Comparator|Placebo Group|Placebo
16410525|NCT03905278|Experimental|Parental guidance|"In the experimental condition, the two significant caregivers of the child or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. The intervention consists of four sessions, centered on supporting the child in the context of parental cancer principally through communication.
~Assessments are conducted at two periods : before and after the intervention."
16410526|NCT03905278|No Intervention|Waiting List group|"In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months.
~Assessments are conducted at 9 weeks of interval."
16410527|NCT03905265|Experimental|Moxidectin 2 mg|Moxidectin 2 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
16410528|NCT03905265|Experimental|Moxidectin 8 mg|Moxidectin 8 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
16410529|NCT03905265|Experimental|Moxidectin 20 mg|Moxidectin 20 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
16410530|NCT03905265|Experimental|Moxidectin 36 mg|Moxidectin 36 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
16410531|NCT03905239|Experimental|algorithm arm|Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
16410532|NCT03905239|No Intervention|no algorithm arm|Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
16410533|NCT03905226||Heart Failure|Patients whom initiated a hospital pathway for heart failure management within the Paris Saint Joseph Hospital Group (GHPSJ) between January 1, 2015 and December 31, 2018.
16410534|NCT03905213|Active Comparator|conventional gauze|Device is a conventional gauze and the change will be to the day 2 and 4 of surgery
16410535|NCT03905213|Experimental|polyurethane dressing|Device is a polyurethane dressing and the change will be to the day 7 of surgery
16410536|NCT03905213|Experimental|vacuum therapy dressing|Device is a vacuum therapy dressing and the change will be to the day 7 of surgery
16410537|NCT03905200||coronary artery disease|Patients who were diagnosed with coronary heart disease at admission and planned to undergo coronary angiography
16410538|NCT03905187|Other|Control Group|Group received education only
16410539|NCT03905187|Other|Traditional CR Group|Group received cardiac rehabilitation including education and exercise
16410540|NCT03905187|Experimental|Stress-Modified CR Group|Group received cardiac rehabilitation including education, exercise and stress management
16410541|NCT03905174|Active Comparator|Standard treatment|A porous collar for either distal or proximal femoral replacements
16410542|NCT03905174|Active Comparator|standard treatment + HA|A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements
16410543|NCT03905174|Active Comparator|standard treatment + HA + autogenic cells|A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements
16410544|NCT03905161||Myasthenia patients|Danish patients with myasthenia gravis seen at the Department of Neurology, Rigshospitalet
16410545|NCT03905148|Experimental|Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.|Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day
16410546|NCT03905148|Experimental|Part B: Group 1|Non-small cell lung cancer with confirmed K-RAS mutations, approximately 15 participants
16410557|NCT03905083|Experimental|Exercise rehab|Investigators aim to evaluate how exercise training may provide beneficial effects on the skeletal muscle and/or pulmonary vasculature in select subjects with pulmonary arterial hypertension, scleroderma or mixed connective tissue disease or patients with exercise pulmonary arterial hypertension
16410558|NCT03905083|No Intervention|No exercsie rehab|Some participants will not be assigned to do exercise rehab so we would be using them as a control arm to intervention group
16410559|NCT03905070||Study Group|The study group consisted of people who had undergone bariatric surgery and who had at least 6 months after the operation.
16410560|NCT03905070||Control Group|The control group will consist of asymptomatic individuals whose BMI is 18-25 kg / m2 and has not participated in any exercise program in the last one year.
16410561|NCT03905057|Sham Comparator|Sham ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), using a sham applicator which is highly similar to the active applicator except that the sham applicator does not emit shockwaves, twice a week (total of 6 weeks) without treatment interval. Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
16410562|NCT03905057|Active Comparator|Active ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks). Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
16410563|NCT03905044||CC|eyes with congenital cataracts
16410564|NCT03905031|Experimental|InfraScanner 2000|All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
16410565|NCT03905018|Experimental|tadalafil|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally
16410566|NCT03905018|Placebo Comparator|calcined magnesia (placebo)|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the second will receive 20 mg of calcined magnesia (placebo),after a single administration
16410567|NCT03905005||Pre-flexed reconstruction plate|Patients who undergo mandibular reconstruction using a pre-flexed osseosynthesis reconstruction plate along with free-tissue transfer for reconstruction of a mandibular continuity defect.
16410568|NCT03905005||Printed reconstruction plate|Patients who undergo mandibular reconstruction using a 3D-printed reconstruction plate made by selective laser melting (SLM), along with free-tissue transfer for reconstruction of a mandibular continuity defect.
16410569|NCT03904992|No Intervention|Non-exposed|Subjects with access to nutritional counseling sessions every 30 days
16410570|NCT03904992|Experimental|Exposed|Subjects with access to the progressive web app in their smartphones.
16410571|NCT03904979|Experimental|Therapeutic Writing Prompts|Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
16410572|NCT03904979|Placebo Comparator|General Writing Prompts|"Participants will be given writing prompts that discuss neutral topics unrelated to their life stress, resilience, or coping."
16410573|NCT03904979|No Intervention|No Writing|Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.
16410574|NCT03904966|Experimental|ESWT+ Kinesiotaping|Low-dye Kinesio taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
16410575|NCT03904966|Sham Comparator|ESWT+Shamtaping|Sham taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
16410576|NCT03904966|Other|ESWT|Extracorporeal shock wave therapy for 5 sessions (5-week)
16410577|NCT03904953|Experimental|Study group|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
16410578|NCT03904953|Active Comparator|Control group|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
16410579|NCT03904940|Experimental|Total Contact Insole Group|Ethyl vinyl acetate insole shaped in the cast of the patient's foot, every 6 months.
16410580|NCT03904940|Sham Comparator|Flat Insole group|Flat insole made the same material ethyl vinyl acetate, every 6 months.
16410581|NCT03904927|Experimental|Experimental Arm|The arm will be treated with combined chemotherapy and local therapy such as radiation, surgery or radiofrequency ablation.
16410582|NCT03904927|Active Comparator|Control Arm|The arm will be treated with chemotherapy alone.
16410583|NCT03904914||AIS group|Patients confirmed with adolescent idiopathic scoliosis (AIS)
16410584|NCT03904901|Active Comparator|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, drink with water and drink before bed. Probiotics contain a dose of 10 9 CFU per capsule.
16410585|NCT03904901|Placebo Comparator|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
16410586|NCT03904888|Other|l-TAPP without local anesthetics|These patients will undergo a laparoscopic surgery without local anaesthetics.
16410587|NCT03904888|Other|l-TAPP with local anesthetics|These patients will undergo a laparoscopic surgery with local anaesthetics.
16410588|NCT03904888|Other|r-TAPP without local anesthetics|These patients will undergo a robot-assisted surgery without local anaesthetics.
16410589|NCT03904888|Other|r-TAPP with local anesthetics|These patients will undergo a robot-assisted surgery with local anaesthetics.
16410804|NCT03903562|Experimental|V503|V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.
16410591|NCT03904862|Experimental|Phase II - Skeletally-mature|Skeletally-mature subjects with refractory or recurrent medulloblastoma of the SHH group
16410592|NCT03904862|Experimental|Surgical|Subjects who are eligible for the Phase I or Phase II arm of the trial and are candidates for surgery, may be enrolled in the surgical arm prior to initiation of the Phase I or Phase II treatment.
16410593|NCT03904849|Active Comparator|Cannabidiol|Cannabidiol 6 mL of 100 mg/mL cannabidiol oral solution per day for 8 days
16410594|NCT03904849|Placebo Comparator|Placebo|Placebo 6 mL oral solution per day for 8 days
16410595|NCT03904836|Experimental|Tobramycin|Subjects with end-stage renal disease who have been involved in an intermittent hemodialysis program and who have suspected or diagnosed Gram-negative rod-type infection
16410596|NCT03904823|Experimental|famitinib, HS-10296|
16410597|NCT03904810|No Intervention|Control|Subjects in this group do not received any intervention
16410598|NCT03904810|Active Comparator|Moderate Intensity Continuous Training ×3/wk|Subjects in this group will receive three sessions of Moderate-Intensity Continuous Training per week throughout the 8 weeks experimental period
16410599|NCT03904810|Active Comparator|High Intensity Interval Training×3/wk|Subjects in this group will receive three sessions of High-Intensity Interval Training per week throughout the 8 weeks experimental period
16410600|NCT03904810|Active Comparator|High Intensity Interval Training×2/wk|Subjects in this group will receive two session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
16410601|NCT03904810|Active Comparator|High Intensity Interval Training×1/wk|Subjects in this group will receive one session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
16410602|NCT03904797|Experimental|e-PRO|EI service coordinators participated in a 90-minute training on the study protocol, to gain clearance to recruit families when they were being contacted to schedule their annual reviews of progress. The recruitment protocol was later modified in response to low enrollment, such that a designated EI staff member was paired with research staff to recruit participants. Eligible and interested caregivers visited the project website to create an account, confirmed study eligibility, provided informed consent and HIPAA authorization for abstracting select EI service use data, and completed a demographic questionnaire and the Young Children's Participation and Environment Measure (YC-PEM) e-PRO. Caregivers received immediate access to an online report summarizing their e-PRO responses to share with their child's EI team
16410603|NCT03904784||School withdrawal teenagers|The study is based on questionnaries, interview with teenagers and/or their familly
16410604|NCT03904771|Active Comparator|Food for Mind -intervention group|Nutrition counselling + peer support
16410605|NCT03904771|Active Comparator|Befriending group -control group|Social activation + peer support
16410606|NCT03904758|Experimental|Monitoring of pH with Restech|The patients with EER randomized into this arm will undergo pH monitoring using Restech system
16410607|NCT03904758|Experimental|Monitoring of oesophageal impedance|The patients with EER randomized into this arm will undergo monitoring of oesophageal impedance
16410608|NCT03904745|Experimental|Atosiban used before embryo transfer|the patients in this group will be administered 6,75mg atosiban intravenously.
16410609|NCT03904745|No Intervention|Control group|the patients in this group will not be administered atosiban before embryo transfer.
16410610|NCT03904732||Cohort 1|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention
16410611|NCT03904732||Cohort 2|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
16410612|NCT03904732||Cohort 3|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for primary prevention
16410613|NCT03904732||Cohort 4|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for secondary prevention
16410614|NCT03904732||Cohort 5|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
16410615|NCT03904732||Cohort 6|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
16410616|NCT03904732||Cohort 7|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for primary prevention
16410617|NCT03904732||Cohort 8|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for secondary prevention
16410618|NCT03904719|Experimental|CM082 plus JS001|CM082 tablets 150mg is orally given once daily in a 28-day cycle, combinational JS001 240mg was given intravenously on day 1 once every 21 days.
16410619|NCT03904706|Experimental|Audits only|"Formalized audit teams with monthly meetings at each facility.
~Audit Intervention phases:
~Identification of facility leadership (i.e physicians or leading health care providers) to be trained on best practices in obstetric and perinatal care in the implementation of the audits.
~Training of identified audit leaders (main investigator is typically a physician)
~a. 5-day training workshop to include: i. Day 1: maternal death and near misses, perinatal, neonatal deaths and morbidity outcomes ii. Day 2: 'Three-delay' framework and identifying modifiable factors iii. Day 3: data collection and setting up the audit system iv. Days 4-5: mentoring on the identification of the audit teams and initiating audit implementation
~Creating audit team (composed of at least two obstetricians, 2 pediatricians plus the main investigator)
~Establishing and launching the audit cycle (monthly meetings)
~Annual re-certification of audit leaders"
16410620|NCT03904706|Experimental|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
16410621|NCT03904706|No Intervention|Control|Monthly outcome data will be collected from health facilities where no audits will be conducted. Data from this group will help evaluate the effectiveness of the intervention arms on perinatal and neonatal mortality.
16410625|NCT03904680|Active Comparator|Methotrexate|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.
16410626|NCT03904680|Active Comparator|Methotrexate and Vitamin D|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.
16410627|NCT03904667||Watson on oncology recommends surgery|
16410628|NCT03904667||Watson on oncology does not recommend surgery|
16410629|NCT03904654|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 60-minute consecutive weekly MBCT group sessions.
16410630|NCT03904641|Experimental|aPDT + ART group|In this group, both aPDT and ART will be performed.
16410631|NCT03904641|Experimental|ART group|In this group, only ART will be performed.
16410632|NCT03904628|Experimental|150 mg, BIW in every 28d|TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
16410633|NCT03904628|Experimental|200 mg, BIW in every 28d|TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
16410634|NCT03904628|Experimental|250 mg, BIW in every 28d|TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
16410635|NCT03904615|Active Comparator|Whey Protein|30 g of whey protein twice daily during hospitalization and for 30 days after discharge
16410636|NCT03904615|Active Comparator|Collagen Protein|30 g of collagen protein twice daily during hospitalization and for 30 days after discharge
16410637|NCT03904615|Placebo Comparator|Placebo|30 g of maltodextrin twice daily during hospitalization and for 30 days after discharge
16410638|NCT03904602|Experimental|Edema Wear|Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.
16410639|NCT03904589||Coronary Heart Disease|
16410640|NCT03904576|Experimental|Treatment (T)|
16410641|NCT03904576|Placebo Comparator|Reference Treatment (R)|
16410642|NCT03904563|Experimental|Bevacizumab|All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with 6 courses of Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for 6 courses.
16410643|NCT03904550|Active Comparator|Cisatracurium + Neostigmine|Patients in the rocuronium/sugammadex group will receive 0.6 mg/kg of rocuronium for neuromuscular paralysis during induction. Additional rocuronium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
16410644|NCT03904550|Active Comparator|Rocuronium + Sugammadex|Patients in the cisatracurium/neostigmine group will receive 0.2 mg/kg of cisatracurium for neuromuscular paralysis during induction. Additional cisatracurium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
16410645|NCT03904537|Experimental|PD1-TIL combined with chemotherapy|Participants would received anti-PD-1 antibody-activated TILs after the final adjuvant chemotherapy.
16410646|NCT03904524|Experimental|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
16410647|NCT03904511|Experimental|Low Dose Souroubea-Platanus|190 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
16410648|NCT03904511|Experimental|High Dose Souroubea-Platanus|380 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
16410649|NCT03904511|Placebo Comparator|Placebo|Inert placebo in an identical vegicap to the experimental treatment groups. Administered once daily for 14 days.
16410650|NCT03904498|Experimental|Tolcapone then Placebo|Participants in this arm will receive tolcapone during the first medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8), and placebo during the second medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8).
16410651|NCT03904498|Experimental|Placebo then Tolcapone|Participants in this arm will receive placebo during the first medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8), and tolcapone during the second medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8).
16410652|NCT03904485||SPKT|patients with end-stage diabetic nephropathy got simultaneous pancreas-kidney transplantation
16410653|NCT03904485||RT|patients with end-stage diabetic nephropathy got single kidney transplantation
16410654|NCT03904472|Experimental|Web-based CBTI|Participants will have 8 weeks to receive 6 therapy sessions. Content is dynamically driven by an animated therapist who guides the user through the program.
16410655|NCT03904459||cases|Children with juvenile idiopathic arthritis
16410656|NCT03904459||controls|healthy children
16410657|NCT03904446|Experimental|Methylergonovine 0.2 mg|Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
16410658|NCT03904446|Placebo Comparator|Placebo (Normal Saline)|Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular
16410659|NCT03904433|Experimental|1. Sunflower oil|Sunflower oil (30 g)
16410660|NCT03904433|Experimental|2. Caprylic acid|Caprylic acid (20 g) + Sunflower oil (10 g)
16410661|NCT03904433|Experimental|3. Caprylic acid + Glucose|Caprylic acid (20 g) + Sunflower oil (10 g) + Glucose (50 g)
16410662|NCT03904433|Experimental|4. Coconut oil|Coconut oil (30 g)
16410663|NCT03904433|Experimental|5. Coconut oil + Glucose|Coconut oil (30 g) + Glucose (50 g)
16410664|NCT03904433|Experimental|6. Coconut oil + Caprylic acid|Coconut oil (30 g) + Caprylic acid (20 g)
16410665|NCT03904420|Experimental|Group A - New Model|Standardized programming and testing method
16410666|NCT03904420|Active Comparator|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
16459035|NCT03572972||Patients prescribed antiplatelet|
16410667|NCT03904407|Experimental|Probiotic|Lactobacillus probiotic capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
16410668|NCT03904407|Placebo Comparator|Placebo|Matching Lactobacillus probiotic placebo capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
16410669|NCT03904394|Placebo Comparator|Placebo Mouthwash|
16410670|NCT03904394|Active Comparator|Antibacterial Mouthwash|
16410671|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in phakic eyes|
16410672|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in pseudophakic eyes|
16410673|NCT03904381|Active Comparator|XEN implantation combined with cataract extraction|
16410674|NCT03904368|Active Comparator|Myomectomy group|women with intramural myoma not reaching endometrial cavity will undergo open myomectomy followed by ovarian stimulation for in vitro fertilization 6 months after the operation
16410675|NCT03904368|Active Comparator|Conservative group|women with intramural myoma not reaching endometrial cavity will undergo ovarian stimulation for in vitro fertilization
16410676|NCT03904355|Active Comparator|Fiboroid group|Women with intramural myoma no reaching the cavity
16410677|NCT03904355|Active Comparator|Non fibroid group|Women without myomas
16410678|NCT03904342|Active Comparator|Sophie CBT|The Sophie Cognitive Behavioral Therapy (CBT) intervention is a tablet-based computerized CBT and self-management education intervention that consists of an evidence-based cognitive behavioral therapy self-management curriculum divided into 6 discrete modules. Patients will have up to 8 weeks to work through the modules on the tablet.
16410679|NCT03904342|Active Comparator|iHope CBT|iHope CBT is a telemedically-delivered CBT package. The iHope system comprises a HIPAA-compliant platform on which real, live, licensed clinicians provide cognitive behavioral therapy via video conferencing, phone calls, and text messaging. iHope will be delivered on subjects' preferred electronic device (mobile phone, laptop, tablet).
16410680|NCT03904329||Obese Patients with non valvular AF|Obese Patients with non valvular AF using oral anti coagulants
16410681|NCT03904316|Experimental|Biodesign graft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with an acellular matrix derived from porcine small intestine submucosa, Biodesign Otologic graft
16410682|NCT03904316|Active Comparator|Autograft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with autologous temporalis fascia.
16410683|NCT03904303|Experimental|Geloprep|Novel and patented Polyethylene glycol 3350 mixture
16410684|NCT03904303|Active Comparator|Moviprep|Standard of care Polyethylene glycol 3350 mixture
16410685|NCT03904290|Other|Pre-PFO closure|Subjects evaluated at 'baseline' prior to percutaneous closure of PFO, and re-evaluated at 3 months post percutaneous closure of PFO
16410686|NCT03904277||No PFO|Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles
16410687|NCT03904277||Small PFO|Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
16410688|NCT03904277||Large PFO|Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.
16410689|NCT03904264|Experimental|Hearing Aid Study|Measure the reduction in tinnitus handicap when mild amplification through receiver-in-the-canal hearing aids is provided to adults with bothersome tinnitus and normal hearing thresholds.
16410690|NCT03904264|No Intervention|VA Clinician Interviews|Document the opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. The data for this arm of the study will be collected via telephone interview.
16410691|NCT03904251|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT."
16410692|NCT03904238|Experimental|CBT-H (Individual format)|Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
16410693|NCT03904238|Experimental|CBT-H (Group format)|Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
16410694|NCT03904225|Experimental|tegio|Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation
16410695|NCT03904225|No Intervention|control|patients was oberved
16410696|NCT03904212|Active Comparator|Adipose tissue injection|Patients will be treated with freshly harvested autologous adipose tissue
16410697|NCT03904212|Placebo Comparator|Placebo|Patients will be treated with saline
16410698|NCT03904199|Experimental|Basal-Prandial-Correctional Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.
16410699|NCT03904199|Active Comparator|Standard of Care Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.
16410700|NCT03904186|Experimental|QUIT Treatment for Smoking Cessation and Distress Tolerance|Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
16410701|NCT03904186|Active Comparator|Time and Intensity-Match Control|Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
16410702|NCT03904186|No Intervention|Standard of Care|At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
16410703|NCT03904173||EMIT-1 - Multi-parameter tests|Patients with hormone sensitive HER2 negative primary breast cancer without lymph node metastasis. Treatment recommendations will be based on the Prosigna test result, in addition to conventional clinicopathological parameters.
16410704|NCT03904160|Sham Comparator|Nurse-lead group|Nurse-lead sessions for weight management. Ten sessions lasting 90 minutes each in three groups of 10-14 participants. Each session comprise education about healthy diet, psychoeducation and discussions.
16410705|NCT03904160|Experimental|Web-based group|Web-based weight management system with peer-based conversation possibility. Three groups of 10-14 participants who gather together for three nurse-lead sessions in the weeks 0, 5, and 12. The web-based program can be used for a year.
16410706|NCT03904160|Experimental|Web-based personal|Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
16410707|NCT03904147|Experimental|Roll-In|TriClip Device treatment for physicians requiring additional training prior to beginning randomized cohort enrollment.
16410708|NCT03904147|Active Comparator|Randomized Cohort|TriClip (Device) Group vs. Medical Therapy (Control) Group
16410709|NCT03904147|Experimental|Single Arm|Subjects in which it is believed TR is not going to be reduced to moderate or less severity will receive the TriClip device.
16410710|NCT03904134|Other|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
16410711|NCT03904134|Other|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
16410712|NCT03904134|Other|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
16410713|NCT03904108|Experimental|Ramucirumab|Ramucirumab 10 mg/kg IV day 1, every 3 weeks for 4 cycles
16410714|NCT03904095|Active Comparator|Psoas compartment block group (PCB)|Single- shot ultrasound (Esaote Mylab30) guided PCB with 15 ml 0.25% bupivacain ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the PCB group (Group I).
16410715|NCT03904095|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the ESP group (Group II).
16410716|NCT03904095|Placebo Comparator|The Control group|The Control group receive no intervention ( Group III).
16410717|NCT03904082|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).
16410718|NCT03904082|Active Comparator|Serratus Anterior Plane Block Group (SAP)|Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).
16410719|NCT03904082|Placebo Comparator|Control Group|The Control group receive no intervetion ( Group III).
16410720|NCT03904069|Experimental|Comparison of different cell doses of AMG 553|Subjects will receive IV infusion of AMG 553
16410721|NCT03904056|Active Comparator|ETDRS-PRP group|Patients with proliferative diabetic retinopathy submitted to panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
16410722|NCT03904056|Experimental|ISQ-RP group|Patients with proliferative diabetic retinopathy submitted to retinal photocoagulation targeted to ischemic retina combined with intravitreal injection of ranibizumab (IVR) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
16410724|NCT03904030|Experimental|Anti-Gravity Treadmill rehabilitation|Patients in the intervention group are participating to the Alter G exercises (n=27). The groups are randomized, so after patients have signed consent, an envelop will be opened and there can be seen in which groups patients will participate.
16410725|NCT03904030|Active Comparator|Traditional rehabilitation|Traditional exercises with instructions are given to the patients (n=27) (as a control group).
16410726|NCT03904017|Experimental|Hyperoxia|Will receive 15liters per minute supplemental oxygen via a partial non-rebreather facemask.
16410727|NCT03904017|Placebo Comparator|Placebo|will receive 15liters per minute medical air via a partial non-rebreather facemask.
16410728|NCT03904004||Esophageal motility disorders|Individuals with sympmtoms related to esophageal motility disorders who receive a endoscopic or surgical treatment
16410729|NCT03903991||Thoracotomy|All patients needing pulmonary surgery under thoracotomy
16410756|NCT03903835|Experimental|Treatment 4: Cabazitaxel|Patients with the TMPRSS2-ERG gene fusion will have increased chance of receiving chemotherapy at study onset.
16410730|NCT03903978|Experimental|CORE condition|CORE is a 6-week web-based prevention programme whose main objective is to teach coping skills and strategies to cope with stressful everyday situations in order to improve resilience, promote self-efficacy and increase well-being. The intervention consists of 6 interactive modules designed for weekly sessions and organized in 6 dimensions: autonomy, self-acceptance, environmental mastery, purpose in life, positive relationships, and personal growth. Each module includes exercises to practice the proposed skills. The program includes multimedia elements: videos, audios, vignettes, images.
16410731|NCT03903978|Active Comparator|Healthy lifestyle|This program will provide information to promote a healthy lifestyle, on issues related to physical and mental health and physical activity, as well as diet and sleep management. The components of psychoeducation are based on the intervention protocol for depression (Castro, et al. 2015) based on low intensity psychological intervention models for mild or moderate depressive symptoms in primary care (Garcia-Herrera et al 2011; NICE, 2009; Nieuwsma et al 2012).
16410732|NCT03903978|No Intervention|Waiting List Control|Participants assigned to the Waiting List control group will be evaluated and monitored at the start of the study, 4 weeks, 8 weeks and follow-ups at 3 months. After the last follow-up evaluation, they will be given access to CORE training.
16410733|NCT03903965||diabetic patients after cataract surgery|diabetic patients after cataract surgery
16410734|NCT03903965||non-diabetic patients after cataract surgery|non-diabetic patients after cataract surgery
16410735|NCT03903952|Other|Papanicolaou smear result (control group)|women who did not have intraepithelial neoplasia as a result of smear
16410736|NCT03903952|Other|Papanicolaou smear result (study group)|women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear
16410737|NCT03903939|Experimental|Iloprost|Patients randomized to active treatment (n = 110 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first
16410738|NCT03903939|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n= 110 patients) will receive continuous infusion of isotonic saline (equal volume) for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
16410739|NCT03903926|Experimental|Cohort one|5000 volunteers (6-35 months)-EV71 vaccine
16410740|NCT03903926|No Intervention|Cohort two|10000 unvaccinated volunteers (6-35 months)
16410741|NCT03903926|No Intervention|Cohort three|500 unvaccinated volunteers (36-71 months)
16410742|NCT03903913|Experimental|Dose Escalation Study|"Subjects will receive up to three inhaled doses of S- 1226. Each dose will be administered over a 2-minute treatment period (with a minimum 2-minute break between treatments) with a nebulizer as follows.
~Three S-1226 formulations will be tested sequentially:
~S-1226(4%) is composed of 3 mL PFOB and 4% CO2
~S-1226(8%) is composed of 3 mL PFOB and 8% CO2
~S-1226(12%) is composed of 3 mL PFOB and 12% CO2
~Each formulation will be administered by inhalation for a period of 2 minutes.The nebulizer will be filled with 3 mL of PFOB. The nebulizer is connected to a compressed medical gas mixture consisting of either 4%, 8% or 12%, CO2. A driving pressure of 20 psi will be used, producing a gas flow rate of 9 L/min."
16410743|NCT03903913|Experimental|Daily Dosing Study|"Eligible subjects will receive S-1226 twice daily for 5 consecutive days. Subjects will receive up to three doses of S-1226 in the morning and afternoon, administered over three 2-minute periods with a Circulaire nebulizer, filled with one of the dosages outlined below, depending on the safety and tolerability data gathered from the dose escalation study for that particular subject.
~S-1226(4%) is composed of 3 mL PFOB and 4% CO2
~S-1226(8%) is composed of 3 mL PFOB and 8% CO2
~S-1226(12%) is composed of 3 mL PFOB and 12% CO2"
16410744|NCT03903900|Experimental|Intervention group|Adults with chronic pain (n=48) matching the inclusion and exclusion criteria will be included.
16410745|NCT03903887|Experimental|PD1-TIL combined with chemotherapy|Participants would receive anti-PD1 antibody-activated TILs after the final cycle of adjuvant chemotherapy.
16410746|NCT03903874|Experimental|DIAL intervention|Deep south Interactive voice response system Active Lifestyle (DIAL) intervention. Participants will receive 12 months of automated physical activity phone counseling. Participants will report their physical activity to the IVR system each day for 3 months, twice/week in months 3-6, and once/week in months 6-12 and receive progress feedback via IVR system, along with community health worker support.
16410747|NCT03903874|No Intervention|Wait List Control|The wait list control participants will be instructed to maintain their normal routine until completion of the 6-month assessments and then receive the same 12-month DIAL intervention. To maintain engagement, these participants will be involved in monthly lunch and learns, focus groups, etc on cancer topics other than PA (e.g., screening) during the wait period.
16410748|NCT03903861|Experimental|Glucose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
16410749|NCT03903861|Experimental|Galactose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
16410750|NCT03903861|Experimental|Glucose and galactose|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
16410751|NCT03903848|Experimental|Exercise session|One session of physical exercise
16410752|NCT03903835|Active Comparator|Control: Standard Care|Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.
16410753|NCT03903835|Experimental|Treatment 1: Enzalutamide|Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment of Abiraterone or Enzalutamide.
16410754|NCT03903835|Experimental|Treatment 2: Abiraterone|Patients with an intact androgen receptor (AR) and without TP53 mutations will have an increased chance of being randomised to treatment of Abiraterone or Enzalutamide.
16410755|NCT03903835|Experimental|Treatment 3: Carboplatin|DNA-repair deficient patients will have an increased chance of receiving Carboplatin.
16410757|NCT03903835|Experimental|Treatment 5: Docetaxel|Patients with the TMPRSS2-ERG gene fusion will have increased chance of receiving chemotherapy at study onset.
16410758|NCT03903835|Experimental|Treatment 6: Niraparib plus Abiraterone acetate plus Prednisone|DNA-repair deficient patients will have an increased chance of receiving the combination treatment with Niraparib plus Abiraterone acetate plus Prednisone.
16410759|NCT03903822|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
16410760|NCT03903822|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
16410761|NCT03903822|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
16410762|NCT03903822|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
16410763|NCT03903822|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
16410764|NCT03903822|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
16410765|NCT03903822|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
16410766|NCT03903822|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
16410767|NCT03903809|Experimental|HS-20039 Pegol-Sihematide|Pegol-Sihematide's starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 13 doses
16410768|NCT03903809|Active Comparator|ReHuman Erythropoietin Injection|ESPO(Recombinant Human Erythropoietin Injection) ESPO's starting dose was 6000 IU per week
16410769|NCT03903796|Experimental|HS-10234 25mg|HS-10234 + TDF placebo for up to 96 weeks
16410770|NCT03903796|Active Comparator|TDF 300mg|TDF + HS-10234 placebo for up to 96 weeks
16410771|NCT03903796|Experimental|Open-label HS-10234|All participants who complete the double-blind period (96 weeks) will be eligible to receive open-label HS-10234 until week 144 of the study.
16410772|NCT03903783|Active Comparator|Cefotaxime|
16410773|NCT03903783|Active Comparator|Ceftriaxone|
16410774|NCT03903770|Experimental|Intervention|Upper extremity rehabilitation
16410775|NCT03903757||Obese subjects with and without T2D|
16410776|NCT03903757||control subjects|
16410777|NCT03903744|Experimental|Treatment arm|Patients treated with cardioneuroablation.
16410778|NCT03903744|Active Comparator|Control arm|Patients treated with standard non-pharmacological methods.
16410779|NCT03903718|Experimental|MEDI8852 (dose 1) - part 1|Participants will receive a single intravenous infusion (IV) of MEDI8852 (dose 1)
16410780|NCT03903718|Sham Comparator|Placebo - part 2|Participants will received a single IV infusion of placebo ( matched to MEDI8852) on day 2
16410781|NCT03903718|Active Comparator|Oseltamivir (OS) 75 mg - part 2|Participants will receive 75 mg orally twice a day for 5 days starting at day 2
16410782|NCT03903718|Experimental|MEDI8852 (dose 2) - part 2|Participants will receive a single IV dose of MEDI8852 on day 2 (dose 2)
16410783|NCT03903718|Experimental|MEDI8852 (dose 1) - part 2|Participants will receive a single IV infusion of MEDI8852 on day 2 (dose 1)
16410784|NCT03903718|Experimental|MEDI8852 (dose 2) +OS 75 mg part 2|Participants will receive a single IV infusion of MEDI8852 (dose 2) on day 2 and 75mg of Oseltamivir twice a day for 5 days starting at day 2
16410785|NCT03903705|Experimental|VEGFR cohort:|Fruquintinib
16410786|NCT03903692|Experimental|Marine polysaccharide dressing|
16410787|NCT03903692|Active Comparator|Carboxymethylcellulose dressing|
16410788|NCT03903679|Active Comparator|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway supreme during the septal surgery.
16410789|NCT03903679|Sham Comparator|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
16410790|NCT03903666|Experimental|Cohort|47 Down syndrome patients age from 4 to 16
16410791|NCT03903653|Active Comparator|Chemodenervation + Serial Casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)
16410792|NCT03903653|Active Comparator|Chemodenervation without serial casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection. Intervention = Botulinum Toxin A injection (350-400 units per treated limb) alone.
16410793|NCT03903640|Experimental|Optune + Ipilimumab + Nivolumab|"Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
~Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses
~Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.
~Treatment may continue for up to 1 year"
16410794|NCT03903627|Experimental|Verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~(1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.
~Those who will not be able to contract will be taught by the ultrasound as a biofeedback."
16410795|NCT03903614|Experimental|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
16410796|NCT03903614|Active Comparator|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
16410797|NCT03903601||Ischemic changes|Patients with ischemic changes in the brain diagnosed by MRI
16410798|NCT03903601||No ischemic changes|Patients without ischemic changes in the brain diagnosed by MRI
16410799|NCT03903588||Normal|Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
16410800|NCT03903588||Glaucoma|Eyes that have been diagnoses with Glaucoma
16410801|NCT03903588||Retinal Disease|Eyes that have been diagnoses with a Retinal Disease
16410802|NCT03903575|Experimental|En Masse Retraction|Group treated by retracting the six anterior teeth simultaneously.
16410809|NCT03903536||Local excision/ Hemorrhoidectomy|Patients with thrombosed external hemorrhoids undergoing local excision/ hemorrhoidectomy
16410810|NCT03903510|Experimental|Virtual Reality|Participants will experience Virtual Reality during their cast removal
16410811|NCT03903510|No Intervention|Standard of care|Participants will receive their usual standard of care treatment during cast removal
16410812|NCT03903497|Other|NBI assessment using the WASP classification|
16410813|NCT03903484|Experimental|Deprescribing intervention|Included patient participants will meet with their clinical pharmacist to complete a survey about medication use and quality of life. Then working with the pharmacist, patients will prioritize medications that are no longer needed for discontinuing. A deprescribing plan will be created and the pharmacist will work with the patient to complete this plan. The patient will also be provided resources from the study toolbox to support the patients as they work through deprescribing the targeted drugs. Once the deprescribing plan is completed there will be a patient survey that will capture satisfaction with the deprescribing experience and patient quality of life.
16410814|NCT03903471|Experimental|22G-ProCore Group|The experimental group with 22G-ProCore needle is expected to enroll 300 patients. The 22G-ProCore needle has a 1.5mm long groove 2.5mm above the needle tip, which is expected to have the advantage of taking more biopsy tissues than the 22G-Standard needle.
16410815|NCT03903471|Active Comparator|22G-Standard Group|The control group of 22G-Standard needle is expected to include 300 patients, and there is no groove above the needle tip compared with 22G-ProCore needle.
16410816|NCT03903458|Experimental|Tinostamustine and Nivolumab|Experimental drug combination arm
16410817|NCT03903445|Experimental|MaPa Kids|"Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids) Parenting training for parents of children aged 2-9
~Program length: 8 consecutive weekly sessions
~Incentive: PHP 500 or approximately £7 per participant
~Participants: N=15 per group"
16410818|NCT03903445|Experimental|MaPa Teens|"Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens) Parenting training for parents of children aged 10-17
~Program length: 9 consecutive weekly sessions
~Adult Incentive: PHP 500 or approximately £7 per participant
~Child incentive: PHP 300 or approximately £4 per participant
~Participants: N=15 per group"
16410819|NCT03903432|Other|45 participants, in one center - Assuta|Patients with chronic sinusitis who are scheduled to undergo ESS at Assuta will be recruited and patients will sign an informed consent form for performing MRI (new protocol-without gadolinium injection) in addition to the routine CT.
16410820|NCT03903419|Experimental|68Ga-PSMA PET-CT and 18F-FDOPA PET-CT|Functional imaging: 68Ga-PSMA and 18F-FDOPA PET-CT Immunohistochemistry of initial chirurgical sample with determination of PSMA expression
16410821|NCT03903393||preeclamptic women|systolic blood pressure(BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg; hypertension diagnosed after 20 weeks gestation; new-onset hypertension with new-onset proteinuria or other signs/symptoms of preeclampsia after 20 weeks or chronic proteinuria with newonset hypertension.
16410822|NCT03903393||controls|Normal pregnant women
16410823|NCT03903380|Active Comparator|MT treatment + Usual care exercise|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where usual care exercise protocol will be introduced.
~The manual therapy protocol that will be used is the one proposed by Beltrán-Alacreu et al. (2015). The mentioned protocol consist of specific passive movements in the facet cervical joints, global mobilization of the cervical spine and high-velocity technique in the thoracic región."
16410824|NCT03903380|Experimental|MT treatment + Augmented reality (AR) exercises|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where AR will be applied as an exercise method.
~The same manual therapy protocol will be used for both groups.
~For this group, the Microsoft HoloLens Development Edition device will be used, which is a holographic device that allows us to interact with high definition holograms in its environment. The application that will be used will be the Roboraid software, this app is a shooter, which requires the cervical movement to move the pointer and be able to play."
16410825|NCT03903367|Active Comparator|control|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
16410826|NCT03903367|Active Comparator|paravertebral block|Bilateral thoracic paraverteberal catheters will be inserted preoperative at level of T4 in order to block thoracic dermatomal levels from T3-T7 and 0.3ml/kg 0.25% bupivacaine bouls dose in each catheter maximum 20 ml in each catheter before induction and testing sensation bilaterally by pinprick and ice after 15-20min from injection then standard GA and after tracheal intubation continuous infusion of 0.1 ml /kg/h 0.25% bupivacaine in each catheter and stopped at the end of the operation , When HR or MBP increased ≥20% from base line readings, increamental dose of fentanyl will be given (2mcg /kg), the catheters will be removed after 24 h.
16410827|NCT03903341|Other|idiopathic blepharospasm (BSP) de novo|bold signal in visual pathway
16410828|NCT03903341|Other|Healthy subjects|bold signal in visual pathway
16410829|NCT03903315||medical treatment alone|Patients with central malignant airway obstructions undergoing medical treatment alone
16410830|NCT03903315||endoscopic + medical treatment|Patients with central malignant airway obstructions undergoing medical and endoscopic treatment
16410831|NCT03903302|Active Comparator|CS 1 I SAD|Single dose pharmacokinetics of CS1 I
16410832|NCT03903302|Active Comparator|CS 1 II SAD|Single dose pharmacokinetics of CS1 II
16410833|NCT03903302|Active Comparator|CS 1 III SAD|Single dose pharmacokinetics of CS1 III
16410834|NCT03903302|Active Comparator|CS 1 II MAD|Multiple dose pharmacokinetics of CS1 II
16410835|NCT03903289|Experimental|Automated red cell exchange|Automated red cell exchange
16410836|NCT03903289|Active Comparator|Manual red cell exchange|Manual red cell exchange
16410837|NCT03903289|Sham Comparator|Simple red cell transfusion|Simple red cell transfusion
16410838|NCT03903276|No Intervention|Control|assessment of pain scale and functional capacity
16410839|NCT03903276|Experimental|Experimental|assessment of pain scale and functional capacity, TENS 30 minutes 3 sessions
16410840|NCT03903250|Placebo Comparator|Sugar|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
16410841|NCT03903250|Experimental|A-GPC|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
16411993|NCT03895411|Active Comparator|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc
16410842|NCT03903224|Active Comparator|Combined PECS II and TTP blocks (PT)|"Modified Pectoralis block (PECS II) : Using ultrasound we proceed to inject 10 ml of bupivacaine 0.25% between the pectoral muscles and 10 ml under Pmm above the serratus muscle.
~Transversus Thoracic Plane block : 10 mL bupivacaine (0.25%) is injected between the transversus thoracic muscle and the internal intercostal muscle between the third and fourth left ribs connecting at the sternum."
16410843|NCT03903224|Active Comparator|Erector Spinae Block (E)|Using ultrasound an echogenic 22-G block needle is inserted in-plane in a cranial-to-caudal direction until contact is made with the T5 transverse process. A total of 30 bupivacaine 0.25% is then injected while seeing the fluid lifting the erector spinae muscle off.
16410844|NCT03903211|Experimental|Cognitively normal individuals|Cognitively normal individualswill receive a single IV injection of [18F]PI-2620.
16410845|NCT03903211|Experimental|Subjects with Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment will receive a single IV injection of [18F]PI-2620.
16410846|NCT03903211|Experimental|Subjects with Alzheimer Disease|Alzheimer Disease Subjects with Alzheimer Disease will receive a single IV injection of [18F]PI-2620.
16410847|NCT03903185|Active Comparator|HCV-infected patients with hematological malignancy|HCV-infected patients with hematological malignancy on maintenance chemotherapy
16410848|NCT03903185|Active Comparator|Control HCV-infected patients|Control HCV-infected patients without haematological malignancy or co-morbidities.
16410849|NCT03903172|Experimental|Binder Arm|Abdominal binder + standard of care postpartum pain management
16410850|NCT03903172|No Intervention|Standard of Care|Standard of care postpartum pain managment
16410851|NCT03903159|Other|Treatment Group|Positive Peer Journaling (PPJ)
16410852|NCT03903146|Experimental|Intervention Group|This group of participants was assigned to receive the intervention by the bicultural/bilingual team of Peer counselor and Lactation Consultant. An intensive support intervention (1 prenatal visit, 1 in-hospital visit, 1 home postpartum visit, and free phone calls) were conducted individually to mothers participating until 6 months after the birth of the infant.
16410853|NCT03903146|No Intervention|Control Group|All participants in this group received traditional prenatal care in the clinic and received the usual educational material (in their proficient language) about breastfeeding during prenatal care provided by the Special Supplemental Nutritional for Women, Infants, and Children (WIC) program implemented in the clinics. Women were also able to receive one breastfeeding consultation during their hospital stay in the birthing center as part of the actual protocol established in the UK Chandler Hospital (Baby-friendly Hospital that includes support of breastfeeding during hospital stay). Women in the usual care group did not have any contact with the study IBCLC/PC.
16410854|NCT03903133|Other|vitamin E supplementation|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
16410855|NCT03903120|Experimental|ASSIST|Study 1 and 2
16410856|NCT03903120|No Intervention|Delayed Control|Study 1 and 2
16410857|NCT03903120|Experimental|Massed ASSIST|Study 3
16410858|NCT03903120|Experimental|Distributed ASSIST|Study 3
16410859|NCT03903107|Placebo Comparator|Conventional His Bundle Pacing|Patients in this arm will receive permanent his bundle pacing using conventional fluoroscopy technique
16410860|NCT03903107|Experimental|Fluoroless His Bundle Pacing|Patients in this arm will receive permanent his bundle pacing utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure
16410863|NCT03903081|Experimental|100 mg single dose|It includes two groups, one group is pilot study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=2) . Another group is formal study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=8) or matching placebo (N=2)
16410864|NCT03903081|Experimental|300 mg single dose|Healthy subjects, receiving a single dose of 300 mg HEC110114 tablet (N=8) or matching placebo (N=2)
16410865|NCT03903081|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
16410866|NCT03903081|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC110114 tablet (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study
16410867|NCT03903081|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg HEC110114 tablet (N=8) or matching placebo (N=2)
16410868|NCT03903081|Experimental|1200 mg single dose|Healthy subjects, receiving a single dose of 1200 mg HEC110114 tablet (N=8) or matching placebo (N=2)
16410869|NCT03903081|Experimental|1600 mg single dose|Healthy subjects, receiving a single dose of 1600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
16410870|NCT03903081|Experimental|600 mg multiple doses|Healthy subjects, receiving 600 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
16410871|NCT03903081|Experimental|800 mg multiple doses|Healthy subjects, receiving 800 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
16410872|NCT03903081|Experimental|1000 mg multiple doses|Healthy subjects, receiving 1000 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
16410873|NCT03903068|Experimental|NEXALIN Stimulator Group|In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.
16410874|NCT03903068|Sham Comparator|Pseudo-Stimulator Group|In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.
16410875|NCT03903042||Group 1|Center 1: Traditional camera(Canon) vs Aurora camera
16410876|NCT03903042||Group 2|Center 2: Traditional camera(Zeiss) vs Aurora camera
16410877|NCT03903042||Group 3|Center 3: Traditional camera(Topcon) vs Aurora camera
16410878|NCT03903029||Low-dose (10mg) rosuvastatin|Four statin benefit groups per 2013 ACC/AHA guideline in Korea
16410879|NCT03903016|Experimental|Test (T)|Insulin Lispro (SAR342434), 200 Units/ml, single dose on day 1 of each period
16410880|NCT03903016|Active Comparator|Reference (R)|Insulin Lispro Sanofi® ,100 Units/ml, single dose on day 1 of each period
16410881|NCT03903003|Active Comparator|preoxygenation mask applied to the cesarean|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
16410882|NCT03903003|Active Comparator|high flow nasal oxygenation applied to the ceserian|In order to protect the mother from hypoxia, preoxygenation is performed with high flow nasal oxygenation mask before induction of anesthesia.
16410883|NCT03902990|Experimental|Dual task|Treadmill training + cognitive tasks + standard exercise programme
16410884|NCT03902990|Active Comparator|Single task|Treadmill training + standard exercise programme
16410885|NCT03902990|Active Comparator|Control|Standard exercise programme
16410886|NCT03902977|Experimental|Arm A|quilting
16410887|NCT03902977|Active Comparator|Arm B|conventional suture
16410888|NCT03902964||women treated for breast cancer in 2017 (cohort A)|all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
16410889|NCT03902964||women treated for breast cancer in 2015 (cohorte B)|all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
16410890|NCT03902951|Experimental|Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)|Patients receive leuprolide SC on day 1, Patients receive a single dose of leuprolide SC on day 1 and apalutamide PO QD and abiraterone acetate PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning 2 months of initiation of ADT, patients also receive SBRT over 1, 3, or 5 fractions in the absence of disease progression or unacceptable toxicity.
16410891|NCT03902938|Experimental|Biodesign Otologic Graft|Graft following canal wall down mastoidectomy.
16410892|NCT03902938|Active Comparator|Autograft temporalis fascia|Graft following canal wall down mastoidectomy.
16410893|NCT03902925|Experimental|Group 1- Sub-tenon plus lidocaine jelly|Patients are going to be submitted to lidocaine 2% jelly topical anesthesia for 5 minutes then to sub-tenon injection of 2-4 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
16410894|NCT03902925|Active Comparator|Group 2- peribulbar|Patients are going to be submitted to peribulbar injection of 4-6 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
16410895|NCT03902912|Experimental|prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
16410896|NCT03902899|Experimental|Intervention-arm|"All endoscopists employed by 9 semi-randomly chosen hospitals in the Netherlands will be exposed to an educational intervention (oral presentation): an oral awareness training which will be delivered twice, first in 2014 and then in 2016/2017.
~In total 38 endoscopists are included from these 9 hospitals."
16410897|NCT03902899|No Intervention|Control arm|A random set of 100 endoscopists will be selected ass a reference group. These 100 endoscopists were unaware of the present study, and were thus blinded for their allocation.
16410898|NCT03902886||cerebral palsy infants|gait analysis
16410899|NCT03902886||typically developed infants|gait analysis
16410900|NCT03902873|No Intervention|usual compression|A group who get no real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
16410901|NCT03902873|Active Comparator|real-time audiovisual feedback|A group who get the real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
16410902|NCT03902847|Experimental|Motor imagery|All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but previously, a mental practice based on kinesthetic mental motor imagery was performed. To reinforce the process of motor imagery, a video with the exercises was shown to the subjects before performing the mental practice. All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
16410903|NCT03902847|Experimental|Action observation|"All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but prior to the real execution, a video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
~All the participants also received a booklet with written information about the indications and exercises to be practiced at home to ensure that the training program was performed properly. Each week, participants received messages to remind and motivate them to undertake the exercise program daily."
16410904|NCT03902847|Active Comparator|Control group|The subjects in this group received an intensive training program based on stabilization exercises of lumbo-pelvic region, which are common exercises used in rehabilitation of patients with chronic non-specific low back pain.
16410905|NCT03902834|Experimental|Intervention|
16410906|NCT03902795||Group of 62 eyes|Group of 62 eyes with rhegmatogenous retinal detachment who underwent successful vitrectomy with SF6 tamponade
16410907|NCT03902782|Experimental|ESP block|patients will receive an ultrasound guided ESP block (technique as described by Forero et al) under strict sterile conditions in the operating room area. After identifying the T5 transverse process (TP) and after infiltration of lidocaine 2% subcutaneously. A 22g 100mm block needle will be advanced under vision, in a cephalad to caudad direction, until the tip contacts the T5 TP. 20 ml of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be injected under the erector spinae muscle. A visible separation of the erector spinae muscle from the TP will be the sign of a successful block. A 20 ml syringe of Normal Saline will be given to the surgeon (unaware of the content) at the end of the surgery, for the intercostal nerve block as per standard present technique.
16410975|NCT03902236||Cystic fibrosis group|Children diagnosed with cystic fibrosis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
16410908|NCT03902782|Sham Comparator|ESP sham block|patients will receive an ultrasound guided sham ESP block under strict sterile conditions in the operating room area as described above. 20 ml of Normal Saline will be injected under the erector spinae muscle. A 20 ml syringe of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be given to the surgeon (blinded to the content) at the end of the surgery for the intercostal nerve block.
16410909|NCT03902769|Experimental|No allogeneic SCT|For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan
16410910|NCT03902769|Active Comparator|Standard post induction therapy|For slow responding AML patients, post induction therapy will be provided according to treating physician discretion
16410911|NCT03902756|Experimental|Flow-Volume loop guided endotracheal cuff inflation|Endotracheal cuff will be inflated by Flow-Volume loop guided until getting proper sealing.
16410912|NCT03902756|Active Comparator|Stethoscope-guided endotracheal cuff infration|Endotracheal cuff will be inflated by Stethoscope-guided until getting proper sealing.
16410913|NCT03902743|Experimental|Intervention group|Participants will receive an Anticipatory Care Plan
16410914|NCT03902743|No Intervention|Control group|Usual care
16410915|NCT03902730|Other|Back Squat Variation One|In a randomized order, traditional back squat will be completed.
16410916|NCT03902730|Other|Back Squat Variation Two|In a randomized order, barefoot back squat will be completed.
16410917|NCT03902730|Other|Back Squat Variation Three|In a randomized order, box squat will be completed.
16410918|NCT03902730|Other|Back Squat Variation Four|In a randomized order, traditional back squat with chains will be completed.
16410919|NCT03902717||minimally invasive cardiac surgery|Group of patients that will undergo minimally invasive cardiac surgery
16410920|NCT03902704|Experimental|Cleverscope|Cleverscope is a new videolaryngoscope used for tracheal intubation. in this group we use this device to intubate participants.
16410921|NCT03902704|Active Comparator|Laryngoscope / Videolaryngoscope C-MAC® Storz|in this group we use a standart comercial device for intubation (laryngoscope or C-MAC) to intubate participants
16410922|NCT03902691|Experimental|Pegol-Sihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks.
16410923|NCT03902691|Active Comparator|ESPO (Recombinant Human Erythropoietin Injection）|ESPO administration 1 to 3 times per week.
16410924|NCT03902678|Experimental|EUS - FNA for benign PVT by imaging|Intervention: Procedure/Surgery: EUS guided fine needle aspiration of portal vein thrombus
16410925|NCT03902665|Experimental|Allogeneic hematopoietic stem cell transplantation|Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor
16410926|NCT03902652|Experimental|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.
~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.
~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.
~During CC+SI the clinical team will only use 21% oxygen."
16410927|NCT03902652|Active Comparator|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.
~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.
~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.
~During CC+SI the clinical team will only use 100% oxygen."
16410928|NCT03902626||Physiotherapy students|Degree course
16410929|NCT03902626||Medical students|Degree course
16410930|NCT03902613|Experimental|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
16410931|NCT03902587||Cervical Elastography|During each sonogram in which cervical lengths are measured, 5 additional cervical indices will be collected using Samsung's E-cervix technology. Each index will then be separated based on characteristics to create a nomogram for singletons, twins, and those with interventions already in place (i.e. cerclage and/or progesterone) at the time of their E-cervix assessment.
16410932|NCT03902574|Experimental|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
16410933|NCT03902574|Experimental|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
16410934|NCT03902574|Experimental|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
16410935|NCT03902548|Experimental|Brain uptake and kinetics in Alzheimer's patients|
16410936|NCT03902548|Experimental|Dosimetry in healthy volunteers|
16410937|NCT03902535||Group I (geriatric and quality of life assessments)|Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion.
16410938|NCT03902535||Group II (quality of life assessment)|Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
16410939|NCT03902522|Experimental|Leronlimab (PRO 140)|Subjects will be on existing ART for one week followed by PRO 140 700mg weekly SC Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
16410940|NCT03902509|Experimental|Pirfenidone|pirfenidone + basic treatment
16410941|NCT03902509|Other|Controll|with basic treatment and without pirfenidone treatment
16410942|NCT03902496|Experimental|Avulux Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
16410943|NCT03902496|Sham Comparator|Sham Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
16410944|NCT03902470|Experimental|Thoracic epidural anaesthesia for vats|"Patients in thoracic epidural (TE) group will pre-medicated using midazolam 3-4 mg intravenous (IV)and fentanyl 50 mcg intravenously(i.v.). Then patients will placed in the lateral decubitus position. An epidural catheter will be inserted between T3-T4 and T4-T5 for all thoracic procedures except sympathectomy and thymectomy. A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5% and 50 mcg of fentanyl.
~The objective is to achieve sensory and motor block between C7 and T7 levels. At this level diaphragmatic respiration is maintained. The anaesthesia level will be monitored by warm-cold discrimination."
16410945|NCT03902470|Active Comparator|General anesthesia for vats|Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
16410946|NCT03902457|Experimental|test site|The sinus mucosa will be elevated and, at the test sites, a collagen membrane will be placed subjacent the sinus mucosa
16410947|NCT03902457|Experimental|control site|The sinus mucosa will be elevated and, at the control sites, a collagen membrane will not be placed subjacent the sinus mucosa
16410948|NCT03902444||Credo® Stent and NeuroSpeed® PTA balloon catheter|Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine
16410949|NCT03902431|No Intervention|Control|CVD risk prior to the patient and clinician training
16410950|NCT03902431|Experimental|Training|CVD risk after the patient and clinician training
16410951|NCT03902405|Active Comparator|Active CEASAR Intervention|"Participants will be given the active CEASAR intervention where they will be trained to avoid cues associated with stimulant use and approach healthy cues based on the orientation of the images presented. Individuals will be asked to approach (pull in) portrait images and avoid (push away) landscape images. In the active condition, pushed pictures (landscape orientation) will exclusively be stimulant-use related pictures. Conversely, healthy images will be in the portrait orientation which will be pulled in."
16410952|NCT03902405|Placebo Comparator|Placebo CEASAR|In the control condition, stimulant use-related pictures will be randomized and equally divided into push (landscape) and pull (portrait) conditions.
16410953|NCT03902392|Active Comparator|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
16410954|NCT03902392|Placebo Comparator|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
16410955|NCT03902379|Experimental|Supportive Care (CCI intervention)|Patients complete 3 modules of online CCI intervention.
16410956|NCT03902366||AUD+/HCV+|"With current Alcohol Use Disorder and with HCV
~About to initiate DAA therapy for HCV"
16410957|NCT03902366||AUD-/HCV+|"Without current Alcohol Use Disorder and with HCV
~About to initiate DAA therapy for HCV"
16410958|NCT03902366||AUD+/HCV-|-With Alcohol Use Disorder and without HCV
16410959|NCT03902366||AUD-/HCV-|-Without Alcohol Use Disorder and without HCV
16410960|NCT03902353|Other|Adults without diagnosis of PH|Adults without diagnosis of PH carrying an heterozygous EIF2AK4
16410961|NCT03902340|Experimental|TENS|Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS)
16410962|NCT03902340|Active Comparator|level 2 systemic analgesic treatments|Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity.
16410963|NCT03902327|Experimental|NAC group|NAC for 12 weeks, 1.6 mg/day, 4x400 mg; a diet based on general recommendations for people with carbohydrate metabolism disorder
16410964|NCT03902327|Active Comparator|Control group|Placebo for 12 weeks and a diet based on general recommendations for people with carbohydrate metabolism disorder
16410965|NCT03902314|Active Comparator|Lidocaine|Lidocaine infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
16410966|NCT03902314|Placebo Comparator|Saline|Saline infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
16410967|NCT03902301|Active Comparator|Dietary group|A diet based on general recommendations for people with insulin resistance for 20 weeks.
16410968|NCT03902301|Experimental|Lactobacillus rhamnosus group|Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.
16410969|NCT03902288|Experimental|Patients with type 2 diabetes|Patients with type 2 diabetes at early stages of type 2 diabetes (FSG: 7.1 15.8 mmol/L)
16410970|NCT03902288|Active Comparator|Healthy individuals|Healthy individuals match age and gender to the experimental group
16410971|NCT03902275|Experimental|Quantra|Evaluation of bloodsamples using the Quantra and Multiplate device
16410972|NCT03902275|Active Comparator|Control|Evaluation of bloodsamples using the ROTEM and Multiplate device
16410973|NCT03902249|Active Comparator|Dexamethasone group|Patients who received 0.15mg/kg of Dexamethasone in 8ml of saline
16410974|NCT03902249|Placebo Comparator|Placebo group|Patients who received the same volume of saline as the study group (8ml)
16414238|NCT03879928|Experimental|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
16410976|NCT03902236||Bronchiectasis group|Children diagnosed with bronchiectasis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
16410977|NCT03902236||Healthy group|Healthy children more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
16410978|NCT03902223|Experimental|Enhanced Screening Protocol For Cardiac Sarcoidosis|Arm will be randomly assigned to undergo enhanced screening methods (ambulatory ECG and echocardiogram) at month 0 and month 24, as well as a phone call/chart review at month 12.
16410979|NCT03902223|Active Comparator|Routine Screening for Suspected Cardiac Sarcoidosis|Arm will be randomly assigned for the routine standard of care/no intervention with enhanced screening methods. They will be offered the EKG and symptom check at months 0 and 24, as well as a phone call/chart review at month 12.
16410980|NCT03902210|Experimental|Online Yoga|The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety & modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.
16410981|NCT03902210|Placebo Comparator|Podcast|The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
16410982|NCT03902197|Experimental|CD19 hsCAR-T|This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR
16410983|NCT03902184|Experimental|Cohort 1: Relapsed/refractory Sezary Syndrome|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
16410984|NCT03902184|Experimental|Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
16410985|NCT03902184|Experimental|Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
16410986|NCT03902171||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
16410987|NCT03902171||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
16410988|NCT03902158|Experimental|Glasses|
16410989|NCT03902158|No Intervention|Distraction techniques|No glasses will be used
16410990|NCT03902145||Intervention Group|Children previously in the intervention group received one egg per day for 6 months beginning when the child was between 6-9 months of age.
16410991|NCT03902145||Control Group|
16410992|NCT03902132|Experimental|Core Stability exercises group|Core Stability exercises
16410993|NCT03902132|Active Comparator|Traditional low back physical therapy group|Traditional low back physical therapy management
16410994|NCT03902119|Experimental|INIBY tool|Patients will undergo a single treatment session consisting of applying a suboccipital muscle inhibition technique using the so-called INYBI tool. The treatment session will last approximately 5 minutes
16410995|NCT03902119|Active Comparator|Manual suboccipital inhibition|Patients will receive a single treatment session consisting of the use of the manual suboccipital muscles inhibition technique.The treatment session will last approximately 5 minutes
16410996|NCT03902106|Active Comparator|beta2-agonist and exercise|Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
16410997|NCT03902106|Sham Comparator|placebo and exercise|Subjects undergo exercise training with administration of sham placebo
16410998|NCT03902093|Experimental|Hearing Aid|Actual Patients in the clinic will be evaluated by their Audiologist, if they are candidates to use the Lyric Hearing aid they will be asked if they want to participate in the study which will include imaging of the ear canal with a device similar to the regular ear device used in the clinic to check if there are any changes to the morphology of the ear canal.
16410999|NCT03902080|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
16411000|NCT03902080|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 24 weeks.
16411001|NCT03902067|Experimental|UC-MSC|UC-MSC transplantation
16411002|NCT03902067|Placebo Comparator|Control Group|Routine treatment
16411003|NCT03902054|Experimental|Experimental Group - High dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV
16411004|NCT03902054|Experimental|Experimental Group - Medium dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV
16411005|NCT03902054|Experimental|Experimental Group - Low dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of low dosage investigational sIPV
16411006|NCT03902054|Active Comparator|Control Group -commercialized sIPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV
16411257|NCT03900351|Experimental|Group B: Control group|They will receive the regular exercise rehabilitation protocol only for 40 minutes, for 3 days per week, for 8 weeks.
16411007|NCT03902054|Active Comparator|Control Group -commercialized IPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV
16411008|NCT03902041||Treatment Group|The patients will receive Eltrombopag treatment after transplantation at d1.
16411009|NCT03902041||Control Group|The patients will not receive Eltrombopag treatment after transplantation.
16411010|NCT03902028|Experimental|Reinforced multidisciplinary follow-up|"Entrance medication reconciliation performed by a pharmacist
~Patient compliance evaluation
~Patient quality of life evaluation
~Pharmaceutical analysis with focus on medication optimization with a specific check-list (according to ESC 2016 recommendations)
~Hospitalisation discharge medication reconciliation
~Patient pharmaceutic interview at the hospitalisation discharge
~Transmission of informations to the general practitioner and the pharmacist's patient
~Multidisciplinary consult at 1 month after hospitalisation discharge"
16411011|NCT03902028|No Intervention|Standard care|"Drug review by a paramedic or a pharmacist
~Pharmaceutical analysis
~Therapeutic optimisation based on the usual practices care of the cardiologic department
~Writing of the prescription given on leaving hospital based on the usual care of the department
~Treatments explanations and support to the patient on the usual care
~Transmission of the hospitalisation report to the patient general practitioner as the usual practice
~Medical consult in usual time frames (an average of 1 month after hospitalisation discharge) at the patient location of choice"
16411012|NCT03902015|Experimental|Nuance Phone case|"Nuance Hearing has developed a technology enabling focused hearing. The Selective Noise Cancellation (SNC) technology consists of an advanced beam-forming algorithm that tones down the ambient sound by up to 15 decibels (dB) in order to focus on a primary audio source. The device consists of a special phone case(for iPhone) containing microphone array. Controlling the direction of focus is enabled through the use of a designated app. The user can place the phone case on his/hers table and can choose the direction of preferred listening, without having to ask the talker to hold the device."
16411013|NCT03902002|Experimental|Group 1: matched healthy subjects|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
16411014|NCT03902002|Experimental|Group 2: subjects with mild hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
16411015|NCT03902002|Experimental|Group 3: subjects with moderate hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
16411016|NCT03902002|Experimental|Group 4: subjects with severe hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
16411017|NCT03901989|Active Comparator|zeolite|50 subjects receive the substance 3 times per day as powder
16411018|NCT03901989|Placebo Comparator|cellulose|50 subjects receive the substance 3 times per day as powder
16411019|NCT03901976|Other|Bed Exit Detection On|prevention of fall by a true bed exit detection
16411020|NCT03901963|Experimental|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
16411021|NCT03901963|Active Comparator|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
16411022|NCT03901950|Experimental|XNW7201|
16411023|NCT03901937|Placebo Comparator|Placebo|parenteral nutrition without ω-3 polyunsaturated fatty acid
16411024|NCT03901937|Experimental|ω-3 fatty acid|parenteral nutrition with ω-3 polyunsaturated fatty acid
16411025|NCT03901924|Active Comparator|Volume Support Mode Mechanical Ventilation|Volume support mode ventilation is a spontaneous mode where a target goal volume is set on the ventilator. This ventilatory strategy is dependent on patients spontaneously breathing and triggering (or activating) the ventilator to support the breath. The ventilator adjusts the amount of pressure support to deliver with each breath (i.e. if the patient's tidal volume is greater than the set target volume, then the ventilator will decrease the amount of pressure support in the subsequent breath to try to achieve the goal volume and vice versa). The respiratory rate is not set in this mode of ventilation and is dependent on the patient. For patients randomized to this mode, the goal tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
16411026|NCT03901924|Active Comparator|Assist Control Mode Mechanical Ventilation|In assist control mode ventilation, the machine is programmed to deliver a set tidal volume and set respiratory rate. Patients can breathe over the set respiratory rate, but the volume of breath that they receive is fixed and delivered by the ventilator. For patients randomized to this mode, the tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
16411027|NCT03901898|Experimental|Training, audit, and reminders|An investigator will deliver a 20-30-minute briefing on intervention delivery to all staff at participating practices, followed by one-on-one audit training (1 hour) with the staff member responsible for conducting the audit. Each practice conducts an audit of their patients with diabetes to identify all people who have not attended retinopathy screening with the national programme. At 6 months, practices conducts a re-audit. Practice staff add electronic alerts to the records of eligible patients, to prompt GPs and nurses to remind patients. Practices are reimbursed at study entry with further payment following intervention cessation based on number of patients audited. Face-to-face verbal reminders are delivered by GPs and practice nurses to eligible patients attending for an appointment during the study period. All eligible patients receive a reminder phone call from a practice nurse and a GP-endorsed reminder letter accompanied by an information leaflet.
16411062|NCT03901703|Active Comparator|Dorsiflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their dorsiflexor muscles alongside standard functional progressive strengthening exercises.
16411028|NCT03901898|Other|Wait list control|In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
16411029|NCT03901885|Other|Major women operated for deep endometriosis|Major women operated for deep endometriosis at the Lyon Sud Hospital Center (CHLS) of the Hospices Civils de Lyon (HCL).
16411030|NCT03901872||Acute Iliofemoral DVT|Suitable patients would be invited to take part in this trial as part of standard of care.
16411031|NCT03901859||Patients with ADHD|drug-naive patients with ADHD, aged 7-18 year old
16411032|NCT03901859||Healthy Controls|drug-naive healthy controls, aged 7-18 year old
16411033|NCT03901846|Other|ColdZyme|"The study is intended to verify the method used to measure the duration of ColdZyme®.
~Each participant will be his own control as samples are taken before application of ColdZyme and used as an internal control."
16411034|NCT03901833|Experimental|Telemedicine Support|Weekly telemedicine breastfeeding support visits for four weeks, delivered via telemedicine
16411035|NCT03901833|Placebo Comparator|Control|Standard of care
16411036|NCT03901820|No Intervention|DrApp Without SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
16411037|NCT03901820|Experimental|DrApp With SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (SIMDA).
16411038|NCT03901807|Experimental|PMX Treatment|Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
16411039|NCT03901807|No Intervention|Control|Standard medical care alone
16411040|NCT03901794||With Clear Sight|record and observe the data including SVI, CI, SVR with clearSight during hemodialysis
16411041|NCT03901781|Experimental|Cohort One|Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
16411042|NCT03901781|Experimental|Cohort Two|Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
16411043|NCT03901781|Experimental|Cohort Three|Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
16411044|NCT03901768|Experimental|Group dexamethasone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
16411045|NCT03901768|Experimental|Group triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
16411046|NCT03901768|Experimental|Group dexamethasone with triamcinolone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
16411047|NCT03901768|Placebo Comparator|Placebo group|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
16411048|NCT03901755||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
16411049|NCT03901755||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
16411050|NCT03901742|Active Comparator|Standard Enteral Nutrition|Standard Enteral Nutrition: cow's milk based infant formula (Nidina, Nestlé, Barcelona, Spain).
16411051|NCT03901742|Active Comparator|Protein-enriched nutrition|Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain)
16411052|NCT03901742|Active Comparator|High Protein-enriched Nutrition|High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
16411053|NCT03901729|Experimental|Arm 1|BAY1753011 30mg in addition to standard of care (SoC) for part A and part B
16411054|NCT03901729|Placebo Comparator|Arm 2|Placebo of BAY1753011 in addition to SoC for part A and part B
16411055|NCT03901729|Experimental|Arm 1-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
16411056|NCT03901729|Active Comparator|Arm 1-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
16411057|NCT03901729|Experimental|Arm 2-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
16411058|NCT03901729|Active Comparator|Arm 2-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
16411059|NCT03901716|Experimental|Sufentanil|Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
16411060|NCT03901716|Experimental|Fentanyl|Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
16411061|NCT03901716|Experimental|Remifentanil|Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
16411063|NCT03901703|Active Comparator|Plantarflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their plantarflexor muscles alongside standard functional progressive strengthening exercises.
16411064|NCT03901703|Active Comparator|Dorsiflexor and Plantarflexor Muscle strengthening Group|The children in this group will receive functional exercises aiming to strengthen both their dorsiflexor and plantarflexor muscles alongside standard functional progressive strengthening exercises.
16411065|NCT03901690|Experimental|Arm Betaglucin|It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.
16411066|NCT03901690|Active Comparator|Arm Imiquimod|51 individuals between the ages of 18 and 50 will receive 5% imiquimod.
16411067|NCT03901677|Experimental|Tai-chi training|Tai-chi training performe as a group exercise. Duration for tai chi exercise will be 60 minutes for 2 days per week for 12 weeks. Each session includes 10 min warm-up and cool-down and 40 min Tai Chi exercises. During exercises, attention paid to correct positioning of the upper and lower extremity joints, and mentally concentration achieve. Slow and controlled movements will carry out by a specialized physiotherapist.
16411068|NCT03901651|Active Comparator|Standard colonoscopy|"Patients submitted for screening, surveillance or diagnostic colonoscopy. A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.
~Each polyp and adenoma will be recorded, including the size and location. Polyps will be removed before the second procedure."
16411069|NCT03901651|Experimental|Retroview colonoscopy|"The same group of patients. A second colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the first colonoscopy findings.
~The operator will record the polyps and adenoma encountered, describing the size and location."
16411070|NCT03901638|Experimental|Tllsh2910 to placebo|Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
16411071|NCT03901638|Experimental|Placebo to Tllsh2910|Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks
16411072|NCT03901625|Active Comparator|ManualTB+Floss|Cleaning teeth with a manual toothbrush and a dental floss three times a day.
16411073|NCT03901625|Experimental|ManualTB+Waterjet|Cleaning teeth with a manual toothbrush and a waterjet three times a day.
16411074|NCT03901625|Experimental|Electric TB+Floss|Cleaning teeth with an electric toothbrush and dental floss three times a day .
16411075|NCT03901625|Experimental|Electric TB +Waterjet|Cleaning teeth with an electric toothbrush and a waterjet three times a day .
16411076|NCT03901612|Placebo Comparator|Saline solution|Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
16411077|NCT03901612|Experimental|Ropivacaine|Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
16411078|NCT03901599||Children between 5-10Kg|Children with a body weight between 5-10Kg
16411079|NCT03901599||Children between 10-20Kg|Children with a body weight between 10-20Kg
16411080|NCT03901599||Children between 20-40Kg|Children with a body weight between 20-40Kg
16411081|NCT03901586|Experimental|Patients who had Richter intervention|
16411084|NCT03901547|Other|Education and Documentation (Tier 1)|Education only. Participants who do not wish to enroll in the behavioral observation group are followed in the education only. This includes participation in a two week palliative medicine elective which is a part of the medical trainees training and training in the serious illness communication guide (SICG). Participants can opt out of the pre and post training confidence surveys, and simulated patient encounters. Electronic documentation of the SICG by these trainees will be monitored prospectively. Participants will be provided reminders and profile information on their own documentation rate of the SICG via email and have the ability to opt out of receiving emails if they wish.
16411085|NCT03901547|Other|Priming and additional measures (Tier 2)|Education and behavioral observation cohort. These participants must sign an informed consent to participate in this part of the study. In addition to all of Tier 1 activities, participants also complete psychological inventories at three time points to measure emotion regulation and burnout, and participate in a semi-structured interview.
16411086|NCT03901534|Other|Moderate to Severe OSA - treated|Moderate-to-severe OSA Treated with and adherent to Auto-CPAP
16411087|NCT03901534|Experimental|Moderate to Severe OSA - withdrawal|Moderate-to-severe OSA Withdrawal of Auto-CPAP
16411088|NCT03901508|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
16411089|NCT03901508|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
16411090|NCT03901495|Experimental|Diaana|"The patient fullfill Diaana
~The resident physician takes connaissance of the Diaana summary
~The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)
~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
16411091|NCT03901495|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)
~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
16411092|NCT03901482|Experimental|STS101 Low Dose|STS101 (dihydroergotamine nasal powder), low dose
16411093|NCT03901482|Experimental|STS101 High Dose|STS101 (dihydroergotamine nasal powder), high dose
16411094|NCT03901482|Placebo Comparator|STS101 Placebo|STS101 Placebo
16411095|NCT03901469|Experimental|Experimental: ZEN003694 in Combination with Talazoparib|ZEN003694 will be administered orally once daily with Talazoparib orally once daily in 28-day cycles, enrolling TNBC patients. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2
16411096|NCT03901456|Experimental|Treatment|Participants in the treatment arm will receive the Care to Plan (CtP) intervention.
16411128|NCT03901222|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
16411097|NCT03901456|Active Comparator|Control|"Usual care control group.
~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
16411098|NCT03901430|Experimental|Class|Group navigation model
16411099|NCT03901417|Active Comparator|Non-ablative Fractional Laser|Non-ablative fractional laser (brand name Fraxel Restore) only on one half of the face.
16411100|NCT03901417|Active Comparator|Non-ablative Fractional Laser Plus Microneedling|Non-ablative fractional laser (brand name Fraxel Restore) in combination with a microneedling device (SkinPen) on the other half of the face.
16411101|NCT03901391||Retinitis Pigmentosa|
16411102|NCT03901378|Experimental|Single Arm|Pembrolizumab 200mg IV day 1 with Carboplatin AUC 6 IV day 1 or Cisplatin 80mg/m2 day 1 with etoposide 100mg/m2 days 1-3 of 21 day cycle. Repeat 4-6 cycles to be followed by maintenance Pembrolizumab 200mg IV day 1 every 21 days until progression or intolerance for up to 2 years.
16411103|NCT03901365|Experimental|Group 1|Patient received manual therapy in addition neuroscience pain education sessions
16411104|NCT03901365|Active Comparator|Group 2|Patient received manual therapy in addition tradition education sessions
16411105|NCT03901352|Experimental|Mirogabalin|"The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
~The patients with creatinine clearance (CLcr) 30 to < 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose"
16411106|NCT03901352|Placebo Comparator|Placebo|Placebo (14-weeks)
16411107|NCT03901339|Experimental|Sacituzumab Govitecan-hziy|Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.
16411108|NCT03901339|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from one of the following single-agent treatment:
~Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic)
~Eribulin: 1.4 mg/m^2 for North American sites, 1.23 mg/m^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle
~Capecitabine: 1000-1250 mg/m^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle
~Gemcitabine: 800-1200 mg/m^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution
~Vinorelbine: 25 mg/m^2 via IV on Day 1 weekly cycle per institution"
16411109|NCT03901326|Experimental|CTA/CT-FFR care group|If the subjects are randomly allocated to CTA/CT-FFR arm, they will be examined by DeepFFR for three major epicardial arteries. If CT-FFR value of one or more major coronary arteries is less than 0.75, ICA will be performed directly; if CT-FFR is 0.75-0.8 (including 0.8), physicians will decide whether to start intensive drug therapy or ICA; if CT-FFR value is more than 0.8, only drug therapy will be needed. The clinical management plan will be suggested including optimal medical therapy, ICA, PCI, CABG and other intervention according to the result of this non-invasive examination.
16411110|NCT03901326|No Intervention|routine clinically-indicated diagnostic care group|If the subjects are randomized to CID arm, attending physicians will decide next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.
16411111|NCT03901313|Experimental|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
16411112|NCT03901313|Experimental|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
16411113|NCT03901313|Experimental|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
16411114|NCT03901313|Experimental|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
16411115|NCT03901313|Experimental|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
16411116|NCT03901313|Experimental|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
16411117|NCT03901300|Experimental|Fundamental Motor Skills (FMS)|The FMS group will utilize the PLAY FMS app that provides instructional lessons, peer modeling videos, and activity breaks to deliver 720 minutes of targeted, structured FMS instruction time to the child over a 12 week period.
16411118|NCT03901300|Active Comparator|Unstructured Physical Activity|The active comparator group will use a version of the PLAY app that provides instructional lessons to promote the equivalent dosage of unstructured physical activity for the child.
16411119|NCT03901287|Experimental|dual energy CT|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
16411120|NCT03901274|Active Comparator|Clinical Services Support Condition|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework.
16411121|NCT03901274|Experimental|Patient-Centered Enhancements|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework. The clinicians in this condition will receive additional training on two Patient-Centered Enhancements (PCE).
16411122|NCT03901261|Experimental|Down syndrome patients|
16411123|NCT03901248||Normoglycemia|Participant with normal blood glucose level with No Intervention
16411124|NCT03901248||Impaired Glucose Tolerance|Participants with Impaired Glucose Tolerance blood glucose level with No Intervention
16411125|NCT03901248||Type 2 Diabetes|Newly diagnosed type 2 diabetes patients with No Intervention
16411126|NCT03901235|Experimental|Mesenchymal Stromal Cells|
16411127|NCT03901222|Active Comparator|Bi-Anodal tDCS|Subjects will receive 20 min of bi-anodal tDCS
16411129|NCT03901209|Experimental|Laser osteotomy|The planned mid-face osteotomy (e.g. LeFort I) is performed using the CARLO osteotomy device, where a patient-specific intervention plan based on preoperative imaging is loaded on the system to allow the device to show and suggest a location for the osteotomy.
16411130|NCT03901196||Interstitial Lung Disease|Ex : sarcoidosis, IPF
16411131|NCT03901183|Experimental|Interventional|Participants receive a 8 week nutritional counseling with weekly group meetings to establish a plant-based diet.
16411132|NCT03901183|No Intervention|Control|Waiting list. Participants receive no intervention during study period, equal intervention is offered after the end of study.
16411133|NCT03901170|Experimental|letrozole|patients with letrozole
16411134|NCT03901170|No Intervention|control|patients without letrozole
16411135|NCT03901157|Experimental|Active yogurt|Contains 120 g yogurt + 60 g oil-gel particles (containing 6 g oil) + 24 g water
16411136|NCT03901157|Active Comparator|Control yogurt|Contains 120 g yogurt + 54 g empty gel particles + 6 g oil in 24 g water
16411137|NCT03901144|Experimental|cream 1107.57|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
16411138|NCT03901144|Active Comparator|Glycerol cream|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
16411139|NCT03901144|Active Comparator|Paraffin cream|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
16411140|NCT03901144|No Intervention|Untreated|Untreated are on the volar forearm
16411141|NCT03901131||BAY98-7040|"Female adult patients of reproductive age, who want to use a contraceptive method, will be enrolled after the investigator has made the decision for treatment with Mesigyna.
~Investigators should prescribe Mesigyna for medically approved indications as per the label of the medicine locally approved."
16411142|NCT03901118|Experimental|chiauranib plus etoposide|Patients receive the combined treatment of chiauranib plus etoposide, 28 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Etoposide is given orally, 50mg once daily for 21 days, 7 days off, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
16411143|NCT03901118|Experimental|chiauranib plus paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
16411144|NCT03901105|Experimental|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
16411145|NCT03901092|Experimental|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
16411146|NCT03901079||CTO BridgePoint system|"BridgePoint CTO System:
~CrossBoss Catheter
~Stingray LP Catheter
~Stingray Guidewire and Extension Wire"
16411147|NCT03901053|Experimental|AB|Participants in this arm will receive the Reaktiv AFO made by FabTech Systems LLC first, then the PhatBrace AFO by Bio-Mechanical Composites Inc. second.
16411148|NCT03901053|Experimental|BA|Participants in this arm will receive the PhatBrace AFO by Bio-Mechanical Composites Inc. first, then the Reaktiv AFO made by FabTech Systems LLC second.
16411149|NCT03901040|Other|obese patient|we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
16411150|NCT03901027|Experimental|Parents of children with chronic illnesses|psycho-educational intervention for parents
16411151|NCT03901014|Active Comparator|Baseline diet|1 week baseline diet
16411152|NCT03901014|Experimental|Very low carbohydrate diet|2 week very low carbohydrate ketogenic diet
16411153|NCT03901001|Active Comparator|oseltamivir and adjunctive sirolimus|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
16411154|NCT03901001|Placebo Comparator|oseltamivir alone|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
16411155|NCT03900988|Active Comparator|intravenous N-acetylcysteine (NAC) and oseltamivir|
16411156|NCT03900988|Placebo Comparator|intravenous 5% dextrose and oseltamivir|
16411157|NCT03900975||Vulvar Paget Disease|Women with vulvar paget disease
16411158|NCT03900962|Experimental|Slow-speed strength training|The slow-speed strength training group performed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds.
16411159|NCT03900962|Experimental|High-speed power training|During the first three weeks of training, the high-speed power training group completed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds. Thereafter, this group completed the concentric phase of five resistance exercises (squat, press-up, incline chest press, seated row and push-press) as fast as possible whilst still taking two seconds to complete the eccentric phase.
16411160|NCT03900949|Experimental|Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)|INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS < 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS >= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.
16411161|NCT03900936||Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
16411162|NCT03900923|Experimental|98% pure CBD|98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.
16411163|NCT03900910|Other|Gastric cancer prevention|13C-urea breath test and anti-H. pylori treatment for those who are tested positive.
16411164|NCT03900884|Experimental|Letrozole + Palbociclib + Venetoclax|"The Letrozole dose is 2.5 mg (D1-28) for all dose levels.
~Starting dose Level 1: Palbociclib 100 mg (D1-21) and Venetoclax 100 mg (D1-21) daily."
16411165|NCT03900871|Experimental|Experimental group|
16411166|NCT03900871|Placebo Comparator|Control group|
16411167|NCT03900858|Experimental|Isoniazid/ Rifapentine 3 times a week|Intervention：Isoniazid/ Rifapentine 3 times a week given by DOT oral Rifapentine (450mg) plus Isoniazid (400mg) for 12 doses
16411168|NCT03900858|No Intervention|No Intervention|No preventive treatment Follow up without intervention. Have already done.
16411169|NCT03900845|Experimental|Environmental Chamber|All participants will wear all three study prostheses in an environmental chamber set at 35 degrees Celsius and 50% relative humidity.
16411170|NCT03900845|Experimental|Field Measurements|All participants will wear all three study prostheses in their home, work, and community environments for two weeks.
16411171|NCT03900832|Placebo Comparator|PAD without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411172|NCT03900832|Experimental|PAD warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411173|NCT03900832|Placebo Comparator|PAD neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411174|NCT03900832|Experimental|PAD heating suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411175|NCT03900832|Experimental|PAD lower limb warm water immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411176|NCT03900832|Placebo Comparator|Healthy subjects without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411177|NCT03900832|Experimental|Healthy subjects warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411178|NCT03900832|Placebo Comparator|Healthy subjects neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411179|NCT03900832|Experimental|Healthy subjects heat suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411180|NCT03900832|Experimental|Healthy subjects lower limb immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
16411181|NCT03900806|Experimental|Basic Cognitive Rehabilitation|The basic arm will consist of a brief cognitive training programme without individual guidance throughout the intervention, involving three to five sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks.
16411182|NCT03900806|Experimental|Extensive Cognitive Rehabilitation|The extensive arm will consist of a comprehensive training program, involving five to eight sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks. After the first session, each further session in the extensive group involves tailored therapy guidance . Cognitive strategy modules will be assigned by the therapist depending on the participants' cognitive profile and personal treatment goals.
16411183|NCT03900806|No Intervention|Waitlist control group|Participants in the waiting list control group will be offered the opportunity to follow the basic cognitive rehabilitation program after completion of the 26-week follow-up measurement.
16411184|NCT03900793|Experimental|Dose Escalation and Expansion|"Part 1: This is a study escalating doses (Dose level 1-3) of losartan on a continuous daily dosing schedule and sunitinib (escalating on dose level 4) on a daily dosing with 4 weeks on, 2 weeks off. A cycle of therapy is 6 weeks (42 days).Dosing will be performed based on body surface area (BSA). This portion of the study uses a 3+3 design (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level).
~Part 2: Once the Maximally Tolerated Dose (MTD) has been determined, 12 patients will enroll to the expansion cohort. These patients will receive the MTD as long as less then 33% of patients experience dose-limiting toxicities."
16411221|NCT03900611|No Intervention|healthy control|
16411258|NCT03900338||PWV>10|Patients with PWV > 10 (SSphygmoCor) in two different measurements
16411185|NCT03900780|Experimental|PGT-A group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
16411186|NCT03900780|Active Comparator|Control group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
16411187|NCT03900767|Experimental|Clinic-Level|"Clinics will receive the AAC intervention consisting of an EHR-based point of care alert that prompts clinic staff to Ask every patient about tobacco use, Advise tobacco using patients to quit, and Connect interested tobacco users to the Utah Tobacco Quit Line
~Assigned Interventions = Electronic Health Record intervention AAC"
16411188|NCT03900767|Experimental|Phase I Group I (Continued EHR and text messages)|Patients receive a weekly text message for one month followed by a monthly text message over the next 5 months (i.e., 6 months of text messages following each tobacco users' clinic visit). All messages will include a motivational message, the Quit Line website, the Quit Line phone number, and simple two-touch response that directly connects interested tobacco users to the Quit Line.
16411189|NCT03900767|Experimental|Phase I Group II (Continued clinic-level EHR intervention only)|Patients receive continued clinic level EHR intervention only (CO).
16411190|NCT03900767|Experimental|Phase II Group I (Text messages, Counseling call)|Patients receive a monthly text message plus 2 brief telephone calls from patient navigators/health educators for 6-12 months following each tobacco user's clinic visit.
16411191|NCT03900767|Experimental|Phase II Group II (Text messages continued)|Patients receive a monthly text message for 6-12 months following each tobacco user's clinic visit that includes a simple one-touch response to directly connect to the Quitline.
16411192|NCT03900754|Experimental|Intranasal Oxytocin|Dosages of oxytocin: 20IU or 40IU.
16411193|NCT03900754|Placebo Comparator|Placebo|Saline
16411194|NCT03900741|Experimental|Submerged healing|Bone regeneration of peri-implantitis defects following a submerged healing
16411195|NCT03900741|Active Comparator|Non-submerged healing|Bone regeneration of peri-implantitis defects following a non-submerged healing
16411196|NCT03900728|Active Comparator|Auriculotherapy with needles (acupuncture) + usual care|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
16411197|NCT03900728|Active Comparator|Auriculotherapy with gold beads (acupressure) + usual care|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
16411198|NCT03900728|Sham Comparator|Placebo group + usual care|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
16411199|NCT03900715|Experimental|Luspatercept Administration|Luspatercept will be administered as a subcutaneous injection every 3 week (21 days; Q3W), at an initial dose level of 1.0 mg/kg. Doses may be titrated up starting at dosing visit Week 7 Day 1 (W7D1)
16411200|NCT03900702|Active Comparator|Active Intervention|Gaze-driven games, played at home on PC with eye-tracker, to train resistance to attention distraction and speed of processing.
16411201|NCT03900702|No Intervention|Wait List Control|Wait list then cross over to active intervention.
16411202|NCT03900689||Health Services Research - Part 1 Survey|Participants will be asked to complete a series of surveys. This will be preferentially completed on the same day of the visit but may be completed at a subsequent visit, over the telephone or taken home and sent back to the clinic.
16411203|NCT03900689||Health Services Research - Part 2 - Focus Group|Patients identified in Part 1 will be offered participation in the focus groups in Part 2. All patients enrolled in Part 1 will be considered for participation in Part 2. Approximately 30 total patients will be invited to participate. Patients who agree to be contacted will receive a telephone call or contacted in clinic and invited to participate in the Part 2 focus group.
16411204|NCT03900676|Experimental|VB-1953 topical gel - 2% QD|VB-1953 topical gel - 2% QD
16411205|NCT03900676|Experimental|VB-1953 topical gel - 2% BID|VB-1953 topical gel - 2% BID
16411206|NCT03900676|Placebo Comparator|VB-1953 topical gel- 0% (Vehicle) QD|VB-1953 topical gel- 0% (Vehicle) QD
16411207|NCT03900676|Placebo Comparator|VB-1953 Vehicle|VB-1953 topical gel- 0% (Vehicle) BID
16411208|NCT03900663||Breast fed infants|
16411209|NCT03900663||Formula fed infants|
16411210|NCT03900663||vaginally delivered infants|
16411211|NCT03900663||Infants delivered by caesarean section|
16411212|NCT03900650|Experimental|Alcoholic beverage|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%.
16411213|NCT03900650|Active Comparator|Non-alcoholic beverage|Participants will receive a beverage that does not contain alcohol (fruit juice only).
16411214|NCT03900650|Experimental|High provocation manipulation|Participants receive an experimental manipulation designed to evoke negative emotions such as frustration.
16411215|NCT03900650|Active Comparator|Low provocation manipulation|Participants receive an experimental manipulation that is designed to evoke neither positive or negative emotions.
16411216|NCT03900637|Experimental|Arm I|"MammaPrint high risk :
~Neoadjuvant chemotherapy : Adriamycin/Cyclophosphamide #4 followed by Docetaxel #4
~MammaPrint low risk :
~Premenopausal women : Letrozole 2.5mg PO QD + leuprorelin acetate 3.6mg SQ every 4weeks during 16 weeks (if needed, maximum for 24 weeks)
~Postmenopausal women : Letrozole 2.5mg PO QD during 16 weeks (if needed, maximum for 24 weeks)"
16411217|NCT03900624|No Intervention|Methylprednisolone Arm|Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
16411218|NCT03900624|Experimental|Dexamethasone Arm|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
16411219|NCT03900611|Experimental|Active stimulation|
16411220|NCT03900611|Sham Comparator|Sham stimulation|
16411222|NCT03900598|Experimental|Part 1 (Dose Escalation): JNJ-67856633|Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
16411223|NCT03900598|Experimental|Part 2 (Cohort Expansion): JNJ-67856633|Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
16411224|NCT03900585|Experimental|Interval walking|Interval walking for 10 weeks, 150 minutes per week administered by an app on the patient's telephone.
16411225|NCT03900585|No Intervention|Control|Patients live as normal, though aerobe training restricted to a maximum of 30 minutes a week.
16411226|NCT03900572|Experimental|HPV vaccine|Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
16411227|NCT03900572|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
16411228|NCT03900559|Experimental|"NO-FEAR Airlines program with still images"|"Intervention group that uses NO-FEAR Airlines program with still images to carry out the exposure."
16411229|NCT03900559|Experimental|"NO-FEAR Airlines program with still and navigable images"|"Intervention group that uses NO-FEAR Airlines program with still and navigable images to carry out the exposure."
16411230|NCT03900559|No Intervention|Waiting list control group|"Participants of this group are able to access NO-FEAR Airlines program after 6 weeks of waiting period.
~After that period, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (only still images or still + navigable images)."
16411231|NCT03900533|Experimental|Adjunctive group emotion regulation skills training|Participants will receive a 7 week group emotion regulation skills training together with parents adjacent to treatment as usual provided by the child- and adolescent psychiatric clinic
16411232|NCT03900533|Active Comparator|Treatment as usual (TAU)|Participants will receive treatment as usual for 7 weeks as provided by the child- and adolescent psychiatric clinic
16411233|NCT03900520||Pneumonia group (PREVAIL-Pneumo)|Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
16411234|NCT03900520||Community group (PREVAIL-Community)|Children aged 1-35 years living in the community with no known systemic illness
16411235|NCT03900520||Economic group (PREVAIL-Econ)|PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
16411236|NCT03900494|Active Comparator|Children treated with VHC 1|In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. We only compare the efficacy of the two VHC devices.
16411237|NCT03900494|Active Comparator|Children treated with VHC 2|In this group children are receiving salbutamol with valved holding chamber number 2. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria.
16411238|NCT03900481|Experimental|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive
16411239|NCT03900468|Experimental|Active Deep Brain Stimulation (DBS)|
16411240|NCT03900455|Experimental|Hydrocellular polyurethane foam multilayer dressing|
16411241|NCT03900455|Active Comparator|standard preventive care|
16411242|NCT03900442|Experimental|PTX-100|IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles
16411243|NCT03900429|Placebo Comparator|Matching Placebo|Placebo Daily
16411244|NCT03900429|Active Comparator|80 mg MGL-3196|80 mg daily
16411245|NCT03900429|Active Comparator|100 mg MGL-3196|100 mg daily
16411246|NCT03900416|Experimental|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
16411247|NCT03900416|No Intervention|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
16411248|NCT03900403|No Intervention|Habitual Intake|This will be the comparative arm, of 6 weeks before and after the study participant is on their habitual diet
16411249|NCT03900403|Experimental|Walnut Intake|Experimental Arm of 12 weeks of Walnut Intake, with study visits at baseline (prior to walnut intake) and after 6 and 12 weeks of 40g of Walnut Intake.
16411250|NCT03900390|Experimental|Cross Ischemic Preconditioning Group|the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions
16411251|NCT03900390|No Intervention|Control Group|The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.
16411252|NCT03900377|Experimental|Lg-B-NHL or MCL|For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.
16411253|NCT03900377|Experimental|DLBCL|For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.
16411254|NCT03900364|Other|robot-assisted partial nephrectomy|partial nephrectomy performed with the da Vinci Surgical System
16411255|NCT03900364|Other|laparoscopic partial nephrectomy|partial nephrectomy performed with conventional laparoscopic surgery
16411256|NCT03900351|Active Comparator|Group A: Study group|They will receive the Wii fit protocol of virtual reality games for 40 minutes, 3 times per week, for 8 weeks, in addition to the regular exercise rehabilitation protocol according to the criterion of Adams et al. (2012).
16411262|NCT03900312|Experimental|Intervention|The program consists of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices.
16411263|NCT03900299|Other|oncoplastic breast surgery|
16411264|NCT03900286|Experimental|Single Arm Study|Total Diet Replacement for 12 weeks, food reintroduction 6 weeks
16411265|NCT03900273|Experimental|Novel measures of cognition and everyday function|"No Practice Effects (NPE) cognitive battery
~Miami Computerized Functional Assessment Scale (CFAS)
~Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52."
16411266|NCT03900273|Active Comparator|Established measures of cognition and everyday function|"Preclinical Alzheimer's Cognitive Composite (PACC)
~Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
~Functional Assessment Questionnaire (FAQ).
~Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period.
~Assessments will take place at baseline, week 12, and week 52."
16411267|NCT03900260|Other|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
16411268|NCT03900234||Residents of the single rural settlement|No interventions will be administered
16411269|NCT03900221||Pregnant women with multiple sclerosis or related neurological|Children born to women with multiple sclerosis or related neurological syndromes.
16411270|NCT03900195|Experimental|Bottle PEP|Bottle PEP is a positive expiratory system that is applied via a tube of more than 5 mm of thickness and a bottle filled with water about 10 cms.
16411271|NCT03900195|No Intervention|Control|No interventions will be applied.
16411272|NCT03900182|Active Comparator|HBO treated group|Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment.
16411273|NCT03900182|Sham Comparator|crossover group|Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT
16411274|NCT03900169||Stemi patient|Stemi patient who underwent Ppci
16411275|NCT03900156|No Intervention|comparison group|The CG received no extra care.
16411276|NCT03900156|Experimental|Intervention Group|Intervention Group, goal-setting with follow-up, will have a structured goalsetting interview using the Bangor Goal-Setting Interview ; once goals are identified and clearly expressed in accordance with SMART principles (specific, measureable, achievable, realistic, and timed)
16411277|NCT03900143|Experimental|Treatment - Tightra|Treatment group with the Tightra device
16411278|NCT03900130|Experimental|Full group|"There is only one arm in this study. The group of 25 subjects all undergo a repeated measures 2 x 2 factorial design, fully crossed such that all subjects are tested under all four combinations of factors.
~The intervention Preload amounts to two factors, caloric load and protein to carbohydrate ratio of the preload, both of which can take on two levels high or low."
16411279|NCT03900117|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
16411280|NCT03900104|Experimental|Transcervical endometrial injection arm|Tracer injection performed by a transcervical catheter in endometrial cancer patients.
16411281|NCT03900104|Active Comparator|Cervical injection arm|Tracer injection was administered via the cervical route in endometrial cancer patients.
16411282|NCT03900091||Cases with clinical meningitis|Patients aged 0-12 years with suspected CNS infection, at the pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda.
16411283|NCT03900091||Control subjects|Patients aged 0-12 years, visiting the outpatient pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda, with fever clinically considered non-severe.
16411284|NCT03900078|Active Comparator|Control group|After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.
16411285|NCT03900078|Experimental|Incisional negative pressure group|After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.
16411286|NCT03900065|No Intervention|Control group|No preconditioning of the flap.
16411287|NCT03900065|Experimental|Preconditioned group|Preconditioning of the flap prior to surgery.
16411288|NCT03900052|No Intervention|Naïve|Conventional cane with no instruction given
16411289|NCT03900052|Active Comparator|Scale training|Conventional cane, scale training, and instruction on proper cane use
16411290|NCT03900052|Active Comparator|Scale recall|Conventional cane with no further instruction or practice given
16411291|NCT03900052|Experimental|Haptics training|Haptic biofeedback cane with explanation and training.
16411292|NCT03900052|Experimental|Haptics recall|Haptic biofeedback cane with no further instruction or practice given.
16411293|NCT03900039|Active Comparator|Conventional Polyethylene versus metal head|This is the more conventional group bearing surfaces
16411294|NCT03900039|Experimental|Conventional Polyethylene versus oxidized zirconium head|This group uses the more conventional polyethylene against the newer head
16411295|NCT03900039|Experimental|Newer Cross linked Polyethylene metal head|In this group we continued with the conventional polyethylene, but added in the new type of head (oxidized zirconium)
16411296|NCT03900039|Experimental|Newer Cross linked Polyethylene versus oxidized zirconium head|In this group, we added both the new head and the new polyethylene
16411297|NCT03900026|Placebo Comparator|Placebo Treatment|Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
16411298|NCT03900026|Experimental|Evolocumab Treatment|Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
16411299|NCT03900013|Experimental|Injectable Platelet Rich Fibrin (i-PRF) with DFDBA|"In i-PRF assigned group, 10 cc of blood per intraosseous defect will be collected right after administering the anaesthesia and will be processed according to the technique proposed by Choukroun et al., 2017 (centrifuged at 700 rpm, for 2-3 minutes). The yellow part will be collected using a syringe and added to a cup that contains the bone grafting material.
~The i-PRF consolidated bone graft will placed into the intraosseous defect."
16411300|NCT03900013|Active Comparator|Demineralized Freeze-Dried Bone Allograft (DFDBA) alone|After debridement and intraoperative recordings, in the control group, the bone graft material will be placed in the intraosseous defect without overfilling.
16411301|NCT03900000|Other|Short_Physiotherapy|one period of physiotherapy (8 weeks)
16411302|NCT03900000|Other|Long_Physiotherapy|two periods of physiotherapy (à 8 weeks)
16411303|NCT03899987|Experimental|Arm I (aspirin, interferon alpha, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24..
16411304|NCT03899987|Experimental|Arm II (aspirin, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7 and rintatolimod IV over 2 hours on days 1-3,and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.
16411305|NCT03899987|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy about 4 weeks after enrollment.
16411306|NCT03899974|Experimental|70% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 70% high-amylose flour)
16411307|NCT03899974|Experimental|85% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 85% high-amylose flour)
16411308|NCT03899974|Active Comparator|Control bread|Mixed meal with 80g of available carbohydrates coming mainly from conventional bread
16411309|NCT03899961|Active Comparator|Oxytocin|Oxytocin 2.5 U i.v.
16411310|NCT03899961|Experimental|Carbetocin|Carbetocin 100 µg i.v.
16411311|NCT03899948|Experimental|Teacher Anxiety Program for Elementary Students (TAPES)|Teachers in the experimental condition attend a 6-hour training on the TAPES program. The teachers learn to implement a brief intervention (5 meetings) with the student and his or her parent, utilize classroom anxiety-reduction strategies, and apply relationship enhancement strategies to improve the relationship with the target student and parents.
16411312|NCT03899948|Active Comparator|Teacher Anxiety Training (TAT)|Teachers in this condition receive training about childhood anxiety and classroom anxiety-reduction strategies using a 3-hour typical teacher professional development training format.
16411313|NCT03899935||Group A: obese patients|Obese patients undergoing laparoscopic surgery for endometriosis
16411314|NCT03899935||Group B: non-obese patients|Non-obese patients undergoing laparoscopy for endometriosis
16411315|NCT03899922||Uveitis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of uveitis of patient treated by a drug, with a chronology compatible with the drug toxicity
16411316|NCT03899909|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 6 dose levels in ascending order
16411317|NCT03899909|Placebo Comparator|Placebo SAD|Single doses of placebo
16411318|NCT03899909|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 4 dose levels in ascending order
16411319|NCT03899909|Placebo Comparator|Placebo MAD|Multiple doses of placebo
16411320|NCT03899883|Experimental|Pegloticase|Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)
16411321|NCT03899857|Experimental|Pembrolizumab|Temozolomide-based radiochemotherapy (TMZ/RT=>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=>TMZ.
16411322|NCT03899844||Cognitively normal|896 of the 1120 enrolled will not exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
16411323|NCT03899844||Cognitively impaired|224 of the 1120 enrolled will exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
16411324|NCT03899831|Experimental|Function-Based Elopement Treatment (FBET)|Participants in this group will receive Function-Based Elopement Treatment (FBET) for 16 weeks.
16411325|NCT03899831|Active Comparator|Parent Education Program (PEP)|Participants in this group will take part in a parent education program (PEP) for 16 weeks.
16411326|NCT03899818|Other|new generation DEB|drug-eluting balloon (DEB)
16411327|NCT03899818|Other|second generation DES|standard therapy with second generation drug-eluting stent (DES)
16411328|NCT03899805|Experimental|Liposarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8
~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
16411329|NCT03899805|Experimental|Leiomyosarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8
~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
16411330|NCT03899805|Experimental|Undifferentiated Pleomorphic sarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8
~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
16411331|NCT03899792|Experimental|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The MTD/recommended dose from Phase 1
16411332|NCT03899779|Active Comparator|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
16411333|NCT03899779|Experimental|Online hypnotherapy|12 weeks treatment with online hypnotherapy
16411335|NCT03899766||Animal Assisted Intervention|children interact and play with the expert of Animal Assisted Intervention (AAI) and his/her trained dog in the waiting room and then, are accompanied by a parent (as standard care) and the AAI in the venipuncture room during and immediately after the procedure
16411336|NCT03899766||Clowns|children interact and play with hospital clowns in the waiting room and then, are accompanied by a parent (as standard care) and the clown in the venipuncture room during and immediately after the procedure
16411337|NCT03899766||Musicians|children interact and play with a musician in the waiting room and then, are accompanied by a parent (as standard care) and the musician in the venipuncture room during and immediately after the procedure
16411338|NCT03899766||Non-clinical Conversation|children are accompanied by a parent in the waiting room and then in the venipuncture room during the procedure, thus receiving standard care
16411339|NCT03899753|Experimental|2-Octyl Cyanoacrylate and mesh|The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
16411340|NCT03899753|Active Comparator|2-Octyl Cyanoacrylate|The wound will be closed with just 2-Octyl Cyanoacrylate
16411341|NCT03899740||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.
~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
16411342|NCT03899727||Pregnant group|pregnant women in the third trimester of pregnancy
16411343|NCT03899727||Non-pregnant group|middle aged women
16411344|NCT03899714|Active Comparator|Ankle evertors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the ankle evertors, the ice bag will be applied to the lateral side of the ankle encompassing the lateral malleolus.The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
16411345|NCT03899714|Active Comparator|Hip adductors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the hip adductors, the ice bag will be applied to the medial side of the thigh, covering the entire area from the groin, to just above the knee joint. The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
16411346|NCT03899701|Experimental|PEC I and PEC II block|Ultrasound guided nerve block group.
16411347|NCT03899688|Experimental|test site|The space obtained underneath the sinus mucosa will be filled with the xenograft without protecting the antrostomy with a collagen membrane in the test sites.
16411348|NCT03899688|Other|control site|The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
16411349|NCT03899675|Experimental|Caffeine|Volunteers will ingest 300mg caffeine one hour before strength training.
16411350|NCT03899675|Placebo Comparator|Placebo|Volunteers will ingest 300mg placebo one hour before strength training.
16411351|NCT03899662|Experimental|Cognitive and Physical Training|24 sessions (8 weeks, 3 times per week) of computer based 45 minute cognitive and 45 minute physical training.
16411352|NCT03899649||IRE Cohort|Patients who received SOC and received IRE
16411353|NCT03899649||SOC Cohort|Patients who received SOC and did not receive IRE
16411354|NCT03899636|Experimental|IRE|
16411355|NCT03899636|Active Comparator|Control|
16411356|NCT03899610|Experimental|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:
~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)
~Interval debulking surgery
~Adjuvant treatment:
~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
16411357|NCT03899597|Experimental|artificial contractions (ARTCON) group|All participating patients in the intervention (ARTCON) group will undergo oxytocin exposure in the form of a continuous intravenous infusion according to dosage guidelines of The Czech Society of Obstetrics and Gynaecology. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed in order for the assumed effects of physiological stress associated with labor to occur.
16411358|NCT03899597|Placebo Comparator|standard approach (SA) group|All participating patients in the control (SA) group will undergo placebo exposure in the form of a continuous intravenous infusion. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed.
16411359|NCT03899584|Active Comparator|Treatment with 4-aminopyridine|The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
16411360|NCT03899584|Placebo Comparator|Placebo oral capsule|Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
16411361|NCT03899571|Active Comparator|5 days|oral oseltamivir 75 mg once daily for 5 days post-exposure
16411362|NCT03899571|Active Comparator|10 days|oral oseltamivir 75 mg once daily for 10 days post-exposure
16411363|NCT03899558|Experimental|Intervention|HNHF device (intervention) + usual care
16411364|NCT03899558|No Intervention|Control|Usual care alone
16411365|NCT03899545|Experimental|Serratus Plane Block|Serratus plane block will be applied after induction of general anesthesia.
16411366|NCT03899545|Active Comparator|Serratus Plane Block plus Pectoral I block|Serratus plane plus pectoral I block will be applied after induction of general anesthesia.
16412243|NCT03893760||Postcapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg and postcapillary wedge pressure (PCWP) >15 mmHg
16411367|NCT03899532|Experimental|Remote Ischemic Conditioning|"Remote ischemic conditioning will be performed using a standard manual blood pressure cuff. The pressure in the blood pressure cuff will be maintained at 30 mm of Hg higher than the patient's systolic blood pressure. 4 cycles of ischemic conditioning will be performed each day for a period of 7 days. Each cycle consists of 5 min of controlled upper limb ischemia (cuff up) followed by 5 min of reperfusion (cuff down). The total duration of the treatment cycle will be 40 min. The study protocol is based on our published literature in traumatic brain injury.
~Blood samples will be collected at 0 hours (before randomization). Then the first 4 cycles of RIC (done consecutively) will be performed, blood samples will be taken at 6 hours post randomization and then at 24 hours post randomization. RIC cycles will then be performed on a daily basis followed by taking a blood sample once daily during the patients' length of stay up to a maximum of 7 days"
16411368|NCT03899532|Placebo Comparator|No Remote Ischemic Conditioning|Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
16411369|NCT03899506||Olanzapine|Patients receiving 10 mg IM Olanzapine per the ED protocol
16411370|NCT03899506||Midazolam|Patients receiving 5 mg IM Midazolam per the ED protocol
16411371|NCT03899493||Primiparous & Multiparous|Women having borne at least one child > 20 weeks gestational age
16411372|NCT03899493||Nulliparous|Women in whom this is their first pregnancy > 20 weeks who are anticipated to deliver
16411373|NCT03899480|Experimental|Haploidentical Natural Killer Cells|Day -7 the subject will undergo inguinal lymph node biopsy & colonoscopy to obtain ileal & rectal biopsies. Blood samples will be obtained. PBMCs will be obtained to sort into CD4 subsets & measure frequencies of HIV RNA & DNA. On Day -1, the donor will undergo apheresis & donor cells will be obtained & incubated overnight. On Day 0 subjects will be infused with N-803 activated NK cells. Subjects will receive 1st dose of N-803 4 hrs after the infusion. Plasma will be obtained at 2, 4 & 12 hrs after. Subjects will return on Days 2, 4, 7, 10, & 14 for blood draw. Subjects will return Days 21 & 42 for blood work & to receive 2 additional doses of N-803, for a total of 3 doses. Subjects will be monitored for toxicity assessment by targeted physical exam & laboratory evaluations on Days 2, 4, 7, 10, 21, & 42. On day 49, we will perform lymph node biopsy & colonoscopy to obtain ileal & rectal tissues. The patient will then be followed until day 100 post infusion.
16411374|NCT03899467|Experimental|Arm 1: biological dose group|"400mg/day of proxalutamide
~Group 1: Post enzalutamide failure
~Group 2: Post abiraterone failure"
16411375|NCT03899467|Experimental|Arm 2: MTD dose group|"500mg/day of proxalutamide
~Group 1: Post enzalutamide failure
~Group 2: Post abiraterone failure"
16411376|NCT03899454|Experimental|Extract administration|administration of a mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
16411377|NCT03899454|Placebo Comparator|Control|Placebo
16411378|NCT03899441|No Intervention|Control|Patients in the control arm will have pre-operative teaching from their physician and sign consent for surgery, as is the current standard of care at the investigators' institution.
16411379|NCT03899441|Experimental|Video arm|Patients in the intervention arm will watch two short animated video about minimally-invasive endometrial cancer surgery followed by focused pre-operative teaching from their physician. They will then sign consent for surgery.
16411380|NCT03899428|Experimental|Immune Checkpoint Therapy|The subjects will receive durvalumab 1500 mg Q4W
16411381|NCT03899428|Experimental|Target Therapy|The subjects will receive tyrosine kinase inhibitors, including sorafenib, lenvatinib, regorafenib, or cabozantinib, daily
16411382|NCT03899415|Experimental|TCR-Redirected T Cells|HBV antigen specific TCR redirected T cells
16411383|NCT03899402|Active Comparator|Control|Standard of care insulin will be used as an active comparator arm for 1/3 of patients (38 patients) for the entire duration of the study.
16411384|NCT03899402|Experimental|Dual Therapy|Once a week injection of Semaglutide (a GLP-1 receptor agonist) in addition to standard of care insulin for the first six months in 2/3 of patients (76 patients). Semaglutide is a clear, colorless solution that contains 2 mg of semaglutide in a 1.5 mL (1.34 mg/mL) pre-filled, disposable, single-patient-use pen injector. Semaglutide will be started at the 0.25 mg dose for the first two weeks, then increased to 0.5 mg at week 2, and then yet again increased to 1.0 mg at week 4.
16411385|NCT03899402|Experimental|Triple therapy|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of Dapagliflozin (an SGLT-2 inhibitor) added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)). Dapagliflozin will be started at 5 mg for one week, and then increased to 10 mg for the remainder of the study
16411386|NCT03899402|Placebo Comparator|Triple therapy control|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of the Placebo form of Dapagliflozin added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)).
16411387|NCT03899389||Acute Coronary Syndrome (ACS)|Patients with STEMI or NSTEMI infarction, who were admitted to the hospital with chest pain.
16411388|NCT03899389||Stable Angina (SA)|Patients with stable angina who were scheduled for conventional coronary angiography.
16411389|NCT03899389||Control Group (CON)|Healthy control group responding by age and gender to examined groups.
16411390|NCT03899376|Active Comparator|Conventional radiotherapy|patients with gynecological cancer treated with adjuvant conventional radiotherapy
16411391|NCT03899376|Experimental|Volumetric modulated arc therapy|Patients with gynecological cancer treated with adjuvant VMAT radiotherapy
16411392|NCT03899363|Experimental|surgery|
16411393|NCT03899363|Active Comparator|custom thermoplastic orthosis|
16411394|NCT03899337|Active Comparator|Standard of Care Arm (CHOP-R)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:
~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5"
16411457|NCT03899038|Experimental|Deceasing|Spinal anesthesia with decreasing dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
16411395|NCT03899337|Experimental|Experimental Arm (CHOP-R + Acalabrutinib)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:
~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5
~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
16411396|NCT03899337|Experimental|Cohort 1 - Acalabrutinib Monotherapy - Platform Trial|Registration arm in platform study. Patients registered to Cohort 1 will receive 100 mg acalabrutinib monotherapy, twice daily, continuously from day 1 until disease progression, toxicity, patient choice or death.
16411397|NCT03899337|Experimental|Cohort 2 - CHOP-R + Acalabrutinib - Platform Trial|"Registration arm in platform study. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:
~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5
~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
16411398|NCT03899324|Experimental|Group 1: Experimental Bumetanide|bumetanide with a titration period
16411399|NCT03899324|Placebo Comparator|Group 2: Placebo comparator|placebo intake identically to group 1
16411400|NCT03899311||PSMF cohort|The cohort is instructed to follow a protein-sparing modified fast diet and is given standard health care in the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital.
16411401|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Autoimmune Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411402|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Orthopedic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411403|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Neurologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411404|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Urologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411405|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Cardiac Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411406|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Renal Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411407|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Pulmonary Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
16411408|NCT03899285|Experimental|Citalopram increase (group A)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of citalopram 20 mg for a length of 14 days. The total dose of citalopram will be 40 mg once daily.
~Follow up will last 8 weeks in total."
16411409|NCT03899285|Placebo Comparator|Placebo (group B)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of placebo (a capsule without medication) for a length of 14 days. The total dose of citalopram will be 20 mg once daily.
~Follow up will last 8 weeks in total."
16411410|NCT03899285|No Intervention|Observational arm (group c)|"Eligible patients to this arm are responders to citalopram. A diminution of at least 30% of the symptoms from baseline with the MADRS is required to enter this arm. At the end of the first phase, these patients will pursue their citalopram 20 mg for the rest of the study (=6 weeks). It's possible that in this group, the treatment approach may vary depending the physician.
~Follow up will last 8 weeks in total."
16411411|NCT03899272||Osteoarthritis|All new patient present to clinic referred for osteoarthritis for considering joint replacement Present with knee pain (unilateral or bilateral) contributed by osteoarthritis
16411412|NCT03899259|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16411413|NCT03899259|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16411414|NCT03899259|Placebo Comparator|Placebo|Placebo administered orally.
16411415|NCT03899246|Experimental|Capsaicin Arm|Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
16411416|NCT03899233|Active Comparator|Fractional CO2 laser combined with Tranexamic acid|one side of the face of all participants will be subjected to low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond for 3 sessions every 6 weeks. In addition to Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, on the 2nd and the 4th week of each laser session. With total treatment time for each patient of 4 months and another month free of sessions for followup.
16411417|NCT03899233|Active Comparator|Tranexamic acid alone|the other side of the face of all participants will be subjected Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, every 2 weeks for 4 months then another month free of sessions for followup.
16411418|NCT03899220|Experimental|Intervention|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence.
16411419|NCT03899220|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Enhanced treatment as usual includes a one session behavioral engagement in care intervention as well as substance use treatment counseling.
16411420|NCT03899207|Experimental|training +acupressure|In the training+acupressure group, 10 women were excluded from the study since they could not participate in acupressure application at different times, 2 women were excluded since they had menstrual irregularities and 4 women were excluded since they could not be contacted.
16411421|NCT03899207|Experimental|training|In the training group, 4 women were excluded since they did not participate in the reminder training, 1 woman was excluded since she had menstrual irregularities, 3 women were excluded since they wanted to withdraw from the study and 3 women were excluded from the study since they could not be contacted.
16411422|NCT03899207|No Intervention|control|In the control group, 4 women were excluded from the study since they could not be reached and 5 women were excluded since they did not agree to participate in the posttest.
16411423|NCT03899194|Active Comparator|escitalopram|Patients will only be treated with escitalopram from the minimum dosage.
16411424|NCT03899194|Experimental|escitalopram+ fish oil capsules|Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.
16411425|NCT03899181|Active Comparator|1 Hz 2400 TNT Treatment|Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..
16411426|NCT03899181|Active Comparator|1 Hz 3600 TNT Treatment|Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.
16411427|NCT03899181|Sham Comparator|Sham TNT Treatment|This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar & 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.
16411428|NCT03899168|Experimental|Social Tag Popularity|Popularity of Social Tags (antidepressants more popular vs. psychotherapy more popular)
16411429|NCT03899168|Experimental|Confidence in Prior Attitudes|Confidence in prior attitudes (high vs. low: recalling situations in which participants were confident or uncertain about their thoughts)
16411430|NCT03899168|Experimental|Source Credibility|Credibility of the source (tagging community: experts - many years of professional experience vs. novices - students in the first semester)
16411431|NCT03899155|Experimental|Nivolumab Dose 1|Specified Dose on Specified Days
16411432|NCT03899155|Experimental|Nivolumab Dose 2|Specified Dose on Specified Days
16411433|NCT03899142|Experimental|human hepatitis B immunoglobulin|once, i.m.
16411434|NCT03899129|Experimental|simultaneous working length control|• Using simultaneous working length control during root canal preparation using E-CONNECT S endomotor with integrated apex locator.
16411435|NCT03899129|Active Comparator|Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
16411436|NCT03899116||G50|The tourniquet cuff pressure will be deflated gradually by 50 mm Hg every 2 minutes till complete deflation.
16411437|NCT03899116||G100|The tourniquet cuff pressure will be deflated gradually by 100 mm Hg every 2 minutes till complete deflation.
16411438|NCT03899116||G0|The tourniquet cuff will be released till complete deflation.
16411439|NCT03899103|Experimental|Repeated Courses of Rituximab Only|First course Course Rituximab at Randomization. Prophylactic 2nd and 3rd course rituximab re-administration will be done at 8 months and 16 months of follow-up if B cell count normalize.
16411440|NCT03899103|Active Comparator|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
16411441|NCT03899090|Experimental|Float Pool|Floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
16411442|NCT03899090|Active Comparator|Float Chair|Floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
16411443|NCT03899090|Experimental|Float Pool Preferred|Floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)
16411444|NCT03899077|Active Comparator|Arm A|The standard hormonal treatment in combination with salvage radiotherapy is ADT by a LHRH agonist or antagonist for 24 weeks. LHRH agonists and antagonists include leuprolide, goserelin, triptorelin, and degarelix.
16411445|NCT03899077|Experimental|Arm B|Patients will receive 6 cycles (each cycle is 30 days) of the study drug (4x 60mg tablets daily in a single intake).
16411446|NCT03899064|Experimental|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
16411447|NCT03899064|Experimental|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
16411448|NCT03899064|Experimental|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
16411449|NCT03899064|Experimental|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
16411450|NCT03899064|Experimental|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
16411451|NCT03899064|Experimental|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
16411452|NCT03899064|Experimental|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
16411453|NCT03899064|Experimental|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
16411454|NCT03899064|Experimental|Challenge: Control, irradiation|No application, but irradiation
16411455|NCT03899051|Experimental|Test group|Papilla reconstruction would be done with platelet rich fibrin
16411456|NCT03899051|Active Comparator|Control group|Papilla reconstruction would be done with subepithelial connective tissue graft
16460996|NCT03559504||Group 6|Elderly:65-80 years old
16411458|NCT03899038|Active Comparator|Similar|Spinal anesthesia with similar dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
16411459|NCT03899025|Other|Suspected scaphoid fracture|Patients with a suspected scaphoid fracture
16411460|NCT03898999||Older adult|Individuals belonging to the population group of the elderly (60 years or more)
16411461|NCT03898986|Experimental|MZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16411462|NCT03898986|Experimental|DZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16411463|NCT03898973|Other|Study Phase|Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
16411464|NCT03898960||Mechanical Thrombectomy|NIMBUS Device
16411465|NCT03898947||Tamoxifen users|Women undergoing therapy with Tamoxifen after surgery for breast cancer.
16411466|NCT03898947||Aromatase inhibitors|Women undergoing therapy with Aromatase Inhibitors after surgery for breast cancer.
16411467|NCT03898947||No treatment|Women who did not undergo any hormonal therapy after surgery for breast cancer.
16411468|NCT03898934|Experimental|Vitamin D group|These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study
16411469|NCT03898934|Placebo Comparator|Placebo group|These group will receive placebo for the same periods of study group
16411470|NCT03898921|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
16411471|NCT03898921|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
16411472|NCT03898908|Experimental|COMBO450|"Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets
~In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death."
16411473|NCT03898895|Experimental|Radiotherapy+anti-PD-1|The total radiation dose is over 40Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
16411474|NCT03898895|Active Comparator|Gemcitabine+cisplatin|Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
16411475|NCT03898882||BMI 20 - 29.9 kg/m2|
16411476|NCT03898882||BMI > 30 kg/m2|
16411477|NCT03898856|Experimental|Crofelemer and Diagnostic tests for cause of chronic diarrhea|125 mg tablets taken by mouth twice daily for 28 days
16411478|NCT03898843|Experimental|Animal assisted therapy group|Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
16411479|NCT03898843|Active Comparator|Control Group|"Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires"
16411480|NCT03898830|Experimental|eon™ FR 1064 nm device|Patient will be treated with the eon™ FR 1064 nm device
16411481|NCT03898817||Taking of cutaneous cells by biopsy|Taking of cutaneous cells by biopsy and a sample of blood
16411482|NCT03898804|Experimental|BCI and FES|Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
16411483|NCT03898791|Experimental|LY3295668 Erbumine Cohort A|LY3295668 erbumine administered orally.
16411484|NCT03898791|Experimental|LY3295668 Erbumine Cohort B|LY3295668 erbumine administered orally.
16411485|NCT03898791|Experimental|LY3295668 Part JP|LY3295668 erbumine administered orally.
16411486|NCT03898765|Experimental|Experimental：Dry blood spot screening|
16411487|NCT03898752|Experimental|Lifestyle intervention|Diet, omega-3 fish oil (1g daily), CoQ10 (100 mg/day) and a normal Multi-vitamin, Smoking cessation, weight loss, exercise,
16411488|NCT03898739|Active Comparator|traction therapy from neutral position|Patients in this group will receive traction decompression from neutral neck position with rope angle (0°)
16411489|NCT03898739|Active Comparator|traction therapy from lateral bending|patients will undergo traction decompression from (30°) lateral bending of the neck toward the non-affected side
16411490|NCT03898739|Active Comparator|traction from flexion with lateral bending and rotation|patients will be treated with traction decompression from (15°) neck flexion, (30°) lateral bending toward non- affected side and (15°) rotation to the affected side.
16411491|NCT03898726|Active Comparator|laparoscopical l cuff closure|needle holder laparoscopic vaginal cuff closure
16411492|NCT03898726|Active Comparator|transvaginal cuff closure|transvaginal cuff closure
16411493|NCT03898700|Active Comparator|coaching face to face|10, 1 hour sessions of face to face strength based coaching sessions
16411494|NCT03898700|Active Comparator|phone coaching|10, 1 hour sessions of strength based coaching via phone.
16411495|NCT03898687|Other|MAGMEN arm|Patients with melanoma of the extremities included in the protocol. SLNB will be performed with the addition of magtrace (SPIO) injection, 0.2 ml around previous scar. The patients will undergo MRI of the involved basin (Axilla-groin)and receive the SpIO injection the day before SLN biopsy. A separate SPIO MRI will be performed before the operation. All patients will receive all 3 methods for SLN identification as described in the protocol.
16411496|NCT03898674|Experimental|GDT feasibility|Patients undergoing microcirculatory goal directed therapy
16411497|NCT03898661|Experimental|local collagenase|Patients receiving local injection of collagenase into the esophageals stricture
16411498|NCT03898648|Experimental|Depressed patients with history of suicide attempt|Depressed patients with a lifetime history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
16411499|NCT03898648|Experimental|Depressed patients without any history of suicide attempt|Depressed patients without history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
16411500|NCT03898635||Background group|The treatment regimen does not include linezolid throughout the treatment course.
16411501|NCT03898635||Background-linezolid group|Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.
16411502|NCT03898635||Linezolid initial group|Linezolid was in initial treatment regimen.
16411503|NCT03898622|Active Comparator|Group with levothyroxine|Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5u / L ) to complete three months of intervention.
16411504|NCT03898622|Placebo Comparator|Group Placebo|"atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria.
~Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5 / month) to complete three months of intervention."
16411505|NCT03898609|Experimental|Low-fat diet|20% fat 20% protein 60% carbohydrate
16411506|NCT03898609|Experimental|Low-carbohydrate diet|45% fat 20% protein 35% carbohydrate
16411507|NCT03898596|Other|ECG Monitoring|ECG readings will be collected for neonatal patients who require or currently have UVC
16411508|NCT03898583|Experimental|Microarray patch A|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
16411509|NCT03898583|Experimental|Microarray patch B|21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
16411510|NCT03898583|Placebo Comparator|Vehicle|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
16411511|NCT03898583|Active Comparator|Daivobet|21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
16411512|NCT03898570||Patients undergoing vascular surgery procedures|Patients will report outcomes via their smartphone.
16411513|NCT03898557|Experimental|Usual Care|"Participants randomized to this arm will receive a card with information to report results via WhatsApp, similar to the existing card used in the STAR program. This card will have a dedicated Usual Care WhatsApp number (different from the existing STAR program numbers).
~Potential self-test recipients will be shown the WhatsApp card and instructed on how to anonymously report use of self-test to the WhatsApp number. Recipients will be instructed to message the WhatsApp number for the following reasons:
~1. So study staff know the self-test recipients used the test and it went ok. 2. So study staff can help the self-test recipients understand the results of the test. 3. If the self-test recipients need support from study staff to access care and services."
16411514|NCT03898557|Experimental|Plan and Pledge|"Participants randomized to this arm will revive the Usual Care WhatsApp card and and a brief template to make a plan and make a pledge for test completion and results reporting, to take the HIV self-test. The card will include a dedicated Plan and Pledge WhatsApp number.
~Potential self-tester recipients will be shown the WhatsApp card, including Plan and Pledge statements, and will be encouraged by STAR field staff to use the card in their own time to make a plan and sign the pledge as part of receiving the test kit and instructions for how to complete the card. Importantly, testers will be able to keep the card for themselves. There is no expectation to share the plan or the pledge signature with the STAR field staff who distribute self-tests. Field staff will clarify for self-tests recipients that the Plan and Pledge process and card do not change the confidentiality of testing in any way."
16411515|NCT03898544||Group primary TKA|Patients operated of primary TKA Stryker for knee osteoarthritis.
16411516|NCT03898544||Group TKA revision|Patients operated of a first revision of TKA for a mechanical failure, with the revision Stryker TKA
16411517|NCT03898531||hip prosthesis metal/polyethylene in simple mobility|
16411518|NCT03898531||hip prosthesis metal/polyethylene in double mobility|
16411519|NCT03898531||hip prosthesis ceramic/polyethylene in simple mobility|
16411520|NCT03898531||hip prosthesis ceramic/polyethylene in double mobility|
16411521|NCT03898531||Primary implanted hip prosthesis|
16411522|NCT03898531||metal / metal prosthesis removed|
16411523|NCT03898531||ceramic / ceramic prosthesis removed|
16411524|NCT03898518|No Intervention|Control Group|The control group was in the facility for all jump rope exercise sessions but did not participate in the exercise intervention.
16411525|NCT03898518|Experimental|Experimental Group|The experimental group performed the jump rope exercise intervention.
16411526|NCT03898505|Placebo Comparator|Placebo|Placebo powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour. Participants in the placebo group will ingest 1 scoop of the placebo material per day (30-35g). Placebo powder is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Placebo will be consumed once per day for 60 days.
16411527|NCT03898505|Experimental|Low Dose|All Participants randomized to the low dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 50 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the low dose group will ingest 1 scoop of this test product per day (30-35g). Low dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Low dose test product will be consumed once per day for 60 days.
16411528|NCT03898505|Experimental|High Dose|All Participants randomized to the high dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 200 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the high dose group will ingest 1 scoop of this test product per day (30-35g). High dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. High dose test product will be consumed once per day for 60 days.
16411529|NCT03898492|Other|Intervention|The participants in this group participated in exercise two times/week for 8 weeks
16411530|NCT03898492|No Intervention|Control|The participants in the control group were instructed to maintain their daily routines.
16411532|NCT03898466|Experimental|Fluticasone Furoate|"Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.
~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
16411533|NCT03898466|Placebo Comparator|Matching Placebo|"Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.
~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
16411534|NCT03898453|Experimental|Group EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
16411535|NCT03898453|Other|Group Control : support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.
~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
16411536|NCT03898427||Individuals with atopic dermatitis|Sensor technology and digital measures will be used to evaluate scratch and sleep in individuals with atopic dermatitis receiving standard of care treatments (SOC) who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
16411537|NCT03898401|Experimental|1 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411538|NCT03898401|Experimental|2 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411539|NCT03898401|Experimental|3 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411540|NCT03898401|Experimental|4 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411541|NCT03898401|Experimental|5 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411584|NCT03898258||neurogenic bladder|individuals with chronic (≥12 months) neurogenic lower urinary tract dysfunction due to spinal cord injury (SCI)
16411585|NCT03898245|Active Comparator|active tDCS|intervention : Intensity 2mA, 30minues, 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS
16411542|NCT03898401|Experimental|6 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411543|NCT03898401|Experimental|7 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411544|NCT03898401|Experimental|8 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411545|NCT03898401|Experimental|9 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411546|NCT03898401|Experimental|10 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411547|NCT03898401|Experimental|11 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411548|NCT03898401|Experimental|12 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411549|NCT03898401|Experimental|13 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411550|NCT03898401|Experimental|14 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411551|NCT03898401|Experimental|15 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411552|NCT03898401|Experimental|16 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411553|NCT03898401|Experimental|17 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411554|NCT03898401|Experimental|18 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411555|NCT03898401|Experimental|19 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411556|NCT03898401|Experimental|20 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411557|NCT03898401|Experimental|21 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411586|NCT03898245|Sham Comparator|sham tDCS|Intensity 2mA, 8 seconds (but looks same as an intervention 30mins), 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS (sham mode)
16411558|NCT03898401|Experimental|22 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411559|NCT03898401|Experimental|23 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411560|NCT03898401|Experimental|24 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411561|NCT03898401|Experimental|25 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411562|NCT03898401|Experimental|26 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411563|NCT03898401|Experimental|27PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411564|NCT03898401|Experimental|28 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411565|NCT03898401|Experimental|29 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411566|NCT03898401|Experimental|30 PRp|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
16411567|NCT03898388|Experimental|Knee Synovial Fluid collection before Regenexx-SD|Measure components of knee synovial fluid 2-4 days before the Regenexx-SD treatment.
16411568|NCT03898375|Experimental|VR-enhanced treadmill walking|Participants will be tested during 4 sessions of 20 minutes treadmill walking.
16411569|NCT03898362|Active Comparator|pneumatically powered wheelchair or scooter|participants will use pneumatic powered wheelchair or scooter
16411570|NCT03898362|Active Comparator|battery powered wheelchair or scooter|participants will use battery powered wheelchair or scooter
16411571|NCT03898349|No Intervention|Non-Texters|"Patients did not receive the automated text messaging system Annie"
16411572|NCT03898349|Active Comparator|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
16411573|NCT03898336|Experimental|broad-spectrum micronutrients|broad-spectrum micronutrients description: capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
16411574|NCT03898336|Placebo Comparator|placebo|capsules containing placebo
16411575|NCT03898323|Experimental|AABM Training|Alcohol Approach Bias Modification (AABM) training is a computer training program that participants interact with by pushing and pulling a joystick. Participants are asked to respond to the format of a presented picture, irrespective of the pictures' content. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. AABM training consists of 3 sessions per week over 2 weeks, for a total of 6 sessions.
16411576|NCT03898310|Experimental|Cranberry Extract Capsules|36mg of proanthocyanidins in cranberry capsules
16411577|NCT03898310|Placebo Comparator|Placebo Capsules|
16411578|NCT03898297||Healthy control|30 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
16411579|NCT03898297||MDD|30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
16411580|NCT03898297||Bipolar|30 subjects with bipolar disorder may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
16411581|NCT03898284||Impulse Oscillometry|Patients with Idiopathic Pulmonary Fibrosis. The objective is to determine whether another lung function technique, impulse oscillometry, is of interest to identify disease progression before changes in forced vital capacity can be ascertained.
16411582|NCT03898271|Experimental|Virtual World Training|Synchronous PTSD training in a virtual world environment
16411583|NCT03898271|Active Comparator|Web-based Video Training|Asynchronous web-based PTSD training
16411587|NCT03898206|Experimental|Prolonged sitting|Participants will remain seated for 5 h and instructed to reduce excessive movement, only rising from the chair to void.
16411588|NCT03898206|Experimental|Breaking up sitting with walking breaks|Participants will rise from the seated position every 30 min throughout the experimental period to walk on a motorised treadmill at a light intensity walking (as determined during the preliminary test) for 3 min. Participants will start walk on a treadmill at 30 min (so physical activity would be at 30-33 min), 60 min (physical activity will be at 60-63 min), 90 min (physical activity will be at 90-93 min), 120 min (physical activity will be 120-123 min), 150 min (physical activity will be at 150-153 min ), and 180 min (physical activity will be at 180-183 min) in the breakfast postprandial period and 30 min (physical activity will be 30-33 min), 60 min (physical activity will be at 60-63 min), and 90 min (physical activity will be at 90-93 min) in the lunch postprandial period. After performing walking activity, they will return to the seated position.
16411589|NCT03898193|Other|Sequence Test-Reference (TR)|17 participants (total number of enrolled volunteers - 34) assigned to sequence TR will receive a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 1 and a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16411590|NCT03898193|Other|Sequence Reference-Test (RT)|17 participants (total number of enrolled volunteers - 34) assigned to sequence RT will receive a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 1 and a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16411593|NCT03898167|Active Comparator|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System.
16411594|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a pre-paid return envelope.
16411595|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
16411598|NCT03898141|Experimental|Animal-assisted placebo condition (AAPL)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream.
~Additionally, they will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high de-gree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Therefore, the distance between participant and dog will always be the same. However, partici-pants will still be able to see the dog."
16411599|NCT03898141|Placebo Comparator|Placebo only (PO)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
16411600|NCT03898141|Experimental|Dog only (DO)|"Participants will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. During the experiment the dog will be lying in the room with some distance to avoid further physical interaction.
~After the introduction of the dog, participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements"
16411601|NCT03898141|No Intervention|No dog, no placebo (ND)|Participants will participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements.
16411602|NCT03898115|Experimental|CHG Bathing Implementation|In a step-wedged design, ICUs and BMT units will be enrolled into a educational program to improve knowledge/compliance with daily CHG bathing
16411603|NCT03898115|No Intervention|Control|In a step-wedged design, ICUs and BMT units will be enrolled over a rolling 4 month time frame; when not enrolled, this data will serve as control data
16411604|NCT03898102|Experimental|Regorafenib treatment with Zn supplement|Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
16411605|NCT03898102|Active Comparator|Regorafenib treatment only|Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.
16411606|NCT03898089|Other|Core Exercise Group|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks.
16411607|NCT03898089|Experimental|Core Exercise plus Myofascial Relaxation Group|In addition to the core stabilization exercises myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks.
16411608|NCT03898063|Active Comparator|Control|participants will receive a standard-of-care brochure detailing HIV status disclosure.
16411609|NCT03898063|Experimental|intervention: 90 DAYS film|participants will watch the film, 90 DAYS
16411610|NCT03898050|Experimental|A-P|Anterior - Posterior pad placement
16411611|NCT03898050|Experimental|A-L|Anterior - Lateral pad placement
16411612|NCT03898037|Experimental|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.
~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
16411613|NCT03898037|Experimental|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.
~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
16411614|NCT03898037|Experimental|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.
~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
16411615|NCT03898037|No Intervention|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
16411616|NCT03898024|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
16411617|NCT03898024|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
16411618|NCT03898024|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
16411619|NCT03898024|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
16411620|NCT03898024|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
16411621|NCT03898011|Other|Sequence Test-Reference (TR)|14 participants (total number of enrolled volunteers - 28) assigned to sequence TR will receive a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 1 and a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16411622|NCT03898011|Other|Sequence Reference-Test (RT)|14 participants (total number of enrolled volunteers - 28) assigned to sequence RT will receive a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 1 and a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16411623|NCT03897998|Active Comparator|Naloxone|NARCAN® Naloxone Nasal Spray will be used to block placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
16411624|NCT03897998|Sham Comparator|Saline|Saline will be used as a sham comparator for blocking placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
16411625|NCT03897972|Active Comparator|Non-personalised general diet advice|Control group to receive non-personalised dietary advice based on general public health dietary recommendations for Northern Europe. Advice will be delivered to the participant via the eNutri web application.
16411626|NCT03897972|Experimental|Personalised diet advice|Intervention group to receive personalised dietary advice generated by the eNutri app from their actual dietary intakes and tailored according to their body mass index and food preferences. Advice will be delivered to the participant via the eNutri app web application and will be generated based on their adherence to an 11-item diet quality score suitable for Northern European populations.
16411627|NCT03897959|Other|Kohli vs Foley Study|Compare various performance characteristics of two urinary catheters.
16411628|NCT03897946|Experimental|Group A: Hepatitis B exposed, with birth dose|"The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study."
16411629|NCT03897946|No Intervention|Group B: Hepatitis B unexposed, no birth dose|"For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B)."
16411630|NCT03897946|Experimental|Group C: Hepatitis B unexposed, with birth dose|"Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule."
16411631|NCT03897933||Erector spinae plane block group (ESP)|Single- shot ultrasound guided ESP block with 30 ml 0.25% bupivacain at the T10 vertebral level will performed preoperatively to patients in the ESP group (Group I).
16411632|NCT03897933||non- blocked Group|consists of the patient group without any procedure
16411633|NCT03897907|Experimental|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
16411634|NCT03897907|Placebo Comparator|Control Education|This arm will provide education of basic knee anatomy and will not address maladaptive psychological behaviors.
16411635|NCT03897894|Experimental|Enhanced Service Package|"The enhanced service package provides 40 sequential sessions selected by CFS program staff in advance and implemented over a twelve-week period. Activities are meant to build upon and reinforce one another and are organized into seven psychosocial themes: 1) Building community: Our space together, 2) Emotional learning: My feelings, 3) Wellbeing and coping: Feeling good, 4) Social support: My friends and family, 5) Relating to others: Being a good friend, 6) Protection and boundaries: My safety, and 7) Building on strengths: All my supports. Each session takes approximately 1.5 - 2 hours to facilitate and will conclude with 1-1.5 hours unstructured free play time."
16411636|NCT03897894|Experimental|Basic Service Package|The basic service package offers a mixture of recreational and non-formal education activities over a twelve-week period. Each session lasts around 1.5 - 3 hours. Structured activities offered include basic literacy and numeracy lessons, life skills exercises, health and hygiene sessions, and traditional song and dance. Many activities are centered around various forms of play that enable expression and age-appropriate skill development. Unstructured free play and playground time is allocated throughout the daily session.
16411637|NCT03897894|No Intervention|Control|Waitlist control will receive delayed treatment of intervention after the primary assessment period.
16411638|NCT03897881|Experimental|mRNA-4157 and Pembrolizumab|Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
16411639|NCT03897881|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
16411640|NCT03897868|Experimental|Experimental 1|HCP1803 High
16411641|NCT03897868|Experimental|Experimental 2|HCP1803 Middle
16411642|NCT03897868|Experimental|Experimental 3|HCP1803 Low
16411643|NCT03897868|Active Comparator|Active Comparator 1|HGP0904 High
16411644|NCT03897868|Active Comparator|Active Comparator 2|HGP0904 Low
16411645|NCT03897868|Active Comparator|Active Comparator 3|HGP0608
16411646|NCT03897868|Placebo Comparator|Placebo Comparator|Placebo
16411647|NCT03897855|Other|Patient (TSPT-R)|Post Traumatic Stress Disorder
16411648|NCT03897855|Experimental|control|No Post Traumatic Stress Disorder
16411649|NCT03897842|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
16411650|NCT03897816||"PERINATAL"|Pregnant women consecutively referred and admitted to the Perinatal Psychiatric Outpatient Department
16411651|NCT03897816||"OUTPTS"|Pregnant women belonging to the Outpatients Psychiatric Department who did not have psychiatric issues linked to their pregnancy or in the relationship with their children
16411652|NCT03897816||Healthy controls|Pregnant women the general population, with no history of mental health issues
16411653|NCT03897803||Group (I):juvenile dermatomyositis (JDM)|"Group (I): twenty children diagnosed to have juvenile dermatomyositis (JDM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.
~."
16411654|NCT03897803||Group (II):idiopathic inflammatory myopathies(IIM)|"Group (II): twenty adults diagnosed to have idiopathic inflammatory myopathies(IIM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.
~•"
16411655|NCT03897803||Group (III): juvenile control group|"20 healthy children matching age and sex as first control group to children with JDM .Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
~."
16411656|NCT03897803||Group (VI):adult control group|20 healthy adults matching age and sex as second control group to adults with IIM. Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
16411657|NCT03897790||Patients under vasoconstrictor|Patients older than 65 years old and hypertensive, requiring vasoconstrictor (phenylephrine or Neosynephrine) during general anesthesia.
16411710|NCT03897335|Placebo Comparator|Placebo|
16411711|NCT03897309|Experimental|Monovalent GI.1|Monovalent GI.1 tableted vaccine group
16411658|NCT03897777|Experimental|Hypertension (Exercise Intervention)|Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
16411659|NCT03897764|Experimental|Superior Hypogastric Block group|The group which superior hypogastric block performed intraoperatively
16411660|NCT03897764|Placebo Comparator|placebo controlled group|The group which placebo used
16411661|NCT03897738|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
16411662|NCT03897738|Placebo Comparator|Placebo|"Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
~Placebo capsules are identical to Amberen and Smart B capsules."
16411663|NCT03897725|Experimental|Telehealth Intervention|Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.
16411664|NCT03897725|No Intervention|Routine Care|The control group will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP.
16411665|NCT03897699|Experimental|active tDCS + Mindful Breathing Training|20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training
16411666|NCT03897699|Sham Comparator|sham tDCS + Mindful Breathing Training|The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session
16411667|NCT03897686|Experimental|NOLTREX™, II-III grade OA|72 patients with II-III grade of gonarthrosis will randomised to receive PAHG
16411668|NCT03897686|Placebo Comparator|Placebo, II-III grade ОА|72 patients with II-III grade of gonarthrosis will randomised to receive saline solution
16411669|NCT03897673|Experimental|Early Iron|Children in the immediate iron group will receive iron syrup for the first three months (84 days) and placebo syrup for the fourth month.
16411670|NCT03897673|Experimental|Delayed Iron|Children in the delayed iron group will receive placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months.
16411671|NCT03897673|No Intervention|Community Control Children|Healthy, non-anemic community children will be enrolled from the same households and villages as the children with malaria. They will not have ZPP tested or receive iron, but they will also be under the same illness surveillance as the children with malaria.
16411672|NCT03897660|Active Comparator|TG form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acidsesterified in a reconstitute triglyceride form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
16411673|NCT03897660|Active Comparator|EE form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in ethyl esters form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
16411674|NCT03897660|Experimental|MaxSimil (MAG form of omega-3)|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
16411675|NCT03897647|Experimental|POCUS Patients|A bedside echocardiogram will be taken using a point-of-care pocket ultrasound (General Electric (GE) Vscan). Central venous pressure (right atrial pressure) and pulmonary capillary wedge pressure (left atrial pressure) will be collected from pulmonary artery catheters.
16411676|NCT03897634|Experimental|Experiences Hearing Aid user|Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
16411677|NCT03897621|Experimental|tranexamic acid|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
16411678|NCT03897621|Placebo Comparator|Normal saline|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
16411712|NCT03897309|Experimental|Monovalent GII.4|Monovalent GII.4 tableted vaccine group
16461468|NCT03556176|Active Comparator|5-HTTLPR or BDNF polymorphisms|
16411680|NCT03897569||patellofemoral pain syndrome|twenty subjects with anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
16411681|NCT03897569||control|twenty-six asymptomatic subject will be recruited for this study and should have no pain or other relevant clinical symptoms in the lower quadrant
16411682|NCT03897556|Active Comparator|High-dose|This arm consists of cancer survivors who receive two guarana energy bars to take per day for six weeks; one in the morning and one around lunch time.
16411683|NCT03897556|Active Comparator|Low-Dose|This arm consists of cancer survivors who receive one guarana energy bar to take per day for six weeks; one in the morning only.
16411684|NCT03897556|Other|Usual Care|This arm receives usual-care only as cancer survivors.
16411685|NCT03897543|Experimental|ABX196|IM injection of 0.1, 0.2, and 0.4 µg of ABX196
16411686|NCT03897530|Experimental|Prevention|During the session, participants are presented with randomly ordered conditions: menthol cigarettes and five flavored e-cigarettes (menthol/mint, fruits, sweets, alcohol, snacks/meals), menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes, non-menthol cigarettes and five flavored e-cigarettes, and non-menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes. Participants' visual attention is evaluated by eye-tracking equipment.
16411687|NCT03897517|Experimental|Proprietary Botanical Blend|Proprietary Botanical Blend - Dietary supplement with alpha amylase and sucrase inhibitory activity. 2 capsules
16411688|NCT03897517|Placebo Comparator|Placebo|Non/minimally nutritive nonactive material: rice flour. 2 capsules
16411689|NCT03897504|Experimental|feminizing genitoplasty using inner surface of the prepuce|Feminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
16411690|NCT03897491|Experimental|Interstitial photodynamic therapy|20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
16411691|NCT03897478||Ischemic Stroke|"Ischemic stroke subjects presenting within 30 hours from symptom onset will have al PAX Gene Blood RNA tubes drawn upon arrival to the Emergency Department (if available) or hospital.
~Biomarker blood draw"
16411692|NCT03897478||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn. Control group matched with ischemic stroke subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.
~Biomarker blood draw"
16411693|NCT03897465|Experimental|Lomatuell Pro|Lomatuell Pro® is a wound contact layer consisting of wide-meshed tulle, impregnated with a polymer matrix, which form a gel on contact with wound exudate to facilitate moist wound healing.
16411694|NCT03897465|Active Comparator|UrgoTul|UrgoTul® is a flexible contact layer with TLC healing matrix comprised of a conformable polyester mesh impregnated with hydrocolloid and petroleum jelly particles.
16411695|NCT03897452|Experimental|Fentanyl for procedural pain|"A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.
~This is not an RCT with several arms."
16411696|NCT03897439|Active Comparator|Usual Care (UC)|196 African American smokers will receive 12 weeks of smoking cessation counseling and 18 weeks of nicotine patch.
16411697|NCT03897439|Experimental|Optimized Care (OPT)|196 African American smokers will receive 12 weeks of smoking cessation counseling. They will receive the nicotine patch and up to two pharmacotherapy adaptations (VAR, BUP+NP) based on verified smoking status at Weeks 2 and 6 for a total of 18 weeks of pharmacotherapy.
16411698|NCT03897426|No Intervention|Standard-of-care arm|Patients randomized to the Standard-of-care-arm were provided 60 minutes of RD time for consultation through in person visits.
16411699|NCT03897426|Experimental|Intervention arm|"Mediterranean Diet - Remote Coaching using a Mobile App.
~Patients randomized to the intervention arm were allotted 60 minutes of RD time through a Mobile App (for remote consultation), given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD. Remote coaching by RD was the intervention."
16411700|NCT03897413|Experimental|Sequence 1|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fed state in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
16411701|NCT03897413|Experimental|Sequence 2|Participants received a single oral dose of 0.75 mg S-888711 in the fed state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
16411702|NCT03897413|Experimental|Sequence 3|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state in period 2, and a single oral dose of 0.75 mg S-888711 in the fed state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
16411703|NCT03897400||study group|women in reproductive age with crohn's disease
16411704|NCT03897400||control group|women in reproductive age without crohn's disease,
16411705|NCT03897361|Experimental|CTNS-RD-04 Gene Therapy|This is a single arm study without randomization. Eligible subjects will receive the final product: CTNS-RD-04.
16411709|NCT03897335|Active Comparator|Aminophylline pre CPB & immediately post CPB|
16411713|NCT03897309|Experimental|Bivalent GI.1 and GII.4 vaccine group|Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine
16411714|NCT03897309|Placebo Comparator|Placebo|Placebo tablets
16411715|NCT03897296|Experimental|healthy subjects examined with water-perfused catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
16411716|NCT03897283|Experimental|Anlotinib + TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16411717|NCT03897270|Experimental|Diagnostic (photoacoustic imaging of the breast)|Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.
16411723|NCT03897244|Experimental|High-dose dual therapy|group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
16411724|NCT03897244|Experimental|Bismuth High-dose dual therapy|group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
16411725|NCT03897244|Active Comparator|Amoxicillin-Metronidazole Bismuth quadruple therapy|group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
16411726|NCT03897218|Placebo Comparator|Group 1|Patients consuming placebo (millet flakes) each day
16411727|NCT03897218|Experimental|Group 2|Patients consuming oatmeal flakes with a low dosage of prebiotic food supplements
16411728|NCT03897218|Experimental|Group 3|Patients consuming oatmeal flakes with a high dosage of prebiotic food supplements
16411729|NCT03897205|Experimental|Imlifidase|Subjects randomized to imlifidase treatment will receive one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
16411730|NCT03897205|Active Comparator|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment will receive 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) may replace PE, at the discretion of the investigator.
16411731|NCT03897179|Experimental|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
16411732|NCT03897166|Experimental|Trimodality Imaging|Positron Emission Tomography coupled with Computed Tomography computed coupled with Magnetic Resonance Imaging and whole-body Biphoton Absorptiometry
16411733|NCT03897153|Experimental|Experimental:Diagnostic|Diagnostic Test: SONAS® Ultrasound Device
16411734|NCT03897140|Experimental|Patients scheduled for an echocardiogram|Patients ≥18 years scheduled for an echocardiographic examination. This is a non-randomized, un-blinded, study in patients with an indication for an echocardiographic examination. Enrolled patients will be stratified into two groups based on known cardiac abnormalities to ensure a sufficient number of patients with cardiac abnormalities and into 3 strata of BMI: normal, overweight and obese.
16411735|NCT03897127|Active Comparator|Standard arm|
16411736|NCT03897127|Experimental|Investigational arm|
16411737|NCT03897114|Experimental|Cocoa group|The cocoa will be provided in sachets. The intervention will be carried out for 10 weeks. Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
16411738|NCT03897114|Placebo Comparator|Placebo group|Maltodextrin will be supplied as a placebo, which will be provided in sachets. Athletes will take 5g of product per day.
16411739|NCT03897101||MILD NE|"gestational age > 35 weeks and weight > 1800 gr
~Apgar score < 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes or evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses
~evidence of mild encephalopathy graded according to Sarnat&Sarnat neurological evaluation
~normal amplitude integrated electroencephalography
~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
16411740|NCT03897101||ISOLATED METABOLIC ACIDOSIS|"gestational age > 35 weeks and weight > 1800 gr
~evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses
~Normal Sarnat&Sarnat neurological evaluation
~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
16411741|NCT03897101||HEALTY CONTROLS|"gestational age > 35 weeks and weight > 1800 gr Normal blood pH or base excess
~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokiness will be evaluated"
16411744|NCT03897075|Experimental|Arm A|
16411745|NCT03897075|Placebo Comparator|Arm B|
16411746|NCT03897062|Active Comparator|Treatment group|Patients (n=64): 20mg tablets of suvorexant nocte daily for six months
16411747|NCT03897062|Placebo Comparator|Placebo group|Placebo control group: Patients (n=64): 1 placebo tablet nocte daily for six months in addition to treatment as usual
16411748|NCT03897049|Experimental|TWC App|The intervention is a mobile app delivered sexual health promotion program designed specifically for transgender women. The mobile app will include more than 30 interactive activities including resource maps, PrEP and PEP content, and communication forums for connecting with other transgender women. The intervention/app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
16411749|NCT03897049|Active Comparator|General Health App|Participants will download a general health mobile app that contains sexual health information. The control mobile app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
16411915|NCT03895983||Thrombus aspiration group|Will include 135 patients who will have PPCI with thrombus aspiration
16411754|NCT03897023||Stable patient|Stable patients who admitted to ICU for observation.
16411755|NCT03897010|Active Comparator|Silica-calcium phosphate composite Group|Participants underwent socket augmentation procedures and dental implant placement in a staged approach. Atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. Free gingival gingival graft (1.5 to 2 mm thick) was taken from the area between the first and second premolar, 5 mm from gingival margin. Bioactive porous SCPC dental bone graft granules in the size range 90-710 micron were mixed with saline and loosely packed in the extraction sockets as per the manufacturer. The grafted SCPC granules were covered with free gingival graft obtained from the palatal tissues and sutured to stabilize the grafting material in place.
16411756|NCT03897010|Placebo Comparator|Control Group|Participants underwent atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. The socket left to heal.
16411757|NCT03896984||Cohort_2LX|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as first liine (1L) after diagnosis of mCRPC who then received Ra-223 monotherapy as second line (2L) treatment
16411758|NCT03896984||Cohort_2LH|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as 1L after diagnosis of mCRPC who then received another NAH monotherapy (i.e., Abiraterone to Enzalutamide or Enzalutamide to Abiraterone) as 2L treatment. None of the patients had ever received Radium-223 dichloride
16411759|NCT03896971|Experimental|Thrombopoietin mimetic plus immunosuppressive therapy|The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
16411760|NCT03896971|No Intervention|Immunosuppressive therapy|A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
16411761|NCT03896945|Placebo Comparator|Placebo|Placebo capsules will be administered orally twice a day over a 15-week period.
16411762|NCT03896945|Experimental|AVP-786|AVP-786 capsules will be administered orally twice a day over a 15-week period.
16411763|NCT03896932|Experimental|minipooled- Intravenous immunoglobulin(MP-IVIG)|• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
16411764|NCT03896919||cases|HLA-DQ mismatched recipient-donor pairs
16411765|NCT03896919||control|HLA-DQ matched recipient- donor pairs
16411766|NCT03896906|Experimental|Group N|pre-oxygenation with High-flow nasal cannula
16411767|NCT03896906|Active Comparator|Group M|pre-oxygenation with simple mask
16411768|NCT03896893|No Intervention|Standard of Care|Routine bathing and skin care as per hospital practice
16411769|NCT03896893|Experimental|1% chlorhexidine gluconate (CHG)|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays (total of 8 days CHG application)
16411770|NCT03896893|Experimental|Emollient therapy|Aquaphor skin cream applied from the neck down daily on weekdays (total of 8 days emollient application)
16411771|NCT03896893|Experimental|1% CHG plus emollient therapy|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays followed immediately by Aquaphor skin cream (total of 8 days CHG application plus emollient application)
16411772|NCT03896880||blood culture positive|hematological malignancy patients with positive blood culture
16411773|NCT03896867|Experimental|Anapod™ Humi-Therm Heated Humidification System|Patient warming will be provided via the Anapod™ Humi-Therm Heated Humidification System Breathing Circuit.
16411774|NCT03896867|Active Comparator|Bair Hugger™ Warming Blanket|Patient warming will be provided via the Bair Hugger™ Warming Blanket.
16411775|NCT03896854|Experimental|CD19 positive relapsed or refractory acute myeloid leukemia|MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia
16411776|NCT03896841||PCOS|premenopausal patients with PCOS
16411777|NCT03896841||control subjects|non-pregnant healthy control subjects
16411778|NCT03896828|Experimental|Sedentary|Sedentary (SED): Participants will remain seated in the lab all-day (7.5 hr).
16411779|NCT03896828|Experimental|Walking Breaks|Walking breaks (WALK): Participants will perform 2-minute walking breaks at 3.1 mph on a treadmill every 30 minutes (7.5 hr).
16411780|NCT03896828|Experimental|Resistance-exercise breaks|"Resistance exercise breaks (RE): Participants will perform 15 squats (1-minute) every 30 minutes. To reduce the risk of injury, standardize squat-depth, and recruit similar muscle groups as walking, the squats performed will be a chair-stand with calf-raise (7.5 hr)."
16411781|NCT03896802|Experimental|Low PEEP|PEEP 5 cmH2O
16411782|NCT03896802|Experimental|High PEEP|PEEP 15 cmH2O
16411783|NCT03896789|No Intervention|Baseline|All sites will collect usual care data from 9 months to 21 months.
16411784|NCT03896789|Experimental|PEGASUS Program (Intervention)|This arm (half of the sites) will receive the PEGASUS program (intervention) from 21 months to 57 months.
16411785|NCT03896789|No Intervention|Usual Care (Control)|This arm (half of the sites) will maintain usual care. They will receive the opportunity for the PEGASUS program training (intervention) at the end of study data collection (57 months) period.
16411786|NCT03896776|Experimental|Community Based Organization (CBO) Delivery|"CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.
~Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Week Follow-up if testing is not provided at their CBO site."
16414239|NCT03879928|Experimental|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
16411787|NCT03896776|Experimental|Direct to Consumer (DTC) Delivery|"In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, likes that are relevant to YMSM (e.g., local LGBT organizations, out celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.
~Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Week Follow-up."
16411788|NCT03896763|Experimental|Supine / CMV|Supine positioning and conventional mechanical ventilation
16411789|NCT03896763|Experimental|Prone / CMV|Prone positioning and conventional mechanical ventilation
16411790|NCT03896763|Experimental|Supine / HVOF|Supine positioning and high-frequency oscillatory ventilation
16411791|NCT03896763|Experimental|Prone / HFOV|Prone positioning and high-frequency oscillatory ventilation
16411798|NCT03896737|Experimental|Dara-VCd|"treatment period includes administration of four 28-day cycles of induction with Dara- VCd; then patients will undergo transplant and finally they will receive two 28-day cycles of Dara-VCd consolidation treatment.
~The response will be assessed after each cycle. Patients in the first randomization will be stratified according to FISH (standard/missing vs high risk,defined as del17, t 4;14, t 14;16) and ISS (I vs II and III).
~TREATMENT SCHEMA - INDUCTION Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4.
~Bortezomib: 1.3 mg/m2 given SC injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or IV infusion on days 1, 8, 15, 22; Dexamethasone: 40 mg given orally or by IV infusion on days 1, 8, 15,22 Repeat for four 4-week induction cycles."
16411799|NCT03896737|Active Comparator|VTd|"treatment period includes administration of four 28-day cycles of induction with VTd; then patients will undergo transplant and finally they will receive two 28-day cycles of VTd consolidation treatment.
~TREATMENT SCHEMA INDUCTION
~ARM VTd:
~Bortezomib: 1.3 mg/m2 given by SC injection on days 1, 4, 8, 11 of 28-day cycle; Thalidomide: 100 mg given orally on days 1-28. Dexamethasone: 20 mg given orally or by IV injection on days 1, 2, 3, 4, 8, 9, 10 and 11 of every 28-day cycle.
~Repeat for four 4-week induction cycles."
16411800|NCT03896724|Experimental|Group 1|"n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year.
~Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season"
16411801|NCT03896724|Experimental|Group 2|"n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year.
~Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season"
16411802|NCT03896724|Placebo Comparator|Group 3 (control group)|n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial.
16411805|NCT03896698|Experimental|TUS treatment|AD patients with TUS treatment
16411806|NCT03896698|No Intervention|Non-TUS treatment|AD patients with Non-TUS treatment
16411807|NCT03896685|Experimental|endTB-Q: BeDeCLi 24 or 39 weeks|endTB-Q regimen: bedaquiline-delamanid-linezolid-clofazimine (BeDeCLi). Subjects who are randomized to this arm will be assigned to duration of 24 or 39 weeks , according to the participant's extent-of-TB-disease phenotype. Participants may take as long as 32 weeks to complete all doses of a 24-week treatment regimen, and up to 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of the experimental regimens will be oral and weight based.
16411808|NCT03896685|Active Comparator|endTB-Q: Control arm|endTB-Q is the control regimen, designed according to latest World Health Organization guidelines.
16411809|NCT03896672|Experimental|Treatment with Continuous Positive Airway Pressure|All patients will undergo to physiotherapeutic treatment based on the previous training of the physiotherapist
16411810|NCT03896659|Experimental|Depressed: Hydrocortisone, then Placebo|"Participants in the depressed' arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
16411811|NCT03896659|Experimental|Depressed: Placebo, then Hydrocortisone|"Participants in the depressed' arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
16411812|NCT03896659|Experimental|Healthy Controls: Hydrocortisone, then Placebo|"Participants in the healthy control arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
16411813|NCT03896659|Experimental|Healthy Controls: Placebo, then Hydrocortisone|"Participants in the healthy control arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
16411814|NCT03896646|Experimental|Treatment (personalized radioembolization, SPECT/CT HIDA)|Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.
16411815|NCT03896633|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
16411816|NCT03896633|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
16411820|NCT03896594|Experimental|HL237 200mg|HL237 100mg 1 tablet twice a day
16411821|NCT03896594|Experimental|HL237 400mg|HL237 100mg 2 tablets twice a day
16411822|NCT03896594|Experimental|HL237 800mg|HL237 400mg 1 tablet twice a day
16411825|NCT03896568|Experimental|Part I (oncolytic adenovirus Ad5-DNX-2401)|Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.
16411826|NCT03896568|Experimental|Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)|Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.
16411827|NCT03896542|Experimental|Commercial video game|the group commercial video game received 30 minutes of conventional therapy plus 30 minutes of rehab training using Xbox Kinect-based games.
16411828|NCT03896542|Experimental|Rehabilitation video game|the group rehabilitation video game received 30 minutes of conventional therapy plus 30 minutes of rehab games.
16411829|NCT03896542|No Intervention|The control group|The control group received 30 minutes of conventional therapy
16411830|NCT03896529|No Intervention|No-stress control group|Participants in this group will perform the psychology tasks (virtual navigation) without any manipulation of psychological stress
16411831|NCT03896529|Experimental|Stress group|Participants in this group will perform the psychology tasks (virtual navigation) under manipulated psychological stress (anticipatory threat of shock)
16411836|NCT03896490|Experimental|ACT|
16411837|NCT03896490|Placebo Comparator|Control|
16411838|NCT03896477|Experimental|Pneumosil|PCV-10
16411839|NCT03896477|Active Comparator|Prevenar 13|PCV-13
16411840|NCT03896477|Active Comparator|Synflorix|PCV-10
16411841|NCT03896464|Active Comparator|Soft-tissue hamstring|All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
16411842|NCT03896464|Active Comparator|Quadriceps tendon|Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
16411843|NCT03896451|Other|GMK Sphere|"Patients receiving total knee replacement surgery with the device Medacta GMK Sphere"
16411844|NCT03896451|Other|GMK PS|"Patients receiving total knee replacement surgery with the device Medacta GMK PS"
16411851|NCT03896412|Experimental|Detection of circulating tumor DNA|sampling of 20 ml of blood the day before surgery, the day after , 6 months after diagnosis and every 3 months thereafter until 18 months of follow up
16411852|NCT03896399|Experimental|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
16411853|NCT03896386|Other|Use of seizure diary|People diagnosed with epilepsy that lives with a dog that is able to anticipate the onset of a seizure. They will be ask to use a diary (bespoke smartphone app) to register the occurrence of seizures and the alerting behaviour of the dogs.
16411854|NCT03896373||Lupus erythematosus|Patients with inactive lupus erythematosus, active lupus erythematosus or newly diagnosed
16411855|NCT03896360|Experimental|Food order behavioral intervention plus standard care|Subjects will receive standard nutrition counseling and additional carbohydrate-last food order behavioral counseling.
16411856|NCT03896360|Other|Standard care|Subjects will receive standard nutrition counseling.
16411857|NCT03896347||ViBone®|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
16411858|NCT03896347||Demineralized Bone Matrix|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
16411859|NCT03896347||Bone Morphogenetic Protein|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
16411860|NCT03896334|Experimental|Isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training will train three times per week, during 24 weeks. They will perform a bout of isometric handgrip exercise: four sets of 2-min of isometric contractions (using alternate hands) at 30% of maximal voluntary contraction.
16411861|NCT03896334|Sham Comparator|Control group|All participants randomized to control group will realize stretching and relaxation exercises, three times per week, during 24 weeks.
16411862|NCT03896321|Active Comparator|Asprin|Patient will receive dual anti platelet asprin And clopidogrel
16411863|NCT03896321|Active Comparator|Clopidogrel|Patient will receive dual anti platelet asprin And clopidogrel
16411864|NCT03896321|Active Comparator|Warfarin|Patient will receive oral anticoagulation
16411865|NCT03896321|Active Comparator|Novel oral anticoagulant|Patient will receive oral anticoagulation
16411866|NCT03896295|Experimental|M281|
16411867|NCT03896282|Active Comparator|daycare facility|After surgery patient stay at daycare facility for mobilisation and stay until discharge or transfer to standard patient ward if nor discharged by 20.000
16411868|NCT03896282|Active Comparator|standard patient ward|After surgery patients are transferred to standard patient ward for mobilisation and stay until discharge.
16411869|NCT03896269|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|"INDUCTION THERAPY: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. After 2-5 weeks, patients who do not achieve a CR/CRi/CRp, have acceptable or no toxicity, and have stable disease and no disease progression may receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Patients who achieve at least a HI response, receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 5-8 weeks, patients who do not show clinically significant disease progression or unacceptable toxicity may receive liposome-encapsulated daunorubicin-cytarabine for up to 12 additional cycles."
16411870|NCT03896256|Experimental|Treatment Arm|Patients will be admitted to the hospital for a total of 5 full days from the time of admission until discharge. Ketamine infusion will be started on day 1. Adjustments to ketamine infusion will be made according to standard acute pain service protocol.
16411871|NCT03896243||Uterine artery ligation (UAL)|"We would like toinvite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.
~They would be evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
16411872|NCT03896243||Control Group:|"We would like to invite the patients to the hospital at least 6 months after C-section who delivered baby without any complication.
~They would be also evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
16411873|NCT03896230|Active Comparator|Arm 1: 0.1 mg/kg ketamine|0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
16411874|NCT03896230|Active Comparator|Arm 1: 0.2 mg/kg ketamine|0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
16411875|NCT03896230|Active Comparator|Arm 1: 0.3 mg/kg ketamine|0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
16411876|NCT03896217|Active Comparator|Simvastatin|Simvastatin is part of the pharmacotherapeutic group of HMG-CoA reductase inhibitors (ATC-Code: C10A A01). Simvastatin is licensed within the EU for hypercholesterolemia and cardiovascular prevention but for this trial its use will be outside its licensed indication. Oral Simvastatin will be taken 40mg daily (one tablet in the evening) for 4 weeks and then at week 4 up titrated to 80mg daily (two tablets in the evening.
16411877|NCT03896217|Placebo Comparator|Placebo|Matched Placebo (one tablet in the evening) for 4 weeks and then at week 4 up titrated to two tablets daily in the evening.
16411878|NCT03896204|Experimental|telephone-supported group|
16411879|NCT03896204|Experimental|Other group|
16411916|NCT03895983||Standard PPCI group|Will include 135 patients who will have PPCI without thrombus aspiration
16411880|NCT03896191||Stable, satisfied primary TKR|Participants who have a stable TKR (as assessed by the surgical team) and are satisfied with their knee replacement (as assessed by a questionnaire).
16411881|NCT03896191||Unstable, dissatisfied primary TKR|Participants who are dissatisfied with their TKR, with instability (including instability due to aseptic loosening) and consequently awaiting revision TKR.
16411882|NCT03896178||Firefighters|
16411883|NCT03896178||Pilots|
16411884|NCT03896178||Police|
16411885|NCT03896178||Military personnel|
16411886|NCT03896178||Controls|Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
16411887|NCT03896165|Experimental|Teaching Reiki|Parent-adolescent pairs will be in the study for a total of nine weeks from enrollment to the follow up visit. During Week 1, the parent will receive Reiki training, a poster with suggested hand positions and a commercially-available book about Reiki in the home. During Week 2 the parent will receive a Reiki booster session with a repeat of the training and may ask questions in the home. At the end of Week 4, measures will be repeated either in person or by phone. During Week 8, measures will be repeated, another hair sample obtained and the parent will participate in a qualitative interview. The qualitative interview will be administered in person by trained Ohio State University College of Nursing study staff as part of the interview session. Interviews will be audio recorded using a hand-held audio recording device. Audio recording is voluntary and participants can choose to not have their interview recorded and still be a part of the study.
16411890|NCT03896139||VUMC EHR cohort|De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).
16411891|NCT03896139||Toxicity induced by kinase inhibitors in Vigibase database|Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity
16411892|NCT03896126||Gastroparesis Patients|20 gastroparesis patient ages 20-49
16411893|NCT03896126||Healthy Controls|40 healthy controls ages 20-49
16411894|NCT03896113|Experimental|Celecoxib|Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery will receive celecoxib 400 mg twice a day, for 15 days before the curative surgery for their endometrial cancer. The patients will undergo an endometrial biopsy at the inclusion and during the surgery.
16411895|NCT03896100||Element 2|Four clinical samples will be taken from each eligible subject and used to assess two clinical removal methods and two in vitro removal methods.
16411896|NCT03896100||Element 3|Four clinical samples will be taken from each eligible subject and used to assess three different storage methods.
16411897|NCT03896100||Element 4|Four clinical samples will be taken from each eligible subject and used to assess different ocular regions.
16411898|NCT03896087|Experimental|clinical performance of the HCV DBS assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the for assays (medical devices) used for the qualitative and quantitative detection of Hepatitis C RNA.
16411899|NCT03896087|Active Comparator|comparison PQ marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
16411900|NCT03896074|Experimental|Atezolizumab|Patients allocated to Arm A will be treated with atezolizumab administered intravenously at 1200 mg every 3 weeks given until disease progression, toxicity or patient refusal
16411901|NCT03896074|Experimental|Atezolizumab plus bevacizumab|Patients in the Arm B will receive atezolizumab administered intravenously at 1200 mg every 3 weeks plus bevacizumab intravenously at 15 mg/kg every 3 weeks given until disease progression, toxicity or patient refusal
16411902|NCT03896048||Successful extubation|
16411903|NCT03896048||Failed extubation|Failed extubation will be defined as a patient who in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.
16411904|NCT03896035|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
16411905|NCT03896035|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
16411906|NCT03896022|Active Comparator|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
16411907|NCT03896022|Active Comparator|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
16411908|NCT03896022|Sham Comparator|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
16411909|NCT03896009|Experimental|AXS-07|Taken once upon a qualifying migraine
16411910|NCT03896009|Active Comparator|Meloxicam|Taken once upon a qualifying migraine
16411911|NCT03896009|Active Comparator|Rizatriptan|Taken once upon a qualifying migraine
16411912|NCT03896009|Placebo Comparator|Placebo|Taken once upon a qualifying migraine
16411913|NCT03895996|Experimental|AVT001 (Treatment)|Infusion of AVT001 (treatment)
16411914|NCT03895996|Placebo Comparator|Matched placebo|Infusion of AVT001-matched placebo
16411917|NCT03895970|Experimental|Lenvatinib plus Pembrolizumab|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
~Pembrolizumab is a recombinant anti-human PD-1 monoclonal antibody."
16411918|NCT03895957|Experimental|Group 1: VR Mind+|Virtual Reality Exposure Therapy VR Mind+
16411919|NCT03895957|Experimental|Group 2: VR Mind|Virtual Reality Exposure Therapy VR Mind
16411920|NCT03895957|Active Comparator|Control group: CBT|Cognitive Behavioral Therapy
16411921|NCT03895944|Experimental|iv low dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10^6) in Leukemia or Lymphoma patients
16411922|NCT03895944|Experimental|iv middle dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10^6) in Leukemia or Lymphoma patients
16411923|NCT03895944|Experimental|iv high dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10^6) in Leukemia or Lymphoma patients
16411924|NCT03895918|Experimental|Delayed Group (delayed parental skills)|Participants continue medication adherence monitoring over 2 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
16411925|NCT03895918|Experimental|Early Group (early parental skills)|Participants continue medication adherence monitoring over 1 week and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
16411926|NCT03895918|Experimental|Late Group (late parental skills)|Participants continue medication adherence monitoring over 3 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
16411927|NCT03895905||Genotype of HR-HPV 16/18|Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy
16411928|NCT03895905||Genotype of HR-HPV Non-16/18|Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy
16411929|NCT03895892|Placebo Comparator|Water Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
16411930|NCT03895892|Experimental|Experimental 1|Ketone salts supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
16411931|NCT03895892|Experimental|Experimental 2|Ketone salts/caffeine supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
16411932|NCT03895879|Experimental|Intervention|Tocilizumab administered every 2 weeks
16411933|NCT03895879|Active Comparator|Control|Tocilizumab administered every week
16411934|NCT03895879|Active Comparator|Standard dose (screening < 15 mg/L)|Tocilizumab administered every week
16411935|NCT03895866||Group A|High-risk HPV persistent infection more than half a year and reversion
16411936|NCT03895866||Group B|High-risk HPV non-infection
16411937|NCT03895853|Active Comparator|Group I (standard of care)|Patients receive standard of care for septic shock.
16411938|NCT03895853|Experimental|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
16411939|NCT03895840|Experimental|Intra-articular Zilretta injection|32 mg Zilretta in a 5ml diluent for each knee, per manufacturer guidelines
16411940|NCT03895827|Active Comparator|Passive Referral Control|Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.
16411941|NCT03895827|Experimental|Recovery Initiation and Management after Overdose (RIMO)|Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.
16411942|NCT03895814|Experimental|Multi-baseline Step Training|"Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week protective step training period. Participants will also be assessed 2 months later at a follow-up visit."
16411943|NCT03895801|Experimental|Group A Experimental + active comparator|IFX-1 + reduced dose GC
16411944|NCT03895801|Active Comparator|Group B Placebo + active comparator|Placebo-IFX-1 + standard dose GC
16411945|NCT03895801|Placebo Comparator|Group C Experimental + placebo comparator|IFX-1 + Placebo-GC
16411946|NCT03895788|Experimental|niraparib and brivanib|Subjects will be assigned into niraparib 100mg+brivanib 200mg, niraparib 200mg+brivanib 200mg, niraparib 200mg+brivanib 400mg, niraparib 200mg+brivanib 600mg dose group at the first day of the first cycle.
16411947|NCT03895749|Active Comparator|Neo40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
16411948|NCT03895749|Placebo Comparator|Placebo|Per Capsule: Beet Juice concentrate, Carmine, Croscarmellose Sodium, D-Mannitol, Magnesium Stearate, Orange flavour, Silicon dioxide, Stevia rebaudiana leaf, Xylitol.
16411949|NCT03895723|Experimental|Minimally Invasive surgery|the intevention of Minimally Invasive procedure contains laparoscopic and robotic liver resection
16411950|NCT03895723|Other|Open surgery|the open surgery means traditional open surgery for liver resection
16411951|NCT03895710||Sleep-deprived group|i. Self-reported time in bed (period from bedtime to get-up time) during school days of <8 hours per day ii. Self-perceived insufficient sleep during school days
16411952|NCT03895710||Normal sleep group|i. Self-reported time in bed during school days of >=8 hours per day ii. Self-perceived sufficient sleep during school days
16411953|NCT03895697|Experimental|Sequence 1|V2: Single fixed dose (sc injection) of dasiglucagon batch B then at V3: Single fixed dose (sc injection) of dasiglucagon batch A
16411954|NCT03895697|Experimental|Sequence 2|V2: Single fixed dose (sc injection) of dasiglucagon batch A then at V3: Single fixed dose (sc injection) of dasiglucagon batch B
16411956|NCT03895671|Experimental|AP-CML|Patient with Philadelphia chromosome positive CML in accelerated phase is defined by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), ≥ 20% basophils in PB or BM, ≥ 30% blasts plus promyelocytes (with blasts <30%) in PB or BM, <100 x109/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome);
16411957|NCT03895671|Experimental|MBC-CML|Patient with Philadelphia chromosome positive CML in myeloid blast crisis is defined by the presence of ≥ 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease.
16411962|NCT03895619|Experimental|Men living with HIV|Uptake of safer conception strategies among men living with HIV and/or their female partners
16411963|NCT03895606||HIPEC|patients undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy due to carcinomatosis.
16411964|NCT03895580|No Intervention|Group 1|Medical nutrition therapy session with no further dietary counseling throughout the study.
16411965|NCT03895580|Experimental|Group 2|Medical nutrition therapy session plus in-store point-of-purchase (POP) education.
16411966|NCT03895580|Experimental|Group 3|Medical nutrition therapy session plus combined in-store/online point-of-purchase (POP) education.
16411967|NCT03895567|Experimental|ABC|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
16411968|NCT03895567|Experimental|ACB|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
16411969|NCT03895567|Experimental|BAC|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
16411970|NCT03895567|Experimental|BCA|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
16411971|NCT03895567|Experimental|CAB|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
16411972|NCT03895567|Experimental|CBA|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
16411973|NCT03895554||Normal volunteers|Normal, healthy volunteers with undergo cardiac PET stress testing.
16411974|NCT03895541|Other|Stratification|All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity.
16411975|NCT03895515||Fiasp®|Participants with type 1 diabetes who have switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin.
16411976|NCT03895502|Experimental|12-month Edoxaban|Edoxaban for 12 months
16411977|NCT03895502|Active Comparator|3-month Edoxaban|Edoxaban for 3 months
16411978|NCT03895489|Experimental|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
16411979|NCT03895489|Active Comparator|Stryker|Stryker Triathlon Total Knee prosthesis
16411980|NCT03895489|Active Comparator|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
16411981|NCT03895476|Active Comparator|control group|palatal wound will not be protected with any material
16411982|NCT03895476|Active Comparator|group 1|palatal wound will be protected with Platelet rich Fibrin
16411983|NCT03895476|Active Comparator|group 2|wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.
16411984|NCT03895476|Active Comparator|group 3|wound will consist of collagen protection with the application
16411985|NCT03895450|Experimental|Aerobic Exercise Protocol (AEP)|Symptom threshold will be determined at baseline and repeated every 3 weeks using the Buffalo Concussion Treadmill Test. Briefly, there will be an initial 4min warm up at 1.7mph. The protocol will start with treadmill speed se to 3.3 mph and 0.0% incline. Each subsequent minute, the incline will increase by 1.0% to a max of 15%. At 15% grade, if the participant is still able to continue, treadmill speed will increase by 0.4mph each minute. Heart rate (HR) and rating of perceived excretion (RPE Borg scale) will be measured every minute. The test will be terminated upon symptom exacerbation at which time HR and RPE will be recorded. Every 3 weeks the symptom threshold test will be repeated for all participants and exercise prescription will be adjusted accordingly.
16411986|NCT03895450|Placebo Comparator|Stretching Protocol (SP)|The exercise testing for the stretching protocol to determine exercise prescription will be the same as described above.
16411987|NCT03895437|Experimental|TOL-3021|TOL-3021 2 mg/mL
16411988|NCT03895437|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
16411989|NCT03895424|Experimental|Iron Fatty Acid Complex (IFAC)|The iron fatty acid complex encapsulated and administered to the participants
16411990|NCT03895424|Experimental|Micellarized iron fatty acid complex (MIFAC)|Micellarized form of the iron fatty acid complex which is enscapsulated and administered to the participants
16411991|NCT03895424|Active Comparator|Control Ferrous Sulfate|Ferrous sulfate that is provided in the form of a solution along with a capsule that contains the same amount of fat that is present in the other two arms.
16411992|NCT03895411|Experimental|Sotalol|Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc
16411994|NCT03895398|Experimental|nutrition and psychosocial intervention arm|"12 selected ECE centers will be selected to be the intervention group. ECE teachers will be trained on psychosocial and nutrition care for children and expected to deliver the information and parenting class to mother.
~Community health officers will be trained on how to monitored the activities regularly and providing technical assistance to ECE teachers if needed.
~mothers will received weekly parenting class. in the parenting class mothers will be informed on how to provide appropriate feeding and psychosocial stimulus to their children. nutrient dense food supplementation in the form of liver and fish floss will be prepared together and distributed.
~underfive children will received nutrient dense food supplementation in the form of liver and fish floss and expected to be eaten everyday for 6 months"
16411995|NCT03895398|No Intervention|control arm|no intervention is given to this arm
16411996|NCT03895385|Experimental|Bimekizumab|Subjects randomized to this arm will receive a single dose bimekizumab followed by inactivated influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
16411997|NCT03895385|No Intervention|No Treatment|Subjects randomized to this arm will receive the influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
16411998|NCT03895372|Experimental|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
16411999|NCT03895372|Experimental|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
16412000|NCT03895372|Experimental|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
16412001|NCT03895372|Experimental|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
16412002|NCT03895372|Experimental|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
16412003|NCT03895359|Active Comparator|Transarterial Chemoembolization (TACE)|
16412004|NCT03895359|Active Comparator|TACE Plus Stereotactic Body Radiation Therapy (SBRT)|
16412005|NCT03895346|Experimental|Mindfulness|Class meeting three times a week for six months, led by a certified mindfulness meditation instructor. Includes instruction and practice on techniques such as breathing, body scan, physical sensations, and yoga.
16412006|NCT03895346|Active Comparator|Brain Games and Puzzles|Class meeting three times a week for six months, led by a qualified instructor. Includes teaching and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
16412007|NCT03895333||study group|women with hearing loss and osteoporosis will develop the study group.
16412008|NCT03895333||control group|women who have hearing loss but have no osteoporosis will constitute the control group.
16412009|NCT03895320|Experimental|Intervention Program|The intervention and control programs will consist of similar, but not identical components. The intervention will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the intervention program, the self-assessment ('Sexual Health Quiz'), score ('Sexual Health Score') and messaging ('Sexual Health Messaging') will pertain to sexual and reproductive health. For the intervention program, the self-assessment, will include a valid clinical prediction tool, established to predict STI positivity. Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen after the risk score. The program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
16412010|NCT03895320|Other|Control Program|The intervention and control programs will consist of similar, but not identical components. The Control Program will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the Control Program, the self-assessment ('Water Sugar Sweetened Beverages (SSB) Quiz'), score ('Water SSB Score') and messaging ('Water SSB Messaging') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment. However, based on the answers given on the control quiz, steps the control participant can take to meet the recommended daily intake of water and sugar sweetened beverages will be displayed on the screen after they complete the quiz. The control program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
16412011|NCT03895307|Experimental|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
16412012|NCT03895307|Placebo Comparator|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
16412013|NCT03895307|Experimental|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
16412014|NCT03895307|Placebo Comparator|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
16412015|NCT03895294|Experimental|Health care under the strategic purchase-Clinical pathway|Health care under the strategic purchase and the Clinical pathway for the treatment of chronic Hepatitis C
16412016|NCT03895294|Active Comparator|Usual care process prior strategic purchase-clinical pathway|Usual care process prior to the establishment of the strategic purchase and the Clinical Pathway
16412017|NCT03895255|Active Comparator|IMA high ligation with routine SFM|Inferior mesenteric artery is ligated close to its origin. Splenic flexure is always mobilized.
16412018|NCT03895255|Experimental|IMA skeletonization and low ligation with selective SFM|Inferior mesenteric artery is ligated below the origin of left colic artery. Splenic flexure is mobilized only if needed.
16412019|NCT03895242|Experimental|Group 1:First supine position,then prone position|First group was supine position then prone position.
16412020|NCT03895242|Experimental|Group 2:First prone position, then supine position|Second group was first prone position, then supine position.
16412021|NCT03895229|Experimental|Experimental Arm|Subjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet [Jardiance]
16412025|NCT03895190|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
16412026|NCT03895190|Experimental|Experimental: Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
16412027|NCT03895177|Experimental|low kVp high mAs CT group|doing pancreatic CT with 80 kVp tube current with more than 500 mA tube current for the evaluation of pancreatic cancer resectability
16412028|NCT03895164|Placebo Comparator|Standard NE|Control Group will receive standard nutrition education package from primary health care.
16412029|NCT03895164|Experimental|Enhanced NE|Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
16412030|NCT03895151|Experimental|Milk supplementation|"Children will receive 130 ml fresh milk, 6 days/week for 20 weeks (January-June 2019).
~Milk will be provided and delivered by appointed supplier directly to school. Milk will be distributed with name of the student on the bottle - during break time.
~Subjects must be consumed with supervision of the teacher at school during the break.
~If they can not finish the milk at once, they can store it in the provided cool box. Student then can consume it again before they go home. Teacher have to record the remaining milk in each bottle that corresponds to every child name and record it in the provided form.
~Prior to holiday, student will be given the milk according to school leave days.
~Enumerators should collect the form every 3 days and make a recap in the provided form."
16412031|NCT03895151|Experimental|Food Based Recommendation (FBR) nutrition education|FBR group will received nutrition education delivered by trained teacher under the supervision of researcher/research assistant once a week. Those who received nutrition education is not only the recruited subjects but also includes their classmates.
16412032|NCT03895151|No Intervention|Control|Control group will receive standard nutrition education
16412033|NCT03895138|Active Comparator|Standard Glucommander Protocol (SGP)|CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
16412034|NCT03895138|Experimental|Optimized Glucommander (OGM)|CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
16412035|NCT03895125|Experimental|[year1] PD group|
16412036|NCT03895125|Active Comparator|[year1] healthy control group|
16412037|NCT03895125|Experimental|[year2-3] freezer|
16412038|NCT03895125|Experimental|[year2-3] non-freezer|
16412039|NCT03895112|Experimental|AVID200|intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
16412040|NCT03895099|Experimental|A - Early follicular phase|Treatment by desogestrel at day 1 to day 3
16412041|NCT03895099|Experimental|B - Medium follicular phase|Treatment by desogestrel at day 4 to day 7
16412042|NCT03895099|Experimental|C - Late follicular phase|Treatment by desogestrel at day 7 to day 11
16412043|NCT03895099|Experimental|D - Ovulatory Phase|Treatment by desogestrel at day 12 to day 15
16412044|NCT03895099|Experimental|E - Luteal phase|Treatment by desogestrel at day 16 to day 30
16412045|NCT03895086|Experimental|Specific Physical Activity|Specific patient care in telephone coaching of fibromyalgia patients.
16412046|NCT03895086|Other|Classic Physical Activity|Classic patient care in common group of multipathological patients.
16412047|NCT03895073||healthy|healthy volunteers' replies to questionnaire
16412048|NCT03895073||heart failure|heart failure patients' replies the questionnaire
16412049|NCT03895060|Experimental|autogenous ring blockls with GBR covered by collagen membrane|Vertical and horizontal ridge augmentation using autogenous onlay ring blocks combined with simultaneous guided bone regeneration using native collagen membrane in atrophic anterior maxilla.
16412050|NCT03895047|Active Comparator|dACC,I,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
16412051|NCT03895047|Active Comparator|dACC,AC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week.12 sessions of Neurofeedback Training, 1-2 times per week."
16412052|NCT03895047|Active Comparator|I,dACC,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
16412053|NCT03895047|Active Comparator|I,AC,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
16412081|NCT03894891|Experimental|Docetaxel+Cisplatin+Nivolumab+Radioimmunotherapy|Docetaxel will be administered per standard institutional every 3 weeks Nivolumab will be administered intravenously every 3 weeks Cisplatin will be administered intravenously every 3 weeks Radioimmunotherapy will be conducted 3 weeks after the last cycle of TPN (docetaxel, cisplatin and nivolumab)
16412082|NCT03894865|Experimental|urban school|Male students from selected urban schools undergo screening for idiopathic scoliosis
16412054|NCT03895047|Active Comparator|AC,dACC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
16412055|NCT03895047|Active Comparator|AC,I,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
16412056|NCT03895034|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
16412057|NCT03895021|Experimental|Intervention|This multifaceted, adapted program focuses preventing falls through balance and strength exercises, teachings from guest experts (e.g., PT, Pharmacist, vision) and at-home safety education. Participants attended weekly 2-hour group sessions (8 -12 persons) over the course of 8 weeks delivered in Spanish by trained Hispanic/Latino personnel in two communities in Wisconsin.
16412058|NCT03895008||Cardia gastric cancer|Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
16412059|NCT03895008||Non-cardia gastric cancer|Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
16412060|NCT03894995|No Intervention|Part 1. Focus group discussions on ventilation preferences|Participant's perceived benefits/detriments of having ventilation options in the household and their opinions on the behavior change material developed to encourage increased household ventilation will be explored using 6-9 focus group discussions with 10-12 participants each.
16412061|NCT03894995|No Intervention|Part 2. PM 2.5 pilot|Indoor, outdoor, and personal particulate matter concentrations among ten mother-child pairs and their homes will be monitored.
16412062|NCT03894995|Experimental|Part 3. Intervention|Households will participate in a baseline survey and a Beck-DeGroot-Marshak auction to establish willingness-to-pay for ventilation. If the household wins, or if it is decided to install ventilation in all intervention households, the household will receive installation of a ventilating mechanism.
16412063|NCT03894995|No Intervention|Part 3. Control|For 12 month after intervention, the air exchange rate will be measured in all control households.
16412064|NCT03894995|No Intervention|Part 4. Spillover|Households that neighbor enrolled study households will be surveyed and asked whether they, on their own, chose to install a window. If they did install a window, they will be asked how much they paid.
16412065|NCT03894982||What is Asthma|"Reviewing asthma is a lung disease. There is no cure, but asthma can be well controlled so that your child can be healthy and join in all their favorite activities.
~Asthma causes the airways (breathing tubes in the lungs) to get smaller, making it hard to breathe.Common symptoms of asthma are coughing, wheezing, chest tightness and trouble breathing.
~These symptoms are ongoing and get better with asthma medicines."
16412066|NCT03894982||Triggers|Reviewing specifics around children with asthma have extra sensitive airways and many things around them can make their asthma worse. The things around your child that cause an asthma attack are called triggers. Triggers are different for each child. Your doctor can help you figure out your child's triggers. Try to keep your child away from their triggers, especially at home and at school where your child spends most of their time.
16412067|NCT03894982||Medications and Asthma Action Plan|Review what is an asthma action plan, how to use an asthma action and the medications listed on each individuals plan.
16412068|NCT03894969|Experimental|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
16412069|NCT03894969|Experimental|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
16412070|NCT03894969|Experimental|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
16412071|NCT03894969|Active Comparator|NTHi-Mcat Group|Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
16412072|NCT03894969|Experimental|Shingrix-Only Group|Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
16412073|NCT03894956||Participants with Hidradenitis Suppurativa (HS)|Participants who along with their treating physician have elected for treatment with Humira as per routine clinical practice for the treatment of HS
16412074|NCT03894943|Experimental|General|All subjects will undergo ordinary surgical treatment for their lumbar disc herniation. Experimentally, all subjects participating in the study will receive PET/CT scans and sensory testing as specified below.
16412075|NCT03894930|Experimental|Metta meditation|Eight-week, guided metta meditation training that is administered online
16412076|NCT03894930|No Intervention|Wait-list|Eight-week wait-list control with no training
16412077|NCT03894917||Group 1|Participants 65 years or older
16412078|NCT03894917||Group 2|Participants less than 65 years
16412079|NCT03894904|Experimental|Premixed Papaverine|2mL of the 50mL premixed syringe of papaverine as dispensed from pharmacy ( NaCl 0.9% inj 48.8 mL + papaverine 6mg+ heparin 100 units).
16412080|NCT03894904|Active Comparator|Heparin|2 ml of the 10 mL of 2 units/mL of heparin from the pressurized fast flush bag from the operating room.
16412203|NCT03893994|Experimental|Stretching group|Posterior shoulder stretching exercises
16412083|NCT03894865|Experimental|countryside schools|Male students from selected countryside schools undergo screening for idiopathic scoliosis
16412084|NCT03894852||AML|cases with denovo AML and t-AML
16412085|NCT03894852||MDS|cases with denovo MDS and t-MDS
16412086|NCT03894839|Active Comparator|glutaraldehyde disinfection and microwave application|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
16412087|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and microwave application|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
16412088|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and microwave application|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
16412089|NCT03894839|Active Comparator|glutaraldehyde disinfection and ozone therapy|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
16412090|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and ozone therapy|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
16412091|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and ozone therapy|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
16412092|NCT03894826|Experimental|TREATMENT|Participants will be administered 230 mg/m2/day of oral Vorinostat [100 mg tablets] in addition to standard of care anti-seizure medication for a duration of 6 weeks.
16412093|NCT03894813|Experimental|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
16412094|NCT03894813|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
16412095|NCT03894800|Active Comparator|Methoxyflurane (M)|"A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
16412096|NCT03894800|Active Comparator|Fentanyl (F1)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
16412097|NCT03894800|Active Comparator|Fentanyl (F2)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
16412098|NCT03894800|Placebo Comparator|NaCl (C)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
16412099|NCT03894774|Experimental|Intensive InPatient Psychotherapy Treatment Group (IG)|Intensive non-pharmaceutical inpatient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic frame where patients live over the whole treatment (approximately a 1:1-ratio caregiver per patient is given) of 6 to 8 month treatment duration.
16412100|NCT03894774|Active Comparator|Waiting Control Group (WCG)|"Treatment as usual (mostly combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy).
~Duration: At least 3 month to a maximum of 6 month."
16412101|NCT03894774|No Intervention|Healthy Control Group (HCG)|"Matched Pairs design to control for gender, age and handedness. HCG measurements are planned and conducted according to the exact durations of their matched inpatient pair of the IG.
~Mandatory to control for effects of factors such as brain maturation."
16412102|NCT03894761|Other|Patients with Rotator Cuff Syndrome|The patients diagnosed with rotator cuff syndrome by clinical and magnetic resonance imaging.
16412103|NCT03894748|Experimental|MT10109L(Botulinum toxin type A)|
16412104|NCT03894748|Active Comparator|BOTOX® 50U(Botulinum toxin type A)|
16412105|NCT03894722|Placebo Comparator|Group I (control; saline only)|Control Group: Intraoperative irrigation with saline solution only.
16412106|NCT03894722|Experimental|Group II (0.5% concentration of PVP-I )|Experimental Group: Intraoperative irrigation with 0.5% concentration of PVP-I solution.
16412107|NCT03894722|Experimental|Group III (1% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 1% concentration of PVP-I solution.
16412204|NCT03893994|No Intervention|Control Group|No exercise will be applied
16412108|NCT03894722|Experimental|Group IV (3% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 3% concentration of PVP-I solution.
16412109|NCT03894709|Experimental|The family-centered care model|Interventions include a family-centered approach to interdisciplinary care and a family caregiving-training component to enhance family caregivers' competence in providing post-operative care and handling behavioral problems of adults with cognitive impairment. The interdisciplinary care model consists of geriatric consultation, continuous rehabilitation, and discharge planning. The family-centered approach involves family caregivers using a structured guide to assess the condition of the hip-fractured patient with cognitive impairment. Habits, daily routines, preferences, behavioral problems and environmental safety and stimuli are explored. The strengths, weakness, and resources of the family are assessed. The behavioral problems and symptoms to target are identified. Both the research nurse and the caregiver will then collaborate on a tentative plan to minimize the behavioral problems.
16412110|NCT03894709|No Intervention|Usual care|During hospitalization, patients receive health teaching for exercise while still in bed. Physical therapy usually starts only for those who received arthroplasty of hip replacement. Physical therapists train patients to use a walker and get in/out of bed through consultation. Usually, patients are discharged from the hospital without home assessment, nor are in-home programs provided for rehabilitation or nursing care. The usual care does not involve interdisciplinary care protocols, continuity of care, or specific care for hip-fractured patients with cognitive impairment.
16412111|NCT03894683|Experimental|Melatonin|Melatonin (10 mg tablets) by oral root, ingested at bedtime for 6 months
16412112|NCT03894683|Placebo Comparator|Placebo|Placebo tablets in the same shape as melatonin tablets, ingested the same as the melatonin tablets.
16412113|NCT03894670|Active Comparator|SmartBar™|The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
16412114|NCT03894670|Experimental|Standard mixed breakfast meal|The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
16412115|NCT03894644|Experimental|Group A: simulation training before instruments|Group A performed simulation training before the recognition of real surgical instruments.
16412116|NCT03894644|Active Comparator|Group B:instruments before simulation training|Group B performed the recognition of real surgical instruments without prior simulation training.
16412117|NCT03894631|Active Comparator|Phaco/KDB|Eyes needing glaucoma and cataract extraction will receive combined KDB and phacoemulsification in one eye of a patient
16412118|NCT03894631|Active Comparator|Phaco/Trabectome|Contralateral eyes needing glaucoma and cataract extraction will receive combined Trabectome and phacoemulsification in contralateral eye of the same patient
16412119|NCT03894618|Experimental|SL-279252|Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
16412120|NCT03894592|Active Comparator|Virtual Reality analgesia|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format
16412121|NCT03894592|No Intervention|Control|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention
16412122|NCT03894579|Experimental|SNK01|SNK01 infused weekly for 4 consecutive weeks
16412123|NCT03894553|Experimental|FUS Mesencephalotomy|Subjects will receive unilateral stereotactic focused ultrasound mesencephalotomy using the ExAblate Neuro device for severe, opioid-resistant pain associated with head and neck cancer.
16412124|NCT03894540|Experimental|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion
~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
16412125|NCT03894540|Experimental|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion
~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
16412126|NCT03894540|Experimental|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion
~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
16412127|NCT03894540|Experimental|IPN60090 food effect|"Part 1: Food Effect of IPN60090
~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
16412128|NCT03894527|Active Comparator|Control|"Subjects with simple obesity will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.
~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
16412129|NCT03894527|Active Comparator|Metabolic Syndrome|"Subjects with metabolic syndrome will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.
~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
16412130|NCT03894501|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
16412205|NCT03893981|Experimental|Proprioception and Balance Training|Proprioception and Balance Program
16412131|NCT03894501|Other|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
16412132|NCT03894475|Active Comparator|Sequence A|Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
16412133|NCT03894475|Active Comparator|Sequence B|Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
16412134|NCT03894462|Active Comparator|Zero Suicide Usual Care|"In Onondaga County, NYS aims to implement a countywide Zero Suicide Safety Net of providers who share enhanced protocols for clinical care, staff training, and data collection (improved EMR coding of suicidal behavior). Participating behavioral health systems have agreed to common protocols for clinical care, training, and data collection. Participating providers receive robust training in suicide prevention best practices. Because of the wide participation of mental health facilities in the NYS-OMH Zero Suicide project, most subjects who engage in outpatient treatment will receive that treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged."
16412135|NCT03894462|Experimental|Zero Suicide Usual Care + ASSIP|"Patients in this treatment arm will receive ASSIP brief therapy in addition to being able to access any usual care as recommended by their provider.
~ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan."
16412136|NCT03894449|Placebo Comparator|Placebo only|
16412137|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt FeSO4|
16412138|NCT03894449|Experimental|Prebiotic GOS & Iron Salt FeSO4|
16412139|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt NaFeEDTA|
16412140|NCT03894449|Experimental|Prebiotic GOS & Iron Salt NaFeEDTA|
16412141|NCT03894410||Continuing Lapatinib|Patients continued using treatment containing Lapatinib after progression on Lapatinib.
16412142|NCT03894410||Change HER-2 treatment|Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).
16412143|NCT03894410||Lapatinib plus capetabine|Patients used lapatinib plus capetabine.
16412144|NCT03894410||Lapatinib plus Trastuzumab and one chemotherapy|Patients used lapatinib plus trastuzumab and one chemo regimen.
16412145|NCT03894397|Experimental|Stimulation of left BNST|
16412146|NCT03894397|Experimental|Stimulation of right BNST|
16412147|NCT03894397|Experimental|Stimulation of bilateral BNST|
16412148|NCT03894397|Placebo Comparator|Stimulation OFF|
16412149|NCT03894384||Group:1|Gastric cancer patients
16412150|NCT03894384||Group:2|Patients with benign gastric diseases
16412151|NCT03894371|Other|Thermage|Subjects will undergo treatment with the Thermage FLX system using a 900 pulse, 4cm2 Total Tip to treat the face and neck and a 450 pulse, 0.25cm2 tip to treat the upper and lower eyelids.
16412152|NCT03894358|Active Comparator|FeFum and 7.5 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
16412153|NCT03894358|Active Comparator|FeFum and 3 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
16412154|NCT03894358|Active Comparator|FeFum and no prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate
16412155|NCT03894345|Experimental|Open-label treatment with Prazosin|"Week 1 Day 1-3: 0.5 mg at bedtime Day 4-7: 1.0 mg at bedtime Week 2 Day 8-10: 2.0 mg at bedtime Day 11-14: 4.0 mg at bedtime Week 3 2 mg in the morning, 4 mg at bedtime Week 4 4 mg in the morning, 4 mg at bedtime Week 5 4 mg in the morning, 6 mg at bedtime Week 6 4 mg in the morning, 8 mg at bedtime
~Dosage of Prazosin will be titrated at the discretion of the study physician."
16412156|NCT03894332||SBT Success|Patients took part of this cohort when succeeding the Spontaneous Breathing Trial (SBT).
16412157|NCT03894332||SBT Failure|"Patients took part of this cohort when failing the Spontaneous Breathing Trial (SBT).
~SBT Failure is defined by one or more of the following criteria occurring during the SBT:
~loss of ≥ 2 points of Glasgow Coma Scale
~respiratory rate/ tidal volume ≥105 breaths/min/L
~arterial partial pressure of oxygen ≤60 mmHg on inspired oxygen fraction (FiO2) ≥0.5 and/or pH <7.32 or a decrease in pH ≥0.07 units at the end of the SBT
~systolic Blood Pressure <90 mmHg or ≥180 mmHg or increased by ≥20%
~Heart Rate >140 beats/min or increased by 20%
~onset of major heart arrhythmias, or electrocardiographic signs of cardiac ischemia
~Respiratory Rate ≥35 breaths/min or increased by ≥50%
~increased effort, respiratory distress (as indicated by diaphoresis, accessory respiratory muscles recruitment, facial signs of distress and/or paradoxical breath)"
16412158|NCT03894332||Extubation Success|Patients took part of this cohort when, after extubation, did not need continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours.
16412159|NCT03894332||Extubation Failure|"Need for continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours from extubation, as defined by:
~Respiratory Rate >25 breaths/min for 2 hours
~Heart Rate >140 beats/min or sustained increase or decrease >20%
~clinical signs of respiratory muscle failure
~arterial partial pressure of oxygen (PaO2) <80 mmHg on inspired oxygen fraction (FiO2) ≥50%
~Arterial partial pressure of carbon dioxide >45 mmHg with pH <7.33"
16412160|NCT03894306||medication lock box + brief counseling|
16412161|NCT03894306||medication lock bag + brief counseling|
16412162|NCT03894306||brief counseling alone|
16412163|NCT03894293||ventilator group|It's a observational study. Participants entry the Respiratory Care Center and are evaluated. If the participant meet the inclusion criteria, the first assessments will be collected. After the weaning training, the second assessment will be collected before the the endotracheal tube is removed.
16412164|NCT03894280|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
16412165|NCT03894280|Active Comparator|Reference Product|SERETIDE DISKUS 250/50
16412166|NCT03894267|Experimental|Experimental Arm|"Self-adhesive silicone bordered foam dressing will be secured to the heels and sacrum.
~Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.
~Follow up 20 days"
16412167|NCT03894267|No Intervention|Control Arm|"Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.
~Follow up for 20 days."
16412168|NCT03894254|Experimental|Patients with subjective cognitive complaint or neurocognitive|: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study
16412169|NCT03894241|Experimental|Sedentary condition|
16412170|NCT03894241|Experimental|Moderate-intensity continuous training|
16412171|NCT03894241|Experimental|Cooperative-high-intensity interval training|
16412172|NCT03894228||Biologics exposed cohort|Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.
16412173|NCT03894228||Immunomodulators exposed cohort|Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.
16412174|NCT03894228||Non-exposed cohort|Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.
16412175|NCT03894215|Experimental|AGEN2034 + Placebo|AGEN2034 administered with placebo monotherapy: approximately 100 patients.
16412176|NCT03894215|Experimental|AGEN2034 + AGEN1884|AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.
16412177|NCT03894202||Ultra-early aneurysm treatment|Ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping within the initial twenty-four hours.
16412178|NCT03894202||Non-ultra-early aneurysm treatment|Non-ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping after the initial twenty-four hours.
16412179|NCT03894189|Active Comparator|doxapram group (GROUP D)|The patients in this group will receive loading dose of (1 mg/kg) followed by an infusion of (1mg/kg/h)
16412180|NCT03894189|Active Comparator|theophylline group (GROUP T)|the therapeutic loading dose (5mg/kg) followed by an infusion of (0.5 mg/kg/h)
16412181|NCT03894176||PTX3 concentration|First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
16412182|NCT03894150|Experimental|F0002-ADC|
16412183|NCT03894137|Experimental|Grains of Paradise|
16412184|NCT03894137|Placebo Comparator|Placebo|
16412185|NCT03894124|Other|Study intervention|Pifeltro® (doravirine 100mg) daily dose for 7 days
16412186|NCT03894111||living patients|living patients in intersivecare unit about 28 days
16412187|NCT03894111||deceased patients|deceased patients in intersivecare unit about 28 days
16412188|NCT03894098|Active Comparator|Single shot regional popliteal and saphenous block|Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery
16412189|NCT03894098|Experimental|High ankle block|High ankle block for acute pain control after elective ankle surgery
16412190|NCT03894085|Experimental|GAD group|"General anxiety disorder(GAD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine (20-40mg) treatment for 4 weeks"
16412191|NCT03894085|Experimental|PD group|"Panic disorder(PD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine (20-40mg)treatment for 4 weeks"
16412192|NCT03894085|Experimental|SAD group|"Social anxiety disorder(SAD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine (20-40mg)treatment for 4 weeks"
16412193|NCT03894085|Experimental|OCD group|"Obsessive-compulsive disorder (OCD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine(40-80mg) treatment for 4 weeks"
16412194|NCT03894085|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
16412195|NCT03894072|Active Comparator|HFHO-CPAP|This group will have HFHO before CPAP
16412196|NCT03894072|Active Comparator|CPAP-HFHO|This group will have CPAP and then HFHO
16412197|NCT03894059||Retrospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period preceding the implementation of the educational intervention for ambulance telecommunicators.
16412198|NCT03894059||Prospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period following the implementation of the educational intervention for ambulance telecommunicators.
16412199|NCT03894046|Experimental|Part A|
16412200|NCT03894046|Experimental|Part B|
16412201|NCT03894007|Experimental|A: Experimental|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide + atezolizumab. In total seven courses of preoperative treatment. Response evaluations after course four.
~Postoperatively, if pathologic complete response, patients receive 14 courses of adjuvant trastuzumab every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
16412202|NCT03894007|Active Comparator|B: Standard|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide. In total seven courses of preoperative treatment. Response evaluations after course four.
~Postoperatively, if pathologic complete response patients receive 14 courses of adjuvant trastuzumab (combined with pertuzumab in case of high-risk disease features) every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
16412209|NCT03893955|Experimental|Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors|Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.
16412210|NCT03893955|Experimental|Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
16412211|NCT03893955|Experimental|Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
16412212|NCT03893955|Experimental|Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
16412213|NCT03893955|Experimental|Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
16412214|NCT03893955|Experimental|Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
16412215|NCT03893955|Experimental|Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
16412216|NCT03893929||Chinese patients with clinical suspicious of prostate cancer|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
16412217|NCT03893916|Experimental|cohort|MEG - EEG HR
16412218|NCT03893903|Experimental|IDH1 peptide vaccine|IDH1R132H peptide vaccine alone
16412219|NCT03893903|Experimental|combination|IDH1R132H peptide vaccine and Avelumab
16412220|NCT03893903|Experimental|Avelumab|Avelumab alone
16412221|NCT03893890||No Treatment|Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
16412222|NCT03893877|Experimental|nasal cannula|device:nasal cannula will be applied to patients for oxygenation under deep sedation
16412223|NCT03893877|Active Comparator|nasal mask|device:nasal mask will be applied to patients for oxygenation under deep sedation
16412224|NCT03893864|Experimental|Intervention Group (CoQ10)|Runner athletes > 50 years old, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions
16412225|NCT03893864|Active Comparator|Control Group|Runner athletes > 50 years old with the same characteristics as the Experimental arm, served as control group, maintaining the training sessions Both groups were evaluated before and after the month of intervention or no intervention.
16412226|NCT03893851|Experimental|ICC-T|Interactions Competencies with Children - for Teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
16412227|NCT03893851|No Intervention|Control|The control schools do not receive any intervention
16412228|NCT03893838||Post refractive surgery without HOA|Patients post refractive surgery that do not complain on the high order aberrations such as glare, halo and starburst.
16412229|NCT03893838||Post refractive surgery with HOA|Patients post refractive surgery that do complain on the high order aberrations such as glare, halo and starburst.
16412230|NCT03893838||Post refractive surgery with rainbow HOA|"Patients post refractive surgery that do complain on:
~the high order aberrations such as glare, halo and starburst but with the chromatic aureola
~difficulties working with LCD projectors, monitors, cell phones and tablets"
16412233|NCT03893799|Other|Administer 240mg FeS/9mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 240 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and be followed for 28 days.
16412234|NCT03893799|Other|Administer 240mg FeS/27mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 240 mg Iron Sucrose and 27 mg of Stannous Protoporphyrin and be followed for 28 days.
16412235|NCT03893799|Other|Administer 240mg FeS/90mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 240 mg Iron Sucrose and 90 mg of Stannous Protoporphyrin and be followed for 28 days.
16412236|NCT03893799|Other|Administer 240mgFeS/27mgSnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 240 mg Iron Sucrose and 27 mg of Stannous Protoporphyrin and be followed for 28 days.
16412237|NCT03893799|Other|Administer 240 FeS/90mg SnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 240 mg Iron Sucrose and 90mg of Stannous Protoporphyrin and be followed for 28 days.
16412238|NCT03893799|Other|Administer 240mgFeS/27mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 240 mg Iron Sucrose and 27 mg of Stannous Protoporphyrin and be followed for 28 days.
16412239|NCT03893799|Other|Administer 240mgFeS/90mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 240 mg Iron Sucrose and 90mg of Stannous Protoporphyrin and be followed for 28 days.
16412240|NCT03893786|Experimental|Robotic Treatment|"Fifteen patients with Parkinson's Disease will perform ten 45-minutes training sessions of the upper limb using the Armeo®Spring applied bilaterally, an electromedical device aimed at improving force and coordination in neurologically affected patients.
~The device was built to sustain the forearm during the upper limb training and it is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
16412241|NCT03893786|Active Comparator|Conventional Treatment|Fifteen patients with Parkinson's Disease will undergo ten 45-minutes training sessions of the upper limb with a traditional approach, performing the same excercises of the experimental group, i.e. flexo-extension of the wrist, prono-supination of the forearm, etcc.
16412242|NCT03893760||No Pulonary Hypertension|the presence of mean pulmonary pressures (PAPm) at the right heart catheterization < 25 mmHg
16412244|NCT03893760||combined postcapillary/precapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg, PAWP >15 mmHg and diastolic peak gradient (DPG - diastolic pulmonary pressure - PCWP) ≥7 mmHg and/or pulmonary vascular resistence (PVR) >3 WU, where available.
16412245|NCT03893747|Experimental|the first batch vaccine producted by 40 L reactor|500 subjects will be randomly received the first batch vaccine producted by 40 L reactor
16412246|NCT03893747|Experimental|the second batch vaccine producted by 40 L reactor|500 subjects will be randomly received the second batch vaccine producted by 40 L reactor
16412247|NCT03893747|Experimental|the third batch vaccine producted by 40 L reactor|500 subjects will be randomly received the third batch vaccine producted by 40 L reactor
16412248|NCT03893747|Experimental|the first batch vaccine producted by 150 L reactor|500 subjects will be randomly received the first batch vaccine producted by 150 L reactor
16412249|NCT03893747|Experimental|the second batch vaccine producted by 150 L reactor|500 subjects will be randomly received the second batch vaccine producted by 150 L reactor
16412250|NCT03893747|Experimental|the third batch vaccine proudected by 150 L reactor|500 subjects will be randomly received the third batch vaccine producted by 150 L reactor
16412251|NCT03893734|Active Comparator|methadone group|Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
16412252|NCT03893734|Placebo Comparator|hydromorphone group|Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
16412253|NCT03893721||malnourished under five children|children from 2 to 5 years with malnutrition
16412254|NCT03893721||well nourished under five children|children from 2 to 5 years without malnutrition
16412255|NCT03893708|Experimental|Prenatal yoga|Each class will be outlined as follows: 1) opening greeting/intention setting, 2) pranayama (i.e., breathing exercises), 3) warm-up/sun salutations (i.e., flowing sequence), 4) yoga sequence (e.g., combination of sun salutations, vinyasa, and standing, seated, and/or balancing poses), 5) cool-down 6) Savasana (i.e., final resting pose), and 7) class closing. Meditation and breath awareness (e.g., linking each movement with breath) will be emphasized throughout each class. All classes will focus on safety and alignment and be appropriate for women during pregnancy by incorporating modifications to poses/exercises as necessary (e.g., yoga block, strap). Certified yoga instructors with a bachelors degree in a health related field and experience teaching pregnant women will instruct all yoga classes. Participants will be provided with a 'yoga during pregnancy' safety packet that includes a list of prenatal yoga poses that women may do at their own leisure at home.
16412256|NCT03893708|Active Comparator|Pregnancy education|Participants will be asked to attend a group-based pregnancy education group (similar to a birth education class). The class format will include a didactic portion followed by group discussion (N=12). The following evidence-based topics (based on the American College of Obstetrics and Gynecologists) to be discussed may include (but not limited to): financial management in preparation for baby, preparing for labor and delivery, transitioning into motherhood, sleep hygiene, and baby bonding. A labor and delivery nurse and certified Dula will instruct all classes.
16412257|NCT03893695|Experimental|metastatic HCC|"Stage one - Dose de-escalation:
~Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001.
~Stage two- the expansion cohort:
~14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort."
16412258|NCT03893682|Experimental|Dose Escalation and Expansion|CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
16412259|NCT03893669|Experimental|Group 1|NBP607 0.5ml
16412260|NCT03893669|Active Comparator|Group 2|Agrippal 0.5ml
16412261|NCT03893643||pediatric population|Pediatric population aged 0 to 15 years with neurofibromatosis type 2
16412262|NCT03893630|Active Comparator|Control Group|Patients will receive standard of care.
16412263|NCT03893630|Experimental|Acetylsalicylic Acid 81mg|Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin).
16412264|NCT03893630|Experimental|Acetylsalicylic Acid 162mg|Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).
16412265|NCT03893617|Active Comparator|Propranolol group|This group will receive a single oral dose (80mg) of propranolol in a blinded capsule during their acute stress study visit.
16412266|NCT03893617|Placebo Comparator|Placebo group|This group will receive a single blinded capsule containing no active medication during their acute stress study visit.
16412267|NCT03893604|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
16412268|NCT03893604|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
16412269|NCT03893591||Body mass index below 35|
16412270|NCT03893591||Body mass index 35 and above|
16412271|NCT03893578|Experimental|Interventional Arm|Access, delivery, and retrieval of the Conveyor system with correct positioning of the valve delivery system to facilitate correct positioning of the implant at the mitral location in patients with a failing bioprosthetic valve.
16412272|NCT03893565|Experimental|GSK2831781-Double blind phase|Eligible participants will receive GSK2831781 intravenously in the double blind induction phase at different dose levels. Participants identified as Responders at Week 10 will then receive GSK2831781 subcutaneously during the double-blind ETP from Week 14 until Week 26
16412273|NCT03893565|Experimental|GSK2831781- Open label phase|Eligible participants will receive GSK2831781 intravenously in the open label induction phase. Participants identified as Non-Responders at Week 10 will receive GSK2831781 from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
16412274|NCT03893565|Placebo Comparator|Placebo matching GSK2831781- Double blind phase|Eligible participants will receive Placebo in the double blind induction phase Participants identified as Responders at Week 10 will continue to receive Placebo subcutaneously during the double-blind ETP from Week 14 until Week 26.
16412275|NCT03893552|Experimental|Patient with sleep disordered breathing symptoms|Patients referring to the clinic of sleep disorders will be asked to participate in this study. A negative expiratory pressure will be applied via a cough-assist attached to a facial mask.
16463494|NCT03542253||micorRNA-R in Plasma exocrine|
16412276|NCT03893539|Other|Robotic Bronchoscopy|The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.
16412277|NCT03893526|Placebo Comparator|Placebo|Participants are subjected to a standardized meal
16412278|NCT03893526|Active Comparator|Entrestro|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
16412279|NCT03893526|Active Comparator|Sitagliptin|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
16412280|NCT03893526|Active Comparator|Entrestro + sitagliptin|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
16412281|NCT03893526|Active Comparator|Valsartan|206mg valsartan as one single dose followed by a standardized meal
16412282|NCT03893500|Experimental|Initiating a new PAH medication|Participants will start a new PAH medication
16412283|NCT03893500|Active Comparator|Continuing previous PAH medication regimen|Participants will continue the medication regimen that they were on prior to enrollment
16412284|NCT03893487|Experimental|Treatment (fimepinostat, tumor resection)|"Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.
~MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor."
16412285|NCT03893474|Other|Control Arm|All investigations are the same in both arms, but patients within this arm will be seen in the hospital as per standard practice.
16412286|NCT03893474|Other|Study Arm|All investigations are the same in both arms, but patients within this arm will be seen in a community optometrist practice.
16412287|NCT03893448|Experimental|V114|Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
16412288|NCT03893448|Active Comparator|Prevnar 13™|Participants receive 4 total 0.5 mL IM vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
16412289|NCT03893435|Experimental|Sacubitril/Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
16412290|NCT03893435|Active Comparator|Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Valsartan with an initial dose of 40 mg PO BID, with subsequent titrations to target maintenance dose of 160 mg BID as tolerated.
16412291|NCT03893422|Experimental|WB-010|3 capsules administered twice daily with morning and evening meal for 12 weeks
16412292|NCT03893422|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 12 weeks
16412293|NCT03893422|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 12 weeks
16412294|NCT03893409||pulmonary function|
16412295|NCT03893409||biological sample detection outcome|
16412298|NCT03893357||Positive for antiphospholipid antibodies|Patients tested positive for antiphospholipid antibodies
16412299|NCT03893357||Negative for antiphospholipid antibodies|Patients tested negative for antiphospholipid antibodies
16412300|NCT03893344||Cases|patients with Multiple Sclerosis in different stages diagnosed clinically according to revised McDonald's criteria 2010
16412301|NCT03893344||Control|Healthy peaple
16412302|NCT03893318|Experimental|Study Group|will receive intravenous lidocaine during and after posterior spinal fusion for AIS
16412303|NCT03893318|Placebo Comparator|Control Group|will receive saline placebo during and after surgery.
16412304|NCT03893292||Preoperative cooled radiofrequency ablation|Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
16412305|NCT03893253|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
16412306|NCT03893253|Active Comparator|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
16412307|NCT03893253|No Intervention|Control group|The control group will receive no booster teaching at all.
16412308|NCT03893240|Other|Participants with Late Onset Pompe disease|This is a multi-center, low-interventional study with a retrospective component in participants with LOPD. During a single study visit, assessments including but not limited to, liver health, neutralizing antibodies to SPK-3006 capsid and GAA, anti-GAA binding antibodies, GAA activity and GAA antigen levels will be performed. Additional information will be collected to provide retrospective evaluations relating to muscle and liver inflammation and/or injury. Historic data relating to Pompe disease will be collected from medical records. The retrospective and laboratory data collected may assist in providing baseline information for a future investigational gene therapy study.
16412309|NCT03893227||Patients|Patients with chronic upper airway inflammation
16412310|NCT03893227||Healthy control|Healthy controls without chronic upper airway inflammation
16412311|NCT03893214|Experimental|intervention group|Virtual reality exposure for acrophobia - this arm receives the virtual reality exposure intervention in the initial phase and has a four-week follow-up assessment.
16412417|NCT03892564|Experimental|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
16463495|NCT03542253||Surgery|
16412312|NCT03893214|Placebo Comparator|waitlist control group|This arm watches a movie in the initial phase in order to control for effects of behavioral approach test that is done before and after the intervention and for time effects. In the second phase after four weeks, this arm receives the virtual reality exposure after collection of outcome measures.
16412313|NCT03893201||Venaseal|Patients that have undergone venaseal
16412314|NCT03893188||People asking for PrEP|All individuals aged >18 years asking for PrEP prescription at one of the participating centers will be asked to participate to the SwissPrEPared Study(consecutive ongoing recruitment). Only HIV negative individuals will be deemed eligible.
16412315|NCT03893175|Experimental|Ibuprofen|"During the double-blind stage, subjects will receive blinded ibuprofen (400 mg by mouth) when pain is at least 4/10 following third molar extraction.
~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.
~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
16412316|NCT03893175|Placebo Comparator|Placebo|"During the double-blind stage, subjects will receive blinded placebo when pain is at least 4/10 following third molar extraction.
~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.
~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
16412317|NCT03893162|Experimental|"Multi-strain probiotic BioKult"|4 capsules daily for 8 weeks
16412318|NCT03893162|Placebo Comparator|Placebo|4 capsules daily for 8 weeks
16412319|NCT03893149|Experimental|Active-Start intervention|Supervised exercise training
16412320|NCT03893149|No Intervention|Control group|No-exercise
16412321|NCT03893136||Control group|The control group mainly consists of healthy volunteers. The whole blood is obtained and frozen to detect the corresponding biochemical markers in the futures. The vascular tissues are obtained from the deserted and free abdominal aorta conjugated to the renal artery in the kidney transplantation.
16412322|NCT03893136||sham TA group|In the TA cohort, patients are divided into two groups mainly, sham TA group and scramble TA group. The sham TA group is the TA group who is given the traditional and classical intervention or treatment and so on.
16412323|NCT03893136||scramble TA group|Compared to sham TA group in the cohort, scramble TA group refers to TA patients who are given novel drugs or new drugs which are safe to treat other autoimmune diseases but have not been used to treat TA yet, or some new interventions and so on.
16412324|NCT03893123||Firefighters|
16412325|NCT03893110|Experimental|Instrumentation with Carbon/PEEK pedicle screw system|Posterior instrumentation using a Carbon/PEEK pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
16412326|NCT03893110|Active Comparator|Instrumentation with titanium pedicle screw system|Posterior instrumentation using a titanium pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
16412327|NCT03893097|Active Comparator|Praziquantel|Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
16412328|NCT03893097|Experimental|Artesunate-Mefloquine|Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.
16412329|NCT03893084|Experimental|Intervention|Preconception guidance prepared by reference to the guidelines published in the literature, women were given pre-pregnancy training.
16412330|NCT03893084|No Intervention|Control|The women in the control group were not given training, and routine practice was performed.
16412331|NCT03893071|Experimental|Hydroxypropyl-β-cyclodextrin IV|Hydroxypropyl-β-cyclodextrin will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
16412332|NCT03893045|Experimental|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
16412333|NCT03893045|Active Comparator|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL)
16412334|NCT03893032|Experimental|Modafinil 200mg|single, 200 mg dose of modafinil
16412335|NCT03893032|Experimental|mixed amphetamine salts|single 10 mg dose of mixed amphetamine salts
16412336|NCT03893032|Placebo Comparator|placebo|placebo
16412337|NCT03893019|Experimental|Dose Level 1: 1x10e5 MB-CART20.1 cells|3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously
16412338|NCT03893019|Experimental|Dose Level 2: 1x10e6 MB-CART20.1 cells|3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously
16412339|NCT03893019|Experimental|Dose Level 3: 1x10e7 MB-CART20.1 cells|3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously
16412340|NCT03893006|Experimental|UnAssisted (UA)|This term refers to driving a vehicle manually without any vehicle automation technology. It will serve as a baseline concerning behaviors, representations and neural results associated with unassisted automobile driving.
16412341|NCT03893006|Experimental|Assisted (A)|This term refers to driving with warning technology which upon activation sounds an a warning when the vehicle is too close to the edge of the road (off-road warning , Navarro, Mars, & Hoc, 2007; Suzuki & Jansson, 2003) or too close to the vehicle in front of it (anti-collision warning; Lee, McGehee, Brown, & Reyes, 2002).
16412342|NCT03893006|Experimental|Shared Control (SC)|This term refers to shared tactical control between the driver and the automated assistive technology, both working simultaneously on the physical trajectory of the vehicle, laterally (Griffiths & Gillespie, 2005; Mulder, Abbink, & Boer, 2012) as well as longitudinal (Adell, Várhelyi, & Hjälmdahl, 2008).
16412557|NCT03891615|Experimental|Niraparib + Osimertinib|"Niraparib will be administered orally once daily
~Osimertinib will be administered by mouth once daily"
16412343|NCT03893006|Experimental|Partly Autonomous (PA)|"This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name Highly Automated Driving (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology."
16412344|NCT03893006|Experimental|Fully Autonomous (FA)|This term refers to a completely automated driving experience. The on-board technologies take over all the driving tasks for any driving situation.
16412345|NCT03893006|Experimental|Any Automation (AA)|This term refers to a situation where the drivers can choose the automation device of their choice among the five types presented above and can change it whenever they think it is good to do so.
16412346|NCT03892993|Experimental|Supportive care (decision aid)|Participants use decision aid and complete questionnaires.
16412347|NCT03892980|Experimental|Nipple Sparing Mastectomy|
16412348|NCT03892967|Experimental|E2C2 Collaborative Care|A guideline-informed intervention that combines low touch automated provision of symptom self-management education, coupled with EHR clinical decision support, for moderate symptoms with conventional, high-touch, collaborative care provided by a nurse-physician team for more intense symptoms. Additionally, the E2C2 intervention will increase the frequency of symptom and function screening. Prior to E2C2 intervention initiation, patients will only be assessed in association with a physician or allied health provider encounter. They will not be assessed when seen for nurse-only visits, or for systemic treatments. Following E2C2 intervention activation, they will be assessed every other week which will require remote, portal-based assessment for patients who lack clinic appointments.
16412349|NCT03892954||adolescents with CFS ( n= 100)|Participants with CFS who had constant or persisting fatigue lasting 3 months with the severe functional disability to such extent that prevents normal school attendance and also had no drug prescriptions (including hormone contraceptives), any medical or psychiatric disorder that might explain the fatigue were included in this study
16412350|NCT03892954||health control ( n=50).|healthy control subjects with no CFS
16412351|NCT03892941|Experimental|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
16412352|NCT03892941|No Intervention|Clinical routine|Mapping of the electrical input of the cochlear implant will be based on a one-size-fits-all, as is part of clinical routine.
16412353|NCT03892928|Placebo Comparator|Propofol group|2-5 mg/kg.h propofol during the whole colonoscopy
16412354|NCT03892928|Other|Dexmedetomidine group|0.1mcg/kg continuous infusion for 15min, 0.7-1mcg/kg.h during the whole colonoscopy
16412355|NCT03892915|Experimental|Depression Care|Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.
16412356|NCT03892915|No Intervention|Usual care|Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).
16412357|NCT03892902|Experimental|Treatment A (50 mg ACT-541468)|1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.
16412358|NCT03892902|Experimental|Treatment B (100 mg ACT-541468)|2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.
16412359|NCT03892902|Experimental|Treatment C (7.5 mg zopiclone)|2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).
16412360|NCT03892902|Experimental|Treatment D (placebo)|2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.
16412361|NCT03892889|Experimental|Abilify MyCite®|Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.
16412362|NCT03892876|Experimental|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
16412363|NCT03892876|Sham Comparator|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
16412364|NCT03892876|Experimental|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
16412365|NCT03892876|Sham Comparator|Control TS-ve|Healthy controls who receive sham comparator
16412366|NCT03892863|Active Comparator|active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
16412367|NCT03892863|Sham Comparator|sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
16412368|NCT03892850|Experimental|nurse prescription|experimental group receiving pharmacological nurse prescription
16412369|NCT03892850|Active Comparator|medical prescription|control group receiving medical prescription
16412370|NCT03892837|Active Comparator|Control group|Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
16412418|NCT03892564|Experimental|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
16412616|NCT03891199|No Intervention|Control|Traditional THA.
16412371|NCT03892837|Experimental|PRP group|Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis. Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
16412372|NCT03892824|Experimental|Vine™ Filter + OAC|Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
16412373|NCT03892811||Infants referred for swallow study|"This is a within-subjects intervention study where each infant in the study will receive all three conditions.
~The three study conditions are bottle-feeding with 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple."
16412374|NCT03892785|Experimental|Tocilizumab group|
16412375|NCT03892785|Active Comparator|Methotrexate group|
16412376|NCT03892772|Experimental|SAS0421a, SAS0421b and SAS0421c|Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.
16412377|NCT03892772|Active Comparator|SAS0421a and SAS0421b|Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
16412378|NCT03892772|Active Comparator|SAS0421c|Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
16412379|NCT03892772|Placebo Comparator|Placebo|Participants will take placebos for 3 days.
16412380|NCT03892759|Other|Evaluation and Treatment|Subjects will be evaluated through inspection and palpation of the thoracic and lumbar spine, and other body regions as necessary. The provider will make a diagnosis of somatic dysfunction based off the TART (tissue texture change, asymmetry, restriction of motion, tenderness/pain) findings.
16412381|NCT03892746|Active Comparator|Active tDCS + task oriented practice|
16412382|NCT03892746|Sham Comparator|Sham tDCS + task oriented practice|
16412383|NCT03892733|Experimental|Intervention|CHEKS (calorie health, education, knowledge and skills) intervention will educate participants about calories in fast-food and teach skills to select lower calorie fast-food items.
16412384|NCT03892733|No Intervention|Control|Participants will receive a brochure about healthier choices in fast-food restaurants.
16412385|NCT03892720|Experimental|Treatment (SBRT)|Patients undergo stereotactic body radiation therapy with either standard radiation treatment software or HyperArc software technology for 2-3 fractions per week over a 2-week period for 5 fractions.
16412386|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
16412387|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
16412388|NCT03892694|Active Comparator|Treatment|MCS
16412389|NCT03892694|Sham Comparator|Sham Control|Sham
16412390|NCT03892681|Other|contrast agents for liver MRI|
16412391|NCT03892668|Experimental|tranexamic acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
16412392|NCT03892668|Active Comparator|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
16412393|NCT03892668|Placebo Comparator|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
16412394|NCT03892642|Experimental|BCG + Avelumab|Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
16412395|NCT03892629|Experimental|Baduanjin exercise group|Participants in this group received Baduanjin exercise
16412396|NCT03892629|Active Comparator|Instrument rehabilitation group|Participants in this group received rehabilitation by using tri-ball respiratory trainer
16412397|NCT03892629|Active Comparator|Baduanjin Exercise and Instrument Rehabilitation|Participants in this group received both instrument rehabilitation and Baduanjin exercise
16412398|NCT03892629|No Intervention|No Intervention|Participants in this group only received routine drug-treatment
16412399|NCT03892616|Experimental|A - B - C|
16412400|NCT03892616|Experimental|D - A - B|
16412401|NCT03892616|Experimental|E - B - A|
16412402|NCT03892616|Experimental|C - A - D|
16412403|NCT03892616|Experimental|A - E - C|
16412404|NCT03892616|Experimental|E - D - A|
16412405|NCT03892616|Experimental|B - C - D|
16412406|NCT03892616|Experimental|C - E - B|
16412407|NCT03892616|Experimental|B - D - E|
16412408|NCT03892616|Experimental|D - C - E|
16412409|NCT03892616|Experimental|C - B - A|
16412410|NCT03892616|Experimental|A - E - D|
16412411|NCT03892603|Experimental|Strengthening exercises program|
16412412|NCT03892603|Experimental|Motor control exercises program|
16412413|NCT03892603|Active Comparator|Education and advice|
16412414|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
16412415|NCT03892577||Patients with advanced hepatobiliary tumors|"2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program:
~Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject;
~Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc;
~Immunotherapy or immunotherapy combined with targeted therapy."
16412416|NCT03892564|Experimental|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
16412518|NCT03891901|Experimental|Cohort 1d: Imatinib (400 mg) + Rifabutin + Isoniazid|Participants will receive 400 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
16412419|NCT03892564|Experimental|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
16412420|NCT03892564|Experimental|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
16412421|NCT03892551||patients admitted to emergency ward|all patients admitted to the emergency ward and awaiting triage are observed
16412422|NCT03892525|Experimental|treatment|
16412423|NCT03892512|Active Comparator|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
16412424|NCT03892512|Active Comparator|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
16412425|NCT03892499|Experimental|Healthy Volunteers|Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.
16412426|NCT03892486|Experimental|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
16412427|NCT03892486|No Intervention|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
16412428|NCT03892473|Experimental|Flexible Assertive Community Treatment (FACT)|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
16412429|NCT03892473|Active Comparator|Care as usual (CAU)|Active Comparator: CAU (Care as usual) Patients with SMI receiving usual care, meaning mostly medical treatment
16412430|NCT03892460|Experimental|Treatment|Neuromuscular electrical stimulation
16412431|NCT03892460|No Intervention|Control|No treatment control
16412432|NCT03892447|Experimental|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
16412433|NCT03892447|Active Comparator|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
16412434|NCT03892434|Active Comparator|Bevacizumab|
16412435|NCT03892434|Active Comparator|Dexamethasone|
16412436|NCT03892421|Experimental|Modified DHAP|Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.
16412437|NCT03892408|Experimental|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
16412438|NCT03892408|No Intervention|Standard|standard anesthesia
16412439|NCT03892395|Active Comparator|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:
~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
16412440|NCT03892395|Placebo Comparator|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:
~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
16412441|NCT03892382|Active Comparator|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
16412442|NCT03892382|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
16412443|NCT03892369|Experimental|Alcohol|The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours.
16412444|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
16412445|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
16412446|NCT03892343||Transplant recipients|Patients undergoing live donor kidney transplant.
16412447|NCT03892343||Non-transplanted|Patients on the deceased donor waiting list without prospect of a live donor transplant.
16412448|NCT03892330|Experimental|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
16412449|NCT03892330|Active Comparator|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
16412450|NCT03892330|Active Comparator|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
16412451|NCT03892330|Active Comparator|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
16412452|NCT03892317|Other|Medication adherence interventions|Pharmacist led medication adherence interventions which will be tailored to individual patient need
16412453|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
16412454|NCT03892291||Civilian mTBI|Civilians with persistent symptoms from mTBI
16412455|NCT03892291||Civilian Control|Civilian healthy controls
16412456|NCT03892291||Active Duty Control|Active duty service member healthy controls
16412457|NCT03892291||Active Duty mTBI|Active duty service members with persistent symptoms from mTBI who are referred for physical therapy due to their symptoms
16412519|NCT03891901|Experimental|Cohort 2a: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
16412520|NCT03891901|Experimental|Cohort 2b: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
16412458|NCT03892278|Experimental|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
16412459|NCT03892278|Experimental|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
16412460|NCT03892278|Active Comparator|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
16412461|NCT03892252||before surgery|no intervention(s)
16412462|NCT03892252||after surgery|no intervention(s)
16412463|NCT03892252||Normal colonoscopy|People who were diagnosed by colonoscopy without colorectal cancer.
16412464|NCT03892239|Experimental|Intervention|Monitoring and suggestion of training progress. Behaviour change strategy based on increasing knowledge.
16412465|NCT03892239|Active Comparator|Control|Monitoring and suggestion of training progress.
16412466|NCT03892226||1, no myocardial injury|normal troponin level (hs-troponin T ≤ 99. percentile, i.e. 14ng/ml)
16412467|NCT03892226||2, chronic myocardial injury|elevated, but stable troponin level; (hs-troponin T> 99. percentile and rise/fall ≤ 20% in the control)
16412468|NCT03892226||3, acute myocardial injury|dynamic troponin elevation; (hs-troponin T> 99. percentile and rise/fall >20% in the control)
16412469|NCT03892213|Other|Benznidazole and E1224|Benznidazole and E1224
16412470|NCT03892200|Experimental|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
16412471|NCT03892200|No Intervention|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
16412472|NCT03892187|Experimental|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
16412473|NCT03892187|No Intervention|Control Group|Participants receive usual care prior to surgery. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
16412474|NCT03892187|No Intervention|Observation Group|Participants who are not frail will receive usual care prior to surgery and charts will be reviewed for outcomes following surgery.
16412475|NCT03892174|No Intervention|Treatment protocol without adsorption|
16412476|NCT03892174|Active Comparator|Treatment protocol with adsorption|
16412477|NCT03892161|Experimental|Standard dose DRV/r|Standard dose DRV/r 800/100mg without Rifampicin
16412478|NCT03892161|Experimental|Standard DRV/r with Rifampicin|Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
16412479|NCT03892161|Experimental|Boosed ritonavir 200mg|Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
16412480|NCT03892161|Experimental|Double dose DRV/r 1600/200mg QD|Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
16412481|NCT03892161|Experimental|Double dose DRV/r 800/100mg BD|Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
16412482|NCT03892148|Active Comparator|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
16412483|NCT03892148|Experimental|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
16412484|NCT03892135||Physicians|3 paediatricians and 3 rheumatologists
16412485|NCT03892135||Parents|Parents
16412486|NCT03892135||Children|Children
16412521|NCT03891888|No Intervention|Control|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
16412522|NCT03891888|Experimental|Intervention|Patients in this group will receive a bone graft in addition to the undergoing standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
16463496|NCT03542240|Experimental|Curcumin|
16412487|NCT03892122|Other|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient
~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
16412488|NCT03892122|Other|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
16412489|NCT03892109|Active Comparator|Gingitrac|The gingitrac cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the selected abutment. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
16412490|NCT03892109|Active Comparator|traxodent|The traxodent cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the tooth. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
16412491|NCT03892109|Experimental|Ultrapk cord|the cord packed into the gingival sulcus around the tooth
16412492|NCT03892109|Placebo Comparator|nocord|used directly in the tray
16412493|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
16412494|NCT03892083|Active Comparator|Anodal tDCS (M1)|tDCS applied over primary motor cortex. Dose: 1mA, 20 minutes
16412495|NCT03892083|Experimental|Anodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
16412496|NCT03892083|Experimental|Cathodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
16412497|NCT03892083|Sham Comparator|Sham tDCS|tDCS applied over the cerebellum Dose: 1mA, 20 minutes (30s ON)
16412498|NCT03892070|Experimental|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
16412499|NCT03892070|Placebo Comparator|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
16412500|NCT03892057|Experimental|Internet-based Positive Psychological Intervention|The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
16412501|NCT03892057|No Intervention|Attention Control Group|Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
16412502|NCT03892044|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16412503|NCT03892018|Active Comparator|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.
~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.
~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
16412504|NCT03892018|Active Comparator|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.
~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.
~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
16412505|NCT03892005||MOTIVATION HIP Total Hip System|All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MOTIVATION HIPTM Total Hip System in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.
16412506|NCT03891979|Experimental|Pembrolizumab + Antibiotics|Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.
16412507|NCT03891966|Active Comparator|Splint|
16412508|NCT03891966|Active Comparator|Soft Dressing|
16412509|NCT03891953|Experimental|DKY709|DKY709 monotherapy
16412510|NCT03891953|Experimental|DKY709 + PDR001|Combination therapy with DKY709 and PDR001
16412511|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia
~Aged from 20-80 years old"
16412512|NCT03891927|Experimental|olive group|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO ( high polypheol Extra virgin olive oil)
16412513|NCT03891927|No Intervention|non olive group|No intervention
16412514|NCT03891914|Experimental|Symptomatic Multiple Myeloma on first-line treatment|
16412515|NCT03891901|Experimental|Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid|Participants will receive 50 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
16412516|NCT03891901|Experimental|Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid|Participants will receive 100 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
16412517|NCT03891901|Experimental|Cohort 1c: Imatinib (200 mg) + Rifabutin + Isoniazid|Participants will receive 200 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
16463719|NCT03540654||Patients with CML discontinuing TKI treatment|
16412523|NCT03891875|Experimental|Elamipretide|40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
16412524|NCT03891875|Placebo Comparator|Placebo|subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
16412525|NCT03891862|Experimental|Open-label Valbenazine|Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
16412526|NCT03891862|Placebo Comparator|Placebo-controlled Placebo|Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
16412527|NCT03891862|Experimental|Placebo-controlled Valbenazine|Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
16412528|NCT03891849|Experimental|octreotide (25 µg/hour) perfusion|octreotide (25 µg/hour) plus norepinephrine will be administered for patient with haemorrhagic shock after variceal bleeding during 2 to 5 days according recommendations and regular protocol in the medical unit
16412529|NCT03891836||medical students|All students from the chosen classes in each study year will be invited to complete self-administered questionnaire
16412530|NCT03891823|Experimental|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.
~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
16412531|NCT03891823|Active Comparator|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.
~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
16412532|NCT03891810|Experimental|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
16412533|NCT03891810|No Intervention|Control|This group was a wait list control group who received the treatment following the intervention period.
16412534|NCT03891797|Experimental|Cognitive Processing Therapy|12 sessions of group-based Cognitive Processing Therapy administered 1x/week for 90 minutes each session.
16412535|NCT03891797|No Intervention|Control|No treatment/treatment as usual. Participants will complete questionnaires at three time points with no intervention.
16412536|NCT03891784|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16412537|NCT03891771|No Intervention|Usual Care|Patients allocated to usual care will receive standard follow-up procedures at their primary care facility.
16412538|NCT03891771|Experimental|Telemonitoring sensors|Patients allocated to this arm will receive a complex sensor platform aimed at detecting falls at home, nocturia and several environmental variables, including carbon monoxide concentrations, humidity and temperature. The system also includes a panic button that can be used to request assistance in emergencies.
16412539|NCT03891758|Experimental|BK1310|
16412540|NCT03891758|Active Comparator|ActHIB® and Tetrabik|
16412541|NCT03891745||prone group|prone extubation
16412542|NCT03891745||supine group|supine extubation
16412543|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
16412544|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
16412545|NCT03891719|Experimental|Changes in nose symmetry|- Direct anthropometric assessment (frontal, oblique, lateral and basal views) and three- dimensional observations of the nose preoperatively and postoperatively in order to evaluate the nostril symmetry, the angles, ratios of the nose and its relation to the face.
16412547|NCT03891693|Experimental|Passeo-18 Lux and SUPERA® stent|Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty
16412548|NCT03891680|Experimental|Botox injection|
16412549|NCT03891680|Active Comparator|Genicular Radio frequency|
16412550|NCT03891667|Experimental|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
16412551|NCT03891667|Active Comparator|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg during week 3, and 500 mg daily during week 4. Placebo capsules are given during weeks 5-8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
16412552|NCT03891654|Experimental|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
16412553|NCT03891641|Experimental|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
16412554|NCT03891641|No Intervention|Control Group|Control Subjects continue their normal daily activities.
16412555|NCT03891628|Experimental|Modified ABC|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
16412556|NCT03891628|Active Comparator|Modified DEF|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
16412558|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
16412559|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
16412560|NCT03891589|Experimental|Optimized CF with Taburia|The intervention groups consisted of promotion of optimized complementary feeding with home fortification (taburia) one sachet per week
16412561|NCT03891589|Experimental|Optimized CF only|The intervention groups consisted of promotion of optimized complementary feeding without home fortification (taburia)
16412562|NCT03891589|Experimental|Taburia|The intervention groups consisted of provision taburia home fortification three sachet per week
16412563|NCT03891589|No Intervention|Control|No intervention but gave a standard education from primary health center
16412564|NCT03891576|Experimental|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
16412565|NCT03891576|Active Comparator|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
16412566|NCT03891576|Other|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
16412567|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:
~Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)
~Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)
~Involving prepubertal (seventh grade or roughly age 12 years) children.
~AND
~Activity Tracker Criteria:
~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking
~- Meets these criteria within either one or both years of follow-up"
16412568|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:
~Participation in more than 1 sport at any physical activity level OR
~Participation in none or low training and/or competition in organized sports for any period of time.
~Involving prepubertal children.
~AND
~Activity Tracker Criteria:
~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking
~- Meets these criteria during both years of follow-up"
16412569|NCT03891550|Experimental|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
16412570|NCT03891524|Experimental|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
16412571|NCT03891524|Experimental|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
16412572|NCT03891524|Experimental|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
16412573|NCT03891524|Experimental|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID orally for 10 to 14 postoperative days.
16412574|NCT03891524|Experimental|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
16412575|NCT03891524|Experimental|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
16412576|NCT03891524|Experimental|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
16412577|NCT03891524|Active Comparator|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
16412578|NCT03891498|Experimental|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
16412579|NCT03891472|Experimental|Arm 1|
16412580|NCT03891459|Experimental|spray+ group|"In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as oxytocin). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks."
16412581|NCT03891459|Placebo Comparator|control group|"In control condition, the materials and procedure were same with the spray+ condition except the nasal spray was told as saline instead. Oxytocin materials used in current experiments were adopted from previous study"
16412582|NCT03891446|Experimental|Bimatoprost SR 10mcg; Lead-in study 192024-093|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
16412583|NCT03891446|Experimental|Bimatoprost SR 15mcg; Lead-in studies 192024-093/-095|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
16412584|NCT03891446|Experimental|Bimatoprost SR 10mcg; Lead-in studies 192024-091/-092|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
16412617|NCT03891199|Active Comparator|Intervention|Robotic-arm assisted THA.
16412618|NCT03891186|Experimental|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
16412585|NCT03891446|Experimental|Bimatoprost SR 15mcg; Lead-in studies 192024-091/-092|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
16412586|NCT03891433|Active Comparator|Carbapenems group|Meropenem (1g intravenously every 8 hours or adjusted to renal function) or Ertapenem (1g intravenously every 24 hours or adjusted to renal function) by 10 days.
16412587|NCT03891433|Active Comparator|Piperacillin/tazobactam.|Piperacillin / Tazobactam (4.5gr intravenously every 6 hours or adjusted to renal function) by 10 days.
16412588|NCT03891420|Experimental|Galidesivir|Galidesivir IV infusion
16412589|NCT03891420|Placebo Comparator|Placebo|Placebo IV infusion
16412590|NCT03891407|Experimental|HIV Self-testing Group|Camp members will receive information about HIV self-testing from peer educators who will be nominated by you and other camp members in your camp. Camp members in the STEP project will receive pretest counseling and a 10 minute demonstration. They will receive 1 oral fluid HIV self-test kit to conduct the self-test at home or in a private location during the next 1 month and a phone number to call in case you need assistance when performing the self-test at home. They will also receive information about the nearest HIV Care and Treatment Center where they can seek a confirmatory HIV test and start HIV treatment in the event of a positive self-test result.
16412591|NCT03891407|No Intervention|Non-intervention Group|Camp members will be encouraged to seek HIV testing at the clinics.
16412592|NCT03891381|Experimental|Tetragraph|Patients will be randomized to receive quantitative monitoring in the operating room. Neuromuscular management will be guided by information provided by the monitor
16412593|NCT03891381|Active Comparator|Qualitative monitoring|The screen of the Tetragraph will be covered so that information is not provided to the clinician. The monitor will therefore function as a standard peripheral nerve monitor (clinicians will only observe the response to nerve stimulation)
16412596|NCT03891355|Experimental|Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D)|"Carfilzomib (K) (maximum period of treatment= 24 cycles)
~K on days 1-2, 8-9, 15-16 during cycles 1-12. The dosage of K will be 20 mg/m2 10' iv infusion on day 1 and 2 during cycle 1 and then 27 mg/m2 10' iv infusion thereafter;
~K: on days 1-2, 15-16 during cycles 13-24. The dosage of K will be 27 mg/m2 10' iv infusion. Lenalidomide (R) (maximum period of treatment= 24 cycles)
~R: 25 mg/daily on day 1 to 21 of a 28 days course; for patients with creatinine clearance ≥ 30 mL/min but < 50 mL/min the dosage of R will be 10 mg/daily on day 1 to 21 of a 28 days course.
~Dexamethasone (D) (maximum period of treatment= 24 cycles) PO or IV D on days 1-2, 8-9, 15-16, 22-23. The dosage will be 20 mg between 30 minutes and 4 hours prior to K. For patients older than 75 years the dosage may be reduced at 10 mg."
16412597|NCT03891342|Experimental|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
16412598|NCT03891342|Experimental|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
16412599|NCT03891329|Other|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family ICDs and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
16412600|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
16412601|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
16412602|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
16412603|NCT03891316||Anaesthesiologists PACU|Anaesthesiologists working in the postoperative care unit.
16412604|NCT03891316||Anaesthesiologists outside the operating room|Anaesthesiologists working outside of the operating room, for example pain service or anaesthesiological walk-in clinic
16412605|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
16412606|NCT03891316||Patients|Patients having undergone sevoflurane anesthesia for elective surgery
16412607|NCT03891303||Transfused group (TR)|Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
16412608|NCT03891303||Non-transfused (non-TR)|Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
16412609|NCT03891277|Active Comparator|Ferrous succinate|Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
16412610|NCT03891277|Placebo Comparator|placebo|placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
16412611|NCT03891264|Experimental|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
16412612|NCT03891238|Experimental|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
16412613|NCT03891225|Experimental|Amniotic Membrane implantation Arm|All consecutive patients undergone pancreaticoduodenectomy with high FRS will be treated with implantation of AM, by overlapping it over the pancreo-jejunal anastomosis.
16412614|NCT03891212|Experimental|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
16412615|NCT03891212|No Intervention|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
16412619|NCT03891186|Active Comparator|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
16412620|NCT03891173|Experimental|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
16412621|NCT03891173|Active Comparator|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
16412622|NCT03891160|Experimental|Group A - 3D models|Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
16412623|NCT03891160|No Intervention|Group B - Control|Group B will be the controls and will not receive a 3D model.
16412624|NCT03891147|Experimental|Electro-acupunture (EA) group|"Patients will receive the treatment of electro-acupuncture with acupoints (i) Riyue (GB-24) ; (2) Danshu (B19) ; (3) Ganshu (B18) ; (4) Qimen (LR14) ; (5) Yanglingquan (GB34)
~The EA will be conducted by using disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length). The needles are inserted at a depth of 10-30 mm vertically or obliquely into acupoints, on which electrical stimulation with continuous waves with 2 Hz and 100 Hz are delivered for 15 min for each frequency through an electrical acupuncture treatment instrument (Hwarto, SDZ-II). The intensities of stimulation are adjusted to a level at which patients feel most comfortable. Each session lasts for 30 minutes."
16412625|NCT03891147|No Intervention|Usual care group|Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
16412626|NCT03891134|Experimental|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
16412627|NCT03891121|Experimental|Occlusal splint|Patients were treated with occlusal splint.
16412628|NCT03891121|Experimental|Botulinum toxin|Patients were treated with botulinum toxin injection.
16412629|NCT03891121|Experimental|Both|Patients were treated with occlusal splint and botulinum toxin injection together.
16412630|NCT03891108|Active Comparator|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
16412631|NCT03891108|Experimental|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
16412632|NCT03891108|Experimental|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
16412633|NCT03891108|Experimental|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
16412634|NCT03891095|Experimental|Intranasal oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)
16412635|NCT03891095|Experimental|L-DOPA|L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)
16412636|NCT03891095|Placebo Comparator|Placebo|Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)
16412637|NCT03891082|Active Comparator|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
16412638|NCT03891082|Active Comparator|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
16412639|NCT03891069|Experimental|Interventional arm|Participants will be invited to play the five different Exergames, for a total of 5 minutes.
16412640|NCT03891056|Active Comparator|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
16412641|NCT03891056|Active Comparator|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
16412642|NCT03891043|Placebo Comparator|Group A, Placebo group|Placebo consisted in a pill of 100 micrograms of starch, to be taken twice a day.
16412643|NCT03891043|Experimental|Group B, Selenium group|Selenium consisted in a pill of 100 micrograms, to be taken twice a day.
16412644|NCT03891030|Experimental|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
16412645|NCT03891030|No Intervention|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
16412646|NCT03891017|Experimental|vacuum casting|Vacuum casting will be performed using the Ottobock vacuum casting system. For our vacuum casting procedures, we will be following the protocols outlined in the Harmony Fabrication Quick Guide
16412647|NCT03891017|Active Comparator|hydrostatic casting|For the aqua casting system, we will be using an in-house manufactured device. This device will be created following guidelines from the PCAST Technical Manual
16412648|NCT03891004|Experimental|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
16412649|NCT03891004|Active Comparator|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
16412650|NCT03890991|Experimental|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
16412651|NCT03890991|Active Comparator|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
16412652|NCT03890991|Active Comparator|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
16412653|NCT03890991|No Intervention|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
16412654|NCT03890978|Experimental|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
16412655|NCT03890978|Other|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
16412656|NCT03890965|Experimental|Experimental|Adult patients with chronic sequelae in the upper limb after neurological damage
16412657|NCT03890952|Experimental|Arm B Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients not undergoing salvage surgery
16412658|NCT03890952|Experimental|Arm A Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients undergoing salvage surgery
16412659|NCT03890939|Experimental|BiPAP AutoSV Advanced System One|
16412660|NCT03890939|Experimental|Dreamstation BiPAP AutoSV|
16412661|NCT03890939|Active Comparator|ResMed S7 VPAP Adapt device|
16412662|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
16412663|NCT03890913||Observation|All childcare centers enrolled to Aim 1 will be observed. The physical activity environment will be examined before and after the implementation of playground stencils.
16412664|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
16412665|NCT03890887|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1291583 alone. Test - BI 1291583 + Itraconazole
16412666|NCT03890874||First year medical students|First year medical students of jubilee mission medical college and research institute
16412667|NCT03890861|Experimental|Physical activity intervention|The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
16412668|NCT03890861|Active Comparator|Active control|The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
16412669|NCT03890848|Experimental|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
16412670|NCT03890848|Active Comparator|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
16412671|NCT03890835|Active Comparator|Mineral Trioxide Aggregate (MTA)|
16412672|NCT03890835|Experimental|Biodentine|
16412673|NCT03890809|Experimental|Normal liver function|Single dose
16412674|NCT03890809|Experimental|Mild liver impairment|Single dose
16412675|NCT03890809|Experimental|Moderate liver impairment|Single dose
16412676|NCT03890809|Experimental|Severe liver impairment|Single dose
16412677|NCT03890796|Experimental|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
16412678|NCT03890796|Sham Comparator|Dementia Care Education Group (DE)|Will received dementia care education
16412679|NCT03890783||Patients after surgery of oropharyngeal cancers|Patients after surgery of oropharyngeal cancers with soft palate with free flap reconstruction and adjuvant radiotherapy
16412680|NCT03890770|Experimental|Normal renal function|Single dose
16412681|NCT03890770|Experimental|Mild renal disease|Single dose
16412682|NCT03890770|Experimental|Moderate renal failure|Single dose
16412683|NCT03890770|Experimental|Severe renal failure|Single dose
16412684|NCT03890770|Experimental|End-stage renal disease requiring dialysis|Two single doses administered with washout
16412685|NCT03890757||serratus anteriorblock|Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe
16412688|NCT03890718|Experimental|Donat lenticul|
16412689|NCT03890705||postpartum women|Women aged (15-49) and had given birth in the past 12 months
16412690|NCT03890692|Experimental|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
16464040|NCT03538626|Experimental|2|5 mg/kg SC x 1
16412691|NCT03890666|Experimental|Digital System (DS) Group|DS group patients utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard
16412692|NCT03890666|Active Comparator|Concurrent Control (CC) Group|CC group patients will be treated with their standard of care albuterol-administering rescue inhalers
16412693|NCT03890653|Experimental|Performance-Based Financing|At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
16412694|NCT03890653|Experimental|Decentralized Facility Financing|In the other half of the LGA's in each treated state, at least one facility per ward will receive Decentralized Facility Financing (DFF) or equivalent financing that is not be linked to any service delivery targets. These payments would be made on a quarterly basis.
16412695|NCT03890653|No Intervention|Control|This is a pure control arm with no additional interventions.
16412696|NCT03890640|Experimental|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
16412697|NCT03890627||Thoracic bio-reactance measurement of cardiac output|
16412698|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
16412699|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
16412700|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
16412701|NCT03890588|Experimental|CKD enhanced clinical decision support (CKD-CDS Intervention)|Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm.
16412702|NCT03890588|No Intervention|Usual Care|A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
16412703|NCT03890575|Experimental|Airway Stent for Malignant Stricture|Patients with malignant stricture were implanted with covered metallic segmented stent modified with 3D printing.
16412704|NCT03890562|Experimental|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
16412705|NCT03890549||obstructive sleep apnea group|The patients were diagnosed by thoracic and ENT (Eye-Nose-Throat) specialist through polysomnography.
16412706|NCT03890536||Biliary atresia|Biliary atresia is an obstructive cholangiopathy of infancy. It is the most common cause of neonatal cholestasis and the most frequent indication for liver transplantation in children. Patients with biliary atresia have conjugated hyperbilirubinemia (serum direct bilirubin > 1mg/dL) AND are scheduled for/undergo exploratory laparotomy for diagnosis and Kasai portoenterostomy for surgical treatment of BA.
16412707|NCT03890536||Non-BA=disease controls|All infants with other cholestatic syndromes (except biliary atresia) will be eligible for study enrollment in disease controls/non-biliary atresia. This involves the diagnosis of liver diseases caused by syndromes of intrahepatic cholestasis with or without hyperbilirubinemia.
16412708|NCT03890536||Normal|All healthy infants with no acute or chronic liver related illness.
16412709|NCT03890523|Experimental|Segmented Airway Stent for Gastro-Respiratory fistula|Segmented covered metallic airway stent modified with 3D printing was used for gastro-respiratory fistula.
16412710|NCT03890510|Active Comparator|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
16412711|NCT03890510|Active Comparator|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
16412712|NCT03890497|Active Comparator|Full dose of IPV|IPV first dose between 9 -13 months with second dose administered 2 months later.
16412713|NCT03890497|Active Comparator|Fractional Dose of IPV|fIPV first dose between 9 -13 months with second dose administered 2 months later
16412714|NCT03890484|Experimental|New Peers|Participants will drink with two new peers (i.e. strangers), who they did not know prior to the study and their Peer Type.
16412715|NCT03890484|Experimental|Close Friends|Participants will recruit and drink with two of their close friends and their Peer Type
16412716|NCT03890471|Experimental|Preoperative telephone call|Patients will receive routine preoperative counseling in the clinic plus a provider initiated telephone call 3 days before surgery.
16412717|NCT03890471|No Intervention|No preoperative telephone call|Patients will receive routine preoperative counseling in the clinic.
16412718|NCT03890458|Experimental|Experimental|
16412719|NCT03890458|No Intervention|Control|
16412720|NCT03890445||Adalimumab Biosimilar (Hyrimoz)|Patients with moderate-to-severe CD receiving Hyrimoz™ treatment according to the Hyrimoz™ label at the discretion of the investigator
16412721|NCT03890445||Infliximab Biosimilar (Zessly)|Patients with moderate-to-severe CD receiving Zessly™ treatment according to the Zessly™ label at the discretion of the investigator
16412722|NCT03890432|Experimental|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
16412723|NCT03890432|Active Comparator|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
16412724|NCT03890432|Other|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
16412725|NCT03890419|Active Comparator|Control Group|Control Group participants will be exposed to full spectrum light during the study.
16412726|NCT03890419|Experimental|Green light Group|Green light Group participants will be exposed to green light during the study.
16412727|NCT03890419|Experimental|Blue light Group|Blue light Group participants will be exposed to blue light during the study.
16412728|NCT03890406|Experimental|Group D|Deep neuromuscular blockade
16412729|NCT03890406|Active Comparator|Group M|Moderate neuromuscular blockade
16412730|NCT03890393||patients with episodic headache|
16412731|NCT03890393||patients with chronic headache|
16412732|NCT03890393||healthy controls|
16412733|NCT03890380|Experimental|Magneto Wire|Patients treated with Magneto Wire
16412734|NCT03890367|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
16412735|NCT03890367|Active Comparator|Group 2: Nimenrix® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
16412736|NCT03890367|Active Comparator|Group 3: NeisVac-C® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of NeisVac-C® vaccine on Day 0.
16412737|NCT03890341|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-64530440|Participants will receive single oral dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and midazolam 2 mg with under fed conditions (high fat meal) on Day 1 followed by JNJ-64530440 2,000 mg on Days 6 under fasted conditions ; JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg under fed conditions on Day 13; JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) from Days 14 to 18; single oral dose of JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg on Day 19 under fed conditions (high fat meal); and JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) on Days 20 to 22.
16412738|NCT03890328|Experimental|RF group|radiofrequency-assisted spleen-preserving therapy group.
16412739|NCT03890328|No Intervention|CT group|Conventional Treatment of Blunt Splenic Injury group.
16412740|NCT03890315||Neuropathic pain|Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of >1 month Unilateral extremity pain will be recruited
16412741|NCT03890315||Control|Age and gender matched control patients will also be recruited to show whether differences exist in outcome measures.
16412742|NCT03890302|Experimental|Cohort A|0.5 mg/kg study drug, or placebo, administered once
16412743|NCT03890302|Experimental|Cohort B|2 mg/kg study drug, or placebo, administered once
16412744|NCT03890302|Experimental|Cohort C|4 mg/kg study drug, or placebo, administered once
16412745|NCT03890302|Experimental|Cohort D|8 mg/kg study drug, or placebo, administered once
16412746|NCT03890302|Experimental|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
16412747|NCT03890289|Experimental|Idelalisib Plus Obinutuzumab|"Single arm: Regimen: GAUDEALIS q28 days
~Obinutuzumab Dose: 1000 mg IV Day 1, 8, 15 (1st cycle)
~Obinutuzumab Dose: 1000 mg IV Day 1 (2nd cycle onward)
~Idelalisib Dose: 150 mg BID oral Daily (24 weeks)"
16412748|NCT03890276|Active Comparator|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
16412749|NCT03890276|Experimental|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
16412750|NCT03890263|Experimental|Opioid deprescribing and self-management|
16412751|NCT03890250|Sham Comparator|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
16412752|NCT03890250|Experimental|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.
~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
16412753|NCT03890237|No Intervention|Control|Business as usual, no intervention
16412754|NCT03890237|Experimental|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
16412755|NCT03890237|Experimental|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
16412756|NCT03890237|Experimental|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
16464041|NCT03538626|Experimental|3|20 mg/kg IV x 1
16412757|NCT03890237|Experimental|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
16412758|NCT03890224|No Intervention|Control group|no home non-invasive ventilation (NIV), only hospital NIV
16412759|NCT03890224|Active Comparator|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
16412760|NCT03890224|Active Comparator|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
16412761|NCT03890224|Active Comparator|Rescue home NIV|home non-invasive ventilation (NIV) on demand
16412762|NCT03890211|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, the mother will be encouraged to provide KMC whenever possible. For hypothermic infants, if the temperature is not rising by ½°C per hour with KMC alone, the Infant Warmer will be offered as an addition. In these cases, the heat will be provided by placing the Infant Warmer over the infant's back while the mother provides KMC. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the Infant Warmer by being placed directly on the warmer as it lies flat. Use of hat and socks will be encouraged by additional clothes will only be added in addition to the warmer per caregiver request, as it reduces heat transfer.
16412763|NCT03890211|No Intervention|Control|Data such as infant temperature, date of birth, etc. will be collected from those who enroll in the control group. No experimental intervention will be administered.
16412764|NCT03890198|Experimental|chimeric Antigen Receptor T cell|LCAR-C182A Cells
16412765|NCT03890185|Experimental|A: Chemo+RT low dose|Chemo + Low dose RT: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin (CDDP) 75mg/m2 IV D1 and radiation therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for a total of 2 cycles every 21 days.
16412766|NCT03890185|Active Comparator|B: Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
16412767|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
16412768|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
16412769|NCT03890159|Experimental|Computer Assisted Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours, and patients will progress to the difficulty level automatically. Their performance during this process (response time etc.) will be recorded.
16412770|NCT03890159|Experimental|Conventional Cognitive Rehabilitation|The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests.
16412771|NCT03890159|No Intervention|Waiting list controls|These patients will get no intervention as means of cognitive rehabilitation, but will get their usual treatments.
16412772|NCT03890146||intensive care patients|patient hospitalised in intensive care unit veinous and capillary ponction
16412773|NCT03890133|Experimental|Ba-Duan-Jin group|The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital; Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks.
16412774|NCT03890133|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.
~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
16412775|NCT03890133|No Intervention|Healthy control group|
16412776|NCT03890120|Experimental|Blinded Phase: Cilofexor|Cilofexor for 96 weeks
16412777|NCT03890120|Placebo Comparator|Blinded Phase: Placebo|Placebo for 96 weeks
16412778|NCT03890120|Experimental|Open-Label Phase: Cilofexor|Cilofexor for 96 weeks
16412779|NCT03890107||Pediatric tympanostomy tube patients|Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the OtoSight
16412780|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
16412781|NCT03890068|Experimental|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
16412782|NCT03890055|Experimental|Clinical trial group|（Carboplatin/cisplatin + etoposide）+ （Anlotinib Hydrochloride 12 mg/day ，Each cycle was defined as 2 weeks on-treatment fol- lowed by 1 week off-treatment）, after 4-6 cycles of treatment, the treatment was continued with anlotinib until disease progression.
16412783|NCT03890042|Active Comparator|Dienogest group|
16412784|NCT03890042|Active Comparator|Gynera group|
16412785|NCT03890029|Other|Intervention|"Once potential participants have given consent and determined eligible, they will undergo an initial assessment.Pre, post- and follow-up testing. This consists of verbal scales including emotional well-being scales and mental health symptom scales. They will be administered in a group 30-60 minute session. Neuropsychological testing and psychophysiological tests given will require 90 minutes. Neuropsychological testing will be completed at pre and post testing only. In order to ensure unbiased assessment, pre- and post- and follow-up testing will be conducted by individuals blinded to study condition.
~Randomization. After pre-testing, all individuals will be randomly assigned to either the active treatment group or minimal attention control condition. After this, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. After five weeks, all participants will be post-tested."
16412821|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
16464042|NCT03538626|Experimental|4|40 mg/kg IV x 1
16412786|NCT03890029|Other|Control|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training
16412787|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
16412788|NCT03890003|Experimental|AID System Containing Insulin Lispro|The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.
16412789|NCT03889990|Other|healthy smokers|"Healthy smokers males, aged >18years, with >10 pack/years,receiving no medications
~Intervention: the use of an IQOS"
16412790|NCT03889977|Experimental|Exercise|Resistance exercise 45 min following breakfast
16412791|NCT03889977|No Intervention|Control|No exercise (resting) following breakfast
16412792|NCT03889964||patients with stable COPD|
16412793|NCT03889951||group 1|group of ALL patients with IKZF1 deletion mutation.
16412794|NCT03889951||group 2|group of ALL patients with no detected mutation
16412795|NCT03889925|Experimental|Autologous conditioned plasma group|Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.
16412796|NCT03889925|Experimental|Autologous conditioned plasma with hyaluronic acid group|Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.
16412797|NCT03889912|Experimental|Cemiplimab|Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion
16412798|NCT03889899|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16412799|NCT03889886|Placebo Comparator|Vehicle|Vehicle
16412800|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
16412801|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
16412802|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
16412803|NCT03889873|Experimental|Drinking; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
16412804|NCT03889873|Experimental|Drinking; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
16412805|NCT03889873|Experimental|Drinking; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
16412806|NCT03889873|Experimental|Drinking; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
16412807|NCT03889873|Experimental|Smartphone; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
16412808|NCT03889873|Experimental|Smartphone; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
16412809|NCT03889873|Experimental|Smartphone; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
16412810|NCT03889873|Experimental|Smartphone; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
16412811|NCT03889860||Uveitis group|
16412812|NCT03889860||Control group|age and sex matched group to the uveitis group
16412813|NCT03889847|Experimental|silicone DLT|Fibreoptic intubation with silicone double lumen tube
16412814|NCT03889847|Experimental|PVC DLT|Fibreoptic intubation with PVC double lumen tube
16412815|NCT03889834|Experimental|Autotransfusion: blood stored at 4 ° C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days
16412816|NCT03889834|Experimental|Autotransfusion: blood stored at -80°C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days
16412817|NCT03889834|Other|Controls not transfused|no transfusion
16412818|NCT03889821|Active Comparator|Child-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM).
16412819|NCT03889821|Experimental|Child- and Parent-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM). Parents also participate in 6 separate, individual sessions of Mindfulness Based Stress Reduction (MBSR).
16412820|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
16412822|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
16412823|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
16412824|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
16412825|NCT03889795|Experimental|Dose Escalation|C3 (Metformin, Simvastatin and Digoxin) will be dosed each day of a 28 calendar day cycle. The starting dose level will be increased with each cohort. There are 3 cohorts. Upon reaching maximum tolerated dose, an expansion cohort will be opened. Cohort 1 - Metformin 850mg po/day, Simvastatin 5mg po/day, Digoxin 0.0625 mg po/day. Cohort 2 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 20 mg po/day, Digoxin 0.25 mg po/day. Cohort 3 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 40 mg po/day, Digoxin 0.25 mg po/day for two weeks, 0.375 mg po/day for the next two weeks for cycle 1. Subjects will receive 0.50 mg po/day in Cohort 3, Cycle 2 and beyond. Metformin to be taken at Breakfast and Dinner time (as applicable), Simvastatin at Bed time and Digoxin in the Morning.
16412826|NCT03889756|Experimental|Ketamine|Ketamine is an FDA-approved anesthetic agent that is commonly used to induce surgical anesthesia due to its low incidence of significant respiratory depression and hypotension. It as a N-methyl-D-aspartate (NMDA) receptor antagonist and glutamatergic modulator, and has been demonstrated in multiple controlled clinical trials to have rapidly acting antidepressant and anti-suicidal effects in adults.
16412827|NCT03889756|Placebo Comparator|Midazolam|Midazolam, the active control in this study, is a medication that is approved by the Food and Drug Administration as a sedative for both children and adults.It is a benzodiazepine with a short half-life that was chosen so as to blind the psychotomimetic effects of Ketamine.
16412828|NCT03889743|Experimental|Dexamethasone|
16412829|NCT03889743|Placebo Comparator|controls|
16412830|NCT03889717|Experimental|400 iu|neonates who will receive vitamin d dose at 400 iu per day
16412831|NCT03889717|Active Comparator|1000 iu|neonates who will receive vitamin d dose 1000 iu per day
16412832|NCT03889704|Experimental|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
16412833|NCT03889691||Control group|The control group consisted of patients who verbal explanation of the surgical procedure and the potential postoperative complications was given with a written informed consent document
16412834|NCT03889691||Study group|Participants in the study group asked to watch impacted lower third molar extraction video which was previously uploaded to the internet with their own device. This video includes only visual components of the surgery such as anesthesia, incision, extraction and suturing. Patients in the second group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document.
16412835|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
16412836|NCT03889665|Experimental|Suspension training group|
16412837|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.
~OCT (investigation) before and after cataract extraction"
16412838|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
16412839|NCT03889639|Experimental|Cohort 1: SAR442168 5 mg Then Placebo|Participants received SAR442168 5 milligrams (mg), orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412840|NCT03889639|Experimental|Cohort 1: SAR442168 15 mg Then Placebo|Participants received SAR442168 15 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412841|NCT03889639|Experimental|Cohort 1: SAR442168 30 mg Then Placebo|Participants received SAR442168 30 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412842|NCT03889639|Experimental|Cohort 1: SAR442168 60 mg Then Placebo|Participants received SAR442168 60 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412843|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 5 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 5 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412844|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 15 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 15 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412906|NCT03889158|Experimental|Acute Inflammation/Antioxidant|"All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
~All participants will receive ascorbic acid (Vit C) on two occasions [oral pill, 2g, 2x (baseline, during acute inflammation)]."
16412845|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 30 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 30 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412846|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 60 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 60 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
16412847|NCT03889626|Experimental|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
16412848|NCT03889626|Experimental|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
16412849|NCT03889626|No Intervention|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
16412850|NCT03889613|Experimental|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
16412851|NCT03889600|Experimental|REDD-CAT Recipient|The nurse care manager will incorporate the administration of the REDD-CAT to the patient as part of the standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
16412852|NCT03889587|Experimental|Innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibula bone flaps. In simultaneous innervated group, neurorrhaphy between the ilioinguinal nerve or fibula flap nerve with inferior alveolar nerve or great auricular nerve will be performed.
~Intervention: Procedure: Innervation"
16412853|NCT03889587|Active Comparator|Non-innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibular bone flaps. In traditional noninnervated group, neurorrhaphy will not be performed.
~Intervention: Procedure: Non-innervation"
16412854|NCT03889574||combination of aspirin, P2Y12 Inhibitor with a NOAC|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
16412855|NCT03889574||combination of aspirin, P2Y12 Inhibitor with warfarin|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
16412856|NCT03889561|Experimental|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
16412857|NCT03889561|No Intervention|Control|SSB taxes
16412858|NCT03889548|Experimental|Mental Imagery|
16412859|NCT03889548|No Intervention|Control|
16412860|NCT03889535|Active Comparator|Resin strip crowns|Current standard full coverage restoration provided for primary incisors. Please see intervention section for detailed description of technique.
16412861|NCT03889535|Experimental|Zirconia crowns|Experimental treatment under study. Zirconia crowns are an alternative restorative option. Please see intervention section for detailed description of technique.
16412862|NCT03889496|Other|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
16412863|NCT03889483|Other|NeuroCatch™ Platform Assessment|All participants will undergo two NeuroCatch™ Platform Assessments.
16412864|NCT03889470|Active Comparator|200 microgram NTG|200 microgram NTG through the radial sheath
16412865|NCT03889470|Placebo Comparator|Saline|Saline infusion through the radial sheath
16412866|NCT03889457||Patients with venous thromboembolic disease|Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.
16412867|NCT03889444||OZURDEX®|Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.
16412868|NCT03889431|Experimental|Capsule group|Group one received iodine capsule
16412869|NCT03889431|Experimental|Iodized salt group|Group two received iodized salt
16412870|NCT03889418|Active Comparator|Electronic medical recorded clinical decision support|Usual care only
16412871|NCT03889418|Active Comparator|stepped opioid collaborative care model|Usual care AND collaborative care with behavioral health integration
16412872|NCT03889405|Experimental|Study group|Healthy 32 weeks or more pregnant women, at an early stage of labor.
16412873|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
16412874|NCT03889379|Experimental|Effects of Albuterol on Immune Cell Composition|This is a single subject repeated measure experimental design with each participant acting as his/her own control.
16412875|NCT03889366|Experimental|NXP001 Oral Capsule|
16412876|NCT03889366|Experimental|NXP001 Oral Suspension|
16412877|NCT03889366|Active Comparator|Emend®|
16412878|NCT03889353|Experimental|BCI sessions|up to 3 test sessions (Day-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (Day 1-Day 5 and Day 8-Day 12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
16412879|NCT03889340||Phase 1 cohort|Subjects resuscitated from cardiac arrest will undergo cooling per standard of care with the IQool device.
16412907|NCT03889145|Active Comparator|Telmisartan, Amlodipine|
16412908|NCT03889145|Active Comparator|Hydrochlorothiazide|
16412909|NCT03889145|Experimental|Telmisartan, Amlodipine, Hydrochlorothiazide|
16412910|NCT03889132||Premenopausal women with obesity|
16412911|NCT03889132||Postmenopausal women with obesity|
16412912|NCT03889132||Men with obesity|
16412913|NCT03889132||Premenopausal women without obesity|
16412914|NCT03889132||Postmenopausal women without obesity|
16412915|NCT03889132||Men without obesity|
16413013|NCT03888339|Active Comparator|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
16412880|NCT03889327|Experimental|Cognitive Feedback and Psychoeducation (CFP)|Participants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
16412881|NCT03889327|Active Comparator|Healthy Eating Habits (HEH)|The control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
16412882|NCT03889314|Experimental|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
16412883|NCT03889314|Placebo Comparator|Placebo|
16412884|NCT03889314|No Intervention|No Treatment|7 day wash-out period between months
16412885|NCT03889301|Experimental|E-E Video|Watch E-E video that incorporates health and educational messages
16412886|NCT03889301|Active Comparator|Discussion|Structured discussion about depression and anxiety
16412887|NCT03889288|No Intervention|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
16412888|NCT03889288|Experimental|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
16412889|NCT03889275|Experimental|Sequential|MEDI5395 and durvalumab administered sequentially
16412890|NCT03889275|Experimental|Concurrent|MEDI5395 and durvalumab administered concurrently
16412891|NCT03889262|Active Comparator|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
16412892|NCT03889262|Active Comparator|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
16412893|NCT03889249|Active Comparator|Tenecteplase (tNK-TPA)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
16412894|NCT03889249|Active Comparator|Alteplase ( tPA)|The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).
16412895|NCT03889236|Experimental|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
16412896|NCT03889236|Experimental|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
16412897|NCT03889236|Placebo Comparator|Placebo|4 capsules a day of the placebo for 3 months.
16412898|NCT03889223|Active Comparator|The LDF neuraxial positioning technique|In the LDF neuraxial positioning technique, fifty participants were planned to lay down the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist. Volunteers jaw touch to chest and legs in abdominal flexion with hands are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
16412899|NCT03889223|Experimental|The SCF neuraxial positioning technique|In the SCF neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
16412900|NCT03889210|Active Comparator|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
16412901|NCT03889210|Placebo Comparator|Placebo|Placebo will be given in a total volume of 100 ml.
16412902|NCT03889197|No Intervention|Control|Standard of care sodium supplementation as directed by the medical care team
16412903|NCT03889197|Active Comparator|Sodium supplementation algorithm|Beginning on the 14th -16th postnatal day and continuing until 36 weeks postmenstrual age, infants randomized to the algorithm will have a spot urine sodium concentration determined every two weeks and sodium supplementation provided according to the algorithm.
16412904|NCT03889184|Experimental|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
16412905|NCT03889184|No Intervention|Usual care|the control group will receive usual care
16413009|NCT03888378|Active Comparator|1% Topical Minocycline Ointment|Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
16412916|NCT03889119|Active Comparator|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
16412917|NCT03889119|Other|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
16412918|NCT03889106||Lassa fever|
16412920|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
16412921|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
16412922|NCT03889080||Control|Age- and gender-matched healthy controls
16412923|NCT03889067|Experimental|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10^4CFU
~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
16412924|NCT03889054|No Intervention|Control|Current clinical management
16412925|NCT03889054|Active Comparator|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
16412926|NCT03889041||Caregivers of children with EA-TEF|Caregivers of children with esophageal atresia and tracheoesophageal fistula will be included in the study.
16412927|NCT03889015|Active Comparator|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
16412928|NCT03889015|Experimental|probiotic yogurt|Probiotics are live microorganisms that confer oral health benefits by adhering to the oral mucosa and surface of teeth as a part of the biofilm thus preventing the adhesion, colonization, and proliferation of cariogenic bacteria inhibiting the formation of pathogenic plaque
16412929|NCT03888989|Other|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
16412930|NCT03888963|Experimental|PRF|
16412931|NCT03888963|Sham Comparator|SHAM|
16412932|NCT03888950|Experimental|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
16412933|NCT03888924|Experimental|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
16412934|NCT03888924|Placebo Comparator|Placebo treated patients|a single dose of placebo.
16412935|NCT03888911|Experimental|High dose IQP-LU-104 (5120mg)|High dose treatment group
16412936|NCT03888911|Experimental|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
16412937|NCT03888911|Placebo Comparator|Placebo|Placebo group
16412938|NCT03888898|Active Comparator|N95 Filtering Facepiece Respirator|control fit testing
16412939|NCT03888898|Experimental|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
16412940|NCT03888885|Experimental|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
16412941|NCT03888885|No Intervention|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
16412942|NCT03888872|Experimental|Group I|Group I (Study): will consist of 20 patients with diabetic neuropathy and will receive High tone power therapy in addition to selected physical therapy program (Wobble board training, AROM exercises for both UL & LL, gentle manual stretching exercises for both UL & LL and graduated gait training). for 10 sessions every other day, each session for 1.45 hours (60 minutes for HiTop and 45 minutes for selected physical therapy program).
16412943|NCT03888872|Experimental|Group II|Group II (Control): will consist of 20 patients with diabetic neuropathy and will receive selected physical therapy program only same as group I. For 10 sessions every other day, each session for 45 minutes.
16412944|NCT03888859|Experimental|Intravenous (i.v.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intravenous (IV) infusion
16412945|NCT03888859|Experimental|Intra-hepatic artery (i.a.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intra-hepatic artery (IA) infusion
16412946|NCT03888859|Experimental|Intratumoral Injections (i.t.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intratumoral injections (i.t.) infusion
16412947|NCT03888846|Other|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
16412948|NCT03888846|Experimental|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
16412949|NCT03888833||Veno arterial extracorporeal membrane oxygenation|
16412950|NCT03888820|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
16412951|NCT03888820|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
16412952|NCT03888807|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
16412953|NCT03888807|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees
16412954|NCT03888781||With Left Ventricular Remodeling|By Echocardiography
16412955|NCT03888781||Without Left Ventricular Remodeling|By Echocardiography
16412956|NCT03888768|Active Comparator|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss >1L and subsequent post operative follow up till 6month
16412957|NCT03888768|No Intervention|Standard Care|patient will received standard hospital practise
16412958|NCT03888755|Experimental|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
16412959|NCT03888742||ADT Group|Participants received continue ADT treatment for at least more than 6 months
16412960|NCT03888742||RRP Group|Participants have radical prostatectomy performed more than 6 months ago.
16412961|NCT03888729|Experimental|HCV treatment-naïve participants|HCV-infected individuals naïve to DAA therapy regimen; in this group we consider also HCV-infected individuals who have failed interferon-based therapy. Sofosbubir/velpatasvir (SOF/VEL) will be administered once daily for 12 weeks to eligible HCV treatment-naïve participants.
16412962|NCT03888729|Experimental|HCV treatment-experienced participants|HCV treatment-experienced participants, i.e.HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen. Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants
16412965|NCT03888703|Experimental|Treatment|
16412966|NCT03888703|No Intervention|Control|
16412967|NCT03888690|Active Comparator|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
16412968|NCT03888690|Active Comparator|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
16412969|NCT03888677|Active Comparator|Standard|Standard FEC (F600, E60, C600) every 3rd week.
16412970|NCT03888677|Experimental|Tailored|Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
16412971|NCT03888677|Active Comparator|Registered|Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
16412972|NCT03888664|Experimental|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
16412973|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
16412974|NCT03888625|Active Comparator|Group A: Conventional ILM peeling|peeling with complete removal of the internal limiting membrane (ILM)
16412975|NCT03888625|Active Comparator|GroupB: Inverted ILM Peeling|the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
16412976|NCT03888612|Experimental|ARV-110|"Part A: Oral tablet(s), once or twice daily in 28 day cycles
~Part B: Oral tablet(s), once or twice daily in 28 day cycles"
16412977|NCT03888586|Experimental|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
16412978|NCT03888586|Experimental|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
16412979|NCT03888573|Active Comparator|Stretch|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms.
16412980|NCT03888573|Active Comparator|Traction|Patients within Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
16413010|NCT03888378|Placebo Comparator|Topical Vehicle Ointment|Topical administration of Topical Vehicle Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
16413011|NCT03888365||Cohort A: Treprostinil|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH.
16413012|NCT03888365||Cohort B: Non-Treprostinil PAH Medications|Participants who are taking other PAH medications (instead of inhaled treprostinil).
16412983|NCT03888547|Experimental|OT-HAWP|"The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules:
~Week 1: Sleep Hygiene Week 2: Fatigue Management Week 3: Cancer-related cognitive impairments Week 4: Stress Management Each session will last 1.5 hours (45 minutes of group education and 45 minutes of individual modifications and strategy recommendations."
16412984|NCT03888534|Experimental|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants >= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m^2) and <1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
16412985|NCT03888521|Experimental|Resound Relief|All participants are in the same group, and receive the same intervention - use of the Resound Relief smartphone app for 6 months
16412986|NCT03888508|Experimental|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
16412987|NCT03888508|No Intervention|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
16412988|NCT03888495|Experimental|Gender socialization (GS)|Gender socialization workshops raised awareness on gender, its social construction and inequality, notions of masculinity and femininity, division of labor, access and control over resources. The workshop also included skill-building sessions on effective communication and negotiation and relationship building.
16412989|NCT03888495|Experimental|GS + Financial literacy (FL)|Financial literacy workshops promoted knowledge and skills in budgeting, financial planning and accessing and using financial services and income generating activities.
16412990|NCT03888495|Experimental|GS + FL + Family planning|Family planning counseling was provided to couples by family planning providers from nearby facilities. Couples were encouraged to seek services in facilities of their choice. A voucher system provided financial support for the poorest couples.
16412991|NCT03888495|No Intervention|Control|Couples were interviewed at baseline, and will be interviewed at endline.
16412992|NCT03888482|Other|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
16412993|NCT03888482|Other|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
16412994|NCT03888469|Other|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
16412995|NCT03888469|Other|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
16412996|NCT03888456|Experimental|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
16412997|NCT03888456|Sham Comparator|Control|participants will receive a single touch sham intervention mimicking the intervention
16412998|NCT03888443||uCP children|15 Children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol twice separated from 2 to 4 weeks
16412999|NCT03888443||uCP children with botulinum toxin injections|5 children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol three times
16413000|NCT03888443||healthy volunteers (TDC children)|20 children aged from 6 to 17 (healthy volunteers) will realize the bimanual protocol once
16413001|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
16413002|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
16413003|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
16413004|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
16413005|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
16413006|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
16413007|NCT03888391|Experimental|Active TNS|Participants will receive trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for up to 12 months of this open-extension trial.
16413008|NCT03888378|Active Comparator|0.3% Topical Minocycline Ointment|Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
16413014|NCT03888339|Experimental|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
16413015|NCT03888326|Experimental|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
16413016|NCT03888326|Sham Comparator|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
16413017|NCT03888326|No Intervention|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
16413018|NCT03888313||Patients participating in the pretreatment group consultation|Patients who chosse to participate in a group consultation (with other patients also in the process of undergoing surgery for colorectal cancer).
16413019|NCT03888300|Experimental|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
16413020|NCT03888287|Experimental|Retrospective Phase|150 patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
16413021|NCT03888287|Experimental|Prospective Phase-Watch Rx system|150 patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
16413022|NCT03888287|Experimental|Retrospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
16413023|NCT03888287|Experimental|Prospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
16413024|NCT03888274|Experimental|Active|
16413025|NCT03888261|Active Comparator|Active Intervention:|Mind-body intervention (incl. Relaxation Response Resiliency Program & the Open and Calm Program)
16413026|NCT03888261|No Intervention|No Intervention|No intervention (Study participants will receive routine clinical practice)
16413027|NCT03888248|Active Comparator|Exercises|Daily muscle-strengthening exercises
16413028|NCT03888248|Experimental|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
16413029|NCT03888235|Experimental|Immediate corrective exercises|"At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.
~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that."
16413030|NCT03888235|Experimental|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.
~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that."
16413031|NCT03888235|Active Comparator|Delayed treatment|"These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.
~The concurrent use of both treatments will be assessed at their last visit one month after that."
16413032|NCT03888222|Placebo Comparator|Placebo|"Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) capsule orally once daily for 3 months (90 days)."
16413033|NCT03888222|Active Comparator|100 mg of Bosutinib|Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 2 will receive the 100 mg of Bosutinib one (1) capsule orally once daily for 3 months (90 days).
16413034|NCT03888209|Experimental|Anodal tDCS|Patients will receive 20min anodal tDCS
16413035|NCT03888209|Sham Comparator|Sham tDCS|Patients will receive 20 minutes of Sham anodal tDCS
16413036|NCT03888196|Experimental|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
16413037|NCT03888196|Placebo Comparator|Control Group|500 mg/day of Celulose. 2 weeks treatment
16413038|NCT03888183|Placebo Comparator|salt solution without 0.15% HA|
16413039|NCT03888183|Active Comparator|preservative-free 0.15% HA|
16413040|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
16413041|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
16413042|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
16413043|NCT03888157||Liraglutide|Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
16413044|NCT03888144|Active Comparator|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
16413045|NCT03888144|Experimental|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
16413046|NCT03888131|Experimental|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
16413047|NCT03888131|Active Comparator|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
16413048|NCT03888118|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
16413049|NCT03888118|No Intervention|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
16413055|NCT03888092|Experimental|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
16413056|NCT03888079||Local anesthetic|Patients who chose local anesthesia for their surgery
16413057|NCT03888079||General anesthetic|Patients who chose general anesthesia for their surgery
16413060|NCT03888053|Active Comparator|BB-101 Treatment Arm|BB-101 liquid formulation concentration of 2 µg/mL or 20 µg/mL will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
16413061|NCT03888053|Placebo Comparator|Placebo Arm|Placebo will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
16413062|NCT03888040|Experimental|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
16413063|NCT03888040|Experimental|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
16413066|NCT03888014||Treatment group|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
16413068|NCT03887975|Active Comparator|Percentage of force in monoplane occlusion|Different occlusal scheme evaluation using tscan
16413069|NCT03887975|Active Comparator|Percentage of force in lingualized occlusion|Different occlusal scheme evaluation using tscan
16413070|NCT03887962|Experimental|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
16413071|NCT03887962|Active Comparator|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
16413072|NCT03887949|Active Comparator|VCV|Volume controlled ventilation
16413073|NCT03887949|Active Comparator|PCV|Pressure controlled ventilation
16413074|NCT03887949|Experimental|PCV-VG|Pressure controlled ventilation with volume guarantee
16413075|NCT03887936|Experimental|Testosterone arm|Testosterone gel 1.62%
16413076|NCT03887936|Placebo Comparator|Placebo arm|Matching placebo will be prepared by the Michael DeBakey VA Medical Center Pharmacy.
16413077|NCT03887923|Experimental|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
16413078|NCT03887910|Experimental|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
16413079|NCT03887910|Experimental|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
16413080|NCT03887910|No Intervention|Control|Usual care with developmental toys.
16413081|NCT03887897|Active Comparator|Airtraq|Airtraq laryngoscope
16413082|NCT03887897|Active Comparator|Macintosh|Macintosh laryngoscope
16413083|NCT03887884|Experimental|CVT-301|Single inhaled dose of CVT-301 84 mg
16413084|NCT03887884|Active Comparator|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
16413085|NCT03887871|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T
~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
16413086|NCT03887871|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T
~Period 2: Harnal-D Tab. 1T"
16413087|NCT03887858|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T
~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
16413088|NCT03887858|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T
~Period 2: Harnal-D Tab. 1T"
16413089|NCT03887845||Open gastrointestinal surgery|All patients enrolled in this group would undergo open gastric and colorectal resection surgery.
16413090|NCT03887845||Laparoscopic gastrointestinal surgery|All patients enrolled in this group would undergo laparoscopic gastric and colorectal resection surgery.
16413091|NCT03887832|Experimental|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
16413092|NCT03887832|Active Comparator|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
16413149|NCT03887429|Experimental|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
16413093|NCT03887793|Experimental|VACs intervention|Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI. Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
16413094|NCT03887793|No Intervention|Wait list control|Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
16413096|NCT03887754|Active Comparator|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
16413097|NCT03887754|Active Comparator|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.
~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
16413098|NCT03887754|Active Comparator|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
16413099|NCT03887754|Placebo Comparator|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
16413103|NCT03887728||Artificial (HRT) Cycles|"Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days
~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.
~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.
~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.
~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.
~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone"
16413104|NCT03887728||Spontaneous natural cycles|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.
~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.
~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).
~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
16413105|NCT03887715|Active Comparator|Active|Group will have VNS activated 2 weeks post implant.
16413106|NCT03887715|Sham Comparator|Control|Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
16413107|NCT03887702|Experimental|Group A (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD immediately or within 42 days after initial dose of chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
16413108|NCT03887702|Experimental|Group B (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD after HBV reactivation during chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
16413109|NCT03887702|Experimental|Group C (TAF, TDF, entecavir, usual care)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD at the discretion of the physician during usual care. Treatment continues for up to 6 months after discontinuation of usual care or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
16413110|NCT03887689|Experimental|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
16413111|NCT03887676|Active Comparator|Arbaclofen|
16413112|NCT03887676|Placebo Comparator|Placebo|
16413113|NCT03887650|Experimental|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
16413114|NCT03887650|Active Comparator|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
16413150|NCT03887429|Experimental|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
16413151|NCT03887429|Experimental|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
16414240|NCT03879928|Experimental|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
16413115|NCT03887637||Danoprevir Sodium triple therapy|"DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg.
~Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours."
16413116|NCT03887637||Sofosbuvir/ Velpatasvir therapy|Sofosbuvir/ Velpatasvir :500mg (two drugs in one tablet) orally once daily for 12 weeks.
16413117|NCT03887637||Ombitasvir/Paritaprevir therapy|Ombitasvir/Paritaprevir: Ombitasvir two tablets orally once daily for 12 weeks; Paritaprevir one tablet orally twice daily for 12 weeks.
16413118|NCT03887637||Grazoprevir/elbasvir therapy|Grazoprevir/elbasvir: 150mg (two drugs in one tablet) orally once daily for 12 weeks.
16413119|NCT03887637||Daclatasvir/Asunaprevir therapy|Daclatasvir (60mg)one tablet once daily and Asunaprevir (100mg)one tablet twice daily for 24weeks
16413120|NCT03887637||Danoprevir Sodium/Sofosbuvir therapy|Danoprevir Sodium: 100mg (one tablet) orally twice daily for 12 weeks;Sofosbuvir:400mg (one tablet) orally once daily for 12 weeks.
16413121|NCT03887624|Experimental|Experimental group|Ethosuximide(2 weeks) + Escitalopram (4 weeks)
16413122|NCT03887624|Placebo Comparator|Control group|Placebo(2 weeks)+Escitalopram(4 weeks)
16413123|NCT03887611||thyroid nodules|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of thyroid surgery or thyroid biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
16413124|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
16413125|NCT03887585|Experimental|Achilles tendon lengthening|Surgery of percutaneous Achilles tendon lengthening by triple hemisection
16413126|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
16413127|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
16413128|NCT03887559|Experimental|Intervention group|Group-based stabilization and skill-training combined with individual treatment.
16413129|NCT03887559|Active Comparator|controls|Individual treatment as usual only.
16413130|NCT03887546|Experimental|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.
~12 weeks, 5 days/week, 15 minutes/day."
16413131|NCT03887546|Active Comparator|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
16413135|NCT03887520|Other|Cardiovascular disease|Patients with established Cardiovascular disease
16413136|NCT03887507|Experimental|Experimental|There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
16413137|NCT03887507|Active Comparator|Standard Therapy|The standard group shall perform 4 sessions of physiotherapy in the same period for two consecutive weeks, with one hour per session in its specialized MS association, on 1st, 3rd, 8th, 10th and 15th days. This will be applied by experienced physiotherapists during the treatment of people with MS. The program will consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept. Patients in this group will walk at least for 20 minutes per day during the study period.
16413138|NCT03887494|Experimental|Y-Strut Implant|Single interventional arm
16413139|NCT03887481|Experimental|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
16413140|NCT03887481|Experimental|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
16413141|NCT03887468|Active Comparator|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
16413142|NCT03887468|Active Comparator|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
16413146|NCT03887442|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
16413147|NCT03887442|Experimental|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
16413148|NCT03887429|Experimental|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
16413152|NCT03887416|Active Comparator|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).
~Dapagliflozin 10 MG Oral Tablet [Farxiga] will be administered through out the planned intervention period of the study (12 weeks).
~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
16413153|NCT03887416|Placebo Comparator|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).
~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
16413154|NCT03887403|Experimental|Multimodal Intervention|Multimodal Intervention Based on Person-centered Communication
16413155|NCT03887403|Active Comparator|Usual Care|Patients receive usual advices in primary health care centers
16413156|NCT03887390|No Intervention|Usual Care|Participants in this arm will receive care as usual.
16413157|NCT03887390|Experimental|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
16413158|NCT03887377|Experimental|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.
~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
16413159|NCT03887377|Placebo Comparator|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
16413160|NCT03887364|Active Comparator|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
16413161|NCT03887364|Experimental|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
16413162|NCT03887351||JGH Cohort|This cohort will not be subjected to any intervention.
16413163|NCT03887351||RVH Cohort|This cohort will not be subjected to any intervention.
16413164|NCT03887338|Other|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
16413165|NCT03887325|Active Comparator|Maxipost|
16413166|NCT03887325|Placebo Comparator|Saline|
16413167|NCT03887312|Experimental|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
16413168|NCT03887312|Active Comparator|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
16413169|NCT03887299|Placebo Comparator|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
16413170|NCT03887299|Active Comparator|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
16413171|NCT03887286|Experimental|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
16413172|NCT03887273|Experimental|Q-Cells dose level 1|One time surgical transplantation of Q-Cells dose level 1 unilaterally into spinal cord demyelinated lesion
16413173|NCT03887273|Experimental|Q-Cells dose level 2|One time surgical transplantation of Q-Cells dose level 2 unilaterally into spinal cord demyelinated lesion
16413174|NCT03887273|Experimental|Q-Cells dose level 3|One time surgical transplantation of Q-Cells dose level 3 unilaterally into spinal cord demyelinated lesion
16413175|NCT03887260|Active Comparator|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
16413176|NCT03887260|Experimental|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
16413177|NCT03887247|Active Comparator|E-Mail Alert|Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
16413178|NCT03887247|No Intervention|As-Usual|As-usual (no email) approach.
16413179|NCT03887234|Active Comparator|Through the coracoid|The semitendinosus tendon graft goes through the 4.5 mm coracoid drill hole.
16413180|NCT03887234|Experimental|Around the coracoid|The semitendinosus tendon graft goes around the coracoid.
16413181|NCT03887221|Experimental|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
16413182|NCT03887221|Experimental|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
16413183|NCT03887208|Experimental|Autologous adipose derived stem cells|Autologous ADSC injection combined with laser therapy of the skin.
16413184|NCT03887208|Placebo Comparator|Placebo - Normal saline injection|Normal sline injection combined with laser therapy of the skin.
16413185|NCT03887195||students|The clinical sample is made up of 501 students (male and female) in the 4th year of medicine at Paris Descartes University, participating at the obligatory training module during the 2018-2019 academic year : this constitutes the entire population concerned by the intervention.
16413186|NCT03887182|Experimental|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
16413187|NCT03887182|Experimental|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
16413188|NCT03887182|Active Comparator|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
16413189|NCT03887169|Experimental|Methionine|
16413190|NCT03887156|Other|Arm 1|One arm
16413191|NCT03887143||Arterial ischemic stroke in patients less than 18 years old|"Patients < 18 years old
~Suspected or confirmed cerebral infarction
~With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy
~Patients treated between January 2015, 1st and May 2018, 31st"
16413192|NCT03887130|Experimental|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
16413193|NCT03887130|Active Comparator|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
16413194|NCT03887130|Active Comparator|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
16413195|NCT03887117|Active Comparator|IQOS-1|"IQOS + Exercise Training Program
~Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program."
16413196|NCT03887117|Active Comparator|IQOS-2|"No Training
~Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program."
16413197|NCT03887117|Active Comparator|Cigarette Smoking|"Cigarette Smoking + Exercise Training Program
~Subjects randomized to continued cigarette smoking and participation in an exercise training program."
16413198|NCT03887117|Active Comparator|Smoking Abstinence|"Smoking Abstinence + Exercise Training Program
~Subjects randomized to smoking abstinence and participation in an exercise training program."
16413199|NCT03887091|Experimental|Postwire© Virtual Education Cohort|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility.
~In randomized into the Virtual Education Cohort:A video based, personalized web page will be created that has information related to the participants therapeutic clinical trial.
~This web page will have videos of a research nurse explaining how to take study medication(s), how to fill out the study drug diary, and a description of the main side effects associated with the study drugs.
~Clinic Visit Video Recording Cycle 1-4/Day 1
~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7"
16413200|NCT03887091|No Intervention|No Video Intervention|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility
~Participants randomized to the control cohort will follow standard of care procedures involving clinic visits that do not include the use of video or access to a personalized web page.
~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7."
16413201|NCT03887078|Experimental|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
16413202|NCT03887078|Experimental|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
16413203|NCT03887078|Experimental|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
16413204|NCT03887078|Experimental|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
16413205|NCT03887078|Experimental|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
16413206|NCT03887078|No Intervention|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
16413207|NCT03887078|Experimental|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
16413208|NCT03887078|No Intervention|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
16413209|NCT03887065|Experimental|Starting dose|Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
16413210|NCT03887065|Experimental|Intermediate dose of JM-4|Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
16413211|NCT03887065|Experimental|High dose of JM-4|Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
16413212|NCT03887052|Experimental|Study Arm|Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)
16413213|NCT03887039||ADHD group|clinical examination
16413214|NCT03887039||normal group|clinical examination
16413215|NCT03887026|Experimental|NKT Low Dose|NKT single dose - Low
16413216|NCT03887026|Experimental|NKT High Dose|NKT single dose - High
16413217|NCT03887026|Placebo Comparator|Placebo|Placebo single dose
16413218|NCT03887013|No Intervention|CHD routine therapy|Patients with CHD will be treated with evidence-based therapy including antiplatelet drugs,beta-blockers,statins,angiotensin-converting enzyme inhibitor (ACEI),nitrates,etc. Percutaneous coronary intervention (PCI) could be performed if needed.
16413219|NCT03887013|Experimental|CHD routine therapy+Trimetazidine|Apart from the drug and PCI therapy mentioned above,patients will be given treatment of trimetazidine.
16413220|NCT03887000|Experimental|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
16413221|NCT03887000|Experimental|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
16413222|NCT03886987|Experimental|Device and Control|"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml
~Negative control: Blank patch Dose: Not applicable"
16413223|NCT03886974||Adults with type 1 diabetes|People with T1D who are 18 years or older.
16413224|NCT03886974||Parents of adults with type 1 diabetes|Parents who have adult children with type 1 diabetes.
16413225|NCT03886974||Healthcare providers managing patients with type 1 diabetes|Licensed healthcare providers who are managing patients with T1D (whether in adult or pediatric practice).
16413226|NCT03886961|Experimental|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
16413227|NCT03886948|Experimental|Prefilled Syringe (PFS) with LY3074828|PFSs containing LY3074828
16413228|NCT03886948|Experimental|AutoInjector (AI) with LY3074828|AI containing LY3074828
16413229|NCT03886935||Fontan patients|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
16413230|NCT03886935||Healthy biventricular controls|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
16413231|NCT03886922|Active Comparator|Glibenclamide and Levcromakalim|Participants will recieve levcromakalim/placebo infusion after glibenclamide administration
16413232|NCT03886922|Active Comparator|Glibenclamide and Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
16413233|NCT03886922|Sham Comparator|Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
16413234|NCT03886909|Active Comparator|Home-Based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant.
16413235|NCT03886909|Active Comparator|Prehabilitation Education|Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute.
16413236|NCT03886896|Experimental|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
16413237|NCT03886896|No Intervention|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
16413238|NCT03886883|Experimental|Exercise-induced hypoalgesia (EIH)|Exercise-induced hypoalgesia - isometric muscle contractions of the hand flexors
16413239|NCT03886883|Active Comparator|Static stretch (SS)|A static stretch of the knee flexors
16413240|NCT03886883|Sham Comparator|Rest|No intervention
16413241|NCT03886883|Experimental|Conditioning painful stimulus (CPM)|Conditioned pain modulation - cold pressure test
16413242|NCT03886870|Experimental|Lifestyle and work intervention|Lifestyle intervention with work focus.
16413243|NCT03886870|Experimental|Lifestyle intervention|Lifestyle intervention without work focus.
16413244|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
16413245|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
16413246|NCT03886831|Experimental|PRT543|PRT543 will be administered orally
16413247|NCT03886818|Experimental|PICO strategy|"Use of PICO™ device from the ankle surgery to the post-surgery day 7.
~Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
16413248|NCT03886818|Active Comparator|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
16413249|NCT03886805|Experimental|Dual task with variable- and fixed-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks. From the 1st to 12th week the participants were trained under variable-priority instructions (half the session was focused on balance motor task and half the session focused on cognitive task performance). From the 13th to 24th week) the participants performed dual tasks under fixed-priority instructions (simultaneous focus attention on balance and cognitive tasks). The motor tasks were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, working memory, among other cognitive tasks.
16413250|NCT03886805|Active Comparator|Dual-task with variable-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks (48 sessions). From the 1st to 24th week, the participants were trained under variable-priority instructions, in which they were asked to spend half the session focused on balance (motor task) and half the session focused on cognitive task performance. The motor tasks (gait and postural balance) of this protocol were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks included activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, rescue working memory, among other cognitive tasks.
16413281|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
16413282|NCT03886597|Experimental|60 Arbequina Table Olives|Pharmacokinetics Study
16413283|NCT03886597|Experimental|120 Arbequina Table Olives|Pharmacokinetics Study
16413251|NCT03886792|Experimental|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
16413252|NCT03886792|Sham Comparator|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
16413253|NCT03886779|Active Comparator|Prolensa (Bromfenac Ophthalmic Solution) 0.07%|Bausch and Lomb, Rochester, NJ Dose: Subjects will instill one drop into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1 hour before surgery and for 14 days after surgery.
16413254|NCT03886779|Active Comparator|Ilevro® (nepafenac ophthalmic suspension ) 0.3%|Alcon Laboratories, Inc., Fort Worth, TX Dose: Subjects will instill one drop of test article into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one day prior to surgery (Day 1), continue on the day of surgery plus1 hour before surgery and for 14 days after surgery.
16413255|NCT03886766|Experimental|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
16413256|NCT03886766|Experimental|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
16413257|NCT03886766|Experimental|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
16413258|NCT03886753||Ease|Subjects using Ease as standard treatment. Registry and PK sampling
16413259|NCT03886753||Dream|Subjects using Dream as standard treatment. Registry and PK sampling
16413260|NCT03886753||Soothe|Subjects using Soothe as standard treatment. Registry and PK sampling
16413261|NCT03886753||Shine|Those subjects using Shine as standard treatment. Registry and PK sampling
16413262|NCT03886740|Experimental|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
16413263|NCT03886740|Experimental|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
16413264|NCT03886727|Active Comparator|Rubber Dam|Isolation of single tooth using rubber dam
16413265|NCT03886727|Active Comparator|Cotton Roll|Isolation of quadrant using cotton rolls
16413266|NCT03886701|Experimental|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
16413267|NCT03886688|Experimental|single ascending|Drug or placebo, oral, fast, single dose ascending
16413268|NCT03886688|Experimental|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
16413269|NCT03886688|Experimental|Food Effect|Drug or placebo, oral, fed or fast, single dose
16413270|NCT03886675|Experimental|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
16413271|NCT03886675|Active Comparator|Saline|Flushing of stent-grafts with saline
16413272|NCT03886662|Experimental|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
16413273|NCT03886649|Experimental|Copanlisib + Venetoclax|Phase Ib -> dose escalation with 2 expansion cohorts
16413274|NCT03886636|Experimental|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
16413275|NCT03886636|Experimental|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
16413276|NCT03886636|Active Comparator|Control group|in Group 3, participants received home exercise program only.
16413277|NCT03886623|Experimental|4-day systematic oral hygiene|The intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
16413278|NCT03886623|Other|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
16413279|NCT03886610||Healthy controls|Individuals without spinal cord injury
16413280|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration >2 weeks)
16413286|NCT03886584|Experimental|Patients with with neuropsychiatric conditions|"In this arm, five groups :
~Patients with DFT, diagnosed according Racovsky criteria
~Patients with Lewi Body dementia, diagnosed according McKeith criteria
~Patients with pre-demential Alzheimer, diagnosed according Dubois criteria
~Patients with Alzheimer, diagnosed according MMSE
~Patients with bipolar disorder, diagnosed according DSM 5"
16413287|NCT03886584|Active Comparator|Healthy subjects|Healthy controls appaired in age, sex and educational level
16413288|NCT03886558|Experimental|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
16413289|NCT03886558|Experimental|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
16413290|NCT03886545||caregivers with shoulder pain|
16413291|NCT03886545||Healthy subjects|
16413292|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
16413293|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
16413294|NCT03886519|Active Comparator|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
16413295|NCT03886519|Active Comparator|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
16413296|NCT03886493|Experimental|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
16413297|NCT03886480|Experimental|SaeboVR|Use of the SaeboVR for task specific upper extremity training
16413298|NCT03886467|Active Comparator|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
16413299|NCT03886467|No Intervention|Control|community development activities only.
16413300|NCT03886441|Experimental|Prevention group|Participants inhaled beclomethasone propionate aerosol daily during chest radical radiotherapy (total dose 60GY).
16413301|NCT03886441|No Intervention|Traditional therapy group|Participants were not given daily inhalation of beclomethasone propionate when undergoing radical chest radiotherapy (total dose 60GY).
16413302|NCT03886428|Experimental|100% Portion Size|Test meal with portion size 100% of baseline
16413303|NCT03886428|Experimental|125% Portion Size|Test meal with portion size 125% of baseline
16413304|NCT03886428|Experimental|150% Portion Size|Test meal with portion size 150% of baseline
16413305|NCT03886428|Experimental|175% Portion Size|Test meal with portion size 175% of baseline
16413306|NCT03886415|Experimental|Jaktinib hydrochloride tablets 1|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 200mg qd dose group
16413307|NCT03886415|Experimental|Jaktinib hydrochloride tablets 2|This is the dose group was given twice a day. Jaktinib hydrochloride tablets 2 100mg bid dose group
16413308|NCT03886402|Experimental|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
16413309|NCT03886389|Experimental|Carbohydrate/intervention group|Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
16413310|NCT03886389|No Intervention|Control group|Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.
16413311|NCT03886376|Experimental|Deep Massage|The deep massage was performed three times during a training week, after a physical training and before the swimming training
16413312|NCT03886376|Active Comparator|Superficial Massage|The superficial massage was performed three times during a training week, after a physical training and before the swimming training
16413313|NCT03886376|No Intervention|Control|The control group kept their normal routine of training. Immediately after the physical training the athletes were instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
16413314|NCT03886363|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
16413315|NCT03886363|No Intervention|Wait-list control|Usual practice
16413316|NCT03886350||Patients with cystic fibrosis|Patients with CF whom follow-up is undertaken at University Hospital of Tours, France
16413317|NCT03886337|No Intervention|Control|The control arm will be surgical care according to usual practice with usual ambient lighting
16413318|NCT03886337|Experimental|Treatment Arm|The treatment arm will include surgical care according to usual practice with germicidal ambient lighting
16413319|NCT03886324|Experimental|DCB Treatment|Stricture patients treated by DCB
16414241|NCT03879928|Experimental|FM101 300 mg under fasted condition for FE|Food Effect of FM101
16413320|NCT03886311|Experimental|Talimogene laherparepvec, Nivolumab and Trabectedin|"This is an open label phase 2 study using known doses of TALIMOGENE LAHERPAREPVEC injected intratumorally, and NIVOLUMAB AND TRABECTEDIN given intravenously.
~A total of 40 previously untreated and treated patients will receive TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks, NIVOLUMAB 240 mg IV over 30 min q 2 weeks and TALIMOGENE LAHERPAREPVEC intratumorally q 2 weeks according to tumor size (see Schematic of Study Design and Imlygic product information; www.accessdata.fda.gov). Patients in this study may continue treatment until significant disease progression (see below for criteria for discontinuation of therapy) or unacceptable toxicity occurs up to one year of therapy."
16413321|NCT03886298|Experimental|radiofrequency splanchnic denervation|
16413322|NCT03886298|Active Comparator|retrocrural celiac denervation|
16413323|NCT03886272|Experimental|BI 730357 (Test)|
16413324|NCT03886272|Experimental|BI 730357 (Reference)|
16413325|NCT03886259|Experimental|Exercise and pain neuroscience education|Subjects with chronic pain after total knee replacement will receive 24 sessions of neuromuscular exercise therapy, supervised by a physiotherapist, and two sessions of pain neuroscience education, conducted by a physiotherapist
16413326|NCT03886259|Active Comparator|Pain neuroscience education|Subjects with chronic pain after total knee replacement will receive two sessions of pain neuroscience education, conducted by a physiotherapist
16413327|NCT03886246|Experimental|Spesolimab (every 6 weeks)|
16413328|NCT03886246|Experimental|Spesolimab (every 12 weeks)|
16413329|NCT03886246|Experimental|Spesolimab (every 4 weeks)|
16413330|NCT03886233||Traditional Treatment for Autoimmune uveitis|Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
16413331|NCT03886233||Biological Treatment for Autoimmune uveitis|Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
16413332|NCT03886220|Experimental|Participants receiving elagolix|Participants will be administered with elagolix
16413333|NCT03886220|Experimental|Participants receiving placebo|Participants will be administered with placebo
16413334|NCT03886207|Experimental|Warm water with ginger powder footbath|Participants who receive a warm water with added ginger powder footbath four times a week over a six-week period.
16413335|NCT03886207|Active Comparator|Warm water only footbath|Participants who receive a warm water only footbath four times a week over a six-week period.
16413336|NCT03886194|Active Comparator|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
16413337|NCT03886194|Experimental|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
16413338|NCT03886181|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16413339|NCT03886168|Experimental|Immediate IGCIP|Immediate signal processing intervention of a biomedical device
16413340|NCT03886168|Active Comparator|Deferred IGCIP|Delayed signal processing intervention of a biomedical device
16413341|NCT03886155||Trigger Finger Biopsy|Biopsy of trigger finger tenosynovial tissue during trigger finger release surgery sent to pathology for amyloid-specific analysis
16413342|NCT03886142|Active Comparator|radiofrequency|genicular nerves pulsed radiofrequency
16413343|NCT03886142|Active Comparator|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
16413344|NCT03886129||Participants with Transient Ischaemic Attack|"Inclusion Criteria:
~Willing to participate
~Capacity to consent
~Aged >18 years
~Able (in the Investigator's opinion) and willing to comply with all study requirements
~A diagnosis of acute (≤7 days) TIA, made by a specialist that fulfils the 2009 American Heart Association definition of TIA
~Good understanding of written and verbal English
~Exclusion Criteria:
~Unwilling to take part
~Unable to consent
~Aged <18 years
~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements
~Female participants who are pregnant, lactating or planning pregnancy during the course of the study
~Atrial fibrillation
~Severe heart failure (Ejection Fraction <30%)
~Severe respiratory disease
~Inadequate bilateral transcranial Doppler windows
~Carotid stenosis ≥70% (unilateral or bilateral)
~Participant enrolled in an interventional research study.
~Poor understanding of written and verbal English"
16413345|NCT03886129||Healthy Control Participants|"Inclusion Criteria:
~Willing to participate
~Capacity to consent to the study
~Aged >18 years
~Able (in the Investigator's opinion) and willing to comply with all study requirements
~Good understanding of written and verbal English
~Exclusion Criteria:
~Unwilling to take part
~Unable to consent
~Aged <18 years
~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements
~Female participants who are pregnant, lactating or planning pregnancy during the course of the study
~Atrial fibrillation
~Severe heart failure (Ejection Fraction <30%)
~Severe respiratory disease
~Inadequate bilateral transcranial Doppler windows
~Carotid stenosis ≥70% (unilateral or bilateral)
~Participant enrolled in an interventional research study.
~Poor understanding of written and verbal English"
16413346|NCT03886116|Active Comparator|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.
~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
16413347|NCT03886116|No Intervention|No Exercise|Patient is not required to do any exercise.
16413348|NCT03886103|Experimental|Healthy volunteer|Single of 14C-PXL770
16413349|NCT03886090|Experimental|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
16413350|NCT03886090|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
16464043|NCT03538626|Experimental|5|Smg/kg SC x 3
16413351|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
16413352|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
16413353|NCT03886064|No Intervention|Control group|Only measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling.
16413354|NCT03886064|Other|Interventional group|Measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling followed by multi-behavioral intervention adapted to local resources.
16413355|NCT03886051|Experimental|test group|Connective Tissue Graft before Orthodontic treatment
16413356|NCT03886051|Active Comparator|control group|Orthodontic treatment only
16413357|NCT03886038|Active Comparator|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDS/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
16413358|NCT03886038|Active Comparator|RA on synthetic or biological DMARDs|RA patients tretad with syntetic or bioloogial DMARDs for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
16413359|NCT03886038|Active Comparator|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
16413360|NCT03886025|Experimental|Combined anodal tDCS and cognitive training|Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
16413361|NCT03886025|Sham Comparator|Combined sham tDCS and cognitive training|Combined sham tDCS and cognitive training. Sham tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). For sham tDCS, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each tDCS session will be 20 minutes.
16413362|NCT03886012|Experimental|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.
~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
16413363|NCT03886012|Sham Comparator|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.
~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
16413364|NCT03885999|Experimental|Fecobionics studies|
16413365|NCT03885973|Experimental|Lactobacillus plantarum|1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10^8 CFU will be given daily for three weeks.
16413366|NCT03885973|Placebo Comparator|Placebo|1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.
16413367|NCT03885947|Experimental|VPA expanded cord blood stem cells|"CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.
~VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation"
16413368|NCT03885934|Experimental|V114, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL intramuscular (IM) injection for 7 to 11 months of age (Pneumococcal conjugate vaccine [PCV]-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
16413369|NCT03885934|Active Comparator|Prevnar 13®, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
16413370|NCT03885934|Experimental|V114, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
16413371|NCT03885934|Active Comparator|Prevnar 13®, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
16413372|NCT03885934|Experimental|V114, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced) (1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
16413373|NCT03885934|Active Comparator|Prevnar 13®, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced)(1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
16413374|NCT03885921|Experimental|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
16413375|NCT03885921|Experimental|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
16413376|NCT03885908|Active Comparator|In-person geriatric co-management group|"In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
16413377|NCT03885908|Experimental|Automated geriatric co-management program group|
16413378|NCT03885895|Active Comparator|Participants with freckles (one side of the face)|one randomized side of the face will be treated by Intradermal Tranexamic acid
16413379|NCT03885895|Active Comparator|Participants with freckles (other side of the face)|other side will be treated by Q switched KTP laser
16413380|NCT03885882|Experimental|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
16413381|NCT03885882|Experimental|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
16413382|NCT03885882|Experimental|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
16413383|NCT03885882|Experimental|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
16413384|NCT03885869||Type 2 Diabetics|Type 2 diabetic individuals aged 30-65 years
16413385|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
16413386|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
16413387|NCT03885843|Experimental|RDN Group|renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
16413388|NCT03885843|Sham Comparator|Sham Group|renal artery angiography group, without any renal nerve stimulation, mapping or denervation
16413389|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
16413390|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
16413391|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
16413392|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
16413393|NCT03885817|Experimental|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
16413394|NCT03885817|Active Comparator|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
16413395|NCT03885804|Sham Comparator|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
16413396|NCT03885804|Active Comparator|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
16413397|NCT03885791|Experimental|Vaginal cryotherapy - intervention|"The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a slushy consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer."
16413398|NCT03885791|Placebo Comparator|Vaginal cryotherapy - control|The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
16413399|NCT03885778|Experimental|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
16413400|NCT03885778|Experimental|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
16413401|NCT03885765||Test group|The first 60 patients recruited.
16413402|NCT03885765||Validation group|The last 100 patients recruited.
16413403|NCT03885752|Active Comparator|the control group|
16413404|NCT03885752|Placebo Comparator|the gum group|
16413405|NCT03885739|Other|Patients with hip fracture|15 consecutive HF patients who were admitted to a single level 3 center and who report severe pain despite a standardized analgesia protocol. Patients were assessed by the Pain Service as part of a multidisciplinary care pathway and a Continuous Pericapsular Nerve Group blocks was offered as a component of a multimodal analgesic regimen.
16413406|NCT03885726|Active Comparator|Treatment as Usual|
16413407|NCT03885726|Experimental|High Velocity Nasal Insufflation|
16413447|NCT03885414|Experimental|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
16413408|NCT03885713|Active Comparator|Patients with treatment|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice, or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)-subcutaneus) per clinical practice
16413409|NCT03885713|No Intervention|healthy control|
16413410|NCT03885700|Experimental|intervention group|
16413411|NCT03885700|No Intervention|control group|
16413412|NCT03885687|Experimental|Exercise with Music Intervention|The Exercise with Music intervention is a recorded exercise playlist, which is tailored to a patient's individual physical abilities and music choices.
16413413|NCT03885687|Active Comparator|Active Control Group|The active control group will receive exercise brochure and will be advised to exercise at least twice daily.
16413414|NCT03885674|Experimental|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
16413415|NCT03885674|No Intervention|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
16413416|NCT03885661|Experimental|Icosapent ethyl|Icosapent ethyl with a total daily dose of 4 grams, as 2 x 1 gram capsules by mouth twice daily, against a statin background
16413417|NCT03885661|No Intervention|Usual Care|Statin background
16413418|NCT03885648||Cases|Women's age will range 25-70 years. Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II.
16413419|NCT03885648||Controls|Controls will be women surgically intervened of breast augmentation or reduction.
16413420|NCT03885635|Active Comparator|Hemiarch repair|Standard hemiarch repair with open distal anastomosis in the proximal arch without replacement of the head vessels.
16413421|NCT03885635|Active Comparator|Extended arch repair|Ascending aortic and arch replacement with or without head vessel re-implantation and single TEVAR device placement within 1 week.
16413422|NCT03885609|Experimental|Treatment - toothwave brush|Subjects using the Silk'n ToothWave RF utilizing toothbrush
16413423|NCT03885609|Sham Comparator|Control - powered toothbrush|Subject using a regular powered toothbrush with no RF.
16413425|NCT03885583|Active Comparator|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
16413426|NCT03885583|Active Comparator|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
16413427|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
16413428|NCT03885557|Experimental|Group I Experimental Dynamic oscillatory stretch(DOS)|Dynamic oscillatory stretch technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group.
16413429|NCT03885557|Active Comparator|Group II Static Stretching(SS) Group|Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group.
16413430|NCT03885544|Active Comparator|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
16413431|NCT03885544|Experimental|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
16413432|NCT03885544|Experimental|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
16413433|NCT03885518|Active Comparator|Intervention|Participants attending the childcare centers randomized to this arm will receive the stencil activities after baseline assessments have been completed. We will follow-up with assessments after 6-8 weeks
16413434|NCT03885518|Placebo Comparator|Wait-List|Participants attending the childcare centers randomized to this arm will receive the stencil activities approximately 8 weeks after enrolling, after baseline and follow-up assessments have been completed.
16413435|NCT03885479||IBD patients|"Full history taking and examination
~Colonoscopy, biopsy and histopathology to determine the extent of the lesion
~An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
~Patients will be categorized into 3 groups (UC patients, Crohn disease patients and controls)
~All of the following factors will be taken into consideration; type and duration of the treatment, age of diagnosis, BMI, smoking status and activity of the disease at the time of the study"
16413436|NCT03885479||Controls|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
16413437|NCT03885466|Experimental|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
16413438|NCT03885466|No Intervention|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
16413439|NCT03885453||Panic Disorder / Agoraphobia|Patients with Panic Disorder / Agoraphobia as major diagnosis
16413440|NCT03885453||Depression|Patients with Depression as major diagnosis
16413441|NCT03885440||Young adult, without OSAS|20<=Age<40 years old, apnea-hypopnea index(AHI)<5
16413442|NCT03885440||Young adult, with OSAS|20<=Age<40 years old, AHI>=5
16413443|NCT03885440||older adult, without OSAS|Age>=40 years old, AHI<5
16413444|NCT03885440||older adult, with OSAS|Age>=40 years old, AHI>=5
16413445|NCT03885427|Experimental|oral ketamine|evaluate sedative,and analgesic effects
16413446|NCT03885427|Active Comparator|nebulized ketamine|evaluate sedative, and analgesic effects
16413496|NCT03885063|Experimental|Benjamin Rose Institute Care Consultation (BRI-CC)|
16413497|NCT03885063|No Intervention|No intervention|
16464044|NCT03538626|Experimental|6|20mg/kg SC x 3
16413448|NCT03885401|Experimental|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
16413449|NCT03885401|No Intervention|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
16413450|NCT03885388|Active Comparator|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
16413451|NCT03885388|Experimental|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
16413452|NCT03885362|Experimental|Dexcom G6 and Abbott Freestyle Libre|"Participants will have a Dexcom G6 sensor and Abbott FreeStyle Libre sensor inserted in the abdomen and upper arm respectively. Participants will be asked to swipe the FreeStyle Libre reader across the sensor a minimum of every 8 hours. Participants will be asked to continue their usual regimen of self-monitoring capillary blood glucose (SMBG).
~During haemodialysis, a dialysis circuit blood sample will be drawn at 0 (pre-dialysis) 30, 60, 90, 120, 150, 180, 210 and 240 minutes and immediately after dialysis. Samples from the circuit will be analysed on the YSI glucose analyser. Participants will be asked to change the FreeStyle Libre sensors at day 14. The blinded CGM data will be uploaded at the time of each sensor change by the research team."
16413453|NCT03885349|Experimental|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
16413454|NCT03885349|Active Comparator|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
16413455|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
16413456|NCT03885323|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
16413457|NCT03885323|Placebo Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
16413458|NCT03885310|Experimental|DCB Treatment|Stricture patients treated by DCB
16413459|NCT03885297||Overweight/obese participants|Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
16413460|NCT03885284|Experimental|Dose Level 1|"mFOLFIRINOX + Proton beam radiation
~Radiation given on days 8-12 of cycle 6"
16413461|NCT03885284|Experimental|Dose Level 2|"mFOLFIRINOX + Proton beam radiation
~Radiation given on days 15-19 of cycle 6"
16413462|NCT03885271|Experimental|Group A (Experimental group) Hall Technique|Clinical examination to assess the clinical inclusion criteria. Radiographic examination.The child will be positioned upright in the dental chair . The correct size of PMC for the tooth will be selected. The tooth will be rinsed and dried, and the PMC dried. The PMC will be filled with glass ionomer luting cement. The PMC will be placed evenly over the tooth and the child instructed to bite down firmly until the crown was pushed down over the tooth;If the child was unable or unwilling to bite down on the PMC, finger pressure will be used to seat the crown Extruded cement will be removed, and the child will be asked to keep biting on the Hall PMC until the cement sets and once cement sets, excess cement is removed, floss will be used to clear the aproximal contacts, and post-fitting instructions will be given (Innes et al. 2007).
16413463|NCT03885271|Active Comparator|Group B (control group) Formecresol Pulpotomy|Clinical examination to assess the clinical inclusion criteria. Radiographic examination. The teeth anesthetized, rubber dam isolation, Complete caries removal achieved with a sterile round steel bur in a slow- speed handpiece. Access to the pulp chamber performed using a sterile slow-speed round steel bur. The pulp amputation with a sterile diamond bur in a high-speed handpiece and pulpal debris removed with a sterile saline solution on a sterile cotton pledget. After pulp amputation haemostasis achieved using a sterile cotton pledget. Formocresol (FC) applied using a sterile cotton pledget for 5 minutes. After removal of the formocresol soaked cotton pledget, the pulp chamber rinsed with water using an air-water syringe. The pulp chamber dried with a sterile cotton pledget, followed by application of Zinc Oxide & Eugenol and zinc phosphate. Tooth preparation done to receive stainless steel crown.
16413464|NCT03885258|Experimental|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
16413465|NCT03885245|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
16413466|NCT03885245|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
16413467|NCT03885232|Experimental|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
16413468|NCT03885232|Active Comparator|Control|Control-Care as usual
16413469|NCT03885219|Experimental|nab-paclitaxel and S-1|chemotherapy of Nab-Paclitaxel and S-1, repeat 21 days for up to 8 cycles. The following treatment including pancreatectomy, continuing same chemotherapy, S-1 maintenance therapy, or radiotherapy will be decided after discussion between physicians and patients.
16413470|NCT03885206|Experimental|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
16413471|NCT03885206|No Intervention|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
16413472|NCT03885193||HMS plus group|HMS plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
16413473|NCT03885193||ACT plus group|ACT plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
16413474|NCT03885180|Experimental|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
16413475|NCT03885180|No Intervention|Stop anticoagulation group|Just stop oral anticoagulation like routine
16413476|NCT03885167||Affected Individuals with Known SCA3|In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
16413477|NCT03885167||Healthy Individual Control Subjects|In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
16413478|NCT03885154|Active Comparator|Valproic Acid|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
16413479|NCT03885154|Active Comparator|Dihydroergotamine|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
16413480|NCT03885154|Active Comparator|Cross-Over to Dihydroergotamine|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
16413481|NCT03885154|Active Comparator|Cross-Over to Valproic Acid|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
16413482|NCT03885141|Placebo Comparator|Men - Placebo|Men - Placebo, 1 tablet if a wake up occurs
16413483|NCT03885141|Experimental|Men - Zolpidem 1.75 mg|Men - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
16413484|NCT03885141|Experimental|Men - Zolpidem 3.5 mg|Men - Zolpidem 3.5 mg, 1 tablet if a wake up occurs
16413485|NCT03885141|Placebo Comparator|Women - Placebo|Women - Placebo, 1 tablet if a wake up occurs
16413486|NCT03885141|Experimental|Women - Zolpidem 1.0 mg|Women - Zolpidem 1.0 mg, 1 tablet if a wake up occurs
16413487|NCT03885141|Experimental|Women - Zolpidem 1.75 mg|Women - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
16413488|NCT03885128|Experimental|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
16413489|NCT03885128|Experimental|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
16413490|NCT03885115|Experimental|Intervention|Participants randomly assigned to the experiential group (EG) will receive a 12-week structured exercise that will consist of two group fitness sessions (i.e. kickboxing, Zumba, fitness yoga, and other aerobic exercises) every week. Certified fitness instructors will lead each session and participants will learn strategies how to be more active during the daily routines at home. Parents or other relatives in the EG will participate in one 2-hour session every four weeks (total of 3 sessions) designed to help them support their children and entire family in being active and eat healthy at home. Parents will meet with a fitness instructor who will provide specific tips on how to increase physical activity at home as well as providing community resources to be active. A basic nutrition education and cooking demonstrations, and healthy recipes will be also provided to parents at these workshops. Data/assessments are collected, pre and post the 12 weeks intervention.
16413491|NCT03885115|No Intervention|Control|Participants randomly assigned to the control group (CG) will receive once a week recreational structured group play/game sessions led by trained BOUNCE interns/staff. The control group will receive 60 minute of structured free play sessions (i.e. recreational games) once a week for 12 weeks. Every 4 weeks, parents will be given (either sent home with their child or via email or mail) basic nutrition information, healthy recipes, and tips to promote physical activity at home as well as community resources to be active. Data/assessments are collected, pre and post the 12 weeks intervention.
16413492|NCT03885102|Experimental|Intervention|12 months intradialytic exercise intervention
16413493|NCT03885102|Active Comparator|Usual care|Usual care according to current guidelines
16413494|NCT03885089||Infliximab [infliximab biosimilar 3]|Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS
16413495|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
16413499|NCT03885024|Active Comparator|Retention Video|"Participants the peer-driven retention arm will receive video-based and in-person training from Retention Specialists on how to encourage study retention. Participants will watch a 7 minute video that standardizes retention messages. A brief face-to-face conversation with the Retention Specialist follows the video viewing to answer questions and reinforce video messages. At the end of the training, participants receive information about their recruit(s) who consented to release their information to their recruiters. Peers remind their enrolled study buddy to attend their scheduled follow up assessments. Participants meet with a study Retention Specialist by phone or in person, at 3 and 9 months after enrollment to answer questions about peer retention strategies and remind participants of their peers' contact information and follow-up schedules."
16413500|NCT03885024|No Intervention|Standard Retention Strategy|Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
16413501|NCT03885011|Experimental|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
16413502|NCT03885011|Active Comparator|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.
~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
16413503|NCT03885011|Active Comparator|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
16413504|NCT03884998|Experimental|Treatment (copanlisib and nivolumab)|Participants receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
16413505|NCT03884985|Experimental|Normal Vision|This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
16413506|NCT03884972|Experimental|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16413507|NCT03884972|Experimental|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
16413508|NCT03884959|Experimental|HepaStem Infusion|A calculated dose based on patient's body weight will be administered via Permanent mesenteric Portal Access and Catheter for four times or a Transient Percutaneous Transhepatic Catheter for three times.
16413509|NCT03884946|Active Comparator|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
16413510|NCT03884946|Placebo Comparator|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
16413511|NCT03884933|Experimental|Mobile team community mental health services|
16413512|NCT03884933|No Intervention|Current clinical services|
16413513|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
16413514|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
16413515|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
16413516|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
16413517|NCT03884881|Other|metagenomic next generation sequencing|Adjust medication for patients with severe pneumonia based on mNGS results
16413518|NCT03884881|Other|Conventional pathogen detection|Blood, bronchoalveolar lavage fluid (BALF), bronchial secretions samples will be collected and microbiologically tested prior to initial empirical antibiotic use.
16413519|NCT03884868|No Intervention|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
16413641|NCT03883945|Placebo Comparator|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
16414242|NCT03879928|Experimental|FM101 300 mg under fed condition for FE|Food Effect of FM101
16413520|NCT03884868|Experimental|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
16413521|NCT03884855|Active Comparator|Classical Cardiac Rehabilitation|Patients benefit from a classic cardiac rehabilitation cycle during 3 months.
16413522|NCT03884855|Experimental|Karate Rehabilitation|Patients benefit from cardiac rehabilitation cycle with traditional karate during 3 months.
16413523|NCT03884842|Active Comparator|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.
~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
16413524|NCT03884842|Placebo Comparator|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
16413525|NCT03884829|Experimental|CYC140 single agent|CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle
16413526|NCT03884803|Other|HealthyMoms web-based program|An on-line self-help psychoeducational website for new moms that includes educational learning modules and tools to prevent/reduce depression. .
16413527|NCT03884803|Other|Control group|No access to the intervention but to continue with standard care. Will complete the same questionnaires as the HealthyMoms group.
16413528|NCT03884790|Experimental|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
16413529|NCT03884764|Experimental|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
16413530|NCT03884764|Active Comparator|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
16413531|NCT03884751|Experimental|CAR-GPC3 T Cells|The subjects are enrolled into 2 dose levels cohorts in sequence
16413532|NCT03884738|Active Comparator|Concentric|Leg Curl Training
16413533|NCT03884738|Active Comparator|Eccentric|Nordic Hamstring Training
16413534|NCT03884738|Active Comparator|Neuromuscular Electrical Stimulation|Stimulation Training
16413535|NCT03884725|Active Comparator|fibrinogen concentrate|patients randomized to fibrinogen group receive intravenous infusion of drug prepared based on ROTEM measurement of maximum clot firmness (MCF)
16413536|NCT03884725|Placebo Comparator|control|patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF)
16413537|NCT03884712|Experimental|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
16413538|NCT03884699|Other|Segmental maxillary lefort I re-positioning|Accuracy of the planned virtually re-positioned segmental Lefort I maxilla using a specifically designed patient implant, comparing the virtual plan to the actual postoperative position.
16413539|NCT03884686|Experimental|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
16413540|NCT03884686|No Intervention|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
16413541|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
16413542|NCT03884634||Dabir Microsurface Overlay Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned ON (in addition to standard operating room table mattress and heating/cooling gel pad).
16413543|NCT03884634||Control Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned OFF (in addition to standard operating room table mattress and heating/cooling gel pad).
16413544|NCT03884621|Experimental|EHP Group|The Enhanced post-discharge home-based care program (EHP) offers one coaching session upon hospital discharge and 12-week home follow-up (including 6 home visits, 6 telephone calls and 24-hour hotline) post hospital discharge to participants by an especially trained nurse case manager with the support of a clinical team. The five intervention protocols integrate with an individualized home-based rehabilitation training and self-care plan.
16413545|NCT03884621|No Intervention|Control Group|Usual discharge care and post-discharge care provided to all stroke patients discharged home.
16413546|NCT03884595||No SIRS|Children without clinical signs of SIRS, according to Goldstein criteria.
16413547|NCT03884595||SIRS|Children with clinical signs of SIRS, according to Goldstein criteria.
16413548|NCT03884595||Sepsis|Children with clinical signs of sepsis, according to Goldstein criteria.
16413549|NCT03884595||Severe sepsis|Children with clinical signs of severe sepsis, according to Goldstein criteria.
16413550|NCT03884595||Septic Shock|Children with clinical signs of septic shock, according to Goldstein criteria.
16413551|NCT03884582||HealthyVolunteers|
16413552|NCT03884569||Patients treated with CLET|"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through drugs-in-special-situation request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account."
16413553|NCT03884556|Experimental|Arm 1, Single Agent|TTX-030
16413554|NCT03884556|Experimental|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
16413555|NCT03884556|Experimental|Arm 3, Chemotherapy Combination|TTX-030 plus docetaxel
16413556|NCT03884556|Experimental|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
16413642|NCT03883945|Active Comparator|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
16414421|NCT03878667|Placebo Comparator|No Diet|No diet or exercise or calcium intervention
16413557|NCT03884543|Experimental|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
16413558|NCT03884543|No Intervention|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
16413559|NCT03884530|Active Comparator|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
16413560|NCT03884530|Active Comparator|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
16413561|NCT03884517|Experimental|BAT8003 0.2mg/kg|BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3
16413562|NCT03884517|Experimental|BAT8003 0.5mg/kg|BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3
16413563|NCT03884517|Experimental|BAT8003 1mg/kg|BAT8003，1mg/kg，intravenous infusion, sample size 3
16413564|NCT03884517|Experimental|BAT8003 2mg/kg|BAT8003，2mg/kg，intravenous infusion, sample size 3
16413565|NCT03884517|Experimental|BAT8003 4mg/kg|BAT8003，4mg/kg，intravenous infusion, sample size 3
16413566|NCT03884517|Experimental|BAT8003 6mg/kg|BAT8003，6mg/kg，intravenous infusion, sample size 3
16413567|NCT03884517|Experimental|BAT8003 8mg/kg|BAT8003，8mg/kg，intravenous infusion, sample size 3
16413568|NCT03884517|Experimental|BAT8003 10mg/kg|BAT8003，10mg/kg，intravenous infusion, sample size 3
16413569|NCT03884517|Experimental|Amplification group|BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg
16413570|NCT03884491|Experimental|Vortioxetine|
16413571|NCT03884478|Experimental|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
16413572|NCT03884478|Experimental|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
16413573|NCT03884478|Other|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use & Control) and Round 4 (Stigma-Coping & Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
16413574|NCT03884465|Experimental|Inhaled dry powder treprostinil (LIQ861)|Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.
16413575|NCT03884452|Experimental|Atorvastatin 80 mg|80 mg atorvastatin taken orally, once daily for 12 weeks
16413576|NCT03884452|Experimental|Ezetimibe + Atorvastatin 40 mg|10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
16413577|NCT03884452|Experimental|Ezetimibe + Atorvastatin 80 mg|10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
16413578|NCT03884452|Experimental|Simvastatin 80 mg|80 mg simvastatin taken orally, once daily for 12 weeks
16413579|NCT03884452|Experimental|Ezetimibe + Simvastatin 40 mg|10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
16413580|NCT03884452|Experimental|Ezetimibe + Simvastatin 80 mg|10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
16413581|NCT03884439||Infliximab [infliximab biosimilar 3]|Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
16413582|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
16413583|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
16413584|NCT03884413||Breast cancer survivors|Study of spontaneous fertility outcomes following breast cancer history
16413585|NCT03884413||Control group|Study of spontaneous fertility outcomes in healthy volonteers population
16413586|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
16413587|NCT03884387|Experimental|Use of a Patient Decision Aid|A Patient Decision Aid is used in this arm in the clinical encounter. A tool designed to facilitate shared decision making when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
16413588|NCT03884387|No Intervention|Usual counceling|Usual counseling in the clinical encounter, when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
16413589|NCT03884374|Experimental|African American Group|African Americans with knee osteoarthritis (OA).
16413590|NCT03884374|Experimental|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
16413591|NCT03884361|Experimental|Vaginal Microbiome as result of aminocentesis|aginal Microbiome as result of aminocentesis by a blood and a vaginal samples that will taken before and after the aminocentesis
16413592|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
16413593|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
16413643|NCT03883945|Placebo Comparator|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
16464045|NCT03538626|Experimental|7|Smg/kg SC and 2000U /ml X 1
16413594|NCT03884335|Active Comparator|epidural group|An epidural catheter was placed at L1-L2 level, and tested, prior to induction. Induction was performed intravenously with fentanyl (1.5mcg•Kg-1), propofol (1.5-2 mg•Kg-1), and rocuronium (0.6 mg•Kg-1). Orotracheal intubation was performed. Prior to skin incision 8 mL of 0.25% levo-bupivacaine were administered epidurally, and a continuous perfusion of 0.125% levo-bupivacaine at 5 mL was started.
16413595|NCT03884335|Experimental|TAP group|Bilateral Transversus abdominis plane blockade (TAP) was performed following induction of anaesthesia ( the same of epidural group) and prior to skin incision, the high-frequency lineal probe (Sonosite MicroMAXXTM) was placed midway between the costal margin and iliac crest, and transversus abdominis muscle located behind the rectus abdominis and below the IOM. 20 mL of LA (bupivacaine 0.375%) was administered via a 22 gauge Quincke spinal needle inserted in-plane on each side of the abdomen. A successful block was recorded if the plane was seen to expand with fluid under ultrasound vision.
16413596|NCT03884322|Experimental|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
16413597|NCT03884322|Active Comparator|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
16413598|NCT03884309|Experimental|Experimental Hydrolyzed Protein Infant Formula|hydrolyzed protein infant formula powder in cans
16413599|NCT03884296|Other|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
16413600|NCT03884270|Experimental|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
16413601|NCT03884257|Experimental|Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).
16413602|NCT03884257|Active Comparator|IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).
16413603|NCT03884244|Active Comparator|taking chewing gum patients|
16413604|NCT03884244|No Intervention|no chewing gum|
16413605|NCT03884231||Leads-only configuration|The leads-only configuration consists of at least one implanted lead protected with a lead protection boot, as well as an optional cranial burr hole cover. Any leads must be completely implanted with the surgical incision closed.
16413606|NCT03884231||Full system configuration|The full system configuration consists of at least one IPG, one lead, one extension, and an optional cranial burr hole cover. All devices must be completely implanted with the surgical incision closed.
16413607|NCT03884218|Other|Thermal Comfort|Infra red thermal image
16413608|NCT03884205||test group|patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
16413609|NCT03884205||control group|patients with PTCL who receive CEOPE as the first-line therapy strategy
16413610|NCT03884192|Experimental|Sintilimab Arm|Sintilimab consolidation therapy
16413611|NCT03884192|No Intervention|Observation Arm|Observation
16413612|NCT03884166||stroke|
16413613|NCT03884166||control|
16413614|NCT03884153|Experimental|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
16413615|NCT03884127||hyperlipidaemia|On the basis of the intervention of therapeutic sexual life style, a case control study was conducted on the intervention of oral ezetimibe tablet and orlistat capsule for 12 weeks and hyperlipidemia patients who persisted in the use of basic treatment.
16413616|NCT03884114|Other|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
16413617|NCT03884101|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
16413618|NCT03884101|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
16413619|NCT03884088|Experimental|Experimental Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
16413620|NCT03884075|Experimental|Arm A: Steatosis|Participants with steatosis on baseline biopsy
16413621|NCT03884075|Experimental|Arm B: NASH|Participants with NASH on baseline biopsy
16413622|NCT03884075|No Intervention|Arm C: Healthy|Healthy Volunteers
16413623|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
16413624|NCT03884049|Experimental|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
16413625|NCT03884049|Sham Comparator|Sham Embolization Group|Group undergoes sham embolization
16413626|NCT03884036|Active Comparator|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
16413627|NCT03884036|Placebo Comparator|Control group|Normal saline 1 cc IM
16413628|NCT03884023||AD group|Alzheimer's disease
16413629|NCT03884023||aMCI group|Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
16413630|NCT03884023||NC group|Normal Control
16413631|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
16413632|NCT03883997||Participants|Professional male soccer players from the second professional Mexican division.
16413633|NCT03883984|Experimental|Cysteamine|Cysteamine Bitartrate plus standard asthma care
16413634|NCT03883984|Placebo Comparator|Placebo Oral Tablet|Placebo plus standard asthma care
16413635|NCT03883971|Experimental|3D model|patient is given 3D printed model of her fetus's face
16413636|NCT03883971|Placebo Comparator|picture|patient is given a fetal picture only.
16413637|NCT03883958|Active Comparator|TPVB|
16413638|NCT03883958|Experimental|ESPB|
16413639|NCT03883945|Placebo Comparator|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
16413640|NCT03883945|Active Comparator|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
16413644|NCT03883945|Active Comparator|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
16413645|NCT03883945|Placebo Comparator|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
16413646|NCT03883945|Active Comparator|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
16413647|NCT03883932|Experimental|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
16413648|NCT03883932|Active Comparator|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
16413649|NCT03883919|Experimental|Group 1: Paricalcitol 75 mcg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.
~Paricalcitol 75 mcg on Days 1 and 8
~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
16413650|NCT03883919|Experimental|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.
~Paricalcitol 7 mcg/kg on Days 1 and 8
~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
16413651|NCT03883906|Experimental|Viral Specific T-cells (VSTs)|
16413652|NCT03883893|Active Comparator|IV Tylenol|Participants will receive IV acetaminophen 15mg/kg in the OR.
16413653|NCT03883893|Placebo Comparator|Normal Saline|Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
16413654|NCT03883880|Experimental|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
16413655|NCT03883880|Experimental|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
16413656|NCT03883880|Experimental|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
16413657|NCT03883867||Normal|The subject population will involve 10 non-pregnant women. The tactile imaging reprifucibility sub-group will include 5 non-pregnant subjects with 2 tactile imaging examinations completed in one session. All other subjects will have a single tactile imaging examination.
16413658|NCT03883867||Pregnant|The subject population will involve 10 pregnant women without known complications at 36-37 weeks of pregnancy scheduled for a regular examination. All pregnant subjects should be examined weekly after completing 36th week of an uncomplicated pregnancy. Routine gynecologic examination includes external and internal obstetrical examination.
16413659|NCT03883854||1 group|"Complete iron profile
~serum iron
~serum ferritin
~total iron binding capacity
~transferrin saturation (TSAT)"
16413660|NCT03883841||Study group|patients with iron deficiency anemia
16413661|NCT03883841||control group|normal pregnant patients
16413662|NCT03883828|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
16413663|NCT03883828|No Intervention|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
16413664|NCT03883815||Assesment treatment intensity|Assesment treatment intensity during neurodevelopmental therapy session and active video games therapy session
16413665|NCT03883802|Experimental|Foxy-5|Arm will receive Foxy-5 as neo-adjuvant therapy prior to surgical removal of tumour and afterwards until initiation of FOLFOX 6 months regimen
16413666|NCT03883802|Active Comparator|Standard therapy|Surgical removal of tumour followed by 6 months FOLFOX regimen
16413667|NCT03883789||Normal pregnancies|Participants who have normal uncomplicated pregnancies
16413668|NCT03883789||Pregnancies with complications|Participants who undergo pregnancy with liver disease or develop liver disease or other conditions
16413669|NCT03883776|Experimental|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.
~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
16413670|NCT03883763|Experimental|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
16413671|NCT03883763|Active Comparator|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
16413672|NCT03883737|Experimental|Group 1: PNM in pain knee|participants in whom PNM will be applied to the femoral nerve of the pain knee
16413749|NCT03883269|Experimental|Erythromycin 4%|Erythromycin 4% topical gel formulation, BID, 4 weeks
16413673|NCT03883737|Experimental|Group 2: PNM in non-pain knee|participants in whom PNM will be applied to the femoral nerve of the non-pain knee
16413674|NCT03883724|Experimental|Brief behavioral treatment for insomnia|This group will undergo behavioral intervention proven to improve sleep among older adults: brief behavioral treatment for insomnia
16413675|NCT03883724|Other|Information-only control|This group is called information-only control. They will be provided sleep-related information. They will also view a video content of which overlap substantially with BBTI but without individualized behavioral instructions.
16413676|NCT03883711||Patients with acute coronary syndrome or myocardial injury|Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
16413677|NCT03883698|Experimental|ESRD, alternate day dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
16413678|NCT03883698|Experimental|ESRD, daily dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
16413679|NCT03883698|Active Comparator|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
16413680|NCT03883685|Experimental|experimental group|40 subjects will be randomly allocated to receive probiotics pills for consecutive 8 weeks.
16413681|NCT03883685|Placebo Comparator|Control group|40 subjects will be randomly allocated to receive placebo pills for consecutive 8 weeks.
16413682|NCT03883672|Experimental|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
16413683|NCT03883659|Active Comparator|traditional paper hangouts group|patients use the traditional paper hangouts to conduct the home exercise program at home
16413684|NCT03883659|Experimental|smartphone group|patients use the smartphone to conduct the home exercise program at home
16413685|NCT03883646|Experimental|Mindfulness|Mindfulness
16413686|NCT03883646|Experimental|Relapse Prevention|
16413687|NCT03883646|No Intervention|Waitlist Control|
16413688|NCT03883646|No Intervention|Treatment as Usual|
16413689|NCT03883633||Enrolled Participants|All participants enrolled will be tracked from initial assessment to study completion.
16413690|NCT03883620|Experimental|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
16413691|NCT03883620|Experimental|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
16413692|NCT03883620|Placebo Comparator|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
16413693|NCT03883620|Experimental|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
16413694|NCT03883620|Placebo Comparator|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
16413695|NCT03883620|Experimental|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
16413696|NCT03883620|Placebo Comparator|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
16413699|NCT03883594|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
16413700|NCT03883581|Experimental|ALS individuals with bulbar dysfunction|Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.
16413701|NCT03883555||Optiflow tm|High flow nasal therapy (HFNT)
16413702|NCT03883555||Non invasive ventilation (NIV)|Non invasive ventilation (NIV)
16413707|NCT03883529|Experimental|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
16413708|NCT03883516|Placebo Comparator|No pre-briefing prior to the simulation training|No pre-briefing prior to the simulation training
16413709|NCT03883516|Active Comparator|Pre-briefing with the current SE treatment guidelines|pre-briefing with the current SE treatment Guidelines published by the American Epilepsy Society
16413710|NCT03883516|Active Comparator|pre- briefing with consolidated SE treatment guideline|"pre-briefing with the consolidated one page SE treatment guideline"
16413711|NCT03883503|Experimental|Beer alone|Consumption of beer (correlated for weight to reach a blood alcohol concentration of 0.8) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
16413712|NCT03883503|Active Comparator|Beer and water|Consumption of beer and additional water (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of water, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
16413713|NCT03883503|Active Comparator|Beer and stock|Consumption of beer and additional stock(correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
16413714|NCT03883503|Placebo Comparator|Water alone|Consumption of water alone (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
16413715|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
16413716|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
16413717|NCT03883477|Experimental|Endoscopic Release|12 patients recommended for surgical treatment of trigger finger will undergo endoscopic release.
16413718|NCT03883477|Active Comparator|Standard Open Release|12 patients recommended for surgical treatment of trigger finger will undergo standard open surgical release.
16413719|NCT03883464|Experimental|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
16413720|NCT03883464|No Intervention|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
16413721|NCT03883451|Experimental|Helmet type|football player helmet model
16413722|NCT03883438|Active Comparator|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
16413723|NCT03883438|Experimental|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
16413724|NCT03883425||Case 1: formal home service recipients|Adults aged 65 or older living at home who receive formal home service (household, meal delivery, transportation, shopping) at least one a week
16413725|NCT03883425||Case 2: formal home care recipients|Adults aged 65 or older living at home who receive formal home care (shower/bath nursing assistance, nursing care) at least once a week
16413726|NCT03883425||Control: free of formal home care or home service|Adults aged 65 or older living at home who do not receive formal home care or home service.
16413727|NCT03883412|Experimental|Exercise Alone|16 weeks of treatment
16413728|NCT03883412|Experimental|Liraglutide alone|16 weeks of treatment
16413729|NCT03883412|Experimental|Exercise + Liraglutide|16 weeks of treatment
16413730|NCT03883399||Colorectal surgeons|Survey among Spanish colorectal surgeons
16413731|NCT03883386|Experimental|Loratadine first|Take treatment daily for 7 days.
16413732|NCT03883386|Placebo Comparator|Placebo first|Take placebo daily for 7 days.
16413733|NCT03883373||Cortical group|Group of patient who had an alveolar bone graft with cancellous bone and a cortical block
16413734|NCT03883373||Cancellous group|Group of patient who had an alveolar bone graft with cancellous bone only
16413735|NCT03883360|Experimental|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
16413736|NCT03883360|Placebo Comparator|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
16413737|NCT03883347|Active Comparator|Group DEX|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.
16413738|NCT03883347|Active Comparator|Group REMI|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.
16413739|NCT03883334|Experimental|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
16413740|NCT03883334|No Intervention|Control group|combine antiretroviral therapy only
16413741|NCT03883321||CBSM|Patients included in this group participate in the CBSM program. They attend 10 sessions of stress management according to the CBSM program, 9 take place over 3 months and the tenth session takes place 3 months after the 9th session. The session is composed of relaxation and cognitive and behavioral therapy, which is carried out in groups of 8 to 10 patients
16413742|NCT03883321||Waiting list|"The CBSM group is compared to the waiting list group that does not benefit from the CBSM program. After completing their assessment in the waiting list group, patients in this group will be integrated into the CBSM group but will not be evaluated as such."
16413743|NCT03883308|Experimental|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
16413744|NCT03883308|Active Comparator|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
16413745|NCT03883295|Experimental|Control|root canal treatment will be initiated
16413746|NCT03883295|Experimental|NeoMTA Plus|vital pulp treatment using neomta plus will be used.
16413747|NCT03883282||study group|Patients who have been participated in RCT in the period from 2011 to 2018 (study group)
16413748|NCT03883282||control group|- Patients who have never participated in RCT
16413752|NCT03883256|Active Comparator|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
16413753|NCT03883256|Active Comparator|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
16413754|NCT03883243|No Intervention|Control|Patients will only receive a brochure explaining the importance of physical activity with recommendations to improve it.
16413755|NCT03883243|Experimental|Telecoaching|Patients will receive a brochure explaining the importance of physical activity with recommendations to improve it. Next to this patients will receive the telecoaching intervention in which a coaching application linked to a step counter is installed on the patients smartphone, which will weekly give a new physical activity goal to improve the amount of steps per day for 8 weeks.
16413756|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
16413757|NCT03883217|Experimental|Vibration first then no vibration|A session with PDVibe2 vibration turned on first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned off.
16413758|NCT03883217|Experimental|No vibration first then vibration|A session with PDVibe2 vibration turned off first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned on.
16413759|NCT03883204|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
16413760|NCT03883204|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
16413761|NCT03883191|Experimental|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
16413762|NCT03883191|Placebo Comparator|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
16413763|NCT03883178|Experimental|Neurolysis|
16413764|NCT03883165|Experimental|high-intensity neck strengthening group|
16413765|NCT03883165|Experimental|low-intensity neck strengthening group|
16413766|NCT03883165|Other|Control group|
16413767|NCT03883152||Head and neck cancer|Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, & Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).
16413768|NCT03883139|Active Comparator|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.
~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 3 hours a week (3 days, 1 hour per day)."
16413769|NCT03883139|Active Comparator|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.
~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 3 hours a week (3 days, 1 hour per day)."
16413770|NCT03883126|Active Comparator|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
16413771|NCT03883126|Active Comparator|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
16413772|NCT03883126|Sham Comparator|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
16413773|NCT03883126|Sham Comparator|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
16413774|NCT03883126|No Intervention|Group E|Group E will have no intervention, they will only complete assessment sessions.
16413775|NCT03883113|Experimental|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
16413776|NCT03883113|Placebo Comparator|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
16413777|NCT03883100|Experimental|HQP1351|
16413778|NCT03883087|Experimental|HQP1351|
16413779|NCT03883074|Experimental|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
16413994|NCT03881527|Other|Resection of the aortic valve leaflets in standard fashion|Patients in which the aortic valve has been resected using a conventional blade or scissor
16413780|NCT03883074|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
16413781|NCT03883061||mortality of sepsis|the study sample would be extracted from electronic health records in emergence departments. risk factor analysis and mathematical modeling would be performed to evaluate the significant and independent risk factors and predictive models.
16413782|NCT03883035|Experimental|EAS-aided group|esophagogastroduodenoscopy examination with the assistance of automatic quality-control system
16413783|NCT03883035|No Intervention|control group|conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system
16413784|NCT03883022|Experimental|Vancomycin (V Group)|
16413785|NCT03883022|Active Comparator|Without Vancomycin (NV Group)|
16413786|NCT03882996|Experimental|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
16413787|NCT03882983|Experimental|Antria Cell Preparation Process|Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments
16413788|NCT03882970|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16413789|NCT03882970|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16413790|NCT03882970|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16413791|NCT03882970|Active Comparator|Insulin Degludec|Insulin degludec administered SC once a day.
16413792|NCT03882957|Active Comparator|Video|videos of media tasks being completed
16413793|NCT03882957|Experimental|media multi-task|media tasks
16413794|NCT03882957|Experimental|sustained attention task|a cognitive task that trains sustained attention
16413795|NCT03882931|Experimental|TMS to left DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the left DLPFC and complete a visuomotor rotation task.
16413796|NCT03882931|Experimental|TMS to right DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the right DLPFC and complete a visuomotor rotation task.
16413797|NCT03882931|Sham Comparator|TMS Control|A Sham Theta Burst Transcranial Magnetic Stimulation will be delivered to the right/left DLPFC and complete a visuomotor rotation task.
16413798|NCT03882931|Experimental|FUS to right/left DLPFC|Low intensity Focused Ultrasound stimulation will be delivered to either the left or right DLPFC depending on the subject's DLPFC response during their functional MRI flanker task.
16413799|NCT03882918|Experimental|OV101|once daily at bedtime (gaboxadol)
16413800|NCT03882905|Experimental|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
16413801|NCT03882905|Placebo Comparator|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
16413802|NCT03882905|Experimental|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
16413803|NCT03882905|Placebo Comparator|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
16413804|NCT03882892|Placebo Comparator|Placebo + Atorvastatin|Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
16413805|NCT03882892|Experimental|Ezetimibe + Atorvastatin|Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.
16413806|NCT03882879|Experimental|Arm 1|Participants in Arm 1 will begin participation in 6 months of karate classes immediately after the pre-intervention study visits.
16413807|NCT03882879|Experimental|Arm 2|Participants in Arm 2 will continue their usual exercise routine for six months followed by karate classes for six months
16413808|NCT03882866|Experimental|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
16413809|NCT03882866|Active Comparator|3D-printed coplanar template|3D-printed coplanar template is used in this group.
16413810|NCT03882853|Active Comparator|Conservative exercise group (CEG)|Conservative exercise group
16413811|NCT03882853|Experimental|Tree pose added exercise group (TPAEG)|Tree pose added exercise group
16413812|NCT03882840|Experimental|itNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
16413813|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
16413814|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
16413815|NCT03882801|Experimental|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
16413816|NCT03882801|Experimental|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
16413817|NCT03882788|Active Comparator|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.
~Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
16413995|NCT03881488|Experimental|Part 1 Dose Escalation|Escalating doses of CTX-471 depending on cohort at enrollment.
16413818|NCT03882788|Active Comparator|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.
~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose)."
16413819|NCT03882775|Experimental|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
16413820|NCT03882775|Active Comparator|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
16413821|NCT03882762|Experimental|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:
~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
16413822|NCT03882762|Experimental|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:
~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
16413823|NCT03882762|Experimental|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:
~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
16413824|NCT03882762|Experimental|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:
~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
16413825|NCT03882723|Active Comparator|BiTrac MaxShield™ with standard elbow (FFM)|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
16413826|NCT03882723|Active Comparator|BiTrac™ Full Face with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
16413827|NCT03882723|Active Comparator|Respironics PerforMax with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
16413828|NCT03882723|Active Comparator|Philips Respironics AF531 with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
16413829|NCT03882710|Experimental|metoprolol XR capsule|
16413830|NCT03882710|Placebo Comparator|placebo capsule|
16413831|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
16413832|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
16413833|NCT03882671|Experimental|Monitoring Device|Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv
16413834|NCT03882645|Experimental|CHH-diet arm|"During the 4-week intervention period, free meals conformed to CHH-diet will be provided 3 times per daily (breakfast, lunch, dinner). Different center offers different meals of different cuisines but all conformed to CHH-diet. The main nutrientional healthy goal of different cuisines will be achieved through specific nutrient targets, including fat, carbohydrate, protein, dietary fiber, sodium, potassium, magnesium and calcium."
16413835|NCT03882645|Other|local usual diet arm|During the 4-week intervention period, three meals per day (breakfast, lunch, dinner) will be provided free of charge in line with local dietary characteristics. The energy,protein, carbohydrate, as week as dietary fiber, sodium, calcium, magnesium and potassium will be kept the same as that in the run-in phase.
16413836|NCT03882632|Experimental|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
16413837|NCT03882619|Experimental|Calligraphy group|
16413838|NCT03882619|No Intervention|Treatment-as-usual group|
16413839|NCT03882606|Other|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
16413840|NCT03882593||Analysis of arterial filters during CPB|This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams
16413841|NCT03882567|Experimental|Electro Neuro adaptative Regulator|8 SCENAR sessions (twice a week) (30 min of duration) following the protocols for treatment several points in the body
16413996|NCT03881488|Experimental|Part 2 Dose Expansion|Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
16413842|NCT03882567|Sham Comparator|Sham Electro Neuro adaptative Regulator|8 Sham SCENAR sessions (twice a week) (30 min of duration), following the same protocol tan experimental group but the machine will be turn off 30 seconds after starting on the treatment.
16413843|NCT03882554|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
16413844|NCT03882541|No Intervention|Control group|headphones without music, without sedation
16413845|NCT03882541|Active Comparator|sedative group|headphones without music, with sedation
16413846|NCT03882541|Experimental|experimental group|headphones with music, without sedation
16413847|NCT03882528|Experimental|Infective controls|Controlled Human Malaria Infection (CHMI) will consist of exposure to Plasmodium falciparum sporozoites through the bites of infected mosquitoes. Beginning 5 days after the challenge, subjects will be evaluated daily for the development of malaria infection using a blood smear.
16413848|NCT03882515|Experimental|Experimental group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after myofascial release
16413849|NCT03882515|Sham Comparator|Sham group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after continuous surface slip technique
16413850|NCT03882515|Active Comparator|Control group|Evaluation and reassessment of asymptomatic individuals
16413851|NCT03882502|Experimental|stimulation group|
16413852|NCT03882502|Sham Comparator|sham stimulation|
16413853|NCT03882489||Cohort 1 : Height 150-165 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 1 includes patients whose the height is between 150 and 165 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 40 mg in the cohort 1 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 25 to 50 mg for cohort 1.
16413854|NCT03882489||Cohort 2 : Height 166-180 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 2 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 45 mg in the cohort 2 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 30 to 55 mg for cohort 2.
16413855|NCT03882489||Cohort 3 : Height 181-195 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 3 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 50 mg in the cohort 3 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 35 to 60 mg for cohort 3.
16413856|NCT03882476|Experimental|Experimental|The experimental arm will involve patients monitored by InSight.
16413857|NCT03882476|No Intervention|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
16413858|NCT03882463|Experimental|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
16413859|NCT03882450|No Intervention|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
16413860|NCT03882450|Active Comparator|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
16413861|NCT03882437|Experimental|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
16413862|NCT03882424|Experimental|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
16413863|NCT03882424|Active Comparator|China-approved Bevacizumab|Intravenous administration
16413864|NCT03882424|Active Comparator|US-licensed Avastin|Intravenous administration
16413865|NCT03882411|Experimental|Electronic shared decision making (eSDM) Tool|When a clinic's randomly allotted intervention period arrives, coronary heart disease patients in a given cluster of clinics will complete a web application, which delivers screening, behavioral activation and shared decision making (eSDM), and providers will receive a patient preference report generated from the application.
16413866|NCT03882411|No Intervention|Usual Care|In the year prior to the allocated intervention period, coronary heart disease patients will receive usual care from their providers.
16413867|NCT03882398|Experimental|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
16413868|NCT03882398|Active Comparator|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
16413997|NCT03881475||healthcare workers|Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
16413869|NCT03882372|Experimental|Nasal high flow|"Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.
~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow."
16413870|NCT03882372|No Intervention|Usual care|"Patient randomized to the control group will have no other specific intervention than their usual care.
~Patients under long-term oxygen will preserve their usual flow."
16413871|NCT03882359|Active Comparator|Definity|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of DEFINITY® 100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
16413872|NCT03882359|Experimental|MVT-100|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of MVT-100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
16413873|NCT03882346|No Intervention|Control Group|Patients in Control Group will receive best supportive care for the disease.
16413874|NCT03882346|Experimental|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
16413875|NCT03882333|Experimental|Acute exercise|Acute exercise (bicycle at stationary cycle).
16413876|NCT03882333|No Intervention|Rest|Rest (lying down or sitting in a chair) for 30 minutes, i.e. same time duration as in experimental arm.
16413877|NCT03882320|Experimental|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
16413878|NCT03882320|Active Comparator|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
16413879|NCT03882307|No Intervention|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
16413880|NCT03882307|Active Comparator|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
16413881|NCT03882294|Experimental|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10^10 CFU/bottle (80 ml)
16413882|NCT03882294|Placebo Comparator|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
16413883|NCT03882281|Experimental|A group|Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
16413884|NCT03882281|Experimental|B group|Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
16413885|NCT03882268|Experimental|MIYCN interventions|10 facilities run by 2 NGOs that will be randomly selected to receive intensified MIYCN interventions.
16413886|NCT03882268|No Intervention|Comparison facilities|10 facilities run by same 2 NGOs that run the intervention facilities, which will not receive any standardized MIYCN interventions.
16413887|NCT03882255|Experimental|Treatment Period 1: Ponesimod (2 mg)|Participants will receive a single dose ponesimod 2 milligram (mg) oral tablet under fed conditions on Day 1. Participants not fulfilling discontinuation criteria can continue to Treatment Period 2 after a washout period of at least 7 days and a maximum of 14 days.
16413888|NCT03882255|Experimental|Treatment Period 2:Ponesimod, Propranolol, Placebo Propranolol|Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.
16413889|NCT03882242|Experimental|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
16413890|NCT03882216|Experimental|test group pouch technique|free connective tissue graft augmentation using pouch technique
16413891|NCT03882216|Experimental|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
16413892|NCT03882203|Experimental|treatment|Patients receive the study protocol: CLAGE sequential with Flu-Bu as conditioning regimen followed by low-dose decitabine maintenance
16413893|NCT03882190|No Intervention|group 1|
16413894|NCT03882190|Experimental|group 2|
16413895|NCT03882177|Experimental|Arm 1: Pravastatin (40 mg) and Rifafour|"Participants will receive pravastatin (40 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens."
16413896|NCT03882177|Experimental|Arm 2: Pravastatin (80 mg) and Rifafour|"Participants will receive pravastatin (80 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens."
16413897|NCT03882177|Experimental|Arm 3: Pravastatin (120 mg) and Rifafour|"Participants will receive pravastatin (120 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens.
~(Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
16413935|NCT03881891|Experimental|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
16413898|NCT03882177|Experimental|Arm 4: Pravastatin (160 mg) and Rifafour|"Participants will receive pravastatin (160 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens.
~(Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
16413899|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
16413900|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
16413901|NCT03882151|Experimental|Epilog Preop|patients receive Epilog preop analysis
16413902|NCT03882138|Active Comparator|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
16413903|NCT03882138|Active Comparator|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
16413904|NCT03882125|Experimental|Mindfulness|Assigned to a 6-week mindfulness-based relapse prevention course
16413905|NCT03882112|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
16413906|NCT03882112|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
16413907|NCT03882099||Pregnant women with pre-eclampsia|
16413908|NCT03882099||Pregnant women with eclampsia|
16413909|NCT03882099||Normotensive pregnant women|
16413910|NCT03882086|Experimental|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
16413911|NCT03882086|No Intervention|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
16413912|NCT03882073|Experimental|Intervention group|Modified amputation procedure
16413913|NCT03882073|Active Comparator|Control group|Standard amputation procedure
16413914|NCT03882060|Experimental|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
16413915|NCT03882060|Placebo Comparator|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
16413916|NCT03882047|Experimental|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
16413917|NCT03882047|Active Comparator|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
16413918|NCT03882047|Placebo Comparator|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
16413919|NCT03882034|Experimental|1|Intervention arm, Patient received pegvisomant
16413920|NCT03882021|Other|Mapping protocol with GRID catheter|All patient will undergo a protocol required mapping protocol using the GRID catheter.
16413921|NCT03882008|Experimental|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
16413922|NCT03881995|Active Comparator|iGlarLixi|Subjects will receive premixed Insulin glargine + lixisenatide once daily for 12 weeks
16413923|NCT03881995|Active Comparator|Insulin glargine|Subjects will receive Insulin glargine once daily for 12 weeks
16413924|NCT03881982|Experimental|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.
~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
16413925|NCT03881982|Other|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.
~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
16413926|NCT03881969|Experimental|Financial incentive offered|Patient offered £100 incentive payment in initial trial invitation letter.
16413927|NCT03881969|Experimental|No incentive. Payment not offered|Patient sent standard trial invitation letter with no offer of incentive payment.
16413928|NCT03881956|Other|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
16413929|NCT03881943|Active Comparator|Ticagrelor|Ticagrelor 60mg BD for 3 months
16413930|NCT03881943|Active Comparator|Aspirin|Aspirin 100mg daily for 3 months
16413931|NCT03881930|Experimental|Experimental group|"Balance rehabilitation with modified visual input:
~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.
~They will perform balance training with modified visual input."
16413932|NCT03881930|Active Comparator|control group|"Balance rehabilitation with no modified visual input:
~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.
~They will perform balance training with no modified visual input."
16413933|NCT03881904|Active Comparator|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
16413934|NCT03881904|No Intervention|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
16413936|NCT03881891|No Intervention|Standard care arm|This arm will comprise of patients who receive the usual care.
16464046|NCT03538626|Experimental|8|20mg/kg SC and 2000U/ml x 1
16413937|NCT03881878|Experimental|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks
~Docetaxel (75mg/m2, IV)
~Atezolizumab (1200mg, IV)
~Trastuzumab (600mg, SC)
~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)
~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks
~Atezolizumab (1200mg, IV)
~Trastuzumab (600mg, SC)
~Pertuzumab (420mg, IV)"
16413938|NCT03881878|Experimental|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks
~Docetaxel (75mg/m2, IV)
~Atezolizumab (1200mg, IV)
~Trastuzumab (600mg, SC)
~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)
~(B, Adjuvant setting) :
~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by
~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
16413939|NCT03881852|Experimental|AXS-12 (reboxetine)|
16413940|NCT03881852|Placebo Comparator|Placebo|
16413941|NCT03881839||patient in emergency department|
16413942|NCT03881826|Experimental|Haematological patients|
16413943|NCT03881826|Active Comparator|Healthy volunteers|
16413944|NCT03881813|Experimental|Fiber reinforced composite retainers|Fiber reinforced composite retainers were inserted in group 1 and were evaluated after every 3 months for a follow up period of 3 months.
16413945|NCT03881813|Experimental|Multistranded stainless steel retainers|Multistranded stainless steel retainers were inserted in group 2 and were evaluated after every 3 months for a follow up period of 3 months.
16413946|NCT03881787|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
16413947|NCT03881787|Active Comparator|Cetuximab|Cetuximab,Erbitux 250mg/m2 single administration
16413948|NCT03881774|Experimental|experimental arm|cord blood derived CAR T cells group
16413949|NCT03881761|Experimental|experimental arm|CAR-T cell group
16413950|NCT03881748|Experimental|Manual acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points.
16413951|NCT03881748|Experimental|Electro-acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points with additional application of weak electrical stimulation
16413952|NCT03881735|Experimental|Cohort A (enasidenib, hematopoietic cell transplantation)|Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
16413953|NCT03881735|Active Comparator|Cohort B (enasidenib)|Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16413954|NCT03881722|Active Comparator|thickened formula|
16413955|NCT03881722|Experimental|Mg alginate|
16413956|NCT03881709|Experimental|The intervention group|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
16413957|NCT03881709|No Intervention|The control group|The control group will receive a health education about prostate biopsy.
16413958|NCT03881696|Experimental|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.
~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.
~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
16413959|NCT03881696|Experimental|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.
~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
16413960|NCT03881696|Placebo Comparator|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.
~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.
~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
16413961|NCT03881696|Experimental|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:
~Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR
~Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.
~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
16413998|NCT03881462|Experimental|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
16413962|NCT03881696|Experimental|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy
~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.
~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
16413963|NCT03881696|Experimental|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.
~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
16413964|NCT03881696|Other|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.
~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:
~Long-term follow-up with dietary consumption of a food;
~Long-term follow-up with avoidance of a food; or
~Rescue OIT for a food.
~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will remain in Stage 3 until December 2023.
~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
16413965|NCT03881683|Experimental|HRD and BRCA mutations|
16413966|NCT03881670|Placebo Comparator|Lotrafilcon B|
16413967|NCT03881670|Active Comparator|Lotrafilcon B Hydraluxe|
16413968|NCT03881657|Experimental|Intervention Group|The intervention group received a reverse colocated integrated behavioral health intervention or usual care
16413969|NCT03881657|Active Comparator|Control Group|The control group received behavioral health services only (usual care)
16413970|NCT03881644|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Imigran infusion (0.4 mg/min) for 10 mins"
16413971|NCT03881644|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Isotonic saline for 10 mins (placebo)"
16413972|NCT03881631|Experimental|Mindfulness Based Stress Reduction (MBSR) Program|The MBSR program is an eight-week-long course designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
16413973|NCT03881631|Active Comparator|Living Well (LW) Program|LW is an eight-week course of group presentations and discussions on topics related to the promotion of health and well-being in the context of dementia caregiving. LW is designed to teach participants how to improve their physical and emotional health as a complement to traditional medical treatments.
16413974|NCT03881631|No Intervention|Usual Care|The usual care arm is a no intervention group wherein participants experience their usual circumstances.
16413975|NCT03881618|Experimental|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
16413976|NCT03881618|Active Comparator|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
16413977|NCT03881605|Experimental|MRI screening|Contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain at baseline, 4 months, 8 months and 12 months.
16413978|NCT03881605|No Intervention|Symptom-directed surveillance|Imaging of the brain will take place only if patients develop symptoms that are suggestive of brain metastases (e.g. headaches, vision changes, gait instability).
16413979|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
16413980|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
16413981|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
16413982|NCT03881579|Other|Usual care|one random half of patients will receive usual care
16413983|NCT03881579|Experimental|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
16413984|NCT03881566||Immunocompetent sepsis patients|Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
16413985|NCT03881566||Immunocompromised sepsis patients|Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
16413986|NCT03881566||Patients without sepsis|Patients who admitted intensive care unit without sepsis
16413987|NCT03881553|Experimental|Premature Infants (NICU)|Premature infants receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
16413988|NCT03881553|Experimental|Opioid-Exposed Newborns (NICU)|Opioid-exposed newborns receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
16413989|NCT03881553|Experimental|Hospitalized Infants (PICU)|Infants receiving treatment in the Pediatric Intensive Care or Inpatient Unit will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
16413990|NCT03881540|Active Comparator|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
16413991|NCT03881540|Active Comparator|tDNA-CC group|Follow tDNA intervention and conventional counselling
16413992|NCT03881540|Other|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
16413993|NCT03881527|Experimental|Resection of the aortic valve leaflets with device|Patients in which the aortic valve has been resected using the nitinol blade
16414243|NCT03879915||Prospective Dental Implant placement|Patients prospectively included and treated following current recommendations
16413999|NCT03881449|Experimental|ABILIFY MYCITE Group|"If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.
~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
16414000|NCT03881449|No Intervention|Treatment as Usual (TAU) Group|"TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.
~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
16414001|NCT03881436|Experimental|Pelvic MRI|"This arm involves patients undergoing a pelvic MRI.
~At the end of the planned sequence, but before any contrast agent injection:
~Acquisition of a an additional anatomical T2 SPACE sequence
~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
16414002|NCT03881436|Experimental|Pelvic surgery|"This arm involves patients undergoing a pelvic surgery and coming for a postoperative MRI. An additional MRI is performed before the surgery and additional sequences are added to the planned postoperative MRI, at the end of the planned sequence, but before any contrast agent injection:
~Acquisition of a an additional anatomical T2 SPACE sequence
~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
16414003|NCT03881423|Active Comparator|Deep block|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
16414004|NCT03881423|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
16414005|NCT03881410|Experimental|Shear-wave elastography-guided|
16414006|NCT03881410|Active Comparator|Convention ultrasound-guided|
16414007|NCT03881397|No Intervention|Control (Track B assessed at Time 2)|A survey regarding tech use, health behaviors and well-being including physical activity, anxiety, and sleep
16414008|NCT03881397|Experimental|Online Family Media Use Plan (Track A)|The Online Family Media Use Plan group will receive a link to American Academy of Pediatrics Family Media Use plan at the end of the survey, which describes internet safety ideas for teens and parents to review and create together.
16414009|NCT03881397|Experimental|Media Use Resources Awareness (Track B assessed at Time 3)|Resources offered to parents and teens that include tools and data for safe technology use among teens
16414010|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
16414011|NCT03881371|Experimental|Safinamide|Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
16414012|NCT03881371|Placebo Comparator|Placebo|Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
16414013|NCT03881358|Active Comparator|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
16414014|NCT03881358|Experimental|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
16414015|NCT03881319|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
16414016|NCT03881319|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
16414017|NCT03881319|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
16414018|NCT03881306|Experimental|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
16414019|NCT03881293|Placebo Comparator|Placebo Lubricant Gel|5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
16414020|NCT03881293|Active Comparator|Lidocaine 2% Gel|5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
16414021|NCT03881280|No Intervention|Control group|Treatment as usual for 4 weeks
16414022|NCT03881280|Experimental|Intervention group|Education through the app for 4 weeks
16414023|NCT03881267|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a venous leg wound in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing and compression
16414024|NCT03881267|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on venous leg wounds in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing and compression
16414025|NCT03881254|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
16414026|NCT03881254|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
16414027|NCT03881241||Study Treatment|EVOS SMALL PLating System
16414088|NCT03880838|Experimental|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
16414028|NCT03881228|Experimental|Intervention|"at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given
~at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive
~weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
16414029|NCT03881228|No Intervention|Standard of care|Routine care at the health facility
16414030|NCT03881215|Experimental|Platelet Rich Plasma|PRP
16414031|NCT03881215|Active Comparator|intra-uterine balloon|
16414032|NCT03881202|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
16414033|NCT03881189|Experimental|SUNEKOS ® 200|"The 1st intradermal treatment (T1i) with Sunekos ® 200 was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)"
16414034|NCT03881176|Experimental|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.
~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
16414035|NCT03881163|Experimental|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
16414036|NCT03881163|Experimental|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
16414037|NCT03881150|Experimental|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.
~Counseling is considered about physical activity, diet, smoking, and medication compliance."
16414038|NCT03881150|Active Comparator|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
16414039|NCT03881137|Experimental|Intervention|Geriatric assessment with management
16414040|NCT03881137|No Intervention|Control|Patients receiving supportive care and follow up according to routine practice
16414041|NCT03881111|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
16414042|NCT03881111|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
16414044|NCT03881072|Other|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
16414045|NCT03881059|Placebo Comparator|Part A: Placebo|
16414046|NCT03881059|Experimental|Part A: BMS-986165 Dose A|
16414047|NCT03881059|Experimental|Part A: BMS-986165 Dose B|
16414048|NCT03881059|Experimental|Part B: Ustekinumab + BMS-986165 Placebo|
16414049|NCT03881059|Experimental|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
16414050|NCT03881059|Experimental|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
16414051|NCT03881046||lung cancer|
16414052|NCT03881046||healthy control group|
16414053|NCT03881033|Placebo Comparator|P12|
16414054|NCT03881033|Active Comparator|P7+5|
16414055|NCT03881020|Experimental|SMART|Silver modified atraumatic restorative treatment group in which advantage Arrest Silver diamine Fluoride 38% (Elevate oral Care, USA ) will be applied to carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
16414056|NCT03881020|Active Comparator|Conventional ART|Conventional atraumatic restorative treatment group in which a sharp excavator will be used to remove caries from carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
16414057|NCT03881007|Experimental|LCM, then placebo|Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.
16414058|NCT03881007|Experimental|Placebo, then LCM|Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months
16414059|NCT03880981|Active Comparator|Acetaminophen|Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain
16414060|NCT03880981|Active Comparator|Ibuprofen|Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain
16414061|NCT03880968||inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
16414062|NCT03880968||inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
16414063|NCT03880968||low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to sequential tapering group (B1).
16414064|NCT03880968||low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
16414065|NCT03880968||low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to discontinuation group (B3).
16414066|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:
~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis
~Failed previous shoulder joint replacement"
16414067|NCT03880942|Active Comparator|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
16414068|NCT03880942|Placebo Comparator|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
16414069|NCT03880916|Experimental|Duloxetine group|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)
~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
16414070|NCT03880916|Placebo Comparator|Placebo group|"Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)
~Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
16414071|NCT03880903|Experimental|normal saline with bronchdilator|will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
16414072|NCT03880903|Experimental|hypertonic saline with bronchodilator|will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
16414073|NCT03880903|Experimental|hypertonic saline only|will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
16414074|NCT03880890|Active Comparator|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
16414075|NCT03880890|Active Comparator|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
16414076|NCT03880877|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).
~Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle."
16414077|NCT03880877|Active Comparator|Regorafenib|Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.
16414078|NCT03880851|Other|Hypofractionated image-guided radiotherapy|"Hypofractionated image-guided radiotherapy IGRT to a total dose of 60 Gy (20 fractions) is performed.
~Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.
~Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy."
16414079|NCT03880838|No Intervention|No contact control|Participants are not contacted.
16414080|NCT03880838|Experimental|Letter|Participants are only contacted through a letter with a personal testimonial.
16414081|NCT03880838|Experimental|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
16414082|NCT03880838|Experimental|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
16414083|NCT03880838|Experimental|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
16414084|NCT03880838|Experimental|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
16414085|NCT03880838|Experimental|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
16414086|NCT03880838|Experimental|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
16414087|NCT03880838|Experimental|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
16414089|NCT03880838|Experimental|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
16414090|NCT03880838|Experimental|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
16414091|NCT03880838|Experimental|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
16414092|NCT03880838|Experimental|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
16414093|NCT03880825|Other|Metformin Only|
16414094|NCT03880825|Other|Levoketoconazole Only|
16414095|NCT03880825|Other|Levoketoconazole + Metformin|
16414096|NCT03880812|Experimental|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
16414097|NCT03880812|No Intervention|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
16414098|NCT03880799|Experimental|Mindfulness Intervention|Newly diagnosed breast cancer patients who undergo a mindfulness session before their surgical appointment.
16414099|NCT03880786|Experimental|PNE test lead|
16414100|NCT03880773|Experimental|Stapler|
16414101|NCT03880773|Active Comparator|ultrasonic shears|
16414102|NCT03880760|Experimental|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
16414103|NCT03880760|Placebo Comparator|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
16414104|NCT03880747||Vagus nerve preserving group|Patients who underwent vagus nerve-preserving distal gastrectomy for early gastric cancer
16414105|NCT03880734|Experimental|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
16414106|NCT03880734|Experimental|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
16414107|NCT03880721||Good prognosis|
16414108|NCT03880721||Poor prognosis|
16414109|NCT03880721||Recurrence|
16414110|NCT03880721||Not Recurrence|
16414111|NCT03880721||Survival|
16414112|NCT03880721||Death|
16414113|NCT03880695|Experimental|Anlotinib+ Liposomal Doxorubicin|Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
16414114|NCT03880682||Study Group|Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
16414115|NCT03880656|Experimental|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
16414116|NCT03880656|No Intervention|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
16414117|NCT03880656|Experimental|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
16414118|NCT03880643||Study Group|Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.
16414119|NCT03880630|Experimental|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
16414120|NCT03880617||Chronic Myeloid Leukemia (CML)|For CML, the first-line targeted drug is imatinib, and then second line as nilotinib and dasatinib. In the past, the median survival of CML is around 4 to 6 years (NCI, 2008). Fortunately, the launch of the targeted therapy, the median survival is expected to approach normal life expectancy for most patients. However, limited to the less than 20 years of advent of TKI, the exact effects on survival time is not yet determined.
16414121|NCT03880617||Gastrointestinal Stromal Tumor (GIST)|For patients with GIST, the imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) (Heinrich et al, 2003) is the first line drug and sunitinib as the second line drug. Sunitinib is an anti-angiogenesis agent by virtue of targeting multiple tyrosine kinases, including the vascular endothelial growth factor receptors (VEGFR). With these target drugs, the survival of advanced GIST patients is prominently prolonged (Lamba, Ambrale, Lee, Gupta, Rafiyath, & Liu D, 2012). The median overall survival (OS) of advanced GIST patients increased from 18 to 57 months with imatinib therapy (Blanke et al, 2008).
16414122|NCT03880604|Active Comparator|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
16414123|NCT03880604|Active Comparator|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
16414124|NCT03880578||surgery (withdrawn, not continuing recruiting)|thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
16414125|NCT03880578||radioiodine|thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
16414126|NCT03880578||control|thyroid patients followed without surgery or radioiodine treatment
16414127|NCT03880565|Experimental|ECMO Facilitated Resuscitation|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation: ECMO is initiated expeditiously, regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
16414156|NCT03880357|Active Comparator|Reference Product|Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)
16414157|NCT03880357|Placebo Comparator|Placebo|Vehicle of the test product (Taro Pharmaceuticals Inc.)
16414128|NCT03880565|Other|Standard ACLS Resuscitation|Standard Advanced Cardiac Life Support (ACLS) Resuscitation: Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
16414129|NCT03880539|Other|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
16414130|NCT03880526||Semi-Structured Interview|Participants will choose to participant in an individual in-depth interview to be conducted by investigators to gain information about the participant's background, cancer status and treatment.
16414131|NCT03880526||Focus Groups|Participants may choose to participate in one of three focus groups of no more than 10 participants in each group to to gain information about the participant's background, cancer status and treatment.
16414132|NCT03880513||Longitudinal study|Patients during overt and after cure of endogenous Cushing's syndrome.
16414133|NCT03880513||Cross-sectional study|Patients with proven endogenous Cushing's syndrome (overt or subclinical).
16414134|NCT03880500|Sham Comparator|Patient|25 Patients will receive a spinal manipulative therapy Intervention, the other 25 Patients receive a sham Intervention.
16414135|NCT03880500|No Intervention|Control|No intervention
16414136|NCT03880487|Experimental|KP-1199|
16414137|NCT03880487|Placebo Comparator|Placebo oral capsules|
16414138|NCT03880487|Active Comparator|Oxycodone oral capsules|
16414139|NCT03880474|Experimental|MVA-NP+M1|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.)
16414140|NCT03880474|Placebo Comparator|Saline Placebo|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
16414141|NCT03880461|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines.
16414142|NCT03880461|No Intervention|Usual Care - Control|Usual Medical Care
16414143|NCT03880448|Experimental|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
16414144|NCT03880448|Placebo Comparator|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
16414145|NCT03880435|Experimental|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
16414146|NCT03880435|No Intervention|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
16414147|NCT03880422|Experimental|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
16414148|NCT03880409|Active Comparator|2% lidocaine with 1:000,000 epinephrine|supplemental intraseptal injections using 0.8 mL 2% lidocaine with 1:000,000 epinephrine
16414149|NCT03880409|Active Comparator|4% articaine with 1:000,000 epinephrine|buccal infiltration of 1.8 ml 4% articaine with 1:000,000 epinephrine
16414150|NCT03880396|Other|hypofractionated Rth with weekly cisplatin 40mg/m2|hypofractionated radioyherapy with weekly cisplatin 40mg/m2
16414151|NCT03880383|Experimental|Group 1 - Coaching|"Upon enrollment to the study, parents in this group will have immediate access to the full intervention:
~Coaching: Telephone contact with coaches, who will provide information, education and support about the child's development. Coaching will be adapted to family needs, situation, preferences and child's condition.
~Online parent education: Parents will be provided access to empowering online tools, such as educational resources, chosen or developed by other parents and researchers.
~Peer support tools: Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge."
16414152|NCT03880383|Other|Group 2- Partial and delayed coaching|"Parents in this group will have delayed and partial access to coaching, at the end of the 18-month period. Parents in this group will have a one-time session with a developmental coach who can give them guidance about their child's development. Parents in this group will also then get access to online parent education and peer support tools, indefinitely, until the online platform is de-activated.
~* Both arms/groups* will obtain usual care for their child, in addition and independent of full or partial coaching."
16414153|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
16414154|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
16414155|NCT03880357|Experimental|Test Product|Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)
16414202|NCT03880175|Experimental|FCC control and High coupon value|
16414158|NCT03880344|Experimental|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
16414159|NCT03880344|Active Comparator|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
16414160|NCT03880331|Active Comparator|Aggressive Debridement|Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
16414161|NCT03880331|Active Comparator|Minimal Debridement|No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
16414162|NCT03880318|Other|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
16414163|NCT03880292|Other|Intraoperative Maneuvers|To document intraoperative maneuvers performed in repsonse to alerts
16414164|NCT03880279|Experimental|TAC01-CD19|TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
16414165|NCT03880266|Active Comparator|Group 1 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
16414166|NCT03880266|Placebo Comparator|Group 1 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
16414167|NCT03880266|Active Comparator|Group 2 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
16414168|NCT03880266|Placebo Comparator|Group 2 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
16414169|NCT03880266|Active Comparator|Group 3 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes
16414170|NCT03880266|Placebo Comparator|Group 3 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes
16414171|NCT03880266|Active Comparator|Group 4 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes
16414172|NCT03880266|Placebo Comparator|Group 4 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes
16414173|NCT03880253|Experimental|CTP-692 Low Dose or Matching Placebo|Once daily dosing
16414174|NCT03880253|Experimental|CTP-692 Mid Dose or Matching Placebo|Once daily dosing
16414175|NCT03880253|Experimental|CTP-692 High Dose or Matching Placebo|Once daily dosing
16414176|NCT03880240|Experimental|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
16414177|NCT03880240|Experimental|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
16414178|NCT03880240|Experimental|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
16414179|NCT03880240|Sham Comparator|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
16414180|NCT03880227|Experimental|Anodal followed by sham stimulation tDCS to rTPJ|cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
16414181|NCT03880227|Active Comparator|Anodal followed by sham stimulation tDCS to dmPFC|cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
16414182|NCT03880227|Experimental|Sham followed by anodal stimulation tDCS to rTPJ|cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
16414183|NCT03880227|Active Comparator|Sham followed by anodal stimulation tDCS to dmPFC|cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
16414184|NCT03880214||stem cells transplanted pediatric patients|screen pediatric patients at least 3 months after they undergo allogeneic hematopoietic stem cells transplantation to detect any risk factors for developing oral manifestations of chronic graft -versus-host disease during this period
16414185|NCT03880201||patient undergoing upper limb orthopaedic surgery|The study will be performed on patient undergoing upper limb orthopaedic surgery which will be performed under ultrasound guided supraclavicular block.
16414186|NCT03880175|Experimental|FCC DEB and Anti-stigma|
16414187|NCT03880175|Experimental|FCC DEB and HIV info|
16414188|NCT03880175|Experimental|FCC DEB and ART info|
16414189|NCT03880175|Experimental|FCC DEB and HIV-ART info|
16414190|NCT03880175|Experimental|FCC DEB and high coupon value|
16414191|NCT03880175|Experimental|FCC DEB and no info|
16414192|NCT03880175|Experimental|FCC non-DEB and Anti-stigma|
16414193|NCT03880175|Experimental|FCC non-DEB and HIV info|
16414194|NCT03880175|Experimental|FCC non-DEB and ART info|
16414195|NCT03880175|Experimental|FCC non-DEB and HIV-ART info|
16414196|NCT03880175|Experimental|FCC non-DEB and high coupon value|
16414197|NCT03880175|Experimental|FCC non-DEB and no info|
16414198|NCT03880175|Experimental|FCC control and Anti-stigma|
16414199|NCT03880175|Experimental|FCC control and HIV info|
16414200|NCT03880175|Experimental|FCC control and ART info|
16414201|NCT03880175|Experimental|FCC control and HIV-ART info|
16414204|NCT03880162|Experimental|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
16414205|NCT03880162|Active Comparator|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
16414206|NCT03880149|Experimental|Omega-3 supplementation|Omega-3 fatty supplementation and vitamin E. Each 1 g omega-3 capsule contain 600 mg omega-3 including 400 mg EPA + 200 mg DHA. Individual omega-3 dose will be determined according to the athlete's body mass, 1 g omega-3 / 15 kg body mass per day and vitamin E: 1 capsule of vitamin E (400 IU) for every five omega-3 capsules
16414207|NCT03880149|Placebo Comparator|Placebo|Medium-chain triglyceride (MCT) and vitamin E. Each MCT capsule contain 1 g, the dose will be 115 mg per kg body mass per day, and vitamin E: 1 capsule of vitamin E (400 IU) for every five MCT capsules
16414208|NCT03880136|Experimental|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
16414209|NCT03880136|Experimental|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
16414210|NCT03880123|Experimental|Selinexor/Ixazomib|Patients will receive combination treatment with selinexor and ixazomib. The dose of ixazomib is fixed at 4 mg, whereas several different dose levels of selinexor may be evaluated. No patients will receive a placebo.
16414211|NCT03880097||Research Biopsy|"The research biopsy is the same procedure as a standard of care percutaneous biopsy. A core (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes."
16414212|NCT03880071|Experimental|DBT + ACT group|- The experimental group (DBT+ ACT) led in Montpellier during 6 months.
16414213|NCT03880071|Other|DBT group|The control group (DBT) led in Geneva during 12 months.
16414214|NCT03880058|Active Comparator|SLI-F06|
16414215|NCT03880058|Placebo Comparator|Formulation Buffer|
16414216|NCT03880045|Active Comparator|Topical TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
16414217|NCT03880045|Active Comparator|placebo to TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid
16414218|NCT03880032|Experimental|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
16414219|NCT03880032|No Intervention|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Transportation will be facilitated to assist participants in attending appointments and medically indicated ultrasounds will be paid for (as in the intervention group).
16414221|NCT03880006|No Intervention|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
16414222|NCT03880006|Experimental|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
16414223|NCT03879993|Experimental|Exercise group|Exercise group was resistance training three times per week, during 45 to 60 minutes per day. Training program was composed by bench press, leg press 45°, lat pulldown, knee extension, dumbbell lateral raise, horizontal leg curl, triceps pulldown, seated calf raise, biceps curls and abdominal. Participants should complete 3 series with 8-12 repetitions of each exercise, which was supervised by trained research personnel. There were 60 seconds of interval between series and exercises were separated by a 120 seconds recovery period.
16414224|NCT03879993|No Intervention|Control group|Control group was not do any exercise during intervention period. Participants was asked to keep their habitual routine until finish the final evaluations.
16414225|NCT03879980|Placebo Comparator|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
16414226|NCT03879980|Experimental|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
16414227|NCT03879967|Experimental|Allograft block graft|For lateral alveolar ridge augmentation, all patients will be treated with allograft block with guided bone regeneration. After a minimal healing phase of six months, implants would be placed in the augmented site. After a healing phase of about 4months, the implants would be loaded and then followed until the control appointment approximately 3 years later.
16414228|NCT03879954|Other|OOP-IJV|Out of plane inetrnal jugular vein catetherization
16414229|NCT03879954|Other|IP-SSV|in plane supraclavicular subclavian vein catetherization
16414230|NCT03879928|Placebo Comparator|Placebo for SAD|Placebo comparator for SAD
16414231|NCT03879928|Experimental|FM101 75 mg for SAD|Single ascending doses of FM101
16414232|NCT03879928|Experimental|FM101 150 mg for SAD|Single ascending doses of FM101
16414233|NCT03879928|Experimental|FM101 300 mg for SAD|Single ascending doses of FM101
16414244|NCT03879915||Retrospective Dental Implant placement|Patients retrospectively included, that did not benefit from current recommendations
16414245|NCT03879889|Experimental|Intervention|Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
16414246|NCT03879889|No Intervention|Control|Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.
16414247|NCT03879876|Experimental|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
16414248|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID|
16414249|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID|
16414250|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
16414251|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
16414252|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
16414253|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
16414254|NCT03879837|Experimental|Investigational Test Product|Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation
16414255|NCT03879837|Active Comparator|Reference Listed Drug|Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation
16414256|NCT03879837|Placebo Comparator|Placebo|Placebo pressurized metered dose inhaler, no active content
16414257|NCT03879824|Experimental|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)
~The active intervention in this arm of the study is secondary radial artery access during TAVI"
16414258|NCT03879824|Active Comparator|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)
~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
16414259|NCT03879811|Experimental|MMR-Proficient Colorectal Cancer|"The first 3 subjects will receive oral TMZ at 150mg/m2 day 1 to 5 during cycle
~1, followed by nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1 (i.e. Cycle 2 day 1). Nivolumab will continue for up for 2 years maximum. If confirmed that TMB increased in at least 2 of 3 subjects following 1 cycle of TMZ, then subsequent patients will continue to receive TMZ during cycle 1 only, and the original three participants will not be replaced. If it is determined that TMB did not increase following 1 cycle of TMZ, then subsequent patients will receive TMZ up to cycle 3, those first 3 patients will discontinue further Nivolumab and be replaced and an additional 6 patients will initially be enrolled. If confirmed that TMB increased in at least 1 of 6 subjects following 3 cycles of TMZ, then 12 more patients will be allowed to enroll for a total of 18 in stage I."
16414260|NCT03879798|Experimental|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan. Dose-Escalation, which enrolled a total of 12 patients at MSK, is completed. Phase 1 of this study determined that the highest and safest dose of DS-3201b in patients was 100 mg daily.
16414261|NCT03879785|Active Comparator|Self-Administration followed by Interviewer-Administered|
16414262|NCT03879785|Active Comparator|Interviewer-Administered followed by Self-Administration|
16414263|NCT03879772|Experimental|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
16414264|NCT03879772|Experimental|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
16414265|NCT03879772|Experimental|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
16414266|NCT03879772|Active Comparator|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
16414267|NCT03879772|Placebo Comparator|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
16414268|NCT03879759|Experimental|Arm 1|NAC - Relapse Prevention (4 wks)
16414269|NCT03879759|Placebo Comparator|Arm 2|NAC - Relapse Prevention (4 wks)
16414270|NCT03879746|Active Comparator|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
16414271|NCT03879746|Active Comparator|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
16414272|NCT03879746|Active Comparator|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
16414273|NCT03879746|Placebo Comparator|placrbo group|the fourth group will include 40 patients will be given placebo
16414274|NCT03879733|Experimental|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
16414275|NCT03879733|Other|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.
~Will receive the intervention from Sept. 2019 - June 2020."
16414276|NCT03879720|Active Comparator|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
16414277|NCT03879720|Experimental|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
16414278|NCT03879707|Experimental|Experimental|Melatonin and magnesium for 14 days
16414279|NCT03879707|Placebo Comparator|Control|Placebo for 14 days
16414280|NCT03879694|Experimental|Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)|Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
16414281|NCT03879681|No Intervention|No Intervention|
16414282|NCT03879681|Experimental|Jelly Snakes|
16414283|NCT03879668||eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
16414284|NCT03879668||Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
16414285|NCT03879655|Experimental|VTS-270|Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the subject, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.
16414286|NCT03879642|Experimental|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
16414287|NCT03879642|No Intervention|Waitlist|10 week no intervention to provide waitlist control condition
16414288|NCT03879629|Experimental|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
16414289|NCT03879629|Experimental|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
16414290|NCT03879629|Active Comparator|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by >10% to a value less than 53% and continued until end of therapy
16414291|NCT03879616|Experimental|An Enhanced Reminder|"Members randomized to this arm of the study will receive an enhanced reminder protocol, which will include multiple reminders, multiple modalities, and motivational messages. The timing of reminders will depend on the wait time between the date the appointment is made and the date of the appointment.
~An email reminder will be sent to all members who have provided their personal email information.
~Members will receive up to two text messages that roll over to an IVR automated phone call if the text cannot be delivered.
~Members scheduled for colonoscopy will also receive a single IVR-T reminder to begin their bowel prep the morning of the calendar day prior to the procedure."
16414292|NCT03879616|Other|Control|"Members randomized to this arm of the study will receive a single text message that rolls over to an IVR automated phone call if the text cannot be delivered. This message will be delivered 7 business days prior to the appointment. This replicates the current protocol for GI procedures. Of note, members who schedule appointments within 7 days of the procedure currently receive no reminders."
16414293|NCT03879603|Experimental|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
16414294|NCT03879603|Experimental|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
16414295|NCT03879603|Experimental|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
16414296|NCT03879603|Experimental|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
16414297|NCT03879603|Experimental|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
16414298|NCT03879603|Experimental|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
16414299|NCT03879590|Experimental|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
16414300|NCT03879590|Active Comparator|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
16414301|NCT03879577|Experimental|Docetaxel|Investigators will give patients docetaxel through drip every 3 weeks for four doses for 12 weeks before a repeat breast ultrasound. After breast ultrasound, if the investigator feels the injection is good, surgery will be done.
16414302|NCT03879577|Other|Herceptin|Herceptin will be given to patients under the skin of the thigh every 3 weeks for 18 times if they are HER2-positive
16414303|NCT03879577|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with a poor response to docetaxal will receive FEC injection by drip every 3 weeks.
16414304|NCT03879577|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years every 3 months for contraception and fertility preservation.
16414305|NCT03879577|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
16414306|NCT03879564|Placebo Comparator|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
16414307|NCT03879564|Experimental|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
16414308|NCT03879551|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere on the hand motor area for 10 consecutive sessions totally over period of 10 days.
16414309|NCT03879551|Sham Comparator|Sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere with coil perpendicular on scalp for 10 consecutive sessions totally over period of 10 days.
16414310|NCT03879538|Active Comparator|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
16414311|NCT03879538|Placebo Comparator|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
16414312|NCT03879525|Experimental|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
16414313|NCT03879525|Active Comparator|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
16414314|NCT03879512|Experimental|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
16414315|NCT03879486|Experimental|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
16414316|NCT03879486|No Intervention|Control arm|controls at transrectal ultrasound guided prostate biopsy
16414317|NCT03879460|Experimental|Open Label|Open label
16414318|NCT03879447||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
16414319|NCT03879447||Lumbar spondylolisthesis group|Lumbar spondylolisthesis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
16414320|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
16414321|NCT03879421|Active Comparator|Group 1 (Epithelium-off accelerated CXL)|patients with corneal thickness > 400 µm (thinnest location) were assigned into Epi-off accelerated CXL procedure
16414322|NCT03879421|Active Comparator|Group 2 (Epithelium-on accelerated CXL)|patients with corneal thickness > 380 µm and < 400 µm thinnest location) were assigned into Epi-on Trans-epithelial accelerated CXL procedure
16414323|NCT03879408|Experimental|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
16414324|NCT03879408|Experimental|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
16414325|NCT03879408|Active Comparator|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
16414326|NCT03879408|Active Comparator|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
16414327|NCT03879408|Placebo Comparator|Placebo tablet|Single dose of four placebo tablets
16414328|NCT03879395||Cohort|Patients with stage IV malignant melanoma with abdominal metastasis (M1c) that underwent abdominal surgery with metastasectomy during the study period.
16414329|NCT03879382|Experimental|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
16414330|NCT03879356|Other|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
16414331|NCT03879343||Clinical group|Children aged six to eleven with clinical diagnosis of attention deficit / hyperactivity disorder were recruited for interview and completion of questionnaires
16414332|NCT03879343||Control group|Normally developing children aged six to eleven studying in local mainstream primary schools were recruited for completion of questionnaires
16414335|NCT03879278|Other|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
16414336|NCT03879278|Other|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
16414337|NCT03879278|Other|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
16414338|NCT03879265||Study group|No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).
16414339|NCT03879252|Experimental|Tooth brushing|
16414340|NCT03879252|Active Comparator|Mouthwash|
16414341|NCT03879239|Active Comparator|Vibrant Capsule mode A|Vibrant Capsule mode A administered 5 times per week
16414342|NCT03879239|Active Comparator|Vibrant Capsule mode B|Vibrant Capsule mode B administered 5 times per week
16414343|NCT03879239|Placebo Comparator|Placebo Capsule|Placebo Capsule administered 5 times per week
16414344|NCT03879226|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
16414345|NCT03879226|Experimental|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
16414346|NCT03879226|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
16414347|NCT03879226|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
16414348|NCT03879213|Experimental|Active|freeze-dried red raspberry powder (25 g) in active breakfast meal
16414349|NCT03879213|Placebo Comparator|Placebo|Placebo breakfast
16414350|NCT03879200|No Intervention|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
16414351|NCT03879200|Experimental|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
16414352|NCT03879187|Experimental|High-fat diet|Participants underwent a 7 day high-fat, high-energy diet intervention with metabolic measurements before and after
16414353|NCT03879174|Experimental|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
16414355|NCT03879148|Active Comparator|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
16414356|NCT03879148|No Intervention|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
16414357|NCT03879135|Experimental|On-Demand|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
16414358|NCT03879135|Experimental|Prophylaxis|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
16414359|NCT03879122|Active Comparator|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
16414360|NCT03879122|Experimental|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
16414361|NCT03879122|Experimental|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
16414362|NCT03879109|Experimental|Arm A: Induction Chemotherapy followed by Pelvic reirradiation|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
~oxaliplatin: 85 mg/m2
~irinotecan: 180 mg/m²
~folinic acid: 400 mg/m2
~5FU : 400 mg/m2 (bolus)
~5FU : 2400 mg/m2 (continuous infusion)
~Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week."
16414363|NCT03879109|Active Comparator|Arm B: Chemotherapy alone|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
~oxaliplatin: 85 mg/m2
~irinotecan: 180 mg/m²
~folinic acid: 400 mg/m2
~5FU : 400 mg/m2 (bolus)
~5FU : 2400 mg/m2 (continuous infusion)"
16414364|NCT03879096|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
16414365|NCT03879083|Experimental|With reproduction of palatal rugae|Participants will receive maxillary complete dentures with a reproduction of the patients's own palatal rugae to the palatal surface.
16414366|NCT03879083|Active Comparator|Without reproduction of palatal rugae (smooth surface)|Participants will receive maxillary complete dentures with smooth palatal surfaces without a reproduction of the patients's own palatal rugae to the palatal surface.
16414367|NCT03879070|Experimental|Intervention group|
16414368|NCT03879070|No Intervention|Control group|
16414369|NCT03879057|Experimental|Surufatinib 200mg/JS001 240mg|Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
16414370|NCT03879057|Experimental|Surufatinib 300mg/JS001 240mg|Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
16414372|NCT03879031||Outpatients with low back pain|"All outpatients with non-specific subacute or chronic low back pain will be submitted to a physical therapy program including:
~information on pain mechanisms and the favorable nature of non-specific low back pain;
~advice on positions, movements and activities recommended or advised against in people with low back pain, both at work and during leisure time;
~active postural correction exercises, overactive muscles lengthening and weak musculature strengthening;
~passive manual techniques, aimed at muscle relaxation and recovery of lumbar joint mobility.
~A cluster of Clinical tests to measure lumbar stability will be administrated before the starting of the first session and at the ending of the last session of the physical therapy program."
16414373|NCT03879018|Experimental|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
16414374|NCT03879018|Experimental|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
16414375|NCT03879005|Other|Renal scintigraphy|5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.
16414376|NCT03878992|Other|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
16414377|NCT03878979|Experimental|Newly diagnosed SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN.
16414378|NCT03878979|Experimental|Reccurence of SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred.
16414379|NCT03878966|Experimental|Invasive Strategy group|Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
16414380|NCT03878953|Experimental|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
16414381|NCT03878940|Other|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
16414382|NCT03878927|Experimental|Cohort A|"CPX-351 : Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2/day on Days 1,3 and 5 (90 minute IV infusion)
~Gemtuzumab ozogamicin: 3mg/m^2/day on Day 1 (2 hour IV infusion)"
16414383|NCT03878927|Experimental|Cohort B|"CPX-351: Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2 on Days 1, 3 and 5 (90 minute IV infusion)
~Gemtuzumab ozogamicin: 3mg/m^2 on Days 1, 4 (2 hour IV infusion)"
16414384|NCT03878927|Experimental|Cohort C|"CPX-351: Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2 on Days 1, 3, and 5 (90 minute IV infusion)
~Gemtuzumab ozogamicin: 3mg/m^2 on Days 1, 4 and 7 (2 hour IV infusion)"
16414385|NCT03878914|Experimental|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)
~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks
~40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.
~Wean off in 4 weeks
~CORTICOSTEROID THERAPY FOR A RELAPSE
~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission
~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
16414386|NCT03878914|Active Comparator|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)
~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks
~40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.
~Wean off in 4-6 weeks
~CORTICOSTEROID THERAPY FOR A RELAPSE
~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission
~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
16414387|NCT03878901|Sham Comparator|control group|Cotton Blanket Warming (CBW) starts 30 min preoperatively and then continues throughout the entire operation.
16414388|NCT03878901|Experimental|warm group|"Warm according to different hypothermia risk for low risk ---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) continues throughout the entire operation.
~moderate risk---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) and fluid warming continues throughout the entire operation.
~high risk ----Forced-air warming(FAW) starts at least 30 min preoperatively, FAW and fluid warming continues throughout the entire operation."
16414389|NCT03878888|Experimental|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
16414390|NCT03878888|No Intervention|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
16414391|NCT03878875||High Noise Exposure|One group (20, 10f:10m) with previous exposure i.e. nightclubs ++
16414392|NCT03878875||Low Noise Exposure|Group (20, 10f:10m) with less exposure measured through NESI
16414393|NCT03878849|Experimental|2X-121|Oral administration of 2X-121 once daily as 600 mg hard gelatin capsules in a 28 days cycle.
16414396|NCT03878810|Experimental|Exergaming, restless legs syndrome (+)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
16414397|NCT03878810|Experimental|Exergaming, restless legs syndrome (-)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
16414398|NCT03878810|No Intervention|Control, restless legs syndrome (+)|No specific intervention.
16414399|NCT03878810|No Intervention|Control, restless legs syndrome (-)|No specific intervention.
16414400|NCT03878784|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Imigrane infusion (0.4 mg/min) for 10 mins"
16414401|NCT03878784|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Isotonic saline for 10 mins (placebo)"
16414402|NCT03878771|Experimental|autologous Platelet rich fibrin in Orabase (PRF)|applied to oral ulcer and/or mucositis 3 times per day
16414403|NCT03878771|Active Comparator|Clobetasol propionate 0.05%(Dermovate cream) in orabase|applied to oral ulcer and/or mucositis 3 times per day
16414404|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
16414405|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
16414406|NCT03878758|Experimental|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
16414407|NCT03878745|Experimental|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
16414408|NCT03878745|Active Comparator|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
16414409|NCT03878732||Caucasian female|
16414410|NCT03878732||Hispanic female|
16414411|NCT03878719|Experimental|Safety Run-in Phase|"binimetinib taken twice daily (BID) and
~encorafenib taken once daily (QD)
~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol."
16414412|NCT03878719|Experimental|Expansion Phase|"binimetinib taken twice daily (BID) and
~encorafenib taken once daily (QD)
~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol."
16414413|NCT03878706||GLP1 and SGLT2i group|40 patients treated with a combination of liraglutide and empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
16414414|NCT03878706||GLP1 group|40 patients treated with liraglutide.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
16414415|NCT03878706||SGLT2i group|40 patients treated with empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
16414416|NCT03878706||Control group|40 patients treated with insulin and metformin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
16414417|NCT03878693|Experimental|A|Oral APAP and IV Fomepizole.
16414418|NCT03878693|Active Comparator|B|Oral APAP.
16414419|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
16414420|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
16414422|NCT03878667|Experimental|High Calorie Diet|High calorie (2,600 calorie) diet and exercise and calcium
16414423|NCT03878667|Experimental|Low Carbohydrate/High Protein Diet|Low carbohydrate (63% protein, 7% carbohydrate, 30% fat) diet and exercise and calcium
16414424|NCT03878667|Experimental|High Carbohydrate/Low Protein|High carbohydrate (15% protein, 55% carbohydrate, 30% fat) diet and exercise and calcium
16414425|NCT03878654|Experimental|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
16414426|NCT03878641|Experimental|Children in Grade 1 to 5 with literacy and language needs|The investigators intend to identify children in Grade 1 to 5 who demonstrate language-based learning difficulties. Using the two-stage screening, the investigators will identify children who produce substantial number of reading miscues and/or self-correct more less 25% of their miscues, and/or who present weaknesses in expressive language skills with a total CUBED score lower than grade-specific cut scores.
16414427|NCT03878628|Experimental|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
16414428|NCT03878615||Elective Hepatic Surgery|Patientes undergoing elective hepatic resection, managed according to departement routine.
16414429|NCT03878602|Active Comparator|Control Group|Newborns will be subjected to umbilical cord immediate clamping
16414430|NCT03878602|Experimental|Study Group|Newborns will be subjected to umbilical cord delayed clamping
16414431|NCT03878589|Active Comparator|Oxytocin Crossover Placebo Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of oxytocin (OT) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of placebo (P) twice a day will be self-administered.
16414432|NCT03878589|Active Comparator|Placebo Crossover Oxytocin Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of placebo (P) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of oxytocin (OT) twice a day will be self-administered.
16414433|NCT03878576|Active Comparator|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
16414434|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
16414435|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
16414436|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
16414437|NCT03878563||ascites with/without SBP|Cirrhosis with ascites and existing SBP or prior SBP
16414438|NCT03878563||ascites and decreased protein concentrati|Cirrhosis with ascites and decreased protein concentration <1,5 g/d
16414439|NCT03878563||ascites and normal protein concentration|Liver cirrhosis witha scites and protein concentration >1,5 g/d
16414440|NCT03878563||Liver cirrhosis without ascites|Patients with liver corrhosis without ascites
16414441|NCT03878563||Healthy controls without liver cirrhosis or other pathology|Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy
16414442|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
16414443|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
16414444|NCT03878524|Experimental|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.
~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health & Science University (OHSU).
~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
16414445|NCT03878511|Experimental|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
16414446|NCT03878511|Placebo Comparator|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
16414447|NCT03878485|Experimental|Stereotactic MRI-guided Adaptive Radiotherapy|-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
16414448|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1|
16414449|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib|
16414450|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
16414451|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
16414452|NCT03878459|Experimental|Intervention|pioglitazone treatment
16414453|NCT03878459|Placebo Comparator|control|subjects will receive placebo
16414454|NCT03878446|Experimental|0.24 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
16414455|NCT03878446|Experimental|0.20 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
16414456|NCT03878446|Experimental|0.16 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
16414457|NCT03878446|Active Comparator|0.035 mg/kg Norditropin®|Same treatment in main period (13 weeks) and extension period (39 weeks)
16414458|NCT03878446|Active Comparator|0.067 mg/kg Norditropin®|Same treatment in main period (13 weeks) and extension period (39 weeks)
16414459|NCT03878433|Active Comparator|Drug|Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
16414460|NCT03878433|Placebo Comparator|No Drug|2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
16414461|NCT03878420|Experimental|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
16414462|NCT03878420|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
16414463|NCT03878394|Experimental|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
16414464|NCT03878394|Experimental|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
16414465|NCT03878381|Experimental|Compounded Skin Care Cream|One side of the face will be randomly chosen as the treatment side
16414466|NCT03878381|Placebo Comparator|Placebo|The other side of the face will be randomly chosen as the control
16414467|NCT03878368|Experimental|Intervention|32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
16414468|NCT03878368|Active Comparator|Control|32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
16414469|NCT03878355|Experimental|radical endoscopic sinus surgery plus Draf 3 surgery|
16414470|NCT03878355|Experimental|radical endoscopic sinus surgery|
16414471|NCT03878355|Experimental|functional endoscopic sinus surgery|
16414472|NCT03878342|Active Comparator|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
16414473|NCT03878342|Experimental|No Radiotherapy|No Irradiation- Active surveillance
16414474|NCT03878329|No Intervention|standard of care|standard of care treatment
16414475|NCT03878329|Experimental|remote home monitoring|use of telemedicine based remote home monitoring
16414478|NCT03878303|Experimental|AC0058TA|AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
16414479|NCT03878303|Placebo Comparator|Placebo AC0058TA|Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
16414480|NCT03878290|Experimental|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
16414481|NCT03878290|No Intervention|Control|Treatment as usual
16414482|NCT03878277|Experimental|Cold Brew Coffee|6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.
16414483|NCT03878264|Experimental|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
16414484|NCT03878264|Experimental|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
16414485|NCT03878251|Other|X fragile syndrome patients|
16414486|NCT03878251|Other|Angelman syndrome patients|
16414487|NCT03878251|Other|Rett syndrome patients|
16414488|NCT03878251|Other|Patients with other genetic rare syndromes with intellectual d|
16414489|NCT03878238|Placebo Comparator|Placebo|
16414490|NCT03878238|Experimental|Probiotic|
16414491|NCT03878225|Active Comparator|Ketone Mono Ester|"The ketone mono ester is commercially available dietary supplement beverage named H.V.M.N. Ketone Ester, marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study."
16414492|NCT03878225|Placebo Comparator|Placebo|The placebo beverage will consist of water added with a colorless, bitter flavor enhancer and a sweetening agent (Stevia) to approximate the taste of the KME beverage as closely as possible. The bitter flavor enhancer used is denatonium benzoate (Bitrex®). The placebo beverage will be delivered to patients in bottles identical to those used in the active arm. Patients, investigators and other caregivers will be blinded to treatment allocation until time of database unlock.
16414493|NCT03878212|Experimental|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
16414535|NCT03877939||Patients with clinical miscarriage|Patients with β-hCG test > 10 UI/L whose sac is implanted inside the uterine cavity, but non-viable pregnancy is confirmed before gestational week 8.
16414494|NCT03878212|Active Comparator|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
16414495|NCT03878212|No Intervention|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
16414496|NCT03878199|Experimental|Treatment (CPX-351, ruxolitinib, allogeneic SCT)|See Detailed Description.
16414497|NCT03878186|Experimental|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
16414498|NCT03878186|Other|Usual Care (UC)|Participants will receive Usual Care only
16414499|NCT03878160|Other|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
16414500|NCT03878160|Other|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
16414501|NCT03878160|Other|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
16414502|NCT03878147|Other|HIV infected|HIV infected children
16414503|NCT03878147|Other|HIV exposed uninfected|HIV exposed, uninfected children
16414504|NCT03878147|Active Comparator|HIV unexposed uninfected|HIV unexposed uninfected children (community controls)
16414505|NCT03878134|Active Comparator|Patients|750 male or female, 18 and older patients
16414506|NCT03878121|Experimental|A1|Ad4-Env150KN at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
16414507|NCT03878121|Experimental|A2|Ad4-Env145NFL at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
16414508|NCT03878121|Experimental|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
16414509|NCT03878121|Experimental|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
16414510|NCT03878108|Active Comparator|LCHF diet then LFHC diet|Low carbohydrate, high fat (LCHF) diet then low fat, high carbohydrate diet (LFHC) diet
16414511|NCT03878108|Active Comparator|LFHC diet then LCHF diet|Low fat, high carbohydrate diet (LFHC) diet then low carbohydrate, high fat (LCHF) diet
16414513|NCT03878082|Active Comparator|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
16414514|NCT03878082|Active Comparator|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
16414515|NCT03878082|Placebo Comparator|IVPCA|pain control with IVPCA
16414516|NCT03878069||ERT with ADA|Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
16414517|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
16414518|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
16414519|NCT03878043||Patients without Readmissions|Patients with TSDH who were not readmitted within a 6-month time period following their initial visit.
16414520|NCT03878043||Patients with Readmissions|Patients with TSDH who were readmitted within a 6-month time period following their initial visit.
16414521|NCT03878030||Subjects with spinal muscular atrophy types 2 and 3|Intrathecal nusinersen will be administered to all subjects per FDA approved label.
16414522|NCT03878017|Experimental|skin marking of clipped axillary LN|all eligible patients underwent skin marking of their clipped axillary LN post neoadjuvant chemotherapy to determine the retrieval rate of the clipped nodes
16414523|NCT03878004|Experimental|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
16414524|NCT03878004|Placebo Comparator|Placebo Group|45 people who will receive placebo in the therapeutic scheme
16414525|NCT03877991|Experimental|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
16414526|NCT03877991|Experimental|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
16414527|NCT03877991|Experimental|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
16414528|NCT03877978||Severe traumatized patients|Severe traumatized patients with an Index Severity Score (ISS) ≥ 15 admitted to the trauma center of Edouard Herriot Hospital.
16414529|NCT03877965||Children with single ventricle congenital heart disease|Receiving digoxin per standard of care during the interstage period
16414530|NCT03877952|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
16414531|NCT03877939||Non-pregnant patients|Patients with β-hCG test < 10 UI/L.
16414532|NCT03877939||Patients with viable pregnancy|Patients with β-hCG test > 10 UI/L whose pregnancy is confirmed between gestational weeks 6 and 8.
16414533|NCT03877939||Patients with biochemical pregnancy|Patients with β-hCG test > 10 UI/L and without sac observed.
16414534|NCT03877939||Patients with ectopic pregnancy|Patients with β-hCG test > 10 UI/L whose sac is implantated outside the uterine cavity.
16414536|NCT03877926|Experimental|AV7909 Lot 1|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
16414537|NCT03877926|Experimental|AV7909 Lot 2|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
16414538|NCT03877926|Experimental|AV7909 Lot 3|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
16414539|NCT03877926|Active Comparator|BioThrax|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. In Group 4, one lot of BioThrax will be administered, per the study visit schedule.
16414540|NCT03877874||Asthmatic children|"Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily
~Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
16414541|NCT03877874||Non-Asthmatic children|no intervention
16414542|NCT03877861||Readiband Sleep Tracking - Patient|This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits.
16414543|NCT03877861||Readiband Sleep Tracking - Control|Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes.
16414544|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.
~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
16414545|NCT03877835|Other|Ropivacaine|SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml
16414546|NCT03877822|Experimental|Habitual activity and 2 days bed rest|Participants will undergo 2 days of habitual activity and 2 days bed rest
16414547|NCT03877809|Experimental|Open label trial|Sirolimus 0.5 mg tablets
16414548|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
16414549|NCT03877783|Experimental|group of intervention|"participants receive
~personalized advice of a dietician about mediterranean diet
~individualized training program,
~recommendation about optimized pharmacological treatment as in high risk groups for cardiovascular diseases"
16414550|NCT03877783|No Intervention|group of control|"participants receive
~written information about the advantages of a healthy diet
~written information about the advantages of physical activity,
~medical treatment according to the latest version of the national guidelines issued by the Swedish Medical Product Agency"
16414551|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
16414552|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
16414553|NCT03877744|Experimental|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
16414554|NCT03877744|Active Comparator|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
16414555|NCT03877731|Active Comparator|hypertrophic cariomyopathy, isolated septal myectomy|Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy
16414556|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + edge-to-edge|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)
16414557|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + sliding plasty|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)
16414558|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + chordae|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection
16414559|NCT03877731|No Intervention|Arterial hypertension + left ventricular hypertrophy|Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
16414560|NCT03877731|No Intervention|Control|Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
16414561|NCT03877718|Experimental|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
16414562|NCT03877718|Experimental|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
16414563|NCT03877718|Experimental|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
16414661|NCT03877003|Experimental|Egg Intake|Consumption of 3 eggs per day for breakfast during 4 weeks
16414564|NCT03877718|Experimental|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
16414565|NCT03877718|Experimental|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
16414566|NCT03877718|Experimental|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
16414567|NCT03877705|Experimental|Dissolving xylitol chewable tablets|Listerine ready tabs 3 times/day
16414568|NCT03877705|Active Comparator|Xylitol chewing gum|Trident original 3 times/day
16414569|NCT03877692|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
16414570|NCT03877692|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
16414571|NCT03877679|Experimental|turmeric paste|Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).
16414572|NCT03877679|Active Comparator|Triamcenolone in orabase|Triamcenolone + na ploycarboxylate
16414573|NCT03877653|Experimental|Interventional|Single arm, active stimulation
16414574|NCT03877653|Placebo Comparator|Placebo|"When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.
~Sites will not have access to WaveCrest programmer. Study devices can only be programmed by Stimwave representatives."
16414575|NCT03877640|Active Comparator|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
16414576|NCT03877640|Sham Comparator|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
16414577|NCT03877627|No Intervention|Negative 1|Patients in this arm will not undergo Pelvic and Peritoneal Lymphadenectomy.
16414578|NCT03877627|Experimental|Negative 2|Patients in this arm will undergo Pelvic and Peritoneal Lymphadenectomy.
16414579|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
16414580|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score<10% will be recognized as the comparison group
16414581|NCT03877601|Experimental|Topical administration of bevacizumab-800CW|The tracer will be topically administered 5 minutes prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform).
16414582|NCT03877588|Other|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
16414583|NCT03877562|Experimental|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
16414584|NCT03877562|Placebo Comparator|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
16414585|NCT03877549|Placebo Comparator|Placebo|10cc 0.0625% bupivacaine
16414586|NCT03877549|Experimental|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
16414587|NCT03877549|Experimental|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
16414588|NCT03877536|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
16414589|NCT03877523|Experimental|Cocarnit|disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg
16414590|NCT03877510|Experimental|Open Label IPX203|Subjects will receive IPX203 140 mg, IPX203 210 mg, IPX203 280 mg, or IPX203 350 mg for approximately 9 months. The dose and dosing frequency will be determined by the investigator.
16414591|NCT03877497|Experimental|SBIRT-A|The screening, brief intervention and referral to treatment (SBIRT) will be adapted and used as the intervention in the experimental arm
16414592|NCT03877497|Active Comparator|INFO-C|The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material
16414593|NCT03877471|Experimental|Low dosage|The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.
16414594|NCT03877471|Experimental|Medium dosage|The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.
16414595|NCT03877471|Experimental|High dosage|The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.
16414596|NCT03877458|Experimental|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
16414597|NCT03877458|Experimental|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
16414598|NCT03877458|Placebo Comparator|Placebo group|Taking 1 Placebo capsule at bed time everyday for three months.
16414599|NCT03877445|Other|Melasma Group exposed left half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
16414600|NCT03877445|Other|Melasma Group exposed right half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
16414601|NCT03877432|Experimental|Dermatome stimulation|Check the effect of improving the function of bladder storage and bladder capacity before and after dermatome stimulation.
16415207|NCT03872973|Experimental|Training Group|Neuromuscular training will be performed in this group for 6 weeks.
16414602|NCT03877406|Active Comparator|Control group|up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor
16414603|NCT03877406|Experimental|Study group|addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents
16414604|NCT03877393|Experimental|PRO-GFD|Probiotic supplementation + gluten-free diet
16414605|NCT03877393|Placebo Comparator|PLA-GFD|Placebo supplementation + gluten-free diet
16414606|NCT03877393|Experimental|PRO-GD|Probiotic supplementation + gluten-containing diet
16414607|NCT03877393|Placebo Comparator|PLA-GD|Placebo supplementation + gluten-containing diet
16414608|NCT03877367|Experimental|Upper Extremity Group, Day 1|"Day 1: This group will receive a pre-test, upper extremity intervention, and post-test.
~Day 2: This group will receive a pre-test, lower extremity intervention, and post-test."
16414609|NCT03877367|Experimental|Lower Extremity Group, Day 2|"Day 1: This group will receive a pre-test, lower extremity intervention, and post-test.
~Day 2: This group will receive a pre-test, upper extremity intervention, and post-test."
16414610|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
16414611|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
16414612|NCT03877328|Experimental|Virtual Coach|BiotechCoachForAll
16414613|NCT03877315|Active Comparator|Stemmed|Subjects operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
16414614|NCT03877315|Active Comparator|Non-Stemmed|Subjects operated with stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
16414615|NCT03877302|Experimental|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
16414616|NCT03877302|No Intervention|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
16414617|NCT03877289|Experimental|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
16414618|NCT03877289|Placebo Comparator|Placebo|Orasweet liquid placebo
16414619|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
16414620|NCT03877276|Experimental|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
16414621|NCT03877276|Experimental|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
16414622|NCT03877276|Experimental|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
16414623|NCT03877276|Experimental|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
16414624|NCT03877276|Experimental|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
16414625|NCT03877276|Experimental|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
16414626|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
16414627|NCT03877263|Other|OB/GYN physician-collected vaginal swab|"Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.
~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
16414628|NCT03877263|Other|Patient-collected vaginal swab|"Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.
~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
16414629|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
16414630|NCT03877237|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
16414631|NCT03877237|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
16414632|NCT03877224|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
16414633|NCT03877224|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
16414634|NCT03877211|Experimental|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
16414635|NCT03877211|Active Comparator|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
16414636|NCT03877198|Experimental|CLiO2|Automated oxygen control by the CLiO2 algorithm
16414637|NCT03877198|Experimental|Oxygenie|Automated oxygen control by the Oxygenie algorithm
16414638|NCT03877185||3-Injection-Protocol Group|Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).
16414639|NCT03877185||Multiple-Injection- Protocol Group|Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.
16414640|NCT03877172|No Intervention|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
16414641|NCT03877172|Active Comparator|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
16414642|NCT03877146|No Intervention|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
16414643|NCT03877146|Experimental|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
16414645|NCT03877120|Sham Comparator|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.
~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
16414646|NCT03877120|Active Comparator|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
16414647|NCT03877107|Other|single cohort|Participants presenting at least 2/3 of symptom triad : gait disturbance, urinary symptoms and cognitive disturbance Ventricular enlargement non explained by cortical atrophy Cognitive capacity to understand the study and give informed consent (mini mental state > 13), speaking and reading french.
16414648|NCT03877094|Active Comparator|Nature Virtual Reality Video|After signing the Informed Consent Form, the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy. In the end of the procedure, the patient you will receive a Ipad (specific to the study and blocked for other functions) to respond a demographic questionnaire to characterize the sample and the likerts questionnaire to measure their pain, comfort, well-being, stress and anxiety during the procedure.
16414649|NCT03877094|No Intervention|Control group|This control group will not receive an intervention.
16414650|NCT03877081|Experimental|Probiotics. Intervention patients|This patients will receive 2 doses of oral probiotics a day, for seven days
16414651|NCT03877081|Placebo Comparator|Placebo group|This patients will receive 2 doses of oral placebo a day, for seven days
16414652|NCT03877068|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
16414653|NCT03877068|Active Comparator|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, PCP or research teams).
16414654|NCT03877055|Experimental|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
16414655|NCT03877042|Experimental|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
16414656|NCT03877029||Study II|"Women with a screen-detected breast cancer after attending BreastScreen Norway
~Women who have never attended BreastScreen Norway despite of several invitation, and who are diagnosed with symtomatic breast cancer.
~Both groups of women will receive the questionnaire."
16414657|NCT03877029||Study III|"Women with a screen-detected breast cancer after attending BreastScreen Norway
~Women with interval breast cancer after attending BreastScreen Norway
~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway
~Women free from breast cancer"
16414658|NCT03877029||Study IV|"Women with a screen-detected breast cancer after attending BreastScreen Norway
~Women with interval breast cancer after attending BreastScreen Norway
~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway"
16414659|NCT03877016|Active Comparator|TENS Eco2|TENS Eco2 is the classical device in patients with chronic neuropathic pain
16414660|NCT03877016|Experimental|actiTENS|ActiTENS is a new TENS device, that seems less cotraining.
16414662|NCT03877003|Experimental|Choline Supplement Intake|Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks
16414663|NCT03876990|Experimental|Multiplex PCR + Current strategy|Results of the multiplex PCR will be send as soon as possible to the infectious disease phycian for quick adaptation of antibiotic treatment. Positive blood cultures will also undergo current diagnosis strategy for bacteremia and fungemia.
16414664|NCT03876990|Active Comparator|Current strategy alone|Current diagnostic strategy based on the identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
16414667|NCT03876951|Experimental|vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery
16414668|NCT03876938|Active Comparator|aprepitant|aprepitant / dexamethasone/ ondansetron
16414669|NCT03876938|Experimental|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
16414670|NCT03876938|Experimental|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
16414671|NCT03876925|Experimental|CT053PTSA|60-100mg
16414672|NCT03876912|Experimental|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 3 weeks after ADT and at development of CRPC
16414673|NCT03876899|Active Comparator|Evening Primrose Oil|
16414674|NCT03876899|Placebo Comparator|Placebo|
16414675|NCT03876886|Active Comparator|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
16414676|NCT03876886|Experimental|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
16414677|NCT03876873|Experimental|Group A|Head Rotation During Face Mask Ventilation. Step 1: Neutral Position (1 minute), Step 2: Head Rotation (1 minute), Step 3: Neutral Position (1 minute)
16414678|NCT03876873|Experimental|Group B|Head Rotation During Face Mask Ventilation. Step 1: Head Rotation (1 Minute), Step 2: Neutral Position (1 minute), Step 3, Head Rotation (1 Minute)
16414679|NCT03876860|Active Comparator|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
16414680|NCT03876860|Experimental|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
16414681|NCT03876847||Spontaneous Coronary Artery Disection|The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
16414682|NCT03876847||Control|A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.
16414683|NCT03876834|Experimental|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
16414684|NCT03876834|No Intervention|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
16414685|NCT03876808|Experimental|Convective pre-warming|Undergo convective warming during the preoperative preparations, completed for a minimum of 60 minutes prior to entering the operating room
16414686|NCT03876808|No Intervention|Standard of care|Undergo standard of care, which includes providing each patient with blankets and sheets, as well as more blankets on patient request.
16414687|NCT03876795|Active Comparator|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
16414688|NCT03876795|Experimental|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
16414689|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
16414690|NCT03876769|Experimental|Single dose of CTL019|"Based on the subject's weight one of two possible dose ranges will be prepared for the subject:
~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight
~OR
~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
16414691|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
16414692|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
16414693|NCT03876743|Experimental|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
16414694|NCT03876743|Experimental|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
16414695|NCT03876743|Experimental|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
16414696|NCT03876743|Experimental|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
16414697|NCT03876730||Study group|3-18 aged children with cerebral palsy
16414698|NCT03876717|Experimental|Colesevelam, active arm|"Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.
~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days"
16414699|NCT03876717|Placebo Comparator|Placebo|Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam
16414700|NCT03876704|Experimental|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
16414701|NCT03876704|Active Comparator|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
16414702|NCT03876691||Do not resuscitate|Patients who are suggested to family about a do-not-resuscitate order treatment by physicians.
16414703|NCT03876678|Experimental|Light therapy and oral L. salivarius AP-32|Light therapy and taking 1 L. salivarius AP-32 probiotic capsule two times everyday for 7 days.
16414704|NCT03876678|Experimental|Light therapy and oral B. Animalis subsp. Lactis CP-9|Light therapy and taking 1 B. Animalis subsp. Lactis CP-9 probiotic capsule two times everyday for 7 days.
16414705|NCT03876678|Placebo Comparator|Light therapy and oral placebo|Light therapy and taking 1 placebo capsule two times everyday for 7 days.
16414706|NCT03876665||Focus Group|"Active Duty Air Force, Army and Navy women diagnosed with PCOS.
~Up to three focus groups per service branch will be conducted. Considering attrition for those who may volunteer and not show up for the FG session, the investigators will recruit up to 20 participants per site, with the goal of including a maximum of six participants per FG to maximize individual participation."
16414707|NCT03876652|Experimental|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
16414708|NCT03876652|Active Comparator|DDD-R|Patients with a pacemaker programmed in DDD-R mode
16414709|NCT03876639|Active Comparator|IPM_2/18|Application of formulation IPM_2/18
16414710|NCT03876639|Active Comparator|PAR_2/18|Application of formulation PAR_2/18
16414711|NCT03876626|Other|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
16414712|NCT03876626|Other|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
16414713|NCT03876613|Active Comparator|Turkish music group|Rast makam
16414714|NCT03876613|Active Comparator|classical western music|Vivaldi
16414715|NCT03876613|Active Comparator|soft rock music|Elvis presley
16414716|NCT03876613|Placebo Comparator|control group|No music
16414717|NCT03876600|Experimental|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.
~In this management patient come to hospital one day before this surgical operation and he is operated next day"
16414718|NCT03876600|Active Comparator|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.
~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
16414719|NCT03876587|Experimental|Pyrotinib Maleate combine with Docetaxel|"Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects.
~Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection."
16414720|NCT03876574|Experimental|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
16414721|NCT03876561|Experimental|Prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 sessions per week before stoma closure and 1 sessions per week during 6 weeks following stoma closure. Complementary sessions are allowed if necessary.
16414722|NCT03876561|No Intervention|No intervention|No pelvic floor prehabilitation will be proposed before stoma closure. The pelvic floor prehabilitation will be proposed to patients suffering from LARS
16414723|NCT03876548|Experimental|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
16414724|NCT03876522||Lafora Disease Patients|Documented genetic diagnosis of Lafora disease; clinical diagnosis of Lafora disease and a sibling with a known mutation in EPM2A or EPM2B; clinical diagnosis of Lafora disease and a previously undescribed mutation in EPM2A or EPM2B; asymptomatic siblings if mutation positive prior to enrollment.
16414725|NCT03876509||Impedance Cardiography|Impedance Cardiography
16414726|NCT03876496|Experimental|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
16414729|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
16414730|NCT03876457|Experimental|Endovascular Thrombectomy plus Medical Management|
16414731|NCT03876457|Active Comparator|Medical Management|
16414856|NCT03875560|Experimental|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
16414732|NCT03876444|Experimental|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
16414733|NCT03876444|Active Comparator|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
16414734|NCT03876431|Active Comparator|Traditional Exercise Group|Only traditional exercises will be performed in the early post-op period.
16414735|NCT03876431|Experimental|Easy-Flex Group|Easy-Flex group will be treated with the Easy-Flex device in addition to the traditional exercise program.
16414736|NCT03876418|No Intervention|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
16414737|NCT03876418|Active Comparator|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
16414738|NCT03876405|Experimental|sensory feedback|"A non-invasive air-mediated sensory feedback system embedded in the prosthesis socket.
~Group description: Individuals with acquired forearm amputation."
16414739|NCT03876392|Experimental|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
16414740|NCT03876353|Other|Left Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
16414741|NCT03876353|Other|Right Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
16414742|NCT03876340|Active Comparator|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
16414743|NCT03876340|Experimental|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
16414744|NCT03876327|Experimental|PD patients that will receive FMT|fecal microbial transplantation once at the beginning of the study-15 patients.
16414745|NCT03876327|No Intervention|PD patients that will not receive FMT|do not receive treatment-35 patients.
16414746|NCT03876327|No Intervention|healthy people live with PD patients|do not receive treatment-50 participants.
16414747|NCT03876314|Experimental|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
16414748|NCT03876314|No Intervention|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
16414749|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
16414750|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
16414751|NCT03876262|Experimental|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
16414752|NCT03876262|Experimental|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
16414753|NCT03876262|Active Comparator|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
16414754|NCT03876262|Experimental|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
16414755|NCT03876249||RSV positive group|Children who had RSV infection within the first 60 days of life
16414756|NCT03876249||RSV negative group|Children without known RSV infection within the first 60 days of life
16414757|NCT03876236||Rest|Quiet rest in supine position, 2 hrs.
16414758|NCT03876210|Other|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101
~Number of subject: 23
~Wash out Period: over 7 days (between each period)
~Dosage: Once daily, at 2D each period"
16414759|NCT03876210|Other|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002
~Number of subject: 23
~Wash out Period: over 7 days (between each period)
~Dosage: Once daily, at 2D each period"
16414760|NCT03876197|Experimental|Autologous Adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
16414761|NCT03876197|Placebo Comparator|Placebo|2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
16414762|NCT03876184|Experimental|RMO FLi® Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
16414763|NCT03876184|Experimental|G&H G4 Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 G&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
16414764|NCT03876184|Experimental|Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
16414765|NCT03876184|Active Comparator|Conventional superelastic Nickel Titanium|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
16414766|NCT03876171|Experimental|CIFFTA|Family Therapy, Individual Therapy, and Psycho-educational Modules
16414767|NCT03876171|Active Comparator|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
16414857|NCT03875560|Experimental|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
16414768|NCT03876158|Active Comparator|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
16414769|NCT03876158|Other|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
16414770|NCT03876145|Experimental|Minimal ovarian stimulation with rec-FSH|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 International Unit (IU) Gonal-f (Follitropin alfa, Merck Serono, Germany) after the seventh day.
16414771|NCT03876145|Experimental|Minimal ovarian stimulation with HMG|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) after the seventh day.
16414772|NCT03876145|No Intervention|Mild ovarian stimulation with rec-FSH|The group of mild ovarian stimulation that will receive 150 IU Gonal-f (Follitropin alfa, Merck Serono, Germany) daily from Day 3 of the menstrual cycle.
16414773|NCT03876145|No Intervention|Mild ovarian stimulation with HMG|The group of mild ovarian stimulation that will receive 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) daily from Day 3 of the menstrual cycle.
16414774|NCT03876119|Experimental|Intraarterial alteplase|"All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.
~Study drug will be prepared according to the following steps:
~Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml
~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
16414775|NCT03876119|Placebo Comparator|Placebo|"The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.
~Study drug will be prepared according to the following steps:
~Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml
~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
16414776|NCT03876106|Experimental|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
16414777|NCT03876106|Experimental|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
16414778|NCT03876106|Experimental|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
16414779|NCT03876080|Experimental|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
16414780|NCT03876080|Sham Comparator|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
16414781|NCT03876067|Experimental|Ozone Group|in which Ozone will be added to cold blood cardioplegia
16414782|NCT03876067|Placebo Comparator|Control Group|: in which in which only cold blood cardioplegia
16414785|NCT03876041|Active Comparator|dexamethasone group|this group will receive Dexamethasone: 0.1 to 0.3 mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
16414786|NCT03876041|Active Comparator|methylprednisolone group|this group will receive Methylprednisolone: 5-10mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
16414787|NCT03876028|Experimental|Ibrutinib (before leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment before leukapheresis
16414788|NCT03876028|Experimental|Ibrutinib (after leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment after leukapheresis.
16414789|NCT03876015||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
16414790|NCT03876002|Experimental|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of [18F]PBR06 PET to measure microglial activation in brain.
16414791|NCT03875989|Active Comparator|Arm A|
16414792|NCT03875989|Experimental|Arm B|
16414793|NCT03875976|Active Comparator|Fast Track Protocol|Patients treated using Fast Track Care Protocol
16414794|NCT03875976|Active Comparator|Standard Protocol|Patients treated using Standard Care Protocol
16414795|NCT03875963|Experimental|Antibiotic loaded bone filler|Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin]. The concurrent use of antibiotics is at the discretion of the treating physician.
16414796|NCT03875963|No Intervention|Standard of care|Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.
16464086|NCT03538301|Placebo Comparator|Placebo|
16414797|NCT03875950|Experimental|Training intervention|In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
16414798|NCT03875950|No Intervention|Standard of care control|In this randomized cluster randomized control trial design, the no intervention arm refers to the 12 study sites that are randomly assigned not to receive the clinician training intervention. Instead, these study sites will receive the standard of care, which is no standardized patient actor training, for health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
16414799|NCT03875937|Experimental|Tranexamic acid 1 gram intramuscularly|Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.
16414800|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
16414801|NCT03875911|Active Comparator|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
16414802|NCT03875911|Active Comparator|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
16414803|NCT03875911|Active Comparator|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
16414804|NCT03875898|Experimental|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
16414805|NCT03875898|Placebo Comparator|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
16414806|NCT03875885|Other|CONNECT Intervention Group - Group A|A web-based intervention (CONNECT) to empower and connect caregivers of newly diagnosed cancer patients to supportive care resources A randomized pilot study will be conducted to assess feasibility and acceptability and obtain data on caregiver and patient outcomes. CONNECT e-tool, re-education and optional referral (2 weeks post CONNECT e-tool). Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
16414807|NCT03875885|Other|CONNECT Comparison Group - Group B|Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
16414808|NCT03875872||Group propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
16414809|NCT03875872||Group inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
16414810|NCT03875859|Experimental|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
16414811|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
16414812|NCT03875833|Experimental|Collagen Nerve Wrap Conduit|
16414813|NCT03875833|No Intervention|Control|
16414814|NCT03875820|Experimental|Dose Escalation Phase|"Escalating doses of RO5126766 and VS-6063 will be evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation will follow a 3+3 design with a maximum of four patient cohorts.
~This arm is now complete."
16414815|NCT03875820|Experimental|Dose Expansion KRAS mutant NSCLC Cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).
16414816|NCT03875820|Experimental|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).
~This arm is now complete."
16414817|NCT03875820|Experimental|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with LGSOC (20 patients).
16414818|NCT03875820|Experimental|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with CRC (10 patients).
~This arm is now complete."
16414819|NCT03875807|Active Comparator|0 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 0 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
16414820|NCT03875807|Active Comparator|30 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 30 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
16414821|NCT03875794|Experimental|Osteopathic Manipulation|"This research will be carried out as a prospective, non-randomized pilot study in women aged 18-40 who are 2 weeks to 28 weeks postpartum.
~The intervention investigated in this study is osteopathic manipulation."
16414822|NCT03875781|Experimental|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:
~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
16414823|NCT03875781|Active Comparator|B: Modified Folfirinox followed by Radiochemotherapy|Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor
16414824|NCT03875768|Experimental|Intervention|Participants will track their daily dietary intake for six months using an app and will receive automated feedback daily via text message based on DASH nutrients. Participants in-need of coaching based on their adherence to the key nutrients in the DASH dietary pattern or engagement in the intervention will receive responsive digital coaching from Nourish registered dietitians.
16414825|NCT03875768|No Intervention|Control|Participants will receive information about the DASH dietary pattern and will track their daily dietary intake using an app for six months.
16414826|NCT03875755|Experimental|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
16414827|NCT03875755|Placebo Comparator|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
16414828|NCT03875742|Other|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
16414829|NCT03875742|Other|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
16414830|NCT03875729|Experimental|teplizumab|Sterile solution for injection.
16414831|NCT03875729|Placebo Comparator|Placebo|Sterile solution for injection
16414832|NCT03875716|Experimental|Low Risk|"Observation without adjuvant therapy
~Pathologic T1-2, N0-1
~Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck
~-≤2 positive lymph nodes confined to level II and/or level III
~No extranodal extension
~Clear margins"
16414833|NCT03875716|Experimental|Intermediate Risk|"Reduced-dose radiation (46Gy)
~Pathologic T1-2N0-2 and any one of the following features:
~->2 positive lymph nodes
~<15 lymph nodes retrieved on neck dissection for each side of the neck
~Positive lymph nodes in level IB, IV, or V
~-≤1mm extranodal extension
~Positive lymph node(s) contralateral to the primary tumor
~Close margins"
16414834|NCT03875716|Experimental|High Risk|"Postoperative radiation (60Gy) without chemotherapy
~Pathologic T1-4N0-2 and any one of the following features:
~->1mm extranodal extension
~Microscopic positive margins"
16414835|NCT03875690|Experimental|Experimental group|
16414836|NCT03875690|Placebo Comparator|Control group|
16414837|NCT03875677|Experimental|HD-tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the defined target area
16414838|NCT03875677|Experimental|Conventional tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
16414839|NCT03875677|Sham Comparator|Sham HD-tDCS group|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
16414840|NCT03875664|Active Comparator|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
16414841|NCT03875664|Placebo Comparator|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
16414842|NCT03875638|Experimental|Early Alzheimer's Disease Group Low Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of low-dose levetiracetam (125 mg twice daily)
16414843|NCT03875638|Experimental|Early Alzheimer's Disease Group High Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of high-dose levetiracetam (500mg twice daily).
16414844|NCT03875638|Placebo Comparator|Early Alzheimer's Disease Group Placebo|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of placebo twice daily.
16414845|NCT03875638|No Intervention|Healthy Control Group|A group of demographically similar subjects without Alzheimer's Disease will undergo baseline testing only, without any intervention
16414846|NCT03875625|Experimental|Morbid obesity- Bariatric surgery group|Morbid obese subjects who will consent to bariatric surgery
16414847|NCT03875625|Experimental|Morbid obesity-Dietitian led life style intervention group|Morbid obese subjects who will not consent to bariatric surgery but instead opt for dietitian led life style intervention
16414848|NCT03875625|Experimental|Mild obesity-Dietitian led life style intervention group|Mild- Moderate subjects assigned through a randomized controlled trial to the dietitian led life style intervention
16414849|NCT03875625|Experimental|Mild obesity-Conventional care group (control)|Mild- Moderate subjects assigned through a randomized controlled trial to conventional care
16414850|NCT03875573|Experimental|Chemotherapy and radiotherapy|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy).
16414851|NCT03875573|Experimental|Chemotherapy and pre-operative radiotherapy plus durvalumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w.
16414852|NCT03875573|Experimental|Chemotherapy & pre-op radiotherapy + durvalumab + oleclumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w and the addition of the anti-CD73 antibody oleclumab IV 3000 mg q2w for 4 administrations, followed by q4w for 3 administrations.
16414853|NCT03875560|Experimental|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
16414854|NCT03875560|Experimental|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
16414855|NCT03875560|Experimental|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
16414858|NCT03875547||Patients with haemophilia B|Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
16414859|NCT03875521||12 hours|
16414860|NCT03875521||< 12hours|
16414861|NCT03875508|Experimental|Risankizumab|Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
16414862|NCT03875495|Experimental|Temferon|"Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene.
~Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny."
16414863|NCT03875482|Experimental|Risankizumab|Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
16414864|NCT03875482|Placebo Comparator|Placebo|Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16
16414865|NCT03875469|Experimental|CT patients_Centargo_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
16414866|NCT03875469|Experimental|CT-patients_Stellant_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
16414867|NCT03875469|Experimental|CT-patients_Centargo_2|Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
16414868|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
16414869|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
16414870|NCT03875417||Group A|Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.
16414871|NCT03875417||Group B|Patients who did not develop recurrences after surgery.
16414872|NCT03875404|Experimental|Deep Brain Stimulation subjects|
16414873|NCT03875391|Experimental|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
16414874|NCT03875391|Placebo Comparator|Placebo and trauma film paradigm|Intervention: Drug: Placebos
16414875|NCT03875378|Experimental|Transdermal estrogen/progesterone|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) patch applied weekly for 18 months
16414876|NCT03875378|Placebo Comparator|Placebo|Placebo patch applied weekly for 18 months
16414877|NCT03875365||POPE Patients|Patients who underwent POPE for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus.
16414878|NCT03875352|Experimental|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
16414879|NCT03875352|Experimental|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
16414880|NCT03875339|Active Comparator|Navigator Arm|Examination of adherence to follow-up with a navigator.
16414881|NCT03875339|No Intervention|Non-Intervention Arm|Examination of adherence to follow-up without a navigator.
16414882|NCT03875326|Sham Comparator|Sham Stimulation|Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
16414883|NCT03875326|Experimental|1 mA Dosage Stimulation|1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
16414884|NCT03875326|Experimental|2 mA Dosage Stimulation|2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
16414885|NCT03875326|Experimental|3 mA Dosage Stimulation|3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
16414886|NCT03875313|Experimental|Cohort 1: CB-839 and Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken daily
16414887|NCT03875313|Experimental|Cohort 2: CB-839 and Talazoparib|800 mg CB-839 taken twice daily and 1 mg talazoparib taken daily
16414888|NCT03875300|Experimental|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
16414889|NCT03875300|No Intervention|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
16414890|NCT03875287|Experimental|Decitabine and Cedazuridine|Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.
16414891|NCT03875274|Placebo Comparator|Ropivacaine group|Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB
16414892|NCT03875274|Experimental|Ropivacaine and morphine group|Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
16414893|NCT03875261|Experimental|Study arm|Participants are treated with the investigational medical product
16414894|NCT03875248|Other|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
16414895|NCT03875248|Other|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
16414896|NCT03875248|Other|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
16414897|NCT03875235|Experimental|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
16414898|NCT03875235|Placebo Comparator|Placebo Arm|Placebo + Gemcitabine + Cisplatin
16414899|NCT03875209|Experimental|Arm 1: 10E8.4/iMab IV or SC HIV-|Arm 1; Groups A-C; 3 dosing groups: HIV-uninfected individuals
16414900|NCT03875209|Experimental|Arm 2: 10E8.4/iMab IV HIV-|Arm 2; Groups D-F; 3 dosing groups: HIV-uninfected individuals
16414901|NCT03875209|Experimental|Arm 3: 10E8.4/iMab IV HIV+|Arm 3; Groups H-I; 2 dosing groups: HIV-infected individuals with HIV-1 RNA levels between 1,000 and 100,000 copies/mL and cluster of differentiation 4 (CD4)>350 cells/mm3
16414902|NCT03875209|Experimental|Arm 4: 10E8.4/iMab SC HIV-|Arm 4; Groups J and K: HIV-uninfected individuals
16414903|NCT03875196|Experimental|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
16414904|NCT03875196|Experimental|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
16414905|NCT03875183|Experimental|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
16414906|NCT03875183|Experimental|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
16414907|NCT03875183|Experimental|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
16414908|NCT03875183|Placebo Comparator|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
16414909|NCT03875170|Experimental|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
16414910|NCT03875170|Active Comparator|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
16414911|NCT03875157|Experimental|IBI318 DL1|
16414912|NCT03875157|Experimental|IBI318 DL2|
16414913|NCT03875157|Experimental|IBI318 DL3|
16414914|NCT03875157|Experimental|IBI318 DL4|
16414915|NCT03875157|Experimental|IBI318 DL5|
16414916|NCT03875157|Experimental|IBI318 DL6|
16414917|NCT03875157|Experimental|IBI318 DL7|
16414918|NCT03875157|Experimental|IBI318 DL8|
16414919|NCT03875157|Experimental|IBI318 DL7b|
16414920|NCT03875157|Experimental|IBI318 DL8b|
16414921|NCT03875157|Experimental|IBI318 RP2D|
16414922|NCT03875144|Experimental|association of PIPAC and systemic chemotherapy|4 PIPAC of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks alternating with standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
16414923|NCT03875144|Active Comparator|systemic chemotherapy alone|6 cycles of Cisplatin 75mg/m² + Pemetrexed 500mg/m²
16414924|NCT03875118|Experimental|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
16414925|NCT03875118|Active Comparator|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
16414928|NCT03875079|Experimental|Part I Safety Run in: RO6874281 + Pembrolizumab|"Cohort 1.1 (CPI naive and experienced melanoma participants):
~Participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.
~Cohort 1.2 (CPI experienced melanoma participants only):
~Participants will receive RO6874281 in combination with Pembrolizumab via an induction and maintenance schedule for RO6874281: QW three times (D1, D8, D15) followed by Q3W dosing (D22 and subsequent). Pembrolizumab is to be administered Q3W, starting on Day 1. Participants will be observed for 2 pembrolizumab cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part III of this study."
16414929|NCT03875079|Experimental|Part II Expansion: RO6874281 + Pembrolizumab|Part II will start once all participants in Part I Cohort 1.1 have completed the observation period. Approximately 34 participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks).
16414930|NCT03875079|Experimental|Part III Expansion: RO6874281 + Pembrolizumab|Part III will start once all participants in Part I Cohorts 1.1 and 1.2 have completed the observation period. Approximately 80 participants will be randomised to receive RO6874281 in combination with Pembrolizumab in either a Q3W or QW/Q3W schedule.
16414931|NCT03875066|Other|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
16414932|NCT03875066|Other|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
16414933|NCT03875053|Experimental|Monitoring device, Quality of Life Assessment, Questionnaire|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
16414934|NCT03875014||group 1|Bipolar hemiarthroplasty grop
16414935|NCT03875014||group 2|Total hip replacement dual mobility group
16414936|NCT03875001|Experimental|BI 1358894|
16414937|NCT03875001|Placebo Comparator|Placebo|
16414992|NCT03874559||Arm A|All patients enrolled will be placed in Arm A. Serum blood draw samples will be collected as well as additional data from medical records will be collected. This data includes demographic data, clinical information from notes, radiology images and reports, diagnostic test results, and procedure and pathology reports.
16414938|NCT03874988|Experimental|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
16414939|NCT03874988|Experimental|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
16414940|NCT03874988|Experimental|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
16414941|NCT03874988|Experimental|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
16414942|NCT03874962|Experimental|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
16414943|NCT03874962|No Intervention|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
16414944|NCT03874949|Active Comparator|SEALITE Regular|zinc oxide eugenol sealer
16414945|NCT03874949|Experimental|SEALITE Ultra|zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)
16414946|NCT03874936|Experimental|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
16414947|NCT03874936|Experimental|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
16414948|NCT03874936|Placebo Comparator|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
16414949|NCT03874923|Active Comparator|250 mL of fluid challenge|
16414950|NCT03874923|Experimental|500 mL of fluid challenge|
16414951|NCT03874897|Experimental|CAR-CLDN18.2 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
16414952|NCT03874884|Experimental|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 4 cycles of treatment. An additional 2 cycles of treatment can be given based on clinical benefit achieved and toxicity experienced.
16414953|NCT03874871||Function preserving gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
16414954|NCT03874871||Standard gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
16414955|NCT03874858|Experimental|Nilotinib|Oral 300 mg hard capsules taken once a day
16414956|NCT03874845|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
16414957|NCT03874845|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
16414958|NCT03874832|Experimental|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
16414959|NCT03874832|Experimental|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
16414960|NCT03874832|Experimental|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
16414961|NCT03874832|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
16414962|NCT03874832|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
16414963|NCT03874819|Active Comparator|Control group|Conventional Hemodialysis using a high-flux dialyzer
16414964|NCT03874819|Experimental|Experimental group|Conventional Hemodialysis using a medium cut-of dialyzer
16414965|NCT03874806|Experimental|single|local anesthetic is delivered as a single bolus
16414966|NCT03874806|Active Comparator|continuous|local anesthetic is delivered as a continuous infusion
16414967|NCT03874793|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
16414968|NCT03874793|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
16414969|NCT03874780|Experimental|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
16464269|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
16414970|NCT03874767|Active Comparator|10th floor south|"The unit in this arm will be assigned physical therapists plus mobility technicians in the first month and only physical therapists in the following month.
~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:
~On evaluation, a PT will assign a JH-HLM scale rating to the patient
~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list
~The mobility technician will then see that patient daily, unless the score is <4
~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate
~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
16414971|NCT03874767|Active Comparator|6th floor Round Wing|"The unit in this arm will be assigned only physical therapists in the first month and physical therapists plus mobility technicians in the following month.
~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:
~On evaluation, a PT will assign a JH-HLM scale rating to the patient
~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list
~The mobility technician will then see that patient daily, unless the score is <4
~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate
~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
16414972|NCT03874754|Experimental|The iHBE program group|an intervention group
16414973|NCT03874754|No Intervention|Usual Care (Control group)|A control group
16414974|NCT03874741|Experimental|Arm - Experimental|Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16414975|NCT03874728||Older people at risk of falls|Older people at risk of falls
16414976|NCT03874715|Experimental|Switching arm: Alternative use of SAR341402 and NovoLog|Alternating use of SAR341402 and NovoLog, self-administered by subcutaneous injection at mealtime, starting with NovoLog for the first 4 weeks, then SAR341402 for 4 weeks, followed by NovoLog for 4 weeks and then SAR341402 for the last 4 weeks on top of Lantus as basal insulin.
16414977|NCT03874715|Active Comparator|Non-Switching arm: NovoLog|Continuous use of NovoLog, self-administrated by subcutaneous injection at mealtime, during the 16-week Treatment Period on top of Lantus as basal insulin.
16414978|NCT03874702||Ischemic stroke patients with <4.5 hours of onset .|analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base.
16414979|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
16414980|NCT03874663||Oral HIV Self-testing|Evaluate the acceptability and performance of a directly assisted oral HIV self-testing (HIVST) in a youth population aged 14-24 in Nigeria
16414981|NCT03874650|Experimental|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.
~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:
~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
16414982|NCT03874650|Experimental|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
16414983|NCT03874650|Placebo Comparator|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
16414984|NCT03874637|Experimental|Treatment|Active therapy
16414985|NCT03874637|Sham Comparator|Sham Control|Sham Control
16414986|NCT03874611|Experimental|electrophysiological data from DBS|
16414987|NCT03874598|Experimental|Ear acupuncture|
16414988|NCT03874598|Active Comparator|Psychoeducation|
16414989|NCT03874585|Active Comparator|Standard Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange) and free nicotine replacement.
16414990|NCT03874585|Experimental|Enhanced Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange), free nicotine replacement, and the 6-week text messaging intervention.
16414991|NCT03874572|Experimental|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
16414993|NCT03874546|Experimental|Prognostic evaluation|Questionnaire at Day1, Day7 and 6 months.
16415333|NCT03872245|Active Comparator|PENS T6|The patients will undergo PENS T6 during 10 weeks.
16414994|NCT03874533|Experimental|self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.
~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
16414995|NCT03874520|Experimental|Video triage|The sick child will be assessed on video by the operator at the call-center.
16414996|NCT03874520|No Intervention|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
16414997|NCT03874507|Experimental|Technology-based therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive either virtual reality (VR) or augmented reality (AR) to improve clinical outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step.
16414998|NCT03874507|No Intervention|Standard of Care therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive physical therapy based on his/her providers recommendations to improve outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step
16414999|NCT03874494|Experimental|Brexpiprazole|2-4 mg/day, once daily for 6 weeks, oral administration
16415000|NCT03874494|Active Comparator|Aripiprazole|10-20 mg/day, once daily for 6 weeks, oral administration
16415001|NCT03874481||PCI|Patients who had stent
16415002|NCT03874442|No Intervention|Controls|
16415003|NCT03874442|Experimental|CliniPup|
16415004|NCT03874429|Experimental|T2259|1 drop in each eye 2 to 4 times daily
16415005|NCT03874429|Active Comparator|Vismed Multi|1 drop in each eye 2 to 4 times daily
16415006|NCT03874416|Experimental|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
16415007|NCT03874416|Active Comparator|Control group|Non-specific rehabilitation of working memory, usual therapy.
16415008|NCT03874403|Experimental|NIVATS|Patients receiving Non-intubated VATS with DSA changes
16415009|NCT03874403|Other|Intubated VATS|Patients receiving intubated VATS with DSA changes
16415010|NCT03874390|Experimental|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
16415011|NCT03874390|Active Comparator|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
16415012|NCT03874377|Experimental|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
16415013|NCT03874364|Active Comparator|Lidocaine gel, counselling, monitor|
16415014|NCT03874364|Active Comparator|Lidocaine gel, counselling, no monitor|
16415015|NCT03874364|Active Comparator|Lidocaine gel, no counselling, monitor|
16415016|NCT03874364|Active Comparator|Lidocaine gel, no counselling, no monitor|
16415017|NCT03874364|Placebo Comparator|Lubricating gel, counselling, monitor|
16415018|NCT03874364|Placebo Comparator|Lubricating gel, counselling, no monitor|
16415019|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, monitor|
16415020|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, no monitor|
16415021|NCT03874351|Experimental|Active tDCS|The active tDCS will involve 20-minutes of direct current at intensity of 1.5 milliamperes (mA).
16415022|NCT03874351|Sham Comparator|Sham tDCS|Sham will include 30 seconds of stimulation at 1.5 mA, followed by 0 mA for the remaining time.
16415023|NCT03874338||Colchicine|
16415024|NCT03874338||Placebo|
16415025|NCT03874325|Experimental|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
16415026|NCT03874325|Experimental|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
16415027|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
16415028|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
16415029|NCT03874299||Kidney Transplant Receipients|
16415030|NCT03874286||Liver Transplant|Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.
16415031|NCT03874273|Experimental|crizotinib +|Patients with unresectable, relapsed or refractory inflammatory myofibroblastic tumor, receiving crizotinib
16415032|NCT03874260|Experimental|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
16415033|NCT03874260|Placebo Comparator|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
16415034|NCT03874247|Experimental|Pelubiprofen|
16415035|NCT03874247|Placebo Comparator|Pelubiprofen placebo|
16415065|NCT03873987|Experimental|Kimyrsa|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Kimyrsa vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
16464270|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
16415036|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 1|Subjects will receive 3 single ascending oral doses (SAD) of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 1 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
16415037|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 2|Subjects will receive 3 SAD of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 2 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
16415038|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 in Cohort 3|Subjects will receive GSK3186899 orally, under fasted condition and fed conditions on Day 1 of cohort 3 in each of the two treatment periods. There will be a wash out period of at least 10 days between each treatment period. A dose level will be determined based on the effect of food on the safety, tolerability and PK of a single dose of GSK3186899, with dose level selected from Cohorts 1 and 2.
16415039|NCT03874234|Experimental|Part B: Subjects receiving GSK3186899|Subjects will receive GSK3186899, orally, twice daily (BID) on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
16415040|NCT03874234|Placebo Comparator|Part B: Subjects receiving placebo|Subjects will receive placebo, orally, BID on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
16415041|NCT03874208|Other|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
16415042|NCT03874208|Other|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
16415043|NCT03874195|Active Comparator|Control|"Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative care)."
16415044|NCT03874195|Experimental|Intervention|Intervention Arm subjects will receive access to PCforMe.
16415045|NCT03874169||High-Risk of GI Bleed|Patients that have a high risk of having a gastrointestinal bleed upon admission into the ICU based on their medical history and symptoms. These patients will have a biosensor watch, the E4 wristband, placed on them to monitor their vital signs.
16415046|NCT03874156|Active Comparator|Intervention group|Atorvastatin 40 mg once daily
16415047|NCT03874156|Placebo Comparator|Placebo group|Matched placebo tablet once daily
16415048|NCT03874143|Experimental|RCom equipped with a smartphone|
16415049|NCT03874143|No Intervention|RCom with paper-based system|
16415050|NCT03874130|Active Comparator|Scopolamine|0.2 mg scopolamine HBr per dose
16415051|NCT03874130|Active Comparator|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
16415052|NCT03874117|Other|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
16415053|NCT03874117|Other|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
16415054|NCT03874104|Experimental|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
16415055|NCT03874091|Active Comparator|GA group|Patients will receive general anaesthesia for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
16415056|NCT03874091|Experimental|ESP group|Patients will receive general anaesthesia with bilateral ESP block for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
16415057|NCT03874052|Experimental|Treatment (ruxolitinib, venetoclax)|Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
16415058|NCT03874039||Healthy Adults|Healthy adults with no prior diagnosis of atopic dermatitis
16415059|NCT03874039||Atopic Dermatitis|Adults with prior diagnosis of Atopic Dermatitis from board certified dermatologist
16415060|NCT03874026|Experimental|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
16415061|NCT03874013|Experimental|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
16415062|NCT03874013|Active Comparator|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
16415063|NCT03874000|Experimental|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
16415064|NCT03873987|Active Comparator|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
16415066|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:
~DualDur dark-field microscopic test
~DualDur dark-field automatic microscopic test
~Western blot IgM and IgG
~Bózsik Western blot IgM and IgG
~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG
~DualDur Polymerase chain reaction"
16415067|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:
~DualDur dark-field microscopic test
~DualDur dark-field automatic microscopic test
~Western blot IgM and IgG
~Bózsik Western blot IgM and IgG
~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG
~DualDur Polymerase chain reaction"
16415068|NCT03873961|Experimental|High-intensity laser therapy|The participants received stretching and exercise guidance and underwent the BTL-6000 High Intensity Laser 12 W with 10 mm pen applicator high intensity laser procedures (mode = continuous, power = 7 W, dose = 120 J/cm2, total time= 7 min. 8 sec.) 3 times per week (total of 8 procedures).
16415069|NCT03873961|Active Comparator|Low-level laser therapy|The participants received stretching and exercise guidance underwent the LAS-Expert with laser shower applicator Low-level Laser therapy procedures (785 nm wavelength, 4,0 J/cm2, 35cm2, 6:40 min) 3 times per week (total of 8 procedures).
16415070|NCT03873948||Control|Healthy patients
16415071|NCT03873948||Periodontitis|Patients with periodontal disease
16415072|NCT03873948||Cardiovascular|Patients with cardiovascular disease
16415073|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
16415074|NCT03873935||Control|Healthy subjects
16415075|NCT03873935||Periodontitis|Patients with periodontal disease
16415076|NCT03873935||Cardiovascular|Patients with cardiovascular disease
16415077|NCT03873935||Periodontitis+Cardiovascular|People with both cardiovascular and periodontitis
16415078|NCT03873922|Experimental|Ketogenic diet intervention|Ketogenic meals will be offered for the participants during the trial.
16415079|NCT03873922|No Intervention|Control group|Conventional hospital meals as usual will be offered during the trial.
16415080|NCT03873909|Active Comparator|Fruit Smoothie|Post-prandial study feeding 155-200 g mamey sapote mesocarp, 6 g of soybean oil , crushed ice and 150-200 g of water to reach a total volume of 450 mL. (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin).
16415081|NCT03873909|Active Comparator|Matrix-Free Shake|Post-prandial study feeding 2 g of carotenoid powder formula (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin), 37.5 g of sugar, 75 µg of citric acid, 6 g of soybean oil emulsified into 300 g of water using 3 g of soy lecithin as well as ca. 100 g of crushed ice, yielding a shake volume of 450 mL.
16415082|NCT03873896|Experimental|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
16415083|NCT03873896|Active Comparator|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
16415084|NCT03873883|Experimental|Dose Escalation- Monotherapy|Specified dose on specified days
16415085|NCT03873883|Experimental|EOS100850 and Pembrolizumab Combination Therapy|Specified dose on specified days
16415086|NCT03873883|Experimental|EOS100850 and SOC Combination Chemotherapy|Specified EOS100850 dose on specified days
16415087|NCT03873870|Experimental|68Ga -DOTATATE PET scan|
16415088|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
16415089|NCT03873844|Experimental|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
16415090|NCT03873831|Active Comparator|Social Skills Control (A-A)|"The children in the A-A condition, a true control, will remain without a dog for the full 10 weeks."
16415091|NCT03873831|Experimental|Social Skills Dog (A-B)|"The A-B condition will involve standard instruction for 5 weeks (A), followed by 5 weeks of group instruction while a therapy dog is present in the room (B)."
16415092|NCT03873831|Experimental|Social Skills Dog (B-A)|"The B-A condition will be identical, except the first 5 weeks of instruction will include the dog, followed by 5 weeks of standard instruction with no dog."
16415093|NCT03873818|Experimental|Treatment (ipilimumab, pembrolizumab)|Patients receive ipilimumab IV over 90 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles for ipilimumab and up to 35 cycles for pembrolizumab in the absence of disease progression or unacceptable toxicity.
16415094|NCT03873805|Experimental|Treatment (PSCA CAR T cells)|Patients may receive lymphodepleting regimen including fludarabine IV on days -5 to -3 and cyclophosphamide IV on days -5 to -3 or on days -4 and/or -3. Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.
16415095|NCT03873792|Other|Allergy pregnant women|
16415096|NCT03873792|Other|Health pregnant women|
16415097|NCT03873779|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
16415098|NCT03873766|Active Comparator|Intrapleural fibrinolytic therapy (IPFT)|"Procedure/Surgery: Pleural Sampling
~Procedure/Surgery: Pleural fluid drainage
~Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.
~Other: Surgical Consultation
~Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.
~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained
~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
16464394|NCT03536260|Active Comparator|Immediate implant with Nanobone|
16415099|NCT03873766|Active Comparator|Surgery|"Procedure/Surgery: Pleural Sampling
~Procedure/Surgery: Pleural fluid drainage: Chest tube placement
~Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.
~Other: Surgical Consultation
~Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon
~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained
~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
16415100|NCT03873753|Experimental|Oral cleaning|The oral cavity will be clean with gauze and mineral water three times a day.
16415101|NCT03873753|Active Comparator|No oral cleaning|The oral cavity will not be cleaned.
16415102|NCT03873740|Experimental|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
16415103|NCT03873740|Experimental|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
16415104|NCT03873740|Experimental|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
16415105|NCT03873740|Experimental|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
16415106|NCT03873727|Experimental|Prevenar13/ Pneumovax|Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).
16415107|NCT03873727|Placebo Comparator|Placebo / Pneumovax|Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)
16415108|NCT03873714|Experimental|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
16415109|NCT03873688|Experimental|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
16415110|NCT03873688|Sham Comparator|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
16415111|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
16415112|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
16415113|NCT03873649||Patients with subacute or chronic hypersensitivity pneumonitis|"Procedures that each subject will undergo include:
~Chest CT scan to determine extent of disease.
~Pulmonary function testing to determine severity of disease.
~Bronchoscopy with lavage.
~Venipuncture."
16415114|NCT03873649||Healthy Controls|"Inclusion:
~Adult between the ages of 18 and 80 years old.
~Non-smoker or previous smoker quit >6months ago.
~Able to understand the consent process and procedures involved in the study.
~Exclusion:
~Unable to understand the consent process or procedures involved in the study.
~Pregnancy.
~Suspicion of current infection or within the past 3 months.
~Bleeding disorder or on anti-coagulants other than aspirin.
~Any co-morbid condition that increases risk of bronchoscopy including but not limited to cardiac disease, uncontrolled hypertension, uncontrolled diabetes and/or morbid obesity."
16415115|NCT03873636|Experimental|Active Stimulation|Active stimulation of targeted brain regions involved in task-switching and dual-tasking.
16415116|NCT03873636|Sham Comparator|Sham Stimulation|Sham stimulation of targeted brain regions involved in task-switching and dual-tasking.
16415117|NCT03873623||Kidney Transplant Recipients|
16415118|NCT03873610|Experimental|Stress and Symptom Management Program 1|
16415119|NCT03873610|Experimental|Stress and Symptom Management 2|
16415120|NCT03873597|Experimental|Tele-coaching + Usual Care|This group will undergo a 12 week physical activity tele-coaching intervention consisting of a step-counter and smartphone application, in addition to usual care. Usual care will also include sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
16415121|NCT03873597|No Intervention|Usual Care|This group will receive sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
16415122|NCT03873532|Experimental|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
16415123|NCT03873532|Active Comparator|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
16415124|NCT03873519|Experimental|Cold North|Group A: Cold color scheme, room facing North
16415125|NCT03873519|Experimental|Cold South|Group B:Cold color scheme, room facing South
16415126|NCT03873519|Experimental|Warm North|Group C: Warm color scheme, room facing North
16415127|NCT03873519|Experimental|Warm South|Group D: Warm color scheme, room facing South
16415128|NCT03873506|Experimental|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
16415204|NCT03872986|Experimental|Giomer only|Beautifil II dental restorative material
16415129|NCT03873493|Experimental|Venetoclax + Ibrutinib|Venetoclax at a predetermined dose according to a prescribed dosing schedule orally once daily (QD) plus Ibrutinib Dose A orally QD.
16415130|NCT03873480|Active Comparator|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
16415131|NCT03873480|No Intervention|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
16415132|NCT03873467|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
16415133|NCT03873467|Other|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
16415134|NCT03873454|Active Comparator|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
16415135|NCT03873454|Other|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
16415136|NCT03873454|Other|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
16415137|NCT03873441|Experimental|Computer Games-Aided Balance Training Group|The participants in CGR group will be asked to sit or stand (as per the screening result) on fixed & compliant surfaces; to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects using bi-manual grip gradually progressing to head rotations (mouse mounted on a cap worn by participant); finally using trunk movements as a part of experimental therapy protocol. While performing CGR; children will be standing on a thin pressure mat (placed over fixed or compliant surface). This will allow us to record the information of COP displacement [body sway] while CGR intervention implementation. This information will be used to quantify therapy dosage. The CGR Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
16415138|NCT03873441|Active Comparator|Conventional Balance Training Group|The control group will be receiving the conventional balance training for static and dynamic balance function improvement. The therapy will be provided in sitting or standing (as per the screening result) in a graded manner progressing from fixed surfaces to movable compliant surfaces. The Conventional Balance Training Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
16415139|NCT03873428|Other|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
16415140|NCT03873415|Experimental|Formulation A|Dosage formulation and area of release varies between arms
16415141|NCT03873415|Experimental|Formulation B|Dosage formulation and area of release varies between arms
16415142|NCT03873415|Experimental|Formulation C|Dosage formulation and area of release varies between arms
16415143|NCT03873415|Experimental|Formulation D|Dosage formulation and area of release varies between arms
16415144|NCT03873415|Experimental|Formulation E|Dosage formulation and area of release varies between arms
16415145|NCT03873415|Experimental|Formulation F|Dosage formulation and area of release varies between arms
16415146|NCT03873415|Experimental|Formulation G|Dosage formulation and area of release varies between arms
16415147|NCT03873415|Experimental|Formulation H|Dosage formulation and area of release varies between arms
16415150|NCT03873389||Ocrelizumab|All participants enrolled in the study. All participants will be receiving the treatment of interest (Ocrelizumab)
16415151|NCT03873376|Experimental|Opt-in|Receive offer to order self-sampling kit
16415152|NCT03873376|Experimental|Opt-out|Receive self-sampling kit unsolicited
16415153|NCT03873376|Experimental|Control|Receive open reminder to be screened by physician
16415154|NCT03873363|Experimental|PS|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
16415155|NCT03873363|Active Comparator|CR|Implantation of a cruciate retaining Total Knee Arthroplasty.
16415156|NCT03873350|Experimental|Living kombucha|
16415157|NCT03873350|Placebo Comparator|Heat-sterilized kombucha|
16415158|NCT03873350|No Intervention|Water|
16415159|NCT03873337|Experimental|NRT + Persistence Targeted Smoking Cessation in Schizophrenia|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling with a focus on task persistence.
16415160|NCT03873337|Active Comparator|NRT + Modified Clearing the Air|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling that does not focus on task persistence.
16415161|NCT03873324|Experimental|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.
~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
16415162|NCT03873324|Placebo Comparator|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
16415163|NCT03873311|Experimental|Azacytidine + HAG Regimen|Azacytidine（75mg/m2 ）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) , Cytarabine 10mg/(m2.d), G-CSF 200ug/(m2.d) )
16415164|NCT03873311|Active Comparator|Azacytidine|75mg/m2
16415165|NCT03873298|Experimental|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
16415166|NCT03873298|Experimental|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
16415205|NCT03872986|Experimental|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
16415206|NCT03872986|Experimental|GIC only|Equia forte dental restorative material
16415167|NCT03873285|Experimental|Genodermatosis patients|Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
16415168|NCT03873272|Active Comparator|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
16415169|NCT03873272|Active Comparator|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
16415170|NCT03873272|Placebo Comparator|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
16415171|NCT03873259|Experimental|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
16415172|NCT03873246|Placebo Comparator|Placebo|
16415173|NCT03873246|Active Comparator|OC-01 0.1%|
16415174|NCT03873246|Active Comparator|OC-01 0.2%|
16415175|NCT03873233|Active Comparator|Volume Controlled Ventilation|Volume Controlled Ventilation with Aisys Carestation ventilator and normal endotracheal tube'
16415176|NCT03873233|Active Comparator|Flow Controlled Ventilation|Flow Controlled Ventilation with Evone ventilator and Tritube
16415177|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
16415178|NCT03873207|Experimental|Intervention|Pedal fat grafting followed by PopSole™ offloading device
16415179|NCT03873207|Other|Standard of care|Pedal fat grafting followed by standard post-operative care with padding of the insoles
16415180|NCT03873194|Experimental|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
16415181|NCT03873194|Other|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
16415182|NCT03873155|Experimental|Mindfulness-based cognitive therapy|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
16415183|NCT03873142|Experimental|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
16415184|NCT03873129|Experimental|A-CHESS|participant will be using the A-CHESS mobile app for 12 months
16415185|NCT03873116|Experimental|BCX7353 110mg once daily|BCX7353 capsules administered orally once daily
16415186|NCT03873116|Experimental|BCX7353 150mg once daily|BCX7353 capsules administered orally once daily
16415187|NCT03873116|Placebo Comparator|Placebo|Matching placebo oral capsules administered orally once daily
16415188|NCT03873090|Experimental|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
16415189|NCT03873077|No Intervention|intravenous analgesia|Patient receives intravenous analgesia: paracetamol 30 mg/kg, diclofenac 75 mg, clonidine 1 µg/kg and morfine 0,05 mg/kg
16415190|NCT03873077|Other|intravenous analgesia + LIA|Patient receives intravenous analgesia and a local infiltration analgesia in the knee
16415191|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
16415192|NCT03873051|Experimental|Challenge-Focused Program|This group will receive the challenge-focused group program
16415193|NCT03873051|Experimental|Rewards-Focused Program|This group will receive the rewards-focused group program
16415194|NCT03873038|Experimental|Part 1, Panel A: MK-2060 (8 mg)|Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.
16415195|NCT03873038|Experimental|Part 1, Panel B: MK-2060 (20 mg)|Participants will receive a single 20-mg dose of MK-2060 via IV infusion.
16415196|NCT03873038|Experimental|Part 1, Panel C: MK-2060 (40 mg)|Participants will receive a single 40-mg dose of MK-2060 via IV infusion.
16415197|NCT03873038|Experimental|Part 2: MK-2060 (25 mg)|Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4).
16415198|NCT03873038|Placebo Comparator|Part 1 (Panels A, B, C) and Part 2: Placebo|Part 1: Participants will receive a single dose of placebo via IV infusion. Part 2: Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via infusion weekly for 3 weeks (Weeks 2-4).
16415199|NCT03873025|Experimental|Pembrolizumab and CXD101|"Initial dose ('dose level 0'):-
~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 20mg twice daily PO (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity.
~Reduced dose level ('Dose level -1'; if >1 DLT observed at dose level 0):
~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 given twice daily, 20mg in the morning and 10mg in the evening (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity."
16415200|NCT03873012||OCT-guided group|OCT-guided PCI with EES or BES
16415201|NCT03873012||Angiography-guidance group|Angio-guided PCI with EES or BES
16415202|NCT03872999|Experimental|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
16415203|NCT03872986|Experimental|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
16415208|NCT03872973|Experimental|Strobe Group|This group will perform neuromuscular training for 6 weeks with a strobe glasses.
16415209|NCT03872973|No Intervention|Control Group|This group will not perform any neuromuscular training program.
16415210|NCT03872960|Experimental|Intervention Arm: Expedited transfer to a CAC|The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-arrest STE patients. This involves pre-alert of the CAC and strategic delivery of the patient to the catheter laboratory (24 hours a day, 7 days a week). Patients will receive definitive post-resuscitation care: intubation and ventilation, where necessary, targeted temperature management, and goal directed therapies including evaluation and identification of underlying cause of arrest with access to immediate reperfusion if necessary. Prognostication will occur no earlier than 72 hours post-cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest to the designated centre.
16415211|NCT03872960|No Intervention|Control Arm: Current standard of care|The control arm comprises the current standard of pre-hospital advanced life support (ALS) care management for patients with ROSC following cardiac arrest of suspected cardiac aetiology. The patient is conveyed to the geographically closest emergency department. Management thereafter will be as per standard hospital protocols however as in the intervention arm, prognostication is to be delayed in trial patients until at least 72 hours post arrest.
16415212|NCT03872947|Experimental|Arm A: TRK-950 + FOLFIRI|"Colorectal Cancer
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
16415213|NCT03872947|Experimental|Arm B: TRK-950 + Gemcitabine/Cisplatin|"Cholangiocarcinoma or Bladder Cancer
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Cisplatin will be administered by infusion. Then, Gemcitabine will be administered as an intravenous infusion."
16415214|NCT03872947|Experimental|Arm C: TRK-950 + Gemcitabine/Carboplatin|"Ovarian Cancer
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Gemcitabine will be administered as an intravenous infusion. On day 1, following the administration of TRK-950 and Gemcitabine, Carboplatin will be administered intravenously."
16415215|NCT03872947|Experimental|Arm D: TRK-950 + Ramucirumab/Paclitaxel|"Gastric Cancer
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Ramucirumab will be administered as an IV infusion. Paclitaxel will be dosed on days 1, 8 and 15, after the Ramucirumab on days 1 and 15 and after the TRK-950 on day 8."
16415216|NCT03872947|Experimental|Arm E: TRK-950 + PD1 inhibitors|"•Solid Tumors
~E-1: TRK-950 + Nivolumab
~•TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.
~E-2: TRK-950 + Pembrolizumab
~•TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
16415217|NCT03872947|Experimental|Arm F: TRK-950 + Imiquimod Cream|"Palpable subcutaneous malignant lesions
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks)."
16415218|NCT03872947|Experimental|Arm G: TRK-950 + Bevacizumab|"Renal Cell Carcinoma
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Bevacizumab will be administered as an IV infusion."
16415219|NCT03872947|Experimental|Arm H: TRK-950 + PD1 inhibitors|"•Melanoma
~H-1: TRK-950 + Nivolumab
~•TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.
~H-2: TRK-950 + Pembrolizumab
~•TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
16415220|NCT03872947|Experimental|Arm I: TRK-950 + Nivolumab/Ipilimumab|"Melanoma
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Nivolumab will be administered as an IV infusion. In cycles 1 through 4 only, after the infusion of Nivolumab, Ipilimumab will be administered intravenously. This cycle will be repeated for four (4) cycles. Beginning with cycle 5, TRK-950 will be administered on days 1, 8, 15, and 22 of a 28 day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion."
16415221|NCT03872947|Experimental|Arm J: TRK-950 + FOLFIRI|"Colorectal Cancer
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
16415222|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
16415223|NCT03872934||classical western music|classical western music (vivaldi)
16415224|NCT03872934||soft rock music|soft rock music (elvis)
16415225|NCT03872934||control group (group not listening music)|control
16415226|NCT03872921|Experimental|norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years
16415227|NCT03872921|Placebo Comparator|Placebo to norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years
16415228|NCT03872908||Cohort 1|Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) versus chilled gloves (non-dominant hand) at the end of paclitaxel administration.
16415229|NCT03872908||Cohort 2|Evaluation of the efficacy of the compression induced by surgical gloves against peripheral neuropathies in patients treated by oxaliplatine after a 595 mg/m2 cumulated dose.
16415230|NCT03872869|Active Comparator|Hip School|The participants in the Hip School were required to attend three 1.5 hour classes which were conducted by specially trained physiotherapists in premise at Lund University.
16415334|NCT03872232|Experimental|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
16464636|NCT03534427|No Intervention|Control group|No exercise intervention
16415231|NCT03872869|Active Comparator|Tai Chi for arthritis (TCA)|The treatment intervention with TCA was scheduled in a group setting. Class size for Tai Chi groups was 8- 10 individuals. The group was led by a physiotherapist, specially trained in the concept, in premise at Lund University. The participants in the Tai Chi group were required to attend classes for 12-16 one- hour sessions, twice a week for the first four weeks and then once a week.
16415232|NCT03872869|No Intervention|Control group|
16415233|NCT03872856|Active Comparator|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
16415234|NCT03872856|No Intervention|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
16415235|NCT03872843|Active Comparator|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
16415236|NCT03872843|Active Comparator|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
16415237|NCT03872830|Experimental|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
16415238|NCT03872830|Experimental|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
16415239|NCT03872830|Experimental|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
16415240|NCT03872830|Placebo Comparator|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
16415241|NCT03872817|Experimental|Intervention ProLiSMentAl|"Experimental Group receive mental health literacy psychoeducational intervention called ProLiSMentAl that consist of 4 sessions of 90 minutes."
16415242|NCT03872817|No Intervention|Control Group|Control Group receive usual approach.
16415243|NCT03872804|Experimental|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
16415244|NCT03872791|Experimental|KN046|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
16415245|NCT03872791|Experimental|KN046 plus nab-paclitaxel|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity
16415246|NCT03872778|Experimental|Phase I Cohort I|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
16415247|NCT03872778|Experimental|Phase I Cohort II|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 60% ECD for 3 cycles (q6w)"
16415248|NCT03872778|Experimental|Phase I Cohort III|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 80% ECD for 3 cycles (q6w)"
16415249|NCT03872778|Experimental|Phase I Cohort IV|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 100% ECD for 3 cycles (q6w)"
16415250|NCT03872778|Experimental|Phase I Cohort V|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 120% ECD for 3 cycles (q6w)"
16415251|NCT03872778|Experimental|Phase I Cohort VI|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 100% ECD for 2 cycles (q6w)"
16415252|NCT03872778|Experimental|Phase IIa|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
16415253|NCT03872765|Other|Patients with chronic anal fissure|Use of laser in surgery of chronic anal fissure instead of the conventional surgical techniques.
16415254|NCT03872752|Experimental|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
16415255|NCT03872739|Experimental|distilled water|Oral distilled water at the rate of 3 mL/kg/h rate during undergoing enhanced computed tomography examination before 1-2 and after 4-6 hours
16415256|NCT03872739|Placebo Comparator|Saline|intravenous saline hydration at the rate of 1 mL/kg/h rate during undergoing enhanced computed tomography examination before and after 12 hours
16415257|NCT03872700|Experimental|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
16415258|NCT03872700|Experimental|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
16415259|NCT03872687|Experimental|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size for 6 months.
16415260|NCT03872687|Active Comparator|interdental brushes|Subjects in this group will only receive interdental brushes 6 months.
16415261|NCT03872674|No Intervention|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
16415262|NCT03872674|Experimental|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
16415335|NCT03872232|Active Comparator|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
16415336|NCT03872232|Active Comparator|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
16415263|NCT03872661|Experimental|Drug and surgery|Neoadjuvant therapy followed by surgery. Neoadjuvant therapy included four drugs. IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles; bevacizumab was administered at a dose of 15 mg/kg; pemetrexed was given 500 mg/m^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles; carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles. Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
16415264|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
16415265|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
16415266|NCT03872635|Experimental|CHO Drinking Grope|receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
16415267|NCT03872635|No Intervention|Traditional fast Grope|fast on standard hospital protocol (8 hour fasting for solid and 4 hour fasting for clear liquid
16415268|NCT03872622|Other|CD patients|New onset Crohn's disease patients
16415269|NCT03872622|Other|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
16415270|NCT03872596|Experimental|Part A: Sequence 1|"Titration Period:
~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.
~Treatment Period:
~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
16415271|NCT03872596|Experimental|Part A: Sequence 2|"Titration Period:
~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.
~Treatment Period:
~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
16415272|NCT03872596|Experimental|Part A: Sequence 3|"Titration Period:
~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.
~Treatment Period:
~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
16415273|NCT03872596|Experimental|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
16415274|NCT03872596|Experimental|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
16415275|NCT03872583|Experimental|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
16415276|NCT03872583|Active Comparator|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
16415277|NCT03872570|Active Comparator|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
16415278|NCT03872570|Active Comparator|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
16415279|NCT03872557|Active Comparator|Tyrosine (TYR) depletion, then oral TYR|"TYR supplementation: Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before oral glucose tolerance test (OGTT). On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.
~Visit 2. Placement of intravenous catheter for the collection of serial blood samples and an OGTT with supplementation with oral tyrosine supplement. To supplement the OGTT with Tyrosine, the contents of four (4) L-Tyrosine 500 mg capsule are given 45 minutes before the oral glucose solution is administered. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity."
16415280|NCT03872557|No Intervention|TYR depletion, then no oral TYR|"Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before OGTT. On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.
~Subsequent Visit 3. This visit will consist of placement of intravenous catheter for the collection of serial blood samples and an OGTT without supplementation with oral tyrosine supplement."
16415281|NCT03872531||Cohort 1|Includes age group 3-5 with a cap at 20 subjects. This is a retrospective, observational study
16415282|NCT03872531||Cohort 2|Includes age group 6-10 with a cap at 30 subjects. This is a retrospective, observational study
16415283|NCT03872531||Cohort 3|Includes age group 11-15 with a cap of 30 subjects. This is a retrospective, observational study
16415284|NCT03872531||Cohort 4|Includes age group 16-20 with a cap of 20 subjects. This is a retrospective, observational study
16415285|NCT03872531||Cohort 5|Includes age group 21-30 with a cap at 20 subjects. This is a retrospective, observational study
16415286|NCT03872531||Cohort 6|Includes age group 31-40 with a cap at 20 subjects. This is a retrospective, observational study
16415287|NCT03872531||Cohort 7|Includes age group 41 and over with a cap at 35 subjects. This is a retrospective, observational study
16415288|NCT03872505|Active Comparator|Chemotherapy + Durvalumab|Arm A: Carboplatin, Paclitaxel and Durvalumab
16415289|NCT03872505|Experimental|Chemo + Durvalumab + Radiation Therapy|Arm B: Carboplatin, Paclitaxel and Durvalumab + Radiation Therapy
16415337|NCT03872219|Placebo Comparator|Placebo|The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.
16415338|NCT03872219|Experimental|intervention arm|The children will receive and they are exposed daily to materials of high microbiological biodiversity.
16416495|NCT03864458|Experimental|KHK7791 A|Patients take KHK7791 low dose BID.
16415290|NCT03872492|Experimental|Patients with Major Depressive Disorder|"Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).
~At the end of phase 1 if the patient is considered as an responder he will make more than one visit at week 12.
~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.
~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments."
16415296|NCT03872453|Active Comparator|Arm 1 - BHV-3500 (zavegepant) 5 mg|One dose of 5 mg
16415297|NCT03872453|Active Comparator|Arm 2 - BHV-3500 (zavegepant) 10mg|One dose of 10 mg
16415298|NCT03872453|Active Comparator|Arm 3 - BHV-3500 (zavegepant) 20mg|One dose of 20mg
16415299|NCT03872453|Placebo Comparator|Arm 4 - Matching BHV-3500 (zavegepant) Placebo|One dose of placebo
16415300|NCT03872440||EGFR T790M patients|EGFR T790M patients who have progressed on osimertinib or other third generation (mutant selective) EGFR TKI therapy
16415301|NCT03872440||EGFR exon 19 del or L858R patients|EGFR exon 19 del or L858R patients who have progressed on first line osimertinib
16415302|NCT03872440||Exon 20 insertion mutations patients|Patients with Exon 20 insertion mutations (n=10; regardless of drug therapy). Includes EGFR Exon 20 and up to two HER2 Exon20 patients
16415303|NCT03872427|Experimental|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16415304|NCT03872414|Experimental|Healthy Younger Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
16415305|NCT03872414|Experimental|Healthy Older Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
16415306|NCT03872414|Experimental|Parkinson Disease Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
16415307|NCT03872414|Active Comparator|Control Group|Participants will receive rt-fMRI training to increase primary auditory cortex activation.
16415308|NCT03872401|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W) for a minimum of 4 years.
16415309|NCT03872401|Experimental|Evolocumab 140 mg Q2W|Participants will receive 140 mg evolocumab by subcutaneous injection once every 2 weeks for a minimum of 4 years.
16415310|NCT03872388|Experimental|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
16415311|NCT03872388|Active Comparator|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
16415312|NCT03872375|Experimental|Intermittent Calorie Restriction + Dietary Counseling|"Participants will be asked to consume a single 530 kilocalorie shake (i.e., High Calorie Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.
~Subjects are also asked to follow RDN dietary recommendations."
16415313|NCT03872375|Active Comparator|Dietary Counseling|A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
16415314|NCT03872362||Training dataset|No interventions
16415315|NCT03872362||External validation1|No interventions
16415316|NCT03872362||External validation2|No interventions
16415317|NCT03872349|Experimental|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 7.1% from saturated fat; 20.7% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
16415318|NCT03872349|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 14.4% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
16415319|NCT03872336|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
16415320|NCT03872336|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
16415321|NCT03872323|Active Comparator|Endovascular treatment|
16415322|NCT03872323|Active Comparator|Open surgery|
16415323|NCT03872310|Active Comparator|Active comparator|Within group
16415324|NCT03872310|Sham Comparator|Sham comparator|Within group
16415325|NCT03872297|Placebo Comparator|Placebo supplement|Consumption of a non active food complement during 3 months.
16415326|NCT03872297|Active Comparator|Naticol supplement|Consumption of the active food complement during 3 months containing Naticol.
16415327|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
16415328|NCT03872271|Experimental|Experimental|ileal pouch-anal anastomosis without diverting loop ileostomy
16415329|NCT03872271|Active Comparator|Control|ileal pouch-anal anastomosis with diverting loop ileostomy
16415330|NCT03872258|Active Comparator|Control|Counseling on physical activity
16415331|NCT03872258|Experimental|Intervention|Add an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle
16415332|NCT03872245|Experimental|PENS T6 + Probiotics|The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
16415339|NCT03872206|Experimental|HPN536-2001 - Part 1 (Dose Escalation)|Part 1 (Dose Escalation): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma, or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion with a fix dose. Dose escalation per cohort until an estimated therapeutic dose level has been reached.
16415340|NCT03872206|Experimental|HPN536-2001 - Part 2 (Dose Expansion)|"Part 2 (Dose Expansion): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant mesothelioma, pancreatic adenocarcinoma or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion.
~Group 1: Eligible patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
~Group 2: Eligible patients with pancreatic adenocarcinoma.
~Group 3: Eligible patients with mesothelioma."
16415341|NCT03872193|Experimental|Physio Therapy|We intervention this group some routine exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees.
16415342|NCT03872193|Experimental|Virtual Reality|This group had physical therapy program plus virtual reality exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees. And virtual reality exercises were done for this group. Skiing,kayak, football,rafting and jumping activities were done in this exerciese.
16415343|NCT03872180|Experimental|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
16415344|NCT03872167|Active Comparator|MANUAL|Manual titration of non-invasive mechanical ventilation using polysomnography and randomized
16415345|NCT03872167|Active Comparator|AUTOMATIC|Automatic titration of the non-invasive mechanical ventilation using the same device in an automatic mode with assured volume and pressure support.
16415346|NCT03872154|Experimental|Intervention|"In this group (intervention), physicians will conduct checklist-guided shared decision making to determine the patient's code status. Additionally, physicians will be given a decision aid, which they are told to use to illustrate impact and outcome of in-hospital cardiac arrests.
~Ancillary project (patients considered as futile): In this group (intervention), physicians will conduct checklist-guided communication."
16415347|NCT03872154|No Intervention|Usual Care|In this group (control), physicians will conduct code status discussions as usually.
16415348|NCT03872141||patients with stage I-III breast cancer|Patients with Stage I-III breast cancer who will receive paclitaxel or docetaxel treatments as part of their standard of care adjuvant or neoadjuvant therapy are eligible for this study.
16415349|NCT03872128|Active Comparator|patients receiving 300mg PREG|30 patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
16415350|NCT03872128|Active Comparator|patients receiving 500mg PREG|30 patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
16415351|NCT03872128|Placebo Comparator|placebo|30 patients randomly assigned to receive a placebo daily.
16415352|NCT03872115|Experimental|Setting 1|PDVibe2 set to high frequency and low amplitude
16415353|NCT03872115|Experimental|Setting 2|PDVibe2 set to high frequency and medium amplitude
16415354|NCT03872115|Experimental|Setting 3|PDVibe2 set to high frequency and high amplitude
16415355|NCT03872115|Experimental|Setting 4|PDVibe2 set to medium frequency and low amplitude
16415356|NCT03872115|Experimental|Setting 5|PDVibe2 set to medium frequency and medium amplitude
16415357|NCT03872115|Experimental|Setting 6|PDVibe2 set to medium frequency and high amplitude
16415358|NCT03872115|Experimental|Setting 7|PDVibe2 set to low frequency and low amplitude
16415359|NCT03872115|Experimental|Setting 8|PDVibe2 set to low frequency and medium amplitude
16415360|NCT03872115|Experimental|Setting 9|PDVibe2 set to low frequency and high amplitude
16415361|NCT03872102||Aim 1: Develop a biomarker of PD disease progression rate|"For Aim 1, we will enroll PD subjects spanning a range of progression rates that have been tracked at UT Southwestern Medical Center.
~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data and known data on clinical progression using statistical techniques to determine a biomarker that associates with progression rate."
16415362|NCT03872102||Aim 2: Develop a biomarker to distinguish between PD, PSP, MSA|"For Aim 2, we will recruit subjects with PD, MSA, and PSP. We will also recruit healthy age/sex-matched controls. All subjects will complete a series of clinical assessments at three different time points, roughly 6-8 months apart:
~Levodopa Equivalent Daily Dose
~Parkinson disease questionnaire
~Schwab and England ADL Scale
~MDS-UPDRS (PD and healthy controls only)
~UMSARS (MSA subjects only)
~PSPRS (PSP subjects only)
~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data from the participants along with prospectively collected information on clinical progression using statistical techniques to determine a biomarker that associates with the differentiation of PD, MSA, and PSP."
16415363|NCT03872089|Experimental|Study participants|Measurements of the temperature of the plantar arch by thermal imaging. Result analysis regarding podologic grade ( 0-1-2-3)
16415364|NCT03872076|Experimental|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
16415365|NCT03872076|Active Comparator|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
16415366|NCT03872063|Experimental|Myofascial|Each session will last 17 minutes, taking place for 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the technique of myofascial induction and eccentric exercises will be performed.
16415431|NCT03871582||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
16415367|NCT03872063|Active Comparator|Eccentric|Each session will have a duration of 9 minutes, taking place during 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the eccentric exercises will be performed.
16415368|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
16415369|NCT03872050||Migraine|Patients who have been diagnosed with migraine
16415370|NCT03872037|Active Comparator|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
16415371|NCT03872037|Experimental|Selective removal of caries and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
16415372|NCT03872024|Experimental|Morbidly obese adult patients|Only one group of patients in the study: morbidly obese adult patients who will have an examination with the XXL probe prototype of the FibroScan 630 Research Model
16415373|NCT03872011|Experimental|Vitamin C,thiamine,hydrocortisone|"The combination of vitamin C, thiamine, hydrocortisone :
~Vitamin C 2g every 6 hours x 5-days Thiamine 200mg every 12 hours x 5-days Hydrocortisone 200mg as a continuous infusion x 5-days"
16415374|NCT03872011|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
16415375|NCT03871998|Experimental|Interventional arm|Skin barrier protection in the first 2 months of life.
16415376|NCT03871998|No Intervention|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
16415377|NCT03871985|Experimental|Lavage combined with aspiration|Intermittent subglottic secretions lavage combined with aspiration
16415378|NCT03871985|Active Comparator|Pure aspiration|Intermittent subglottic secretions aspiration
16415379|NCT03871972|Experimental|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
16415380|NCT03871959|Experimental|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
16415381|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels > 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
16415382|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was <100 mg/dL and who agreed to participate in the study.
16415383|NCT03871933||AECOPD|acute exacerbation of COPD
16415384|NCT03871933||stable COPD|
16415385|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
16415386|NCT03871907|Active Comparator|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
16415387|NCT03871907|No Intervention|Control|standard cardiac rehabilitation program
16415388|NCT03871894|Active Comparator|Control arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy as per the standard enteral nutritional practice in a critical care setting in cirrhotics till the period admitted in ICU(Intensive care unit) 35-40 Kcal/Kg IBW/day; 1.5-2g protein per kg per day.
16415389|NCT03871894|Experimental|Intervention arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy based on indirect calorimetry measurements till the period admitted in ICU(Intensive care unit)
16415390|NCT03871881||Atrial septal defect|Patients with an open atrial septal defect, diagnosed in childhood
16415391|NCT03871881||Ventricular septal defect|Patients who had surgical closure of a ventricular septal defect in childhood
16415392|NCT03871881||Healthy control|Healthy, young adults matched on age, gender and education
16415393|NCT03871868||study group|In Woman With Myoma Uteri
16415394|NCT03871868||control group|In Woman Without Myoma Uteri
16415395|NCT03871855|Experimental|A:SHR-1702 Dose Escalation|SHR-1702 given intravenously (IV).
16415396|NCT03871855|Experimental|B:SHR-1702 Dose Expansion|SHR-1702 given intravenously (IV).
16415397|NCT03871855|Experimental|C:SHR-1702 and Camrelizumab Dose Escalation|SHR-1702 and Camrelizumab given intravenously (IV).
16415398|NCT03871855|Experimental|D:SHR-1702 and Camrelizumab Dose Expansion|SHR-1702 and Camrelizumab given intravenously (IV).
16415399|NCT03871842|Active Comparator|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
16415400|NCT03871842|Sham Comparator|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
16415401|NCT03871829|Active Comparator|Arm A: Carfilzomib+Dexamethasone (Kd)|Participants will receive carfilzomib 20 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1 and then 70 mg/m^2 on Days 8 and 15 of Cycle 1 and thereafter on Days 1, 8, 15 of Cycle 2 onwards. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
16415402|NCT03871829|Experimental|Arm B: Dara-SC in combination with Kd (DKd)|Participants will receive daratumumab subcutaneous (Dara-SC) 1800 mg by SC injection on Days 1, 8, 15, 22 for Cycle 1 and 2, Days 1 and 15 for Cycle 3-6, Day 1 for Cycle 7 onwards. Participants will receive carfilzomib 20 mg/m^2 IV on Cycle 1 Day 1 and then 70 mg/m^2 on Day 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
16415432|NCT03871569|Active Comparator|telemedecine nursing home|One buccodental teleexpertise at the completion day and a second buccodental teleexpertise at the end of study
16415433|NCT03871569|No Intervention|control nursing home|Only one buccodental teleexpertise at the end of study
16415403|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
16415404|NCT03871803|Active Comparator|Arm A|"Controlled Withdrawal of Beta-blockers and Cardiopulmonary Exercise Testing (CPET) Patient will be assessed for chronotr0pic incompetence by CPET. If the patient exhibits chronotropic incompetence, we will reduce half dose of previous beta-blocker.
~A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day.
~After second CPET, the patient will introduce the half-dose of beta-blocker and will be evaluated in 3 days. If clinical stability, the patient will introduce the previous dose of beta-blocker A third CPET will be performed at 15-day"
16415405|NCT03871803|Active Comparator|Arm B|"Cardiopulmonary Exercise Testing (CPET) and Controlled Withdrawal of Beta-blockers Patient will be assessed for chronotropic incompetence by CPET.If the patient exhibits chronotropic incompetence, a cardiologist will evaluate clinically the patient and the heart rate in 3 days and will be assessed by CPET at 15-day.
~After second CPET, the patient will reduce half dose of previous beta-blocker. A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day."
16415406|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
16415407|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
16415408|NCT03871777|Active Comparator|Vegetarians|Healthy vegetarians (vegans and lacto-ovo vegetarians) 18 and 50 years formed this arm.
16415409|NCT03871777|Sham Comparator|Omnivores|Healthy omnivores with similar characteristics of vegetarians (age, body mass index, gender and physical activity levels) formed this arm
16415410|NCT03871751|Experimental|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
16415411|NCT03871738|Experimental|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
16415412|NCT03871738|No Intervention|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
16415413|NCT03871725|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
16415414|NCT03871712|Experimental|Motivational Interview (MI)|In the MI arm, a NAV case worker will meet the participants after the baseline assessment (electronic questionnaires) and randomisation and conduct the MI. The NAV case-worker will either meet (or call) again after a few weeks (anticipated 2-4 weeks) and conduct another MI.
16415415|NCT03871712|Active Comparator|Stratified vocational advice intervention (SVAI)|A trained physiotherapist will call the participants after the baseline assessment and randomisation. The SVAI intervention will be stratified due to the participants risk of long term sick leave estimated by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. The low/moderate risk group will receive 1-2 phone calls, and the high risk group will be followed up 2-4 times. The follow-up can include face to face Meetings bewteen the Physical therapist and the participant, and also the employer and general practitioner when needed. The intervention will include an assessment of the participants obstacles for returning to work and help to develop and implement an action plan to overcome obstacles. The physical therapists' will cooperate with other health care providers and employer when needed.
16415416|NCT03871712|No Intervention|Usual follow-up|This arm will be the control group receiving usual NAV follow-up. The other two groups will also receive usual NAV follow-up additionally to the interventions.
16415417|NCT03871699|Experimental|Iron Reposition|The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.
16415418|NCT03871686|Experimental|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
16415419|NCT03871686|No Intervention|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
16415420|NCT03871673|Active Comparator|Cornstarch|Ingestion of cornstarch, the standard treatment for hepatic GSD.
16415421|NCT03871673|Experimental|Sweet Polvilho|Ingestion of sweet polvilho, the starch in study.
16415422|NCT03871660|Other|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
16415423|NCT03871660|Other|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
16415424|NCT03871647||POAF group|Patients who will experience AF at any time during the first six days after the operation.
16415425|NCT03871647||Non POAF group|Patients with a sinus rhythm during the first six days after the operation.
16415426|NCT03871621|Experimental|Previous diabetic medical treatment & Dapagliflozin|Previous diabetic medication add on SGLT2 inhibitor (Dapagliflozin 10 mg) daily for 6 months
16415427|NCT03871621|Active Comparator|Previous diabetic medical treatment & standard care|Previous diabetic medication with drug adjustment by standard diabetes care except SGLT2 inhibitors for 6 months
16415428|NCT03871608||DTM Disorders|Patient with DTM Disorders with Examination of functional etiologies on DTM Disorders and Assessment of symptoms on DTM Disorders
16415429|NCT03871595|Experimental|Test Treatment|Non-fasting state
16415430|NCT03871595|Experimental|Reference Treatment|Fasting state
16415434|NCT03871556|Experimental|Experimental Group|
16464873|NCT03532880|Experimental|Participants with Small Cell Lung Cancer|
16415435|NCT03871543|Other|Part 1|All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1
16415436|NCT03871543|Other|Part 2|All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.
16415437|NCT03871530|Experimental|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
16415438|NCT03871530|Experimental|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
16415439|NCT03871530|Experimental|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
16415440|NCT03871530|Experimental|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
16415441|NCT03871530|Experimental|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
16415442|NCT03871530|Experimental|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
16415443|NCT03871530|Experimental|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
16415444|NCT03871530|Experimental|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
16415445|NCT03871530|Experimental|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
16415446|NCT03871530|Experimental|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
16415447|NCT03871530|Experimental|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
16415448|NCT03871530|Experimental|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
16415449|NCT03871530|Experimental|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
16415450|NCT03871530|Experimental|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
16415451|NCT03871517|Experimental|Indobufen|Drug: Indobufen and aspirin mimetic Day 1: The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg
16415452|NCT03871517|Active Comparator|Aspirin|Drug: Aspirin and Indobufen mimetic Day 1:The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.
16415453|NCT03871504|Experimental|submaximal isometric exercise.|submaximal isometric exercise will be performed.
16415454|NCT03871504|No Intervention|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
16415455|NCT03871491|Experimental|Intervention|The study intervention is a single 2 g dose of directly observed oral azithromycin.
16415456|NCT03871491|Placebo Comparator|Placebo|By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.
16415457|NCT03871478|Active Comparator|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
16415458|NCT03871478|Active Comparator|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
16415459|NCT03871478|Active Comparator|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.
~Injected at the start of every Mohs excision stage"
16415460|NCT03871465|Experimental|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
16415461|NCT03871465|Experimental|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
16415462|NCT03871465|Experimental|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
16415463|NCT03871452|Active Comparator|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
16415464|NCT03871452|Active Comparator|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
16415465|NCT03871439|Experimental|PF-05221304 Formulation A|
16415466|NCT03871439|Experimental|PF-05221304 Formulation B|
16415467|NCT03871413|Active Comparator|Manual repositioning maneuver|Diagnostics and treatment of BPPV with manual repositioning maneuvers. In case of posterior canal involvement, Epley's maneuver will be used. In case of horizontal canal involvement, the log roll maneuver will be used.
16415468|NCT03871413|Experimental|Treatment in mechanical rotational chair (TRV-chair)|"Diagnostics and treatment of BPPV with the use of a TRV chair. In case of posterior canal involvement, Epley's maneuver will be used with the addition of 10 kinetic impulses in each position.
~In case of horizontal canal involvement, the log roll maneuver will be used with the addition of 10 kinetic impulses in each position."
16415469|NCT03871400|Other|NanoMetalene/PEEK|
16415470|NCT03871400|Other|NanoMetalene/Allograft|
16415471|NCT03871387|Experimental|Deep Block Group|"Continuous Rocuronium infusion during surgery
~Maintain TOF = 0 & PTC= 1~2
~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
16415472|NCT03871387|Active Comparator|Moderate Block Group|"Continuous Rocuronium infusion during surgery
~Maintain TOF 1~2
~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
16415505|NCT03871088|Active Comparator|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
16415506|NCT03871088|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
16415507|NCT03871088|Active Comparator|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
16415473|NCT03871361|Experimental|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.
~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.
~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
16415474|NCT03871348|Experimental|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
16415475|NCT03871348|Experimental|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
16415476|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
16415477|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
16415478|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
16415479|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
16415480|NCT03871322|Active Comparator|Vitamin D group|vitamin D supplementation - time to fracture healing
16415481|NCT03871322|Active Comparator|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
16415482|NCT03871322|Placebo Comparator|Placebo group|Placebo - time to fracture healing
16415483|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
16415484|NCT03871270||Participants|Those with severe chronic illnesses, which included but were not limited to various forms of advanced cancer, blood dyscrasias, graft vs. host disease, and rare genetic conditions.
16415487|NCT03871244|Experimental|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
16415488|NCT03871244|Active Comparator|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
16415489|NCT03871231|Experimental|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
16415490|NCT03871218|Active Comparator|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
16415491|NCT03871218|No Intervention|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
16415492|NCT03871205|Experimental|Vaccinated group|Neoantigen loaded-DC vaccination will be performed with 6 doses in total, once per week, adjacent lymph-node injection.
16415493|NCT03871192|Experimental|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
16415494|NCT03871192|Active Comparator|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
16415495|NCT03871192|Experimental|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
16415496|NCT03871192|Active Comparator|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
16415497|NCT03871192|Experimental|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
16415498|NCT03871192|Active Comparator|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
16415499|NCT03871153|Other|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
16415500|NCT03871127||Left main coronary disease|
16415501|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
16415502|NCT03871114||Control group|
16415503|NCT03871101|Active Comparator|Scalpel|Soft tissue incision with scalpel in second- stage implant surgery.
16415504|NCT03871101|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz H mode, 10% water and 10% air) in second-stage implant surgery.
16415620|NCT03870295|Active Comparator|Control patients|Type C fibre conduction velocity determination in control patients
16415508|NCT03871075|Experimental|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
16415509|NCT03871075|Experimental|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
16415510|NCT03871075|Active Comparator|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
16415511|NCT03871075|Active Comparator|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
16415512|NCT03871062|Active Comparator|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
16415513|NCT03871062|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
16415514|NCT03871049|Placebo Comparator|group 1|intathecal bupivacaine
16415515|NCT03871049|Active Comparator|group 2|intrathecal bupivacaine with dexamethasone
16415516|NCT03871036|Experimental|Tremelimumab 75 (R1)|"Run-in phase-1 (R1): n=3 patients will be treated with:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 75 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
16415517|NCT03871036|Experimental|Tremelimumab 225 (R2)|"Run-in phase-2 (R2): n=3 patients will be treated with:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 225 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
16415518|NCT03871036|Experimental|Tremelimumab vs Tremelimumab+Durvalumab (R3)|"Run-in phase-3 (R3): n=2 x 3 patients will be randomized over 2 arms:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45
~OR
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 75 mg on day 1 of cycles 2-5
~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
16415519|NCT03871036|Experimental|Tremelimumab 300 (R4)|"Run-in phase-4 (R4): n=3 patients will be treated with:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 300 mg once on day 1 of cycle 2
~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
16415520|NCT03871036|Experimental|Tremelimumab 750 (A)|"Arm A:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
16415521|NCT03871036|Experimental|Tremelimumab+Durvalumab (B)|"Arm B:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 300 mg once on day 1 of cycle 2
~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
16415522|NCT03871036|Experimental|Tremelimumab without paclitaxel (C)|"Arm C (control arm):
~• tremelimumab 750 mg on day 1 of cycles 1-5 and then every 12 weeks until week 41"
16415523|NCT03871023|Active Comparator|Simple dressing|Standard, waterproof dressing applied to wound
16415524|NCT03871023|Active Comparator|PICO Dressing|Negative Wound pressure applied second cohort
16415525|NCT03871023|Active Comparator|PREVENA Dressing|Negative wound presure applied to third cohort
16415526|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
16415527|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
16415528|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
16415529|NCT03870997|Experimental|Diabetes Digital Intervention|
16415530|NCT03870997|Experimental|Generic Digital Intervention|
16415531|NCT03870997|No Intervention|No Influenza Vaccination Intervention|
16415532|NCT03870984|Experimental|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
16415533|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
16415534|NCT03870958|Experimental|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
16415535|NCT03870958|Active Comparator|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
16415536|NCT03870945|Experimental|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
16415537|NCT03870945|Experimental|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
16415538|NCT03870932|Experimental|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
16415539|NCT03870932|Active Comparator|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
16415540|NCT03870919|Other|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks. After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
16415541|NCT03870906|Experimental|WhatsApp interaction|Individual and group chat interactions.
16415542|NCT03870906|Placebo Comparator|Text message|Regular text messages with similar frequency to those in the Intervention group.
16415543|NCT03870893|Experimental|Intervention group|Intervention is administered to patients in this Arm.
16415544|NCT03870893|No Intervention|control group|No intervention
16415545|NCT03870880|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during the open label extension.
16415546|NCT03870880|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during the open label extension.
16415547|NCT03870867||Seniors who have fallen|Emergency department patients over the age of 65 who present to the emergency department after a fall.
16415548|NCT03870854|Experimental|PEFA targeted substrate ablation|Use of PEFA strategy to identify and target VT isthmuses.
16415549|NCT03870841|Experimental|PC945|PC945 5mg once daily
16415550|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.
~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
16415551|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
16415552|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
16415553|NCT03870815||CABG|Patients with CAD who undergoing CABG
16415554|NCT03870815||PCI|Patients with CAD who undergoing PCI with second-generation DES
16415555|NCT03870789||Retrospective|The Investigators will examine data from 1-year prior to paramedic implementation of the Hamilton Early Warning Score tool.
16415556|NCT03870789||Prospective|The Investigators will examine data from 1-year after paramedic implementation of the Hamilton Early Warning Score tool.
16415557|NCT03870776|Placebo Comparator|Placebo|Patients will receive the placebo during 42 days.
16415558|NCT03870776|Experimental|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
16415559|NCT03870776|Experimental|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
16415560|NCT03870763|Experimental|Dimethyl Fumarate 240 mg|Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
16415561|NCT03870763|Experimental|Peginterferon Beta-1a 125 µg|Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
16415562|NCT03870763|Placebo Comparator|Placebo|Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
16415563|NCT03870750|Experimental|Arm I (SPC)|Patients undergo SPC on days -15 before to +56 after transplant. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
16415564|NCT03870750|Experimental|Arm II (CMC)|Patients undergo a CMC program on days -15 to 56. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT..
16415565|NCT03870750|Experimental|Arm III (SPC and CMC)|Patients undergo interventions as outlined in Arm I and Arm II. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
16415566|NCT03870750|Active Comparator|Arm IV (standard of care)|Patients receive standard of care. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
16415621|NCT03870282|Experimental|9h 15m Goal|
16415567|NCT03870737|Experimental|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
16415568|NCT03870711|Experimental|group A|10% lidocaine spray
16415569|NCT03870711|Placebo Comparator|group B|sterile water
16415570|NCT03870698|Experimental|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
16415571|NCT03870698|No Intervention|Open group|The patients who underwent open procedures for periampullary tumors
16415572|NCT03870685|Active Comparator|TAP block with Exparel|Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.
16415573|NCT03870685|Active Comparator|Surgical Site Infiltration of Exparel|Patients will receive surgical site infiltration of Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by surgeon.
16415574|NCT03870672|Active Comparator|CCFES + rTMS facilitating cHMC|"This rTMS paradigm is the New Approach. Facilitation of the intact hemisphere target (cHMC) will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
16415575|NCT03870672|Active Comparator|CCFES + rTMS facilitating iM1|"This rTMS paradigm is the Conventional Approach.Facilitation of M1 will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
16415576|NCT03870672|Sham Comparator|CCFES + Sham rTMS|"This rTMS paradigm is the Sham Approach. Immediately after sham rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
16415577|NCT03870646|Experimental|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
16415578|NCT03870646|Placebo Comparator|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
16415579|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
16415580|NCT03870607|Experimental|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
16415581|NCT03870607|No Intervention|Control group|This group will lead nutritionally based just before starting Ch-RT.
16415582|NCT03870594||diabetic|patients suffer from diabetes mellitus
16415583|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
16415584|NCT03870581|Experimental|AI-SMART group|Participants' warfarin therapy were guided by an AI-based miniprogram embedded in the Wechat social software.
16415585|NCT03870581|Active Comparator|Human-SMART group|Participants' warfarin therapy were guided by an human-based miniprogram embedded in the Wechat social software.
16415586|NCT03870555|Experimental|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.
~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.
~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.
~A washout period of at least 16 days will be maintained between each Treatment Period."
16415587|NCT03870555|Experimental|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.
~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.
~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.
~A washout period of at least 16 days will be maintained between each Treatment Period."
16415588|NCT03870555|Experimental|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.
~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.
~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
16415589|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
16415590|NCT03870529|Experimental|Vitamin A compound|Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.
16415591|NCT03870529|Active Comparator|Therapeutic Conventional Surgery|Description Participants undergo surgical resection.
16415592|NCT03870516|Placebo Comparator|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
16415622|NCT03870282|Experimental|"9h 15m Goal | Texts B"|
16415623|NCT03870282|Experimental|"9h 15m Goal | Texts A"|
16415593|NCT03870516|Active Comparator|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
16415594|NCT03870503|Active Comparator|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
16415595|NCT03870503|Active Comparator|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol
16415596|NCT03870503|Active Comparator|Carbetocin|The patient will be received Carbetocin 100 mic gm IV
16415597|NCT03870490|Experimental|Healthy Subjects|VNRX-5133 + cefepime
16415598|NCT03870477|Other|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
16415599|NCT03870464||Prospective arm|Quality of Life questionnaires EORTC-QoL30 and Euro EQ-5D-5L questionnaires are distributed. Blood samples are collected consecutively during ICI and at a follow-up period of one year. CT-scans extended of thorax, abdomen and the lower extremities are performed at baseline and at 6 months. MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.Prospective registration of irAEs are registered during ICI and for one year of follow-up.Enrolment period 1th of April 2018- 31th of January 2020.
16415600|NCT03870451|Experimental|Cohort 1 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
16415601|NCT03870451|Experimental|Cohort 2 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
16415602|NCT03870438|Experimental|Intervention|"Children infected with HIV-1 will be referred to the National Programme for confirmed HIV diagnosis and immediate ART.
~For children that are not HIV-1 infected, the results on the mother's viral load will guide the next steps:
~Mothers with a detectable plasma viral load (≥ 1000 copies/mL): their children will be initiated on lamivudine oral solution.
~Mothers with an undetectable viral loads (<1000 copies/mL): their children will not be initiated on lamivudine oral solution at 6-8 weeks of age. However, additional monitoring on the viral load of the mother and the diagnosis of the child will take place at 6 months: If the maternal plasmatic viral load is ≥ 1000 copies/mL, the child will be initiated on lamivudine oral solution."
16415603|NCT03870438|No Intervention|Control|Routine Option B+ national guidelines including HIV-1 plasmatic viral load testing will be adhered to. Visits will take place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred to the National Programme for confirmed diagnosis and immediate ART.
16415604|NCT03870425|Placebo Comparator|MINCED-SKEWED|Minced meat administered with a skewed protein distribution pattern
16415605|NCT03870425|Experimental|MINCED-EVEN|Minced meat administered with an even protein distribution pattern
16415606|NCT03870412|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle.
16415607|NCT03870399|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
16415608|NCT03870386|Experimental|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts < 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts > 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
16415609|NCT03870386|Active Comparator|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
16415610|NCT03870373||Test Subject|neonatal patients undergoing complex cardiac surgical procedures
16415611|NCT03870360|Experimental|HOLA: A Culturally-Tailored Health Promotion Intervention|16 week, multicomponent, health promotion intervention
16415612|NCT03870360|Active Comparator|Healthy lifestyles education program|Educational material on mental health, physical activity, and information on community resources
16415613|NCT03870347||Biliary Dilation Cohort|Patients referred for endoscopic evaluation of biliary dilation
16415616|NCT03870321|Experimental|Core training|The subjects who are in the experimental group will carry out the Core training routine
16415617|NCT03870321|No Intervention|Control|The subjects who are in the control group will not receive intervention and will continue with their daily routine and training
16415618|NCT03870308|Experimental|Deep Brain Stimulation subjects|
16415619|NCT03870295|Experimental|Patients suffering from polyneuropathies|Type C fibre conduction velocity determination in patients suffering from polyneuropathy
16415653|NCT03870269|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
16415654|NCT03870269|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
16415655|NCT03870256|Active Comparator|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
16415656|NCT03870256|Active Comparator|Carbetocin|Patient receives 100 mic gm carbetocin IV
16415659|NCT03870230|Experimental|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
16415660|NCT03870230|Experimental|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
16415661|NCT03870230|Experimental|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
16415662|NCT03870230|Experimental|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
16415663|NCT03870230|Experimental|OHT|patients with ocular hypertension
16415664|NCT03870230|Experimental|controls|healthy, age and sex matched, control subjects
16415665|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
16415666|NCT03870191|Active Comparator|Twin Block Group|This group will receive twin block injections.
16415667|NCT03870191|Active Comparator|Trigger Point Injection Group|This group will receive trigger point injections.
16415668|NCT03870178|Active Comparator|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
16415669|NCT03870178|Sham Comparator|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
16415670|NCT03870165|Active Comparator|Salmon|After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
16415671|NCT03870165|Experimental|Isolated mixture|After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
16415672|NCT03870152|Experimental|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: an AFB surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further AFB surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
16415673|NCT03870152|No Intervention|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB surveillance at 6, 12, 24, and at 36 months post-randomisation; with further AFB surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
16415674|NCT03870139|Active Comparator|Cerebral stimulation|"Active transcranial direct current stimulation
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the dominant lower limb) and supraorbital cathode (ipsilateral to the dominant lower limb)."
16415675|NCT03870139|Experimental|Combined stimulation 1|"Active peripheral electrical stimulation (PES_sensorial) combined with active transcranial direct current stimulation
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
16415676|NCT03870139|Active Comparator|Peripheral stimulation|"Active peripheral electrical stimulation (PES_motor).
~PES: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
16415677|NCT03870139|Experimental|Combined stimulation 2|"Active sensorial peripheral electrical stimulation (PES_sensorial) combined with active motor peripheral electrical stimulation (PES_motor)
~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level
~PES_motor: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
16415678|NCT03870126|Placebo Comparator|Flavored Beverage Mix 1|Flavored still beverage
16415679|NCT03870126|Experimental|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
16415680|NCT03870126|Experimental|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
16415681|NCT03870126|Experimental|Flavored Beverage Mix 4|Flavored still beverage with caffeine
16415682|NCT03870113|Experimental|Vaccinated group|Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
16415683|NCT03870100|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
16415684|NCT03870100|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
16415685|NCT03870100|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
16415686|NCT03870100|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
16415687|NCT03870100|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
16415688|NCT03870087||Robotic PCI|All subjects treated with CorPath GRX during the PCI procedure.
16415689|NCT03870074||Responders|Patients with improvement of at least one NYHA class after one year from CRT.
16415690|NCT03870074||Non-responders|Patients with no improvement of at least one NYHA class after one year from CRT.
16415691|NCT03870061|No Intervention|Control|
16415692|NCT03870061|Experimental|Treatment|This arm receives the full New Incentives' conditional cash transfer program (All Babies Are Equal Initiative).
16415693|NCT03870048|Active Comparator|tDCS effects on pain and fatigue|tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
16415694|NCT03870048|Placebo Comparator|Sham effects on pain and fatigue|Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
16465007|NCT03531970|Experimental|Dexamethasone|lidocaine & Dexamethasone
16415695|NCT03870022|Other|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
16415696|NCT03870009|Experimental|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
16415697|NCT03869996|Active Comparator|fast track total knee arthroplasties|patients treated using fast track care protocol
16415698|NCT03869996|Active Comparator|standard care total knee arthroplasties|patients treated using standard care protocol
16415699|NCT03869983|Active Comparator|Active Comparator|Omnipaque™ (iohexol) Injection, 755 mg/mL iohexol (350 mgI/mL)
16415700|NCT03869983|Experimental|Experimental|CE-Iohexol Injection, 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL
16415701|NCT03869970|Active Comparator|Rest|Discharge instructions focused on 24 - 48 hours of rest then symptom guided activity, Fitbit monitored.
16415702|NCT03869970|Active Comparator|mHealth|"Use of the resilience application on a smart phone to assess daily symptoms over 14 days and follow a self directed, symptom guided return to physical activity. Also Fitbit monitored."
16415703|NCT03869970|Active Comparator|Activity|Low intensity activity regardless of symptoms using their Fitbit to measure said activity with goals (eg. 10,000 steps/ day.
16415704|NCT03869970|Active Comparator|Both Activity and mHealth|"This group will receive both interventions and utilize the SuperBetter app. Interventions will be integrated by having research assistants support the subject to set and physical activity goals and milestones to the subject's pre-programmed general resilience goals in the SuperBetter© app (e.g. take a 30 min walk, march in place for 5 minutes, increase my step count by 2000 today, achieve 10,000 steps today)."
16415705|NCT03869957|Experimental|Intervention group|We will use ~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day [Omegaven® ](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
16415706|NCT03869957|No Intervention|Control group|Will be administering ~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
16415707|NCT03869944|Experimental|Intervention|Lamivudine Oral Solution
16415708|NCT03869931|Experimental|Fenofibrate|(Refer to intervention)
16415709|NCT03869918|No Intervention|Usual Care|Participant is assigned to undergo standard of care.
16415710|NCT03869918|Experimental|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
16415711|NCT03869918|No Intervention|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
16415712|NCT03869905|Experimental|Aquamin®|To be taken for 180 days
16415713|NCT03869905|Placebo Comparator|Placebo first then Aquamin®|Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)
16415714|NCT03869892|Experimental|S95005 + Bevacizumab|
16415715|NCT03869892|Active Comparator|Capecitabine + Bevacizumab|
16415716|NCT03869879|Active Comparator|Feedback-assisted physical therapy|During a visual feedback session, therapists will spend 30min per session using the Mobility Rehab system for gait training with patients. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
16415717|NCT03869879|Placebo Comparator|Traditional physical therapy|During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
16415718|NCT03869866|Experimental|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
16415719|NCT03869853|Experimental|intervention|Entrepreneurial stimulation and integrated education
16415720|NCT03869853|Experimental|control|no intervention
16415721|NCT03869827||IUGR|All birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea with isolated intrauterine growth restriction at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2016.
16415722|NCT03869827||Control|To each of these children with intrauterine growth restriction is matched a control child: the child without intrauterine growth restriction of the same gestational age whose date of birth is consecutive to that of the case.
16415723|NCT03869814||Non-cancer|900 asymptomatic individuals without prior history of cancer
16415724|NCT03869814||Cancer|900 individuals with confirmed malignancy
16415725|NCT03869801|Active Comparator|ESP Block|
16415726|NCT03869801|Active Comparator|QLB block|
16415727|NCT03869775||control group|no additional disease
16415728|NCT03869775||working group-1|additional disease only DM and no cardıovascular autonomous neuropathıa
16415729|NCT03869775||working group-2|additional disease only DM and pozitif cardıovascular autonomous neuropathıa
16415730|NCT03869762|Experimental|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.
~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
16415731|NCT03869749|Experimental|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
16415732|NCT03869749|Active Comparator|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
16415733|NCT03869736|Experimental|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
16415734|NCT03869736|Sham Comparator|Placebo|Oxygen-air mixture
16415735|NCT03869723||Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
16415736|NCT03869723||Virtual planning|Fibula free flap in mandibular reconstruction using preoperative virtual planning, cutting guides and osteosynthesis plates. Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
16415737|NCT03869710|Experimental|Dry-Needling|Ultrasound-Guided Dry-Needling Therapy focused on the active and latent myofascial trigger points.
16415738|NCT03869697|Experimental|SCB-313|Cohorts in SAD phase: 5 mg, 10mg, 20mg, 40mg, 80 mg. Cohort in MAD phase: biological effective dose determined from SAD phase. 1 intrapleural injection of SCB-313 on Day 1 for the SAD cohorts, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
16415739|NCT03869684|Experimental|MT-0814 High dose|
16415740|NCT03869684|Experimental|MT-0814 Low dose|MT-0814 plus placebo
16415741|NCT03869684|Placebo Comparator|Placebo|
16415742|NCT03869671|Experimental|PrEP uptake/adherence intervention|A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
16415743|NCT03869671|Active Comparator|Harm reduction standard of care|Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
16415744|NCT03869632|Experimental|YL-13027|YL-13027 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
16415745|NCT03869619||All enrolled patients|All patient who signed the consent form for participation to the study
16415746|NCT03869593||Patients presenting E. coli and S. aureus bacteremia|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
16415747|NCT03869580||Stent infection|Patients diagnosed with urinary tract infection associated with double J stent
16415748|NCT03869580||No stent infection|Patients with double J stent without infection during the study period
16415749|NCT03869567|Experimental|Cone beam CT|A cone beam CT wll be performed just after thrombectomy on patients with acute ischemic stroke
16415750|NCT03869554|Experimental|Renal disease|detection of Fabry disease
16415751|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
16415752|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
16415753|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
16415754|NCT03869528|Active Comparator|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
16415755|NCT03869528|Experimental|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
16415758|NCT03869489|Experimental|Anodal left dorsolateral prefrontal cortex tDCS stimulation|
16415759|NCT03869489|Experimental|Anodal right dorsolateral prefrontal cortex tDCS stimulation|
16415760|NCT03869489|Sham Comparator|Sham tDCS stimulation|
16415761|NCT03869476|Experimental|BioscoreSMP cohort|
16415762|NCT03869463|Experimental|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function & processing speed.
16415763|NCT03869463|Active Comparator|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
16415764|NCT03869463|Placebo Comparator|Waitlist Control|This group will not receive cognitive training during study participation.
16415765|NCT03869450|Experimental|Restylane Volyme|According to the treatment algorithm, treated with Restylane Volyme
16415766|NCT03869450|Experimental|Restylane Defyne|According to the treatment algorithm, treated with Restylane Defyne
16415767|NCT03869450|Experimental|Restylane Lyft Lidocaine|According to the treatment algorithm, treated with Restylane Lyft Lidocaine
16415768|NCT03869437|Experimental|Cefiderocol|Participants will receive Cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for up to 14 days
16415769|NCT03869437|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and intravenously administered per country-specific guidelines
16415770|NCT03869424|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
16415771|NCT03869424|No Intervention|No-treatment control group|Participants do not receive the nasal spray.
16415915|NCT03868618|Experimental|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
16415916|NCT03868605|Experimental|EMR/ESD|Standard EMR or ESD technique
16415772|NCT03869411|Experimental|aerobic exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
16415773|NCT03869411|Experimental|home exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness.The home exercise group will give the exercise recommendation based on ACSM's guideline, and it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
16415774|NCT03869411|Active Comparator|health control group|This study will recruit subjects without type 2 diabetes and the age matched to the diabetes groups.
16415775|NCT03869398|No Intervention|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
16415776|NCT03869398|Experimental|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
16415777|NCT03869385|Experimental|Albumin group|Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
16415778|NCT03869385|No Intervention|Control group without albumin:|The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.
16415779|NCT03869372|Experimental|Healthy subjects|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.
~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
16415780|NCT03869372|Experimental|Subjects with IBS|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.
~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
16415781|NCT03869372|Experimental|Subjects with FD|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.
~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
16415782|NCT03869359|Experimental|Group A|Gluten-free diet with placebo powder vs Gluten-free diet with gluten powder
16415783|NCT03869359|Experimental|Group B|Gluten-free diet with gluten powder vs Gluten-free diet with placebo powder
16415784|NCT03869346||GG|wild-type homozygote (CYP3A4*1/*1, GG)
16415785|NCT03869346||GA|mutant heterozygote (CYP3A4*1/*1G, GA),
16415786|NCT03869346||AA|mutant homozygote (CYP3A4*1G/*1G, AA)
16415787|NCT03869333|Experimental|Invaplex[AR-Detox] 2.5 μg|Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
16415788|NCT03869333|Experimental|Invaplex[AR-Detox] 10 μg|Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
16415789|NCT03869333|Experimental|Invaplex[AR-Detox] 25 μg|Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
16415790|NCT03869333|Placebo Comparator|Placebo|Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.
16415791|NCT03869320|Experimental|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
16415792|NCT03869320|Placebo Comparator|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
16415793|NCT03869320|Experimental|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
16415794|NCT03869320|Placebo Comparator|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
16415795|NCT03869307|Experimental|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
16415796|NCT03869307|Active Comparator|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
16415797|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
16415798|NCT03869281||PTA|patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
16415799|NCT03869281||Controls|outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
16415917|NCT03868605|Experimental|Over- the- scope full- thickness resection device|Endoscopic full thickness resection
16415800|NCT03869268|Active Comparator|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).
~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
16415801|NCT03869268|Active Comparator|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).
~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
16415802|NCT03869268|Active Comparator|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).
~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
16415803|NCT03869268|Active Comparator|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).
~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
16415804|NCT03869268|Active Comparator|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).
~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
16415805|NCT03869268|Active Comparator|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.
~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
16415806|NCT03869268|Active Comparator|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).
~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
16415807|NCT03869268|Active Comparator|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.
~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
16415808|NCT03869255||Hospitalized patients|Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
16415809|NCT03869255||Community patients|"People coming to donate blood in Etablissement Français du Sang will be included and a nasal swab will be performed"
16415810|NCT03869242|Experimental|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
16415811|NCT03869242|Active Comparator|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
16415812|NCT03869229|Active Comparator|osteoarthritis of the knee|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
16415813|NCT03869229|Active Comparator|osteoarthritis of the hip|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
16415814|NCT03869229|Active Comparator|osteoarthritis of the glenohumeral joint|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
16415817|NCT03869203|Experimental|Enhanced recovery after surgery (ERAS) patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the ERAS perioperative care.
16415818|NCT03869203|No Intervention|Control patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the traditional perioperative care.
16415918|NCT03868592|Experimental|Gastric sleeve surgery|before and after weight loss from bariatric surgery
16415836|NCT03869177|Other|Intervention arm|Clusters (psychiatric outpatient clinics) in the intervention arm receives a comprehensive implementation support program during the trial period.
16415837|NCT03869177|No Intervention|Control arm|Clusters (psychiatric outpatient clinics) in the control arm receives no implementation support during the trial period.
16415838|NCT03869164|Experimental|ValmpClamp Arm|
16415839|NCT03869138|Experimental|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
16415840|NCT03869125||Obstructive sleep apnoea group|Blood pressure measurement
16415841|NCT03869112|Experimental|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
16415842|NCT03869112|Experimental|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
16415843|NCT03869112|No Intervention|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
16415844|NCT03869099||Sindh|
16415845|NCT03869099||KPK|
16415846|NCT03869099||Punjab|
16415847|NCT03869099||Balochistan|
16415848|NCT03869086|Experimental|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
16415849|NCT03869086|Experimental|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
16415850|NCT03869073|Experimental|Low Dose|This treatment arm will receive the highest dose of evolocumab currently marketed and approved: 420mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
16415919|NCT03868579|Experimental|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
16415920|NCT03868566|Experimental|SNP-612 dose1|dose1 once a day orally for 12 weeks
16415851|NCT03869073|Experimental|High Dose|This treatment arm will receive double the highest dose of evolocumab currently marketed and approved: 840mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
16415852|NCT03869073|Placebo Comparator|Placebo|This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
16415853|NCT03869060|Experimental|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose [0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL)] inoculated subcutaneously.
16415854|NCT03869047|Active Comparator|quadratus lumborum block(dexmedetomidine+bupivacaine)|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine ,total volume 20 ml.
16415855|NCT03869047|Active Comparator|quadratus lumborum block(bupivacaine)|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20%.
16415856|NCT03869034|Experimental|Combined group (TAI+PD-1)|Patients receive PD-1 inhibitor of Sintilimab on the first day of TAI+PD1 treatment. On the day 2-3 during the same hospitalization, the FOLFOX chemotherapy regimen of TAI is perform for 48 hours. The TAI+PD1 treatment will repeat every 3 weeks until patients receive surgical resection or detect disease progression.
16415857|NCT03869034|Active Comparator|Control group (TAI only)|Patients only receive TAI treatment without PD-1. The FOLFOX chemotherapy regimen of TAI is same as the experimental group and repeat every 3 weeks until patients receive surgical resection or detect disease progression.
16415858|NCT03869021|Active Comparator|Computer guided surgery|A surgical guide is 3d printed to guide through the surgery, the patients of this group will have the distraction surgery by a guide designed by Mimics 19.0, Materialise NV,Belgium
16415859|NCT03869021|Other|No surgical guide (free hand surgery)|control group added to investigate the effect of surgical guide
16415860|NCT03869008|Sham Comparator|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.
~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
16415861|NCT03869008|Experimental|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
16415862|NCT03868995|Sham Comparator|Sham injection|Dextrose water injection to subcutaneous layer at tender point
16415863|NCT03868995|Experimental|Tendon injection|Dextrose water injection to injured tendon
16415864|NCT03868982|Experimental|NAVA group|Participent in this group will received NAVA for two days
16415865|NCT03868982|No Intervention|Control group|Participent in this group will received standard care
16415866|NCT03868969|Experimental|Fosfomycin|Fosomycin tromethamine, one sachet for 21 days
16415867|NCT03868956|Experimental|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
16415868|NCT03868943|Experimental|Solriamfetol|Given orally daily
16415869|NCT03868930|Experimental|STEP-Home|The STEP-Home Arm involves a skills-based intervention focused on Emotional Regulation, Problem Solving, and Attention Training strategies.
16415870|NCT03868930|Active Comparator|PCGT|The Present Center Group Therapy (PCGT) Arm involves a nonspecific, supportive intervention, focused on identifying and discussing current life stressors.
16415871|NCT03868917|No Intervention|ultrasound group|The participants have continuous thoracic paravertebral block performed using only the ultrasound approach.
16415872|NCT03868917|Experimental|pressure measurement group|The participants have continuous thoracic paravertebral block performed using the ultrasound-guided approach combined with pressure measurement techniqueduring needle advancement.
16415873|NCT03868904||OCS Lung INSPIRE Trial|
16415874|NCT03868891|Experimental|EMST150|Subjects with or without cleft palate will use the EMST150 2 times a day for 8 weeks.
16415875|NCT03868878|Experimental|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
16415876|NCT03868878|Sham Comparator|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
16415877|NCT03868865|Experimental|Integrative mind-body-medicine group program|The 66 hour program encompasses mindfulness training, yoga, moderate exercise, nutrition, naturopathic self-help strategies, cognitive restructuring and acupuncture for the management of side effects caused by chemotherapy.
16415878|NCT03868852|Experimental|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
16415879|NCT03868839|Experimental|Telmisartan Pill|Subjects will start telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
16415880|NCT03868813||Interview with People with Diabetes|One-on-One interview with people with diabetes
16415881|NCT03868813||Interview with Health Coaches|One-on-One interview with health coaches
16415921|NCT03868566|Experimental|SNP-612 dose2|dose2 once a day orally for 12 weeks
16415922|NCT03868566|Experimental|SNP-612 dose3|dose3 once a day orally for 12 weeks
16415923|NCT03868566|Placebo Comparator|SNP-612 placebo|placebo once a day orally for 12 weeks
16415924|NCT03868553||Under-10|
16415925|NCT03868553||Under-12|
16415926|NCT03868553||Under-16 female|
16415927|NCT03868553||Under-16 male|
16415928|NCT03868540|Experimental|BI 1291583|
16415929|NCT03868540|Placebo Comparator|Placebo|
16415882|NCT03868800|Other|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
16415883|NCT03868787|Experimental|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
16415884|NCT03868787|Sham Comparator|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
16415885|NCT03868774|Active Comparator|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
16415886|NCT03868774|Active Comparator|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
16415887|NCT03868761|Other|Single Arm|21 male and female teenage participants will be randomized to one of three varying baseline assessment periods of two, four, or six weeks. Multiple baseline is a type of single-case experimental design (SCED) that is a time- and cost-effective method for evaluating efficacy of a new treatment, Sonoma Rises. The randomization of participants to baseline periods of varying lengths enables assessment of whether symptom changes occur when, and only when, the intervention is applied.
16415888|NCT03868748|Placebo Comparator|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
16415889|NCT03868748|Experimental|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
16415890|NCT03868748|Experimental|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
16415891|NCT03868735|Experimental|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
16415892|NCT03868735|No Intervention|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
16415893|NCT03868722|Experimental|Treatment arm|Treatment with Acalabrutinib and Venetoclax is initiated within 14 days after randomization.
16415894|NCT03868722|No Intervention|Observation arm|Observation period is initiated within 14 days after randomization.
16415895|NCT03868709|Experimental|Penehyclidine group|Penehyclidine inhalation is administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
16415896|NCT03868709|Placebo Comparator|Placebo group|Placebo inhalation is administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
16415897|NCT03868696|Sham Comparator|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
16415898|NCT03868696|Experimental|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
16415899|NCT03868683|Other|Glucose Reference 1|Glucose solution containing 30 g of glucose
16415900|NCT03868683|Other|Glucose Reference 2|Glucose solution 2 containing 30 g of glucose
16415901|NCT03868683|Other|Glucose Reference 3|Glucose solution 3 containing 30 g of glucose
16415902|NCT03868683|Experimental|Sucrose|Sucrose solution containing 30 g of sucrose
16415903|NCT03868683|Experimental|Regular Bake beans in tomato sauce|Bake bean in tomato sauce with high levels of sucrose (37%)
16415904|NCT03868683|Experimental|Bake beans in tomato sauce, reduced sugar|Bake bean in tomato sauce with medium levels of sucrose (29.9%)
16415905|NCT03868683|Experimental|Bake beans in tomato sauce, low GI|Bake bean in tomato sauce with low levels of sucrose (18.5%)
16415906|NCT03868670|Experimental|Responsive Neurostimulation|Surgical arm. Patients expected to receive treatment.
16415907|NCT03868657|Active Comparator|Moxifloxacin|Per os, 800 mg, once daily for 4 days
16415908|NCT03868657|Placebo Comparator|Placebo|Per os, 800 mg, once daily for 4 days
16415909|NCT03868644|Experimental|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
16415910|NCT03868644|Experimental|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
16415911|NCT03868644|Experimental|VCT and Condoms|Youth are offered both VCT and condoms.
16415912|NCT03868644|No Intervention|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
16415913|NCT03868631|Active Comparator|Soy protein group|
16415930|NCT03868527||Hematological diseases|Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital
16415931|NCT03868514||TiLOOP Bra Pocket|Medical Device
16415932|NCT03868501|Experimental|High Working memory load: n-back task|During the intervention, each participant of this group will finish the 3-back task.
16415933|NCT03868501|Experimental|Low Working memory load: n-back task|During the intervention, each participant of this group will finish the 1-back task.
16415934|NCT03868488|Experimental|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
16415935|NCT03868488|Experimental|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
16415936|NCT03868475|Experimental|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.
~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.
~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
16415937|NCT03868475|Active Comparator|Open surgical excision|"Patients will undergo standard open surgical excision.
~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.
~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
16415938|NCT03868462|Other|Optical Coherence Tomography (OCT)|
16415939|NCT03868449|Experimental|Question Prompt List|Participants will be given a Question Prompt list that has been developed by the research team
16415940|NCT03868449|Active Comparator|3 questions list|Participants will be given 3 questions from the AskShareKnow method
16415941|NCT03868436|Other|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
16415942|NCT03868423|Experimental|Treatment (brigatinib)|Patients receive brigatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16415943|NCT03868410|Active Comparator|cPMD rTMS + Training|New Approach
16415944|NCT03868410|Active Comparator|iM1 rTMS + Training|Conventional Approach
16415945|NCT03868397|Experimental|Liver MRI|In this study, MRI refers to phase-contrast 4D flow sequence.
16415946|NCT03868371|Active Comparator|1. high - 2. low|These are the patients receiving a high phosphorous containing meal in the first trial day, and a low phosphorous containing meal in the second trial day.
16415947|NCT03868371|Active Comparator|1. low - 2. high|These are the patients receiving a low phosphorous containing meal in the first trial day, and a high phosphorous containing meal in the second trial day.
16415948|NCT03868358|Active Comparator|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
16415949|NCT03868358|Placebo Comparator|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
16415950|NCT03868332||inflammatory bowel diease patients|
16415951|NCT03868332||normal indivuals|
16415952|NCT03868319|Experimental|control group|nonprotective ventilation with a tidal volume of 9 ml kg-1 PBW with ZEEP
16415953|NCT03868319|Experimental|LPV group|a tidal volume of 6 ml kg-1 PBW with a 7 cmH2O level PEEP
16415954|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
16415955|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
16415956|NCT03868293|Experimental|Drug-Resistant Epilepsy (temporal lobe)|Pulsed low intensity focused ultrasound
16415957|NCT03868280|Active Comparator|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
16415958|NCT03868280|Active Comparator|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
16415959|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
16415960|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
16415961|NCT03868241|Experimental|Bactiguard-coated Devices|Patients will receive endotracheal tube, central venous catheter and urinary cather coated with gold, silver and palladium (Bactiguard coating)
16415962|NCT03868241|Placebo Comparator|Control|Shelf endotracheal tube, central venous catheter and urinary cather available at each intensive care unit without any type of coating designed to prevent infection
16415963|NCT03868228|Experimental|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
16415964|NCT03868215||Patients with endoscopically removed malignant polyps|Patients with endoscopically removed malignant polyps
16415965|NCT03868202|No Intervention|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
16415966|NCT03868202|Active Comparator|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
16415967|NCT03868189|Experimental|electroneuromyography|
16415968|NCT03868189|Placebo Comparator|control|
16415969|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
16415970|NCT03868176||Active comparator: standard of care|
16415971|NCT03868163||Glecaprevir plus Pibrentasvir|"Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
16415972|NCT03868150|Active Comparator|Inducible Atrial Fibrillation|Treatment with Amiodarone
16415973|NCT03868150|Other|Inducible Atrial Fibrillation - Standard Care|No initial Amiodarone Treatment unless POAF seen on post operative care unit.
16415974|NCT03868150|Other|Non-Inducible Atrial Fibrillation|Amiodarone treatment if POAF seen on post-operative care unit
16415975|NCT03868137|Placebo Comparator|Placebo|3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion
16415976|NCT03868137|Experimental|Ibuprofen|3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.
16415977|NCT03868124|Experimental|Implant Group 1|G2TR intraocular implant containing Travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
16415978|NCT03868124|Experimental|Implant Group 2|G2TR intraocular implant containing Travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
16415979|NCT03868124|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
16415980|NCT03868111|Experimental|Sufentanil|Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
16415981|NCT03868111|Experimental|Remifentanil|Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.
16415982|NCT03868098|Active Comparator|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
16415983|NCT03868098|Placebo Comparator|Placebo ointment (vehicle)|Placebo
16415984|NCT03868072|Experimental|Reference/Test|"Period 1: XELJANZ 5Mg Tablet 1T
~Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
16415985|NCT03868072|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tofacitinib Tablet 1T
~Period 2: XELJANZ 5Mg Tablet 1T"
16415986|NCT03868059|Experimental|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
16415987|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
16415988|NCT03868033|Experimental|Continuous Denosumab|Continuous anti-resorptive therapy by Denosumab for 2 years
16415989|NCT03868033|Experimental|Zoledronic acid to Denosumab|treat with Zoledronic acid for one year and then shift to Denosumab for another one year
16415990|NCT03868033|Experimental|Continuous Zoledronic acid|Continuous anti-resorptive therapy by Zoledronic acid for 2 years
16415991|NCT03868033|Experimental|Zoledronic acid to observation|"treat with Zoledronic acid for one year and then close follow up by bone turn over marker.
~resume another dose of Zoledronic acid if elevated CTX level above normal range"
16415992|NCT03868020|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
16415993|NCT03868007|Experimental|RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent RIC twice daily for 14 days.And the RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
16415994|NCT03868007|Sham Comparator|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
16415995|NCT03867994|Experimental|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
16415996|NCT03867994|Experimental|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
16415997|NCT03867994|Experimental|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
16415998|NCT03867981|Experimental|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
16415999|NCT03867981|Experimental|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
16416000|NCT03867981|Active Comparator|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
16416001|NCT03867968|Experimental|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
16416002|NCT03867968|Active Comparator|Control|An existing website related to traumatic brain injury.
16416003|NCT03867955||Patients who have a neurosurgical intervention|Patients who have a neurosurgical intervention will be included. They will have a collection of datas.
16416004|NCT03867942|Active Comparator|monolayer group|monolayer of Gemigliptin/Rosuvastatin
16416005|NCT03867942|Experimental|bilayer group|bilayer of Gemigliptin/Rosuvastatin
16416006|NCT03867929||STUDY|Patient with serum 25-Hydroxy vitamin D level <27.32
16416007|NCT03867929||CONTROL|Patient with serum 25-Hydroxy vitamin D level >27.32
16416009|NCT03867877|Experimental|Periodized Training with Motor Practice|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
16416010|NCT03867877|Experimental|Simple Periodized Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and 60-75% of subjects' maximum strength for the hypertrophy day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down
16416011|NCT03867864|Experimental|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
16416012|NCT03867864|Other|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
16416013|NCT03867851|Experimental|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
16416014|NCT03867851|Active Comparator|Heparin|Heparin treatment according to clinical praxis.
16416015|NCT03867838|Experimental|Stroke survivors|Stroke survivors with upper extremity motor impairments
16416016|NCT03867812|No Intervention|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
16416017|NCT03867812|Experimental|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
16416018|NCT03867812|Active Comparator|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
16416019|NCT03867812|Active Comparator|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
16416020|NCT03867799|Experimental|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
16416021|NCT03867786|Experimental|Exercise Condition|Participants will undergo a 40 minute exercise protocol
16416022|NCT03867786|Active Comparator|Video Control Condition|Participants will view a 40 minute nature video
16416023|NCT03867773|Experimental|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
16416024|NCT03867773|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
16416025|NCT03867773|Experimental|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
16416026|NCT03867760|Experimental|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
16416027|NCT03867760|Active Comparator|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
16416028|NCT03867747|Experimental|Cardiac Radiosurgery|25 Gy in a single fraction
16416029|NCT03867734|Experimental|2g Aztreonam|Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea
16416030|NCT03867721|Experimental|Ventilator PB560 (Covidien)|The non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
16416031|NCT03867721|Experimental|Ventilator Trilogy (Philips Respironics)|The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
16416032|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
16416033|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
16416034|NCT03867695|Experimental|Serratus Block|"At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
~Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle.
~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product."
16416035|NCT03867695|Placebo Comparator|Placebo Block - Control Group|"Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle.
~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product."
16416036|NCT03867682|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 1 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).
~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.
~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
16416037|NCT03867669|Experimental|Single Patient Room|Patients randomized to this arm will be admitted to a NICU single patient room.
16416038|NCT03867669|Placebo Comparator|Open Bay|Patients randomized to this arm will be admitted to the open bay NICU Unit.
16416039|NCT03867656|Experimental|GLP-2|Glucagon-like peptide 2
16416040|NCT03867656|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
16416041|NCT03867656|Placebo Comparator|Placebo|Saline
16416042|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
16416043|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
16416044|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
16416045|NCT03867617|Experimental|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
16416046|NCT03867617|Active Comparator|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
16416047|NCT03867604|Sham Comparator|Sham injection|Subcutaneous injection at upper trapezium muscle level
16416048|NCT03867604|Experimental|Fascia injection|Fascia injection, below upper trapezium muscle
16416049|NCT03867591|Experimental|Gastro-AD® Group|The participants randomized to this group 1 g of Gastro-AD® powder per sachet + flavoring agents.
16416050|NCT03867591|Placebo Comparator|Placebo Group|Participants in this arm will take a sachet containing maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
16416051|NCT03867578|Other|Exploratory Phase - Standard CT Imaging and HR-MRI|The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
16416052|NCT03867578|Other|Testing Phase- Conventional and HR-MRI and Ultrasound|Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
16416053|NCT03867565|No Intervention|No nutritional diagnosis|Patients without nutritional diagnosis get SOC
16416054|NCT03867565|Experimental|Nutritional diagnosis|Patients with nutritional diagnosis get nutritional intervention by dietitian.
16416055|NCT03867552|Experimental|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
16416056|NCT03867552|Active Comparator|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
16416057|NCT03867539|Active Comparator|Control Group; Bupivacaine + opioids|"This is the standard of care arm. This group will receive pre-operative opioid education and standard of care, which consists of an injection of 10cc bupivacaine (plus ~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies."
16416058|NCT03867539|Experimental|Experimental Group: Exparel, no opioids|This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel (liposomal bupivacaine), ~5cc of bupivacaine, and ~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
16416059|NCT03867513||mTBI cases|Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
16416060|NCT03867513||Acute trauma controls|Non-head trauma controls matched for age and sex with the mTBI group
16416061|NCT03867500|Experimental|Niacin|Intravenous niacin infusion
16416062|NCT03867500|Placebo Comparator|Saline|Intravenous saline infusion
16416063|NCT03867487|Experimental|Study intervention|Empagliflozin 10 mg will be taken daily
16416064|NCT03867487|Placebo Comparator|Control arm|Placebo oral tablet will be taken daily
16416065|NCT03867474|Experimental|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
16416066|NCT03867474|No Intervention|Control - Usual Care|Control
16416067|NCT03867461|Active Comparator|Group A|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group A: Initial Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-80 mmHg, End tidal CO2 38-40 mmHg."
16416068|NCT03867461|Active Comparator|Group B|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group B: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg,"
16416069|NCT03867461|Active Comparator|Group C|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group C: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 24-26 mmHg, Subsequent Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg,"
16416070|NCT03867461|Active Comparator|Group D|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group D: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-100 mmHg, End tidal CO2 24-24 mmHg,"
16416071|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with posssible endocrine conditions.
16416074|NCT03867409|Experimental|Concordant virtual human|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
16416075|NCT03867409|Experimental|Dis-concordant virtual human|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
16416076|NCT03867409|Experimental|Concordant text|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
16416077|NCT03867409|Experimental|Dis-concordant text|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
16416078|NCT03867396|Active Comparator|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
16416079|NCT03867396|Active Comparator|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
16416080|NCT03867396|Experimental|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
16416081|NCT03867383|Experimental|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).
~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
16416166|NCT03866824|Active Comparator|reference treatment|
16416082|NCT03867383|Placebo Comparator|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.
~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
16416083|NCT03867370|Experimental|Group A|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
16416084|NCT03867370|Experimental|Group B (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
16416085|NCT03867370|Active Comparator|Group C (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
16416086|NCT03867344|Active Comparator|Hypoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute hypoglycemic hyperinsulinemic clamp procedure (50mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
16416087|NCT03867344|Placebo Comparator|Normoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute normoglycemic hyperinsulinemic clamp procedure (90mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
16416088|NCT03867331|Experimental|5 microgram VLPM01|5 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
16416089|NCT03867331|Experimental|15 microgram VLPM01|15 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
16416090|NCT03867331|Experimental|30 microgram VLPM01|30 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
16416091|NCT03867331|Experimental|Controlled Human Malaria Infection (CHMI) Phase|Infectivity Control Participants, n=6
16416092|NCT03867318|Experimental|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
16416093|NCT03867318|Experimental|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
16416094|NCT03867305|Experimental|MOBIDERM group|
16416095|NCT03867305|No Intervention|Control group|
16416096|NCT03867292|Experimental|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
16416097|NCT03867292|Active Comparator|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
16416098|NCT03867279|Experimental|Flossing|The subjects included in this group will perform a protocol of reeducation exercises plus the application of the Flossing technique. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
16416099|NCT03867279|Active Comparator|Reeducation exercises|The subjects included in this group will carry out a protocol of reeducation exercises. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
16416100|NCT03867253|Active Comparator|ORY-2001 Low dose|0.6mg ORY-2001 capsule
16416101|NCT03867253|Active Comparator|ORY-2001 High dose|1.2mg ORY-2001 capsule
16416102|NCT03867253|Placebo Comparator|Placebo|Placebo capsule
16416103|NCT03867240|Experimental|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
16416104|NCT03867240|Placebo Comparator|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
16416105|NCT03867214|Experimental|Experimental|"Receiving TXA, Study group
~Tranexamic acid, Study group tranexamic acid 1g,
~intravenous injection, pre-operationally"
16416106|NCT03867214|Placebo Comparator|Placebo Comparator|"Normal saline, Control group
~Not receiving tranexamic acid, Control group Normal
~saline 100mL, intravenous injection, pre-operationally"
16416107|NCT03867201|Experimental|Erenumab|Administered by pre-filled syringe
16416108|NCT03867201|Placebo Comparator|Placebo|Administered by pre-filled syringe
16416109|NCT03867188|Experimental|Liiposomal Bupivacaine Group|Qualified participants with a soft tissue sarcoma of the thigh will be given the alternative protocol utilizing liposomal bupivacaine (Exparel®). The alternative protocol will utilize general or spinal anesthesia, but will also include the use of intraoperative liposomal bupivacaine instead of a regional nerve block.
16416110|NCT03867188|No Intervention|Control Group|A retrospective control group will be assembled from electronic medical records of 3 patients who underwent resection of a soft tissue sarcoma of the thigh and will be accessed and analyzed for the variable of interest.
16416111|NCT03867175|Experimental|Arm 1 Stereotactic Body Radiation Therapy/Pembrolizumab|3-10 treatments of SBRT/ pembrolizumab IV for 30 minutes every 3-4 weeks for 1 year at doctor's discretion.
16416112|NCT03867175|Experimental|Arm 2 Pembrolizumab|Patients receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
16416113|NCT03867162|Experimental|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
16416114|NCT03867149|Other|patient with first thalamic infarct|Patient with first thalamic infarct, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
16416115|NCT03867149|Other|healthy subject matched with control|Healthy subject matched with control, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
16416116|NCT03867136|Experimental|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
16416117|NCT03867136|Active Comparator|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
16416118|NCT03867123|Experimental|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + 2-OHOA (during Concurrent phase - duration 6 weeks)*:
~2-OHOA will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).
~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.
~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.
~* One extra week may be allowed."
16416119|NCT03867123|Experimental|Arm 2 (maintenance phase)|"TMZ + 2-OHOA (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):
~2-OHOA will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. 2-OHOA will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).
~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.
~Both arms will be followed by a 4-week safety follow-up"
16416120|NCT03867110|Placebo Comparator|Placebo|Placebo is to be taken orally once a day (QD) in the morning for 12 consecutive weeks.
16416121|NCT03867110|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) is to be taken orally QD in the morning for 12 consecutive weeks.
16416122|NCT03867110|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416123|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416124|NCT03867110|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416125|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416126|NCT03867110|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416127|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 40 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416128|NCT03867110|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416129|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 80 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
16416130|NCT03867097|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
16416131|NCT03867097|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
16416134|NCT03867071|Experimental|erythropoietin (EPO) group|
16416135|NCT03867071|Placebo Comparator|Placebo (PLA) group|
16416136|NCT03867058||Cochlear implant users with Nucleus and AB devices|"Temporal processing acuity will be compared using electrodes or electrode configurations that create broad versus sharp spatial excitation.
~Speech recognition will be compared in the same group of subjects using electrode-dependent focused versus monopolar stimulation."
16416137|NCT03867045|Experimental|mRCC treated with cabozantinib|Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
16416138|NCT03867032|Experimental|Cochlear implant users|The group will receive auditory training (psychophysical), and will be evaluated for speech recognition to determine the effect of training.
16416139|NCT03867019||Subjects with BPPV|"Patients diagnosed with BPPV, who meet the following criteria:
~Main complain of spinning sensation (Vertigo) when changes are made in head position relative to gravity.
~Positive Dix-Hallpike / Supine Roll Test, confirmed by presence of nystagmus."
16416140|NCT03867019||Subjects without BPPV (Control group)|Patients who do not suffer from dizziness / spinning sensation (Vertigo), and do not meet the exclusion criteria in the study.
16416141|NCT03867006|No Intervention|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
16416142|NCT03867006|Experimental|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
16416143|NCT03867006|Experimental|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
16416144|NCT03866993|Experimental|AK105 plus Carboplatin and Paclitaxel|Subjects receive AK105 200 mg intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
16416145|NCT03866993|Placebo Comparator|placebo plus Carboplatin and Paclitaxel|Subjects receive placebo intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
16416146|NCT03866980|Experimental|AK105 plus Carboplatin and Pemetrexed|Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
16416147|NCT03866980|Placebo Comparator|Placebo plus Carboplatin and Pemetrexed|Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
16416148|NCT03866967|Experimental|AK105|Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
16416149|NCT03866954|Experimental|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
16416150|NCT03866941||synthetic cannibinoids users|
16416151|NCT03866928|Experimental|Stiripentol|
16416152|NCT03866915||Patients undergoing elective surgery|All patients older than 18 years undergoing elective surgery that receive a preoperative visit by anesthesiologists in which Aortic pulse wave velocity measurement and the 6 minutes walking test (6MWT) is carried out
16416153|NCT03866902|Experimental|Nutrition and Physical Activity Intervention|"Classes for the intervention mothers will be run by a bilingual interventionist and will last 105 minutes weekly for 12 weeks and then monthly for 6 months.
~Classes for intervention group children will be 105 minutes weekly for 12 weeks and then monthly for 6 months."
16416154|NCT03866902|Active Comparator|English for Second Language Intervention|"Mothers in the control group will receive English as a Second Language (ESL) classes taught by professional ESL teachers; they will receive the same number of contacts and time as the intervention group mothers for 105 minutes weekly for 12 weeks and 105 minutes monthly for 6 months.
~Children in the control group will be read to and color with crayons 105 minutes weekly for 12 weeks and then 105 minutes monthly for 6 months."
16416155|NCT03866889|Experimental|Strength|Maximum strength protocol based on a Maximum Repetition (1RM). The aim of the application of the training is to produce an increase in strength based on training with high loads (80% 1RM), individually and covering the muscles of the lower extremity (quadriceps, hamstrings, gluteus maximus).
16416156|NCT03866889|Active Comparator|Normal activity|The subjects included in the control group will perform the same physical activity to improve the strenght until the beginning of the study. The exercises will be done in the same conditions and with the same period (4 days / week)
16416157|NCT03866876||Hôpital Femme Mère Enfants births|
16416158|NCT03866863||HFME births.|All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.
16416159|NCT03866850||Cochlear implant users with late-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration).
~Examine neural spatial excitation patterns with long and short phase duration. Measure speech recognition using long and short phase duration stimulation patterns."
16416160|NCT03866850||Cochlear implant users with early-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration) and compare that with the late-onset group.
~Examine neural spatial excitation patterns with long and short phase duration within the non-leaky phase duration range.
~Measure speech recognition using long and short phase duration stimulation patterns."
16416161|NCT03866837|Active Comparator|Study group A: GOS|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and galacto-oligosaccharides (GOS), 7.5 mg.
16416162|NCT03866837|Active Comparator|Study group B: bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), bovine lactoferrin (bLF), 1.0 g.
16416163|NCT03866837|Active Comparator|Study group C: GOS + bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.
16416164|NCT03866837|Placebo Comparator|Study group D|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).
16416165|NCT03866824|Experimental|PRP group|
16416167|NCT03866811|Experimental|Intervention arm|The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
16416168|NCT03866811|No Intervention|Control arm|Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
16416169|NCT03866798|Experimental|Panzyga|Panzyga
16416170|NCT03866785|Other|STEP 1: Patient with prostate cancer|First, patients with prostate cancer will be included during step 1. They will have an interview.
16416171|NCT03866785|Other|STEP 2: Patient with prostate cancer and a physical activity|"Secondly, patient with prostate cancer and a physical activity will be included during step 2. They are called peer.
~They will have a questionnaire Adult Physical Activity Questionnaire (APAQ), an activity actigraph and a peer training. The peer will help patients to realize the Physical Activity Program during step 3."
16416172|NCT03866785|Other|STEP 3: Physical Activity Program|"Finally, patients with prostate cancer (different from step 1) and who agrees to participate at the Physical Activity Program will be included during step 3.
~They will have an activity actigraph and a questionnaire Adult Physical Activity Questionnaire (APAQ) at inclusion and 3 months later.
~They will receive the Physical Activity Program."
16416173|NCT03866772|Active Comparator|MISOPROSTOL|"oral misoprostol, 50 microgram, every 4 hours
~Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm
~maximal number of doses: 6
~Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.
~Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.
~Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
16416174|NCT03866772|Active Comparator|DOUBLE BALLOON|"Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.
~Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration
~If AROM cannot be performed- oxytocin infusion will be initiated at first.
~If Bishop <3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
16416175|NCT03866772|Active Comparator|MISOPROSTOL+DOUBLE BALLOON|
16416176|NCT03866746|Active Comparator|Group A|received aflibercept injections alone
16416177|NCT03866746|Experimental|Group B|received 3 aflibercept injections followed by micropulsed laser
16416178|NCT03866733|Active Comparator|Narcotics group (group N)|intervention: injection of boluses of intra venous Narcotics (fentanyl) in the dose of (3-5 mcg/kg) during the surgery after induction of anesthesia. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till 48 hours after surgery. NSAID every 12 hrs if there is no contraindication and iv acetaminophine igm/6hrs.
16416179|NCT03866733|Experimental|Erector spinea block group (group B)|intervention: after induction our intervention will be the performance of ultrasound guided bilateral continous Erector spinea block with insertion of catheters then 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 8 ml/h. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till extubation and iv acetaminophine igm/6hrs.
16416180|NCT03866720|Active Comparator|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
16416181|NCT03866720|Experimental|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
16416182|NCT03866720|No Intervention|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
16416183|NCT03866694|Experimental|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
16416184|NCT03866694|Active Comparator|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
16416185|NCT03866681|Experimental|Patients cohort|A total of 40 patients with refractory classic PNH will be included and will be intervened by a combined therapy including sirolimus and low-dose warfarin
16416186|NCT03866668|Experimental|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
16416187|NCT03866655|Experimental|Intervention|
16416188|NCT03866655|No Intervention|Control|
16416189|NCT03866629||Lifitegrast 5%|Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.
16416190|NCT03866616|Active Comparator|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
16416191|NCT03866616|Experimental|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
16416195|NCT03866590||Patients being at risk for Pyruvate Kinase Deficiency|Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology
16416196|NCT03866577|Experimental|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
16416197|NCT03866577|Experimental|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
16416496|NCT03864458|Experimental|KHK7791 B|Patients take KHK7791 middle dose BID.
16416198|NCT03866577|Experimental|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
16416199|NCT03866577|Experimental|Part D|ITP patients will receive repeated doses of M254
16416200|NCT03866564||Multi-Afflicted|Participants with multiple self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
16416201|NCT03866564||Un-Afflicted|Participants who report no afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
16416202|NCT03866564||Single Afflicted|Participants with one self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
16416203|NCT03866551|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
16416206|NCT03866525|Experimental|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.
~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
16416207|NCT03866512|Experimental|Acipimox ingestion during immobilization|Oral ingestion of Acipimox during 2 days of forearm immobilization
16416208|NCT03866512|Experimental|B-agonist during immobilization|Oral ingestion of salbutamol during 2 days of forearm immobilization
16416209|NCT03866512|Placebo Comparator|Placebo ingestion during immobilization|Oral ingestion of a placebo 2 days of forearm immobilization
16416210|NCT03866499|Experimental|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
16416211|NCT03866499|Active Comparator|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
16416212|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
16416213|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
16416214|NCT03866473|Experimental|Retilux Photobiomodulation|670nm wavelength device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device).
16416215|NCT03866473|Sham Comparator|Sham Light Device|Broad spectrum light device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device)
16416216|NCT03866460||Hearing evaluation DPOAE|Post IA hearing evaluation will be allowed up until 9 months after IA completion (or roughly one year from initiation of treatment). After completion of standard treatment for RB that included IA carboplatin.
16416217|NCT03866447|Active Comparator|vitamin D versus placebo|This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
16416218|NCT03866447|Active Comparator|Adapalene versus placebo|this group will be treated by topical Adapalene (0.1%) versus versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
16416219|NCT03866434|Experimental|SPD422 + Omeprazole|Participants will receive 1 milligram (mg) of SPD422 (Anagrelide hydrochloride) (2*0.5 mg) capsule orally on Day 1 in fasted state (10 hours prior to and until 4 hours following administration of anagrelide), followed by 40 mg of Omeprazole capsule orally once daily (prior to breakfast) on Days 2 to Day 7, followed by 1 mg of Anagrelide in fasted state in combination with Omeprazole 40 mg on Day 8.
16416220|NCT03866421||Kidney transplanted patients|"Number of patients: 16
~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.
~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).
~Same interventions as in the control Group.
~Including/ Exclusion criteria are listed under the section Eligibility"
16416221|NCT03866421||Control group|"Number of patients: 16
~Participants in this group are matched on age and BMI according to the kidney transplanted patients.
~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.
~Furthermore, participants have to have normal kidney function.
~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
16416222|NCT03866408|Active Comparator|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
16416250|NCT03866187|Experimental|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
16465852|NCT03526211|Experimental|Experimental|Patients with FES Cycling
16416223|NCT03866408|Placebo Comparator|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
16416224|NCT03866408|Active Comparator|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
16416225|NCT03866408|Active Comparator|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.
~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
16416226|NCT03866395|No Intervention|Control Group|drug therapy according to the guidelines
16416227|NCT03866395|Experimental|Ivabradine Group|drug therapy according to the guidelines + Ivabradine 5 mg twice a day
16416229|NCT03866369|Experimental|Experimental|IMP Under investigation
16416230|NCT03866369|Placebo Comparator|Placebo to Match|
16416231|NCT03866356|Experimental|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
16416232|NCT03866356|No Intervention|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
16416233|NCT03866343|Active Comparator|Low AGE diet|Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
16416234|NCT03866343|Other|High AGE diet|Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
16416235|NCT03866330|Active Comparator|osteoarthritis of the knee|Intraarticular injection of WJMSC
16416236|NCT03866330|Active Comparator|osteoarthritis of the hip|Intraarticular injection of WJMSC
16416237|NCT03866330|Active Comparator|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
16416238|NCT03866317|Experimental|Secukinumab|Secukinumab 300 mg injection at week 0, 1, 2, 3, 4, then every 4 weeks until week 12
16416239|NCT03866304|Experimental|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
16416240|NCT03866291||ESBL carrier|"This cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group.
~Sera is donated after 4-6 weeks and in year."
16416241|NCT03866291||Non ESBL-carrier|No further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
16416242|NCT03866265|Active Comparator|Supplement Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a food supplement capsule (containing 0.125 g of FGE-Salmon-PLs) per day for a period of 28 days.
~After the period of 28 days, each participant will provide blood samples at the 29th day.
~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.
~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the food supplement will now be administered the placebo capsules for 28 days (a placebo capsule per day)"
16416243|NCT03866265|Placebo Comparator|Placebo Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a placebo capsule (containing 0.125 g of glycerin) per day for a period of 28 days.
~After the period of 28 days, each participant will provide blood samples at the 29th day.
~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.
~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the placebo capsules will now be administered the food supplement capsules for 28 days (a food supplement capsule per day)"
16416244|NCT03866252|Experimental|Treatment Arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
16416245|NCT03866252|Active Comparator|Control Arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
16416247|NCT03866213||Quantitative Measurement of Bilirubin|Bilirubin content of the neonate will be measured by the following: BiliSpec, laboratory spectophotometric bilirubinometer (Reichert UNISTAT), and transcutaneous bilirubinometer. The infant may or may not be receiving phototherapy treatment at the time of sample measurement.
16416248|NCT03866200|Experimental|resveratrol|
16416249|NCT03866200|Placebo Comparator|Placebo|
16416251|NCT03866187|Active Comparator|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
16416252|NCT03866187|Placebo Comparator|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
16416253|NCT03866187|Experimental|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
16416254|NCT03866187|Active Comparator|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
16416255|NCT03866187|Active Comparator|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
16416256|NCT03866187|Experimental|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
16416257|NCT03866187|Active Comparator|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
16416258|NCT03866174|Experimental|Psilocybin|Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water.
16416259|NCT03866174|Active Comparator|Niacin|Participants will receive a single 100 mg dose of niacin along with the Set and Setting protocol. Niacin is administered orally as a capsule and taken with water.
16416260|NCT03866161||CPAP group|Obstructive sleep apnea patients treated with continuous positive airway pressure
16416261|NCT03866148|Active Comparator|ILR|Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
16416262|NCT03866148|No Intervention|No ILR|Participants who will not get the Implantable Loop Recorder (Reveal-LINQ).
16416263|NCT03866135||patients with osteoporosis|Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) assessment. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD)
16416264|NCT03866135||patients without osteoporosis|Bone mineral densities of patients were based on the World Health Organization (WHO) classification of a T score between -1 and -2.5 for osteopenia
16416265|NCT03866122|Experimental|Neonatal Temperature Monitor|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
16416266|NCT03866109|Experimental|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
16416267|NCT03866096|Experimental|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
16416268|NCT03866096|Active Comparator|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
16416269|NCT03866083|Experimental|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
16416270|NCT03866083|Active Comparator|Stadard Medical treatment|Stadard Medical treatment
16416271|NCT03866070|Experimental|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
16416272|NCT03866070|Active Comparator|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
16416273|NCT03866057||1 study group|All patients hospitalized in 4 intensive rehabilitation Structures of Don Gnocchi Foundation during the enrollment period, suffering from acute (within 30 days) ischemic or emorragic stroke
16416274|NCT03866044||Parkinson's Disease (PD)|"Patients with Parkinson's Disease meeting the following criteria:
~Inclusion criteria:
~Aged 18 or more.
~Clinically established or probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease
~Signed informed consent
~Exclusion criteria:
~Pregnancy or breastfeeding
~History of other neurologic or psychiatric disease
~Pacemaker or other implanted electronic devices
~Claustrophobia"
16416275|NCT03866044||Healthy participants|"Healthy participants age- and sex-matched to the PD group.
~Inclusion criteria:
~Age- and sex-matched to PD group (aged 18 or more)
~Signed informed consent
~Exclusion criteria:
~Pregnancy or breastfeeding
~History of neurologic or psychiatric disease
~Pacemaker or other implanted electronic devices
~Claustrophobia"
16416276|NCT03866031|Experimental|M:2.75|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 2.75 mm
16416277|NCT03866031|Experimental|M3.25|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 3.25 mm
16416278|NCT03866031|Experimental|S3.75|12 Patients will be provided with 2 standard sized implant-supported mandibular overdentures d: 3.75 mm
16416279|NCT03866018|Experimental|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
16416280|NCT03866005|Placebo Comparator|Placebo Arm - Standard Treatment|50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration
16416281|NCT03866005|Experimental|Experimental Arm - 2 DiVFuSS formula softgel capsules|50 subjects receiving two DiVFuSS softgels per day
16416282|NCT03866005|Experimental|Experimental Arm - 4 DiVFuSS formula softgel capsules|50 subjects receiving 4 DiVFuss softgels per day
16416283|NCT03865992|Experimental|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
16416284|NCT03865992|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
16416285|NCT03865979|Active Comparator|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.
~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
16416286|NCT03865979|No Intervention|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
16416287|NCT03865953|Active Comparator|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
16416288|NCT03865953|Placebo Comparator|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
16416289|NCT03865940|Experimental|Lidocaine then Lidocaine + Guanfacine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1).
~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine."
16416290|NCT03865940|Experimental|Lidocaine + Guanfacine then Lidocaine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1).
~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine."
16416293|NCT03865914||Type 2 diabetic nephropathy|The cohort will be followed for at least two years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
16416294|NCT03865901||Non-diabetic pregnant women|Non-diabetic women with singleton pregnancy undergoing screening for gestational diabetes who provide plasma samples for testing with the Mellitus GCD59 Test
16416295|NCT03865888|Active Comparator|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
16416296|NCT03865888|Active Comparator|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
16416297|NCT03865875|Experimental|Multimodal Prehabilitation Program|"Pretreatment exercise program and nutrition program
~-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation"
16416298|NCT03865862|Experimental|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
16416299|NCT03865862|Active Comparator|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
16416300|NCT03865849|Active Comparator|Conventional radiofrequent treatment|The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15°. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip
16416301|NCT03865849|Active Comparator|Cooled radiofrequent treatment|The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief).
16416302|NCT03865823||anal Fistula|patient with anal fistula with indication to surgical treatment
16416303|NCT03865810||Gastric Surgery|Adult patients undergoing elective gastric surgery for cancer
16416304|NCT03865797|Experimental|Experimental|Before carrying out each session of the intervention, each subject included in the experimental group will have a sports bandage on both ankles. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
16416305|NCT03865797|Active Comparator|Control|The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
16416306|NCT03865784|Experimental|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
16416336|NCT03865563|Experimental|Pancreatic adenocarcinoma|Participants with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma will receive pancreatic retrograde venous infusion of gemcitabine/lipiodol
16416337|NCT03865550|Placebo Comparator|Placebo|
16416307|NCT03865784|Active Comparator|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
16416308|NCT03865771|Experimental|EPILEPSY GROUP|"Patients with typical BECTS (benign group) or atypical BECTS or ECSWS (severe group)
~Medical visit
~Neuropsychological testing
~Neuropsychological procedure
~Video EEG and polysomnography (standard of care procedure): 2h wake and whole night
~Sleep diary"
16416309|NCT03865771|Other|CONTROL GROUP|"Patients hospitalized for non neurologic illness (diabetes, nephropathy, chronic intestinal disease)
~Medical visit
~Neuropsychological testing
~Neuropsychological procedure
~Video EEG and polysomnography : 2h wake and whole night
~Sleep diary"
16416310|NCT03865758|Experimental|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
16416311|NCT03865758|No Intervention|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
16416312|NCT03865745|Experimental|Korean Red Ginseng|Product: Red ginseng Everytime 1 pack(3g/day)
16416313|NCT03865732|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
16416314|NCT03865732|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
16416315|NCT03865719|Other|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
16416316|NCT03865706|Experimental|Inulin 32 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.
16416317|NCT03865706|Experimental|Inulin 16 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.
16416318|NCT03865706|Placebo Comparator|Placebo|Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.
16416319|NCT03865693|Experimental|scarmbler treatment group|Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
16416320|NCT03865693|Sham Comparator|sham treatment group|conservative management without scarmbler therapy
16416321|NCT03865680|Experimental|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
16416322|NCT03865680|Active Comparator|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
16416323|NCT03865667||Primary Total Hip Arthroplasty|Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
16416324|NCT03865654|Experimental|Surveillance Mammography Communication Tool|"Conduct 30 telephone-based patient interviews
~4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography
~Perform cognitive testing of the communication tool"
16416325|NCT03865641|Experimental|Virtual reality intervention|Experimental group : virtual reality intervention
16416326|NCT03865641|No Intervention|Control group|conventional rehabilitation without virtual reality intervention
16416327|NCT03865615|Experimental|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
16416328|NCT03865615|Experimental|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
16416329|NCT03865602|Experimental|Sepsis Transition And Recovery (STAR)|Virtual sepsis navigation delivered across the peri-hospital discharge interval
16416330|NCT03865602|Active Comparator|Usual Care|Patients and their providers will have no access to the STAR program. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
16416332|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
16416333|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
16416334|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
16416335|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
16416338|NCT03865550|Active Comparator|Ketamine|
16416339|NCT03865537|Experimental|Cold snare & Eleview injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview
16416340|NCT03865537|Experimental|Cold Snare & Placebo injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo
16416341|NCT03865537|Active Comparator|Hot snare & Eleview injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview
16416342|NCT03865537|Active Comparator|Hot snare & Placebo injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo
16416343|NCT03865524|Experimental|Experimental|Total knee arthroplasty implanted with GPS navigation system.
16416344|NCT03865524|Active Comparator|Control|Total knee arthroplasty implanted with standard guides.
16416345|NCT03865511|Experimental|TAGRISSO® 80mg (Osimertinib)|"Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
~Tumor biopsies performed at baseline and clinical progression. ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial."
16416346|NCT03865498|Experimental|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
16416347|NCT03865498|Experimental|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
16416348|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
16416349|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
16416350|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
16416351|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters;
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
16416352|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster:high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
16416353|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
16416354|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
16416383|NCT03865290|Placebo Comparator|Non-ulcer dyspepsia (NUD) Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
~Oral matched placebo administered three times a day for weeks 3-6"
16416494|NCT03864471|Active Comparator|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
16416355|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
16416356|NCT03865472|Experimental|Arm I (rTMS)|Patients undergo rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
16416357|NCT03865472|Sham Comparator|Arm II (sham rTMS)|Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
16416358|NCT03865459|Experimental|Video group|The video group watched relaxing video with a ceiling mounted television during the whole cystoscopy.
16416359|NCT03865459|No Intervention|Control group|The control group received the standard treatment from a surgical technician who works in the cystoscopy during the whole procedure.The control group didn't watch relaxing video during the procedure.
16416360|NCT03865446|Experimental|Cohort 1 (Dacomitinib)|severe hepatic impairment group
16416361|NCT03865446|Experimental|Cohort 2 (Dacomitinib)|normal hepatic function
16416362|NCT03865433|Experimental|Exercise Group|Intervention: aerobic exercise Subjects in the exercise group will be prescribed exercise at a target heart rate (THR) of approximately 80% of the achieved heart rate during the Buffalo Concussion Treadmill Test (BCTT). They will be given this prescription in writing to provide to their athletic trainer. Subjects will complete 30 minutes of daily exercise (including 5 minutes of warm up and 5 minutes of cool down) on an exercise bike or walking and supervised by an athletic trainer. This program may be modified by increasing heart rate threshold 5-10 beats per minute per week by the athletic trainer as the heart rate for symptom exacerbation increases.
16416363|NCT03865433|Placebo Comparator|Placebo/Stretching|Intrvention: stretching program Subjects assigned to the Stretching/Placebo group will be given a stretching protocol and instructions to report to their athletic trainer on a daily basis as soon as possible. . Subjects will then complete a 15-25 minute stretching program under supervision by the athletic trainer or other designated research personnel. The stretching protocol will be progressive and will change weekly as subjects continue their recovery.
16416364|NCT03865407|Active Comparator|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
16416365|NCT03865407|No Intervention|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
16416366|NCT03865394|Experimental|Allogeneic ADSC cells in fibrin solution|"Application of allogeneic ADSC stem cells in fibrin gel, to cover wound surface with thin cells layer.
~Therapy is based on standard procedure of diabetic foot ulcer treatment combined with application of allogeneic ADSC stem cells in fibrin solution onto the wound surface."
16416367|NCT03865394|Active Comparator|Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.|Application of fibrin gel to cover wound surface.
16416368|NCT03865381|Other|Virtual Diabetes Clinic|The Onduo Virtual Diabetes Clinic (VDC) is the suite of diabetes management services including remote monitoring, diet/lifestyle coaching, medication management accessed via Onduo App and partner apps. Subjects will engage with a Care Lead through the App and will have a medical consultation via telemedicine with an Onduo VDC Physician.
16416369|NCT03865368|Experimental|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
16416370|NCT03865368|Active Comparator|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
16416371|NCT03865355||Cohort 1 / High grade Glioma|"Cohort 1:
~Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))
~Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
16416372|NCT03865355||Cohort 2 / Low grade Glioma|"Cohort 2:
~Histologically confirmed low-grade (grade I/II) glioma
~Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy"
16416373|NCT03865355||Cohort 3 / Conditionally healthy volunteers|"Cohort 3:
~No oncological disease was diagnosed
~Planned treatment (reconstructive surgery after craniofacial trauma)"
16416374|NCT03865342|Experimental|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
16416375|NCT03865342|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
16416376|NCT03865329|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
16416377|NCT03865316|Experimental|SedLine Vs Comparator Test Group|
16416378|NCT03865290|Experimental|Healthy Control Ondansetron 8 mg|Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
16416379|NCT03865290|Experimental|Diabetic (DM) gastroenteropathy Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
16416380|NCT03865290|Experimental|Non-ulcer dyspepsia (NUD) Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
16416381|NCT03865290|Placebo Comparator|Healthy Control Placebo|Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
16416382|NCT03865290|Placebo Comparator|Diabetic (DM) gastroenteropathy Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
~Oral matched placebo administered three times a day for weeks 3-6"
16416451|NCT03864861||Elective Bariatric Surgery|Patients older than 18 undergoing elective bariatric surgery
16467182|NCT03517306||Changzhou|No interventions
16416384|NCT03865277|Other|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
16416385|NCT03865277|Experimental|dose-escalated radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
16416386|NCT03865277|Experimental|escalated radiochemoth., carbon boost, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
16416387|NCT03865277|Other|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
16416388|NCT03865277|Other|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
16416389|NCT03865264|Active Comparator|Living Liver donor|"Recovery enhancement program:
~At least 6 weeks of physical and relaxation skills training pre-transplant.
~Taking nutritional drink for 5 days before and after the surgery.
~Opioid sparing pain management."
16416390|NCT03865264|Active Comparator|Living Kidney donor|"Recovery Enhancement Program
~At least 4 weeks of physical and relaxation skills training pre-transplant.
~Taking nutritional drink for 5 days before and after the surgery.
~Opioid sparing pain management."
16416391|NCT03865264|No Intervention|Living Kidney donor (Control)|"Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.
~To control post-op pain, subject will use medication per standard of care, including PCA pump."
16416392|NCT03865251|Experimental|experimental group|Kinesiology tape application to dominant leg during lying and standing positions
16416393|NCT03865238|Experimental|EV71vac|
16416394|NCT03865238|Placebo Comparator|Placebo|
16416395|NCT03865225|Sham Comparator|Control group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes sham-biofeedback over a period of three days
16416396|NCT03865225|Active Comparator|Treatment group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes biofeedback sessions over period of three days
16416397|NCT03865212|Experimental|Group A (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1.
16416398|NCT03865212|Experimental|Group B (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1. Cycle 1 continues for 28 days, with subsequent cycles repeating every 21 days in the absence of disease progression or unacceptable toxicity.
16416399|NCT03865199|Experimental|Intervention Group|The intervention arm will view a digital story on a tablet created by the research team, then respond to a writing prompt. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
16416400|NCT03865199|No Intervention|Control Group|The control group will receive care as usual at the abortion clinic. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
16416401|NCT03865186|Experimental|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
16416402|NCT03865186|Experimental|control group|no intervention was applied to the control group
16416403|NCT03865160|Active Comparator|Atropine eye drops, 0.01%|Atropine eye drops, 0.01%, both eyes at bedtime
16416404|NCT03865160|Placebo Comparator|Placebo (NaCl 0.9%) eye drops|Placebo (NaCl 0.9%) eye drops, both eyes at bedtime
16416405|NCT03865147|Experimental|Phase 1 open, pilot phase|A pilot group of 10 patients who will receive Tri-Solfen only (non-randomised) once, prior to debridement
16416406|NCT03865147|Experimental|Phase 2 - Tri-Solfen|A group of 20 patients who will receive EMLA cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by a single application of Tri-Solfen.
16416407|NCT03865147|Active Comparator|Phase 2 - Standard Care|A group of 20 patients who will receive EMLA Cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by standard of care post-operative analgesia.
16416408|NCT03865147|Experimental|Phase 3 - Tri-Solfen|A group of 20 patients who will receive two applications of Tri-Solfen (2mL/10cm2), once prior to debridement and once on completion of the procedure.
16416409|NCT03865147|Active Comparator|Phase 3 - EMLA|A group of 20 patients who will receive EMLA Cream (60-minute application) prior to surgical debridement
16416410|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
16416411|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
16416412|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
16416493|NCT03864471|Experimental|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
16416413|NCT03865121|Experimental|Nicotine Nasal Spray 10 MG/ML|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
16416414|NCT03865108|Experimental|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
16416415|NCT03865108|Placebo Comparator|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
16416416|NCT03865082|Experimental|IO Naive Subjects MSS CRC|8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
16416417|NCT03865069|Active Comparator|automated oxygen control with VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) with automated pressure control (Volume Guarantee®).
16416418|NCT03865069|Active Comparator|automated oxygen control without VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) without automated pressure control (Volume Guarantee®).
16416419|NCT03865056|Experimental|High-Flow Nasal Cannula|
16416420|NCT03865056|Experimental|Noninvasive ventilation|
16416421|NCT03865030|Active Comparator|psoriatic patients|psoriatic patients that are recruited from the dermatology clinic. This arm will undergo audiovestibular evaluation.
16416422|NCT03865030|Active Comparator|healthy volunteers|Healthy volunteers that are members of the hospital staff and will be recruited from the hospital. This arm will undergo audiovestibular evaluation.
16416423|NCT03865017|Experimental|Regulatory T cells|Biologicals: Autologous Regulatory T cells (1.7*10^5 cells/kg, i.v) other name: GB301
16416424|NCT03865017|Placebo Comparator|Placebo|Saline+cell suspension solution infusion
16416425|NCT03865004|Placebo Comparator|Placebo|
16416426|NCT03865004|Active Comparator|Paracetamol|
16416427|NCT03865004|Active Comparator|Dexketoprofene|
16416428|NCT03864991|No Intervention|Routine Care|This group will be followed up for routine care, maintaining a standard log book for documenting blood sugar and insulin dosages per advice and explanation by doctors, nurses and nutritionists.
16416429|NCT03864991|Active Comparator|e-device for step count (fit-bit)|This group will receive e-device for step count (fit-bit) in addition to routine care.
16416430|NCT03864991|Active Comparator|e-messages for log book|This group will receive daily e-messages for maintaining log book in addition to routine care.
16416431|NCT03864991|Active Comparator|e-messages for log book & fit-bit|This group will receive e-device for step count (fit-bit), daily e-messages for maintaining log book for blood sugar, insulin dosages and step count in addition to routine care.
16416432|NCT03864978|Experimental|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
16416433|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
16416434|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
16416435|NCT03864978|Placebo Comparator|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
16416438|NCT03864939|Experimental|dHAM|dHAM wrap is placed during RRP.
16416439|NCT03864939|Placebo Comparator|Standard|A standard RRP is performed.
16416440|NCT03864926|Active Comparator|Standard of Care|Standard of Care Tacrolimus
16416441|NCT03864926|Experimental|Experimental|Envarsus XR
16416442|NCT03864913|Experimental|Randomized SQ vs IM|Subjects randomized to either SQ or IM testosterone injections follow study protocol.
16416443|NCT03864913|Experimental|Non-randomized SQ|Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.
16416444|NCT03864913|Experimental|Non-randomized IM|Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.
16416445|NCT03864900|Experimental|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
16416446|NCT03864900|No Intervention|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
16416447|NCT03864887||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
16416448|NCT03864887||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
16416449|NCT03864887||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
16416450|NCT03864887||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
16467636|NCT03514524|Experimental|aMCI and MBI|
16416452|NCT03864835|Experimental|Moderate intensity aerobic exercise|All subjects will undergo DXA and CRF measurement (relative VO2max) under the supervision of an American College of Sports Medicine (ACSM)-certified fitness professional and study physician at the Penn State PM&R Research Laboratories. Subjects selected for the interventional pilot trial will receive a FitBit Charge2 HR and be instructed on how to use a FitBit Hear Rate monitor, Fitbit application, Fitbit website, and Fitabase (secure data management platform utilized by >400 clinical trials). Participants will record their daily food and beverage intake through the Fitbit app. Individualized feedback will be provided by a registered dietician (RD). Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist.
16416453|NCT03864822|Experimental|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
16416454|NCT03864822|Placebo Comparator|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
16416455|NCT03864809||psoriasis patients|sleep disturbance
16416456|NCT03864809||atopic dermatites patients|sleep disturbance
16416457|NCT03864809||control|sleep disturbance
16416458|NCT03864796||cases of newly diagnosed ITP|no intervention
16416459|NCT03864796||cases of ITP after responding to treatment|no intervention
16416460|NCT03864796||healthy subjects|no intervention
16416461|NCT03864783|Experimental|Curcumin (Meriva®)|Meriva® 500 mg tablet (contains 100 mg curcumin) Dosage: 2 tablets twice daily for 42 days (+/- 3 days)
16416462|NCT03864783|Placebo Comparator|Placebo|Placebo. Dosage: 2 tablets twice daily to mimic Meriva® tablets.
16416463|NCT03864770|Experimental|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
16416464|NCT03864770|Active Comparator|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
16416465|NCT03864757|Experimental|UVFP correction surgery|Short-term implantation of VOIS and evaluation of voice quality and glottal closure.
16416466|NCT03864731|Other|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
16416467|NCT03864718||complex anal fistula|
16416468|NCT03864692||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
16416469|NCT03864692||Normotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
16416470|NCT03864679|Experimental|Exercise|Subjects will perform a cycling tests
16416471|NCT03864666|Other|Sequence 1|Treatment RTRT
16416472|NCT03864666|Other|Sequence 2|Treatment TRTR
16416473|NCT03864653|Other|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
16416474|NCT03864640||Colorectal cancer|Patients with colorectal cancer
16416475|NCT03864627|Placebo Comparator|Placebo|Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1, 15, 29 and 43 given concomitantly with a medium potency TCS once daily until Day 57.
16416476|NCT03864627|Experimental|MOR106 320 mg|Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
16416477|NCT03864614|Experimental|SAGE-217|
16416478|NCT03864601|Experimental|14C-JNJ-56136379|Participants will receive a single oral 25 milligram (mg) dose of 14C-JNJ-56136379 on Day 1 under fed conditions.
16416479|NCT03864588|Placebo Comparator|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
16416480|NCT03864588|Experimental|Intervention|Surgeon preforms inter-operative adductor canal block
16416481|NCT03864575|Experimental|Combination Group|Celecoxib 400 mg/d Nivolumab 240 mg q2w
16416482|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
16416483|NCT03864562||White European|Healthy individuals of white European descent
16416484|NCT03864549|Experimental|probiotic femina II|research group will receive the probiotic formula Femina II (2 capsules/day) until delivery.
16416485|NCT03864549|Placebo Comparator|Placebo|control group will receive a placebo (2 capsules/day) until delivery.
16416486|NCT03864536|No Intervention|No-contact control|No-contact control
16416487|NCT03864536|Active Comparator|Psychoeducation control|Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
16416488|NCT03864536|Experimental|Psychoeducation + CogRx|Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
16416489|NCT03864523|Experimental|XAMNPIO|Pioglitazone 15 mg tablets 2/day during 2 years
16416490|NCT03864497||Orthotopic liver transplantation candidates|No intervention, imaging test and risk stratification as part of routine clinical care.
16416491|NCT03864484|Experimental|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
16416492|NCT03864484|Active Comparator|Usual rehabilitation|The control group receives usual rehabilitation.
16416497|NCT03864458|Experimental|KHK7791 C|Patients take KHK7791 high dose BID.
16416498|NCT03864458|Experimental|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
16416499|NCT03864458|Placebo Comparator|Placebo|Patients take Placebo BID.
16416500|NCT03864445|Experimental|KHK7791|Patients take KHK7791 BID and can down titrate, based on a GI tolerability question.
16416501|NCT03864445|Placebo Comparator|Placebo|Patients take Placebo BID.
16416502|NCT03864432|Experimental|25mg SAD|
16416503|NCT03864432|Experimental|50mg SAD|
16416504|NCT03864432|Experimental|100mg SAD|
16416505|NCT03864432|Experimental|50mg Multiple dosing|
16416506|NCT03864419|Experimental|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
16416507|NCT03864419|Experimental|Cohort II (DLBCL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
16416508|NCT03864419|Experimental|Cohort III (Adult BL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
16416509|NCT03864419|Experimental|Cohort IV (MCD)|Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
16416512|NCT03864393|Experimental|Multimodal overground locomotor training|Individuals with Parkinson's Disease that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 12-week multimodal exercise training intervention performed twice per week.
16416513|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :
~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
16416514|NCT03864367||Device|This group will use the MWeST lift device along with regular physical therapy. The lift device is the Prism Medical FGA-700 Bariatric Floor Lift including a sling to assist in walking.
16416515|NCT03864367||Control|This group will only receive regular physical therapy.
16416516|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
16416517|NCT03864341|Experimental|Homelessness Prevention Services|
16416518|NCT03864328|Experimental|RVT-1601 Low Dose|
16416519|NCT03864328|Experimental|RVT-1601 Mid Dose|
16416520|NCT03864328|Experimental|RVT-1601 High Dose|
16416521|NCT03864328|Placebo Comparator|Placebo|
16416522|NCT03864315|Experimental|Vitiligo|30 Patients with Vitiligo
16416523|NCT03864302|Experimental|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.
~Table 1: PEELP framework:
~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I…"
16416524|NCT03864302|No Intervention|Control|The control group proceeds directly to standard VR-simulator training.
16416525|NCT03864289|Experimental|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours.
16416526|NCT03864276|Experimental|inhalation anesthesia (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
16416527|NCT03864276|Experimental|Total intravenous anesthesia (propofol) group|Anesthesia is induced and maintained with propofol and sufentanil
16416528|NCT03864263||Children with HBsAg-positive patients|Children from a father or mother who are infected with HBV
16416529|NCT03864263||Children without a family history of HBV|Children without a family history of HBV infection
16416530|NCT03864250|Experimental|Tacrolimus monotherapy|
16416531|NCT03864250|Active Comparator|Tacrolimus combined with hormone therapy|
16416532|NCT03864237|Experimental|Alcohol texts|Participants assigned to this arm will receive a text message each day for 10 weeks, containing factual information about campus drinking norms.
16416533|NCT03864237|Placebo Comparator|Attention control|"Participants assigned to this arm will receive a text message each day for 10 weeks, containing this day in history facts."
16416534|NCT03864211|Active Comparator|Toripalimab monotherapy|Toripalimab is administrated intravenously (240mg, Q3W) continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
16416535|NCT03864211|Experimental|Thermal ablation plus toripalimab|One to five target lesions will be ablated completely. Toripalimab therapy will be initiated on day 3 or day 14 after ablation ((240mg, Q3W) ). Toripalimab is administrated continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
16416536|NCT03864198|Other|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
16416537|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody positive)|
16416538|NCT03864185|Placebo Comparator|Placebo group (IgG4 autoantibody positive)|
16416539|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody negative)|
16416540|NCT03864172|Placebo Comparator|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
16416541|NCT03864172|Active Comparator|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
16416542|NCT03864172|Active Comparator|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
16416543|NCT03864172|Active Comparator|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
16416544|NCT03864159|Experimental|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time.The intervention through the suction cups will consist of its application and produce increased flexibility of the hamstring musculature. The technique will be performed with the subject in prone position, on the stretcher, while the physiotherapist will be placed next to the member to be treated. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
16416545|NCT03864159|Active Comparator|Foam roller|The intervention will be carried out before starting the training session. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
16416546|NCT03864146|Experimental|Pioglitazone|Pioglitazone titrated to 45mg by mouth each day
16416547|NCT03864146|Placebo Comparator|Placebo|placebo, identical 45mg pill
16416548|NCT03864133|Other|Omidria|Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.
16416549|NCT03864094|Active Comparator|Ephedrine Propofol Remifentanil|Prophylactic Ephedrine
16416550|NCT03864094|Active Comparator|Phenylephrine Propofol Remifentanil|Prophylactic Phenylephrine
16416551|NCT03864094|Active Comparator|Norepinephrine Propofol Remifentanil|Prophylactic Norepinephrine
16416552|NCT03864094|Sham Comparator|Sodium chloride Propofol Remifentanil|NaCl Placebo
16416553|NCT03864068|Placebo Comparator|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
16416554|NCT03864068|Experimental|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
16416555|NCT03864068|Experimental|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
16416556|NCT03864068|Experimental|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
16416557|NCT03864055||Pediatric Otogenic CSVT|Children with Otogenic Cerebral Sinus Vein Thrombosis (CSVT)
16416558|NCT03864042|Experimental|Arm 1 - CYP Probe Cocktail|"Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:
~25 mg losartan oral tablet
~30 mg dextromethorphan oral capsule
~50 mg caffeine oral liquid
~20 mg omeprazole oral capsule
~2 mg midazolam oral syrup
~encorafenib/binimetinib continuous daily dosing starting Day 1:
~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
~All drugs will be taken within 10 minutes."
16416559|NCT03864042|Experimental|Arm 2 - Rosuvastatin and Bupropion|"Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:
~10 mg rosuvastatin oral tablet
~75 mg bupropion immediate release (IR) oral tablet
~encorafenib/binimetinib continuous daily dosing starting Day 1:
~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
~All drugs will be taken within 10 minutes."
16416560|NCT03864042|Experimental|Arm 3 - Modafinil|"Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:
~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
~then receive continuous treatment of modafinil on Day 15 through Day 21:
~- 400 mg modafinil tablet once daily (QD)"
16416561|NCT03864016|Other|Standard group|
16416562|NCT03864016|Experimental|Pupillometry group|
16416563|NCT03864003|Experimental|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
16416564|NCT03864003|Active Comparator|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
16416565|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
16416566|NCT03863977|Active Comparator|Dex4 group|After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
16416567|NCT03863977|Active Comparator|Dex8 group|After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
16416568|NCT03863977|Active Comparator|control group|After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.
16416569|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 minutes|Blood test
16416570|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 7 minutes|Blood test
16416571|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 15 minutes|Blood test
16416572|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 30 minutes|Blood test
16416573|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1 hour|Blood test
16416574|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1.5 hours|Blood test
16416575|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2 hours|Blood test
16416576|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2.5 hours|Blood test
16416577|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 hours|Blood test
16416578|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3.5 hours|Blood test
16416579|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4 hours|Blood test
16416580|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4.5 hours|Blood test
16416581|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 5 hours|Blood test
16416582|NCT03863951||Patients with poststroke depression|No intervention
16416583|NCT03863951||Patients without poststroke depression|No intervention
16416584|NCT03863938|Experimental|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
16416585|NCT03863938|Experimental|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
16416586|NCT03863938|Experimental|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
16416587|NCT03863925|Experimental|Propofol Target Controlled Infusion Group (Group T)|Patients in group T underwent anesthesia with Propofol (dosage form: 10mg/mL) target controlled infusion by Schnider model, starting at concentration of effect site (Ce) of 1.5 mcg/mL and titrating to achieve Observer's Assessment of Alertness/Sedation (OAA/S) Scale level 3 (responds only after name called loudly or repeatedly). Patients were paralyzed with suxamethonium (dosage form: 20mg/mL; dosage: 1mg/kg) once adequate sedation level achieved. TCI was stopped once the psychiatrist applied electroconvulsive stimulation to patients' bilateral frontal regions. Assisted ventilation with bag-valve-mask device by experienced anesthesiologists was began since patients were sedated until adequate spontaneous respiration was regained after each single electroconvulsive therapy (ECT) session. Every patient receive total six to twelve ECT sessions, and each ECT session was conducted one day apart.
16416588|NCT03863925|Active Comparator|Propofol Bolus Group (Group B)|Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
16416589|NCT03863912|Active Comparator|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
16416590|NCT03863912|Other|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
16416591|NCT03863899|Experimental|Nerve block|ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)
16416592|NCT03863899|Active Comparator|Local infiltration|local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)
16416593|NCT03863886|Experimental|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
16416594|NCT03863886|Experimental|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
16416595|NCT03863886|Experimental|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
16416596|NCT03863873|Active Comparator|PRP Injection Group|PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
16416597|NCT03863873|Active Comparator|Steroid injection Group|A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection
16416598|NCT03863860|Experimental|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
16416599|NCT03863860|Placebo Comparator|Placebo capsules, 50mg per capsule|Placebo capsules, PO
16416600|NCT03863847|Active Comparator|Online Neurofeedback|This intervention entails online feedback of pain-related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
16416601|NCT03863847|Sham Comparator|Online Sham Neurofeedback|This intervention entails online sham feedback of non-pain related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
16416602|NCT03863834|Experimental|Treatment arm|Subjects receive the RFAL treatment
16416603|NCT03863821|Experimental|HHHFNC group|Practice 6 MWT with HHHFNC
16416604|NCT03863821|No Intervention|non-HHHFNC group|Practice 6 MWT without HHHFNC
16416633|NCT03863613|Active Comparator|Cerclage plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
16416693|NCT03863223|Placebo Comparator|B|Placebo plus trastuzumab and docetaxel
16416605|NCT03863808|Experimental|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.
~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.
~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
16416606|NCT03863808|Active Comparator|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).
~Exercises will be graduated according to the patient pain tolerance."
16416607|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
16416608|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
16416609|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
16416610|NCT03863743|Other|Control|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. Patient will undergo treating physician's standard of care for total hip or knee replacement. Patient will receive bladder scans in PACU, upon admission to the nursing unit, and prior to discharge (post-void).
16416611|NCT03863743|Experimental|Experimental|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. If considered high risk (determined by IPSS), then patient Patient will undergo integrated care pathway that avoids narcotics. Bladder volume will be measured in PACU, after admission to the nursing unit, and prior to discharge from the hospital (post-void).
16416612|NCT03863730|Experimental|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
16416613|NCT03863730|Active Comparator|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
16416614|NCT03863717|Experimental|Arm Endurance Exercise Training Group|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
16416615|NCT03863717|Active Comparator|Control Group|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
16416616|NCT03863704|Sham Comparator|nerve stimulation ear then leg|Subjects in this arm will be randomized to receive nerve stimulation with TENS of the ear followed by leg stimulation
16416617|NCT03863704|Sham Comparator|nerve stimulation leg then ear|Subjects in this arm will be randomized to receive leg nerve stimulation with TENS followed by ear nerve stimulation
16416618|NCT03863704|Other|Subjects receiving Infliximab|Subjects on Infliximab as part of their clinical care will not be randomized as the study treatment for these subjects will be the same. The sham arm is not included for patients on infliximab.
16416619|NCT03863691|Active Comparator|amisulpride group|300 mg of the atypical antipsychotic drug amisulpride
16416620|NCT03863691|Placebo Comparator|placebo group|Similar looking capsules for placebo control
16416621|NCT03863678|Experimental|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
16416622|NCT03863678|Experimental|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
16416623|NCT03863665|Experimental|Telemetric Bluetooth home BP monitors|Telemetric Bluetooth home BP monitors will be provided to participants during their inpatient stay or clinic visit, and will commence 3- times-daily readings immediately. The BP monitoring team will assess BP readings daily and advise medication adjustments to achieve a target BP of <120/80 mm Hg
16416624|NCT03863665|No Intervention|Standard clinical care|Standard clinical care including usual BP treatment, without home monitoring, undertaken in the clinical care setting
16416625|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
16416626|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
16416627|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
16416628|NCT03863626|Active Comparator|Frusemide IV shots = group A|Frusemide as IV shots
16416629|NCT03863626|Active Comparator|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
16416630|NCT03863613|Active Comparator|Pessary group|A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
16416631|NCT03863613|Active Comparator|Cerclage group|Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
16416632|NCT03863613|Active Comparator|Pessary plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
16416634|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
16416635|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
16416636|NCT03863587|Experimental|HLX12 group|HLX12 are given intravenous infusion 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
16416637|NCT03863587|Active Comparator|Cyramza (Ramucirumab) group|Ramucirumab are given intravenous infusion of Cyramza 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
16416638|NCT03863574|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
16416639|NCT03863574|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
16416640|NCT03863574|Placebo Comparator|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
16416641|NCT03863561||Waiting room sample|Patients with type 1 or type 2 diabetes attending an LMC Diabetes & Endocrinology specialist clinic in Ontario completed the SCPI in the waiting room while attending their usual appointment with their healthcare provider.
16416642|NCT03863561||DSME Intervention|Patients with poor glycemic control (A1C >8.0%) were enrolled into a diabetes self-management education (DSME) program. The SCPI was completed at their first and last visit and and their individual results were incorporated into the care paths that were then customized for that participant. The patient met with a diabetes educator five to seven times over the course of three to four months.
16416643|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
16416644|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
16416645|NCT03863535|Experimental|Intravitreal conbercept+Panretinal coagulation|
16416646|NCT03863535|Active Comparator|Panretinal coagulation|
16416647|NCT03863522|Other|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
16416648|NCT03863509||Exclusive Smokers|Smokes Daily; >/= 5 cigarettes/day for last 6 months
16416649|NCT03863509||Exclusive E-Cig users|E-cig usage >/= 5 days/week for last 3 months
16416650|NCT03863509||Never users|< 100 cigarettes in lifetime, none for > 5 years; < 3 E-cig usage in lifetime
16416651|NCT03863496|Other|Neuromuscular scoliosis|Efficacy of Surgical Treatment by Different Pedicle Screw Systems in Pediatric Neuromuscular Spinal Deformity
16416652|NCT03863483|Experimental|Sintilimab plus chemotherapy|Sintilimab (200 mg) plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
16416653|NCT03863483|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
16416654|NCT03863470|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 12 weeks of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the ICU. The length of the control phase will differ for each ICU cluster, depending on the sequence in which ICU-clusters are assigned to switch to the intervention phase.
16416655|NCT03863470|Active Comparator|Early mobilization intervention|The clinical team will set a standardized mobility goal for each patient during morning rounds and display the goal on the patient's door. A facilitator will be established in the ICU to communicate mobility goals and activities across clinical personnel shifts. Patient mobility scores will be displayed to clinical and administrative staff in the ICU via the ICU board.
16416656|NCT03863444|Active Comparator|Control Group|Routine Care
16416657|NCT03863444|Experimental|Intervention Group|Routine Care + Prenatal Preparation Education
16416658|NCT03863431|Active Comparator|High-fat diet|"Participants will consume a diet rich in fat (approximately 65% of total energy) and low in carbohydrate for 14 days.
~Measurements will be made at 0, 7 and 14 days."
16416659|NCT03863431|Active Comparator|High-carbohydrate diet|"Participants will consume a diet rich in carbohydrate (approximately 70% of total energy) and low in fat for 14 days.
~Measurements will be made at 0, 7 and 14 days."
16416660|NCT03863418|Experimental|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
16416661|NCT03863418|Placebo Comparator|placebo|maltodextrin
16416662|NCT03863405|Experimental|Metformin Group|850 mg metformin twice daily for six months in addition to standard therapy
16416663|NCT03863405|Active Comparator|Control Group|placebo in addition to standard therapy for rheumatoid arthritis
16416664|NCT03863392|Experimental|oral|patients undergoing induction of labour using misoprostol oral solution
16416665|NCT03863392|Experimental|vaginal|patients undergoing induction of labour using vaginal misoprostol
16416666|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
16416667|NCT03863379||Control group|Able bodied persons
16416668|NCT03863366|Experimental|Prucalopride|1mg prucalopride capsule
16416669|NCT03863366|Placebo Comparator|Placebo|Lactose placebo capsule
16416670|NCT03863353|Experimental|Education Intervention|This group will receive the scenario-tailored STOMP educational feedback
16416671|NCT03863353|No Intervention|Control|This group will receive only standard of care information.
16416672|NCT03863340|Experimental|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
16416673|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-1)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-1 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
16416674|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-2)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-2 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
16416675|NCT03863327||Acute severe 3-vessel disease or critical left main stenosis|"Severe 3-vessel disease: >/=75% stenosis in all three major coronary vessels (or equivalents in the case of anatomic variants or preexisting bypass) with an acute culprit lesion (TIMI<3) or
~Left main stenosis > 50% (see Smith review paper for reference): acute left main culprit of any TIMI score, or any lesion of the left main with TIMI<3 or
~Any other cardiac catheterization findings prompting initiation of emergent coronary artery bypass grafting within the next 120 hours"
16416676|NCT03863327||No evidence of acute coronary occlusion|"At least three sequential negative cardiac biomarkers within 24 hours of presentation
~cardiac catheterization showing no culprit lesion.
~Angiogram showing an acute culprit lesion but both no occlusion (TIMI 2 or greater) and troponins not exceeding the cutoff above
~If positive troponin values present but no angiography, then the patient must have echocardiography showing no wall motion abnormality and troponin values less than the above cutoff
~If the patient has insufficient data to classify into one of these categories, the patient must be excluded from the study as they cannot be classified as ACO or non-ACO. For example, patients with extremely high troponin but no culprit seen on cath may have acute occlusion with complete autolysis of thrombus, myocarditis, spasm, etc. Thus the investigators cannot classify them as NO ACO when the possibility of ACO remains and cannot be disproven."
16416677|NCT03863314|Active Comparator|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
16416678|NCT03863314|Experimental|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
16416679|NCT03863301|Experimental|MR-guided single dose preoperative PBI|
16416680|NCT03863288|Placebo Comparator|Intranasal Spray Placebo|Nasal spray of placebo liquid solution as a single dose. fMRI scan pre and post administration.
16416681|NCT03863288|Active Comparator|Oxytrocin Intranasal Spray 8IU|Nasal spray of Oxytocin8IU liquid solution as a single dose. fMRI scan pre and post administration.
16416682|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 24IU|Nasal spray of Oxytocin 24IU liquid solution as a single dose. fMRI scan pre and post administration.
16416683|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 48IU|Nasal spray of Oxytocin 48IU liquid solution as a single dose. fMRI scan pre and post administration.
16416684|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 80IU|Nasal spray of Oxytocin 80U liquid solution as a single dose. fMRI scan pre and post administration.
16416685|NCT03863275|Other|No intervation|Children between the ages of 7 and 12 diagnosed with class II dental classification, who attend the Leonardo Da Vinci School after carrying out an intraoral and extraoral photography study and diagnostic impressions with study models accepting participation in the study, Children over the age of 12 who have an agreement according to the results of medical care. Patients with Pierre Robin syndrome or any form of cleft.
16416686|NCT03863275|Experimental|Myofunctional apparatus|Boys and girls between 7 and 12 years skeletal class II, for the study group the individuals will be selected from the UNICIEO postgraduate clinic of orthopedic clinic orthodontics after conducting a full clinical case study exposed to a board of specialist teachers in orthodontics, where by means of several diagnostic methods a skeletal class II is confirmed that involves a treatment with myofunctional apparatus SN1; patients presenting syndromes that generate craniofacial alterations, patients with previous orthopedic treatment, patients with signs of condyle lesions, patients with Pierre Robin syndrome or any form of slit will be excluded.
16416687|NCT03863249|Active Comparator|The exCELLigence system|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.
~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.
~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.
~The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit."
16416688|NCT03863249|Active Comparator|Origen|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.
~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.
~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.
~The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit."
16416689|NCT03863249|Active Comparator|Echevarne|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.
~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.
~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.
~The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit."
16416690|NCT03863236|Active Comparator|regular diet|The control group (group 1) will continue their regular diet.
16416691|NCT03863236|Active Comparator|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support two weeks before the operation and the nutritional support will continue 10 days after the operation.
16416694|NCT03863210|Experimental|Participants who received informations about lifestyle change|
16416695|NCT03863197|Experimental|Intervention group|During a 12-week period children receive 3-4 sessions of progressive strength training per week on top of the usual care. All children will be provided with an individualized training program and supporting equipment. One or 2 session per week will be performed under supervision of the physical therapist, whilst the remaining sessions will be performed at home. Progression is closely monitored by the principal investigator and training programs are adjusted if necessary.
16416696|NCT03863197|No Intervention|Waitlist-control group|The waitlist-control group will continue their usual care without additional treatment for 12-weeks, followed by a 12-week period of progressive supervised home-based strength training.
16416697|NCT03863184|Experimental|ALR in Combination|Acalabrutinib, lenalidomide, and rituximab in combination
16416698|NCT03863171||Ocular ischemia syndrome|Patients with ocular ischemia syndrome
16416699|NCT03863171||Control|Patients with age-related macular degeneration
16416700|NCT03863145|Experimental|1|Part 1 (Dose Escalation): 100 mg daily.
16416701|NCT03863132|Active Comparator|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
16416702|NCT03863132|No Intervention|Medical Treatment Group|Patients will receive optimal medical treatment alone.
16416703|NCT03863093|Experimental|An erythritol powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
16416704|NCT03863093|Active Comparator|ultrasonic instrumentation|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
16416705|NCT03863080|Experimental|Regimen A|RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
16416706|NCT03863080|Experimental|Regimen B|RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
16416707|NCT03863080|Placebo Comparator|Placebo|Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
16416709|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
16416710|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
16416711|NCT03863041|Other|Additional MRI SCAN sequence|Additional sequence performed during MRI scan
16416712|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
16416713|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
16416714|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
16416715|NCT03863015|Active Comparator|Tocilizumab|A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
16416716|NCT03863015|Placebo Comparator|Isotonic saline|A one hour infusion of isotonic saline
16416717|NCT03863002|No Intervention|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).
16416718|NCT03863002|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
16416719|NCT03862976|Experimental|computerized cardiotocography|computerized cardiotocography
16416720|NCT03862976|Active Comparator|standard cardiotocography|standard cardiotocography non stresstest
16416721|NCT03862963|Active Comparator|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
16416722|NCT03862963|Experimental|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
16416723|NCT03862950|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
16416724|NCT03862950|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
16416725|NCT03862937|Experimental|Experimental|The experimental group will perform 12 weeks of strength training twice a week associated with whey protein supplementation.
16416726|NCT03862937|Placebo Comparator|Placebo|The placebo group will perform 12 weeks of strength training twice a week associated with maltodextrin supplementation.
16416727|NCT03862924|Experimental|Active condition|Participants in the active condition will be provided with the Standardized Research Electronic Cigarette (SREC) and will be encouraged to use the SREC whenever they would normally smoke a cigarette.
16416728|NCT03862924|No Intervention|Standard Condition|Participants in this condition will be asked to continue to smoke their usual brand of cigarettes.
16416821|NCT03862261|No Intervention|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
16416729|NCT03862911|Active Comparator|Standard of Care Treatment (Arm 1)|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
16416730|NCT03862911|Experimental|Stereotactic Arm (Arm 2)|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
16416731|NCT03862898|Experimental|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
16416732|NCT03862898|Active Comparator|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
16416733|NCT03862872|Experimental|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
16416734|NCT03862872|Active Comparator|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
16416735|NCT03862872|Placebo Comparator|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
16416736|NCT03862859|Active Comparator|Treatment with Warfarin|Warfarin with dosing targeting an international normalized ratio of 2-3.
16416737|NCT03862859|No Intervention|No treatment|No treatment
16416738|NCT03862846|Experimental|Group|REN001 Low Dose
16416739|NCT03862833|Experimental|experimental group|"Zoledronic acid and IL-2 Zoledronic acid: 4 mg
~Three IL2 levels will be tested:
~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion"
16416740|NCT03862833|No Intervention|control group|no experimental treatment
16416741|NCT03862807|Experimental|Patisiran|Participants will receive patisiran during the Treatment Period.
16416742|NCT03862794|Experimental|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
16416743|NCT03862794|Active Comparator|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
16416744|NCT03862794|Experimental|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
16416745|NCT03862794|Active Comparator|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
16416746|NCT03862794|Experimental|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
16416747|NCT03862794|No Intervention|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
16416748|NCT03862781|Other|Intra-corporeal|Right Hemicolectomy
16416749|NCT03862781|Other|Extra-corporeal|Right Hemicolectomy
16416750|NCT03862768|Experimental|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
16416751|NCT03862768|Active Comparator|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
16416752|NCT03862755|Experimental|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
16416753|NCT03862742||Patients admitted to the hospital|We will recruit patient volunteers from the Scripps Green Hospital and Scripps Memorial Hospital inpatient teaching services.
16416754|NCT03862729||Early minimally invasive surgery group|For patients in minimally invasive surgery group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
16416755|NCT03862729||conventional treatment group|Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
16416756|NCT03862716|Experimental|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
16416757|NCT03862716|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
16416758|NCT03862703|Experimental|Experimental group|PTSD Help intervention combined with care as usual.
16416759|NCT03862703|No Intervention|Control group|Care as usual.
16416760|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
16416761|NCT03862677||Patients with (suspicion of) primary EOC|
16416762|NCT03862677||Patients with recurrent EOC|
16416763|NCT03862651|Experimental|Cangrelor|Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period
16416764|NCT03862651|No Intervention|placebo|patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered
16416765|NCT03862638|Experimental|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
16416768|NCT03862612|Active Comparator|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
16416769|NCT03862612|Experimental|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
16416770|NCT03862599|Sham Comparator|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
16416771|NCT03862599|Active Comparator|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
16416772|NCT03862586|Experimental|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
16416773|NCT03862586|Placebo Comparator|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
16416774|NCT03862573|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during the dental procedure
16416775|NCT03862573|No Intervention|Control (Standard of Care)|Participants are distracted with Standard-of-Care by dentists and/or parents.
16416776|NCT03862560|Experimental|Experimental group|Female soccers that perform a strength training
16416777|NCT03862560|No Intervention|Control group|Female soccers that do not perform a strength training
16416778|NCT03862547|Experimental|Men with ED and diabetes|"A peripheral blood sample from the cubital vein
~A collection of peripheral blood from the routinary cubital vein for hormone dosage and metabolic evaluation
~An introverted cavernous infiltration of Prostaglandin E1 to achieve erection (Aprostadil);
~A blood sample from both the corpus cavernosum and the cubital vein, once the erection is achieved Baseline interaction of prostaglandin E1 on the concentration of NGF released in the medium and on the expression of its receptors Evaluation of NGF and Cytokine levels Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs"
16416779|NCT03862534|Experimental|CAF|After the restoration of the enamel patients were treated with a CAF
16416780|NCT03862534|Experimental|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
16416781|NCT03862521|Experimental|Low carbohydrate diet group|Low carb diet, carbohydrates make up 30-40% of total daily calories.
16416782|NCT03862521|Experimental|Very low carbohydrate diet|Very low carb diet, carbohydrates make up 20-29% of total daily calories.
16416783|NCT03862508|Experimental|Experimental|Five Plyometric exercises
16416784|NCT03862508|No Intervention|Control|Subjects included in the control group will not receive any intervention
16416785|NCT03862495|Experimental|Chlamydia Screening and Treatment|At the time of recruitment and prior to delivery, this group will have immediate testing for C. trachomatis and N. gonorrhoeae. Physicians will notify C. trachomatis positive results to pregnant women and suggest them and their spouses to get treated according to the national standard treatment plan for Chlamydia (Azithromycin 1g, single oral administration). Patients will be followed up to confirm cure of C. trachomatis in one month. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
16416786|NCT03862495|Experimental|Control|This group will have testing after delivery (immediately following childbirth) or in the event of an adverse pregnancy outcome for C. trachomatis and N. gonorrhoeae. In the event of a positive test, patients will be informed of the positive test results the same way as the intervention group. Specific treatment options will be the same as the intervention group. Physicians will ask patients to return to Nanhai Hospital one month after treatment for test of cure. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
16416787|NCT03862482|Active Comparator|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at one site
16416788|NCT03862482|Experimental|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Device placement: B (Brånemark® dental implant) placed at one site, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at two sites
16416789|NCT03862482|Experimental|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at one site, SC (Screw-Vent® dental implant) placed at two sites
16416790|NCT03862469|Other|Study Procedure (all participants)|"Diagnostic Phase (2 months): at-home urine hormone testing and completion of daily online surveys.
~Individualized Task (-6 to -2 days from the subsequent menstrual cycle)"
16416791|NCT03862456|Experimental|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
16416792|NCT03862456|Active Comparator|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
16416822|NCT03862261|Experimental|Intervention|Integrated pediatric TB services
16416823|NCT03862248|Experimental|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
16416793|NCT03862443|Experimental|Fixed Incentive|Eligible to earn a weekly payment during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will win $5; high adherence threshold (brushing twice per day for 14 days in a week) will win $10.
16416794|NCT03862443|Experimental|Drawing Incentive|Eligible to earn a weekly drawing entry with different winning probabilities during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
16416795|NCT03862443|No Intervention|Control - Delayed Incentive|No rewards during the first 2-months, but information on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app. After the Month 2 follow-up visit, may opt to participate in a delayed 2-month open label extension to earn the same monetary rewards the fixed incentive intervention group could earn Baseline through Month 2. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
16416796|NCT03862430|Experimental|NVX 108|NVX-108 infusion in conjunction with Radiation Treatment and temozolimide
16416797|NCT03862430|Placebo Comparator|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolimide
16416798|NCT03862417|Experimental|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
16416799|NCT03862417|No Intervention|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
16416800|NCT03862404|Placebo Comparator|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
16416801|NCT03862404|Experimental|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
16416802|NCT03862391|Active Comparator|Postsurgical Pain|pain is defined as unpleasant sensation that can range from mild, localized discomfort to agony.
16416803|NCT03862391|Active Comparator|Postanesthesia nausea and vomiting|nausea defined as feeling of sickness or discomfort in the stomach that may come with an urge to vomit.
16416804|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
16416805|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
16416806|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
16416807|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
16416808|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
16416809|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
16416810|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
16416811|NCT03862352||Coronary artery perforation (iatrogenic)|Any coronary artery perforation defined according to the Ellis criteria.
16416812|NCT03862326|Other|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
16416813|NCT03862326|Experimental|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
16416814|NCT03862326|Experimental|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
16416815|NCT03862313|Experimental|active-rtACS arm|Active rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
16416816|NCT03862313|Sham Comparator|sham-rtACS arm|Sham rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
16416817|NCT03862287|Active Comparator|Intrathecal Lidocaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
16416818|NCT03862287|Active Comparator|Intrathecal Bupivacaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
16416819|NCT03862274||CLN2 Natural History Control Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
16416820|NCT03862274||CLN2 Treatment Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
16416824|NCT03862248|Experimental|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
16416825|NCT03862248|Active Comparator|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
16416826|NCT03862235||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.
~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
16416827|NCT03862235||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.
~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
16416828|NCT03862235||Sedentary control|"This group were sedentary men without cardiovascular disease.
~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
16416829|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
16416830|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
16416831|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
16416832|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
16416833|NCT03862209|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
16416834|NCT03862209|No Intervention|Standard care|Health care settings and their providers randomised to the control condition receive usual care: participant will gain standard care; ambulatory care, day hospitals or hospital admission.
16416835|NCT03862196|Experimental|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
16416836|NCT03862196|No Intervention|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
16416837|NCT03862183||dyslipidemia in hypertension|
16416838|NCT03862183||hypertension|
16416839|NCT03862170|Active Comparator|Ciprofloxacin|Patients in this arm will receive Ciprofloxacin 400mg IV 120mn (prophylactic antibiotic) before their HDR brachytherapy
16416840|NCT03862170|Experimental|Cefazolin|Patients in this arm will receive Cefazolin 2000mg IV 60mn (prophylactic antibiotic) before their HDR brachytherapy
16416841|NCT03862170|No Intervention|No prophylactic antibiotics|Patients in this arm will not receive any prophylactic antibiotics before their HDR brachytherapy
16416842|NCT03862157|Experimental|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16416843|NCT03862144|Experimental|Netupitant/Palonosetron & Dexamethasone|"Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.
~Dexamethasone 12 mg will be added on day 1 only of each cycle."
16416844|NCT03862131|Experimental|MyoStrain® unblinded treatment arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk Group
~The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.
~Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.
~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
16416845|NCT03862131|Active Comparator|MyoStrain® blinded control arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk group
~The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care
~Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.
~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
16416846|NCT03862105|Experimental|Health App with Provider Monitoring/Care|30 patients enrolled by the study team will receive notifications through a mobile health app (Twistle) before and after surgery. Patient Reported Outcome data will be collected through patient responses in this app and timely clinician feedback will be provided to patients to prevent complications and readmission.
16416847|NCT03862092|Experimental|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
16416848|NCT03862079|Experimental|Arm I (TGD + FMT)|Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
16416849|NCT03862079|Experimental|Arm II (FMT)|Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
16416850|NCT03862079|Active Comparator|Arm III (standard therapy)|Patients receive standard of care.
16416851|NCT03862066||Received Nivolumab|
16416852|NCT03862066||Nivolumab Naive|
16416853|NCT03862053|Active Comparator|Manuka honey eyedrops|optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study
16416854|NCT03862053|Placebo Comparator|Normal saline 0.9% eyedrops|sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study
16416855|NCT03862040|Experimental|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
16416856|NCT03862027|Experimental|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed > 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
16416857|NCT03862014|Experimental|SDF only|SDF will be applied on molars with MIH
16416858|NCT03862014|Active Comparator|SDF+ARR|SDT+ARR will be applied on molars with MIH
16416859|NCT03862001|Experimental|LungCARE Group|The intervention group will receive the LungCARE intervention
16416860|NCT03862001|No Intervention|Comparison Group|The comparison group will receive usual care.
16416861|NCT03861988|Experimental|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
16416862|NCT03861988|Experimental|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
16416863|NCT03861988|Placebo Comparator|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
16416864|NCT03861975|Experimental|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
16416865|NCT03861949|No Intervention|Conventional|preoxygenation done with 100% oxygen in supine position
16416866|NCT03861949|Experimental|Positive-pressure|preoxygenation done with 5 cmH2O CPAP (continuous positive airway pressure) in supine position with 100% oxygen
16416867|NCT03861949|Experimental|Head-up|preoxygenation done in 25 degree head-up position with 5 cmH2O CPAP with 100% oxygen
16416868|NCT03861936|Experimental|BOTOX® 72U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 72 units (U) total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
16416869|NCT03861936|Experimental|BOTOX® 48U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
16416870|NCT03861936|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
16416871|NCT03861923|Experimental|Dry needling and exercise|
16416872|NCT03861923|Sham Comparator|Sham dry needling and exercise|
16416873|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
16416874|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
16416875|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
16416876|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
16416877|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
16416878|NCT03861897|Experimental|Intervention KRP-NI + KM|Realization of Non instrumental pleural chest physiotherapy and Mobilization physiotherapy sessions (KRP-NI)
16416879|NCT03861897|Active Comparator|Control KM|Realization of mobilization physiotherapy sessions (KM)
16416880|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
16416881|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
16416882|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
16416883|NCT03861871|Experimental|Fenfluramine Hydrochloride|
16416884|NCT03861858|Experimental|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, & Linehan, 2007; Rathus & Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
16416885|NCT03861845|Active Comparator|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
16416886|NCT03861845|Experimental|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
16416887|NCT03861845|Experimental|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education & training on how to use the pillbox.
16416888|NCT03861832|Experimental|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
16416889|NCT03861832|Placebo Comparator|Placebo|A placebo that looks the same and is in a similar bottle
16416977|NCT03861234|Experimental|BI 836880|Single Rising Dose part followed by a Multiple Rising Dose part
16416890|NCT03861819|Experimental|VIIT Intervention|This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.
16416891|NCT03861806|Experimental|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
16416892|NCT03861806|Sham Comparator|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
16416893|NCT03861793|Experimental|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
16416894|NCT03861793|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.
16416898|NCT03861767|Experimental|SPRY: Metformin LD-SC|"LD-SC (low-dose, short course)
~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416899|NCT03861767|Experimental|SPRY: Metformin LD-IC|"LD-IC (low-dose, intermediate course)
~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416900|NCT03861767|Experimental|SPRY: Metformin LD-LC|"LD-LC (low-dose, long course)
~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416901|NCT03861767|Experimental|SPRY: Metformin ID-SC|"ID-SC (intermediate-dose, short course)
~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416902|NCT03861767|Experimental|SPRY: Metformin ID-IC|"ID-IC (intermediate-dose, intermediate course)
~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416903|NCT03861767|Experimental|SPRY: Metformin ID-LC|"ID-LC (intermediate-dose, long course)
~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416904|NCT03861767|Experimental|SPRY: Metformin HD-SC|"HD-SC (high-dose, short course)
~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416905|NCT03861767|Experimental|SPRY: Metformin HD-IC|"HD-IC (high-dose, intermediate course)
~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416906|NCT03861767|Experimental|SPRY: Metformin HD-LC|"HD-LC (high-dose, long course)
~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
16416907|NCT03861767|Placebo Comparator|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
16416908|NCT03861754|Experimental|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
16416909|NCT03861754|Experimental|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:
~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
16416910|NCT03861754|Experimental|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:
~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
16416911|NCT03861754|No Intervention|Control Group|Control group, no intervention, only measurements and questionnaires
16416912|NCT03861741|Experimental|Participants|All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases. Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records. Data on imaging investigations will be obtained from TTE and MRI. Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci. Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
16416913|NCT03861728|Experimental|Viral Conjunctivitis Treatment|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with 0.01% Hypochlorous acid
16416914|NCT03861728|Placebo Comparator|Viral Conjunctivitis Placebo|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with Basic Sterile Saline
16416915|NCT03861715||Single Dose antagonist Degarelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.
16416916|NCT03861715||Multidose antagonist Ganirelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.
16416918|NCT03861689|Active Comparator|Tight control arm|Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
16416919|NCT03861689|No Intervention|Control arm|Patients in the control arm will have management according to physician own decision.
16416920|NCT03861676|Experimental|Focal brachytherapy|"Drug: 18F-DCFPyl Other names: PET, PSMA
~Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy"
16416921|NCT03861663|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
16416922|NCT03861650|Experimental|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
16416923|NCT03861650|Sham Comparator|Saline|Sham or placebo drug in the control group
16416924|NCT03861637|Active Comparator|drug : ESA for p correction of PTA|ESA (Aranesp or mir-CERA) injection 1 mg per kg sc every week for 1 year to correct PTA to level between 12-13g/dl.
16416925|NCT03861637|Active Comparator|ara or cera|ESA (Aranesp) 1mg/ kg (or equivalent doses) of MIR-CERA injection for 1 year to correct PTA to level between 13-15g/dl.
16416926|NCT03861624|Experimental|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
16416927|NCT03861624|Active Comparator|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
16416928|NCT03861611|Experimental|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
16416929|NCT03861611|Experimental|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
16416930|NCT03861611|Experimental|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
16416931|NCT03861598|Experimental|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
16416932|NCT03861585|Experimental|semantic group|"Half of the participants (named the semantic group) perform a semantic categorisation task."
16416933|NCT03861585|Experimental|emotional group|"Half of the participants (named the emotional group) perform an emotional evaluation task."
16416934|NCT03861572|Experimental|Isokinetic eccentric group|The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
16416935|NCT03861572|Active Comparator|Traditional eccentric training|Participants will be engaged in an intervention program consisting of 12 weeks of traditional eccentric training. The training will be carried out with the volunteers at gym in stand position. Concentric phase will be realized with both legs and the eccentric one only with one of them. Training progression will be the same from de isokinetic eccentric group. The same periodization from eccentric group will be used to permit us a posteriori comparison between groups. Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions. Each training session will comprise the same specific warming protocol for the ankle joint from the eccentric training.
16416936|NCT03861559|Experimental|mometasone furoate nasal spray|Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
16416937|NCT03861559|Placebo Comparator|placebo nasal spray|Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.
16416938|NCT03861546|Experimental|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
16416939|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
16416940|NCT03861507|Other|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
16416941|NCT03861494|Other|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
16416942|NCT03861494|Other|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
16416943|NCT03861481|Experimental|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
16416944|NCT03861481|Placebo Comparator|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
16416945|NCT03861468|No Intervention|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
16416946|NCT03861468|Active Comparator|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
16416947|NCT03861455|Experimental|dupilumab group|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
16416948|NCT03861455|Placebo Comparator|placebo group|patient receive placebo
16416949|NCT03861429|Experimental|Me & My Wishes Intervention/Group 1|In Group 1 (early intervention group) NHs, video recording, editing, and viewing will occur within three months of baseline.
16416950|NCT03861429|Other|Me & My Wishes Wait-list control/Group 2|In Group 2 (delayed sharing) NHs, residents will be on a wait-list; after the delayed start, their video will be produced and viewed within three months.
16416951|NCT03861416|Experimental|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
16416952|NCT03861416|Experimental|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
16416953|NCT03861416|Placebo Comparator|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
16416954|NCT03861403|Experimental|All Solid Tumors|"Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle
~Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle"
16416955|NCT03861403|Experimental|Advanced Triple Negative Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
16416956|NCT03861403|Experimental|Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
16416957|NCT03861403|Experimental|Advanced Metastatic Castration-Resistant Prostate Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
16416958|NCT03861403|Experimental|Advanced Platinum-Resistant Ovarian Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
16416959|NCT03861390|Active Comparator|Prednisone, then Placebo|
16416960|NCT03861390|Placebo Comparator|Placebo, then Prednisone|
16416961|NCT03861377|Active Comparator|Remifentanil R2|Low dose Remifentanil induction dose (R2)
16416962|NCT03861377|Active Comparator|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
16416963|NCT03861377|Active Comparator|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
16416964|NCT03861364|Active Comparator|High Propofol|High Propofol induction dose
16416965|NCT03861364|Active Comparator|Low Propofol|Low Propofol induction dose
16416966|NCT03861351|Experimental|Mini WELL Toric Ready intraocular lens|
16416967|NCT03861338|Experimental|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
16416968|NCT03861312|Experimental|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
16416969|NCT03861312|Experimental|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
16416970|NCT03861299|Experimental|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
16416971|NCT03861299|Active Comparator|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
16416972|NCT03861273|Experimental|PF-06838435/ fidanacogene elaparvovec|
16416973|NCT03861260|Other|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
16416974|NCT03861260|Other|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
16416975|NCT03861247|Active Comparator|Control group|
16416976|NCT03861247|Experimental|Intervention group|
16416979|NCT03861208|Experimental|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
16416980|NCT03861208|Other|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
16416981|NCT03861195||Da Vinci Robotic Surgical System|
16416982|NCT03861195||conventional laparoscopic surgery|
16416983|NCT03861182|Other|Adult Healthy Volunteers|
16416984|NCT03861182|Other|Neonates|
16416985|NCT03861169|Experimental|Viscoeleastic delivery & trabeculotomy|Patients with open angle glaucoma and cataract
16416986|NCT03861156|Experimental|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
16416987|NCT03861143|Experimental|BT-11 low-dose (500 mg)|Oral
16416988|NCT03861143|Experimental|BT-11 high-dose (1,000 mg)|Oral
16416989|NCT03861143|Placebo Comparator|Placebo|Oral
16416990|NCT03861130||Kawasaki disease|Kawasaki disease affected childrens
16416993|NCT03861104|Active Comparator|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.
~intervention is watching informative video."
16416994|NCT03861104|No Intervention|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
16416995|NCT03861091|Experimental|Risedronate|Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
16416996|NCT03861091|Placebo Comparator|Matching Placebo|Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
16416997|NCT03861078|Active Comparator|Own brand cigarette use|During each session, participants will complete a 10-puff, directed product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
16416998|NCT03861078|Experimental|ECIG 15 mg nicotine, sweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
16416999|NCT03861078|Experimental|ECIG 15 mg nicotine, unsweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
16417000|NCT03861078|Experimental|ECIG 0 mg nicotine, sweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
16417001|NCT03861078|Experimental|ECIG 0 mg nicotine, unsweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
16417002|NCT03861065|Experimental|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
16417003|NCT03861065|Active Comparator|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
16417004|NCT03861052|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16417005|NCT03861052|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16417006|NCT03861052|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16417007|NCT03861052|Active Comparator|0.75 mg Dulaglutide|0.75 mg dulaglutide administered SC once a week.
16417008|NCT03861039|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16417009|NCT03861039|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16417010|NCT03861039|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16417011|NCT03861026|Experimental|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.
~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
16417012|NCT03861026|No Intervention|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.
~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
16417013|NCT03861013|Experimental|Intervention group|Participation in a multidimensional stress prevention program (GeDStress).
16417014|NCT03861013|No Intervention|Wait-list control group|Participants on the wait-list control group will not receive any treatment between the baseline and last follow-up. After the study has ended, they have the option to participate in the program.
16417015|NCT03861000|Experimental|Whole body PET Scan with intravenous 11C-T-1650|10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.
16417016|NCT03861000|Experimental|Brain PET scan with 11C-T-1650 and blocking with BPN14770|Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.
16417017|NCT03860987|Experimental|1|Treatment
16417018|NCT03860974|Experimental|Serratus Plane (single injection)|A single injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL on each side for bilateral surgery)
16417019|NCT03860974|Active Comparator|Paravertebral (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery)
16417020|NCT03860961|Active Comparator|Standard Survivorship Care Plan (SCP)|Practices review a SCP with patients and send it to the PCP during the last week of RT.
16417021|NCT03860961|Experimental|Enhanced Survivorship Care Plan (SCP)|Practices review a treatment plan with patient and send it to the PCP at the beginning of RT. Practices also review a SCP with patients and send it to the PCP during the last week of RT.
16417022|NCT03860948|Experimental|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
16417023|NCT03860948|Experimental|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
16417024|NCT03860935|Experimental|acoramidis 800 mg|Subjects will receive acoramidis 800 mg twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The frequencies of deaths, cardiovascular-related hospitalizations, and change in distance walked on the 6MWT will be assessed after 30 months of treatment.
16417025|NCT03860935|Placebo Comparator|Placebo|Subjects will receive placebo to match twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The frequencies of deaths, cardiovascular-related hospitalizations, and change in distance walked on the 6MWT will be assessed after 30 months of treatment.
16417026|NCT03860896|Experimental|GB004|GB004 for oral administration daily
16417027|NCT03860896|Placebo Comparator|Placebo|Placebo for oral administration daily
16417028|NCT03860883|Experimental|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
16417029|NCT03860883|Active Comparator|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
16417030|NCT03860870|Experimental|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
16417031|NCT03860870|Placebo Comparator|Placebo|Subjects ingest placebo tablets
16417032|NCT03860857|Experimental|Age 60-65 ApoE e4+|Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417033|NCT03860857|Experimental|Age 66-70 ApoE e4-|Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417034|NCT03860857|Experimental|Age 66-70 ApoE e4+|Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417035|NCT03860857|Experimental|Age 71-75 ApoE e4-|Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417036|NCT03860857|Experimental|Age 71-75 ApoE e4+|Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417037|NCT03860857|Experimental|Age 76-80 ApoE e4-|Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417038|NCT03860857|Experimental|Age 76-80 ApoE e4+|Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417039|NCT03860857|Experimental|Age 81-85 ApoE e4-|Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417040|NCT03860857|Experimental|Age 81-85 ApoE e4+|Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
16417041|NCT03860844|Experimental|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
16417042|NCT03860831|Experimental|intranasal (IN)|"Group IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg).
~the calculated dose will be equally divided into the two nostrils by the parents"
16417043|NCT03860831|Active Comparator|intramuscular (IM)|"Group IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
~Mild to moderate restraint was done with the help of the parents during drug administration."
16417044|NCT03860818|No Intervention|Control Arm|Usual Care
16417045|NCT03860818|Experimental|Intervention Arm|Technology-enabled pharmacist intervention
16417046|NCT03860805|Active Comparator|Laparoscopic tubal ligation|Patients who seek for surgical permanent contraception and randomized to laparoscopic tubal ligation
16417047|NCT03860805|Active Comparator|Laparoscopic bilateral salpingectomy|Patients who seek for surgical permanent contraception and randomized to laparoscopic bilateral salpingectomy
16417048|NCT03860792|Experimental|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
16417100|NCT03860441|Experimental|Intervention group|Participants in the intervention group received 24 sessions of computerized cognitive training, with a total time of 960 min.
16468055|NCT03511846|Experimental|Cold water irrigation and High Flow Oxygen|
16417049|NCT03860792|Active Comparator|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy. Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
16417050|NCT03860766|Sham Comparator|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
16417051|NCT03860766|Experimental|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
16417052|NCT03860766|Experimental|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
16417053|NCT03860766|Experimental|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
16417054|NCT03860753|Experimental|Pioglitazone|
16417055|NCT03860753|Placebo Comparator|Placebo|
16417056|NCT03860740||High intensity physical exercise|Supervised Exercise Group: Customized and supervised exercise high intensity training program during 2-3 weeks previous surgery.
16417057|NCT03860740||Control|Supervised Stretching Group: a stretching and body balance classes will be developed to control the possible confounders and to control the exercise level of participants.
16417058|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
16417059|NCT03860688|Experimental|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
16417060|NCT03860675|Active Comparator|persons with Multiple Sclerosis (MS)|
16417061|NCT03860675|Placebo Comparator|Healthy controls|
16417062|NCT03860662|Active Comparator|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
16417063|NCT03860662|Other|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
16417064|NCT03860649|Experimental|Nordic Walking|The patient walk program consists of 3 moments: warm up, walk and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.
16417065|NCT03860649|Experimental|Jogging|This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.
16417066|NCT03860649|Experimental|Dance|This group will undergo 24 Dance sessions inspired by Forró dance rhythm and Samba dance rhythm. Classes will be divided into four stages: Joint warm up and stretching on the chairs; strengthening, balance and rhythm exercises with the support of the barre; exercises inspired by the Samba and Forró dance (Brazilian ballroom dance) basic steps; and Final cool down. The intensity of the classes will be measured according to the beats per minute (BPMs) of the songs used in each moment and by the Borg Scale of Perceived Exertion.
16417067|NCT03860649|Experimental|Pilates Training|"Classes composed of three phases: Warming up, main part and back to calm. Warming up will begin with pre-Pilates training exercises for 5 minutes (eg. breathing exercises, hip joint mobilization, shoulder girdle, etc.), the main part of the lesson will be the Pilates training drill sequence for the beginner level that will be conducted for 50 minutes in which all exercises will be performed on the floor.
~The sequence of the eighteen exercises of the main part of the lesson is described in the table below. Back to Calm: will be carried out for 5 final minutes with standing exercises with the subject reclining on the wall to reconnect the subject with orthostatic posture.
~In the each of the phases of the lesson will be shown to the subject the table of BORG with the objective of measuring the intensity of perceived exertion, using the Borg Scale of Perceived Exertion."
16417068|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.
~The day they receive their HCG trigger,
~The day of transvaginal oocyte retrieval (TVOR) and
~The day of embryo transfer (ET)."
16417069|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.
~The day we coordinate with embryologist (day of progesterone +/-1)
~The day of embryo transfer (ET)."
16417070|NCT03860623||Overweight|Otherwise healthy overweight and obese men (BMI 30-40kg/m2) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
16417071|NCT03860623||Normal Weight|Healthy normal weight men (BMI 18-25kg/m2, but including those with BMI up to 28kg/m2 if waist circumference <96cm) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
16417072|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
16417073|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
16417074|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
16417075|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
16417076|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
16417077|NCT03860597|Active Comparator|Memantine|
16417078|NCT03860597|Placebo Comparator|Placebo|
16417079|NCT03860584|Experimental|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.
16417080|NCT03860584|Placebo Comparator|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
16417081|NCT03860571|Placebo Comparator|Placebo|
16417082|NCT03860571|Experimental|BT-11|
16417083|NCT03860558|Experimental|Lifestyle Intervention|20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.
16417084|NCT03860558|Active Comparator|No-Intervention Controls|10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
16417085|NCT03860558|Active Comparator|Healthy Controls|10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
16417086|NCT03860545||non-AKI|patient without acute kidney injury (AKI) during perioperative observation period
16417087|NCT03860545||AKI|patient with diagnosis acute kidney injury (AKI) established during perioperative observation period
16417088|NCT03860532|Active Comparator|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
16417089|NCT03860532|Active Comparator|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
16417090|NCT03860519|Experimental|Intervention Group|"The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has poor adherence ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR at risk alerts if a patient transitions to a not well controlled or poorly controlled status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard)."
16417091|NCT03860519|Experimental|Control Group|The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
16417092|NCT03860506|Experimental|PSI-697|
16417093|NCT03860506|Placebo Comparator|Placebo|
16417094|NCT03860493||Study group|Only patients who might benefit from intraoperative fluorescent tissue perfusion assessment according to the primary surgeon will be enrolled in the study. The patients will be screened and consent during their office visit with their surgeon at the Cleveland Clinic Foundation. Each surgeon will follow the standard Open surgical protocol of his/her subspecialty, and will comply with the following additional steps according to the type of surgery:
16417095|NCT03860480|Active Comparator|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.
~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.
~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
16417096|NCT03860480|Sham Comparator|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.
~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.
~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
16417097|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
16417098|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
16417099|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
16469092|NCT03504839|Other|Intervention|S-ICD implantation.
16417101|NCT03860441|Active Comparator|Active control group|Participants in the control group attended activities separate activities, such as learning about healthy lifestyle, had cooking and other social lessons for the same amount as the intervention group performed cognitive training.
16417102|NCT03860428|Active Comparator|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
16417103|NCT03860428|Active Comparator|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
16417104|NCT03860428|Sham Comparator|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
16417105|NCT03860415|Experimental|Probiotic|Vivomixx
16417106|NCT03860415|Placebo Comparator|Placebo|
16417107|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
16417108|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
16417109|NCT03860389|Experimental|Exercise effects on anxiety|An exercise programme will be administered 3 times a week for up to an 16 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will involve aspects of fundamental movement skills and will be fun for the students to participate in.
16417110|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
16417111|NCT03860363||Treatment Group|Patients selected to participate.
16417112|NCT03860350|Active Comparator|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
16417113|NCT03860350|Placebo Comparator|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
16417114|NCT03860337|Experimental|Alginate then Control|This group will be given the alginate then the control sausages
16417115|NCT03860337|Experimental|Control then Alginate|This group will be given the control then alginate sausages
16417116|NCT03860324|No Intervention|Control-group|No peripheral nerve block
16417117|NCT03860324|Experimental|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
16417118|NCT03860324|Active Comparator|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
16417119|NCT03860311|Experimental|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
16417120|NCT03860311|Active Comparator|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
16417121|NCT03860298|Experimental|NaviFUS System|FUS treatment for 10 minutes
16417122|NCT03860272|Experimental|3-Week Monotherapy|Experimental: Open Label 3+3 Dose escalation of AGEN1181, every 3 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg administered by IV.
16417123|NCT03860272|Experimental|6-Week Monotherapy|3+3 Dose escalation of AGEN1181, every 6 weeks, starting at dose level 1 mg/kg up to 4 mg/kg administered by IV.
16417124|NCT03860272|Experimental|6-Week Combination Therapy|3+3 Dose escalation of AGEN2034, every 3 weeks, at dose level 3 mg/kg in combination with AGEN1181, every 6 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg administered by IV.
16417125|NCT03860259|Placebo Comparator|Control|Auriculotherapy will be performed by PI using a cryopuncture device in the pre-operative setting with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
16417126|NCT03860259|Active Comparator|Intervention|Auriculotherapy will be performed by PI using a cryopuncture device in the pre-operative setting with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
16417127|NCT03860233|Experimental|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
16417128|NCT03860233|Experimental|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
16417129|NCT03860220|Active Comparator|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
16417130|NCT03860220|Placebo Comparator|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
16417131|NCT03860207|Experimental|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
16417173|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose B|Resected participants are administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
16417210|NCT03859570|Experimental|Pentoxifylline|Pentoxifylline and standard of care therapy
16417132|NCT03860194|Experimental|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.
~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
16417133|NCT03860194|No Intervention|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.
~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
16417134|NCT03860181|Active Comparator|Traditional Dermabond + subcuticular sutures - Surgeon 1|Subcuticular sutures with traditional Dermabond applied to incision.
16417135|NCT03860181|Active Comparator|Metal staples - Surgeon 2|Metal staples
16417136|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 1|Dermabond PRINEO System
16417137|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 2|Dermabond PRINEO System
16417138|NCT03860168|Other|PICU Up! pre- and post-implementation|Each unit will begin in the baseline, usual care phase and then be randomized to implement the PICU Up! program during a set time period, followed by the post-implementation phase.
16417139|NCT03860155|Experimental|allo-APZ2-ACLF|Application of IMP into peripheral vein (arm) by use of a perfusor.
16417140|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
16417141|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
16417142|NCT03860129|Other|ISO|Drug name: Isoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (0.5 Vol%)
16417143|NCT03860129|Other|SEVO|Drug name: Sevoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (1.0 Vol%)
16417144|NCT03860129|Other|DES|Drug name: Desflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (3.0 Vol%)
16417145|NCT03860116|Experimental|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
16417146|NCT03860116|Active Comparator|control group|participants in the control arm receive standard-of-care followup service
16417147|NCT03860090|Active Comparator|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
16417148|NCT03860090|Active Comparator|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
16417149|NCT03860077|Experimental|Very Low Nicotine Content Cigarettes|
16417150|NCT03860077|Active Comparator|Normal Nicotine Content Cigarettes|
16417152|NCT03860025||Single dislocation.|Patients with a single postoperative hip dislocation without subsequent revision surgery.
16417153|NCT03860025||Recurrent dislocation.|Patients with two or more postoperative hip dislocations without subsequent revision surgery.
16417154|NCT03860025||Revision due to dislocation.|Patients with one or more postoperative hip dislocations with subsequent revision surgery due to recurrent instability.
16417155|NCT03860025||Controls.|Matched patients without postoperative hip dislocation or revision of any reason.
16417156|NCT03860012|Experimental|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
16417157|NCT03859986|Experimental|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
16417158|NCT03859986|Placebo Comparator|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
16417161|NCT03859947||Patients with acute bronchiolitis|
16417162|NCT03859934|Active Comparator|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
16417163|NCT03859934|Placebo Comparator|Placebo|Placebo each day 1 hour before bedtime for 3 months
16417164|NCT03859921|Experimental|Dydrogesterone group|Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.
16417165|NCT03859921|Placebo Comparator|Placebo group|Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.
16417166|NCT03859908|Experimental|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
16417167|NCT03859908|Active Comparator|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
16417168|NCT03859895||Observational (without bone scan)|Former Observational Arm participants of the ZiPP trial.
16417169|NCT03859895||Observational (with bone scan)|Former Interventional Arm participants of the ZiPP trial.
16417170|NCT03859882|Experimental|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
16417171|NCT03859882|Placebo Comparator|placebo|in 2 administration (08:00 and 14:00) per day
16417172|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose A|Resected participants are administered with Pancrelipase dose A. At week 1,5, or 9, participants who meet dose modification criteria will be administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
16417174|NCT03859869|Experimental|Non-Resected Participants Receiving Pancrelipase Dose B|Non-resected participants are administered with Pancrelipase dose B.
16417175|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
16417176|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
16417177|NCT03859843|Active Comparator|PRP|
16417178|NCT03859843|Active Comparator|Chemical peeling (Salycilic acid)|
16417179|NCT03859843|Active Comparator|Chemical peeling (Jessenr's solution)|
16417180|NCT03859830|Experimental|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
16417181|NCT03859830|Active Comparator|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
16417182|NCT03859817||Patients with albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
16417183|NCT03859817||patients with normo albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
16417184|NCT03859804|Experimental|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
16417185|NCT03859804|Active Comparator|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
16417186|NCT03859778||pharmacy students|
16417187|NCT03859765|Experimental|HCT Symptoms and Steps|HCT Symptoms and Steps participants will complete in-person (3) and video-conferencing (4) coping skills training and activity coaching sessions teaching cognitive behavioral coping skills to manage pain, fatigue, and distress and increase activity. Participants will be given a wireless activity tracker and a smartphone for accessing the study mobile app.
16417188|NCT03859765|No Intervention|HCT Education|HCT Education participants will receive 1 brief in clinic session prior to discharge home providing education related to symptom management and physical activity, and a wireless activity tracker. HCT Education participants will also receive 6 brief phone calls upon return home.
16417189|NCT03859752|Experimental|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
16417190|NCT03859739|Experimental|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.
16417191|NCT03859739|Experimental|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
16417192|NCT03859739|Experimental|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
16417193|NCT03859739|Experimental|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
16417194|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
16417195|NCT03859726||Non compliance group|6hLC<10%
16417196|NCT03859713|Experimental|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
16417197|NCT03859713|Experimental|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
16417198|NCT03859713|Experimental|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
16417199|NCT03859713|Experimental|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
16417200|NCT03859700|Experimental|DBV712 250mcg|
16417201|NCT03859687|Experimental|Intervention group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) plus a liquid oral vitamin A supplementation
16417202|NCT03859687|Experimental|Control group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) only, 'No vitamin A supplementation'
16417203|NCT03859648|Experimental|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
16417204|NCT03859635|Active Comparator|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
16417205|NCT03859635|Active Comparator|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
16417206|NCT03859635|Active Comparator|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
16417207|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
16417208|NCT03859583|Experimental|Capsaicin|4 tsp of cayenne pepper in a 60g omelette
16417211|NCT03859570|Placebo Comparator|Placebo|Placebo and standard of care therapy
16417212|NCT03859557||4-Quadrant Random Forceps Biopsy|Random sampling within a quadrant of esophageal tissue using forceps.
16417213|NCT03859557||WATS biopsies|Wide area transepithelial sampling with computer aided pathologic interpretation of tissue.
16417214|NCT03859531||CF patients planned to receive Orkambi|CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
16417215|NCT03859518||patients with Vitiligo|
16417216|NCT03859518||control|
16417217|NCT03859505|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
16417218|NCT03859505|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) active.
16417219|NCT03859492||Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
16417220|NCT03859479|Experimental|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
16417221|NCT03859479|Active Comparator|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
16417222|NCT03859466|Experimental|Intervention Arm|For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information: This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
16417223|NCT03859466|No Intervention|Control Arm|For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
16417224|NCT03859440|Experimental|DSiHy (test lens)|
16417225|NCT03859440|Active Comparator|Silicone hydrogel soft contact lens CE-marked for daily use|
16417232|NCT03859401|Experimental|Control - Experimental Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
16417233|NCT03859401|Experimental|Experimental - Control Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Experimental-Control Arm will undergo the Experimental Admission first, utilizing an artificial pancreas (AP) controller that has the ability to anticipate exercise (EnMPC), followed by the Control Admission, which will utilize an AP controller that does not have the ability to anticipate exercise (rMPC). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
16417234|NCT03859388||Chronic ABMR|Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
16417235|NCT03859375||2 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint two of a predefined area of the skin.
16417236|NCT03859375||3 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint three of a predefined area of the skin.
16417303|NCT03859102|No Intervention|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
16417237|NCT03859362|Experimental|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
16417238|NCT03859349|Active Comparator|Systematic Sampling|Patients will undergo systematic sampling of lymph node stations in the mediastinum with a minimum sampling of 3 stations: 4R, 4L and 7, as is the standard of care. Other stations may be included at the endoscopist's discretion. CLNS is not used for this arm.
16417239|NCT03859349|Experimental|Selective Targeted Sampling|"Patients will first undergo endosonographic assessment of 3 mediastinal lymph node stations (i.e. 4R, 4L, and 7) using the four criteria of the CLNS. Lymph node stations that exhibit a CLNS >1/4 will be biopsied as is standard of care. Lymph node stations with CLNS ≤ 1/4 will be marked as not requiring biopsy but will be biopsied nevertheless, so that there is no deviation from the standard of care. Other stations may be included at the endoscopist's discretion."
16417240|NCT03859336|Experimental|Transdermal Neuromodulation Stimulation|"Day 1 of Transdermal Neuromodulation Stimulation (TENS) is a one-day sham stimulation, consisting of: 30 seconds of sensation in which amplitude is increased up to the threshold of salient sensation, followed by 19 minutes of no stimulation (device is turned off), followed by 30 more seconds of salient stimulation. Day 1 is used to exclude those who cannot tolerate study procedures and placebo responders; it will also serve as baseline for anxiety measures. TENS treatment begins one day after sham, and lasts 3 days with 20 minutes of stimulation per day. One day following open label treatment all participants will once again receive sham stimulation following the same procedures utilized at Day 1.
~Treatment amplitude is adjusted for each participant, in which the stimulation will be administered just below the participant's sensation threshold. Amplitude from the TENS device does not exceed 20mA. Frequency will be at 300hz."
16417241|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
16417242|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
16417243|NCT03859323|Experimental|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
16417244|NCT03859323|Experimental|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
16417245|NCT03859323|Experimental|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
16417246|NCT03859323|Placebo Comparator|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
16417247|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
16417248|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
16417249|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
16417250|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
16417251|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
16417252|NCT03859323|Placebo Comparator|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
16417253|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
16417254|NCT03859310||Glaucoma|diagnosis of glaucoma
16417255|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
16417256|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
16417257|NCT03859297|Experimental|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
16417258|NCT03859297|No Intervention|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
16417259|NCT03859297|Active Comparator|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
16417260|NCT03859284|Active Comparator|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.
~other names: ''flowable composite ''"
16417261|NCT03859284|Experimental|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
16417262|NCT03859284|Experimental|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
16417263|NCT03859271|Experimental|brief motivational interviewing|Participants will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
16417264|NCT03859271|Placebo Comparator|Placebo Control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
16417267|NCT03859245|Experimental|Experimental group|Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
16417268|NCT03859245|Active Comparator|Control group|Subjects in the control group will follow current dietary protocol (Standard American Diet- SAD). Photobiomodulation therapy,via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
16417269|NCT03859232|Experimental|Delta Dry® Pantaloon Group|
16417270|NCT03859232|Active Comparator|Cotton Padding Group|
16417271|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417272|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417273|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417274|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417275|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417276|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417277|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417278|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
16417279|NCT03859219|Placebo Comparator|Placebo in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
16417280|NCT03859219|Placebo Comparator|Placebo in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
16417281|NCT03859219|Placebo Comparator|Placebo in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
16417282|NCT03859206|Experimental|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :
~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.
~the intervention : is breaking the septation within the loculated empyema"
16417283|NCT03859206|No Intervention|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
16417284|NCT03859193|No Intervention|Standard care|
16417285|NCT03859193|Experimental|Video|Participants will watch an Nutritional video at their second high risk visit
16417286|NCT03859180|Experimental|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
16417287|NCT03859180|No Intervention|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
16417288|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
16417289|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
16417290|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.
~AND consenting to be part of the study"
16417291|NCT03859141|Experimental|Experimental group-phase Ⅰ|Quadrivalent influenza vaccine
16417292|NCT03859141|Experimental|Experimental group-phase Ⅲ|Quadrivalent influenza vaccine
16417293|NCT03859141|Active Comparator|Control group 1-phase Ⅲ|Trivalent influenza vaccine (contains B/Victoria strain)
16417294|NCT03859141|Active Comparator|Control group 2-phase Ⅲ|Trivalent influenza vaccine (contains B/Yamagata strain)
16417295|NCT03859128|Active Comparator|Group A|TORIPALIMAB 240mg ,Q3W, up to 16 Weeks
16417296|NCT03859128|Placebo Comparator|Group B|Placebo 240mg Q3W, up to 16 Weeks
16417297|NCT03859115|Active Comparator|preanesthesia-TENS|Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.
16417298|NCT03859115|Sham Comparator|preanesthesia-sham|Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.
16417299|NCT03859115|Experimental|sevoflurane-TENS|Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.
16417300|NCT03859115|Active Comparator|sevoflurane-sham|Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.
16417301|NCT03859115|Experimental|propofol-TENS|Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.
16417302|NCT03859115|Active Comparator|propofol-sham|Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.
16469883|NCT03499392|Other|psychological investigation|
16417304|NCT03859102|Experimental|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.
~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.
~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
16417305|NCT03859076|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
16417306|NCT03859076|Active Comparator|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
16417307|NCT03859063|Experimental|Intervention|Regular follow up by a community based stroke coordinator
16417308|NCT03859063|Active Comparator|Control|Usual care
16417309|NCT03859050|Experimental|LPS arm|
16417310|NCT03859037|Experimental|Umbilical cord milking|One group will have umbilical cord milking and will ba assessed for blood pressure,oxygen saturation and heart rate by monitor
16417311|NCT03859037|Placebo Comparator|Immediate cord clamping|One group will have immediate cord clamping and will be assessed for bloob pressure,heart rate,oxygen saturation by monitor
16417312|NCT03859024|Active Comparator|Standard Protocol|Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
16417313|NCT03859024|Experimental|Enhanced Recovery Protocol|A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
16417314|NCT03859011|Experimental|Acupuncture|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
16417315|NCT03859011|Placebo Comparator|"Usual care"|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments) for 6 months. Questionnaires will be readministered at 2.5 and 6 months. After the control phase the participants will continue usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks, 8.5 months), then no acupuncture between 8.5 months and 12 months.
16417316|NCT03858998|Experimental|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
16417317|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
16417318|NCT03858985|Active Comparator|Transcutaneous Vagus Nerve Stimulation|Cervical Transcutaneous vagus nerve stimulation. Participants will undergo once daily cervical transcutaneous vagus nerve stimulation.
16417319|NCT03858985|Sham Comparator|Sham Vagus Nerve Stimulation|Sham Cervical Transcutaneous Vagus Nerve Stimulation. Participants will undergo once daily sham cervical transcutaneous vagus nerve stimulation.
16417320|NCT03858972|Experimental|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.
~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
16417321|NCT03858959|Experimental|HYBENX® Oral Tissue decontaminantTM (HBX)|HYBENX® Oral Tissue decontaminantTM is a concentrated aqueous solution of sulfonated aromatics and free sulphates. Once placed onto susceptible organic material, the product instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution by virtue of its porous structure and high water content.
16417322|NCT03858959|Active Comparator|Chlorhexidine Digluconate CorsodylTM (CHX)|Chlorhexidine Digluconate CorsodylTM Dental Gel 1% is an antiseptic gel with cationic nature, effective against a wide range of Gram positive and negative bacteria, favourable to the plaque control and oral inflammation prevention.
16417323|NCT03858946|Sham Comparator|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
16417324|NCT03858946|Experimental|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
16417325|NCT03858933|Experimental|Limbic Modulation Index Neurofeedback|"This arm of the study will undergo a novel neurofeedback treatment, targeting downregulation of deep limbic structures, specifically the amygdalae.
~Participants in this arm will complete 15 neurofeedback sessions."
16417326|NCT03858933|Active Comparator|Alpha/Theta Neurofeedback|"This arm of the study will undergo a proven PTSD neurofeedback treatment, alpha/theta regulation, during which participants will try various mental strategies to increase the presence of theta waves.
~Participants in this arm will complete 15 neurofeedback sessions."
16417327|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
16417328|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
16417329|NCT03858894|Experimental|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
16417330|NCT03858894|Experimental|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
16417331|NCT03858881|Active Comparator|PROJECT PERSONALITY|
16417332|NCT03858881|Experimental|VR PERSONALITY PROJECT|
16417333|NCT03858881|Placebo Comparator|SHARING FEELINGS PROGRAM|
16417334|NCT03858868|Experimental|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
16417335|NCT03858868|Other|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
16417336|NCT03858855|Experimental|Group I (bergamot essential oil)|Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
16417337|NCT03858855|Experimental|Group II (chamomile essential oil)|Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
16417338|NCT03858855|Experimental|Group III (ginger essential oil)|Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
16417339|NCT03858855|Active Comparator|Group IV (almond essential oil)|Patients inhale 7 drops of almond essential oil and complete journal as in group I.
16417340|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
16417341|NCT03858829|Experimental|fear of movement scale|
16417342|NCT03858816|Experimental|Mixture probiotics|The probiotic contain 1 ×10^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
16417343|NCT03858816|Placebo Comparator|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
16417344|NCT03858803|Active Comparator|FM2 first, LAST delayed|Parent intervention, Families Matter 2 (FM2), immediate, adolescent intervention, Living as a Safer Teen (LAST), delayed six months
16417345|NCT03858803|Active Comparator|FM2 and LAST simultaneous|Parents participate in Families Matter 2 (FM2) and adolescents in Living as a Safer Teen (LAST) intervention immediately following the baseline assessment.
16417346|NCT03858803|Active Comparator|Comparison arm|Comparison arm in which both parents and adolescents will be offered their respective interventions following the final assessment. Following the final assessment parents will be offered the Families Matter (FM2) intervention and youth the Living as a Safer Teen (LAST) intervention as an ethically justified service.
16417347|NCT03858790|Experimental|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
16417348|NCT03858790|Sham Comparator|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
16417349|NCT03858777|Active Comparator|Sarcoidosis patients without evidence of active myocarditis|A single blood draw.
16417350|NCT03858777|Experimental|Sarcoidosis patients with evidence of active myocarditis|Two blood draws 2 months apart.
16417351|NCT03858777|Active Comparator|Acute ST elevation myocardial infarction (STEMI)|Three blood draws, baseline, 6 hours and 24 hours.
16417352|NCT03858777|Placebo Comparator|Healthy controls|A single blood draw
16417353|NCT03858751|Placebo Comparator|Placebo|Placebo capsule before bedtime
16417354|NCT03858751|Experimental|LTM1201AZ|LTM1201AZ capsule before bedtime
16417355|NCT03858751|Experimental|LTM1201AT|LTM1201AT capsule before bedtime
16417356|NCT03858751|Experimental|LTM1201AG|LTM1201AG capsule before bedtime
16417357|NCT03858751|Experimental|LTM1201AD|LTM1201AD capsule before bedtime
16417358|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.
~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
16417359|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
16417360|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
16417361|NCT03858725|Experimental|D569/CKD-374 5mg|"Period 1: D569 Tab. 1T
~Period 2: CKD-374 5mg Tab. 1T"
16417362|NCT03858725|Experimental|CKD-374 5mg/D569|"Period 1: CKD-374 5mg Tab. 1T
~Period 2: D569 Tab. 1T"
16417363|NCT03858712|Other|Passive Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.
~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice
~ePRO Home: -- ePRO oral between visits at home.
~Passive care team alert -- EHR inBasket notification"
16417464|NCT03858023|Experimental|Hippotherapy|Children in hippotherapy arm will participate in hippotherapy (30 min/sessions, twice a week, 15 weeks)
16417465|NCT03858023|No Intervention|Control|Children in control group will not receive hippotherapy
16417364|NCT03858712|Other|Active Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.
~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice
~ePRO Home: -- ePRO oral between visits at home.
~Active care team alert -- practice nurse monitoring of ePRO home responses score = 3 indicating a moderate-severe toxicity (grade 3 or higher"
16417365|NCT03858699||Individuals with stroke|Participants in sub-acute and chronic phases post-stroke (>1 month post-stroke) will be recruited for participation in this study.
16417366|NCT03858699||Adult control participants|Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.
16417367|NCT03858686|Active Comparator|400 mg FP-025 capsules|Based on a double-blind randomized schedule, 16 subjects will receive FP-025 capsules in Period 1 and matching placebo FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
16417368|NCT03858686|Placebo Comparator|FP-025 Placebo Capsules|Based on a double-blind randomized schedule, 16 subjects will receive matching placebo FP-025 capsules in Period 1 and FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
16417369|NCT03858673||Ligations group|VTH via the Tsuzi method with residual uterine ligament ligation (ligations group)
16417370|NCT03858673||Without ligations group|Traditional VTH without residual uterine ligament ligation (without ligations group)
16417371|NCT03858660||Elderly|Healthy elderly No intervention.
16417372|NCT03858647||Sensorineural hearing loss patients post cochlear implant|Patients who have documented sensorineural hearing loss and have received cochlear implantation (per standard of care).
16417373|NCT03858634|Experimental|KPL-716|Weekly for 8 weeks
16417374|NCT03858634|Placebo Comparator|Placebo|Weekly for 8 weeks
16417375|NCT03858621|Experimental|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
16417376|NCT03858621|No Intervention|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
16417377|NCT03858608|Experimental|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.
~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.
~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention [target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%]"
16417378|NCT03858608|Active Comparator|Usual asthma care|Usual asthma management
16417379|NCT03858595|Experimental|Intervention|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. Investigators will train our study participants (high-risk pregnant women) on how to use Salu Health Gauge to measure BP as well as how to charge them. Trained FFWs will visit the households weekly and synchronize the device with a tablet computer to collect the stored data. The FFWs will measure the weight of the participants using a digital weighing scale at enrollment and on a monthly bases thereafter. Investigators will keep monitoring up to termination of pregnancy. in any health issue arises, our health worker will ensure that an appropriate referral is made to a tertiary care facility. This intervention will be in addition to the conventional antenatal and postnatal care."
16417380|NCT03858595|No Intervention|Control group|All those women randomized to the control arm will receive conventional antenatal and postnatal care only. Investigators will collect the outcome data from the households and/or the health centers by follow-up visits or over phone. Investigators will consell participants, women both in the control group, to make at least four antenatal visits. In addition, Investigators will provide counselling about eating healty and keeping physically active during pregnancy. Investigators will provide general nutrition education on taking balanced energy and protein diet.
16417381|NCT03858582|Experimental|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
16417382|NCT03858582|Experimental|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
16417383|NCT03858582|Experimental|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
16417384|NCT03858569|Active Comparator|Oxytocin|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus
16417385|NCT03858569|Active Comparator|Oxytocin plus uterine massage|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus and transabdominal uterine massage will be performed.
16417386|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.
~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
16417387|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.
~-No treatment"
16417388|NCT03858543|Experimental|Fractional laser treatment & Poly-L Lactic Acid (Sculptra)|One Fractional laser treatment on half of the body with Sciton Laser and Scluptra
16417389|NCT03858543|Active Comparator|Fractional laser treatment|One Fractional laser treatment on half of the body with Sciton Laser
16417466|NCT03857997||Patients|
16417467|NCT03857997||Parents|
16417390|NCT03858530|Experimental|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
16417391|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:
~Aseptic necrosis of the humeral head
~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis
~Failed previous total shoulder replacement, resurfacing or other procedure"
16417392|NCT03858504|Experimental|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
16417393|NCT03858504|Active Comparator|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
16417394|NCT03858491|Experimental|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
16417395|NCT03858478|Experimental|Biktarvy arm|one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks
16417396|NCT03858465|Active Comparator|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
16417397|NCT03858465|Active Comparator|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
16417398|NCT03858452|Active Comparator|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
16417399|NCT03858452|Active Comparator|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
16417400|NCT03858452|Active Comparator|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
16417401|NCT03858439|Experimental|Intervention|Single arm study. All participants will receive dietary intervention.
16417402|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:
~Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)
~And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids
~Exclusion criteria:
~Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)
~Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
16417403|NCT03858413||Chronic kidney disease stage V|No intervention
16417404|NCT03858413||Chronic kidney disease stage III|No intervention
16417405|NCT03858387||Meropenem|Critically ill patients who require meropenem therapy
16417406|NCT03858387||Imipenem|Critically ill patients who require imipenem therapy
16417407|NCT03858374|Experimental|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
16417408|NCT03858374|Active Comparator|control group 1|Patients in control group 1 were transferred by slide board.
16417409|NCT03858374|Active Comparator|control group 2|Patients in control group 2 were transferred by bedsheet.
16417410|NCT03858348||fluticasone / salmeterol treatment|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol (Group A)
16417411|NCT03858348||fluticasone / salmeterol and extra LAMA|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol and extra a long-acting muscarinic receptor antagonist (anticholinergic, LAMA) (Group B).
16417412|NCT03858335|Experimental|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
16417413|NCT03858335|No Intervention|Control|Children in control group will receive only traditional rehab therapies without wearing splint
16417414|NCT03858322|Experimental|Carboplatin + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle
~Carboplatin will be administered intravenously 3 times per cycle"
16417415|NCT03858322|Experimental|Cyclophosphamide + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle
~Cyclophosphamide will be administered once per cycle"
16417416|NCT03858309|Experimental|Breathing Group 1|Arm 1 will receive an 8-week intervention that consists of a set of breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
16417417|NCT03858309|Active Comparator|Breathing Group 2|Arm 2 will receive an 8-week intervention that consists of slow breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
16417418|NCT03858296|Experimental|Emotional awareness|4 modules of emotional awareness training
16417419|NCT03858296|Experimental|Cognitive reappraisal|4 modules cognitive reappraisal training
16417420|NCT03858296|Experimental|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
16417421|NCT03858283|Experimental|Mindfulness Based Health Care Program|
16417422|NCT03858283|No Intervention|Control|
16417423|NCT03858270|Experimental|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
16417424|NCT03858270|Placebo Comparator|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
16417463|NCT03858036|Active Comparator|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
16417632|NCT03856827|Placebo Comparator|Placebo|Matching placebo tablets administered orally
16417425|NCT03858257|Experimental|High flow nasal oxygen|The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation. The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered. The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e. increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy). Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
16417426|NCT03858257|Other|Standard oxygenation|Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice. The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
16417427|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
16417428|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
16417429|NCT03858231|Active Comparator|Opioid|
16417430|NCT03858231|Active Comparator|Non-opioid|
16417431|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
16417432|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
16417434|NCT03858192|Experimental|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
16417435|NCT03858192|Experimental|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
16417436|NCT03858192|Experimental|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
16417437|NCT03858179|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
16417438|NCT03858179|Experimental|PBMT + training/ placebo + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
16417439|NCT03858179|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
16417440|NCT03858179|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
16417441|NCT03858166|Active Comparator|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
16417442|NCT03858166|Experimental|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy.
16417443|NCT03858153|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
16417444|NCT03858153|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
16417445|NCT03858127||Male infants born <32 weeks gestation|
16417446|NCT03858114|Experimental|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
16417447|NCT03858114|Active Comparator|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
16417448|NCT03858101||PKU subjects|
16417449|NCT03858101||Age and sex-matched non-PKU comparison subjects|
16417450|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
16417451|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
16417452|NCT03858075|Experimental|Single ascending doses with BLU-782|
16417453|NCT03858075|Placebo Comparator|Single ascending doses with placebo|
16417454|NCT03858075|Experimental|Multiple ascending doses with BLU-782|
16417455|NCT03858075|Placebo Comparator|Multiple ascending doses with placebo|
16417456|NCT03858075|Experimental|Food effect of BLU-782 taken with food|
16417457|NCT03858075|Experimental|Food effect of BLU-782 taken without food|
16417458|NCT03858062|Active Comparator|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
16417459|NCT03858062|Experimental|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
16417460|NCT03858049|Experimental|Crinone|
16417461|NCT03858049|Experimental|Crinone plus Duphaston|
16417462|NCT03858036|Active Comparator|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
16417502|NCT03857711|Active Comparator|Conventional CABG|Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
16417468|NCT03857984|Experimental|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
16417469|NCT03857971|Other|Coronary OCT imaging of non flow-limiting lesion|Coronary OCT imaging will be performed of fractional flow reserve (FFR) negative lesions to assess plaque morphology.
16417470|NCT03857958|Experimental|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
16417471|NCT03857958|Active Comparator|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
16417472|NCT03857945|Active Comparator|Mobility Device Training Group|Patients receiving preoperative mobility device(s) training before surgery
16417473|NCT03857945|No Intervention|No Mobility Device Training Group|Patients not receiving preoperative mobility device(s) training before surgery
16417474|NCT03857932|Experimental|SLNB and non-slns resection|"Participants only receive SLNB
~preoperative CT lymphography
~SLNB with stained non-SLN resection
~SLNB with ARM dissection"
16417475|NCT03857932|Experimental|SLNB group|Participants only receive SLNB
16417476|NCT03857919|Experimental|TearCare|Subjects will have heat applied to the eyelids for 15 minutes followed by manual expression of the meibomian glands.
16417477|NCT03857919|Active Comparator|LipiFlow|Subjects will have heat and pressure applied to the eyelids for 12 minutes.
16417478|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
16417479|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
16417480|NCT03857893|Active Comparator|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
16417481|NCT03857893|Experimental|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.
~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
16417482|NCT03857867|Experimental|Tactile Stimulation Glove|Patient will receive active stimulation for a minimum of 3 months and a maximum of 13 months
16417483|NCT03857854|Experimental|treatment group|pirfenidone group
16417484|NCT03857854|Placebo Comparator|placebo group|control group
16417485|NCT03857841|Experimental|20 pmol phospholipid/kg body weight|UNEX-42 administered at 20 pmol phospholipid/kg body weight
16417486|NCT03857841|Experimental|60 pmol phospholipid/kg body weight|UNEX-42 administered at 60 pmol phospholipid/kg body weight
16417487|NCT03857841|Experimental|200 pmol phospholipid/kg body weight|UNEX-42 administered at 200 pmol phospholipid/kg body weight
16417488|NCT03857841|Placebo Comparator|Placebo|Phosphate-buffered saline
16417489|NCT03857815|Experimental|SBRT in combined with anti-PD-1 antibody|HCC Patients will be received stereotactic body radiation therapy (SBRT) to primary lesions or metastatic lesions, such as liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
16417490|NCT03857802|Experimental|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
16417491|NCT03857802|No Intervention|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
16417492|NCT03857789|Other|Regular care|Participant will be received by Healthcare professional (HCP). The HCP will administer a questionnaire. The HCP will discuss the results.
16417493|NCT03857789|Experimental|New care|Participant will be received by Healthcare professional (HCP). The social robot will administer a questionnaire. The HCP will discuss the results.
16417494|NCT03857776|Other|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.
~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
16417495|NCT03857776|Other|Standard care|Standard care including referral to a homepage about complementary alternative medicine
16417496|NCT03857763|Experimental|Apatinib+Paclitaxel+Cisplatin+RT|Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w
16417497|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
16417498|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
16417499|NCT03857737|Experimental|ESD group|This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
16417500|NCT03857737|Active Comparator|Surgery group|This group include patients who are going to undergo surgery for early gastric cancer.
16417501|NCT03857724|Experimental|prolapse surgery|
16417628|NCT03856853|Experimental|treatment group|pirfenidone group
16417503|NCT03857711|Active Comparator|CABG+ PVI|CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
16417504|NCT03857711|Active Comparator|CABG+ PVI+amiodarone|CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
16417505|NCT03857711|Active Comparator|CABG+amiodarone|CABG+class III antiarrhythmic drug- amiodarone, group, n=70
16417506|NCT03857698|Experimental|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
16417507|NCT03857698|Experimental|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
16417508|NCT03857698|Experimental|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
16417509|NCT03857698|Experimental|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
16417510|NCT03857698|Experimental|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
16417511|NCT03857698|Experimental|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
16417512|NCT03857698|Experimental|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
16417513|NCT03857685||Proliferation in an in-vitro model|An in-vitro model is used to study lens epithelial cell proliferation
16417514|NCT03857672|Experimental|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
16417515|NCT03857672|No Intervention|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
16417516|NCT03857659|Experimental|Point of care ultrasound (POC-US)|Point of care ultrasound (POC-US) to measure abdominal circumference and amniotic fluid every 4 weeks from 28-36 weeks
16417517|NCT03857659|Active Comparator|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
16417518|NCT03857646|Other|Intralipid|
16417519|NCT03857646|Other|SMOF lipid|
16417520|NCT03857633||Pre Dialysis (CKD Stage 4/5)|Patients recruited from low clearance clinic with advanced CKD (stage 4/5). Patients will undergo Cardiac MRI 1 - With Gadolinium Contrast at the time of recruitment and Cardiac MRI 2 - With Gadolinium Contrast at time of commencement on renal replacement therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
16417521|NCT03857633||Haemodialysis Dialysis (CDK Stage 5d)|Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
16417522|NCT03857633||Peritoneal Dialysis (CDK Stage 5d)|Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
16417523|NCT03857620|Active Comparator|Arm I (usual care)|Healthcare providers/institutions perform usual care.
16417524|NCT03857620|Experimental|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
16417525|NCT03857620|Experimental|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
16417526|NCT03857594||Individuals at risk of hereditary cancer syndrome|All individuals at risk of a hereditary cancer syndrome with or without a known germline mutation from clinical genetic testing.
16417527|NCT03857581|Experimental|Clozapine Arm|
16417528|NCT03857581|Active Comparator|Olanzapine Arm|
16417529|NCT03857568|Experimental|SHR0410 group|SHR0410 will be dosed
16417530|NCT03857568|Experimental|Placebo|Placebo will be dosed
16417531|NCT03857542|Experimental|AGN-190584|Ophthalmic solution, one drop, dosed bilaterally, once daily for 30 days
16417532|NCT03857542|Placebo Comparator|Vehicle|Matching ophthalmic solution, one drop, dosed bilaterally, once daily for 30 days
16417533|NCT03857529|Experimental|conventional tDCS concurrent with CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
16417534|NCT03857529|Experimental|unconventional tDCS concurrent with CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
16417535|NCT03857529|Experimental|conventional tDCS preceding CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
16417536|NCT03857529|Experimental|unconventional tDCS preceding CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
16417537|NCT03857529|Sham Comparator|sham tDCS with CCFES|sham tDCS preceding and concurrent with CCFES
16417538|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
16417539|NCT03857503||Coronary Lesion Assessment with iFR|Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.
16417540|NCT03857490|Experimental|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
16417541|NCT03857490|Placebo Comparator|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
16417542|NCT03857477||Stage 1|Caucasian men aged 55-69 to undergo genetic SNP profiling.
16417543|NCT03857477||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer will be offered an MRI scan, prostate biopsy and prostate cancer screening.
16417544|NCT03857464|Other|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C. difficile infections using the centralized testing facilities.
16417545|NCT03857464|Other|Crossover Arm Two|Hospital wards in this arm will utilize testing for C. difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
16417546|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
16417547|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
16417548|NCT03857425|Experimental|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks
16417549|NCT03857425|Experimental|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
16417550|NCT03857425|Experimental|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
16417551|NCT03857412|Sham Comparator|Non capsular polishing|No capsular polishing taking place during cataract surgery
16417552|NCT03857412|Active Comparator|Capsular polishing|Capsular polishing taking place during cataract surgery
16417553|NCT03857399|Experimental|Arm-1|Patients will be assigned to receive intravenous local caspofungin (70 mg on day 1 and 50 mg once daily),If the study therapy was well tolerated but fever persisted for four or more days and the patient's clinical condition deteriorated, the dosage could be increased to 70 mg once daily.For patients who have no evidence of baseline or breakthrough fungal infection, study therapy was administered until the absolute neutrophil count was at least 500 per cubic millimeter and for up to 72 hours thereafter. The onsite investigator determined the duration of therapy for patients with baseline or breakthrough fungal infections; however,it was recommended that treatment be given for at least 14 days and for at least 7 days after neutropenia and symptoms resolved.
16417554|NCT03857399|Active Comparator|Arm-2|Patients will be assigned to receive intravenous original caspofungin (70 mg on day 1 and 50 mg once daily),the therapeutical duration is 4 Days.
16417555|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
16417556|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
16417557|NCT03857373||Renal Cancer|Patients identified with RCC
16417558|NCT03857360|Active Comparator|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
16417559|NCT03857360|Placebo Comparator|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
16417560|NCT03857347|Experimental|Brief Psychoeducation Intervention|2 group session psychoeducation intervention feasibility study
16417561|NCT03857334|Experimental|Arm A|
16417562|NCT03857334|Active Comparator|Arm B|
16417563|NCT03857321|Experimental|Insulin first, then placebo|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive placebo at visit 3 during second intervention period.
16417629|NCT03856853|Placebo Comparator|placebo group|placebo group
16417753|NCT03856021|Active Comparator|Microfracture with Bone Marrow Aspirate Concentrate|
16417564|NCT03857321|Experimental|Placebo first, then insulin|Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
16417565|NCT03857308|Experimental|Mindfulness Training|
16417566|NCT03857308|Active Comparator|Reappraisal Training|
16417567|NCT03857282|Active Comparator|Aerobic Exercises|Bicycling Exercise (lower Limb)
16417568|NCT03857282|Experimental|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
16417569|NCT03857269|Experimental|Acupoint Massage group|Choose Chinese medicine acupuncture points： Shenting, Baihui, Sishencong, Diwei, Chengling, Fengchi, Fengfu，Zusanli and Sanyinjiao，32 points per acupressure.32 times per acupoint.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
16417570|NCT03857269|Experimental|Aromatherapy group|Make a 5x5cm bag and put a cotton ball in the bag and the bag is clipped to the patient's collar.Dispense 10% lavender essential oil, 2-3 drops a day in cotton balls.Cotton ball replacement daily. Intervention frequency will be monday to saturday per week for 6 months.（n=30）
16417571|NCT03857269|Experimental|Acupoint Massage and Aromatherapy group|At the same time as the acupressure, the essential oil is applied to the collar and begins to sniff.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
16417572|NCT03857269|No Intervention|Blank control group|The group selects elderly people with MCI who do not receive intervention after informed.Participate in routine activities of Nursing homes.
16417575|NCT03857243|Experimental|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
16417576|NCT03857243|Placebo Comparator|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
16417577|NCT03857230|Experimental|Sequence A: Primapur - Gonal-F|Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
16417578|NCT03857230|Active Comparator|Sequence B: Gonal-F - Primapur|Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
16417579|NCT03857217||Post-cardiotomy patients|Patients submitted to cardiac surgery
16417580|NCT03857204|Experimental|performing US scans for fetal weight assessment.|
16417581|NCT03857191||Patients already treated for OSA|The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation
16417582|NCT03857191||Patients with a high OSA risk|This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
16417583|NCT03857191||Patients with a low OSA risk|This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
16417584|NCT03857165|Experimental|Low dose SAP-001|SAP-001 (Experimental drug) low dose versus placebo
16417585|NCT03857165|Experimental|Mid dose SAP-001|SAP-001 (Experimental drug) mid dose versus placebo
16417586|NCT03857165|Experimental|High dose SAP-001|SAP-001 (Experimental drug) high dose versus placebo
16417587|NCT03857152|Other|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
16417588|NCT03857139|Experimental|NRT smoking Cessation Intervention|All participants will be provided with the Nicotine Patch as an intervention
16417589|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.
~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
16417590|NCT03857113||PSMA-radioguided surgery|Tc-99m-PSMA combined with a gamma probe, guidance of the surgical resection of recurrent PC lymph node metastases
16417591|NCT03857100|Active Comparator|Intervention|Receives letter and report
16417592|NCT03857100|No Intervention|Control|Does not receive letter and report
16417594|NCT03857074|Experimental|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
16417595|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
16417596|NCT03857048|Active Comparator|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
16417630|NCT03856840||Bullous Pemphigoid Patients|Bullae and blood serum, which are obtained before and under treatment, will be compared in each other regardless of any condition.
16417631|NCT03856827|Experimental|IW-6463|IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food
16469999|NCT03498677|Active Comparator|Method of presentation two|
16417597|NCT03857048|Experimental|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
16417598|NCT03857048|Active Comparator|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
16417599|NCT03857035|Experimental|Piezosurgery group|"One side of the patients will be randomly selected and labeled as experimental group. In experimental group, impacted third molar will be extracted using piezosurgery."
16417600|NCT03857035|Placebo Comparator|Rotary Instruments Group|"The other side will be accepted as control group. In the control group, impacted third molar will be extracted using conventional rotary instruments."
16417601|NCT03857022|Experimental|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
16417602|NCT03857022|No Intervention|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
16417603|NCT03857009||Symptomatic|No intervention.
16417604|NCT03857009||Asymptomatic|No intervention.
16417605|NCT03856996|Experimental|Group 1: Stable CH505TF gp120 + GLA-SE|Participants in Group 1 will receive 100 mcg of Stable CH505TF gp120 admixed with 10 mcg of GLA-SE by intramuscular (IM) injection at Months 0, 2, and 6.
16417606|NCT03856996|Experimental|Group 2: Transient CH505TF gp120 + GLA-SE|Participants in Group 2 will receive 100 mcg of Transient CH505TF gp120 admixed with 10 mcg of GLA-SE by IM injection at Months 0, 2, and 6.
16417607|NCT03856983|No Intervention|Control group|Control group who will do usual rehabilitation.
16417608|NCT03856983|Experimental|Experimental group|Experimental group who will do usual rehabilitation and visualization of point-light human actions
16417609|NCT03856970|Experimental|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
16417610|NCT03856970|Experimental|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
16417611|NCT03856970|Experimental|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).
~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
16417612|NCT03856957|Experimental|Endocuff colonoscopy|Colonoscopy performed with Endocuff
16417613|NCT03856957|Placebo Comparator|Conventional colonoscopy|Colonoscopy performed without any device
16417614|NCT03856944|Experimental|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
16417615|NCT03856918|Experimental|PEEP 3 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 3 cm of water during thoracic surgery.
16417616|NCT03856918|Experimental|PEEP 6 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 6 cm of water during thoracic surgery.
16417617|NCT03856918|Experimental|PEEP 9 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 9 cm of water during thoracic surgery.
16417618|NCT03856905|Active Comparator|Physical therapy group|The children in this group will receive the conventional physical therapy program (CPTP). It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neuro-developmental techniques, and gait training. The total program will be conducted for 1 h, three sessions/week for 12 weeks.
16417619|NCT03856905|Experimental|Extra-corporeal shock wave therapy group|The children in this group only will receive the extra-corporeal shock wave therapy (ESWT). An electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG) will be used. The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode, one session/week for 12 weeks. The treatment is painless and does not require any kind of anesthesia or the use of analgesic drugs
16417620|NCT03856905|Experimental|Functional electrical stimulation group|"The children in this group will receive the functional electrical stimulation (FES). The FES will be applied by using the WalkAide system (Innovative Neurotronics, Austin, TX, USA).
~The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait."
16417621|NCT03856892|Experimental|Active intervention|Intensive breath-based Hatha yoga program (more breath, more hours of practice)
16417622|NCT03856892|Active Comparator|Active Control|Less intensive practice on body (not breath) based yoga practices
16417623|NCT03856892|No Intervention|Passive control|No intervention is followed other than daily duties while in the same environment as both of the active groups.
16417624|NCT03856879|No Intervention|Usual care|Providers in this arm will provide usual care to their HIV+ patients with COPD.
16417625|NCT03856879|Experimental|Proactive E-consult|Providers in this arm will receive proactive E-consults with expert recommendations for COPD care prior to appointments with HIV+ patients with COPD.
16417626|NCT03856866|Experimental|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
16417627|NCT03856866|Placebo Comparator|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
16417633|NCT03856814||Patients with varicose veins|Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators.
16417634|NCT03856801|Experimental|Whole-body vibration in normoxia condition|Training session in normoxia condition
16417635|NCT03856801|Experimental|Whole-body vibration in hypoxia condition|Training session in hypoxia condition
16417636|NCT03856788|Placebo Comparator|Saline|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with normal saline on the ipsilateral side as the extraction site.
16417637|NCT03856788|Active Comparator|Bupivacaine|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with bupivacaine on the ipsilateral side as the extraction site.
16417638|NCT03856762|Experimental|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
16417639|NCT03856762|Experimental|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
16417640|NCT03856762|Experimental|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
16417641|NCT03856749|Experimental|Treatment|The wheelchair user and caregiver will be trained together on wheelchair skills using remote technology (Zoom for healthcare and/or Facetime).
16417642|NCT03856749|No Intervention|Control|The wheelchair user and caregiver will receive the same self-study materials provided to the Treatment arm. Usual care, which may include wheelchair skills training for both wheelchair users and caregivers( but which often does not do so to an adequate extent) by wheelchair user's clinical therapist.
16417643|NCT03856736|Experimental|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
16417644|NCT03856736|Experimental|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
16417645|NCT03856710|Active Comparator|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
16417646|NCT03856710|Active Comparator|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
16417647|NCT03856697|Experimental|Abivertinib Maleate Capsules+ Placebo Gefitinib Tablets|Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Placebo Gefitinib Tablets (250 mg orally, once daily), in accordance with the randomization schedule.
16417648|NCT03856697|Active Comparator|Gefitinib Tablets+ Placebo Abivertinib Maleate Capsules|Placebo Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Gefitinib Tablets(250 mg orally, once daily), in accordance with the randomization schedule.
16417653|NCT03856671|Experimental|oral antibiotics+mechanical bowel preparation|Liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. A combination of neomycin 1g and metronidazole 0.2g every 6 hours was also administrated. Enteroclysis was conduted for patients on surgical morning.
16417654|NCT03856671|No Intervention|simple mechanical bowel preparation|Only liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. Enteroclysis was conduted for patients on surgical morning.
16417655|NCT03856658|Experimental|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
16417656|NCT03856645|Experimental|OKG-0301 0.012% w/v|
16417657|NCT03856645|Experimental|OKG-0301 0.03% w/v|
16417658|NCT03856645|Placebo Comparator|Vehicle Control|
16417659|NCT03856632|Active Comparator|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
16417684|NCT03856437|Experimental|Loss-framed messages|Participants in this arm receive loss-framed HPV vaccination messages.
16417754|NCT03856008|Experimental|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
16417660|NCT03856632|Experimental|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
16417662|NCT03856606|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will not be asked to perform interval exercise.
16417663|NCT03856606|Experimental|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
16417664|NCT03856593|Experimental|Letter A Intervention|The intervention arm will involve letter A sent to prescribers in Los Angeles County.
16417665|NCT03856593|Experimental|Letter B Intervention|The intervention arm will involve letter B sent to prescribers in Los Angeles County.
16417666|NCT03856580|Experimental|Self-injection|Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
16417667|NCT03856580|Experimental|"Injection by HCP at drop-in clinics"|"Participants will report to a drop-in clinic, where a healthcare provider will inject them with an inert version of injectable cabotegravir. Visits will take <10 minutes, and participants will be able to come whenever they want (when their injection is due) during clinic drop-in hours, which will be staggered in 2-hour windows during each week day. The inert substance that will be injected is intended to mimic injectable cabotegravir as closely as possible (described above). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as drop-in clinic hours, directions to the drop-in clinic site, study contact information, etc..."
16417668|NCT03856580|No Intervention|Control group|Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
16417669|NCT03856554|Experimental|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
16417670|NCT03856541|Experimental|SHR-A1403 Dose Escalation|SHR-A1403 given intravenously (IV).
16417671|NCT03856515|Experimental|E-cigarettes with Nicotine|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
16417672|NCT03856515|Placebo Comparator|E-cigarettes without Nicotine|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
16417673|NCT03856502|Experimental|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
16417674|NCT03856502|Active Comparator|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
16417675|NCT03856489||Patients|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 10 am.
16417676|NCT03856489||Nurses|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 7:30 am.
16417677|NCT03856476||Dyslipidemia group|Children and adolescents with dyslipidemia
16417678|NCT03856476||Control group|Children and adolescents without dyslipidemia
16417679|NCT03856463|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay patient navigator who will provide information regarding early advance care planning, documentation of goals of care, and coordinating home-based care. The intervention arm will also receive usual care as provided by their local oncologists.
16417680|NCT03856463|Active Comparator|Control Group Arm|The control group will receive usual care as provided by their local oncologists.
16417681|NCT03856450|Active Comparator|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
16417682|NCT03856450|Experimental|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
16417683|NCT03856437|Experimental|Gain-framed messages|Participants in this arm receive gain-framed HPV vaccination messages.
16470400|NCT03495778|Experimental|Test Granola|50.5 g Test Granola
16417685|NCT03856424|Other|Modality 1 - Washout - Modality 2 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
16417686|NCT03856424|Other|Modality 1 - Washout - Modality 3 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
16417687|NCT03856424|Other|Modality 2 - Washout - Modality 1 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
16417688|NCT03856424|Other|Modality 2 - Washout - Modality 3 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
16417689|NCT03856424|Other|Modality 3 - Washout - Modality 2 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
16417690|NCT03856424|Other|Modality 3 - Washout - Modality 1 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
16417691|NCT03856411|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
16417692|NCT03856411|Placebo Comparator|Group Placebo combined with standard chemotherapy|
16417693|NCT03856385|Experimental|Mindful Walking|Four weekly 60 minute sessions of mindful walking.
16417694|NCT03856385|No Intervention|Control|Weekly email messages encouraging physical activity.
16417695|NCT03856372|Experimental|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
16417696|NCT03856372|Active Comparator|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
16417697|NCT03856359|Experimental|Rifaximin|rifaximin 550 milligrams (mg) orally twice daily for 3 months
16417698|NCT03856346||Phaco-vitrectomy|
16417699|NCT03856333|Other|traditional treatment|30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
16417700|NCT03856320|No Intervention|Usual Care|Patient attends a MOVE! visit (weight management visit).
16417701|NCT03856320|Experimental|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
16417702|NCT03856294|Experimental|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
16417703|NCT03856294|Placebo Comparator|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
16417704|NCT03856281|Experimental|Intervention Group A|LymphAssist IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
16417705|NCT03856281|Experimental|Intervention Group B|Sequential IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
16417706|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
16417707|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
16417708|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
16417709|NCT03856255|Experimental|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
16417710|NCT03856242|No Intervention|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
16417711|NCT03856242|Active Comparator|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
16417712|NCT03856242|Active Comparator|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
16417713|NCT03856229|Active Comparator|Group A conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
16417714|NCT03856229|Experimental|Group B shortened steroid regimen|"Subjects will receive the shortened steroid regimen for the severity of pneumonia with prednisone or equivalent with methylprednisolone, depending the severity of pneumonia:
~Moderate PCP. 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).
~Severe PCP. 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
16417715|NCT03856216|Experimental|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
16417716|NCT03856216|Experimental|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
16417717|NCT03856190|Active Comparator|"Fasting and best practice nutrition"|Initial fasting followed by 11 weeks plant-based diet
16417718|NCT03856190|Active Comparator|Standard Nutrition Counselling|12 weeks standard antiinflammatory diet
16417719|NCT03856177|Experimental|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
16417750|NCT03856047|Placebo Comparator|Placebo 3.0 mg (Liraglutide)|Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
16417751|NCT03856034|Experimental|Fetoscopic repair|
16417752|NCT03856021|Active Comparator|Microfracture|
16417720|NCT03856177|Experimental|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
16417721|NCT03856164|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
16417722|NCT03856164|Placebo Comparator|Placebo|Normal saline for intravenous administration.
16417723|NCT03856151|Active Comparator|Group 1|"For Group 1, each subject will receive Treatment 1# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 2#.
~Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks."
16417724|NCT03856151|Active Comparator|Group 2|"For Group 2, each subject will receive Treatment 2# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 1#.
~Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks.
~Treatment 1# will be regular dialysis 3 times per week for 4 weeks."
16417725|NCT03856138||diarrhea with probiotics supplement|The children suffered from diarrhea, gastroenteritis oral probiotics during the clinical course
16417726|NCT03856138||diarrhea without probiotics supplement|The children suffered from diarrhea, gastroenteritis no oral probiotics during the clinical course
16417727|NCT03856138||healthy control|The children without diarrhea/ gastroenteritis
16417728|NCT03856125|Experimental|PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
16417729|NCT03856125|Sham Comparator|Sham PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of sham percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
16417730|NCT03856112|Experimental|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16417731|NCT03856112|Active Comparator|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16417732|NCT03856112|Experimental|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
16417733|NCT03856099|Experimental|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
16417734|NCT03856086|Active Comparator|Enhanced usual care (EUC)|"ICs randomized to EUC following baseline questionnaire completion will be given instructions (Appendix I) on how to access or create an account to access the myMSK online portal IC Resources page (https://my.mskcc.org/login). If the caregiver does not wish to enroll in MyMSK, the research study staff will send them an email with sample referral material ( Appendix D. The IC Resources page includes links to extant MSK educational materials for ICs (e.g., A Guide for Caregivers [47]), contact information for psychosocial services (e.g., Caregivers Clinic in the MSK Counseling Center), and external resources (e.g., educational materials and services through the CSC, American Cancer Society, and others) (Appendix D,)."
16417735|NCT03856086|Experimental|CancerSupportSource-CG screening plus consultation (S+C)|"ICs randomized to S+C will complete the web-based CSS-CG (Appendix C) using a tablet immediately following baseline study measures. In case of technical issues, ICs may complete Appendix C with the guidance of a member of the research study team. The CSS-CG asks ICs to rate their level of concern for 33 different possible problems: if a need is rated as low (i.e., A little or less concern), after each problem is rated ICs will be prompted to request pertinent educational materials if they are interested. If a need is endorsed (i.e., Moderate or greater concern), ICs are asked through the web-based electronic platform (https://mskcc.mycarereport.com) whether they would like educational materials and/or to speak with someone about that need (i.e., receive a referral)."
16417736|NCT03856073|Experimental|Novice|Anesthesiologists without experiment of manufacturing bronchoscopy.
16417737|NCT03856060|Experimental|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
16417738|NCT03856060|Experimental|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
16417739|NCT03856047|Experimental|NNC0174-0833, 4.5 mg|Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
16417740|NCT03856047|Experimental|NNC0174-0833, 2.4 mg|Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
16417741|NCT03856047|Experimental|NNC0174-0833, 1.2 mg|Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
16417742|NCT03856047|Experimental|NNC0174-0833, 0.6 mg|Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
16417743|NCT03856047|Experimental|NNC0174-0833 0.3 mg|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
16417744|NCT03856047|Placebo Comparator|Placebo 2.4 mg (NNC0174-0833)|Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
16417745|NCT03856047|Placebo Comparator|Placebo 4.5 mg (NNC0174-0833)|Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
16417746|NCT03856047|Placebo Comparator|Placebo 1.2 mg (NNC0174-0833)|Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
16417747|NCT03856047|Placebo Comparator|Placebo 0.6 mg (NNC0174-0833)|Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
16417748|NCT03856047|Placebo Comparator|Placebo 0.3 mg (NNC0174-0833)|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
16417749|NCT03856047|Active Comparator|Liraglutide 3.0 mg|Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
16470401|NCT03495778|Placebo Comparator|Control Granola|54.3 Control Granola
16417755|NCT03856008|Experimental|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
16417756|NCT03856008|No Intervention|Control.|No intervention will be applied.
16417760|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
16417761|NCT03855956|Experimental|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
16417762|NCT03855956|Other|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
16417763|NCT03855943|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
16417764|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.
~All patients will go through functional MRI study"
16417765|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
16417766|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
16417767|NCT03855917|Experimental|Sof plus G/P|Four weeks of sofosbuvir (400mg) plus glecaprevir-pibrentasvir (300mg/120mg) will be administered, followed by immediate retreatment of virological relapse with glecepravir/pibrentasvir (300mg/120mg) for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
16417768|NCT03855904|Experimental|TC-325|The intervention (experimental) arm patients are treated initially with TC-325 alone. Treatment failure for TC-325 is defined as endoscopists cannot achieve hemostasis with 1 syringe (20gm) of TC-325.
16417769|NCT03855904|Active Comparator|Traditional treatment (Control group)|Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
16417770|NCT03855891|Experimental|Study group|A group of patients with blood tests
16417771|NCT03855865|Experimental|Rapastinel|Rapastinel (450 mg prefilled syringe, weekly intravenous IV administration).
16417772|NCT03855865|Active Comparator|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
16417773|NCT03855865|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
16417774|NCT03855852|Active Comparator|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
16417775|NCT03855852|Experimental|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
16417776|NCT03855839||Healthy participants|Participants will be ask to perform a repetitive upper limb task while posture is being monitored.This will be done while wearing a posture shirt, compression shirt or no shirt.
16417777|NCT03855826|Experimental|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
16417778|NCT03855826|Active Comparator|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
16417779|NCT03855813|Other|Test-retest reliability|Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.
16417780|NCT03855800|Experimental|Clinical Follow-up|"Participants not undergoing surgery will be assigned to the Clinical Follow-up study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, or for 3 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted"
16417863|NCT03855176|Active Comparator|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
16417781|NCT03855800|Other|Surgical|"Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the Immediate Surgery study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known."
16417782|NCT03855787|Active Comparator|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
16417783|NCT03855787|Active Comparator|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
16417784|NCT03855774|Other|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
16417785|NCT03855761|Experimental|Intervention group|Experimental Occupational Therapy services
16417786|NCT03855761|Active Comparator|Comparison group|Treatment as usual
16417787|NCT03855735|Experimental|Intervention Group (IG)|Those who give birth and relatives who have been arbitrarily assigned to the control group receive online training on different communication models competencies and will gain access to the digital app.
16417788|NCT03855735|No Intervention|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app. The control group will receive a paper-pencil version.
16417789|NCT03855722|Experimental|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
16417790|NCT03855722|Sham Comparator|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
16417793|NCT03855683|Experimental|Group therapy (Unified Protocol)|Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.
16417794|NCT03855657||Inflammatory Bowel Disease Patient|Patient with confirmed diagnosis of Inflammatory Bowel Disease
16417795|NCT03855657||Healthy control|Controls (non-IBD) will comprise individuals undergoing colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms, and friends and spouses or partners of patients at Prince of Wales Hospital or Alice Ho Miu Ling Nethersole Hospital, or any individuals who are interested to participate in this study.
16417796|NCT03855657||Healthy relatives of Inflammatory Bowel Disease patient|Relatives or household members of both patients with IBD or other diseases and controls will be recruited.
16417797|NCT03855644||Pelvic fracture patients|(1) 1<Age<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
16417798|NCT03855631||Kabuki syndrome/ unaffected parents|Intervention on primary cultured cells from 4 patients with KS and sex match parents
16417799|NCT03855618||1 case group|Consecutive 10 post-stroke patients in intensive rehabilitation treatment with an acute event occurring no later than 15 days from admission to the SOR Neurological Foundation don Gnocchi ONLUS IRCCS; age 18-90. It is required to sign an informed consent to the patient's participation in the study or if unable to sign, of the proxy.
16417800|NCT03855579|Experimental|Levosimendan|Intraoperative infusion of Levosimendan
16417801|NCT03855579|Active Comparator|Milrinone|Intraoperative infusion of Milrinone
16417802|NCT03855566|Other|Intervention|Enrolled participants will receive the intervention.
16417803|NCT03855553|Experimental|FBT|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
16417804|NCT03855553|Experimental|CBT-E|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
16417805|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score > 2 (for females > 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
16417806|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.
~Propensity matching according to the:
~CHA2DS2-VASc parameters
~LVEF: preserved (<40%), mid-range (40-49%) and reduced (>50%)
~Presence of diastolic dysfunction
~Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)
~Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone
~BMI: (<30kg/m2), (30-39kg/m2) and (≥40kg/m2)
~Smoking (>5 cigarettes per day)"
16417807|NCT03855527|Experimental|Silver Diamine Fluoride (SDF) group|Atraumatic restorative technique will be performed. Then the cavities will be dried with a gentle flow of compressed air. One drop of silver diamine fluoride (Advantage Arrest Silver Diamine Fluoride 38% - Bottle) will be dispensed into a dappen dish. A micro brush will be bent, dipped into SDF and dabbed on the side of the dappen dish to remove excess liquid before application. SDF will be applied directly to affected tooth surface and dried with gentle flow of compressed air for 1 minute. Excess SDF will be removed with cotton roll. Teeth will be restored with glass ionomer cement (GC Fuji IX).
16417808|NCT03855527|Active Comparator|Chlorhexidine group|Atraumatic restorative treatment will be performed. Then, the cavities will be disinfected by placing a cotton pellet soaked in chlorhexidine solution (Consepsis®2% Chlorhexidine Antibacterial Solution) for 1 minute, air dried and restored using glass ionomer cement.
16417864|NCT03855176|Experimental|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
16417865|NCT03855163|Experimental|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
16417809|NCT03855527|Sham Comparator|Atraumatic Restorative Treatment without Disinfection|Cavities will be cleaned according to the ART approach.The cavity will be enlarged if needed using sterile hatchet.The carious dentin will be removed with excavators starting at the enamel-dentine junction. The unsupported thin enamel will be fractured off with the hatchet. The caries will be removed carefully until firm dentin is reached (physically resistant to hand excavation). The cavity will be cleaned with wet cotton pellets. Cavities will be restored immediately using conventional glass ionomer cement. All the cavities in the 3 groups will be temporary restored with glass ionomer cement handled according to manufacturer's instructions, however acid etching will not be carried out in order to make sample collection easier following the experimental period.
16417810|NCT03855514|Active Comparator|NuShield|NuShield® is a sterile, dehydrated placental allograft
16417811|NCT03855514|No Intervention|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
16417812|NCT03855501|Active Comparator|Mineral trioxide aggregate|The root canals were gently instrumented with K-files and copious irrigation was done with 2.5% sodium hypochlorite(NaOCI) by means of a 30 gauge endodontic irrigating needle . After drying with large sterile paper points, calcium hydroxide(CH) paste was mixed with saline and applied to the root canal with a lentulo spiral filler at low speed. A cotton pellet was used to gently compress CH into the root canal and its placement was examined radiographically before placing ZOE as temporary restoration into the access cavity. After one week, CH was removed from the canal by using both the files and the irrigation with 2.5% NaOCI and 17% ethylenediaminetetraacetic acid (EDTA). A final irrigation was made with 2% chlorhexidine (CHX) before obturation. Following drying the root canal with sterile paper points, MTA was placed with a MTA Endo Gun into the apical portion of canals with a minimum 4-mm thickness and adapted to the canal walls with an endodontic hand plugger.
16417813|NCT03855501|Active Comparator|Calcium hydroxide|After using the same biomechanical root canal preparation protocol, the root canal was filled to working length with CH paste. Both clinical and radiographical examinations were performed to evaluate the barrier formation and periapical healing. When a continuous hard tissue barrier was observed apically on radiographs that was verified by clinical probing and complete or significant periapical healing was noticed, the root canal was obturated and coronary restorations were completed as done in MTA group
16417814|NCT03855488|Experimental|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
16417815|NCT03855488|Experimental|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
16417816|NCT03855488|Placebo Comparator|Neutral Control Condition|Listen to descriptions of neutral scenarios
16417817|NCT03855475|Experimental|Aerobic exercise|Exercise training
16417818|NCT03855475|Active Comparator|Stretching|Control
16417819|NCT03855462|Experimental|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :
~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.
~MCT ablation after 4 to 6 weeks (after effective retinopexy)"
16417820|NCT03855449|Other|Task Analysis Intervention Group|DECIDE problem-solving curriculum will be delivered in a group setting.
16417821|NCT03855423|Experimental|Tocotrienol-rich Fraction (TRF)|Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.
16417822|NCT03855410|Experimental|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
16417823|NCT03855410|Experimental|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
16417824|NCT03855397|Experimental|Microneedles|Application of microneedle patch, 30G hypodermic needle (positive control) and flat patch (negative control) in the lip, buccal, tongue, palatal and gingival mucosa for pain and safety assessment
16417825|NCT03855384|Experimental|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
16417826|NCT03855384|Placebo Comparator|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
16417827|NCT03855371|Experimental|Decitabine plus arsenic trioxide|decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
16417828|NCT03855358|Experimental|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
16417829|NCT03855345|Experimental|Control group|In this group, the participants will be submitted to the conventional treatment. The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
16417866|NCT03855163|Experimental|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
16417830|NCT03855345|Experimental|aPDT group|In this group, besides the conventional treatments, patients will also receive aPDT. aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F & A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
16417831|NCT03855332|Placebo Comparator|Placebo|"All participants will undergo three phases in random order:
~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
16417832|NCT03855332|Experimental|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
16417833|NCT03855332|Active Comparator|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
16417834|NCT03855319|Experimental|SMR neurofeedback training to MCI|"A sensorimotor/theta neurofeedback training consisted of 20 individuals sessions, twice a week during 11 weeks maximum. For each subject, NF was planned and conducted by a neuropsychologist experienced in neurophysiology an neurofeedback. Each session lasted 1h10 minutes and was conducted as follows:
~Preparation and installation of the electrodes, verification of the impedance, adjustement of the calibration.
~NF training (tasks and video described below)(45minutes)
~Feedback and debriefing about the session (15 minutes)"
16417835|NCT03855306|Experimental|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
16417836|NCT03855306|Active Comparator|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
16417837|NCT03855293|Other|Study group|rhexis protection shield
16417838|NCT03855293|No Intervention|Control group|regular surgery
16417839|NCT03855280|Experimental|APVO101|
16417840|NCT03855267|Placebo Comparator|Group A|Propofol 20 mg/ml, recommended anesthesia induction dose of 0.1~0.125 ml/kg, anesthesia maintenance pump speed of 0.2~0.5ml/kg/h. keep bispectral index within 40 # 60
16417841|NCT03855267|Active Comparator|GroupB|EP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
16417842|NCT03855267|Active Comparator|Group C|EP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
16417843|NCT03855267|Active Comparator|Group D|EP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
16417844|NCT03855254|Experimental|Positive communication|
16417845|NCT03855254|No Intervention|Control (neutral communication)|
16417846|NCT03855254|Experimental|Negative communication|
16417847|NCT03855241|Active Comparator|Informational Sheet|Persons picking up an opioid prescription will receive an informational sheet that describes how to properly dispose of leftover opioid medications
16417848|NCT03855241|Active Comparator|Drug Disposal Kit|Persons picking up an opioid prescription will receive a drug disposal kit (DisposeRx Drug Disposal kit) and instructions on how to use it
16417849|NCT03855241|No Intervention|No intervention|Persons picking up an opioid prescription will receive no additional information or materials on disposal.
16417850|NCT03855228|Experimental|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
16417851|NCT03855228|Active Comparator|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
16417852|NCT03855228|Active Comparator|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
16417853|NCT03855228|Placebo Comparator|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
16417854|NCT03855215|Experimental|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.
~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.
~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:
~CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended."
16417855|NCT03855215|No Intervention|Control|Working as routine
16417856|NCT03855202|Experimental|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
16417857|NCT03855202|Experimental|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
16417858|NCT03855202|Experimental|infusion group 3|PS,dose is 70mg/kg
16417859|NCT03855202|Placebo Comparator|Placebol|0.9% sodium chloride installation after 24 hours
16417860|NCT03855189|Experimental|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
16417861|NCT03855189|Active Comparator|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
16417862|NCT03855189|Placebo Comparator|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
16417867|NCT03855163|Experimental|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
16417868|NCT03855163|No Intervention|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
16417869|NCT03855137|Active Comparator|Atogepant 30 mg BID|Taken twice daily
16417870|NCT03855137|Active Comparator|Atogepant 60 mg|Taken once daily
16417871|NCT03855137|Placebo Comparator|Placebo|Taken twice daily
16417872|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
16417877|NCT03855098|Other|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
16417878|NCT03855072|Experimental|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback
~- intervention:
~All cases will undergo one surgery under general anesthesia.
~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region
~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.
~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS
~The customized fixation plate is positioned to fix the proximal and distal segment together"
16417879|NCT03855072|Active Comparator|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation
~- intervention:
~All cases will undergo one surgery under general anesthesia
~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .
~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.
~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
16417880|NCT03855059|Placebo Comparator|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
16417881|NCT03855059|Active Comparator|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
16417882|NCT03855046|Experimental|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
16417883|NCT03855046|Active Comparator|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
16417884|NCT03855033|Experimental|Media Aware Sexual Health - High School|Students received the web-based Media Aware Sexual Health - High School program.
16417885|NCT03855033|No Intervention|Typical Health Education Programming|Students received their regular health education programming not related to sexual health education.
16417886|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
16417887|NCT03855007|Experimental|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
16417888|NCT03854994|Experimental|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
16417889|NCT03854981|Placebo Comparator|Standard Care|If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.
16417890|NCT03854981|Active Comparator|Exercise + Standard Care|Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.
16417891|NCT03854968|Experimental|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
16417892|NCT03854955|Experimental|iScribes|Device-based scribing service used for dictation and documentation.
16417893|NCT03854955|No Intervention|Traditional Dictation|Standard dictation and documentation methods used.
16417894|NCT03854942|Other|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
16417895|NCT03854942|Other|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
16417896|NCT03854942|Other|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
16417897|NCT03854929|Active Comparator|Ciprofloxacin|Each sachet CIPROFLOXACIN of 3g powder contains: 250mg Ciprofloxacin HCl, dissolved in water, dosed to 15mg/kg body weight /twice daily (apart 12 hours)/ 3 days.
16417898|NCT03854929|Experimental|Azithromycin|Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days
16417899|NCT03854916|Experimental|Caminemos Juntas App|Participants use the Caminemos app.
16417900|NCT03854916|Active Comparator|World Walking App|Participants use the World of Walking App.
16417901|NCT03854903|Experimental|Dose Level A1|"Palbociclib: 75mg daily for 21 days of each 28 day cycle
~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle
~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
16417902|NCT03854903|Experimental|Dose Level A2|"Palbociclib: 75mg daily for the first 21 days of each 28 day cycle
~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
16417903|NCT03854903|Experimental|Dose Level B1|"Palbociclib: 100mg daily for 21 days of each 28 day cycle
~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle
~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
16417904|NCT03854903|Experimental|Dose Level B2|"Palbociclib: 100mg daily for 21 days of each 28 day cycle
~Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle
~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
16417905|NCT03854890|No Intervention|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
16417906|NCT03854890|Experimental|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
16417907|NCT03854877|Experimental|Health behaviour intervention|Personalised health behaviour e-health intervention. The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to promote health habits. Based on personal needs participants can choose tasks for physical activity, relaxation, healthy eating, sleep etc. They get regular feedback, tasks and support from their personal trainer via phone and computer.
16417908|NCT03854877|No Intervention|Control group|Only before and after measurements
16417909|NCT03854864||Oncologists|French oncologists
16417910|NCT03854851|Experimental|NALDEBAIN|In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.
16417911|NCT03854851|Active Comparator|MORPHINE|In group MORPHINE, subjects will receive morphine as needed after surgery.
16417912|NCT03854838|Experimental|Toripalimab +Radiotherapy|Radiotherapy, intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks ) will be administered as an intravenous infusion over 60 minutes.
16417913|NCT03854825||AKI|patients with postoperative AKI defined by KDIGO
16417914|NCT03854825||no AKI|patients without postoperative AKI defined by KDIGO
16417915|NCT03854812|Active Comparator|Group M|magnesium sulphate as adjuvant to propofol
16417916|NCT03854812|Active Comparator|Group F|fentanyl as adjuvant to propofol
16417917|NCT03854799|Experimental|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:
~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
16417918|NCT03854786|Active Comparator|Oxyjun|Oxyjun- 400 mg OD after breakfast
16417919|NCT03854786|Placebo Comparator|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
16417920|NCT03854773|Active Comparator|Erector spinae block (Group ESPB)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
16417921|NCT03854773|Active Comparator|Thoracal paravertebral block group (Group TPVB)|In group B, TPVB will be performed. US probe will be placed 2-3 cm laterally following the visualization T5 spinous process in sagittal orientation. The ribs and transverse processes will be visualized as hyperechoic structures. The costotransverse ligament will be visualized in the superior, and the pleura in the anterior region. Using in plane technique, the block needle will be inserted in the cranio-caudal direction until the costotransverse ligament will be passed. For confirmation of correct position of the needle, 5 ml saline will be injected. After the negative aspiration of cerebrospinal fluid, blood and air; 20 ml of 0.25% bupivacaine will be performed and it will be seen of moving downwards of the pleura during the injection
16417922|NCT03854773|Other|Control group (Group C)|Patients in control group will be only received fentanyl via a patient controlled analgesia (PCA) device.
16417923|NCT03854760|Experimental|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
16417926|NCT03854734|No Intervention|Usual Care|Educational emails about broad health topics to keep control group engaged
16417927|NCT03854734|Active Comparator|Multi-Component Intervention|(1) a community event to raise parental awareness of the importance of vaccination; (2) social marketing to target parents' attitudes and knowledge around vaccinations in the form of educational material
16417928|NCT03854721|Experimental|VAX014|Intravesical VAX014 (dose: 3.33x10^10 - 9.0x10^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
16417929|NCT03854708|Experimental|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg*min of pancreatic polypeptide was intravenously infused.
16417930|NCT03854708|Experimental|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg*min of pancreatic polypeptide was intravenously infused.
16417931|NCT03854708|Placebo Comparator|Placebo|0.9 % saline solution was intravenously infused.
16417932|NCT03854695||Cohort 1|Cohort 1: clinically uninfected (1A and 1C) ulcers.
16417933|NCT03854695||Cohort 2|Cohort 2: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) with no recent antibiotic therapy (within 28 days)
16417934|NCT03854695||Cohort 3|Cohort 3: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) on antibiotic therapy
16417935|NCT03854682|Experimental|Surgical|Radiofrequency microtenotomy (RF): A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
16417936|NCT03854682|Active Comparator|Non-surgical|Strength training: Consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
16417937|NCT03854669|Experimental|Assessing pain reporting accuracy|Subjects will undergo pre-operative evaluation of their pain reporting accuracy ability in order to assess its relation to post-operative acute pain and analgesic consumption
16417938|NCT03854656|No Intervention|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
16417939|NCT03854656|Experimental|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
16417940|NCT03854643|Experimental|Pilates group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
16417941|NCT03854643|Experimental|Control group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
16417942|NCT03854630|Active Comparator|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
16417943|NCT03854630|Experimental|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
16417944|NCT03854617|Experimental|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
16417945|NCT03854617|Active Comparator|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period.
16417946|NCT03854591||Gunshot related injury|Patients admitted to orthopaedic trauma service with gunshot related injury
16417947|NCT03854578|Experimental|BI 1358894|
16417948|NCT03854578|Experimental|Citalopram|
16417949|NCT03854578|Experimental|Placebo matching BI 1358894|
16417950|NCT03854565||Mild ARDS|patients have mild ARDS according to Berlin definition
16417951|NCT03854565||Moderate ARDS|patients have moderate ARDS according to Berlin definition
16417952|NCT03854565||Severe ARDS|patients have severe ARDS according to Berlin definition
16417953|NCT03854552|Experimental|BI 764198|Single rising oral doses
16417954|NCT03854552|Placebo Comparator|Placebo|Single rising oral doses
16417955|NCT03854539|Experimental|Active Stimulation 0.5|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
16417956|NCT03854539|Sham Comparator|Sham Stimulation|0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles
16417957|NCT03854539|No Intervention|No Stimulation|0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles
16417958|NCT03854539|Experimental|Active Stimulation 1.0|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.
16417959|NCT03854539|Experimental|Active Stimulation 0.25|0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
16417960|NCT03854526||Patients without Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months and with at least one tooth with coronal dental restoration
16417961|NCT03854526||Patients with Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months, with at least one tooth with coronal dental restoration and presenting a Gougerot Sjogren disease
16417962|NCT03854513||-Group 1 (anuric)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output less than 100ml / day
16417963|NCT03854513||Group 2 (good UOP)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output 400ml / day or more
16417964|NCT03854500|Active Comparator|Tenecteplase|Tenecteplase
16417965|NCT03854500|Active Comparator|Alteplase|Alteplase
16417966|NCT03854487|Experimental|Mirror therapy|
16417967|NCT03854487|Sham Comparator|Sham mirror|
16417968|NCT03854487|Active Comparator|Covered mirror|
16418053|NCT03853993|Experimental|Experimental group-phase III|Quadrivalent influenza vaccine
16417970|NCT03854461|Active Comparator|Educational material|Participants will be given written educational material to encourage dietary change towards a better quality diet. Educational material will be adapted from resources used in previous dietary intervention studies.
16417971|NCT03854461|Experimental|Personalised dietary advice and educational material|Participants will also be given the educational material, but will be encouraged to make dietary change using individualized recommendations incorporating food markers of specific components of a high quality diet. Food markers of diet quality will be used to develop an algorithm to deliver personalized dietary advice. Based on biomarker data, a system of categorization of biomarker status will be developed, alongside dietary advice related to this biomarker categorization, and decision trees created, as previously described in the Food4Me study, to ensure standardized delivery of advice within this intervention arm.
16417972|NCT03854435|Experimental|Heart rate assessed by using a stethoscope (auscultation)|Heart rate will be assessed by using a stethoscope (auscultation) in newborn infants immediately after birth
16417973|NCT03854435|Active Comparator|Heart rate assessed by palpation of the umbilical cord|Heart rate will be assessed by palpation of the umbilical in newborn infants immediately after birth
16417974|NCT03854422|Active Comparator|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
16417975|NCT03854422|Active Comparator|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
16417976|NCT03854422|Active Comparator|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
16417977|NCT03854409|Experimental|Part A - Deltoid Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
16417978|NCT03854409|Experimental|Part A - Gluteal Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
16417979|NCT03854409|Experimental|Part A - Deltoid Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
16417980|NCT03854409|Experimental|Part A - Gluteal Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
16417981|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (X)|Participants will receive a single dose of aripiprazole LAI.
16417982|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (Y)|Participants will receive a single dose of aripiprazole LAI.
16417983|NCT03854409|Experimental|Part B - Gluteal Site: Group 2|Participants will receive a single dose of aripiprazole LAI.
16417984|NCT03854396|Active Comparator|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
16417985|NCT03854396|Placebo Comparator|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
16417986|NCT03854383|Sham Comparator|Misoprostol alone|Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses
16417987|NCT03854383|Active Comparator|Isosorbide mononitrate with misoprostol|Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses
16417988|NCT03854370|Experimental|Baby shampoo|Baby shampoo used for surgical site prep
16417989|NCT03854370|Active Comparator|Peridex (Chlorhexidine)|Peridex used for surgical site prep
16417990|NCT03854370|Active Comparator|TechniCare (chloroxynel)|TechniCare used for surgical site prep
16417991|NCT03854370|Active Comparator|Betadine (Povidone- iodine)|Betadine used for surgical site prep
16417992|NCT03854357|Experimental|Additional Isolated Subscapularis Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
16417993|NCT03854357|Active Comparator|Standard Post-Operative TSA Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
16417994|NCT03854344|Experimental|Group 1|Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
16417995|NCT03854344|Active Comparator|Group 2|Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
16417996|NCT03854331|Experimental|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
16417997|NCT03854331|No Intervention|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
16417998|NCT03854318||Family|Direct family members of enrolled patients will be asked to enroll in the study to provide specimens for genetic testing, next-generation sequencing, and other related studies.
16417999|NCT03854318||RUNX1|Patients enrolled in this protocol will have been referred with a known or suspected RUNX1 mutation.
16418000|NCT03854305|Experimental|PRV-6527|Oral administration, 2X daily for 12 weeks
16418001|NCT03854305|Placebo Comparator|Placebo|Oral administration, 2X daily for 12 weeks
16418002|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
16418003|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
16418004|NCT03854279|Experimental|Bizact|Tonsillectomy will be done With the Bizact device
16418005|NCT03854279|Active Comparator|Electro-scissor|Tonsillectomy will be done With electro-scissors
16418006|NCT03854266|Experimental|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
16418007|NCT03854266|Active Comparator|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
16418008|NCT03854253|Experimental|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
16418009|NCT03854253|Active Comparator|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
16418010|NCT03854240|Active Comparator|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
16418011|NCT03854240|Active Comparator|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
16418012|NCT03854227|Experimental|Dose Escalation|Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
16418013|NCT03854227|Experimental|Non small cell lung cancer monotherapy|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
16418014|NCT03854227|Experimental|Urothelial carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
16418015|NCT03854227|Experimental|Head and neck squamous cell carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
16418016|NCT03854227|Experimental|Non small cell lung cancer PF-06939999 plus docetaxel|Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
16418017|NCT03854227|Experimental|Non small cell lung cancer dose finding|Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
16418018|NCT03854214|Active Comparator|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
16418019|NCT03854214|Sham Comparator|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
16418020|NCT03854201|Experimental|Personalized Exercise Counseling (PEC)|The Personalized Exercise Counselling intervention includes 3 face-face counseling sessions and 4-6 phone calls during six months. In addition, the participants are provided with the ExSed® interactive accelerometer to record their physical activity 24/7 from which they will receive personal daily feedback on their smart phone, which is provided to each person not having a suitable one of their own to be used during the 6-month intervention period.
16418021|NCT03854201|No Intervention|Control-arm|The participants only take part in the study measurements at baseline and the three follow-up time points. They will be provided personal written information by the UKK Institute on their blood sugar and lipid profiles, objectively measured physical activity (light, moderate, vigorous), standing, sedentary behaviour and sleep, and the three fitness tests measuring flexibility, muscular strength and cardiorespiratory fitness.
16418022|NCT03854188|Experimental|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
16418023|NCT03854175|Active Comparator|Sildenafil group|40 women are give sildenafil citrate 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle, in addition to oral 2mg of estradiol valerat 6-8 hourly from the day 2-14 of the menstrual cycle
16418024|NCT03854175|Active Comparator|estradiol group|40 women are given oral estradiol valerate tablets 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium in addition to placebo in the same way as sildenafil
16418051|NCT03854006|Active Comparator|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
16470570|NCT03494504|Placebo Comparator|Vehicle Ophthalmic Solution|
16418025|NCT03854162|Active Comparator|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
16418026|NCT03854162|Active Comparator|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
16418027|NCT03854162|Active Comparator|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
16418028|NCT03854162|Active Comparator|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
16418029|NCT03854149||Adults with CHD & non-valvular atrial arrhythmias|Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)
16418030|NCT03854123||Old MS patients|"75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP)."
16418031|NCT03854110|Experimental|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 of a 28 day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
16418032|NCT03854097|Experimental|Active PAD group|-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
16418033|NCT03854097|Experimental|Placebo PAD group|-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
16418034|NCT03854097|Experimental|Healthy Volunteers|-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
16418035|NCT03854084|Experimental|Intervention group|The cranial osteopathic techniques
16418036|NCT03854084|Sham Comparator|control group|Control group
16418037|NCT03854071|Other|Group 1|Heart failure patients with preserved ejection fraction
16418038|NCT03854071|Other|Group 2|Heart failure patients with reserved ejection fraction
16418039|NCT03854071|Other|Group 3|Patients with pulmonary hypertension
16418040|NCT03854071|Other|Group 4|Patients with acute myocardial infarction
16418041|NCT03854071|Other|Group 5|Patients with suspected but not treated coronary artery disease
16418042|NCT03854071|Other|Group 6|Healthy Volunteers
16418043|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)
~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning ~ evening), bicarbonate < 27 mmol/L awake)
~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning > evening, bicarbonate ≥ 27 mmol/L awake)
~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) > 45 mmHg awake)
~stage IV: OHS with end organ damage (hypercapnia , PCO2 > 45 mmHg awake, cardiometabolic comorbidities)
~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
16418044|NCT03854045|Experimental|Home-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the home with 2 clinicians present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR but are not eligible for Medicaid reimbursement.
16418045|NCT03854045|Active Comparator|Clinic-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the clinic with 1 clinican present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR and eligible for Medicaid reimbursement.
16418048|NCT03854019|Experimental|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
16418049|NCT03854019|Placebo Comparator|Placebo|Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
16418050|NCT03854006|Active Comparator|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is < 75 s. In case of TTI>75s a 240s bonus freeze is applied.
~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
16418052|NCT03853993|Experimental|Experimental group-phase I|Quadrivalent influenza vaccine
16418054|NCT03853993|Active Comparator|Control group-1-phase III|Trivalent influenza vaccine (contains B/Victoria strain)
16418055|NCT03853993|Active Comparator|Control group-2-phase III|Trivalent influenza vaccine (contains B/Yamagata strain)
16418056|NCT03853980|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
16418057|NCT03853967|Experimental|screening|participants performed lung cancer screening by Low Dose CT scan
16418058|NCT03853954|Experimental|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: <15 minutes
16418059|NCT03853941|No Intervention|Control|Patients in the control group will receive treatment as usual.
16418060|NCT03853941|Experimental|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
16418061|NCT03853928|Experimental|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
16418062|NCT03853928|Placebo Comparator|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
16418063|NCT03853915|Experimental|FDG PET Scan|[F-18] - FDG PET Scan and blood sample to measure HPV DNA
16418064|NCT03853902|Experimental|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
16418065|NCT03853902|Active Comparator|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
16418066|NCT03853889|Active Comparator|preepidural ONSD|The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
16418067|NCT03853889|Experimental|post epidural ONSD|The diameter of the optic nerve sheath to be measured with the help of ultrasonography Immediately after epidural anesthesia(post epidural ONSD) (T1), 15 minutes (T2), 30 min (T3), 60. min (T4) epidural anesthesia. The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
16418068|NCT03853863|Experimental|minimalist shoes walking group (MSW)|Subjects in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., in-school walking training with minimalist shoes).
16418069|NCT03853863|Active Comparator|traditional shoes walking group (TSW)|Subjects in the TSW group will be given a pair of protective shoes with arch support while following the same wearing pattern as the MSW group (i.e., in-school walking training with protective shoes).
16418070|NCT03853850|Experimental|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
16418071|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
16418072|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
16418073|NCT03853824|Other|Intervention arm|Patients randomised to increased postoperative surveillance.
16418074|NCT03853824|Other|Control arm|Patients randomised to usual postoperative care.
16418075|NCT03853811|Experimental|Mitchell Shoe + AFO|Group will receive standard Mitchell shoes along with the custom orthotic insert.
16418076|NCT03853811|No Intervention|Standard Mitchell Shoe (Control - Standard Treatment)|Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.
16418077|NCT03853798|Experimental|Cohort 1|"Participants who received placebo in Study AG348-C-006 will enroll in Cohort 1.
~Part 1 (Dose Optimization Period, 12 weeks): Participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day and then to 50 mg twice a day depending on their response to AG-348 and tolerability.
~Part 2 (Fixed Dose Period, 12 weeks): Last dose received in Part 1, twice a day.
~After completion of Part 2, participants who, in the opinion of the Investigator, have demonstrated clinical benefit from AG-348 treatment will continue AG-348 treatment in the Continued Treatment Period."
16418078|NCT03853798|Experimental|Cohort 2|"Participants who received AG-348 in Study AG348-C-006 will enroll in Cohort 2.
~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-006."
16418079|NCT03853798|Experimental|Cohort 3|"Participants who received AG-348 in Study AG348-C-007 will enroll in Cohort 3.
~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-007."
16418080|NCT03853785|Active Comparator|Intralesional MMR vaccine|Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
16418081|NCT03853785|Active Comparator|intralesional candida antigen|intralesional candida antigen in genital warts
16418082|NCT03853785|Active Comparator|Topical Podophyllin|Topical Podophyllin in genital warts
16418083|NCT03853759||Patients with Heart Failure|
16418084|NCT03853759||Healthy İndividuals|
16418085|NCT03853746|Experimental|Ocrelizumab|All participants will receive Ocrelizumab
16418086|NCT03853720|Experimental|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
16418087|NCT03853707|Experimental|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16418247|NCT03852641|Experimental|Continuous feeds|Continuous feeds over 2.0 hrs
16470635|NCT03493997|Active Comparator|Radiotherapy only|Radiotherapy only
16418088|NCT03853707|Active Comparator|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16418089|NCT03853707|Experimental|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16418090|NCT03853694|Active Comparator|Group 1 (Standard of Care Group)|150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
16418091|NCT03853694|Experimental|Group 2 (Duramorph + EXPAREL TAP)|50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
16418092|NCT03853694|Experimental|Group 3 (EXPAREL TAP)|EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
16418093|NCT03853681|Other|additional blood sampling|
16418094|NCT03853668|Active Comparator|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.
~Exercise intensity is 50-65%of maximal heart rate (MHR)"
16418095|NCT03853668|Experimental|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
16418096|NCT03853655|No Intervention|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
16418097|NCT03853655|Experimental|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
16418098|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
16418099|NCT03853629||CF|"Age 1-17
~Diagnosis of Cystic Fibrosis
~Living in or around London"
16418100|NCT03853629||Controls|"Age 1-17
~Healthy
~Living in or around London"
16418101|NCT03853616|Experimental|Phase I: DL 0: 1x10e5 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
16418102|NCT03853616|Experimental|Phase I: DL 1: 5x10e5 MB-CART19.1 cells|Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
16418103|NCT03853616|Experimental|Phase I: DL 2: 1x10e6 MB-CART19.1 cells|Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
16418104|NCT03853616|Experimental|Phase I: DL 3: 3x10e6 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.
16418105|NCT03853616|Experimental|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively.
16418106|NCT03853603|Placebo Comparator|Placebo|Maltodextrin
16418107|NCT03853603|Active Comparator|Santa herba extract|Santa herba extract
16418108|NCT03853590|Active Comparator|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
16418109|NCT03853590|Experimental|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
16418110|NCT03853577|Active Comparator|Psilocybin|
16418111|NCT03853577|Placebo Comparator|Placebo|
16418112|NCT03853564|Experimental|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
16418113|NCT03853564|Sham Comparator|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
16418114|NCT03853551|Experimental|Single|Single arm
16418115|NCT03853538|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
16418116|NCT03853538|Active Comparator|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
16418117|NCT03853525|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with BAY207543 is investigated.
16418118|NCT03853525|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with vaseline is investigated.
16418119|NCT03853512|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
16418120|NCT03853512|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
16418121|NCT03853499||Successful vacuum extraction|Patients for whom vacuum extraction was successful
16418122|NCT03853499||Failed vacuum extraction|Patients who had an emergency caesarean section after failed vacuum extraction
16418123|NCT03853473|No Intervention|Standard of Care|Study participants will receive standard of care.
16418124|NCT03853473|Experimental|Remote Ischemic Preconditioning|Study participants will perform remote ischemic preconditioning daily, at home, from study enrollment to their date of surgery.
16418125|NCT03853460|Active Comparator|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
16418126|NCT03853460|Active Comparator|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
16418127|NCT03853447||Diagnostic imaging|"The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including
~Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.
~Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.
~Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria."
16418128|NCT03853434|Experimental|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
16418129|NCT03853434|No Intervention|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
16418130|NCT03853421|Experimental|Dose cohort 3 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
16418131|NCT03853421|Experimental|Dose cohort 6 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
16418132|NCT03853421|Experimental|Dose cohort 9 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
16418133|NCT03853408||First Admission|Cholecystectomy during first admission
16418134|NCT03853408||Second Admission|Cholecystectomy during second admission
16418135|NCT03853395|Active Comparator|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
16418136|NCT03853395|Experimental|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
16418137|NCT03853382|Experimental|Cognitive Analytic Informed Brief Therapy|
16418138|NCT03853382|No Intervention|Treatment As Usual|
16418139|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|
16418140|NCT03853343|Placebo Comparator|Placebo|3 capsules per day (1 before each meal) of cellulose
16418141|NCT03853343|Active Comparator|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
16418142|NCT03853330|Active Comparator|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
16418143|NCT03853330|Active Comparator|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
16418144|NCT03853317|Experimental|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on Blinded Independent Central Review (BICR).
16418145|NCT03853304|Experimental|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
16418146|NCT03853304|Experimental|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
16418147|NCT03853304|Experimental|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
16418148|NCT03853304|Active Comparator|Double-fortified salt (DFS)|Salt fortified with iron and iodine
16418561|NCT03850353||OSAS|Patients with Obstructive Sleep Apnea (AHI>15 in a sleep study)
16418149|NCT03853291|Experimental|PICT Workbook|PICT Workbook components will include: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set.
16418150|NCT03853291|Active Comparator|Information Pamphlet|Informational pamphlet about pain in dementia and a link to the Alzheimer's Association website.
16418151|NCT03853278|Experimental|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
16418152|NCT03853278|No Intervention|No intervention control group|The control group will receive health education leaflets.
16418153|NCT03853265|No Intervention|Control|
16418154|NCT03853265|Experimental|Virtual Reality|Simulated dental office visit
16418155|NCT03853252|Other|Skin biopsy|
16418156|NCT03853239|Active Comparator|face mask crossover nasal ventilation|
16418157|NCT03853239|Active Comparator|nasal ventilation crossover face mask|
16418158|NCT03853213|Experimental|Cognitive Bias Modification Training|"Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., death, chest pain) and toward neutral stimuli (e.g., curve, barn doors). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign."
16418159|NCT03853213|Sham Comparator|Attention Control Training|Participants in this placebo control group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is the placebo version of Cognitive Bias Modification Training for Attention. It is designed NOT to train attention toward or away from threatening or neutral information. The second task is the placebo version of Cognitive Bias Modification Training for Interpretation. It is designed NOT to train the interpretation of information as either threatening or benign.
16418160|NCT03853200|Experimental|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
16418161|NCT03853200|Active Comparator|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
16418162|NCT03853200|Active Comparator|Group III|17% EDTA with no antibacterial activity . the control group
16418164|NCT03853174|Active Comparator|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
16418165|NCT03853174|Other|RT|Resistance training were prformed. Intensity was gradually increased.
16418166|NCT03853161|Experimental|Vapotherm arm|Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA
16418167|NCT03853161|Experimental|NIPPV arm|Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator
16418168|NCT03853148|Active Comparator|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
16418169|NCT03853148|Active Comparator|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
16418170|NCT03853148|Active Comparator|Otago + GYYB + Behavioral activation|This condition will incorporate OEP and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
16418171|NCT03853148|Experimental|Caregiver Gentle yoga & yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the GYYB group each exercise and their perceived benefits.
16418172|NCT03853135||Behçet group|Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed.
16418173|NCT03853135||control group|including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed.
16418174|NCT03853122|Active Comparator|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:
~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).
~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).
~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
16418175|NCT03853122|Experimental|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):
~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
16418185|NCT03853096|Experimental|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.
~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
16418186|NCT03853083|Experimental|Hypoxi Equipment|
16418187|NCT03853083|Active Comparator|Recumbent Bicycle|
16418188|NCT03853057|Experimental|non-invasive ventilation|Non-invasive positive pressure at different body positions: sitting - supine - prone - right lateral and left lateral.
16418189|NCT03853044|Experimental|Chidamide plus CHOP|Participants received six 21-day cycles of chidamide, combined with six cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (21-day cycles).
16418190|NCT03853031|Active Comparator|LVEDA guided intraoperative fluid therapy|Patients in TEE group will be given crystalloid fluids during surgery guided by LVEDA cm2 to be maintained between 10 -18 cm2 , if LVEDA < 10 cm2 then 200ml colloid bolus will be given and increase in LVEDA noted.
16418191|NCT03853031|Active Comparator|CVP guided intraoperative fluid therapy|Patients in CVP group will be given crystalloid fluids during surgery guided by CVP values to be maintained between 10 -16 cms of water H2O ,if CVP value < 10 cms H2O then 200 ml colloid bolus will be given and increase in CVP value noted.
16418192|NCT03853018|No Intervention|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
16418193|NCT03853018|Experimental|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
16418194|NCT03853018|Experimental|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
16418195|NCT03853005|Placebo Comparator|Group A (controlled group)|They will not receive HVHDF treatment
16418196|NCT03853005|Active Comparator|Group B (HVHDF group)|They will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.
16418197|NCT03852992|Experimental|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:
~Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)
~Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)
~Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
16418198|NCT03852992|Placebo Comparator|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage
~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
16418199|NCT03852992|Experimental|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage
~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
16418200|NCT03852992|Experimental|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage
~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure
~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
16418201|NCT03852979|Experimental|neo-adjuvant chemotherapy|The patients are given weekly paclitaxel 80 mg/m2 + carboplatin AUC=2 (or AUC=6 per three weeks) during 12 weeks/4 courses followed by conization if tumor size is reduced to <2 cm
16418202|NCT03852966|Experimental|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
16418203|NCT03852953||Study 1: Under- and overdiagnosed group|Non-proportional stratified sample of women diagnosed with interval or screen-detected breast cancers after participation in BreastScreen Norway. This sample will include under- or overdiagnosed cancers, as well as cancers that were not under- or overdiagnosed.
16418204|NCT03852953||Study 2: Rate of overdiagnosis group|Women residing in Norway, born between 1927 and 1934 (inclusive). This cohort will include women who have attended screening and who have not attended screening.
16418205|NCT03852953||Study 3: Awareness and knowledge group|Women aged 50-69, and practising family doctors aged 25-75, currently living in Norway.
16418206|NCT03852940|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
16418207|NCT03852940|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
16418208|NCT03852914|Experimental|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
16418209|NCT03852901|Experimental|Single Arm|Single group
16418210|NCT03852888|Experimental|mtugroup|All patients managed for rheumatoid arthritis (according to the ACR / EULAR 2010 criteria) in the Rheumatology Department of the University Hospital of Reims and treated with methotrexate monotherapy.
16418211|NCT03852875|Experimental|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
16418212|NCT03852875|Sham Comparator|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
16418213|NCT03852862|Experimental|Serratus plane block with paravertebral block|Association of Serratus plane block and paravertebral block for anesthesia
16418214|NCT03852862|Active Comparator|paravertebral block alone|Paravertebral block for anesthesia
16418215|NCT03852849|No Intervention|routine care group|Medical institutions will provide patients routine care according to the national program standard.
16418216|NCT03852849|Experimental|medicine intervention group|The dosage of 400 mg EFV will be used in the antiviral therapy.
16418217|NCT03852849|Experimental|consolidated intervention group|Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
16418218|NCT03852836|Other|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
16418219|NCT03852836|Other|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
16418220|NCT03852823|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
16418223|NCT03852797|Active Comparator|Ketamine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
16418224|NCT03852797|Active Comparator|Ketamine + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
16418225|NCT03852797|Active Comparator|Propofol|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
16418226|NCT03852797|Active Comparator|Propofol + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
16418227|NCT03852797|Active Comparator|Etomidate|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
16418228|NCT03852797|Active Comparator|Etomidate + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
16418229|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
16418230|NCT03852771|Experimental|Treatment|All participants will receive the intervention
16418231|NCT03852758|Experimental|Outdoor Exercise|2 sessions of outdoor exercise per week
16418232|NCT03852758|Experimental|Indoor Exercise|2 sessions of indoor exercise per week
16418233|NCT03852745|Other|Cognitive Behavioral Therapy|Online cognitive behavioral therapy intervention for 2 hours a week for 12 weeks.
16418234|NCT03852732|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
16418238|NCT03852706|Experimental|LORETA|In the first session, Low Resolution Brain Electromagnetic Tomography (LORETA) will be used in combination with Z-scores to identify participants' resting state EEG differences relative to a database of norms of their demographic. EEG abnormalities which are consistent with the research literature on neural changes associated with AVH will then be targeted for normalization using neurofeedback training using LORETA in combination with Z-scores.
16418239|NCT03852706|Other|Treatment as usual|Maintenance use of an atypical antipsychotic (e.g., clozapine) with support, when needed, of a community nurse.
16418242|NCT03852667|No Intervention|Control|No intervention between the two test sessions
16418243|NCT03852667|Active Comparator|Pain Neuroscience Education|Two sessions (30 min) of Pain Neuroscience Education
16418244|NCT03852667|Experimental|Pain neuroscience education - exercise|2 sessions of PNE and 5 sessions of exercise therapy.
16418245|NCT03852654|Experimental|treatment|
16418246|NCT03852641|Experimental|Bolus gavage feeds|Bolus gavage feeds over 15-30 minutes
16418248|NCT03852628|Active Comparator|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol
~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
16418249|NCT03852628|Placebo Comparator|Placebo|"Placebo (SL pill qd, IM injection q4weeks)
~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
16418250|NCT03852615|Experimental|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
16418251|NCT03852615|Other|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
16418252|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
16418253|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
16418254|NCT03852589|Active Comparator|C-MAC Videolaryngoscope|C-MAC Videolaryngoscope: An intubating device that is used for endotracheal intubation. Proseal laryngeal mask airway will be inserted with C-MAC Videolaryngoscope
16418255|NCT03852589|Active Comparator|Blind|Proseal laryngeal mask airway will be inserted with digital finger
16418256|NCT03852576|Experimental|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
16418257|NCT03852563|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
16418258|NCT03852563|Active Comparator|Women_Hemiface Vaseline|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
16418259|NCT03852550|Experimental|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition[TM] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
16418260|NCT03852550|No Intervention|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
16418261|NCT03852537|Active Comparator|Usual Care|Usual care as determined by the patient's primary team.
16418262|NCT03852537|Experimental|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP < 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level > 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
16418265|NCT03852511|Experimental|Intravenous|Patients will receive three single doses of NG-350A by IV infusion, followed by multiple cycles of check point inhibitor treatment.
16418266|NCT03852498|Experimental|Lenti-D Drug Product|
16418267|NCT03852485||Normal|no glaucoma or retinal pathology or corneal conditions
16418268|NCT03852485||Glaucoma|diagnosis of glaucoma
16418269|NCT03852485||Retina|diagnosis of AMD, DR or other retinal pathology
16418270|NCT03852485||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
16418271|NCT03852472|Placebo Comparator|Group A|Placebo b.i.d
16418272|NCT03852472|Active Comparator|Group B|Avacopan 10 mg b.i.d
16418273|NCT03852472|Active Comparator|Group C|Avacopan 30 mg b.i.d
16418274|NCT03852459|Experimental|Active Arm|S-Ibuprofen Topical Gel 5%
16418275|NCT03852459|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
16418276|NCT03852446|Experimental|Part 1: Single Ascending Dose|
16418277|NCT03852446|Experimental|Part 2: Bioavailability and Food Effect|"Single dose of Indoximod HCL (F2) formulation under fasting conditions
~Single dose of Indoximod HCL (F2) formulation under fed conditions
~Single dose of Indoximod base formulation under fasting conditions"
16418278|NCT03852433|Active Comparator|Arm A - Peginterferon alfa-2a|Peginterferon alfa-2a for 48 weeks with additional 48 weeks follow up
16418279|NCT03852433|Experimental|Arm B - Bulevirtide 2 mg/day|Bulevirtide 2 mg/day in combination with peginterferon alfa-2a for 48 weeks followed by Bulevirtide 2 mg/day for 48 weeks and additional 48 weeks follow up
16418280|NCT03852433|Experimental|Arm C - Bulevirtide 10 mg/day|Bulevirtide 10 mg/day in combination with peginterferon alfa-2a for 48 weeks followed by Bulevirtide 10 mg/day for 48 weeks and additional 48 weeks follow up
16418281|NCT03852433|Experimental|Arm D - Bulevirtide 10 mg/day|Bulevirtide 10 mg/day for 96 weeks with additional 48 weeks follow up
16418282|NCT03852420|Experimental|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
16418343|NCT03851874|Active Comparator|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
16418283|NCT03852407|Experimental|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
16418284|NCT03852407|Experimental|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
16418285|NCT03852381|Experimental|Spinal Cord Stimulation|"At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.
~The trial will proceed as follows:
~Day 1-4: Paresthesia-based SCS (PB-SCS)
~Day 5-8: No SCS (placebo)
~Day 9-12: PF-SCS
~Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.
~Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density)."
16418286|NCT03852368|Experimental|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
16418287|NCT03852368|Experimental|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
16418288|NCT03852368|Experimental|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
16418289|NCT03852355|Active Comparator|Radiofrequency|bilateral 3rd occipital nerve RF under fluoroscopic guidance
16418290|NCT03852355|Active Comparator|Systemic steroid|received systemic steroids oral prednisolone tablet, 10 mg/day.
16418291|NCT03852329|Experimental|Navigated|Lateral skull base navigation intervention is applied
16418292|NCT03852316|Experimental|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
16418293|NCT03852303|Active Comparator|ivermectin once a year|Ivermectin one dose per year and anti-epileptic treatment
16418294|NCT03852303|Experimental|ivermectin 2 times a year|Ivermectin one dose 2 times a year and anti-epileptic treatment
16418295|NCT03852303|Experimental|ivermectin 3 times a year|vermectin one dose 3 times a year and anti-epileptic treatment
16418296|NCT03852251|Experimental|AK104|AK104 IV every 2 weeks (q2w)
16418297|NCT03852251|Experimental|AK104 and chemotherapy|"AK104 IV every 2 weeks (q2w)
~oxaliplatin IV 85 mg/m2 q2w
~capecitabine 1000 mg/m2，twice a day (bid) for day 1 to day 10 per cycle"
16418298|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
16418299|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
16418300|NCT03852225||OHCA patients|Patients resuscitated for out-of-hospital cardiac arrest of non-traumatic origin and investigated by intra-arrest echocardiography.
16418301|NCT03852212|No Intervention|Control Group|The control group did not received any treatment
16418302|NCT03852212|Experimental|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
16418303|NCT03852199||Case Group|Our study was performed with 30 healthy individuals at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. The FS of the knee joint was measured with a Pressure Biofeedback Device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN), a device similar to a sphygmomanometer. To correlate the outcomes of biofeedback device, simultaneously, a surface electromyography (EMG) data of M. Quadriceps femoris muscle activation levels from the individuals were recorded.
16418304|NCT03852186|Active Comparator|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
16418305|NCT03852186|Experimental|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
16418306|NCT03852173|Experimental|"Intervention group Wasserschulen"|Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
16418307|NCT03852173|No Intervention|Control group|No intervention (usual education). Schools do not receive any project material. Schools got the information that they are part of a study on drinking and eating habits of third grade elementary school children.
16418308|NCT03852160|Experimental|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram [mg] [initial dose for elderly participants 65-74 years of age] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg [initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study] or 84 mg [maximum uptitrated esketamine dose]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
16418344|NCT03851874|Active Comparator|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
16470636|NCT03493984|Experimental|Ginger exosomes|
16418309|NCT03852160|Active Comparator|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
16418310|NCT03852147|Active Comparator|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
16418311|NCT03852147|Experimental|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
16418312|NCT03852134|Experimental|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
16418313|NCT03852134|Active Comparator|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.
~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
16418314|NCT03852121|Experimental|Intervention group|Participants will receive bibliotherapy without withdrawing from the usual care. They will be asked to read the designated manual (consists of eight chapters) within a recommended period of time (over 8 weeks). Weekly telephone coaching will also be provided to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves. An orientation will be organized before the first session. Two booster sessions will be organized during the study.
16418315|NCT03852121|No Intervention|Control group|The participants in the control group will only receive usual care provided by the community health professionals.
16418316|NCT03852108|Experimental|Group comfort care|Socio-aesthetic care
16418317|NCT03852108|No Intervention|Group control|Conventional care
16418318|NCT03852095||minor trauma|Child from 1 to 18 years old suffering an isolated minor trauma presenting at the hospital emergency services.
16418319|NCT03852069|Placebo Comparator|Placebo|16 g maltodextrin/day + recipes based on vegetables poor in inulin-type fructans
16418320|NCT03852069|Experimental|Inulin|16 g inulin/day + recipes based on vegetables rich in inulin-type fructans
16418321|NCT03852056|Placebo Comparator|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
16418322|NCT03852056|Experimental|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
16418323|NCT03852043|Experimental|High-intensity interval training|
16418324|NCT03852043|Active Comparator|Moderate-intensity continuous training|
16418325|NCT03852030|Experimental|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.
~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
16418326|NCT03852030|Placebo Comparator|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
16418327|NCT03852030|No Intervention|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
16418328|NCT03852017|Experimental|Mindfulness Audio Program|Mindfulness Audio Program is a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life
16418329|NCT03852017|Active Comparator|Music Audio Program|Music Audio Program is a daily audio session of peaceful and relaxing music
16418330|NCT03852004|Experimental|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
16418331|NCT03852004|Placebo Comparator|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
16418332|NCT03851991|Active Comparator|arbidol|200mg, three times per day, for 2-5 Days.
16418333|NCT03851991|Placebo Comparator|Placebos|two capsules, three times per day, for 2-5 Days.
16418334|NCT03851978|Experimental|Pharmacist Vaccine Education|
16418335|NCT03851952|Other|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
16418336|NCT03851939|Experimental|treatment group|Transarterial Chemoinfusion (TAI) Combine Toripalimab
16418337|NCT03851913|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
16418338|NCT03851913|No Intervention|control group|no neo-adjuvant treatment before operation
16418339|NCT03851900|Experimental|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
16418340|NCT03851900|Active Comparator|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
16418341|NCT03851900|Placebo Comparator|Distilled water|Distilled water with no desensitizing components.
16418342|NCT03851887|Experimental|treatment group|TAI combine SBRT
16470637|NCT03493984|Experimental|Aloe exosomes|
16418345|NCT03851861|Experimental|Mediterranean Diet|Participants will be given individualized diet education on the Mediterranean diet and instructed to follow the diet for the 5-week intervention period. Individualized diet education will be administered by a licensed, registered dietitian nutritionist (RDN) followed by weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
16418346|NCT03851848|Experimental|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
16418347|NCT03851848|Experimental|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
16418348|NCT03851835|Experimental|Ondansetron Oral Solution|Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg. One dose every 8 hours (q8h). Six doses over 48 hours.
16418349|NCT03851835|Placebo Comparator|Placebo Oral Solution|Compounded Placebo Oral Solution to match experimental arm
16418350|NCT03851809|Experimental|neurologic intensive care in acute brain injury|With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
16418353|NCT03851783|Experimental|Solar-powered oxygen|Solar panels used to drive an oxygen concentrator will deliver medical grade oxygen at a rate of 1-5L/min, for the treatment of children with hypoxemia.
16418354|NCT03851783|No Intervention|Standard of care|Patients presenting with hypoxemia and pneumonia will be treated by standard of care prior to the implementation of solar-powered oxygen at a chosen site. This may include some allocation of oxygen via cylinders, but will likely be minimal or not available.
16418355|NCT03851770|Other|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
16418356|NCT03851757|Active Comparator|waist-shaped interdental brush|waist-shaped interdental brush, use four times per interdental space
16418357|NCT03851757|Active Comparator|cylindric interdental brush|cylindric interdental brush, use four times per interdental space
16418358|NCT03851744|Active Comparator|Sea Level|Carbohydrate metabolism measured at SL
16418359|NCT03851744|Experimental|High Altitude|Carbohydrate metabolism measured at HA
16418360|NCT03851731|Experimental|Naltrexone|Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
16418361|NCT03851731|Experimental|Naloxone|Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
16418362|NCT03851731|Experimental|Naltrexol|Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
16418363|NCT03851718|Experimental|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
16418364|NCT03851718|Active Comparator|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
16418365|NCT03851705|Experimental|Part 1 - Inclisiran|Participants will receive a dose of 300 milligram (mg) Inclisiran sodium administered by SC injection on Day 1 and Day 90.
16418366|NCT03851705|Placebo Comparator|Part 1 - Placebo|Participants will receive a dose of placebo administered by SC injection on Day 1 and Day 90.
16418367|NCT03851705|Experimental|Part 2 - Inclisiran|All participants will receive a dose of 300 mg inclisiran sodium administered by SC injection on Days 270, 450 and 630. (Participants who were on placebo in Part 1, will receive the first dose of inclisiran on Day 180.)
16418785|NCT03848702|Experimental|Healthy volunteers|All volunteers wore the DRFB
16418368|NCT03851692|Active Comparator|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
16418369|NCT03851692|Active Comparator|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
16418370|NCT03851679||pregnancy woman|woman who are submitted to elective Cesarean Section in spinal anesthesia
16418371|NCT03851666|Placebo Comparator|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
16418372|NCT03851666|Experimental|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).
~The daily dose administrated is 15 grams."
16418373|NCT03851666|Active Comparator|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).
~The daily dose administrated is 15 grams."
16418374|NCT03851653|Experimental|Lifestyle Intervention Group (LIG)|Participants from this group will receive a cognitive-behavioral intervention addressing weight loss and lifestyle habits such as hypocaloric diet, moderate exercise, smoking and alcohol avoidance, and sleep hygiene. This behavioral intervention will be combined with the usual treatment for OSA, i.e. CPAP.
16418375|NCT03851653|No Intervention|Control group|Participants from the control group will not receive any type of intervention apart from the usual care (CPAP).
16418376|NCT03851640|Experimental|HC-1119|80mg;
16418377|NCT03851640|Placebo Comparator|placebo|80mg;
16418378|NCT03851627|Active Comparator|Testosterone undecanoate|intramuscular Testosterone undecanoate 1000mg/4ml
16418379|NCT03851627|Placebo Comparator|Testosterone like Placebo|intramuscular Testosterone undecanoate like Placebo
16418380|NCT03851614|Experimental|Cohort A|Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
16418381|NCT03851614|Experimental|Cohort B|Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
16418382|NCT03851601||ECP|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
16418383|NCT03851588|Active Comparator|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
16418384|NCT03851588|Placebo Comparator|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
16418385|NCT03851575|Active Comparator|Control arm|Usual guideline therapy
16418386|NCT03851575|Experimental|Accelerated arm|Accelerated treatment of endocarditis
16418387|NCT03851562|Experimental|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
16418388|NCT03851562|Placebo Comparator|Placebo (physiological saline solution)|Placebo (physiological saline solution)
16418389|NCT03851549|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)
16418390|NCT03851536|Experimental|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
16418391|NCT03851536|Experimental|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
16418392|NCT03851471|Experimental|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
16418395|NCT03851445|Other|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
16418396|NCT03851432|Experimental|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
16418397|NCT03851432|Experimental|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
16418398|NCT03851432|Placebo Comparator|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
16418399|NCT03851419||People living with HIV|People living with HIV (ART naive or on ART)
16418400|NCT03851419||People not infected with HIV|HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
16418401|NCT03851406|Active Comparator|5% Hypertonic Saline|Subjects will inhale 5% hypertonic saline
16418402|NCT03851406|No Intervention|No Treatment|No inhaled treatment
16418403|NCT03851393|Experimental|Peptest™ analysis of saliva pepsin|Induction of cough with inhaled citric acid and measurement of saliva pepsin following citric acid cough challenge using the peptest lateral device
16418404|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
16418405|NCT03851367|Experimental|Sling suspension therapy|3-week duration of exercises using red cord and consisting of 15 sessions for 30 minutes each.
16418406|NCT03851367|Active Comparator|Swiss ball therapy|3-week duration exercise for trunk muscles strengthening and posture improvement consisting of 15 sessions for 30 minutes each.
16418407|NCT03851354|Other|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
16418408|NCT03851341|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
16418409|NCT03851341|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
16418410|NCT03851315||LBBAP group|patients received left bundle branch area pacing
16418411|NCT03851315||traditional RVP group|Age and sex-matched patients received traditional right ventricular pacing
16418412|NCT03851302|Experimental|Active RIC + isometric hand exercise|Subjects will receive an active remote ischemic conditioning (200mmHg cuff pressure) before an active isometric hand exercise.
16418413|NCT03851302|Sham Comparator|Sham RIC + isometric hand exercise|Subjects will receive an sham remote ischemic conditioning (10 mmHg below the subjects' diastolic blood pressure) before an active isometric hand exercise.
16418414|NCT03851289|Experimental|test (PRF-CS)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and calcium sulfate was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
16418415|NCT03851289|Active Comparator|control (PRF-X)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and xenograft (MinerOss® X) was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
16418416|NCT03851276|Other|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
16418417|NCT03851263|Experimental|Evolocumab|All subjects are treated with evolocumab 140mg every 2 weeks (q2w) starting on day 1 and ending on day 1071 (week 153).
16418418|NCT03851250|Experimental|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10^9 to 10^10 Colony Forming Units.
~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
16418419|NCT03851250|Placebo Comparator|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.
~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
16418423|NCT03851224|Active Comparator|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
16418424|NCT03851224|Active Comparator|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
16418425|NCT03851224|Active Comparator|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
16418426|NCT03851198|Experimental|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
16418427|NCT03851198|Active Comparator|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
16418428|NCT03851172|Experimental|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
16418429|NCT03851172|Experimental|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
16418430|NCT03851172|Placebo Comparator|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
16418431|NCT03851159|Placebo Comparator|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
16418432|NCT03851159|Experimental|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
16418433|NCT03851159|Placebo Comparator|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
16418434|NCT03851159|Experimental|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
16418435|NCT03851146|Experimental|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.
~Dose level : Target Number LeY CART cells infused *
~-1 (if needed): 1 x 10e8
~2 x 10e8
~5 x 10e8
~1 x 10e9
~5 x 10e9
~Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols
~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
16418437|NCT03851120|Experimental|Intervention|150 pregnant women will be given Probiotics and 480 mg DHA, psychosocial stimulation, and healthy eating education
16418438|NCT03851120|Placebo Comparator|Control|150 pregnant women will be given placebo probiotics and 240 mg DHA, psychosocial stimulation, and healthy eating education
16418439|NCT03851107|Experimental|Community-based activity program|Engagement in 6-week community-based activity program
16418440|NCT03851094|No Intervention|Standard of Care (Group A)|Standard of care is dictated by the HME normal practices for new CPAP patients.
16418441|NCT03851094|Experimental|Wellth App (Group B)|Intervention is use of the Wellth app during the initial compliance period.
16418443|NCT03851068|Experimental|Tria Aortic Valve|Patients receiving the Foldax Tria Aortic Valve
16418444|NCT03851055|Active Comparator|intervention group|will receive zinc supplementation
16418445|NCT03851055|No Intervention|Control group|Patients will receive placebo only
16418446|NCT03851042|Experimental|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
16418447|NCT03851042|Active Comparator|No intervention|Routine PACU care post hysterectomy for up to 4 hours
16418448|NCT03851029|Experimental|Tai chi|(Yang 24 postures) Moderate intensity HRR (40%-60%)
16418449|NCT03851029|Active Comparator|Aerobic Training|Elliptical Moderate intensity HRR (40%-60%)
16418450|NCT03851016|Experimental|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
16418451|NCT03851016|Experimental|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
16418452|NCT03851003|Experimental|Endometrial suturing|Uterine incision repair including suturing of the endometrium
16418453|NCT03851003|Experimental|Non - Endometrial suturing|Uterine incision repair without suturing of the endometrium
16418454|NCT03850990|Experimental|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
16418455|NCT03850990|Experimental|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
16418456|NCT03850977||Patients and controls|Patients diagnosed with chronic pancreatitis or cirrhosis and healthy controls
16418457|NCT03850964|Active Comparator|Pazopanib|Pazopanib 50mg oral daily dosing [two 25mg capsules]. If after 3mths primary endpoint not achieved, and safety is maintained, consideration for advance in dose to up to 100mg daily
16418458|NCT03850964|Placebo Comparator|Placebo oral capsule|Placebo
16418459|NCT03850951|Experimental|"Lingual appliances AO®"|Patients with moderate crowding will be treated without extraction using lingual fixed appliances from American Orthodontics company.
16418460|NCT03850951|Experimental|"Labial appliances AO®"|Patients with moderate crowding will be treated without extraction using labial fixed appliances from American Orthodontics company.
16418461|NCT03850938|Experimental|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
16418462|NCT03850938|Active Comparator|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
16418463|NCT03850925|Experimental|Picosecond laser|Intervention: four consecutive sessions of 1,064-nm picosecond laser at 3-week intervals
16418464|NCT03850925|Active Comparator|Fractional laser|Intervention: four consecutive sessions of nonablative fractional laser at 3-week intervals
16418465|NCT03850912|No Intervention|Activity 1: Stakeholder Feedback|"Obtain stakeholder feedback to inform eSyM finalization and implementation from:
~patient advisory councils
~health system leaders
~clinicians
~clinic support staff/administration
~IT/Informatics"
16418466|NCT03850912|No Intervention|Activity 2: eSym Build|"Build and deploy eSyM
~Finalize training materials based on findings from stakeholder engagement"
16418467|NCT03850912|Experimental|Activity 3: Pilot Test eSyM App|"Pilot testing of the eSyM app will include:
~Activity 3a (eSyM app usage by patients)
~Activity 3b (User acceptability testing)
~Activity 3c (Medical record abstraction)"
16418468|NCT03850912|Experimental|Activity 4: eSyM+ Participants|"These patients (and/or proxy) will report their symptoms in eSyM
~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM+ version)
~A medical record abstraction will be completed for ALL eSyM+ patients"
16418529|NCT03850509|Experimental|OPS-2071 300 mg BID|Participants received OPS-2071 300 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 6 weeks.
16418469|NCT03850912|Experimental|Activity 4: eSyM- Participants|"These patients (and/or proxy) will NOT report their symptoms in eSyM
~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM- version)
~A medical record abstraction will be completed for ALL eSyM- patients"
16418470|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
16418471|NCT03850899||Controls|Heavy drinkers without significant liver disease
16418472|NCT03850899||Donor|Healthy non-drinkers
16418473|NCT03850886|Experimental|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
16418474|NCT03850886|Active Comparator|Control group|diabetes management including metformin or Sulphonylurea
16418475|NCT03850873|Experimental|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily
16418476|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
16418477|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
16418478|NCT03850847||Multi-Methods Study|"Step 1: Semi-structured Interviews
~Step 2: National Telephone Survey"
16418479|NCT03850834|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|
16418480|NCT03850834|Placebo Comparator|Placebo Enteric-coated Tablets|
16418481|NCT03850821|Experimental|Connect Social Mechanisms Intervention|"The primary components of the intervention included: Get-to-know-you sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging."
16418482|NCT03850821|No Intervention|Typical ASP curriculum wait-list control|No intervention was implemented within the active wait-list control condition, which served as the typical ASP curriculum control/comparison. After completion of the 8-week intervention (12 weeks including baseline and post-intervention data collection), the control condition received the social mechanisms curriculum as a token of appreciation for participating in measurement.
16418483|NCT03850808||decline in left ventricular function|This group will be patients in whom a decline in left ventricular systolic function was found.
16418484|NCT03850808||preserved left ventricular function|This group will consist of patients in whom left ventricular systolic function is preserved.
16418489|NCT03850769|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
16418490|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
16418491|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers"
16418492|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers Predisposition to kidney injury biomarkers
~Also tobacco consumption will be measured"
16418493|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers
~Also Tobacco consumption will be measured"
16418494|NCT03850730|Experimental|Pazopanib|Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
16418495|NCT03850717||Traditional Chinese Acupuncture|"Use traditional acupuncture, stronger, deeper, harder-acupuncture"
16418496|NCT03850717||Japanese Acupuncture|"Use traditional shallow, lighter acupuncture, softer-acupuncture"
16418497|NCT03850691|Experimental|Cohort 1: Nivolumab|
16418498|NCT03850691|Experimental|Cohort 2: Nivolumab & Ipilimumab|
16418530|NCT03850509|Experimental|OPS-2071 600 mg BID|Participants were to receive OPS-2071 600 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 12 weeks.
16418501|NCT03850665|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
16418502|NCT03850665|Active Comparator|Anterolateral approach|Anterolateral Approach surgery to replace the hip.
16418503|NCT03850665|Active Comparator|Posterolateral approach|Posterolateral Approach surgery to replace the hip.
16418504|NCT03850652|Active Comparator|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
16418505|NCT03850652|Placebo Comparator|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
16418506|NCT03850639|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
16418507|NCT03850639|No Intervention|Wait list control|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.
16418508|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
16418509|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
16418510|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
16418511|NCT03850613|Experimental|Intervention arm|Participants in the intervention arm download the E-painting mobile app and use this app to make their own painting.
16418512|NCT03850600|Experimental|Diet-CD|dietary intervention: 8-10 weeks of diet intervention
16418513|NCT03850600|No Intervention|No-Diet-CD|Usual diet with no intervention
16418514|NCT03850600|No Intervention|No-Diet-Control|Unaffected controls at the same gestational stage will follow usual diet and no intervention
16418515|NCT03850587|Experimental|YYC301-1 & Celocoxib placebo|"YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.
~*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex)."
16418516|NCT03850587|Experimental|YYC301-2 & Celocoxib placebo|"YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.
~*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)"
16418517|NCT03850587|Experimental|YYC301-3 & Celocoxib placebo|"YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.
~*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)"
16418518|NCT03850587|Active Comparator|YYC301 placebo & Celecoxib|Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
16418519|NCT03850574|Experimental|HM43239|This phase 1/2 study consists of dose escalation and expansion. Dose escalation cohort is planned up to 10 dose levels. If subject in the dose escalation cohort at any dose level achieves clinical response then the dose level will continue to enroll.
16418520|NCT03850561|Active Comparator|Coenzyme Q10 200|Coenzyme Q10 200mg/day for 3 months
16418521|NCT03850561|Active Comparator|Coenzyme Q10 400|Coenzyme Q10 400mg/day for 3 months
16418522|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
16418523|NCT03850535|Experimental|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
16418524|NCT03850535|Experimental|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
16418525|NCT03850535|Experimental|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
16418526|NCT03850535|Experimental|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
16418527|NCT03850522|Experimental|Vaccination|Vaccination with PD-L1 peptide
16418528|NCT03850509|Experimental|OPS-2071 150 mg BID|Participants were to receive OPS-2071 150 mg, tablets, orally, twice daily (BID) in the morning and evening (8 to 12 hours apart) with 240 milliliters (mL) of water for up to 12 weeks.
16418531|NCT03850509|Placebo Comparator|Placebo|Participants received OPS-2071-matched placebo, tablets, orally, BID in morning and evening (8 to 12 hours apart) with 240 mL of water for up to 4 weeks.
16418532|NCT03850496|No Intervention|Group A|No device utilised for 6 weeks.
16418533|NCT03850496|Experimental|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
16418534|NCT03850496|Experimental|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
16418535|NCT03850483|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
16418536|NCT03850483|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
16418537|NCT03850483|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
16418538|NCT03850483|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
16418539|NCT03850483|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
16418540|NCT03850483|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
16418541|NCT03850483|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
16418542|NCT03850483|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
16418543|NCT03850483|Experimental|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
16418544|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
16418545|NCT03850444|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
16418546|NCT03850444|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
16418547|NCT03850431|Experimental|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
16418548|NCT03850431|Experimental|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
16418549|NCT03850431|Experimental|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
16418550|NCT03850431|Experimental|Combination of all Nudges|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
16418551|NCT03850431|No Intervention|Usual Care|An appointment reminder that includes basic appointment information on date, location, and phone number(s) for scheduling changes.
16418552|NCT03850418|Experimental|AZA|azacitidine
16418553|NCT03850405|Experimental|Chocolate|20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day
16418554|NCT03850405|No Intervention|Control|20 patients (matched per gender) undergoing a low-fat dietary regimen
16418555|NCT03850392|Active Comparator|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).
~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
16418556|NCT03850392|Active Comparator|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
16418557|NCT03850392|No Intervention|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
16418562|NCT03850353||Dizziness|Patients with Dizziness (defined as a non-spinning sensation, without illusion of movement)
16418563|NCT03850353||No OSAS No Dizziness|Patients without dizziness and no evidence for OSAS (subjects referred for the ENT or the Sleep clinic with no dizziness and no evidence of OSAS )
16418564|NCT03850327|Experimental|BIOMONITOR III|
16418565|NCT03850314|Experimental|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
16418566|NCT03850301|Experimental|Etifoxine then XBD173|
16418567|NCT03850301|Experimental|XBD173 then Etifoxine|
16418568|NCT03850288||Anorexia Nervosa|"Patients with a diagnosis of anorexia nervosa (According to the DSM-V criteria). These patients are characterized by a restriction of food intake leading to weight loss or a failure to gain weight resulting in a significantly low body weight of what would be expected for someone's age, sex and height. Moreover, there is a fear of becoming fat or of gaining weight.Then, these patients have a distorted view of themselves and of their condition."
16418569|NCT03850288||Bulimia Nervosa|"Patients with a diagnosis of bulimia nervosa. According to the DSM-V criteria, these patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time, an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode, recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise.
~The binge eating and inappropriate compensatory behaviours both occur, on average, at least once a week for three months. Moreover, there is a self-evaluation influenced by body shape and weight."
16418570|NCT03850288||Binge Eating Disorder|Patients with a diagnosis of Binge Eating Disorder. These patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time (e.g. within any 2-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode. The binge eating episodes are associated with three or more of the following: eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts of food when not feeling physically hungry, eating alone because of feeling embarrassed by how much one is eating, feeling disgusted with oneself, depressed or very guilty afterward,marked distress regarding binge eating is present. Moreover, binge eating occurs, on average, at least once a week for three months
16418571|NCT03850275|Experimental|Experimental: Placebo, then caffeinated placebo, then e+shots|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
16418572|NCT03850275|Experimental|Experimental: Caffeinated placebo, then placebo, then e+shots|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
16418573|NCT03850275|Experimental|Experimental: placebo, then e+shots, then caffeinated placebo|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received e+shots and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
16418574|NCT03850275|Experimental|Experimental: caffeinated placebo, then e+shots, then placebo|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the e+shots and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
16418575|NCT03850275|Experimental|Experimental: e+shots, then caffeinated placebo, then placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
16418576|NCT03850275|Experimental|Experimental: e+shots, then placebo, then caffeinated placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
16418577|NCT03850262||patients with posterolateral corner trauma of the knee|
16418578|NCT03850210|Experimental|Short Splint|
16418579|NCT03850210|Active Comparator|Traditional, Long Splint|
16418580|NCT03850197||TMM followed by EarPopper + Tympanometry|"Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
16418581|NCT03850197||EarPopper + Tympanometry followed by TMM|"Participants will be asked to complete the EarPopper plus tympanometry then TMM tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize ET pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
16418582|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
16418583|NCT03850171|Experimental|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
16418584|NCT03850171|No Intervention|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
16418585|NCT03850158|Experimental|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
16418586|NCT03850132|Experimental|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
16418587|NCT03850119|Experimental|Intradermal Nanofat|This side of the scar received intradermal injection of nanofat during the closure of the donor site.
16418588|NCT03850119|No Intervention|Control|This side of the scar received no injection.
16418589|NCT03850106|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose)
16418590|NCT03850106|Active Comparator|Indus810|Indus810 ( 500mg/d)
16418591|NCT03850093|Active Comparator|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
16418592|NCT03850093|Active Comparator|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
16418593|NCT03850093|Placebo Comparator|control|placebo was given to patients of control group 2 hours preoperative
16418594|NCT03850080|Experimental|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
16418595|NCT03850067|Experimental|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
16418596|NCT03850067|Experimental|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
16418597|NCT03850067|Experimental|Nivolumab combination|"When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy.
~A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each."
16418598|NCT03850028|Other|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
16418599|NCT03849989|Experimental|Hailey Hailey|"Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.
~Skin biopsy specimens will be taken before and after lasertherapy at three time points.
~Before treatment:
~Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction
~Immediately after treatment of the treated area:
~2 mm punch for histopathology
~Six weeks after treatment:
~Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy"
16418600|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
16418601|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
16418602|NCT03849963|Experimental|Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection ([13C]pyruvate) during magnetic resonance spectroscopic imaging
16418603|NCT03849950|Experimental|SMARTCare|"Training in self-management support (SMS) strategies for ambulatory nursing staff
~A web-based self-management education (I-Can-Manage Cancer) for patients
~Telephone-based, nurse-led health coaching
~Optional end of study patient interview (sub-study)"
16418604|NCT03849950|Active Comparator|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
16418605|NCT03849937|Experimental|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
16418606|NCT03849937|Active Comparator|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
16418607|NCT03849924|Experimental|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
16418608|NCT03849924|Experimental|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
16418609|NCT03849924|No Intervention|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
16418610|NCT03849898||Mandibular Fracture|"Elderly patients of > 60 years who present a mandibular fracture
~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
16418611|NCT03849885|No Intervention|Standard Skin Prep|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.
~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
16418612|NCT03849885|Experimental|Experimental Skin Prep with BPO|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.
~Following the CHG wipes, patients will be prepped with 5% BPO gel applied directly to the biopsy site.
~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
16418613|NCT03849872|Experimental|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) [14C]-ONO-5788 in 6 healthy male subjects.
16418614|NCT03849872|Experimental|Part 2 Mass Balance|Single oral dose of 10 mg [14C]-ONO-5788 capsule containing 4.1 MBq (111 μCi) [14C]-radioactivity in 6 healthy male subjects.
16418615|NCT03849859|Active Comparator|Single plastic stent|Deployment of single plastic stent
16418616|NCT03849859|Active Comparator|Multiple plastic stents|Deployment of multiple plastic stent
16418617|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
16418618|NCT03849833|Other|Vitamin D3 supplementation|All participants will be selected for treatment with cholecalciferol, vitamin D3 supplementation and included in this single arm
16418619|NCT03849820|Active Comparator|Robotic-assisted partial nephrectomy|da Vinci surgical robotic assisted partial nephrectomy
16418620|NCT03849820|Active Comparator|Open partial nephrectomy|Open partial nephrectomy surgery
16418621|NCT03849807|Experimental|Experimental group|Chiropractic care
16418622|NCT03849807|Active Comparator|Control group|Usual health care
16418623|NCT03849794|Experimental|Experimental group|Chiropractic Care Plus Physiotherapy
16418624|NCT03849794|Active Comparator|Control group|Physiotherapy
16418625|NCT03849781|Active Comparator|Intervention|NeoBeat will be placed on all newborns immediately after birth to assess the heartrate for at least 5 minutes, or longer if the newborn needs resuscitation. Intervention subjects will have a visible display of the heart rate on the NeoBeat, to guide healthcare providers in further management of the newborn.
16418626|NCT03849781|No Intervention|Standard Care|NeoBeat will be placed on the newborn to collect information on heart rate, but heart rate is not displayed to the healthcare providers. If the newborn is in need of resuscitation to initiate spontaneous respiration, the baby will be transferred to the resuscitation bay. According to recommendations the heart rate should be assessed and positive pressure ventilation initiated within one minute of life. Standard care is to assess heart rate by conventional ECG and/or pulse oximetry, alternatively auscultation of the heart.
16418627|NCT03849768|Experimental|HS-10296|110mg PO once daily
16418628|NCT03849768|Active Comparator|Gefitinib|250mg PO once daily
16418629|NCT03849755|Other|PEPPER/Control|Group with intervention applied (PEPPER system) during the first three months and then, after wash -out period, swap to control group (using standard bolus calculator) for the next 3 months.
16418630|NCT03849755|Other|Control/PEPPER|Group without intervention applied (using standard bolus calculator) during the first three months and then, after wash -out period, swap to intervention group (using PEPPER system) for the next 3 months.
16418631|NCT03849742|Experimental|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
16418632|NCT03849729|Active Comparator|Phentermine|Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.
16418633|NCT03849729|Placebo Comparator|Placebo|Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.
16418634|NCT03849716||Participants with atopic dermatitis (AD)|Participants included in observational study OBS15333 (atopic dermatitis pediatric registry) who consent to enter this companion study LPS15496. Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enter either protocol, and neither protocol OBS15333 nor LPS15496 specifies assignment of any drug intervention
16418635|NCT03849703|Experimental|Full Intervention #1|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the coparenting curriculum before the romantic relationships curriculum.
16418636|NCT03849703|Experimental|Full Intervention #2|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the romantic relationships curriculum before the coparenting curriculum.
16418637|NCT03849703|Other|Partial Intervention #1|Participants will receive the romantic relationships curriculum along with the control curriculum.
16418638|NCT03849703|Other|Partial Intervention #2|Participants will receive the coparenting curriculum along with the control curriculum.
16418639|NCT03849690|Experimental|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
16418640|NCT03849677||Omnivore|
16418641|NCT03849677||Vegan|
16418642|NCT03849664|Experimental|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
16418643|NCT03849664|Placebo Comparator|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
16418786|NCT03848702|Experimental|Patients with DRF|All patients wore the DRFB
16418644|NCT03849651|Experimental|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.
~Cells for infusion are prepared using the CliniMACS system."
16418645|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
16418646|NCT03849612|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
16418647|NCT03849599|Experimental|PRV-300|Subjects in this arm will receive the study drug, PRV-300, via IV infusion, followed by an 8-week follow-up period.
16418648|NCT03849599|Placebo Comparator|Placebo|Subjects in this arm will receive placebo via IV infusion, followed by an 8-week follow-up period.
16418649|NCT03849573|Experimental|Mindfulness-based stress reduction + Hormone Therapy Education|
16418650|NCT03849573|Active Comparator|Hormone Therapy Education + Overall Health Education|
16418651|NCT03849560|Experimental|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)
~Active ingredients:
~type A (H1N1) influenza virus antigen 5 µg;
~type A (H3N2) influenza virus antigen 5 µg;
~type B (Yamagata lineage) influenza virus antigen 5 µg;
~type B (Victoria lineage) influenza virus antigen 5 µg;
~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
16418652|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.
~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)
~Active ingredients:
~type A (H1N1) influenza virus antigen 5 µg;
~type A (H3N2) influenza virus antigen 5 µg;
~type B (Yamagata lineage) influenza virus antigen 5 µg;
~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
16418653|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.
~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)
~Active ingredients:
~type A (H1N1) influenza virus antigen 5 µg;
~type A (H3N2) influenza virus antigen 5 µg;
~type B (Victoria lineage) influenza virus antigen 5 µg;
~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
16418654|NCT03849547|Experimental|App training group|Subjects in App training group will receive App Balance training via smartphone application.
16418655|NCT03849547|Active Comparator|Home training group|Subjects in Home training group will receive Home Balance training advised by physical therapist.
16418656|NCT03849547|No Intervention|Control group|Control group will receive only education of ankle injury prevention related information.
16418657|NCT03849534|Active Comparator|Soft occlusal appliance|Individually casted appliances
16418658|NCT03849534|Active Comparator|Jaw exercises|Resistance exercises to do twice a day
16418659|NCT03849534|Active Comparator|Counseling|Just information at the first visit
16418660|NCT03849521||Asymptomatic group|Group with asymptomatic patients with carotid atherosclerosis.
16418661|NCT03849521||Symptomatic group|Group with symptomatic patients with carotid atherosclerosis.
16418662|NCT03849508|Active Comparator|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
16418663|NCT03849508|Experimental|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
16418664|NCT03849495|Experimental|Group A|"Period 1: D745
~Period 2: CKD-370"
16418665|NCT03849495|Experimental|Group B|"Period 1: CKD-370
~Period 2: D745"
16418666|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:
~Clinical Evaluation;
~Fine Needle Aspiration Cytology;
~Multiparametric Magnetic Resonance Imaging.
~Postoperative Collection of Final Histopathological Diagnosis"
16418667|NCT03849469|Experimental|Arm 1|Arm 1: XmAb®22841 Monotherapy
16418668|NCT03849469|Experimental|Arm 2|Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
16418669|NCT03849456|Experimental|GWP42006|Oral solution taken twice daily with food for 52 weeks.
16418674|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
16418675|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
16418676|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
16418677|NCT03849404|Experimental|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
16418678|NCT03849404|Experimental|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
16418679|NCT03849391|Experimental|Skate group|This group takes Skate Skin extract for 12 weeks
16418680|NCT03849391|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
16418681|NCT03849378|Experimental|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
16418682|NCT03849378|Placebo Comparator|Placebo group|This group takes Placebo Extract for 12 weeks.
16418741|NCT03849014|Active Comparator|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
16418683|NCT03849365|Experimental|TOOKAD VTP|TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
16418684|NCT03849352|Other|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
16418685|NCT03849339|Experimental|Group 1|"Period 1: D635
~Period 2: CKD-387"
16418686|NCT03849339|Experimental|Group 2|"Period 1: CKD-387
~Period 2: D635"
16418687|NCT03849326|Experimental|"Non-fatigued patients"|
16418688|NCT03849326|Experimental|"Fatigued patients"|
16418689|NCT03849313|Experimental|AVT02 100mg/mL|Biosimilar Adalimumab AVT02
16418690|NCT03849313|Active Comparator|EU-Humira 100mg/mL|EU Approved Adalimumab originator Humira
16418691|NCT03849313|Active Comparator|US-Humira 100mg/mL|US licensed Adalimumab originator Humira
16418692|NCT03849300|No Intervention|Control Group|No exercise intervention
16418693|NCT03849300|Experimental|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.
~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).
~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
16418694|NCT03849300|Experimental|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.
~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).
~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
16418695|NCT03849300|Active Comparator|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.
~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.
~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
16418696|NCT03849287|Experimental|Group 1|"Period 1: CKD-333, formula I
~Period 2: CKD-333, formula II
~Period 3: CKD-330, D090"
16418697|NCT03849287|Experimental|Group 2|"Period 1: CKD-333, formula I
~Period 2: CKD-330, D090
~Period 3: CKD-333, formula II"
16418698|NCT03849287|Experimental|Group 3|"Period 1: CKD-333, formula II
~Period 2: CKD-330, D090
~Period 3: CKD-333, formula I"
16418699|NCT03849287|Experimental|Group 4|"Period 1: CKD-333, formula II
~Period 2: CKD-333, formula I
~Period 3: CKD-330, D090"
16418700|NCT03849287|Experimental|Group 5|"Period 1: CKD-330, D090
~Period 2: CKD-333, formula I
~Period 3: CKD-333, formula II"
16418701|NCT03849287|Experimental|Group 6|"Period 1: CKD-330, D090
~Period 2: CKD-333, formula II
~Period 3: CKD-333, formula I"
16418702|NCT03849274|Experimental|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
16418703|NCT03849274|Active Comparator|Pressure Garment|For control group, subject will be intervened by conventional PG only
16418704|NCT03849274|No Intervention|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
16418705|NCT03849261|Experimental|Group 1|"Period 1: D635
~Period 2: CKD-387"
16418706|NCT03849261|Experimental|Group 2|"Period 1: CKD-387
~Period 2: D635"
16418707|NCT03849248|Experimental|Intervention|This group of babies will have a maternal scented cloth placed under their heads
16418708|NCT03849248|No Intervention|Control|This group of babies will have a clean non- maternal scented cloth placed under their head
16418709|NCT03849222|Active Comparator|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
16418710|NCT03849222|Experimental|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
16418711|NCT03849222|Active Comparator|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
16418712|NCT03849222|Experimental|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
16418783|NCT03848715|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight; 1 infusion
16418713|NCT03849209|Experimental|Stylet Slow-Pull Technique group|In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
16418714|NCT03849209|Active Comparator|Standard Suction Technique group|In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
16418715|NCT03849196|Experimental|2L PEG-Asc|2L PEG-Asc for bowel preparation
16418716|NCT03849196|Active Comparator|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
16418717|NCT03849183|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (0.5cc) is subcutaneously injected before radial artery cannulation.
16418718|NCT03849183|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation.
16418719|NCT03849170|Experimental|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
16418720|NCT03849170|Placebo Comparator|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration & performance.
16418721|NCT03849157|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
16418722|NCT03849157|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
16418723|NCT03849144|Experimental|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
16418724|NCT03849144|Active Comparator|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
16418725|NCT03849118|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
16418726|NCT03849105|Experimental|Single administration of 131I-IPA (1f group)|Study participants with GBM receive a single administration of 4-L-[131I]iodo-phenylalanine (131I-IPA), followed by 18 cycles of external radiotherapy, each cycle being of 2 Gy.
16418727|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-parallel group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above, 1- 3 days prior to 1st XRT. The 2nd and 3rd 131I-IPA fractions will be administered after 5-9 XRT fractions (subject to investigator's discretion and day of IMP administration) following the previous 131I-IPA fraction. The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.
16418728|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-sequential group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above 1- 3 days prior to 1st XRT. The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.
16418729|NCT03849105|Experimental|Dose escalation of fractionated dosing|Dose escalation will be made in steps of 2.0 GBq, i.e. 4.0 (3*1.33 GBq), 6.0 GBq (3*2.0 GBq), up to 8.0 GBq (3*2.67 GBq) until the maximum tolerated dose (MTD) is reached, using cohorts of N=3 patients.
16418730|NCT03849092|Experimental|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
16418731|NCT03849092|Experimental|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
16418732|NCT03849092|No Intervention|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
16418733|NCT03849079|Experimental|Hyponut|
16418734|NCT03849066||Part 1: Cross-Sectional PRSA|This will be a cross-sectional analysis of 300 children with neurological impairment and polypharmacy.
16418735|NCT03849066||Part 2: Longitudinal PRSA|This will be a 12-month prospective cohort study of 50 children with neurological impairment and polypharmacy.
16418736|NCT03849053|Experimental|Mézières method|
16418737|NCT03849053|Active Comparator|Control Group|
16418738|NCT03849027|Experimental|Methoxyflurane|"Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .
~Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®)."
16418739|NCT03849027|Sham Comparator|Sham Methoxyflurane|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test
16418740|NCT03849014|Active Comparator|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
16418742|NCT03849001|Experimental|Exercise Conditions|"Participants will undergo four Exercise Conditions (i.e., light intensity leg cycling, moderate intensity leg cycling, vigorous intensity leg cycling, and a seated, quiet rest) in a randomized, counterbalanced order."
16418743|NCT03848975|Experimental|Simulation training for ECV|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the Control group for VE : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
16418744|NCT03848975|Experimental|Simulation training for VE|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the the control group for for ECV : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
16418745|NCT03848962||Subjects for observational study|Various conditions & healthy subjects
16418746|NCT03848949|Experimental|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
16418747|NCT03848949|No Intervention|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
16418748|NCT03848936||adult cerebral palsy patients|>18 age cerebral palsy diagnosed patients evaluated with a survey.
16418749|NCT03848910|Experimental|Investigational device - Sound Processor|
16418750|NCT03848897|Experimental|Non falling elderly|
16418751|NCT03848897|Experimental|Falling elderly|
16418752|NCT03848897|Experimental|Non falling patients with Parkinson's disease|
16418753|NCT03848884|Experimental|Adherence monitoring and education|
16418754|NCT03848871|Experimental|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
16418755|NCT03848858|Experimental|EMDR plus TAU|20 individual weekly sessions of 60 minutes each of Eye Movement Desensitization and Reprocessing Therapy (EMDR), plus Treatment as Usual (TAU), applying first the standard EMDR protocol (Shapiro, 2005), and then a specific protocol for the sequelae of somatic illness and medical trauma (Hase, 2018).
16418756|NCT03848858|No Intervention|TAU only|The patients in this condition are newly diagnosed and will be introduced to the study in their first appointment with the Infectious Diseases Unit, in which analyses of HIV-related biological markers are taken. In a follow up appointment between 1 and 2 weeks later, antiretroviral treatment is initiated. There is a further check-up 1-2 months after initiating antiretroviral treatment, and then 6-monthly check-ups. In these checkups, measures of CD4 and the CD4/CD8 ratio are taken and treatment adherence is reviewed. The patients receiving EMDR therapy will also participate in these activities.
16418759|NCT03848832|Experimental|5 milligrams per kilogram per day (mg/kg/day) GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
16418760|NCT03848832|Experimental|15 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
16418761|NCT03848832|Placebo Comparator|Placebo|Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
16418762|NCT03848819|Other|Control pursed lip breathing|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe adopting the pursed lip breathing technique. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
16418763|NCT03848819|Experimental|pNIV|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe via the VitaBreath device. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
16418764|NCT03848806|Experimental|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
16418784|NCT03848715|Placebo Comparator|Placebo|same volume of 0.9% saline
16418765|NCT03848806|Active Comparator|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
16418766|NCT03848793|Other|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
16418767|NCT03848793|Other|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
16418768|NCT03848793|Other|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
16418769|NCT03848793|Other|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
16418770|NCT03848780|Experimental|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
16418771|NCT03848780|No Intervention|Control Group|No pharmacological preconditioning was implemented
16418772|NCT03848767|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
16418777|NCT03848741|Placebo Comparator|Non-exercise control with placebo|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
16418778|NCT03848741|Experimental|Non-exercise control with HMB+VitD|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
16418779|NCT03848741|Active Comparator|Resistance exercise training with placebo|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
16418780|NCT03848741|Experimental|Resistance exercise training with HMB+VitD|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
16418781|NCT03848728|Experimental|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
16418782|NCT03848728|No Intervention|Control Clinics|Optimized country standard of care
16470638|NCT03493984|Experimental|Ginger and aloe exosomes|
16418787|NCT03848689||FQ PPA Group|Fluoroquinolone Preprescription Authorization from Infection Control consult, once, prior to prescribing fluoroquinolone
16418788|NCT03848689||Control Group|No preprescription authorization needed from Infection control prior to prescribing fluoroquinolone
16418789|NCT03848663|Experimental|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
16418790|NCT03848663|Active Comparator|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
16418791|NCT03848650|Experimental|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
16418792|NCT03848637|Experimental|Group 1|"Period 1: D387 (reference drug)
~Period 2: CKD-387 (test drug)"
16418793|NCT03848637|Experimental|Group 2|"Period 1: CKD-387 (test drug)
~Period 2: D387 (reference drug)"
16418794|NCT03848624|Experimental|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
16418795|NCT03848611|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
16418796|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
16418797|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
16418798|NCT03848585|Experimental|Pilloxa Pillbox|
16418799|NCT03848585|Sham Comparator|Non active Pilloxa Pillbox|
16418800|NCT03848572|No Intervention|Usual care|Patients will enter standard 12-month clinical follow-up
16418801|NCT03848572|Experimental|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
16418802|NCT03848559|Experimental|Airway device placement|airway device is placed during the dive
16418803|NCT03848546|Experimental|PDA|Intervention group: receives the personalized dietary advice
16418804|NCT03848546|Active Comparator|Control|Receives the general advice (two flyers containing information about fiber intake)
16418805|NCT03848533|Experimental|melatonin plus metformin|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.
~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days."
16418806|NCT03848533|Active Comparator|metformin plus placebo|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.
~Will administrate homologated placebo once a day in the night (before bedtime) per 90 days."
16418807|NCT03848533|Experimental|melatonin plus placebo|"It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.
~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days."
16418808|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (>=9) activity-scale score at anytime between preoperatively and now.
16418809|NCT03848507|Experimental|20% Albumin|Administration of 3ml per kg bodyweight of 20% albumin within 30 min during cystectomy.
16418810|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
16418811|NCT03848481|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
16418812|NCT03848481|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
16418813|NCT03848468|Active Comparator|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
16418814|NCT03848468|Experimental|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
16418815|NCT03848455||Parkinson's disease group|"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;
~Newly diagnosed primary PD patients, diagnosed within 3-6 months;
~informed consent to the study;
~age > 18 older."
16418816|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.
16418817|NCT03848442|Experimental|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
16418818|NCT03848416|Experimental|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
16418819|NCT03848416|Experimental|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
16418820|NCT03848416|Experimental|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
16418821|NCT03848403|Experimental|Ixekizumab (Reference)|Reference formulation 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection in a prefilled syringe in one of three study periods.
16418822|NCT03848403|Experimental|Ixekizumab (Test 1)|Test 1 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
16418823|NCT03848403|Experimental|Ixekizumab (Test 2)|Test 2 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
16418824|NCT03848390|Experimental|Modified Time-restricted Feeding|
16418825|NCT03848390|Active Comparator|Conventional diet|
16418862|NCT03848208|Placebo Comparator|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418863|NCT03848208|Experimental|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418864|NCT03848208|Placebo Comparator|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418826|NCT03848377||Automated EMG/SSEP monitored|"In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored.
~As this is an observational study, no intervention is planned."
16418827|NCT03848364|Experimental|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
16418828|NCT03848351|No Intervention|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
16418829|NCT03848351|Active Comparator|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.
~Oral Hygiene Instruction (OHI)
~Professional supragingival scaling and polishing"
16418830|NCT03848338|Other|Pilot Group|Intra and Post-operative Electrocochleography
16418831|NCT03848325|Experimental|Sleep deprivation|All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2).
16418832|NCT03848312|Experimental|Computerized Cognitive Training|Participants will complete computerized cognitive training.
16418833|NCT03848312|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities.
16418834|NCT03848299|Experimental|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
16418835|NCT03848286|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
16418836|NCT03848273||Ischemic|questionnaire, physical-neurological examination, labor investigations, EEG
16418837|NCT03848273||Hemorrhagic|questionnaire, physical-neurological examination, labor investigations, EEG
16418838|NCT03848273||Control|questionnaire, physical-neurological examination, labor investigations, EEG
16418839|NCT03848260|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time (duration: 30-120 mins/each time) and 3 times within 3 months.
~Intervention: using the magnetic device prototype"
16418840|NCT03848247|Experimental|Control group|Participants will be injected with 0.5ml Isotonic saline into a neck muscle
16418841|NCT03848247|Experimental|Neck pain|Participants will be injected with 0.5ml NGF into the a neck muscle
16418842|NCT03848234|Experimental|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
16418843|NCT03848234|Placebo Comparator|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
16418844|NCT03848221|Experimental|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
16418845|NCT03848221|Active Comparator|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
16418846|NCT03848221|No Intervention|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
16418847|NCT03848208|Experimental|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418848|NCT03848208|Placebo Comparator|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418849|NCT03848208|Experimental|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418850|NCT03848208|Placebo Comparator|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418851|NCT03848208|Experimental|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418852|NCT03848208|Placebo Comparator|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418853|NCT03848208|Experimental|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418854|NCT03848208|Placebo Comparator|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418855|NCT03848208|Experimental|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418856|NCT03848208|Placebo Comparator|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418857|NCT03848208|Experimental|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418858|NCT03848208|Placebo Comparator|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418859|NCT03848208|Experimental|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418860|NCT03848208|Placebo Comparator|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418861|NCT03848208|Experimental|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
16418865|NCT03848182|Experimental|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
16418866|NCT03848169|Experimental|Experimental group|Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
16418867|NCT03848169|Sham Comparator|Control Group|Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.
16418868|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
16418869|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
16418870|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
16418871|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
16418872|NCT03848143|Experimental|BOTOX|"Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
~1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
~Each patient will receive 50 U of onabotulinum toxin A."
16418873|NCT03848130|Active Comparator|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
16418874|NCT03848130|Active Comparator|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
16418875|NCT03848130|Active Comparator|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
16418876|NCT03848117|Active Comparator|(DTF massage & Mill's manipulation)(Group 1)|For any given subject in group 1, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in 1st group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
16418877|NCT03848117|Active Comparator|( Taping & MWM) (Group 2).|For any given subject in group 2, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
16418878|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
16418879|NCT03848091||Antibiotic pretreatment|patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
16418983|NCT03847402|Experimental|GDD intervention|The early integrated intervention for GDD
16418880|NCT03848078|Other|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
16418881|NCT03848078|No Intervention|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
16418882|NCT03848065|Experimental|V114-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of V114 on Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
16418883|NCT03848065|Experimental|V114-IM|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
16418884|NCT03848065|Active Comparator|PCV13-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13) at Visit 1, 2, 3 and 5(approximately 3, 4, 5, and 12 to 15 months of age).
16418885|NCT03848039|Experimental|Gardasil-9|Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
16418886|NCT03848039|Placebo Comparator|Placebo|Placebo injection at 0, 2 and 6 months
16418887|NCT03848026||Group 1|middle ear fluid viscosity <439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
16418888|NCT03848026||Group 2|middle ear fluid viscosity >439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
16418889|NCT03848013|Active Comparator|Treatment|Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
16418890|NCT03848013|No Intervention|Follow -up period|follow up of the treated cases for 2 months
16418891|NCT03848000|Experimental|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
16418892|NCT03848000|Active Comparator|NHS Standard Care only|Alcohol addiction counselling.
16418893|NCT03847987|Experimental|Part 1|Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses.
16418894|NCT03847987|Experimental|Part 2|Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses.
16418895|NCT03847974|Experimental|LIB003|LIB003
16418896|NCT03847961|No Intervention|Control Group|The control group receive routine treatment of sepsis only. All sites agree, when feasible, to follow the tenets of the Surviving Sepsis Campaign clinical practice guidelines for management of sepsis.
16418897|NCT03847961|Experimental|Experimental Group|The experimental group receive routine treatment of sepsis combined with hemoperfusion with cytokine adsorption column (CA330).
16418898|NCT03847935||Surgery|Patients who underwent surgical release of A1 pulley
16418899|NCT03847935||corticosteroid injections only|Patients who underwent local corticosteroid injections only, and no other treatment
16418900|NCT03847935||hand therapy only occupational/physical|1 visit: orthosis fabrication, range of motion, nodule and ice massage.
16418901|NCT03847935||Injection and Hand therapy|This group of participants received a combination of corticosteroid injection in the affected finger and one visit of hand therapy.
16418902|NCT03847935||Modality Hand Therapy|Ongoing hand therapy treatment, which included the above plus modalities such as ultrasound or iontophoresis.
16418903|NCT03847935||Injection and Modality Hand Therapy|Ccombination of local cortiscosteroid injection to the affected digit and ongoing hand therapy with modalities.
16418904|NCT03847922|Placebo Comparator|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
16418905|NCT03847922|Experimental|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
16418906|NCT03847909|Experimental|DCR-PHXC|Intervention, drug, DCR-PHXC
16418907|NCT03847909|Placebo Comparator|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
16418908|NCT03847896|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
16418909|NCT03847896|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
16418910|NCT03847896|Active Comparator|BD MDI (PT008) 160 µg|
16418911|NCT03847896|Active Comparator|AS MDI (PT007) 180 µg|
16418912|NCT03847896|Placebo Comparator|Placebo MDI|
16418913|NCT03847883|Active Comparator|0.6 mg/kg Ateplase|Low dose 0.6 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke (n = 26 in cohort A)
16418914|NCT03847883|Active Comparator|0.75 mg/kg Ateplase|Low dose 0.75 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A)
16418915|NCT03847883|Active Comparator|0.9 mg/kg Ateplase|Low dose 0.9 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A and n= 330 in Cohort B)
16418916|NCT03847857|Experimental|Surgery+PFS|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during McKeown esophagectomy.
16418917|NCT03847857|Placebo Comparator|Surgery|Arm B underwent conventional anastomosis during McKeown esophagectomy.
16418918|NCT03847844|Experimental|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
16418919|NCT03847844|Placebo Comparator|Group B|Placebo (normal saline) and standard treatment
16418920|NCT03847831|Experimental|PPASF Group|"Schools enrolled in the postprimary active school flag program. All 17 elements are included. Feasibility is measured of the 17 elements.
~Student representatives are selected to have accelerometer, physical health measures and perceived health collected for feasibility purposes."
16418921|NCT03847818|Experimental|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
16418944|NCT03847675|No Intervention|Control|The research assistant gives routine advice on child development including importance of reading and advice on nutrition and safety and gives parents a leaflet about early child development and complementary feeding
16418922|NCT03847805|Experimental|Experimental|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
16418923|NCT03847805|Active Comparator|Control|The control group followed a program of glenohumeral stabilization exercises,
16418924|NCT03847792|Active Comparator|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
16418925|NCT03847792|Active Comparator|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
16418926|NCT03847792|Placebo Comparator|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
16418927|NCT03847779|Experimental|Non-neuropathy|"Type 2 diabetic without neuropathy:
~Negative findings on Semmes-Weinstein monofilament
~Neuropathy symptom score (NSS) <3
~Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.
~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
~rest cutaneous microcirculation (perfusion and vasomotion)
~Exercise cutaneous microcirculation (perfusion and vasomotion)
~Foot lowering cutaneous microcirculation (perfusion and vasomotion)
~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)
~blood sampling
~heart rate variability at rest
~pedometer during 4 days
~international Physical Activity Questionary
~Qualify of Life questionary (EQVOD)"
16418928|NCT03847779|Experimental|Neuropathy|"Type 2 diabetic with neuropathy
~Positive findings on Semmes-Weinstein monofilament
~Neuropathy symptom score (NSS) >3
~Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.
~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
~rest cutaneous microcirculation (perfusion and vasomotion)
~Exercise cutaneous microcirculation (perfusion and vasomotion)
~Foot lowering cutaneous microcirculation (perfusion and vasomotion)
~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)
~blood sampling
~heart rate variability at rest
~pedometer during 4 days
~international Physical Activity Questionary
~Qualify of Life questionary (EQVOD)"
16418929|NCT03847779|Experimental|Controls|"matched for age, sexe and BMI with diabetic patients.
~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
~rest cutaneous microcirculation (perfusion and vasomotion)
~Exercise cutaneous microcirculation (perfusion and vasomotion)
~Foot lowering cutaneous microcirculation (perfusion and vasomotion)
~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)
~blood sampling
~heart rate variability at rest
~international Physical Activity Questionary
~Qualify of Life questionary (EQVOD)"
16418930|NCT03847766|Experimental|PRO-based follow-up|Patients will receive a questionnaire every 3 months. The PRO questionnaire is used as decision aid together with other available clinical data to decide whether the patient needs a visit or not. Hence, patients only visit the outpatient clinic if there is a clinical need or a patient's wish. The actual response for each questionnaire automatically results in a colour code (green, yellow or red). A red or yellow response indicates that the patient needs to be contacted. A green colour indicates no need for a visit. Based on an overview of the questionnaire and the patient's blood samples a physician decides whether this patient should have a telephone consultation or the patient needs to be seen in the clinic.
16418931|NCT03847766|Experimental|PRO-based telephone consultations|Patients receive an electronic questionnaire every 3 months prior to a scheduled telephone consultation.The PRO questionnaire is used as dialogue support during the telephone consultation. The actual response for each item automatically results in a colour code (green, yellow or red). A red response indicates that the patient has a problem; a yellow colour indicates a potential problem, while a green colour indicates no problems.
16418932|NCT03847766|No Intervention|Usual outpatient follow-up visits|Patients in the control group will continue to have usual scheduled outpatient follow-up visits at the hospital initiated by the physician every 3 months. These patients do not use the clinical PRO questionnaire, but complete the research questionnaires.
16418933|NCT03847753||Danish population|The cohort includes all those born in Denmark between 1900-2015, and who resided there in the period of 2000-2016.Whether they received a diagnosis of one of the following mental disorders will be ascertained: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Eating Disorders, Neurotic Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders The risk of receiving a later diagnosis of one of the following types of general medical conditions will then be estimated: Circulatory, Endocrine, Pulmonary and Allergy, Gastrointestinal, Urogenital, Musculoskeletal, Hematological, Cancer, Neurological
16418934|NCT03847740|Experimental|Right Isometric Thumb Force (ITF) handle|
16418935|NCT03847740|Experimental|Left Isometric Thumb Force (ITF) handle|
16418936|NCT03847727||Experimental: 6 cycles BR -> 4 x BR|Induction plus BR as maintenance (N=56)
16418937|NCT03847727||Proper historical control: 6 cycles BR|Induction only (N=56)
16418938|NCT03847714|Active Comparator|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
16418939|NCT03847714|Placebo Comparator|Placebo|3g of a similar looking and tasting powder, twice daily
16418942|NCT03847688||Treatment resistant Major Depressive Disorder|
16418943|NCT03847675|Experimental|Intervention|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age. A 4:50 minutes video clip would be shown during the initial visit. This video discusses the benefits of reading displaying practical tips for parents; it includes tips on how to read, pointing at the words.
~A schematic pamphlet highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents.
~After each visit participants will receive an age appropriate book for their child.
~Focus groups will be conducted by a qualitative researcher"
16418978|NCT03847441|Active Comparator|Group III|
16418979|NCT03847441|Placebo Comparator|Group IV|
16418945|NCT03847662||Community Based Production and Access of Complimentary Foods|"Nine communes were randomly selected with the cluster inclusion criteria as having high levels of; agricultural production, childhood under-nutrition and food security. This was carried out in the three rural mountainous provinces of Lao Cai, Lai Chau, and Ha Giang. In each of these provinces, one district and three subsequent communes were selected, for a total of 9 communes. The districts of Bat Xat, Tam Duong, and Vi Xuyen were selected in Lao Cai, Lai Chau and Ha Giang province respectively. This second stage district sampling selected sites with similar characteristic of population density, area, number of women of reproductive age(15-35y), percentage of children(<2y), income primarily from agricultural production, poverty and climate data.
~Changes were observed on food security and nutritional status with exposure to community based self reported purchasing local agricultural products and access to locally produced fortified complimentary foods."
16418946|NCT03847649|Active Comparator|Cohort 1: High Risk|
16418947|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm A|
16418948|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm B|
16418949|NCT03847636|Active Comparator|Familial Adenomatous Polyposis (FAP)|Individuals with duodenal adenomas (DAs) and FAP with Spigelman class 2,3 or 4, treated with cryoballoon ablation (intervention)
16418950|NCT03847636|Active Comparator|Sporadic duodenal adenomas|Individuals with at least 1 sporadic duodenal adenoma (DA) between 1-5 cm in maximum diameter, treated with cryoballoon ablation (intervention)
16418951|NCT03847623|Experimental|Curcumin|Capsules, taken orally, 8g per day (Bi-daily dosing)
16418952|NCT03847623|Placebo Comparator|Placebo|Capsules, taken orally, bi-daily dosing
16418953|NCT03847610|Experimental|Healthy volunteer|
16418954|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
16418955|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
16418956|NCT03847571||Acetazolamide|Oral administration of acetazolamide 5 mg/kg/day for 4 weeks
16418957|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
16418958|NCT03847545|Experimental|Intervention|The participants who have an effect of 20% or more after 14 days of Fampridine treatment, measured using 6 Spot Step Test (SSST) or Timed 25 Footwalk (F25-FW), will continue as cases and will receive Fampridine throughout the trial.
16418959|NCT03847545|No Intervention|Non-treated controls|Participants who do not have an effect of 20% or more after 14 days of Fampridine treatment, measured using 6 Spot Step Test (SSST) or Timed 25 Footwalk (F25-FW), will continue as untreated controls. They will not receive Fampridine in the remainder of the trial.
16418960|NCT03847532|Other|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
16418961|NCT03847532|Other|Patients with multiple colon polyps|Number of polyps from 4+
16418962|NCT03847532|Other|Control sample|Patients who did not have colon polyps
16418963|NCT03847519|Experimental|Safety Phase Part A|"Enroll subjects with metastatic squamous or non-squamous NSCLC who have become refractory or intolerant to standard therapy. ADXS-503 monotherapy will be evaluated at 2 planned escalating dose levels:
~Dose level 1: 1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.
~Dose level 2: 5e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
16418964|NCT03847519|Experimental|Safety Phase Part B|"Enroll subjects with metastatic squamous or non-squamous NSCLC. ADXS-503 will be evaluated at 2 planned escalating dose levels in combination with a fixed dose of pembrolizumab:
~Dose level 1: 1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.
~Dose level 2: 5e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
16418965|NCT03847519|Experimental|Efficacy Phase Part C|"Enroll subjects with metastatic squamous or non-squamous NSCLC.
~1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
16418966|NCT03847506|Experimental|EZE/ROS+CAN/AML|Ezetimibe/Rosuvastatin 10 mg/10 mg and Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
16418967|NCT03847506|Active Comparator|CAN/AML|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
16418968|NCT03847506|Active Comparator|EZE/ROS+CAN|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg, once a day for 6 weeks
16418969|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
16418970|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
16418971|NCT03847480|Experimental|Dose painting|Dose painting
16418972|NCT03847467|Experimental|2'-Fucosyllactose|"Phase I: 36 young adult participants aged 18-25 years. Group 1: 1 gm per day n=12 (6UC/6CD) Group 2: 5 gm per day n=12 (6UC/6CD) Group 3: 10 gm per day n=12 (6UC/6CD)
~Phase II (post Phase I interim safety analysis): 120 participants aged 11-25 years Group 1: 1 gm per day n=40 (20UC/20CD) Group 2: 5 gm per day n=40 (20UC/20CD) Group 3: 10 gm per day n=40 (20UC/20CD)"
16418973|NCT03847467|Placebo Comparator|Placebo|"Phase I: 20 young adult participants age 18-25 years dosed at 2 gm placebo per day. (10UC/10CD)
~Phase II (post Phase I interim safety analysis): 40 participants age 11-25 years dosed at 2 gm placebo per day. (20UC/20CD)"
16418974|NCT03847454|Experimental|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
16418975|NCT03847454|Active Comparator|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
16418976|NCT03847441|Active Comparator|Group I|
16418977|NCT03847441|Active Comparator|Group II|
16418984|NCT03847402|Active Comparator|GDD non-intervention|Community intervention for GDD
16418985|NCT03847402|Experimental|ASD intervention|The early integrated intervention for ASD
16418986|NCT03847402|Active Comparator|ASD non-intervention|Community intervention for ASD
16418987|NCT03847402|Experimental|ADHD intervention|The early integrated intervention for ADHD
16418988|NCT03847402|Active Comparator|ADHD non-intervention|Community intervention for ADHD
16418989|NCT03847389|Other|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
16418990|NCT03847363||general anesthesia|patients underwent general anesthesia
16418991|NCT03847363||general and epidural anesthesia|patients underwent general and epidural anesthesia
16418992|NCT03847363||general anesthesia combined with nerve block|patients underwent general anesthesia combined with nerve block
16418993|NCT03847337|Experimental|New to diagnosis|We will test two telemedicine tools with children who have not been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
16418994|NCT03847337|Experimental|Previously diagnosed|We will test two telemedicine tools with children who have been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
16418995|NCT03847324|Active Comparator|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
16418996|NCT03847324|Experimental|PNE|Usual care + Preoperative Pain Neuroscience Education
16418997|NCT03847324|Experimental|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
16418998|NCT03847311|Placebo Comparator|Placebos|Subjects will receive sugar pill.
16418999|NCT03847311|Active Comparator|Sulfasalazine|Subjects will receive the active drug.
16419000|NCT03847298||Pacemaker|
16419001|NCT03847298||Control|
16419002|NCT03847272|Experimental|Patients|
16419003|NCT03847259||A(public school)|"it will be consists of 200 adolescent female from public schools, their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire.
~pain will be evaluated by VISUAL ANALOG SCALE(VAS) .stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21)."
16419004|NCT03847259||B(international school)|it will be consists of 200 adolescent female from international schools their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire .pain will be evaluated by VISUAL ANALOG SCALE (VAS).stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21).
16419005|NCT03847246|Active Comparator|Baraclude® tablets，1.0 mg|
16419006|NCT03847246|Experimental|Entecavir tablets，1.0 mg|
16419007|NCT03847233|Experimental|Jetstream Atherectomy System|
16419008|NCT03847207|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
16419009|NCT03847207|Experimental|Part 2 Pasireotide PD Assessment|Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
16419010|NCT03847207|Experimental|Part 3 Proof of Pharmacological Effect|Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
16419016|NCT03847168|Experimental|KN026|Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
16419017|NCT03847155|Experimental|Nicotine|The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.
16419018|NCT03847155|Placebo Comparator|Placebo|The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.
16419019|NCT03847142|Experimental|ASTHMAXcel arm|The ASTHMAXcel arm represents the study intervention, which is a patient-facing mobile application for adult patients with asthma.
16419020|NCT03847142|Active Comparator|Usual care arm|This arm represents usual care delivered in the outpatient primary care setting at the study sites.
16419021|NCT03847129|Experimental|Biofeedback training group|The participants in the biofeedback training group attend a 30 minute biofeedback protocol per session, two times a week for six to eight weeks that is also combined with the regular diabetic care treatment in the Occupational Therapy Room.
16419022|NCT03847129|Active Comparator|Home-based training group|The participants in this group receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment.
16419023|NCT03847129|No Intervention|Control group|The participants in the control group receive only diabetes disease prevention consultation once and outcome assessments twice.
16419024|NCT03847103|Experimental|Robotic-aided rehabilitation with bilateral practice|In addition to a 10-minutes sensorimotor stimulation programs, the experimental group received 40-minutes Robotic-assisted Therapy with Bilateral Practice programs.
16419025|NCT03847103|Active Comparator|Unilateral task-specific training|In addition to a 10-minutes sensorimotor stimulation programs, the control subjects received 40-minute unilateral task-specific training.
16419026|NCT03847090|Experimental|Reloxaliase|Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
16419027|NCT03847090|Placebo Comparator|placebo|placebo capsule
16419028|NCT03847077|Experimental|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application
16419029|NCT03847077|Active Comparator|Standard counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
16419030|NCT03847038|Experimental|Intervention|Multimodal lifestyle-interventional. Participants are disclosed their 5-year dementia risk estimate
16419031|NCT03847025||Lead extraction|Patients undergoing clinically indicated lead extraction procedures.
16419032|NCT03847012|Experimental|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
16419033|NCT03846999||Long-term breast cancer survivors|"Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
~Analyze comorbidities and patterns of use of health services by tumor characteristics."
16419034|NCT03846999||Women without history of cancer|Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
16419035|NCT03846986|Active Comparator|Apple Juice1|100% Apple Juice
16419036|NCT03846986|Experimental|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
16419037|NCT03846986|Placebo Comparator|Raw Apple|Raw Apple
16419038|NCT03846973|Experimental|Tranexamic acid|group-I will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes followed by an intravenous infusion of 1 g TXA to be given and completed over 8 h in the hospital
16419039|NCT03846973|Placebo Comparator|Placebo|group-II will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes but will receive placebo (normal saline) infusion to be given and completed over 8 h in the hospital
16419040|NCT03846960|Experimental|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
16419041|NCT03846947|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
16419042|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
16419043|NCT03846921||Viral infection|Patients with proven viral infections will have laboratory blood test taken
16419044|NCT03846921||Bacterial Infection|Patients with proven bacterial infections will have laboratory blood test taken
16419045|NCT03846908|Experimental|MCT|subjects start with MCT fat load
16419046|NCT03846908|Experimental|SFA|subjects start with SFA fat load
16419047|NCT03846908|Experimental|MUFA|subjects start with MUFA fat load
16419048|NCT03846895|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.
~The laser parameters that will be used are the following:
~Power: 40 watts,
~Dwell time:1000μs,
~Spacing 1000 μm,
~Depth: SmartStak parameter 3
~D-pulse mode."
16419049|NCT03846895|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.
~The laser parameters that will be used are the following:
~Power: 0.5 watts,
~Dwell time:1000μs,
~Spacing 1000 μm,
~Depth: SmartStak parameter 1,
~Smart-pulse mode."
16419050|NCT03846869|Experimental|major cations|bood sample
16419051|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
16419052|NCT03846843|Experimental|OCR-002 - Treatment A|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions
16419053|NCT03846843|Experimental|OCR-002 - Treatment B|A single 5 g oral dose of OCR-002 oral solution administered under fed conditions
16419054|NCT03846843|Experimental|OCR-002 - Treatment C|A single 5 g intravenous dose of OCR-002 solution infused over 1 hour under fasting conditions
16419055|NCT03846843|Experimental|OCR-002 - Treatment D|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions following discontinuation of lactulose
16419056|NCT03846843|Experimental|OCR-002 - Treatment E|6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
16419057|NCT03846843|Experimental|OCR-002 - Treatment F|12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
16419058|NCT03846843|Experimental|OCR-002 - Treatment G|21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
16419084|NCT03846609|Active Comparator|no double balloon platform|Device: no double balloon interventional platform (DiLumen)
16419059|NCT03846830|Active Comparator|IVE/VPT 6 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 5 weeks, 6 weeks washout, and then crossover into the other group for a final 5 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout each of the 5 weeks epochs of training.
16419060|NCT03846830|Experimental|IVE/VPT 3 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training will not start until the washout period.
16419061|NCT03846830|Active Comparator|IVE/VPT 3 week crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving every other day exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout the 3 weeks of exercise.
16419062|NCT03846817|Experimental|FAIS with intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.
~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).
~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
16419063|NCT03846817|Experimental|FAIS without intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.
~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).
~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
16419064|NCT03846765|Experimental|Phenylephrine continuous infusion|
16419065|NCT03846765|Experimental|Dobutamine continuous infusion|
16419066|NCT03846752|Active Comparator|7 Fr. radial access|radial artery access for complex PCI
16419067|NCT03846752|Active Comparator|7 Fr. femoral access|femoral artery access for complex PCI
16419068|NCT03846739|Active Comparator|Oxytocin & Placebo, 6 IU|Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
16419069|NCT03846739|Active Comparator|Oxytocin & Placebo, 12 IU|Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
16419070|NCT03846739|Active Comparator|Oxytocin & Placebo, 24 IU|Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
16419071|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
16419072|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
16419073|NCT03846713|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
16419074|NCT03846713|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
16419075|NCT03846700|Experimental|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume > 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
16419076|NCT03846700|Active Comparator|holep|patients with prostatic volume > 65 ml will be treated with holmium laser technique (Holep)
16419077|NCT03846700|Active Comparator|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
16419078|NCT03846661|Active Comparator|Physiomesh|Patients undergoing laparoscopic incisional hernia repair reinforced with a Physiomesh.
16419079|NCT03846661|No Intervention|other mesh|Patients undergoing laparoscopic incisional hernia repair reinforced with other meshes than Physiomesh.
16419080|NCT03846648|Active Comparator|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.
~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.
~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
16419081|NCT03846648|Placebo Comparator|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
16419082|NCT03846635||Patients with Suspected Cellulitis|"Patients who undergo an infectious diseases consultation for suspected cellulitis of the upper or lower limbs are eligible to be enrolled. Patients who consent to participation will have chart data extracted and undergo a skin surface temperature measurement of the affected area and surrounding skin using a commercially available infrared thermometer. The dimensions of suspected cellulitis are also measured.
~Patients with cellulitis admitted to hospital undergo daily measurements of temperature and dimensions. These patients are also asked standardized questions about their symptoms based on the patient global impression of improvement scale."
16419083|NCT03846609|Experimental|double balloon platform|Device: double balloon interventional platform (DiLumen)
16419085|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
16419086|NCT03846583|Experimental|Dose Escalation|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
16419087|NCT03846583|Experimental|Arm A: Active Brain Metastases|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
16419088|NCT03846583|Experimental|Arm B: Surgical Resection Needed|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
16419089|NCT03846583|Experimental|Arm C: Progressive Extracranial Disease|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
16419090|NCT03846570|Active Comparator|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
16419091|NCT03846570|Placebo Comparator|Placebo|Matching placebo (identically package) administered BID
16419092|NCT03846557||Treatment|Transcatheter Aortic Valve Implantation (TAVI)
16419093|NCT03846544|No Intervention|control group|
16419094|NCT03846544|Experimental|double pick up group|
16419095|NCT03846531|Active Comparator|Nano-Pulse Stimulation (NPS) Lesion|Three of four selected SK lesions receive Nano-Pulse Stimulation treatment.
16419096|NCT03846531|No Intervention|Non-Treated Lesion|One of four SK lesions is randomized to not receiving Nano-Pulse Stimulation treatment.
16419097|NCT03846518|Active Comparator|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
16419098|NCT03846518|Experimental|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
16419099|NCT03846505|Experimental|Oxytocin|"A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
16419100|NCT03846505|Placebo Comparator|Placebo|"A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
16419101|NCT03846492|Experimental|Active tDCS|The direct current will be delivered at 2 mA intensity via rubber electrodes in saline- soaked sponges for 30 min per day for 2 weeks, 5 days/week. Inhibitory stimulation will be delivered to the frontal lobes.
16419102|NCT03846492|Sham Comparator|sham tDCS|Sham tDCS will use the same parameters except that the device will automatically turn off after a certain duration.
16419103|NCT03846479|Experimental|Itacitinib|Itacitinib 200 mg administered orally daily
16419104|NCT03846466|Experimental|Part1 Dose 1A|Single administration
16419105|NCT03846466|Placebo Comparator|Part1 Dose 1P|Single administration
16419106|NCT03846466|Experimental|Part1 Dose 2A|Single administration
16419107|NCT03846466|Placebo Comparator|Part1 Dose 2P|Single administration
16419108|NCT03846466|Experimental|Part1 Dose 3A|Single administration
16419109|NCT03846466|Placebo Comparator|Part1 Dose 3P|Single administration
16419110|NCT03846466|Experimental|Part1 Dose 4A|Single administration
16419111|NCT03846466|Placebo Comparator|Part1 Dose 4P|Single administration
16419112|NCT03846466|Experimental|Part1 Dose 5A|Single administration
16419113|NCT03846466|Placebo Comparator|Part1 Dose 5P|Single administration
16419114|NCT03846466|Experimental|Part1 Dose 6A|Single administration
16419115|NCT03846466|Placebo Comparator|Part1 Dose 6P|Single administration
16419116|NCT03846466|Experimental|Part1 Dose 7A|Single administration
16419117|NCT03846466|Placebo Comparator|Part1 Dose 7P|Single administration
16419118|NCT03846466|Experimental|Part2 Dose 1A|Multiple administration
16419119|NCT03846466|Placebo Comparator|Part2 Dose 1P|Multiple administration
16419120|NCT03846466|Experimental|Part2 Dose 2A|Multiple administration
16419121|NCT03846466|Placebo Comparator|Part2 Dose 2P|Multiple administration
16419122|NCT03846453|Experimental|0.25% HL036 Ophthalmic Solution|HL036 ophthalmic solution
16419123|NCT03846453|Placebo Comparator|Placebo|Placebo vehicle solution
16419124|NCT03846440||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
16419125|NCT03846427|Experimental|Zanubrutinib|
16419126|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
16419127|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
16419128|NCT03846388|Other|Patients with unexplained infertility|
16419129|NCT03846388|Other|patients with tubal, male factor or polycystic ovary syndrome|
16419130|NCT03846375|Experimental|Participants in DBT|Psychotherapy: The participants will be given standard DBT treatment.
16419131|NCT03846375|Other|Control Group|Control Group at preintervention.
16419132|NCT03846362|Experimental|intermediate risk MRD2>0,1%|MRD2>0,1% - FLA - MRD3 - HSCT
16419166|NCT03846193|Experimental|GT005 Dose 1, 2 or 3 with Orbit Subretinal Delivery Sysem|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
16419133|NCT03846349|Experimental|Study Group|Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week
16419134|NCT03846349|Sham Comparator|Control group|"Participants from the control group will perform a sham reeducation protocol using an EMT threshold at minimal resistance. The expiratory pressure will remain unchanged over the weeks."
16419135|NCT03846336|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
16419136|NCT03846336|Other|Healthy individuals|20 healthy volunteers with matching ages and genders.
16419137|NCT03846323|Experimental|Visiting policies: open 24h/24|Visiting policies: 24 hours a day, 7 days a week
16419138|NCT03846323|Other|Restriction of visiting policies|Restriction of visiting policies < 6 hours
16419139|NCT03846310|Experimental|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
16419140|NCT03846310|Experimental|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
16419141|NCT03846310|Experimental|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
16419142|NCT03846310|Experimental|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
16419143|NCT03846284|Placebo Comparator|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
16419144|NCT03846284|Experimental|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.
~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
16419145|NCT03846284|Experimental|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
16419146|NCT03846271|Experimental|Oxytocin then placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
16419147|NCT03846271|Experimental|Placebo then oxytocin|Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
16419148|NCT03846258|Active Comparator|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
16419149|NCT03846258|Active Comparator|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
16419150|NCT03846245||Young adults group|Cognitively unimpaired 18-25 years old
16419151|NCT03846245||Old adults group|Cognitively unimpaired >= 70 years old
16419152|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
16419153|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
16419154|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
16419155|NCT03846219|Experimental|IMU-838 (30 mg/day)|"Tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets.
~Duration: until the end of the main treatment period (24 weeks) and, optionally, during the extended treatment period (up to 9.5 years)."
16419156|NCT03846219|Experimental|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.
~Duration: until the end of the main treatment period (24 weeks) and, optionally, during the extended treatment period (up to 9.5 years)."
16419157|NCT03846219|Placebo Comparator|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.
~Duration: until the end of the main treatment period (24 weeks). For the optional extended treatment period, patients receiving placebo during the main treatment period will be randomized to 30 or 45 mg/day IMU-838."
16419158|NCT03846206|Experimental|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
16419159|NCT03846206|No Intervention|Usual diet|Patients do usual diet for three months
16419160|NCT03846193|Experimental|GT005 Dose 1|A single dose of GT005 will be administered via subretinal injection
16419161|NCT03846193|Experimental|GT005 Dose 2|A single dose of GT005 will be administered via subretinal injection
16419162|NCT03846193|Experimental|GT005 Dose 3|A single dose of GT005 will be administered via subretinal injection
16419163|NCT03846193|Experimental|GT005 Dose 1, 2 or 3|A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3
16419164|NCT03846193|Experimental|GT005 Dose 2 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
16419165|NCT03846193|Experimental|GT005 Dose 3 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
16419247|NCT03845530|Active Comparator|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
16419167|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
16419168|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
16419169|NCT03846167||FTT PET/CT|"The imaging procedure may include one or both of the following imaging sessions; 1) a 45- 60 minute dynamic scan, starting at approximately the same time as the injection and/or 2) a skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT.
~Participants will be asked to complete the following research procedures: [18F]FTT PET/CT scan before surgery or treatment [18F]FTT PET/CT scan after you start treatment (optional)"
16419170|NCT03846154|Experimental|Intervention group|"Children and adolescents in the intervention group received:
~A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.
~Access to schools and school material
~Family visits
~Their parents received training regarding agriculture and microcredit projects, and financial assistance
~FORNET if affected by trauma-related symptoms, and/or acting aggressive
~If needed medical assistance is provided
~If needed legal assistance is provided"
16419171|NCT03846154|No Intervention|Control group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
16419172|NCT03846141|Placebo Comparator|Placebo|Room air for inhalation
16419173|NCT03846141|Experimental|Hydrogen|Hydrogen (4%) for inhalation
16419174|NCT03846115|Experimental|Peer-Led Seeking Safety app|This app is designed for Peer-Led Seeking Safety and includes enhanced app features.
16419175|NCT03846115|Active Comparator|Control app|This is a basic app that controls for time and attention. The basic app serves as the intervention in this trial.
16419176|NCT03846102|Experimental|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)
~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)
~[<64 kg : 100 mg : 2.0 mg/kg : 40 ml]
~[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml]
~[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml]
~Acetaminophen 1 gram (tablets) 4 times daily.
~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
16419177|NCT03846102|Placebo Comparator|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.
~Ideal Body Weight : Total volume (ml)
~[<64 kg : 40 ml]
~[65-74 kg : 45 ml]
~[≥ 75 kg : 50 ml]
~Acetaminophen 1 gram (tablets) 4 times daily.
~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
16419178|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
16419179|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
16419180|NCT03846076|Experimental|Internet-delivered CBT|10 weeks of CBT delivered via the Internet.
16419181|NCT03846063|Experimental|Intervention: Home-based rehabilitation program|"A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.
~The intervention group will be compared with existing patientdata who received usual care in the Netherlands"
16419182|NCT03846050|Experimental|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.
~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
16419183|NCT03846050|Experimental|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.
~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
16419184|NCT03846050|Placebo Comparator|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.
~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
16419185|NCT03846037|Placebo Comparator|Ground|Participants in this group perform protocol exercises on a stable surface.
16419186|NCT03846037|Experimental|vibrating platform|Participants in this group perform protocol exercises on a vibrating platform.
16419187|NCT03846024|Experimental|RibFx belt arm|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
16419248|NCT03845530|Active Comparator|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
16419249|NCT03845517|Placebo Comparator|Placebo|Placebo
16419250|NCT03845517|Experimental|PF-06700841 15 mg|PF-06700841 15 mg
16419251|NCT03845517|Experimental|PF-06700841 30 mg|PF-06700841 30 mg
16419252|NCT03845517|Experimental|PF-06700841 45 mg|PF-06700841 45 mg
16419188|NCT03846024|No Intervention|Control|"Patients in the control arm receive normal standard of care for rib fractures at the participating institution.
~The current standard of care for rib fractures at the University of Vermont (participating institution) is as follows: includes oral and IV analgesia and other multimodal pain control as appropriate, including muscle relaxants such as methocarbamol (robaxin) unless there is a contraindication, pulmonary hygiene/toilet and respiratory care (including frequent evaluations by physicians, respiratory therapists, and nursing staff, early mobilization, and monitoring for pulmonary complication (via vital signs, pulse oximetry, oxygen requirement, chest imaging if appropriate)."
16419189|NCT03846011||Experiment group|All eligible patients administered for active stone removal.
16419190|NCT03845998|Experimental|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.
~The intervention is to use the three-finger method."
16419191|NCT03845998|Active Comparator|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.
~The intervention is to use the weight-related method."
16419192|NCT03845985|Experimental|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
16419193|NCT03845985|No Intervention|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
16419194|NCT03845972|No Intervention|before SSFTB|
16419195|NCT03845972|Experimental|after SSFTB|
16419196|NCT03845959|Experimental|TD0019.6cap|estimated dose, 2 oral capsules/time x 3 times/day
16419197|NCT03845959|Experimental|TD0019.9cap|1.5 times of estimated dose 2 oral capsules/time x 3 times/day
16419198|NCT03845959|Placebo Comparator|Placebo|Placebo 2 placebo oral capsules /time x 3 times/day
16419199|NCT03845946||Hereditary angioedema type I/II|Hereditary angioedema with C1Inh deficiency
16419200|NCT03845946||Acquired angioedema|Angioedema with acquired C1Inh deficiency
16419201|NCT03845946||Drug induced angioedema|Angioedema associated with ACEi used
16419202|NCT03845946||Mast cell induced angioedema|Spontaneous mast cell induced isolated angioedema
16419203|NCT03845946||Hereditary angioedema with nC1Inh|Hereditary angioedema with normal C1Inh and with F12, PLG, ANGPT2 mutations
16419204|NCT03845933|Active Comparator|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
16419205|NCT03845933|Active Comparator|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
16419206|NCT03845920|Other|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])
16419207|NCT03845920|Experimental|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
16419208|NCT03845920|Experimental|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])
16419209|NCT03845920|Experimental|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
16419210|NCT03845907|Active Comparator|Imagio Gen 1B|Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe
16419211|NCT03845907|Active Comparator|Imagio Gen 1|Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System
16419212|NCT03845894|Active Comparator|Liposomal Bupivacaine ISB|
16419213|NCT03845894|Active Comparator|Bupivacaine with adjuvants ISB|
16419214|NCT03845881|Active Comparator|Opioid|Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
16419215|NCT03845881|Placebo Comparator|Non Opioid|Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
16419216|NCT03845868||Egang hospital physical examination center|
16419217|NCT03845868||Ezhou CDC physical examination center|
16419218|NCT03845855|Experimental|Virtual reality with robotic gait|virtual reality treatment with robotic gait therapy 2 times for week by 6 weeks.
16419219|NCT03845855|Active Comparator|Robotic gait therapy only|only robotic gait therapy 2 times for week by 6 weeks
16419220|NCT03845842|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour and are asked to tick critical situations/appropriate responses that might be useful to them."
16419221|NCT03845842|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour. Implementation intentions are formed by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
16419222|NCT03845829|Experimental|Patients with TBAD treated with TEVAR|In situ laser assisted fenestration for the left subclavian artery during the TEVAR procedure for TBAD.
16419223|NCT03845777||Surgical Staff|The surgical staff group is the only group of the study. Blood samples of the surgical staff before and after the using antiseptics solution that include iodine were analyzed.
16419224|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
16419225|NCT03845751|Experimental|ADT protocol|ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). Additionally, oral antiandrogen bicalutamide 50 mg once per day is given for 3 months, starting the same day of LHRH agonist injection. ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
16419226|NCT03845712|Experimental|MT1621, dC/dT|This is an open label study with all participants in a single arm. Patients will take MT1621 up to a maximum of 400 mg/kg/day. MT1621 is deoxycytidine (dC) and deoxythymidine (dT) powders for solution for reconstitution in water. Study drug will be supplied as powder in packets containing 0.5 or 2.0 g or 4.0 g of dC or dT, and is typically dosed three times/day. MT1621 should be administered with food.
16419227|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, < 4 weeks post stroke, age >18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, <4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
16419228|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (>3 months post-stroke)
16419229|NCT03845673|Experimental|Psyllium|This group of patients was given psyllium for 6 weeks
16419230|NCT03845673|Experimental|Bowel recipe|This group was administered a specialized bowel recipe for 6 weeks
16419231|NCT03845660|No Intervention|Usual Care|Providers taking care of patients randomized to this arm will have no alert related to the patients prognosis.
16419232|NCT03845660|Experimental|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
16419233|NCT03845647|Experimental|Tumor diameter<=2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
16419234|NCT03845647|Experimental|Tumor diameter>2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
16419235|NCT03845621|Active Comparator|CM-OA-OA-CM Sequence|Use of a conventional custom-made mouthguard (CM) while playing water polo for first and fourth weeks and the occlusal-adjusted custom-made mouthguard (OA) for the second and third weeks.
16419236|NCT03845621|Active Comparator|OA-CM-CM-OA Sequence|Use of an occlusal-adjusted custom-made mouthguard (OA) for the first and fourth weeks and a conventional custom-made mouthguard (CM) while playing water polo for the second and third weeks.
16419237|NCT03845608|Experimental|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
16419238|NCT03845608|Other|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
16419239|NCT03845608|No Intervention|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
16419240|NCT03845595|Experimental|(LF-rTMS) group|Patients in the study group were treated with the contralesional (LF-rTMS) once per day for 20 minutes, Daily, 5 sessions per week (Sunday to Thursday), for 2 consecutive weeks in addition to the conventional upper limb physical therapy interventions.
16419241|NCT03845595|Active Comparator|Control group|Patients in the control group were treated with the conventional upper limb physical therapy interventions (40 minutes to 1 hour, daily, 5 times per week for two consecutive weeks )
16419242|NCT03845582|Experimental|ALK-001|Capsule
16419243|NCT03845582|Placebo Comparator|Placebo|Capsule
16419244|NCT03845569|Other|Habitual Protein phase|A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
16419245|NCT03845569|Experimental|Moderate Protein Phase|A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
16419246|NCT03845543|Experimental|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
16419253|NCT03845504|Experimental|Open Label|Open-label rTMS sessions will occur within ~2 days after the baseline session with daily sessions delivered to left DLPFC over 2-6 weeks. Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
16419254|NCT03845491||SR Classic|SR (Trevo®]) + BGC (FlowGate2] or Merci)
16419255|NCT03845491||SR Combination|"SR (Trevo) + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump
~+ LS (AXS Infinity LS, AXS Infinity LS Plus)
~or
~SR (Trevo) + Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2 or Merci)"
16419256|NCT03845491||Direct Aspiration|"Asp Cath (AXS Catalyst DAC, Vecta) ± Pump + LS (AXS Infinity LS, AXS Infinity LS Plus)
~or
~Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2, Merci)"
16419257|NCT03845478|Active Comparator|Control Group (CG)|Education, modifying diet and physical activity
16419258|NCT03845478|Experimental|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
16419259|NCT03845465|Active Comparator|Education|Participants in the Education group will complete a behavioral health contract and will receive an educational packet.
16419260|NCT03845465|Experimental|PA + Education|Participants in the Positive Affect + Education group will complete a behavioral health contract and receive an educational packet. In addition, they will receive intervention components aimed at inducing positive affect.
16419261|NCT03845413|Active Comparator|Intervention|The intervention arm consisted of 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
16419262|NCT03845413|Active Comparator|Control|The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
16419263|NCT03845400||Type I or Type II HAE Participants|Participants will be followed for 36 months after the enrollment date up to the time of withdrawal, lost to follow-up, death or end of follow-up (36 months) whichever comes first.
16419264|NCT03845387|Experimental|KDT-3594|
16419265|NCT03845387|Other|Pramipexole|Reference drug
16419266|NCT03845374|Experimental|Conventional Antibiotics+ Hyper-CL™ lens|Conventional treatment with topical Antibiotics+ Hyper-CL™ lens
16419267|NCT03845374|No Intervention|Conventional Antibiotics|Conventional treatment with topical Antibiotics
16419268|NCT03845361|Experimental|C. hand|Radial artery cannulation
16419269|NCT03845361|No Intervention|N.C. hand|No cannulation of the radial artery
16419270|NCT03845348|Experimental|TD3|TD3, bi-daily x 4 weeks
16419271|NCT03845348|Experimental|TD7|TD7, bi-daily x 4 weeks
16419272|NCT03845348|Active Comparator|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
16419273|NCT03845335|Experimental|HA-coated hybrid implant|Patient allocated to this group will receive an iMAX® Hyaluronic Acid-coated hybrid dental implant for their dental implant-supported restoration.
16419274|NCT03845335|Active Comparator|Moderately rough implant|Patient allocated in this group will receive an iMAX® non-coated moderately rough dental implant with a machined neck their dental implant-supported restoration.
16419275|NCT03845322|Experimental|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
16419276|NCT03845322|Placebo Comparator|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
16419277|NCT03845309|Experimental|Nutritional intervention for CHF|
16419278|NCT03845296|Experimental|Treatment (rucaparib)|Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16419279|NCT03845283|Experimental|Physical Activity|Participants will receive the core 6-month weight loss program and the tailored intervention to promote structured physical activity.
16419280|NCT03845283|Experimental|Core Program|Participants will receive the core 6-month weight loss program alone. This program includes weekly lessons for the first 12 weeks and monthly lessons for the remaining 12 weeks. Participants will track their intake, physical activity, and weight, input these data into the system, and received tailored feedback.
16419281|NCT03845283|Experimental|Physical Activity & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the virtual meetings to support weight loss.
16419282|NCT03845283|Experimental|Virtual Meetings|Participants will receive the core 6-month weight loss program and the virtual meetings to support weight loss.
16419283|NCT03845283|Experimental|Physical Activity & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and access to the virtual reality platform for behavioral weight loss skills training.
16419284|NCT03845283|Experimental|Virtual Reality|Participants will receive the core 6-month weight loss program and access to the virtual reality platform for behavioral weight loss skills training.
16419285|NCT03845283|Experimental|Physical Activity, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the virtual meetings to support weight loss, and access to the virtual reality platform for behavioral weight loss skills training.
16419286|NCT03845283|Experimental|Virtual Reality & Virtual Meetings|Participants will receive the core 6-month weight loss program, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
16419287|NCT03845283|Experimental|Physical Activity & Bite Counter|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the Bite Counter device to reduce dietary intake.
16419288|NCT03845283|Experimental|Bite Counter|Participants will receive the core 6-month weight loss program and the Bite Counter device to reduce dietary intake.
16419289|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
16419290|NCT03845283|Experimental|Bite Counter & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
16419291|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
16419292|NCT03845283|Experimental|Bite Counter & Virtual Reality|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
16419293|NCT03845283|Experimental|Physical Activity, Bite Counter, Virtual Reality & Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
16419294|NCT03845283|Experimental|Bite Counter, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
16419295|NCT03845270|Experimental|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
16419296|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:
~Blood eosinophils
~FeNO
~Eosinophils in bronchoalveolar lavage
~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
16419297|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:
~Blood eosinophils
~FeNO
~Eosinophils in bronchoalveolar lavage
~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
16419298|NCT03845244|Active Comparator|Flow reduction first group|Flow reduction first -> FiO2 reduction -> conventional oxygen therapy
16419299|NCT03845244|Active Comparator|FiO2 reduction first group|FiO2 reduction first -> flow reduction -> conventional oxygen therapy
16419300|NCT03845244|Active Comparator|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -> conventional oxygen therapy
16419301|NCT03845231|Other|unvaccinated|will receive no Flucelvax vaccination and will receive human challenge virus
16419302|NCT03845231|Experimental|Vaccinated|will receive Flucelvax vaccination and human challenge virus
16419303|NCT03845218||single arm|participants with and without RP
16419304|NCT03845205|Experimental|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
16419305|NCT03845205|No Intervention|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
16419306|NCT03845192|Other|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
16419307|NCT03845179|Placebo Comparator|Placebo|Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
16419308|NCT03845179|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
16419309|NCT03845166|Experimental|XL092 Single-Agent Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 3-6 subjects in a standard 3 plus 3 design."
16419310|NCT03845166|Experimental|XL092 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
16419311|NCT03845166|Experimental|XL092 + Atezolizumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
16419312|NCT03845166|Experimental|XL092 + Atezolizumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).
16419313|NCT03845166|Experimental|XL092 + Avelumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
16419314|NCT03845166|Experimental|XL092 + Avelumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in advanced urothelial carcinoma (UC).
16419315|NCT03845153|Active Comparator|Metformin|20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.
16419316|NCT03845153|Placebo Comparator|Placebo|20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.
16470639|NCT03493984|Placebo Comparator|Placebo|
16419322|NCT03845127|Experimental|Revivent TC Ventricular Enhancement System plus GDMT|Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
16419323|NCT03845127|Active Comparator|GDMT Only|Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
16419324|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 40%|
16419325|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 80%|
16419326|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 40%|
16419327|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 80%|
16419328|NCT03845101|Experimental|CBT in virtuo|Receives CBT in group format with Virtual Reality Exposure Therapy
16419329|NCT03845101|Active Comparator|CBT in vivo|Active comparator, receives CBT in group format. Treatment as usual.
16419330|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: <12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
16419331|NCT03845075|Experimental|active arm|The active medication arm will be given co-administration of 0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks.
16419332|NCT03845075|Placebo Comparator|placebo arm|The placebo arm will receive matching placebo tablets.
16419333|NCT03845049|Experimental|group aflibercept|
16419334|NCT03845049|Placebo Comparator|control group|
16419335|NCT03845036|Experimental|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
16419336|NCT03845036|Active Comparator|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
16419337|NCT03845023|Placebo Comparator|Placebo|Placebo
16419338|NCT03845023|Active Comparator|Dose 1|AD036 Dose 1
16419339|NCT03845023|Active Comparator|Dose 2|AD036 Dose 2
16419340|NCT03845023|Active Comparator|Dose 3|AD036 Dose 3
16419341|NCT03845010|Active Comparator|Sotalol|
16419342|NCT03845010|Active Comparator|Flecainide and verapamil|
16419343|NCT03845010|Active Comparator|Catheter ablation|
16419344|NCT03844997|Experimental|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).
~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
16419345|NCT03844984|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
16419346|NCT03844984|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
16419347|NCT03844971|Experimental|Computer assisted surgery|Intervention will be fabrication of patient specific surgical guide for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction using patient computed tomography with the aid of computer aided surgical simulation software
16419348|NCT03844958|Experimental|Red Furu|Volunteer was randomized into group red furu
16419349|NCT03844958|Experimental|Fresh Tofu|Volunteer was randomized into group tofu
16419350|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
16419351|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
16419352|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
16419353|NCT03844945|Placebo Comparator|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
16419354|NCT03844932|Experimental|ST-0529 18.75 mg*|"ST-0529: 18.75 mg orally twice daily (BID)
~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
16419355|NCT03844932|Experimental|ST-0529 37.5 mg*|"ST-0529: 37.5 mg orally twice daily (BID)
~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
16419356|NCT03844932|Experimental|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
16419357|NCT03844932|Placebo Comparator|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
16419358|NCT03844919|Experimental|rTMS + CBIT|Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
16419359|NCT03844919|Active Comparator|Sham rTMS + CBIT|Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
16419360|NCT03844906|Experimental|SAGE-718|
16419361|NCT03844906|Placebo Comparator|Placebo|
16419362|NCT03844880|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
16419386|NCT03844711|Experimental|Inspiratory Muscle training (IMT)|The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax.
16419363|NCT03844880|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
16419364|NCT03844867|Experimental|Filippo Cea and Carmel|Subjects <65 years.
16419365|NCT03844854|No Intervention|Control Group|Without intervention.
16419366|NCT03844854|Experimental|Research Group|With providing stabilization occlusal splint and manual therapy.
16419367|NCT03844841|Active Comparator|Propofol|Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous
16419368|NCT03844841|Active Comparator|Dexmedetomidine|Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous
16419369|NCT03844828|Experimental|POD FT IOL Implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT and POD F.
16419370|NCT03844815|Experimental|Treatment|"Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21
~Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21
~During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21"
16419371|NCT03844802|Experimental|Local dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 dry needling session a week during 3 consecutive weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
16419372|NCT03844802|Active Comparator|Distal dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in distant area from the location of active or latent myofascial trigger points of different neck-shoulder muscles. Therefore, dry needling will be applied in the same muscle but at a remote site from the locus of the myofascial trigger point, and, therefore, without evoking local twitch responses. Patients will receive 1 dry needling session a week during 3 weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
16419373|NCT03844802|Active Comparator|Sham/placebo dry needling and exercise|"The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 placebo dry needling session a week during 3 weeks (3 sessions in total). Therefore, participants in this group will receive simulated dry needling (with sham placebo needles, that will not actually penetrate the skin) in those neck muscles with active or latent myofascial trigger points. As formerly stated, the placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.They will also undergo the neck exercise program at home during these three weeks, and for the next three months."
16419374|NCT03844802|Active Comparator|Neck Exercise|The intervention protocol will consist only a home-based neck and shoulder exercise program. Participants in this group will be also assessed for the presence of active or latent myofascial trigger points in the neck-shoulder muscles. As in the other groups, they will be advised to carry out the exercise protocol for three weeks and the following three months.
16419375|NCT03844789|Experimental|Closed Loop Control (CLC)|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology & Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
16419376|NCT03844789|Active Comparator|Control Group|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.
16419377|NCT03844776|Active Comparator|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
16419378|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
16419379|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
16419380|NCT03844763|Experimental|Phase I - II trial of CTX, RT, Avelumab|CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.
16419381|NCT03844750|Experimental|Treatment (vactosertib, pembrolizumab, surgery)|Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 300 mg vactosertib (PO BID, 5 days per week x 2 weeks). Adjuvant pembrolizumab (400 mg IV) + vactosertib (300 mg PO BID, 5 days per week) will be administered for up to eight 6-week cycles.
16419382|NCT03844737|Experimental|VisuXL® Treatment|
16419383|NCT03844724|Experimental|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
16419384|NCT03844724|Active Comparator|Group B|subjects using the peripheral balloon dilatation catheter
16419385|NCT03844711|Experimental|Transcutaneous electrical diaphragmatic stimulation (TEDS)|For transcutaneous electrical diaphragmatic stimulation, surface electrodes will be used that will be positioned at the transcutaneous motor points of the diaphragm.
16419387|NCT03844711|Active Comparator|Conventional physiotherapy|The protocol of physiotherapy by the physiotherapists of HCPA will be twice a day and consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
16419388|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
16419389|NCT03844685|Experimental|Treatment group|1 tablet /day of MCE-11 (Promensil) taken orally for 24 months
16419390|NCT03844685|Placebo Comparator|Placebo group|Placebo tablet (without active principle) given once a day for 24 months
16419391|NCT03844672|Experimental|Low Concentration / Low Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a low power for three weeks.
16419392|NCT03844672|Experimental|Low Concentration / High Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a high power for three weeks.
16419393|NCT03844672|Experimental|High Concentration / Low Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a low power for three weeks.
16419394|NCT03844672|Experimental|High Concentration / High Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a high power for three weeks.
16419397|NCT03844646|Experimental|CGM plus dietitian|Intermittent use of a continuous glucose monitor (CGM) plus dietitian support
16419398|NCT03844646|Other|Dietitian only|Dietitian support only
16419399|NCT03844633|Experimental|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
16419400|NCT03844633|Placebo Comparator|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
16419401|NCT03844633|No Intervention|Open arm|No intervention provided
16419402|NCT03844620|Experimental|Arm I (ctDNA testing, regorafenib, TAS-102)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.
16419403|NCT03844620|Active Comparator|Arm II (SOC)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle as per standard of care. Patients in this arm will continue treatment in the absence of disease progression or unacceptable toxicity.
16419404|NCT03844607|Experimental|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
16419405|NCT03844607|Sham Comparator|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
16419406|NCT03844594|Experimental|Eptifibatide Drug: Eptifibatide Injection|
16419407|NCT03844581|Active Comparator|interferential current|interferential current with a constant frequency of 100Hz for pain relief, then using rhythmic frequency of 1-100 Hz that help to disperse infiltration and adhesions for 8 successive weeks
16419408|NCT03844581|Active Comparator|anticholinergics|anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks
16419409|NCT03844568|Experimental|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
16419410|NCT03844568|No Intervention|Control group|Usual pneumonia treatment
16419411|NCT03844555|Experimental|End Stage Renal Disease|Single oral dose of elafibranor 120mg
16419412|NCT03844555|Experimental|Healthy|Single oral dose of elafibranor 120mg
16419413|NCT03844542|Experimental|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
16419414|NCT03844542|No Intervention|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
16419415|NCT03844529|Experimental|Sunmax FULLSGEN with Lidocaine|A subject would only receive single injection treatment(day 1) using Sunmax FULLSGEN , and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
16419416|NCT03844529|Active Comparator|Sumax FACIALGAIN collagen Implant with Lidocaine|A subject would only receive single injection treatment(day 1) using Sumax FACIALGAIN collagen Implant with Lidocaine, and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
16419417|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
16419418|NCT03844516|Sham Comparator|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
16419419|NCT03844503|Placebo Comparator|Cereal Bar no fiber|Cereal bar without fiber
16419420|NCT03844503|Active Comparator|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
16419421|NCT03844503|Active Comparator|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
16419422|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
16419423|NCT03844490|Experimental|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.
~At this time, cord clamping will be made."
16419424|NCT03844477|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
16419425|NCT03844477|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
16419426|NCT03844451|Experimental|Liposomal bupivicaine with nerve block|The treatment group will receive an intraoperative V2 trigeminal nerve block using liposomal bupivacaine in addition to a standard bupivacaine nerve block.
16422174|NCT03825029|No Intervention|Control Group|They will receive a normal total hip arthroplasty.
16419427|NCT03844451|Placebo Comparator|Nerve block only|The control group will undergo conventional perioperative management without an ERAS protocol and standard bupivacaine intraoperative nerve block.
16419428|NCT03844438|Experimental|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
16419429|NCT03844425|Active Comparator|Conventional Vacuum-Formed Retainers|Vacuum-formed retainers constructed on conventional stone models.
16419430|NCT03844425|Experimental|Vacuum-Formed Retainers From SLA|Vacuum-formed retainers constructed on 3D reconstructed models using stereolitography (SLA) technique.
16419431|NCT03844425|Experimental|Vacuum-Formed Retainers From FDM|Vacuum-formed retainers constructed on 3D reconstructed models using fused deposition modeling technique (FDM).
16419432|NCT03844412|Active Comparator|peripheral treatment|5% lidocaine/5 mg/ml 0.02% estradiol compound cream
16419433|NCT03844412|Active Comparator|central treatment|tricyclic antidepressant nortriptyline pill
16419434|NCT03844412|Active Comparator|combined peripheral and central treatments|5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill
16419435|NCT03844412|Placebo Comparator|placebo|placebo cream and placebo pill
16419436|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
16419437|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
16419438|NCT03844386|Experimental|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
16419439|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
16419440|NCT03844386|Placebo Comparator|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
16419441|NCT03844373|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.
16419442|NCT03844360|Experimental|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
16419443|NCT03844347|Experimental|C-Bien|
16419444|NCT03844347|No Intervention|Control|
16419445|NCT03844321|Experimental|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
16419446|NCT03844321|Experimental|Brief Mindfulness|3 sessions of online mindfulness therapy
16419447|NCT03844308|Experimental|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
16419448|NCT03844308|Active Comparator|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
16419449|NCT03844295|Experimental|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
16419450|NCT03844295|Placebo Comparator|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
16419451|NCT03844282||CArBON (baseline)|The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
16419452|NCT03844282||CARS (exposure to a potentially concussive event)|The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
16419453|NCT03844269|Experimental|AKL-T01|
16419454|NCT03844256|Experimental|Regimen A|"Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.
~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
16419455|NCT03844256|Experimental|Regimen B|"Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.
~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
16419456|NCT03844256|Experimental|Regimen C|"Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.
~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
16419457|NCT03844243|Experimental|NGF condition + Control condition|"All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.
~After 4 weeks:
~All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
16419458|NCT03844243|Experimental|Control condition + NGF condition|"All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.
~After 4 weeks:
~All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
16419459|NCT03844230|Other|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
16419460|NCT03844230|Other|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
16419461|NCT03844217|Experimental|Macimorelin 0.5mg/kg body weight|"Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.
~Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.
~Macimorelin 0.75mg/kg body weight"
16419462|NCT03844204|Experimental|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
16419463|NCT03844204|Active Comparator|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
16419464|NCT03844191|Experimental|Part 1 Cohort 1|Cohort 1: 0.05 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
16419465|NCT03844191|Experimental|Part 1 Cohort 2|Cohort 2: 0.075 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
16419466|NCT03844191|Experimental|Part 2 Cohort 1|Cohort 1: initial dose to be selected by the Safety Review Committee (SRC) after completion of Part 1 (the same initial dose used in Part 1 or one of the previously studied higher doses that is lower than the overall RUC-4 BED) 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
16419467|NCT03844191|Experimental|Part 2 Cohorts 2-3|7 subjects (6 receiving RUC-4, 1 receiving placebo) will be enrolled in each dose cohort, with a safety evaluation performed after 2 subjects in a dose cohort receive RUC 4 and at the completion of dosing for all subjects in the dose cohort. Dose escalation to be determined by the SRC charter and will continue until identification of the overall RUC-4 BED or MTD
16419468|NCT03844191|Experimental|Part 2 Dose Expansion Cohort 1|"14 subjects will receive a selected dose of RUC-4 based on SRC review of dose escalation data.
~In the expansion cohort, 7 subjects weighing 55 to 65 kg and 7 subjects weighing 100 to 120 kg will be enrolled; 12 subjects will receive a single subcutaneous dose of RUC-4 and 2 will receive matched placebo"
16419469|NCT03844178|Active Comparator|The right eyes with compensation for Pupil centroid shift|
16419470|NCT03844178|Active Comparator|The left eyes without compensation for Pupil centroid shift|
16419471|NCT03844165|Experimental|Diet change (red rice) with yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
16419472|NCT03844165|Active Comparator|Yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
16419473|NCT03844152|Experimental|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
16419474|NCT03844139||Feeding pump group(continous)|Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours
16419475|NCT03844139||Glycerin syringe group(intermittent)|Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times
16419476|NCT03844126|Experimental|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
16419477|NCT03844113|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
16419478|NCT03844113|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo for 6 months
16419479|NCT03844100|Experimental|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia
~Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week
~Person with above symptoms that started at least 6 months before and continused for minimum 3 months
~Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease
~Person who do not respond to at least 2 general treatments for FD
~Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =>5)"
16419480|NCT03844087|Experimental|multiplanar neuromuscular training arm|The intervention arm will be involved in the training intervention outlined. Briefly, each participant will be asked to train on the TopSpin360 3 times per week for 3-5 sets for the duration of the study. Each set will take roughly 15-30 seconds to perform and training will take part during regularly scheduled training sessions.
16419481|NCT03844074|Experimental|bevacizumab|ONS-5010
16419482|NCT03844074|Active Comparator|ranibizumab|
16419483|NCT03844061|Experimental|MMF + Rituximab + Belimumab|Two infusions of 1000 mg of Rituximab, two weeks apart, weekly subcutaneous injections of 200 mg of Belimumab, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
16419484|NCT03844061|Placebo Comparator|MMF + Placebo + Placebo|Two placebo infusions of normal saline, two weeks apart, weekly saline placebo subcutaneous injections, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
16419516|NCT03843801|Active Comparator|Volume reduction|Intragastric sutures are done to reduce the volume of the stomach
16419517|NCT03843801|Active Comparator|Gastric emptying reduction|Intragastric sutures are done to slower the gastric emptying
16419518|NCT03843801|Active Comparator|Increasing distension|Intragastric sutures are done to maximalize the gastric distension
16419943|NCT03840746|Experimental|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
16419486|NCT03844035|Experimental|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator(oxytet oral irrigatör).All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual).PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites.Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
16419487|NCT03844035|Experimental|Interdental brush group|Fifteen patients using toothbrush and interdental brush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
16419488|NCT03844035|Active Comparator|Control group|Fifteen patients using only toothbrush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
16419489|NCT03844022||McArdle disease|Glycogen storage disease
16419490|NCT03844022||Healty controls|Age and gender matched
16419491|NCT03844009|Experimental|Debriefing|Participant's of the debriefing group had a computer integrated debriefing at the end of each scenario of the computer-based simulator
16419492|NCT03844009|No Intervention|No debriefing|Participant's of the debriefing group had no computer integrated debriefing at the end of each scenario of the computer-based simulator
16419493|NCT03843996|Experimental|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
16419494|NCT03843996|Experimental|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
16419495|NCT03843983|Other|Lipiflow treatment|Lipiflow® application: Treated with Lipiflow. All patients in this study are treated with Lipiflow once.
16419496|NCT03843970|Experimental|Levobupivacaine Hydrochloride 0,5%|The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.
16419497|NCT03843970|Active Comparator|isobaric bupivacaine 0,5%|The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.
16419498|NCT03843957|Experimental|"Clinic Patients on high touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
16419499|NCT03843957|Experimental|"Clinic Patients on low touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
16419500|NCT03843957|Experimental|"Clinic personnel on high touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
16419501|NCT03843957|Experimental|"Clinic personnel on low touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
16419502|NCT03843944|Experimental|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
16419503|NCT03843931|Active Comparator|GLA:D|8 weeks of education (1 session/week for 2 weeks) and exercise therapy (2 sessions/week for 6 week)
16419504|NCT03843931|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injection (5 ml of 0.9% sodium chloride) every 2 weeks over an 8-week period
16419505|NCT03843918|Experimental|Group A (Phase II only)|LAE001+ADT
16419506|NCT03843918|Placebo Comparator|Group B (Phase II only)|Placebo+ADT
16419507|NCT03843879|Active Comparator|TAP Block|Single-injection transversus abdominis plane block
16419508|NCT03843879|Active Comparator|IV Lidocaine|Continuous intravenous lidocaine infusion
16419509|NCT03843866|Active Comparator|Suture & steri-strips|
16419510|NCT03843866|Active Comparator|Adhesive Glue|
16419511|NCT03843853|Experimental|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
16419512|NCT03843840||Diseased Retina|
16419513|NCT03843827|Active Comparator|Group A (LMA Group)|Active Comparator: Group A (LMA Group) LMA-Classic™ laryngeal mask airway (Classic™LMA) by Dr. Archie Brain into clinical practice in 1988 brought about a revolution in anesthesia. In the literature, there are over 2,500 studies supporting Classic™ LMA usage. Following the success and popularity of Classic™ LMA, many different variants of this device have been designed and marketed,trying to offer a simple and effective alternative to the endotracheal intubation.
16419514|NCT03843827|Active Comparator|Group B (I gel Group)|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature,thus minimising air leakage
16419515|NCT03843814|Experimental|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.
~Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.
~An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.
~Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
16419519|NCT03843788|Experimental|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
16419520|NCT03843788|Experimental|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
16419521|NCT03843788|No Intervention|Post-CS Routine Care|Routine pharmacologic care will be provided.
16419522|NCT03843788|No Intervention|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
16419523|NCT03843775|Experimental|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
16419524|NCT03843762||Adolescents|Adolescents, male or female, ages 11 - 17. Participants will complete 7 days/nights of actigraphy and sleep-based EEG and questionnaires.
16419525|NCT03843749|Experimental|HER2-positive Metastatic Colorectal Cancar|
16419526|NCT03843736|No Intervention|Health control group|Participants are healthy women and there are no interventions.
16419527|NCT03843736|Experimental|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
16419528|NCT03843736|Experimental|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
16419529|NCT03843736|Experimental|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
16419530|NCT03843710|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16419531|NCT03843710|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16419532|NCT03843710|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16419533|NCT03843710|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16419534|NCT03843697|Experimental|Patients with IBD who develop resistance to anti TNF|Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs
16419535|NCT03843684|Experimental|Knee osteoarthritis patients|
16419536|NCT03843671|Experimental|Group 1|Hyperbaric oxygen Hyperbaric chamber
16419537|NCT03843671|Sham Comparator|Group 2|Sham for hyperbaric oxygen Hyperbaric chamber
16419538|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
16419539|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
16419540|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
16419541|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
16419542|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
16419543|NCT03843645|Active Comparator|general anesthesia group|patients allocated to the general anesthesia group will be subjected to general anesthesia with sevoflurane (inhalational agent) used for maintenance
16419544|NCT03843645|Active Comparator|regional anesthesia group|patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with ropivacaine and fentanyl
16419545|NCT03843632|Experimental|VARIVAX™|All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
16419546|NCT03843619||Non-E-referral|Patients who are referred in the traditional manner between two separate organizations.
16419547|NCT03843619||E-referral|Patients who are referred in an automated manner between two separate organizations.
16419548|NCT03843606|Experimental|diet 1|60% fat, 15% protein, 25% carbohydrates
16419549|NCT03843606|Experimental|diet 2|70% fat, 15% protein, 15% carbohydrates
16419550|NCT03843606|Experimental|diet 3|80% fat, 15% protein, 5% carbohydrates
16419551|NCT03843593||Melanoma patients|This is a pilot prospective study to identify the factors patients consider in deciding whether or not to undergo adjuvant therapy. Patients are eligible regardless of whether they decide to accept adjuvant therapy. If the researcher plans to treat the participant with pembrolizumab instead of nivolumab, it should be known that although the video discusses nivolumab, the risks and benefits are the same.
16419552|NCT03843580|No Intervention|Standard Allocation|apnea without oxygenation like usual traitement
16419553|NCT03843580|Experimental|oxygenation optiflow|optiflow oxygenation during apnea
16419554|NCT03843567|Placebo Comparator|Didactic Training|Training will be conducted in a classroom for those participants randomised to receive didactic training, with training provided via a PowerPoint (Microsoft Inc., Redmond, Washington, USA) presentation by an expert endoscopist. An endoscopist with extensive experience in optical characterisation using virtual chromoendoscopy reviewed all teaching material.
16419555|NCT03843567|Active Comparator|Computer-based self-training|Participants randomised to the computer-based self-learning group will be given the same PowerPoint presentation as the didactic group and completed the training in a separate room. Participants completed training without feedback interaction.
16419611|NCT03843112|Active Comparator|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
16422175|NCT03825016|Experimental|Lidocaine|Lidocaine Hydrochloride
16419558|NCT03843541|Experimental|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
16419559|NCT03843541|Active Comparator|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
16419560|NCT03843541|Placebo Comparator|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
16419561|NCT03843528|Experimental|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.
~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
16419562|NCT03843515|Experimental|Neoadjuvant nivolumab|All subject will receive 400mg flat dose nivolumab in the neoadjuvant setting
16419563|NCT03843502|Experimental|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
16419566|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
16419567|NCT03843463|Experimental|Naming Treatment + Escitalopram|10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)
16419568|NCT03843463|Placebo Comparator|Naming Treatment + Placebo|10 mg placebo daily for three months
16419569|NCT03843437|Experimental|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
16419570|NCT03843437|Placebo Comparator|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
16419571|NCT03843424|Active Comparator|Enhanced Standard of Care (eSOC)|This group will receive the eSOC program. A minimum of 6 visits to the primary care provider (PCP) and includes assessment of weight status, patient/family motivation and readiness to change, promotion of healthy eating and activity habits, and use of health behavior change strategies.
16419572|NCT03843424|Active Comparator|Family-Based Behavioral Treatment (FBT + eSOC)|This group will receive eSOC plus the FBT program. Family-based behavioral treatment (FBT), an effective treatment that targets both child and parents meeting regularly with a health coach for healthy eating, activity, positive parenting strategies, and managing environmental cues.
16419573|NCT03843398|Experimental|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
16419574|NCT03843398|Active Comparator|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
16419575|NCT03843385|Experimental|faecal microbiota filtrate|Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
16419576|NCT03843385|Active Comparator|faecal microbiota|Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
16419577|NCT03843385|Sham Comparator|Placebo|Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
16419578|NCT03843372|Experimental|First night HFNC group|The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
16419579|NCT03843372|Active Comparator|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.
16419580|NCT03843359|Experimental|Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort|
16419581|NCT03843359|Experimental|Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort|
16419582|NCT03843346||Cohort 1: Postoperative group|"Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.
~Tumours of any size will be eligible
~Between 1 and 3 lymph nodes involved by tumour as assessed by Consultant Pathologist
~Micro metastases (<=0.2mm) will be eligibile
~Isolated tumour cells only (node negative i+/i-) are excluded"
16419583|NCT03843346||Cohort 2: Preoperative group|"Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.
~Min tumour size 2.1mm (T2)
~Histological proof of involvement of at 1 lymph node, including micrometastases (<=0.2mm)"
16419584|NCT03843333|Experimental|CHW Intervention|CHWs will deliver three intervention components (Tai Ji Quan: Moving for Better Balance, Behavioral Activation, and Resource Navigation) to all participants at intervention sites over a 6-month period.
16419585|NCT03843333|Active Comparator|Enhanced Usual Care|Comparison participants will receive a guide on community resources for older adults, and assistance from the research team in making initial connections to resources if desired.
16419612|NCT03843112|Placebo Comparator|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
16420002|NCT03840317|Experimental|Senl_1904B CD19 CAR-T|Autologous CD19-targeting CAR T cells,dosage 3*10^5/kg, intravenous injection once
16419586|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.
~Patients will be enrolled in this group only if the device is one of the following:
~INSPIRIS RESILIA;
~EDWARDS INTUITY;
~Carpentier-Edwards PERIMOUNT Magna-Ease."
16419587|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.
~Patients will be enrolled in this group only if the device is one of the following:
~SAPIEN 3;
~SAPIEN XT."
16419588|NCT03843307|Experimental|Electrical stimulation|
16419589|NCT03843294|Experimental|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
16419590|NCT03843281|Experimental|Paracetamol|Paracetamol 1 g (100 mL) IV + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
16419591|NCT03843281|Placebo Comparator|Placebo|Placebo (NaCl 0.9% 100 mL IV) + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
16419592|NCT03843268|Active Comparator|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
16419593|NCT03843268|Placebo Comparator|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
16419594|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
16419595|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
16419596|NCT03843242|Experimental|Pacemaker with Fixed long AV delay|"Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible.
~The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months.
~Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As ~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap ~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec"
16419597|NCT03843242|Experimental|Pacemaker with VpS® algorithm on|Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.
16419598|NCT03843242|Experimental|Pacemaker with IRSplus algorithm on|IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.
16419599|NCT03843229|Experimental|treatment group|The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
16419600|NCT03843229|Other|control group|The control group only receives Transarterial Chemoembolization (TACE).
16419601|NCT03843203|Sham Comparator|s-tDCS|- Intervention: 'Transcranial Direct Current Stimulation - tDCS The patients will receive tDCS sham treatment. The patients will receive sham tDCS treatment over primary motor cortex. According to 10-20 EEG system, anode will be placed at left C3 and cathode at o contralateral F3. In sham stimulation the device only release flow current, in the first 30 s of session and in the remaining 30s in the end of the session, during 20 minutes.
16419602|NCT03843203|Active Comparator|M1 a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS
~The patients will receive tDCS active treatment over primary motor cortex.
~According to 10-20 EEG system, anode will be placed at left C3 and cathode at contralateral supraorbital Fp2.
~Active stimulation uses a 2 milliamperes current during 20 minutes."
16419603|NCT03843203|Active Comparator|DLPFC a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS
~The patients will receive tDCS active treatment over dorsolateral prefrontal cortex.
~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.
~Active stimulation uses a 2 milliamperes current during 20 minutes."
16419604|NCT03843190|Experimental|Take Off Pounds Sensibly (TOPS)|This group will receive TOPS intervention at the start of the study.
16419605|NCT03843190|Other|Waitlist control|This group will be the control group for the initial year of the study. Then at the completion of the study they will receive the TOPS intervention.
16419606|NCT03843177||Ingrown toenails|
16419607|NCT03843177||Control|
16419608|NCT03843151|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1358894 alone. Test - BI 1358894 + Itraconazole
16422176|NCT03825016|Experimental|Diclofenac|Oral Diclofenac
16419613|NCT03843099|Active Comparator|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
16419614|NCT03843099|Experimental|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
16419615|NCT03843086|Active Comparator|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
16419616|NCT03843086|Active Comparator|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
16419617|NCT03843073|Experimental|Connected Catheter Users|
16419618|NCT03843060|Experimental|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
16419619|NCT03843060|Experimental|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
16419620|NCT03843047|Other|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
16419621|NCT03843047|Other|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
16419622|NCT03843034||Study group|Infertile women with autoimmune disease
16419623|NCT03843034||Control group|Women from couples with severe male infertility
16419624|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
16419625|NCT03843008|Experimental|Melatonin Group|Participants will receive 3mg of melatonin at 18:00 (+/- one hour) each evening up to seven days or for the duration of his or her hospital stay.
16419626|NCT03843008|No Intervention|No Melatonin Group|Participants will receive no melatonin for the length of their hospital stay.
16419627|NCT03842995|Placebo Comparator|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
16419628|NCT03842995|Experimental|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
16419633|NCT03842956|Active Comparator|Primary wound healing|Primary woundclosure in Allgöwer suture technique
16419634|NCT03842956|No Intervention|Secondary wound healing|no closure, open wound healing
16419758|NCT03842007|Active Comparator|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
16419635|NCT03842943|Experimental|Combination T-VEC/Pembrolizumab|"Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab
~T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.
~Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection."
16419636|NCT03842930|Other|Platinum-fibered Microcoils (FPC)|Embolization using platinum fibred Coils (Cook Incorporated, Bloomington, IN, USA)
16419637|NCT03842930|Other|MVP® Vascular Plug|Embolization using MVP®-Plug (Medtronic Inc., Minneapolis, MI, USA).
16419638|NCT03842917||Patient starting bevacizumab treatment for cancer|Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
16419639|NCT03842904|Experimental|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
16419640|NCT03842904|Active Comparator|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
16419641|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
16419642|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
16419643|NCT03842839|Experimental|COPD in Grade A|Patient with Grade A COPD (according to GOLD 2019), will start to use Tiotropium once daily.
16419644|NCT03842839|Active Comparator|COPD in Grade C|Patient with Grade C COPD (according to GOLD 2019), will start to use Olodaterol + Tiotropium once daily.
16419645|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
16419646|NCT03842800|Other|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
16419647|NCT03842800|Other|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
16419648|NCT03842800|Other|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
16419649|NCT03842800|Experimental|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
16419650|NCT03842787||SLE patients with lupus Nephritis|"14 SLE patients with lupus Nephritis
~Biological analysis and biopsy were (routinely) performed
~Ethics The protocol will be submitted to a randomly chosen Institutional Review Board (Comité de Protection des Personnes), in compliance to French regulation.
~Investigators will include patients followed for routine care. Patients will be informed that samples (serum and kidney biopsy) that are performed for routine patient care will subsequently be used for research purposes, with no additional blood draw/biopsy. They will sign informed consent."
16419651|NCT03842774|Experimental|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
16419652|NCT03842774|Placebo Comparator|Control group|taken 3 tablets of placebo once a day for 12 weeks
16419653|NCT03842761|Experimental|Dose group 1|Low Dose
16419654|NCT03842761|Experimental|Dose group 2|Medium Dose
16419655|NCT03842761|Experimental|Dose group 3|High Dose
16419656|NCT03842761|Experimental|Dose Group 4|Dose for healthy volunteers dependent on results from prior dose groups with patients
16419657|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
16419658|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
16419659|NCT03842735|Experimental|exercise and rehabilitation counselling|Subjects enrolled in exercise group make physical exercises and receive rehabilitative counselling indications
16419660|NCT03842735|Other|rehabilitation counselling|Subjects enrolled in exercise group only receive rehabilitative counseling indications.
16419661|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
16419662|NCT03842709|Placebo Comparator|Standard Treatment + Placebo|Patients reporting sub-optimal results of pain therapy, assigned to placebo in addition to routine care.
16419663|NCT03842709|Experimental|Standard Treatment + Pramipexole|Patients reporting sub-optimal results of pain therapy, assigned to receive pramipexole in addition to routine care.
16419664|NCT03842696|Experimental|Vorinostat|
16419665|NCT03842670|Active Comparator|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
16419759|NCT03841994||Preterm infant cohort|Preterm infants who were born <28 weeks of gestational age
16419760|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
16419666|NCT03842670|Active Comparator|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
16419667|NCT03842657|Other|calcium-free citrate-containing dialysate|Dialysis session will be performed with a non-heparin grafted membrane, a dialysate without calcium (0 mmol/L) and citrate 0.8 mmol/L, a reinjection of a calcium solution (300 mM) according to the ionic dialysance, and no heparin addition
16419668|NCT03842657|Other|heparin-grafted membrane|dialysis session will be performed with a heparin-grafted membrane, a dialysate with calcium (1.65 mmol/L) and citrate 0.8 mmol/L, and no heparin addition
16419669|NCT03842644|Experimental|Tension Reduction|Tension reduction device for 3 months post surgery
16419670|NCT03842644|No Intervention|Control|No tension reduction
16419671|NCT03842631||Superficial Group|Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
16419672|NCT03842631||Deep Group|Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
16419673|NCT03842605|Experimental|Strength training|
16419674|NCT03842579|Experimental|Exercise and Protein (EXEPROT)|Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
16419675|NCT03842579|Active Comparator|Protein-only (PROT)|"Participants in PROT-group receive the nutritional intervention: The high-protein diet.
~The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.
~Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake."
16419676|NCT03842579|Active Comparator|Recommendations (REC)|"Participants in the REC-Group receive the comparative intervention: Recommendations.
~The official national dietary recommendations for adults >65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.
~During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition)."
16419677|NCT03842566||20-29 Years Old|
16419678|NCT03842566||30-39 Years Old|
16419679|NCT03842566||40-49 Years Old|
16419680|NCT03842566||50-59 Years Old|
16419681|NCT03842566||60-69 Years Old|
16419682|NCT03842566||70-79 Years Old|
16419683|NCT03842553||Police officers|Police officers from the cantonal police forces in Bern, Switzerland
16419684|NCT03842553||Firefighters|Firefighters from the professional fire service of the Canton Bern, Switzerland
16419685|NCT03842553||Ambulance personnel|Ambulance personnel of the Canton Bern, Switzerland
16419686|NCT03842553||Emergency nurses|Emergency nurses of the Emergency Unit of the University Hospital of Bern, Switzerland
16419687|NCT03842553||Psychiatric nurses|Psychiatric nurses of the University Hospital of Psychiatry, University of Bern, Switzerland
16419688|NCT03842540|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
16419689|NCT03842540|Active Comparator|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
16419690|NCT03842527|Active Comparator|Standard Fasting Group|Ultrasound scan of gastric antrum 1 hour prior to procedure. Patients assigned to this group will follow standard fasting procedures of no eating or drinking 8 hours prior to C-section.
16419761|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
16419762|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
16419691|NCT03842527|Experimental|Carbohydrate Loading Group|"Ultrasound scan of gastric antrum 1 hour prior to procedure.
~Patients assigned to this group must stop eating 8 hours prior to their scheduled C-section time.
~The night before their C-section they must drink 800mL of 100% apple juice (not from concentrate) OR 800mL of cranberry juice cocktail, not both
~The day of their C-section, starting 3 hours before surgery and to be finished 2 hours before surgery time, patients must drink 400mL of 100% apple juice OR 400mL of cranberry juice cocktail, not both
~Please note:
~The apple juice must be 100% juice, not from concentrate
~The cranberry juice cocktail must not be plain cranberry juice"
16419692|NCT03842514|Experimental|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)
~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate
~Phase 3: No intervention - 7 days washout with usual diet
~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
16419693|NCT03842514|Experimental|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)
~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate
~Phase 3: No intervention - 7 days washout with usual diet
~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
16419694|NCT03842501|Placebo Comparator|Placebo|
16419695|NCT03842501|Experimental|Release supplement|
16419696|NCT03842488|Experimental|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
16419697|NCT03842488|Active Comparator|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
16419698|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
16419699|NCT03842475||Control|Healthy volunteers with normal body mass index
16419700|NCT03842462|Active Comparator|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
16419701|NCT03842462|Active Comparator|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
16419702|NCT03842462|Experimental|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:
~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
16419703|NCT03842449|Experimental|Smoking pregnant woman withCO measurement|
16419704|NCT03842449|Other|Smoking pregnant woman without CO measurement|
16419705|NCT03842449|Other|Non Smoking pregnant woman|
16419706|NCT03842436|Experimental|Digital Pills|Digital Pills containing Truvada ingested once daily as PrEP
16419707|NCT03842423||Study Group|All patients under the age of 18 who were treated for upper extremity injuries between 2002 and 2018 and receiving brachial plexus anaesthesia.
16419708|NCT03842410|Other|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
16419709|NCT03842397|Experimental|Implanted Patients|Implantation of Kephalios Device 1
16419710|NCT03842384|Experimental|distress tolerance training|computer- and text- message delivered intervention that enhances motivation through personalized feedback and increases tolerance of distress through skills training.
16419711|NCT03842384|Other|treatment as usual|standard outpatient buprenorphine treatment
16419712|NCT03842371||Sepsis with type 2 diabetes|Sepsis patients with type 2 diabetes
16419713|NCT03842371||Sepsis without type 2 diabetes|Sepsis patients without type 2 diabetes
16419714|NCT03842371||Volunteers|Healthy volunteers
16419715|NCT03842358|Experimental|Phase I - Training Set|"20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data
~A hand-held hybrid probe will be used for the scans"
16419716|NCT03842358|Experimental|Phase 2: Prospective Trial|"US-DOT (US/NIR) Imaging Exam
~Breast biopsy or FNA performed (standard of care)
~A hand-held hybrid probe will be used for the scans"
16419717|NCT03842345||Psychiatric patients|Major depression, Bi-polar, schizophrenia, ADHD, OCD, PTSD
16419718|NCT03842345||healthy controls|young healthy controls to serve as norm.
16419719|NCT03842332|Experimental|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
16419720|NCT03842332|No Intervention|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
16419721|NCT03842319|Experimental|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
16419763|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
16419722|NCT03842319|Experimental|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
16419723|NCT03842306||Study Cohort|Patients undergoing rapid sequence intubation in the emergency department for which end tidal oxygen was monitored.
16419724|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
16419725|NCT03842267|Active Comparator|Gemigliptin 50mg|
16419726|NCT03842267|Placebo Comparator|Gemigliptin Placebo|
16419727|NCT03842254|Experimental|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
16419728|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
16419729|NCT03842241||Without foot orthoses|Other: without foot orthoses
16419731|NCT03842215||silver hair people|Exam subject's physical function by a smart physical exam
16419732|NCT03842202|Experimental|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
16419733|NCT03842202|Placebo Comparator|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
16419735|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
16419736|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
16419737|NCT03842163||Patients with LVH of unknown etiology|
16419738|NCT03842150||derivation cohort|
16419739|NCT03842150||validation cohort|
16419740|NCT03842137|Active Comparator|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
16419741|NCT03842137|Sham Comparator|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
16419742|NCT03842124|Active Comparator|Intervention|Use of bidirectional rail (superior and inferior approaches) and force sensing using a force gauge to optimize Force application to less than 8 lbs during the extraction procedure.
16419743|NCT03842124|No Intervention|Control|Conventional lead extraction procedures using a superior approach is performed by experienced operators. Although force information is available the operators are blinded to the information. Inferior rail is left to the discretion of the operator.
16419744|NCT03842111||Region XI Head Start children and families|children (1049) parents (1049) classrooms/teachers (73) program directors (21) center directors (36)
16419745|NCT03842098||Musculoskeletal Disorders patients|Enroll the post operative musculoskeletal disorders patients and follow up their clinic visits and treatment regimen to analyze their utility in healthcare
16419746|NCT03842085|Experimental|MBS301|Drug: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
16419747|NCT03842072|No Intervention|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
16419748|NCT03842072|Active Comparator|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
16419749|NCT03842059|Experimental|Computer-aided detection|
16419750|NCT03842059|Placebo Comparator|Standard colonoscopy|
16419751|NCT03842046|Active Comparator|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
16419752|NCT03842046|Active Comparator|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
16419753|NCT03842033|Other|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
16419754|NCT03842033|Other|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
16419755|NCT03842033|Other|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
16419756|NCT03842020|Experimental|Amiodarone dosage|Blood pharmacokinetics samples
16419757|NCT03842007|Active Comparator|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
16419764|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
16419765|NCT03841968|Active Comparator|Dynamic needle tip positioning|Dynamic needle tip positioning
16419766|NCT03841968|Active Comparator|Conventional long-axis|Conventional long-axis
16419767|NCT03841955|Experimental|Experimental group|Peripheral implantation of central venous catheters and accessories with high pressure tolerance
16419768|NCT03841955|Experimental|Control group|Peripheral intubation of central venous catheter
16419769|NCT03841942|Other|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
16419770|NCT03841942|Other|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
16419771|NCT03841929|Experimental|Study Arm|ELGANs recruited to the study group in addition to standard of care will have continuous cerebral NIRS monitoring for the initial 72 hours and TNE studies at definitive time frames and a hemodynamic report will be provided to the clinical team using the results of the multimodal monitoring and clinical data. The report will be a description of the hemodynamic status without any suggestions for management.
16419772|NCT03841929|No Intervention|Standard Arm|ELGANs recruited into Standard arm will have the standard monitoring including cardiorespiratory monitoring. The invasive blood pressure monitoring, NIRS and TNE monitoring as per the clinical team's discretion - consistent with the current standard of care. No hemodynamic report will be provided routinely.
16419773|NCT03841903||relapsing-remitting MS undergoing spinal cord MRI|
16419774|NCT03841903||secondary progressive MS undergoing spinal cord MRI|
16419775|NCT03841903||primary progressive MS undergoing spinal cord MRI|
16419776|NCT03841903||healthy control (HC) undergoing spinal cord MRI|
16419777|NCT03841890|Experimental|Intubation with the Clarus Video System as a video stylet|
16419778|NCT03841890|Experimental|Intubation with the Clarus Video System as a lightwand|
16419779|NCT03841890|Active Comparator|Intubation with direct laryngoscope|
16419780|NCT03841877|Experimental|AH Plus-Cervical|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned at the cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
16419781|NCT03841877|Experimental|MTA Fillapex-Cervical|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned at the cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
16419782|NCT03841877|Experimental|AH Plus-2mm|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned 2 mm below cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
16419783|NCT03841877|Experimental|MTA Fillapex-2mm|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned 2 mm below cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
16419784|NCT03841864|Other|Grade 1 Vein Visualization|Visual vein classification grade described as excellent Visualization. Objective vein criteria to be included in this group are vein raised above skin and wider than 1mm. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
16419785|NCT03841864|Other|Grade 2A Vein Visualization|Veins that don't fit grade 1 or 2b classification (see respective group descriptions). This groups visual vein classification is described as fair visualization. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
16419786|NCT03841864|Other|Grade 2b Vein Visualization|Only faint vein shadow appearance described as poor visualization. Initial IV placement attempt will be ultrasound guided
16419787|NCT03841864|Other|Grade 3 Vein Visualization|No vein visualization. Initial IV placement attempt will be ultrasound guided
16419788|NCT03841851|No Intervention|temporization without soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.
~Atraumatic extraction of badley decayed teeth in the aesthetic area
~traditional drilling for immediate implant placement .
~immediate temporization ."
16419789|NCT03841851|Active Comparator|temporization with soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.
~Atraumatic extraction of badley decayed teeth in the aesthetic area
~traditional drilling for immediate implant placement .
~immediate temporization .
~subepithelial connective tissue graft from the palate ."
16419790|NCT03841838|Experimental|Energy drink|Two 12 oz bottles of energy drink
16419791|NCT03841838|Placebo Comparator|Placebo|Two 12 oz bottles of placebo drink
16419792|NCT03841825|No Intervention|Control|No messages or oral hygiene instructions
16419793|NCT03841825|Experimental|Text message reminders|Standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays
16419794|NCT03841825|Active Comparator|In-person oral hygiene instructions|Oral hygiene instructions and motivation during visit
16419795|NCT03841825|Experimental|Text messages and in-person instructions|standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays and oral hygiene instructions and motivation during visit
16422177|NCT03825003||Basketball Players|Outcome assessments were done.
16419796|NCT03841812|Experimental|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
16419797|NCT03841812|Experimental|Propofol & Sevoflurane|2mg/kg/h Propofol & 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
16419798|NCT03841786|Placebo Comparator|Control diet|Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.
16419799|NCT03841786|Experimental|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.
16419800|NCT03841773|Experimental|TNX-102 SL Tablet 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
16419801|NCT03841773|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
16419802|NCT03841760|Experimental|PSMA PET/CT|One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL
16419803|NCT03841747|Experimental|Pembrolizumab + Paclitaxel|200 mg Pembrolizumab intravenously (IV) every 3 weeks (Q3W) plus 80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
16419804|NCT03841747|Active Comparator|Paclitaxel|80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
16419805|NCT03841734|Experimental|Treatment bosentan|
16419806|NCT03841721|Experimental|linezolid 300 mg|
16419807|NCT03841708|Active Comparator|Pleth Variability Index|In the experimental group patients will be hemodynamically resuscitated in the early phases after ROSC based on the pleth variability index on top of standard non invasive monitoring
16419808|NCT03841708|Placebo Comparator|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG.
16419809|NCT03841695|Experimental|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
16419810|NCT03841695|Active Comparator|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
16419815|NCT03841643|Active Comparator|C group|In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department.
16419816|NCT03841643|Experimental|P group|In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany).
16419817|NCT03841630|Experimental|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
16419818|NCT03841630|Placebo Comparator|Placebo|Matching placebo administered as an injection under the skin in healthy participants
16419819|NCT03841617|Active Comparator|124I PET/CT scan after rhTSH|124I PET/CT scan after preparation with human recombinant TSH
16419820|NCT03841617|Active Comparator|124I PET/CT scan after thyroid hormone withdrawal|124I PET/CT scan after preparation with thyroid hormone withdrawal
16419821|NCT03841604|Experimental|Experimental|Safinamide methanesulfonate film coated tablets once daily
16419822|NCT03841604|Placebo Comparator|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily
16419823|NCT03841591|Active Comparator|Insulin Group|This includes women with GDM allocated to receive insulin treatment. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
16419824|NCT03841591|Active Comparator|Metformin Group|This includes women with GDM allocated to receive metformin treatment. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
16419825|NCT03841578|Experimental|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
16419826|NCT03841565|Experimental|Treatment (pomalidomide, daratumumab, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable toxicity.
16419862|NCT03841305|Active Comparator|portal vein embolization|Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
16419944|NCT03840733||Participants from NCT01985568|All subjects who previously enrolled in the Parent Study's behavioral weight loss intervention (NCT01985568).
16419827|NCT03841552|Experimental|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
16419828|NCT03841552|Active Comparator|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
16419829|NCT03841539|Experimental|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
16419830|NCT03841539|Active Comparator|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
16419831|NCT03841526|Experimental|Glucagon RTU, 50% insulin pump reduction|
16419832|NCT03841526|Placebo Comparator|Placebo, 50% insulin pump reduction|
16419833|NCT03841526|Experimental|Glucagon RTU, no basal rate reduction|
16419834|NCT03841513|No Intervention|Control|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
16419835|NCT03841513|Active Comparator|Laparoscopic Burch Colposuspension|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
16419836|NCT03841500|Active Comparator|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).
~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
16419837|NCT03841500|Active Comparator|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).
~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
16419838|NCT03841487||Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI).
16419839|NCT03841487||PCI alone|In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
16419840|NCT03841474|Experimental|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
16419841|NCT03841474|No Intervention|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
16419842|NCT03841474|Experimental|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
16419843|NCT03841461||Academicians|The academicians working in any program of any higher education institution
16419846|NCT03841435|Experimental|Hypofractionated Radiotherapy|15 Gy given in 3 fractions over 2 weeks
16419847|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
16419848|NCT03841396|Active Comparator|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
16419849|NCT03841396|Active Comparator|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
16419850|NCT03841383||Healthy controls|
16419851|NCT03841383||Hypertensive patients|
16419852|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.
~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
16419853|NCT03841357|Experimental|Abatacept and Usual Care|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
16419854|NCT03841357|Active Comparator|Usual Care|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
16419855|NCT03841344|Active Comparator|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
16419856|NCT03841344|Active Comparator|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
~Patients diagnosed with PAH initiating PAH therapy for the first time"
16419857|NCT03841344|Active Comparator|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
16419858|NCT03841344|Active Comparator|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
~Patients with PAH who are NOT undergoing changes in their treatment regime"
16419859|NCT03841331|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
16419860|NCT03841331|Placebo Comparator|5 mg Placebo Tablets|Placebo Tablets
16419861|NCT03841318|Experimental|Sjogren's Syndrome|
16419863|NCT03841305|Experimental|liver venous deprivation|Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.
16419864|NCT03841292|Active Comparator|Active tDCS+Varenicline|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
16419865|NCT03841292|Sham Comparator|Sham tDCS+Varenicline|Sham tDCS (Nuraleve, Canada)(30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
16419866|NCT03841253|Experimental|Observation Phase|A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
16419867|NCT03841253|Experimental|Treatment Phase|If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
16419868|NCT03841227|Active Comparator|Active-tDCS|10 patients will receive Active-tDCS intervention (2mA, 20 min) at home.
16419869|NCT03841227|Sham Comparator|Sham-tDCS|10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.
16419870|NCT03841201|Experimental|Treatment|"Lenvatinib peroral qd (8 mg for patients with body weight <60kg and 12 mg for patients with body weight ≥ 60kg)
~Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
16419871|NCT03841188|Other|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
16419872|NCT03841162||Patients with suspected sepsis|Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology
16419873|NCT03841149||VolUS3D patients|Patients with renal tumour
16419874|NCT03841136|Experimental|anlotinib combined with EP|anlotinib combined with etoposide and platinum
16419875|NCT03841123|Experimental|Intervention|At the maternity wards mothers will receive dietary counseling and leaflets as a reminder to prevent the early introduction of added sugar and ultra-processed foods.
16419876|NCT03841123|No Intervention|Control|At the maternity wards mothers assigned to control groups will have all the health assistance related to the maternity routine without any interference from the study protocol.
16419880|NCT03841097|Active Comparator|Extended Release Tacrolimus Tablets|Dosed once daily in the morning and started at a dose of 0.14 mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
16419881|NCT03841097|Active Comparator|Immediate Release Tacrolimus Capsules|Dosed twice daily 12 hours apart and started at a dose of 0.1mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
16419882|NCT03841084|Active Comparator|Conservative Oxygen Management Strategy|Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
16419883|NCT03841084|Active Comparator|Liberal Oxygen Management Strategy|Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
16419884|NCT03841071||ROM/CFS intervention|The ROM/CFS group (N>100), consists of patients who have undergone urostomy, colostomy, or ileostomy operations, and who are included in the routine follow-up program of the outpatient ostomy clinic at the Department of Surgery, Førde Central Hospital from April 2018 to June 2021.
16419885|NCT03841058|Active Comparator|Abaloparatide|Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
16419886|NCT03841058|Placebo Comparator|Placebo|Placebo administered subcutaneously with a pen once daily for 6 months
16419887|NCT03841045||ulcerative colitis patient|people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
16419888|NCT03841045||CD patient|people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
16419889|NCT03841045||Health people|control group. no IBD patients can be included. patients with other diseases can be included.
16419890|NCT03841032|Experimental|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
16419891|NCT03841019|Experimental|magnetic seizure therapy|12 treatment sessions of MST, three times per week.
16419892|NCT03841019|Active Comparator|electroconvulsive therapy|12 treatment sessions of ECT, three times per week.
16419893|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
16419894|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
16419895|NCT03840993|Experimental|MT-2990|MT-2990, IV, over 16 weeks
16419898|NCT03840954|Experimental|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
16419899|NCT03840954|No Intervention|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
16419900|NCT03840941||Frail patients with COPD|No intervention
16419901|NCT03840941||Non-frail patients with COPD|No intervention
16419902|NCT03840928||Ankylosing Spondylitis|
16419903|NCT03840928||Fibromyalgia|
16419904|NCT03840928||Gout|
16419905|NCT03840928||Crohn's-related Arthritis|
16419906|NCT03840928||Juvenile Idiopathic Arthritis|
16419907|NCT03840928||Lupus|
16419908|NCT03840928||Myositis|
16419909|NCT03840928||Osteoarthritis|
16419910|NCT03840928||Osteoporosis|
16419911|NCT03840928||Psoriasis|
16419912|NCT03840928||Psoriatic Arthritis|
16419913|NCT03840928||Rheumatoid Arthritis|
16419914|NCT03840928||Scleroderma|
16419915|NCT03840915|Experimental|Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824|
16419916|NCT03840915|Experimental|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824|
16419917|NCT03840915|Experimental|Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824|
16419918|NCT03840915|Experimental|Cohort D: Docetaxel + M7824|
16419919|NCT03840902|Experimental|Arm 1: cCRT plus M7824 followed by M7824|Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with M7824 followed by M7824.
16419920|NCT03840902|Active Comparator|Arm 2: cCRT plus placebo followed by durvalumab|Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with placebo matched to M7824 followed by durvalumab.
16419921|NCT03840889||Women with a severe late PPH|Women with a severe late PPH will be recruited prospectively after verification of the inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who will provide the patients information about the study and include them unless they object
16419922|NCT03840876|Experimental|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
16419923|NCT03840876|No Intervention|Group I|Patients were ventilated with a small size endotracheal tube.
16419924|NCT03840863|Experimental|Commercially-Available Energy drink|Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks
16419925|NCT03840850|Experimental|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
16419926|NCT03840850|No Intervention|Usual care only|Usual care including personalized lifestyle advice
16419929|NCT03840824||Cancer Survivor|Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
16419930|NCT03840824||Similar aged healthy controls|Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
16419931|NCT03840824||Late Reproductive Age|Pre-menopausal, healthy women of late reproductive age
16419932|NCT03840811|Experimental|Group 1|Subjects (n = up to 8) will receive a bacterial inoculum containing only the isogenic mutant N. gonorrhoeae strain
16419933|NCT03840811|Experimental|Group 2|Subjects (n = up to 8) will receive a bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain.
16419934|NCT03840811|Experimental|Group 3|Subjects (n= up to 16) will receive a bacterial inoculum containing a mixture of equivalent numbers the isogenic mutant and WT strain
16419935|NCT03840798||Pretest/Baseline period|
16419936|NCT03840798||Posttest/go-live period|
16419937|NCT03840785|Experimental|interventional group A|2 tango session per week during 6 month (M0 to M6)
16419938|NCT03840785|Placebo Comparator|Control group B|2 tango session per week during 3 month (M3 to M6)
16419939|NCT03840772|Experimental|Eribulin|"Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.
~Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision."
16419940|NCT03840759|Experimental|usual care|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant and inpatient geriatric consultation team after a complete geriatric assessment (CGA). The CGA includes the assessment of depression, dementia, physical performance of Activity of Daily Living (ADL) and nutrition using Geriatric Depression Scale (GDC-15), Mini-Mental State Examination (MMSE), Barthel Index (BI), and Mini Nutritional Assessment-Short Form (MNA®-SF) respectively. Besides the geriatric physician, our multidisciplinary team included a social worker, nutritionist and physical therapist. In the control group, the participants only received routine hospital care and no geriatric physician was consulted.
16419941|NCT03840746|No Intervention|Habitual diet|participants remain on their habitual diet
16419942|NCT03840746|Experimental|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
16419945|NCT03840707|Experimental|Experimental group|"LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants).
~Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital."
16419946|NCT03840707|No Intervention|Control group|Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease
16419947|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
16419948|NCT03840694|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
16419949|NCT03840681|Experimental|Ridge augmentation by collagen membrane|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~Flap will be done.
~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at defected area then covered at the defected area by a collagen membrane which will be stabilized by tacks.
~The site will then be copiously irrigated with saline in preparation for closure.
~The flap will then be closed using interrupted 4/0 resorbable sutures."
16419950|NCT03840681|Active Comparator|augmentation by titanium reinforced PTFE|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~Flap will be done.
~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.
~The site will then be copiously irrigated with saline in preparation for closure.
~The flap will then be closed using interrupted 4/0 resorbable sutures."
16419951|NCT03840668|Experimental|Dry eye|Participants who will be using the USB-powered eye mask.
16419952|NCT03840655||palmar hyperhidrosis|VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions.
16419953|NCT03840642|Active Comparator|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
16419954|NCT03840642|Experimental|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
16419955|NCT03840629||Hypotonic fluid maintenance|exclusive administration of 0.33% saline mixed with potassium and dextrose 5%
16419956|NCT03840629||Isotonic fluid maintenance|exclusive administration of 0.9% saline
16419957|NCT03840616|Experimental|VT-1161 150 mg capsule|
16419958|NCT03840616|Active Comparator|Fluconazole 150 mg|
16419959|NCT03840603|No Intervention|Control|Usual care of patients with suspected Low RespiratoryTract Infection at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.
16419960|NCT03840603|Experimental|Film Array RP2 Assay guided|In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected Low RespiratoryTract Infection for the Film Array RP2 Assay guided plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.
16419961|NCT03840590|Experimental|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
16419962|NCT03840590|Active Comparator|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
16419963|NCT03840577|Placebo Comparator|Clinical monitoring group|In the clinical monitoring group, the doses of sedative drugs will be regulated according to the patient's RASS. The RASS of the patient will be evaluated twice per nursing shift (every 4 hours). The BIS monitor will be placed on the patient, but blind to the nursing team, with the objective to measure the BIS values.
16419964|NCT03840577|Experimental|BIS group|"In the group Sedation guided by BIS, the sedation will be guided by the value of BIS. The BIS value of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The objective of BIS will be between 40 and 60.
~According to the BIS value of the patient at the time of the evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target BIS, with 20% modifications of the current dose at the time of evaluation."
16419965|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
16419966|NCT03840564||control group|the analyzes will be done at the central laboratory
16419967|NCT03840551|Other|Subjects|Subjects involved are required to do some specific motor tasks, commonly found in all main sports. Evaluated with inertial sensors (XSENS) and marker-based motion capture (BTS)
16419968|NCT03840538|Experimental|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
16419969|NCT03840538|Placebo Comparator|Placebo group|Placebo capsule taken twice daily for 5 weeks
16419970|NCT03840525|Experimental|Qigong Intervention|The qigong intervention consists of 1 hour/week qigong classes for 12 weeks at our community partner site. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
16422178|NCT03825003||Sedentary Peers|Outcome assessments were done.
16419971|NCT03840525|Sham Comparator|Sham Qigong|This group will also have 1 hour/weekly classes that include movements that are similar to qigong but will not include the meditation or breathwork that will be included in the actual qigong intervention arm.
16419972|NCT03840525|No Intervention|Treatment-as-usual|This group will receive no classes.
16419973|NCT03840512|Experimental|Oral CBD 75 BID|
16419974|NCT03840512|Experimental|Oral CBD 150 BID|
16419975|NCT03840512|Experimental|Oral CBD 300 BID|
16419976|NCT03840499||Willing to participate in clinical study|
16419977|NCT03840499||Not-willing to participate in clinical study|
16419978|NCT03840486|Active Comparator|Non-rebreather mask (NRBM)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 LPM for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
16419979|NCT03840486|Active Comparator|Non-invasive ventilator mask (NIV)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-invasive ventilator mask (NIV) overlying the sensor. Participants will be randomized to the order of their treatment sequence as follows: NIV at 50% FiO2 for 3 minutes, NIV at 75% FiO2 for 3 minutes, NIV at 100% FiO2 for 3 minutes, the maximal reading at the end of this trial will be recorded. The study subjects will be allowed to rest until their EtO2 returns to their baseline, then they will be placed back on NIV at 100% FiO2, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
16419980|NCT03840473|Experimental|MET+ICT+Conventional intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by ICT (90-second hold-time) and MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
16419981|NCT03840473|Experimental|MET+Conventional Intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
16419982|NCT03840473|Active Comparator|Conventional Intervention|Received hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) only.
16419983|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
16419984|NCT03840447|Experimental|Chronic Disease Self-Management programme|
16419985|NCT03840434|Other|CCS group|Measurements by intramuscular punction and non invasive tool
16419986|NCT03840421|Experimental|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
16419987|NCT03840421|Active Comparator|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
16419988|NCT03840408|Experimental|Mitochondrial therapy with radiofrequency ablation|
16419989|NCT03840408|Active Comparator|Surgery|
16419990|NCT03840395|Active Comparator|Active PES|Patients randomized to receive active Pharyngeal Electrical Stimulation (PES) via a Phagenyx Catheter.
16419991|NCT03840395|Sham Comparator|Sham PES|Patients randomized to sham will not receive any Pharyngeal Electrical Stimulation (PES) but will still have the Phagenyx Catheter inserted.
16419992|NCT03840382|Experimental|Tele-PrEP Intervention|The telemedicine intervention will allow participants to discuss HIV prevention and PrEP with PrEP specialists at an academic medical center via videoconference from their local community based organization (CBO). During the intervention, participants will gain information related to HIV and PrEP, view a video to improve motivation for engagement in PrEP related care, and receive resources to address barriers to care.
16419993|NCT03840369|Experimental|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
16419994|NCT03840369|Experimental|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
16419995|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
16419996|NCT03840343|Experimental|Lower Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
16419997|NCT03840343|Experimental|Higher Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
16419998|NCT03840330|Experimental|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
16419999|NCT03840330|Experimental|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
16420000|NCT03840330|No Intervention|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
16420001|NCT03840317|Experimental|Senl_1904A CD19 CAR-T|Autologous CD19-targeting CAR T cells, dosage 3*10^5/kg, intravenous injection once
16420003|NCT03840304|Experimental|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
16420004|NCT03840304|No Intervention|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
16420005|NCT03840291|Experimental|Edoxaban treatment|"Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.
~Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi
~Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:
~Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)
~Low body weight ≤ 60 kg
~Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
16420006|NCT03840278|Experimental|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).
~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
16420007|NCT03840278|Experimental|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).
~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
16420008|NCT03840265|Other|Carotid endarterectomy|All patients in this study will undergo carotid endarterectomy procedure
16420009|NCT03840252|Active Comparator|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.
~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
16420010|NCT03840252|Active Comparator|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.
~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
16420011|NCT03840252|Active Comparator|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.
~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
16420012|NCT03840239|Experimental|TNT arm|"Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.
~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
16420013|NCT03840239|Active Comparator|CRT arm|"Drug: Neoadjuvant chemotherapy, Capecitabine, 5 weeks; adjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles.
~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
16420014|NCT03840226|Active Comparator|Magnesium|oral magnesium oxide tablets [Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel]
16420015|NCT03840226|Placebo Comparator|Placebo|Placebo tablets
16420016|NCT03840213||Patients undergoing chemotherapy treatment|Patients over 18 years of age, followed at the ICLN day hospital or hospitalized and undergoing chemotherapy treatment
16420017|NCT03840200|Experimental|Ipatasertib + Rucaparib|A Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer. There will be a 7-day run-in period with ipatasertib alone prior to Cycle 1, Day 1. After the completion of the ipatasertib run-in period, participants will begin Cycle 1, Day 1 of the ipatasertib and rucaparib combination treatment. Each cycle has 28 days. Participants will be split into 4 cohorts: Dose Level 1 group - 300 mg ipatasertib once daily (QD) + 400 mg rucaparib twice daily (BID), Dose Level 2a: 300 mg ipatasertib QD + 600 mg rucaparib BID, Dose Level 2b: 400 mg ipatasertib QD + 400 mg rucaparib BID, Dose Level 3: 400 mg ipatasertib QD + 600 mg rucaparib BID
16420018|NCT03840200|Experimental|Part 2: Ipatasertib + Rucaparib|A Dose-Expansion Phase (Part 2) - The recommended dose identified in Part 1 (highest dose level of ipatasertib and rucaparib with an acceptable safety profile and less than one-third of participants experience a dose limiting toxicity) will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
16420019|NCT03840174|Experimental|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2 and Month 6
16420020|NCT03840174|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2 and Month 6
16420021|NCT03840148|Experimental|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
16420022|NCT03840148|Active Comparator|Meropenem|Meropenem will be administered q8h IV over 30 minutes.
16420023|NCT03840135|Experimental|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
16420024|NCT03840135|Placebo Comparator|Placebo|Placebo, nasal and sublingual spray - 7 days.
16420025|NCT03840122|Experimental|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
16420026|NCT03840122|Active Comparator|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
16422574|NCT03822364|Experimental|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
16420027|NCT03840109||All Participants|All participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. The participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
16420028|NCT03840096|Experimental|Quadriceps NMES using Breg Flex|
16420029|NCT03840096|No Intervention|Control|
16420030|NCT03840083|Experimental|Sleep|Individuals will either nap (Exps 1, 4) or have overnight sleep (Exps 2, 3, 5, 6)
16420031|NCT03840083|No Intervention|Wake|Individuals will stay awake for the same amount of time as they slept in the sleep condition
16420032|NCT03840070|Experimental|Potenfill|
16420033|NCT03840057|Experimental|Azithromycin|Participants randomized to the azithromycin arm would receive 250mL of reconstituted solution containing 500mg of generic azithromycin to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic or renal impairment. No dose adjustment is made for geriatric population.
16420034|NCT03840057|Experimental|Metoclopramide|Participants randomized to the metoclopramide arm would receive 2mL of solution containing 10mg of generic metoclopramide to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic impairment. A 50% dose reduction is made for those with creatinine clearance of less than 40mL/minute. No dose adjustment is made for geriatric population.
16420035|NCT03840057|Placebo Comparator|Placebo|Participants randomized to the placebo arm during Part 1 (azithromycin) of the study would receive 250mL of 0.9% sodium chloride solution to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. Participants randomized to the placebo arm during Part 2 (metoclopramide) of the current study would receive 2mL of 0.9% sodium chloride solution to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy.
16420036|NCT03840044|Other|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
16420037|NCT03840044|Other|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
16420038|NCT03840031|Experimental|Orange Fleshed Sweet Potato High Iron|Meal sequence B, OFSP High Fe
16420039|NCT03840031|Active Comparator|Orange Fleshed Sweet Potato Control|Meal sequence A, OFSP control
16420040|NCT03840018|No Intervention|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
16420041|NCT03840018|Other|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
16420042|NCT03840005|Placebo Comparator|Placebo|2:1 in favour of UDCA
16420043|NCT03840005|Experimental|Ursonorm (Ursodeoxycholic acid)|UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.
16420044|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
16420045|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
16420046|NCT03839966|Experimental|Active Treatment|Interpretation Bias Modification for Loneliness
16420047|NCT03839966|Active Comparator|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
16420048|NCT03839953|Active Comparator|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
16420049|NCT03839953|Experimental|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
16420050|NCT03839940|Experimental|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
16420051|NCT03839940|Placebo Comparator|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
16420052|NCT03839927||Evaluation Group|Survey Application
16420053|NCT03839914|Active Comparator|Intervention - Vancomycin|Intervention: 1g vancomycin powder locally applied to the deep wound and subcutaneous layer prior to closure.
16420054|NCT03839914|No Intervention|Control - No vancomycin application|No intervention, control group All other wound closure procedure and wound care and monitoring are the same
16420055|NCT03839901|Experimental|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
16420056|NCT03839901|Experimental|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
16420057|NCT03839888|Experimental|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
16420058|NCT03839875|Experimental|Active Treatment|
16420059|NCT03839862||Responder|Patient responding to TNF-inhibition
16420060|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
16420061|NCT03839849|Experimental|i-PRF (Test)|injected subgingivally i-PRF after scaling and root planing
16420062|NCT03839849|Active Comparator|saline (Control)|injected subgingivally saline after scaling and root planing
16420063|NCT03839836|No Intervention|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
16420088|NCT03839706|Experimental|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
16420089|NCT03839693|Placebo Comparator|Vehicle|Vehicle
16420064|NCT03839836|Experimental|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
16420065|NCT03839836|Experimental|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
16420066|NCT03839836|Experimental|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
16420067|NCT03839836|Experimental|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
16420068|NCT03839823|Active Comparator|Comparator arm|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine will be administer to patients enrolled in the control group. The chemotherapy regimen will be decided by the treating physician.
16420069|NCT03839823|Experimental|Ribociclib arm|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.
~Ribociclib (600 mg) is dosed orally for the first 21 days out of a 28 day cycle.
~Letrozole (2.5 mg) or anastrozole (1 mg) are dosed orally daily (28 days out of the 28 day cycle).
~Goserelin (3.6 mg) is continuously released via a subcutaneous implant injected on Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days."
16420070|NCT03839810|Experimental|stochastic resonance|stochastic resonance electrical stimulation is applied to the upper extremity during the subjects perform upper extremity motor function.
16420071|NCT03839810|Sham Comparator|sham stimulation|sham electrical stimulation (same electrode location, but no electrical current is applied) is applied to the upper extremity during the subjects perform upper extremity motor function.
16420072|NCT03839797|Experimental|Cadet Healthy Personal Skills|Cadet Healthy Personal Skills
16420073|NCT03839797|Active Comparator|Standard Health Education|Standard Health Education
16420074|NCT03839784||Neurocognitive Assessment Arm|
16420075|NCT03839771|Placebo Comparator|Arm A: Placebo|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |
~The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day
~The dosage for Placebo for AG-221 (IDH2): 100mg dose/day"
16420076|NCT03839771|Experimental|Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |
~The dosage for AG-120 (IDH1): 500 mg dose/day
~The dosage for AG-221 (IDH2): 100mg dose/day"
16420077|NCT03839758|Active Comparator|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
16420078|NCT03839758|Active Comparator|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
16420079|NCT03839758|Experimental|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
16420080|NCT03839758|Experimental|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
16420081|NCT03839745|Other|Power level 10, 35, or 70 watts|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
16420082|NCT03839745|Other|1 of the other 2 remaining power levels|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
16420083|NCT03839745|Other|Remaining power level|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level
16420084|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
16420085|NCT03839719|Experimental|Group OC|"Ocimum sanctum (OC) is a natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is also listed by the U.S. FDA as an herb Generally Recognized As Safe (GRAS) for its intended use as a therapeutic herb. Pharmacological constitutes present in the extract are eugenol, Urosolic acid, Carvacrol, linalool , limatrol, caryophyllene, and methyl carvicol. The literature showed that Ocimum sanctum extract has significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
~Other Names:
~Tulsi Holy Basil"
16420086|NCT03839719|Active Comparator|Group CHX|"Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in a variety of oral disorders in various formulations.
~As an antimicrobial agent, chlorhexidine is effective in vitro against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes and yeasts and fungi. The digluconate of chlorhexidine (1:6Di 4' chlorophenyl-diguani-dohexane) is a synthetic antimicrobial drug which has been widely used as a broad spectrum antiseptic.
~Other Names:
~Chlorhexidine"
16420087|NCT03839719|Placebo Comparator|Group PI|"Group PI: Placebo (Distilled water) as the mouthrinse.
~Placebo (Distilled water) 10 ml is used as mouthrinse. Distilled water is commonly used as an excipient in a variety of drugs and it is also widely used as a placebo.
~Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
~Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria."
16420092|NCT03839667|Experimental|intensive diet intervention group|The participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
16420093|NCT03839667|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
16420094|NCT03839667|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
16420095|NCT03839654|Experimental|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
16420096|NCT03839654|No Intervention|non-continuous positive airway pressure|The non-CPAP treatment group received baseline medicine treatment without CPAP treatment.
16420097|NCT03839641|Experimental|High Fat Meal First|Arm 1 participants randomized to receive high fat meal first, and low fat meal second
16420098|NCT03839641|Experimental|High Fat Meal Second|Arm 2 participants randomized to receive low fat meal first, and high fat meal second
16420099|NCT03839628|Experimental|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
16420100|NCT03839615|Active Comparator|guided bone regeneration using ptfe|"Augmented anterior maxillary bone ridge using ptfe with 1:1 autogenous bone and xenograft mixture
~Patients of both groups will be subjected to CBCT (diagnostic for upper arch).
~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~intervention:
~Flap will be done.
~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a ptfe membrane which will be stabilized by tacks."
16420101|NCT03839615|Experimental|collagen membrane|"Local anesthesia will be given to the patient. intervention:
~Flap will be done.
~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks."
16420102|NCT03839602|Experimental|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
16420103|NCT03839589|Experimental|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
16420104|NCT03839589|Placebo Comparator|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
16420105|NCT03839576|Experimental|Computerized cognitive training|The computerized cognitive training will take place at each participant's residence. Participants will be asked to practice at least 1 session a day for 6 months, and a session lasts for 60 minutes.
16420106|NCT03839576|Experimental|Lower extremity strengthening|"This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months.
~Each session will last 60 min."
16420107|NCT03839576|Experimental|Tai chi chuan|The 8-form Yang-style tai chi intervention will take place at a subject's residence or the neighborhood once a week for 6 months, and each session will last for 60 minutes.
16420108|NCT03839576|No Intervention|Social interaction|Immediately after the baseline assessment, the care manager will visit the subject in this group once for comparability with the other two intervention groups.
16420109|NCT03839563|Experimental|Conventional exercise|This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months. Each session will last 60 min.
16420110|NCT03839563|Experimental|Tai chi chuan|The 8-form Yang-style tai chi chuan intervention will take place at a subject's residence or in the neighborhood once a week for 6 months, and each session will last 60 min.
16420111|NCT03839563|No Intervention|Health education/usual physical activity|After the baseline, the case manager will visit subjects in this group once for comparability with the other two intervention groups and instruct them to maintain their usual physical activity.
16420112|NCT03839550|Experimental|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
16420113|NCT03839550|Active Comparator|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
16420114|NCT03839524|Experimental|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
16420115|NCT03839498|Experimental|Axitinib (AG-013736)|Subjects with Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma will receive 16 weeks of therapy (Axitinib), and be seen in clinic every 4 weeks to monitor therapy.
16420116|NCT03839485|Active Comparator|Pasta Guedes-Pinto|Endodontic treatment using Guedes-Pinto Paste
16420117|NCT03839485|Experimental|Pasta Guedes-Pinto without antibiotic|Endodontic using Guedes-Pinto paste without antibiotic
16420367|NCT03837756|Active Comparator|Arm D: Lefitolimod/3BNC117 + 10-1074|This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
16420118|NCT03839472|Experimental|Continuous Bladder Irrigation (CBI)|"Each subject will have a TURBT procedure performed per standard of care procedure, which will be followed by the study intervention - Continuous Bladder Irrigation (CBI) for up to two hours after procedure.
~Six samples of discarded bladder irrigation will be collected from each participant (N=20) immediately after TURBT and after the completion of each liter of normal saline 0.9% irrigation (1 to 5 L) for a total of 120 samples."
16420119|NCT03839459|Experimental|Denosumab|
16420120|NCT03839446|Experimental|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
16420121|NCT03839433|Active Comparator|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
16420122|NCT03839433|Placebo Comparator|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
16420123|NCT03839420|Experimental|CZM IOL|
16420124|NCT03839420|Active Comparator|Competitor IOL|
16420125|NCT03839407|Experimental|MUSE device Class 21|Participants will utilize the MUSE device for 12 weeks during the intervention period.
16420126|NCT03839407|No Intervention|No MUSE device Class 21|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
16420127|NCT03839407|Experimental|MUSE device Class 22|Participants will utilize the MUSE device for 12 weeks during the intervention period.
16420128|NCT03839407|No Intervention|No MUSE device Class 22|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
16420129|NCT03839394|Experimental|Educational pamphlets + telephone|
16420130|NCT03839394|Active Comparator|Educational pamphlets|
16420131|NCT03839368|Experimental|K plate|fixation of angle fracture using K plate versus two miniplates
16420132|NCT03839368|Active Comparator|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
16420133|NCT03839355|Active Comparator|Eliquis|
16420134|NCT03839355|Active Comparator|Warfarin|
16420135|NCT03839342|Experimental|Binimetinib + Encorafenib|Binimetinib and encorafenib are administered orally on a twice daily or once daily schedule, respectively in 28-day cycles. Treatment will continue until it is discontinued due to unacceptable toxicity, clinical or radiological disease progression as per RECIST 1.1, investigator decision, and/or withdrawal of consent.
16420136|NCT03839329|Experimental|ACT Group Condition|The ACT group condition will receive two 90-minute group Acceptance and Commitment Training (ACT) workshops (scheduled approximately one week apart) and will complete assessments.
16420137|NCT03839329|No Intervention|Assessment-Only Condition|The Assessment-only condition will not receive any intervention and will only complete assessments.
16420138|NCT03839316|Active Comparator|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).
~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.
~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
16420139|NCT03839316|Sham Comparator|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
16420140|NCT03839303|Experimental|Mini Implant Supported Appliance|this group will receive an Infra-zygomatic Mini Implant Supported Appliance after leveling and alignment of the four upper incisors for 8 months or till class I canine or incisors realation is reached with follow up every month
16420141|NCT03839303|Active Comparator|Headgear|this group will receive a high pull headgear appliance attached to a removable acrylic maxillary splint for 8 months or till class I canine or incisors realation is reached with follow up every month
16420142|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
16420143|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
16420144|NCT03839277|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
16420145|NCT03839277|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
16420146|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
16420147|NCT03839251|Other|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
16420148|NCT03839238|Experimental|Meniscus Injured patients|hESC Derived MSC Like Cell
16420149|NCT03839225|Other|Children, Adolescents and Adults|children, adolescents and adults who have been victims of the armed conflict in the municipalities of Soacha-Cundimanarca (Colombia)
16420150|NCT03839212|Experimental|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
16420151|NCT03839173|No Intervention|Retrospective Chart Review|Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
16422575|NCT03822364|Placebo Comparator|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
16420152|NCT03839173|Experimental|Prospective|"All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent.
~Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data."
16420153|NCT03839160|Active Comparator|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
16420154|NCT03839160|Placebo Comparator|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
16420155|NCT03839147|Experimental|Education and Counseling|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. This education consisted of the definition and the purpose of hysterosalpingography, when and how it was applied, in what cases it was applied, whether it was a painful procedure, possible side effects and additional benefits of infertility treatment
16420156|NCT03839147|No Intervention|Control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography. Within 5 minutes of completing the hysterosalpingography procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale .
16420157|NCT03839134|Experimental|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
16420158|NCT03839134|Active Comparator|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
16420159|NCT03839134|Experimental|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
16420160|NCT03839134|Active Comparator|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
16420161|NCT03839134|Experimental|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
16420162|NCT03839134|Active Comparator|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
16420163|NCT03839121||single arm: CRT-DX|
16420164|NCT03839108|Active Comparator|Paraffin wax group|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
16420165|NCT03839108|Experimental|Prolotherapy group|"Drug = prolotherapy (%15 dextrose solution) into hand joints
~%15 dextrose solution will be injected into medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period."
16420166|NCT03839082|Active Comparator|Usual Care then FitBit|This is the waitlist control arm.
16420167|NCT03839082|Experimental|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
16420168|NCT03839069|Experimental|Minor Salivary Gland Transplantation|Cicatrizing conjunctivitis patients that received minor salivary gland transplantation for dry eye treatment.
16420169|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
16420170|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
16420171|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
16420172|NCT03839043|Experimental|"Quit for a bit"|"Brief behavioral intervention (~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
16420173|NCT03839043|Active Comparator|"Quit for good"|"Brief behavioral intervention (~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
16420174|NCT03839030|Experimental|MBHP-Educa|Experimental: Intervention Group A novel Mindfulness-based Health Promotion program for Educators for active teachers will be employed. The intervention will be held once a week for 8-weeks, two-hour meetings (16.0-h total). Participants will be encouraged to meditate for 10-30 min/day via audio recording.
16420175|NCT03839030|No Intervention|Control Group|Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
16420176|NCT03839017|Experimental|Digital cognitive aid|The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
16420177|NCT03839017|Experimental|Without digital cognitive aid|The leader practices advanced combat casualty care without the digital cognitive aid designed as a smartphone app. Intervention: Device: SIMMAXMARCHERYAN2 Without digital cognitive aid during the management of simulated war wounded.
16420178|NCT03839004|Experimental|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
16420179|NCT03839004|No Intervention|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
16420180|NCT03838991|Experimental|Monostotic fibrous dysplasia|Patients with monostotic Fibrous dysplasia.
16420181|NCT03838991|Experimental|Polyostotic fibrous dysplasia|Patients with polyostotic Fibrous dysplasia.
16420182|NCT03838991|Active Comparator|Controls|Control patients having a scheduled surgery for osteoarthritis.
16420183|NCT03838978|Experimental|Calypso Knee System|Calypso Knee System
16420184|NCT03838965|Experimental|biobeat sensor|
16420185|NCT03838952|Experimental|Chinese herbal medicine group|drug for the subjects
16420186|NCT03838939|Experimental|interventional group|"M3 (group with 3 to 10 patients) Intensification Biotherapy Education Workshops : Subcutaneous injection education and biotherapy management"
16420187|NCT03838939|Placebo Comparator|Control group|"M3 (individual) Intensification Biotherapy Education: Subcutaneous injection education and biotherapy management."
16420188|NCT03838926|Experimental|Trichostatin A|
16420189|NCT03838913||IPNB|intraductal papillary neoplasm of the bile duct
16420190|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
16420191|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
16420192|NCT03838887||control group|"Pregnant women:
~Age between 18-35 years
~Parity: primigravidas and multiparas.
~Have no history of preeclampsia or eclampsia.
~Have no history of chronic hypertension.
~Not diabetic.
~Not have antiphospholipid syndrome.
~Not have autoimmune disease such as SLE"
16420193|NCT03838887||High risk group|"Pregnant women with:
~History of preeclampsia -Eclapmsia
~Chronic hypertension
~Diabetic
~Antiphospholipid syndrome.
~Autoimmune syndrome such as SLE."
16420194|NCT03838874|Active Comparator|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
16420195|NCT03838874|Active Comparator|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
16420196|NCT03838861|Active Comparator|Control|Standard follow-up in doctors setting
16420197|NCT03838861|Experimental|Intervention|Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
16420198|NCT03838848|Experimental|Safety cohort KN046 3mg|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
16420199|NCT03838848|Experimental|Safety cohort KN046 5mg|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
16420200|NCT03838848|Experimental|Efficacy cohort KN046|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
16420201|NCT03838835|Experimental|Equine-facilitated group therapy|
16420202|NCT03838835|Experimental|Augmented equine-facilitated CBT group program|
16420203|NCT03838835|Other|Wait List Control (WLC)|
16420204|NCT03838822|Experimental|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
16420205|NCT03838809|Experimental|INTERVENTION|A group that underwent a neurological physiotherapy program with electromyography-biofeedback on the hand and the foot
16420206|NCT03838809|Active Comparator|CONTROL|A group that underwent a conventional physiotheraphy intervention
16420207|NCT03838796|Active Comparator|lenvatinib|use lenvatinib after liver resection in HCC patients
16420208|NCT03838796|Active Comparator|lenvatinib and TACE|use lenvatinib and TACE after liver resection in HCC patients
16420209|NCT03838783|No Intervention|Usual CSII|Continue to use the established CSII insulin therapy
16420210|NCT03838783|Experimental|Untethered CSII|Basal dosing - total CSII basal dose will be delivered by 50% through continuing CSII therapy used prior to study enrollment and 50% through the addition of once daily insulin degludec injected in the morning; Bolus dosing - continue the established bolus insulin dose
16420211|NCT03838770|Experimental|Active|
16420212|NCT03838770|Placebo Comparator|Sham|
16420213|NCT03838757||Patients|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
16420214|NCT03838757||Healthy controls|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
16420251|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
16420215|NCT03838744|Active Comparator|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy at the dose 1.5 or 1.3 mg/m2 (according institutional practice) given as intravenous infusion at day 1 every 3 weeks (21 days cycle)
16420216|NCT03838744|Experimental|Experimental arm: Trabectedin + Olaparib|Trabectedin at the dose 1.1mg/m2 given as intravenous infusion at day 1 every 3 weeks (21 days cycle) plus Olaparib per os at the dose of 150 mg twice a day
16420217|NCT03838731|Experimental|REGN1908-1909|
16420218|NCT03838731|Placebo Comparator|Placebo|
16420219|NCT03838705|Other|bariatric surgery patients|patients aged 18-65 years with ASA status II-III, BMI>40 who were undergoing bariatric surgery operation
16420220|NCT03838692|Experimental|Ponatinib Arm|Ponatinib tablets will be taken by mouth, continuously, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment can be taken with water, with or without food, at approximately the same time each day.
16420221|NCT03838679||Cohort 1|80 participants with neovascular AMD and a minimum history of 12 months of anti- VEGF therapy will be included in cohort 1 and examined only once (1 study visit).
16420222|NCT03838679||Cohort 2|40 participants with treatment-naive neovascular AMD receiving standardized anti- VEGF therapy will be included in cohort 2 and followed for 12 months (6 study visits).
16420223|NCT03838666|Experimental|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
16420224|NCT03838653||Left main bronchus (LMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the left main bronchus (correct placement).
16420225|NCT03838653||Right main bronchus (RMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the right main bronchus (incorrect placement).
16420226|NCT03838640|Experimental|Study group|Consecutive eligible patients requiring endoscopic surgery for sinonasal pathology Transnasal localization of internal carotid artery with TEE ECHO device will be performed
16420227|NCT03838614|Experimental|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
16420228|NCT03838614|Experimental|RAS group|Rhythmical auditory stimulation gait training group
16420229|NCT03838614|Experimental|MPT group|Muscle power training group
16420230|NCT03838614|Other|Control group|Usual care group
16420231|NCT03838601|Experimental|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
16420232|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:
~st: 10 Days after patients received radical resection.
~nd: When patients finished the chemotherapy or target drug delivery two cycles.
~rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.
~th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
16420233|NCT03838575|Active Comparator|A - NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.
~No drapes or sponges of any kind may be used."
16420234|NCT03838575|Active Comparator|B - SKIN PREP|"Mechanism: A broad-spectrum antiseptic to clean and prepare the skin prior to surgery.
~Supplier: BD"
16420235|NCT03838575|Active Comparator|C - DRAPE|"Mechanism: A thin impregnated plastic sheet applied to the prepared skin prior to incision to maintain sterility.
~Supplier: 3M Infection Prevention"
16420236|NCT03838575|Active Comparator|D - SPONGE|"Mechanism: Small absorbable sponges placed into the wound at the time of closure which deliver high concentrations of antibiotic locally to kill pathogens present that may go on to cause SSI.
~Supplier: SERB"
16420237|NCT03838575|Active Comparator|E - SKIN PREP and DRAPE|See descriptions in single arms (B & C)
16420238|NCT03838575|Active Comparator|F - SKIN PREP and SPONGE|See descriptions in single arms (B & D)
16420239|NCT03838575|Active Comparator|G - DRAPE and SPONGE|See descriptions in single arms (C & D)
16420240|NCT03838575|Active Comparator|H - SKIN PREP and DRAPE and SPONGE|See descriptions in single arms (B, C & D)
16420241|NCT03838562|Experimental|Virtual Reality Arm|
16420242|NCT03838562|Active Comparator|Control Arm|
16420243|NCT03838549|Experimental|implant for breast reconstruction|20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy. They will have a prophylactic mastectomy with immediate breast reconstruction
16420244|NCT03838536|Experimental|Whole egg powder|Participants are given whole egg powder which contains high levels of the nutrients choline, lutein, and docosahexaenoic acid.
16420245|NCT03838536|Placebo Comparator|Egg white powder|The participants are given an egg white powder that does not contain the target nutrients (choline, lutein, and docosahexaenoic acid).
16420246|NCT03838523|Experimental|OLP group|"At baseline, patients are given an explanation about why placebos without deception might be effective.
~Women allocated to this group receive an 4-week Open Label Placebo treatment. After 4 weeks, they are randomized again to either continue or discontinue the OLP treatment for another 4 weeks."
16420247|NCT03838523|No Intervention|No-treatment group|"At baseline, patients are given an explanation about why placebos without deception might be effective.
~Women assigned to the no-treatment group do not receive any treatment as part of the study."
16420248|NCT03838510|Experimental|Brief Counseling Intervention|
16420249|NCT03838510|No Intervention|Control Group|
16420250|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
16420252|NCT03838484|Experimental|Healthy: placebo first, nicotine last|Healthy controls will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
16420253|NCT03838484|Experimental|Healthy: nicotine first, placebo last|Healthy controls will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
16420254|NCT03838484|Experimental|SCZ: placebo first, nicotine last|Subjects with schizophrenia (SCZ) will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
16420255|NCT03838484|Experimental|SCZ: nicotine first, placebo last|Subjects with schizophrenia (SCZ) will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
16420256|NCT03838471||Central sensitization symptoms|This group will contain persons with a clinically relevant degree of symptoms of CS (CSI score ≥40).
16420257|NCT03838471||No Central sensitization symptoms|This group will contain persons with a lower degree of symptoms of CS (CSI score < 40).
16420258|NCT03838458||Study|Children with isolated hypospadias
16420259|NCT03838458||Control|Children with planned circumcision
16420260|NCT03838445|Experimental|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
16420261|NCT03838432|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
16420262|NCT03838419|Active Comparator|BCS + WBI|breast conserving surgery followed by whole breast irradiation
16420263|NCT03838419|Experimental|BCS + IORT|Breast conserving surgery incl intraoperative radiotherapy
16420264|NCT03838406|Experimental|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy
~FOLFOX :
~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.
~CAPOX:
~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
16420265|NCT03838406|Active Comparator|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy
~FOLFOX :
~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.
~CAPOX:
~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
16420266|NCT03838380|No Intervention|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
16420267|NCT03838380|Experimental|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
16420268|NCT03838367|Experimental|Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
16420269|NCT03838367|Experimental|Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
16420270|NCT03838367|Experimental|Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
16420271|NCT03838367|Experimental|Phase II- MTD to be established for the combination treatment|MTD PRO 140 SC + AUC 5 Carboplatin in 30 subjects
16420272|NCT03838354|Experimental|A|Chidamide 2.5 mg po tiw
16420273|NCT03838354|Experimental|B|Chidamide 5 mg po tiw
16420274|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
16420275|NCT03838328|Experimental|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
16420276|NCT03838328|Experimental|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
16420277|NCT03838328|Active Comparator|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
16420278|NCT03838315|Experimental|Neural Mobilization with Soft Tissue Mobilization|"Neural Mobilization with Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization and Post Isometric Relaxation Techniques.
~Frequency for Neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 40mints each session)"
16420279|NCT03838315|Active Comparator|Neural mobilization without Soft Tissue Mobilization|Neural Mobilization without Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural Mobilization Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 30mints each session)
16420280|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
16420281|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
16420282|NCT03838289||Individuals with absent filling of CVs|Individuals with absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
16420335|NCT03837977|Active Comparator|docetaxel|75mg/m*2 intravenously over 60 minutes) every 21 days]
16420336|NCT03837964|Experimental|Treatment T|Fed
16420283|NCT03838289||individuals without any absent filling of CVs|Individuals without any absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
16420284|NCT03838276|Active Comparator|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
16420285|NCT03838276|Experimental|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
16420286|NCT03838263|Experimental|Experimental arm|Experimental arm with nivolumab 2 infusions (2 weeks apart) before Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
16420287|NCT03838263|Active Comparator|Control arm|Control arm: Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
16420288|NCT03838250|Experimental|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
16420289|NCT03838237||Fabry Disease patients|Patients with genetic diagnosis of Fabry Disease, clinical indication to Migalastat and signs of cardiac involvement (early or advanced) will undergo cardiological evaluation before and 18 months after therapy with Migalastat (123 mg every other day)
16420290|NCT03838224|Experimental|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
16420291|NCT03838224|Sham Comparator|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
16420292|NCT03838211|Experimental|stimulation group|Anodal tDCS + intensive cognitive Training
16420293|NCT03838211|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
16420294|NCT03838198|Other|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
16420295|NCT03838198|Other|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
16420296|NCT03838198|Other|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
16420297|NCT03838198|Other|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
16420298|NCT03838185|Experimental|Study Drug|Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
16420299|NCT03838185|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
16420300|NCT03838172||Parents|Parents who have a burned child
16420301|NCT03838159|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment (paclitaxel+carboplatin+nivolumab) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)
~Adjuvant treatment (Nivolumab): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months."
16420302|NCT03838159|Active Comparator|Control: Neo-Adjuvant chemotherapy|"Neoadjuvant treatment (paclitaxel+carboplatin) will start within 1-3 days from enrollment/ randomisation. 3 cycleswill be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)"
16420303|NCT03838146|No Intervention|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
16420304|NCT03838146|Experimental|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
16420337|NCT03837964|Experimental|Treatment R|Fasted
16420338|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
16420339|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
16420368|NCT03837743|Experimental|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
16420305|NCT03838146|Experimental|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts[17-19]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
16420306|NCT03838146|Experimental|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
16420307|NCT03838133|Experimental|TLC590 dose 1 (152 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16420308|NCT03838133|Experimental|TLC590 dose 2 (190 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16420309|NCT03838133|Experimental|TLC590 dose 3 (228 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16420310|NCT03838133|Active Comparator|Naropin®|Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)
16420311|NCT03838133|Placebo Comparator|Placebo|Normal Saline (0.9% sodium chloride, 10 mL)
16420312|NCT03838133|Active Comparator|Bupivacaine|Bupivacaine HCl 50 mg (0.5%, 10 mL)
16420314|NCT03838107||Inpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the inpatient FIRST clinic at CCHMC and one of their parents or legal guardian.
16420315|NCT03838107||Outpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the outpatient Pain Management Center at CCHMC and one of their parents or legal guardian.
16420316|NCT03838107||Healthy Controls|For comparison purposes, healthy controls and one of their parents or legal guardian will be enrolled in this study as well.
16420317|NCT03838094|Active Comparator|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
16420318|NCT03838094|Experimental|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
16420319|NCT03838081|Experimental|Group 1|Group 1: Patients who were given only basic information verbally
16420320|NCT03838081|Experimental|Group 2|Group 2: Patients with detailed written information about preoperative, intraoperative, and postoperative periods
16420321|NCT03838081|Experimental|Group 3|Group 3: Patients with previous experience and knowledge about third molar extraction
16420322|NCT03838068|Active Comparator|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
16420323|NCT03838068|Experimental|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
16420324|NCT03838055|Experimental|SLN only|Pelvic SLN's defined by ICG injected cervically
16420325|NCT03838042|Experimental|Nivolumab and Entinostat|Combination Study of Nivolumab and Entinostat
16420326|NCT03838029|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.
16420327|NCT03838029|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
16420328|NCT03838016|Experimental|Treatment cohort with classic galactosemia|These children and their parents receive the Babble Boot Camp intervention and also participate in the close monitoring activities (progress reports that the speech-language pathologist generates during the online meeting with the family; monthly daylong audio recording; questionnaires that are sent out every three to six months; formal speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years).
16420329|NCT03838016|Experimental|Treatment cohort with classic galactosemia, delayed start|The children in the control cohort enter the study when they are younger than 5 months old and participate in the close monitoring until they are 24 months old. They start getting the same treatment type and intensity as the treatment cohort but at a delayed age, when they turn 15 months.
16420330|NCT03838016|No Intervention|Older control cohort with classic galactosemia|The children in the older control cohort are 6 months to 4 1/2 years old and provide standardized test results in the area of speech and language development at child ages 2 1/2, 3 1/2, and 4 1/2 years. They receive no treatment and no close monitoring. These families provide questionnaire information every three months until child age 24 months.
16420331|NCT03838016|No Intervention|Typical controls|These children are free of any medical or developmental diagnosis. They enter the study at ages 2 to 5 months and provide close monitoring data until they are 24 months old, then they receive standardized speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years, just like the treatment cohort, but the typical controls receive no treatment under this study.
16420332|NCT03838003|Experimental|Experimental: Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
16420333|NCT03838003|No Intervention|No Intervention: Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
16420334|NCT03837977|Active Comparator|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
16474156|NCT03469921||acute leukemia|acute leukemia
16420340|NCT03837938|Experimental|Levopront® syrup 30 mg/5 ml|Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml t.i.d. for 7 days The study drugs will be taken t.i.d. (with the interval of not less than 6 hours, between meals) during 7 days.
16420341|NCT03837938|Active Comparator|Libexin® 100 mg tablets|"Libexin® (prenoxdiazine) 100 mg tablets
~1 tablet t.i.d. for 7 days."
16420342|NCT03837925|Experimental|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
16420343|NCT03837925|Placebo Comparator|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
16420344|NCT03837912|Experimental|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
16420345|NCT03837912|No Intervention|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
16420347|NCT03837886|Experimental|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
16420348|NCT03837886|Placebo Comparator|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
16420349|NCT03837873|Experimental|DLCL002 protocol|Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.
16420353|NCT03837847|Experimental|Intervention|Participants in this group will receive 12 weekly health coaching calls followed by 12 weeks of living a normal life.
16420354|NCT03837847|Active Comparator|Attention Control|Participants in this group will receive 6 educational guides and 6 calls to remind them to read the educational guides (over a 12 week period). The participants will then move to 12 weeks of weekly health coaching calls.
16420355|NCT03837834|Experimental|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
16420356|NCT03837834|Experimental|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
16420357|NCT03837821|Experimental|All Subjects|Abemaciclib 200 mg oral, every 12 hours
16420358|NCT03837808|Experimental|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
16420359|NCT03837808|Active Comparator|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
16420360|NCT03837795|Experimental|Neurofeedback therapy group|
16420361|NCT03837782|Experimental|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.
~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
16420362|NCT03837782|No Intervention|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.
~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).
~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
16420363|NCT03837769|Experimental|Aktiia SA PulseWatch|Aktiia OBPM PulseWatch wrist device
16420364|NCT03837756|Placebo Comparator|Arm A: Placebo/Placebo|This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
16420365|NCT03837756|Active Comparator|Arm B: Lefitolimod/Placebo|This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
16420366|NCT03837756|Active Comparator|Arm C: Placebo/3BNC117 + 10-1074|This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
16420369|NCT03837743|Placebo Comparator|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
16420370|NCT03837717|Experimental|Holding First|Holding will occur on the second day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
16420371|NCT03837717|Experimental|No Holding First|Holding will occur on the third day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
16420372|NCT03837704|Active Comparator|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
16420373|NCT03837704|Active Comparator|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
16420374|NCT03837704|Active Comparator|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
16420375|NCT03837691|Experimental|g-Cath EZ|Placement of Snowshoe suture anchors from g-Cath EZ Delivery Catheters, in a defined pattern in the mid and distal portions of the stomach, along with a moderate intensity diet & exercise program, to treat primary obesity.
16420376|NCT03837691|No Intervention|Diet and Exercise|A moderate intensity diet & exercise program to treat primary obesity
16420377|NCT03837665|Experimental|PRP Treatment|Participants receive platelet rich plasma treatment. Participants will be asked to make up to 5 trips to the clinic (one for eligibility, one for the PRP, three follow-up visits). Participation is expected to last up to about 6 weeks. After the second visit and application of PRP, patients will be monitored closely for any complications or concerns. This will include a follow up phone call 3-5 days after the initial application of PRP. Patients will also be followed closely in 2 week intervals or sooner should any problems or concerns arise.
16420378|NCT03837639|Experimental|Arm crank ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
16420379|NCT03837639|Experimental|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
16420380|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
16420381|NCT03837626|Placebo Comparator|Placebo|6 months of daily placebo
16420382|NCT03837626|Experimental|Amiloride|6 months of amiloride (max dose 5 mg) treatment
16420383|NCT03837613||Group 1 (TT<4mm)|Patients with a preoperative tumor thickness less than 4 mm. Intervention: tumor resection and neck dissection
16420384|NCT03837613||Group 2 (TT >= 4mm)|Patients with a preoperative tumor thickness equal to or more than 4 mm Intervention: tumor resection and neck dissection
16420385|NCT03837600||Healthy Cohort|Participants who have smoked less than 5 pack-years, have quit smoking for more than 15 years and have no known lung diseases.
16420386|NCT03837600||High-risk Cohort|Participants who are at high risk for lung cancer including current smokers who have smoked for more than 30 pack-years and have not quit within 15 years.
16420387|NCT03837600||Cancer Cohort|Participants who have been diagnosed with lung cancer.
16420388|NCT03837587||Patients group|Patients with temporomandibular disorders
16420389|NCT03837561|Experimental|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
16420390|NCT03837561|Active Comparator|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
16420391|NCT03837548|Experimental|Training with Neurofeedback|
16420392|NCT03837548|Experimental|The other Training with Neurofeedback|
16420393|NCT03837535||Patients undergoing surgery|Swedish patients, >18 years undergoing surgery 2007-2014
16420394|NCT03837522|Active Comparator|Procurement Biopsy: Frozen section|In the routine care condition, biopsies will be processed immediately as a frozen section.
16420395|NCT03837522|Active Comparator|Procurement Biopsy: Permanent section|In the intervention group, the biopsy processing will be delayed to permanent section, and therefore not available until allocation is complete.
16420396|NCT03837509|Experimental|INCB001158 + daratumumab SC|INCB001158 + daratumumab
16420397|NCT03837509|Active Comparator|Daratumumab monotherapy and crossover to INC001158+ daratumumab SC|Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
16420398|NCT03837509|Experimental|INCB001158 monotherapy and crossover to INC001158+ daratumumab SC|INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
16420422|NCT03837314|Experimental|Deep Brain Stimulation|"Deep Brain stimulation using a novel device. Bioinduction Picostim Deep Brain Stimulation system"
16474157|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
16420402|NCT03837483|Experimental|Gene Therapy|OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene
16420403|NCT03837470|Experimental|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
16420404|NCT03837457|Experimental|Cobomarsen|
16420405|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
16420406|NCT03837405|Active Comparator|Diet Education|All participants will receive instruction in the Carbohydrate-Restricted (CR) diet and basic behavioral strategies in weekly, in-person, group sessions for 3 months. The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat.
16420407|NCT03837405|Experimental|Diet Education + Mindfulness|In addition to the diet components described above, participants randomized to the Education + Mindfulness (Ed+MBI) group will receive MBI components using the Eat Right Now (ERN) platform. This will consist of two integrated components: 1) use of the ERN app at home, during the week, to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based discussions of how the mindful eating practices are going, trouble-shooting obstacles/pain points, and doing group exercises and reflecting on them.
16420408|NCT03837392|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) - participants in this arm will take part in an online ACT + psychoeducation intervention. The intervention will provide psychoeducation surrounding perinatal anxiety and depression as well as on engaging social support and coping strategies. The ACT portion of the intervention will focus on developing psychological flexibility, which is defined as behaviorally pursuing one's values even in the presence of barriers (e.g., thoughts, emotions). Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
16420409|NCT03837392|Active Comparator|Supportive Psychoeducation|Control group - participants in this arm will take part in an online psychoeducation and support intervention. This intervention will focus on psychoeducation surrounding perinatal anxiety and depression, as well as on engaging social support and coping strategies. Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
16420410|NCT03837379|Other|Treatment As Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
16420411|NCT03837379|Experimental|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
16420412|NCT03837366|Experimental|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
16420413|NCT03837366|Active Comparator|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
16420414|NCT03837353|Experimental|Cohort 1A|"Cohort 1A Dose Level 1: DKN-01 300 mg intravenously (IV) on Days 1 and 15, docetaxel 75 mg/m2 on Day 1 every 3 weeks (21- day cycles).
~Dose Level 2: DKN-01 600 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles).
~Dose Level -1: DKN-01 150 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles)."
16420415|NCT03837353|Experimental|Cohort 1B|Cohort 1B: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)
16420416|NCT03837353|Experimental|Cohort 1C|Cohort 1C: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)
16420417|NCT03837353|Experimental|Cohort 2A|"Dose Level 1: DKN-01 300 mg IV on Days 1 and 15 of a 28-day cycle. Dose Level 2: DKN-01 600 mg IV on Days 1 and 15 of a 28-day cycle.
~Dose Level -1: DKN-01 150 mg IV on Days 1 and 15 of a 28-day cycle."
16420418|NCT03837353|Experimental|Cohort 2B|Cohort 2B: DKN-01 at MTD or highest dose tested: Days 1 and 15 (28-day cycles)
16420419|NCT03837340|Experimental|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
16420420|NCT03837340|Active Comparator|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
16420421|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
16474158|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
16420423|NCT03837301|Experimental|NESS-EFTR|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation (basin dissection)
16420424|NCT03837288|No Intervention|Vaginal progesterone only|continue on vaginal progesterone only
16420425|NCT03837288|Experimental|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
16420426|NCT03837275|Experimental|humsfe|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique)
16420427|NCT03837275|Active Comparator|closed sinus lift|transcrestal maxilllary sinus floor elevation
16420428|NCT03837262|Experimental|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
16420429|NCT03837249|Placebo Comparator|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
16420430|NCT03837249|Active Comparator|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
16420431|NCT03837249|Active Comparator|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
16420432|NCT03837236|Experimental|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
16420433|NCT03837223||"patients underwent rescue protocols and fresh embryotransfer"|they were patients with good prognosis with a mean age of 34.13 ± 4.42 years, with a good ovarian reserve
16420434|NCT03837210|Experimental|Test Drug|This group is treated with Herbal formulation.
16420435|NCT03837210|Active Comparator|Control Drug|This group is treated with Quintuple therapy
16420436|NCT03837197|Experimental|Kidney-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
16420437|NCT03837197|No Intervention|Kidney-Static Cold Storage|Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
16420438|NCT03837197|Experimental|Liver-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
16420439|NCT03837197|No Intervention|Liver-Static Cold Storage|Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
16420440|NCT03837184|Experimental|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
16420441|NCT03837171|Active Comparator|Liberal strategy|Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
16420442|NCT03837171|Experimental|Restrictive strategy|Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
16420443|NCT03837158|Experimental|Control-group|Two Tissue Level TiZr Sand blasted long grit acid-etched (SLA) implants placed in positions 33 and 43 (diameter 3.3mm, length ≥10mm), early loading
16420444|NCT03837158|Experimental|Experimental-group|Four narrow-diameter implants (NDI) TiZr SLA implants in positions 34, 32, 42, and 44 (diameter 2.4mm, length ≥10mm), immediate loading
16420445|NCT03837145||Liver transplant recipients|Adult patients requiring elective post-operative ventilation after a living donor liver transplant receiving intravenous propofol infusion for sedation titrated to Bi-Spectral Index (BIS) score of 60-80,as per our institutional protocol.
16420446|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
16420447|NCT03837119||Heterozygous Hemoglobinopathy|pregnancy outcome in women with heterozygous hemoglobinopathy
16420448|NCT03837119||No Heterozygous Hemoglobinopathy|pregnancy outcome in women without heterozygous hemoglobinopathy
16420449|NCT03837106|Experimental|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
16420450|NCT03837106|No Intervention|No intervention|Control group, no intervention
16420451|NCT03837093|Experimental|dose A|ILT-101
16420452|NCT03837093|Experimental|dose B|ILT-101
16420453|NCT03837093|Experimental|dose C|ILT-101
16420454|NCT03837093|Experimental|dose D|ILT-101
16420455|NCT03837093|Experimental|dose E|ILT-101
16420456|NCT03837093|Experimental|Placebo|
16420457|NCT03837080|Experimental|Nutrition Education|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care will go through a series of individual and group nutrition educations. Educations are specifically tailored for chronic pain patients, based on our preliminary findings on this group of patients.
16420458|NCT03837080|No Intervention|Control|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
16420459|NCT03837054|Other|Breast cancer patients with external polychemotherapy|
16420460|NCT03837041|Active Comparator|Reconditioning Proprioception group|Training Proprioception 1 hour for 2 day a week
16420461|NCT03837041|No Intervention|Control group|
16420462|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.
~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
16420463|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
16420464|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
16420465|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
16420466|NCT03837015|Active Comparator|Estring alone|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
16420467|NCT03837015|Active Comparator|Estring and vaginal RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30
16420468|NCT03837015|Active Comparator|Estring and oral RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.
16420469|NCT03837015|Active Comparator|Vaginal RepHresh Pro-B|Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.
16420470|NCT03837002|Experimental|foot care protocol|foot examination at the first interview, foot care and training once a month and weekly follow-up for 3 months, foot examination at the last interview (six month)
16420471|NCT03837002|No Intervention|Control|foot examination at the first interview, foot examination at the last interview (six month)
16420472|NCT03836989|Experimental|High-volt electrical stimulation|"Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.
~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.
~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.
~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved."
16420473|NCT03836989|Placebo Comparator|Subsensory electrical stimulation|"Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.
~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
16420474|NCT03836976|Experimental|All participants|All participants receive auditory gamma sensory stimulation.
16420480|NCT03836937|Experimental|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
16420481|NCT03836937|No Intervention|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
16420482|NCT03836924||Perampanel|Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
16420483|NCT03836911|Active Comparator|serious game|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a serious game
16420484|NCT03836911|Other|Classic program|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a classical exercise program in older subjects living in a nursing home
16420485|NCT03836898|Experimental|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
16420486|NCT03836885|Experimental|Apremilast|Oral tablet
16420487|NCT03836885|Placebo Comparator|Placebo|Oral tablet
16420521|NCT03836625|No Intervention|Control|The control arm will receive standard CareConekta, which will track their mobility with no additional features.
16475634|NCT03460223|Experimental|Conventional plus MSC treatment|
16420488|NCT03836872|Experimental|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
16420489|NCT03836872|Sham Comparator|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
16420490|NCT03836872|No Intervention|Standard Control Group|The third arm will be a standard care control arm.
16420491|NCT03836859|Experimental|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
16420492|NCT03836859|Placebo Comparator|Placebo|Vehicle: formulation containing L-methionine as excipient.
16420493|NCT03836846|Placebo Comparator|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
16420494|NCT03836846|Active Comparator|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
16420495|NCT03836833|Experimental|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
16420496|NCT03836833|Experimental|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
16420497|NCT03836820|Experimental|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
16420498|NCT03836820|Experimental|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
16420499|NCT03836820|Experimental|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
16420500|NCT03836807|Experimental|Ketoprofen|Single oral administration of Ketoprofen lysine salt 40 mg granules
16420501|NCT03836807|Placebo Comparator|Placebo|Single oral administration of placebo granules
16420502|NCT03836781|Active Comparator|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
16420503|NCT03836781|Other|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
16420504|NCT03836768|Experimental|Experimental Treatment|DTRMWXHS-12, oral capsule, daily, 28 days as a cycle
16420505|NCT03836755|Other|METACOS|Required to do some motor tasks during static and dynamic RSA
16420506|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
16420507|NCT03836729|Experimental|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
16420508|NCT03836716|Experimental|Arimoclomol|Arimoclomol, capsule
16420509|NCT03836703|Active Comparator|Single Dose Daily Iron|single dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
16420510|NCT03836703|Experimental|Double dose Daily iron|Double dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
16420511|NCT03836690|Experimental|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
16420512|NCT03836677|Experimental|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
16420513|NCT03836677|Experimental|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
16420514|NCT03836664|Experimental|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
16420515|NCT03836664|Placebo Comparator|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
16420516|NCT03836651|Active Comparator|Control Group|Following completion of baseline data collection, participants will be randomized to one of two groups. The research assistant will open a pre-assigned envelope in which group assignment was determined by a random number/block generator. The intervention is designed to complement guideline directed medical management. Therefore, both the intervention and control group will continue to be medically managed by their health care provider as usual. In order to avoid introducing the confound of extra attention paid to the intervention group, the control group will have the same visit and call schedule as the intervention group.
16420517|NCT03836651|Experimental|Intervention Group|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
16420518|NCT03836638|Experimental|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
16420519|NCT03836638|Experimental|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
16420520|NCT03836638|Active Comparator|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
16420522|NCT03836625|Experimental|Intervention|The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >50 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
16420523|NCT03836612||People with inflammatory bowel disease|Adults (18+) with inflammatory bowel disease registered with a contributing GP practice during the study period
16420524|NCT03836612||Controls|Adults (18+) without inflammatory bowel disease registered with a contributing GP practice during the study period
16420525|NCT03836599|Experimental|24 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
16420526|NCT03836599|Experimental|12 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.
16420527|NCT03836599|Placebo Comparator|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
16420528|NCT03836586|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
16420529|NCT03836586|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
16420530|NCT03836573|Experimental|E-cigarette only decision aid|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of information on e-cigarettes only. Patients will only be enrolled in this group in phase II if they self-identify as 'uninterested in quitting cigarettes'. During the physician encounter will be given harm-reduction guidance.
16420531|NCT03836573|Experimental|E-cigarette and Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. Patients will only be enrolled in this group in phase II if they self identify as 'interested in quitting and using e-cigarettes'. During the physician encounter will be given e-cigarette cessation guidance.
16420532|NCT03836573|Experimental|Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. All patients in phase I will be enrolled in this group. In addition, patients in phase II who self-identify as 'interested in quitting but do not use e-cigarettes' will also be enrolled in this group. During the physician encounter will be given standard smoking cessation guidance.
16420533|NCT03836560|Active Comparator|Usual group|"Usual group with nicotine patch only:
~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
16420534|NCT03836560|Active Comparator|Intervention group|"Nicotine patch and nicotine gum:
~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
16420535|NCT03836547|Experimental|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
16420536|NCT03836547|Active Comparator|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
16420537|NCT03836534||patient coming to the emergency department|the group studied only concern adult adults consulting in the emergency departments and leaving after their consultations, during the permanence of care
16420538|NCT03836508|Active Comparator|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
16420539|NCT03836508|Active Comparator|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
16420540|NCT03836495|Experimental|White bread unfortified (WB)|bread with no lysine no phosphorus
16420541|NCT03836495|Experimental|White bread fortified with lysine (WB-L)|Bread with lysine
16420542|NCT03836495|Experimental|White bread fortified with phosphorus (WB-P)|bread with phosphorus
16420543|NCT03836495|Experimental|White bread fortified with lysine and phosphorus (WB-LP)|Bread with phosphorus and lysine
16420544|NCT03836482|Experimental|Selective Cytopheretic Device|
16420545|NCT03836456|Experimental|Experimental Intervention|Mindfulness Based Stress Resilience Training: This approach will be conducted with study participants for 4 weeks. One evening per week.
16420546|NCT03836456|Active Comparator|Active Control Intervention|Health Enhancement Program: This is a validated active comparator used in Mindfulness-based training studies. It will be conducted with the participants one evening per week for 4 weeks.
16420547|NCT03836443|Active Comparator|NAFL patients (group 1)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
16420548|NCT03836443|Active Comparator|NASH patients (group 2)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
16420586|NCT03836157|Experimental|Mirvetuximab and Bevacizumab|"Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.
~Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
16420549|NCT03836430|Experimental|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
16420550|NCT03836430|No Intervention|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
16420552|NCT03836404|Experimental|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
16420553|NCT03836391|Experimental|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).
~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
16420554|NCT03836378|Experimental|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
16420555|NCT03836378|No Intervention|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
16420556|NCT03836365|Active Comparator|Preoperative counseling office visit|Participants will present for an in-person preoperative counseling office visit (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
16420557|NCT03836365|Active Comparator|Preoperative counseling phone call|Participants will receive a preoperative counseling phone call (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
16420558|NCT03836352|Experimental|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
16420559|NCT03836352|Experimental|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
16420560|NCT03836326|Experimental|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
16420561|NCT03836326|Other|Control|Infants in the control group will receive standard care only.
16420562|NCT03836313|Experimental|cryoneurolysis treatment|TKA patients randomized to receive preoperative rehabilitation and cryoneurolysis treatment with the iovera° device (n=70)
16420563|NCT03836313|No Intervention|no cryoneurolysis treatment (standard of care)|TKA patients randomized to receive preoperative rehabilitation only (no cryoneurolysis treatment) (n=70)
16420564|NCT03836300|Experimental|Infants with FXS and their parent/primary caregiver|Implement intervention in two phases
16420565|NCT03836287|Experimental|Active|Sofpironium bromide, 15% gel, once per day
16420566|NCT03836287|Placebo Comparator|Vehicle|Vehicle gel, once per day
16420567|NCT03836274|Experimental|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
16420568|NCT03836261|Experimental|Acalabrutinib, Venetoclax|Acalabrutinib in combination with Venetoclax
16420569|NCT03836261|Experimental|Acalabrutinib, Venetoclax, Obinutuzumab|Acalabrutinib in combination with Venetoclax with or without Obinutuzumab
16420570|NCT03836261|Active Comparator|Chemoimmunotherapy|"Chemoimmunotherapy
~FCR: Fludarabine, Cyclophosphamide and Rituximab"
16420571|NCT03836248|Other|1-Current practice Medication treatment|Medication treatment according to current practice.
16420572|NCT03836248|Sham Comparator|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
16420573|NCT03836248|Experimental|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
16420574|NCT03836222|Experimental|PCS499 MR Tablet Prototype 2|600 mg single dose
16420575|NCT03836222|Active Comparator|Trental MR tablet 400mg|single dose
16420576|NCT03836222|Experimental|PCS499 MR Tablet Prototype 4|600mg single dose
16420577|NCT03836222|Experimental|PCS499 MR Tablet Prototype 1|600mg single dose
16420578|NCT03836222|Active Comparator|Trental MR Tablet|400 mg multiple dose
16420579|NCT03836222|Experimental|PCS499 MR Tablet 900mg|multiple dose
16420580|NCT03836222|Experimental|PCS499 MR Tablet 600mg|multiple dose
16420581|NCT03836209|Experimental|Arm A|"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.
~Consolidation: High-dose cytarabine and gilteritinib."
16420582|NCT03836209|Active Comparator|Arm B|"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.
~Consolidation: High-dose cytarabine and midostaurin."
16420583|NCT03836196|Experimental|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
16420584|NCT03836183|Other|ultrasound|"ultrasound is the only study group for all the patients
~pleuropulmonary ultrasound
~clinical examination
~fibroscopy."
16420585|NCT03836170|Experimental|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
16422576|NCT03822351|Experimental|Control Arm (Durvalumab monotherapy)|durvalumab IV
16420587|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
16420588|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
16420589|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).
~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
16420590|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
16420591|NCT03836079|Experimental|ADHF Patients|Treatment with preCARDIA System
16420592|NCT03836066|Experimental|Experimental: Atezolizumab plus Bevacizumab arm|1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
16420593|NCT03836053|Experimental|AMG 420|Single Arm Design
16420594|NCT03836040|Experimental|Dose level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
16420595|NCT03836040|Experimental|Dose level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
16420596|NCT03836040|Placebo Comparator|Placebo|
16420597|NCT03836014|Experimental|Fixed duration therapy for 24 months.|Daratumumab, Lenalidomide, Dexamethasone
16420598|NCT03836014|Active Comparator|Continuous therapy|Daratumumab, Lenalidomide, Dexamethasone
16420599|NCT03836001|Placebo Comparator|Placebo Oral Tablet|We aim to recruit at least 20 patients who will undergo two months of dosing with placebo (inactive drug or sugar pill), followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant at 5 mg (taken by mouth) daily for continued safety monitoring.
16420600|NCT03836001|Active Comparator|Serlopitant Tablet|We aim to recruit at least 20 patients who will undergo two months of Serlopitant dosing, followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant 5 mg (taken by mouth) daily for continued safety monitoring.
16420601|NCT03835988|Experimental|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
16420602|NCT03835975|Active Comparator|13vPnC|Pneumococcal conjugate vaccine
16420603|NCT03835975|Active Comparator|PPSV23|Pneumococcal polysaccharide vaccine
16420604|NCT03835975|Experimental|20vPnC|Pneumococcal conjugate vaccine
16420605|NCT03835962|Experimental|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
16420606|NCT03835949|Experimental|TJ004309 plus Atezolizumab|TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
16420607|NCT03835936|Active Comparator|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
16420608|NCT03835936|Experimental|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
16420609|NCT03835923|Experimental|lifestyle intervention|Telemedicine-supported lifestyle intervention trough individual structured exercise training (endurance and strength training), increase in daily physical activity, and individual nutritional recommendations
16420610|NCT03835923|Active Comparator|usual care|general exercise and nutritional recommendations according to current guidelines
16420611|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
16420612|NCT03835910|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.
~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
16420613|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
16420614|NCT03835910|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.
~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
16420615|NCT03835884|Experimental|AR-13503 Implant 10.6 Dose|Single dose of AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
16420616|NCT03835884|Experimental|AR-13503 Implant 21.2 Dose|Single dose of AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
16420617|NCT03835884|Experimental|AR-13503 Implant 42.4 Dose|Single dose of AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
16420618|NCT03835884|Experimental|AR-13503 Implant 63.6 Dose|Dose of AR-13503 Implant 63.6 Dose (63.6 µg) administered into a single eye of up to 5 subjects (DME) who will be followed for 24 weeks. Subjects may qualify to receive an additional dose at Week 12.
16422577|NCT03822351|Experimental|Arm A (durvalumab + oleclumab):|durvalumab IV and oleclumab IV
16420619|NCT03835871|Experimental|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 12 weeks
16420620|NCT03835871|Experimental|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg per day Daily dose of Beclomethasone 200 µg 1 inhalation 100 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
16420621|NCT03835871|Experimental|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg per day Daily dose of Beclomethasone 100 µg 1 inhalation 50 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
16420622|NCT03835871|Placebo Comparator|placebo|Intervention: Drug: placebo 2 inhalations 2 times a day for 12 weeks
16420623|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
16420624|NCT03835845|Experimental|PICO7Y|PICO 7Y is a single-use NPWT System consisting of a small portable pump & pump clip, 2 AA batteries, 2 large multisite dressings, 2 extension tubes and secondary fixation strips.
16420625|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
16420626|NCT03835819|Experimental|IMGN853 + Pembrolizumab|"Pembrolizumab is administered intravenously once every 3 weeks
~IMGN853 is administered intravenously once every 3 weeks"
16420627|NCT03835806|Active Comparator|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
16420628|NCT03835806|Experimental|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
16420629|NCT03835793||Early-RRSO|"RRSO before the age of 45 years
~RRSO was done 10 or more years ago"
16420630|NCT03835793||Late-/non-RRSO group|"Natural menopause ≥ 50 years of age
~No RRSO ≤ age of 55
~No treatment-induced menopause ≤ 50 years of age"
16420631|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
16420632|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
16420633|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
16420634|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
16420635|NCT03835767|Experimental|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: -All participants who eat baked milk less than once per month. -Participants who never eat baked milk or straight milk. .On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
16420636|NCT03835767|Experimental|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
16420637|NCT03835767|Experimental|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: -All participants who eat peanut less than once per month -Participants who never eat peanut. never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
16420638|NCT03835767|Experimental|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
16420639|NCT03835754|Experimental|OCS Preservation|
16420640|NCT03835741|Experimental|Automated Oxygen titration|In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
16420641|NCT03835741|Other|Manual Oxygen titration|In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff
16420644|NCT03835715|Experimental|Vortioxetine|
16420645|NCT03835702|No Intervention|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
16420646|NCT03835702|Experimental|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
16420647|NCT03835689|Experimental|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
16420648|NCT03835689|Experimental|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
16420683|NCT03835507|Experimental|Low dose group|Inject 500IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
16420649|NCT03835689|No Intervention|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
16420650|NCT03835676|Experimental|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
16420651|NCT03835663||Patients with non erosive reflux|Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
16420652|NCT03835663||Patients with erosive reflux|Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
16420653|NCT03835663||Patients with no reflux|Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
16420654|NCT03835650||PGP|Patients in early postpartum period experiencing PGP, confirmed with dedicated functional tests
16420655|NCT03835650||no PGP|Patients in early postpartum period, with no symptoms and signs of PGP
16420656|NCT03835637|Experimental|Regimen A|
16420657|NCT03835637|Experimental|Regimen B|
16420658|NCT03835637|Experimental|Regimen C|
16420659|NCT03835637|Experimental|Regimen D|
16420660|NCT03835637|Experimental|Regimen F|
16420661|NCT03835637|Experimental|Regimen H|
16420662|NCT03835637|Experimental|Regimen I|
16420663|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
16420664|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.
~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
16420665|NCT03835611|Experimental|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
16420666|NCT03835611|Active Comparator|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
16420667|NCT03835598||Patients with cardiac biological prosthesis|
16420668|NCT03835585|Experimental|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
16420669|NCT03835585|Active Comparator|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
16420670|NCT03835572|Experimental|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
16420671|NCT03835572|Active Comparator|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
16420672|NCT03835559|Active Comparator|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure for treatment of incompetent Saphenous Veins is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
16420673|NCT03835559|Active Comparator|Surgical stripping|For treatment of incompetent Saphenous Veins, surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries under all types of anesthesia (general, spinal, regional block, or local anesthesia). The saphenous vein is then removed using a stripper. Compression stocking is apply.
16420674|NCT03835546||Early treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy presenting recent HIV-1 infection. Recent HIV-1 infection was defined as having a positive plasma viral load and/or p24 antigen with a negative ELISA or having a positive ELISA and undetermined Western-Blot, or having a positive ELISA and absence of p31 antigen in a positive Western-Blot, or seroconversion ELISA in less than 3 months.
16420675|NCT03835546||Regularly treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy, did not fulfil the criteria for recent HIV-1 infection, and had an estimated time >6 months reported by the patient and/or by the responsible physician since HIV transmission.
16420676|NCT03835546||Seronegative volunteers|HIV-uninfected volunteers, matched to age, sex, and educational level with groups A and B.
16420677|NCT03835533|Experimental|Cohort A: NKTR-214 + Nivolumab|
16420678|NCT03835533|Experimental|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
16420679|NCT03835533|Experimental|Cohort C: CDX-301 + INO-5151 + Nivolumab|
16420680|NCT03835520|Experimental|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
16420681|NCT03835520|Experimental|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
16420682|NCT03835507|Placebo Comparator|Control group|Inject Normal saline 100ml * 12 times (1month apart)
16420684|NCT03835507|Experimental|High dose group|Inject 750IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
16420685|NCT03835494|Experimental|Fallot patients|Fallot patients
16420686|NCT03835494|Experimental|healthy controls|healthy volunteers
16420687|NCT03835481|Placebo Comparator|Placebo|Blinded period of Placebo until Week 12
16420688|NCT03835481|Experimental|BI 730357 Fasted Condition|Blinded period of BI 730357 until Week 12 (4 dose levels or placebo as continued from trial 1407-0030). Open label period of BI30357 from Week 12 to end of trial (2 dose levels).
16420689|NCT03835481|Experimental|BI 730357 Fed Condition|Patients entering extension trial from Part 2 of trial 1407-0030
16420690|NCT03835468|Experimental|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
16420691|NCT03835468|Placebo Comparator|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
16420692|NCT03835442|Active Comparator|baclofen arm|baclofen 10mg tid for 4 weeks
16420693|NCT03835442|Placebo Comparator|placebos arm|placebo tid for 4 weeks
16420694|NCT03835429|Experimental|MyTAP oral appliance plus mouth shield|MyTAP plus mouth shield
16420695|NCT03835416|Experimental|WL-Control|0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability.
16420696|NCT03835416|Experimental|WL-Protein|>30 g of high quality protein per meal, 1.2 g protein/kg body weight/day. Fourteen servings of high quality (30 g/serving) protein (lean meats, low fat dairy products) provided to participants each week to increase compliance.
16420697|NCT03835403|No Intervention|Usual Care (control arm)|These cardiac arrests will receive standard EMS response.
16420698|NCT03835403|Experimental|HeartRunner Activation|For these cardiac arrests, HeartRunners will be activated in addition to standard EMS response.
16420699|NCT03835390|Experimental|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
16420700|NCT03835377|Experimental|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
16420701|NCT03835377|Active Comparator|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety)
16420702|NCT03835351|Other|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
16420703|NCT03835351|No Intervention|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
16420704|NCT03835338|Experimental|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
16420705|NCT03835338|Active Comparator|Control Group|The control group will receive Pulmonary Vein Isolation
16420706|NCT03835325|Experimental|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
16420707|NCT03835312|Experimental|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
16420708|NCT03835299|No Intervention|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
16420709|NCT03835299|Experimental|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
16420710|NCT03835299|No Intervention|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
16420711|NCT03835286|Experimental|Vitamin C|Vitamin C experimental group
16420712|NCT03835286|Placebo Comparator|Control|Placebos Controlled group
16420713|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
16420714|NCT03835273||Minimally invasive surgery|Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.
16420715|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
16420716|NCT03835260|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
16420717|NCT03835221|Experimental|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
16420718|NCT03835208|Experimental|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:
~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
16420719|NCT03835208|Experimental|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.
~This means a distribution of carbohydrate as follows:
~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
16420720|NCT03835195|Experimental|Diabetes Disease Management Program|Diabetes Disease Management Program
16420721|NCT03835195|Active Comparator|Usual Care Process|Usual care process
16420722|NCT03835182|Active Comparator|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
16420924|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) < 5 injections
16420723|NCT03835182|Active Comparator|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
16420724|NCT03835182|Other|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
16420725|NCT03835117|Experimental|Wide-spectrum nutritional supplement|The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.
16420726|NCT03835117|Placebo Comparator|Placebo control|Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.
16420727|NCT03835104|Active Comparator|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).
~There will be only 1 test at study entry"
16420728|NCT03835104|Experimental|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).
~There will be only 1 test at study entry"
16420729|NCT03835091||Patient with mechanical ventilation and sedation|All patient hospitalized in intensive care under sedation and mechanical ventilation without neurologic disorder
16420730|NCT03835078|Experimental|methalfilcon A contact lenses / fanfilcon A contact lenses|All subjects will first wear methafilcon A contact lenses for four (4) weeks of daily wear, then be refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
16420731|NCT03835065|Active Comparator|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
16420732|NCT03835065|Experimental|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
16420733|NCT03835039||HIE|Infants with a diagnosis of HIE
16420734|NCT03835013|Placebo Comparator|Part A - Infusion A|"60 minute intravenous infusion of 0.9% saline
~Followed by:
~60 minute intravenous infusion of 0.9% saline"
16420735|NCT03835013|Active Comparator|Part A - Infusion B|"60 minute intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min and 0.9% saline.
~Followed by:
~60 minute infusion of GLP-1 7-36 amide 1.2pmol/kg/min and 0.9% saline"
16420736|NCT03835013|Active Comparator|Part A - Infusion C|"60 minute intravenous infusion of glucagon 25ng/kg/min and 0.9% saline.
~Followed by:
~60 minute infusion of glucagon 50ng/kg/min and 0.9% saline"
16420737|NCT03835013|Active Comparator|Part A - Infusion D|"60 minute intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min and glucagon 25ng/kg/min.
~Followed by:
~60 minute infusion of GLP-1 7-36 amide 0.6pmol/kg/min and glucagon 50ng/kg/min"
16420738|NCT03835013|Active Comparator|Part A - Infusion E|"60 minute intravenous infusion of GLP-1 7-36 amide 1.2pmol/kg/min and glucagon 25ng/kg/min.
~Followed by:
~60 minute infusion of GLP-1 7-36 amide 1.2pmol/kg/min and glucagon 50ng/kg/min."
16420739|NCT03835013|Active Comparator|Part B - Infusion A|A 60 minute intravenous infusion of 0.9% saline
16420740|NCT03835013|Active Comparator|Part B - Infusion B|A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes followed by 25ng/min) and 0.9% saline
16420741|NCT03835013|Active Comparator|Part B - Infusion C|A 60 minute intravenous infusion of glucagon (25ng/kg/min) and 0.9% saline
16420742|NCT03835013|Active Comparator|Part B - Infusion D|A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes then 25ng/min) and glucagon (25ng/kg/min)
16420743|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
16420744|NCT03834974|Experimental|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
16420745|NCT03834974|Active Comparator|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
16475964|NCT03457870|Experimental|Chewing|Mastication intervention: chewing
16420747|NCT03834948|Experimental|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
16420748|NCT03834948|Experimental|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
16420749|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
16420750|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
16420751|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
16420752|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + pembrolizumab.
16420753|NCT03834935|Experimental|Pim|20 patients receiving topical Elidel (pimecrolimus 1%) bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
16420754|NCT03834935|Placebo Comparator|Pl|20 patients receiving placebo (control group), cold cream bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
16420755|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
16420756|NCT03834922||Sternotomy|Patients undergoing sternotomy
16420757|NCT03834922||Breast|Patients undergoing breast surgery
16420758|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
16420759|NCT03834909|Active Comparator|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
16420760|NCT03834909|Experimental|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
16420761|NCT03834896|Experimental|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
16420762|NCT03834883|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
16420763|NCT03834883|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
16420764|NCT03834883|Experimental|Premenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
16420765|NCT03834883|Placebo Comparator|Premenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
16420766|NCT03834870|Experimental|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
16420767|NCT03834857|Other|single|Implantation of Stentrode TM device
16420768|NCT03834844|No Intervention|Usual Care|patient receives same care as patients not enrolled in study intervention
16420769|NCT03834844|Experimental|AF education|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week.
16420770|NCT03834844|Experimental|Mindfulness Meditation Practice|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
16420771|NCT03834844|Experimental|Weekly Phone Calls|Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
16420772|NCT03834844|Experimental|AF Education and Mindfulness Meditation|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
16420773|NCT03834844|Experimental|AF Education and Weekly Phone Calls|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
16420774|NCT03834844|Experimental|Mindfulness Meditation and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
16420775|NCT03834844|Experimental|Meditation and Education and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
16420776|NCT03834831|Active Comparator|Coenzyme Q10|Coenzyme Q10 200mg/day for 3 months
16420777|NCT03834831|Active Comparator|Selenium|Selenium mcg/day for 3 months
16420811|NCT03834558|Experimental|Intervention Group|They will perform the mixed exercise program
16420778|NCT03834818|Experimental|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
16420779|NCT03834805|Experimental|Pregnant women with a normal pregnancy|Assesment of fetal lung and liver stiffness with 2D Ultrasounds Shear Wave Elastography
16420780|NCT03834779|Other|DOORS-CHW Intervention|"The type of intervention is behavioral.
~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
16420781|NCT03834779|No Intervention|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
16420782|NCT03834766|Active Comparator|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
16420783|NCT03834766|Placebo Comparator|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
16420784|NCT03834753|Experimental|bevacizumab|ONS-5010
16420785|NCT03834753|Active Comparator|ranibizumab|
16420786|NCT03834740|Experimental|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:
~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
16420787|NCT03834740|Experimental|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:
~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
16420788|NCT03834740|Experimental|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:
~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
16420789|NCT03834714|Active Comparator|Noise Stimulus and Infrared Light|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive infrared light therapy for 2 out of the 4 visits and sham infrared light therapy for the other 2 visits.
16420790|NCT03834714|Sham Comparator|Noise Stimulus and Sham|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive sham infrared light therapy for 2 out of the 4 visits and infrared light therapy for the other 2 visits.
16420791|NCT03834701|Experimental|EUS guided radiofrequency ablation|Radiofrequency ablation will be performed using a system that consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure.
16420792|NCT03834688|Experimental|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
16420793|NCT03834662|Experimental|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
16420794|NCT03834662|Experimental|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
16420795|NCT03834662|Experimental|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
16420796|NCT03834649|Active Comparator|Mucograft|Soft tissue augmentation of the defective alveolar ridge using Mucograft inside the prepared vestibular pouch leaving part of the mucograft exposed at the crestal area and will be sutured using 5/0 suture material around the defect margin and secured in the vestibular pouch.
16420797|NCT03834649|Experimental|Partially de-epithelialized connective tissue graft|Soft tissue augmentation of the defective alveolar ridge using Partially de-epithelialized connective tissue graft by preparing vestibular pouch at the defect site and place the de-epithelialized part inside the pouch leaving the epithelialized part sutured and exposed at the crestal area
16420798|NCT03834636|Active Comparator|Nanoparticulated composite - self-etch|
16420799|NCT03834636|Active Comparator|Nanoparticulated composite - total-etch|
16420800|NCT03834636|Active Comparator|Nanohybrid composite - self-etch|
16420801|NCT03834636|Active Comparator|Nanohybrid composite - total-etch|
16420802|NCT03834623|Experimental|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
16420803|NCT03834610|Active Comparator|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
16420804|NCT03834610|Active Comparator|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
16420805|NCT03834610|Active Comparator|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
16420806|NCT03834610|Placebo Comparator|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
16420807|NCT03834584|Experimental|AG-636|AG-636 dosed orally.
16420808|NCT03834571|Experimental|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.
~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
16420809|NCT03834571|Active Comparator|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.
~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
16420810|NCT03834558|No Intervention|Control Group|They will follow their daily routine without added exercise
16476051|NCT03457233|Active Comparator|Overweight|BMI 25-29.9 kg/m2
16420812|NCT03834545||cycling group|They attended three sessions of exercise on three different conditions : a classic ergometric bicycle without chairback, an ergometric bicycle with chairback with virtual environment and the other session without virtual environment
16420813|NCT03834532|Experimental|Intervention|Participants randomized to the intervention group will receive a breast reconstruction decision aid. Participants will be provided instructions on how to access and navigate the decision aid. Participants will access the decision aid through a website link that is emailed to them or on a tablet at the study site.
16420814|NCT03834532|Active Comparator|Control|Participants randomized to the control group will receive two website pages on healthy living with breast cancer from an educational website. Participants will be provided instructions on how to access and navigate the website pages. Participants will access the website pages through a link that is emailed to them or on a tablet at the study site.
16420815|NCT03834519|Experimental|Pembrolizumab + Olaparib|Participants receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).
16420816|NCT03834519|Active Comparator|Abiraterone + Prednisone or Enzalutamide|Participants receive abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone 10 mg as one 5 mg tablet BID until progression OR Participants receive enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.
16420817|NCT03834506|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
16420818|NCT03834506|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).
~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
16420819|NCT03834493|Experimental|Pembrolizumab + Enzalutamide|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.
16420820|NCT03834493|Placebo Comparator|Placebo + Enzalutamide|Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.
16420821|NCT03834480|Experimental|• Steroid Group (S)|
16420822|NCT03834480|Experimental|• Platelet rich plasma Group (PRP)|
16420823|NCT03834467|Experimental|Arm 1 - Elevation Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 1 then presents the Moral Elevation stimulus video after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
16420824|NCT03834467|Sham Comparator|Arm 2 - Control Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 2 then presents the control stimulus (nature video) after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
16420825|NCT03834454|Active Comparator|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
16420826|NCT03834454|Active Comparator|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
16420827|NCT03834441|Other|Oral screening|
16420828|NCT03834441|Other|Written screening|
16420829|NCT03834428|Active Comparator|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
16420830|NCT03834428|Experimental|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
16420831|NCT03834415|Experimental|Lactobacillus reuteri DSM17038|Lactobacillus reuteri DSM17038, 1x108 CFU once a day for 30 days
16420832|NCT03834415|Placebo Comparator|Placebo probiotics|Placebo for probiotics, pols drops similar in consistency and flavor as experimental product
16420833|NCT03834389|Experimental|Experimental Group|Experimental group: case-based teaching method applied
16420834|NCT03834389|No Intervention|Control Group|Control group: classical teaching method applied
16420835|NCT03834363|Active Comparator|Morphine capsules and Placebo patch|Morphine retard 10 mg twice daily Placebo patch, change every three days.
16420836|NCT03834363|Experimental|Placebo capsules and Fentanyl patch|Placebo capsules twice daily Fentanyl patch 12 mcg/hr, change every three days
16420837|NCT03834363|Placebo Comparator|Placebo capsules and Placebo patch|Placebo capsules twice daily Placebo patch, change every three days
16420839|NCT03834324|Experimental|intervention|FES
16420840|NCT03834311|Experimental|isokinetic|
16420841|NCT03834311|Active Comparator|exercise band|
16420889|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
16421545|NCT03829631|No Intervention|Control|Participants will be instructed to follow their current low back pain management program.
16420842|NCT03834298|Experimental|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
16420843|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
16420844|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
16420845|NCT03834272|Experimental|1st Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
16420846|NCT03834272|Experimental|2nd Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.5 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
16420847|NCT03834272|Experimental|3rd Tier Dose Level- LUM Imaging System|12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
16420848|NCT03834259|Active Comparator|Group 1|12.5 mg 0.5% hyperbaric bupivacaine
16420849|NCT03834259|Active Comparator|Group 2|10 mg 0.5% hyperbaric bupivacaine
16420850|NCT03834259|Active Comparator|Group 3|12.5 mg 0.5% hyperbaric bupivacaine
16420851|NCT03834233|Experimental|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
16420853|NCT03834207|Experimental|Intervention Group|Use of the C3-Cloud IT system
16420854|NCT03834194|Experimental|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
16420855|NCT03834194|Experimental|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
16420856|NCT03834194|Experimental|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
16420857|NCT03834194|Experimental|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
16420858|NCT03834194|Experimental|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
16420859|NCT03834194|Experimental|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
16420860|NCT03834194|Experimental|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
16420921|NCT03833869|No Intervention|Control|Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
16420922|NCT03833843||TGA|
16476052|NCT03457233|Active Comparator|Obese|BMI ≥ 30 kg/m2
16420861|NCT03834194|Experimental|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
16420862|NCT03834181|Experimental|Monitoring evaluation|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"
16420863|NCT03834168|Other|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
16420864|NCT03834155|Experimental|Hospital-based CR + Mobile Application|Traditional hospital-based cardiac rehabilitation with mobile application.
16420865|NCT03834155|Experimental|Choice CR + Mobile Application|Choice of hospital or home-based cardiac rehabilitation with mobile application.
16420866|NCT03834155|Experimental|Hospital-based CR + Mobile Application + Nudge|Hospital-based cardiac rehabilitation with mobile application and nudges.
16420867|NCT03834155|Experimental|Choice CR + Mobile Application + Nudges|Choice of Hospital or home-based cardiac rehabilitation with mobile application and nudges.
16420868|NCT03834142|Experimental|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
16420869|NCT03834142|No Intervention|Control|No intervention, subject receives standard of care
16420870|NCT03834129|Experimental|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
16420871|NCT03834129|Placebo Comparator|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
16420872|NCT03834116|Experimental|Inspiratory muscle training group|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
16420873|NCT03834116|No Intervention|Control group|The control group will receive standard treatment in a fast-track design.
16420874|NCT03834103|Other|Arm 1: Self-rehabilitation arm|Self-rehabilitation arm
16420875|NCT03834090|Experimental|rESWT|the group receiving rESWT
16420876|NCT03834090|Active Comparator|supervised exercises|the group receiving supervised exercises
16420877|NCT03834077|Experimental|Tissue flossing|Conventional physiotherapy consisted in electrotherapy and stretching in addition to tissue flossing.
16420878|NCT03834077|Placebo Comparator|Placebo comparator|Conventional physiotherapy consisted in electrotherapy and stretching in addition with tissue flossing without tension.
16420879|NCT03834064|Experimental|Intervention|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the intervention arm. Caregivers working in that home will receive the oral health promotion strategy/intervention over the course of a year.
16420880|NCT03834064|No Intervention|Control|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the control arm. Caregivers in that home will not receive the oral health promotion strategy/intervention over the course of a year but will be offered a compressed intervention after a year.
16420881|NCT03834051|Experimental|Open Label|Fecal Microbiota Transplantation
16420882|NCT03834038|Experimental|Open Label Lyophilized Fecal Microbiota Transplantation|Eligible participants with history of recurrent or refractory CDI
16420883|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
16420884|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
16420885|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
16420886|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
16420887|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
16420888|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
16420923|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) >20 injections
16421582|NCT03829345|Experimental|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
16420890|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
16420891|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
16420892|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
16420893|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
16420894|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
16420895|NCT03834012|Experimental|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
16420896|NCT03834012|Active Comparator|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
16420897|NCT03834012|Placebo Comparator|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
16420898|NCT03834012|Experimental|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
16420899|NCT03833999|Experimental|Ondansetron and lactulose|Ondansetron 8mg three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
16420900|NCT03833999|Placebo Comparator|Placebo and lactulose|placebo oral capsule, one three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
16420901|NCT03833986|Experimental|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
16420902|NCT03833986|No Intervention|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
16420903|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
16420904|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
16420905|NCT03833960||1-cN0/pN0|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was ypN0.
16420906|NCT03833960||2-cN+/pN0|Patients with initially clinically involved axilla (cN1-2), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was complete axillary remission (ypN0).
16420907|NCT03833960||3-cN0/pN+|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within SLNB was done, followed by ALND because of positive pathological report of sentinel node(s).
16420908|NCT03833960||4-cN+/pN+|Patients with initially clinically positive axilla (cN1-3) submitted to neoadjuvant treatment, followed by surgical procedure within ALND was done and the final pathological report was ypN1-3.
16420909|NCT03833947|Experimental|lignocaine with bicarbonate|Endotracheal tube cuff was filled with mixture of 7.5% sodium bicarbonate with 2% lignocaine in a ratio of 0.5:9.5 ml
16420910|NCT03833947|Active Comparator|lignocaine with dexamethasone|Endotracheal tube cuff was filled with mixture of dexamethasone with 2% lignocaine in a ratio of 0.5:9.5 ml
16420911|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
16420912|NCT03833921|Other|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
16420913|NCT03833908|Experimental|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
16420914|NCT03833908|No Intervention|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
16420915|NCT03833895|Experimental|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
16420916|NCT03833895|Experimental|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
16420917|NCT03833895|Placebo Comparator|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
16420918|NCT03833882|Experimental|MAF1217/Cationorm|
16420919|NCT03833882|Experimental|Cationorm/MAF1217|
16420920|NCT03833869|Experimental|Assisted hatching|Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
16420925|NCT03833817|Experimental|Intervention arm|This study is a single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
16420926|NCT03833804|Experimental|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
16420927|NCT03833791|Active Comparator|Control Group (CON)|education and modifying diet
16420928|NCT03833791|Experimental|Moderate physical activity Group (PAM)|education, modifying diet and physical activity prescription
16420929|NCT03833791|Experimental|Intensity physical activity Group (PAI)|education, modifying diet and physical activity prescription
16420930|NCT03833778|Other|Intervention group|Answering disease related questions during playing a tablet game
16420931|NCT03833778|No Intervention|control group|
16420932|NCT03833765|Experimental|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
16420933|NCT03833765|Active Comparator|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
16420934|NCT03833752|Experimental|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
16420935|NCT03833752|Active Comparator|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
16420936|NCT03833739|Experimental|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.
~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
16420937|NCT03833739|Experimental|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.
~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
16420938|NCT03833726|Experimental|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
16420939|NCT03833726|Sham Comparator|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
16420940|NCT03833713|Experimental|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
16420941|NCT03833713|Active Comparator|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
16420944|NCT03833687|Experimental|Profhilo®|"The 1st treatment was performed during the basal visit and repeated after 1 month.
~3 mL of Profhilo® for each brachial zone, 1.5 mL for hemiabdomen was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 horizontal-levels for each tested areas (3-4-3 injection points respectively for the 1st, the 2nd and the 3rd horizontal-level). The amount of product to be injected was of 0.3 ml for each point."
16420945|NCT03833674|Experimental|Adults with incomplete SCI|Adults with chronic, incomplete SCI who have >20% impairment in respiratory function, who will complete a battery of clinical assessments and 4 randomly ordered intervention and testing blocks (Daily AIH Block, Sham dAIH Block, Respiratory Strength Training Block and AIH + Strength Training Block).
16420946|NCT03833661|Experimental|M7824|
16421669|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
16420947|NCT03833648|No Intervention|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
16420948|NCT03833648|Experimental|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
16420949|NCT03833635|Experimental|OMT|
16420950|NCT03833635|Placebo Comparator|Control|
16420951|NCT03833622|Experimental|Shared decision aid assessment|Patients will be selected to have a goals of care discussion with an emergency physician utilizing a pilot decision aid and will be asked for feedback to assist with refinement of the decision aid.
16420952|NCT03833609|Experimental|Online yoga training (Group A)|Participants will receive an e-pamphlet on physical exercise developed by The Arthritis Society, and will be invited to complete a yoga training program. The yoga training program is a structured low-intensity Vishwas-Raj. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
16420953|NCT03833609|Experimental|Online aerobic dance training (Group B)|Participants will receive the e-pamphlet on physical exercise and will be invited to complete an aerobic dance program. The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
16420954|NCT03833609|No Intervention|Wait list control (Group C)|Participants will receive the e-pamphlet on physical exercise and will be instructed to continue with their current medical care while they are on the wait list (12 weeks). After the completion of the study, the yoga and aerobic dance training videos will be available to all participants including those in the control group. In recruitment documents, this group will be termed the e-pamphlet group.
16420955|NCT03833596|Active Comparator|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
16420956|NCT03833596|Experimental|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
16420957|NCT03833596|Experimental|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
16420958|NCT03833583|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
16420959|NCT03833583|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
16420960|NCT03833570|Experimental|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment
~Symptomatic treatment which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks
~Symptomatic treatment dose: Three times a day for six weeks"
16420961|NCT03833570|Active Comparator|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Dose: Three times a day for six weeks"
16420962|NCT03833557|Active Comparator|Nanohydroxyapatite Pulpotomy|"Biphasic calcium phosphate. Straumann BoneCeramic Regenerative Pulpotomy of 24 mandibular second primary molars using Nanohydroxyapatite
~In Group 1: 24 mandibular second primary molars Caries removal and deroofing of pulp chamber Following the manufacturer's instructions, Nanohydroxyapatite was mixed with distilled water to homogeneous consistency then introduced into the pulp chamber and condensed properly against the pulp orifices.
~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.
~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy"
16420963|NCT03833557|Active Comparator|MTA Pulpotomy|"Angelus Grey MTA , Regenerative Pulpotomy Pulpotomy of 24 mandibular second primary molars using MTA Caries removal and deroofing of pulp chamber The MTA powder was mixed with sterile water in a 3:1 powder/water ratio according to the manufacturer's instructions to obtain a thick creamy paste, then placed on the floor of the pulp chamber using a messing gun and compacted against the pulp orifices with a condenser over a moist cotton pellet.
~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.
~Clinical and radiographic evaluation at one, three ,six & 12 months after pulpotomy."
16420964|NCT03833557|Active Comparator|Formocresl Pulpotomy|"Buckley' s Formocresol , Fixation pulpotomy Pulpotomy of 24 mandibular second primary molars using Formocresol Caries removal and deroofing of pulp chamber
~A cotton pellet with formocresol was placed on the pulp stumps then removed and ZO/E dressing was condensed against the pulp stumps.
~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.
~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy for clinical and radiographic evaluation. Independently, two examiners evaluated the teeth clinically and radiographically."
16420965|NCT03833544|Experimental|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
16420966|NCT03833531|Active Comparator|PTSD-ImRS|PTSD treatment
16420967|NCT03833531|Experimental|Integrated SFT-ImRS|Integrated PTSD-PD treatment
16420968|NCT03833518|Experimental|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
16420969|NCT03833505||Group 1,|E. vermicularis-positive
16420970|NCT03833505||Group 2|E. vermicularis-negative
16420971|NCT03833492|Experimental|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
16420972|NCT03833492|No Intervention|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
16420973|NCT03833479|Experimental|No further treatment|No further treatment
16420974|NCT03833479|Experimental|TSR-042|TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted).
16420975|NCT03833466|Experimental|metformin and chemotherapy|
16420976|NCT03833453|Active Comparator|PTSD-EMDR|PTSD treatment
16420977|NCT03833453|Experimental|Integrated DBT-EMDR|Integrated PTSD-PD-treatment
16420978|NCT03833440|Experimental|Durvalumab + Monalizumab|
16420979|NCT03833440|Experimental|Durvalumab + MEDI9447|
16420980|NCT03833440|Experimental|Durvalumab + AZD6738|
16420981|NCT03833440|Active Comparator|Docetaxel|
16420982|NCT03833427|Experimental|Selumetinib at Dose Level 1 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; every three weeks [Q3W]) in combination with selumetinib at dose level 1 (dosed orally; twice daily [BID]) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420983|NCT03833427|Experimental|Selumetinib at Dose Level 2 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 2 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420984|NCT03833427|Experimental|Selumetinib at Dose Level 3 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 3 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420985|NCT03833427|Experimental|Selumetinib at Dose Level 4 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 4 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420986|NCT03833427|Experimental|Selumetinib at Dose Level 5 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 5 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420987|NCT03833427|Experimental|Selumetinib at Dose Level 6 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 6 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420988|NCT03833427|Experimental|Selumetinib at Dose Level 7 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 7 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
16420989|NCT03833414||(Group1)|Triceps lifting approach .
16420990|NCT03833414||(Group 2)|olecranon osteotomy approach
16420991|NCT03833401|Sham Comparator|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation. This will serve as control group.
16420992|NCT03833401|Experimental|Autologous tissue transplantation|Root canal disinfection will be performed and revascularization will be induced with autologous tissue transplantation.
16420993|NCT03833388|Experimental|TOP1630 Ophthalmic Solution|
16420994|NCT03833388|Placebo Comparator|Placebo to TOP1630 Ophthalmic Solution|
16420995|NCT03833375|No Intervention|Usual Care (n=20)|Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
16420996|NCT03833375|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
16420997|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally
~Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
16420998|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally
~Placebo Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
16420999|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally
~Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
16421800|NCT03827720|Experimental|Intracranial Hemorrhage|Intracranial hemorrhage patients monitored with Sense Device
16421000|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally
~Placebo Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
16421001|NCT03833349|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16421002|NCT03833349|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16421003|NCT03833349|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16421004|NCT03833336|Placebo Comparator|Placebo|normal saline solution plus oral lactose capsules
16421005|NCT03833336|Active Comparator|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
16421006|NCT03833336|Active Comparator|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
16421007|NCT03833336|Active Comparator|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
16421008|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
16421009|NCT03833284|Experimental|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
16421010|NCT03833284|Experimental|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
16421011|NCT03833271|Active Comparator|TNF-alpha inhibitor|
16421012|NCT03833271|Active Comparator|Methotrexate|
16421013|NCT03833271|Active Comparator|Healthy|
16421014|NCT03833258|No Intervention|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
16421015|NCT03833258|Experimental|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
16421016|NCT03833245|No Intervention|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
16421017|NCT03833245|Experimental|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
16421018|NCT03833232|Experimental|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
16421019|NCT03833232|No Intervention|gastrectomy without omentopexy|Gastric section without omentopexy
16421020|NCT03833219|No Intervention|Control (monitor only)|Continue in monitoring only mode
16421021|NCT03833219|Experimental|Social comparison feedback|Report user's handheld phone use/ hour of driving for week. Compare this week's performance to distribution for driver cohort.
16421022|NCT03833219|Experimental|End of rating period incentive|Monitor throughout intervention period and compare overall use to distribution for cohort. Notify participant at end of intervention period regarding the amount they have earned.
16421023|NCT03833219|Experimental|End of rating period incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant at end of intervention period regarding the amount they have earned.
16421024|NCT03833219|Experimental|Weekly loss-framed incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned.
16421025|NCT03833219|Experimental|Larger weekly loss-framed incentive+social comparison feedback|"Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned. Incentive amount is higher than Weekly loss-framed incentive + social comparison feedback Arm."
16421026|NCT03833206|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
16421027|NCT03833206|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
16421028|NCT03833193|Experimental|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
16421034|NCT03833154|Experimental|SoC SBRT + Durvalumab Therapy|"SBRT - delivered in 3, 4, 5 or 8 fractions.
~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met."
16421035|NCT03833154|Placebo Comparator|SoC SBRT + Placebo Therapy|"SBRT - delivered in 3, 4, 5 or 8 fractions.
~Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met."
16421036|NCT03833128|Experimental|Group 1 - Part A|REN001 Low Dose oral once daily x 12 weeks
16421037|NCT03833128|Experimental|Group 2 - Part A|REN001 High Dose oral once daily x 12 weeks
16421038|NCT03833128|Experimental|Group 3 - Part B|REN001 High Dose oral once daily x 12 weeks
16421039|NCT03833115|Experimental|vaginal gel containing sodium lauryl sulfate|
16421040|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
16421041|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:
~Severe patients
~Non-severe patients"
16421042|NCT03833089|No Intervention|Control|ICD recipients in optimal Medical treatment as per guidelines according to their comorbidity
16421043|NCT03833089|Experimental|Targeted serum potassium levels|ICD recipients recipients in optimal Medical treatment as per guidelines according to their comorbidity. In addition to guideline recommended treatment, this cohort will be treated to increase serum potassium levels to 4.5-5.0 mEq/L.
16421044|NCT03833076|Experimental|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.
~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
16421045|NCT03833076|Placebo Comparator|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.
~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
16421046|NCT03833063|Placebo Comparator|placebo|injections with sodium chloride
16421047|NCT03833063|Active Comparator|botulinum toxin A|injections with botulinum toxin A
16421048|NCT03833050||Heart Transplant Recipients|"Heart Transplant Recipients meeting the criteria for enrollment and consented will be followed post transplant for 1 year after enrollment into the study.
~Blood samples will be obtained at their 1, 3, 6, 12 months and any for cause heart biopsy's obtained. There will be no active intervention for recipients that are enrolled. Results from the samples will not be obtained in real time."
16421049|NCT03833024|Active Comparator|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
16421050|NCT03833024|Placebo Comparator|Placebo|"Placebo for 6 months
~1 Tablet, BID (morning and evening) for 6 months"
16421051|NCT03833011|No Intervention|no intervention|
16421052|NCT03833011|Experimental|Osteopathic manipulation|
16421053|NCT03832998|Experimental|Dose Level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
16421054|NCT03832998|Experimental|Dose Level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
16421055|NCT03832998|Placebo Comparator|Placebo|
16421056|NCT03832985|Experimental|Receive an adult-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
16421057|NCT03832985|Experimental|Receive a pediatric-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
16421058|NCT03832985|Active Comparator|Control - No result|Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
16421059|NCT03832972||Women using birth control|
16421060|NCT03832972||Women not using birthcontrol|
16421061|NCT03832959|No Intervention|Non esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.
16421062|NCT03832959|Experimental|Esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM
16421063|NCT03832946|Experimental|A. GB0139 3 mg once a day|Inhalation of GB0139
16421064|NCT03832946|Placebo Comparator|B. Placebo once a day|Inhalation of Placebo
16421065|NCT03832933|Experimental|High Protein Diet|
16421066|NCT03832933|Active Comparator|Standard Protein Diet|
16421067|NCT03832907|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.
~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
16421068|NCT03832894|Active Comparator|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.
~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
16421069|NCT03832894|Placebo Comparator|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
16421070|NCT03832868|Experimental|Pre-visit decision aid|Patients receiving the decision aid pre-visit will be given a paper copy of the decision aid in the waiting room and will have a minimum of 15 minutes to review it - either in the waiting room or in the exam room while waiting for the electrophysiologist.
16421071|NCT03832868|Experimental|Post-visit decision aid|Patients receiving the decision aid after the encounter will meet with the electrophysiologist first and receive the aid afterward.
16421072|NCT03832855|Experimental|Treatment|4 mg pING-hHER3FL ID or IM
16421073|NCT03832829|Experimental|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
16421074|NCT03832816|Placebo Comparator|Placebo|Distilled Water
16421075|NCT03832816|Experimental|Vaporized THC alone|5mg pure THC
16421076|NCT03832816|Experimental|Vaporized low CBD alone|50mg pure CBD
16421077|NCT03832816|Experimental|Vaporized medium CBD alone|100mg pure CBD
16421078|NCT03832816|Experimental|Vaporized high CBD alone|200mg pure CBD
16421079|NCT03832816|Experimental|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
16421080|NCT03832816|Experimental|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
16421081|NCT03832816|Experimental|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
16421082|NCT03832803|Experimental|Empty Bladder|Empty bladder prior to treatment.
16421083|NCT03832803|Other|Full Bladder|Conventional drinking protocol - 200ml water prior to treatment.
16421084|NCT03832790||adolescents with type 1 diabetes|Adolescents ages 14-19 with type 1 diabetes
16421085|NCT03832777|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
16421086|NCT03832777|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
16421087|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
16421088|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
16421089|NCT03832751|Experimental|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
16421090|NCT03832751|Active Comparator|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
16421091|NCT03832738|Experimental|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
16421092|NCT03832738|Experimental|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
16421093|NCT03832738|Placebo Comparator|Placebo|Placebo Tablets daily for 16 weeks.
16421094|NCT03832725|Active Comparator|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
16421095|NCT03832725|Active Comparator|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
16421096|NCT03832712|Active Comparator|Surgical|Participants randomized to surgery
16421097|NCT03832712|Active Comparator|Medical|Participants randomized to best medical treatment
16421098|NCT03832699|Experimental|Oral progesterone|
16421099|NCT03832699|Active Comparator|Vaginal progesterone|
16421100|NCT03832686|Experimental|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
16421130|NCT03832465|Experimental|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
16421101|NCT03832686|No Intervention|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
16421102|NCT03832673|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
16421103|NCT03832660|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
16421104|NCT03832660|Active Comparator|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
16421105|NCT03832660|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
16421108|NCT03832634|Other|Fetal Genome Profiling|Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.
16421109|NCT03832621|Experimental|temozolomide + nivolumab + ipilimumab|Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
16421110|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
16421111|NCT03832595|Active Comparator|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
16421112|NCT03832595|Experimental|Intervention Arm|Patients will receive a care bundle
16421113|NCT03832582|Experimental|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
16421114|NCT03832569|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
16421115|NCT03832556|Experimental|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.
~CT scan with biphasic injection of contrast product;
~MRI with injection of contrast."
16421116|NCT03832530|Experimental|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
16421117|NCT03832517|Active Comparator|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
16421118|NCT03832517|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
16421119|NCT03832517|Active Comparator|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
16421120|NCT03832517|Placebo Comparator|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
16421121|NCT03832504|Experimental|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
16421122|NCT03832504|Experimental|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
16421123|NCT03832504|Experimental|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
16421124|NCT03832504|Experimental|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
16421125|NCT03832504|Experimental|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
16421126|NCT03832504|Experimental|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
16421127|NCT03832491|Other|Control Group|"Home Based Therapy: 16 patients with PCD
~Airway clearence techniques, everday of the week, during eight weeks"
16421128|NCT03832491|Experimental|Game and home based therapy group|"Game based approach programme: 16 patients with PCD
~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.
~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.
~Airway clearence techniques, everday of the week, during eight weeks"
16421129|NCT03832478|Experimental|Virtual Reality Headset Given|Virtual Reality headset (Samsung Gear VR) with mindfulness meditation app is given for patient use prior to surgery date and for duration of postoperative stay.
16422578|NCT03822351|Experimental|Arm B (durvalumab + monalizumab)|durvalumab IV and monalizumab IV
16421131|NCT03832465|Active Comparator|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
16421132|NCT03832452|Experimental|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
16421133|NCT03832452|Placebo Comparator|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
16421134|NCT03832452|Active Comparator|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
16421135|NCT03832452|Experimental|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
16421136|NCT03832452|Experimental|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
16421137|NCT03832452|Placebo Comparator|Part B: Treatment D|A single oral dose of placebo
16421138|NCT03832439|Active Comparator|Probiotic|This arm will be receiving probiotic supplements.
16421139|NCT03832439|Placebo Comparator|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
16421140|NCT03832426|Experimental|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
16421141|NCT03832426|Experimental|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
16421142|NCT03832426|Experimental|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
16421143|NCT03832426|Experimental|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
16421144|NCT03832413||Stroke|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421145|NCT03832413||TBI|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421146|NCT03832413||ABD|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421147|NCT03832413||Fibromyalgia|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421148|NCT03832413||PDD|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421149|NCT03832413||ADHD|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421150|NCT03832413||MCI|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421151|NCT03832413||Dementia|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421152|NCT03832413||Healthy|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421153|NCT03832413||Cognitive impairment|Diagnostic Test: DELPhI (TMS-EEG analysis)
16421154|NCT03832400|Experimental|MET-2 20 g|Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily
16421155|NCT03832400|Experimental|MET-2 40 g|Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily
16421156|NCT03832400|Placebo Comparator|Placebo oral capsule|Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules
16421157|NCT03832387|Experimental|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.
~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
16421158|NCT03832387|Active Comparator|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.
~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
16421159|NCT03832361|Experimental|IMGN853|IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
16421160|NCT03832348|Experimental|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
16421161|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
16421162|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
16421163|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
16421164|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
16421165|NCT03832309|Active Comparator|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
16421232|NCT03831867|Experimental|Pilates|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
16421166|NCT03832309|Other|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
16421167|NCT03832296|Experimental|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
16421168|NCT03832296|Active Comparator|Health Education (Attention Control)|Health Education Intervention
16421169|NCT03832283|Other|Usual Care Depression Screening|Patients randomized to this intervention arm will receive usual care annual depression screening when they come in for a clinic visit and are due for screening. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression screening. The CAD-MDD/CAT-DI screening during clinic visit will occur in a patient room, prior to their appointment with a primary care provider.
16421170|NCT03832283|Experimental|Population MyChart Depression Screening|Patients randomized to this intervention arm will continue to receive usual care annual depression screening when they come in for a clinic visit and are due for screening. In addition, they will receive email invitations to complete the CAD-MDD/CAT-DI screening via MyChart. Email invitations will be sent at preset intervals until depression screening is completed, or the end of the 1-year follow-up period, whichever comes first.
16421171|NCT03832283|Other|Usual Care Depression Monitoring|Patients who have depression and are randomized to this intervention arm will receive usual care PHQ-9 monitoring during clinic visits. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression assessment.
16421172|NCT03832283|Experimental|Population MyChart Depression Monitoring|Patients who have depression and are randomized to this intervention arm will continue to receive usual care depression monitoring when they come for clinic visits. In addition, they will receive email invitations at preset intervals to complete the CAT-DI monitoring via MyChart. Invitations will be sent until major depressive disorder (MDD) remission is achieved, or the 1-year follow-up period ends, whichever comes first.
16421173|NCT03832270|Experimental|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
16421174|NCT03832270|Active Comparator|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
16421175|NCT03832257|Experimental|ECHO CT Intervention|Weekly video conference between hospitalist at Beth Israel and skilled nursing facilities.
16421176|NCT03832257|Other|Matched Non- Participating Facilities|Matched non-participating facilities
16421177|NCT03832244||Simple snoring|Patients undergoing to Sub-mental ultrasonography with Normal sleep: Fewer than 5 events per hour measured in over-night polysomnography
16421178|NCT03832244||Mild OSA|Patients undergoing to Sub-mental ultrasonography with Mild sleep apnea: 5 to 14 events per hour measured in over-night polysomnography
16421179|NCT03832244||Moderate OSA|Patients undergoing to Sub-mental ultrasonography with Moderate sleep apnea: 15 to 29 events per hour measured in over-night polysomnography
16421180|NCT03832244||Severe OSA|Patients undergoing to Sub-mental ultrasonography with Severe sleep apnea: 30 or more events per hour measured in over-night polysomnography
16421181|NCT03832231|Experimental|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
16421182|NCT03832218|Other|Mitochondrial disease|Psychiatric assessment
16421183|NCT03832205||Capaciflector monitoring group|Patients undergoing their pre-planned, routine cardiopulmonary exercise test (CPET). Additional, non-invasive capaciflector monitoring only - no therapeutic intervention.
16421184|NCT03832192|Experimental|care.coach Avatar|
16421185|NCT03832192|No Intervention|Control|
16421186|NCT03832179|Active Comparator|Anti-vascular endothelial growth factor|Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
16421187|NCT03832179|Experimental|Ozurdex|Intravitreal Ozurdex
16421188|NCT03832166|Experimental|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F & V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 18 weeks with minimal contact
16421189|NCT03832166|Experimental|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
16421190|NCT03832153||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
16421191|NCT03832153||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
16421192|NCT03832140||Patients with monoclonal gammopathy|
16421193|NCT03832140||patients with a normal plasma protein electrophoresis|
16421194|NCT03832127|Experimental|Fludatep|PET with 18F-Fludarabine
16421195|NCT03832114|Experimental|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
16421196|NCT03832114|Experimental|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
16421233|NCT03831867|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
16421234|NCT03831854|Active Comparator|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
16421197|NCT03832101|Experimental|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
16421198|NCT03832101|Experimental|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
16421199|NCT03832101|Active Comparator|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
16421200|NCT03832088|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated for sarcopenia and balance disorders
16421201|NCT03832075|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
16421202|NCT03832049|Active Comparator|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
16421203|NCT03832049|Experimental|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
16421204|NCT03832049|Experimental|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
16421205|NCT03832049|Experimental|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
16421206|NCT03832049|Experimental|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
16421207|NCT03832036|Experimental|Patients with lumbar disc herniation|
16421208|NCT03832023|No Intervention|Facility-based model|Standard of care of each country
16421209|NCT03832023|Experimental|Community-based model|Screening and initiating preventive therapy in communities
16421210|NCT03832010|Active Comparator|Crisaborole|Participants will be instructed to apply emollient, topical steroid, and or crisaborole (blinded) to affected areas with eczema.
16421211|NCT03832010|Placebo Comparator|Vehicle|Participants will be instructed to apply emollient, topical steroid, and or vehicle (blinded) to affected areas with eczema.
16421212|NCT03832010|Sham Comparator|Control|Participants will be instructed to apply emollient, topical steroid, and or emollient (blinded) to affected areas with eczema.
16421213|NCT03831997||Historical Controls|The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
16421214|NCT03831997||Prospective Arm|The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
16421215|NCT03831984|Active Comparator|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
16421216|NCT03831984|Placebo Comparator|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
16421217|NCT03831971|Experimental|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
16421218|NCT03831958||Family member|Family member of survivor of pediatric Cushing disease
16421219|NCT03831958||Subjects|survivor of pediatric Cushing disease
16421220|NCT03831945|Active Comparator|Single infusion of VRC01 and 10-1074|Single infusion of 40 mg/kg VRC-HIVMAB060-00-AB (VRC01) in 100 mL of saline and 30 mg/kg of 10-1074 in 250 mL of saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
16421221|NCT03831945|Placebo Comparator|Single infusion of Normal Saline|Single infusion of 100 mL and 250 mL of normal saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
16421222|NCT03831932|Experimental|Treatment (telaglenastat HCl, osimertinib)|Patients receive telaglenastat hydrochloride PO BID and osimertinib PO QD (starting cycle 1 day 16 of phase I). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16421223|NCT03831919|Experimental|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
16421224|NCT03831919|Placebo Comparator|control|Wear single vision spectacles (no add)
16421225|NCT03831906|No Intervention|Control|"All children admitted in the hospital and presenting with WHO-defined severe pneumonia will be immediately managed as part of routine care per the WHO Standard of Care (SOC), including broad spectrum antibiotics, oxygen therapy if required, additional supportive care and specific therapies for comorbidities such as HIV infection.
~For research purposes, children will benefit from HIV testing, malaria testing, and complete blood count (CBC) if not systematically performed as routine care in the country/hospital, as well as from a digitalized chest X-ray (CXR). Additionally, samples will be collected for future biomarkers studies (biobank)."
16421226|NCT03831906|Experimental|Interventional|Children will benefit from the WHO SOC and additional strategies for research purposes (HIV and malaria testing, CBC, CXR, and biobank) as described in the control arm, plus the study intervention.
16421227|NCT03831893|Sham Comparator|Control|A food product similar to the test products but without nopal
16421228|NCT03831893|Experimental|Nopal food product 1|Food product with Nopal
16421229|NCT03831893|Experimental|Nopal food product 2|Food product with Nopal
16421230|NCT03831880|Other|Daily to Weekly|Genotropin to somatrogon
16421231|NCT03831880|Other|Weekly to Daily|somatrogon to Genotropin
16421235|NCT03831854|Placebo Comparator|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
16421236|NCT03831841|Experimental|Intervention|Multicomponent exercise programe involving all physical fitness paramenters and consisting on sesions of 1 hour, 3 days a week.
16421237|NCT03831841|No Intervention|Control|Control group with no intervention programe
16421238|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
16421239|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
16421240|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
16421241|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
16421242|NCT03831802|Experimental|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
16421243|NCT03831802|Active Comparator|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
16421244|NCT03831789|Active Comparator|Unilateral cerebellar rTMS|
16421245|NCT03831789|Experimental|Bilateral cerebellar rTMS|
16421246|NCT03831776|Experimental|Bosutinib-Ropeginterferon combination|
16421247|NCT03831776|Active Comparator|Bosutinib monotherapy|
16421248|NCT03831763|Active Comparator|ColdZyme|
16421249|NCT03831763|No Intervention|Optional care only|
16421250|NCT03831750|Experimental|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
16421251|NCT03831750|No Intervention|Control|Participants will receive the standard of care for IBD.
16421252|NCT03831737|Experimental|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.
~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
16421253|NCT03831737|Experimental|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.
~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
16421254|NCT03831724|Experimental|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
16421255|NCT03831711|Experimental|Diagnostic (68-Ga RM2, PET/MRI)|Patients receive 68-Ga RM2 IV and after 45 minutes undergo PET/MRI over 30-60 minutes.
16421256|NCT03831698|Experimental|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
16421257|NCT03831646||dermatological patients|atopic dermatitis and psoriasis patients with mild and moderate severity of dermatoses in the stage of exacerbation
16421258|NCT03831633|Experimental|AKYNZEO|
16421259|NCT03831633|Active Comparator|Standard of Care|
16421260|NCT03831607|Experimental|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
16421261|NCT03831594|Experimental|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
16421262|NCT03831594|Active Comparator|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
16421263|NCT03831581|Experimental|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
16421264|NCT03831568||Children with given device for mechanical cough|
16421265|NCT03831555|Active Comparator|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
16421266|NCT03831555|No Intervention|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
16421267|NCT03831542||direct aspiration group|Transvaginal ultrasound-guided oocyte retrieval was performed 36 hours after ovulation trigger. A 17-gauge double lumen needle will be used to aspirate a single follicle without flushing. If an oocyte is obtained, the subject will be assigned to group 1. If not, operator will proceed with follicular flushing.
16421268|NCT03831542||flushing group|If an oocyte is not obtained with direct aspiration, operator will proceed to follicular flushing and the subject will be assigned to group 2 if an oocyte is obtained following follicular flushing.
16421269|NCT03831529||ICU older patient|Older patient (> 65 years old) admitted to ICU with severe acute cholangitis
16421270|NCT03831516||Non Invasive Electroanatomical Mapping|Patients will undergo non invasive electroanatomical mapping (CardioInsight by Medtronic) prior and during an invasive electrophysiology study and ablation of ventricular Arrhythmias.
16421276|NCT03831477|Experimental|80 pin applicator|
16421277|NCT03831477|Active Comparator|160 pin applicator|
16421278|NCT03831464|Experimental|Metformin treatment group|
16421279|NCT03831464|Placebo Comparator|Placebo control group|
16421280|NCT03831451|Experimental|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
16421281|NCT03831451|Active Comparator|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
16421282|NCT03831438|Other|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).
~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
16421283|NCT03831425|Experimental|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
16421284|NCT03831425|Placebo Comparator|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
16421285|NCT03831412|Active Comparator|CBT-I|5 sessions of treating insomnia
16421286|NCT03831412|Active Comparator|ERRT|5 sessions of treating post-trauma nightmares
16421287|NCT03831399|Placebo Comparator|Control Group|"Subjects in control group will receive placebo (lactose) 6g/day in two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.
~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
16421288|NCT03831399|Active Comparator|Intervention Group|"Subjects in intervention group will receive leucine 6g/day, in tin two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.
~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
16421289|NCT03831386|Active Comparator|Vacuum|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.
16421290|NCT03831386|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
16421291|NCT03831373|Experimental|Upper-limb-focused resistance training|
16421292|NCT03831373|Experimental|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
16421293|NCT03831373|Active Comparator|Stretching exercise|Stretching exercise program in a sitting position.
16421296|NCT03831347|Experimental|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
16421297|NCT03831334|Experimental|Minoxidil Treatment|Low dose oral minoxidil
16421298|NCT03831321|Active Comparator|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
16421299|NCT03831321|Placebo Comparator|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
16421300|NCT03831308||Breast cancer new diagnosis|group will include volunteer women, diagnosed with breast cancer, in any stage, aged 18y or more; at least 100 patients will be recruited in medical oncology appointments; all subjects should be periodically submitted to non-invasive evaluation tests - that is, clinical test/clinical and physical assessment to collect information on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
16421301|NCT03831295|Experimental|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.
~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
16421353|NCT03830905|Experimental|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
16421302|NCT03831282|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
16421303|NCT03831269|Active Comparator|Azithromycin|The dose of azithromycin will be 10mg/kg/day oral suspension for 3 consecutive days for pediatric patients (<12 years old) and 500mg/day in three consecutive days for adults. The cycle will be repeated every seven days (3 cycles/month) and will be repeated if required according to patient's response up to 6 cycles. Side effects of therapy will be recorded. This protocol is based on previous case reports.
16421304|NCT03831269|Active Comparator|Nb UVB|Patients recruited for nbUVB phototherapy will have an initial dose of 0.3J-0.5J according to Fitzpatrick's skin type. The dosage will be increased by 0.3J in every other treatment session. The sessions will be given 3 times weekly until improvement is noted or reaching 8 weeks at the EOS. We arrived at this initial dose based on our previous experience with Egyptian patients in Kasr Alainy phototherapy unit in Dermatology Department, Cairo University.
16421305|NCT03831256|Active Comparator|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
16421306|NCT03831256|Experimental|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
16421307|NCT03831243|Active Comparator|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
16421308|NCT03831243|Experimental|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy & Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
16421309|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
16421310|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
16421311|NCT03831191|Experimental|50 mg LY3375880|"Induction Period:
~Participants received 50 mg LY3375880 administered SC Q4W."
16421312|NCT03831191|Experimental|150 mg LY3375880|"Induction Period:
~Participants received 150 mg LY3375880 administered SC Q4W."
16421313|NCT03831191|Experimental|600 mg LY3375880|"Induction Period:
~Participants received 600 mg LY3375880 administered SC Q4W."
16421314|NCT03831191|Placebo Comparator|Placebo|"Induction Period:
~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W)."
16421315|NCT03831178|Experimental|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
16421316|NCT03831178|Placebo Comparator|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
16421317|NCT03831165|Experimental|melatonin 3mg + Acyclovir 400mg|GI - melatonin 3mg + Acyclovir 400mg
16421318|NCT03831165|Active Comparator|Acyclovir 400mg|GII - Acyclovir 400mg twice a day
16421319|NCT03831165|Placebo Comparator|placebo + melatonin 3mg|GIII - placebo + melatonin 3mg
16421320|NCT03831152|Experimental|Experimental ADV7103|All patients receive ADV7103 at their individualized dose
16421321|NCT03831139|Experimental|Prevention|TIM&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
16421322|NCT03831139|No Intervention|Control|The youth participate in school as usual.
16421323|NCT03831126||betamethasone treatment|
16421324|NCT03831113|Experimental|Buprenorphine Magnitude Group|Subjects will receive alternating reductions of 1 mg and then 2 mg weekly. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
16421325|NCT03831113|Experimental|Buprenorphine Frequency Group|Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
16421354|NCT03830905|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
16421517|NCT03829800|Experimental|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
16421326|NCT03831113|Experimental|Buprenorphine Dosing Group|Subjects will receive dose reductions identical to either the Magnitude (alternating 1 and 2 mg reductions) or Frequency (2 mg reductions on alternating 1 and 2 week intervals) groups. Subjects on BID dosing, as prescribed by their MAT provider, will be assigned to the Dosing group (n=10).
16421327|NCT03831100|Experimental|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
16421328|NCT03831100|Placebo Comparator|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
16421329|NCT03831087|Other|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
16421330|NCT03831087|Other|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
16421331|NCT03831061|Experimental|Cognitive stimulation|"10 sessions of 45 minutes/week during 10 weeks. Each session included : (a) temporo-spatial orientation , (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.
~There are 54 participants subdivided into two groups of 27 participants that perform the same intervention in different days of the week."
16421332|NCT03831061|No Intervention|Control group (No intervention)|There are 68 participants in total. These participants did not receive intervention.
16421333|NCT03831048|Experimental|DCD Heart Possible|
16421334|NCT03831048|Active Comparator|Standard of Care Heart Only|
16421335|NCT03831035||15 patients and both parents.|The patients are aged 12 months or under hospitalized in the ICU suffering from multiple congenital malformations and/or neurologic symptoms.
16421336|NCT03831009|Active Comparator|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
16421337|NCT03831009|Active Comparator|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
16421338|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
16421339|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
16421340|NCT03830983||Stroke of likely cardioembolic cause or undetected mechanism|Lesions in at least one territory on MRI & absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% in arteries supplying the ischemic area(s) & absence of severe small vessel disease including micro-bleeds on Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% & absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
16421341|NCT03830983||Atherosclerotic stroke|Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% leading to the infarcted territory & absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% and presence of severe small vessel disease possibly including micro bleeds.
16421342|NCT03830983||Controls|Age and sex matched healthy controls with no history of stroke or AF.
16421343|NCT03830970|Experimental|1 cup of canned beans of multiple varieties|Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
16421344|NCT03830970|Experimental|1/2 cup of canned beans of multiple varieties|Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
16421345|NCT03830970|Other|1 cup of White rice|Consumption of 1 cup of white rice each day for 4 weeks
16421346|NCT03830957|Active Comparator|Ivabradine|
16421347|NCT03830957|Active Comparator|metoprolol|
16421348|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI
~Interventions:
~Blood sampling
~transthoracic echocardiography
~Late Gadolinium-Enhancement Cardiac Magnetic Resonance
~Coronary Angio Computed Tomography"
16421349|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI
~Interventions:
~Blood sampling
~transthoracic echocardiography
~Late Gadolinium-Enhancement Cardiac Magnetic Resonance
~Coronary Angio Computed Tomography"
16421350|NCT03830931||Primary knee arthroplasty patients|Fasting Plasma Glucose test will be obtained the morning after surgery and the frequency of hyperglycemia in non diabetic and diabetic patients will be evaluated
16421351|NCT03830918|Experimental|Arm A (temozolomide, niraparib, atezolizumab)|Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
16421352|NCT03830918|Active Comparator|Arm B (atezolizumab)|Patients receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
16421355|NCT03830892|Active Comparator|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
16421356|NCT03830892|Active Comparator|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
16421357|NCT03830879||No treatment|This cohort study have any no treatment.
16421358|NCT03830866|Experimental|Durvalumab (intravenous infusion)|durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
16421359|NCT03830866|Placebo Comparator|Placebo (matching placebo for intravenous infusion)|placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
16421360|NCT03830853||Successful CTO PCI achieved|Patients will have successful CTO PCI (chronic total occlusion percutaneous coronary intervention) followed by physiological and intracoronary imaging. These measurements will be repeated at a 3 month follow up angiogram procedure.
16421361|NCT03830840||Adult Individuals with Type 2 diabetes|Individuals ≥18 years of Hispanic/Latino heritage with an established diagnosis of type 2 diabetes
16421362|NCT03830840||Adult Family member|Adult family members, ≥18 years, of the individual with type 2 diabetes
16421363|NCT03830840||Child family member with diabetes|Child, ≥7 years but <18 years, family member with diabetes
16421364|NCT03830840||Child family member without diabetes|Child, ≥7 years but <18 years, family member without diabetes
16421365|NCT03830827|Experimental|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.
~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
16421366|NCT03830827|Experimental|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.
~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
16421367|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
16421368|NCT03830801|Experimental|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
16421369|NCT03830788|Active Comparator|Brachytherapy|radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate
16421370|NCT03830788|Experimental|stereotactic body radiotherapy (SBRT)|radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.
16421371|NCT03830775|Experimental|Experimental - PRP injection|2cc of PRP is injected into the ulnocarpal joint
16421372|NCT03830775|Placebo Comparator|control - Saline injection|2cc of 0.9% sterile saline is injected into the ulnocarpal joint
16421373|NCT03830762|Experimental|Cohort 1 / Cohort 2 (Active)|20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.
16421374|NCT03830762|Placebo Comparator|Cohort 1 / Cohort 2 (Placebo)|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
16421375|NCT03830749|Experimental|Single Arm|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
16421376|NCT03830736|Placebo Comparator|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
16421377|NCT03830736|Experimental|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
16421378|NCT03830736|Experimental|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
16421379|NCT03830736|Experimental|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
16421380|NCT03830736|Experimental|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
16421381|NCT03830723|Other|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
16421382|NCT03830710||Group A|30 patients diagnosed with oral leukoplakia
16421383|NCT03830710||Group B|30 patients diagnosed with oral lichen planus
16421384|NCT03830710||Group C|30 patients having oral squamous cell carcinoma with the tongue being the most commonly affected site
16421385|NCT03830710||Group D|30 age and gender matched individuals having no oral mucosal lesions acting as a control group
16421386|NCT03830697|Experimental|Menstruation situation TCM symptom score standard|
16421387|NCT03830697|Placebo Comparator|Sham intervention|
16421388|NCT03830684|Experimental|low-dose group|Baicalein Tablets group
16421389|NCT03830684|Experimental|high-dose group|Baicalein Tablets group
16421391|NCT03830671|Experimental|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
16421392|NCT03830658|Experimental|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
16421393|NCT03830658|Active Comparator|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
16421394|NCT03830645|Experimental|Platelet rich plasma group|
16421395|NCT03830632|Experimental|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
16421396|NCT03830632|Active Comparator|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .
~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
16421397|NCT03830619||lung cancer patients|
16421398|NCT03830619||normol volunteers|
16421399|NCT03830606|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
16421400|NCT03830593||Group 1|laparoscopic adrenalectomy group 1: tumor size as < 6 (group1)
16421401|NCT03830593||Group 2|Laparoscopic adrenalectomy group2: tumor size ≥ 6 cm (group2)
16421402|NCT03830593||Learning Curve|The patients, underwent laparoscopic adrenalectomy, were also classified into group A (1-25), B (26-50), C (51-75), and D (76-102) according to the chronological order of their surgery in order to evaluate the learning curve.
16421403|NCT03830580|Experimental|Sung voice|
16421404|NCT03830580|No Intervention|Control|
16421405|NCT03830567||Pharmacist prescription|
16421406|NCT03830567||Clinician prescription|
16421407|NCT03830554|Experimental|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
16421408|NCT03830554|No Intervention|control group|participants of this group received no intervention.
16421409|NCT03830528|Experimental|Part A-1|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
16421410|NCT03830528|Experimental|Part A-2|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
16421411|NCT03830528|Experimental|Part A-3|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
16421412|NCT03830528|Experimental|Part B|There will be one cohort of Japanese healthy men dosed with multiple doses of KW-6356 or placebo and one potential additional cohort (KW-6356 dose as determined in Part A or placebo)
16421413|NCT03830528|Experimental|Part C-1|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
16421414|NCT03830528|Experimental|Part C-2|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
16421415|NCT03830528|Placebo Comparator|Placebo|
16421416|NCT03830515|Experimental|Closure of lacerations with microMend|Laceration closure with microMend
16421417|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
16421418|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
16421419|NCT03830489|Experimental|Large volume based preparation|This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.
16421420|NCT03830489|Active Comparator|Low volume based preparation|This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet
16421421|NCT03830476|Experimental|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
16421422|NCT03830476|Active Comparator|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
16421423|NCT03830463|Experimental|CTP-692|
16421424|NCT03830463|Placebo Comparator|Placebo|
16421425|NCT03830437||Case group|The group will be subjected to double weighing, before and after the next 6 breastfeeding. Breastfeeding will be carried out each 4 hr.
16421426|NCT03830437||Control group|The group will be subjected to monitoring of body weight only at 24, 36 hr and 48 hr of life.
16421427|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
16421428|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
16422654|NCT03821818||Control|Food Allergen Elimination only
16421429|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
16421430|NCT03830411|Experimental|Arm A: Sintilimab|Participants will receive Sintilimab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
16421431|NCT03830411|Active Comparator|Arm B: Chemotherapy (Docetaxel or Pemetrexed)|Participants randomized to the chemotherapy arm will receive docetaxel or pemetrexed until disease progression per standard RECIST v1.1 or unacceptable toxicity.
16421432|NCT03830398|Active Comparator|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
16421433|NCT03830398|Active Comparator|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
16421434|NCT03830398|Placebo Comparator|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
16421435|NCT03830385|Experimental|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
16421436|NCT03830372|Experimental|VR Tier One|"Patients will receive:
~10 sessions of 20 minutes of VR Tire One therapeutic game,
~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,
~30 minutes individual aerobic training,
~30 minutes balance exercises."
16421437|NCT03830372|Active Comparator|Control|"Patients will receive:
~10 sessions of 20 minutes of Schultz Autogenic Training,
~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,
~30 minutes individual aerobic training,
~30 minutes balance exercises."
16421438|NCT03830359|Other|T2769|T2769 Ophthalmic solution One drop in each eye 3 to 6 times daily
16421439|NCT03830346|Experimental|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
16421440|NCT03830346|Experimental|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
16421443|NCT03830320|Active Comparator|Healthy Volunteers|In the first stage, twenty (20) healthy adult subjects will be injected with [64Cu]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
16421444|NCT03830320|Experimental|Atrial Fibrillation Patients|In the second stage, forty (40) patients with LAA thrombus documented by TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care.
16421445|NCT03830307|Experimental|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
16421446|NCT03830294|Experimental|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
16421447|NCT03830294|Active Comparator|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
16421448|NCT03830281|Active Comparator|Insulin Lispro (Humalog)|Participants received individual dose of 100 U/mL insulin lispro (Humalog) by CSII; where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
16421449|NCT03830281|Experimental|Ultra-Rapid Lispro|Participants received individual dose of 100 units per milliliter (U/mL) ultra rapid lispro by continuous subcutaneous insulin infusion (CSII); where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
16421450|NCT03830268|Experimental|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.
~Interventions:
~No MCT intake with breakfast, no lunch (i.e. CTL)
~No MCT intake with lunch, no breakfast (i.e CTL inverted)
~10g of Betaquik with breakfast, no lunch (i.e BQ10)
~20g of Betaquik with breakfast, no lunch (i.e BQ20)
~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
16421451|NCT03830268|Experimental|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.
~Interventions:
~No MCT intake with breakfast, no lunch (i.e. CTL)
~No MCT intake with lunch, no breakfast (i.e CTL inverted)
~10g of Betaquik with breakfast, no lunch (i.e BQ10)
~20g of Betaquik with breakfast, no lunch (i.e BQ20)
~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
16421452|NCT03830255||Renal Transplant patients treated with cyclosporine|Detecting the genetic polymorphism affecting cyclosporine level
16421453|NCT03830255||Renal Transplant patients treated with tacrolimus|Detecting the genetic polymorphism affecting tacrolimus level
16421454|NCT03830242|Experimental|<Sup>18<Sup>F-FDG PET/CT study group|<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
16421455|NCT03830242|Other|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
16421456|NCT03830229||1/Germline positive mesothelioma|Individuals with mesothelioma who have a BAP1 or other DNA repair/cancer predisposition mutation regardless of CLIA confirmation
16421457|NCT03830229||2/CLIA confirmed germline mutation without mesothelioma|Individuals with a CLIA confirmed BAP1 or other DNA repair/cancer predisposition mutation who do not have a diagnosis of mesothelioma
16421458|NCT03830216|Experimental|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
16421459|NCT03830216|Sham Comparator|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
16421460|NCT03830203|Experimental|BAT1806|BAT1806 injection: 8 mg/kg, intravenous infusion by 60 min
16421461|NCT03830203|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 8 mg/kg, intravenous infusion by 60 min
16421462|NCT03830190|Experimental|Intervention group|Parkinson's disease nurse specialist care
16421463|NCT03830190|No Intervention|Control group|No intervention
16421464|NCT03830177|Experimental|Adults|All adults in the study will receive the treatment for dry scalp.
16421465|NCT03830177|Experimental|Children|All children in the study will receive the treatment for dry scalp.
16421466|NCT03830164|Experimental|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
16421467|NCT03830151|Experimental|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
16421468|NCT03830138||Acute coronary syndrome patients:|One hundred patients with acute coronary syndrome.
16421469|NCT03830138||Controls:|Fifty healthy control
16421470|NCT03830125|Experimental|Single Ascending Doses|
16421471|NCT03830125|Experimental|Multiple Ascending Doses|
16421472|NCT03830112|Experimental|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).
~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).
~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.
~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).
~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
16421473|NCT03830112|Active Comparator|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).
~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).
~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).
~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
16421474|NCT03830086|Other|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
16421475|NCT03830086|Other|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
16421476|NCT03830073||Group I:|Seventy patients with pancreatitis
16421477|NCT03830073||Group II:|Thirty healthy controls
16421478|NCT03830060||Group I:|Fifty AP patients on admission
16421479|NCT03830060||Group II:|The previous AP patients after 72 hours
16421480|NCT03830047|Active Comparator|nd yag laser|Applying nd yag laser to vulva
16421481|NCT03830047|Sham Comparator|Co2 laser|Applying CO2 laser to vulva
16421482|NCT03830034|Experimental|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
16421483|NCT03830034|Active Comparator|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.
16421484|NCT03830021|Experimental|Salt reduction program|Salt reduction program.
16421485|NCT03830021|Active Comparator|Healthy lifestyle program|Healthy lifestyle program.
16421518|NCT03829800|Experimental|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
16421519|NCT03829800|Active Comparator|Glicolab®|Glucose solution
16421808|NCT03827668|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
16421486|NCT03830008|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
16421487|NCT03830008|Experimental|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
16421488|NCT03829995|No Intervention|Control group|Participants in the control group received the normal care following the Danish standard procedure.
16421489|NCT03829995|Active Comparator|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
16421490|NCT03829982|Experimental|bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
16421491|NCT03829982|Experimental|dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
16421492|NCT03829969|Experimental|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
16421493|NCT03829969|Placebo Comparator|placebo|Placebo combine with paclitaxel and cisplatin
16421494|NCT03829956|Other|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
16421495|NCT03829943||Vitamin D deficiency|The study group will be males discovered to have Vitamin D deficiency.
16421496|NCT03829943||Control group|The control group will be males with normal Vitamin D status
16421497|NCT03829930|Experimental|Entinostat and Enzalutamide|Entinostat and Enzalutamide
16421498|NCT03829917|Experimental|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day [50 mg tid] for 28 days.
16421499|NCT03829917|Active Comparator|Miltefosine|Miltefosine pills alone [2.5 mg/day [50 mg tid] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
16421500|NCT03829917|Active Comparator|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
16421501|NCT03829904|Experimental|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
16421502|NCT03829904|Placebo Comparator|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
16421503|NCT03829891|Experimental|Beinaglutide|"Beinaglutide for 8 weeks,
~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
16421504|NCT03829891|Active Comparator|glargine|"Glargine for 8 weeks,
~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
16421505|NCT03829878|Experimental|CP101|CP101 (Full Spectrum Microbiota) Capsule
16421506|NCT03829878|Placebo Comparator|Placebo|Placebo for CP101
16421507|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
16421508|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
16421509|NCT03829839|Active Comparator|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
16421510|NCT03829839|Active Comparator|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
16421511|NCT03829826||Patients receiving IVIg|Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.
16421512|NCT03829826||de novo SCIg patients/IVIg-Naive Group|This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
16421513|NCT03829813|Experimental|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
16421514|NCT03829813|Experimental|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
16421515|NCT03829813|Experimental|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
16421516|NCT03829800|Experimental|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
16477203|NCT03449199|Placebo Comparator|TMX-049 Placebo|
16421520|NCT03829787||Bipolar without Anxiety or Substance Use Disorder|Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
16421521|NCT03829787||Bipolar disorder with a current anxiety disorder only|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
16421522|NCT03829787||Bipolar disorder with a current anxiety disorder and a current|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
16421523|NCT03829787||Bipolar disorder with a current substance use disorder only|Subjects who are diagnosed with bipolar disorder & a substance use disorders but not a current anxiety disorder
16421524|NCT03829787||Healthy Volunteers|
16421525|NCT03829774|Experimental|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
16421526|NCT03829774|Placebo Comparator|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
16421527|NCT03829761|Experimental|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
16421528|NCT03829761|Sham Comparator|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
16421529|NCT03829748|Experimental|Intermittent aspiration|Empty syringe of 10cc and intermittent aspiration during puncture
16421530|NCT03829748|No Intervention|Continous/standard aspiration|Empty syringe of 10cc and continous aspiration during puncture
16421531|NCT03829735|Experimental|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
16421532|NCT03829722|Experimental|Nivolumab, Carboplatin/Paclitaxel, Radiotherapy|Therapy will continue for 21 weeks total. This includes 4 doses of of nivolumab (240mg/m2) before and concurrent with RT/carboplatin/paclitaxel and 4 adjuvant nivolumab doses (480mg/m2) after the end of RT.
16421533|NCT03829709|Experimental|Intervention Group|The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
16421534|NCT03829696|Experimental|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.
~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
16421535|NCT03829683|Active Comparator|Vitamin C infusion (ascorbic acid)|Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)
16421536|NCT03829683|Placebo Comparator|Placebo|Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours
16421537|NCT03829670||Delirium Group|"UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.
~The participant may decline participation after this UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) assessment and will be removed from the study.
~The Short IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) is administered to the legally authorized representative or caregiver by Dr. Schmidt. If the potential participant scores 3.3 or lower, the participant will continue in the delirium group. If higher, patient likely with pre-existing dementia. These patients are not eligible for study participation.
~Delirium Rating Scale 98 will be performed on the ALGH (Advocate Lutheran General Hospital) rehabilitation unit
~Cytochrome P450 testing
~Delirium Status: Admission, Hospital Discharge, Outpatient Visit
~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
16421538|NCT03829670||Patients without delirium|"Cytochrome P450 testing
~Delirium Status: Admission, Hospital Discharge, Outpatient Visit
~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
16421542|NCT03829644|Experimental|Intervention|Participants in the intervention arm will be fitted with a semi-rigid prefabricated lumbar brace (Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618) in addition to their current back pain management program.
16421543|NCT03829644|No Intervention|Control|Participants in this arm will be instructed to follow their current back pain management program.
16421544|NCT03829631|Experimental|Intervention|Participants will be instructed to follow their current low back pain management program, in addition, they will be instructed to wear a lumbar brace (Horizon 627 Lumbar Brace) during the day for four weeks only when they are in pain in addition to their current management program.
16477499|NCT03447093||Hashimoto's thyroiditis group|30 HT patients
16421546|NCT03829618|Active Comparator|Topical Lidocaine|16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.
16421547|NCT03829618|Active Comparator|Nebuliser Solution|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.
16421548|NCT03829618|Active Comparator|Nebuliser Suspension|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.
16421549|NCT03829605||Group I:|Fifty AMI patients on admission
16421550|NCT03829605||Group II:|The previous AMI patients after 12 hours
16421551|NCT03829592|Placebo Comparator|misoprostol in neutral media|Intervention : misoprostol in a neutral media will be given to women to induce labour
16421552|NCT03829592|Active Comparator|Misoprostol in acidic media|Intervention : misoprostol in acidic media will be given to induce labour
16421553|NCT03829592|Sham Comparator|Misoprostol in alkaline media|Intervention : misoprostol in alkaline media will be given to induce labour
16421554|NCT03829566|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
16421555|NCT03829553|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
16421556|NCT03829553|Active Comparator|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
16421557|NCT03829540|Experimental|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
16421558|NCT03829527|Experimental|Psychotherapy|
16421559|NCT03829514|Experimental|Fenofibrate|Single arm. Participants will take study medication
16421560|NCT03829501|Experimental|KY1044 monotherapy phase 1|KY1044 monotherapy dose escalation
16421561|NCT03829501|Experimental|KY1044 and atezolizumab phase 1|KY1044 and atezolizumab combination dose escalation
16421562|NCT03829501|Experimental|KY1044 monotherapy phase 2|KY1044 monotherapy
16421563|NCT03829501|Experimental|KY1044 and atezolizumab phase 2|KY1044 and atezolizumab combination
16421564|NCT03829488|Experimental|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
16421565|NCT03829488|Active Comparator|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
16421566|NCT03829475|Experimental|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
16421567|NCT03829475|Placebo Comparator|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
16421568|NCT03829462|Experimental|Irinotecan + regorafenib (REGIRI)|irinotecan (180 mg/m2) at day1 of each cycle + regorafenib (160 mg/day) from day 2 to day 8
16421569|NCT03829462|Active Comparator|regorafenib|Regorafenib (160 mg/day) for 3 weeks followed by 1 week off
16421570|NCT03829449|Experimental|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
16421571|NCT03829436|Experimental|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
16421572|NCT03829436|Experimental|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression.
16421573|NCT03829436|Experimental|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
16421574|NCT03829436|Experimental|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
16421575|NCT03829410|Experimental|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m2 orally Day 1 through 5 every 14-days over two treatment courses (1 cycle) in combination with FOLFIRI (180 mg/m2 irinotecan, 400 g/m2 leucovorin, 400 mg/m2 bolus 5-fluorouracil (5-FU), and 2400 mg/m2 continuous intravenous infusion 5-FU) + 5 mg/kg bevacizumab.
~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) orally Day 1 through 5 every 14-days over two treatment courses (1 cycle) in combination with FOLFIRI (180 mg/m2 irinotecan, 400 g/m2 leucovorin, 400 mg/m2 bolus 5-fluorouracil (5-FU), and 2400 mg/m2 continuous intravenous infusion 5-FU) + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
16421576|NCT03829384|Experimental|mRNA-1944|Escalating dose levels
16421577|NCT03829384|Placebo Comparator|Placebo|Saline
16421578|NCT03829371|Experimental|ARM A|"ARM A
~Velcade (V):
~1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;
~1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.
~Melphalan (M):
~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.
~Prednisone (P):
~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
16421579|NCT03829371|Experimental|ARM B|"ARM B:
~Lenalidomide (R):
~-25 mg orally on days 1-21 of each cycle.
~Dexamethasone (d):
~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
16421580|NCT03829358|Experimental|Probiotic|Lactobacillus plantarum IS-10506
16421581|NCT03829358|Placebo Comparator|Placebo|Placebo
16421585|NCT03829319|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
16421586|NCT03829319|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
16421587|NCT03829293|Experimental|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
16421588|NCT03829293|No Intervention|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
16421589|NCT03829280|Experimental|Cognitive Adaptation Training|Psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery.
16421590|NCT03829280|Active Comparator|Community Treatment|Medication follow-up and case management as provided by the community mental health center according to usual care.
16421591|NCT03829267|Experimental|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
16421592|NCT03829267|Active Comparator|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
16421593|NCT03829254|Experimental|NUC-7738|NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
16421594|NCT03829241|Experimental|Arm 1: BHV-4157- Experimental|
16421595|NCT03829241|Placebo Comparator|Arm 2: Placebo Comparator Drug|
16421597|NCT03829215|Experimental|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.
~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.
~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
16421598|NCT03829215|No Intervention|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.
~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.
~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
16421599|NCT03829202|Experimental|A-B-A Group|Daily use of own mechanical knee for 4 weeks (A), followed by RheoKnee microprocessor prosthetic knee for 4 weeks (B), and concluding with own mechanical knee for 4 weeks (A).
16421600|NCT03829202|Experimental|B-A-B Group|Daily use of RheoKnee microprocessor prosthetic knee for 4 weeks (B), followed by own mechanical knee for 4 weeks (A), and concluding with RheoKnee microprocessor prosthetic knee for 4 weeks (B).
16421601|NCT03829189|Active Comparator|inulin|
16421602|NCT03829189|Placebo Comparator|maltodextrin|
16421603|NCT03829176|No Intervention|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
16421604|NCT03829176|Experimental|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
16421605|NCT03829163|Active Comparator|Conventional Walker Group|
16421606|NCT03829163|Experimental|HAW Group|
16421607|NCT03829150|Experimental|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
16421904|NCT03827005|Experimental|L-arginine|3 g L-arginine once per day for one day.
16421608|NCT03829150|Experimental|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
16421609|NCT03829137|Experimental|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
16421610|NCT03829137|Sham Comparator|Sham laser acupuncture|sham laser acupuncture (no laser output)
16421611|NCT03829124|Experimental|ketamine + propofol group|use ketamine + propofol for ECT induction
16421612|NCT03829124|Active Comparator|propofol group|use propofol only for ECT induction
16421613|NCT03829111|Active Comparator|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16421614|NCT03829111|Experimental|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16421615|NCT03829085|Active Comparator|Early oral refeeding|"The patients will be started the oral refeeding from the first day of admission in the hospital.
~Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day"
16421616|NCT03829085|No Intervention|FASTING|The oral diet will be reintroduced in a traditional stepwise manner until the symptoms, signs, inflammatory parameters of AP have resolved
16421617|NCT03829072|Experimental|cooking Education and adapted physical activity|
16421618|NCT03829046|Placebo Comparator|Placebo|Placebo SC QM
16421619|NCT03829046|Active Comparator|Evolocumab|Evolocumab SC 420mg/dL QM
16421620|NCT03829033|Active Comparator|Radiotherapy delivered with photons|
16421621|NCT03829033|Experimental|Radiotherapy delivered with protons|
16421622|NCT03829020|Experimental|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-14, nelfinavir mesylate PO BID on days 1-14, and bortezomib SC on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16421623|NCT03829007|Experimental|PD-L1 imaging|89Zr-durvalumab iv injection followed by a PET/CT scan at day 5 after injection.
16421624|NCT03828994|Experimental|TECH-PN|Participants receive community health nurse visits, text-messaging support, additional testing and field based visits with a nurse practitioner.
16421625|NCT03828994|No Intervention|TECH-N|Participants receive enhanced standard of care with community health nurse visits and text-messaging support.
16421626|NCT03828981|Active Comparator|fast-track recovery program|"Pre-operative Verbal and video information Tobacco cessation Daily physical activity Light meal 6 hours and clear liquids up to 2 hours before surgery No bowel preparation A warm blanket Premedication paracetamol 1g and tematsepam 20mg
~Intraoperatively For nausea and voimiting dexamethasone 10mg, dehydrobensperidol 1mg and ondancetron 4mg before emergence Analgesia: ropivacain at port sites before incision and at vaginal vault Opioids intravenously at discretion of anesthesiologist supplemented with Dexketoprofen 50mg Urinary catheter early removal Postoperative Pain: tramadol 50mg and ketoprofen100mg i.v., oral opioid if needed; patients with normal pain control receive oral pregabalin 25mg every 8 hours, paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours until discharge Out of bed after 2 hours from the end of surgery A liquid diet, if tolerated regular normal diet. For emesis ondansetron 4mg"
16421627|NCT03828981|No Intervention|conventional recovery program|"Preoperative preparation Verbal and written information Cessation of oral intake after previous midnight. Premedication paracetamol 1g+ diatsepam 5mg.
~Intraoperative A warm blanket at the start of procedure. Prophylaxis for nausea and vomiting: Dexamethasone 5mg at induction, and Dehydrobenzperidol 1mg, ondancetron 4mg before emergence. Analgesia: injection of ropivacain 5% 20ml at port sites at the end of surgery, Opioids i.v. (oxycodone)
~Postoperative Pain medication:Opioids i.v. (oxycodone), paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours Urinary catheter removal on next morning. Prolonged bowel and bed rest and gradual reintroduction of feeding."
16421628|NCT03828968|Other|Bladder scan|Bladder scan performed on resident in homes for aged
16421629|NCT03828955|Experimental|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage.
16421630|NCT03828955|Placebo Comparator|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.
16421631|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
16421632|NCT03828929|Experimental|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
16421633|NCT03828929|Placebo Comparator|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
16421634|NCT03828916|Other|NuShield|
16421635|NCT03828903|Experimental|pleural effusion patients|medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained
16421636|NCT03828890|Other|Single Arm Trial|Intervention includes screening eye exam using Optos technology
16421637|NCT03828877|No Intervention|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
16421638|NCT03828877|Active Comparator|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
16421639|NCT03828864|Active Comparator|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
16421640|NCT03828864|Placebo Comparator|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
16421641|NCT03828851|Experimental|Experimental group|ADL training program.
16421642|NCT03828851|No Intervention|Control group|Receive rehabilitation program in the hospital.
16421643|NCT03828838|Experimental|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
16421644|NCT03828825|Experimental|Patent Foramen Ovale Closure|The percutaneous closure of Patent Foramen Ovale is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis.
16421645|NCT03828812|Active Comparator|Breakfast promotion|Receiving the recommendation of daily breakfast
16421646|NCT03828812|Active Comparator|Nighttime snack reduction|Receiving the recommendation of reducing nighttime snack frequency
16421647|NCT03828812|Experimental|Breakfast promotion + nighttime snack reduction|Receiving the recommendation of daily breakfast + reducing nighttime snack frequency
16421648|NCT03828799|Experimental|Folfirinox-R|Folfirinox + regorafenib
16421649|NCT03828786|Active Comparator|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
16421650|NCT03828786|No Intervention|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
16421651|NCT03828773|Other|high-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): homozygous for rs230561 and/or rs381652
16421652|NCT03828773|Other|low-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): other than homozygous for rs230561 and/or rs381652
16421653|NCT03828760|Experimental|Music Listening|Patients will receive music of choice to listen to using a music-playing device in the waiting room prior to IUD insertion, as well as during the procedure.
16421654|NCT03828760|No Intervention|Standard Care|Patients will receive standard care (excluding the use of music) from providers at the clinic to minimize pain and anxiety during the procedure.
16421657|NCT03828734|Experimental|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
16421658|NCT03828734|Experimental|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
16421659|NCT03828721|Active Comparator|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
16421660|NCT03828721|Experimental|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
16421661|NCT03828708|Experimental|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
16421662|NCT03828708|Experimental|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
16421663|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
16421664|NCT03828682|Experimental|Prospective Arm|"De novo kidney transplant recipients receiving:
~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
16421665|NCT03828682|Active Comparator|Comparator arm|"Historical control arm consisting of the following
~De novo kidney transplant recipients receiving:
~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
16421666|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
16421667|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
16421668|NCT03828656|Experimental|Open Label Treatment Arm|Open-label Intervention with the NightWare Therapeutic System every night.
16421670|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
16421671|NCT03828617|Experimental|20vPnC Lot 1|20vPnC Lot 1
16421672|NCT03828617|Experimental|20vPnC Lot 2|20vPnC Lot 2
16421673|NCT03828617|Experimental|20vPnC Lot 3|20vPnC Lot 3
16421674|NCT03828617|Active Comparator|13vPnC|13vPnC
16421675|NCT03828604|Experimental|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
16421676|NCT03828604|Active Comparator|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
16421677|NCT03828591|Other|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
16421678|NCT03828591|Other|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
16421679|NCT03828578|Experimental|High flow oxygen therapy|"Patients allocated to the intervention group will receive high flow oxygen therapy via the tracheostomy tube from cessation of mechanical ventilation. The HFOT will provide oxygen therapy at a flow rate of 50-60 litres per minute at a FiO2 titrated by the bedside clinician to maintain a peripheral oxygen saturation of 95% of more (unless otherwise clinically indicated and documented by an appropriate consultant).
~Once transferred to the ward patients will continue to receive HFOT 24 hours per day at a rate of 50-60 litres per minute at a maximum oxygen concentration of 40% to achieve oxygen saturations 95% and above (unless otherwise documented).
~Patients may be disconnected from the HFOT for short periods for toileting, mobilising etc. Tracheostomy weaning will continue as per standard practice with an aim of cuff deflation followed by decannulation once clinically appropriate. systems. Following decannulation patients will resort to standard oxygen therapy as needed."
16421680|NCT03828578|No Intervention|Standard Care|Patients randomised to the standard care study arm will receive routine post-operative care as currently performed within the host organisation. Following cessation of mechanical ventilation, oxygen therapy will be delivered using equipment and rates appropriate to the clinical picture. On transfer to the ward patients will continue with existing methods of oxygen therapy and will be weaned from these accordingly. Patients will continue to use heat moisture exchanges (e.g. Swedish nose or Buchannan protectors) as clinically indicated, as well as having saline nebulisers prescribed and administered as per standard. Tracheostomy weaning will continue in accordance with current practice. Data on all of the applied procedures will be recorded.
16421681|NCT03828565|Active Comparator|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
16421682|NCT03828565|No Intervention|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
16421683|NCT03828539|Experimental|Erenumab|70 mg and 140 mg Erenumab
16421684|NCT03828539|Active Comparator|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
16421685|NCT03828526|Experimental|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.
~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.
~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
16421686|NCT03828526|Active Comparator|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
16421687|NCT03828513|Active Comparator|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
16421688|NCT03828513|Active Comparator|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2> 90%.
16421689|NCT03828500|Experimental|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
16421690|NCT03828500|No Intervention|Control Arm|
16421691|NCT03828487|Experimental|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
16421692|NCT03828474|Experimental|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
16421693|NCT03828474|Experimental|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
16421694|NCT03828461|Experimental|BITS + VR|Facilitated group therapy with behavioral practice; 16 weeks
16421695|NCT03828448|Experimental|ublituximab + umbralisib|"Ublituximab: 900 mg administered through Cycle 12, via IV infusion
~Umbralisib: 800 mg administered through Cycle 24, via daily oral tablet"
16421696|NCT03828435|Experimental|healthy control|This group does not undergo any treatment . Intervention : rTMS
16421697|NCT03828435|Experimental|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.
~Intervention : rTMS"
16421698|NCT03828422||patients with essential thrombocythemia|"essential thrombocythemia with JAK2 V617F positive mutation
~patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014
~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
~all signed the informed consent
~examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019
~blood for laboratory tests
~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
16421801|NCT03827720|Experimental|Acute Ischemic Stroke with LOV|Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
16421699|NCT03828422||control group|"the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives
~they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease
~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
~all signed the informed consent
~blood for laboratory tests
~examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019
~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
16421700|NCT03828409|Active Comparator|Short stitch|short stitch used as one arm
16421701|NCT03828409|Active Comparator|Long stitch|Long stitch as conventional mass-closure technique
16421702|NCT03828396||High risk (positive)|Colorectal cancer and advanced adenoma
16421703|NCT03828396||Low risk (Negative)|Healthy people and other colorectal diseases
16421704|NCT03828383|Experimental|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
16421705|NCT03828383|Sham Comparator|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
16421706|NCT03828370|Active Comparator|Usual & Customary Information Group|"Study Cohort Assessment:
~Baseline 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
16421707|NCT03828370|Experimental|B-SMART Intervention Group|"Study Cohort Assessment:
~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
16421708|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
16421709|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
16421710|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
16421711|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
16421712|NCT03828344|Experimental|hUC-MSC treatment|BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.
16421713|NCT03828344|Placebo Comparator|Placebo control|The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit.
16421714|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
16421715|NCT03828318|Experimental|Patient Activation Arm|
16421716|NCT03828318|No Intervention|Standard Care Arm|
16421717|NCT03828305|Experimental|Training and creation of the Network-CPR|Training in CPR
16421718|NCT03828305|Active Comparator|Control Group|Primary Care Center Emergency Personnel
16421719|NCT03828292|Experimental|Part 1: Belantamab mafodotin Monotherapy|
16421720|NCT03828292|Experimental|Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone|
16421721|NCT03828292|Experimental|Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone|
16421722|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
16421723|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
16421724|NCT03828240|Other|Enhanced rehabilitation|
16421725|NCT03828227|Active Comparator|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :
~Serum albumin level ≥ 30g/L,
~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).
~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
16421726|NCT03828227|Active Comparator|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :
~Serum albumin level ≥ 30g/L,
~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).
~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
16421727|NCT03828227|Active Comparator|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:
~Serum albumin level < 30g/L.
~And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).
~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
16421728|NCT03828201|Experimental|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
16421729|NCT03828201|Experimental|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
16421954|NCT03826615|No Intervention|No medication|Control group
16421730|NCT03828201|Experimental|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
16421731|NCT03828201|Experimental|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
16421732|NCT03828188|Experimental|group A|"Red Ginseng Concentrated Powder in 12 weeks → rest in 4 weeks → Placebo 12 weeks.
~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)
~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
16421733|NCT03828188|Experimental|group B|"Placebo 12 weeks→ rest in 4 weeks → Red Ginseng Concentrated Powder in 12 weeks.
~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)
~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
16421734|NCT03828175|Other|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
16421735|NCT03828149|Active Comparator|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
16421736|NCT03828149|Placebo Comparator|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
16421737|NCT03828136|Experimental|ACDF with Novum Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
16421738|NCT03828136|Active Comparator|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
16421739|NCT03828123|Experimental|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
16421740|NCT03828110||Children with neurological impairment|
16421741|NCT03828097|Experimental|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
16421742|NCT03828097|Placebo Comparator|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
16421743|NCT03828084|Experimental|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
16421744|NCT03828084|Experimental|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
16421745|NCT03828084|Experimental|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
16421746|NCT03828084|Active Comparator|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
16421747|NCT03828071|Other|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
16421748|NCT03828058|Experimental|Envarsus XR|Envarsus XR orally administered Daily
16421749|NCT03828058|Active Comparator|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus
~Dosage of prograf will be determined by trough levels and adjusted accordingly"
16421750|NCT03828045||Psoriatic Arthritis patients on Apremilast|Patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration.
16421751|NCT03828032|Experimental|Mannitol injection|The participant receive mannitol injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
16421752|NCT03828032|Experimental|Hypertonic saline injection|The participant receive hypertonic saline of specific concentration injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
16421753|NCT03828019|Active Comparator|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.
~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
16421754|NCT03828019|Active Comparator|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.
~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
16421755|NCT03828006|Experimental|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
16421756|NCT03828006|Placebo Comparator|Placebo Group|One tablet per day of placebo.
16421757|NCT03827993|No Intervention|Routine surveillance|"Routine surveillance consists of attending gynecologic oncology office visits and being provided with an educational pamphlet discussing common sexual health concerns in gynecologic cancer patients, describing vaginal dilators, moisturizers, and lubrication. Resources for psychosocial counseling, physical therapy, and the sexual health clinic will be provided as well.
~Participants will have follow up at baseline, 3, 6, 9, and 12 months. Baseline visit consists of the initial visit where the Female Sexual Function Index (FSFI) screen was performed. Subsequent follow up visits will consist of FSFI, Female Sexual Distress Scale (FSDS), Kessler 10 surveys, and clinical assessment with Vaginal Assessment Scale and Vulvar Assessment Scale (VAS and VuAS)."
16421802|NCT03827720|Experimental|AIS without LOV|Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
16421803|NCT03827707|Experimental|Noise|
16421804|NCT03827707|Sham Comparator|Silence|
16421805|NCT03827694||Patients with possible PIMI|
16421806|NCT03827681|Experimental|TIPS + Vasoactive Drug|
16421807|NCT03827681|Active Comparator|SEMS + Vasoactive Drug|
16421758|NCT03827993|Experimental|Dedicated sexual health clinic appointment|"Dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This will consist of the provider performing a focused history and physical, who will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
~The participants will follow up at 3, 6, 9, and 12 months after initial visit, either with the sexual health focused provider or their primary gynecologic oncologist, as determined by the needs of the participant per the provider."
16421759|NCT03827967|Experimental|1x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
16421760|NCT03827967|Experimental|2x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
16421761|NCT03827967|Experimental|4x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
16421762|NCT03827967|Experimental|8x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
16421763|NCT03827954|Experimental|Experimental Treatment|HeartMapp+CT
16421764|NCT03827941|Active Comparator|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
16421765|NCT03827941|Active Comparator|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
16421766|NCT03827928|Experimental|Yoga/meditation|A 6-week yoga/meditation intervention.
16421767|NCT03827928|No Intervention|Wait list|A wait list control period.
16421768|NCT03827915|No Intervention|Third trial of DC cardioversion|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive a third trial of DC cardioversion (Standard of care)
16421769|NCT03827915|Experimental|Double sequential external defibrillation|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive DSED
16421770|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
16421771|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
16421772|NCT03827889|Experimental|WMP of fluoride varnish|Whole mouth protocol group
16421773|NCT03827889|Experimental|TWLP of fluoride varnish|Tooth with lesion Protocol
16421774|NCT03827889|Active Comparator|DHP (educational intervention)|Diet and Hygiene guidance Protocol
16421775|NCT03827876|Experimental|Open Label Enstilar|once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
16421776|NCT03827863||ARDS WITH ACP|"Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg < PaO2/FIO2≤300 mmHg), moderate (100 mmHg < PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.
~Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR>2.8m/s; RVEDA/LVEDA>0.6 or Right ventricle/left ventricle basal diameter ratio>1.0 or systolic D sign; IVC >2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity >2.2m/s."
16421777|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
16421778|NCT03827850|Active Comparator|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
16421779|NCT03827850|Active Comparator|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
16421780|NCT03827850|Active Comparator|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
16421781|NCT03827837|Experimental|SHR-1210 combined with Famitinb|SHR-1210 + Famitinib
16421782|NCT03827824|Experimental|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
16421783|NCT03827824|Active Comparator|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
16421784|NCT03827811||PandrTB cohort|endTB participants on experimental regimen
16421789|NCT03827785|Experimental|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
16421790|NCT03827785|Sham Comparator|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
16421791|NCT03827772|Experimental|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
16421792|NCT03827772|Other|Control Arm|Nutritional supplementation, supportive management
16421793|NCT03827759||septic arthritis (group A)|Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;
16421794|NCT03827759||inflammatory arthritis (group B)|Patients with idiopathic juvenile arthritis
16421795|NCT03827759||control (group C)|10 healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.
16421796|NCT03827733||AD patients|Participants who are diagnosed with AD.
16421797|NCT03827733||Partners of the AD patients|Partners of AD patients who live together with the AD patients.
16421798|NCT03827733||Elderly participants with normal cognition|Community dwelling elderly with normal cognition and with AD.
16421799|NCT03827720|Experimental|Control|Healthy volunteers monitored with Sense Device
16477500|NCT03447080|Other|Control 1|White bread
16421809|NCT03827655|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
16421810|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
16421811|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
16421812|NCT03827642|Experimental|Cohort 1: Treatment Sequence A-D-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
16421813|NCT03827642|Experimental|Cohort 2: Treatment Sequence B-C-D-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
16421814|NCT03827642|Experimental|Cohort 3: Treatment Sequence C-A-B-D|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
16421815|NCT03827642|Experimental|Cohort 4: Treatment Sequence D-B-A-C|Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
16421816|NCT03827629|Experimental|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
16421817|NCT03827629|Experimental|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
16421818|NCT03827629|Experimental|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
16421819|NCT03827629|Experimental|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
16421820|NCT03827629|Experimental|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
16421821|NCT03827629|Experimental|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
16421822|NCT03827616|Active Comparator|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
16421823|NCT03827616|Active Comparator|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
16421824|NCT03827603|Experimental|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
16421825|NCT03827590|Experimental|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
16421826|NCT03827590|Active Comparator|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
16421827|NCT03827590|Active Comparator|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
16421828|NCT03827590|Placebo Comparator|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
16421829|NCT03827577|Experimental|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.
~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
16421830|NCT03827577|Active Comparator|Control Arm|"Standard medical treatment
~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
16421831|NCT03827564|Experimental|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
16421832|NCT03827564|Experimental|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
16421833|NCT03827551|Experimental|Parkinson's Patients|
16421834|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
16421835|NCT03827499|Experimental|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
16421836|NCT03827499|Experimental|NoEx-HMB|HMB Dietary supplementation
16421837|NCT03827499|Placebo Comparator|Ex-Plac|Multicomponent physical exercise program
16421838|NCT03827499|No Intervention|Controls|No intervention
16421839|NCT03827486|Active Comparator|Standard of care|
16421840|NCT03827486|Experimental|Domicilary exercise program|
16421841|NCT03827473|Experimental|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16421842|NCT03827473|Experimental|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
16421843|NCT03827460|Experimental|Free access alcohol self-administration|During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking
16421844|NCT03827460|Experimental|Clamped alcohol exposure|A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.
16421845|NCT03827460|Experimental|2 year followup|Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
16421848|NCT03827434|Active Comparator|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
16421849|NCT03827434|Placebo Comparator|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
16421850|NCT03827408|Active Comparator|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
16421851|NCT03827408|Experimental|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
16421852|NCT03827408|Experimental|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
16421853|NCT03827395|Experimental|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
16421854|NCT03827395|Placebo Comparator|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
16421855|NCT03827382|Active Comparator|Intervention|Patients with intensive Lifestyle intervention
16421856|NCT03827382|No Intervention|Control|Patients with Standard Diabetes care
16421857|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
16421858|NCT03827356|Experimental|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
16421859|NCT03827356|Active Comparator|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
16421860|NCT03827343||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
16421861|NCT03827330||Patients|Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
16421862|NCT03827317|Other|HER2 positive metastatic breast cancer|8 HER2 positive patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
16421863|NCT03827317|Other|HER2 negative metastatic breast cancer|8 HER2 negative patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
16421864|NCT03827304|Experimental|Burns dressings patients|Virtual Reality pain distraction games scenarios
16421865|NCT03827291|Experimental|Quadratus lumborum block|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
16421866|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia.
16421867|NCT03827278|Experimental|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
16421868|NCT03827278|Experimental|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
16421869|NCT03827265|Experimental|TMS on SMA|"Device: repetitive transcranial magnetic stimulation (real)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the Supplementary Motor Area (SMA).
~Other Name: rTMS (active stimulation)"
16421870|NCT03827265|Experimental|TMS on PPC|"Device: repetitive transcranial magnetic stimulation (rTMS)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the posterior parietal cortex (PPC).
~Other Name: rTMS (active stimulation)"
16421871|NCT03827265|Experimental|TMS on dlPFC|"Device: repetitive transcranial magnetic stimulation (rTMS)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain.This arm will target the dorsolateral prefrontal cortex (dlPFC).
~Other Name: rTMS (active stimulation)"
16421872|NCT03827265|Sham Comparator|TMS (Sham Stimulation)|"Device: repetitive transcranial magnetic stimulation (rTMS)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will be a sham stimulation.
~Other Name: rTMS (sham stimulation)"
16421873|NCT03827239|No Intervention|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
16421874|NCT03827239|Experimental|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
16421875|NCT03827213|Experimental|Exparel|an injection of the drug Exparel, a form of the anesthetic bupivacaine
16421876|NCT03827213|Active Comparator|Indwelling Catheter|ropivacaine, given through a catheter inserted between the shoulders
16421877|NCT03827200|Experimental|Ambrisentan|Ambrisentan
16421878|NCT03827187|Experimental|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
16421879|NCT03827174|Active Comparator|Comparison intervention|Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee.
16421880|NCT03827174|Experimental|Experimental intervention|"Return To Work Coordination + Behaviour Change Ability Programme
~Behaviour Change Ability Programme:
~Return to work coordination
~Education for employers and employees in pain neuroscience, validation, and problem-solving
~Patient specific goal setting for return to work
~Exercise and behavioural skills training related to return to work"
16421881|NCT03827161|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
16421882|NCT03827161|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
16421883|NCT03827148|Experimental|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
16421884|NCT03827148|No Intervention|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
16421885|NCT03827135|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
16421886|NCT03827135|Experimental|Cyriax manipulation|Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle stretching.
16421887|NCT03827122|Experimental|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
16421888|NCT03827109|Experimental|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics. Due to the COVID-19 pandemic, these activities can be conducted virtually.
16421889|NCT03827109|Active Comparator|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community. Due to the COVID-19 pandemic, participants are encouraged to interact socially in safe ways, e.g., outdoors or virtually.
16421890|NCT03827096|Experimental|Human AMSC (passage 3) 3P in 1.5 mL|Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
16421891|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
16421892|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
16421893|NCT03827070|Experimental|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
16421894|NCT03827057|Experimental|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
16421895|NCT03827057|Active Comparator|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
16421896|NCT03827044|Experimental|Avelumab|6 months of 2 weekly Avelumab
16421897|NCT03827044|No Intervention|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
16421898|NCT03827031|No Intervention|Control group|
16421899|NCT03827031|Experimental|B1 interventional group|
16421900|NCT03827031|Experimental|B2 interventional group|
16421901|NCT03827018|Active Comparator|mavrilimumab|Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
16421902|NCT03827018|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
16421903|NCT03827005|Placebo Comparator|placebo|3 grams cornstarch once per day for one day.
16421905|NCT03826992|Experimental|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days 1-21 per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 21 doses of venetoclax will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.
~Venetoclax is given daily by mouth per assigned dose level."
16421906|NCT03826979|Experimental|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
16421907|NCT03826953|Other|Nurse led allergy clinic|nurse led allergy clinic
16421908|NCT03826940|Experimental|NF1 - experimental|
16421909|NCT03826940|Placebo Comparator|NF1 - control|
16421910|NCT03826940|Experimental|ASD - experimental|
16421911|NCT03826940|Placebo Comparator|ASD - control|
16421912|NCT03826927||AF and cerebrovascular event|patients with AF and recent (< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events
16421913|NCT03826914|Experimental|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
16421914|NCT03826914|Placebo Comparator|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
16421915|NCT03826901|Experimental|Part 1: adults and adolescents (12 years and above)|Delgocitinib cream (dosage: A mg/g).
16421916|NCT03826901|Experimental|Part 2: children (2-11 years)|Delgocitinib cream (dosage: B mg/g).
16421917|NCT03826875|Experimental|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
16421918|NCT03826875|Placebo Comparator|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
16421919|NCT03826862|Experimental|intervention group|All patients receive CT three-dimensional reconstruction before surgery.
16421920|NCT03826862|No Intervention|control group|All patients did not receive CT three-dimensional before surgery
16421921|NCT03826849|No Intervention|Waitlist Control|Assessment only condition for all 12 weeks of participation.
16421922|NCT03826849|Experimental|Insomnia Coach|Intervention condition that involves use of the Insomnia Coach app for 6 weeks.
16421923|NCT03826836|No Intervention|Control Group|Treatment as usual (i.e. best medical treatment).
16421924|NCT03826836|Experimental|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
16421925|NCT03826823|Experimental|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
16421926|NCT03826810|Experimental|aPDT + ART group|In this group, both aPDT and ART were performed.
16421927|NCT03826810|Experimental|ART group|In this group, only ART was performed.
16421928|NCT03826784|Experimental|BHA|Subjects treated with BHA + standard of care
16421929|NCT03826784|No Intervention|Control|Subjects treated as per standard of care
16421930|NCT03826771|Experimental|POWER training|high velocity strength training
16421931|NCT03826771|Active Comparator|Stretching|Upper and lower body range of motion exercises
16421932|NCT03826758|Other|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
16421933|NCT03826758|No Intervention|Standard care|No change in their clinical practice.
16421934|NCT03826732|Experimental|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
16421935|NCT03826732|No Intervention|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
16421936|NCT03826719|Experimental|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
16421937|NCT03826719|Active Comparator|Agrippal|1 dose of 0.5mL by Intramuscular injection
16421938|NCT03826706|Active Comparator|C-MAC Videolaryngoscope D blade|Patients was intubated with C-MAC videolaryngoscope D blade.
16421939|NCT03826706|Active Comparator|McGrath MAC Videolaryngoscope X3 blade|Patients was intubated with McGrath MAC Videolaryngoscope X3 blade
16421940|NCT03826693|Experimental|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
16421941|NCT03826693|Placebo Comparator|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
16421942|NCT03826680|Active Comparator|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
16421943|NCT03826680|Active Comparator|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
16421944|NCT03826654|Experimental|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
16421945|NCT03826654|Placebo Comparator|control|daily intake of plain oil
16421946|NCT03826641|Experimental|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
16421947|NCT03826641|Experimental|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
16421948|NCT03826641|Experimental|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
16421949|NCT03826641|Experimental|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
16421950|NCT03826628|Experimental|0.5% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
16421951|NCT03826628|Experimental|1.0% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
16421952|NCT03826628|Placebo Comparator|Placebo|Placebo cream topical, applied once daily before bed on affected area for 26 weeks
16421953|NCT03826615|Experimental|Gabapentin|Gabapentin premedication group
16421955|NCT03826602|Experimental|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
16421956|NCT03826589|Experimental|Avelumab and Axitinib|"Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)
~Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
16421957|NCT03826576|Experimental|Intervention Group|Intervention group will receive a Multicomponent Intervention.
16421958|NCT03826576|No Intervention|Control Group|Control group will not receive any kind of intervention, only it will receive information about AMED criteria and allergens of food.
16421959|NCT03826563|Placebo Comparator|Placebo|Subjects will receive pill placebo nightly
16421960|NCT03826563|Experimental|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
16421961|NCT03826550|Experimental|Diclofenac Sodium Gel3%|Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.
16421962|NCT03826550|Active Comparator|Solaraze|Solaraze Gel dosed twice daily for 60 days.
16421963|NCT03826550|Placebo Comparator|Placebo|Placebo Gel dosed twice daily for 60 days.
16421964|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
16421965|NCT03826524|Active Comparator|Low Dose Epinephrine|Epinephrine up to 2mg total
16421966|NCT03826524|Active Comparator|Standard Dose Epinephrine|Epinephrine up to 6mg total
16421967|NCT03826511|Active Comparator|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
16421968|NCT03826511|Active Comparator|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
16421969|NCT03826498|Experimental|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
16421970|NCT03826498|Other|Standard therapy|Patients with standard therapy as control group
16421971|NCT03826485|Experimental|A group|Period 1: PRIC Period 2: Pranlukast hydrate
16421972|NCT03826485|Experimental|B group|Period 1: Pranlukast hydrate Period 2: PRIC
16421973|NCT03826472|Experimental|Almond Butter|Participants will consume one ounce per day (~32 g) of almond butter as an evening snack (i.e., after dinner and before sleep).
16421974|NCT03826472|No Intervention|No-snack Control|Participants will consume nothing besides water after dinner/bed sleep.
16421975|NCT03826459|Active Comparator|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
16421976|NCT03826459|Experimental|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
16421977|NCT03826446|Other|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
16421978|NCT03826446|Other|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
16421979|NCT03826433|Experimental|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)
16421980|NCT03826433|No Intervention|Control Group|Control Group: Using basic contrast .
16421981|NCT03826420|Experimental|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
16421982|NCT03826420|Experimental|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
16421983|NCT03826420|Experimental|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
16421984|NCT03826420|No Intervention|Control Group|
16421985|NCT03826407||DOC patients|Patients in coma (GCS score of 3-8) or with other disorder of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state)
16421986|NCT03826407||Healthy Control|Matched healthy controls without current neurological diagnoses
16421987|NCT03826394|Experimental|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
16421988|NCT03826394|Experimental|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
16421989|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54
~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is > 60, absence of clinical proteinuria.
~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.
~The patients are examined once."
16421990|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54
~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR <60).
~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.
~The patients are examined once."
16421991|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
16421992|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
16421993|NCT03826355|Active Comparator|Stripping technique|The endometrioma is removed according to standard surgery.
16421994|NCT03826355|Experimental|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
16421995|NCT03826342|Experimental|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
16421996|NCT03826342|Active Comparator|Time, attention, and information-matched control|Well-validated
16421997|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
16421998|NCT03826316|Experimental|Mutonpain Injection 10 mg/ml|
16421999|NCT03826303|Experimental|E-cigarette with ethanol, 1 puff|
16422000|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 1 puff|
16422001|NCT03826303|Experimental|E-cigarette with ethanol, 10 puffs|
16422002|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 10 puffs|
16422003|NCT03826290|Experimental|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
16422004|NCT03826290|No Intervention|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
16422005|NCT03826277|Experimental|Melanostop peel treatment group|"Adult women aged between 20-50 years old.
~Melasma on the face
~Fitzpatrick phototypes I-IV
~Presenting facial melasma
~In good health condition"
16422006|NCT03826264||Korea Centers|Seoul, Korea All Patients undergoing TAVR
16422007|NCT03826264||Stanford University|California, USA All Patients undergoing TAVR
16422008|NCT03826264||Northwestern University|Evanston, Illinois, USA All Patients undergoing TAVR
16422009|NCT03826264||Cheng-Hsin Hospital|Taipei, Taiwan All Patients undergoing TAVR
16422010|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
16422011|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
16422012|NCT03826238||ARBD and depression|10 patients with ARBD and at least moderate depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale ≥ 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
16422013|NCT03826238||ARBD and no depression|10 patients with ARBD and no clinically relevant depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale < 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
16422014|NCT03826238||Healthy|10 healthy controls (no ARDB, no depression, no cognitive deficit). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
16422015|NCT03826225||Study Cohort|All participants are considered to be in the study cohort and will have the study device placed externally on their skin in order to collect human ECG data.
16422016|NCT03826212|Experimental|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
16422017|NCT03826212|Placebo Comparator|Placebo|Placebo 1,600 mg/day for 12 weeks.
16422018|NCT03826186|Active Comparator|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
16422019|NCT03826186|Experimental|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
16422020|NCT03826173|Experimental|Positive Psychology|On a weekly basis, participants will engage in group-based intervention sessions that focus on personal strengths and the value of positive emotions and cognitions. Participants will receive daily text-messages addressing the content introduced during group sessions.
16422021|NCT03826173|Active Comparator|Physical Activity Promotion|On a weekly basis, participants will engage in group-based intervention sessions that focus on the standard physical activity promotion components of the PPPA condition. Participants will receive daily text-messages addressing the content introduced during group sessions.
16422022|NCT03826160||Tesamorelin|Individuals who plan to initiate tesamorelin clinically
16422023|NCT03826160||No Treatment|Individuals who decline to initiate tesamorelin despite a clinical indication
16422024|NCT03826147|Active Comparator|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
16422025|NCT03826147|Placebo Comparator|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
16422026|NCT03826134|Experimental|[11C]-PXT012253|
16422027|NCT03826121|Experimental|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
16422028|NCT03826121|Placebo Comparator|Placebo|placebo for 12 weeks
16422029|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
16422030|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
16422031|NCT03826095||Multiple Sclerosis|Patients with a clinically definitive diagnosis of MS, 0-5.5 Extended Disability Status Scale range.
16422032|NCT03826095||Healthy individuals|Voluntary healthy individuals with similar age and gender
16422131|NCT03825341|Active Comparator|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.
16422033|NCT03826069|Active Comparator|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
16422034|NCT03826069|Experimental|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
16422035|NCT03826056|Active Comparator|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
16422036|NCT03826056|Experimental|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
16422037|NCT03826043|Experimental|Experimental arm|Hospitalized patient
16422038|NCT03826030|Sham Comparator|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
16422039|NCT03826030|Active Comparator|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
16422040|NCT03826030|Active Comparator|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
16422041|NCT03826017|Experimental|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
16422042|NCT03826017|Placebo Comparator|Placebo|Placebo for 12 weeks.
16422043|NCT03826004|Placebo Comparator|Placebo|Saline solution 2ml before anesthetic induction
16422044|NCT03826004|Experimental|Clemastine|Clemastine fumarate 2mg/2ml before anesthetic induction
16422045|NCT03825991||Control group|Cohort 1 is a a control group matched 1:5 to the exposed group on sex and age. This group i randomly assigned via Statistics Denmark and does not have a diagnosis of back pain in the time period 2008-2013. They do however have another diseases registered in the Danish Patient Registry, which only contains information on patients having had contacts with the hospital sector i Denmark. Used for study 1.
16422046|NCT03825991||Specific back pain (unexposed)|Cohort 2 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Spinal Disc Herniation DM51.1 and Spinal stenosis DM48.0 (ICD-10 classification).
16422047|NCT03825991||Unspecific back pain (exposed)|Cohort 3 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Other intervertebral disc disorders DM51*-51.1, Dorsalgia DM54, Other disorders of muscle DM62, Postprocedural musculoskeletal disorders not elsewhere classified DM96 and Segmental and somatic dysfunction DM99 (ICD-10 classification)
16422048|NCT03825991||Total population (DM*)|Cohort 4 is the total population including all BPD diagnosis in the time period 2008-2013 in Denmark. This cohort will be used as basis for study 2 and 3, although de definitions of the groups specific back pain (unexposed) and unspecific back pain (exposed) will used in sub-analysis.
16422049|NCT03825978|Active Comparator|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
16422050|NCT03825978|No Intervention|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
16422051|NCT03825965|Experimental|Cannabidiol (CBD)|Oral medicinal cannabis (125 mg cannabidiol daily suspended in oil)
16422052|NCT03825965|Placebo Comparator|Placebo|Visually identical placebo (medium chain triglyceride oil)
16422053|NCT03825952|Experimental|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
16422054|NCT03825939|Experimental|Intravenous Tranexamic Acid|"1g TXA administered intravenous piggyback at start of surgery OR
~1g TXA administered intravenous piggyback at start and at time of closure of surgery"
16422055|NCT03825939|Placebo Comparator|Intravenous Placebo|- IV 0.9% sterile saline
16422056|NCT03825939|Active Comparator|Intravenous Tranexamic Acid followed by Intravenous Placebo|"1g TXA administered intravenous piggyback at start of surgery OR
~1g TXA administered intravenous piggyback at start and at time of closure of surgery
~IV 0.9% sterile saline"
16422057|NCT03825926||Gestational Diabetes Mellitus|The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
16422058|NCT03825926||Non-Gestational Diabetes Mellitus|normal group
16422171|NCT03825042|Experimental|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
16422172|NCT03825042|Placebo Comparator|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
16422059|NCT03825913|Active Comparator|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.
~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.
~Participants in the exercise intervention will complete 24 sessions."
16422060|NCT03825913|Sham Comparator|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
16422061|NCT03825900|Active Comparator|Active tDCS|Active transcranial direct current stimulation
16422062|NCT03825900|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
16422063|NCT03825887|Active Comparator|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
16422064|NCT03825887|Experimental|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
16422065|NCT03825874||amikacin IV|Febrile urinary tract infection treated with amikacin IV
16422066|NCT03825874||Other antibiotics|Febrile urinary tract infection treated with other antibiotic, according to the recommendations: ceftriaxone or cefixime
16422067|NCT03825861|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
16422068|NCT03825848|Experimental|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
16422069|NCT03825848|Experimental|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
16422070|NCT03825835|Active Comparator|30% group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
16422071|NCT03825835|Experimental|60% group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
16422072|NCT03825822|Experimental|ImPaC Resource Intervention (INT)|The INT arm will receive the 7-step web-based ImPaC intervention to use over 6 months. The intervention is divided into the Plan Stage and the Change Stage. The Plan Stage (steps 1-4) is expected to be completed in 1 month. The Change Stage (steps 5-7) is expected to be completed in 1-2 months. We anticipate that Change Teams will be able to complete 2 cycles of change over the 6-month intervention period.
16422073|NCT03825822|Other|Standard Practice (SP)|The SP arm will continue as usual with their unit or institutional standard pain practices and any strategies that they would normally use to improve them (e.g. new staff orientation).
16422074|NCT03825809|Experimental|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:
~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
16422075|NCT03825809|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
16422077|NCT03825783|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single infusion in subjects with severe LAD-I
16422078|NCT03825770|Experimental|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
16422079|NCT03825770|Active Comparator|General Education|General Education about Kidney Disease
16422080|NCT03825757|Experimental|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
16422081|NCT03825757|Placebo Comparator|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
16422082|NCT03825744|Experimental|Hetrombopag Olamine+Standard Therapy|
16422083|NCT03825744|Placebo Comparator|Placebo+Standard Therapy|
16422084|NCT03825731|Experimental|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
16422085|NCT03825718|Experimental|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
16422086|NCT03825705|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
16422173|NCT03825029|Experimental|Pillow Group|There will be a pillow placed between the patients legs during their operation.
16477501|NCT03447080|Other|Control 2|White bread
16422087|NCT03825692|Experimental|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule Arm is Zhizhu Kuanzhong Capsule, Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd. ; Approval number: NMPA approval number: GUOYAOZHUNZI Z20020003; Dosage and administration: 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals
16422088|NCT03825692|Placebo Comparator|Zhizhu Kuanzhong Placebo Capsule|Zhizhu Kuanzhong Placebo Capsule Arm is Zhizhu Kuanzhong Capsule Mimics composed of microcrystalline cellulose, mannitol and magnesium stearate, which used for filling agent and lubricant respectively; Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd.; Dosage and administration: Be identical with the investigational drug.
16422089|NCT03825666|Experimental|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
16422090|NCT03825666|No Intervention|Control|control group following standard guidelines
16422091|NCT03825653||one group|"This study will be carried out on three hundred postmenopausal.They will be selected from gynecological outpatient clinic of (Oum El Masryn Hospital).
~their age will range from 60-70 years.Their BMI will not exceed 30 kg/m2. They are complaining from stress urinary incontinence."
16422092|NCT03825640|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.
~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
16422093|NCT03825627|Active Comparator|Antisaccade Task (active tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
16422094|NCT03825627|Sham Comparator|Antisaccade Task (sham tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm sham Transcranial Direct Current Stimulation will be used during the task.
16422095|NCT03825627|Active Comparator|Approach Avoidance Task (active tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
16422096|NCT03825627|Sham Comparator|Approach Avoidance Task (sham tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
16422097|NCT03825614|Experimental|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
16422098|NCT03825614|Active Comparator|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
16422099|NCT03825614|No Intervention|Control group|Participants in the control group have no exercise in this study.
16422100|NCT03825601|Other|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
16422101|NCT03825601|Other|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
16422102|NCT03825588|Experimental|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
16478417|NCT03440957|Other|Osteopathy treatment|
16422103|NCT03825588|Experimental|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
16422104|NCT03825588|Experimental|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
16422105|NCT03825588|Active Comparator|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
16422106|NCT03825575|Experimental|Incontinence and low level laser therapy|Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
16422107|NCT03825562|Experimental|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
16422108|NCT03825562|Active Comparator|control group|Control group is offered to attend the intervention afterwards
16422109|NCT03825549|No Intervention|Control|No intervention
16422110|NCT03825549|Experimental|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
16422111|NCT03825549|Experimental|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
16422112|NCT03825549|Experimental|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
16422113|NCT03825536|Experimental|Oral methamphetamine|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the experimental treatment arm, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
16422114|NCT03825536|Placebo Comparator|Placebo oral capsule|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the placebo treatment arm, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
16422115|NCT03825523|Experimental|Group A Immediate treatment (iART)|Other: time to start the ART within 48 hours of admission to hospitalization
16422116|NCT03825523|Active Comparator|Group B Conventional treatment (cART)|Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.
16422117|NCT03825510|Experimental|Treatment Arm|
16422118|NCT03825497|Experimental|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
16422119|NCT03825497|No Intervention|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
16422120|NCT03825471|Experimental|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
16422121|NCT03825471|Placebo Comparator|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
16422122|NCT03825445|Experimental|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
16422123|NCT03825445|Experimental|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
16422124|NCT03825393||Fibromyalgia|Non-anemic FMS patients who were diagnosed based on 2011 FMS diagnostic criteria of the American Rheumatology College
16422125|NCT03825393||Control|Non-anemic women without a FMS diagnosis
16422126|NCT03825380|Experimental|T4032|
16422127|NCT03825380|Active Comparator|Lumigan®|
16422128|NCT03825367|Other|Open label design|Nivolumab and 5-azacytidine,
16422129|NCT03825354|Experimental|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
16422130|NCT03825354|No Intervention|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
16478457|NCT03440645|Experimental|Family or Household Members|
16422132|NCT03825341|Active Comparator|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
16422133|NCT03825328|Experimental|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
16422134|NCT03825315|Experimental|DAXI for Injection: LOW Dose|LOW Dose Group
16422135|NCT03825315|Experimental|DAXI for Injection: HIGH Dose|HIGH Dose Group
16422136|NCT03825315|Placebo Comparator|Placebo|Placebo Group.
16422137|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
16422138|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
16422140|NCT03825276|Experimental|Mango consumption|
16422141|NCT03825263|No Intervention|Control|Participants receive normal treatment
16422142|NCT03825263|Experimental|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
16422143|NCT03825250|No Intervention|Group A: Control|Standard of care
16422144|NCT03825250|Experimental|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
16422145|NCT03825250|Experimental|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
16422146|NCT03825250|Experimental|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
16422147|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
16422148|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
16422149|NCT03825211|Experimental|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
16422150|NCT03825211|Active Comparator|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
16422151|NCT03825198|Active Comparator|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.
~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
16422152|NCT03825198|Sham Comparator|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
16422153|NCT03825185|Experimental|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
16422154|NCT03825185|Experimental|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
16422155|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
16422156|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
16422157|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
16422158|NCT03825159|Experimental|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
16422159|NCT03825159|Active Comparator|brace group|Using spinal orthosis BRACE
16422160|NCT03825146|Experimental|Treatment Arm (AMPC)|AMPC will be intravenously infused.
16422161|NCT03825133|Experimental|Bone Marrow Aspirate Concentrate|Patients treated with single injection of BMAC in the knee
16422162|NCT03825133|Experimental|Leukocyte Rich Platelet Rich Plasma|Patients treated with single injection of LR-PRP in the knee
16422163|NCT03825133|Experimental|Hyaluronic Acid|Patients treated with 3 single injection of high molecular HA in the knee ( one injection weekly)
16422164|NCT03825120||Women from original OVA cohort|
16422167|NCT03825081|Experimental|Intervention|"Interventions will be the drugs:
~pilocarpine - 0.5%
~brimonidine - 0.2%
~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
16422168|NCT03825068|Active Comparator|ESP block group|patients receive ESP Bock with local anaesthetics
16422169|NCT03825068|Placebo Comparator|control group|general anaestesia
16422170|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
16422179|NCT03824990|No Intervention|Before-intervention phase|All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
16422180|NCT03824990|Experimental|Intervention phase|All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
16422181|NCT03824990|Experimental|Sustainability intervention phase|All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
16422182|NCT03824951|Experimental|Anti-CD19 iCAR NK Cells|
16422183|NCT03824938|Experimental|Aspirin|Aspirin 650 mg capsule by mouth, single dose
16422184|NCT03824938|Active Comparator|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
16422185|NCT03824938|Placebo Comparator|Placebo|Placebo 650 mg capsule by mouth, single dose
16422186|NCT03824925|Placebo Comparator|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
16422187|NCT03824925|Experimental|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
16422188|NCT03824912|Experimental|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
16422189|NCT03824912|Active Comparator|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
16422190|NCT03824912|Placebo Comparator|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
16422191|NCT03824899|Experimental|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
16422192|NCT03824886|Experimental|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
16422193|NCT03824886|No Intervention|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
16422194|NCT03824873|Active Comparator|internal iliac artery ligation + cesarean hysterectomy|
16422195|NCT03824873|Active Comparator|cesarean hysterectomy|
16422196|NCT03824860|Experimental|Yoga Program|Eight-weeks, therapist and self-guided yoga
16422197|NCT03824860|No Intervention|Treatment as usual|Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
16422198|NCT03824847|Active Comparator|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
16422199|NCT03824847|Placebo Comparator|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
16422200|NCT03824834|Experimental|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) with supervised exercise training.
16422201|NCT03824834|Placebo Comparator|Exercise training with placebo|Placebo treatment with supervised exercise training.
16422202|NCT03824821||IBS|
16422203|NCT03824808|Active Comparator|Treatment group|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
16422204|NCT03824808|Placebo Comparator|Control group|0.9% Sodium Chloride Injection
16422205|NCT03824795|Active Comparator|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
16422206|NCT03824795|Active Comparator|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
16422207|NCT03824795|Active Comparator|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
16422208|NCT03824782|No Intervention|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
16422209|NCT03824782|Experimental|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
16422210|NCT03824769|Active Comparator|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
16422211|NCT03824769|Experimental|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
16422212|NCT03824756|Experimental|NGO supported GMP program|Intervention: NGO supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
16422213|NCT03824756|Active Comparator|Non-supported GMP program|Comparison: Non-supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
16422214|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
16422215|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
16422751|NCT03821168|Active Comparator|intravitreal injection of bevacizumab|bevacizumab:1.25 mg
16422216|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
16422217|NCT03824717|Other|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
16422218|NCT03824704|Experimental|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)
~Cohort A1
~Cohort A2"
16422219|NCT03824691|Experimental|Cabozantinib + Durvalumab|Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily
16422220|NCT03824678|Experimental|Administration of CC-220|All subjects will receive one 1-mg CC-220 capsule administered orally with approximately 240 mL of non-carbonated, room temperature water, and administered by trained clinical staff.
16422221|NCT03824665|Active Comparator|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
16422222|NCT03824665|Active Comparator|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
16422223|NCT03824665|Active Comparator|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
16422224|NCT03824652|Experimental|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
16422225|NCT03824652|Active Comparator|Usual Diet|Usual diet for 4-10 weeks
16422226|NCT03824639|Experimental|Exercise group|Structured exercise
16422227|NCT03824639|Active Comparator|Control group|Health education
16422228|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
16422229|NCT03824613||Endometrial cancer patients|
16422230|NCT03824613||Control group|Patients without cancer
16422231|NCT03824587|Experimental|Tenapanor 30 mg BID|"During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).
~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period."
16422232|NCT03824587|Placebo Comparator|Placebo|same size, weight and appearance of experimental drug
16422233|NCT03824574|Experimental|Treatment arm|Subjects receiving the clear mandibular advancement appliance
16422234|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
16422235|NCT03824535|Experimental|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
16422236|NCT03824522||All Study Participants|All participants enrolled will be treated with ADYNOVATE for hemophilia A at the time of enrollment according to a regimen determined by the study site treating physician/investigator.
16422237|NCT03824509||Patients with an echocardiagram who suffered a stroke or TIA|"Medical record number
~Sex
~Age
~BMI
~Body surface area
~Smoking status
~Congestive heart failure
~Hypertension
~Diabetes,
~Previous history of heart attack or vascular disease
~Previous history of stroke
~Date of stroke
~Type of stroke
~CHA2DS2-VASc scores
~On an anticoagulant yes/no at time of stroke
~Date of atrial fibrillation diagnosis
~Date of echocardiogram
~Echocardiographic features:
~a. Left atrial volume, indexed to body surface area (BSA) b. Left ventricular hypertrophy 4. Stroke outcome:
~Mortality
~NIH Stroke Scale
~Modified Rankin Scale
~Discharge placement:
~i. Home ii. Long term care iii. Skilled nursing facility e. 6-month survival"
16422238|NCT03824509||Control Group - matched CHA2DS2-VASc score, age, and gender|"Controls from both PBMC and MMC will be obtained. Controls are patients from 2014-2017 with matched age (+/- 5 years), gender, and CHA2DS2-VASc score who had atrial fibrillation and had not had a documented stroke or TIA in EPIC or the Get with the Guidelines registry maintained at PBMC. Controls must have an echocardiogram on record and have a diagnosis of atrial fibrillation at the time of the echocardiogram."
16422239|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
16422240|NCT03824483|Experimental|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
16422241|NCT03824470||Group E(rocuronium)|E, after the administration of 1 mg / kg lidocaine, 2 mg / kg propofol, 1 mcg / kg remifentanil and 0.6 mg / kg rocuronium intravenously, patients will be intubated and general anesthesia will be performed when the Tof value is 0.
16422242|NCT03824470||Group R (remifentanil)|1 mg / kg lidocaine, 4 mcg / kg remifentanil and 2 mg / kg propofol intravenously.patients will be intubated and general anesthesia will be performed when the Tof value is 0
16422243|NCT03824457|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
16422244|NCT03824457|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
16422245|NCT03824444|Experimental|Treatment|Implant and followup
16422246|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):
~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .
~."
16422752|NCT03821155|Active Comparator|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
16422247|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
16422248|NCT03824418||Chromoendoscopy follow-up|
16422249|NCT03824418||Autofluorescence follow-up|
16422250|NCT03824405|Active Comparator|BTX 1204|BTX 1204 twice daily
16422251|NCT03824405|Placebo Comparator|Vehicle|Vehicle twice daily
16422252|NCT03824392|Experimental|Cohort 1|ATYR1923 1.0 mg/kg or placebo
16422253|NCT03824392|Experimental|Cohort 2|ATYR1923 3.0 mg/kg or placebo
16422254|NCT03824392|Experimental|Cohort 3|ATYR1923 5.0 mg/kg or placebo
16422255|NCT03824379|Experimental|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
16422256|NCT03824379|Active Comparator|Control|30 patients will receive the standard therapy (anti-diabetic)
16422257|NCT03824366|Experimental|Volumetric MR imaging planning|"All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.
~Patients will receive standard of care palliative radiation therapy"
16422258|NCT03824353|Experimental|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
16422259|NCT03824353|Placebo Comparator|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
16422260|NCT03824340|Active Comparator|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
16422261|NCT03824340|No Intervention|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
16422262|NCT03824327|Experimental|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
16422263|NCT03824314|Experimental|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
16422264|NCT03824314|Experimental|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.
~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
16422265|NCT03824301|Active Comparator|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
16422266|NCT03824301|Active Comparator|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
16422267|NCT03824301|No Intervention|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
16422268|NCT03824288|Active Comparator|The landmark technique|PTA a needle aspiration attempted according to the landmark technique is conducted. If the initial aspiration is unsuccessful, two additional attempts are made in the middle and lower pole of the tonsil.
16422269|NCT03824288|Experimental|Ultrasound-guided aspiration|An intraoral ultrasound is conducted with a Burr-Hole N11C5s transducer (BK Ultrasound) and if an abscess cavity is suspected, an ultrasound-guided aspiration is performed with an in-plane needle guide attached to guide the needle.
16422270|NCT03824275|Experimental|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
16422271|NCT03824262|Experimental|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
16422272|NCT03824262|Active Comparator|Group II|Mistral-Air Plus forced-air warming device
16422273|NCT03824249|Experimental|Spontaneous breathing|Performance of indirect calorimetry in spontaneously breathing children through the use of indirect calorimetry.
16422274|NCT03824249|Experimental|NIV-CPAP|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 centimeters of water (cmH2O). CPAP will be applied via single-limb circuit with intentional leak.
16422275|NCT03824249|Experimental|NIV-PS|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 cmH2O and Pressure support (PS) of 8 cmH2O. Non-invasive ventilation will be applied via single-limb circuit with intentional leak.
16422276|NCT03824236|Experimental|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
16422277|NCT03824236|Experimental|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
16422278|NCT03824236|No Intervention|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
16422279|NCT03824223|Other|new/old HCT component order|"new/old hypoxic challenge test (HCT) component order
~Where the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen and the old test uses pulse oximetry to titrate supplementary oxygen."
16422341|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:
~Pre-eclampsia requiring hospital admission.
~Hyperemesis gravidarum.
~Major postpartum haemorrhage."
16422280|NCT03824223|Other|old/new HCT component order|"old/new hypoxic challenge test (HCT) component order
~Where the old test uses pulse oximetry to titrate supplementary oxygen and the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen."
16422281|NCT03824210||Stage 1|School children age 11-18 (from two nominated schools) and young carers 11-18
16422282|NCT03824210||Stage 2|Young carers from Young Carers in Herts 11-18
16422283|NCT03824197|Other|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
16422284|NCT03824197|Other|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
16422285|NCT03824184|Active Comparator|manipulation of endometrium|Manipulation of endometrium with saline
16422286|NCT03824184|No Intervention|control group|Control group : No intervention
16422287|NCT03824171|Experimental|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
16422288|NCT03824171|Experimental|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
16422289|NCT03824158|Active Comparator|Facilitated advance care planning (in-person or telephonic)|Patients randomized to this arm will participate in in-person or telephonic facilitated advance care planning (ACP) discussions using the Respecting Choices model.
16422290|NCT03824158|Active Comparator|Web-based advance care planning|Patients randomized to this arm will participate in web-based ACP via the PREPARE website.
16422291|NCT03824145|Experimental|Immediate Intervention|"The experimental arm will receive a 12-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 12-week intervention includes:
~1) a curriculum binder covering 12-weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 12-weeks, with four in-person supervised exercise sessions and eight telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to three cooking classes emphasizing plant-based eating."
16422292|NCT03824145|No Intervention|Wait List Control|The Wait List Control group receives no intervention for 12-weeks. Following the 12-week waitlist period, the wait list control group participants receive the experimental intervention.
16422293|NCT03824132|Experimental|Intervention Group|
16422294|NCT03824132|Active Comparator|Waitlist Control Group|
16422295|NCT03824119|Active Comparator|Standard Postpartum Care|Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.
16422296|NCT03824119|Active Comparator|Standard Postpartum Care without NSAIDs|Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.
16422297|NCT03824106|Experimental|Arm1.Socialization|Participants will attend twice-weekly classes (one-hour each) at the YMCA led by an experienced instructor and volunteers who will help facilitate social interactions. Sessions will include structured social activities (such as icebreakers and cards) and guest speakers with topics relevant to seniors. Light refreshments will be served at each session.
16422298|NCT03824106|Experimental|Arm2.Group Exercise|"Participants will attend the exercise program, twice-weekly, classes at one of three YMCA sites in Hamilton/Brantford/Burlington for 6-months. In the first 15-minutes, participants will check-in and report any injuries/concerns. The exercise component will be an hour followed by time allotted for participants to socialize.
~Supplemental Home Exercise: In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults."
16422299|NCT03824106|Experimental|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2. However, participants in each arm of the trial will attend separate exercise classes at the YMCA to avoid possible contamination.
~Protein Supplementation: the protein supplement (each serving) contains 350 kcal, 20-gram protein, 1.5 g β-Hydroxy β-Methylbutyrate (HMB), and participants are advised to take this with a meal or within 3 hours of exercise on activity days."
16422300|NCT03824093|Active Comparator|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
16422301|NCT03824093|Active Comparator|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
16422302|NCT03824080|Experimental|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles without a treatment-free period in between.
~Responding patients (as per criteria of European LeukaemiaNet and International MDS working Group (2006)) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
16422303|NCT03824067|Active Comparator|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
16422304|NCT03824067|Experimental|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
16422305|NCT03824054||colorectal resection arm|Patients affected by symptomatic deep infiltrating endometriosis involving the bowel and submitted to colo-rectal resection
16422306|NCT03824041|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
16422307|NCT03824041|Experimental|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
16422308|NCT03824041|Experimental|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
16422309|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
16422310|NCT03824015|Experimental|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
16422311|NCT03824015|Other|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
16422312|NCT03824002|Experimental|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
16422313|NCT03824002|Active Comparator|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
16422314|NCT03823989|Experimental|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
16422315|NCT03823989|Experimental|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
16422316|NCT03823989|Experimental|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
16422317|NCT03823963|Other|Standard care|pressure ulcer prevention standard care
16422318|NCT03823963|Experimental|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
16422319|NCT03823950|Experimental|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.
~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
16422320|NCT03823950|No Intervention|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
16422321|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
16422322|NCT03823937||Control|18-70 years healthy subjects
16422323|NCT03823924||Psoriatic arthritis|
16422324|NCT03823924||Healthy volunteers|
16422325|NCT03823911|Active Comparator|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
16422326|NCT03823911|Experimental|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
16422327|NCT03823911|Experimental|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
16422328|NCT03823898|Experimental|Supervised exercise|"Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants were involved in two supervised exercise sessions per week plus healthy lifestyle interactive sessions.
~The experimental intervention consisted of: a) monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study; b) The supervised exercise sessions were prescribed using an aerobic mode performed at a moderate-to-vigorous intensity during 45 minutes, twice a week, preferably during the weekends."
16422329|NCT03823898|Active Comparator|Control Group|Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants received no intervention
16422330|NCT03823898|Experimental|Monthly behavioral sessions|"Participants in this group received a lifestyle intervention from baseline to 4 months and then from 4 to 16 months participants were involved in non-supervised exercise group sessions with monthly behavioral sessions.
~The experimental intervention consisted of monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study"
16422331|NCT03823885|Experimental|E-cig|One time exposure to e-cig
16422332|NCT03823885|Experimental|sham|One time exposure to empty e-cig
16422333|NCT03823872|Experimental|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
16422334|NCT03823872|Experimental|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
16422335|NCT03823859||Healthy volunteers|"Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)
~Indirect calorimetry
~Dual energy X-ray Absorptiometry (DXA)"
16422336|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism
~Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)
~Indirect calorimetry
~Dual energy X-ray Absorptiometry (DXA)"
16422337|NCT03823846|Experimental|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
16422338|NCT03823846|Active Comparator|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
16422339|NCT03823820||Cesarean section|Women attending for elective CS.
16422340|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
16422342|NCT03823820||control|Gestational age matched controls.
16422343|NCT03823807|Experimental|SH-1028|QD,Oral
16422344|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
16422345|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
16422346|NCT03823781|Experimental|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
16422347|NCT03823781|Placebo Comparator|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
16422348|NCT03823768|Active Comparator|Arm 1: Control|Tacrolimus immediate release twice daily for 6 months
16422349|NCT03823768|Experimental|Arm 2: Intervention|Envarsus daily for 6 months.
16422350|NCT03823742|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
16422351|NCT03823742|Experimental|Low FODMAP diet|Low FODMAP diet
16422352|NCT03823729|Experimental|Elosan Cabin|Treatment with Elosan cabin
16422353|NCT03823729|No Intervention|No Treatment|Continuation of taking pain medication as prescribed before study start.
16422354|NCT03823703|Experimental|Miricorilant- 900 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 900 mg miricorilant once daily for 12 weeks.
16422355|NCT03823703|Experimental|Miricorilant- 600 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg miricorilant plus placebo once daily for 12 weeks.
16422356|NCT03823703|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive placebo once daily for 12 weeks.
16422357|NCT03823690|Active Comparator|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.
~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
16422358|NCT03823690|Active Comparator|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
16422359|NCT03823677|No Intervention|control group 15|"Protein expression and emotional test
~15 minutes normoxia
~Interventions:
~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels
~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
16422360|NCT03823677|No Intervention|control group 30|"30 minutes normoxia
~Interventions:
~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels
~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
16422361|NCT03823677|No Intervention|control group 60|"60 minutes normoxia
~Interventions:
~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels
~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
16422362|NCT03823677|Experimental|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
16422363|NCT03823677|Experimental|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
16422364|NCT03823677|Experimental|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
16422365|NCT03823677|Experimental|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
16422366|NCT03823677|Experimental|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
16422367|NCT03823677|Experimental|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
16422368|NCT03823677|Experimental|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
16422369|NCT03823677|Experimental|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
16422370|NCT03823677|Experimental|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
16422371|NCT03823677|Experimental|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
16422372|NCT03823677|Experimental|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
16422373|NCT03823677|Experimental|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
16422374|NCT03823664||Type 2 Diabetic|"Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L). OR * A1C ≥6.5% (48 mmol/mol). OR * Patients with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).OR* 2-h Plasma Glucose ≥200 mg/dL (11.1 mmol/L) during oral glucose tolerance test*
~* American Diabetes As. (ADA) type 2 diabetes diagnosis criteria"
16422375|NCT03823664||Prediabetic|"Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (Impaired Fasting Glucose)* OR A1C 5.7-6.4% (39-47 mmol/mol)* OR 2-h Plasma Glucose during 75-g Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (Impaired Glucose Tolerance)*
~* ADA prediabetes criteria"
16422376|NCT03823664||Healthy|Healthy glucose metabolism and according to endocrinology visit no health problems related or affect cardiorespiratory fitness and other parameters examined in this study.
16422377|NCT03823651|Experimental|Patient|These are patients undergoing hematopoetic stem cell transplant. Patients will complete Interval training, undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
16422378|NCT03823651|Experimental|Caregiver|These are the assigned caregivers for transplant patients. Caregivers will undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
16422379|NCT03823638|Experimental|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
16422380|NCT03823638|Placebo Comparator|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
16422381|NCT03823625|Experimental|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
16422441|NCT03823183|Experimental|Physical activity|Group that receives control cognitive activity and physical training
16422382|NCT03823625|Experimental|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
16422383|NCT03823612|Experimental|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
16422384|NCT03823612|Active Comparator|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient
~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
16422385|NCT03823599|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
16422386|NCT03823599|Active Comparator|control group|Alcohol brief intervention
16422387|NCT03823586||Children|
16422388|NCT03823586||Adolescents|
16422389|NCT03823573|Experimental|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
16422390|NCT03823573|Active Comparator|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
16422391|NCT03823560|Experimental|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.
~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:
~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;
~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
16422392|NCT03823560|Placebo Comparator|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.
~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:
~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;
~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
16422393|NCT03823534|Experimental|Experimental Arm|For the first 24 hours following surgery, patients younger than 65 years old will be administered a maximum of 120 mg/day bolus IV ketorolac (30 mg every 6 hours). Patients older than 65 years old or with history of advanced renal impairment will receive a maximum of 60 mg/day bolus IV ketorolac (15 mg every 6 hours). All patients may also be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate- severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. At discharge, they will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours, quantity 50. Those with preexisting liver disease will be prescribed the equivalent in oxycodone and will not receive acetaminophen for mild pain.
16422394|NCT03823534|Placebo Comparator|Control|Following surgery, patients will be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate-severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. They will also be given a placebo injection of normal saline every 6 hours for the first 24 hours following surgery. At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours PRN quantity 50, unless they have preexisting liver disease, in which case they will be prescribed the equivalent in oxycodone. They will not receive a nerve block.
16422396|NCT03823508|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (left dorsolateral prefrontal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
16422397|NCT03823508|Placebo Comparator|sham tDCS|Patients will receive sham tDCS (15 secondes of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
16422398|NCT03823495|Experimental|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
16422399|NCT03823495|No Intervention|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
16422400|NCT03823482|Experimental|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
16422401|NCT03823482|No Intervention|Control group|Participants in control group will have general anesthesia without lidocaine administration.
16422402|NCT03823469|Active Comparator|Intervention: Nutritional counseling + CCTP|Nutritional counseling + Culinary Coaching Telemedicine Program (CCTP)
16422403|NCT03823469|Active Comparator|Control: Nutritional counseling only|Two 30-minute nutritional counseling sessions
16422404|NCT03823456|Experimental|True self-acupressure group|"True self-acupressure group [Enhanced standard care + True self-acupressure intervention protocol]:
~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
16422405|NCT03823456|Placebo Comparator|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
16422406|NCT03823456|No Intervention|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
16422407|NCT03823417|Placebo Comparator|Normal saline placebo|the participant will get saline 0.9% intravenous infusion for the duration of the surgery
16422408|NCT03823417|Experimental|Intravenous Tranexamic acid|Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
16422409|NCT03823404|Experimental|COR388 80 mg bid|
16422410|NCT03823404|Experimental|COR388 40 mg bid|
16422411|NCT03823404|Placebo Comparator|Placebo bid|
16422412|NCT03823391|Experimental|ABBV-3373 Followed by Placebo|Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
16422413|NCT03823391|Experimental|Adalimumab|Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
16422414|NCT03823378|Experimental|ABBV-599 in M16-063/ABBV-599 in M16-763|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
16422415|NCT03823378|Experimental|ABBV-105 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
16422416|NCT03823378|Experimental|ABBV-105 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
16422417|NCT03823378|Experimental|ABBV-105 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
16422418|NCT03823378|Experimental|UPA 15 mg/ABBV-105 placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
16422419|NCT03823378|Experimental|Placebo in M16-063/ABBV-599 in M16-763|Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
16422420|NCT03823365|Experimental|Indolent NHL or CLL patients|Adults diagnosed with indolent non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL) in need of first line treatment consisting of either FCR or BR as per investigator assessment
16422421|NCT03823352|Experimental|Antroquinonol|Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
16422422|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
16422423|NCT03823313|Experimental|Spiritual Care Assessment and Intervention|
16422428|NCT03823261|Experimental|CBT|
16422429|NCT03823248|Experimental|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
16422430|NCT03823248|Active Comparator|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
16422431|NCT03823235|Experimental|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
16422432|NCT03823235|No Intervention|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
16422433|NCT03823222|Experimental|Duckweed protein|20 gram of isolated protein
16422434|NCT03823222|Experimental|Whey protein|20 gram of isolated protein
16422435|NCT03823209|Experimental|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.
~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.
~All social network members will be asked about intervention exposure at 6- and 15-month followups."
16422436|NCT03823209|Active Comparator|Comparison|Participants will receive brief HIV counseling at baseline visit.
16422437|NCT03823196|Experimental|Verum900|The arm will receive 900 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
16422438|NCT03823196|Experimental|Verum1800|The arm will receive 1800 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
16422439|NCT03823183|Experimental|Multi-domain training|Group that receives cognitive training and physical training
16422440|NCT03823183|Experimental|Cognitive training|Group that receives cognitive training and physical control activity
16422442|NCT03823183|Active Comparator|Active control|Group that receives cognitive control activity and physical control activity
16422443|NCT03823170|Experimental|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
16422444|NCT03823170|Active Comparator|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
16422445|NCT03823170|Experimental|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
16422446|NCT03823157|Experimental|Tai Chi|Tai Chi exercise
16422447|NCT03823144|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.
16422448|NCT03823131|Experimental|Arm A: Tavo-EP, pembrolizumab, epacadostat|tavo-EP:pUMVC3-hIL-12-NGVL33 (tavo-EP) will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks. Epacadostat will be administered at the dose level determined in the dose escalation safety lead-in.
16422449|NCT03823131|Experimental|Arm B: Tavo-EP, pembrolizumab|tavo-EP:pUMVC3-hIL-12-NGVL33 (tavo-EP) will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks.
16422450|NCT03823118|Experimental|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
16422451|NCT03823105|Experimental|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
16422452|NCT03823092||Normal|phakic participants with no evidence of eye disorders
16422453|NCT03823092||Cataract|participants with cataract
16422454|NCT03823092||AMD|participants with age related macular degeneration
16422455|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
16422456|NCT03823092||other macula|participants with macular ddisorders other than AMD
16422457|NCT03823092||DR|participants with diabetic retinopathy
16422458|NCT03823079|Experimental|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)
~Concurrent Chemoradiotherapy:
~Radiation: judged according to the tumor site and radiotherapy purpose.
~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)
~Raltitrexed: 3 mg/m2 q3w"
16422459|NCT03823079|Active Comparator|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)
~Concurrent Chemoradiotherapy:
~Radiation: judged according to the tumor site and radiotherapy purpose.
~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)
~Raltitrexed: 3 mg/m2 q3w"
16422460|NCT03823066|Experimental|Coach Pepper|Pepper is a humanoid socially assistive robot
16422461|NCT03823053|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
16422462|NCT03823053|Experimental|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
16422463|NCT03823040|Active Comparator|Tinox® group|Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
16422464|NCT03823040|Experimental|Oxiconazole nitrate SLNs loaded gel group|13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
16422465|NCT03823027|Experimental|Single-arm|The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
16422466|NCT03823014|Experimental|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
16422467|NCT03823001|Experimental|Virtual prostate biopsy (VB) monitoring|"Prostate-specific antigen (PSA) and digital rectal exam (DRE) are standard of care for monitoring patients on active surveillance or at risk of having low-risk prostate cancer. A novel virtual biopsy (VB) monitoring protocol will be implemented:
~PSA bi-annually or more often according to the discretion of the urologist.
~Annual DRE.
~Visit with the urologist bi-annually.
~Multi-parametric MRI (mpMRI) every year for 3 years.
~Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
16422468|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
16422573|NCT03822364|Placebo Comparator|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
16422469|NCT03822975|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
16422470|NCT03822975|Active Comparator|Heparin|Heparin alone during primary PCI
16422471|NCT03822962|Other|Standard Tylenol Regimen|"Patient will be given a standard regimen:
~Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed."
16422472|NCT03822962|Active Comparator|Ibuprofen 600mg|Tylenol 1000 mg by mouth every 6 hours scheduled and ibuprofen 600 mg tablet by mouth every 8 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
16422473|NCT03822949|Experimental|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
16422474|NCT03822949|Sham Comparator|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
16422475|NCT03822936|Experimental|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
16422476|NCT03822923|Experimental|Experimental group|Neurodynamics (Dynamic Neural Mobilization) with conventional treatment (stretching, AROM) will be applied.
16422477|NCT03822923|Active Comparator|control group|Conventional treatment (stretching, AROM) will be applied
16422478|NCT03822910||Healthy Controls|Matched Healthy Controls
16422479|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
16422480|NCT03822897|Other|Two Treatment Options|"Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks
~Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy"
16422481|NCT03822884|Experimental|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
16422482|NCT03822884|Experimental|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
16422483|NCT03822884|Active Comparator|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
16422484|NCT03822871|Experimental|Cohort A-J|Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled.
16422485|NCT03822871|Experimental|Cohort K - at Recommended Phase 2 Dose|Cohort F: Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled at the recommended phase 2 dose.
16422486|NCT03822845|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
16422487|NCT03822832|Experimental|Spesolimab|i.v.
16422488|NCT03822832|Placebo Comparator|Placebo|i.v.
16422489|NCT03822819|Experimental|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
16422490|NCT03822819|Placebo Comparator|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
16422491|NCT03822806|Experimental|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise (using the videogame JustDance) for the first 30 minutes of those 2 hours using the video game (continuing to wear the patch for 90 minutes after exercise).
16422492|NCT03822793|Placebo Comparator|Placebo|Patient will be included in this group by randomization and they will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.
16422493|NCT03822793|Experimental|Group 1: perfusion of 500 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive a perfusion of 500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
16422494|NCT03822793|Experimental|Group 2: perfusion of 1000 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive a perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
16422495|NCT03822793|Experimental|Group 3: perfusion of 1500 mg Exacyl|Patient will be included in the group 3 by randomization and they will receive a perfusion of 1500 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
16422496|NCT03822793|Experimental|Group 4: perfusion of 3000 mg Exacyl|Patient will be included in the group 4 by randomization and they will receive a perfusion of 3000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
16422497|NCT03822780|Experimental|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.
~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
16422498|NCT03822767|Experimental|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
16422499|NCT03822767|Active Comparator|Control Group|wIPV-wIPV-bOPV vaccination schedule
16422500|NCT03822754|Experimental|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
16422501|NCT03822754|Active Comparator|Control Group|wIPV-bOPV-bOPV vaccination schedule
16422502|NCT03822728|No Intervention|Without 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
16422503|NCT03822728|Experimental|With 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
16422504|NCT03822715|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
16422505|NCT03822702|No Intervention|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.
~The same tasks will be ask to do again three days later."
16422506|NCT03822702|No Intervention|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.
~The same tasks will be ask to do again three days later."
16422507|NCT03822702|No Intervention|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
16422508|NCT03822702|Experimental|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.
~For post-test, the same procedure will be ask to do again about one and a half month later .
~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
16422509|NCT03822702|Experimental|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.
~For post-test, the same procedure will be ask to do again about one and a half month later .
~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
16422510|NCT03822702|No Intervention|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.
~The same procedure will be ask to do again about one and a half month later."
16422511|NCT03822689|Active Comparator|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
16422512|NCT03822689|Active Comparator|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
16422513|NCT03822676|Experimental|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
16422514|NCT03822676|No Intervention|No stent|No prophylactic stent before surgery
16422515|NCT03822663|Experimental|Caffeine supplementation|Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
16422516|NCT03822663|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo.
16422517|NCT03822637|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
16422518|NCT03822637|Placebo Comparator|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
16422519|NCT03822624|Experimental|Probiotic group|
16422520|NCT03822624|Placebo Comparator|Placebo group|
16422521|NCT03822611|Experimental|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
16422522|NCT03822611|No Intervention|No subsidy|In these communities, no household receives a voucher.
16422523|NCT03822598|Experimental|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
16422524|NCT03822598|Active Comparator|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
16422525|NCT03822585|Other|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters & Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
16422526|NCT03822572|Experimental|A - endurance exercise|All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
16422527|NCT03822572|Other|B - control arm|Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
16422528|NCT03822559|Experimental|DE-111A eye drops|
16422529|NCT03822559|Active Comparator|0.0015% tafluprost eye drops|
16422530|NCT03822546|Experimental|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
16422531|NCT03822546|Active Comparator|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
16422532|NCT03822546|Active Comparator|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
16422533|NCT03822546|Active Comparator|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
16422534|NCT03822546|Active Comparator|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
16422535|NCT03822546|Active Comparator|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
16422536|NCT03822533|Other|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.
~Patients can seek a physician anytime after the first assessment with the physiotherapist."
16422537|NCT03822533|Other|Physician as primary assessor|"The Healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.
~Patients can seek a physiotherapist anytime after the first assessment with the physician."
16422538|NCT03822520|Experimental|Celecoxib, Moxifloxacin, Water in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days
~Wash-out period (3~6 days)
~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day
~Wash-out period (3~6 days)
~Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
16422539|NCT03822520|Experimental|Celecoxib, Water, Moxifloxacin in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days
~Wash-out period (3~6 days)
~Intervention Pure water: Water 150ml by mouth without any drug, once for one day
~Wash-out period (3~6 days)
~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
16422540|NCT03822520|Experimental|Moxifloxacin, Water, Celecoxib in order|"Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day
~Wash-out period (3~6 days)
~Intervention Pure water: Water 150ml by mouth without any drug, once for one day
~Wash-out period (3~6 days)
~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
16422541|NCT03822520|Experimental|Water, Moxifloxacin, Celecoxib in order|"Intervention Pure water: Water 150ml by mouth without any drug, once for one day
~Wash-out period (3~6 days)
~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day
~Wash-out period (3~6 days)
~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
16422542|NCT03822507|Experimental|KHK7580 1mg-12mg|
16422543|NCT03822507|Active Comparator|Cinacalcet 25mg-100mg|
16422544|NCT03822494|Experimental|Dose Escalated CyberKnife SBRT|
16422545|NCT03822481|Experimental|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
16422546|NCT03822481|No Intervention|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
16422547|NCT03822468|Experimental|Ribociclib 400 mg|Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
16422548|NCT03822468|Active Comparator|Ribociclib 600 mg|Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
16422549|NCT03822455|Active Comparator|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
16422550|NCT03822455|Placebo Comparator|Placebo DPI|Placebo DPI containing lactose and excipients
16422551|NCT03822429||women < 35 years old|
16422552|NCT03822429||women between 36 and 38 years old|
16422553|NCT03822429||women between 39 and 40 years|
16422554|NCT03822429||women > 41 years old|
16422555|NCT03822416|Experimental|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
16422556|NCT03822416|Other|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
16422557|NCT03822403|Active Comparator|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
16422558|NCT03822403|Active Comparator|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
16422559|NCT03822390||Patients|Patients older than 18 years undergoing colonoscopy in one the participating centres.
16422560|NCT03822377|Experimental|Ticagrelor orodispersible tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.
~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
16422561|NCT03822377|Active Comparator|Ticagrelor standard tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.
~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
16422562|NCT03822364|Experimental|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
16422563|NCT03822364|Experimental|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
16422564|NCT03822364|Experimental|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
16422565|NCT03822364|Placebo Comparator|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
16422566|NCT03822364|Active Comparator|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
16422567|NCT03822364|Placebo Comparator|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
16422568|NCT03822364|Experimental|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
16422569|NCT03822364|Placebo Comparator|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
16422570|NCT03822364|Experimental|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
16422571|NCT03822364|Placebo Comparator|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
16422572|NCT03822364|Experimental|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
16422579|NCT03822338|Experimental|Pneumoperitoneum preconditioning group|Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.
16422580|NCT03822338|Sham Comparator|Control group|Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation.
16422581|NCT03822312|Experimental|DBT-TOBI|"Subjects will be imaged using DBT-TOBI at the time points indicated in the Study Calendar (Baseline, before cycle 2, and additional optional time points).
~Both breasts will be measured in turn.
~Each breast is symmetrically centered on the x-ray detector/optical illuminator and is first compressed according to standard mammography procedures to determine the amount of force needed for each given patient
~An optional Magnetic Resonance Imaging TOBI (MRI-TOBI) scan will also be performed."
16422582|NCT03822299|No Intervention|Placebo|Patients receive suspension of their own feces.
16422583|NCT03822299|Active Comparator|30 g donor dose|Patients receiving 30 g of a healthy donor feces.
16422584|NCT03822299|Active Comparator|60 g donor dose|Patients receiving 60 g of a healthy donor feces.
16422585|NCT03822286|Experimental|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
16422586|NCT03822286|Active Comparator|Control|Traditional classroom teaching course programs.
16422587|NCT03822273|Experimental|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
16422588|NCT03822273|Active Comparator|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
16422589|NCT03822273|Placebo Comparator|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
16422590|NCT03822260||Sur1/ Trpm 4 acitivities at SAH|only after collecting sample,
16422591|NCT03822247|Experimental|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.
~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
16422592|NCT03822247|No Intervention|Conventional Perioperative Care|Patients undergoing conventional care
16422593|NCT03822234|Experimental|Modified ileal conduit|With our modified ileal conduit technique
16422594|NCT03822234|No Intervention|Conventional ileal conduit|Conventional ileal conduit
16422595|NCT03822221|Experimental|SK20º|MVIC and NMES with hip at 85º and knee at 20º
16422596|NCT03822221|Experimental|SK60º|MVIC and NMES with hip at 85º and knee at 60º
16422597|NCT03822221|Experimental|LK20º|MVIC and NMES with hip at 0º and knee at 20º
16422598|NCT03822221|Experimental|LK60º|MVIC and NMES with hip at 0º and knee at 60º
16422599|NCT03822208|Active Comparator|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
16422600|NCT03822208|Placebo Comparator|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
16422601|NCT03822195||asymptomatic|asymptomatic patients undergoing carotid endoarterectomy for stenosis >70% (velocimetric criteria at echodoppler)
16422602|NCT03822195||symptomatic|symptomatic (TIA, crescendo TIA, minor stroke) patients undergoing carotid endoarterectomy, independently from stenosis evaluated by echodoppler
16422603|NCT03822182|Other|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
16422604|NCT03822182|Active Comparator|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
16422605|NCT03822182|Active Comparator|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
16422606|NCT03822169|Experimental|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
16422607|NCT03822169|Active Comparator|Choline added as a salt|control shake with choline added as a salt and added DHA.
16422608|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
16422609|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
16422610|NCT03822143|Experimental|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
16422611|NCT03822130|Placebo Comparator|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
16422612|NCT03822130|Experimental|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
16422613|NCT03822130|Experimental|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
16422614|NCT03822117|Experimental|Pemigatinib|"Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements* (not eligible for Cohort A)).
~*Only FGFR fusions or rearrangements with an intact kinase domain are eligible"
16422615|NCT03822104|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
16422616|NCT03822104|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
16422617|NCT03822091|Active Comparator|TERLIPRESSIN GROUP|
16422618|NCT03822091|Experimental|TERLIPRESSIN WITH NORADRENALINE GROUP|
16482497|NCT03413306|Experimental|Eltrombopag + IST (ATG + CsA)|
16422619|NCT03822078|Placebo Comparator|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
16422620|NCT03822078|Experimental|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
16422621|NCT03822065|Experimental|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
16422622|NCT03822065|Experimental|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
16422623|NCT03822052|Active Comparator|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
16422624|NCT03822052|Active Comparator|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
16422625|NCT03822052|Active Comparator|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
16422626|NCT03822052|Active Comparator|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
16422627|NCT03822026|Other|patients with severe TBI|Patients with severe TBI enrolled in the study undergo an hyperventilation test, in which the alveolar ventilation is increased by a stepwise increase in tidal volumes and respiratory rate until a reduction of etCO2 of 0.7 kPa is achieved.
16422628|NCT03822013|Experimental|Miglustat|"Miglustat is administered, dose is adjusted according to Body Surface Area as below:
~>1.25 : 200 mg TDS 0.88-1.25 : 200mg BID 0.73-0.88 :100mg TDS 0.47-0.73 : 100mg BID <0.47 :100mg daily"
16422629|NCT03822013|No Intervention|No Miglustat|
16422630|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
16422631|NCT03821987|Experimental|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.
~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
16422632|NCT03821974|Experimental|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
16422633|NCT03821974|Experimental|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
16422634|NCT03821961|Experimental|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
16422635|NCT03821948||Average CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure
16422636|NCT03821948||Increased CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure
16422637|NCT03821935|Experimental|ABBV-151 Monotherapy|Various doses of ABBV-151 administered during dose escalation, followed by dose expansion of ABBV-151 administered at the Recommended Phase 2 Dose (RP2D).
16422638|NCT03821935|Experimental|ABBV-151 + Budigalimab Combination Therapy|Various doses of ABBV-151 plus budigalimab Dose A administered every 4 weeks (Q4W) during dose escalation, followed by dose expansion of ABBV-151 administered at the RP2D plus budigalimab Dose A administered Q4W.
16422639|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
16422640|NCT03821922||Control|Those healthy pregnant women
16422641|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
16422642|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
16422643|NCT03821896|Experimental|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
16422644|NCT03821896|Active Comparator|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
16422645|NCT03821883|Experimental|Aspirin group|Study patients assigned to Aspirin group will receive enteric coated aspirin (100 mg/day).
16422646|NCT03821883|Placebo Comparator|Control group|Study patients assigned to control group will receive placebo.
16422647|NCT03821870||Standard treatment|Standard first line treatment
16422649|NCT03821844|Experimental|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
16422650|NCT03821844|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
16422651|NCT03821831||Continuous Positive Airway Pressure|This group consists of consenting patients and their parents who choose Continuous Positive Airway Pressure (CPAP). The CPAP is a type of therapy that applies mild air pressure to a person's upper airway to keep their airway open so that they can breathe normally while they sleep.
16422652|NCT03821831||Orthodontic Intervention|This group consists of consenting patients and their parents who choose orthodontic intervention will be seen by participating orthodontists who will determine types of orthodontic intervention; mandibular advancement devices or rapid maxillary expansion devices. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
16422653|NCT03821831||Control|This group consists of consenting patients and their parents who choose to remain untreated. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
16422655|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise > 75% max HR), five times/day.
16422656|NCT03821805|Experimental|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
16422657|NCT03821805|No Intervention|Control group|Rest for 30 min
16422658|NCT03821792|Experimental|Treatment (abiraterone acetate, prednisone, apalutamide)|Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
16422659|NCT03821779|Experimental|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.
~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).
~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
16422660|NCT03821779|Experimental|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:
~real exposure: oral presentation to a panel of examiners
~virtual reality : oral presentation to virtual examiners
~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.
~Psychometric evaluation will be performed prior to experimental sessions."
16422661|NCT03821779|Experimental|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:
~virtual reality : oral presentation to virtual examiners
~real exposure: oral presentation to a panel of examiners
~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.
~Psychometric evaluation will be performed prior to experimental sessions."
16422662|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
16422663|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)> 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
16422664|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
16422665|NCT03821714|Experimental|Glucocorticoid combination therapy Group|Hydrocortisone 200mg continuous intravenous infusion(24h) combined with vitamin C1.5g intravenous infusion every 6 hours and vitamin B1 200mg intravenous infusion every 12 hours.
16422666|NCT03821714|Active Comparator|Glucocorticoid Group|Hydrocortisone 200mg continuous intravenous infusion(24h)
16422667|NCT03821701|Experimental|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
16422668|NCT03821701|Active Comparator|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
16422669|NCT03821701|Experimental|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
16422670|NCT03821701|Active Comparator|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
16422671|NCT03821688|Experimental|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
16422672|NCT03821688|Active Comparator|MGB|laparoscopic mini gastric bypass
16422673|NCT03821688|Active Comparator|LSG|laparoscopic sleeve gastrectomy
16422674|NCT03821675|Active Comparator|Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
16422675|NCT03821675|Sham Comparator|Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
16422676|NCT03821662|Experimental|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
16422677|NCT03821649|Experimental|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
16422678|NCT03821649|Active Comparator|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
16422679|NCT03821636|Sham Comparator|Standard Roux-en-Y|
16422680|NCT03821636|Active Comparator|Long alimentary limb Roux-en-Y|
16422681|NCT03821623|Experimental|Nicotinamide riboside|Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.
16422682|NCT03821623|Placebo Comparator|Placebo|Subjects will take placebo pills twice a day for 3 months.
16422683|NCT03821610|Active Comparator|Fludarabine / Melphalan / Alemtuzumab|Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells
16422817|NCT03820635||Non-calcified|those with no evidence of vascular calcification
16422684|NCT03821610|Experimental|Cyclophosphamide / TBI (8Gy)|Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow
16422685|NCT03821597|Experimental|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
16422686|NCT03821597|Active Comparator|No sequential compression devices|No sequential compression devices are applied.
16422687|NCT03821571|Experimental|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
16422688|NCT03821571|Active Comparator|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
16422689|NCT03821558|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak exercise performance) and low-intensity intervals (60-70% of peak exercise performance).
16422690|NCT03821558|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo moderate continuous exercise training at 75% of peak exercise performance.
16422691|NCT03821545|Active Comparator|Lidocaine Group|
16422692|NCT03821545|Active Comparator|Ketamine Group|
16422693|NCT03821545|Active Comparator|Lidocaine and Ketamine Group|
16422694|NCT03821545|Placebo Comparator|Placebo (0.9% NaCl) Group|
16422695|NCT03821532|No Intervention|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
16422696|NCT03821532|Experimental|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
16422697|NCT03821519|Experimental|Relapsed after Haplo transplant|
16422698|NCT03821506|Experimental|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
16422699|NCT03821506|Placebo Comparator|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
16422700|NCT03821493|Experimental|PF-06651600 treatment arm|This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
16422701|NCT03821480|Experimental|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
16422702|NCT03821480|Active Comparator|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
16422703|NCT03821467|Experimental|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
16422704|NCT03821454|Experimental|Capecitabine|The experimental group received oral capecitabine for eight cycles.
16422705|NCT03821454|Placebo Comparator|Placebo|The placebo group received oral placebo for eight cycles.
16422706|NCT03821441|Experimental|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.
~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
16422707|NCT03821441|Experimental|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.
~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
16422708|NCT03821441|Experimental|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
16422709|NCT03821428|Experimental|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
16422710|NCT03821428|Placebo Comparator|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
16422711|NCT03821415|Experimental|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
16422712|NCT03821415|Experimental|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
16422713|NCT03821415|Experimental|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
16422714|NCT03821415|Placebo Comparator|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
16422715|NCT03821402|Experimental|DAXI for injection dose LOW DOSE|LOW dose group
16422716|NCT03821402|Experimental|DAXI for injection dose MEDIUM DOSE|MEDIUM dose group
16422717|NCT03821402|Experimental|DAXI for injection Dose HIGH DOSE|HIGH dose group
16422718|NCT03821402|Placebo Comparator|Placebo|Placebo group
16422719|NCT03821389|Experimental|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
16422720|NCT03821389|Active Comparator|NIOD Frequencer of 60Hz|
16422721|NCT03821376|Experimental|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
16422722|NCT03821363|Experimental|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
16422723|NCT03821363|Experimental|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
16422724|NCT03821363|Experimental|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
16422725|NCT03821350|No Intervention|Control Group|The control group was given verbal information
16422726|NCT03821350|Experimental|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
16422727|NCT03821337|Experimental|rTMS|Participants will receive 18 sessions of active rTMS delivered at 120% rMT.
16422728|NCT03821337|Placebo Comparator|Sham TMS|Participants will receive 18 sessions of sham rTMS delivered through an inactive coil.
16422729|NCT03821324|Other|Intervention|Device: Venus Viva
16422730|NCT03821311|Experimental|Computed tomography examination|Each patient will undergo a low-dose supine position chest CT scan including end-inspiratory and expiratory acquisitions, corresponding to the routine protocol for COPD patients, except that this end-inspiratory/end-expiratory CT is repeated 3 times for total of 6 CT acquisitions.
16422731|NCT03821298|Experimental|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
16422732|NCT03821285|Experimental|pulmonary rehabilitation|Pulmonary rehabilitation program
16422735|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
16422736|NCT03821246|Experimental|Cohort A (atezolizumab)|Patients receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
16422737|NCT03821246|Experimental|Cohort B (atezolizumab, tocilizumab)|Patients will receive one (1) cycle of neoadjuvant atezolizumab and one (1) cycle of tocilizumab, 6mg/kg will be administered IV on day 1 of a 14 day IV prior to RP; atezolizumab will be administered in an identical fashion as Cohort A. RP will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
16422738|NCT03821246|Experimental|Cohort C (atezolizumab, etrumadenant)|Patients will receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle and etrumadenant will be taken at a dose of 150mg PO, once daily, until 48 hours prior to RP, for at least 12 days. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
16422739|NCT03821233|Experimental|ZW49|
16422740|NCT03821220|Active Comparator|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
16422741|NCT03821220|Active Comparator|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
16422742|NCT03821220|Active Comparator|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
16422743|NCT03821207|Active Comparator|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
16422744|NCT03821207|Active Comparator|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
16422745|NCT03821207|Placebo Comparator|The control group|The control group will perform no exercise or massage.
16422746|NCT03821194|Experimental|Gua sha group|do gua sha for the subjects
16422747|NCT03821194|Active Comparator|control group|give hot pack for the subjects
16422748|NCT03821181|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
16422749|NCT03821181|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
16422750|NCT03821168|Active Comparator|intravitreal injection of bevacizumab and erythropoietin|erythropoietin:
16422753|NCT03821155|Experimental|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
16422754|NCT03821142|Experimental|Calistar S|Single arm cohort trial
16422755|NCT03821129|Other|GORE® CARDIOFORM Septal Occluder|Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
16422756|NCT03821116|Experimental|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
16422757|NCT03821116|Experimental|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
16422758|NCT03821103|Experimental|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
16422759|NCT03821103|Experimental|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
16422760|NCT03821090||cases|"Eighty rheumatoid arthritis patients fulfilling American College of Rheumatology (ACR) 2010 classification criteria, all of them will be subjected to
~History including disease duration , course and associated diseases
~Clinical examination with specific joint examination
~RA disease activity will be evaluated by a 28- joint DAS (DAS28).
~The Framingham 10 year risk of general cardiovascular disease score will be calculated 5-12-lead ECG
~6-Echocardiography 7-Carotid intima media thickness (cIMT)using carotid doppler 8-Venous blood will be withdrawn to do the following laboratory tests
~CBC
~ESR &CRP
~RF& Anti-ccp
~Urine analysis , Urea and creatinine , and GFR
~Uric acid level
~Lipogram
~HA1C
~TNF α
~High sensitive cardiac troponin I (hs-cTnI)"
16422761|NCT03821090||control|"Eighty healthy subjects age and sex matched will be included , all of them will be subjected to
~History
~Clinical examination .
~The Framingham 10 year risk of general cardiovascular disease score will be calculated 4-12-lead ECG
~5-Echocardiography 6-Carotid intima media thickness (cIMT)using carotid doppler 8-Venous blood will be withdrawn to do the following laboratory tests
~Complete Blood Count (CBC)
~Erythrocyte Sedimentation Rate (ESR) &C Reactive Protein(CRP)
~Rheumatoid Factor (RF)& Anti-ccp
~Urine analysis , Urea and creatinine , and Glomerular Filtration Rate(GFR)
~Uric acid level
~Lipogram
~HA1C
~TNF α
~High sensitive cardiac troponin I (hs-cTnI)"
16422762|NCT03821064|Experimental|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
16422765|NCT03821025|Active Comparator|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
16422766|NCT03821025|Active Comparator|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
16422767|NCT03821012||CSCAP-1|STEMI with symptom onset within 12 h regardless of whether receiving reperfusion or symptom onset within 12-24 h of needing PPCI
16422768|NCT03821012||CSCAP-2|STEMI patients with symptom onset within 30 days
16422769|NCT03821012||CSCAP-3|STEMI patients with symptom onset within 30 days
16422770|NCT03820999|Experimental|Teaching arm|The Primary Health Care physicians getting oral and written information on tick-bites and Lyme disease with focus on Lyme neuroborreliosis.
16422771|NCT03820999|No Intervention|Passive arm|The Primary Health Care physicians that does not get contacted with an offer to receive oral and written information.
16422772|NCT03820986|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
16422773|NCT03820986|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
16422774|NCT03820973|Experimental|Brief CBT for Anxiety|Participants will receive Brief Cognitive Behavioral Therapy for Anxiety (bCBT). Sessions with clinicians will be provided via VA Video Connect to Home (VVC-H). Participants will have the option to select from a list of skills to tailor to his/her preferences. Participants will be able to receive up to 9 total sessions and generally last 30 to 40 minutes. For the purpose of this study, treatment duration will be limited to 3 months to ensure standardization of study outcome measures.
16422775|NCT03820947|Experimental|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
16422776|NCT03820947|Active Comparator|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
16422777|NCT03820947|Active Comparator|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
16422778|NCT03820947|Other|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
16422779|NCT03820934|Other|Patients undergoing Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these test. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
16422815|NCT03820648|Active Comparator|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
16422816|NCT03820635||Calcified|those with evidence of vascular calcification
16422780|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.
~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
16422781|NCT03820908|Experimental|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
16422782|NCT03820882|Experimental|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
16422783|NCT03820882|Active Comparator|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
16422784|NCT03820869|Active Comparator|Control|Children with ASD
16422785|NCT03820869|Experimental|Intervention|Children with ASD
16422786|NCT03820856|Experimental|acupuncture plus fire needle group|
16422787|NCT03820856|Active Comparator|acupuncture group|
16422788|NCT03820843|Experimental|Art therapy|Art therapy and standard orthophonic rehabilitation
16422789|NCT03820843|No Intervention|Control group|Only standard orthophonic rehabilitation
16422790|NCT03820830|Experimental|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
16422791|NCT03820830|Active Comparator|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
16422793|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
16422794|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
16422795|NCT03820791|Experimental|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
16422796|NCT03820791|No Intervention|No poster|No poster is placed in patients' room.
16422797|NCT03820778|Experimental|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
16422798|NCT03820752||Pediatric chronically ill patients|"Through a questionnaire parents of chronically ill patients will be asked about the vaccination status of all recommended vaccines of their child. Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.
~A blood sample to determine antibodies against measles, mumps, rubella and pertussis will be drawn from children who consent to sampling.
~The following groups of patients will be questioned: diabetes, allergy, congenital heart disease, cystic fibrosis, immunodeficiency and transplant patients, cancer patients."
16422799|NCT03820752||Adult chronically ill patients|"Through a questionnaire chronically ill patients will be asked about their vaccination status of diphtheria, tetanus,pertussis, flu, pneumococcal and hepatitis B vaccine(s). Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.
~A blood sample to determine antibodies against diphtheria, tetanus and pertussis will be drawn.
~The following groups of patients will be questioned: diabetes, chronic kidney disease, heart failure, COPD, immunodeficiency and transplant patients, HSCT patients."
16422800|NCT03820739||Cohort 1|Subjects who received an Ebola vaccine prime vaccination in EBOVAC-Salone are eligible for enrolment in this study. Adults are defined as participants 18 years of age or older at the time of prime vaccination, and children are defined as participants aged 1 to 17 years at the time of prime vaccination in EBOVAC-Salone.
16422801|NCT03820739||Cohort 2 (offspring)|Infants conceived by a female participant in EBOVAC-Salone during the 3 months following vaccination with Ad26.ZEBOV or during the 28 days following vaccination with MVA-BN®-Filo.
16422803|NCT03820713|Experimental|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
16422804|NCT03820713|Placebo Comparator|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
16422805|NCT03820700|No Intervention|Control group|[Randomized] Patients in control group will receive regular nursing care but no behavioral therapy intervention.
16422806|NCT03820700|Experimental|Hypnosis (Hypn)|[Randomized] Patients will receive a hypnosis recorded audiotape.
16422807|NCT03820700|Experimental|Virtual reality (VR)|[Randomized] Patients will see a 3D movie with a beautiful landscape.
16422808|NCT03820700|Experimental|Virtual reality hypnosis (VRH)|[Randomized] Patients will see the same 3D film combined with a hypnotic voice.
16422809|NCT03820687|Active Comparator|Intervention Group|Participants in the intervention group will receive 3 components: 1) a culturally tailored clinical trial educational video, 2) a brochure and 3) support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trials by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option for cancer.
16422810|NCT03820687|Active Comparator|Usual Care Control Group|Participants in the usual care control group will receive a general clinical trial fact sheet.
16422811|NCT03820674|Experimental|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
16422812|NCT03820674|Active Comparator|Health Education Intervention|Receiving control intervention
16422813|NCT03820661|Other|High Resolution Ultasound|Diagnostic high resolution ultrasound pre-operatively and intraoperatively
16422814|NCT03820648|Experimental|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
16482498|NCT03413306|Active Comparator|IST (ATG + CsA)|
16422818|NCT03820622|Experimental|DIOR group|in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
16422819|NCT03820622|Active Comparator|Bingo group|in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)
16422820|NCT03820609|Experimental|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
16422821|NCT03820596|Experimental|Sintilimab+Chidamide|"Sintilimab：200mg(fixed dosage), ivd, qd, q21d
~Chidamide:
~Phase I: 20mg-30mg,biw,continued oral，to evaluate RP2D. Phase II：RP2D，continued oral"
16422822|NCT03820570|Experimental|lichtenstein|hernia repair
16422823|NCT03820557|Experimental|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
16422824|NCT03820544|Experimental|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
16422825|NCT03820544|Active Comparator|Standard of care surgical resection|Patients undergo standard of care surgical resection.
16422826|NCT03820531|Experimental|Suspected mucinous pancreas cyst|In all pancreas cysts > 15mm and/or pancreas duct dilatation > 5mm in patients who are fit for surgery EUS-guided pancreas cyst fluid aspiration is conducted. In cyst fluid CEA and lipase examination, cytology and Next Generation Sequencing is performed. After that, the pancreas cyst will be resected and histopathologically analysed.
16422827|NCT03820518|Experimental|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
16422828|NCT03820518|Experimental|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
16422829|NCT03820492|Other|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
16422830|NCT03820479||Apfel score 1|Female
16422831|NCT03820479||Apfel score 2|Female, non smoker
16422832|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
16422833|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
16422834|NCT03820466|Active Comparator|Aspirin|Aspirin 100 mg once daily and Placebo Atorvastatin once daily
16422835|NCT03820466|Active Comparator|Atorvastatin|Atorvastatin 20 mg once daily and Placebo Aspirin once daily
16422836|NCT03820466|Experimental|Aspirin-Atorvastatin|Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
16422837|NCT03820466|Placebo Comparator|Placebo|Placebo Aspirin once daily and Placebo Atorvastatin once daily
16422838|NCT03820453|Experimental|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
16422839|NCT03820453|Placebo Comparator|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
16422840|NCT03820440|Experimental|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:
~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
16422841|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
16422842|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
16422843|NCT03820414|Experimental|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
16422844|NCT03820414|Experimental|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
16422845|NCT03820414|Experimental|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
16422846|NCT03820414|Experimental|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
16422847|NCT03820414|Placebo Comparator|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
16422848|NCT03820401|Experimental|Solacea_postHDF_1/1anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro, Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422849|NCT03820401|Experimental|Solacea_postHDF_1/2anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422850|NCT03820401|Experimental|FX800_postHDF_1/1anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422851|NCT03820401|Experimental|FX800_postHDF_1/2anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422852|NCT03820401|Experimental|Solacea_HD_1/1anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro, Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: standard anticoagulation dose
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422853|NCT03820401|Experimental|Solacea_HD_1/2anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro, Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422854|NCT03820401|Experimental|FX800_HD_1/1anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422855|NCT03820401|Experimental|FX800_HD_1/2anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422856|NCT03820401|Experimental|FX800_HD_1/2anticoagulation_albuprime|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~preparation of dialyzer: the dialyzer was preprimed with albumin solution
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422857|NCT03820401|Experimental|Evodial_HD_no anticoagulation|"intervention:
~choice of dialyzer: Evodial 1.3 (Baxter, USA)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: no anticoagulation is administered
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422858|NCT03820401|Experimental|Evodial_HD_no anticoagulation_albuprime|"intervention:
~choice of dialyzer: Evodial 1.3 (Baxter, USA)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: no anticoagulation is administered
~preparation of dialyzer: the dialyzer was preprimed with albumin solution
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422859|NCT03820401|Experimental|Solacea_preHDF_1/4anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: pre dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422860|NCT03820401|Experimental|Solacea_postHDF_1/4anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422861|NCT03820401|Experimental|Solacea_HD_1/4anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose
~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422862|NCT03820401|Experimental|Solacea_preHDF_no anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: pre dilution hemodiafiltration
~choice of anticoagulation strategy: no anticoagulation is administered
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422863|NCT03820401|Experimental|Solacea_postHDF_no anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: no anticoagulation is administered
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422864|NCT03820401|Experimental|Solacea_HD_no anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: no anticoagulation is administered
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
16422865|NCT03820388|Experimental|Propofol Group|Propofol 2 mg/kg
16422866|NCT03820388|Experimental|Etomidate Group|Etomidate 0.3 mg/kg
16422867|NCT03820388|Experimental|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
16422868|NCT03820349||Cystic Fibrosis|Subjects with cystic fibrosis
16422869|NCT03820349||controls|matched healthy controls
16422870|NCT03820336|Experimental|Extra Virgin Olive Oil|
16422871|NCT03820336|Placebo Comparator|Control Oil|
16422872|NCT03820323|No Intervention|Standard of Care|Participants in the Standard-of-Care control arm will receive laboratory based VL testing based on the existing Kenyan national guidelines. DRM testing will be done if there is a failing 2nd line ART regimen based on the current Kenyan guideline.
16422873|NCT03820323|Experimental|Intervention|POC VL and targeted DRM testing.
16422874|NCT03820310|Experimental|Experimental group|traditional therapy plus autologous Tcm cellular immunotherapy.
16422875|NCT03820310|No Intervention|control group|traditional therapy alone, such as radiotherapy or chemotherapy.
16422876|NCT03820297|Other|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
16422877|NCT03820284||Group A|Group A inflammatory bowel disease with helicobacter pylori infection
16422878|NCT03820284||Group B|Inflammatory bowel disease without helicobacter pylori infection
16422879|NCT03820271|Other|SuperMELD|
16422880|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks|Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
16422881|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
16423011|NCT03819309|Active Comparator|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
16422882|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
16422883|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
16422884|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 3 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
16422885|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to < 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
16422886|NCT03820245|Experimental|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
16422887|NCT03820245|Experimental|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
16422888|NCT03820245|Active Comparator|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
16422889|NCT03820245|Placebo Comparator|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
16422890|NCT03820232||Surgical patients|Patients who were candidates for major or urological surgery under general anaesthesia will be observed. In particular, the core body temperature will be measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
16422891|NCT03820219|Placebo Comparator|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
16422892|NCT03820219|Active Comparator|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
16422893|NCT03820206|Active Comparator|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
16422894|NCT03820206|Placebo Comparator|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
16422895|NCT03820193|Experimental|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
16422896|NCT03820193|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
16422897|NCT03820180|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16422898|NCT03820180|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
16422899|NCT03820167||Fresh sample|"Morphologically good embryos will be cultured in a culture dish and the supernatants will be collected freshly from culture system at day 3 and stored at -20 ̊ c until being tested.
~Quantification of mtDNA in fresh and frozen culture media using qPCR technique."
16422900|NCT03820167||Frozen embryos|Morphologically good embryos scheduled for freezing will be cryopreserved for less than one year and thawed, the supernatant will be collected and stored at -20 ̊ c until being tested. Quantification of mtDNA in fresh and frozen culture media using qPCR technique.
16422901|NCT03820154|Active Comparator|Skin Prick Test TAPE|"The Skin Prick Test Tape is an innovative sterile all-in drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names."
16422902|NCT03820154|Active Comparator|Skin Prick Test|The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.
16422903|NCT03820141|Experimental|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
16422904|NCT03820128|Active Comparator|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.
~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
16422905|NCT03820128|Active Comparator|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .
~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
16422906|NCT03820115|Experimental|Elastic abdominal binder|
16422907|NCT03820115|No Intervention|No binder|
16422908|NCT03820102||Vit D deficiency|Chronic HCV patients with vitamin D deficiency Sustained virological response after treatment
16422909|NCT03820102||Normal Vit D|Chronic HCV patients with normal vitamin D level Sustained virological response after treatment
16422910|NCT03820076|Experimental|dose 1|AZT-04
16422911|NCT03820076|Experimental|dose 2|AZT-04
16422912|NCT03820076|Experimental|dose 3|AZT-04
16422938|NCT03819881|Experimental|STMC-103H|"Oral administration of STMC-103H twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:
~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
16422913|NCT03820063|Experimental|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8
~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1
~Carboplatin AUC 6mg•ml/min administered intravenously on day 1
~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)
~Treatment cycles are repeated on day 22
~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
16422914|NCT03820037|Active Comparator|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
16422915|NCT03820037|Experimental|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
16422916|NCT03820024|Experimental|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
16422917|NCT03820024|No Intervention|No Messages|No feedback messages
16422918|NCT03820011|Experimental|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 26 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
16422919|NCT03819998||PCOS group|women who have PCOS
16422920|NCT03819998||control group|women who donnot have PCOS
16422921|NCT03819985|Experimental|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
16422922|NCT03819972|Placebo Comparator|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
16422923|NCT03819972|Active Comparator|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
16422924|NCT03819972|Active Comparator|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
16422925|NCT03819972|Active Comparator|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
16422926|NCT03819959||Intensive Care Patients|Polytrauma patients who have been admitted to intensive care
16422927|NCT03819946|Experimental|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
16422928|NCT03819946|Active Comparator|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
16422929|NCT03819933|Other|Pregnant women and their partners|"For the qualitative arm of this mixed method study, using an exploratory sequential design, investigators will enroll ~ 30 adult pregnant women admitted estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners to participate in a post-counseling semi-structured interview to explore preferred language and approaches, and better inform questionnaire development. Sample size will be up to 30 families, or until thematic saturation is achieved (total up to 60 if all partners agree to participate).
~For the quantitative arm of this study, investigators will enroll ~100 adult pregnant women admitted between estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners (up to total ~200 if all partners present and agree to participate)."
16422930|NCT03819933|Other|Counseling MFM and Neonatology providers|Investigators will enroll ~100 counseling Maternal-Fetal Medicine (MFM) specialists and 100 counseling Neonatologists (total ~200 providers), who provided counseling to the enrolled pregnant women between 22 0/7-25 6/7 weeks' estimated gestation for anticipated extremely preterm delivery. This assumes 1 counseling provider from MFM and 1 from Neonatology per pregnant woman, although there could be more if a consult is performed by both an attending physician and a training fellow or practitioner, or less, if a counseling provider declines to participate in the study. There will be anticipated repetition of counseling providers, accounted for in the statistical analysis. Providers will be asked to complete educational interventions to improve counseling at extreme prematurity.
16422931|NCT03819920|Placebo Comparator|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
16422932|NCT03819920|Active Comparator|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
16422933|NCT03819907|No Intervention|Control|"15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).
~Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer"
16422934|NCT03819907|Active Comparator|Audiovisual (AV) Guided Relaxation|Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
16422935|NCT03819907|Experimental|Virtual Reality (VR) Guided Relaxation|"Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
~Other Names:
~• Samsung Galaxy 7s/Samsung adaptable VR headset"
16422936|NCT03819894|Experimental|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
16422937|NCT03819894|No Intervention|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
16482499|NCT03413293||Nosocomial infected cirrhotic patients|
16422939|NCT03819881|Placebo Comparator|Placebo|"Oral administration of placebo twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:
~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
16422940|NCT03819868|Active Comparator|High Cost|Restoration using a high-cost sealant
16422941|NCT03819868|Experimental|Low Cost|Restoration using a low-cost sealant
16422942|NCT03819842|No Intervention|Aphakic Measure only|Eye measured in aphakic state only
16422943|NCT03819842|Active Comparator|Pseudophakic measure|Eye measured in aphakic state then again in pseudophakic state with toric IOL using the ORA System. Pseudophakic measurement obtained will provide data about placement of toric iol and the surgeon will use that data to rotate the iol if necessary.
16422945|NCT03819816|Experimental|DEA-App|The intervention (DEA) group will receive the newly developed app.
16422946|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
16422947|NCT03819803|Experimental|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.
~Intervention: Fecal microbiota transplantation"
16422948|NCT03819790|Experimental|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
16422949|NCT03819790|Active Comparator|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
16422950|NCT03819777||Idiopathic PAH|
16422951|NCT03819777||CTD-PAH|
16422952|NCT03819777||CTD without PAH|
16422953|NCT03819764|Active Comparator|Aerobic Exercise & Repetitive Task Practice|"Participants will perform the following:
~45 minutes of cycling
~45 minutes of upper extremity repetitive arm exercises"
16422954|NCT03819764|Active Comparator|Upper Extremity Repetitive Task Practice Only|"Participants will perform the following:
~1. 90 minutes of upper extremity repetitive arm exercises"
16422955|NCT03819751|Other|MRI-targeted prostate biopsy|Participants receive both type of MRI-targeted biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.
16422956|NCT03819738|Experimental|fMRI intervention|
16422957|NCT03819725|Other|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla® ) and glucose measurements will be monitored during 2-5 days. Oral food intake will be recorded.
16422958|NCT03819712|Experimental|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
16422959|NCT03819712|Experimental|Recurrent UTI|
16422960|NCT03819699|Experimental|Cohort 1 - dose regimen 1|Cohort 1: encompasses patients enrolled prior to the PA1
16422961|NCT03819699|Experimental|Cohort 2 - dose regimen 2|Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
16422962|NCT03819699|Experimental|Cohort 2 - dose regimen 3|Cohort 2: 10 patients who will not receive a booster vaccine
16422963|NCT03819686|Experimental|Living ACTS website|In addition to the provision of standard transplant education procedures, a patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching the 20-minute video).
16422964|NCT03819686|Other|Standard transplant education procedures|Usual Care, which involves the provision of standard transplant education procedures at each transplant center, which entail reviewing a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two 10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
16422965|NCT03819673|Experimental|Intervention Group (IG)|Care based on the computerised decision-support tool
16422966|NCT03819673|No Intervention|Control Group (CG)|Usual care advice by primary care provider or dietitian of participating hospital
16422967|NCT03819660|Experimental|amifampridine phosphate|Oral tablets, 15 to 80 mg per day in divided doses 3 to 4 times a day for up to 18 months.
16422968|NCT03819647|Experimental|stiripentol (Diacomit)|
16422969|NCT03819634|Experimental|Lantern infusion set|Multi-slitted lantern infusion set
16422970|NCT03819621|Experimental|OCULAR PROSTHESIS MOTILITY|All participants ocular prosthesis motility will be measured using the mediGrid app, Image J software in comparison to the ruler as a gold standard.
16422971|NCT03819608|Experimental|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
16422972|NCT03819608|Active Comparator|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
16423009|NCT03819322|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
16423174|NCT03818152|Other|study group|Reliability study isokinetic strength assessment of the lower limbs.
16422973|NCT03819608|Active Comparator|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
16422974|NCT03819608|Active Comparator|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
16422975|NCT03819595|Experimental|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
16422976|NCT03819595|Active Comparator|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
~After 3 months, it become supervised arm"
16422977|NCT03819582|Experimental|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
16422978|NCT03819569|Active Comparator|Biopsy|Subjects receive a renal cell biopsy prior to making a decision about treatment
16422979|NCT03819569|Sham Comparator|No Biopsy|Subjects do not receive a renal cell biopsy prior to making a decision about treatment
16422980|NCT03819556|Active Comparator|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
16422981|NCT03819556|No Intervention|Control|Diet free from milk protein
16422982|NCT03819543|Experimental|Transcranial Direct Current Stimulation|
16422983|NCT03819530|Experimental|Supplementation Group|Receives baseline deworming medication. Intervention: receive daily micronutrient supplementation packets- 6 month supply, to be taken every day. Blood iron and anthropometric measurements taken at 0 and 6 months.
16422984|NCT03819530|No Intervention|Control Group|Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 6 months.
16422985|NCT03819517|Active Comparator|Resveratrol|500 mg of time released micronized trans-Resveratrol
16422986|NCT03819517|Placebo Comparator|Placebo|Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented
16422987|NCT03819504|Experimental|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
16422988|NCT03819491|Experimental|Group A|100 mg OD
16422989|NCT03819491|Experimental|Group B|100 mg BID
16422990|NCT03819478|Placebo Comparator|RecProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
16422991|NCT03819478|Active Comparator|6-mo HiProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
16422992|NCT03819478|Active Comparator|18-mo HiProt|"Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643):
~Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.
~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
16423001|NCT03819426|Experimental|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
16423002|NCT03819426|Experimental|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
16423003|NCT03819387|Experimental|NBF-006|
16423004|NCT03819361||Suspected OSA|
16423005|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
16423006|NCT03819335|Active Comparator|Standard care|Usual follow-up of diabetes type 1 with face-to-face visits
16423007|NCT03819335|Experimental|mySugr app|Telemedical assistance with mySugr app
16423008|NCT03819322|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.
~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
16423010|NCT03819309|Experimental|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
16423012|NCT03819296|Experimental|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.
~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.
~PROJECT 3: Patients undergo FMT."
16423013|NCT03819283|Other|Hepatic evaluation|
16423014|NCT03819270|Experimental|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
16423015|NCT03819270|Placebo Comparator|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
16423016|NCT03819257||Patients with perianal Crohn's disease.|
16423017|NCT03819244|Experimental|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
16423018|NCT03819244|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
16423019|NCT03819231|Experimental|Mindfulness and intranasal oxytocin|Given oxytocin through intranasal administration and self-directed mindfulness training.
16423020|NCT03819231|Active Comparator|Mindfulness and placebo|Given sterile saline through intranasal adminstration and self-directed mindfulness training.
16423021|NCT03819231|Sham Comparator|Sham mindfulness and placebo|Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.
16423022|NCT03819218|Experimental|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
16423023|NCT03819205|Experimental|kinesiotaping group(before/after)|"Hemiplegic CP:Kinesiotaping on the affected side
~Diplegic, tetraplegic CP: side of upper extremity which children have been used to but have obstacles in daily life
~intervention Duration: For 1 week at least 2-3 hours a day, renewing if it's necessary.
~Note:Patients will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day.
~Evaluation: In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion"
16423024|NCT03819192||neonates with signs of EONS|
16423025|NCT03819192||neonates without signs of EONS|
16423026|NCT03819192||pregnant women with PPROM|
16423027|NCT03819179|Experimental|Serum|Burt's Bees Serum
16423028|NCT03819179|Experimental|Serum with Biulin|Burt's Bees Serum with Biulin
16423029|NCT03819179|Experimental|Serum with Berenew Complex|Burt's Bees Serum with Berenew Complex
16423030|NCT03819179|Experimental|Serum with Ecoskin|Burt's Bees Serum with Ecoskin
16423031|NCT03819179|Experimental|Serum with Bonicell|Burt's Bees Serum with Bonicell
16423032|NCT03819166|Experimental|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
16423033|NCT03819166|Sham Comparator|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
16423034|NCT03819153|Experimental|Semaglutide|Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
16423035|NCT03819153|Placebo Comparator|Placebo|Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
16423036|NCT03819140|Active Comparator|Continuous OCP Therapy|Participants randomly assigned to this arm will receive 8 packs of a 21 day oral contraceptive pills (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which comes in a formulation of 21 days of active hormone and 7 days of sugar pills. In this arm, participants will only be expected to take active hormone pills (colored pills) for the 6 months straight without stopping or taking the sugar pills in each pack.
16423037|NCT03819140|Active Comparator|Cyclical OCP Therapy|Participants randomly assigned to this arm will receive 6 packs of a 21 day oral contraceptive pill (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which has 21 days of active hormone and 7 days of sugar pills. Participants will take one pill daily for 6 months and be expected to take the sugar pills at the end of each monthly pack prior to starting a new pack.
16423038|NCT03819127|Active Comparator|Metformin|metformin 1 g twice a day for 24 weeks
16423039|NCT03819127|Experimental|Metformin plus vildagliptin|metformin 1 g plus vildagliptin 50 mg twice a day for 24 weeks
16423040|NCT03819114|Experimental|A: LNG EC 1.5 mg among women on EFV-based ART (randomized)|Participants will receive one 1.5 mg tablet of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
16423041|NCT03819114|Experimental|B: LNG EC 3.0 mg among women on EFV-based ART (randomized)|Participants will receive two 1.5 mg tablets (3 mg) of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
16423042|NCT03819114|Experimental|C: LNG EC 1.5 mg among women on DTG-based ART (assigned)|Participants will receive one 1.5 mg tablet of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
16423043|NCT03819114|Experimental|D: LNG EC 3.0 mg among women on RIF-INH TB Therapy (assigned)|Participants will receive two 1.5 mg tablets (3 mg) of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
16423044|NCT03819101|No Intervention|Arm A|Standard of Care (SOC) for CRPC
16423045|NCT03819101|Experimental|Arm B|SOC + acetylsalicylic acid 100 mg daily
16423046|NCT03819101|Experimental|Arm C|SOC + atorvastatin 80 mg daily
16423047|NCT03819101|Experimental|Arm D|SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8
16423048|NCT03819088|Experimental|Group I (zinc months 1 and 2)|Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
16423049|NCT03819088|Experimental|Group II (zinc months 3 and 4)|Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
16423050|NCT03819075|Experimental|Laser|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units.
16423051|NCT03819075|Active Comparator|Control|Standard periimplantitis treatment will be conducted in the control group.
16423052|NCT03819062|Experimental|Refractory Constipation with LLLT|Low level laser therapy (LLLT) will be administered to patients with severe refractory chronic constipation
16423053|NCT03819049|Experimental|Cohort 1: ExPEC10V (Low Dose)|Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.
16423054|NCT03819049|Experimental|Cohort 1: ExPEC10V (Medium dose)|Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.
16423055|NCT03819049|Experimental|Cohort 1: ExPEC10V (High dose)|Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.
16423056|NCT03819049|Experimental|Cohort 1: ExPEC4V|Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.
16423057|NCT03819049|Experimental|Cohort 1: Prevnar 13|Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.
16423058|NCT03819049|Experimental|Cohort 2: ExPEC10V|Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
16423059|NCT03819049|Placebo Comparator|Cohort 2: Placebo|Participants will be randomized to receive a single IM injection of matching placebo on Day 1.
16423060|NCT03819036|Experimental|Patients|Questionnaires for patients requiring dental emergencies care
16423061|NCT03819023|No Intervention|Normal subjects|
16423062|NCT03819023|Active Comparator|respiratory suppressing drugs|
16423063|NCT03819010|Active Comparator|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
16423064|NCT03819010|Active Comparator|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
16423065|NCT03818997|Experimental|BTC Cohort|Patient in BTC cohort will receive immune therapy and DKN-01 IV until PD
16423066|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab + paclitaxel (Arm 1)|Patient randomized in the EGC Arm 1 will receive immune therapy, DKN-01 and chemotherapy intravenously (IV) until PD.
16423067|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab without paclitaxel (Arm 2)|Patient randomized in the EGC Arm 2 will receive immune therapy and DKN-01 IV until PD
16423068|NCT03818984|Experimental|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
16423072|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
16423073|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
16423074|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
16423075|NCT03818958||fibromyalgia|subjects with fibromyalgia
16423076|NCT03818945|Other|Sodium Fluoride Varnish|
16423077|NCT03818945|Active Comparator|PRG barrier Giomer|
16423078|NCT03818932|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
16423079|NCT03818932|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
16423080|NCT03818919|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
16423081|NCT03818919|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
16423082|NCT03818906|Active Comparator|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
16423083|NCT03818906|Experimental|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
16423084|NCT03818906|Experimental|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
16423085|NCT03818906|Experimental|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
16423086|NCT03818893|Experimental|New Combination Immunotherapy|"Patients will receive Pembrolizumab once every 3 weeks and a maximum of 35 doses over 105 weeks .
~The patients should be inpatient during treatment with GEN0101 in each treatment cycle and may be outpatient during off-treatment period with GEN0101, observation period, follow-up period with Pembrolizumab.
~GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously (including skin tumor site). Nonetheless, it will not be deemed as deviation if an injection has been given subcutaneously unintentionally, e.g., leakage around the peri-injection sites.
~A dose will be 60,000 mNAU in total, and 1 mL per injection site should be administered to 6 injection sites in total. For a patient, the total dose in a treatment cycle will be 360,000 mNAU (360 NAU), and the total dose over 2 treatment cycles will be 720,000 mNAU (720 NAU)."
16423088|NCT03818867|Experimental|Cerclage arm|Pregnancies which had cervical cerclage inserted.
16423089|NCT03818867|No Intervention|No-cerclage arm|Pregnancies which did not have cervical cerclage inserted.
16423090|NCT03818854|Experimental|Human Mesenchymal Stromal Cells|A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.
16423091|NCT03818854|Experimental|Cell Reconstitution Media|A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes.
16423092|NCT03818841|Experimental|High-flow nasal cannula group|Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
16423093|NCT03818841|Other|Non-rebreathing oxygen mask group|In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
16423094|NCT03818828|Experimental|TTAX01|TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
16423095|NCT03818815|Active Comparator|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
16423096|NCT03818815|Placebo Comparator|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
16423097|NCT03818802|Active Comparator|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
16423098|NCT03818802|Placebo Comparator|Placebo|Correspondent placebo, a pill not containing the active component.
16423099|NCT03818789|Experimental|Mindfulness|A mindfulness training is applied to see if it supports exercise endurance in-lab and during follow-up
16423100|NCT03818789|Placebo Comparator|Control|A study skills video is shown intended to have no effect on exercise but to match for time.
16423101|NCT03818776|Experimental|Arm 1 - 60 CGyE in 20 fractions|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.
~Radiation will follow dose escalation scheme:
~60 CGyE in 20 fractions (3+3 participants, 3-6 total)"
16423102|NCT03818776|Experimental|Arm 2 - 69 CGyE in 23 fractions followed by expansion cohort a|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.
~Radiation will follow dose escalation scheme:
~69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)"
16423104|NCT03818750|Experimental|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :
~light drinkers (score between 1 to 3)
~heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
16423105|NCT03818737|Experimental|Autologous BMAC versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either bone marrow derived mesenchymal stem cells (MSCs) or corticosteroid (CS) injection (30:10). All subjects randomized to this arm will undergo bone marrow aspiration, but will only receive one of the injections. At each site, 30 subjects in this arm will receive a standard Orthobiologic injection of Bone Marrow Concentrate (BMAC) and 10 will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
16423106|NCT03818737|Experimental|Adipose-derived SVF versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either an injection of Adipose-derived Stromal Vascular Fraction (SVF) or corticosteroid (CS) (30:10). All subjects randomized to this arm will undergo small volume lipoplasty, but will only receive one of the injections. At each site, 30 subjects in this arm will receive the Adipose-derived Stromal Vascular Fraction (SVF) and 10 subjects will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
16423175|NCT03818126|Experimental|del Nido cardioplegia|
16423107|NCT03818737|Experimental|Umbilical Cord Tissue (UCT) versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either an injection of cryopreserved doses of cord tissue MSCs or corticosteroid (30:10) injected into the knee. At each site, 30 subjects in this arm will receive the umbilical cord tissue MSCs and 10 subjects will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
16423108|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
16423109|NCT03818711|Experimental|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
16423110|NCT03818711|Active Comparator|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
16423111|NCT03818685|Experimental|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
16423112|NCT03818685|Active Comparator|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
16423113|NCT03818672|Experimental|Rifaximin|Rifaximin 550 mg BID
16423117|NCT03818633|Experimental|Elastic abdominal binder|
16423118|NCT03818633|No Intervention|No binder|
16423119|NCT03818607|Other|T (ABP 959) / R (eculizumab)|ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
16423120|NCT03818607|Other|R (eculizumab) / T (ABP 959)|Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
16423121|NCT03818581|Active Comparator|Treatment Group|
16423122|NCT03818581|Placebo Comparator|Placebo Responders|
16423123|NCT03818581|Active Comparator|Placebo Non-responders Re-randomized to Treatment|
16423124|NCT03818581|Placebo Comparator|Placebo Non-responders Re-randomized to Placebo|
16423125|NCT03818568|Experimental|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
16423126|NCT03818568|Active Comparator|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
16423127|NCT03818555|Other|Sebacia Microparticles Treatment|
16423128|NCT03818542|Experimental|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
16423129|NCT03818542|Experimental|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
16423130|NCT03818542|Experimental|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
16423131|NCT03818542|Experimental|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
16423132|NCT03818516|Experimental|Oral Glucose Tolerance Test (OGTT)|Medically stable participants with schizophrenia and a range of insulin resistance will have an oral glucose tolerance test.
16423133|NCT03818503||OligoCare|Patients with oligometastatic disease treated with radical radiotherapy
16423134|NCT03818503||ParticleCare|Patients with cancer treated with particle therapy
16423135|NCT03818490|Experimental|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
16423136|NCT03818490|No Intervention|Control|Patients in this group did not experience an intervention.
16423137|NCT03818451|No Intervention|Control Group|"All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:
~Surgical evacuation of hemorrhagic masses and brain contusion
~Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures
~Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage"
16423138|NCT03818451|Experimental|Study Group|Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
16423173|NCT03818165|Experimental|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
16423139|NCT03818438||Case subjects adult patients with chronic ankle instability|"Male or female subjects aged 18-45, presenting :
~at least one acute lateral ankle sprain (i.e. initial ankle sprain more than 12 months before inclusion),
~at least one residual symptom (giving way OR sensation of instability OR recurrent ankle sprain), confirmed by a score < 24 on the Chronic Ankle Instability Tool (CAIT)
~Impact on activities of daily living and sport, score < 90% on Foot and Ankle Ability Measure (FAAM) and < 80% on FAAM-sport Case subjects are free of any other lower extremity pathologies or pain Subjects presenting bilateral chronic ankle instability are excluded"
16423140|NCT03818438||Healthy subjects|Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
16423141|NCT03818425||Clinical Population|In- and Out-Patients diagnosed with depression (F32, F33), anxiety disorder (F40, F41; ICD-10) or posttraumatic stress disorder (F43.1; ICD-10)
16423142|NCT03818425||Healthy Controls|Subjects with no previous or actual mental disorder
16423143|NCT03818412|Experimental|Soft Tissue Sarcoma|"A sample of archival tumor tissue will be collected.
~Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken:
~Prior to planned radiation treatment
~2-4 weeks after cancer surgery
~Every 12 weeks after surgery for up to 2 years"
16423144|NCT03818399|Experimental|overdose patients|subjects that receive acute administration of SUBOXONE sublingual film in the ED followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, and receive monthly SUBLOCADE injections for 6 months in the context of outpatient treatment.
16423145|NCT03818386|Experimental|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT
~Other Names:
~Gadolinium-chelated polysiloxane based nanoparticles
~3 intravenous injections at 100mg/kg
~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)
~Fr1: AGuIX® injection before the first radiation session
~Fr6: AGuIX® injection before the sixth radiation session
~30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
16423146|NCT03818386|Active Comparator|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
16423147|NCT03818373|Other|Patients with univentricular congenital heart disease|Patients 8 years old or more with functionally univentricular congenital heart disease
16423149|NCT03818347|Experimental|oxyhydrogen generator (AMS-H-03)|Model: AMS-H-03 Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively In this group, the patients will inhale hydrogen and oxygen with oxyhydrogen generator. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16423150|NCT03818347|Placebo Comparator|Control|In this group, the patients will inhale normal air with analogue machine. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16423151|NCT03818334|Experimental|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
16423152|NCT03818334|Active Comparator|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
16423153|NCT03818321|Experimental|Methenamine Hippurate with Cranberry|Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
16423154|NCT03818321|Placebo Comparator|Placebo with Cranberry|"Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016."
16423155|NCT03818308|Experimental|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
16423156|NCT03818295|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-praliciguat
16423157|NCT03818282|Experimental|Paclitaxel for injection (albumin-bound)|
16423158|NCT03818269|Other|Septic shock|
16423159|NCT03818269|Other|Control|
16423160|NCT03818256|Experimental|CORT118335- 600 mg|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
16423161|NCT03818256|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
16423162|NCT03818243|Experimental|RLS-|patients with Parkinson disease without RLS
16423163|NCT03818243|Experimental|RLS+|patients with Parkinson disease with RLS
16423164|NCT03818217|Experimental|Coach Pepper group|Pepper is a humanoid socially assistive robot.
16423165|NCT03818217|Other|Tablet group|Tablet training
16423166|NCT03818204|Experimental|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl & NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.
~-Intervention - Magnetic Levator Prosthesis (MLP)"
16423167|NCT03818204|Other|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.
~-Intervention - Magnetic Levator Prosthesis (MLP)"
16423168|NCT03818191|Active Comparator|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
16423169|NCT03818191|Placebo Comparator|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
16423170|NCT03818178|Experimental|Intralipid|
16423171|NCT03818178|Experimental|Palm Oil|
16423172|NCT03818178|Placebo Comparator|Saline|
16423177|NCT03818113||HTK-Bretschneider cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with HTK-Bretschneider cardioplegic solution
16423178|NCT03818113||St. Thomas cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with St. Thomas cardioplegic solution
16423179|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
16423180|NCT03818074|Experimental|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
16423181|NCT03818061|Experimental|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
16423182|NCT03818061|Experimental|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
16423183|NCT03818048|Experimental|Group Propofol|propofol infusion
16423184|NCT03818048|Experimental|Group Sevoflurane|inhalation with sevoflurane
16423189|NCT03818022|Experimental|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
16423190|NCT03818022|No Intervention|Control|
16423191|NCT03818009||women undergoing elective CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
16423192|NCT03818009||women undergoing emergency CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
16423193|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.
~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure <90 mm Hg or the need for norepinephrine), oliguria (urine output <0.5 mL/kg/hr), and cool, mottled extremities.
~Their CO increases >15% after passive leg raising."
16423194|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase >15% after passive leg raising maneuver.
16423195|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
16423196|NCT03817970|Experimental|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
16423197|NCT03817970|Experimental|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
16423198|NCT03817970|Experimental|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
16423199|NCT03817957|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
16423200|NCT03817957|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
16423201|NCT03817957|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
16423202|NCT03817931|Placebo Comparator|Placebo|Placebo pill identical will be identical to tablets in the other 2 arms.
16423203|NCT03817931|Active Comparator|Anticholinergic|Solifenacin 5 mg tablet orally once daily for 30 days
16423204|NCT03817931|Active Comparator|Beta-3 agonists, adrenergic|Mirabegron 25 mg tablet orally once daily for 30 days
16423205|NCT03817918|Experimental|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
16423206|NCT03817905|Experimental|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
16423207|NCT03817892|No Intervention|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).
~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
16423208|NCT03817892|Experimental|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).
~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
16423241|NCT03817632||B Elite|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
16423209|NCT03817892|Experimental|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
16423210|NCT03817892|Experimental|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
16423211|NCT03817879|Experimental|VivaSight double-lumen tube|
16423212|NCT03817879|Active Comparator|Conventional double-lumen tube|
16423213|NCT03817866||BRAHMS CgA II KRYPTOR|Adult patients with well defined grade 1 and grade 2 GEP-NETs. Serial serum samples from all patients will be analyzed using the BRAHMS CgA II KRYPTOR Assay.
16423215|NCT03817827|Experimental|Acupuncture|this group will receive Acupuncture therapy for 30 minutes three times per week
16423216|NCT03817827|Experimental|diet modification|this group will receive diet using soy products a
16423217|NCT03817827|Experimental|combined group|will receive both acupuncture therapy and soy products
16423219|NCT03817801|Experimental|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
16423220|NCT03817801|Active Comparator|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
16423221|NCT03817788|Active Comparator|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
16423222|NCT03817788|Experimental|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
16423223|NCT03817775|No Intervention|Control|The control group will undergo coronary angiography without music intervention.
16423224|NCT03817775|Experimental|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
16423225|NCT03817749|Experimental|Experimental|"Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.
~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.
~All meals will be provided throughout the supplementation period
~Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period."
16423226|NCT03817749|Placebo Comparator|Placebo|Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm
16423227|NCT03817736|Experimental|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.
~Procedure of TACE will be standardized.
~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
16423228|NCT03817723||Specialist surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy. C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
16423229|NCT03817723||Resident surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy.C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
16423230|NCT03817697||Drug users|The cohort will be constituted of adult patients drug users, substituted/weaned or not, consulting at the Croix-Rousse CSAPA
16423231|NCT03817684|Experimental|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
16423232|NCT03817684|Experimental|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
16423233|NCT03817684|Placebo Comparator|Placebo|
16423234|NCT03817671|Other|Control arm (5% O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 5% O2, and 89.3% N2 till embryo transfer
16423235|NCT03817671|Experimental|Experimental arm (2%O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 2% O2, and 92.3% N2 till embryo transfer
16423236|NCT03817658|Experimental|SHR-1210|SHR-1210
16423237|NCT03817658|Placebo Comparator|placebo|placebo
16423238|NCT03817645|Experimental|Panaceo MED|Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.
16423239|NCT03817645|Placebo Comparator|Control|Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.
16423240|NCT03817632||A Standard|Computer assisted primary total knee replacement with OrthoPilot FS 101 navigation system and Software 5.1
16423242|NCT03817619|Active Comparator|Treatment R (reference)|Single-dose ELB/GZR as a whole tablet in a fasted state.
16423243|NCT03817619|Experimental|Treatment T (test)|Single-dose crushed ELB/GZR in a fasted state.
16423244|NCT03817606|Experimental|Tritanium Posterior Lumbar Cage|Surgical placement of the Tritanium Posterior Lumbar Cage
16423245|NCT03817606|Active Comparator|AVS PEEK UniLIF|Surgical placement of the AVS PEEK UniLIF Posterior Lumbar Cage
16423246|NCT03817593||Transcendental Meditation (TM)|"Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
~To ensure the quality of practice, a group follow-up will be performed 10 days after a completion of the course, and then each participant will receive personal meetings with TM instructor on a weekly basis during the first month, and twice a month for the second and third months.
~After additional 3 months participants in this group will be examined again, to assess sustainability of the effect"
16423247|NCT03817593||controls|Control group - Treatment as usual (TAU)
16423251|NCT03817567|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W
16423252|NCT03817554|Experimental|Treatment group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
16423253|NCT03817554|Placebo Comparator|Control group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.
16423254|NCT03817541|Experimental|Bariatric surgery|Patients due for bariatric surgery, BMI > 30
16423255|NCT03817541|Experimental|Cholecystectomy|Normal weight patients due for cholecystectomies
16423256|NCT03817528|Experimental|ITI-007|Open-Label ITI-007 40-60 mg
16423257|NCT03817502|Experimental|Cariprazine 1.5 mg/d|Cariprazine capsules, oral administration, once daily.
16423258|NCT03817502|Experimental|Cariprazine 4.5 mg/d|Cariprazine capsules, oral administration, once daily.
16423259|NCT03817502|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
16423260|NCT03817489|Experimental|Intervention: Baduanjin qigong|This arm of participants will be receiving the Baduajin qigong intervention.
16423261|NCT03817489|Experimental|Intervention: Mindfulness meditation|This arm of participants will be receiving the Mindfulness meditation intervention.
16423262|NCT03817489|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a Wait-list Control group.
16423263|NCT03817476|Experimental|T1-T2-R|
16423264|NCT03817476|Experimental|T1-R-T2|
16423265|NCT03817476|Experimental|T2-T1-R|
16423266|NCT03817476|Experimental|T2-R-T1|
16423267|NCT03817476|Experimental|R-T1-T2|
16423268|NCT03817476|Experimental|R-T2-T1|
16423270|NCT03817450|Experimental|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
16423271|NCT03817450|No Intervention|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
16423272|NCT03817424|Experimental|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
16423273|NCT03817424|Experimental|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
16423274|NCT03817424|Experimental|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
16423275|NCT03817424|Placebo Comparator|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
16423276|NCT03817411|Active Comparator|Telatinib+Capecitabine+Oxaliplatin|Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
16423277|NCT03817411|Placebo Comparator|Placebos+Capecitabine+Oxaliplatin|Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
16423278|NCT03817398|Experimental|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
16423279|NCT03817385|Experimental|repetitive TMS (Transcranial Magnetic Stimulation)|rTMS and physical / occupational therapy
16423280|NCT03817385|Experimental|robotic GT (Gait Training)|robotic gait training for 20 times and physical / occupational therapy
16423281|NCT03817385|No Intervention|traditional rehabilitation|patient only received traditional rehabilitation program
16423282|NCT03817372|Active Comparator|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
16423359|NCT03816891|Experimental|Phase 2b - Vixarelimab 540 mg SC Q4W (DBL)|Vixarelimab 540 mg SC, every 4 weeks for 16 weeks during Double Blind Period
16423283|NCT03817372|Active Comparator|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
16423284|NCT03817359|Experimental|Mix infusion using single TCI pump|participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump infusion
16423285|NCT03817359|No Intervention|Separate infusion using two TCI pumps|participants receive total intravenous anesthesia with remifentanil and propofol separately by two TCI pumps infusion
16423286|NCT03817346|Active Comparator|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
16423287|NCT03817346|Placebo Comparator|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
16423288|NCT03817333||ACOS smoking history >20 pack-years|Subjects with asthma-COPD overlap syndrome
16423289|NCT03817333||IRAO smoking history <5 pack-years|Subjects with an incomplete reversibility of airway obstruction
16423290|NCT03817320|Other|Open label design|Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin
16423291|NCT03817307|Experimental|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2* weighted MRI scan (prior to surgery).
16423292|NCT03817294|Active Comparator|Eccentric cycling|
16423293|NCT03817294|Active Comparator|Concentric cycling|
16423294|NCT03817294|Active Comparator|Single leg cycling|
16423295|NCT03817294|Active Comparator|Lower limb resistance training|
16423296|NCT03817281||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
16423297|NCT03817268|Experimental|Capecitabine monotherapy group|
16423298|NCT03817268|No Intervention|Control group|
16423299|NCT03817255|Experimental|Substance use|In this screening intervention, participants complete a substance use questionnaire (=intervention).
16423300|NCT03817255|Active Comparator|Physical activity|In this screening control condition, participants complete a physical activity questionnaire (=control).
16423301|NCT03817242|Active Comparator|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
16423302|NCT03817242|Active Comparator|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
16423303|NCT03817229|Active Comparator|Control Group|mHealth education module and automated digital reminders
16423304|NCT03817229|Experimental|Treatment Group|mHealth education module, automated digital reminders, and individualized adherence feedback (stage 1 SMART). After three months of intervention, the treatment group will be evaluated for responsiveness (> 95%) based on the 30-day adherence outcome (stage 2 SMART). If participants in the treatment group demonstrate adherence > 95%, they will continue with the treatment arm of receiving automated digital reminders and individualized adherence feedback. If they are deemed to be non-responsive (adherence < 95%), they will be re-randomized to either: 1) continued automated digital reminders and individualized adherence feedback or 2) a mHealth problem solving module with three therapist-guided problem-solving sessions.
16423305|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
16423306|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
16423307|NCT03817216|Active Comparator|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
16423308|NCT03817203|Experimental|Kinesio tape group|Kinesio tape application and pelvic floor exercise have been applied
16423309|NCT03817203|Sham Comparator|Control group|Sham kinesio tape application and pelvic floor exercise have been applied
16423310|NCT03817190|Experimental|2g Oral DS107|2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
16423311|NCT03817190|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 16 weeks
16423312|NCT03817177|Placebo Comparator|nasal prong|conventional nasal prong application after the surgery in postanesthetic care unit (PACU)
16423313|NCT03817177|Experimental|high flow nasal cannula oxygenation|high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)
16423314|NCT03817164|Active Comparator|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
16423315|NCT03817164|Sham Comparator|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
16423316|NCT03817125|Placebo Comparator|SER-401 Matching Placebo/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.
16423317|NCT03817125|Experimental|SER-401/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.
16423318|NCT03817112|Active Comparator|Dexmedetomidine|Infusion of dexmedetomidine
16423319|NCT03817112|Active Comparator|Propofol|Propofol infusion
16423320|NCT03817099|Experimental|My Dia-RNP|In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
16423321|NCT03817099|Active Comparator|Usual Care|Participant in this group will continue in a usual care (UC) group. They will receive dietary advice based on the Practical Guide to Diabetes Management in Ramadan produced by Ministry of Health (2015).
16423360|NCT03816891|Experimental|Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL)|Vixarelimab 360 mg SC, every 4 weeks for 16 weeks during Double Blind Period
16423322|NCT03817086|Experimental|Hand coordination and mental practice|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to mentally imagine doing the task with an action observation of perfect performance.
16423323|NCT03817086|Active Comparator|Hand coordination and action observation|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to observe a visual feedback of performance.
16423324|NCT03817073|Experimental|Iowa Oral Performance Instrument (IOPI)|All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).
16423325|NCT03817060|Active Comparator|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
16423326|NCT03817060|Active Comparator|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
16423327|NCT03817047|Experimental|Physical active learning (PAL)|"Three components:
~Physical education (60 minutes)
~Physical active learning (30 minutes)
~Physical activity (30 minutes)"
16423328|NCT03817047|Experimental|Don't worry - be happy|"Two components:
~Physical education (60 minutes) - don't worry class
~Physical activity (60 minutes) - be happy class"
16423329|NCT03817047|No Intervention|Control group|Current practice
16423330|NCT03817034|Experimental|Multimodal Analgesia|
16423331|NCT03817021|Experimental|All Factors On|Nutrition and Physical Activity Self-Assessment of Childcare (Core NAP SACC) will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned on
16423332|NCT03817021|Experimental|NAP SACC on/ECE on/Parent RF on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned off
16423333|NCT03817021|Experimental|NAP SACC on/ECE on/Child Regulation on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned on
16423334|NCT03817021|Experimental|NAP SACC on/ECE on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned off
16423335|NCT03817021|Experimental|NAP SACCon/Parent RF on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned on
16423336|NCT03817021|Experimental|NAP SACC on/Parent RF on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned off
16423337|NCT03817021|Experimental|NAP SACC on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned on
16423338|NCT03817021|Experimental|NAP SACC on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned off
16423339|NCT03816995|Active Comparator|Alexis O Wound Protector|Participants will undergo standard surgical procedure using the Alexis O wound protector.
16423340|NCT03816995|Experimental|CleanCision Wound Protector|Participants will undergo standard surgical procedure using the CleanCision Wound Retraction and Protection System
16423341|NCT03816982|Active Comparator|Bupivacaine HCl/Bupivacaine CISB|23 patients will be enrolled to receive a single-injection bupivacaine HCL interscalene block with bupivacaine CISB added.
16423342|NCT03816982|Experimental|Liposomal Bupivacaine Added to Interscalene Block|23 patients will be enrolled to receive a single-injection bupivacaine HCl interscalene block with liposomal bupivacaine added to same injection.
16423343|NCT03816969|Active Comparator|Self-pressurized air-Q with blocker|Self-pressurized air-Q with blocker has a greater seal pressure compared to Air-Q blocker, easier and faster in insertion and has less morbidity and complications while and after insertion
16423344|NCT03816969|Active Comparator|Air-Q ILA blocker|It has a drain tube through which a suction tube is passed
16423345|NCT03816956|Experimental|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
16423346|NCT03816956|Placebo Comparator|Placebo treatment|Control group: Placebo administered intravenously the day of enrolment.
16423347|NCT03816943|No Intervention|Control|control group with no intervention
16423348|NCT03816943|Experimental|Whatsapp|intervention group receiving a Whatsapp instant text message with encouraging words after bond up of fixed appliances
16423349|NCT03816943|Experimental|Call|intervention group receiving a phone cal with encouraging words after bond up of fixed appliances
16423350|NCT03816930|Active Comparator|Mechanical cord usage|Mechanical retraction
16423351|NCT03816930|Active Comparator|Chemical contained retraction usage|Chemical retraction
16423352|NCT03816930|Active Comparator|MZ-6 laser tip used throughing|Laser retraction
16423353|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
16423354|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
16423355|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
16423356|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
16423357|NCT03816891|Experimental|Phase 2a - Vixarelimab 360 mg SC QW|Vixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
16423358|NCT03816891|Placebo Comparator|Phase 2a - Placebo SC QW|Placebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
16423361|NCT03816891|Experimental|Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL)|Vixarelimab 120 mg SC, every 4 weeks for 16 weeks during Double Blind Period
16423362|NCT03816891|Placebo Comparator|Phase 2b - Placebo SC, Q4W (DBL)|Placebo SC, every 4 weeks for 16 weeks during Double Blind Period
16423363|NCT03816891|Experimental|Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE)|Vixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension
16423364|NCT03816878|Experimental|Cohort 1: pLAIV Recipients|Participants who have received the pandemic live attenuated influenza vaccines (pLAIVs) H2N2, H6N1, or H9N2 during a previous CIR study will receive a single dose of 0.5 mL H5N1 pISV vaccine at Day 0.
16423365|NCT03816878|Experimental|Cohort 2: pLAIV Naive|Participants who have never previously received a pLAIV will receive one dose of 0.5 mL H5N1 pISV vaccine at Day 0.
16423366|NCT03816852|Experimental|High dose group|Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml
16423367|NCT03816852|Experimental|Medium dose group|Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml
16423368|NCT03816852|Experimental|Low dose group|Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml
16423369|NCT03816839|Experimental|SAR439859|administered orally once daily or twice daily as monotherapy in fasted or fed state
16423370|NCT03816826|Experimental|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
16423371|NCT03816826|Experimental|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
16423372|NCT03816826|Experimental|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
16423373|NCT03816800|Placebo Comparator|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
16423374|NCT03816800|Active Comparator|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
16423375|NCT03816787|Experimental|dry cupping for patients of low back pain|Patients will receive four consecutive dry cupping therapy application in one month.
16423376|NCT03816787|Active Comparator|dry cupping for health people|Health people will receive four consecutive dry cupping therapy application in one month.
16423377|NCT03816774|No Intervention|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
16423378|NCT03816774|Active Comparator|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
16423379|NCT03816761|Experimental|Fast-acting insulin aspart, default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
16423380|NCT03816761|Experimental|Fast-acting insulin aspart, non-default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
16423381|NCT03816748|Experimental|intervention|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept HFNC treatment
16423382|NCT03816748|No Intervention|control|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept usual care
16423383|NCT03816735|Active Comparator|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
16423384|NCT03816735|Active Comparator|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
16423385|NCT03816722|Experimental|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
16423386|NCT03816722|Experimental|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
16423387|NCT03816709|Other|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
16423388|NCT03816696|Experimental|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
16423389|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 3 months and treatment is ongoing at the time of enrollment.
16423390|NCT03816670|Experimental|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
16423391|NCT03816670|Experimental|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
16423392|NCT03816670|Experimental|normal responders day 2|"normal responders women stimulated with CF from day 2"
16423393|NCT03816670|Experimental|normal responders day 4|"normal responders women stimulated with CF from day 4"
16423394|NCT03816670|Experimental|high responders day 2|"high responders women stimulated with CF from day 2"
16423395|NCT03816670|Experimental|high responders day 4|"high responders women stimulated with CF from day 4"
16423396|NCT03816657||Cohort1|Cohort1 (PD-L1+/low NLR)
16423397|NCT03816657||Cohort2|Cohort 2 (PD-L1-/High NLR)
16423468|NCT03816215|Experimental|Adolescent Participants|Participants will be assigned to participate in community service (from a menu of options) for 30 hours.
16423398|NCT03816644|Experimental|5-Cog|The 5-Cog coupled with a decision tree is a simple, 5-minute procedure that will identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. The 5-Cog includes the Picture Memory Impairment Screen (PMIS), Motoric Cognitive Risk syndrome (MCR), and the Symbol Match test. The 5-Cog will be given after randomization and before the patients sees the physician. The 5-Cog will sort patients with 'cognitive impairment' from those with 'no cognitive impairment'. After completing the 5-Cog, the non-physician tester will send a message through the Electronic medical record (EMR) system to provide the physician with the 5-Cog results and guide the them through the follow-up based on the results.
16423399|NCT03816644|Active Comparator|Health Literacy & Grip Assessment|The 5 minute assessment includes the Short Assessment of Health Literacy (SAHL) and a grip assessment measured using a handgrip dynamometer. After completing the SAHL and grip assessment, the non-physician tester will send a message through the EMR to provide the physician with the results from the assessments and guide the them through the follow-up based on the results.
16423400|NCT03816631|Experimental|Part A: Group 1: Severe hepatic function|Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2*300 mg tablet) under fasted condition on Day 1.
16423401|NCT03816631|Experimental|Part A and B: Group 2: Normal hepatic function|Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
16423402|NCT03816631|Experimental|Part B: Group 3: Moderate hepatic function|Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
16423403|NCT03816631|Experimental|Part B: Group 4: Mild hepatic function|Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
16423404|NCT03816618|Experimental|CONTROL|CONTROL GROUP
16423405|NCT03816618|Experimental|TREATMENT1|TREATMENT GROUP 1
16423406|NCT03816618|Experimental|TREATMENT2|TREATMENT GROUP 2
16423407|NCT03816618|Experimental|TREATMENT3|TREATMENT GROUP 3
16423408|NCT03816605||control|Cells were cultured in the basic medium containing 2× penicillin and streptomycin antibody.
16423409|NCT03816605||Recombinant FGF19|Cells were cultured in the basic medium with recombinant FGF19 at concentration of 100ng/ml.
16423410|NCT03816605||High-glucose|Cells were cultured in the high-glucose medium at concentration of 25mM.
16423411|NCT03816605||FGF19 and HG|Cells were cultured in the medium with both recombinant FGF19 and high-glucose.
16423412|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
16423413|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
16423414|NCT03816579|Experimental|PRO-A|Beef protein
16423415|NCT03816579|Experimental|PRO-B|Complementary proteins at each meal
16423416|NCT03816579|Experimental|PRO-C|Complementary proteins over 24 hours
16423417|NCT03816579|No Intervention|CON|Low protein (<5 g) meal
16423418|NCT03816566|Experimental|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
16423419|NCT03816553|Experimental|SHR-1210 + Apatinib|Participants receive SHR-1210 200mg (3mg/kg for underweight patients) intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
16423420|NCT03816540|Experimental|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
16423421|NCT03816540|Active Comparator|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
16423422|NCT03816527||AUD patients|Individuals with alcohol use disorder
16423423|NCT03816527||Healthy controls|Healthy controls
16423424|NCT03816514|Experimental|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
16423425|NCT03816514|Active Comparator|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
16423426|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones.
16423427|NCT03816501|Other|no music|preoperative music will not be listened
16423428|NCT03816488|Experimental|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
16423429|NCT03816488|Experimental|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
16423430|NCT03816488|No Intervention|Placebo|Self-administered placebo taken 2 hours prior to surgery
16423431|NCT03816475|Experimental|Hypofractionated radiotherapy|5x5 Gy radiotherapy and delayed surgery (after 6-8 weeks)
16423432|NCT03816449|Active Comparator|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
16423469|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
16423470|NCT03816189||Diffuse SSc|Recruitment of 20 patients with diffuse SSc
16423433|NCT03816449|Placebo Comparator|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
16423434|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
16423435|NCT03816423|No Intervention|Traditional counseling|Patients will undergo routine prenatal care visit with clinical practicioner only
16423436|NCT03816423|Experimental|video group|"Participants randomized to the intervention group (video education) will view the prenatal screening video How to Decide About Prenatal Genetic Testing, followed by a routine prenatal appointment."
16423437|NCT03816410|Experimental|LAA amputation group|
16423438|NCT03816410|No Intervention|No LAA amputation group|
16423439|NCT03816397|Active Comparator|Continue adalimumab|Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.
16423440|NCT03816397|Placebo Comparator|Stop adalimumab|Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.
16423441|NCT03816384|Active Comparator|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
16423442|NCT03816384|Experimental|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
16423443|NCT03816384|Experimental|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
16423444|NCT03816371|Active Comparator|supine 0 degree head-of-bed elevation|0 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
16423445|NCT03816371|Experimental|30 degree head-of-bed elevation|30 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
16423446|NCT03816371|Experimental|45 degree head-of-bed elevation|45 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
16423451|NCT03816332|Experimental|Treatment (tacrolimus, prednisone, nivolumab, ipilimumab)|"Patients receive tacrolimus PO BID and prednisone PO QD. Within 28 days, patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 24 cycles (96 weeks) in the absence of disease progression or unacceptable toxicity.
~Patients who experience PD or patients who have experienced allograft loss at 16 weeks receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Patients also receive tacrolimus PO BID and prednisone PO QD. Cycles repeat every 3 weeks for 4 cycles (12 weeks) in the absence of disease progression or unacceptable toxicity. Starting 6 weeks later, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 21 cycles (84 weeks) in the absence of disease progression or unacceptable toxicity."
16423454|NCT03816306||Single group study|
16423455|NCT03816293|Active Comparator|Negative Pressure Wound Therapy|NPWT use on closed incision for 7 days after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
16423456|NCT03816293|No Intervention|Control Dressing|Standard dressing on closed incisions after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
16423457|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
16423458|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
16423459|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
16423460|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
16423461|NCT03816267|Active Comparator|Nebulizer|Containing salbutamol
16423462|NCT03816267|Experimental|Metered Dose Inhaler and spacer|Containing Salbutamol
16423463|NCT03816241|No Intervention|Control|Vignette contains no extra information.
16423464|NCT03816241|Experimental|Frame|Vignette is framed in a particular manner
16423465|NCT03816241|Experimental|Norms|Vignette contains extra information about norms
16423466|NCT03816241|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
16423467|NCT03816228||Experimental Flortaucipir|
16423472|NCT03816189||Healthy subjects|Recruitment of 20 healthy subjects (control)
16423473|NCT03816176|Experimental|Isavuconazonium sulfate|Participants will receive a loading dose of isavuconazonium sulfate (via intravenous or oral administration at the investigator's discretion) every 8 hours (± 2 hours) on Days 1 and 2 followed by once-daily maintenance dosing
16423476|NCT03816137|Active Comparator|ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
16423477|NCT03816137|Active Comparator|EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100G Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
16423478|NCT03816137|Active Comparator|ConS UFO and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
16423479|NCT03816137|Active Comparator|EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
16423480|NCT03816137|Active Comparator|ConS UFO and ConM SOSIPs and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0 and 3 months
~ConM SOSIP Administered at 12 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
16423481|NCT03816124|Experimental|Genicular RF|Patients who will receive genicular radiofrequency ablation
16423482|NCT03816111|Experimental|TEACH-PD Training Curriculum|All patients at sites randomized to this arm will receive the TEACH-PD Training Curriculum
16423483|NCT03816111|Active Comparator|Current Standard PD Training|All patients at sites randomized to this arm will receive the unit's current PD training materials and plan
16423484|NCT03816098||elderly patients with dysphagia|
16423485|NCT03816098||elderly patients without dysphagia|
16423486|NCT03816085|Experimental|Shoe with 4 cm heel|Shoes with 4 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
16423487|NCT03816085|Experimental|Shoe with 10 cm heel|Shoes with 10 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
16423488|NCT03816085|No Intervention|Without shoes|Women will be included in the tests to measure balance, muscular endurance and function without shoes.
16423489|NCT03816072|Active Comparator|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
16423490|NCT03816072|Active Comparator|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
16423491|NCT03816059||Hospitalized - ACS|Hospitalized patients with acute coronary syndrome
16423492|NCT03816059||Hospitalized - stroke|Hospitalized patients with stroke
16423493|NCT03816059||Hospitalized - chronic lung disease|Hospitalized patients with exacerbation of chronic lung disease
16423494|NCT03816059||Outpatient|Outpatients
16423495|NCT03816046|Experimental|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
16423496|NCT03816046|Experimental|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
16423497|NCT03816033|Active Comparator|Cryotherapy|Cryotherapy ablation energy will be utilised in the catheter ablation procedure
16423498|NCT03816033|Active Comparator|Radiofrequency|Radiofrequency ablation energy will be utilised in the catheter ablation procedure
16423499|NCT03816020|Active Comparator|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
16423500|NCT03816020|Placebo Comparator|Placebo Group|Participant receiving Placebo BIDfor 30 days
16423501|NCT03816007|Experimental|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
16423502|NCT03816007|Active Comparator|Relaxation/Health Education|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator.
16423503|NCT03815994|Experimental|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
16423504|NCT03815994|Sham Comparator|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
16423505|NCT03815981||Allergic|Collection of blood, stool, urin samples
16423506|NCT03815981||Sensitized|Collection of blood, stool, urin samples
16423507|NCT03815981||Non-Allergic|Collection of blood, stool, urin samples
16423508|NCT03815968|Experimental|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
16424568|NCT03808974|Experimental|Intervention|The intervention group will be shown an educational video
16423509|NCT03815968|No Intervention|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
16423510|NCT03815955|Experimental|Non-Sedentary Behaviour Group|Participants in this arm will model the primary care team as they engage in minimal sedentary behaviour and replace sitting with standing and light, incidental movements.
16423511|NCT03815955|No Intervention|Standard Care Control Group|Participants that are limited to standing, due to amputations, diabetic foot pain and ulcers, or sensory diabetic neuropathy, will follow standard care and attend the DIGMA in a seated position.
16423512|NCT03815942|Experimental|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
16423513|NCT03815942|Experimental|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
16423514|NCT03815929|Active Comparator|Standard replacement therapy regimen|100 mcg transdermal estradiol patch (or equivalent oral dose)
16423515|NCT03815929|Active Comparator|Titrated replacement therapy regimen|Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level
16423516|NCT03815929|No Intervention|Timed Control Group|Healthy age-matched subjects not on hormone therapy
16423517|NCT03815916|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16423518|NCT03815916|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16423519|NCT03815916|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16423520|NCT03815916|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
16423521|NCT03815903|Active Comparator|A - induction chemotherapy|
16423522|NCT03815903|Experimental|B - chemoradiotherapy|
16423523|NCT03815890|Experimental|1A; LumB|Nivolumab
16423524|NCT03815890|Experimental|1B; TNBC|Nivolumab
16423525|NCT03815890|Experimental|2A; LUMB|Nivolumab and ipilimumab
16423526|NCT03815890|Experimental|2B; TNBC|Nivolumab and ipilimumab
16423527|NCT03815890|Experimental|3B; TNBC, High TIL|Nivolumab and ipilimumab
16423528|NCT03815877|Active Comparator|The intervention group (C group receiving caffeinated coffee)|100cc coffee at 3, 6 and 9 hours after the Cesarean section
16423529|NCT03815877|Placebo Comparator|The control group (N group receiving decaffeinated coffee)|100cc decaf coffee at 3, 6, 9 hours after the Cesarean section
16423530|NCT03815864||D2SA+|Median fluoresce intensity > or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
16423531|NCT03815864||D2SA-|Median fluoresce intensity < 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
16423532|NCT03815851|Experimental|experimental：prophylactic drainage|leave prophylactic drainage after surgery
16423533|NCT03815851|No Intervention|control|not leave prophylactic drainage after surgery
16423534|NCT03815838|Experimental|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
16423537|NCT03815812|Experimental|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
16423538|NCT03815812|Placebo Comparator|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
16423539|NCT03815799|Experimental|Erector Spinae Plane Block Group|"Procedure:
~In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve erector spinae block under ultrasound guidence after the strict aseptic precautions."
16423540|NCT03815799|Sham Comparator|Control|Routine standard perioperative and postoperative analgesic protocol will be given.
16423541|NCT03815786|Experimental|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
16423542|NCT03815786|Other|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
16423543|NCT03815760|Experimental|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.
~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.
~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
16423544|NCT03815760|Active Comparator|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.
~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
16423545|NCT03815747|Experimental|Treatment Group|Treatment with the investigational device - High- Intensity Focused Electromagnetic (HIFEM) Field Device
16423546|NCT03815734|No Intervention|control group|Non intervention group
16423547|NCT03815734|Experimental|intervention group|motor imagery group
16423548|NCT03815721|Experimental|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
16423549|NCT03815721|Experimental|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
16423550|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
16482883|NCT03410173|Experimental|Taurine|2.4mg/d for 12 weeks
16423551|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
16423558|NCT03815682|Experimental|RPTR-147:1|Arm A: Escalating doses of RPTR-147:1 as a monotherapy in solid tumors and lymphomas
16423559|NCT03815682|Experimental|RPTR-147:1 and Pembrolizumab|Arm B: Escalating doses of RPTR-147:1 in combination with Pembrolizumab in solid tumors and lymphomas
16423560|NCT03815682|Experimental|RPTR-147:2|Arm C: Escalating doses of RPTR-147:2 in patients with HPV positive tumors
16423561|NCT03815669||Arthroscopic subacromial decompression|Patients referred to arthroscopic subacromial decompression
16423562|NCT03815656|Experimental|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
16423563|NCT03815643|Experimental|Avelumab|
16423564|NCT03815630|Experimental|PD-1 and dc-cik treatment group|
16423565|NCT03815617|Active Comparator|Probiotic|The study design is a crossover randomized double-blind two-block placebo-controlled single center trial with an allocation ratio of 1:1 conducted between February 2017 and May 2018. Subjects are randomized at baseline visit to receive Block 1 (Zircombi 3 g, containing Bifidobacterium longum BB536 four billion CFU, Lactobacillus rhamnosus HN001 one billion CFU with B6 vitamin 1.4 mg) and Block 2 (placebo: maltodextrins, corn starch, silicon dioxide) depending on the randomization sequence. Subjects received one sachet pack daily containing placebo or probiotic. The active treatment was undistinguishable from placebo by physical and organoleptic characteristics. Participants in the study followed a free diet.
16423566|NCT03815617|Placebo Comparator|Placebo|Same appearance of probiotic.
16423567|NCT03815604|Experimental|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
16423568|NCT03815604|Active Comparator|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
16423569|NCT03815604|Experimental|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
16423570|NCT03815604|Active Comparator|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
16423571|NCT03815591|Experimental|adolescents between ages of 10-16|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, attitudes, intentions, social norms, and behaviors around tobacco use, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
16423572|NCT03815578|Experimental|Rheumatoid Arthritis (RA) patients|RA according to the ACR/EULAR 2010 classification criteria
16423573|NCT03815565|Experimental|levobupivacaine 0.125%|continuous femoral block with levobupivacaine 0.125%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
16423574|NCT03815565|Active Comparator|ropivacaine 0.2%|continuous femoral block with ropivacaine 0.2%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
16423575|NCT03815552|Experimental|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
16423576|NCT03815539|Experimental|dry eye group|Part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
16423577|NCT03815526|Experimental|Dynamic tape|
16423578|NCT03815526|Experimental|Kinesio tape|
16423579|NCT03815526|Experimental|Sport tape|
16423580|NCT03815513|Experimental|cases|Patient with spontaneous intracerebral hemorrhage
16423581|NCT03815513|Experimental|controls|Healthy control without history of symptomatic cerebrovascular diseases
16423582|NCT03815500|Experimental|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
16423583|NCT03815487|Experimental|Therapy with Hybrid Closed Loop (HCL)|"The Intervention is the specific function of the Insulin Pump from Medtronic® with the name MiniMed® 670G (MMT-1780) to deliver Insulin as medication.
~This Medtronic MiniMed 670G Insulin Pump in Auto Mode is an Hybrid closed loop (HCL) system including an Auto Mode function. It provides as intervention several additional effects concerning automatically insulin delivery by pump: e.g. in case of high values (or predicted) - more insulin will be administered automatically, in case of low values (or predicted) - the insulin infusion will be decreased a suspended and resumed again. The patients will wear the pump continuously."
16423584|NCT03815487|Active Comparator|Sensor Augmented Pump (SAP) therapy|"The Intervention is the specific therapy of the Sensor Augmented Insulin Pump MiniMed® 670G (MMT-1780) without Auto Mode.
~This Medtronic MiniMed 670G Insulin Pump without Auto Mode' is a Sensor Augmented Pump (SAP) therapy and means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. The patients will wear the pump also continuously, but have to respond manually after the alarm. There are no automatically steps from the pump."
16423585|NCT03815474|Experimental|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
16423586|NCT03815461|Experimental|experiment group|Nab-paclitaxel+S-1
16423587|NCT03815448|Experimental|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
16423588|NCT03815448|Placebo Comparator|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
16423589|NCT03815435|Experimental|Balanced anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/ kg) + Propofol (2-3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: Desflurane 0.8-1.2 MAC + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60
16423590|NCT03815435|Experimental|Total intravenous anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/kg) + Propofol (2 -3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: continuous administration of Propofol 6-12 mg /kg/h + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60 Hypotensives: Nitro Pohl 1mg/ml 0-10 ml/h
16423591|NCT03815409|Experimental|BWSTT group|The sessions were conducted on a treadmill with partial weight unload.
16423592|NCT03815409|Other|Control group|The traditional PT rehabilitation treatment included passive, active and active-assisted exercises, according to the methods commonly used (Kabat, Bobath).
16423593|NCT03815396|Experimental|Part 1 Single Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
16423594|NCT03815396|Experimental|Part 2 Multiple Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
16423595|NCT03815383|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
16423596|NCT03815370|Placebo Comparator|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
16423597|NCT03815370|Experimental|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
16423598|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. >2 years in some, >6 months in others.
16423599|NCT03815344|Active Comparator|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
16423600|NCT03815344|Experimental|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
16423601|NCT03815331|Experimental|PD treatment with Xiaflex® plus Aveed|Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
16423602|NCT03815318|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
16423603|NCT03815305|Active Comparator|Topical CA and Placebo Oral Drug|Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
16423604|NCT03815305|Placebo Comparator|Petroleum Jelly and placebo oral drug|Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
16423605|NCT03815305|Experimental|Centella asiatica extract and Topical CA|Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
16423606|NCT03815292|Experimental|MMH-MAP|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
16423607|NCT03815292|Placebo Comparator|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
16423608|NCT03815279|Experimental|High-risk SMM and MM|"Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.
~Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.
~Maintenance (1 year):
~Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks."
16423609|NCT03815279|Experimental|Intermediate-risk SMM|"Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.
~Maintenance (1 year):
~Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks."
16423610|NCT03815266|Experimental|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).
~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
16423641|NCT03815019|Placebo Comparator|Placebo|Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
16423642|NCT03815006|Experimental|Free Style Libre device|At the start, a blood sample will be taken for the measurement of HbA1c. Training and education on the use of FSL will be provided by the research team. Participants will be advised to use flash glucose monitoring continuously for the next 24 weeks.
16482884|NCT03410173|Placebo Comparator|Placebo|2.4mg/d for 12 weeks
16423611|NCT03815253|Experimental|Acupuncture group|"Body electro-acupuncture will be conducted for 2 sessions per week over 8 consecutive weeks.
~Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.
~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
16423612|NCT03815253|Placebo Comparator|sham-acupuncture group|"As to the participants allocated to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to act as sham control at the same acupoints with same stimulation modality. However, the needles will be only adhered to the skin instead of insertion. The validity and credibility of this model has been well demonstrated."
16423613|NCT03815240|Other|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
16423614|NCT03815240|Active Comparator|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
16423615|NCT03815240|Active Comparator|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
16423616|NCT03815240|Active Comparator|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
16423617|NCT03815227|Experimental|Outpatient birth|Maternity out the same date or the next day of the birth
16423618|NCT03815214|Experimental|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4&2&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
16423619|NCT03815214|Placebo Comparator|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
16423620|NCT03815201|Placebo Comparator|Group 1|exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
16423621|NCT03815201|Active Comparator|Group 2|exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
16423622|NCT03815188||Heart Valve Surgery|Pre-operative patients undergoing heart valve surgery will be selected and data recorded from each patient on the day of their surgery. This patient cohort is required in order to be able to accurately measure their JVP upon physical examination. Patients must have a central line inserted as part of their ongoing clinical management.
16423623|NCT03815175|Experimental|XIENCE|XIENCE + 1 month DAPT
16423624|NCT03815162|Experimental|High Flavanol Cocoa extract|278mg total flavanols (38.3mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (836 mg total flavanols; 115mg epicatechin) for 3 months
16423625|NCT03815162|Placebo Comparator|Alkalised cocoa|0mg total flavanols (0mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (0mg total flavanols; 0mg epicatechin) for 3 months
16423626|NCT03815149||patients with intracranial aneurysm(s)|Standard of care elective, unscheduled or emergency procedures for the treatment of an unruptured or ruptured intracranial aneurysm(s) using a Pipeline™ Flex Embolization Device(s) with Shield Technology™
16423627|NCT03815136|Active Comparator|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
16423628|NCT03815136|Placebo Comparator|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
16423629|NCT03815097|Experimental|Intervention|Monitored anesthesia care with a mapleson circuit and nasal trumpet
16423630|NCT03815097|No Intervention|Standard of care|Standard monitored anesthesia care
16423631|NCT03815084|Experimental|PD-1 and DC-NK treatment group|
16423632|NCT03815071|Experimental|ips-nsc treatment group|
16423633|NCT03815058|Experimental|Safety Run-in Period: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of RO7198457.
16423634|NCT03815058|Active Comparator|Randomized Period: Arm A: Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with RO7198457 plus pembrolizumab (Arm B) after confirmed disease progression.
16423635|NCT03815058|Experimental|Randomized Period: Arm B: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of RO7198457.
16423636|NCT03815045|Active Comparator|Landmark-based lumbar puncture|Landmark-based LP
16423637|NCT03815045|Active Comparator|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
16423638|NCT03815032|Experimental|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:
~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
16423639|NCT03815032|Experimental|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
16423640|NCT03815019|Experimental|Megestrol|"Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is off label to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect.
~The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable."
16423643|NCT03815006|No Intervention|Self-monitoring of blood glucose|At the start, a blood sample will be taken for the measurement of HbA1c. Masked FSL will be applied for two weeks, during the last two weeks of control period. Education will focus on using fingerstick measurement for treatment optimisation.
16423644|NCT03814980|Experimental|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
16423645|NCT03814967|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
16423646|NCT03814967|Active Comparator|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
16423647|NCT03814967|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
16423648|NCT03814954|Active Comparator|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
16423649|NCT03814954|Experimental|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
16423650|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.
~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
16423651|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.
~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
16423652|NCT03814928|Experimental|Caregivers e-Learning Intervention|
16423653|NCT03814915||Study 1 - Prediabetes|"The primary objective of Study 1 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in non-diabetic high-risk participants.
~Participants in Study 1 were recruited from existing prospective cohort studies in or around each of the following European cities: Malmö, Sweden (Malmö Diet and Cancer Study); Amsterdam, The Netherlands (Hoorn Study); Copenhagen, Denmark (Inter99); and Kuopio, Finland (METSIM). A clinically practicable screening tool (DIRECT-DETECT) was used to identify at-risk participants from existing cohort studies, who were then recruited into this new prospective cohort study (Study 1)."
16423654|NCT03814915||Study 2- Diabetic|The primary objective of Study 2 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in people who have recently been diagnosed with type 2 diabetes. Participants in Study 2 of DIRECT are recruited from or nearby each of the following European cities: Malmö, Sweden; Amsterdam, the Netherlands; Copenhagen, Denmark; Exeter, UK; Newcastle, UK; Dundee, UK. Potential participants are recruited through targeted searches of existing databases and research registers combined with person-to-person contact at educational clinics and through routine retinal screening programmes.
16423655|NCT03814902|Experimental|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
16423656|NCT03814889|Active Comparator|Vibration pattern 1|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423657|NCT03814889|Active Comparator|Vibration pattern 2|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423658|NCT03814889|Active Comparator|Vibration pattern 3|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423659|NCT03814889|Active Comparator|Vibration pattern 4|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423660|NCT03814889|Active Comparator|Vibration pattern 5|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423661|NCT03814889|Active Comparator|Vibration pattern 6|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423662|NCT03814889|Active Comparator|Vibration pattern 7|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423663|NCT03814889|Active Comparator|Vibration pattern 8|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423664|NCT03814889|Active Comparator|Vibration pattern 9|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423665|NCT03814889|Active Comparator|Vibration pattern 10|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
16423666|NCT03814889|Placebo Comparator|No vibration|A light will blink instead of a vibration pattern being displayed.
16423667|NCT03814876|Experimental|SCI intervention|Spinal cord injury intervention group
16423668|NCT03814876|Active Comparator|SCI control|Spinal cord injury control
16423669|NCT03814876|Experimental|TBI intervention|Traumatic brain injury intervention group
16423670|NCT03814876|Active Comparator|TBI control|Traumatic brain injury control group
16423671|NCT03814850|Experimental|Treatment group: standard blood pressure cuff|A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
16423672|NCT03814850|Sham Comparator|Sham group: standard blood pressure cuff|The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
16423673|NCT03814824|Active Comparator|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
16423674|NCT03814824|Active Comparator|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
16423675|NCT03814811||Bone metastasis(+) with low cOC|Patients who have bone metastasis with low number of circulating osteocalcin-positive (cOC) cells
16423676|NCT03814811||Bone metastasis(+) with high cOC|Patients who have bone metastasis with high number of circulating osteocalcin-positive (cOC) cells
16423677|NCT03814811||Bone metastasis(-) with low cOC|Patients who have metastasis only in extraskeletal sites with low number of circulating osteocalcin-positive (cOC) cells
16423678|NCT03814811||Bone metastasis(-) with high cOC|Patients who have metastasis only in extraskeletal sites with high number of circulating osteocalcin-positive (cOC) cells
16423679|NCT03814798|Experimental|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
16423680|NCT03814798|Experimental|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
16423681|NCT03814798|Experimental|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
16423682|NCT03814798|Experimental|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
16423683|NCT03814772||Liver transplant|"18 years to 65
~48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
16423684|NCT03814759|Experimental|SP+CCRT|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks
16423685|NCT03814746|Experimental|Crizanlizumab (SEG101) at 5.0 mg/kg|Participants will receive Crizanlizumab (SEG101) at 5.0 mg/kg
16423686|NCT03814746|Experimental|Crizanlizumab (SEG101) at 7.5 mg/kg|Participants will receive Crizanlizumab (SEG101) at 7.5 mg/kg
16423687|NCT03814746|Placebo Comparator|Placebo|Participants will receive the placebo drug.
16423688|NCT03814733|Experimental|Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423689|NCT03814733|Experimental|Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423690|NCT03814733|Active Comparator|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423691|NCT03814733|Active Comparator|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423692|NCT03814733|Placebo Comparator|Placebo for Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423693|NCT03814733|Placebo Comparator|Placebo for Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423694|NCT03814733|Placebo Comparator|Placebo for Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
16423695|NCT03814720|Experimental|Group 1|5 subjects, ages 18-40 will be administred 20 mcg IM of H1ssF 3928 on Day 0.
16423696|NCT03814720|Experimental|Group 2A|12 subjects, ages 18-40 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
16423697|NCT03814720|Experimental|Group 2B|12 subjects, ages 41-49 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
16423698|NCT03814720|Experimental|Group 2C|12 subjects, ages 50-59 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
16423699|NCT03814720|Experimental|Group 2D|12 subjects, ages 60-70 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
16423700|NCT03814707|Active Comparator|Topical application 0.2%Hyaluronic Acid|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting and covered by periodontal pack
16423701|NCT03814707|Experimental|Platelet Rich Fibrin|Palatal donor site will receive a platelet rich fibrin and then will be sutured by criss cross suture then covered by periodontal pack.
16423702|NCT03814694|Experimental|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
16423703|NCT03814694|Active Comparator|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
16423704|NCT03814668|Experimental|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
16423705|NCT03814668|Active Comparator|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
16423706|NCT03814668|Placebo Comparator|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
16423707|NCT03814655|Experimental|Full digital workflow|"Intraoral scan of the partially edentulous site, antagonists and occlusion registration. Radiopaque tray customization over the partially edentulous arch.
~CBCT with customized radiopaque tray.
~Merging files in R2 Gate software and implant planning.
~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.
~Digital impression for final screw-retained crown/bridge.
~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
16423708|NCT03814655|Active Comparator|Partially digital workflow|"Impression of the edentulous arch and antagonist, occlusion registration. Radiopaque tray customization over the edentulous arch.
~CBCT with customized radiopaque tray.
~Stone models alone, maximum intercuspal position and customized radiopaque tray will be scanned using a desktop scanner.
~Merging files (CBCT and model stl) in R2 Gate software and implant planning.
~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.
~Classic impression in customized tray with Impregum.
~Functional models will be scanned using the same desktop scanner.
~Final screw-retained crown/bridge manufacturing.
~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
16423709|NCT03814642|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
16423710|NCT03814642|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
16423711|NCT03814642|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
16423712|NCT03814629|Other|precancerous lesions of gastric cancer|120 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia,It was randomly divided into 60 cases of treatment group and 60 cases of control group,treatment group was given Weifuchun tablets,The control group was given vitamin tablets.
16423713|NCT03814616|Experimental|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
16423714|NCT03814616|Experimental|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
16423715|NCT03814616|Experimental|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
16423716|NCT03814603||African Americans|
16423717|NCT03814603||Non-Hispanic Whites|
16423732|NCT03814577|Active Comparator|Desflurane|Anesthesia will be maintained with Desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture.Total Intravenous Anesthesia will not be used in this group. While target desflurane minimum alveolar concentration (MAC) will be 1-1.5 and Bispectral Index values will be between 40-60, the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
16423733|NCT03814577|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia: Anesthesia will be maintained with inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture. Desflurane will not be used in this group. Total Intravenous Anesthesia (propofol and remifentanyl infusion) will be performed to the patients while target Bispectral Index values were between 40-60. Also the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
16423734|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
16423735|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
16423819|NCT03813953|Active Comparator|Epidural|Conventional practice following liver resection
16423736|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.
~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
16423737|NCT03814551||Comparison|Cohort of participants who regularly eat in cafeteria without health signage.
16423738|NCT03814551||Signage|Cohort of participants who regularly eat in cafeteria in which health signage is placed.
16423739|NCT03814525|Active Comparator|Photobiomodulation group|PBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
16423740|NCT03814525|Placebo Comparator|Control group|Participants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
16423741|NCT03814512|Experimental|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
16423742|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
16423743|NCT03814473|Experimental|Dietary intervention|All participants will follow an ad libitum self-administered Paleo diet for 8-weeks
16423744|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
16423745|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
16423746|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
16423747|NCT03814447|Experimental|anti- MESO CAR-T cells|The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).
16423748|NCT03814434|Experimental|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
16423749|NCT03814434|Experimental|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
16423750|NCT03814434|Experimental|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
16423751|NCT03814434|Experimental|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
16423752|NCT03814421|Experimental|Low dose intermittent|Pantoprazole 40mg as a bolus injection daily for 72hours
16423753|NCT03814421|Active Comparator|High dose continous|Pantoprazole 40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours
16423754|NCT03814408|Experimental|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
16423755|NCT03814395||Exposure group|Group with environmental, nutritional or lifestyle exposures
16423756|NCT03814395||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
16423757|NCT03814382|Experimental|Acupuncture|All subjects will receive up to 10 needles for 20 minutes for 1 treatment using acupuncture needles.
16423758|NCT03814369|Experimental|AmplifEYE colonoscopy|Colonoscopy performed with AmplifEYE equipped
16423759|NCT03814369|No Intervention|Standard colonoscopy|Standard colonoscopy performed
16423760|NCT03814356|Experimental|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
16423761|NCT03814343|Active Comparator|Active comparator|10 patients with NDMs onychomycosis treated with amphotericin B in 30% DMSO.
16423762|NCT03814343|Placebo Comparator|control comparator|10 patients with NDMs onychomycosis treated with 30% DMSO.
16423763|NCT03814330|Placebo Comparator|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
16423764|NCT03814330|Active Comparator|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
16423765|NCT03814317|Experimental|Study Group|"Sarcoidosis patients with interstitial lung disease and precapillary pulmonary hypertension based on right heart catheterization (RHC).
~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
16423820|NCT03813940|Experimental|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
16423766|NCT03814304|Experimental|Personalized tDCS|Personalized tDCS: This intervention is designed to facilitate the excitability of the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
16423767|NCT03814304|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
16423768|NCT03814291|Experimental|cohort 1 IBI302 treated with first dose level of IBI302|
16423769|NCT03814291|Experimental|cohort 2 IBI302 treated with second dose level of IBI302|
16423770|NCT03814291|Experimental|cohort 3 IBI302 treated with third dose level of IBI302|
16423771|NCT03814291|Experimental|cohort 4 IBI302 treated with fourth dose level of IBI302|
16423772|NCT03814291|Experimental|cohort 5 IBI302 treated with fifth dose level of IBI302|
16423773|NCT03814291|Experimental|cohort 6 IBI302 treated with sixth dose level of IBI302|
16423774|NCT03814278|Experimental|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
16423775|NCT03814278|Experimental|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
16423776|NCT03814265|Experimental|Intervention|Laughter yoga group
16423777|NCT03814265|No Intervention|Control|No intervention
16423778|NCT03814252|Experimental|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
16423779|NCT03814239||no protocol|liberal fluid therapy
16423780|NCT03814239||protocol|fluid therapy according to stroke volume variation (SVV) monitor, tranexamic acid administration, use of cell saver
16423781|NCT03814226|Experimental|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
16423782|NCT03814226|Active Comparator|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
16423783|NCT03814213||No-CGA|Patients were not initially offered CGA due to no booking for CGA
16423784|NCT03814213||CGA alone|Patients had CGA, but no tailored follow-up upon identified problems
16423785|NCT03814213||CGA with tailored care|CGA and a tailored follow-up and care for 90 days following the CGA
16423786|NCT03814200|Experimental|Treatment period A|"Treatment A1: saline 0.9%
~followed by
~Treatment A2: ACT-246475"
16423787|NCT03814200|Experimental|Treatment period B|"Treatment B1: rifampicin
~followed by
~Treatment B2: ACT-246475"
16423789|NCT03814148|Experimental|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
16423790|NCT03814148|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
16423791|NCT03814135|Experimental|HIPNOS 3|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Hipnos 3 and 1 placebo tablet, oral, once a day."
16423792|NCT03814135|Experimental|HIPNOS 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Hipnos 5 and 1 placebo tablet, oral, once a day."
16423793|NCT03814135|Placebo Comparator|HIPNOS Placebo|The study is double-dummy. Thus, the patient will take 2 tablet of placebo, oral, once a day.
16423794|NCT03814122|Experimental|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
16423795|NCT03814122|Active Comparator|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
16423796|NCT03814109|Experimental|LENINGRADO|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:
~1 tablet Leningrado association,1 tablet indapamide placebo, 1 tablet levamlodipine placebo, oral, once a day."
16423797|NCT03814109|Active Comparator|Indapamide|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:
~1 tablet indapamide 1,5 mg, 1 tablet Leningrado association placebo, and 1 tablet levamlodipine placebo, oral, once a day."
16423798|NCT03814109|Active Comparator|Levamlodipine|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:
~1 tablet levamlodipine 2.5/ 5 mg, 1 tablet indapamide placebo, and 1 tablet Leningrado association placebo, oral, once a day."
16423799|NCT03814096|Experimental|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test [GTT]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
16423821|NCT03813940|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
16423822|NCT03813927|Experimental|Vitamin D|supplementation with tablet 170 μg Vitamin D each day.
16423823|NCT03813927|Placebo Comparator|Placebo|Placebo, tablet with 20 μg Vitamin D each day.
16424569|NCT03808974|Active Comparator|Control|The control group will be given an educational leaflet
16423800|NCT03814083|Experimental|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
16423801|NCT03814083|Active Comparator|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
16423802|NCT03814083|Sham Comparator|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
16423803|NCT03814070|Active Comparator|Non-reinforced full arch acrylic restorations|
16423804|NCT03814070|Experimental|full arch acrylic restorations with fiber-reinforced framework|
16423805|NCT03814057||Elderly Medical Patients at hospital admission|
16423806|NCT03814031||EAD|Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST > 2,000 IU/L within the first 7 days.
16423807|NCT03814031||Non EAD|No EAD
16423808|NCT03814005|Experimental|Control Arm (Normal Renal and Hepatic Function)|Pevonedistat 20 milligram per square meter (mg/m^2), infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
16423809|NCT03814005|Experimental|Renal Arm (Severe Renal Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day1 through Day7 or Day1 through Day5, and on Days 8-9 in combination with pevonedistat 15 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies and docetaxel 75 mg/m^2 OR carboplatin AUC4, infusion, intravenously, once along with paclitaxel 135 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 15 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
16423810|NCT03814005|Experimental|Mild Hepatic Arm (Mild Hepatic Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies, and carboplatin AUC4, infusion, intravenously, once along with paclitaxel 135 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
16423811|NCT03814005|Experimental|Moderate Hepatic Arm (Moderate Hepatic Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 10 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies, and carboplatin AUC4, infusion, intravenously, once along with paclitaxel 90 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 10 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
16423812|NCT03813992|Active Comparator|MED2005 0.2%|MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt
16423813|NCT03813992|Active Comparator|MED2005 0.4%|MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt
16423814|NCT03813992|Active Comparator|MED2005 0.6%|MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt
16423815|NCT03813992|Placebo Comparator|Placebo vehicle|Placebo vehicle applied topically prior to a sexual intercourse attempt
16423816|NCT03813979|Experimental|Hepatic impairment group|Dolutegravir in HIV-seronegative subjects with severe hepatic impairment (child-Pugh score 10 or greater)
16423817|NCT03813979|Active Comparator|Matched controls|Dolutegravir in control group matched for gender, age and BMI with subjects in hepatic impairment group
16423818|NCT03813953|Experimental|Local Anaesthetic Wound Infiltration|Wound catheter delivering local anaesthetic for 48 hours post-operatively following liver resection
16423987|NCT03812744|Experimental|WCCE|
16423824|NCT03813914|Experimental|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
16423825|NCT03813914|Placebo Comparator|Placebo comparator|placebo 2 pills/day for 3 months
16423826|NCT03813901|Experimental|Samalochana Counselling group|Arsha Vidya advaita vedanta based counselling were given to the women
16423827|NCT03813901|Other|Wait-list control group|Wait list group were not given any supportive care during the period. After that, they were offered the similar program as Counselling group.
16423828|NCT03813888|Experimental|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
16423829|NCT03813888|Other|Usual Activity Group|After school, control group were asked to conitue their usual routine.
16423830|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.
~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1~5mg per patient), alfentanil (200~1000mcg per patient) and propofol (small boluses of 10~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
16423831|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.
~LMA group: routine induction medications include propofol (50~200mg per patient), fentanyl (50~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
16423832|NCT03813836|Experimental|pembrolizumab + best supportive care|Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
16423833|NCT03813823||Phobic|Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders
16423834|NCT03813823||Nonphobic|Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders
16423835|NCT03813810||Normal|People without any chronic pulmonary diseases.
16423836|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
16423837|NCT03813810||Asthma|Patients with asthma
16423838|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
16423839|NCT03813797|Experimental|Arm A: Low Pressure (5-7 mmHg)|Laparoscopic colectomy surgery with low pressure (5-7mmHg)
16423840|NCT03813797|Active Comparator|Arm B: Standard pressure (12-15 mmHg)|Laparoscopic colectomy surgery with standard pressure (12-15mmHg)
16423841|NCT03813784|Experimental|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
16423842|NCT03813784|Active Comparator|B|Capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m^2, IV q3w
16423843|NCT03813784|Experimental|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210
16423844|NCT03813771|Experimental|Abnormal T-cells: Benepali + T2T Care|"Treatment Arm C will receive Benepali and methotrexate combination therapy and followed as per T2T care over a total duration of 24 weeks. Sulfasalazine or Hydroxychloroquine may be added to therapy at follow up visits in-line with T2T care.
~Benepali will be administered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
~Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks."
16423845|NCT03813771|Active Comparator|Abnormal T-cells: Methotrexate + T2T Care|"Treatment Arm B will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination synthetic DMARD (Including sulfasalazine and/or hydroxychloroquine).
~therapy if not achieving low disease activity (LDA) at, or after, 8 weeks)."
16423846|NCT03813771|Other|Normal T-cells: Methotrexate + T2T Care|Treatment Arm A will receive standard T2T care as per Arm B.
16423847|NCT03813758||finger after digital nerve cut|
16423848|NCT03813758||healthy finger|
16423849|NCT03813745||early denudation|Cumulus-oocyte complexes will be denudated in 30 min after oocyte retrieval
16423850|NCT03813745||late denudation|Denudation will be done 2 hr after oocyte retrieval
16423851|NCT03813732|Other|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
16423852|NCT03813719||All patients attending Rapid access Gynaecology Clinic|All patients attending Rapid access Gynaecology Clinic for the first time.
16423853|NCT03813706|Active Comparator|LN-prRLN dissection|
16423854|NCT03813706|Experimental|no LN-prRLN dissection|
16423855|NCT03813693|Experimental|towels with chlorhexidine gluconate 2%|Composed of 25 patients, who received 2 towels with chlorhexidine gluconate 2% packages each containing six towels and detailed instructions on the form and sequence of application of the towels; the time of application, that is, the night before surgery, between 20 and 22h, and, on the morning of surgery, between 5 and 6h; besides other general orientations.
16423856|NCT03813693|Active Comparator|chlorhexidine gluconate 2% liquid|Composed of 23 patients, two 100 ml flasks of chlorhexidine gluconate 2% liquid were supplied, and detailed instruction manual for the product, containing form and application sequence; time of application (the night before surgery, between 20 and 22h, and on the morning of surgery, between 5 and 6h); and general guidelines.
16423857|NCT03813680|Active Comparator|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
16423988|NCT03812744|Placebo Comparator|Placebo|
16423858|NCT03813680|Active Comparator|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
16423859|NCT03813680|Active Comparator|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
16423860|NCT03813667|No Intervention|Control|The control patients have standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist and recorded in the medical record
16423861|NCT03813667|Experimental|Intervention|The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in end-of-life palliative care.
16423862|NCT03813654|No Intervention|Control (Group A)|During the intervention block of the Field Trial, at the end of the first night shift, the participant will be told about their randomization group. In the control group (Group A), participants will not be given any instructions about the timing or duration of their sleep, but will be instructed to follow their usual night shift sleep routine.
16423863|NCT03813654|Experimental|8-h Afternoon-Evening Sleep (Group B)|In the 8-h afternoon-evening sleep intervention group (Group B), participants will be instructed to go to bed between 13:00 and 14:00 (depending on their individual commute time) and to remain in bed attempting to sleep for 8 hours (until 21:00-22:00) before the next two night shifts.
16423864|NCT03813654|Experimental|8-h Free Sleep (Group C)|In the 8-h free sleep group (Group C), participants will be instructed to remain in bed for 8 continuous hours before the next two night shifts, but will not be given any instruction regarding which 8 hours they should sleep.
16423865|NCT03813641|Experimental|RALOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
16423866|NCT03813641|Active Comparator|CAPOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
16423867|NCT03813628|Experimental|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
16423868|NCT03813628|Experimental|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
16423869|NCT03813628|Active Comparator|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
16423870|NCT03813615|Experimental|"Pilot Proof-of-Concept"|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear (breast, prostate, and endometrial) or non-linear (lung) dosing schedule for a minimum of 2 weeks.
16423871|NCT03813615|Experimental|Phase 1a: Dose-Finding / Escalation|Individualized, progressive aerobic training consisting of treadmill walking ranging from a total of 90 mins/wk to 450 mins/wk delivered over 3 to 7 sessions/wk following a linear or non-linear dosing schedule for a minimum of 2 weeks.
16423872|NCT03813615|Experimental|Phase 1b: Dose-Expansion|Individualized, progressive aerobic training consisting of treadmill walking delivered to achieve the RP2D identified in the phase 1a trial for a minimum of 2 weeks.
16423873|NCT03813602|Experimental|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
16423874|NCT03813589||PMK patients|Patients already implanted with double chamber pacemaker able to detect automatically congestive heart failure and collect atrial events.
16423875|NCT03813576|Other|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
16423876|NCT03813563||Mix group|Patients who used two balanced salt solutions during icu stay
16423877|NCT03813563||RL group|Patients who have only used lactated Ringer's during icu stay
16423878|NCT03813563||PLA group|Patients who have only used PlasmaLyte during icu stay
16423879|NCT03813550|Other|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
16423880|NCT03813537|No Intervention|Standard of Care|The control will be discharged with standard of care follow-up instructions and scheduled for a standard follow-up clinic visit within 2-3 weeks post-op.
16423881|NCT03813537|Experimental|Phone Call|The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
16423882|NCT03813524|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
16423883|NCT03813498|Experimental|intervention group|
16423884|NCT03813498|Other|control group|
16423885|NCT03813485|Active Comparator|Dry needling in upper trapezius|"Patients receive dry needling in latent myofascial trigger point in upper trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
16423886|NCT03813485|Experimental|Dry needling in lower trapezius|"Patients receive dry needling in latent myofascial trigger point in lower trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
16423887|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
16423888|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
16423889|NCT03813459||Subsyndromal delirium positive|Presence of Subsyndromal delirium in Intensive Care patients
16423890|NCT03813459||Delirium positive|Presence of Delirium in Intensive Care patients
16423891|NCT03813459||No delirium|Non subsyndromal delirium or delirium in Intensive Care patients
16423892|NCT03813433|Experimental|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
16423893|NCT03813433|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
16423894|NCT03813420||Physiotherapy students|"Pittsburgh Sleep Quality Index-PSQI:The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month
~International Physical Activity Questionnaire-IPAQ: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as the intensity of physical activity in the last seven days.
~Short Form-36-SF-36: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts."
16423895|NCT03813407|Experimental|Active Arm ( Sodium Zirconium Cyclosilicate SZC)|"Dosage formulation: 5 g sachets 2.5 g sachets 0.25 g sprinkle capsules 0.125 g sprinkle capsules (can be manufactured to support participants <2 years of age)
~Route of administration: Oral
~Dosing instructions: SZC is provided as a powder that should be mixed with water to the appropriate concentration.
~Packaging and labelling: Study treatment will be provided in sachets packed in cartons or sprinkle capsules in high density polyethylene (HDPE) bottles, as appropriate for the dose. Each carton of sachets, individual sachets, and bottle of capsules will be labelled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement. Participant-specific dosing cards (diary) will be provided."
16423896|NCT03813407|Placebo Comparator|Placebo Arm|"Silicified microcrystalline cellulose (placebo)
~Dosage formulation: Placebo to match 2.5 g sachets Route of administration: Oral Dosing Instructions: Placebo should be prepared in the same manner as the active drug product
~Packaging and labelling: Placebo is packaged in sachets packed in cartons or sprinkle capsules in HDPE bottles in accordance with the active drug product.
~Microcrystalline cellulose (placebo) Dosage formulation: Placebo to match 0.25 g sprinkle capsules
~Route of administration: Oral Dosing Instructions: Placebo should be prepared in the same manner as the active drug product
~Packaging and labelling: Placebo is packaged in sachets packed in cartons or sprinkle capsules in HDPE bottles in accordance with the active drug product."
16423897|NCT03813394|Experimental|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
16423898|NCT03813394|Experimental|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
16423899|NCT03813381|Experimental|Intervention Arm (IA)|Patients randomized in the Intervention Arm (IA) will be given personalized diet based on calorie and protein restriction. Calorie restriction will be up to 600 kcal below patients' energy requirements and the amount of protein will be 0.8g of protein/Kg body weight mostly form plant-origin food.
16423900|NCT03813381|No Intervention|Control Arm (CA)|Participants in the CA will be given information about the importance of a healthy lifestyle in reducing the risk of cancer and will receive a leaflet based on WCRF/AICR recommendations.
16423901|NCT03813355|Experimental|Active stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
16423902|NCT03813355|Sham Comparator|Sham stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations
16423903|NCT03813342|Experimental|Multichannel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 4 channels of visual information, each of which represents a joint angle (right and left hips, right and left knees).
16423904|NCT03813342|Experimental|Single Channel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 1 channel of visual information that encompasses information from 4 lower limb joint angles (right and left hips, right and left knees).
16423905|NCT03813329|Placebo Comparator|Placebo|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of Calcium carbonate
16423906|NCT03813329|Active Comparator|Acute Sodium Bicarbonate|3 doses of calcium carbonate (110 mg·kg-1, 130 mg·kg-1, 160 mg·kg-1), followed by one acute does (300 mg·kg-1) of sodium bicarbonate.
16423907|NCT03813329|Experimental|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
16423908|NCT03813316|Experimental|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
16423909|NCT03813316|Experimental|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
16423910|NCT03813303|Active Comparator|Midazolam group|Midazolam and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist . Complications and procedure and recovery times were recorded for comparison with the Fentanyl group.
16423911|NCT03813303|Active Comparator|Fentanyl group|Fentanyl and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist .Complications and procedure and recovery times have were recorded for comparison with the Midazolam group.
16423912|NCT03813290|Experimental|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.
~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
16423913|NCT03813277|Experimental|Dexmedetomidine|Dexmedetomidine 100microg/ml
16423914|NCT03813264|Experimental|preliminary arm|pairs of patients and their therapists
16423915|NCT03813251|Experimental|Assigned Interventions|ForConti Contix Fecal Incontinence Management System (FIMS)
16423916|NCT03813238|Experimental|Deutetrabenazine|administered as oral tablets at a starting dose of 6 mg once daily
16423917|NCT03813238|Placebo Comparator|Placebo|Matching placebo
16424211|NCT03811327|Experimental|Treatment group|Zero-time Exercise group
16424212|NCT03811327|No Intervention|Waitlist group|
16423918|NCT03813225|No Intervention|Conventional Analgesia|"These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation for handling an analgesic in cardiovascular surgery, this start in surgery with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.
~and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus."
16423919|NCT03813225|Experimental|Serrato intercostal plane Block|These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.In this Arm the patient will give a bilateral serratus intercostal plane block, will be performed echo-guided puncture in the line anterior axillar with fifth costal arch, whit 21 ml of anesthetic mass, 20 ml of Levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone. and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus
16423920|NCT03813199|Experimental|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks
~+ methotrexate"
16423921|NCT03813199|Experimental|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks
~+ methotrexate"
16423922|NCT03813199|Placebo Comparator|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks
~+ methotrexate"
16423923|NCT03813186|Experimental|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
16423924|NCT03813186|Experimental|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
16423925|NCT03813173|Active Comparator|central cervical dissection|
16423926|NCT03813173|Experimental|non central cervical dissection|
16423927|NCT03813160|Experimental|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
16423928|NCT03813160|Experimental|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
16423929|NCT03813160|Placebo Comparator|Placebo|Subjects will receive placebo twice daily
16423930|NCT03813147|Experimental|Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)|Patients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of each cycle. Patients then receive azacitidine IV over 15 minutes QD on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients with CNS2 or CNS3 receive cytarabine intrathecally or methotrexate intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and 11-34. Cycles continue for 35 days in the absence of disease progression or unacceptable toxicity. Patients with stable or greater with non-hematologic toxicities probably or definitely related to pevonedistat may receive an additional cycle of treatment.
16423931|NCT03813134|Active Comparator|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg).
~No mechanical support device allowed."
16423932|NCT03813134|Experimental|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
16423933|NCT03813121|Experimental|midazolam intravenous infusion|single midazolam infusion (0.02 mg/kg over 20 minutes)
16423934|NCT03813121|Placebo Comparator|placebo intravenous infusion|single placebo infusion (saline over 20 minutes)
16423935|NCT03813121|Experimental|ketamine intravenous infusion|single ketamine infusion (0.5 mg/kg over 20 minutes)
16423936|NCT03813108|Experimental|1: 3: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
16423937|NCT03813108|Experimental|2: 3: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
16423938|NCT03813108|Experimental|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
16423939|NCT03813108|Experimental|4: 3: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
16423940|NCT03813108|Other|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
16423941|NCT03813108|Other|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
16423942|NCT03813108|Other|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
16423943|NCT03813095|Experimental|APH-1501 400mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
16423944|NCT03813095|Experimental|APH-1501 600mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 600mg BID ( twice daily) for 28 days.
16423945|NCT03813095|Experimental|APH-1501 800mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 800mg BID ( twice daily) for 28 days.
16423946|NCT03813095|Placebo Comparator|Placebo Comparator: Placebo|Nano-encapsulated for oral delivery. The study is planned for patients to receive a placebo dose BID ( twice daily) for 28 days.
16423947|NCT03813082|Experimental|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
16423948|NCT03813082|Experimental|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
16423949|NCT03813069|Other|Laboratory study|
16423950|NCT03813069|Other|Field study: IR3535|
16423951|NCT03813069|Other|Field study: Permethrin lower dose|
16423952|NCT03813069|Other|Field study: Permethrin higher dose|
16423953|NCT03813069|No Intervention|Field study: control arm|
16423954|NCT03813056|Experimental|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
16423955|NCT03813056|Placebo Comparator|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
16423956|NCT03813043|Other|Midazolam|Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly
16423957|NCT03813030|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
16423958|NCT03813030|Experimental|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
16423959|NCT03813004|Experimental|Young healthy adults|
16423960|NCT03812991|No Intervention|Non-Treatment Group|This is the Non-Treatment Arm of the study. No intervention is to be administered.
16423961|NCT03812991|Experimental|Miacalcin Calcitonin Salmon Nasal Spray|1 spray (200 IU) qDay, alternate nostrils daily
16423962|NCT03812978|No Intervention|Control|Standard treatment
16423963|NCT03812978|Experimental|Intervention|Standard treatment and intervention (Smart phone application)
16423964|NCT03812965|Experimental|Group 1 - Botulinum Toxin type A (4 points of application)|4 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle and Levators labii superioris muscle (n=10 Patients)
16423965|NCT03812965|Experimental|Group 2 - - Botulinum Toxin type A (2 points of application)|2 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle (n=10 Patients)
16423966|NCT03812913||Turner Syndrome|"35 girls with Turner syndrome (except patients with part of a Y chromosome in their karyotype and r(X) cases).
~age : 7 years -16 years and 11 months.
~Psychological evaluation of cognition, social cognition and affective cognition"
16423967|NCT03812913||isolated GHD|"35 girls with isolated Growth Hormone Deficiency (GHD).
~age : 7 years -16 years and 11 months.
~Psychological evaluation of cognition, social cognition and affective cognition"
16423968|NCT03812900|Experimental|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
16423969|NCT03812900|Experimental|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
16423970|NCT03812900|Active Comparator|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
16423971|NCT03812900|Active Comparator|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
16423972|NCT03812874|Experimental|PTX-9908 Injection group|IV injection.
16423973|NCT03812874|Placebo Comparator|Placebo/Vehicle group|IV injection
16423974|NCT03812861|Experimental|CAMDS bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients with the help of a cognitive aid bundle
16423975|NCT03812861|No Intervention|No bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients without the help of a cognitive aid bundle
16423976|NCT03812848|No Intervention|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
16423977|NCT03812848|Experimental|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
16423978|NCT03812822|Experimental|Insole Group|Gait and foot posture analysis with and without the insole.
16423979|NCT03812822|No Intervention|Control Group|Gait and foot posture analysis.
16423980|NCT03812809|Experimental|BPI-7711|BPI-7711: 180mg, QD, oral
16423981|NCT03812796|Experimental|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
16423982|NCT03812783|Experimental|HAIC of FOLFIRINOX plus sorafenib|
16423983|NCT03812783|Active Comparator|HAIC of FOLFOX plus sorafenib|
16423984|NCT03812770|Experimental|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
16423985|NCT03812770|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
16423986|NCT03812757||Supraclavicular fossa US scanning|Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
16423989|NCT03812731|Active Comparator|Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2 mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.
~Children in will then receive CEB with 0.2 % ropivacaine 1-ml/kg for maintaining analgesia"
16423990|NCT03812731|Active Comparator|Non- Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2-mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.
~Children in will then receive fentanyl citrate 1-mcg/kg/hr for maintaining analgesia"
16423991|NCT03812718|Active Comparator|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
16423992|NCT03812718|Active Comparator|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
16423993|NCT03812705|Experimental|fecal microbiome transplantation|"Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;
~If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;
~If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
16423994|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
16423995|NCT03812679|Experimental|AMIA APD Solution Generation System|A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.
16423996|NCT03812666||Severe stroke|Patients with severe (defined as NIHSS score of > 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
16423997|NCT03812666||Moderately stroke|Patients with moderately severe (defined as NIHSS score of > 5 but < 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
16423998|NCT03812666||Mild stroke|Patients with mild (defined as NIHSS score of <6) acute stroke, either ischemic or hemorrhagic. (n= 25)
16423999|NCT03812653|Experimental|Intervention Arm: CPAP with Usual Care.|6 months of CPAP plus usual medical therapy.
16424000|NCT03812653|No Intervention|Control Arm: Usual Care.|6 months of usual medical therapy alone.
16424001|NCT03812640|Experimental|Vicryl|Vicryl suture
16424002|NCT03812640|Active Comparator|Nylon|Nylon suture
16424003|NCT03812627|Experimental|Re-intervention of hip prosthesis made of ceramic or metal|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
~50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal
~(25 patients by group)"
16424004|NCT03812627|Experimental|Re-intervention of hip prosthesis of stainless steel ball|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
~50 patients for re-intervention of hip prosthesis of stainless steel ball."
16424005|NCT03812627|Experimental|Re-intervention of knee prosthesis|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
~50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal."
16424006|NCT03812627|Experimental|Dead patients IMD holders autopsied|Autopsy: 80 dead patients IMD holders will be autopsied.
16424007|NCT03812627|Active Comparator|Dead patients non-IMD holders autopsied|Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.
16424008|NCT03812627|Active Comparator|patients before first prosthesis surgery|Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done
16424009|NCT03812614|Experimental|FAM ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:
~Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.
~Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting 1-2 ½ hours each.
~Receive case management contacts with a Community Health Worker (CHW) every 2-4 weeks for approximately 20 minutes each time for the remainder of the 12-month enrollment period."
16424213|NCT03811314|Experimental|Strength training|Muscle strength training programs
16424010|NCT03812614|Active Comparator|I-DSME + CM|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:
~Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.
~Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting 45 min to 2 hours each.
~Receive case management contacts with a Community Health Worker (CHW) every 2-4 weeks for approximately 20 minutes each time for the remainder of the 12-month enrollment period."
16424011|NCT03812588|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
16424012|NCT03812588|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
16424013|NCT03812588|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
16424014|NCT03812588|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
16424018|NCT03812562|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
16424019|NCT03812549|Experimental|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.
~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
16424020|NCT03812536|No Intervention|SOC Voiding Protocol|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
16424021|NCT03812536|Experimental|No Void Intervention|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
16424022|NCT03812523|Active Comparator|Control|Duloxetine 60 mg qd
16424023|NCT03812523|Experimental|Intervention|Lorcaserin 10 mg bid
16424024|NCT03812510|Experimental|A-101|Topical Solution
16424025|NCT03812497|Experimental|Obese Children Group|To reduce the weight, every obese children will receive individualized education program about a way of dietary control and exercise in their usual life. This individualized education program, developed by investigators, specialized dietitian and exercise teacher, is scheduled once a month.
16424026|NCT03812497|No Intervention|Normal Weight Children Group|Normal weight children
16424027|NCT03812484|Experimental|SCF Parole|Parolee supervised under the SCF Supervision model
16424028|NCT03812484|Active Comparator|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
16424031|NCT03812458|Experimental|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
16424032|NCT03812458|No Intervention|Control|The families who will not receive the brochure and are not encouraged to visit the website.
16424033|NCT03812445|No Intervention|No Intervention|the patients in this arm will not receive probiotics.
16424034|NCT03812445|Experimental|Experimental|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus for 3 months.
16424035|NCT03812432|Experimental|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
16424036|NCT03812419|Active Comparator|group I|Esomeprazole 40 mg capsules once daily for 6 months
16424037|NCT03812419|Active Comparator|group II|Pantoprazole 40 mg tablets once daily for 6 months
16424038|NCT03812406|Experimental|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
16424039|NCT03812406|Active Comparator|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
16424040|NCT03812393|Experimental|Treatment|TNBC patients with HER2 signal positive are treated with neratinib for 3 weeks followed by 12 weeks of neratinib in combination with weekly paclitaxel and carboplatin
16424214|NCT03811314|Experimental|Aerobic training|Aerobic training programs
16424041|NCT03812380|Experimental|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
16424042|NCT03812380|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
16424043|NCT03812367||Group 1|The denosumab naïve group
16424044|NCT03812367||Group 2|The zoledronic acid naïve group
16424045|NCT03812367||Group 3|The chronic denosumab (> 1 year with at least 3 biannual injections)
16424046|NCT03812367||Group 4|The chronic zoledronic acid (≥2 years with at least 2 annual injections)
16424047|NCT03812354|Active Comparator|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
16424048|NCT03812354|Experimental|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.
~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand."
16424049|NCT03812328|Experimental|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
16424050|NCT03812328|Active Comparator|Enoxaparin|SC, QD for up to 10 ± 2 days
16424051|NCT03812328|Experimental|SelK2|I.V., single-dose
16424052|NCT03812315|Experimental|Propolis chewing gum|2 % pure raw propolis, 20-35% gum base, 2.5% flavors, 0.3% sorbitol and 0.3% coloring substance. Children will be instructed to chew the specially prepared propolis chewing gum for at least 20 minutes, twice daily, after breakfast and before bedtime.
16424053|NCT03812315|Active Comparator|Propolis mouthwash|The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
16424055|NCT03812289|Experimental|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
16424056|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
16424057|NCT03812263|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
16424058|NCT03812250|Active Comparator|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
16424059|NCT03812250|Active Comparator|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
16424060|NCT03812237|Experimental|(EWB) Early Weight Bearing (2 Weeks Post-op)|Subjects in the EWB group were allowed to begin bearing 50 pounds (lbs) through their hindfoot in either the boot or the short leg cast at the two-week visit. They were allowed to advance their weightbearing as tolerated by 25 lbs every four days until full weightbearing through the hindfoot was achieved.
16424061|NCT03812237|No Intervention|(SOC) Standard of Care Weight Bearing (6-8 Weeks Post-op)|Subjects in the SOC group were allowed to heel touch weightbear for balance only on the operative foot until the six to eight week visit. At this visit all subjects were placed into a short leg walking boot. Non-weightbearing patients were permitted to begin the progressive weightbearing protocol, without hindfoot restriction.
16424062|NCT03812224|Experimental|Erenumab|Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
16424063|NCT03812224|Placebo Comparator|Placebo|Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
16424064|NCT03812211|Active Comparator|Active Supplement|Participants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
16424065|NCT03812211|Placebo Comparator|Placebo|Participants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
16424066|NCT03812198|Active Comparator|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
16424067|NCT03812198|Active Comparator|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
16424068|NCT03812198|Experimental|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.
~The formulation depends on the outcome of Part 1."
16424069|NCT03812198|Experimental|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.
~The formulation depends on the outcome of Part 1."
16424070|NCT03812198|Experimental|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.
~The formulation depends on the outcome of Part 1."
16424071|NCT03812198|Placebo Comparator|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
16424072|NCT03812198|Placebo Comparator|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
16424073|NCT03812185|No Intervention|TEE image before suctioning orogastric tube|for intraoperative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. This Arm is TEE image BEFORE suctioning.
16424074|NCT03812185|Experimental|TEE image after suctioning orogastric tube|This Arm is TEE image AFTER suctioning
16424075|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
16424076|NCT03812159|Experimental|Presurgical planning|Undergo crania-vault reconstruction following the presurgical planning (iCSPlan)
16424077|NCT03812146|Experimental|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
16424078|NCT03812146|Active Comparator|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
16424079|NCT03812133||Surgical patients|Patients who were electively scheduled for surgery.
16424080|NCT03812120|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
16424081|NCT03812120|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
16424082|NCT03812107|Experimental|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
16424083|NCT03812107|Active Comparator|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
16424084|NCT03812094|Active Comparator|Basic Bladder advice|Basic bladder advice as given from a pre-specified document, study nurse
16424085|NCT03812094|Active Comparator|Alarm|Alarm Enurad 400
16424086|NCT03812094|No Intervention|No treatment|No treatment during study period.
16424087|NCT03812081|Active Comparator|Group A Baska Mask|In which Baska Mask Airway (size 3,4,5) will used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
16424088|NCT03812081|Active Comparator|Group B Proseal Mask|In which Laryngeal Mask Airway- Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
16424089|NCT03812068|Experimental|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
16424090|NCT03812068|Active Comparator|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
16424091|NCT03812055||LSD|Subjects diagnosed or suspected to have any of the following lysosomal storage diseases: Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidoses.
16424092|NCT03812055||Control|Subjects with no known lysosomal storage disorder
16424093|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
16424094|NCT03812029|Experimental|EYP001a 100 mg BID|Oral dose twice daily for 12 weeks (84 days)
16424095|NCT03812029|Experimental|EYP001a 200 mg QD|Oral dose once daily for 12 weeks (84 days)
16424096|NCT03812029|Experimental|EYP001a 400 mg QD|Oral dose once daily for 12 weeks (84 days)
16424097|NCT03812029|Placebo Comparator|Placebo|Oral dose twice daily for 12 weeks (84 days)
16424098|NCT03812029|Experimental|EYP001a 100 mg QD|Oral dose once daily for 12 weeks (84 days)
16424099|NCT03812016|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time ( duration: 30-120 mins/each time) and 3 times within 3 months.
~Intervention: using the magnetic device prototype"
16424100|NCT03812003|Experimental|remifentanil|After emergence and extubation of endotracheal tube, remifentanil 1mcg/kg were diluted with 0.9% saline to 50 ml, added in IV bag, and drip for 30 minutes.
16424101|NCT03812003|No Intervention|no intervention|After emergence and extubation of endotracheal tube, 0.9% saline 50ml were added in IV bag and drip for 30 minutes.
16424102|NCT03811990|No Intervention|Control|
16424103|NCT03811990|Active Comparator|Intervention|
16424104|NCT03811977|Experimental|Test group|Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.
16424105|NCT03811977|Placebo Comparator|Placebo group|Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.
16424106|NCT03811964|Other|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
16424107|NCT03811964|Other|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
16424108|NCT03811964|Other|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
16424109|NCT03811964|Other|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
16424110|NCT03811964|Other|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
16424111|NCT03811964|Other|group control|healthy subject
16424112|NCT03811951|Experimental|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
16424113|NCT03811951|Experimental|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
16424114|NCT03811938|Active Comparator|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
16424115|NCT03811938|Experimental|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
16424116|NCT03811925|Other|DCB|
16424117|NCT03811925|Other|Stenting|
16424118|NCT03811912|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
16424119|NCT03811912|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
16424120|NCT03811899|Experimental|18F-DCFPyL PET/CT imaging|We will use technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
16424121|NCT03811886|Experimental|Phase I: Natalizumab|"Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg
~Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study."
16424122|NCT03811873|Other|Intervention|Single-Arm trial
16424123|NCT03811860|Active Comparator|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
16424124|NCT03811860|Active Comparator|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
16424125|NCT03811847|Experimental|Methylphenidate|During this study, participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order.
16424126|NCT03811847|Placebo Comparator|Placebo|During this study the participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order. Placebo is being used in this study to compare to see if any improvements in cognition other areas are due to the study drug or due to other reasons.
16424127|NCT03811834|Experimental|Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by [14C]-mobocertinib 50 mcg (approximately 2 microcurie [mcCi]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by [14C]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
16424128|NCT03811821|Active Comparator|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
16424129|NCT03811821|Active Comparator|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
16424130|NCT03811808||MSA patients|patients diagnosed with possible or probable multiple system atrophy
16424131|NCT03811795|Other|Arm 1-Repeat Cryoballoon Ablation|Subjects will be randomized to repeat cryoballoon ablation.
16424132|NCT03811795|Other|Arm 2-Radiofrequency Ablation|Participants will have radiofrequency ablation guided by high-fidelity mapping (Rhythmia) following an initial cryoballoon ablation.
16424133|NCT03811782|Experimental|Single-task Training Group|Single-task walking group
16424134|NCT03811782|Experimental|Dual-task Training Group|Dual-task walking group
16424135|NCT03811782|Experimental|Analogy Training Group|Analogy walking group
16424136|NCT03811769|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
16424137|NCT03811769|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best medical treatment
16424138|NCT03811756|Active Comparator|Test group|Participants will receive investigational product - Test syrup containing CoQ10 and collagen (daily dose 10 mL: fish collagen (Peptan®): 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg).
16424139|NCT03811756|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
16424140|NCT03811743|Experimental|Adolescents Participants|Adolescents will participate in the Dyad Plus program along with their caregivers. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
16424141|NCT03811743|Experimental|Caregivers of adolescents participants|Adult caregivers will participate in the Dyad Plus program along with their youth participants. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
16424215|NCT03811301|Experimental|Interventional|Wireless Implantable Neurodevice Microsystem
16424142|NCT03811730|Experimental|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
16424143|NCT03811730|Active Comparator|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
16424144|NCT03811717|Experimental|FAST+EX - FAST|FAST+EX then FAST alone
16424145|NCT03811717|Experimental|FAST - FAST+EX|FAST alone then FAST+EX
16424146|NCT03811704|Experimental|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
16424147|NCT03811691|Other|1.5 Tesla MRI Scan|Subjects will undergo 1.5T MRI exam
16424148|NCT03811691|Other|3 Tesla MRI Scan|Subjects will undergo 3T MRI exam
16424149|NCT03811678|Experimental|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
16424150|NCT03811678|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
16424151|NCT03811678|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
16424152|NCT03811678|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
16424153|NCT03811678|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
16424154|NCT03811678|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
16424155|NCT03811678|Experimental|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
16424156|NCT03811678|Experimental|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
16424157|NCT03811678|Experimental|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
16424158|NCT03811665|Experimental|Stereotactic body radiation therapy (SBRT)|
16424159|NCT03811665|Active Comparator|Radiofrequency Ablation (RFA)|
16424160|NCT03811652|Experimental|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
16424161|NCT03811652|Experimental|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
16424162|NCT03811652|Experimental|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
16424163|NCT03811652|Experimental|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
16424164|NCT03811652|Experimental|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
16424165|NCT03811652|Experimental|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
16424166|NCT03811639|Active Comparator|RF ablation|Patients treated with point-by-point radio-frequency ablation
16424167|NCT03811639|Experimental|Cryoballoon ablation|Patients treated with cryoballoon ablation
16424168|NCT03811626|Experimental|Intervention|Patient who underwent cognitive-behavioral rehabilitation
16424169|NCT03811626|No Intervention|Comparator|Patient with no specific management
16424170|NCT03811613|Experimental|Photobiomodulation group|"17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).
~Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks."
16424171|NCT03811613|Sham Comparator|Sham group|"18 Parkinson´s disease patients were randomly assigned to the sham group.
~Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group)."
16424172|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
16424173|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
16424174|NCT03811587|Experimental|Treatment group|Diabetes type 2 patients will take a fasting mimicking diet of 5 consecutive days a month, for a duration of 12 months. Besides this, they will receive usual diabetes care from the general practitioner.
16424175|NCT03811587|No Intervention|Control group|Diabetes type 2 Patients will have no intervention, they will receive usual diabetes care from the general practitioner.
16424216|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
16482960|NCT03409614|Experimental|Placebo+Chemo|Part 2: Placebo plus chemo
16424176|NCT03811574|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.
16424177|NCT03811574|Placebo Comparator|Placebo (semaglutide 2.4 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.
16424178|NCT03811574|Experimental|Semaglutide 1.7 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.
16424179|NCT03811574|Placebo Comparator|Placebo (semaglutide 1.7 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.
16424182|NCT03811548|Experimental|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
16424183|NCT03811548|Experimental|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
16424184|NCT03811548|Experimental|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
16424185|NCT03811535|Experimental|Somapacitan weekly|Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
16424186|NCT03811535|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks (main trial period).
16424187|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
16424188|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
16424189|NCT03811509|Active Comparator|AI with osteoporosis|Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
16424190|NCT03811509|No Intervention|AI without osteoporosis|All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
16424191|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
16424192|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
16424193|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
16424194|NCT03811483||Female gender|
16424195|NCT03811483||Male gender|
16424196|NCT03811470||1|Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
16424197|NCT03811457|Experimental|Welgenaleucel (UWC19)|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage: 100mL in total Frequency:the first day, the second day, the third day Duration:total three times
16424198|NCT03811444|Experimental|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
16424199|NCT03811444|Experimental|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
16424200|NCT03811444|Experimental|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
16424201|NCT03811431|Experimental|CEUS guidance|SonoVue 2, 4 ml
16424202|NCT03811431|Experimental|Conventional US guidance|No drugs
16424203|NCT03811418|Experimental|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
16424204|NCT03811418|Active Comparator|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
16424205|NCT03811405|Experimental|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
16424206|NCT03811392|Active Comparator|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
16424207|NCT03811392|Active Comparator|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
16424208|NCT03811379|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
16424209|NCT03811353||Children with cerebral palsy|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
16424210|NCT03811353||Healthy children|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
16424217|NCT03811275|Experimental|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
16424218|NCT03811275|Experimental|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
16424219|NCT03811262|Active Comparator|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
16424220|NCT03811262|Active Comparator|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
16424221|NCT03811249|Experimental|Implantation-Non-randomized|Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively for an additional 36 month period to measure long term safety and effectiveness outcomes.
16424222|NCT03811236|Experimental|Cold exposure|
16424223|NCT03811236|No Intervention|Room temperature|
16424224|NCT03811223|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
16424225|NCT03811223|Placebo Comparator|Placebo|Placebo injection once every 2 weeks for 12 weeks
16424226|NCT03811197|Experimental|individual MNT|Dietary counseling via face to face meeting
16424227|NCT03811197|Experimental|Individual MNT and T|Dietary counseling via face to face meeting and Telemedicine
16424228|NCT03811197|Experimental|Individual MNT and HS|Dietary counseling via face to face meeting and Hypnotic Suggestions
16424229|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
16424230|NCT03811158|Experimental|HHHFNC group|On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
16424231|NCT03811158|Sham Comparator|UHFOM group|On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min
16424232|NCT03811145|Experimental|Tendoncel|Topically applied experimental gel - Tendoncel. 80ul applied once a day for 21 consecutive days.
16424233|NCT03811145|Placebo Comparator|Placebo control gel|Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
16424234|NCT03811132||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
16424235|NCT03811132||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
16424236|NCT03811132||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
16424237|NCT03811132||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
16424238|NCT03811119|Active Comparator|MANTA vascular closure device|Arteriotomy closure with a collagen-based vascular closure device (MANTA™)
16424239|NCT03811119|Active Comparator|Suture based vascular closure device|Arteriotomy closure with 2 or more suture-based vascular closure devices (ProGlide)
16424240|NCT03811106|Active Comparator|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
16424241|NCT03811106|Other|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
16424242|NCT03811093|Experimental|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
16424243|NCT03811093|Placebo Comparator|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
16424244|NCT03811080|Experimental|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
16424245|NCT03811080|Experimental|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
16424246|NCT03811080|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
16424247|NCT03811067|No Intervention|Control group|
16424248|NCT03811067|Active Comparator|TAP group|Transversus abdominis plane block administered group
16424249|NCT03811067|Active Comparator|RS group|Rectus sheath block administered group
16424250|NCT03811054|Experimental|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
16424251|NCT03811041|Experimental|PC articulated with MDA|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.
16424252|NCT03811041|Active Comparator|Routine cares|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.
16424253|NCT03811041|Experimental|Parental depression|Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.
16424254|NCT03811028|Experimental|SOBI003|"SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.
~SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined."
16424260|NCT03810989|Experimental|infra-red sauna|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
16424261|NCT03810989|Experimental|argometer and treadmill|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
16424262|NCT03810989|Experimental|combination of sauna and hot bath|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
16424263|NCT03810989|Experimental|combination of sauna and hot bath in CKD|During the ﬁrst month (control phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be calculated. During the next two months (intervention phase) the patient will be subjected to three session of sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the patients will be immersed up to neck for one hour in water at 37 -43 C .
16424264|NCT03810976|Experimental|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
16424265|NCT03810963|Experimental|FES Cycling and Nutrition Counseling|"Device:
~HIIT-FES cycling will be performed 30 minutes per session, 3 times per week for 3 weeks combined with
~Behavior:
~Nutrition counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
16424266|NCT03810963|Other|Nutritional Counseling Only|"Behavior:
~Nutritional counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
16424267|NCT03810950|Experimental|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
16424268|NCT03810950|Active Comparator|Control Condition|Participants reads newspaper before Barlab-Exposure
16424269|NCT03810937|Active Comparator|Group sniffing (S)|intervention: Head position changes : we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.
16424270|NCT03810937|Active Comparator|Group Flat (F)|intervention: Head position changes same procedure will be done but starting from sniffing position and the patient will be intubated in flat position.
16424271|NCT03810924|Active Comparator|Control|Participants reads newspaper before Barlab-Exposure
16424272|NCT03810924|Experimental|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
16424273|NCT03810924|Experimental|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
16424274|NCT03810911|Active Comparator|Early start|Participants given study drug immediately at randomization
16424275|NCT03810911|No Intervention|Delayed start|Participants given study drugs 12 weeks after randomization
16424276|NCT03810898|Experimental|Phase 1 (a & b)|"Radioligand [¹¹C]CHDI-00485180-R and/or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 young (< 35) HCs/ Imaging- MRI and PET/
~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
16424353|NCT03810313|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
16424354|NCT03810300|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
16424277|NCT03810898|Experimental|Phase 2a|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/
~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs
~1 Radioligand administered 1x- HCs/"
16424278|NCT03810898|Experimental|Phase 2b|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/
~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs
~1 Radioligand administered 1x -HCs/"
16424279|NCT03810898|Experimental|Phase 2c|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/
~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs
~1 Radioligand administered 1x- HCs/"
16424280|NCT03810885|Experimental|Salt reduced bread|Bread with reduced salt content
16424281|NCT03810885|Experimental|Dietary advice and Salt reduced bread|bread with reduced salt content, dietary advice
16424282|NCT03810885|Placebo Comparator|Normal bread|Bread with standard salt content
16424283|NCT03810872|Other|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
16424284|NCT03810859|Experimental|All patients|Blood sample
16424285|NCT03810846|Experimental|Exercise|Walking football exercise program
16424286|NCT03810833|Experimental|Participants with Brilliance sensor placement|Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
16424287|NCT03810820|Other|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
16424288|NCT03810807|Experimental|Dacomitinib and Osimertinib|"Patients will begin on combination dacomitinib and osimertinib at the prescribed doses.
~A cycle will be 28 days in duration. The study will use a standard 3+3 dose escalation design."
16424289|NCT03810794|Experimental|Acupuncture Treatment Group|Participants in this group will be given acupuncture treatment in combination with donepezil for 12 weeks.
16424290|NCT03810794|Active Comparator|Donepezil Group|Participants in this group will be given only donepezil for 12 weeks.
16424291|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
16424293|NCT03810755|Other|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
16424294|NCT03810755|Other|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
16424295|NCT03810742|Experimental|Nanoliposomal Irinotecan + TAS-102|different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
16424296|NCT03810729|Active Comparator|Modified Allen's Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on the participant's hand. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
16424297|NCT03810729|Active Comparator|Smartphone assessment|The smartphone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's index finger and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
16424298|NCT03810716|Experimental|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
16424299|NCT03810716|No Intervention|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
16424300|NCT03810703|Placebo Comparator|placebo arm|Participant will receive placebo oral capsule during this four hour session.
16424301|NCT03810703|Experimental|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
16424302|NCT03810703|Experimental|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
16424303|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3704
16424304|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3704
16424305|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3704
16424306|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
16424307|NCT03810690|Experimental|Dose Expansion Phase: mRNA-3704|
16424308|NCT03810677||Patients with varicose veins, eligible for EVLA|
16424309|NCT03810664|Experimental|Somatrogon pre-filled PEN|
16424310|NCT03810664|Active Comparator|Somatrogon frozen liquid formulation|
16424311|NCT03810651|Other|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
16424312|NCT03810638||Heart Failure Patients|All Heart Failure Patients seen at 3 major academic medical centers.
16424313|NCT03810625|Experimental|Sequence AB|D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
16424314|NCT03810625|Experimental|Sequence BA|D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
16424315|NCT03810599|Other|Early cardiac rehabilitation|Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.
16424355|NCT03810300|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
16424316|NCT03810586|Experimental|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
16424317|NCT03810573|Experimental|NB1-1.5|NB1 low dose
16424318|NCT03810573|Experimental|NB1-2.0|NB1 high dose
16424319|NCT03810573|No Intervention|Autograft|Autograft
16424320|NCT03810560|No Intervention|open flap debridement|surgical treatment of periodontal pocket without any intervention
16424321|NCT03810560|Active Comparator|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
16424322|NCT03810547|Active Comparator|Spinal anesthesia|Patients undergoing abdominoplasty under spinal anesthesia may need to drug administration like propofol or ketamine or change anesthesia to general anesthesia.
16424323|NCT03810547|No Intervention|General anesthesia|General anesthesia for abdominoplasty
16424324|NCT03810534|Experimental|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
16424325|NCT03810534|No Intervention|Control|Standard discharge planning at the skilled nursing facility only.
16424326|NCT03810521|Experimental|CLT low-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
16424327|NCT03810521|Experimental|CLT medium-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
16424328|NCT03810521|Experimental|CLT high-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
16424329|NCT03810495|Experimental|OLANI (naltrexone implant)|2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
16424330|NCT03810482|Experimental|The study population|"The study population as described by eligibility criteria.
~Intervention: 6 minute walking test Intervention: pedometer"
16424331|NCT03810456|Active Comparator|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
16424332|NCT03810456|Active Comparator|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
16424333|NCT03810456|No Intervention|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
16424334|NCT03810443|Experimental|pulmonary arterial hypertension|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
16424335|NCT03810430|Active Comparator|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
16424336|NCT03810430|No Intervention|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
16424339|NCT03810404|Experimental|Sodium bicarbonate supplementation|Group taking oral SB supplementation in a different-dose regimen.
16424340|NCT03810404|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (NaCl).
16424341|NCT03810391|Experimental|preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group A were >11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
16424342|NCT03810391|Placebo Comparator|preoperative anxiety and saline|preoperative anxiety scores of patients in Group B were >11 and received an infusion of the same volume of physiological saline
16424343|NCT03810391|Experimental|non-preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group C were ≤ 11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
16424344|NCT03810391|Placebo Comparator|non-preoperative anxiety and saline|preoperative anxiety scores of patients in Group D were ≤11 and received an infusion of the same volume of physiological saline
16424345|NCT03810378|Experimental|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
16424346|NCT03810378|Experimental|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
16424347|NCT03810365|Experimental|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
16424348|NCT03810365|Active Comparator|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
16424349|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
16424350|NCT03810339|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
16424351|NCT03810326|Experimental|Intervention|
16424352|NCT03810313|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
16424356|NCT03810300|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
16424357|NCT03810300|Experimental|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
16424358|NCT03810300|Experimental|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
16424359|NCT03810300|Experimental|Control|No transfer, no behavior change communication
16424360|NCT03810287|Experimental|Patients receiving Domperidone|Patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.
16424361|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
16424362|NCT03810261|Experimental|Oil-based vitamin D group|Oil-based vitamin D, 1000 IU/day for 8 weeks
16424363|NCT03810261|Experimental|Water-based vitamin D group|Water-based vitamin D, 1000 IU/day for 8 weeks
16424364|NCT03810261|Experimental|Vitamin D capsules group|Vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks
16424365|NCT03810261|No Intervention|Control group|This group will receive no intervention.
16424366|NCT03810235|Active Comparator|Transdermal Lidocaine Patch|Drug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
16424367|NCT03810235|Placebo Comparator|Transdermal Hydrocolloid Placebo Patch|Drug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
16424368|NCT03810209|Active Comparator|magnesium sulphate group|The investigator injected 28.5 mL of bupivacaine 0.5% and 1.5 ml MgSo4 (150 mg), a total volume of 30 ml, it was confirmed visually by the ultrasound.
16424369|NCT03810209|Placebo Comparator|control group|The investigator injected 28.5 mL of Bupivacaine 0.5% and 1.5 mL of normal saline, a total volume of 30 ml, it was confirmed visually by the ultrasound.
16424370|NCT03810196|Other|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
16424371|NCT03810196|Other|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
16424372|NCT03810183|Experimental|QAW039 450 mg|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet.
16424373|NCT03810183|Placebo Comparator|Placebo|Placebo once daily for 6 weeks administered orally as a tablet.
16424374|NCT03810170|Active Comparator|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
16424375|NCT03810170|Experimental|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
16424376|NCT03810157|Experimental|Laser-assisted hatching system|Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.
16424377|NCT03810157|No Intervention|Control group|Nothing is done.
16424378|NCT03810144||Vectra Guided|For patients in the guided care arm, treating physicians will receive the Vectra DA MBDA Test score prior to the patient visit and will have a set of guidance for decision-making based on these scores. Treating physicians will be strongly encouraged to follow the guidance but will not be required to do so. For test results to be available at the time of each visit in the MBDA guided treatment arm, blood testing will be performed 7-10 days before the visit.
16424379|NCT03810144||Usual Care|For patients in the UC arm, treating physicians will not have access to MBDA scores until the end of the study.
16424380|NCT03810131|No Intervention|Waitlist control|This is a group who are waiting for treatment (the control group)
16424381|NCT03810131|Experimental|BOA online intervention|The is the group who are receiving the BOA online intervention.
16424382|NCT03810118|Experimental|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
16424383|NCT03810105|Experimental|Castration Sensitive Biochemically Recurrent Prostate Cancer|Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer
16424384|NCT03810079|Active Comparator|Anodal tDCS High Vigilance|Patients will undergo continuous 8 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined high level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
16424385|NCT03810079|Active Comparator|Anodal tDCS Low Vigilance|Patients will undergo continuous 8 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined low level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
16424386|NCT03810079|Sham Comparator|Sham tDCS Random Vigilance|Patients will undergo continuous 8 channels EEG and receive sham tDCS (bilateral prefrontal stimulation) at a random level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
16424387|NCT03810066|Experimental|Osimertinib|
16424417|NCT03809897|Active Comparator|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21 mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
16424567|NCT03808987|Experimental|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
16424389|NCT03810040|Active Comparator|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
16424390|NCT03810040|Experimental|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
16424391|NCT03810027||OAB with nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Precence of nocturnal polyuria will be classified in this group.
16424392|NCT03810027||OAB without nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Absence of nocturnal polyuria will be classified in this group.
16424393|NCT03810014|Experimental|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
16424394|NCT03810014|Experimental|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
16424395|NCT03810014|Experimental|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
16424396|NCT03810014|Experimental|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
16424397|NCT03810001|No Intervention|standard ICSI procedure|a single spermatozoon was injected into the ooplasm
16424398|NCT03810001|Experimental|modified ICSI procedure|slight mechanical stimulation before standard ICSI procedure
16424399|NCT03809988|Experimental|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
16424400|NCT03809988|Active Comparator|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
16424401|NCT03809975|Active Comparator|Control Arm|"Current model of care
~Patients will undergo the current standard of care in the Orthopaedic Outpatient Clinic in Tan Tock Seng Hospital. Patients will undergo routine consultation with an orthopaedic surgeon and will be provided with standard treatment as necessitated based on the assessment of the orthopaedic surgeon. Subsequent follow up appointments will be scheduled at the discretion of the orthopaedic surgeon. Patients will be referred to the physiotherapists, dietitian and psychologists as necessary for regular or adhoc sessions at the discretion of the allied health professional."
16424402|NCT03809975|Experimental|Intervention Arm|"Multidisciplinary Community Program
~Community based, personalized, structured, 12-week multidisciplinary program that includes Orthopaedics, Physiotherapy, Dietitics, Psychology interventions. This intervention involves the use of formal assessment such as BMI and psychological questionnaires to determine the need for dietetics or psychological intervention. In addition, there are educational sessions to improve patient's understanding of osteoarthritis and improve their activation level. An optional support group session will be arranged at approx. 3-4 months after completion of the 12-week intervention program to improve sustainability of treatment effect."
16424403|NCT03809962||Ostenil® Plus|1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
16424404|NCT03809949|Active Comparator|Fentanyl Opioid Anesthesia|Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
16424405|NCT03809949|Placebo Comparator|Saline Nonopioid Anesthesia|Opioid free anesthesia (syringe of saline is given instead of fentanyl) and the same general anesthesia is given as group A(muscle relaxant ,propofol, inhalation for maintance).
16424406|NCT03809936|Active Comparator|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
16424407|NCT03809936|Sham Comparator|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
16424408|NCT03809923|Experimental|Dexmedetomidine Combined With Lidocaine Infusion Affect PONV|
16424409|NCT03809923|Experimental|Effect of infusion saline on PONV|
16424410|NCT03809923|Experimental|Effect of infusion lidocaine on PONV|
16424411|NCT03809923|Experimental|Effect of infusion dexmedetomidine on PONV|
16424412|NCT03809910|Experimental|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
16424413|NCT03809910|Experimental|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
16424414|NCT03809910|Sham Comparator|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
16424415|NCT03809910|Active Comparator|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
16424416|NCT03809897|Experimental|Varenicline|Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
16424507|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
16424418|NCT03809884|Experimental|Dietary Counselling|All enrolled patients will undergo a 1:1 counselling with a registered dietitian (with possible inclusion of family members, as appropriate). The dietitian will undertake an assessment of the comorbidities (e.g. diabetes), dietary intake, dietary habits (e.g. eating out, food preparation, socio-cultural aspects) and provide an individually tailored strategy to increase potassium in the diet. Secondly, on a weekly basis, the dietitian will contact the patient by telephone, or electronically (as preferred by the patient) to reinforce the advice and provide support/advice as necessary.
16424419|NCT03809884|Active Comparator|Potassium Citrate Supplement|Patients who are not able to successfully increase their potassium intake at 4 weeks with dietary counselling will receive potassium citrate supplements. They will receive oral potassium supplementation in the form of 50 to 100 mmol of potassium citrate (as 25 to 50 ml of the liquid solution).
16424420|NCT03809871|Experimental|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
16424421|NCT03809871|No Intervention|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
16424422|NCT03809858|Experimental|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
16424423|NCT03809858|Experimental|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
16424424|NCT03809845|Active Comparator|Motor neuron disease|
16424425|NCT03809845|Active Comparator|Benign fasciculation syndrome|
16424426|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
16424427|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
16424428|NCT03809819||Patients with MRKHS|Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
16424429|NCT03809819||Control group|A control group of 13 age-matched, childless, sexually active women
16424430|NCT03809806|Other|patients after hysterectomy|modified anterior transvaginal mesh surgery
16424431|NCT03809793|Active Comparator|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
16424432|NCT03809793|Placebo Comparator|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
16424433|NCT03809780|Experimental|Lenalidomide,dexamethasone|"high dose: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly
~low dose: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly Schedule"
16424434|NCT03809767|Experimental|CS1003 monoclonal antibody|
16424435|NCT03809754|Experimental|OCT-guided PCI|
16424436|NCT03809754|Sham Comparator|Angiography-guided PCI|
16424437|NCT03809741|Experimental|Preventing L&D Infections|Low-cost bundled L&D infection prevention interventions will be implemented, including education, visual reminders, feedback, and alcoholic hand rub supply. Infection control practices and child delivery outcomes will be assessed after implementation of these interventions.
16424438|NCT03809728|Other|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
16424439|NCT03809702|Active Comparator|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
16424440|NCT03809702|Placebo Comparator|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
16424441|NCT03809689|Other|acute infarction|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
16424442|NCT03809689|Other|acute infarction requiring reperfusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
16424443|NCT03809689|Other|chronic ischemic occlusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment
16424444|NCT03809676||heaart transplant recipients|
16424445|NCT03809676||healthy controls|
16424446|NCT03809663|Experimental|Tezepelumab high dose|subcutaneous injection every 2 weeks
16424447|NCT03809663|Experimental|Tezepelumab low dose|subcutaneous injection every 4 weeks
16424448|NCT03809663|Experimental|Tezepelumab medium dose|subcutaneous injection every 2 weeks
16424449|NCT03809663|Placebo Comparator|Placebo|subcutaneous injection every 2 weeks or every 4 weeks
16424450|NCT03809650|Experimental|Open-label treatment period|oral administration of macitentan 10 mg once daily
16424451|NCT03809637|Experimental|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
16424452|NCT03809624|Experimental|Single Agent Escalation|INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.
16424453|NCT03809624|Experimental|Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
16424454|NCT03809624|Experimental|Expansion Cohort Melanoma|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
16424508|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
16424455|NCT03809624|Experimental|Expansion Cohort PD-L1 Positive Basket|Patients with gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
16424456|NCT03809624|Experimental|Expansion Cohort Head and Neck Squamous Cell Carcinoma|Patients with head and neck squamous cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
16424457|NCT03809624|Experimental|INBRX-105 Escalation in Combination with Pembrolizumab|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.
16424458|NCT03809624|Experimental|Combination Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with INBRX-105 in combination with Pembrolizumab.
16424459|NCT03809624|Experimental|Combination Expansion Cohort Melanoma|Patients will be treated with INBRX-105 in combination with Pembrolizumab.
16424460|NCT03809624|Experimental|Combination Expansion Cohort Cohort PD-L1 Positive Basket|Patients with head and neck squamous cell carcinoma, gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.
16424461|NCT03809624|Experimental|Combination Expansion Cohort Treatment Naive Non-small Cell Lung Cancer|Treatment naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.
16424462|NCT03809611|Experimental|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
16424463|NCT03809611|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
16424464|NCT03809598|Experimental|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
16424465|NCT03809598|No Intervention|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
16424466|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
16424467|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
16424468|NCT03809572|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support.
16424469|NCT03809572|No Intervention|Treatment as usual (TAU)|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
16424470|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
16424471|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
16424472|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
16424473|NCT03809546|Placebo Comparator|Placebo|
16424474|NCT03809546|Active Comparator|7.5 mg THC|
16424475|NCT03809546|Active Comparator|15 mg THC|
16424478|NCT03809520|Experimental|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
16424479|NCT03809507||NC Clinicians|Qualtrics Survey of NC Clinicians with DEA registration
16424480|NCT03809494|Experimental|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
16424481|NCT03809494|Placebo Comparator|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
16424482|NCT03809481|Experimental|Danaparoid Sodium|Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.
16424483|NCT03809481|Active Comparator|Argatroban|Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.
16424484|NCT03809468|No Intervention|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
16424485|NCT03809468|Experimental|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
16424486|NCT03809455|Experimental|FAR Arm|
16424487|NCT03809455|Placebo Comparator|Placebo Arm|
16424488|NCT03809442|Experimental|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.
~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
16424489|NCT03809442|Experimental|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.
~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.
~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
16424490|NCT03809442|Experimental|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
16424491|NCT03809442|Experimental|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
16424492|NCT03809442|Experimental|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.
~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
16424493|NCT03809442|Placebo Comparator|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.
~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
16424494|NCT03809429|Experimental|FE 999049 + GnRH agonist (GONAPEPTYL)|
16424495|NCT03809429|Experimental|FE 999049 + GnRH antagonist (CETROTIDE)|
16424496|NCT03809416|No Intervention|Control|32 biopsy specimens from acne scars will be excised without any treatment.
16424497|NCT03809416|Sham Comparator|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
16424498|NCT03809416|Active Comparator|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
16424499|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
16424500|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
16424501|NCT03809390|Experimental|Vaginal seeding group|Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
16424502|NCT03809390|No Intervention|Control group|Managed based on the standard practice in the study site
16424503|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
16424504|NCT03809364|Experimental|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is 5 sessions in length and conducted weekly. Sessions are 60 - 75 minutes. Couples have the option of completing up to 3 additional booster sessions. Total treatment therefore ranges between 5 to 8 sessions.
16424505|NCT03809364|No Intervention|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
16424506|NCT03809351|Experimental|[F-18]AV-1451-PET/MRI|All participants in this study will undergo a tau-PET imaging using the tracer [F-18]AV-1451 with a simultaneous PET/MRI system. The [F-18]AV-1451 dosage is 740MBq (10 mCi) given intravenously, and the PET/MRI imaging will occur 75-105 min after tracer injection.
16424509|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
16424510|NCT03809312|Active Comparator|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
16424511|NCT03809312|Placebo Comparator|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
16424512|NCT03809312|Active Comparator|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
16424513|NCT03809312|Placebo Comparator|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
16424514|NCT03809299|Other|Ad libitum meal timing first|This arm will receive the ad libitum meal timing intervention first, followed by the twice a day feeding intervention.
16424515|NCT03809299|Other|Twice a day meals first|This arm will receive the twice a day feeding intervention first, followed by the ad libitum meal timing intervention.
16424516|NCT03809286|Experimental|Active Stimulation|Participants will be receiving active rTMS.
16424517|NCT03809286|Sham Comparator|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
16424518|NCT03809273|Experimental|Yangxinshi|
16424519|NCT03809273|Active Comparator|Trimetazidine|
16424520|NCT03809260|Experimental|Part 1|Metformin/Vancomycin
16424521|NCT03809260|Experimental|Part 2|Metformin
16424522|NCT03809234|Experimental|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
16424523|NCT03809234|Placebo Comparator|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
16424524|NCT03809221|Experimental|early follicular phase down-regulation|Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle. If complete pituitary down-regulation is achieved after 28-42 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours after pre-ovulatory hCG injection transvaginally under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
16424525|NCT03809221|Active Comparator|luteal phase down-regulation|Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle. If complete pituitary down-regulation is achieved after 14-21 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and the serum hormone level and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours later under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
16424526|NCT03809195|Experimental|Hypnosis Intervention|The intervention is clinical hypnosis--a single in-person session followed by instructions to listen to audio recordings at home. The sessions consist of the provider's voice guiding the participant into a relaxed and focused state and providing therapeutic suggestions--for example, to replace discomfort with a more pleasant sensation, to ease anxiety, and to increase energy.
16424527|NCT03809195|No Intervention|Waitlist Control|This group will serve as a control comparison and be offered the intervention after control data collection is complete.
16424528|NCT03809182|Experimental|Dexmedetomidine|After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
16424529|NCT03809182|Placebo Comparator|0.9% Sodium-chloride|After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
16424530|NCT03809169|Experimental|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
16424531|NCT03809169|Experimental|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
16424532|NCT03809169|Experimental|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
16424533|NCT03809169|Experimental|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
16424534|NCT03809156|Experimental|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
16424535|NCT03809143|Experimental|Depot buprenorphine arm|All participants will receive monthly injections of depot buprenorphine (RBP-6000, Sublocade)
16424536|NCT03809130|Experimental|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
16424537|NCT03809130|Active Comparator|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
16424538|NCT03809117|Experimental|Experimental|Gastrointestinal Polymerase Chain Reaction test performed and results communicated to treatment provider. Followed by usual care per treating physician.
16424539|NCT03809117|Active Comparator|Control|Gastrointestinal Polymerase Chain Reaction test performed at the conclusion of the study. Clinician will not be informed of results. Usual Care performed per treating physician.
16424540|NCT03809104|Experimental|elderly with sarcopenia|Virtual reality-based rehabilitation programs
16424541|NCT03809091||Bronchiectasis|The patient with bronchiectasis who has no apparent bronchiectasis-causing etiology will be enrolled. The patient's family who has no bronchiectasis will be also enrolled to identify the patient-specific variants.
16424542|NCT03809078|Experimental|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
16424543|NCT03809078|Experimental|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
16424544|NCT03809065|Experimental|group N|Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
16424545|NCT03809065|Active Comparator|group L|Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .
16424546|NCT03809052|Experimental|A1 - 5 mg GB1211 single dose and Placebo|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
16424547|NCT03809052|Experimental|A2 - 20 mg GB1211 single dose and Placebo|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
16424548|NCT03809052|Experimental|A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
16424549|NCT03809052|Experimental|A4 - 100 mg GB1211 single dose and Placebo|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
16424550|NCT03809052|Experimental|A5 - 200 mg GB1211 single dose and Placebo|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
16424551|NCT03809052|Experimental|B1 - GB1211 multiple ascending doses, 50mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.
16424552|NCT03809052|Experimental|B2 - GB1211 multiple ascending doses, 100mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..
16424553|NCT03809052|Experimental|A6 - 50mg GB1211 single dose and Placebo|8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
16424554|NCT03809052|Experimental|A7 - 400 mg GB1211 single dose and Placebo|8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
16424555|NCT03809052|Experimental|Part A - Placebo for GB1211|In Part A - 2 subjects from each arm (A1-A5) will receive placebo.
16424556|NCT03809052|Experimental|Part B - Placebo for GB1211 (BID)|Part B - 3 subjects from each arm B1 and B2 will receive placebo.
16424557|NCT03809039|Experimental|Single Ascending Dose: MT-6345 & Placebo|
16424558|NCT03809039|Experimental|Multiple Ascending Dose: MT-6345 & Placebo|
16424559|NCT03809026||Study group|Couples where the men have Klinefelter's syndrome, maturation stop in the spermatogenesis or failed retrieval of testicular sperm by conventional techniques with needle or TruCut, and where testicular sperm could be obtained by micro-TESE.
16424560|NCT03809026||Control group|Couples as in the study group, but where testicular sperm could not be obtained by micro-TESE. The oocytes therefore must be fertilized using donor sperm.
16424561|NCT03809013|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
16424562|NCT03809000|Active Comparator|Salvage Radiation Therapy + Standard ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog with or without 1-4 months of bicalutamide.
16424563|NCT03809000|Experimental|Salvage Radiation Therapy + Enhanced ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog + 24 months of enzalutamide.
16424564|NCT03808987|Experimental|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
16424565|NCT03808987|Experimental|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
16424566|NCT03808987|Experimental|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
16424570|NCT03808961|Active Comparator|Group 1 ? Niacin Arm|Oral 100 mg fixed dose twice daily x 18-months (200 mg total / day) with assessments @ baseline, 6 month, 12 month and 18 months
16424571|NCT03808961|Active Comparator|Group 2 ? Niacinamide Arm|Oral 100 mg fixed dose twice daily (200 mg total / day) x 18-months with assessments @ baseline, 6 month, 12 month and 18 months
16424572|NCT03808961|Placebo Comparator|Group 3 ? Placebo Wait-listed Arm|Oral placebo twice daily x 18- months with assessments @ baseline, 6 month, 12 month and 18 months
16424573|NCT03808948|Experimental|All Patients|VFI dose: 47 mg / 3 mL Number of doses: 2 Route of administration: intravenous
16424574|NCT03808935|Experimental|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
16424575|NCT03808935|Placebo Comparator|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.
~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
16424576|NCT03808922|Experimental|Cohort 1 and Cohort 2 Treatment|DAS181 4.5mg qd x 7 OR 10 days
16424577|NCT03808922|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|Placebo qd x 7 OR 10 days
16424578|NCT03808922|Experimental|Cohort 3|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (< 40kg)
16424579|NCT03808922|Experimental|Cohort 4|DAS181 4.5mg qd x 7 OR 10 days
16424580|NCT03808922|Experimental|DAS181 COVID-19 Treatment|DAS181 4.5mg q12h x 7 OR 10 days
16424581|NCT03808922|Placebo Comparator|DAS181 COVID-19 Placebo|Placebo q12h x 7 OR 10 days
16424582|NCT03808909|Experimental|Doula|Participants will be assigned a doula.
16424583|NCT03808909|No Intervention|Control|Participants will not be assigned a doula.
16424584|NCT03808896|Active Comparator|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
16424585|NCT03808896|Active Comparator|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
16424586|NCT03808896|No Intervention|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
16424587|NCT03808870|Experimental|NBM-BMX|
16424588|NCT03808857|Experimental|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
16424589|NCT03808844|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
16424590|NCT03808844|Active Comparator|Propofol|2.0mg/kg/1.0mg/kg
16424591|NCT03808831|Experimental|Experimental groups|Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
16424592|NCT03808831|Sham Comparator|Sham group|In the sham group, subjects wear a sham system with record but no alert function.
16424593|NCT03808818|Active Comparator|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
16424594|NCT03808818|Experimental|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
16424595|NCT03808805|Experimental|studied group|Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days
16424596|NCT03808805|Active Comparator|comparative group|Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days
16424597|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
16424598|NCT03808779|Experimental|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
16424599|NCT03808779|Active Comparator|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
16424600|NCT03808766|Other|Tumor <=3cm|Embolization with particulate or liquid embolic agent
16424601|NCT03808766|Other|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
16424602|NCT03808766|Other|Tumor > 7cm|Embolization with particulate or liquid embolic agent
16424603|NCT03808753|Experimental|Treatment - hemodynamic tests: EEOT and mFC|Interventions: all the enrolled patients will be tested using the EEOT and the mFC.
16424604|NCT03808740|Experimental|Roux-en-Y gastric bypass (RYGB)/Atomoxetine|Participants with standard of care RYGB will receive atomoxetine, 0.5 mg/kg/day for 3 days
16424605|NCT03808740|Experimental|Vertical sleeve gastrectomy (VSG) /Atomoxetine|Participants with standard of care VSG will receive atomoxetine 0.5 mg/kg/day for 3 days
16424606|NCT03808740|Placebo Comparator|Roux-en-Y gastric bypass (RYGB)/Placebo|Participants with standard of care RYGB will receive placebo 0.5 mg/kg/day for 3 days
16424607|NCT03808740|Placebo Comparator|Vertical sleeve gastrectomy (VSG)/ Placebo|Participants with standard of care VSG will receive placebo 0.5 mg/kg/day for 3 days
16424610|NCT03808714|Active Comparator|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
16485415|NCT03392636|Experimental|Group A|Mitchell Banks Herniotomy
16424611|NCT03808714|Active Comparator|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
16424612|NCT03808701|Experimental|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16424613|NCT03808701|Experimental|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16424614|NCT03808688|Other|Netarsudil Ophthalmic Solution 0.02%|
16424615|NCT03808675|Experimental|Aerobic|Participants randomized to aerobic exercise
16424616|NCT03808675|Other|Control|Participants randomized to usual care with PD specific health education
16424617|NCT03808662|Experimental|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
16424618|NCT03808662|Active Comparator|Arm 2:Standard of Care|
16424619|NCT03808649|Active Comparator|Individualized group|Participants are given different volume of a preparation of mannitol based on BMI as oral contrast agent over an hour prior to the examination.
16424620|NCT03808649|Experimental|conventional group|Participants are given 1500ml of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
16424621|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
16424622|NCT03808610|Experimental|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
16424623|NCT03808597|Experimental|Intervention group|The participants in this group will be exposed to digital health promotion. Please note that the participants are not randomly chosen, but stratified after the project villages. The participants in this group belong to the villages: Izazi and Migoli.
16424624|NCT03808597|No Intervention|Control group|"The participants in this group will be not be exposed to digital health promotion, but the villages will receive the intervention after one year. Please note that the participants are not randomly chosen, but stratified after the project villages.
~The participants in this group belong to the villages: Kimande and Idodi."
16424625|NCT03808584|No Intervention|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
16424626|NCT03808584|Experimental|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
16424627|NCT03808571||Study group|Pregnancies complicated with intrauterine growth restricted fetuses
16424628|NCT03808571||Control group|Healthy pregnancies
16424629|NCT03808558|Experimental|TVB-2640|Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
16424630|NCT03808545|Active Comparator|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
16424631|NCT03808545|Experimental|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
16424632|NCT03808532|Experimental|High-Risk with Moisturizer|
16424633|NCT03808532|No Intervention|High-Risk without Moisturizer|
16424634|NCT03808519|Experimental|n3 PUFA|n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
16424635|NCT03808519|Placebo Comparator|Placebo|Organic Sunflower Oil 5000mg per day
16424636|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
16424637|NCT03808493|Experimental|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
16424638|NCT03808493|Experimental|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
16424639|NCT03808493|Experimental|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
16424640|NCT03808493|Experimental|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
16424641|NCT03808480|Experimental|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.
~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
16424642|NCT03808467|Experimental|CRT + TAU|Cognitive Remediation Therapy + Treatment As Usual
16424643|NCT03808467|Other|TAU only|Treatment As Usual
16424644|NCT03808454|Experimental|Platelet rich plasma (PRP)|PRP injection only
16424645|NCT03808454|Experimental|PRP+Rehabilitation|PRP injection combined with rehabilitation
16424646|NCT03808454|Active Comparator|Rehabilitation|Rehabilitation treatment only
16424647|NCT03808441|No Intervention|Standard Arm|"Dabrafenib + Trametinib
~Switch to N+I at first progression"
16424648|NCT03808441|Active Comparator|ctDNA Guided Switch|"Dabrafenib + Trametinib
~Switch to N+I when ctDNA levels in the blood have dropped by ≥80%."
16424649|NCT03808428|Experimental|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
16424650|NCT03808415|Experimental|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
16424651|NCT03808402||High dose surfactant|Infants who receive a first dose of surfactant between 170 and 200 mg/kg
16424652|NCT03808402||Low dose surfactant|Infants who receive a first dose of surfactant between 100 and 130 mg/kg
16424653|NCT03808389|Experimental|Treatment group: Donor FMT|Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
16424654|NCT03808389|Sham Comparator|Control group: Autologous FMT|Fecal microbiota transplantation using the patient's own fecal matter.
16424655|NCT03808376|Experimental|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
16424656|NCT03808363|Experimental|High Intensity Interval Training Group|Approximately eight individuals with spinal cord injuries will participate in high intensity interval training for 6 weeks
16424657|NCT03808350|Placebo Comparator|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
16424658|NCT03808350|Active Comparator|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
16424659|NCT03808337|Active Comparator|Standare of Care|Patients with newly diagnosed metastatic non-small cell lung cancer or triple negative breast cancer may be enrolled on protocol prior to receiving any systemic therapy. If these patients are randomized to the standard of care arm (Arm 1), they will initiate appropriate therapy as determined by their oncologist. Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist.
16424660|NCT03808337|Experimental|Stereotactic Body Radiotherapy (SBRT) + Standard of Care|Patients enrolled on Arm 2 of the study will undergo Stereotactic Body Radiotherapy/SBRT to all known metastases seen on imaging studies performed prior to enrollment. Radiotherapy will be given concurrently to all metastatic sites. Minimum BED for ablative SBRT is more than or equal to 48 Gy10. Patients can undergo systemic therapy concurrently with SBRT at the discretion of treating radiation oncologist and medical oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
16424661|NCT03808324|Experimental|Heart transplant recipients|
16424662|NCT03808311|Experimental|Intensive BP treatment arm|Participants in the intensive BP treatment arm will be treated to a systolic BP target of <120 mmHg.
16424663|NCT03808311|Other|Standard BP treatment arm|Participants in the standard BP treatment arm will be treated to a systolic BP target of <140 mmHg.
16424664|NCT03808298|Experimental|Treatment Sequence 1: A, B, C|
16424665|NCT03808298|Experimental|Treatment Sequence 2: A, C, B|
16424666|NCT03808298|Experimental|Treatment Sequence 3: B, A, C|
16424667|NCT03808298|Experimental|Treatment Sequence 4: B, C, A|
16424668|NCT03808298|Experimental|Treatment Sequence 5: C, A, B|
16424669|NCT03808298|Experimental|Treatment Sequence 6: C, B, A|
16424670|NCT03808298|Experimental|Treatment Sequence 7: A, B, D|
16424671|NCT03808298|Experimental|Treatment Sequence 8: A, D, B|
16424672|NCT03808298|Experimental|Treatment Sequence 9: B, A, D|
16424673|NCT03808298|Experimental|Treatment Sequence 10: B, D, A|
16424674|NCT03808298|Experimental|Treatment Sequence 11: D, A, B|
16424675|NCT03808298|Experimental|Treatment Sequence 12: D, B, A|
16424676|NCT03808285||mandibular osteomylitis|description of mandibular osteomylitis due to denosumab
16424678|NCT03808259|Experimental|Part 1: OTF Sublingual and IV|Participants will receive (S)-ketamine oral thin film (OTF) at a dose of 7 milligram (mg) [cohort 1], 14 mg [cohort 2], and 28 mg [cohort 3] via sublingual route or 14 mg (S)-ketamine intravenous (IV) infusion for 40 minutes or matching placebo in 1 of 3 serial cohorts. Dose escalation decisions to further cohorts of Part 1 will be made based on safety and tolerability profile of the preceding lower dose level.
16424679|NCT03808259|Experimental|Part 2: IV Different Infusion Duration|Participants will receive single dose (S)-ketamine less than or equal to (<=)14 mg IV at a different infusion duration or matching placebo at a different infusion duration. The infusion duration and dose will be chosen after completion of Part 1.
16424680|NCT03808246|Experimental|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
16424681|NCT03808246|Experimental|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
16424682|NCT03808246|Experimental|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
16424683|NCT03808246|Experimental|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
16424684|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
16424685|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
16424686|NCT03808220||post-surgical patients|post-surgical patients > 18 years
16424687|NCT03808220||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
16424760|NCT03807752|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
16424688|NCT03808207|Experimental|Intervention group|Increase of the average intake of dietary DHA: dietary advices concerning the concentration of docosahexaenoic acid (DHA) in several foods; the recommended daily or weekly intake of different food options (animal, vegetal) in order to reach the average intake of 300-350 mg DHA/day
16424689|NCT03808207|No Intervention|Control group|No specific dietary advice; Only endorsement and promotion of breastfeeding.
16424690|NCT03808194|Active Comparator|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
16424691|NCT03808194|Experimental|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
16424692|NCT03808181|Other|Active treatment with ChloraSolv|Single arm
16424693|NCT03808168|Active Comparator|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
16424694|NCT03808168|Active Comparator|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
16424695|NCT03808155|Active Comparator|Tamsulosin|The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.
16424696|NCT03808155|Placebo Comparator|Placebo Oral Tablet|The placebo is taken once a day per os five days prior to the operation and two days after the operation.
16424697|NCT03808142||Treatment|During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).
16424698|NCT03808129|Active Comparator|ESP Group: Bupivacaine and lidocaine|ESP Group: Bupivacaine and lidocaine: Erector Spinae Plane Block : (1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine) was administered.
16424699|NCT03808129|No Intervention|control group|Control Group:
16424700|NCT03808116|Experimental|SmartBx biopsy collection|"Biopsy cores will be collected from the breast during US guided biopsy procedure.
~The number of cores taken will be decided per the physician discretion according to the clinical demand.
~Additional two biopsy core will be taken the SmartBx cassette"
16424701|NCT03808103|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
16424702|NCT03808103|Experimental|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
16424703|NCT03808090|Experimental|Normal Individuals|Normal individuals: no prior history of KS, no obesity, no diabetes
16424704|NCT03808090|Experimental|Calcium Oxalate Kidney Stone Formers|Those individuals that have a high propensity to form calcium oxalate kidney stones
16424705|NCT03808090|Experimental|Type 2 Diabetes|Those individuals that have been diagnosed with type 2 diabetes
16424706|NCT03808090|Experimental|Type 2 diabetic kidney stone formers|Those individuals that have been diagnosed with type 2 diabetes and kidney stones.
16424707|NCT03808077|Experimental|Interventional Group: Deep Neuromuscular Blockade|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
16424708|NCT03808077|Active Comparator|Control Group: Moderate Neuromuscular Blockade|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
16424709|NCT03808064|Experimental|FCHV home visit|
16424710|NCT03808064|No Intervention|FCHV no visit|
16424711|NCT03808051|Experimental|Physiological-based cord clamping|Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
16424712|NCT03808051|Active Comparator|Time-based cord clamping|Infants are clamped first and then moved to the standard resuscitation table for further treatment and intervention needed for cardiopulmonary stabilisation. Clamping is time based and performed immediately or delayed at 30-60 seconds, depending on the clinical condition of the infant. Uterotonic drugs are administered immediately after cord clamping.
16424713|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
16424714|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
16424715|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
16424716|NCT03808025|Experimental|education|The teaching arm would consist of a standardized dialogue the surgeon will complete with the patient in order to familiarize the patient with the risks of over-prescribing opioid medication and set patient expectations regarding the clinic's opioid prescribing pattern protocol, in an effort to minimize the number of opioid pills prescribed or refills required, the amount actually used, and the untoward side effects of opioid use (e.g. respiratory depression, nausea, sedation, restriction from driving, and access to and use by those the medication was not intended).
16424717|NCT03808025|No Intervention|no education|Standard preoperative care without dedicated teaching regarding opioid use and risks
16424718|NCT03808012|Experimental|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
16424719|NCT03807999|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
16424759|NCT03807752|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
16424720|NCT03807999|Experimental|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
16424721|NCT03807986|Experimental|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
16424722|NCT03807986|Experimental|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
16424723|NCT03807973|Experimental|Fibromyalgia|
16424724|NCT03807973|Experimental|Chronic Fatigue Syndrome|
16424725|NCT03807973|Experimental|Multiple Sclerosis|
16424726|NCT03807973|Experimental|Healthy Controls|
16424727|NCT03807960|Experimental|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
16424728|NCT03807960|Experimental|written|The written form which include the same knowledge will give to the patient for reading.
16424729|NCT03807960|Other|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
16424730|NCT03807947|Experimental|Radial access|
16424731|NCT03807947|Active Comparator|Transfemoral Access|
16424732|NCT03807934|Experimental|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
16424733|NCT03807934|Sham Comparator|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
16424734|NCT03807921|Experimental|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.
~Aspirin will be administered 100 mg daily."
16424735|NCT03807921|Active Comparator|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
16424736|NCT03807908|Experimental|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.
~Subjects will wear the tape for as long as possible up to 5-7 days."
16424737|NCT03807908|Sham Comparator|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.
~Subjects will wear the tape for as long as possible up to 5-7 days."
16424738|NCT03807895|Experimental|REBT Career Intervention|High-school students in the experiment group attend to eight modules of career intervention with rational emotive behavioral therapy (REBT) techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive Restructuring, Exposure/behavior activation and problem solving, Planning, Goal Setting.
16424739|NCT03807895|Active Comparator|Regular Career Intervention|High-school students in the treatment as usual group attend to eight modules of career intervention with regular career intervention techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Problem solving, Planning, Goal Setting.
16424740|NCT03807882|Experimental|Test group|Bilateral Maintenance ECT (B/L M-ECT)
16424741|NCT03807882|Active Comparator|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
16424742|NCT03807869|Experimental|coexisting glaucoma and cataract|Patients with coexisting glaucoma and cataract qualified to combined glaucoma surgery
16424743|NCT03807856|Active Comparator|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
16424744|NCT03807856|Active Comparator|Standard of Care|Standard treatment for acute pancreatitis
16424745|NCT03807843|Experimental|Treatment Arm|Subjects randomized to the treatment arm will receive two vaccinations with MV-CHIK, a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. The vaccinations will be provided on days 0 and 28 after enrollment.
16424746|NCT03807843|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive two injections of sterile physiological saline. The injections will be provided on days 0 and 28 after enrollment.
16424747|NCT03807830|Other|One arm feasbility study|
16424748|NCT03807817|Experimental|Moderate Alcohol|
16424749|NCT03807817|Experimental|Low Alcohol|
16424750|NCT03807817|Active Comparator|Placebo Alcohol|
16424751|NCT03807817|Active Comparator|No Alcohol|
16424752|NCT03807804|Experimental|HLCM051 group【ARDS caused by pneumonia cohort】|"Patients will receive the standard therapy
~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
16424753|NCT03807804|No Intervention|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
16424754|NCT03807804|Experimental|HLCM051 group【ARDS caused by COVID-19 cohort 】|"Patients will receive the standard therapy
~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
16424755|NCT03807791|Experimental|Patient living in the Unit of Long Term Care|Patient living in the Unit of Long Term Care without any limit time
16424756|NCT03807778|Experimental|TAK-788, Phase 1 Part|TAK-788 40 milligrams (mg) (as the starting dose), capsules, orally, once daily on Days 1-28 of each 28-day treatment cycle for up to disease progression or intolerable toxicity, or another discontinuation criterion, and increasing until 160 mg, once daily (for up to approximately 10-12 cycles).
16424757|NCT03807778|Experimental|TAK-788, Phase 2 Part|TAK-788 160 mg, once daily, for up to approximately 10-12 cycles.
16424758|NCT03807765|Experimental|Nivolumab followed by stereotactic radiosurgery (SRS)|480 mg Nivolumab will be given intravenously every 4 weeks, followed by SRS the week after the initial dose of Nivolumab.
16485416|NCT03392636|Experimental|Group B|Fergusson Gross Herniotomy
16424761|NCT03807739|Experimental|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
16424762|NCT03807739|Experimental|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
16424763|NCT03807726|Experimental|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
16424764|NCT03807726|No Intervention|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
16424765|NCT03807713|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
16424766|NCT03807700|Experimental|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
16424767|NCT03807700|No Intervention|No adhesive|In this arm, participants will not use any denture adhesive.
16424768|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
16424769|NCT03807674|Other|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
16424770|NCT03807674|Experimental|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
16424771|NCT03807661|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
16424772|NCT03807635|Experimental|simulation of skin pricking type 450|The evaluator simulated the capillary blood sampling with the safety lancet type 450
16424773|NCT03807635|Experimental|simulation of skin pricking type 610|The evaluator simulated the capillary blood sampling with the safety lancet type 610
16424774|NCT03807609|Experimental|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
16424775|NCT03807609|Experimental|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
16424776|NCT03807609|Experimental|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
16424777|NCT03807596|Active Comparator|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling & root planing (SRP) alone.
16424778|NCT03807596|Experimental|Hyaluronic acid & SRP group|Chronic periodontitis & type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling & root planing (SRP) with the adjunctive use of hyaluronic acid.
16424779|NCT03807583|No Intervention|Control group|
16424780|NCT03807583|Active Comparator|AMINOVEN® 10%|"The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.
~The product is administered per os during the first hour of dialysis sessions for the duration of the study."
16424781|NCT03807583|Experimental|RENORAL®|"The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.
~The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins."
16424782|NCT03807570|Experimental|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
16424783|NCT03807570|Placebo Comparator|Placebo|Placebo 30 ml/day for 12 weeks
16424784|NCT03807557|Experimental|Robotic mCIMT group|1 hour unilateral robotic therapy, followed by 30 minutes of functional practice of affected UE using shaping technique, 3/week for 8 weeks and restraint of the unaffected limb at home for 2 hrs per day
16424785|NCT03807557|Active Comparator|Control group|conventional upper extremity rehabilitation training 1.5 hours per session, 3/week for 8 weeks and home exercise 2 hrs per day
16424786|NCT03807544|Experimental|TENS treatment arm|This study is a usability study, where all subjects will receive the same experimental treatment for their single visit.
16424787|NCT03807531|Other|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
16425193|NCT03804749|Experimental|Group 1-1|The dose of suramin sodium is 10 mg/kg
16424788|NCT03807518|Experimental|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
16424789|NCT03807518|No Intervention|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
16424790|NCT03807505|Active Comparator|Interscalene nerve block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot interscalene brachial plexus nerve block or an interscalene brachial plexus nerve catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
16424791|NCT03807505|Active Comparator|Erector Spinae Plane block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot erector spinae plane block or receive erector spinae plane catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
16424792|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
16424793|NCT03807479|Experimental|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
16424794|NCT03807466|Active Comparator|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
16424795|NCT03807466|No Intervention|Static/Paginated Report|LTC physician receives static/paginated report only
16424796|NCT03807466|Active Comparator|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report
~[note: this is not part of randomization assignment, but a quasi-experimental study]"
16424797|NCT03807466|No Intervention|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report
~[note: this is not part of randomization assignment, but a quasi-experimental study]"
16424798|NCT03807453||Psoriasis Vulgaris patients-Lesion|
16424799|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
16424800|NCT03807453||Seborrheic Dermatitis-Lesion|
16424801|NCT03807453||Seborrheic Dermatitis-Lesion free|
16424802|NCT03807453||Control Group|
16424803|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
16424804|NCT03807427|Experimental|READY-Nepal|Skills groups based on dialectical behavior therapy principles delivered over 10-12 weeks in a classroom format.
16424805|NCT03807427|No Intervention|Waitlist Control|Adolescent participants assigned to the control condition will be placed on a waitlist for future enrollment in READY-Nepal. After primary data collection has ceased, those assigned to the control arm will receive the identical READY-Nepal intervention delivered in the experimental condition.
16424806|NCT03807414||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing treatment with oXiris will be prospectively observed.
16424807|NCT03807401|Active Comparator|Classical prismatic adaptation|Classical prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
16424808|NCT03807401|Experimental|Virtual prismatic adaptation|virtual prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
16424809|NCT03807401|Experimental|Imaged prismatic adaptation|Imaged prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
16424810|NCT03807388|Experimental|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.
~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
16424811|NCT03807388|Other|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
16424812|NCT03807375|Other|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
16424813|NCT03807375|No Intervention|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
16424814|NCT03807362|Experimental|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
16424815|NCT03807349|Other|N-Force Screws|N-Force Screws augmented with N-Force Blue in Intracapsular Femur Fractures.
16424816|NCT03807336|Experimental|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
16424817|NCT03807336|Active Comparator|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
16424818|NCT03807323|Experimental|'Lifestyle counselling and exercise' .|The study is a single-arm study where all participants undergo the same intervention 'Lifestyle counselling and exercise' .
16489216|NCT03366389||Case|patients with irritable bowel syndrome
16424819|NCT03807310|Experimental|Group Long-drink|"83 COPD patients will receive:
~Targeted nutrient supplementation (Long-drink) once daily
~Counselling once monthly"
16424820|NCT03807310|Placebo Comparator|Group Placebo|"83 COPD patients will receive:
~Isocaloric placebo supplement once daily
~Counselling once monthly"
16424821|NCT03807310|No Intervention|Healthy control group|30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.
16424822|NCT03807297|Other|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
16424823|NCT03807297|Other|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
16424824|NCT03807284|Experimental|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
16424825|NCT03807284|No Intervention|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
16424826|NCT03807271|Experimental|Smart Pilot(R) View|Anesthesia provided by standard procedure, additionally guided by Smart Pilot(R) View, a device with calculated and graphically produced depth of anesthesia.
16424827|NCT03807271|No Intervention|Standard|Anesthesia provided by standard procedure.
16424828|NCT03807258|Experimental|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
16424829|NCT03807258|Active Comparator|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
16424830|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
16424831|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
16424832|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
16424833|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
16424834|NCT03807232||pbARDS|Burn patients who developed post-burn ARDS
16424835|NCT03807232||No pbARDS|Burn patients without development of post-burn ARDS
16424836|NCT03807219|Active Comparator|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
16424837|NCT03807219|Placebo Comparator|Placebo|80 subjects will be on the Placebo arm.
16424838|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
16424839|NCT03807193|Experimental|Fixed treatment, weekly support|Receives a predetermined treatment program and have weekly support.
16424840|NCT03807193|Experimental|Fixed treatment, support on demand|Receives a predetermined treatment program and have access to support on demand.
16424841|NCT03807193|Experimental|Selected treatment, weekly support|Select their own treatment material and have weekly support.
16424842|NCT03807193|Experimental|Selected treatment, support on demand|Select their own treatment material and have access to support on demand.
16424843|NCT03807180|Other|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
16424844|NCT03807180|No Intervention|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
16424845|NCT03807167|Experimental|Patients|
16424846|NCT03807167|Active Comparator|healthy controls|
16424847|NCT03807154|Experimental|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
16424848|NCT03807154|Experimental|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
16424849|NCT03807154|No Intervention|Wait-list|Wait-list control group
16424850|NCT03807141|Experimental|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.
~The ongoing antiepileptic medication will be continued unchanged"
16424851|NCT03807141|No Intervention|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
16424852|NCT03807115|Other|Intervention|Arm: Intervention: Implementation of stroke mobility guidelines
16424853|NCT03807115|No Intervention|Control|Arm: Control: Usual care
16424854|NCT03807102|Experimental|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
16424855|NCT03807089|Experimental|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
16424856|NCT03807089|Active Comparator|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
16424857|NCT03807076|Other|GIP-A|Infusion of GIP-A alone as a study tool.
16424858|NCT03807076|Placebo Comparator|Placebo|Saline
16424901|NCT03806829|Experimental|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (>900 kcal, 50g fat)
16424859|NCT03807063|Experimental|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
16424860|NCT03807050|Experimental|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
16424861|NCT03807037|Experimental|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
16424862|NCT03807037|Placebo Comparator|Control|Matching Placebo (Placebo oral capsule)
16424863|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
16424864|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
16424865|NCT03807011|Active Comparator|fentanyl|A bolus dose of fentanyl 2 μg/kg was administered intravenously at anesthetic induction
16424866|NCT03807011|Active Comparator|remifentanil|Remifentanil was continuously infused at a rate of 0.2 μg/kg/min from anesthetic induction to the end of surgery
16424867|NCT03806998|Experimental|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
16424868|NCT03806998|Placebo Comparator|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
16424869|NCT03806985|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
16424870|NCT03806985|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
16424871|NCT03806985|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
16424872|NCT03806985|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
16424873|NCT03806985|Experimental|High Dose Psilocybin/Low Dose Psilocybin|Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
16424874|NCT03806985|Experimental|Low Dose Psilocybin/High Dose Psilocybin|Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.
16424875|NCT03806959|Other|Pan Capsule and colonoscopy|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only
16424876|NCT03806946||group1|ADHD with normal EEG
16424877|NCT03806946||group 2|ADHD with abnormal EEG
16424878|NCT03806946||group 3|Epilepsy
16424879|NCT03806946||group 4|Healthy control group
16424880|NCT03806946||group 5|ADHD and epilepsy
16424881|NCT03806933|Experimental|NT 201 Dose group 1|Stage 1 and 2. Intramuscular injection into the glabellar area.
16424882|NCT03806933|Experimental|NT 201 Dose group 2|Stage 1. Intramuscular injection into the glabellar area.
16424883|NCT03806933|Experimental|NT 201 Dose group 3|Stage 1. Intramuscular injection into the glabellar area.
16424884|NCT03806933|Experimental|NT 201 Dose group 4|Stage 2. Intramuscular injection into the glabellar area.
16424885|NCT03806933|Experimental|NT 201 Dose group 5|Open Label Extension Period. Intramuscular injection into the glabellar area.
16424886|NCT03806920|Active Comparator|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:
~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
16424887|NCT03806920|Active Comparator|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:
~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
16424888|NCT03806920|Active Comparator|Intervention C|"Nutritional intervention in healthy subjects:
~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
16424889|NCT03806920|Active Comparator|Intervention D|"Nutritional intervention in healthy subjects:
~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
16424890|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
16424891|NCT03806894||Arab populations|Muslim, Christian, Druze
16424892|NCT03806881||Treatment group|Patients treated with a Glenius Glenoid Reconstruction System
16424893|NCT03806868|Active Comparator|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
16424894|NCT03806868|Sham Comparator|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
16424895|NCT03806855||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
16424896|NCT03806855||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
16424897|NCT03806842|Experimental|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
16424898|NCT03806829|Active Comparator|Water + Meal|250 ml Water and a high calorie, high fat meal (>900 kcal, 50g fat)
16424899|NCT03806829|Experimental|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (>900 kcal, 50g fat)
16424900|NCT03806829|Experimental|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (>900 kcal, 50g fat)
16424902|NCT03806816|Experimental|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
16424903|NCT03806816|Experimental|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
16424906|NCT03806790|Experimental|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
16424907|NCT03806790|Active Comparator|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
16424908|NCT03806777|Experimental|Intra-nasal dexmedetomidine|A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.
16424909|NCT03806764|No Intervention|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
16424910|NCT03806764|Other|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.
~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
16424911|NCT03806751|Experimental|[O-15]water PET/MRI|Volunteers will have two brain PET/MRI scans; first scan after injection of [O-15]water; second scan after injection of 1 gram of acetazolamide followed by injection of [O-15]water.
16424912|NCT03806738|Experimental|Shared Decision Making Questionnaire|"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.
~One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
16424913|NCT03806738|Other|Standard of Care Questionnaire|"Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.
~One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
16424914|NCT03806725||Liver transplant (LTx) candidates with eGFR>=60|Liver transplant candidates with renal function defined by eGFR above or equal to 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement.
16424915|NCT03806725||LTx candidates with eGFR<60|"Liver transplant candidates with decreased renal function.
~Defined by eGFR less than 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement."
16424916|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
16424917|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
16424918|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
16424919|NCT03806699|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
16424920|NCT03806699|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
16424921|NCT03806699|Placebo Comparator|Control group|Participants will receive 0.5 mL (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
16424922|NCT03806686|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
16424923|NCT03806686|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
16424924|NCT03806686|Placebo Comparator|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
16424925|NCT03806673|Active Comparator|primipara|primipara subjected to their first epidural block
16424926|NCT03806673|Active Comparator|multipara|multipara subjected to their repeated epidural block.
16424927|NCT03806621||Rotational Atherectomy|
16424928|NCT03806608|Experimental|Crestal|Implants were placed with the implant-abutment interface(IAI) at the level of the the alveolar ridge
16424929|NCT03806608|Experimental|Subcrestal|Implants were placed with the implant-abutment interface(IAI) 1 mm below the level of the alveolar ridge
16424930|NCT03806595|Experimental|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
16424931|NCT03806595|Placebo Comparator|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
16424932|NCT03806582|Active Comparator|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
16424933|NCT03806582|No Intervention|control|control group; treatment according to current standards, observation of the effect on right ventricular function
16424934|NCT03806569|Active Comparator|MAC-cbt group treatment for adult ADHD|"The patients will be treated with psychological group treatment for 8 sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process. This will be called Mindfulness, Acceptance and Commitment-Therapy for adult Patients with ADHD"
16424935|NCT03806569|Sham Comparator|Relaxation-group for adult ADHD|"The patients will be treated with a relaxation-treatment, long-time established as Jacobson muscle relaxing technique."
16424989|NCT03806218|Active Comparator|SC-RFA|Switching monopolar RFA using separable clustered electrodes
16424936|NCT03806556|Experimental|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
16424937|NCT03806556|Placebo Comparator|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
16424938|NCT03806530|Active Comparator|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
16424939|NCT03806530|Placebo Comparator|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
16424940|NCT03806530|Placebo Comparator|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
16424941|NCT03806530|Placebo Comparator|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
16424942|NCT03806517||Tremor dominant type group|Tremor dominant type (TDT) group will consist of the patients with tremor premotor symptoms.
16424943|NCT03806517||PIGD dominant type group|Postural instability and gait difficulty dominant type (PIGDT) group will consist of the patients with axial premotor symptoms.
16424944|NCT03806517||Healthy control group|Healthy control group will consist of the subjects with same age and sex matched individuals in PD group.
16424945|NCT03806504|Active Comparator|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
16424946|NCT03806504|Active Comparator|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
16424947|NCT03806491|Experimental|CBT-I + AUD-TAU|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
16424948|NCT03806491|Active Comparator|Sleep Hygiene + AUD-TAU|Sleep hygiene education delivered once to all participants
16424949|NCT03806478|Experimental|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
16424950|NCT03806478|Experimental|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
16424951|NCT03806478|Experimental|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
16424952|NCT03806478|Placebo Comparator|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
16424953|NCT03806465||Feasibility survey|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age. For the midline household survey, this would be restricted to children aged 12-23 months of age.
16424954|NCT03806465||Sentinel hospital surveillance|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age who are hospitalized in the 18 sentinel hospitals.
16424955|NCT03806465||Community mortality surveillance|These will be children whose deaths are reported in the vaccinating and in non-vaccinating areas aged less than 5 years of age .
16424956|NCT03806452|Experimental|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.
~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
16424957|NCT03806452|Placebo Comparator|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.
~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
16424958|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
16424959|NCT03806426|Experimental|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
16424960|NCT03806426|Placebo Comparator|Treatment Group B|Placebo 500mg
16424961|NCT03806413||Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
16424962|NCT03806374|Active Comparator|Fentanyl|Administered propofol and fentanyl for induction.
16424963|NCT03806374|Active Comparator|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
16424966|NCT03806348|Experimental|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
16424967|NCT03806348|No Intervention|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
16424968|NCT03806335|Experimental|Infiltration|Patients will receive pre-incision infiltration of 2.5 ml local anesthesia mixture in each tonsil.
16424969|NCT03806335|Placebo Comparator|Placebo|Patients will receive pre-incision infiltration of 2.5 ml saline in each tonsil.
16424970|NCT03806322|Experimental|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
16424990|NCT03806192|Experimental|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
16424971|NCT03806322|Experimental|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
16424975|NCT03806296|Experimental|Manipulation|"For ~2 weeks, participants will be asked to adhere to the following:
~Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)
~Decrease evening blue light exposure via blue blocker goggles (2 h before bed)
~Increase morning bright light exposure via bright light goggles (30 m after rise)
~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
16424976|NCT03806296|Active Comparator|Control|"For ~2 weeks, participants will asked to adhere to the following:
~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
16424977|NCT03806283||Cohort 1 no Preeclampsia|Cohort 1: 16 mothers with no diagnosis of preeclampsia during pregnancy (8 male, 8 female neonate) Omental Biopsy and placental collection will be performed
16424978|NCT03806283||Cohort 2 mild or severe Preeclampsia|Cohort 2: 16 mothers with diagnosis of mild or severe preeclampsia during pregnancy (8 male, 8 female neonate) Omental Biopsy and placental collection will be performed
16424979|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.
~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
16424980|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.
~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
16424981|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.
~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
16424982|NCT03806257|No Intervention|Control|Subjects in the control arm will receive standard of care, which consists of mobilization to a bedside chair at least once, and ambulate one-half ICU circumference on postoperative day one. On postoperative days two through five, the subject will be mobilized to the bedside chair at least once, and ambulated at least once with target of one full ICU circumference. These subjects will receive gait training and safe ambulation education, and wear a FitBit Charge 2 watch for five days after surgery.
16424983|NCT03806257|Experimental|Enhanced Physical Therapy Protocol|Subjects in the experimental arm will recieve a FitBit Charge 2 watch, and will be mobilized to the bedside chair on postoperative day zero. On postoperative day two subjects will be mobilized to the bedside chair twice, ambulate one-half of the ICU circumference, and receive gait and safe ambulation training. On postoperative days two through five, subjects will mobilize to the bedside chair three times, and will be encouraged to ambulate three times, each time with a target of one full ICU circumference.
16424984|NCT03806244|No Intervention|PREOP|Navigation without intraoperative acquisition of images: Use of conventional preoperative images (CT-MRI) to establish intraoperative navigation.
16424985|NCT03806244|Experimental|PEROP|Navigation with intraoperative acquisition of images: Intraoperative acquisition (robotic c-Arm) of images to establish intraoperative navigation.
16424986|NCT03806231|Experimental|Outpatient Cervical Ripening|Patients randomized to the outpatient cervical ripening arm will come in for a scheduled visit in Labor and Delivery prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be monitored for 2 hours and sent home after a the following are present: (1) reactive non-stress test (NST) (2) category 1 tracing x 2 hours (3) no vaginal bleeding (4) normal maternal vital signes (5) intact bag of water (BOW) and (6) less than 1 contraction every 10 minutes at the time of discharge. The patient will remove the insert the following morning prior to her scheduled induction.
16424987|NCT03806231|Active Comparator|Inpatient Cervical Ripening|The patient will be admitted into the Labor and Delivery unit prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be watched with continuous fetal monitoring for 2 hours. The patient remains hospitalized and the following morning the induction will be started per Intermountain Healthcare protocol.
16424988|NCT03806218|Active Comparator|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
16424991|NCT03806192|Experimental|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
16424992|NCT03806179|Experimental|Betalutin with rituximab treatment|Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
16424993|NCT03806166|Experimental|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
16424994|NCT03806166|Active Comparator|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
16424995|NCT03806153|Active Comparator|Conventional morphology arm (reference method)|
16424996|NCT03806153|Experimental|Morphokinetic arm|
16424997|NCT03806140|Active Comparator|Intervention group|Receive daily text messages
16424998|NCT03806140|No Intervention|Control group|No text messages, only written educational materials
16424999|NCT03806127|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
16425000|NCT03806127|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
16425001|NCT03806114|Other|Anterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
16425002|NCT03806114|Other|Posterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
16425003|NCT03806114|Other|Anterior Approach No Precautions|This group receives does not precautions and have a total hip arthroplasty with an anterior approach.
16425004|NCT03806114|Other|Posterior Approach No Precautions|This group receives does not receive precautions and have a total hip arthroplasty with a posterior approach.
16425005|NCT03806101|Experimental|Arm 1|Single dose of rosuvastatin on Day 1 of Period 1 and Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 2.
16425006|NCT03806101|Experimental|Arm 2|Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 1 and single dose of rosuvastatin on Day 1 of Period 2.
16425007|NCT03806088||patients of chronic kidney disease|no interventions
16425008|NCT03806075|Experimental|Peutz-Jeghers patients|All Peutz-Jeghers patients meet the clinical criteria
16425009|NCT03806075|Placebo Comparator|Health persons|Those without Peutz-Jeghers syndrome
16425010|NCT03806062|Active Comparator|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
16425011|NCT03806062|Active Comparator|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.
~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
16425012|NCT03806062|Active Comparator|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
16425013|NCT03806049|Experimental|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
16425014|NCT03806049|Experimental|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
16425015|NCT03806049|Active Comparator|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
16425016|NCT03806036|Active Comparator|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
16425017|NCT03806036|Placebo Comparator|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
16425018|NCT03806023|Experimental|All subjects|All subjects undergo same full protocol, including PNS and TMS at rest and active hand movements (signals from thumb muscle) triggered PNS and TMS.
16425019|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
16425020|NCT03805997|Experimental|Experimental Group|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
16425021|NCT03805997|Placebo Comparator|Control Group|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
16425022|NCT03805984|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
16425023|NCT03805984|Placebo Comparator|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
16425024|NCT03805984|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
16425025|NCT03805984|Placebo Comparator|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
16425026|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
16425027|NCT03805958|Experimental|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
16425028|NCT03805958|Active Comparator|Real time|Confirmed landmark by ultrasound scan during procedure
16425029|NCT03805945|Experimental|dexmedetomidine group|After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
16425030|NCT03805945|Placebo Comparator|control group|Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
16425032|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-related risk genes
16425033|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
16425034|NCT03805854|Experimental|Transcranial alternating current stimulation (tACS)|
16425035|NCT03805841|Experimental|Active|tarloxotinib bromide
16425036|NCT03805828|Experimental|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
16425037|NCT03805828|Active Comparator|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis[a whooping cough]),(3) communicable diseases of childhood (Measles,Mumps,rubella[German Measles]and Poliomyelitis(,and (4) infection control.
16425038|NCT03805802|Experimental|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
16425039|NCT03805802|Placebo Comparator|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
16425045|NCT03805776|Experimental|Interventional|Will observe intermittent fasting
16425046|NCT03805776|No Intervention|Control|
16425047|NCT03805763|Experimental|Large extent of ILM Peeling|Extent of ILM peeling is 4DD and the ILM flap is inserted
16425048|NCT03805763|Experimental|Small extent of ILM Peeling|Extent of ILM peeling is 2DD and the ILM flap is inserted
16425051|NCT03805737|Experimental|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
16425052|NCT03805737|Active Comparator|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
16425053|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level & probing depth ≤ 3 mm. Plaque samples will be collected.
16425054|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
16425055|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
16425056|NCT03805711|Experimental|Aortic Valve Replacement with HLT® Transcatheter System|Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
16425057|NCT03805698|Experimental|Platelet-rich Plasma (PRP) group|"Twenty-four (24) subjects undergoing arthroscopic debridement for TFCC tears will be treated intraoperatively with PRP (24 subjects).
~Intervention: use of Cascade device; Autologous Fibrin & Platelet System; once processed, the PRP is injected into the debrided wrist"
16425058|NCT03805698|Active Comparator|Standard Treatment group|"Twenty-four (24) subjects undergoing arthroscopic debridement for TFCC tears will undergo treatement, as is standard of care, followed by no treatment with PRP (24 subjects).
~Intervention: No PRP injection into debrided wrist"
16425059|NCT03805672|Active Comparator|Low Dose Enoxaparin|Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
16425060|NCT03805672|Active Comparator|High Dose Enoxaparin|Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.
16425061|NCT03805659|Experimental|HD-tDCS, then Sham|Subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
16425062|NCT03805659|Experimental|Sham, then HD-tDCS|Subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
16425063|NCT03805646|No Intervention|No Mobile Phone-administered Triage Tool|For each hospital site: Baseline data will be collected for six months.
16425064|NCT03805646|Experimental|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year."
16425065|NCT03805633||Sarcoidosis Patients|Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.
16425066|NCT03805633||Diabetes Patients|Patients followed by UAB Endocrinology with diabetes mellitus.
16425067|NCT03805633||Sarcoidosis and Diabetes patients|Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.
16425068|NCT03805620|Active Comparator|Phys Group|physical training group
16425069|NCT03805620|Active Comparator|Cog Group|cognitive training group
16425070|NCT03805620|Experimental|Phys-Cog Group|combined physical-cognitive training group
16425071|NCT03805620|No Intervention|Con Group|educational control group
16425072|NCT03805607|Placebo Comparator|Placebo|1 ml of normal saline
16425073|NCT03805607|Experimental|Ketorolac|30 mg of ketorolac in 1 ml
16425074|NCT03805594|Experimental|Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
16425075|NCT03805594|Experimental|Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
16425076|NCT03805594|Experimental|Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)|Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
16425077|NCT03805581|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
16425078|NCT03805568|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
16425079|NCT03805568|Active Comparator|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5~2.5 ng/ml) during the surgery
16425080|NCT03805555|Active Comparator|Radiofrequency ablation|Best radiofrequency ablation
16425081|NCT03805555|Experimental|Cryoballoon ablation|Best cryoballoon ablation
16425082|NCT03805542|No Intervention|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
16425083|NCT03805542|Experimental|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
16425084|NCT03805516|Experimental|Intervention|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.
~12 weekly SCOPP-CW educational modules delivered via WeChat.
~6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
16425085|NCT03805516|Active Comparator|Control|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.
~12 weekly non-tailored educational modules on general health topics delivered via WeChat."
16425086|NCT03805503|Experimental|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.
~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.
~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
16425087|NCT03805477|Experimental|Nintedanib|Nintedanib 150 mg Kps bid (oral)
16425088|NCT03805464|Experimental|Knee Joint Effusion|Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.
16425089|NCT03805451|Experimental|Life Steps for PrEP for Youth|Life Steps for PrEP for Youth was derived from our prior PrEP work supported by the National Institute of Mental Health and will be tailored for YMSM/TWSM based on the findings from 20 qualitative interviews with YMSM and TWSM and 10 qualitative interviews with key informants. It will likely consist of four weekly sessions at the time of PrEP initiation and two booster sessions, which occur two and three months after PrEP initiation. Overall, the core components of the intervention will focus on medication adherence, sexual behavior, and problem solving barriers to adherence, using motivational interviewing when needed.
16425090|NCT03805451|No Intervention|Standard of Care|After being prescribed PrEP, participants will receive standard-of-care adherence support for PrEP. They will have blood collected for medication adherence measures and will complete computer assisted behavioral surveys during study visits. Participants in this arm will also be followed for 6 months.
16425091|NCT03805438|Experimental|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).
~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
16425092|NCT03805425|Experimental|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
16425093|NCT03805412|Active Comparator|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
16425094|NCT03805412|No Intervention|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
16425095|NCT03805399|Experimental|pyrotinib with capecitabine|If patients were LAR subtype with HER2 gene activated mutation
16425096|NCT03805399|Experimental|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype without HER2 gene activated mutation, but had PIK3CA mutation, enter into arm B1; If patients were LAR subtype without HER2 gene activated mutation or PIK3CA mutation, enter into arm B2
16425097|NCT03805399|Experimental|anti PD-1 with nab-paclitaxel|If patients were IM subtype(CD8 positive T cell more than 20%)
16425098|NCT03805399|Experimental|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation
16425099|NCT03805399|Experimental|BLIS with anti-VEGFR included therapy|If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation
16425100|NCT03805399|Experimental|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation
16425101|NCT03805399|Experimental|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation
16425102|NCT03805386|Active Comparator|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
16425103|NCT03805386|Experimental|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
16425104|NCT03805360|Sham Comparator|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
16425105|NCT03805360|Experimental|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
16425106|NCT03805347|Experimental|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
16425107|NCT03805347|Placebo Comparator|Starch|Starch in capsule，1gm/time, 3 times daily
16425108|NCT03805334|Experimental|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn ~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
16425109|NCT03805308|No Intervention|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
16425110|NCT03805308|Experimental|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
16425111|NCT03805295|Experimental|Spring 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Winter-Spring 2018. They will serve as the control group in Fall 2018.
16425112|NCT03805295|Experimental|Fall 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Fall 2018.
16425113|NCT03805282|Experimental|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
16425114|NCT03805282|Active Comparator|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
16425115|NCT03805282|Active Comparator|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
16425116|NCT03805282|Active Comparator|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
16425117|NCT03805269|Experimental|TAP block|USG guided TAP block
16425118|NCT03805269|Active Comparator|wound infiltration|local anesthetics infiltration at surgical incision site
16425119|NCT03805243|Experimental|test of sensors for somnonaute device|monitoring with sensors
16425120|NCT03805243|Experimental|test of sensors for uronaute device|monitoring with sensors
16425121|NCT03805243|Experimental|test of sensors for toconaute device|monitoring with sensors
16425122|NCT03805243|Experimental|test of sensors for cardioskin device|monitoring with sensors
16425123|NCT03805243|Experimental|test of sensors for neuronaute device|monitoring with sensors
16425124|NCT03805230||Cohort A|all patients admitted to participating hospitals during 7 consecutive days
16425125|NCT03805230||Cohort B|30 sequential patients with a single additional inclusion criterion
16425126|NCT03805178|Experimental|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
16425127|NCT03805178|Experimental|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
16425128|NCT03805152|Active Comparator|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
16425129|NCT03805152|Active Comparator|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
16425130|NCT03805139|Experimental|Ajwa Dates group|55-65gms Ajwa dates 7 days a week for 6 weeks
16425131|NCT03805139|No Intervention|Control|No intervention
16425132|NCT03805126|Experimental|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
16425133|NCT03805126|Active Comparator|Usual Care|Usual care includes consultation with a social worker and a community health worker.
16425134|NCT03805113|Experimental|Intervention group|Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.
16425135|NCT03805113|Placebo Comparator|Control group placebo|Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.
16425136|NCT03805100|Experimental|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
16425137|NCT03805100|Active Comparator|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
16425138|NCT03805087|Experimental|Coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
16425139|NCT03805061|Active Comparator|Aerobic exercise group|Group 1 was 'aerobic exercise group'. Patients in this group were included in an aerobic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise.
16425140|NCT03805061|Active Comparator|Isokinetic exercise group|Group 2 was 'isokinetic exercise group'. Patients in this group were included in an isokinetic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study.
16425141|NCT03805048|Other|Native Vessel PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
16425142|NCT03805048|Other|Graft PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
16425143|NCT03805035|Sham Comparator|sham EA group|Minimal needling at ST36 and GB34 (n=10)
16425144|NCT03805035|Experimental|true EA group|EA at ST36 and GB34 (n=10)
16425145|NCT03805035|Active Comparator|EA+antihistamine(low dose) group|EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
16425146|NCT03805035|Active Comparator|EA+antihistamine(high dose) group|EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)
16425147|NCT03805022|Experimental|Arm A|"Control-Arm phase III high-risk CINSARC:
~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 3 cycles in neoadjuvant setting.
~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
16425148|NCT03805022|Experimental|Arm B|"Experimental-Arm phase III high-risk CINSARC:
~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 6 cycles in neoadjuvant setting.
~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
16425149|NCT03805022|Experimental|Prospective cohort|Patients will be treated at the discretion of the investigator
16425150|NCT03805009|Experimental|Robotic Group (RG)|Robotic Group (RG) will perform, in addition to conventional therapy, gait training using an end-effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 20 sessions. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
16425151|NCT03805009|No Intervention|Conventional Group (CG)|Conventional Group (CG) will perform conventional gait rehabilitation program. The treatment will include: muscle strengthening exercises and stretching of the lower limb, and static and dynamic exercises for the recovery of balance in the supine and standing positions using assistive devices; training gait exercises with parallel bars or in open spaces performed both with and without assistive devices; training to climb up and down stairs; exercises to improve proprioception in the supine, sitting and standing positions, using a proprioceptive footboard; exercises to improve trunk control.
16425152|NCT03804996|Experimental|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
16425153|NCT03804996|Experimental|TG-1101|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy.
16425194|NCT03804749|Placebo Comparator|Group 1-2|The placebo is 0.9% sodium chloride injection
16425195|NCT03804749|Experimental|Group 2-1|The dose of suramin sodium is 15mg/kg
16425196|NCT03804749|Placebo Comparator|Group 2-2|The placebo is 0.9% sodium chloride injection
16425197|NCT03804749|Experimental|Group 3-1|The dose of suramin sodium is 20mg/kg
16425154|NCT03804983|Active Comparator|Hybrid Closed Loop (HCL)|Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ with Hybrid Closed Loop (HCL) or the Control-IQ with MyTDI. Participants randomized to Control-IQ, participants will continue using their home insulin parameters during the ski admission and then 5 additional days at home.
16425155|NCT03804983|Experimental|Control-IQ with MyTDI|"Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ or the Control-IQ with MyTDI. Participants randomized to Control-IQ with MyTDI, participants will be adjusted as noted below during the ski admission and will then continue these parameters for 5 additional days at home:
~A single basal rate equal to total daily insulin (TDI)/48 will be implemented across the whole day
~A single correction factor (CF) of 1650/TDI will be implemented across the whole day
~Carbohydrate ratios (CR) will be set at:
~00:00-04:00 CR=450/TDI
~04:00-11:00 CR=360/TDI
~11:00-00:00 CR=450/TDI TDI will be set at the internal Control-IQ estimation total daily dose; if not available, total daily dose over the last 5 days will be used."
16425156|NCT03804970|Experimental|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
16425157|NCT03804970|Experimental|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
16425158|NCT03804970|Active Comparator|Control group|Watching brief video and basic explanation for disease
16425159|NCT03804957|Active Comparator|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
16425160|NCT03804957|Experimental|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
16425161|NCT03804944|Active Comparator|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
16425162|NCT03804944|Active Comparator|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
16425163|NCT03804944|Active Comparator|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
16425164|NCT03804944|Active Comparator|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
16425165|NCT03804931|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation
16425166|NCT03804931|Sham Comparator|placebo fecal microbiota transplantation|Infusion of Saline
16425167|NCT03804931|Other|Traditional treatments|Drug:5-Aminosalicylic acid(5-ASA) and/or Prednisone
16425168|NCT03804918|Experimental|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
16425169|NCT03804905|Experimental|Drug cards|Eligible patients of physicians allocated to the drug cards arm will receive drug cards from their physician.
16425170|NCT03804905|No Intervention|Usual care|Eligible patients of physicians allocated to the usual care arm will continue to access their medications through self-pay or other mechanisms.
16425171|NCT03804892|Experimental|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
16425172|NCT03804892|Other|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
16425173|NCT03804879|Experimental|LMB763|LMB763 capsules
16425174|NCT03804879|Placebo Comparator|Placebo|Placebo comparator
16425175|NCT03804866|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
16425176|NCT03804866|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
16425177|NCT03804853|Experimental|Immediate Active Shoulder Rehabilitation|
16425178|NCT03804853|Active Comparator|Traditional Should Rehabilitation|
16425179|NCT03804840|Placebo Comparator|Placebo|
16425180|NCT03804840|Active Comparator|7.5 mg THC|
16425181|NCT03804840|Active Comparator|15 mg THC|
16425182|NCT03804827||Heart Failure With Sleep Disordered Breathing|AHI3% >/= 5 events per hour of sleep.
16425183|NCT03804827||Heart Failure without Sleep Disordered Breathing|AHI3% < 5 events per hour of sleep.
16425184|NCT03804814|Active Comparator|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
16425185|NCT03804814|No Intervention|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
16425186|NCT03804801|Experimental|Intervention Arm (or Group)|This arm will receive the intervention (Hibiscus Sabdariffa extract supplement)
16425187|NCT03804801|No Intervention|Control Arm (or Group)|This arm will receive no intervention whatsoever, not even placebo
16425188|NCT03804788|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
16425189|NCT03804788|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
16425190|NCT03804775||case group|patients presenting with gallstone disease
16425198|NCT03804749|Placebo Comparator|Group 3-2|The placebo is 0.9% sodium chloride injection
16425199|NCT03804736|Active Comparator|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
16425200|NCT03804736|Experimental|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
16425201|NCT03804723|Experimental|GC withdrawal|
16425202|NCT03804723|Placebo Comparator|non GC withdrawal|
16425203|NCT03804710|Experimental|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
16425204|NCT03804710|Experimental|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
16425205|NCT03804710|Placebo Comparator|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
16425206|NCT03804697|Experimental|selective anticoagulation group|"Selective anticoagulation group used anticoagulant when thromboelastogram（TEG） indicated hypercoagulability.
~TEG was performed 1 day before the surgery, 1 day after the surgery, 3 days after the surgery, and 5 days after the surgery.
~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
16425207|NCT03804697|Active Comparator|conventional anticoagulation group|"The Intervention for conventional anticoagulation group was using anticoagulant until one month after surgery routinely.
~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
16425208|NCT03804684|Experimental|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases. Eyes will have normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal, reliable standard automatic perimetry and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
16425209|NCT03804684|Experimental|Mild Glaucoma|Subjects between 21 and 80 years of age with Mild Glaucoma. Eyes will have reliable standard automatic perimetry with no more than -6 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
16425210|NCT03804684|Experimental|Moderate Glaucoma|Subjects between 21 and 80 years of age with Moderate Glaucoma. Eyes will have reliable standard automatic perimetry with between -6 mean and -12 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
16425211|NCT03804671|Experimental|All Subjects|Test treatment T followed by Reference treatment R
16425212|NCT03804645|Experimental|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
16425213|NCT03804645|Experimental|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
16425214|NCT03804645|Experimental|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
16425215|NCT03804645|Experimental|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
16425216|NCT03804645|Experimental|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
16425217|NCT03804632||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from October to December 2017 with age 18 and above
16425218|NCT03804619|Experimental|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
16425219|NCT03804619|Experimental|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
16425220|NCT03804606|Experimental|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
16425221|NCT03804606|No Intervention|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
16425222|NCT03804606|Active Comparator|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
16425223|NCT03804593||Group 1|Diagnosis of cirrhosis and no HCC confirmed by medical imaging including MRI or CT performed within 6 months of study enrollment. If lesions are present, a Liver Imaging Reporting and Data System (LI-RADS) score of LR-1 or LR-2.
16425312|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
16425224|NCT03804593||Group 2|Diagnosis of HCC confirmed by medical imaging (MRI or CT performed within 6 months of study enrollment with LI-RADS score of LR-5) and/or biopsy with histopathology.
16425225|NCT03804580|Experimental|osimertinib|All patients recieve osimertinib
16425226|NCT03804567|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
16425227|NCT03804567|Active Comparator|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
16425228|NCT03804554||Patients taking nivolumab|
16425229|NCT03804541|Experimental|[14C]Ensartinib|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。
16425230|NCT03804528|Experimental|Exercise group|Each participant will engage in 60 minute daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions).
16425231|NCT03804515|Experimental|14C-labeled Poziotinib|
16425232|NCT03804502|Experimental|TearCare|Subjects will receive one TearCare treatment at the baseline visit
16425233|NCT03804489|Experimental|Decision aids group|Shared decision making using decision aids,
16425234|NCT03804489|No Intervention|Control group|Standard oral explanation with booklet.
16425235|NCT03804476|Experimental|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
16425236|NCT03804476|Placebo Comparator|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
16425237|NCT03804463|Experimental|radical surgery group|Endometrial cancer radical surgery to be administered in this arm.
16425238|NCT03804463|Experimental|fertility preservation group|Fertility-sparing surgery to be administered in this arm.
16425239|NCT03804463|Experimental|ovarian preservation group|Ovarian preservation surgery to be administered in this arm.
16425240|NCT03804450|Experimental|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
16425241|NCT03804450|Experimental|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
16425242|NCT03804424|Experimental|Cohort 1: Pilot 64Cu-LLP2A Imaging|"16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers)
~All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry
~6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
16425243|NCT03804424|Experimental|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"20 patients with MM will be recruited
~Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
16425244|NCT03804411|Experimental|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
16425245|NCT03804411|Experimental|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
16425246|NCT03804398|Experimental|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
16425247|NCT03804398|Active Comparator|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
16425248|NCT03804385|Other|intercostal tube|insertion of intercostal tube is surgical operation used in pneumothorax
16425249|NCT03804372|Experimental|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
16425250|NCT03804359|No Intervention|GEMRITUX protocol|6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
16425313|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
16425314|NCT03803865|Active Comparator|Headspace|30-day smartphone based mindfulness training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
16425251|NCT03804359|Experimental|Personalized treatment|"restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)
~restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;
~Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6."
16425252|NCT03804333|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
16425253|NCT03804333|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16425254|NCT03804320|Other|Patients with small renal masses|Active surveillance
16425255|NCT03804307|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
16425256|NCT03804307|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16425257|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
16425258|NCT03804281|Experimental|Test group|esthetic crown lengthening with microsurgical approach
16425259|NCT03804281|Active Comparator|Control group|esthetic crown lengthening with conventional approach.
16425260|NCT03804268|Experimental|AGN-190584|One drop bilaterally, once daily for 30 days
16425261|NCT03804268|Placebo Comparator|Vehicle|One drop bilaterally, once daily for 30 days
16425262|NCT03804255||Observational (survey)|Participants complete a self-administered web-based Biomarker Survey and may also complete an Outcome Validation Survey.
16425263|NCT03804242|Experimental|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
16425264|NCT03804242|No Intervention|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
16425265|NCT03804229|Experimental|active group|Take two pills (100 mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
16425266|NCT03804229|Placebo Comparator|control group|Take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
16425267|NCT03804203|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
16425268|NCT03804203|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16425269|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
16425270|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
16425271|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
16425272|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
16425273|NCT03804177|Experimental|implant with hyaluronic melatonin vit c|implant placement with topical application of hyaluronic and melatonin and systemic administration of vitamin C
16425274|NCT03804177|Active Comparator|immediate implant|immediate implant placement alone without melatonin or hyauronic acid nor vitamin c
16425275|NCT03804164|Experimental|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
16425276|NCT03804151|Experimental|FitSpirit Intervention|FitSpirit physical activities and events are organized by participants' schools during the school year. Girl-only activities such as physical activity sessions, speaking engagements, turnkey running program and special events can be offered. The number, type and frequency of activities are decided by each school.
16425277|NCT03804138||Patient|patient with COPD
16425278|NCT03804138||control group|patient without COPD
16425279|NCT03804086|Experimental|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
16425280|NCT03804086|Active Comparator|Control Group|Open flap debridement alone.
16425281|NCT03804073|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
16425282|NCT03804073|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16425283|NCT03804060|Experimental|Cooling + Recanalization|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after recanalization.
16425284|NCT03804060|Active Comparator|Recanalization only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.
16425285|NCT03804047|Experimental|Kinesio Tape (KTG)|Participants allocated into the KTG will receive a single time application of the kinesio tape flexible tape (Kinesio® Tex, Albuquerque, NM, USA) in the upper-body (i.e., back part of the trunk) and in the lower-body (i.e., legs and ankle) according to standardized procedures (https://kinesiotaping.com/how-to/). The tape is latex-free and wearable for weeks without causing skin irritation (i.e., hypoallergenic); and safe for populations ranging from pediatric to geriatric. The tape will be applied by a Physical Therapist with experience in tape application. Tape application will be conducted in a private room with a complete structure for the procedure.
16425286|NCT03804047|Sham Comparator|Sham Tape (STG)|Participants allocated into the STG will receive a single time application of an inflexible tape (i.e., sham tape) in the same body segments as the intervention condition. Tape application will be conducted in a private room with a complete structure for the procedure.
16425287|NCT03804034|Experimental|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
16425288|NCT03804034|Experimental|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
16425289|NCT03804034|Experimental|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
16425290|NCT03804034|No Intervention|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
16425291|NCT03804021||1|Subjects who received a dose of ADVM-043 in a prior clinical study
16425292|NCT03804008|Active Comparator|Fundamental advice and a heel cup|
16425293|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise|
16425294|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise and injection|
16425295|NCT03803995|Other|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
16425296|NCT03803982|Experimental|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
16425297|NCT03803982|No Intervention|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
16425298|NCT03803969|Other|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
16425299|NCT03803956|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
16425300|NCT03803956|Placebo Comparator|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
16425301|NCT03803943|Experimental|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
16425302|NCT03803943|Placebo Comparator|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
16425303|NCT03803930|Other|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
16425304|NCT03803930|Other|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
16425305|NCT03803930|Other|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
16425306|NCT03803930|Other|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
16425307|NCT03803917|Other|Treatment|Injection with freshly collected autologous adipose tissue
16425308|NCT03803904|Experimental|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
16425309|NCT03803904|Active Comparator|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
16425310|NCT03803891||Endoscopic full-thickness resection|Patients with neoplastic lesions less than 30mm unresectable en bloc by other less invasive endoscopic techniques, including lesions suggestive of T1 colorectal cancer, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting sign (recurrent, incomplete prior resection or untreated lesions).
16425311|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
16425315|NCT03803865|Active Comparator|Recharge|30-day smartphone based reflection and problem solving training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
16425316|NCT03803852|Experimental|0°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 0°
16425317|NCT03803852|Experimental|45°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 45°
16425318|NCT03803852|Experimental|90°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 90°
16425319|NCT03803852|Experimental|135°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 135°
16425320|NCT03803839|Active Comparator|Clodronate|1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
16425321|NCT03803839|Placebo Comparator|Saline|1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
16425322|NCT03803826|Experimental|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:
~adjust the atrioventricular interval so that E and A waves do not overlap
~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.
~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
16425323|NCT03803826|No Intervention|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
16425324|NCT03803813||sepsis group|Patients have developed sepsis at ICU admission or during their ICU stay.
16425325|NCT03803813||non-sepsis group|Patients do not develope sepsis at ICU admission or during their ICU stay.
16425326|NCT03803800|Experimental|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
16425327|NCT03803800|Placebo Comparator|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
16425328|NCT03803800|Experimental|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
16425329|NCT03803800|Placebo Comparator|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
16425330|NCT03803787|Experimental|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
16425331|NCT03803787|No Intervention|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
16425332|NCT03803787|Experimental|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
16425333|NCT03803787|No Intervention|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
16425335|NCT03803761|Experimental|Treatment (copanlisib, fulvestrant)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16425336|NCT03803748|Experimental|Eyestil Plus®|"It's a clinical comparative performance study. Eyestil Plus® eyedrops multidose to be not inferior to Vismed multidose eye drops. Eyestil Plus is an ophthalmic aqueous formulation, multidose sterile preservative free, medical device, class IIB and CE marked. It contains 0.4% sodium hyaluronate. It is not available yet in the French Market.
~The dosage per medical device will be 6 drops a day per dry eye during the three months study period,"
16425337|NCT03803748|No Intervention|Vismed|"Vismed Multi® is also a sterile multidose preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate.
~The dosage per medical device will be 6 drops a day per dry eye during the three months study period.
~The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes."
16425338|NCT03803722|Experimental|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.
~dosage: 6 drops a day for three months period."
16425339|NCT03803722|No Intervention|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.
~dosage: 6 drops a day for three months period."
16425340|NCT03803709|Placebo Comparator|placebo|"maltodextrin received at 4g/day on day 3 and 4
~maltodextrin received at 8g/day from day 5 to 14
~maltodextrin received at 16g/day from day 15 to 20"
16425341|NCT03803709|Experimental|inulin|"inulin received at 4g/day on day 3 and 4
~inulin received at 8g/day from day 5 to 14
~inulin received at 16g/day from day 15 to 20"
16425388|NCT03803319|Placebo Comparator|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
16425342|NCT03803696|Active Comparator|Enhanced Standard Care|"Baseline data collection, registration and randomization
~Inform primary transplant clinician of sexual dysfunction causing distress
~Receive American Cancer Society sexual educational material"
16425343|NCT03803696|Active Comparator|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization
~3 Monthly visits with trained study nurse practitioners
~Referral to specialist if
~Psychological etiology
~Sexual Trauma
~Relationship Discord
~Concern for Malignancy or anatomic scarring requiring surgery"
16425344|NCT03803683|Experimental|mLab App Intervention|Youth randomized to the intervention arm (arm 1) will be provided with the mLab App, 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at their 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
16425345|NCT03803683|Active Comparator|Standard of Care HIV Information Control Arm|Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
16425346|NCT03803683|Active Comparator|HIV Home Tests|Youth randomized to the HIV home testing arm (arm 3) will be provided with the 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at the 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
16425347|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
16425348|NCT03803657||Neonates|Neonates 0-28 days
16425349|NCT03803657||Infant|29 days to 1 year
16425350|NCT03803657||Child|>1 year and <10 kg
16425351|NCT03803644|Experimental|Administration of CC-92480 - Part 1|dose escalation
16425352|NCT03803644|Experimental|Administration of CC-92480 under fasted conditions - Part 2|Food effect
16425353|NCT03803644|Experimental|Administration of CC-92480 under fed conditions - Part 2|food effect
16425354|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with <5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
16425355|NCT03803618||Control|Age and sex matched neighborhood controls
16425356|NCT03803605|Experimental|VRC07-523LS + Vorinostat (VOR)|Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.
16425357|NCT03803592|Experimental|Dyadic MCS program|"Participants from the experimental group will receive a dyadic multisensory and cognitive stimulation (MCS) programme.
~The MCS program is a 15- week program. In the first 4 weeks, participants will attend the center-based Face-to-face (FTF) session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers with the PWD at home and was suggested to deliver the intervention 3 times/week at home. The home-based sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions over the intervention period."
16425358|NCT03803592|No Intervention|Control group|Participants from the control group will receive usual care and no intervention will be received.
16425359|NCT03803566|Experimental|Faster|This group will comprise participants who complete the grooved pegboard test at baseline with a time of less than 71 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
16425360|NCT03803566|Experimental|Slower|This group will comprise participants who complete the grooved pegboard test at baseline with a time of greater than 70 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
16425361|NCT03803553|Experimental|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance
~- ctDNA-POSITIVE: FOLFIRI Protocol
~FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).
~infusions will consist of the drugs
~5-Fluorouracil
~Irinotecan
~Leucovorin"
16425362|NCT03803553|Active Comparator|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance
~-- Active surveillance.
~Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.
~After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.
~Additional scans and tumor markers will be at the discretion of the clinician. ."
16425389|NCT03803306|Experimental|Vedic Medical Astrology Group (VMA)|
16425390|NCT03803306|Sham Comparator|Placebo vedic medical astrology (PMA)|
16425391|NCT03803293|Other|Primary cohort|All eligible Biobank participants that receive the majority of their care at Mayo Clinic based on EHR length and depth had pharmacogenomic testing done.
16425363|NCT03803553|Active Comparator|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance
~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.
~Additional scans and tumor markers will be at the discretion of the clinician"
16425364|NCT03803553|Experimental|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.
~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab
~-ctDNA-Positive, MSI-H: Nivolumab Protocol
~Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).
~infusions will consist of the drug Nivolumab"
16425365|NCT03803553|Experimental|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.
~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab
~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol
~Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).
~infusions will consist of the drug Cetuximab"
16425366|NCT03803540|Experimental|Fecal Microbiota Transplantation|Lean healthy donor frozen fecal microbiota will be administered via duodenal infusion in an upper gastrointestinal endoscopy
16425367|NCT03803527|Experimental|EST|"All subjects enrolled into the study will:
~Complete a clinical history
~Have vitals obtained
~Complete Patient-reported outcomes
~Have Esophageal mucosal biopsies collected as part of standard of care at the time of the most recent endoscopy to report the peak eosinophilia per hpf.
~Complete the Esophageal String test"
16425368|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb < 10 g/dL). Ambulatory hemodialysis 3 times per week.
~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.
~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
16425369|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb > 10 g/dL). Ambulatory hemodialysis 3 times per week.
~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.
~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
16425370|NCT03803488|Experimental|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
16425371|NCT03803475|Experimental|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 millicurie (mCi) +/- 10% of 68Ga-PSMA-11.
16425372|NCT03803449|Active Comparator|Control group|Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam
16425373|NCT03803449|Experimental|Fentanyl group|Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.
16425374|NCT03803436|Experimental|Study arm|Liver transplant
16425375|NCT03803436|Active Comparator|Parallel arm|Chemotherapy
16425376|NCT03803423|Experimental|The Donor App|Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
16425377|NCT03803397|Experimental|PV-001-DC alone|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells
16425378|NCT03803384|Experimental|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
16425379|NCT03803384|Experimental|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
16425380|NCT03803371|Experimental|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets by mouth on Day 1 of period 1 or 2
16425381|NCT03803371|Active Comparator|Ultracet tablet|Ultracet tablet (Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg) by mouth on Day 1 of period 1 or 2
16425382|NCT03803358|Experimental|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
16425383|NCT03803358|Active Comparator|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
16425386|NCT03803319|Active Comparator|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
16425387|NCT03803319|Active Comparator|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
16425392|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
16425393|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
16425394|NCT03803267|Active Comparator|Erector spinae plane block|Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique
16425395|NCT03803267|Active Comparator|Quadratus lumborum block|Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique
16425396|NCT03803254|Experimental|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
16425397|NCT03803254|Active Comparator|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
16425398|NCT03803241|Experimental|PVE + CD133|preop portal vein embolization + stem cells infusion
16425399|NCT03803241|Sham Comparator|PVE|only preop portal vein embolization
16425400|NCT03803228|Experimental|DUOSTIM|(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted.
16425401|NCT03803228|Active Comparator|Conventional stimuli|"(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted.
~(stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1"
16425402|NCT03803215||Theophylline group|Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
16425403|NCT03803215||Control untreated group|A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder
16425404|NCT03803202|Experimental|Stage 1, Group 1 ASP3772 in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
16425405|NCT03803202|Active Comparator|Stage 1, Group 1 PCV13 in Adults|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
16425406|NCT03803202|Experimental|Stage 2, Group 2 ASP3772 in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
16425407|NCT03803202|Active Comparator|Stage 2, Group 2 PCV13 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
16425408|NCT03803202|Active Comparator|Stage 2, Group 3 PPSV23 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
16425409|NCT03803189|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports each time they complete a survey, and their PCP will receive supports in the EMR to facilitate postpartum mental healthcare.
16425410|NCT03803189|No Intervention|Usual care|The control arm will not receive intervention materials, unless they express suicidality, in which case they will receive a message with supports for suicidality including local emergency departments and crisis lines and an urgent message via EMR and fax will be sent to their PCP. Control arm participants will be asked to complete a baseline e-survey in their third trimester, and a follow-up e-survey 24-weeks after their baby is born.
16425411|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
16425412|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling & root planing.
16425413|NCT03803163|Experimental|TransCon Treprostinil|
16425414|NCT03803150|Experimental|PRA approach|PRA extends downward in curvilinear fashion in cervicomastoid skin crease
16425415|NCT03803150|Active Comparator|RT approach|RT begins 5mm below the ear lobe and continues 3 to 3.5cm inferiorly.
16425416|NCT03803137|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
16425417|NCT03803124|Active Comparator|Tolvaptan|"Drug: Tolvaptan
~1 tablet before renography"
16425418|NCT03803124|Placebo Comparator|Placebo|"Placebo
~1 tablet before renography"
16425419|NCT03803111|Experimental|Initial FCM|Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program
16425420|NCT03803111|Experimental|Initial exercise|Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM
16425421|NCT03803085|Experimental|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
16425422|NCT03803085|Experimental|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
16425423|NCT03803072|Experimental|Time restricted eating (TRE)|prolonging the duration of fasting between the last evening meal and the first meal of the next day
16425424|NCT03803072|No Intervention|control|Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy
16425425|NCT03803059|Experimental|Fine lines and wrinkles|Microneedle treatment to face and neck areas.
16425686|NCT03801187|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
16425426|NCT03803033|Experimental|Intervention|The objective of the group was to introduce an experimental clinical pharmacy-based home medication review service in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan. The intervention under evaluation in the study is the pharmacy-based home medication review service.
16425427|NCT03803033|No Intervention|Control|The objective of the control group was to identify changes in treatment and associated costs that take place in patients as part of the usual practice, as compared to the intervention arm, regardless of the clinical pharmacist service intervention.
16425428|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.
~fractional flow reserve and SPECT detection before and after intervention."
16425429|NCT03803007|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
16425430|NCT03803007|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
16425431|NCT03802994|Experimental|1.Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
16425432|NCT03802994|Active Comparator|2.Young RT|Renal transplant recipients between 35-45 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
16425433|NCT03802994|Active Comparator|3.Healthy elderly|Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
16425434|NCT03802994|Active Comparator|4.Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
16425435|NCT03802994|Experimental|5.Healthy young|Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
16425436|NCT03802955|Experimental|ADG106 Dose escalation|
16425437|NCT03802942|Experimental|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
16425438|NCT03802942|No Intervention|Control|Regular meal plan supplied by the hospital
16425439|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:
~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.
~Derivation Cohort of Prognostic Prediction Model:
~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
16425440|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:
~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.
~Validation Cohort of Prognostic Prediction Model:
~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
16425441|NCT03802916|Experimental|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
16425442|NCT03802916|Experimental|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
16425443|NCT03802903|Experimental|Remo-Wax|Test product will be applied into ear canal for 20-60 minutes.
16425444|NCT03802877|Active Comparator|Resource bank|The web-based resource bank includes information and perspectives about GDM, nutrition, and physical activity. The information is presented through video capsules, on-line text, printable pdfs, and podcasts. It is presented by health care professionals and patients.
16425445|NCT03802877|Experimental|Resource bank and ePlatform|In addition to resource bank access, participants will receive a digital scale, physical activity monitor (pedometer), and ePlatform log-in information. They will track daily weights and step counts. They will receive prompts to access educational and motivational tools based on the data that they enter and whether or not they enter data. The investigators will use the ePlatform developed by StepsCount, a Canadian pedometer company with a well-developed ePlatform for pedometer data upload, tracking, and automated messaging. The company is permitting us further customization for study purposes. Data will be uploaded onto a secure cloud-based platform controlled by the pedometer and digital scale companies.
16425446|NCT03802877|Experimental|Resource bank and health coach|"In addition to resource bank access, the coach will contact the participant weekly (telephone, text, email) to discuss progress and challenges in terms of achieving physical activity goals, rate of GWG, and maintaining health eating patterns, as well as any concerns.Participants not randomized to a coaching strategy will be advised to consult with their treating healthcare team directly if they develop symptoms of concern.
~The coach will encourage participants to track their weight gain and physical activity (e.g., walks, classes, activity lists, etc.) and to share this information. However, they will not have access to the study ePlatform and will not be provided with pedometers or digital scales."
16425447|NCT03802877|Experimental|Resource bank with ePlatform and coach|Participants will have resource bank access as well as ePlatform and coaching interventions.The health coach will have access to the data on the ePlatform. They will receive telephone calls from the research assistant/health coach if they are off target despite the platform tools and support. They will be encouraged to consult the resource bank and will brainstorm with the health coach to decide how to achieve their GWG and step count targets.
16425482|NCT03802630|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
16425448|NCT03802864|Experimental|Liposomal Bupivacaine|Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
16425449|NCT03802864|Active Comparator|Standard Bupivacaine|Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
16425450|NCT03802851|Experimental|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
16425451|NCT03802851|No Intervention|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
16425452|NCT03802838|Active Comparator|Acupuncture|Acupuncture+Amisulpride
16425453|NCT03802838|Other|Amisulpride|Amisulpride only.
16425454|NCT03802825|Active Comparator|Patient Navigation|Participants randomized to the patient navigation only arm will be referred to a KPNW patient navigator using a standard electronic health record-based referral process. Once the participant has completed the Your Current Life Situation (YCLS) assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 month period by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention. Participant will also receive monthly mailing of American Diabetes Association educational materials.
16425455|NCT03802825|Experimental|Patient Navigation+Diabetes Self-Management Training|"In addition to receiving patient navigation as described above, participants in this arm will also be referred to Project Access NOW by study staff using REDCap. As part of the partnership with KPNW, Project Access NOW will be provided with participants' contact information via REDCap to facilitate the referral to a certified CHW within a community-based organization. Project Access NOW will connect participants to a community-based organization based on their preference, previous experience with an agency, geography, and capacity.
~The CHW will follow-up with the participant to conduct a home visit and follow-up on community-based referrals already placed by the KPNW patient navigator and assess for additional needs. The timing of the diabetes self-management training will be based on the needs of the participant."
16425456|NCT03802812|No Intervention|Conventional arm|"Perform bronchial washing using conventional methods.
~CT-guided thick bronchoscope"
16425457|NCT03802812|Active Comparator|Investigational arm|"Perform bronchial washing using investigational methods.
~virtual bronchoscopic navigation (VBN)-guided thin bronchoscope (4.0mm of outer diameter)"
16425458|NCT03802799|Experimental|ZYN002|ZYN002 - CBD Transdermal Gel
16425459|NCT03802786|Experimental|Moderate hepatic impairment|Single dose of Imeglimin
16425460|NCT03802786|Experimental|Normal hepatic function|Single dose of Imeglimin
16425461|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
16425462|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
16425463|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
16425464|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab Alone|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab.
16425465|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab + Tremelimumab|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab + Tremelimumab.
16425466|NCT03802734|Experimental|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
16425467|NCT03802734|No Intervention|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
16425468|NCT03802721|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
16425469|NCT03802721|Experimental|Brussels sprouts before 50 ng dose|Subjects will consume 50 g (about 1/2 cup) of lightly steamed Brussels sprouts each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
16425470|NCT03802721|Experimental|DIM supplement before 50 ng dose|Subjects will consume 300 mg DIM supplement ( 2 capsules of BioResponse DIM® 150) each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP). A 300 mg DIM dose will be co-administrated with the 50 ng BaP dose
16425471|NCT03802708|Other|control|control
16425472|NCT03802682|Experimental|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A [reference]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B [test]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
16425473|NCT03802682|Experimental|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B [test]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A [reference]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
16425474|NCT03802669||caries free children aged between 3-6|
16425475|NCT03802669||caries active children aged between 3-6|
16425476|NCT03802669||caries free children aged between 6-12|
16425477|NCT03802669||caries active children aged between 6-12|
16425478|NCT03802669||caries free adult aged between 18-25|
16425479|NCT03802669||caries active adult aged between 18-25|
16425480|NCT03802656|Experimental|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
16425481|NCT03802630|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
16425483|NCT03802617|Experimental|MR13A9 low dose|
16425484|NCT03802617|Experimental|MR13A9 medium dose|
16425487|NCT03802604|Experimental|Talimogene laherparepvec + Atezolizumab|"Talimogene laherparepvec: Cycle 1 - 10^6 PFU/mL. Cycle 2, 3, 4 & 5 - 10^8 PFU/mL.
~Atezolizumab 840 mg"
16425488|NCT03802591|Experimental|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
16425489|NCT03802591|Placebo Comparator|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
16425490|NCT03802578|Experimental|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
16425491|NCT03802578|No Intervention|CONTROL GROUP|Patients in the control group continued their usual medical care.
16425492|NCT03802565|Experimental|Tolperisone 50 mg|TID (150 mg/day)
16425493|NCT03802565|Experimental|Tolperisone 100 mg|TID (300 mg/day)
16425494|NCT03802565|Experimental|Tolperisone 150 mg|TID (450 mg/day)
16425495|NCT03802565|Experimental|Tolperisone 200 mg|TID (600 mg/day)
16425496|NCT03802565|Placebo Comparator|Placebo|TID
16425497|NCT03802552|Experimental|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
16425498|NCT03802552|Experimental|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
16425499|NCT03802539|Experimental|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
16425500|NCT03802539|No Intervention|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
16425501|NCT03802526|Experimental|NVP-1805-R1|"Drug: NVP-1805-R1
~1 tablet, oral dosing"
16425502|NCT03802526|Experimental|NVP-1805-R2|"Drug: NVP-1805-R2
~1 tablet, oral dosing"
16425503|NCT03802526|Experimental|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
16425504|NCT03802513|Other|Single arm|This study has 1 health-related intervention. Veterans with somatosensory tinnitus will receive individualized physiotherapy.
16425505|NCT03802487|Experimental|Sotagliflozin|One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.
16425506|NCT03802474||Group A|girls with primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
16425507|NCT03802474||Group B|girls with normal painless menstruation without primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
16425508|NCT03802461|Active Comparator|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
16425509|NCT03802461|No Intervention|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
16425510|NCT03802448|Active Comparator|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.
~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
16425511|NCT03802448|Experimental|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.
~Myofascial wrist retinaculum (Transverse carpal ligament) release.
~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
16425512|NCT03802435|Experimental|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
16425513|NCT03802435|Active Comparator|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
16425514|NCT03802435|Placebo Comparator|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
16425515|NCT03802422|Experimental|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
16425516|NCT03802422|Placebo Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
16425517|NCT03802396|Experimental|CN-105|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
16425518|NCT03802396|Placebo Comparator|Placebo|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
16425519|NCT03802370|Other|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
16425520|NCT03802357|Experimental|High training intensity|Exercise Training with high intensities consists of a cycling Interval Training at 100% of the individual Peak work rate, resistance Training for 3 sets à 8 repetitions and squats on a Vibration plate.
16425521|NCT03802357|Active Comparator|moderate training intensity|Exercise Training with moderate intensities consists of a cycling endurance Training at 60% of the individual Peak work rate, resistance Training for 3 sets à 20 repetitions and squats on the floor.
16425522|NCT03802344|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
16425523|NCT03802344|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
16425524|NCT03802344|Placebo Comparator|Vehicle|One application daily for 8 weeks
16425525|NCT03802331|Experimental|Test Treatment|fed
16425526|NCT03802331|Experimental|Reference Treatment|fasted
16425687|NCT03801174|Experimental|Partner-assisted intervention|Patients and partners will receive intervention
16425527|NCT03802318|Experimental|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
16425528|NCT03802318|Placebo Comparator|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
16425529|NCT03802318|Experimental|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
16425530|NCT03802318|Placebo Comparator|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
16425531|NCT03802305|Experimental|Computerized intraosseous technique (Quicksleeper™)|patients will receive the anesthetic solution with computerized intraosseous technique anesthesia near the tooth roots involved.
16425532|NCT03802305|Active Comparator|loco-regional anesthesia (IANB technique)|patients will receive the anesthetic solution with the loco-regional anesthesia technique: near the place where the nerve goes into the jaw, based on osteo muscular markers.
16425533|NCT03802292|Active Comparator|Single Ascending Dose YQ23|
16425534|NCT03802292|Placebo Comparator|Single Dose Placebo|
16425535|NCT03802279||Rhabdomyolysis with myoblasts back up|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited from a diagnostically muscle biopsy and whose myoblasts are available.
~Patients benefit from an effort test as part of their care."
16425536|NCT03802279||Rhabdomyolysis|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited or not from a diagnostically muscle biopsy but whose myoblasts are not available.
~Patients benefit from an effort test as part of their care."
16425537|NCT03802279||Witness patients : effort test|10 patient-matched healthy controls for age and sex having performed an effort test and cardiac exploration as part of their care.
16425538|NCT03802279||Witness patients : myoblasts|6 healthy controls matched by age and sex having performed a muscle biopsy as part of their care and whose myoblasts are kept.
16425539|NCT03802266|Experimental|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
16425540|NCT03802266|Active Comparator|CT group|CT-guided Transthoracic Needle Aspiration
16425541|NCT03802253|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
16425542|NCT03802253|Active Comparator|RCD|Participants in this group will focus on standard care with daily reduced calorie diet (RCD)
16425543|NCT03802240|Experimental|Sintilimab +IBI305+Pemetrexed+Cisplatin|
16425544|NCT03802240|Experimental|Sintilimab +Placebo2+Pemetrexed+Cisplatin|
16425545|NCT03802240|Active Comparator|Placebo1+Placebo2+Pemetrexed+Cisplatin|
16425546|NCT03802227|Experimental|Group 1|NKTR-181 400 mg and oxycodone IR placebo
16425547|NCT03802227|Experimental|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
16425548|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
16425549|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
16425550|NCT03802201|Experimental|PTG-300 Active|Drug: PTG-300 Subcutaneous
16425551|NCT03802188||SLE Cohort|Investigators will use existing data collected on adult SLE patients enrolled into respective study cohorts from participating centers.
16425552|NCT03802188||Qualitative group|For the interviews, patients with SLE who are currently or have taken Hydroxychloroquine will be recruited from rheumatology clinics in Calgary and Montreal to participate in an interview and/or participate in a brief survey.
16425553|NCT03802162|Experimental|CKD-355A|
16425554|NCT03802162|Experimental|CKD-355B|
16425555|NCT03802162|Active Comparator|D797, D324|
16425556|NCT03802149|Experimental|Ulipristal Acetate|Participants will be administered a one time dose of 90mg ulipristal acetate 18-24-hours prior to dilation and evacuation (surgical abortion) for cervical preparation.
16425557|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
16425558|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
16425559|NCT03802123|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
16425560|NCT03802110|Experimental|Single Arm|Defibrillation threshold (DFT) testing Arm
16425561|NCT03802097|Experimental|Treatment group|No antimicrobial prophylaxis
16425562|NCT03802097|No Intervention|Control group|Antimicrobial prophylaxis
16425563|NCT03802084|Experimental|vactosertib/imatinib combination|
16425564|NCT03802071|Experimental|Durvalumab+doxorubicin combination|
16425565|NCT03802058|Experimental|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
16425566|NCT03802045|Experimental|Low frequency EA|"25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 2Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm)."
16425591|NCT03801902|Experimental|Arm I (durvalumab, ACRT)|Patients receive durvalumab IV over 60 minutes on day 1 starting 2 weeks prior to radiation therapy. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ACRT 1 fraction per day, 5 days per week for 15 fractions.
16425592|NCT03801902|Active Comparator|Arm II (durvalumab, standard RT)|Patients receive durvalumab as in Arm I. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions.
16425593|NCT03801889|Experimental|Cohort 1|SP-420 initially at 28 mg/kg
16425594|NCT03801889|Experimental|Cohort 2|SP -20 initially at 56 mg/kg
16425567|NCT03802045|Experimental|High frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
16425568|NCT03802045|Experimental|Alternating frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz and 2Hz for 3 seconds each; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
16425569|NCT03802045|Active Comparator|Control Group|"25 participants will follow exactly the same protocol as the experimental groups, however they will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient.
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
16425570|NCT03802045|Placebo Comparator|Placebo Group|"25 participants will will follow exactly the same protocol as the experimental groups, however an adhesive moxa (Dong Yang®) will be placed on each acupoint and the needle will be inserted over it, so that the participant only feels the needle prick, but without perforation of the skin and the deQi sensation. In addition, as in the control group, the electrodes will be connected to the needles, however, no electrical current will be applied.
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
16425571|NCT03802032|Experimental|Study Group|15g of Topical Xylocaine gel
16425572|NCT03802032|Placebo Comparator|Control group|15g of KY Jelly
16425573|NCT03802019|Experimental|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
16425574|NCT03802019|Experimental|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
16425575|NCT03802019|Experimental|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
16425576|NCT03802019|Experimental|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
16425577|NCT03802019|Experimental|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
16425578|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
16425579|NCT03801993||All Subjects|Subjects with a diagnosis of Cystic Fibrosis (CF) who meet all the inclusion and none of the exclusion criteria will be eligible for participation in this study.
16425580|NCT03801980|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
16425581|NCT03801980|Placebo Comparator|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
16425582|NCT03801967|Experimental|AZD9977|Each participant will receive AZD9977 at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
16425583|NCT03801967|Placebo Comparator|Placebo|Each participant will receive placebo at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
16425584|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
16425585|NCT03801941|Experimental|Group A|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with the ATLAS Device at the 4th day and without the device at the 5th day of a 4 weeks rehabilitation program.
16425586|NCT03801941|Experimental|Group B|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without the ATLAS Device at the 4th day and with the device at the 5th day of a 4 weeks rehabilitation program.
16425587|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
16425588|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
16425589|NCT03801915|Experimental|1/Arm 1|Pre-operative escalation doses of MVT-5873,pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
16425590|NCT03801915|Experimental|2/Arm 2|Pre-operative RD of MVT-5873, pancreatectomy orhepatectomy and post-operative MVT-5873 treatment
16425596|NCT03801876|Experimental|Group I (PBT, Chemotherapy, Esophagectomy)|Patients undergo PBT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU [with capecitabine as an acceptable substitute for 5-FU]) per institutional standards while undergoing PBT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
16425597|NCT03801876|Active Comparator|Group II (IMRT, Chemotherapy, Esophagectomy)|Patients undergo IMRT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU [with capecitabine as an acceptable substitute for 5-FU]) per institutional standards while undergoing IMRT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
16425598|NCT03801863||Ultrasound-guided Erector Spinae Block|Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
16425599|NCT03801863||No Ultrasound-guided Erector Spinae Block|Patients with no peripheral nerve block to serve as the control.
16425600|NCT03801850|Experimental|observational cohort|
16425601|NCT03801837|Active Comparator|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
16425602|NCT03801837|Placebo Comparator|Control Diet|This group will continue with their Habitual Diet
16425603|NCT03801824|Active Comparator|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
16425604|NCT03801824|Experimental|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
16425605|NCT03801798|Experimental|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.
~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL
~V2 to V17 : IV bolus injection twice a week
~V18 to V33 : IV bolus injection once a week"
16425606|NCT03801798|Placebo Comparator|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.
~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL
~V2 to V17: IV bolus injection twice a week
~V18 to V33: IV bolus injection once a week"
16425607|NCT03801785|Experimental|Children induced to suck pacifiers.|Children will suck a pacifier of identical shape and type and will be allowed other NNS habits.
16425608|NCT03801785|No Intervention|Children induced to stop sucking.|Children will be induced by DDSs to stop sucking and their parents will be advised how to stop their children's NNS habits.
16425609|NCT03801772|Active Comparator|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
16425610|NCT03801772|No Intervention|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
16425611|NCT03801759|Experimental|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
16425612|NCT03801759|Experimental|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
16425613|NCT03801759|Experimental|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
16425614|NCT03801746|Experimental|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
16425615|NCT03801746|Experimental|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
16425616|NCT03801746|Experimental|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
16425617|NCT03801733|Experimental|Rosuvastatin, Vadadustat|Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.
16425618|NCT03801733|Experimental|Sulfasalazine. Pravastatin, Vadadustat|"Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.
~Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
16425619|NCT03801733|Experimental|Atorvastatin, Simvastatin, Vadadustat|"Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.
~Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
16425620|NCT03801720|No Intervention|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
16425621|NCT03801720|Experimental|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
16425622|NCT03801707|Experimental|Intervention group|kidney transplant recipients who receive kidney allograft from hepatitis C viremic donors followed by treatment with direct acting antiviral therapies.
16425623|NCT03801681||myocarditis|patients with clinically suspected myocarditis
16425624|NCT03801668|Experimental|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
16425625|NCT03801668|Active Comparator|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
16425626|NCT03801655|Experimental|Bio-Kult|4 capsules/day
16425627|NCT03801655|Placebo Comparator|Placebo|4 capsules/day
16425628|NCT03801642|Experimental|Dapagliflozin|10 mg dapagliflozin oral tablet taken once daily for 12 weeks
16425629|NCT03801642|Placebo Comparator|Matching placebo|Placebo oral tablet taken once daily for 12 weeks
16425630|NCT03801629|Experimental|High Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.07 mg/kg).
16425631|NCT03801629|Experimental|Low Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.04 mg/kg).
16425632|NCT03801616|Experimental|Virtual Reality|Every participant is provided with a VR headset
16425633|NCT03801603|Experimental|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
16425634|NCT03801590|Experimental|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
16425635|NCT03801577|Experimental|Hepaxa|Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)
16425636|NCT03801564|Experimental|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
16425637|NCT03801564|Experimental|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
16425638|NCT03801551|Experimental|Patient|
16425639|NCT03801538|Experimental|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.
~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.
~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
16425640|NCT03801538|Other|NAs group|CHB patients do not need to change their NAs treatment.
16425641|NCT03801525|Experimental|ublituximab + umbralisib + venetoclax|
16425642|NCT03801525|Experimental|ublituximab + umbralisib|
16425643|NCT03801512|Experimental|Steroid Injections|Inject steroid at neuritis nerve root.
16425644|NCT03801512|Experimental|Acupuncture|Acupuncture at acupoints BL23 to BL26.
16425645|NCT03801512|Experimental|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
16425646|NCT03801499|Experimental|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16425647|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
16425648|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
16425649|NCT03801473|Experimental|robot assisted training (RAT)|RoboGait which is an automated locomotor therapy system was used for treating RAT group. The system composed of a robotic lower extremity orthosis, adjustable dynamic gait support, synchronized treadmill and biofeedback utilities
16425650|NCT03801473|Active Comparator|conventional training (CT)|Participants in CT group had physiotherapist assisted walking exercises on the parallel bars and on the ground with aids/cane, tripod or walker.
16425651|NCT03801460|No Intervention|SOC|Standard of Care
16425652|NCT03801460|Experimental|RAPR|Remotely administered physiological reconditioning program
16425653|NCT03801434|Experimental|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.
16425654|NCT03801421|Experimental|Continous suture group|The surgical incision will be treated by mass continous suture with PDS.
16425655|NCT03801421|Active Comparator|Control group|The surgical incision will be treated by interrupted suture with thread.
16425656|NCT03801382|Other|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
16425657|NCT03801382|Other|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
16425688|NCT03801174|Active Comparator|Patient-only intervention|Patients will receive intervention
16425658|NCT03801382|Other|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
16425659|NCT03801382|Other|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
16425660|NCT03801382|Other|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
16425661|NCT03801369|Experimental|Treatment (Olaparib and Durvalumab)|Patients with biopsy proven TNBC will undergo a pre-treatment biopsy, after which they will receive a 28 days induction treatment of olaparib (oral, twice a day). At the 2 week mark, patients will then undergo a repeat on-treatment biopsy. Beginning cycle 2, durvalumab will be administered (IV over 1 hr) every 4 weeks, in addition to olaparib. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, may continue on therapy beyond the planned 13 cycles.
16425662|NCT03801356|Other|Selective Nerve Root Block|Patient will receive a Selective Nerve Root Block injection at the target level prior to surgical intervention.
16425663|NCT03801343|Experimental|Nutrakos®|12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement
16425664|NCT03801330|Active Comparator|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
16425665|NCT03801330|Experimental|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
16425666|NCT03801317|Experimental|BC/ egg|4.3 grams egg powder + 5.7 grams bovine colostrum
16425667|NCT03801317|Placebo Comparator|Control|15 grams corn-soya blend
16425668|NCT03801304|Experimental|Atezolizumab associated with vinorelbine|"Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.
~Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
16425669|NCT03801291|Active Comparator|Transvaginal repair|Repair of anterior rectocele via the vagina
16425670|NCT03801291|Active Comparator|Transperineal repair|Repair of anterior rectocele via the perineum
16425671|NCT03801265|Active Comparator|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
16425672|NCT03801265|Experimental|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
16425673|NCT03801252|Experimental|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
16425674|NCT03801252|Placebo Comparator|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
16425675|NCT03801239||patients with Overactive Bladder (OAB)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
16425676|NCT03801239||patients with Mixed Urinary incontinence (MUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
16425677|NCT03801239||patients with Stress Urinary Incontinence (SUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
16425678|NCT03801226|Experimental|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
16425679|NCT03801226|Active Comparator|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
16425680|NCT03801213|Active Comparator|Urinary catheterization|
16425681|NCT03801213|Experimental|manual bladder stimulation Technique|
16425682|NCT03801200|Experimental|Apatinib combined with Radiotherapy|"Drugs: Apatinib Apatinib (500 mg/d) was given orally for one week before the brain radiotherapy, and then, continued to be administered at the same way during the brain radiotherapy period (3 weeks). It was given for another one week after the end of the brain radiotherapy.
~Radiotherapy: Intensity-modulated radiotherapy (IMRT).
~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:
~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;
~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy/15 to patients with 1-5 metastatic lesions."
16425683|NCT03801200|No Intervention|Radiotherapy alone|"Radiotherapy: Intensity-modulated radiotherapy (IMRT).
~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:
~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;
~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy /15 to patients with 1-5 metastatic lesions."
16425684|NCT03801187|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
16425685|NCT03801187|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
16425690|NCT03801161|Experimental|Infants with an inflammatory condition|Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
16425691|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
16425692|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
16425693|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
16425694|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
16425695|NCT03801135|No Intervention|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
16425696|NCT03801135|Experimental|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
16425697|NCT03801135|Active Comparator|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
16425698|NCT03801122|Experimental|Tranexamic acid 3g/day|Administration of tranexamic acid 3g/day, with 3 injections/8 hours.
16425699|NCT03801122|Experimental|Tranexamic acid 1.5g/day|Administration of tranexamic acid 1.5g/day, with 3 injections/8 hours.
16425700|NCT03801122|No Intervention|No treatment|No treatment (no administration of tranexamic acid)
16425701|NCT03801109|Experimental|Hyperbaric group|
16425702|NCT03801109|Experimental|Magnetic group|
16425703|NCT03801109|Active Comparator|Physical group|
16425704|NCT03801109|No Intervention|Baseline group|
16425705|NCT03801096|Experimental|Narrative Based Therapuetic Assessment|
16425706|NCT03801096|Active Comparator|Health Education (HE)|
16425707|NCT03801083|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic biliary tract cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
16425708|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
16425709|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
16425710|NCT03801057|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
16425711|NCT03801057|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
16425712|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
16425713|NCT03801031|Active Comparator|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
16425714|NCT03801031|Placebo Comparator|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
16425715|NCT03801018||Parents who have used the donation of gametes|
16425716|NCT03801018||Children born of gametes donation|
16425717|NCT03800979|Experimental|Tofacitinib|All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
16425718|NCT03800966|Experimental|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
16425719|NCT03800966|Placebo Comparator|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
16425720|NCT03800953|Experimental|Avelumab (Bavencio)|This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
16425721|NCT03800940|Experimental|Fistulography and trans-drain occlusion|Fistulography is performed to assess the condition of the fistula, and trans-drain occlusion is performed by injecting glue (NBCA and Lipiodol) through the drain to occlude the tract.
16425722|NCT03800940|Sham Comparator|Fistulography|Fistulography is performed to assess the condition of the fistula, without trains-drain occlusion.
16425723|NCT03800927|Placebo Comparator|Sham Ultrasound Device|No ultrasound treatment
16425724|NCT03800927|Active Comparator|Active Ultrasound Device|Active treatment
16425725|NCT03800914|Experimental|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
16425825|NCT03800303|Experimental|two-week family-based treatment|Active treatment includes a two-week family-based partial hospitalization treatment utilizing and integrated therapeutic design.
16425726|NCT03800914|Active Comparator|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
16425727|NCT03800901|Active Comparator|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
16425728|NCT03800901|Experimental|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
16425729|NCT03800888|Experimental|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
16425730|NCT03800888|Experimental|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
16425731|NCT03800888|No Intervention|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
16425732|NCT03800875|Experimental|Insulin-Pramlintide Closed-Loop Strategy|Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
16425733|NCT03800875|Active Comparator|Insulin-alone Closed Loop Strategy|"Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal.
~Drug(s): Insulin (FiAsp)"
16425734|NCT03800862||CTP and CT-FFR|"This will be a prospective, observational study designed to include a convenience sample of all qualifying patients undergoing myocardial CTP and CT-FFR.
~The study will enroll patients who have chest discomfort and will require further evaluation for the presence of coronary artery disease. Patients in the study will include those who have had a clinically indicated CCTA for suspicion of coronary artery disease and are determined to have a coronary stenosis ≥50% and ≤99%. However, patients with Left main disease greater than 50% and occluded vessels Coronary Artery Disease Reporting and Data System (CAD RADS 5) will be excluded from the study. CCTA is a clinically indicated and standard of care procedure at Lancaster General Hospital.
~."
16425735|NCT03800836|Experimental|Arm A1: Ipat + Atezo + Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425736|NCT03800836|Experimental|Arm A2: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425737|NCT03800836|Experimental|Arm A3: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425738|NCT03800836|Experimental|Arm B1: Ipat + Atezo + Nab-Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425739|NCT03800836|Experimental|Arm B2: Ipat + Atezo + Nab-Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425740|NCT03800836|Experimental|Arm C1: (Ipat + Pacl) (2 weeks) + Atezo|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425856|NCT03800043||Children with own caries experience|Children with own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
16425741|NCT03800836|Experimental|Arm C2 (Ipat + Pacl) (2 weeks) + Atezo|Expansion (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425742|NCT03800836|Experimental|Arm D1: (Atezo + Pacl) (2 weeks) + Ipat|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425743|NCT03800836|Experimental|Arm D2: (Atezo + Pacl) (2 weeks) + Ipat|Expansion (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425744|NCT03800836|Experimental|Arm E: Ipat + Atezo|Participants (Cohort 2) will receive Ipatasertib orally daily on Days 1-28 of Cycle 1 (35-day cycle) and on Days 1-21 of subsequent cycles (28-day cycles). Atezolizumab will be administered by IV infusion on Days 8 and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425745|NCT03800836|Experimental|Arm F1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
16425746|NCT03800836|Experimental|Arm F2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
16425747|NCT03800836|Experimental|Arm G1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
16425748|NCT03800836|Experimental|Arm G2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
16425749|NCT03800836|Experimental|Arm H: Ipat + Atezo + Pacl|Participants (Cohort 4) will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
16425750|NCT03800823|Experimental|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
16425751|NCT03800823|Active Comparator|Standard care|Standard care for overweight and obesity
16425752|NCT03800810|Experimental|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
16425753|NCT03800810|Experimental|Intervention 1|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
16425754|NCT03800810|Experimental|Intervention 2|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
16425755|NCT03800810|Experimental|Intervention 3|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
16425756|NCT03800797|Experimental|LX-P group|loxoprofen sodium hydrogel patch (LX-P) 100 mg per day for 4 weeks
16425757|NCT03800797|Active Comparator|LX-T group|loxoprofen sodium tablet (LX-T) 60 mg t.i.d. for 4 weeks
16425758|NCT03800784|Experimental|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
16425759|NCT03800771|Experimental|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
16425760|NCT03800758|Experimental|Expressive Helping writing|"Writing sessions 1-3: Participants complete one 20-minute expressive writing session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.
~Writing session 4: One 20-40 minute peer support writing session about 1 week after completion of writing session 3."
16425761|NCT03800758|Active Comparator|Factual Writing|"Writing sessions 1-3: Participants complete one 20-minute factual session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.
~Writing session 4: One 20-40 minute factual writing session about 1 week after completion of writing session 3."
16425762|NCT03800745|No Intervention|No Medication|No intervention is assigned in Arm A.
16425763|NCT03800745|Experimental|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
16425764|NCT03800745|Experimental|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
16425765|NCT03800732|Experimental|Night workers.|Night workers of the military police of Minas Gerais, Uberlândia, who will participate in the three interventions of the study.
16425766|NCT03800719|Experimental|Intervention Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, regular messages through Instant Messaging (IM), psychosocial support and referral to SC services through IM
16425767|NCT03800719|Active Comparator|Control Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, SMS message on general health
16425768|NCT03800706|Experimental|TQB2450|
16425769|NCT03800693|Active Comparator|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16425770|NCT03800693|Experimental|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16425771|NCT03800680|No Intervention|Usual Care (Arm 1)|Participants will receive usual care by their diabetes clinics.
16425772|NCT03800680|Experimental|DMP (Arm 2)|Participants will receive usual care by their diabetes clinics and the Diabetes Management Package (DMP).
16425773|NCT03800680|Experimental|DMP + M-POWER Rewards (Arm 3)|Participants will receive usual care by their diabetes clinics, the Diabetes Management Package (DMP), and the financial incentive program, M-POWER Rewards.
16425774|NCT03800667|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1000 mg of vitamin C for one month,
16425775|NCT03800667|No Intervention|Women not taking vitamin C|Women who are undergoing elective gynecological surgeries and who are randomized not to take any vitamin C for one month.
16425776|NCT03800654|Other|Mindful Action for Pain (MAP) Development|In the first arm, MAP will be fully developed.
16425777|NCT03800654|Active Comparator|MAP vs. CBT-CP|In the second arm, MAP will be compared to CBT-CP to establish feasibility of a larger, future trial.
16425778|NCT03800641|Experimental|oral administration|oral administration of dexmedetomidine 4μg/kg
16425779|NCT03800641|Active Comparator|intravenous administration|intravenous administration of dexmedetomidine 0.8μg/kg
16425780|NCT03800641|Experimental|nasal administration|nasal administration of dexmedetomidine 1μg/kg
16425781|NCT03800602|Experimental|Treatment (nivolumab, metformin)|Patients receive metformin PO BID starting on day 1. After 14 days of metformin only period patients also receive nivolumab IV every 4 weeks starting on day 15. Courses repeat every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity or consent withdrawal.
16425782|NCT03800589|Active Comparator|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
16425783|NCT03800589|Active Comparator|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
16425784|NCT03800563|Experimental|Laser assisted liposuction|Laser Assisted Liposuction with the LipoLife system.
16425857|NCT03800043||Children without own caries experience|Children without own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
16425785|NCT03800550|Experimental|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
16425786|NCT03800550|Experimental|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
16425787|NCT03800537|Experimental|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
16425788|NCT03800524|Experimental|Tauroursodeoxycholic acid (TUDCA)|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules
~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
~Mode of administration: orally
~Duration: 18 months"
16425789|NCT03800524|Placebo Comparator|Reference therapy|"Placebo capsules identical to active compound
~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
~Mode of administration: orally
~Duration: 18 months"
16425790|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
16425791|NCT03800498|Experimental|Intervention|For twelve weeks, only intervention group were given DASH education
16425792|NCT03800498|No Intervention|Controlled|Controlled group not received DASH education
16425793|NCT03800485|Experimental|IMT-GE|the participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will increase from the 15% of the maximal inspiratory preassure until the 60% of the maximal inspiratory preassure.
16425794|NCT03800485|Placebo Comparator|IMT-GP|The participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will be the 10% of the maximal inspiratory preassure during all the 8 weeks
16425795|NCT03800472|Experimental|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
16425796|NCT03800472|Placebo Comparator|Placebo SAD IR (Part 1)|Single doses of Placebo IR
16425797|NCT03800472|Experimental|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
16425798|NCT03800472|Placebo Comparator|Placebo SAD MR (Part 2)|Single doses of Placebo MR
16425799|NCT03800472|Experimental|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
16425800|NCT03800472|Experimental|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
16425801|NCT03800472|Placebo Comparator|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
16425802|NCT03800472|Experimental|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
16425803|NCT03800472|Placebo Comparator|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
16425804|NCT03800459|Experimental|Experimental: Intervention group|Experimental: Intervention group
16425805|NCT03800459|No Intervention|Control:no intervation group|Control:no intervation group
16425806|NCT03800446|Other|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
16425807|NCT03800433|No Intervention|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
16425808|NCT03800433|Experimental|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
16425809|NCT03800420|Experimental|BBT-401-1S|BBT-401-1S, Oral capsule, QD
16425810|NCT03800420|Placebo Comparator|Placebo|Placebo, Oral capsule, QD
16425811|NCT03800407||EFV-based ART|ART-naïve HIV-infected children aged 3 - 14 years who initiate EFV-based ART
16425812|NCT03800407||Concurrent EFV-based ART plus anti-TB therapy|ART-naïve HIV-infected children aged 3 - 14 years with TB coinfection who initiate EFV-based ART while receiving first-line anti-TB therapy
16425813|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
16425814|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
16425815|NCT03800381||Active TB only|Children with clinical diagnosis or acid-fast bacilli (AFB) smear positive TB disease
16425816|NCT03800381||Active TB with HIV Co-infection|Children with clinical diagnosis or AFB smear positive TB disease who test positive for HIV infection
16425817|NCT03800368|Experimental|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
16425818|NCT03800368|Experimental|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
16425819|NCT03800368|Active Comparator|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
16425820|NCT03800355||Male breast cancer|The study target population is all cases of male breast cancer (MBC), diagnosed with invasive breast cancer between the years 2000 and 2017, and treated in the Medical Oncology Departments of participating sites.
16425821|NCT03800342|Experimental|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
16425822|NCT03800329|Active Comparator|Snap40 Monitor|Patients randomly assigned to wear the Snap40 monitor will wear the device for 48 hours following discharge from the hospital.
16425823|NCT03800329|Placebo Comparator|No Monitor|Patients randomly assigned to not wear the Snap40 monitor will continue with their follow-up surgical care in the ordinary fashion.
16425824|NCT03800316|Experimental|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
16425928|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
16425826|NCT03800290|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.
~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
16425827|NCT03800290|Placebo Comparator|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.
~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
16425828|NCT03800277|Experimental|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
16425829|NCT03800277|Experimental|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
16425830|NCT03800277|Experimental|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
16425831|NCT03800277|Placebo Comparator|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
16425832|NCT03800264|Active Comparator|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
16425833|NCT03800264|Active Comparator|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
16425834|NCT03800251|Other|Fasting parturients at term|Fasting parturients at term, admitted for elective cesarean section, who consent to partake in the study
16425835|NCT03800238|Experimental|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
16425836|NCT03800238|Active Comparator|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
16425837|NCT03800225|Experimental|Repair|Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
16425838|NCT03800225|Active Comparator|Patella tendon graft|The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.
16425839|NCT03800199|Experimental|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
16425840|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
16425841|NCT03800173|Experimental|Galidesivir|Galidesivir IV infusion
16425842|NCT03800173|Placebo Comparator|placebo|Placebo IV infusion
16425843|NCT03800147|Active Comparator|High-fat diet|"Participants will follow a high-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).
~Blood samples, stool samples and clinical information will be collected during the study."
16425844|NCT03800147|Active Comparator|Low-fat diet|"Participants will follow a low-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).
~Blood samples, stool samples and clinical information will be collected during the study."
16425845|NCT03800134|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy|"Durvalumab (MEDI4736) in concurrence with platinum-based chemotherapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:
~carboplatin/paclitaxel
~cisplatin/gemcitabine
~pemetrexed/cisplatin
~pemetrexed/carboplatin"
16425846|NCT03800134|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy|"Placebo in concurrence with platinum-based chemotherapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:
~carboplatin/paclitaxel
~cisplatin/gemcitabine
~pemetrexed/cisplatin
~pemetrexed/carboplatin"
16425847|NCT03800121||localized and metastatic sarcomas|"In total, several blood tests specific to the EXOSARC study will be necessary:
~A first blood test of 7 mL during the initial assessment (inclusion)
~Then four blood samples of 32mL distributed over 6 months (localized sarcoma group) or three blood samples of 32mL performed during chemotherapy treatments (metastatic sarcoma group)."
16425848|NCT03800108|Other|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
16425849|NCT03800095|Experimental|Conventional haematological care|Patients with haematological malignancy Conventional haematological care
16425850|NCT03800095|Experimental|Conventional care associated with a monthly consultation|Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
16425851|NCT03800082|No Intervention|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
16425852|NCT03800082|Experimental|Treatment|Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
16425853|NCT03800069||Arm 1|A finger stick sample is collected and tested on the study device.
16425854|NCT03800056||Group 1 APS 1|Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.
16425855|NCT03800056||Group 2 APS2|Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
16425929|NCT03799640|Experimental|Standard Yoga|Yoga will be performed using linear forward and backward movements.
16425858|NCT03800030|Experimental|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
16425859|NCT03800030|Experimental|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
16425860|NCT03800030|Experimental|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
16425861|NCT03800030|Experimental|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
16425862|NCT03800030|Experimental|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
16425863|NCT03800030|Experimental|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
16425864|NCT03800017|Experimental|Hyperoxia|During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
16425865|NCT03800017|Placebo Comparator|Healthy Controls|During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
16425866|NCT03799991|Experimental|Vestibular therapy|Vestibular therapy (Vestibular physical therapy) entails an 8-week course of exercises delivered by a physical therapist designed to improve vestibular function.
16425867|NCT03799991|Active Comparator|Active control|"The active control regimen consists of eye movement exercises (e.g. smooth pursuit eye movements) and also general conditioning exercises (e.g. range of motion exercises, lifting light weights with the arms and legs). This regimen is vestibular neutral in that head movements which specifically challenge the vestibular system are avoided."
16425868|NCT03799978|Experimental|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
16425869|NCT03799978|Experimental|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
16425870|NCT03799965|Active Comparator|ERAS protocol are evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital
~It is to compare the incidences of complications of the groups"
16425871|NCT03799965|Active Comparator|ERAS protocol are not evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital
~It is to compare the incidences of complications of the groups"
16425872|NCT03799952|Experimental|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
16425873|NCT03799952|No Intervention|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
16425874|NCT03799939|Active Comparator|Intervention group|Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.
16425875|NCT03799939|No Intervention|Control group|Participants in control group are operated with no preventive mesh.
16425876|NCT03799926|Experimental|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
16425877|NCT03799926|Experimental|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
16425878|NCT03799926|Experimental|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
16425879|NCT03799926|Experimental|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
16425880|NCT03799926|Experimental|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
16425881|NCT03799926|Experimental|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
16425882|NCT03799926|Experimental|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
16425883|NCT03799926|Experimental|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
16425884|NCT03799913|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
16425885|NCT03799900|Experimental|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
16425886|NCT03799900|Placebo Comparator|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
16425887|NCT03799900|Experimental|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
16425888|NCT03799900|Placebo Comparator|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
16425889|NCT03799900|Experimental|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
16425890|NCT03799900|Placebo Comparator|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
16425891|NCT03799900|Experimental|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
16425892|NCT03799900|Placebo Comparator|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
16425893|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
16425894|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
16425895|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
16425896|NCT03799900|Active Comparator|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
16425897|NCT03799900|Placebo Comparator|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
16425898|NCT03799887|Active Comparator|0% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
16425899|NCT03799887|Experimental|10% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
16425900|NCT03799887|Experimental|20% unweighed BWSTT|20% unweighed Body Weight Supported Treadmill Training
16425901|NCT03799874|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 3 days.
16425902|NCT03799874|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
16425903|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
16425904|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
16425905|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
16425906|NCT03799848|Experimental|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
16425907|NCT03799835|Active Comparator|Arm A : control arm|"BCG therapy only
~BCG therapy will be administered in two phases:
~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)
~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
16425908|NCT03799835|Experimental|Arm B: experimental arm|"BCG therapy + administration of atezolizumab
~BCG therapy will be administered in two phases:
~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)
~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).
~atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum)."
16425909|NCT03799822|Active Comparator|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
16425910|NCT03799822|Experimental|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
16425911|NCT03799822|Experimental|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
16425912|NCT03799809|Active Comparator|Voriconazole|Will receive 400 mg of Intrabronchial Voriconazole every week for 4 weeks along with standard medical therapy.
16425913|NCT03799809|No Intervention|Control|Will receive standard medical therapy alone (hemostatics, anti-tussive and others as deemed appropriate by treating physician)
16425914|NCT03799796|Experimental|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
16425915|NCT03799783|Experimental|Dexmedetomidine|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
16425916|NCT03799757|Active Comparator|Bupivacaine|The wound was installed by 40ml of 0.25% bupivacaine through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes.
16425917|NCT03799757|Placebo Comparator|Placebo|The wound was installed by 40ml of 0.9% normal saline through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes. (placebo group)
16425918|NCT03799744|Experimental|VCN-01 and Durvalumab; concomitant.|Combination VCN-01 (single iv dose) with Durvalumab, Concomitant schedule; Dose Escalation of VCN-01
16425919|NCT03799744|Experimental|VCN-01 and Durvalumab; sequential|Combination VCN-01 (single iv dose) with Durvalumab, Delayed schedule (14 days); Dose Escalation of VCN-01
16425920|NCT03799731|Experimental|Cohort I: GM102 single agent|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22 of each 28-day cycle
16425921|NCT03799731|Experimental|Cohort II: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
16425922|NCT03799718|Experimental|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
16425923|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
16425924|NCT03799692|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
16425925|NCT03799679|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1* 12 cycles ( weekly), followed by epirubicin 90mg/m2, iv, d1 + cyclophosphamide 600mg/m2, iv, d1 * 4 cycles (14 days per cycle)
16425926|NCT03799666|Experimental|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
16425927|NCT03799666|Active Comparator|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
16425930|NCT03799640|Experimental|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
16425931|NCT03799640|Experimental|Educational Control|Lectures on Health and Wellness
16425932|NCT03799627|Experimental|Vadadustat|The initial dose of vadadustat (300, 450, or 600 milligrams [mg]) will be based upon the dose of epoetin alfa dose participants had received prior to vadadustat treatment
16425933|NCT03799627|Experimental|Vadadustat TIW|Participants randomized to vadadustat (Main and erythropoiesis-stimulating agent [ESA] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
16425934|NCT03799627|Active Comparator|Epoetin alfa|Epoetin alfa
16425935|NCT03799614|Experimental|Lower dose vibration|RMBand lower dose vibration
16425936|NCT03799614|Experimental|Higher dose vibration|RMBand higher dose vibration
16425937|NCT03799601|Experimental|combination of docetaxel, carboplatin and anlotinib|
16425938|NCT03799588|Experimental|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
16425939|NCT03799575||A|Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
16425940|NCT03799575||B|Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
16425941|NCT03799562|Experimental|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
16425942|NCT03799562|Placebo Comparator|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
16425943|NCT03799536|Experimental|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16425944|NCT03799536|Active Comparator|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16425945|NCT03799523|Experimental|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
16425946|NCT03799510|Experimental|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
16425947|NCT03799510|Experimental|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
16425948|NCT03799510|No Intervention|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
16425949|NCT03799497||Patients suffering from Anorexia Nervosa|Subjects with a diagnostic of anorexia nervosa disorder
16425950|NCT03799497||Control group|Healthy subjects with no psychiatric disorder
16425951|NCT03799484|Other|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
16425952|NCT03799484|Other|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
16425953|NCT03799471||IBD with MSK pain|IBD patients with self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, MSK pain features, co-morbidity, and IBD features
16425954|NCT03799471||IBD without MSK pain|IBD patients without self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, co-morbidity, and IBD features
16425955|NCT03799471||Healthy Controls|Healthy controls. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, and co-morbidity.
16425956|NCT03799458|Active Comparator|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
16425957|NCT03799458|Sham Comparator|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
16425958|NCT03799458|No Intervention|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
16425959|NCT03799445|Experimental|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
16426043|NCT03798808|No Intervention|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
16426191|NCT03797794|Experimental|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
16425960|NCT03799432|Experimental|TF-CBT Learning collaborative + COAST-IS|In addition to participating in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls, organizations will receive additional training and tailored implementation support.
16425961|NCT03799432|Active Comparator|TF-CBT Learning collaborative|Organizations will participate in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls.
16425962|NCT03799419|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
16425963|NCT03799419|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
16425964|NCT03799419|Experimental|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
16425965|NCT03799419|Sham Comparator|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
16425966|NCT03799406|Active Comparator|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
16425967|NCT03799406|Placebo Comparator|Placebo group|placebo
16425968|NCT03799393|Active Comparator|Control Group|"The control group will receive a brief tablet-based questionnaire followed by standard, paper discharge instructions on car safety. Children ≥13 years old and above will answer questions themselves. They will complete a questionnaire on the usefulness of their discharge education.
~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
16425969|NCT03799393|Experimental|Experimental/CIAS Group|"The Experimental/CIAS Group will receive a brief tablet-based questionnaire followed by the intervention - CIAS, an interactive tablet computer program that gives educational information customized to the patient's age and size. Children ≥13 years old will answer questions and interact with the program themselves. They will complete a questionnaire on the usefulness of their discharge education.
~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
16425970|NCT03799380|Active Comparator|Control - Standard of Care|Standard of care nutritional support
16425971|NCT03799380|Experimental|Experimental - Gatorade|Standard of care nutritional support with the addition of daily Gatorade G2
16425972|NCT03799354|Experimental|Treatment Group|Maximal strenght training (MST) plus endurance training (ET)
16425973|NCT03799354|Active Comparator|Control group|Endurance training (ET)
16425974|NCT03799341|Experimental|Tangible Prize-Based Contingency Management (TangiblePBCM)|For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
16425975|NCT03799341|Experimental|Voucher Prize-Based Contingency Management (VoucherPBCM)|For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
16425976|NCT03799341|Active Comparator|Treatment As Usual (TAU)|Participants in all arms will be engaged with TAU outpatient substance use services and will be recommended to participate in at least two outpatient group and/or individual psychotherapy encounters per week. Participants assigned to the TAU only arm will be asked to engage with recommended outpatient treatment services for 12-weeks (as described above) but will not receive adjunctive PBCM during this time period. Participants in the TAU arm will additionally be asked to provide urine specimens on a twice-weekly basis for lab-based urinalysis. However, these participants will not interact with a CM provider or receive contingent reinforcement based on urinalysis results.
16425977|NCT03799328|Experimental|multi-OIT|Low dose OIT with multiple allergens
16425978|NCT03799315|Experimental|Jail-Based Use of Smoking Cessation Treatment (JUST)|Participants will receive guidline-based smoking cessation counseling while in jail and phone-based smoking cessation counseling sessions and nicotine lozenges after release from jail.
16425979|NCT03799315|No Intervention|Enhanced Treatment As Usual (TAU)|Participants will receive the usual, limited smoking cessation treatment while in jail, plus an additional health and wellness education session in jail. Nicotine lozenges will be offered at the end of the study to those who did not quit smoking.
16425980|NCT03799302|No Intervention|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
16425981|NCT03799302|Experimental|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
16425984|NCT03799276|Experimental|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients
~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
16425985|NCT03799250|Experimental|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.
~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.
~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.
~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.
~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
16425986|NCT03799250|Active Comparator|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
16425987|NCT03799237|Experimental|GOS trap and dengue NS1 antigen kit|Gravid Oviposition Sticky (GOS) traps will be placed to trap adult Aedes mosquitoes and changed weekly. NS1 will be used to detect dengue in trapped Aedes mosquitoes. When dengue NS1 positive mosquitoes are found, community will be alerted via flyers, banners and other means. Routine Aedes/dengue control and surveillance will be carried out as usual as per the current Ministry of Health guidelines.
16425988|NCT03799237|No Intervention|Control|The GOS traps will be placed randomly in the control arm once per month for entomological survey. Routine Aedes control and surveillance will be carried out as per the current Ministry of Health guidelines. Dengue control measure will be initiated by the health authorities when human cases are reported from this arm.
16425989|NCT03799224|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT
~Details:
~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
16425990|NCT03799224|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.
~Details:
~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
16425991|NCT03799211|Experimental|Motivational Interviewing|
16425992|NCT03799211|Active Comparator|Usual Care|
16425995|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
16425996|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
16425997|NCT03799146|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
16425998|NCT03799146|Experimental|Waiting List control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
16425999|NCT03799133|Experimental|Patients with Florence device|Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.
16426000|NCT03799120|Placebo Comparator|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
16426001|NCT03799120|Experimental|tamsulosin BID|0.4 mg tamsulosin BID
16426002|NCT03799107||Retrospective|Children born with assistance
16426003|NCT03799107||Prospective|People who have sought evaluation/treatment for infertility
16426004|NCT03799094|Experimental|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
16426005|NCT03799094|Experimental|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
16426006|NCT03799081|Other|Fetoscopy in missed abortion|Women who have decided to undergo fetoscopy in missed abortion
16426007|NCT03799068|Active Comparator|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
16426008|NCT03799068|Active Comparator|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
16426009|NCT03799055||easy intubation|Cormack _Lehane : 1&2
16426010|NCT03799055||difficult intubation|Cormack _Lehane : 3&4
16426011|NCT03799042|Experimental|Vitural Reality|Virtual Reality 3D glass
16426012|NCT03799042|Active Comparator|Inter-generation interaction|Elders-teenager interaction
16426013|NCT03799029|Active Comparator|active control group low-intensity|Low intensity version of the same cognitive training program Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
16426014|NCT03799029|Experimental|experimental training group cognitive training|a multifactorial cognitive program that tackles working memory, attention, inhibition, planification and reasoning Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
16426015|NCT03799029|No Intervention|control healthy participants|Just a control group including healthy participants No intervention
16426016|NCT03799003|Experimental|ASP1951 Monotherapy Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1951.Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
16426017|NCT03799003|Experimental|ASP1951 Monotherapy Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in a monotherapy or combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
16426018|NCT03799003|Experimental|ASP1951 Optional Monotherapy Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
16426019|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Escalation|The combination escalation cohort will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
16426020|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in the combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable. Once the high dose RP2D and schedule of ASP1951 in combination with pembrolizumab has been determined, expansion cohorts may be opened to enroll participants with NSCLC (all PD-L1 status), NSCLC PD-L1 high, SCCHN and cervical cancer (if any of these tumor specific expansion cohorts are not already opened). Also, low dose cohorts of ASP1951 in combination will be opened in NSCLC (all PD-L1 status), SCCHN and cervical cancer for further evaluation of response and safety and establishing a possible low dose RP2D based on clinical and biomarker activity.
16426021|NCT03799003|Experimental|ASP1951 plus pembrolizumab Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
16426022|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
16426023|NCT03798964||Elective term cesarean|Low-risk women undergoing elective term cesarean section
16426024|NCT03798964||Term vaginal delivery|Low-risk women undergoing term vaginal delivery
16426025|NCT03798964||Preterm vaginal delivery|Women undergoing preterm vaginal delivery
16426026|NCT03798951|Experimental|Prehabilitation program|The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient. The program will have a duration of, at least, 4 weeks.
16426027|NCT03798951|No Intervention|Control|The patients included in this group will, also, receive a basal evaluation by a physiotherapist, a nutritionist and a psychologist. These patients will not receive a tailored prehabilitation program and will be revaluated the day before surgery.
16426028|NCT03798912|Active Comparator|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
16426029|NCT03798912|Experimental|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
16426030|NCT03798912|Experimental|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
16426031|NCT03798912|Experimental|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
16426032|NCT03798899|Experimental|Penthrox® (Methoxyflurane)|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.
~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).
~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
16426033|NCT03798899|Placebo Comparator|Normal Saline|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.
~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).
~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
16426034|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
16426035|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
16426036|NCT03798873|Experimental|FeelWell™ Compression garment use with increase mobility|"Subjects are randomized to wear custom-fitted FeelWell™ Compression garment daily during regular and exercise activities.
~Subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity."
16426037|NCT03798873|Other|Increase mobility|For the control group, subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity. The control group will not be assigned a compression garment during the trial.
16426038|NCT03798834|Experimental|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
16426039|NCT03798834|Placebo Comparator|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
16426040|NCT03798821|Experimental|Experimental|One capsule a day will be consumed. At breakfast for the six weeks.
16426041|NCT03798821|Placebo Comparator|Comparator|One capsule a day will be consumed. At breakfast for the six weeks.
16426042|NCT03798808|Experimental|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
16426044|NCT03798782|Experimental|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
16426045|NCT03798782|Active Comparator|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
16426046|NCT03798769|Experimental|Supportive Oncology Care at Home|"The Supportive Oncology Care at Home intervention entails the following:
~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers for phone calls and home visits by Medically Home based on a clinician-derived algorithm
~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;
~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
16426047|NCT03798743|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
16426048|NCT03798730|Experimental|Solid Model|"Cake
~-Control Vanilla Cake and Protein Fortified Vanilla Cake
~Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
16426049|NCT03798730|Experimental|Liquid Model|"Whey Protein Beverages
~Native sample (protein unheated)
~Denatured whey protein (protein heated to denature)"
16426050|NCT03798717|No Intervention|Control|Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
16426051|NCT03798717|Experimental|Pre OGTT|Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
16426052|NCT03798717|Experimental|Post OGTT|Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
16426053|NCT03798691|Active Comparator|Anti-TNF monotherapy|Patients with IBD on Anti-TNF monotherapy will be given the shingrix vaccine. Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
16426054|NCT03798691|Active Comparator|Vedolizumab|"Patients with IBD on vedolizumab monotherapy will be given the shingrix vaccine.
~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
16426055|NCT03798678|Experimental|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
16426056|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
16426057|NCT03798639|Experimental|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
16426058|NCT03798639|Active Comparator|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
16426063|NCT03798613|Active Comparator|Apple Watch 4 Series Device|Apple watch 4 series heart rate monitoring device
16426064|NCT03798613|Active Comparator|Continuous Telemetry|Standard continuous telemetry monitoring device
16426065|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.
~Inclusion Criteria:
~Adult ICU patients (>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).
~Exclusion criteria:
~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score > 6)"
16426098|NCT03798353|Active Comparator|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
16426099|NCT03798340|Experimental|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
16426100|NCT03798340|Active Comparator|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
16426101|NCT03798327|Experimental|Home Palliative Care|Randomized to Intervention Arm
16426066|NCT03798587||OS patients|"Patients with age ≥18 years that were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).
~Patients with age <18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.
~The target group corresponds to patients hospitalized at Istituto Ortopedico Galeazzi, undergoing surgical eradication of primary osteosarcoma.
~Patients will be considered eligible for enrollment in the study if able to sign the consent to the procedure after appropriate information from the reference surgeon or signed by parents or legal guardian after appropriate information from the reference surgeon (if age <18).
~Inclusion Criteria:
~Indication for primary OS eradication surgery
~Patients hospitalized in Istituto Ortopedico Galeazzi
~Exclusion criteria:
~-Patients not able to sign the Informed Consent."
16426067|NCT03798574||IMD Case|No intervention
16426068|NCT03798574||Control|No intervention
16426069|NCT03798561|Experimental|82 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 82 µg/cm2 single application in 7 days or Placebo TG (6 subjects ASN008: 2 subjects placebo) (6:2)
16426070|NCT03798561|Experimental|164 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 164 µg/cm2 single application in 7 days or Placebo (6:2)
16426071|NCT03798561|Experimental|328 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 328 µg/cm2 single application in 7 days or Placebo (6:2)
16426072|NCT03798561|Experimental|492 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 492 µg/cm2 single application in 7 days or Placebo (6:2)
16426073|NCT03798561|Experimental|ASN008 TG TBD Cohort 1 or Placebo|Part B: ASN008 TG Cohort 1 daily application for 15 days or Placebo (9 subjects ASN008: 3 subjects Placebo) (9:3)
16426074|NCT03798561|Experimental|ASN008 TG TBD Cohort 2 or Placebo|Part B: ASN008 TG Cohort 2 daily application for 15 days or Placebo (9:3)
16426075|NCT03798561|Experimental|ASN008 TG TBD Cohort 3 or Placebo|Part B: Placebo TG Cohort 3 daily application for 15 days or Placebo (9:3)
16426076|NCT03798548|Experimental|Brief Bedside CBT|
16426077|NCT03798548|No Intervention|Treatment As Usual|
16426078|NCT03798522|Experimental|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
16426079|NCT03798522|Active Comparator|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
16426080|NCT03798509|Experimental|Human CD19 targeted T Cells Injection|
16426081|NCT03798483|Experimental|Individualized exercise|Participants after a lateral kneecap dislocation will be enrolled into an individualized exercise intervention supervised by a physiotherapist
16426082|NCT03798470|Experimental|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
16426083|NCT03798457||Patients with CAP hospitalized in IM|Data of Patients with Community-acquired pneumonia (CAP) hospitalized in Internal Medicine Units will be collected for this study; no intervention is planned for this study
16426084|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score>-2.5.
16426085|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
16426086|NCT03798431|Experimental|M-ROCC|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
16426087|NCT03798418|Active Comparator|exercise group|elastic band strengthening exercise
16426088|NCT03798418|Experimental|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
16426089|NCT03798405|Experimental|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:
~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
16426090|NCT03798405|No Intervention|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
16426091|NCT03798392|Active Comparator|SP group|
16426092|NCT03798392|Active Comparator|Baska group|
16426093|NCT03798379|Active Comparator|Exercise group|Eligible patients who were planned to receive neurotoxic chemotherapy
16426094|NCT03798379|No Intervention|Control group|Patients eligible for the study and received the 3rd cycle of chemotherapy
16426095|NCT03798366|Experimental|GLPG1690 600 mg|Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.
16426096|NCT03798366|Placebo Comparator|Placebo|Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.
16426097|NCT03798353|Experimental|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.
~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
16426102|NCT03798327|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their dementia and other illnesses.
16426103|NCT03798314|Experimental|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
16426104|NCT03798301|Experimental|Treatment Arm|Suspension of CMV-specific T-cells in 10 mL of 0.9% NaCl with 2% HSA. Single dose max. 25,000 T cells/kg body weight (BW) of the recipient delivered via IV bolus injection.
16426105|NCT03798288|Experimental|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.
~The weekly plan includes three categories of content;
~information/education
~recommended daily number of steps
~recommended strength and flexibility exercises"
16426106|NCT03798288|Active Comparator|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
16426107|NCT03798275|Active Comparator|the study group|healthy pregnant women with borderline oligohydramnios who accept to drink a cup of coffee
16426108|NCT03798275|No Intervention|the control group|healthy pregnant women with normal amniotic volume
16426109|NCT03798262|Active Comparator|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
16426110|NCT03798262|Placebo Comparator|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
16426111|NCT03798249|Active Comparator|Gluten|Patients will receive acutely 16 g of gluten and 2 muffins glutenfree with 8 g of gluten, twice a day, during 5 days
16426112|NCT03798249|Placebo Comparator|Placebo|Patients will receive acutely 16 g of whey protein and 2 glutenfree muffins, twice a day, during 5 days
16426113|NCT03798236|Experimental|PBF-1650 40mg|
16426114|NCT03798236|Experimental|PBF-1650 80mg|
16426115|NCT03798236|Experimental|PBF-1650 120mg|
16426116|NCT03798236|Experimental|PBF-1650 240mg|
16426117|NCT03798236|Placebo Comparator|Placebo|
16426118|NCT03798223|Experimental|180/low|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
16426119|NCT03798223|Experimental|180/high|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
16426120|NCT03798223|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
16426121|NCT03798223|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
16426122|NCT03798210|Placebo Comparator|Placebo|Look and taste-alike placebo tablets in white plastic vials.
16426123|NCT03798210|Experimental|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
16426124|NCT03798197|Active Comparator|30 mg estetrol (E4) without food (fasted)|Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.
16426125|NCT03798197|Experimental|30 mg estetrol (E4) with food (fed)|Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.
16426126|NCT03798184|Experimental|Selective-etch with bioglass surface roughening|
16426127|NCT03798184|Active Comparator|Selective-etch without bioglass surface roughening|
16426128|NCT03798184|Experimental|Self-etch with bioglass surface roughening|
16426129|NCT03798184|Active Comparator|Self-etch without bioglass surface roughening|
16426130|NCT03798145|Experimental|Surgical Retinotomy|Surgical retinotomy will be constructed in the area of the scotoma.
16426131|NCT03798119|Experimental|Switch to TAF|Subjects who meet the inclusion and exclusion criteria will switch prior NUCs to TAF 25 mg/day for 96 weeks
16426132|NCT03798106|Experimental|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
16426133|NCT03798093|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
16426134|NCT03798093|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
16426135|NCT03798080|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning with or without metformin for 30 weeks
16426136|NCT03798080|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day with or without metformin for 30 weeks
16426137|NCT03798054|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
16426138|NCT03798054|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
16426139|NCT03798054|Active Comparator|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
16426140|NCT03798041|Experimental|Debridement group|The subjects in this group will be debrided within 24 hours after surgery.
16426141|NCT03798041|No Intervention|Control group|The subjects in this group will experience wound dressing change regularly 24 hours after surgery.
16426142|NCT03798028|Experimental|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.
16426143|NCT03798028|No Intervention|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
16426144|NCT03798015||mitral valve surgery|outcome of mitral valve surgery (stroke yes or no)
16426145|NCT03798002|Experimental|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
16426146|NCT03798002|Active Comparator|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
16426147|NCT03797989|Experimental|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
16426148|NCT03797989|Experimental|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
16426149|NCT03797989|Experimental|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
16426150|NCT03797989|Experimental|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
16426151|NCT03797989|Experimental|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
16426152|NCT03797989|Experimental|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately sixteen months (and up to twenty months) later after their secondary challenge.
16426153|NCT03797989|Experimental|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
16426154|NCT03797989|Experimental|Phase C: Group 9|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
16426155|NCT03797989|Experimental|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately five months (and up to ten months) after their secondary challenge.
16426156|NCT03797989|Experimental|Phase D: Group 10|The four to eight volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
16426157|NCT03797989|Experimental|Phase D: Group 12|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
16426158|NCT03797989|Experimental|Phase E: Group 11|The four to eight volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
16426159|NCT03797989|Experimental|Phase E: Group 13|The four to eight volunteers from Group 12 in Phase D will undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 13 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
16426160|NCT03797989|Experimental|Phase E: Group 15|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 11 and 13.
16426161|NCT03797989|Experimental|Phase F: Group 14|The four to eight volunteers from Group 13 in Phase E will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 14 in Phase F. This will occur approximately five months (and up to ten months) after their secondary challenge.
16426162|NCT03797989|Experimental|Phase F: Group 16|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 14.
16426163|NCT03797976|Experimental|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
16426164|NCT03797963|Active Comparator|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
16426165|NCT03797963|Experimental|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
16426166|NCT03797950|No Intervention|Control|No active intervention
16426639|NCT03794635|Experimental|Caregivers|Caregivers of Latino/a advanced cancer patients
16426167|NCT03797950|Experimental|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
16426168|NCT03797950|Experimental|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
16426169|NCT03797937|Experimental|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
16426170|NCT03797937|No Intervention|Healthy controls|Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
16426171|NCT03797937|No Intervention|Multiple sclerosis (MS) patients undergoing a relapse|Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
16426172|NCT03797937|No Intervention|Multiple sclerosis (MS) patients from multiplex MS families|Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
16426173|NCT03797924|Active Comparator|ICBN with ropivacaine|Participants will receive ICBN with ropivacaine. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
16426174|NCT03797924|Placebo Comparator|No ICBN block|Participants will have the site prepped, but no ICBN block given. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
16426175|NCT03797911|Experimental|active resistive capacitive monopolar radiofrequency|"Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): The intervention group will receive the treatment with activated resistive capacitive monopolar radiofrequency system, with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.
~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
16426176|NCT03797911|Placebo Comparator|Inactive resistive capacitive monopolar radiofrequency|"Application of the technique in the control group (inactivated resistive capacitive monopolar radiofrequency therapy): The control group will receive the treatment with inactivated resistive capacitive monopolar radiofrequency system (placebo), with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.
~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
16426177|NCT03797898|Experimental|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
16426178|NCT03797898|No Intervention|Control|usual care well child care
16426179|NCT03797885||Patients with type 2 diabetes mellitus (T2DM)|Patients with type 2 diabetes, at the hospital setting.
16426180|NCT03797885||Patients with T2DM and established cardiovascular disease|Subgroup of patients with type 2 diabetes and established cardiovascular disease
16426181|NCT03797872|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice. Commonly Initial therapy will be with methotrexate alone unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (sulfasalazine or leflunomide). In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
16426182|NCT03797872|Experimental|Local/IM steroid injections|Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local injections of methylprednisolone or triamcinolone to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication. All active joints will be treated with injections. Injections can be either be given as an intra-articular injection or as an intra-muscular injection. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy).
16426183|NCT03797846|Active Comparator|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
16426184|NCT03797846|Active Comparator|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
16426185|NCT03797833|No Intervention|Standard treatment|ECV according to standard practice.
16426186|NCT03797833|Active Comparator|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
16426187|NCT03797807|Experimental|MINST|Minimally invasive non surgical treatment
16426188|NCT03797807|Active Comparator|MIST|Minimally invasive surgical treatment
16426189|NCT03797807|Active Comparator|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
16426190|NCT03797807|Active Comparator|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
16426192|NCT03797794|Sham Comparator|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
16426193|NCT03797781|Experimental|High protein|
16426194|NCT03797781|Experimental|Low protein|
16426195|NCT03797781|Experimental|Minimum protein|
16426196|NCT03797768|Experimental|Intervention|
16426197|NCT03797768|No Intervention|Control|
16426198|NCT03797755||Palliative Cancer Patients|Stage IV cancer patients evaluated for palliative radiotherapy.
16426199|NCT03797742||NC|Patients without heart failure.
16426200|NCT03797742||DCM|Dilated cardiomyopathy patients.
16426201|NCT03797742||ICM|Ischemic cardiomyopathy patients.
16426202|NCT03797729|Placebo Comparator|Normal saline|
16426203|NCT03797729|Experimental|Tirofiban|
16426204|NCT03797716|No Intervention|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.
~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.
~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
16426205|NCT03797716|Experimental|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
16426206|NCT03797703|Experimental|Treatment|Patients will be randomly allocated into the treatment group. The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
16426207|NCT03797703|No Intervention|Control|Patients will be randomly allocated into the control group. The control group will not receive a rectal enema.
16426208|NCT03797690|Experimental|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure. End of treatment will be considered as the last session of needle aponeurotomy.
16426209|NCT03797690|Active Comparator|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy). End of surgical treatment will be considered as the removal of the stitches (two weeks after the surgical treatment).
16426210|NCT03797677|Experimental|Home based airway clearance with Metaneb|"Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
~The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment."
16426211|NCT03797664|Experimental|Experimental: CDX-6114|7.5, 15.0 and 22.5g
16426212|NCT03797664|Placebo Comparator|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
16426213|NCT03797651|Active Comparator|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
16426214|NCT03797651|Experimental|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
16426215|NCT03797638|Experimental|Patients with writer's cramp|Patients with writer's cramp
16426216|NCT03797638|Other|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
16426217|NCT03797625|Experimental|Endostar Combined With IP|Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1
16426218|NCT03797612|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
16426219|NCT03797612|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
16426220|NCT03797599|Experimental|20 minutes of mindfulness practice|Two sessions a week for two weeks of: 5 minutes listening to audio book excerpts followed by 20 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
16426221|NCT03797599|Active Comparator|5 minutes of mindfulness practice|Two sessions a week for two weeks of: 20 minutes listening to audio book excerpts followed by 5 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
16426222|NCT03797599|Placebo Comparator|Audio book control|Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
16426253|NCT03797339||Validation corhort|3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort. During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
16426223|NCT03797586|Experimental|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal , where patients will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
16426224|NCT03797586|Sham Comparator|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
16426225|NCT03797573|Active Comparator|active tDCS|Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
16426226|NCT03797573|Sham Comparator|sham tDCS|Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
16426227|NCT03797560|Experimental|Ba-Duan-Jin group|"Ba-Duan-Jin therapy: The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital.
~Placebo pregabalin capsules: Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks."
16426228|NCT03797560|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.
~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
16426229|NCT03797534|No Intervention|Standard anticoagulant group|
16426230|NCT03797534|Experimental|Bayesian model group|
16426235|NCT03797508|Other|threatened miscarriage|ultrasound ,CA125,progesterone
16426236|NCT03797482||Intra-operative tumour tissue biopsies|Intra-operative tumour tissue biopsies will be collected for all patients
16426237|NCT03797469|Active Comparator|Nicotinamide and Pyruvate (N&P)|This group will receive two separate sets of tablets containing 3 x 1000 mg of Vitamin B3 (nicotinamide) and 2 x 1500 mg of Pyruvate.
16426238|NCT03797469|Placebo Comparator|Placebo|This group will receive an equal number of tablets as the N&P group.
16426239|NCT03797456|Experimental|ICP-022|
16426240|NCT03797443|Experimental|AA NABPLAGEM|Ascorbic Acid Paclitaxel protein-bound cisplatin gemcitabine
16426241|NCT03797417||Disease|patients with vitiligo
16426242|NCT03797417||Healthy Control|healthy control
16426243|NCT03797404||Mepolizumab|Patients receiving mepolizumab
16426244|NCT03797404||Patients w/o mepolizumab (retrospective)|Retrospective control group of patients not exposed to mepolizumab, included in the COBRA cohort and the ASMATHERM protocol, who had 2 sets of biopsies and BAL within a 6 to 12 month-interval, without change in their treatment. Clinical data for this patients are available at inclusion and after 12 months.
16426245|NCT03797391|Experimental|Dose Escalation-Part 1, Expansion-Part 2|"In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.
~In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks)."
16426248|NCT03797365|Active Comparator|Classical rehabilitation|Twenty women will benefit from two-phases perineal rehabilitation: first phase pelvic floor muscles (PFM)'s analytic rehabilitation, then a functional rehabilitation.
16426249|NCT03797365|Experimental|Classical and cognitive associated rehabilitation|Twenty women will receive, added to the classic perineal rehabilitation, the cognitive rehabilitation and will have to execute twice a day the rehabilitation protocol.
16426250|NCT03797352|No Intervention|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
16426251|NCT03797352|Experimental|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
16426252|NCT03797339||Discovery cohort|1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
16426256|NCT03797313||Patient's expectations met at Hospital discharge|ARF survivors whose expectations for recovery at hospital discharge are fully met 6 months later.
16426257|NCT03797313||Patient's with unmet expectations at Hospital Discharge|ARF survivors whose expectations for recovery at hospital discharge are not fully met 6 months later.
16426258|NCT03797300|Experimental|Primary|
16426259|NCT03797287|Experimental|Tensor Tunnler|The Tensor Tunneler (Chattanooga, TN) will be used to create the bone tunnels during the arthroscopic procedure. This is an FDA approved device and is used currently in routine clinical practice.
16426260|NCT03797287|Active Comparator|Smith and Nephew PEEK Helicoil Anchor|The anchors used in this trial are FDA approved and are used currently in routine clinical practice (Anchor Rotator Cuff Repair).
16426262|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
16426263|NCT03797248||Cohort 2|adjuvant chemotherapy only
16426264|NCT03797235|Experimental|Dominant Arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the dominant forearm
16426265|NCT03797235|Active Comparator|Non-dominant arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the non-dominant forearm.
16426266|NCT03797222|Experimental|Vitamin E Supplementation|Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.
16426267|NCT03797209|Experimental|AXIOS Patient|
16426268|NCT03797196|Active Comparator|group 1|standard tacrolimus with mycophenolate mofetil
16426269|NCT03797196|Experimental|group 2|low dose tacrolimus with everolimus
16426270|NCT03797183||Premature Infants|Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
16426271|NCT03797183||Chronic Respiratory Disease|Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
16426272|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
16426273|NCT03797183||Healthy Controls|Age and height matched healthy controls
16426274|NCT03797157|Experimental|H2MF|Human milk-based breast milk fortifier
16426275|NCT03797157|Active Comparator|Standard fortifier|Standard care: bovine milk-based breast milk fortifier
16426276|NCT03797144|Experimental|Fenestrated Screw System|
16426277|NCT03797131|Experimental|KB195 Arm|
16426278|NCT03797118|Experimental|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
16426279|NCT03797105|No Intervention|Control, 0 days|control group, no intervention
16426280|NCT03797105|Experimental|1 day|received the intervention 1 day/week
16426281|NCT03797105|Experimental|3 days|received the intervention 3 days/week
16426282|NCT03797105|Experimental|5 days|received the intervention 5 days/week
16426283|NCT03797092|Active Comparator|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
16426284|NCT03797092|No Intervention|Control group|No treatment
16426285|NCT03797079|Active Comparator|Group A (ESP block)|Ultrasound-guided ESP block will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
16426286|NCT03797079|Active Comparator|Group B (TEA)|TEA will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
16426287|NCT03797053||Cohort 1 : metastatic cohort|Cohort1: Cohort of patients with stage III inoperable or IV metastatic melanoma This cohort will enable the achievement of objectives 1 (proof of concept) and 2 (establishment of prognostic and predictive value).
16426288|NCT03797053||Cohort 2 : adjuvant cohort|"Cohort 2: Cohort of patients with melanoma who are candidates for sentinel lymph node analysis.
~This group includes patients with melanoma in whom sentinel lymph node testing is performed. According to current French recommendations, these are patients whose primary melanoma has a Breslow index (thickness) of more than 1 mm or ulcerated primary melanoma (loss of the epidermis)."
16426289|NCT03797040|Experimental|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
16426290|NCT03797027|Other|No cushion|Patients in no cushion group undergo prone percutaneous nephrolithotomy without an abdominal cushion
16426291|NCT03797027|Other|5 cm cushion|Patients in 5 cm cushion group undergo prone percutaneous nephrolithotomy with an 5 cm abdominal cushion
16426292|NCT03797027|Other|10 cm cushion|Patients in 10 cm cushion group undergo prone percutaneous nephrolithotomy with an 10 cm abdominal cushion
16426293|NCT03797014|Experimental|B/F/TAF|Treatment group (1-arm study)
16426294|NCT03797001|Experimental|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
16426295|NCT03797001|Placebo Comparator|placebo|Placebo subcutaneous injection, daily for 24 weeks
16426296|NCT03796988|Experimental|Intervention arm|The donor area will be anesthetized with injected local anesthesia, harvested with the ART device, and bandaged with an occlusive dressing. The skin harvested will be placed on the recipient wound area. The area will be bandaged will a non-stick silicone dressing (covered by appropriate primary and secondary dressings) and left intact for 1-7 days.
16426297|NCT03796975|Experimental|Combination of Pioglitazone and Metformin Tablets|dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
16426640|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
16426298|NCT03796975|Active Comparator|Metformin Hydrochloride Tablets|dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
16426299|NCT03796962|Experimental|25 mg XEN1101|Capsule filled with 25 mg XEN1101
16426300|NCT03796962|Experimental|20 mg XEN1101|Capsule filled with 20 mg XEN1101
16426301|NCT03796962|Experimental|10 mg XEN1101|Capsule filled with 10 mg XEN1101
16426302|NCT03796962|Placebo Comparator|Placebo|Placebo capsule
16426303|NCT03796949||threatened preterm birth|Women with either preterm labor or preterm prelabor rupture of the membranes. Blood samples taken at time of inclusion in the study.
16426304|NCT03796949||Controls|Women with normal pregnancies. Blood samples taken at time of inclusion in the study, either prelabor (during pregnancy) or during active phase of labor.
16426305|NCT03796936|Experimental|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
16426306|NCT03796936|Active Comparator|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
16426307|NCT03796923|Active Comparator|Intervention I|Intervention (I): early follow-up visit from the community nurse within 24 hours after discharge
16426308|NCT03796923|Experimental|Intervention II|Intervention (II): early follow-up by the geriatric team within 24 hours after discharge
16426309|NCT03796923|Other|Control|Usual care: individualized follow-up performed by the GP and municipality services
16426310|NCT03796910|Experimental|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
16426311|NCT03796910|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
16426312|NCT03796910|Experimental|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
16426313|NCT03796910|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
16426314|NCT03796897|Experimental|Leucine-enriched protein + exercise|whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
16426315|NCT03796897|Sham Comparator|Habitual diet + exercise|habitual diet only
16426316|NCT03796884|Experimental|Arm I (linaclotide)|Patients receive linaclotide PO daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
16426317|NCT03796884|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
16426318|NCT03796871|Experimental|Dermapol|Use of the experimental medical device
16426319|NCT03796858|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).
16426320|NCT03796858|Experimental|Group 2: Placebo followed by Guselkumab|Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.
16426321|NCT03796845|Experimental|No-limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
16426322|NCT03796845|Active Comparator|Limited movement after surgery|Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
16426323|NCT03796832|Experimental|Flat Flexible Shoes+Exercise Therapy|This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
16426324|NCT03796832|Active Comparator|Stable Supportive Shoes+Exercise Therapy|This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
16426325|NCT03796819|Experimental|lymphadenectomy|This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
16426326|NCT03796819|No Intervention|No lymphadenectomy|This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
16426327|NCT03796793|Experimental|Wound Edge Debridement Group|Participants in this group will receive wound edge debridement in addition to standard of care (SOC) treatment for up to 4 weeks.
16426328|NCT03796793|Active Comparator|Standard care group|Participants in this group will receive only the standard care of treatment for up to 4 weeks.
16426329|NCT03796780|Active Comparator|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
16426330|NCT03796780|Placebo Comparator|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
16426331|NCT03796767|Experimental|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
16426332|NCT03796767|Experimental|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
16428826|NCT03779295|Experimental|Pulse laser therapy applied to right side of face|
16426333|NCT03796767|Experimental|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
16426334|NCT03796754|Active Comparator|YoBEKA Intervention|
16426335|NCT03796754|No Intervention|Control group|
16426336|NCT03796728|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Initial treatment with Juvéderm® VOLIFT™ with Lidocaine injectable gel to augment the lips on Day 1, with an optional touch-up treatment 14 days later, if applicable. Volume was determined by the Investigator not to exceed 3.0 milliliters (mL).
16426337|NCT03796715||Red Cell Distribution Width (RDW)|RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
16426338|NCT03796715||Presepsin (sCD14-ST)|Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
16426339|NCT03796702|Experimental|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
16426340|NCT03796702|Experimental|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
16426343|NCT03796676|Placebo Comparator|Placebo|Placebo
16426344|NCT03796676|Experimental|PF-04965842 100 mg QD|active
16426345|NCT03796676|Experimental|PF-04965842 200 mg QD|active
16426346|NCT03796663|Active Comparator|Mindful Parenting Only|"Participants in this arm will receive only the Mindful Parenting Program at the start of the study. Bögels and Restifo's (2014) Mindful Parenting Program is an adaptation for parents of MBCT, and MBSR; the program will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.
~Following the completion of the Mindful Parenting Sessions, participants in this arm will be asked continue to participate in data collection for the post-intervention assessment time point (i.e. 8 weeks after the completion of the Mindful Parenting group sessions) and for the 2-month follow up assessment time point (i.e. 16 weeks after the completion of the Mindful Parenting group sessions). After they have completed both assessments, they will be offered the opportunity to participate in the MATCH BPT program if they so choose (no data will be collected)."
16426347|NCT03796663|Experimental|Mindful Parenting and BPT Combined|"Participants in this arm will receive the Mindful Parenting Program at the start of the study, which will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.
~Following the completion of the Mindful Parenting Sessions, participants in this arm will receive receive individually-implemented MATCH BPT sessions, which will consist of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 1 hour sessions. The MATCH manual is comprised of 33 modules (i.e. coping, giving effective instructions, learning to relax, etc.). For the purpose of this study we will be utilizing the section on BPT, which consists of 12 modules with corresponding handouts and worksheets."
16426348|NCT03796650|Experimental|Fecal microbiota transplantation|Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
16426349|NCT03796650|Active Comparator|Antibiotic treatment|Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.
16426350|NCT03796637|Experimental|nmDMD Participants|Participants who have been receiving ataluren, dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for >=9 months from ongoing PTC-sponsored nmDMD clinical trials.
16426351|NCT03796624|Experimental|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
16426352|NCT03796624|Active Comparator|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
16426353|NCT03796611||multiple sclerosis patient|MS is defined according to McDonald criteria 2017. MS patients included have a disease duration of less than 1 year
16426354|NCT03796611||other neurological inflammatory disease|autoimmune encephalitis, myasthenia gravis, chronic inflammatory demyelinating polyradiculitis
16426355|NCT03796611||neurological non inflammatory disease|benign intracranial hypertension, degenerative disorder
16426356|NCT03796611||healthy controls|transfusion volunteers from transfusion center
16426357|NCT03796598|Placebo Comparator|Placebo|Oral and rectal placebo at visit 2 Oral placebo at day 30
16426358|NCT03796598|Active Comparator|Group 3: Oral placebo and rectal FMT|Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
16426359|NCT03796598|Active Comparator|Group 2: Oral FMT and rectal placebo|Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
16426360|NCT03796598|Experimental|Group 1: Dual Oral and rectal FMT|Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
16426361|NCT03796585|Experimental|Intervention|Pharmacists assigned to this group will receive an immunization registry training program and informational flyer.
16426362|NCT03796585|Active Comparator|Control|Pharmacists assigned to this group will receive an informational flyer. They will not receive training.
16426363|NCT03796572|Experimental|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
16426364|NCT03796572|Sham Comparator|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
16426365|NCT03796559|Experimental|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
16426366|NCT03796533|Other|Posaconazole pharmacokinetics|Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
16426641|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
16426367|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
16426368|NCT03796507|Experimental|Temozolomide Arm|This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.
16426369|NCT03796494|Active Comparator|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
16426370|NCT03796494|Experimental|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
16426371|NCT03796481||Cases|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) with comorbid insomnia
16426372|NCT03796481||Controls|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) without comorbid insomnia
16426373|NCT03796468|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
16426374|NCT03796468|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best treatment medical
16426375|NCT03796455|Experimental|Fish Oil|2.0 g EPA + DHA / day + placebo powder
16426376|NCT03796455|Experimental|Fish Oil and HMB|2.0 g EPA + DHA + 3.0 g HMB / day
16426377|NCT03796455|Placebo Comparator|Placebo|3 g/d soy oil: corn oil (50:50 ratio) + placebo powder
16426378|NCT03796442|Experimental|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
16426379|NCT03796442|Active Comparator|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
16426380|NCT03796429|Experimental|GS+Toripalimab|
16426381|NCT03796416|Active Comparator|misoprostol|"Induction using misoprostol:
~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
16426382|NCT03796416|Experimental|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:
~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.
~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
16426383|NCT03796403|Experimental|diclofenac and bupivacaine group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
16426384|NCT03796403|Placebo Comparator|bupivacaine only group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.
16426385|NCT03796390|Experimental|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
16426386|NCT03796377|Other|Rivaroxaban|Single oral dose of 20 mg rivaroxaban
16426387|NCT03796377|Other|Rivaroxaban after CYP- and P-gp induction|Single oral dose of 20 mg rivaroxaban after pretreatment with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
16426388|NCT03796364|Active Comparator|control group|standard SRILI treatment
16426389|NCT03796364|Experimental|observation group|Endostar® plus standard treatment
16426390|NCT03796351|Experimental|MT10107(botulinum toxin type A)|Subjects will be administered a single equivalent dose of MT10107 by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
16426391|NCT03796351|Active Comparator|BOTOX® 50U(botulinum toxin type A)|Subjects will be administered a single equivalent dose of BOTOX® 50U by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
16426392|NCT03796338||Critically ill patients|age > 18 years
16426393|NCT03796325||Depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities and depression
16426394|NCT03796325||No-depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities without depression
16426395|NCT03796312|Experimental|Tub Bathing|In this group, preterm infants were given tub bathing.
16426396|NCT03796312|Active Comparator|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
16426397|NCT03796299||1|Patients with bladder cancer
16426398|NCT03796299||2|Patients with upper urinary tract cancer
16426399|NCT03796299||3 (control)|Controls
16426400|NCT03796286|Placebo Comparator|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
16426401|NCT03796286|Experimental|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
16426402|NCT03796286|Experimental|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
16426403|NCT03796273|Experimental|Arm I (ketoconazole)|Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
16426404|NCT03796273|Active Comparator|Arm II (standard surgery)|Patients undergo standard surgery.
16426405|NCT03796260|Experimental|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
16426470|NCT03795844|Active Comparator|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
16426406|NCT03796260|Experimental|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
16426407|NCT03796247||multiple sclerosis|
16426408|NCT03796247||healthy control|
16426409|NCT03796234|Experimental|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
16426410|NCT03796234|Experimental|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
16426411|NCT03796221|Active Comparator|Control Group|Will receive standard pediatric obesity treatment
16426412|NCT03796221|Experimental|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
16426413|NCT03796208|Experimental|Tobacco Intervention|Participants in this group will be randomized to the Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC) intervention.
16426414|NCT03796208|Active Comparator|Treatment As Usual|Participants in this group will be randomized to tobacco treatment as usual.
16426415|NCT03796195|Experimental|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
16426416|NCT03796182|Experimental|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
16426417|NCT03796182|Experimental|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
16426418|NCT03796169|Experimental|Endoscopist|Intervention for personal notification, open notification and colonoscopy quality education by a GI faculty
16426419|NCT03796156|Experimental|Aspirin|75mg of non enteric coated aspirin once daily added to usual medications
16426420|NCT03796156|No Intervention|Usual care|Usual medications only
16426421|NCT03796143|Experimental|ACT self-help book condition|Participants in this condition will be asked to read The Mindfulness and Acceptance Workbook for Depression by Strosahl and Robinson (2008), a self-help book based on acceptance and commitment therapy.
16426422|NCT03796143|Active Comparator|CBT self-help book condition|Participants in this condition will be asked to read Cognitive Behavioral Workbook for Depression by Knaus (2006), a self-help book based on acceptance and commitment therapy.
16426423|NCT03796143|Other|Choice of two self-help books|Participants in this condition will have the option of receiving either the self-help book by Strosahl and Robinson (2008) or the book by Knaus (2006).
16426424|NCT03796130|Experimental|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm
~The participants will be randomlyallocated intotwo groups.
~In group (A): myomectomy will be performed before ART
~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
16426425|NCT03796130|No Intervention|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm
~The participants will be randomly allocated into two groups.
~In group (B):women will have their trial of ART without myomectomy"
16426426|NCT03796117|Experimental|Experimental Group 1: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
16426427|NCT03796117|Experimental|Experimental Group 2: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
16426428|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
16426429|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
16426430|NCT03796091|Active Comparator|Educational Brochure|Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.
16426431|NCT03796091|Active Comparator|Body Project Traditional|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice & Shaw, 2001).
16426432|NCT03796091|Active Comparator|Body Project Expanded|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).
16426433|NCT03796078|Active Comparator|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
16426434|NCT03796078|Active Comparator|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
16426435|NCT03796078|Active Comparator|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
16426436|NCT03796065|Experimental|FSI-R Treatment|Families randomized into the FSI-R Treatment arm will receive the 10-module Family Strengthening Intervention in addition to any outside services or programs they are participating in.
16426437|NCT03796065|No Intervention|FSI-R Control|Families randomized into the FSI-R Control arm will not receive the FSI-R treatment. Instead, they will continue with their usual care, referred to as Treatment as Usual (TAU).
16426438|NCT03796052|Experimental|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
16426439|NCT03796039|Experimental|Standing and Social Intervention|Participants be exposed to an additional 100 minutes of standing per week. Participants will do this by standing for 20 minutes Monday through Friday.
16426440|NCT03796039|No Intervention|Control Group|Control group will receive social visits, but no exposure to standing
16426642|NCT03794596|Experimental|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
16426441|NCT03796026|Experimental|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram [mg] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
16426442|NCT03796026|Experimental|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
16426443|NCT03796013|Experimental|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
16426444|NCT03796013|Experimental|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
16426445|NCT03796000||colonoscopy: obese and smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
16426446|NCT03796000||colonoscopy: obese and non-smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
16426447|NCT03796000||colonoscopy: lean and smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
16426448|NCT03796000||colonoscopy: lean and non-smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
16426449|NCT03796000||gastroscopy: obese and non-smoker undergoing bariatric surgery|"6 small tissue samples of the gastric corpus and 6 of the Duodenum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample
~1cm long piece of the jejunum, which is usually disposed during bariatric surgery."
16426450|NCT03796000||gastroscopy: lean and non-smoker|"6 small tissue samples of the gastric corpus and 6 of the Duodenum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
16426451|NCT03795987|Experimental|Open Label Treatment Arm|Intervention with NightWare Therapeutic System
16426452|NCT03795974|Active Comparator|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
16426453|NCT03795974|Experimental|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
16426454|NCT03795961|Experimental|Active tDCS group|This group will include 42 patients with CTS Intervention (active transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
16426455|NCT03795961|Sham Comparator|Sham tDCS group|This group will include 42 patients with CTS Intervention (sham or inactive transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
16426456|NCT03795948|Other|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
16426457|NCT03795935|Experimental|Treatment|Patients who were previously implanted with a traditional DBS lead and have subsequently developed stimulation induced side effects will gain significantly more tremor control without side effects when re-implanted with a directional DBS lead. We expect these patients' quality of life will improve. These patients typically will have had significant tremor relief (greater than 75% reduction from preoperative tremor rating scale) without side effects at their one year post operative follow-up. With the expected disease progression they will have had to increase their DBS stimulation to the degree that their DBS now causes side effects in order to block their tremor
16426458|NCT03795922|Experimental|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
16426459|NCT03795922|Placebo Comparator|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
16426460|NCT03795909|Experimental|Ruxolitinib and Placebo|Ruxolitinib 2.5 mg twice daily by oral
16426461|NCT03795909|Placebo Comparator|Placebo and Ruxolitinib|Sugar pill 2.5 mg twice daily by oral
16426462|NCT03795896|Experimental|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
16426463|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
16426464|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
16426465|NCT03795870|Active Comparator|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
16426466|NCT03795870|Active Comparator|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
16426467|NCT03795844|Active Comparator|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
16426468|NCT03795844|Active Comparator|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
16426469|NCT03795844|Active Comparator|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
16426643|NCT03794596|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
16426471|NCT03795831||Cohort|Adult patients, undergoing surgery requiring general anesthesia, planned to be monitored with a system that accurately measures and stores the intra-arterial waveform.
16426472|NCT03795818|Other|IPT-A|Interpersonal psychotherapy for adolescents (IPT-A) is a psychosocial treatment for adolescents. It has been shown to be effective for adolescents with depression. It is now being studied as to its benefit for adolescents who meet criteria for PTSD or have subthreshold PTSD symptoms.
16426473|NCT03795805|Other|TKA and Tourniquet|Total knee arthroplasty and use of tourniquet limb cuff at 270 mmHg
16426474|NCT03795805|Experimental|Intraarticular lidocain|Total knee arthroplasty with Intaarticular lidocain
16426475|NCT03795792|Experimental|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
16426476|NCT03795792|Placebo Comparator|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
16426477|NCT03795779|Experimental|CLL1-CD33 cCAR T cells|CLL1-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs
16426478|NCT03795753|Experimental|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
16426479|NCT03795753|Sham Comparator|Non-functioning Communicator|Non-functioning study communication device is used.
16426480|NCT03795740|Experimental|Precise|precise PEA therapy with the guide of 3-D imaging techniques
16426481|NCT03795740|Placebo Comparator|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
16426482|NCT03795727|Experimental|Sectional matrix|precontoured sectional matrix band
16426483|NCT03795727|Active Comparator|Circumferential matrix|Circumferential matrix band applied by tofflemire retainer
16426484|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
16426485|NCT03795701|Placebo Comparator|Placebo|Subjects in placebo group will receive placebo plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will also be asked to maintain physical activity.
16426486|NCT03795701|Experimental|Liraglutide 3.0|Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will be asked to maintain physical activity. The dose of Saxenda® will be increased weekly in the first 4 weeks (.6; 1.2; 1.8; 2.4 mg) and maintained on 3 mg for 12 weeks.
16426487|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.
~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
16426488|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
16426489|NCT03795675|Experimental|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
16426490|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
16426491|NCT03795649|No Intervention|The control group (Group K)|The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
16426492|NCT03795649|Active Comparator|Group A, Tranexamic acid|The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
16426493|NCT03795649|Other|Group B, autologous transfusion|The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
16426494|NCT03795649|Other|Group C, alogenous transfusion|The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
16426495|NCT03795636|Experimental|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract
~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
16426496|NCT03795636|Active Comparator|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
16426497|NCT03795623|Sham Comparator|Conventional arm|Muted audio recordings of the patients relatives.
16426498|NCT03795623|Experimental|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
16426499|NCT03795610|Experimental|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 21 days
16426526|NCT03795441|Experimental|Ad26.RSV.preF|Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
16426644|NCT03794583|Experimental|Inhaled Treprostinil Solution|Inhaled treprostinil solution (0.6 milligrams per milliliter [mg/mL], 6 mcg/breath) QID during waking hours.
16426500|NCT03795597|Experimental|Carfilzomib IV at dose: 20 mg/m2|The participants will receive Carfilzomib IV at dose: 20 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and Granulocyte-Colony stimulating factor (G-CSF) given daily until engraftment occurs.
16426501|NCT03795597|Experimental|Carfilzomib IV at dose: 27 mg/m2|The participants will receive Carfilzomib IV at dose: 27 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
16426502|NCT03795597|Experimental|Carfilzomib IV at dose: 36 mg/m2|The participants will receive Carfilzomib IV at dose: 36 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
16426503|NCT03795597|Experimental|Carfilzomib IV at dose: 45 mg/m2|The participants will receive Carfilzomib IV at dose: 45 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
16426504|NCT03795597|Experimental|Carfilzomib IV at dose: 56 mg/m2|The participants will receive Carfilzomib IV at dose: 56 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
16426505|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
16426506|NCT03795571|Experimental|R2-GOD|
16426507|NCT03795558|Experimental|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
16426508|NCT03795558|Experimental|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
16426509|NCT03795558|Experimental|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
16426510|NCT03795558|Experimental|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
16426511|NCT03795558|Experimental|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
16426512|NCT03795558|Experimental|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
16426513|NCT03795545|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.
~The rest of the session at 22kv (full power)."
16426514|NCT03795545|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
16426515|NCT03795532|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
16426516|NCT03795532|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
16426517|NCT03795519|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-olinciguat
16426518|NCT03795506|Experimental|Active TLA Device|12 week overnight treatment with the active Temperature Controlled Laminar Airflow device.
16426519|NCT03795506|Placebo Comparator|Placebo TLA Device|12 week overnight treatment with the placebo Temperature Controlled Laminar Airflow device.
16426520|NCT03795493|Experimental|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
16426521|NCT03795493|No Intervention|Control Group|Standard chemotherapy treatment and oncology care.
16426522|NCT03795480|Experimental|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
16426523|NCT03795480|No Intervention|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
16426524|NCT03795454|Experimental|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
16426525|NCT03795454|No Intervention|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
16426645|NCT03794570|Sham Comparator|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
16426527|NCT03795428|Experimental|Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose|Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.
16426528|NCT03795415||Immediate Arm (G1)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G1 will receive the intervention Gundo-So immediately. (From month 3 to month 6).
~112 women will be in immediate arm in 14 groups of 8 women."
16426529|NCT03795415||Delayed Arm (G2)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G2 will receive the intervention Gundo-So 3 months after. (From month 6 to month 9).
~112 women will be in delayed arm in 14 groups of 8 women."
16426530|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
16426531|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
16426532|NCT03795389|Experimental|3.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).
16426533|NCT03795389|Experimental|5.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
16426534|NCT03795389|Experimental|8.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
16426535|NCT03795350|Experimental|TRIMBOW|"Experimental: BDP/FF/GB
~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
16426536|NCT03795337|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
16426537|NCT03795324|Experimental|Redlove Apple|"Redlove Apple intervention
~This product is a biofortified cultivar apple with anthocyanins."
16426538|NCT03795324|Experimental|Green Apple|"Green Apple intervention
~This product is a common cultivar apple without anthocyanins."
16426539|NCT03795324|Experimental|Aronia Drink|"Aronia drink intervention
~This product is an infusion of aronia fruit extract rich in anthocyanin."
16426540|NCT03795311|Experimental|Administration of chemotherapy molecules|"The treatment period is divided into 15-day periods.
~Schema of the administration to the treatments which will proceed in the same way with each cycle:
~Bevacizumab (5 mg/kg; during 30 min) + Oxaliplatine (85 mg/m2, during 2 hours) + Acide folinique (400 mg/m2) or Levofolinate de calcium (200 mg/m2) AND Irinotecan (during 2 hours) + 5-fluorouracile (2400 mg/m2 ; 46 hours) + Irinotecan (1 hour)"
16426541|NCT03795298|Experimental|WATCHMAN FLX|WATCHMAN FLX implant including modified post-implant drug regimen.
16426542|NCT03795298|Active Comparator|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
16426543|NCT03795285||Septic neonates:|fifty neonates with sepsis.
16426544|NCT03795285||Controls:|twenty healthy neonates.
16426545|NCT03795272|Experimental|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
16426546|NCT03795272|Placebo Comparator|Placebo|Patients will be treated with oral placebo twice daily for 24 months
16426547|NCT03795259|Active Comparator|Sevoflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 2% sevoflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
16426548|NCT03795259|Active Comparator|Desflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 6% desflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
16426549|NCT03795246|Experimental|Study Process|Consultation, Biological Test, Pelvic Ultrasound
16426550|NCT03795233|Experimental|Fecal microbiota transplantation|Fecal microbiota transplant G3 capsules will be administered after standard of care with oral vancomycin therapy in participants with primary Clostridium difficile infection.
16426551|NCT03795233|Active Comparator|Oral vancomycin alone (Control)|Oral vancomycin therapy will be administered as per standard of care in participants with primary clostridium difficile infection.
16426552|NCT03795220|Active Comparator|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
16426553|NCT03795220|Active Comparator|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
16426554|NCT03795220|Active Comparator|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
16426555|NCT03795220|Active Comparator|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
16426556|NCT03795207|Experimental|Arm SBRT + DURVALUMAB|"Radiation (SBRT) + Immunotherapy treatment (Durvalumab)
~64 patients will be enrolled in this arm
~Durvalumab, will be started one month prior to SBRT and then given for a total of 12 months.
~Patient will receive one injection per months (1500 mg/cycle)
~SBRT will be started one month after Durvalumab and patients will receive 3 fractions of radiation"
16426557|NCT03795207|Active Comparator|Arm SBRT|"Radiation (SBRT)
~32 patients will be enrolled in this arm
~Patients will receive only 3 fractions of radiation"
16426558|NCT03795194|Other|8-day|8-day course of ampicillin clavulanate antibiotic
16426559|NCT03795194|Other|4-day|4--day course of ampicillin clavulanate antibiotic
16426606|NCT03794869|Experimental|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of the core: awareness of breathing, front and side plate abdominal, glute bridge/hip elevations, lift extended leg, pelvic tilt, hamstring stretch, strengthening lower abdominals, cat-camel posture, trunk rotations with flexed knees, rolling in sitting and lumbar extension with hip extensión in prone
16426560|NCT03795168|Experimental|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.
~Outcomes measured:
~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise
~at the first and last visit: force plate system assessment (balance)"
16426561|NCT03795168|Sham Comparator|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.
~Outcomes measured:
~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise
~at the first and last visit: force plate system assessment (balance)"
16426562|NCT03795142|Experimental|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
16426563|NCT03795142|Placebo Comparator|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
16426564|NCT03795129|Experimental|SleepLife Application w/FitBit|"Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.
~Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application."
16426565|NCT03795129|Active Comparator|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it).
~Subjects will receive no training with regard to how to access SleepLife Application.
~Subjects' physicians will receive no subject sleep data."
16426566|NCT03795116|Experimental|LED-RL phototherapy|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
16426567|NCT03795116|Sham Comparator|Mock irradiation|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
16426568|NCT03795103|Experimental|Patients achieving neuromuscular electrical stimulation|LEPAD patients achieving a 12-week program of neuromuscular electrical stimulation. Group of arteriopathic patients who will perform electrostimulation sessions at home and independently. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
16426569|NCT03795103|Other|Control|Group of artriopathic patients who will maintain their usual drug management. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
16426570|NCT03795103|Other|Healthy volunteers|Ancillary study. Participants will perform a precise program of walking sessions performed outdoors and independently and the same biological parameters as those assessed in arteriopathic patients will be assessed
16426571|NCT03795090|Active Comparator|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
16426572|NCT03795090|Experimental|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
16426573|NCT03795077|No Intervention|Control group|Control group followed traditional lectures about professional ethics during 3 months as usual.
16426574|NCT03795077|Experimental|Experimental group|Experimental group followed the programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used. Techniques used: concept maps, glossaries, brainstorming, four corners activity, aquarium, philip 6-6, kahoot, Realm Individual-Process Situation, reduced groups, guided debates, and discussion groups.
16426575|NCT03795064|Experimental|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
16426576|NCT03795064|Active Comparator|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
16426577|NCT03795051|Experimental|Navigated TMS|Each participant will receive 30 sessions of 10 Hz or 20 Hz navigated transcranial magnetic stimulation over the left DLPFC.
16426607|NCT03794869|Active Comparator|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
16426608|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
16426578|NCT03795038|Other|Lipoprotein Apheresis MONET and DALI|"Patients routinely treated with MONET:
~The first subgroup will be treated first with the MONET adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber System.
~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the MONET adsorber system"
16426579|NCT03795038|Other|Lipoprotein Apheresis DIAMED and DALI|"Patients routinely treated with DIAMED:
~The first subgroup will be treated first with the DIAMED adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber system.
~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DIAMED adsorber System."
16426580|NCT03795025|Experimental|3x10RM + no training|
16426581|NCT03795025|Experimental|6x10RM + no training|
16426582|NCT03795025|Experimental|3x10RM + 6x10RM|
16426583|NCT03795025|No Intervention|Control|This arm includes 3 weeks of testing and 7 weeks of no intervention and post tests, followed by 7 weeks of progressive unilateral strength training 3 times per week for 7 weeks. Both legs exercises individually with 3 sets of 10 maximal repetitions.
16426584|NCT03795012|Active Comparator|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
16426585|NCT03795012|Active Comparator|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
16426589|NCT03794986|Experimental|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
16426590|NCT03794986|Active Comparator|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
16426591|NCT03794973|Experimental|TOL-3021|TOL-3021 2 mg/mL
16426592|NCT03794973|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
16426593|NCT03794960|Experimental|TOL-3021|
16426594|NCT03794960|Placebo Comparator|TOL-3021 Placebo|
16426595|NCT03794947|Experimental|Remote Ischaemic Conditioning|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg (arm) and 220 mmHg (leg). RIC will be completed 3 times weekly for 4 weeks.
16426596|NCT03794947|Sham Comparator|Sham Intervention|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The arm and leg blood pressure cuffs in the sham intervention will inflate to 20mmHg. Sham will be completed 3 times weekly for 4 weeks.
16426597|NCT03794934|Placebo Comparator|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
16426598|NCT03794934|Active Comparator|Intervention|provide structured education when applying CGM for 3 months
16426599|NCT03794921|No Intervention|Usual Care|Patients referred to conventional PR or eligible for PR but declined. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
16426600|NCT03794921|Experimental|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website as often as they wish, but at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be prominently displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
16426601|NCT03794908|Experimental|Light therapy A via the Re-Timer®|"60 minutes/day
~For the first hour after waking"
16426602|NCT03794908|Active Comparator|Light therapy B via the Re-Timer®|"60 minutes/day
~For the first hour after waking"
16426603|NCT03794895|Experimental|Single arm clinical trial|
16426604|NCT03794882|Experimental|QLB + Medical Management|Subjects will undergo Intervention: Procedure/Surgery: Quadratus Lumborum Block and receive Intervention: Procedure: Standard Medical Management as needed.
16426605|NCT03794882|Active Comparator|Standard Medical Management|Subjects will receive Intervention: Procedure: Standard Medical Management as needed.
16426609|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
16426634|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
16426610|NCT03794843|Experimental|Nimodipine Injection (II)|The specification of this injection is 5 ml: 4 mg , which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:16 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
16426611|NCT03794843|Experimental|Nimodipine Injection|The specification of this injection is 50 ml: 10 mg ,which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:4 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
16426612|NCT03794830|Experimental|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
16426613|NCT03794830|Active Comparator|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
16426614|NCT03794804|Active Comparator|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.
~The IP use should start when following conditions have been fulfilled:
~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND
~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache
~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
16426615|NCT03794804|Placebo Comparator|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.
~The IP use should start when following conditions have been fulfilled:
~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND
~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache
~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
16426616|NCT03794791||education|Education will be used to see whether or not improve the HCV screening and diagnosis in HBsAg(+) patients. Blood test ,HCV-RNA quantification test and HCV genotyping will be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
16426617|NCT03794791||no education|There is no education at all.Screening and diagnosis of HCV infection in HBsAg(+) patients are based on voluntary. Blood test ,HCV-RNA quantification test and HCV genotyping will still be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
16426618|NCT03794778|Experimental|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
16426619|NCT03794778|Active Comparator|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
16426620|NCT03794765|Experimental|Antibiotic|Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
16426621|NCT03794765|Placebo Comparator|Placebo|Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
16426622|NCT03794752|Other|Vision Aided by a Head Mounted Device|A Head-Mounted Visual Enhancement Device developed by Evergaze Technology LLC has designed an electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation.
16426623|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
16426624|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
16426625|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
16426626|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
16426627|NCT03794726|Active Comparator|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
16426628|NCT03794726|Experimental|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
16426629|NCT03794713|Experimental|Patient support tool group|Subjects were managed the HR by using the Patient Support Tool through a smart phone application and a wristband and be guided by physicians
16426630|NCT03794713|No Intervention|Control group|Subjects were received a usual patient care at baseline, which left to the discretion of physicians, without any specific intervention at follow-up period
16426631|NCT03794700|No Intervention|Control|
16426632|NCT03794700|Other|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
16426633|NCT03794687||Distal Radial Artery|Left heart catheterization via the distal radial artery (dorsal aspect of the hand at the base of the thumb).
16426635|NCT03794661|Experimental|Single Arm|Clinician programmer electrode screening mode tool
16426646|NCT03794570|Experimental|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
16426647|NCT03794557|Experimental|PUL-042|PUL-042 Inhalation Solution
16426648|NCT03794557|Placebo Comparator|Placebo|Sterile Water for injection
16426649|NCT03794544|Experimental|Arm A: Durvalumab monotherapy|durvalumab IV
16426650|NCT03794544|Experimental|Arm B: Durvalumab + Oleclumab|durvalumab IV and oleclumab IV
16426651|NCT03794544|Experimental|Arm C: Durvalumab + Monalizumab|durvalumab IV and monalizumab IV
16426652|NCT03794544|Experimental|Arm D: Durvalumab + Danvatirsen|danvatirsen IV and durvalumab IV
16426653|NCT03794518|Experimental|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
16426654|NCT03794518|Placebo Comparator|Placebo|Beta blockers, ACEI, ARB, and aldosterone
16426655|NCT03794505|Active Comparator|Shoulder infiltration|Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg
16426656|NCT03794505|Experimental|Suprascapular nerve block|Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg
16426657|NCT03794492|Experimental|Mycophenolate mofetil|One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
16426658|NCT03794479||Travellers|Adults planning for travel
16426659|NCT03794453||Stroke patients|
16426660|NCT03794440|Experimental|Sintilimab +IBI305|
16426661|NCT03794440|Active Comparator|Sorafenib|
16426662|NCT03794427|Experimental|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
16426663|NCT03794427|Active Comparator|Spinal anesthesia|spinal anesthesia will be performed
16426664|NCT03794414|Experimental|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
16426665|NCT03794414|Experimental|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
16426666|NCT03794388|Experimental|Arm CAPSAICINE topical|"Application of capsaicin patches at 8% on the painful area
~1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later."
16426667|NCT03794388|Active Comparator|Arm PREGABALINE|"Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.
~An interval of 3 to 7 days must be observed between each dose increase."
16426668|NCT03794375|Active Comparator|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
16426669|NCT03794375|Experimental|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.
~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
16426678|NCT03794336|Experimental|Alogliptin|Single dose of alogliptin once daily for 16 weeks
16426679|NCT03794336|Active Comparator|Acarbose|Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2
16426680|NCT03794323|Experimental|BI 764122|
16426681|NCT03794323|Placebo Comparator|Placebo|
16426682|NCT03794310|Experimental|NPF-08 （1-day treatment）|
16426683|NCT03794310|Experimental|NPF-08 （2-day split dose）|
16426684|NCT03794310|Active Comparator|Moviprep（1-day treatment）|
16426685|NCT03794297|Experimental|Treatment (dabrafenib mesylate, trametinib dimethyl sulfoxide)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16426686|NCT03794271|Experimental|Pupilometer group|In this group, intraoperative analgesia is performed using pupilometer guided anesthesia.
16426687|NCT03794271|Active Comparator|SPI group|In this group, intraoperative analgesia is performed using SPI guided anesthesia
16426688|NCT03794258|Experimental|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
16426689|NCT03794258|Experimental|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
16426690|NCT03794245|Experimental|Men-Centered HIV Testing|Mobile HIV testing is conducted at sites in the community where men gather.
16426691|NCT03794245|Active Comparator|Clinic-based HIV Testing|Men are referred to the nearest clinic for HIV counseling and testing
16426692|NCT03794245|Experimental|Linkage to Care for HIV+ Men|The patient coordinator arranges an appointment time at the clinic and accompanies the patient to the initial visit
16426693|NCT03794245|Active Comparator|Clinic Referral for HIV+ Men|Men diagnosed with HIV are referred to the nearest clinic for treatment of HIV
16426694|NCT03794232|Experimental|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
16426695|NCT03794232|Placebo Comparator|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
16426696|NCT03794219|Experimental|Kinesio tape plus NSAID|Kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions in addition to 750 mg/day oral naproxen.
16426697|NCT03794219|Active Comparator|NSAID|750 mg/day oral naproxen is administered for 10 days.
16426698|NCT03794206|Experimental|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
16426699|NCT03794180|Experimental|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
16426700|NCT03794180|Placebo Comparator|Placebo|0 mg/kg via single IV infusion
16426701|NCT03794167|Experimental|busulfan cyclophosphamide etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
16426702|NCT03794167|Active Comparator|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
16426703|NCT03794154|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
16426704|NCT03794154|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
16426705|NCT03794141|Experimental|Tervas|Follow up group from an earlier study. Information on risk gene status. All test persons were given information on healthy diet and life style.
16426706|NCT03794141|Experimental|Informed|Information on risk gene status was given before intervention. All test persons were given information on healthy diet and life style.
16426707|NCT03794141|Active Comparator|non informed|Information on risk gene status was not given before intervention. All test persons were given information on healthy diet and life style.
16426708|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
16426709|NCT03794128||2 - shared neoantigen cancer vaccine screening|
16426710|NCT03794102|Active Comparator|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
16426711|NCT03794102|Active Comparator|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
16426712|NCT03794089|Experimental|Brief anxiety intervention|Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
16426713|NCT03794089|Active Comparator|Usual PC-MHI care|Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care
16426714|NCT03794076|Active Comparator|Cromoglycate|Cromoglycate nasal spray
16426715|NCT03794076|Placebo Comparator|Placebo|Saline nasal spray
16426716|NCT03794063||Robson group 1|Nulliparous women, single cephalic, more than or equal to 37 weeks, in spontaneous labour
16426717|NCT03794063||Robson Group 2|Nulliparous women, single cephalic, more than or equal to 37 weeks, induced or Caesarean section before labour
16426718|NCT03794063||Robson Group 3|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more than or equal 37 weeks gestation in spontaneous labour
16426719|NCT03794063||Robson Group 4|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more or equal 37 weeks gestation who had labour induced or were delivered by Caesarean section before labour
16426720|NCT03794063||Robson Group 5|All Multiparous women with at least one CS with a single cephalic pregnancy, more or equal to 37 weeks gestation
16426721|NCT03794063||Robson Group 6|All nulliparous women with a single breech pregnancy
16426722|NCT03794063||Robson Group 7|Multiparous women with a single breech pregnancy including women with previous Caesarean section
16426723|NCT03794063||Robson Group 8|All women with multiple pregnancies including women with previous Caesarean sections
16426724|NCT03794063||Robson Group 9|All women with a single pregnancy with a transverse or oblique lie, including women with previous Caesarean Section (s)
16426725|NCT03794063||Robson Group 10|All women with a single cephalic pregnancy less than 37 weeks gestation, including women with previous Caesarean section (s)
16426726|NCT03794050|Experimental|resistance training exercise|All participants complete one session of resistance training exercise
16426727|NCT03794050|Experimental|aerobic training exercise|All participants complete one session of aerobic training exercise
16426728|NCT03794037|Active Comparator|control|dydrgesterone 10 mg( tab)/12hs/14 days
16426729|NCT03794037|Experimental|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
16426730|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
16426731|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
16426732|NCT03794011|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
16426733|NCT03793985|Experimental|A (R+T+R+T)|Period 1 : R Period 2 : T Period 3 : R Period 4 : T
16426734|NCT03793985|Active Comparator|B (T+R+T+R)|Period 1 : T Period 2 : R Period 3 : T Period 4 : R
16426735|NCT03793972|Experimental|Triage with referral to primary care|Triage and referral according to eMTS.
16426736|NCT03793972|Active Comparator|Triage without referral to primary care|Weekends with usual care
16426737|NCT03793959|Experimental|Synbiotic Supplement|Daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis, identical to Placebo-- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
16426738|NCT03793959|Placebo Comparator|Placebo Supplement|Daily placebo supplement (5g maltodextrin, identical to Experimental -- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
16426739|NCT03793946|Experimental|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
16426740|NCT03793946|No Intervention|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
16426741|NCT03793920|Experimental|PEA patients without alcohol disorder|A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.
16426742|NCT03793920|Sham Comparator|PEA patients with alcohol disorder|A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.
16426743|NCT03793920|Sham Comparator|Healthy controls with AD father|A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
16426744|NCT03793920|Sham Comparator|Healthy controls without AD father|A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
16426745|NCT03793907|Active Comparator|Cohort 2 (walking program)|Patients receive a Fitbit to track their physical activity, and complete an unsupervised walking program daily at home, increasing physical activity stepwise weekly, for 6 months.
16426746|NCT03793907|Experimental|Cohort 1 (strength training)|Patients receive a Fitbit to track their physical activity, and complete an in-person personalized and supervised full-body strength training program over 1 hour BID up to 52 sessions for 6 months.
16426747|NCT03793894|Active Comparator|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
16426748|NCT03793894|Experimental|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
16426749|NCT03793881|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
16426750|NCT03793881|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
16426751|NCT03793868|Experimental|Low dose|Perampanel 4mg PO x1
16426752|NCT03793868|Placebo Comparator|Placebo|Receiving placebo
16426753|NCT03793868|Experimental|High dose|Perampanel 8 mg PO x1
16426754|NCT03793855|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
16426755|NCT03793855|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
16426756|NCT03793842|Experimental|Usual care then PEEP titration by EIT|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan ARDS protocol high-PEEP arm
16426757|NCT03793842|Experimental|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
16426758|NCT03793829|Experimental|GM-CSF and H2NVAC vaccine|GM-CSF Dose and route: 125 mcg admixed with vaccine; intradermal injection Every 14 days ± 2 days for a maximum of 4 cycles H2NVAC vaccine 4 peptides, at dose level as shown below, admixed with GM-CSF; intradermal injection. Every 14 days ± 2 days for a maximum of 4 cycles
16426759|NCT03793816|Active Comparator|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:
~Incision of the anterior palatal arch
~Locating of the cranial pole of the tonsil
~Dissection of the tonsil capsule
~Localized coagulation of bleeding vessels
~Detaching of the inferior pole from the pharynx tissue"
16426760|NCT03793816|Active Comparator|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
16426761|NCT03793803|Experimental|Home Palliative Care|Randomized to Intervention Arm
16426762|NCT03793803|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their primary illness(es).
16426763|NCT03793790|Experimental|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
16426764|NCT03793790|Experimental|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
16426765|NCT03793790|Experimental|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
16426766|NCT03793790|Experimental|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
16426767|NCT03793790|Sham Comparator|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
16426768|NCT03793777|Placebo Comparator|placebo|microcrystalline cellulose supplementation
16426769|NCT03793777|Experimental|Aronia|aronia melanocarpa supplementation
16426770|NCT03793764|Active Comparator|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
16426771|NCT03793764|Active Comparator|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
16426772|NCT03793764|No Intervention|Group C|In this group no intervention will be performed after the end of operation.
16491276|NCT03351881|Active Comparator|Opt In|
16426773|NCT03793751|Experimental|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
16426774|NCT03793751|Placebo Comparator|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
16426775|NCT03793738|Active Comparator|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
16426776|NCT03793738|Active Comparator|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
16426777|NCT03793725|Experimental|SHR-1210 + Apatinib|Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd
16426778|NCT03793712|Experimental|Lu AF11167 low dose|
16426779|NCT03793712|Experimental|Lu AF11167 high dose|
16426780|NCT03793712|Placebo Comparator|Placebo|
16426781|NCT03793699||case group : realized a suicide attempt|adults having realized a suicide attempt and without histories of suicide attempt.
16426782|NCT03793699||control group : only suicidal ideas|adults having suicidal ideas without suicidal acting out and without histories of suicide attempt.
16426783|NCT03793686|Experimental|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
16426784|NCT03793686|Placebo Comparator|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
16426785|NCT03793673|Other|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.
~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
16426786|NCT03793673|Other|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
16426787|NCT03793673|Other|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.
~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
16426788|NCT03793673|Other|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
16426789|NCT03793647|Active Comparator|Low Intensity EMS|Conventional Stimulation
16426790|NCT03793647|Experimental|High Intensity EMS|Russian Stimulation
16426791|NCT03793647|Placebo Comparator|Placebo|no Stimulation, supported by phone contact
16426792|NCT03793634|Experimental|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
16426793|NCT03793634|Active Comparator|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
16426794|NCT03793621|Experimental|BI 730357|
16426795|NCT03793621|Placebo Comparator|Placebo|
16426796|NCT03793608|Experimental|Dupilumab|Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
16426797|NCT03793595|Experimental|Seated Battle Ropes Protocol|
16426798|NCT03793595|Active Comparator|Seated Upper Extremity Arm Bike|
16426799|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
16426800|NCT03793569|No Intervention|Control group|Participants will be recruited and asked to complete Edinburgh Postnatal Depression Scale (EPDS) at specific timepoints postpartum.
16426801|NCT03793569|Experimental|Intervention group|Participants will be recruited, asked to complete Edinburgh Postnatal Depression Scale at specific timepoints postpartum, and attend a peer discussion group.
16426802|NCT03793556|Experimental|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
16426803|NCT03793556|Active Comparator|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
16426804|NCT03793543|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
16426805|NCT03793530|Experimental|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
16426806|NCT03793530|Active Comparator|Control group|Transforaminal lumbar interbody fusion with local bone graft
16426807|NCT03793517|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT.
~Details:
~The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2."
16426808|NCT03793517|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant.
~Details:
~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3."
16426809|NCT03793491||Patients having Parkinson's disease|Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
16427085|NCT03791580|Experimental|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
16426810|NCT03793478|Experimental|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
16426812|NCT03793439|Experimental|Open-label treatment|All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.
16426813|NCT03793439|Experimental|Open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
16426814|NCT03793426||Fibryga|Fibryga (human plasma-derived fibrinogen concentrate)
16426815|NCT03793413|Experimental|Surgical group|
16426816|NCT03793413|No Intervention|Observation group|
16426817|NCT03793387|Experimental|Pre-op|
16426818|NCT03793387|Active Comparator|Intra-op|
16426819|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
16426820|NCT03793361|Experimental|Arm A|Regorafenib
16426821|NCT03793361|Placebo Comparator|Arm B|Placebo
16426822|NCT03793348|Experimental|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
16426823|NCT03793335||Gastric cancer prevention|This prospective study consists of 40,000 participants; after randomization, each arm has 20,000 participants. Arm 1: participants receive H. pylori stool antigen test; Arm 2: participants receive the combination of H. pylori stool antigen test and serum pepsinogen test.
16426824|NCT03793335||Colorectal cancer prevention|This prospective study consists of 40,000 participants; after randomization; each arm has 20,000 participants. Arm 1: participants with positive fecal immunochemical test (FIT) receive routine referral confirmatory diagnosis approach; Arm 2: participants with positive FIT receive routine referral confirmatory diagnosis approach and participants with high FIT results receive additional aggressive referral confirmatory diagnosis approach.
16426825|NCT03793322|Experimental|Indocyanine-Green(ICG) injection group|
16426826|NCT03793309|Experimental|Low dose|Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
16426827|NCT03793309|Experimental|High dose|Subjects in this group receive 800 IU vitamin D daily for 4 weeks.
16426828|NCT03793296|Experimental|Paravalvular leak|After transcatheter- or surgical valve replacement
16426829|NCT03793283||Continous Subcutaneous Insulin Infusion|"All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII.
~Forty-five patients are actually treated with CSII in our hospital."
16426830|NCT03793283||Multiple dose insulin injections (MDI):|"Forty-five T1DM adult patients attended in Ciudad Real General University Hospital and treated with MDI.
~MDI patients will be selected through simple random sampling (1:1) from our T1DM patient database."
16426831|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).
~drugs described in the clinic."
16426832|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
16426833|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
16426834|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
16426835|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
16426836|NCT03793231||Fungal Cases|Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.
16426837|NCT03793231||Control patients|Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.
16426838|NCT03793218|Experimental|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
16426839|NCT03793218|Active Comparator|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
16426840|NCT03793205|Experimental|Long-acting G-CSF group|Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
16426841|NCT03793205|Experimental|Short-acting G-CSF group|Patients in long-acting G-CSF group only accept short-acting G-CSF.
16426842|NCT03793192|Experimental|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
16426843|NCT03793192|No Intervention|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
16491277|NCT03351881|Active Comparator|Opt Neutral|
16426849|NCT03793153|No Intervention|Control|Standard Lower Segment Cesarean Section (LSCS) will be done.
16426850|NCT03793153|Active Comparator|Study|Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
16426851|NCT03793140|Experimental|CPI-613|CPI-613 IV induction (Days 1-5 for first 2 Cycles [14-day cycles]), followed by CPI-613 IV maintenance (Days 1-5 for all Cycles thereafter [21-day cycles].
16426852|NCT03793127|Other|Young group|20-40 years of age
16426853|NCT03793127|Other|Old group|60-80 years of age
16426854|NCT03793114|Experimental|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
16426855|NCT03793114|Active Comparator|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
16426856|NCT03793114|No Intervention|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
16426857|NCT03793114|Other|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
16426858|NCT03793114|Other|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
16426859|NCT03793114|Experimental|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
16426860|NCT03793114|Experimental|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
16426861|NCT03793114|Active Comparator|Cardiovascular and inflammatory biomarkers|Compare cardiovascular and inflammatory biomarker profiles in patients with and without residual production of adrenocortical steroids
16426862|NCT03793101||BiMICS 1.4|Group 1.4 - Patients operated with 1.4 mm BiMICS technique
16426863|NCT03793101||BiMICS 1.8|Group 1.8 - Patients operated with 1.8 mm BiMICS technique
16426864|NCT03793075|Placebo Comparator|Propofol group (P)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
16426865|NCT03793075|Active Comparator|Ketamine group ((K)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
16426866|NCT03793036|No Intervention|FAST group|preoperative fasting
16428827|NCT03779295|Experimental|Pulse laser therapy applied to left side of face|
16426867|NCT03793036|Experimental|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
16426868|NCT03793010|Experimental|FX006|FX006 32mg
16426869|NCT03793010|Placebo Comparator|Normal Saline|Normal Saline
16426870|NCT03792997|Active Comparator|control|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid
16426871|NCT03792997|Experimental|study|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid but the investigators add in this arm lipid emulsion & prednisolone & LMWH
16426872|NCT03792984|Placebo Comparator|Metformin + Placebo|
16426873|NCT03792984|Experimental|Calcium carbonate + Vitamin D3 + Metformin|
16426874|NCT03792971|Experimental|Fixed Sequence|
16426875|NCT03792958|Experimental|CM082|CM082 tablet
16426876|NCT03792945|Active Comparator|extracorporeal shock wave therapy|ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
16426877|NCT03792945|Active Comparator|local injection|40 mg of local Depomedrol (methylprednisolone) injection will be applied to group 2 once. Injection will be made from wrist with carpal tunnel syndrome.Patients will be given a splint at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
16426878|NCT03792945|No Intervention|carpal tunnel wrist brace|"Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day.
~Participants will use the carpal tunnel wrist brace 3 months."
16426879|NCT03792932|Active Comparator|Laparoscopic distal pancreatectomy|
16426880|NCT03792932|Active Comparator|Open distal pancreatectomy|
16426881|NCT03792919|Experimental|Cessation of NAs treatment|Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
16426882|NCT03792919|Active Comparator|Keep on current NAs treatment|Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
16426883|NCT03792906|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
16426884|NCT03792906|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
16426885|NCT03792893|Experimental|Higher Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
16426886|NCT03792893|Experimental|Lower Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
16426887|NCT03792880|Active Comparator|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
16426888|NCT03792880|Experimental|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
16426889|NCT03792867|Experimental|Radical Resection and HIPEC|
16426890|NCT03792841|Experimental|Part 1 Dose-exploration: acapatamab treatment|Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.
16426891|NCT03792841|Experimental|Part 1 Dose-expansion: acapatamab treatment|Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.
16426892|NCT03792841|Experimental|Part 2: acapatamab + Pembrolizumab|Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
16426893|NCT03792841|Experimental|Part 3: acapatamab + Etanercept Prophylaxis|Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.
16426894|NCT03792841|Experimental|Part 4: acapatamab 24 Hour Monitoring|Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.
16426895|NCT03792841|Experimental|Part 5: acapatamab Outpatient Cohort|Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.
16426896|NCT03792841|Experimental|Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction|Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
16426897|NCT03792828|Active Comparator|Control|Duloxetine HCl 30mg is not used.
16426898|NCT03792828|Experimental|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
16426899|NCT03792815|Experimental|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2
16426900|NCT03792802|Active Comparator|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
16426901|NCT03792802|Active Comparator|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
16426902|NCT03792789|Experimental|mCIMT with real rTMS|Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
16426962|NCT03792386|Active Comparator|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
16426963|NCT03792373||frailty|
16426964|NCT03792373||nonfrailty|
16426903|NCT03792789|Sham Comparator|mCIMT with sham rTMS|Modified Constraint Induced Movement Therapy with sham Repetitive Transcranial Magnetic Stimulation (using sham coil). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with sham rTMS over contralateral primary motor cortex using sham coil which simulated sound and touch of real coil but has no electro-magnetic waves.
16426904|NCT03792776|Active Comparator|Air|Endotracheal tube cuff inflation with air
16426905|NCT03792776|Experimental|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
16426906|NCT03792776|Experimental|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
16426907|NCT03792763|Experimental|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
16426908|NCT03792763|Placebo Comparator|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution
~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
16426910|NCT03792737|Experimental|Investigational group 1|Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.
16426911|NCT03792737|Experimental|Investigational group 2|Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.
16426912|NCT03792737|Active Comparator|Control group|Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.
16426913|NCT03792724|Experimental|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
16426914|NCT03792724|Experimental|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
16426915|NCT03792711|Experimental|HMB group|2 servings (440 mL)/day Ensure® Plus Advance for use as a supplement with or between meals
16426916|NCT03792711|No Intervention|Control group|Standard of care includes mainly dietary consultation for healthy aging by dietitians to reach sufficient dietary protein intake.
16426917|NCT03792698|Experimental|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
16426918|NCT03792685|Experimental|Normal weight|Normal weight men. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
16426919|NCT03792685|Experimental|Overweight/obesity|Men with overweight or obesity. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
16426920|NCT03792685|Experimental|Diabetes|Men with prediabetes or type 2 diabetes mellitus. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
16426921|NCT03792672|Experimental|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
16426922|NCT03792672|Experimental|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
16426923|NCT03792672|Experimental|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
16426924|NCT03792672|Experimental|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
16426925|NCT03792672|Experimental|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
16426965|NCT03792360|Experimental|Single Arm|
16491579|NCT03349801||early AMD|No interventions.
16426926|NCT03792672|Experimental|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
16426927|NCT03792659||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
16426928|NCT03792646|Experimental|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
16426929|NCT03792646|Placebo Comparator|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
16426930|NCT03792633|Experimental|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
16426931|NCT03792633|Experimental|Poor Response to Prior B Cell Directed Engineered cell therapy|
16426932|NCT03792620|Experimental|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).
~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
16426933|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
16426934|NCT03792594||Historical control group|The patients receive arthroscopic repair only
16426935|NCT03792581|Active Comparator|EV1000 monitor|MAP management will be done as usual ( adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
16426936|NCT03792581|Experimental|EV1000 monitor + closed-loop system|fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
16426937|NCT03792568|Experimental|ALK mutation|
16426938|NCT03792555|Experimental|Paltusotine|
16426939|NCT03792555|Placebo Comparator|Placebo|
16426940|NCT03792542|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
16426941|NCT03792529||breast cancer with HER2 overexpression|
16426942|NCT03792529||hormone receptor-positive breast cancer|
16426943|NCT03792529||triple negative breast cancer|
16426944|NCT03792516|Experimental|Artesunate ointment 40%, 1 cycle|Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.
16426945|NCT03792516|Experimental|Artesunate ointment 40%, 2 cycles|Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.
16426946|NCT03792516|Experimental|Artesunate ointment 40%, 3 cycles|Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.
16426947|NCT03792503|Experimental|Apatinib，Pemetrexe|Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
16426948|NCT03792490|Experimental|Fasudil 30 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days
16426949|NCT03792490|Experimental|Fasudil 60 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days
16426950|NCT03792490|Placebo Comparator|Placebo|Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%
16426951|NCT03792477|Experimental|Part 1: Treatment A|Single 200mg IM testosterone cypionate solution (Test formulation)
16426952|NCT03792477|Active Comparator|Part 1: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
16426953|NCT03792477|Experimental|Part 2: Treatment A|Single 200 mg IM testosterone cypionate solution (Test formulation)
16426954|NCT03792477|Active Comparator|Part 2: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
16426955|NCT03792425|Other|implant with immediate temporization|Immediate nonfunctional loading
16426956|NCT03792425|Other|Delayed implant without temporization|Conventional loading protocol
16426957|NCT03792412|Experimental|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
16426958|NCT03792412|Other|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
16426959|NCT03792399|Experimental|Immediate feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to immediate feedback after data downloaded into computer.
16426960|NCT03792399|Other|Delayed feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to delayed feedback (standard care, i.e., CGM graphs interpretation at scheduled 3 months outpatient visit).
16426961|NCT03792386|Active Comparator|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
16426966|NCT03792347|Experimental|Arm 1|Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 15 and 29. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
16426967|NCT03792321|Active Comparator|Testosterone|Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
16426968|NCT03792321|Placebo Comparator|Placebo|Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.
16426969|NCT03792308|Experimental|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.
~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.
~."
16426970|NCT03792308|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).
~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.
~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
16426971|NCT03792295|Experimental|Multimodal Therapy|Patients will receive scheduled ibuprofen 400mg po q 4 hours and acetominophen 1gram po q 8 hours during the post operative phase and oxycodone 5mg po q 4 to 6 hours as needed for pain control.
16426972|NCT03792295|Active Comparator|Classic/standard opiod Therapy|Patients will receive oxycodone 5mg po q 4 to 6 hours as needed during their post operative phase for pain control.
16426973|NCT03792282|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
16426974|NCT03792282|Active Comparator|RCD|Participants in this group will focus on daily reduced calorie diet (RCD).
16426975|NCT03792269|Experimental|Multi-channel chemotherapy|Patients will receive intraperitoneal irinotecan (50mg, d1, q2w).
16426976|NCT03792269|Active Comparator|Control Group|Patients will receive intravenous oxaliplatin (130mg/m^2, d1, q3w), and oral capecitabine (1.0g, d1-14, q3w).
16426977|NCT03792256|Experimental|Treatment (Palbociclib)|Patients receive Palbociclib 50 mg/m^2 (starting dose with maximum dose of 100 mg) PO (or via NG-tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.
16426978|NCT03792243||Parastomal hernia|Patients undergoing parastomal hernia repair in Denmark between 2007 and 2017
16426979|NCT03792230|Experimental|Video|This group received educatıon via video material
16426980|NCT03792230|Experimental|Brochure|This group received education via written material (brochure)
16426981|NCT03792230|No Intervention|Control|This group received standart clinical education
16426982|NCT03792217|Experimental|1.3% NaOCl|Root canal irrigation done using 1.3% NaOCl.
16426983|NCT03792217|Active Comparator|5.25% NaOCl|Root canal irrigation done using 5.25% NaOCl.
16426984|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.
~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
16426985|NCT03792191|Experimental|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
16426986|NCT03792191|Active Comparator|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
16426987|NCT03792178|Active Comparator|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
16426988|NCT03792178|Experimental|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
16426989|NCT03792165|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
16426990|NCT03792165|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
16426991|NCT03792152|Experimental|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
16426992|NCT03792152|Active Comparator|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
16426993|NCT03792139|Experimental|LY3200882|LY3200882 administered orally.
16426994|NCT03792139|Experimental|Itraconazole + LY3200882|Itraconazole + LY3200882 administered orally.
16426995|NCT03792126|No Intervention|Standard Care|
16426996|NCT03792126|Experimental|Implicit Learning Approach|
16427238|NCT03790462|Experimental|Music intervention group 3|"Raga C will be played for 10 minutes & data collected."
16426997|NCT03792113|Experimental|Autologous fibrin glue|The periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to 2 mm from the coronal margin and repositioned back on to the root surface. Thereafter, the tissues will be kept in position with a gentle pressure using a wet gauze for 30 - 60 seconds.
16426998|NCT03792113|Active Comparator|4-0 silk suture|The periodontal flap will be approximated using 4-0 black silk suture.
16426999|NCT03792100|Experimental|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
16427000|NCT03792100|Active Comparator|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
16427001|NCT03792087|Experimental|SmofKabiven Peripheral|Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
16427002|NCT03792087|Active Comparator|Hospital compounded emulsion|Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
16427003|NCT03792074|Experimental|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
16427004|NCT03792074|Active Comparator|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
16427005|NCT03792061|Experimental|Strategy Training|Strategy training is an activity intervention training approach developed based on the theoretical tenets of metacognitive training. The purpose of strategy training is to guide individuals to generate problem-solving skills to address challenges that they identify in daily activities.
16427006|NCT03792061|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
16427007|NCT03792048|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
16427008|NCT03792048|No Intervention|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
16427009|NCT03792035|Experimental|Experimental group|First time given 8 capsules of Tongxinluo, then given 4 capsules of Tongxinluo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
16427010|NCT03792035|Placebo Comparator|Control group|First time given 8 capsules of placebo, then given 4 capsules of placebo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
16427011|NCT03792022||Group 1|Adherence to timely vaccine uptake
16427012|NCT03792009|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
16427013|NCT03792009|Placebo Comparator|Paracervical block with normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
16427014|NCT03791996|No Intervention|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
16427015|NCT03791996|Experimental|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
16427016|NCT03791983|Experimental|Therapy Group|
16427017|NCT03791983|Other|Control Group|
16427018|NCT03791970|Experimental|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
16427019|NCT03791970|Active Comparator|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
16427020|NCT03791957||Group A - Healthy Periodontium|Absence of clinical signs of inflammation like bleeding on probing, erythema, edema, attachment loss, bone loss, patient symptoms, (bone levels at 1-3mm apical to CEJ) n=20
16427021|NCT03791957||Group B - Gingivitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla, n=20
16427022|NCT03791957||Group C - Periodontitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla,periodontal pocketing, clinical attachment loss, radiographically assessed bone loss n=20
16427023|NCT03791944|Experimental|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
16427024|NCT03791944|Active Comparator|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
16427025|NCT03791944|Experimental|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
16427026|NCT03791944|Active Comparator|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
16427027|NCT03791931|Other|Patients|Oxidative stress measurement in cleavage state embryos
16427028|NCT03791918|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16427029|NCT03791918|Active Comparator|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
16427030|NCT03791905|Experimental|TP Arm|Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
16427031|NCT03791905|Experimental|FOLFOX Arm|Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
16427032|NCT03791892|Experimental|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
16427033|NCT03791892|Active Comparator|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
16427034|NCT03791879|Active Comparator|• Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k|
16427035|NCT03791879|Active Comparator|• Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.|
16427036|NCT03791879|Active Comparator|• Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/|
16427037|NCT03791879|Active Comparator|• Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.|
16427038|NCT03791866|Experimental|30% target total enteral nutrition|
16427039|NCT03791866|Experimental|60% target total enteral nutrition|
16427040|NCT03791866|Active Comparator|100% target total enteral nutrition|
16427041|NCT03791853||Light-CT|All specimens are detected using Light-CT
16427042|NCT03791840||Ultrasound evaluation|Eligible patients undergo lymph node biopsy or lymph node dissection. Before surgery, the status of axillary lymph node status was evaluated using ultrasound. After surgery, all lymph node specimens would be collected and be assessed using ultrasound in a special evaluation system in vitro.
16427043|NCT03791827||Corticosteroid|Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
16427044|NCT03791827||Corticosteroid and cyclophosphamide|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
16427045|NCT03791827||Corticosteroid and mycophenolate mofetil|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
16427046|NCT03791827||Corticosteroid and azathioprine|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
16427047|NCT03791827||Corticosteroid and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
16427048|NCT03791827||Corticosteroid and cyclosporine A|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
16427049|NCT03791827||Corticosteroid, mycophenolate mofetil and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
16427050|NCT03791827||Retuximab|An option for refractory lupus nephritis
16427051|NCT03791814|Experimental|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
16427052|NCT03791801|Active Comparator|Neostigmine|Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1
16427053|NCT03791801|Active Comparator|Sugammadex|Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).
16427054|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
16427055|NCT03791775|Experimental|Polidocanol 3% Foam|Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany).
16427056|NCT03791762|Experimental|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
16427057|NCT03791762|Experimental|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
16427058|NCT03791762|Experimental|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
16427059|NCT03791749|Experimental|Breastfeeding Support|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
16427060|NCT03791749|No Intervention|Standard Care|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. No intervention will be administered.
16427061|NCT03791736|Experimental|Sandostatine|Injection of Sandostatine
16427062|NCT03791723|Experimental|Sacubitril/valsartan|After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
16427063|NCT03791723|Active Comparator|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
16427064|NCT03791710|Placebo Comparator|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
16427065|NCT03791710|Active Comparator|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
16427084|NCT03791580|Experimental|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
16491580|NCT03349801||intermediate AMD|No interventions.
16427066|NCT03791697|Active Comparator|Telephone Group|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.
~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.
~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes."
16427067|NCT03791697|No Intervention|In Person Clinic Visit Group|For the patient randomized into the clinic group, the clinic visit will entail questions about common postoperative complications (including fever, nausea/vomiting, pain, urinary symptoms, constipation, etc.). As per usual, vital signs and a focused physical examination will be completed at the clinic visit. All clinic visits will be performed by an FPRMS fellow and/or attending physician
16427068|NCT03791684|Active Comparator|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
16427069|NCT03791684|Active Comparator|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
16427070|NCT03791671|Experimental|individual balance training|"After the initial assessments, the three week intervention time begins, which is completed with the reassessments.
~The patients receive 2x weekly individual balance training for 25 minutes each. This runs in addition to the normal, prescribed rehabilitation program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period."
16427071|NCT03791671|Active Comparator|group balance training|"The patients receive 2x weekly group balance training for 25 minutes each. This runs in addition to the normal, prescribed rehab program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period.
~In group therapy are 3 to 6 patients with different neurological diagnoses. As it is usual in rehabilitation everyday life."
16427072|NCT03791658|Other|Asthmatics|"From the patients file the following information will be collected by the investigators:
~Age
~Sex
~FEV1 derived from the last spirometry (including spirometry performed on day of study visit).
~GINA step (Global Initiative for Asthma).
~Number of exacerbations in the year prior to the study.
~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.
~FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).
~Patients will fill out:
~The 12-question TAI-questionnaire (test for the adherence to inhalers)
~The Asthma Control Test (ACT)"
16427073|NCT03791658|Other|COPD-patients|"From the patients file the following information will be collected by the investigators:
~Age
~Sex
~Pack Years
~GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)
~Number of exacerbations in the year prior to the study.
~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.
~Patients will fill out:
~The 12-question TAI-questionnaire (test for the adherence to inhalers)
~The COPD Assessment Test (CAT)"
16427074|NCT03791645|Experimental|SKY Intervention|Participants in the intervention group will get to participate in the SKY program, for 5 days with each day session taking 3 hours/day. SKY program involves a) specific breathing exercises and social interaction with other participants in the program. Following completion of the program, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use. After completion of the 5 day SKY program, participants will practice SKY every day at home for 30 days. They will also need to attend 4 weekly group sessions during this period and each session is expected to last 1 hour. At the end of the 30 day period, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use.
16427075|NCT03791645|No Intervention|Usual treatment|Participants assigned to the control group will not have access to the SKY program but will continue with usual care. They will also complete questions after 5 days and again after 30 days.
16427076|NCT03791632|No Intervention|witness|2 control CE2 classes without oral sensitization actions
16427077|NCT03791632|Experimental|group intervention 1|2 CE2 classes with a classical lecture style presentation
16427078|NCT03791632|Experimental|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
16427079|NCT03791632|Experimental|group intervention 3|2 CE2 classes with digital media intervention
16427080|NCT03791619|Active Comparator|Higher Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
16427081|NCT03791619|Active Comparator|Lower Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
16427082|NCT03791593|Experimental|Experimental group|The patient will receive evolocumab 420 mg/month on top of guideline-driven medical treatment
16427083|NCT03791593|No Intervention|Control group|The patient will continue guideline-driven medical treatment
16427086|NCT03791580|Experimental|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
16427087|NCT03791580|No Intervention|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
16427088|NCT03791554|Active Comparator|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.
~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
16427089|NCT03791554|Active Comparator|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:
~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.
~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
16427090|NCT03791541|No Intervention|No Intervention|Only surveys will be done and re admissions tracked. No additional interventions based on survey results will be done.
16427091|NCT03791541|Experimental|Intervention|"Pharmacist Services
~Surveys plus increased outpatient pharmacist/pharmacy student services including but not limited to pre and post clinic visit phone calls, prescription counseling, and helping with adherence and compliance with medications. Increased services will be given based on survey results."
16427092|NCT03791528|Active Comparator|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
16427093|NCT03791528|No Intervention|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
16427094|NCT03791515|Active Comparator|Calcitonin Gene-Related Peptide (CGRP)|"30 patients with PPTH will be allocated to receive intravenous infusion of 1.5 µg/min calcitonin-gene related peptide over 20 minutes
~Other Name: CGRP"
16427095|NCT03791515|Placebo Comparator|Placebo|"30 patients with PPTH wil be allocated to receive 40 mL Placebo (isotonic saline) over 20 minutes.
~Other Name: Isotonic Saline"
16427096|NCT03791502|Experimental|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
16427097|NCT03791502|Experimental|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
16427098|NCT03791502|No Intervention|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
16427099|NCT03791489|Experimental|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
16427100|NCT03791476|Placebo Comparator|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
16427101|NCT03791476|Experimental|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
16427102|NCT03791463|Experimental|After meal|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
16427103|NCT03791463|Experimental|Fasting|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered at the end of a 10-hour fast.
16427104|NCT03791450||pancreaticoduodenectomy|patients underwent pancreaticoduodenectomy in recent ten years.
16427105|NCT03791437|Experimental|Experiment groups|Post chest operative use Digital chest drainage system until Patient's discharge day
16427106|NCT03791437|Active Comparator|Control groups|Post chest operative use traditional drainage system until Patient's discharge day Not use Digital chest drainage system
16427107|NCT03791424|Experimental|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
16427108|NCT03791424|Placebo Comparator|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
16427109|NCT03791398|Experimental|ONC201 Level 1 (Starting Dose Level)|625mg ONC201 Cycle 1 Day -7 dose then once week
16427110|NCT03791398|Experimental|ONC201 Level 2|500 mg ONC201 Cycle 1 Day -7 dose then once week
16427111|NCT03791398|Experimental|ONC201 Level 3|375 mg ONC201 Cycle 1 Day -7 dose then once week
16427112|NCT03791398|Experimental|Nivolumab|240mg IV flat dose q 2 weeks
16427113|NCT03791385|Experimental|Study subjects|Children with ASD and their parents/caregivers were trained on tooth-brushing twice, two weeks apart using Picture Exchange Communication System (PECS) PECS as a pictures/cards series showing a structured tooth-brushing method.
16491581|NCT03349801||late AMD|No interventions.
16427114|NCT03791372|Placebo Comparator|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
16427115|NCT03791372|Experimental|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells>1*10^7/kg). The infusion speed is 1ml/min.
16427116|NCT03791333||multi trauma patients group|
16427117|NCT03791307|Experimental|Traditional Pilates group|This group will perform only exercises based on the traditional Pilates method
16427118|NCT03791307|Experimental|Modified Pilates group|This group will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer
16427119|NCT03791307|No Intervention|Control group|This group will not perform any physical exercise during the trial period.
16427120|NCT03791294|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
16427121|NCT03791294|No Intervention|Control|No treatment
16427122|NCT03791281|Experimental|BASIS|Received a 3-hour BASIS implementation strategy.
16427123|NCT03791281|Active Comparator|Attention Control|Received a 3-hour session designed to control for dose, information provided, and presenter effects.
16427124|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
16427125|NCT03791255|Experimental|Resin Modified Calcium Silicate|light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
16427126|NCT03791255|Active Comparator|Light Cured Calcium Hydroxide|gold standard for pulp capping, It allows for the formation of a reparative dentine bridge through cellular differentiation, extracellular matrix secretion and subsequent mineralization.
16427127|NCT03791242|Active Comparator|Group 1|33 morbidly obese patients with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
16427128|NCT03791242|Active Comparator|Group 2|33 morbidly obese patients with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
16427129|NCT03791216||Psoriasis patients to be treated only topically|
16427130|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
16427131|NCT03791216||Age-, sex- and BMI percentile-matched controls|
16427132|NCT03791216||Patients being treated with isotretinoin for acne|
16427133|NCT03791203|Experimental|Calorie restriction (MACR)|Participants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
16427134|NCT03791203|No Intervention|Control group|Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
16427135|NCT03791190|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
16427136|NCT03791190|Experimental|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.
~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
16427137|NCT03791177|Experimental|Study Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
16427138|NCT03791177|Sham Comparator|Control Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
16427139|NCT03791164|Experimental|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
16427140|NCT03791164|Active Comparator|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
16427141|NCT03791138|Experimental|intervention group|Care as usual and an online patient decision aid
16427142|NCT03791138|No Intervention|control group|Care as usual with a standard information leaflet
16427143|NCT03791125|Experimental|Experimental|
16427144|NCT03791125|Placebo Comparator|Placebo|
16427145|NCT03791112|Experimental|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
16427146|NCT03791112|Experimental|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
16427147|NCT03791112|Experimental|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
16429227|NCT03776617|Sham Comparator|Group sham|general anesthesia + Scalp block with 40ml Normal Saline
16427148|NCT03791112|Experimental|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
16427149|NCT03791112|Experimental|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
16427150|NCT03791112|Experimental|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
16427151|NCT03791099|Experimental|Metronidazole|19,8 mg of metronidazole in one polymer matrix
16427152|NCT03791099|No Intervention|Only SRP|standard non-surgical treatment- scaling/root planing
16427153|NCT03791086||Patients with bronchiectasis|Adult patients with bronchiectasis meeting the inclusion criteria.
16427154|NCT03791060|Experimental|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.
~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
16427155|NCT03791047|Experimental|Experimental Group: Balance analysis|Sixty older subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
16427156|NCT03791047|Active Comparator|Control Group:Balance Analysis|Sixty young subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
16427157|NCT03791021||third trimester pregnant women|the group of participants in this research would include approximately 100 subjects in the third trimester of their pregnancy. the participants would be collected in the central area of Israel from various socioeconomic groups. each participant would be asked to make draw a person (DAP) test, and answer a number of questionnaires including Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory II (BDI-II), and Traumatic Events Questionnaire (TEQ).
16427158|NCT03790995||High risk prostate cancer|"Patients with initial cT2c-3-4, cN +, Gleason score (GS) more than 7 or PSA > 20ng/mL were labelled as high-risk prostate cancer.
~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
16427159|NCT03790995||Low - intermediate risk prostate cancer|"Initial PSA levels less or equal than 20 ng/mL with GS of 7 or less and cT1-2a-2b, 2 were labelled as low and intermediate risk prostate cancer and served as a control group.
~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
16427160|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
16427161|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
16427162|NCT03790982|Experimental|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
16427163|NCT03790982|Experimental|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
16427164|NCT03790969|Experimental|26 gauge needle|intervention group
16427165|NCT03790969|Active Comparator|23 gauge needle|control group
16427166|NCT03790956|Experimental|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
16427167|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
16427168|NCT03790904|Active Comparator|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
16427169|NCT03790904|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
16427170|NCT03790904|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
16427171|NCT03790891|Experimental|CD19-TriCAR-T/SILK|CD19-TriCAR-T/SILK cells will be administered intravenously
16427172|NCT03790878|Experimental|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
16427173|NCT03790878|Active Comparator|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
16427174|NCT03790878|Placebo Comparator|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
16427175|NCT03790865|Experimental|Low-Dose Livoletide|Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
16427176|NCT03790865|Experimental|High-Dose Livoletide|Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
16427177|NCT03790865|Placebo Comparator|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
16427178|NCT03790852|Experimental|KSI-301 2.5 mg|KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
16427179|NCT03790852|Experimental|KSI-301 5 mg|KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
16427239|NCT03790462|No Intervention|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
16427240|NCT03790449|Experimental|PreLiFe-programme|A Mobile Preconception Lifestyle programme
16427180|NCT03790839|Experimental|Sequential arm ABC|A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
16427181|NCT03790826|Experimental|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.
~Interventions: cystoscopy"
16427182|NCT03790813|Experimental|Eligible patients|
16427183|NCT03790800|Experimental|Intervention group|If systolic blood pressure>180:IV Urapidil 25mg If systolic blood pressure>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
16427184|NCT03790800|No Intervention|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is >220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
16427185|NCT03790787|Experimental|Sequential arm ABC|A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
16427186|NCT03790774|Experimental|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
16427187|NCT03790761|Experimental|PREP 8.0 Curriculum|All participants enrolled in the program will be given the PREP 8.0 curriculum - there will be no comparison group.
16427188|NCT03790748|Experimental|Conventional Epidural Technique|Procedure: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L4-5 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
16427189|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|Procedure: 25G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
16427190|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 27G Whitacre needle|Procedure: 27G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
16427191|NCT03790735||Diagnostic test|Targeted chromosomal aberrations detection by FISH (MDA TEST).
16427192|NCT03790722|Experimental|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
16427193|NCT03790722|Experimental|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
16427194|NCT03790709|Experimental|High dose ANAVEX2-73|High dose active once daily orally
16427195|NCT03790709|Experimental|Mid dose ANAVEX2-73|Mid dose active once daily orally
16427196|NCT03790709|Placebo Comparator|Placebo oral capsule|Placebo dose once daily orally
16427197|NCT03790696|Experimental|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
16427198|NCT03790696|Sham Comparator|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
16427199|NCT03790683|Experimental|EnsoETM + Standard of Care|Participants receive esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU.
16427200|NCT03790683|Active Comparator|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
16427201|NCT03790670|Experimental|Leukine Treatment|24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
16427202|NCT03790657|Experimental|tDCS Dosage A|"mild electrical stimulation (Dosage level A) delivered to the frontal region of the brain during practice of a complex walking task"
16427203|NCT03790657|Experimental|tDCS Dosage B|"mild electrical stimulation (Dosage level B) delivered to the frontal region of the brain during practice of a complex walking task"
16427204|NCT03790644|Experimental|exoskeleton assist|walking with assist of a powered exoskeleton
16427205|NCT03790631||imipenem TDM|Adult patients receiving imipenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427206|NCT03790631||meropenem TDM|Adult patients receiving meropenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427207|NCT03790631||piperacillin TDM|Adult patients receiving piperacillin (with or without tazobactam) for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427208|NCT03790631||flucloxacillin TDM|Adult patients receiving flucloxacillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427209|NCT03790631||amoxicillin TDM|Adult patients receiving amoxicillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427210|NCT03790631||ceftazidime TDM|Adult patients receiving ceftazidime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427211|NCT03790631||cefepime TDM|Adult patients receiving cefepime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
16427212|NCT03790618|Placebo Comparator|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
16427213|NCT03790618|Experimental|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
16427214|NCT03790618|Experimental|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
16427215|NCT03790618|Experimental|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
16427241|NCT03790449|Other|Attention Control|Attention Control Programme
16427242|NCT03790436|Experimental|Betaquik|
16427216|NCT03790605|Experimental|1% curcumin chip|Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
16427217|NCT03790605|Placebo Comparator|Placebo chip|Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
16427218|NCT03790592|Experimental|trifocal IOL|patients implanted with a trifocal intraocular lens
16427219|NCT03790579||Women with gestational diabetes|We randomly selected the 40 pregnant women diagnosed GDM by two-step procedure based on Carpenter-Coustan criteria at this hospital. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
16427220|NCT03790579||Healthy women|We also randomly selected 40 healthy pregnant with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
16427221|NCT03790566|Experimental|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
16427222|NCT03790566|Active Comparator|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
16427223|NCT03790553|Active Comparator|50.4Gy|Total radiotherapy dose of 50.4Gy.
16427224|NCT03790553|Experimental|61.2Gy|Total radiotherapy dose of 61.2Gy.
16427225|NCT03790540|Experimental|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.
~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
16427226|NCT03790540|Active Comparator|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
16427227|NCT03790527|Experimental|CBM training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.
~Half of the participants will be random-assigned into the CBM training group; Each participant will do these task twice( e.g. Before training and after training)"
16427228|NCT03790527|Sham Comparator|Sham training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.
~Half of the participants will be random-assigned into the sham training group; Each participant will do these task twice( e.g. Before training and after training)"
16427229|NCT03790514|Experimental|Heat Wrap Group|
16427230|NCT03790514|Placebo Comparator|Control Group|
16427231|NCT03790501||People living with HIV (PLHIV).|We will recruit and enroll 850 people living with HIV (PLHIV) to participate in this longitudinal observational study.
16427232|NCT03790488|Experimental|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
16427233|NCT03790475|No Intervention|Current screening practice.|Subjects randomized into this group will receive named invitations for colonoscopy with pre-specified date, contact details of dedicated screening center. Invitations will be sent 6 weeks prior to suggested date of screening test. All subjects not responding to the invitation will receive a reminder letter 3 weeks prior to proposed appointment date. Additionally, a re-invitation for colonoscopy (screening test in 6 weeks) will be sent to participants not responding to the first invitation and the reminding letter.
16427234|NCT03790475|Experimental|Sequential screening strategy.|"Subjects randomized into this group will be initially invited to participate in a screening colonoscopy as per group 1. All subjects who will refuse colonoscopy or do not respond to invitation within 6 weeks since the first letter, will receive another invitation letter with FIT test enclosed.
~The screening office will contact persons with a positive test result in order to determine the date of the colonoscopy appointment.
~A negative test result will be sent together with a recommendation to have another screening test performed 2 years later and information about the possible delivery of the test in two years."
16427235|NCT03790475|Experimental|Multiple options screening strategy.|"Subjects in this group will receive a letter with an offer to choose between colonoscopy or FIT screening.
~The first letter will include an invitation with a scheduled date of colonoscopy (in 6 weeks) and a FIT kit.
~Three weeks before a scheduled date of colonoscopy subjects randomized into this group will receive a reminder letter with an information about proposed screening methods. After the scheduled date of the colonoscopy examination, subjects who will not respond to the invitation for colonoscopy and will not send the FIT test back to the laboratory will receive another invitation for colonoscopy (in 6 weeks) and a FIT kit."
16427236|NCT03790462|Experimental|Music intervention group 1|"Raga A will be played for 10 minutes & data collected."
16427237|NCT03790462|Experimental|Music intervention group 2|"Raga B will be played for 10 minutes & data collected."
16427243|NCT03790423|Experimental|18F-ASIS PET|One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection
16427244|NCT03790410|Active Comparator|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:
~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
16427245|NCT03790410|Active Comparator|Inspiratory muscle training group|"Complex pulmonary rehabilitation:
~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
~Inspiratory muscle training
~The training program contains strengthening exercises on the diaphragm muscle."
16427246|NCT03790384|No Intervention|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
16427247|NCT03790384|Experimental|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
16427248|NCT03790371|Active Comparator|misoprostol group|misoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
16427249|NCT03790371|Placebo Comparator|placebo|while the control group received a placebo tablet in the same regimen as the study group.
16427250|NCT03790358|Placebo Comparator|Placebo|Placebo
16427251|NCT03790358|Experimental|low dose MDMA|6.5ug dose of serotonin agonist
16427252|NCT03790358|Experimental|medium dose|13ug dose of serotonin agonist
16427253|NCT03790358|Experimental|high dose|26ug dose of serotonin agonist
16427254|NCT03790345|Experimental|Experimental group 1|15 subjects will be randomly assigned to adjuvant treatment with 200mg of vitamin B6 (pyridoxine).
16427255|NCT03790345|Experimental|Experimental group 2|15 subjects will be randomly assigned to adjuvant treatment with 2mg of vitamin B12 (cobalamin).
16427256|NCT03790345|Sham Comparator|Placebo oral tablet|15 subjects will be randomly assigned to adjuvant treatment with placebo.
16427257|NCT03790332|Experimental|Phase 1/2|"Part A: Subjects ≥1 to <12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED).
~Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED.
~Part B: Subjects ≥1 to <12 years of age( upper age limit is < 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily."
16427258|NCT03790319||Single Workshop 'The Emotional Backpack'|Subjects of this group are participating in one single workshop over three days.
16427259|NCT03790319||Year Program 'The Power of Feelings'|Subjects of this group are participating in three workshops of over 3 days each in a continuing group over nine months. They are animated to deal with the content inbetween the workshops through biweekly e-mails and to exchange in couples.
16427260|NCT03790293|Experimental|Rituximab|Rituximab in combination with reduced corticosteroids is administrated
16427261|NCT03790293|Active Comparator|Standard corticosteroid|Standard corticosteroid is administrated
16427262|NCT03790280|Experimental|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
16427263|NCT03790280|No Intervention|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
16427264|NCT03790267||Hip arthroplasty|
16427265|NCT03790267||Knee arthroplasty|
16427266|NCT03790267||Shoulder arthroplasty|
16427267|NCT03790241|Experimental|Young males of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
16427268|NCT03790241|Experimental|Young females of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
16427269|NCT03790241|Experimental|Aged males of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
16427270|NCT03790241|Experimental|Aged females of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
16427271|NCT03790241|Experimental|Obese young males|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
16427272|NCT03790241|Experimental|Obese young females|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
16427273|NCT03790241|Experimental|Obese aged males|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
16427274|NCT03790241|Experimental|Obese aged females|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
16427275|NCT03790228|Experimental|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
16427276|NCT03790215|Experimental|cohort for treatment|Participants enrolled are given dydrogesterone tablet of 10mg twice a day, from day 15 to day 24 of the menstrual cycle over a period of 3 months.
16427277|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
16427278|NCT03790189|Experimental|Bone Marrow Concentrate|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
16427279|NCT03790176|Other|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
16427280|NCT03790176|Other|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
16427411|NCT03789214|Placebo Comparator|Placebo|Placebo sleep medication (Placebo oral capsule)
16427281|NCT03790163|Placebo Comparator|levobupivacaine at ( 23˚C)|Levobupivacine hydrochloride at ( 23˚C) will be received 3.5 ml levobupivacaine at the operating room temperature 23˚C will be administered
16427282|NCT03790163|Active Comparator|Warm levobupivacaine at (30˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (30˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
16427283|NCT03790163|Active Comparator|Warm levobupivacaine at (37˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (37˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
16427284|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
16427285|NCT03790137|Experimental|Treatment group|The treatment group will include approximately 10 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for up to 6 months.
16427286|NCT03790111|Experimental|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg plus 1L therapy for the duration of the study
16427287|NCT03790098|Experimental|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
16427288|NCT03790098|No Intervention|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
16427289|NCT03790085|Experimental|Risperidone|It can be used after schizophrenia is diagnosed. Risperidone affects prolactin and may affect menstruation in young women, so we will try not to use it in such patients. Patients were randomized to a single Risperidone control trial for 8 weeks to evaluate the clinical efficacy of the patients. Risperidone routine daily 2-6 mg, up to 8 mg, can be taken orally twice a day.
16427290|NCT03790085|Experimental|Olanzapine|It can be used after schizophrenia is diagnosed. Olanzapine is not generally used in patients with diabetes and hyperlipidemia. Patients were randomized to a single Olanzapine control trial for 8 weeks to evaluate the clinical efficacy of the patients. Olanzapine is available once or twice a day, starting at 5 mg daily and up to 20 mg daily.
16427291|NCT03790085|Experimental|Aripiprazole|It can be used after schizophrenia is diagnosed. Aripiprazole has no specific contraindications. Patients were randomized to a single Aripiprazole control trial for 8 weeks to evaluate the clinical efficacy of the patients. Aripiprazole is taken orally once a day, starting at 10 mg daily and up to 30 mg daily.
16427292|NCT03790072|Experimental|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.
~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
16427293|NCT03790059|Experimental|RFA combined with H101 group|The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
16427294|NCT03790059|Other|Conventional RFA group|The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
16427295|NCT03790033|Experimental|UCHA group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Shinhwa Pharmaceutical company
16427296|NCT03790033|Placebo Comparator|Placebo group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Tsumura Co., Tokyo, Japan
16427297|NCT03790020|Active Comparator|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
16427298|NCT03790020|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
16427299|NCT03790020|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
16427300|NCT03790020|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
16427301|NCT03790007|Active Comparator|Transversus Abdominis Plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
16427302|NCT03790007|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
16427303|NCT03790007|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the gallbladder excision area-periportal area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periportal area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
16427304|NCT03790007|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
16427305|NCT03789994|Experimental|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.
~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
16427306|NCT03789994|Other|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
16427307|NCT03789981||At diagnosis|Immunogenic profile in patients affected by primary or secondary AML at diagnosis
16427308|NCT03789981||At relapse|Immunogenic profile in patients affected by primary or secondary AML at relapse
16427309|NCT03789955|Experimental|Fluoroscopic-guided TEB|After assessment of the epidural space using the loss of resistance technique with air under fluoroscopic guidance, six fluoroscopic views will be obtained: true anteroposterior, contralateral oblique (CLO) at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral for comparison CLO view with lateral view.
16427310|NCT03789942|Active Comparator|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
16427311|NCT03789942|Active Comparator|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.
~Oral surgery procedures Suturing End of procedure"
16427312|NCT03789942|Active Comparator|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.
~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
16427313|NCT03789929||The Emotional Backpack|Healthy adults participating in the offered online-course on their own initiative.
16427314|NCT03789929||Feelings as Powers|Healthy adults participating in the offered online-course on their own initiative.
16427315|NCT03789916|Experimental|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
16427316|NCT03789916|Active Comparator|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
16427317|NCT03789890|Experimental|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
16427320|NCT03789864||single-arm, non-randomized Biodynamic imaging (BDI)|Single-arm, non-randomized, Biodynamic phenotypic profiling of cancer (specifically, mycosis fungoides) therapy, gemcitabine . Standard of Care treatment with gemcitabine in this setting is 1200 mg/m2 as a 30 minute infusion given intravenously on days 1, 8, and 15 of every 28-day treatment cycle. Standard dose reductions are expected in patients experiencing unacceptable toxic effects of treatment. All subjects will undergo standardized staging tests, with tumor stage defined according to established guidelines. For this study, three 6-mm x 4-mm dermal punch biopsies from one or more target lesions will be collected prior to treatment initiation and submitted for Biodynamic imaging (BDI). All patients will be considered off-study after completing cycle 2.
16427321|NCT03789851|Experimental|core needle biopsy|All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
16427322|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
16427323|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
16427324|NCT03789812|Active Comparator|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
16427325|NCT03789812|Experimental|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
16427326|NCT03789812|Experimental|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
16427327|NCT03789812|Experimental|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
16427328|NCT03789799|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
16427329|NCT03789799|Placebo Comparator|Placebo|From the first postoperative day for ten days, single vaginal capsule per day of sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
16427330|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
16427331|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
16427333|NCT03789760|Experimental|active group|take two pills (120 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
16427334|NCT03789760|Placebo Comparator|control group|take two pills (120 mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
16427335|NCT03789734|Experimental|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
16427412|NCT03789214|Active Comparator|Low Dose Suvorexant|Low dose sleep medication
16427336|NCT03789734|Experimental|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
16427337|NCT03789734|Experimental|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
16427338|NCT03789734|Experimental|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
16427339|NCT03789721||Adrenoleukodystrophy|All patients living in the United States diagnosed with adrenoleukodystrophy, either by newborn screen, based on family history or otherwise, are eligible to participate in this study.
16427340|NCT03789708|Experimental|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
16427341|NCT03789708|Placebo Comparator|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
16427342|NCT03789708|Experimental|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
16427343|NCT03789708|Experimental|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
16427344|NCT03789695|Experimental|Dabigatran etexilate|Dabigatran etexilate (Pradaxa) 110 mg b.i.d. or 150 mg b.i.d. according SmPC during 2 years
16427345|NCT03789695|Active Comparator|Warfarin|Warfarin under the control of INR once a month (target range 2.0 - 3.0) during 2 years
16427346|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
16427347|NCT03789669|Experimental|Investigational|In phase I the investigators will use the investigational Cheetah femtosecond laser and Cheetah patient interface (PI) on one eye to create a LASIK flap (worst seeing eye should be preferred). Refractive correction via corneal ablation with a commercial excimer laser will be performed at the discretion of the investigator.If refractive correction is performed on the study eye, the fellow eye may receive standard LASIK treatment, otherwise, fellow eye will remain untreated.
16427348|NCT03789669|Active Comparator|Investigational/Control|"In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).
~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
16427349|NCT03789669|Active Comparator|Control/Investigational|"In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).
~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
16427350|NCT03789656|Experimental|Paltusotine|
16427351|NCT03789643|Experimental|JTT-251 Dose 1|One dose of study drug by mouth daily for 24 weeks
16427352|NCT03789643|Experimental|JTT-251 Dose 2|One dose of study drug by mouth daily for 24 weeks
16427353|NCT03789643|Experimental|JTT-251 Dose 3|One dose of study drug by mouth daily for 24 weeks
16427354|NCT03789643|Placebo Comparator|Placebo|One dose of study drug by mouth daily for 24 weeks
16427355|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
16427356|NCT03789617|Experimental|EBViNT Cell|
16427359|NCT03789591|Active Comparator|Standard Arm|Participants randomized to the standard arm will receive a starting dose of hydroxyurea of 20 mg/kg/day.
16427360|NCT03789591|Experimental|Alternative Arm|Participants randomized to the alternative arm will receive a pharmacokinetic guided starting dose of hydroxyurea based on PK labs drawn at a baseline visit to target an area under the curve (AUC) of 115 mg*h/L in an attempt to approximate maximum tolerated dose (MTD). This dose will not exceed the maximum tolerated dose of 35 mg/kg/day.
16427361|NCT03789578|Experimental|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
16427362|NCT03789578|Experimental|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
16427363|NCT03789578|Experimental|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
16427364|NCT03789565||Group 1. Healthy individuals from periodontal perspective:|GI < 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
16427365|NCT03789565||Group 2. Individuals diagnosed with Gingivitis|GI > 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
16427366|NCT03789565||Group 3. Individuals diagnosed with CP|GI > 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography.
16427367|NCT03789552|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.
~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
16427368|NCT03789552|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.
~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
16427369|NCT03789552|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
16427413|NCT03789214|Active Comparator|High Dose Suvorexant|High dose sleep medication
16427370|NCT03789539|Active Comparator|LD Universal Influenza Vaccine Uniflu|low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
16427371|NCT03789539|Active Comparator|HD Universal Influenza Vaccine Uniflu|high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
16427372|NCT03789539|Placebo Comparator|Placebo|saline 0.5 ml
16427373|NCT03789526|Experimental|Group 1|Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
16427374|NCT03789526|No Intervention|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
16427375|NCT03789513|Other|Triage with different options|"All women will have an HPV test, partial genotyping (16/18/45 versus other high-risk HPV [hr-HPV]) and VIA. The different options for triage that will be compared are:
~Participants hr-HVP+ and VIA+ participants selected for treatment;
~Participants HPV 16/18/45+ selected for treatment;
~Participant HPV 16/18/45+ and/or VIA+ selected for treatment;"
16427376|NCT03789487|Experimental|Non-responders to CRT|Non-responders to CRT who will undergo an electrical optimization of the settings of their device
16427377|NCT03789474|No Intervention|Group A|No intervention was done ,served as a control group.
16427378|NCT03789474|Experimental|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
16427379|NCT03789461|Experimental|Fecal Microbiota Transplantation|FMT infusion
16427380|NCT03789448|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
16427381|NCT03789448|Experimental|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
16427382|NCT03789435||Amputees|Patients underwent trans-tibial and trans-femoral amputation of any etiology at the Rizzoli Orthopedic Institute from 2015 to 2017 with the presence of analgesia data for surgery in a computerized record (SIR, Rizzoli information system). A questionnaire for the detection of residual limb pain will be administrate to all the survivors.
16427383|NCT03789422|Active Comparator|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
16427384|NCT03789422|Active Comparator|one drug|Levocetirizine 20 mg/day for a month
16427385|NCT03789409|Experimental|Intermittent Fasting|Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
16427386|NCT03789409|No Intervention|Ad libitium|Participants will be allowed to have hospital meals and all the desired intake without time limit.
16427387|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
16427388|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
16427389|NCT03789370|Active Comparator|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
16427390|NCT03789370|Active Comparator|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
16427391|NCT03789357||Single Arm|All patients admitted to the Acute Stroke Unit
16427392|NCT03789344|Experimental|Acupuncture treatment|
16427393|NCT03789344|Active Comparator|Psychotherapy|
16427394|NCT03789344|Placebo Comparator|blank control|
16427395|NCT03789331||Transgender Male individuals|"Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery.
~Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
16427396|NCT03789331||Normal healthy female individuals|"Group Description: Healthy women with normal sexual orientation.
~Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
16427397|NCT03789318|Active Comparator|CA-008|
16427398|NCT03789318|Placebo Comparator|Placebo|
16427399|NCT03789305||Critically ill patients|Critically ill patients admitted to intensive care for more than 48 hours
16427400|NCT03789292|Experimental|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
16427401|NCT03789292|Active Comparator|Humira SC (adalimumab)|Humira SC (adalimumab)
16427402|NCT03789279||Distal transradial arterial access|Patients undergoing invasive coronary angiography via the distal radial approach (anatomical snuffbox)
16427403|NCT03789266|Experimental|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
16427404|NCT03789266|Other|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
16427405|NCT03789253||AS cohort with progression|AS cohort with tumor progression
16427406|NCT03789253||AS cohort without progression|AS cohort without tumor progression
16427408|NCT03789227|Placebo Comparator|Group C|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 4 ml saline in a total volume 12 ml.
16427409|NCT03789227|Active Comparator|Group D|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 8 mg dexamethasone with 4 ml saline in a total volume 12 ml.
16427410|NCT03789227|Active Comparator|Group K|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 15 mg ketorolac with 4 ml saline in total volume 12 ml.
16427414|NCT03789201|Experimental|Healthy Volunteers|thematic permission to use non-invasive techniques regarded as having minimal risk in healthy individuals, such as, MRI, EEG, EMG, lowfrequency stimulation(= 1 Hz), electrical stimulation of the skin to mimic thesomatosensory artifact of TMS, and behavioral tests
16427415|NCT03789188||Healthy Volunteers|CC Registered Nurses
16427416|NCT03789175|Other|Nicotinamide riboside (NR) in Li-Fraumeni syndrome|Nicotinamide riboside (NR) to be initiated at week 0 at dose of 250 mg twice a day. At Week 1, NR will be titrated to 500 mg twice a day. At Week 6, NR will be titrated to 750 mg twice a day. At Week 7, NR will be titrated to 1000 mg twice a day or as tolerated until end of week 12. At week 12, if participant responds to primary endpoint, participant will washout of NR at week 18 then restart NR at week 24 until week 30. If there is not response to NR treatment at week 12, the participant may continue taking NR at a tolerated dose until week 24 and the primary endpoint will be re-measured. If participant has a positive response to NR treatment at week 24, then the participant will washout of NR until week 30, at which time the primary endpoint will be re-measured to ensure return to baseline. If there is no response to continued NR treatment at week 24, the study will be ended.
16427417|NCT03789162||Confirmed CRC with Residual Lesion|A diagnosis of CRC confirmed with a tissue biopsy or a colorectal lesion at least 1 cm in size suspicious for adenoma (including sessile serrated adenoma) or CRC on a pre-enrollment colonoscopy.
16427418|NCT03789149|Experimental|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
16427419|NCT03789136||Primary colon cancer|
16427420|NCT03789136||Liver metastases|
16427421|NCT03789136||Inguinal hernia (control)|
16427422|NCT03789136||Abdominal hysterectomy (control)|
16427423|NCT03789123|Experimental|Study Group (patients with OMA)|"I) Untreated patients (n=142)
~II) Dienogest (n=142)
~III) Dienogest/Estradiol valerate+Dienogest (n=142)"
16427424|NCT03789123|Sham Comparator|Control Group(patients without OMA)|"I) Untreated patients (n=142)
~II) Dienogest/Estradiol valerate+Dienogest (n=142)"
16427425|NCT03789110|Experimental|Nivolumab+Ipilimumab|"Ipilimumab is administered intravenously every 6 weeks
~Nivolumab is administered intravenously every 2 weeks"
16427427|NCT03789084|Experimental|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
16427428|NCT03789084|Other|Referral to mental health provider|Provider makes referral to a mental health provider
16427429|NCT03789071||Patient scheduled for general anesthesia with intubation|Patients in this group (only group) will have clinical airway assessment and external ultrasound assessment of the airway
16427430|NCT03789058|Active Comparator|Surgical with conventional NSAID 3 times/day|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
16427431|NCT03789058|Experimental|Surgical with conventional NSAID 2 times/days|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
16427432|NCT03789045||Obese men|Metabolic thresholds and fat oxidation points relationship in Obese males, age 18-60y, body fat > 30%
16427433|NCT03789045||Male athletes cyclists|Metabolic thresholds and fat oxidation points relationship in Athletic males, cyclist, age 18-60y, >12h of training weekly
16427434|NCT03789045||Sedentary females|Metabolic thresholds and fat oxidation points relationship in Sedentary nonactive females, age 40-60y,
16427435|NCT03789045||Moderately trained males|Metabolic thresholds and fat oxidation points relationship in moderately trained males, different sports, age 18-60y, < 3h of training weekly
16427436|NCT03789045||Male athletes runners|Metabolic thresholds and fat oxidation points relationship in Athletic males, different sports, age 18-60y, >12h of training weekly
16427437|NCT03789032|Experimental|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
16427438|NCT03789019|Experimental|BP-C1|"Dose-response part: patients who have completed the first 32-day treatment period with BP-C1 under Protocol BMC2011-1/Protocol MBC-BPC1/IIB or Protocol BMC2012-4, and having a maximum of moderate toxicity at the end of treatment are offered to continue in the second 32-day treatment period with BP-C1 under the protocol BMC2011-02. Patients completing 64-day treatment period with BP-C1 will be followed up for 28 days.
~Follow-up study: the patients will be given BP-C1 as long as they obtain benefit from the treatment (i.e. until disease progression or increase in toxicity not above moderate grade)."
16427439|NCT03789006|Active Comparator|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
16427440|NCT03789006|Active Comparator|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
16427444|NCT03788967|Experimental|TBPM-PI-HBr 300 mg film-coated tablets|TBPM-PI-HBr 600 mg administered orally three times per day for 7 to 10 days.
16427445|NCT03788967|Active Comparator|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 10 days.
16427446|NCT03788954|Active Comparator|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
16427447|NCT03788954|Active Comparator|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
16427448|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
16427449|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
16427450|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
16427451|NCT03788941||Catheter ablation|Patients will only receive catheter ablation of atrial fibrillation for treatment.
16427452|NCT03788915|Active Comparator|Online dietician lifestyle counseling|Online dietetic lifestyle counseling
16427454|NCT03788902|Experimental|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
16427455|NCT03788902|No Intervention|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
16427456|NCT03788889|Active Comparator|Lorazepam + Ketamine + Placebo A|"Ketamine - infusion (0.15 - 0.4 mg/kg/hr) and placebo injections titrated by increases of 0.075 mg/kg/hr every 30 minutes for Clinical Institute Withdrawal Assessment for Alcohol (revised version) (CIWA-Ar) greater than or equal to 10 in addition to lorazepam symptom-triggered therapy
~Ketamine dosing will be based on ideal body weight
~Ketamine infusion will be discontinued once CIWA-Ar less than 10 for 4 hours"
16427457|NCT03788889|Active Comparator|Lorazepam + Phenobarbital + Placebo B|"Phenobarbital - IV push (260 mg loading followed by 130 mg q1 hour) with placebo infusion until CIWA-Ar less than 10 with a maximum daily dose of 10mg/kg in addition to lorazepam symptom-triggered dosing for recurrent symptoms (Gold 2007)
~Maximum daily dose will be used in order to prevent over sedation as well as provide adequate storage in pharmacy monitored refrigerators for study drugs"
16427458|NCT03788889|Placebo Comparator|Lorazepam + Placebo A + Placebo B|Lorazepam will be administered every 30 minutes as indicated based on CIWA-Ar protocol for Cottage Health in addition to placebo injections and placebo infusion
16427459|NCT03788876|Active Comparator|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
16427460|NCT03788876|Sham Comparator|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
16427461|NCT03788863||Pregnant women exposed to glucocorticoids|Pregnant women exposed to any glucocorticoid or corticosteroid or steroids in early pregnancy or first trimester of pregnancy
16427462|NCT03788863||Non-exposed pregnant women|Women not using any glucocorticoid or corticosteroid or steroids during pregnancy
16427463|NCT03788837|Experimental|intravenous Ilomedin|a first dose of Ilomedin of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
16427464|NCT03788837|Placebo Comparator|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
16427465|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
16427466|NCT03788811||Control subjects|Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.
16427467|NCT03788811||Patients with schizophrenia (SZ)|Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
16427468|NCT03788811||Patients with bipolar disorder Type I (BP1)|Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
16427469|NCT03788798|No Intervention|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
16427470|NCT03788798|Experimental|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
16427471|NCT03788785|Experimental|Experimental arm|The specific tobacco cessation intervention of the treatment group will begin during the diagnostic phase of the HNSCC by three ½ hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days top. The most important point is that this intervention will be provided by trained nurses of the health care team within the ENT department, rather than in an external smoking cessation center.
16427472|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
16427473|NCT03788772|Experimental|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
16427474|NCT03788759|Experimental|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
16427475|NCT03788759|Placebo Comparator|Placebo group|25 subjects will be randomized to placebo.
16427476|NCT03788746||Patients diagnosed with advanced urothelial carcinoma|Patients with a confirmed diagnosis of advanced urothelial carcinoma, prior to or during first line therapy, who have available tumor tissue samples collected as part of standard of care
16427477|NCT03788733|Experimental|Melatonin|Melatonin ORAL FILM 3mg will be taken by the subject once a day for 8 weeks
16427478|NCT03788733|Placebo Comparator|placebo|ORAL FILM 3mg placebo will be taken by the subject once a day for 8 weeks
16427479|NCT03788720|Experimental|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
16427480|NCT03788720|Sham Comparator|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
16493493|NCT03336229|Active Comparator|Intervention|
16427481|NCT03788707|Experimental|Passive leg raising|Passive leg raising for 3 minutes after 20 seconds of lying flat
16427482|NCT03788694|Experimental|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
16427483|NCT03788681|Active Comparator|"oral estradiol  estradiol valerate"|"this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI .This group will receive oral estradiol  estradiol valerate  (Cyclo-Progynova® , 2mg , Bayer Schering Pharma Ag , Germany ) from within 24 hours ovum pickup of the cycle."
16427484|NCT03788681|Placebo Comparator|placebo|this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI . This group will receive oral placebo (tablets) from within 24 hours ovum pickup of the cycle
16427485|NCT03788668|Active Comparator|Hyoid suspension with barbed reposition pharyngoplasty|
16427486|NCT03788668|No Intervention|barbed reposition pharyngoplasty|
16427487|NCT03788642|Active Comparator|Control LED Shoe arm|Patients with DFU will wear LED shoe 30 minutes per day
16427488|NCT03788642|Active Comparator|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes per day
16427489|NCT03788629|Experimental|Study Group 1|Bobath Concept+ Talocrural joint Mulligan MWM techniques were applied to this group.
16427490|NCT03788629|Active Comparator|Study Group 2|Subtalar joint Mulligan MWM techniques were applied to this group in addition to Bobath Concept+ Talocrural joint Mulligan MWM techniques
16427491|NCT03788616|Active Comparator|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
16427492|NCT03788616|Active Comparator|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
16427493|NCT03788603|Experimental|Rogaratinib (BAY1163877)|Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
16427494|NCT03788590|Experimental|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
16427495|NCT03788577|Experimental|Oligonol intake group|This experimental arm will be applied for Oligonol 200mg/tab 1 tab per day. The program will last for 12 weeks.
16427496|NCT03788577|Placebo Comparator|Placebo group|This Placebo arm will be given capsules made of starch 1 tab per day. The program will last for 12 weeks.
16427497|NCT03788538|No Intervention|group 1 with no dexmedetomidine|
16427498|NCT03788538|Experimental|group 2 with dexmedetomidine 0.25μg/kg/h|
16427499|NCT03788538|Experimental|group 2 with dexmedetomidine 0.5μg/kg/h|
16427500|NCT03788525|Experimental|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
16427501|NCT03788525|Experimental|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
16427502|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
16427503|NCT03788499|No Intervention|Control arm|routine oral care and functional exercise.
16427504|NCT03788499|Experimental|Massage arm|Massage of Maxillofacial and oral cavity plus routine oral care and functional exercise
16427505|NCT03788486|Experimental|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
16427506|NCT03788473||Control.|Healthy Pregnant
16427507|NCT03788473||Case.|Pregnant with Periodontal Disease
16427508|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.
~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
16427509|NCT03788447|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
16427510|NCT03788447|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
16427511|NCT03788434|Experimental|VE303 High Dose|Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.
16427512|NCT03788434|Experimental|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.
16427513|NCT03788434|Placebo Comparator|Placebo|Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.
16427514|NCT03788421|Active Comparator|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
16427515|NCT03788421|Active Comparator|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
16427516|NCT03788408|Experimental|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
16427517|NCT03788408|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
16427518|NCT03788395|Experimental|Symbicort Turbohaler plus Turbo+|10 asthmatic children
16427519|NCT03788395|Active Comparator|Symbicort Turbohaler without Turbo+|10 asthmatic children
16427520|NCT03788369||Multivessel coronary artery disease|must include left anterior descending artery
16427521|NCT03788356|Experimental|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
16427522|NCT03788356|Experimental|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
16427523|NCT03788356|Experimental|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
16427524|NCT03788356|Experimental|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
16427525|NCT03788343|Experimental|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.
~Female
~<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0
~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0
~Male
~<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0
~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0
~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.
~Patients will take Phe for 4 weeks."
16427526|NCT03788343|Placebo Comparator|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.
~Patients will take the Placebo for 4 weeks."
16427527|NCT03788330|Experimental|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
16427528|NCT03788330|Placebo Comparator|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
16427529|NCT03788330|No Intervention|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
16427530|NCT03788304|Active Comparator|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -
~Positive End Expiratory Pressure (PEEP): 5 cmH2O.
~Pressure support (PS): 12-20 cmH2O.
~FiO2 will be adjusted to achieve a SpO2 at least 95%"
16427531|NCT03788304|Experimental|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .
~will be set with: -
~Temperature at 37°C or 34°C
~Flow rate 30: 50 L/min.
~FiO2 will be adjusted to achieve a SpO2 at least 95%"
16427532|NCT03788291|Experimental|Acalabrutinib and Rituximab treatment|"Rituximab: administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, Then 50 mg SQ thereafter.
~Acalabrutinib: 100 mg po BID starting on day 8 of cycle 1.
~Patients who have attained a complete response who are also MRD negative at cycle 12 will undergo a BM biopsy to confirm CR and MRD negatively. If confirmed, the patient will stop therapy and be followed until disease progression.
~Patients not in a MRD negative CR, will continue acalabrutinib.
~Repeat response assessments (CTs, MRD testing in blood) will be performed at 24 cycles of therapy for those continuing on acalabrutinib. If both negative the patient will undergo a BM biopsy to confirm CR and MRD negativity. If confirmed, the patient will stop therapy and be followed until disease progression. In the absence of a CR or if MRD +, acalabrutinib may be continued until disease progression, unacceptable toxicity or physician/patient discretion."
16427533|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.
~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.
~Participants will be required to answer digital questionnaires twice a day via smartphone."
16427534|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.
~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.
~Participants will be required to answer digital questionnaires twice a day via smartphone."
16427535|NCT03788265|Experimental|injection|
16427536|NCT03788252|Active Comparator|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
16427537|NCT03788252|No Intervention|Non-Renamezin|no use of Renamezin
16427538|NCT03788239|Experimental|Arm 1|Right knee wound closure by staples and Left Knee wound closure by sutures
16427539|NCT03788239|Experimental|Arm 2|Right knee wound closure by sutures and Left Knee wound closure by staples
16427540|NCT03788226|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
16427541|NCT03788226|Active Comparator|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.
~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.
~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
16427542|NCT03788213|Active Comparator|3 week RT|Adjuvant Radiotherapy delivered over 3 weeks
16427543|NCT03788213|Experimental|1 Week RT|Adjuvant Radiotherapy delivered over 1 week
16427544|NCT03788200|Active Comparator|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
16427545|NCT03788200|Active Comparator|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
16427546|NCT03788174|Experimental|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
16427547|NCT03788161|Experimental|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
16427548|NCT03788161|Placebo Comparator|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
16427549|NCT03788135|Experimental|Quadriceps cooling|Participants in this group will receive a cold pack on anterior thigh muscles for 20 minutes.
16493494|NCT03336229|No Intervention|Control|
16427550|NCT03788135|Experimental|Hamstring cooling|Participants in this group will receive a cold pack on posterior thigh muscles for 20 minutes.
16427551|NCT03788135|Experimental|Calf cooling|Participants in this group will receive a cold pack on posterior leg muscles for 20 minutes.
16427552|NCT03788135|Experimental|Back cooling|Participants in this group will receive a cold pack on posterior low back muscles for 20 minutes.
16427553|NCT03788135|No Intervention|Control|The participants in the control group will be rested for 20 minutes without any intervention.
16427554|NCT03788122|Other|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
16427555|NCT03788109|Other|device: combined solid state HRiM|combined solid state high resolution esophageal impedance and manometry (HRiM)
16427556|NCT03788096|Experimental|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
16427557|NCT03788096|Placebo Comparator|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
16427558|NCT03788083|Placebo Comparator|placebo|
16427559|NCT03788083|Active Comparator|TriMix|
16427560|NCT03788057|Other|stable asthma|"In patients with previously stable course of the asthma, every 3 months the symptoms are evaluated and the dose of ICS is customized - in accordance with the GINA guidelines. This decision is based solely on clinical data (control of symptoms) and is the same as in patients not participating in the study.
~In patients participating in the study, inflammatory parameters are also measured (sputum eosinophilia, eNO, EBT, bronchial reactivity), but results are not known to clinician taking decision about possible ICS dose reduction."
16427561|NCT03788044|Experimental|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
16427562|NCT03788044|Experimental|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
16427563|NCT03788044|Experimental|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
16427564|NCT03788044|No Intervention|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
16427565|NCT03788031|Experimental|Perceptual learning group - Amblyopia|Visual training
16427566|NCT03788031|Active Comparator|Perceptual learning group - Control|Visual training
16427567|NCT03788031|Placebo Comparator|Occlusion therapy - Amblyopia|Patching
16427568|NCT03788018|Experimental|Effect of IV lidocaine and dexmedetomidine on PONV|
16427569|NCT03788018|Experimental|Effect of IV saline on PONV|
16427570|NCT03788005|Active Comparator|Intervention group|"Early mobilization as soon as possible, within a maximum of 12 hours post-surgery.
~Subdural drains will be closed when the patient is allowed to mobilize and will be open during a nocturnal period of 8 hours. Subdural drains will be removed past 48 hours of surgery."
16427571|NCT03788005|No Intervention|Control Group|Bed rest with head of bed at 0 degrees for 48h. Subdural drains will be removed past 48 hours of surgery.
16427572|NCT03787992|Experimental|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
16427573|NCT03787992|Active Comparator|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
16427574|NCT03787979|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
16427575|NCT03787979|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
16427576|NCT03787966|Experimental|ATOPE-B|An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
16427577|NCT03787966|Active Comparator|ATOPE-I|An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
16427578|NCT03787953||Anti-PD-1/PD-L1 antibodies|Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
16427579|NCT03787940|Active Comparator|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
16427580|NCT03787940|Active Comparator|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
16427581|NCT03787940|Experimental|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
16430371|NCT03768700||Cohort|Hospitalization in a Post-Resuscitation Rehabilitation Care Units (SRPR)
16427582|NCT03787927|Other|5 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
16427583|NCT03787927|Other|5 day RTP, then 5 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
16427584|NCT03787927|Other|5 day RTP, then 10 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
16427585|NCT03787927|Other|5 day RTP, then 15 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
16427586|NCT03787927|Other|10 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
16427587|NCT03787927|Other|15 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
16427588|NCT03787914|Experimental|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
16427589|NCT03787914|Active Comparator|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
16427590|NCT03787901|Experimental|Morula Vitrification Arm|
16427591|NCT03787901|Active Comparator|Blastocyst Vitrification Arm|
16427592|NCT03787875||Control|The control group included 10 periodontally healthy subjects without signs or symptoms of periodontal disease.
16427593|NCT03787875||Study|"The study group included 15 subjects diagnosed with mild or advanced chronic periodontitis. Each periodontal patient had one non-affected single-rooted tooth (healthy site) and another single-rooted tooth with periodontitis (periodontitis site) with the following features:
~Healthy site: a single-rooted tooth with probing depths below or equal to 3 mm without recession and without bleeding on probing.
~Periodontitis site: another single-rooted tooth from the same patient with clinical attachment loss equal to or greater than 6 mm and bleeding upon probing."
16427594|NCT03787862||Hyperspectral Imaging (HSI)|Patients scheduled for foot surgery will be imaged using the HSI device. Data will be gathered from the electronic medical record for one year to determines the outcomes of the surgery, any complications, re-hosptializations, re-ulcerations or amputation.
16427595|NCT03787849|Active Comparator|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction . After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
16427596|NCT03787849|Active Comparator|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
16427597|NCT03787836|No Intervention|Controls|The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
16427598|NCT03787836|Experimental|Exercisers (Maintained)|The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
16427599|NCT03787836|Experimental|Exercisers (Increased Intensity)|The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
16427600|NCT03787823|Other|Retzius-sparing RARP|Arm B randomizes men with an indication for radical robotic Prostatectomy (RARP) to retzius-sparing transdouglas RARP
16427601|NCT03787823|Other|anterior transperitoneal RARP|Arm A randomizes men with an indication for radical robotic Prostatectomy (RARP) to anterior transperitoneal RARP
16427602|NCT03787784|Experimental|AI visible group|
16427603|NCT03787784|No Intervention|AI invisible group|
16427604|NCT03787771||FMT recipents|Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research
16427605|NCT03787771||FMT donors|Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research.
16427606|NCT03787758|Experimental|SAGE-718|
16427607|NCT03787745|Active Comparator|Ischemic postconditioning|In addition to state of the art primary PCI in patients with TIMI0-1 ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed, however thrombectomy will not be allowed
16427608|NCT03787745|Placebo Comparator|Conventional|State of the art primary PCI in patients with TIMI0-1 will be performed, however thrombectomy will not be allowed
16427609|NCT03787732|Active Comparator|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
16427610|NCT03787732|Active Comparator|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
16427611|NCT03787719|Experimental|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
16427612|NCT03787719|No Intervention|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
16427613|NCT03787706|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
16427614|NCT03787706|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
16427615|NCT03787693|No Intervention|Stroke Symmetric Non-VR|In this control arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
16427616|NCT03787693|Experimental|Stroke Symmetric VR|In this experimental arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
16427617|NCT03787693|No Intervention|Stroke Asymmetric Non-VR|In this control arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
16427618|NCT03787693|Experimental|Stroke Asymmetric VR|In this experimental arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
16427619|NCT03787680|Experimental|Cohort 1 (DRPro)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
16427620|NCT03787680|Experimental|Cohort 2 (DRDef)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
16427621|NCT03787667||Patients with pathologically diagnosed colorectal cancer|Patients with pathologically diagnosed colorectal cancer
16427622|NCT03787654|Experimental|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
16427623|NCT03787654|Sham Comparator|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
16427624|NCT03787654|Active Comparator|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
16427625|NCT03787641|Other|Protamine doze|Protamine Sulfate will be administered through an infusion pump in aliquots at a predefined rate (25 mg/min). Blood samples will be withdrawn after each aliquot and quantified for anti-Xa, IIa and ACT.
16427628|NCT03787615|Other|The sipIT tools|The wrist-worn sensors used to detect a drinking event (FitBit Versa with custom algorithm), an H2OPal connected water bottle and fluid consumption monitoring mobile applications.
16427629|NCT03787602|Experimental|Experimental: Stage 1, Arm 1b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
16427630|NCT03787602|Experimental|Experimental: Stage 1, Arm 2b|KRT-232 180mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
16427631|NCT03787589|Experimental|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
16430838|NCT03765632|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
16427632|NCT03787589|No Intervention|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
16427633|NCT03787563|Active Comparator|Active Herbal tea|One tea bag infusion three times a day each before breakfast, lunch and dinner.
16427634|NCT03787563|Placebo Comparator|Placebo Tea|Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.
16427635|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
16427636|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
16427637|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
16427638|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
16427639|NCT03787511|Other|Diabetic patients with chronic cough|Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
16427640|NCT03787511|Other|Diabetic patients without chronic cough|Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
16427641|NCT03787498|Experimental|PLX2853|Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.
16427642|NCT03787485||LINKS Participants|Study participants who took part in the LINKS intervention.
16427643|NCT03787485||Electronic Medical Record Controls|The principal analytical strategy is propensity score matching, which will lead to the generation of a natural control group from the health centers existing electronic medical records. Propensity matching is highly effective in addressing selection bias of known confounders and enables causal inferences when randomization is not possible, feasible or appropriate, by creating matched groups with similar covariate distributions. Matched controls will be extracted from the electronic medical record from the participating clinics.
16427644|NCT03787472|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
16427645|NCT03787472|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
16427646|NCT03787459|Active Comparator|oseltamivir plus placebo|
16427647|NCT03787459|Experimental|oseltamivir plus arbidol|
16427648|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
16427649|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
16427650|NCT03787433||ARC - Assisted Rehabilitation Care|All study participants will be asked to use ARC during for their post-stroke home based rehabilitation for up to 6 months.
16427651|NCT03787420|Active Comparator|traditional communication system|
16427652|NCT03787420|Experimental|intelligent communication system|
16427653|NCT03787407|Experimental|Mindfulness training with neurofeedback|mindfulness training with neurofeedback using mobile application instruction and review of the application will be provided
16427654|NCT03787407|Active Comparator|Mindfulness training|mindfulness training using mobile application instruction and review of the application will be provided
16427655|NCT03787407|No Intervention|Self-care|
16427656|NCT03787394|Experimental|FAAA-enriched|food products enriched with FAAA-conjugates
16427657|NCT03787394|Placebo Comparator|Plain|Food products without FAAA-conjugates
16427658|NCT03787381|Other|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
16427659|NCT03787368|Experimental|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
16427660|NCT03787368|Experimental|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
16427661|NCT03787368|Placebo Comparator|Placebo|Single intravenous infusion placebo
16427662|NCT03787355|Experimental|Cone Morse Connection Implants|2 neighboring Morse connection Implants
16427663|NCT03787355|Active Comparator|platform matched implants|2 neighboring platform matched implants.
16427664|NCT03787342|Experimental|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
16427665|NCT03787342|Experimental|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
16427722|NCT03786978|Experimental|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
16427723|NCT03786978|Active Comparator|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
16427724|NCT03786965|Other|On-pump CABG.|On-pump CABG.
16427725|NCT03786965|Other|Off-pump CABG.|Off-pump CABG.
16427666|NCT03787342|Experimental|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
16427667|NCT03787342|Active Comparator|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
16427668|NCT03787329||Bone marrow concentration group|The patients receive core decompression surgery with bone marrow concentration.
16427669|NCT03787329||Historical control group|The previous age-, gender-, and stage-matched patients who received core decompression surgery only.
16427670|NCT03787316|Experimental|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
16427671|NCT03787303|Experimental|Triiodothyronine (T3)|Following discontinuation of L-thyroxine (T4), triiodothyronine (T3) will be initiated at a 3:1 ratio. The dose will be titrated by the investigator to maintain levels of free T4 < 50% of normal range while maintaining a euthyroid state. Triiodothyronine (T3) tablets for oral administration will be prescribed once or twice daily depending on the total dose. Treatment duration will be approximately 9 months during which time the subjects will continue to be treated and monitored as usual for their metastatic breast cancer. During the study period and at the conclusion of the study period, there will be continuous evaluations of the disease status and thyroid status with the option of resuming the original thyroid replacement or continuation of the triiodothyronine (T3).
16427672|NCT03787290|Experimental|Tocilizumab|Participants will receive tocilizumab followed by whole-body hyperthermia
16427673|NCT03787290|Active Comparator|Placebo|Participants will receive a placebo followed by whole-body hyperthermia
16427674|NCT03787264|Experimental|BAAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated
~Induction: 6 cycles (q 28d) of Obinutuzumab + Acalabrutinib + Venetoclax
~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Acalabrutinib + Venetoclax
~Maintenance treatment will be continued until (whichever occurs first):
~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity
~maintenance cycle 8
~progression of CLL or start of a subsequent therapy
~unacceptable toxicity"
16427675|NCT03787251|Experimental|experimental group|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
16427676|NCT03787251|Active Comparator|Control group|"The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected).
~The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.
~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice."
16427677|NCT03787238|Experimental|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
16427678|NCT03787238|No Intervention|Standard of Care|Standard of Care treatment
16427679|NCT03787225|Experimental|NNC0174-0833 (0.3 mg)|Participants will receive single dose of NNC0174-0833
16427680|NCT03787225|Experimental|NNC0174-0833 (0.9 mg)|Participants will receive single dose of NNC0174-0833
16427681|NCT03787225|Experimental|NNC0174-0833 (1.8 mg)|Participants will receive single dose of NNC0174-0833
16427682|NCT03787225|Placebo Comparator|Placebo (NNC0174-0833)|Participants will receive placebo (NNC0174-0833)
16427683|NCT03787212|Experimental|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
16427684|NCT03787212|Experimental|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
16427685|NCT03787199|Experimental|Andago|Application of walking over-ground with body-weight support in the Andago
16427686|NCT03787199|Active Comparator|Treadmill|Application of walking on a treadmill with body-weight support
16427687|NCT03787186|Experimental|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by [14C]-GLPG1690 solution for infusion
16427688|NCT03787186|Experimental|[14C]-GLPG1690 capsules|[14C]-GLPG1690 capsules
16427689|NCT03787173|No Intervention|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
16427690|NCT03787173|Active Comparator|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
16427691|NCT03787173|Experimental|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
16427726|NCT03786965|Other|Pump-assisted CABG.|Pump-assisted CABG.
16427727|NCT03786965|Other|Heart Valve Procedure without CABG.|Heart Valve Procedure without CABG.
16427728|NCT03786965|Other|Heart Valve Procedure with CABG.|Heart Valve Procedure with CABG.
16427729|NCT03786952|Experimental|Stress, immediate, males|Stress immediately before learning in males
16427730|NCT03786952|Experimental|Stress, delayed, males|Stress 30 minutes before learning in males
16432195|NCT03756428|Placebo Comparator|Sham technique in tibialis posterior|Placebo tibialis dry needling
16427692|NCT03787160|Active Comparator|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
16427693|NCT03787160|Other|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
16427694|NCT03787147|Other|Spinal Injection|Adults receiving Spinal Injection(SI) without Virtual Reality(VR).
16427695|NCT03787147|Active Comparator|Google Cardboard|Adults receiving SI while using Google Cardboard Virtual reality head mounted display powered by a iPod touch
16427696|NCT03787147|Active Comparator|Oculus|Adults receiving SI while using VR with Oculus Rift.
16427697|NCT03787134|Experimental|2016-0500-Healthy YoungAdults|working memory and attention
16427698|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
16427699|NCT03787095|Experimental|Cohort 1: Cemiplimab|"Participants will receive 0.3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
16427700|NCT03787095|Placebo Comparator|Cohort 1: Placebo|"Participants will receive placebo, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
16427701|NCT03787095|Experimental|Cohort 2: Cemiplimab|"Participants will receive 1 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
16427702|NCT03787095|Placebo Comparator|Cohort 2: Placebo|"Participants will receive placebo, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
16427703|NCT03787095|Experimental|Cohort 3: Cemiplimab|"Participants will receive 3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
16427704|NCT03787095|Placebo Comparator|Cohort 3: Placebo|"Participants will receive placebo, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
16427705|NCT03787082|Experimental|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
16427706|NCT03787082|Placebo Comparator|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
16427707|NCT03787069|Experimental|Lignocaine group|This group will be given 1.5 mg/kg I/V lignocaine before intubation
16427708|NCT03787069|Placebo Comparator|Placebo|This group will be given 6 ml normal saline before intubation
16427709|NCT03787056|Other|Cancer patients|420 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 17 cohorts will be open, including: breast cancer, head and neck carcinomas, renal cell carcinoma, prostate carcinoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, thyroid cancer, pancreatic adenocarcinoma, ovarian adenocarcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma, B-cell lymphoma, gastric carcinomas. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies. Other cohort will be open (stability cohorts) : nychtemer cohort and post-operative kinetic cohort.
16427710|NCT03787043|Experimental|Sequence Group A|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted
~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed"
16427711|NCT03787043|Experimental|Sequence Group B|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed
~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted"
16427712|NCT03787030|Experimental|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
16427713|NCT03787030|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
16427714|NCT03787017|Experimental|Sequence Group A|"1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted
~2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted"
16427715|NCT03787017|Experimental|Sequence Group B|"1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted
~2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted"
16427716|NCT03787004|Experimental|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
16427717|NCT03787004|Experimental|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
16427718|NCT03787004|Experimental|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
16427731|NCT03786952|Sham Comparator|Sham control, immediate, males|Sham control immediately before learning in males
16427732|NCT03786952|Sham Comparator|Sham control, delayed, males|Sham control 30 minutes before learning in males
16427733|NCT03786952|Experimental|Stress, immediate, females|Stress immediately before learning in females
16427734|NCT03786952|Experimental|Stress, delayed, females|Stress 30 minutes before learning in females
16427735|NCT03786952|Sham Comparator|Sham control, immediate, females|Sham control immediately before learning in females
16427736|NCT03786952|Sham Comparator|Sham control, delayed, females|Sham control 30 minutes before learning in females
16427737|NCT03786939|Other|On-pump CABG.|On-pump CABG.
16427738|NCT03786939|Other|Off-pump CABG.|Off-pump CABG.
16427739|NCT03786939|Other|Pump-assisted CABG.|Pump-assisted CABG.
16427740|NCT03786926|Experimental|Treatment|All patients take HMPL-689 taken daily
16427741|NCT03786913||children with muscle disease|fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
16427742|NCT03786913||control group|20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
16427743|NCT03786887|Experimental|Nalbuphine|
16427744|NCT03786874|Active Comparator|20 teams the first year (G1)|control group
16427745|NCT03786874|Experimental|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
16427746|NCT03786861|Active Comparator|42 eyes in aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free in aberration free group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
16427747|NCT03786861|Active Comparator|24 eyes in corneal WFG group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing corneal WFG patterns in corneal WFG group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
16427748|NCT03786848|Experimental|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
16427749|NCT03786835|No Intervention|Control (No intervention)|Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
16427750|NCT03786835|Experimental|Nutrition group|Participants will receive protein enriched food to supplement the diet for 6 months.
16427751|NCT03786835|Experimental|Exercise group|Participants will exercise 3 times a week for 60 minutes each time over 6 months.
16427752|NCT03786835|Experimental|Nutrition + Exercise group|Participants will receive protein enriched food to supplement the diet and exercise 3 times a week for 60 minutes each time over 6 months.
16427753|NCT03786822|Experimental|Non-fluoroscopic Cryoballoon PVI|"Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.
~Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.
~Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
16427754|NCT03786822|Active Comparator|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
16427755|NCT03786809|Experimental|Experimental|Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
16427756|NCT03786809|Placebo Comparator|Placebo|Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
16427757|NCT03786796|Experimental|Olaparib|Participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L that have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy with measureable disease on CT imaging according to RECIST 1.1 criteria. Participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily provided there are no grade 3 or greater adverse events experienced. Reassessment will occur at least monthly for toxicity. Radiological scans will be performed every 3 months to assess disease response. Treatment will be continued until clinical and/or radiographic progression according to RECIST 1.1 criteria or unmanageable toxicity requiring cessation.
16427758|NCT03786783|Experimental|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
16427759|NCT03786770|Experimental|Cohort 1: Dose A|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
16427760|NCT03786770|Experimental|Cohort 2: Dose B|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
16427761|NCT03786770|Experimental|Cohort 3: Dose C|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
16427762|NCT03786770|Experimental|Cohort 4: Dose D|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
16427763|NCT03786757|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy.
16427764|NCT03786757|No Intervention|dual antiplatelet therapy (DAPT)|Conventional dual antiplatelet therapy will be adopted.
16427765|NCT03786744|Experimental|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
16427766|NCT03786744|Other|Standard therapy.|Patients with standard therapy as control group.
16427767|NCT03786731|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
16427768|NCT03786731|No Intervention|CAU group|Care-As-Usual group
16427769|NCT03786718|Experimental|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
16427848|NCT03786081|Experimental|A: Tisotumab Vedotin + bevacizumab|Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
16428601|NCT03780972|Active Comparator|Cohort 3 Dose C|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3
16427770|NCT03786705||Trauma patients' SBP ≥ 90 mm Hg with EMS|Only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm Hg at the ER were included in this study. The enrolled trauma patients divided into 2 groups, those who had received blood transfusion ≥ 10 U (massive transfusion) and those who had not (non-massive transfusion).
16427771|NCT03786692|Experimental|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
16427772|NCT03786692|Active Comparator|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
16427773|NCT03786679|Active Comparator|Orthosis group|An orthosis with the broken arm in neutral position fixed for four weeks. After these four weeks the patient is instructed to start rehabilitation.
16427774|NCT03786679|Active Comparator|Early rehabilitation group|The patient is instructed to start early rehabilitation about one week after the trauma.
16427776|NCT03786627|Experimental|Combined NMES and motor control|This group will receive combined 15-minute neuromuscular electrical stimulation and 30-minute motor control training based on movement system impairment concept.
16427777|NCT03786627|Placebo Comparator|Motor control and placebo NMES|This group will receive placebo NMES for 15 minutes followed by 30 minutes motor control training based on movement system impairment concept.
16427778|NCT03786614|Active Comparator|Discontinuation arm|This group will be discontinued from serotonergic antidepressants and shifting them to other categories of antidepressants, i.e., medications that work through dopamine or nor-epinephrine, or by reducing the serotonin signal rather than increasing synaptic serotonin, as might be accomplished with low dose, sub-anti-psychotic doses of some second-generation anti-psychotics.
16427779|NCT03786614|Active Comparator|Continuation arm|This group will continue taking serotonergic antidepressants which is the standard care of treatment.
16427780|NCT03786601||Group A,|High-risk HPV infection in postmenopausal women
16427781|NCT03786601||Group B|High-risk HPV negative in postmenopausal women
16427782|NCT03786601||Group C|High-risk HPV infection in gestational women
16427783|NCT03786601||Group D|High-risk HPV negative in gestational women
16427784|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
16427785|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
16427786|NCT03786575|Experimental|NGS detection group|Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
16427787|NCT03786562|Placebo Comparator|Placebo group|
16427788|NCT03786562|Active Comparator|Nalbuphine group|
16427789|NCT03786549|No Intervention|Control|Patients included in this arm wil have usual follow-up.
16427790|NCT03786549|Experimental|Care transitional program|"Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent
~Three axes are :
~Educative, family (patient and parent), at home
~Psychological, with the patient individually
~Medico-social orientation, group of patients"
16427791|NCT03786536|Experimental|Treatment|All volunteers will receive the same treatment
16427792|NCT03786523|Experimental|TRF|Time Restricted Feeding
16427793|NCT03786523|Active Comparator|CER|Continuous Energy Restriction
16427794|NCT03786510|Active Comparator|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
16427795|NCT03786510|Experimental|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
16427796|NCT03786510|Experimental|Intensive program only|The INT only group participated in a 4-week intensive program
16427797|NCT03786484|Experimental|PBF-999 20 mg|
16427798|NCT03786484|Experimental|PBF-999 40 mg|
16427799|NCT03786484|Experimental|PBF-999 80 mg|
16427800|NCT03786484|Experimental|PBF-999 120 mg|
16427801|NCT03786484|Experimental|recommended phase 2 dose (RP2D)|
16427802|NCT03786471|Active Comparator|Health Systems-Based Dementia Care|Dementia care that is based in the health care system, which partners with community-based organizations to provide comprehensive, coordinated, patient-centered care. The health system-based dementia care arm uses a Dementia Care Specialist (Nurse Practitioner or Physician Assistant) supervised by a physician to tailor and facilitate dementia care delivery in collaboration with the primary care physician (co-management). The Health Systems-Based Dementia Care arm is based on UCLA's Alzheimer's and Dementia Care Program.
16427803|NCT03786471|Active Comparator|Community-Based Dementia Care|Dementia care that is based in community organizations, which gives equal attention to patients and their primary family or friend caregivers. The community-based dementia care arm uses Care Consultants (Social Workers or Nurses). Patients with dementia are engaged in the program whenever possible. Caregivers can be the sole program participant, when patients are too impaired. The program establishes a long-term relationship between Care Consultants and families. The exact content of assistance provided is tailored to the preferences of individual patients and caregivers, and is holistic in the range of potential concerns of problems addressed. The Community-Based Dementia Care arm is based on the Benjamin Rose Institute on Aging's Care Consultation Program.
16427804|NCT03786471|Other|Enhanced Usual Care|Dementia care that most closely corresponds to traditional care. This arm will also receive standardized educational materials (hard copies and internet-based resources), referral to the Alzheimer's Association 1-800 national helpline to speak to a master's level consultant for decision-making support, crisis assistance, and caregiver education, as well as referral to local programs and services.
16427805|NCT03786458|Experimental|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
16427806|NCT03786432|Experimental|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
16432380|NCT03755219||Fibrin glue|Biologic glue/sealant produced from human donor blood
16427807|NCT03786419|Experimental|Atezolizumab|Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
16427808|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
16427809|NCT03786393||Fibromyalgia|100 participants diagnosed with fibromyalgia according to ACR 1990 criteria.
16427810|NCT03786393||Control|
16427811|NCT03786380|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
16427812|NCT03786367||CTEPH|Clinically stable patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) recruited from the Pulmonary Hypertension outpatient clinics at Hotel Dieu Hospital, Kingston, Ontario.
16427813|NCT03786367||Control|Age and sex-matched healthy control data collected as part of previous studies will be used as historic controls for this study.
16427814|NCT03786354|Experimental|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
16427815|NCT03786354|Experimental|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
16427816|NCT03786341|Experimental|with auxiliary illuminator|the walking training was by conventional strategy with lase quad-cane.
16427817|NCT03786341|Placebo Comparator|control group|Ambulation training WITHOUT laser quad-cane.
16427818|NCT03786328|Other|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
16427819|NCT03786328|Other|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
16427820|NCT03786315||Usual care|Older patients with multimorbidity and the GPs with whom they consult, from across five GP practices in Devon
16427821|NCT03786302|Experimental|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
16427822|NCT03786302|Active Comparator|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
16427823|NCT03786289|Experimental|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection
16427824|NCT03786289|Active Comparator|Recombinant human erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection
16427825|NCT03786276|Experimental|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
16427826|NCT03786276|Experimental|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
16427827|NCT03786276|Experimental|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
16427828|NCT03786263||Prospective Treatments for NS|"Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.
~Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.
~Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome."
16427829|NCT03786237|Experimental|Treatment Oral Capsules / Intravenous|
16427830|NCT03786224|Experimental|Abstinent|
16427831|NCT03786211|Active Comparator|IANB without panoramic|They will get Ianb without using panoramic
16427832|NCT03786211|Experimental|IANB with panoramic|They will get IANB by the guide of panoramic
16427833|NCT03786198|Experimental|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
16427834|NCT03786198|Active Comparator|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
16427835|NCT03786185|Experimental|Adolescents with dyslexia|MusicPlast training
16427836|NCT03786185|Active Comparator|Adolescents without dyslexia|MusicPlast training
16427837|NCT03786185|Experimental|Young Adults|MusicPlast training
16427838|NCT03786185|Active Comparator|Young Adults Control|MusicPlast Control, in a similar design as MusicPlast
16427839|NCT03786185|Experimental|Seniors|MusicPlast training
16427840|NCT03786172|Experimental|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
16427841|NCT03786172|Active Comparator|Usual care|A 10-second brief advice to quit smoking
16427842|NCT03786133||type 2 diabetics|Analysis of microbiological tests in chronic periodontitis patients with type 2 diabetes mellitus
16427843|NCT03786133||non-diabetics|Analysis of microbiological tests in chronic periodontitis patients without type 2 diabetes mellitus
16427844|NCT03786120||1|First 25 subjects
16427845|NCT03786120||2|Second cohort of 25 subjects
16427846|NCT03786094|Active Comparator|Eribulin|
16427847|NCT03786094|Experimental|Balixafortide + eribulin|
16428112|NCT03784300|Active Comparator|100 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.
16427849|NCT03786081|Experimental|B: Tisotumab vedotin + pembrolizumab|Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
16427850|NCT03786081|Experimental|C: Tisotumab vedotin + carboplatin|Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
16427851|NCT03786081|Experimental|D: Tisotumab vedotin + carboplatin|Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
16427852|NCT03786081|Experimental|E: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
16427853|NCT03786081|Experimental|F: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
16427854|NCT03786081|Experimental|G: Tisotumab vedotin monotherapy|Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
16427855|NCT03786055|Experimental|Somatic Yoga and Meditation (SYM)|Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
16427856|NCT03786042|Active Comparator|E-cigarette ad exposure|Participants in the e-cigarette ad exposure condition will view e-cigarette ads on the computer screen while having their eye movements tracked
16427857|NCT03786042|Sham Comparator|non e-cigarette ad exposure|Participants in the non e-cigarette ad exposure condition will view non e-cigarette ads on the computer screen while having their eye movements tracked
16427858|NCT03786029|Experimental|A (Acetaminophen)|22 children will receive 320mg (10ml) 30 minutes before the local anesthesia injection.
16427859|NCT03786029|Placebo Comparator|B (Placebo)|22 children will receive 10ml 30 minutes before the local anesthesia injection.
16427860|NCT03786029|Experimental|C (Ibuprofen)|22 children will receive 200mg (10ml) 30 minutes before the local anesthesia injection.
16427861|NCT03786016|Experimental|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
16427862|NCT03786003|Experimental|VATS|Video-assisted thoracoscopic surgery
16427863|NCT03786003|Active Comparator|Thoracotomy|Open surgery
16427864|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
16427865|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.
~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
16427866|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).
~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
16427867|NCT03785977||Air-Q 5-9kg|Participants weighing 5-9kg may be chosen to wear the Air-Q device.
16427868|NCT03785977||Air-Q 10-14kg|Participants weighing 10-14kg may be chosen to wear the Air-Q device.
16427869|NCT03785977||Air-Q 15-20kg|Participants weighing 15-20kg may be chosen to wear the Air-Q device.
16427870|NCT03785977||ETT 5-9kg|Participants weighing 5-9kg may be chosen to wear the ETT device.
16427871|NCT03785977||ETT 10-14kg|Participants weighing 10-14kg may be chosen to wear the ETT device.
16427872|NCT03785977||ETT 15-20kg|Participants weighing 15-20kg may be chosen to wear the ETT device.
16427873|NCT03785964|Experimental|Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
16427874|NCT03785964|Placebo Comparator|Placebo|Placebo 150 mg by mouth, twice daily
16427875|NCT03785951|Experimental|Whey Protein Isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
16427876|NCT03785951|Experimental|Wheat Protein|Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
16427877|NCT03785951|Experimental|Wheat protein with leucine|Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
16427878|NCT03785938|Experimental|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:
~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
16427879|NCT03785938|Placebo Comparator|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:
~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day
~Placebo will be delivered in similar, packaging, appearance and taste."
16427881|NCT03785912|Experimental|Internet-based self-help|The self-help program consists of eight text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
16427882|NCT03785912|No Intervention|Waiting control group|Access to internet-based intervention after 12 weeks.
16427883|NCT03785899|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
16427884|NCT03785899|Experimental|SPOCnew and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 2s."
16427885|NCT03785899|Experimental|SPOCnew and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 8s."
16428113|NCT03784300|Placebo Comparator|100 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.
16427886|NCT03785899|Active Comparator|SPOCold and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 2s."
16427887|NCT03785899|Active Comparator|SPOCold and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 8s."
16427888|NCT03785886|Experimental|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.
~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
16427889|NCT03785886|Experimental|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.
~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
16427890|NCT03785886|Experimental|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.
~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
16427891|NCT03785873|Experimental|Nal-Irinotecan and Nivolumab|
16427892|NCT03785860|Placebo Comparator|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
16427893|NCT03785860|Active Comparator|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
16427894|NCT03785821|Experimental|BMSO|Bitter melon seed oil supplementation
16427895|NCT03785821|Placebo Comparator|OO|Olive oil supplementation
16427896|NCT03785808|Experimental|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
16427897|NCT03785808|Experimental|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
16427898|NCT03785808|Active Comparator|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which ~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
16427899|NCT03785795||Uncertain diagnosis of true labor|Patients who cannot be accurately classified as experiencing true labor or false labor based on standard clinical assessments.
16427900|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
16427901|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
16427902|NCT03785769|Active Comparator|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by HVGIC restoration.
16427903|NCT03785769|Experimental|HVGIC restoration with non pre-etching|HVGIC restoration without the pre-etching of the surface.
16427904|NCT03785756|Experimental|Prolonged Release Group|Ibuprofen 300 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
16427905|NCT03785756|Active Comparator|Immediate Release Group|Ibuprofen 200 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
16427906|NCT03785756|Placebo Comparator|Placebo Group|Placebo of IR tablet Placebo of PR tablet
16427907|NCT03785743|Experimental|TLPD|Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
16427908|NCT03785743|Experimental|OPD|Open pancreaticoduodenectomy for pancreatic cancer
16427909|NCT03785730|Experimental|Non-restorative cavity control - NRCC|Enlargement with metallic sandpaper associated with toothbrushing/1000 ppm fluoride toothpaste.
16427910|NCT03785730|Active Comparator|Resin composite restoration - RCR|Selective carious lesion removal and restoration with resin composite.
16427911|NCT03785717|Active Comparator|ROG only|cancellous (1-2 mm) & cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
16427912|NCT03785717|Active Comparator|ROG & ESWT|cancellous 1-2mm & cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
16427913|NCT03785704|Experimental|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
16427914|NCT03785704|No Intervention|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
16427915|NCT03785691|Experimental|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).
~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
16427916|NCT03785691|Experimental|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.
~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
16427917|NCT03785691|Placebo Comparator|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.
~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
16427918|NCT03785678|Experimental|Tenecteplase|Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
16427919|NCT03785678|Placebo Comparator|Placebo|Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
16427920|NCT03785665|Experimental|Participants|All study participants will be examined by the MD1 capsules, 2-5 capsules per person, one capsule at a time. Efforts will be made to maintain balanced numbers between men and women and even distribution of ages
16427921|NCT03785652|Experimental|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
16427922|NCT03785652|Placebo Comparator|Placebo|Placebo tablet
16427923|NCT03785613|Experimental|Test Product T1: Buprenorphine patch (9 mg)|"Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.
~Matching placebo patch to T1: simultaneous application for 96 hours on the upper back."
16427924|NCT03785613|Experimental|Test Product T2: Buprenorphine patch (3.8 mg)|"Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters. Single application of patch during 96 hours, on skin in the midclavicular line directly under the clavicle.
~Matching placebo patch to T2: simultaneous application for 96 hours on the upper back."
16427925|NCT03785613|Active Comparator|Reference Product R: Transtec patch (20 mg)|"Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.
~Matching placebo patch to R: simultaneous application for 96 hours on the upper back."
16427926|NCT03785600|Experimental|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
16427927|NCT03785600|Sham Comparator|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
16427928|NCT03785587|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 24 weeks
16427931|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
16427932|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
16427933|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
16427934|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
16427935|NCT03785535|Experimental|Actual treatment|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (2-90 Hz), low intensity and long daily duration (3h).
16427936|NCT03785535|Sham Comparator|Sham|Sham treatment will be applied using identical instruments and with power and duration programmed identically. However, in this case, the output will not be the signal activating the vibration motors, but rather an electrical signal turning on an incorporated pilot light indicating that the (simulated) treatment was operating
16427937|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
16427938|NCT03785496|Experimental|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
16427939|NCT03785483|Experimental|Motivation|Using implementation intention techniques such as action planning. Every week, participants state when, where, and what kind of prescribed exercises they will do.
16432381|NCT03755219||Non-fixation|Mesh is deployed without fixation
16427940|NCT03785483|Active Comparator|Mindfulness|10 minutes of audio recordings daily. Recordings contain: awareness of the breath, acceptation of thoughts and emotions, awareness of postures, awareness during stretching, awareness of a single movement (moving legs up while standing).
16427941|NCT03785483|No Intervention|Treatment as usual|Physical activity prescribe 120 minutes per week.
16427942|NCT03785470|Experimental|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
16427943|NCT03785457|Experimental|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
16427944|NCT03785457|Experimental|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
16427945|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
16427946|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
16427947|NCT03785431|Experimental|Intervention|Patient diagnosed with ST elevation myocardial infarction will undergo bioresorbable stent deployment in culprit lesion.
16427948|NCT03785418|Experimental|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
16427949|NCT03785418|No Intervention|Control Arm|Standard Clinical Practice
16427951|NCT03785392|Active Comparator|Group 1 Inplane|Study with the technique Inplane group
16427952|NCT03785392|Active Comparator|Group 2 out of plane|Study with the technique out of plane
16427953|NCT03785379|Active Comparator|Caloric restriction and early SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
16427954|NCT03785379|Active Comparator|Caloric restriction and late SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
16427955|NCT03785366|Experimental|VeraCept|VeraCept subjects will be inserted with VeraCept on Day 1. At Day 57 subjects will be informed that they received VeraCept and may continue in the study for up to 5 years
16427956|NCT03785366|Active Comparator|ParaGard|ParaGard subjects will be inserted with ParaGard on Day 1. At Day 57 subjects will be informed that they received ParaGard and may choose to have the ParaGard removed or continue use per standard of clinical care.
16427957|NCT03785353|Experimental|PNE Group|A group of Spanish-speaking individuals will listen to a translated lecture related to PNE (PNE lecture). They will fill out the R-NPQ pre and post the lecture.
16427958|NCT03785340|Experimental|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
16427959|NCT03785340|Placebo Comparator|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
16427960|NCT03785327|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
16427961|NCT03785327|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
16427962|NCT03785327|Experimental|Autism Training Program|Training program designed to increase autism understanding followed by behavioral testing Intervention:Training program
16427963|NCT03785327|No Intervention|Social interaction without intervention|Control condition: Behavioral testing without an intervention component
16427964|NCT03785314|Active Comparator|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
16427965|NCT03785314|Active Comparator|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
16427966|NCT03785301|Experimental|FGM group|Diabetic patients will use FreeStyle Libre Flash Glucose Monitoring (FGM) system(unmasked) to monitor glucose level once a month for 3 months.
16427967|NCT03785301|No Intervention|SMBG group|Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
16427968|NCT03785288|Active Comparator|HDR VBT 3 fxs of 7Gy|Arm 1: HDR vaginal brachytherapy 3 fractions of 7Gy
16427969|NCT03785288|Active Comparator|HDR VBT 6 fxs of 4Gy|Arm 2: HDR vaginal brachytherapy 6 fractions of 4Gy
16427970|NCT03785275||Subjects with stable near-normal T1D|"Mixed-meal tolerance test
~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
16427971|NCT03785275||Subjects with unstable T1D|"Mixed-meal tolerance test
~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
16427974|NCT03785249|Experimental|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
16427975|NCT03785249|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
16427976|NCT03785249|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
16427977|NCT03785249|Experimental|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
16427978|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
16427979|NCT03785249|Experimental|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
16427980|NCT03785236||Tx-group|T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
16427981|NCT03785236||Control group|T1D patients that await islet of Langerhans transplantation
16427982|NCT03785223|Experimental|Methylphenidate Hydrochloride Controlled-Release Capsules|Flexibly dosed at 25-100 mg per day
16427983|NCT03785223|Placebo Comparator|Placebo Capsules|1-4 capsules daily
16427984|NCT03785210|Experimental|1/ Arm 1|Nivolumab, tadalafil and oral vancomycin
16427985|NCT03785184|Experimental|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
16427986|NCT03785171||Moyamoya disease|The cohort includes patients with Moyamoya disease diagnosed by DSA examination who are treated by surgical revascularization.
16427987|NCT03785158|Active Comparator|Melatonin|3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
16427988|NCT03785158|Placebo Comparator|Placebo Group|Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
16427989|NCT03785145|Experimental|MT10109L|MT10109L will be injected into the LCL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
16427990|NCT03785145|Placebo Comparator|Placebo|Placebo will be injected into the LCL: initial double-blind treatment on Day 1.
16427991|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
16427992|NCT03785119||Standard strategy|According to embryo quality (morphologic criteria)
16427993|NCT03785119||Experimental strategy|Association of embryo quality and sCD146 rate
16427994|NCT03785106|Experimental|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
16427995|NCT03785106|Active Comparator|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
16427996|NCT03785093||Chinese Family|Chinese parents and their offsprings
16427997|NCT03785080|Experimental|restart NOAC very early|restart NOAC within 24 hours
16427998|NCT03785080|Active Comparator|restart NOAC early|restart NOAC at 72 - 84 hours
16427999|NCT03785067|Experimental|Triple Pill (Active Treatment)|"Main Study: Fixed low-dose combination BP-lowering pill (Triple Pill) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg
~Sub-Study: single-arm"
16428000|NCT03785067|Placebo Comparator|Placebo|"Main Study: Matched placebo, received via blinded study capsules
~Sub-Study: single-arm"
16428001|NCT03785054|Experimental|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
16428002|NCT03785054|Experimental|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428003|NCT03785054|Experimental|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428004|NCT03785054|Experimental|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428005|NCT03785054|Experimental|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428006|NCT03785054|Experimental|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428007|NCT03785054|Experimental|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428008|NCT03785054|Experimental|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428009|NCT03785054|Experimental|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
16428010|NCT03785041|Active Comparator|Levobupivacaine and tramadol Preemptive|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
16428011|NCT03785041|Active Comparator|Tramadol and levobupivacaine postoperative|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
16428012|NCT03785041|Active Comparator|Tramadol and levobupivacaine preemptive and postoperative|20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
16428013|NCT03785041|Active Comparator|Levobupivacaine|20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
16428014|NCT03785028|Experimental|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
16428015|NCT03785015|Experimental|Withold aspirin till after endoscopic haemostasis|Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.
16428016|NCT03785015|Active Comparator|Withold aspirin till 72 hours|Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.
16428017|NCT03785002|Experimental|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
16428018|NCT03785002|Active Comparator|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
16428019|NCT03784976|Experimental|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
16428020|NCT03784976|No Intervention|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
16428021|NCT03784963|Experimental|Primary Prevention Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
16428022|NCT03784963|Placebo Comparator|Primary Prevention Non-Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
16428023|NCT03784963|Experimental|Secondary Prevention Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
16428024|NCT03784963|Placebo Comparator|Secondary Prevention Non-Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
16428025|NCT03784950|Experimental|Rating tool only|Rating eConsults from peer specialists in first phase
16428026|NCT03784950|Experimental|Feedback only|Receiving feedback from peer specialists in first phase
16428027|NCT03784950|Experimental|Rating Tool plus Feedback|Both rating and feedback in second phase.
16428028|NCT03784924||Initial prostate biopsy|Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.
16428029|NCT03784911||During Cancer Treatment Group|Participants' body composition will be estimated using a SOZO device at 5 different time points across their cancer treatment. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, cancer distress assessment, ECOG performance status, hand grip strength test, and 24-hour food recall. DEXA scans will be performed before treatment and after completion of treatment.
16428030|NCT03784898|Other|Participants Diagnosed With ITP|Participants with RMS who developed ITP after Lemtrada treatment were included in this study and provided blood samples for future genetic testing and biomarker analysis.
16428031|NCT03784885|Experimental|30 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 30 μg of AD07010
16428032|NCT03784885|Experimental|45 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 45 μg of AD07010
16428033|NCT03784885|Active Comparator|AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine
16428034|NCT03784859||All patients in study|5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.
16428035|NCT03784846|Experimental|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
16428036|NCT03784846|Active Comparator|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
16428037|NCT03784846|No Intervention|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
16428038|NCT03784820|Experimental|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
16428039|NCT03784820|Active Comparator|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
16428040|NCT03784807||Infected|Patients with prosthetic joint or osteoarticular infection
16428041|NCT03784807||Not infected|Patients with implant failure not due to infection
16428042|NCT03784794|Experimental|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
16428043|NCT03784794|Active Comparator|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
16428044|NCT03784781||Asthmatic children|Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
16428045|NCT03784781||Controls|Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
16428114|NCT03784300|Active Comparator|200 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.
16428046|NCT03784768|Experimental|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
16428047|NCT03784768|Active Comparator|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
16428048|NCT03784755|Active Comparator|Arm 1 (standard of care)|"Standard systemic therapy
~+ Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden"
16428049|NCT03784755|Experimental|Arm 2 (standard systemic therapy + ablative therapy))|"Local Ablative therapy to all sites of disease (including untreated prostate primary)
~+ Standard systemic therapy"
16428050|NCT03784742|Active Comparator|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
16428051|NCT03784742|Placebo Comparator|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
16428052|NCT03784729|Experimental|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted."
16428053|NCT03784729|Sham Comparator|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm.
16428054|NCT03784716|Experimental|Ketogenic Diet|Ketogenic Diet for 28 Days
16428055|NCT03784716|Active Comparator|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
16428056|NCT03784703|Experimental|Atrovastatin|atorvastatin (40 mg per day) for 6 months
16428057|NCT03784703|Experimental|Rosuvastatin|Rosuvastatin (10 mg per day) for 6 months
16428058|NCT03784690|Experimental|Individualized BP group|Individualized intraoperative BP management
16428059|NCT03784690|Placebo Comparator|Standard treatment group|Standard intraoperative BP management
16428060|NCT03784677|Experimental|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16428061|NCT03784664|Active Comparator|Arterial blood gas|
16428062|NCT03784664|Experimental|Veinous blood gas|
16428063|NCT03784638|Experimental|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
16428064|NCT03784638|Placebo Comparator|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
16428065|NCT03784625|Experimental|therapeutic dose activity (level 1)|[131]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
16428066|NCT03784625|Experimental|therapeutic dose activity (level 2)|[131]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
16428067|NCT03784625|Experimental|therapeutic dose activity (level 3)|[131]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
16428068|NCT03784625|Experimental|therapeutic dose activity (level 4)|[131]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
16428069|NCT03784612|Experimental|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.
~Intervention: App-technology for healthy eating habits."
16428070|NCT03784612|No Intervention|Control group|The control group will receive standard care.
16428071|NCT03784599|Experimental|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks
~Osimertinib 80 mg once daily, orally, continuous
~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
16428072|NCT03784586||Positive EPS - ICD|Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
16428073|NCT03784586||Negative EPS - PMK|All non inducible patients underwent PMK implantation
16428074|NCT03784573|Active Comparator|Dog + handler|
16428075|NCT03784573|Placebo Comparator|No dog|
16428076|NCT03784560||study group|anesthesia residents with 24 hours working shift
16428077|NCT03784547||multiple sclerosis patients|multiple sclerosis patients receiving ocrelizumab 600 mg endovenous every 6 months
16428078|NCT03784534|Experimental|Healthy volunteers|"Subjects will be asked to perform:
~high= density (64 sensors) EEG
~clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
~anatomical MRI (T1 and tensor imaging) scan)"
16428079|NCT03784534|Experimental|Patients|"Patients will be asked to perform:
~high= density (64 sensors) EEG
~clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth
~anatomical MRI (T1 and tensor imaging) scan)"
16428080|NCT03784521|Experimental|In-line filtration|For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).
16428115|NCT03784300|Placebo Comparator|200 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.
16428081|NCT03784521|Active Comparator|Control|For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.
16428082|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
16428083|NCT03784495|Placebo Comparator|Placebo (P)|Placebo.
16428084|NCT03784495|Experimental|Melatonin (M)|1 mg/day of melatonin.
16428085|NCT03784495|Experimental|Essential Aminoacids (eAA)|4 g/day of essential aminoacids
16428086|NCT03784495|Experimental|Essential Aminoacids + Melatonin (eAAM)|4 g/day of essential aminoacids and 1 mg/day of melatonin
16428087|NCT03784469|Experimental|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
16428088|NCT03784469|No Intervention|Control group|No changing body position in bed,remaining supine position in complete bed rest and immobilized for four hours.
16428089|NCT03784456|Experimental|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
16428090|NCT03784456|Active Comparator|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
16428091|NCT03784443|Active Comparator|Iluvien Arm|Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
16428092|NCT03784443|Sham Comparator|Control Arm|To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
16428093|NCT03784430|Active Comparator|Implant|Immediate dental implant placement
16428094|NCT03784430|Experimental|Implant+CTG|Immediate dental implant placement with CTG.
16428095|NCT03784417|Experimental|EUS-guided laser ablation|Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
16428096|NCT03784404|Active Comparator|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
16428097|NCT03784404|Active Comparator|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
16428098|NCT03784391||Treatment|Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
16428099|NCT03784391||Reference|Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment
16428100|NCT03784378|Experimental|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
16428101|NCT03784365|Active Comparator|First group|This group will receive an intravenous antibiotic for three days. The first dose will be given within half hour before the POEM procedure.
16428102|NCT03784365|Experimental|Second group|This group will receive only one dose of intravenous antibiotic within half hour before the POEM procedure
16428103|NCT03784352|Experimental|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
16428104|NCT03784352|No Intervention|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
16428105|NCT03784339|Placebo Comparator|Physiotherapy|Participants will receive standard physiotherapy care, which will involve strength exercises and taping.
16428106|NCT03784339|Experimental|Physiotherapy + education|Physiotherapy + education Standard physiotherapy care plus 30 minute education session addressing fear of movement and catastrophizing thoughts.
16428107|NCT03784326|Experimental|Treatment (oxaliplatin, fluorouracil, atezolizumab, surgery)|Patients receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 4-6 weeks of treatment completion, patients undergo surgical resection. Beginning 6 weeks after surgery, patients continue to receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive atezolizumab monotherapy IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16428108|NCT03784313|Experimental|Perforators flaps (PF group)|
16428109|NCT03784313|Sham Comparator|Secondary intention wound healing|
16428110|NCT03784300|Active Comparator|50 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.
16428111|NCT03784300|Placebo Comparator|50 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.
16428116|NCT03784287|Experimental|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
16428117|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
16428118|NCT03784261|Active Comparator|SAR, usually subucutaneous injection every 2 weeks|
16428119|NCT03784261|Active Comparator|TCZ, usually subucutaneous injection every 2 weeks|
16428120|NCT03784261|Active Comparator|ABT, usually subucutaneous injection every week|
16428121|NCT03784248||asymptomatic carrier|
16428122|NCT03784248||uninfected subjects|
16428125|NCT03784222|Experimental|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
16428126|NCT03784222|Other|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
16428127|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
16428128|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
16428129|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
16428130|NCT03784183|Experimental|moderate AD-experimental|Experimental Intervention: The CS shall be carried out in groups (5-7 participants), twice a week. Each session lasts 90 minutes. CS sessions begin with a training for temporal and spatial orientation in which participants are asked to recognize and recall the date and the place with the help of some environmental aids (calendars, clocks, pictures and maps). Then the participants complete an array of cognitive tasks for memory, attention, language, visuo-spatial functions and executive functions. These tasks range from individual paper-and-pencil exercises to verbal-learning exercises that have to be solved by the group.
16428131|NCT03784183|Experimental|mild AD-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
16428132|NCT03784183|Experimental|MCI-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
16428133|NCT03784183|No Intervention|moderate AD-placebo|
16428134|NCT03784183|No Intervention|mild AD-placebo|
16428135|NCT03784183|No Intervention|MCI-placebo|
16428136|NCT03784170|Experimental|Treatment|FemPulse System at one device setting
16428137|NCT03784170|Sham Comparator|Control|FemPulse System at a different device setting
16428138|NCT03784144|Experimental|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
16428139|NCT03784144|Active Comparator|Control|The patients will perform both tests without any cognitive condition
16428140|NCT03784131|Experimental|Personalized Tissue Engineered Vein|P-TEV
16428141|NCT03784118|Experimental|Children|Children who are followed up after arterial catheterization for evaluation of complications, using ultrasonography
16428142|NCT03784105|Experimental|Codeine|
16428143|NCT03784105|Placebo Comparator|Siripus simplex|
16428144|NCT03784092|No Intervention|control|
16428145|NCT03784092|Experimental|feedback|
16428146|NCT03784079|Experimental|Part 1: GSK3640254 10 mg|Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.
16428147|NCT03784079|Experimental|Part 1: GSK3640254 200 mg|Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.
16428148|NCT03784079|Placebo Comparator|Part 1: Placebo|Participants will receive placebo capsules, orally for 10 days.
16428149|NCT03784079|Experimental|Part 2: GSK3640254 40 mg|Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.
16428150|NCT03784079|Experimental|Part 2: GSK3640254 80 mg|Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.
16428151|NCT03784079|Experimental|Part 2: GSK3640254 140 mg|Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.
16428152|NCT03784079|Placebo Comparator|Part 2: Placebo|Participants will receive placebo capsules, orally for 7 days.
16428153|NCT03784066|Active Comparator|A|Durvalumab
16428154|NCT03784066|Active Comparator|B|Durvalumab + Tremelimumab
16428155|NCT03784053||Immersive virtual reality|Participants will receive eight 30-minute sessions of immersive virtual reality.
16428156|NCT03784040|Experimental|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
16428157|NCT03784040|Experimental|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.
16428158|NCT03784027|Experimental|Automated closed loop insulin delivery (intervention arm)|"Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.
~Intervention: Device: CamAPS FX"
16428159|NCT03784027|Active Comparator|Sensor augmented pump therapy (control arm)|Sensor augmented pump therapy over 16 weeks.
16428160|NCT03784014|No Intervention|Arm No NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.
~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
16428179|NCT03783884|No Intervention|Control|Subject does not receive Lungpacer LIVE Catheter or DPTS. Subject receives only Standard of care for weaning from mechanical ventilation.
16428180|NCT03783871|Experimental|Single-arm|Subjects will be treated with microwave ablation.
16428181|NCT03783858|Other|Single|
16432382|NCT03755206|Other|Intervention|Interrupted time series design
16428161|NCT03784014|Experimental|Arm NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. After tumor assessment at the end of first-line systemic treatment and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.
~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
16428162|NCT03784014|Experimental|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
16428163|NCT03784001|Active Comparator|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
16428164|NCT03784001|Experimental|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
16428165|NCT03784001|Active Comparator|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
16428166|NCT03783988|Other|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
16428167|NCT03783975|Experimental|Simplified Cascade Screening|Free, mail-in, saliva-based screening for the KCNQ1 Thr224Met variant.
16428168|NCT03783962|Experimental|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the Nutrition and Food Sciences (NFS) foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
16428169|NCT03783962|Active Comparator|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
16428170|NCT03783949|Active Comparator|Standard arm (arm A)|Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w)
16428171|NCT03783949|Experimental|First experimental arm (arm B)|Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w)
16428172|NCT03783949|Experimental|Second experimental arm (arm C)|Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)
16428173|NCT03783936|Other|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days
~mFOLFOX6
~oxaliplatin 85 mg/m2 IV Day 1 and
~leucovorin 400 mg/m2 IV Day 1 and
~5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and
~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and
~Avelumab 800 mg IV Day 1
~Cycles 10 and subsequent; Maintenance; Cycle = 14 days
~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
16428174|NCT03783923|Experimental|Deflazacort|Participants will receive deflazacort 0.6 milligrams per kilograms per day (mg/kg/day) orally. The dose could be reduced in case of tolerability issues. Any participant assigned to placebo prior to the Version 4.0 amendment (prior to or after 01 February 2020) will have the option to be consented under Version 4.0 and will be switched to deflazacort for 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (prior to 01 February 2020) will have the option to re-consent under Protocol Version 4.0 and continue for an additional 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (after 01 February 2020) will have the option to re-consent under Protocol Version 4.0 at their Week 13 Visit and continue treatment until Week 26. Any new participant enrolled until 31 May 2020 will receive deflazacort for 26 weeks.
16428175|NCT03783910|Experimental|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).
~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
16428176|NCT03783910|Placebo Comparator|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
16428177|NCT03783897|Experimental|EDP-305 and Oral Contraceptive|
16428178|NCT03783884|Active Comparator|Treatment|Subject receives Lungpacer LIVE Catheter insertion for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.
16428182|NCT03783845|Experimental|test group|"Metronidazole 400mg,three times daily for two weeks
~Amoxicillin 500mg,three times daily for two weeks."
16428183|NCT03783845|No Intervention|control group|no intervention during study period
16428184|NCT03783819|Active Comparator|Active treatment|One forearm will be treated with ointment containing Hypericum perforatum oil. Forearm (left or right) will be chosen according to randomization protocol.
16428185|NCT03783819|Placebo Comparator|Placebo treatment|Other forearm will be treated with placebo ointment. Forearm (left or right) will be chosen according to randomization protocol.
16428186|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
16428187|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
16428188|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
16428189|NCT03783793|Experimental|Mindfulness Training App|
16428190|NCT03783793|Active Comparator|Cognitive Training With 2048|
16428191|NCT03783780|Experimental|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
16428192|NCT03783767|Experimental|Leadership Intervention Group|Teachers in the intervention group will receive a half day workshop from a member of the research team. These teachers will then provide a four week training program to Grade 6/7 students, who will then deliver a 10-week fundamental movement skill (FMS) training program to Grade 3/4 students.
16428193|NCT03783767|No Intervention|Waitlist Control|This group of students and teachers will act as a waitlist control group. Therefore, during the same time that the other group is receiving the intervention, this group will proceed with their normal practices.
16428194|NCT03783754|Experimental|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
16428195|NCT03783754|Placebo Comparator|Placebo|received via blinded study oral capsules
16428196|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
16428197|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
16428198|NCT03783702|Experimental|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
16428199|NCT03783702|Active Comparator|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
16428200|NCT03783689|Active Comparator|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
16428201|NCT03783689|Sham Comparator|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
16428202|NCT03783676|Experimental|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
16428203|NCT03783676|Placebo Comparator|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
16428204|NCT03783663|Experimental|Sleep education plus Misfit Shine 2|This arm receives sleep education from the study nurse and also receives a Misfit Shine 2 to wear for 12 weeks to self-monitor sleep.
16428205|NCT03783663|No Intervention|sleep education only|This arm receives only sleep education from the study nurse.
16428206|NCT03783650|Experimental|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry & BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
16428207|NCT03783650|Active Comparator|Cohort 2|0-6 months: Control condition Usual Care and Registry & BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
16428208|NCT03783637|Other|Whole Grain Oat|Volunteers will consume a breakfast meal containing whole grain oats after 7 days of a whole grain free diet.
16428209|NCT03783637|Other|Whole Grain Wheat|Volunteers will consume a breakfast meal containing whole grain wheat after 7 days of a whole grain free diet.
16428210|NCT03783624|Experimental|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic… a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again…."
16428211|NCT03783624|Placebo Comparator|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
16428212|NCT03783624|No Intervention|Usual care|Patients continue with their usual treatments
16428375|NCT03782584|Experimental|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
16428213|NCT03783611|Experimental|Intervention group|The intervention group has access to the MyPlan 2.0. eHealth intervention. MyPlan is a eHealth intervention designed to increase physical activity. The intervention is based on the self-regulation theory and focuses on pre- and post-intentional processes to increase physical activity.
16428214|NCT03783611|No Intervention|control group|The control group receives no intervention
16428215|NCT03783598|Experimental|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
16428216|NCT03783598|No Intervention|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
16428217|NCT03783585|Experimental|cognitive behavioral therapy for insomnia (CBT-I)|Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
16428218|NCT03783585|Experimental|CBT-I + biweekly support|Participants randomized to this arm will participate in a 6-week web-based CBT-I program. In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
16428219|NCT03783572|Experimental|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
16428220|NCT03783572|Active Comparator|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
16428221|NCT03783559|Experimental|Arm A|TACE plus chemotherapy ± target therapy
16428222|NCT03783559|Active Comparator|Arm B|chemotherapy ± target therapy
16428223|NCT03783546|Experimental|Immediate Acupuncture|"Will receive a standardized acupuncture protocol for a 10-week period
~20 sessions: twice a week for 10 weeks
~After the completion of the 10 weeks main study period, participants will cross over to the usual care as a follow-up without acupuncture for additional 10 weeks."
16428224|NCT03783546|Active Comparator|Delayed acupuncture|"Will receive standard usual care without acupuncture for 10 weeks
~Participants will cross over to receive the same acupuncture protocol for 10 weeks --10 sessions: once a week for 10 weeks before exiting the study"
16428225|NCT03783533|Experimental|Adolescents|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
16428226|NCT03783520|Experimental|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
16428227|NCT03783520|Active Comparator|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
16428228|NCT03783507|Experimental|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
16428229|NCT03783507|Experimental|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
16428230|NCT03783507|Experimental|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
16428231|NCT03783507|Experimental|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
16428232|NCT03783494|Experimental|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
16428233|NCT03783481|Experimental|Mobile community group|join the mobile community via the smartphone application
16428234|NCT03783481|Active Comparator|No community group|
16428235|NCT03783468|Experimental|light sedation pressure support ventilation|
16428236|NCT03783455|Active Comparator|Non arthroscopic joint lavage (NAJL)|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper.
16428237|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the NAJL plus corticosteroid group was given an intra-articular injection containing 40 mg of triamcinolone acetonide.
16428376|NCT03782584|Other|Control Group|they will be given daily life advises to prevent neck pain
16428238|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the patients were given an intra-articular injection containing 4 ml of a bioengineered hyaluronic acid.
16428239|NCT03783455|Active Comparator|Intraarticular injection of hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
16428240|NCT03783455|Active Comparator|Intraarticular injection of corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 40 mg of triamcinolone acetonide.
16428241|NCT03783442|Experimental|Tislelizumab + chemotherapy|Tislelizumab administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
16428242|NCT03783442|Active Comparator|Placebo + chemotherapy|Placebo administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
16428243|NCT03783429|Active Comparator|Intervention group|The intervention group will receive low-dose digoxin
16428244|NCT03783429|Placebo Comparator|Placebo group|The placebo group will receive a matching placebo
16428245|NCT03783416|Experimental|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
16428246|NCT03783416|Placebo Comparator|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
16428250|NCT03783390|No Intervention|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
16428251|NCT03783390|No Intervention|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
16428252|NCT03783390|No Intervention|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
16428253|NCT03783390|No Intervention|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
16428254|NCT03783390|No Intervention|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
16428255|NCT03783390|Experimental|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
16428256|NCT03783377|Experimental|ARO-APOC3|
16428257|NCT03783377|Placebo Comparator|Placebo|
16428258|NCT03783364|Experimental|preoperative|preoperative radiotherapy
16428259|NCT03783364|Active Comparator|postoperative|postoperative radiotherapy
16428260|NCT03783351|No Intervention|Conventional Therapy|Patients randomized to the Conventional Therapy arm will receive either clopidogrel or ticagrelor, according to the clinical and procedural characteristics of patients. CYP2C19 genotyping will be performed at the end of study.
16428261|NCT03783351|Active Comparator|CYP2C19 Genotyping|CYP2C19 genotyping will be performed within 48 hours after randomization. CYP2C19 *2 or *3 reduced function allele patients will receive ticagrelor 90 mg bid, whereas non-*2 or -*3 CYP2C19 patients will receive clopidogrel 75 mg once daily.
16428262|NCT03783338|Active Comparator|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
16428263|NCT03783338|Experimental|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
16428264|NCT03783338|Experimental|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
16428265|NCT03783325|Other|UV Counseling|Evaluate the effectiveness of dosimetry feedback on sun exposure behaviors, attitudes, and awareness in patients diagnosed with melanoma.
16428266|NCT03783325|Experimental|Visual Analysis - UV Photo|Assess the relationships between UV camera score, silicone mold of a skin patch, phenotypic evaluation and sun-exposure behaviors. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
16428267|NCT03783325|Experimental|Biological Sample|Determine the relationship between measures of sun exposure and genomic characteristics of tumors in melanoma patients. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
16428377|NCT03782571|Experimental|Test1/Test2/Control/Test3|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
16428268|NCT03783312|Placebo Comparator|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
16428269|NCT03783312|Active Comparator|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
16428270|NCT03783312|Active Comparator|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
16428271|NCT03783299|Experimental|Village-based MTAT|"Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older.
~The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
16428272|NCT03783299|Experimental|Peer navigator-led FTAT|"Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals.
~The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
16428273|NCT03783273|Experimental|Whey protein complex-bound D3 + juice|200 microgram vitamin D3 in a whey protein-complex added to 500 mL of juice.
16428274|NCT03783273|Active Comparator|D3 + juice|200 microgram vitamin D3 added to 500 mL of juice.
16428275|NCT03783273|Active Comparator|D3 + milk|200 microgram vitamin D3 added to 500 mL of skimmed-milk.
16428276|NCT03783273|Active Comparator|D3 droplets|200 microgram vitamin D3 as droplets + 500 mL of water.
16428277|NCT03783273|Placebo Comparator|No vitamin D|500 mL of Water.
16428278|NCT03783260|Experimental|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
16428279|NCT03783247|Experimental|FIB|hip fracture with fascia Iliaca block
16428280|NCT03783247|Experimental|PENG|Hip fracture with Pericapsular nerve group block
16428281|NCT03783234||Older Adult Patients|ED patients age of ≥ 75 who have nurse assessed Clinical Frailty Scale ≥ 4.
16428282|NCT03783221|Experimental|High-fat diet|
16428283|NCT03783221|Active Comparator|High-residue diet|
16428284|NCT03783208|Experimental|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
16428285|NCT03783208|Placebo Comparator|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
16428286|NCT03783195|Experimental|High GRS group|This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
16428287|NCT03783195|Experimental|Low GRS group|This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
16428288|NCT03783182|Active Comparator|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
16428289|NCT03783182|Placebo Comparator|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
16428290|NCT03783169||Symptomatic patients|All pregnant women (under the care of the Maternal-Fetal Medicine physicians or Faculty Medical Center physicians with MFM involvement) experiencing a hypertensive emergency (sustained systolic blood pressure > 160 mmHg or sustained diastolic blood pressure > 110 mmHg {or both} on at least two consecutive occasions 15 minutes apart). All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
16428291|NCT03783169||Asymptomatic patients|All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
16428292|NCT03783156|Other|hot snare|polypectomy with hot snare
16428293|NCT03783156|Other|cold snare|polypectomy with cold snare
16428296|NCT03783130|Experimental|Group 1: Trimer 4571 (100 mcg) IM with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
16428297|NCT03783130|Experimental|Group 2: Trimer 4571 (100 mcg) SC with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
16428298|NCT03783130|Experimental|Group 3: Trimer 4571 (500 mcg) IM with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
16428299|NCT03783130|Experimental|Group 4: Trimer 4571 (500 mcg) SC with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
16428413|NCT03782259|Active Comparator|Active|10mg tabs of dapagliflozin
16428443|NCT03782090|Experimental|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
16428300|NCT03783117|Experimental|Magnetic field treatment|Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
16428301|NCT03783104|Experimental|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
16428302|NCT03783104|Active Comparator|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
16428303|NCT03783091|Experimental|Hydroxocobalamin|Single IV infusion administered over a 10-15 minute period
16428304|NCT03783091|Placebo Comparator|Saline Placebo|Single IV saline administered over a 10-15 minute period.
16428305|NCT03783078|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
16428306|NCT03783065|Experimental|Experimental group|Procedure: Laparoscopic splenectomy and pericardial devascularization Drug: Propranolol
16428307|NCT03783065|Active Comparator|Control group|Procedure: Endoscopic therapy Drug: Propranolol
16428308|NCT03783052|Other|Healthy volunteers|11 Healthy volunteers
16428309|NCT03783052|Other|Obese volunteers|11 Obese Volunteers
16428310|NCT03783052|Other|Roux-en-Y Gastric Bypass patients|6 volunteers with a Roux-en-Y Gastric Bypass
16428311|NCT03783052|Other|Sleeve Gastrectomy patients|6 volunteers with a Sleeve Gastrectomy
16428312|NCT03783052|Other|Volunteers with obesity|6 obese volunteers
16428313|NCT03783039|Experimental|SURGICEL Powder|SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
16428314|NCT03783039|Active Comparator|SURGICEL Original|SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form
16428316|NCT03783013|Other|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
16428317|NCT03783013|Other|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
16428318|NCT03783000|Experimental|All subjects|Treatment T followed by Treatment R
16428319|NCT03782987|Experimental|Treatment T|BI 730357 plus Itraconazole
16428320|NCT03782987|Experimental|Treatment R|BI 730357 alone
16428321|NCT03782974|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
16428322|NCT03782974|Placebo Comparator|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
16428323|NCT03782961|Experimental|Stand up|After application of the product (sodium lactate and combination of polymers) will remain standing for 30 minutes
16428324|NCT03782961|Experimental|Lying down|After application of the product (sodium lactate and combination of polymers) remained lying down with the legs stretched for 30 minutes;
16428325|NCT03782948|Active Comparator|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,
~walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;
~practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
16428326|NCT03782948|Experimental|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,
~walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;
~practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;
~practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
16428327|NCT03782935|Experimental|prenatal multivitamin mineral supplement|received prenatal multivitamin mineral supplement at time of enrollment TheraVit multivitamin/mineral prenatal supplement with instructions to take 1 per day through the remainder of pregnancy
16428328|NCT03782935|Experimental|prenatal multivitamin mineral supplement plus choline|received prenatal multivitamin mineral supplement plus additional choline supplemental vitamin TheraVit multivitamin mineral supplement plus 750 mg. choline with instructions to take1 multivitamin mineral supplement and 750 mg. per day of choline through the remainder of pregnancy
16428329|NCT03782935|No Intervention|Comparison|Advised to follow obstetrics standard of care which is to take a prenatal vitamin/mineral supplement
16428330|NCT03782922|Experimental|Exercise Training Program|
16428331|NCT03782922|No Intervention|Control|
16428332|NCT03782909|Experimental|Behaviour change intervention|Intensive behaviour change for 6 weeks, followed by a maintenance phase for 6 weeks
16428333|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
16428334|NCT03782857|Experimental|Intervention group|Initiation/stepwise escalation of antihypertensive medication in case of blood pressure above individual target Initiation/stepwise escalation of cholesterol lowering medication in case of LDL-cholesterol above individual target Advice on healthy lifestyle and life long adherence to preventive medication
16428335|NCT03782857|No Intervention|Control group|Participants had the usual treatment: all patients were invited to one visit in the outpatient clinic three months after discharge with a diagnosis of stroke/TIA
16428336|NCT03782844|Experimental|Conventional fixed CPAP and simple CPAP|Participants in this group were manually titrated . They were treated with conventional fixed pressure CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
16428337|NCT03782844|Experimental|Auto CPAP and simple CPAP|Participants in this group after being manually titrated were treated with Auto RemStar CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
16428338|NCT03782831|Experimental|TACE plus PD-1 antibody|Patients received hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16428339|NCT03782831|Active Comparator|TACE alone|Patients received hepatic intra-arterial infusion with lipiodol mixed with hemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received placebos intravenously every 2 weeks
16428340|NCT03782818|Experimental|Olaparib|After a 4-week pre-treatment phase to ensure that patients are on stable doses of PAH medication, patients will be given progressive doses of olaparib up to 300 mg BID for 24 weeks.
16428341|NCT03782805|Experimental|treatment group|Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.
16428342|NCT03782805|Placebo Comparator|Placebo group|Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months
16428343|NCT03782792|Experimental|Spesolimab|
16428344|NCT03782792|Experimental|Placebo|
16428345|NCT03782779|Experimental|Breathing program and regular exercise|Diaphragmatic Breathing Program plus regular upper and lower limb exercises
16428346|NCT03782779|Active Comparator|Regular Exercise|Regular upper and lower limb exercises
16428347|NCT03782766|Experimental|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
16428348|NCT03782766|No Intervention|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
16428349|NCT03782766|Other|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
16428350|NCT03782753||Group A|25 LRRK2-PD patients
16428351|NCT03782753||Group B|25 idiopathic PD patients
16428352|NCT03782753||Group C|25 HC subjects
16428353|NCT03782740|Experimental|Dysmenorrhea Melatonin 10 mg|In the dysmenorrhea group: 2 capsules with 5 mg melatonin will be given in the evening for seven days consecutively during menstruation for two mentrual cycles. Compared with placebo.
16428354|NCT03782740|Experimental|Endometriosis Melatonin 20 mg|In the endometriosis group: 4 capsules with 5 mg melatonin will be given every evening during eight weeks. Compared with placebo.
16428355|NCT03782714|Experimental|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
16428356|NCT03782714|No Intervention|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
16428357|NCT03782701|Active Comparator|Lumify Eye Drop|Participants will be randomized to receive a single drop of Lumify to either the left or right eye.
16428358|NCT03782701|Active Comparator|Saline Solution Eye Drop|Participants will be randomized to receive a single drop of sterile balanced saline solution to either the left or right eye.
16428359|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
16428360|NCT03782675|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device the device is turned on or not.
16428361|NCT03782675|Experimental|Air Barrier System|In the experimental (interventional) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
16428362|NCT03782662|Experimental|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
16428363|NCT03782662|Experimental|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
16428364|NCT03782662|Experimental|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
16428365|NCT03782662|Experimental|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
16428366|NCT03782662|Placebo Comparator|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
16428367|NCT03782649|Experimental|RSP-08|All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.
16428368|NCT03782636|Experimental|Aldesleukin|Ultra-low dose aldesleukin injected subcutaneously, at a dose of 0.2 x 106 IU/m2 twice-weekly , three days apart, for 6 months.
16428369|NCT03782636|Placebo Comparator|Placebo|Placebo sc, at a similar dose (expressed in ml) to the active drug
16428370|NCT03782623||Intensive care patients after elective open aortic surgery|
16428371|NCT03782623||Intensive care patients after bilateral lung transplantation|
16428372|NCT03782623||Anesthetic intensive care patients, unplanned admission|
16428373|NCT03782610||Primary Study Cohort|450 Infants
16428374|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
16432698|NCT03752944|Experimental|prebent plate|fixation of le fort I osteotomy using prebent plate
16428378|NCT03782571|Experimental|Test2/Test3/Test1/Control|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
16428379|NCT03782571|Experimental|Test3/Control/Test2/Test1|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
16428380|NCT03782571|Experimental|Control/Test1/Test3/Test2|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
16428381|NCT03782558||Patients with CTS|Surgical transection of transverse ligament
16428384|NCT03782519|Experimental|Incremental hemodialysis|Patients who will begin HD with two treatment sessions per week
16428385|NCT03782519|Active Comparator|Conventional hemodialysis|Patients who will begin HD three times a week
16428386|NCT03782506|Experimental|Interactive Music Therapy|Ten 45-minute individual interactive music therapy sessions.
16428387|NCT03782506|Active Comparator|Verbal-based Support|Ten 45-minute individual verbal support sessions.
16428388|NCT03782493|Experimental|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
16428389|NCT03782493|No Intervention|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
16428390|NCT03782480|Active Comparator|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
16428391|NCT03782480|Placebo Comparator|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
16428392|NCT03782467|Experimental|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
16428393|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
16428394|NCT03782441|Experimental|RSP-19|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 42 days.
16428395|NCT03782428|Active Comparator|Probiotic group|27 participants received probiotics twice daily for six months
16428396|NCT03782428|Placebo Comparator|Placebo group|25 participants received placebo twice daily for six months
16428397|NCT03782415|Experimental|MN-166 and temozolomide|Part 1: Combination treatment of MN-166 60 mg/day (30 mg twice a day) for 28 days and temozolomide 150 mg/m² on Days 1-5 of 28-day cycle. Part 2: Open-label, fixed-dose MN-166 and temozolomide combination treatment for 6 cycles until disease progression, unacceptable tolerability and/or toxicity or loss of life.
16428398|NCT03782402|Experimental|Cannabinoids of varied strength|Strengths of cannabinoids will vary across groups
16428399|NCT03782402|Active Comparator|Cannabinoids of various strengths|Strengths of cannabinoids will vary across groups
16428400|NCT03782389||Elite football players aged 16-40 years|
16428403|NCT03782363|Experimental|Autologous CIK Dose level 1|autologous CIK at dose level 1
16428404|NCT03782363|Experimental|Autologous CIK Dose level 2|autologous CIK at dose level 2
16428405|NCT03782363|Experimental|Autologous CIK Dose level 3|autologous CIK at dose level 3
16428406|NCT03782363|Experimental|Autologous CIK Dose level 4|autologous CIK at dose level 4
16428407|NCT03782350|Experimental|Tranexamic Acid Dosage 1|A bolus of 30 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 16 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 2 mg/kg.
16428408|NCT03782350|Active Comparator|Tranexamic Acid Dosage 2|A bolus of 10 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 2 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 1 mg/kg.
16428409|NCT03782311||2 groups: OHSE-high and OHSE-low|"OHSE-high: Group with ≥ 50 OHSE scores received motivation and oral hygiene instructions .
~OHSE-low: Group with < 30 OHSE scores received motivation and oral hygiene instructions ."
16428410|NCT03782272|Experimental|AA-ORS|Those receiving enterade oral re-hydration solution with amino acids
16428411|NCT03782272|Placebo Comparator|Placebo|Those receiving placebo solution without amino acids or rehydration salts
16428412|NCT03782259|Placebo Comparator|Placebo|10mg tabs placebo matching dapagliflozin.
16428414|NCT03782246|No Intervention|Usual Care|No intervention, participant will continue their usual care for pain and MS. We will collect information about what treatments are used by the usual care participants. They will be offered the opportunity to participate in one of the two active study treatments (MBCT or CBT) after completion of the 6-month followup.
16428415|NCT03782246|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Participants will attend eight, 2-hour group treatment MBCT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. MBCT integrates mindfulness meditation practices within a CBT-oriented framework to address not only unhelpful pain cognitions and behaviors but also attentional control, decoupling of attention from emotion, mindful cognitions, and meditative behavior.
16428416|NCT03782246|Experimental|Cognitive Behavioral Therapy (CBT)|Participants will attend eight, 2-hour group treatment CBT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. CBT focuses on increasing adaptive pain coping strategies and reducing unhelpful thoughts and behaviors related to pain. Strategies include relaxation techniques, goal-setting, activity pacing, and changing unhelpful thinking patterns.
16428417|NCT03782233|Experimental|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
16428418|NCT03782233|Other|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
16428419|NCT03782220|Experimental|Kinesio taping group|"Kinesio taping group
~Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.
~Once a week , for 4 weeks"
16428420|NCT03782220|Placebo Comparator|Shame taping group|"Shame taping group
~Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.
~Once a week , for 4 weeks"
16428421|NCT03782207||Cohort 1 (UC LOT2+later lines[LOT2+] & platinum eligible LOT1)|"Participants diagnosed with locally advanced or metastatic Urothelial Cancer previously treated with platinum-containing chemotherapy.
~Enrollment is closed."
16428422|NCT03782207||Cohort 2 (NSCLC LOT2 plus later lines [LOT2+])|"Participants diagnosed with Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after prior chemotherapy. Participants with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumor mutations should also have received targeted therapy.
~Enrollment closed."
16428423|NCT03782207||Cohort 3 (NSCLC LOT1 plus EGFR+/ALK+ LOT2+)|"EMA: Participants diagnosed with locally advanced/metastatic non-squamous NSCLC not previously treated. Participants with EGFR-activating mutations or ALK-positive tumor mutations should have received at least one line of targeted therapy.
~FDA: for the treatment of adult participants with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Participants with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ."
16428424|NCT03782207||Cohort 4 (ES-SCLC LOT1)|Participants diagnosed with extensive stage (ES) small cell lung cancer (SCLC) not previously treated.
16428425|NCT03782207||Cohort 5 (NSCLC LOT1)|Participants diagnosed with metastatic Non-Small Cell Lung cancer with high PD-L1 expression, previously untreated.
16428426|NCT03782207||Cohort 6 (HCC LOT1)|Participants diagnosed with unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
16428427|NCT03782194|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MRI data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
16428428|NCT03782194|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
16428429|NCT03782181|Active Comparator|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
16428430|NCT03782181|No Intervention|Control group|No intervention arm
16428433|NCT03782155|Experimental|HMB and glutamine supplementation|Patients with type 2 diabetes with supplementation HMB 3g, powder once a day and glutamine powder 14g once a day supplementation during 15 days.
16428434|NCT03782155|Placebo Comparator|placebo patients|Patients with type 2 diabetes with placebo( calcium caseinate) supplementation during 15 days 17g of powder once a day
16428435|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
16428436|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- [darunavir+cobicistat combination]
16428437|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
16428438|NCT03782129||Diabetic patients with DFU|Diabetic patients with DFU diagnosed in 2010
16428439|NCT03782103|Experimental|Zurex Prep (70% IPA)|Isopropyl alcohol (IPA) 70%
16428440|NCT03782103|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
16428441|NCT03782103|Placebo Comparator|Zurex Prep Vehicle|Zurex Prep without IPA
16428442|NCT03782090|Active Comparator|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
16428444|NCT03782064|Experimental|Nivolumab+DC/myeloma fusions/GM-CSF|"Nivolumab will be given every two weeks
~The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
16428445|NCT03782051|Active Comparator|Phacovisco group|group had combined phacoemulsification and viscocanalostomy
16428446|NCT03782051|Active Comparator|OloPhacovisco group|group had combined phacoemulsification and viscocanalostomy and Ologen
16428447|NCT03782038|Experimental|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
16428448|NCT03782025||Patients with increased PK-INR|Critically ill patients with spontaneously increased prothrombin complex (PK-INR) who are given phytomenadione intravenously at the discretion of the treating physician
16428449|NCT03782012|Experimental|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
16428450|NCT03782012|Experimental|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
16428451|NCT03781999|Experimental|Actiful|a supplement containing 500 mg orange extract and 200 mg pomegranate actives
16428452|NCT03781999|Placebo Comparator|Placebo|Maltodextrin
16428455|NCT03781973|No Intervention|Pre-intervention|"Those whose last pediatric visit was in the year before the intervention (2018).
~Medical record data abstracted from patient charts at the time of the final pediatric visit."
16428456|NCT03781973|Other|Early Intervention|"Those whose last pediatric visit was in the year immediately after the start of the intervention (2019).
~The intervention will begin on Jan 1, 2019 and includes the following :
~Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .
~Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.
~Patient transition experience surveys at the final pediatric visit and 12 months later.
~Diabetes teams may direct patients and families to online transition resources."
16428457|NCT03781973|Other|Post-Intervention|"Those whose last pediatric visit was in the second year after the intervention (2020).
~The intervention includes the following :
~Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .
~Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.
~Patient transition experience surveys at the final pediatric visit and 12 months later.
~Diabetes teams may direct patients and families to online transition resources."
16428458|NCT03781960|Experimental|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
16428459|NCT03781947|Experimental|90 mg s.c.|A single s.c. injection of 90 mg teverelix TFA administered on Day 1
16428460|NCT03781947|Experimental|60 mg s.c.|A single s.c. injection of 60 mg teverelix TFA administered on Day 1
16428461|NCT03781947|Experimental|90 mg i.m.|A single i.m. injection of 90 mg teverelix TFA administered on Day 1
16428462|NCT03781947|Experimental|120 mg s.c.|A single s.c. injection of 120 mg teverelix TFA administered on Day 1
16428463|NCT03781934|Experimental|MIV-818 + Pembrolizumab|Phase 2a expansion cohort HCC
16428464|NCT03781934|Experimental|MIV-818 + Lenvatinib|Phase 2a expansion cohort HCC
16428465|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
16428466|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
16428467|NCT03781908|Experimental|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
16428468|NCT03781908|Active Comparator|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
16428469|NCT03781895|Placebo Comparator|A0|"A0- On day 0,before intervention placebo,
~Microcrystalline Cellulose (303.8gm)
~Butylated Hydroxy Toluene (0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~weekly,orally,for 90days"
16428470|NCT03781895|Placebo Comparator|A90|"A90- On day 90,after intervention placebo,
~Microcrystalline Cellulose (303.8gm)
~Butylated Hydroxy Toluene (0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~weekly,orally,for 90days"
16428471|NCT03781895|Active Comparator|B0|"B0- On day 0,before intervention cholecalciferol,
~Cholecalciferol (40,000IU)
~Microcrystalline Cellulose (58.1 gm)
~Butylated Hydroxy Toluene ( 0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~80.000IU/week,orally,for 90 days"
16428472|NCT03781895|Active Comparator|B90|"B90- On day 90,after intervention cholecalciferol,
~Cholecalciferol (40,000IU)
~Microcrystalline Cellulose (58.1 gm)
~Butylated Hydroxy Toluene ( 0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~80.000IU/week,orally,for 90 days"
16428473|NCT03781882|Active Comparator|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
16428474|NCT03781882|Active Comparator|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
16428475|NCT03781869|Experimental|Anlotinib + Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, and Anlotinib 12mg/d on day 1 to day 14 , repeated every 21 days, a total of 4-6 cycles, and then continue to take Anlotinib 12mg/d on day 1 to day 14, repeated every 21 days until progressive Disease(PD).
16428476|NCT03781869|Placebo Comparator|Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, repeated every 21 days, a total of 4-6 cycles, and then follow up observation until PD.
16428477|NCT03781856|Experimental|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
16428478|NCT03781856|Active Comparator|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
16432934|NCT03751384|Active Comparator|Drink|Dietary Supplement: Nutrifriend Cachexia
16428479|NCT03781843|Active Comparator|Genicular nerve block with lidocaine|The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 6 mL of a solution containing 6 mL of 2% lidocaine or 6 mL dextrose or 6 mL saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves Interventions: Drug: 6 mL 2% lidocaine Procedure: Genicular nerve block
16428480|NCT03781843|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.
~Interventions:Drug: Saline Procedure: Genicular nerve block"
16428481|NCT03781843|Placebo Comparator|Genicular nerve block with dextrose|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a dextrose was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.
~Interventions:Drug: Dextrose Procedure: Genicular nerve block"
16428482|NCT03781830|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
16428483|NCT03781817|Active Comparator|Intravenous ketamine|Participants randomized to IV ketamine will be receive IV ketamine and Intranasal normal saline.
16428484|NCT03781817|Experimental|Intranasal ketamine|Participants randomized to Intranasal Ketamine group will receive Intranasal ketamine and IV normal saline.
16428485|NCT03781804|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
16428486|NCT03781804|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
16428487|NCT03781804|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
16428488|NCT03781791|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
16428489|NCT03781791|Placebo Comparator|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
16428490|NCT03781778|Experimental|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
16428491|NCT03781778|Active Comparator|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
16428492|NCT03781765|Active Comparator|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
16428493|NCT03781765|Active Comparator|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
16428494|NCT03781752|Experimental|Methylphenidate|Youth with ADHD
16428495|NCT03781739|Experimental|MANP|subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
16428496|NCT03781739|Placebo Comparator|Placebo|subjects receiving placebo (saline solution, single subcutaneous injection)
16428497|NCT03781726|Experimental|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
16428498|NCT03781713|Active Comparator|STUDY GROUP|patients who triggered triggers and had interventions. Kdigo: interventions to prevent renal replacement therapy Delta SOFA: interventions to improve SOFA score Hypoglycemia: Interventions to prevent new episodes of hypoglycemia in the next 24 hours Drug interaction risk D or X - Intervention in the therapeutic plan in order to avoid adverse drug reactions. Antimicrobial stewardship: optimization of antimicrobial therapy based on Gram stain, MALDI TOF, MIC, antimicrobial susceptibility
16428499|NCT03781713|No Intervention|CONTROL GROUP|patients who did not triggered triggers
16428500|NCT03781700|Experimental|Prednisolone|Prednisolone
16428501|NCT03781700|Placebo Comparator|Placebo|Placebo oral tablet
16428502|NCT03781687|Active Comparator|Bilateral|Bilateral ESP block will be performed
16428503|NCT03781687|Active Comparator|Unilateral|Unilateral ESP block will be performed
16428504|NCT03781674|Active Comparator|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
16428505|NCT03781674|Active Comparator|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
16428506|NCT03781674|Placebo Comparator|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
16428507|NCT03781661|Experimental|Intervention Group|The participants in the intervention group will be provided with extended information of the advantages of the CT examination of the heart's arteries. This will be given to the participants both orally and written in form of a leaflet. In addition will they be given the opportunity for a visual go-through of their own calcium score images. After this they will be informed of the normal examination result.
16428508|NCT03781661|No Intervention|Control group|Control Group receives standard care.
16428509|NCT03781648|Other|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
16428535|NCT03781466|Active Comparator|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
16428510|NCT03781648|Experimental|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
16428511|NCT03781635|Active Comparator|bolus of intravenous ketamine|A bolus of 0.25mg.kg-1 of ketamine will be first administered at the time of incision (T0) then every single hour for the rest of the surgery. Study starts at incision (T0) for ketamine administration and ends when the surgical team starts closing the deep layers of the abdominal incision.
16428512|NCT03781635|Experimental|continuous infusion of intravenous ketamine|An infusion of 0.25 mg.kg-1.h-1 is started at T0 (incision) with an infusion pump and is kept at the same rate until the surgical team starts closing the deep layers of the abdominal incision. Consumption of the infusion pump is noted at T0 (incision) and at each hour during the surgery until the infusion is discontinued.
16428513|NCT03781622|Experimental|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
16428514|NCT03781609|Active Comparator|Roller system group (RG)|A group performing motor learning manual wheelchair propulsion repetitions on a roller system.
16428515|NCT03781609|Active Comparator|Overground group (OG)|A group performing motor learning manual wheelchair propulsion repetitions overground.
16428516|NCT03781609|Placebo Comparator|Placebo - Wheelchair skills group (WSG)|A group receiving conventional manual wheelchair skills training.
16428517|NCT03781596|Experimental|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
16428518|NCT03781596|Placebo Comparator|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
16428519|NCT03781583|Experimental|HMD|"We have several versions (listed below) of a headworn smartHMD. Each can provide verbal and/or tactile feedback to the user. Feedback is controlled by either the experimenter or by computer vision algorithms.
~1. The ODG Smartglasses is commercially available. This system uses computer vision to guide a user to the destination using audio and/ or vibration feedback.
~2) Tactile stimulator array. This device uses an Arduino Micro, HC-05 Bluetooth Module, L293D Motor Driver and coin vibration motors attached to a head-worn headband or glasses frame. The motors can be controlled directly by an experimenter or by computer vision algorithms.
~3) Computer Vision Navigation prototyping system consists of two components: Intel RealSense camera and Alienware M15 laptop.
~All participants will receive the same 3 interventions: no HMD used, HMD worn but not active, and HMD worn and active. Participants may be tested with any or all of the systems described above."
16428520|NCT03781557|Experimental|High-concentrated DHA|High-concentrated DHA fish oil softgels
16428521|NCT03781557|Experimental|High-concentrated EPA|High-concentrated EPA fish oil softgels
16428522|NCT03781557|Placebo Comparator|Olive Oil|Olive Oil softgels
16428523|NCT03781544|Experimental|Diclofenac|Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
16428524|NCT03781544|Active Comparator|Paracetamol|"Paracetamol (Paracetamol Sintetica):
~A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm)."
16428525|NCT03781544|Experimental|Tramadol|"Tramadol (Tramadol-Mepha):
~A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm)."
16428526|NCT03781531||Venous thromboembolism|Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
16428527|NCT03781518|Experimental|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
16428528|NCT03781518|Active Comparator|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
16428529|NCT03781505|Experimental|Intravenous paracetamol with Caudal Ropivacaine|"Paracetamol is widely accepted and most commonly used as an adjuvant for postoperative analgesia. It also improves the quality of recovery by attenuating the pain associated with the surgical position. Adverse effects associated with the paracetamol are rare <1/10000, which includes malaise, increased level of hepatic transaminases and hypersensitivity reaction. It has been studied in combination with caudal analgesia with bupivacaine through the rectal route 7,8 with variable results.
~Caudal anaesthesia is effective in alleviating pain below the umbilicus. Also if the caudal block is administered at the beginning of surgery, the effect will start wearing off 2 to 3 hours post surgery. Administration of paracetamol towards end of surgery may help with both these issues. In this study we aim to investigate the effect of adding intravenous paracetamol in combination with caudal analgesia with ropivacaine, hoping that it may improve quality of postoperative analgesia and recovery."
16428530|NCT03781505|Placebo Comparator|Placebo|Intravenous Normal Saline with Caudal Ropivacaine
16428531|NCT03781479|Experimental|Amifampridine Phosphate - Placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
16428532|NCT03781479|Experimental|Placebo - Amifampridine Phosphate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
16428533|NCT03781466|Active Comparator|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
16428534|NCT03781466|Active Comparator|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
16428600|NCT03780972|Active Comparator|Cohort 2 Dose B|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2
16428536|NCT03781440|Experimental|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
16428537|NCT03781440|Placebo Comparator|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
16428538|NCT03781427|Active Comparator|Standard care|Cardiac resynchronization therapy: Usual output programming
16428539|NCT03781427|Experimental|High output|Cardiac resynchronization therapy: High output programming
16428540|NCT03781414|Active Comparator|Arm 1|Control/Standard of Care: TAC + MMF + Corticosteroids
16428541|NCT03781414|Experimental|Arm 2|CFZ533 dose A + MMF + Corticosteroids
16428542|NCT03781414|Experimental|Arm 3|CFZ533 dose B + MMF + Corticosteroids
16428543|NCT03781388|Experimental|Starting dose of Bupivacaine (9 mg)|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
16428544|NCT03781388|Experimental|Subsequent dose|
16428545|NCT03781375|Placebo Comparator|Methotrexate + Placebo|Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
16428546|NCT03781375|Experimental|Methotrexate + Etanercept|Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
16428547|NCT03781362|Experimental|CPI-100 Monotherapy|"Dose Escalation Groups:
~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study
~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
16428548|NCT03781362|Experimental|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
16428549|NCT03781349|Active Comparator|MENS|MENS are applied through placement of six electrodes (size of 4x4cm), of which four were placed exactly like the TENS electrodes and the other two, one in the palm and the other at the height of the asteroid ganglion. Duration of the intervention was 24 min for a total of 15 sessions. The frequency was 50 Hz and the intensity was 100 μA.
16428550|NCT03781349|Active Comparator|TENS|TENS are applied through the placement of four electrodes on either side of the deltoid muscle, on the front and back surfaces of the shoulder joint for 20 min and each patient received 15 sessions (five per week). A constant current of high frequency was used (100 HZ) and its intensity was initiated at 10mA and was then gradually increased to 15mA
16428551|NCT03781336|Experimental|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
16428552|NCT03781336|No Intervention|Life as usual control|Life as usual control (5 weeks)
16428553|NCT03781323|Experimental|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.
~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
16428554|NCT03781310|Experimental|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
16428555|NCT03781310|Active Comparator|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
16428558|NCT03781284|Experimental|PET/MRI with bowel purgation|
16428559|NCT03781284|Experimental|PET/MRI without bowel purgation|
16428560|NCT03781271|Experimental|Fraction 1-Addition of EMN|During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
16428561|NCT03781271|Experimental|Fraction 3-Addition of EMN|For the second group of patients in the trial the same protocol will be followed as in the first group, the only difference will be that the electromagnetic navigation is used during the second implantation procedure immediately preceding fraction 3 as opposed to fraction 1, the time at which it was used for the first group of patients.
16428562|NCT03781258|Other|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
16428563|NCT03781245|Experimental|Early|Intervention is administered for cycle 1 and 2 with researchers and following this the company continues intervention independently.
16428564|NCT03781245|Active Comparator|Lagged|Intervention is not administered for cycle 1; researchers administer intervention in cycle 2 and following this the company continues intervention independently.
16428565|NCT03781232|Experimental|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
16428566|NCT03781232|Experimental|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
16428567|NCT03781219|Experimental|HL-085 plus Vemurafenib|HL-085 will be administered as BID with specified dose. And the Vemurafenib will be taken as the instruction in the label ( 960 mg, BID)
16428568|NCT03781206|No Intervention|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
16428569|NCT03781206|Experimental|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
16428570|NCT03781167|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 52 weeks.
16428571|NCT03781154|Experimental|Group-based exercise|Virtually-delivered supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components.
16428572|NCT03781154|No Intervention|Control Group|A physical activity education control group
16428573|NCT03781141|Experimental|Absorbable suture|Wound closure with absorbable suture.
16428574|NCT03781141|Active Comparator|Non-absorbable suture|Wound closure with non-absorbable suture.
16428575|NCT03781128|Other|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
16428576|NCT03781128|Other|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
16428577|NCT03781115|Experimental|Ziprasidone|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug ziprasidone (Geodon). The investigators will start with a single 20mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 40 and 60mg tablets). If Ziprasidone causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG) taken.
16428578|NCT03781115|Experimental|Olanzapine|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug olanzapine (Zyprexa). The investigators will start with a single 2.5 mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 5, 7.5, and 10 mg tablets).If olanzapine causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG).
16428579|NCT03781115|Placebo Comparator|Placebo Comparator|The investigators have prepared a placebo which duplicates the exact color and size of the study drug capsule to use as a non-drug control.
16428580|NCT03781102|Experimental|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
16428581|NCT03781102|Other|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
16428582|NCT03781089|Experimental|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L.
16428583|NCT03781089|No Intervention|Usual care arm|Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
16428584|NCT03781076|Experimental|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
16428585|NCT03781076|No Intervention|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
16428586|NCT03781063|Experimental|Lasofoxifene|5 mg/d of oral lasofoxifene
16428587|NCT03781063|Active Comparator|Fulvestrant|500 mg fulvestrant intramuscular (IM)
16428588|NCT03781050|Experimental|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months
~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
16428589|NCT03781037|Experimental|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
16428590|NCT03781011|Experimental|TMAO high producer|Low carnitine/choline diet intervention
16428591|NCT03781011|Active Comparator|TMAO low producer|Low carnitine/choline diet intervention
16428592|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
16428593|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
16428594|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
16428595|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
16428596|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
16428597|NCT03780985|Active Comparator|intrauterine device insertion with a suture fixation|Intruterine device through hysterotomy incision during cesarean section with a suture fixation
16428598|NCT03780985|Active Comparator|intrauterine device insertion without a suture fixation|IUD through hysterotomy incision during cesarean section without a suture fixation
16428599|NCT03780972|Active Comparator|Cohort 1 Dose A|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1
16432935|NCT03751371|Experimental|Walking Training with the HWA Device|Training with HWA device
16428602|NCT03780972|Active Comparator|Cohort 4 Dose D|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4
16428603|NCT03780959|Placebo Comparator|Etanercept/Placebo|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
16428604|NCT03780959|Experimental|Etanercept/Etanercept|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.
16428605|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
16428606|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
16428607|NCT03780933|No Intervention|control group|conventional treatment (corticosteroids, mechanical ventilation)
16428608|NCT03780933|Experimental|test group (vitamin C)|high dose vitamin c iv infusion
16428609|NCT03780920|Active Comparator|Osteopathic treatment|
16428610|NCT03780920|No Intervention|Control group|
16428611|NCT03780907|Experimental|E2007 1 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
16428612|NCT03780907|Experimental|E2007 2 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
16428613|NCT03780907|Placebo Comparator|Placebo|Tablet, once daily to be taken in the morning, one hour before breakfast, with a glass of water.
16428614|NCT03780894|Experimental|Experimental treatment|The active treatment consists of intravenous injection of 2g of fibrinogen concentrate, 1g of tranexamic acid, 2 red bood cells concentrate O Rh(D) negative (Banc de Sang i Teixits, Barcelona, Spain), and crystalloids at pre-hospital phase of care.
16428615|NCT03780894|Active Comparator|Standard treatment|Patients in the control arm will be treated according the existing protocols based on crystalloids and tranexamic acid administration.
16428616|NCT03780881|Experimental|Expectation confirmation|The participants in this group receive manipulated feedback indicating that their performance was very good in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
16428617|NCT03780881|Experimental|Expectation disconfirmation|The participants in this group receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
16428618|NCT03780868|Active Comparator|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .
~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
16428619|NCT03780868|Active Comparator|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.
~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
16428620|NCT03780855|Experimental|nerve scaffold group|the experimental group of cases with peripheral sensory nerve injuries will be treated with nerve scaffold.
16428621|NCT03780855|No Intervention|non-nerve scaffold group|the control group of cases will be treated without nerve scaffold.
16428622|NCT03780842|Experimental|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
16428623|NCT03780842|Experimental|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
16428624|NCT03780829|Experimental|hypoxia plus training|combined hypoxia treatment with exercise training
16428625|NCT03780829|Sham Comparator|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
16428626|NCT03780829|Experimental|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
16428627|NCT03780829|Placebo Comparator|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
16428628|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
16428629|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
16428630|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
16428631|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
16428632|NCT03780803|Experimental|Patients with PAH|home cardiac rehabilitation and respiratory rehabilitation
16428633|NCT03780803|Experimental|Patients with HFREF|home cardiac rehabilitation and respiratory rehabilitation
16428634|NCT03780803|Experimental|Patients with IHD|home cardiac rehabilitation and respiratory rehabilitation
16428635|NCT03780803|No Intervention|Control group|No rehabilitation
16428636|NCT03780790|Active Comparator|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the anterior layer of the thoracolumbar fascia between psoas major and quadratus lumborum muscles
16428637|NCT03780790|Active Comparator|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
16432936|NCT03751371|Other|Usual Care|Usual Care
16428638|NCT03780790|Active Comparator|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
16428639|NCT03780777|Experimental|Home Hazard Removal Group|A tailored home-modification (home-hazard removal) intervention for residents with a high fall risk, delivered in the home by occupational therapists over one to two visits and with a booster session at three months.
16428640|NCT03780764|Active Comparator|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
16428641|NCT03780764|Experimental|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
16428642|NCT03780751|Experimental|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
16428643|NCT03780751|Experimental|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
16428644|NCT03780751|No Intervention|Waitlist|Participants will receive no immediate treatment but will be able to choose either MIND or COPE after a six months waiting period.
16428645|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
16428646|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
16428647|NCT03780725|Experimental|All Subjects|Part 1 followed by Part 2
16428648|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
16428649|NCT03780686|Active Comparator|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
16428650|NCT03780686|Active Comparator|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
16428651|NCT03780686|No Intervention|Standard fluid management|Standard fluid managements.
16428652|NCT03780673|Experimental|Simvastatin 20 mg + Rifaximin 400 mg|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 months
16428653|NCT03780673|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin|Placebo of simvastatin and placebo of rifaximin orally for 12 months
16428654|NCT03780647||Patients with suspicion of thoracic outlet syndrome|
16428655|NCT03780634|Experimental|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16428656|NCT03780634|Active Comparator|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16428657|NCT03780621|Experimental|Andrographis and Withania|Active ingredient: 550 mg of Andrographis paniculata (standardized to 40 mg andrographolides) and Withania somnifera (standardized to 10 mg withanolides) taken twice daily, once in the morning and once in the evening
16428658|NCT03780621|Placebo Comparator|Placebo|550 mg capsule visually identical to the active dietary supplement, containing brown sugar, microcrystalline cellulose, corn starch, and magnesium stearate
16428659|NCT03780608|Experimental|GC|Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.
16428660|NCT03780608|Experimental|Melanoma|Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
16428661|NCT03780595|Experimental|Passiflora|
16428662|NCT03780595|Placebo Comparator|Control|
16428663|NCT03780582|Experimental|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
16428664|NCT03780582|Experimental|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
16428665|NCT03780582|Experimental|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
16428666|NCT03780569|Experimental|NovoTTF-200A/Radiotherapy/Temozolomide|Patients will receive multiple 1 month courses of continuous NovoTTF-200A treatment together with standard Radiotherapy/Temozolomide followed by maintenance Temozolomide.
16428667|NCT03780556|Active Comparator|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
16428668|NCT03780556|Active Comparator|Pethidine|Patients received pethidine 50mg intravenous to control pain
16428669|NCT03780543|Active Comparator|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care nucleos(t)ide (SOC NrtI)-suppressed and HBeAg-negative will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years.
16428701|NCT03780322|Active Comparator|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
16428670|NCT03780543|Active Comparator|HBeAg-positive Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated. Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years. Subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.
16428671|NCT03780543|Active Comparator|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.
~Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 96 weeks, after which time their viral response will be evaluated at Week 148. Subjects who meet the virologic response criteria at Week 148 will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years, while those subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.
~Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks."
16428672|NCT03780530|Active Comparator|subcuticular suturing|
16428673|NCT03780530|Active Comparator|surgical glue|
16428674|NCT03780530|Active Comparator|adhesive steri-strip tape|
16428675|NCT03780517|Experimental|BOS172738|In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.
16428676|NCT03780491|No Intervention|Control|The first 50 patients will have usual care with providers conducting the visit in their typical manner.
16428677|NCT03780491|Experimental|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
16428678|NCT03780478|Experimental|SPG Block|Sphenopalatine ganglion block
16428679|NCT03780478|Placebo Comparator|Placebo Control|Saline injection
16428680|NCT03780465|Active Comparator|Oral idronoxil|10 male and female subjects randomised to 400 mg active Oral idronoxil suspension or oral placebo suspension (n=8 active; n= 2 placebo).
16428681|NCT03780465|Experimental|NOX66 400 mg|10 male and female subjects randomised to 400 mg active NOX66 (A) suppository or 400 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
16428682|NCT03780465|Experimental|NOX66 600 mg|10 male and female subjects randomised to 600 mg active NOX66 (A) suppository or 600 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
16428683|NCT03780452||Tibiotalocalcaneal arthrodesis with DynaNail|Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
16428684|NCT03780439||infection group and non-infection group|patients were divided into 2 sub-groups according to the presence of infection or not after radical gastrectomy for gastric cancer.
16428685|NCT03780426|Experimental|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
16428686|NCT03780426|Experimental|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
16428687|NCT03780413|Active Comparator|PR-ESSENCE treatment|The treatment group receives PR-ESSENCE for 10 weeks. Outcome measures are collected pre- and post-treatment, and after 6 months and one year.
16428688|NCT03780413|Active Comparator|Control (TAU)|"The control group receives 10 weeks of treatment as usual (TAU) (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year."
16428689|NCT03780400|Experimental|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
16428690|NCT03780387|Experimental|Inhaled Allergen Challenge|Felis Catus sensitive, mild asthmatics will undergo inhaled allergen challenge.
16428691|NCT03780374|Active Comparator|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
16428692|NCT03780374|Experimental|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
16428693|NCT03780374|Experimental|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
16428694|NCT03780361|Experimental|Aflibercept injection group|"drug: Eylea (aflibercept) (11.12mg/0.278ml) dose: 2mg (0.05ml) usage: With topical anesthesia and intravitreal injection of aflibercpt in aseptic condition.
~frequency and duration: monthly intravitreal aflibercept injections."
16428695|NCT03780348|Experimental|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
16428696|NCT03780348|Active Comparator|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
16428697|NCT03780348|Experimental|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
16428698|NCT03780335||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
16428699|NCT03780335||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
16428700|NCT03780322|Experimental|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
16433092|NCT03750344|Experimental|ChroniSense Polso Respiratory Rate|
16428702|NCT03780309|Active Comparator|EXERCISE|Participants participated in a the exercise training program and engaged in exercise self-monitoring.
16428703|NCT03780309|Experimental|EXERCISE+PEH|Participants participated in the exercise training program and engaged in exercise self-monitoring and blood pressure self-monitoring (daily and before and after exercise).
16428704|NCT03780296|Experimental|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
16428705|NCT03780283|Experimental|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
16428706|NCT03780283|No Intervention|placebo|observation
16428707|NCT03780270|Active Comparator|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.
~=> Group: Fluoride Varnish"
16428708|NCT03780270|Experimental|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.
~=> Group: Curodont Repair + Fluoride Varnish"
16428709|NCT03780270|Experimental|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).
~=> Group: Curodont Repair + Curodont Protect"
16428710|NCT03780257|Experimental|QR-421a|Single dose administration
16428711|NCT03780257|Sham Comparator|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
16428712|NCT03780244|Experimental|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
16428713|NCT03780244|Active Comparator|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
16428714|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
16428715|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
16428716|NCT03780205||Bilateral Group|Patients have bilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 each eye.
16428717|NCT03780205||Unilateral Group|Patients have unilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
16428718|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
16428719|NCT03780179|Experimental|MMRvaxpro|
16428720|NCT03780179|Placebo Comparator|Placebo|
16428721|NCT03780166|Experimental|Parsaclisib|
16428722|NCT03780114||interns|intern pediatric dentists
16428723|NCT03780088|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
16428724|NCT03780075|Experimental|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
16428725|NCT03780075|Experimental|1.85GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
16428726|NCT03780075|Experimental|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
16428727|NCT03780062|Experimental|S100B protein dosing|
16428728|NCT03780049|Experimental|HAIC plus H101|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery
16428729|NCT03780049|Active Comparator|HAIC|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery
16428730|NCT03780036|Experimental|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
16428731|NCT03780036|Experimental|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
16428732|NCT03780010|Experimental|TRC105 + B + P + C|TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
16428733|NCT03779997|Experimental|Video-based DOT Application|
16428734|NCT03779997|No Intervention|Treatment as Usual (TAU)|
16428735|NCT03779971|Placebo Comparator|Control|The placebo comparator will be a fully controlled diet made from typical American foods and containing no beans or pulses.
16428736|NCT03779971|Experimental|Lentil|The lentil arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain lentils.
16428737|NCT03779971|Experimental|Chickpeas|The chickpea arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain chickpeas.
16428738|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
16428739|NCT03779945|Active Comparator|posteriolateral lumbar fusion +bone graft+ PRP|the addition of autologous platelet rich plasma to the bone graft
16428740|NCT03779945|Active Comparator|posteriolateral lumbar fusion+bone graft only|posteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
16428741|NCT03779919|Experimental|High Energy|Extracorporeal shock wave therapy with 0.3 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
16493540|NCT03335956|Placebo Comparator|MAD Placebo Cohort 3|
16428742|NCT03779919|Experimental|Low Energy|Extracorporeal shock wave therapy with 0.05 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
16428743|NCT03779919|Placebo Comparator|Sham|Extracorporeal shock wave therapy with 0 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
16428744|NCT03779906|Experimental|ISOVUE|Isovue will be given to all subjects per the standard of clinical care.The specific iodine concentration and volume of ISOVUE used during the radiologic procedure will depend on the type of procedure and the standards in place at the site where the procedure is performed.
16428745|NCT03779893|Active Comparator|conventional group|Conventional resin based Pits & fissures sealant 3M™ Clinpro™ Sealant is administrated
16428746|NCT03779893|Experimental|bioactive group|Bioactive Pits & fissures sealant BioCoat® by Premier®.
16428747|NCT03779867|Experimental|Arm I (acute exercise)|Participants undergo a moderate-intensity acute exercise bout over 45 minutes.
16428748|NCT03779867|Active Comparator|Arm II (rest)|Participants rest by sitting for 45 minutes.
16428749|NCT03779854|Experimental|Arm I (chemotherapy, naive T-cell depleted PBSC)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.
~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.
~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.
~TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0.
~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
16428750|NCT03779854|Active Comparator|Arm II (chemotherapy, unmanipulated T cell replete BM)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.
~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.
~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.
~TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0.
~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
16428751|NCT03779841|Experimental|AGN-151607 (250 U)|Injections of 50 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
16428752|NCT03779841|Experimental|AGN-151607 (125 U)|Injections of 25 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
16428753|NCT03779841|Placebo Comparator|Placebo|Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
16428754|NCT03779815|Experimental|[18F]Florbetaben PET/CT imaging|"Maximally 18 subjects with multiple myeloma (up to 6 subjects in whom amyloidosis in suspected and up to 12 subjects in whom amyloidosis is not suspected)
~Intravenous injection of [18F]Florbetaben and PET/CT scanning
~Intervention: Drug ([18F]Florbetaben)"
16428755|NCT03779802|Experimental|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
16428756|NCT03779789|Experimental|vortioxetine|
16428757|NCT03779789|Active Comparator|SSRIs|
16428758|NCT03779776|Experimental|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
16428759|NCT03779776|Placebo Comparator|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
16428760|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
16428761|NCT03779737|Active Comparator|Habitual training|The control group will be monitored passively for the detection of adverse or secondary events.
16428762|NCT03779737|Experimental|Muscular resistance training|This phase includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week.
16428763|NCT03779737|Experimental|Cardiorespiratory training|In stage, a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.
16428764|NCT03779724|Experimental|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
16428765|NCT03779724|Active Comparator|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
16428766|NCT03779711|Experimental|Treatment|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
16428788|NCT03779542||open-angle group|ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope
16428789|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
16428767|NCT03779711|Active Comparator|Control|Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
16428768|NCT03779698|Experimental|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
16428769|NCT03779698|Active Comparator|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
16428770|NCT03779685|Active Comparator|General anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
16428771|NCT03779685|Experimental|Regional anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
16428772|NCT03779672|Active Comparator|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.
~Dose regimen:
~Memantine Hydrochloride
~Week #1: 5 mg id (am), 1 caps
~Week #2: 5 mg bid (am and pm), 2 caps
~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps
~Washout (Weeks #7-8)
~Placebo
~Week #9: id (am), 1 caps
~Week #10: bid (am and pm), 2 caps
~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps"
16428773|NCT03779672|Placebo Comparator|Placebo Memantine Hydrochloride 10 mg|"Placebo
~Week #1: id (am), 1 caps
~Week #2: bid (am and pm), 2 caps
~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps
~Washout (Weeks #7-8) Memantine Hydrochloride
~Week #9: 5 mg id (am), 1 caps
~Week #10: 5 mg bid (am and pm), 2 caps
~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
16428774|NCT03779659|Experimental|Synapse TENS device|SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
16428775|NCT03779659|Active Comparator|Topical anesthetic gel|Topical anesthetic Gel is the active comparator in this study. The topical anesthesia (anesthetic gel) Centrix LolliCaine with 20% benzocaine in single package of 0.3 ml will be used. The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure. This will be done based American Association of Pediatric Dentistry guidelines for the use of local anesthesia.
16428776|NCT03779646|Experimental|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
16428777|NCT03779646|No Intervention|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
16428778|NCT03779633|Experimental|Linoladiol Estradiol|Linoladiol Estradiol cream 6 weeks before surgery of pelvic organ prolapse
16428779|NCT03779633|Placebo Comparator|Placebo|Placebo cream 6 weeks before surgery of pelvic organ prolapse
16428780|NCT03779620|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
16428781|NCT03779607|Active Comparator|IPS e.max Press(lithium di silicate)|Lithium disilicate reinforced glass ceramics are available in the market in two forms according to the technique of manufacturing, either heat pressed ingots or CAD/CAM blocks for milling. The heat pressed lithium disilicate glass ceramic consists of approximately 70% lithium disilicatecrystals(the main crystal phase) having a needle like shape that are embedded in a glassy matrix. The crystals length is about 3 to 6 μm. The heat pressed ingots are fully crystallized and the restoration is fabricated by the lost wax technique where the lithium disilicate ingots are pressed into the investment mold at high temperature. The pressed lithium disilicate has strong flexural strength values(range 400 ± 40 MPa)
16428782|NCT03779607|Experimental|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.
~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
16428783|NCT03779594|Experimental|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
16428784|NCT03779581|Experimental|Exercise Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting. In addition, 7 of the randomly selected patients received De-rotation Breathing Exercises.
16428785|NCT03779581|Active Comparator|Control Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting.
16428786|NCT03779568|Experimental|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
16428787|NCT03779555||Patients taking lenalidomide for multiple myeloma|-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
16428790|NCT03779529|Active Comparator|Arm label extra-vergin olive oil (EVOO)|Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be >10mg.
16428791|NCT03779529|Active Comparator|Arm label refined olive oil (ROO)|Participants will ingest two tablespoons of refined olive oil during the day: one spoon containing 10 g of refined olive oil at lunch and one at dinner.
16428792|NCT03779516|Active Comparator|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
16428793|NCT03779516|Active Comparator|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
16428794|NCT03779503|Active Comparator|midafilcon A|Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.
16428795|NCT03779503|Active Comparator|somofilcon A|Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.
16428796|NCT03779477|Experimental|Coping with Stress Course|The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
16428797|NCT03779477|No Intervention|Control|There will be no intervention in the control group. If the program will be effective, this group will also undergo the Coping with Stress Program after the termination of the study.
16428798|NCT03779464|Experimental|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
16428799|NCT03779464|Active Comparator|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
16428800|NCT03779451|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery
16428801|NCT03779451|Active Comparator|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily at bedtime starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
16428802|NCT03779451|No Intervention|control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
16428803|NCT03779438|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
16428804|NCT03779438|Placebo Comparator|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
16428805|NCT03779425|Experimental|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
16428806|NCT03779412|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
16428807|NCT03779412|Active Comparator|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
16428808|NCT03779399||Patient with benign ovarian tumor|25 patients with benign ovarian tumor (cystadenoma) were admitted to IInd Department of Gynecology, Lublin Medical University, Lublin, Poland.
16428809|NCT03779399||Patient with borderline tumor|11 women with borderline ovarian tumor were admitted to IInd Department of Gynecology
16428810|NCT03779399||Patient with ovarian cancer|24 women with ovarian cancer were admitted to IInd Department of Gynecology
16428811|NCT03779399||Patient without ovarian pathology|20 patient with unexpleined infertility were admitted to IInd Department of Gynecology
16428812|NCT03779386|Experimental|Music during labor and delivery|Music during labor and delivery
16428813|NCT03779386|No Intervention|No music during labor and delivery|No music during labor and delivery
16428814|NCT03779373|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
16428815|NCT03779373|Experimental|EV1000 monioring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
16428816|NCT03779360|Active Comparator|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
16428817|NCT03779360|Experimental|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
16428818|NCT03779360|Active Comparator|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
16428819|NCT03779347|Experimental|Schistosomiasis treated during pregnancy|Praziquantel 40mg/kg once will be given during pregnancy at second to third trimester
16428820|NCT03779347|Active Comparator|Schistosomiasis treated after pregnancy|Praziquantel 40mg/kg once will be given to parturient after delivery during lactation
16428821|NCT03779347|Experimental|All study participants|UCP-LF CAA and composite diagnostic reference test based on extensive egg microscopy, plus serology, plus qPCR on egg DNA, and plus POC-CC will be used to detect schistosomiasis infection in pregnant women
16428822|NCT03779334|Experimental|Open-label Arm|Participants will be enrolled to receive risdiplam orally once daily at a dose selected to achieve the targeted exposure range.
16428823|NCT03779321|Other|Lean panelists|Lean panelists or normal weight panelists with a BMI between 18.5 and 24.9 Acceptability was assessed
16428824|NCT03779321|Other|Obese panelists|Obese panelists with a BMI between 25 and 29.9 Acceptability was assessed
16428825|NCT03779308|Experimental|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
16428828|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
16428829|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
16428830|NCT03779269|Experimental|color meditation|only color meditation
16428831|NCT03779269|Experimental|Sound meditation|Only sound mediation
16428832|NCT03779269|Experimental|Color and sound combined meditation|Combined group
16428833|NCT03779269|No Intervention|Control group|Only control group
16428834|NCT03779256||Women with bowel endometriosis.|"Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D transvaginal ultrasound before surgery at Hospital St John of God, Vienna, Austria; Oslo university hospital, Oslo, Norway and Nepean Hospital, Sydney, Australia.
~The women recruited at Oslo university hospital, Norway will also have a magnetic resonance imaging (MRI) of the abdomen and pelvis before surger."
16428835|NCT03779243|Experimental|5mg Melatonin and Sleep Education|Participants will take 5mg Melatonin nightly, 1 hour before bedtime and be provided educational materials to improve sleep hygiene. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits.
16428836|NCT03779243|Placebo Comparator|Placebo Control|"Participants will be given placebo pills to be taken daily 1 hour before bedtime and are a sleep aid. Participants will not receive any sleep education materials. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits."
16428837|NCT03779230|Experimental|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
16428838|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
16428839|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
16428840|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
16428841|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
16428842|NCT03779204|Experimental|Rent subsidies + Mentorship|Participants in this arm (n = 12) will receive rent subsidies (ranging from $400 - $500/month) for 24 months as part of the intervention and be matched with an adult mentor recruited by one of the community partners.
16428843|NCT03779204|Active Comparator|Rent subsidies only|Participants in this arm (n = 12) will receive rent subsidies only (ranging from $400 - $500/month) for 24 months as part of the comparator group intervention. This group will not receive mentorship.
16428844|NCT03779191|Experimental|Intervention|Patients in this intervention arm will receive the therapeutic combination of Alectinib dosed PO 600 mg bis in die (BID) with meals and Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
16428845|NCT03779178|Experimental|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
16428846|NCT03779178|Placebo Comparator|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
16428847|NCT03779152||non asthmatic subjects|
16428848|NCT03779152||intermittent asthmatics|
16428849|NCT03779152||severe asthmatics sensitive to corticosteroids|
16428850|NCT03779152||severe asthmatics resistant to corticosteroids|
16428851|NCT03779152||moderate asthmatics|
16428852|NCT03779139|Active Comparator|Intrahepatic islets alone|
16428853|NCT03779139|Experimental|Intrahepatic and omental pouch islets|
16428854|NCT03779139|Sham Comparator|Normal Volunteers|
16428855|NCT03779126|Experimental|Active comparator|Low frequency electrical stimulation for 60 minutes, three times a week during 60 days.
16428856|NCT03779126|Experimental|Other|High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
16428857|NCT03779126|Experimental|Experimental group|Low and High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
16428858|NCT03779126|Placebo Comparator|Placebo|Placebo electrical stimulation for 60 minutes, three times a week during 60 days. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current
16428859|NCT03779113|Experimental|Treatment|All patients to received study drug (HMPL-523)
16428860|NCT03779100|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16428861|NCT03779087|Experimental|10d TL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
16428862|NCT03779087|Active Comparator|10d AL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, amoxicillin 500 mg and metronidazole 250 mg q.i.d. for 10 days
16428863|NCT03779074|Active Comparator|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
16428864|NCT03779074|Experimental|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
16428865|NCT03779074|Experimental|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
16428866|NCT03779061|Experimental|Remimazolam Tosilate|
16428867|NCT03779061|Active Comparator|Propofol|
16428898|NCT03778853|Experimental|Anlotinib Hydrochloride|Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
16428868|NCT03779048|Active Comparator|Behavioral Treatment + Placebo|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.
~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
16428869|NCT03779048|Active Comparator|Behavioral Treatment + Medication|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.
~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
16428870|NCT03779035|Experimental|Gemcitabine plus Capecitabine|Gemcitabine (1000 mg per square meter) on days 1 and 8 Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
16428871|NCT03779035|Active Comparator|Capecitabine|Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
16428872|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
16428873|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
16428874|NCT03779009|Experimental|Tracer injection|
16428875|NCT03778996|Experimental|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
16428876|NCT03778996|Experimental|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
16428877|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
16428878|NCT03778983||Control group|The reference group included same age- and gender-matched children without a chronic health condition.
16428879|NCT03778970|Experimental|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
16428880|NCT03778970|Active Comparator|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
16428881|NCT03778957|Experimental|Arm A|Transarterial Chemoembolization (TACE) in combination with Durvalumab
16428882|NCT03778957|Experimental|Arm B|Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab
16428883|NCT03778957|Placebo Comparator|Arm C|Transarterial Chemoembolization (TACE) in combination with Placebos
16428884|NCT03778944|Active Comparator|M group|Mannitol infusion
16428885|NCT03778944|Active Comparator|D group|Dopamine infusion
16428886|NCT03778944|Active Comparator|C group|Adequate hydration
16428887|NCT03778931|Experimental|Elacestrant|Subjects in Arm 1 will receive elacestrant
16428888|NCT03778931|Active Comparator|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
16428889|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
16428890|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
16428891|NCT03778905||stroke patient with complete post-acute care hospitalization|This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.
16428892|NCT03778892|Experimental|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
16428893|NCT03778892|No Intervention|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
16428894|NCT03778879|Experimental|Group 1:With CCX872-B|Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
16428895|NCT03778879|No Intervention|Group 2:Without CCX872-B|SBRT Alone: 25 Gy in 5 fractions over 5-7 days
16428896|NCT03778866|Experimental|Bicarbonate-buffered Medium|
16428897|NCT03778866|No Intervention|HEPES-MOPS-buffered Medium|
16428931|NCT03778580|Placebo Comparator|identical placebo|identical placebo po bid for one year
16428899|NCT03778827|Experimental|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of one weekly 60-minute individual parent training session and 12 weekly hours ( 3 hours per day for 4 days per week) with the child in center-based therapy environment for a total of 13 weekly treatment hours.
16428900|NCT03778827|No Intervention|Delayed Treatment Group (DTG)|Delayed Treatment Group will consist of treatment as usual. At the end of controlled phase, participants in the DTG will be offered PRT-C in a preschool setting in an open-label fashion with a design similar to the double-blind phase.
16428901|NCT03778814|Experimental|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
16428902|NCT03778801||fibromyalgia syndrome|Thirty patients with a diagnosis of fibromyalgia syndrome according to the 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria and a disease duration of longer than three months
16428903|NCT03778801||chronic neck pain|30 patients with chronic neck pain lasting for more than three months and didn't meet 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria.
16428904|NCT03778801||healthy controls|30 healthy controls without pain or additional disease
16428905|NCT03778788|Active Comparator|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
16428906|NCT03778788|Active Comparator|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
16428907|NCT03778788|Active Comparator|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
16428908|NCT03778775||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and liver stiffness measurement by FibroTouch.
16428909|NCT03778762|Active Comparator|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
16428910|NCT03778762|Placebo Comparator|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
16428911|NCT03778749|Experimental|electromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
16428912|NCT03778749|Experimental|acceleromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
16428913|NCT03778749|Experimental|acceleromyographic NMT monitoring at the eyebrow|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
16428914|NCT03778736|Experimental|Cumulase denudation|
16428915|NCT03778736|No Intervention|Hyaluronidase denudation|
16428916|NCT03778723|Experimental|Total intravenous anesthesia (TIVA)|Patients will receive total intravenous anesthesia using Propofol and Midazolam
16428917|NCT03778723|Active Comparator|Inhalation Anesthesia|Patients will receive Inhalation anesthesia using Sevoflurane
16428918|NCT03778697|Experimental|Adolescent Endosleeve|Patients who will undergo endoscopic sleeve gastroplasty
16428919|NCT03778684|Experimental|Normal Body mass index without central obesity|
16428920|NCT03778684|Experimental|High Body mass index with central obesity|
16428924|NCT03778658|Experimental|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
16428925|NCT03778632|Experimental|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
16428926|NCT03778632|Active Comparator|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
16428927|NCT03778619|Experimental|single arm|"Phase 1
~MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly
~Group 1: 1 x 10^7 cells/㎏
~Group 2: 3 x 10^7 cells/㎏
~Group 3: 9 x 10^7 cells/㎏
~Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.
~Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)
~Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle
~Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1."
16428928|NCT03778606|Experimental|Potato starch supplementation|Twelve patients found to be colonized with C. difficile will undergo twice a day potato starch supplementation.
16428929|NCT03778593|Experimental|mFOLFIRINOX|D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks
16428930|NCT03778580|Experimental|pyridoxamine|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
16493541|NCT03335956|Experimental|MAD Active Cohort 3|
16428932|NCT03778567|Other|lamivudine + nucleotide analogue|At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued
16428933|NCT03778554|Experimental|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice
~Bisoprolol up to a total dose of 10 mg daily
~Carvedilol up to a total dose of 50 mg daily
~Metoprolol succinate up to a total dose of 200 mg daily
~Nebivolol up to a total dose of 10 mg daily"
16428934|NCT03778554|No Intervention|No beta blocker treatment|Standard care without beta blocker treatment
16428935|NCT03778541|Experimental|CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
16428936|NCT03778541|Active Comparator|RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
16428937|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
16428938|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
16428939|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
16428940|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
16428943|NCT03778476|Experimental|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
16428944|NCT03778476|No Intervention|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
16428945|NCT03778463|Experimental|Synovectomy|
16428946|NCT03778463|No Intervention|No synovectomy|
16428947|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
16428948|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
16428949|NCT03778437|Active Comparator|landmark techniques|Subclavian vein catheterization is performed without the guidance of ultrasound. The needle was inserted 1 cm inferior and 1 cm lateral to the junction of the middle and medial thirds of the clavicle (infraclavicular approach)
16428950|NCT03778437|Experimental|ultrasound-guided with aiming method|Subclavian vein catheterization is performed with our newly proposed aiming method with the guidance of ultrasound.
16428951|NCT03778437|Experimental|ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique.
16428952|NCT03778411||cACLD|200 people with compensated advanced chronic liver disease who have not undergone liver transplant
16428953|NCT03778411||cACLD-post transplant|100 people with compensated advanced chronic liver disease who have previously undergone liver transplant
16428954|NCT03778398|Experimental|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
16428955|NCT03778385|Experimental|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
16428956|NCT03778385|Experimental|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
16428957|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
16428958|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
16428959|NCT03778359||Gonadotropin-releasing hormone agonist treatment|Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment
16428960|NCT03778359||Intrauterine device treatment|Endometriosis post-operative intrauterine device treatment
16428961|NCT03778359||Hormone therapy|Endometriosis post-operative hormone therapy
16428962|NCT03778359||Oral contraceptive|Endometriosis post-operative oral contraceptive
16428963|NCT03778346|Experimental|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.
16428964|NCT03778333|Experimental|Open label single arm study|All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.
16428965|NCT03778320|Experimental|CTP-692|
16428966|NCT03778320|Active Comparator|D-Serine|
16428967|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
16428968|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
16429006|NCT03777982|Experimental|LHRH Agonist or Antagonist|-LHRH agonist or antagonist should be prescribed per standard of care
16429035|NCT03777774|Active Comparator|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
16428969|NCT03778294|Experimental|Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)|Patients receive 18F-DOPA IV and undergo PET/MRI or PET/CT imaging scan. Patients then receive proton beam radiotherapy over 5 or 10 consecutive days excluding weekend and standard of care temozolomide on days 1-7 or 1-14. Beginning cycles 2, patients receive standard of care temozolomide on days 1-5. Cycles with temozolomide repeat every 28 days for up to 7 cycles in the in the absence of disease progression or unacceptable toxicity.
16428970|NCT03778281|Experimental|Baclofen group|Treatment of Chemotherapy-related Hiccups With Baclofen
16428971|NCT03778281|Other|Methoxyclopramide group|Treatment of Chemotherapy-related Hiccups With Methoxyclopramide
16428972|NCT03778281|Experimental|Baclofen group 2|After 3 days, if the metoclopramide treatment is ineffective, it will cross into the baclofen group 2.
16428973|NCT03778281|Other|Methoxyclopramide group 2|After 3 days, if the baclofen treatment is ineffective, it will cross into the metoclopramide group 2.
16428974|NCT03778268|Experimental|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
16428975|NCT03778255|Experimental|Undergoing sentinel lymph node biopsy|
16428976|NCT03778242|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1 gm tranexamic acid ( 2 ampoules) in 100 ml saline by slow infusion
16428977|NCT03778242|Active Comparator|oxytocin plus placebo to TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus2 placebo ampoules to tranexamic acid(TA) in 100 ml saline by slow infusion
16428978|NCT03778229|Experimental|osimertinib + savolitinib|osimertinib + savolitinib
16428979|NCT03778216|Experimental|FBT-ARFID|Family Based Treatment of child ARFID
16428980|NCT03778216|No Intervention|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
16428981|NCT03778190|Experimental|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
16428982|NCT03778177|Experimental|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
16428983|NCT03778164|Experimental|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
16428984|NCT03778164|Active Comparator|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
16428985|NCT03778151|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus to modulate DMN activity. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
16428986|NCT03778151|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The SHAM protocol will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
16428987|NCT03778138|Experimental|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
16428988|NCT03778112|Experimental|Negative mpMRI Prostate Scan|SBRT to the whole prostate
16428989|NCT03778112|Experimental|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
16428990|NCT03778099|Experimental|Cinnamon Group|Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
16428991|NCT03778099|Placebo Comparator|Placebo Group|"Placebo capsules will contain 450 mg of starch and 50 mg of cinnamon powder (to improve blindness regarding taste and odor). Color, shape, and size of placebo capsules will be exactly the same as the cinnamon capsules.
~2g/day along with clomiphene citrate"
16428992|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
16428993|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
16428994|NCT03778073|Experimental|Cohort A|Cosibelimab (TG-1501) single-agent
16428995|NCT03778073|Experimental|Cohort B|Cosibelimab + Ublituximab + Bendamustine combination
16428996|NCT03778073|Experimental|Cohort C|Cosibelimab + Ublituximab + Bendamustine combination
16428997|NCT03778060|Experimental|Transcutaneous stimulation|Participants in the clinical study will consist of subjects with essential tremor who are scheduled more than 3 months in advance to undergo deep brain stimulation surgery for treatment of essential tremor at Mayo Clinic. Subjects will wear a Cala TWO stimulator to reduce hand tremors.
16428998|NCT03778047|Experimental|enzalutamide|160mg
16428999|NCT03778047|Experimental|HC-1119|To be determined
16429000|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
16429001|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
16429002|NCT03778021|Experimental|Intervention Group|Students in the intervention group will receive the curriculum and school garden during the second academic school year (Year 2)
16429003|NCT03778021|Active Comparator|Delayed Intervention Group|For the delayed intervention group schools, students will receive the intervention at the beginning of Year 3
16429004|NCT03778008|Experimental|Recombinant bovine basic fibroblast growth factor|
16429005|NCT03778008|Active Comparator|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
16429007|NCT03777982|Experimental|Prednisone+Apalutamide+Abiraterone Acetate +LHRH Agonist|"LHRH agonist or antagonist should be prescribed per standard of care
~Abiraterone acetate will be taken once daily
~Prednisone will be taken twice daily
~Apalutamide will be taken once daily"
16429008|NCT03777956|Active Comparator|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
16429009|NCT03777956|Placebo Comparator|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
16429010|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
16429011|NCT03777930|Experimental|chemotherapy group|the patients were recepted chemotherapy alone
16429012|NCT03777930|Experimental|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
16429013|NCT03777930|Experimental|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
16429014|NCT03777930|Experimental|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
16429015|NCT03777917|Experimental|Belotero Balance®|
16429016|NCT03777917|No Intervention|No treatment|
16429017|NCT03777904||Children with high serum ferritin|Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.
16429018|NCT03777891|Experimental|group A|received Silicone gel phonophoresis: Silicone gel (strataderm) was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes. The Ultrasound Device is Sonopulse 590: Nonius, sonopuls 590, S.NO.03-202 type 14663.900 was a therapeutic ultrasound device manufactured by Enraf Holland.
16429019|NCT03777891|Experimental|group B|received Contractubex phonophoresis: Contractubex (Merz Pharma, Frankfurt, Germany was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes.
16429020|NCT03777891|Experimental|group C|received Corticosteroid phonophoresis: A thin film of coupling medium (gel) was put on the hypertrophic scar and sufficient quantity of Triamcinolone was put by a syringe over the whole scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes
16429021|NCT03777878|Active Comparator|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
16429022|NCT03777878|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
16429023|NCT03777878|Active Comparator|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
16429024|NCT03777865|Experimental|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
16429025|NCT03777852|Experimental|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
16429026|NCT03777852|Active Comparator|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
16429027|NCT03777826|Other|Open label (1 arm)|Open label use of study product (post-marketing): PKU Synergy
16429028|NCT03777813|Experimental|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):
~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)
~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:
~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)
~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node
~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):
~IV oxaliplatin 85 mg/m² in 2 h on D1
~IV Leucovorin 200 mg/m² in 2 h on D1, followed by
~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by
~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
16429029|NCT03777813|Active Comparator|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:
~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)
~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node
~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):
~IV oxaliplatin 85 mg/m² in 2 h on D1
~IV Leucovorin 200 mg/m² in 2 h on D1, followed by
~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by
~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
16429030|NCT03777800|Experimental|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
16429031|NCT03777800|Active Comparator|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
16429032|NCT03777787|Experimental|Bitter|A single intragastric administration of denatonium benzoate (1 µmol/kg)
16429033|NCT03777787|Placebo Comparator|Placebo|A single intragastric administration of placebo (water)
16429034|NCT03777774|Active Comparator|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
16429036|NCT03777774|Active Comparator|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
16429037|NCT03777761|Experimental|Treatment Sequence ABC|tucatinib + placebo + moxifloxacin (administered in sequential treatment periods)
16429038|NCT03777761|Experimental|Treatment Sequence CAB|moxifloxacin + tucatinib + placebo (administered in sequential treatment periods)
16429039|NCT03777761|Experimental|Treatment Sequence BCA|placebo + moxifloxacin + tucatinib (administered in sequential treatment periods)
16429040|NCT03777761|Experimental|Treatment Sequence CBA|moxifloxacin + placebo + tucatinib (administered in sequential treatment periods)
16429041|NCT03777761|Experimental|Treatment Sequence ACB|tucatinib + moxifloxacin + placebo (administered in sequential treatment periods)
16429042|NCT03777761|Experimental|Treatment Sequence BAC|placebo + tucatinib + moxifloxacin (administered in sequential treatment periods)
16429043|NCT03777748|Experimental|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
16429044|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
16429045|NCT03777722|Experimental|Aim 1: Active Intervention then Placebo|Tailored Lighting intervention (TLI). The active TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The active lighting intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the placebo control intervention for 8 weeks.
16429046|NCT03777722|Experimental|Aim 1: Placebo Intervention then Active|The placebo lighting intervention is designed to have no effect on the circadian system. The control intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the active tailored lighting intervention for 8 weeks.
16429047|NCT03777709|Experimental|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
16429048|NCT03777709|No Intervention|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
16429049|NCT03777696|Active Comparator|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
16429050|NCT03777696|Active Comparator|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
16429051|NCT03777696|Placebo Comparator|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
16429052|NCT03777683|Experimental|Dietary Supplement (OLIGOPIN)|Intervention group will receive French maritime pine bark extract supplement (OLIGOPIN) in the form oral capsules containing 50 mg French maritime pine bark extract plus 130 mg Microcrystalline Cellulose. OLIGOPIN powder of each capsule are dissolved in 10 ml deionized water and given to patients via gavage (3 capsule per day) for 10 days
16429053|NCT03777683|Placebo Comparator|Placebo|Control group will receive oral capsules containing 130 mg Microcrystalline Cellulose with 10 ml of deionized water via gavage (3 capsule per day) for 10 days.
16429054|NCT03777670||Cases|Infants with suspected sepsis
16429055|NCT03777670||Controls|Infants with no suspicion of sepsis
16429056|NCT03777657|Experimental|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
16429057|NCT03777657|Placebo Comparator|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
16429058|NCT03777644|Experimental|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
16429059|NCT03777644|Placebo Comparator|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
16429060|NCT03777631|No Intervention|Standard medical therapy group|The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
16429061|NCT03777631|Active Comparator|Catheter ablation group|Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed >100 CA annually were participated in the present study in principle.
16429062|NCT03777605|Experimental|"NTG1523, rapid absorbable capsule"|"Nitroglycerine 0.4 milligram taken as ordinary tablets or NTG1523 rapid absorbable capsule once in the morning, and subsequently blood samples and observations for 2 hours are performed"
16429063|NCT03777592|Active Comparator|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
16429064|NCT03777592|Sham Comparator|ESPB with saline|ESPB will be performed using 20ml of saline.
16429065|NCT03777579|Experimental|JS001 Plus Nab-Paclitaxel|Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
16429066|NCT03777579|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
16429067|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
16429068|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
16429069|NCT03777553|Experimental|VETNET|Narrative Exposure Therapy for Justice-Involved Veterans
16429070|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients > 85 years; Elective and urgent surgery.
16429071|NCT03777514|Active Comparator|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.
~Participants in this group will also receive oral vitamin C as a placebo."
16429072|NCT03777514|Active Comparator|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
16429073|NCT03777501|Experimental|non-random whole body vibration group|Each participant will receive the non-random type whole body vibration treatment about one hour after the administration of medicine.
16429074|NCT03777501|Active Comparator|conventional therapy group|For the conventional therapy group, participants will receive the occupational therapy including dynamic balance training and functional ambulatory training. Each session is 10 minutes.
16429075|NCT03777488|Experimental|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:
~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
16429076|NCT03777488|Experimental|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:
~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
16429077|NCT03777488|Experimental|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:
~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
16429078|NCT03777488|Experimental|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:
~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
16429079|NCT03777488|Experimental|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:
~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
16429080|NCT03777488|Experimental|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:
~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
16429081|NCT03777475|Experimental|low dose|low oxaliplatin (85mg/m2)
16429082|NCT03777475|Active Comparator|high dose|high oxaliplatin (135mg/m2)
16429083|NCT03777462|Active Comparator|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
16429084|NCT03777462|Experimental|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
16429085|NCT03777462|Experimental|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
16429086|NCT03777449||Vertical bone loss|Infra-osseous defects
16429087|NCT03777449||Horizontal bone loss|Supra-osseous defects
16429088|NCT03777449||Combined bone loss|Combined supra-osseous and infra-osseous defects
16429089|NCT03777436|Experimental|Arm A- Apremilast with Placebo|Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
16429090|NCT03777436|Experimental|Arm B - Apremilast 30 mg|All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
16429091|NCT03777423|Experimental|PEEK framework partial dentures|High performance ketone polymers introduced lately.These polymer-based frameworks provide better esthetics, higher elasticity, lighter in weight, have low water sorption and solubility, and are easily repaired and reproduced.
16429092|NCT03777423|Active Comparator|Cobalt-chromium framework partial dentures|it is considered the gold standard framework. These frameworks are less bulky with high strength, conduct heat and electricity well, and have good durability. some disadvantages include hypersensitivity, adverse tissue reactions and bad aesthetics.
16429093|NCT03777410||Vanguard|(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
16429094|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
16429095|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
16429096|NCT03777345|Active Comparator|cobalt-chromium framework partial dentures|It's the gold standard biocompatible metal alloy used in thin sections, provide high strength and stiffness ,conduct heat and cold for a more natural experience, and is resistant to corrosion but their disadvantages include esthetic issues with metal display, oral galvanism, adverse tissue reactions,and osteolysis of abutment teeth.
16429097|NCT03777345|Experimental|PEEK framework partial dentures|It's a promising polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
16429098|NCT03777332|Experimental|(Cohort 1) Pegcetacoplan, 15 mg/100 μL, monthly for up to 60 months|
16429099|NCT03777332|Experimental|(Cohort 2) Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|
16429100|NCT03777332|Experimental|(Cohort 2) Pegcetacoplan, 15 mg/100 μL, every other month for up to 36 months|
16429105|NCT03777293|Experimental|training cohort|ultrasound viscoelasticity
16429106|NCT03777293|Other|testing cohort|ultrasound viscoelasticity
16429107|NCT03777280|Experimental|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
16429108|NCT03777280|Active Comparator|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
16429109|NCT03777267|Experimental|Experimental: Active CR|For this single arm, open label, exploratory trial this will be the intervention arm using active CR.
16429110|NCT03777254|Experimental|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E
~Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E
~Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E
~Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
16429111|NCT03777241|Active Comparator|Behavioral Intervention Team|The participants in this arm will receive the Behavioral Intervention Team.
16429112|NCT03777241|Active Comparator|Standard of Care|The participants in this arm will receive the standard of care.
16429113|NCT03777228||Control|Individuals without traumatic brain injury
16429114|NCT03777228||Mild TBI|Individuals with mild traumatic brain injury
16429115|NCT03777228||Moderate to Severe TBI|Individual with moderate to severe traumatic brain injury
16429116|NCT03777215|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of angiotensin-(1-7). The doses are: 2, 4, and 8 ng/kg/min. Each dose will be maintained for 10 minutes, with the highest dose maintained for an additional 90 minutes. The total infusion period is 120 minutes.
16429117|NCT03777215|Placebo Comparator|Placebo|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7). The total infusion period is 120 minutes.
16429118|NCT03777202|Experimental|High-flow nasal oxygen during sleep endoscopy|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
16429119|NCT03777202|Active Comparator|Low-flow nasal oxygen during sleep endoscopy|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
16429120|NCT03777189|Experimental|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
16429121|NCT03777176|Experimental|Standard of Care + dasiglucagon|8 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
16429122|NCT03777176|Other|Standard of Care|4 weeks of standard of care + 4 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
16429123|NCT03777163|Other|Butantan Trivalent Influenza Vaccine|"Butantan Institute Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen
~Patients will receive one dose (0,5 ml) via intramuscular injection."
16429124|NCT03777163|Other|Sanofi Trivalent Influenza Vaccine|"Sanofi Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen
~Patients will receive one dose (0,5 ml) via intramuscular injection."
16429125|NCT03777150|Experimental|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
16429126|NCT03777150|Experimental|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
16429127|NCT03777137||TMS during heat pain stimuli|This is a single institution, single-blinded, long-term exploratory study using participant as his/her own control to evaluate and compare the analgesic effect of experimental heat pain of TMS during early versus late times on a vigilance behaviors toward pain (CPT, Continuous Performance Task). Vigilance behaviors include errors, reaction times and activation.
16429128|NCT03777124|Experimental|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
16429129|NCT03777124|Active Comparator|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
16429130|NCT03777111|Active Comparator|Single Task Training Group|"Gait and balance exercises will be applied in single task training group.
~Semi-tandem, tandem stand with eyes open and close
~One leg stance with eyes open and close
~Gait exercises; walking forwards, backwards, sidewards, semi-tandem and tandem walking
~Reaching forward and sidewards with eyes open and close"
16429185|NCT03776786|Placebo Comparator|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429186|NCT03776786|Experimental|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429131|NCT03777111|Experimental|Dual Task Training Group|"The exercises given in the single task training group will be combined with the cognitive tasks.
~Semi-tandem, tandem stand with recall a sequence of numbers
~One leg stance with writing pre-defined letters or words with other foot
~Semi-tandem or tandem walking with saying previous number (one or two previous) from number that researcher has given before
~Walking sidewards with collecting numbers that researcher has given
~Walking backwards with counting forward by one (then two or three)
~Reaching forward with counting backward one (then two or three)
~Reaching sidewards with saying next number (one or two next) from number that researcher has given before"
16429132|NCT03777085|Experimental|TQB2303|
16429133|NCT03777085|Active Comparator|Rituximab|
16429134|NCT03777059|Placebo Comparator|Placebo|Placebo-matching atogepant tablets orally once daily for 12 weeks.
16429135|NCT03777059|Experimental|Atogepant 10 mg|Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
16429136|NCT03777059|Experimental|Atogepant 30 mg|Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
16429137|NCT03777059|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
16429138|NCT03777046|No Intervention|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
16429139|NCT03777046|Active Comparator|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
16429140|NCT03777046|Experimental|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
16429141|NCT03777033|No Intervention|Control Group|Patients after thyroidectomy will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.
16429142|NCT03777033|Experimental|Study group|Intervention: the patients will be given prophylactically ca and vit D. Patients after thyroidectomy will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb Intervention: The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days)
16429143|NCT03777020|Experimental|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
16429144|NCT03777020|Other|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
16429145|NCT03777007|Experimental|Experimental|The application used is build upon the company's category-defining, SPARTA Platform and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
16429146|NCT03776994|Experimental|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate
~Vaccinations on Day 0, Day 28, and Day 140"
16429147|NCT03776994|Experimental|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone
~Vaccinations on Day 0, Day 28, and Day 140"
16429148|NCT03776994|Experimental|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone
~Vaccinations on Day 0, Day 28, and Day 140"
16429149|NCT03776994|Experimental|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)
~Vaccinations on Day 0, Day 28, and Day 140"
16429150|NCT03776994|Experimental|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)
~Vaccinations on Day 0, Day 28, and Day 140"
16429151|NCT03776994|Experimental|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)
~Vaccinations on Day 0, Day 28, and Day 140"
16429152|NCT03776981|No Intervention|Baseline Gait Comparisons of Groups|Determine if kinetic (time to first peak ground reaction force [T1] and second peak ground reaction force [F2], both in the sagittal plane) and kinematic (peak stance knee flexion angle [KFA] and external knee adduction moment [KAM]) gait variables, and speed, differ between patients with KOA and age and gender matched controls during self-selected paced ambulation, and determine which ones have predictive relationships with Knee Injury and Osteoarthritis Outcome Score (KOOS) scores in the patients with KOA.
16429187|NCT03776786|Placebo Comparator|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429188|NCT03776786|Experimental|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429153|NCT03776981|Experimental|Gait with core activation|Determine if volitional core activation alters gait kinetics (T1 and F2), kinematics (KFA and KAM), and speed in patients with and without KOA during self-selected paced ambulation when compared to ambulating without volitional core activation, and whether the subjective pain complaints are significantly changed in the group with KOA. Determine whether there are baseline differences in core activation between those with and without KOA.
16429154|NCT03776981|Experimental|Knee OA Gait After core stabilization|Determine if a six-week core stabilization program alters KOOS score, and the kinetics (T1 and F2), kinematics (KFA and KAM), and speed of gait in patients with KOA during self-selected paced ambulation as compared to their pre-intervention baselines. Determine if there is a predictive relationship between the number of completed intervention sessions performed and these observed changes.
16429155|NCT03776968|Experimental|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
16429156|NCT03776955|Experimental|Oral Carvedilol|6.25 mg or 12.5 mg if tolerated
16429157|NCT03776955|Placebo Comparator|Oral Placebo|
16429158|NCT03776929|No Intervention|Standard Care|No intervention - Standard care only. Group of 32 subjects
16429159|NCT03776929|Experimental|Dialectical Behavioral Therapy|Dialectical Behavioral Therapy in addition to standard care. Four hour and a half group sessions (or one-on-one sessions, if not enough for a group session) commencing after surgery while still inpatient. Each session is designed to stand-alone, allowing for enrolling patients on a rolling basis.
16429160|NCT03776916|Experimental|Group 1|"Simethicone administration 20-30 min before the procedure:
~Patients intake simethicone solution 20-30 min before the procedure."
16429161|NCT03776916|Experimental|Group 2|"Simethicone administration 31-60 min before the procedure:
~Patients intake simethicone solution 31-60 min before the procedure."
16429162|NCT03776916|Experimental|Group 3|Simethicone administration >60 min before the procedure; Patients intake simethicone solution >60 min before the procedure.
16429163|NCT03776903||endemic|Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.
16429164|NCT03776903||non-endemic|Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.
16429165|NCT03776890|Experimental|DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=30) will be recruited to participate.
16429166|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.
~The participation in the study will consist in:
~Plasmatic collection at the time of AIS, for study of plasma biomarkers
~Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
16429167|NCT03776864|Experimental|Treatment (pembrolizumab, umbralisib)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib PO daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16429168|NCT03776851|Experimental|Erythropoietin|Erythropoietin plus standard of care (RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability)
16429169|NCT03776851|No Intervention|No Intervention|Standard of care: RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability
16429170|NCT03776838|Experimental|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
16429171|NCT03776838|Active Comparator|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
16429172|NCT03776825||Perianal Crohn's Disease|Permacol Paste injection
16429173|NCT03776812|Experimental|Continuous Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
16429174|NCT03776812|Experimental|Intermittent Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
16429175|NCT03776812|Active Comparator|Nab-paclitaxel Comparator|Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
16429176|NCT03776799|Other|Stent-avoiding approach|using clinically proven drug coated balloons
16429177|NCT03776799|Other|Stent-based approach|using drug eluting nitinol stents. Interwoven nitinol stents in heavily calcified lesions at the operator's discretion.
16429178|NCT03776786|Experimental|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
16429179|NCT03776786|Placebo Comparator|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16429180|NCT03776786|Experimental|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
16429181|NCT03776786|Experimental|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
16429182|NCT03776786|Experimental|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
16429183|NCT03776786|Experimental|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
16429184|NCT03776786|Experimental|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16493542|NCT03335956|Placebo Comparator|MAD Placebo Cohort 4|
16429189|NCT03776786|Placebo Comparator|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429190|NCT03776786|Experimental|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429191|NCT03776786|Placebo Comparator|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
16429192|NCT03776773|Active Comparator|patients AR (+) and sleep apnea (+)|Patients with AR and obstructive sleep apnea (OSA) will have sleep and pollution exposure recordings
16429193|NCT03776773|Active Comparator|AR (-) and sleep apnea (+)|Patients without allergic rhinitis (+ sleep apnea) will have sleep and pollution exposure recordings
16429194|NCT03776773|Active Comparator|AR (+) and sleep apnea (-)|Patients with allergic rhinitis but no sleep apnea will have sleep and pollution exposure recordings
16429195|NCT03776773|Sham Comparator|AR (-) and sleep apnea (-)|Volunteers without allergic rhinitis and no sleep apnea will have sleep and pollution exposure recordings
16429196|NCT03776760||Fingerstick Point of Care GeneXpert HCV Test|Participants will have HCV testing using the finger-stick point of care GeneXpert quantitative HCV RNA assay.
16429197|NCT03776760||Treat - SOF/VEL|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - sofosbuvir/velpatesvir
16429198|NCT03776760||Treat - G/P|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - glecaprevir/pibrentasvir
16429199|NCT03776747|Experimental|Group One: Prone MRI Scans|Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
16429200|NCT03776747|Active Comparator|Group Two: Supine MRI scans|Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
16429201|NCT03776734|Experimental|cryotherapy application|effect of cold application
16429202|NCT03776721|Experimental|Active treatment|
16429203|NCT03776721|Placebo Comparator|Placebo treatment|
16429204|NCT03776708|Experimental|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
16429205|NCT03776708|Sham Comparator|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
16429206|NCT03776695|Experimental|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16429207|NCT03776695|Placebo Comparator|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16429208|NCT03776695|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16429209|NCT03776695|Placebo Comparator|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16429210|NCT03776695|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16429211|NCT03776695|Placebo Comparator|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16429212|NCT03776695|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16429213|NCT03776695|Placebo Comparator|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
16429214|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
16429215|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
16429216|NCT03776669|Active Comparator|LSG alone|"Intervention: laparoscopic sleeve gastrectomy alone.
~LSG will be performed laparoscopically via a 5-port technique. The greater omentum is dissected by using the 5-mm laparoscopic LigaSure or Harmonic from 4 cm proximal to the pyloric ring to the angle of His. Sleeve calibration is done by a 36-French bougie inserted along the lesser curvature. Then the stomach is transected with sequential firings of linear green, gold, and blue 60 mm staplers starting about 4 cm proximal to the pylorus and ending approximately 2 cm distal to the left of the esophagus. The staple-line of the remnant gastric tube is oversewn with 3-0 V-Loc to prevent leakage and hemorrhage."
16429217|NCT03776669|Experimental|LSG + HHR|"Intervention: concomitant laparoscopic sleeve gastrectomy + hiatal hernia repair.
~The surgical detail of LSG is the same as described in LSG alone arm, and the surgical detail of HHR is described as below.
~The hiatus is approached from the right side of the EGJ, through the lesser omentum. The hiatal defect is repaired by 1-0 Surgilon interruptedly, and then a commercialized U-shaped Biodesign Hiatal Hernia Graft is placed to the EGJ to cover the posterior side but spare the anterior side of the hiatus. Care must be taken to avoid direct contact of mesh to the esophagus to avoid any unnecessary complication. After the mesh is appropriately placed and oriented, 2 ml of TISSEEL solution for sealant is applied all over the mesh for fixation."
16429218|NCT03776656|Experimental|Allopurinol|Oral administration of Allopurinol (Zyloric®) for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure
16429219|NCT03776643|Experimental|ILT-101 (ld-IL2)|Subcutaneous injections of ILT-101
16429220|NCT03776643|Placebo Comparator|placebo|Subcutaneous injections of placebo
16429224|NCT03776617|Experimental|Group Ropivacaine|general anesthesia + scalp block with 20 ml xylocaine 1% and 20ml ropivacaine 0.5%
16429225|NCT03776617|Experimental|Group Ropivacaine-Dexmedetomidine|general anesthesia + scalp block with 20 ml xylocaine 1%, 20ml ropivacaine 0.5% and 1mcg/kg dexmedetomidine
16429226|NCT03776617|No Intervention|Group control|general anesthesia
16429228|NCT03776604|Experimental|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.
~Dosing time: 48 h after chemotherapy."
16429229|NCT03776591|Experimental|Open D3|Right colectomy Open surgery Central lymphadenectomy and vascular ligation
16429230|NCT03776591|Active Comparator|Laparoscopic CME with CVL|Right colectomy Laparoscopic surgery Central lymphadenectomy and vascular ligation
16429231|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
16429232|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
16429233|NCT03776565||Operative hysteroscopy|women with an operative hysteroscopy planned
16429234|NCT03776565||Planned caesarean section|Pregnant women with a planned caesarean section
16429235|NCT03776552|Active Comparator|Low energy diet (LED)|8-week LED (<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks <1300 kcal/day and 4 weeks <1500 kcal/day)
16429236|NCT03776552|Active Comparator|Gradual weight loss (GWL)|16-week standard GWL-course (controls)
16429237|NCT03776539|Experimental|ELX-02|Drug: ELX-02
16429238|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
16429239|NCT03776513|Experimental|experimental group|Thirty obese boys (12-17 years old) undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
16429240|NCT03776513|Other|control group|Thirty healthy boys (12-17 years old) paired for pubertal stage, level of education and socio-economic level undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
16429241|NCT03776500|Experimental|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
16429242|NCT03776500|Placebo Comparator|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
16429243|NCT03776500|Experimental|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
16429244|NCT03776500|Placebo Comparator|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
16429245|NCT03776500|Experimental|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
16429246|NCT03776500|Placebo Comparator|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
16429247|NCT03776500|Experimental|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
16429248|NCT03776500|Placebo Comparator|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
16429249|NCT03776487|Experimental|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.
~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
16429250|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
16429251|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
16429252|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
16429253|NCT03776461|Experimental|80 pin applicator|
16429254|NCT03776461|Active Comparator|160 pin applicator|
16429255|NCT03776448|Experimental|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by [Bioextract Ltd, Sri Lanka] and is available commercially.
16429256|NCT03776448|Placebo Comparator|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially.
16429257|NCT03776435||CT-exposed group|
16429258|NCT03776435||CT-unexposed group|
16429259|NCT03776422|Experimental|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
16429260|NCT03776409||vancomycin plus piperacillin/tazobactam|Critically ill patients who received the combination of VAN (vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and PTZ were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
16429293|NCT03776175|Experimental|PF-05221304 and PF-06865571 Combination|15 mg PF-05221304 BID 300 mg PF-06865571 BID
16429633|NCT03773679|No Intervention|Control Group|The preterm infants in the control group did not receive the daily exercise program, only the standard clinical routine.
16429261|NCT03776409||vancomycin plus other beta-lactams|Critically ill patients who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
16429262|NCT03776396||Experimental cohort|"33 patient undergoing to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania, in which an innovative Perioperative Goal Directed Therapy (PGDT) protocol will be used."
16429263|NCT03776396||Historical control group|"33 patients underwent to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania in 2015, in which a PGDT protocol was not used, but a common hemodynamic monitoring, based on parameters such as central venous pressure and / or invasive arterial pressure, was performed."
16429264|NCT03776383|Active Comparator|Antibiotic use feedback letter 1|Antibiotic use feedback letter 1 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic prescribing for acute respiratory conditions
16429265|NCT03776383|Active Comparator|Antibiotic use feedback letter 2|Antibiotic use feedback letter 2 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic durations for common infections
16429266|NCT03776383|No Intervention|Control|Controls will not receive a letter
16429267|NCT03776370|Experimental|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
16429268|NCT03776370|Active Comparator|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery
16429269|NCT03776357|Experimental|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
16429270|NCT03776344|Experimental|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
16429271|NCT03776344|No Intervention|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
16429272|NCT03776331||Myeloma Patients|
16429273|NCT03776331||Controll group|
16429274|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
16429275|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
16429276|NCT03776305|Experimental|Imipenem ECMO|1-h infusion of 0.5 g of imipenem, q6h
16429277|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
16429278|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
16429279|NCT03776279|Experimental|Mitoxantrone Hydrochloride Liposome Injection|4 weeks is a treatment cycle, and the first day of each cycle is administered.
16429280|NCT03776253|Experimental|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.
~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
16429281|NCT03776240|Experimental|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
16429282|NCT03776240|Active Comparator|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
16429283|NCT03776240|Active Comparator|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
16429284|NCT03776227|Experimental|Sotagliflozin Test|One tablet of sotagliflozin administered orally under fasting conditions
16429285|NCT03776227|Active Comparator|Sotagliflozin Reference|Two tablets of sotagliflozin administered orally under fasting conditions
16429286|NCT03776201|Experimental|Internal Focus|"The internal focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The Internal Focus group will be reminded to focus their attention internally via the prompt keep your feet as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
16429287|NCT03776201|Experimental|External Focus|"The external focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The external focus group will be reminded to focus their attention externally via the prompt please keep the board as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
16429288|NCT03776201|No Intervention|Control|The control group will not receive any balance training
16429289|NCT03776188||no groups - observational study|no groups - observational study
16429290|NCT03776175|Placebo Comparator|Placebo|Placebo (PF 05221304) BID Placebo (PF 06865571) BID
16429291|NCT03776175|Experimental|PF-05221304 Monotherapy|15 mg PF-05221304 BID Placebo (PF-06865571) BID
16429292|NCT03776175|Experimental|PF-06865571 Monotherapy|Placebo (PF-05221304) BID 300 mg PF-06865571 BID
16429355|NCT03775720|Experimental|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
16429294|NCT03776162|Active Comparator|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
16429295|NCT03776162|Experimental|Bridge Enhanced ACL Repair|Procedure/Surgery Bridge Enhanced ACL Repair (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to group into.
16429296|NCT03776149|Experimental|Beetroot juice (dietary nitrate)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of beetroot juice (Beet It (HeartBeet Ltd.), Ipswich, UK). During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
16429297|NCT03776149|Placebo Comparator|Black currant juice (placebo control)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of a nitrate-depleted placebo. During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
16429298|NCT03776136|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
16429299|NCT03776110|Experimental|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.
~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
16429300|NCT03776110|Experimental|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.
~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
16429301|NCT03776110|Experimental|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.
~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
16429302|NCT03776110|Experimental|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.
~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
16429303|NCT03776097||Defect Fill.|Observational study of the patients that were treated with biomaterials at the surgery in the previous study
16429304|NCT03776097||No defect Fill.observational|Observational study of the patients that were not treated with biomaterials at the surgery of te previous study
16429305|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
16429308|NCT03776058|Experimental|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
16429309|NCT03776058|Placebo Comparator|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
16429310|NCT03776045|No Intervention|Standard care|This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study.
16429311|NCT03776045|Experimental|Standard care plus exercise|This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy.
16429312|NCT03776032|Experimental|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
16429313|NCT03776032|Placebo Comparator|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
16429314|NCT03776019|Experimental|Modulated|modulated music
16429315|NCT03776019|Sham Comparator|Typical|typical music
16429316|NCT03776006||TPLA|
16429317|NCT03775993|Active Comparator|GHD|
16429318|NCT03775993|Placebo Comparator|Placebo|
16429356|NCT03775720|Experimental|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
16429700|NCT03773120|Experimental|Using Neuromonitoring to find EBSLN|With Neuromonitoring of the EBSLN using nerve monitoring system
16429319|NCT03775954||1) Fetal Congenital Heart Disease|Pregnancy with major fetal congenital heart disease, after 20 weeks gestation, and as neonate following delivery. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
16429320|NCT03775954||2) History of fetal demise (Stillbirth)|Pregnancy with a history of an unexplained fetal demise (stillbirth at 20 -40 weeks gestation) during any prior pregnancy. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
16429321|NCT03775954||3) Fetal hydrops, immune or non-immune|Pregnancy with fetal hydrops, immune or non-immune, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
16429322|NCT03775954||4) Fetal gastroschisis|Pregnancy with fetal gastroschisis, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
16429323|NCT03775954||5) Twin pregnancy, monochorionic|Twin pregnancy, monochorionic, with or without twin-twin transfusion syndrome, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (fMCG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
16429324|NCT03775941||Cross-Sectional Lifespan Connectomics Study|
16429325|NCT03775928|Experimental|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
16429326|NCT03775928|Active Comparator|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
16429327|NCT03775915|Experimental|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
16429328|NCT03775915|Sham Comparator|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
16429329|NCT03775902|Experimental|Healthy subjects|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
16429330|NCT03775902|Experimental|Pre and/or type 2 diabetics|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
16429331|NCT03775889|Experimental|Behavioral|Behavioral Gardening Exposure
16429332|NCT03775876|Active Comparator|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
16429333|NCT03775876|Active Comparator|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
16429334|NCT03775863||Latin American multicenter Cohort|Transplanted patients with HCC in LATAM from 2005-2011
16429335|NCT03775863||French mutlicenter Cohort|Transplanted patients with HCC in France from 2003-2005
16429336|NCT03775863||Italian multicenter Cohort|Transplanted patients with HCC in Italy from 2005-2011
16429337|NCT03775850|Experimental|Cohort A|Cohort A includes patients with microsatellite stable (MSS) colorectal cancer (CRC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
16429338|NCT03775850|Experimental|Cohort B|Cohort B includes patients with Triple Negative Breast Cancer (TNBC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
16429339|NCT03775850|Experimental|Cohort C|Cohort C includes patients with non-small-cell lung cancer (NSCLC), bladder cancer; gastroesophageal (GE) cancer, any microsatellite unstable, or renal cell carcinoma (RCC) who are relapsed to prior PD-1/L1 therapy. Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
16429340|NCT03775837|Experimental|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
16429341|NCT03775837|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
16429342|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
16429343|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
16429344|NCT03775785|Experimental|tailored enteral nutrition|Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
16429345|NCT03775785|No Intervention|standard enteral nutrition|Standard fortification will be added according to the unit protocol.
16429346|NCT03775772|Other|Oral Health - Test Group|- study population is randomly assigned to control and test group
16429347|NCT03775772|Other|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
16429348|NCT03775759|Experimental|Study arm|Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy
16429349|NCT03775759|Active Comparator|Control arm|LVAD implantation plus medical therapy
16429350|NCT03775746|Experimental|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
16429351|NCT03775746|Active Comparator|Clopidogrel|Clopidogrel 75mg o.d.
16429352|NCT03775746|Active Comparator|Ticagrelor|Ticagrelor 90mg b.i.d.
16429353|NCT03775733|Experimental|Hydrolysed red ginseng extract|Hydrolysed red ginseng extract 2.4g/day for 12 weeks
16429354|NCT03775733|Placebo Comparator|Placebo|Placebo for 12 weeks
16429357|NCT03775707|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16429358|NCT03775681|Experimental|Device feasibility (Laryngeal Mask Airway, ERCP)|Patients wear Laryngeal Mask Airway after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.
16429359|NCT03775668|Experimental|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
16429360|NCT03775655|Active Comparator|LD-DEX|This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).
16429361|NCT03775655|No Intervention|Control group|This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).
16429362|NCT03775642|Experimental|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
16429363|NCT03775642|Placebo Comparator|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
16429364|NCT03775629|Experimental|Polmacoxib and Tramadol combination|Tramadol HCl 300mg once/day + 2 mg Polmacoxib capsule once/day for 14 days
16429365|NCT03775629|Active Comparator|Polmacoxib|Polmacoxib 2mg 14days
16429366|NCT03775629|Active Comparator|Tramadol|Tramadol hydrochloride (HCl) 150mg 5days
16429367|NCT03775616|Experimental|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
16429368|NCT03775590|Active Comparator|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
16429369|NCT03775590|Active Comparator|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
16429370|NCT03775590|Active Comparator|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
16429371|NCT03775577||HFpEF|Participants with Heart Failure with Preserved Ejection Fraction
16429372|NCT03775577||HFrEF|Participants with Heart Failure with Reduced Ejection Fraction
16429373|NCT03775577||Hypertensive Subjects|Participants with Hypertension
16429374|NCT03775577||Healthy Subjects|Participants without heart failure and without commodities
16429375|NCT03775564|Experimental|REMEDRUGBY|TAU + RemedRugby Program
16429376|NCT03775564|Active Comparator|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
16429377|NCT03775551|No Intervention|Control|The participants belonging to the hospitals assigned to the control group the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC following usual practice.
16429378|NCT03775551|Experimental|Improvement cycle|In participants belonging to the hospitals assigned to the intervention group,the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC using innovative intervention to assure continuity of care and assistant level approach. This innovations will be crafted from the rapid improvement cycles considering the environment and key aspects of the every day care at the participating centers.
16429379|NCT03775538|Experimental|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
16429380|NCT03775538|Experimental|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
16429381|NCT03775525|Experimental|Experimental: monotherapy|GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
16429382|NCT03775512|Experimental|Main Arm|Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation with nMARQ RF Generator
16429383|NCT03775512|Experimental|Second Arm (variable flow)|subjects will be treated with QDOT Micro catheter with variable flow nMARQ RF generator
16429384|NCT03775499|Other|Period 1: Placebo - Period 2: BL NCC 2705|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
16429385|NCT03775499|Other|Period 1: BL NCC 2705 - Period 2: Placebo|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
16429386|NCT03775486|Experimental|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:
~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
16429387|NCT03775486|Experimental|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
16429388|NCT03775473|Other|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
16429389|NCT03775460|Placebo Comparator|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
16429420|NCT03775239|Other|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
16433300|NCT03748940|Experimental|Part A: LY3074828|LY3074828 administered SC
16429390|NCT03775460|Experimental|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
16429391|NCT03775447||Parkinson's Disease Patients|"A diagnosis of Parkinson's disease in the opinion of the enrolling investigator
~Disease duration: any
~Male or female age 18 years or older at time of PD diagnosis."
16429392|NCT03775447||Healthy Control (HC) Subjects|• Male or female age 18 years or older at Screening.
16429393|NCT03775434|Experimental|B244|B244 suspension in 30ml/bottle
16429396|NCT03775395|Experimental|HAIC plus Lenvatinib|
16429397|NCT03775395|Active Comparator|HAIC plus Sorafenib|
16429398|NCT03775382|Placebo Comparator|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
16429399|NCT03775382|Active Comparator|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
16429400|NCT03775369|Active Comparator|Endurance training|"Endurance Training (warm-up; endurance on bike; brisk walking; cooling down; group sessions; supervised; moderate and individualized exercising load):
~6 weeks, 2 sessions/week, 40-60min/session"
16429401|NCT03775369|Active Comparator|Resistance training|"Resistance Training (warm-up; resistance training units; cooling down; group sessions; supervised; moderate and individualized exercising load):
~6 weeks, 2 sessions/week, 40-60min/session"
16429402|NCT03775369|Active Comparator|Control condition|"Control condition (individualized counselling, but not intended as a bona fide intervention, that is to say: not intended to actively improve participants' well-being):
~6 weeks, social support and counseling,1-2 sessions/week; 30 min/session"
16429403|NCT03775356|No Intervention|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
16429404|NCT03775356|Active Comparator|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
16429405|NCT03775343||General Anesthesia|"General anesthesia:
~25 patients older than 65 years, undergoing elective eye surgery under general anesthesia.
~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative.
~Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
16429406|NCT03775343||Local anesthesia with sedoanalgesia|"25 patients older than 65 years, undergoing elective eye surgery under local anesthesia in combination with sedoanalgesia.
~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
16429407|NCT03775343||Control Group|"25 patients, not undergoing any operative intervention. To determine a normal reference value of cognitive functions, a group of 25 individuals without an operative intervention will be recruited as a control group.
~Intervention: neurocognitive testing (Neurocognitive Test Battery) at 3 determined time points (0, 6 and 24 hours)"
16429408|NCT03775330|Experimental|SRS|Stereotactic radiosurgery
16429409|NCT03775330|Experimental|SRS plus WBRT|Stereotactic radiosurgery plus whole brain radiation
16429410|NCT03775317|Experimental|Video Laryngoscopy|
16429411|NCT03775317|Active Comparator|Direct Laryngoscopy|
16429412|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
16429413|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
16429414|NCT03775278|Experimental|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
16429415|NCT03775278|Placebo Comparator|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
16429418|NCT03775252|Experimental|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
16429419|NCT03775239|Other|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
16429526|NCT03774498|Active Comparator|Sensodyne repair and protect|NovaMin & fluoride toothpaste
16429421|NCT03775226|Experimental|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
16429424|NCT03775200|Experimental|Low dose|Low dose Psilocybin
16429425|NCT03775200|Experimental|Medium dose|Medium dose Psilocybin
16429426|NCT03775200|Experimental|High dose|High dose Psilocybin
16429427|NCT03775161|Experimental|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
16429428|NCT03775148|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
16429429|NCT03775148|No Intervention|CAU Group|Care-As-Usual group
16429430|NCT03775135||Children with neuromuscular diseases|Questionnaires will be administered by children with neuromuscular disease between 12 and 25 years and their parents
16429431|NCT03775122|Placebo Comparator|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)
~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
16429432|NCT03775122|Experimental|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.
~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
16429433|NCT03775109|Active Comparator|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
16429434|NCT03775109|Placebo Comparator|Dextrose|
16429435|NCT03775096|Experimental|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
16429436|NCT03775070|Experimental|Simvastatin|Simvastatin, 0.5mg/kg/d(maximum 20mg), once daily
16429437|NCT03775057|Experimental|MyDose Coach app intervention|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
16429438|NCT03775044|Experimental|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
16429439|NCT03775031|Active Comparator|Fraxel 1927nm|Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
16429440|NCT03775031|Active Comparator|Fraxel 1550nm|Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
16429441|NCT03775031|Active Comparator|25% TCA Peel|25% TCA on 5 x 5 cm of sun exposed back
16429442|NCT03775031|Placebo Comparator|Control|Patient serves as their own control
16429443|NCT03775018|Experimental|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
16429444|NCT03775018|Active Comparator|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
16429445|NCT03775005|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
16429446|NCT03775005|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16429447|NCT03774992|Experimental|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
16429448|NCT03774992|Experimental|Cross over|Subjects randomized to SVS in the CONTROL-study
16429449|NCT03774979|Experimental|SHR-1701|intravenous infusion
16429450|NCT03774966|Active Comparator|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
16429451|NCT03774966|Experimental|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
16429452|NCT03774953|Experimental|Intervention group|protein and vitamin supplementation
16429453|NCT03774953|No Intervention|Control group|No supplementations
16429454|NCT03774940|Experimental|fever|patients that have fever after PNL
16429455|NCT03774940|Active Comparator|No fever|Patients without fever after PNL
16429456|NCT03774927|Experimental|10 Hz treatment group|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
16429457|NCT03774927|Experimental|20 Hz treatment group|In active rTMS, 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
16429458|NCT03774927|Sham Comparator|Control Group|In sham rTMS, all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
16429459|NCT03774914||Lemtrada|Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
16429460|NCT03774901|Experimental|avelumab maintenance|Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
16429461|NCT03774888|Experimental|connective tissue graft|Connective tissue grafting (CTG) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
16429462|NCT03774888|Experimental|Acellular Dermal Matrix|Acellular Dermal matrix (ADM) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
16493543|NCT03335956|Experimental|MAD Active Cohort 4|
16429463|NCT03774888|Active Comparator|No soft tissue graft|Control group where no soft tissue graft is added to the lateral ridge augmentation.Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
16429464|NCT03774875|Experimental|Apremilast 30 mg twice daily|Subjects will take oral tablets of apremilast for up to 52 weeks (30 mg twice daily).
16429465|NCT03774875|Placebo Comparator|Placebo followed by Apremilast 30mg twice daily|Subjects will take placebo for 16 weeks. After Week 16, subjects will be switched to receive apremilast (30 mg twice daily) until Week 52.
16429466|NCT03774862||Medullary carcinoma of colorectal cancers|
16429467|NCT03774862||non-medullary carcinomas of the colorectal cancers|
16429468|NCT03774849|Experimental|Picoway™ 532nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
16429469|NCT03774849|Experimental|PicoWay™ 730nm wavelength|PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
16429470|NCT03774849|Experimental|PicoWay ™1064nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
16429471|NCT03774836|Active Comparator|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
16429472|NCT03774836|Active Comparator|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
16429473|NCT03774836|Placebo Comparator|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
16429474|NCT03774823|Experimental|Freeze Plus|Subjects in this arm will receive treatment using RF and PEMF
16429475|NCT03774823|Experimental|Ultrasound|Subjects in this arm will receive treatment using ultrasound
16429476|NCT03774810|Experimental|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
16429477|NCT03774810|Experimental|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
16429478|NCT03774810|Experimental|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
16429479|NCT03774810|Experimental|Low Frequency Intermittent Dosing|1 to 3 active doses per week PRN. The intervention is zolpidem tartrate 5 mg or 10 mg.
16429480|NCT03774797||Pre-Implementation Patients|Enrolled patients will take online surveys following a prenatal or a postpartum visit.
16429481|NCT03774797||Post-Implementation Patients|All enrolled patients will take online surveys following a prenatal or a postpartum visit. A subset will be interviewed after the postpartum survey.
16429482|NCT03774797||Post-Implementation Providers|All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
16429483|NCT03774784||ALECT2 Disease|
16429484|NCT03774771|Placebo Comparator|Placebo|In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
16429485|NCT03774771|Experimental|Cinacalcet 50 mg QD|In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
16429486|NCT03774771|Experimental|Cinacalcet 75 mg QD|In Part 1 participants received 75 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 40 mg cinacalcet capsules twice a day for 15 days.
16429487|NCT03774771|Experimental|Cinacelcet 100 mg QD|In Part 1 participants received 100 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 50 mg cinacalcet capsules twice a day for 15 days.
16429488|NCT03774758||Cohort 1A: Benign nodule on screening CT|"High-risk patients eligible for lung cancer screening but with negative radiographic findings on CT screening (Lung RADS ≤2).
~≥30 pack-year history of cigarette smoking
~≥55 years of age
~Current smoker or quit within the past 15 years"
16429489|NCT03774758||Cohort 1B: Incidental benign nodule|"Patients with lung nodules ≥ 6 mm on routine (non-lung cancer screening) CT evaluation deemed suspicious for malignancy by initial physician judgment but not malignant by ≥2 years of radiographic stability and consensus clinical opinion.
~1- Age ≥40 years."
16429490|NCT03774758||Cohort IC: Presumed lung cancer|"Patients with lung cancer (histologically proven or presumed by consensus opinion of tumor board); prior to definitive therapy.
~1- Age ≥40 years."
16429491|NCT03774758||Cohort 2A: Suspicious nodule|"High-risk patients with newly diagnosed suspicious nodule of Lung RADS ≥3 on CT screening.
~≥30 pack-year history of cigarette smoking
~≥55 years of age
~Current smoker or quit within the past 15 years"
16429492|NCT03774758||Cohort 2B: Suspicious incidental nodule|"Patients with newly diagnosed incidentally-found lung nodules ≥ 6 mm on routine CT evaluation deemed suspicious for malignancy by physician judgment.
~1- Age ≥40 years."
16429493|NCT03774758||Cohort 2C: Post-treatment lung cancer|"Patients with previously treated lung cancer (histologically proven or by consensus opinion); status-post completion of definitive therapy (resection +/- chemotherapy or SBRT with curative intent) within the previous year with no current evidence of disease.
~1- Age ≥40 years."
16429494|NCT03774745|Experimental|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).
~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
16429495|NCT03774745|Placebo Comparator|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
16429527|NCT03774498|No Intervention|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
16429528|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
16429529|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
16429530|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
16429496|NCT03774732|Experimental|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.
~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.
~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).
~Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
16429497|NCT03774732|Active Comparator|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:
~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )
~Non squamous-cell lung carcinoma:
~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)
~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
16429498|NCT03774719|Experimental|Hand-carried ultrasound arm|This is the only arm of the study. It will be comprised of 154 inpatients who had a renal ultrasound ordered or performed within the past 4 hours. The intervention will be performing hand-carried ultrasound to evaluate for presence and degree of hydronephrosis.
16429499|NCT03774706|Active Comparator|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
16429500|NCT03774706|Active Comparator|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
16429501|NCT03774693|Active Comparator|GS [General anesthesia]|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
16429502|NCT03774693|Active Comparator|GR [General anesthesia + regional block]|"Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
~Also patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block. Fentanyl boluses of 0.5 mcg.Kg-1 will be given when needed to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1."
16429503|NCT03774680|Active Comparator|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
16429504|NCT03774680|Placebo Comparator|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
16429505|NCT03774667||Placenta Previa|Pregnant women is diagnosed with placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
16429506|NCT03774667||None-Placenta Previa|Pregnant women is diagnosed without placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
16429507|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
16429508|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
16429509|NCT03774641||Taking Lamotrigine|Lamotrigine (Lamictal), dosage will be based on a reference concentration of blood-serum levels
16429510|NCT03774628|Experimental|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
16429511|NCT03774628|Experimental|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
16429512|NCT03774615|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
16429513|NCT03774602|Experimental|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
16429514|NCT03774589|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
16429515|NCT03774589|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
16429516|NCT03774576|Experimental|RO7017773|Single dose of RO7017773
16429517|NCT03774576|Experimental|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
16429518|NCT03774537|Experimental|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.
16429519|NCT03774537|Other|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
16429520|NCT03774524|Active Comparator|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
16429521|NCT03774524|Active Comparator|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
16429522|NCT03774524|Placebo Comparator|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
16429523|NCT03774511|Active Comparator|Study group 1|High Intensity Interval Excercise
16429524|NCT03774511|Active Comparator|Study group 2|Moderate Intensity Interval Exercise
16429525|NCT03774511|No Intervention|Control group|No Intervention
16429531|NCT03774472|Experimental|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Patients with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, cycles may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
16429532|NCT03774459|Experimental|High dose ANAVEX2-73|High dose ANAVEX2-73
16429533|NCT03774459|Experimental|Mid dose ANAVEX2-73|Mid dose ANAVEX2-73
16429534|NCT03774459|Placebo Comparator|Placebo oral capsule|Placebo oral capsule
16429535|NCT03774446|Experimental|Seliciclib|Up to 800 mg/day oral seliciclib for 4 days each week for 4 weeks
16429536|NCT03774433|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
16429537|NCT03774407|Other|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
16429538|NCT03774407|Experimental|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
16429539|NCT03774394|Experimental|Diabetes Mellitus patients with Chronic Kidney Disease|"Patients with CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.
~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
16429540|NCT03774394|Active Comparator|Diabetes Mellitus patients without Chronic Kidney Disease|"Patients without CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.
~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
16429541|NCT03774381|Experimental|Bifidobacterium breve B-3 group|160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
16429542|NCT03774381|Placebo Comparator|Control group|160 mg of placebo was orally administered per day for 12 weeks.
16429543|NCT03774368|Other|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
16429544|NCT03774368|Other|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
16429545|NCT03774355|Experimental|CG1801|Dosing 'CG1801' followed by dosing 'CGL1802'
16429546|NCT03774355|Experimental|CGL 1802|Dosing 'CGL1802' followed by dosing 'CG1801'
16429547|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
16429548|NCT03774329|Experimental|physical activity program|Child with an adapted physical activity program
16429549|NCT03774329|Other|Usual care|
16429550|NCT03774303|Experimental|mobile intervention|families to be prepared for day surgery with a mobile application
16429551|NCT03774303|Active Comparator|control group|families to be prepared for day surgery with current practice
16429552|NCT03774290|Experimental|PBF-680 10 mg|10 mg of PBF-680 once a day
16429553|NCT03774290|Placebo Comparator|Placebo oral capsules|Placebo once a day
16429554|NCT03774277|Experimental|Intervention Communities|Packed Promise for a Healthy Heart intervention, free Tribal Wellness Center membership, a Fitbit, and the AYA culturally based mobile walking app.
16429555|NCT03774277|No Intervention|Control Communities|Free Tribal Wellness Center membership, Fitbit, and the AYA culturally based mobile walking app
16429556|NCT03774264||Xiaflex group|"Patients will be evaluated in our urology clinic at baseline for possible inclusion in our study. All patients at baseline evaluation will be evaluated for duration of symptoms, relationship stability, IIEF and PDQ. All patients will obtain a penile Doppler ultrasound with the aid of a vasoactive substance by a specially trained technician. During this visit, plaque measurements will be taken: location of plaque, distance of plaque from the tip of the penis, degree of curvature measured by goniometer.
~Ultrasound characteristics will be documented: Type (Type 1: The plaque appears as a thickening of the tunica albuginea without acoustic shadowing. Type 2: A moderately calcified plaque with a typical ultrasound shadow. Type 3: A severely calcified plaque with typical ultrasound shadowing) and Grade of calcification (grade 1 (<0.3 cm), grade 2 (>0.3 cm, <1.5 cm), grade 3 (>1.5 cm; or ≥ 2 plaques >1.0 cm). Sample data sheet attached as appendix 2."
16429557|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - PRP Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to undergo platelet rich plasma injection
16429558|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - ESWT Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to extracorporeal shock wave therapy
16429559|NCT03774238|Experimental|COPD patients|FMD analysis Endothelial progenitors Exercise test Exercise training
16429560|NCT03774238|Experimental|Healthy subject|FMD analysis Endothelial progenitors Exercise test
16429561|NCT03774225|Experimental|Manual and verbal guidance (MVG)|The MVG Group will be done by experimental group with the manual and verbal guidance of a physiotherapist using four games of X-Box Kinect system®
16429562|NCT03774225|Experimental|No manual and verbal guidance (NMVG)|The NMVG Group will be done by experimental group using four games of X-Box Kinect system® in the presence of a physiotherapist that will care about the safety of the participants without interfere in their moviment pattern.
16429563|NCT03774225|Active Comparator|Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
16429634|NCT03773666|Experimental|Durvalumab|-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
16429564|NCT03774212|Experimental|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
16429565|NCT03774212|Experimental|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
16429566|NCT03774199|Other|Pulse oximeter calibration population|
16429567|NCT03774186|Active Comparator|Sensor-augmented pump therapy (SAPT)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor but there will be no automated insulin adjustments made by the system.
16429568|NCT03774186|Experimental|Hybrid closed-loop therapy (HCL)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor with automated insulin adjustments made by the system, but continued meal boluses from the women.
16429569|NCT03774173|Experimental|Aramchol 300 mg|Aramchol 300 mg twice daily (every 12 hours)
16429570|NCT03774173|Experimental|Aramchol 600 mg|Aramchol 600 mg once daily (every 24 hours)
16429571|NCT03774160|Experimental|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
16429572|NCT03774160|No Intervention|Comparison|No intervention is implemented in the comparison arm.
16429573|NCT03774134||CME group|The CME group consisted of patients, who underwent elective CME for sigmoid colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2014.
16429574|NCT03774134||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for sigmoid adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
16429575|NCT03774121|Experimental|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
16429576|NCT03774121|Sham Comparator|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
16429577|NCT03774108|Experimental|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
16429578|NCT03774108|Placebo Comparator|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
16429579|NCT03774095|No Intervention|No oil|6-hour oral glucose tolerance test
16429580|NCT03774095|Active Comparator|Hydrolyzed pine nut oil|6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
16429581|NCT03774095|Active Comparator|Hydrolyzed pine nut oil and olive oil|3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
16429583|NCT03774069|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
16429584|NCT03774069|Active Comparator|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
16429585|NCT03774056|Experimental|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
16429586|NCT03774043|Experimental|Single session of Acute Intermittent Hypoxia (AIH)|
16429587|NCT03774043|Placebo Comparator|Single session of Sham Acute Intermittent Hypoxia (Sham AIH)|
16429588|NCT03774043|Experimental|Two successive sessions of AIH|
16429589|NCT03774043|Placebo Comparator|Two successive sessions of Sham AIH|
16429590|NCT03774030|Experimental|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
16429591|NCT03774017|Other|Traditional microsurgery group|Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
16429592|NCT03774017|Experimental|Hybrid operation group|Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
16429593|NCT03773991||Maintenance Hemodialysis Patients|"Patients on chronic hemodialysis therapy due to end-stage renal disease.
~Proton Lung MRI
~Sodium MRI of the leg
~Chest CT
~Transthoracic Echocardiography
~Fractional Exhaled Nitric Oxide
~Six-Minute Walk Test
~Pulmonary Function Tests
~Blood sampling
~Self-administered dyspnea questionnaires"
16429594|NCT03773978|Experimental|Baricitinib Open-Label|Baricitinib given orally.
16429595|NCT03773978|Experimental|Baricitinib Double Blind|Baricitinib given orally.
16429596|NCT03773978|Placebo Comparator|Placebo Double Blind|Placebo given orally.
16429598|NCT03773952|Experimental|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
16429599|NCT03773952|Placebo Comparator|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
16429600|NCT03773939||Derivation cohort|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624, NCT03577405, and NCT03553069)
16429601|NCT03773939||External validation cohort|We will create a multicenter cohort based on prospectively collected data derived from the Dutch National Intensive Care Evaluation (NICE) registry
16429632|NCT03773679|Experimental|Exercise Group|"Daily exercise program involved Range of Motion (ROM) exercises against extremity resistances and extension and flexion in upper and lower extremities. Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes."
16429602|NCT03773926|Experimental|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.
~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
16429603|NCT03773913||Four facilities in Kozah District|Baseline estimated population of 33,412 served by four public sector facilities in Kozah District.
16429604|NCT03773900|Experimental|Chitin-Glucan supplementation|
16429605|NCT03773900|Placebo Comparator|Placebo supplementation|
16429606|NCT03773887|Other|acute alcoholic hepatitis|collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
16429607|NCT03773887|Other|Alcoholic cirrhosis|collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
16429608|NCT03773887|Other|Without chronic liver disease|collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
16429609|NCT03773861|Other|Participants|Active BLS- Instructors at the Bern Simulation and CPR- Center (BeSiC), at the Bern University Hospital, Bern, Switzerland. Participants have to oversee a BLS instructional session, where standardized errors are performed by trained volunteers.
16429610|NCT03773848|Experimental|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
16429611|NCT03773848|Experimental|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
16429612|NCT03773835|Experimental|HSK3486|0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
16429613|NCT03773822|Placebo Comparator|Placebo of hydrocortisone and placebo of fludrocortisone|Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
16429614|NCT03773822|Experimental|Combination of hydrocortisone + fludrocortisone|Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
16429615|NCT03773809|Placebo Comparator|Group A0|Vitamin D3 deficient ACO patients with placebo at day 0.
16429616|NCT03773809|Placebo Comparator|Group A90|Vitamin D3 deficient ACO patients with placebo at day 90.
16429617|NCT03773809|Active Comparator|Group B0|Vitamin D3 deficient ACO patients with vitamin D3 at day 0.
16429618|NCT03773809|Active Comparator|Group B90|Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
16429619|NCT03773796|Other|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
16429620|NCT03773783|Active Comparator|Twin Block|Twin Block appliance
16429621|NCT03773783|Experimental|Button and Bead|Button and Bead appliance
16429622|NCT03773757|Experimental|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
16429623|NCT03773757|No Intervention|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
16429624|NCT03773744|Experimental|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
16429625|NCT03773744|Experimental|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
16429626|NCT03773731|Experimental|High intensity interval training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:
~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test
~30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.
~10 minutes with 30% of maximal power output."
16429627|NCT03773731|Active Comparator|Moderate intensity continuous training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:
~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test
~30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output
~10 minutes with 30% of maximal power output."
16429628|NCT03773718||Russkoe pole|400 patients
16429629|NCT03773705|Active Comparator|Electrocautery group|Electrocautery used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
16429630|NCT03773705|Active Comparator|Scalpel group|Scalpel used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
16429631|NCT03773692|Experimental|Passive feedback and JITAI|"Passive feedback and JITAI
~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
16429635|NCT03773666|Experimental|Durvalumab + Oleclumab|"Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
~Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle"
16429636|NCT03773653|Experimental|BMT to be combined with BAT|Participants in this group will receive bilateral robotic priming and bilateral arm training or mirror therapy within the 90-minute training sessions.
16429637|NCT03773653|Experimental|BMT to be combined with MT|Participants in this group will receive bilateral robotic priming and mirror therapy within the 90-minute training sessions.
16429638|NCT03773653|Active Comparator|BMT to be combined with IOT|Participants in this group will receive bilateral robotic priming and impairment-oriented training within one 90-minute training session.
16429639|NCT03773640|Experimental|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
16429640|NCT03773640|Active Comparator|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
16429641|NCT03773601|Experimental|Athletes|Athletes will undergo a 4-days sleep monitoring with the use of the Sleep Profler. At the same time, they will fill the Total Quality of Recovery (TQR) scale and the Pittsburgh Sleep Quality Index (PSQI).
16429642|NCT03773588|Active Comparator|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
16429643|NCT03773588|Active Comparator|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
16429644|NCT03773575|Experimental|Prevena|PREVENA™ PEEL & PLACE™ Dressing Kit
16429645|NCT03773575|No Intervention|Standard Care|sterile gauze dressing supplemented with an Ace wrap
16429646|NCT03773562|Other|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
16429647|NCT03773549||Body dysmorphic disorder|Meet DSM-5 criteria for principal body dysmorphic disorder, assessed via the Structured Clinical Interview for the DSM-V Axis I Disorders (SCID)
16429648|NCT03773549||Healthy control|Individuals who do not have a current psychiatric diagnosis, assessed via the Mini-International Neuropsychiatric Interview (MINI)
16429649|NCT03773536|Experimental|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
16429650|NCT03773523|Experimental|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
16429651|NCT03773523|Sham Comparator|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
16429652|NCT03773510|Active Comparator|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
16429653|NCT03773510|Experimental|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.
~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
16429654|NCT03773497|Other|Common snack combination|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of a combination of common snack foods (pretzels, potato chips, and popcorn).
16429655|NCT03773497|Other|Cheese broccoli|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli.
16429656|NCT03773497|Other|Cheese broccoli with Daikon radish powder|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder.
16429657|NCT03773497|Other|Uncooked broccoli with ranch-type dip|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of uncooked, freeze-dried broccoli with ranch-type dip.
16429658|NCT03773484|Experimental|Clinical Decision Support nudges|"Clinical decision support nudges within the electronic health record to discourage unnecessary opioid prescribing through the application of behavioral insights-empirically-tested social and psychological interventions that affect choice. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart."
16429661|NCT03773458|Other|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
16429662|NCT03773432|Other|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
16429663|NCT03773432|Other|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
16429664|NCT03773419|Experimental|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
16429665|NCT03773419|Active Comparator|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
16429666|NCT03773406|Active Comparator|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
16429667|NCT03773406|Active Comparator|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
16429668|NCT03773406|Active Comparator|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
16429669|NCT03773406|Sham Comparator|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
16429670|NCT03773393|Experimental|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
16429671|NCT03773380|Experimental|Feasibility|50 patients will be recruited to take part in this feasibility study. They will all undergo this Breathe Anew Program post-surgery. Breathe Anew consists of radiological surveillance, physical rehabilitation using a Fitbit, mindfulness therapy, and referral for symptom management specialists when needed.
16429672|NCT03773367|Experimental|Treatment with chemotherapy pre- and postoperative.|
16429673|NCT03773354|Experimental|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
16429674|NCT03773328|Experimental|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.
~Cohort dosing will be as follows:
~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
16429675|NCT03773315|Experimental|UMH group|This group takes UMH extract for 12 weeks
16429676|NCT03773315|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
16429677|NCT03773302|Experimental|Infigratinib (BGJ398) 125 mg|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
16429678|NCT03773302|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
16429679|NCT03773276|Experimental|Norepinephrine boluses|Single arm study
16429680|NCT03773263|Experimental|sequential oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. COCs were removed from aspirated follicular fluid and transferred into HEPES-buffered collection medium. The immature oocytes will be cultured in sequential IVM medium 1 for 6 hours (37℃, 5% CO2), and removed into sequential IVM medium 2 for further cultivation. After 24 and 40 hours cultivation, the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle.
16429681|NCT03773263|Active Comparator|traditional oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
16429682|NCT03773250|Experimental|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
16429683|NCT03773250|No Intervention|Control|No intervention will be provided.
16429684|NCT03773237|Active Comparator|SMOFLipid|SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
16429685|NCT03773237|Active Comparator|IntraLipid|Intralipid is a lipid emulsion that contains soybean oil
16429686|NCT03773224|Active Comparator|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
16429687|NCT03773224|No Intervention|Control|The surgical wound is closed layer by layer without irrigation
16429688|NCT03773211|Experimental|Renaparin|Solution administered once to kidney ex-vivo
16429689|NCT03773211|Placebo Comparator|Placebo|Placebo administered once to kidney ex-vivo
16429690|NCT03773198|Experimental|ERCS Group|
16429691|NCT03773198|Placebo Comparator|Control Group|
16429692|NCT03773172|Placebo Comparator|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
16429693|NCT03773172|Active Comparator|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
16429694|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
16429695|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
16429696|NCT03773146|No Intervention|Control|No airtime incentive was given for completing the survey
16429697|NCT03773146|Experimental|1X Incentive|1X Airtime Incentive
16429698|NCT03773146|Experimental|Lottery|Lottery Airtime Incentive
16429699|NCT03773133|Experimental|Treatment|i.v. administrations of up to three radioactivity levels of Satoreotide tetraxetan.
16494649|NCT03329443|Placebo Comparator|placebo|
16429701|NCT03773120|No Intervention|No Using Neuromonitoring to find EBSLN|Without Neuromonitoring of the EBSLN using nerve monitoring system
16429702|NCT03773107|Experimental|Phase I|Cohort 1) 5mg ruxolitinib, Cohort 2) 10mg ruxolitinib, Cohort 3) 15mg ruxolitinib
16429703|NCT03773107|Other|Phase II|Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen
16429704|NCT03773094|Experimental|Guava leaves extract|A natural product that is prepared as a mouthwash
16429705|NCT03773094|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
16429706|NCT03773081|Other|Magmaris implantation|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice.
16429707|NCT03773068|Experimental|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
16429708|NCT03773068|Experimental|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg [13C715N]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
16429709|NCT03773068|Experimental|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
16429710|NCT03773055|Active Comparator|NPC-06 (High dosage)|18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
16429711|NCT03773055|Active Comparator|NPC-06 (Low dosage)|15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
16429712|NCT03773055|Placebo Comparator|Placebo|Saline will be administered intravenously
16429713|NCT03773042|Experimental|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
16429714|NCT03773042|Active Comparator|Propofol|1.0mg/kg, 2.0mg/kg
16429715|NCT03773029|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 capsules)
16429716|NCT03773029|Placebo Comparator|control|2 capsules of placebo
16429717|NCT03773016|Experimental|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
16429718|NCT03773016|Experimental|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
16429719|NCT03773003|Active Comparator|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
16429720|NCT03773003|Placebo Comparator|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
16429721|NCT03773003|Active Comparator|Arm 3: Healthy control group|Group receiving probiotics
16429722|NCT03773003|Placebo Comparator|Arm 4: Healthy control group|Group receiving placebo (corn starch)
16429723|NCT03772990|Experimental|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
16429724|NCT03772990|Placebo Comparator|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
16429725|NCT03772977|Experimental|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
16429726|NCT03772977|No Intervention|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
16429727|NCT03772964|Experimental|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
16429728|NCT03772964|Experimental|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
16429729|NCT03772964|Experimental|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
16429730|NCT03772951|Active Comparator|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
16429731|NCT03772951|Placebo Comparator|Clozapine|Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
16429732|NCT03772938|Active Comparator|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
16429733|NCT03772938|Sham Comparator|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
16429734|NCT03772925|Experimental|Treatment (belinostat, pevonedistat)|Patients receive belinostat IV QD over 30 minutes on days 1-5 and pevonedistat IV QD over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16429735|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
16429736|NCT03772899|Experimental|Study Intervention|Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.
16429737|NCT03772886|Experimental|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
16429738|NCT03772886|No Intervention|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
16429741|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
16429742|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
16429743|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
16429744|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
16429745|NCT03772847|Experimental|ginkgolide group|ginkgolide plus alteplase
16429746|NCT03772847|No Intervention|control|alteplase
16429747|NCT03772834|Experimental|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
16429748|NCT03772834|Active Comparator|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
16429749|NCT03772834|Active Comparator|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
16429750|NCT03772834|Active Comparator|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
16429751|NCT03772808|Experimental|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
16429752|NCT03772795|Active Comparator|Group 1- Alignment with fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Uniteks, 0.022 Roth prescription brackets.Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
16429753|NCT03772795|Experimental|Group 2- Alignment with clear aligners|Clear aligner orthodontic appliance (EON, Eon Dental NV, Belgium). Teeth alignment with clear aligners.
16429754|NCT03772769|Experimental|Subjects with advanced deep space odontogenic infection|Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
16429755|NCT03772756|Experimental|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
16429756|NCT03772756|Active Comparator|control group|the control group will receive chemoradiotherapy only
16429757|NCT03772743|Other|Culprit-only revascularization|All patients randomized to culprit only revascularization must not undergo percutaneous coronary intervention (PCI) any lesion except from the culprit lesion already treated at the moment of the randomization. Staged procedures are considered protocol violation.
16429758|NCT03772743|Other|Complete functionally-guided revascularization|Patients who are randomized to this strategy will receive revascularization of the culprit lesion and guided by functional assessment on all non-culprit lesions. Functional evaluation is mandatory for all stenosis with diameter stenosis % between 50 and 90% at visual estimation. Revascularization must be guided by functional assessment on all vessels. The system utilized to obtain functional evaluation is left to Operator's discretion. PCI is allowed only if functional evaluation is positive according to the threshold of the chosen functional system. It is suggested to achieve functional complete revascularization within the index procedure, while it is mandatory to obtain it within the index hospitalization.
16429759|NCT03772730||Group 1|Multiply injured patients having at least one operative orthopaedic injury to the pelvis, acetabulum, femur, or diaphyseal tibia with planned definitive fixation to occur prior to discharge.
16429760|NCT03772717|Experimental|Vital EMS+|Participants will receive electrical neuromuscular stimulation via a Vital EMS+ device, along with the standard of care treatment.
16429761|NCT03772717|Sham Comparator|Sham device|Participants will receive a sham device that does not deliver electrical neuromuscular stimulation, along with the standard of care treatment.
16429764|NCT03772678|Placebo Comparator|Placebo|0.9% Saline For SAD and MAD arms.
16429765|NCT03772678|Experimental|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
16429766|NCT03772678|Experimental|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
16429767|NCT03772678|Experimental|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
16429768|NCT03772665|Experimental|Emixustat|10 mg
16429769|NCT03772665|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
16429770|NCT03772652||Peri-implantitis|Subjects who were diagnosed with peri-implantitis and received treatment at least five years ago at the Graduate Periodontics Clinic at University of Michigan with sufficient baseline data. Soft tissue measurements (observation) of the implant will be completed.
16429771|NCT03772639|Experimental|Experimental group|The experimental group received a standard medical and pharmacological care in a daily format and shared decision making (SDM). The general framework of SDM was developed focusing on self-management goals which include education that addresses continuous use of medication, behavioral change, breathing training, learning to interpret changes in the disease and its consequences, and use of medical and community resources.
16429772|NCT03772639|No Intervention|Control Group|The control group received standard care and pharmacological care including systemic steroids, antibiotics, inhaled bronchodilators, and oxygen therapy.
16429773|NCT03772626|Experimental|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
16429774|NCT03772613|Active Comparator|Low ACT Target|ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
16429775|NCT03772613|Active Comparator|Medium ACT Target|ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
16429776|NCT03772613|Active Comparator|High ACT Target|ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
16429777|NCT03772600|Experimental|Dexcom G6|Use a Dexcom G6 CGM for 36 months
16429778|NCT03772600|No Intervention|FreeStyle Libre|"Keep using their FreeStyle Libre for 6 months. Before the 6 month time point is reached, patients will wear a blinded Dexcom G6 for 28 days, together with their FreeStyle Libre.
~Cross-over to Dexcom G6 for 30 months."
16429784|NCT03772574|Experimental|THRIVE|THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).
16429785|NCT03772574|Active Comparator|Facemask|Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).
16429786|NCT03772561|Experimental|AZD5363+Olaparib+Durvalumab|"A traditional 3+3 design will be used during the dose escalation part of the study.
~Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities."
16429787|NCT03772548||Patients with spinal cord injury|
16429788|NCT03772548||Healthy subjects|
16429789|NCT03772535|No Intervention|Control Group|Subjects in this arm will receive the standard postoperative pain prescription protocol.
16429790|NCT03772535|Active Comparator|Pharmacogenomics Guided Group|Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.
16429791|NCT03772522|Experimental|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.
~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.
~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
16429792|NCT03772522|Placebo Comparator|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.
~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
16429793|NCT03772509|Experimental|CATI|Introduction and consent via computer assisted telephone interview
16429794|NCT03772509|No Intervention|IVR|Introduction and consent via interactive voice response
16429795|NCT03772496|Experimental|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
16429796|NCT03772483|Active Comparator|Control group|Local anesthesia with conventional syringe
16429797|NCT03772483|Active Comparator|Virtual reality group|Local anesthesia with conventional syringe + VR device
16429798|NCT03772470|No Intervention|Control|No airtime incentive was given for completing the survey
16429799|NCT03772470|Experimental|1X Incentive|1X airtime incentive
16429800|NCT03772470|Experimental|2X incentive|2X airtime incentive
16429801|NCT03772470|Experimental|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
16429802|NCT03772444|Active Comparator|Beetroot juice|
16429803|NCT03772444|Placebo Comparator|Control group 1|
16429804|NCT03772444|Sham Comparator|Control group 2|
16429805|NCT03772431|Experimental|Male Informational|Male voice, informational introduction
16429806|NCT03772431|Experimental|Male Motivational|Male voice, motivational introduction
16429807|NCT03772431|Experimental|Female Informational|Female voice, informational introduction
16429808|NCT03772431|Experimental|Female Motivational|Female voice, motivational introduction
16429809|NCT03772418|Placebo Comparator|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
16429810|NCT03772418|Active Comparator|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
16429811|NCT03772405|Experimental|Nascum Plus and ACC|In a cross-over design, patients are exposed to pollen in the ACC twice for 4 hours each 3 weeks apart. Subjects will receive treatment with Nascum Plus either 5 minutes before the first or the second 4 hour pollen challenge.
16429812|NCT03772379|Experimental|tooth borne hyrax expander group|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars .
16429813|NCT03772379|Experimental|tooth borne hyrax expander with microosteoperforation|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars and microosteoperforation .
16429814|NCT03772366||Warfarine|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Warfarine
16429815|NCT03772366||Fluindione|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
16429816|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
16429817|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
16429818|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
16429956|NCT03771573|Placebo Comparator|Control group|Will not be submitted to the Cardiovascular Physiotherapy Rehabilitation protocol for unsupervised domiciliary, only monitorization of cardiovascular variables.
16430102|NCT03770611|Active Comparator|Prebiotic|Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
16429819|NCT03772353|Experimental|Pyrotinib Combined with Letrozole and SHR6390|Data from phase Ib showed the triplet of pyrotinib, SHR6390, and letrozole had an acceptable safety profile and encouraging efficacy, potentially offering a chemotherapy-sparing treatment option for patients with HER2-positive/HR-positive MBC. Based on DLTs and clinical efficacy, pyrotinib 320mg/d, SHR6390 125mg/d, and letrozole 2.5mg/d was declared as RP2D. The pharmacokinetic analysis had not yielded conclusive results and would involve more samples in phase II trial.
16429820|NCT03772340|Experimental|Tradipitant|
16429821|NCT03772340|Placebo Comparator|Placebo|
16429822|NCT03772327|Experimental|Routine counseling + AdhereTech bottle|"Participants will receive routine medication adherence counseling and be given the AdhereTech smart bottle with reminders."
16429823|NCT03772327|Active Comparator|Routine counseling|Participants will receive routine medication adherence counseling.
16429824|NCT03772314|Active Comparator|Modafinil|Participants in this study arm will take modafinil.
16429825|NCT03772314|Experimental|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
16429826|NCT03772301||Group 1|At least 200 Jewish Holocaust survivors of the first generation living in Germany and Israel - an equal number in each country
16429827|NCT03772301||Group 2|The second generation, whose parents lived in Europe during the Second World War, now live in Germany (originating from Western and Eastern Europe) - at least 200 participants.
16429828|NCT03772301||Group 3|Third generation of Jewish Holocaust survivors who participated in the first phase, currently living in Germany and Israel - at least 200 participants including at least 100 subjects in each country. These are adults only. The research program does not include children and adolescents
16429829|NCT03772288|Experimental|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
16429830|NCT03772288|Experimental|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
16429831|NCT03772275|Active Comparator|New york Heart Association Class II-IV|New york Heart Association Class II-IV heart failure
16429832|NCT03772275|Active Comparator|New york Heart Association Class I|New york Heart Association Class I with no heart failure
16429833|NCT03772262|Experimental|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
16429834|NCT03772262|Experimental|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
16429835|NCT03772249|Experimental|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
16429836|NCT03772249|Placebo Comparator|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
16429837|NCT03772249|Experimental|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
16429838|NCT03772249|Placebo Comparator|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
16429839|NCT03772249|Experimental|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
16429840|NCT03772249|Placebo Comparator|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
16429841|NCT03772249|Experimental|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
16429842|NCT03772249|Placebo Comparator|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
16429843|NCT03772249|Experimental|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
16429844|NCT03772249|Placebo Comparator|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
16429845|NCT03772249|Experimental|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
16429846|NCT03772249|Placebo Comparator|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
16429847|NCT03772249|Experimental|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
16429848|NCT03772249|Placebo Comparator|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
16429849|NCT03772249|Experimental|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
16429850|NCT03772249|Placebo Comparator|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
16429851|NCT03772249|Experimental|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
16429852|NCT03772249|Placebo Comparator|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
16429853|NCT03772249|Experimental|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)
~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)
~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
16429854|NCT03772249|Experimental|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
16429855|NCT03772249|Experimental|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
16429856|NCT03772249|Experimental|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
16494650|NCT03329443|Active Comparator|Spironolactone|
16429857|NCT03772223|Experimental|Treatment sequence 1 (ABC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027) , Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
16429858|NCT03772223|Experimental|Treatment sequence 2 (BCA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
16429859|NCT03772223|Experimental|Treatment sequence 3 (CBA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
16429860|NCT03772223|Experimental|Treatment sequence 4 (ACB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
16429861|NCT03772223|Experimental|Treatment sequence 5 (BAC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
16429862|NCT03772223|Experimental|Treatment sequence 6 (CAB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
16429863|NCT03772210|Active Comparator|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
16429864|NCT03772210|Sham Comparator|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
16429865|NCT03772210|Active Comparator|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
16429866|NCT03772210|Sham Comparator|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
16429867|NCT03772210|Active Comparator|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
16429868|NCT03772210|Sham Comparator|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
16429869|NCT03772210|Experimental|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.
~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
16429870|NCT03772184|Active Comparator|cervical inversion|
16429871|NCT03772184|No Intervention|no cervical inversion|
16429872|NCT03772158|Experimental|Treatment A|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
16429873|NCT03772158|Experimental|Treatment B|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.
16429874|NCT03772158|Experimental|Treatment C|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
16429875|NCT03772158|Active Comparator|Treatment D|Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
16429876|NCT03772158|Active Comparator|Treatment E|Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
16429877|NCT03772145||Tofacitinib|Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy
16429878|NCT03772132|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
16429879|NCT03772119||Surgical treatment of hemivertebra|cohort of children with a vertebral malformation treated by surgical resection
16429880|NCT03772106|Experimental|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
16429881|NCT03772106|Experimental|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
16429882|NCT03772093|Active Comparator|Patients with manual massage therapy|30 patients were randomly assigned to massage therapy. The procedures were performed for ten days, with weekend break. Manual massage of lumbar area was performed by certified massage therapist with the typical course of the procedure. The technique was consisted of stroking, kneading, grinding, patting and shaking. The procedure lasted twenty minutes.
16429957|NCT03771573|Active Comparator|Professional seupervision based|eight weeks of supervised activities by professional. Each day and for 20 days (20 sessions), volunteers will undergo exercises on cycle ergometer during 30 minutes for upper and lower limbs
16429883|NCT03772093|Active Comparator|Patients with Trabert current therapy|30 patients were randomly assigned to Trabert current therapy. The Trabert current was administered by 143 frequency, time of 2 ms impulse, time of break 5 ms. The current was generated by Pulsotronic ST-6D device (ZAMED©). The electric pads were placed on the lumbar area, in the middle part of spine. The anode in the lower part, near to buttocks. The intensity of current was regulated between 15-25 mA. The time of procedure lasted fifteen minutes.
16429884|NCT03772080|Experimental|Early counseling of prematurity in high-risk pregnancies|
16429885|NCT03772080|No Intervention|Standard counseling of prematurity in high-risk pregnancies|
16429886|NCT03772067|Experimental|MBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will contain 38 g protein mostly from milk and dairy products.
16429887|NCT03772067|Active Comparator|OBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will 38 g protein without milk or dairy products mostly from other proteins, i.e. eggs, tuna, soy, oatmeal. Milk product will be avoided in this diet also in other meals along the day.
16429888|NCT03772054|Active Comparator|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
16429889|NCT03772054|Experimental|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
16429890|NCT03772041|Experimental|OPC-61815 injection 16 mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
16429891|NCT03772041|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
16429892|NCT03772028|No Intervention|conventional surgery|Primary cytoreductive surgery without HIPEC
16429893|NCT03772028|Experimental|HIPEC|Primary cytoreductive surgery with HIPEC with cisplatin
16429894|NCT03772015||Study|"Patients who had the operation of laparoscopic lateral mesh suspension for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month"
16429895|NCT03772015||Control|Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
16429896|NCT03772002|Experimental|HCV screening|
16429897|NCT03771989|Active Comparator|Intervention|Patients are treated with an intra articular injection with autologous, micro-fragmented adipose tissue.
16429898|NCT03771989|Placebo Comparator|Control|Patients are treated with an intra articular injection with saline (placebo).
16429899|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
16429900|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
16429901|NCT03771963|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously (SC), once on Day 1 (first dose) and Day 90 (second dose).
16429902|NCT03771950|Experimental|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
16429903|NCT03771950|No Intervention|Control group|Treatment as usual.
16429904|NCT03771937|Experimental|Intervention|Intervention group received a telephone follow-up intervention, which consisted of a pre-discharge education program and three telephone follow-up sessions based on the RAM.
16429905|NCT03771937|No Intervention|Control group|the control group received routine care.
16429906|NCT03771924|Experimental|inorganic phosphate|"Experimental intervention:
~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
16429907|NCT03771924|Placebo Comparator|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
16429908|NCT03771911|Other|AED guided|"Laypeople will be guided by an Automatic External Defibrillator's (AED) voice instructions during the cardiopulmonary resuscitation.
~No other help is available."
16429909|NCT03771911|Other|Telephone guided|"Laypeople will be guided by telephone assistance (from an Emergency Call Center) during the cardiopulmonary resuscitation.
~AED voice instructions are also available."
16429910|NCT03771898|Experimental|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 210 weeks.
16429911|NCT03771885|Experimental|Group A|4 weeks place followed by 4 weeks IMP
16429912|NCT03771885|Experimental|Group B|4 weeks IMP followed by 4 weeks placebo
16429913|NCT03771872|Experimental|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
16429914|NCT03771872|Sham Comparator|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
16429915|NCT03771859||Participants who initiate adjuvant treatment with nivolumab|
16429916|NCT03771846|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
16429917|NCT03771846|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
16429918|NCT03771833|Other|Main MARIA scan visit|For Arm 1, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 1 participants will receive study information that they will be sent home with and informed that they will be approached via a telephone call in 2-3 days (or the closest working day to that date) to enquire if they would like to schedule an appointment for the study visit. If so, this will be scheduled to occur around 7 days from the date of the phone call.
16429919|NCT03771833|Other|Same-day MARIA scan visit|"For Arm 2, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 2 participants will receive study information and as much time as possible to consider their involvement with the study (at least 1 hour). If the patient agrees to participate, they will be scheduled to have their MARIA scans at a time that suits their commitments that day.
~This arm also includes the 2b group, who can optionally consent to a dielectric constant reading of their routinely-aspirated cyst fluid before this is disposed of as per usual site process."
16429920|NCT03771820|Experimental|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
16429921|NCT03771820|Active Comparator|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
16429922|NCT03771807|Placebo Comparator|Placebo & facial cleansing|"Maltodextrin and food coloring
~Subjects will clean the right side of their face with a cosmetic instrument daily"
16429923|NCT03771807|Active Comparator|Beauty From Within & facial cleansing|"Study Product contains collagen hydrolysate, ceramide wheat extract oil and lutein
~Subjects will clean the right side of their face with a cosmetic instrument daily"
16429924|NCT03771794|Active Comparator|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
16429925|NCT03771794|Sham Comparator|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
16429926|NCT03771781|Other|Empagliflozin Tablets|The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
16429927|NCT03771781|Other|Empagliflozin Tab 25 MG|The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
16429928|NCT03771768|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
16429929|NCT03771768|Experimental|Diode laser|Diode laser 980 nm & 100mWatt.
16429930|NCT03771755|Active Comparator|Ibuprofen group|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
16429931|NCT03771755|Placebo Comparator|Acetaminophen group|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
16429932|NCT03771742|Active Comparator|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
16429933|NCT03771742|Experimental|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
16429934|NCT03771729|Experimental|LCZ696 treatment|LCZ696 200mg twice daily
16429935|NCT03771716|Experimental|African Dance|This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
16429936|NCT03771716|Active Comparator|African Cultural Immersion|This is the active control group. Participants will participate in a variety of educational activities related to African Culture, including traditional cooking, lectures, crafts, music and films. They will meet 3 times per week for the same duration as the Dance group. However, they will not participate in aerobic activity during the classes, and most activities will be conducted in a seated position.
16429937|NCT03771690|No Intervention|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
16429938|NCT03771690|No Intervention|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
16429939|NCT03771690|Experimental|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
16429940|NCT03771690|Experimental|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
16429941|NCT03771677|Active Comparator|Active Comparator:NAs group|"Active Comparator:nucleotide analogues(NAs)
~patients continue to use NAs"
16429942|NCT03771677|Experimental|Experimental:PEG-IFN group|"Experimental: peg-interferon alfa-2a
~patients switch to sequential peg-interferon α-2a"
16429945|NCT03771651|Experimental|Aspirin|Subjects will take 81mg tablets of aspirin daily for 14 days prior to surgery for removal of fallopian tubes.
16429946|NCT03771638|Experimental|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
16429947|NCT03771638|Other|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
16429948|NCT03771625||single-group studies|All the patients received chemotherapy and radiotherapy.
16429949|NCT03771612|Active Comparator|Naproxen|
16429950|NCT03771612|Placebo Comparator|Placebo|
16429951|NCT03771599|Active Comparator|Control group|"Routine physical therapy
~[Time Frame: Twelve weeks]"
16429952|NCT03771599|Experimental|Intervention group|"Traditional massage + Routine physical therapy
~[Time Frame: Twelve weeks]"
16429953|NCT03771586|Experimental|SAGE-718|
16429954|NCT03771586|Placebo Comparator|Placebo|
16429955|NCT03771573|Experimental|Home based intervention|will be submitted to a total of 24 sessions of an unsupervised Cardiovascular Physical Therapy protocol, composed of the following steps: warm up, proper training (aerobic training + muscle training for upper and lower limbs with theraband in 5 series with 10 repetitions) often three times a week for eight weeks.
16429958|NCT03771560|Experimental|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
16429959|NCT03771547||More 80|The first group included ERCP patients aged 80 and above.
16429960|NCT03771547||Less 80|The second group included those ERCP patients younger than 80.
16429961|NCT03771534|Experimental|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
16429962|NCT03771508||PillCam SB3 procedure|Subjects with normal/abnormal PillCam SB3 procedure
16429963|NCT03771495|Experimental|Hip Joint Mobilization|passive accessory movement on femur in anterior/posterior direction, grade III for four minutes and passive physiological movement of the most restricted hip joint movement, grade III for one minute (without pain), and a verbal education of hypothesized underlying effect mechanisms.
16429964|NCT03771495|Sham Comparator|Laying on of Hands|grade I, very small amplitude without encountering any tissue resistance for five minutes, thus effectively a Laying on of Hands, with a verbal education of hypothesized underlying effect mechanisms.
16429965|NCT03771482|Active Comparator|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
16429966|NCT03771482|Active Comparator|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
16429967|NCT03771469|Experimental|Questionnaires and sleep studies|Caregivers of patients meeting eligibility criteria will be invited to participate. If they agree to participate, baseline SRBD-PSQ, OSA-18, and PedsQL questionnaires along with written informed consent forms will be mailed to them along with their standard scheduling paperwork. Caregivers will be asked to review the consent form and complete the questionnaires and bring the paperwork to clinic on the day of their visit. Sleep study testing will also be ordered prior to their visit so that it can be scheduled within a month of the initial clinic visit and again three months later.
16429968|NCT03771443|Experimental|gluten free toothpaste|experimental gluten free toothpaste with natural ingredients prepared for the study to be used 3 times per day for six months
16429969|NCT03771430|Experimental|Non-surgical group|Osteoarthritis education, exercise and eCBT
16429970|NCT03771430|Experimental|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
16429971|NCT03771430|Active Comparator|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
16429972|NCT03771417|Experimental|Resistance Exercise|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week.
16429973|NCT03771417|Experimental|RE plus Low Intensity Physical Activity|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week and regular unsupervised low intensity physical activity breaks in sedentary time 5 days per week [6x10 min breaks/d at 2 metabolic equivalents (METS) or ~30-40% peak oxygen consumption (VO2 peak), ~500 kcal/wk above resting metabolism].
16429974|NCT03771417|Active Comparator|RE plus Moderate IntensityExercise|Exercise Intervention: Participants will be asked to complete supervised RE 2 days per week and supervised calorically matched moderate intensity physical activity 3 days per week (50 min/session at 4 METS (~60-75% VO2 peak), ~500 kcal/week above resting metabolism).
16429975|NCT03771404|Other|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
16429976|NCT03771391|Experimental|4 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 4 weeks.
16429977|NCT03771391|Experimental|8 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 8 weeks.
16429978|NCT03771391|Experimental|12 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 12 weeks.
16429979|NCT03771378|Experimental|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
16429980|NCT03771378|Active Comparator|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
16429981|NCT03771365||Standard-PCNL|Perform PCNL with ≥24 Fr access tract for the treatment of ≥2 renal stones
16429982|NCT03771365||Mini-PCNL|Perform PCNL with 12-20 Fr access tract for the treatment of ≥2 renal stones
16429983|NCT03771365||Super-mini PCNL|Perform SMP for the treatment of ≥2 renal stones
16429984|NCT03771352|Other|RxSight RxLAL IOL|Eligible patients will be implanted with the RxSight RxLAL intraocular lens (IOL)
16429985|NCT03771339|Active Comparator|Continuous Epidural Analgesia|Continuous epidural analgesia using ropivacaine 0.375% 3 mL boluses followed by ropivacaine 0.2% with rate 6 mL per hour for 24 hours
16429986|NCT03771339|Experimental|Bilateral Quadratus Lumborum Block|Bilateral Quadratus lumborum block using ropivacaine 0.2% 20 mL each injection after surgery
16429987|NCT03771326|Experimental|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
16430020|NCT03771092|Experimental|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
16429988|NCT03771326|Experimental|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
16429989|NCT03771313|Other|PK/PD|Open-label prospective study with participants receiving treating physician-approved intravenous ceftaroline, dosed according to current recommendations. Blood samples collected at baseline, 1 hour, 1.5 hours, 3 hours, and 6 hours after infusion.
16429990|NCT03771300|Experimental|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
16429991|NCT03771300|Experimental|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
16429992|NCT03771300|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
16429993|NCT03771287|Experimental|OpenSound Navigator (OSN) Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
16429994|NCT03771287|Active Comparator|omni-directional Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the Omni-directional microphone system enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
16429995|NCT03771274|Experimental|Tecnis ZLB00 & Symfony IOL|The Tecnis multifocal ZLB00 and the Symfony IOLs are presbyopia correcting lenses designed to improve the vision at distance, intermediate and near reducing the need for glasses in patients undergoing cataract surgery.
16429996|NCT03771261|Placebo Comparator|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d.
16429997|NCT03771261|Active Comparator|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of > 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
16429998|NCT03771248|Active Comparator|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
16429999|NCT03771248|Experimental|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
16430000|NCT03771235|Experimental|Mindfulness-based Intervention for Tics|8-week group-based mindfulness-based program
16430001|NCT03771235|Active Comparator|Tic Information and Coping Strategies|8-week group-based educational and supportive therapy program
16430002|NCT03771222|Experimental|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 ~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 ~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
16430003|NCT03771222|No Intervention|No prophylactic DLI|
16430004|NCT03771209|Experimental|ultrasound assessment|The aim of this study is the creation of a five-step ultrasound examination to evaluate and monitor HF patients during hospitalization and short follow-up.
16430005|NCT03771196|Experimental|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
16430006|NCT03771196|Active Comparator|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
16430007|NCT03771170|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
16430008|NCT03771170|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
16430009|NCT03771157|Experimental|Shingrix shingles vaccine treatment|On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
16430010|NCT03771144|Experimental|Experimental|
16430011|NCT03771131|Experimental|Experimental group|Group receiving the multi-domain cognitive training
16430012|NCT03771131|No Intervention|Control group|Passive control group
16430013|NCT03771105|Experimental|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
16430014|NCT03771105|Active Comparator|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
16430015|NCT03771105|Active Comparator|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
16430016|NCT03771105|Active Comparator|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
16430017|NCT03771092|Experimental|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
16430018|NCT03771092|Experimental|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
16430019|NCT03771092|Experimental|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
16494651|NCT03329430|Experimental|Foot orthoses|Customize foot orthoses
16430021|NCT03771092|Experimental|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
16430022|NCT03771066|Experimental|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
16430023|NCT03771066|Placebo Comparator|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
16430024|NCT03771053|Experimental|Ezetimibe with simvastatin group|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
16430025|NCT03771053|Active Comparator|Simvastatin group|simvastatin 40mg everyday for 12 months after PCI
16430026|NCT03771040|Experimental|Masitinib (titration to 6.0 mg/kg/day)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
16430027|NCT03771040|Placebo Comparator|Placebo|Participants receive matched placebo
16430028|NCT03771027|Experimental|Low FODMAP diet group|four weeks of the low FODMAP diet based on Monash University low FODMAP diet App.
16430029|NCT03771027|Active Comparator|Control group|four weeks of the diet based on NICE guidelines and contained products with different FODMAP content
16430030|NCT03771014|Experimental|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
16430031|NCT03771014|No Intervention|Standard care|Patients will receive standard physiotherapy regimen
16430032|NCT03771001|Other|Convenience sample participants|In this feasibility study all participants will receive the intervention.
16430033|NCT03770988|Experimental|poziotinib single arm study|Single Arm study
16430034|NCT03770975|Active Comparator|Delayed implant placement with immediate provisionalization|Single delayed implant placement in the esthetic zone with placing an immediate temporary crown placed within 48 hours after the surgery
16430035|NCT03770975|Experimental|Implant with immediate temporization and soft tissue graft|Single delayed implant placement in the esthetic zone with placing a subepithelial connective tissue graft buccal to the implant and immediate temporary crown within 48 hours after the surgery
16430036|NCT03770962|Experimental|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
16430037|NCT03770962|No Intervention|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
16430038|NCT03770936|No Intervention|Control group|No intervention
16430039|NCT03770936|Active Comparator|Candesartan|Candesartan 8 mg/day
16430040|NCT03770936|Active Comparator|Ramipril|Ramipril 1.25 mg/day
16430041|NCT03770923|No Intervention|No intervention|No intervention
16430042|NCT03770923|Active Comparator|Rupatadine|Rupatadine 10 mg once daily.
16430043|NCT03770923|Active Comparator|Montelukast|Montelukast 10 mg daily
16430044|NCT03770910|Placebo Comparator|Placebo+placebo|Saline infusions
16430045|NCT03770910|Active Comparator|GIP+placebo|GIP(1-42), receptor agonist
16430046|NCT03770910|Experimental|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
16430047|NCT03770910|Experimental|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
16430048|NCT03770910|Experimental|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
16430049|NCT03770910|Experimental|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
16430050|NCT03770897|Experimental|3D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed with 3d technology device by young surgeons, tutored by an expert assistant.
16430051|NCT03770897|Active Comparator|2D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed by young surgeons (tutored by an expert assistant) with the standard 2D viewing method.
16430052|NCT03770884||Rheumatoid arthritis|EULAR-ACR criteria Whatever the treatment and the disease activity
16430053|NCT03770884||Axial spondyloarthritis|ASAS criteria for axial disease Whatever the treatment and the disease activity
16430054|NCT03770884||digital osteoarthritis|According to ACR criteria Whatever the treatment and the disease activity
16430055|NCT03770871|Active Comparator|IPT using Dycal (TM )|Indirect pulp treatment; IPT using Dycal (TM ); (2 paste system) by partial caries removal
16430056|NCT03770871|Experimental|IPT using Vitrebond (TM )|Indirect pulp treatment; IPT using Vitrebond (TM );(powder and liquid) by partial caries removal
16430057|NCT03770858||Crisaborole and wearable sensor|Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
16430058|NCT03770832||Infants at Risk for Atypical Motor Development (high-risk)|
16430059|NCT03770832||Infants Expected to Have Typical Motor Development (low-risk)|
16430060|NCT03770819|Placebo Comparator|Placebo group|Application of placebo gel followed by sham Photodynamic therapy
16430061|NCT03770819|Active Comparator|Zinc oxide gel group|Application of Zinc oxide gel followed by sham Photodynamic therapy.
16430062|NCT03770819|Experimental|PDT group|Application of placebo gel followed by Photodynamic therapy.
16430063|NCT03770819|Experimental|Zinc oxide and PDT group|Application of Zinc oxide gel followed by Photodynamic therapy.
16430064|NCT03770806|Experimental|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
16430065|NCT03770806|Experimental|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
16430066|NCT03770806|Experimental|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
16430101|NCT03770611|Active Comparator|Probiotic|Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
16494996|NCT03327116|Experimental|Methotrexate|
16430067|NCT03770793|Experimental|Lung-sono guided|Before starting one-lung ventilation, alveolar recruitment is performed under the examination with ultrasound. Find the minimal airway pressure that actually starts to resolve the observed atelectasis. Repeat alveolar recruitment with the minimal pressure untill the atlelectasis is not visible.
16430068|NCT03770793|No Intervention|Conventional|Before starting one-lung ventilation, alveolar recruitment is performed with the pressure of 30mmHg for 10 seconds which is a conventional method.
16430069|NCT03770780|Experimental|SAGE-718|
16430070|NCT03770780|Placebo Comparator|Placebo|
16430071|NCT03770767|Experimental|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
16430072|NCT03770767|Active Comparator|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
16430073|NCT03770754|Experimental|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
16430074|NCT03770754|Experimental|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
16430075|NCT03770754|Experimental|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
16430076|NCT03770741|Experimental|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
16430077|NCT03770741|Other|Treatment as usual|Treatment according local guidelines and practices.
16430078|NCT03770728|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (prefilled syringe) administered once weekly for 30 weeks
16430079|NCT03770728|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (prefilled syringe) administered once weekly for 30 weeks
16430080|NCT03770728|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (prefilled syringe) administered once weekly for 30 weeks
16430081|NCT03770728|Placebo Comparator|Placebo|Matching placebo (prefilled syringe) administered once weekly for 30 weeks
16430082|NCT03770702|No Intervention|Control group|No intervention
16430083|NCT03770702|Active Comparator|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
16430084|NCT03770702|Active Comparator|Statins|Statin + Traditional therapy.
16430085|NCT03770689|Experimental|Peposertib + Capecitabine + RT|
16430086|NCT03770676|Experimental|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
16430087|NCT03770676|Experimental|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
16430088|NCT03770676|Experimental|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
16430089|NCT03770663|Experimental|European strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12
~In association with:
~6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day"
16430090|NCT03770663|Experimental|American strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12
~In association with:
~Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL."
16430091|NCT03770650|Experimental|IVUS-guided DK crush stenting|"In the IVUS-guided DK crush stenting group, IVUS will be before side branch stenting, after rewiring side branch, after 1st kissing balloon inflation, after rewiring side branch, after 2nd kissing balloon inflation.
~For LM bifurcation lesions involving ostial LAD and LCX: minimum stent are (MSA) should be ≥10mm2 (LM), 7 mm2 (LAD), and 6 mm2 (LCX), with stent expansion index ≥90% (CSA≥90% of distal reference lumen area in LCX) and symmetry index >0.8.
~For non-LM bifurcation lesion involving the MSA should be ≥6 mm2 in the main vessel; and the MSA in the ostial side branch should be ≥5 mm2 and ≥90% of distal reference lumen area; and symmetry index should be >0.8."
16430092|NCT03770650|Active Comparator|Angiography-guided DK crush stenting|In the Angiography-guided DK crush stenting group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of ≥Type B dissection.
16430093|NCT03770637|Experimental|Glucagon RTU (glucagon injection)|Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
16430094|NCT03770637|Placebo Comparator|Placebo|Non-active vehicle for Glucagon RTU; 60 μL injection
16430095|NCT03770624|Experimental|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
16430096|NCT03770624|Experimental|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
16430097|NCT03770624|Experimental|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
16430098|NCT03770624|Experimental|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
16430099|NCT03770624|Experimental|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
16430100|NCT03770624|Active Comparator|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
16430103|NCT03770611|Experimental|Symbiotic|Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
16430104|NCT03770611|Placebo Comparator|Placebo|Subjects receiving placebo of probiotic and prebiotic per day during 3 months
16430105|NCT03770598|Active Comparator|Distressed|Study participants who do indicate distress or who do meet criteria for depression or anxiety will be randomized to receive either treatment as usual (referral to Psychiatry or Psychology for evaluation and further treatment) or team based care model.
16430106|NCT03770598|Active Comparator|Non-Distressed|Study participants who do not indicate distress or who do not meet criteria for depression or anxiety will be randomize to monitoring only or to receive psycho-education regarding subjects that when used can promote wellness.
16430107|NCT03770585|Active Comparator|Group 1(Fluoroscopy guided group)|IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
16430108|NCT03770585|Active Comparator|Group2 (Ultrasound guided group)|In Ultrasound guided group, with Ultrasound guidance, , a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml(20mg) methylprednisolone acetate is administered intra-articular (until resistance was encountered) and injected around the posterior facet joint capsule.
16430109|NCT03770572|Experimental|Open-label, single-dose, dose-escalation study of AT-GTX-502|"Cohort 1: AT-GTX-502 Low-Dose
~Cohort 2: AT-GTX-502 High-Dose"
16430110|NCT03770559|Active Comparator|Open-RAMPS|Patients with pancreatic cancer treated by traditional open surgery
16430111|NCT03770559|Experimental|MI-RAMPS|Patients with pancreatic cancer treated by laparoscopic surgery
16430112|NCT03770546|Experimental|Osteoarthritis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
16430113|NCT03770546|Active Comparator|Osteoarthritis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
16430114|NCT03770546|Experimental|Adhesive Capsulitis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
16430115|NCT03770546|Active Comparator|Adhesive Capsulitis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
16430116|NCT03770533|Other|MR-proADM guided|
16430117|NCT03770533|No Intervention|Standard Care|
16430118|NCT03770520|Experimental|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
16430119|NCT03770520|Active Comparator|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
16430120|NCT03770507|Experimental|Treadmill Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
16430121|NCT03770507|Experimental|Cyclo Ergometer Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
16430122|NCT03770494|Experimental|LY3405105|LY3405105 administered orally.
16430123|NCT03770481|Experimental|Assess the NLCS' feasibility|"Hypothesis: No significant differences will be observed in recruitment and attrition between NLCS intervention and control groups.
~Approach: Determine rates of enrollment and drop-outs between groups."
16430124|NCT03770481|Experimental|Assess the NLCS' acceptability|"Hypothesis: More surrogates agree that the NLCS is suitable, appropriate, effective and willing to adhere versus treatment as usual (TAU) communication.
~Approach: Assess outcome using the validated instrument, Client Satisfaction Questionnaire (CSQ-8)."
16430125|NCT03770481|Experimental|Assess the NLCS' preliminary effects|Hypothesis: NLCS improves communication and decreases surrogates' psychological distress (e.g., anxiety and depression) Approach: Compare pre- and post-intervention scores of the Quality of Communication (QOC) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Decisional Conflict Scale (DCS) between intervention and control groups.
16430126|NCT03770455|Experimental|Avelumab + 2nd generation ADT|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
16430127|NCT03770442|Experimental|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.
~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.
~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
16430128|NCT03770442|Active Comparator|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
16430129|NCT03770429|Experimental|AZD6738|Patients will receive AZD6738 orally on a 28-day cycle
16430130|NCT03770416|Experimental|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
16430131|NCT03770416|Experimental|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
16430132|NCT03770403|Experimental|ARGX-113|
16430133|NCT03770390|Other|The study population|"Patients included in this study have pectus excavatum. The have either already undergone corrective surgery during the four years prior to the inclusion period, or are scheduled for surgery during the inclusion period.
~Intervention: Surgical correction of pectus excavatum"
16430369|NCT03768713|Experimental|Drug (Suvorexant)|20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)
16430134|NCT03770377|Experimental|Stroke without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
16430135|NCT03770377|Experimental|Stroke with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
16430136|NCT03770377|Experimental|SCA6 without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
16430137|NCT03770377|Experimental|SCA6 with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
16430138|NCT03770377|Active Comparator|Age-Matched Controls|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
16430139|NCT03770338|No Intervention|Control|Recruitment for fusion surgery as usual
16430140|NCT03770338|Experimental|Teriparatide|Preoperative 1 month use of teriparatide, before lumbar fusion surgery
16430141|NCT03770325|Experimental|Berberine|berberine (500 mg orally twice a day)
16430142|NCT03770325|Placebo Comparator|Placebo|placebo (500 mg orally twice a day)
16430143|NCT03770312|Active Comparator|Low intensity statin group|Taking low intensity statin
16430144|NCT03770312|Active Comparator|Moderate intensity statin group|Taking moderate intensity statin
16430145|NCT03770299|Experimental|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
16430146|NCT03770299|Active Comparator|Arm B|SOC (chemotherapy in eligible participants or observation)
16430147|NCT03770286|Active Comparator|Fluoride Varnish alone|5% sodium fluoride varnish will be applied to all teeth the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
16430148|NCT03770286|Experimental|SDF with Super Floss|SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
16430149|NCT03770286|Experimental|SDF without Super Floss|SDF will be applied to around the (buccal, lingual, and occlusal) embrasures of the target interproximal lesions with the use of a microbrush for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
16430150|NCT03770273|Active Comparator|placebo|8 SC injections of placebo
16430151|NCT03770273|Active Comparator|sarilumab|8 (SC) injections of 200 mg/1.14 mL of sarilumab over 16 weeks
16430152|NCT03770260|Experimental|Treatment (ixazomib citrate, pevonedistat)|Patients receive ixazomib citrate PO QD on days 1, 8, and 15, and pevonedistat IV over 60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16430153|NCT03770247|Experimental|intraoperative group (IOCPN group)|Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.
16430154|NCT03770247|Active Comparator|CT group (CTCPN group)|CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection
16430155|NCT03770234|Experimental|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
16430156|NCT03770234|Experimental|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
16430157|NCT03770221|Experimental|Financial Incentive|"Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
~Additionally, participants in this arm will receive $20 for every week they maintain contact with CATCH service providers, as required by their care plan. Contact can be by phone, text, email, or in person with CATCH service providers over 6 months of follow up, or until they are successfully transitioned to longer-term supports (for up to $80/month per participant)."
16430158|NCT03770221|Active Comparator|Usual Care|Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
16430159|NCT03770208|Placebo Comparator|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
16430224|NCT03769766|Active Comparator|Curcumin|"Other names for the supplement: BCM-95 CG (Biocurcumax),Tumeric
~Manufacture- DolCas Biotech, LLC.
~Classification - type of agent: Supplement
~Protocol dose: 500 mg twice"
16430160|NCT03770208|Experimental|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
16430161|NCT03770195||Abdominoplasty Patients|Patients undergoing full abdominoplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
16430162|NCT03770182|Experimental|Group A|"NEUROLITH
~Cycle 1: Active treatment
~Cycle 2: Sham treatment"
16430163|NCT03770182|Experimental|Group B|"NEUROLITH
~Cycle 1: Sham treatment
~Cycle 2: Active treatment"
16430164|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
16430165|NCT03770143||Group 1|Infants feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life
16430166|NCT03770143||Group 2|Infants feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life
16430167|NCT03770143||Group 3|Having similar demographical properties with infants feeding with breast milk (gender, age, weight, height)
16430168|NCT03770130|Experimental|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
16430169|NCT03770130|Placebo Comparator|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
16430170|NCT03770117||Prehabilitation|"In this arm of the study, participants will undergo prehabilitation prior to surgery. This is intended to increase the participants overall health prior to surgery to try and increase their general well-being during and after surgery.
~Prehabilitation is multimodal therapy comprising:
~Assessment for malnutrition and nutritional support dependent on the outcome
~Optimisation of management of pancreatic exocrine insufficiency
~Assessment of muscle mass and strength
~Individually tailored, goal directed exercise regimen under the care of physiotherapy"
16430171|NCT03770117||Standard Procedure|In this arm, participants will not receive any Rehabilitation prior to the surgery. This is the current standard care and will act as the control data for this study.
16430172|NCT03770104|Experimental|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
16430173|NCT03770104|Experimental|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
16430174|NCT03770091|Experimental|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
16430175|NCT03770091|Placebo Comparator|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
16430176|NCT03770091|Experimental|Foam alone|Patients will use Theraworx foam without compression wrap
16430177|NCT03770078|Experimental|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
16430178|NCT03770065||Group A|
16430179|NCT03770065||Group B|
16430180|NCT03770052|Experimental|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
16430181|NCT03770052|Active Comparator|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
16430182|NCT03770039|Experimental|2-period, fixed sequence|fixed sequence with 2 treatment period
16430183|NCT03770026|Active Comparator|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
16430184|NCT03770026|Experimental|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
16430185|NCT03770013|Active Comparator|bupivacaine 0.25% and Dexmedetomidine|bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)
16430186|NCT03770013|Active Comparator|bupivacaine and clonidine|20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP
16430187|NCT03770013|Placebo Comparator|bupivacaine and placebo|bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP
16430188|NCT03770000|Experimental|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
16430225|NCT03769766|Placebo Comparator|Placebo|"Drug: placebo
~placebo orally twice a day Other Names: •sugar pill"
16430370|NCT03768713|Placebo Comparator|Placebo|20 mg of Placebo daily (taken orally ~1 hour before bedtime)
16495713|NCT03321968|Experimental|Lot 3|Quadrivalent VLP Influenza Vaccine
16430189|NCT03769974|Experimental|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
16430190|NCT03769974|Experimental|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
16430191|NCT03769974|Placebo Comparator|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
16430192|NCT03769961||ET (DBS-, Ataxia+)|Essential Tremor without DBS with Ataxia on examination
16430193|NCT03769961||ET (DBS-, Ataxia-)|Essential Tremor without DBS and without Ataxia on examination
16430194|NCT03769961||ET (DBS+, Ataxia+)|Essential Tremor with DBS with Ataxia on examination
16430195|NCT03769961||ET (DBS+, Ataxia-)|Essential Tremor with DBS without Ataxia
16430196|NCT03769935|Experimental|experimental arm|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
~S1 25 mg/m2 oral, everyday until progression disease"
16430197|NCT03769935|Active Comparator|active comparator|cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
16430198|NCT03769922|Experimental|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
16430199|NCT03769922|Active Comparator|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
16430200|NCT03769896|Active Comparator|Treatment Group|Nabilone 0.25 mg
16430201|NCT03769896|Placebo Comparator|Placebo Group|Placebo (corn starch)
16430202|NCT03769883|Experimental|Dietary control (DCON)|The macro-nutrient distributions are in line with the current guidelines from the national Diabetes Association and Canadian guidelines, where individualization in macronutrient distribution should lie within the range of 45-60E% carbohydrate, 15-20E% protein and 20-35E% fat. The dietary plan will aim at reducing saturated fat intake <7E% aiming at a caloric deficit of 500 kilo calories/day
16430203|NCT03769883|Experimental|Moderate Exercise Dose (MED)|Two aerobic training sessions per week of 45-60 min duration and one session per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
16430204|NCT03769883|Experimental|High Exercise Dose (HED)|Four aerobic training sessions per week of 45-60 min duration and two sessions per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
16430205|NCT03769883|No Intervention|Control|No intervention
16430206|NCT03769870|Other|Teneligliptin|
16430207|NCT03769870|Other|Atorvastatin|
16430208|NCT03769870|Other|Teneligliptin + Atorvastatin|
16430209|NCT03769857|Experimental|NEM® + BIOCURC®|"NEM® + BIOCURC®
~NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks"
16430210|NCT03769857|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
16430211|NCT03769844|Experimental|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
16430212|NCT03769844|Experimental|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
16430213|NCT03769844|Experimental|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
16430214|NCT03769844|Experimental|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
16430215|NCT03769831|Experimental|SHR2285|Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
16430216|NCT03769831|Experimental|Placebo|Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.
16430217|NCT03769818|Active Comparator|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
16430218|NCT03769818|Active Comparator|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
16430219|NCT03769818|Placebo Comparator|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
16430220|NCT03769805|Experimental|Anlotinib Arm|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
16430221|NCT03769792|Experimental|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.
~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.
~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.
~The planned interventions are:
~Blood and faeces tests
~Impedance spectroscopy test
~Full gynecological and proctological examination
~Transanal ultrasonography
~Anorectal manometry"
16430222|NCT03769779|Experimental|Treatment|Lutein (FloraGLO™) in safflower oil
16430223|NCT03769779|Placebo Comparator|Placebo|safflower oil
16430335|NCT03768973||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
16430226|NCT03769753|Experimental|intraoperative use of IRE|Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
16430227|NCT03769740||CPR Group|
16430228|NCT03769714|Active Comparator|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
16430229|NCT03769714|Experimental|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
16430230|NCT03769701|Active Comparator|Group 1, SMGC four times/day|Women with GDM and SMGC 4 times/day; fasting and 1-hour post-prandial of breakfast, lunch and dinner
16430231|NCT03769701|Experimental|SMGC two times/day|Women with GDM and SMGC 2 times/day; pre-prandial and 1-hour post-prandial of breakfast, lunch or dinner alternating the meal each day.
16430232|NCT03769688|Experimental|Cervicovaginal secretions|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of cervicovaginal secretions (10 mg in 1 ml total volume, 0.9 ml normal saline).
16430233|NCT03769688|Placebo Comparator|Saline placebo|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of sterile saline placebo (1 ml total volume).
16430234|NCT03769675|Experimental|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
16430235|NCT03769662|Experimental|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
16430236|NCT03769649|Experimental|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
16430237|NCT03769623|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter
16430238|NCT03769623|Active Comparator|Powerline|Balloon dilated catheter
16430239|NCT03769610|Active Comparator|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
16430240|NCT03769610|Experimental|Outpatient Foley catheter|Subjects are asked to return to the hospital ~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
16430241|NCT03769597|Experimental|Iohexol administration|After injecting a loading dose of 5ml of Iohexol Inj 300 MG/ML bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
16430242|NCT03769571|Other|parental coaching program at ESDM (P-ESDM)|
16430243|NCT03769571|No Intervention|CONTROL|
16430244|NCT03769558||JIA patients prescribed abatacept|
16430245|NCT03769532|Experimental|Pembrolizumab + Azacitidine|"Pembrolizumab (IMP): 200 mg i.v. (fixed dose) / Azacitidine (SOC): 75 mg/m2 s.c.
~maximum duration of treatment: up to 24 weeks"
16430246|NCT03769519|No Intervention|Control (Group 1)|This group is considered the control group. This group will have scheduled texts and emails for the monthly surveys after the participant completes the baseline questionnaires.
16430247|NCT03769519|Experimental|ARICA Intervention (Group 2)|This group is considered the intervention group. Participants in this group will receive weekly texts and emails containing asthma facts and myths. They will also complete monthly surveys and participate in asthma education sessions.
16430248|NCT03769506|Active Comparator|ASP-1929 Photoimmunotherapy|Use of ASP1929 PIT therapy
16430249|NCT03769506|Active Comparator|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
16430250|NCT03769493|Experimental|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
16430251|NCT03769480||Study Group|Study Group=Athletes with Disability
16430252|NCT03769480||Control Group|Control Group=Healthy Athletes
16430253|NCT03769467|Experimental|tabelecleucel in combination with pembrolizumab|Tabelecleucel will be administered initially to 12 subjects at a dose of 2 x 10^6 cells/kg intravenously (IV) on Day 1, Day 8, and 15 of a 21-day cycle. For Cohort 1, if there is a dose-limiting toxicity, the dose of tabelecleucel will be reduced to 1 x 10^6 cells/kg. Pembrolizumab will be administered to adult subjects at 200 mg or to pediatric subjects (12 to < 18 years of age) at 2 mg/kg IV every 3 weeks.
16430254|NCT03769454|Experimental|PP-001 low dose group|
16430255|NCT03769454|Placebo Comparator|Placebo low dose group|
16430256|NCT03769454|Experimental|PP-001 mid dose group|
16430257|NCT03769454|Placebo Comparator|Placebo mid dose group|
16430258|NCT03769454|Experimental|PP-001 high dose group|
16430259|NCT03769454|Placebo Comparator|Placebo high dose group|
16430260|NCT03769441|Active Comparator|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
16430261|NCT03769441|Placebo Comparator|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
16430262|NCT03769428|Active Comparator|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)
~An intravenous patient controlled analgesia device will be given to the patients postoperatively"
16430263|NCT03769428|Placebo Comparator|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected
~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
16430264|NCT03769415|Experimental|Intrinsic subtyping of Primary Breast Cancer|Intrinsic subtype of primary breast tissue from metastatic breast cancer subject will be determined
16430265|NCT03769402|Active Comparator|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
16430266|NCT03769402|Placebo Comparator|Control|Control test
16430267|NCT03769389|Experimental|assessing the GI + GL of Birhi + YEO 0% fat yoghurt|47g of total carbohydrate in which contains 43.6g of Freeze-dried of Birhi powder+ 150g of 0% fat yoghurt
16430268|NCT03769389|Experimental|assessing the GI + GL of Khassab + YEO 0% fat yoghurt|47g of total carbohydrate in which contains34.6g of freeze-dried Khassab powder+ 150g of 0% fat yoghurt
16430269|NCT03769389|Experimental|assessing the GI + GL of 50g of Glucose in 100 ml of water|50g of pure glucose dissolved in 100ml of water
16430270|NCT03769376|Active Comparator|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
16430271|NCT03769376|Active Comparator|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
16430272|NCT03769350|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
16430273|NCT03769350|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
16430274|NCT03769337||Infected|Serum biomarkers in patients with diagnosis of prosthetic joint infection
16430275|NCT03769337||Not Infected|Serum biomarkers in patients with implant failure not caused by infection
16430276|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
16430277|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
16430278|NCT03769311|Experimental|Pre-Operative Cetuximab Therapy|Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
16430279|NCT03769298|Experimental|Envarsus XR|Envarsus XR (extended release) will be administered orally, once-daily, for 6 months.
16430280|NCT03769285|Experimental|Nicotinamide|
16430281|NCT03769285|Placebo Comparator|Placebo|
16430282|NCT03769272||Echocardiographic targeting|
16430283|NCT03769272||Electrogram targeting|
16430284|NCT03769259|Experimental|Brief Cognitive Behavioral Therapy|
16430285|NCT03769259|Active Comparator|Present-Centered Therapy|
16430286|NCT03769246|Experimental|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.
~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
16430287|NCT03769246|Active Comparator|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
16430288|NCT03769233|Experimental|Mindfulness-based Intervention|5 week, manual-based group MBI treatment for depressive and anxious symptoms
16430289|NCT03769220||inpatient rehabilitation ward|"The first 20 participants will be recruited from the inpatient rehabilitation ward at Robert-Bosch-Hospital (RBK). The treating medical doctor will inform potentially eligible participants about the possibility of being involved in this study. Should participants confirm their interest a research assistant will complete a detailed information session and obtain written informed consent prior enrolment.
~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
16430290|NCT03769220||outpatient rehabilitation clinic|"Further 20 participants will be recruited through the outpatient rehabilitation clinic at Robert-Bosch-Hospital (RBK). The treating doctor will again inform the potential participant about the study and invite them to participate. A research assistant will complete a detailed information session and written informed consent will be obtained prior enrolment.
~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
16430291|NCT03769220||community dwelling older adults|"Lastly 20 community dwelling older adults will be invited to participate. Recruitment will occur through advertisement at a locally run seniors fitness group, conducted every Thursday at RBK. Older adults who are interested in being involved will be invited to receive additional information about the study and the involved procedures before providing written informed consent and being enrolled.
~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
16430292|NCT03769207|Other|Ambulatory ECG|
16430293|NCT03769194|Active Comparator|VLA15 low dose|VLA15 low dose with Alum.
16430294|NCT03769194|Active Comparator|VLA15 medium dose|VLA15 medium dose with Alum.
16430295|NCT03769194|Active Comparator|VLA15 high dose|VLA15 high dose with Alum.
16430296|NCT03769194|Placebo Comparator|Placebo|
16430297|NCT03769181|Experimental|Phase 1: cHl/DLBCL/PTCL|Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose
16430298|NCT03769181|Experimental|Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
16430299|NCT03769181|Experimental|Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
16430300|NCT03769181|Experimental|Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
16430301|NCT03769181|Experimental|Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
16430302|NCT03769168|Experimental|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
16430303|NCT03769168|Experimental|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
16430304|NCT03769155|Experimental|A (VX15/2503, nivolumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and nivolumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
16430305|NCT03769155|Experimental|B (VX15/2503, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and ipilimumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
16430306|NCT03769155|Experimental|C (VX15/2503, nivolumab, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes, nivolumab IV over 30 minutes, and ipilimumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
16430307|NCT03769155|Experimental|D (nivolumab, surgery)|Participants receive nivolumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
16430308|NCT03769155|Active Comparator|E (surgery)|Participants undergo surgery.
16430309|NCT03769129|Experimental|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
16430310|NCT03769129|Other|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
16430311|NCT03769116|Experimental|SRP-9001 in Part 1 Followed by Placebo in Part 2|Patient will receive SRP-9001 at Part 1 followed by matching Placebo at Part 2 followed by an open-label extension at Part 3.
16430312|NCT03769116|Experimental|Placebo in Part 1 Followed by SRP-9001 in Part 2|Patient will receive matching Placebo at Part 1 followed by SRP-9001 at Part 2 followed by an open-label extension at Part 3.
16430313|NCT03769103|Active Comparator|SRS + Osimertinib|Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
16430314|NCT03769103|Experimental|Osimertinib alone|Osimertinib 80mg PO daily
16430315|NCT03769090|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
16430316|NCT03769090|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
16430317|NCT03769090|Active Comparator|AS MDI (PT007) 90 µg|
16430318|NCT03769077|Experimental|Exergaming (Case) Group|"Participants assigned to the exergame condition will play the exergames for 30 minutes, 5 days a week for 3 weeks (15 exergame sessions). Outcomes will be acquired at baseline (before intervention), and at the end of every week during the 3 week intervention phase. Participants will also receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital.
~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
16430319|NCT03769077|No Intervention|Comparison Group|"Participants will receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital and will complete questionnaires and assessments at the same time points during study participation.
~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
16430320|NCT03769064|Experimental|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
16430321|NCT03769064|Experimental|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
16430322|NCT03769064|Experimental|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
16430323|NCT03769064|Experimental|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
16430324|NCT03769064|Experimental|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
16430325|NCT03769064|Experimental|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
16430326|NCT03769038|Other|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
16430327|NCT03769025|Experimental|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
16430328|NCT03769025|Active Comparator|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
16430329|NCT03769012|Experimental|Treatment|Beta-Glucan
16430330|NCT03769012|Placebo Comparator|Placebo|Placebo
16430331|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
16430332|NCT03768986|Active Comparator|Treatment Group A|Standard referral for HIV testing and online HIV risk reduction training
16430333|NCT03768986|Experimental|Treatment Group B|Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
16430334|NCT03768973||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
16430336|NCT03768960|Experimental|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
16430337|NCT03768947|Experimental|Heat Therapy Arm|Participants in this open-label pilot study will undergo heat therapy via hot water immersion (hot-tub).
16430338|NCT03768934|No Intervention|Control|No airtime incentive for completing the survey
16430339|NCT03768934|Experimental|1X Incentive|1X airtime incentive
16430340|NCT03768934|Experimental|2X incentive|2X airtime incentive
16430341|NCT03768934|Experimental|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
16430342|NCT03768921|Experimental|PEEP Titriation|patients with respiratory distress syndrome will undergo alveolar recruitment in the mechanical ventilator and will have their final positive mechanical ventilator pressure determined by ventilator evaluation by the electrical impedance tomograph. The increase of the peep in the mechanical ventilator to perform the alveolar recruitment will be of 2 in 2 cmH2O every 2 minutes until the pressure reaches 25 cmH20, after the pressure was reduced in the same way being evaluated in the tomograph what will be the point with greater alveolar recruitment, having greater ventilation, without alveolar hyperdistension or alveolar collapse.
16430343|NCT03768908|Active Comparator|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
16430344|NCT03768908|Active Comparator|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose.
16430345|NCT03768895||MRI group|The criteria for patient inclusion were: Age > 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age < 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
16430346|NCT03768882|Experimental|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
16430347|NCT03768882|Experimental|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
16430348|NCT03768869|Experimental|Low Risk: Oupatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
16430349|NCT03768869|Active Comparator|Low Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
16430350|NCT03768869|Active Comparator|High Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
16430351|NCT03768856|Experimental|Temporally Feathered Radiation Therapy (TFRT)|"Temporally feathered radiation therapy is designed for targets within close proximity to multiple organs at risk. The foundation of this planning technique is the rotation of radiation dose to the nearby organs at risk on a daily basis, and hence the term feathering."
16430352|NCT03768843|Other|traumatic odontoid fracture|C1 C2 fusion screws
16430353|NCT03768830|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
16430354|NCT03768830|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
16430355|NCT03768830|Experimental|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
16430356|NCT03768830|No Intervention|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
16430357|NCT03768817||Patients treated with triheptanoin|Patients with LC-FAOD treated with triheptanoin before 01 September 2018 under eIND
16430358|NCT03768804|Other|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
16430359|NCT03768804|Other|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
16430360|NCT03768791|Experimental|SCS off|
16430361|NCT03768791|Experimental|SCS on|
16430362|NCT03768778|Other|Debridement|
16430363|NCT03768765||Long Term Medication Usage|Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
16430364|NCT03768765||Short Term Medication Usage|Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)
16430365|NCT03768752||Diastolic Dysfunction|Patients with pre-existing or new diastolic dysfunction.
16430366|NCT03768752||Normal Diastolic Function|Patients with normal diastolic function.
16430367|NCT03768739||CICU extubated patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
16430368|NCT03768726|Experimental|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
16430372|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration > 4 weeks and/or > five admissions last year.
~Assessment of diagnoses, functioning and health services"
16430373|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.
~Assessment of diagnoses, functioning and health services"
16430374|NCT03768661||SILC Group|patients with symptomatic cholelithiasis submitted to a single-incision laparoscopic cholecystectomy
16430375|NCT03768661||Laparoscopy Group|patients with symptomatic cholelithiasis submitted to a standard three trocar laparoscopic cholecystectomy
16430376|NCT03768648|Experimental|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
16430377|NCT03768648|Active Comparator|Control|40 Healthy controls (HC)
16430378|NCT03768635||Necrotizing external otitis|description of necrotizing external otitis
16430379|NCT03768622||surgery for femoral neck fracture|patients with proximal femoral fracture (type: femoral neck fracture) with surgical procedure: partial hip arthroplasty
16430380|NCT03768622||surgery for pertrochanteric femoral fractures|patients with proximal femoral fracture (type:pertrochanteric femoral fractures) with surgical procedure: intramedullary nail type Gamma® Nail or similar
16430381|NCT03768609|Experimental|Group 1: Sequence AB|Participants will receive Treatment A (pimodivir 600 milligram [mg] orally as two tablets of 300 mg each) on Day 1 in Period 1 followed by Treatment B (pimodivir 600 mg as two tablets of 300 mg each plus cyclosporine 400 mg orally as four capsules of 100 mg each) on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
16430382|NCT03768609|Experimental|Group 2: Sequence BA|Participants will receive Treatment B on Day 1 in Period 1 followed by Treatment A on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
16430383|NCT03768596|Experimental|Nudge|receiving nudge and form
16430384|NCT03768596|Active Comparator|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
16430385|NCT03768596|No Intervention|No intervention|receiving no nudge nor form
16430386|NCT03768583|Experimental|Group TSM ICT sneakers|"ICT with sneaker
~five weeks
~twice a week
~half hour."
16430387|NCT03768583|Experimental|Group TSM ICT barefoot|"ICT barefoot
~five weeks
~twice a week
~half hour."
16430388|NCT03768583|Experimental|Group TSM health barefoot|"Health with sneaker
~five weeks
~twice a week
~half hour."
16430389|NCT03768583|Experimental|Group TSM health sneakers|"Health barefoot
~five weeks
~twice a week
~half hour."
16430390|NCT03768570|No Intervention|Surveillance|
16430391|NCT03768570|Active Comparator|Durvalumab|
16430392|NCT03768557|Experimental|Minocycline|single dose of minocycline (200mg)
16430393|NCT03768557|Placebo Comparator|Placebo|lactose pills (400mg)
16430394|NCT03768544|Experimental|Self-help guided by a lay provider|
16430395|NCT03768544|Other|Waiting list where participants wait for delayed treatment|
16430396|NCT03768531|Experimental|Arm A: Nivolumab|
16430397|NCT03768531|Experimental|Arm B: Nivolumab and Cabrilizumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
16430398|NCT03768505|Experimental|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
16430399|NCT03768492|Experimental|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
16430400|NCT03768492|Placebo Comparator|Placebo|placebo cream during and for 4 weeks following radiation
16430401|NCT03768479|Experimental|FES-Fulvestrant|Patients with ER positive breast cancer receive Fulvestrant as the first line treatment enrolled in the study would receive 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant.
16430402|NCT03768466|Experimental|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
16430403|NCT03768440|Experimental|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
16430404|NCT03768440|Active Comparator|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
16430405|NCT03768427|Experimental|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
16430406|NCT03768427|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
16430407|NCT03768427|Experimental|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
16430408|NCT03768427|Active Comparator|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
16430409|NCT03768414|Experimental|Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride)|Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16430410|NCT03768414|Experimental|Arm II (cisplatin, gemcitabine hydrochloride)|Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16430450|NCT03768193|Experimental|Deep serratus anterior plane block|Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
16430519|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
16430411|NCT03768401|Experimental|Educational Seminars and Wellness Clinics|"I. Community outreach educational seminars about wellness and exercise while living with a neurological physical disability and measurement of the effects of these seminars for training individuals with neurological physical disabilities and their care givers (family, therapists, community personal trainers and community funders such as Lions or Rotary Clubs) about how to create a safe cost-effective exercise program .
~II. Creation and measurement of the effects of a wellness clinic for those with a neurological physical disability."
16430412|NCT03768388|Other|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
16430413|NCT03768388|Other|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
16430414|NCT03768375|Experimental|target therap|The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
16430415|NCT03768375|Experimental|FORFIRINOX|The patients wil receive conventional chemotherapy(FORFIRINOX)
16430416|NCT03768362|Experimental|Undergoing plication strabismus surgery|
16430417|NCT03768362|Active Comparator|Undergoing resection strabismus surgery|
16430418|NCT03768349|Experimental|PET/CT Ga-68 PSMA|Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT
16430419|NCT03768349|Experimental|PET/CT F-18 Labeled PSMA 1007|F-18 Labeled PSMA 1007 PET/CT
16430420|NCT03768336|Active Comparator|Waitlist Control|"The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions
~Mini relaxation practice
~Weekly goal check-ins
~RR-practice"
16430421|NCT03768336|Experimental|3RP Group Sessions|"The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions
~Mini relaxation practice
~Weekly goal check-ins
~RR-practice"
16430422|NCT03768323|No Intervention|Control|No airtime incentive was given for completing the survey
16430423|NCT03768323|Experimental|1X incentive|1X airtime incentive
16430424|NCT03768323|Experimental|2X incentive|2X airtime incentive
16430425|NCT03768310|Experimental|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.
~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
16430426|NCT03768310|Experimental|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.
~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
16430427|NCT03768297|Experimental|immediate implant with dual zone therapeutic concept|
16430428|NCT03768297|Active Comparator|immediate implant with buccal bone fill|
16430429|NCT03768284||Psoriasis patients|Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
16430430|NCT03768284||Parents of psoriasis patients|Parents of patients who developed psoriasis before 12 years of age
16430431|NCT03768284||Up to third-degree family members with or without psoriasis|Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
16430432|NCT03768245|Experimental|Behaviour|Physical activity and the Health Education programs are applied.
16430433|NCT03768245|Active Comparator|Nutrition|In this Arm, the the Physical activity, the Health education and Nutrition program are applied.
16430434|NCT03768219|Experimental|Stage 1 (SAD) Cohort 1|6 subjects will receive 2 mcg/kg of APVO210 2 subjects will receive placebo
16430435|NCT03768219|Experimental|Stage 1 (SAD) Cohort 2|6 subjects will receive 5 mcg/kg of APVO210 2 subjects will receive placebo
16430436|NCT03768219|Experimental|Stage 1 (SAD) Cohort 3|6 subjects will receive 10 mcg/kg of APVO210 2 subjects will receive placebo
16430437|NCT03768219|Experimental|Stage 1 (SAD) Cohort 4|6 subjects will receive 20 mcg/kg of APVO210 2 subjects will receive placebo
16430438|NCT03768219|Experimental|Stage 1 (SAD) Cohort 5|6 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
16430439|NCT03768219|Experimental|Stage 1 (SAD) Cohort 6|6 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
16430440|NCT03768219|Experimental|Stage 1 (SAD) Cohort 7|6 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
16430441|NCT03768219|Experimental|Stage 1 (SAD) Cohort 8|6 subjects will receive 320 mcg/kg of APVO210 2 subjects will receive placebo
16430442|NCT03768219|Experimental|Stage 2 (MAD) Cohort 9|8 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
16430443|NCT03768219|Experimental|Stage 2 (MAD) Cohort 10|8 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
16430444|NCT03768219|Experimental|Stage 2 (MAD) Cohort 11|8 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
16430445|NCT03768219|Experimental|Stage 2 (MAD) Cohort 12|8 subjects will receive 360 mcg/kg of APVO210 2 subjects will receive placebo
16430446|NCT03768219|Experimental|Expansion Cohort (Psoriasis)|"12 subjects will receive the starting dose for the Psoriasis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.
~8 subjects will receive placebo"
16430447|NCT03768219|Experimental|Expansion Cohort (Ulcerative Colitis)|"12 Subjects will receive the starting dose for the Ulcerative Colitis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.
~8 subjects will receive placebo"
16430448|NCT03768206|Experimental|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity & assist with goal setting during therapy sessions.
16430449|NCT03768206|Active Comparator|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
16430451|NCT03768193|Active Comparator|Surgically-placed paravertebral block|Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
16430452|NCT03768180||Patient with infective endocarditis|All patients diagnosed with infective endocarditis after TAVR
16430453|NCT03768167|Other|patients with metastatic spinal lesions|corpectomy
16430454|NCT03768154|Experimental|study arm|all patients will receive all four intervention in the same sequential method
16430455|NCT03768141||Liver surgery|Any type of liver surgery
16430456|NCT03768089|Experimental|Part A: VX-121 in Healthy Subjects (HS)|Single dose escalation.
16430457|NCT03768089|Placebo Comparator|Part A: Placebo|
16430458|NCT03768089|Experimental|Part B: VX-121 in HS|Multiple-dose escalation.
16430459|NCT03768089|Placebo Comparator|Part B: Placebo|
16430460|NCT03768089|Experimental|Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-121 in TC with TEZ/IVA.
16430461|NCT03768089|Placebo Comparator|Part C: Placebo|
16430462|NCT03768089|Experimental|Part D: VX-121 in TC with TEZ/IVA in subjects with CF|VX-121 in TC with TEZ/IVA in subjects with CF.
16430463|NCT03768089|Placebo Comparator|Part D: Placebo|
16430464|NCT03768063|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawl of study consent, unacceptable toxicity, pregnancy, patient non-compliance, or study termination by the Sponsor, whichever occurs first.
16430465|NCT03768050|Active Comparator|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
16430466|NCT03768050|No Intervention|Standard care|Usual care at the community and geriatric residences by primary care physicians
16430467|NCT03768037|Experimental|Anlotinib plus Pemetrexed|Anlotinib plus Pemetrexed
16430468|NCT03768037|Other|Pemetrexed|Pemetrexed
16430469|NCT03768024|Experimental|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430470|NCT03768024|Experimental|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430471|NCT03768024|Experimental|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430472|NCT03768024|Experimental|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430473|NCT03768024|Experimental|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430474|NCT03768024|Experimental|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430475|NCT03768024|Experimental|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
16430476|NCT03767998|Experimental|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
16430477|NCT03767998|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
16430478|NCT03767998|Experimental|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
16430479|NCT03767985|Active Comparator|Occlusion therapy|Participants are prescribed 2 hours of occlusion therapy per day, 7 days a week.
16430480|NCT03767985|Experimental|Dichoptic video game therapy|Participants receive dichoptic video game therapy: 1 hour per week at the out-patient clinic under direct supervision.
16430481|NCT03767972|Experimental|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
16430482|NCT03767959|Experimental|Chen's U-Suture|Patients in this group will treated by Chen's U-suture technique in pancreaticojejunostomy.
16430483|NCT03767959|Active Comparator|Classic pancreatic duct to mucosa|Patients in this group will treated by classic pancreatic duct to mucosa technique in pancreaticojejunostomy.
16430484|NCT03767946||Group 1|"Children both genders according to age:
~*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
16430485|NCT03767946||Group 2|"Children both genders according to age:
~*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
16433301|NCT03748940|Placebo Comparator|Part B: Placebo|Placebo administered SC
16430486|NCT03767946||Group 3|"Children both genders according to age:
~*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
16430487|NCT03767946||Group 4|"Children both genders according to age:
~*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
16430488|NCT03767933|Active Comparator|Non-Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo, both administered once during the study at the time of recruitment.
16430489|NCT03767933|Experimental|Non-Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg), both administered once during the study at the time of recruitment.
16430490|NCT03767933|Active Comparator|Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
16430491|NCT03767933|Experimental|Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg) + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
16430492|NCT03767933|Experimental|Opioid Trial: Arm 3|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone (0.05mg/kg, maximum 5 mg), all administered once during the study at the time of recruitment.
16430493|NCT03767920|Active Comparator|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
16430494|NCT03767920|Active Comparator|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
16430495|NCT03767907|Experimental|Online Cognitive Behavioural Therapy|Computer-based training for cognitive behavioural therapy (CBT4CBT) consists of seven modules, and includes a series of interactive videos presenting characters portrayed by professional actors struggling with real-life situations. These characters first experience a common risky situation or problem and then demonstrate the application of a targeted skill. The program further comprises games and interactive exercises to teach and model effective use of skills and strategies.
16430496|NCT03767907|Active Comparator|Treatment as Usual|Treatment as usual consists of weekly group and/or individual psychotherapy as determined by the clinical team. Psychotherapy will include structured relapse prevention, include cognitive and behavioural techniques, motivational enhancement, mindfulness, and specialized topics (e.g., vocational training, rainbow services) as appropriate.
16430497|NCT03767894|Experimental|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
16430498|NCT03767881|Experimental|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
16430499|NCT03767855|Experimental|CK-3773274 for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274
16430500|NCT03767855|Placebo Comparator|Placebo for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo
16430501|NCT03767855|Experimental|CK-3773274 for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274
16430502|NCT03767855|Placebo Comparator|Placebo for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo
16430503|NCT03767855|Experimental|CK-3773274 for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274
16430504|NCT03767855|Placebo Comparator|Placebo for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo
16430505|NCT03767855|Experimental|Food Effect|Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion
16430506|NCT03767855|Experimental|Relative Bioavailability|Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.
16430507|NCT03767829|Experimental|Part A: SAD: ALN-AAT02|Participants will be administered a single dose of ALN-AAT02.
16430508|NCT03767829|Placebo Comparator|Part A: SAD: Placebo|Participants will be administered a single dose of matching placebo.
16430509|NCT03767829|Experimental|Part B: MAD: ALN-AAT02|Participants will be administered multiple doses of ALN-AAT02.
16430510|NCT03767829|Placebo Comparator|Part B: MAD: Placebo|Participants will be administered multiple doses of matching placebo.
16430511|NCT03767816|Experimental|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
16430512|NCT03767816|Active Comparator|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
16430513|NCT03767803||Positive Preeclampsia group|A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery
16430514|NCT03767803||Study Cohort|A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.
16430515|NCT03767790|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
16430516|NCT03767790|No Intervention|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
16430517|NCT03767777|Experimental|Intervention arm|Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
16430518|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
16430520|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
16430521|NCT03767764||Control|Normal human serum from donors without liver disease
16430522|NCT03767738|Experimental|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
16430523|NCT03767725|Experimental|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART19 cells.
16430524|NCT03767673|Experimental|Patients after esophageal atresia|Patients older than 12 years following surgical repair of congenital esophageal atresia will be included after written informed consent. Patients will be subjected to spirometry to determine their age, weight (determined by Kilogram (kg) on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
16430525|NCT03767673|Active Comparator|Control group|Age and sex matched adolescents will be recruited as control group and will be included after written informed consent. Adolescents will be subjected to spirometry to determine their age, weight (determined by Kilogram on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
16430526|NCT03767660|Experimental|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
16430527|NCT03767647|Experimental|Intervention group|Receives 6 lessons in 6 different weeks on Emotional Intelligence
16430528|NCT03767647|No Intervention|Control group|Receives no intervention.
16430529|NCT03767634||Neonatal population (Project A)|Neonates born between 1st January 2012 and 31st December 2017 and admitted to a neonatal unit in England, Scotland and Wales).
16430530|NCT03767634||No PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who did not receive any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
16430531|NCT03767634||PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who received any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
16430532|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
16430533|NCT03767608||Patients with type 2 diabetes mellitus|Patients diagnosed with T2DM according to the ADA
16430534|NCT03767608||Lean healthy controls|Lean healthy controls
16430535|NCT03767595|Experimental|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
16430536|NCT03767582|Experimental|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
16430537|NCT03767582|Experimental|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
16430538|NCT03767582|Experimental|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
16430539|NCT03767569|Experimental|Myo-inositol|Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology)
16430540|NCT03767569|Other|Folic acid|Folic acid 0.4 mg daily during 12 weeks before start of ART
16430541|NCT03767556|No Intervention|Control|This group will not receive intervention
16430542|NCT03767556|Experimental|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
16430543|NCT03767543|Experimental|iGlarlixi DAILY|Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
16430544|NCT03767543|Active Comparator|iGlarlixi WEEKLY|Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
16430545|NCT03767530|Experimental|Mibo Thermoflo (thermal device)|3 sessions at 2 weeks interval (basal, week 2, week 4)of 11 minutes per eye of thermal therapy with Mibo Thermoflo.
16430546|NCT03767530|Active Comparator|Warm compresses and eyelid massage|2 times per day, 11 minutes per eye.
16430547|NCT03767517|Experimental|Active Intervention|Usual Care + Tele-consult Intervention
16430548|NCT03767517|Active Comparator|Usual Care|Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
16430549|NCT03767504|Experimental|Musclin|Thymol based dietary supplement
16430550|NCT03767491|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
16430551|NCT03767491|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
16430552|NCT03767478|Sham Comparator|Group A - Sham Comparator|12 Months of Sham Comparator (Sham Revitive Medic Neuromuscular Stimulation Device).
16430553|NCT03767478|Active Comparator|Group B1 - Active Comparator & Active Comparator|Active Comparator for 6 months (Revitive Medic Neuromuscular Stimulation Device). Then randomisation into active comparator (Revitive Medic Neuromuscular Stimulation Device) for further 6 months.
16430587|NCT03767309|Active Comparator|Control group|SCTG will be harvested from the palate using Zucchilli's technique (zucchelli, 2010) in the control group (coronally advanced flap and conventionally de-epithelialized free gingival graft)
16430554|NCT03767478|Active Comparator|Group B2 - Active Comparator & Sham Comparator|Active Comparator for 6 months (Revitive Medic Neuromuscular Stimulation Device). Then randomisation into sham comparator (Sham Revitive Medic Neuromuscular Stimulation Device) for further 6 months.
16430555|NCT03767465||PembroHIV|HIV-infected subjects with advanced melanoma or other oncological conditions in which the use of immunological checkpoint inhibitors is clinically indicated
16430556|NCT03767452|Experimental|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
16430557|NCT03767439|Experimental|Nivolumab, Vismodegib, Ipilimumab|"Patients will receive a two week run-in of Vismodegib 150 mg PO daily followed by concurrent Nivolumab 480 mg IV every 4 weeks and Vismodegib 150 mg PO daily.
~In an exploratory fashion, patients will have the option to receive combination Ipilimumab 1 mg/kg IV every 6 weeks and Nivolumab 360 mg IV every 3 weeks at the time of disease progression."
16430558|NCT03767426|No Intervention|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
16430559|NCT03767426|Active Comparator|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
16430560|NCT03767426|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
16430561|NCT03767413|Active Comparator|PNF group|It will be consisted of 15 -25 healthy subjects receiving only proprioceptive nueromuscular facilitation training for 5 weeks with 17 days follow up after completion of program.
16430562|NCT03767413|Experimental|PNFMP|It will be consisted of 15 -25 healthy subjects receiving proprioceptive nueromuscular facilitation training and mental practice technique for 5 weeks with 17 days follow up after completion of program.
16430563|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
16430564|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
16430565|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
16430566|NCT03767387|Active Comparator|Prehabilitation + standard care|Trimodal Prehabilitation consisting on motivation, personalisation and supervision of physical activity before major surgery
16430567|NCT03767387|No Intervention|Standard care|Standard care before major surgery
16430568|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital
~Inguinal swab sample
~Anal swab sample
~Fecal sample
~Risk factor assessment"
16430569|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).
~Inguinal swab sample
~Anal swab sample
~Fecal sample
~Risk factor assessment"
16430570|NCT03767361|Active Comparator|Fresh PRBCs|Neonates will receive fresh packed red blood cells transfusion within 7 days of donation
16430571|NCT03767361|Active Comparator|Old PRBCs|Neonates will receive fresh packed red blood cells transfusion older than 7 days yet within the standard range accepted universally will be transfused to this group.
16430572|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
16430573|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors
16430574|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in superficial tumors|Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
16430575|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors|Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
16430576|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
16430577|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
16430578|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer
16430579|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy
16430580|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy
16430581|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy
16430582|NCT03767335|Experimental|MEN1611|MEN1611 + Trastuzumab +/- Fulvestrant
16430583|NCT03767322|Active Comparator|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
16430584|NCT03767322|Placebo Comparator|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
16430585|NCT03767322|Active Comparator|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
16430586|NCT03767309|Experimental|Test group|SCTG will be harvested from the palate in the intervention group (coronally advanced flap and abrasively de-epithelialized free gingival graft)
16430588|NCT03767296|Experimental|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
16430589|NCT03767296|Experimental|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
16430590|NCT03767296|Experimental|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
16430591|NCT03767296|Experimental|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
16430592|NCT03767270|Experimental|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
16430593|NCT03767270|Placebo Comparator|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
16430594|NCT03767257|Experimental|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
16430595|NCT03767244|Experimental|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment.
16430596|NCT03767244|Experimental|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment.
16430597|NCT03767231|Experimental|HCV POC VL Group|This group will receive the POC HCV viral load testing via fingerstick using the novel Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
16430598|NCT03767231|No Intervention|Reference Group|This group will receive the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing only. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
16430599|NCT03767218|Experimental|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 12 of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
16430600|NCT03767218|Active Comparator|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
16430601|NCT03767205|Experimental|stroke patients|All participants perform overground walking and treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot).
16430602|NCT03767192|Experimental|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
16430603|NCT03767192|Sham Comparator|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
16430604|NCT03767179||Study Group|The study group consisted of 30 fertile, under 35 years old women who were included in the study for the first time missed abortus diagnosis.
16430605|NCT03767179||Control Group|30 cases with the same trimester, fertile, and under 35 years old who were referred to Obstetrics clinic, who had no systemic disease, were included in the study.
16430606|NCT03767153|Experimental|80 pin applicator|
16430607|NCT03767153|Active Comparator|160 pin applicator|
16430608|NCT03767140|Experimental|Verum acupucnture|Real acupuncture treatment
16430609|NCT03767140|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
16430610|NCT03767127||Appropriate transfusion policy|Patients transfused with high arterial-venous oxygen difference (≥3.7 ml/dl) or non-transfused with low arterial-venous oxygen difference (<3.7 ml/dl)
16430611|NCT03767127||Non-Appropriate transfusion policy|Patients transfused despite low arterial-venous oxygen difference or non-transfused with high arterial-venous oxygen difference
16430612|NCT03767114|Experimental|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
16430613|NCT03767114|Experimental|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
16430614|NCT03767101|Experimental|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
16430615|NCT03767101|Active Comparator|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
16430726|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
16430727|NCT03766373|Active Comparator|Drug: OP0201|
16430616|NCT03767101|Other|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
16430617|NCT03767088|Active Comparator|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
16430618|NCT03767088|Active Comparator|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
16430619|NCT03767088|Sham Comparator|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
16430620|NCT03767075|Experimental|Module 1 Arm 1 - atezolizumab|"Genomically selected populations will all receive the same drug (6 groups of mutation will be evaluated)
~Arm 1A: BRCA1 or BRCA2 mutations
~Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations
~Arm 1C: tumors with POLE mutation, POLD1 mutation.
~Arm 1D: hypermutated tumors
~Arm 1E: tumors with other mutations in DNA-repair genes.
~Arm 1F: tumors with amplified PDL1
~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 100 patients in part B of module 1."
16430621|NCT03767062|Active Comparator|Topiramate|Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
16430622|NCT03767062|Active Comparator|Greater Occipital +Supratrochlear Nerve Block|"Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼ (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood."
16430623|NCT03767049||Lung transplant patients readmitted in ICU|
16430624|NCT03767036|Active Comparator|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
16430625|NCT03767036|Active Comparator|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
16430626|NCT03767036|Experimental|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
16430627|NCT03767023||Stable AAA|"= patients with a small abdominal aortic aneursym diameter < 55 mm "
16430628|NCT03767023||instable AAA|"=patients with a large abdominal aortic aneursym diameter > 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair EVAR"
16430629|NCT03767010|Experimental|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
16430630|NCT03767010|Experimental|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
16430631|NCT03766997|Experimental|local injection|Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.
16430632|NCT03766997|Active Comparator|topical|Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.
16430633|NCT03766984|Experimental|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
16430634|NCT03766984|Experimental|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
16430635|NCT03766984|Experimental|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
16430636|NCT03766971|Experimental|Early-onset Cigarette Smokers|Participants who began smoking cigarettes earlier in life (<16 years old) will be randomized to 7 or 21 days of tobacco cessation.
16430637|NCT03766971|Experimental|Late-onset Cigarette Smokers|Participants who began smoking cigarettes later in life (>16 years old) will be randomized to 7 or 21 days of tobacco cessation.
16430638|NCT03766958||Registry Patients With BDX-XL2 Results|Patients providing consent to have data collected to observe how BDX-XL2 results were used in the clinical management of their lung nodules.
16430639|NCT03766958||Contemporaneous Group Without BDX-XL2|Contemporaneous group who did not have BDX-XL2 test results for use in the clinical management of their lung nodules.
16430640|NCT03766932||Blood culture candida positive group|
16430641|NCT03766932||Tracheal aspiration candida culture positive group|
16430642|NCT03766932||Urine candida culture positive group|
16430643|NCT03766932||Other aseptic humoral candida positive group|
16430644|NCT03766919|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead)
16430645|NCT03766906|Experimental|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
16430685|NCT03766607|Experimental|Trastuzumab with Ramucirumab and Paclitaxel|Single arm study of trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) every 21 days + ramucirumab (8 mg/kg) on days 1 & 15 every 28 days + paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days
16430728|NCT03766373|Placebo Comparator|Drug: Placebo|
16430646|NCT03766893|Experimental|Pharmacy based opioid use disorder care|A single-arm pilot study to test the collaborative pharmacy practice agreement for MAT (using the medications buprenorphine or injectable naltrexone) care model with up to 12 patients with opioid use disorder, assessing feasibility of medication dispensing, administration, and monitoring in the pharmacy, and determining patient acceptability of this model.
16430647|NCT03766880|Experimental|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
16430648|NCT03766867|Experimental|Vortioxetine|
16430649|NCT03766867|Placebo Comparator|Placebo|
16430650|NCT03766854|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.
~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
16430651|NCT03766854|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.
~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
16430652|NCT03766841|Experimental|Facilitated Enrollment|Patients will be aided in the account creation and usage of a consumer informatics tool to collect and report patient-contextual data within the electronic health record
16430653|NCT03766841|No Intervention|Usual Care|Patients will be invited to use the patient contextual data tool as per usual care, but will not receive additional assistance in account creation and usage.
16430654|NCT03766828||inside-out-access technique with inside-out access device|
16430655|NCT03766828||access technique including Sharp recanalization|
16430656|NCT03766815|Placebo Comparator|Placebo|Fiber supplement mixed with jelly will be ingested for 18 days with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
16430657|NCT03766815|Experimental|BCAA 200mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (200mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
16430658|NCT03766815|Experimental|BCAA 400mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (400mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
16430659|NCT03766802|Active Comparator|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.
~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
16430660|NCT03766802|Active Comparator|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises
~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
16430661|NCT03766802|Sham Comparator|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
16430662|NCT03766789|Active Comparator|Intervention|They will receive the cell phone application, as reminder of medications time and dose.
16430663|NCT03766789|No Intervention|Control|Patients will receive standard of care recommendations.
16430664|NCT03766776|Experimental|Anlotinib Arm|
16430665|NCT03766763|Experimental|ARM A VENETOCLAX|VENETOCLAX
16430666|NCT03766750|Experimental|LIMA|
16430667|NCT03766750|Active Comparator|Tradjenta®|
16430668|NCT03766750|Active Comparator|Forxiga®|
16430669|NCT03766737|Other|Eligible patients for AI test.|Device: An intelligent visual acuity diagnostic system for children. An artificial intelligence to evaluate children's vision.
16430670|NCT03766724|Experimental|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
16430671|NCT03766724|Experimental|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
16430672|NCT03766724|Experimental|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
16430673|NCT03766724|Experimental|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
16430674|NCT03766711|Experimental|Actual - Augmented|Reaching task as a physical therapy intervention. First with 1:1 visual feedback, then with augmented forward symmetry.
16430675|NCT03766711|Experimental|Augmented - Actual|Reaching task as a physical therapy intervention. First with augmented forward symmetry, then with 1:1 visual feedback.
16430676|NCT03766685|Experimental|Bimekizumab-SS|Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
16430677|NCT03766685|Experimental|Bimekizumab-AI|Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
16430678|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
16430679|NCT03766659|Other|MOSE|EUS-FNB with MOSE
16430680|NCT03766659|Other|ROSE|EUS-FNA with ROSE
16430681|NCT03766646|Experimental|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
16430682|NCT03766646|Active Comparator|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
16430683|NCT03766633||Living liver donors|This is a group of living liver donors that underwent a CT prior to donating their partial liver to a recipient.
16430684|NCT03766620||Tube Fed Participants|Individuals with diabetes and malnutrition receiving tube feed as sole source nutrition.
16430729|NCT03766360|Experimental|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
16430686|NCT03766594|Active Comparator|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
16430687|NCT03766594|Active Comparator|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
16430688|NCT03766581|Placebo Comparator|BMS-986177 Placebo|Specified Dose on Specified Days
16430689|NCT03766581|Experimental|Dose 1: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430690|NCT03766581|Experimental|Dose 2: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430691|NCT03766581|Experimental|Dose 3: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430692|NCT03766581|Experimental|Dose 4: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430693|NCT03766581|Experimental|Dose 5: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430694|NCT03766581|Experimental|Dose 6: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430695|NCT03766581|Experimental|Dose 7: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
16430696|NCT03766568|Experimental|Diagnostic with JGG endoscope|
16430697|NCT03766555|Experimental|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
16430698|NCT03766555|Active Comparator|Liver Resection|Liver resection will be performed in patients randomized to this arm.
16430699|NCT03766542|Active Comparator|CPAP|Oronasal CPAP therapy applied as per current international guidelines
16430700|NCT03766542|Experimental|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
16430701|NCT03766516||Cohort|"Any patient planning to administer BrentuximabVedotin to treat the target disease.
~Any patient administering BrentuximabVedotin to treat the target disease.
~Any patient tracing BrentuximabVedotin after treating the target disease.
~Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin."
16430702|NCT03766503|Other|Intervention|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
16430703|NCT03766490|Experimental|Anlotinib Hydrochloride plus gefitinib or icotinib|
16430704|NCT03766477||Individuals with sleep bruxism|"Individuals with sleep bruxism evaluated in three different methods regarding their sleep quality:
~Pittsburgh Sleep Quality Index (IQSP) and Johansson
~Smartphone APP
~Polysomnography"
16430705|NCT03766464||with sleep bruxism, apnea and DTM|"Patients who will undergo analysis of:
~Evaluation of TMD and pain sensitivity Evaluation of SB Evaluation of AB"
16430706|NCT03766438|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
16430707|NCT03766438|No Intervention|Control|The comparison group will receive usual clinical care.
16430708|NCT03766425|Experimental|Aflibercept|Aflibercept applied intraoperatively as a subconjunctival injection at a dose of 0.05 ml (40 mg / ml) and one week after the operation at the same dose, also subconjunctival.
16430709|NCT03766425|Active Comparator|Mitomycin|Mitomycin applied during a surgery at a concentration of 0.3mg / ml for 3 min. on a soaked sponge.
16430710|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
16430711|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
16430712|NCT03766399|Experimental|Part 1a (SAD) Cohort 1|6 participants will receive inhaled dose 1 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
16430713|NCT03766399|Experimental|Part 1a (SAD) Cohort 2|6 participants will receive inhaled dose 2 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
16430714|NCT03766399|Experimental|Part 1a (SAD) Cohort 3|6 participants will receive inhaled dose 3 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
16430715|NCT03766399|Experimental|Part 1a (SAD) Cohort 4|6 participants will receive inhaled dose 4 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
16430716|NCT03766399|Placebo Comparator|Part 1a (SAD) Cohort 5|6 participants will receive inhaled dose 5 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
16430717|NCT03766399|Experimental|Part 1a (SAD) Cohort 6|6 participants will receive inhaled dose 6 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
16430718|NCT03766399|Experimental|Part 1b (IV cohort 1)|All 6 participants will receive single IV dose of AZD0449 solution.
16430719|NCT03766399|Experimental|Part 2a (MAD) Cohort 1|6 participants will receive inhaled dose 7 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
16430720|NCT03766399|Experimental|Part 2a (MAD) Cohort 2|6 participants will receive inhaled dose 8 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
16430721|NCT03766399|Experimental|Part 2b (MAD/healthy volunteers) Cohort 3|18 healthy volunteers will receive inhaled dose 9 of AZD0449 nebulized suspension and 12 healthy volunteers will receive inhaled placebo.
16430722|NCT03766399|Experimental|Part 3a (DPI/PoM)|18 participants will receive inhaled dose 10 of AZD0449 DPI and 6 participants will receive inhaled placebo.
16430723|NCT03766399|Experimental|Part 1b (IV cohort 2)|6 healthy volunteers will receive single IV dose of AZD0449 solution.
16430724|NCT03766399|Experimental|Part 3b (DPI/healthy volunteers)|Part 3b is optional. 8 healthy volunteers; 6 volunteers will receive AZD0449 DPI and 2 volunteers will recieve placebo.
16430725|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
16430730|NCT03766360|No Intervention|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
16430731|NCT03766347||Pediatric Neuromyelitis Optica|Participants under the age of 18 that are positive for Aquaporin-4 antibody.
16430732|NCT03766334|Experimental|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
16430733|NCT03766334|No Intervention|Diabetes Diet|only Diabetes Diet
16430734|NCT03766321|Active Comparator|Fecal microbiota transplantation (FMT)|"Fecal microbiota transplantation will be performed during two endoscopic procedures (at baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum. Fecal microbiota will be diluted in saline solution 200 ml and infused at 30 ml/minute speed. Every endoscopic procedure will be performed with sedation of the patient.
~Feces for FMT will be obtained by known healthy donors for C. difficile infection according to standard selection procedures."
16430735|NCT03766321|Placebo Comparator|Placebo|"ALS patients will undergo upper GI endoscopy with small-intestine biopsies at baseline and after 6 months. Patients in the placebo arm will not receive any treatment during these procedures, but will undergo intestinal biopsy.
~Every endoscopic procedure will be performed with sedation of the patient."
16430736|NCT03766308|Experimental|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
16430737|NCT03766308|Active Comparator|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
16430738|NCT03766295|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
16430739|NCT03766295|Active Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
16430740|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
16430741|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
16430742|NCT03766269|Other|Baseline Opioid|One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
16430743|NCT03766256|Experimental|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
16430744|NCT03766243|Experimental|Brochure and DVD plus nursing training|"In addition to the control intervention, see below, the experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. The nurse provided theoretical explanations on the exercises, watched the explanatory DVD with the patients, answering questions and commenting relevant points, and then had the patients repeat the exercises in front of a mirror under direct observation, so that any errors could be pointed out and corrected."
16430745|NCT03766243|Active Comparator|Brochure and DVD only|"After recruitment, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use. At the same time, she contacted the research nurse to obtain the random allocation to one of the study groups for that patient.
~These exercises had to be done every day for the entire duration of the program (12 months) and registered in the diary with any comments."
16430746|NCT03766230||peribulbar anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using peribulbar anesthesia
16430747|NCT03766230||topical anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using topical anesthesia
16430748|NCT03766230||peribulbar anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using peribulbar anesthesia
16430749|NCT03766230||topical anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using topical anesthesia
16430750|NCT03766230||peribulbar anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using peribulbar anesthesia
16430751|NCT03766230||topical anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using topical anesthesia
16430752|NCT03766230||peribulbar anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using peribulbar anesthesia
16430753|NCT03766230||topical anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using topical anesthesia
16430754|NCT03766230||peribulbar anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using peribulbar anesthesia
16430755|NCT03766230||topical anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using topical anesthesia
16430756|NCT03766217|Experimental|Mesenchymal stem cells associated with biomaterials|Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).
16430757|NCT03766217|Active Comparator|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations.
16430758|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
16430839|NCT03765619|Experimental|Aspirin|250 patients will be randomized to receive Aspirin postoperatively.
16430759|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
16430760|NCT03766191|Active Comparator|Food Ads and fMRI|
16430761|NCT03766191|Sham Comparator|Non-Food Ads and fMRI|
16430762|NCT03766191|Active Comparator|Food Ads and TV show|
16430763|NCT03766191|Sham Comparator|Non-Food Ads and TV show|
16430764|NCT03766178|Experimental|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
16430765|NCT03766165|Experimental|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
16430766|NCT03766165|Other|Control|Job announcements only
16430767|NCT03766152|Other|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
16430768|NCT03766139|Experimental|SUPERCELL GLUE(STEM CELLS AND PRFM)|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .
16430769|NCT03766139|Active Comparator|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites
16430770|NCT03766126|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
16430771|NCT03766113|Other|Healthy volunteer|"50 subjects
~A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
16430772|NCT03766113|Other|Patients at the early stage after stroke|"30 subjects
~Effectiveness of an electroencephalogram-neurofeedback"
16430773|NCT03766113|Other|Patients at the chronic stage after stroke|"36 subjects
~Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
16430774|NCT03766100|Experimental|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
16430775|NCT03766100|No Intervention|Control group|Insomnia is untreated.
16430776|NCT03766087|Experimental|surgery group|Decompressive craniectomy associated with optimal medical management of intracranial pressure.
16430777|NCT03766087|No Intervention|conservative group|Optimal medical management of intracranial pressure only.
16430778|NCT03766074|Experimental|Intervention|vitamin D supplement every other week
16430779|NCT03766074|Placebo Comparator|control|Placebo every other week
16430780|NCT03766061|Active Comparator|Onlay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with onlay mesh hernioplasty in which we placed mesh on the anterior rectus sheath
16430781|NCT03766061|Active Comparator|Sublay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with sublay mesh hernioplasty in which we placed mesh in the retromuscular space
16430782|NCT03766048|Experimental|Single-Anterior-Mesh, SAM|
16430783|NCT03766048|Sham Comparator|Double-Mesh, DM|
16430784|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
16430785|NCT03766022|Experimental|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
16430786|NCT03766022|Active Comparator|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
16430787|NCT03766009|Active Comparator|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
16430788|NCT03766009|Experimental|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
16430789|NCT03765996|Active Comparator|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
16430790|NCT03765996|Experimental|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
16430791|NCT03765983|Experimental|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
16430792|NCT03765983|Experimental|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
16430793|NCT03765957|Experimental|Mesenchymal Stem Cells|The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
16430794|NCT03765944|Active Comparator|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
16430795|NCT03765944|Active Comparator|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
16430796|NCT03765931|Active Comparator|subjects treated with doxycycline|The participants treated by doxycycline 100 mg will have one dose but followed 5 days
16430797|NCT03765931|Placebo Comparator|subjects treated with amoxycilline|The participants treated with amoxycilline 500 mg will have 2 doses per days during 5 days treatement and follwed during these 5 days
16430835|NCT03765658|Experimental|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
16497061|NCT03312244|Placebo Comparator|Placebo|Placebo
16430800|NCT03765905||PCOS diagnosis area|The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)
16430801|NCT03765905||PCOS is not diagnosed|Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study
16430802|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
16430803|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
16430804|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
16430805|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
16430806|NCT03765879|Experimental|Verum VGAIT Group|Participants in this group will receive verum (real) acupuncture and verum video-guided acupuncture imagery treatment (VGAIT).
16430807|NCT03765879|Placebo Comparator|Sham VGAIT Group|Participants in this group will receive sham acupuncture and sham VGAIT.
16430808|NCT03765866|No Intervention|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
16430809|NCT03765866|Experimental|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
16430810|NCT03765853|Other|Stretching Postural®|
16430811|NCT03765853|No Intervention|Control|
16430812|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
16430813|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
16430814|NCT03765827|Experimental|Vitamin E acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
16430815|NCT03765827|Sham Comparator|Control group|No ointment will be applied
16430816|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fed)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
16430817|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fasting)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
16430818|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fed)|Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
16430819|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fasting)|Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
16430820|NCT03765788|Experimental|Secukinumab|Participants will receive secukinumab at a dose of 300 milligrams (mg) as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
16430821|NCT03765788|Placebo Comparator|Placebo|Participants will receive placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
16430822|NCT03765775|Experimental|Anlotinib Hydrochloride+Sintilimab|Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
16430823|NCT03765762|Experimental|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
16430824|NCT03765762|Placebo Comparator|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
16430825|NCT03765749||Community onset 3rd generation cephalosporin resistant entero|Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic
16430826|NCT03765749||Nosocomial onset 3rd generation cephalosporin resistant ente|Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic
16430828|NCT03765710|Experimental|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
16430829|NCT03765710|Experimental|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
16430830|NCT03765697|Experimental|Lidocaine 5% medicated plaster|Up to 3 plasters were applied per day.
16430831|NCT03765671|Experimental|Mild Child-Pugh A|Single oral dose of elafibranor 120mg
16430832|NCT03765671|Experimental|Moderate Child-Pugh B|Single oral dose of elafibranor 120mg
16430833|NCT03765671|Experimental|Severe Child-Pugh C|Single oral dose of elafibranor 120mg
16430834|NCT03765671|Experimental|Healthy|Single oral dose of elafibranor 120mg
16430836|NCT03765645|Active Comparator|3 doses on intra venous antibiotics|Patients will receive 3 doses of intra venous antibiotics. (1 dose preoperative, 1 intra operative and 1 post-operative)
16430837|NCT03765645|Active Comparator|9 doses of intra venous antibiotics|Patients will receive 9 doses of intra venous antibiotics. (1 dose preoperative, rest 8 doses at equal intervals)
16430840|NCT03765619|No Intervention|Non-Aspirin|250 patients will be randomized to not receive Aspirin postoperatively.
16430841|NCT03765606|Placebo Comparator|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg & theobromine, 93mg)
16430842|NCT03765606|Experimental|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg & theobromine, 0.2mg)
16430843|NCT03765593||Study group 1|Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
16430844|NCT03765593||Study group 2|Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
16430845|NCT03765593||Study group 3|Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
16430846|NCT03765593||Control group|Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
16430847|NCT03765580|Placebo Comparator|Control group|No fish
16430848|NCT03765580|Experimental|1 portion of fish per week|140g fish/week
16430849|NCT03765580|Experimental|2 portions of fish per week|280g fish/week
16430850|NCT03765567|Experimental|Intervention Arm|Subjects randomized to the Intervention Arm will receive usual care plus two (2) grams of Vancomycin powder administered topically. In the emergency room prior to surgical intervention, a qualified member of the study team or clinical team member will apply 2 grams of vancomycin powder directly to the open fracture site such that all visible surfaces of the wound are completely and uniformly covered, including bone edges.
16430851|NCT03765567|No Intervention|Control Arm|Subjects randomized to the Control Arm will receive usual care for open long bone fracture as determined by the treating physician.
16430852|NCT03765567|No Intervention|Observational Arm|Subjects who otherwise meet the criteria to be included in the study but are not able to provide consent, either themselves or through a Legally Authorized Representative, will be placed in the Observational Arm and receive usual care with no experimental intervention.
16430853|NCT03765554|Experimental|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
16430854|NCT03765554|Experimental|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
16430855|NCT03765541|Experimental|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
16430856|NCT03765541|Active Comparator|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
16430857|NCT03765515|Experimental|Q-Fix|"Q-Fix has the advantages of all-suture implant and has the same or better performance than the traditional anchor.
~Consistent activation effect
~Excellent performance
~Streamlined technique Q-fix is an experimental Arm."
16430858|NCT03765515|Active Comparator|Twinfix Ti|The Smith & Nephew's marketed Twinfix Suture Anchor is selected as the control product. This product is composed of anchor, suture, suture needle and inserter. The anchor is made of Ti6Al4V titanium alloy conforming to ISO5832-3. The Durabraid suture is made of polyester (Polyethylene terephthalate) conforming to YY 0167. Ultrabraid suture is made of two materials of UHMWPE and polypropylene monofilaments conforming to GB/T 19701.1. The suture needle is made of Type 420B stainless steel conforming to YY/T 0726. The stem portion of inserter that comes into contact with the body is made of Type 630B stainless steel conforming to YY/T 0726.
16430859|NCT03765502|Experimental|Nasal Glucagon Device (NG)|Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
16430860|NCT03765502|Active Comparator|Glucagon Emergency Kit (GEK)|Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
16430861|NCT03765489|Experimental|electrical muscle stimulation|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al. plus electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction"
16430862|NCT03765489|Active Comparator|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
16430863|NCT03765476|Active Comparator|TAU|treatment as usual
16430864|NCT03765476|Experimental|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
16430865|NCT03765463|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
16430866|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
16430867|NCT03765437|Experimental|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine (split-virion, inactivated) Northern hemisphere seasonal formulation 2018-2019
16430868|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).
~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:
~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.
~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
16430869|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
16430870|NCT03765411||Open Proctectomy Patients|Patients who underwent Proctectomy through an open approach
16430871|NCT03765411||Laparoscopic Proctectomy Patients|Patients who underwent Proctectomy through a Laparoscopic approach
16430872|NCT03765411||Robotic Proctectomy Patients|Patients who underwent Proctectomy through a Robotic approach
16430873|NCT03765398|Experimental|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
16430874|NCT03765385|Experimental|High-intensity training|Each high-intensity training (HIT) session will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIT is 20 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
16430875|NCT03765385|Active Comparator|Moderate-intensity continuous training|Each moderate-intensity continuous training (MICT) session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is 40 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
16430876|NCT03765359|Active Comparator|metforminhydrochloride|Metformin medication starts on 12-14 weeks of gestation. The starting dosage is 1 tablet (500 mg) x1 and it is increased gradually 1 tablet a week up to 2+2 tablets (2000mg) daily. Duration of the treatment is approximately until one week before delivery. Otherwise metformin treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
16430877|NCT03765359|Placebo Comparator|Placebo Oral Tablet|Placebo tablets starts on 12-14 weeks of gestation. The starting dosage is 1 tablet x1 and it is increased gradually 1 tablet a week up to 2+2 tablets daily. Duration of the treatment is approximately until one week before delivery. Otherwise placebo treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
16430878|NCT03765346|Experimental|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
16430879|NCT03765346|Active Comparator|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
16430880|NCT03765346|Placebo Comparator|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
16430881|NCT03765307|Experimental|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
16430882|NCT03765307|Active Comparator|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
16430883|NCT03765294|Experimental|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
16430884|NCT03765294|Placebo Comparator|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
16430885|NCT03765281|Experimental|Navigation|Navigation intervention plus Resource List
16430886|NCT03765281|Active Comparator|Self-Navigation|Resource List intervention
16430887|NCT03765268|Active Comparator|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
16430888|NCT03765268|Active Comparator|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
16430889|NCT03765255|Experimental|In the Know (ITK): sexual health education|Cohorts/participants in the experimental (treatment) arm receive an intervention that combines 6 hours of in-person sexual health and adolescent development education with an app that includes a resource locator, text message reminders (for one month), goal setting, and other resources.
16430890|NCT03765255|No Intervention|Control: do not receive ITK intervention|Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
16430891|NCT03765242||Patient initiating warfarin|
16430892|NCT03765242||Patient initiating apixaban|
16430893|NCT03765229|Experimental|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
16430894|NCT03765216|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
16430895|NCT03765216|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).
~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
16431341|NCT03762057||Surgical patients|All postoperative patients admitted to surgical ICU with foley catheter in place
16430896|NCT03765203|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to Natera's dd-cfDNA test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
16430897|NCT03765203|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to Natera's dd-cfDNA test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
16430898|NCT03765190|Experimental|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
16430899|NCT03765177|Experimental|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
16430900|NCT03765164|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
16430901|NCT03765164|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
16430902|NCT03765151|Experimental|LLLT group|Low-level laser therapy and orthodontic retention
16430903|NCT03765151|Placebo Comparator|control group|orthodontic retention and no laser treatment.
16430904|NCT03765138|Experimental|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
16430905|NCT03765125|Experimental|collagen peptide test|1 x daily consumption of 1 blister package of the collagen-peptide test powder dissolved in water over a period of 90 days
16430906|NCT03765125|Placebo Comparator|collagen peptide placebo|1y daily consumption of 1 blister package of the placebo powder dissolved in water over a period of 90 days
16430907|NCT03765112|Experimental|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
16430908|NCT03765099|Experimental|Animal-Assisted Interactions|Children and their caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
16430909|NCT03765099|Active Comparator|Usual Care|Children and their caregivers randomly assigned to the usual care group will receive usual care which may include play therapy, music therapy or visits with a social worker during their visits to the hospital.
16430910|NCT03765086|Active Comparator|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
16430911|NCT03765086|Active Comparator|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
16430912|NCT03765073|Experimental|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
16430913|NCT03765073|Experimental|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
16430914|NCT03765073|Experimental|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
16430915|NCT03765073|Experimental|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
16430916|NCT03765073|Experimental|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
16430917|NCT03765073|Experimental|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
16430918|NCT03765073|Experimental|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
16430919|NCT03765073|Experimental|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
16430920|NCT03765073|Experimental|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
16430921|NCT03765073|Placebo Comparator|Stage 1 Placebo|Saline control
16430922|NCT03765073|Placebo Comparator|Stage 2 Placebo|Saline control
16430923|NCT03765073|Placebo Comparator|Stage 3 Placebo|Saline control
16430924|NCT03765060|Experimental|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):
~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).
~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
16430925|NCT03765060|Active Comparator|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).
~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).
~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
16430926|NCT03765047|Experimental|Intervention Arm|"This study arm includes the schools where the School Team (school teachers, coordinator) receives the physical activity intervention. The intervention consists of four parts:
~School Engagement and Assessment
~Training
~Physical Activity Equipment and Resources
~Ongoing Assessment and Technical Assistance"
16430927|NCT03765047|No Intervention|Control Arm|The control arm includes the schools where the School Team does not receive any intervention but all the necessary data will be collected.
16430928|NCT03765034|Experimental|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
16430929|NCT03765034|Active Comparator|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
16430930|NCT03765021|Experimental|Tranexamic acid injection (Kapron)|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
16430931|NCT03765021|Active Comparator|Fractional CO2 laser resurfacing|The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
16430932|NCT03765008|Active Comparator|High Water intake|5-days of High water intake according to IOM guidelines
16430933|NCT03765008|Experimental|Low Water Intake|5-days of Low water intake of 500 mL/day
16430934|NCT03764995|Experimental|Abdominal Massage|
16430935|NCT03764995|Placebo Comparator|Placebo Ultrasound|
16430936|NCT03764969|Active Comparator|standard smoking cessation program (SCP)|standard smoking cessation program
16430937|NCT03764969|Experimental|SCP + CRT|SCP plus cognitive remediation treatment (CRT)
16430938|NCT03764969|Experimental|SCP + ICHT|SCP plus an implicit computer-based habit-modifying training (ICHT)
16430939|NCT03764956|Experimental|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
16430940|NCT03764956|Active Comparator|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
16430941|NCT03764943|Experimental|Immunonutrition Intervention|Participants will consume 3 'Impact Advanced Recovery' shakes daily for 5 days prior to surgery 2 hours prior to surgery.
16430942|NCT03764891||Uphold|Patients who underwent Uphold procedure
16430943|NCT03764891||Perigee|Patients who underwent Perigee procedure
16430944|NCT03764878||Normal weight|BMI 18.5-24.9 kg/m^2 low risk pregnancy
16430945|NCT03764878||Pregestational diabetes mellitus|Type 1 or Type 2 diabetes mellitus diagnosed prior to the pregnancy or in the first trimester
16430946|NCT03764878||Obese|Pre-pregnancy BMI ≥ 30.0 kg/m^2
16430947|NCT03764865|Experimental|day 3 embryo transfer|embryo transfer 3 days after fertilization
16430948|NCT03764865|Experimental|day 5 embryo transfer|embryo transfer 5 days after fertilization
16430949|NCT03764852|Experimental|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
16430950|NCT03764839|No Intervention|Active Control Group (Digital Health Education)|"Demographics survey
~Baseline surveys
~Participants receive a digital information sheet on nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery
~Post-surgery:
~Pain check-ins (2 times per week) (detailed above)
~Patients receive 30 second booster videos at 7, 14, and 21 days after surgery
~Follow-up surveys (4, 8, and 12 weeks after surgery)"
16430951|NCT03764839|Experimental|"My Surgical Success Treatment Group"|"Demographics survey
~Baseline surveys
~Intervention:
~45-minute digital behavioral pain medicine intervention My Surgical Success that emphasized cognitive and emotional regulation of pain and downregulation of physiologic arousal.
~downloadable app with an audio file
~personalized plan that allows learners to incorporate the treatment information
~Post-video survey (detailed above)
~Post-surgery:
~Pain check-ins (2 times per week) (detailed above)
~Follow-up surveys (4, 8, and 12 weeks after surgery) Intervention: Behavioral: Perioperative Digital Behavioral Pain Medicine My Surgical Success"
16430952|NCT03764826|Experimental|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
16430953|NCT03764826|Active Comparator|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
16430954|NCT03764787|Experimental|Radiation+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
16430955|NCT03764774|Experimental|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
16430956|NCT03764774|Placebo Comparator|Placebo Single dose|Single dose of placebo administered SC
16430957|NCT03764774|Experimental|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
16430958|NCT03764774|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered SC
16430959|NCT03764761|Experimental|AAC Intervention|Participants will use AAC technology of different designs delivered on iMacs or Surface tablets
16430960|NCT03764748|Experimental|mini-FMT|Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
16430961|NCT03764735|Placebo Comparator|SkQ1 Vehicle|SkQ1 (Vehicle)
16430962|NCT03764735|Active Comparator|Low Dose - SkQ1|Low-dose ophthalmic solution
16430963|NCT03764735|Active Comparator|High Dose - SkQ1|High-dose ophthalmic solution
16430964|NCT03764722|Experimental|Levosimendan|
16430965|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.
~The experimental arm will wear wireless monitoring for 5 days after transfer in subacute care unit"
16430966|NCT03764709|Active Comparator|Control arm GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.
~The active comparator arm will be monitored by nursing staff."
16430967|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.
~The experimental arm will wear wireless monitoring for 5 days after discharge at home"
16431000|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
16430968|NCT03764709|Active Comparator|Control Arm GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.
~The active comparator arm will perform usual checks by caregivers at home."
16430969|NCT03764696|No Intervention|air, the first and second stage of labor|"Patients randomized to the group will receive room air.
~The therapy will continue until after delivery"
16430970|NCT03764696|Experimental|oxygen, the first and second stage of labor|"Patients randomized to the group will receive oxygen administered by high flow facemask oxygen at 10 L/min oxygen.
~The therapy will continue until after delivery"
16430971|NCT03764683|Experimental|Drug-Drug|This arm will receive the active drug in the first and second phase of the study.
16430972|NCT03764683|Other|Placebo-Drug|This arm will receive placebo in the first phase of the study and the active drug in the second phase.
16430973|NCT03764683|Placebo Comparator|Placebo-Placebo|This arm will receive placebo in the first phase and second phase of the study.
16430974|NCT03764657||"16 patients, named Hot group"|"We considered 16 sinus excision by diathermy as a case group (named Hot group)"
16430975|NCT03764657||"13 patients, named Cold group"|"13 procedures performed by knife as control group (named Cold group)."
16430976|NCT03764644|Experimental|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
16430977|NCT03764644|Sham Comparator|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
16430978|NCT03764631||subjects with Type 2 Diabetes mellitus|
16430979|NCT03764618|Experimental|Fostamatinib|Initial dose is 100 mg PO bid. At week 4 dose will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
16430980|NCT03764618|Placebo Comparator|Placebo|Initial dose is 100 mg PO bid. At week 4 dose will be increased to placebo 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
16430981|NCT03764605|Experimental|Metformin|"Patients will take metformin starting from 500 mg a day. They will up-titrate every week, if tolerating IMP, adding one 500 mg dose 8 hours after the former, till reaching 500 mg thrice a day.
~The minimum tolerated dose requested in order to be admitted to the study is 500 mg twice a day.
~Those reaching eGFR<45 ml/min will reduce the dose by one third. Those reaching eGFR<30 will drop out the study."
16430982|NCT03764605|Active Comparator|Tolvaptan|Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
16430983|NCT03764592||VF BrS/ERS patients|Only patients that diagnosed with BrS or ERS based on ECG criteria
16430984|NCT03764579|Active Comparator|sleep and diet intervention|
16430985|NCT03764579|Active Comparator|diet intervention|
16430986|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
16430987|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
16430988|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
16430989|NCT03764553|Experimental|Liposomal irinotecan, leucovorin and 5FU|IV Nal-IRI 80 mg/m² (expressed as irinotecan hydrochloride (HCl) salt), folinic acid 400 mg/m², fluorouracil 2400 mg/m² over 46 h, every 2 weeks.
16430990|NCT03764553|Experimental|Carboplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and carboplatin area under the curve (AUC5), every three weeks.
16430991|NCT03764553|Experimental|oxaliplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2, every three weeks.
16430992|NCT03764540|Experimental|Cabazitaxel plus prednisone|"Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).
~Prednisone will be administered by oral route"
16430993|NCT03764540|Active Comparator|Docetaxel plus prednisone|"Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.
~Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).
~Prednisone will be administered by oral route"
16430994|NCT03764527|Active Comparator|Artemether-lumefantrine (AL)|One tablet of artemether-lumefantrine (Coartem®) was administered twice daily for 3 days to children with a body weight of 9 to <15 kg, and 2 tablets were administered twice daily for 3 days to children with a body weight of >15 to 25 kg. All doses were taken under direct observation.
16430995|NCT03764527|Active Comparator|Artesunate + Amodiaquine (AA)|Artesunate + amodiaquine (ASAQ) was administered as follows: 4 mg/kg body weight of artesunate plus 10 mg/kg body weight of amodiaquine once daily for 3 days under direct observation.
16430996|NCT03764514||Spinal Cord Stimulator - Permanent Implantation|
16430997|NCT03764501|Active Comparator|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
16430998|NCT03764501|No Intervention|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
16430999|NCT03764488|Experimental|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
16431001|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
16431002|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
16431003|NCT03764475|Other|Long-term Safety of ARQ-151|Open Label Long-term Safety of ARQ-151
16431004|NCT03764462|Experimental|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
16431005|NCT03764462|Experimental|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
16431006|NCT03764449|Experimental|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
16431007|NCT03764449|Experimental|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
16431008|NCT03764436|Experimental|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
16431009|NCT03764436|Experimental|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
16431010|NCT03764436|Experimental|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
16431011|NCT03764423|Experimental|Salmon fishmeal|7,5 g fishmeal and 7,5 g microcrytalline cellulose per day in capsules by mounth for 8 weeks
16431012|NCT03764423|Placebo Comparator|Microcrystalline cellulose|7,5 g microcrystalline cellulose per day in capsules by mounth for 8 weeks
16431013|NCT03764410|Experimental|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
16431014|NCT03764410|Active Comparator|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
16431015|NCT03764397|Experimental|Prehabilitation group|A 4-week prehabilitation educational programme (i.e., a behavioral change intervention) and to pilot that prehabilitation in combination with a 6-week gentle self-paced walking programme (with weekly telephone support) in people with FM.
16431016|NCT03764384||Hospital Monitoring Group - ALSFRS-R cohort|All patients will be first recruited to this cohort unless at their first visit the investigator deems them eligible for the Home Monitoring Device Group. At the initial screening visit, all patients recruited into the study will undergo routine assessments according to the existing MND protocol, and additionally complete the ALSFRS-R symptom-based assessment questionnaire by interview with the study researchers (with assistance from spouse, family member or carer if required). Patients will continue to complete the ALSFRS-R symptom-based questionnaire at each clinic attendance.
16431017|NCT03764384||Home Monitoring Cohort|"If eligible patients will use the N Tidal CTM, up to 3 times a day (morning, midday and evening) throughout the home monitoring period until the final outpatient clinic visit.
~In addition subjects will complete a weekly diary symptom monitoring diary which asks them about their respiratory symptoms, GP attendances, respiratory infections. Patients routine standard of care assessments will also be documented according to the protocol as well as completing the ALSFRS-R at each visit."
16431018|NCT03764371||sMPLC|Lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules).
16431019|NCT03764358|Active Comparator|Arteriovenous fistula|
16431020|NCT03764358|Experimental|Tunneled Cuffed Catheter|
16431021|NCT03764345|Experimental|Sofosbovir/Ledipasvir Daily|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
16431022|NCT03764332|Other|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
16431023|NCT03764319|Active Comparator|Intervention group|Ultra-protective ventilator settings in patients with ARDS and ECMO.
16431024|NCT03764319|Active Comparator|Control group|Standard ventilator settings in patients with ARDS and ECMO.
16431025|NCT03764306|Active Comparator|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
16431026|NCT03764306|Active Comparator|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
16431027|NCT03764293|Experimental|SHR-1210|SHR-1210+Apatinib
16431028|NCT03764293|Active Comparator|Control|Sorafenib
16431029|NCT03764280|No Intervention|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
16431030|NCT03764280|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
16431031|NCT03764267|Active Comparator|remifentanil|MAC group
16431032|NCT03764267|Active Comparator|general anesthetic|TIVA group
16431033|NCT03764241|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy
16431034|NCT03764241|Active Comparator|Vitamin K Antagonist|warfarin will be added in addition to dual antiplatelet therapy
16431035|NCT03764228|Experimental|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10^6, 2×10^6, 5×10^6 cell/kg, successively.
16431036|NCT03764215|Experimental|Group 1|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
16431401|NCT03761680|Active Comparator|Control Group|Patients receive ONS between meals or at their request as usual
16431037|NCT03764202|Other|CSEA，1μg/kg•d|"The puerpera received combined spinal epidural anesthesia
~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
16431038|NCT03764202|Other|CSEA，1.5μg/kg•d|"The puerpera received combined spinal epidural anesthesia
~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
16431039|NCT03764202|Other|GA，1μg/kg•d|"The puerpera received general anesthesia
~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
16431040|NCT03764202|Other|GA，1.5μg/kg•d|"The puerpera received general anesthesia
~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
16431041|NCT03764202|Other|CSEA，Epidural analgesia|"The puerpera received combined spinal epidural anesthesia
~Postoperative analgesia was performed with epidural analgesia
~Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
16431042|NCT03764189|No Intervention|en masse retraction only|anterior segment retraction on miniscrews without microosteoperforation
16431043|NCT03764189|Active Comparator|en masse retraction with alveocentesis|anterior segment retraction on miniscrews with microosteoperforation
16431044|NCT03764176|Active Comparator|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
16431045|NCT03764176|Experimental|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
16431046|NCT03764163|Experimental|Study Participants|Pulmonary Function Test, Questionnaires, CT scans, perfusion scan, ventilation scan, Xenon gas ventilation CT scan with hyperpolarized 3-Helium MRI Scan.
16431047|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2> 45 mmHg
16431048|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 <45 mmHg)
16431049|NCT03764137|Experimental|[89Zr]Panitumumab-PET/MRI patients|All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
16431050|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
16431051|NCT03764111||large mobile ultrasound system|the ultrasound transducer is based on piezoelectric technology.
16431052|NCT03764111||handheld ultrasound machine|The handheld device utilizes Capacitive micro-machined ultrasound transducers (CMUTs) instead of piezoelectric technology
16431053|NCT03764098|Experimental|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
16431054|NCT03764098|Placebo Comparator|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
16431055|NCT03764085|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
16431056|NCT03764085|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
16431057|NCT03764072|Experimental|VX-150|
16431058|NCT03764072|Placebo Comparator|Placebo|
16431059|NCT03764059|Experimental|Interventional|The experimental group (Filtek Bulk fill posterior restoration) .After restoration,subjects will return to site for follow up visit at 1 week and 1 year postoperative for further clinical assessments.
16431060|NCT03764059|Active Comparator|observational|The control group (Filtek™ Z350XT Universal Restorative which was approved by CFDA in 2010 and has been in the market for 5 years with some validated clinical data).After restoration,subjects will return to the site for follow up visits at 1 week and 1 year postoperative for for further clinical assessments.
16431061|NCT03764033|Experimental|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
16431062|NCT03764033|Active Comparator|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
16431063|NCT03764020|Experimental|Melatonin|"Intervention group1:
~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
16431064|NCT03764020|Placebo Comparator|Placebo|"Intervention group2 :
~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
16431066|NCT03763994||Control group 1|Never low back pain in the last 3 months
16431067|NCT03763994||Control group 2|occasionally (1-30days) low back pain in the last 3 months
16431068|NCT03763994||Low back pain group 3|frequently (31-60days) low back pain in the last 3 months
16431069|NCT03763994||Low back pain group 4|daily (61-90days) low back pain in the last 3 months
16431070|NCT03763981|Active Comparator|prolene seton|Prolene thread will be used as seton treatment for perianal fistulas
16431071|NCT03763981|Active Comparator|silk seton|Silk thread will be used as seton treatment for perianal fistulas
16431072|NCT03763955||PD patients|PD patients at 1-5 H&Y stage undergoes 4week Multidisciplinary Intensive Rehabilitation Treatment
16431073|NCT03763942|Experimental|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
16431074|NCT03763942|Placebo Comparator|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
16431075|NCT03763929|Experimental|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
16431076|NCT03763929|Placebo Comparator|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
16431077|NCT03763916|Active Comparator|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus [above the site of placental insertion], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus [in presence of the placenta] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
16431078|NCT03763916|Active Comparator|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter.
16431079|NCT03763903|Other|3D training|Basic laparoscopic skills (FLS tasks) training using 3D visualization
16431080|NCT03763903|Other|2D training|Basic laparoscopic skills (FLS tasks) training using 2D visualization
16431085|NCT03763864|Other|Inherited disorders|
16431086|NCT03763851|Experimental|Cannabis group|"Delta-9 Tetrahydrocannabidiol (THC) /Cannabidiol (CBD) ratio 1:1 capsule
~These capsules contain different cannabis formulations with low-dose and high-dose preparations according to the treatment group:
~Cannabis group low-dose capsule contains THC 1mg CBD 1mg
~Cannabis group high-dose capsule contains THC 2.5mg CBD 2.5mg"
16431087|NCT03763851|Placebo Comparator|Placebo group|"The placebo capsule will have no cannabis, it will look identical to the active treatment capsule, and it will also be prepared in low-dose and high-dose presentations."
16431088|NCT03763838|Experimental|Acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are known to affect physiology. Participants will also receive standard of care.
16431089|NCT03763838|Sham Comparator|Sham acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are not known to affect physiology. Participants will also receive standard of care.
16431090|NCT03763838|Other|Standard of care|Participants will receive standard of care only.
16431091|NCT03763825|Experimental|Intervention group|Patient will receive the Mini-AFTERc intervention after completion of primary breast cancer treatment.
16431092|NCT03763825|No Intervention|Control group|Patients will receive usual care after completion of primary breast cancer treatment.
16431093|NCT03763812|Other|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
16431094|NCT03763812|Other|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
16431095|NCT03763799|Experimental|multiplex PCR strategy|FilmArray® Pneumonia Panel plus
16431096|NCT03763799|Active Comparator|standard strategy|
16431097|NCT03763786|Experimental|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
16431098|NCT03763786|Active Comparator|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
16431099|NCT03763760|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
16431100|NCT03763760|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
16431101|NCT03763747|Experimental|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
16431102|NCT03763734|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
16431103|NCT03763734|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
16431104|NCT03763721|Experimental|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
16431105|NCT03763721|Active Comparator|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
16431106|NCT03763708|Experimental|Spinal Cord Stimulation|Each subject will be programmed to different settings.
16431107|NCT03763695||Retrospective control group|Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
16431436|NCT03761394|Experimental|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
16431108|NCT03763695||Prospective group|Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
16431109|NCT03763682|Experimental|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
16431110|NCT03763669|Experimental|Intervention|Pregnant women randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) and myo-inositol supplementation
16431111|NCT03763669|Placebo Comparator|Control|Pregnant women randomly assigned to receive (n. 40) only diet and folic acid (400 mcg per day)
16431112|NCT03763656|Experimental|Open Label|Novel oral solution formulation of hydroxyurea
16431113|NCT03763643|Experimental|Rituximab + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day 0 or -1 prior to kidney transplantation in addition to standard plasmapheresis.
16431114|NCT03763643|Placebo Comparator|Placebo + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day 0 or -1 prior to kidney transplantation in addition to standard plasmapheresis.
16431115|NCT03763630|Active Comparator|Intervention arm|House dust-mite SLIT
16431116|NCT03763630|Placebo Comparator|Control arm|Normal saline
16431117|NCT03763630|No Intervention|Observation cohort|ITEC observational cohort, no intervention administered
16431118|NCT03763617|Active Comparator|Test group|A d-ptfe membrane will be placed between the buccal bone and periosteum of an extraction socket during a 4 months healing time before it is surgically removed.
16431119|NCT03763617|No Intervention|Control group|The extraction socket will be left to heal naturally without a socket preservation intervention.
16431120|NCT03763591|Experimental|Psychological Skills Group (e.g., Active Intervention)|10-week Psychological Skills Group.
16431121|NCT03763578|Experimental|Licorice|licorice is one of the natural products that is listed by the Food and Drug Administration (FDA) as GRAS (generally regarded as safe) when used as food flavoring and sweetening agent which has an antimicrobial, anti-inflammatory and antiviral activity.
16431122|NCT03763578|Active Comparator|Chlorhexidine|"The gold standard of oral therapeutics is Chlorhexidine due to its prolonged broad- spectrum antimicrobial effect."
16431123|NCT03763578|No Intervention|Control Group|Participants in this group will follow only the standard preventive measures which is brushing twice a day after breakfast and before bed time and daily flossing interdentally before bed time. (No Mouthwash is used)
16431124|NCT03763565||Vaccinated group|Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
16431125|NCT03763565||Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
16431126|NCT03763539|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.
~The rest of the session at 22kv (full power)."
16431127|NCT03763539|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
16431128|NCT03763513|Active Comparator|ESWT|the first group:The group that will receive Extra corporeal shock wave therapy
16431129|NCT03763513|Experimental|ESWT+KT|the second group:The group that will receive Extra corporeal shock wave therapy + Kinesiotaping application
16431130|NCT03763500|No Intervention|Care as usual|"Regular care at participating hospitals:
~Extended written information and education of patients with atrial fibrillation."
16431131|NCT03763500|Active Comparator|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
16431132|NCT03763487|Experimental|Patients|Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling
16431133|NCT03763487|No Intervention|healthy blood donors|No intervention in this group.
16431134|NCT03763474|Experimental|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
16431135|NCT03763474|No Intervention|Control|
16431136|NCT03763461|Experimental|HFNC|HFNC will be started at flow of 40 L/min and FiO2 of 40%.
16431137|NCT03763461|Other|Oxygen Mask|Standard non-humidified oxygen therapy via an oxygen mask at 6 l/min will be performed.
16431138|NCT03763448|Experimental|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
16431139|NCT03763448|Active Comparator|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
16431140|NCT03763435||Antenatal Classes Received|Women who are involved into at least 3 comprehensive session of Antenatal pregnancy classes (educational) during the prenatal period.
16431141|NCT03763435||Without education|Groups are not randomized for not to give rise to ethical problems in order to maximize the community health care. Only women who are not involved into the educational classes due to their inaccessibility related to their own conditions or wishes.
16431142|NCT03763422|Experimental|Early Treatment arm|Radiotherapy + Temozolomide
16431143|NCT03763422|Active Comparator|Active surveillance arm|Treatment as per local practice
16431144|NCT03763409|Experimental|losartan|50 mg single-dose oral losartan
16431145|NCT03763409|Placebo Comparator|placebo|microcellulose placebo in identical capsule
16431146|NCT03763396|Experimental|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
16431147|NCT03763396|Experimental|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
16501408|NCT03281928|Placebo Comparator|High Sodium plus placebo|
16431148|NCT03763396|Experimental|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
16431149|NCT03763396|Experimental|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
16431150|NCT03763383||Free lateral arm flap|included patients who had free lateral Arm flap
16431151|NCT03763383||pedicled lateral arm flap|included patients who had pedicled lateral arm flap
16431152|NCT03763357|Experimental|Heat Therapy|Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.
16431153|NCT03763344|Experimental|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:
~the first cognitive assessment (Baseline),
~intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,
~a post-treatment cognitive assessment (Week 7), and
~a follow up cognitive assessment (Week 11)"
16431154|NCT03763344|No Intervention|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:
~the first cognitive assessment (baseline),
~seven weeks of no intervention,
~a post-treatment cognitive assessment (week 7), and
~a follow up cognitive assessment (week 11)"
16431155|NCT03763331|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks..
16431156|NCT03763331|Active Comparator|Heat Therapy|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
16431157|NCT03763318|Experimental|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
16431158|NCT03763318|Experimental|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
16431159|NCT03763318|Placebo Comparator|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
16431160|NCT03763305|Experimental|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3~5mcg/mL Propofol Fresenius and 3~5ng/mL and Remifentanil [Ultiva] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
16431161|NCT03763305|Experimental|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution [Sojourn] is used to maintain 1 age-related minimum alveolar concentration (MAC).
16431162|NCT03763305|Experimental|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane [Suprane] is used to maintain 1 age-related minimum alveolar concentration (MAC).
16431163|NCT03763292|Experimental|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
16431164|NCT03763292|No Intervention|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
16431165|NCT03763279|Experimental|Triclosan-coated barbed suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone barbed suture
16431166|NCT03763279|Experimental|Triclosan-coated monofilament suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone monofilament suture
16431167|NCT03763279|Sham Comparator|Monofilament suture|Abdominal wall closure will be performed using a monofilament suture
16431168|NCT03763266|Experimental|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
16431169|NCT03763266|Active Comparator|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
16431170|NCT03763253|Active Comparator|Control Arm: Standard of Care (SOC)|"Standard of Care (SOC) treatment as determined by treating physician (positive control) (androgen deprivation with or without docetaxel chemotherapy or other systemic standard of care treatment including but not limited to Abiraterone or Enzalutamide).
~Radiotherapy to the prostate in this arm is defined as cytoreductive (for symptom control) in high volume (>/=4) metastases or to mirror current accepted local radiotherapy dose regimens for men with low volume metastases (<4 metastases).
~Metastases directed therapy will not be permitted in the control arm. Palliative radiotherapy for symptom control or for prevention of fracture will be permitted as standard clinical practice."
16431171|NCT03763253|Active Comparator|Intervention Arm 1: Minimally Invasive Ablative Therapy (MIAT)|"MIAT to prostate in form of cryotherapy or high intensity focused ultrasound (HIFU), in addition to SOC systemic treatment. No local prostate radiotherapy will be given as part of this intervention. Radiotherapy can be given subsequently for palliative reasons.
~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
16431172|NCT03763253|Active Comparator|Intervention Arm 2: Radical Therapy|"Radical therapy in form of prostatectomy (any approach) or external beam radiotherapy (radical dose) in addition to SOC systemic treatment. Modality based on physician and patient preference and patient co-morbidities.
~For patients undergoing radical prostatectomy no local prostate radiotherapy will be given as part of the intervention. Radiotherapy can be given subsequently for palliative reasons.
~Radical radiotherapy doses in this arm will be higher than SOC.
~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
16431173|NCT03763240|Active Comparator|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
16431276|NCT03762486|Active Comparator|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
16431174|NCT03763240|Placebo Comparator|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
16431175|NCT03763227|Active Comparator|Carbonic Anhydrase Inhibitor (CAI) Arm|Patients who have received carbonic anhydrase inhibitor (CAI) therapy namely oral acetazolamide or topical brinzolamide
16431176|NCT03763227|Experimental|Intravitreal ranibizumab (IVR) arm|"Intravitreal ranibizumab (IVR) injection administered to patients who have not shown adequate response or who have not tolerated CAI therapy
~IVR therapy = Three 0.5mg IVR injection at monthly intervals"
16431177|NCT03763214|Experimental|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
16431178|NCT03763214|Active Comparator|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
16431179|NCT03763201||rheumatoid arthritis|recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
16431180|NCT03763201||control group|age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
16431181|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
16431182|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
16431183|NCT03763175|Active Comparator|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
16431184|NCT03763175|Active Comparator|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
16431185|NCT03763175|Placebo Comparator|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
16431186|NCT03763162|Experimental|Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)|Patients receive daratumumab IV over 3.5-6.5 hours on days 1, 8, and 15, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and PO on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16431187|NCT03763149|Experimental|IBI188|"Part 1: Accelerated Titration Phase 0.1 mg/kg IV; QW 0.3 mg/kg IV QW; 1 mg/kg IV QW
~Part 2 : Dose Escalation Phase with initial fixed priming dose Priming dose of 1mg/kg on C1D1 followed by 3 mg/kg IV QW; 10 mg/kg IV QW; 20 mg/kg IV QW; 30 mg/kg IV QW."
16431188|NCT03763136|Experimental|hPSC-CM Therapy|Procedure: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
16431189|NCT03763136|Sham Comparator|Control|Procedure: Coronary artery bypass grafting surgery only.
16431190|NCT03763123|Experimental|Sevacizumab +Chemotherapy Combined chemotherapy drug including|Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.
16431191|NCT03763110|Experimental|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
16431192|NCT03763110|Active Comparator|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
16431193|NCT03763097||participants|Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
16431194|NCT03763084|Experimental|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
16431195|NCT03763084|Active Comparator|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
16431196|NCT03763071||Participants|Pregnant women in the 2nd or 3th trimester Patient-reported scales to measure sleep disorders
16431197|NCT03763058|Other|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
16431198|NCT03763045|Experimental|Sildenafil 25|Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.
16431199|NCT03763045|Experimental|Sildenafil 50|Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.
16431200|NCT03763045|Placebo Comparator|Placebo|Twenty hemodialysis patients will receive a placebo tablet daily for 3 months.
16431201|NCT03763032|Experimental|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
16431202|NCT03763019|Active Comparator|Respiratory rehabilitation|"Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
~Respiratory exercises 30 minutes, once daily, (incentive spirometric trainer, forced expiration, percussion, postural drainage etc.)"
16431338|NCT03762096|Experimental|Resveratrol|
16431339|NCT03762096|Placebo Comparator|Placebo|
16431203|NCT03763019|Placebo Comparator|Conventional rehabilitation|Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
16431204|NCT03763006|Experimental|Ocudox lid wiped|
16431205|NCT03763006|Active Comparator|Povidone Iodine|
16431206|NCT03762993|Experimental|Healthy Adults|Participants will complete vocal rest and controlled phonation
16431207|NCT03762993|Experimental|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
16431208|NCT03762980|Experimental|Right hemiplegic patients|
16431209|NCT03762980|Experimental|Left hemiplegic patients|
16431210|NCT03762967|Experimental|Lipoaspiration and SVF introduction I.|Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
16431211|NCT03762967|Active Comparator|Standard therapy I.|Patients with azoospermia that introduce with Standard therapy only.
16431212|NCT03762967|Experimental|Lipoaspiration and SVF introduction II|Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
16431213|NCT03762967|Active Comparator|Standard therapy II.|Patients with oligospermia that introduce with Standard therapy only.
16431214|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
16431215|NCT03762941||Elderly patients acutely admitted|Elderly patients (aged ≥ 65 year) admitted to emergency departments at the Hospital of Southern Jutland or Odense University
16431216|NCT03762928|Experimental|midazolam/efavirenz|
16431217|NCT03762928|Experimental|PF-06651600/midazolam/efavirenz|
16431218|NCT03762915|Experimental|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
16431219|NCT03762915|No Intervention|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
16431220|NCT03762889|Experimental|Eyeprotx™ Group|This group of participants will use the Eyeprotx™ General Anesthesia Protective Goggles when intubated perioperatively under general anesthesia.
16431221|NCT03762889|Active Comparator|Eyelid Tape Group|This group of participants will be receiving the eyelid tape as the preventative measure when intubated perioperatively under general anesthesia.
16431222|NCT03762889|Active Comparator|Eye Ointment Group|This group of participants will be receiving the ointment application when intubated perioperatively under general anesthesia.
16431223|NCT03762863|Experimental|Appropriate application of a CAT tourniquet|All study subjects attended an American College of Surgeons Stop the Bleed Basic course with live training by approved instructors. 6 months after participation in the Stop the Bleed class volunteers study subjects are randomly solicited to return for a refresher session. During this refresher session the volunteer study subjects are observed to determine if they have retained tourniquet application skills and to what degree they have retained them. A 10 point check list will be used to evaluated tourniquet application skill retention.
16431224|NCT03762850|Experimental|sparsentan|Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg and continue treatment to Week 110.
16431225|NCT03762850|Active Comparator|irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
16431226|NCT03762837||Exposure group：Benign gallbladder disease|Patients with benign gallbladder diseases, such as gallbladder polyps, gallstones, etc.
16431227|NCT03762837||Non-exposed group: healthy people|Patients without benign gallbladder diseases
16431228|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
16431229|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
16431230|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
16431231|NCT03762824|Active Comparator|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
16431232|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
16431233|NCT03762811|Other|NanoFUSE® PMCF|NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.
16431234|NCT03762798|Experimental|Treatment|All participants will receive the Bridge device.
16431235|NCT03762785|Active Comparator|nebulized dexmedetomidine 2ug/kg|inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
16431236|NCT03762785|Active Comparator|nebulized dexmedetomidine 3ug/kg|inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
16431237|NCT03762772|Experimental|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
16431238|NCT03762759|Experimental|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
16431239|NCT03762759|Active Comparator|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
16431240|NCT03762746|Active Comparator|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
16431241|NCT03762746|Sham Comparator|Control|Control group is received treatment as usual
16431244|NCT03762720|Experimental|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
16431245|NCT03762694|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
16431246|NCT03762694|No Intervention|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
16431247|NCT03762681|Experimental|Part 1: Single Ascending Dose, HV|Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).
16431248|NCT03762681|Experimental|Part 2a: Multi-dose, CHB|Participants with chronic hepatitis B will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.
16431249|NCT03762681|Experimental|Part 2b: Multi-dose, CHB (Optional)|Additional study arm to open based on data collected from Part 2a. Participants with chronic hepatitis B will be administered different doses and frequencies of RO7239958 or placebo SC.
16431250|NCT03762668|Other|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
16431251|NCT03762668|Other|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
16431252|NCT03762655|Experimental|Neuro-Spinal Scaffold Arm|Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery.
16431253|NCT03762655|No Intervention|Comparator Arm|Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold.
16431254|NCT03762642||Mastectomy|
16431255|NCT03762642||Breast-Conserving Surgery|
16431256|NCT03762629|Experimental|Obese intervention group|Obese children were received exercise and diet intervention for 6 weeks.
16431257|NCT03762629|No Intervention|Normal weight control group|Normal weight children were recruited as a control group without any intervention.
16431258|NCT03762616|Experimental|Micro-Ultrasound Biopsy|
16431259|NCT03762616|Experimental|MRI Targeted Biopsy|
16431260|NCT03762603|Experimental|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
16431261|NCT03762590|Experimental|Doxy.me plus Color Genomics Arm (Arm 1)|"Participants in this arm will receive genetic education through an online platform called Doxy.me
~The Doxy.me session will consist of two parts: 1) a pre-recorded genetic education video 2) a live interactive video conferencing session with a GENERATE genetic counselor
~After completing the Doxy.me session and post intervention questionnaires, participants will be directed to the Color Genomics study portal where they may elect to review Color Genomics' genetic education content or proceed directly to order genetic testing
~Intervention is Doxy.me genetic education +/- genetic education via Color Genomics website"
16431262|NCT03762590|Experimental|Color Genomics Only Arm (Arm 2)|"Participants in this arm will access genetic education on the Color Genomics website which includes both written information and an educational video
~After accessing the Color Genomics website, participants may elect to review educational content or proceed directly to order genetic testing
~Intervention is genetic education via Color Genomics website"
16431263|NCT03762577|Experimental|Training Group|Training group will attend ground-based walking training under the supervision of a physiotherapist for 2 days and 30 minutes a week. Patients will walk for 1-2 days in a week without supervision.
16431264|NCT03762577|No Intervention|Control Group|Patient education will be given and no intervention will be made.
16431265|NCT03762564|Experimental|Arm A (Paclitaxel + Ramucirumab)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 plus Ramucirumab 8 mg/kg as 1 hour intravenous infusion on day 1 and 15 qd 28
16431266|NCT03762564|Active Comparator|Arm B (control arm)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 qd 28
16431267|NCT03762551|Experimental|vitiligo|assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
16431268|NCT03762551|Active Comparator|psoriasis|assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
16431269|NCT03762551|Other|controls|assess the level of JAK1 in controls
16431270|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
16431271|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
16431272|NCT03762525|Other|ECG gated CTA pre and post operative at Gore IBE|To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component. Each patient will have an ECG gated CTA scan before the operation and 6-8 weeks after operation, in stead of a regular CT scan.
16431273|NCT03762525|Other|ECG gated CTA post operative at Gore IBE and Cook IBD|To compare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device. Each patient will have an ECG gated CTA after the operation, at the first doctor's appointment, in stead of a regular CT scan.
16431274|NCT03762499|Active Comparator|Prospective participants|250 participants will be recruited prospectively during the hypertension clinic, where a full set of data will be collected from each participant as part of their standard hypertension clinical service. An additional echocardiography scan will be performed for this cohort by the study team, if the scan has not been performed as a part of the clinical care service
16431275|NCT03762499|No Intervention|Retrospective participants|500 participants will be recruited retrospectively, and no additional echocardiography scan will be required for them.
16431277|NCT03762486|Active Comparator|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
16431278|NCT03762486|No Intervention|No stimulation|No stimulation was performed to the patients in the control group.
16431279|NCT03762473|Experimental|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of < 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
16431280|NCT03762473|Active Comparator|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
16431281|NCT03762460|Experimental|Online eHealth Tool|Participants randomized to this group will use a personally-owned smartphone, tablet, or computer to access the online eHealth tool.
16431282|NCT03762460|Placebo Comparator|Informational website (control)|Participants randomized to this group will receive information about online resources for mental health
16431283|NCT03762447|Experimental|INCB086550|
16431284|NCT03762434|Active Comparator|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
16431285|NCT03762434|Active Comparator|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
16431286|NCT03762421|Experimental|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
16431287|NCT03762421|Active Comparator|Control Arm|The control group will receive 5 routine training induction sessions.
16431288|NCT03762408|Experimental|ENKO 1|ENKO 1 administered by single intra-articular injection.
16431289|NCT03762408|Active Comparator|Durolane|Durolane administered by single intra-articular injection.
16431290|NCT03762395|Experimental|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
16431291|NCT03762395|Placebo Comparator|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
16431292|NCT03762382|Experimental|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
16431293|NCT03762382|Experimental|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
16431294|NCT03762382|Placebo Comparator|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
16431295|NCT03762369|Experimental|CKD-351|Latanoprost+D930
16431296|NCT03762369|Active Comparator|Latanoprost|
16431297|NCT03762369|Active Comparator|D930|
16431298|NCT03762343|Experimental|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
16431299|NCT03762343|Placebo Comparator|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
16431300|NCT03762330|Active Comparator|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
16431301|NCT03762330|No Intervention|Usual care|COPD participants receiving only usual care
16431302|NCT03762317|Active Comparator|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
16431303|NCT03762317|Placebo Comparator|Placebo|Placebo solution will be given for the duration of the study period
16431304|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
16431305|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
16431340|NCT03762083|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of BV.
16431307|NCT03762278|Experimental|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
16431308|NCT03762278|Active Comparator|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
16431309|NCT03762278|Placebo Comparator|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
16431310|NCT03762278|Placebo Comparator|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
16431311|NCT03762265|Experimental|Experimental|
16431312|NCT03762265|Placebo Comparator|Placebo|
16431313|NCT03762252|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
16431314|NCT03762252|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
16431315|NCT03762239|Active Comparator|Purified air|Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
16431316|NCT03762239|Sham Comparator|Normal air|Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
16431317|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
16431318|NCT03762213|Experimental|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.
~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.
~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.
~The entire duration of the experience will be kept at 10 minutes."
16431319|NCT03762213|Placebo Comparator|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
16431320|NCT03762200|Other|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
16431321|NCT03762187|Experimental|Self-affirmation|Participants completed a written self-affirmation manipulation before completing the standard counseling provided by the clinic.
16431322|NCT03762187|Active Comparator|Positive living counseling|Participants completed the standard counseling provided by the clinic (treatment as usual control condition).
16431323|NCT03762161|Experimental|Intervention TAS-102|
16431324|NCT03762148|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
16431325|NCT03762148|Experimental|ferrous sulphate|labelled iron as ferrous sulphate
16431326|NCT03762148|Experimental|ferric pyrophosphate|labelled iron as ferric pyrophosphate
16431327|NCT03762148|Experimental|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
16431328|NCT03762148|Experimental|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
16431329|NCT03762148|Experimental|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
16431330|NCT03762148|Experimental|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
16431331|NCT03762148|Experimental|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
16431332|NCT03762148|Experimental|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
16431333|NCT03762135|Experimental|Full version of the LIITah App.|Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
16431334|NCT03762135|Active Comparator|Partial App. (ELI and SNAP only)|Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.
16431335|NCT03762122|Experimental|Rogaratinib|Rogaratinib is given at a dose of 600 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.
16431336|NCT03762109|Experimental|Dantrolene Group|Patients will receive 25 mg of Dantrolene orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
16431337|NCT03762109|Placebo Comparator|Placebo Oral Tablet Group|Patients will receive a 25 mg of a placebo pill orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
16431342|NCT03762044|Experimental|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
16431343|NCT03762044|Active Comparator|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
16431344|NCT03762031|Experimental|GC4711 30mg|
16431345|NCT03762031|Experimental|GC4711 60mg|
16431346|NCT03762031|Experimental|GC4711 90mg|
16431347|NCT03762031|Experimental|GC4711 120mg|
16431348|NCT03762031|Placebo Comparator|Placebo|
16431349|NCT03762031|Experimental|GC4711 75mg|
16431350|NCT03762031|Experimental|GC4711 105mg|
16431351|NCT03762018|Active Comparator|Bevacizumab plus chemotherapy|Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
16431352|NCT03762018|Experimental|Atezolizumab plus bevacizumab plus chemotherapy|Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
16431353|NCT03762005|Experimental|CRT guided resuscitation|Fluid resuscitation will be aimed at normalizing capillary refill time (CRT) during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of CRT until achieving normal values, or the patient becomes fluid unresponsive, or a safety issue develops.
16431354|NCT03762005|Active Comparator|Lactate guided resuscitation|Fluid resuscitation will be aimed at normalizing or decreasing lactate levels by more than 20% every 2 hours during the intervention during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of lactate every 2 hours until reaching target, or the patient becomes fluid unresponsive, or a safety issue develops.
16431355|NCT03761992|Active Comparator|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
16431356|NCT03761992|Placebo Comparator|Placebo|Placebo Pill
16431357|NCT03761979|Active Comparator|Strontium dose of 170 mg|The Sponsor provided each 170 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
16431358|NCT03761979|Active Comparator|strontium dose of 340 mg|The Sponsor provided each 340 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
16431359|NCT03761979|Active Comparator|Strontium dose of 680 mg|The Sponsor provided each 680 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
16431360|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
16431361|NCT03761953|Experimental|Oritavancin|Single IV infusion of 1200mg of oritavancin
16431362|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
16431363|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
16431364|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
16431365|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
16431366|NCT03761927|Active Comparator|Hearing Aid without NR enabled.|Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
16431367|NCT03761927|Experimental|Hearing Aid with NR(1)|Hearing Aid with Noise Reduction I (NR) enabled.
16431368|NCT03761927|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
16431369|NCT03761914|Experimental|Colorectal Cancer (CRC)|"N=20;
~Metastatic CRC priorly Rxed with ≥2 lines of ChemoRx (3rd/4th line); must have documented disease progression post last administration of or intolerance to standard therapies, which must have included a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS wild-type, cetuximab or panitumumab. Prior regorafenib or trifluridine/tipiracil is allowed, but not mandated;
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
16431399|NCT03761693|Experimental|Mild MCADD|"Mild MCADD will be defined by the remaining ACADM genotype variants and residual MCAD enzyme activity ≥ 10%.
~Interventions include fasting challenges at two and six months of age."
16431400|NCT03761680|Experimental|MEDPass Group|Allocation of ONS in the MEDPass mode
16431370|NCT03761914|Experimental|Ovarian Cancer (OvC)|"N=20;
~Metastatic OvC priorly Rxed with ≥1 line of platinum-containing ChemoRx (2nd/3rd line) with either relapse or disease refractoriness; interval surgery permitted, as long as subjects have measurable disease by imaging and concomitant CA-125 increase, and/or biopsy showing OvC; must have either received (or been offered) bevacizumab therapy; those with BRCA germline mutations (gBRCA mut) must have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors.
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
16431371|NCT03761914|Experimental|Small Cell Lung Cancer (SCLC)|"N=20;
~Advanced SCLC priorly Rxed with 1 line of ChemoRx (2nd line); must have measurable disease by imaging after they progressed or were resistant to 1 prior systemic therapy; asymptomatic or treated brain metastases are allowed;
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
16431372|NCT03761914|Experimental|Triple Negative Breast Cancer (TNBC)|"N=15;
~TNBC priorly Rxed with 1 line of ChemoRx with residual or recurrent disease (2nd line); estrogen (ER) and progesterone receptor (PgR) negative, and HER2(-) by IHC AND HER2 non-amplified by fluorescence in situ hybridization; weak IHC positivity for ER or PgR (i.e., < 5%) eligible; must have undergone 2nd line therapy after 1st line Rx could include: neoadjuvant Rx if macroscopic disease still present after surgery OR adjuvant Rx but only if relapse occurred > 6 months from the start of pembrolizumab (P);
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
16431373|NCT03761914|Experimental|Acute Myelogenous Leukemia (AML)|"N=15;
~Pts with AML who are not eligible for allogeneic stem cell transplant and have been able to achieve morphological partial remission (PR) as their best ever response at the time of completion of their 4th cycle of upfront Rx with HMA; prior initial upfront hydroxyurea or leukapheresis Rx or history of induction early failure after up to 2 cycles of ChemoRx (7+3 or similar regimen) with seamless immediate transitioning to HMA Rx eligible; must remain on HMA therapy throughout the trial.
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
16431374|NCT03761901||Patients with EGFR mutation positive NSCLC|
16431375|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
16431376|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
16431377|NCT03761875|Other|CHB patients|a blood sample is done during a follow-up visit
16431378|NCT03761875|Other|Control group|a blood sample
16431379|NCT03761862||Control|The control group with bilateral tubal ligation
16431380|NCT03761862||Neural Therapy|The treatment group
16431384|NCT03761836|Experimental|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
16431385|NCT03761823||Healthy subjects|Healthy subjects
16431386|NCT03761823||Patients|Patients extubated after > 5 days of mechanical ventilation.
16431387|NCT03761810|Experimental|S6G5T-3|topical cream
16431388|NCT03761810|Placebo Comparator|S6G5T-8|topical cream
16431389|NCT03761797||Subjects with type 2 Diabetes Mellitus|
16431390|NCT03761784|Experimental|S6G5T-3|topical cream
16431391|NCT03761784|Placebo Comparator|S6G5T-8|topical cream
16431392|NCT03761771||colonoscopy withdrawal with the ADS monitoring|The ADS automatically initiated once the ileocecal valve was pictured by the colonoscopist or the colonoscopist recorded any image of colon during the insertion. When colonoscopists withdrew the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the ADS, which made it feasible to identify and classify lesions in real time.
16431393|NCT03761758|Experimental|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
16431394|NCT03761758|Experimental|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
16431395|NCT03761758|Experimental|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
16431396|NCT03761732|Experimental|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
16431397|NCT03761706|Experimental|Intervention Cohort|This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
16431398|NCT03761693|Experimental|Severe/classical MCADD|"Severe MCADD will be defined by ACADM mutations associated with clinical ascertainment or residual MCAD enzyme activity < 10 %, as defined previously (Touw et al., 2012).
~Interventions include fasting challenges at two and six months of age."
16431402|NCT03761667|Experimental|NBI|The group of NBI inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
16431403|NCT03761667|No Intervention|White light endoscopy (WLE)|The group of WLE inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
16431404|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
16431405|NCT03761628|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
16431406|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
16431407|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).
~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.
~The Serum selenium concentrations are 18-40μg/L."
16431408|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.
~The Serum selenium concentrations are more than 40μg/L."
16431409|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.
~The Serum selenium concentrations are less than 18μg/L."
16431410|NCT03761589|Experimental|AFL Intervention Group|The AFL intervention consisted of twice a week physical activity and nutrition sessions for children and twice a week educational and physical activity sessions for parents. Each session lasted 90 minutes and all sessions were conducted in a municipal recreation center. The child program was delivered in English while the parent program was delivered in separate English-only or Spanish-only classes.
16431411|NCT03761589|Other|Wait-List Control Group|The wait-list control group received the 12-week AFL intervention after all follow-up data had been completed.
16431412|NCT03761550||Stage 2|The Process Implementation Stage
16431415|NCT03761524|Experimental|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
16431416|NCT03761524|Active Comparator|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
16431417|NCT03761511|Active Comparator|Treatment arm|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
16431418|NCT03761511|Placebo Comparator|Placebo arm|Matching Placebo (capsules) once daily
16431419|NCT03761498||Normal Growth|Require less than or equal to 110 kcal/kg/day to maintain growth curve
16431420|NCT03761498||Slow Growth|Require more than 110 kcal/kg/day to maintain growth curve
16431421|NCT03761485|Experimental|Dentifrice 750 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
16431422|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF neutral|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
16431423|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
16431424|NCT03761472|Active Comparator|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
16431425|NCT03761472|Active Comparator|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
16431426|NCT03761472|No Intervention|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
16431427|NCT03761472|No Intervention|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
16431428|NCT03761446|Experimental|Older adults with Type 2 Diabetes|Male and female older adults between the ages 65-80 with type 2 diabetes
16431429|NCT03761446|Experimental|Older adults without Type 2 Diabetes|Male and female older adults between the ages 65-80 without type 2 diabetes
16431430|NCT03761433||SPI group|All patients who received the liver resection surgery will receive surgical pleth index
16431431|NCT03761420||breast cancer postoperative|got surgery for breast cancer in St Olavs Hospital, Trondheim, during 2004-2013
16431432|NCT03761407|Experimental|Group 1 (100 mg GRT0151Y)|"The dose of 100 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 100 mg. On Day 5 the last dose of 100 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group."
16431433|NCT03761407|Experimental|Group 2 (125 mg GRT0151Y)|"The dose of 125 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 125 mg. On Day 5 the last dose of 125 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group"
16431434|NCT03761407|Experimental|Group 3 (150 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 150 mg. On Day 5 the last dose of 150 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group"
16431435|NCT03761407|Experimental|Group 4 (225 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the dose of 225 mg will be administered twice (b.i.d.). On Day 5 the last dose of 225 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group"
16501530|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
16431437|NCT03761394|Active Comparator|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
16431438|NCT03761394|Experimental|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
16431439|NCT03761394|No Intervention|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
16431440|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
16431441|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
16431442|NCT03761368|Experimental|RIPC group|The RIPC group underwent Remote Ischemic Preconditioning.
16431443|NCT03761368|Sham Comparator|Control group|Patients from control group had sham Remote Ischemic Preconditioning.
16431444|NCT03761355||medical student of 6th Year|Students of medical faculty of 6th Year in Medical University of Bialystok, Poland.
16431445|NCT03761342|No Intervention|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
16431446|NCT03761342|Experimental|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
16431447|NCT03761342|Experimental|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
16431448|NCT03761329|Active Comparator|Bier's block|Upperarm intravenous regional anesthesia (Bier's block) with lidocaine 0.5% 40ml
16431449|NCT03761329|Experimental|Mini-Bier's block|Forearm intravenous regional anesthesia (mini-Bier's block) with lidocaine 0.5% 25ml
16431450|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
16431451|NCT03761303|Active Comparator|active rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
16431452|NCT03761303|Sham Comparator|sham rTMS|Patients in the control group receive sham rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
16431453|NCT03761290||Pseudphypoparathyroidism type 1A (PHP1A)|Case
16431454|NCT03761290||Pseudopseudohypoparathyroidism (PPHP)|Case
16431455|NCT03761290||Controls|Matched control group
16431457|NCT03761264|Experimental|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
16431458|NCT03761264|Active Comparator|Intra-canal Pulpdent|Single visit placement of Pulpdent
16431459|NCT03761264|Active Comparator|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
16431460|NCT03761251|Experimental|Pet Fish|Participants will be instructed to partner thrice daily and once weekly fish care activities with diabetes care activities for 3 months
16431461|NCT03761238|Experimental|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
16431462|NCT03761238|Active Comparator|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
16431463|NCT03761225|Experimental|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
16431464|NCT03761225|Placebo Comparator|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
16431465|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
16431466|NCT03761212||Healthy controls|Age and sex matched healthy controls
16431467|NCT03761199|Experimental|a group of patients with AD|15 people with clinically diagnosed atopic dermatitis (AD), established on the basis of criteria Hanifin and Rajka
16431468|NCT03761199|Other|control group|15 healthy persons which will form the control group
16431469|NCT03761186|Active Comparator|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
16431470|NCT03761186|Experimental|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
16431471|NCT03761186|Experimental|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
16431472|NCT03761173||FlowTriever|Mechanical thrombectomy for pulmonary embolism
16431473|NCT03761173||Conservative Therapy Sub-Study|Anticoagulation medication for pulmonary embolism (as directed by treating physician)
16431474|NCT03761160|Experimental|Mobile Health App|"The developed mobile health app will include the following facets:
~Physical activities
~Dietary regimen.
~The physical activities facet will encourage patients to engage in physical activities, with daily prompts, encouragement, and tips.
~Users will be asked to record the type of physical activity they engaged in during the week, and for how long.
~The dietary aspect will ask patients to log what they ate during the day and to rate how 'healthy' it is"
16431475|NCT03761160|Active Comparator|Usual Care|Usual care per hospital guideline
16431476|NCT03761147|Experimental|Paula Method|
16431477|NCT03761147|No Intervention|Standard of Care|
16431478|NCT03761134|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
16433302|NCT03748940|Experimental|Part B: LY3074828|LY3074828 administered SC
16431479|NCT03761134|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
16431480|NCT03761134|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
16431481|NCT03761121|Experimental|Primary Testing Group|"This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes
~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution
~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
16431482|NCT03761121|Experimental|Software Testing Group|"Participants will receive hour research-only scan
~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution
~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
16431483|NCT03761108|Experimental|REGN5458|Phase 1: Cohorts of multiple REGN5458 dose levels Phase 2: Until disease progression or other discontinuation criterion is met
16431486|NCT03761056|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, axicabtagene ciloleucel
16431487|NCT03761043|No Intervention|Pre-Intervention Arm|The nurses will have not been exposed to the behavior change intervention.
16431488|NCT03761043|Experimental|Post-Intervention Arm|The nurses will have been exposed to the behavior change intervention.
16431489|NCT03761030|Experimental|L-DOPA Arm|Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose
16431490|NCT03761030|Placebo Comparator|Placebo Arm|Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.
16431491|NCT03761017|Experimental|MGD019|Bispecific DART protein binding PD-1 and CTLA-4
16431492|NCT03761004|Experimental|WD-1603 single dose|"WD-1603 single dose:
~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
16431493|NCT03761004|Experimental|WD-1603 BID dose|"WD-1603 BID dose:
~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.
~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
16431494|NCT03761004|Active Comparator|Sinemet single dose|"Sinemet single dose:
~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
16431495|NCT03760991|Experimental|Insulin glargine (U300)|Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin
16431496|NCT03760978||dex group|Critically ill patients <18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
16431497|NCT03760965|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
16431498|NCT03760965|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
16431499|NCT03760965|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
16431500|NCT03760939|Experimental|Ambulatory care|Colorectal surgery in ambulatory care
16431501|NCT03760939|Other|Standard hospitalization|Colorectal surgery with standard hospitalization for retrospective patients who benefit from the ERAS program, selected by statistical matching.
16431502|NCT03760926|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
16431503|NCT03760913|Experimental|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
16431504|NCT03760913|Experimental|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
16431505|NCT03760913|Placebo Comparator|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
16431506|NCT03760913|Placebo Comparator|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
16431507|NCT03760900|Experimental|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
16431508|NCT03760887|Sham Comparator|No Home Sensory training|Patients who perform a home exercise program only
16431509|NCT03760887|Experimental|Home sensory training|Patients who perform home exercise and home sensory training
16431510|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
16431511|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
16433303|NCT03748940|Experimental|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
16431512|NCT03760861|Experimental|Prototype Microcapsule Treatment Arm|Intervention by placement of prototype weight-loss microcapsule in the stomach. Subjects will have a weight-loss microcapsule deployed endoscpically in the stomach. The intragastric balloon in the capsule will be inflated using an external magnet..
16431513|NCT03760848|Other|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
16431514|NCT03760835|Experimental|Dual-release hydrocortisone|
16431515|NCT03760835|Active Comparator|Conventional glucocorticoids|
16431516|NCT03760822|Experimental|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
16431517|NCT03760822|Active Comparator|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
16431518|NCT03760809|Experimental|group A|Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
16431519|NCT03760809|Experimental|group B|Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia
16431520|NCT03760796|Experimental|Corrie Health Digital Platform group|Receives the Corrie Health intervention plus the standard of care
16431521|NCT03760783|Other|Effect of microgravity on human sperm|Simulated microgravity flight
16431522|NCT03760770|Experimental|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
16431523|NCT03760770|Experimental|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
16431524|NCT03760757|Experimental|PCSO-524® (no krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. Amounts per day equal to 800 mg olive oil, 400 mg lipid extract (~58 mg EPA and 44 mg DHA) and 1.8 mg vitamin E (d-alpha-tocopherol).
16431525|NCT03760757|Experimental|ESPO-572® (75% PCSO-524®, 25% krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
16431526|NCT03760744|Experimental|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
16431527|NCT03760744|Active Comparator|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
16431528|NCT03760731|Experimental|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
16431529|NCT03760731|Active Comparator|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
16431530|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 1|40 ml of preservative-free 1% chloroprocaine
16431531|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 2|40 ml of preservative-free 2% chloroprocaine
16431532|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 3|40 ml of preservative-free 3% chloroprocaine
16431533|NCT03760705||Coronary Artery Disease|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)
~Clinical, administrative, pharmacy, financial data collected by each participating hospital
~Administrative data collected by the Ministry of Health"
16431534|NCT03760705||Heart Failure|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)
~Clinical, administrative, pharmacy, financial data collected by each participating hospital
~Administrative data collected by the Ministry of Health"
16431535|NCT03760705||Atrial Fibrillation|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)
~Clinical, administrative, pharmacy, financial data collected by each participating hospital
~Administrative data collected by the Ministry of Health"
16431536|NCT03760692|Active Comparator|Group i-gel|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
16431537|NCT03760692|Experimental|Group Ambu Auragain|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
16431538|NCT03760679|Active Comparator|Laryngeal mask Supreme|Device: Laryngeal mask Supreme
16431539|NCT03760679|Experimental|i-gel|Device: i-gel
16431540|NCT03760666|Experimental|Brequinar|Brequinar dosed orally. Multiple doses.
16431541|NCT03760666|Other|Brequinar + Ribavirin|Subjects in Cohort 2 may roll over to add ribavirin dosing; subjects in Cohort 3 will start with brequinar alone then add ribavirin dosing.
16431542|NCT03760653|Experimental|Physical Exercise and probiotic group|The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
16431543|NCT03760653|Experimental|Probiotic group|Participants will follow their usual sedentary lifestyle (i.e to practice less than 3 days a week of physical exercise, as is specified in the inclusion criteria). They will take the probiotic supplementation at the established dose. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum
16431544|NCT03760653|Placebo Comparator|Placebo group|They will follow their sedentary lifestyle. Placebo probiotic will consist of a maltodextrin capsule.
16433304|NCT03748927||1/ Cohort 1|Subjects with FL-HCC.
16431545|NCT03760640|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
16431546|NCT03760640|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
16431549|NCT03760614|Experimental|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
16431550|NCT03760601|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
16431551|NCT03760601|Experimental|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
16431552|NCT03760588|Experimental|Sacubitril/valsartan|Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.
16431553|NCT03760588|Placebo Comparator|Placebo|Matched to the comparator.
16431554|NCT03760575|Experimental|Pembrolizumab with image-guided surgery and chemotherapy|
16431555|NCT03760549||Extension of NasoVAX high dose|A serum sample will be collected from each eligible subject who received NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201 for evaluation of influenza hemagglutination assay against influenza A/California/07/2009(H1N1), a strain homologous to the one used for NasoVAX (monovalent AdcoCA09.HA). Ad5 antibody neutralization assay may also be performed.
16431556|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
16431557|NCT03760523|Experimental|Minnelide Dose Escalation|A 3+3 design will be used. The first 3 patients will be treated at dose level 1. If none experience a Dose Limiting Toxicity (DLT), the next 3 patients will be treated at dose level 2. If a DLT is observed in 1 out of 3 patients at dose level 1, up to an 3 more patients will be enrolled and treated at that dose level. If 2 patients at dose level have DLTs, dosing will be lowered to dose level -1 (.5 mg daily, taken orally). If 2 or more of the up to 6 patients at any dose level have DLTs, the preceding dose will be declared the Maximum Tolerated Dose (MTD). If more than 1 DLT occurs at Dose Level -1, the investigators will consider stopping the study. Once the MTD has been established, an additional 10 patients will be enrolled at this level to better characterize safety and tolerability.
16431558|NCT03760510|Experimental|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
16431559|NCT03760510|Experimental|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
16431560|NCT03760497|Experimental|CIV Group|Temporary Restoration with Glass Ionomer (Equia Forte® - GC Corporation, Tokyo, Japan) for 30 days + Restoration in Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA).
16431561|NCT03760497|Experimental|Composite Resin Group|Restoration with Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, United States).
16431562|NCT03760497|Experimental|Composite Resin Group + Laser|Composite Resin Restoration (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA) + Application of Diode Laser.
16431563|NCT03760484|Experimental|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
16431564|NCT03760471|Experimental|Collaborative palliative and oncology care|
16431570|NCT03760445|Experimental|Part 1 - first line (1L) AML|1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
16431571|NCT03760445|Experimental|Part 1 - relapsed/refractory (R/R) AML|R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
16431572|NCT03760445|Experimental|Part 2 - Expansion Cohort 1|1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
16431573|NCT03760445|Experimental|Part 2 - Expansion Cohort 2|1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
16431574|NCT03760445|Experimental|Part 2 - Expansion Cohort 3|1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
16431575|NCT03760445|Experimental|Part 2 - Expansion Cohort 4|R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
16431576|NCT03760445|Experimental|Part 3 - DDI Cohort 1|R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
16431577|NCT03760445|Experimental|Part 3 - DDI Cohort 2|R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
16431578|NCT03760432|Experimental|Surgery|OCT-guided custom laser CXL
16431579|NCT03760419|Active Comparator|Intervention Arm|Effectiveness of the EHR-based antibiotic decision support application for promoting guideline-concordant antibiotic prescribing in children presenting for emergency care will be evaluated in a pragmatic, cluster randomized crossover study conducted over a period of 18 months that includes two respiratory seasons. The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive standard of care management. All treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
16431580|NCT03760419|No Intervention|Control Arm|The investigator will conduct a randomized controlled trial comparing a prognostic tool (intervention arm) to usual care (control arm) over a period of 24 months. Randomization will occur at the patient level. Allocation to intervention or control will be based on medical record number (even vs. odd) and will be assigned automatically once a provider confirms the diagnosis of pneumonia via the radiology alert tool. All standard of care treatment options will be available and decision-making will not be restricted in any way in either group.
16431581|NCT03760406|Experimental|Severe essential tremor treated by DBS|
16431582|NCT03760393|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
16431583|NCT03760393|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
16431584|NCT03760380|Experimental|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
16431585|NCT03760380|Experimental|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
16431586|NCT03760367|Experimental|Blue Covarine Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste containing blue covarine (Pepsodent White Now Gold, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
16431587|NCT03760367|Active Comparator|Control Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
16431588|NCT03760354|Experimental|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
16431589|NCT03760354|Placebo Comparator|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
16431590|NCT03760341|Active Comparator|cold adenoidectomy group|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - cold method
16431591|NCT03760341|Active Comparator|hot method adenoidectomy|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - hot method
16431592|NCT03760328|Active Comparator|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
16431593|NCT03760328|Sham Comparator|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
16431594|NCT03760315||targeted treatment by mNGS|In the mNGS targeted treatment group，Clinicians figure out sepsis patients' microbe by mNGS and alter or confirm targeted treatment.
16431595|NCT03760315||targeted treatment by Culture|In the Culture targeted treatment group，Clinicians figure out sepsis patients' microbe by Culture and alter or confirm targeted treatment.
16431596|NCT03760315||Experience treatment|In the experience treatment group，Clinicians didn't figure out sepsis patients' microbe even with Culture and mNGS of the plasm and other secretion to alter or confirm targeted treatment.
16431597|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
16431598|NCT03760276|Experimental|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
16431599|NCT03760263|Active Comparator|Envarsus|Once-daily extended-release tacrolimus
16431600|NCT03760263|Active Comparator|Prograf|twice-daily tacrolimus
16433344|NCT03748602|No Intervention|Conservative therapy|Physiotherapy and pain relief
16431601|NCT03760250|Experimental|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
16431602|NCT03760237||Acute Leukemia|Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
16431603|NCT03760224|Experimental|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
16431604|NCT03760224|Active Comparator|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
16431605|NCT03760211|Experimental|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Battle Viro on their mobile phones, an electronic pill monitoring device, and, for 24 weeks, game-related text messages guided by medication adherence data (collected from an electronic pill monitoring device).
16431606|NCT03760211|Active Comparator|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game and an electronic pill monitoring device.
16431607|NCT03760198|Experimental|botulinum toxin type A|
16431608|NCT03760198|Placebo Comparator|Placebo|
16431609|NCT03760185|Experimental|All patients|All patients in this arm will receive eye drops to be applied to one eye only. The alternative eye will not receive any eye drops and as such will serve as the control.
16431610|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
16431611|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
16431612|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
16431613|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
16431614|NCT03760159||Group RESPIRATORY SIMUL (Study A)|In 46 healthy subjects, a computer program will generate random instructions of periods of normal breathing, voluntary end-expiratory breathing cessation periods (as surrogate of central apnoea) and Muller's manœuvre (as surrogate of obstructive apnoea). Meanwhile, the KCG will record the parameters of biological interest. ECG, heart rate, beat to beat non-invasive blood pressure (Finometer), ventilation, end-tidal CO2 (AD instruments), O2 saturation (Nellcor), cardiac output (CO) (Philips) will also be recorded.
16431615|NCT03760159||Group SDB (Study B)|In patients suspected of sleep apnoea and admitted to the sleep unit of the Erasme hospital to perform sleep test as required by their medical condition, the investigators will simultaneously record KCG and PSG and qualitatively compare the data (Bland-Altman plots).
16431616|NCT03760159||Group nCPAP (Study C)|In patients with a diagnosis of sleep apnea, the investigators will determine if KCG is capable to reliably assess the efficacy of the nCPAP therapy in comparison to simultaneous PSG recording. Ongoing adjustment in the CPAP therapy pressure during the night, and its effect on cardiovascular haemodynamic assessed by the KCG, will be taken into account as well.
16431617|NCT03760159||Group UNSELECTED (Study D)|After validation of the three previous steps, the investigators plan to extend the recordings on 100 unselected consecutive patients, without recruitment restrictions, which will undergo PSG recordings because of complains of sleep apnoea.
16431618|NCT03760146|Experimental|60 years and above 20vPnC/Saline|20vPnC and saline
16431619|NCT03760146|Active Comparator|60 years and above 13vPnC/PPSV23|13vPnC and PPSV23
16431620|NCT03760146|Experimental|50 through 59 years of age 20vPnC|20vPnC
16431621|NCT03760146|Experimental|18 through 49 years of age 20vPnC|20vPnC
16431622|NCT03760146|Active Comparator|50 through 59 years of age 13vPnC|13vPnC
16431623|NCT03760146|Active Comparator|18 through 49 years of age 13vPnC|13vPnC
16431624|NCT03760133|Active Comparator|with Probiotics|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
16431625|NCT03760133|No Intervention|without Probiotics|Participants included in this group will not be taken probiotics for 1 month after bowel preparation for colonoscopy.
16431626|NCT03760120|Active Comparator|PEP standard|
16431627|NCT03760120|Sham Comparator|PEP sham|
16431628|NCT03760107|Experimental|Incentive Level High, Call|
16431629|NCT03760107|Experimental|Incentive Level High, No Call|
16431630|NCT03760107|Experimental|Incentive Level Medium, Call|
16431631|NCT03760107|Experimental|Incentive Level Medium, No Call|
16431632|NCT03760107|Experimental|No Incentive, Call|
16431633|NCT03760107|Experimental|No Incentive, No Call|
16431634|NCT03760094|Experimental|Study group|patients with lymphadenopathy
16431635|NCT03760081|Experimental|ASP1650 Escalation|An initial dose level of ASP1650 (Safety Lead-In Phase) will be evaluated in a 3-participant cohort (cohort 1) and if well tolerated, a new participant cohort (cohort 2) (minimum 3 and up to 4 participants) will be opened at the next dose level according to the Bayesian Optimal Interval (BOIN) design. Based on tolerability observed in cohort 2, an additional participant cohort (cohort 3) (minimum 3 and up to 4 participants) will be opened at the same dose level of cohort 2 or de-escalation will occur if cohort 2 is not tolerable.
16431636|NCT03760068|Active Comparator|MYL-1601D Product (100 U/mL)|
16431637|NCT03760068|Active Comparator|FlexPen NovoLog® (100 U/mL)|
16431638|NCT03760055||Glaucoma and glaucoma suspects|Patients with at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits. Patients considered suspects for glaucoma must have an intraocular pressure (IOP) greater than 21 millimeters of mercury (mmHg) or suspicious appearance of the optic nerve head but with reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
16431672|NCT03759847|Experimental|Vanguard|Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
16431639|NCT03760055||Age-related macular degeneration|"Patients will be considered as having AMD if one or more of the following are present on posterior biomicroscopy (fundoscopy), indirect ophthalmoscopy or Optical Coherence Tomography (OCT) exams:
~Presence of at least intermediate-size drusen (63µm or larger in diameter)
~Retinal pigment epithelium (RPE) abnormalities such as hypopigmentation or hyperpigmentation
~Reticular pseudodrusen (also called sub retinal drusenoid deposit)
~Presence of any of the following features: geographic atrophy of the RPE, choroidal neovascularization (exudative, wet), polypoidal choroidal vasculopathy, or retinal angiomatous proliferation."
16431640|NCT03760055||Other eye diseases|Patients with other retinal degenerations such as retinitis pigmentosa or with other diseases affecting the visual pathways such as tumors, ischemic neuropathy or optic neuritis may also be included. Their diagnosis will be extracted from their clinical visits.
16431641|NCT03760055||Healthy subjects|To be considered healthy, subjects have to have IOP < 22 mmHg with no history of elevated IOP and with at least two reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
16431642|NCT03760042|Other|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
16431643|NCT03760042|Other|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.
~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
16431644|NCT03760029|Other|Study arm|All subjects in this study will be observed for 24-30 months.
16431645|NCT03760016|Active Comparator|Moderate-Intensity Aerobic Training|
16431646|NCT03760016|Experimental|High-Intensity Interval Training|
16431647|NCT03760003|Experimental|ABX464|ABX464 will be administrated orally (Capsules) and daily for 16 weeks
16431648|NCT03760003|Placebo Comparator|Matching Placebo|Matching placebo will be adminstrated orally (Capsules) and daily for 16 weeks
16431649|NCT03759990|Active Comparator|insertion time|
16431650|NCT03759990|Active Comparator|intubation time|
16431651|NCT03759977|Experimental|Adapted Physical Activity group|This group will receive 3 sessions per week of specific physical activity.
16431652|NCT03759977|No Intervention|Usual accompaniment group|This group will continue to follow the usual accompaniment of the nursing home.
16431653|NCT03759964|Active Comparator|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
16431654|NCT03759964|Placebo Comparator|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
16431655|NCT03759951|Experimental|Control|No intervention. Participated only in measurements at baseline, at 6 months and at 12 months.
16431656|NCT03759951|Experimental|DoIT-1|Participated in a supervised 1-year workout exercise training program once per week and in measurements at baseline, at 6 months and at 12 months.
16431657|NCT03759951|Experimental|DoIT-2|Participated in a supervised 1-year workout exercise training program twice per week and in measurements at baseline, at 6 months and at 12 months.
16431658|NCT03759951|Experimental|DoIT-3|Participated in a supervised 1-year workout exercise training program thrice per week and in measurements at baseline, at 6 months and at 12 months.
16431659|NCT03759938|Experimental|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
16431660|NCT03759938|Active Comparator|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
16431661|NCT03759925|Experimental|Nutritional Support|The intervention consists of home delivery of medically-appropriate food support (DASH and diabetic diet compliant) in the form of prepared meals and/or groceries and monthly individual nutritional counseling with a Registered Dietician.
16431662|NCT03759925|No Intervention|Standard of Care|The control group will receive standard of care follow up care after their hospitalization for acute decompensated heart failure.
16431663|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
16431664|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
16431665|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
16431666|NCT03759873|Experimental|Incentives|Patient earns incentives for completing cardiac rehabilitation sessions.
16431667|NCT03759873|Experimental|Case Management|Patient is assigned a case manager while in hospital.
16431668|NCT03759873|Experimental|Incentives and Case Management|Patient receives both the Incentives and Case Management interventions.
16431669|NCT03759873|No Intervention|Usual care|This control condition does not receive either intervention.
16431670|NCT03759860|Experimental|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.
~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.
~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
16431671|NCT03759860|Sham Comparator|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.
~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
16431729|NCT03759431|Active Comparator|Complete Larynx Radiotherapy|
16501566|NCT03280680|Experimental|Female+male group sessions|
16431673|NCT03759834|Experimental|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
16431674|NCT03759821|Experimental|Nutrition, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
16431675|NCT03759821|Experimental|Nutrition, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and the groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
16431676|NCT03759821|Experimental|Nutrition+parenting, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
16431677|NCT03759821|Experimental|Nutrition+parenting, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
16431678|NCT03759821|No Intervention|Standard of care control|Local standard of care
16431680|NCT03759795|Experimental|Intervention Group|Acceptance and Commitment Training (ACTr)
16431681|NCT03759795|No Intervention|Wait-list control|No intervention during trial. Participants in this group will be offered the training once the study is complete.
16431682|NCT03759782|Experimental|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
16431683|NCT03759782|Active Comparator|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if <70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
16431684|NCT03759769|Experimental|simulator|Practice at home all activities of the wheelchair simulator, at least 20 minute per session, at least one session every second day
16431685|NCT03759769|Active Comparator|control|Practice on a computer video game, at least 20 minute per session, at least one session every second day
16431686|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
16431687|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
16431688|NCT03759743|Experimental|Probiotics|
16431689|NCT03759743|Placebo Comparator|Placebo|
16431690|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
16431691|NCT03759691||Stroke patients|Structured interviews of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
16431692|NCT03759691||Bystander|Structured interviews of bystanders of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
16431693|NCT03759678|Experimental|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.
~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).
~Patients 6-12 years old will receive weight-tiered doses:
~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
16431694|NCT03759678|No Intervention|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
16431695|NCT03759665|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.
~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).
~Patients 6-12 years old will receive weight-tiered doses:
~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
16431696|NCT03759665|No Intervention|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
16431697|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
16431698|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
16431699|NCT03759639|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.
~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).
~Patients 6-12 years old will receive weight-tiered doses:
~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
16431700|NCT03759639|No Intervention|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
16431701|NCT03759626|Active Comparator|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
16431702|NCT03759626|Active Comparator|pupils benefiting from the reflective intervention|Second year students from general high schools.
16431703|NCT03759613|Experimental|Experimental Group|Thirty subjects with unilateral upper burn injury will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. Their evaluations will be made within 5 days following burn injury.
16431704|NCT03759613|Active Comparator|Control Group|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, they will be asked to walk their natural walking.
16431705|NCT03759613|Sham Comparator|Control Grup (Restricted arm swing)|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, their arms will be fixed with a bandage on their bodies. Their arm swing will be restricted.
16431706|NCT03759600|Experimental|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 - 28 of each 28-day treatment cycle up to 6 cycles till data cut-off: 01 July 2019.
16431707|NCT03759587|Experimental|Niraparib 300 mg|Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment Cycle (Up to 3 Cycles till data cut-off 17 March 2019).
16431708|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
16431709|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
16431710|NCT03759561|Active Comparator|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscop under cervical collar application.
16431711|NCT03759561|Active Comparator|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
16431712|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
16431713|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
16431714|NCT03759535||Control group and Case group|"Control group:
~The allograft kidneys function normally. The rejection of allograft kidneys are excluded. The patients have no infectious complications.
~Case group:
~There is obvious evidence for acute rejection of the allograft kidneys. The patients have no infectious complications."
16431715|NCT03759522|Experimental|Healthy Controls|
16431716|NCT03759522|Experimental|Fibromyalgia Subjects|
16431717|NCT03759522|Experimental|Chronic Fatigue Syndrome Subjets|
16431718|NCT03759522|Experimental|Multiple Sclerosis Subjects|
16431719|NCT03759509|Experimental|aerobic exercise training|three times a week, a total of twenty-four times in eight weeks
16431720|NCT03759509|No Intervention|control|routine activity
16431721|NCT03759496|Experimental|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
16431722|NCT03759483||AI group|The visual field reports in this group will be evaluated by the convolutional neural network.
16431723|NCT03759483||Human group|The visual field reports in this group will be evaluated by 3 ophthalmologists independently.
16431724|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .
~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
16431725|NCT03759457|Experimental|High Flow Nasal Cannula|High Flow Nasal Cannula is a relatively new technique able to deliver both oxygen and high flow in order to improve oxygenation and waking out CO2 from the upper airways
16431726|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)
~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
16431727|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)
~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
16431728|NCT03759431|Experimental|Vocal-cord Radiotherapy|
16431730|NCT03759405|Experimental|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
16431731|NCT03759392|Experimental|Omecamtiv Mecarbil|
16431732|NCT03759392|Placebo Comparator|Placebo|
16431736|NCT03759353|Active Comparator|Lactoferrin Group|Includes 49 pregnant women receiving lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin (R) , Hygint pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
16431737|NCT03759353|Active Comparator|Ferrous Sulfate Group|Includes 49 pregnant women receiving 200 mg of dried ferrous sulfate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset (Feosol (R) , Meda pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
16431738|NCT03759340|Experimental|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
16431739|NCT03759301|Active Comparator|Growth Hormones Somatropin Recombinant|Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup for the treatment group which consists of 70 women.
16431740|NCT03759301|Placebo Comparator|Placebo saline solution|Control group consisting of 70 women who will receive subcutaneous placebo injection in the same dosing as the treatment group
16431741|NCT03759288|Experimental|(Stage 1) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
16431742|NCT03759288|Experimental|(Stage 1) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
16431743|NCT03759288|Placebo Comparator|(Stage 1) Placebo|Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
16431744|NCT03759288|Experimental|(Stage 2) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
16431745|NCT03759288|Experimental|(Stage 2) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous on Day 85 and every 4 weeks through Week 48
16431746|NCT03759288|Active Comparator|(Stage 2) Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50
16431747|NCT03759275||Stage 1|For the Baseline Investigation and Technical Preparation Stage
16431748|NCT03759262|Experimental|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
16431749|NCT03759249|Experimental|Treatment group|Standard Treatment of Sleep disorder according to applicable guideline
16431750|NCT03759249|No Intervention|Waiting list|Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines
16431751|NCT03759236|Experimental|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
16431752|NCT03759236|Active Comparator|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
16431753|NCT03759223|Experimental|E-PST|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
16431754|NCT03759223|Active Comparator|Control|Healthy Living Messages (Control) arm. Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
16431755|NCT03759197|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
16431756|NCT03759197|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
16431757|NCT03759184|Experimental|1|DOSE ESCALATION: IL-15 by civ infusion at escalating doses of 0.5, 1, and 2 mcg/kg/day on days 1-5 of each 4-week cycle (max 6 cycles), with obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the MTD
16431758|NCT03759184|Experimental|2|DOSE EXPANSION: 3 to 6 patients to receive IL-15 by civ infusion at the MTD on days 1-5 of cycles 1-6 with obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
16431759|NCT03759171|Experimental|Immediate Entry Group|Following the baseline interview, veterans randomized to the immediate entry group directly engaged in the Guitars for Vets Intervention and were interviewed at the end of the intervention period, roughly 6 weeks later. The intervention content and duration (6 weeks) was the same across both groups.
16433520|NCT03747445||Obese controls|Severely obese non-diabetic adult female patients not scheduled for RYGB
16431760|NCT03759171|Experimental|Delayed Entry Group|Those randomized to the delayed entry group had their baseline interview repeated at the end of the delayed entry period (4 weeks) prior to receiving the 6-week Guitars for Vets Intervention as well as after intervention completion. The intervention content and duration (6 weeks) was the same across both groups.
16431761|NCT03759158|Experimental|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
16431762|NCT03759158|Placebo Comparator|Placebo|
16431763|NCT03759145|Experimental|Intervention arm, usual rehabilitation + Jintronix exergame|On top of the usual out-patient rehabilitation sessions planned for the participant, participants attend sessions to use the Jintronix system for up 30 minutes up to 3 times per week
16431764|NCT03759145|Other|Control group|Participants continue their prescribed rehabilitation sessions
16431765|NCT03759132|Experimental|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.
~Dose: 2mA, 20 minutes"
16431766|NCT03759132|Sham Comparator|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.
~Dose: 2mA, 20 minutes (30s ON)"
16431767|NCT03759119|Experimental|Tummy Time and Parent Education|This group will receive tummy time and parent education and be encouraged to perform tummy time on their own. They will utilize the PT Pal application to record their tummy time adherence. The primary investigator performs the intervention to the participants two times a day for 10 minutes for 4 weeks.
16431768|NCT03759119|No Intervention|Parent education|This group will receive parent education only and utilize the PT Pal application to record their adherence. The primary caregiver will be encouraged to perform the same dosage of tummy time (2x/day, 10 minutes each, 4 weeks) and record their adherence on the PT Pal application.
16431769|NCT03759106|Other|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
16431770|NCT03759106|Experimental|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
16431771|NCT03759093|Active Comparator|Standard of Care|Dosing of VCD(bortezomib, cyclophosphamide, dexamethasone) or VTD (bortezomib, thalidomide, dexamethasone) combinations according to standard of care
16431772|NCT03759093|Experimental|CURATE.AI-guided dosing|CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone) or bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) combinations
16431773|NCT03759080|Active Comparator|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
16431774|NCT03759080|Experimental|MP|PNFMP group:30 individuals, these subjects received mental practice.
16431775|NCT03759067|Active Comparator|LD group|clopidogrel 600 mg once loading, usually 2-24 h before the procedure
16431776|NCT03759067|Experimental|MD group|After randomization, the routine therapy using daily clopidogrel 75mg
16431777|NCT03759067|Active Comparator|RL group|After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.
16431778|NCT03759041|Placebo Comparator|Placebo (after placebo pre-treat.)|Once-daily dosing of Placebo (after placebo pre-treatment)
16431779|NCT03759041|Experimental|SER-287 Induction Dosing (after vanco. pre-treat.)|Once-daily dosing of SER-287 (Induction Dose, after vancomycin pre-treatment)
16431780|NCT03759041|Experimental|SER-287 Step-Down Induction Dosing (after vanco. pre-treat.)|Once-daily dosing of SER-287 (Step-Down Induction Dose, after vancomycin pre-treatment)
16431781|NCT03759028|Experimental|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
16431782|NCT03759028|Active Comparator|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
16431783|NCT03759015|Other|Health education|This arm's subjects are tasked to create an original 10-minute theater that is required to use the guidelines about physical activity and diet/nutrition.
16431784|NCT03759002||Patients|Children with end stage renal disease
16431785|NCT03759002||Controls|Healthy sex- and age adjusted children
16431786|NCT03758989|Experimental|Baseline PET|R-CHOP
16431787|NCT03758963|Experimental|Active Laser|"Once the energy to be applied for the treatment is determined through the laser irradiation testing, conduct laser therapy after selecting T corresponding to treatment laser on GUI.
~At irradiation, excluding the circle area with a 100 μm radius (200 μm diameter) from the center of the fovea, irradiate laser in the form of surrounding the leakage site with an interval of 0.5-1 spot diameter (fovea = 1 spot size). As for the test spots, the serial number needs to be given for each treatment spot with the order of irradiation, as described above.
~If pigment epithelial detachment (PED) occurs at the leakage site, irradiate laser around the PED (excluding the circle area with a 100 μm radius (200 μm diameter) from the center), not to the leakage site.
~Within 2 hours after therapy, perform tests for efficacy evaluation (color fundus photography and fluorescein angiography)."
16431788|NCT03758963|Sham Comparator|Sham Laser procedure|"Select C corresponding to Sham Therapy on GUI of the laser device, and then perform Sham therapy.
~During Sham therapy, for patient's blinding, both light from the slit lamp and sound from laser oscillation are same as laser irradiation, and no laser oscillation will occur for treatment.
~Perform subsequent procedures in the same manner as the procedure of study group."
16431789|NCT03758950|Placebo Comparator|Placebo|Once daily inhaled placebo
16431790|NCT03758950|Active Comparator|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
16431791|NCT03758937|Active Comparator|volume-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
16431792|NCT03758937|Active Comparator|pressure-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
16431793|NCT03758924|Experimental|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
16431794|NCT03758924|Placebo Comparator|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
16431795|NCT03758911||bone marrow/blood stem cell donors|Participants underwent a one time semi-structured telephone interview to understand the perspectives of bone marrow/stem cell donors experience, including how family dynamics impacted participants' decision to donate and identifying unique supportive care needs of bone marrow/stem cell donors.
16431796|NCT03758898|Experimental|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
16431797|NCT03758898|Placebo Comparator|Group 2|only mobilisation was applied to the patients in the second group
16431798|NCT03758885|Experimental|Nolasiban 900 mg|Nolasiban dispersible tablets for single oral administration
16431799|NCT03758885|Placebo Comparator|Placebo|Placebo dispersible tablets for single oral administration
16431800|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
16431801|NCT03758859|Experimental|sodium hyaluronate eye drops|the randomly allocated eye will receive sodium hyaluronate drops, followed by a repeat OCT scan; images are then evaluated for clarity by the masked assessor.
16431802|NCT03758846|Experimental|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
16431803|NCT03758846|Active Comparator|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
16431804|NCT03758846|Experimental|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
16431805|NCT03758846|Experimental|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
16431806|NCT03758846|Active Comparator|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
16431807|NCT03758833|Active Comparator|SET|patients receiving the elective single embryo transfer
16431808|NCT03758833|Experimental|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
16431809|NCT03758833|Active Comparator|DET|patients receiving the elective double embryo transfer
16431810|NCT03758833|Experimental|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
16431811|NCT03758820|Experimental|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.
~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
16431812|NCT03758820|No Intervention|Control group|Usual local practice
16431813|NCT03758807|Sham Comparator|Passive treatment|Passive treatment will consist of Manual Therapy with biomechanical explanation of the technique.
16431814|NCT03758807|Experimental|Active Treatment|Active treatment will consist of Manual Therapy with a neuroplasticity explanation of the technique.
16431815|NCT03758794|Active Comparator|interactive lecture module|interactive lecture
16431816|NCT03758794|Active Comparator|online educational module|online educational using a special link
16431817|NCT03758781|Experimental|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
16431818|NCT03758768|Experimental|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
16431819|NCT03758768|Active Comparator|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.
~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
16431820|NCT03758755|Experimental|BFR Therapy|This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
16431821|NCT03758755|Active Comparator|No BFR|This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR
16431822|NCT03758742|Experimental|High-Fruit Diet|
16431823|NCT03758729|Experimental|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
16431824|NCT03758716|Experimental|FB825|Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.
16431825|NCT03758703|Experimental|Pre-recorded music intervention group|The experimental group will be receiving the pre-recorded music care intervention. The intervention is to be delivered once a day for 30 minutes, over one week, on a portable Bluetooth speaker system. Participants will select their own music from the list of pre-recorded songs playlist and are free to switch to another playlist within their treatment arm should they desire. This music was specifically designed for use in palliative care. Specifically, all songs are played at 60 beats per minute to mimic resting heart rate. Instrumentation was specifically chosen to be soothing and calming
16431826|NCT03758703|Active Comparator|Pre-recorded soothing poetry group|The control group will be provided pre-recorded soothing poetry which they will self-select. Participants are allowed to switch playlists within their treatment arm each day should they desire. This control group is designed to control time, attention, and placebo effect. Thus, the soothing poetry will be offered the identical time duration of listening to recorded soothing poetry readings and played at the same time the intervention group receives the pre-recorded music.
16431827|NCT03758690|Experimental|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
16431828|NCT03758677|Experimental|Patients who progressed after EGFR-TKI without T790M mutation|Single arm; Plan to enroll 30 cases; Patients who progressed after EGFR-TKI treatment without T790M mutation
16431829|NCT03758664|Experimental|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
16431830|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
16431831|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
16431832|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
16431833|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
16431834|NCT03758638|Experimental|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).
~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
16431835|NCT03758638|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual
16431836|NCT03758625|Experimental|ARM A|a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
16431837|NCT03758625|Experimental|ARM B|a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
16431838|NCT03758625|Active Comparator|ARM C|a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
16431839|NCT03758625|Experimental|ARM D|pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
16431840|NCT03758625|Experimental|ARM E|pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
16431841|NCT03758625|Active Comparator|ARM F|pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
16431842|NCT03758612|Active Comparator|Cohort 1 (sentinel group) - Active|Single dose of TBI-223 50 mg (n=2) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
16431843|NCT03758612|Placebo Comparator|Cohort 1 (sentinel group) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
16431844|NCT03758612|Active Comparator|Cohort 1 (remainder of cohort) - Active|Single dose of TBI-223 50 mg (n=4).
16431845|NCT03758612|Placebo Comparator|Cohort 1 (remainder of cohort) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1).
16431846|NCT03758612|Active Comparator|Cohort 2 - Cohort 7 - Active|Single dose of TBI-223 100, 300, 600, 1200, 2000, 2600 mg; n=3 per dosing group.
16431847|NCT03758612|Placebo Comparator|Cohort 2 - Cohort 7 - Placebo|Single dose of matching Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg, n=1 per dosing group.
16431848|NCT03758612|Active Comparator|Cohort 3b - Active - Oral Capsule|Single dose of 300 mg in oral enteric capsule, n=4 per dosing group.
16431849|NCT03758612|Placebo Comparator|Cohort 3b - Placebo - Oral Capsule|Single dose of placebo for 300 mg in oral enteric capsule, n=1 per dosing group.
16431850|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 1|Single dose of TBI-223 sustained-release (SR) tablet prototype 1, 3 x 600 mg, n=6 per cohort.
16431851|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 2|Single dose of TBI-223 SR tablet prototype 2, 3 x 600 mg, n=6 per cohort.
16431852|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 3|Single dose of TBI-223 SR tablet prototype 3, 2 x 900 mg, n=6 per cohort.
16431853|NCT03758612|Active Comparator|Cohort 8 - IR Tablet fasted|Single dose of TBI-223 immediate-release (IR) tablet prototype 4, 2 x 1000 mg, n=6 per cohort; fasted prior to dose.
16431854|NCT03758612|Active Comparator|Cohort 9 - IR Tablet with meal|Single dose of TBI-223 immediate-release (IR) tablet, 2 x 1000 mg, n=6 per cohort; fed prior to dose.
16431912|NCT03758235|Active Comparator|Onabot/A 100 U|Onabot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
16431855|NCT03758599|Experimental|Climbing Exercise Group|At the beginning of each session, a standardized body-centered, mind-setting warmup of ten minutes will take place. The general warm-up will be followed by climbing specific warm-up, which will consist of bouldering (20-30 minutes). Afterwards the rope climbing session will start. Climbing sessions also contain several sport-specific skill-development training sessions to familiarize the participants with gear and rope management, to acquire footwork and route finding, and to locate good belay spots and resting positions while climbing. At the end of the climbing session a short cool-down of five minutes will be executed.
16431856|NCT03758599|Experimental|Aerobic Exercise Group|As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
16431857|NCT03758599|Active Comparator|Social Contact Control Group|Patients allocated to the social contact control group will receive the same amount of social interaction as the exercise groups. A physiotherapist or sport scientist will be present while participants watch movies with relevant content to disease followed by interactive group discussions. This group is required to control for the impact of social contact/support on AD/PTSD and secondary outcomes.
16431858|NCT03758586|Active Comparator|Study group|Surgical residents undergoing spatial skill training.
16431859|NCT03758586|Sham Comparator|Control group|Surgical residents not undergoing spatial skill training.
16431860|NCT03758573|Experimental|Inspiratory Muscle Training (IMT)|IMT by means of the Powerbreath equipment (Classic, London, UK), according to the following parameters: initial loading of 40% of MIP, 3 sets of 10 repetitions with interval of 1 minute between each sets, 7 days a week, 2 times a day , with the patients in the bed with the angulation of 45 °. The IMT load settings will be adjusted according to the values evaluated weekly. If there is need for addition of supplemental oxygen will be performed to perform the IMT.
16431861|NCT03758573|Active Comparator|Intensive Physiotherapy (IPT)|IPT will be to individualized and supervised intervention program consisting of any of the following procedures: passive, assisted, active or resisted mobilization, sedation and orthostasis depending on the functional level of the patient, as well as bronchial hygiene therapy and pulmonary expansion therapy.
16431862|NCT03758547|Experimental|in-exufflator and percussion technique|"assess the physiological effects, of a common daily practice of secretion removal in intubated patients, that are: in-exufflator technique and percussion technique"
16431863|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging [MRI/MRS/DTI], Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]), and yearly bio-specimen collection.
16431864|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
16431865|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
16431866|NCT03758508|Active Comparator|HFO|Continuous high flow oxygen through nasal cannula for 45 hours; longer if the clinical need persists
16431867|NCT03758508|Active Comparator|NIV/HFO|Alternating noninvasive ventilation (3 hours) and high flow oxygen through nasal cannula (3 hours) for 45 hours; longer if the clinical need persists
16431868|NCT03758495||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
16431869|NCT03758495||Patients with Major Depressive Disorder|Individuals who have been previously diagnosed with major depressive disorder and meet our research criteria for symptoms indicative of major depressive disorder within their lifetime.
16431870|NCT03758495||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
16431871|NCT03758482|Other|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
16431872|NCT03758482|Other|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
16431873|NCT03758469|Experimental|HSK3486|0.4 mg/kg
16431874|NCT03758469|Experimental|rifampin , HSK3486|600 mg;0.4 mg/kg
16431875|NCT03758456|Placebo Comparator|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
16431876|NCT03758456|Experimental|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
16431877|NCT03758456|Experimental|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
16431878|NCT03758456|Experimental|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
16431879|NCT03758443|Experimental|Active Treatment TD-1473 Dose A|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
16431880|NCT03758443|Experimental|Active Treatment TD-1473 Dose B|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
16431881|NCT03758443|Experimental|Active Treatment TD-1473 Dose C|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
16431882|NCT03758443|Placebo Comparator|Placebo|Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose).
16431883|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
16431884|NCT03758417|Experimental|LCAR-B38M Chimeric Antigen Receptor T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
16431885|NCT03758404|Experimental|Low dose AAV - CNGA3|Subretinal administration of a single low dose of range AAV - CNGA3
16431886|NCT03758404|Experimental|Intermediate dose AAV - CNGA3|Subretinal administration of a single intermediate dose of range AAV - CNGA3
16431887|NCT03758404|Experimental|High dose AAV - CNGA3|Subretinal administration of a single high dose of range AAV - CNGA3
16431888|NCT03758391|No Intervention|Traditional Didactic Education|Education will be provided to fellows using the traditional didactic approach (lecture-based).
16431889|NCT03758391|Experimental|Flipped Classroom Education|Education will be provided to fellows using the flipped classroom approach.
16431890|NCT03758378|Experimental|Dietary intervention|
16431891|NCT03758365|Experimental|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
16431892|NCT03758365|Active Comparator|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
16431893|NCT03758365|Active Comparator|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
16431894|NCT03758365|Active Comparator|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
16431895|NCT03758365|Active Comparator|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
16431896|NCT03758365|Active Comparator|Desonide 0.05% cream|Single application of Desonide 0.05%
16431897|NCT03758365|Placebo Comparator|Vehicle cream|Single application of Vehicle
16431898|NCT03758352|Experimental|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
16431899|NCT03758352|Other|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
16431900|NCT03758339|Experimental|Tucatinib|
16431901|NCT03758326|Other|Eating disorder|Measurement of body image via Body App and relationship to body measurement
16431902|NCT03758326|Other|Healthy comparison|Measurement of body image via Body App and relationship to body measurement
16431903|NCT03758300|Experimental|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
16431904|NCT03758300|Sham Comparator|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
16431905|NCT03758287|Experimental|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.
~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .
~Gefitinib will be administered daily, at a dose of 250 mg orally ."
16431908|NCT03758261|Other|Erector Spinae Nerve Block|Erector Spinae nerve block
16431909|NCT03758261|Other|Paravertebral Nerve Block|Paravertebral nerve block
16431910|NCT03758235|Experimental|Incobot/A 100 U|Incobot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
16431911|NCT03758235|Experimental|Incobot/A 200 U|Incobot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered in patients performin intermittent catheterization.
16431946|NCT03758014|Experimental|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
16431913|NCT03758235|Active Comparator|Onabot/A 200 U|Onabot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered to patients performing intermittent catheterization
16431914|NCT03758222|Experimental|Arm-1: Device implantation for 1 month|Treatment group receives intervention with the XFLO Expander System implantation for 1 month, and then retrieved.
16431915|NCT03758222|Experimental|Arm-2: Device implantation for 6 months|Treatment group receives intervention with the XFLO Expander System implantation for 6 months, and then retrieved.
16431916|NCT03758222|Experimental|Arm-3: Device implantation for 12 months|Treatment group receives intervention with the XFLO Expander System implantation for 12 months, and then retrieved.
16431917|NCT03758209|Experimental|Prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:
~Physical status (walking, respiratory training)
~Nutrition (nutritional supplements)
~Mental status (weekly groups led by clinical psychologist on anxiety and depression management).
~Each patient will be treated in an ERAS program preoperatively."
16431918|NCT03758209|Active Comparator|ERAS|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
16431919|NCT03758196|Experimental|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
16431920|NCT03758196|No Intervention|optimized medication regimen|optimized medication regimen
16431921|NCT03758183||two-stage algorithm|Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)
16431922|NCT03758183||one-stage algorithm|total knee arthroplasty (TKA)
16431923|NCT03758170|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
16431924|NCT03758170|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
16431925|NCT03758157||Temperature Measurement|Each subject will have his or her temperature measured by both the welloStationX Automated Non-Contact Thermometer and the Welch Allyn SureTemp Oral Thermometer.
16431926|NCT03758144|Active Comparator|study|
16431927|NCT03758144|No Intervention|CONTROL GROUP|
16431928|NCT03758131|Experimental|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
16431929|NCT03758131|Active Comparator|Motivational Interviewing|In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
16431930|NCT03758131|Placebo Comparator|Waitlist Control|Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
16431931|NCT03758118|Active Comparator|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
16431932|NCT03758118|No Intervention|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
16431933|NCT03758105|Experimental|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
16431934|NCT03758105|Active Comparator|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
16431935|NCT03758092||SGA vs AGA infants|infants, born at term (37+0/41+3 week gestation), aged 24 months, with a birth weight <10th percentile or between 10th and 90th percentile for sex, gestational age, and birth order, according to Italian neonatal anthropometric charts
16431936|NCT03758079|Active Comparator|Doxepin|10 mg Doxepin daily for 4 weeks
16431937|NCT03758079|Active Comparator|Gabapentin|Gabapentin 100mg after each dialysis session
16431938|NCT03758066|Other|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
16431939|NCT03758053||Individuals with alcohol use disorder + ACE|Individuals with AUD and varying levels of adverse childhood experiences (ACE)
16431940|NCT03758053||Healthy controls|Healthy individuals without AUD
16431941|NCT03758053||Individuals with alcohol use disorder, no ACE|Individuals with AUD and no adverse childhood experiences (ACE)
16431942|NCT03758040|Experimental|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
16431943|NCT03758040|Experimental|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
16431944|NCT03758027|Experimental|CARESS|"The proposed intervention for this study has three stages: communicate alternatively (CA), release endorphins (RE), and self-soothe (SS) (CARESS)
~CARESS is a combined skill of three activities. Each section is timed and has specific activities:
~CA - will last eight (8) minutes, and will be expression of emotion with drawing with crayons.
~RE - will last six (6) minutes, and will be a butterfly hug with a blanket. SS - will last six (6) minutes, and will be a pre-recorded music selection."
16431945|NCT03758027|Active Comparator|ISOMETRIC|This is a one time five-minute isometric circuit involving contracting muscles in different parts of the body. In order to be equivalent in time spent with the experimental intervention, this circuit will be performed three times with a five-minute break between each instance
16433574|NCT03747094|Experimental|Ketamine group|
16431947|NCT03758014|Active Comparator|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
16431948|NCT03758001|Experimental|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
16431949|NCT03758001|Experimental|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.
~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
16431950|NCT03757988|Experimental|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
16431951|NCT03757975||TAH|patients before and after total abdominal hysterectomy (TAH)
16431952|NCT03757975||TLH|patients before and after total laparoscopic hysterectomy (TLH)
16431953|NCT03757975||TVH|patients before and after total vaginal hysterectomy (TVH)
16431954|NCT03757975||SAH|patients before and after abdominal supracervical hysterectomy (SAH)
16431955|NCT03757975||SLH|patients before and after supracervical laparoscopic hysterectomy (SLH)
16431956|NCT03757962|Experimental|Dietary intervention|
16431957|NCT03757949|Experimental|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
16431958|NCT03757949|Placebo Comparator|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
16431959|NCT03757936|Experimental|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
16431960|NCT03757923|Experimental|metformin|TAB METFORMIN 500mg TDS
16431961|NCT03757923|Experimental|pioglitazone|TAB PIOGLITAZONE 30 mg OD
16431962|NCT03757910|Experimental|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
16431963|NCT03757910|Active Comparator|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
16431964|NCT03757897|Experimental|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
16431965|NCT03757884|Experimental|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
16431966|NCT03757871|Experimental|Laser Stimulation|laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.
16431967|NCT03757871|Placebo Comparator|Placebo|The placebo group will have an application of the pen according to the same extinguished laser criteria.
16431968|NCT03757858|Experimental|HT+ACT|
16431969|NCT03757858|Experimental|HT+ACT+PD-1|
16431970|NCT03757858|Experimental|HT+ACT+CT|
16431971|NCT03757858|Active Comparator|HT+CT|
16431972|NCT03757845|No Intervention|Control diet|
16431973|NCT03757845|Experimental|Mediterranean diet|
16431974|NCT03757819|Experimental|Before Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
16431975|NCT03757819|Experimental|During Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
16431976|NCT03757806|Experimental|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
16431977|NCT03757806|No Intervention|Control group|The control group will receive usual care only.
16431978|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
16431979|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
16431980|NCT03757767|Experimental|Intervention arm|Fasting for 26-hours.
16431981|NCT03757754|Experimental|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
16431982|NCT03757754|Experimental|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
16431983|NCT03757754|Experimental|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
16431984|NCT03757754|Experimental|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
16431985|NCT03757754|Experimental|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
16431986|NCT03757754|Experimental|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
16431987|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
16431988|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
16433641|NCT03746587|Experimental|Arimoclomol I|Arimoclomol, oral capsule
16431989|NCT03757728|Other|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
16431990|NCT03757728|Other|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
16431991|NCT03757728|Other|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit [Biolitec Co]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
16431992|NCT03757715|Experimental|Treatment Group|20 mL of 1.3% bupivacaine with 2 mg dexamethasone injected locally in the location for sensory nerves of the sinus cavities and face during the functional endoscopic sinus surgery (FESS) procedure
16431993|NCT03757715|No Intervention|Control Group|No regional anesthetic of any kind during the functional endoscopic sinus surgery (FESS) procedure
16431994|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
16431995|NCT03757702||Healthy group|healthy women and being volunteereed
16431996|NCT03757689|Experimental|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
16431997|NCT03757676|Experimental|No Play|This 'no play' group functioned as the control group.
16431998|NCT03757676|Experimental|At Will Play|This group functioned as 1 of the 2 play groups.
16431999|NCT03757676|Experimental|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
16432000|NCT03757663|Experimental|UV Dosimeter|UV Dosimeter will measure participants' UV exposure for two separate 3-week periods.
16432001|NCT03757650|Active Comparator|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
16432002|NCT03757650|Active Comparator|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
16432003|NCT03757650|No Intervention|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
16432004|NCT03757637|No Intervention|General module|"Control group will be case manager care only group. Eligible patients will also invite and receive their first time assessment as baseline during hospitalization. The usual cancer care group will receive routine cancer care in the inpatient wards through OPD visits."
16432005|NCT03757637|Experimental|NLSCP|NLSCP group will receive 5 section of NLSCP. Contents of scheduled intervention will be developed baed on the literature mentioned above. Ex 1 group, patients will receive at least 3 times face-to-face NLSCP, and two times by telephone calls for following up.
16432006|NCT03757637|Experimental|ICT supported HAP|The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For this group, patients will receive two face to face interventions in the first two sections (pre-discharge from hospital and 5th week post-op). It will be delivered by research nurse to intervene patients and help them to build up the App system. Research nurse will also help patients to be familiar with the operation system. The rest parts of the intervention will all through Apps in the scheduled time. Patients can raise their questions and concerns through APPs. Patients in the HAP can raise their concerns or questions through APP and receive interventions or answers through App interactively.
16432007|NCT03757624|Active Comparator|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
16432008|NCT03757624|Active Comparator|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
16432009|NCT03757611|Experimental|tabetri|Tabetri capsule will be administered orally twice daily for 12 weeks
16432010|NCT03757611|Placebo Comparator|Placebo|Placebo capsule will be administered orally twice daily for 12 weeks
16432011|NCT03757598|No Intervention|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
16432012|NCT03757598|Experimental|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
16432013|NCT03757585|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
16432014|NCT03757585|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
16432015|NCT03757572|Experimental|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.
~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.
~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
16432078|NCT03757143|Experimental|PVI et Nexiva|Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
16433642|NCT03746587|Experimental|Arimoclomol II|Arimoclomol, oral capsule
16432016|NCT03757572|Active Comparator|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.
~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
16432017|NCT03757559|Experimental|Cebranopadol 200 micrograms (Treatment A)|"Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
16432018|NCT03757559|Experimental|Cebranopadol 400 micrograms (Treatment B)|"Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
16432019|NCT03757559|Experimental|Cebranopadol 800 micrograms (Treatment C)|"Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
16432020|NCT03757559|Active Comparator|Hydromorphone IR 8 milligrams (Treatment D)|"Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.
~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
16432021|NCT03757559|Active Comparator|Hydromorphone IR 16 milligrams (Treatment E)|"Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.
~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
16432022|NCT03757559|Placebo Comparator|Placebo (Treatment F)|"Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.
~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
16432023|NCT03757559|Placebo Comparator|Placebo (Treatment G)|"Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
16432024|NCT03757533|Experimental|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
16432025|NCT03757533|Other|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
16432026|NCT03757520|Active Comparator|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
16432027|NCT03757520|Active Comparator|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
16432028|NCT03757507|Experimental|Optoacoustic imaging|Optoacoustic Imaging before and after tracer administration
16432029|NCT03757494|Experimental|Use of Alpha Stim|Use of Alpha Stim Device
16432030|NCT03757481|Other|no intervention|patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin
16432031|NCT03757468|Active Comparator|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
16432032|NCT03757468|Experimental|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
16432033|NCT03757455|Experimental|Enchanced recovery after surgery protocol|ERAS-protocol as described in low risk patients after pancreaticoduodenectomy or total pancreatectomy
16432034|NCT03757455|No Intervention|Standard protocol|Standard recovery protocol after pancreaticoduodenectomy or total pancreatectomy
16432035|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
16432036|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
16432037|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
16432038|NCT03757403|Experimental|RDD1609 followed by Placebo|Application on the perianal area BID
16432039|NCT03757403|Experimental|Placebo followed by RDD1609|Application on the perianal area BID
16432040|NCT03757390|Experimental|Sequence 1|"period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg
~period 2: receive CJ-30060 5/160/10mg"
16432041|NCT03757390|Experimental|Sequence 2|"period 1: receive CJ-30060 5/160/10mg
~period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
16432042|NCT03757377|Active Comparator|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
16432043|NCT03757377|Placebo Comparator|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
16432383|NCT03755193|Active Comparator|SERM plus ELD|To examine the effects of SERM plus ELD in osteoporosis patients
16432044|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
16432045|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
16432046|NCT03757351|Experimental|DNL747 First, Placebo Second|
16432047|NCT03757351|Experimental|Placebo First, DNL747 Second|
16432048|NCT03757351|Experimental|Open-Label Extension|Conducted in the Netherlands only.
16432049|NCT03757338|Active Comparator|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
16432050|NCT03757338|Experimental|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
16432051|NCT03757325|Experimental|DNL747 First, Placebo Second|Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
16432052|NCT03757325|Experimental|Placebo First, DNL747 Second|Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
16432053|NCT03757312|Experimental|Fontan|Patients undergoing Fontan procedure to redirect blood flow from the lower body to the lungs.
16432054|NCT03757312|Active Comparator|Non-Fontan|Patients undergoing other cardiac surgeries requiring cardiopulmonary bypass.
16432055|NCT03757299|Experimental|Self HPV|
16432056|NCT03757286|Experimental|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
16432057|NCT03757286|Active Comparator|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
16432058|NCT03757273|Experimental|FFF with CAD/CAM customized cutting guide|Mandibular reconstruction using free fibular flap with CAD/CAM customized osteotomy guide.
16432059|NCT03757273|Active Comparator|FFF without customized cutting guide|Mandibular reconstruction using free fibular flap without customized osteotomy guide. CAD/CAM 3D model for mandible will be used.
16432060|NCT03757260|Experimental|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
16432061|NCT03757260|Placebo Comparator|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
16432062|NCT03757234|Experimental|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
16432063|NCT03757234|Experimental|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
16432064|NCT03757234|Experimental|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
16432065|NCT03757234|Experimental|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
16432066|NCT03757234|Active Comparator|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
16432067|NCT03757221|Experimental|Combination ixazomib + daratumumab without dexamethasone|Elderly Relapse Refractory Multiple Myeloma Patients treated by Combination ixazomib + daratumumab without dexamethasone
16432068|NCT03757208|No Intervention|Fasting group|
16432069|NCT03757208|Active Comparator|Carbohydrate rich drink (CHD) group|
16432070|NCT03757195|Experimental|augmentation by xenograft|xenograft mixed with plasma extracted from blood
16432071|NCT03757182||Wearable activity monitor|Continuous activity monitoring with Fitbit Charge HR from baseline to up to 1 year from end-of-study.
16432072|NCT03757169|Active Comparator|Control group|Verbal informations about the disease, and exercise behavior, and nutrition.
16432073|NCT03757169|Active Comparator|Hand grip group|Three supervised sessions por week: 4 series (2 at each arm) of two minutes of isometric hand grip contraction at 30% of maximal voluntary contraction. Between series there will be two minutes to rest.
16432074|NCT03757156|No Intervention|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
16432075|NCT03757156|Experimental|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
16432076|NCT03757143|Active Comparator|PVI et Insyte|Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
16432077|NCT03757143|Experimental|CHG et Insyte|Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
16433643|NCT03746587|Experimental|Arimoclomol III|Arimoclomol, oral capsule
16432079|NCT03757143|Experimental|CHG et Nexiva|Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
16432080|NCT03757130|Experimental|AMG 598|Multiple ascending dose cohorts
16432081|NCT03757130|Placebo Comparator|Placebo-controlled|Multiple ascending dose cohorts
16432082|NCT03757130|Experimental|AMG 598, liraglutide|"Multiple ascending dose cohorts
~Additionally liraglutide is escalated to a dose of 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day."
16432083|NCT03757130|Placebo Comparator|Placebo controlled, liraglutide|"Multiple ascending dose cohorts
~Additionally liraglutide is escalated to a dose of 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day."
16432084|NCT03757130|Experimental|AMG 598, stable liraglutide|AMG 598 at a to be determined (TBD) dose in addition to liraglutide 3.0 mg/day
16432085|NCT03757130|Placebo Comparator|Placebo controlled, stable liraglutide|Placebo at a to be determined (TBD) volume in addition to liraglutide 3.0 mg/day
16432086|NCT03757117|Experimental|Intervention|Feminizing hormone therapy and peer navigation
16432087|NCT03757104|Experimental|micro-incentives|micro-incentives only (8 communities)
16432088|NCT03757104|Experimental|EPIC-HIV|Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities)
16432089|NCT03757104|Experimental|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities)
16432090|NCT03757104|No Intervention|control|standard of care
16432091|NCT03757091|Active Comparator|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
16432092|NCT03757091|Experimental|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
16432093|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
16432094|NCT03757065||Systemic Lupus Erythematosus|
16432095|NCT03757065||Sjogren's Syndrome|
16432096|NCT03757065||Multiple Sclerosis|
16432097|NCT03757065||Systemic Sclerosis|
16432098|NCT03757065||Crohn's Disease|
16432099|NCT03757065||Ulcerative Colitis|
16432100|NCT03757065||Inflammatory Myositis|
16432101|NCT03757052|Experimental|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
16432102|NCT03757039|Experimental|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
16432103|NCT03757039|Active Comparator|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
16432104|NCT03757026|Active Comparator|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
16432105|NCT03757026|Experimental|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
16432106|NCT03757026|Experimental|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
16432107|NCT03757013||Patients treated with Apremilast|Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
16432108|NCT03757000|Experimental|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).
~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
16432109|NCT03756987|Experimental|ESPB group|Patient will receive a single shot of Ropivacaine injection 0.5% 25 mL injected at the erector spinae plane.
16432110|NCT03756987|Placebo Comparator|Control Group|Patient will receive a single shot of normal saline 25 mL injected at the erector spinae plane.
16432111|NCT03756974|Experimental|BX-1 (dronabinol)|BX-1
16432112|NCT03756974|Placebo Comparator|Placebo|Placebo of BX-1
16432113|NCT03756961|Active Comparator|Control|"Control group: The patients receive the routine based anesthesiological treatment during bariatric surgery (Gastric By-Pass or Sleeve Gastrectomy). It consists of:
~General anesthesia induction: TCI Remifentanil Cpt 6 ng/ml/ Cp 3.2 ng/m, Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).
~Maintained by Desflurane MAC (0.6-0.8) adjusted via BIS (40-60) and Remifentanil Cp 4-10 ng/ml.
~Post-operative pain management: Oxycodone 2.5 mg iv if the pain is rated by patient NRS ≧3. Paracetamol 1 g/6 h and Diclofenac 80 mg/24 h."
16432114|NCT03756961|Experimental|Intervention|"Induction: Dexmedetomidine 0.2 micrograms/kg/h iv 5 min, Esketamine 0.1mg/kg + Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).
~Maintained by Desflurane MAC (0.6-0.8) BIS (40-60), Dexmedetomidine 0.2 micrograms/kg/h, Esketamine 0.1-0.3mg/kg/h och 0.1 mg/kg in case of hypertension. At the end of surgery, Lidocaine 1 mg/kg iv (max 4 mg/kg /4 h)
~Post-operative: Dexmedetomidine (0.1-0.2 micrograms/kg/h up to 4 h post-operative). If the pain is rated NRS ≧3: Transcutaneous Nerve Stimulation (TENS) with high intensive 40-50 mA for 1 minute, if the patient still NRS ≧3, the TENS treatment is repeated one more time. If pain NRS ≧3 after two treatments with TENS: Esketamine 0.1mg/kg iv + Lidocaine 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS still ≧3 within 30 minutes after both TENS and Esketamine/Lidocaine, 2.5 mg Oxycodone iv, with a 10 minutes intervals until NRS < 3. Perioperative and at discharge, PCC will be used for the second half of the intervention."
16432115|NCT03756948|Active Comparator|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
16432116|NCT03756948|Experimental|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
16432117|NCT03756922|Experimental|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
16432118|NCT03756922|Experimental|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
16432119|NCT03756922|Experimental|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
16432120|NCT03756922|Experimental|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
16432121|NCT03756909||adenoidectomy group|Operations of adenoidectomy
16432122|NCT03756909||adenotonsillectomy group|Operations of adenotonsillectomy
16432123|NCT03756896|Experimental|Carfilzomib, pomalidomide, dexamethasone|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16432124|NCT03756883|Experimental|Test|Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
16432125|NCT03756883|Active Comparator|Reference|ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
16432126|NCT03756883|Placebo Comparator|Placebo|Placebo
16432127|NCT03756870|Experimental|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
16432128|NCT03756870|No Intervention|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
16432129|NCT03756857|Experimental|Afterload transfer|First, an empty catheter passes to the level of the lower uterine segment under ultrasound guidance to a point where the inner catheter enters the endometrial cavity. The inner sheath is removed slowly, leaving the outer sheath just beyond the internal os. After verifying the catheter's position on the TA ultrasound scan, the physician gives the signal to the embryologist to start the embryo loading. The embryologist brings the loaded inner catheter and inserts it into the outer sheath, which is maintained in its position by the physician.
16432130|NCT03756857|Experimental|Trial Followed by Transfer|First a trial transfer is performed using both the inner catheter and outer sheath connected together in standard configuration, just before the actual embryo transfer. It is passed up to and just through the the internal os. When it appears that the actual transfer will be possible without great difficulty ,the trial catheter is withdrawn. An embryo transfer catheter is loaded and the actual transfer is performed
16432131|NCT03756844|Experimental|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
16432132|NCT03756831|Active Comparator|Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
16432133|NCT03756831|Active Comparator|Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
16432134|NCT03756831|Active Comparator|Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
16432135|NCT03756818|Experimental|Treatment (TAK-659 and paclitaxel)|Patients receive spleen tyrosine kinase inhibitor TAK-659 PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16432136|NCT03756805|Active Comparator|Group 1 (CPAP)|Patient, who are receiving a CPAP
16432137|NCT03756805|Experimental|Group 2 (UAS)|Patient, who are receiving a device for upper airway stimulation
16432171|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
16432384|NCT03755193|Active Comparator|BP plus ELD|To examine the effects of BP plus ELD in osteoporosis patients
16432142|NCT03756779|Experimental|Low Saturated Fat Diet|Goal will be to attain <7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
16432143|NCT03756779|Active Comparator|High Saturated Fat Diet|Goal will be to attain 15% of daily calories from saturated fat. Decrease intake of monounsaturated fat.
16432144|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).
~Group 1 participants are categorised into 4 groups as follows:
~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.
~Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
16432145|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.
~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
16432146|NCT03756753|Experimental|Intervention group- results known|Providers of patients enrolled in this arm of the study will be notified of the point of care respiratory testing results
16432147|NCT03756753|No Intervention|Control group- results not known|Providers of patients enrolled in the study will not be notified of the point of care respiratory testing results
16432148|NCT03756740|Experimental|Telerehabilitation|After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home. The exercises will be sent as a video to his/her mobile or e-mail according to the subject's preference. The exercises will be previously recorded and accompanied with a verbal explanation and instructions on how to correctly perform the exercises, paying close attention to specific points. In total, there will be 10 videos of exercises found effective for LBP patients.. After each face to face meeting, the physical therapist will choose from these 10 videos suitable exercises for the patients.
16432149|NCT03756740|Active Comparator|Control|"After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home.
~subjects will receive the same exercises given to experimental group according to the results of the face to face meeting. The exercises will be shown as printed pictures on paper"
16432150|NCT03756727|Experimental|Ascorbic acid group|the patients received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery.
16432151|NCT03756727|Placebo Comparator|Control comparator group|the patients received 10ml saline at the night before surgery, during the surgery and five days after surgery.
16432152|NCT03756701|Experimental|Group 1|Initial participants in the 10 mind body sessions
16432153|NCT03756701|Active Comparator|Group 2|10 week no intervention groups - receives the mind body interventions after group 1 has completed.
16432154|NCT03756688|No Intervention|Group 1: Control|No treatment will be administered for the entirety of the study (6 months)
16432155|NCT03756688|Experimental|Group 2: Treatment|PTT for 30 min 2x/ day x 3 months, followed by no treatment x 3 months
16432156|NCT03756688|Experimental|Group 3: Treatment|PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months
16432157|NCT03756688|Experimental|Group 4: Treatment|PTT for 30 min 2x day x 6 months
16432158|NCT03756675||haplotype PBSCT group|"Subjects in this group will receive haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system in the treatment of acute leukemia."
16432159|NCT03756649||Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
16432160|NCT03756649||Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
16432161|NCT03756636|Other|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
16432162|NCT03756623|Experimental|Drug: Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
16432163|NCT03756623|Experimental|Drug: Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
16432164|NCT03756623|Placebo Comparator|Drug: Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
16432165|NCT03756610|Active Comparator|Active tACS & active boosting group|The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
16432166|NCT03756610|Other|Active tACS & sham boosting group|The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
16432167|NCT03756610|Sham Comparator|Sham tACS & sham boosting group|The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
16432168|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population
~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.
~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
16432169|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:
~Are suspected of the same cancer or part of an at risk-group
~Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)
~Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
16432170|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
16432172|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population
~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
16432173|NCT03756584|Experimental|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
16432174|NCT03756584|Active Comparator|Control stimulation|iTBS will be performed on the vertex
16432175|NCT03756571|Experimental|Ankle Foot Orthoses-Footwear Combination|The intervention is a Ankle Foot Orthoses Footwear Combination (AFO-FC). This is some form of solid ankle AFO combined with modified footwear individually designed per algorithm.
16432176|NCT03756571|Active Comparator|Traditional Solid Ankle AFO (TSAFO)|"The intervention is a solid AFO (SAFO) aligned with the ankle at 90 degrees and worn with regular footwear. We'll refer to this as the traditional SAFO (TSAFO)..."
16432177|NCT03756558|Experimental|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
16432178|NCT03756519|Experimental|Exercise|Participants in the exercise intervention arm will receive the usual care protocol plus a standardized, evidence informed exercise intervention provided by trained physiotherapy students. The exercise intervention will begin with a brief assessment to rule out contraindications to exercise and to identify any directional preferences (e.g. pain with lumbar flexion and relief with extension). The PT will then be taught four standardized exercises: the pelvic tilt exercise, a rotational exercise, a tailored graded walking program taking into account the current abilities of the patient, and an exercise based on the directional preference of the individual. These will be re-enforced with a handout including the rationale, instructions and dosage recommendations for the exercises.
16432179|NCT03756519|Active Comparator|Usual care|Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
16432180|NCT03756506|Active Comparator|Novel Microbicidal Liquid Polymer|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.
~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply product with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. The Polymer will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
16432181|NCT03756506|No Intervention|Control group: no Novel Microbicidal Liquid Polymer|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.
~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.
~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
16432182|NCT03756493|Experimental|OFD+ABG+L-PRF treated patients|Periodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures.
16432183|NCT03756493|Active Comparator|OFD+ABG treated patients|Periodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
16432184|NCT03756493|Active Comparator|OFD treated patients|Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
16432185|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management
~100 participants"
16432186|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation
~35 participants"
16432187|NCT03756467|No Intervention|Arm 1|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff
16432188|NCT03756467|Experimental|Arm 2|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up
16432189|NCT03756467|Active Comparator|Arm 3|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up.
16432192|NCT03756441|Experimental|Experimental: Mindfulness group|This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion protocol. They will group with have eight meetings, one per week, during a half hour and will learn the techiques to practice everyday during the week.
16432193|NCT03756441|Active Comparator|Psychotherapy group|This group will learn group problem solving techniques during eight weeks
16432194|NCT03756428|Experimental|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
16501567|NCT03280680|Experimental|Female group sessions|
16432196|NCT03756415|Experimental|mask plus CO2 removal device|"a traditional mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask R,"
16432197|NCT03756415|Active Comparator|traditional face mask|Traditional mask without a CO2 clearance device inserted
16432198|NCT03756402||Healthy Subjects|All subjects underwent protein loading test and IRRIV test on the same day. The renal resistive index (RRI) measurements were performed by one trained sonographer using a multi-frequency convex probe through a manual RRI calculations. The RRIs were measured on three interlobular arteries (superior, middle and inferior) in each kidney, and expressed as a mean value. RFR was measured using an oral protein loading test and was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Urinary creatinine and sCr were measured by the enzymatic method (IL testTM Instrumentation(R), Laboratory SpA, Milano, Italy) and by ILab650 (Instrumentation Laboratory, Werfen Group, Barcelona, Spain).
16432199|NCT03756389|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
16432200|NCT03756389|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
16432201|NCT03756376||IRRIV and RFR|Enrolled patients will receive IRRIV test and RFR assessment. RFR will be evaluated through a protein loading test. (1.2 g of protein/Kg of body weight) performed with cooked beef. The RFR was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Concerning the IRRIV test, a weight of 10% of the patient's body weight is applied on the abdominal wall. RRIs is recorded in a middle interlobular artery, every minute for 10 minutes during the echo-renal stress test. The lowest RRI reached is taken as reference (stress RRI). The IRRIV is defined as the percentage difference between baseline RRI and stress RRI
16432202|NCT03756363|Experimental|Non-solvent|Non-solvent use of a rotary retreatment system
16432203|NCT03756363|Experimental|Solvent|Solvent use in combination with a rotary retreatment system
16432204|NCT03756350|Experimental|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
16432207|NCT03756324|Experimental|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.
~Education, basic medical order."
16432208|NCT03756324|Experimental|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.
~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.
~Education, basic medical order."
16432209|NCT03756324|Active Comparator|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.
~Education, basic medical order."
16432210|NCT03756298|Experimental|Combination|Atezolizumab + capecitabine combination arm
16432211|NCT03756298|Active Comparator|Control|Capecitabine alone arm
16432212|NCT03756285|Experimental|AZD4831|AZD4831 tablets taken orally for for 90 days.
16432213|NCT03756285|Placebo Comparator|Placebo|Placebo tablets taken orally for 90 days.
16432214|NCT03756272|Experimental|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
16432215|NCT03756272|Placebo Comparator|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
16432216|NCT03756259|Other|Pneumonia perception arm|Caregivers of children under five will be interviewed qualitatively to understand in depth on perception of pneumonia. These will be mothers, fathers and grandmothers of these children. Once the formative research is done, it will inform design of an intervention whereby the caregivers will be recruited to be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject. The LHWs will also be trained on pneumonia case finding which they will manage at their end and refer if required while doing daily field visits.
16432217|NCT03756246|Experimental|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
16432218|NCT03756246|Active Comparator|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
16432219|NCT03756233|Active Comparator|Remifentanil gradually withdrawal group|20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes.
16432220|NCT03756233|Active Comparator|Remifentanil immediately stop group|The control group stopped remifentanil 10 minutes before the end of the operation.
16432221|NCT03756220|Experimental|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
16432222|NCT03756220|Placebo Comparator|Control|Normal Saline Solution
16432223|NCT03756207|Experimental|Multidisciplinary Therapy|Multidisciplinary bladder-preservation therapy: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
16432224|NCT03756194|Experimental|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.
~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
16432225|NCT03756194|Other|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.
~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
16501568|NCT03280680|Other|No group sessions|
16432226|NCT03756194|No Intervention|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.
~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
16432227|NCT03756181|Experimental|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of compassion: self-kindness, mindfulness, and common humanity, and will work on soothing the processes of self-criticism, self-neglect and perfectionism that are believed to withhold upon experiencing psychological distress. There will also be sessions dedicated to incorporating self-compassion in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
16432228|NCT03756181|Active Comparator|Five-week Mindfulness-based Stress Reduction program (MBSR5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator will perform a brief check-in and may discuss the student's experience within the course of the session. These discussions will reinforce the guiding principles of meditation: awareness, non-judgment and acceptance and will work on automatic mental processes that are believed to be at the root of experiencing psychological distress. There will also be sessions dedicated to incorporating mindfulness into daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
16432229|NCT03756168|Experimental|Treatment subjects|Single group of subjects with will have the treatment of a 1060 nm diode laser administered to them
16432230|NCT03756155|Experimental|Group 1|Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30%-40% value.
16432231|NCT03756155|Experimental|Group 2|Group 2 will complete a protocol with 5 sets of 20 second isometric holds followed by 20 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30% value.
16432232|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
16432233|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
16432234|NCT03756129|Experimental|MIJ821 low dose weekly|Infusion. MIJ821 low dose weekly - 0.16 mg/kg
16432235|NCT03756129|Experimental|MIJ821 low dose bi-weekly|Infusion. MIJ821 low dose bi-weekly - 0.16 mg/kg
16432236|NCT03756129|Experimental|MIJ821 high dose weekly|Infusion. MIJ821 high dose weekly - 0.32 mg/kg
16432237|NCT03756129|Experimental|MIJ821 high dose bi-weekly|Infusion. MIJ821 high dose bi-weekly - 0.32 mg/kg
16432238|NCT03756129|Placebo Comparator|Placebo weekly|Infusion. Placebo weekly
16432239|NCT03756129|Active Comparator|Ketamine 0.5 mg/kg weekly|Infusion. Ketamine 0.5 mg/kg weekly
16432240|NCT03756116|Experimental|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
16432241|NCT03756116|Active Comparator|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
16432242|NCT03756103|Experimental|SPH3127 tablet Dose 1|Low-dose group
16432243|NCT03756103|Experimental|SPH3127 tablet Dose 2|Mid-dose group
16432244|NCT03756103|Experimental|SPH3127 tablet Dose 3|High-dose group
16432245|NCT03756103|Placebo Comparator|SPH3127 tablet Placebo|Placebo Control group
16432246|NCT03756090|Experimental|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
16432247|NCT03756090|Placebo Comparator|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
16432248|NCT03756077||Primary diagnosis and staging|Patients suspected of or diagnosed with prostate cancer who want a differential diagnosis and staging by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT before treatment
16432249|NCT03756077||Evaluation of recurrence|Patients with a history of prostate cancer and elevated PSA level after treatment, who need to determining whether or not there are recurrences/metastatic lesions and its locations by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
16432250|NCT03756064|Experimental|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
16432251|NCT03756064|Placebo Comparator|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
16432252|NCT03756051||Cohort|This study will collect prospective longitudinal data to characterize rates and identify correlates of a) physical harms due to follow-up tests, b) financial harms, and c) inappropriate screening using electronic medical record data and manual chart review. The study will also use surveys and semi-structured interviews to characterize rates and identify correlates of screening-related psychological harms, e.g. cancer specific worry, situational anxiety, mood disturbances, and decisional regret. Lastly, investigators will create and disseminate a balance sheet of benefits and harms to inform patients, providers, healthcare organizations, payers, and policymakers about the role of hepatocellular carcinoma screening in patients with cirrhosis.
16432253|NCT03756038|Experimental|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
16432254|NCT03756038|Placebo Comparator|Drug: Oral Placebo|
16432255|NCT03756025|Experimental|Vitro Molar® (DFL, Rio de Janeiro, Brazil)|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Vitro Molar® (DFL, Rio de Janeiro, Brazil).
16432256|NCT03756025|Active Comparator|Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).
16432257|NCT03756012|Active Comparator|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths <500 μsec.
16432258|NCT03756012|Active Comparator|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths >1000 μsec
16433644|NCT03746587|Placebo Comparator|Placebo|Placebo oral capsule matching experimental arm
16432259|NCT03755999|Experimental|PIOMI treat group|Preterm infant receive oral massage using the premature infant oral motor intervention (PIOMI)
16432260|NCT03755999|No Intervention|Routine care group|Preterm infant receive routine care of neonatal intensive care unit(NICU)
16432261|NCT03755986|Other|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
16432262|NCT03755973|Experimental|CFA plus step-down rFSH (1A)|"A single dose of 150 IU of CFA followed by daily rFSH will be administered. The initial rFSH administration will be dosed between 100 IU and 200 IU according to the following criteria:
~200 IU: <3 follicles above 13 mm visible on transvaginal ultrasound;
~150 IU, >2 follicles above 13 mm and circulating day-8 follicle-stimulating hormone (FSH) levels ≤20 IU/mL.
~100 IU, >2 follicles above 13 mm and circulating day-8 FSH levels >20 IU/mL;
~Subjects will perform a step-down daily rFSH dose (fixed decreases in the dosing of 25 IU/day) until the triggering criteria are met or a minimum of 50 IU/day is reached. Subjects with <3 follicles above 13 mm visible will maintain 200 IU/day of rFSH until this criterion is met, initiating a fixed 25 IU/day stepdown protocol only from then onwards."
16432263|NCT03755973|Experimental|CFA plus fixed daily dose rFSH (1B)|A single dose of 150 IU of CFA followed by a fixed daily rFSH dosing protocol of 200 IU will be administered as ovarian stimulation
16432264|NCT03755973|Active Comparator|Fixed daily dose rFSH only|A fixed daily rFSH dosing protocol of 200 IU will be administered as ovarian stimulation
16432265|NCT03755960|Experimental|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
16432266|NCT03755960|Active Comparator|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
16432267|NCT03755947|Experimental|IGV|"Cytoreduction 3 cycles (I) Ibrutinib, [Imbruvica, Janssen]
~Induction 6 cycles (G) Obinutuzumab, [Gazyva, Roche]
~Consolidation 12 cycles (V) Venetoclax, [Venclexta, Abbvie]."
16432273|NCT03755921|Experimental|Brief and intensive therapy|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, daily
16432274|NCT03755921|Active Comparator|Therapy Weekly|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, weekly
16432275|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
16432276|NCT03755895|Experimental|experimental|patients to benefit from brachytherapy detachment under KALINOX and formal hypnosis
16432277|NCT03755895|Active Comparator|active comparator|patients to benefit from brachytherapy detachment under KALINOX
16432278|NCT03755882|Experimental|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
16432279|NCT03755882|Experimental|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
16432280|NCT03755869|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
16432281|NCT03755830|Active Comparator|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
16432282|NCT03755830|Experimental|healthy controls|A skin biopsy will be taken from each control subject.
16432283|NCT03755817|Experimental|Scenar application|Application of SCENAR device on
16432284|NCT03755817|Placebo Comparator|Scenar application with the device off|Application of SCENAR device off
16432285|NCT03755804|Experimental|Low-Risk|Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
16432286|NCT03755804|Experimental|Intermediate-Risk|Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
16432287|NCT03755804|Experimental|High-Risk|Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
16432288|NCT03755791|Experimental|Experimental arm|Subjects with advanced HCC will receive cabozantinib 40 mg oral, qd + atezolizumab 1200 mg infusion, q3w
16432289|NCT03755791|Active Comparator|Control arm|Subjects with advanced HCC will receive sorafenib 400 mg bid (twice a day)
16432290|NCT03755791|Other|Single-Agent Cabozantinib arm|Subjects with advanced HCC will receive cabozantinib 60 mg qd
16432291|NCT03755778|Experimental|EDP-938 and itraconazole interaction (Part 1)|
16432292|NCT03755778|Experimental|EDP-938 and rifampin interaction (Part 2)|
16432293|NCT03755778|Experimental|EDP-938 and quinidine interaction (Part 3)|
16432294|NCT03755765|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
16432295|NCT03755765|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
16432296|NCT03755752|Experimental|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
16432297|NCT03755752|Experimental|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
16432298|NCT03755739|Experimental|Pembrolizumab via localized infusion|"This group dividied into two subgroups:
~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.
~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a total dose of 150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
16432299|NCT03755739|Active Comparator|Checkpoint inhibitor (CPI) Pembrolizumab via vein infusion|Checkpoint inhibitor (CPI) such as Pembrolizumab is administrated with a total dose of 2mg/kg via vein infusion (30 min), every 3 weeks.
16432303|NCT03755700|Placebo Comparator|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
16432304|NCT03755700|Active Comparator|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
16432305|NCT03755700|Active Comparator|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
16432306|NCT03755687|Experimental|Art Therapy Intervention|Standardized mixed media art therapy directives (e.g. drawing/painting/collaging within a circle)
16432307|NCT03755674|Experimental|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
16432308|NCT03755674|No Intervention|CONTROL|Patients following a traditional or conventional hypocaloric diet
16432309|NCT03755661|Experimental|Intervention|This intervention arm is a combined in-person text messaging intervention
16432310|NCT03755661|No Intervention|Assessment Only Control|The is the assessment only comparison condition
16432311|NCT03755648|Experimental|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
16432312|NCT03755648|Other|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
16432313|NCT03755648|Experimental|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
16432314|NCT03755635|No Intervention|Standard of care|Continuously monitoring of neonatal sepsis under standard of care at one site
16432315|NCT03755635|Experimental|Hand hygiene|The WHO multimodal hand hygiene strategy is implemented at one site
16432316|NCT03755622|Active Comparator|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
16432317|NCT03755622|Experimental|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
16432318|NCT03755609|Active Comparator|patients with oxycodone|
16432319|NCT03755609|Sham Comparator|patients with fentanyl|
16432320|NCT03755596|Experimental|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
16432321|NCT03755583|Other|EEN group|Received exclusive enteral nutrition after enrollment.
16432322|NCT03755570||CRT: Main Arm|"Cardiac Resynchronisation Therapy (CRT): Main Arm ~98 participants
~Prior to CRT Implantation & Post-Implant 6-Month Device Follow-Up Clinic:
~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning, Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B
~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
16432371|NCT03755232|Experimental|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
16432372|NCT03755232|Experimental|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
16432373|NCT03755232|Active Comparator|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
16432323|NCT03755570||ICD and PPM: Control Arm|"Implantable Cardioverter-Defibrillator (ICD) and Permanent Pacemaker (PPM): Control Arm ~98 participants
~Prior to ICD or PPM Implantation & Post-Implant 6-Month Device Follow-Up Clinic:
~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B
~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
16432324|NCT03755557|Placebo Comparator|Placebo|Application of a placebo nasal spray once daily for 8 days Nasal Sprays
16432325|NCT03755557|Active Comparator|Rhinocort|"Nasal Sprays Application of Rhinocort Aqua 64 micrograms, nasal spray once daily for 8 days. Daily dosage 256 µg/d"
16432326|NCT03755557|Experimental|Budesolv|Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays
16432327|NCT03755544||Asthma patients|"Male or female patients with diagnosed asthma who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.
~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
16432328|NCT03755544||COPD patients|"Male or female patients with diagnosed COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.
~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
16432329|NCT03755531|Experimental|Carbetocin|One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection after labor of the baby at once.
16432330|NCT03755531|Active Comparator|Oxytocin|One ml of Oxytocin (10 IU), was given as a bolus intravenous injection after labor of the baby at once.
16432331|NCT03755518|Experimental|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
16432332|NCT03755518|Experimental|Administration of Luspatercept 1.33 mg/kg|Administered as a subcutaneous injection concomitantly with Fedratinib at 3-week (21 day) cycles
16432333|NCT03755505||Healthy Smoker|Healthy smoker with normal spirometry value
16432334|NCT03755505||COPD|Patients with smoking history at least 10 pack-year Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
16432335|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
16432336|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
16432337|NCT03755479||Single Arm Group|Patient on multiple daily injections will start Hybrid Closed Loop System Insulin Pump Minimed 670G
16432338|NCT03755466|Active Comparator|BARI|
16432339|NCT03755466|Active Comparator|Bio|
16432340|NCT03755466|Active Comparator|Tofa|
16432341|NCT03755453|Active Comparator|Audéo B-Direct fitted with fitting method A|Traditional standard fitting method which do not include adjustments from the participants.
16432342|NCT03755453|Experimental|Audéo B-Direct fitted with fitting method B|Alternative fitting method which includes additional adjustments from the participants.
16432343|NCT03755440|Experimental|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
16432344|NCT03755427|Experimental|15μg H7N9 Vaccine|Participants will be inoculated with 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
16432345|NCT03755427|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will be first inoculated with one dose of seasonal influenza vaccine and followed with one dose of aluminum hydroxide adjuvant at 21-day intervals.
16432346|NCT03755414|Experimental|Pilot Study: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy
~Stem cell transplantation on Day 0
~Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently
~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
16432347|NCT03755414|Experimental|Expansion Phase: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy
~Stem cell transplantation on Day 0
~Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently
~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
16432348|NCT03755401|Experimental|TFPP|TFPP is a manualized 16-24 session psychodynamic psychotherapy targeted on trauma symptoms of PTSD
16432349|NCT03755401|Active Comparator|TAU|TAU in this study is treatment for PTSD as currently delivered at the VA
16432350|NCT03755388|Experimental|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
16432374|NCT03755232|Active Comparator|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
16432375|NCT03755219||StdPPM|Standard pure polypropylene mesh
16432376|NCT03755219||LWM|Lightweight mesh: Either a pure polypropylene mesh, or a polypropylene-based composite mesh
16432377|NCT03755219||Tacks, metal|Metal staples or tacks
16432378|NCT03755219||Tacks, absorbable|Absorbable synthetic staples or tacks
16432379|NCT03755219||Tacks, uncategorized|Staples or tacks were in SHR 2005-2011 not further categorized
16432351|NCT03755375|Active Comparator|E-stim Group|The E-stim Group will start treatment after the assessment. Interventions:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
16432352|NCT03755375|Active Comparator|Postural Group|The Postural Group will star treatment after the assessment. The interventions will be: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
16432353|NCT03755375|Placebo Comparator|E-stim Control Group|The E-stim Control Group will start treatment 3 months after the assessment: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
16432354|NCT03755375|Placebo Comparator|Postural Control Group|The Postural Control Group will start treatment 3 months after the assessment:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
16432355|NCT03755362|Active Comparator|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
16432356|NCT03755362|Experimental|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
16432357|NCT03755349|Experimental|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
16432358|NCT03755349|Active Comparator|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
16432359|NCT03755310|Experimental|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
16432360|NCT03755310|Placebo Comparator|Placebo|Equivalent dosage, route of administration and dose regimen.
16432361|NCT03755297|Other|Rheumatoid arthritis|Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
16432362|NCT03755297|Other|Osteoarthritis|Control patients and Blood sample analysis of patients treated as standard care
16432363|NCT03755297|Other|Rheumatoid arthritis with JAK/STAT inhibitors|Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care
16432364|NCT03755284|Experimental|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.
~For the pregnant women included in the experimental group:
~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
16432365|NCT03755284|No Intervention|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.
~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.
~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.
~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.
~Birth action follow-up form and postpartum interview forms were applied"
16432366|NCT03755258|Experimental|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
16432367|NCT03755258|Experimental|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
16432368|NCT03755258|Experimental|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
16432369|NCT03755258|Placebo Comparator|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
16432370|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical
16432385|NCT03755193|Active Comparator|ELD alone|To examine the effects of ELD alone in osteoporosis patients
16432386|NCT03755180|Experimental|Group 1|Exercise Group
16432387|NCT03755180|Active Comparator|Group 2|Compression Group
16432388|NCT03755167|Experimental|IPL344|IV IPL344 administered once a day
16432389|NCT03755154|Experimental|S65487 - initial scheme|
16432390|NCT03755154|Experimental|S65487 - alternative scheme|
16432391|NCT03755141|Experimental|Herzuma|Herzuma + TPC
16432393|NCT03755115|Experimental|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, D1,30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
16432394|NCT03755102|Experimental|Cohort 1: Participants treated with dacomitinib alone|Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.
16432395|NCT03755102|Experimental|Cohort 2: Participants treated with dacomitinib in combination with osimertinib|Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation
16432396|NCT03755089|Active Comparator|Oral Phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200mg phenazopyridine to take by mouth 1-2 hours before their scheduled procedure.
16432397|NCT03755089|Active Comparator|Intravesical Lidocaine|Patients randomized to the intravesical lidocaine arm will have the bladder back-filled with 30mL 2% lidocaine for the 20 minutes immediately preceding their procedure.
16432398|NCT03755076|Experimental|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
16432399|NCT03755063|Experimental|Treatment arm|Tablet with speech therapy apps
16432400|NCT03755063|No Intervention|Standard of Care|The standard care provided by speech language therapists.
16432401|NCT03755050||Sleigh Accident|Accident while using a sleigh
16432402|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
16432403|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
16432404|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
16432405|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
16432406|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
16432407|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
16432408|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
16432409|NCT03755037|Active Comparator|Estradiol and cc|"Group 1 received estradiol, cc and placebo simillar to sildenafil for induction of ovulation.
~CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient then ethinyl estradiol 0.05mg orally twice daily on the 8th day of same cycle till 11th day."
16432410|NCT03755037|Active Comparator|Sildenafil and cc|Group 2 received CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient, sildenafil citrate (Respatio) 20 mg tab orally 3 times daily from8th day of same cycle till 11th day and placebo simillar to estradiol.
16432411|NCT03755037|Placebo Comparator|Placebo and cc|Group 3 received cc and placebo similar to sildenafil and placebo similar to estradiol with the same doses.
16432412|NCT03755024||normal group|fetuses with normal growth
16432413|NCT03755024||Growth retardation group|fetuses with retarded growth
16432414|NCT03755011|Experimental|patients exposed to white noise|Six patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined; pausing will be at nurse, provider, and patient discretion during routine care and conversations with the patients.
16432415|NCT03755011|Placebo Comparator|usual care|Six patients exposed to normal ICU activity noise.
16432416|NCT03754998|Experimental|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
16432417|NCT03754985||Hyperbaric Oxygen Therapy|The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.
16432418|NCT03754972|Experimental|Lumbar spinal stenosis surgery candidate|Patients with lumbar spinal stenosis and spondylolisthesis that have previously consented to surgical treatment. After recording the initial surgical plan, the Sagittal plane shear index (SPSI) will be provided to the surgeon. The surgeon may change the initial surgical plan based on the stability metric.
16432419|NCT03754959|Experimental|Dose Group 1|
16432420|NCT03754959|Experimental|Dose Group 2|
16432421|NCT03754959|Experimental|Dose Group 3|
16432422|NCT03754959|Experimental|Dose Group 4|
16432423|NCT03754959|Experimental|Dose Group 5|
16432424|NCT03754933|Experimental|Ad/PNP + fludarabine phosphate, 5 cycles|
16432425|NCT03754920|Experimental|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
16432495|NCT03754361|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis treatment 3-4 times per week,2-4 hours each time.
16432426|NCT03754907|Experimental|stapled anastomosis group|Following the first side-to-side anastomosis at the antimesenteric border in both intestinal limbs, the staple lines are oversewn to reinforce the crotch. Thereafter, the stapler is again fired across the joined intestinal limbs to close the enterotomies. The suture line of the side-to-side anastomosis should not overlap, and the staple lines are oversewn to reinforce the double-stapled areas.
16432427|NCT03754907|Active Comparator|hand-sewn anastomosis group|Patients chose HA group will performed in an end-to-end manner using absorbable suture material.
16432428|NCT03754894|Experimental|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
16432429|NCT03754894|Experimental|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
16432430|NCT03754855||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria
16432431|NCT03754842|Placebo Comparator|Placebo|
16432432|NCT03754842|Experimental|Nicotinamide Riboside + Pterostilbene|
16432433|NCT03754829|Experimental|HSKA - Web Group|The first experimental group will receive direct access to the web version of HSKA.
16432434|NCT03754829|Experimental|HSKA - Mobile Group|The second experimental group will receive direct access to the mobile app of HSKA as well as automated supportive text messages based on PST.
16432435|NCT03754829|No Intervention|Control Group|The control group consists of a wait-list and for ethical reasons, participants in this group will gain access to the intervention (either web or mobile application) four months after the baseline.
16432436|NCT03754816|Experimental|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
16432437|NCT03754803||Treatment naïve subjects with HIV infection|Treatment naïve HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included
16432438|NCT03754803||Pre-treated subjects with HIV infection|Pre-treated HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included.
16432439|NCT03754790|Experimental|Fitusiran|Participants will be administered fitusiran as an subcutaneous injection once monthly or every other month for 48 months
16432440|NCT03754777|Experimental|Modified ERAS protocol group|"Laparoscopic appendectomy with modified ERAS protocol group Preadmission. Not available due to the emergency setting. Preoperative care.
~1) Patient brochure with a detailed description of the type of pathology, surgery procedure, rehabilitation process, possible complications, and other.
~Surgery.
~Low pressure (8-9 mmHg) pneumoperitoneum.
~Routinely remove of appendix mesentery in presence of any signs of its inflammation.
~Additional local anesthesia with 0.25% ropivacaine.
~Abdominal cavity draining only in patients with perforated appendicitis and diffuse peritonitis (Gomes 5).
~Postoperative care.
~Early mobilization (2 h after surgery)
~Early fluid intake (2 h after surgery)
~Early liquid food (6 h after surgery)"
16432441|NCT03754777|Placebo Comparator|Standard care group|"Standard care laparoscopic appendectomy. Preadmission. Not available due to emergency setting. Preoperative care. 1) Patient oral informing about the type of pathology, surgery procedure and possible complications. No brochure.
~Surgery.
~Standard pressure (12-14 mmHg) pneumoperitoneum
~Abdominal draining for patients with perforated and not perforated appendicitis complicated by abscess, local or diffuse peritonitis (Gomez ≥ 3A).
~Appendix mesentery removing in the appearance of its necrotic changes.
~No intraabdominal anesthesia. Postoperative care.
~1) Mobilization in 4-6 h after surgery 2) Fluid intake in 6 hours 3) Liquid food intake in 12 hours"
16432442|NCT03754751|Experimental|Modified ERAS program group|Laparoscopic cholecystectomy with the implementation of modified ERAS program
16432443|NCT03754751|Active Comparator|Conventional care group|Laparoscopic cholecystectomy with standard perioperative treatment
16432444|NCT03754738|Experimental|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
16432445|NCT03754738|Active Comparator|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
16432446|NCT03754725|Experimental|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
16432447|NCT03754725|Placebo Comparator|Control|this group will only receive the placebo (sugar pill)
16432448|NCT03754712|Active Comparator|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
16432449|NCT03754712|No Intervention|SSRIs|Patients treated with SSRIs
16432450|NCT03754699|Experimental|Patients with a therapeutic educational intervention|Arm 1 : Interventional group: A therapeutic educational intervention is performed following pre-anesthesia assessment
16432451|NCT03754699|Active Comparator|Patients without therapeutic educational intervention|Arm 2 : Control group: standard information on pain is performed following pre anesthesia assessment
16432452|NCT03754686|Active Comparator|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
16432453|NCT03754686|Active Comparator|Paracetamol|best medical care and oral paracetamol twice daily for five days.
16432454|NCT03754660|Experimental|Untreated patients (Part A)|Untreated PAH and CTEPH patients will be enrolled to test 3 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 1000 µg.
16432455|NCT03754660|Experimental|Untreated patients (Part B)|The highest safe, well tolerated and effective dose of Part A will be chosen for Part B.
16432456|NCT03754660|Experimental|Monotherapy (Part B)|The highest safe, well tolerated and effective dose chosen from Part A will be tested in patients pretreated with PH specific monotherapy.
16432457|NCT03754660|Experimental|Combined therapy (Part B)|The highest safe, well tolerated and effective dose from Part A will be tested in patients dually pretreated with PH specific therapy.
16432458|NCT03754647|No Intervention|Patients receiving SSRIs|This group will be receive SSRIs only
16432459|NCT03754647|Active Comparator|Patients receiving Vitamin C with SSRIs|This group will be receive vitamin C (500mg) twice daily with SSRIs for 8 weeks
16432460|NCT03754634|Experimental|drugs|Eltrombopag and Diacerein
16433733|NCT03745898|Sham Comparator|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
16432461|NCT03754621||Pregnants|400 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment and are TPOAb negative. Serum thyroid functions tests will be obtained on the first visit.
16432462|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
16432463|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
16432464|NCT03754595|Active Comparator|2D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 2D Laparoscopic pancreatoduodenectomy
16432465|NCT03754595|Experimental|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
16432466|NCT03754582|Experimental|Perampanel|Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).
16432467|NCT03754569|Experimental|Peritoneal biopsies|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
16432468|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
16432469|NCT03754543|Active Comparator|Testmeal A|A new, whole-grain infant cereal fortified with ferrous fumarate
16432470|NCT03754543|Active Comparator|Testmeal B|An alternative new whole-grain infant cereal recipe fortified with ferrous fumarate
16432471|NCT03754543|Placebo Comparator|Testmeal C|An existing, refined grain infant cereal fortified with ferrous fumarate
16432472|NCT03754543|Active Comparator|Testmeal D|An existing, whole-grain infant cereal fortified with ferrous fumarate
16432473|NCT03754543|Active Comparator|Testmeal E|An existing, whole-grain infant cereal fortified with ferrous bisglycinate
16432474|NCT03754530|Experimental|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(>3 with WBRT or <=3 with SRS) after PD
16432475|NCT03754530|Experimental|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(>3), or SRS(<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
16432476|NCT03754517||Serofast status|The syphilitic patients who remain in a serologically positive state after therapy
16432477|NCT03754517||Untreated|untreated syphilis cases
16432478|NCT03754517||Serological cure|"In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.
~In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer."
16432479|NCT03754504|Experimental|Cranberry|Whole Cranberry Powder Supplements
16432480|NCT03754504|Placebo Comparator|Placebo|Placebo
16432481|NCT03754491|Experimental|One stage stone removal in mild cholangitis|one-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
16432482|NCT03754491|Experimental|One stage stone removal in moderate cholangitis|one-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
16432483|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
16432484|NCT03754465|Experimental|ALLO-ASC-DFU|Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
16432485|NCT03754465|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
16432486|NCT03754439||Inborn|"Infants born within Nottingham University hospitals
~< 32 weeks gestational age
~< 72 hours old"
16432487|NCT03754439||Transported|- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 < 32 weeks gestational age and <72 hours old Phase 2 any gestation and age
16432488|NCT03754413|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
16432489|NCT03754413|Other|Comparator device|No-treatment
16432490|NCT03754400|Experimental|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
16432491|NCT03754400|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
16432492|NCT03754387|Active Comparator|Antibiotic therapy group|Ceftazidime will chosen as the antibiotic for this study because of its efficacy as a monotherapy for serious intraabdominal infections, requiring only a single, daily dose. Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) is administered for 3 days to patients in the AT group, with the first dose given in the emergency department. The clinical status of patients in the AT group is reevaluated within 12 to 24 hours after admission by the surgeon on call. If the surgeon suspected progressive infection, perforated appendicitis, or peritonitis, the patient will underwent appendectomy. Intravenous antibiotic treatment will followed by 7 days of oral cefuroxime (250mg twice daily).
16432493|NCT03754387|Experimental|Laparoscopic Appendectomy group|Laparoscopic appendectomy will performed using. Prophylactic antibiotics (ceftazidime sodium 50mg/kg/dose ) will administered approximately 30 minutes before the incision was made. No further antibiotics will given to patients in the surgical group unless a wound infection was suspected postoperatively.
16432494|NCT03754361|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment
16432496|NCT03754348|Experimental|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
16432497|NCT03754348|Other|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
16432498|NCT03754348|Experimental|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
16432499|NCT03754335|Experimental|Lumbar puncture|Lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
16432500|NCT03754335|Active Comparator|Sham lumbar puncture|Sham lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
16432501|NCT03754322|Active Comparator|Standard of care|One third of individuals get allocated to the standard of care arm. At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy. If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
16432502|NCT03754322|Experimental|Intervention arm|The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT). If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines. If both are negative then they receive no treatment.
16432503|NCT03754309|Experimental|KY1005 lower dose|Low dose KY1005
16432504|NCT03754309|Experimental|KY1005 higher dose|High dose KY1005
16432505|NCT03754309|Placebo Comparator|Placebo|Matched placebo
16432506|NCT03754296||CATCHVIEW stent retriever|
16432507|NCT03754283|Experimental|Silicone|Indirect bonding performed with the silicone trays
16432508|NCT03754283|Active Comparator|Vacuum formed|Indirect bonding performed with the vacuum formed trays
16432509|NCT03754270|Active Comparator|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
16432510|NCT03754270|Experimental|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
16432511|NCT03754257|Experimental|High-frequency Electrical Stimulation|High-frequency Electrical Stimulation for 40 minutos + conventional physiotherapy, during seven days.
16432512|NCT03754257|Sham Comparator|Sham Electrical Stimulation|Sham Electrical Stimulation for 40 minutes + conventional physiotherapy, during seven days.
16432513|NCT03754244|Experimental|TQB3456|p.o. qd
16432514|NCT03754231|Experimental|Aingeal|All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.
16432515|NCT03754218|Experimental|Amnion membrane product treatment area|The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.
16432516|NCT03754218|Active Comparator|SOC Wound Covering treatment area|The donor wound site (Site B) will be covered per SOC (Standard of care).
16432517|NCT03754205|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.
~The laser parameters that will be used are the following: (1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode."
16432518|NCT03754205|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.
~The laser parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode."
16432519|NCT03754192|Other|perfusion computed tomography|Will be realsed before liver surgery
16432520|NCT03754179|Experimental|Arm A phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.
~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
16432521|NCT03754179|Active Comparator|Arm B phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.
~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily until disease progression. At disease progression, add-on of hydroxychloroquine 200 mg twice daily. Treatment until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment"
16432522|NCT03754179|Experimental|Phase 1|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.
~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
16432621|NCT03753451|Active Comparator|Group 4|20 patients with periodontal disease and without coronary artery disease received treatment of periodontal disease
16432523|NCT03754166|Experimental|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).
~Visual spatial cueing is displayed in the bedroom and the bathroom."
16432524|NCT03754166|No Intervention|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
16432525|NCT03754153|Experimental|Balanced Binocular Viewing (BBV)|The experimental intervention will be BBV treatment, i.e. viewing movies for one hour or 2x30min/day on a Nintendo 3DSXL console. With this technology, the Investigators will show blurred images to the better-seeing eye and normal images to the amblyopic eye, encouraging the use of the amblyopic eye and improving acuity.
16432526|NCT03754153|Active Comparator|Standard Therapy - Occlusion (patching) or blurring (atropine)|The control intervention will be either atropine eyedrops twice a week or daily occlusion (patching) therapy of the better-seeing eye (which are the current standards). As per clinical standard, parents will be offered the choice of occlusion or eyedrop treatment.
16432527|NCT03754140|Experimental|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
16432528|NCT03754127|Experimental|Active group|tDCS
16432529|NCT03754127|Sham Comparator|Sham group|Sham tDCS
16432530|NCT03754114|Active Comparator|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
16432531|NCT03754114|Active Comparator|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
16432532|NCT03754088||Cystic fibrosis|Three cystic fibrosis patients who are homozygous for the p.Phe508del mutation.
16432533|NCT03754088||Healthy subjects|Three healthy subjects.
16432534|NCT03754075||CME group|The CME group consisted of patients, who underwent elective CME for right-sided colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2013.
16432535|NCT03754075||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for right-sided adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
16432536|NCT03754062|Placebo Comparator|Placebo|Placebo control
16432537|NCT03754062|Experimental|Haloperidol 3mg|Haloperidol
16432538|NCT03754062|Experimental|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
16432539|NCT03754049|Experimental|TLC599 12 mg|12 mg DSP with 100 μmol phospholipid via IA injection;
16432540|NCT03754049|Experimental|TLC599 6 mg|6 mg DSP with 50 μmol phospholipid via IA injection.
16432541|NCT03754049|Active Comparator|DSP 4mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.
16432542|NCT03754036|Experimental|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
16432543|NCT03754036|Experimental|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
16432544|NCT03754010|Placebo Comparator|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
16432545|NCT03754010|Experimental|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
16432546|NCT03754010|Experimental|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
16432547|NCT03754010|Experimental|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
16432548|NCT03753997|No Intervention|Conventional therapy|Patiens´s will come to the clinic for regular contact with a diabetes nurse.
16432549|NCT03753997|Experimental|Treatment by a Psychologist|Patients will meet with a diabetes educated psychologist over 9 months and will come to the clinic for regular contact with a diabetes nurse
16432550|NCT03753984|Experimental|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
16432551|NCT03753984|Experimental|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
16432552|NCT03753971|Experimental|Apneas with and without intervention|Each patient will be his own control.
16432622|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
16432623|NCT03753425||PEG4L, four liters polyethylene glycol|PEG4L, four liters polyethylene glycol
16432553|NCT03753958|Experimental|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
16432554|NCT03753958|Experimental|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
16432555|NCT03753945|Experimental|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.
~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
16432556|NCT03753932|Experimental|Intervention|Dentures (fixed oral prosthesis) compared with standard treatment (removable oral prosthesis).
16432557|NCT03753919|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.
16432558|NCT03753906|Experimental|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
16432559|NCT03753880|Experimental|Hemopatch|Hemopatch used to cover the resection surface after LR
16432560|NCT03753867|Experimental|Acitretin treatment|
16432561|NCT03753854|Active Comparator|SS patients|"Homozygous sickle cell patients
~Each patient will undergo the following:
~polysomnography and oxygen saturation exam
~calculation of VOC rate within the two previous years
~Blood samples
~Physiological measurements"
16432562|NCT03753854|Experimental|SS patients apneic|"Homozygous sickle cell patients after one year of continuous positive airway pressure treatment
~Each patient will undergo the following:
~polysomnography and oxygen saturation exam
~calculation of VOC rate within the two previous years
~Blood samples
~Physiological measurements"
16432563|NCT03753841|Active Comparator|Adjustment of oral diet|Patients who need a change in their diet regime, in whom FEES shows that they have not the adequat diet.
16432564|NCT03753841|No Intervention|No adjustment of oral diet|Patients who have the adequat diet based on FEES findings.
16432565|NCT03753828||patients de novo colonized by fungi|Patients in Cystic Fibrosis de novo colonized by fungi during their follow-up
16432566|NCT03753815|Active Comparator|19G FNA needle|Patients referred for EUS-guided tissue acquisition of AIP
16432567|NCT03753815|Active Comparator|20G FNB needle|Patients referred for EUS-guided tissue acquisition of AIP
16432568|NCT03753802|Experimental|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
16432569|NCT03753802|Placebo Comparator|Control|The control group will not receive physiotherapy treatment.
16432570|NCT03753789|Experimental|Microwave Ablation|NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.
16432571|NCT03753776|Placebo Comparator|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
16432572|NCT03753776|Experimental|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
16432573|NCT03753776|Placebo Comparator|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
16432574|NCT03753776|Experimental|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
16432575|NCT03753763|Experimental|Active|Safinamide methanesulfonate film-coated tablets once daily
16432576|NCT03753763|Placebo Comparator|Placebo|Safinamide Methanesulfonate matching placebo film-coated tablets once daily
16432577|NCT03753750|Experimental|Actual stimulation|Subjects enrolled in the
16432578|NCT03753750|Sham Comparator|Sham stimulation|
16432579|NCT03753737||Chemsex|Men who have Sex with Men (MSM) attending an addiction care center for past or present mild, moderate or severe substance-related disorder(s) according to DSM-V criteria, occurring in a sexual context and concerning cathinones, GHB/GBL, methamphetamine, cocaine and/or ketamine.
16432580|NCT03753737||Control|Men who have Sex with Men (MSM) consulting for a PrEP (HIV Pre-Exposure Prophylaxis) prescription who have never used cathinones, GHB/GBL, methamphetamine, cocaine or ketamine before or during sex.
16432581|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
16432582|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
16432583|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
16432584|NCT03753711|Experimental|LDH (lumbar disc hernia)|
16432585|NCT03753698|Experimental|eCoin|Neuromodulation of posterior tibial nerve
16432586|NCT03753685|Experimental|X-396(Ensartinib) Capsule|
16432587|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
16432588|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
16432589|NCT03753659|Experimental|Pembrolizumab with local ablation|"Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2
~Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3
~Pembrolizumab 200mg IV administration 2 days after local ablation
~Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
16432590|NCT03753646|Experimental|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
16432591|NCT03753646|No Intervention|Only lactating allowance|Mothers will receive only lactating allowance
16432592|NCT03753633|Experimental|Speech therapy Group|25 patients will be treated with speech therapy, once a week, during 40 minutes for 12 weeks. Oropharyngeal exercises will be performed under the supervision of a speech therapist. Patients will perform the oropharyngeal exercises at home every day.
16432593|NCT03753633|Sham Comparator|Control Group|25 patients will perform inspiratory and expiratory exercises recruiting diaphragmatic muscle.
16432594|NCT03753620|Experimental|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
16432595|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
16432596|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
16432597|NCT03753581|Experimental|Care protocol plus microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.
~Intervention with microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer."
16432598|NCT03753581|Placebo Comparator|Care protocol plus placebo microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.
~Placebo microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer previously handled that do not emit current."
16432599|NCT03753568|Experimental|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
16432600|NCT03753555|Active Comparator|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
16432601|NCT03753555|Experimental|high-dose statin group|high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.
16432602|NCT03753542|Experimental|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
16432603|NCT03753542|No Intervention|Control|The Control group will receive routine care
16432604|NCT03753529|Experimental|deep friction massage group|
16432605|NCT03753529|Experimental|pressure release group|
16432606|NCT03753529|Experimental|control group|
16432607|NCT03753516|Active Comparator|Laparoscopic - Vaginal Cuff Closure|
16432608|NCT03753516|Active Comparator|Vaginal - Vaginal Cuff Closure|
16432609|NCT03753503|Experimental|PD-TR|"Intervention:
~exercise, dose: 8-week HIIT program (three times a week) & conventional physical therapy"
16432610|NCT03753503|Active Comparator|PD-NTR|conventional physical therapy
16432611|NCT03753503|No Intervention|Healthy controls|healthy controls without any kind of therapy
16432612|NCT03753490|Other|ABC score guided therapy|Individual treatment recommendations based on the ABC-scores for stroke and bleeding.
16432613|NCT03753490|Other|Standard care|Management according to local practice, national and international guidelines.
16432614|NCT03753477|Experimental|Test Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
16432615|NCT03753477|Active Comparator|Reference Drug|Sevikar and Crestor
16432616|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
16432617|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
16432618|NCT03753451|No Intervention|Group 1|20 patients without periodontal disease and coronary artery disease
16432619|NCT03753451|No Intervention|Group 2|20 patients without periodontal disease and with coronary artery disease
16432620|NCT03753451|Active Comparator|Group 3|20 patients with periodontal disease and with coronary artery disease received treatment of periodontal disease
16432624|NCT03753425||PEG2L, two liters polyethylene glycol with ascorbic acid|PEG2L, two liters polyethylene glycol with ascorbic acid
16432625|NCT03753425||Pico, sodium picosulfate|Pico, sodium picosulfate
16432626|NCT03753425||NaP, sodium phosphate|NaP, sodium phosphate
16432627|NCT03753425||MPS, sodium, magnesium and potassium sulphates|MPS, sodium, magnesium and potassium sulphates
16432628|NCT03753412||ICUAW ECMO group|The physical and psychological effects of ICUAW on patients receiving extracorporeal membrane oxygenation for severe cardiorespiratory failure will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
16432629|NCT03753399|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
16432630|NCT03753399|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
16432631|NCT03753399|No Intervention|Usual care|Chemotherapy without acupuncture
16432632|NCT03753386|Experimental|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
16432633|NCT03753373|Experimental|Acupuncture and Home Exercise|Acupuncture plus the prescribed home exercise program
16432634|NCT03753373|Active Comparator|Home Exercise Only|The prescribed home exercise program alone
16432635|NCT03753360|Other|Intervention Group|internet-based mindfulness meditation program
16432636|NCT03753360|Other|Active Control Group|relaxing music
16432637|NCT03753347|Experimental|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
16432638|NCT03753334|Experimental|MAG-EPA group|5g/day of omega-3-rich fish oil capsules, which include 4g of purified EPA, to be taken once a day, for 12 months.
16432639|NCT03753334|Placebo Comparator|Placebo group|5g/day of high-oleic sunflower oil capsules, to be taken once a day, for 12 months.
16432640|NCT03753321|Experimental|Whey protein|Whey protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
16432641|NCT03753321|Experimental|Soy protein|Soy protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
16432642|NCT03753321|Placebo Comparator|Placebo (maltodextrin)|Isoenergetic, maltodextrin (7 day pre-loading phase and 3 day training phase)
16432643|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling
~Eligibility criteria :
~Male or female, Age of 18 or older, Weight over 40kg
~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA
~Patients who signed a non-opposition
~Patient affiliated to social security insurance
~HBsAg positive for more than 6 months
~known status of HBeAg (positive or negative)
~Treated or not with an antiviral"
16432644|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy
~Eligibility criteria :
~Male or female, Age of 18 or older, Weight over 40kg
~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA
~Patients who signed a non-opposition
~Patient affiliated to social security insurance
~HBsAg positive for more than 6 months
~known status of HBeAg (positive or negative)
~Treated or not with an antiviral
~Patient with a liver biopsy indication as part of the treatment within 3 months."
16432645|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy
~Eligibility criteria :
~Male or female, Age of 18 or older, Weight over 40kg
~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA
~Patients who signed a non-opposition
~Patient affiliated to social security insurance
~The existence of at least one element of metabolic syndrome
~Steatosis detected by non-invasive tests (echo, CAP, MRI)"
16432646|NCT03753308||3, Blood samples from healthy donors|"No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.
~The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
16432647|NCT03753295||Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
16432648|NCT03753295||Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
16432649|NCT03753295||Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
16432650|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
16432651|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
16432652|NCT03753269|Experimental|Fasudil Hydrochloride|Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
16432653|NCT03753269|Placebo Comparator|Placebo saline|Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
16432654|NCT03753256|Active Comparator|Transbond XT|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm
~the development of demineralization
~its adverse effects after application"
16432655|NCT03753256|Experimental|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).
~The investigators will evaluate in this arm
~its abrasion behavior and the development of demineralization
~its adverse effects after the application"
16432656|NCT03753256|Experimental|Pro Seal®|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).
~The investigators will evaluate in this arm
~its abrasion behavior and the development of demineralization
~its adverse effects after the application"
16432657|NCT03753256|Experimental|Opal® Seal|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).
~The investigators will evaluate in this arm
~its abrasion behavior and the development of demineralization
~its adverse effects after the application"
16432658|NCT03753243|Experimental|Intervention|Treatment will be planned for a total of 14 to 16 weeks. Pembrolizumab will be administered every 3 weeks via IV infusion with a dose of 200 mg per infusion. Enzalutamide will be given orally and dispensed to the patient on the date of their first infusion. The dosage of Enzalutamide will be 160 mg, administered once daily for approx. 16 weeks. GNRH agonist therapy will be administered as a standard of care therapy and will follow a standard dosage to maintain castrate levels.
16432659|NCT03753230|Experimental|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
16432660|NCT03753230|Experimental|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
16432661|NCT03753230|Active Comparator|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
16432662|NCT03753217|Experimental|qCON Monitor|Simultaneous measurement of BIS and qCON
16432664|NCT03753191|Experimental|People with Dementia|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. A 2mA direct current for active tDCS (current density : .057 mA/cm2) with a 20 mins stimulation period
16432665|NCT03753191|Sham Comparator|Health Control|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. After a fade in period of 10s to mimic initial tDCS peripheral skin sensations, the stimulator will be turned off in order to prevent the induction of any neuromodulatory effect.
16432666|NCT03753178||patients|70 participants presented with clinical and motor electrophysiological evidence of common peroneal neuropathy at the fibular neck
16432667|NCT03753178||controls|70 controls
16432668|NCT03753165|Experimental|High Intensity Interval Exercise group|Patients suffering from chronic low back pain perform 12 sessions of high intensity interval exercise (HIIE) over a period of 6 weeks at an intensity of 80% of their maximal Heart rate. In addition they also receive conventional physiotherapy in the form of hot pack or TENS
16432669|NCT03753165|No Intervention|Conventional physiotherapy|Patients suffering from chronic low back pain will receive conventional physiotherapy such as TENS and hot packs applied over appropriate areas over a period of 6 weeks
16432670|NCT03753152|Experimental|Investigational medical device|Neuramis® Deep Lidocaine
16432671|NCT03753152|Active Comparator|Comparator device|YVOIRE® Volume Plus
16432672|NCT03753139||Atrial fibrillation|Patients with atrial fibrillation as recorded by Holter
16432673|NCT03753139||Sinus rhythm|Patients with sinus rhythm as recorded by Holter
16432674|NCT03753126|Other|Cardiac CT imaging|
16432675|NCT03753113|Experimental|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
16432676|NCT03753113|Active Comparator|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
16432677|NCT03753100|Active Comparator|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
16432678|NCT03753100|Active Comparator|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
16432679|NCT03753087|Experimental|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
16432680|NCT03753087|Active Comparator|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
16432681|NCT03753074|Experimental|Treatment Arm A (TAF)|390 subjects administered Tenofovir Alafenamide 25 mg once daily
16432682|NCT03753074|No Intervention|Treatment Arm B (Best supportive care)|"390 subjects received best supportive care
~During treatment period, among treatment arm B, subjects who are indicated for antiviral treatment by AASLD 2018 Guidelines of CHB (ALT 70≥ for male, 50≥ for female) will be treated with Tenofovir Alafenamide ."
16432683|NCT03753061|Experimental|Aspiration Catheter|Mechanical thrombectomy with Aspiration Catheter.
16432684|NCT03753061|Active Comparator|Stent Retriever (Solitaire FR)|Mechanical thrombectomy with Solitaire FR.
16432685|NCT03753048|Active Comparator|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
16432686|NCT03753048|Active Comparator|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
16432687|NCT03753035||epileptic children|Completion of questionnaire, during medical consultation, on compliance and quality of life
16432688|NCT03753022|Sham Comparator|Group G5|Patients submitted to CABG and peep 5
16432689|NCT03753022|Experimental|Group G10|Patients submitted to CABG and peep 10
16432690|NCT03753022|Experimental|Group G15|Patients submitted to CABG and peep 15
16432691|NCT03753009||iontophoretic transepithelial corneal cross-linking (I-ON CXL)|Twenty eyes of 15 patients with keratoconus (mean age 13±3.5 [SD] years, range 9 to 18) underwent Iontophoresis epi-on CXL
16432692|NCT03753009||epithelium-off collagen cross-linking (epi-off CXL)|Twenty eyes of 13 patients with keratoconus (14±4 [SD] years, range 10 to 18) underwent standard epi-off CXL
16432693|NCT03752996|Experimental|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
16432694|NCT03752983||cases|patients with SLE
16432695|NCT03752983||controls|Healthy people
16432699|NCT03752944|Active Comparator|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
16432700|NCT03752931|Active Comparator|Celiprolol|receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
16432701|NCT03752931|Active Comparator|Diltiazem|receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
16432702|NCT03752918|Experimental|MDMA|MDMA (1.5mg/kg)
16432703|NCT03752918|Placebo Comparator|Niacin|Niacin (250mg)
16432704|NCT03752905|Experimental|PTR-01 0.1 mg/kg|Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
16432705|NCT03752905|Experimental|PTR-01 0.3 mg/kg|Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
16432706|NCT03752905|Experimental|PTR-01 1.0 mg/kg|Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
16432707|NCT03752905|Placebo Comparator|Normal Saline|Saline control to mimic PTR-01.
16432708|NCT03752905|Experimental|PTR-01 3.0 mg/kg|Three intravenous infusions of PTR-01 at 3.0 mg/kg with doses 2 weeks apart.
16432709|NCT03752892|Experimental|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
16432710|NCT03752892|Active Comparator|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
16432711|NCT03752879||Case (Kristaller Group)|Group of kristeller maneuver applied in the second stage of labor due to clinical necessity.
16432712|NCT03752879||Control (no Kristaller Group)|The control group not required to kristeller maneuver
16432713|NCT03752866|Experimental|Portico™ Valve, Delivery System(s) and Loading Systems(s)|
16432714|NCT03752853|Experimental|iCBT for depression - behavioral activation first (BAF)|internet-based intervention for mild to moderate depression: patients receive behavioral activation first, followed by cognitive restructuring
16432715|NCT03752853|Experimental|iCBT for depression - cognitive restructuring first (CRF)|internet-based intervention for mild to moderate depression: patients receive cognitive restructuring first, followed by behavioral activation
16432716|NCT03752840|Experimental|Screening|
16432717|NCT03752840|Active Comparator|Case detection|
16432718|NCT03752827|Experimental|Adipose Derived Regenerative Cells|Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear
16432719|NCT03752827|Active Comparator|Corticosteroid|Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
16432720|NCT03752814|Experimental|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
16432721|NCT03752801||Script Review Parents/Caregivers|will have script reviewed and evaluated by parents/caregivers in groups of 5 up to 40 participants until 4/5 parents/caregivers demonstrate that script is understandable and acceptable.
16432722|NCT03752801||Video Review Parents/Caregivers|review and evaluation of the developed educational videos by parents/caregivers up to 20 parents who have not participated in the script review
16432723|NCT03752788|Experimental|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.
~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
16432724|NCT03752788|Active Comparator|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.
~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
16432725|NCT03752775|Experimental|subacute device assisted group|
16432726|NCT03752775|Active Comparator|subacute conventional group|
16432727|NCT03752775|Other|chronic device assisted group|
16432728|NCT03752762|No Intervention|Standard Care|Participants will receive standard health care services provided by the Health Secretary
16432729|NCT03752762|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
16432730|NCT03752749|Experimental|Prednisolone + Acute Intermittent Hypoxia|
16432731|NCT03752749|Placebo Comparator|Placebo + Acute Intermittent Hypoxia|
16432732|NCT03752736|Active Comparator|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
16432733|NCT03752736|No Intervention|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.
~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
16432734|NCT03752723|Experimental|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination
~Assigned interventions: CPA, GX-I7 and pembrolizumab"
16432735|NCT03752723|Experimental|combination with GX-I7, and pembrolizumab|"Experimental: combination
~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
16432736|NCT03752710||Acute primary angle closure|
16432737|NCT03752710||Acute secondary angle closure induced by LS|
16432738|NCT03752710||Cataract|
16432739|NCT03752710||Primary chronic angle closed glaucoma|
16432740|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
16432741|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
16432742|NCT03752684|Experimental|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine and plasma.
~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
16432743|NCT03752684|Experimental|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.
~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
16432744|NCT03752684|Experimental|Oxalobacter formigenes|Subjects will ingest a liver preparation of O.formigenes
16432745|NCT03752671|Experimental|the IntraSPINE® device associated with discectomy|
16432746|NCT03752671|Active Comparator|discectomy alone|
16432747|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
16432748|NCT03752645|Experimental|intervention|Transverse Many Channels Laser Instrument
16432749|NCT03752645|No Intervention|control|
16432750|NCT03752632|Experimental|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
16432751|NCT03752632|Active Comparator|Tourniquet (control)|Control: Tourniquet
16432752|NCT03752619|Experimental|Contraction Producing Peripheral Nerve Stimulation|This group will receive: 1) muscle contraction producing peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
16432753|NCT03752619|Active Comparator|Non Contracting Producing Peripheral Nerve Stimulation|This group will receive: 1) non contraction producing peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
16432754|NCT03752606|Active Comparator|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
16432755|NCT03752606|No Intervention|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
16432756|NCT03752593||Obese|Patients with a BMI of greater than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
16432757|NCT03752593||Non-Obese|Patients with a BMI of less than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
16432758|NCT03752580|Experimental|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
16432759|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
16432760|NCT03752541|Experimental|BCMA-UCART|Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1*10~6/KgBW, 1-2*10~6/KgBW,2-3*10~6/KgBW.
16432761|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
16432762|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
16432763|NCT03752515||case|
16432764|NCT03752515||control|
16432765|NCT03752502|Experimental|Cerebral stimulation|"Active transcranial direct current stimulation
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
16432766|NCT03752502|Experimental|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
16432767|NCT03752502|Sham Comparator|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)
~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
16432768|NCT03752502|Experimental|Peripheral stimulation|"Active peripheral electrical stimulation (PES).
~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
16432769|NCT03752489|Experimental|Fluid treatment-specific algorithm|The experimental arm will involve patients monitored by the fluid treatment-customized version of InSight.
16432770|NCT03752489|Active Comparator|Standard InSight|The control arm will involve patients monitored with the standard, non-treatment specific version of InSight.
16432771|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
16432772|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
16432773|NCT03752463|Experimental|DAOI-A group|
16432774|NCT03752463|Experimental|DAOI-B group|
16432775|NCT03752463|Experimental|DAOI-C group|
16432776|NCT03752463|Placebo Comparator|Placebo group|
16432777|NCT03752450||ICU patients|All patients admitted to ICU >48 hours will be included. Eventually, a number of these patients will develop hypernatremia and form the cases. The patients who will not develop hypernatremia will be assigned as the controls.
16432778|NCT03752437|Experimental|Real Weight|Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
16432779|NCT03752437|Experimental|Ideal Weight|Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
16432780|NCT03752424|Active Comparator|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
16432781|NCT03752424|Placebo Comparator|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
16432782|NCT03752411|Experimental|Research Bottle|This group will have medication dispensed in a research bottle.
16432783|NCT03752411|Placebo Comparator|Regular prescription Bottle|This group will have medication dispensed in a regular prescription bottle
16432784|NCT03752398|Experimental|XmAb®23104 Monotherapy|XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles
16432785|NCT03752398|Experimental|XmAb®23104 Combination Therapy with Ipilimumab|XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab)
16432786|NCT03752385|No Intervention|Control Group|No intervention
16432787|NCT03752385|Experimental|Intervention Group|"Will cut their smartphone screen time in half, sleep without phone in bedroom, and have a bedtime for their phone use."
16432788|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
16432789|NCT03752359|Experimental|whey protein group|Participants received a dose of 35 grams of whey protein after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
16432790|NCT03752359|Placebo Comparator|placebo group|Participants received a dose of 35 grams of maltodextrin after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
16432791|NCT03752346|No Intervention|control group|Control group maintained their regular lifestyle and received the routine care
16432792|NCT03752346|Experimental|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
16432793|NCT03752333|Experimental|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
16432794|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
16432795|NCT03752307|Experimental|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
16432796|NCT03752307|Placebo Comparator|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
16432797|NCT03752294|Active Comparator|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
16432798|NCT03752294|Placebo Comparator|Placebo|Participants will receive placebo daily for a total of 9-months.
16432799|NCT03752294|Active Comparator|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
16432800|NCT03752281||Health and activity|The cohort consists of long-term social assistance recipients where there is need to investigate the health status and working ability.
16432801|NCT03752268|No Intervention|Enhancing Cancer Pain Management Part 1|"Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline
~Will then use MEMS to monitor LA opioid intake over approximately 8 weeks
~A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
16432844|NCT03752099|Experimental|VERU-111 45mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
16432802|NCT03752268|Experimental|Enhancing Cancer Pain Management Part 2|"Enhancing Cancer Pain Management will consist of 3 individual manualized sessions
~The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.
~Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.
~Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
16432803|NCT03752255|Experimental|Anxiety measurement method|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). Then patients will watch a video about impacted tooth. This video will include the complications that patients may face and what should be done after the procedure. After the watching the video, patients will fill the both DAS and STAI.
16432804|NCT03752255|Placebo Comparator|Control|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). The verbal information in detail will be given to the patients by the surgeon.This verbal information will include the complications that patients may face and what should be done after the procedure.
16432805|NCT03752242|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
16432806|NCT03752242|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Acne of the face.
16432807|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 610|
16432808|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
16432809|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 430|
16432810|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 420|
16432811|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 520|
16432812|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 450|
16432813|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 545-549|
16432814|NCT03752229|Experimental|Owem Mumford lancet|
16432815|NCT03752229|Experimental|Medicore lancet|
16432816|NCT03752229|Experimental|Arkray lancet|
16432817|NCT03752229|Experimental|Medipurpose lancet|
16432818|NCT03752229|Experimental|Sterilance lancet|
16432819|NCT03752229|Experimental|Dynarex lancet|
16432820|NCT03752229|Experimental|Ypsomed lancet|
16432821|NCT03752229|Experimental|Promismed lancet|
16432822|NCT03752229|Experimental|Cambridge Sensors lancet|
16432823|NCT03752216|Experimental|NIRAPARIB|Oral Niraparib Daily
16432824|NCT03752203|Experimental|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
16432825|NCT03752190|Experimental|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
16432828|NCT03752164|Experimental|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
16432829|NCT03752151|Experimental|MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode|Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.
16432830|NCT03752138|Experimental|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
16432831|NCT03752138|Experimental|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
16432832|NCT03752138|Experimental|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
16432833|NCT03752138|Experimental|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
16432834|NCT03752138|Experimental|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
16432835|NCT03752125|Experimental|Flavonoid, caffeine|Flavonoid, caffeine capsules
16432836|NCT03752125|Placebo Comparator|Placebo|Placebo capsules
16432837|NCT03752112|Experimental|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
16432838|NCT03752112|Other|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
16432839|NCT03752099|Experimental|VERU-111 4.5mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
16432840|NCT03752099|Experimental|VERU-111 9mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
16432841|NCT03752099|Experimental|VERU-111 18mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
16432842|NCT03752099|Experimental|VERU-111 27mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
16432843|NCT03752099|Experimental|VERU-111 36mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
16432845|NCT03752086|Experimental|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
16432846|NCT03752086|Experimental|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
16432847|NCT03752073|Experimental|Trans-cervical cervical balloon|17 F non-latex Foley catheter will be placed and balloon filled with 30 cc of sterile normal saline.
16432848|NCT03752073|Experimental|Hygroscopic cervical dilators|Dilapan-S hygroscopic dilators will be placed into the cervix at the level of the internal os.
16432849|NCT03752060|Experimental|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
16432850|NCT03752060|Active Comparator|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
16432851|NCT03752060|No Intervention|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
16432852|NCT03752047||Suspicion of Sepsis|Patients who are admitted and are diagnosed with sepsis will be recruited for this investigation.
16432853|NCT03752034|Experimental|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
16432854|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
16432855|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
16432856|NCT03752008|Experimental|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
16432857|NCT03752008|Experimental|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
16432858|NCT03751995|No Intervention|Control|Participants from medical centers assigned to the control arm will receive usual care.
16432859|NCT03751995|Experimental|Intervention|Participants from medical centers assigned to the intervention arm will receive access to their choice of a mindfulness app or a webinar-based mindfulness course for 6 weeks.
16432860|NCT03751982|Active Comparator|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
16432861|NCT03751982|Experimental|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
16432862|NCT03751969|Experimental|HSK3486|"0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg)
~."
16432863|NCT03751956|Experimental|HSK3486|0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection
16432864|NCT03751943|Other|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
16432865|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
16432866|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
16432867|NCT03751917||APL patients|The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
16432868|NCT03751904|Other|AcoustiCare|Single Arm
16432869|NCT03751891|Experimental|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
16432870|NCT03751891|Active Comparator|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_A which will be fitted to the participants individual Hearing loss.
16432871|NCT03751891|Active Comparator|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_B which will be fitted to the participants individual Hearing loss.
16432872|NCT03751878|Experimental|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
16432873|NCT03751878|Other|Control arm|Standard peer review process.
16432874|NCT03751865|Experimental|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
16432875|NCT03751865|Active Comparator|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
16432876|NCT03751852|Experimental|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
16432877|NCT03751852|Active Comparator|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
16432878|NCT03751839|Experimental|Diagnostic|The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
16432879|NCT03751826|Experimental|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
16432880|NCT03751826|Experimental|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
16432881|NCT03751826|Active Comparator|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
16432882|NCT03751813|Placebo Comparator|Placebo|placebo supplement
16432883|NCT03751813|Experimental|Supplement|actual supplement
16432884|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
16432885|NCT03751787|Experimental|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
16432886|NCT03751787|Placebo Comparator|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
16432887|NCT03751774|Experimental|MAMAACT|Training of midwives in intercultural communication. A 6 hours course and 2 one hour booster sessions. Distribution of health education materials on warnings signs of pregnancy and health system navigation to pregnant women during antenatal care visits.
16432888|NCT03751774|No Intervention|Control|Care as usual
16432889|NCT03751761|Experimental|durvalumab, tremelimumab, paclitaxel|
16432890|NCT03751748|Sham Comparator|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
16432891|NCT03751748|Experimental|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
16432892|NCT03751735|Experimental|Dose 1|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up
16432893|NCT03751709|Experimental|Subjects|Blinatumomab+Haplo-Mismatched Cell Therapy (HMCT)
16432894|NCT03751696|Experimental|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 1-1.5 hours. The sessions will be conducted by experienced social workers online.
16432895|NCT03751696|Active Comparator|SMS Self-help tips|The participants in the control group will receive four self-help tips on mental well-being on the same schedule as the group coaching group.
16432896|NCT03751670|Experimental|PR+conventional treatment|Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
16432897|NCT03751670|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician.
16432898|NCT03751657|Experimental|Insulin 287|Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.
16432899|NCT03751657|Active Comparator|Insulin glargine|Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.
16432932|NCT03751423|Experimental|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
16432933|NCT03751384|Experimental|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
16432900|NCT03751644|Experimental|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
16432901|NCT03751644|No Intervention|Placebo|Patients will not submitted to electrical stimulation.
16432902|NCT03751631|Experimental|Phenylephrine-tropicamide|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser
16432903|NCT03751631|Active Comparator|Phenylephrine|Phenylephrine 2.5% ophthalmic solution administered using a microdose dispenser
16432904|NCT03751631|Active Comparator|Tropicamide|Tropicamide 1% ophthalmic solution administered using a microdose dispenser
16432905|NCT03751618|Experimental|Capsular suture|Capsular suture at the end of hip arthroscopy
16432906|NCT03751618|Active Comparator|No capsular suture|No capsular suture at the end of hip arthroscopy
16432907|NCT03751592|Experimental|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
16432908|NCT03751566|Active Comparator|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
16432909|NCT03751566|Experimental|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
16432910|NCT03751553|Experimental|obstetric gel group|they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel.
16432911|NCT03751553|No Intervention|no intervention group|they will receive the standard care during labor and delivery without the use of the obstetrical gel
16432912|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
16432913|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
16432914|NCT03751527|Experimental|ZENFLEX stent Group|subjects applying ZENFLEX peripheral stent system
16432915|NCT03751514|Experimental|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.
~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.
~Intervention to be administered: Bordetella Pertussis B1917"
16432916|NCT03751514|Experimental|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.
~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.
~Intervention to be administered: Bordetella Pertussis B1917"
16432917|NCT03751514|Experimental|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.
~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
16432918|NCT03751501|Experimental|Experimental Group|Indocyanine green-Guided Targeted Laser photocoagulation combines routine procedures, that are, the detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT. Indocyanine green-Guided Targeted Laser photocoagulation is administered in combination with anti VEGF treatment
16432919|NCT03751501|Sham Comparator|Control Group|Sham laser is administered at randomization visit and repeated if needed 3 month later in combination with anti VEGF treatment
16432920|NCT03751488|Experimental|LY03010 351mg|LY03010 at 351 mg
16432921|NCT03751488|Experimental|LY03010 156 mg|LY03010 at 156 mg
16432922|NCT03751488|Experimental|LY03010 117mg|LY03010 at 117mg
16432923|NCT03751488|Active Comparator|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
16432924|NCT03751475|Experimental|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
16432925|NCT03751475|Active Comparator|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
16432926|NCT03751462|Experimental|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
16432927|NCT03751449|Experimental|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
16432928|NCT03751449|Active Comparator|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
16432929|NCT03751436|Experimental|Treatment (venetoclax, enzalutamide)|Patients receive venetoclax PO QD and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16432930|NCT03751423|Active Comparator|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
16432931|NCT03751423|Active Comparator|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
16504506|NCT03259997|Active Comparator|Probiotic supplement|
16432937|NCT03751358|Experimental|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
16432938|NCT03751345|No Intervention|Treatment As Usual (TAU)|The TAU condition consists of the standard treatment elements offered to all Gateway (study site) patients, and will be received by patients in both the PW and the TAU-only condition. TAU services during the adolescent's treatment are typically eclectic and mainly entail meeting with the adolescent alone to provide support and psychoeducation, with occasional family therapy sessions. Medication management is offered as needed.
16432939|NCT03751345|Experimental|Parenting Wisely (PW)|In addition to TAU services, the PW arm includes in-person sessions where parents complete computer-administered PW sessions, in-person session including therapist coaching to reinforce PW material and personalize treatment by applying PW skills to individual issues, and access to PW material remotely so parents can access information and skills from home as needed.
16432940|NCT03751332|Other|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
16432941|NCT03751319|Active Comparator|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
16432942|NCT03751319|No Intervention|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
16432943|NCT03751306|Active Comparator|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
16432944|NCT03751306|Placebo Comparator|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
16432945|NCT03751306|Experimental|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
16432946|NCT03751293|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
16432947|NCT03751280|Experimental|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
16432948|NCT03751280|Sham Comparator|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
16432949|NCT03751267|Experimental|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
16432950|NCT03751267|No Intervention|Wait-list control|This group of patients will receive Tuina (massage) 4 weeks after baseline assessments.
16432951|NCT03751254|Experimental|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
16432952|NCT03751241|Experimental|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
16432953|NCT03751228|Experimental|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
16432954|NCT03751215|Experimental|Monofocal IOL|Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery
16432955|NCT03751202|Experimental|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
16432956|NCT03751202|Active Comparator|Reference product|ADVAIR DISKUS® 500/50
16432957|NCT03751176|Experimental|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
~FOLFIRI:
~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
16432958|NCT03751176|Active Comparator|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
16432959|NCT03751163|Active Comparator|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
16432960|NCT03751163|Placebo Comparator|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
16432961|NCT03751150|No Intervention|Control|Normal training, no intervention
16432962|NCT03751150|Experimental|Intervention INT|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recent prospective study in Gothenburg, Sweden. The exercises included cover muscle control training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
16432963|NCT03751137||Breast Feeding|Infants who, when enrolled, are exclusively breast feeding.
16432964|NCT03751137||Formula Feeding|Infants who, when enrolled, are exclusively formula feeding.
16432965|NCT03751124|Experimental|Relugolix plus E2/NETA|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
16504507|NCT03259997|Placebo Comparator|Placebo|
16432966|NCT03751124|Placebo Comparator|Placebo tablets and capsules|"Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.
~Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns."
16432967|NCT03751111|Experimental|Naloxone|Naloxone at an sublingual dose of 40 mg daily will be given to each subject.
16432968|NCT03751111|Placebo Comparator|Placebo|Sublingual placebo will be given to each subject.
16432969|NCT03751098|Experimental|Phenylephrine-tropicamide|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser
16432970|NCT03751098|Placebo Comparator|Placebo|Eyewash solution administered using a microdose dispenser
16432971|NCT03751085|Experimental|AW frame|AW frame biopsy
16432972|NCT03751072||Relapse/Refractory|
16432973|NCT03751072||MRD positive|
16432974|NCT03751059|Active Comparator|NSAID|Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op
16432975|NCT03751059|Active Comparator|Steroid|Dexamethasone: used from one week post-op to three months post-op
16432976|NCT03751046|Experimental|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
16432977|NCT03751046|Experimental|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
16432978|NCT03751033|Experimental|BSS and DisCoVisc|Following lens removal and removal of all OVD from the anterior chamber during cataract surgery, the chamber will be filled with BSS and the main incision hydrated with BSS. Intraoperative aberrometry, using the Optiwave® Refractive Analysis with VerifEye+ (ORA), will be performed, and the results of aphakic refraction and suggested IOL power will be recorded in triplicate. Immediately following, the BSS will be replaced with DisCoVisc; and, triplicate readings will be measured under the same conditions.
16432979|NCT03751020|Experimental|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
16432980|NCT03751020|Experimental|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
16432981|NCT03751020|Placebo Comparator|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
16432982|NCT03751007|Experimental|AG019 Cohort 1 - Low Dose/Adults|
16432983|NCT03751007|Experimental|AG019 Cohort 2 - High Dose/Adults|
16432984|NCT03751007|Experimental|AG019 Cohort 3 - Low Dose/Adolescents|
16432985|NCT03751007|Experimental|AG019 Cohort 4 - High Dose/Adolescents|
16432986|NCT03751007|Experimental|Combination Cohort 1 - Adults|
16432987|NCT03751007|Experimental|Combination Cohort 2 - Adolescents|
16432988|NCT03750981|Other|A 12-week pilot intervention study introducing a high-intensi|
16432989|NCT03750968|Experimental|Carotenoid group|The Carotenoid group will receive a commercially available prenatal vitamin/mineral tablet plus a softgel containing lutein/zeaxanthin, vitamin E and docosahexaenoic acid (DHA).
16432990|NCT03750968|Active Comparator|Control group|The Control group will receive the same prenatal vitamin/mineral tablet plus a softgel containing only vitamin E and DHA.
16432991|NCT03750955|Experimental|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where plaque induced gingivitis results from a cessation of oral hygiene in a sextant using a stent-induced biofilm overgrowth model.
16432992|NCT03750955|Active Comparator|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene (tooth brushing with fluoride toothpaste and flossing twice daily) is maintained.
16432993|NCT03750942|Experimental|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
16432994|NCT03750942|No Intervention|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
16432995|NCT03750929|No Intervention|Non physical exercises|Patients will not be submmitted to combined acute physical exercises (strength and aerobic)
16432996|NCT03750929|Experimental|Physical exercises|Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
16432997|NCT03750916|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
16432998|NCT03750903|Experimental|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
16432999|NCT03750903|Active Comparator|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
16433000|NCT03750877|Active Comparator|median approach|Spinal anesthesia will be performed with a conventional median approach
16433001|NCT03750877|Active Comparator|paramedian approach|Spinal anesthesia will be applied with a paramedian approach.
16433002|NCT03750864|Experimental|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
16433131|NCT03750006|Experimental|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
16433003|NCT03750851|Placebo Comparator|GPlacebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
16433004|NCT03750851|Experimental|GCPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
16433005|NCT03750851|Experimental|GLaser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
16433006|NCT03750851|Experimental|GLaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
16433007|NCT03750838|Experimental|Text Messaging Intervention Group|Participants in the TM Intervention condition will be provided a predetermined number of messages per week (based partially on responses from Phase 2 focus group) for 6 weeks delivered on Thursdays, Fridays, and Saturdays, which are the most common days of the week that heavy drinking occurs as well as other days and times that focus group participants indicated would be the most helpful.
16433008|NCT03750838|Active Comparator|Active Control|Participants in the attention only control condition will receive a series of TM based on nutritional data on the same schedule as those in the TM intervention and will complete a 6 week post-intervention assessment as well as all follow-ups.
16433009|NCT03750825|Experimental|Vapers|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
16433010|NCT03750825|No Intervention|Smokers|Smokers will continue to smoke.
16433011|NCT03750825|No Intervention|Nonsmokers non-vapers|Control nonsmokers non-vapers will continue to refrain from smoking or vaping.
16433012|NCT03750812|Active Comparator|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
16433013|NCT03750812|Active Comparator|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
16433014|NCT03750812|Active Comparator|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
16433015|NCT03750812|Active Comparator|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
16433016|NCT03750812|Active Comparator|Highly fit older adults - TV|This arm will sit at rest and watch television
16433017|NCT03750812|Active Comparator|Poorly fit older adults - TV|This arm will sit at rest and watch television
16433018|NCT03750812|Active Comparator|Highly fit young adults - TV|This arm will sit at rest and watch television
16433019|NCT03750812|Active Comparator|Poorly fit young adults - TV|This arm will sit at rest and watch television
16433020|NCT03750799|Experimental|Experimental group|Whole body vibration was applied on the right lower extremity.
16433021|NCT03750799|Sham Comparator|Sham group|Unlike the experimental group, sham vibration was applied to the control group.
16433022|NCT03750786|Experimental|Group A|ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
16433023|NCT03750786|Active Comparator|Group B|mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
16433024|NCT03750773|Active Comparator|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
16433025|NCT03750773|Placebo Comparator|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
16433026|NCT03750760|Active Comparator|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.
~Atorvastatin (80 mg), oral administration daily."
16433027|NCT03750760|Active Comparator|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
16433028|NCT03750747|Experimental|Intervention (Pulse Oximeter)|The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
16433029|NCT03750747|No Intervention|Comparison|The comparison facilities will continue providing routine IMCI services as per the existing guidelines. In routine IMCI services, IMCI service providers classify and treat children presenting with cough and difficult breathing based on history and clinical signs only. In routine IMCI services in Bangladesh, PO has not been introduced. Therefore, in the comparison facilities all children clinically classified as 'Pneumonia' will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day)
16433030|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
16433031|NCT03750734||COPD|Chronic obstructive pulmonary disease participants
16433032|NCT03750734||Cystic fibrosis|Cystic fibrosis participants
16433033|NCT03750734||Healthy volunteers|Healthy volunteers
16433132|NCT03749993|Other|Screening Arm|Screening
16504955|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
16433034|NCT03750721||Role of rifampin in staphylococcal PJI|retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period
16433035|NCT03750708|Other|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
16433036|NCT03750708|No Intervention|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
16433037|NCT03750695|Experimental|Acute Resistance Exercise|One acute exercise session of 40 minutes of resistance exercise
16433038|NCT03750695|Experimental|Acute Aerobic Exercise|One acute session of 40 minutes of aerobic exercise
16433039|NCT03750695|Placebo Comparator|Acute Resting Session|One session of 40 minutes of quiet rest
16433040|NCT03750682|Active Comparator|Physical Activity Intervention (PA)|The PA intervention will consist of a twice per week group-based moderate-intensity program that includes aerobic, strength, flexibility, and balance training.
16433041|NCT03750682|Placebo Comparator|Health Education Intervention (HE)|The HE intervention will consist of bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics including relevance to older adults, including nutrition, understanding the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services, information on resources, etc.
16433042|NCT03750669|Experimental|Neoadjuvant Chemotherapy|Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.
16433043|NCT03750669|No Intervention|control|Patients receive surgical treatment without any neoadjuvant treatments.
16433044|NCT03750656|Active Comparator|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
16433045|NCT03750656|Active Comparator|Tamsulosin|0.4 mg tab orally daily
16433046|NCT03750643|Experimental|LY3454738 - Part A|Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants
16433047|NCT03750643|Placebo Comparator|Placebo - Part A|Placebo administered IV to healthy participants
16433048|NCT03750643|Experimental|LY3454738 - Part B|LY3454738 administered IV to healthy participants
16433049|NCT03750643|Placebo Comparator|Placebo - Part B|Placebo administered IV to healthy participants
16433050|NCT03750643|Experimental|LY3454738 - Part C|LY3454738 administered IV to participants with atopic dermatitis (AD)
16433051|NCT03750643|Placebo Comparator|Placebo - Part C|Placebo administered IV to participants with AD
16433052|NCT03750617|Experimental|pre-endoscopic screening risk assessment|
16433053|NCT03750617|No Intervention|routine screening|
16433054|NCT03750604|Active Comparator|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.
~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.
~And in males:
~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
16433055|NCT03750604|Placebo Comparator|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.
~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
16433056|NCT03750591||Integrative Korean medicine treatment group|"Observation of pain, function, quality of life, satisfaction, and adverse events in inpatients with lumbar intervertebral disc herniation hospitalized at 4 Korean medicine hospitals
~Interventions:
~Drug: Herbal medicine Procedure/Surgery: Chuna manual therapy Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s)"
16433057|NCT03750578|Experimental|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
16433058|NCT03750578|No Intervention|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
16433059|NCT03750565|Experimental|Cohort 1|Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
16433060|NCT03750565|Experimental|Cohort 2|Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
16433061|NCT03750565|Experimental|Cohort 3|Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
16433062|NCT03750565|Experimental|Cohort 4|Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
16433063|NCT03750552|Experimental|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
16433064|NCT03750552|Placebo Comparator|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
16433065|NCT03750539|Active Comparator|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
16504956|NCT03256760|Placebo Comparator|Placebo|Placebo
16433066|NCT03750539|Experimental|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
16433067|NCT03750526|Experimental|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
16433068|NCT03750526|Active Comparator|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
16433069|NCT03750526|Active Comparator|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
16433070|NCT03750526|Active Comparator|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
16433071|NCT03750513|Experimental|Treatment (LET optimized IMPT)|Patients receive LET optimized IMPT for up to 6 weeks.
16433072|NCT03750500|Experimental|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
16433073|NCT03750500|Placebo Comparator|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
16433074|NCT03750487|Experimental|e-screening & brief intervention (e-SBI)|A two-session (20 minutes each) computer-delivered screening and brief motivational intervention targeting alcohol and drug use. Computerized screening is conducted using the ASSIST. Session 1 of the BI includes personalized feedback, readiness to change interventions, and goal setting around substance use. Session 2 will contain motivational content reinforcing engagement in home visiting and information around other challenges mothers may experience including tobacco use, postpartum depression, and intimate partner violence.
16433075|NCT03750487|Sham Comparator|Control|The control group will receive a similar 2-session brief motivational intervention. Session 1 focuses on nutrition and healthy eating, session 2 focuses on exercising while pregnant or in the postpartum period.
16433076|NCT03750474|Experimental|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
16433077|NCT03750474|Other|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
16433078|NCT03750461|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
16433079|NCT03750448|Active Comparator|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
16433080|NCT03750448|Active Comparator|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
16433081|NCT03750448|Active Comparator|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
16433082|NCT03750435|Experimental|Ablation for AF or left-sided AT|The patient will be admitted in hospital as for a standard ablation procedure and discharged the next day. The procedure will be carried out without using fluoroscopy and relying on the visualization of the electroanatomical mapping system.
16433083|NCT03750422|Active Comparator|Stratacel|medical grade silicone gel following Picoway Laser treatment
16433084|NCT03750422|Sham Comparator|Vehicle|Clear ultrasound gel following Picoway Laser treatment
16433085|NCT03750409|Active Comparator|Helmet Active Device|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
16433086|NCT03750409|Sham Comparator|Helmet Sham|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
16433087|NCT03750396|Experimental|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.
~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.
~Local treatments for metastatic lesions will be added in this group.
~Local treatments include modalities described below:
~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
16433088|NCT03750383|Experimental|EDP-938 and cyclosporine interaction (Part 1)|
16433089|NCT03750383|Experimental|EDP-938 and prednisone interaction (Part 2)|
16433090|NCT03750357|Experimental|Primary Relief v 2.0 with Paracetamol|Group A will be treated with Primary Relief v 2.0(1 - 100Hz) sweep stimulation with increase in power of the stimulation for fixed interval of time.
16433091|NCT03750357|No Intervention|Only Paracetamol|Group B will be treated with paracetamol drug.
16433093|NCT03750331|Active Comparator|traditional patient follow-up|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule (every other week up to 6 months post-transplant, once a month up to year 1, every three months up to year 2 and every 6 months thereafter)
16433094|NCT03750331|Experimental|medically-tailored follow-up with Ap'Telecare|a group of patients assisted by Ap'Telecare and consulting their Transplant Centre following a less stringent schedule of consultations (every month up to 6 months, every other month up to year 1, every six months up to year 2 and once a year thereafter).
16433095|NCT03750318|Experimental|Aingeal|All patients will wear the Aingeal device as part of the vital sign monitoring with opioid delivery system at ward setting.
16433096|NCT03750305|Active Comparator|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
16433097|NCT03750305|Experimental|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
16433098|NCT03750292|Experimental|HEPAirX air filter|
16433099|NCT03750292|Placebo Comparator|Control air filter|
16433100|NCT03750279|Active Comparator|Exercise therapy + LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.
~LLLT applied to the knee 3 times per week for 3 weeks from baseline."
16433101|NCT03750279|Placebo Comparator|Exercise therapy + sham LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.
~Sham LLLT applied to the knee 3 times per week for 3 weeks from baseline."
16433102|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
16433103|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy to relieve pain after arthroscopy for osteochondral lesions of talus
16433104|NCT03750240|Experimental|12 Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
16433105|NCT03750227|Active Comparator|Arm A (Post-operative SRS)|Patients undergo surgery on day 1. Within 2 weeks, patients undergo stereotactic radiosurgery.
16433106|NCT03750227|Experimental|Arm B (Pre-operative SRS)|Patients undergo stereotactic radiosurgery on day 1. Within 4 weeks, patients undergo surgery.
16433107|NCT03750214|Experimental|Biop Coplposcopy System|Biop Colposcopy system procedure
16433108|NCT03750201|Experimental|Direct Selective Trabeculoplasty|Treatment by the investigational device.
16433109|NCT03750201|Active Comparator|Selective Trabeculoplasty|Treatment by the comparator device.
16433110|NCT03750175||Colorectal cancer patients|"Clinical utility of ctDNA analysis for treatment decision
~Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer"
16433111|NCT03750162|Experimental|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
16433112|NCT03750162|Experimental|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
16433113|NCT03750162|Experimental|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
16433114|NCT03750149|Experimental|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
16433115|NCT03750136|Experimental|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
16433116|NCT03750136|Active Comparator|high-dose furosemide|furosemide i.v.
16433117|NCT03750123||Kawasaki Disease (KD)|Children 5 years after Kawasaki Disease
16433118|NCT03750123||Healthy controls (HC)|Age- and sexmatched healthy siblings of children after Kawasaki Disease
16433119|NCT03750110|Active Comparator|Usual Care|Smoking Cessation NICE PH48 Guidelines
16433120|NCT03750110|Active Comparator|Intervention|Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
16433121|NCT03750097|Experimental|Walking protocol|Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.
16433122|NCT03750071|Experimental|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
16433123|NCT03750058|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
16433124|NCT03750045|Experimental|Experimental group|For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
16433125|NCT03750032|Experimental|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
16433126|NCT03750032|Experimental|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
16433127|NCT03750032|Experimental|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
16433128|NCT03750019|Experimental|Satisfying rehearsal|Participants completed the satisfying rehearsal task where they rehearsed the satisfying aspects of the lunchtime meal.
16433129|NCT03750019|Experimental|Dissatisfying rehearsal|Participants completed the dissatisfying rehearsal task where they rehearsed the dissatisfying aspects of the lunchtime meal.
16433130|NCT03750019|Active Comparator|Neutral rehearsal|Participants completed the neutral rehearsal task where they rehearsed their journey to campus that day.
16433133|NCT03749967|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433134|NCT03749967|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433135|NCT03749967|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433136|NCT03749967|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433137|NCT03749967|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433138|NCT03749967|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433139|NCT03749967|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433140|NCT03749967|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433141|NCT03749967|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433142|NCT03749967|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
16433143|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
16433144|NCT03749928|Experimental|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
16433145|NCT03749928|Placebo Comparator|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
16433146|NCT03749915|Active Comparator|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
16433147|NCT03749915|Experimental|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
16433148|NCT03749902|Other|Oxytocin infusion|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.
~The oxytocin group will not receive misoprostol after the membranes have ruptured."
16433149|NCT03749902|Other|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).
~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)
~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted
~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
16433150|NCT03749889|Experimental|100 g carbs|100 grams of carbohydrate allowance for the day
16433151|NCT03749889|Active Comparator|MyPlate|Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.
16433211|NCT03749486|Experimental|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
16433152|NCT03749876|Active Comparator|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
16433153|NCT03749876|Experimental|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
16433154|NCT03749863|Experimental|Serial PRP injections|This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to a unilateral vocal fold mucosa for a total of 4 injections.
16433155|NCT03749850|Experimental|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide
~Single arm study"
16433156|NCT03749837|Experimental|C- MAC VS|Intubation with C- MAC VS
16433157|NCT03749837|Active Comparator|Video Endoscope|Intubation with standard fiberoptic scope
16433158|NCT03749824|Experimental|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
16433159|NCT03749824|Placebo Comparator|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
16433160|NCT03749811|Experimental|Pupillometry group|A group of participants who receive remifentanil infusion under pupillometry monitoring.
16433161|NCT03749811|No Intervention|Conventional group|A group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.
16433162|NCT03749798|Experimental|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
16433163|NCT03749785|Active Comparator|Regular carbohydrate feeding|Ingestion of 75 g sucrose, given in regular doses for the first 75 minutes of exercise during a time to exhaustion run
16433164|NCT03749785|Active Comparator|Single carbohydrate bolus|Ingestion of 75 g sucrose, given in a single bolus after 75 minutes of exercise, during a time to exhaustion run
16433165|NCT03749772|Experimental|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
16433166|NCT03749772|No Intervention|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
16433167|NCT03749759|Experimental|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
16433168|NCT03749746|Active Comparator|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
16433169|NCT03749746|Experimental|Home Blood Pressure Monitoring|In addition to usual care outlined above, each participant will receive a Bluetooth-enabled blood pressure cuff along with a checklist of proper technique and instructions on use. Women will be prompted to measure their BP across the first week of each month during the intervention. Based on guidelines, participants will take their blood pressure in the morning and evening, each time taking two readings separated by one minute.
16433170|NCT03749746|Experimental|Heart Health 4 New Moms|Participants randomized to this group will receive instruction on the use of Heart Health 4 New Moms internet-based lifestyle intervention and home blood pressure monitoring. The internet-based intervention is comprised of four key components: an online curriculum with modules on healthy eating and physical activity, a self-monitoring and tracking program, a registered dietitian will act as a lifestyle coach for participants and a customized online toolbox.
16433171|NCT03749733|Experimental|Test Product|"Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.
~The tablet will be taken with water and in a fasting condition."
16433172|NCT03749733|Active Comparator|Reference Product|"Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.
~The tablet will be taken with water and in a fasting condition."
16433173|NCT03749720|Other|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
16433174|NCT03749707|Other|SLNs from early-stage cervical cancer patients|Tissue from SLNs removed from early-stage cervical cancer patients are analyzed for HPV.
16433175|NCT03749655|No Intervention|PR+CBT|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy
16433176|NCT03749655|Experimental|PR+CBT+PA Promotion.|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy and physical activity promotion.
16433177|NCT03749642|Experimental|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
16433178|NCT03749642|Experimental|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
16433179|NCT03749642|Experimental|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
16433180|NCT03749642|Placebo Comparator|placebo|Two capsules, three times a day, for 8 weeks.
16433181|NCT03749642|Active Comparator|Gabapentin|"according to the following scheduling dosage regimen:
~100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);
~300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);
~400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);
~300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
16433212|NCT03749473|Active Comparator|Control|Participants receive a daily message with their step count on the prior day to serve as an active control for 24 weeks (daily performance feedback). No other interventions during the 24-week study
16433182|NCT03749629|Active Comparator|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
16433183|NCT03749629|Placebo Comparator|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
16433184|NCT03749616|Active Comparator|Non-operative Acetaminophen|Acetaminophen will be given to participants for pain control following their injury.
16433185|NCT03749616|Active Comparator|Operative Acetaminophen|Acetaminophen will be given to participants for pain control following their surgery for arm fracture.
16433186|NCT03749616|Experimental|Non-operative NSAID|Ibuprofen will be given to participants for pain control following their injury.
16433187|NCT03749616|Experimental|Operative NSAID|Ibuprofen will be given to participants following their surgery for arm fracture.
16433188|NCT03749603|Experimental|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
16433189|NCT03749590|Experimental|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.
~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
16433190|NCT03749590|Placebo Comparator|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.
~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
16433191|NCT03749577|Experimental|L-citrulline|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
16433192|NCT03749577|Experimental|Beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
16433193|NCT03749577|Placebo Comparator|L-citrulline placebo|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
16433194|NCT03749577|Placebo Comparator|Denitrated beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
16433195|NCT03749564|Experimental|SMT Only|All patients receive 2 SMT sessions in the first week.
16433196|NCT03749564|Experimental|SMT extended|All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
16433197|NCT03749564|Experimental|SMT with Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm receives 6 additional sessions of activation exercises."
16433198|NCT03749564|Experimental|SMT with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm involves 6 additional sessions of mobilizing exercise."
16433199|NCT03749564|Experimental|SMT with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm involves 6 additions sessions including both activation and mobilizing exercises."
16433200|NCT03749564|Experimental|SMT extended with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm includes 6 additional sessions including both SMT and mobilizing exercises."
16433201|NCT03749564|Experimental|SMT extended with Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm includes 6 additional sessions including both SMT and activation exercises."
16433202|NCT03749564|Experimental|SMT extended with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm includes 6 additional sessions including SMT, activation and mobilizing exercises."
16433203|NCT03749551||Participants|diagnostic test - patients serving as their own controls
16433204|NCT03749538|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: three times, once per day.
16433205|NCT03749538|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session.
16433206|NCT03749525|Placebo Comparator|placebo group|5% GS solution
16433207|NCT03749525|Active Comparator|control group|shenfu injection
16433208|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
16433209|NCT03749499|No Intervention|Usual Care|Participants randomized to usual care will receive preprinted discharge instructions on HTN and a 48-72-hour referral to our FQHC (or other community health center if pre-assigned though Illinois Medicaid) to schedule their follow-up appointment (current standard of care)
16433210|NCT03749499|Active Comparator|Educational and Empowerment Intervention|"Participants receive:
~HTN Educational Video about high BP, how it is diagnosed, and importance of treatment to prevent secondary complications.
~Visual Echocardiogram Image Clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change behavior and improve their BP.
~Mobile Health and Remote BP monitoring- participants receive an FDA-approved home blood pressure monitoring (HBPM) kit that includes the Nokia wireless BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
~A Post-Acute Care HTN Transition consultation (PACHT-c) with a clinical pharmacist or advanced practice nurse (APN)."
16433213|NCT03749473|Experimental|Choice + Immediate|Participants choose a step goal between 1000-3000 steps greater than their baseline (choice). They are asked to reach their full step goal upon intervention start (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
16433214|NCT03749473|Experimental|Choice + Gradual|Participants are asked to choose a step goal between 1000-3000 steps greater than their baseline (choice). They will be asked to increase their step goal by even increments of 12.5% each week for the 8 weeks of the ramp-up period (gradual). After the 8-week ramp-up period, they will be asked to maintain the step goal for the study. They may change their goal within the range at anytime. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
16433215|NCT03749473|Experimental|Assigned + Immediate|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to reach their full step goal as soon as the intervention begins (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
16433216|NCT03749473|Experimental|Assigned + Gradual|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to achieve their step goal of 2000 steps incrementally over the 8 weeks of the ramp-up period (gradual). After the first 8 weeks, they will be asked to maintain their full step goal of 2000 for the the study. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
16433217|NCT03749460|Experimental|Treatment (nivolumab, ipilimumab, SBRT)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.
16433218|NCT03749447|Experimental|Bardoxolone methyl|"The maximum dosage is determined by proteinuria status from the last on-treatment visit in the prior qualifying study or a screening visit, if necessary. Initial daily dose of bardoxolone methyl will dose-escalate at Week 2, Week 4, and Week 6.
~Patients under the age of 18 will start dosing with bardoxolone methyl capsules every other day during Week 1 and daily at Week 2.
~Patients will receive doses of bardoxolone methyl capsules in an escalating scheme from 5 mg up to no more than 30 mg."
16433219|NCT03749434||Adults with HAIs after VAD therapy|Adult patients who have received a ventricular assist device implant.
16433220|NCT03749421||Prosigna Assay|"Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay
~The results of Prosigna assay will be provided to the study team in a standardized report.
~This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
16433221|NCT03749408|Active Comparator|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
16433222|NCT03749408|Experimental|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
16433223|NCT03749395|Active Comparator|Erector Spinae Plane Block group|"The Erector Spinae Plane block will be done as follow,the patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
~All patients will receive general anesthesia as described in conventional group"
16433224|NCT03749395|No Intervention|Conventional group|"Nothing will be injected
~All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCo2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperative when either heart rate or Non Invasive Blood Pressure report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria."
16433225|NCT03749382|Experimental|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
16433226|NCT03749382|Experimental|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
16433227|NCT03749382|No Intervention|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
16433228|NCT03749369|Active Comparator|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
16433229|NCT03749369|Placebo Comparator|SRP only|Subjects receiving scaling and root planing only
16433230|NCT03749356|Experimental|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
16433231|NCT03749330|Other|CHOP CICU|CICU Team And Loved Ones Communicating (CICU TALC)
16433232|NCT03749317|Experimental|Treatment|IVIEW-1201; four times per day (QID) for 7 days
16433233|NCT03749317|Placebo Comparator|Placebo|Placebo; four times per day (QID) for 7 days
16433234|NCT03749304|Experimental|ANI monitor|
16433235|NCT03749291|Experimental|Obemat2.0 Intervention Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
16433236|NCT03749291|Active Comparator|Control Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
16433237|NCT03749278|Experimental|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
16433238|NCT03749278|Active Comparator|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
16433239|NCT03749252|Experimental|CNS Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI
16433240|NCT03749252|Experimental|CNS Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI
16433241|NCT03749252|Experimental|CNS Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI
16433242|NCT03749252|Experimental|Body Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
16433243|NCT03749252|Experimental|Body Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
16433244|NCT03749252|Experimental|Body Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
16433245|NCT03749239|Experimental|Effects of collagen protein.|Non-hydrolized collagen protein
16433246|NCT03749226|Active Comparator|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
16433247|NCT03749226|No Intervention|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
16433248|NCT03749213|Experimental|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
16433249|NCT03749200|Experimental|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
16433250|NCT03749200|Active Comparator|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
16433251|NCT03749187|Experimental|Arm A (BGB-290, temozolomide)|Patients with grades III-IV newly diagnosed IDH1/2 mutant glioma receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16433252|NCT03749187|Experimental|Arm B (BGB-290, temozolomide)|"Patients with grades I-IV recurrent IDH1/2 mutant glioma receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
~Cohort B0: Patients who are surgical candidates with grades I-IV recurrent IDH1/2 mutant glioma receive PARP inhibitor BGB-290 PO BID for 7 days, pre-surgery. After recovery from surgery, patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
16433253|NCT03749174|Active Comparator|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
16433254|NCT03749174|Active Comparator|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
16433255|NCT03749174|Active Comparator|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthosis for postoperative immobilisation
16433256|NCT03749174|Active Comparator|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
16433257|NCT03749161|Experimental|Lentis comfort|Patient will receive the low-add multifocal IOL during cataract surgery
16433258|NCT03749161|Experimental|Lentis L-313|Patient will receive the monofocal IOL Lentis L-313 during cataract surgery
16433259|NCT03749148|Active Comparator|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
16433260|NCT03749148|Placebo Comparator|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
16433261|NCT03749135|Active Comparator|Dupilumab|Dupilumab (anti-IL4Ra), s.c. administration
16433262|NCT03749135|Placebo Comparator|Placebo Comparator|matching Placebo, s.c. administration
16433263|NCT03749109|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.
16433264|NCT03749109|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
16433265|NCT03749096|Active Comparator|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
16433266|NCT03749096|Placebo Comparator|Placebo|
16433267|NCT03749083||Tumor Sequencing|"Quality of life assessments will be collected using The Functional Assessment of Cancer Therapy- Colorectal
~Blood for circulating tumor DNA will be collected"
16433268|NCT03749070|Active Comparator|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
16433269|NCT03749070|Placebo Comparator|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
16433270|NCT03749057|Other|rivaroxaban|15-20 mg rivaroxaban daily
16433271|NCT03749044|Experimental|Patient Educational Tool|At the baseline visit, after having responded to the questionnaire, participants in the education arm will be given the patient educational tool.
16433272|NCT03749044|No Intervention|Standard of Care|Subjects in the standard of care arm will not receive the patient educational tool. If participants ask specific questions on pregnancy complications and/or preeclampsia, the clinicians will provide relevant information as they judge appropriate, but without handing out the patient educational tool.
16433273|NCT03749031|Placebo Comparator|Orange juice only|16 oz. orange juice per day for 4 weeks
16433274|NCT03749031|Experimental|orange juice + orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
16433275|NCT03749031|Placebo Comparator|Apple juice only|16 oz. apple juice per day for 4 weeks
16433276|NCT03749031|Experimental|Apple Juice + Apple Pomace|16 oz. apple juice + apple Pomace per day for 4 weeks
16433277|NCT03749018|Experimental|Treatment (nivolumab, DA-REPOCH)|Patients receive rituximab IV and nivolumab IV over 60 minutes on day 1. Patients also receive etoposide, vincristine sulfate and doxorubicin hydrochloride IV continuously over 96 hours, cyclophosphamide IV bolus, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After course 6, patients receive nivolumab IV over 60 minutes on day 1 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16433278|NCT03748992|Experimental|gNO|Subjects will be receiving nitric oxide every week day for 3 weeks.
16433279|NCT03748979|Experimental|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
16433280|NCT03748979|Experimental|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433281|NCT03748979|Experimental|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433282|NCT03748979|Experimental|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433283|NCT03748979|Experimental|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433284|NCT03748979|Experimental|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433285|NCT03748979|Placebo Comparator|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
16433286|NCT03748979|Experimental|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
16433287|NCT03748979|Experimental|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433288|NCT03748979|Experimental|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433289|NCT03748979|Experimental|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433290|NCT03748979|Placebo Comparator|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
16433291|NCT03748979|Experimental|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433292|NCT03748979|Experimental|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433293|NCT03748979|Placebo Comparator|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
16433294|NCT03748979|Experimental|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
16433295|NCT03748979|Experimental|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
16433296|NCT03748966|Experimental|Adults with XLH|Adults with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
16433297|NCT03748966|Experimental|Children with XLH|Children (age 6-17) with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
16433298|NCT03748953|Experimental|Ixazomib|Ixazomib 3 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 1 through Cycle 4, during which period if the participants have been tolerated, the dose may be escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 5 through Cycle 26. Participants who received placebo-matching capsules before unblinding and have not yet experienced disease progression will cross over to receive ixazomib.
16433299|NCT03748940|Placebo Comparator|Part A: Placebo|Placebo administered subcutaneously (SC)
16433305|NCT03748914|Experimental|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
16433306|NCT03748914|Active Comparator|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
16433307|NCT03748901||Full analysis set|Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
16433308|NCT03748888|Experimental|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
16433309|NCT03748888|No Intervention|Control Group|Sedentary participants.
16433310|NCT03748875|Experimental|Intervention group|an 8-session mindfulness-based relapse prevention program
16433311|NCT03748875|No Intervention|Control group|treatment as usual
16433312|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.
~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
16433313|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
16433314|NCT03748849||Low back pain group|Males and females who have had low back pain lasting between 12 weeks - 5 years without any other health problems (physical or psychological). Following baseline measurements, all subjects are offered individualized physiotherapy. The interventions mainly consist of exercises targeting their functional limitations. These are supplemented by a thorough explanation of their pain condition. This is done within the boundaries of the current understanding of musculoskeletal pain. This is supplemented with encouragement to do regular exercise and with manual therapy if needed/indicated.
16433315|NCT03748849||Control group|"Healthy males and females who have no current musculoskeletal pain problem (specific to the low back and/or in general). Likewise, they cannot have a previous history of on-going musculoskeletal pain. On-going pain is defined as a condition that limited their function for 3 months or more.
~Participants in the control group take part in the baseline measurement and then another measurement after 6-8 weeks"
16433316|NCT03748836|Active Comparator|Single Ascending Dose ALPN-101|
16433317|NCT03748836|Placebo Comparator|Single Dose Placebo|
16433318|NCT03748836|Active Comparator|Multiple Ascending Dose ALPN-101|
16433319|NCT03748836|Placebo Comparator|Multiple Dose Placebo|
16433320|NCT03748810||Triple OADs failure|Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.
16433321|NCT03748797|Experimental|Exercise group|8-week moderate intensity exercise training under supervision
16433322|NCT03748797|No Intervention|Control group|No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have
16433323|NCT03748784|Experimental|Dose 1|6E11 vg of ADVM-022
16433324|NCT03748784|Experimental|Dose 2|2E11 vg of ADVM-022
16433325|NCT03748758|Active Comparator|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
16433326|NCT03748758|Placebo Comparator|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
16433327|NCT03748758|Active Comparator|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
16433328|NCT03748745|Experimental|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
16433329|NCT03748745|Experimental|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
16433330|NCT03748719|Experimental|Stereotactic Body Radiation Therapy, followed by Prostatectomy|Patients will receive 6 Gy per day of Stereotactic Body Radiation Therapy (SBRT) per day for 5 days, followed by prostatectomy in 3 weeks.
16433331|NCT03748706|Experimental|Simufilam (PTI-125)|Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)
16433332|NCT03748693||POP Group|Women with POP undergoing surgery in our OB/GYN department.
16433333|NCT03748693||Non-POP Group|Women undergoing hysterectomy for other indications.
16433334|NCT03748680|Active Comparator|A|Intensified follow-up schedule
16433335|NCT03748680|Experimental|B|Adjuvant chemotherapy + intensified follow-up schedule
16433336|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
16433337|NCT03748654|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
16433338|NCT03748641|Experimental|Cohort 1: Participants with mCRPC and HRR Gene Alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
16433339|NCT03748641|Experimental|Cohort 2: Participants with mCRPC and No HRR Gene Alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
16433340|NCT03748641|Experimental|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
16433341|NCT03748628|Experimental|Single arm EDP-305|
16433342|NCT03748615|Experimental|Computer Guided ridge splitting in posterior mandible|fabrication of a computer aided surgical guide and performing ridge splitting in posterior mandible using piezosurgery
16433343|NCT03748602|Experimental|TOD|Thoracic Outlet Decompression (TOD)
16433345|NCT03748589|Experimental|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
16433346|NCT03748589|Experimental|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
16433347|NCT03748589|Experimental|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
16433348|NCT03748589|Experimental|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
16433349|NCT03748576|Experimental|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
16433350|NCT03748576|No Intervention|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
16433351|NCT03748563|Experimental|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
16433352|NCT03748550|No Intervention|Control|Participants will receive standard of care treatment for their breast cancer.
16433353|NCT03748550|Experimental|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
16433354|NCT03748537|Experimental|Hydrocortisone|Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped.
16433355|NCT03748537|No Intervention|No Hydrocortisone|In control group, patient will not receive any corticosteroids for seven day after inclusion.
16433356|NCT03748524|Experimental|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
16433357|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
16433358|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
16433359|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
16433360|NCT03748498|Experimental|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
16433361|NCT03748498|Placebo Comparator|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
16433362|NCT03748485|Experimental|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
16433363|NCT03748485|Active Comparator|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
16433364|NCT03489018|Active Comparator|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
16433365|NCT03489018|Experimental|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
16433366|NCT03489018|Experimental|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
16433367|NCT03489018|Active Comparator|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
16433368|NCT03489018|Experimental|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
16433369|NCT03489018|Experimental|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
16433370|NCT03489018|Active Comparator|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
16433371|NCT03748472|Experimental|Bolus feeding|
16433372|NCT03748472|Experimental|continuous gavage feeding|
16433373|NCT03748459||Permanent suture|Subjects will have skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
16433374|NCT03748459||Resorbable suture|Subjects will have skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty
16433375|NCT03748446|Active Comparator|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.
~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
16433376|NCT03748446|Placebo Comparator|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
16433377|NCT03748433|Experimental|Continuous Glucose Monitoring (CGM)|The RT CGM group will receive a Dexcom G6 transmitter and sensors, as well as a structured education refresher focusing on hypoglycaemia avoidance, recognition, and management.
16433378|NCT03748433|No Intervention|Self Monitoring Blood Glucose (SMBG)|The SMBG group will additionally undergo blinded CGM at weeks 1 and 2, weeks 4 to 6 and weeks 9 to 12 using the Dexcom G6 system. Participants in this group will be shown how to insert the Dexcom G6 at the first clinic visit and sensors provided so they can do this at home.
16433379|NCT03748433|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
16433380|NCT03748420|No Intervention|Usual Care|Basic clinical decision support alone
16433381|NCT03748420|Experimental|ReachOut Adherence intervention|Adherence-enhanced clinical decision support plus pharmacist-based adherence outreach
16433382|NCT03748407|Other|dosages in Healthy volunteers|"Only one arm : healthy volunteer blood donors. Performing a blood test for the determination of parameters that explore thyroid status : only once.
~Absence of other healthy volunteers group all healthy volunteers have a blood test performed in the same way."
16433383|NCT03748394|Experimental|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
16433384|NCT03748394|Active Comparator|Physical activity|Physical activity according to national health recommendations
16433385|NCT03748381|Experimental|Trifocal IOL|The patients will receive two different diffractive trifocal IOLs in each eye (AT Lisa tri vs. Rayner trifocal) during cataract surgery
16433386|NCT03748368|Active Comparator|Cataract presentation|Cataract presentation prior to surgery
16433387|NCT03748368|Placebo Comparator|Placebo presentation|Placebo presentation prior to surgery
16433388|NCT03748355|Other|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
16433389|NCT03748342|No Intervention|Standard Endotracheal Tube|
16433390|NCT03748342|Active Comparator|Second-Generation LMA|
16433391|NCT03748303|Experimental|Allo IM cohort|Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
16433392|NCT03748290|Experimental|People with a SCI who will receive Lyrica 75mg for 12 weeks|
16433393|NCT03748290|Placebo Comparator|People with a SCI who will receive Placebo for 12 weeks|
16433394|NCT03748277|Experimental|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
16433395|NCT03748277|Active Comparator|Open Fusion|Bilateral decompression, open fusion + screw fixation
16433396|NCT03748264|Active Comparator|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant. Therapy information is available continuously to site staff personnel in the standard care arm.
16433397|NCT03748264|Experimental|DreamMapper Application|The DreamMapper Application group will receive the site's therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. Participants in this group will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously as well
16433398|NCT03748264|Experimental|DreamMapper Application with Therapist Assist|The DreamMapper Application wit Therapist Assist group will not receive the site's therapy initiation standard of care but will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, and their Philips Respironics mask. and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously as well
16433399|NCT03748251|Experimental|Short fermented pizza|the patients ate a pizza that fermented for 8 hours
16433400|NCT03748251|Experimental|Long fermented pizza|the patients ate a pizza that fermented for 24 hours
16433401|NCT03748238|Experimental|Injury group|Endometrial injury with hysteroscopy
16433402|NCT03748238|No Intervention|Control group|No hysteroscopy
16433403|NCT03748212|Active Comparator|Group 1|D935 Cap. 1T
16433404|NCT03748212|Experimental|Group 2|CKD-385 Tab. 1T
16433405|NCT03748199|Experimental|POL6014|multiple ascending doses: 80, 160 and 40 mg once or twice daily
16433406|NCT03748199|Placebo Comparator|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
16433407|NCT03748186|Experimental|STRO-002 treatment|"Dose Escalation: STRO-002 at increasing dose levels
~Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg"
16433408|NCT03748173|Experimental|Treatment|Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is > 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at > 4 but < 24 hours if the initial response was positive and there has been subsequent deterioration.
16433409|NCT03748173|No Intervention|Usual Care|The only difference in care between treatment and usual care will be treatment with up to two doses of aerosolized Infasurf®.
16433410|NCT03748160|No Intervention|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
16433411|NCT03748160|Active Comparator|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
16433412|NCT03748160|Active Comparator|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
16433413|NCT03748147|Active Comparator|Control|Standard of care, misoprostol 25 mcg po every four hours
16433414|NCT03748147|Experimental|Intervention|Misoprostol 50 mcg po every four hours
16433415|NCT03748134|Experimental|Sintilimab + chemotherapy|"Sintilimab in combination with investigator's choice of chemotherapy
~TP regimen: Cisplatin + paclitaxel
~or
~CP regimen: Cisplatin + fluorourcil"
16433416|NCT03748134|Active Comparator|Placebo + chemotherapy|"Placebo in combination with investigator's choice of chemotherapy
~TP regimen: Cisplatin + paclitaxel
~or
~CP regimen: Cisplatin + fluorourcil"
16433417|NCT03748121|Experimental|Pranayama assisted Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|To prepare patients for the TF-CBT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-CBT units.
16433418|NCT03748121|Active Comparator|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Patients wait for 10 TF-CBT units and then are offered to learn pranayama.
16433419|NCT03748108|Experimental|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
16433420|NCT03748108|Placebo Comparator|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
16433518|NCT03747445||Roux-en-Y gastric bypass patients|severely obese non-diabetic adult female patients scheduled for RYGB
16433421|NCT03748082|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
16433422|NCT03748082|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
16433423|NCT03748069||Influenza positive CAPIV|All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
16433424|NCT03748069||Influenza negative CAPIV|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
16433425|NCT03748056|Experimental|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
16433426|NCT03748056|Active Comparator|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
16433427|NCT03748043|Experimental|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
16433428|NCT03748043|Experimental|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
16433429|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
16433430|NCT03748017|Placebo Comparator|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
16433431|NCT03748017|Active Comparator|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
16433432|NCT03748004|Experimental|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.
~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
16433433|NCT03748004|Placebo Comparator|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.
~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
16433434|NCT03747991||Control Infants|Infants ages 2 months to 12 months who are not on H2RA medication.
16433435|NCT03747991||Treated Infants|Infants ages 2 months to 12 months who are taking H2RA medication.
16433436|NCT03747978|Experimental|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
16433437|NCT03747978|Active Comparator|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
16433438|NCT03747965|Experimental|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
16433439|NCT03747939|Experimental|Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD|Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
16433440|NCT03747939|Placebo Comparator|Placebo|Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.
16433441|NCT03747926|Experimental|BI 705564|
16433442|NCT03747926|Placebo Comparator|Placebo|
16433443|NCT03747913|Experimental|Antioxidative Supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
16433444|NCT03747900|Experimental|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
16433445|NCT03747900|Active Comparator|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
16433446|NCT03747887|Active Comparator|School as Usual|School as usual comparison condition.
16433447|NCT03747887|Experimental|Daily Report Card|A coach will establish a Daily Report Card based on IEP goals and objectives with the parents/teachers of the child in this arm.
16433448|NCT03747874|Other|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
16433519|NCT03747445||Normal weight controls|normal weight healthy non-diabetic adult females
16505712|NCT03251976|Active Comparator|Usual care|
16433449|NCT03747861|Other|Arm for HRV monitoring|For monitoring HRV each subject will put Wristband for registration of ECG RR intervals for one hand, SenceBand in the left wrist and Holter monitor electrodes will be placed in standard configurations places.
16433450|NCT03747848|Experimental|CBT group|Subjects will participate in group treatment sessions (once a week for six weeks).
16433451|NCT03747835|Active Comparator|Exposure and Response Prevention|Inpatients will be provided three 90-minute sessions of Exposure and Response Prevention therapy each week.
16433452|NCT03747835|Active Comparator|Motivational Interviewing|Inpatients will be provided two 60-minute sessions of Motivational Interviewing each week.
16433453|NCT03747822|Active Comparator|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
16433454|NCT03747822|Active Comparator|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
16433455|NCT03747822|Other|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
16433456|NCT03747809||Patients with CIEDs having Remote Monitoring|
16433457|NCT03747809||Patients with CIEDs having no Remote Monitoring|
16433458|NCT03747796|Active Comparator|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
16433459|NCT03747796|Experimental|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
16433460|NCT03747783||Survival Group|status from radical operation to follow-up
16433461|NCT03747783||Non-Survival Group|status from radical operation to follow-up
16433462|NCT03747770|No Intervention|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
16433463|NCT03747770|Active Comparator|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
16433464|NCT03747770|Active Comparator|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
16433465|NCT03747770|No Intervention|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
16433466|NCT03747770|No Intervention|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
16433467|NCT03747757|Experimental|Supportive Care (CBT)|Patients undergo CBT consisting of 7 counseling sessions, up to 45 minutes each over the phone.
16433468|NCT03747744|Experimental|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
16433469|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.
~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.
~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
16433470|NCT03747718|Experimental|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
16433471|NCT03747718|Placebo Comparator|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
16433472|NCT03747692|Experimental|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
16433473|NCT03747692|Placebo Comparator|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
16433474|NCT03747679|Experimental|A- Bosutinib in water|200 Mg of bosutinib (50 mg capsule x4) in Water solution
16433475|NCT03747679|Experimental|B- bosutinib in sorbitol|200 Mg of bosutinib sorbitol base in water solution
16433476|NCT03747679|Experimental|C- - bosutinib mannitol|200 Mg of bosutinib powder mannitol base in water solution
16433477|NCT03747679|Experimental|D - bosutinib in mannitol low sweet|200 Mg of bosutinib mannitol low sweet solution
16433478|NCT03747679|Experimental|E- - bosutinib in mannitol high sweet|200 Mg of bosutinib High % sweet mannitol solution
16433479|NCT03747679|Experimental|F- - bosutinib low flavour|Taste assessment of 200 Mg of bosutinib low % Flavour
16433480|NCT03747679|Experimental|G- bosutinib high flavour|Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
16433481|NCT03747679|Experimental|H- - bosutinib capsules in low sweet|Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
16433482|NCT03747679|Experimental|I - bosutinib capsules high sweet|200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
16433483|NCT03747679|Experimental|J- - bosutinib capsules low flavour|Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
16433484|NCT03747679|Experimental|K - bosutinib capsules high flavour|Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
16433485|NCT03747679|Experimental|L - bosutinib capsules applesauce|200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
16433486|NCT03747679|Experimental|M - bosutinib capsules full fat yougurt|200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
16433487|NCT03747679|Experimental|N - bosutinib capsules in water (retest)|200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
16433488|NCT03747666|Experimental|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
16433489|NCT03747666|Experimental|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
16433490|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
16433491|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
16433492|NCT03747640|Experimental|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
16433493|NCT03747640|Sham Comparator|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
16433494|NCT03747614|Experimental|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
16433495|NCT03747614|Experimental|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
16433496|NCT03747601|Experimental|Temporal Interference (TI) Stimulation|Temporal Interference stimulation applied to the head via standard electrodes
16433497|NCT03747588|Experimental|Laparoscopic Pancreaticoduodenectomy|LPD
16433498|NCT03747588|Placebo Comparator|Open Pancreaticoduodenectomy|OPD
16433499|NCT03747575|Experimental|Treatment|Participants will receive MSTT1041A
16433500|NCT03747575|Placebo Comparator|Placebo|Participants will receive placebo matched to MSTT1041A
16433501|NCT03747562|Experimental|Experimental group|"Patients randomised to the experimental group will receive a prescription for a gabapentin starting dose of 100 mg three times a day (ter in die, t.i.d) /day per orally, additional to the analgesics according to standard local practices.
~Gabapentin dosage may be gradually increased based on individual patient response and tolerability, and as per standard practice in accordance with the drug label. The dose can be further increased in 300 mg/day increments (dose increments of 50% - 100%) every two to three days, up to a maximum dose of 3600 mg/day. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of two weeks, and to reach 3600 mg/day is a total of three weeks."
16433502|NCT03747562|Placebo Comparator|Control group|Patients randomised to the control group will receive a prescription for a matching placebo. The starting dose will be the same as in the experimental group (100 mg three times a day per orally), additional to the analgesics according to standard local practices. Placebo can optionally follow the same dose scheme as described in the experimental arm.
16433503|NCT03747549|Experimental|Acupuncture and Home Exercise|Acupuncture and home exercise.
16433504|NCT03747549|Active Comparator|Home Exercise Alone|The prescribed home exercise program alone.
16433505|NCT03747536|Experimental|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
16433506|NCT03747536|Placebo Comparator|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
16433507|NCT03747523|Experimental|Healthy Group|40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)
16433508|NCT03747523|Experimental|ADTKD-MUC1 Group|40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)
16433509|NCT03747510|Experimental|CarpX Device|Transverse carpal ligament release with CarpX Device
16433510|NCT03747497|Experimental|contezolid acefosamil|contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days
16433511|NCT03747497|Active Comparator|linezolid|linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days
16433512|NCT03747484|Experimental|Treatment (TCR-T cells, avelumab or pembrolizumab)|Approximated 5 days prior to receiving FH-MCVA2TCR T-cells, patients undergo radiation therapy for 1 fraction per standard of care. Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Beginning 14 days after receiving FH-MCVA2TCR T-cells, patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells.
16433513|NCT03747484|Experimental|Treatment 2 (TCR-T cells, avelumab or pembrolizumab)|Approximated 5 days prior to receiving FH-MCVA2TCR T-cells, patients undergo radiation therapy for 1 fraction per standard of care. Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Beginning 14 days after receiving FH-MCVA2TCR T-cells, patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells.
16433514|NCT03747471|Experimental|Experimental Arm|Intervention: Diabetic Conversation Map x 4 Sessions
16433515|NCT03747471|No Intervention|Control Arm|No intervention
16433516|NCT03747458|Active Comparator|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks
~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
16433517|NCT03747458|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
16433521|NCT03747432|Experimental|Propofol|Conscious sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
16433522|NCT03747432|Experimental|Dexmedetomidine|Conscious sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
16433523|NCT03747419|Experimental|Avelumab and Bladder-Directed Radiation|"Avelumab will be administered every 2 weeks intravenously for 6 doses unless there is unacceptable toxicity
~Two radiation dose regimens are allowed, and the regimen selected is at the discretion of the treating radiation oncologist"
16433524|NCT03747406|Experimental|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
16433525|NCT03747406|Experimental|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
16433526|NCT03747406|No Intervention|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
16433527|NCT03747393|Active Comparator|DoD/VA CPG Core Set|The standard core set of interventions recommended by the DoD/VA clinical practice guidelines for non-surgical management of knee OA.
16433528|NCT03747393|Experimental|DoD/VA CPG Core Set + PT|In addition to DoD/VA clinical practice guidelines, patients will be referred to physical therapy (PT). Physical therapy will consist of evidence-based interventions that can be provided by a PT (exercise, manual therapy, education).
16433529|NCT03747380|Experimental|inspiratory muscle program|Inspiratory muscle training preoperative with standard of care
16433530|NCT03747380|Other|no inspiratory muscle program|standard of care: postoperative spirometry with enhanced recovery program in thoracic surgery
16433531|NCT03747367|No Intervention|Baseline|8 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab. Repeated for visit 1 and visit 2.
16433532|NCT03747367|Experimental|Insufficient Sleep|3 days with 3 hour sleep opportunities in lab, immediately following baseline on both visit 1 and visit 2.
16433533|NCT03747354|Active Comparator|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
16433534|NCT03747354|Active Comparator|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
16433535|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment
~1=placebo + fentanyl,
~2=low dose buprenorphine + fentanyl,
~3 (optional)=low dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
16433536|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment
~1=placebo + fentanyl,
~2=high dose buprenorphine + fentanyl,
~3 (optional)=high dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
16433537|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment
~1=low dose buprenorphine + fentanyl,
~2=placebo + fentanyl,
~3 (optional)=low dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
16433538|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment
~1=high dose buprenorphine + fentanyl,
~2=placebo + fentanyl,
~3 (optional)=high dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
16433539|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.
~Two treatment periods:
~1=placebo (Day 1),
~2=low dose buprenorphine + fentanyl (Day 3)
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
16433540|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.
~Two treatment periods:
~1=placebo (Day 1),
~2=mid dose buprenorphine + fentanyl (Day 3)
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
16433541|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.
~Two treatment periods:
~1=placebo (Day 1),
~2=high dose buprenorphine + fentanyl (Day 3)
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
16433542|NCT03747328|Experimental|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
16433543|NCT03747315||Familial Mediterranean Fever (patients)|Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)
16433544|NCT03747315||Control group (patients)|Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.
16433545|NCT03747315||Healthy donors|Patients without symptoms (anonymous blood donors)
16433546|NCT03747302|Experimental|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
16433547|NCT03747302|Other|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
16433548|NCT03747289|Experimental|weight bearing group|performing exercises in a weight bearing posture
16433549|NCT03747289|Active Comparator|non-weight bearing group|performing exercises in a non- weight bearing posture
16433550|NCT03747276|Other|Clinical Trial Kiosk|
16433551|NCT03747263|Experimental|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
16433552|NCT03747263|Active Comparator|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
16433553|NCT03747250|Experimental|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
16433554|NCT03747250|Active Comparator|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
16433555|NCT03747237|Experimental|1. method, Edema measurement methods|"The surgeon will measure from three different places on the patient's face with the help of a paper ruler to measure the edema.
~Tragus-Pogonion Tragus-Labial Comissura Angulus Mandible-Latheral Cantus Measurements will be made preoperative, postoperative 2. and 7. days and saved as milimetre."
16433556|NCT03747237|No Intervention|2. method, Edema measurement methods|Patients will be given edema scale.With the help of the edema scale, the patients will be evaluated the edema by themselves. When the patient stand in front of the mirror, they will be assessed the edema on their face. And a value between 0 and 5 will be pointed on the scale postoperative 2. and 7. days.
16433557|NCT03747224|Experimental|ARO-ANG3|
16433558|NCT03747224|Placebo Comparator|Placebo|
16433559|NCT03747211|Experimental|Aerobic exercise intervention|Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
16433560|NCT03747211|No Intervention|Control group|No intervention for 12 weeks
16433561|NCT03747198|Experimental|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
16433562|NCT03747198|Placebo Comparator|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
16433563|NCT03747185|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
16433564|NCT03747185|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
16433565|NCT03747159|Experimental|BLM+RTX treatment arm|"Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.
~Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.
~Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L."
16433566|NCT03747159|No Intervention|Standard of Care treatment arm|"Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.
~Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab."
16433567|NCT03747146|Active Comparator|Continuous Adductor Canal Catheter (ACC)|Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
16433568|NCT03747146|Sham Comparator|Adductor Canal block with sham catheter|Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.
16433569|NCT03747133|Experimental|Stereotactic Ablative Radiotherapy|Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
16433570|NCT03747120|Active Comparator|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab
~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
16433571|NCT03747120|Experimental|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab
~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
16433572|NCT03747120|Experimental|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab
~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
16433573|NCT03747094|Active Comparator|Fentanyl group|
16433575|NCT03747081|Experimental|Rivoroxaban|Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
16433576|NCT03747081|Active Comparator|warfarin|Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
16433577|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
16433578|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
16433579|NCT03747055|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
16433580|NCT03747055|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
16433581|NCT03747042|Experimental|Treatment|"Drug: letrozole Take by mouth at a dose of 2.5 mg on days 7-56
~Other: Blood Collection Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
~Procedure: biopsy/lumpectomy/mastectomy Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis"
16433582|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
16433583|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.
~."
16433584|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.
~No intervention is provided."
16433585|NCT03747016|Experimental|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
16433586|NCT03747016|Active Comparator|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
16433587|NCT03747016|Placebo Comparator|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
16433588|NCT03747016|No Intervention|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
16433589|NCT03747016|Experimental|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
16433590|NCT03747016|Active Comparator|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
16433591|NCT03747016|Placebo Comparator|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
16433592|NCT03747003||HIV-infected male patients|Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
16433593|NCT03746990||observational|Total of 2015 Libyan school children aged 7 to 16 years, from urban (Tobruk) and rural (Kufra) areas were included in the main study. The children were of almost equal number of both sexes from each age group (table-I) .The total of 1935 children were examined for enamel fluorosis
16433594|NCT03746977|Active Comparator|energy restriction and protein supplementation|Energy restriction of 500 kcal/d and total Protein Uptake (including Supplementation) of 1.2 g/kg body mass/d
16433595|NCT03746977|Active Comparator|Energy restriction, walking and protein|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d) and total protein uptake (including supplementation) of 1.5 g/kg body mass/d
16433596|NCT03746977|Active Comparator|Energy restriction, walking, protein and WB-EMS|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d), total protein uptake (including supplementation) of 1.5 g/kg body mass/d and WB-EMS application 1,5x 20 min/week
16433597|NCT03746951|Active Comparator|Fascia iliaca compartment block (FICB)|FICB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the groin.
16433598|NCT03746951|Active Comparator|Lumbar plexus block (LPB)|LPB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the back.
16433599|NCT03746938|Experimental|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
16433600|NCT03746925|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
16433601|NCT03746925|Experimental|SuperPATH|SuperPATH approach surgery to replace the hip.
16433602|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
16433603|NCT03746873|Experimental|COPD Web|Participants randomised to experimental group will be introduced to the COPD Web by a letter containing written information. All participants will receive a pedometer and written information about the importance of physical activity.
16433604|NCT03746873|No Intervention|Control|Other than receiving a pedometer and written information about the importance of physical activity the patients in the control group will not receive any intervention.
16433605|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
16433606|NCT03746834|Experimental|Treatment arm|Patients are given NASHA/Dx as a perianal injection
16433607|NCT03746821|Other|Biotin|Volunteers to take biotin suppliment
16433608|NCT03746808|Placebo Comparator|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
16433683|NCT03746314||Supportive Care Leader|A staff member who is knowledgeable about supportive care services for adult oncology patients.
16433609|NCT03746808|Active Comparator|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
16433610|NCT03746795|No Intervention|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
16433611|NCT03746795|Experimental|EIT alone|Spirometric examinations realized using the EIT
16433612|NCT03746795|Experimental|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
16433613|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
16433614|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
16433615|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
16433616|NCT03746769|Experimental|Single Arm Study|
16433617|NCT03746756|Experimental|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
16433618|NCT03746756|Experimental|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
16433619|NCT03746743||Preterm neonates|Neonates born between 32 and 37 weeks gestation
16433620|NCT03746743||Fullterm neonates|Neonates born at or after 37 weeks gestation
16433621|NCT03746717|Experimental|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
16433622|NCT03746717|Active Comparator|Staples|Skin closure with staples
16433623|NCT03746704|Experimental|Part A: Cohort 1|Part A: Cohort 1 will receive a single IV dose of 89Zr˗DFO˗REGN3504
16433624|NCT03746704|Experimental|Part A: Cohort 2|Part A: Cohort 2 will receive a single IV dose of 89Zr˗DFO˗REGN3504. Doses in Part A are sequentially ascending.
16433625|NCT03746704|Experimental|Part A: Cohort 3|Part A: Cohort 3 will receive a single IV dose of 89Zr˗DFO˗REGN3504. Doses in Part A are sequentially ascending.
16433626|NCT03746704|Experimental|Part B|Part B will receive IV doses of 89Zr˗DFO˗REGN3504
16433627|NCT03746691|Experimental|Citalopram, 20 mg, IV|After placement of a high resolution impedance manometry catheter (transnasally), citalopram will be administered IV over 30 minutes (20 mg in 100ml saline). Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
16433628|NCT03746691|Placebo Comparator|Placebo, IV|After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
16433629|NCT03746678||C-Care Mobile Application|
16433630|NCT03746665|Experimental|meningococcal serogroup A conjugate|mothers will be vaccinated with meningococcal serogroup A conjugate vaccine between 28 - 34 weeks gestation
16433631|NCT03746665|No Intervention|control|serological samples from 100 control mother-infant pairs already recruited as part of the PROPEL trial, (SCC1433), NCT02628886
16433632|NCT03746652|Experimental|DId|Daratumumab, Ixazomib, Dexamethasone
16433633|NCT03746639|Active Comparator|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
16433634|NCT03746639|Other|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
16433635|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
16433636|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
16433637|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
16433638|NCT03746613|Experimental|Minimally invasive robotic cochlear implantation with HEARO|
16433639|NCT03746600|Experimental|Immediate Intervention Group|"Receives the eight-week intervention, Project TRAC: Tracking and Reducing Alcohol Consumption, immediately upon enrollment. This intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
16433640|NCT03746600|Other|Waitlist Control Group|"Receives the Project TRAC: Tracking and Reducing Alcohol Consumption alcohol reduction intervention after an 8-week, assessment-only period. This 8-wek intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
16433645|NCT03746574|Experimental|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
16433646|NCT03746574|No Intervention|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
16433647|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
16433648|NCT03746548|Other|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
16433649|NCT03746548|Other|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
16433650|NCT03746535|Active Comparator|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
16433651|NCT03746535|Experimental|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
16433652|NCT03746522|Experimental|Setmelanotide|Dosage form: Subcutaneous injection Dosage: 3 mg Frequency: daily
16433653|NCT03746522|Placebo Comparator|Placebo|Dosage form: Subcutaneous injection Dosage: 3 mg equivalent volume Frequency: daily
16433654|NCT03746509|Experimental|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
16433655|NCT03746509|Experimental|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
16433656|NCT03746509|Active Comparator|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
16433657|NCT03746509|Active Comparator|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
16433658|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
16433659|NCT03746470|Experimental|insertion preserving|ACL reconstruction preserving insertion
16433660|NCT03746470|Active Comparator|insertion detaching|ACL reconstruction detaching insertion
16433661|NCT03746457|No Intervention|Control ART Center|Control arm with no intervention throughout the course of the study
16433662|NCT03746457|Active Comparator|Control and Cycle 3 integrated package|Control arm in Cycles 1 and 2 and in Cycle three converts to experimental
16433663|NCT03746457|Experimental|GI + CA + IC|Receives one alternative sequence of three interventions
16433664|NCT03746457|Experimental|IC + GI + CA|Receives a second alternative sequence of three interventions
16433665|NCT03746457|Experimental|CA + IC + GI|Receives a third alternative sequence of three interventions
16433666|NCT03746444|Active Comparator|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).
~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
16433667|NCT03746444|Active Comparator|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
16433668|NCT03746431|Experimental|[225Ac]-FPI-1434 Single-Dose Escalation|
16433669|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose Escalation|
16433670|NCT03746431|Experimental|FPI-1175 Cold Antibody|
16433671|NCT03746418|Placebo Comparator|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
16433672|NCT03746418|Active Comparator|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
16433673|NCT03746405|Active Comparator|Repetitive TMS (rTMS)|excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
16433674|NCT03746405|Sham Comparator|Sham repetitive TMS (rTMS)|electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)
16433675|NCT03746392|Experimental|Jumpstart Intervention|
16433676|NCT03746392|No Intervention|Usual Care|
16433677|NCT03746366|Experimental|Alcohol use disorders|[C-11]Pittsburgh Compound B (PiB) PET scan
16433678|NCT03746366|Experimental|Healthy controls|[C-11]Pittsburgh Compound B (PiB) PET scan
16433679|NCT03746353|Experimental|Early closure of ileostomy|Early clousure of ileostomy before 30 days
16433680|NCT03746353|Active Comparator|Conventional closure of ileostomy|Conventional closure of ileostomy after 30 days
16433681|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
16433682|NCT03746327|Experimental|Sivextro arm|200 mg milligram per day during 4 weeks
16506637|NCT03245788|Experimental|Lay Navigation|Patients with even MRN.
16433684|NCT03746314||Oncology Providers|Physicians, nurses, physicians assistants, nurse practitioners who routinely provide cancer care to adult oncology patients.
16433686|NCT03746288|Experimental|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
16433687|NCT03746288|Active Comparator|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
16433688|NCT03746275||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events
16433689|NCT03746262||Patients - Stage I treated with surgery|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations, and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
16433690|NCT03746262||Patients - Stage I treated with radiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
16433691|NCT03746262||Patients - Stage II treated with surgery & chemotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
16433692|NCT03746262||Patients - Stage III treated with chemoradiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
16433693|NCT03746249|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16433694|NCT03746223|Experimental|R2-R/IV-MTX（methotrexate）|experimental arm will be treated rituximab plus lenalidomide (R2) regimen for 6 cycles and followed by lenalidomide maintenance for 2 years, meanwhile intravitreal methotrexate will be given as protocol
16433695|NCT03746197|Experimental|Project EVO Multi- Treatment|Treatment group receives video game device treatment. Participant plays the game for 30 minutes a day, at least five days a week for four weeks.
16433696|NCT03746197|No Intervention|Control|No contact control
16433697|NCT03746184||Knee osteoarthritis|Treatment course
16433698|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
16433699|NCT03746158|Experimental|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
16433700|NCT03746145|Experimental|Bifidobacterium longum 1714|Participants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
16433701|NCT03746145|Experimental|Placebo|Participants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
16433702|NCT03746132|Active Comparator|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
16433703|NCT03746132|No Intervention|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
16433704|NCT03746119|Active Comparator|Nicotine-free e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine-free vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
16433705|NCT03746119|Active Comparator|Nicotine e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine containing vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
16433706|NCT03746106|Active Comparator|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
16433707|NCT03746106|Experimental|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
16433708|NCT03746106|Experimental|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
16433709|NCT03746093|Placebo Comparator|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
16433710|NCT03746093|Experimental|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
16433711|NCT03746080|Experimental|Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy|After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
16433712|NCT03746067|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
16433713|NCT03746067|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
16433714|NCT03746054|Experimental|active prevention|optimal medical treatment
16433715|NCT03746054|Sham Comparator|usual clinical practice|usual clinical practice in each center
16433716|NCT03746041|Experimental|abaloparatide and bevacizumab treatment|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
16433717|NCT03746015|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in flavivirus-naïve participants (Group 1) and dengue-immune participants (Group 2). TDV comprised of 1 molecularly characterized, attenuated dengue virus strain and 3 chimeric dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) respectively.
16433720|NCT03745989|Experimental|MK-8353 and Selumetinib Dose Escalation|Starting Dose (Dose Level [DL] 1): MK-8353 + selumetinib
16433721|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
16433722|NCT03745963|Experimental|Skin-to-skin contact|"Infants will be placed in full ventral skin-to-skin with their mother at least fifteen minutes prior to heel lance to allow time to settle and recover following transfer. Positioning will be determined based on individual maternal preference in order to optimize comfort as well as facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Skin to skin contact will continue until the procedure is completed.
~In addition, infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) during SSC. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
16433723|NCT03745963|Active Comparator|24% Oral sucrose|"Infants will be placed in a cot or in an incubator, depending on their gestational age, for the duration of the blood collection. Administration of 0.12mls (0.04mls per drop) of 24 percent oral sucrose will occur two minutes prior to the heel lance.
~The infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
16433724|NCT03745950|Experimental|Olaparib|"The Olaparib arm :
~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
16433725|NCT03745950|Placebo Comparator|Placebo|"The placebo arm :
~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
16433726|NCT03745937|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous (SC) dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week treatment extension period (TEP).
16433727|NCT03745937|Placebo Comparator|Placebo Cohort 1|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the uptitration period and thereafter once daily through 3 week TEP.
16433728|NCT03745937|Experimental|MEDI0382 Cohort 2|Participants will receive SC dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week TEP.
16433729|NCT03745937|Placebo Comparator|Placebo Cohort 2|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
16433731|NCT03745911|Experimental|Paclitaxel plus TAK-228|"Paclitaxel will be given on days 1, 8, and 15 of each 28 day cycle intravenously (every Monday or first day of business week if holiday), the day before the first TAK-228 dose. It should be given over approximately one hour.
~TAK-228 will be given orally on Days 2-4, 9-11, 16-18 and 23-25 of each 28-day cycle."
16433732|NCT03745898|Active Comparator|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
16433734|NCT03745885|Experimental|0.15mg Supaglutide or placebo|0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
16433735|NCT03745885|Experimental|0.375mg Supaglutide or placebo|0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
16433736|NCT03745885|Experimental|0.75mg Supaglutide or placebo|0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
16433737|NCT03745885|Experimental|1.5mg Supaglutide or placebo|1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
16433738|NCT03745885|Experimental|3.0mg Supaglutide or placebo|3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
16433739|NCT03745872|Experimental|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
16433740|NCT03745846|Experimental|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
16433741|NCT03745846|Placebo Comparator|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
16433742|NCT03745833|Experimental|Intervention|Participants will be shown a brief VR-based mindfulness intervention after meals.
16433743|NCT03745820|Experimental|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
16433744|NCT03745820|Experimental|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
16433745|NCT03745820|Placebo Comparator|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
16433746|NCT03745807|Experimental|Combination|NKTR-214 + nivolumab
16433747|NCT03745794|Active Comparator|Arm I (QL block, standard of care)|Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.
16433748|NCT03745794|Experimental|Arm II (second QL block)|Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.
16433749|NCT03745781|Experimental|open-label placebo|open-label placebo
16433750|NCT03745781|No Intervention|treatment as usual|
16433751|NCT03745768|Experimental|Active iTBS Treatment|Intermittent theta burst stimulation to the dorsolateral prefrontal cortex
16433752|NCT03745768|Sham Comparator|Sham Stimulation|Sham stimulation to the dorsolateral prefrontal cortex.
16433753|NCT03745742|Other|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
16433754|NCT03745742|Experimental|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
16433755|NCT03745729|Experimental|Treatment group|
16433756|NCT03745729|Placebo Comparator|Control group|
16433757|NCT03745716|Experimental|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
16433758|NCT03745716|Experimental|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
16433759|NCT03745703|Experimental|MOCHA|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
16433760|NCT03745703|Experimental|"MOCHA+, Stories Matter"|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
16433761|NCT03745703|No Intervention|Wait-list control|There is no intervention to be administered during the 12-week wait-list control period
16433762|NCT03745690|Experimental|Treatment (near-infrared image guided surgical resection)|Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
16433763|NCT03745677|Experimental|Phase I|Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
16433764|NCT03745677|Experimental|Phase II|During Implementation Phase II, Advanced and Integrated MicroSystems (AIMS) interventions are being implemented on additional, phase II implementation units, leveraging lessons learned during phase I.
16433765|NCT03745664|Active Comparator|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).
~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
16433766|NCT03745664|Placebo Comparator|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
16433767|NCT03745651|Experimental|Ruxolitinib cream|
16433768|NCT03745651|Placebo Comparator|Vehicle cream|
16433769|NCT03745638|Experimental|Ruxolitinib cream|
16433770|NCT03745638|Placebo Comparator|Vehicle cream|
16433771|NCT03745625|Experimental|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
16433772|NCT03745625|Active Comparator|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
16433773|NCT03745612|Experimental|TRF|Time restricted feeding
16433774|NCT03745612|Active Comparator|CER|continuous energy restriction
16433775|NCT03745599|Experimental|Diclofenac|Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
16434639|NCT03739710|Experimental|Part 2: Participants receiving GSK3359609 and Ipilimumab combination|
16433776|NCT03745599|Experimental|Flurbiprofen|Flurbiprofen group, which received flurbiprofen 100 mg capsules and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
16433777|NCT03745599|Experimental|Benzydamine|Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules. Placebo capsules contained starch.
16433778|NCT03745586|Experimental|All study participants|
16433779|NCT03745573|Experimental|Empateach Intervention|All teachers in intervention schools will be invited to participate. Participants in the intervention condition will receive Empateach, a 10-week group intervention. Groups meet 14 times for 1-1.5 hour length sessions, which are led by peers. The aim of the Empateach intervention is to improve 'student and teacher well-being; self-regulation; teacher classroom management and teacher's use of positive discipline techniques. The intervention uses cognitive behavioural therapy techniques to change negative thought and behaviour patterns related to corporal punishment. The teachers receive information on alternatives to corporal punishment, planning exercises and reinforcement SMS, and because the intervention is in a group setting, social support to change their behaviours. They discuss their experiences and challenges in group sessions.
16433780|NCT03745573|No Intervention|Wait-list control|Teachers in wait-list control schools will receive no specific interventions related to violence prevention during the study, but will receive the intervention after the study is over if it is shown to be effective (pending donor funding).
16433781|NCT03745521||X-linked Hypophosphatemia (XLH)|Hypophosphatemic Rickets/osteomalacia
16433782|NCT03745508|Active Comparator|Caffeinated Coffee (200 mg caffeine)|~200 mg of caffeine from instant coffee
16433783|NCT03745508|Active Comparator|Caffeinated Coffee (400 mg caffeine)|~400 mg of caffeine from instant coffee
16433784|NCT03745508|Placebo Comparator|Decaffeinated Coffee|Decaffeinated instant coffee
16433785|NCT03745495||Group 1|300 To determine the effect of HIVST on PrEP uptake among older adolescent MSM and TGW
16433786|NCT03745495||Group 2|300 To determine the effect of HIVST on retention of older adolescent MSM and TGW in HIV service
16433787|NCT03745482|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
16433788|NCT03745482|No Intervention|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.
~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
16433789|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
16433790|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
16433791|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
16433792|NCT03745443|Experimental|Intervention group|Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
16433793|NCT03745443|No Intervention|Control|Ventilation with PEEP 3 during anesthesia and surgery
16433795|NCT03745417|Experimental|UCMSCs group|Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks.
16433796|NCT03745404|Experimental|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
16433797|NCT03745404|Experimental|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
16433798|NCT03745404|Placebo Comparator|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
16433799|NCT03745391|Active Comparator|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
16433800|NCT03745391|Active Comparator|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
16434272|NCT03742050|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
16433801|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
16433802|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
16433803|NCT03745365|Experimental|sleeve gastrectomy|"The greater omentum is divided 5 cm from the pylorus with an energy device. The antral pouch is measured 2-6cm from the pylorus along greater curve as risk benefit ratio is best within these limits.
~Devascularization is continued up the greater curve of the stomach to the short gastric vessels with the help of the assistant who maintains traction and exposure during this process. Eventually, one reaches the left crus which is an important landmark of dissection. We selectively explore the hiatus of the symptomatic and endoscopically proven hiatus hernia , and the hernia should be reduced and repaired."
16433804|NCT03745365|Experimental|sleeve gastrectomy with loop bipartition|Sleeve gastrectomy is performed first, then a loop gastro-ileostomy 200-250 cm from doudeno-jejunal junction was created at the dependent part of the antrum with 2 layers of with stapler but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastro-ileostomy. The staple line and anastomosis was tested with methylene blue. A drain is inserted.
16433805|NCT03745352|Experimental|Arm A (pevonedistat, azacitidine)|Patients receive pevonedistat intravenously (IV) over 60 minutes on days 1, 3, and 5 and azacitidine IV over 10-40 minutes or subcutaneously (SC) on either days 1-7, or days 1-5 and 8-9, or days 1-6 and 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16433806|NCT03745352|Active Comparator|Arm B (azacitidine)|Patients receive azacitidine IV or SC as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16433810|NCT03745326|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
16433811|NCT03745326|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
16433812|NCT03745313|Experimental|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
16433813|NCT03745300|Active Comparator|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
16433814|NCT03745300|Active Comparator|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
16433815|NCT03745300|Placebo Comparator|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
16433816|NCT03745287|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
16433817|NCT03745274|Experimental|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
16433818|NCT03745274|Placebo Comparator|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
16433819|NCT03745261|Experimental|YCC capsule+conventional medicine|Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
16433820|NCT03745261|Experimental|BL capsule + conventional medicine|Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
16433821|NCT03745248|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
16433822|NCT03745248|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
16433823|NCT03745235|Experimental|"Mindfulness group"|
16433824|NCT03745235|Other|Control group|Treatment as Usual
16433825|NCT03745222|Experimental|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
16434640|NCT03739710|Experimental|Part 2: Participants receiving GSK3359609 and Niraparib combination|
16433826|NCT03745222|Experimental|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
16433827|NCT03745222|Placebo Comparator|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
16433828|NCT03745209|Experimental|Ultrasound-guided peripheral IV.|Ultrasound-guided peripheral IV cannulation
16433829|NCT03745209|No Intervention|Traditional landmark technique|Traditional landmark technique
16433830|NCT03745196|Experimental|PC945|PC945 5mg once-daily, nebulized
16433831|NCT03745196|Placebo Comparator|Placebo|Placebo, nebulized
16433832|NCT03745183|Experimental|Senna alata leaf decoction|The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
16433833|NCT03745170|Experimental|Sintilimab+ Oxaliplatin +capecitabine|
16433834|NCT03745170|Active Comparator|placebo +Oxaliplatin + Capecitabine|
16433835|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
16433838|NCT03745131||Pre-exposure prophylaxis recipients|40 healthcare workers who provide specialist medical care to patients with monkeypox and who received vaccine as pre-exposure prophylaxis.
16433839|NCT03745131||Post-exposure prophylaxis recipients|40 healthcare workers who received vaccine as post-exposure prophylaxis following monkeypox-exposure risk assessments.
16433840|NCT03745131||Control Group 1|20 healthcare workers who provided specialist medical care to patients with monkeypox but declined the offer of vaccine as pre-exposure prophylaxis.
16433841|NCT03745131||Control Group 2|Healthcare workers not involved in the care of, and have not had known exposure to, patients with monkeypox and, therefore, were not offered vaccine.
16433842|NCT03745118|Other|Monitoring Device|Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
16433843|NCT03745105|Experimental|dexamethasone|Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)
16433844|NCT03745105|Experimental|piroxicam|Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)
16433845|NCT03745105|Active Comparator|Mepivacaine HCL|Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)
16433846|NCT03745092|Experimental|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
16433847|NCT03745092|Placebo Comparator|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
16433848|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time
~Esophagus
~Skin near to temporal artery
~Skin near to carotid artery"
16433849|NCT03745053|Experimental|XLIMUS DES|Xlimus DES Implantation during coronary angioplasty
16433850|NCT03745053|Active Comparator|Synergy DES|Synergy DES Implantation during coronary angioplasty
16433851|NCT03745040|Experimental|Group A: Exparel|"Standard of Care plus Liposomal bupivacaine (Exparel®). Dosage: Exparel® 20 mL single use vial, 1.3% (13.3 mg/mL), Maximum dose of 266 mg (20 mL).
~Frequency: Single intraoperative administration"
16433852|NCT03745040|No Intervention|Group B: No Exparel|Standard of Care
16433853|NCT03745027|Experimental|In vitro fertilization|Paients undergoing in vitro fertilization with Gonadotropin-releasing Hormone agonist. Follicular fluid sialic acid levels will be measured.
16433854|NCT03745014|Active Comparator|Pheno|
16433855|NCT03745014|Active Comparator|Standard of Care|
16433856|NCT03745001|Experimental|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
16433857|NCT03745001|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
16433858|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
16433859|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
16433860|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
16433861|NCT03744975|Placebo Comparator|Placebos|Control Intervention will be 1 Placebo Capsule given orally, one time
16433862|NCT03744975|Active Comparator|LCZ 696|1st Experimental Arm will be 1 capsule of LCZ 696 given orally, one time
16434397|NCT03741179|Experimental|ASA-withdrawn group|ASA treatment will be withdrawn if patients present an sFlt/PlGF < 38 at 24+0-27+6 weeks of gestation.
16433863|NCT03744949|Experimental|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
16433864|NCT03744949|Experimental|Remifentnil dose 1 ug/kg|Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
16433865|NCT03744949|Experimental|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
16433866|NCT03744949|Experimental|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
16433867|NCT03744936|Experimental|DA4Afib|Developing a tool to use during the encounter
16433868|NCT03744923|Active Comparator|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
16433869|NCT03744923|Active Comparator|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.
~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
16433870|NCT03744923|No Intervention|control group|the patients will not receive any blocks
16433871|NCT03744910|Active Comparator|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.
16433872|NCT03744910|Placebo Comparator|Placebo|Physiologic saline solution that is administered subcutaneously.
16433873|NCT03744897|Experimental|Hypnotic analgesia|"Intervention:
~- Subjects will receive hypnotic analgesia"
16433874|NCT03744897|Experimental|a-tDCS|"Intervention: transcranial direct current stimulation - tDCS
~active tDCS stimulation
~montage: bilateral DLPFC anodal/left and cathodal/right
~current:2 milliamps
~time: 20 minutes"
16433875|NCT03744897|Sham Comparator|s-tDCS|"Sham comparator: transcranial direct current stimulation - tDCS
~sham tDCS stimulation
~montage: bilateral DLPFC anodal/left and cathodal/right
~current: 0 milliamps
~time: 20 minutes"
16433876|NCT03744897|Experimental|Hypnotic analgesia + a-tDCS|"Intervention:
~hypnotic analgesia
~active tDCS stimulation
~montage: bilateral DLPFC anodal/left and cathodal/right
~current:2 milliamps
~time: 20 minutes"
16433877|NCT03744884|Experimental|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
16433878|NCT03744884|No Intervention|CP control group|Regular activity control group, for participants with CP.
16433879|NCT03744884|Experimental|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
16433880|NCT03744884|No Intervention|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
16433881|NCT03744871|Active Comparator|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
16433882|NCT03744871|No Intervention|No intervention|No respirators will be worn by the control group (control limb, n=100)
16433883|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
16433884|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
16433885|NCT03744845|No Intervention|Control group|Usual anesthetic care.
16433886|NCT03744845|Experimental|Virtual Reality Intervention Group|Virtual Reality Distraction
16433946|NCT03744325|Active Comparator|Hen's egg OIT|Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
16433947|NCT03744325|No Intervention|Hen's egg avoidance|Hen's egg is avoidance diet is continued.
16433948|NCT03744312|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
16433887|NCT03744832|Experimental|Point of Care Testing|"Point of care testing using the Alere i™ Strep A assay for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. If test is positive, patients will be started on antibiotics prior to discharge from the ED. If test is negative, patients will not be started on antibiotics.
~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
16433888|NCT03744832|Active Comparator|Standard Care|"Conventional testing using a standard bacterial throat culture for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. Patients will be discharged with a post-dated prescription and will be contacted in approximately 3 days if their culture results are positive to fill/take the antibiotics.
~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
16433889|NCT03744806||treated with intravitreal bevacizumab.|
16433890|NCT03744806||control group|
16433891|NCT03744793|Experimental|Treatment (pemetrexed, avelumab)|Patients receive pemetrexed IV over 10 minutes on day 1. Starting cycle 2, patients also receive avelumab IV over 60 minutes. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16433892|NCT03744780|Experimental|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
16433893|NCT03744767|Experimental|Single treatment arm|
16433894|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
16433895|NCT03744728|Active Comparator|Accelerate Pheno|Fast ID and AST of positive blood culture bottles using the Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System
16433896|NCT03744728|Active Comparator|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
16433897|NCT03744715|Experimental|Poziotinib|Poziotinib
16433898|NCT03744702|Experimental|Treatment|All patients will receive ascorbic acid as this is a pilot study.
16433899|NCT03744689|Active Comparator|Erector Spinae Plane Block|"Erector Spinae Plane Block Group
~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
16433900|NCT03744689|Sham Comparator|Control Group|Sham block will be done with serum physiologic.
16433901|NCT03744676|Experimental|Lisocabtagene maraleucel|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
16433902|NCT03744663|Active Comparator|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
16433903|NCT03744663|Experimental|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
16433904|NCT03744650|Experimental|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
16433905|NCT03744637|Experimental|Panel A (Parts 1 and 2)|Participants will receive a single inhaled dose of MK-5475 120 µg or a matching placebo in Period 1, MK-5475 165 µg or a matching placebo in Period 2 and MK-5475 240 µg or a matching placebo in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2, participants will receive a single inhaled dose of MK-5475 240 µg and undergo an right heart catheterization (RHC) and will receive a single inhaled dose of MK-5475 240 µg and undergo an functional respiratory imaging (FRI).
16433906|NCT03744637|Experimental|Panel B (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 300 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 360 µg and have an FRI. In Period 3, participants receive a single inhaled dose of MK-5475 360 µg and have an RHC.
16433907|NCT03744637|Experimental|Panel C (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 300 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 360 µg and have an FRI. In Period 3, participants will receive a single inhaled dose of MK-5475 360 µg and have an RHC.
16433908|NCT03744637|Experimental|Panel D (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 480 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 120 µg and have an FRI. In Period 3, participants will receive a single inhaled dose of MK-5475 120 µg and have an RHC.
16433909|NCT03744624|Experimental|With 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing both 3D printed model and computed tomography (or/and magnetic resonance imaging)
16433910|NCT03744624|Active Comparator|Without 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing only standard medical imaging computed tomography (or/and magnetic resonance imaging) without development of 3D printed model
16433911|NCT03744611|Experimental|CE|CE capsule administered orally twice daily for 12 weeks.
16433912|NCT03744611|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
16433913|NCT03744585||Cohort 1|Subjects who received at least one dose of cabozantinib during the Authorization for Use (ATU) period (12/09/2016 to 09/12/2016) for the treatment of advanced Renal Cell Carcinoma (RCC).
16433914|NCT03744585||Cohort 2|Subjects who received at least one dose of cabozantinib during the first six months after the ATU period (10/12/2016 to 16/02/2018).
16433949|NCT03744312|Active Comparator|No cognitive impairment|Healthy Controls
16433950|NCT03744299|Other|Intervention|Patients and caregivers are asked to complete a questionnaire
16433951|NCT03744286|Experimental|Balance Slip|"Perform standard clinical balance assessments
~Determine the optimal slip distance by 10 passes each with plank movement of 2, 4, 6 and 8 on visit 1"
16433915|NCT03744559|Experimental|R-E (Retrieval Extinction) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a lab-based smoking-related cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the R-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
16433916|NCT03744559|Experimental|R-E (Retrieval Extinction) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a smoking-related cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
16433917|NCT03744559|Other|NR-E (No R-E) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a lab-based non-smoking or neutral cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the NR-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
16433918|NCT03744559|Other|NR-E (No R-E) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a non-smoking or neutral cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
16433919|NCT03744533|Experimental|head-down position treatment|
16433920|NCT03744533|Active Comparator|guideline-based treatment|
16433921|NCT03744520|Experimental|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
16433922|NCT03744507||Uterine Fibroids|Premenopausal women with uterine fibroids confirmed by an ultrasound.
16433923|NCT03744507||Endometriosis|Premenopausal women with endometriosis diagnosed or confirmed by surgical or direct visualization, or histopathology within 10 years of the Screening visit.
16433924|NCT03744494|Experimental|Bilateral simple orchidectomy (BSO)|The patients would have the testis, epididymis and distal cord structures excised
16433925|NCT03744494|Experimental|Subcapsular orchidectomy (BSCO)|The tunica albuginea was incised longitudinally and the testicular parenchyma scraped off it. The hilar region was secured with a haemostat and the parenchyma excised off it. A haemostatic suture was applied at the hilum. A running interlocking water-tight capsular suture was inserted
16433926|NCT03744494|Experimental|Epididymal-sparing orchidectomy (BESO)|The epididymal sinus was developed. The epididymal vessels were sequentially clamped and divided, removing the testicle from the epididymis. The caput was looped to meet the head and the adjoining surfaces of the body sutured together (epididymoplasty) Vasectomy done to reduce future risk of epididymitis
16433927|NCT03744468|Experimental|Phase 1 Dose Escalation|Dose escalation of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors
16433928|NCT03744468|Experimental|Phase 2 Dose Expansion|Further explore the safety and clinical activity of BGB-A425 in combination with tislelizumab in participants with NSCLC, HNSCC and RCC.
16433929|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
16433930|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
16433931|NCT03744442|Active Comparator|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
16433932|NCT03744442|Active Comparator|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
16433933|NCT03744442|Active Comparator|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
16433934|NCT03744429|Experimental|Mediterranean Meal Plan|This is a single arm study in which participants will receive meals that follow a Mediterranean diet plan for 4 weeks. Breast milk samples will be collected before, during, and after the intervention period.
16433935|NCT03744416|Experimental|Intervention group|Counseling based on Epstein's active decision making on birth plan
16433936|NCT03744416|No Intervention|Control group|The standard midwife's advice on birth plan during prenatal care.
16433937|NCT03744403|Experimental|CS1001 monoclonal antibody|
16433938|NCT03744390|Experimental|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
16433939|NCT03744364|Active Comparator|Misoprostol|Group of women allocated to misoprostol induction.
16433940|NCT03744364|Active Comparator|Dinoprostone|Group of women allocated to dinoprostone induction.
16433941|NCT03744351|Other|Healthy volunteer|"45 subjects
~A single visit"
16433942|NCT03744351|Other|Clinically Isolated Syndrome|• 35 subjects
16433943|NCT03744351|Other|Non-MS patients with neurological inflammatory disease|• 30 subjects
16433944|NCT03744351|Other|MS patients (remitting or progressive untreated)|"30 untreated remittent patients
~30 progressive untreated patients"
16433945|NCT03744338||Group 1|
16433952|NCT03744247|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16433953|NCT03744247|Active Comparator|Lenvatinib alone|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received placebo intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
16433954|NCT03744234|Experimental|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
16433955|NCT03744234|Active Comparator|Steroid Injection|Steroid injection in the sacroiliac joint
16433956|NCT03744221|Experimental|Corn protein|Corn protein powder
16433957|NCT03744221|Experimental|Bovine plasma protein|Bovine plasma protein powder
16433958|NCT03744221|Active Comparator|control benchmark protein Whey|Whey protein powder
16433959|NCT03744208|Experimental|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16433960|NCT03744195|Experimental|Group I Experimental Kinesotaping|Application of kinesotaping along with conventional treatment
16433961|NCT03744195|Active Comparator|Group II conventional training group|Application of conventional treatment
16433962|NCT03744182|Experimental|HM15211|
16433963|NCT03744182|Placebo Comparator|Placebo|
16433964|NCT03744169||Children with acute respiratory failure|Point-of-care lung ultrasound on admission to the PICU to determine the cause of respiratory failure.
16433965|NCT03744156|Experimental|Cognitive Behavioral Treatment-Insomnia|Cognitive Behavioral Treatment-Insomnia. 8 Session treatment focusing on behavior and cognitions related to sleep and pain.
16433966|NCT03744156|Experimental|Sleep Hygiene Education|Sleep Hygiene Education. 8 Session treatment focusing on sleep hygiene education.
16433967|NCT03744143|Other|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
16433968|NCT03744143|Other|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
16433969|NCT03744130|Experimental|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.
~Diagnostic Test: Contrast-enhanced Ultrasound"
16433970|NCT03744130|Experimental|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
16433971|NCT03744117|Experimental|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
16433972|NCT03744104|Experimental|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
16433973|NCT03744104|Active Comparator|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
16433974|NCT03744104|Active Comparator|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
16433975|NCT03744091|Active Comparator|10 mg P1|10 mg of P1 will be administered and compared with an active dose of 20 mg P1 on crossover
16433976|NCT03744091|Active Comparator|20 mg P1|20 mg of P1 will be administered and compared with an active dose of 10 mg P1 on crossover
16433977|NCT03744078|Active Comparator|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
16433978|NCT03744078|No Intervention|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
16433979|NCT03744065|Active Comparator|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
16433980|NCT03744065|Experimental|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
16433981|NCT03744052|Experimental|Adult Participants|Messages regarding physical activity will be texted to participants.
16433982|NCT03744026|Experimental|SonoCloud-9 Ultrasound + Carboplatin|SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)
16433983|NCT03744013|Active Comparator|Perforated|Fortiva® 1mm perforated ADM
16433984|NCT03744013|Active Comparator|Non-perforated|Fortiva® 1mm non-perforated ADM
16433985|NCT03744000|Placebo Comparator|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
16433986|NCT03744000|Active Comparator|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
16433987|NCT03743987|Sham Comparator|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
16433988|NCT03743987|Experimental|MTA group|Root resection was applied and MTA was inserted through the apical foramen
16433989|NCT03743987|Experimental|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
16433990|NCT03743987|Experimental|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
16433991|NCT03743974|Active Comparator|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
16434063|NCT03743519|Placebo Comparator|Placebo|
16434064|NCT03743519|Experimental|Cherry juice|
16433992|NCT03743974|Experimental|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
16433993|NCT03743961||Group A : control group|"Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions) and QoL EORTC Q30 (Quality Qf Life with 30 Questions)
~for patients with G8 score > 14/17"
16433994|NCT03743961||Group B : geriatric intervention group|Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))
16433995|NCT03743948|Experimental|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
16433996|NCT03743935|Experimental|Early cardiac MRI post-STEMI|Early stages post-STEMI (within the first 5 days)
16433997|NCT03743922|Experimental|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
16433998|NCT03743922|Placebo Comparator|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
16433999|NCT03743909||patients with aberrant CD markers|by flowcytometry from hospital information system
16434000|NCT03743909||patients without aberrant CD markers|by flowcytometry from hospital information system
16434001|NCT03743896|No Intervention|Control group|No intervention
16434002|NCT03743896|Experimental|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
16434003|NCT03743883||Low-dose ASA cohort|A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
16434004|NCT03743883||Comparison unexposed cohort|When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
16434005|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
16434006|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
16434007|NCT03743857|Experimental|Manual Therapy|6 sessions of ankle manual therapy
16434008|NCT03743857|No Intervention|Control|No intervention
16434009|NCT03743844|Experimental|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
16434010|NCT03743844|No Intervention|Control group|Weight management treatment as usual
16434011|NCT03743831|Other|orotracheal intubation direct|
16434012|NCT03743831|Other|orotracheal intubation indirect|
16434013|NCT03743818|Experimental|dry needling|dry needling in trigger point in vastus medialis of quadriceps
16434014|NCT03743818|Active Comparator|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
16434015|NCT03743818|Active Comparator|hialuronic acid|infiltration of hyaluronic acid in the affected knee
16434016|NCT03743805|Experimental|Reversal drugs|Flumazenil and naloxone
16434017|NCT03743792|Experimental|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
16434018|NCT03743792|Placebo Comparator|Placebo|Placebo breakfast
16434019|NCT03743779||Intervention|Participants enrolled in Mastering Diabetes.
16434020|NCT03743766|Experimental|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).
~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
16434021|NCT03743766|Experimental|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.
~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
16434022|NCT03743766|Experimental|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
16434023|NCT03743753|No Intervention|Control|The control group will receive the current standard educational information from the surgeon along with an information package.
16434024|NCT03743753|Experimental|Experimental|The experimental group will receive an additional educational session before their operation about what to expect during their reconstructive journey, in addition to the current standard educational information from the surgeon along with an information package.
16434025|NCT03743740|Experimental|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
16434026|NCT03743740|Experimental|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
16434027|NCT03743727|Experimental|Combined Therapy LDV and SOF|
16434028|NCT03743714|Experimental|males|healthy, sedentary males
16434029|NCT03743714|Experimental|females|healthy, sedentary females
16434030|NCT03743701|Active Comparator|Transrectal ultrasound in В-mode|
16434031|NCT03743701|Experimental|Transrectal ultrasound examination using three-di|
16434141|NCT03742999|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
16434032|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
16434033|NCT03743675|Experimental|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
16434034|NCT03743675|Experimental|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
16434035|NCT03743675|Experimental|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
16434036|NCT03743675|No Intervention|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
16434037|NCT03743662|Experimental|Recurrent Glioblastoma, No Surgery|One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan
16434038|NCT03743662|Experimental|Recurrent Glioblastoma, Surgery|The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.
16434039|NCT03743649|Experimental|Group I (haloperidol, placebo)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
16434040|NCT03743649|Experimental|Group II (lorazepam, placebo)|Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
16434041|NCT03743649|Experimental|Group III (haloperidol, lorazepam)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
16434042|NCT03743649|Experimental|Group IV (placebo, lorazepam)|Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
16434043|NCT03743636|Active Comparator|Nicotinamide riboside + resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 1,000 mg of NR and 125 mg of reservatrol daily for six months.
16434044|NCT03743636|Active Comparator|Nicotinamide riboside + placebo|Participants randomized to the NR + placebo arm of the study will receive 1,000 mg of NR and a placebo daily for six months.
16434045|NCT03743636|Placebo Comparator|Placebo + placebo|Participants randomized to the placebo + placebo arm of study will receive placebo pills.
16434046|NCT03743623|Experimental|Treatment Group|Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a magnetic field with pre-determined strength.
16434047|NCT03743623|Placebo Comparator|Placebo Group|The placebo control is a mock treatment in which a subject will go through the same procedures as subjects assigned to the treatment group, only without being actually exposed to electromagnetic waves and magnetic fields.
16434048|NCT03743610|Experimental|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work.
16434049|NCT03743610|Experimental|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
16434050|NCT03743610|Active Comparator|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
16434051|NCT03743610|Placebo Comparator|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
16434052|NCT03743597|Experimental|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.
~All examinations will be conducted in all participants and with both stockings one after the other."
16434053|NCT03743597|Active Comparator|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.
~All examinations will be conducted in all participants and with both stockings one after the other."
16434054|NCT03743584|Experimental|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
16434055|NCT03743584|Active Comparator|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
16434056|NCT03743571|Active Comparator|anodal tDCS during exposure|anodal transcranial direct current stimulation (2mA) will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
16434057|NCT03743571|Sham Comparator|sham tDCS during exposure|sham transcranial direct current stimulation will be applied over EEG coordinate FpZ during exposure therapy at a level that provides the physical sensations of tDCS but which is non-therapeutic
16434058|NCT03743558|Experimental|children with adenoamygdala hypertrophy|
16434059|NCT03743545|Active Comparator|conventional drilling with irrigation|
16434060|NCT03743545|Experimental|low speed without irrigation|
16434061|NCT03743532|Experimental|JUUL/e-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes. They will receive a JUUL e-cigarette device and JUULpods during the first 4 weeks following a scheduled switch date.
16434062|NCT03743532|Experimental|Financial Incentives + JUUL/e-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes, and they will receive a JUUL e-cigarette device and JUULpods during the first 4 weeks following a scheduled switch date. Participants will also receive weekly financial incentives for biochemically-verified cigarette abstinence during the first 4 weeks following the switch date.
16434065|NCT03743506|Experimental|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
16434066|NCT03743493||Prevalence numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017)
16434067|NCT03743493||Prevalence denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017)
16434068|NCT03743493||Guideline A numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
16434069|NCT03743493||Guideline A denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
16434070|NCT03743493||Guideline B numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO inpatient cancer diagnosis OR cancer procedure in the year prior to the index event
16434071|NCT03743493||Guideline B denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO in-patient cancer diagnosis OR cancer procedure in the year prior to the index event
16434072|NCT03743480|No Intervention|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
16434073|NCT03743480|Experimental|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
16434074|NCT03743467||Control group|Health subjects
16434075|NCT03743467||PD patients Hoehn Yahr 1|Patients with Hoehn Yahr stage 1
16434076|NCT03743467||PD patients Hoehn Yahr 2-3|Patients with Hoehn Yahr stage 2 and 3
16434077|NCT03743454||Men|
16434078|NCT03743454||Women|
16434079|NCT03743441|Active Comparator|Exercise + Cryotherapy + LLLT|
16434080|NCT03743441|Sham Comparator|Exercise + Cryotherapy + Sham LLLT|
16434081|NCT03743428|Experimental|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
16434082|NCT03743428|Active Comparator|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
16434083|NCT03743415|Experimental|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
16434084|NCT03743415|Experimental|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
16434085|NCT03743402|Experimental|Pain self-management|"This intervention will have 4 components:
~telephone-delivered evidence-based pain self-management training,
~web-based video of successfully tapered patients with motivational interviewing debriefing,
~a voluntary, self-paced opioid taper
~opioid and non-opioid prescribing guidance for the patient's primary care provider."
16434086|NCT03743402|Active Comparator|usual care|Patients randomized to usual care will continue to receive care as usual from their Kaiser primary care provider.
16434087|NCT03743389|Experimental|12G pigtail catheter|
16434088|NCT03743389|Active Comparator|16F chest tube|
16434089|NCT03743376|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
16434090|NCT03743376|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
16434091|NCT03743376|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
16434092|NCT03743363|Experimental|Exergame 3/week|The group does active training for 8 weeks after not training.
16434093|NCT03743363|Experimental|Exergame 2/week|The group does active training for 8 weeks after not training.
16434094|NCT03743363|Experimental|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
16434095|NCT03743324||BR group|Breast reconstruction without radiation therapy
16434096|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
16434097|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
16434098|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
16434099|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
16434100|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
16434101|NCT03743298|Experimental|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
16434142|NCT03742999|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
16434102|NCT03743285|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
16434103|NCT03743272||Liver condition|Participants who have a history of of liver disease
16434104|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
16434105|NCT03743259|Experimental|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
16434106|NCT03743259|Experimental|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
16434107|NCT03743259|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
16434108|NCT03743246|Experimental|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
16434109|NCT03743233|Active Comparator|Hand file instrumentation|
16434110|NCT03743233|Active Comparator|Reciprocating instrumentation|
16434111|NCT03743207|Experimental|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
16434112|NCT03743207|Experimental|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
16434113|NCT03743194|Active Comparator|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.
~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
16434114|NCT03743194|Placebo Comparator|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
16434115|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
16434116|NCT03743181||control|will received standard care by physician in attendance
16434117|NCT03743168|Experimental|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
16434118|NCT03743168|Experimental|Continuous stretch|2 minutes continuous stretch
16434119|NCT03743155|Experimental|treatment with mesenchymal stem cells|xerostomy using mesenchymal stem cells adult autologous bone marrow
16434120|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
16434121|NCT03743129|Experimental|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
16434122|NCT03743129|No Intervention|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
16434123|NCT03743116||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
16434124|NCT03743116||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
16434125|NCT03743103|Experimental|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
16434126|NCT03743103|Active Comparator|Nitroprusside, Sodium|0.5 mcg / kg / min every 3 minutes until reaching the pressure target
16434127|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
16434128|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
16434129|NCT03743077|Experimental|Individuals with spinal cord injury|Volunteers will participate in the the spinal mobility fitness training program which includes exercise training with inspiratory muscle training.
16434130|NCT03743064|Experimental|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
16434131|NCT03743064|Placebo Comparator|Placebo|Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
16434132|NCT03743051|Experimental|100mg Anamorelin HCl|
16434133|NCT03743051|Placebo Comparator|placebo|
16434134|NCT03743038|Experimental|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
16434135|NCT03743038|Experimental|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
16434136|NCT03743025|Experimental|Dulaglutide Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
16434137|NCT03743025|Placebo Comparator|Placebo Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
16434138|NCT03743012|Experimental|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
16434139|NCT03743012|Active Comparator|Usual Care|Participants receiving usual care only
16434140|NCT03742999|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
16434143|NCT03742986|Experimental|HER2-negative, including TNBC or HR-positive|
16434145|NCT03742973|Experimental|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
16434146|NCT03742973|Placebo Comparator|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
16434147|NCT03742973|Experimental|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
16434148|NCT03742973|Placebo Comparator|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
16434149|NCT03742960|Experimental|Behavioral Sleep Restriction|Participants will be required to go to sleep half an hour later than their usual bedtime. Wake up time will be determined via their usual wake time.
16434150|NCT03742947|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
16434151|NCT03742947|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
16434152|NCT03742934|Experimental|Formula group|short peptide formula prior to capsule endoscopy
16434153|NCT03742934|Other|Control group|regular liquid diet
16434154|NCT03742921||Relapsed or Refractory T-Cell Lymphoma patients with Istodax|Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
16434155|NCT03742908|No Intervention|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
16434156|NCT03742908|Experimental|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
16434157|NCT03742908|Experimental|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
16434159|NCT03742882|Experimental|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
16434160|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
16434161|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
16434162|NCT03742843||Group of adenomyosis|Patients with adenomyosis with or without endometriosis
16434163|NCT03742843||Group of endometriosis|Patients with endometriosis without adenomyosis
16434164|NCT03742843||Group of control|Patients without adenomyosis or endometriosis
16434165|NCT03742817|Experimental|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
16434166|NCT03742817|Placebo Comparator|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
16434167|NCT03742817|Experimental|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
16434168|NCT03742817|Active Comparator|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
16434169|NCT03742804|Experimental|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
16434170|NCT03742791|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
16434171|NCT03742791|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
16434172|NCT03742778|Experimental|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
16434173|NCT03742778|Experimental|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
16434398|NCT03741179|No Intervention|ASA group|ASA treatment will continue until 36 weeks of gestation if patients present an sFlt/PlGF ratio < 38 at 24+0-27+6 weeks of gestation.
16506638|NCT03245788|No Intervention|Usual Care|Patients with odd MRN.
16434174|NCT03742765|Experimental|Incentivizing Planning|Participants will receive three texts each week asking a question to help plan for the next workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout).
16434175|NCT03742765|Experimental|Incentivizing Exercise|Participants will receive three texts each week asking a question about their workout. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout).
16434176|NCT03742752|Experimental|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).
~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
16434177|NCT03742752|Active Comparator|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
16434178|NCT03742726|Experimental|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
16434179|NCT03742713|Experimental|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
16434180|NCT03742700|Experimental|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
16434181|NCT03742700|Experimental|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
16434182|NCT03742700|Experimental|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
16434183|NCT03742700|Placebo Comparator|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
16434184|NCT03742687|Experimental|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
16434185|NCT03742687|Experimental|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
16434186|NCT03742674||Cohort patients post stroke|
16434187|NCT03742661|Experimental|Treatment Group|SPEAC System
16434188|NCT03742661|No Intervention|Standard of Care|Standard of Care
16434189|NCT03742648|Active Comparator|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
16434190|NCT03742648|Experimental|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
16434191|NCT03742635|Experimental|GMA Assessment|"Conduct General Movements Assessment (GMA) in-person/via-telemedicne (real-time) and recorded (standard of care)"
16434192|NCT03742622|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
16434193|NCT03742609|No Intervention|Information only|provision of written information regarding consequences of using a hearing aid and not using a hearing. For example using a hearing aid will improve ability to hear others.
16434194|NCT03742609|Active Comparator|Physical reminder only|provision of written information regarding consequences of using a hearing aid and not using a hearing and physical reminder to use a hearing aid. For example, a hearing aid box as a physical reminder to use the hearing aids.
16434195|NCT03742609|Active Comparator|Behaviour Plan only|provision of written information regarding consequences of using a hearing aid and not using a hearing and creation of behaviour plan to use a hearing aid. For example, when and where to use the hearing aids.
16434196|NCT03742609|Experimental|Info, Reminder and Plan|provision of written information regarding consequences of using a hearing aid and not using a hearing, physical reminder and creation of behaviour plan to use a hearing aid
16434197|NCT03742596|Experimental|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
16434198|NCT03742596|Other|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
16434199|NCT03742583|Active Comparator|Square Knot|
16434200|NCT03742583|Active Comparator|Reversing Half-Hitch Alternating Post Knot|
16434201|NCT03742570||CBBDQ|A Questionnaire
16434202|NCT03742557|Active Comparator|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.
~The intervention will be done twice weekly for 8 weeks."
16434203|NCT03742557|Placebo Comparator|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
16434204|NCT03742531|Active Comparator|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
16434205|NCT03742531|Active Comparator|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
16434206|NCT03742518|Experimental|Topical SM04554 0.15% solution|Topical SM04554 0.15% solution, once daily for up to 48 weeks
16434207|NCT03742518|Experimental|Topical SM04554 0.25% solution|Topical SM04554 0.25% solution, once daily for up to 48 weeks
16434208|NCT03742518|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for up to 48 weeks
16434641|NCT03739710|Experimental|Part 2: Participants receiving GSK3359609 and Dostarlimab plus Cobolimab combination|
16434209|NCT03742505|Experimental|Vitamin D|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Vitamin D Group and will receive a single dose of cholecalciferol at enrolment.
~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
16434210|NCT03742505|Placebo Comparator|Placebo|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Placebo Group and will receive a single dose of placebo at enrolment.
~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
16434211|NCT03742492|Experimental|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
16434212|NCT03742492|Placebo Comparator|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
16434213|NCT03742479|Experimental|Hyaluronic Acid Microinjection|
16434214|NCT03742466|Active Comparator|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
16434215|NCT03742466|Active Comparator|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
16434216|NCT03742453|Experimental|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
16434217|NCT03742440|Other|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
16434218|NCT03742427|Experimental|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
16434219|NCT03742414|Active Comparator|Control arm (Standard of care)|The study doctors will provide standard of care with routine reactive topical products for atopic dermatitis flares
16434220|NCT03742414|Experimental|Active Intervention arm (proactive treatment)- Epiceram|Participants will receive proactive sequential skin care with the twice-daily use of a tri-lipid skin barrier cream (SBC). Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).
16434221|NCT03742414|Experimental|Active Intervention arm (proactive treatment)- Moisturizer|Participants will receive proactive sequential skin care with the twice-daily use of a moisturizer. Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).
16434222|NCT03742401|Active Comparator|Surgery|Surgery
16434223|NCT03742401|Active Comparator|HIFU (Echopulse)|HIFU (Echopulse)
16434224|NCT03742375|Experimental|HPV genotyping|
16434225|NCT03742362|Experimental|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
16434226|NCT03742349|Experimental|1: spartalizumab + LAG525 + NIR178|phase Ib (escalation and expansion)
16434227|NCT03742349|Experimental|2: spartalizumab +LAG525 +capmatinib|phase Ib (escalation and expansion)
16434228|NCT03742349|Experimental|3: spartalizumab + LAG525 + MCS110|phase Ib (escalation and expansion)
16434229|NCT03742349|Experimental|4: spartalizumab +LAG525 +canakinumab|phase Ib (escalation and expansion)
16434230|NCT03742336|Experimental|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
16434231|NCT03742336|Experimental|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
16434232|NCT03742323|Experimental|Idelalisib|
16434233|NCT03742310|Experimental|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
16434234|NCT03742310|No Intervention|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
16434235|NCT03742297|Active Comparator|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
16434236|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
16434237|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
16434238|NCT03742284|Other|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
16434239|NCT03742271|Experimental|senofilcon A|Subjects that are habitual spectacle wearers that have never worn contact lenses and have had an eye exam and an updated spectacle prescription in the last 6 months will be enrolled and fitted into the senofilcon A TEST Lens for a total period of 4 weeks.
16434240|NCT03742258|Experimental|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
16434273|NCT03742037|Experimental|Cenerimod 0.5 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
16434468|NCT03740724|Experimental|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
16434241|NCT03742245|Experimental|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.
~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
16434242|NCT03742232|Experimental|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
16434243|NCT03742232|Active Comparator|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
16434244|NCT03742219|Experimental|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
16434245|NCT03742206|Experimental|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
16434246|NCT03742206|Active Comparator|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
16434247|NCT03742193|Experimental|Apatinib + GD group|Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
16434248|NCT03742180|Experimental|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
16434249|NCT03742180|Active Comparator|sublingual ketorolac|this group is planned for sublingual ketorolac
16434250|NCT03742167|Experimental|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
16434251|NCT03742167|No Intervention|Control|The control arm will receive pediatric medical control physician consultation via telephone.
16434252|NCT03742154|Experimental|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
16434253|NCT03742154|No Intervention|Control Group|49 participants will be enrolled in this group.
16434255|NCT03742115|Experimental|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
16434256|NCT03742115|Experimental|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
16434257|NCT03742115|Active Comparator|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
16434263|NCT03742089||Treatment|Bone Anchored Hearing Surgery using a BHX implant manufactured by Oticon Medical
16434264|NCT03742076|Active Comparator|High-dose prebiotic|10 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
16434265|NCT03742076|Active Comparator|Low-dose prebiotic|5 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
16434266|NCT03742076|Placebo Comparator|Placebo|2 gm powdered fiber daily for at least 6 weeks
16434267|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
16434268|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
16434269|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
16434270|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
16434271|NCT03742050|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
16434274|NCT03742037|Experimental|Cenerimod 1 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
16434275|NCT03742037|Experimental|Cenerimod 2 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
16434276|NCT03742037|Experimental|Cenerimod 4 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will will be re-randomized in a double-blinded fashion in TP2 in a 1:1 ratio to placebo or cenerimod 2 mg."
16434277|NCT03742037|Placebo Comparator|Placebo|"Subjects will receive matching placebo once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
16434278|NCT03742024||Children and adolescents|Children and adolescents between the ages of 4 and 17 years old (inclusive)
16434279|NCT03741998|No Intervention|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
16434280|NCT03741998|Active Comparator|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
16434281|NCT03741985|Placebo Comparator|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
16434282|NCT03741985|Experimental|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
16434283|NCT03741972||Treatment|Patients with diabetes and heart failure that are treated with iSGLT2
16434284|NCT03741959|Experimental|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
16434285|NCT03741959|Active Comparator|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
16434286|NCT03741946|Other|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
16434287|NCT03741933|Experimental|Apremilast|30 mg twice daily to be administered for a period of 6 months
16434288|NCT03741920|Experimental|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
16434289|NCT03741920|Active Comparator|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
16434290|NCT03741907|Experimental|FAUCS|French Ambulatory C-section
16434291|NCT03741907|Active Comparator|MLC|Gold Standard
16434292|NCT03741894|Placebo Comparator|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
16434293|NCT03741894|Experimental|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
16434294|NCT03741894|Experimental|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
16434296|NCT03741868||Stage IV non-small cell lung cancer|60 - stage IV non-small cell lung cancer patients will be recruited through the Wake Forest Baptist Comprehensive Cancer Center to complete the quantitative portion of the study. We will use purposive sampling to assure representation of patients at different stages in immunotherapy (i.e., initiating treatment, anticipating scan results, after onset of immune-related side effects).12-15 of the 60 patients who complete the survey and who express interest in providing feedback on programs and participating in future research will be recruited to complete the qualitative portion of the study
16434297|NCT03741855|Experimental|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
16434298|NCT03741855|Experimental|Self-Monitoring Program|Cloud Dx kit with self-monitoring
16434299|NCT03741855|No Intervention|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
16434336|NCT03741608|Active Comparator|Education only|High blood pressure management education
16434337|NCT03741595|Experimental|Single Arm|
16507573|NCT03239353|Other|0.5 mg ETV IR tablet|
16434300|NCT03741842|Experimental|COMBO-KEY group|"The participants in the intervention group will receive a home visiting and phone coaching self-management programme (Coaching Ongoing Momentum Building On stroKe rEcovery journeY COMBO-KEY) which is underpinned by Bandura's constructs of self-efficacy and outcome expectation."
16434301|NCT03741842|No Intervention|Usual care group|The participants in the usual care group will receive usual rehabilitation services offered, including services by a community rehabilitation network such as exercise training, physical rehabilitation, or activities organised by stroke support groups.
16434302|NCT03741829||Samples from transbronchial Biopsy|Samples from participants with SCLC.
16434303|NCT03741816|Active Comparator|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
16434304|NCT03741816|Experimental|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
16434305|NCT03741803|Active Comparator|Delayed cord clamping|
16434306|NCT03741803|Active Comparator|Early cord clamping|
16434307|NCT03741777|Active Comparator|3 ml/kg of clear oral fluid|This group of patient will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
16434308|NCT03741777|Active Comparator|5 ml/kg of clear oral fluid|This group of patient will consume 5 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
16434309|NCT03741777|Active Comparator|7 ml/kg of clear oral fluid|This group of patient will consume 7 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
16434310|NCT03741777|Active Comparator|10 ml/kg of clear oral fluid|This group of patient will consume 10 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
16434311|NCT03741764|Other|Vivosorb|Only arm in study
16434312|NCT03741751|Experimental|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
16434313|NCT03741751|Sham Comparator|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
16434314|NCT03741738||Non-segmental vitiligo :|"A. Patients aged 19 years or older who were clinically diagnosed with non-segmented leukopenia at Severance Hospital.
~B. Patients (36 patients) who experienced worsening symptoms within the last 3 months and 10 patients whose symptoms were stable within 3 months C. Patients with vitiligo lesion at least 3% of the skin"
16434315|NCT03741738||Segmental VT or Focal VT|A. The investigators evaluated patients who were diagnosed as segmental vitiligo clinically on Severance hospital and who were 19 years old or older.
16434316|NCT03741738||Normal control|A. Subjects aged 19 or older who do not have not only vitiligo but also other skin and systemic diseases
16434317|NCT03741725|Experimental|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
16434318|NCT03741725|Experimental|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
16434319|NCT03741725|No Intervention|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
16434320|NCT03741712|Experimental|SHR2554|Participants will receive SHR2554 orally
16434321|NCT03741712|Experimental|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
16434322|NCT03741699|Experimental|Arm 1 - experimental group|Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
16434323|NCT03741699|No Intervention|Arm 2 - control (no pre-treatment) group|The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
16434324|NCT03741686|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
16434325|NCT03741686|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
16434326|NCT03741673|Experimental|Group I (pre-operative SRS)|Patients undergo SRS within 15 days of randomization followed by surgery within 15 days. Patients may undergo additional SRS if disease returns after treatment.
16434327|NCT03741673|Active Comparator|Group II (post-operative SRS)|Patients undergo surgery within 15 days of randomization followed by standard of care SRS within 30 days. Patients may undergo additional SRS if disease returns after treatment.
16434328|NCT03741660|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
16434329|NCT03741660|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
16434330|NCT03741634|Experimental|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
16434331|NCT03741634|No Intervention|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
16434332|NCT03741621|Experimental|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
16434333|NCT03741621|Experimental|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
16434334|NCT03741621|Experimental|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
16434335|NCT03741608|Active Comparator|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
16434395|NCT03741192|Experimental|Treatment Group|SPEAC System
16434338|NCT03741582||Control - San Cristobal|"1000 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
16434339|NCT03741582||Intervention - Ciudad Bolviar|1000 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
16434340|NCT03741569|Other|parturients (gestational age ≥37 weeks).|
16434341|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
16434342|NCT03741530|Experimental|Glibenclamide group|Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
16434343|NCT03741530|Placebo Comparator|Control group|Giving standard management for ICH
16434344|NCT03741504|No Intervention|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
16434345|NCT03741504|Experimental|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
16434346|NCT03741491||Birkebeiner with AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) with AF.
16434347|NCT03741491||Birkebeiner without AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) without AF
16434348|NCT03741491||Control with AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier with AF
16434349|NCT03741491||Control without AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier without AF
16434350|NCT03741478|Experimental|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.
~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).
~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.
~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.
~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
16434351|NCT03741478|Experimental|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).
~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
16434352|NCT03741465|Active Comparator|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
16434353|NCT03741465|Experimental|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
16434354|NCT03741452|Experimental|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
16434355|NCT03741452|No Intervention|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
16434356|NCT03741439|Experimental|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
16434357|NCT03741439|Sham Comparator|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
16434358|NCT03741426|Experimental|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
16434359|NCT03741426|Experimental|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
16434360|NCT03741426|Active Comparator|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
16434361|NCT03741426|Experimental|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
16434362|NCT03741426|Active Comparator|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
16434396|NCT03741192|No Intervention|Standard of Care|
16434363|NCT03741413|Experimental|Gain-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to save their lives. Thank you for your support. were send to donors in this group."
16434364|NCT03741413|Experimental|Loss-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to prevent them from death. Thank you for your support. were send to donors in this group."
16434365|NCT03741413|Experimental|Control SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can donate blood again. Thank you for your support. were send to donors in this group."
16434366|NCT03741413|No Intervention|Control group|Donors in this group were not received SMS reminders.
16434367|NCT03741400|Experimental|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
16434368|NCT03741400|No Intervention|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
16434369|NCT03741387|Experimental|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
16434370|NCT03741387|Experimental|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
16434371|NCT03741374|Experimental|Minimally-invasive non-surgical therapy|Intrabony defects treated with Minimally-invasive non-surgical therapy (MINST)
16434372|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
16434373|NCT03741348|Active Comparator|ES|Erector Spinae Plane Block
16434374|NCT03741348|Placebo Comparator|control|the control group will not receive block
16434375|NCT03741335|Experimental|Strength Training|Participants wear a weighted vest while performing exercises using functional movement patterns used in everyday activities (chair rises, 90° squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step ups). Participants attend supervised, group-based moderate-intensity strength training program remotely 3 times per week for 60 minutes per session.
16434376|NCT03741335|Active Comparator|Stretching Control|Participants attend a supervised flexibility program where they will perform a series of whole body stretching exercises with a focus on developing and maintaining a healthy back. Participants attend a supervised, group-based supervised flexibility program remotely 3 times per week for 60 minutes per session.
16434377|NCT03741335|Experimental|Tai Ji Quan Training|An integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements. Participants attend a supervised, group-based tai ji quan program remotely where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
16434378|NCT03741322||Infants ages 3-24 months with respiratory infections|
16434379|NCT03741309|Active Comparator|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
16434380|NCT03741309|Sham Comparator|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
16434381|NCT03741309|Placebo Comparator|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
16434382|NCT03741296|Active Comparator|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
16434383|NCT03741296|Active Comparator|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).
~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.
~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
16434384|NCT03741283|Experimental|Optimisation of nutrition and medication|"N=approx.
~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
16434385|NCT03741283|No Intervention|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
16434386|NCT03741270|Experimental|Vaccine|
16434387|NCT03741257|Active Comparator|Group A|Received Hypertonic saline 3% as resuscitation fluid.
16434388|NCT03741257|Active Comparator|Group B|Received Hypertonic saline 1.8% as resuscitation
16434389|NCT03741244|Experimental|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).
~After 6 cycles,apatinib single drug maintained until progress."
16434390|NCT03741244|Active Comparator|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
16434391|NCT03741218|Experimental|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
16434392|NCT03741218|Experimental|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
16434393|NCT03741205|Experimental|Treatment Group|SPEAC System
16434394|NCT03741205|No Intervention|Standard of Care|Standard of Care
16434399|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
16434400|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
16434401|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
16434402|NCT03741140|Other|medial frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
16434403|NCT03741140|Other|lateral frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
16434404|NCT03741140|Other|Healthy participants|20 healthy participants (up to 10 healthy participants can be replaced) will be included in this arm, and will undergo motivation phenotyping.
16434405|NCT03741127|Other|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
16434406|NCT03741114|Active Comparator|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
16434407|NCT03741114|Active Comparator|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
16434408|NCT03741101|Experimental|single arm study|children treated with trametinib
16434409|NCT03741088|Experimental|VORTX Rx treatment|Focused ultrasound ablation of liver tumors.
16434410|NCT03741075|Active Comparator|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
16434411|NCT03741075|Experimental|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
16434412|NCT03741062|Experimental|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
16434413|NCT03741062|Sham Comparator|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
16434414|NCT03741049||Consultants|
16434415|NCT03741049||Trainee anaesthetists|
16434416|NCT03741049||Paramedics|
16434417|NCT03741049||Students|
16434418|NCT03741036|Active Comparator|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
16434419|NCT03741036|Active Comparator|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was > 3 mm.
16434420|NCT03741036|Active Comparator|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
16434421|NCT03741023|Other|Trauma Patients|"During Hospitalization:
~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.
~Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury."
16434422|NCT03741023|Other|Invasive Elective Surgery Patients|"During Hospitalization:
~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume).
~Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery."
16434423|NCT03741023|Other|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
16434424|NCT03740997|Experimental|Patients with body weight ≥20 to ≤28 kg|In children weighing ≥20 to ≤28 kg, 0.1 or 0.2 mL of OPTISON per injection will be given in ascending order. The cumulative dose will not exceed 1.0 mL.
16434425|NCT03740997|Experimental|Patients with body weight >28 to ≤40 kg|If children weigh >28-≤40 kg, 0.2 or 0.3 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.5 mL.
16434426|NCT03740997|Experimental|Patients with body weight >40 kg|For children whose weight is >40 kg, 0.2 or 0.4 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.8 mL.
16434469|NCT03740711|Experimental|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
16434578|NCT03740022|Active Comparator|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
16434427|NCT03740984|Experimental|Hypnosis / Hypnotherapy|Hypnosis intervention has been created by a certified hypnosis therapist (Prof. Reinhard) has been audio-recorded. The hypnosis intervention is based on the patient's happy place as well as many other interventions which all focus on support and wellbeing (total recording time ca. 4 ½ hours). All patients are advice to start with the beginning, however during the course of chemotherapy they are allowed to skip mp3 files, if they prefer to listen to a new intervention.
16434428|NCT03740984|Experimental|Music therapy|"For the music therapy the following music recordings have been used. All patients were allowed to skip tracks if they did not like to listen to that particular track.
~Purple Waves - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Black Garden View - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Sunset Destination - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Crystal Tree - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Best nature sounds / Ocean Volume 2 - Best Relaxation Music - Deep Sleep Top 10 Serse: Aria Ombra mai Fu - Andreas Scholl, Akademie für Alte music Berlin - Händel Johann Sebastian Bach: Jesus Bleibet Meine Freude (Studio) - Eduard Stan - Piano Recital Mozart: Concerto pour violon no 4 en re majeur, KV (Köchel listing) 218 - Christian Ferras; Pietro Argento; Orchestra Scarlatti di Nap - La fete a Stradivarius
~... etc."
16434429|NCT03740984|Placebo Comparator|Standard therapy|In this standard therapy the patient listens to a short explanation that they were randomized into the control arm and that they are allowed to listen to silence (tracks with no music or intervention).
16434430|NCT03740971|Experimental|Guideline-based therapy+RIC|RIC is given twice a day with 200mmHg pressure.
16434431|NCT03740971|Active Comparator|Guideline-based therapy|
16434432|NCT03740958|Experimental|Argatroban combined with rt-PA|Drug: Argatroban combined with rt-PA Argatroban as a 100 ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
16434433|NCT03740958|Active Comparator|rt-PA|Drug: rt-PA Intravenous throbolysis with 0.9mg/kg rtPA.
16434434|NCT03740945|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
16434435|NCT03740945|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
16434436|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
16434437|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
16434438|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
16434439|NCT03740919|Experimental|LY900014|LY900014 administered subcutaneously (SC).
16434440|NCT03740919|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) administered SC.
16434441|NCT03740919|Experimental|LY900014 Open Label|LY900014 administered SC.
16434442|NCT03740893|No Intervention|Cohort A (standard care reference cohort)|
16434443|NCT03740893|Experimental|Cohort B (AZD6738 monotherapy)|
16434444|NCT03740893|Experimental|Cohort C (olaparib monotherapy)|
16434445|NCT03740893|Experimental|Cohort D (durvalumab monotherapy)|
16434446|NCT03740880|Active Comparator|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
16434447|NCT03740880|Experimental|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
16434448|NCT03740867|Experimental|Group1|"Those with poor cognition (MOCA score<23)
~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
16434449|NCT03740867|Experimental|Group2|"Those with good cognition (MOCA score≥23)
~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
16434450|NCT03740854|Active Comparator|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
16434451|NCT03740854|Active Comparator|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
16434452|NCT03740841|Other|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
16434453|NCT03740841|No Intervention|Without LUNII|Usual pre-operative visit.
16434454|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
16434455|NCT03740815|Experimental|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
16434456|NCT03740789||HBeAg positive|HBeAg positive：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
16434457|NCT03740789||HBeAg negative|HBeAg negative：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
16434458|NCT03740763|Active Comparator|Spinal Cord Stimulation (SCS)|"Spinal Cord Stimulation (SCS)
~Pharmacological analgetic treatment and treatment with SCS for 3 months
~Add-on physiotherapy for 6 months to SCS and pharmacological analgetic treatment
~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
16434459|NCT03740763|Active Comparator|Physiotherapy|"Physiotherapy
~Pharmacological analgetic treatment for 3 months
~Physiotherapy for 3 months and pharmacological analgetic treatment
~Add-on SCS in combination with physiotherapy and pharmacological analgetic treatment for 3 months
~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
16434460|NCT03740750|Placebo Comparator|control|sham heat and sham TENS
16434461|NCT03740750|Experimental|heat only|heat applied to the back for 4 hours with sham TENS
16434462|NCT03740750|Experimental|Tens only|Tens applied for 4 hours with sham heat
16434463|NCT03740750|Experimental|Heat and Tens continuous|Heat and Tens applied together for 4 hours
16434464|NCT03740750|Experimental|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
16434465|NCT03740750|Experimental|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
16434470|NCT03740711|Active Comparator|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
16434471|NCT03740698|No Intervention|SAP, open-loop|Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)
16434472|NCT03740698|Experimental|BiAP, fixed bolus calculator|Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator
16434473|NCT03740698|Experimental|BiAP, ABC4D|Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)
16434474|NCT03740685||Patients with acute pancreatitis|All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
16434475|NCT03740659|Experimental|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).
~Limbal paracentesis will be performed prior to cataract surgery."
16434476|NCT03740659|Active Comparator|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).
~Limbal paracentesis will be performed prior to cataract surgery."
16434477|NCT03740659|Active Comparator|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).
~Limbal paracentesis will be performed prior to cataract surgery."
16434478|NCT03740633|Experimental|Study group|Patients in the study group accept functional training and regular care.
16434479|NCT03740633|Active Comparator|Control group|Patients in the control group only accept regular care.
16434480|NCT03740620|Active Comparator|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
16434481|NCT03740620|Active Comparator|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
16434482|NCT03740607|Experimental|Virtual reality during PIV placement|Randomized consented adult subjects will participate in a six-minute healthcare virtual reality software program via Samsung Gear virtual reality headsets while receiving 18 or 20-gauge peripheral intravenous catheter placement in peri-operative suite in preparation for surgery. They will be asked to rate their pain and discomfort afterwards using a graphic rating scale. They will be asked several questions about satisfaction, in order to elicit clinical significance of this intervention. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
16434483|NCT03740607|Placebo Comparator|Standard PIV placement|Adult control arm subjects will receive 18 or 20-gauge peripheral intravenous catheter placement according to current standard protocol, without virtual reality distraction .They will be asked to rate pain and discomfort afterwards using a graphic rating scale. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
16434484|NCT03740594|Active Comparator|KMC 60 min group|
16434485|NCT03740594|Active Comparator|KMC 120 min group|
16434486|NCT03740594|Active Comparator|control group|
16434487|NCT03740581|Active Comparator|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin >= 3 times per day
16434488|NCT03740581|No Intervention|Conventional|Old anti-diabetic drug regimen with or without Insulin (<3 times per day) to be continued as before
16434489|NCT03740568|Other|Normal Progesterone group|Progesterone level >10.64 ng/mL on day 4 of progesterone supplementation
16434490|NCT03740568|Experimental|Low Progesterone group|Progesterone level <10.64 ng/mL on day 4 of progesterone supplementation
16434491|NCT03740555|Experimental|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose,
16434492|NCT03740555|Placebo Comparator|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose
16434493|NCT03740555|Experimental|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route
16434494|NCT03740555|Placebo Comparator|Placebo, multiple ascending doses|Placebo, multiple ascending doses, Intravenous route,
16434495|NCT03740542|Active Comparator|Esophagectomy with Pyloroplasty|Esophagectomy with Pyloroplasty
16434496|NCT03740542|Experimental|Esophagectomy without Pyloroplasty|Esophagectomy without Pyloroplasty
16434497|NCT03740529|Experimental|Phase I Dose Escalation (LOXO-305) Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of LOXO-305 to be evaluated
16434498|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
16434499|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
16434500|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
16434501|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
16434502|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
16434503|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
16434504|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 7|(Not otherwise specified) Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late Phase studies of LOXO-305 would remain eligible to enroll in this cohort.
16434505|NCT03740529|Experimental|Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax
16434506|NCT03740529|Experimental|Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax and Rituximab
16434507|NCT03740529|Experimental|Phase 1 Dose Expansion (LOXO-305 Monotherapy)|Patients to receive the recommended Phase 2 dose of LOXO-305.
16434636|NCT03739710|Experimental|Part 1: Participants receiving GSK3359609 and Dostarlimab plus Cobolimab|
16434508|NCT03740490|Experimental|Smart-T + NRT|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT).
16434509|NCT03740490|Active Comparator|NCI QuitGuide + NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT).
16434510|NCT03740477|Experimental|Intrevention|Eligible participants will receive a 30-second smartphone-based ECG
16434511|NCT03740464|Experimental|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
16434512|NCT03740464|Active Comparator|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
16434513|NCT03740451|Experimental|Experimental group 1|Active mobilization of soft tissues
16434514|NCT03740451|Experimental|Experimental group 2|Passive mobilization
16434515|NCT03740451|No Intervention|Control group|No intervention
16434516|NCT03740425||Transfusion|Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
16434517|NCT03740425||No Transfusion|Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
16434518|NCT03740412|Experimental|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
16434519|NCT03740412|No Intervention|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
16434520|NCT03740399|Active Comparator|Group sitting|we are performing spinal anesthesia in sitting position pregnant patients
16434521|NCT03740399|Active Comparator|Group lateral decubitus position|we are performing spinal anesthesia in lateral decubitus position pregnant patients
16434522|NCT03740399|Active Comparator|Group Modified 45-degree head-up tilt|we are performing spinal anesthesia in Modified 45-degree head-up tilt position pregnant patients
16434523|NCT03740386|Experimental|lidocaine|lidocaine 2% 1:80000
16434524|NCT03740386|Experimental|articaine|articaine 4% 1:200000
16434525|NCT03740386|Experimental|bupivacaine|bupivacaine 0,5% 1:200000
16434526|NCT03740373|Experimental|Treatment Sequence 1|Subjects will receive BGF MDI with 10 s breath hold during Treatment Period 1 and BGF MDI with 3 s breath hold during Treatment Period 2
16434527|NCT03740373|Experimental|Treatment Sequence 2|Subjects will receive BGF MDI with 3 s breath hold during Treatment Period 1 and BGF MDI with 10 s breath hold during Treatment Period 2
16434528|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
16434529|NCT03740334|Experimental|Ribociclib (RIBO) + Dexamethasone (DEX)|"Ribociclib administered daily for 21 consecutive days
~Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
16434530|NCT03740334|Experimental|RIBO + Everolimus (EVE) + DEX|"Ribociclib administered daily for 21 consecutive days
~Dexamethasone administered intravenously on days 1-5 and again on days 11-15
~Everolimus administered daily for 21 consecutive days"
16434531|NCT03740334|Experimental|RIBO + EVE+ DEX (dose expansion)|"Ribociclib administered daily for 21 consecutive days. Dosing at RDE
~Dexamethasone administered intravenously on days 1-5 and again on days 11-15
~Everolimus administered daily for 21 consecutive days. Dosing at RDE"
16434532|NCT03740321|Experimental|Embospheres 500-700 microns|Intervention.Embolization with 500-700 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
16434533|NCT03740321|Experimental|Embospheres 700-900 microns|Intervention.Embolization with 700-900 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
16434534|NCT03740308|Active Comparator|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
16434535|NCT03740308|Experimental|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
16434536|NCT03740295|Placebo Comparator|Control Multiple Sclerosis|
16434537|NCT03740295|Experimental|Intervention Multiple Sclerosis|
16434538|NCT03740282|Experimental|Lapiplasty|All study participants receiving Lapiplasty procedure
16434539|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
16434540|NCT03740256|Experimental|Treatment Phase|"Seven dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.
~Dose Level 1 CAdVEC = 5.00E+9 HER2 specific CAR-T cells = 0
~Dose Level 2 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 0
~Dose Level 3 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 1.00E+06
~Dose Level 4 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+06
~Dose Level 5 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+07
~Dose Level 6 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+07
~Dose Level 7 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+08"
16434541|NCT03740243|Active Comparator|buprenorphine|"Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24
~Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
16434542|NCT03740243|Experimental|buprenorphine/naloxone|"Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24
~Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
16434543|NCT03740230||Hepatitis C|Participants with Hepatitis C Genotypes 1 to 6 receiving Maviret (glecaprevir/pibrentasvir) for 8, 12, or 16 weeks.
16434544|NCT03740217|Other|Treatment A|Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.
16434545|NCT03740217|Other|Treatment B:|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.
16434546|NCT03740217|Other|Treatment C|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.
16434547|NCT03740204|Experimental|17-β estradiol with cyclic progesterone|
16434548|NCT03740204|Placebo Comparator|Placebo|
16434549|NCT03740191|Other|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:
~'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire
~kV x-ray images
~Conebeam CT"
16434550|NCT03740178|Experimental|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
16434551|NCT03740178|Placebo Comparator|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
16434552|NCT03740165|Experimental|Pembrolizumab + Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
16434553|NCT03740165|Experimental|Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
16434554|NCT03740165|Active Comparator|Placebo for Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
16434555|NCT03740152|Experimental|Transcranial Light Therapy|All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
16434556|NCT03740139|Experimental|Intervention|"The Police-Mental Health Linkage System
~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
16434557|NCT03740139|No Intervention|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
16434558|NCT03740126|Experimental|Arm A, PET/CT|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) replacing computed tomography (CT) at months 6, 12, 18 and 24, otherwise as B with CT scan months 9, 15 and 21. Quality of life assessment and liquid biopsy every 3 months for later analysis.
16434559|NCT03740126|No Intervention|Control arm B|CT-scan and clinical evaluation every 3 months. Quality of life assessment and liquid biopsy at every 3 months for later analysis.
16434560|NCT03740113|Experimental|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
16434561|NCT03740113|No Intervention|Control|Control arm receives no intervention
16434562|NCT03740100|Other|Open single arm|Bimiralisib capsules orally
16434563|NCT03740087|Experimental|Omnivorous diet|This group was assigned a meal containing beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice.
16434564|NCT03740087|Active Comparator|Vegan diet|This group was assigned a control meal consisted of salad (lettuce, tomato, lentils) and a cup of rice.
16434565|NCT03740074|Experimental|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
16434566|NCT03740061||Antwerp|
16434567|NCT03740061||Barcelona|
16434568|NCT03740061||Istanbul|
16434569|NCT03740061||Oldenburg|
16434570|NCT03740061||Krakow|
16434571|NCT03740061||Bialystok|
16434572|NCT03740061||Rome|
16434573|NCT03740061||Madrid|
16434574|NCT03740061||Leuven|
16434575|NCT03740048|Experimental|Hemodialysis and Pharmacologic Therapy|Hemodialysis regimen at the initiation of dialysis treatment: Twice-weekly hemodialysis plus adjunctive pharmacologic therapy (loop diuretic, potassium-binding agent, and sodium bicarbonate) for six consecutive weeks, continued by thrice-weekly hemodialysis (intervention group)
16434576|NCT03740048|Active Comparator|Conventional Hemodialysis Regimen|Hemodialysis regimen at the initiation of dialysis treatment: thrice-weekly hemodialysis
16434577|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
16434637|NCT03739710|Active Comparator|Part 2: Participants receiving Docetaxel|
16434579|NCT03740022|Experimental|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
16434580|NCT03740009|Experimental|Perimenopausal women, depressed|Participants will take Bazedoxifene/Conjugated Estrogen orally for 3 weeks
16434581|NCT03739996|Experimental|CAB LA + VRC07-523LS|"Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.
~Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.
~VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.
~Step 3: SOC oral ART regimen for approximately 48 weeks."
16434583|NCT03739970|Experimental|Investigational Group- Silk Peptide|"Ingredient: Silk Peptide
~Type: Yellow granule stick
~Weight: Silk Peptide 9g/day
~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)
~Duration of use: 8 weeks"
16434584|NCT03739970|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose
~Type: Yellow granule stick
~Weight: Silk Peptide 0g/day
~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)
~Duration of use: 8 weeks"
16434585|NCT03739957|Experimental|BPCO Media Kit|The kit is composed of a Bluetooth pulse oximeter and an APP for Android system downloadable from Google Play and installed on the Android smartphone of the patient from version 4.1 on.
16434586|NCT03739944|Active Comparator|Laparotomic radical hysterectomy|
16434587|NCT03739944|Active Comparator|Laparotomic radical trachelectomy|
16434588|NCT03739944|Active Comparator|Laparoscopic radical hysterectomy|
16434589|NCT03739944|Active Comparator|Laparoscopic radical trachelectomy|
16434592|NCT03739918||patients with adrenal masses|patients with adrenal mass managed by adrenalectomy
16434593|NCT03739905|Experimental|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
16434594|NCT03739892|Other|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
16434595|NCT03739879|Experimental|Inspiratory muscle training (IMT)|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
16434596|NCT03739866|Experimental|Part A: Lenacapavir 20 mg|Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
16434597|NCT03739866|Experimental|Part A: Lenacapavir 50 mg|Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434598|NCT03739866|Experimental|Part A: Lenacapavir 150 mg|Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434599|NCT03739866|Experimental|Part A: Lenacapavir 450 mg|Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434600|NCT03739866|Experimental|Part A: Lenacapavir 750 mg|Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434601|NCT03739866|Placebo Comparator|Part A: Placebo|Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434602|NCT03739866|Experimental|Part B: TAF 200 mg|Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434603|NCT03739866|Experimental|Part B: TAF 600 mg|Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
16434604|NCT03739853|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy[19-22]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
16434605|NCT03739853|Experimental|Combination csDMARD|Arm 2 - Combination DMARD arm. All participants will be prescribed methotrexate with an additional DMARD (either sulfasalazine or leflunomide) at baseline. Response will be assessed after 12 weeks of therapy using the Minimal Disease Activity (MDA) criteria. Participants who achieve the MDA criteria by week 12 on this combination therapy will continue . Participants who show a significant response by in week 12 (a reduction in tender and swollen joint counts of at least 20%) but do not yet meet the MDA criteria should continue on this therapy for an additional 12 weeks before review. Participants failing to show significant response (reduction in joint counts by less than 20%) by week 12 on this combination therapy or those failing to meet MDA criteria by week 24 will be eligible for rescue therapy
16434638|NCT03739710|Experimental|Part 2: Participants receiving GSK3359609 and Docetaxel combination|
16434606|NCT03739853|Experimental|Early TNF inhibition|Early biologic arm. All participants will be prescribed methotrexate (given weekly) with a TNF inhibitor (adalimumab given every two weeks) at baseline. Treatment with TNF inhibitor will be continued until week 24 at which time the TNF inhibitor will be tapered to week 32. The TNF inhibitor will be stopped completely after week 32 and participants will continue on methotrexate. In case of flare of disease, participants will be eligible for rescue therapy
16434611|NCT03739827||1/Cohort 1|Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)
16434612|NCT03739827||2/Cohort 2|Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor
16434613|NCT03739827||3/Cohort 3|Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor.
16434614|NCT03739827||4/ Cohort 4|Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3)
16434615|NCT03739814|Experimental|Cohort 1 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description
16434616|NCT03739814|Experimental|Cohort 2 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description.
16434617|NCT03739801|Experimental|Treatment (ramucirumab, liposomal irinotecan[MM-398])|Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16434618|NCT03739788|Experimental|BMS-986165|Oral and intravenous administration
16434620|NCT03739762|Experimental|i-STAND|i-STAND participants have a Baseline visit followed by their first Coaching visit. They are offered wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, a workbook and 10 phone-based coaching sessions focused on sitting less and standing more. At 3 months they will participate in a measurement visit. The program ends at 6 months where they wear an activPAL and participate in a measurement. Their coach will provide feedback on their sitting time from the activPAL after all activPAL wears (Baseline, 3, 6 and 12 month). They may also opt in to wear an activPAL at 6 weeks and receive feedback. They will be re-randomized at 6 months, where half will be assigned to intervention boosters (5 more phone coaching sessions / one 9-month optional activPAL wear) before the 12 month time point for a final activPAL wear and final measurement visit. Those not randomized to receive boosters will have no further contact with the study team until the 12 month time point.
16434621|NCT03739762|Active Comparator|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by their first phone-based Coaching visit. They are not offered any prompting devices or desks, and their coaching sessions focus on a variety of topics related to healthy living, but without a focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants are given a workbook. All content is from Kaiser Permanente Washington and is available to all members. Participants will select topics of interest and review them with their health coach. At 3 months, participants will participate in a measurement visit. The program ends at 6 months where participants will wear an activPAL and participate in a measurement visit. After that, they will not have contact with the study team until 12 months when they will again wear an activPAL and participate in their final measurement visit.
16434622|NCT03739749|Active Comparator|Fascia lata autograft|Arthroscopic superior capsular reconstruction using a fascia lata autograft
16434623|NCT03739749|Active Comparator|Fascia lata allograft|Arthroscopic superior capsular reconstruction using a fascia lata allograft
16434624|NCT03739749|Active Comparator|Achilles tendon allograft|Arthroscopic superior capsular reconstruction using an achilles tendon allograft
16434625|NCT03739749|Active Comparator|Bovine pericardium allograft|Arthroscopic superior capsular reconstruction using a bovine pericardium allograft
16434626|NCT03739749|Active Comparator|Swine dermal xenograft|Arthroscopic superior capsular reconstruction using a swine dermal xenograft
16434627|NCT03739749|Active Comparator|Collagen allograft|Arthroscopic superior capsular reconstruction using a collagen allograft
16434628|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
16434629|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
16434630|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
16434631|NCT03739723|No Intervention|Usual Care Arm|Programs will continue to conduct normal quality improvement activities.
16434632|NCT03739723|Experimental|Intervention Arm|The intent of the intervention arm is to provide programs with resources to inform and improve surgical training culture.
16434633|NCT03739710|Experimental|Part 1: Participants receiving GSK3359609 (feladilimab) and Ipilimumab high dose|
16434634|NCT03739710|Experimental|Part 1: Participants receiving GSK3359609 and Ipilimumab low dose|
16434635|NCT03739710|Experimental|Part 1: Participants receiving GSK3359609 and Niraparib|
16434642|NCT03739697|Active Comparator|spontaneous breathing|spontaneous breathing after adminitration of anesthetics
16434643|NCT03739697|No Intervention|mechanical ventilation|mechanical ventilation after adminitration of anesthetics and neuromuscula blockade
16434644|NCT03739684|Experimental|18F-DCFPyL Injection|9 mCi (333 MBq) IV injection of 18F-DCFPyL
16434645|NCT03739671|Placebo Comparator|Non-vitamin D supplementation|Group not receiving vitamin D supplementation
16434646|NCT03739671|Experimental|Vitamin D supplementation|Group receiving vitamin D supplementation
16434647|NCT03739658|Experimental|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
16434648|NCT03739658|Experimental|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
16434649|NCT03739658|No Intervention|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
16434650|NCT03739645|Experimental|1 group. patients with intracranial electrodes for epilepsy.|Exploratory study with 1 intervention.which is painful (laser) stimulation conditioned fear with patient as his/her own control. EEG activity will be recorded from the brain during this behavioral state, an opportunity afforded by implantation of electrodes in the brain for treatment of epilepsy. Electrical activation of parts of the brain will be measured by event related spectral perturbations (ERSP).
16434651|NCT03739632|Experimental|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
16434652|NCT03739632|Experimental|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
16434653|NCT03739632|Experimental|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
16434654|NCT03739632|Placebo Comparator|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
16434655|NCT03739619|Experimental|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
16434656|NCT03739606|Experimental|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16434657|NCT03739593|Experimental|AR-1105-CF1|Single dose of AR-1105-CF1 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
16434658|NCT03739593|Experimental|AR-1105-CF2|Single dose of AR-1105-CF2 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
16434659|NCT03739580|Experimental|drug-coating balloon|drug-coating balloon (Orchid) intervention
16434660|NCT03739580|Active Comparator|stent deployment|metal bare stent intervention
16434661|NCT03739554|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15 after the venetoclax ramp-up schedule is completed. Venetoclax will be taken daily at a dose that is deemed safe and tolerable after the ramp-up schedule. One cycle will be 28 days or 4 weeks.
16434662|NCT03739541|Experimental|[14C]-Benznidazole|A single dose of 100 mg [14C]-BNZ, orally administered on Day 1 following an overnight fast.
16434663|NCT03739528|Experimental|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
16434664|NCT03739528|Active Comparator|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
16434665|NCT03739515|Experimental|HSCP team|Patients in this arm will receive comprehensive assessment and/or pre-discharge services by an ED-based HSCP team
16434666|NCT03739515|Active Comparator|Routine care|Patients in this arm will receive routine ED care
16434667|NCT03739502|Experimental|HBO arm|
16434668|NCT03739502|No Intervention|non-HBO arm|
16434669|NCT03739489|Active Comparator|rTMS-PSI|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the posterior superior insula right.
16434670|NCT03739489|Active Comparator|rTMS-M1|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the right primary motor cortex.
16434671|NCT03739489|Active Comparator|rTMS-F3|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the left pre frontal dorsolateral cortex.
16434672|NCT03739476|Experimental|Interventional|Quetiapine 25 miligrames 1 hour after surgery and each 12 hours for 3 days
16434673|NCT03739476|Placebo Comparator|control|Placebo 1 hour after surgery and each 12 hours for 3 days
16434674|NCT03739463|Experimental|MAG-DHA|1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks
16434675|NCT03739463|Placebo Comparator|Placebo|1500 MG of oleic acid per day until childbirth or for up to 2 weeks
16434676|NCT03739450|Experimental|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
16434677|NCT03739450|Active Comparator|Education|Participants in this arm will only receive the TBI-specific education intervention.
16434678|NCT03739437|Experimental|Mobile Contingency Management|
16434679|NCT03739437|Active Comparator|Standard Care|
16434680|NCT03739424|Experimental|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
16434681|NCT03739424|Active Comparator|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
16434682|NCT03739424|Placebo Comparator|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
16434683|NCT03739411|Experimental|Cohort I (hyperpolarized C13, MRI)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
16434684|NCT03739411|Experimental|Cohort II (hyperpolarized C13, MRI, radiation, temozolomide)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before standard treatment with radiation therapy and temozolomide and 4 weeks after completion of radiation therapy.
16434685|NCT03739398|Experimental|LUTRONIC GENUS laser with LASEMD laser|
16434686|NCT03739398|Active Comparator|LUTRONIC GENUS laser without LASEMD laser|
16434687|NCT03739385|Experimental|Intergenerational Group|Pre-school children and residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
16434688|NCT03739385|Active Comparator|Peer Group Children|Pre-school children will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
16434689|NCT03739385|Active Comparator|Peer Group Seniors|Residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
16434690|NCT03739385|No Intervention|Control Group Children|Pre-School children will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
16434691|NCT03739385|No Intervention|Control Group Seniors|Residential seniors will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
16434692|NCT03739372|Experimental|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
16434693|NCT03739372|Experimental|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
16434694|NCT03739359|Active Comparator|Gas flow 50 L/min|In this group, nasal cannula gas flow will be set at 50 L/min.
16434695|NCT03739359|Experimental|GF:IF=1|In this group, nasal cannula gas flow will be set at each individual patient's own inspiratory flow (GF:IF=1)
16434696|NCT03739359|Experimental|GF:IF=0.5|In this group, nasal cannula gas flow will be set at 50% of each individual patient's own inspiratory flow (GF:IF=0.5)
16434697|NCT03739346|Experimental|Control|Tell, show, do technique
16434698|NCT03739346|Experimental|Intervention|Hypnosis.
16434699|NCT03739333|Experimental|patients with glioblastoma|implementation of 11C-Methionine PET-MRI
16434700|NCT03739294|Experimental|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
16434701|NCT03739294|Experimental|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
16434702|NCT03739294|Experimental|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
16434703|NCT03739294|Experimental|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
16434704|NCT03739294|Experimental|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
16434705|NCT03739294|Experimental|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
16434706|NCT03739281|Other|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
16434707|NCT03739268|Active Comparator|sevelamer|Patients with type 2 diabetes treated with sevelamer
16434708|NCT03739268|Placebo Comparator|placebo|Patients with type 2 diabetes treated with placebo
16434709|NCT03739255|Experimental|Cacicol20|One drop of Cacicol20 will be applied 4-6 hours after the surgery, in one of the randomly chosen eye, and thereafter one drop daily until the reepithelialization is completed.
16434710|NCT03739255|Placebo Comparator|Placebo|One drop of conservative free artificial tear (Oculac, Thea Laboratories) will be applied to one eye at the same time when Cacicol20 is instilled to the other eye.
16434711|NCT03739242|Experimental|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
16434712|NCT03739242|Placebo Comparator|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
16434713|NCT03739229|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
16434714|NCT03739229|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
16434715|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
16434716|NCT03739203|Experimental|Cariprazine 1.5 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
16434717|NCT03739203|Experimental|Cariprazine 3 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).
16434718|NCT03739203|Placebo Comparator|Placebo|During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
16434719|NCT03739190|Experimental|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
16434720|NCT03739190|Active Comparator|Reference condom A: Medium Thickness NRL Condom|
16434721|NCT03739190|Active Comparator|Reference condom B: Thick NRL Condom|
16434722|NCT03739151|Other|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
16434723|NCT03739138|Experimental|MK-4621/JetPEI™ Monotherapy (Arm 1)|Participants receive MK-4621/JetPEI™ once a week (Q1W) during each 21-day cycle for a maximum duration of 6 cycles.
16434724|NCT03739138|Experimental|MK-4621/JetPEI™ + Pembrolizumab (Arm 2)|Participants receive escalating doses of MK-4621/JetPEI™ Q1W during each 21-day cycle for a maximum duration of 6 cycles in combination with pembrolizumab at a fixed dose 200 mg every 3 weeks (Q3W) for a maximum duration of 6 cycles. Participants may continue on treatment with pembrolizumab after Cycle 6 for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621/JetPEI™ will be based on safety and tolerability.
16434725|NCT03739138|Experimental|Intrahepatic MK-4621/JetPEI™ + Pembrolizumab (Arm 3)|Participants receive MK-4621/JetPEI™ as monotherapy on Day 1 only of the first 21-day cycle (run-in phase). After the run-in phase, participants receive escalating doses of MK-4621/JetPEI™ Q3W in combination with pembrolizumab at a fixed dose 200 mg Q3W for a maximum duration of 5 cycles (Cycles 2-6). Participants may continue on treatment with pembrolizumab for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621/JetPEI™ will be based on safety and tolerability.
16434726|NCT03739125|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
16434727|NCT03739125|Placebo Comparator|Placebo|Placebo
16434728|NCT03739112|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
16434729|NCT03739112|Active Comparator|Quadrivalent Comparator Vaccine|Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine
16434732|NCT03739073|Experimental|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
16434733|NCT03739060|Active Comparator|Active TENS group|Conventional transcutaneous electric nerve stimulation
16434734|NCT03739060|Placebo Comparator|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
16434735|NCT03739047|Experimental|Desensitization with flipped spoon|Children in this study will receive behavioral feeding treatment. This arm will include desensitization.
16434736|NCT03739047|Placebo Comparator|flipped spoon|Children in this study will receive behavioral feeding treatment.
16434737|NCT03739034|Experimental|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
16434738|NCT03739021|Experimental|Group 1 (30 participants)|
16434739|NCT03739021|Experimental|Group 2 (30 participants)|
16434740|NCT03738982|Experimental|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
16434741|NCT03738969||Laparotomy group|Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.
16434742|NCT03738969||Laparoscopy group|Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.
16434743|NCT03738956|Experimental|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
16434744|NCT03738943|Experimental|ATP, Ach, SNP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.
~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Acetylcholine: 1, 4, 8, and 16 μg/dl forearm volume/min for 3 minutes each.
~Sodium Nitroprusside: 0.25, 0.5, 1, and 2 μg/dl forearm volume/min for 3 minutes each.
~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.
~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
16434768|NCT03738813|Active Comparator|Participants Usual Care (PUC)|The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.
16434769|NCT03738800|Experimental|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
16434770|NCT03738800|Experimental|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
16434745|NCT03738943|Experimental|ATP, ADP, AMP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.
~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Adenosine Diphosphate: 20, 40, 80, and 160 μg/dl forearm volume/min for 3 minutes each.
~Adenosine Monophosphate: 25, 50, 100, and 200 μg/dl forearm volume/min for 3 minutes each.
~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.
~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
16434746|NCT03738943|Experimental|ATP, UTP, Adenosine|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.
~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Uridine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Adenosine: 3.125, 6.25, 12.5, and 25 μg/dl forearm volume/min for 3 minutes each.
~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.
~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
16434747|NCT03738930|No Intervention|normal follow-up group|normal follow-up in ACS patients after PCI
16434748|NCT03738930|Experimental|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
16434749|NCT03738917|Active Comparator|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
16434750|NCT03738917|Active Comparator|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
16434751|NCT03738917|Active Comparator|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
16434752|NCT03738917|Placebo Comparator|Usual clinical practice|Usual care.
16434755|NCT03738891|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen.
16434756|NCT03738878|Active Comparator|valsartan then LCZ696|"After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.
~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
16434757|NCT03738878|Active Comparator|LCZ696 then valsartan|"After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.
~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
16434758|NCT03738865|Experimental|G-Pen followed by Novo Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit
16434759|NCT03738865|Active Comparator|Novo Glucagon followed by G-Pen|1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
16434760|NCT03738852|Experimental|Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months|Continuous Glucose Monitor for 3 months duration
16434761|NCT03738852|Experimental|Aim 1: Impact of hypoglycemia on brain connectivity Type 1|Healthy controls, T1 aware, and T1 unawares
16434762|NCT03738852|Experimental|Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1|Healthy controls, T1 aware, and T1 unawares
16434763|NCT03738839|Experimental|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
16434764|NCT03738839|Experimental|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
16434765|NCT03738839|Active Comparator|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
16434766|NCT03738826|Experimental|Intervention arm|Lupus clinic providers will use Surescripts refill information to assess adherence level and address adherence barriers. We will assess the feasibility and acceptability of the intervention.
16434767|NCT03738813|Experimental|Treatment Group|"The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.
~In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen."
16434771|NCT03738800|Placebo Comparator|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
16435124|NCT03736317|Experimental|real mPFC cTBS group|The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.
16434772|NCT03738787|Experimental|Pancreatic duct occlusion|Patients considered at high risk for pancreatic fistula or oncological relapse due to introperative evaluation submitted to pancreatic duct occlusion with Neoprene-based glue.
16434773|NCT03738787|Active Comparator|Pancreato-Jejunal anastomosi|Patients considered at low risk for pancreatic fistula submitted to pancreato-jejunal anastomosis.
16434774|NCT03738761|Experimental|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
16434775|NCT03738761|Experimental|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
16434776|NCT03738748|Experimental|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
16434777|NCT03738748|Active Comparator|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
16434778|NCT03738735|No Intervention|Control|Patients will receive standard of care lactated ringer's solution for the arthroscopic irrigation during surgery.
16434779|NCT03738735|Experimental|Intervention|Patients will receive hyperosmolar saline for the arthroscopic irrigation during surgery.
16434780|NCT03738722|Experimental|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
16434781|NCT03738709|Experimental|Occupational therapy group sessions|In the collective experimental group, the care includes 6 group sessions of one hour each, programmed over 2 weeks and progressive courses.
16434782|NCT03738709|Active Comparator|Individual Occupational therapy sessions|In the individual control group, care consists of 6 individual sessions of 45 minutes each, not programmed over 2 weeks and progressive courses.
16434783|NCT03738696|Experimental|Liposomal bupivacaine Interscalene Block|"Interscalene block:
~10cc (133mg) liposomal bupivacaine;PLUS
~10cc 0.25% bupivacaine"
16434784|NCT03738696|Active Comparator|Ropivacaine Interscalene Catheter|"20cc 0.25% bupivacaine interscalene block; PLUS
~Ropivacaine 0.25% interscalene catheter (6ml/hr for 48hrs)"
16434785|NCT03738670|Experimental|RFA|Single-arm prospective observational study
16434786|NCT03738657||Screening|Olfactory screening
16434787|NCT03738657||On Study|Taste testing
16434788|NCT03738631||Under 35 years|
16434789|NCT03738631||Over 44 years|
16434790|NCT03738618|Experimental|Follitropin delta|
16434791|NCT03738618|Placebo Comparator|Placebo|
16434792|NCT03738605|Experimental|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
16434793|NCT03738605|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
16434794|NCT03738592|Experimental|cochlear implant children|18 cochlear implant children wil include in this study
16434795|NCT03738592|Other|normal hearing children|18 normal hearing children wil include in this study
16434796|NCT03738579|Active Comparator|Control Group|After standard of care debridement and irrigation (using normal saline), Mepilex foam dressing will be used. Foam dressing will be used throughout the study, including for mid-week dressing changes.
16434797|NCT03738579|Active Comparator|Antibacterial Control|After standard of care debridement and irrigation (using normal saline), Mepilex AG foam dressing will be used. This dressing will be used throughout the study, including for mid-week dressing changes.
16434798|NCT03738579|Experimental|Next Science Group|Standard of care debridement will be performed as well as irrigation using TorrentX Wound Wash,then BlastX Wound gel will be applied to the wound before covering treatment site with Mepilex foam dressing (no AG component). BlastX will re-applied again mid-week during mid-week dressing change.
16434799|NCT03738566|Other|Endoscopic Dilation|Patients randomized to the observation group will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
16434800|NCT03738566|Active Comparator|Esophageal Self Dilation|Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.
16434801|NCT03738540|Experimental|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
16434802|NCT03738540|Active Comparator|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
16434803|NCT03738527|Experimental|TXA arm|
16434804|NCT03738527|Placebo Comparator|Placebo arm|
16434805|NCT03738514|Active Comparator|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
16434806|NCT03738514|Sham Comparator|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
16434807|NCT03738514|Placebo Comparator|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
16434808|NCT03738501|Experimental|Chest physiotherapy with SET|Chest physiotherapy will be provided by a single physiotherapist not involved in outcomes assessment. Airway clearance technique will be Slow Expiratory Technique (SET). SET is a slow modulation of airflow in order to remove bronchial secretions within infants lungs. Experimental group will also benefit for standard medical and non-pharmacological care (e.g Standard Treatment)
16434809|NCT03738501|Active Comparator|Standard treatment|Medical treatment, health education for parents, rhinopharyngeal clearance using isotonic saline solution, advices.
16434810|NCT03738488|Experimental|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
16434811|NCT03738488|Active Comparator|Images|Surgery planification with all the images available
16434812|NCT03738475|Experimental|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
16434813|NCT03738475|Placebo Comparator|Placebo|Normal saline administered intravenously on days 1 and 8.
16434814|NCT03738449|Experimental|Group 1|"Period 1: D484
~Period 2: CKD-387"
16434815|NCT03738449|Experimental|Group 2|"Period 1: CKD-387
~Period 2: D484"
16434816|NCT03738436|Active Comparator|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
16434817|NCT03738436|Experimental|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
16434818|NCT03738423|Experimental|Treatment 1|
16434819|NCT03738423|Experimental|Treatment 2|
16434820|NCT03738423|Experimental|Treatment 3|
16434821|NCT03738423|Experimental|Treatment 4|
16434822|NCT03738423|Experimental|Treatment 5|Matching placebo
16434823|NCT03738410|Active Comparator|Control Arm|The control arm will receive standard of care.
16434824|NCT03738410|Experimental|Mobile Health Messaging Arm|The Mobile Health Messaging Arm will receive standard of care, as well as the mobile health intervention. The mHealth intervention includes psycho-educational messaging as well.
16434825|NCT03738410|No Intervention|Focus Group Arm|The results of the focus groups will contribute to the wording and design of the intervention.
16434826|NCT03738397|Experimental|Participants administered with upadacitinib|Participants are administered with upadacitinib from baseline to week 24 and placebo pre-filled syringe at baseline visit (2 injections) followed by an injection every other week until week 22
16434827|NCT03738397|Experimental|Participants administered with dupilumab|Participants are administered with dupilumab (2 injections) at baseline followed by one every other week until week 22 and placebo tablets daily from baseline to week 24
16434828|NCT03738384|Experimental|TKR Patients|Any patient 3-6 weeks post-op from a TKR
16434829|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
16434830|NCT03738358|Experimental|Trehalose|
16434831|NCT03738358|Placebo Comparator|Placebo|
16434832|NCT03738345|Experimental|Oxygenation on hypoxemia patients|Adult patients with hypoxemia will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then patients will be placed on high flow nasal cannula (HFNC), HFNC flow will be titrated based on the hospital's policy or protocol and patient's comfort, patient's clinical effects on oxygenation will be monitored and recorded during the titration process.
16434833|NCT03738345|Experimental|Lung expansion on healthy volunteer|Adult healthy volunteers will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then they will be placed on HFNC, HFNC flow will be increased sequentially by research protocol and their comfort, subjects' lung expansion effects in different flow will be quantified by Electrical impedance tomography (EIT), a noninvasive assessment tool. Their comfort will also be assessed using a visual scale.
16434834|NCT03738332|Other|Low-level laser therapy|Single arm
16434835|NCT03738319||HGSOC group|This group includes patients of high grade serous ovarian cancer (HGSOC).
16434836|NCT03738319||Control group|This group includes patients of benign gynecologic diseases as control.
16434837|NCT03738306|Experimental|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
16434838|NCT03738306|Active Comparator|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
16434839|NCT03738254|Active Comparator|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
16434840|NCT03738254|Active Comparator|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
16434841|NCT03738254|Experimental|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
16434842|NCT03738241|Experimental|Arm 1|Participants will have prior administration of 2013 A/H7N9 IIV with MF59. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
16434843|NCT03738241|Experimental|Arm 2|Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
16434876|NCT03738033||use of the educational platform|Before the hand-on practice and assessements, the participants use the platform for learning.
16434877|NCT03738033||without use of the educational platform|Before the hand-on practice and assessements, the participants did not use the platform for learning.
16434844|NCT03738241|Experimental|Arm 3|Participants will have prior administration of 2013 A/H7N9 IIV 15 mcg or 45 mcg unadjuvanted. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
16434845|NCT03738241|Experimental|Arm 4|Participants will have prior administration of 2013 A/H7N9 IIV + MF59 or AS03 (1st) then 2013 A/H7N9 IIV 15 mcg (2nd). Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
16434846|NCT03738241|Experimental|Arm 5|Participants who are A/H7 IIV-Naïve. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
16434847|NCT03738228|Experimental|Arm A (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.
16434848|NCT03738228|Experimental|Arm B (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.
16434849|NCT03738215|Experimental|Cariprazine 1.5 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
16434850|NCT03738215|Experimental|Cariprazine 3 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).
16434851|NCT03738215|Placebo Comparator|Placebo|During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
16434852|NCT03738202|Experimental|Intervention|Multifaceted intervention package will be implemented at textile mills in the intervention arm.
16434853|NCT03738202|No Intervention|Control|No intervention will be provided to mills in the control arm.
16434854|NCT03738176|Experimental|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
16434855|NCT03738176|Active Comparator|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
16434856|NCT03738163|Other|Epaderm Cream|This is an open, non randomised single arm study.
16434857|NCT03738150|Experimental|Sotatercept|Each participant will receive standard of care (SOC) plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. Dose will escalate to 0.7 mg/kg SC at Cycle 2 through the remainder of the treatment period. Dosing will be every three weeks during the 24 weeks Treatment Period and every three weeks during the 18 month Extension Period.
16434858|NCT03738137|Experimental|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
16434859|NCT03738137|Experimental|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
16434860|NCT03738137|Experimental|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
16434861|NCT03738137|Experimental|Lidocaine|Only topical anesthesia was applied.
16434862|NCT03738124|Experimental|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
16434863|NCT03738111|Experimental|TG02 Citrate|TG02 citrate capsules given orally.
16434864|NCT03738098|Active Comparator|Traditional Genetic Counseling|Standard of care genetic counseling session
16434865|NCT03738098|Experimental|GUÍA|Standard of care genetic counseling session with Genomic Understanding, Information and Awareness (GUÍA).
16434866|NCT03738085||Previous abdominal surgery group|Previous abdominal surgery group underwent total laparoscopic hysterectomy
16434867|NCT03738085||No previous abdominal surgery group|No Previous abdominal surgery group underwent total laparoscopic hysterectomy
16434868|NCT03738085||Obese patients underwent TAH|BMI≥30 kg/m2
16434869|NCT03738085||Obese patients underwent TLH|BMI≥30 kg/m2
16434870|NCT03738072|Experimental|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
16434871|NCT03738059|Placebo Comparator|group I (placebo)|will receive intravenous normal saline (NS)
16434872|NCT03738059|Experimental|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
16434873|NCT03738059|Experimental|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
16434874|NCT03738059|Experimental|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
16434875|NCT03738046|Experimental|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
16434878|NCT03738020|Experimental|HA IDF|
16434882|NCT03737994|Experimental|ALK L1198F mutation (alone or combination with ALK inhibitor)|Patients with ALK L1198F mutation (alone or in combination with another ALK mutation) receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434883|NCT03737994|Experimental|C1156Y|Patients with Cy1156Y mutation receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434884|NCT03737994|Experimental|Compound mutation|Patients with a compound mutation receive lorlatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434885|NCT03737994|Experimental|F1174|Patients with F1174 receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434886|NCT03737994|Experimental|G1202 (including G1202del and G1202R)|Patients with G1202 (including G1202del and G1202R) receive either lorlatinib PO QD or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434887|NCT03737994|Experimental|I1171|Patients with I1171 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434888|NCT03737994|Experimental|L1196 (including L1196M)|Patients with L1196 (including L1196M) mutation receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, or ensartinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434889|NCT03737994|Experimental|MET amplification|Patients with MET amplification receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434890|NCT03737994|Experimental|No ALK-resistance mutations|Patients with no ALK-resistant mutations receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, ensartinib PO QD, or pemetrexed IV over 10 minutes on day 1 with or without either cisplatin IV or carboplatin IV on day 1. ALK inhibitor cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Pemetrexed-based treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance treatment of pemetrexed may continue until disease progression or unacceptable toxicity.
16434891|NCT03737994|Experimental|V1180|Patients with V1180 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16434894|NCT03737968|Experimental|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
16434895|NCT03737968|Active Comparator|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
16434896|NCT03737955|Experimental|Treatment (gemtuzumab ozogamicin)|Patients receive gemtuzumab ozogamicin IV on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Responders and non-responders, without significant adverse events during the first course, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.
16434897|NCT03737942||control group|"Motor nerve conduction studies:
~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
16434898|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:
~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
16434899|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:
~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
16434900|NCT03737929|Experimental|Hybrid ablation procedure|In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.
16435294|NCT03735121|Experimental|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
16434901|NCT03737929|Active Comparator|Percutaneous endocardial catheter ablation procedure|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).
16434902|NCT03737916|Experimental|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
16434903|NCT03737916|Placebo Comparator|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
~Drug: Normal Saline Normal saline is safe for perineural injection."
16434904|NCT03737890|Experimental|Inspiratory muscle Training|4 weeks of inspiratory muscle training
16434905|NCT03737890|Active Comparator|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
16434906|NCT03737877|Experimental|Diet modification|
16434907|NCT03737864|Active Comparator|Motivational Interview|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
16434908|NCT03737864|Experimental|Patient navigation and MI|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification plus patient navigation for 30 days, or until the patient is successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
16434909|NCT03737851|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
16434910|NCT03737851|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
16434911|NCT03737851|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
16434912|NCT03737825|Active Comparator|Program 1|Computerized gaming rehabilitation Program 1.
16434913|NCT03737825|Placebo Comparator|Program 2|Computerized gaming rehabilitation Program 2.
16434914|NCT03737812|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
16434915|NCT03737812|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
16434916|NCT03737812|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
16434917|NCT03737799||Group 1 Age 18-50 at diagnosis|Diagnosed with diabetes within the previous 1 year. Aged between 18 and 50 years at the time of diabetes diagnosis
16434918|NCT03737799||Group 2 Late Onset (insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated with insulin therapy
16434919|NCT03737799||Group 3 Late Onset (no insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated without insulin
16434920|NCT03737786|Active Comparator|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
16434921|NCT03737786|Active Comparator|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
16434922|NCT03737773|Active Comparator|group prisms|Patients that receive active prismatic lenses
16434923|NCT03737773|Placebo Comparator|group placebo lenses|Patients that receive non-active prismatic lenses
16434924|NCT03737760||Older Adults|Community-dwelling men and women age 70+ years
16434925|NCT03737760||Younger Adults|Healthy young adults, age 20-40 years for baseline assessments only
16434926|NCT03737734|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
16434927|NCT03737721|Experimental|Avelumab and Radical radiotherapy|Single-arm combining Avelumab with radical radiotherapy.
16434928|NCT03737708|Experimental|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
16434929|NCT03737708|Active Comparator|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
16434930|NCT03737695||Ancillary-Correlative (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
16434931|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
16434932|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
16434933|NCT03737669|Experimental|Mirasol-treated Fresh Whole Blood|Standard Fresh Whole Blood, treated with Mirasol Pathogen Reduction Technology
16434934|NCT03737669|Placebo Comparator|Standard Fresh Whole Blood|Standard-issue fresh whole blood
16434935|NCT03737656|Experimental|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
16434936|NCT03737656|Experimental|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
16434937|NCT03737656|Experimental|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
16434942|NCT03737630|Experimental|GExp|This group will perform the inspiratory muscle training with moderate load
16434943|NCT03737630|Active Comparator|GCon|This group will initiate inspiratory muscle training with low load
16434944|NCT03737617|Experimental|Active arm|Weekly subcutaneous immunoglobulin therapy (0.1g/Kg) Cuvitru 20% Injectable Solution for 1 Year
16434945|NCT03737617|No Intervention|Control|Standard Care arm without immunoglobulin replacement therapy
16434946|NCT03737604|Active Comparator|Ropivacaine Continuous Infusion Catheter|Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.
16434947|NCT03737604|Active Comparator|Single dose liposomal bupivicaine|Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.
16434948|NCT03737591||Healthy individuals|Healthy individuals
16434949|NCT03737591||Patients with Colorectal cancer|Stage I-IV colorectal cancer patients
16434950|NCT03737591||Patients with Colorectal Adenomas|Patients with Colorectal Adenomas
16434951|NCT03737578|Experimental|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.
~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
16434952|NCT03737578|Active Comparator|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.
~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
16434953|NCT03737565||Coronary Artery Disease|
16434954|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
16434955|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
16434956|NCT03737539||Stage II colorectal cancer|Patients diagnosed with stage II colorectal cancer
16434957|NCT03737539||Stage III colorectal cancer|Patients diagnosed with stage III colorectal cancer
16434958|NCT03737500|Active Comparator|Standard silicone-based breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)
16434959|NCT03737500|Experimental|B-Lite® light weight breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant
16434960|NCT03737474|Experimental|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
16434961|NCT03737461|Experimental|Allogenic BM-MSCs Injection|Injection of a dose of 20.106 allogenic BM-MSCs via imaging control into the disk affected by DDD where they are expected to exert their therapeutic effects.
16434962|NCT03737461|Sham Comparator|Sham Procedure|anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment
16434963|NCT03737448|Experimental|Group 1|"AD with serum creatinine ≥ 1 and < 2 mg/dL, OR
~ACLF 1 with
~liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
~liver failure and West Haven grade 1-2 hepatic encephalopathy, or
~coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
~coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR
~ACLF 2 with
~liver failure and coagulation failure, or
~liver failure and West Haven grade 3-4 hepatic encephalopathy."
16434964|NCT03737448|Experimental|Group 2|"ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR
~ACLF 2 with
~liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or
~coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL)."
16434965|NCT03737422|Active Comparator|hesperidin and flaxseed|
16434966|NCT03737422|Placebo Comparator|control|
16434967|NCT03737409|Experimental|Oxygen therapy with POC (AOT group)|Patients will receive ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
16434968|NCT03737409|Sham Comparator|Sham oxygen therapy with POC (air group)|Patients will receive sham ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
16434969|NCT03737396|Active Comparator|Electronic health screening|Self-administered electronic health screening on tablet
16434970|NCT03737396|No Intervention|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
16434971|NCT03737383|Experimental|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
16434972|NCT03737370|Experimental|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m^2 [level 1] and 50mg/m^2 [level 2]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).
~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
16435295|NCT03735121|Experimental|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
16434973|NCT03737370|Experimental|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
16434974|NCT03737357|Experimental|SLActive® implant|
16434975|NCT03737357|Active Comparator|SLA® implant|
16434976|NCT03737344|Active Comparator|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
16434977|NCT03737344|Placebo Comparator|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
16434978|NCT03737331|Experimental|Fractal visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be fractal (i.e., pink noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
16434979|NCT03737331|Active Comparator|Periodic visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be periodic (i.e., invariant). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
16434980|NCT03737331|Sham Comparator|Random visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be random (i.e., white noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
16434981|NCT03737331|No Intervention|Control|Natural walking.
16434982|NCT03737318|Experimental|Group 1|Traditional articulation treatment
16434983|NCT03737318|Experimental|Group 2|Biofeedback--visual-acoustic
16434984|NCT03737318|Experimental|Group 3|Biofeedback-ultrasound
16434985|NCT03737305|Active Comparator|Control Group|Control group of conventional therapy with manual distraction performed by the physiotherapist in the office (active comparator)
16434986|NCT03737305|Experimental|Distractor Test Group|Test group with manual distraction performed by the physiotherapist in the office and the condylar distraction performed by the patient with the condylar distraction device in an ambulatory basis.
16434987|NCT03737292|Experimental|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
16434988|NCT03737292|Active Comparator|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
16434989|NCT03737279|Experimental|Meditation|"Intervention Group:
~Routine care plus twice daily mindful meditation"
16434990|NCT03737279|Active Comparator|Routine care|"Control Group:
~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
16434991|NCT03737266|Experimental|Sonographically assisted breast surgery|Sonography assisted breast surgery
16434992|NCT03737266|Active Comparator|Conventional breast surgery|Conventional breast surgery
16434993|NCT03737253|Active Comparator|Follitropin alpha|Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
16434994|NCT03737253|Active Comparator|Menotropin|Menotropin (Menopur, Ferring GmbH, Kiel, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
16434995|NCT03737240|Experimental|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
16434996|NCT03737240|Active Comparator|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
16434997|NCT03737227|Other|Cinematographic recording|Cinematographic recordings of the asymptomatic participants during flexion and extension of the lumbar spine.Cinematographic recordings will be performed twice with an interval of two weeks.
16434998|NCT03737214|Experimental|Lucerastat|Dose will be based on subject's eGFR.
16434999|NCT03737201|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
16435000|NCT03737201|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
16435001|NCT03737201|Active Comparator|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
16435002|NCT03737175|Experimental|Carotid Artery Stenting group|Carotid Artery Stenting
16435003|NCT03737175|Active Comparator|Carotid Endarterectomy group|Carotid Endarterectomy
16435004|NCT03737162|Experimental|Covered stent group|Covered stent
16435005|NCT03737162|Active Comparator|Bare-metal stent group|Bare-metal stent
16435006|NCT03737149|Experimental|mymobility with Apple Watch|Post-operative mobile application-guided education and exercise paired with accurate and sensitive activity monitoring.
16435007|NCT03737149|No Intervention|Standard of Care Physical Therapy|Standard of care patient education and post-operative physical therapy, as determined by local site guidelines and care pathways.
16435008|NCT03737136|No Intervention|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
16435009|NCT03737136|Active Comparator|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
16435010|NCT03737123|Experimental|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
16435011|NCT03737110|Experimental|Rilonacept|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.
~RW period: eligible participants randomized to double-blinded administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.
~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
16435012|NCT03737110|Placebo Comparator|Placebo|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.
~RW period: eligible participants randomized to placebo SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.
~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
16435013|NCT03737097|Experimental|Online Spaced Education|The intervention cohort will participate in an online spaced education on fall prevention education developed for patients with multiple sclerosis.
16435014|NCT03737097|Active Comparator|Brochure Education|The control cohort will receive the fall prevention education in bolus through a Brochure developed by the National Multiple Sclerosis Society. The brochure was translated to portuguese and will be used in the study with authorization of the Society.
16435015|NCT03737084|Experimental|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
16435016|NCT03737084|No Intervention|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
16435017|NCT03737071|Experimental|Low Carbohydrate Diet|Low Carbohydrate Diet
16435018|NCT03737045|Other|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
16435019|NCT03737032|Experimental|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
16435020|NCT03737032|Experimental|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
16435021|NCT03737032|Experimental|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
16435022|NCT03737032|Experimental|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
16435023|NCT03737032|Experimental|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
16435024|NCT03737032|Experimental|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
16435025|NCT03737019|Experimental|ACT in County Council of Kalmar|Group education with ACT in six primary health care centers in County Council of Kalmar
16435026|NCT03737019|Placebo Comparator|Control health care centers of County Council of Jönköping|Five primary health care centers of County Council of Jönköping that do not get education.
16435027|NCT03737006||1-(HLHS) effected pregnancies|Consent,blood draw, nose swab, stool collection,questionnaire and review of medical records.
16435028|NCT03737006||2-Other Congenital Heart Defect (OCHD)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
16435029|NCT03737006||3-Healthy Controls (UC)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
16435030|NCT03736993|Other|Additional blood sampling|non-small cell lung cancer (NSCLC)
16435031|NCT03736980|Experimental|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
16435032|NCT03736980|Experimental|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
16435033|NCT03736980|Experimental|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
16435034|NCT03736980|Experimental|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
16435035|NCT03736967|Experimental|REGN3500|
16435036|NCT03736967|Experimental|Dupilumab|
16435039|NCT03736954|Experimental|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
16435040|NCT03736941|Experimental|Patients with venous leg|"After inclusion, the medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. Follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
~During the various visits, clinical data will be collected in the patient's medical file as well as the answers to the questionnaires."
16435041|NCT03736928|Placebo Comparator|Placebo|Intramuscular single treatment
16435042|NCT03736928|Experimental|AbobotulinumtoxinA dose level 1 or 2|Intramuscular single treatment
16435043|NCT03736928|Experimental|AbobotulinumtoxinA dose level 3|Intramuscular single treatment
16435044|NCT03736928|Experimental|AbobotulinumtoxinA dose level 4|Intramuscular single treatment
16435045|NCT03736915|Active Comparator|1 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
16435046|NCT03736915|Active Comparator|3 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
16435047|NCT03736915|Active Comparator|5 cc needle with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
16435048|NCT03736889|Experimental|Tislelizumab (BGB-A317) Injection|
16435049|NCT03736876|Experimental|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
16435050|NCT03736876|No Intervention|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
16435051|NCT03736863|Experimental|Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）
16435052|NCT03736850|Experimental|CS3006|
16435053|NCT03736837|Experimental|Anlotinib Plus Icotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
16435054|NCT03736811|Active Comparator|Absorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 [Vicryl] or polydioxanone [PDS II] sutures.
16435055|NCT03736811|Experimental|Nonabsorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester [Ethibond Excel] or polypropylene [Prolene] sutures.
16435056|NCT03736785|Experimental|LY3209590 Algorithm 1|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of <140 milligram per deciliter (mg/dL).
16435057|NCT03736785|Experimental|LY3209590 Algorithm 2|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of <120 mg/dL.
16435058|NCT03736785|Active Comparator|Insulin Degludec|Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C <7%.
16435059|NCT03736772|Experimental|LY3090106|LY3090106 administered subcutaneously (SC)
16435060|NCT03736772|Placebo Comparator|Placebo|Placebo administered SC
16435061|NCT03736759|Experimental|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
16435062|NCT03736759|Active Comparator|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
16435063|NCT03736759|No Intervention|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
16435064|NCT03736746|Experimental|Motivational Interviewing|"Will entail two-to-four Motivational Interviewing sessions per participant
~Will include a battery of questionnaires
~Investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs).
~The investigator will elicit questions and goals that participants will be encouraged to discuss with their palliative care providers"
16435065|NCT03736733|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
16435066|NCT03736733|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
16435067|NCT03736720|Experimental|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
16435068|NCT03736707|Experimental|Selective HFOV|Selective HFOV will be provided
16435069|NCT03736707|Active Comparator|CMV|CMV will be provided
16435070|NCT03736694|Experimental|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, & Swanson, et al, 2014; Morin, Savard, Ouellet, & Daley, 2003). One workshop has the capacity of 30 participants.
16435071|NCT03736694|Experimental|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
16435072|NCT03736694|Active Comparator|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
16435073|NCT03736681|Experimental|40cc|40c buffered 0.5% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
16435074|NCT03736681|Active Comparator|20cc|20cc 1% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
16435075|NCT03736668|Experimental|Patients with Type 2 diabetes|"One year after patient's inclusion, during the additional cardiology consultation, an echocardiography will be performed by the investigator to evaluate any changes.
~Two years after the patient's inclusion, an investigator will contact by phone the general practitioner, cardiologist and / or diabetologist treating the patient to find out if any cardiovascular events occurred."
16435076|NCT03736655|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
16435077|NCT03736642||restrictive anorexia nervosa with hunger|
16435078|NCT03736642||restrictive anorexia nervosa without hunger|
16435079|NCT03736642||constitutional thinness|
16435080|NCT03736642||control subjects without eating disorders|
16435083|NCT03736616|Experimental|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 & Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.
~BEAM chemotherapy & autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT
~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
16435084|NCT03736616|Experimental|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.
~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
16435085|NCT03736603|Experimental|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
16435086|NCT03736603|Experimental|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
16435087|NCT03736603|No Intervention|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
16435088|NCT03736590|Experimental|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
16435089|NCT03736590|Active Comparator|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
16435090|NCT03736577|Experimental|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.
~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
16435091|NCT03736577|No Intervention|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
16435092|NCT03736564|Experimental|68Ga-DOTATATE PET/CT|Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
16435093|NCT03736551|Experimental|Intervention|The intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing ~600 kcal/day and 100% of the RNI for vitamins and minerals.
16435094|NCT03736551|Active Comparator|Standard Care|Renal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
16435095|NCT03736538|Experimental|Nitrous Oxide|"Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive inhaled nitrous oxide."
16435096|NCT03736538|Placebo Comparator|Placebo Gas|"Placebo gas given at 50% nitrogen [inert]/50% oxygen.
~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive placebo gas."
16435097|NCT03736525|Experimental|Design For Wellness (DWELL)|Intervention participants will: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
16435098|NCT03736525|Other|Wait list control group|After the close of the study, we will open the Facebook group to all, and wait list control group participants can receive a delayed form of the intervention, which includes: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
16435099|NCT03736486||Type 2 Diabetes|Male and female adults of Hispanic and/or Latino heritage with an established diagnosis of Type 2 diabetes.
16435100|NCT03736473|Other|MEDI9447 monotherapy|Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies
16435101|NCT03736460|Experimental|Mindfulness-based intervention|
16435102|NCT03736460|Active Comparator|Physical training|
16435103|NCT03736460|No Intervention|Wait-list|
16435104|NCT03736447|Active Comparator|AR101 powder (Peanut allergen formulation)|Subjects will be randomized to active arm of ARC005 and will be administered IP (AR101) in escalating doses for approximately 6 months.
16435105|NCT03736447|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC005 and will be administered escalating doses of IP (placebo) for approximately 6 months.
16435106|NCT03736434|Experimental|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
16435107|NCT03736434|Active Comparator|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
16435108|NCT03736434|No Intervention|Control Group|Continue care as usual without intervention.
16435109|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
16435110|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
16435111|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
16435112|NCT03736408||1. Group without Pain - TMJ disorders symptoms|1. The symptoms concerning joints were: the type of sound symptoms (clicking or popping), their frequency and the phase of the movement of lowering and lifting the jaw during which they occurred, occurrence of the tension type headache or back pain. Hypertension of the mastication muscles is frequently connected with a parafunction activity like grinding or clenching the teeth, which cause abnormal pressure on the joints
16435113|NCT03736408||2. Group with Pain and symptoms TMJ disorder|The pain form of the disease is manifested by spontaneous pain in the preaural region, accompanied by pain or tenderness of the mastication muscle. Pain that appears during palpation examination of temporomandibular joints is frequently not related to inflammation of the soft tissue around the temporomandibular joints, as it is claimed by several authors of the paper. The cause of this problem is a long-term overload of soft tissue causally associated with excessive muscle tension, that sometimes even persists for years
16435114|NCT03736395|Active Comparator|Control|Schools in this condition will be provided a four-day training about Schoolwide Positive Behavioral Interventions and Supports, and bi-yearly feedback about progress monitoring and action planning.
16435115|NCT03736395|Experimental|I-RIM Intervention|Schools in this condition will be provided the same basic training as the control condition, plus the elements of the Idaho Rural Implementation Model (I-RIM).
16435116|NCT03736382|Experimental|Experimental Group|The experimental group is comprised of participants with OSA and hypertension [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2) = 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
16435117|NCT03736382|Sham Comparator|Control Group|The control group is comprised of hypertensive OSA participants [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the protocol.
16435118|NCT03736369|Experimental|DWP14012 40mg|Orally, once daily
16435119|NCT03736369|Active Comparator|Esomeprazole 40mg|Orally, once daily
16435120|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 1|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
16435121|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 2|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
16435122|NCT03736330|Experimental|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
16435123|NCT03736317|Sham Comparator|control group|Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.
16435296|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
16435125|NCT03736317|Experimental|real dlPFC iTBS group|The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.
16435126|NCT03736317|Experimental|real dlPFC iTBS + real mPFC cTBS group|Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.
16435127|NCT03736304|Placebo Comparator|Usual care|Patients will receive standard clinical care by the doctor in charge.
16435128|NCT03736304|Experimental|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
16435129|NCT03736291|Active Comparator|active rTMS|"The Active rTMS: The magnetic head uses the Magro X100's 8-shaped coil, and the intervention site is the cerebellar vermis (1 cm below the occipital carina). The stimulation intensity is gradually increased by the 80%-100% exercise threshold according to the patient's tolerance. The total number of stimulation pulses per day is 600, the basic frequency is 5 Hz, and one short burst stimulus is given every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and every 10 short bursts are stimulated for 8 s. A total of 200 short bursts of stimulation. Intervention once a day, 5 times a week, intervention for 2 weeks, a total of 10 times."
16435130|NCT03736291|Sham Comparator|sham rTMS|"The sham rTMS: The sham stimulation method was to invert the 8 shaped coil, which was 180° to the scalp, and other intervention parameters were consistent with the study group."
16435131|NCT03736265|Experimental|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
16435132|NCT03736265|No Intervention|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
16435133|NCT03736213|Experimental|Condition 1: Visual-acoustic biofeedback|Behavioral: Biofeedback--visual-acoustic
16435134|NCT03736213|Experimental|Condition 2: Ultrasound biofeedback|Behavioral: Biofeedback-ultrasound
16435135|NCT03736200|Active Comparator|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
16435136|NCT03736200|Active Comparator|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
16435137|NCT03736200|Active Comparator|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
16435138|NCT03736187|Experimental|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
16435139|NCT03736187|Experimental|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
16435140|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
16435141|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
16435142|NCT03736161|Experimental|Group A- Tofacitinib|Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
16435143|NCT03736161|Placebo Comparator|Group B- Methotrexate|Methotrexate in increasing dose starting from 15 mg weekly to a maximum dose of 25 mg weekly from the end of 1st month. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD.
16435144|NCT03736148|Experimental|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
16435145|NCT03736148|Active Comparator|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
16435146|NCT03736148|Placebo Comparator|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
16435147|NCT03736148|No Intervention|Control|No contact was given to the subject.
16435148|NCT03736122|Experimental|BSG-001|Inhalation route, daily
16435149|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
16435150|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
16435151|NCT03736083|Active Comparator|Freestyle Libre Group|Freestyle Libre Group: Participants will use the Freestyle Libre flash glucose monitoring system throughout the study for 2-3 months.
16435152|NCT03736083|No Intervention|Control Group (standard diabetes care)|This group will receive standard care. At the around 1 week and 2 month visits, control group subjects will use a blinded Freestyle Libre Pro to provide data that can be used to compare glucose variability between groups. The Libre sensor will allow the study team to measure glucose values but the subjects will not have access to this information for management/treatment decisions and usual diabetes care will be unaffected. The Freestyle Libre Pro last 14 days, can be activated in clinic, and the sensor can be returned in person or via mail where the investigators will download the data.
16435153|NCT03736044|Experimental|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
16435154|NCT03736044|No Intervention|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
16435155|NCT03736031|Experimental|Intervention (Promotora)|The intervention group will have three face-to-face meetings with the promotora. Participant will continue to receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
16435199|NCT03735745|Experimental|Caucasian, HPV positive, Non Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
16435156|NCT03736031|No Intervention|Self-Education (Control)|Participant will receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
16435157|NCT03736018|Active Comparator|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
16435158|NCT03736018|No Intervention|ICA only|Invasive coronary angiogram (ICA) performed only.
16435159|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
16435160|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
16435161|NCT03735992|Experimental|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
16435162|NCT03735992|No Intervention|Wait list|Treatment as usual.
16435163|NCT03735979|Experimental|Argatroban|100µg/kg bolus followed by 3µg/kg per minute for 12 hours
16435164|NCT03735979|Experimental|Eptifibatide|135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours
16435165|NCT03735979|Placebo Comparator|Placebo|
16435166|NCT03735966|Experimental|Pyrotinib plus trastuzumab and docetaxel and carboplatin|Pyrotinib + trastuzumab + docetaxel+carboplatin
16435167|NCT03735953|Experimental|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
16435168|NCT03735953|No Intervention|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
16435169|NCT03735940|No Intervention|Control phase|no intervention, i.e. care as usual
16435170|NCT03735940|Experimental|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
16435171|NCT03735927|No Intervention|Control phase|no intervention, i.e. care as usual
16435172|NCT03735927|Experimental|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
16435173|NCT03735914|Experimental|neuralgic patients|MRI experimentation
16435174|NCT03735901|Active Comparator|Experimental Intervention|White Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg.
16435175|NCT03735901|Placebo Comparator|Control Intervention|Matching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group.
16435176|NCT03735875|Experimental|Treatment (venetoclax, quizartinib)|Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
16435177|NCT03735862||Observations Group|Patients who have undergone a hiatal hernia repair with MIROMESH.
16435178|NCT03735849|Experimental|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
16435179|NCT03735849|Experimental|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
16435180|NCT03735836|Experimental|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
16435181|NCT03735836|Experimental|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
16435182|NCT03735810|Experimental|SAD - Cohort 1|50 mg LBS-008 or placebo
16435183|NCT03735810|Experimental|SAD - Cohort 2|100 mg LBS-008 or placebo
16435184|NCT03735810|Experimental|SAD - Cohort 3|200 mg LBS-008 or placebo
16435185|NCT03735810|Experimental|SAD - Cohort 4|400 mg LBS-008 or placebo
16435186|NCT03735810|Experimental|SAD - Cohort 5|25 mg LBS-008 or placebo
16435187|NCT03735810|Experimental|MAD - Cohort 1|10 mg LBS-008 or placebo
16435188|NCT03735810|Experimental|MAD - Cohort 2|25 mg LBS-008 or placebo
16435189|NCT03735810|Experimental|MAD - Cohort 3|5 mg LBS-008 or placebo
16435190|NCT03735810|Experimental|MAD - Cohort 4|12 mg LBS-008 or placebo
16435191|NCT03735784|Experimental|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
16435192|NCT03735784|No Intervention|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
16435193|NCT03735771|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
16435194|NCT03735771|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
16435195|NCT03735771|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
16435196|NCT03735771|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
16435197|NCT03735758|Experimental|Pazopanib|Pazopanib; 800 mg; daily; oral
16435198|NCT03735758|Active Comparator|Chemotherapy|Guideline-conform chemotherapy
16435297|NCT03735108||normal control group|no history of pregnancy loss
16435200|NCT03735745|Experimental|Caucasian, HPV positive, Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
16435201|NCT03735745|Experimental|Newly diagnosed, African American/Black, HPV negative, Smoking|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
16435202|NCT03735745|Experimental|Young (<40 years old), Oral Cavity (Tongue) patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
16435203|NCT03735745|Experimental|Neoadjuvant PD-1 Blockade patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
16435204|NCT03735732||weight status|
16435205|NCT03735732||mindset|
16435206|NCT03735719||STEMI patients|Patients with first STEMI treated with primary PCI are recruited in this study.
16435207|NCT03735719||Control group|The control group will consist of patients with risk factors for cardiovascular diseases, but without history of coronary artery disease or heart failure.
16435208|NCT03735706|Active Comparator|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.
~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
16435209|NCT03735706|Experimental|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.
~A radiation dose reduction from 120 to 90 kV.
~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
16435210|NCT03735706|Experimental|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.
~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
16435211|NCT03735706|Experimental|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.
~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
16435213|NCT03735667|Experimental|ACURATE Valve - Randomized|"Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
~*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
16435214|NCT03735667|Experimental|ACURATE Valve - Single-arm Roll-in|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
16435215|NCT03735667|Active Comparator|Commercial Valve - Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System
~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.
~*A minimum of 200 subjects will also be enrolled in the 4D CT Imaging Substudy."
16435216|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
16435217|NCT03735628|Experimental|Dose escalation|"Copanlisib:
~45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)
~Nivolumab:
~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
16435218|NCT03735628|Experimental|Dose expansion|"Copanlisib:
~Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)
~Nivolumab:
~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
16435219|NCT03735615|Experimental|chronic obstructive lung disease|
16435220|NCT03735615|Experimental|healthy control|
16435221|NCT03735602|Experimental|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
16435222|NCT03735589|Experimental|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
16435223|NCT03735576|Experimental|LLD-adapted cognitive behavioural therapy (CBT)|manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
16435224|NCT03735576|Active Comparator|supportive unspecific intervention (SUI)|manualized 15-session individually-delivered supportive unspecific intervention (SUI)
16435225|NCT03735563|Experimental|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
16435226|NCT03735563|Experimental|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
16435227|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
16435259|NCT03735303|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
16435228|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
16435229|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.
~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).
~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
16435230|NCT03735537|Active Comparator|Teriparatide and zoledronic acid|Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector, given subcutaneously using a self-administered injection device for two years (24 months) followed by a single intravenous 5mg infusion of zoledronic acid.
16435231|NCT03735537|No Intervention|Standard Care|Continuation of existing bone modifying treatment (i.e. bisphosphonate treatment) or no active bone modifying treatment according to the clinical judgement of the local investigator.
16435232|NCT03735524|Experimental|Exercise|Conventional rehabilitation
16435233|NCT03735498|Experimental|Psychological Intervention|"Qualitative interview will be conducted
~7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online
~A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills
~A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty
~A self-care component to promote caregiver health and well-being"
16435234|NCT03735485|Experimental|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
16435235|NCT03735485|Experimental|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
16435236|NCT03735485|Experimental|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
16435237|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
16435238|NCT03735459|Experimental|Patient reminder|"Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema.
~Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider.
~Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life.
~Enrollment: Participants will complete FDLQI and PO-SCORAD.
~Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ.
~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
16435239|NCT03735459|No Intervention|No patient reminder/control|"Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment.
~Enrollment: Participants will complete FDLQI and PO-SCORAD.
~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
16435240|NCT03735446|Experimental|Prexasertib+MEC|"Cytarabine is administered intravenously on days 1-5.
~Etoposide is administered intravenously on days 1-5.
~Mitoxantrone is administered intravenously on days 1-5.
~Prexasertib is administered intravenously on days 1, 3, and 5."
16435241|NCT03735433|No Intervention|81 mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
16435242|NCT03735433|Active Comparator|162mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
16435243|NCT03735420|Experimental|Xanthohumol|Participants will receive 24 mg of 98% pure xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
16435244|NCT03735420|Placebo Comparator|Placebo oral capsule|Participants will receive vehicle (rice protein) by mouth once daily with the first daily meal.
16435245|NCT03735407|Experimental|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
16435246|NCT03735394|Experimental|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller & Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
16435247|NCT03735381|Active Comparator|Intervention 1: pedometer|"Minimum intervention:
~Use of pedometer watch from 12 to 32 GW
~Recommendations of physical activity"
16435248|NCT03735381|Experimental|Intervention 2: pedometer+goal+reminds|"Maximum intervention:
~Use of pedometer from 12 to 32 GW
~Recommendations of physical activity
~Information about get a goal of 11000 steps/day
~Reminds the goal every two weeks."
16435249|NCT03735381|No Intervention|Control: without pedometer|Women receive some recommendations of physical activity during pregnancy. They do not use the pedometer during pregnancy
16435250|NCT03735368|Placebo Comparator|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
16435251|NCT03735368|Active Comparator|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
16435252|NCT03735355|Experimental|Balloon dilation|TTS balloon dilation
16435253|NCT03735355|Active Comparator|Surgery|Resection of the fibrostenotic area
16435254|NCT03735342|Experimental|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
16435255|NCT03735342|No Intervention|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
16435256|NCT03735329|Experimental|Pulse oximetry monitoring|
16435257|NCT03735316|Experimental|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
16435258|NCT03735316|Placebo Comparator|Placebo|Subjects will receive placebo
16435260|NCT03735303|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
16435261|NCT03735303|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
16435262|NCT03735303|Experimental|control group|no intervention was given
16435263|NCT03735290|Experimental|Phase 1b: Cohort 1, ilixadencel + pembrolizumab|3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w
16435264|NCT03735290|Experimental|Phase 1b: Cohort 2, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w
16435265|NCT03735290|Experimental|Phase 1b: Cohort 3, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w
16435266|NCT03735290|Experimental|Phase 1b: Cohort 4, ilixadencel + pembrolizumab|Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w
16435267|NCT03735290|Experimental|Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.
16435268|NCT03735290|Active Comparator|Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.
16435269|NCT03735277|Experimental|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters.
16435270|NCT03735264|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
16435271|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A>1，DT 160~220 ms，S/D >1，AR 0.22-0.32m/sec，E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A< 1，DT > 220 ms，S/D > 1，AR 0.21-0.28 m/sec，E/e'<10 Pseudo-normalization pattern：E/A> 1，DT 150~210 ms，S/D < 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT < 150 ms，S/D <1，AR ≥0.25m/sec，E/e'≥10
16435272|NCT03735238||Lupus Patients|All lupus patients, regardless of if they are having an active flare
16435273|NCT03735225|Experimental|IV Dasiglucagon|Dasiglucagon 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
16435274|NCT03735225|Experimental|SC 0.6 mg Dasiglucagon|Dasiglucagon 0.6 mg administered SC as a single dose
16435275|NCT03735225|Placebo Comparator|IV Placebo|Placebo 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
16435276|NCT03735212|Experimental|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
16435277|NCT03735212|No Intervention|Control Group|Participants in this group receive services as usual.
16435278|NCT03735199|Experimental|PCL-TCP scaffold|During the surgery, the PCL-TCP scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A Geistlich Bio-Gide collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
16435279|NCT03735199|Active Comparator|Geistlich Bio-Gide collagen membrane|"No space filler will be inserted in the extraction socket but similar to the test group, a Geistlich Bio-Gide collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
~denture overlying the extraction site will be completely relieved."
16435280|NCT03735186|No Intervention|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
16435281|NCT03735186|Experimental|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
16435282|NCT03735173|Active Comparator|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
16435283|NCT03735173|Active Comparator|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
16435284|NCT03735173|Active Comparator|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
16435285|NCT03735173|Active Comparator|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
16435286|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
16435287|NCT03735147|Experimental|All children|Administration of live attenuated influenza vaccine (LAIV)
16435288|NCT03735134|Active Comparator|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
16435289|NCT03735134|Active Comparator|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
16435290|NCT03735134|Active Comparator|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
16435291|NCT03735121|Experimental|Atezolizumab (Part 2)|Atezolizumab
16435292|NCT03735121|Experimental|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
16435293|NCT03735121|Experimental|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
16435298|NCT03735095|Experimental|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
16435299|NCT03735082|Experimental|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
16435300|NCT03735069|Experimental|IPT (Indirect pulp treatment) group|In this group, complete caries excavation from the dentin-enamel junction will be done. Caries near the pulp will be removed with caution until the remaining dentin shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material will be placed (Vitrebond; St.Paul, MN), followed by resin-modified glass ionomer (RMGI) build-up material (Vitremer; St. Paul, MN), and the final restoration of choice for MIH involved teeth; a preformed Stainless Steel Crown (SSC).
16435301|NCT03735069|Experimental|Cvek/partial pulpotomy group|"In this group, partial pulpotomy will be attempted first, inflamed pulp tissue will be removed until healthy pulp tissue is reached (2-4mm depth), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated twice if required; otherwise, cervical pulpotomy will be done.
~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be placed in the pulp chamber (2-3mm thickness), a moist cotton pellet will be placed and Intermediate Restorative Material (IRM) to ensure setting. Patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
16435302|NCT03735069|Experimental|Cervical pulpotomy group|"In this group, a cervical pulpotomy procedure will be done where all pulp chamber tissue shall be removed until healthy pulp tissue is reached, as indicated by bleeding from all canals and arrest of hemorrhage upon pressure (for maximum 6 minutes).
~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be mixed according to manufacturer instructions and will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with Intermediate Restorative Material (IRM), the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
16435303|NCT03735056|No Intervention|Group 1 (Usual care)|Receives usual care only.
16435304|NCT03735056|Experimental|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl & Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
16435305|NCT03735056|Experimental|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
16435306|NCT03735043|Experimental|ccNexfin ©|
16435307|NCT03735030|Experimental|human hCG|
16435308|NCT03735030|Active Comparator|recombinant hCG|
16435309|NCT03735017|Active Comparator|Non-Interactive|Participants will receive non-interactive virtual reality walking sessions.
16435310|NCT03735017|Experimental|Interactive|Participants will receive interactive virtual reality walking sessions.
16435311|NCT03735004|Experimental|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
16435312|NCT03735004|Active Comparator|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
16435313|NCT03735004|Sham Comparator|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
16435314|NCT03734991|Experimental|Ibrexafungerp (SCY-078)|300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
16435315|NCT03734991|Placebo Comparator|Placebo|Matching Placebo
16435316|NCT03734978||A blood group|prematurity with sepsis
16435317|NCT03734978||O blood group|prematurity with sepsis
16435318|NCT03734978||B blood group|prematurity with sepsis
16435319|NCT03734978||AB blood group|prematurity with sepsis
16435320|NCT03734965|Active Comparator|AWAKEN INTUBATION FIBEROPTIC|awaken intubation
16435321|NCT03734965|Experimental|AWAKEN INTUBATION VIDEOLARYNGOSCOPY|awaken intubation
16435322|NCT03734952|Experimental|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
16435323|NCT03734952|Other|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
16435324|NCT03734926|Experimental|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
16435325|NCT03734926|Experimental|Part 2 Cohort A|Participants with hepatocellular carcinoma.
16435326|NCT03734926|Experimental|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
16435327|NCT03734913|Experimental|Part 1|Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.
16435328|NCT03734913|Experimental|Part 2 Cohort A|Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.
16435329|NCT03734913|Experimental|Part 2 Cohort B|Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.
16435330|NCT03734900|Placebo Comparator|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
16435331|NCT03734900|Experimental|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
16435332|NCT03734900|Experimental|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
16435333|NCT03734887|Active Comparator|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
16435334|NCT03734887|Experimental|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
16435335|NCT03734874|Active Comparator|hesperidin|
16435336|NCT03734874|Placebo Comparator|control|
16435337|NCT03734861|Experimental|BreatheSmart System|"BreatheSmart mobile application that tracks medication usage and sends real time reminders
~HeroTracker sensor that counts dosage and monitors real-time medication adherence
~CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
16435338|NCT03734861|Active Comparator|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
16435339|NCT03734848|No Intervention|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
16435340|NCT03734848|Active Comparator|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
16435341|NCT03734835|Active Comparator|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
16435342|NCT03734835|Placebo Comparator|control|no supplementation
16435343|NCT03734835|Active Comparator|flaxseed|30 grams flaxseed
16435344|NCT03734835|Active Comparator|hesperidin|1000 mg hesperidin as two capsules
16435345|NCT03734822|Other|CF|Cystic fibrosis patients undergoing general anesthesia.
16435346|NCT03734809|Experimental|pembrolizumab|"Total 51 weeks for 17 doses of pembrolizumab:
~Neoadjuvant pembrolizumab-chemotherapy: 6 weeks (2 doses of pembrolizumab)
~Concurrent pembrolizumab-chemoradiation: 9 weeks (3 doses of pembrolizumab
~Maintenance pembrolizumab: 36 weeks (12 doses of pembrolizumab)"
16435347|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
16435348|NCT03734783||Patients|HBsAg positive more than 6 months
16435349|NCT03734783||health control|
16435350|NCT03734770|Active Comparator|Subcutaneous progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
16435351|NCT03734770|Active Comparator|Vaginal progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
16435352|NCT03734757|Experimental|Trimodality|PET-CT with fluorocholine and MRI
16435353|NCT03734744|Experimental|Adults with Cystic Fibrosis|CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
16435354|NCT03734744|Experimental|Non-CF Controls with Low vitamin D|Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
16435355|NCT03734731|Other|Objective Nerve Conduction testing|Therapy of chronic pain and swelling with Monochromatic Infrared Photo Energy (MIRE) in combination with Transcutaneous Electrical Nerve Stimulation (TENS) and Cannabis or Opioids, to determine which treatment is deemed as the most successful, through objective nerve conduction testing with Neural Scan or AXON-II testing systems. Other types of therapies may be introduced during comparison reviews.
16435356|NCT03734718|Active Comparator|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
16435357|NCT03734718|Placebo Comparator|Placebo|Saline
16435358|NCT03734705|Experimental|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
16435359|NCT03734705|Sham Comparator|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
16435360|NCT03734692|Experimental|cisplatin + rintatolimod + pembrolizumab|Intraperitoneal (IP) cisplatin 50mg/m^2 solution with IP rintatolimod 200 mg solution and IV pembrolizumab 200 mg solution.
16435361|NCT03734679|Experimental|Surveil drug coated balloon|
16435362|NCT03734666|Experimental|Mindfulness Based Relapse Prevention|Participants will receive Mindfulness Based Relapse Prevention (MBRP), an existing substance use treatment, which has been modified to focus explicitly on smoking cessation and reduced alcohol use, creating Mindfulness Based Relapse Prevention - Smoking and Alcohol (MBRP-SA).
16435363|NCT03734666|Active Comparator|Cognitive Behavioral Therapy|Participants will receive Cognitive Behavioral Therapy (CBT) a well-established and commonly used treatment for substance abuse behaviors that utilizes problem solving and coping skills.
16435455|NCT03734081|Experimental|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
16435364|NCT03734653|Experimental|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
16435365|NCT03734640|Placebo Comparator|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
16435366|NCT03734640|Active Comparator|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
16435367|NCT03734627||Upper Gastrointestinal Surgery - Transit|
16435368|NCT03734627||Control - Transit|
16435369|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
16435370|NCT03734627||Control - Gut Function|
16435371|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
16435372|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
16435373|NCT03734601|Experimental|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
16435374|NCT03734588|Experimental|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
16435375|NCT03734575|Experimental|ClariCore System|Biopsy tissue, correlative spectral data, T2-weighted MR scans and ultrasound images acquired with the ClariCore System will be collected and recorded during standard practice transperineal biopsy.
16435376|NCT03734562|Experimental|Ablation|Substrate-based radiofrequency catheter ablation
16435377|NCT03734562|Active Comparator|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
16435378|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
16435379|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
16435380|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
16435381|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
16435382|NCT03734536|Other|REGENETEN™ Bioinductive Implant|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
16435383|NCT03734536|Other|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
16435384|NCT03734523||Pilot Group: 12 week study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for 12 weeks. As this is an observational study, there is no control group.
~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
16435385|NCT03734523||Study Group: 6 month study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for six months. As this is an observational study, there is no control group.
~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
16435386|NCT03734510|Active Comparator|hesperidin and flaxseed|
16435387|NCT03734510|Placebo Comparator|control|
16435388|NCT03734510|Active Comparator|flaxseed|
16435389|NCT03734510|Active Comparator|hesperidin|
16435390|NCT03734497|Active Comparator|Group Control|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
16435391|NCT03734497|Experimental|Group Preloading|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
16435392|NCT03734497|Experimental|Group Carotis FTc|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
16435393|NCT03734484|Experimental|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
16435394|NCT03734484|No Intervention|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
16435395|NCT03734471|Active Comparator|Traditional|
16435396|NCT03734471|Experimental|Reactor Device|
16435397|NCT03734458|Experimental|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
16435398|NCT03734458|Experimental|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
16435528|NCT03733678|Experimental|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
16435399|NCT03734458|Active Comparator|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
16435400|NCT03734445|Experimental|Vitamin supplement|Effervescent tablets containing Vitamin C, Vitamin D and zinc
16435401|NCT03734445|Placebo Comparator|Placebo|Effervescent tablets not containing Vitamin C, Vitamin D and zinc
16435402|NCT03734432|Experimental|Patients|IGAR-Breast TeleOp
16435403|NCT03734406|Experimental|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.
~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.
~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
16435404|NCT03734406|No Intervention|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.
~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
16435405|NCT03734393|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
16435406|NCT03734393|No Intervention|HIVD-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
16435407|NCT03734393|No Intervention|HIVD-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120
16435408|NCT03734380|Experimental|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
16435409|NCT03734380|Experimental|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
16435410|NCT03734380|Experimental|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
16435411|NCT03734367|Active Comparator|Emotional abilities training program|Intervention program on emotional abilities that will be carried out for 10 hours distributed over 5 weeks, in two and a half hour session. The work methodology will be eminently practical, working in groups including real case analysis and interactive simulation
16435412|NCT03734367|No Intervention|Control group|Control group that will not receive the training program on emotional abilities but usual care.
16435413|NCT03734354|Experimental|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
16435414|NCT03734354|Experimental|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
16435415|NCT03734354|Experimental|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
16435416|NCT03734341|Experimental|EZ START Titration|"CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.
~Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period)."
16435417|NCT03734341|Active Comparator|APAP Titration|"CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.
~Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period)."
16435418|NCT03734328|Active Comparator|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)
~Other names:
~5/0 silk suture"
16435419|NCT03734328|Experimental|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)
~Other names:
~-5/0 silk suture"
16435420|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
16435421|NCT03734302|Experimental|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
16435456|NCT03734081|Experimental|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
16435424|NCT03734276|Experimental|High intensity exercise|
16435425|NCT03734276|Active Comparator|Control|
16435426|NCT03734263|Experimental|open label|sodium phenylbutyrate
16435427|NCT03734250||Group Sugammadex HD|Sugammadex used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30ng/ml
16435428|NCT03734250||Group neostigmine HD|Neostigmine used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30 ng/ml
16435429|NCT03734250||Group Sugammadex LD|Sugammadex used as neuromuscular reverse agent with Vitamin D status under 30 ng/ml
16435430|NCT03734250||Group Neostigmine LD|Neostigmine used as neuromuscular reverse agent with Vitamin D status under 30ng/ml
16435431|NCT03734237|Active Comparator|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
16435432|NCT03734237|Active Comparator|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
16435433|NCT03734237|Active Comparator|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
16435434|NCT03734224|Active Comparator|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
16435435|NCT03734224|Active Comparator|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
16435436|NCT03734211|Experimental|Evolocumab|Evolocumab (Repatha®) will be administered subcutaneously once monthly in the abdomen, thigh, or upper arm for the duration of the treatment period (one year). The 420 mg evolocumab/placebo will be administered by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
16435437|NCT03734211|Placebo Comparator|Placebo|The placebo is presented in an identical prefilled autoinjector. It is supplied as a sterile, single-use, preservative-free solution for subcutaneous injection in a disposable, spring-based prefilled autoinjector. The prefilled autoinjector contains a 1.0 mL deliverable volume of 1.1% (w/v) sodium carboxymethylcellulose, 250 mM proline, 10 mM acetate, and 0.01% (w/v) polysorbate 80, pH 5.0.
16435438|NCT03734198|Experimental|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day
~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.
~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.
~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.
~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
16435439|NCT03734185|Experimental|Learning and Coping|A health pedagogical strategy that builds on inductive teaching with high involvement of the participants. Characteristics of Learning and Coping are that 'experienced patients' plan, teach and evaluate, in cooperation with health professionals.
16435440|NCT03734185|Active Comparator|Usual Cardiac Rehabilitation|The theoretical frameworks used in some of these local healthcare services are empowerment, self-efficacy and self-management
16435441|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
16435442|NCT03734159|Experimental|parasternal block|preoperative parasternal block by ropivacaine injection
16435443|NCT03734159|Placebo Comparator|physiological serum|sodium chloride injection
16435444|NCT03734146|Experimental|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
16435445|NCT03734146|Experimental|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
16435446|NCT03734146|Experimental|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
16435447|NCT03734146|No Intervention|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
16435448|NCT03734133|Experimental|Foot orthoses|Different foot orthoses
16435449|NCT03734120||men|men undergoing routine semen analysis for infertility
16435452|NCT03734094|Experimental|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
16435453|NCT03734094|Active Comparator|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
16435454|NCT03734081|Experimental|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
16435457|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
16435458|NCT03734055|Experimental|Peer Mentoring|The program will consist of 12 sessions of peer mentoring that will include one standard educational session by telephone or video for approximately 60 minutes every 2 weeks. Additional interaction will be discouraged, but mentees and mentors will be asked to report any additional social interaction should it occur. The bi-weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. 60-minute calls are necessary for the delivery of educational content and mentors and mentees to be able to discuss their own experiences and potential solutions.
16435459|NCT03734055|Active Comparator|Social Support Group|Mentees randomized to the social support control group will be enrolled in a lupus support group designed specifically for this project.
16435462|NCT03734029|Experimental|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
16435463|NCT03734029|Active Comparator|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:
~Capecitabine
~Eribulin
~Gemcitabine
~Paclitaxel
~Nab-paclitaxel"
16435464|NCT03734016|Experimental|Zanubrutinib|Zanubrutinib will be orally administered until disease progression or unacceptable toxicity.
16435465|NCT03734016|Active Comparator|Ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
16435466|NCT03734003|Experimental|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.
~Common warts, plantar warts, and condyloma acuminata"
16435467|NCT03734003|Active Comparator|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
16435473|NCT03733964|Experimental|Manual therapy|A group of 50 people using manual therapy as a treatment method.
16435474|NCT03733964|Experimental|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
16435475|NCT03733964|Experimental|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
16435476|NCT03733964|Experimental|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
16435477|NCT03733951|Experimental|KN046|
16435478|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
16435480|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
16435481|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
16435482|NCT03733899|Experimental|Upper lid margin/Lower lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences of an ocular surface region. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
16435483|NCT03733899|Experimental|Lower lid margin/Cornea/ Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
16435484|NCT03733899|Experimental|Cornea/Upper lid margin/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
16435485|NCT03733899|Experimental|Cornea/Lower lid margin/Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
16435486|NCT03733899|Experimental|Upper lid margin/Cornea/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
16435487|NCT03733899|Experimental|Lower lid margin/Upper lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
16435488|NCT03733886|Active Comparator|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.
~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
16435489|NCT03733886|Sham Comparator|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
16507965|NCT03236701|No Intervention|Control|usual diet
16435490|NCT03733873|Experimental|desmopressin plus Suoquan|Drug1. name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months Drug2 name:Suoquan mixture form:liquid dosage:10ml/time frequence:bid duration:3 months
16435491|NCT03733873|Active Comparator|desmopressin|name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months
16435492|NCT03733860|Active Comparator|Cavernous sparing group|
16435493|NCT03733860|Other|Conventional technique group|
16435494|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
16435495|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
16435496|NCT03733821||CUD patients on HF-rTMS treatment|Patients fulfilling the Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM 5) criteria for Cocaine Use Disorder undergoing a High Frequency rTMS protocol stimulating over the left dorsolateral prefrontal cortex (DLPFC).
16435497|NCT03733808|Active Comparator|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
16435498|NCT03733808|Sham Comparator|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
16435499|NCT03733795||Control|'Healthy babies' to establish 'normal' blood flow in neonates.
16435500|NCT03733795||ECMO|Children undergoing extracorporeal membrane oxygenation for acute respiratory failure.
16435501|NCT03733795||Conventional|Neonates undergoing conventional treatment for acute respiratory failure.
16435502|NCT03733782|Active Comparator|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine < 2.0 mg/dl.
16435503|NCT03733782|No Intervention|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
16435504|NCT03733769|Experimental|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
16435505|NCT03733756|Experimental|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
16435506|NCT03733756|Active Comparator|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
16435507|NCT03733743|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
16435508|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled prior to July 2020 (Cohort 1)|ACRYSOF IQ RESTOR Multifocal Toric IOL (+3.0 D or +2.5 D) implanted in at least one eye during cataract surgery
16435509|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled after July 2020 (Cohort 2)|ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL or ACRYSOF IQ RESTOR +2.5 D Multifocal IOL implanted in at least one eye during cataract surgery
16435510|NCT03733717|Experimental|Isatuximab|Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.
16435511|NCT03733704|Experimental|Healthy volunteers|Healthy volunteers
16435512|NCT03733691|Experimental|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
16435513|NCT03733691|Experimental|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
16435514|NCT03733678|Experimental|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
16435515|NCT03733678|Experimental|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
16435516|NCT03733678|Experimental|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
16435517|NCT03733678|Experimental|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
16435518|NCT03733678|Experimental|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
16435519|NCT03733678|Experimental|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
16435520|NCT03733678|Experimental|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
16435521|NCT03733678|Experimental|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
16435522|NCT03733678|Experimental|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
16435523|NCT03733678|No Intervention|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
16435524|NCT03733678|Experimental|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
16435525|NCT03733678|Experimental|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
16435526|NCT03733678|Experimental|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
16435527|NCT03733678|Experimental|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
16435529|NCT03733678|Experimental|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
16435530|NCT03733678|Experimental|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
16435531|NCT03733678|Experimental|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
16435532|NCT03733678|Experimental|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
16435533|NCT03733678|Experimental|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
16435534|NCT03733665||Heart failure patients|All patients in NICOR's National Heart Failure Audit will be matched to those in NHS Digital's HES database who have a 4-character primary diagnosis of I50.0-I50.9.
16435535|NCT03733652|No Intervention|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
16435536|NCT03733652|Active Comparator|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
16435537|NCT03733639|Active Comparator|Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm Tisseel® surgeon dispenses the product all over the anastomosis. The rest of the surgical procedure is as usual."
16435538|NCT03733639|Other|no Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm  noTisseel® surgeon performs the surgical procedure as usual."
16435539|NCT03733626|Active Comparator|ViviGen® Cellular Bone Matrix|20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system
16435540|NCT03733626|Placebo Comparator|Local Bone Autograft|20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system.
16435541|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
16435542|NCT03733600||Glaucoma|All patients followed for either early or moderate forms of primary or secondary open-angle glaucoma who had undergone surgery for Xen alone or in combination with cataract surgery for phacoemulisation of the lens.
16435543|NCT03733587|Experimental|Cyclophosphamide and GX-I7|Cyclophosphamide and determined dose of GX-I7 of each cycle
16435544|NCT03733574|Experimental|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
16435545|NCT03733574|Experimental|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
16435546|NCT03733561|Experimental|LY03003|LY03003
16435547|NCT03733561|Active Comparator|Neupro transdermal patch|Neupro transdermal 4 mg patch
16435548|NCT03733548|Experimental|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
16435549|NCT03733535|Experimental|Treatment|Benralizumab 30mg subcutaneous injection on study days 0, 28 and 56 and 1.0 L 129-Xenon/4-Helium mixture, twice per visit, on days 0, 14, 28 and 112.
16435550|NCT03733522|Active Comparator|Rubber dam isolation|"Absolute isolation
~local anesthesia
~use of dental clamp and rubber dam
~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
16435551|NCT03733522|Experimental|Relative isolation|"Relative isolation
~no local anesthesia
~use of cotton roll and saliva ejector
~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
16435552|NCT03733509|Experimental|Intraoperative Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of Bupivacaine 0.25%.
~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml of saline solution (NaCl 0.9%)."
16435553|NCT03733509|Active Comparator|Ultrasound Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of of saline solution (NaCl 0.9%).
~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml Bupivacaine 0.25%."
16435554|NCT03733496||Participants from VY-AADC01 clinical studies:|Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study
16435555|NCT03733483|Experimental|Sleep Deprivation|
16435556|NCT03733470|Experimental|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
16435557|NCT03733470|Experimental|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
16435558|NCT03733457|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
16435559|NCT03733444|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
16435560|NCT03733444|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
16435561|NCT03733444|Experimental|Placebo|Placebo to match will be administered as matching film-coated tablets for oral use once daily.
16435562|NCT03733431|Active Comparator|Standard dose vagal stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
16435563|NCT03733431|Active Comparator|High dose vagal stimulation|A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
16435564|NCT03733431|Sham Comparator|Sham stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
16435565|NCT03733418||VIOLET participants|Neuropsychological evaluations will be conducted 12 (+/-4) months after randomization among a subset of 140 survivors enrolled in the VIOLET parent study at 7 (out of 42) PETAL sites.
16435566|NCT03733405|Experimental|Postpartum Visit 6 Weeks|Participants will have a postpartum visit scheduled 6 weeks after birth
16435567|NCT03733405|Experimental|Postpartum Visit 2 and 6 Weeks|Participants will have postpartum visits scheduled 2 and 6 weeks after birth
16435568|NCT03733379|Placebo Comparator|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
16435569|NCT03733379|Experimental|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
16435570|NCT03733379|Experimental|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
16435571|NCT03733379|Experimental|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
16435572|NCT03733353|Other|Cohort 1|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose=55 mg, capsule, once daily, 15 days
16435573|NCT03733353|Other|Cohort 2|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose= 550 mg, capsule, once daily, 15 days
16435574|NCT03733353|Other|Cohort 3|12 subjects with mild to moderate psoriasis; 8 on EDP1815, 4 on placebo. Dose= 550 mg, capsule, once daily, 29 days
16435575|NCT03733353|Other|Cohort 4|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 2.76 g, capsule, once daily, 29 days
16435576|NCT03733353|Other|Cohort 5|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 2.76 g, capsule, once daily, 29 days
16435577|NCT03733353|Other|Cohort 6|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose=550 mg, capsule, once daily, 28 days.
16435578|NCT03733353|Other|Cohort 7|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 550 mg, capsule, once daily, 28 days
16435579|NCT03733340|Experimental|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
16435580|NCT03733340|No Intervention|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
16435581|NCT03733327|Experimental|BUCYE|For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2.
16435582|NCT03733314|Experimental|E6011|
16435583|NCT03733314|Placebo Comparator|Placebo|
16435584|NCT03733301|Experimental|4 Milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
16435585|NCT03733301|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
16435586|NCT03733301|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with TCS.
16435587|NCT03733288|Experimental|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
16435588|NCT03733288|Experimental|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
16435589|NCT03733275|Experimental|local anesthetic group|local aensthetic group receive preopetaive lidocaine spray and lidocaine-bupivacine mixture-soaked nasal pacing after nasal reduction surgery
16435590|NCT03733275|Placebo Comparator|control group|control group receive preoperative normal saline spray and normal saline-soaked nasal packing after nasal reduction surgery
16435591|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
16435592|NCT03733249|Experimental|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)
~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
16435593|NCT03733236|Experimental|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
16435594|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
16435595|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
16435596|NCT03733210|Experimental|Lymph Node-positive Tumor|Participants whose lymph nodes are positive for cancer
16435597|NCT03733210|Experimental|Lymph Node-negative Tumor|Participants whose lymph nodes are negative for cancer
16435598|NCT03733197|Experimental|Culture specific|"The culture-specific arm may entail FIT kits plus barbers as motivational interviewers."
16435599|NCT03733197|Experimental|Control|Distribution of CRC screening brochures & FIT (Fecal Immunochemical Test) kits by barbers
16435600|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
16435779|NCT03731962|Active Comparator|Developed Contrast Induced Nephropathy|Coronary Angiography
16435601|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
16435602|NCT03733171|Active Comparator|Platelet rich plasma|endoscopic injection of PRP
16435603|NCT03733171|Placebo Comparator|CONTROL GROUP|diluted epinephrine
16435604|NCT03733158|Experimental|Normal airway|intubation in normal aurway condition
16435605|NCT03733158|Experimental|Tongue edema|intubation in Tongue edema condition
16435606|NCT03733158|Experimental|Pharyngeal obstruction|intubation in Tongue edema condition
16435607|NCT03733158|Experimental|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
16435608|NCT03733158|Experimental|Cervical collar stabilization|intubation in Cervical collar stabilization condition
16435609|NCT03733158|Experimental|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
16435610|NCT03733145|Experimental|Participants on ACE inhibitors|Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
16435611|NCT03733145|Experimental|Participants on ARBs|Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
16435612|NCT03733145|Experimental|Other Classes of Antihypertensive Agents|Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.
16435613|NCT03733132|Placebo Comparator|Placebo|Participants in placebo group will receive Placebo Oral Tablets identical to the metformin tablets for 10 months.
16435614|NCT03733132|Active Comparator|Metformin|Participants in placebo group will receive an escalating dose of Metformin hydrochloride tablets up to a dose of 2500mg for 10 months.
16435615|NCT03733119|Experimental|Arm A (Akt/ERK inhibitor ONC201)|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16435616|NCT03733119|Experimental|Arm B (Akt/ERK inhibitor ONC201, methionine-restricted diet)|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Participants also receive methionine-restricted diet PO on days 1-5, 8-12, and 15-19. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16435617|NCT03733106|Experimental|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
16435618|NCT03733106|Active Comparator|control|standard two dimension digital mammography
16435619|NCT03733093||1|HIV Positive
16435620|NCT03733080||1|ages 18 and older
16435623|NCT03733054||Men|Men with lower limb amputation
16435624|NCT03733054||Women|Women with lower limb amputation
16435625|NCT03733041|Active Comparator|rTMS|This group will be randomized to receive rTMS
16435626|NCT03733041|Sham Comparator|Sham|This group will be randomized to receive sham treatment
16435627|NCT03733041|Other|No intervention|This group will receive no intervention
16435628|NCT03733028|Experimental|Mobile Intervention for Reducing Anger (MIRA)|Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.
16435629|NCT03733028|Active Comparator|Mindfulness Intervention|Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.
16435630|NCT03733015|Active Comparator|cTBS group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. TBS refers to a rTMS protocol where pulses are applied in bursts of three, delivered at a frequency of 50 Hz and an inter-burst interval of 200 ms (5 Hz)."
16435631|NCT03733015|Active Comparator|High frequenct rTMS group|High frequency refers to a rTMS protocol where pulses are applied in at 10Hz frequency
16435632|NCT03733002|Experimental|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
16435633|NCT03733002|Placebo Comparator|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
16435634|NCT03732989|Active Comparator|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
16435635|NCT03732989|Experimental|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
16435636|NCT03732976|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
16435637|NCT03732976|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
16435638|NCT03732963|Placebo Comparator|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
16435639|NCT03732963|Active Comparator|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
16435640|NCT03732950|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab intravenously IV on day 1. Courses repeat every 3 weeks for up to 35 courses (2 years) in the absence of disease progression or unacceptable toxicity.
16435641|NCT03732937||Control group|Pregnant ladies with no medical disorders from 16 weeks till term
16435642|NCT03732937||case group|Pregnant ladies with medical disorders from 16 weeks till term
16435643|NCT03732924|Experimental|Five minute rest|
16435644|NCT03732924|Active Comparator|Zero minute rest|
16435645|NCT03732911|Experimental|Intervention|Intervention arm
16435647|NCT03732885|Experimental|densah burs drilling group|maxillary sinus floor elevation during implant placement using Densah burs
16435648|NCT03732885|Experimental|Summers osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
16435649|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
16435650|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
16435651|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
16435652|NCT03732846|Experimental|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
16435653|NCT03732833|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
16435654|NCT03732833|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
16435655|NCT03732833|Placebo Comparator|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
16435656|NCT03732820|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.
~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
16435657|NCT03732820|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.
~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
16435658|NCT03732807|Experimental|Sequence A|Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
16435659|NCT03732807|Experimental|Sequence B|Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
16435660|NCT03732807|Experimental|Sequence C|Maintenance dose #1 given QD for 48 weeks
16435661|NCT03732807|Experimental|Sequence D|Maintenance dose #2 given QD for 48 weeks
16435662|NCT03732807|Experimental|Sequence E|Maintenance dose #3 given QD for 48 weeks
16435663|NCT03732807|Experimental|Sequence F|Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
16435664|NCT03732807|Experimental|Sequence G|Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
16435665|NCT03732794|Experimental|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
16435666|NCT03732781|Experimental|Radspherin|
16435667|NCT03732768|Experimental|Radspherin|
16435668|NCT03732755|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
16435669|NCT03732742|Experimental|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
16435670|NCT03732742|Experimental|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
16435671|NCT03732729|Experimental|Massage chair|lifestyle modification education(once)+ Using massage chair
16435672|NCT03732729|No Intervention|Control|lifestyle modification education(once)
16435673|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
16435674|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
16435675|NCT03732703|Experimental|Sub-Protocol A1|Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435676|NCT03732703|Experimental|Sub-Protocol B1|Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435677|NCT03732703|Experimental|Sub-Protocol C1|Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435678|NCT03732703|Experimental|Sub-Protocol D1|Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435679|NCT03732703|Experimental|Sub-Protocol E1|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
16435680|NCT03732703|Experimental|Sub-Protocol Y1|Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435780|NCT03731962|Other|Without CIN|Coronary Angiography
16435681|NCT03732703|Experimental|Sub-Protocol Y2|Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435682|NCT03732703|Experimental|Sub-Protocol Y3|Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)
16435683|NCT03732690|Other|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
16435684|NCT03732690|Other|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
16435685|NCT03732677|Experimental|Arm 1|Chemotherapy + Durvalumab
16435686|NCT03732677|Active Comparator|Arm 2|Chemotherapy alone
16435687|NCT03732664|Other|Single arm|
16435688|NCT03732651|Experimental|non-pulsatile blood flow|
16435689|NCT03732651|Experimental|pulsatile blood flow|
16435690|NCT03732638|Experimental|Rimegepant|Rimegepant - Randomization Phase: Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks.
16435691|NCT03732638|Placebo Comparator|Placebo|Placebo - Randomization Phase: Participants received a single oral dose of matching placebo tablet every other day (EOD) for 12 weeks.
16435692|NCT03732625|Experimental|Raltegravir|Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)
16435693|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
16435694|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
16435695|NCT03732599|Active Comparator|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
16435696|NCT03732599|Active Comparator|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
16435697|NCT03732586|Experimental|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
16435698|NCT03732586|Placebo Comparator|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
16435699|NCT03732573|Experimental|Intervention Group|This group will receive 9 text messages over 3 weeks. Messages will be based on goal-setting in the first week, goal-operating in the second week, and self-monitoring in the third week.
16435700|NCT03732573|No Intervention|Control Group|Participants in this group will receive no messages during the intervention period.
16435701|NCT03732560||Patients undergoing treatment with nivolumab and ipilimumab|
16435702|NCT03732560||Patients undergoing treatment with nivolumab|
16435703|NCT03732547|Experimental|'PolyIC plus PD-1 mAb' and 'PD-1 mAb'|"'PolyIC plus PD-1 mAb' group: PolyIC, 2mg, i.m., every other day, for three weeks. PD-1 mAb, 200mg, i.v., every three weeks.
~'PD-1 mAb' group: PD-1 mAb, 200mg, i.v., every three weeks."
16435704|NCT03732534|Experimental|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
16435705|NCT03732521|Experimental|Intervention group|educational therapy
16435706|NCT03732521|No Intervention|Control group|usual clinical practice
16435707|NCT03732508|Experimental|Irinotecan liposome plus SHR1316 plus fluorouracil|
16435708|NCT03732495|Experimental|Trial arm|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.
~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.
~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.
~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.
~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.
~Study drugs will be continued until a treatment discontinuation criterion is met."
16435709|NCT03732482|Placebo Comparator|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
16435710|NCT03732482|Experimental|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
16435711|NCT03732469|Experimental|Fentanyl/propofol + acetaminophen|In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
16435712|NCT03732469|Active Comparator|Fentanyl/propofol only|Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.
16435713|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
16435714|NCT03732430|Experimental|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
16435715|NCT03732417||Stroke patients|Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
16435716|NCT03732417||Telematic model treatment of patients with Stroke|The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
16435717|NCT03732404|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
16435718|NCT03732404|Placebo Comparator|Placebo|The control group will receive plain water with the same volume and timing of treatment
16435719|NCT03732391|Experimental|single arm|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will come continued with the same schedule until unacceptable toxicity or disease progression
16435720|NCT03732378|Experimental|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
16435721|NCT03732378|Placebo Comparator|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
16435722|NCT03732365|Experimental|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
16435723|NCT03732365|Active Comparator|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
16435724|NCT03732352|Experimental|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16435725|NCT03732339|Experimental|GILUPI CellCollector®|
16435726|NCT03732313|Active Comparator|Central toenail resection|Under local ring anaesthesua using xylocaine injection in base of big toe ,Surgical resection of the central part of toenail with underlying germinal matrix.the defect is sutures by prolene.
16435727|NCT03732313|Active Comparator|wedge toenail resection|Under local ring anaesthesiausing xylocaine injection around the base of big toe. Resect lateral wedge of toenail with removal of ingrown toenail and periungual skin. The wound is then sutured.
16435728|NCT03732300|Experimental|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
16435729|NCT03732300|No Intervention|TAU|Treatment as usual
16435730|NCT03732287|Experimental|-5 degrees Celsius for 10 seconds|
16435731|NCT03732287|Experimental|-5 degrees Celsius for 20 seconds|
16435732|NCT03732287|Experimental|-10 degrees Celsius for 10 seconds|
16435733|NCT03732287|Experimental|-10 degrees Celsius for 20 seconds|
16435734|NCT03732274|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
16435735|NCT03732261|Experimental|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
16435736|NCT03732261|No Intervention|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
16435737|NCT03732248|Active Comparator|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
16435738|NCT03732248|Placebo Comparator|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
16435739|NCT03732235||TACE+ systemic Bevacizumab|"TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
~Bevacizumab (5 mg/kg) therapy was initiated 15 days after first round of TACE and was repeated every two weeks, for a total of 8 cycles."
16435740|NCT03732235||FOLFIRI+Bevacizumab|FOLFIRI consists of 5-FU administered as a 48-hour continuous infusion to a total dose of 3,200 mg/m2 without a bolus, leucovorin 200 mg/m2, irinotecan 165 mg/m2 Bevacizumab (5 mg/kg) therapy was repeated every two weeks, for a total of 8 cycles.
16435741|NCT03732235||TACE|TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
16435742|NCT03732222|Experimental|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
16435743|NCT03732222|Experimental|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
16507969|NCT03236675||T790M EGFR|T790M positive patients
16435744|NCT03732222|Experimental|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
16435747|NCT03732183|Experimental|Podcast SMART-3RP|"The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new podcast session will be delivered every day."
16435748|NCT03732170|Experimental|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
16435749|NCT03732170|Active Comparator|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
16435750|NCT03732157||outpatient management of parathyroidectomy|
16435751|NCT03732157||conventional management of parathyroidectomy|
16435752|NCT03732144|Experimental|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
16435753|NCT03732144|Other|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
16435754|NCT03732118||Minimal hepatic encephalopathy|
16435755|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
16435756|NCT03732105|Experimental|Radiotherapy|Patients in radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization. After radiotherapy, patients on the control arm will be actively monitored.
16435757|NCT03732105|Experimental|Apatinib|Patients in apatinib group will receive oral apatinib at an initial dose of 500mg daily until recurrence,death, patient withdrawal or unacceptable toxic effects.
16435758|NCT03732105|Experimental|Radiotherapy and apatinib|Patients in radiotherapy+apatinib group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50 Gy/25 fraction after randomization and after radiotherapy they will receive oral apatinib at an initial dose of 500mg/qd until recurrence,death,patient withdrawal or unacceptable toxic effects.
16435759|NCT03732105|No Intervention|Control group|Patients on the control arm will be actively monitored after randomization.
16435760|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
16435761|NCT03732079||Research group|Women with early postpartum hemorrhage.
16435762|NCT03732079||Control group|Postpartum women without abnormal bleeding.
16435763|NCT03732066|Experimental|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
16435764|NCT03732066|Other|Control Group|The control group will receive usual text messages only.
16435765|NCT03732053|Experimental|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
16435766|NCT03732053|No Intervention|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
16435767|NCT03732040|Sham Comparator|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
16435768|NCT03732040|Experimental|miswak stick|use of miswak stick twice daily
16435769|NCT03732040|Experimental|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
16435770|NCT03732027|Active Comparator|Transversus Abdominis Block [TB] group|Patients will receive Surgical Transversus Abdominis Plane Block
16435771|NCT03732027|Active Comparator|Rectus Sheath Block [RB] group|Patients will receive Surgical Rectus Sheath Block
16435772|NCT03732001|Experimental|Anlotinib combined Docetaxel|patients treated with Anlotinib and Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
16435773|NCT03732001|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
16435774|NCT03731988|Experimental|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
16435775|NCT03731988|Experimental|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
16435776|NCT03731988|Experimental|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
16435777|NCT03731975|Active Comparator|CTZ Paste|Endodontic treatment with CTZ paste.
16435778|NCT03731975|Experimental|GP Paste|Endodontic treatment with Guedes-Pinto paste.
16435781|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
16435782|NCT03731923|Experimental|High risk group of HCC|High risk group of HCC with chronic hepatitis or liver cirrhosis. Participants undergo biannual ultrasonography and annual abbreviated liver MRI.
16435783|NCT03731910|Experimental|HCC group|Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.
16435784|NCT03731897|Experimental|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.
~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
16435785|NCT03731897|Placebo Comparator|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.
~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.
~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
16435786|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
16435787|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
16435788|NCT03731845|Experimental|patient|
16435789|NCT03731832|Experimental|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
16435790|NCT03731832|Experimental|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
16435791|NCT03731819|Experimental|Follow-up participants|Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI.
16435792|NCT03731793|Placebo Comparator|Placebo Group|Placebo. For 90 days one capsule/day.
16435793|NCT03731793|Experimental|Intervention Group|600 mg/day of non-animal Chondroitin Sulphate. One capsule/day for 90 days.
16435794|NCT03731780|Experimental|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
16435795|NCT03731780|Experimental|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
16435796|NCT03731780|Active Comparator|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
16435797|NCT03731767|Other|Subject group|Distraction thrust manipulation of the talocural joint in supine position
16435798|NCT03731754|Active Comparator|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
16435799|NCT03731754|Experimental|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
16435800|NCT03731741|Experimental|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
16435801|NCT03731741|No Intervention|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
16435802|NCT03731728|Experimental|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
16435803|NCT03731728|Experimental|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
16435804|NCT03731728|No Intervention|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
16435805|NCT03731715|Experimental|Cohort I|Subjects ≥18 years of age. Carisbamate, 200 mg, will be administered on Day 1 and 2 of the single-dose period. Carisbamate will be administered at 100 mg twice daily (BID) during the multiple-dose period.
16435806|NCT03731715|Experimental|Cohort II|Subjects 12 to <18 years of age. Carisbamate, 140 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 70 mg twice daily (BID) during the multiple-dose period.
16435807|NCT03731715|Experimental|Cohort III|Subjects 6 to <12 years of age. Carisbamate, 60 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 30 mg twice daily (BID) during the multiple-dose period.
16435808|NCT03731715|Experimental|Cohort IV|Subjects 2 to <6 years of age. The starting doses for the single dose and multiple-dose periods will be based on the PK and safety results of the first 3 cohorts.
16435809|NCT03731702||General Individuals|Any adult working at the NCI who has not used antibiotics in the past 3 months.
16435810|NCT03731689|No Intervention|Control group|Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.
16435811|NCT03731689|Experimental|Intrauterine lavage therapy group|Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.
16435812|NCT03731689|Experimental|Intrauterine gel-injection therapy group|Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.
16435813|NCT03731689|No Intervention|Healthy control group|Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.
16435922|NCT03730948|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
16435814|NCT03731676|Active Comparator|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
16435815|NCT03731676|Active Comparator|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
16435816|NCT03731663|Experimental|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
16435817|NCT03731663|Sham Comparator|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
16435818|NCT03731650|Experimental|active comparator|
16435819|NCT03731650|Experimental|placebo|
16435820|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
16435821|NCT03731624||SLK|
16435822|NCT03731624||GVHD|
16435823|NCT03731624||Dry eye|
16435824|NCT03731624||Control|
16435825|NCT03731611|Active Comparator|Group A|umbilical cord milking will be done for preterm infants <34 gestational age without placental insufficiency
16435826|NCT03731611|Active Comparator|Group B|umbilical cord milking will be done for preterm infant <34 gestational age with placental insufficiency
16435827|NCT03731611|No Intervention|Group C|Immediate cord clamping for preterm infants <34 gestational age with placental insufficiency
16435828|NCT03731585|Experimental|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
16435829|NCT03731585|Experimental|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
16435830|NCT03731572|Experimental|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
16435831|NCT03731572|Active Comparator|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
16435832|NCT03731559|Active Comparator|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
16435833|NCT03731559|Active Comparator|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
16435834|NCT03731546|No Intervention|Group A|Placental insufficiency and ICC : Immediate cord clamping after delivery of the fetus in preterm infants with placental insufficiency
16435835|NCT03731546|Active Comparator|Group B|Placental insufficiency and DCC: Cord clamping 60 seconds after delivery of fetus in preterm infants with placental insufficiency
16435836|NCT03731546|Active Comparator|Group C|Normal placenta with DCC:Cord clamping 60 seconds after delivery of fetus in preterm infants without placental insufficiency
16435837|NCT03731533|Experimental|WellStart|WellStart is a 12-week virtual intensive therapeutic lifestyle program utilizing web-based encounters with physicians, dietitians, health coaches and additional resources.
16435838|NCT03731533|No Intervention|Usual Care|The control group will continue with usual care.
16435839|NCT03731520|Experimental|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
16435840|NCT03731507|Experimental|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
16435841|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
16435842|NCT03731481|Experimental|CHIP - Urban|Participants randomized by urban location of residence to receive CHIP Lifestyle Medicine program intervention.
16435843|NCT03731481|Experimental|CHIP - Rural|Participants randomized by rural location of residence to receive CHIP Lifestyle Medicine program intervention.
16435844|NCT03731481|Experimental|FPD2- Urban|Participants randomized by urban location of residence to receive FPD2 Lifestyle Medicine program intervention.
16435845|NCT03731481|Experimental|FPD2 - Rural|Participants randomized by rural location of residence to receive FPD2 Lifestyle Medicine program intervention.
16435846|NCT03731468|Active Comparator|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
16435847|NCT03731468|Sham Comparator|control group|isobaric bupivacaine will be given on each side
16435848|NCT03731455|Experimental|Investigational and Comparator devices|Investigational (WISE Cortical Strip, WCS) and comparator (Subdural Strip Electrode, Ad-Tech Medical Instruments Corporation) devices will be used together.
16435849|NCT03731442|Experimental|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
16435919|NCT03730974|Experimental|Experimental arm BA (TAU + Ball blanket)|Patients that are randomized to the BA sequence receive treatment B (TAU) in the first period and intervention A in the second period (Protac Ball BlanketTM 7kg Flexible).
16435850|NCT03731442|Experimental|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
16435851|NCT03731429|Experimental|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
16435852|NCT03731429|Placebo Comparator|Placebo|group that receives 0.9% saline solution
16435853|NCT03731416|Placebo Comparator|GBR by xenograft|"Patients of both groups will be subjected to CBCT (diagnostic for upper arch).
~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~Flap will be done.
~In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.
~• The site will then be copiously irrigated with saline in preparation for closure.
~The flap will then be closed using interrupted 4/0 resorbable sutures."
16435854|NCT03731416|Active Comparator|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
16435855|NCT03731403|Experimental|MI Varnish|
16435856|NCT03731403|Active Comparator|Profluorid Varnish|
16435857|NCT03731390|Experimental|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
16435858|NCT03731390|Experimental|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
16435859|NCT03731390|Experimental|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
16435860|NCT03731390|Experimental|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
16435861|NCT03731377|Experimental|Intubated group|Patient in this group will receive general anesthesia with endotracheal tube intubation to perform one lung ventilation. Patient will be paralyzed and controlled ventilation will be implied.
16435862|NCT03731377|Experimental|Non-intubated group|Patient in this group will receive general anesthesia with laryngeal mask insertion. Patients in this group will not be paralyzed and keep spontaneous breathing to maintain one lung ventilation.
16435863|NCT03731364|Active Comparator|CA-008 - Pilot Stage|
16435864|NCT03731364|Placebo Comparator|Placebo - Pilot Stage|
16435865|NCT03731338||Reassured and discharged|patients who are reassured and discharged after first attendance
16435866|NCT03731338||Further diagnostic testing|Patients who went on to have further diagnostic testing
16435867|NCT03731325|Experimental|Episodic Future Thinking Group|The experimental group (N=20 families; N=40 total) will receive the Episodic Future Thinking (EFT) intervention. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now [Atance].
16435868|NCT03731325|Placebo Comparator|Healthy Thinking Group|The placebo group (N=20 families; N=40 total) will receive the Healthy Thinking (HT) intervention. HT encourages individuals to focus on the nutritional characteristics of food and the healthy benefits of physical activity.
16435869|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
16435870|NCT03731299||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
16435871|NCT03731299||Healthy adults|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
16435872|NCT03731286|Active Comparator|Alpinia galanga|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
16435873|NCT03731286|Active Comparator|Composite (Alpinia galanga + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
16435874|NCT03731286|Placebo Comparator|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
16435882|NCT03731247|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
16435883|NCT03731247|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
16435920|NCT03730961|Experimental|Placebo+Diuretic to BMS-986231+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
16435884|NCT03731234|Experimental|Ibrutinib+R-CHOP|Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)
16435885|NCT03731221|Experimental|Bupi HCl plus liposomal bupi|PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine
16435886|NCT03731221|Active Comparator|Bupi HCl plus saline|PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline
16435887|NCT03731208|Experimental|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
16435888|NCT03731182|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
16435889|NCT03731182|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
16435890|NCT03731169|Active Comparator|TDM Only|This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
16435891|NCT03731169|Experimental|Genotyping + TDM|After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
16435892|NCT03731143|Experimental|study arm|surgical opening the lower punctum using the pig tail probe and a scalpel followed by insertion of self retaining bicanalicular stent (FCI®; Paris, France).
16435893|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
16435894|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
16435895|NCT03731117|Experimental|FST|FUROSEMIDE STRESS TEST
16435896|NCT03731091|Experimental|Calcipotriene/ betamethasone dipropionate topical foam|Topical foam once daily for 4 weeks (28 days)
16435897|NCT03731091|Active Comparator|Enstilar®|Topical foam once daily for 4 weeks (28 days)
16435898|NCT03731091|Placebo Comparator|Placebo|Topical foam once daily for 4 weeks (28 days)
16435899|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
16435900|NCT03731065|Active Comparator|Fructose-maltodextrin ingestion|Ingestion of fructose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
16435901|NCT03731065|Experimental|Fructose-maltodextrin hydrogel ingestion|Ingestion of fructose and maltodextrin (glucose polymers) encapsulated in alginate-pectin hydrogel, drinks at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
16435902|NCT03731065|Active Comparator|Glucose-maltodextrin ingestion|Ingestion of glucose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
16435903|NCT03731052|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
16435904|NCT03731052|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
16435905|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
16435906|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
16435907|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
16435908|NCT03731026|Other|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
16435909|NCT03731026|Experimental|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
16435910|NCT03731026|Experimental|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
16435911|NCT03731013|Experimental|Mediterranean diet (MedDiet)|
16435912|NCT03731013|Experimental|Physical activity (PA)|
16435913|NCT03731013|Experimental|Mediterranean diet and physical activity|
16435914|NCT03731013|No Intervention|Control|
16435915|NCT03731000|Experimental|PHIL® device|Using device
16435918|NCT03730974|Experimental|Experimental arm AB (Ball blanket + TAU)|"Participants will be randomized into either sequence AB or BA each lasting four weeks.
~Patients that are randomized to the AB sequence receive intervention A (Protac Ball BlanketTM 7 kg Flexible) in the first two weeks and treatment B treatment as usual (TAU) in the second period."
16435921|NCT03730961|Experimental|BMS-986231+Diuretic to Placebo+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
16435923|NCT03730935|Experimental|Intervention|Respiratory muscle endurance training (30 minutes of volitional hyperpnoea at a target ventilation of 60-70% of the individual maximal voluntary ventilation for 5 days per week for 4 weeks).
16435924|NCT03730935|Sham Comparator|Sham|Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
16435925|NCT03730922|Experimental|A: Delayed-immediate reconstruction|"Primary Surgery: Skin sparing mastectomy (nipple sparing if appropriate) and axillary surgery according to guidelines or protocol. Reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix.
~Delayed reconstruction: Final reconstruction with any reconstructive procedure - being it autologous or implant-based (one- or two-stage, +/- acellular dermal matrix (ADM)) - is performed 6-12 months after completion of chemotherapy and PMRT. Any contralateral procedure is allowed when doing the delayed surgery, but not in relation to the initial cancer surgery."
16435926|NCT03730922|Active Comparator|B: Delayed reconstruction|"Primary surgery: Total mastectomy and axillary surgery according to guidelines or protocol.
~Delayed reconstruction: 6-12 months after completion of PMRT: final recon-struction with any reconstructive procedure - being it autologous or implant-based (one-or two-stage, +/- ADM). Any contralateral procedure is allowed at any time point after PMRT has been delivered"
16435927|NCT03730909|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
16435928|NCT03730909|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
16435929|NCT03730896|No Intervention|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
16435930|NCT03730896|Experimental|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
16435931|NCT03730883|Experimental|Central line removal at 100ml/kg/day.|"In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.
~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in this group may continue to receive parenteral nutrition via peripheral venous access, depending on the decision of the physician taking care for the infant.
~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
16435932|NCT03730883|Active Comparator|Central line removal at 140 ml/kg/day.|"In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake (full enteral intake). In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.
~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant.
~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
16435933|NCT03730870|Experimental|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
16435934|NCT03730870|No Intervention|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
16435935|NCT03730857|Active Comparator|olanzapine|olanzapine has a dose of 10 to 20 mg daily for 12 weeks
16435936|NCT03730857|Active Comparator|risperidone|risperidone at a dose of 4 to 6 mg daily for 12 weeks
16435937|NCT03730857|Active Comparator|paliperidone|paliperidone at a dose of 6 to 12 mg daily for 12 weeks.
16435938|NCT03730844||Critically ill children|Children admitted to the PICU.
16435939|NCT03730844||Healthy controls|Healthy controls, not admitted to the PICU, without pre-existing medical conditions.
16435940|NCT03730831|Experimental|Intervention|Narrative Exposure Therapy The Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed treatment and will be performed according to the manual of Schauer et al., 2011. In the NET the experiences experienced as traumatic are worked on and placed in the context of the entire life story.
16435941|NCT03730831|No Intervention|Control|Waiting List
16435942|NCT03730818|Experimental|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.
~Each session will consist of:
~10 minutes of warm-up: general mobilisation, walking, active stretching
~40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands
~10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
16435943|NCT03730818|Active Comparator|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.
~Each session will consist of the same structure as the Water-based Exercise Group including:
~10 minutes warm up
~40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)
~10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
16435944|NCT03730805|Experimental|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
16435945|NCT03730805|Experimental|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
16435946|NCT03730805|Experimental|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
16436075|NCT03729869|Placebo Comparator|Placebo Females|35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
16435947|NCT03730805|Experimental|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
16435948|NCT03730805|Experimental|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
16435949|NCT03730805|No Intervention|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
16435950|NCT03730792|Experimental|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
16435951|NCT03730792|No Intervention|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
16435952|NCT03730779|Experimental|O2 recieving|Patients who receive hyperoxia
16435953|NCT03730766|Experimental|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
16435954|NCT03730753|Active Comparator|Control group|Continuous infusion + patient controlled epidural analgesia
16435955|NCT03730753|Experimental|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
16435956|NCT03730740|Experimental|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
16435957|NCT03730727|Active Comparator|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
16435958|NCT03730727|Experimental|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
16435959|NCT03730727|Experimental|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
16435960|NCT03730727|Experimental|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
16435961|NCT03730714|Active Comparator|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
16435962|NCT03730714|Active Comparator|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
16435963|NCT03730714|Active Comparator|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
16435964|NCT03730701|Experimental|Prevention treatment group|Prevention program with 10 week blended intervention utilizing both a digital health app, group-sessions with peers and a interprofessional team of health-care workers chairing 5+1 themed group-sessions as support to change lifestyle habits in to a pattern of activities (behaviors and actions) in everyday life that can promote health and wellbeing and decrease risk for stroke. Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
16435965|NCT03730701|No Intervention|Standard treatment group|Usal care in Swedish primary health care. In addition a Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
16435966|NCT03730688|Experimental|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
16435967|NCT03730675|Experimental|irradiation stent plus TACE|Portal irradiation stent placement will be performed before TACE procedures.
16435968|NCT03730675|Active Comparator|Sorafenib plus TACE|TACE will be performed in patients randomized to Arm B, with sequential sorafenib.
16435969|NCT03730662|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
16435970|NCT03730662|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
16435971|NCT03730662|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
16435972|NCT03730662|Active Comparator|Insulin Glargine|Insulin glargine administered SC once a day.
16435973|NCT03730649|Active Comparator|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
16435974|NCT03730649|Active Comparator|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
16435977|NCT03730623|No Intervention|Control group|Usual care. Conservative management of IC
16435978|NCT03730623|Experimental|Intervention|Supervised exercise
16435979|NCT03730610|Experimental|Exercise intervention|Six months of exercise training
16435980|NCT03730597|Active Comparator|glenosphere 42|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 42. reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
16435981|NCT03730597|Active Comparator|glenosphere 38 ECC|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 38 ECC reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
16435982|NCT03730584|Experimental|Patient with Hereditary Epidermolysis Bullosa|
16435983|NCT03730571|Experimental|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
16435984|NCT03730545|Experimental|EIN group|Enteral formula including not only basic energy components, but also immune components such as omega-3 fatty acids, glutamine (Gln), arginine (Arg), and nucleotide.
16435985|NCT03730545|Active Comparator|SEN group|Enteral formula including only basic energy components.
16435986|NCT03730532|Experimental|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
16435987|NCT03730532|Experimental|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
16435988|NCT03730532|Experimental|Preference CAT|Cognitive Analytic Therapy Guided Self Help
16435989|NCT03730532|Experimental|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
16435990|NCT03730519|Active Comparator|Patients with refractory hypertension|Patients with refractory hypertension which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
16435991|NCT03730519|Active Comparator|Patients with highly variable BP|Patients with symptomatic highly variable blood pressure due to afferent baroreceptor failure which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
16435992|NCT03730506|Experimental|CBCT|
16435993|NCT03730506|Experimental|IOS|
16435994|NCT03730506|Active Comparator|desktop scanner|
16435995|NCT03730493|Experimental|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
16435996|NCT03730493|No Intervention|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
16435997|NCT03730454|Experimental|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
16435998|NCT03730454|Experimental|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
16435999|NCT03730428||pneumonitis group|Patients who developed drug-related pneumonitis after treated with everolims
16436000|NCT03730428||non-pneumonitis group|Patients who didn't develop drug-related pneumonitis after treated with everolims
16436001|NCT03730415|Experimental|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
16436002|NCT03730415|No Intervention|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
16436003|NCT03730402|Active Comparator|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
16436004|NCT03730402|Active Comparator|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
16436005|NCT03730402|Placebo Comparator|saline block|laparoscopic assisted plane block with placebo saline injection
16436006|NCT03730389|Experimental|EPVL Group|In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.
16436007|NCT03730389|No Intervention|Traditional Group|patients with 4-10mm ureteral stone, were treated by traditional treatment methods, including drinking a minimum of 2500 ml water daily and taking more exercise.
16436008|NCT03730376|No Intervention|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
16436009|NCT03730376|Experimental|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
16436010|NCT03730363|Experimental|Pentamidine + ICE|Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
16436011|NCT03730350|Experimental|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
16436012|NCT03730350|No Intervention|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
16436013|NCT03730337|Experimental|ONO-7475 monotherapy|
16436014|NCT03730337|Experimental|ONO-7475 in combination with ONO-4538|
16436015|NCT03730324|Active Comparator|Standard care|Study subject will undergo sampling of plasma and urine biomarkers.
16436016|NCT03730324|Experimental|Magnetic Resonance Imaging.|Prior to biopsies a magnetic resonance imaging scan will be performed.
16436017|NCT03730311|Experimental|Elpida 120 mg once weekly|elsulfavirine 120mg or placebo orally once weekly for 4 weeks
16436018|NCT03730311|Experimental|Elpida 200 mg once weekly|elsulfavirine 200mg or placebo orally once weekly for 4 weeks
16436019|NCT03730311|Experimental|Elpida 280 mg once weekly|elsulfavirine 280mg or placebo orally once weekly for 4 weeks
16436020|NCT03730298|Experimental|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
16436021|NCT03730298|Placebo Comparator|Placebo|Placebo: 1 cpr twice a day orally for 3 months
16436022|NCT03730285|Active Comparator|Telemedicine|Discharge with telemedicine contact to emergency nurse, doctor, and municipality
16436023|NCT03730285|No Intervention|Control|Standard care with 24-48 h observation at emergency unit
16436024|NCT03730259|Experimental|WebTIPS|A Tailored Program for Perioperative Anxiety and Pain (WebTIPS) aims at reducing perioperative anxiety and pain in children via an internet and mobile platform with short message service (SMS) two-way communication between a healthcare provider and patient/parent. The Web-based Tailored Intervention Preparation for Surgery (WebTIPS) program is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent surgical experience, and reduced resource utilization during the surgical episode.
16436025|NCT03730259|No Intervention|Control|Subjects in this attention control group, the Web-based Information (WebINFO) group will not be provided tailored content or access to two-way communication. Instead, this group will only receive basic information regarding the management of perioperative anxiety and postoperative pain via the internet and/or mobile platform.
16436026|NCT03730233|Active Comparator|Tension-free|Hiatal hernia repair by tension-free mesh closure
16436027|NCT03730233|Active Comparator|Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
16436028|NCT03730220||Induction of labour|
16436029|NCT03730207|Experimental|Xpede™ Bone Cement|The subjects in this group will be injected the Xpede™ Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
16436030|NCT03730207|Active Comparator|Mendec Spine Bone Cement|The subjects in this group will be injected the Mendec Spine Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
16436031|NCT03730194|Experimental|Melatonin Only|Participants in this arm will take 3 mg of melatonin 30 minutes before bedtime.
16436032|NCT03730194|Experimental|Bedtime Bank Only|Participants in this arm will utilize the Bedtime Bank, a behavioral sleep intervention.
16436033|NCT03730194|Experimental|Combination (Melatonin+Bedtime Bank)|Participants in this arm will take 3 mg melatonin 30 minutes before bedtime and utilize the Bedtime Bank, a behavioral sleep intervention.
16436034|NCT03730181|Experimental|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
16436035|NCT03730168|Experimental|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .
~The control group were on there prescribed medications only ."
16436036|NCT03730155|Experimental|CCT intervention|CCT intervention. 8 weeks with 2 hours session every week. Homework approx. 25 min. of meditation daily.
16436037|NCT03730155|No Intervention|Control waitlist|No treatment given. Participants only answer questionnaire packages.
16436038|NCT03730142|Experimental|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)
~WXFL10030390 continuous oral dosing (0.2 mg once a day)
~WXFL10030390 continuous oral dosing (0.4 mg once a day)
~WXFL10030390 continuous oral dosing (0.7 mg once a day)
~WXFL10030390 continuous oral dosing (1.1 mg once a day)
~WXFL10030390 continuous oral dosing (1.4 mg once a day)
~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
16436039|NCT03730129|Experimental|Ig replacement|Subjects will receive Hizentra 0.4 mg/kg subq once weekly.
16436040|NCT03730116||the patients with HT and concomitant stable CAD|
16436041|NCT03730103|No Intervention|Historical control group|The investigators will use data from a historical control group discharged on POD 1 after minimally invasive sacrocolpopexy to examine Aim 1 and Aim 2. This is a cohort of 60 women matching our eligibility criteria from a prospective randomized trial of two different types of lightweight polypropylene mesh (IRB #14-354). This study completed recruitment 2017. It consists of a group of women who underwent minimally invasive sacrocolpopexy using the same surgical approaches, at the same institutions
16436042|NCT03730103|Experimental|Same day discharge group|47 women will be recruited for same day discharge after laparoscopic sacrocolpopexy. We will compare aim 1 and 2 (serious adverse events and procedure-related costs) between the two groups
16436043|NCT03730077|Experimental|18F-MISO PET/CT Test Retest|Up to 5 of the 30 intended subjects will participate in a test-retest group that will undergo a second 18F-FMISO scan. Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
16436074|NCT03729869|Experimental|Progesterone Female|35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
16436044|NCT03730077|Experimental|18F-MISO PET/CT|The investigators anticipate enrolling up to 30 subjects who will undergo 18F-FMISO PET/CT.Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
16436045|NCT03730064|Experimental|Bipolar depressed|
16436046|NCT03730051|Active Comparator|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
16436047|NCT03730051|Experimental|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
16436048|NCT03730038|Experimental|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
16436049|NCT03730038|Active Comparator|Life-style modification|
16436050|NCT03730025|Experimental|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
16436051|NCT03730025|Active Comparator|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
16436052|NCT03730012|Experimental|Gilteritinib plus Atezolizumab|Participants will be treated with gilteritinib once daily for the phase 1 portion of the study to establish the recommended dose for the phase 2 portion. In the phase 2 portion, the participants will be treated with gilteritinib once daily at dose determined by the phase 1 portion of the study. Atezolizumab will be administered once every 2 weeks for the phase 1 and 2 portions of the study. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria; whichever occurs first.
16436053|NCT03729999|Experimental|Ultrasonography|Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation.
16436054|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
16436055|NCT03729973|Active Comparator|Group (K)|"Group (K) (n=25): patients nebulized ketamine 50 mg(milgram) (1ml) plus 4ml normal saline.So total volume (5ml).
~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized 1ml ketamine (Ketalar 50mg/VI Solution for Injection) by compressor nebulizing for 15 minutes."
16436056|NCT03729973|Active Comparator|Group (M)|"Group M(n=25) : patients nebulized isotonic magnesium sulfate 250mg (3ml)( 50% Magnesium Sulfate Injection)plus 1ml normal saline.
~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized by compressor nebulizing for 15 minutes."
16436057|NCT03729973|Active Comparator|Group (L)|"Group (L) (n=25): patients nebulized lidocaine 2% 100mg .So total volume (5ml). In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized by compressor nebulizing for 15 minutes."
16436058|NCT03729973|Active Comparator|Group (C)|"Group (C) (n=25): patients nebulized normal saline(0.9%). 5ml .In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized by compressor nebulizing for 15 minutes."
16436059|NCT03729960|Other|LENA|Lena device with Fitbit and Cocooncam being optional
16436060|NCT03729947|Active Comparator|Drain placed|Subfascial drain at end of procedure
16436061|NCT03729947|Placebo Comparator|No drain placed|No drain left at the end of study
16436062|NCT03729934|No Intervention|Control|This arm receives no treatment control.
16436063|NCT03729934|Experimental|Ketone Ester|This arm receives 25 g ketone ester.
16436064|NCT03729934|Experimental|Ketone Salt|This arm receives 25 g ketone salt.
16436065|NCT03729921|Active Comparator|gastric variceal obturation|gastric variceal obturation
16436066|NCT03729921|Experimental|gastric variceal ligation|gastric variceal ligation
16436067|NCT03729908|Experimental|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
16436068|NCT03729908|Active Comparator|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
16436069|NCT03729895|Experimental|patients with OSAS in different degrees|OSAS patients will be treated with an adjustable oral appliance and evaluated with cone-beam computed tomography and polysomnography.
16436070|NCT03729882|Other|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).
~All procedures will be performed under general anesthesia."
16436071|NCT03729882|Other|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.
~All procedures will be performed under general anesthesia."
16436072|NCT03729869|Experimental|Progesterone Males|35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
16436073|NCT03729869|Placebo Comparator|Placebo Males|35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
16436271|NCT03728478|No Intervention|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
16436076|NCT03729856|Experimental|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
16436077|NCT03729856|Experimental|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
16436078|NCT03729856|Experimental|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
16436079|NCT03729843||CBCT and intraoral digital radiography|simulated bone defects will be detected and measured by 2 techniques using CBCT and using intraoral digital radiography and the all measurements will be compared with the gold standard real measurements on the dry jaws
16436080|NCT03729817|Experimental|Submaximal balloon angioplasty|Endovascular intervention with submaximal balloon angioplasty
16436081|NCT03729804|Experimental|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
16436082|NCT03729804|Experimental|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
16436083|NCT03729791|Experimental|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
16436084|NCT03729791|Active Comparator|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
16436085|NCT03729778|Active Comparator|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
16436086|NCT03729778|Active Comparator|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
16436087|NCT03729765|Experimental|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
16436088|NCT03729765|No Intervention|standard care|The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.
16436089|NCT03729752|Active Comparator|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
16436090|NCT03729752|Experimental|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
16436091|NCT03729752|Experimental|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
16436092|NCT03729739|Experimental|QFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR).
~Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice."
16436093|NCT03729739|Active Comparator|FFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR).
~Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice."
16436094|NCT03729726|Experimental|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction & homework support), 30 hours of health (social emotional learning & sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
16436095|NCT03729726|No Intervention|Control|
16436096|NCT03729713|Experimental|Intervention|Computerized Cognitive Rehabilitation
16436097|NCT03729713|Sham Comparator|Placebo|Video game
16436098|NCT03729700|Experimental|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
16436099|NCT03729700|No Intervention|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
16436100|NCT03729687|Experimental|LARCT-US|Short Course Radiation Therapy (5 x 5 Gy in 1 week, scRT) followed by 4 cycles of Pre-operative Chemotherapy using capecitabine and oxaliplatin (CAPOX) and Surgery in High-risk Rectal Cancer
16436101|NCT03729674||Biosimilar|Exposed group
16436102|NCT03729674||Originator (legacy) drug|Reference group
16436103|NCT03729661|Experimental|Breath hold|Patients who receive a breathhold CT- and treatment
16436104|NCT03729648|Experimental|Intervention|This arm of participants will be receiving Expressive Arts Therapy as intervention
16436105|NCT03729648|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a wait-list control group
16436106|NCT03729635|Experimental|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
16436107|NCT03729622|Active Comparator|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
16436272|NCT03728478|Experimental|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
16436108|NCT03729622|Placebo Comparator|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
16436109|NCT03729609||Brentuximab vedotin 1.2 mg/kg (body weight)|Brentuximab vedotin 1.2 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every two weeks (up to 12 times). The dose should be adjusted depend on the participant's condition. Participants received interventions as part of routine medical care.
16436112|NCT03729583|Active Comparator|Control group|The control group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining All patients were medically stable and referred by their caring respiratory consultant
16436113|NCT03729583|Experimental|Active group|The active group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme with breathing retraining exercises. All patients were medically stable and referred by their caring respiratory consultant
16436114|NCT03729570|Experimental|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to & from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
16436115|NCT03729570|No Intervention|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
16436116|NCT03729557||Kidney Donors|
16436117|NCT03729557||Control group|
16436118|NCT03729544|Experimental|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
16436119|NCT03729544|No Intervention|No Alert|No provider notification
16436120|NCT03729531|Active Comparator|Conventional|The perivascular tissue is stripped off when harvesting the vein, and saline will be used to distend the vein to check for leakage.
16436121|NCT03729531|Experimental|No-touch|The vein will be harvested by frequency electrotome and the perivascular tissue will be preserved, the vein will not be distended.
16436122|NCT03729518|Experimental|Arm 1|All patients will have the volume treated and radiation dose delivered to the regional lymphatics decreased according to the characteristics of the primary site and involved lymph nodes. The high risk neck will receive 50 Gy instead of 60 Gy, and the treated volume of the contralateral low risk neck will be reduced and receive only 45 Gy.
16436123|NCT03729505|Active Comparator|Pyloric injection of magnesium sulfate and lidocaine mixture|After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine
16436124|NCT03729505|Active Comparator|Pyloric injection of saline|After sleeve gastrectomy, the pylorus is injected with normal saline
16436125|NCT03729492|Other|CTEPH/CTED work-up|
16436126|NCT03729479|Experimental|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
16436127|NCT03729479|Experimental|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
16436128|NCT03729479|Experimental|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
16436129|NCT03729479|Experimental|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
16436130|NCT03729466|No Intervention|Control group|There will be no intervention for 8 weeks
16436131|NCT03729466|Experimental|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
16436132|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
16436133|NCT03729440||corrosive patients|
16436134|NCT03729427|Experimental|Treatment Arm|ESP Block
16436135|NCT03729427|No Intervention|Control Arm|Standard of Care
16436136|NCT03729414|Active Comparator|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
16436137|NCT03729414|Experimental|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
16436138|NCT03729401|Active Comparator|DAPT - Aspirin and Ticagrelor|As per results of the PEGASUS trial, patients will be treated with aspirin 81mg daily and ticagrelor 60mg twice daily
16436139|NCT03729401|Experimental|Ticagrelor Monotherapy|Patients will only receive ticagrelor 60mg twice daily.
16436140|NCT03729401|Experimental|Personalized Therapy Arm|Patients allocated to the personalized arm (PA) will have a DAPT score calculated. For those with a score of < 2, only aspirin at 81 mg daily will be prescribed. For those with a score of ≥ 2, P2Y12 inhibitor choice will be dependent on carrier status of CYP2C19 LOF alleles. Heterozygous or homozygous carriers will receive be prescribed ticagrelor 60mg twice daily and non-carriers with will be prescribed clopidogrel 75mg daily.
16436141|NCT03729375|Experimental|10cc Patients|Intervention: Group 1 will receive 10cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
16436142|NCT03729375|Active Comparator|20cc Patients|Intervention: Group 2 will receive 20cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
16436143|NCT03729362|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
16436144|NCT03729362|Active Comparator|alglucosidase alfa/placebo|Participants received alglucosidase alfa co-administered with placebo capsules.
16436146|NCT03729336|Experimental|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
16436147|NCT03729336|Placebo Comparator|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
16436148|NCT03729323|Experimental|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
16436149|NCT03729323|Active Comparator|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
16436150|NCT03729310|Other|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
16436151|NCT03729310|Other|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
16436152|NCT03729297|Experimental|cabozantinib|cabozantinib 60 mg tablets OD
16436153|NCT03729284|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
16436154|NCT03729284|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
16436155|NCT03729271|Experimental|Rifaximin and breath tests|Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
16436156|NCT03729258|Experimental|Cefpodoxime 200 (b.i.d)|
16436157|NCT03729258|Active Comparator|Cefpodoxime 400 (q.d)|
16436158|NCT03729245|Experimental|Combination of bempegaldesleukin + nivolumab|Patients in Arm A will receive bempegaldesleukin in combination with nivolumab.
16436159|NCT03729245|Active Comparator|sunitinib or cabozantinib|Patients in Arm B will receive the Investigator's choice of either one of two treatment options.
16436160|NCT03729219|Experimental|ETVAX|Contains inactivated Tetravalent ETEC vaccine, 10 ug Double-mutant heat-labile toxin (dmLT) and effervescent power for oral solution administered twice 14 (plus minus 7) days intervals.
16436161|NCT03729219|Placebo Comparator|Placebo|Effervescent power for oral solution administered wice 14 (plus-minus 7) days intervals
16436162|NCT03729206|Experimental|Sublingual microscopy|
16436163|NCT03729193||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 soccer players.
16436164|NCT03729193||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 basketball players.
16436165|NCT03729193||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 volleyball players.
16436166|NCT03729193||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 archers.
16436167|NCT03729193||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 kickboxers.
16436168|NCT03729193||table tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 table tennis athletes.
16436169|NCT03729193||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 runners.
16436170|NCT03729193||field tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 field tennis athletes.
16436171|NCT03729180|Other|Pain Cohort|Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
16436172|NCT03729180|Experimental|Pharmacogenomic (PGx) Arm [Randomization Arm 1]|All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
16436173|NCT03729180|Other|Control Arm [Randomization Arm 2]|All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
16436174|NCT03729167|Experimental|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
16436175|NCT03729154|Experimental|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
16436176|NCT03729154|No Intervention|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
16436177|NCT03729141|Experimental|Added Cholesterol|
16436178|NCT03729141|Active Comparator|No Added Cholesterol|
16436179|NCT03729128|Experimental|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
16436180|NCT03729128|Placebo Comparator|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
16436181|NCT03729115|Other|Screening Arm|Enrolled patients will undergo Magnetic Resonance Imaging (MRI) every 6 months (2x/year) in addition to an annual screening mammogram.
16436182|NCT03729102|Active Comparator|Control group|Persons who had received primary immunization
16436183|NCT03729102|Experimental|Study group|Persons who had received primary immunization and later received booster vaccination for at least 3 times
16436184|NCT03729089|Experimental|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
16436185|NCT03729089|No Intervention|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
16436186|NCT03729076|Experimental|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
16436187|NCT03729076|Active Comparator|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
16436188|NCT03729063|Experimental|Twice daily expired CO measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
16436189|NCT03729063|Active Comparator|Control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
16436190|NCT03729050|Experimental|Intervention with rehabilitation coordinator|
16436191|NCT03729050|No Intervention|Control|
16436192|NCT03729037|Experimental|Serious game|Intervention: CPR self-training with serious game.
16436193|NCT03729037|Active Comparator|Training video|Intervention: CPR self-training with Keynote presentation with the addition of voice-over narration.
16436194|NCT03729024|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
16436195|NCT03729011|Active Comparator|Volatile anesthesia group|
16436196|NCT03729011|Active Comparator|TIVA group|
16436197|NCT03728998|Other|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
16436198|NCT03728985|Active Comparator|Primary Study Arm|TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)
16436199|NCT03728985|Experimental|Secondary Study Arm|TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)
16436200|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)|
16436201|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)|
16436202|NCT03728959|Experimental|Liquid meal (Nutridrink)|Liquid meal (Nutridrink)
16436203|NCT03728959|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
16436204|NCT03728959|Experimental|GLP-2|Glucagon-like peptide-2
16436205|NCT03728959|Experimental|Placebo (saline)|Placebo (saline)
16436206|NCT03728946|Experimental|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
16436207|NCT03728946|No Intervention|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
16436208|NCT03728933|Experimental|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
16436209|NCT03728933|Experimental|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
16436210|NCT03728933|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
16436561|NCT03726424||control|patients not carrying the pathogenic mutation(s)
16436211|NCT03728907|Active Comparator|Audiologist-adjusted first|This arm will complete the field trial with the audiologist-adjusted fitting first, followed by the user-adjustment fitting.
16436212|NCT03728907|Experimental|User-adjusted first|This arm will complete the trial with the user-adjusted fitting first followed by the audiologist-adjusted fitting.
16436213|NCT03728894|Active Comparator|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
16436214|NCT03728894|Experimental|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
16436215|NCT03728881|Experimental|Group I (Cervarix)|Participants 9-14 years old receive Cervarix IM at baseline.
16436216|NCT03728881|Active Comparator|Group II (Gardasil)|Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
16436217|NCT03728868|Placebo Comparator|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
16436218|NCT03728868|Active Comparator|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
16436219|NCT03728868|Active Comparator|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
16436220|NCT03728855|No Intervention|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
16436221|NCT03728855|Experimental|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
16436222|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
16436223|NCT03728829||Trastuzumab+TP neoadjuvant chemotherapy|100 cases of patients with stage II-III HER2+ breast cancer will be assigned participants to neoadjuvant treatment regimen, including Trastuzumab combined with Docetaxel and Carboplatin. 5-10 ml peripheral blood will be collected from each patient and formalin fixed paraffin embedded (FFPE) blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals before and after neoadjuvant therapy. The genomic characteristics between patients achieved pCR and non-pCR will be analyzed. The clinically actionable mutations for future therapy instructions will be identified.
16436224|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
16436225|NCT03728803|Sham Comparator|Sham inspiratory muscle training|"Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance.
~The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks."
16436226|NCT03728803|Active Comparator|Active inspiratory muscle training|Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
16436227|NCT03728790|No Intervention|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
16436228|NCT03728790|Experimental|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
16436229|NCT03728777|Placebo Comparator|Placebo|
16436230|NCT03728777|Experimental|Resveratrol|Over the counter supplement
16436231|NCT03728764|Other|single arm|
16436232|NCT03728751|Experimental|study group|Study group receiving dry needling and pupil diameter will be studied up to 23 minutes after needle placement.
16436233|NCT03728738|Experimental|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
16436234|NCT03728738|Active Comparator|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
16436235|NCT03728725||TB case detection Group|Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.
16436407|NCT03727464|Experimental|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
16436236|NCT03728725||RIF-resistance MTB Group|"An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.
~/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations."
16436237|NCT03728712||Never smokers|Participants with no history of cigarette smoking
16436238|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
16436239|NCT03728686|Experimental|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
16436240|NCT03728686|Active Comparator|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
16436241|NCT03728686|No Intervention|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
16436242|NCT03728673|Experimental|escitalopram|
16436243|NCT03728660|Experimental|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
16436244|NCT03728660|Active Comparator|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
16436245|NCT03728647|Experimental|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
16436246|NCT03728647|Active Comparator|regular health education|The regular (traditional) education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
16436247|NCT03728634|Experimental|AKCEA-TTR-LRx|Single and multiple doses of AKCEA-TTR-LRx administered subcutaneously
16436248|NCT03728634|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator administered subcutaneously
16436249|NCT03728621|Experimental|Individual-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
16436250|NCT03728621|Experimental|Group-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
16436251|NCT03728608|Active Comparator|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
16436252|NCT03728608|Active Comparator|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
16436253|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:
~venepuncture
~spirometry."
16436254|NCT03728582|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be verb naming therapy in a sentence context. This will be followed by sham tDCS plus speech-language therapy after a 2 month washout period.
16436255|NCT03728582|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. Language therapy will be verb naming therapy in a sentence context. This will be followed by active tDCS plus speech-language therapy after a 2 month washout period.
16436256|NCT03728569|Other|Subjects over the age of 70 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
16436257|NCT03728569|Other|Subjects between 18 and 30 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
16436258|NCT03728556|Experimental|CS1001monoclonal antibody|
16436259|NCT03728556|Placebo Comparator|CS1001 Placebo|
16436260|NCT03728543|Experimental|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
16436261|NCT03728543|Active Comparator|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
16436262|NCT03728530|Experimental|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
16436263|NCT03728530|No Intervention|Control Group|The participants from control group did not perform any exercise.
16436264|NCT03728517||Subjects who undergo gynecologic surgery|Subjects who will undergo gynecologic surgery via vaginally, laparoscopic , or robotic who require observation or inpatient stay overnight. This group will receive pain medication in the hospital and will also be discharged home with pain medication.
16436265|NCT03728504|Experimental|ASN002 40 mg|40 mg ASN002
16436266|NCT03728504|Experimental|ASN002 80 mg|80 mg ASN002
16436267|NCT03728504|Placebo Comparator|Placebo oral tablet|Matching placebo for ASN002 doses
16436268|NCT03728491|Experimental|Healthy Figurant|Hands-on training on healthy figurants for gaining competence in TUS
16436269|NCT03728491|Experimental|Simulator|Hands-on training on US Mentor simulator for gaining competence in TUS
16436270|NCT03728491|No Intervention|Controls|Controls with no hands-on training
16436273|NCT03728465|Experimental|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
16436274|NCT03728439|Experimental|Before|LED applications at the beginning, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
16436275|NCT03728439|Experimental|Interval|The LED therapy applied in the tests interval will be performed after the first block of tests, with a maximum duration of 10 minutes and dose of 8 J/cm2. Then the second block of maximum tests will be performed.
16436276|NCT03728439|Experimental|After|LED applications at the end will be performed 10 minutes after the second battery of tests, also with 8 J/cm2 and in the same muscles irradiated in the other moments of application.
16436277|NCT03728439|No Intervention|Baseline|On that day, participants will not receive any intervention.
16436278|NCT03728426|Experimental|Letermovir|Open label letermovir will be administered daily for up to 12 weeks. The study allows an optional additional 12 weeks of treatment for secondary prophylaxis if clinically indicated.
16436279|NCT03728413|Other|Elderly Non-smoking|RSV A Memphis 37 will be given as intra-nasal drops.
16436280|NCT03728413|Other|Elderly ex and current smokers|RSV A Memphis 37 will be given as intra-nasal drops.
16436281|NCT03728413|Other|Young non-smokers|RSV A Memphis 37 will be given as intra-nasal drops.
16436282|NCT03728400||Patients in neurovascular intensive care|During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.
16436283|NCT03728387|Experimental|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
16436284|NCT03728374|Experimental|Anlotinib|
16436285|NCT03728361|Experimental|Treatment (nivolumab, temozolomide)|Patients receive nivolumab IV on day 1 of a 28 day cycle. Patients also receive temozolomide PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16436286|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
16436287|NCT03728335|Experimental|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16436288|NCT03728322|Experimental|iHSCs treatment group|
16436289|NCT03728296|Experimental|islet body treatment group|
16436290|NCT03728283|Active Comparator|Conventional Implant placement|conventional implant placement following the manufacturer's instructions
16436291|NCT03728283|Experimental|Implant and Connective tissue grafting|implant placement in combination with connective tissue grafting
16436292|NCT03728270|Experimental|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.
~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.
~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.
~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.
~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.
~A multilayer closure of the incisions will be accomplished using Vicryl sutures."
16436293|NCT03728270|Active Comparator|Inlay Autogenous Bone Graft|"A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.
~One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.
~After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.
~The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
16436294|NCT03728257|Experimental|LTGO-Home Based Exercise|The lung transplant recipient will receive LTGO- Home Based Exercise, a behavioral exercise intervention that consists of in-home exercise training integrated with behavioral coaching using tele-rehabilitation.
16436295|NCT03728257|Active Comparator|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
16436296|NCT03728244|Experimental|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
16436297|NCT03728244|Experimental|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
16436298|NCT03728244|No Intervention|negative control group|Patients scheduled for free gingival graft harvesting
16436299|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).
~Functional Performance Tests:(12)
~Fatigue severity scale (13).
~Short-Form Health Survey 36 (SF-36) (14).
~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).
~frequency intensity time (FIT) index of kasari (16). :* Disease activity Score(DAS)(17)"
16436300|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).
~Functional Performance Tests:(12)
~Fatigue severity scale (13).
~Short-Form Health Survey 36 (SF-36) (14).
~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).
~frequency intensity time (FIT) index of kasari (16). :* SLE Disease activity Index(SLEDAI)(18)"
16436301|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).
~Functional Performance Tests:(12)
~Fatigue severity scale (13).
~Short-Form Health Survey 36 (SF-36) (14).
~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).
~frequency intensity time (FIT) index of kasari (16)."
16436302|NCT03728218|Experimental|Orthokeratology Contact lenses|
16436303|NCT03728218|Experimental|Soft Multifocal Contact lenses|
16436304|NCT03728205|Experimental|Observational|All 10 pilot subjects will be taking yoga
16436305|NCT03728192|Experimental|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:
~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
16436306|NCT03728192|No Intervention|Untreated group|H357 and HeLa cell line without any drug intervention.
16436307|NCT03728179|Experimental|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
16436308|NCT03728179|Experimental|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
16436309|NCT03728179|Experimental|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
16436310|NCT03728179|Experimental|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
16436311|NCT03728179|Experimental|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
16436312|NCT03728179|Experimental|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
16436313|NCT03728179|Experimental|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
16436314|NCT03728166|Experimental|Alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
16436315|NCT03728166|No Intervention|No Alert|No notification to the provider.
16436316|NCT03728153|Experimental|20mg dose|Fluoxetine 20 MG Oral Tablet
16436317|NCT03728140|Experimental|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
16436318|NCT03728140|No Intervention|New Culture Medium|embryo transfer with new culture medium in IVF-ET
16436319|NCT03728127|Experimental|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
16436320|NCT03728127|Active Comparator|DicaBr group (DCB)|Brazilian cardioprotective diet
16436321|NCT03728114|Experimental|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
16436322|NCT03728114|Sham Comparator|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
16436323|NCT03728114|Experimental|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
16436324|NCT03728114|Sham Comparator|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
16436325|NCT03728101|Experimental|Single arm|"Dabigatran etexilate
~Simvastatin + Dabigatran etexilate"
16436326|NCT03728088||Surgical Candidates|"Under- and postgraduate candidates applying for surgical training in general surgery, orthopedics, urology or plastic surgery at Ghent University Hospital.
~All candidates will complete the rating scales concerning non-technical attributes in the period prior to the surgical selections."
16436327|NCT03728088||Surgical trainees|"Surgical trainees active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital or an affiliated non-academic training hospital.
~All trainees will be invited to participate in the study. Trainees who agree to participate will complete the rating scales concerning non-technical attributes."
16436328|NCT03728088||Surgical staff|"Surgical staff members active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital.
~All surgical staff members will be invited to participate in the study. Surgical staff members who agree to participate will complete the rating scales concerning non-technical attributes."
16436329|NCT03728075|No Intervention|Control group|standard protocol for cardiac rehabilitation
16436330|NCT03728075|Experimental|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
16436331|NCT03728062|Experimental|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
16436332|NCT03728062|Experimental|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
16436333|NCT03728062|No Intervention|Control group|Participants continue their normal lunch routine.
16436334|NCT03728049|Experimental|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
16436335|NCT03728049|Other|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
16436336|NCT03728023|Experimental|AZD4205|Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days
16436337|NCT03728023|Placebo Comparator|Placebo|placebo single dose in SAD and once daily for 14 days
16436338|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
16436339|NCT03727997||AKI patients stage 3|
16436340|NCT03727971|Active Comparator|omalizumab arm|The treatment is initiated with one injection with weight and serum-Immunoglobulin E balanced omalizumab one time per cyclus
16436341|NCT03727971|Placebo Comparator|placebo arm|Participants will be administered placebo (NaCl), one time per cyclus
16436342|NCT03727958|Active Comparator|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
16436343|NCT03727958|Active Comparator|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
16436344|NCT03727945|Experimental|abdominopelvic exercise and posture|N=21 received supervised physiotherapy abdominopelvic exercise previous postural correction.
16436345|NCT03727945|Experimental|abdominopelvic exercise|N=21 received supervised physiotherapy abdominopelvic exercise.
16436346|NCT03727932|Other|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
16436347|NCT03727919|Experimental|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
16436348|NCT03727919|Experimental|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
16436349|NCT03727919|No Intervention|Control Group|N = 20 Intervention = standard care including conventional physiotherapy
16436350|NCT03727906|Other|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.
~Interventions (order is randomly assigned):
~no pre-sleep arousal manipulation night;
~pre-sleep arousal down-regulation night
~pre-sleep arousal up-regulation night."
16436351|NCT03727906|Other|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.
~Interventions (order is randomly assigned):
~no pre-sleep arousal manipulation night;
~pre-sleep arousal down-regulation night
~pre-sleep arousal up-regulation night."
16436352|NCT03727893|Active Comparator|Roller-based intervention Group (IG)|A group participating in a high-intensity exercise on a roller-based system.
16436353|NCT03727893|Placebo Comparator|Control Group (CG)|A group participating in an independent workout program at an accessible community-based fitness facility.
16436354|NCT03727880|Experimental|Arm A - Pembrolizumab and Defactinib|
16436355|NCT03727880|Experimental|Arm B - Pembrolizumab|
16436356|NCT03727867|Placebo Comparator|Drug group|Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
16436357|NCT03727867|Experimental|Drug plus SBRT group|After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
16436358|NCT03727854|Experimental|Premeal protein group|Premeal protein enriched bar with dietary modification
16436359|NCT03727854|Other|Dietary modofication only group|Dietary modification only
16436360|NCT03727841|Experimental|1/Arm 1|Marizomib at days 1, 8, and 15 of each 28-day cycle
16436361|NCT03727841|No Intervention|P/Pregnancy Evaluation|Data collection on pregnancy, birth and Health of Child
16436362|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
16436363|NCT03727828||healthy control|
16436364|NCT03727815|Experimental|Mindfulness Pain Management Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target pain management through mindfulness.
16436365|NCT03727815|Experimental|Mindfulness Self Esteem Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target self esteem through mindfulness.
16436366|NCT03727815|No Intervention|Non-intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
16436367|NCT03727802|Experimental|TRK-250|
16436368|NCT03727802|Placebo Comparator|Placebo|
16436369|NCT03727789|Experimental|Treatment (CBL0137)|Patients receive FACT complex-targeting curaxin CBL0137 IA over 15 minutes.
16436370|NCT03727776|Experimental|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
16436371|NCT03727776|No Intervention|Controls|Subjects will be managed per the standard of care.
16436372|NCT03727763|Experimental|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
16436373|NCT03727750|Experimental|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
16436374|NCT03727737|No Intervention|Sham|Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
16436375|NCT03727737|Active Comparator|ACTIVE|Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
16436377|NCT03727711|Experimental|Home Treatment|Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
16436378|NCT03727711|Active Comparator|Hospital Treatment|Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
16436379|NCT03727698|Experimental|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
16436380|NCT03727685|No Intervention|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
16436381|NCT03727685|Active Comparator|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
16436382|NCT03727672||Tension type headache patients|30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
16436383|NCT03727672||Migraine patients|30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
16436384|NCT03727672||age matched controls|30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
16436385|NCT03727659|Experimental|SHADE therapy + CONNECT FaceBook support|SHADE is a 10-week, 10-session, computerized CBT/MET intervention for Cannabis Use Disorder and depression. At each visit, a study clinician meets with participants for a 'check-in' session, which includes: review of homework; plans for completing homework; suicide risk and mood assessment. The CONNECT FB intervention component will facilitate social support for between-session homework and CBT skills practice for managing depression and preventing relapse, and bolstering motivation to change. Daily posts will be delivered. Only those participating in the study will know about the existence of this group and will be able to access it. A weekly real-time, Facebook chat session will be held to provide feedback concerning homework practice or answer questions.
16436386|NCT03727646|Experimental|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:
~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)
~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily
~Washout Day of LVAD Surgery and/or Day 15: None"
16436387|NCT03727646|No Intervention|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
16436388|NCT03727633|Experimental|Treatment arm|hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol
16436389|NCT03727620|Experimental|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
16436390|NCT03727620|Active Comparator|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
16436391|NCT03727607|Active Comparator|Gass|DESFLURANE ANESTHESIA
16436392|NCT03727607|Active Comparator|TIVA|TOTAL INTRAVENOUS ANESTHESIA
16436393|NCT03727568|Experimental|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
16436394|NCT03727568|Experimental|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from <5 seconds for the following biopsies.
16436395|NCT03727555|Experimental|Lentivirus-mediated delivery of ABCD1 to the CNS.|Intracerebral injection with lentiviral TYF-ABCD1 vector carrying the functional gene
16436396|NCT03727542|Experimental|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
16436397|NCT03727529|Experimental|Intervention group|
16436398|NCT03727529|Active Comparator|Control group|
16436399|NCT03727516||patients undergone elbow surgery|Patients undergone elbow surgery at routine follow up at 2 or 6 months
16436400|NCT03727503|Other|group/cohort|operated patients from cardiac surgery. Once they arrived in the ICU, we will measure PPV with the capstesia and the PICCO device at baseline, and after a volume expansion of 500 ml of crystalloid.
16436401|NCT03727490|Active Comparator|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
16436402|NCT03727490|Experimental|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
16436403|NCT03727464|Experimental|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
16436404|NCT03727464|Experimental|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
16436405|NCT03727464|Active Comparator|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
16436406|NCT03727464|Experimental|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
16436408|NCT03727464|Active Comparator|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
16436409|NCT03727451|Experimental|PH-Pulmonary Fibrosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
~Part 2: Optional open label long term extension at the optimal dose as identified in Part 1"
16436410|NCT03727451|Experimental|PH-Sarcoidosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
~Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1"
16436411|NCT03727438|Experimental|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
16436412|NCT03727438|Active Comparator|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
16436413|NCT03727425|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
16436414|NCT03727412|Active Comparator|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
16436415|NCT03727412|Placebo Comparator|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
16436416|NCT03727386|Experimental|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
16436417|NCT03727386|Placebo Comparator|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
16436418|NCT03727360|Experimental|Exercise Training|Group exercise and treadmill walking
16436419|NCT03727360|Active Comparator|Flexibility Control|Group exercise and flexibility exercise
16436420|NCT03727347|Experimental|InSeca Stylus Treatment Group|Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
16436421|NCT03727334|Experimental|Treatment|For the treatment arm, the participants will complete the intervention protocol following the first in-person study visit 6 months post-injury. The intervention involves 16 weeks of online, in-home spatial navigation training. During the 16 weeks, the participant will complete exercises for 1 hour/day, every other day.
16436422|NCT03727334|No Intervention|Control|The control arm participants will receive their typical standard of care; they will not complete the intervention but will complete all of the in-person visits at the same post-injury time-points as the treatment group.
16436423|NCT03727321|Placebo Comparator|Placebo|Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
16436424|NCT03727321|Experimental|Fecal Microbial Transplant and cellulose|"Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
~Cellulose x 6weeks"
16436425|NCT03727321|Experimental|Fiber|Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
16436426|NCT03727321|Experimental|Fecal Microbial Transplant and Fiber|"Fecal Microbial Transplant
~Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS)."
16436427|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.
~- Medical abortion pills sourced from pharmacies"
16436428|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.
~- Medical abortion pills sourced from health clinics"
16436429|NCT03727295|Experimental|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
16436430|NCT03727295|Experimental|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
16436431|NCT03727295|Placebo Comparator|The placebo group|60 cases, placebo, 3 times / day, oral
16436432|NCT03727282|Other|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
16436433|NCT03727282|Experimental|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
16436434|NCT03727269|Experimental|Wii Fit Training Experimental Group|receiving Wii fit based abdomino-pelvic training
16436435|NCT03727269|Active Comparator|Conventional Training Control Group|receiving conventional pelvic floor exercises.
16436436|NCT03727256|Active Comparator|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
16436437|NCT03727256|Active Comparator|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
16436438|NCT03727243||Septic/septic shock patients|Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.
16436439|NCT03727243||Non-septic/sterile inflammation patients|Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.
16436440|NCT03727243||Healthy control patients|Active comparator group.
16436441|NCT03727230|Other|"Asia type DEL recipients"|"To identify Asia type DEL patients by phenotyping and gentoyping methods in the Chinese recipients and then blood transfusion of D+ blood rather than the rare D negative blood to the identified Aisa type DEL recipients."
16436442|NCT03727217|Experimental|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
16436443|NCT03727204||Aarhus University Hospital|100 patients undergoing on-pump cardiac surgery at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
16436444|NCT03727204||Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand|50 patients undergpoing on-pump cardiac surgery at at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
16436445|NCT03727191|Active Comparator|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
16436446|NCT03727191|Experimental|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
16436447|NCT03727165|Active Comparator|Continuous infusion|Patients with continuous infusion enteral nutrition in the intensive care unit at San Ignacio University Hospital
16436448|NCT03727165|Experimental|Cyclic infusion|Patients formulated with cyclic enteral nutrition infusion, administrated at night hours, from 4pm until 7am.
16436449|NCT03727152|Other|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
16436450|NCT03727139||Rasagiline 1 mg|Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
16436451|NCT03727126|Experimental|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
16436452|NCT03727126|Active Comparator|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
16436453|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
16436454|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
16436455|NCT03727100|Active Comparator|Clonidine Micropellets|single dose injection into the lumbar epidural space
16436456|NCT03727100|Sham Comparator|Sham Control|non-epidural needle placement
16436457|NCT03727087||Melanoma|Subjects with clinically confirmed melanoma or high suspicion of a primary malignancy of melanoma based on skin exam or imaging and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16436458|NCT03727074|Experimental|5-FU Cream|topical cream
16436459|NCT03727074|Active Comparator|Efudex®|topical cream
16436460|NCT03727074|Placebo Comparator|Vehicle|topical cream
16436461|NCT03727061|Active Comparator|Arm A (standard of care chemotherapy at doctor's discretion)|Patients receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion
16436462|NCT03727061|Experimental|Arm B(porfimer sodium, I-PDT, SoC chemotherapy)|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later. Patients also receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion at either 7 days, 14 days, or 28 days later.
16436463|NCT03727048|Active Comparator|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
16436464|NCT03727048|Experimental|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
16436465|NCT03727035||Group I|Group I :40 Generalized chronic periodontitis subjects without type II diabetes mellitus
16436466|NCT03727035||Group II|Group II: 40 Generalized chronic periodontitis subjects diagnosed with type II diabetes mellitus
16436467|NCT03727022|Experimental|0.07 mg SM04690|Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
16436468|NCT03727022|Placebo Comparator|Vehicle|Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
16436469|NCT03727009||Hematologic Malignancy|Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
16436470|NCT03726996|Experimental|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
16436471|NCT03726983|Experimental|eHMP experimental group|"The experimental group received health management support and counseling,including:
~GDM health care knowledge
~self-awareness of health
~self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)
~participation in discussions or browsing forums
~healthy lifestyle guidance and counseling
~reminder systems
~a token system of earning points in exchange for prizes."
16436472|NCT03726983|No Intervention|Control group|only received usual care
16436473|NCT03726970|Experimental|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
16436474|NCT03726970|Experimental|MAR tool|MAR option in the software off and on
16436475|NCT03726957|Experimental|Intervention group|The intervention arm included households which received improved cookstoves
16436476|NCT03726957|No Intervention|Control group|The control group included households, which did not receive improved cookstoves, and cooked in their usual traditional cookstoves.
16436477|NCT03726944|Other|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
16436478|NCT03726944|Other|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
16436479|NCT03726944|Other|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
16436480|NCT03726944|Other|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
16436481|NCT03726931|Experimental|[18F]FES|All patients will receive an additional PET/CT scan: [18F]FES PET/CT scan.
16436482|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
16436483|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
16436484|NCT03726905|Experimental|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
16436485|NCT03726905|Sham Comparator|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
16436486|NCT03726892|Active Comparator|The SYNERGY stent|
16436487|NCT03726892|Active Comparator|Xience|
16436488|NCT03726879|Experimental|Atezolizumab +ddAC-PacHP|Participants will receive atezolizumab (atezo) 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 & cyclophosphamide 600 mg/m2 IV), followed by atezo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8mg/kg IV loading dose) Q3W for 4 cycles, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant and adjuvant setting: atezo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezo+trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL dated 3 Feb 2021 treatment with atezo must be discontinued.
16436489|NCT03726879|Placebo Comparator|Placebo + ddAC-PacHP|Participants will receive placebo 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 & cyclophosphamide 600 mg/m2 IV), followed by placebo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W for 4 cycles & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant & adjuvant setting: placebo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL, dated 3 Feb 2021 treatment with placebo must be discontinued.
16436490|NCT03726866|Experimental|Sequence 1|Sequence 1
16436491|NCT03726866|Experimental|Sequence 2|Sequence 2
16436492|NCT03726866|Experimental|Sequence 3|Sequence 3
16436493|NCT03726866|Experimental|Sequence 4|Sequence 4
16436494|NCT03726866|Experimental|Sequence 5|Sequence 5
16436495|NCT03726866|Experimental|Sequence 6|Sequence 6
16436496|NCT03726853|Experimental|CKD-497 200mg|CKD-497 200mg
16436497|NCT03726853|Experimental|CKD-497 300mg|CKD-497 300mg
16436498|NCT03726853|Active Comparator|Active Comparator|compartor
16436499|NCT03726853|Placebo Comparator|Placebo|CKD-497 placebo and comparator placebo
16436500|NCT03726840|No Intervention|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
16436501|NCT03726840|Experimental|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
16436502|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
16436503|NCT03726814|Experimental|EPC treatment group|
16436504|NCT03726801|Experimental|Stratum C|"N 32 C
~Women who are going to be mastectomized, conservate surgery and ostomy who attend the health education together with their immediate family member prior to surgery"
16436505|NCT03726801|Placebo Comparator|Stratum E|"N 32 E
~Patients who are going to be subjected to a mastectomized, conservate surgery and ostomy who come alone to the health education prior to surgery"
16436506|NCT03726788|Experimental|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
16436507|NCT03726788|Experimental|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
16436508|NCT03726788|Active Comparator|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
16436509|NCT03726775|Experimental|RT-durvalumab|durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.
16436510|NCT03726762|Experimental|Diet Beverages|'Diet beverages' after the main meal
16436511|NCT03726762|Experimental|Water|'Water' after the main meal
16436512|NCT03726749|Experimental|Tocilizumab and prednisone|"TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.
~Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
16436513|NCT03726736|Experimental|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
16436514|NCT03726736|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
16436515|NCT03726710|Experimental|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
16436516|NCT03726697|Experimental|Tahneek|Infants receiving a single dose of soft date, prepacked by the pharmacy containing glucose equivalent to 200mg/kg at 1 hour after birth in the nursery.
16436517|NCT03726697|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
16436518|NCT03726684|Experimental|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
16436519|NCT03726671|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16436520|NCT03726671|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16436521|NCT03726671|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16436560|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
16436522|NCT03726671|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16436523|NCT03726671|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16436524|NCT03726671|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16436525|NCT03726658|Experimental|AGN-241751 3mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
16436526|NCT03726658|Experimental|AGN-241751 10mg|AGN-241751, oral administration, once per day
16436527|NCT03726658|Experimental|AGN-241751 25mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
16436528|NCT03726658|Placebo Comparator|Placebo|Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
16436529|NCT03726645|Active Comparator|Study group|Allogeneic fecal microbiota transplantation (from donor)
16436530|NCT03726645|Placebo Comparator|Control group|Autologous fecal microbiota transplantation (own stool)
16436531|NCT03726619|Experimental|e-CHEC-uP|Group 1 will receive the education study intervention after the first baseline questionnaire. Participants will be asked to take part in a one-time, 1 to 1.5-hour online education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker to help address any barriers in order to help receive a mammogram or a Pap test.
16436532|NCT03726619|Active Comparator|CHEC-uP|Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
16436533|NCT03726606|Experimental|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
16436534|NCT03726606|Active Comparator|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
16436535|NCT03726593|Experimental|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
16436536|NCT03726593|Experimental|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
16436537|NCT03726593|Experimental|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
16436538|NCT03726580||control group|regional anesthesia
16436539|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
16436540|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
16436541|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
16436542|NCT03726567|Active Comparator|Bariatric surgery group|Patients who are undergoing bariatric surgery for weight loss
16436543|NCT03726567|No Intervention|Non bariatric surgery group|Patients who are undergoing abdominal surgery for non-weight loss reasons
16436544|NCT03726554||Comp. Rev. Porous Augmented Glenoid|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Porous Augmented Glenoid.
16436545|NCT03726554||Comp. Rev. Mini Humeral Tray|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Mini Humeral Tray
16436546|NCT03726541|Experimental|Early physiotherapy group|breathing exercise incentive spirometry training ambulation coughing
16436547|NCT03726515|Experimental|CART-EGFRvIII + Pembrolizumab|
16436548|NCT03726502|Active Comparator|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
16436549|NCT03726502|Placebo Comparator|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
16436550|NCT03726502|Active Comparator|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
16436551|NCT03726502|Placebo Comparator|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
16436552|NCT03726489|Other|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
16436553|NCT03726489|Active Comparator|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
16436554|NCT03726476|Experimental|Patient Centered pre-op education|Patient centered pre-operative education and patient centered post-operative care.
16436555|NCT03726476|Active Comparator|Routine Pre-op education|Participants will receive routine pre-operative education and post-op will receive a standardized number of narcotics
16436556|NCT03726463||polycystic kidney disease|patients with polycystic kidney disease who receive kidney transplantation at Asan Medical Center
16436557|NCT03726450|Experimental|Andrositol Plus|all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
16436558|NCT03726437|Experimental|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
16436559|NCT03726437|Placebo Comparator|Stress and Mood Management|A 3-hour general mental health web-based program.
16436562|NCT03726411|Experimental|periodontitis group|in this group, prolactin in GCF will be assessed at baseline and after 3 months of receiving non-surgical periodontal treatment
16436563|NCT03726411|No Intervention|control group|in this group of systemically and periodontally healthy participants, prolactin in GCF will be assessed at baseline only
16436564|NCT03726398|Experimental|Opsumit|Opsumit 10 mg tablet by mouth once daily
16436565|NCT03726385||Group I|Group I: The control group. Participants in this group received only NDT based upper extremity rehabilitation. Number of the participants were 19.
16436566|NCT03726385||Group II|Group II: The study group. Participants in this group received NDT based upper extremity rehabilitation + Cogniboard® Light Trainer training. Number of the participants were 19.
16436567|NCT03726372|Experimental|deep neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given by continuous infusion at a dose that reaction to train of four (TOF) stimulation is depressed to zero
16436568|NCT03726372|Experimental|moderate neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given at a dose by intermittent injection that reaction to train of four (TOF) stimulation is kept 1 to 2
16436569|NCT03726359|Experimental|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
16436570|NCT03726346|Experimental|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
16436571|NCT03726333|Active Comparator|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
16436572|NCT03726333|Active Comparator|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
16436573|NCT03726333|Experimental|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic imapirment
16436574|NCT03726333|Experimental|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
16436575|NCT03726333|Experimental|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
16436576|NCT03726320|Experimental|Intervention Group|a decision aid along with decision coaching on PSA screening from a Community Health Worker (CHW)
16436577|NCT03726320|Active Comparator|Control Group|a decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control.
16436578|NCT03726307|Experimental|DCreg: 0.5 million cells/kg+SOC|"N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion.
~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:
~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).
~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
16436579|NCT03726307|Experimental|DCreg: 1.2 million cells/kg+SOC|"N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion.
~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:
~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).
~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
16436580|NCT03726307|Experimental|DCreg:2.5 to 5.0 million cells/kg+SOC|"N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion.
~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:
~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).
~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
16436581|NCT03726294|Experimental|NBM-BMX|
16436582|NCT03726281|Experimental|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
16436583|NCT03726268|Active Comparator|IV methadone|Intraoperative and post-operative IV methadone
16436584|NCT03726268|Active Comparator|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
16436585|NCT03726255||Stromal Vascular fraction|31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)
16436586|NCT03726255||Autologous mesenchymal stem cells|9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)
16436587|NCT03726255||Allogenic mesenchymal stem cells|12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)
16436588|NCT03726242|Active Comparator|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
16436733|NCT03725241|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
16436589|NCT03726242|Placebo Comparator|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
16436590|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
16436591|NCT03726216||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in France
16436592|NCT03726203|Experimental|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
16436593|NCT03726203|Active Comparator|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
16436594|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
16436595|NCT03726177|Active Comparator|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
16436596|NCT03726177|Active Comparator|aspirin 81 mg plus placebo|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
16436597|NCT03726164|Active Comparator|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
16436598|NCT03726164|Placebo Comparator|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
16436599|NCT03726151|No Intervention|Usual Care|
16436600|NCT03726151|Experimental|Parent Reminders|
16436601|NCT03726151|Experimental|Multicomponent clinic-system strategies|
16436602|NCT03726151|Experimental|Combined Condition|
16436603|NCT03726125|Experimental|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
16436604|NCT03726125|Experimental|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
16436605|NCT03726125|Experimental|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
16436606|NCT03726125|Experimental|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
16436607|NCT03726125|Experimental|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
16436608|NCT03726125|Experimental|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
16436609|NCT03726112|Active Comparator|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
16436610|NCT03726112|Sham Comparator|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
16436611|NCT03726099|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy containing esomeprazole, amoxicillin, tetracycline and furazolidone.
16436612|NCT03726073|Experimental|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
16436613|NCT03726073|Sham Comparator|Non-intervention group|Usual care
16436614|NCT03726060|Other|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.
~The splint will be subsequently delivered to the patient with the relative indications of use.
~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
16436615|NCT03726060|Other|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.
~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.
~The cycle will consist of 10 sessions distributed over 3 months."
16436616|NCT03726047|No Intervention|Control|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).
16436617|NCT03726047|Experimental|Exercise|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
16436618|NCT03726034|Experimental|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
16436619|NCT03726034|Active Comparator|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
16436620|NCT03726021|Experimental|experimental arm|Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.
16436621|NCT03726008|Experimental|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
16436622|NCT03726008|No Intervention|Control group|The control group will receive the regular perinatal care
16436623|NCT03725995|Active Comparator|A (Midazolam)|21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
16436624|NCT03725995|Experimental|B (Lidocaine-Midazolam)|21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
16436625|NCT03725995|Placebo Comparator|C (Placebo)|21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.
16436626|NCT03725982|Experimental|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
16436627|NCT03725982|Experimental|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
16436628|NCT03725969|Experimental|Healthy individuals (camel milk)|
16436629|NCT03725969|Experimental|Healthy individuals (cow milk)|
16436630|NCT03725956|Experimental|endoscopic sinus surgery|Single group of patients with nasal polyposis eligible for endoscopic sinus surgery
16436631|NCT03725943|Experimental|Healthy adults|Dreem
16436632|NCT03725930|Active Comparator|Clonidine|This arm will receive intra nasal Clonidine as a premedication before surgery
16436633|NCT03725930|Placebo Comparator|Placebo|This arm will receive intra nasal Placebo as a premedication before surgery
16436634|NCT03725917|Experimental|Experimental Group|The intervention will be a progressive physiotherapy protocol formed by therapeutic exercise and manual therapy
16436635|NCT03725917|No Intervention|Control Group|The control group will not receive physiotherapy treatment.
16436636|NCT03725904|Experimental|IVF/FET|
16436637|NCT03725891|Active Comparator|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
16436638|NCT03725891|Active Comparator|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
16436639|NCT03725878|Experimental|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
16436640|NCT03725878|Active Comparator|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
16436641|NCT03725865|Experimental|iNSC treatment group|
16436642|NCT03725852|Experimental|GLPG1205 100 mg|Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
16436643|NCT03725852|Placebo Comparator|Placebo|Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
16436644|NCT03725839|Experimental|Arm|F&P Interface will be used by OSA participants in-home for 2 weeks.
16436645|NCT03725826||Acute Myocardial Infarction|Patients (aged 18 and above) with either ST segment elevation or Non-ST segment elevation MI by biomarkers of cardiac injury and symptoms. Cut-off for CPK >2 times and troponin >3 times the upper limit for the lab. Only Patients who undergo coronary revascularization (PCI, CABG), New York Heart Association (NYHA) functional class I-III, and with LVEF < 45% will be enrolled.
16436646|NCT03725813|Experimental|Person-centred inpatient care|Person-centred inpatient care
16436647|NCT03725800||Aspirin|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using aspirin for mono-antiplatelet therapy.
16436648|NCT03725800||Clopidogrel|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using clopidogrel for mono-antiplatelet therapy.
16436649|NCT03725800||ASIDE|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using ASIDE for mono-antiplatelet therapy.
16436650|NCT03725787|Experimental|CuroCell S.A.M. ® pro mattress|Mattresses of eligible participants will be replaced by a static air pressure redistribution mattress (CuroCell S.A.M. ® Pro).
16436651|NCT03725774|Experimental|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
16436652|NCT03725761|Experimental|IMMU-132 Treatment|Subjects enrolled in this study will receive IMMU-132 as treatment for Castrate-Resistant Prostate Cancer. Dose will be calculated per protocol in milligrams based on the subject's body weight at the beginning of each cycle or more frequently if weight changes >10%. Subjects will be treated on days 1 and 8 in a 21-day cycle, minimum 3 cycles.
16436653|NCT03725748|No Intervention|no irrigation group|nothing used for irrigation of cs scar
16436654|NCT03725748|Placebo Comparator|saline irrigation group|saline used for irrigation the cs scar before closure
16436655|NCT03725748|Experimental|betadine irrigation group|betadine used for irrigation of cs scar
16436656|NCT03725735|Experimental|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
16436657|NCT03725722|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
16436658|NCT03725722|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
16436659|NCT03725722|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
16436660|NCT03725722|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
16436661|NCT03725722|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
16436662|NCT03725709||All patients|spinal anesthesia
16436663|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
16436734|NCT03725241|Experimental|Experimental: Glutathione|Intervention: Dietary Supplement: Glutathione supplement
16436664|NCT03725683|Experimental|Incrementing groups|Each of the Increased caliber balloon capsules was predilated one by one, and the order of the increased balloon capsules was as follows: Balloon 2 diameter = target lesion reference vessel diameter minus 1; Balloon 3 diameter = target lesion reference vessel diameter;
16436665|NCT03725683|Experimental|matching groups|Pre-dilatation of the matched caliber balloon, whose diameter = the target lesion's diameter as a reference vessel, was applied.
16436666|NCT03725670|Experimental|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
16436667|NCT03725657||Pediatric|Pediatric Type1 Diabetes Mellitus patients
16436668|NCT03725644|Experimental|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
16436669|NCT03725644|Experimental|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
16436670|NCT03725631|Experimental|Biopsy proven NAFLD patients|150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.
16436671|NCT03725618|Experimental|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
16436672|NCT03725618|Experimental|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
16436673|NCT03725618|Experimental|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
16436674|NCT03725605|Experimental|LTX-315 plus TIL infusion|LTX-315 intratumoural 5mg per injection time point (number of injections per dosing days is dependent upon lesion size), TILs expansion and infusion.
16436675|NCT03725592|Active Comparator|Standard Treatment|Receives arsenic removal device and written instructions and phone calls on how to use the device (Arsenic Removal Device)
16436676|NCT03725592|Experimental|Intensive Education|Receives the Standard Treatment plus in-person visits and phone calls for follow-up (Community Participatory Arsenic Mitigation)
16436677|NCT03725579|Experimental|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
16436678|NCT03725579|Active Comparator|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
16436679|NCT03725566|Experimental|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
16436680|NCT03725553|Experimental|Intramyometrial Vasopressin|the experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
16436681|NCT03725553|Placebo Comparator|Placebo|the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)immediately after delivery, as soon as the umbilical cord was clamped.
16436682|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
16436683|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
16436684|NCT03725527|Active Comparator|Rectus sheath catheter block|Patients will receive ultrasound-guided rectus sheath block with catheter insertion performed after induction of general anesthesia and before surgery.
16436685|NCT03725527|Active Comparator|Epidural Catheter block|Patients will receive thoracic epidural at the level of T7 performed before anesthesia induction.
16436686|NCT03725514|Active Comparator|conventional|Conventional blood clot technique
16436687|NCT03725514|Experimental|PRF|Platelet Rich Fibrin Technique
16436688|NCT03725501|Experimental|Ranibizumab + ALS-L1023 600mg|"ALS-L1023 600 mg - Take 2 tablets orally twice a day.
~Ranibizumab (Lucentis®)
~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.
~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
16436689|NCT03725501|Experimental|Ranibizumab + ALS-L1023 1200mg|"ALS-L1023 1200 mg - Take 2 tablets orally twice a day.
~Ranibizumab (Lucentis®)
~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.
~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
16436690|NCT03725501|Placebo Comparator|Ranibizumab + Placebo|"Placebo - Take 2 tablets orally twice a day.
~Ranibizumab (Lucentis®)
~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.
~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
16436691|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
16436692|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
16436693|NCT03725475||Stage III|stage III Non-small Cell Lung Cancer (NSCLC )
16436694|NCT03725462|Experimental|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
16436695|NCT03725462|Experimental|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
16436696|NCT03725449|Experimental|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
16436829|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
16436697|NCT03725449|Experimental|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
16436698|NCT03725449|Experimental|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
16436699|NCT03725436|Experimental|Treatment (paclitaxel, ALRN-6924)|Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16436700|NCT03725423|Experimental|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
16436701|NCT03725410|Active Comparator|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
16436702|NCT03725410|Placebo Comparator|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
16436703|NCT03725397|Experimental|Outpatients with a transcervical Foley catheter|Women with a transcervical Foley catheter in place that will spend the night at home.
16436704|NCT03725397|Active Comparator|Inpatients with a transcervical Foley catheter|"Women to be admitted to the hospital overnight which has been a standard of care."
16436705|NCT03725384|Experimental|Ferrous Sulfate and Vitamin C every other day|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every other day for 12 weeks
16436706|NCT03725384|Active Comparator|Ferrous Sulfate and Vitamin C daily|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every day for 12 weeks
16436707|NCT03725358|Experimental|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
16436708|NCT03725358|Experimental|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
16436709|NCT03725358|Experimental|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
16436710|NCT03725358|Experimental|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
16436711|NCT03725358|Experimental|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
16436712|NCT03725358|Experimental|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
16436713|NCT03725358|Experimental|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
16436714|NCT03725358|Experimental|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
16436715|NCT03725358|Experimental|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
16436716|NCT03725345|Experimental|Alcohol Group|Participants will consume an alcoholic beverage consisting of a 1:5 ratio of 95% ethyl alcohol and orange juice
16436717|NCT03725345|Placebo Comparator|Placebo Group|Participants will consume a placebo beverage of orange juice
16436720|NCT03725319||Epinephrin injection|Diluted Epinephrin (1:100) in small amounts from 1 to 5 ml is injected into apex of the papilla to stop post sphincterotomy-bleeding
16436721|NCT03725319||Plastic stent insertion|A plastic stent (diameter: 8-11,5F and length of 50 -100mm) is inserted into the common bile duct to stop post sphincterotomy-bleeding
16436722|NCT03725306|Experimental|Librata|Librata Endometrial Ablation Device
16436723|NCT03725293|Active Comparator|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
16436724|NCT03725293|Active Comparator|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
16436725|NCT03725280||Transgender men I|Transgender men after testosterone treatment
16436726|NCT03725280||Transgender men II|Transgender men before testosterone treatment
16436727|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
16436728|NCT03725280||Egg donors|IVF- egg donors patients
16436729|NCT03725267|Experimental|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
16436730|NCT03725267|Placebo Comparator|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
16436731|NCT03725254|Active Comparator|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
16436732|NCT03725254|Experimental|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
16436735|NCT03725228|Active Comparator|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
16436736|NCT03725228|Experimental|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
16436737|NCT03725215|Experimental|Split-Belt Treadmill Training 1:2|Split-Belt Training with a steady ratio of 1:2.
16436738|NCT03725215|Experimental|Split-Belt Treadmill Training 3:4|Split-Belt Training with a steady ratio of 3:4.
16436739|NCT03725215|Experimental|Split-Belt Treadmill Training Changing|Split-Belt Training with changing ratios between 3:4 to 1:2.
16436740|NCT03725215|Active Comparator|Split-Belt Treadmill Training Tied-Belt|Split-Belt Training with tied belts.
16436744|NCT03725189|Experimental|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
16436745|NCT03725163|Experimental|Treatment|This arm will begin treatment immediately after completing the initial intake assessment.
16436746|NCT03725163|Other|Waitlist Control|Participants assigned to the waitlist control condition will begin a 12-week waiting period after completing the initial intake assessment before starting treatment.
16436747|NCT03725137||Group A (young stroke)|Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI
16436748|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
16436749|NCT03725124||Partners|Partners of women with IBD.
16436750|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
16436751|NCT03725111|Experimental|arterio venous leg ulcers|
16436752|NCT03725098|Experimental|HEMOBLAST Bellows (Hemostatic Device)|Bleeding sites will be treated with HEMOBLAST Bellows per its approved Indications for Use
16436753|NCT03725098|Active Comparator|FLOSEAL (Hemostatic Device)|Bleeding sites will be treated with FLOSEAL per its approved Indications for Use
16436754|NCT03725085|Experimental|Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)|"2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.
~GGE = Guaifenesin
~BID = Twice in a day"
16436755|NCT03725072|Experimental|Evobrutinib|
16436758|NCT03725046|No Intervention|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
16436759|NCT03725046|Experimental|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
16436760|NCT03725033|Experimental|Subetta|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
16436761|NCT03725033|Placebo Comparator|Placebo|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
16436762|NCT03725020|Experimental|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
16436763|NCT03725020|Placebo Comparator|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
16436830|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
16436764|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose A|Participants of age group 12 to <18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
16436765|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose B|Participants of age group 12 to <18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
16436766|NCT03725007|Experimental|Participants of age group 6 to <12 years receiving dose A|Participants of age group 6 to <12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
16436767|NCT03725007|Experimental|Participants of age group 2 to <6 years receiving dose A|Participants of age group 2 to <6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
16436768|NCT03724994||Study cohort|All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö and Lund
16436769|NCT03724981|Experimental|Dulaglutide Pen|Injection of commercial dulaglutide pen on a practice pad.
16436770|NCT03724981|Experimental|Semaglutide Pen|Injection of commercial semaglutide pen on a practice pad.
16436771|NCT03724968|Experimental|Arm A|Nivolumab and Relatlimab
16436772|NCT03724968|Experimental|Arm B|Nivolumab and Ipilimumab
16436773|NCT03724955|Experimental|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
16436774|NCT03724955|Placebo Comparator|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
16436775|NCT03724942|Experimental|Brexpiprazole|
16436776|NCT03724929|Experimental|Ulcerative Colitis patients|"To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :
~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.
~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization."
16436777|NCT03724916|Experimental|TAK-079|TAK-079 injection, subcutaneously, once every 3 weeks for up to 12 weeks in combination with principal investigator-directed background therapy for SLE. Dose escalation of TAK-079 dose will be based on PK, safety and tolerability data.
16436778|NCT03724916|Placebo Comparator|Placebo|TAK-079 placebo-matching injection, subcutaneously, once every 3 weeks for up to 12 weeks in combination with principal investigator-directed background therapy for SLE.
16436779|NCT03724903|Experimental|Ductal lavage|Ductal lavage and breast massage for two weeks.
16436780|NCT03724903|Active Comparator|Corticosteroids therapy|Oral corticosteroids therapy for 6 months.
16436781|NCT03724890|Experimental|Part A: M3814 + Avelumab|
16436782|NCT03724890|Experimental|Part B: M3814 + Avelumab + Radiotherapy (RT)|
16436783|NCT03724890|Experimental|Part FE: M3814 + Avelumab (fasted/fed state)|
16436784|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
16436785|NCT03724864|Experimental|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
16436786|NCT03724864|Active Comparator|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
16436787|NCT03724864|Placebo Comparator|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
16436788|NCT03724851|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
16436789|NCT03724838|Active Comparator|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
16436790|NCT03724838|Active Comparator|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
16436791|NCT03724838|Placebo Comparator|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
16436792|NCT03724825||obese men|Adult obese men (BMI ≥ 30 kg/m2)
16436793|NCT03724825||normal men|normal weight men (18.5 ≤ BMI < 25 kg/m2 )
16436794|NCT03724812|Experimental|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
16436795|NCT03724799|Experimental|single arm|Intravenous low level laser therapy
16436796|NCT03724786|Experimental|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
16436797|NCT03724786|No Intervention|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
16436798|NCT03724773|Active Comparator|Long-Arm Cast|Reduction and long-arm cast application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
16436799|NCT03724773|Active Comparator|Sugar-Tong Splint|Reduction and sugar-tong splint application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
16436800|NCT03724760|Experimental|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
16436801|NCT03724760|No Intervention|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
16436802|NCT03724747|Experimental|BAY2315497 dose escalation|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
16436803|NCT03724747|Experimental|BAY2315497 dose escalation in combination with darolutamide|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. In addition, Darolutamide oral dosing at the approved dose of twice daily 600 mg will be initiated 14 days prior to the first BAY2315497 Injection dose on Day 1 of the first cycle. Daily darolutamide dosing will continue throughout the entire BAY2315497 Injection treatment period until withdrawal criteria from study treatment period are met.
16436804|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 1|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
16436805|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 2|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
16436806|NCT03724734|Experimental|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
16436807|NCT03724734|Active Comparator|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
16436808|NCT03724721|Experimental|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
16436809|NCT03724708|Experimental|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
16436810|NCT03724708|Active Comparator|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
16436811|NCT03724708|Active Comparator|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
16436812|NCT03724695|No Intervention|Control|Usual Care
16436813|NCT03724695|Experimental|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
16436814|NCT03724682|Experimental|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
16436815|NCT03724669|Placebo Comparator|waiting list|
16436816|NCT03724669|Experimental|Benzodiazepines and Z-drugs knowledge|
16436817|NCT03724656|Experimental|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
16436818|NCT03724656|Sham Comparator|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
16436819|NCT03724643|Experimental|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
16436820|NCT03724643|No Intervention|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
16436821|NCT03724617|Experimental|stem cell therapy|
16436822|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
16436823|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
16436824|NCT03724591|Experimental|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
16436825|NCT03724591|Active Comparator|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
16436826|NCT03724578|Sham Comparator|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
16436827|NCT03724578|Active Comparator|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
16436828|NCT03724578|Experimental|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
16436831|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
16436832|NCT03724552|Experimental|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
16436833|NCT03724539|Experimental|STRIPA intervention|"GPs in the intervention group will perform a STRIPA analysis for each of their 8-10 patients after the recruitment of the patient into the OPTICA trial, so that the results can be discussed in the next consultation and a shared decision-making can be performed.
~STRIPA is a structured method to perform pharmacotherapy optimization. The STRIPA intervention in the OPTICA trial consists of 4 steps:
~recording medication and diagnoses in STRIPA (upload from data from the 'Family medicine ICPC Research using Electronic medical records' (FIRE) database)
~structured drug review through the GP based on the STRIPA with the integrated STOPP/START criteria
~shared decision-making between GP and patient with possible adaptation of the recommendation
~follow-up through study team"
16436834|NCT03724539|Sham Comparator|Sham intervention|Patients in the control group will receive a sham intervention, which consists of a usual medication review by their GP as well as a shared decision making of the latter.
16436835|NCT03724526|Experimental|Intervention-Text messaging|Participates will receive regular 6 text messages per week for 12 months. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week. Each message will be sent on 6 of 7 randomly selected weekdays and arrived at random times the day during working hours.
16436836|NCT03724526|No Intervention|Control|Participates in control group will not receive text messages.
16436837|NCT03724487|Experimental|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
16436838|NCT03724487|Experimental|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
16436839|NCT03724474|Experimental|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
16436840|NCT03724474|Active Comparator|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
16436841|NCT03724461|Active Comparator|High intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg is established as control.
16436842|NCT03724461|Active Comparator|Light intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes light-moderate intensity resistance training (12 weeks) and the other leg is established as control.
16436843|NCT03724461|Experimental|High vs Light intensity (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg undergoes light-moderate intensity resistance training.
16436844|NCT03724461|Experimental|High intensity (Acute)|Analysis of the effects of one High Intensity resistance training session, with a crossover design.
16436845|NCT03724461|Experimental|Light intensity (Acute)|Analysis of the effects of one Light-moderate Intensity resistance training session, with a crossover design.
16436846|NCT03724448|Experimental|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
16436847|NCT03724448|Placebo Comparator|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
16436848|NCT03724435||Pancreatic Cancer Participants|No intervention will be administered. Assessments are performed as standard of care.
16436849|NCT03724422|No Intervention|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
16436850|NCT03724422|Experimental|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
16436851|NCT03724409|Experimental|Cohort 1|Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
16436852|NCT03724409|Experimental|Cohort 2|Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
16436853|NCT03724409|Experimental|Cohort 3|Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
16436854|NCT03724409|Experimental|Cohort 4|Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
16436855|NCT03724409|Experimental|Cohort 5|Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
16436856|NCT03724409|Experimental|Cohort 6|Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
16436857|NCT03724396|Experimental|Novel Executive Function Training - NEXT|Same as BWL with some additional strategies targeted at improving executive function to help adherence to BWL skills.
16436890|NCT03724136|Active Comparator|Arm 2|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Near Infrared Light exposure .
16436858|NCT03724396|Active Comparator|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
16436859|NCT03724383|No Intervention|Control|Participants in the control arm will receive standard care.
16436860|NCT03724383|Experimental|Intervention|Participants in the intervention group will receive risk factor management consultations and take part in 1-hour biweekly diet classes and stress management classes for the first 3 months. This will be followed by 3 months of 1-hour biweekly high intensity interval training exercise classes. At the 6-month time point, participants will be prescribed a home based exercise program and will have the option of participating in weekly group walking sessions. During the final 6 months, participants will use a step/activity tracker to track their steps and heart rate.
16436861|NCT03724370|Experimental|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
16436862|NCT03724370|Active Comparator|VHA-SRM|VHA-SRM will be active comparator
16436863|NCT03724357|Experimental|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
16436864|NCT03724344||Dimensions with Behavioral and psychological symptoms|
16436865|NCT03724331|Experimental|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
16436866|NCT03724331|Experimental|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
16436867|NCT03724331|Active Comparator|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
16436868|NCT03724318|Active Comparator|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
16436869|NCT03724318|No Intervention|Control|The left atrium appendage will remain open in patients randomized to the control group
16436870|NCT03724305|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
16436871|NCT03724305|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
16436872|NCT03724292|Placebo Comparator|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
16436873|NCT03724292|Experimental|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
16436874|NCT03724292|Experimental|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
16436875|NCT03724292|Experimental|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
16436876|NCT03724292|Experimental|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
16436877|NCT03724292|Experimental|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
16436878|NCT03724279|Experimental|ByCross Atherectomy and Thrombectomy|Percutaneous intervention including ByCross atherectomy and Thrombectomy potentially followed with PTA and/or stent placement
16436879|NCT03724266|Experimental|chitosan|chitosan as intracanal medication 0.2% in form of gel
16436880|NCT03724266|Active Comparator|calcium hydroxide|intracanal medication
16436881|NCT03724253|Experimental|Phase II dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
16436882|NCT03724253|Experimental|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
16436883|NCT03724240|Placebo Comparator|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
16436884|NCT03724240|Experimental|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
16436885|NCT03724214|No Intervention|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
16436886|NCT03724214|Active Comparator|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
16436887|NCT03724175|Experimental|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
16436888|NCT03724149|Experimental|Direct-acting antiviral treatment for HCV|
16436889|NCT03724136|Active Comparator|Arm 1|Intravenous Bone Marrow Stem Cell (BMSC) Fraction
16436922|NCT03723902|No Intervention|Control|No intervention
16436891|NCT03724136|Active Comparator|Arm 3|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Intranasal topical Bone Marrow Stem Cell (BMSC) Fraction.
16436892|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
16436893|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
16436894|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
16436895|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
16436896|NCT03724097||Group 3|Patients receiving palliative care
16436897|NCT03724084|Experimental|Treatment (pinometostat)|"Patients receive pinometostat IV continuously on days 1-35, daunorubicin hydrochloride IV over 10-30 minutes on days 8-10 and cytarabine IV continuously on days 8-14 in the absence of disease progression or unacceptable toxicity.
~Patients who do not achieve CR/CRi after treatment receive pinometostat IV continuously on days 1-28, daunorubicin hydrochloride IV over 10-30 minutes on days 1 and 2 and cytarabine IV continuously on days 1-5 in the absence of disease progression or unacceptable toxicity."
16436898|NCT03724071|Experimental|Phase 1, Arm A - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with repeated administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
16436899|NCT03724071|Experimental|Phase 1, Arm B - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with closer administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
16436900|NCT03724071|Experimental|Phase IIa - Efficacy of TG6002 and flucytosine combination|Repeated administrations of TG6002 in combination with flucytosine in patients with colorectal cancer and liver metastases
16436901|NCT03724058|Experimental|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
16436902|NCT03724058|Active Comparator|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
16436903|NCT03724045|Experimental|Back Side of the Moon|"Patients will be screened and enrolled at the ICU. Extraordinary measurements concerning nutritional status will be performed, to investigate whether patients at the ICU actually meet their nutritional needs. The same patients as above will be followed up, once discharge from ICU to a low-care ward has taken place. From there, they will be followed up until discharge from the hospital. The procedures are the same as in the ICU. The results obtained at the low-care ward will be compared to those from the ICU. 6 months after hospital discharge, morbidity and mortality will be assessed.
~A substudy of included COVID-19 positive patients will be analysed and compared to non COVID-19 patients."
16436904|NCT03724032|Active Comparator|TMD Patients Active Group: Active Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
16436905|NCT03724032|Sham Comparator|TMD Patients Sham Group: Sham Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
16436906|NCT03724032|No Intervention|Healthy Control Group|"20 Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).
~Healthy volunteer data (n </= 10) may be used from a prior study (NIDCR-R56-DE022637 project [IRBMED #HUM00080911; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
16436907|NCT03724019||Group Q|20 milliliter of ketamine (0.5mg / kg ideal body weight) at induction of anesthesia.
16436908|NCT03724019||Group S|20 milliliter of sodium chloride at induction of anesthesia.
16436909|NCT03724006|Experimental|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
16436910|NCT03724006|No Intervention|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
16436911|NCT03723993|Placebo Comparator|Control group|control group will have non inflated cuff around the arm.
16436912|NCT03723993|Active Comparator|RIPC group|Inflated cuff will be done systematically and regularly
16436913|NCT03723980|Active Comparator|Control Group or Group I or Calcium hydroxide Group|
16436914|NCT03723980|Experimental|Experimental Group or Group II or Propolis Group|
16436915|NCT03723967|Experimental|Durvalumab with Carboplatin/Paclitaxel|Combination of Durvalumab with Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
16436916|NCT03723941|Experimental|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
16436917|NCT03723941|Other|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
16436918|NCT03723928|Active Comparator|Arm I (usual care)|Patients will have imaging studies (modality and frequency per treating physician, however at a minimum frequency of every 12 weeks) alone or in conjunction with STMs (frequency determined by treating physician). Patients will continue with usual care disease monitoring for up to 312 weeks in the absence of disease progression.
16436919|NCT03723928|Experimental|Arm II (serum tumor directed disease monitoring)|Patients undergo disease specific serum tumor marker evaluation (CEA and either CA 15-3 or CA 27.29, whichever were tested at Step 1 Registration and Step 2 Registration) every 4-8 weeks (starting from randomization) without imaging until an elevation of at least one disease specific STM. In the event of an elevated STM, the patient will have imaging within 4 weeks to evaluate for disease progression. Patients continue with STMDDM for up to 312 weeks in the absence of disease progression.
16436921|NCT03723902|Experimental|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
16436923|NCT03723889||PDA|Evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
16436924|NCT03723889||noPDA|No evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
16436925|NCT03723876|Active Comparator|Intervention group|Twelve occasions of Basic body awareness therapy, administered once a week, alongside treatment as usual (such as structured everyday support, medicine, contact with social worker).
16436926|NCT03723876|No Intervention|Control group|No extra intervention except treatment as usual.
16436927|NCT03723863|Experimental|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
16436928|NCT03723850|Experimental|Older, active tDCS, dlPFC|"Older adults (ages 60-75) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
~2."
16436929|NCT03723850|Sham Comparator|Older, sham tDCS, dlPFC|Older adults (ages 60-75) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
16436930|NCT03723850|Experimental|Younger, active tDCS, dlPFC|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
16436931|NCT03723850|Sham Comparator|Younger, sham tDCS, dlPFC/parietal|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to either the left dorsolateral prefrontal cortex (area F3 using the 10-20 EEG system, n = 25), or the left parietal cortex (area P5 using the 10-20 EEG system, n = 25). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
16436932|NCT03723850|Active Comparator|Younger, active tDCS, parietal cortex|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left parietal cortex (area P5 using the 10-20 EEG system). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
16436933|NCT03723837|Active Comparator|Study Arm A|Children {Age > 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
16436934|NCT03723837|Active Comparator|Study arm B|Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month
16436935|NCT03723824|Experimental|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
16436936|NCT03723811|Experimental|1|SJP002 BID
16436937|NCT03723811|Experimental|2|SJP002 QID
16436938|NCT03723811|Placebo Comparator|Placebo 1|SJP002 Placebo 1
16436939|NCT03723811|Placebo Comparator|Placebo 2|SJP002 Placebo 2
16436940|NCT03723798|Experimental|1|SA001 Low dose
16436941|NCT03723798|Experimental|2|SA001 Mid dose
16436942|NCT03723798|Experimental|3|SA001 High dose
16436943|NCT03723798|Placebo Comparator|Placebo|SA001 Placebo
16436944|NCT03723785|Experimental|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
16436945|NCT03723785|Experimental|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
16436946|NCT03723785|Experimental|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
16436947|NCT03723785|Experimental|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
16436948|NCT03723785|Experimental|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
16436949|NCT03723772|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling where subjects are treated with once daily (OD) insulin glargine.
~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
16436950|NCT03723772|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.
~After insulin glargine treatment, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling."
16436951|NCT03723759|Experimental|Group A|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E.
~The dosing visits will be separated by wash-out periods (2-21 days)."
16436952|NCT03723759|Experimental|Group B|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL.
~The dosing visits will be separated by wash-out periods (2-21 days)."
16436953|NCT03723759|Experimental|Group C|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D.
~The dosing visits will be separated by wash-out periods (2-21 days)."
16437090|NCT03722706|Experimental|Handbook|handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
16436954|NCT03723759|Experimental|Group D|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B.
~The dosing visits will be separated by wash-out periods (2-21 days)."
16436955|NCT03723759|Experimental|Group E|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C.
~The dosing visits will be separated by wash-out periods (2-21 days)."
16436956|NCT03723759|Experimental|Group F|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A.
~The dosing visits will be separated by wash-out periods (2-21 days)."
16436957|NCT03723746|Experimental|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day [SD] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
16436958|NCT03723746|Experimental|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
16436959|NCT03723746|Experimental|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day [MD] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
16436960|NCT03723746|Experimental|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
16436961|NCT03723746|Experimental|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
16436962|NCT03723746|Experimental|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
16436963|NCT03723746|Experimental|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
16436964|NCT03723746|Experimental|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
16436965|NCT03723746|Experimental|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
16436966|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
16436967|NCT03723707|Experimental|Intervention (INT)|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
16436968|NCT03723707|Placebo Comparator|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
16436969|NCT03723694|Active Comparator|650 mg of Cocoapro flavanols|Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
16436970|NCT03723694|Placebo Comparator|0mg Cocoapro flavanols|Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
16436971|NCT03723681|Experimental|Quizartinib 20 mg|Participants receive 20 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
16436972|NCT03723681|Experimental|Quizartinib 40 mg|Participants receive 40 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
16436973|NCT03723668||OPTN data system|In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
16436974|NCT03723668||CRISTAL registry|In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
16436975|NCT03723655|Experimental|Group 1|Active Treatment for participants with base target trough concentration
16436976|NCT03723655|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
16436977|NCT03723655|Experimental|Group 3|Active Treatment for participants dose titrated to clinical response
16437017|NCT03723330|Experimental|Plant sterol with a healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
16436978|NCT03723642|Active Comparator|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
16436979|NCT03723642|Active Comparator|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
16436980|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
16436981|NCT03723616|Active Comparator|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
16436982|NCT03723616|Active Comparator|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
16436983|NCT03723603|Experimental|Fibrillar Collagen Powder Dressing|
16436985|NCT03723577|Experimental|Fibrillar Collagen Powder Dressing|
16436986|NCT03723564|Experimental|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
16436991|NCT03723525|Experimental|Package of HIV care|Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.
16436992|NCT03723525|Experimental|Standard HIV care|Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.
16436993|NCT03723512|Experimental|Whole group|Whole group
16436994|NCT03723499||endoscopic treatment|Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.
16436995|NCT03723486||Roux-en-Y gastric bypass surgery (RYGB)|Morbidly obese patients undergoing gastric bypass surgery
16436996|NCT03723473||PAOD patients statin (+)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) and statin treatment.
~They will have Magnetic Resonance Imaging (MRI; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
16436997|NCT03723473||PAOD patients statin (-)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) without statin treatment .
~They will have Magnetic Resonance Imaging (MRI ; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
16436998|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
16436999|NCT03723447|Active Comparator|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
16437000|NCT03723447|Active Comparator|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
16437001|NCT03723434|Active Comparator|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
16437002|NCT03723434|Experimental|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
16437003|NCT03723421|Experimental|Rapid Injection Group Without Aspiration|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position by rapid injection technique without aspiration.
16437004|NCT03723421|Experimental|Control|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position with the standard injection technique.
16437005|NCT03723408|Other|Single Arm post-approval study|Single Arm post-approval study.
16437006|NCT03723395|Experimental|Part A|Tucatinib plus Itraconazole
16437007|NCT03723395|Experimental|Part B|Tucatinib plus Rifampin
16437008|NCT03723395|Experimental|Part C|Tucatinib plus Gemfibrozil
16437009|NCT03723395|Experimental|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
16437010|NCT03723395|Experimental|Part E|Tucatinib plus Digoxin
16437011|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
16437012|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
16437013|NCT03723356||MS Patients|Definite diagnosis of RRMS
16437014|NCT03723356||Healthy Controls|gender aged match healthy
16437015|NCT03723343||Experimental: GP+IMRT|Test group: GP-induced chemotherapy (Gemcitabine 1000 mg/m2 d1, 8+Cisplatin 80 mg/m2 d1, once every 3 weeks, 4/6 course) + IMRT radiotherapy alone
16437016|NCT03723343||Active Comparator: TPF+IMRT|Control group: TPF-induced chemotherapy (Docetaxel: 75 mg/m2d1, Cisplatin 75 mg/m2, d1~d5, 5-fluorouracil 750 mg/m2/dd1~d5, 4/6 course) + IMRT radiotherapy alone
16437018|NCT03723330|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
16437019|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
16437020|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
16437021|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
16437022|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
16437023|NCT03723291|Active Comparator|Arm A|The current best standard of care [rehabilitation exercises]
16437024|NCT03723291|Experimental|Arm B|The current best standard of care [rehabilitation exercises] + the experimental intervention
16437025|NCT03723278||Healthy individuals|Young, male and healthy volunteers without any significant disease
16437026|NCT03723252|Experimental|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
16437027|NCT03723252|Placebo Comparator|Placebo group|Participants will receive placebo po qd.
16437028|NCT03723239|Experimental|TricValve® System Single-Arm|Minimally invasive catheter-supported, bicaval tricuspid valve (self-expanding) replacement
16437029|NCT03723226|Active Comparator|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
16437030|NCT03723226|Experimental|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
16437031|NCT03723187|Experimental|experimental group|use Normal saline
16437032|NCT03723187|Active Comparator|comparator group|use Heparin
16437033|NCT03723174||Single Arm|baseline data will be calculated before the oral health educational program using gingival index and after 3 months from the intervention
16437034|NCT03723161||Treatment|Bone Anchored Hearing surgery using a BHX implant manufactured by Oticon Medical
16437035|NCT03723122|Experimental|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
16437036|NCT03723122|No Intervention|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
16437037|NCT03723070|Experimental|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
16437038|NCT03723044|Experimental|healthy volunteers|
16437039|NCT03723031|Active Comparator|rectal misopristol|will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion.
16437040|NCT03723031|Active Comparator|intrauterine misopristol|will receive 400 microgram misoprostol inserted intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta.
16437041|NCT03723018|Experimental|Meditation - Headspace|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by the commercially available app/website Headspace (provided to participants for free). Participants in this arm will have access to the other meditation arm once they finish the study.
16437042|NCT03723018|Experimental|Meditation - Respite|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
16437043|NCT03723018|No Intervention|Observational|Participants in this arm will not receive any intervention. Their only study activity will be taking online surveys. They will have access to the two meditation arms once they finish the study.
16437044|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
16437045|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
16437046|NCT03722992|Other|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
16437047|NCT03722979|Other|All patients|
16437089|NCT03722719|Active Comparator|Group III (the Knack + PFMT)|
16437091|NCT03722706|No Intervention|Control|standard management alone
16437052|NCT03722953|Other|Aerobic Exercise|"Control: Cerebrovascular function and peripheral vascular function will be measured.
~Aerobic Exercise: Across four separate visits, participants will perform light intensity exercise, light intensity exercise plus an additional task, vigorous intensity exercise and vigorous intensity exercise to match the energy expenditure of light intensity exercise visit."
16437053|NCT03722940|Active Comparator|Magnesium sulphate|Group M
16437054|NCT03722940|Placebo Comparator|Na CL 0.9%|group C
16437055|NCT03722927|Experimental|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
16437056|NCT03722927|Experimental|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
16437057|NCT03722914|Active Comparator|benzonatate soft capsules group|
16437058|NCT03722914|Placebo Comparator|control group|
16437059|NCT03722901||Late preterm infants|34 weeks and 0-6 days gestational age
16437060|NCT03722901||Moderate preterm infants|32 weeks and 0-6 days gestational age
16437061|NCT03722901||Reference|Term infants 9m/39-40
16437062|NCT03722888|Experimental|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
16437063|NCT03722875|Experimental|SHR-1210+ apatinib|"SHR-1210 (200mg fixed dose every 3 weeks, one cycle is three weeks, total
~1 year ) will be administered as an intravenous infusion over 30 minutes.
~apatinib 250 mg qd ， one cycle is three weeks, total 1 year"
16437064|NCT03722862|Placebo Comparator|Control Arm|Healthy volunteers will continue normal healthy diet with a placebo.
16437065|NCT03722862|Experimental|Low fiber|Healthy volunteers will be randomized to receive 3 grams of Sunfiber.
16437066|NCT03722862|Experimental|High fiber|Healthy volunteers will be randomized to receive 6 grams of Sunfiber.
16437067|NCT03722849|Experimental|Chronic cough participant|"Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.
~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
16437068|NCT03722849|Experimental|Healthy control participant|"Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.
~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
16437069|NCT03722823|Active Comparator|Group 1: Healthy|Match-controlled healthy subjects with normal hepatic function
16437070|NCT03722823|Experimental|Group 2: Mild Hepatic Impairment|Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)
16437071|NCT03722823|Experimental|Group 3: Moderate Hepatic Impairment|Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)
16437072|NCT03722823|Experimental|Group 4: Severe Hepatic Impairment|Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)
16437073|NCT03722810|Active Comparator|Active comparator: patient interview|This intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
16437074|NCT03722810|Sham Comparator|Sham comparator: document|In this intervention, the student's allocated GP teacher will give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher.
16437075|NCT03722797||Unilateral Transtibial Amputation|Individuals with a unilateral, transtibial amputation.
16437076|NCT03722797||Controls|Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.
16437077|NCT03722784|Experimental|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
16437078|NCT03722784|Active Comparator|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
16437079|NCT03722771|Experimental|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.
~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
16437080|NCT03722771|Sham Comparator|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
16437081|NCT03722758|Active Comparator|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
16437082|NCT03722758|Active Comparator|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
16437083|NCT03722745|Experimental|Study group 1|Juvenile offenders will attend 4-session Trauma Affect Regulation: Guide for Education & Treatment (TARGET) groups led by one or two juvenile staff members
16437084|NCT03722745|Active Comparator|study group 2|Juvenile offenders will receive treatment-as-usual (TAU).
16437085|NCT03722732|Active Comparator|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
16437086|NCT03722732|Active Comparator|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
16437087|NCT03722719|Experimental|Group I (the Knack)|
16437088|NCT03722719|Active Comparator|Group II (PFMT)|
16437092|NCT03722693||Experimental group|Experimental group included subacute stroke patients with initial wrist extension. Each participant will receive 28 therapy sessions in total, that are divided into four blocks of 7 sessions. During the first 7 sessions the participant will receive standard care treatment (S), this block will be followed by first Functional electrical stimulation based treatment (FES intervention) block with 7 sessions of protocol A (AUTO or FUNCTION). Third block will consider additional 7 sessions of standard care (S). Fourth block will include 7 sessions of Functional electrical stimulation based treatment (FES intervention) with other type of treatment B (FUNCTION or AUTO).
16437093|NCT03722680|Experimental|Riluzole|The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
16437094|NCT03722680|Placebo Comparator|Placebo|Posology, administration and duration of treatment will be equivalent to riluzole group.
16437095|NCT03722667|Placebo Comparator|Technology-Based Component|A Technology-based interventions comprised of three technolgy components accessible via smartphone to support self-managing hypertension.
16437096|NCT03722667|Experimental|TechSupport|A Technology-based interventions comprised of three technolgy components plus positive psychological training accessible by smartphone to support self-managing hypertension.
16437097|NCT03722654|Experimental|MTFS|MTFS-I Installation
16437098|NCT03722654|No Intervention|Control|
16437099|NCT03722641|Placebo Comparator|Bread reference|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread.
16437100|NCT03722641|Experimental|Product 1: Milk|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on milk.
16437101|NCT03722641|Experimental|Product 2: Full fat milk + oat|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on full fat milk and oat with high fiber content.
16437102|NCT03722641|Experimental|Product 3: Skim milk + oat, high fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with high fiber content.
16437103|NCT03722641|Experimental|Product 4: Skim milk + oat, low fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with low fiber content.
16437104|NCT03722628||HCC with TTT|Blood sample from all HCC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
16437105|NCT03722628||HCC without TTT|Blood sample from all HCC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
16437106|NCT03722628||LC with TTT|Blood sample from all LC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
16437107|NCT03722628||LC without TTT|Blood sample from all LC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
16437108|NCT03722628||Healthy control|MMP1-genotype polymorphism will be applied on those healthy people to detect which type of mutation occur in healthy rather than diseased.
16437109|NCT03722602|Experimental|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
16437110|NCT03722589|Active Comparator|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
16437111|NCT03722589|Active Comparator|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
16437112|NCT03722589|Active Comparator|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
16437113|NCT03722589|Active Comparator|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
16437114|NCT03722589|Active Comparator|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
16437115|NCT03722576|Experimental|Vidofludimus Calcium (VC)|Daily dosing of VC over 6 months
16437116|NCT03722563|Active Comparator|TLHS|total laparoscopic hysterectomy with sacrocolpopexy will be performed
16437117|NCT03722563|Experimental|TLHLS|total laparoscopic hysterectomy with lateral suspension will be performed
16437118|NCT03722550|Active Comparator|Control Group|Standard Starter Infant Formula, Standard Follow-up Formula, and Standard Growing-up Milk
16437119|NCT03722550|Experimental|Test Group 1|Starter Infant Formula (same as Control Group) supplemented with 1.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
16437120|NCT03722550|Experimental|Test Group 2|Starter Infant Formula (same as Control Group) supplemented with 2.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
16437121|NCT03722550|Active Comparator|Breastfed Group|Non-randomized Breastfed reference group
16437122|NCT03722537|Active Comparator|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
16437123|NCT03722537|Experimental|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
16437156|NCT03722277|Experimental|Variable load training|"The participants will be training two times per week in 10 weeks. Training will consist of variable load training in knee flexion- and extension.
~Training will be based on symptoms in isometric strength at five different angles of flexion- and extension."
16437124|NCT03722524||Patients with arterial hypertension|"The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.
~Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients."
16437125|NCT03722511|Active Comparator|NET with carcinoid syndrome|Participants with NET and carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
16437126|NCT03722511|Active Comparator|NET w/o cardinoid syndrome|Participants with NET w/o carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
16437127|NCT03722498|Experimental|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil
16437128|NCT03722498|Active Comparator|Sorafenib|Sorafenib 400 mg orally twice a day
16437129|NCT03722485|Experimental|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|V.A.C. VeraFlo Cleanse Choice Dressing, V.A.C.Ulta Therapy Unit and saline solution
16437130|NCT03722485|Active Comparator|Collagenase Ointment|Collagenase Ointment
16437131|NCT03722472|Experimental|Single-vial ID93 + GLA-SE|Single-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
16437132|NCT03722472|Active Comparator|Two-vial ID93 + GLA-SE|Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
16437133|NCT03722459|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
16437134|NCT03722446|Other|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
16437135|NCT03722446|Other|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
16437136|NCT03722433|Experimental|probiotic plus 14-day sequential therapy|D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
16437137|NCT03722433|Placebo Comparator|placebo plus 14-day sequential therapy|D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
16437138|NCT03722420|Experimental|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
16437139|NCT03722420|Active Comparator|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
16437140|NCT03722407|Experimental|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
16437141|NCT03722394|Experimental|Pain Neuroscience Education|Subjects received a 15-minute verbal, one-on-one Pain Neuroscience Education (PNE) session
16437142|NCT03722368|Experimental|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
16437143|NCT03722368|Experimental|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
16437144|NCT03722368|Other|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
16437145|NCT03722355|Active Comparator|Arm 1: Conventional RT + Carmustine|Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
16437146|NCT03722355|Experimental|Arm 2: Hyperfractionated RT + Carmustine|Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
16437147|NCT03722342|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
16437148|NCT03722329|Experimental|SB12|SB12 (proposed eculizumab biosimilar)
16437149|NCT03722329|Active Comparator|EU Soliris|EU sourced Soliris (eculizumab)
16437150|NCT03722329|Active Comparator|US Soliris|US sourced Soliris (eculizumab)
16437151|NCT03722316|Experimental|MCI/Mild Dementia|"Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
16437152|NCT03722316|Active Comparator|Healthy Older Adults|"Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
16437153|NCT03722303|Active Comparator|Steroid Injection|Subjects with CTS will receive steroid injection.
16437154|NCT03722303|Experimental|Fat Injection|Subjects with CTS will receive fat injection.
16437155|NCT03722290|Experimental|Metformin|Metformin 500mg twice a day per os for 9 weeks
16437157|NCT03722277|Active Comparator|Conventional strength training|The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
16437158|NCT03722264|Experimental|OpalSeal|"OpalSeal will be applied
~to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or
~to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
16437159|NCT03722264|Placebo Comparator|Transbond XT|"TransbondXT will be applied
~to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or
~to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
16437160|NCT03722251|Experimental|Glucose Beverage|50 g of glucose in solution
16437161|NCT03722251|Experimental|Control Beverage|Sucralose in solution
16437162|NCT03722251|Experimental|Glucose beverage and active video game playing|50 g of glucose in solution and 30 min of active video game playing
16437163|NCT03722251|Experimental|Control Beverage and active video game playing|Sucralose in solution and 30 min of active video game playing
16437164|NCT03722238|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
16437165|NCT03722225|Experimental|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
16437166|NCT03722212|Other|Patients for METAglut1|"The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.
~Already diagnosed patients are included retrospectively."
16437167|NCT03722199|Experimental|Healthy persons|In this interventional study the investigators ask the patient (healthy persons) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
16437168|NCT03722199|Experimental|Persons with essential hypertension|In this interventional study the investigators ask the patient (persons with essential hypertension) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
16437169|NCT03722199|Experimental|Persons with type 2 diabetes|In this interventional study the investigators ask the patient (persons with type 2 diabetes) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
16437170|NCT03722186|Experimental|SHR-1603|Multiple escalating doses of SHR-1603
16437171|NCT03722173|Experimental|All subjects|Period 1:Treatment R (BI 894416 alone) followed by Period 2:Treatment T (BI 894416 + itraconazole)
16437172|NCT03722160|Other|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
16437173|NCT03722147|Experimental|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
16437174|NCT03722134|Experimental|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
16437175|NCT03722134|Active Comparator|EVLA|The refluxing GSV was treated with endovenous laser ablation.
16437176|NCT03722134|Active Comparator|RFA|The refluxing GSV was treated with radiofrequency ablation.
16437177|NCT03722108|Experimental|Regorafenib and Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.
16437178|NCT03722108|Active Comparator|Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity
16437179|NCT03722095|Active Comparator|active tDCS + active iTBS|Participants will receive 20 minutes of active tDCS, during the last 7 minutes active iTBS will be applied.
16437180|NCT03722095|Sham Comparator|sham tDCS + active iTBS|Participants will receive 20 minutes of sham tDCS, during the last 7 minutes active iTBS will be applied.
16437181|NCT03722082|Experimental|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
16437182|NCT03722082|Placebo Comparator|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
16437183|NCT03722069|Other|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
16437184|NCT03722069|Other|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
16437185|NCT03722056||gastric GIST|patients with suspected gastric GIST with size > 2cm are subjected for laparoscopic resection.
16437212|NCT03721874|Active Comparator|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.
~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
16437300|NCT03721172|Experimental|Extension Phase: Apremilast 30 mg|Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
16437186|NCT03722043|Experimental|Parenting Program|"All study participants will receive our parenting program curriculum. There will not be a control group.
~The parenting program will include the topics of mindful parenting strategies, emotional regulation, positive discipline, and positive parenting/attachment. Participants will be provided skills to develop strategies for each of the modules. Each session will contain elements of group troubleshooting and practice in-session. Practice at home will be assigned so that participants can continue to practice and implement these skills and strategies in their homes.
~The program is taken from a published, empirically based program called Everyday Parenting: A Professional's Guide to Building Family Management Skills written by Thomas Dishion, Elizabeth Stormshak, and Kathryn Kavanagh."
16437187|NCT03722030|Experimental|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
16437188|NCT03722030|Placebo Comparator|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
16437189|NCT03722017|No Intervention|Control--usual care|"Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:
~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, [OTC medications] and active in-hospital medications. Pre-hospital [and OTC] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event."
16437190|NCT03722017|Experimental|Intervention--deprescribing protocol|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.
~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
16437191|NCT03722004|Active Comparator|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
16437192|NCT03722004|Active Comparator|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
16437193|NCT03722004|Active Comparator|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
16437194|NCT03722004|Active Comparator|bOPV only|bOPV administered at 6, 10, and 14 weeks.
16437195|NCT03721991|Active Comparator|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
16437196|NCT03721991|Placebo Comparator|PLACEBO|Matching placebo capsules to GABA
16437197|NCT03721978|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
16437198|NCT03721978|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
16437199|NCT03721965|Experimental|Itacitinib + Corticosteroids|
16437200|NCT03721952|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
16437201|NCT03721952|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
16437202|NCT03721939|Experimental|FLEX Scoring Catheter plus DEB|The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
16437203|NCT03721926|Experimental|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
16437204|NCT03721926|Active Comparator|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
16437205|NCT03721913|Experimental|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
16437206|NCT03721913|No Intervention|Control group|The control group will not receive the intervention during the study.
16437207|NCT03721900|Experimental|SHX-001 Active Low Dose|Ketamine transdermal patch
16437208|NCT03721900|Placebo Comparator|Placebo|placebo transdermal patch
16437209|NCT03721900|Experimental|SHX-001 Active high dose|ketamine transdermal patch
16437210|NCT03721887|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
16437211|NCT03721887|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
16437298|NCT03721172|Experimental|Placebo-controlled Phase:|Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
16437213|NCT03721874|Placebo Comparator|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.
~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
16437214|NCT03721848|Experimental|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
16437215|NCT03721848|Active Comparator|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
16437216|NCT03721848|No Intervention|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
16437217|NCT03721835|Other|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
16437218|NCT03721822|Experimental|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 5 cigarettes per day, 5 days per week for the past 1 year with no history of e-cigarette use (cannabis or nicotine) or cannabis smoking during the 30 days prior to study enrollment
16437219|NCT03721822|Experimental|Non-Smokers|Reported non-smoking history or < 100 lifetime cigarettes, < 100 e-cigarette use episodes and < 100 lifetime cannabis use episodes
16437220|NCT03721822|Experimental|Nicotine Vapers|Reported current e-cigarette use of nicotine at least 5 days per week for the past year with no current combustible cigarette use, cannabis vaping or cannabis smoking during the 30 days prior to study enrollment
16437221|NCT03721822|Experimental|Cannabis Vapers|Reported current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking or nicotine vaping during the 30 days prior to study enrollment
16437222|NCT03721822|Experimental|Dual Smokers/Vapers|Reported current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 days prior to study enrollment
16437223|NCT03721809|Other|macrophage activation syndrome secondary to bacterial sepsis|Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
16437224|NCT03721809|Other|bacterial sepsis/septic shock|Patients hospitalized in medical intensive care for sepsis / septic shock
16437225|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
16437226|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
16437227|NCT03721783||children with soft tissue lesions|All children who undergo cryoablation therapy for benign soft tissue lesions
16437228|NCT03721770||Relatives|Relative or adult companion (age <18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
16437229|NCT03721757|Other|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.
~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.
~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).
~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).
~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
16437230|NCT03721757|Other|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.
~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.
~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).
~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.
~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
16437231|NCT03721744|Experimental|Napabucasin+Paclitaxel+Gemcitabine|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose).Paclitaxel 80 mg/m^2 will be administered intravenously. Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on RECIST 1.1 criteria
16437232|NCT03721744|Active Comparator|Standard of care treatment options|Patients will receive standard of care treatment options treatment, including Fluorouracil and Leucovorin, Gemcitabine, Onivyde plus Fluorouracil and Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region), or best supportive care (BSC) alone, one of which will be assigned by the investigator for each patient.
16437233|NCT03721718|Experimental|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
16437234|NCT03721718|Experimental|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
16437235|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
16437236|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
16437299|NCT03721172|Experimental|Placebo-controlled Phase: Apremilast 30 mg|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
16437237|NCT03721705|Experimental|Treatment Arm|The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
16437238|NCT03721705|Sham Comparator|Sham Arm|The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
16437239|NCT03721692|Experimental|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
16437240|NCT03721692|No Intervention|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
16437241|NCT03721679|Experimental|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections
~Weeks 3-25:
~Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND
~ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:
~Nivolumab (Opdivo), OR
~Pembrolizumab (Keytruda), OR
~Cemiplimab (Libtayo) OR
~Atezolizumab (Tecentriq) OR
~Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
16437242|NCT03721653|Active Comparator|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)
~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.
~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
16437243|NCT03721653|Experimental|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)
~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.
~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
16437244|NCT03721640||Preterm neonates (< 33 weeks GA)|Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.
16437245|NCT03721627|Experimental|Treatment group|Ledipasvir/sofosbuvir fixed dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily for 12 weeks for those 12-18 years, Wt 35 kg or more and half the dose (45 mg ledipasvir, 200 mg sofosbuvir) once daily for 12 weeks for those 6-11 years, Wt Less than 35 kg.
16437246|NCT03721614|Experimental|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
16437247|NCT03721614|Active Comparator|Xience family Everolimus Coronary Stent Systems|
16437248|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
16437249|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
16437250|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
16437251|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
16437252|NCT03721575|Active Comparator|Scarpa's preserving hernio-abdominoplasty|Hernio-abdominoplasty is performed with preservation of Scarpa's fascia.
16437253|NCT03721575|Active Comparator|Classical hernio-abdominoplasty|Hernio-abdominoplasty is performed with removalof Scarpa's fascia.
16437254|NCT03721549|Experimental|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10^5 genome copies
16437255|NCT03721549|Experimental|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10^6 genome copies
16437256|NCT03721536|Active Comparator|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
16437257|NCT03721536|Active Comparator|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
16437258|NCT03721510|Active Comparator|Group 1A|HIV-uninfected volunteers receiving one IV infusion
16437259|NCT03721510|Active Comparator|Group 1B|HIV-uninfected volunteers receiving one IV infusion
16437260|NCT03721510|Active Comparator|Group 2|HIV-infected volunteers on ART receiving three or six IV infusions
16437261|NCT03721497|Active Comparator|Testosterone Undecanoate|Inj. Testosterone undecanoat (Nebido®), 1000 mg im preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
16437262|NCT03721497|Placebo Comparator|Placebo|Inj. placebo preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
16437301|NCT03721159||Group I|30 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease.
16437263|NCT03721471||Frail, non-frail|"Frail Group: Those individuals identified as frail by low hand-grip-strength and/or the Clinical Frailty Scale.
~Non-frail Group: Those individuals identified as not frail by hand-grip-strength and/or the Clinical Frailty Scale."
16437264|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
16437265|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
16437266|NCT03721432|Experimental|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
16437267|NCT03721432|Placebo Comparator|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
16437268|NCT03721419|Experimental|High Flow High Humidity device|High Flow High Humidity device arm subjects will be placed on a High Flow Airvo device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen. This device has its own flow generator built in.
16437269|NCT03721419|Active Comparator|Low Flow High Humidity Device|Low Flow High Humidity device arm patients will be placed on a Low Flow device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen.
16437270|NCT03721406|Other|Ropivacaine|"25 ml single dose of 0.5% ropivacaine
~continuous infusion of ropivacaine 0.2% with a constant infusion rate of 14 ml/h"
16437271|NCT03721393||Group 1: Syncope patients|Patients that have undergone an ARS assessment and diagnosed with orthostatic hypotension or reflex syncope.
16437272|NCT03721393||Group 2: Control patients|Patients that have undergone an ARS assessment and are control subjects.
16437273|NCT03721380|Experimental|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
16437274|NCT03721380|Other|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
16437275|NCT03721367||Urea Cycle Disorders|
16437276|NCT03721354|Experimental|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
16437277|NCT03721341|Active Comparator|Standard arm|Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.
16437278|NCT03721341|Experimental|Stereotactic Arm|Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.
16437279|NCT03721328|Experimental|Experimental|Joint irrigation with vancomycin and tobramycin
16437280|NCT03721315|No Intervention|Control|This group will receive the standard of care for this condition.
16437281|NCT03721315|Experimental|Intervention|This group will receive additional education along with their designated health support person prior to hospital discharge. This intervention does not include drugs/or devices.
16437282|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
16437283|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
16437284|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
16437285|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
16437288|NCT03721263|Experimental|ASLAN004 Single Ascending Dose|"Up to 10 dose levels are planned.
~ASLAN004 by IV route: 0.1 mg/kg (Cohort 1), 0.3 mg/kg (Cohort 2), 1 mg/kg (Cohort 3), 3 mg/kg (Cohort 4) and 10 mg/kg (Cohort 5), 20 mg/kg (Cohort 6 [optional]).
~ASLAN004 SC route: 75 mg (Cohort 7), 150 mg (Cohort 8), 300 mg (Cohort 9), and 600 mg (Cohort 10 [optional])."
16437289|NCT03721250||thoracic epidural|patients receiving thoracic epidural
16437290|NCT03721237|Experimental|EBC-assisted|A nasogastric tube, equipped with esophageal and gastric balloons, will be inserted in each patient enrolled in the study. After definitive catheter positioning has been obtained, Esophageal ballon calibration will be run in volume-controlled ventilation, pressure support ventilation and sigh + pressure support ventilation.
16437291|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
16437292|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
16437293|NCT03721211|Experimental|[11C]Martinostat|"Subjects will be administered [11C]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center
~All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake
~All subjects will be scanned using [11C]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner
~PET imaging will begin concomitant with radiotracer administration"
16437294|NCT03721198|Active Comparator|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
16437295|NCT03721198|Experimental|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
16437296|NCT03721185|Active Comparator|LC|Lypolitic cream with hypocaloric diet and physicial activity in 51 patients
16437297|NCT03721185|Placebo Comparator|NLC|Hypocaloric diet and physicial activity alone in 51 patients
16437302|NCT03721159||Group II|30 Generalized chronic periodontitis subjects without coronary heart disease.
16437303|NCT03721159||Group III|30 Systemically healthy patients with no chronic periodontitis or coronary heart disease.
16437304|NCT03721133|Other|circulating tumor cell|Recurrent predictive power of circulating tumor cell in non small cell lung cancer patients who receive curative
16437305|NCT03721120|Experimental|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
16437306|NCT03721120|No Intervention|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
16437307|NCT03721107|Experimental|Cohort C Active|two capsules Blautix administered twice daily to subjects diagnosed with IBS-C
16437308|NCT03721107|Placebo Comparator|Cohort C Placebo|two capsules placebo administered twice daily to subjects diagnosed with IBS-C
16437309|NCT03721107|Experimental|Cohort D Active|two capsules Blautix administered twice daily to subjects diagnosed with IBS-D
16437310|NCT03721107|Placebo Comparator|Cohort D Placebo|two capsules placebo administered twice daily to subjects diagnosed with IBS-D
16437311|NCT03721094|Other|Immersive virtual reality|Completing the procedures in immersive virtual reality
16437312|NCT03721094|No Intervention|Conventional virtual reality|Completing the procedures in conventional virtual reality
16437313|NCT03721081|Placebo Comparator|Na Cl 0.9%/Epi 1:200000|Subcutaneous infiltration of Na Cl 0.9%/Epi 1:200000
16437314|NCT03721081|Active Comparator|Lidocaine 1%/Epi 1:200000|Subcutaneous infiltration of Lidocaine 1%/Epi 1:200000
16437315|NCT03721068|Experimental|iC9.GD2.CAR.IL-15 T-cells|The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10^6 cells/kg, 1.0 x 10^6 cells/kg, 1.5 x 10^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10^6 cells/kg.
16437316|NCT03721055|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
16437317|NCT03721042|Experimental|exhaled air|exhaled air analysis of patients
16437318|NCT03721029|Experimental|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
16437319|NCT03721029|Active Comparator|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
16437320|NCT03721016|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
16437321|NCT03721016|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
16437322|NCT03721016|Placebo Comparator|Placebo|Placebo will be injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
16437323|NCT03720990|Experimental|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
16437324|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
16437325|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
16437326|NCT03720951|Experimental|Group I(Pudendal n.)|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
16437327|NCT03720951|Experimental|Group II(Sacral n.)|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
16437328|NCT03720938|No Intervention|Control Group|Physically inactive children who did not play AVGs.
16437329|NCT03720938|Experimental|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
16437330|NCT03720925|Experimental|TDI treatment|"The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and from between 3 to 6 months after the TDI treatment ."
16437331|NCT03720912|Experimental|Online Family Education Modules|Patients will receive online family education modules.
16437332|NCT03720912|No Intervention|Control|Patients will not receive any intervention.
16437333|NCT03720899|Experimental|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
16437334|NCT03720899|Active Comparator|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
16437335|NCT03720886|Experimental|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
16437336|NCT03720886|Experimental|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
16437337|NCT03720886|Active Comparator|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
16437338|NCT03720873|Experimental|EGFR-TKIs and Anlotinib|Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d
16437339|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
16437340|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
16437341|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
16437342|NCT03720847|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
16437343|NCT03720847|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
16437344|NCT03720834||Patients|Questionnaire on risk perception
16437345|NCT03720834||Clinicians|Questionnaire on risk perception
16437346|NCT03720821|Experimental|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A & B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.
~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
16437347|NCT03720808|Experimental|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
16437348|NCT03720808|Experimental|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
16437349|NCT03720808|Experimental|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
16437350|NCT03720808|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
16437351|NCT03720795|Other|Stepped Care CBT|Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
16437352|NCT03720769|Experimental|Step-by-Step|
16437353|NCT03720769|Active Comparator|Enhanced care as usual|
16437354|NCT03720756|Experimental|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
16437355|NCT03720756|Active Comparator|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
16437356|NCT03720743|Experimental|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
16437357|NCT03720743|No Intervention|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
16437358|NCT03720730|Experimental|Study participants|Patients with a recent history of suicidal crisis (within the last 7 days) will use a smartphone application to evaluate sleep, appetite and social parameters.
16437359|NCT03720717|Experimental|Opioid Tolerant - baclofen|
16437360|NCT03720717|Placebo Comparator|Opioid Tolerant - placebo|
16437361|NCT03720717|Experimental|Opioid Naive - baclofen|
16437362|NCT03720717|Placebo Comparator|Opioid Naive - placebo|
16437363|NCT03720704||GORE VIABAHN VBX Balloon Expandable Endoprosthesis|The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.
16437364|NCT03720691|Active Comparator|Real rTMS Supplementary motor area|Real rTMS will be applied over the supplementary motor area
16437365|NCT03720691|Sham Comparator|Sham rTMS Supplementary motor area|Sham rTMS will be applied over the supplementary motor area
16437366|NCT03720678|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
16437367|NCT03720678|Experimental|Dose Expansion-GE|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal cancer
16437523|NCT03719586|Experimental|Control|Zmapp plus optimized Standard of Care (oSOC)
16437849|NCT03717506|Experimental|Test product|GDC 268 Lotion applied topically as directed.
16437368|NCT03720678|Experimental|Dose Expansion-CRC|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with colorectal cancer
16437369|NCT03720665|Active Comparator|Caffeine group|"200mg caffeine tablet
~transcranial alternating current stimulation (140 Hz tACS) at 1 mA
~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA
~transcranial alternating current stimulation (140 Hz tACS) sham
~paired associative stimulation (PAS 25)"
16437370|NCT03720665|Placebo Comparator|Placebo group|"Non-active tablet
~transcranial alternating current stimulation (140 Hz tACS) at 1 mA
~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA
~transcranial alternating current stimulation (140 Hz tACS) sham
~paired associative stimulation (PAS 25)"
16437371|NCT03720652|Experimental|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
16437372|NCT03720652|Experimental|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
16437373|NCT03720639|Active Comparator|Abbott, Inc Confirm Rx™|Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.
16437374|NCT03720639|Active Comparator|Medtronic, Inc Reveal LINQTM|Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.
16437375|NCT03720613||Naldemedine|Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
16437376|NCT03720613||Lubiprostone|Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
16437377|NCT03720613||Naloxegol|Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
16437378|NCT03720600|Experimental|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
16437379|NCT03720600|Other|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
16437380|NCT03720600|No Intervention|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
16437381|NCT03720574|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
16437382|NCT03720574|Placebo Comparator|Matching Placebo BID|Matching Placebo tablet each morning and evening
16437383|NCT03720561||Group: Ibrutinib Treatment|Participants will not receive any intervention as a part of this study. This study will collect retrospective and prospective real-world data to describe retention rates for participants of chronic lymphocytic leukemia (CLL) receiving ibrutinib in routine Italian clinical practice over a 2-year follow-up period. Participants with CLL who have started ibrutinib treatment within 3 months before enrollment visit or in case ibrutinib was prescribed before or on the enrollment day as per routine clinical practice within the 30 days after enrollment visit will be included in the study. The primary data source for this observational study will be the medical records of each enrolled participant, as well as questionnaires concerning quality of life and treatment adherence. Data will be collected every 3 months for the first year and every 6 months for the second year during prospective period.
16437384|NCT03720548|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
16437385|NCT03720548|Placebo Comparator|Placebo (Part A)|Placebo administered IV to healthy participants.
16437386|NCT03720548|Experimental|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
16437387|NCT03720548|Placebo Comparator|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
16437388|NCT03720522||Group 1: Patients suffering from acute myocardial infarction|Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
16437389|NCT03720522||Group 2: Patients suffering from chronic myocardial infarction|Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
16437390|NCT03720522||Group 3: Patients suffering from stunned neurogenic myocardium|"Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.
~These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.
~Patients with normal (< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3."
16437391|NCT03720522||Group 4: Control|Patients with normal (< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
16437392|NCT03720496|Experimental|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
16437393|NCT03720483|Experimental|N-acetyl cysteine then placebo|This arm will receive NAC followed by placebo
16437394|NCT03720483|Experimental|Placebo then N-acetyl cysteine|This arm will receive placebo followed by NAC
16437395|NCT03720470|Experimental|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
16437396|NCT03720470|Experimental|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
16437397|NCT03720470|Active Comparator|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
16437398|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
16437399|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
16437400|NCT03720457|Experimental|Human CD19 targeted T Cells Injection|
16437401|NCT03720444||MDT (mechanical diagnosis and therapy) method|
16437402|NCT03720431|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
16437403|NCT03720418|Experimental|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
16437404|NCT03720418|Experimental|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
16437405|NCT03720418|Experimental|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
16437406|NCT03720418|Experimental|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
16437407|NCT03720418|Sham Comparator|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
16437408|NCT03720392|Experimental|FMT Capsules|"Two doses of FMT: one standard dose starting within four (4) days from the start of the conditioning regimen prior to HCT and one non-standard dose starting within 4 weeks after engraftment after HCT.
~A standard dose of oral FMT is 15 capsules per day for two consecutive days,"
16437409|NCT03720392|Placebo Comparator|Placebo Capsules|"Two doses of placebo, instead of FMT: one starting within four (4) days from the start of the conditioning regimen prior to HCT and the second one starting within 4 weeks after engraftment after HCT.
~A standard dose of oral Placebo is 15 capsules per day for two consecutive days,"
16437410|NCT03720379|Active Comparator|Fluoride Varnish - Fluor PROTECTOR S|"Fluor Protector S - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor, 1.5% ammonium fluoride (7700 ppm fluoride), additional ingredients
~APPLICATION OF Fluor Protector S will be performed AT BASELINE, after 3,6 months (control 1) and after 9 and 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
16437411|NCT03720379|Placebo Comparator|PLACEBO|"- Placebo - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor.
~APPLICATION OF PLACEBO will be performed AT BASELINE, after 3,6 months (control 1) and after 9 AND 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
16437412|NCT03720366|Experimental|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
16437413|NCT03720366|Experimental|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
16437414|NCT03720366|Experimental|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
16437415|NCT03720353|Active Comparator|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
16437416|NCT03720353|Active Comparator|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
16437417|NCT03720353|Placebo Comparator|Placebo|Participants will take placebo for 10 days.
16437418|NCT03720340|Active Comparator|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
16437419|NCT03720340|Placebo Comparator|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
16437420|NCT03720327|Active Comparator|Get FIT|The Get FIT intervention
16437421|NCT03720327|Experimental|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
16437422|NCT03720314||IBS|Irritable bowel syndrome patients
16437423|NCT03720314||control|healthy controls
16437424|NCT03720301|Experimental|Treatment|Study arm who will receive pre operative and intraoperative treatments intended to effect POST severity.
16437425|NCT03720301|Sham Comparator|Sham|Sham are who will receive a preoperative treatment not intended to effect POST outcomes.
16437483|NCT03719833||2-T2-T3 N0 M0|"Breast cancer patients in T2-T3 N0 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by surgery (quadrantectomy/mastectomy + sentinel lymph node biopsy). For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made.
~All patients will be followed for 5 years after surgery"
16437426|NCT03720288|Experimental|Acetazolamide|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.
16437427|NCT03720288|Experimental|Placebo|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
16437428|NCT03720275|Experimental|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
16437429|NCT03720262|Experimental|Mesh reinforcement|Retro muscular mesh at the stoma site.
16437430|NCT03720262|Placebo Comparator|No reinforcement|Standard closure of the abdominal wall
16437431|NCT03720249|Experimental|supplementation of compound nutrients|Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.
16437432|NCT03720249|Placebo Comparator|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.
16437433|NCT03720236|Experimental|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
16437434|NCT03720236|Experimental|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
16437435|NCT03720236|Experimental|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
16437436|NCT03720236|Experimental|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
16437437|NCT03720223|Experimental|Liposomal Bupivacaine|20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.
16437438|NCT03720223|No Intervention|Control|No local anesthetics injected to the buccal mucosal graft harvest site
16437439|NCT03720210|Experimental|RFA group|RFA
16437440|NCT03720197||Participants aged less than 14 years old|
16437441|NCT03720197||Participants aged 14 years old and older|
16437442|NCT03720184|Experimental|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
16437443|NCT03720184|No Intervention|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
16437444|NCT03720171|Experimental|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb.
16437445|NCT03720158|Experimental|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
16437446|NCT03720158|Placebo Comparator|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
16437447|NCT03720145|Experimental|Treatment Group|lifestyle medicine group
16437448|NCT03720145|No Intervention|CAU group|Care-As-Usual group
16437449|NCT03720132|Experimental|Patients with port catheter: flushing|In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.
16437450|NCT03720106|Other|treatment arm|In this arm the GOAL therapy plan is used.
16437451|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
16437452|NCT03720067|Active Comparator|Phase 1: Propranolol (PPL)|Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
16437453|NCT03720067|Active Comparator|Phase 1: Carvedilol (CVD)|HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
16437454|NCT03720067|Active Comparator|Phase 2: PPL non-responders/rosuvastatin|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
16437455|NCT03720067|Placebo Comparator|Phase 2: PPL non-responders/placebo|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
16437456|NCT03720067|Active Comparator|Phase 2: CVD non-responders/rosuvastatin|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
16437457|NCT03720067|Placebo Comparator|Phase 2: CVD non-responders/placebo|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
16437458|NCT03720054|Experimental|MapTrek|Veterans in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so veterans can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
16437459|NCT03720054|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the veterans a Fitbit.
16437460|NCT03720041|Active Comparator|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
16437461|NCT03720041|Experimental|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
16437462|NCT03720041|Active Comparator|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
16437463|NCT03720041|Experimental|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
16437464|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
16437465|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
16437466|NCT03720015|Experimental|Concurrent training|Three sessions per week of concurrent training during radiotherapy period. Each session will begin with warm-up (5-min cardiovascular activity at low-moderate intensity, joint mobility and one set of resistance exercises circuit at 30-40% 1RM). Resistance training will follow the warm-up, including 9 standard exercises involving major muscle groups of the lower and upper body: vertical bench press, parallel bar dip for triceps, seated rowing, standing dumbbell curl for biceps, leg press, deadlift and shoulder press. All these exercises will be realized following circuit training with 4 sets of 8-12 repetitions, using a training load of 70-80% RM. When patient will able to complete more than 12 repetitions, load will be increased progressively 10%. Cardiovascular training will be completed 20-30 min after resistance training, and it will include High-Intensity Interval Training (HIIT) of 3 min near to the second ventilatory threshold and 2 min near to the first ventilatory threshold.
16437467|NCT03720015|Experimental|Nutritional management|Prescribed diet controlling macronutrients according to patient body weight (~4g/kg/day for carbohidrates, ~2g/kg/day for proteins, and ~1g/kg/day for fats). Patient will take one single dosage per day of probiotics (Arkoprobiotics® Defenses), 1 or 2 capsules of omega-3 fish oil concentrate (Solgar®, 600-1200mg depending on fat sources intake during the day), and a combine ingestion of 3g beta-hydroxybeta-methylbutyrate (HMB), 14g arginine, and 14g glutamine (HSN Raw Series®, all pure ingredients and making the ingestion adding each of them individually in a solution with 300-400 ml of water). During concurrent training sessions, between resistance exercise and HIIT, patient will also take 6g of BCAA's (HSN Raw Series®, 2:1:1) along with a banana. Additionally, patient could take whey isolated protein (Amix® IsoPrime CFM) to meet with some of the prescribed proteins intakes.
16437468|NCT03720002|Experimental|Active treatment|Will receive HF2 add-on
16437469|NCT03720002|Placebo Comparator|Placebo|Will receive placebo
16437470|NCT03719989|Experimental|Treatment arm|This study is sing-arm study. Therefore, all enrolled patients will be treated with azacitidine plus R-GDP regimen
16437471|NCT03719976|Experimental|Healthcare navigation workshops|All enrolled caregivers and parents will partake in the group-based educational intervention.
16437472|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
16437473|NCT03719937|Experimental|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
16437474|NCT03719924|Experimental|arm A: ONIVYDE|ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours
16437475|NCT03719924|Active Comparator|Arm B: TAXOL|TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15
16437476|NCT03719911|Experimental|Live diabetes coaching program|Live diabetes coaching program
16437477|NCT03719898|Experimental|Brigatinib|90 mg daily orally for 7 days, then 180 mg daily orally during first cycle; 180 daily orally thereafter during every subsequent cycle. Each cycle has 28 days
16437478|NCT03719885|Experimental|Intervention|
16437479|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
16437480|NCT03719859|Experimental|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
16437481|NCT03719859|Active Comparator|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
16437482|NCT03719833||1-control group-T1-T2 N0 M0|"Breast cancer patients in T1 N0 M0 stage at time of diagnose who initial undergo surgical treatment (quadrantectomy/mastectomy + sentinel lymph node biopsy).
~All patients will be followed for 5 years after surgery"
16437522|NCT03719586|Experimental|C|REGN-EB3 plus optimized Standard of Care (oSOC)
16437484|NCT03719833||3-T1-T3 N1-N2 M0|"Breast cancer patients in T1-T3 N1-N2 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by ultrasound reevaluation of axillary lymph nodes that indicate complete clinical axillary remission. Surgical procedure that would be performed is quadrantectomy/mastectomy + sentinel lymph node biopsy.
~Before initiating neoadjuvant treatment biopsy (FNA) proven positive node will be marked with titanium clip and at the time of surgery removed and pathological examined regardless presenting as a sentinel node or not.
~For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made All patients will be followed for 5 years after surgery"
16437485|NCT03719820||Intracranial Atherosclerosis|First-ever stroke patients attributed to intracranial artery stenosis (> 50% or occlusion) who receive aggressive medical management
16437486|NCT03719807|Active Comparator|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
16437487|NCT03719807|Experimental|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
16437488|NCT03719794|Active Comparator|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
16437489|NCT03719794|Placebo Comparator|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
16437490|NCT03719781||Group1|patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
16437491|NCT03719768|Experimental|Avelumab and Whole Brain Radiotherapy|Avelumab 800 mg intravenously (IV) and 3000 centriGray units (cGy) Whole Brain Radiotherapy once every 2 weeks
16437492|NCT03719755|Active Comparator|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
16437493|NCT03719755|Placebo Comparator|Normal Saline|Cystoscopic distention media of normal saline.
16437494|NCT03719742|Experimental|Sponsor Test Products|"Baby Bee Foaming Cleanser(at least once daily)
~BB Baby Ultra Gentle Lotion (twice daily)"
16437495|NCT03719729|Experimental|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
16437496|NCT03719716|Experimental|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
16437497|NCT03719716|No Intervention|Usual care group|No change to standard care from oncology services and primary care
16437498|NCT03719703||Case 1|Children conceived by frozen embryo transfer
16437499|NCT03719703||Case 2|Children conceived by fresh embryo transfer
16437500|NCT03719703||Control|Naturally conceived children
16437501|NCT03719690|Experimental|AIM-HN|Tipifarnib, Oral Tablet. Dose Level 1 orally, bid on days 1-7 and 15-21 of 28-day treatment cycles
16437502|NCT03719690|No Intervention|SEQ-HN|To obtain historical information of first line therapy in subjects enrolled in AIM-HN, in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
16437503|NCT03719677|Experimental|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
16437504|NCT03719664|Experimental|Cohort 1: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
16437505|NCT03719664|Experimental|Cohort 2: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
16437506|NCT03719664|Active Comparator|Control Arm 1: Baseline ART|Subjects continuing on baseline ART
16437507|NCT03719664|Experimental|Cohort 3: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
16437508|NCT03719664|Experimental|Cohort 4: albuvirtide & 3BNC117|albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
16437509|NCT03719664|Experimental|Optimal Dose: albuvirtide & 3BNC117|albuvirtide and 3BNC117 every 2 or 4 weeks
16437510|NCT03719664|Active Comparator|Control Arm 2: Baseline ART|Subjects continuing on baseline ART
16437511|NCT03719651|Experimental|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.
~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
16437512|NCT03719651|Active Comparator|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).
~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
16437513|NCT03719638|Active Comparator|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
16437514|NCT03719638|Active Comparator|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
16437515|NCT03719625|Experimental|norepinephrin group|The patients of this group will recieve 0.5 micro gr/kg of norepinephin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
16437516|NCT03719625|Experimental|Ephedrin group|The patients of this group will recieve 0,3mg/kg of Ephedrin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
16437517|NCT03719612|Experimental|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
16437518|NCT03719599||Children|Children 6 -12 months of age presenting for routine clinic visits
16437519|NCT03719599||Pregnant Women|Pregnant Women 18 years and older presenting for routine clinic visits
16437520|NCT03719586|Experimental|A|Remdesivir plus optimized Standard of Care (oSOC)
16437521|NCT03719586|Experimental|B|MAb114 plus optimized Standard of Care (oSOC)
16437524|NCT03719573|Experimental|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
16437525|NCT03719573|No Intervention|control.|Usual treatment and care.
16437526|NCT03719560|Experimental|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
16437527|NCT03719547|Experimental|Robot-assisted radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
16437528|NCT03719547|Active Comparator|Abdominal radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
16437529|NCT03719534|Active Comparator|Haplo-SCT|people enrolled in this arm will receive a typical haplo-identical donor SCT
16437530|NCT03719534|Experimental|Haplo-cord SCT|people enrolled in this arm will receive a co-infusion of cord blood unit in addition to a typical haplo-identical donor SCT
16437531|NCT03719521|Experimental|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.
~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
16437532|NCT03719521|Active Comparator|Control Arm|Routine existing services
16437533|NCT03719495||Cohort 1|Pre-menopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
16437534|NCT03719495||Cohort 2|Postmenopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
16437535|NCT03719495||Cohort 3|Pre-menopausal women initiating tamoxifen after standard of care local-regional therapy after surgery +/- radiation.
16437536|NCT03719495||Cohort 4|Pre-menopausal women initiating ovarian suppression plus aromatase inhibition after surgery +/- radiation.
16437537|NCT03719495||Cohort 5|Postmenopausal women initiating endocrine therapy with aromatase inhibition after standard of care surgery +/- radiation.
16437538|NCT03719482|Experimental|[18F]MNI-1054|To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
16437539|NCT03719469||Green tea group|A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University,After starting green tea supplement (4 to 6 cups/day; 60 to 125 mg catechins), patients were evaluated for therapeutic response at baseline and 12, and 24 weeks.
16437540|NCT03719469||control group|fifty healthy normal subjects were included in this study as controls.
16437541|NCT03719456|Experimental|Flexible ureteroscope|
16437542|NCT03719443|Experimental|VIS649|A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
16437543|NCT03719443|Placebo Comparator|Placebo|Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
16437544|NCT03719430|Experimental|Doxorubicin/APX005M|"Patients will be treated with doxorubicin and APX005M in 21 day cycles. All patients receive the same treatment (there is no placebo arm). After completing 8 cycles of study treatment, patients without evidence of disease progression or unacceptable toxicity may continue treatment with APX005M alone. Doxorubicin will not be continued beyond cycle 8 due to the risk for cardiac toxicity from cumulative dosing."
16437545|NCT03719417|Active Comparator|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
16437546|NCT03719417|Active Comparator|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
16437547|NCT03719404|Experimental|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
16437548|NCT03719404|Experimental|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
16437549|NCT03719391|Experimental|JUUL 5% Virginia Tobacco ENDS|Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.
16437550|NCT03719391|Experimental|JUUL 5% Cool Mint ENDS|Treatment with JUUL Cool Mint flavored 5.0% ENDS product.
16437551|NCT03719391|Experimental|JUUL 5% Mango ENDS|Treatment with JUUL Mango flavored 5.0% ENDS product.
16437552|NCT03719391|Experimental|JUUL 5% Creme Brulee ENDS|Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.
16437553|NCT03719391|Active Comparator|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine product.
16437554|NCT03719391|Active Comparator|Nicotine Gum|Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.
16437555|NCT03719391|Active Comparator|Usual Brand Combustible Cigarette|Treatment with usual brand combustible cigarette.
16437556|NCT03719378|No Intervention|Traditional Fluid|"NPO Clears and Food after midnight.
~2 Liters of lactated ringers administered by anesthesia intraoperatively.
~Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).
~Normal diet postoperatively."
16437557|NCT03719378|Experimental|Oral Fluid|"Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)
~NPO Food/Milk: none beginning 8 hours prior to procedure time.
~Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)
~Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.
~PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
16437558|NCT03719365|Experimental|NAVAPSV|Each patient enrolled in the study will be submitted to 3 ventilation trials during PSV and NAVA ventilation modes, assigned in a randomized order.
16437559|NCT03719352|Experimental|Deep dry needling|Deep dry needling will be applied in the upper trapezius myofascial trigger point
16437560|NCT03719352|Experimental|Superficial dry needling|Superficial dry needling will be applied in the upper trapezius myofascial trigger point
16437561|NCT03719352|Placebo Comparator|Placebo Gastrocnemius dry needling|A technique simulating dry needling will be applied in the gastrocnemius myofascial trigger point with a needle guard guide tube, without any therapeutic manoeuvre will be applied.
16437562|NCT03719326|Experimental|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
16437563|NCT03719326|Experimental|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
16437564|NCT03719326|Experimental|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
16437565|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
16437566|NCT03719326|Experimental|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
16437567|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
16437568|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
16437569|NCT03719313|Experimental|Group 1|Lonafarnib 50 mg BID + Ritonavir 100 mg BID
16437570|NCT03719313|Experimental|Group 2|Lonafarnib 50 mg BID + Ritonavir 100 mg BID + PEG IFN alfa-2a 180 mcg QW
16437571|NCT03719313|Active Comparator|Group 3|placebo Lonafarnib + placebo Ritonavir + PEG IFN-alfa-2a 180 mcg QW
16437572|NCT03719313|Placebo Comparator|Group 4|placebo Lonafarnib + placebo Ritonavir
16437573|NCT03719300|Experimental|Single Arm BC-819|inodiftagene vixteplasmid
16437574|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
16437575|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
16437576|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
16437577|NCT03719274|Experimental|non-surgical vitamin c depigmentation|locally injected vitamin c is used to depigment the hyperpigmented gingival tissues
16437578|NCT03719274|Active Comparator|surgical depigmentation|the conventional scalpel surgical technique is used to depigment the hyperpigmented gingival tissues
16437579|NCT03719261|Active Comparator|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
16437580|NCT03719261|Experimental|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
16437581|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
16437582|NCT03719248|Active Comparator|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
16437583|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
16437584|NCT03719248|Active Comparator|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
16437585|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
16437586|NCT03719248|No Intervention|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
16437587|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
16437588|NCT03719248|No Intervention|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
16437589|NCT03719235|Other|column|ultra-low dose CBCT versus digital panoramic radsiography
16437590|NCT03719209|Placebo Comparator|Standard Practice|Patients and families will be shown images of their endoscopic procedure per standard practice.
16437591|NCT03719209|Experimental|Virtual Reality|Patients and families will be showed the results of their endoscopic procedure via a virtual reality application called HealthVoyager, in addition to standard practice images.
16437592|NCT03719196|Experimental|Reading glass provided|"Randomization took place after conducting the census survey. Participants were selected based on the inclusion criteria.
~423 random households were surveyed at the baseline. These households have been given reading glasses free of cost."
16437593|NCT03719196|No Intervention|Non-reading glass|A total of 824 households were surveyed at the baseline survey. Among them, 423 households have been provided reading glasses. The 401 remaining households were not given reading glasses during the baseline survey. The endline survey will be conducted in March 2018. Upon completing the endline survey, the non-reading glasses group will be provided reading glasses.
16437594|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.
~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
16437595|NCT03719170|Experimental|De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
16437596|NCT03719170|No Intervention|No De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and will not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
16437597|NCT03719157|Active Comparator|Unilateral ESP Block|Before general anaesthesia, Ultrasound guided unilateral ESP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
16437598|NCT03719157|Active Comparator|Unilateral OSTAP block|Under general anaesthesia, Ultrasound guided unilateral OSTAP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
16437599|NCT03719157|Active Comparator|Injection of Local Anesthetic to Trocar Insertion|After the laparoscopic surgery was completed, the trocar incision sites were closed. Following the infiltration rules, local anesthetic (15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine) was applied to the trocar sites of skin, fascia, muscle, and preperitoneal area by the surgical team after the operation. A total of 20 mL of local anesthetic was used, with 6 mL for trocar sites of 10 mm, and 4 mL for trocar sites of 5 mm .Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
16437600|NCT03719157|Sham Comparator|multimodal analgesia|Perioperative and postoperative routine analgesic protocol will be performed with no additional regional anesthesia method.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
16437601|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
16437602|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
16437603|NCT03719131|Active Comparator|Arm A (standard of care)|This is standard of care arm: induction with 4 cycles (21 days each) of Ipilimumab and nivolumab followed by continuation with nivolumab alone every month X1 year (13 doses).
16437604|NCT03719131|Experimental|Arm B (rituximab, hyaluronidase human)|This includes induction with 4 cycles of ipilimumab and nivolumab X 4 cycles followed by continuation with nivolumab alone every month for 1 year as in standard of care arm. Each induction cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). First dose of Rituxan will be administered one week following the start of cycle 1 of ipilimumab and nivolumab. All treatments will have a +/-3 business day window for administration.
16437605|NCT03719118|Experimental|Genotyping group|The patients undergo pretreatment of genotyping for three genes (TPMT, NUDT15 and FTO)
16437606|NCT03719118|Active Comparator|Non-genotyping group|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping.
16437607|NCT03719105|Experimental|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.
~Chemotherapy Regimen:
~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.
~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.
~Allogeneic Stem Cell Transplant if donor available and not in PD."
16437608|NCT03719105|Experimental|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).
~Chemotherapy Regimen:
~Cycle 1 & 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 & 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 & 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
16437609|NCT03719092|Experimental|Prevention (vitamin A compound)|Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.
16437610|NCT03719079||Heart Failure Patients|Patients with primary diagnosis as heart failure
16437611|NCT03719066|Active Comparator|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
16437612|NCT03719066|Experimental|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
16437613|NCT03719066|Experimental|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
16437614|NCT03719053|Experimental|Truvada|single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)
16437615|NCT03719027|Experimental|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
16437616|NCT03719014|Experimental|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
16437617|NCT03719001|Experimental|Phenylephrine|Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg
16437618|NCT03719001|Experimental|Dexmedetomidine|Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg
16437619|NCT03719001|Experimental|Clevidipine|Clevidipine infusion will be used to increase blood pressure by 20 mmHg
16437620|NCT03719001|Experimental|Calcium Chloride|Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration
16437621|NCT03719001|Experimental|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone
16437622|NCT03719001|Experimental|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.
16437623|NCT03718988|Experimental|Meat Phase first|Participants will be asked to consume traditional meat products for 8 weeks, then switch to plant-based meat alternative products for another 8 weeks.
16437624|NCT03718988|Experimental|Plant Alternative Phase first|Participants will be asked to consume plant-based meat alternative products for 8 weeks, then switch to traditional meat products for another 8 weeks.
16437684|NCT03718546||Sibling recipients and caregivers|
16437685|NCT03718546||Non-donor sibling|From the donor-recipient families
16437625|NCT03718975|Experimental|Successor of Phonak Audéo B90|The successor of the Phonak Audéo B90 is a Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
16437626|NCT03718975|Active Comparator|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
16437627|NCT03718962|Active Comparator|needling|needling + phototherapy
16437628|NCT03718962|Placebo Comparator|phototherapy|phototherapy
16437629|NCT03718884|Experimental|Drug Cocktail|Drug cocktail administered orally once in Period 1
16437630|NCT03718884|Experimental|Mirikizumab + Drug Cocktail|Drug cocktail administered orally once in Period 2 (day 116). Mirikizumab administered subcutaneously (SC) on multiple occasions in Period 2.
16437631|NCT03718871|Experimental|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
16437632|NCT03718871|No Intervention|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
16437633|NCT03718858|Experimental|Interscalene block|Under sterile precautions, a high frequency linear array transducer [6-13 Megahertz (MHz), Sonosite M-Turbo] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is adjacent to the C5 and C6 roots. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
16437634|NCT03718858|Active Comparator|Superior Trunk Nerve block|Under sterile precautions, a high frequency linear array transducer [6-13 Megahertz (MHz), Sonosite M-Turbo] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. The superior trunk will be identified by tracing the C5 and C6 nerve roots caudally towards the supraclavicular fossa on the anterior lateral portion of the neck. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is properly positioned. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots.
16437635|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
16437636|NCT03718832|Experimental|Treatment Group-Begin Now|"Group 1- Will be randomized to the treatment (Begin Now) group for the Fresh Food Farmacy program. Subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program right away when the program opens in their geographic area. Data will be collected during the first 12 months of subject participation and EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total)."
16437637|NCT03718832|No Intervention|Control Group-Begin Later|"Group 2- Will be randomized to the control (Begin Later) group for the FFF program. These subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program approximately 6 months after the program opens in their geographic area. Data will be collected during the first 6 months of subject participation and used as control data for the study. EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total from the start of the trial)."
16437638|NCT03718806|Experimental|Regimen A|3 g zoliflodacin oral suspension; oral administration after an overnight fast
16437639|NCT03718806|Experimental|Regimen B|3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
16437640|NCT03718806|Experimental|Regimen C|4 g zoliflodacin oral suspension; oral administration after an overnight fast
16437641|NCT03718806|Experimental|Regimen D|4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
16437643|NCT03718780|Experimental|A1: Patient in intensive care|"Patient in intensive care (n=10):
~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).
~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
16437644|NCT03718780|Experimental|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.
~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
16437645|NCT03718780|Experimental|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.
~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
16437646|NCT03718780|Experimental|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
16437686|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
16437687|NCT03718546||Healthy comparison|A matched sample
16437647|NCT03718780|Experimental|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
16437648|NCT03718780|Experimental|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
16437649|NCT03718780|Experimental|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
16437650|NCT03718780|Experimental|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
16437651|NCT03718767|Experimental|1/Nivolumab|Nivolumab is given IV as flat dose of 240 mg for Cycles 1-4 and 480 mg for Cycles 5-16.
16437652|NCT03718754|Active Comparator|En-Bloc TURB|
16437653|NCT03718754|Active Comparator|Conventional TURB|
16437654|NCT03718741|Experimental|Adiuvant Radiotherapy +/- CT|"The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:
~R0: PTVb + PTVn 50 Gy in 25 fractions
~R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).
~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:
~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy
~Patients with ECOG PS<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery."
16437655|NCT03718728|Active Comparator|Standard group|A personalized diet and physical exercise recommendations.
16437656|NCT03718728|Experimental|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
16437657|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
16437658|NCT03718702|Experimental|Intervention group|ePain will be accessible by the intervention group.
16437659|NCT03718702|No Intervention|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
16437660|NCT03718689|Experimental|Group L|The second group of teeth (Group L) were etched with Er:YAG laser.
16437661|NCT03718689|Experimental|Group A+L|The third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid.
16437662|NCT03718689|No Intervention|Group A|The first group of teeth (Group A) were not etched with Er:YAG laser.
16437663|NCT03718676|Other|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
16437664|NCT03718676|Experimental|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
16437665|NCT03718676|Experimental|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
16437666|NCT03718663||Knee OA patients (part 1)|Painful knee OA patients signed up for standardized exercise therapy
16437667|NCT03718663||Healthy subjects (part 2)|Healthy subjects (age 18-28) signed up military service in Defence Command Denmark
16437668|NCT03718650|Experimental|Scans, Surgical Resection and Assessment|Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m^2 pimonidazole (HydroxyProbe).
16437669|NCT03718637|Active Comparator|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
16437670|NCT03718637|Experimental|Experimental|Identical surgical treatment plus Smith & Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
16437671|NCT03718624|Experimental|paclitaxel,apatinib and S-1|
16437672|NCT03718611|Experimental|Sequence 1|BR900A - Wash out - BR9001
16437673|NCT03718611|Experimental|Sequence 2|BR9001 - Wash out - BR900A
16437674|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
16437675|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
16437676|NCT03718585||nocturnal group|Chronic kidney disease patients with nocturnal hypertension
16437677|NCT03718585||non-nocturnal group|Chronic kidney disease patients without nocturnal hypertension
16437678|NCT03718585||non-CKD group|patients without chronic kidney disease
16437679|NCT03718572||Scoring factors|
16437680|NCT03718572||Difficulty criteria|
16437681|NCT03718559|Experimental|Edoxaban alone|
16437682|NCT03718559|Active Comparator|Combination of edoxaban plus single antiplatelet|
16437683|NCT03718546||Sibling pediatric donors|
16437688|NCT03718533|Experimental|Eltrombopag|Patients will receive eltrombopag orally once daily up to 36 weeks.
16437691|NCT03718507|Active Comparator|GROUP Fentanyl|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
16437692|NCT03718507|Experimental|GROUP Sucrose|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
16437693|NCT03718494|Experimental|Follow up|Subjects will receive F-18 Florbetapir PET
16437694|NCT03718494|Experimental|Follow up - Mayo Clinic Sites only|Subjects will receive F-18 AV-1451 PET and F-18 Florbetapir PET
16437695|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
16437696|NCT03718468|Experimental|GC Flu Quadrivalent|
16437697|NCT03718468|Active Comparator|Fluarix tetra|
16437698|NCT03718455|Experimental|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
16437699|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
16437700|NCT03718429|Experimental|aspirin|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
16437701|NCT03718429|Experimental|aspirin and clopidogrel|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
16437702|NCT03718429|Experimental|aspirin and ticagrelor|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
16437703|NCT03718429|No Intervention|rivaroxaban|A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg/qd) as per standard of care will be recruited and will undergo a single PD assessment.
16437704|NCT03718403|Experimental|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
16437705|NCT03718390|Experimental|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
16437706|NCT03718390|Experimental|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
16437707|NCT03718390|Experimental|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
16437708|NCT03718390|Experimental|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
16437709|NCT03718390|Experimental|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
16437710|NCT03718377|Experimental|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
16437711|NCT03718377|Active Comparator|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
16437712|NCT03718351|Active Comparator|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
16437713|NCT03718351|Experimental|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
16437714|NCT03718338||Clinical Evaluations|Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
16437717|NCT03718312|Experimental|Arm 1|Patients with aortic clamping withpre-conditioning
16437718|NCT03718312|No Intervention|Arm 2|Patients with aortic clamping without pre-conditioning
16437719|NCT03718299|Other|tildrakizumab 100 mg|
16437720|NCT03718286|Experimental|Alirocumab|
16437721|NCT03718286|Sham Comparator|Sham Control|
16437850|NCT03717506|Active Comparator|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
16437722|NCT03718273|Active Comparator|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance <60ml / min,
16437723|NCT03718273|Experimental|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
16437724|NCT03718260|Experimental|Cohort 1|Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
16437725|NCT03718260|Experimental|Cohort 2|Men with biochemical failure after initial prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
16437726|NCT03718260|Experimental|Cohort 3|Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
16437727|NCT03718260|Experimental|Cohort 4|Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
16437728|NCT03718260|Experimental|Cohort 5|Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
16437729|NCT03718260|Experimental|Cohort 6|Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
16437730|NCT03718260|Experimental|Cohort 7|[18F]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.
16437731|NCT03718234|Experimental|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
16437732|NCT03718234|Active Comparator|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
16437733|NCT03718221|Active Comparator|Usual Care FIT Screening Strategy|"Mailed outreach invitation to complete FIT include: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage). Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion. Centralized processes to promote guideline-based follow-up."
16437734|NCT03718221|Experimental|GeoMail FIT Screening Strategy|The experimental arm differs from the active comparator in one way: patients living in treated ZIP codes will receive the mailed outreach at the same time.
16437735|NCT03718208|Experimental|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.
~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
16437736|NCT03718195|Other|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.
~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
16437737|NCT03718182|Active Comparator|Arm A - Cholecalciferol 400iu|Vitamin D3 (Cholecalciferol) 400 iu. Daily oral capsule. To be taken for 24 weeks (6 months)
16437738|NCT03718182|Experimental|Arm B - Cholecalciferol 3200iu/800iu|"Vitamin D3 (Cholecalciferol) supplement 3,200iu daily oral capsule. To be taken for 12 weeks (3 months).
~Then switch to vitamin D3 supplement 800iu daily oral capsule. To be taken for 12 weeks (3 months)."
16437739|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
16437740|NCT03718156|Experimental|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
16437741|NCT03718156|No Intervention|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
16437742|NCT03718143|Experimental|Arm A: Elderly Newly diagnosed AML|"Combination AZD1775 with AraC
~Elderly, newly diagnosed AML"
16437743|NCT03718143|Experimental|Arm B:Relapsed AML and MDS|"Combination AZD1775 with AraC
~Relapsed/Refractory AML & HMA failure AML/ MDS"
16437744|NCT03718143|Active Comparator|Arm C: Relapsed AML, MDS and MF|"AZD1775 only
~Relapsed/Refractory AML & HMA failure AML/ MDS and Relapsed/Refractory Primary & Secondary MF"
16437745|NCT03718130|Experimental|Group 1: 0.6 mg HTNV - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
16437746|NCT03718130|Experimental|Group 2: 3.0 mg HTNV - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
16437781|NCT03718000|Experimental|Daily Self-Weighing (DSW)|Participants in this group performed daily self-weighing using digital WiFi scales during the holiday season
16437851|NCT03717506|Placebo Comparator|Placebo|GDC Vehicle lotion applied topically as directed.
16437747|NCT03718130|Experimental|Group 3: 0.6 mg PUUV - Intradermal (ID)|0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
16437748|NCT03718130|Experimental|Group 4: 3.0 mg PUUV - Intramuscular (IM)|0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
16437749|NCT03718130|Experimental|Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
16437750|NCT03718130|Experimental|Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
16437751|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
16437752|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
16437753|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
16437754|NCT03718091|Experimental|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437755|NCT03718091|Experimental|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437756|NCT03718091|Experimental|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437757|NCT03718091|Experimental|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437758|NCT03718091|Experimental|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437759|NCT03718091|Experimental|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437760|NCT03718091|Experimental|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437761|NCT03718091|Experimental|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437762|NCT03718091|Experimental|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437763|NCT03718091|Experimental|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437764|NCT03718091|Experimental|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437765|NCT03718091|Experimental|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
16437766|NCT03718078|Experimental|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
16437767|NCT03718065|Experimental|Lofexidine Men|Men will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
16437768|NCT03718065|Experimental|Lofexidine Women|Women will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
16437769|NCT03718065|Placebo Comparator|Placebo Men|Men will receive matching placebo for five weeks.
16437770|NCT03718065|Placebo Comparator|Placebo Women|Women will receive matching placebo for five weeks.
16437771|NCT03718052|Experimental|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
16437772|NCT03718052|Active Comparator|Conventional care|Conventional care according to the 2015 European guidelines.
16437773|NCT03718039|Experimental|Treatment Group 1|HTX-011
16437774|NCT03718039|Experimental|Treatment Group 2|aprepitant
16437775|NCT03718039|Experimental|Treatment Group 3|HTX-011 and a scheduled multimodal analgesic regimen (oral ibuprofen and acetaminophen).
16437776|NCT03718026||Patients with Multiple Sclerosis|"The timed 360° turn test
~Berg Balance Scale
~Timed Up and Go test
~Functional Reach Test
~One-leg stance test
~Four square step test"
16437777|NCT03718026||Healthy Controls|-The timed 360° turn test
16437778|NCT03718013|Experimental|accelerated dTMS|
16437779|NCT03718013|Active Comparator|standard dTMS|
16437780|NCT03718000|No Intervention|Control|Participants in this group received no intervention during t he holiday season
16438231|NCT03715101|Experimental|Rosuvastatin 20 mg PO|Rosuvastatin 20 mg daily for 21 days
16437782|NCT03717987|Active Comparator|Botulinum toxin A injection|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
16437783|NCT03717987|Active Comparator|Zinc supplementationj prior to Botulinum toxin A injection|"Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
16437784|NCT03717974|Experimental|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
16437785|NCT03717974|Active Comparator|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
16437786|NCT03717961|Experimental|" BTX-A group"|"BOTOX® solution
~Saline serum
~lidocaine/prilocaine cream
~Nitrous oxide/oxygen (50%/50%)
~Intervention Description :
~BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)
~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer
~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
16437787|NCT03717961|Placebo Comparator|Placebo group|"Saline serum
~lidocaine/prilocaine cream
~Nitrous oxide/oxygen (50%/50%)
~Intervention Description :
~Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).
~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.
~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
16437788|NCT03717948|Experimental|CTL - BFR|CTL Exercise then BFR Exercise
16437789|NCT03717948|Experimental|BFR - CTL|BFR Exercise then CTL Exercise
16437790|NCT03717935|Experimental|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
16437791|NCT03717935|Placebo Comparator|Placebo|4 weeks: Placebo- 15g 2/day
16437792|NCT03717922|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MR data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
16437793|NCT03717922|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
16437794|NCT03717909|Experimental|Experimental Group|Sodium Valproate 200Mg E/C Tablet (active treatment)
16437795|NCT03717909|Placebo Comparator|Control Group|Sodium Valproate matched placebo (inactive treatment)
16437796|NCT03717896|Experimental|Thiamine|200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
16437797|NCT03717896|Placebo Comparator|Placebo|100mL 0.9% saline twice daily for two days
16437798|NCT03717883||Healthy subjects|
16437799|NCT03717883||Subjects with ADPKD|
16437800|NCT03717870|Experimental|Surgery|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
16437801|NCT03717870|Active Comparator|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
16437802|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
16437803|NCT03717857||Focus Groups|"Three focus groups with middle school students [N = 5], caregivers [N =5], and school staff [N = 5] will be conducted to inform the development of the intervention.
~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.
~The school staff focus group will include school personnel from the targeted schools."
16437804|NCT03717831||Healthy|Healthy subjects will be enrolled as age and activity matched controls for muscle power assessment at one time-point to establish normative values.
16437805|NCT03717831||ICU|Observational, subjects enrolled initially in the ICU and followed for six months after hospital discharge. ICU subdivided based on diagnosis
16437806|NCT03717818|Experimental|Good Psychiatric Management-Brief|
16437807|NCT03717818|Placebo Comparator|Treatment as Usual-Brief|
16437846|NCT03717532|Experimental|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
16437847|NCT03717532|Placebo Comparator|Patients with Patellopain syndrome with Placebo Cuff|
16437808|NCT03717805|Experimental|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
16437809|NCT03717805|No Intervention|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
16437810|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
16437811|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
16437812|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
16437813|NCT03717753|No Intervention|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
16437814|NCT03717753|Experimental|After Group|We plan to have 70 patients studied after initiation of a pathway.
16437815|NCT03717740|Experimental|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
16437816|NCT03717740|Placebo Comparator|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
16437817|NCT03717727|Experimental|Exergame|Home-based exergame intervention and usual treatment.
16437818|NCT03717727|Experimental|Control|Home-exercise by standard protocol and usual treatment.
16437819|NCT03717714|Active Comparator|Glucosamine 1500mg|Glucosamine 1500 mg per day for 12 weeks
16437820|NCT03717714|Experimental|Polycan & Glucosamine 750mg|Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
16437821|NCT03717714|Experimental|Polycan & Glucosamine 1500mg|Polycan 50 mg + Glucosamine 1500 mg per day
16437822|NCT03717701|Experimental|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
16437823|NCT03717701|Placebo Comparator|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
16437824|NCT03717688|Placebo Comparator|Placebo|No treatment. Participants are subjected to a standardized meal
16437825|NCT03717688|Active Comparator|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
16437826|NCT03717688|Active Comparator|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
16437827|NCT03717688|Active Comparator|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
16437828|NCT03717675|Experimental|Interventional|Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure.
16437829|NCT03717662|Experimental|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
16437830|NCT03717649|Active Comparator|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
16437831|NCT03717649|Active Comparator|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
16437832|NCT03717649|Experimental|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
16437833|NCT03717636|Experimental|Hospital Day|Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.
16437834|NCT03717636|Other|Outpatient clinic|The patients in control group will return for medical evaluation 30 days at the outpatient clinic.
16437835|NCT03717623|Experimental|Posaconazole prophylaxis|Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
16437836|NCT03717610|Experimental|Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min|
16437837|NCT03717597|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
16437838|NCT03717571||Control group|age and sex matched healthy control persons
16437839|NCT03717571||isolated tear|patients with isolated complete supraspinatus muscle tear
16437840|NCT03717571||combined tear|patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
16437841|NCT03717558|Active Comparator|Stromectol R|Stromectol R = ivermectin 3mg (tablet)
16437842|NCT03717558|Experimental|ivermectin T1|T1= ivermectin low grade particle Size Distribution
16437843|NCT03717558|Experimental|ivermectin T2|T2= ivermectin medium grade particle Size Distribution
16437844|NCT03717558|Experimental|ivermectin T3|T= ivermectin high grade particle Size Distribution
16437845|NCT03717545|Experimental|intervention arm|second allogeneic stem cell transplantation
16437848|NCT03717519||s-CRLM|Patients with synchronous colorectal liver metastases who underwent surgical resection
16437852|NCT03717493|Experimental|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking & Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
16437853|NCT03717493|No Intervention|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
16437854|NCT03717480|Experimental|TCR α/β Reagent System|"The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.
~CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
16437855|NCT03717467|Placebo Comparator|S group|Isotonic saline as placebo will be given.
16437856|NCT03717467|Active Comparator|M group|Magnesium sulfate will be given
16437857|NCT03717454|Experimental|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
16437858|NCT03717454|Experimental|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
16437859|NCT03717428|Experimental|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
16437860|NCT03717428|Active Comparator|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
16437861|NCT03717415|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
16437862|NCT03717415|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin
~Triple-negative breast cancer
~Platinum-sensitive Ovarian cancer
~Mesothelioma"
16437863|NCT03717402|Other|Activity 3 Participants (UAT)|"Activity 3 (User acceptability testing):
~Patients will utilize the STAMP app in an observed setting.
~Patients will complete a validated usability survey
~A series of 6 patients will be video-recorded as they are asked to think aloud for 30 minutes as they use STAMP
~Laboratory UAT will be conducted within the DFCI HCC communications laboratory, among (1) patients using opioids for chronic cancer pain, and (2) oncology providers"
16437864|NCT03717402|Other|Activity 4 Participants (Pilot Testing)|"Activity 4 (pilot testing):
~Participants will utilize the STAMP app for 4-weeks.
~STAMP will prompt patients to complete tdaily pain assessments
~The nurse will review PRO's in the STAMP portal and call patients to discuss symptoms, self-management challenges, assist patients in problem-solving, and offer medical advice
~The nurse will monitor the STAMP dashboard daily (Mon-Fri), review clinical alerts, contact patients for symptom problems, and confer with oncologists as needed"
16437865|NCT03717402|Other|Activity 5 Participants (Patient Qualitative Interviews)|"Activity 5 (patient qualitative interviews):
~Eligible patients will take part in a one-time, 1-hour interview with the study team
~Up to 30 patients (including DFCI inpatients and outpatients) will be interviewed about their experiences with a cancer diagnosis and chronic pain management."
16437866|NCT03717363|Active Comparator|Control group|Educational talk: an educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
16437867|NCT03717363|Experimental|Interventional group|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
16437868|NCT03717350|Placebo Comparator|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
16437869|NCT03717350|Active Comparator|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
16437870|NCT03717337|Experimental|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
16437871|NCT03717337|Active Comparator|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
16437872|NCT03717324||First evaluation group (survey_1)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA)
16437873|NCT03717324||Co-creation group|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA) who want to participate in the co-creation workshop
16437874|NCT03717324||Second evaluation group (survey_2)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA), after improvements are made
16437875|NCT03717311|Experimental|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
16437877|NCT03717285|Experimental|Group 1:Under direct vision|Patients in Group 1 insert the UAS under direct vision.In this procedure,the investigators will insert the ureteroscope into urinary bladder beside the guidewire to observe the process of uas insertion into the ureter.
16437878|NCT03717285|Active Comparator|Group 2:Under non direct vision|Patients in Group 2 insert the UAS under non direct vision.In this procedure,the investigators will insert the UAS under fluoroscopy control.
16437879|NCT03717272|Experimental|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
16437880|NCT03717272|Placebo Comparator|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
16437881|NCT03717259|Active Comparator|Open nephrectomy|These patients will undergo an open nephrectomy.
16437882|NCT03717259|Active Comparator|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
16437883|NCT03717259|Active Comparator|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
16437884|NCT03717246|Experimental|Sleep Smart Latino|Sleep Smart Latino is a sleep hygiene intervention culturally tailored to be consistent with the beliefs, behaviors and needs of urban Latino middle school children and families. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting, and 2 60-minute long home based sessions that involve the student and their caregiver. The intervention focuses on sleep education, including effective sleep hygiene practices, use of electronics and caffeine and their impact on sleep.
16437885|NCT03717246|Active Comparator|Basic Sleep Education and Child Health|The basic sleep education and child health condition includes education regarding sleep hygiene , and the effects of sleep on child functioning integrated with additional child health topics such as nutrition, physical activity and safety. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting
16437886|NCT03717246|No Intervention|No treatment control|Students randomly assigned to this arm, will receive standard of care , which is no treatment and will not participate in any group sessions.
16437887|NCT03717233|Experimental|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
16437888|NCT03717220|Other|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
16437889|NCT03717207||type 2 diabetes mellitus (T2DM) patients|T2DM patients affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
16437890|NCT03717207||patients without T2DM|Patients without T2DM affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
16437891|NCT03717194|Experimental|Ertugliflozin|Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
16437892|NCT03717194|Placebo Comparator|Control group|Placebo in addition to their preexisting metformin and/or DPP4 inhibitor
16437893|NCT03717168|Active Comparator|Recombinant human growth hormone|Patients who received growth hormone immediately after tracheostomy.
16437894|NCT03717168|Active Comparator|Control|Patients who did not receive growth hormone and followed the conventional weaning trials
16437895|NCT03717155|Experimental|Avelumab + Cetuximab + Gemcitabine + Cisplatin|
16437896|NCT03717142|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
16437897|NCT03717142|Experimental|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
16437898|NCT03717142|Experimental|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
16437899|NCT03717142|Experimental|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
16437900|NCT03717129|Active Comparator|Genvoya Oral dose|Single observed oral dose of Genvoya whole tablet
16437901|NCT03717129|Experimental|Genvoya Crushed Dose|Single observed oral dose of Genvoya crushed tablet
16437902|NCT03717116||control-normocalcemia group|
16437903|NCT03717116||hypocalcemia group|
16437904|NCT03717103|Experimental|IBI188|
16437905|NCT03717090||Patients with PJI|
16437906|NCT03717077|Experimental|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
16437907|NCT03717077|No Intervention|Usual home care service|The control group maintains home care service
16437908|NCT03717064|Experimental|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.
~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
16437909|NCT03717051|Experimental|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
16437910|NCT03717051|Active Comparator|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
16437911|NCT03717038|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
16437912|NCT03717038|Active Comparator|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
16437913|NCT03717025|Active Comparator|Mini Punch Grafting|
16437914|NCT03717025|Active Comparator|Suction Blister Epidermal Grafting|
16437915|NCT03717025|Active Comparator|Non Cultured Epidermal Cell Suspension|
16437916|NCT03717012|Active Comparator|Nintedanib treatment alone|
16437917|NCT03717012|Experimental|Nintedanib with a pulmonary rehabilitation program|
16437918|NCT03716999||Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
16437919|NCT03716986|Other|SatO2|
16437920|NCT03716973|Experimental|High density programming|High density programming of spinal cord stimulator for paraesthesia-free therapy.
16438396|NCT03713918|Active Comparator|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
16437921|NCT03716960|Experimental|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
16437922|NCT03716960|Placebo Comparator|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
16437923|NCT03716947|Active Comparator|ORBIT Mechanical disc prosthesis|"Surgical procedure with total disc replacement using mechanical disc prosthesis device, ORBIT, Globus Medical"
16437924|NCT03716947|Experimental|ZACK viscoelastic disc prosthesis|"Surgical procedure with total disc replacement using viscoelastic disc prosthesis device, ZACK, FH Orthopaedics"
16437925|NCT03716947|Active Comparator|ORBIT SASCA|Surgical procedure with total disc replacement (TDR) using ORBIT disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
16437926|NCT03716947|Experimental|ZACK SASCA|Surgical procedure with total disc replacement (TDR) using ZACK disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
16437927|NCT03716934|Experimental|Cryoablation|Cryoablation for bidirectional block of all pulmonary veins
16437928|NCT03716934|Active Comparator|Antiarrythmics|The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.
16437929|NCT03716921|Experimental|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
16437930|NCT03716921|No Intervention|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
16437933|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.
~At every cry, parent should answer the questionnaire of cry in infant."
16437934|NCT03716869|No Intervention|Targeted Screening Arm (Current Process)|Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
16437935|NCT03716869|Experimental|Universal Screening Arm (Intervention)|"Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores >10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm."
16437936|NCT03716856|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16437937|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients
~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
16437938|NCT03716830|Experimental|verum acupuncture + real tDCS|
16437939|NCT03716830|Experimental|sham acupuncture + real tDCS|
16437940|NCT03716830|Experimental|verum acupuncture + sham tDCS|
16437941|NCT03716830|Sham Comparator|sham acupuncture + sham tDCS|
16437942|NCT03716817|Experimental|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
16437943|NCT03716804|Experimental|Intervention group|"Intervention:
~To the prescribers- Educational intervention about guideline and present sensitivity trend.
~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
16437944|NCT03716804|Active Comparator|Control Group|"Intervention:
~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
16437945|NCT03716791|Placebo Comparator|Placebo Control Group|pill capsules containing white rice flour
16437946|NCT03716791|Active Comparator|Methylsulfonylmethane Group|pill capsules containing MSM
16437947|NCT03716778|Other|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
16437948|NCT03716778|Experimental|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
16437949|NCT03716765|Experimental|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
16437950|NCT03716765|Active Comparator|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
16437951|NCT03716752|Active Comparator|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
16437952|NCT03716752|Experimental|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
16437953|NCT03716739|Active Comparator|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
16437954|NCT03716739|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks.
16437955|NCT03716726|Experimental|Intervention-WE CARE|"The WE CARE SDoH Screening Survey will be given at all visits by the front desk staff to all parents of Sickle Cell Anemia patients who present to the pediatric hematology clinic. They will also be provided the Family Resource Book.
~Clinical team members (i.e. medical assistants and providers) will be trained to review the WE CARE Social Determinants of Health survey at visits and to provide community resource information sheets to parents with needs. The completed surveys will be scanned into the electronic health record."
16437956|NCT03716726|Experimental|Control-Standard of Care|Standard of care for pediatric patients with sickle cell anemia will be delivered.
16437957|NCT03716713|Experimental|CeraShield Endotracheal Tube|Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.
16437958|NCT03716700||Cohort 1|Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.
16437959|NCT03716700||Cohort 2|Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.
16437960|NCT03716700||Cohort 3|Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.
16437961|NCT03716687|Experimental|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.
~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
16437962|NCT03716687|No Intervention|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
16437963|NCT03716674|Experimental|Parkinson's Disease patients|
16437964|NCT03716661|No Intervention|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
16437965|NCT03716661|No Intervention|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.
~Arm 2: Patients randomized to conservative plaster treatment"
16437966|NCT03716661|Other|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.
~Arm 3: Patients randomized to operative treatment (ORIF)"
16437967|NCT03716648|Active Comparator|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
16437968|NCT03716648|Experimental|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
16437969|NCT03716648|Experimental|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
16437970|NCT03716635|Experimental|cryotherapy|2.5c cold saline as a final flush after chemicomechanical debridement
16437971|NCT03716635|Other|normal saline|room temperature saline is used as a final flush after chemicomechanical preparation
16437972|NCT03716622|Active Comparator|bismuth-clarithromycin-containing group|Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d
16437973|NCT03716622|Experimental|bismuth-furazolidone-containing quadruple group|patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d
16437974|NCT03716609|Experimental|Magnesium supplement group|Subjects receive citrate acid drinks with additional magnesium citrate (300mg magnesium)
16437975|NCT03716609|Placebo Comparator|placebo group|Subjects receive citrate acid drinks without additional magnesium
16437976|NCT03716596|Experimental|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
16437977|NCT03716583|Experimental|Melatonin/DMSO|25 mg melatonin in 1 g cream twice daily for the duration of the radiation therapy
16437978|NCT03716583|Placebo Comparator|Placebo|1 g of cream once daily
16437979|NCT03716570|Experimental|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
16437980|NCT03716570|Experimental|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
16437981|NCT03716570|Experimental|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
16437982|NCT03716570|Placebo Comparator|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
16437983|NCT03716557|Experimental|Spinal Cord Stimulation 4000Hz|Patients will trial Spinal Cord Stimulation 4000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
16437984|NCT03716557|Experimental|Spinal Cord Stimulation 10000Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
16437985|NCT03716557|Active Comparator|Spinal Cord Stimulation 40Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
16437986|NCT03716544|No Intervention|Waiting list control group|There will be no treatment for 12 months.
16437987|NCT03716544|Experimental|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
16437988|NCT03716544|Active Comparator|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
16437989|NCT03716531|Experimental|IORT|"IORT will be administered as determined to be best practice by the treating radiation oncologist,
~Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
16437990|NCT03716518|Experimental|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
16437991|NCT03716518|Placebo Comparator|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
16437992|NCT03716505|Active Comparator|gammaCore Sapphire active|"Treatment 3 times per day, every day for the 12-week treatment period
~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
16437993|NCT03716505|Sham Comparator|gammaCore Sapphire Sham|"Treatment 3 times per day, every day for the 12-week treatment period
~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
16437994|NCT03716479|Experimental|0 fiber|0 grams fiber added to orange juice
16437995|NCT03716479|Experimental|low fiber|20 grams of acacia gum added to orange juice
16437996|NCT03716479|Experimental|high fiber|40 grams of acacia gum added to orange juice
16437997|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
16437998|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
16437999|NCT03716453|Placebo Comparator|Control group|Intraoperative fentanyl administration will be guided by standard protocol
16438000|NCT03716453|Experimental|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
16438001|NCT03716440|Experimental|Nature group|Nature exposure intervention.
16438002|NCT03716440|Active Comparator|Non-nature group|Non-nature exposure intervention.
16438003|NCT03716427|Experimental|Active Treatment- CT1812 560 mg|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)
16438004|NCT03716414||Experimental SLN arm|"Experimental SLN arm
~Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.
~Full bilateral laparoscopic lymphadenectomy and hysterectomy:
~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.
~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
16438005|NCT03716401||Bari: Biopsy Arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Additionally, participants at the Bari site will have an additional renal biopsy at baseline."
16438006|NCT03716401||Bordeaux: MRI Follow-up arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Additionally, participants at the Bordeaux site will have an additional ultrasound US and MRI in Follow-up year 2."
16438007|NCT03716401||Exeter: Microvascular arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Participants at the Exeter site will undergo microvascular measurements including estimating glycocalyx thickness at baseline and at 2 years follow-up."
16438008|NCT03716401||Leeds: Microstructure MRI arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection.
~Participants at the Leeds' site will have an extended MRI scan at baseline including novel microstructure MRI measurements."
16438009|NCT03716401||Turku: PET arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Additionally, participants at the Turku site will undergo a renal Positron Emission Tomography (PET) scan at the baseline timepoint."
16438010|NCT03716388|Experimental|FMT Vs Placebo|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)
16438011|NCT03716388|Active Comparator|FMT Vs Mesalamine|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
16438012|NCT03716388|Active Comparator|Placebo Infusion Vs Mesalamine|Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
16438013|NCT03716375|Experimental|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
16438014|NCT03716375|No Intervention|no use of any drug|Chest tube drainage
16438015|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
16438016|NCT03716349|Experimental|System A|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system w/Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan), informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment, clinical assessment
16438017|NCT03716349|Active Comparator|System B|ScotchBond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M) will randomly be applied to the other tooth informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment and clinical assessment at periodic timepoints.
16438018|NCT03716336|Other|aerobic exercise|walking on treadmill
16438019|NCT03716336|Other|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
16438020|NCT03716323|Experimental|immediate premolar implant with xenograft and allograft|Immediate Implant Placement in Maxillary Premolar zone with grafting the jumping gap using xenograft and allograft
16438021|NCT03716310||septic shock patients|Inclusion criteria of the study were diagnosis of septic shock and a platelet count >150*103/mcL.
16438022|NCT03716245|Experimental|supraclavicular lymph node dissection and raidiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
16438023|NCT03716245|Active Comparator|supraclavicular area radiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
16438024|NCT03716232|Active Comparator|Multiple plastic stents|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.
~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
16438025|NCT03716232|Experimental|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..
~- Stent will be extracted endoscopically after 6 months."
16438026|NCT03716219|Other|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
16438027|NCT03716219|Experimental|Subjects with Asthma|Subjects with asthma who received exercise training
16438028|NCT03716206|Experimental|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
16438029|NCT03716206|Active Comparator|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
16438030|NCT03716193|Experimental|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
16438031|NCT03716193|Experimental|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
16438032|NCT03716193|Experimental|Cohort 3|Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
16438033|NCT03716193|Experimental|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
16438034|NCT03716180|Experimental|Paclitaxel+Trastuzumab+Pertuzumab|Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
16438035|NCT03716167|Experimental|Laser Treatment|Summus Laser treatment with infrared light
16438036|NCT03716167|Sham Comparator|Sham treatment|Sham Summus Laser treatment with no infrared light
16438037|NCT03716154|Experimental|SRP and diode laser|In a split mouth design either left or right sites randomly treated by SRP and diode laser as an adjunct
16438038|NCT03716154|No Intervention|SRP alone|The other sites in the other side will be treated by SRP alone
16438039|NCT03716141|Active Comparator|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
16438040|NCT03716141|Active Comparator|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
16438041|NCT03716128||Low turnover bone disease|PTH<150 pg/ml
16438042|NCT03716128||High turnover bone disease|PTH>300 pg/ml
16438043|NCT03716128||Normal renal function|Patients under examination for prostate cancer
16438044|NCT03716115|Experimental|Colostrum|Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
16438045|NCT03716115|Experimental|GInNAC|N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
16438046|NCT03716115|Experimental|Teduglutide|Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
16438047|NCT03716115|Experimental|Budenoside|Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
16438048|NCT03716115|No Intervention|Standard care|Standard care following WHO guidelines for management of SAM.
16438049|NCT03716102|Experimental|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
16438050|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
16438051|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
16438052|NCT03716076|Experimental|Participant receives 50 mcg of carbetocin post-delivery.|Participant receives 50 mcg of carbetocin post-delivery.
16438053|NCT03716076|Experimental|Participant receives 100 mcg of carbetocin post-delivery.|Participant receives 100 mcg of carbetocin post-delivery.
16438054|NCT03716063|Experimental|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
16438397|NCT03713905|Experimental|GLS-010|Use Full-human anti-pd-1 monoclonal antibodies for treatment
16438055|NCT03716063|Placebo Comparator|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
16438056|NCT03716050|Other|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
16438057|NCT03716050|Active Comparator|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
16438058|NCT03716050|Active Comparator|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
16438059|NCT03716050|Active Comparator|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
16438060|NCT03716050|Active Comparator|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
16438061|NCT03716050|Active Comparator|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
16438062|NCT03716050|Active Comparator|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
16438063|NCT03716050|Active Comparator|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
16438064|NCT03716037|Experimental|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
16438065|NCT03716037|No Intervention|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
16438066|NCT03716024|Experimental|PTK 0796|
16438067|NCT03716024|Active Comparator|Linezolid|
16438068|NCT03716011|Other|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
16438069|NCT03715998|Experimental|Group 1: firibastat 50 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
16438070|NCT03715998|Experimental|Group 2: firibastat 250 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
16438071|NCT03715998|Active Comparator|Group 3: ramipril 2.5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
16438072|NCT03715985|Experimental|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
16438073|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
16438074|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.
~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
16438075|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
16438076|NCT03715959|Experimental|Diagnostic (nipple aspiration fluid)|Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
16438077|NCT03715946|Experimental|Radiotherapy (RT) + Nivolumab Injection|RT of 45 or 50 Gy in 25 daily fractions, 6 fractions per week. Nivolumab will be administered at 240 mg every 2 weeks during radiotherapy, and at 480 mg every 4 weeks for 6 doses after radiotherapy.
16438078|NCT03715933|Experimental|Dose Escalation|INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.
16438079|NCT03715933|Experimental|Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
16438080|NCT03715933|Experimental|Expansion Gastric Adenocarcinoma|Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
16438081|NCT03715933|Experimental|Expansion Colorectal Adenocarcinoma|Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
16438082|NCT03715933|Experimental|Expansion Sarcomas|Subjects with certain sarcoma subtypes will be treated with single-agent INBRX-109 at either the MTD or RP2D.
16438083|NCT03715933|Experimental|Combination Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with INBRX-109 in combination with chemotherapies (carboplatin, cisplatin, carboplatin and pemetrexed, or cisplatin and pemetrexed)
16438084|NCT03715933|Experimental|Combination Expansion Pancreatic Adenocarcinoma|Subjects with pancreatic adenocarcinoma will be treated with INBRX-109 in combination with 5FU/irinotecan based chemotherapy
16438085|NCT03715933|Experimental|Combination Expansion Ewing Sarcoma|Subjects with Ewing sarcoma will be treated with INBRX-109 in combination with irinotecan/temozolomide based chemotherapy
16438398|NCT03713892|Experimental|CKD-504|investigational Drug
16438086|NCT03715920|Active Comparator|High Voltage Pulsed Galvanic Current|HVPG current is a new form of neuromuscular electrical stimulation.The total output voltage of the device ranged from 0 to 500 volts and the current intensity was increased until the sensible contraction of the applied muscle was achieved without causing too much sense of discomfort
16438087|NCT03715920|Placebo Comparator|Russian Current|"Russian currents are a high frequency current of 2500 Hz and reduce the resistance of the skin and it would penetrate deeper and reach deeper motor nerves.Russian movement, a protocol developed by Kots, also known as Russian Technique, was used in the literature. There were 10 muscle contractions per treatment session in this protocol. Each contraction lasted for 10 seconds and a resting time of 50 seconds were given for the next contraction (transition: rest ratio was 1/5)."
16438088|NCT03715920|Sham Comparator|Isometric Exercise|"Isometric or static strength training is exercises performed without joint movement and changing muscle length during muscle contraction.
~The body and knee of the participants in the isometric exercise group were positioned and stabilized at 75 ° flexion and 60 ° flexion angle, respectively as in the stimulation groups. Participants were asked to do 10 repetitions as 10 seconds of maximum voluntary contractions and 10 seconds of rest."
16438089|NCT03715907|No Intervention|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
16438090|NCT03715907|Experimental|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
16438091|NCT03715907|Experimental|Incentives: W34|Informational W34 mailer and incentive to close gap
16438092|NCT03715907|No Intervention|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
16438093|NCT03715907|Experimental|Information only: LSC|Informational LSC mailer and incentive to close gap
16438094|NCT03715907|Experimental|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
16438095|NCT03715907|No Intervention|Control: IMA|No mailer for IMA (immunizations) gap
16438096|NCT03715907|Experimental|Information only: IMA|Informational IMA mailer
16438097|NCT03715907|Experimental|Incentives: IMA|Informational IMA mailer and incentive
16438098|NCT03715907|No Intervention|Control: CDC|No mailer for CDC (clinical diabetes care) gap
16438099|NCT03715907|Experimental|Information only: CDC|Informational CDC mailer
16438100|NCT03715907|Experimental|Incentives: CDC|Informational CDC mailer and incentive
16438101|NCT03715907|No Intervention|Control: CCS|No mailer for CCS (cervical cancer screening)
16438102|NCT03715907|Experimental|Information only: CCS|Informational CCS mailer
16438103|NCT03715907|Experimental|Incentives: CCS|Informational CCS mailer and incentive
16438104|NCT03715907|No Intervention|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
16438105|NCT03715907|Experimental|Information only: AWC|Informational AWC mailer
16438106|NCT03715907|Experimental|Incentives: AWC|Informational AWC mailer and incentive
16438107|NCT03715894||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI
16438108|NCT03715881|Active Comparator|Oral prednisolone administration|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
16438109|NCT03715881|Active Comparator|Intravenous Erythropoietin injection|2. 1000 units of erythropoietin every 12 hours for three days
16438110|NCT03715868|Active Comparator|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
16438111|NCT03715868|No Intervention|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
16438112|NCT03715855|Experimental|exhaled air|exhaled air analysis of patients
16438113|NCT03715842|Experimental|Tub shaped design|The tub-shaped preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
16438114|NCT03715842|Active Comparator|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
16438115|NCT03715829|Experimental|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
16438116|NCT03715829|Experimental|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
16438117|NCT03715829|Experimental|Cohort 3|Maintenance dose A given QD for 24 weeks
16438118|NCT03715829|Experimental|Cohort 4|Maintenance dose B given QD for 24 weeks
16438119|NCT03715829|Experimental|Cohort 5|Maintenance dose C given QD for 24 weeks
16438120|NCT03715829|Placebo Comparator|Cohort 6|Placebo given QD for 24 weeks
16438121|NCT03715829|Experimental|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
16438122|NCT03715829|Experimental|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
16438123|NCT03715829|Experimental|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
16438124|NCT03715829|Experimental|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
16438125|NCT03715829|Experimental|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
16438126|NCT03715829|No Intervention|Extension Cohort 6|Observation period for 24 weeks
16438127|NCT03715816|No Intervention|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
16438399|NCT03713892|Placebo Comparator|Placebo|investigational Drug
16438128|NCT03715816|Experimental|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
16438129|NCT03715816|Experimental|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
16438130|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
16438131|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
16438132|NCT03715790||EP Referred Group|Subjects with EF ≤ 40% or meeting one of the referral criteria
16438133|NCT03715790||Non-Referred Group|Subjects with 40%< EF <50%.
16438134|NCT03715777|Experimental|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.
~Name of each active substance (INN or proposed INN if available):
~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
16438135|NCT03715764|Other|Physical therapy assessment|Patients allocated to the intervention group will be assigned to an assessment and evaluation by a physical therapist. If they are diagnosed with knee osteoarthritis they will get an offer to participate in a patient education program and physical training with an individualized exercise program made by a physical therapist. Patients will be offered individual treatment if they decline to participate in the education program, or if they have another diagnosis than osteoarthritis. Anytime after the first assessment by the physical therapist, the patient will be able to contact a physician if they want to.
16438136|NCT03715764|Other|Physician assessment|Allocation to the control group will involve an assessment and evaluation made by a physician. Further measures will then be determined by attending physician and the procedures that might get included are drug prescriptions, referral to x-ray examination, referral to a physical therapist or another health care provider. Anytime after the first assessment by the physician, the patient will be able to contact a physical therapist if they want to, even though if they have not been referred by the physician.
16438137|NCT03715751|Active Comparator|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
16438138|NCT03715751|Active Comparator|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
16438139|NCT03715738|Experimental|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).
~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.
~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.
~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.
~Once this measurement is completed, participation in the study is complete"
16438140|NCT03715725||Registry cohort|Registries in Norway are nation-wide and provision of the information is mandatory, which eliminates the risk of both selection and re-call bias. The large and detailed dataset also makes it possible to adjust for other risk factors on which information is available.
16438141|NCT03715725||Electronic Medical Records (EMR) cohort|Patients with NVAF diagnosis will be identified through extraction of patient-level data from EMRs from a number of hospitals in Norway, in order to describe these patients more closely regarding their clinical characteristics that are not available in nation-wide registers (e.g., in-patient treatments, anthropometric data and laboratory test results).
16438142|NCT03715712|Experimental|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
16438143|NCT03715712|Active Comparator|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
16438144|NCT03715699|Experimental|Group 1|Patients treated with single glucocorticoid
16438145|NCT03715699|Experimental|Group 2|Patients treated with Leflunomide and glucocorticoid
16438146|NCT03715686|Experimental|Wire localization|Intervention: procedure: wire localization
16438147|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
16438148|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
16438170|NCT03715530|Active Comparator|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
16438232|NCT03715088|Experimental|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
16438149|NCT03715660|Experimental|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
16438150|NCT03715647||Sepsis|"The puerperal / postpartum women who evolved with sepsis, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
16438151|NCT03715647||HELLP Syndrome|"The puerperal / postpartum women who evolved with HELLP syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
16438152|NCT03715647||Respiratory Distress Syndrome, Adult|"The puerperal / postpartum women who evolved with Adult Respiratory Distress Syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
16438153|NCT03715634|Experimental|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
16438154|NCT03715634|Placebo Comparator|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
16438155|NCT03715608|No Intervention|Control group|Patients in the control group received routine TKA surgery and perioperative management without any other interventions.
16438156|NCT03715608|Experimental|Intervention group|The patients in the intervention group received professional psychological interventions include psychological counseling and corresponding medication after the operation. Other perioperative treatments were the same as the patients in the control group. Psychotherapy was based on the clinical expertise of the psychosocial specialist, who selected the most appropriate plan for each patient.
16438157|NCT03715595|Experimental|SSDM group|The patients in will use the SSDM at home every month for one year.
16438158|NCT03715595|No Intervention|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
16438159|NCT03715582|Experimental|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
16438160|NCT03715582|Experimental|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
16438161|NCT03715569||Cohort with CNS infections|"Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.
~Biomarker is a protein found in the inner ear examined in the cerebral fluid."
16438162|NCT03715569||OAE/WBT control: Healthy individuals|Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.
16438163|NCT03715569||OAE/WBT control: Systemic infection|Otoacoustic emission during admission
16438164|NCT03715569||OAE/WBT control: ICP changes|Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).
16438165|NCT03715569||Biomarker control|Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.
16438166|NCT03715556|Active Comparator|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
16438167|NCT03715556|Placebo Comparator|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
16438168|NCT03715543|Experimental|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
16438169|NCT03715530|Experimental|Pregnant subjects|These are pregnant women that are admitted to Labor &Delivery (L&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
16438226|NCT03715127|Active Comparator|Psilocybin|one oral dose of 0.215mg/kg psilocybin (verum)
16438171|NCT03715530|Sham Comparator|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
16438172|NCT03715517|Experimental|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine
~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)"
16438173|NCT03715517|Active Comparator|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia
~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)
~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)
~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)
~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)."
16438174|NCT03715504|Experimental|Single Arm TP-3654|TP-3654 by oral administration
16438175|NCT03715478|Experimental|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
16438178|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
16438179|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
16438180|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
16438181|NCT03715426|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
16438182|NCT03715426|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
16438183|NCT03715413|Other|Tamoxifen group|they was received Tamoxifen 10 mg daily.
16438184|NCT03715413|Active Comparator|Tamoxifen and pulsed radiofrequency group|they was received Tamoxifen 10 mg daily and pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.
16438185|NCT03715400|No Intervention|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
16438186|NCT03715400|Experimental|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
16438187|NCT03715387|Experimental|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
16438188|NCT03715387|Placebo Comparator|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
16438189|NCT03715374|Experimental|PRF+ABB treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A prf membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
16438190|NCT03715374|Active Comparator|Collagen Membrane + ABB treated patients|Periodontal surgery with collagen membrane is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A collagen membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
16438191|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
16438192|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
16438193|NCT03715348|Active Comparator|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)
~FFP will be provide as a solution for intravenous administration, once thawed.
~The dose of the FFP will be ~ 15 mL/kg.
~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
16438194|NCT03715348|Experimental|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at ~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.
~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
16438195|NCT03715335|No Intervention|Baseline|Current STI screening rates.
16438227|NCT03715114|Experimental|GV-971 900 mg|900 mg oral
16438228|NCT03715114|Experimental|GV-971 1200 mg|1200 mg oral
16438196|NCT03715335|Active Comparator|Targeted STI Screening|"Data from the Sexual Health Screen (SHS) will be integrated into the Electronic Health Record (EHR) and will provide Clinical Decision Support (CDS) for GC/CT testing based on SHS-calculated STI risk. Patients will be classified as at high risk for STIs, at risk or low risk if they deny any history of sexual activity. When patients classify as at high risk, clinicians will receive CDS that STI testing is highly recommended; when they care for patients who classify as at risk, they will receive CDS that STI testing is recommended; when caring for patients who classify as at low risk, they will receive CDS that STI testing is not necessary at this time. If the clinician chooses to follow the recommendation for screening based on patient's risk assessment, and the patient consents to testing on the tablet device, urine GC/CT testing will be performed."
16438197|NCT03715335|Active Comparator|Universally Offered STI Screening|During the universally offered screening intervention, STI screening will be offered to all eligible adolescents, regardless of risk. All eligible patients will also complete the SHS, will be informed of the CDC GC/CT testing recommendations and then be given the option to decline STI testing using the tablet device. During this phase, the SHS results will not be available to the clinician. STI testing recommendations will be based only on the patient's decision to undergo GC/CT testing. Like the process followed in the targeted screening phase, if the clinician follows the CDS that informs the clinician that the patient agreed to GC/CT screening and consequently orders testing, urine GC/CT testing will be performed.
16438198|NCT03715322|Active Comparator|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
16438199|NCT03715322|Placebo Comparator|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
16438200|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
16438201|NCT03715309|Experimental|Revlimd|
16438202|NCT03715283|Experimental|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
16438203|NCT03715283|Experimental|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
16438204|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
16438205|NCT03715257|Active Comparator|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.
~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.
~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
16438206|NCT03715257|Active Comparator|Tube changing catheter|"Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.
~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
16438207|NCT03715244||Study group 1|n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
16438208|NCT03715244||Study group 2|n= 220 patients for routine data of general anesthesia (current standard)
16438209|NCT03715244||No intervention: Control group postoperative cognitive deficit|n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
16438210|NCT03715231|Experimental|Glaucoma & Glaucoma Suspect Patients|Patients with Glaucomatous optic neuropathy
16438211|NCT03715218|Experimental|Mother Touch Program|Post natal care provided by trained carer after the birth. 6 weeks of care included massage, special diet, physical and mental relaxations.
16438212|NCT03715218|Other|Usual care Program|Usual care and supervision was provided as usual.
16438213|NCT03715205|Experimental|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
16438214|NCT03715205|Experimental|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
16438215|NCT03715192|Experimental|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
16438216|NCT03715192|Placebo Comparator|Placebo|Normal saline administered as a single IV infusion in healthy participants
16438217|NCT03715192|Experimental|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
16438218|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
16438219|NCT03715166|Experimental|Bumetanide/S95008|
16438220|NCT03715166|Placebo Comparator|Placebo|
16438221|NCT03715153|Experimental|BUMETANIDE/S95008|
16438222|NCT03715153|Placebo Comparator|PLACEBO|
16438223|NCT03715140|Experimental|Patients who will recieve crucumin|patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.
16438224|NCT03715140|Placebo Comparator|Patients who will receive placebo|Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.
16438225|NCT03715127|Placebo Comparator|Placebo|one oral dose of 100% mannitol (placebo)
16438233|NCT03715088|Experimental|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
16438234|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
16438235|NCT03715062|Experimental|Intervention group|Receives education in diagnosing urinary tract infection and use of observation, reflection and communication tool.
16438236|NCT03715062|No Intervention|Control group|No intervention
16438237|NCT03715049|Other|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
16438238|NCT03715036|No Intervention|Fundal height|Patients will have routine fundal height measurement
16438239|NCT03715036|Experimental|Point-of-care US|Patients will receive POC US for DVP and AC.
16438240|NCT03715023|Experimental|Active + SoC|Daily doses of PC786 for 3 days + SoC
16438241|NCT03715023|Placebo Comparator|Placebo + SoC|Daily doses of Placebo for 3 days + SoC
16438242|NCT03715010|Active Comparator|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
16438243|NCT03715010|Placebo Comparator|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
16438244|NCT03714997|Experimental|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
16438245|NCT03714997|Active Comparator|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
16438246|NCT03714984|Experimental|Pre operative exercise|The educational pelvic floor intervention group will receive one months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction. Patients and care giver will receive a daily exercise diary to fill at home and will be advised to follow the exercise program.
16438247|NCT03714984|Active Comparator|Control group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
16438248|NCT03714971|Experimental|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
16438249|NCT03714971|No Intervention|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
16438250|NCT03714958|Experimental|combination HDM201 - Trametinib|"HDM201: Therapeutic class HDM2 inhibitor, given Per Os every D1 and D8 over a 28 day cycle. Four dose-levels possible in dose escalation part: 40 mg, 80mg, 100 mg, 120mg.
~Trametinib: Therapeutic class Protein kinase inhibitor of MEK1 and MEK2 activation and kinase activity. Administrated daily, countinous dosing , twodose-level possible in dose escalation: 1.5 mg and 2mg"
16438251|NCT03714945||Case Group with Allergic Rhinitis|"- Inclusion Criteria
~Both genders of 11-14 years, diagnosed with allergic rhinitis on basis of screening instruments, medical history, clinical assessment (by general ORL examination including nasal endoscopy)
~Chinese in ethnicity
~Positive skin prick test with wheal diameter >= 3mm
~Ability to understand the nature, scope, and possible consequences of the study
~Capability and willingness to comply with the requirements of the protocol"
16438252|NCT03714945||Control Group without Allergic Rhinitis|"- Inclusion Criteria
~Both genders of 11-14 years
~Chinese in ethnicity
~Subjects who have not been diagnosed with a long term medical or psychiatric problem
~Subjects who are not currently undergoing any long term medical treatment."
16438253|NCT03714919|Experimental|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan & acetaminophen and intraoperative intravenous dexmedetomidine & ketamine.
16438254|NCT03714906|Experimental|Treatment|Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
16438255|NCT03714906|No Intervention|Control|Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
16438256|NCT03714880|Experimental|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
16438257|NCT03714880|Placebo Comparator|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
16438400|NCT03713879|Experimental|indomethacin|rectal indomethacin 100 mg to be administered before or after ERCP
16438258|NCT03714867|Experimental|Treatment|Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
16438259|NCT03714867|Placebo Comparator|Control|Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
16438260|NCT03714854|Active Comparator|Deep brain stimulation ON|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
16438261|NCT03714854|Placebo Comparator|Deep brain stimulation OFF|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
16438262|NCT03714841|Experimental|CRP value|The patients point of care CRP value is known by the treating physician
16438263|NCT03714841|Active Comparator|CRP value unknown|The patients point of care CRP value is not known by the treating physician
16438264|NCT03714828|Experimental|Treatment (talimogene laherparepvec)|The subject participation period will be approximately 48 weeks. This will include a screening visit, 4 injection visits and 5 follow up visits. Total length of study/patient is 8.5 to 10.5 months. TVEC will be administered by injection with a needle directly into one or more tumors.
16438266|NCT03714802|Experimental|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
16438267|NCT03714802|Placebo Comparator|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
16438268|NCT03714789||Meropenem|Patients requiring dialysis and receiving meropenem for infection or suspended infection.
16438269|NCT03714789||Vancomycin|Patients requiring dialysis and receiving vancomycin for infection or suspended infection.
16438270|NCT03714789||Ceftriaxone|Patients requiring dialysis and receiving ceftriaxone for infection or suspended infection.
16438271|NCT03714776|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx injected subcutaneously once-weekly
16438272|NCT03714776|Placebo Comparator|Placebo|Placebo matching solution injected subcutaneously once-weekly
16438273|NCT03714763|Experimental|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
16438274|NCT03714763|Experimental|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
16438275|NCT03714750|Active Comparator|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
16438276|NCT03714750|Experimental|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
16438277|NCT03714737|Experimental|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
16438278|NCT03714737|Active Comparator|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
16438279|NCT03714737|Experimental|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
16438280|NCT03714737|Experimental|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
16438281|NCT03714737|Active Comparator|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
16438282|NCT03714737|Experimental|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
16438283|NCT03714737|Active Comparator|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
16438284|NCT03714737|Experimental|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
16438285|NCT03714737|Active Comparator|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
16438286|NCT03714724|Active Comparator|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.
~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
16438287|NCT03714724|Active Comparator|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
16438288|NCT03714724|Active Comparator|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
16438289|NCT03714711||Total hip arthroplasty|Patient who are scheduled to undergo total hip replacement.
16438290|NCT03714711||Total knee arthroplasty|Patient who are scheduled to undergo total knee replacement.
16438291|NCT03714698|Active Comparator|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
16438292|NCT03714698|Placebo Comparator|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
16438293|NCT03714685|Experimental|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
16438294|NCT03714672|Experimental|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
16438465|NCT03713450|Active Comparator|Control without imaging guidance|
16438295|NCT03714672|Experimental|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
16438296|NCT03714672|Active Comparator|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
16438297|NCT03714672|Active Comparator|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
16438298|NCT03714659|Experimental|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
16438299|NCT03714646|Placebo Comparator|Placebo|
16438300|NCT03714646|Active Comparator|beta glucan|
16438301|NCT03714646|Experimental|beta glucan and Resistant Starch|
16438302|NCT03714633|Experimental|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Home-based post-discharge intervention for extreme premature babies and their parents. The intervention consists of one hospital visit, nine home-visits and two telephone calls during the first year corrected age, specifically from one week before discharge to 12 months corrected age. The intervention is strengths-based working with the infant-parent interaction, supporting infant development and strengthening the parent in his/her role.
16438303|NCT03714633|No Intervention|Control|The participants of the Control Group receives treatment as usual, which consists of a regular follow-up program with neurodevelopmental assessment at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 66 months corrected age. Compared to children not participating in the study, the control group will receive an extended follow-up program, with assessment and questionnaires at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 36 months corrected age. Participants in the control group will be referred to specialized care when needed.
16438304|NCT03714620|Active Comparator|0.15 mg/kg IV Ketamine|
16438305|NCT03714620|Active Comparator|0.3 mg/kg IV Ketamine|
16438306|NCT03714607|Experimental|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
16438307|NCT03714607|No Intervention|Control|No intervention
16438308|NCT03714594|Active Comparator|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
16438309|NCT03714594|Active Comparator|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
16438310|NCT03714594|Active Comparator|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
16438311|NCT03714581|Experimental|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
16438312|NCT03714581|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
16438313|NCT03714568|Experimental|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
16438314|NCT03714568|Experimental|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
16438315|NCT03714555|Active Comparator|Nab-Paclitaxel/Gemcitabine + DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
16438316|NCT03714555|Active Comparator|FOLFIRINOX +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
16438317|NCT03714555|Active Comparator|Single-Agent Gemcitabine +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
16438318|NCT03714542|Other|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
16438319|NCT03714529|Experimental|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.
~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
16438321|NCT03714503|Other|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
16438354|NCT03714282|Other|Healthy Control Group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
16438355|NCT03714269|Experimental|Children with cerebral palsy of the spastic type|
16438466|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
16438322|NCT03714490|Experimental|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
16438323|NCT03714490|Active Comparator|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
16438324|NCT03714477|Active Comparator|Treatment Arm|immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list
16438325|NCT03714477|No Intervention|Control Arm|delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later
16438326|NCT03714464|Experimental|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.
~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
16438327|NCT03714464|Experimental|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.
~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
16438328|NCT03714464|Experimental|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.
~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
16438329|NCT03714451|Experimental|Onyx Group|Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).
16438330|NCT03714451|Active Comparator|Wheat Flour Group|Patients with T2DM will receive food products with wheat flour.
16438331|NCT03714438|Experimental|Medicago sativa|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
16438332|NCT03714438|Placebo Comparator|Placebo|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
16438333|NCT03714425|Active Comparator|High frequency device|Subjects will use high frequency Quell devices.
16438334|NCT03714425|Sham Comparator|Low frequency device|Subjects will use low frequency Quell devices.
16438335|NCT03714412|Experimental|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
16438336|NCT03714399||ICUAW group|The physical and psychological effects of ICUAW on patients undergoing aortic valvular surgery will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
16438337|NCT03714386|Experimental|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
16438338|NCT03714386|Active Comparator|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
16438339|NCT03714373|Experimental|DCCR|75 - 450 mg DCCR
16438340|NCT03714360|Experimental|TXA tranexamic acid|a single dose of 10 mg/kg of TXA, with a maximum dose of 1g. Administered as IV injection and marked as 'project-drug' and amount (mL) in the medical record.
16438341|NCT03714360|Placebo Comparator|Sodium Chloride 0,9%|an equivalent volume 0.9 % Sodium Chloride.
16438342|NCT03714347|Active Comparator|Group Control|routine monitoring will be applied to this group
16438343|NCT03714347|Active Comparator|Group Oxygen|cerebral oxygen monitoring is applied to this group
16438344|NCT03714334|Experimental|DNX-2440 injection|all the patients included will be treated with the experimental agent
16438345|NCT03714321|Experimental|Mechanical insufflation-exsufflation arm|MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
16438346|NCT03714321|No Intervention|CPAP arm|CPAP will be given as prescribed by the physician responsible at the intermediate care unit, typically every 4 hours. CPAP will be administered with standard settings of H2O and an oxygen flow of 15L/min.
16438350|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
16438351|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
16438352|NCT03714282|Experimental|Noninvasive Spinal Stimulation with Gait Training|May receive up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
16438353|NCT03714282|Active Comparator|Conventional Gait Training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
16438395|NCT03713918|Experimental|Reinforced lithium silicate endocrown|Device: Endocrown restoration
16438356|NCT03714256|Experimental|Children 6-17 months|"Device, patient mobility, powered:
~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
16438357|NCT03714256|Experimental|Children 18 - 36 months|"Device, patient mobility, powered:
~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
16438358|NCT03714243|Experimental|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
16438359|NCT03714217|Experimental|Intervention|Telenutrition counseling
16438360|NCT03714204|Experimental|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
16438361|NCT03714204|No Intervention|Control Group|Participants assigned to this group served as wait-list controls
16438362|NCT03714191||Improved outcomes|
16438363|NCT03714191||Regulatory reminder|
16438364|NCT03714191||Billing and documentation|
16438365|NCT03714178|Experimental|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
16438366|NCT03714152|Experimental|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
16438367|NCT03714152|Placebo Comparator|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
16438368|NCT03714139|Experimental|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
16438369|NCT03714139|No Intervention|non implant loading|there is not immediate prosthetic restoration
16438370|NCT03714126||HF patients|HF patients will use the Cordio Medical app to record in their hospital visits and at home.
16438371|NCT03714113|Experimental|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
16438372|NCT03714100|Experimental|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
16438373|NCT03714087|Experimental|T1 Conventional treatment before aligner|T1 before aligner: Conventional orthodontic treatment patients before the essix aligner
16438374|NCT03714087|Experimental|T2 After essix aligner|T2 after the aligner: Essix aligner appliance with setup for 3 weeks full time
16438375|NCT03714087|Active Comparator|Historic control group|Conventional orthodontic treatment without finishing protocol UdeA2
16438376|NCT03714074|Experimental|PEEK abutment|PEEK abutment restored with PEEK superstructure
16438377|NCT03714074|Experimental|Zirconia abutment|zirconia abutment restored with PEEK superstructure
16438378|NCT03714061|Experimental|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
16438379|NCT03714061|Active Comparator|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
16438380|NCT03714048||Perioperative|
16438381|NCT03714048||Cardiogenic shock minus arrest|
16438382|NCT03714048||Cardiogenic shock plus arrest|
16438383|NCT03714048||Preventive|
16438384|NCT03714022|Experimental|Treatment A|Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
16438385|NCT03714022|Active Comparator|Treatment B|Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
16438386|NCT03714009|Active Comparator|Fasting group|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. They should take adequate water and non calorie beverages intake daily (2-3 liters)"
16438387|NCT03714009|Other|Non fasting group|no fasting, patients will have usual balanced diet as 3 meals and 2 snacks all over the day. They should take adequate water and non calorie beverages intake daily (2-3 liters)
16438388|NCT03713996|Experimental|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
16438389|NCT03713996|Active Comparator|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
16438390|NCT03713970|Experimental|Celtra duo press|Celtra duo press ingot 20g for three laminate veneers
16438391|NCT03713970|Active Comparator|IPS e.max press|IPS e.max press ingot 20g for three laminate veneers
16438392|NCT03713957|Experimental|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
16438393|NCT03713957|Placebo Comparator|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
16438394|NCT03713944|Experimental|Carboplatin, Pemetrexed, Atezolizumab plus Bevacizumab|"Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.
~Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities."
16438401|NCT03713879|Experimental|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
16438402|NCT03713879|Experimental|indomethacin plus pancreatic stenting|"[rectal indomethacin 100 mg to be administered before or after ERCP] plus [a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire]"
16438403|NCT03713866|Experimental|EP Imaging and Testing|MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.
16438404|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
16438405|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
16438406|NCT03713840|Experimental|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
16438407|NCT03713840|No Intervention|Control|Child care centers in the control arm received access to intervention materials at a later date.
16438408|NCT03713827|Active Comparator|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
16438409|NCT03713827|Active Comparator|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
16438410|NCT03713814|Experimental|Experimental Group|8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.
16438411|NCT03713814|No Intervention|Control group|After the 8 weeks of intervention, the pilots will receive explanation and handbook demonstration of the same exercises.
16438412|NCT03713801|Experimental|Metformin|Dosage is increased over the first 3 weeks up to three 500 mg tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
16438413|NCT03713801|Placebo Comparator|Placebo|Placebo tablet dosage is increased over the first 3 weeks up to three tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
16438414|NCT03713788|Experimental|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
16438415|NCT03713788|No Intervention|Control group|Participants rested in a seated position for 5 minutes.
16438416|NCT03713775|Experimental|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
16438417|NCT03713775|Active Comparator|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
16438418|NCT03713762|Experimental|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
16438419|NCT03713762|Experimental|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
16438420|NCT03713749|Experimental|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
16438421|NCT03713749|No Intervention|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
16438422|NCT03713736|Other|Female patients with spondyloarthritis or rheumatoid arthritis|Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.
16438423|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
16438424|NCT03713710|Experimental|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
16438425|NCT03713710|Experimental|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
16438426|NCT03713697|Experimental|Pap testing|Women assigned to this arm were invited to get a Pap testing at the Basic Health Unit
16438427|NCT03713697|Experimental|Self-Collection for HPV testing|Women assigned to this arm were provided with a kit to engage in self-collection for HPV testing
16438428|NCT03713697|Experimental|Choice|Women assigned to this arm were given a choice between a Pap testing at the local Basic Health Unit or self-collection for HPV testing
16438429|NCT03713684|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (prefilled syringe) administered once weekly for 56 weeks
16438430|NCT03713684|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (prefilled syringe) administered once weekly for 56 weeks
16438431|NCT03713684|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (prefilled syringe) administered once weekly for 56 weeks
16438432|NCT03713684|Placebo Comparator|Placebo|Matching placebo (prefilled syringe) administered once weekly for 56 weeks
16438435|NCT03713658|Experimental|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
16438436|NCT03713658|Experimental|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
16438437|NCT03713658|Experimental|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
16438438|NCT03713645|Experimental|Tacrolimus extended-release 0.13mg/kg/day|Tacrolimus extended-release is initiated within post-operative day 3 of kidney transplant
16438443|NCT03713619|Active Comparator|secukinumab 1|Secukinumab 300mg every 2 weeks
16438444|NCT03713619|Active Comparator|secukinumab 2|Secukinumab 300mg every 4 weeks
16438445|NCT03713619|Placebo Comparator|placebo 1|Placebo group to secukinumab 300mg every 2 weeks
16438446|NCT03713619|Placebo Comparator|placebo 2|Placebo group to secukinumab 300mg every 4 weeks
16438447|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
16438448|NCT03713593|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
16438449|NCT03713593|Active Comparator|lenvatinib plus placebo|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
16438450|NCT03713580|Experimental|Venetoclax+BEAM x 1 cycle prior to ASCT|"Venetoclax dose escalation cohorts + BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) begin with dose level 1 (800mg on Day -7 and Day -6). The dosing cohorts are escalated in a 3 + 3 design but with increasing duration instead of increasing dosage.
~Carmustine 300 mg/m2 by IV over 2 hours on Day -7.
~Etoposide 100 mg/m2 by IV over 6 hours daily for 4 consecutive days, Day-6 through Day-3.
~Cytarabine 200 mg/m2 by IV over 2 hours every 12 hours for 3 consecutive days, Day-6 through Day-4.
~Melphalan 140 mg/m2 by IV over 30 minutes or IV push once on Day -2.
~Following V+BEAM therapy, participants will receive Autologous Stem Cell Transplant (ASCT): infusion of previously collected autologous stem cells and supportive care per institutional guidelines"
16438451|NCT03713567|Placebo Comparator|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
16438452|NCT03713567|Experimental|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
16438453|NCT03713541||Patients with Anorexia nervosa (AN)|Female patients with Anorexia nervosa (AN, ICD-10: F50.0/1) of 14 years and older, receiving an initial treatment due to their AN (start of initial treatment no longer than 3 months ago, inpatient care: at least 7 days inpatient; outpatient care: at least 5 sessions with the same therapist) with sufficient language skills and no serious organic or psychiatric illnesses and no acute suicidality will be consecutively included in the study. No intervention.
16438454|NCT03713541||Carers of patients with AN|Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
16438455|NCT03713541||Physicians of patients with AN|Resident general practitioner, pediatrician, internist or gynecologist with at least one medical patient contact within the last 12 months. No intervention.
16438456|NCT03713528|Other|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, acute hematogenous infection, or unresectable infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
16438457|NCT03713515|Experimental|Practice Faciliation|Will be supported by a practice facilitator
16438458|NCT03713515|No Intervention|Usual Care|Using a stepped wedge design, all practice sites begin as part of the Usual Care (UC) control condition and will receive standard hypertension management that is part of the current clinic procedure. No practice facilitation will occur at this time.
16438459|NCT03713489|Experimental|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
16438460|NCT03713489|No Intervention|standard medical treatment group|standard medical treatment
16438461|NCT03713476|Experimental|Robot-assisted training|The participants will receive 20 minutes of robot assisted tenodesis-grip therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
16438462|NCT03713476|Active Comparator|Traditional occupational therapy|The participants will receive 20 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
16438463|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
16438464|NCT03713450|Experimental|Control with imaging guidance|
16438467|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
16438468|NCT03713424|Active Comparator|Clav|4-day 125 bid oral capsule administration
16438469|NCT03713424|Placebo Comparator|Placebo|4-day, twice-daily oral capsule administration
16438470|NCT03713411|No Intervention|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
16438471|NCT03713411|Active Comparator|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
16438474|NCT03713385||Aged group (n =49)|Determined the optimal endotracheal tube size according to age of the child (internal diameter [ID] in mm = [age in years + 16] /4) suggested by Cole
16438475|NCT03713385||Subglottic diameter group (n =49)|The subglottic transverse diameter was estimated with ultrasonography on the middle of the anterior region of the neck at the level of cricoid cartilage
16438476|NCT03713385||Epiphyseal diameter group (n =49)|The epiphyseal transverse diameter of the distal radius was estimated with ultrasonography.
16438477|NCT03713372|Experimental|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16438478|NCT03713359|Active Comparator|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:
~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
16438479|NCT03713359|Active Comparator|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.
~Subcutaneous injection"
16438480|NCT03713346|Other|Lactose digester|
16438481|NCT03713346|Other|Lactose maldigester|
16438482|NCT03713333|Experimental|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
16438483|NCT03713333|No Intervention|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
16438484|NCT03713320|Experimental|Cobomarsen|
16438485|NCT03713320|Active Comparator|Vorinostat|
16438487|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.
~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
16438488|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
16438489|NCT03713268||Surgical patients|Adult and minor (> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
16438490|NCT03713255|Active Comparator|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
16438491|NCT03713255|Experimental|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
16438492|NCT03713255|Sham Comparator|control group|local anesthetic infiltration subcutaneous 1% lidocaine
16438493|NCT03713242|Experimental|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
16438494|NCT03713242|Experimental|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
16438495|NCT03713242|Experimental|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
16438496|NCT03713242|Experimental|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
16438497|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
16438498|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
16438499|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
16438500|NCT03713216|Experimental|Naldebain|Subjects will receive one dose of Naldebain before surgery.
16438501|NCT03713216|Active Comparator|Morphine|Subjects will receive morphine after surgery.
16438562|NCT03712787|Experimental|ABBV-8E12 Dose 1|Participants will receive ABBV-8E12 Dose 1.
16438502|NCT03713203|Experimental|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
16438503|NCT03713190|Active Comparator|Empagliflozin|SGLT-2 inhibitor
16438504|NCT03713190|Placebo Comparator|placebo|A substance without specific pharmacology principles.
16438505|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
16438506|NCT03713177||Interns|Dental interns of Cairo University
16438507|NCT03713164|Active Comparator|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
16438508|NCT03713164|Active Comparator|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
16438509|NCT03713151|Experimental|Dividat FIT: Computer based exercise|One arm with 10-15 Haemophilia patients and 10-15 Myositis patients.
16438510|NCT03713138|Experimental|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
~Intervention/ Dietary Supplement:
~Flax seed powder
~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
~Other Name: intervention"
16438511|NCT03713138|No Intervention|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.
~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
16438512|NCT03713125|Active Comparator|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
16438513|NCT03713125|No Intervention|Business as Usual|Instruction as usual within schools
16438514|NCT03713112|Active Comparator|Weekly MDT deprescribing rounds|Weekly MDT deprescribing rounds for certain drugs will be performed on top of usual care.
16438515|NCT03713112|No Intervention|Control (Usual Care)|"Usual Care includes the following:
~De-prescribing at the discretion of the ward doctors
~Initial medication reconciliation by pharmacist on admission
~Ward rounds to be conducted 3 weekdays per week for rehabilitative patients and daily on weekdays for sub-acute patients."
16438516|NCT03713099|Experimental|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
16438517|NCT03713086|Active Comparator|Rabipur®|
16438518|NCT03713086|Experimental|CV7202 Dose level 1|
16438519|NCT03713086|Experimental|CV7202 Dose level 2|
16438520|NCT03713086|Experimental|CV7202 Dose level 3|
16438521|NCT03713073|Experimental|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
16438522|NCT03713073|Active Comparator|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
16438523|NCT03713060|Other|Women with RYGB and fetus/ child|20 pregnant women with previous gastric bypass surgery. During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
16438524|NCT03713060|Other|Matched controls and fetus/ child|20 pregnant women matched on age, prepregnancy-BMI and parity (n = 20). During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
16438525|NCT03713034|Experimental|Active Game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.
~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
16438526|NCT03713034|Active Comparator|Control Game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.
~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
16438527|NCT03713021|Experimental|TraceIT Tissue Marker|"Following successful tumor resection, TraceIT Tissue Marker will be applied in 0.2 to 0.5 mL injections at 5 locations to mark the tumor bed: superiorly, inferiorly, laterally, medially, and center of resection. The marginal injections will be within 3 mm of the resection edge and within 5 mm deep. The center of the resection bed will be injected within 5 mm deep if possible.
~Within 6 weeks after surgery, a CT simulation scan will be performed per normal protocol for patients receiving surgery followed by adjuvant therapy. This scan will be used to generate the IMRT treatment plan
~Two treatment plans will be performed per patient using the simulation CT scan. One will be the standard of care treatment plan and will be the basis of the actual radiation treatment they receive. The second treatment plan will be based on utilizing the TraceIT hydrogel markers as a guide for the resection bed."
16438528|NCT03713008|Experimental|Fluid bolus|Patients included in the study will receive fluid bolus.
16438529|NCT03712995|Experimental|Cutler-Beard modified with graft|Reconstruction of Upper Eyelid With a Newly Modified Cutler-Beard Technique With Tarsoconjunctival Graf
16438535|NCT03712969|Experimental|Intervention group|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
16438536|NCT03712969|No Intervention|Control group|Patients receive conventional adjuvant chemotherapy.
16438537|NCT03712956|Experimental|Caelyx® for 8 courses|Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.
16438540|NCT03712930|Experimental|Pamiparib|Participants will receive pamiparib for a period up to 1 year
16438541|NCT03712917|Active Comparator|Greater Occipital Nerve Block|"The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼ (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood."
16438542|NCT03712917|Active Comparator|Topiramate|Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
16438543|NCT03712917|Active Comparator|Flunarizine|Flunarizine is introduced with a single dose of 10 mg/day.
16438544|NCT03712904|Experimental|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
16438545|NCT03712904|Experimental|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
16438546|NCT03712891|Experimental|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
16438547|NCT03712891|No Intervention|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
16438548|NCT03712878|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.
~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.
~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.
~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.
~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
16438549|NCT03712852|Active Comparator|PRF+CAF treated patients|The clot collected from the blood samples is pressed through a calibrated compression system into the PRF box the folded membrane is transferred on a sterile gauze. A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the PRFs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
16438550|NCT03712852|Active Comparator|SCTG+ CAF treated patients|SCTG is taken from the opposite palate area of gingival defect. The graft is collected with a single incision technique and it is measured and adjusted to 1 mm by measuring with a standard caliper.A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the SCTGs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
16438551|NCT03712852|Active Comparator|CAF treated patients|A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the flap is sutured over the enamel in a tension free position.
16438552|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
16438553|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of < 5 on the PCRS Scale.
16438554|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
16438555|NCT03712826|Experimental|anti TNF|Crohn patient with antiTNF treatment
16438556|NCT03712826|Experimental|Ustekinumab|Crohn disease with ustekinumab treatment
16438557|NCT03712813|Experimental|Macrodyne LivMD plate|
16438558|NCT03712813|No Intervention|Wait-Listed Control|
16438559|NCT03712800|Experimental|Rhythmical massage|Participants who receive rhythmical massage for three months.
16438560|NCT03712800|Experimental|HRV biofeedback|Participants who perform HRV biofeedback for three months.
16438561|NCT03712800|No Intervention|Control group|Participants who do not receive an intervention during the three-month intervention period but are advised to stay with their usual care during menstrual pain. For ethical and compliance reasons, these participants receive a series of rhythmical massage treatments after the initial three-month intervention/control period.
16438563|NCT03712787|Experimental|ABBV-8E12 Dose 2|Participants will receive ABBV-8E12 Dose 2.
16438564|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
16438565|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
16438566|NCT03712761||Supplementation with Enriched Protein®|Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
16438567|NCT03712761||Low protein breakfast|No supplementation
16438568|NCT03712761||High protein breakfast|No supplementation
16438569|NCT03712748|Experimental|Imaginal Exposure Session|
16438570|NCT03712735|Active Comparator|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:
~PIEB flow rate = high; interval = 60 min"
16438571|NCT03712735|Experimental|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
16438572|NCT03712735|Experimental|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
16438573|NCT03712722||rCDI|Adult patients with recurrect Clostridium difficile infection
16438574|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
16438575|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
16438576|NCT03712696|Experimental|DIGNICAP™|DigniCap® System
16438577|NCT03712683|Experimental|Sub clinical hypothyroid women|"Levothyroxine sodium(Euthyrox 50µg and 25 µg MerckSerono) treatment was initiated and the women were followed in a combined clinic of endocrinologist and Gynecologist.
~2.5 µg of Thyroxine daily was prescribed to women with TSH more than 2.5 mIU/L. Women with TSH more than 4mIU/L were given 50 µg daily . When pregnancy was confirmed Thyroxine was continued till 13 weeks gestation ."
16438578|NCT03712670|Active Comparator|AM group|Intravitreal aflibercept monotherapy
16438579|NCT03712670|Experimental|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
16438580|NCT03712670|Experimental|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
16438581|NCT03712657|Experimental|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
16438582|NCT03712657|No Intervention|conservative group|normal treatment
16438583|NCT03712644|No Intervention|Conservative|Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.
16438584|NCT03712644|Experimental|Invasive|"In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization
~All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR>0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.
~For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible."
16438585|NCT03712631|Active Comparator|bone without a collagen membrane|not covering bone with collagen membrane
16438586|NCT03712631|Experimental|bone with collagen membrane|covering bone with collagen membrane
16438587|NCT03712618|Active Comparator|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
16438588|NCT03712618|Active Comparator|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
16438591|NCT03712592|Experimental|160km|
16438592|NCT03712592|Experimental|40km|
16438593|NCT03712592|Experimental|100km|
16438594|NCT03712592|Experimental|4x40km|
16438595|NCT03712579|Experimental|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
16438596|NCT03712579|Experimental|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
16438597|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
16438598|NCT03712553|Active Comparator|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
16438599|NCT03712553|Experimental|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
16438657|NCT03712228|Active Comparator|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
16438658|NCT03712228|Active Comparator|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
16438600|NCT03712553|Experimental|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
16438601|NCT03712553|Experimental|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
16438602|NCT03712553|Active Comparator|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
16438603|NCT03712553|Experimental|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
16438604|NCT03712553|Active Comparator|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
16438605|NCT03712553|Experimental|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
16438606|NCT03712540|Experimental|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
16438607|NCT03712527|Experimental|Platelet-Rich Plasma|
16438608|NCT03712527|Placebo Comparator|Placebo|
16438609|NCT03712514|Other|Rugby players|Destabilization of the upper cervical spine with Cervistab
16438610|NCT03712514|Other|Healthy non rugby players|Destabilization of the upper cervical spine with Cervistab
16438611|NCT03712501|Experimental|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
16438612|NCT03712501|No Intervention|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
16438613|NCT03712475|Experimental|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
16438614|NCT03712475|Active Comparator|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
16438615|NCT03712462|Experimental|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
16438616|NCT03712462|Active Comparator|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
16438617|NCT03712449|Experimental|BELKYRA Treatment|"BELKYRA was injected into the subcutaneous fat for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose did not exceed 100 milligrams (mg) [10 milliliters (mL)] in a single treatment.
~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11.
~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8. The volume of filler injected at initial and touch-up treatments was determined by the investigator.
~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 9 and Month 10."
16438618|NCT03712449|Experimental|Non-BELKYRA Treatment|"Participants who did not receive BELKYRA.
~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 0 to Month 5.
~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 0 to Month 2. The volume of filler injected at initial and touch-up treatments was determined by the investigator.
~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 3 and Month 4."
16438619|NCT03712436|Experimental|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
16438620|NCT03712436|Active Comparator|patients receiving standard oncological care|Patients receiving standard oncologic care.
16438621|NCT03712423|Experimental|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed < 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
16438622|NCT03712410|Active Comparator|Group 1 (PISCES face to face)|"Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely Attitude and Defining the Problem and Setting Realistic Goals. During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works."
16438659|NCT03712228|Active Comparator|CSL312-F|Subjects with FXII or plasminogen mutation (FXII/PLG) HAE receiving CSL312
16438623|NCT03712410|Experimental|Group 2 (PISCES delivered in a hybrid format)|In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
16438624|NCT03712410|Experimental|Group 3 (PISCESplus)|"PISCESplus is meant to be an enhanced version of the PISCES intervention including the original problem solving therapy modules with the addition of positive reappraisal elements. The suggested timeline for the first session which will be in person is 5-7 days after hospice admission. At the end of the first session, the interventionist will ask the caregiver to take the time to think about and identify some positive aspects of caregiving.
~At the end of the second session (which is scheduled to take place via video approx. 11-13 days after admission) the interventionist will ask the caregiver to go over the benefits or positive aspects of caregiving that they had identified and ask them to comment as to why they perceive these as positive or beneficial.
~The third session will also take place via video."
16438625|NCT03712397|Experimental|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
16438626|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
16438627|NCT03712371|Experimental|Chitosan dose escalation|
16438628|NCT03712358|Experimental|Cohort 0 (PVSRIPO)|A single dose of PVSRIPO into a single lesion.
16438629|NCT03712358|Experimental|Cohort 1 (PVSRIPO)|A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
16438630|NCT03712358|Experimental|Cohort 2 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
16438631|NCT03712358|Experimental|Cohort 3 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
16438632|NCT03712358|Experimental|Cohort 4 (PVSRIPO)|A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
16438633|NCT03712345|Experimental|Group A|Will receive IFX-1 low dose regimen diluted in sodium chloride solution
16438634|NCT03712345|Experimental|Group B|Will receive IFX-1 high dose regimen diluted in sodium chloride solution
16438635|NCT03712345|Placebo Comparator|Group C|Will receive placebo
16438636|NCT03712332|Experimental|Distress Tolerance Group|6 session inpatient distress tolerance group intervention twice a week for 1.5 hours for up to three weeks.
16438637|NCT03712319|Experimental|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
16438638|NCT03712319|Active Comparator|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
16438639|NCT03712319|No Intervention|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
16438640|NCT03712306|No Intervention|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
16438641|NCT03712306|Experimental|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
16438642|NCT03712306|Experimental|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
16438643|NCT03712293|Experimental|BBB Disruption with Chemotherapy Arm|All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
16438644|NCT03712280|Experimental|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
16438645|NCT03712280|Experimental|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
16438646|NCT03712280|Experimental|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
16438647|NCT03712280|Active Comparator|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
16438650|NCT03712241|Experimental|Treatment A|K-285 dose/application method A
16438651|NCT03712241|Experimental|Treatment B|K-285 dose/application method B
16438652|NCT03712241|Experimental|Treatment C|K-285 dose/application method C
16438653|NCT03712241|Active Comparator|Treatment D|Indomethacin capsule
16438654|NCT03712228|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
16438655|NCT03712228|Active Comparator|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
16438656|NCT03712228|Active Comparator|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
16438660|NCT03712215|Experimental|Experimental Group 1|synchronized FES mode, according to the parameters based on the Gueddes et al., (1991): current frequency (F) 30 Hz; pulse width (T) 0,4 ms; upload time (Rise) 1s; time of muscle contraction (On time) 1 s; down time (Decay) 2s e muscle relaxation time (Off time) 1 s.
16438661|NCT03712215|Experimental|Experimental Group 2|the same apparatus will be used, differing in the parameters that will be based on the studies of Cancelliero et al., (2012) for the EDET procedure, being used in synchronized FES mode, with frequency of 30 Hz; pulse width (T) 0,4 ms, climb (ramp) of 0,7 s (maximum value). The support was of 0.4 s, already standardized and fixed in the apparatus
16438662|NCT03712215|No Intervention|Control Group|The control group (CG) with the same characteristics of the experimental groups will perform conventional physiotherapy
16438663|NCT03712202|Experimental|Group I Arm A (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16438664|NCT03712202|Experimental|Group I Arm B (ABVD, nivolumab)|Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16438665|NCT03712202|Experimental|Group II (AVD, brentuximab vedotin, nivolumab)|Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16438666|NCT03712189|No Intervention|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
16438667|NCT03712189|Experimental|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
16438668|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
16438669|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
16438670|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 1)|
16438671|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 2)|
16438672|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 3)|
16438673|NCT03712163|Experimental|Norketotifen or Placebo (Multiple Dose)|
16438674|NCT03712150||Healthy|"Healthy adults
~- Participants will receive single session of tdcs after application"
16438675|NCT03712137|Experimental|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional maintenance treatment at Month 12.
16438676|NCT03712137|Experimental|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
16438677|NCT03712124|Experimental|CNSA-001|Patients will receive CNSA-001 (sepiapterin) 20 mg/kg/day (10 mg/kg twice daily) for 14 days as an oral suspension.
16438678|NCT03712124|Placebo Comparator|Placebo|Patients will receive a placebo oral suspension twice daily for 14 days.
16438679|NCT03712111|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
16438680|NCT03712111|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
16438681|NCT03712098|Experimental|Smoking Cessation Counseling & Liraglutide|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of the medication liraglutide. Liraglutide comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which follows FDA guidelines and is documented to be safe and well-tolerated in prior clinical studies, will begin at 0.6 mg and increase weekly by 0.6 mg until the recommended dose of 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
16438682|NCT03712098|Active Comparator|Smoking Cessation Counseling & Placebo|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of placebo. The placebo comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which is the same as the liraglutide regimen, will begin at 0.6 mg and increase weekly by 0.6 mg until 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
16438683|NCT03712085|Active Comparator|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
16438684|NCT03712085|Sham Comparator|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
16438685|NCT03712085|No Intervention|Control Group|Upper limb rehabilitation only
16438686|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
16438687|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
16438688|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
16439000|NCT03709953|Experimental|apatinib|apatinib, 500 mg, po, QD; 28 days every cycle
16438689|NCT03712059||diagnostic group|All 10000 patients receive FIT test and colonoscopy, whose age, sex, family history, smoking history, body mass index (BMI), and diabetes history of the patients are collected by researchers through pad, equipped with a specially designed database and app. Using colonoscopy results as the gold standard, the diagnostic value of the APCS score and FIT test for the Chinese population is explored, and the optimal strategy of colonoscopy practice for the Chinese established initially.
16438690|NCT03712059||Adenoma resection group|During the polypectomy of 2000 patients, for all pathologically confirmed or NBI-predicted adenomas with size<10mm, 1-2 biopsies were randomly performed on the edge after resection to determine the completion rate of the polypectomy.
16438691|NCT03712059||Identification and classification group|For 12000 patients regardless of cancer diagnosis or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
16438692|NCT03712046|Experimental|Main arm|PET-CT imaging of the ankles and feet following injection of 18F-FDG
16438693|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.
~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
16438694|NCT03712007|Experimental|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
16438695|NCT03712007|Active Comparator|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
16438696|NCT03711994|No Intervention|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
16438697|NCT03711994|Active Comparator|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
16438698|NCT03711994|No Intervention|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
16438699|NCT03711994|Active Comparator|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
16438700|NCT03711981|Active Comparator|TAP block of 10cc Liposomal bupivacaine|Patients in this arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery.
16438701|NCT03711981|No Intervention|Routine pre-incisional injections at trocar incision sites|The patients in the control arm of the study would receive routine pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.
16438702|NCT03711968|Active Comparator|Treatment group|"Rehabilitative treatment protocol:
~Therapeutic exercise 8 mono-weekly sessions, 5 patients per group, duration 60 minutes and two sessions of single treatment, duration 60 minutes (duration of treatment about two months, considering also any recovery sessions)"
16438703|NCT03711968|No Intervention|Waiting list|Intervention: The WL patients will be taken into the same treatment at the end of the experimental protocol, after T2 evaluation. In this period they act like a control group.
16438704|NCT03711955|Experimental|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
16438705|NCT03711955|Experimental|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
16438706|NCT03711942|Active Comparator|Periodontally Healthy IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar.
16438707|NCT03711942|Experimental|Periodontally Healthy Base|2mm thick base was applied in periodontally health teeth.
16438708|NCT03711942|Experimental|Periodontally healthy control|coronal access was restored with composite resin without any base.
16438709|NCT03711942|Active Comparator|Periodontally diseased IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar
16438710|NCT03711942|Active Comparator|Periodontally diseased Base|2mm thick Base of GIC was applied under composite restoration
16438711|NCT03711942|Active Comparator|Periodontally diseased control|coronal access was restored with composite resin without any base
16438712|NCT03711929|Experimental|Test Arm: DE-109 Injectable Solution|Intravitreal injection of DE-109 440 µg in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects).
16438806|NCT03711214|Active Comparator|pSS patients|We will evaluate 40 patients with pSS (EULAR/ACR Classification Criteria, 2016) of both sexes before and after periodontal disease treatment.
16438713|NCT03711929|Sham Comparator|Control Arm: Sham Procedure|Sham procedure administered to the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects). The sham procedure mimics an intravitreal injection without penetrating the eye.
16438714|NCT03711929|Other|Dummy Arm: DE-109 Injectable Solution|Dummy Arm: Intravitreal injection of DE-109 at an undisclosed, fixed dose (within the range of 44 µg to 880 µg) in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 40 subjects). This study arm (which has the same route of administration and frequency as the test arm).
16438715|NCT03711916|Experimental|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
16438716|NCT03711916|No Intervention|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
16438717|NCT03711903|Experimental|Treatment arm|The study drug, CN-105, will be administered at 1.0 mg/kg every 6 + 2 hours. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
16438718|NCT03711903|Placebo Comparator|Placebo arm|The Placebo arm will be given 0.9% NaCL
16438719|NCT03711890|Experimental|Diagnostic (resection, OCT)|Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
16438720|NCT03711877|Experimental|scalp cooling system|'Scalp cooling device' will be used to prevent alopecia during chemotherapy regimen infusion.
16438721|NCT03711877|Active Comparator|cold cap|'Cold cap' will be used to prevent alopecia during chemotherapy regimen infusion.
16438722|NCT03711864|Experimental|IM21 CAR-T cells|IM21 CAR-T cells
16438723|NCT03711851|Experimental|Web-based|Self-help Acceptance and commitment therapy (Web-based)
16438724|NCT03711851|Experimental|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
16438725|NCT03711851|Active Comparator|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
16438726|NCT03711838|Experimental|N-Acetylcysteine|N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
16438727|NCT03711838|Active Comparator|Placebo|Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).
16438728|NCT03711825|Experimental|Sentinel/Main|Sentinel dosing of two subjects in clinic of LYN-057 (50 mg), followed by Main, i.e. remaining 6 subjects, for total of 8 subjects doses; followed by imaging assessment (MRI/abdominal U/S)
16438729|NCT03711812|Active Comparator|Serratus Anterior Plane Catheter|
16438730|NCT03711812|Placebo Comparator|Thoracic Epidural|
16438731|NCT03711799|No Intervention|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
16438732|NCT03711799|Experimental|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
16438733|NCT03711786|Active Comparator|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
16438734|NCT03711786|Experimental|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
16438735|NCT03711773|Experimental|Group Physical Therapy Class|Group Physical Therapy Classes. Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
16438736|NCT03711760|Experimental|intervention|telepsychology treatment
16438737|NCT03711760|No Intervention|usual care|standard of care
16438739|NCT03711734|Experimental|Acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.
~Patients will have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally with electrostimulation at Shen men and Hypothalamus at 30 hz."
16438740|NCT03711734|No Intervention|No acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.
~Patients will not have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally."
16438741|NCT03711721|Experimental|Food basket|
16438742|NCT03711721|Experimental|Ready-to-Use Therapeutic Food|
16438743|NCT03711708|Experimental|Zoloft Oral Solution|50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
16438744|NCT03711708|Active Comparator|Zoloft Tablets|Zoloft 50 mg tablet.
16438745|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
16438746|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
16438747|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
16438748|NCT03711682|Experimental|Cinnamon (Intervented)|
16438749|NCT03711682|Placebo Comparator|Wheat Flour (Placebo)|
16438750|NCT03711656|Experimental|isCGM and Physical exercise tracker|"Participants will perform CGM during 12 weeks using an isCGM (intermittently scanned Continuous Glucose Monitoring), Freestyle Libre, (Abbott Diabetes Care, Witney, Oxon, UK). Insulin dose (rapid-acting and long acting), carbohydrates and Self-monitoring blood glucose (SMBG) per day will be recorded by the patient in the reader or in the App (LibreLink, Abbott Diabetes Care, Witney, Oxon, UK). Moreover, participants will be instructed to collect data about moderate or high intensity exercise, illness and other disturbances occurring during the study period at home.
~Patients will wear a physical exercise tracker (Fitbit Alta HR® wristband (Fitbit, Inc., San Francisco, California, USA)) to track physiological variables such as heart rate, steps, activity level and sleep quality."
16438751|NCT03711643|Experimental|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
16438752|NCT03711643|Active Comparator|standard pain management|
16438753|NCT03711630|Experimental|Meditation|The study cohort will participate in self-guided meditation practice over the course of eight weeks.
16438754|NCT03711617||CKD-ND|patients with non-dialysis CKD
16438755|NCT03711617||CKD-MHD|patients with maintenance hemodialysis
16438756|NCT03711604|Experimental|Tenalisib|Participants receive Tenalisib (RP6530) BID Orally
16438757|NCT03711578|Experimental|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
16438758|NCT03711565|Active Comparator|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
16438759|NCT03711565|Active Comparator|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
16438760|NCT03711552||Quality of recovery|All enrolled patients will be asked to complete the ObsQoR-11 and QoR-15 questionnaires pre-surgery if feasible and at 24 and 48 hours post-surgery.
16438761|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
16438762|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
16438763|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than >3 hours / week, ii) have a history of smoking (> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
16438764|NCT03711513|Experimental|Exposure only|Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
16438765|NCT03711513|Experimental|Cognitive restructuring plus exposure|PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
16438766|NCT03711513|Experimental|Relaxation plus exposure|PE (plus homework) + Relaxation (RE) (plus homework) + RE (plus homework) + EX (plus homework) + EX: 20 participants will receive two relaxation exercises group sessions after the psycho-education session. In these two session they will practice muscle relaxation and breathing exercises. After the relaxation sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
16438767|NCT03711500|Experimental|D-serine|
16438768|NCT03711500|Placebo Comparator|Placebo|
16438769|NCT03711487|Experimental|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
16438770|NCT03711487|No Intervention|No intervention|No intervention.
16438807|NCT03711214|Active Comparator|Healthy individuals|We will evaluate 40 healthy controls before and after periodontal disease treatment.
16440691|NCT03698799||Non-LPV|Patients do not receive LPV strategy at the initiation of MV support.
16438771|NCT03711474|Experimental|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
16438772|NCT03711474|Placebo Comparator|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
16438773|NCT03711461|Active Comparator|nonintubated|patients received nonintubated during thoracoscopy
16438774|NCT03711461|Experimental|intubated|patients receiving intubated during thoracoscopy
16438775|NCT03711448|Active Comparator|Control group|
16438776|NCT03711448|Experimental|Experimental group|
16438777|NCT03711435||control group|15 subjects was enrolled in the control group，they are healthy controls
16438778|NCT03711435||training IPF group|30 subjects was enrolled in the training IPF group，they are IPF patients，the group is designed to identify differential metabolites between IPF and control groups.
16438779|NCT03711435||Validation group|15 subjects was enrolled in the Validation IPF group，they are IPF patients，the group is designed to validate differential metabolites identified in the previous groups.
16438780|NCT03711422|Experimental|Part A|Standard dose oral afatinib. If patients in Part A do not benefit from the regimen, they can be enrolled into Part B
16438781|NCT03711422|Experimental|Part B|Intermittent high dose oral afatinib
16438782|NCT03711409|Experimental|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
16438783|NCT03711409|Experimental|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
16438784|NCT03711396|Experimental|Advance Care Planning Group Visits|Participants will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
16438785|NCT03711383|Placebo Comparator|Placebo|isocaloric maltodextrin the day before CIDs
16438786|NCT03711383|Active Comparator|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
16438787|NCT03711383|Experimental|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
16438788|NCT03711370|Experimental|Opaque Bottle Group|This group will be given a set of opaque bottles that are to be used during infant feedings for a full 12-week period.
16438789|NCT03711370|Active Comparator|Clear Bottle Group|This group will be given a set of clear bottles that are to be used during infant feedings for a full 12-week period.
16438790|NCT03711357|Active Comparator|laser|980 nm diode laser (maximum output of 3 watts and coupled with a fiber optic tip of 200 µm diameter) will be used for four irradiations, of 5 seconds each, after chemo-mechanical preparation procedures.
16438791|NCT03711357|Placebo Comparator|Placebo|After chemo-mechanical preparation procedures, the diode laser fiber optic tip will be inserted inside the root canals but not activated.
16438792|NCT03711344|Experimental|Culturally adapted Cognitive Behavioral therapy|The experimental group will receive the culturally adapted version of cognitive behavioral therapy.
16438793|NCT03711344|Active Comparator|Non-adapted Cognitive Behavioral therapy|The control group will receive the original (non-adapted) version of cognitive behavioral therapy.
16438794|NCT03711331|Experimental|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
16438795|NCT03711331|Sham Comparator|Standard care|patients benefiting from usual standard care
16438796|NCT03711318|Experimental|Short-term treatment with buprenorphine|Short-term treatment with buprenorphine
16438797|NCT03711305|Experimental|SHR-1316 + carboplatin + etoposide|Participants will receive SHR-1316 intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) SHR-1316 until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
16438798|NCT03711305|Active Comparator|Placebo + carboplatin + etoposide|Participants will receive placebo intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
16438799|NCT03711292|Experimental|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
16438800|NCT03711279|Experimental|SHR-1210 plus Apatinib|
16438801|NCT03711279|Active Comparator|ADM Plus IFO or IFO Alone|
16438802|NCT03711266|Experimental|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
16438803|NCT03711253|Other|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
16438804|NCT03711240|Experimental|bevacizumab+mFOLFOXIRI|
16438805|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
16438808|NCT03711201|Active Comparator|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
16438809|NCT03711201|No Intervention|Group NoIORE|The patient's hemodynamic data will be measured in the evening service before surgery. The patient will be brought to the operating room by the anesthesiologist on the day of surgery and hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured in the preop unit. The hemodynamic data and the ST-STAI scale will measure the anxiety level in the operating room.
16438810|NCT03711188|Experimental|IMM-101 (and nivolumab or ipilimumab)|IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
16438811|NCT03711175|Other|Group A|The subscapularis is repaired. Receives device
16438812|NCT03711175|Other|Group B|The subscapularis is not repaired. Receives device
16438813|NCT03711162|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
16438814|NCT03711162|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
16438815|NCT03711162|Placebo Comparator|Placebo|Placebo to match will be administered as film-coated tablets for oral use once daily.
16438816|NCT03711149|Experimental|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
16438817|NCT03711149|No Intervention|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
16438818|NCT03711136||Frozen elephant trunk surgery|
16438819|NCT03711136||Standart surgery|
16438820|NCT03711123|Experimental|Group metacognitive therapy (GMCT)|10 weekly sessions of GMCT With 90 minutes duration
16438821|NCT03711123|Active Comparator|Clinical Management|10 weekly individual sessions with up to 60 minutes duration
16438822|NCT03711110|Experimental|Primary prevention strategy|Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.
16438823|NCT03711110|Other|Secondary prevention strategy (control)|Current clinical practice: cardiac care is based on the onco-hematologist criteria.
16438824|NCT03711097|No Intervention|Control|Upper left or right central and lateral incisor
16438825|NCT03711097|Experimental|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
16438826|NCT03711084|Placebo Comparator|Water|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
16438827|NCT03711084|Experimental|Natural high potency sweetener from leaf extract|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
16438828|NCT03711084|Experimental|Glucose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
16438829|NCT03711084|Experimental|Sucrose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
16438830|NCT03711084|Experimental|Maltodextrin|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
16438831|NCT03711071|Experimental|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
16438832|NCT03711071|No Intervention|Control Group|This group will not get the intervention before data collection.
16438833|NCT03711058|Experimental|Phase I - Copanlisib and Nivolumab (De-Escalation)|
16438834|NCT03711058|Experimental|Phase II - Copanlisib and Nivolumab|
16438835|NCT03711045||Suicide Risk Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) also have a history of suicide attempt in the past 6 months.
16438836|NCT03711045||Disorder Control Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) and without suicide ideation or behavior.
16438837|NCT03711045||Healthy Control Group|
16438843|NCT03711019|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
16438844|NCT03711019|Active Comparator|RUL-UB ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q
16438845|NCT03711019|Active Comparator|Bitemporal ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q
16438846|NCT03711006|Experimental|FMT treated patients|Seven patients with active Ulcerative Colitis treated with 25 multi-donor FMT Capsules daily.
16438847|NCT03710980||Healthy Adult Volunteer|
16438848|NCT03710967|Experimental|Bilateral TMS|
16438849|NCT03710967|Active Comparator|Unilateral TMS|
16438958|NCT03710226||cases|women with recurrent miscarriage (two or more consecutive miscarriages)
16438850|NCT03710954|Experimental|Experimental Group|All the volunteers were evaluated through numerical evaluation of pain that assumes a subjective condition, the researcher showed the numerical scale of pain, being 0 without pain, 1 to 4 mild pain, 5 moderate pain, 6 to 9 severe pain and 10 worse pain possible pain, which was interpreted by the volunteer. In the Fuzzy Pain Scale, the evaluation of the range of motion was done where the evaluator used the goniometer (plastic instrument that verifies the angulation of the joint movement) and supplied the Fuzzy system with these data.
16438851|NCT03710941|Experimental|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
16438852|NCT03710941|Experimental|Placebo|Single, sequential, repeat-dose IV
16438853|NCT03710928|Experimental|very low carbohydrate diet|Dietary Intervention, food delivery
16438854|NCT03710928|Active Comparator|standard diet|Dietary Intervention, food delivery
16438855|NCT03710915|Experimental|HG146 capsule treat multiple myeloma|"Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).
~Intervention: Drug: HG146 capsule"
16438856|NCT03710902|Experimental|Intervention|
16438857|NCT03710902|No Intervention|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
16438858|NCT03710889|Experimental|Abaloparatide|Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.
16438861|NCT03710863|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
16438862|NCT03710850|Experimental|Responders|Responders in terms of fecal butyrate production after acute inulin test.
16438863|NCT03710850|Experimental|Non-responders|Non-responders in terms of fecal butyrate production after acute inulin test.
16438864|NCT03710837|Experimental|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
16438865|NCT03710837|Experimental|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
16438866|NCT03710824||Subjects with Idiopathic Pulmonary Fibrosis|
16438867|NCT03710811||Type 2 Diabetes|drug naive Type 2 Diabetes received insulin therapy
16438868|NCT03710811||normal control|healthy volunteers as normal control
16438869|NCT03710798|Experimental|Low carbohydrate high fat diet|Low carbohydrate high fat (LCHF) diet
16438870|NCT03710785|Experimental|forward neck posture syndrome patients|Patients diagnosed with forward neck posture syndrome in cervical plain X-ray have a cervical spine extension exercise for 4 weeks
16438871|NCT03710772|Experimental|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.
~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours BID on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
16438872|NCT03710772|Experimental|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.
~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive maintenance therapy as in group I."
16438873|NCT03710772|Experimental|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
16438874|NCT03710759|Experimental|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
16438875|NCT03710746|Experimental|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
16438876|NCT03710746|Experimental|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
16438877|NCT03710746|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
16438878|NCT03710746|Experimental|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
16438879|NCT03710746|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
16438880|NCT03710746|Experimental|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
16438881|NCT03710733|Active Comparator|Sequential boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus sequential boost 10 Gy/4 fx (2.5 Gy/fx) to lumpectomy cavity
16438882|NCT03710733|Experimental|Concomitant boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus concomitant boost 8 Gy/15 fx (0.53 Gy/fx) to lumpectomy cavity
16438883|NCT03710720|Experimental|TF-CBT plus TIPS app|
16438884|NCT03710720|Active Comparator|TF-CBT|
16438885|NCT03710707|Experimental|DNL201 low dose|
16438886|NCT03710707|Experimental|DNL201 high dose|
16438887|NCT03710707|Placebo Comparator|Placebo|
16438888|NCT03710694|Experimental|DAV132 group|Patients randomized to the DAV132 arm will be administered DAV132 concomitantly with fluoroquinolones.
16438889|NCT03710694|No Intervention|No DAV132 group|Patients randomized to the No DAV132 arm will receive only fluoroquinolones, according to local standard of care.
16438890|NCT03710681|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
16438891|NCT03710681|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
16438892|NCT03710655|Experimental|treatment group|skin test, dose escalation, final dose of 1.5mg weekly over 16 weeks of Apitox pure honeybee toxin
16438893|NCT03710655|Placebo Comparator|placebo group|histamine placebo administered intradermally in dose escalation, final dose of 1.5mg weekly over 16 weeks
16438894|NCT03710642|Active Comparator|Treatment (Prazosin)|"Eligible participants will be randomized using a 2:1 schedule to prazosin or placebo and stratified by site and gender, and will follow a fixed titration scheme for the first 15 days, followed by a flexible does titration from days 15-29, then a maintenance phase stable dose from days 29 to the end of the 12 weeks study period.
~Prazosin Fixed titration dose schedule for Days 1 to 14 1 mg QHS for Days 1 to 3
~1 mg QAM and 1 mg QHS for days 4 to 7
~mg QAM and 2 mg QHS for days 8 to 10
~mg QAM and 2 mg QHS for days 11 to 14
~Prazosin Flexible titration dose schedule for Days 15 to 29. 3 mg QAM and 3 mg QHS on day 15, 4 mg QAM and 4 mg QHS on day 22, 4 mg QAH and 6 mg QHS on day 29,
~Dose increases will be allowed only during the fixed and flexible dosing periods."
16438895|NCT03710642|Placebo Comparator|Placebo oral capsule|Placebo medication will be administered in a titration schedule mimicking the active comparator treatment.
16438896|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
16438897|NCT03710603|Active Comparator|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
16438898|NCT03710603|Experimental|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
16438899|NCT03710590|Active Comparator|Cigarette smokers|
16438900|NCT03710590|Active Comparator|Electronic cigarette users|
16438901|NCT03710577|Experimental|Yoga|40 minutes of Vinyasa yoga
16438902|NCT03710577|Placebo Comparator|Quiet Rest|40 minutes of quiet rest
16438903|NCT03710564|Experimental|Masked Arm 1|Brolucizumab 6 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
16438904|NCT03710564|Active Comparator|Masked Arm 2|Aflibercept 2 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
16438905|NCT03710551|Experimental|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
16438906|NCT03710551|Active Comparator|Standard Infant Formula|Standard bovine milk-based infant formula.
16438907|NCT03710538|No Intervention|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
16438908|NCT03710538|Experimental|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
16438909|NCT03710538|Experimental|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
16438910|NCT03710538|Experimental|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
16438911|NCT03710525|Experimental|Own-Price Elasticity|"The price of vegetables will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
16438912|NCT03710525|Experimental|Cross-Price Elasticity|"The price of vegetables will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
16438913|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
16438914|NCT03710512||Control|patients not receiving hydroset at osteotomy site
16438915|NCT03710499|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 8 consecutive weeks.
16438916|NCT03710486||Cohort 1: Vedolizumab|Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
16438959|NCT03710226||controls|women without recurrent miscarriage and delivered at least once before
16439001|NCT03709940|Experimental|Placebo, MPH|"Dose order: placebo, methylphenidate (MPH)
~Participants receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 and a clinically effective dose of short-acting MPH (20 mgs) on DAY 2."
16438917|NCT03710486||Cohort 2: Other Biologic|Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab [UC only]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.
16438918|NCT03710460|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
16438919|NCT03710460|Experimental|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
16438920|NCT03710460|Experimental|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
16438921|NCT03710447|Experimental|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
16438922|NCT03710447|Experimental|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
16438923|NCT03710447|Experimental|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
16438924|NCT03710447|Experimental|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
16438925|NCT03710434|Experimental|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
16438926|NCT03710434|Experimental|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
16438927|NCT03710434|Experimental|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
16438928|NCT03710434|Experimental|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
16438929|NCT03710434|Experimental|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
16438930|NCT03710434|Experimental|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
16438931|NCT03710434|Experimental|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional [14C] AZD4635 IV microtracer.
16438932|NCT03710434|Experimental|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
16438933|NCT03710421|Experimental|Treatment (leukapheresis, chemotherapy, CS-1 CAR T therapy)|Patients undergo leukapheresis over 2-4 hours. Beginning 3-4 weeks, patients receive cyclophosphamide IV on days -4 and/or -3 or fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients then undergo CS1-CAR T therapy over 10-15 minutes on day 0.
16438934|NCT03710408|Experimental|Subcutaneous hydration|
16438935|NCT03710408|Active Comparator|Intravenous hydration|
16438936|NCT03710395|Active Comparator|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
16438937|NCT03710395|Experimental|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.
16438938|NCT03710382|Experimental|Walking epidural|Parturients will receive a lower concentration of bupivacaine in their epidural infusion and will be encouraged to walk during labor.
16438939|NCT03710369|Sham Comparator|Normoxia|Exercise in room air (normoxia). Sildenafil
16438940|NCT03710369|Active Comparator|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
16438941|NCT03710356|Experimental|Danazol|Danazol
16438942|NCT03710343|Experimental|Metformin|Metformin oral tablet will be taken by mouth, once or twice a day for 16 weeks.
16438943|NCT03710343|Placebo Comparator|Placebo|The placebo oral tablet will be taken by mouth once or twice a day for 16 weeks.
16438944|NCT03710330|Placebo Comparator|normal saline|the patients receives 110 ml normal saline IV just before skin incision
16438945|NCT03710330|Active Comparator|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
16438946|NCT03710330|Active Comparator|0.5 gm tranexamic acid|0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
16438947|NCT03710317|Active Comparator|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
16438948|NCT03710317|Experimental|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
16438949|NCT03710304|Active Comparator|oxytocin|20 IU oxytocin ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal(ranitidine) plus 110 ml saline iv
16438950|NCT03710304|Active Comparator|Tranexamic acid plus misoprostol|400 μg misoprostol (2 tablets of 200 μg) or two placebo tablets were given buccally after spinal anesthesia and few minutes before skin incision; then 1 gm TA will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision, plus 500 ml normal saline intravenous solution infusion over 15 min after delivery of the baby
16438951|NCT03710291|Experimental|TRC101|
16438952|NCT03710291|Placebo Comparator|Placebo|
16438953|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
16438954|NCT03710265|Experimental|SHR-1701|
16438955|NCT03710252|Experimental|Single|Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)
16438956|NCT03710239|Active Comparator|Dilapan-S|Synthetic osmotic dilator
16438957|NCT03710239|Active Comparator|Laminaria|Seaweed-based osmotic dilator
16438960|NCT03710213|No Intervention|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
16438961|NCT03710213|Experimental|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
16438962|NCT03710200|Active Comparator|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
16438963|NCT03710200|Experimental|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
16438964|NCT03710200|Experimental|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
16438965|NCT03710200|Experimental|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
16438966|NCT03710200|Experimental|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
16438967|NCT03710200|Experimental|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
16438968|NCT03710200|Experimental|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
16438969|NCT03710200|Experimental|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
16438970|NCT03710187|Experimental|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
16438971|NCT03710187|Active Comparator|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
16438972|NCT03710174|No Intervention|Control group|Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
16438973|NCT03710174|Experimental|LED group|The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
16438974|NCT03710174|Experimental|Occlusal splint group|They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
16438975|NCT03710174|Placebo Comparator|Placebo group|Subjects with bruxism. The same procedures as LED group, but the device will be turn off.
16438976|NCT03710161|Experimental|4000 IU Vitamin D|4000 IU Vitamin D taken daily for six months
16438977|NCT03710161|Active Comparator|800 IU Vitamin D|800 IU Vitamin D taken daily for six months
16438978|NCT03710122|Experimental|Vancomycin|
16438979|NCT03710122|Placebo Comparator|Placebo|
16438980|NCT03710109||Concussion|Individuals who have sustained a recent concussion
16438981|NCT03710109||Control Healthy Volunteers|No Intervention
16438982|NCT03710096|Experimental|Mac grath group|
16438983|NCT03710096|Active Comparator|Macintosh Group|
16438984|NCT03710083|Experimental|Study arm|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).
16438985|NCT03710070|Experimental|Intervention|In the presence of a significant coronary artery stenosis and randomization to the intervention group: Catheter-based permanent occlusion of the ipsilateral (to the culprit coronary lesion) IMA will be performed at the projected height of inferior vena cava confluence and right atrium using a dedicated occlusion device (Amplatzer vascular plug 4, CE0086).
16438986|NCT03710070|Sham Comparator|Sham-Control|In the presence of a significant coronary artery stenosis, and randomization to the sham-procedure: IMA will be selectively intubated using an appropriate catheter. Angiography of the IMA and the pericardiacophrenic branch will be performed.
16438987|NCT03710044|Experimental|Cyclosporine A treatment|Oral cyclosporine A treatment
16438988|NCT03710031||HSCT Survivors|PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
16438989|NCT03710018||A Patient who underwent open cavity BCS|Patients undergoing Open cavity Breast Conservative Surgery
16438990|NCT03710018||B Patient who underwent close cavity BCS|Patients undergoing Close cavity Breast Conservative Surgery
16438991|NCT03710018||C Patient who underwent oncoplasty|Patients undergoing oncoplasty for breast cancer
16438992|NCT03710005|Experimental|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
16438993|NCT03710005|Active Comparator|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
16438994|NCT03709992|Active Comparator|Trospium|Patients will receive 30 mg of Trospium chloride tablet twice daily
16438995|NCT03709992|Active Comparator|Tamsulosin|Patients will receive 0.4 mg of Tamsulosin tablet once daily
16438996|NCT03709979|Active Comparator|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
16438997|NCT03709979|Placebo Comparator|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
16438998|NCT03709966|Experimental|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
16438999|NCT03709966|Active Comparator|Routine|Physical activity promotion supported by a kinesiologist
16439034|NCT03709771||No treatment|
16439002|NCT03709940|Experimental|MPH, Placebo|"Dose order: methylphenidate (MPH), placebo
~Participants receive a clinically effective dose of short-acting MPH (20 mgs) on DAY 1 and a placebo tablet (ascorbic acid 50 mgs) on DAY 2."
16439003|NCT03709927|Experimental|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
16439004|NCT03709927|Experimental|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
16439005|NCT03709927|Active Comparator|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
16439006|NCT03709927|Placebo Comparator|Placebo IV|IV 0.9% normal saline solution
16439007|NCT03709914|Experimental|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
16439008|NCT03709914|Experimental|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
16439009|NCT03709914|Experimental|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
16439010|NCT03709914|Experimental|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
16439011|NCT03709914|Experimental|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
16439012|NCT03709901|Experimental|Active Allograft|Injection of viable allograft
16439013|NCT03709901|Placebo Comparator|Placebo|Injection of saline
16439014|NCT03709901|No Intervention|Conservative Care|Continued conservative care treatment
16439015|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
16439016|NCT03709875|Experimental|TR Treatment|TR will be delivered by means of an advanced video-conferencing system, and patients will be provided with low-cost monitoring devices, able to collect data about the health status and QoL. All treatments from remote are based on scheduled videoconferences between the patient's home and the Clinical Units, and therapists can control and modify the exercises. A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech and cognitive exercises will be delivered from the two Research Institutes to the patient's home.
16439017|NCT03709875|Other|Conventional Treatment|"In this group patients will be treated with conventional physiotherapy and speech training, adjusted in reason of the clinical needs, as usually. Treatments for motor limbs activity will be focused on functional active-assistive and active exercises. Conventional paper and pencil training will be used to improve cognitive function."
16439018|NCT03709862||Syphilis|Patients with syphilis and detectable Treponema pallidum DNA in a routinely collected clinical sample
16439019|NCT03709849|Experimental|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
16439020|NCT03709849|Active Comparator|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
16439021|NCT03709823|Experimental|1.5 mg Cytisine, Commercial Schedule|1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
16439022|NCT03709823|Experimental|3.0 mg Cytisine, Commercial Schedule|3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
16439023|NCT03709823|Placebo Comparator|Placebo, Commercial Schedule|Placebo tablets using the commercial 25-day titration schedule + behavioral support
16439024|NCT03709823|Experimental|1.5 mg Cytisine, TID Schedule|1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
16439025|NCT03709823|Experimental|3.0 mg Cytisine, TID Schedule|3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
16439026|NCT03709823|Placebo Comparator|Placebo, TID Schedule|Placebo tablets for 25 days using a simplified TID schedule + behavioral support
16439027|NCT03709810|Experimental|Test Denture Adhesive|Test denture adhesive will be applied directly from the tubes using a continuous strip pattern to the upper and lower denture which will then be placed in mouth of the participants.
16439028|NCT03709810|Other|Control|Participants will not apply any denture adhesive in this treatment arm.
16439029|NCT03709797|Experimental|Experimental group|Experimental group will receive dry needling treatment.
16439030|NCT03709797|Sham Comparator|Control group|Control group will receive sham dry needling treatment.
16439031|NCT03709771||VEGF inhibitor alone|
16439032|NCT03709771||Immune Checkpoint Inhibitor (ICI) alone|
16439033|NCT03709771||Combination (VEGF inhibitor + ICI, or combination of ICI)|
16439035|NCT03709758|Experimental|Venetoclax+Daunorubicin+Cytarabine|"Venetoclax administered orally on days 1 to 11 daily
~Daunorubicin administered intravenously on days 2-4
~Cytarabine administered on days 2-8 by continuous IV infusion"
16439036|NCT03709745|Active Comparator|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
16439037|NCT03709745|Active Comparator|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
16439038|NCT03709732||Spinal cord injury|Persons with a spinal cord injury. No intervention
16439039|NCT03709732||Caregivers spinal cord injury|Caregivers for persons with a spinal cord injury. No intervention
16439040|NCT03709732||Controls for patients|Control group for patient cohort. No intervention
16439041|NCT03709732||Controls for caregivers|Control group for caregivers cohort. No intervention
16439042|NCT03709719|Experimental|blinatumomab|
16439043|NCT03709706|Experimental|Arm A: lete-cel monotherapy|In Arm A, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel monotherapy. Participants who subsequently progress by Week 25 will be offered pembrolizumab.
16439044|NCT03709706|Experimental|Arm B: lete-cel plus pembrolizumab|In Arm B, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
16439045|NCT03709706|Experimental|Arm C: lete-cel plus pembrolizumab|In Arm C, participants with NSCLC (with actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
16439046|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
16439047|NCT03709680|Experimental|Single Arm|Palbociclib in combination with temozolomide and irinotecan Palbociclib in combination with topotecan and cyclophosphamide
16439048|NCT03709667|Experimental|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
16439049|NCT03709667|Placebo Comparator|CON|The control condition is a health-education intervention.
16439050|NCT03709654|Experimental|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
16439051|NCT03709654|Placebo Comparator|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
16439052|NCT03709641|Experimental|Restylane Defyne receiver|Participants will receive Restyane Defyne injected into punctum of one eye.
16439053|NCT03709628|Experimental|Patients with active Crohn's disease|EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
16439054|NCT03709615|No Intervention|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
16439055|NCT03709615|Experimental|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
16439056|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
16439057|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
16439058|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
16439059|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
16439060|NCT03709589||Group-B|Patients with Modified Early Warning Score of < 5
16439061|NCT03709576|Experimental|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
16439062|NCT03709563|Active Comparator|Oral Nutraceutical Supplement|
16439063|NCT03709563|Placebo Comparator|Placebo|
16439064|NCT03709550|Experimental|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16439065|NCT03709537|Experimental|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
16439066|NCT03709537|No Intervention|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
16439067|NCT03709524|Active Comparator|insertion time|1 minute Airtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
16439068|NCT03709524|Active Comparator|intubation time|2 minutesAirtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
16439069|NCT03709511|No Intervention|Conventional Treatment Group|This arm will receive usual care. In accordance with current guidelines a cardiologist sees all patients 4 to 6 weeks after heart valve surgery. At the follow-up visit a clinical examination, biochemistry and echocardiography are performed. All patients are given general information on anticoagulation and endocarditis prophylaxis. During the trial period the patients will be seen by a physician at The Guangdong General Hospital, for the follow-up visit, after 1 and 12 months. All patients are instructed to initiate their usual activities of daily living. Patients in the control group have accepted not to receive local rehabilitation at the hospital or community setting in their written consent.
16439486|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IID|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation
16439070|NCT03709511|Active Comparator|Cardiac Rehabilitation Group|Rehabilitation starts preoperatively with education and exercise management.After screening with cardiopulmonary exercise test,the participant will receive daily preoperative exercise rehabilitation till surgery.It lasts for 20 minutes per day, starting with a 40-60% anaerobic threshold and gradually advancing to 80%.Each patient was motivated to adhere to the basic protocol, but individual adjustments were allowed in case of slower progress. Physical exercise starts 1 month postoperative after the first cardiopulmonary exercise testing, and comprises the following three elements: individual planning of the physical exercise, a specially trained physiotherapist conduction, and integrating detailed information concerning medical treatment and diet.The exercise diary and the heart rate monitor recordings are essential in monitoring during the whole intervention.
16439071|NCT03709485|Experimental|prostate biopsy patients|a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.
16439072|NCT03709472|Experimental|Computer Assisted CIFFTA|CA CIFFTA (Computer Assisted Culturally Informed and Flexible Family Based Treatment for Adolescents) consists of a hybrid intervention utilizing office-based CIFFTA and technology-delivered material. Over 16 weeks CIFFTA participants receive 45 minutes of face-to-face sessions plus approximately 45 minutes of web-based intervention per week. During the continuing care phase participants access website resources and receive targeted messages (e.g., handling family conflicts). CA CIFFTA will: 1) deliver psycho-educational modules (e.g., depression, emotion regulation), 2) collect diary-card information, and 3) provide additional resources. During videos parents and adolescents can report symptoms and information that is automatically transmitted to therapists and used in the next session
16439073|NCT03709472|Active Comparator|Behavioral: Traditional face-to-face treatment-no technology|Participants randomized to Treatment-As-Usual (TAU) work over a 16-week period with their community agency. They may receive individual or family treatment. The team coordinates with the TAU agencies to minimize the overlap of data collected. The team will refer out to service locations that are most convenient for the participant. A great deal of thought has gone into the selection of the Treatment as Usual condition. The investigators wanted to compare CA CIFFTA's ability to retain and bring about change in participants with what is typically done in the community. Although running an in-house comparison condition gives more control of the delivery of services and tracking of clients, it is difficult to know how that compared to the services that are typically provided in the community
16439074|NCT03709446|Experimental|Leflunomide|Women with metastatic triple negative breast cancer. Leflunomide tablet orally daily
16439075|NCT03709433|Experimental|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
16439076|NCT03709420|Placebo Comparator|Placebo|Matching placebo capsule
16439077|NCT03709420|Experimental|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.
~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.
~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
16439078|NCT03709407|Experimental|cervical stimuli|Godoy´s maneuver with traction-sliding in supraclavicular fossa
16439079|NCT03709407|Experimental|terminus|Vodder´s maneuver with medial and anterior traction in supraclavicular fossa
16439080|NCT03709407|Sham Comparator|placebo|maneuver with sliding ON clavicular
16439081|NCT03709407|No Intervention|Control group|only lying down
16439082|NCT03709394|Active Comparator|Group A: Full utrasound guidance|Full utrasound guidance of cathether insertion. Intervention: Ultrasound portable device used for the identification of the target vein and for the ultrasound control of proper catheter placement during the procedure of peripheral venous cannula insertion.
16439083|NCT03709394|Active Comparator|Group B: Partial ultrasound guidance|Catheter insertion under partial ultrasound guidance. Intervention: Ultrasound portable device used only for the identification of the target vein, the catheter placement will be done by conventional approach.
16439084|NCT03709394|Active Comparator|Group C: No ultrasound guidance|Catheter insertion by conventional approach, without ultrasound guidance
16439085|NCT03709381|Experimental|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
16439086|NCT03709368|Experimental|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
16439087|NCT03709368|Experimental|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
16439088|NCT03709368|Active Comparator|Control|Hardware CLTS+PHAST Placebo
16439089|NCT03709355|Active Comparator|Elpida®|Single dose of Elpida® (capsule 20 mg)
16439090|NCT03709355|Experimental|Rifampin & Elpida®|Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose
16439091|NCT03709355|Experimental|Rifabutin & Elpida®|Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose
16439092|NCT03709355|Experimental|Clarithromycin & Elpida®|Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose
16439093|NCT03709355|Experimental|Omeprazole & Elpida®|Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose
16439094|NCT03709355|Experimental|Atorvastatin & Elpida®|Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose
16439095|NCT03709355|Experimental|Levonorgestrel+Ethinylestradiol & Elpida®|Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose
16439096|NCT03709342|Experimental|All Patients|
16439097|NCT03709329|Experimental|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
16439726|NCT03705286|Experimental|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
16439098|NCT03709329|Active Comparator|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
16439099|NCT03709316|Experimental|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
16439100|NCT03709316|Placebo Comparator|Placebo|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
16439101|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
16439102|NCT03709290||1st group|30 patients were diagnosed with MS according to revised MacDonald's criteria 2017 & collected from Neuropsychiatry department in Assuit university hospital
16439103|NCT03709290||2nd group|30 healthy volunteers subjects matched with age, sex & education level were recruited from outpatient clinic neuropsychiatry department and included only if they had no current or previous history of any neurological illness and their neurological examination was free
16439104|NCT03709277|Experimental|Pharmacist-Driven Intervention|The study group will receive a targeted, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
16439105|NCT03709277|No Intervention|Standard of Care|The Standard of Care Group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
16439106|NCT03709264|Experimental|Amino Acids infusion|
16439107|NCT03709264|Placebo Comparator|Placebo|
16439108|NCT03709251|Experimental|High Intensity Walking|HIW (70-80% Heart Rate max)
16439109|NCT03709251|Experimental|Casual Speed Walking|Self selected pace
16439110|NCT03709238||Alzheimers diseased patients|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
16439111|NCT03709238||Healthy participants|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
16439112|NCT03709225|Experimental|Music-based meditation|"The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:
~Introduction to music therapy and mindfulness
~Music-based meditation
~Using personal music to shift energy, mood, and support relaxation
~Mindfulness through active music making
~Discuss bringing mindfulness to daily activities"
16439113|NCT03709212||Individual semi-structured interview|"20 participants will undergo individual semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
~Participants will be recruited from three ethnic backgrounds; Black African/ Caribbean, South Asian and White Caucasian."
16439114|NCT03709212||Focus Group 1|10 participants female black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
16439115|NCT03709212||Focus Group 2|10 participants male Black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
16439116|NCT03709212||Focus Group 3|10 participants female South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
16439117|NCT03709212||Focus Group 4|10 participants male black South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
16439118|NCT03709212||Focus Group 5|10 participants female White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
16439119|NCT03709212||Focus Group 6|10 participants male White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
16439120|NCT03709173||Premanifest HDGEC participants|
16439121|NCT03709173||Early-manifest HDGEC participants|
16439122|NCT03709173||Companions of Premanifest HDGEC|
16439123|NCT03709173||Companions of Early-manifest|
16439124|NCT03709160|Experimental|BUMETANIDE|we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.
16439125|NCT03709160|Active Comparator|INDAPAMIDE|we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.
16439126|NCT03709147|Experimental|FAME arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles
~pemetrexed 500 mg/mq every three weeks
~pembrolizumab 200 mg flat dose every three weeks
~metformin hydrochloride up to a daily dosage of 1500 mg
~every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
16439127|NCT03709147|Experimental|MERCY arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles
~pemetrexed 500 mg/mq every three weeks
~pembrolizumab 200 mg flat dose every three weeks
~metformin hydrochloride up to a daily dosage of 1500 mg"
16439128|NCT03709147|No Intervention|BORN arm|Standard clinical approach.
16439129|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
16439130|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
16439131|NCT03709121|Placebo Comparator|Vehicle Ophthalmic Solution|
16439727|NCT03705273|Experimental|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
16439132|NCT03709108|Other|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
16439133|NCT03709108|Other|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
16439134|NCT03709095|Active Comparator|Moderate Intensity Continuous Training|Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
16439135|NCT03709095|Experimental|Sprint Interval Training|"The SIT protocol was adopted from Gillen and colleagues (See Ref), and consisted of 3 x 20 second all-out efforts at ≥ 100% of an individuals peak power output. Each sprint was interspersed by 120 seconds of active recovery at 10% of an individuals peak power output. Total training duration was 10 mins."
16439136|NCT03709082|Experimental|Phase 1: Palbociclib 75 mg|Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
16439137|NCT03709082|Experimental|Phase 1: Palbociclib 100 mg|Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
16439138|NCT03709082|Experimental|Phase 1: Palbociclib 125 mg|Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
16439139|NCT03709082|Experimental|Phase 2: RP2D|Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
16439140|NCT03709069|No Intervention|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.
~Wounds of patients will be managed by closed dressing to be changed on every third day."
16439141|NCT03709069|Experimental|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
16439142|NCT03709056|Experimental|HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg|
16439143|NCT03709056|Active Comparator|Propofol 2.0/1.0mg/kg group|
16439144|NCT03709043|Experimental|Kudzu|Standardized kudzu
16439145|NCT03709043|Placebo Comparator|Control|Placebo
16439146|NCT03709030|No Intervention|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
16439147|NCT03709030|Experimental|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
16439148|NCT03709004|Experimental|Pacifier|Mother given a pacifier during birth hospitalization, along with other baby items
16439149|NCT03709004|No Intervention|Control|Mother not given a pacifier, just the other baby items
16439150|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
16439151|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
16439152|NCT03708978||mammography group|women who receives mammography because of suspected breast lesion(s)
16439153|NCT03708965|Experimental|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.
~During the study, the dose of all subjects will be switched to the selected one."
16439154|NCT03708939|Experimental|glucose|
16439155|NCT03708939|Experimental|aspartame|
16439156|NCT03708939|Experimental|sucralose|
16439157|NCT03708939|Experimental|saccharin|
16439158|NCT03708939|Experimental|Stevia|
16439159|NCT03708939|Experimental|No supplement control|
16439160|NCT03708926|Experimental|abaloparatide|abaloparatide 80 mcg subcutaneously once daily for 90 days
16439161|NCT03708926|Placebo Comparator|placebo|placebo formulated similarly but without active abaloparatide injected subcutaneously once daily for 90 days
16439162|NCT03708913|Experimental|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
16439163|NCT03708900|Experimental|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
16439164|NCT03708887|Experimental|Low dose group|Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.
16439165|NCT03708887|Experimental|High dose group|High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.
16439166|NCT03708887|Placebo Comparator|Control group|Control drug, matching placebo capsules, 1 gram per day for 1 year.
16439167|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
16439168|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
16439169|NCT03708861|Experimental|MVC + ATV/r|maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)
16439170|NCT03708848|Experimental|Tailored Therapy|Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.
16439171|NCT03708835|Experimental|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
16439172|NCT03708835|No Intervention|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
16439173|NCT03708822|Experimental|Docetaxel and Cisplatin and Nimotuzumab|
16439174|NCT03708809|Experimental|Immediate insertion|The intrauterine system will be inserted immediately after surgical termination of pregnancy, before awakening from anesthesia
16439175|NCT03708809|Experimental|Delayed insertion|The intrauterine system will be inserted on the first menstruation after termination of pregnancy. Women allocated to this arm will be asked to contact the study coordinator in order to visit the hospital on the proper timing for IUD insertion.
16439176|NCT03708809|Other|Control|Women who refuse to actively participate in the intervention groups will be offered consultation on other options for contraception during gynecological clinic visit after fist menstruation from termination of pregnancy.
16439177|NCT03708783|Experimental|No. 10 Lymph Node Dissection group|Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
16439178|NCT03708770|Other|endoAVF|
16439179|NCT03708757|Experimental|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles
~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
16439180|NCT03708757|Active Comparator|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.
~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
16439181|NCT03708744|Experimental|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
16439182|NCT03708744|Experimental|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
16439183|NCT03708744|Experimental|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
16439184|NCT03708744|Active Comparator|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
16439185|NCT03708731||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study.
16439186|NCT03708718|Active Comparator|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.
~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).
~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
16439187|NCT03708718|Placebo Comparator|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.
~From August 2020 - no placebo capsule will be administered."
16439188|NCT03708705||Relapse|Relapse of tumor within two years after liver transplantation
16439189|NCT03708705||Non-relapse|Non-relapse of tumor within two years after liver transplantation
16439190|NCT03708692||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
16439191|NCT03708692||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
16439192|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
16439193|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
16439194|NCT03708666|Other|Telemonitoring of blood pressure|Patients measure their blood pressure and register their results on the app or website.
16439195|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
16439196|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
16439197|NCT03708640|Placebo Comparator|Physical Activity Counseling|"Group receives baseline physical activity counseling.
~Group does not receive personalized, health coaching via smart text messages."
16439198|NCT03708640|Experimental|Digital Activity Tracker/Smart Text Messaging|"Group receives baseline physical activity counseling.
~Group receives personalized, health coaching via smart text messages informed by digital activity tracker."
16439199|NCT03708627|Experimental|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
16439200|NCT03708627|No Intervention|Control|Bimatoprost is not instilled in the patient's fellow eye
16439201|NCT03708614|Other|Controlled energy intake with elevated protein intake|Dietary intervention - Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks.
16439202|NCT03708588|Experimental|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
16439728|NCT03705273|Active Comparator|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
16439203|NCT03708588|Active Comparator|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL of water. (180mg)
16439204|NCT03708562|Other|endoAVF|
16439207|NCT03708536|Experimental|bevacizumab plus s-1|
16439208|NCT03708536|Active Comparator|bevacizumab plus capecitabin|
16439209|NCT03708510|Experimental|Filtek Silorane-Er,Cr:YSGG Laser|
16439210|NCT03708510|Experimental|Filtek Silorane- Diamond Bur|
16439211|NCT03708510|Experimental|Kalore- Er,Cr:YSGG Laser|
16439212|NCT03708510|Experimental|Kalore- Diamond Bur|
16439213|NCT03708497|Active Comparator|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
16439214|NCT03708497|Experimental|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
16439215|NCT03708497|Active Comparator|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
16439216|NCT03708484|Active Comparator|Aerobic Interval Training|Aerobic Interval Training is active comparator
16439217|NCT03708484|Experimental|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
16439218|NCT03708471|Experimental|Two-stage hybrid abltaion|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will receive percutaneous catheter ablation and recommendations about cardiovascular risk control.
16439219|NCT03708471|Active Comparator|Thoracosopic surgical ablation|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will only receive recommendations about cardiovascular risk control.
16439220|NCT03708458|Active Comparator|Control group|Control group - patients receiving 100 mg indomethacin suppository immediately post ERCP
16439221|NCT03708458|Active Comparator|Group A|Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP
16439222|NCT03708458|Active Comparator|Group B|Group B - patients receiving indomethacin suppository 50 mg before and 50 mg after ERCP
16439223|NCT03708445|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
16439224|NCT03708432||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
16439225|NCT03708419|Experimental|Optimal diet|Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
16439226|NCT03708419|Experimental|Suboptimal diet|Participants will follow a diet for a total duration of 12 weeks, suboptimal for their metabolic phenotype. For participants with liver insulin resistance (LIR) this will be a diet high in monounsaturated fatty acids, for participants with muscle insulin resistance (MIR) this will be a diet high in protein and fiber and low in fat.
16439227|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
16439228|NCT03708406||Children with Cleft palate|Children with Cleft palate
16439229|NCT03708393|Active Comparator|Imagio IUS|Read 1 - Mammo (as available) + Imagio Ultrasound
16439230|NCT03708393|Experimental|Imagio (IUS+OA)|Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)
16439231|NCT03708380|Experimental|Dietary intervention|Community-based dietary intervention to Black and African American barbers identified as having previously undiagnosed diabetes and prediabetes
16439232|NCT03708367|Experimental|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
16439233|NCT03708367|Other|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
16439234|NCT03708354|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
16439235|NCT03708354|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
16439236|NCT03708341|Experimental|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
16439237|NCT03708341|Placebo Comparator|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
16439238|NCT03708328|Experimental|Dose Escalation Part A: Once Every 2 Weeks (Q2W)|RO7121661 will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.
16439487|NCT03706833|Experimental|Edwards PASCAL System - CLASP IIF|Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation
16439239|NCT03708328|Experimental|Expansion Part B1: Metastatic Melanoma Cohort|This cohort will comprise participants with checkpoint inhibitor (CPI) experienced, second line and beyond metastatic melanoma. The starting dose of RO7121661 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
16439240|NCT03708328|Experimental|Expansion Part B2: NSCLC Cohort 1|This cohort will comprise participants with CPI and platinum experienced, second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
16439241|NCT03708328|Experimental|Expansion Part B3: NSCLC Cohort 2|This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
16439242|NCT03708328|Experimental|Expansion Part B4: SCLC Cohort|This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to, standard therapy. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
16439243|NCT03708328|Experimental|Expansion Part B5: ESCC Cohort|This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
16439244|NCT03708315|Active Comparator|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
16439245|NCT03708315|Placebo Comparator|Order 2|Subjects will be given a sublingual film of placebo.
16439246|NCT03708302|Active Comparator|Study Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.2% ropivacaine.
16439247|NCT03708302|Sham Comparator|Control Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.9% saline.
16439248|NCT03708276|Experimental|My MS Toolkit|20 Participants asked to use My MS Toolkit.
16439249|NCT03708263|Active Comparator|532nm KTP Laser|Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.
16439250|NCT03708263|Experimental|585 nm yellow laser|PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.
16439251|NCT03708237|Placebo Comparator|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
16439252|NCT03708237|Experimental|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
16439253|NCT03708237|Experimental|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
16439254|NCT03708224|Experimental|Atezolizumab Monotherapy|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery.
16439255|NCT03708224|Experimental|Atezolizumab (Adjuvant)|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery. The first 9 participants in Arm A (atezolizumab monotherapy) will also receive adjuvant atezolizumab 16 weeks after standard of care surgery and radiation, or chemoradiation therapy, at a fixed dose of 1200 mg IV every 3 weeks for an additional 12 cycles.
16439256|NCT03708224|Experimental|Atezolizumab + Tiragolumab|Participants will receive 840 mg of atezolizumab IV and 600 mg of Tiragolumab during the 15-day neoadjuvant period prior to definitive surgery.
16439257|NCT03708224|Experimental|Atezolizumab + Tocilizumab|Participants will receive 840 mg of atezolizumab IV and 6 mg/kg of Tocilizumab during the 15-day neoadjuvant period prior to definitive surgery.
16439258|NCT03708211|Experimental|Part1: TAK-931 80 mg PIC + TAK-931 80 mg Tablet|TAK-931 80 milligram (mg), PIC, orally, once on Day 1 Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, tablet, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until progressive disease (PD), or unacceptable toxicity or any treatment discontinuation is determined.
16439259|NCT03708211|Experimental|Part1: TAK-931 80 mg Tablet + TAK-931 80 mg PIC|TAK-931 80 mg, tablet, orally, once on Day 1 of Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, PIC, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until PD, or unacceptable toxicity or any treatment discontinuation is determined.
16439260|NCT03708211|Experimental|Part 2: TAK-931 Fed + TAK-931 Fasted + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fed state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fasted state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
16439261|NCT03708211|Experimental|Part 2: TAK-931 Fasted + TAK-931 Fed + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fasted state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fed state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
16439262|NCT03708198|Other|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
16439263|NCT03708185|Experimental|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
16439488|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IIF|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation
16439264|NCT03708185|Experimental|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
16439265|NCT03708172|Active Comparator|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
16439266|NCT03708172|Sham Comparator|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
16439267|NCT03708159|Experimental|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
16439268|NCT03708159|Sham Comparator|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
16439269|NCT03708146|Experimental|Cohort 1 (BIA 5-1058 /50 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439270|NCT03708146|Experimental|Cohort 2 (BIA 5-1058 /25 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 25 mg (as 1 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439271|NCT03708146|Experimental|Cohort 3 (BIA 5-1058 /100 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439272|NCT03708146|Experimental|Cohort 4 (BIA 5-1058 /50 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo 12 active and 3 placebo)
16439273|NCT03708146|Experimental|Cohort 5 (BIA 5-1058 /150 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 150 mg (as 1 x 100 mg and 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439274|NCT03708146|Experimental|Cohort 6 (BIA 5-1058 /75 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 75 mg (as 3 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439275|NCT03708146|Experimental|Cohort 7 (BIA 5-1058 /200 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439276|NCT03708146|Experimental|Cohort 8 (BIA 5-1058 /100 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439277|NCT03708146|Experimental|Cohort 9 (BIA 5-1058 /400 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439278|NCT03708146|Experimental|Cohort 10 (BIA 5-1058 /200 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439279|NCT03708146|Experimental|Cohort 11 (BIA 5-1058 /400 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
16439280|NCT03708133|Experimental|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:
~Test treatment
~Reference treatment"
16439281|NCT03708133|Experimental|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:
~Reference treatment
~Test treatment"
16439282|NCT03708120|Experimental|Consumer Dose and Tick Repellency|Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
16439283|NCT03708107|Experimental|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.
~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
16439284|NCT03708107|Experimental|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.
~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
16439285|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
16439286|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
16439287|NCT03708081||Group 1|Root canal treatments will be completed by ProTaper Next instruments with rotational motion
16439288|NCT03708081||Group 2|Root canal treatments will be completed TF Adaptive instruments with adaptive motion.
16439289|NCT03708068|Experimental|Early Exclusive Enteral Nutrition|"Feeds will start at least at 80% of reference daily fluid intake from day one of life.
~Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feed."
16439290|NCT03708068|No Intervention|Conventional Enteral Nutrition|"Infants will be fed as per current Neonatal Intensive Care Unit feeding tables:
~Infants with birth weight 1000-1500 g will be fed on 15-20 ml/kg human milk in day one. Feeds will be advanced by 15-20 ml/kg per day on second day onwards until infant reaches full enteral feeds.
~Infants with birth weight >1500 g will be started on 20-30 ml/kg per day on day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feeds."
16439291|NCT03708055|Experimental|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
16439292|NCT03708042|Experimental|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day.
16439293|NCT03708042|Active Comparator|Neoadjuvant Radiochemotherapy|Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
16439294|NCT03708029|Experimental|Intervention Treatment|Will receive Revita allograft for wound treatment
16439295|NCT03708029|No Intervention|Control|Will receive current standard of care for wound treatment
16439296|NCT03708016|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
16439297|NCT03708016|Active Comparator|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
16439298|NCT03708003|Experimental|venetoclax + ibrutinib|Ibrutinib lead-in followed by venetoclax plus ibrutinib administered until cycle 31. The combination treatment will be continued as maintenance treatment or stopped depending on MRD-neg CR/CRi status.
16439299|NCT03707990|Experimental|NNC0165-1875|Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2).
16439300|NCT03707990|Placebo Comparator|Placebo|Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2).
16439301|NCT03707977|Experimental|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
16439302|NCT03707977|Experimental|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
16439303|NCT03707977|Experimental|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
16439304|NCT03707964|Placebo Comparator|Control|Subjects allocated to the control arm will receive standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles, as part of their regular teaching schedule.
16439305|NCT03707964|Experimental|Intervention|Subjects allocated to the intervention arm will receive education on crisis resource management (CRM) and teaching targeting the cognitive skills required to monitor and challenge a superior's decision, and conflict resolution tools, in addition to standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
16439306|NCT03707951|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
16439307|NCT03707951|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
16439308|NCT03707938|Experimental|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16439310|NCT03707912|Experimental|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.
~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
16439311|NCT03707912|Placebo Comparator|Placebo|Placebo using Anaferon regimen until the end of the study.
16439312|NCT03707899|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
16439313|NCT03707899|Active Comparator|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
16439314|NCT03707886|Experimental|Pain SMART (Intervention Arm)|The Intervention Arm will be invited to participate in a one-time group intervention, Pain SMART
16439315|NCT03707886|Placebo Comparator|Minimally Enhanced Usual Care|The Minimally Enhanced Usual Care group will receive educational information via mail.
16439316|NCT03707873|Experimental|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
16439317|NCT03707873|Experimental|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
16439489|NCT03706820||normal rest and exercise hemodynamics|
16439490|NCT03706820||normal rest and abnormal exercise hemodynamics|
16439318|NCT03707873|No Intervention|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
16439319|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
16439320|NCT03707847|Experimental|Crizotinib + etoposide capsule+Auto-HSCT|"Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.
~Crizotinib: 250mg, bis in die （BID）, PO.
~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.
~Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT."
16439321|NCT03707834|No Intervention|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
16439322|NCT03707834|Experimental|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
16439323|NCT03707821|Experimental|senofilcon A TEST Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
16439324|NCT03707821|Active Comparator|senofilcon A CONTROL Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
16439325|NCT03707795|Experimental|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
16439326|NCT03707795|Active Comparator|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
16439327|NCT03707782||Individuals with immune deficiencies|aged 18 years or older and have an immune deficiency
16439328|NCT03707782||Family members|aged 18 years or older and are related to a person who has an immune deficiency
16439329|NCT03707769|Experimental|Fistula treatment|Treatment of fistula with TIPS microspheres
16439330|NCT03707730|Experimental|AGY|capsule containing egg yolk with AGY
16439331|NCT03707730|Placebo Comparator|placebo|capsule containing plain egg yolk
16439332|NCT03707717|Experimental|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
16439333|NCT03707717|Experimental|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
16439334|NCT03707717|Experimental|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
16439335|NCT03707704||SCI patients in primary rehabilitation|
16439336|NCT03707691|Experimental|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
16439337|NCT03707691|Experimental|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
16439338|NCT03707691|Experimental|Control Participants|
16439339|NCT03707678|Experimental|Subjects receiving GSK2245035|Eligible subjects will be administered 20 nanograms (ng) of GSK2245035 nasal spray solution using a metered Valois VP7 pump (1 spray=10 ng per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol metered dose inhaler (MDI) will be given for symptom relief from screening to the end of the study.
16439340|NCT03707678|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.
16439341|NCT03707652|Experimental|Cohort A (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
16439342|NCT03707652|Experimental|Cohort A (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
16439343|NCT03707652|Experimental|Cohort A (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
16439344|NCT03707652|Experimental|Cohort A (oral supplement A)-1 or 4 capsules|Oral supplement A (1 or 4 capsules) administered daily for 3 days
16439345|NCT03707652|Experimental|Cohort A (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
16439346|NCT03707652|Experimental|Cohort A (oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
16439347|NCT03707652|Experimental|Cohort B (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
16439348|NCT03707652|Experimental|Cohort B (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
16439349|NCT03707652|Experimental|Cohort B (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
16439350|NCT03707652|Experimental|Cohort B (oral supplement C)- 1 or 4 capsules|Oral supplement C (1 or 4 capsules) administered daily for 3 days
16439351|NCT03707652|Experimental|Cohort B (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
16439352|NCT03707652|Experimental|Cohort B(oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
16439353|NCT03707639|Experimental|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
16439354|NCT03707626||LAD with collaterals with and without wellens sign|
16439481|NCT03706859|Experimental|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=[SBP+10]/KTP)
16439491|NCT03706820||resting pulmonary hypertension|
16439492|NCT03706820||abnormal wedge pressure at exercise|
16439355|NCT03707613|Experimental|DWT learning curve|Initial cannulation is performed with a wire-guided sphincterotome by a trainee. If the cannulation proves difficult (cannulation time >10min, cannulation attemtps >5 or inadvertent PD cannulation >1) and PD is inadvertently entered, DWT will be performed by one of the two trainees. If DWT fails within 5min or 5 attempts, a trainer will take over and continue the cannulation. To prevent PEP, all patients receive prophylactic PD stent and post-ERCP rectal indomethacin. Aggressive hydartion will be administrated at the discretion of endoscopists.
16439356|NCT03707600|Sham Comparator|Sham|The sham coil setting is designed to mimic the auditory artifact and scalp sensations evoked by the real coil without stimulating the brain.
16439357|NCT03707600|Active Comparator|TMS|Active TMS
16439360|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
16439361|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
16439362|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
16439363|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
16439364|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
16439365|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
16439366|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
16439367|NCT03707548|Experimental|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)
~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
16439368|NCT03707535|Experimental|CT-P13|
16439369|NCT03707535|Active Comparator|China-approved Remicade|
16439370|NCT03707522|Experimental|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
16439371|NCT03707522|Experimental|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
16439372|NCT03707522|Experimental|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
16439373|NCT03707522|Placebo Comparator|Control + Control|2 doses online daily activity scheduling interactive article (control)
16439374|NCT03707509|Experimental|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
16439375|NCT03707509|Active Comparator|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
16439376|NCT03707496||DeWinterCohort|Patients with de Winter syndrome pattern ECG
16439377|NCT03707483|Experimental|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
16439378|NCT03707483|Active Comparator|Comparator|using platelet rich fibrin alone
16439379|NCT03707470|Experimental|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
16439380|NCT03707470|Active Comparator|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
16439381|NCT03707470|Sham Comparator|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
16439382|NCT03707457|Experimental|Arm A: Nivolumab + anti-GITR|Patients receive nivolumab intravenously (IV) over 30 minutes and anti-GITR intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16439383|NCT03707457|Experimental|Arm B: Nivolumab + IDO1 inhibitor|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1 and IDO1 inhibitor daily by mouth. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16439384|NCT03707457|Experimental|Arm C: Nivolumab + Ipilimumab|Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab intravenously (IV) over 90 minutes on Day 1. Courses repeat every 21 days for up to 4 doses. After ipilimumab is discontinued, courses of nivolumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16439385|NCT03707444||Scrambler Therapy|All participants get the same device treatment with the Scrambler Therapy device, up to 10 treatments.
16439386|NCT03707431|Experimental|Web-based CBT (WebMAP)|Receives access to WebMAP
16439387|NCT03707431|Active Comparator|Pain Education (WebED)|Receives access to WebED
16439388|NCT03707418|Active Comparator|Bivalirudin Injection (Angiomax)|This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
16439389|NCT03707418|Active Comparator|Heparin Sodium|This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
16439518|NCT03706638|Other|Intermittent (Every other day)|Patient's randomized to this arm will take ferrous sulfate 325 mg every other day.
16440920|NCT03697291|Active Comparator|Certodyn|Commercially available iECG system - Certodyn
16439390|NCT03707405|Active Comparator|ROC-sit|Ride-On Cars with Sitting Posture (ROC-sit) The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary. The natural play session can be divided into two 20-to-25 sessions depending on the participant's condition. Training will concentrate on building the concept of casual-effect on the switch and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person) in public spaces (e.g., hallways, convenient stores, garden, museum) and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying motor skills for mobility and socialization in natural play session. All the programs will be discussed by the family, the treating therapist and the research team.
16439391|NCT03707405|Active Comparator|ROC-sit45 and stand25|Ride-On Cars with 45-min Sitting and 25-min Standing Postures (ROC-sit45 and stand25) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 45-minute driving with sitting posture and then transfers to the standing posture for driving 25 minutes.
16439392|NCT03707405|Active Comparator|ROC-sit25 and stand45|Ride-On Cars with 25-min Sitting and 45-min Standing Postures (ROC-sit25 and stand45) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 25-minute driving with sitting posture and then transfers to the standing posture for driving 45 minutes.
16439393|NCT03707405|Active Comparator|ROC-stand|Ride-On Cars with Standing Postures (ROC-stand) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute standing session can be divided into two 30-minute sessions with 10-minute break, depending on the child's condition with the standing posture.
16439394|NCT03707392|Active Comparator|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
16439395|NCT03707392|Experimental|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
16439396|NCT03707379||common care group|diabetic patients under common care group
16439397|NCT03707366|Experimental|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
16439398|NCT03707366|No Intervention|Control group|Services as usual
16439399|NCT03707353|Experimental|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
16439400|NCT03707353|Experimental|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
16439401|NCT03707353|Experimental|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
16439402|NCT03707353|Experimental|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
16439403|NCT03707353|No Intervention|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
16439404|NCT03707353|No Intervention|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
16439405|NCT03707353|Experimental|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
16439406|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
16439407|NCT03707327|Experimental|Game Ready group|the participants performed cryotherapy by compression with Game Ready
16439408|NCT03707327|Experimental|Ice pack|the participants performed cryotherapy for ice pack
16439409|NCT03707314|Other|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
16439410|NCT03707314|Other|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
16439411|NCT03707301||Cancer patients performing sophrology sessions|Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
16439412|NCT03707288|Other|Spine exercise program|"The preclinical second year medical students will be prospectively randomized into two (2) groups, a control group (Group A) and an intervention group (Group B) that will be given a standardized spine exercise program. They will be asked to complete a Questionnaire B to evaluate changes in knowledge, attitude and practice towards musculoskeletal problem of the back and neck pain after intervention; the numeric rating scale (NRS), and the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) at eight (8) weeks.
~The standardized spine exercise program will be provided in a handout and given only to the intervention Group B subjects, these are basic low back exercises to be done three (3) times per week for 20mins, as well as a few very brief stretching exercises to be done during periods of sitting for greater than sixty (60) minutes."
16439413|NCT03707275|Experimental|Alexa+ Arm|
16439414|NCT03707275|Other|Standard of Care Arm|
16439415|NCT03707262|Experimental|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.
~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:
~5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)
~10 doses of TLI (120 centigray [cGY] x 10 fractions, starting the day after transplant)"
16439416|NCT03707249|Experimental|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
16439417|NCT03707249|Sham Comparator|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
16439482|NCT03706859|Active Comparator|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
16439418|NCT03707236|Experimental|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
16439419|NCT03707236|No Intervention|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
16439420|NCT03707223|Experimental|experimental|"The interfaces Program"
16439421|NCT03707223|Active Comparator|control group|supported employment using the individual placement and support (IPS) model
16439422|NCT03707210|Experimental|Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
16439423|NCT03707210|No Intervention|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
16439424|NCT03707197|Experimental|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
16439425|NCT03707197|No Intervention|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
16439426|NCT03707184|Experimental|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
16439427|NCT03707171|Active Comparator|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
16439428|NCT03707171|Placebo Comparator|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
16439429|NCT03707158|Active Comparator|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
16439430|NCT03707158|Active Comparator|Face-to-Face CBT|The Cool Kids suite of face-to-face (office-based or telehealth) CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The face-to-face cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face-to-face suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
16439431|NCT03707145|Active Comparator|Professional led with online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.
~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
16439432|NCT03707145|Active Comparator|Professional led without online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.
~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
16439433|NCT03707145|Experimental|Patient empowered with online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.
~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
16439434|NCT03707145|Active Comparator|Patient empowered without online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.
~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
16439435|NCT03707132||Tourniquet Group|'Tourniquet: Folley catheter in the low segment of the uterus
16439436|NCT03707132||Control Group|Standard hysterectomy is performed
16439437|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
16439438|NCT03707106|Experimental|VR based cue exposure smoking cessation|an established CBT intervention for smoking cessation supported by cue exposure in virtual reality
16439439|NCT03707106|Active Comparator|PMR supported smoking cessation|an established CBT intervention for smoking cessation supported supported by specific stress reduction (Progressive Muscle Relaxation, Jacobson)
16439440|NCT03707093|Experimental|ADG106 Dose escalation|
16439441|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.
~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
16439483|NCT03706846|Other|Fasting 2 hours|Fasting 2 hours
16439484|NCT03706846|Other|Fasting 6 hours|Fasting 6 hours
16439485|NCT03706833|Experimental|Edwards PASCAL System - CLASP IID|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation
16439442|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
16439443|NCT03707067|Experimental|Custom fitted compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
16439444|NCT03707067|Sham Comparator|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
16439445|NCT03707054|Experimental|Study Arm|Measurements of optic nerve diameter, Urine and plasma osmolality, Serum vasopressin.
16439446|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
16439447|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
16439448|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
16439449|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
16439450|NCT03707041|Experimental|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
16439451|NCT03707041|Active Comparator|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
16439452|NCT03707028|Experimental|Rivoceranib (apatinib) with Paclitaxel|Oral daily doses of rivoceranib (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on day 1, day 8, and day 15.
16439453|NCT03707002|Active Comparator|scFOS|scFOS consumed at 5g/day for 6 weeks
16439454|NCT03707002|Placebo Comparator|Placebo|maltodextrin consumed at 5g/day for 6 weeks
16439455|NCT03706989|Experimental|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to >75 years old.
16439456|NCT03706976|Experimental|CTOM|
16439459|NCT03706950||Elpida® + 2 NRTIs|Elpida® 20mg qd in the first line of therapy for HIV-1 infected patients with a background standard ART.
16439460|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
16439461|NCT03706924|Experimental|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
16439462|NCT03706924|Active Comparator|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
16439463|NCT03706911|Experimental|VM-1500A-LAI 50mg|VM-1500A-LAI 50mg IM single dose
16439464|NCT03706911|Experimental|VM-1500A-LAI 150mg|VM-1500A-LAI 150mg IM single dose
16439465|NCT03706911|Experimental|VM-1500A-LAI 300mg|VM-1500A-LAI 300mg IM single dose
16439466|NCT03706911|Experimental|VM-1500A-LAI 600mg|VM-1500A-LAI 600mg IM single dose
16439467|NCT03706911|Experimental|VM-1500A-LAI 1200mg|VM-1500A-LAI 1200mg IM single dose
16439468|NCT03706911|Experimental|VM-1500A-LAI XXX5mg Multiple|VM-1500A-LAI selected dose IM, 2 injections monthly
16439469|NCT03706911|Experimental|VM-1500A-LAI XXX6mg Multiple|VM-1500A-LAI double selected dose IM, 2 injections monthly
16439470|NCT03706898|Experimental|Elpida® fasting|Elpida® 20 mg single dose fasting
16439471|NCT03706898|Experimental|Elpida® after meal|Elpida® 20 mg single dose after meals
16439472|NCT03706898|Experimental|Elpida® (in subjects with mild hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with mild hepatic impairment (Child - Pugh Class А)
16439473|NCT03706898|Experimental|Elpida® (in subjects with moderate hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with moderate hepatic impairment (Child - Pugh Class B)
16439474|NCT03706898|Experimental|Elpida® & sofosbuvir & daclatasvir|Drug-drug interactions of sofosbuvir 400 mg + daclatasvir 60 mg and Elpida® 20 mg, single dose fasting
16439475|NCT03706898|Experimental|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
16439476|NCT03706885|Placebo Comparator|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
16439477|NCT03706885|Active Comparator|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
16439478|NCT03706885|Active Comparator|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
16439479|NCT03706872|Experimental|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care.
16439480|NCT03706872|No Intervention|Control Group|Provision of usual prenatal care
16439493|NCT03706807|Experimental|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
16439494|NCT03706807|Active Comparator|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
16439495|NCT03706807|No Intervention|Naïve|It's a waiting list group which will receive no intervention.
16439496|NCT03706794|Experimental|Clinical Decision Support Tool|Tailored education provided via a smartphone application
16439497|NCT03706794|Active Comparator|Headache Education|Non-tailored education provided via a smartphone application.
16439498|NCT03706781|Experimental|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
16439499|NCT03706781|Active Comparator|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
16439500|NCT03706768|Other|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
16439501|NCT03706755|Active Comparator|A|group A: will receive 1 mcg/Kg of Norepinephrine intravenously
16439502|NCT03706755|Active Comparator|B|group B: will receive 0.5 mcg/Kg of Norepinephrine intravenously
16439503|NCT03706742|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
16439504|NCT03706742|Active Comparator|Mailed outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
16439505|NCT03706729|Experimental|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
16439506|NCT03706716|Other|Intervention with use of decision aid in the consultation|With use of developed decision aid for pelvic organ prolapse / At the beginning of the consultation the IF will be opened within the patients electronic journal. The conversation will take its starting point from the generated IF which should define the area of interest rather for the patient.
16439507|NCT03706716|No Intervention|Control with no use of decision aid in the consultation|Without decision aid / The conversation during the consultation will follow the general standard for consultation conversations in the department.
16439508|NCT03706703|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
16439509|NCT03706690|Experimental|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression)
16439510|NCT03706690|Placebo Comparator|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
16439511|NCT03706677|Active Comparator|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.
~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
16439512|NCT03706677|Active Comparator|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.
~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
16439513|NCT03706664|Other|Training of machine learning algorithm|113 MR Enterography images labelled by Radiologists will be used to develop a machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal.
16439514|NCT03706664|Other|Testing of machine learning algorithm|"113 MR Enterography images labelled by Radiologists will be used to test the accuracy of the machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal compared to Radiologists opinion.
~Cross Validation analysis will be used for data analysis."
16439515|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
16439516|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
16439517|NCT03706638|Other|Daily|Patients randomized to this arm will take ferrous sulfate 325 mg every day.
16439519|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
16439520|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
16439521|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
16439522|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
16439523|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
16439524|NCT03706599|Experimental|Fever therapeutic education session|Therapeutic education session on fever
16439525|NCT03706599|Placebo Comparator|Control therapeutic education session|Control therapeutic education session (on household accidents)
16439526|NCT03706586|Active Comparator|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
16439527|NCT03706586|Experimental|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
16439528|NCT03706547|Experimental|anti-CD19/BCMA CAR-T cells|"Chemotherapy with a classic combination with fludarabine and cyclophosphamide;
~Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
16439529|NCT03706534|Active Comparator|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
16439530|NCT03706534|Experimental|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
16439531|NCT03706534|Experimental|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
16439532|NCT03706521|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
16439533|NCT03706495|Experimental|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
16439534|NCT03706495|Experimental|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
16439535|NCT03706482|Experimental|Postnatal|"15 participants.
~Administration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
16439536|NCT03706482|Experimental|Prenatal|"15 participants.
~Administration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
16439537|NCT03706482|No Intervention|Prospective control (untreated)|"1-30 participants.
~Subjects eligible for the trial but not willing/able to participate in any of the experimental arms."
16439538|NCT03706482|No Intervention|Historic control|"30-150 participants.
~Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
16439539|NCT03706469|Experimental|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
16439540|NCT03706469|Experimental|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
16439607|NCT03706092||After|Elderly patients > = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
16439541|NCT03706469|Experimental|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
16439542|NCT03706469|Experimental|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
16439543|NCT03706456|Experimental|Darvadstrocel 24 mL|Darvadstrocel (Cx601) 24 mL suspension of 120 million cells of expanded allogeneic adipose-derived stem cells (eASC) as an intralesional injection, once on Day 1.
16439544|NCT03706443|Active Comparator|Systane® Complete|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Complete, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
16439545|NCT03706443|Active Comparator|Systane® Ultra|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Ultra, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
16439546|NCT03706417|Experimental|Telemedicine|Babies that received telemedicine consult intervention.
16439547|NCT03706417|No Intervention|Historical control|Historical controls who have not received a telemedicine consult.
16439548|NCT03706404|Experimental|Point-of-care Testing and Ultrasound pathway|
16439549|NCT03706404|No Intervention|Classical pathway|
16439550|NCT03706391||ALS and PMA Reversals|
16439551|NCT03706378|Other|Glucose Reference 1|50g glucose dissolve in 250 ml of water
16439552|NCT03706378|Other|Glucose Reference 2|50g glucose dissolve in 250 ml of water
16439553|NCT03706378|Other|Glucose Reference 3|50g glucose dissolve in 250 ml of water
16439554|NCT03706378|Experimental|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
16439555|NCT03706378|Experimental|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
16439556|NCT03706378|Experimental|Rice Roll|Steamed 197.6g of rice roll
16439557|NCT03706378|Experimental|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
16439558|NCT03706378|Experimental|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
16439559|NCT03706378|Experimental|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
16439566|NCT03706352|Experimental|tunneling group|Epidural Catheter Insertion and fixation by subcutaneous tunneling procedure.
16439567|NCT03706352|Active Comparator|taping group|Epidural Catheter Insertion and fixation by use of adhesive tape without tunneling.
16439568|NCT03706339|Placebo Comparator|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
16439569|NCT03706339|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
16439570|NCT03706339|Experimental|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
16439571|NCT03706326|Experimental|Treatment with Anti-MUC1 CAR-T cells|Anti-MUC1 CAR-T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
16439572|NCT03706326|Experimental|Combination Therapy: CAR-T combining PD-1 knockout T Cells|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
16439573|NCT03706326|Experimental|Treatment with PD-1 knockout Engineered T cells|PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
16439608|NCT03706079|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
16439609|NCT03706079|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
16439610|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
16439611|NCT03706053|Placebo Comparator|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
16439574|NCT03706313|Active Comparator|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
16439575|NCT03706313|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
16439576|NCT03706300|Experimental|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
16439577|NCT03706300|Active Comparator|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
16439578|NCT03706287|Experimental|Anlotinib + AP/PC|
16439579|NCT03706274|Experimental|CX-188 Escalation|
16439580|NCT03706274|Experimental|CX-188 Alternative Dosing Schedule|
16439581|NCT03706261|Experimental|Offspring Cohort|Racially/ethnically diverse subjects with or without a positive family history of Alzheimer's disease (AD) will have one PET scan with 18F-MK-6240 over a 30 to 60-minute scanning period, and one PET scan with 18F-Florbetaben over a 20-minute scanning period.
16439582|NCT03706248||No recurrence|"CT scan has confirmed that subjects are without recurrence. Blood can be drawn up to 4 weeks after scan.
~Effective Feb 28, 2019, this group is closed to accrual as it has reached the goal."
16439583|NCT03706248||Recurrence|CT scan has confirmed that subjects are have recurrence of their colorectal cancer. Blood can be drawn prior to any treatment for the recurrent disease.
16439584|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
16439585|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
16439586|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
16439587|NCT03706209|Experimental|150 mg MP1032 bid|3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
16439588|NCT03706209|Experimental|300 mg MP1032 bid|6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
16439589|NCT03706209|Placebo Comparator|Placebo bid|6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
16439590|NCT03706196||high incidence crohn's disease area|subjects living in high incidence crohn's disease area coming in dentist for dental extraction linked to medical indication
16439591|NCT03706196||low incidence crohn's disease area|subjects living in low incidence crohn's disease area coming in dentist for dental extractionlinked to medical indication
16439592|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
16439593|NCT03706183||Control Group|The IMA levels will be determined.
16439594|NCT03706170|Experimental|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
16439595|NCT03706170|Experimental|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
16439596|NCT03706170|Experimental|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
16439597|NCT03706170|Experimental|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
16439598|NCT03706157|Active Comparator|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
16439599|NCT03706157|Active Comparator|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
16439600|NCT03706144|Experimental|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
16439601|NCT03706144|No Intervention|Control Group|Instruction as usual = TAU
16439602|NCT03706131|Experimental|experimental group|one session 15 minutes cervical mobilisation and home exercise
16439603|NCT03706131|No Intervention|control grup|no intervention
16439604|NCT03706118|Experimental|MRI and Neuropsychologic testing|"102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36.
~102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36."
16439605|NCT03706105|Experimental|Intervention - Cardiac Rehabilitation|
16439606|NCT03706092||Before|Elderly patients > = 70 in ICU without any intervention of the pharmacists and of the geriatricians
16439612|NCT03706053|Experimental|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
16439613|NCT03706053|Experimental|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
16439614|NCT03706040|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for 16 weeks (Period A) followed by either DB risankizumab Dose 1 or DB risankizumab Dose 2 for 24 weeks (Period B).
16439615|NCT03706040|Experimental|Risankizumab Dose 1|Participants randomized to receive double-blind (DB) risankizumab Dose 1 for 16 weeks (Period A) followed by DB risankizumab Dose 1 for 24 weeks (Period B).
16439616|NCT03706040|Experimental|Risankizumab Dose 2|Participants randomized to receive double-blind (DB) risankizumab Dose 2 for 16 weeks (Period A) followed by DB risankizumab Dose 2 for 24 weeks (Period B).
16439617|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 3 fractions|
16439618|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 5 fractions|
16439619|NCT03706014|Experimental|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
16439620|NCT03706014|Placebo Comparator|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
16439621|NCT03706001|Experimental|Experimental Arm|Participants will receive psychotherapy for once a week.
16439622|NCT03706001|No Intervention|Control Arm|Participants will not receive any treatment for depression.
16439623|NCT03705988|Experimental|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA~2mA.
16439624|NCT03705988|Sham Comparator|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
16439625|NCT03705975|Active Comparator|edit arms|classical physiotherapy and manual treatment. Classical physiotherapy consisting of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Manual treatment is consist of scapular mobilization, glenohumeral joint inferior and posterior mobilization. Treatment modality is implemented by physical therapist three times a week for 8 weeks.
16439626|NCT03705975|Active Comparator|edit arm/intervention cross|classical physiotherapy and proprioceptive neuromusculer fasilitation. Classical physiotherapy consist of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Scapular PNF and upper extremity PNF (flexion-abduction-external rotation) pattern. Treatment programme was implemented by physical therapist three times a week for 8 weeks.
16439627|NCT03705962|Experimental|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
16439628|NCT03705962|Placebo Comparator|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
16439629|NCT03705949|Active Comparator|Study group|Sodium Hyaluronate 0.1% drops
16439630|NCT03705949|Active Comparator|Control group|Sodium Hyaluronate 0.2% drops
16439631|NCT03705936|Sham Comparator|Sham 1Hz rTMS--5Hz rTMS|Participants will receive sham 1Hz rTMS, then immediately followed by 5Hz rTMS.
16439632|NCT03705936|Experimental|1Hz rTMS--5Hz rTMS|Participants will receive 1Hz rTMS, then immediately followed by 5Hz rTMS.
16439633|NCT03705936|Experimental|1Hz rTMS--30-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 30 minutes break, then followed by 5Hz rTMS.
16439634|NCT03705936|Experimental|1Hz rTMS--60-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 60 minutes break, then followed by 5Hz rTMS.
16439635|NCT03705936|Sham Comparator|Sham 5Hz rTMS--1Hz rTMS|Participants will receive sham 5Hz rTMS, then immediately followed by 1Hz rTMS.
16439636|NCT03705936|Experimental|5Hz rTMS--1Hz rTMS|Participants will receive 5Hz rTMS, then immediately followed by 1Hz rTMS.
16439637|NCT03705936|Experimental|5Hz rTMS--45-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 45 minutes break, then followed by 1Hz rTMS.
16439638|NCT03705936|Experimental|5Hz rTMS--90-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 90 minutes break, then followed by 1Hz rTMS.
16439639|NCT03705923|Experimental|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
16439724|NCT03705299|Experimental|NeuMeDex NICVP (Non-Invasive CVP) vs Standard CVP|Three pressure readings recorded for both NeuMeDex NICVP and central line pressure catheter over a 10 minute period.
16439725|NCT03705286|Active Comparator|PVC-ETT|Polyvinylchloride endotracheal tube
16439640|NCT03705910|Active Comparator|Perceptive Rehabilitation (PR-group)|"This treatment will include small latex cones with different resistance. In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.
~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture."
16439641|NCT03705910|Active Comparator|Mobilisation Techniques (Mob-group)|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.
~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
16439642|NCT03705910|No Intervention|Control Group (C-group)|This group will not receive any intervention during this period. C-group will attend assessments.
16439643|NCT03705897|Other|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
16439644|NCT03705884|Other|Cardiac Sarcoidosis|Patients with an established diagnosis of cardiac sarcoidosis.
16439645|NCT03705884|Other|Healthy volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
16439646|NCT03705871|Experimental|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
16439647|NCT03705871|Active Comparator|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
16439648|NCT03705858|Experimental|Ac-lintuzumab|Subjects with AML will receive Ac-lintuzumab.
16439649|NCT03705845|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
16439650|NCT03705845|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
16439651|NCT03705832|Experimental|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
16439652|NCT03705832|Placebo Comparator|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
16439653|NCT03705819|Experimental|Healthy Volunteers|In Stage 1, five healthy volunteers will receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate [11C]-NOP46 biodistribution and derive dosimetry estimates.
16439654|NCT03705819|Experimental|Individuals with Focal Pain|In Stage 2, up to 30 subjects with focal pain will receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
16439655|NCT03705793|Experimental|Mometasone Furoate Nasal Irrigation|The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
16439656|NCT03705793|Active Comparator|Mometasone Nasal Spray|The study intervention will be mometasone nasal spray (50 mcg/spray) and placebo nasal irrigation. The placebo will contain lactose monohydrate and will be supplied in capsules identical to the budesonide capsules. Participants will be required to dissolve the contents of the two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
16439657|NCT03705780|Other|the short OSAS scale|In preoperative interview，distributing the short OSAS screening scales to children's parents，and the scale was completed preoperative，calculate the score of the scale
16439658|NCT03705780|Experimental|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
16439659|NCT03705754|Active Comparator|Tattoo arm|Tattoo will be placed by endoscopic submucosal injection of carbon black suspension
16439660|NCT03705754|No Intervention|Control arm|Tattoo will not be placed but case will follow standard procedure
16439661|NCT03705741|Experimental|Exercise group|Resistance exercise twice a week
16439662|NCT03705741|No Intervention|Control group|
16439663|NCT03705728|Experimental|Intravenous group|"Propofol & remifentanil administration using the closed-loop controller with the Easy-TIVA platfrom."
16439664|NCT03705728|Active Comparator|volatile anesthesia group|Sevoflurane will be administered manually according to the BIS values. Remifentanil will be administered manually using a Target Controlled Infusion pump using the Minto model.
16439665|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
16439666|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
16439667|NCT03705702|Active Comparator|Intervention Group (IG)|The intervention of active comparator will be education program plus behavioral intervention through physical activity counseling program combined with a monitoring-and-feedback tool.
16439668|NCT03705702|Sham Comparator|Control Group (CG)|The intervention of sham comparator will be an education program in asthma and physical activity recommendations.
16439669|NCT03705676|Active Comparator|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
16439670|NCT03705676|Experimental|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
16439671|NCT03705676|Active Comparator|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
16439672|NCT03705676|Experimental|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
16439673|NCT03705676|Active Comparator|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
16439674|NCT03705676|Experimental|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
16439675|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
16439676|NCT03705650|Experimental|Medicare Primary Care Provider (PCP) Patients|This is a non-randomized study of non-significant risk (NSR) that will be conducted at Northwestern's Central Dupage Hospital. Medicare patients > 65 years who are scheduled for a routine physical exam with their PCP that meet inclusion and exclusion criteria will be asked to participate in this study. Consenting patients will be scheduled for 2 back to back ultrasound scans including 5 standard 2D echocardiogram views each. The first scan will be performed by a non-ultrasound specialist using EchoGPS experimental guidance technology and the second control exam will be performed by a trained sonographer using a cleared conventional ultrasound platform.
16439677|NCT03705637|Experimental|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
16439678|NCT03705624|No Intervention|Standard of Care|Standard of care with passively monitored malaria incidence at health centers that receive appropriate diagnostic and clinical supplies and Seasonal Malaria Chemoprevention (SMC) for children less than 5 years of age
16439679|NCT03705624|Experimental|CCM|Standard of care supplemented with enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with artemether-lumefantrine (AL) according to national guidelines
16439680|NCT03705624|Experimental|CCM+MSAT|Standard of Care supplemented with CCM and Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
16439681|NCT03705611|No Intervention|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
16439682|NCT03705611|Experimental|HIV self-testing only|HIV self-testing only
16439683|NCT03705611|Experimental|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
16439684|NCT03705598|Placebo Comparator|Light physical exercise|Normal walking, light intensity resistance exercise and stretching, and health education discussions.
16439685|NCT03705598|Active Comparator|Tai Chi|Joint rotations and balance games, Tai Chi walking drills and the 8 forms.
16439686|NCT03705585|Experimental|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
16439687|NCT03705585|Experimental|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
16439688|NCT03705585|No Intervention|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
16439689|NCT03705572|Active Comparator|Dietary Supplement: Phospholipid drink.|Participant in an intervention parallel group consumed a drink with added phospholipids (Lacprodan PL20).
16439690|NCT03705572|Placebo Comparator|Dietary Supplement: Placebo milk drink.|Participant in an intervention parallel group consumed a drink without added phospholipids.
16439691|NCT03705559|Experimental|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
16439692|NCT03705559|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
16439693|NCT03705559|Experimental|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
16439694|NCT03705533|Other|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16439695|NCT03705533|Other|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
16439696|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
16439697|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
16439698|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
16439699|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
16439700|NCT03705494|Active Comparator|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
16439701|NCT03705494|No Intervention|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
16439702|NCT03705481|Other|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
16439703|NCT03705468||Ketamine sedation|Ketamine sedation
16439704|NCT03705468||Propofol sedation|Propofol sedation
16439705|NCT03705455|Active Comparator|ISAP SMS|ISAP SMS will be sent to enrolled caregivers
16439706|NCT03705455|No Intervention|No ISAP SMS|No ISAP SMS will be sent to enrolled caregivers
16439707|NCT03705442|Placebo Comparator|Placebo|Placebo
16439708|NCT03705442|Experimental|Probiotics|Omni-Biotic 10
16439709|NCT03705429|Active Comparator|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
16439710|NCT03705429|Placebo Comparator|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
16439711|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
16439712|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
16439713|NCT03705403|Active Comparator|Control|Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
16439714|NCT03705403|Experimental|Experimental treatment|Standard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
16439715|NCT03705390|Experimental|ILB|ILB subcutaneous injection
16439716|NCT03705377||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360), family service staff (168)
16439717|NCT03705364|No Intervention|Wait List Control Group|Wait list control group
16439718|NCT03705364|Experimental|Fall Management program|Intervention arm
16439719|NCT03705351|Experimental|Treatment|Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.
16439720|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
16439721|NCT03705325|Experimental|Spirobank smart spirometer with VitalFlo mobile app|In this single arm study, all participants will be receive the spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app.
16439722|NCT03705312|Placebo Comparator|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
16439723|NCT03705312|Experimental|Transcatheter Mitral valve repair|MitraClip treatment
16441115|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
16439729|NCT03705260|Active Comparator|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C > 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
16439730|NCT03705260|Active Comparator|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
16439731|NCT03705260|Experimental|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C > 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
16439732|NCT03705260|Experimental|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
16439733|NCT03705234|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
16439734|NCT03705234|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
16439735|NCT03705221|Experimental|Group programme|Healthy Parent Carers group programme: A group-based peer led manualised programme called Healthy Parent Carers. The programme content is organised into 12 modules, which can be delivered over six longer (4-hour) sessions or 12 shorter (2-hour) sessions.
16439736|NCT03705221|Active Comparator|Online resources|Healthy Parent Carers online resources: Online resources from the Healthy Parent Carers programme, including materials for 12 modules and related videos and audio files to illustrate the content.
16439737|NCT03705208|Experimental|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).
~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.
~The curriculum is imparted by school teachers are trained and certified by CorStone."
16439738|NCT03705208|No Intervention|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
16439739|NCT03705195|No Intervention|No Intervention|All participants in study will complete two matched clamp studies (OGTT + IGII). The first matched clamp without any intervention the second matched clamp with low dose gliclazide
16439740|NCT03705195|Experimental|Low Dose Gliclazide|"The first 8 participants will complete the dose-ranging phase of LOGIC study. Low dose gliclazide is being used a physiological stimulus. In the dose-ranging phase, 4 participants will receive 10mg gliclazide, the remaining 4 will receive 20mg gliclazide. The allocation to 10mg or 20mg will be randomised and unblinded. The study will analyse after the first 8 participants to assess which dose produces the greatest augmentation of insulin secretion when acting synergistically with the incretin effect.
~The further 12 participants will complete the study with the identified best dose."
16439741|NCT03705182|Experimental|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
16439742|NCT03705182|No Intervention|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
16439743|NCT03705169|Experimental|Arm A, Cohort 1A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.
16439744|NCT03705169|Experimental|Arm A, Cohort 1B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
16439745|NCT03705169|Experimental|Arm A, Cohort 2A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
16439746|NCT03705169|Experimental|Arm A, Cohort 2B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
16439747|NCT03705169|Experimental|Arm A, Cohort 3A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
16439748|NCT03705169|Experimental|Arm A, Cohort 3B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
16439749|NCT03705169|Experimental|Arm A, Cohort 4A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
16439750|NCT03705169|Experimental|Arm A, Cohort 4B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
16439751|NCT03705169|Experimental|Arm B, Cohort 5: SAR441236|Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
16439752|NCT03705169|Experimental|Arm B, Cohort 6: SAR441236|Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
16439753|NCT03705169|Experimental|Arm B, Cohort 7: SAR441236|Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
16439754|NCT03705169|Experimental|Arm B, Cohort 8: SAR441236|Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
16439755|NCT03705169|Experimental|Arm B, Cohort 9: SAR441236|Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
16439756|NCT03705169|Experimental|Arm C, Cohort 10A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.
16439757|NCT03705169|Experimental|Arm C, Cohort 10B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.
16439758|NCT03705169|Experimental|Arm C, Cohort 11A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
16439759|NCT03705169|Experimental|Arm C, Cohort 11B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
16439760|NCT03705156|Experimental|ZL-2306|The starting dose is 300 mg or 200 mg based on patient's body weight.
16439761|NCT03705156|Placebo Comparator|Placebo|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
16439762|NCT03705143|Placebo Comparator|Treatment as Usual|Participants will receive no additional intervention besides the services they are currently receiving at the MMT clinic.
16439763|NCT03705143|Experimental|Chinese translated LETS ACT|In addition to services participants are currently receiving at the MMT clinic, individuals will attend six group-based one-hour behavioral activation treatment sessions.
16439764|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
16439765|NCT03705117|Experimental|V565|V565 orally three times daily for up to 7 days
16439766|NCT03705104|Experimental|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
16439767|NCT03705104|No Intervention|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
16439768|NCT03705091||Transplant|Incident patients receiving a kidney transplant for end stage kidney disease. Patients will undergo functional magnetic resonance imaging at 2 months, 6 months and 12 months following transplantation.
16439769|NCT03705078|Other|early TIPS|Transjugular portosytemic shunt within 72h
16439770|NCT03705078|Other|Glue obliteration|glue obliteration repeated sessions
16439771|NCT03705065|Experimental|Treatment Group 1|Bupivacaine HCI by instillation into each pectoral pocket.
16439772|NCT03705065|Experimental|Treatment Group 2|Bupivacaine HCI by injection into each pectoral pocket.
16439773|NCT03705052|Other|Intervention|Patients and caregivers were asked to complete a questionnaire
16439774|NCT03705039|Active Comparator|Treatment Group|pulsed ultrasound treatment
16439775|NCT03705039|Placebo Comparator|Control Group|sham ultrasound treatment
16439776|NCT03705013||Baseline Cologuard positive and negative colonoscopy|Those whose Cologuard T0 result was positive and colonoscopy result was negative.
16439777|NCT03705013||Baseline Cologuard positive and no colonoscopy|Those whose Cologuard T0 result was positive and subject declined to complete a colonoscopy per protocol.
16439778|NCT03705013||3-year follow-up Cologuard positive and negative colonoscopy|Those whose Cologuard result at T3 was positive and colonoscopy result at T3 was negative.
16439779|NCT03705013||3-year follow-up Cologuard positive and no colonoscopy|Those whose Cologuard result at T3 was positive and subject declined to complete a colonoscopy per protocol.
16439780|NCT03705000|Experimental|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
16439781|NCT03705000|Active Comparator|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
16439782|NCT03704987|Active Comparator|Klinefelter|Male patients followed with the diagnosis of klinefelter
16439783|NCT03704987|Active Comparator|Control|healthy male subjects
16439784|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
16439785|NCT03704961|Experimental|classical music|
16439786|NCT03704961|Experimental|Turkish music|
16439787|NCT03704961|Experimental|audiobook|
16439788|NCT03704948|Experimental|Listening Visits|Listening Visits delivered by a nurse.
16439789|NCT03704948|Active Comparator|Standard of Care (Social Work)|Standard mental health services provided by social workers.
16439790|NCT03704922|Experimental|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
16439791|NCT03704922|Experimental|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
16439792|NCT03704909|Active Comparator|Group Adrenaline: Group A|All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.
16439793|NCT03704909|Active Comparator|Group Ephedrine: Group E|All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E
16439794|NCT03704870|Active Comparator|Daily Chest Xray (standard)|
16439795|NCT03704870|Experimental|Chest Xray post chest tube removal only|
16439796|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
16441116|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
16439797|NCT03704857|Experimental|Foraminal enlargement with sodium hypochlorite and PDT|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, PDT, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
16439798|NCT03704857|Experimental|Foraminal enlargement with chlorhexidine as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, chlorhexidine as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
16439799|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with AH Plus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
16439800|NCT03704857|Active Comparator|Foraminal enlargement with conventional irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, conventional irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
16439801|NCT03704857|Experimental|Foraminal enlargement with passive ultrasonic irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, passive ultrasonic irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
16439802|NCT03704844||Patients with renal congestion|
16439803|NCT03704844||Patients without renal congestion|
16439804|NCT03704831||IPACK group|IPACK group
16439805|NCT03704831||Surgical infiltration group|Surgical infiltration group
16439806|NCT03704818|Experimental|Dapagliflozin 5mg|
16439807|NCT03704818|Experimental|Placebo|
16439808|NCT03704805|Experimental|Problem-Solving Therapy|Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.
16439809|NCT03704805|Active Comparator|Enhanced Standard of Care|Participants in the control group receive enhanced standard of care.
16439810|NCT03704792|Experimental|Adult CLD Group|Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.
16439811|NCT03704779|Experimental|Multimodal Mindfulness Activity Program|Students assigned to the intervention will receive 8 weeks of the mindfulness activity intervention.
16439812|NCT03704779|No Intervention|Control Group|Students assigned to the control group will not receive any intervention.
16439813|NCT03704766|Experimental|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
16439814|NCT03704766|Active Comparator|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
16439815|NCT03704753|Active Comparator|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
16439816|NCT03704753|Placebo Comparator|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
16439817|NCT03704753|Active Comparator|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
16439818|NCT03704753|Active Comparator|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
16439819|NCT03704753|Active Comparator|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
16439820|NCT03704753|Placebo Comparator|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
16439821|NCT03704740|Experimental|NBP607-QIV|One or two doses of 0.5mL of NBP607-QIV by intramuscular injection
16439822|NCT03704740|Active Comparator|Agrippal|One or two doses of 0.25mL of Agrippal by intramuscular injection
16439867|NCT03704454|Experimental|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
16439823|NCT03704727|Experimental|probiotic treatment|Probiotic: VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus. Administred orally
16439824|NCT03704714|Experimental|Treatment (nivolumab and R-CHOP)|Participants receive nivolumab IV over 30 minutes on day 1. Participants also rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone PO on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16439825|NCT03704688|Experimental|Phase I: Dose Level -3|Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
16439826|NCT03704688|Experimental|Phase I: Dose Level -2|Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
16439827|NCT03704688|Experimental|Phase I: Dose Level -1|Trametinib 1.5 mg PO q daily 15mg PO q daily
16439828|NCT03704688|Experimental|Phase I: Dose Level 1|Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
16439829|NCT03704688|Experimental|Phase I: Dose Level 2|Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
16439830|NCT03704688|Experimental|Phase II|Maximum tolerated dose as established in Phase I portion
16439831|NCT03704675|Experimental|Group I (Fasted->Fed)|Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2
16439832|NCT03704675|Experimental|Group II(Fed->Fasted)|Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2
16439833|NCT03704662|Other|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
16439834|NCT03704662|Other|Preoperative Fractionated Radiation Therapy and Chemotherapy|Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).
16439835|NCT03704649|No Intervention|Standard nutrition education|The comparison group for the participatory video intervention.
16439836|NCT03704649|Experimental|Participatory nutrition education|Intervention arm integrates participatory video model to standard girls' club sessions to promote nutrition education.
16439837|NCT03704636|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.
16439838|NCT03704623|Active Comparator|Paracetamol|Patients will receive IV 1 g of Paracetamol
16439839|NCT03704623|Active Comparator|Parecoxib|Patients will receive 40 mg of Parecoxib IV
16439840|NCT03704610|Experimental|INFLIXIMAB|Infliximab 5 mg/kg D1-D15, then infliximab every 4 weeks W6-W10-W14
16439841|NCT03704610|Other|Placebo|placebo injection D1-D15 then infliximab 5 mg/kg W6-W8-W12-W16-W20
16439842|NCT03704597|Active Comparator|7-hour cryotherapy|Standard of care
16439843|NCT03704597|Experimental|2-hour cryotherapy|Experimental treatment
16439844|NCT03704584|Active Comparator|Treatment Group (corticosteroid injection plus lidocaine)|Treatment Group (corticosteroid injection plus lidocaine) subjects will receive (Methylprednisolone acetate injectable suspension and Lidocaine HCl) for their upper extremity condition for their upper extremity condition
16439845|NCT03704584|Other|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (Methylprednisolone acetate injectable suspension) for their upper extremity condition
16439846|NCT03704571|Experimental|Tailored Group|In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
16439847|NCT03704571|Active Comparator|Control Group|In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
16439848|NCT03704545|No Intervention|Control group|
16439849|NCT03704545|Experimental|Experimental group from the hospital|
16439850|NCT03704545|Experimental|Experimental group from the city|
16439851|NCT03704532||Operative treatment|Patients having undergone an operative treatment of achilles tendon rupture
16439852|NCT03704532||Nonoperative treatment|Patients having undergone a nonoperative treatment with functional rehabilitation of achilles tendon rupture
16439853|NCT03704519|Experimental|Men_EPD|Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
16439854|NCT03704519|Experimental|Men_DEP|Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
16439855|NCT03704519|Experimental|Men_PDE|Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
16439856|NCT03704519|Experimental|Men_DPE|Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
16439857|NCT03704519|Experimental|Men_EDP|Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
16439858|NCT03704519|Experimental|Men_PED|Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
16439859|NCT03704506|Experimental|treatment group 1|Reyanning mixture+amoxil capsule simulator
16439860|NCT03704506|Experimental|treatment group 2|Reyanning mixture +amoxil capsule
16439861|NCT03704506|Active Comparator|control group|Reyanning mixture simulator +amoxil capsule
16439862|NCT03704493|No Intervention|Image Group|The patients were looking at a static image of a lavender flower while exercising on the treadmill.
16439863|NCT03704493|Experimental|Video Group|The patients were watching a video of a group of amateur runners while exercising on the treadmill.
16439864|NCT03704480|Experimental|Amended ARM A|"One cycle equals 4 weeks (D1=D28);
~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.
~Tremelimumab: 300 mg by IV infusion on D1 at cycle 1 only."
16439865|NCT03704467|Experimental|Part A: Carboplatin + M6620 + Avelumab|
16439866|NCT03704454|Experimental|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
16439868|NCT03704454|Experimental|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
16439869|NCT03704454|Experimental|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
16439870|NCT03704441|Other|bupivacaine 6mg|bupivacaine 6mg
16439871|NCT03704441|Other|bupivacaine 7mg|bupivacaine 7mg
16439872|NCT03704441|Other|bupivacaine 8mg|bupivacaine 8mg
16439873|NCT03704441|Other|bupivacaine 9mg|bupivacaine 9mg
16439874|NCT03704441|Other|bupivacaine 10mg|bupivacaine 10mg
16439875|NCT03704441|Other|bupivacaine 11mg|bupivacaine 11mg
16439876|NCT03704441|Other|bupivacaine 12mg|bupivacaine 12mg
16439877|NCT03704428|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
16439878|NCT03704428|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
16439879|NCT03704428|Experimental|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
16439880|NCT03704428|Experimental|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
16439881|NCT03704428|Experimental|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
16439882|NCT03704415|Active Comparator|Extended|Extended sinus surgery including all sinuses
16439883|NCT03704415|Active Comparator|Limited|Limited sinus surgery with partial ethmoidectomy
16439884|NCT03704402||alcohol policy group|High schools that introduced the policy
16439885|NCT03704402||control group|High schools that did not introduce the policy
16439886|NCT03704389|Experimental|Clinical decision support intervention|Participating clinicians will receive any of three clinical decision support nudges within the electronic health record when all eligibility criteria are met within a patient's chart.
16439889|NCT03704363|Experimental|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
16439890|NCT03704363|Placebo Comparator|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
16439897|NCT03704337|Experimental|Commercially Available Food Bar|62 g. Food Bar
16439898|NCT03704337|Placebo Comparator|Placebo|25 g. Dextrose
16439899|NCT03704311|Experimental|Single|Evaluation of mitochondrial function after muscle biopsy and follow-up for surgical complications.
16439901|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
16439902|NCT03704272|No Intervention|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
16439903|NCT03704272|Experimental|Treatment|SunBrite
16439904|NCT03704246|Other|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
16439905|NCT03704233||Cryobiopsy|Transbronchial cryobiopsy is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
16439906|NCT03704220|Other|Single anti-thrombotic treatment|Single anti-thrombotic treatment
16439907|NCT03704207|Other|Nasal Nitric Oxide testing and collection of clinical data|Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
16439908|NCT03704194|Experimental|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
16439909|NCT03704194|Sham Comparator|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
16439910|NCT03704181|Experimental|colchicine|colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year
16439911|NCT03704181|Active Comparator|placebo|"placebo tablet by mouth every 12 hours, for 1 year
~pill manufactured to mimic coclchicine 0,5 mg tablet"
16439912|NCT03704168|Experimental|CRYOABLATION ARM|
16439913|NCT03704155|Experimental|Experimental group (EG)|The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
16439914|NCT03704155|Active Comparator|Control group (CG)|GC was treated with physiotherapy (stretching, balancing training, functional walking training).
16439915|NCT03704142|Experimental|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
16439916|NCT03704142|Experimental|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
16439917|NCT03704142|Experimental|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
16439918|NCT03704142|Experimental|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
16439919|NCT03704129|Experimental|"Tutor group"|"After a theoretical part through the administration of a video-tutorial, a 10-point questionnaire will be administered to evaluate the level of learning for each participant. Every single participant will pass the test if he/she correctly answer to >70% of the questions. Those passing the test, will be randomized to two groups.
~The interventional group will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself."
16439920|NCT03704129|No Intervention|"No tutor group"|This control group will directly perform the ultrasound examination of the diaphragm. The expert tutor will only show the learners how to use the various functions of the ultrasound, the linear and convex probes both in two-dimensional and in M-mode.
16439921|NCT03704116|Active Comparator|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
16439922|NCT03704116|Placebo Comparator|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
16439923|NCT03704103|Experimental|iSage for adjustment of insulin|The provider will prescribe the iSage app to the subject and choose a treatment algorithm within the app to make insulin dose adjustments.
16439924|NCT03704103|No Intervention|Conventional management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet.
16439925|NCT03704090|Active Comparator|Control|Standard non-pharmacological intervention during 5 days after surgery.
16439926|NCT03704090|Experimental|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
16439927|NCT03704077|Experimental|Cohort A: relatlimab + nivolumab + paclitaxel|
16439928|NCT03704077|Experimental|Cohort A: nivolumab + paclitaxel|
16439929|NCT03704077|Active Comparator|Cohort A: ramucirumab + paclitaxel|Standard-of-care
16439930|NCT03704077|Experimental|Cohort B: relatlimab + nivolumab|
16439931|NCT03704077|Active Comparator|Cohort B: nivolumab|Standard-of-care
16439932|NCT03704077|Experimental|Cohort C: relatlimab + nivolumab|
16439933|NCT03704064|Experimental|Stigma + BWL Intervention|Participants in this group will receive the standard behavioral weight loss (BWL) program, which will be combined with a stigma-reduction intervention (more details provided in the Intervention section). All group meetings will be 90 minutes. Beginning at week 5, the 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the monthly and every-other-month weight loss maintenance sessions from weeks 21-72, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically with physical activity.
16439934|NCT03704064|Active Comparator|Standard BWL Intervention|Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
16439935|NCT03704051|Experimental|Breast- versus Bottle-feeding|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
16439936|NCT03704038|Active Comparator|PEEP 5|
16439937|NCT03704038|Active Comparator|PEEP 0|
16439938|NCT03704038|Experimental|PEEP 10|
16439939|NCT03704025|Active Comparator|Current guidelines rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by diary.
16439940|NCT03704025|Experimental|Mobile device guided rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by virtual augmented reality glasses or by mobile device.
16439941|NCT03704012|No Intervention|Routine Care|Control Group receives routine care.
16439942|NCT03704012|Experimental|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
16439943|NCT03703999||type 1 diabetic patients freestyle Libre|group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria
16439944|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
16439945|NCT03703986||non-END group|The patients in this group had a slight increase of < 2 points or a decrease in NIHSS within 7 days of stroke onset.
16440048|NCT03703336|Experimental|ROTAVIN Liquid Formulation|Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
16439946|NCT03703973||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.We also measure their preoperative leukocyte telomere length.
16439947|NCT03703973||control group|We enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
16439948|NCT03703960|Experimental|"Group 1 Hypnosis"|
16439949|NCT03703960|Active Comparator|"Group 2 music"|
16439950|NCT03703960|No Intervention|Control group|
16439951|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
16439952|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
16439953|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
16439954|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
16439955|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
16439956|NCT03703934||Healthy Controls|Patients without a painful condition
16439957|NCT03703908|Experimental|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
16439958|NCT03703895|Active Comparator|Active Comparator|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule. Subjects will complete up to 4 study visits where Topical AFX5931 will be applied twice daily for 28 days.
16439959|NCT03703895|Placebo Comparator|Placebo Comparator|Placebo Comparator, Topical Placebo. Subjects will complete up to 4 study visits where Topical Placebo will be applied twice daily for 28 days.
16439960|NCT03703882|Experimental|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
16439961|NCT03703882|Placebo Comparator|Placebo|Matching placebo
16439962|NCT03703869||Insulin glargine (U300)|Insulin glargine (U300) dosage and dosing time as per local product labeling
16439963|NCT03703856|Active Comparator|Memantine|
16439964|NCT03703856|Placebo Comparator|Placebo|
16439965|NCT03703843|Experimental|Active|ARTUS MONO
16439966|NCT03703830|Experimental|Experimental|Cerebellar transcranial current stimulation associated with locomotor training
16439967|NCT03703830|Sham Comparator|Sham comparator|Cerebellar transcranial current stimulation sham associated with locomotor training
16439968|NCT03703817||tofacitinib citrate users|patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
16439969|NCT03703817||adalimumab users|patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
16439970|NCT03703804||Women postpartum|Women -over 18 years, ability to understand Swedish in spoken and written terms, gave birth to a child approximately 3 months ago via vaginal delivery or cesarean section will be included. Exclusion criteria will be chronic pain in the pelvis or back (defined as pain in pelvic or back in more than 3 months before pregnancy), major rupture of the pelvic floor at delivery e.g. sphincter rupture grade III/IV or other diseases or surgery that prevents examination of the pelvic floor or abdominal muscles.
16439971|NCT03703791|Active Comparator|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
16439972|NCT03703791|No Intervention|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
16439973|NCT03703778||bilateral orchidectomy|Patients with advanced prostate cancer who receive surgical androgen deprivation therapy - bilateral orchidectomy
16439974|NCT03703778||GnRH agonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH agonist
16439975|NCT03703778||GnRH antagonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH antagonist
16439976|NCT03703765|Experimental|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.
~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
16439977|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
16439978|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
16439979|NCT03703739|Active Comparator|Reference meal 1|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
16439980|NCT03703739|Active Comparator|Reference 2|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with bean sauce.
16439981|NCT03703739|Experimental|Test meal A|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice cofortified with zinc oxide and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
16439982|NCT03703739|Experimental|Test meal B|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
16439983|NCT03703739|Experimental|Test meal C|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
16439984|NCT03703739|Experimental|Test meal D|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfafe and sodium pyrophosphate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
16439985|NCT03703739|Experimental|Test meal E|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with bean Sauce.
16439986|NCT03703726|Active Comparator|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
16439987|NCT03703726|Experimental|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
16439988|NCT03703726|Active Comparator|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
16439989|NCT03703726|Experimental|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
16439990|NCT03703726|Experimental|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
16439991|NCT03703726|Active Comparator|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
16439992|NCT03703726|Active Comparator|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
16439993|NCT03703713||Hyponatremia|Patients treated for hyponatremia (<125 mmol/L Sodium) in the intensive care department.
16439994|NCT03703700|Experimental|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
16439995|NCT03703700|Placebo Comparator|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
16439996|NCT03703687|Experimental|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
16439997|NCT03703674|Active Comparator|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
16439998|NCT03703674|Experimental|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
16439999|NCT03703661|Other|Control|primary closure with gauze and adhesive/occlusive dressing
16440000|NCT03703661|Experimental|Negative Pressure|primary closure with gauze and adhesive/occlusive dressing under negative pressure
16440001|NCT03703635|Experimental|Intracranial Angioplasty|Intracranial balloon angioplasty and aggressive medical care.
16440002|NCT03703635|No Intervention|Aggressive Medical Care|Aggressive medical care alone.
16440003|NCT03703622|Experimental|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
16440004|NCT03703622|Active Comparator|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
16441827|NCT03690830|Experimental|Case group IRPL|blood samples, analyzing endometrial cells
16440005|NCT03703609|Experimental|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
16440006|NCT03703609|No Intervention|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
16440007|NCT03703596|Experimental|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
16440008|NCT03703596|Experimental|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
16440009|NCT03703583||Exclusively/predominantly Breastfeeding group|
16440010|NCT03703583||Exclusively/predominantly Formula feeding group|
16440011|NCT03703570|Experimental|KW-6356 Low Dose|Oral administration
16440012|NCT03703570|Experimental|KW-6356 High Dose|Oral administration
16440013|NCT03703570|Placebo Comparator|placebo|Oral administration
16440014|NCT03703557|Experimental|Sorbstar®|Odour sampling: Rub hands with Sorbstar® before and post-surgery
16440015|NCT03703557|Experimental|Dog detection|Odour sampling: Sleep over a night with a compress on the affected breast before and after surgery
16440016|NCT03703544|Experimental|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
16440017|NCT03703544|Experimental|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
16440018|NCT03703531||Patients resuscitated in Istria county|Cardiopulmonary resuscitation performed for OHCA
16440019|NCT03703518|Experimental|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
16440020|NCT03703518|Active Comparator|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
16440021|NCT03703505|Experimental|AG-348|On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) [13C6]AG-348, 1 hour post-oral dose.
16440022|NCT03703492|Experimental|Research Arm|Directed breast PET/MRI with 18F-FES; 18F-FES uptake of the known malignancy to be measured on the PET/MRI examination
16440023|NCT03703479|Experimental|A-PRF group|Socket site that will receive A-PRF clot
16440024|NCT03703479|No Intervention|control|socket site that will not receive any intervention
16440025|NCT03703466|Experimental|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
16440026|NCT03703466|Experimental|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
16440027|NCT03703466|Experimental|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
16440028|NCT03703453|Experimental|REBOA|Patients undergoing REBOA for medical cardiac arrest
16440029|NCT03703440|Experimental|Active|≥3 group education sessions (60 minutes per session) in addition to usual diabetes care, every 3 months for 12 months. Each group session (3-8 patients per group) will be facilitated by a diabetes nurse educator and/or dietitian. The group session content will be guided by the needs of the group participants. The group discussion will end with participants setting goals for their next appointment.
16440030|NCT03703440|Other|Control|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual diabetes care, an individual education session and written information will be provided before formal transfer.
16440031|NCT03703427|Experimental|Capecitabine|
16440032|NCT03703427|Experimental|Vinorelbine|
16440033|NCT03703414||Control|Healthy controls
16440034|NCT03703414||ECT|MDD patients receiving ECT treatment
16440035|NCT03703414||SSRI|MDD patients receiving SSRI treatment
16440036|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
16440037|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
16440038|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
16440039|NCT03703388|Experimental|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
16440040|NCT03703388|Experimental|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
16440041|NCT03703388|Experimental|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
16440042|NCT03703375|Experimental|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
16440043|NCT03703375|Active Comparator|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
16440044|NCT03703375|Active Comparator|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
16440045|NCT03703362|Experimental|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
16440046|NCT03703349|Experimental|Preoperative oral Magnesium|Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
16440047|NCT03703349|Placebo Comparator|Control|Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention
16440049|NCT03703336|Active Comparator|ROTAVIN-M1 Frozen Formulation|Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
16440050|NCT03703323|Experimental|Rotative thromboelastometry analysis|Evaluation of diagnostic properties of coagulation by rotative thromboelastometry in patient with digestive hemorrhage in predictive value of mortality.
16440051|NCT03703310|Experimental|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
16440052|NCT03703310|Placebo Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
16440053|NCT03703297|Experimental|Durvalumab + Placebo|Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
16440054|NCT03703297|Experimental|Durvalumab + Tremelimumab|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
16440055|NCT03703297|Placebo Comparator|Placebo + Placebo|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
16440056|NCT03703284||LHI Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
16440057|NCT03703284||LHI Non-Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
16440058|NCT03703284||Healthy control|Healthy individuals
16440059|NCT03703271|Active Comparator|chemotherapy|Methotrexate 0.4mg/kg·d, im ,*5d started at the first day of cycle, two weeks a cycle
16440060|NCT03703271|Experimental|study group|hysteroscopic repeat curettage
16440061|NCT03703258|Experimental|Intervention|"The THRIVE app involves 3 weeks of daily activities. Day 1 involves identification of activities to add to a self-care activity list with guidance around selecting activities that increase social contact, reduce alcohol use, and reduce avoidance. They will also complete an active-learning exercise about cognitive distortions and create a stuck point to-do list consisting of their cognitive distortions. In subsequent days, participants will be prompted to complete activities from both lists. They will also have access optional activities on topics such as asking for help, preventing isolation, deciding whether to disclose an assault, coping with negative reactions to disclosure, and thinking in helpful ways about social support. They will be prompted to complete brief daily surveys in the app, which will populate a symptom tracker. Participants in will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use."
16440062|NCT03703258|No Intervention|Assessment-only control|The assessment-only control condition will involve access to a version of the app that includes daily surveys and a symptom tracker populated by these surveys, but without any of the other exercises included in the experimental version of the app. Participants in the control condition will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.
16440063|NCT03703245||Experimental Dentifrice|Participants were advised to brush their teeth twice daily with a full strip of experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies covering the entire head of the toothbrush for 1 minute.
16440064|NCT03703245||Control Dentifrice|Participants were advised to brush their teeth with control dentifrice containing 0% w/w sodium bicarbonate covering the entire head of the toothbrush for 1 minute.
16440065|NCT03703232|Other|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
16440066|NCT03703219||Mother Touch Program|Forty days of rest period of the mother after delivery, Full body massage, diet and belly binding methods were administered by trained carer.
16440067|NCT03703219||Usual care Program|comparison cohort were followed in usual care under the supervision of health professionals.
16440068|NCT03703206|Experimental|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
16440069|NCT03703206|No Intervention|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
16440070|NCT03703193|Experimental|Dry needling|The experimental group will receive a single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
16440071|NCT03703193|Active Comparator|Physical Therapy|This group will receive a single session of modulatory interventions targeting modulation of central nervous system.
16440072|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
16440073|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
16440074|NCT03703167|Experimental|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
16440075|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
16440076|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
16440077|NCT03703141|Experimental|Sucralose 48 mg|Sucralose 48 mg in 60 ml of water O.D. for ten weeks
16440078|NCT03703141|Experimental|Sucralose 96 mg|sucralose 96 mg in 60 ml of water O.D. for ten weeks
16440079|NCT03703141|Placebo Comparator|Placebo|60 ml of water as placebo O.D. for ten weeks
16440080|NCT03703128||Informants of suicide victims|Partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who received a definitive verdict of suicide in the Dutch-speaking part of Belgium (Flanders). The suicide should have taken place more than 3 months ago and less than 5 years ago.
16440081|NCT03703128||Control group|Informants i.e., partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who have mental health problems.
16440082|NCT03703115|Active Comparator|Fasting|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day."
16440083|NCT03703115|No Intervention|Nonfasting|Patients will have usual balanced diet as 3 meals and 2 snacks all over the day. Both groups should take adequate water and non calorie beverages intake daily ( 2-3 liters daily)
16440084|NCT03703102|Placebo Comparator|Arm A|Subcutaneous administration of placebo
16440085|NCT03703102|Experimental|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
16440086|NCT03703102|Experimental|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
16440087|NCT03703102|Experimental|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
16440088|NCT03703102|Experimental|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
16440089|NCT03703089|Experimental|Gemcitabine and Nab-Paclitaxel|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
16440090|NCT03703063|Experimental|Resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
16440091|NCT03703063|Experimental|Borderline resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
16440092|NCT03703050|Experimental|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
16440093|NCT03703050|Experimental|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
16440094|NCT03703037||Cohort|"This will be a nested case-control study. Women with low risk pregnancies at or beyond 41 weeks, who will be referred to our Maternal-fetal unit and admitted 1 to 2 days prior to induction of labour according institutional protocol will constitute the cohort.
~Then women with intrapartum abnormal fetal heart rate tracings (cases) will be identified and match with controls. The primary outcome will be to obtain odds ratios for the Doppler ultrasound parameters (middle cerebral artery pulsatility index, mean uterine artery pulsatility index and Middle cerebral artery pulsatility index to mean uterine artery pulsatility index ratio) and Ultrasound assessment of amniotic fluid index that would be associated with intrapartum category III fetal heart rate tracing."
16440095|NCT03703037||Cases|"Cases will be patients with abnormal intrapartum cardiotocogram (category III fetal heart rate tracing).
~Intervention: Ultrasound and Doppler ultrasound"
16440096|NCT03703037||Controls|"Those will be patients with normal intrapartum cardiotocogram (category I fetal heart rate tracing) or category II that converted into category I after intrauterine resuscitation methods.
~Intervention: Ultrasound and Doppler ultrasound"
16440097|NCT03703024|Placebo Comparator|Placebo|Maltodextrin
16440098|NCT03703024|Active Comparator|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
16440099|NCT03703024|Active Comparator|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
16440100|NCT03703011|Experimental|Interventional|Subjects aged >70 years, hospitalized in the rehabilitation geriatric ward in the Paul Brousse hospital, France, able to walk 10 meters, ready to be discharged, and a Mini mental state examination ≥ 20/30
16440101|NCT03702998||HIV-infected individuals +/- HBV/ HCV|"1 All HIV-infected individuals followed up in all public HIV clinics with and without HBV and/or HCV co-infection will be included in the analysis.
~1.1 Inclusion criteria for HIV-infected individuals with and without HBV or HCV co-infection: 1.1.1 Positive HIV antibody 1.1.2 At least one visit in one of the HIV clinics 1.1.3 Subjects with positive HBsAg and/or anti-HBc will be regarded as having HBV co-infection 1.1.4 Subjects with positive HCV antibody will be regarded as having HCV co-infection"
16440102|NCT03702998||HBV/HCV mono-infected individuals|"2 All HBV and/or HCV-infected individuals followed up in public hospitals will be identified from the Hospital Authority electronic database.
~2.1 Inclusion criteria for HBV/HCV mono-infected individuals 2.1.1 Documented diagnosis of hepatitis B or hepatitis C infection, or 2.1.2 Positive HBsAg and/or anti-HBc, or 2.1.3 Positive HCV antibody, and 2.1.4 Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription"
16440136|NCT03702777|Placebo Comparator|Placebo|Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.
16440137|NCT03702764||VP-SG 01|Study subjects that present concentric coronary plaques
16440138|NCT03702764||VP-SG 02|Study subjects that present eccentric coronary plaques
16440103|NCT03702985|Active Comparator|Capecitabine and Irinotecan without Amifostine|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
16440104|NCT03702985|Experimental|Capecitabine and Irinotecan with Amifostine|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) Amifostine: 400mg/m2 per week
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
16440105|NCT03702959||Betamethasone group 1|Betamethasone Group 1 (5am-11am)
16440106|NCT03702959||Betamethasone Group 2|Betamethasone Group 2 (11am-5pm)
16440107|NCT03702959||Betamethasone Group 3|Betamethasone Group 3 (5pm-11pm)
16440108|NCT03702959||Betamethasone Group 4|Betamethasone Group 4 (11pm-5am).
16440109|NCT03702946|Experimental|study group|
16440110|NCT03702946|No Intervention|control group|
16440111|NCT03702933||Placebo|starch
16440112|NCT03702933||High Dose|3.5 g/d D-serine adjuvant treatment
16440113|NCT03702933||Low Dose|2.1 g/d D-serine adjuvant treatment
16440114|NCT03702920|Experimental|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
16440115|NCT03702920|Active Comparator|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
16440116|NCT03702907||Normal Cognition|No diagnosis of a cognitive disorder
16440117|NCT03702907||Cognitive Disorder|Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
16440118|NCT03702894|Experimental|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
16440119|NCT03702894|Active Comparator|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
16440120|NCT03702881|Experimental|Bonded Spurs associated with posterior build-ups Group|The experimental group will consist of 25 patients treated with bonded spurs associated with build-ups.
16440121|NCT03702881|Active Comparator|Conventional bonded spurs Group|Active comparator group will consist of 25 patients treated with conventional bonded spurs
16440122|NCT03702855|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
16440123|NCT03702855|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
16440124|NCT03702842|Experimental|Immediate effects|All participants will complete 2 sessions of walking with tsDCS separated by at least 72 hours. The only difference between sessions will be the dosage of stimulation (higher or lower dosage tsDCS using the Soterix Medical tsDCS stimulator). During each session, participants will be asked to walk for up to 30 minutes on a treadmill while the stimulation is delivered. Assessments will be completed before and after the bout of treadmill walking.
16440125|NCT03702842|Experimental|Interventional effects: Higher dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the higher dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the higher dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
16440126|NCT03702842|Active Comparator|Interventional effects: Lower dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the lower dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the lower dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
16440127|NCT03702829|Experimental|Experimental Drug|Inotersen, a transthyretin (TTR) antisense oligonucleotide. Administered subcutaneously weekly. Each dose shall contain 300 mg of active drug. Subsequent visits will occur at 3, 6, 12, 18 and 24 months. Every 2 weeks, blood will be monitored for renal function and platelet count and urine will be tested by dipstick for proteinuria.
16440128|NCT03702816|Experimental|Alzheimer's Disease|"Alzheimer's Disease (N=20)
~GE180 PET Scan"
16440129|NCT03702816|Experimental|Parkinson's Disease|"Parkinson's Disease (N=20; 10 with PD-MCI, 10 PD with no cognitive impairment)
~GE180 PET Scan"
16440130|NCT03702816|Experimental|Control|"Control Group (N=10)
~GE180 PET Scan"
16440131|NCT03702816|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment (N=20; 10 florbetapir positive, 10 florbetapir negative)
~GE180 PET Scan"
16440132|NCT03702803|Experimental|Galphimia glauca standardized extract|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the experimental group and will be assigned the treatment consisting of hard gelatin capsules with a pharmaceutical formulation prepared with a standardized extract from G. glauca, which will be administered once a day.
16440133|NCT03702803|Active Comparator|alprazolam 1mg|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the control group and will be assigned the treatment consisting of hard gelatin capsules with the drug Alprazolam (1 mg ), which will be administered once a day.
16440134|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
16440135|NCT03702777|Experimental|ASP8302 100mg|Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.
16440139|NCT03702751|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
16440140|NCT03702751|Active Comparator|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
16440141|NCT03702738|Experimental|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
16440142|NCT03702738|No Intervention|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
16440143|NCT03702725|Experimental|Dose Escalation|"Dose escalation will consist of three different drug levels of Ibrutinib, Lenalidomide, and Dexamethasone.
~Dose Escalation (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
16440144|NCT03702725|Experimental|Dose Expansion|"Dosage of the combination will depend on the determine of maximum tolerated dose learned from the Dose Escalation phase.
~Dose Expansion (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
16440145|NCT03702712|Active Comparator|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
16440146|NCT03702712|Active Comparator|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
16440147|NCT03702712|Experimental|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
16440148|NCT03702699||KOA group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
16440149|NCT03702699||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
16440150|NCT03702686|Experimental|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
16440151|NCT03702673|Experimental|Treatment A|K-877 CR Tablet A
16440152|NCT03702673|Experimental|Treatment B|K-877 CR Tablet B
16440153|NCT03702673|Experimental|Treatment C|K-877 CR Tablet E
16440154|NCT03702673|Experimental|Treatment D|K-877 IR Tablet
16440155|NCT03702660|Experimental|GIP(3-30)NH2|GIP receptor antagonist
16440156|NCT03702660|Placebo Comparator|Placebo|Placebo (saline infusions)
16440157|NCT03702660|Active Comparator|GLP-1|
16440158|NCT03702660|Experimental|GLP-1 + GIP(3-30)NH2|
16440159|NCT03702647|Experimental|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
16440160|NCT03702647|Placebo Comparator|Normal Saline|30mL of normal saline placed in the POEM tunnel
16440161|NCT03702634|No Intervention|Control (Usual Care)|Surrogate will receive usual care in the hospital, which could include visits from the unit chaplain or other staff from the spiritual care department.
16440162|NCT03702634|Experimental|Intervention|Spiritual Care Assessment and Intervention (SCAI) framework
16440163|NCT03702621|Active Comparator|Liposomal Bupivacaine|"LB (Liposomal Bupivacaine) group - This group will be receiving 20ml EXPAREL (266mg) and 40ml of 0.125% bupivacaine in total, 30ml on each side.
~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
16440164|NCT03702621|Active Comparator|Standard Bupivacaine|"SB (Standard Bupivacaine) group - This group will be receiving 60ml of 0.25% bupivacaine in total, 30ml on each side.
~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
16440165|NCT03702608|Other|EluNIR 38mm|
16440166|NCT03702595|Experimental|Interventional group|Hip flexors stretching protocol
16440167|NCT03702582|Experimental|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)
~Dosage form: Per Os (Oral)
~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.
~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
16440168|NCT03702582|Active Comparator|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors
~Dosage form: Per Os (Oral)
~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.
~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
16440169|NCT03702569||Patients needing a volume expansion|
16440170|NCT03702556|Active Comparator|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
16440225|NCT03702140|Active Comparator|TPTD 12-24M|
16440171|NCT03702556|Active Comparator|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
16440172|NCT03702556|Active Comparator|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
16440173|NCT03702530|Experimental|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
16440174|NCT03702530|Placebo Comparator|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
16440175|NCT03702517|Experimental|lateral stair walking exercise|The experimental group received 15 minutes of lateral stair walking exercise
16440176|NCT03702517|Active Comparator|traditional physiotherapy|strengthening exercise, balance training and gait training
16440177|NCT03702491|Experimental|Apatinib with SOX(Tegafur,Oxaliplatin)|Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
16440178|NCT03702491|Active Comparator|SOX( Tegafur,Oxaliplatin)|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
16440179|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
16440180|NCT03702465|Active Comparator|Control Arm|Pre-diabetic participants will receive general health guidelines according to the NICE guidelines, as per standard care. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
16440181|NCT03702465|Active Comparator|Intervention Arm|DNA-based dietary intervention: participants will receive DNA-based health guidelines via a genetic report. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
16440182|NCT03702465|Experimental|Exploratory Arm|DNA-based dietary intervention using an app: participants will receive DNA-based health guidelines via the DnaNudge App.
16440183|NCT03702452|Experimental|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
16440184|NCT03702452|Experimental|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
16440185|NCT03702426|Experimental|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
16440186|NCT03702426|Active Comparator|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
16440187|NCT03702413|No Intervention|Best medical treatment|
16440188|NCT03702413|Experimental|Endovascular treatment|Best medical treatment plus endovascular treatment
16440189|NCT03702400|Active Comparator|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
16440190|NCT03702400|Experimental|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
16440191|NCT03702387|No Intervention|Control Group|Patients in this group will have standard intravenous regional anesthesia (IVRA) performed before the start of their surgery.
16440192|NCT03702387|Experimental|Esmarch Reapplication Group|Patients in this group will have all the standard intravenous regional anesthesia (IVRA) procedures performed before the start of their surgery with one exception: After standard intravenous regional anesthesia (IVRA) is performed, The elastic Esmarch bandage will be reapplied again on the same arm then will be released. then the surgery will be initiated. the only difference between groups is that the Esmarch reapplied group will be applied the esmach two times. First time, at the standard standard intravenous regional anesthesia (IVRA) before the lidocaine injection and second time, after the injection is completed.
16440193|NCT03702374|Experimental|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
16440194|NCT03702374|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
16440195|NCT03702361|Experimental|Rapid infusion of Vpriv|Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease
16440196|NCT03702348|Experimental|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
16440197|NCT03702348|No Intervention|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
16440198|NCT03702335|Experimental|Dietary Counselling|Each subject will receive a comprehensive dietary counselling for the first 12-weeks of the study, which will be followed by another 12-weeks without dietary counselling.
16440199|NCT03702335|No Intervention|No Dietary Counselling|Subjects in the control group will be followed for 24-weeks without any dietary counselling.
16440200|NCT03702322|Other|Participants|All participants will undergo each treatment.
16440201|NCT03702309||LIBERATE|Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
16440202|NCT03702296|Other|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
16440203|NCT03702296|No Intervention|Control|No ear plugs or eye masks provided.
16440204|NCT03702283|Experimental|Penicillin Allergic ICU Patients|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
16440205|NCT03702270|Experimental|Penicillin Allergic Floor Patients- Experimental|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
16440206|NCT03702270|No Intervention|Penicillin Allergic Floor Patients- Control|Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
16440207|NCT03702257|Other|Bronchial fibroscopy|Bronchial fibroscopy with trans-bronchial biopsies
16440208|NCT03702244|No Intervention|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging [including PET], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
16440209|NCT03702244|Other|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
16440210|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
16440211|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
16440212|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
16440213|NCT03702218|Experimental|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.
~Liver Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6
~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30
~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30
~Kidney Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6
~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
16440214|NCT03702218|Experimental|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is >1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.
~Liver Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6
~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30
~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30
~Kidney Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6
~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
16440215|NCT03702218|Active Comparator|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
16440216|NCT03702205|Experimental|Betaine supplementation|The experimental procedure for each athlete includes a 3-week betaine supplementation either 2.5 g or 5 g daily. Betaine will be administered in the form of capsules containing either 0.5 or 1 g betaine. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 5 betaine capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
16440217|NCT03702205|Experimental|Placebo treatment|The experimental procedure for each athlete included a 3-week placebo administration. Placebo will be capsules with starch. Placebo will be ingested with at least 250 mL of water. Each athlete will ingest 5 placebo capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
16440218|NCT03702192|Experimental|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
16440219|NCT03702179|Experimental|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.
~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
16440220|NCT03702166|Other|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
16440221|NCT03702153|Experimental|Infected abdominal wall group|A cohort of 40 patients carrying an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with synthetic mesh.
16440222|NCT03702153|Active Comparator|Clean control group|A cohort of 40 patients with ventral hernias, and submitted to clean ventral hernia repair with synthetic mesh.
16440223|NCT03702140|Active Comparator|TPTD 6M|
16440224|NCT03702140|Active Comparator|TPTD 6-12M|
16440226|NCT03702127|Experimental|TMS in patients with intracranial electrodes|We will administer TMS to neurosurgical patients with intracranial electroencephalography in order to better understand the effects TMS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
16440227|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
16440228|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
16440229|NCT03702101||Orofacial pain group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
16440230|NCT03702101||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
16440231|NCT03702075|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
16440232|NCT03702075|No Intervention|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
16440233|NCT03702062|Experimental|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
16440234|NCT03702049|Experimental|RN/CHW TBI|Nurse-led Community Health Worker TBI (RN/CHW TBI) program
16440235|NCT03702023|Active Comparator|Intervention Group|Patients in the intervention group with receive the study medication 1000mg acetaminophen orally one time prior to their scheduled electrophysiology procedure.
16440236|NCT03702023|Placebo Comparator|Placebo Oral Tablet|Patients in the control group will receive a placebo orally one time prior to their scheduled electrophysiology procedure.
16440237|NCT03702010|Active Comparator|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
16440238|NCT03702010|Experimental|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
16440239|NCT03701997||EXCOR Pediatric|Pediatric (age 0 - 21) patients who are transplant eligible in need of mechanical circulatory support and are supported with the EXCOR® Pediatric
16440240|NCT03701984|Experimental|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
16440241|NCT03701984|Active Comparator|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
16440242|NCT03701984|Placebo Comparator|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
16440243|NCT03701971|Experimental|Music Therapy|"a medical examination
~Before and after music therapy, patients will have to answer questionnaires :
~Before :
~Questionnaire 5D itch scale Itchy Quality of Life Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC
~• Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :
~Before :
~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC"
16440244|NCT03701971|Active Comparator|Emollient cream|"a medical examination
~Before and after music therapy, patients will have to answer questionnaires :
~Before :
~Questionnaire 5D itch scale
~Itchy Quality of Life
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~PGIC
~Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :
~Before :
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~PGIC"
16440245|NCT03701958|Other|Exalt DScope 01|Subjects will have a clinically indicated per standard of care ERCP procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
16440246|NCT03701945|Experimental|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to every patient that accepts the intervention and presents an acute exacerbation
16440247|NCT03701932|Experimental|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
16440248|NCT03701932|Active Comparator|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
16440249|NCT03701919|Experimental|Botulinum toxin pyloroplasty|Intraoperative laparoscopic intramuscular injection of 100units (10cc) of Botulinum toxin into the pylorus
16440250|NCT03701919|Placebo Comparator|Normal saline pyloric injection|Intraoperative laparoscopic intramuscular injection of 10cc normal saline into the pylorus
16440251|NCT03701906|Active Comparator|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
16440252|NCT03701906|Active Comparator|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
16440253|NCT03701893|Experimental|Lactobacillus PS11610|Lactobacillus PS11610 for couples with genital dysbiosis and infertility. Each dose contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610.Two daily doses for her and one daily dose for him until pregnancy or end of study period (6 months).
16440254|NCT03701880|Experimental|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least <70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
16440255|NCT03701880|Active Comparator|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
16440256|NCT03701867|Experimental|Metabolic Flexibility Tests Group|
16440257|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
16440258|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
16440259|NCT03701841||PEG-rhG-CSF primary prophylaxis|Patients receiving chemotherapy who have a overall FN risk >=20% receive PEG-rhG-CSF for primary prophylaxis
16440260|NCT03701841||PEG-rhG-CSF secondary prophylaxis|Patients receiving chemotherapy who had FN or dose-limited neutropenia receive PEG-rhG-CSF for secondary prophylaxis
16440261|NCT03701828|Experimental|Weight loss|Participants will undergo weight loss surgery
16440262|NCT03701815|Experimental|Post-stroke|Patients will receive a 12-week lifestyle medicine program.
16440263|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
16440264|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
16440265|NCT03701789|Other|Patients with Rheumatoid Arthritis|In-label treatment with Baricitinib
16440266|NCT03701776|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
16440267|NCT03701776|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
16440271|NCT03701750|Experimental|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
16440272|NCT03701750|No Intervention|Control Arm|routine luteal phase support
16440273|NCT03701724|Experimental|Systematic maintenance rTMS (arm A)|Active rTMS treatment followed, for responders, by systematic maintenance rTMS Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
16440274|NCT03701724|Experimental|rTMS course in case of relapse (arm B)|Active rTMS treatment followed, for responders, by additional rTMS courses, in case of relapse Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
16440275|NCT03701724|Sham Comparator|Sham rTMS (arm C)|sham rTMS followed, for responders, by either systematic sham mTMS (50%) or additional sham rTMS course in case of relapse(50%) Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
16440276|NCT03701711|Experimental|Lenalidomide escalation and expansion|Among the participants who will be receiving lenalidomide, the first 12 participants will be in the dose escalation phase; with the subsequent 8 participants anticipated to receive dose expansion.
16440277|NCT03701698|Experimental|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.
~Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
~Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days."
16440278|NCT03701685|Other|nerve grafting|The stumps of digital nerve are connected with nerve graft
16440279|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
16440280|NCT03701659|Experimental|TUPKRP+MAB Group|These patient will be treated by TUPKRP and MAB.
16440281|NCT03701659|Active Comparator|MAB Group|These patient will be treated by MAB only.
16440282|NCT03701646||arterial line|Pediatric patients admitted tot he ICU with a medically indicated arterial line.
16440283|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
16440405|NCT03700827|No Intervention|Control Group|The control group must attend sessions but will not exercise.
16440284|NCT03701633||Prior to breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
16440285|NCT03701633||After breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
16440286|NCT03701607||PD-L1|
16440287|NCT03701594|Experimental|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
16440288|NCT03701594|Active Comparator|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
16440289|NCT03701594|Active Comparator|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
16440290|NCT03701581|Experimental|Group A: Investigational Treatment|"4-Aminopyridine (FDA-approved drug)
~Subjects will not take more than 2 tablets in a 24-hour period
~Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.
~The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.
~Study drug can be taken with or without food.
~If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.
~Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine)."
16440291|NCT03701581|Placebo Comparator|Group B: Placebo|"Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by The University of Iowa Pharmaceuticals, 115 South Grand Avenue G-20, Iowa City, IA 52242. The Investigational Drug Service at the University of Rochester will manage the placebos.
~Placebo composition will include:
~97% Microcrystalline Cellulose, NF (Avicel Ph 102) 2% Sodium Starch Glycolate, NF
~1% Magnesium Stearate, NF
~The placebo will be covered in White Opadry, formulation OY-S-9603 and tooled to look similar to the investigational treatment."
16440292|NCT03701555|Experimental|Part 1, Cohort 1A-1 to 1D-1 Healthy Participants|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
16440293|NCT03701555|Experimental|Part 1, Cohort 1E-1 Healthy Participants|A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
16440294|NCT03701555|Experimental|Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
16440295|NCT03701555|Experimental|Part 1, Cohort 1E-2 CeD|A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
16440296|NCT03701555|Experimental|Part 2, Cohort 2A - Cohort 2C Healthy Participants|Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
16440297|NCT03701555|Experimental|Part 2, Cohort 2D Healthy Participants|Participants will receive PvP001 placebo or MFD of PvP001.
16440298|NCT03701555|Experimental|Part 2, Cohort 2E Healthy Participants|Participants will receive PvP002 placebo or MFD of PvP002.
16440299|NCT03701555|Experimental|Part 2, Cohort 2F- Cohort 2H Healthy Participants|Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
16440300|NCT03701555|Experimental|Part 2, Cohort 2I and Cohort 2J Healthy Participants|Participants will receive the PvP001 placebo and 900 mg of PvP001.
16440301|NCT03701555|Experimental|Part 3, Cohorts 3A and 3B Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
16440302|NCT03701555|Experimental|Part 3, Cohorts 3C and 3D Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
16440303|NCT03701555|Experimental|Part 3, Cohorts 3E and 3F Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
16440304|NCT03701555|Experimental|Part 3, Cohorts 3G and 3H Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
16440305|NCT03701555|Experimental|Part 4, Cohorts 4A and 4B Healthy Participants|Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
16441052|NCT03696394|Active Comparator|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
16440306|NCT03701555|Experimental|Part 3, Cohorts 3I and 3J Healthy Participants|Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
16440307|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
16440308|NCT03701529|Experimental|Sevoflurane|1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.
16440309|NCT03701529|Active Comparator|Propofol|2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.
16440310|NCT03701516|Experimental|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
16440311|NCT03701516|Experimental|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
16440312|NCT03701503|Experimental|Obese|"Women age 20-40, with BMI ≥ 25-35 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.
~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
16440313|NCT03701503|Active Comparator|Non Obese|"Women age 20-40, with BMI 18,5-23 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.
~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
16440314|NCT03701490|Experimental|Prolutex|
16440315|NCT03701490|Experimental|Progeffik|
16440316|NCT03701477|Experimental|Trans-diagnostic approach|Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
16440317|NCT03701477|Sham Comparator|Control|General relaxation/stress management therapeutic session In this arm, patients will attend a 3-hour meeting in which basic techniques of relaxation and overcoming stress and anxiety will be discussed.
16440318|NCT03701464|Experimental|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
16440319|NCT03701464|Active Comparator|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
16440320|NCT03701451|Experimental|decitabin and cisplatin induced chemotherapy followed by CC|Treated by demethylated drug decitabine injection combined with cisplatin induced chemotherapy followed by concurrent chemoradiotherapy
16440321|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
16440322|NCT03701425|Experimental|Mediterranean diet and exercise plan|"Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the distribution of macronutrients: Protein contribution 0.8-1.2 gram, Carbon Hydrates 45-50% Lipids 30% An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
16440323|NCT03701425|Experimental|Mediterranean diet|Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the following distribution of macro nutrients: Protein contribution 0.8-1.2 gram Carbon Hydrates 45-50% Lipids 30%
16440324|NCT03701425|Active Comparator|Only exercise|"An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
16440325|NCT03701425|Active Comparator|Low standard low fat diet|Random assignment, through software, to 4 groups of treatment: consume the low standard low fat diet: according to the definition, with the following distribution of macro nutrients:Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 20%
16440328|NCT03701386|Active Comparator|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
16440329|NCT03701386|Experimental|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
16440330|NCT03701373|Experimental|S-1 maintenance group|S-1 maintenance
16440331|NCT03701373|Other|Observation group|Observation without anti-tumor treatment
16440332|NCT03701360||Aspirin alone group|- Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
16440333|NCT03701360||Aspirin + Clopidogrel resinate group|"Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
~Clopidogrel resinate: 75mg once per day, initial loading dose of 300mg/d is allowed"
16440334|NCT03701347|Active Comparator|Reeve's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Reeve's simulators
16440335|NCT03701347|Active Comparator|Hefler's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Hefler's simulators
16440336|NCT03701347|Experimental|Ida's Model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Ida's simulators
16440339|NCT03701321|Experimental|Phase I (DVd, venetoclax)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16440340|NCT03701321|Experimental|Phase II Arm D (DVd, venetoclax)|Patients receive venetoclax PO QD on days 1-21, daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16440341|NCT03701321|Active Comparator|Phase II Arm E (DVd)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16440344|NCT03701295|Experimental|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
16440345|NCT03701282|Experimental|Arm A (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO daily on days 1-28 and obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-28 of cycles 3-14. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity.
16440346|NCT03701282|Active Comparator|Arm B (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO and obinutuzumab as in arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16440347|NCT03701256|Experimental|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
16440348|NCT03701256|Active Comparator|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
16440349|NCT03701243|Experimental|mNT-BBAVF|These patients will receive a modified non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) at elbow for hemodialysis acess.
16440350|NCT03701243|Active Comparator|RCAVF|These patients will receive a radiocephalic arteriovenous fistula (RCAVF) at wrist for hemodialysis acess.
16440351|NCT03701230|Experimental|low temperature rota-flush solution|A total of 55 patients are assigned to low temperature rota-flush solution group after randomization schedule.
16440352|NCT03701230|No Intervention|room temperature rota-flush solution|A total of 55 patients are assigned to room temperature rota-flush solution group after randomization schedule.
16440353|NCT03701217|Experimental|Eltrombopag treatment|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
16440354|NCT03701217|Active Comparator|Eltrombopag free|Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
16440355|NCT03701204|Experimental|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
16440356|NCT03701204|No Intervention|Control|Treatment as usual
16440357|NCT03701191|Experimental|Grpup A (Test group)|Inverted periosteal pedicle flap will be carried out
16440358|NCT03701191|Active Comparator|Group B (Control group)|Coronally advanced flap with subepithelial connective tissue graft
16440359|NCT03701178|Active Comparator|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
16440360|NCT03701178|Experimental|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
16441081|NCT03696186|Active Comparator|Neuroendocrine type-1|Standard treatment
16440361|NCT03701165|Other|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
16440362|NCT03701152|Experimental|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
16440363|NCT03701152|Experimental|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
16440364|NCT03701139|Experimental|posterior capsulotomy|Primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing during phacoemulsification.
16440365|NCT03701139|Active Comparator|Nd:YAG laser capsulotomy|Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
16440366|NCT03701126|Active Comparator|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
16440367|NCT03701126|Active Comparator|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
16440368|NCT03701113|Active Comparator|Milk-based protein matrix (MBPM)|Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
16440369|NCT03701113|Other|CONTROL|Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
16440370|NCT03701100|Active Comparator|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
16440371|NCT03701100|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
16440372|NCT03701087|No Intervention|normal serum vitamin D|normal serum vitamin D
16440373|NCT03701087|Experimental|low serum level of vitamin D|this arm will intake vitamin D 2800 IU daily
16440374|NCT03701087|Placebo Comparator|low serum vitamin D|this arm will intake placebo omega 3
16440375|NCT03701074|Experimental|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
16440376|NCT03701074|Active Comparator|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
16440377|NCT03701061|Experimental|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
16440378|NCT03701061|Active Comparator|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
16440379|NCT03701048|Active Comparator|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
16440380|NCT03701048|Active Comparator|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
16440381|NCT03701035|Experimental|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
16440382|NCT03701035|Active Comparator|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
16440383|NCT03701022|Experimental|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
16440384|NCT03701009|Other|Stone removal (Saline 50ml each time)|After CBD stone removal via lithotripsy, and the cholangiogram showed normal, residual CBD stones were detected by SpyGlass in the first round, if CBD not clean, sterile saline 50ml were intermittently irrigated into the CBD. After that, if bile duct clearance was not achieved, another 50ml saline will be irrigated into CBD again until the clear bile duct determined by SpyGlass.
16440385|NCT03700983|Experimental|Nutri-PEITC jelly|a single serving of 200 g Nutri-PEITC jelly
16440406|NCT03700814|Experimental|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
16440407|NCT03700814|No Intervention|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
16440408|NCT03700801|Experimental|Triple combination therapy group|triple combination therapy group: Triple oral hypoglycemic therapy based on metformin 0.5mg twice a day, dapagliflozin 10mg per day plus saxagliptin 5mg per day.
16440386|NCT03700970|Experimental|TAP block with liposomal bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
16440387|NCT03700970|Active Comparator|TAP block with regular bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of 0.25% bupivacaine injected on each side.
16440388|NCT03700957|Experimental|Docosahexaenoic Acid Group|participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
16440389|NCT03700957|Placebo Comparator|Control Group|participants will recieve placebo
16440390|NCT03700944|Experimental|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
16440391|NCT03700944|No Intervention|CON|The control group (CON) had normal life.
16440392|NCT03700931|Experimental|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
16440393|NCT03700931|Active Comparator|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
16440394|NCT03700918|Experimental|DaVingiTR System Single Arm|single-arm, open label, multi-center study.
16440395|NCT03700905|Experimental|Neoadjuvant/adjuvant Nivolumab and Ipilimumab|"Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
~Surgical resection of primary tumor including neck dissection according to standard of care
~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery
~Arm Ia:
~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
~Arm Ib:
~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months"
16440396|NCT03700905|Active Comparator|Surgical resection + adjuvant radio(-chemo)therapy|"Surgical resection of primary tumor including neck dissection according to standard of care
~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery
~Standard follow-up"
16440397|NCT03700892|Experimental|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
16440398|NCT03700892|Experimental|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
16440399|NCT03700892|No Intervention|Healthy Controls|Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
16440400|NCT03700866|Experimental|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.
~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
16440401|NCT03700866|Active Comparator|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
16440402|NCT03700840|Other|Clinical examination and sample|"Cross-sectional observational study
~Measure of 6 indices:
~Bleeding on Intergental Brush Index (BOIB)
~Gingivitis Score (GI)
~Plaque index score (PI)
~ICDAS
~Salivary test
~Individual caries risk assessment
~Determination of interdental brushes adapted to each interdental site
~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.
~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.
~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
16440403|NCT03700827|Experimental|Resistance Training Group|Resistance training will consist of 3 whole body circuits per week for 3 weeks lasting approximately 1 hour per session. All major muscle groups will be involved (leg press, bent-over-row, bench press, back squat, dumbbell jump squats, dead-lifts, and weighted abdominal crunches). Each participant will go through each circuit three times with 30 seconds between each exercise and 2 minutes between each set.
16440404|NCT03700827|Experimental|Aerobic Training Group|Aerobic interval training will consist of 3 sessions/week for 3 weeks for approximately 45-50 minutes per session depending on exercise energy expenditure. There will be two periods of intervals. The first period will be 3 minutes of high-intensity activity and the second period will be reduced to moderate-intensity for 2 minutes. The speed/incline will change depending on the participants perception or Borg's rating of perceived exertion. Intensity will be measured using Lactate levels after each session.
16440409|NCT03700801|Active Comparator|Premixed insulin therapy group|premixed insulin therapy group: The initial total dose is 0.3U-0.5U/Kg, twice a day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level detected by the blood glucose meter
16440410|NCT03700788|Experimental|Clorhexidine|2% Chlorhexidine
16440411|NCT03700788|Active Comparator|Calcium Hydroxide|Calcium Hydroxide
16440412|NCT03700775|Experimental|Telemonitoring intervention|
16440413|NCT03700762||pathologically results|finally proved by pathologically results
16440414|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
16440415|NCT03700749|Active Comparator|2%chlorhexidine + non-coated suture|2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
16440416|NCT03700749|Active Comparator|2%chlorhexidine + coated suture|2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
16440417|NCT03700749|Active Comparator|10% povidone-iodine + non-coated suture|10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
16440418|NCT03700749|Active Comparator|10%povidone-iodine + coated suture|10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
16440419|NCT03700736|Active Comparator|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
16440420|NCT03700736|Active Comparator|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
16440421|NCT03700723|Experimental|Resusix|The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
16440422|NCT03700723|Active Comparator|FP24 (Frozen Plasma)|The active comparator FP24 will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
16440423|NCT03700710|Active Comparator|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.
~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry."
16440424|NCT03700710|Experimental|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants.
~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.
~The web platform will be used to share participant dietary and weight data with dietitians."
16440425|NCT03700697|Experimental|Family Stress Module Intervention|Primary care clinicians will use the CHADIS Family Stress Module including the reviewing ACE, Positive Childhood Experiences, and FASS Plus questionnaires at designated child ages; address family stressors revealed using the motivational interviewing teleprompter and refer parents with stressors as indicated using the care coordination functionality.
16440426|NCT03700697|No Intervention|Controls|Control primary care providers will provide care as usual.
16440427|NCT03700684|Experimental|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
16440428|NCT03700684|Experimental|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
16440429|NCT03700684|Active Comparator|Control|Persons with Parkinsons disease do not receive voice intervention
16440430|NCT03700671|Experimental|High intensity interval training|HIIT was set at > 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
16440431|NCT03700671|Active Comparator|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
16440432|NCT03700658|Experimental|TV-46046 - 1|One of 24 sequences
16440433|NCT03700658|Experimental|TV-46046 - 2|One of 24 sequences
16440434|NCT03700658|Active Comparator|medroxyprogesterone acetate injectable suspension|One of 24 sequences
16440435|NCT03700658|Placebo Comparator|TV-46046 Placebo|One of 24 sequences
16440921|NCT03697278|No Intervention|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
16440436|NCT03700645|No Intervention|PCI and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.
16440437|NCT03700645|Active Comparator|PCI, standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.
16440438|NCT03700645|No Intervention|CABG and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.
16440439|NCT03700645|Active Comparator|CABG standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.
16440440|NCT03700632|Experimental|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
16440441|NCT03700632|No Intervention|Control|no intervention will be done
16440442|NCT03700606|Active Comparator|Nasal CPAP - Period 1|"Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater bubble system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP."
16440443|NCT03700606|Active Comparator|High Flow Nasal Cannula (HFNC) - Period 2 & 3|Respiratory support will be crossed over to a HFNC Optiflow Jr 2 (Fisher & Paykel Healthcare, Auckland, New Zealand) at a flow rate of 8 LPM. The size of the nasal cannula will be determined according to the manufacturer's instructions in order to maintain a leak at the nares. Identical data collection will occur for two 15 minute periods on HFNC, at the beginning and end of the six hour Study period.
16440444|NCT03700606|Active Comparator|Nasal CPAP - Period 4|After 6 hours of HFNC of 8 LPM, or sooner if the infant meets failure criteria, the infant will then be crossed back to the nCPAP device and at the settings previously utilized in Study Period 1. The infant will remain on the nCPAP device with identical data collection for 15 minutes. The total duration of the study and data collection will be 8 hours. The infant's body position will be similar for each lung volume measurement during the study periods.
16440445|NCT03700593||Single Port Robotic Colorectal Surgery Patients|All patients who undergo a single port robot colorectal surgery.
16440446|NCT03700580|Active Comparator|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
16440447|NCT03700580|Experimental|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
16440448|NCT03700567|Experimental|low temperature contrast|A total of 150 patients are assigned to low temperature contrast group after randomization schedule.
16440449|NCT03700567|No Intervention|room temperature contrast|A total of 150 patients are assigned to room temperature contrast group after randomization schedule.
16440450|NCT03700554|Experimental|Pleuralvent™|Patients treated with Pleuralvent™ device
16440451|NCT03700554|Active Comparator|Chest tube|Patients treated with Chest tube
16440452|NCT03700541|Active Comparator|Morphine|Morphine-based perioperative analgesia
16440453|NCT03700541|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
16440454|NCT03700528|Experimental|Intervention|This is a single-cohort ACT based intervention.
16440455|NCT03700515|Placebo Comparator|Placebo|Saline infusion
16440456|NCT03700515|Experimental|EPO|Erythropoetin infusion (9 IU/kg)
16440457|NCT03700515|Experimental|EPO II|Erythropoetin infusion (20 IU/kg)
16440458|NCT03700502||patients with painful diabetic neuropathy|
16440459|NCT03700502||diabetics with non-pain neuropathy|
16440460|NCT03700502||gender and age matched healthy controls|
16440461|NCT03700489|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
16440462|NCT03700489|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
16440463|NCT03700476|Experimental|Sintilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
16440464|NCT03700476|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
16440465|NCT03700450|Experimental|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
16440466|NCT03700437|Experimental|Fasting-Mimicking Diet (FMD)|"Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides ~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements
~Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy."
16440467|NCT03700424|Experimental|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
16440468|NCT03700424|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
16440469|NCT03700411|Active Comparator|Morphine|Morphine-based perioperative analgesia
16440470|NCT03700411|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
16440471|NCT03700411|Active Comparator|Epidural|Perioperative epidural analgesia containing an opioid
16440472|NCT03700398|Experimental|first OE|
16440473|NCT03700398|Other|First WLI|
16440474|NCT03700385|Experimental|IOWA Approach Endocardial Ablation|Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.
16440475|NCT03700372|Experimental|IOWA Approach Cardiac Ablation|Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.
16440476|NCT03700359|Experimental|Anlotinib/Lobaplatin/Etoposide|EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
16440477|NCT03700359|Active Comparator|Lobaplatin/Etoposide|EL regimen for 4 cycles
16440478|NCT03700346|Other|survivors|survivor at ICU discharge muscle microdialysis
16440479|NCT03700346|Other|Non survivors|death before ICU discharge muscle microdialysis
16440480|NCT03700333|Experimental|S-1 Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Tegafur,Gimeracil and Oteracil Potassium Capsules (S-1)
16440481|NCT03700333|Active Comparator|Pemetrexed Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Pemetrexed
16440482|NCT03700320|Active Comparator|Oral SOC Migraine Preventive Medication|Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
16440483|NCT03700320|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
16440484|NCT03700307|Experimental|pulmonary vein isolation|patients will receive circumferential pulmonary vein isolation using cryoballoon ablation
16440485|NCT03700307|Experimental|pulmonary vein and left atrial roof linear isol|patients will receive circumferential pulmonary vein and left atrial roof linear isolation using cryoballoon ablation
16440486|NCT03700294|Experimental|ADCT-601|
16440487|NCT03700281|No Intervention|Control|No intervention
16440488|NCT03700281|Experimental|Messaging|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail
16440489|NCT03700281|Experimental|Messaging plus incentive|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail, and will be eligible to receive a gift card as incentive for receiving flu vaccine
16440490|NCT03700268|Experimental|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
16440491|NCT03700268|Experimental|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
16440492|NCT03700255|Experimental|Group A|Group A will undergo the PickUpSimTM simulation training program
16440493|NCT03700255|No Intervention|Group B|Group B will only have the classic training with no simulation.
16440494|NCT03700242|Experimental|Group 1|1 IM dose of human diploid cell vaccine (HDCV) on D0 and D7 (short HDCV IM PrEP regimen), followed by 1 IM dose of HDCV on Year (Y)1 and Y1 + 3 days
16440495|NCT03700242|Active Comparator|Group 2|1 IM dose of HDCV on D0, D7, and D21 (reference), followed by 1 IM dose of HDCV on Y1 and Y1 + 3 days
16440496|NCT03700242|Experimental|Group 3|2 intradermal (ID) doses of HDCV on D0 and D7 (short HDCV ID PrEP regimen), followed by 1 ID dose of HDCV on Y1 and Y1 + 3 days
16440497|NCT03700242|Experimental|Group 4|1 IM dose of purified Vero cell rabies vaccine (PVRV) on D0 and D7 (short PVRV IM PrEP regimen), followed by 1 IM dose of PVRV on Y1 and Y1 + 3 days
16440498|NCT03700242|Experimental|Group 5|2 ID doses of PVRV on D0 and D7 (short PVRV ID PrEP regimen), followed by 1 ID dose of PVRV on Y1 and Y1 + 3 days
16440499|NCT03700229|Experimental|Bortezomib +Rituximab|Bortezomib +Rituximab
16440500|NCT03700203||Early cardiac arrest patients|Cases will be consecutive adult patients with EMS-treated OHCA and transport to the 14 emergency departments of participating hospitals. A prospective OHCA patient cohort will be developed and all survived OHCA cases will be followed at 1-month and 6-month after ED discharge by telephone. During the study period, the investigators aim to recruit a total 1,780 cases (200 cases between September 2017 and August 2018, 600 cases between September 2018 and August 2020, 80 cases between September 2020 and December 2020, and 900 cases between January 2021 and December 2023).
16440501|NCT03700203||Matched community-based controls|Matched community-based controls (2:1 matching) will be selected from two health screening centers. Controls are those who visit the participating health screening centers for their annual routine physical examinations. During the study period, the investigators aim to recruit a total 3,560 controls (400 controls between September 2017 and August 2018, 1200 controls between September 2018 and August 2020, 160 controls between September 2020 and December 2020, and 1800 controls between January 2021 and December 2023).
16440502|NCT03700190||Control|Healthy child
16440503|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
16440504|NCT03700177|Active Comparator|ropivacaine + dexamethasone|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
16440505|NCT03700177|Placebo Comparator|ropivacaine + placebo|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).
16440656|NCT03699124|Active Comparator|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
16440506|NCT03700164|Experimental|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
16440507|NCT03700164|Other|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.
~The duration will be matched to that during the cold exposure."
16440508|NCT03700151|Experimental|Children with SSD|Participants will receive a piloted treatment programme for children with severe speech sound disorders, especially childhood apraxia of speech.
16440509|NCT03700138|Experimental|Privigen|TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).
16440510|NCT03700138|Placebo Comparator|Placebo|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
16440511|NCT03700125|Experimental|ECMO resuscitation|6 patients who meet the eligibility criteria will be treated by pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable and can establish ECMO flow within 30 minutes of collapse
16440512|NCT03700112|Experimental|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method
~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
16440513|NCT03700112|Experimental|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method
~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
16440514|NCT03700112|Experimental|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method
~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
16440515|NCT03700112|Experimental|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method
~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
16440516|NCT03700112|Experimental|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method
~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
16440517|NCT03700112|Experimental|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method
~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
16440518|NCT03700112|Experimental|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method
~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
16440519|NCT03700112|Experimental|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
16440520|NCT03700099|Other|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
16440521|NCT03700086|Experimental|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
16440522|NCT03700086|Active Comparator|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
16440523|NCT03700073|Experimental|Walk training plus virtual reality|Experimental group (GTVR): The intervention consisted of treatment with the robotic CL1Walker gait training system in combination with virtual reality
16440524|NCT03700073|Active Comparator|Walk training|Control group (GT): The intervention consisted of treatment with the robotic CL1Walker gait training system
16440525|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
16440526|NCT03700034|Experimental|mHealth Integrated Antenatal Care|The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.
16440527|NCT03700034|No Intervention|Routine Antenatal Care|In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs).
16440528|NCT03700008|Other|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.
~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
16440529|NCT03700008|Other|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
16440530|NCT03699995|Experimental|Screening (imaging, biopsy)|Participants undergo imaging of suspicious moles via smartphone app MoleMapper/Sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. Participants then receive lidocaine SC and undergo shave or punch biopsy of suspected melanomas.
16440531|NCT03699982|Experimental|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
16440532|NCT03699969|Experimental|Hypofractionated dose escalated VMAT|Hypofractionated dose escalated VMAT radiotherapy
16440533|NCT03699969|No Intervention|Conventional concurrent chemoradiation|Conventional concurrent chemoradiation
16440534|NCT03699956|Experimental|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks
~Cisplatin/carboplatin plus etoposide (up to 4 cycles):
~Cisplatin or Carboplatin:
~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR
~Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks
~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
16440535|NCT03699956|Active Comparator|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):
~Cisplatin or Carboplatin:
~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR
~Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks
~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
16440536|NCT03699943|Active Comparator|CaverStem 1.0 - Low|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
16440537|NCT03699943|Active Comparator|CaverStem 1.0 - High|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
16440538|NCT03699943|Active Comparator|Caverstem 2.0 - Clinical Registry|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
16440539|NCT03699930|Active Comparator|tDCS + speech therapy|Participants will receive 20 minutes of anodal tDCS paired with speech and language therapy over five consecutive days.
16440540|NCT03699930|Sham Comparator|sham + speech therapy|Participants will receive 20 minutes of sham tDCS paired with speech and language therapy over five consecutive days.
16440541|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
16440542|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
16440543|NCT03699904|Experimental|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
16440544|NCT03699904|Placebo Comparator|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
16440545|NCT03699878||patients undergoing robotic esophagectomy|Patients 20 years or older who undergo robotic esophagectomy
16440546|NCT03699865|Experimental|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
16440547|NCT03699865|Experimental|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
16440548|NCT03699865|Experimental|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
16440549|NCT03699852|Experimental|LED group|The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
16440550|NCT03699852|Other|Control group|The participants remained and were evaluated under the same conditions. The only difference between the groups is that no LED photobiomodulation session was applied to the control group.
16440551|NCT03699839|Experimental|High dose influenza vaccine|Administration of high-dose influenza vaccine
16440552|NCT03699839|Experimental|MF59-adjuvanted influenza vaccine|Administration of MF59-adjuvanted vaccine
16440553|NCT03699839|Active Comparator|Standard influenza vaccine|Administration of standard intramuscular influenza vaccine
16440554|NCT03699826|Experimental|TMS|
16440555|NCT03699813||scoliosis bleeding management based on aPTT/PT|"Bleeding and coagulopathy during surgery managed by clinical approach and aPTT/PT tests.
~Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed."
16440556|NCT03699813||scoliosis bleeding management based on ROTEM|Bleeding and coagulopathy during surgery managed by ROTEM. Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed.
16440557|NCT03699800|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
16440558|NCT03699800|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
16440559|NCT03699787|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
16440560|NCT03699787|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
16440561|NCT03699774|Experimental|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.
~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
16440562|NCT03699761|Experimental|Pelvic Peritonization|
16440563|NCT03699761|No Intervention|Without Pelvic Peritonization|
16440564|NCT03699748|Experimental|Intervention Group Arm|"Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice).
~The intervention arm will also receive usual care as provided by Unite Here Health and their local oncologists."
16440565|NCT03699748|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by Unite Here Health and their local oncologists.
16440657|NCT03699124|Active Comparator|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
16440566|NCT03699735|Active Comparator|Hearing Aid with beam form principle_A|Device: Hearing Aid beam former principle_A (simulation of real ear condition). Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
16440567|NCT03699735|Experimental|Hearing Aid with beam form principle_B|Device: Hearing Aid beam former principle_B. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
16440568|NCT03699735|Experimental|Hearing Aid with beam form principle_C|Device: Hearing Aid beam former principle_C. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
16440569|NCT03699722|Experimental|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
16440570|NCT03699722|Active Comparator|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
16440571|NCT03699709|Experimental|Intervention Arm|
16440572|NCT03699709|No Intervention|Control Arm|
16440573|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
16440574|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
16440575|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
16440576|NCT03699683|Experimental|Physical Combined Activity Program|Before and after a 6-months supervised and individualized program that combined aerobic and resistance training were performed in post bariatric patients. Body composition, physical fitness and cardiovascular risk factors were measured before, after the physical activity program and 6 months later (13 months sinde the program started)
16440577|NCT03699657|Active Comparator|RFA with DSM mode|RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
16440578|NCT03699657|Active Comparator|RFA with SSM mode|RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
16440579|NCT03699644|Active Comparator|Healthy Control|Healthy controls will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all healthy controls will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
16440580|NCT03699644|Active Comparator|Alzheimer's Dementia|Subjects with Alzheimer's Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all subjects with Alzheimer's Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
16440581|NCT03699644|Active Comparator|Frontotemporal Dementia|Subjects with Frontotemporal Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, subjects with Frontotemporal Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
16440582|NCT03699631|Experimental|Tacrolimus/Methotrexate/Tocilizumab|"Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.
~Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.
~Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days)."
16440583|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
16440584|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
16440585|NCT03699605|Experimental|VESMP|"Participants used VESMP at least half hour session thrice a week over an average of 4 months. The instruction before every domain included using it independently on the participant's own smart phone, or with a trained person either in the clinic or on their phone brought to the participant's home.
~Total 25 patients with diagnosis of severe non-fluent aphasia included, ages 40+, at least 3 months post-onset of single unilateral CVA affecting the language dominant hemisphere at the time of baseline testing also including, Participant demographics, aphasia classification and severity. All subjects participated in an intensive 2-week VESMP treatment program prior to beginning the individualized programs."
16440586|NCT03699605|Active Comparator|Traditional Therapy|Control group received traditional therapy total 25 patients with diagnosis of severe non-fluent aphasia included, All subjects participated in an traditional therapy group in routine and received language therapy for 4 months of periods with three sessions per week.
16440587|NCT03699592|No Intervention|Control|
16440588|NCT03699592|Experimental|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
16440589|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.
~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
16440590|NCT03699553|Experimental|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
16440591|NCT03699553|Active Comparator|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
16440592|NCT03699540|Experimental|Active Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of active marijuana, under double-blind conditions
16440593|NCT03699540|Placebo Comparator|Inactive Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive marijuana, under double-blind conditions
16440594|NCT03699540|Active Comparator|Active Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of active alcohol, under double-blind conditions
16440595|NCT03699540|Placebo Comparator|Inactive Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive alcohol, under double-blind conditions
16440596|NCT03699514||Subject who completed or will complete a BNA test|
16440597|NCT03699501||Patients|
16440598|NCT03699501||Voluntary patients|
16440599|NCT03699475|Experimental|A: haplo-HSCT plus rivogenlecleucel|"αβ T-cell and CD19+ B-cell-depleted haploidentical stem cell transplantation plus rivogenlecleucel
~Rimiducid will be administered to inactivate rivogenlecleucel in the event of GVHD not responsive to standard of care treatment"
16440600|NCT03699475|Active Comparator|B: haplo-HSCT followed by cyclophosphamide|haploidentical stem cell transplantation followed by cyclophosphamide post-transplant
16440601|NCT03699462|Active Comparator|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
16440602|NCT03699462|Experimental|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
16440603|NCT03699449|Experimental|olaparib + cediranib|olaparib+cediranib combination therapy
16440604|NCT03699449|Experimental|durvalumab + olaparib|durvalumab + olaparib combination therapy
16440605|NCT03699449|Experimental|durvalumab + chemotherapy|durvalumab +chemotherapy
16440606|NCT03699449|Experimental|durvalumab + tremelimumab + chemotherapy|durvalumab + tremelimumab + chemotherapy
16440607|NCT03699449|Experimental|durvalumab + tremelimumab + paclitaxel|durvalumab + tremelimumab + paclitaxel
16440608|NCT03699449|Experimental|durvalumab +chemotherapy|durvalumab +chemotherapy
16440609|NCT03699436|Experimental|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
16440610|NCT03699436|Active Comparator|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
16440611|NCT03699423|Active Comparator|0.01% atropine eye drops|Participants will receive one drop per eye every night for two weeks
16440612|NCT03699423|Active Comparator|0.02% atropine eye drops|Participants will receive one drop per eye every night for two weeks
16440613|NCT03699423|Active Comparator|0.03% atropine eye drops|Participants will receive one drop per eye every night for two weeks
16440614|NCT03699397|Experimental|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
16440615|NCT03699384|Experimental|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
16440616|NCT03699371|Experimental|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of continuous renal replacement therapy (CRRT) 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU for the purpose of the study.
16440617|NCT03699371|No Intervention|Late Supplemental Parenteral Nutrition|Control group: would receive EN reaching up to 20 % of daily nutritional requirements and late (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day ) in SPN on 7th day of stay in ICU if it is not already met via enteral route.
16440618|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
16440619|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
16440620|NCT03699345||Edwards CENTERA THV|
16440621|NCT03699332|Experimental|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
16440658|NCT03699124|Active Comparator|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
16440659|NCT03699085|Experimental|ED-LINC Intervention Condition|Patients in this arm will receive the ED-LINC intervention. Elements of ED-LINC are based on evidence-based treatments and are central components of collaborative care. ED-LINC will be supported by a novel Emergency Department Information Exchange (EDIE) technology platform that allows for the creation of ED care plans and electronic alerts and will assist in care coordination of this complex population.
16440755|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for > 3 months (i.e. CKD stage 4).
~Blood and urine samples are collected for every 3rd hour during 24 hours"
16440622|NCT03699319|Experimental|Standard Dose Cohort: CPI-613 + mFOLFIRINOX|"Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.
~Consists of a Standard Dose Cohort and Dose escalation cohort using a standard 3 + 3 design starting at 750 mg/m^2 given at a rate of 4 ml/min (dose level (DL) 2). Participants receiving a dose of 1000mg/m^2 will be treated over 2 hours. In the absence of any DLT, the next DL will begin enrollment. If 1 DLT occurs, the DL will be expanded by 3 participants. If <33% of participants experience a DLT, the next DL will be opened and will proceed in similarly. Only 2 DLs are expected to be studied: 750 mg/m^2 and 1000 mg/m^2.
~Participants may be enrolled in this cohort after the accrual goal of the standard cohort is met but prior to the completion of treatment of all patients in the standard dose cohort
~Participants experiencing a DLT will be allowed to continue on the study at the standard DL of 500 mg or lower."
16440623|NCT03699306|Active Comparator|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
16440624|NCT03699306|Active Comparator|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
16440625|NCT03699306|Active Comparator|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
16440626|NCT03699293|Active Comparator|ASA and Celecoxib|Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
16440627|NCT03699293|Active Comparator|ASA and Naproxen|Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
16440628|NCT03699280|Experimental|Virtual Reality|VR video to be played during the procedure
16440629|NCT03699280|No Intervention|Standard Procedure|Routine protocol outpatient hysteroscopy
16440630|NCT03699267||UBR TRAM / GBA|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
16440631|NCT03699267||UBR TRAM / GBA + TAP|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
16440632|NCT03699267||M + UBR TRAM / GBA|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
16440633|NCT03699267||M + UBR TRAM / GBA + TAP|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
16440634|NCT03699254|Active Comparator|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:
~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.
~Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above> 38 copies/mL (> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
16440635|NCT03699254|Experimental|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):
~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.
~Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
16440636|NCT03699241|Placebo Comparator|Group 1|HIV-Uninfected participants
16440637|NCT03699241|Placebo Comparator|Group 2|HIV-Uninfected participants
16440638|NCT03699241|Placebo Comparator|Group 3|HIV-Uninfected participants
16440639|NCT03699241|Placebo Comparator|Group 4|HIV-Uninfected participants
16440640|NCT03699241|Placebo Comparator|Group 5|HIV-Uninfected participants
16440641|NCT03699215|Placebo Comparator|placebo|solution for intravenous infusion, with similar organoleptic characteristics than active treatment.
16440642|NCT03699215|Experimental|levosimendan|Concentrate for solution for perfusion. Pack with a 5 ml vial
16440643|NCT03699202|Experimental|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
16440644|NCT03699202|Experimental|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
16440645|NCT03699202|Experimental|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
16440646|NCT03699202|Placebo Comparator|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
16440647|NCT03699189|Experimental|Immediate ANAIS|Participants that attend the training course immediately.
16440648|NCT03699189|No Intervention|Delayed ANAIS|Participants that attend the training course a year later.
16440649|NCT03699176|Experimental|Vilaprisan|2 treatment periods of 12 weeks without a break
16440650|NCT03699176|Placebo Comparator|Placebo|2 treatment periods of 12 weeks without a break
16440651|NCT03699163||Endoscopy patients|Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure.
16440652|NCT03699163||Colorectal cancer patients|Patients who have known pre-diagnosed colorectal cancer (adenocarcinoma) attending hospital as part of their clinical care will be asked to give a breath sample prior to their cancer operation.
16440653|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
16440654|NCT03699137||Cases with confirmed ACS|Cases with confirmed diagnosis of acute coronary syndrome in the MINAP database (national registry of ACS patients). No interventions apply to this group as this is an observational study.
16440655|NCT03699137||EMS personnel|Emergency Medical Service (EMS) personnel will take part in the focus group. No intervention applies to this group in this qualitative component of the study.
16440660|NCT03699085|No Intervention|Usual Care Condition|Patients in this arm may receive a spectrum of consulting services visits including social work services, psychiatric consultation, inpatient psychiatry consult, rehabilitation psychology consultation, addiction intervention services, pain team consultation services that include MD psychiatric and PhD psychologist providers, spiritual care or other consulting services which shall count as usual care.
16440661|NCT03699059|Other|Health Care Professionals|A purposeful sample of 5 HCP's from the transplant team will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
16440662|NCT03699059|Other|Kidney Transplant Patients|A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
16440663|NCT03699046|Active Comparator|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
16440664|NCT03699046|Sham Comparator|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
16440665|NCT03699033|Experimental|Radiation|2.5 Gy/Fraction
16440666|NCT03699020|Experimental|Acceptance and Commitment Therapy (ACT)|The intervention will consists of eight weekly two hour group ACT sessions led by trained lay personnel and followed by homework. ACT is a behavioral therapy.
16440667|NCT03699020|Experimental|Education Control|Consists of eight weekly two hour group chronic pain education sessions led by trained lay personnel and followed by homework.
16440668|NCT03699007|Experimental|Graded Exposure Therapy (GET Living)|GET Living is jointly delivered by a pain psychologist and a physical therapist. The GET Living treatment was based on a published graded in-vivo exposure treatment manual for adults with adaptations to target a pediatric audience.
16440669|NCT03699007|Active Comparator|Typical Pain Management (TPM)|TPM is a treatment intervention that is representative of current standards of care in a multidisciplinary pain clinic setting. It consists of Cognitive Behavioral Therapy (CBT) and Physical Therapy (PT) sessions, delivered separately by a pain psychologist and a physical therapist.
16440670|NCT03698994|Experimental|Treatment (ulixertinib)|Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16440671|NCT03698981|Experimental|Mothers Moving towards Empowerment (MME)|The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
16440672|NCT03698981|No Intervention|Treatment As Usual (TAU)|Control condition participants will receive Treatment as usual (TAU), including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the MME intervention group.
16440673|NCT03698968|Other|Single prospective intervention|
16440674|NCT03698955|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
16440675|NCT03698955|Active Comparator|Mediterranean diet|The diet group will be asked to follow a Mediterranean diet for 16 weeks.
16440676|NCT03698929|Active Comparator|Dietary Effect of Cholesterol - Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the egg phase participants will consume two egg yolks a day for four weeks. Each week, participants will be given a week's worth of baked goods containing two egg yolks each.
16440677|NCT03698929|Placebo Comparator|Dietary Effect of Cholesterol - No-Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the no-egg phase participants will consume an egg-free product for four weeks. Each week participants will be given a week's worth of egg-free baked goods.
16440678|NCT03698903|Experimental|Take a STAND 4 Health: Immediate|Receives the coaching calls + mHealth intervention first, then receives only the mHealth intervention after the 4 week assessment.
16440679|NCT03698903|Active Comparator|Take a STAND 4 Health: Delayed|Will receive no intervention for the first 4 weeks but then after assessment will be provided the opportunity to receive the full coaching calls + mHealth intervention.
16440680|NCT03698890|No Intervention|Control|Usual care of 3 to 6-monthly clinic visit
16440681|NCT03698890|Experimental|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
16440682|NCT03698864|Experimental|PCS499 900mg twice a day|
16440683|NCT03698851|Experimental|Test Group|Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).
16440684|NCT03698851|Active Comparator|Control Group (C)|Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).
16440685|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
16440686|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
16440687|NCT03698825|Experimental|Dose Escalation of TEW-7197|TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
16440688|NCT03698812||CTL group|control group
16440689|NCT03698812||EXP group|Colonoscope
16440690|NCT03698799||LPV|Patients receive LPV strategy at the initiation of MV support. The LPV strategy is defined as ventilation with tidal volume of <8 mL/kg of PBW plus applying PEEP of at least 5 cm H2O.
16440692|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.
~Participants will be required to exercise on one occasion."
16440693|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.
~Participants will be required to exercise on one occasion."
16440694|NCT03698773|Active Comparator|Baseline Group|Access to existing educational materials about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
16440695|NCT03698773|Experimental|Website Group|Access to a tablet computer set to display an educational website (thepainlesspush.com) with information about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
16440696|NCT03698760|Experimental|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
16440697|NCT03698760|Experimental|Control Group|Participants without cognitive disorders
16440698|NCT03698747||mTBI Study Group with McDESPOT sequence|Study group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
16440699|NCT03698747||Control Group|Control group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)
16440700|NCT03698734|Active Comparator|Evening primrose oil|
16440701|NCT03698734|Placebo Comparator|placebo|
16440702|NCT03698708|Experimental|CARES Intervention|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
16440703|NCT03698695|Experimental|THN201|THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days
16440704|NCT03698695|Active Comparator|Donepezil|Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days
16440705|NCT03698695|Placebo Comparator|Placebo|Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days
16440706|NCT03698682|Experimental|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
16440707|NCT03698682|Experimental|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
16440708|NCT03698669|Experimental|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
16440709|NCT03698669|Active Comparator|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
16440710|NCT03698630|Experimental|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
16440711|NCT03698630|Active Comparator|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
16440712|NCT03698617|Experimental|HSK3486|"Dose Escalation Cohort:
~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg."
16440713|NCT03698617|Active Comparator|Propofol|Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg
16440714|NCT03698604|Active Comparator|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
16440715|NCT03698604|Active Comparator|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
16440716|NCT03698591|Experimental|Transcranial magnetic stimulation (TMS), then Sham TMS.|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes after stimulation, experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
16440717|NCT03698591|Sham Comparator|Sham TMS, then Transcranial magnetic stimulation (TMS)|Experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject. Experimenters have defined the target coordinates for the stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes post sham stimulation, experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates.
16440718|NCT03698578|Experimental|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
16441031|NCT03696511|Active Comparator|group 3: palatal insertion|Orthodontic miniscrew insertion; palatal insertion
16440719|NCT03698578|Experimental|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
16440720|NCT03698565|Experimental|PPI and ANI measurements|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.
~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
16440721|NCT03698552|Experimental|ADCT-602|Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
16440722|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.
~Spontaneous hand gestures and stutter frequency are investigated in this group."
16440723|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.
~Spontaneous hand gestures are investigated in this group"
16440724|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
16440725|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
16440726|NCT03698526|Active Comparator|Palliative care I|Palliative care
16440727|NCT03698526|Active Comparator|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
16440728|NCT03698526|Active Comparator|Control III|Patients before colonoscopy
16440729|NCT03698513|Experimental|BMS-986177 + Aspirin + Clopidogrel (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
16440730|NCT03698513|Experimental|BMS-986177 (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5)
16440731|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin + Clopidogrel (Part 1)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
16440732|NCT03698513|Experimental|BMS-986177 (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5)
16440733|NCT03698513|Placebo Comparator|BMS-986177 placebo + Clopidogrel (Part 2)|BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
16440734|NCT03698513|Experimental|BMS-986177 + Clopidogrel (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
16440735|NCT03698513|Experimental|BMS-986177 (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5)
16440736|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin (Part 3)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
16440737|NCT03698513|Experimental|BMS-986177 + Aspirin (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
16440738|NCT03698500|Other|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
16440739|NCT03698487|No Intervention|Retrospective Chart Review|"Specifically, it consists of:
~A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).
~A before/after intervention
~A multiple case study (a sub-study of the before/after intervention)"
16440740|NCT03698487|Active Comparator|Intervention|"A before/after intervention
~A multiple case study (a sub-study of the before/after intervention)"
16440741|NCT03698474|Active Comparator|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
16440742|NCT03698474|Active Comparator|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
16440743|NCT03698474|Active Comparator|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
16440744|NCT03698474|Active Comparator|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
16440745|NCT03698474|Active Comparator|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
16440746|NCT03698474|Active Comparator|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
16440747|NCT03698461|Experimental|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
16440748|NCT03698448|Placebo Comparator|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
16440749|NCT03698448|Active Comparator|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
16440750|NCT03698448|Active Comparator|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
16440751|NCT03698448|Active Comparator|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
16440752|NCT03698435||Prophylaxis|Patients who receive (val)ganciclovir for prophylaxis of cytomegalovirus
16440753|NCT03698435||Treatment|Patients who receive (val)ganciclovir for treatment of cytomegalovirus
16440754|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) > 60 mL/min for > 3 months and no known current or chronic medical or surgical conditions.
~Blood and urine samples are collected for every 3rd hour during 24 hours"
16440781|NCT03698292|Active Comparator|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
16440756|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for > 3 months for ESKD and with anuria (urine excretion < 100 mL/day).
~Blood and urine samples are collected for every 3rd hour during 24 hours"
16440757|NCT03698409|No Intervention|Botox in preservative-free saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative-free saline, as recommended by the manufacturer. 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites)
16440758|NCT03698409|Active Comparator|Botox in preserved saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative saline (i.e. bacteriostatic saline). 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites).
16440759|NCT03698396|Experimental|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
16440760|NCT03698383|Experimental|Herzuma plus Gedatolisib|
16440761|NCT03698370|Experimental|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
16440762|NCT03698370|Experimental|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
16440763|NCT03698357|Experimental|Interactive video balance-based exercise|Fifteen participants in group A will undergo 30 minutes a day and 3 days a week interactive video balance-based exercise intervention for four weeks.
16440764|NCT03698357|Active Comparator|Conventional physiotherapy|Another 15 participants allocated to the group B will receive 30 minutes a day and 3 days a week conventional rehabilitation for four weeks.
16440765|NCT03698344|Experimental|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
16440766|NCT03698331|Experimental|Valbenazine|Valbenazine or placebo oral capsules administered once daily for 7 weeks.
16440767|NCT03698331|Placebo Comparator|Placebo|Placebo oral capsules administered once daily for 7 weeks.
16440768|NCT03698318|Experimental|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440769|NCT03698318|Experimental|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440770|NCT03698318|Experimental|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440771|NCT03698318|Experimental|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440772|NCT03698318|Experimental|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440773|NCT03698318|Experimental|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440774|NCT03698318|Experimental|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440775|NCT03698318|Experimental|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440776|NCT03698318|Experimental|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440777|NCT03698318|Experimental|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
16440778|NCT03698305|Experimental|ASP5354 Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.
16440779|NCT03698305|Placebo Comparator|Placebo Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.
16440780|NCT03698292|Active Comparator|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
16440911|NCT03697304|Experimental|Cohort 1 - Module A|
16440782|NCT03698279|Experimental|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16440783|NCT03698279|Experimental|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16440784|NCT03698279|Experimental|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16440785|NCT03698279|Active Comparator|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16440786|NCT03698279|Experimental|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than [<] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16440787|NCT03698279|Active Comparator|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to <24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16440788|NCT03698266|Other|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
16440789|NCT03698253|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followedby Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).
~Regorafenib is administered at adjusted doseage of 120 mg daily for 3 weeks in a 4-week cycle."
16440790|NCT03698240|Experimental|Mindfulness-based program|Children and parents receive the program
16440791|NCT03698240|No Intervention|Waiting-list|Children and parents receive no-interventions.
16440792|NCT03698227|Experimental|Study treatment|"Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.
~Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles
~Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles
~Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle"
16440793|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1.
16440794|NCT03698201||Cohort 1 / High grade Glioma|"Cohort 1:
~Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV)
~Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
16440795|NCT03698201||Cohort 2 / Low grade Glioma|"Cohort 2:
~Histologically confirmed low grade (grade II) glioma
~Planned treatment either
~expectant monitoring or
~RT alone or
~Chemotherapy alone or
~a combination of RT/Chemotherapy"
16440796|NCT03698188|Experimental|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
16440797|NCT03698188|Active Comparator|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
16440798|NCT03698175|Experimental|Three good things exercise|
16440799|NCT03698175|Placebo Comparator|Unspecific childhood memory recall exercise|
16440802|NCT03698149|Experimental|Electrocorticography-based brain computer interface|
16440803|NCT03698136|Experimental|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
16440804|NCT03698123|Experimental|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
16440805|NCT03698110|Experimental|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
16440806|NCT03698110|No Intervention|Control Group|Participated in one introductory session and in a closing session.
16440807|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
16440912|NCT03697304|Experimental|Cohort 2 - Module A|
16440913|NCT03697304|Experimental|Cohort 3 - Module A|
16440808|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
16440809|NCT03698071|Experimental|ANCA associated vasculitis|
16440810|NCT03698058|Experimental|A2 Growing Up Milk|
16440811|NCT03698058|No Intervention|Traditional non-A2 milk|
16440812|NCT03698058|Active Comparator|Other Growing Up Milk|
16440813|NCT03698045|Experimental|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
16440814|NCT03698032|Active Comparator|Water Arm|Participants will consume water only as the intervention
16440815|NCT03698032|Active Comparator|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
16440816|NCT03698032|Active Comparator|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
16440819|NCT03698006|Experimental|Tibial nerve block|Adductor canal and tibial nerve blocks performed by the anesthetist under ultrasound guidance before spinal block.
16440820|NCT03698006|Active Comparator|Local infiltration analgesia|Adductor canal block by the anesthetist under ultrasound guidance before spinal block. Infiltration of the knee by the surgeon with local anesthetic at the end of the surgery.
16440821|NCT03697993|Experimental|Strategy 1|Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317
16440822|NCT03697993|Experimental|Strategy 2|Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317
16440823|NCT03697980||HVAD|
16440824|NCT03697967|Experimental|Supine|Infant placed supine for 120 seconds before cord clamping
16440825|NCT03697967|Experimental|Prone|Infant placed prone for 120 seconds before cord clamping
16440826|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
16440827|NCT03697941||Surgical cut-down and arterial puncture under direct vision|
16440828|NCT03697941||Percutaneous arteriotomy closed with closure device|
16440829|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.
~Subjects will be classified as trained, physical active and untrained according to their VO2max.
~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
16440830|NCT03697915|Experimental|Experimental group|Experimental group, in which a physical therapy programme supplemented by the James lift system was applied
16440831|NCT03697915|Placebo Comparator|Control|Control group, in which a conventional physical therapy programme was applied.
16440832|NCT03697889|Experimental|Treatment Sequence AB|Participants will receive Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 1 followed by Treatment B (reference product Nalgesin, 1 x 275 mg) dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
16440833|NCT03697889|Experimental|Treatment Sequence BA|Participants will receive Treatment B (reference product Nalgesin, 1 x 275 mg) at dosing period 1 followed by Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
16440834|NCT03697876|Experimental|PRO-165|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
16440835|NCT03697876|Active Comparator|1. Artelac® Nightime Gel|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
16440836|NCT03697863||Noninvasive Adjusted Ventilatory Assist|
16440837|NCT03697863||Noninvasive Pressure Support|
16440838|NCT03697850|Experimental|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
16440839|NCT03697837|Experimental|Parent Management Training|Parents will receive a web-based parenting intervention for tantrums and disruptive behavior in young children
16440840|NCT03697824|Experimental|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
16440841|NCT03697811|Experimental|DE-117 Ophthalmic Solution 0.002%|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
16440842|NCT03697798|Active Comparator|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
16440843|NCT03697798|Active Comparator|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
16440914|NCT03697304|Experimental|Cohort 1 - Module C|
16440844|NCT03697798|Active Comparator|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
16440845|NCT03697798|Active Comparator|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
16440846|NCT03697785|Experimental|Beacon Caresystem with weaning advice|Beacon care system set up to give weaning advice and options to accept or reject advice.
16440847|NCT03697785|Other|Beacon Caresystem for monitoring only|Beacon care system attached but only for data collection purposes. No advice will be given.
16440848|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
16440849|NCT03697759|Experimental|Usual care + selfBACK|Participants will use the selfBACK system and app
16440850|NCT03697746|Active Comparator|Paracetamol|1000 mg Paracetamol vial intravenously
16440851|NCT03697746|Active Comparator|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
16440852|NCT03697746|Active Comparator|Ibuprofen|400 mg Ibuprofen vial intravenously
16440853|NCT03697733|Experimental|Oral Etoricoxib group|Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure
16440854|NCT03697733|Placebo Comparator|Intravenous Fentanyl group|Subjects will receive oral placebo [folic acid] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure
16440855|NCT03697720|Experimental|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
16440856|NCT03697707|Experimental|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
16440857|NCT03697707|Experimental|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
16440858|NCT03697694|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
16440859|NCT03697694|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
16440860|NCT03697681|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
16440861|NCT03697681|Placebo Comparator|Placebo|placebo
16440862|NCT03697668|Experimental|imatinib-Dihydroartemisinin-piperaquine|triple combination
16440863|NCT03697668|Active Comparator|Dihydroartemisinin-piperaquine|standard of care
16440864|NCT03697655|Experimental|PREDATOR-BR Cohort A|n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
16440865|NCT03697655|No Intervention|PREDATOR-BR Cohort B|n=46, Control Group, Observation (no treatment)
16440866|NCT03697655|Experimental|PREDATOR-MRD Cohort A|n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
16440867|NCT03697655|No Intervention|PREDATOR-MRD Cohort B|n=59, Control Group, Observation (no treatment)
16440868|NCT03697642|Experimental|NG tube placement with nasopharyngeal tube|
16440869|NCT03697642|Active Comparator|NG tube placement without nasopharyngeal tube|
16440870|NCT03697629|Experimental|Daratumumab|Increased infusion rate daratumumab monotherapy
16440871|NCT03697616|Experimental|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
16440872|NCT03697603|Experimental|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
16440873|NCT03697603|Experimental|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
16440874|NCT03697603|Placebo Comparator|Placebo|Tablets, Oral, once daily, 14 weeks
16440875|NCT03697590|Experimental|PDT with no curettage|
16440876|NCT03697590|Active Comparator|Standard PDT|
16440877|NCT03697577||ER+/HER2- metastatic breast cancer|Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)
16440878|NCT03697564|Experimental|gemcitabine +nivolumab + cabiralizumab|
16440879|NCT03697551|Experimental|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
16440880|NCT03697538|Experimental|Adductor Canal Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
16440915|NCT03697304|Experimental|Cohort 2 - Module C|
16440916|NCT03697304|Experimental|Cohort 3 - Module C|
16440917|NCT03697304|Experimental|Cohort 4 - Module C|
16440918|NCT03697304|Experimental|Cohort 5 - Module C|
16440919|NCT03697291|Experimental|PS wire|self-invented iECG wire
16440881|NCT03697538|Active Comparator|Femoral Nerve Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
16440882|NCT03697525|Experimental|Vibration Group (VG)|VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
16440883|NCT03697525|Sham Comparator|Control Group (CG)|CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
16440884|NCT03697512|Experimental|Ibrutinib and Rituximab|"Induction PART A, from Day 1 to Day 56.
~Patients will be treated with:
~Ibrutinib 560 mg/day continuously up to Day 56;
~Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.
~Induction PART B, from Day 57 to Day 196.
~Patients will be treated with:
~Ibrutinib 560 mg/day continuously up to Day 196;
~Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.
~Maintenance PART C, from Day 197 to Day 730.
~Patients will be treated with:
~- Ibrutinib 560 mg/day continuously up to Day 730."
16440885|NCT03697499|Experimental|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
16440886|NCT03697499|Sham Comparator|fish oil and shame exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
16440887|NCT03697499|Placebo Comparator|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
16440888|NCT03697499|Other|soy oil and shame exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
16440889|NCT03697486|Experimental|High Protein|(40,6% protein)
16440890|NCT03697486|Experimental|Moderate Protein|(23.5% protein)
16440891|NCT03697486|Experimental|Low Protein|(12.4% protein)
16440892|NCT03697473|Active Comparator|Nordic Hamstring Exercise Group|Participants were required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they could no longer lower themselves as such, they were instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touched the ground they were instructed to immediately return to the starting position by pushing up with their hands.
16440893|NCT03697473|Experimental|Hip Extension Exercise Group|The participant lay on an exercise bench at a 45° angle with their hips held just over the top of the bench, their trunk erect and hips extended and their heel supported. Participants slowly flexed their hip until they reached 90° from the starting position and were then required to return to the starting position by extending through the hip while maintaining a neutral pelvic and trunk posture throughout. This exercise was then repeated on the opposite leg
16440894|NCT03697460|Experimental|INCB018424|INCB018424 Cream
16440895|NCT03697447|Experimental|Endermotherapy treated scar|Endermotherapy massage treatment
16440896|NCT03697447|No Intervention|Control scar|No intervention, standard of care
16440897|NCT03697434|Experimental|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
16440898|NCT03697421||Local Evaluation|The SHR program intends to serves couples who are over 18 years of age, are in a romantic relationship, and have at least one child (biological or adopted) under the age of 18 residing in the home or are expecting.
16440899|NCT03697408|Experimental|Itacitinib and everolimus|
16440900|NCT03697382|Experimental|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
16440901|NCT03697382|Experimental|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
16440902|NCT03697382|Experimental|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
16440903|NCT03697369||Observation group|Individuals with T1D ages 0-20 years who switched management modality from MDI to pump as part of their clinical care and were followed up prospectively in the next 12 months.
16440904|NCT03697356|Experimental|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|
16440905|NCT03697343|Other|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
16440906|NCT03697343|Other|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
16440907|NCT03697330|Active Comparator|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:
~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
16440908|NCT03697330|Active Comparator|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:
~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
16440909|NCT03697317|Experimental|Televideo Lifestyle Coaching|
16440910|NCT03697317|Active Comparator|Enhanced Usual Care|
16440922|NCT03697278|Experimental|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
16440923|NCT03697265|Experimental|Sepranolone (UC1010) low dose|Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase
16440924|NCT03697265|Experimental|Sepranolone (UC1010) high dose|Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase
16440925|NCT03697265|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) during the luteal phase
16440926|NCT03697252|Experimental|KarXT|
16440927|NCT03697252|Placebo Comparator|Placebo|
16440928|NCT03697239|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
16440929|NCT03697226|Experimental|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
16440930|NCT03697226|Experimental|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
16440931|NCT03697226|Experimental|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
16440932|NCT03697226|Experimental|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
16440933|NCT03697226|Experimental|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
16440934|NCT03697213||General Practitioners|Registered General Practitioners in one of the six participating countries.
16440935|NCT03697200|Active Comparator|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
16440936|NCT03697200|Sham Comparator|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
16440937|NCT03697200|Other|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
16440938|NCT03697187||Hereditary Angioedema|Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).
16440939|NCT03697174|Experimental|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
16440940|NCT03697174|Sham Comparator|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
16440941|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 1|Once Daily
16440942|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 2|Twice Daily
16440943|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 3|Three Times Daily
16440944|NCT03697148|Experimental|Diagnostic (mpMRI)|Patients undergo mpMRI within 3 months prior to schedule surgery.
16440945|NCT03697135||Seed Contacts|Initial participants who will invite previous injecting contacts to take a hepatitis C test using a respondent driven sampling method
16440946|NCT03697135||Initial Nominations for Testing|Contacts of initial participants who consent to be tested and enrol in the study using a respondent driven sampling method
16440947|NCT03697135||Second Level Nominations for testing|Contacts of wave one participants who consent to be tested and enrol in the study using a respondent driven sampling method
16440948|NCT03697122|Experimental|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
16440949|NCT03697109|Experimental|Relacorilant (open-label phase)|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
16440950|NCT03697109|Experimental|Relacorilant (randomized-withdrawal phase)|Patients who meet any of the response criteria will advance to the randomized-withdrawal phase of the study and receive the same highest dose as in the open-label phase.
16440951|NCT03697109|Placebo Comparator|Placebo (randomized-withdrawal phase)|Placebo matched to study drug
16440952|NCT03697096|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
16440953|NCT03697096|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
16440954|NCT03697083|Experimental|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
16440955|NCT03697083|Active Comparator|Active Control Arm|Participants will be asked to think about where they will store their prescription.
16440956|NCT03697083|Active Comparator|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
16440957|NCT03697070|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
16440958|NCT03697070|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
16440959|NCT03697057||patients|Patients scheduled for elective ambulatory gynaecological surgery, which was performed under standardised general anaesthesia
16440960|NCT03697057||healthy volunteers|Female healthy volunteers matched to the patient group regarding the age
16440962|NCT03697018|Experimental|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
16440963|NCT03697018|Active Comparator|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
16440964|NCT03697005|Experimental|BioHPP PEEK single posterior crowns|BioHPP PEEK copings veneered with composite resin
16440965|NCT03697005|Active Comparator|zirconia-based single posterior crowns|yttria stabilized tetragonal zirconia used as copings to be veneered with porcelain
16440966|NCT03696992|Experimental|NBI|Tandem colonoscopy with NBI follow by WL
16440967|NCT03696992|Active Comparator|BLI|Tandem colonoscopy with BLI follow by WLI
16440968|NCT03696992|Experimental|WLI|Tandem colonoscopy with WLI follow by WL
16440969|NCT03696979|Active Comparator|myofascial induction|Twice a week for 8 weeks. Lumbar interfacial field stroke application, Lumbar interfacial field to deep application, Lumbar region cross-hands induction technique, Hip flexor region induction.
16440970|NCT03696979|Active Comparator|Therapeutic Pain education|Pain education,twice a week for 8 weeks. The mechanism of pain,Pain processing in the center, How sensitive the central nervous system is in chronic pain, Pain becomes chronic with the contribution of factors, Problems related to fear of pain will be explained in detail.
16440971|NCT03696966|Active Comparator|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
16440972|NCT03696966|Experimental|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
16440973|NCT03696953|Experimental|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule
~1 capsule daily from 28 weeks until the time of birth."
16440974|NCT03696953|No Intervention|Placebo|Microcrystalline Cellulose
16440975|NCT03696940|Experimental|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
16440976|NCT03696940|Active Comparator|Control Group|2 tablets of: Atorvastatin 10 mg
16440977|NCT03696927|Experimental|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
16440978|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
16440979|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
16440980|NCT03696901||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in Germany
16440981|NCT03696888|Experimental|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
16440982|NCT03696888|Active Comparator|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
16440983|NCT03696875|Experimental|Multilevel Guided Discharge Planning|
16440984|NCT03696875|Active Comparator|Standard of care|
16440985|NCT03696862|Experimental|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
16440986|NCT03696849|Active Comparator|glazed emax Press|
16440987|NCT03696849|Experimental|Polished emax Press|
16440988|NCT03696836|Experimental|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
16440989|NCT03696810|Other|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
16440992|NCT03696784|Experimental|Single Arm iC9.CAR19 T cells|"The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)
~-1 1 x 10^5
~1 x 10^6
~2 x 10^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks, then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1, 3 more subjects will be enrolled. If DL 1 is not tolerable, a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.
~Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.
~AP1903 (0.4 mg/kg), a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)."
16440993|NCT03696784|Experimental|Expansion Cohort iC9-CAR19 cells|After the tolerable cell dose (TCD) has been determined in adults, up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).
16440994|NCT03696771|Experimental|NJH395|Includes non-breast HER2-positive advanced malignancies
16440995|NCT03696758|Experimental|Sildenafil followed by Metoprolol|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
16441050|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
16441051|NCT03696394|No Intervention|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
16441082|NCT03696186|Experimental|Neuroendocrine type-2|Experimental treatment
16440996|NCT03696758|Experimental|Metoprolol followed by Sildenafil|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
16440997|NCT03696745|Placebo Comparator|Placebo|preterm infants with severe hypoxic ischemic encephalopathy receive only 0.9% Sodium-chloride
16440998|NCT03696745|Experimental|infusion|preterm infants with severe hypoxic ischemic encephalopathy will receive up to 4 infusions of their own volume reduced cord blood stem cells. The number of doses will be determined by the amount of available cord blood stem cells. The dose for each infusion is 5x107 cells/kg
16440999|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
16441000|NCT03696719|Active Comparator|Undergoing surgery under general anesthesia|Patients will undergo the surgery under general anesthesia, anesthetic regime will be according to standard clinical practice.
16441001|NCT03696719|Active Comparator|Undergoing surgery under regional anesthesia|Patients will undergo the surgery under neuroaxial anesthesia.
16441002|NCT03696706|Active Comparator|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
16441003|NCT03696706|Placebo Comparator|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
16441004|NCT03696706|No Intervention|Control group|In this group, the participants will only be evaluated. No intervention will take place.
16441005|NCT03696693||children with chronic rhinosinusitis|Children aged 6-18 years presented with symptoms of chronic rhinosinusitis will be recruited from the otorhinolaryngology out-patient clinic and department at Assiut University Hospital from October, 2018 to October, 2019.
16441006|NCT03696693||children without chronic rhinosinusitis|Children have the same age and number in the study group which are presented with vocal symptoms and have not chronic rhinosinusitis will be recruited for the same duration.
16441007|NCT03696680|Experimental|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
16441008|NCT03696667|Active Comparator|Affective BCI training|15 participants in the intervention group will undergo 24 sessions of BCI-based emotion regulation training over an 8-week period. Each session will take about 30-minute to complete where participants will listen to music with audio feedback to regulate emotions toward positive affect.
16441009|NCT03696667|No Intervention|Control group|15 participants in the control group will take part in 24 music sessions (with no audio feedback) over an 8-week period. Each session will take about 30-minute to complete.
16441010|NCT03696654|No Intervention|Before treatment|
16441011|NCT03696654|Active Comparator|After treatment|
16441012|NCT03696641|Active Comparator|glazed IPS e.max|lithium disilicate glazed crowns that proved to have a good color stability
16441013|NCT03696641|Experimental|polished IPS e.max|polished lithium disilicate crowns with the polishing kit
16441014|NCT03696628|Other|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
16441015|NCT03696628|Other|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
16441016|NCT03696615|Experimental|Tabata Kettlebell Swings|"Participants in this group performed:
~A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)
~Receive instruction on the kettlebell swing
~Performed a high-intensity workout in a Tabata Kettlebell Swings format, which involves 20 seconds of all out effort followed by 10 seconds of rest, repeated for a total of 8 times."
16441017|NCT03696615|Active Comparator|Control Group|"Participants in this group performed:
~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)"
16441018|NCT03696602||test with methacholine|
16441019|NCT03696602||test with exercise|
16441020|NCT03696576|Active Comparator|PhoRTE|This group will undergo standard PhoRTE therapy.
16441021|NCT03696576|Experimental|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
16441022|NCT03696563|Active Comparator|Control group|In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
16441023|NCT03696563|Experimental|FreeO2 group|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration to reach the SpO2 target set by paramedic.
16441024|NCT03696550|Experimental|Cohort 1|"Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age.
~Age group (years) Dose (mg/kg) 12 to <18 (Cohort 1) 1.50"
16441025|NCT03696550|Experimental|Cohort 2|"Eravacycline will be administered as a single 60 minute IV infusion according to age.
~Age group (years) Dose (mg/kg) 8 to <12 (Cohort 2) 1.75"
16441026|NCT03696537|Experimental|Fludarabine + Total Marrow Irradiation|
16441027|NCT03696524|Experimental|Intervention Group|This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
16441028|NCT03696524|No Intervention|Usual Care|The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
16441029|NCT03696511|Active Comparator|group 1:maxillary insertion|Orthodontic miniscrew insertion; maxillary insertion. buccal
16441030|NCT03696511|Active Comparator|group 2: mandible insertion|Orthodontic miniscrew insertion; mandible insertion.
16441083|NCT03696186|Active Comparator|Atypical type-1|Standard treatment
16441032|NCT03696498|Experimental|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.
~Intervention: A permanent resin restoration is placed on top of the remained caries."
16441033|NCT03696498|Active Comparator|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.
~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
16441034|NCT03696485|Experimental|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
16441035|NCT03696485|Experimental|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
16441036|NCT03696472|Experimental|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
16441037|NCT03696472|Active Comparator|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
16441038|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 1|Participants will receive single oral dose of JNJ-53718678, 2000 milligram (mg) suspension or matching placebo on Day 1, under fasted conditions.
16441039|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 2|Participants will receive single oral dose of JNJ-53718678, of maximum 3000 mg suspension or matching placebo on Day 1, under fasted conditions.
16441040|NCT03696459|Experimental|Part 1 (Dose escalation): Panel 3|Participants will receive single oral dose of JNJ-53718678 4500 mg suspension (this dose may be used in Part 2, Treatment F) or matching placebo on Day 1, under fasted condition.
16441041|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 4 (Optional)|Participants will receive single oral dose of JNJ-53718678 (dose to be decided [this dose may be used in Part 2, Treatment F]) suspension or matching placebo on Day 1, under fasted condition, if 4500 mg dose in Panel 3 is considered safe and tolerable and if pharmacokinetic data require further dose escalation to reach the target exposure.
16441042|NCT03696459|Experimental|Part 2 Group 1: Treatment Sequence EHFG|Participants will receive single oral dose of JNJ-53718678, 500 mg suspension with single oral dose of moxifloxacin placebo and JNJ 53718678 placebo (Treatment E) in Period 1, then participants will receive single oral dose of moxifloxacin 400 mg with single oral dose of JNJ-53718678 placebo (Treatment H) in Period 2 then will receive single oral dose of JNJ-53718678, 4500 mg (dose will be based on review of safety, tolerability, and PK data obtained in Part 1 [either from Panel 3 or 4], this dose may be lower/higher) suspension with single oral dose of moxifloxacin placebo (Treatment F) in Period 3 followed by single oral dose of JNJ-53718678 placebo with single oral dose of moxifloxacin placebo (Treatment G) in Period 4, on Day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
16441043|NCT03696459|Experimental|Part 2 Group 2: Treatment Sequence FEGH|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment G in Period 3 followed by Treatment H in Period 4 on Day 1 of each treatment period.
16441044|NCT03696459|Experimental|Part 2 Group 3: Treatment Sequence GFHE|Participants will receive Treatment G in Period 1, then Treatment F in Period 2, then Treatment H in Period 3 followed by Treatment E in Period 4 on Day 1 of each treatment period.
16441045|NCT03696459|Experimental|Part 2 Group 4: Treatment Sequence HGEF|Participants will receive Treatment H in Period 1, then Treatment G in Period 2, then Treatment E in Period 3 followed by Treatment F in Period 4 on Day 1 of each treatment period.
16441046|NCT03696446|Experimental|Virtual Cardiac Rehabilitation Program|This group will receive access to the NWC (NexJ Connected Wellness TM (NCW) and will be provided with a fitness tracker (Garmin Vivofit 3) to monitor their exercise, sedentary behaviours, and sleep patterns. The NWC platform includes components for education (health library, workbooks etc), collaboration (personal care plan, appointment scheduler, secure messaging system etc), and motivation (motivational messages on their homepage etc). With the Health Coach, participants will engage in: reviews of their risk factor profile and health priorities; goal setting and action planning; problem solving and skill building; and discussions of relapse prevention. Participants will receive a total of seven hours of health coaching delivered across nine sessions over a 26-week period
16441047|NCT03696446|Other|Case Managed Home Program|The Case Managed Home Program (CMHP) is delivered primarily via telephone. Following their CR intake, patients are linked with their CMHP Health Coach and attends their visit (in person or over the phone) which includes a comprehensive review of their health history, current symptoms, medications, activity, and individual concerns. Following this visit, participants will receive a total of 10 individualized telephone calls over a 26 week period. The program action plan is individually formulated based on the participant's goals and learning needs. Participants are provided with educational kits (exercise, nutrition, stress management or prevention) that are based on the principle of single point learning and incorporate behavioural change techniques.
16441048|NCT03696433|Experimental|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
16441049|NCT03696433|Experimental|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
16441053|NCT03696381|Experimental|Real tRNS|Real tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
16441054|NCT03696381|Sham Comparator|Sham tRNS|Sham tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
16441055|NCT03696355|Experimental|Stratum A1|"Dose Escalation Phase:
~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
~Dose Expansion Phase
~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
16441056|NCT03696355|Experimental|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
16441057|NCT03696342|Experimental|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic
~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
16441058|NCT03696342|Active Comparator|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic
~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
16441059|NCT03696329|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
16441060|NCT03696329|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
16441061|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
16441062|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
16441063|NCT03696303||Controls with URI|Children 5 years of age or younger with upper respiratory infection (URI) (controls with URI)
16441064|NCT03696290|Active Comparator|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
16441065|NCT03696290|Placebo Comparator|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
16441066|NCT03696290|Active Comparator|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
16441067|NCT03696290|Placebo Comparator|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
16441068|NCT03696277|Experimental|Stereotactic ablative body radiation (SABR)|SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
16441069|NCT03696264|Experimental|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
16441070|NCT03696251||master's nursing program|the graduates of master's nursing program in recent three years in Taiwan
16441071|NCT03696238|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
16441072|NCT03696238|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
16441073|NCT03696225|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
16441074|NCT03696225|Active Comparator|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
16441075|NCT03696212|Experimental|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
16441076|NCT03696199|No Intervention|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
16441077|NCT03696199|Experimental|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
16441078|NCT03696199|Experimental|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
16441079|NCT03696186|Active Comparator|Luminal type-1|Standard treatment
16441080|NCT03696186|Experimental|Luminal type-2|Experimental treatment
16441087|NCT03696160|Experimental|Biktarvy|"Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.
~Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.
~Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).
~Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food."
16441088|NCT03696160|Experimental|Symtuza|"Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.
~Symtuza® received marketing authorisation valid throughout the EU in September 2017.
~Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)
~Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food."
16441089|NCT03696121|Experimental|Intervention|Desmopressin injection
16441090|NCT03696121|Placebo Comparator|Control|Normal Saline
16441091|NCT03696108|Experimental|Geapixant 45 mg BID|Participants will receive a gefapixant 45 mg film-coated tablet twice daily (BID) during the study period (52 weeks).
16441092|NCT03696108|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg film-coated tablet BID during the study period (52 weeks).
16441093|NCT03696095|Active Comparator|Continous infusion ropivacaine|Continuous infusion via peri-neural femoral nerve catheter of Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode) at rate of 6ml/h + patient controlled bolus of 3ml ...
16441094|NCT03696095|Experimental|PIB ropivacaine|Programmed intermittent bolus of Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode) : 6ml each 60min + patient controlled bolus 3ml ...
16441095|NCT03696082|Experimental|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
16441096|NCT03696082|Experimental|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
16441097|NCT03696082|Experimental|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
16441098|NCT03696082|Experimental|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
16441099|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
16441100|NCT03696056|Experimental|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
16441101|NCT03696056|Active Comparator|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
16441102|NCT03696043|Active Comparator|EVD placement|Catheter placement is most commonly performed via a freehand approach using external anatomical landmarks to help identify the location of the lateral ventricle within the brain without the aid of imaging. Proper identification of the ventricles on pre-procedure imaging, surgeon skill, and estimation of pathologic perturbations to the normal location of the ventricles all factor into the success of catheter placement. Multiple passes are often required. The accuracy rate from the freehand technique has been reported to range from 40 to 98 percent.
16441103|NCT03696043|Experimental|Axium Stealth Image Guidance|The novelty of this study is to investigate whether using image guidance technology can improve EVD catheter placement. Image guidance is used very commonly for EVD and shunt placement in the operating room with excellent accuracy and precision. We hypothesize that using this same workflow at the bedside will improve accuracy; decrease the number of passes needed for a successful placement, decrease the number of post-placement hemorrhagic events, and help improve the effectiveness of the catheter as well as patient outcomes.
16441104|NCT03696030|Experimental|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
16441105|NCT03696017||Group 1|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse opioids (40 patients per group).
16441106|NCT03696017||Group 2|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse benzodiazepines (BZD) (40 patients per group).
16441107|NCT03696017||Group 3|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse BZD/opioid (40 patients per group).
16441108|NCT03696004|Active Comparator|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
16441109|NCT03696004|Active Comparator|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
16441110|NCT03695991||Study group|Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital
16441111|NCT03695978||Nuwiq|All patients receiving Nuwiq (recombinant FVIII)
16441112|NCT03695978||Octanate|All patients receiving Octanate (plasma derived FVIII)
16441113|NCT03695978||Wilate|All patients receiving Wilate (plasma derived FVIII/von Willebrand factor [VWF])
16441114|NCT03695965||study group|patients with history of ankle trauma or chronic lateral ankle pain
16441118|NCT03695926|Experimental|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
16441119|NCT03695913|Experimental|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:
~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.
~Phase II (part 2) - low carb diet:
~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
16441120|NCT03695900|Other|Targeting SpO2 at 93-95% followed by targeting at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
16441121|NCT03695900|Other|Targeting SpO2 at 90-92% followed by targeting at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours.
16441122|NCT03695887|Experimental|Nitrous Oxide Inhalant Product|Nitrous oxide
16441123|NCT03695887|Placebo Comparator|Placebo|placebo comparator
16441124|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:
~over 18 years
~able to read French
~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology
~who received the information and did not object to participate in the study"
16441125|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:
~over 18 years
~able to read French
~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology
~who received the information and did not object to participate in the study"
16441126|NCT03695861|Experimental|Whole-body 18F-FDG PET-CT scan|
16441127|NCT03695835||Adenocarcinoma treated with MyVaccx|MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
16441128|NCT03695822|Experimental|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
16441129|NCT03695796|Other|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
16441130|NCT03695783|Experimental|Online decision aid called IBD&me|IBD&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace. It includes an educational component and an interactive exercise with a series of ratings tasks that generates a personalized preferences report for patients to share and discuss with their physician.
16441131|NCT03695783|Active Comparator|Standardized educational material|PDF file corresponding to the CCFA's online resource on biologic therapies, which is a well-researched and clearly presented overview of IBD biologic therapies, but without an active shared-decision making component.
16441132|NCT03695770|Experimental|target population|All the target population should be included in the experimental arm
16441133|NCT03695757|Experimental|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
16441134|NCT03695757|Experimental|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
16441135|NCT03695744|Experimental|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
16441136|NCT03695731|Experimental|Patients without Neuropathy|activation of cold induced brown adipose tissue
16441137|NCT03695731|Experimental|Patients with Neuropathy|activation of cold induced brown adipose tissue
16441138|NCT03695705|Other|Primary prophylaxis arm|28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
16441139|NCT03695705|Other|Secondary prophylaxis arm|26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
16441140|NCT03695692|Experimental|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
16441141|NCT03695692|Experimental|Control group|Pelvic floor exercises alone have been applied
16441142|NCT03695679|Experimental|Intervention group|Interactive computer-based intervention
16441143|NCT03695679|No Intervention|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
16441144|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
16441145|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
16441146|NCT03695653|Active Comparator|Drink Tracking (MA) Condition|Ps will receive weekly mobile assessment trick tracking described above for six months in addition to the guidelines on safe drinking.
16441147|NCT03695653|Experimental|TA Intervention|The TA intervention is tailored but will adapt over time too
16441148|NCT03695653|Experimental|Tailored Content Only (TO)|The TO treatment arm includes tailored text messages sent at 6pm daily based on the baseline assessment.
16441149|NCT03695640|Active Comparator|Group L|continuous femoral nerve block with levobupivacaine
16441150|NCT03695640|Experimental|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
16441151|NCT03695627|Experimental|Meditation Group|Participants in the meditation group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks
16441152|NCT03695627|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
16441153|NCT03695614|Experimental|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
16441154|NCT03695601||HeartCare|Diagnostic Test: Heart Care 2300 patients managed with HeartCare (AlloMap® and AlloSure-Heart® )
16441155|NCT03695601||Control|A historical control group will be matched to the estimated 1150 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
16441156|NCT03695588|Active Comparator|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
16441157|NCT03695588|Sham Comparator|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
16441158|NCT03695575|Other|Study sample|A repeated-measures model will be used. This means that participants in a single arm will be tested in all conditions. Speech recognition and listening effort outcomes will be measured in two conditions: with and without a bone-conduction headset.
16441159|NCT03695562|Experimental|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
16441160|NCT03695562|Active Comparator|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
16441161|NCT03695549|Active Comparator|intervention|CAF+ APRF
16441162|NCT03695549|Active Comparator|control|CAF+SCTG
16441163|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
16441164|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
16441165|NCT03695523|Experimental|PLAY (PhysicaL ActivitY) Policy Intervention|The childcare physical activity policy will be adopted for 8 weeks within participating toddler and preschool classrooms of facilities allocated to the experimental group.
16441166|NCT03695523|No Intervention|Control group|Childcare centres will maintain their typical daily programming and standard of care for the duration of the 8-week intervention period.
16441167|NCT03695510|Experimental|Study arm|afatinib + pembrolizumab
16441168|NCT03695497|Experimental|Direct anterior approach|total hip arthroplasty with direct anterior approach
16441169|NCT03695497|Experimental|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
16441170|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
16441171|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
16441172|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.
~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
16441173|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.
~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
16441174|NCT03695471|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity. Patients receiving complete response during courses 2-9 are held for the remaining courses. If patients relapse while treatment is being held, the patient will then complete remaining courses.
16441175|NCT03695458|Placebo Comparator|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
16441176|NCT03695458|Active Comparator|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
16441177|NCT03695458|Active Comparator|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
16441178|NCT03695445||Peripheral Norepinephrine|Patients who will undergo surgery with need for vasopressor support.
16441179|NCT03695432|Experimental|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
16441180|NCT03695432|Experimental|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
16441181|NCT03695432|Placebo Comparator|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
16441182|NCT03695432|Placebo Comparator|Placebo probiotic|capsul
16441183|NCT03695406|Experimental|Mind-Body Group Intervention|
16441184|NCT03695393|Experimental|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
16441185|NCT03695393|No Intervention|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
16441250|NCT03694964|Placebo Comparator|Placebo|Patients will receive placebo (one tablet by day) during 45 days
16441192|NCT03695354|Experimental|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
16441193|NCT03695354|Active Comparator|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
16441194|NCT03695341||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
16441195|NCT03695341||Everolimus plus Exemestane|Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day
16441196|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
16441197|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
16441198|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
16441199|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
16441200|NCT03695289|Experimental|iOTA-SMI|Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.
16441201|NCT03695289|Active Comparator|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.
16441202|NCT03695276|Experimental|PuSHCon model|A health coach will contact patients with poorly controlled asthma or COPD. The health coach will gather information from the patient and medical record and review the case with a pulmonary specialist. The specialist will provide recommendations to the primary care clinician based on the case review; the specialist may request an in-person patient visit if needed. The health coach will follow up with the primary care clinician and will support implementation of recommendations that the the primary care clinician accepts,
16441203|NCT03695276|Active Comparator|Usual care|Patients with poorly controlled asthma or COPD will receive the standard of care, which usually means management within primary care. The study team will provide in-service sessions on COPD and asthma guidelines to primary care clinicians in both arms. As in standard practice, a primary care clinician may refer a patient for specialty consultation or diagnostic testing at any time.
16441204|NCT03695263|Experimental|N-of-1 Trial|Multiple crossovers between one of the available intervention options (mindfulness meditation, gratitude journaling, physical activity, laughter therapy, or random acts of kindness) and usual activities
16441205|NCT03695250|Experimental|Treatment (BMS-986205 and nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-14 and nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16441206|NCT03695237|Experimental|Participants receiving Leuprolide Acetate (LA)|Participants with Central Precocious Puberty receiving LA
16441207|NCT03695224||Group A|Subjects with normal topological perception
16441208|NCT03695224||Group B|Subjects with abnormal topological perception
16441209|NCT03695211|Active Comparator|LM group|LM group use conventional landmark technique, which selects the midpoint of the posterior border of the sternocleidomastoid muscle as the puncture point of superficial cervical plexus block
16441210|NCT03695211|Experimental|GAN Group|This group firstly locate the superficial cervical plexus by ultrasound scanning of the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle (GAN Point). GAN Group apply the precise block technique, selects the GAN Point as the puncture point of superficial cervical plexus block
16441211|NCT03695198|Experimental|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
16441212|NCT03695198|Placebo Comparator|Placebo - SC|Placebo administered SC
16441213|NCT03695198|Experimental|LY3361237 - Intravenous (IV)|LY3361237 administered IV
16441214|NCT03695198|Placebo Comparator|Placebo - IV|Placebo administered IV
16441215|NCT03695185|Experimental|ABBV-323|Participants administered with ABBV-323 dose A IV at Week 0 and ABBV-323 dose B for 12 Weeks. Participants who achieve clinical response may enter the maintenance period in which participants are administered with ABBV-323 dose B
16441216|NCT03695172|Active Comparator|TAP block|Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
16441217|NCT03695172|Active Comparator|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
16441218|NCT03695172|Active Comparator|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
16441285|NCT03694691|Experimental|Biopsy|Biopsies taken at protocol specified time points
16441385|NCT03694028|Active Comparator|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
16441418|NCT03693755|Active Comparator|Out-of-plane Group|In this Group the femoral nerve catheter will be placed with the out-of-plane technique.
16441219|NCT03695146|Experimental|Paced breathing|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
16441220|NCT03695146|Active Comparator|Relaxing music|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
16441221|NCT03695146|No Intervention|No intervention|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
16441222|NCT03695133|Experimental|intervention group|"Group-based interventions Group-based interventions include physical activity, sightseeing, picnics, theater, cinema, group educations.
~Individual interventions Individual interventions include interventions in the Omaha System Nursing Interventions Scheme that is specific to health problems of elderly women."
16441223|NCT03695133|No Intervention|control group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks.
16441224|NCT03695120|No Intervention|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
16441225|NCT03695120|Active Comparator|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
16441226|NCT03695107||XBDP1-|
16441227|NCT03695107||XBDP2-|
16441228|NCT03695094|Experimental|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
16441229|NCT03695094|Experimental|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
16441230|NCT03695081|Experimental|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital
~Medication review post surgery
~Optimised list of drugs in the discharge summary, in accordance with hospital procedures
~Medication reconciliation, six weeks after discharge
~Medication review, six weeks after discharge"
16441231|NCT03695081|No Intervention|No intervention|Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
16441234|NCT03695055|Experimental|Arm 1|Rituximab maintenance
16441235|NCT03695055|Active Comparator|Arm 2|DPP/DCEP-G alternation regimen
16441236|NCT03695055|No Intervention|Arm 3|
16441237|NCT03695042|Experimental|BFR THEN without BFR|Will perform exercises with BFR at the first visit and without BFR at the second visit
16441238|NCT03695042|Experimental|Without BFR THEN with BFR|Will perform exercises without BFR at the first visit and with BFR at the second visit
16441239|NCT03695029|Experimental|treatment group|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
16441240|NCT03695029|No Intervention|control group|control group receive no drug, only follow-up
16441241|NCT03695016|Experimental|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
16441242|NCT03695016|Other|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
16441243|NCT03695003|Active Comparator|600 mg sage/polyphenol combination|600 mg of this sage/polyphenol combination will be consumed, via capsule, per day for 29 days.
16441244|NCT03695003|Placebo Comparator|Placebo|The same number of aesthetically similar capsules will be consumed per day for 29 days.
16441245|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
16441246|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
16441247|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
16441248|NCT03694977|Experimental|MCS110/PDR001 combination|
16441249|NCT03694964|Experimental|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
16441251|NCT03694951|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of reducing their daily sedentary behaviour to <7 hours per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for reducing their daily sedentary behaviour. Strategies may include: setting an alarm while studying to break up sedentary behaviour, to stand rather than sit on transit, and/or to achieve an active step profile (i.e., ≥10,000 steps a day) through pedometer self-monitoring.
16441252|NCT03694951|No Intervention|Control Group|The control group will not receive any behavioural intervention.
16441253|NCT03694938|Experimental|Magnetic resonance imaging|Annual MRI during 3 years
16441254|NCT03694925||Primary total knee arthroplasty|Primary TKA patients included in the study, to provide a baseline level for calprotectin.
16441255|NCT03694925||Aseptic revision total knee arthroplasty|Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
16441256|NCT03694925||Revision septic total knee arthroplasty|Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
16441257|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
16441258|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
16441259|NCT03694899|Experimental|one|acetaminophen 650 mg three times/day ibuprofen 600 mg three times/day opioid dose based on use in hospital day prior to discharge
16441260|NCT03694886|Active Comparator|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
16441261|NCT03694886|Active Comparator|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
16441262|NCT03694886|Placebo Comparator|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
16441263|NCT03694886|Placebo Comparator|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
16441264|NCT03694873|Experimental|tramadol|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
16441265|NCT03694873|Active Comparator|celecoxib|one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
16441266|NCT03694847||Asthma with CRSwNP|Asthmatic patients with a diagnosis of CRSwNP
16441267|NCT03694847||Asthma without CRSwNP|Asthmatic patients without a diagnosis of CRSwNP
16441268|NCT03694834|Experimental|Single Arm - Pembrolizumab|Single dose of Pembrolizumab 200mg IV administered prior to hysterectomy and surgical staging.
16441269|NCT03694821|Experimental|Ketorolac|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
16441270|NCT03694821|Active Comparator|Corticosteroid|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
16441271|NCT03694821|Active Comparator|Hyaluronic Acid|One knee injection of Hylan G-F 20 (Synvisc-One)
16441272|NCT03694808|Active Comparator|Fluad Vaccine|A single adjuvanted dose (AD) intramuscular injection
16441273|NCT03694808|Active Comparator|Fluzone Vaccine|A single high dose (HD) intramuscular injection
16441274|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
16441275|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
16441276|NCT03694769||All participants|Semi-structured interview and drop attack diary
16441277|NCT03694756|Other|Pre-biopsy patients|Patients identified by a radiologist at the time of diagnostic evaluation. Once consent is obtained, the TMEM-MRI will be scheduled. After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA at the time of core biopsy (preceding the core biopsy). MenaINV and MenaCalc will be calculated from the FNA material. After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be also calculated from the specimen obtained at the time of definitive surgery. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
16441278|NCT03694756|Other|Post-biopsy patients|Patients after breast biopsy. Once consent is obtained, patients will undergo TMEM-MRI. The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
16441279|NCT03694743|Experimental|2Shape rotary system|root canal preparation using 2Shape rotary system in mandibular molars with symptomatic pulpitis
16441280|NCT03694743|Active Comparator|Protaper Next rotary system|root canal preparation using Protaper Next rotary system comparing to 2Shape rotary system in mandibular molars with symptomatic pulpitis
16441281|NCT03694730|Experimental|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
16441282|NCT03694730|Active Comparator|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
16441283|NCT03694717||Patients|The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
16441284|NCT03694704|Experimental|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
16441286|NCT03694678|Experimental|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
16441287|NCT03694678|No Intervention|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
16441288|NCT03694665|Other|Morbidly anesthetized obese|Morbidly obese patients undergoing bariatric surgery (single-arm study) will receive a Lung recruitment maneuver to treat atelectasis..
16441289|NCT03694652|Experimental|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
16441290|NCT03694652|Active Comparator|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
16441291|NCT03694639|No Intervention|Pregabaline group|where patients received pregabaline 150 mg twice daily.
16441292|NCT03694639|Active Comparator|Pregabaline plus ganglion impar block group|where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.
16441293|NCT03694626|Active Comparator|Healthy Control subjects|
16441294|NCT03694626|Active Comparator|TBI Patients without photosensitivity|
16441295|NCT03694626|Active Comparator|Migraine patients without photosensitivity|
16441296|NCT03694626|Active Comparator|Migraine patients with photosensitivity|
16441297|NCT03694626|Active Comparator|TBI patients with photosensitivity|
16441298|NCT03694613|Other|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
16441299|NCT03694600||men or women between 21-84|Multi-analyte blood test screening alone and as combination with multi-analyte Test and Ultrasound in subjects diagnosed with liver cirrhosis
16441300|NCT03694587|Active Comparator|Test IMP|
16441301|NCT03694587|Active Comparator|Reference IMP|
16441302|NCT03694574|Other|Low schizotypy|Schizotypy score < 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
16441303|NCT03694574|Other|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
16441304|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
16441305|NCT03694548|Other|Part A Survey: Group 1 Adolescent Patients with SCD|Adolescent patients with SCD and chronic pain completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
16441306|NCT03694548|Other|Part A Survey: Group 2 Parents of Adolescent Patients with SCD in Part A|Parents of adolescent patients with SCD and chronic pain from Group 1 completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
16441307|NCT03694548|Experimental|Part B Yoga Program|Participants from Part A Group 1 had the opportunity to enroll in Part B to receive eight in-person instructor-led group yoga sessions.
16441308|NCT03694535|Experimental|Bladder wall thermochemotherapy|Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer
16441309|NCT03694522|Active Comparator|bemarituzumab (FPA144)+mFOLFOX6|"15mg/kg of bemarituzumab (FPA144) given intravenously and mFOLFOX6 administered after the end of the bemarituzumab (FPA144) infusion
~*Cycle 1 will consist of a one-time dose of 7.5 mg/kg of bemarituzumab (FPA144) given intravenously on Day 8
~Treatment is repeated every 2 weeks."
16441310|NCT03694522|Placebo Comparator|Placebo+mFOLFOX6|"Placebo given intravenously and mFOLFOX6 administered after the end of the placebo infusion
~* Cycle 1 will consist of a one-time dose of placebo given intravenously on Day 8
~Treatment is repeated every 2 weeks."
16441311|NCT03694509|Experimental|Breakfast tea with full fat milk|Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
16441312|NCT03694509|Active Comparator|Water|Water 250ml
16441313|NCT03694496|Experimental|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
16441314|NCT03694496|No Intervention|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
16441317|NCT03694457|Active Comparator|deltopectoral approach|the patients are treated with deltopectoral approach surgery
16441318|NCT03694457|Other|lateral approach|the patients are treated with a lateral approach surgery
16441319|NCT03694444|Active Comparator|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
16441383|NCT03694041|Placebo Comparator|Drug Interaction - metabolic probe|Experimental: metabolic probe
16441320|NCT03694444|Placebo Comparator|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
16441321|NCT03694431|Active Comparator|Standard HBPC|Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
16441322|NCT03694431|Experimental|Tech-supported HBPC|Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.
16441323|NCT03694418|Other|Cluster 1|Cluster 1 is 1 school on the Fort Peck Reservation that will be randomized into the intervention in 2019. Cluster 1 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
16441324|NCT03694418|Other|Cluster 2|Cluster 2 includes 2 schools on the Fort Peck Reservation that will be randomized in the intervention in 2019-2020. Cluster 2 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
16441325|NCT03694418|Other|Cluster 3|Cluster 3 are the remaining 2 schools on the Fort Peck reservation that will be randomized into the intervention in 2020-2021. Cluster 3 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
16441326|NCT03694405|Experimental|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
16441327|NCT03694405|Experimental|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
16441328|NCT03694405|Experimental|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
16441329|NCT03694405|Experimental|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
16441330|NCT03694405|Experimental|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
16441331|NCT03694405|Experimental|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
16441332|NCT03694405|Experimental|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
16441333|NCT03694405|Experimental|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
16441334|NCT03694405|Experimental|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
16441335|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
16441336|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
16441337|NCT03694379|Experimental|Apneic Oxygenation|Participants receiving apneic oxygenation
16441338|NCT03694379|No Intervention|No Apneic Oxygenation|Participants not receiving apneic oxygenation
16441339|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
16441340|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
16441341|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
16441342|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
16441343|NCT03694353|Experimental|Pegvaliase|
16441344|NCT03694340|Other|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 4 months before follow up.
16441345|NCT03694327|Experimental|Treatment A Mobile Application|Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
16441346|NCT03694327|Active Comparator|Treatment B Mobile Application|Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
16441347|NCT03694314|Experimental|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
16441348|NCT03694314|Placebo Comparator|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
16441349|NCT03694288|Active Comparator|Removal Group|The implant removal group will have surgery scheduled 6 months after their initial surgical fixation.
16441350|NCT03694288|No Intervention|Retention Group|The implant retention group will retain their implant for a minimum of 2 years from the time of their initial surgery.
16441384|NCT03694028|Experimental|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
16441351|NCT03694275|Experimental|Soticlestat Dup 15q|Soticlestat tablets twice daily (BID) orally or via gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, BID. Participants with Dup 15q weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
16441352|NCT03694275|Experimental|Soticlestat CDD|Soticlestat tablets BID orally or via G-tube/ PEG tube, BID. Participants with CDD weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
16441353|NCT03694262|Experimental|Treatment|Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing
16441354|NCT03694249|Experimental|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
16441355|NCT03694249|Placebo Comparator|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
16441356|NCT03694236|Experimental|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
16441357|NCT03694223|Experimental|Booklets|Health education delivery method: Booklet. Patients will be given 2 leaflets on the low FOMDAP diet produced by the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London. These booklets have been produced by dietitians and are commonly used in clinical practice across the UK.
16441358|NCT03694223|Experimental|Mobile application|Health education delivery method: Mobile application. Patients will be asked to download an application on their mobile phones or tablets. This application has been produced by dietitians from the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London.
16441359|NCT03694223|Active Comparator|One to one consultation with dietitian|Health education delivery method:One-to-one consultation with dietitian. Patients will attend a clinic visit for a one-to-one consultation with a dietitian. As per current clinical practice, the initial visit will last for 1 hour. During the visit, tailored information on the low FOMDAP diet will be given to match patients' individual needs. During the visit, either the leaflets (used in group 1) or the application (used in group 2) will be used to facilitate the visit. The choice of using the leaflets or the app during the visit will be based on the dietitian's judgment based on the patients' needs.
16441360|NCT03694210|Experimental|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
16441361|NCT03694197|Experimental|Open label|
16441362|NCT03694158|Experimental|Treatment group|Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week.
16441363|NCT03694158|Placebo Comparator|Placebo group|Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.
16441364|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
16441365|NCT03694132|Experimental|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
16441366|NCT03694132|Experimental|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
16441367|NCT03694132|Experimental|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
16441368|NCT03694119|Active Comparator|Phenelzine|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Phenelzine arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 31, then receiving Phenelzine 15mg BID plus ozanimod placebo QD from Days 32 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
16441369|NCT03694119|Placebo Comparator|Placebo|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Placebo arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
16441370|NCT03694119|Experimental|ozanimod|Following tyramine challenging in Period 1, eligible subjects randomly assigned to ozanimod arm are receiving Phenelzine placebo BID plus ozanimod 1.84mg QD from Days 11 to 38, including dose escalation days. Subjects receive second tyramine challenge from Day 39 to up to Day 49
16441371|NCT03694093||Patients with Hyperhidrosis|Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
16441372|NCT03694080|Experimental|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
16441373|NCT03694067||Androgenetic alopecia patients|Two 1 mm scalp punch skin biopsy will be taken per patient
16441374|NCT03694054|Experimental|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
16441375|NCT03694054|No Intervention|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
16441376|NCT03694054|Experimental|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
16441377|NCT03694041|Experimental|SAD: APX-115|Experimental: APX-115 SAD group
16441378|NCT03694041|Placebo Comparator|SAD: Placebo|Experimental: Placebo group
16441379|NCT03694041|Experimental|MAD: APX-115|Experimental: APX-115 MAD group
16441380|NCT03694041|Placebo Comparator|MAD: Placebo|Experimental: Placebo group
16441381|NCT03694041|Active Comparator|Food effect - Fasting condition|Experimental: APX-115 under fasting condition
16441382|NCT03694041|Active Comparator|Food effect - fed condition|Experimental: APX-115 under fed condition
16441386|NCT03694015|Active Comparator|SUPR (Arm 1)|"Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard.
~Minimum of kV image matching on unit daily."
16441387|NCT03694015|Active Comparator|VMAT rapid (Arm 2)|"Contouring: GTV based on available imaging (CT sim scan alone-no special imaging), expect to be between 1.5cm and 20cm clinically or from imaging. CTV-optional in all scenarios. If using CTV=GTV +0.5 to 0.7cm adjust to anatomy as follows:
~If only bone involved: recommend not to expand past bone; but a 0.5-0.7cm CTV expansion outside of bone into muscle or soft tissue is allowed at RO discretion
~If bone and soft tissue involved: 0.5 to 0.7cm CTV expansion is optional, allowed at RO discretion
~If spinal metastases: CTV is optional. If used can include whole vertebral body at RO discretion PTV=CTV or GTV+(1 to 1.5)cm at RO discretion. PTV_eval=PTV cropped 0.5cm below skin. OARs: max 2 OARs permitted for VMAT arm. OAR constraints are at RO discretion. If lung/kidneys are within 5cm of PTV, absence of constraints for contours should be noted in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at RO's discretion. Kidneys considered 1 organ"
16441388|NCT03694002|Experimental|Arm A (ramucirumab, carboplatin, paclitaxel)|Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
16441389|NCT03694002|Active Comparator|Arm B (carboplatin, paclitaxel)|Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16441390|NCT03693989|Experimental|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
16441391|NCT03693989|Active Comparator|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
16441392|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
16441393|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
16441394|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
16441395|NCT03693963|Other|Single Arm, treated with Serranator|Subjects treated with Serrantor
16441396|NCT03693950|Experimental|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
16441397|NCT03693950|Active Comparator|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
16441398|NCT03693911|Experimental|Prevention group|AcceptME- digital gamified Acceptance and Commitment Therapy prevention program
16441399|NCT03693911|No Intervention|Waitlist control|Waitlist control group
16441400|NCT03693898|Other|Persons with collagen VI defect|Observational
16441401|NCT03693885|Experimental|OCT-group|Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.
16441402|NCT03693885|No Intervention|Control|standard procedure before planned caesarean section
16441403|NCT03693872|Other|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
16441404|NCT03693872|Other|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
16441405|NCT03693859|Experimental|Behavioral Weight Loss + Gaming|Treatment will consist of 12-weekly, one-hour group sessions of approximately 15 participants per group. Participants will provide logs of serious gaming (intervention).
16441406|NCT03693859|Active Comparator|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
16441407|NCT03693846|Experimental|Nivolumab and Ipilimumab|Treatment will consist of nivolumab 480mg every 4 weeks and ipilimumab 1mg/kg every 8 weeks.
16441408|NCT03693833|Experimental|Intervention|10mg Cannabidiol (CBD) tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
16441409|NCT03693833|Placebo Comparator|Placebo|10mg Placebo Oral tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
16441410|NCT03693820|Active Comparator|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
16441411|NCT03693820|Placebo Comparator|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
16441412|NCT03693807|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
16441413|NCT03693781|Active Comparator|Colchicine 0.01mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
16441414|NCT03693781|Active Comparator|Colchicine 0.005 mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
16441415|NCT03693781|Placebo Comparator|Placebo + Riluzole 100 mg|Placebo pills will be administered at fast, while taking Riluzole 100 mg/day
16441416|NCT03693768|Experimental|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
16441417|NCT03693755|Active Comparator|In-plane Group|In this Group the femoral nerve catheter will be placed with the in-plane technique.
16441419|NCT03693742|Experimental|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
16441420|NCT03693742|Placebo Comparator|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
16441421|NCT03693729|Experimental|Active DLPFC during task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
16441422|NCT03693729|Active Comparator|Active DLPFC after task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min after the memory and metamemory task and during a filler task.
16441423|NCT03693729|Sham Comparator|Sham DLPFC during task|Sham HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
16441424|NCT03693716|Experimental|Dynamic Anterior Stabilization|Arthroscopic Dynamic Anterior Capsular Stabilization with Trans subscapular Long Head of the Biceps Tenodesis
16441425|NCT03693703|Experimental|bi-parametric MRI|Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)
16441426|NCT03693703|Active Comparator|multi-parametric MRI|Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)
16441427|NCT03693677|Experimental|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months
~Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
~Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)
~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :
~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).
~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
16441428|NCT03693677|Experimental|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
16441429|NCT03693677|Active Comparator|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)
~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :
~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).
~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
16441430|NCT03693651||Parent of a Premature infant / PP|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
16441431|NCT03693651||Parent of a baby born on time / PT|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
16441432|NCT03693638|Active Comparator|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
16441433|NCT03693638|Active Comparator|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
16441434|NCT03693625|Experimental|Parent Study: GDC-0853|Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
16441435|NCT03693625|Placebo Comparator|Parent Study: Placebo|Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
16441436|NCT03693612|Experimental|Part 1: feladilimab +tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
16441437|NCT03693612|Experimental|Part 2: feladilimab +tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
16441438|NCT03693612|Active Comparator|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
16441439|NCT03693599|Experimental|carbetocin|600 women received single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
16441440|NCT03693599|Active Comparator|Syntometrine|600 women received one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 micrograms of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
16441441|NCT03693573|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab in combination with bevacizumab.
16441442|NCT03693560|Experimental|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
16441443|NCT03693560|Experimental|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
16441444|NCT03693547|Experimental|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
16441445|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
16441446|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
16441447|NCT03693521|Experimental|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
16441448|NCT03693521|Active Comparator|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
16441449|NCT03693508|Experimental|Arm 1|Naive HIV patients with severe immunosuppression.
16441450|NCT03693495|Experimental|ellume·lab Group A Streptococcus Test|"ellume·lab Group A Streptococcus Test
~Pharyngeal samples from participants will be tested with:
~ellume.lab Group A Streptococcus Test; Polymerase Chain Reaction (PCR) and bacterial culture."
16441451|NCT03693469|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during immunization.
16441452|NCT03693469|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
16441453|NCT03693456|Experimental|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
16441454|NCT03693456|Experimental|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
16441455|NCT03693456|Experimental|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
16441456|NCT03693430|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
16441457|NCT03693430|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
16441458|NCT03693417|Active Comparator|Control|
16441459|NCT03693417|Experimental|Heat|
16441460|NCT03693404|Experimental|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
16441461|NCT03693404|Active Comparator|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
16441462|NCT03693391|Experimental|Cohort 1: JNJ-64140284|Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.
16441463|NCT03693391|Experimental|Cohort 2: JNJ-64140284|Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
16441464|NCT03693391|Experimental|Cohort 3: JNJ-64140284|Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
16441465|NCT03693391|Experimental|Cohort 4: JNJ-64140284|Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
16441466|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.
~Classification ASA 2-4"
16441467|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
16441468|NCT03693339|Experimental|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
16441469|NCT03693326|Experimental|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
16441470|NCT03693313|Experimental|CrossFit KAMP Group 1|14 weeks of CrossFit Kids exercise program
16441471|NCT03693313|Active Comparator|CrossFit KAMP Wait-list Group|Waitlist group that waits 14 weeks while group 1 does exercise program. After first 14 weeks will then participate in 14 weeks of CrossFit Kids exercise program
16441472|NCT03693300|Experimental|WHO/ECOG PS 0 to 1 Cohort|100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
16441473|NCT03693300|Experimental|WHO/ECOG PS 2 Cohort|up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
16441502|NCT03693131|Active Comparator|EPADEL CAPSULES 300 1.8 g|EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.
16441503|NCT03693131|Active Comparator|EPADEL CAPSULES 300 2.7 g|EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.
16441504|NCT03693118|Experimental|Grup1, Grup2|
16441505|NCT03693118|Experimental|Grup1,Grup2|
16441506|NCT03693105|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
16441474|NCT03693287|Active Comparator|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.
~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.
~Intravenous macronutrient intakes:
~PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.
~PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.
~PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.
~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.
~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
16441475|NCT03693287|Experimental|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).
~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.
~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
16441476|NCT03693274|Experimental|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
16441477|NCT03693274|No Intervention|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
16441478|NCT03693261||Coronary Artery Disease (CAD)|Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.
16441479|NCT03693261||controls|Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).
16441480|NCT03693248|Experimental|Two cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.
~Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
16441481|NCT03693248|No Intervention|Three cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.
~Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
16441482|NCT03693235|Experimental|70 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 70 degrees.
16441483|NCT03693235|Experimental|80 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 80 degrees.
16441484|NCT03693235|Experimental|90 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 90 degrees.
16441485|NCT03693222|Experimental|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
16441486|NCT03693222|Experimental|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
16441487|NCT03693209|Experimental|General trigger|"VHS with one general trigger: If I am getting angry... and 10 strategies (e.g. Then I will take deep breaths). Participants are instructed to link trigger with strategies."
16441488|NCT03693209|Experimental|Specific triggers|"VHS with a list of 10 specific situations that can act as anger triggers (e.g. If I am getting angry when people act like they know it all) and 10 strategies. Participants are instructed to link triggers with strategies."
16441489|NCT03693209|No Intervention|Control|List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
16441490|NCT03693196|Other|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
16441491|NCT03693196|Other|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
16441492|NCT03693196|Other|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
16441493|NCT03693183|Experimental|Ketorolac/HPMC|"Drug: Ketorolac/HPMC Ophthalmic Solution
~1 drop administered in each eye 4 times per day for 2 days"
16441494|NCT03693183|Active Comparator|HPMC|"Drug: 0.80% Hydroxypropyl Methylcellulose(HMPC) Ophthalmic Solution
~1 Drop administered in each eye 4 times per day for 2 days"
16441495|NCT03693183|Placebo Comparator|Vehicle|"Drug: Vehicle Ophthalmic Solution
~1 drop administered in each eye 4 times a day for 2 days"
16441496|NCT03693170|Experimental|1 Arm|encorafenib plus binimetinib plus cetuximab
16441497|NCT03693144|Experimental|Intervention Group 1 Full LIITA3H App|Participants will be given the LIITA3H app, which is a combination product consisting of 3 main features that will track their visits to fast food restaurants (using the ELI feature), send tailored text messages to prompt healthy choices when they are in a fast food restaurant (using the POP feature), and allow them to submit pictures of their food (using the SNAP feature).
16441498|NCT03693144|Active Comparator|Control Group 2 Partial LIITA3H App|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) and they will submit pictures of their food (using the SNAP feature). However, they will not receive tailored text messages.
16441499|NCT03693144|Other|Control Group 3 LIITA3H Location only|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) but they will not receive tailored messages or submit pictures of their food.
16441500|NCT03693131|Experimental|MND-2119 2 g|MND-2119 2 g, orally, once daily after breakfast for 12 weeks.
16441501|NCT03693131|Experimental|MND-2119 4 g|MND-2119 4 g, orally, once daily after breakfast for 12 weeks.
16441507|NCT03693105|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
16441508|NCT03693079|Experimental|Wet Cupping|wet cupping therapy will be applied to all participants
16441509|NCT03693066|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
16441510|NCT03693066|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
16441511|NCT03693066|Active Comparator|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
16441512|NCT03693040|Experimental|DHFS with IS-Truvada|Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
16441513|NCT03693027|Experimental|PTx800|Qualified subjects will dissolve one oral lozenge (PTx800 lozenges) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
16441514|NCT03693027|Placebo Comparator|Placebo|Qualified subjects will dissolve one oral lozenge (placebo control) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
16441515|NCT03693014|Experimental|Stereotactic Body Radiotherapy|Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity.
16441516|NCT03693001|Experimental|IC/FM Patients|All patients had been diagnosed with fibromyalgia and were suffering from IC by standard criteria.
16441517|NCT03692988|Experimental|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
16441518|NCT03692988|No Intervention|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
16441519|NCT03692975|Experimental|CIS patients|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation
16441520|NCT03692975|Active Comparator|Control|50 Healthy controls
16441521|NCT03692962|Sham Comparator|Sleep restriction without acoustic stimulation|
16441522|NCT03692962|Experimental|Sleep restriction with acoustic stimulation|
16441523|NCT03692949|Experimental|LY3451838 Part A|Single ascending doses, administered intravenously (IV)
16441524|NCT03692949|Experimental|LY3451838 Part B|Single doses administered subcutaneously (SC)
16441525|NCT03692949|Placebo Comparator|Placebo Part A|Matching single doses administered intravenously (IV)
16441526|NCT03692949|Placebo Comparator|Placebo Part B|Matching single doses administered subcutaneously (SC)
16441527|NCT03692923|No Intervention|control group|participants received ordinary prenatal care.
16441528|NCT03692923|Experimental|virtual community group|participants were invited to join a virtual community to interact with peers in addition to their ordinary prenatal care.
16441529|NCT03692910|Experimental|SAGE-217|
16441530|NCT03692871|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of double-blind V114 at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
16441531|NCT03692871|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
16441532|NCT03692858|Active Comparator|Group A|
16441533|NCT03692858|Active Comparator|Group B|
16441534|NCT03692845|Other|O-TLIF group|Spinal fusion ,Transforaminal lumbar interbody fusion procedure will be performed through open surgery.
16441535|NCT03692845|Other|MI-TLIF group|Spinal fusion,Transforaminal lumbar interbody fusion procedure will be performed through minimally invasive surgery using a tubular retractor.
16441536|NCT03692832|Experimental|Group L|
16441537|NCT03692832|Active Comparator|Group V|
16441538|NCT03692819|Active Comparator|placebo|Periodontal debridement treatment will be performed in a single session after the therapy will be administered the Placebo Oral Tablet twice a day for 21 days.
16441539|NCT03692819|Experimental|Metronidazole and Amoxicillin|Periodontal debridement treatment in a single session Metronidazole 400mg + Amoxicillin 500mg every 8 hours for 7 days.
16441540|NCT03692819|Experimental|Lactobacillus reuteri|Periodontal debridement treatment in a single session Lactobacillus reuteri Oral Drops twice a day for 21 days.
16441541|NCT03692806|Experimental|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
16441542|NCT03692806|Placebo Comparator|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
16441543|NCT03692793|Experimental|Pulmonary rehabilitation|The PRP (24-session, three times for week) will be delivered according to ATS/ERS (Spruit et al, 2013),
16441544|NCT03692780|Experimental|Careseng 1370|
16441545|NCT03692780|Placebo Comparator|Matched Placebo|
16441546|NCT03692767|Experimental|Anti-CD22 CAR NK cells|Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0
16441828|NCT03690830|Active Comparator|Control group|blood samples, analyzing endometrial cells
16441547|NCT03692754|Active Comparator|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
16441548|NCT03692754|Active Comparator|AT with 20 mg/d|The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
16441549|NCT03692754|Experimental|Dexamethasone|The patients will be given dexamethasone 40mg/d for 4 days.
16441550|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
16441551|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: >6.0 Diopters; astigmatism: >3.0 Diopters) were excluded from NV group.
16441554|NCT03692702|Experimental|WE PLAY|Teachers in this condition received the WE PLAY training.
16441555|NCT03692702|No Intervention|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
16441556|NCT03692689|Experimental|SCT200|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16441557|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
16441558|NCT03692663|Experimental|anti-PSMA CAR NK cells treatment group|
16441559|NCT03692637|Experimental|anti-Mesothelin Car NK Cells|Total dose of 0.5-3 million /kg cells will be administered at day0
16441560|NCT03692624|Experimental|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
16441561|NCT03692624|No Intervention|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
16441562|NCT03692611|Experimental|Skills to Manage Pain (STOMP)|The intervention group will receive treatment as usual plus the STOMP behavioral intervention. The STOMP behavioral intervention consists of 12 intervention sessions (6 group and 6 individual sessions). The sessions will be completed over a period of 12-16 weeks from enrollment. The first intervention session will be a group session for all participants followed by individual and then alternating group and individual sessions for the rest of the intervention. The intervention group will utilize a study manual on pain management in which they will use with each session.
16441563|NCT03692611|Active Comparator|comparison group|The comparison group will receive treatment as usual.The comparison group will also be provided with the intervention manual, however, no additional treatment will be provided to participants allocated to the control group. The group will not receive the PSM intervention.
16441564|NCT03692598|Experimental|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
16441565|NCT03692598|Experimental|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
16441566|NCT03692572|Active Comparator|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
16441567|NCT03692572|Placebo Comparator|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
16441568|NCT03692559|Experimental|full sterile dressing|Patients receive full sterile dressing
16441569|NCT03692559|No Intervention|usual standard care|Patients receive usual standard care
16441570|NCT03692546|Experimental|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
16441571|NCT03692546|No Intervention|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
16441572|NCT03692533|Active Comparator|Group A|Group (A) [study cases] Adult patients who will undergo radical or partial nephrectomy.for primary renal cell carcinoma.
16441573|NCT03692533|Active Comparator|Group B|Group (B) [control cases] Adult patients who will undergo simple nephrectomy for benign causes
16441574|NCT03692520|Experimental|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
16441575|NCT03692507|Experimental|HMB only|Taking HMB supplements three times a day
16441576|NCT03692507|Experimental|Protein and HMB|Drinking Ensure Enlive shakes
16441577|NCT03692507|Experimental|Current ERAS (High Protein)|Drinking Ensure surgery shakes + Ensure pre-surgery
16441578|NCT03692494|Experimental|Unilateral vocal fold paralysis standard of care voice therapy|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.
16441579|NCT03692494|Experimental|Unilateral paralysis standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
16441580|NCT03692494|Experimental|Parkinson's disease standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
16441581|NCT03692481|Experimental|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
16441582|NCT03692468|Experimental|Intervention Group|Participants will engage in a 5 session psychotherapy intervention focused on improving pain and mood.
16441583|NCT03692468|No Intervention|Control Group|Patients will receive treatment as usual from their care providers.
16441584|NCT03692455|Experimental|BPG Group|Patients will be submitted to Roux-en-Y Bypass Gastric Surgery.
16441585|NCT03692455|Experimental|Sleeve Group|Patients will be submitted to Vertical Sleeve Gastrectomy Surgery.
16441586|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
16441587|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
16441588|NCT03692429|Experimental|CYAD-101 with FOLFOX|Infusion after standard FOLFOX chemotherapy
16441589|NCT03692429|Experimental|CYAD-101 with FOLFIRI|Infusion after standard FOLFIRI chemotherapy
16441590|NCT03692416|Active Comparator|Ibuprofen|"Patients in this group will receive:
~Ibuprofen
~Oral
~At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.
~Duration of therapy: 4 - 6 weeks."
16441591|NCT03692416|Active Comparator|Prednisone Oral or Methylprednisolone IV|"Steroids:
~Pednisone (for mild/moderate cases):
~Oral
~Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.
~Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.
~Methylprednisolone (for severe/acute cases):
~IV
~10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.
~The duration is variable according to the condition of the patient."
16441592|NCT03692416|Active Comparator|Methotrexate|"Patients in this group will receive:
~Methotrexate
~Oral
~At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.
~Duration of therapy: 6 - 12 weeks."
16441593|NCT03692403|Experimental|Quinagolide 360 µg|Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
16441594|NCT03692403|Experimental|Quinagolide 720 µg|Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
16441595|NCT03692403|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
16441596|NCT03692403|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
16441597|NCT03692390|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
16441598|NCT03692390|No Intervention|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
16441599|NCT03692377||Children Aged 2-6|Children 2 to 6 years of age who are arriving with a guardian to the Emergency Department with a low acuity condition (Canadian Triage scale (CTAS) 4 or 5) and are waiting to be seen by the doctor, or are waiting for test results.
16441600|NCT03692364|Active Comparator|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
16441601|NCT03692364|Experimental|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
16441602|NCT03692351|Active Comparator|Cup with screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US), screw fixation (2 or 3 screws)
16441603|NCT03692351|Experimental|Cup without screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US) without screw holes, press-fit fixation
16441604|NCT03692338|Experimental|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).
~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
16441605|NCT03692338|Experimental|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.
~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
16441606|NCT03692338|No Intervention|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
16441607|NCT03692325|Experimental|Nivolumab|"Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle
~Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
16441608|NCT03692312|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
16441609|NCT03692312|Placebo Comparator|Placebo|Matching placebo, orally, once daily
16441610|NCT03692299|Active Comparator|Saccaromyces boulardii oral tablet|Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
16441611|NCT03692299|Active Comparator|Metronidazole plus S. boulardii|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
16441612|NCT03692299|Active Comparator|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.
16441613|NCT03692286|Active Comparator|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
16441614|NCT03692286|Active Comparator|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
16441615|NCT03692286|Active Comparator|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
16441616|NCT03692273|Experimental|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
16441617|NCT03692273|Experimental|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
16441618|NCT03692273|No Intervention|No treatment|3x3cm2 area designated as no treatment that will serve as a control
16441619|NCT03692260|Active Comparator|intervention group|3D stent in Herbert screw insertion vs titanium plate
16441620|NCT03692260|No Intervention|control group|titanium plate
16441621|NCT03692247|Other|Quantitative Sensory Testing|After answering brief questionnaires assessing psychosocial factors related to anxiety, catastrophizing, and pain, participants will undergo quantitative sensory tests where they will use a simple numeric rating scale (0-10) to rate pain and anxiety at several points during two QST sessions. During the second QST session, participants will use Unwind, a smartphone-based music intervention.
16441622|NCT03692234|Placebo Comparator|placebo|placebo capsules containing lactose - oral once weekly administration for six month
16441623|NCT03692234|Active Comparator|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
16441624|NCT03692221|Experimental|MSC treatment group 1|Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution
16441625|NCT03692221|Active Comparator|MSC treatment group 2|High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution
16441626|NCT03692221|Active Comparator|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
16441627|NCT03692208|Experimental|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
16441628|NCT03692208|Active Comparator|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
16441629|NCT03692195|Experimental|Week WHOOP is worn|Participants will wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
16441630|NCT03692195|Placebo Comparator|Week WHOOP is not worn|Participants will not wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
16441631|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
16441632|NCT03692169||CSC patients|Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
16441633|NCT03692143||teriparatide group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide
16441634|NCT03692143||PVP group plus alendronate|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.
16441635|NCT03692143||teriparatide and PVP group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty
16441636|NCT03692130|Active Comparator|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
16441637|NCT03692130|Sham Comparator|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
16441638|NCT03692091|Active Comparator|Anterior portal|Injection in to subacromial space from anterior portal
16441639|NCT03692091|Active Comparator|Lateral portal|Injection in to subacromial space from lateral portal
16441640|NCT03692078|No Intervention|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
16441641|NCT03692078|Experimental|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
16441642|NCT03692078|Experimental|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
16441643|NCT03692078|Experimental|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
16441644|NCT03692078|Experimental|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
16441645|NCT03692078|Experimental|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
16441646|NCT03692065|Active Comparator|Apixaban film coated tablets 2.5 mg|Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.
16441647|NCT03692065|Active Comparator|Apixaban film coated tablets 5 mg|Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.
16441648|NCT03692052|Experimental|AG-348|"Core period: Participants will receive AG-348 for up to 24 weeks. Depending on the safety observations and hemoglobin (Hb) concentrations, they may undergo one potential dose-level increase from 50 to 100 mg BID.
~Extension Period: Eligible participants will continue to receive AG-348 for up to an additional 10 years at the same dose they were receiving at the Week 24 visit."
16441649|NCT03692039|Experimental|M-pro files|Instrumentation using M-pro files in rotating motion
16441650|NCT03692039|Active Comparator|ProTaper Next files|Instrumentation using ProTaper Next files in rotating motion
16441651|NCT03692026|Experimental|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
16441652|NCT03692026|Active Comparator|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
16441653|NCT03692013|Experimental|nighttime group|patients with nocturnal hypertension taking losartan at nighttime
16441654|NCT03692013|Active Comparator|daytime group|patients with nocturnal hypertension taking losartan at daytime
16441655|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
16441656|NCT03691987|Experimental|Preprocessed thawed donor FMT|"The active transplants are processed in a 2-3 weeks period before treatment of the first participant. Fifty to eighty grams of freshly delivered feces from donors is mixed with 100 mL isotonic saline and 25 mL 85% glycerol, homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60 ml luerlock syringes and stored at -40°C.
~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the FMT-syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in an enema bag prior to installation."
16441657|NCT03691987|Placebo Comparator|Preprocessed thawed autologous FMT|"The placebo transplant from each participant is prepared during the inclusion process four to six weeks before intervention and stored at -40°C. Fifty to eighty grams of freshly delivered feces from participants is mixed with 100 mL isotonic saline and 25 mL 85% glycerol is homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60ml Luerlock syringes.
~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the Luerlock syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in the enema bag prior to installation."
16441658|NCT03691974|Experimental|Fasinumab|
16441659|NCT03691974|Placebo Comparator|Placebo|
16441660|NCT03691961|Experimental|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.
~Hair sampling after 4 months treatment.
~Analysis of hair's drug concentrations."
16441661|NCT03691961|Experimental|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.
~Hair sampling after 4 months treatment.
~Analysis of hair's drug concentrations."
16441662|NCT03691948|Experimental|ROPEs|
16441663|NCT03691948|Active Comparator|Control|
16441664|NCT03691935|Experimental|Ropivicaine|Erector Spinae Block of 20ml 0.5% ropivicaine bolus, connected to a pump containing 0.2% ropivicaine receiving 15ml every 3 hrs.
16441665|NCT03691935|Sham Comparator|Normal Saline|Erector Spinae Block of 20ml normal saline placebo bolus, then connected to pump of normal saline receiving 15ml every 3 hrs.
16441666|NCT03691922|Active Comparator|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
16441667|NCT03691922|Other|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
16441668|NCT03691909|Experimental|Treatment Arm|Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.
16441669|NCT03691896|Experimental|Lower dose|cholecalciferol 400UNT, oral solution
16441670|NCT03691896|Active Comparator|Middle dose|cholecalciferol 800UNT, oral solution
16441671|NCT03691896|Experimental|Higher dose|cholecalciferol 1200UNT, oral solution,
16441672|NCT03691883||TB patients|TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.
16441673|NCT03691870|Active Comparator|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.
~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.
~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.
~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
16441714|NCT03691649|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
16441829|NCT03690817||Bilateral vestibulopathy|Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).
16441674|NCT03691870|Experimental|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.
~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).
~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
16441675|NCT03691857|Other|Acute non-traumatic dyspnea patients|Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
16441676|NCT03691844|Experimental|AMZ001 + Placebo|on the target knee
16441677|NCT03691844|Experimental|AMZ001|on the target knee
16441678|NCT03691844|Placebo Comparator|Placebo|on the target knee
16441679|NCT03691844|Active Comparator|Comparator|Diclofenac gel on the target knee
16441680|NCT03691831|Active Comparator|Active|A-101 45% (Topical solution, hydrogen peroxide 45%)
16441681|NCT03691831|Placebo Comparator|Vehicle|Topical solution, isopropyl alcohol and water
16441682|NCT03691818|Experimental|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
16441683|NCT03691818|Active Comparator|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
16441684|NCT03691818|Placebo Comparator|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
16441685|NCT03691818|Experimental|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
16441686|NCT03691818|Active Comparator|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
16441687|NCT03691818|Placebo Comparator|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
16441688|NCT03691818|Experimental|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
16441689|NCT03691818|Active Comparator|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
16441690|NCT03691818|Placebo Comparator|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
16441691|NCT03691805|Active Comparator|anodal tDCS over rDLPFC|Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).
16441692|NCT03691805|Sham Comparator|sham tDCS|Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.
16441693|NCT03691792|Experimental|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
16441694|NCT03691792|Active Comparator|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
16441697|NCT03691766|Experimental|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
16441698|NCT03691766|Placebo Comparator|Control|Placebo device with different wavelengths of light without known physiologic effect.
16441699|NCT03691753|Experimental|Experimental arm|Patients will be treated with Fitaya Vena Cava Filter System.
16441700|NCT03691753|Active Comparator|Control arm|Patients will be treated with Aegisy Vena Cava Filter.
16441701|NCT03691740|Experimental|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
16441702|NCT03691740|Placebo Comparator|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
16441703|NCT03691727|Experimental|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.
~MRI Neurological Exam Vital Signs Questionnaires"
16441704|NCT03691727|Active Comparator|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
16441705|NCT03691714|Experimental|Durvalumab and Cetuximab|Durvalumab 1500mg IV every 4 weeks Cetuximab 400mg/m2 IV loading dose followed by weekly Cetuximab 250mg/m2 IV Treatment with Durvalumab continues for a maximum of 24 months while Cetuximab may continue as maintenance
16441706|NCT03691701|Experimental|Strict SBP Target|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
16441707|NCT03691701|No Intervention|Usual SBP Target|Usual care, no home SBP target
16441708|NCT03691688||Aspirin|Aspirin 100mg
16441709|NCT03691688||Clopidogrel|Clopidogrel 75mg
16441710|NCT03691675|Experimental|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
16441711|NCT03691662|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
16441712|NCT03691662|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
16441713|NCT03691649|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
16441715|NCT03691636|Experimental|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
16441716|NCT03691636|Active Comparator|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
16441717|NCT03691623|Experimental|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
16441718|NCT03691623|Experimental|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
16441719|NCT03691623|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
16441720|NCT03691623|Experimental|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
16441721|NCT03691623|Experimental|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
16441722|NCT03691623|Placebo Comparator|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
16441727|NCT03691597|Active Comparator|Adhesive resin cement|type of cement used for cementation of crowns have a good adhesion bond
16441728|NCT03691597|Experimental|Bioactive cement|recent cement improve the marginal integrity
16441729|NCT03691584|Experimental|BAL PK study|Bronchoalveolar lavage procedure performed at either 2, 4, 8, or 24 hours after final dose of TP-6076 on Day 4
16441730|NCT03691571|Experimental|Esophageal Cooling|Patients randomized to Group A receive the EnsoETM (Attune Medical Esophageal Heat Transfer Device).
16441731|NCT03691571|Active Comparator|Control|Patients randomized to Group B receive standard of care treatment (standard temperature probe monitoring).
16441732|NCT03691558|Experimental|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
16441733|NCT03691558|Active Comparator|Western Diet|Subjects followed 5 weeks of a western diet
16441734|NCT03691545|Experimental|Intervention Group|(1) 12 weekly interactive sessions with a health coach to help them set goals and make changes toward becoming physically active and consuming the recommended number of fruits and vegetables.
16441735|NCT03691532|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~60 min (duration of exercise performed in other arm). Following the intervention they are fed a liquid meal.
16441736|NCT03691532|Experimental|Arm cycle exercise (ACE)|Participants complete continuous arm cycle exercise (ACE) for ~60 min. Following the intervention they are fed a liquid meal.
16441737|NCT03691519|Placebo Comparator|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.
~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
16441738|NCT03691519|Experimental|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
16441739|NCT03691506|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
16441740|NCT03691506|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
16441741|NCT03691493|Experimental|Radiation, palbociclib, hormone therapy|Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21. At the discretion of treating physician, patients also receive letrozole, anastrozole, exemestane, or tamoxifen PO QD on days 1-28, or fulvestrant IM on days 1 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16441742|NCT03691480|Experimental|simple exsufflation|
16441743|NCT03691480|Experimental|Fuhrman catheter and ambulatory care|
16441744|NCT03691467|Experimental|immediate implant with hyaluronic acid.|immediate dental implant with topical application of hyaluronic acid.
16441745|NCT03691467|Active Comparator|immediate implant.|immediate dental implant placement with placebo gel
16441746|NCT03691454|Experimental|DOS|Docetaxel+Oxaliplatin+S-1
16441747|NCT03691454|Active Comparator|SOX|Oxaliplatin+S-1
16441748|NCT03691441|Experimental|Resection/adjuvant radio(-chemo)therapy|"Transoral surgical resection within 4 weeks after randomization
~Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization
~6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery"
16441749|NCT03691441|Active Comparator|Adjuvant radio(-chemo)therapy/salvage neck dissection|"6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization
~70-72 Gy, SIB possible
~Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33
~+/- Salvage neck dissection 12±2 weeks after treatment"
16441750|NCT03691428|Experimental|Intervention|
16441751|NCT03691428|Other|Wait-list|Participants will get the WOOP training after the last outcome assessment.
16441752|NCT03691415||BELKYRA Inj.|Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
16441822|NCT03690869|Experimental|Efficacy with Recurrent HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
16441823|NCT03690856|Experimental|depressiv people|
16441824|NCT03690843||DCD Group|Children diagnosed with DCD or at-risk DCD at two or three years of age
16441825|NCT03690843||Control Group|Typically developing children
16441755|NCT03691376|Experimental|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
16441756|NCT03691363|Experimental|M-STEP|Mobile exercise intervention
16441757|NCT03691350|Active Comparator|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
16441758|NCT03691350|Experimental|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
16441759|NCT03691350|Experimental|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
16441760|NCT03691350|Experimental|Group IV (usual cigarette brand, nicotine-containing SREC)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the nicotine-containing SREC for 2 weeks and use both their usual brand of cigarettes and the nicotine-containing SREC starting day 15 for 8 weeks with the intention of smoking reduction to 5 cigarettes or less per day. Participants undergo a second bronchoscopy on day 71.
16441761|NCT03691350|Experimental|Group V (NRT)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 2 days before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
16441762|NCT03691337|Active Comparator|Low dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.11 mL x subject height)
16441763|NCT03691337|Active Comparator|High dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.22 mL x subject height)
16441764|NCT03691337|Placebo Comparator|Placebo|Preoperative fascia iliaca block with Sodium Chloride 0.9% (0.11 mL x subject height)
16441765|NCT03691324|Experimental|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
16441766|NCT03691324|No Intervention|Standard care|Patients receive standard care and follow up of their COPD-treatment
16441767|NCT03691311|Experimental|Denosumab|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
16441768|NCT03691311|No Intervention|Control|Control group
16441769|NCT03691298||Arthroscopic hip repair|
16441770|NCT03691285|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
16441771|NCT03691285|Active Comparator|Two-implant mandibular overdenture|Participants allocated to this group will have two implants placed in the inter-foraminal region after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
16441772|NCT03691272|Experimental|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
16441773|NCT03691272|Sham Comparator|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
16441774|NCT03691259|Experimental|Dance Group|Dance group will participate in one-hour ballet classes twice per week for 10 weeks
16441775|NCT03691259|No Intervention|Control Group|The control group will not participate in the ballet classes
16441776|NCT03691220|Experimental|Telemetric Intervention Arm|Adolescent with MLVI>2 to receive the telemetric intervention.
16441777|NCT03691220|No Intervention|Standard of Care Arm|Adolescent with MLVI>2 to receive standard of care.
16441778|NCT03691207|Experimental|SINGLE-ARM|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
16441779|NCT03691194|Experimental|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
16441780|NCT03691194|Active Comparator|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
16441826|NCT03690830|Experimental|Case group RIF|blood samples, analyzing endometrial cells
16441781|NCT03691181|Experimental|Open Ambulatory Ventilation|"monitoring with the use of the Life2000 Open Ventilation System for a period of six months with measures of nutrition, feeling of breathlessness, exercise tolerance, and quality of life.
~BODE Index B - BMI - BMI stands for body mass index, a calculation made by comparing height vs weight.
~O - Airway obstruction - Airway obstruction is measured by evaluating FEV1 - the amount of air that can be forcefully exhaled in 1 second after a deep breath.
~D - Dyspnea - Dyspnea refers to the degree of breathlessness someone experiences while living with COPD.
~E - Exercise tolerance - Exercise testing refers to how well some does on a 6-minute walk test.
~Modified Medical Research Council Dyspnea Scale"
16441782|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
16441783|NCT03691129|Experimental|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
16441784|NCT03691129|No Intervention|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
16441785|NCT03691116|Experimental|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
16441786|NCT03691116|Active Comparator|Treatment as usual|Psychological assessment and treatment as usual.
16441787|NCT03691090|Experimental|SHR-1210 + paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
16441788|NCT03691090|Active Comparator|placebo+paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance
16441789|NCT03691077|Experimental|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
16441790|NCT03691064||LUTATHERA|Treated per labeled LUTATHERA dosing regimen.
16441791|NCT03691051|Experimental|Pyrotinib Plus Capecitabine|Pyrotinib + Capecitabine
16441792|NCT03691038|Active Comparator|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
16441793|NCT03691038|Experimental|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
16441794|NCT03691025||RALPD|
16441795|NCT03690999|Placebo Comparator|Placebo group|Placebo product
16441796|NCT03690999|Experimental|Prebiotic Supplement, low dose|
16441797|NCT03690999|Experimental|Prebiotic Supplement, high dose|
16441798|NCT03690986|Experimental|Group A (VX15/2503)|Patients receive VX15/2503 IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
16441799|NCT03690986|Experimental|Group B (VX15/2503, ipilimumab)|Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
16441800|NCT03690986|Experimental|Group C (VX15/2503, nivolumab)|Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
16441801|NCT03690986|Experimental|Group D (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
16441802|NCT03690986|Experimental|Group E (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
16441803|NCT03690986|No Intervention|Group F (no treatment)|Patients undergo standard of care surgery.
16441804|NCT03690973|Active Comparator|Alveolar socket preservation with graft and flap surgery|
16441805|NCT03690973|Experimental|Immediate implant placement with bone using flapless surgery|
16441806|NCT03690973|Experimental|Immediate implant placement with bone and flap surgery|
16441807|NCT03690973|Experimental|Alveolar socket preservation with graft and flapless surgery|
16441808|NCT03690960|Experimental|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
16441809|NCT03690960|Active Comparator|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
16441810|NCT03690947|Experimental|Combination Therapy Group|
16441811|NCT03690947|Active Comparator|Intravitreal Ranibizumab Group|
16441812|NCT03690934|Experimental|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
16441813|NCT03690934|Active Comparator|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
16441814|NCT03690921|Experimental|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
16441815|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
16441816|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
16441817|NCT03690895||Cases|
16441818|NCT03690882||Cases of unclassified acute cervical pain|
16441819|NCT03690869|Experimental|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive REGN2810 monotherapy. Each Cohort will have 2 subgroups by age (0 to <12 years, 12 to <18 years).
16441820|NCT03690869|Experimental|Efficacy with Newly Diagnosed DIPG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
16441821|NCT03690869|Experimental|Efficacy with Newly Diagnosed HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
16441830|NCT03690817||Healthy controls|Subjects without vestibular or neurological diseases (DHI<5), and with normal hearing thresholds according to their age.
16441831|NCT03690804|Experimental|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
16441832|NCT03690791|Active Comparator|MediCabilis CBD Oil|
16441833|NCT03690791|Placebo Comparator|Placebo Oil|
16441834|NCT03690778|Experimental|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
16441835|NCT03690778|Experimental|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
16441836|NCT03690765||Endometriosis/Dydrogesterone|Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®
16441837|NCT03690752|Sham Comparator|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.
~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
16441838|NCT03690752|Experimental|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.
~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
16441839|NCT03690739|Active Comparator|platinum-based chemotherapy|According to the investigator's discretion
16441840|NCT03690739|Active Comparator|PLD + Trabectedin|PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
16441841|NCT03690726|Experimental|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
16441842|NCT03690726|Sham Comparator|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
16441843|NCT03690713||Patient and Vessels underwent physiologic evaluation|The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.
16441844|NCT03690700|Active Comparator|active BFRE|14 consecutive paraplegic SCI patients are block-randomized to active arm
16441845|NCT03690700|Sham Comparator|sham BFRE|14 consecutive paraplegic SCI patients are block-randomized to sham arm
16441846|NCT03690687||Group I. Primary anastomosis|Resection of the small bowel to place primary anastomosis into small intestine or transverse colon during relaparotomy.
16441847|NCT03690687||Group II. Delayed anastomosis|Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
16441848|NCT03690687||Group III. Enterostomy|Resection of the small intestine with enterostomy. In case there was no postoperative peritonitis relief and was organ dysfunction progression, anastomosis was not placed. The surgery was completed with enterostomy to perform open abdomen.
16441849|NCT03690674|Experimental|Lifestyle Enhancement for ADHD Program|There is no comparison/control arm.
16441850|NCT03690661|Experimental|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
16441851|NCT03690661|Placebo Comparator|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
16441852|NCT03690648||Saliva collection|"Clinical examination;
~Quality of life survey;
~Saliva collection for genetical analysis"
16441853|NCT03690648||Saliva and Blood collection|"Clinical examination;
~Quality of life survey;
~Saliva and blood collection for genetical analysis"
16441854|NCT03690635|Experimental|VISTA technique|evolution of a newer approach known as Vestibular Incision Subperiosteal Tunnel Access (VISTA) was proposed to avoid some of the potential complications occurring with other intrasulcular tunneling techniques
16441855|NCT03690635|Active Comparator|tunneling technique|Several modifications of tunnel technique have been described in order to preserve esthetics, avoid relapse of gingival recession and maintain papillary integrity. These modifications also attend to avoid scar formation and delayed healing related to vertical releasing incision
16441856|NCT03690622|Sham Comparator|BSS|Balanced salt solution
16441857|NCT03690622|Active Comparator|Dexmedetomidine|dexmedetomidine (0.0055%)
16441858|NCT03690609|Active Comparator|Nutraceutical intervention, 3 capsules daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 3 capsules daily in the morning.
16441859|NCT03690609|Active Comparator|Nutraceutical intervention, 2 capsules twice daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 4 capsules daily: Two in the morning and two later in the day.
16441860|NCT03690596|Experimental|NRT + QuitBuddy|This smartphone app will identify high-risk situations through real-time EMA data collected before and during a quit attempt. One week of pre-quit smoking behaviors will be integrated with passively sensed GPS data to create hotspot maps. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
16441861|NCT03690596|Experimental|NRT + QuitBuddy-Recall|This smartphone app will identify high-risk situations through retrospective recall of locations where the patient typically smoked. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
16441862|NCT03690596|Active Comparator|NRT Control (treatment as usual)|Standard Care Control is intended to approximate the real-world experience where smokers obtain over-the-counter NRT and, after brief instructions at the outset (~1 lozenge per hour, during cravings, and <20 per day), determine usage for themselves.
16441863|NCT03690583|Experimental|Zinc group|Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
16441864|NCT03690583|Placebo Comparator|Placebo group|Glucose
16441865|NCT03690557|Experimental|IncentaHealth|All patients who decide to join the weight loss program will be enrolled in the commercially-available IncentaHealth program - a comprehensive, evidence-based, behavioral weight management program designed to help patients initiate and maintain weight loss. The program is delivered completely online, via website, emails, mobile app, and (if requested by the participant) text messaging over 12 months. Each participant will be given a digital scale that wirelessly syncs with a smartphone app. Participants' weights are automatically uploaded to the Incentahealth online portal. In the informed consent process, participants will need to agree to release their weight data to researchers at the University of Nebraska Medical Center in order to participate in this program.
16441866|NCT03690544|Experimental|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
16441867|NCT03690531||Take Pause Virtual Reality Head Set|The mbVR intervention arm will be a Take-Pause virtual reality simulation will be for 5 minutes shown through a virtual reality goggle, headset and iPhone.
16441868|NCT03690531||Passive Distraction Group_IPAD|The Passive Distraction group will utilize the standard or passive distraction technique of using an IPAD lasting 5 minutes.
16441869|NCT03690518|No Intervention|Control|Controls will have a regular follow-up without any intervention (no rehabilitation program)
16441870|NCT03690518|Active Comparator|Rehabilitaiton|Cardiac rehabilitation: Rehabilitation will have a regular follow-up with intervention (rehabilitation program)
16441871|NCT03690505|Other|Assessment|Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
16441872|NCT03690492|Experimental|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
16441873|NCT03690492|No Intervention|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
16441874|NCT03690479|Active Comparator|Ball Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the new trial tip (ball-end probe, 0.6mm diameter).
16441875|NCT03690479|Active Comparator|Florida Probe Straight Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip (straight-end probe, 0.45mm diameter).
16441876|NCT03690466|Experimental|Study device treatment|Transcutaneous non-invasive ultrasound will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
16441877|NCT03690466|Sham Comparator|Sham device treatment|Sham treatment will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
16441878|NCT03690453|Experimental|Healthy volunteer for Clinical Trial|
16441879|NCT03690453|No Intervention|Healthy volunteer for blood donor|
16441880|NCT03690427|Experimental|Endothelial function|Brachial artery flow-mediated dilation will be used to measure endothelial function
16441881|NCT03690427|Experimental|Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness
16441882|NCT03690427|Experimental|Biomarkers of|Prooxidant and inflammatory plasma biomarkers will be used to assess oxidative stress and inflammatory status
16441883|NCT03690414|Active Comparator|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
16441884|NCT03690414|Active Comparator|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
16441885|NCT03690414|Active Comparator|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
16441886|NCT03690401||Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed before treatment and after completion of treatment. Moving On assessments will be performed at first and last study visits.
16441887|NCT03690401||Non-Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed at first and last study visits.
16441888|NCT03690388|Experimental|Cabozantinib|cabozantinib (60 mg) once daily orally (qd)
16441889|NCT03690388|Placebo Comparator|Placebo|placebo once daily orally (qd)
16441890|NCT03690375|Experimental|BBL Left|Left arm selected to be treated with BBL, right arm not treated
16441891|NCT03690375|Experimental|BBL Right|Right arm selected to be treated with BBL, left arm not treated
16441892|NCT03690362|Experimental|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
16441893|NCT03690362|Experimental|Group 2 - Mild Renal Impairment|Mild renal impairment
16441894|NCT03690362|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
16441895|NCT03690362|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
16441896|NCT03690362|Experimental|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
16441897|NCT03690349||Skin test in severe asthma exacerbation|Skin test in asthmatic children hospitalized due to severe asthma exacerbation in a preceding year
16441898|NCT03690349||skin test in outpatient|Skin test in asthmatic children without severe asthma exacerbation in a preceding year
16441899|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
16441900|NCT03690323|Experimental|RFA|"RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.
~After recovery of the RFA patients will continue chemotherapy:
~FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy"
16441901|NCT03690323|Active Comparator|Chemotherapy|"Patients will continue chemotherapy:
~FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy"
16441902|NCT03690310|Experimental|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
16441903|NCT03690297|Experimental|LCI|Linked Color Imaging
16441904|NCT03690297|Active Comparator|WL|White Light
16441905|NCT03690284|Active Comparator|Conventional Double Lumen Tube|Patient will be intubated with conventional double lumen endotracheal tube for single lung ventilation during thoracic surgery.
16441906|NCT03690284|Experimental|VivaSight Double Lumen Tube|Patient will be intubated with VivaSight double lumen endotracheal tube for single lung ventilation during thoracic surgery.
16441907|NCT03690271||Groupe 5-5|"Patients for whom the clinician has prescribed local anesthetics in the epidural:
~fixed dose administered every hour in a systematic way : 5 ml
~dose to be administered every hour by the patient : 5 ml"
16441908|NCT03690271||groupe 6-6|"Patients for whom the clinician has prescribed local anesthetics in the epidural:
~fixed dose administered every hour in a systematic way : 6 ml
~dose to be administered every hour by the patient : 6 ml"
16441909|NCT03690271||groupe 7-7|"Patients for whom the clinician has prescribed local anesthetics in the epidural:
~fixed dose administered every hour in a systematic way :7 ml
~dose to be administered every hour by the patient :7 ml"
16441910|NCT03690258|Experimental|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.
~Data available at: http://nhance.se/"
16441911|NCT03690258|Experimental|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.
~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
16441912|NCT03690245|Active Comparator|Control|Infants will have immediate cord clamping and respiratory support afterwards
16441913|NCT03690245|Experimental|Initiation of Resuscitation While Attached to the Cord|Infants will receive respiratory support for 120 seconds while attached to the cord.
16441914|NCT03690232|Experimental|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
16441915|NCT03690232|Active Comparator|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
16441919|NCT03690193|Experimental|Ketogenic Diet Arm|All participants will be assigned to the 3-month ketogenic diet intervention. Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein). Participants will be provided medium chain triglyceride oil with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
16441920|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.
~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
16441921|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.
~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
16441922|NCT03690167|Active Comparator|Concentrated Growth Factor (CGF)|Participants with impacted lower third molar
16441923|NCT03690167|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|Participants with impacted lower third molar
16441924|NCT03690167|Sham Comparator|Control|Participants with impacted lower third molar
16441925|NCT03690154|Experimental|FN-1501|
16441926|NCT03690141|Experimental|tomivosertib (eFT508)|Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.
16441927|NCT03690128|Active Comparator|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
16441928|NCT03690128|Active Comparator|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.
~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
16441929|NCT03690115|Experimental|Experimental|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
16441930|NCT03690102|Experimental|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.
~During the scenario test, the participant will receive T-CPR."
16441931|NCT03690102|Experimental|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.
~During the scenario test, the participant will not receive T-CPR."
16441932|NCT03690102|Experimental|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.
~During the scenario test, the participant will receive T-CPR."
16441933|NCT03690089|Experimental|Intervention Group (Atropine 0.01%)|The intervention group will receive 0.01% atropine sulfate eye drops, administered once daily for two years.
16441934|NCT03690089|Placebo Comparator|Placebo Group|The control group will receive placebo eye drops, administered once daily for two years.
16441935|NCT03690076||Control|patients with normal weight (23 < BMI < 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
16441936|NCT03690076||Endocarditis|patients with normal weight (23 < BMI < 27) carriers of endocarditis with surgery indication
16441937|NCT03690076||Obese|obese patients (BMI > 30 with waist to hip ratio > or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
16441938|NCT03690050|Experimental|Diode Subthreshold Micropulse Laser|"DSML is a relatively new laser technology aimed at minimising damage (tissue-sparing) to choroid and retina but maintaining treatment efficacy by its selective effect on the retinal pigment epithelium (RPE). It is performed using laser that, instead of delivering a continuous-wave laser beam, as the standard laser, it provides very small, repetitive, low energy pulses of laser separated by a brief rest period. This rest period allows the tissue to cool down between laser pulses avoiding the increased tissue heat that would be produced by continuous laser and allowing the use of lower laser energy power to achieve an effect. The reduced heat produced in the tissue and the reduced energy power required for the treatment may reduce side effects."
16441939|NCT03690050|Active Comparator|Standard threshold laser (532 nm laser)|Green-yellow argon laser photocoagulation at threshold levels has been used for many years as the standard laser for the treatment of many retinal disorders including DMO. The ETDRS demonstrated the efficacy of laser in preventing visual loss in patients with DMO.
16441940|NCT03690037|Experimental|Intervention Group 1|Intervention Group 1: 1g intravenous Tranexamic Acid 100 milligrams (MG)/ML peri-operatively plus 1g oral Tranexamic Acid 500mg Tablets every 8hrs for up to 24hrs
16441941|NCT03690037|Experimental|Intervention Group 2|Intervention Group 2: 1g intravenous Tranexamic Acid 100 MG/ML peri-operatively
16441942|NCT03690037|No Intervention|Control Group 3|Standard care - no TXA
16441943|NCT03690011|Experimental|CD7.CAR/28zeta CAR T Cells|Three dose levels will be evaluated. The T cells will be administered following lymphodepleting chemotherapy with cyclophosphamide and fludarabine.
16441944|NCT03689998|Experimental|implant placement with melatonine|immediate implant placement with melatonine
16441945|NCT03689998|Active Comparator|immediate implant placement alone|immediate implant placement alone
16441946|NCT03689985|Experimental|General|One arm study: smART Feeding Tube System.
16441947|NCT03689972|Experimental|Part 1: Standard Interval Dosing (SID) IV|Participants will receive natalizumab 300 milligram (mg) intravenous (IV) infusion every 4 weeks (-2/+5 days) up to Week 72.
16441948|NCT03689972|Experimental|Part 1: Extended Interval Dosing (EID) IV|Participants will receive natalizumab 300 mg IV infusion every 6 weeks (-2/+5 days) up to Week 72.
16441949|NCT03689972|Experimental|Part 2: EID SC, then EID IV|Participants will receive natalizumab 300 mg SC injection every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion every 6 weeks from Week 132 through Week 150.
16441950|NCT03689972|Experimental|Part 2: EID IV, then EID SC|Participants will receive natalizumab 300 mg IV infusion every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg SC injection every 6 weeks from Week 132 through Week 150.
16441951|NCT03689959|Experimental|Patients|13 child with fixed knee flexion deformity more than 10° on one or both sides with 12 months or more predicted growth remaining subjected to eight plate hemiepiphysiodesis of the distal femur
16441952|NCT03689946|Experimental|Evolocumab, F18-NaF PET, CCTA|Evolocumab self-administration for 18 months. Baseline (pre-treatment) and follow-up 18F-NaF PET and CCTA (possible beta-blocker and nitroglycerin, if medically safe).
16441953|NCT03689933|Experimental|root analog implant|The tooth indicated for extraction will be extracted atraumatically using periotome, socket preservation using Iodoform packing strips, and then optical scanning of the remaining tooth structure with optical scanner will be made to obtain a 3D virtual model, this model will be modified by addition of macro-retentions strictly to the interdental area to avoid any fracture in thin cortical bone, the cervical portion of implant circumference will be decreased by 0.1 to 0.2 mm to avoid pressure resorption of alveolar crest of bone and addition of prepared crown stump for the future crown to be placed.
16441954|NCT03689933|Active Comparator|conventional stock root-form titanium implant|Using a conventional implant as a comparator as it's the gold stander in restoring the non-restorable teeth.
16441957|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.
~At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
16441958|NCT03689894|Experimental|Ibrutinib plus Rituximab|"Rituximab
~*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)
~Ibrutinib
~420 mg (140 mg capsule x3) by mouth daily
~May be given beyond 3-6 months (for maintenance)."
16441959|NCT03689881|Experimental|Tomosynthesis|Tomosynthesis of SI joints
16441960|NCT03689868|Experimental|Virtual Reality|
16441961|NCT03689868|No Intervention|Control|
16442039|NCT03689322|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
16441962|NCT03689855|Experimental|Ramucirumab + Atezolizumab|"Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.
~Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
16441963|NCT03689842|Experimental|Couple donor - recipient|
16441964|NCT03689829|Experimental|MOR106 Single Dose A, i.v. infusion, Part 1|A single dose of MOR106 will be administered by i.v. infusion.
16441965|NCT03689829|Experimental|MOR106 Single Dose B, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
16441966|NCT03689829|Experimental|MOR106 Single Dose C, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
16441967|NCT03689829|Experimental|MOR106 Single Dose D, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
16441968|NCT03689829|Experimental|MOR106 Repeated Doses E, s.c. injection, Part 2|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
16441969|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 2|Corresponding Placebo will be administered by s.c. injection.
16441970|NCT03689829|Experimental|MOR106 Repeated Doses F, s.c. injection, Part 3|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
16441971|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 3|Corresponding Placebo will be administered by s.c. injection.
16441972|NCT03689816|Experimental|bone density|bone density
16441973|NCT03689803|Active Comparator|Lipidemia|
16441974|NCT03689790|Active Comparator|liver function|liver function
16441975|NCT03689777|Active Comparator|Glomerular Filtration Rate|
16441976|NCT03689764|Experimental|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
16441977|NCT03689764|Experimental|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
16441978|NCT03689751|No Intervention|LSCS Control Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
16441979|NCT03689751|Experimental|LSCS Intervention ArmIntervention Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (LSCS Video) as an additional educational resource.
16441980|NCT03689751|No Intervention|TVT/TOT Control Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
16441981|NCT03689751|Experimental|TVT/TOT Interventional Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (TVT/TOT Video) as an additional educational resource.
16441982|NCT03689738|Experimental|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
16441983|NCT03689738|Active Comparator|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
16441984|NCT03689725|Experimental|Preterm music group|Music exposure with headphones
16441985|NCT03689725|No Intervention|Preterm control group|headphones without music
16441986|NCT03689725|No Intervention|Full-term control group|
16441987|NCT03689712|Experimental|GC4419|
16441988|NCT03689712|Placebo Comparator|Placebo|
16441989|NCT03689699|Experimental|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
16441990|NCT03689699|Experimental|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
16441991|NCT03689686|Experimental|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
16441992|NCT03689660|Experimental|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
16441993|NCT03689660|Experimental|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
16441994|NCT03689660|Other|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
16441995|NCT03689647|Experimental|Single Group Experimental|Each participant will act as their own control with variables of interest measured while walking without the assistive device and while walking with the assistive device.
16441996|NCT03689634|Experimental|Move For Surgery Preconditioning Program Intervention Group|
16441997|NCT03689634|No Intervention|Standard Preoperative Care Group|
16441998|NCT03689621|Active Comparator|Transcutaneous vagal nerve stimulation (tVNS)|tVNS administered for 4 hours each day and behaviour is recorded.
16441999|NCT03689621|Placebo Comparator|Baseline|tVNS worn but not switched on whilst collecting behavioural data.
16442000|NCT03689608|Experimental|Intermittent Fasting (IF)|3 days fasting per week
16442001|NCT03689608|Experimental|Daily Restriction (DR)|daily energy restriction
16442002|NCT03689608|Other|standard care (SC)|usual care
16442003|NCT03689595||Specimen Collection|"Samples of blood (2-4 tablespoons) from 3 tubes will be collected
~Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute"
16442004|NCT03689582|Experimental|68Ga-PSMA|PET/CT imaging
16442591|NCT03685578||Mechanical Thrombectomy|EmboTrap® Revascularization Device
16442005|NCT03689569|Experimental|Exercise|Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.
16442006|NCT03689569|Experimental|Resistant Starch|Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training
16442007|NCT03689569|Experimental|Exercise & Resistant Starch|Exercise & resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period
16442008|NCT03689569|Placebo Comparator|Starch|Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks
16442009|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
16442010|NCT03689543|Experimental|Arm 1|LY500307 at 25mg per day
16442011|NCT03689543|Active Comparator|Arm 2|LY500307 at 75mg per day
16442012|NCT03689543|Placebo Comparator|Arm 3|Matched placebo
16442013|NCT03689530|Experimental|Peer Support Arm.|Participants randomized to peer support will be matched with a peer supporter.
16442014|NCT03689530|Active Comparator|Enhanced Usual Care|Participants randomized to enhanced usual care will receive brief education and folder of information and resources.
16442015|NCT03689517|Experimental|placebo arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. Participants took placebos (pills made by starch) that were told to be an effective analgesic
16442016|NCT03689517|Sham Comparator|sham arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. But participants do not take placebos
16442017|NCT03689504|Active Comparator|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
16442018|NCT03689504|Experimental|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
16442019|NCT03689491|Experimental|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
16442020|NCT03689491|Active Comparator|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
16442021|NCT03689491|Active Comparator|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
16442022|NCT03689478|Experimental|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
16442023|NCT03689465|Active Comparator|PTCy-ATG group|PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).
16442024|NCT03689465|Active Comparator|ATG group|ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).
16442025|NCT03689452|Placebo Comparator|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
16442026|NCT03689452|Experimental|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
16442027|NCT03689413|Experimental|1 mg/kg|"For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.
~We will use Sugammadex 200 MG in 2 ML Injection for this."
16442028|NCT03689413|Active Comparator|2 mg/kg|"For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.
~We will use Sugammadex 200 MG in 2 ML Injection for this."
16442029|NCT03689374|Experimental|Semaglutide|"Run-in period (12 weeks): subjects will be treated with metformin and insulin glargine (IGlar) U100.
~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in will receive semaglutide for 52 weeks in addition to metformin and IGlar U100.
~Metformin will be considered as background therapy during the trial."
16442030|NCT03689374|Active Comparator|Insulin aspart|"Run-in period (12 weeks): subjects will be treated with metformin and insulin IGlar U100.
~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in receive insulin aspart for 52 weeks in addition to metformin and IGlar U100.
~Metformin will be considered as background therapy during the trial."
16442031|NCT03689361|Other|with migraine aura.|patient with migraine aura detected by MRI, then MRI control 3 month after
16442032|NCT03689361|Other|without migraine aura|patient without migraine aura detected by MRI, then telephone consultation 3 month after
16442033|NCT03689348|Placebo Comparator|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
16442034|NCT03689348|Experimental|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
16442035|NCT03689348|Experimental|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
16442036|NCT03689348|Experimental|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
16442037|NCT03689335|Active Comparator|Operative|Surgical fixation of the humeral shaft fracture
16442038|NCT03689335|Active Comparator|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
16442040|NCT03689322|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
16442041|NCT03689322|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
16442042|NCT03689309|No Intervention|1. Classic SBT (C-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but oxygen delivered through a heat humidifier filter that is usually connected on tracheotomy.
16442043|NCT03689309|Experimental|2. High Flow Oxygen SBT (HFO-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
16442044|NCT03689296||Users|Person with a long-term mental disorder
16442045|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
16442046|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
16442047|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
16442048|NCT03689283|Experimental|Dry Needling Group|Individuals in the DN arm will receive two treatment sessions of DN to latent trigger points of the gastrocnemius muscle.
16442049|NCT03689283|Sham Comparator|Control Group|Individuals in the control group will receive two treatment sessions of sham dry needling.
16442050|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
16442051|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
16442052|NCT03689244|Experimental|Selexipag DB|During the double blind treatment period, subjects in this group will receive selexipag. Each subject will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
16442053|NCT03689244|Placebo Comparator|Placebo DB|During the double-blind treatment period, subjects in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
16442054|NCT03689244|Experimental|Selexipag OL|All subjects who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
16442055|NCT03689218|No Intervention|Control|The control arm will receive routine public and private health services available in the area.
16442056|NCT03689218|Experimental|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
16442057|NCT03689205||Patients that BMI> 30kg / m2 (Group A)|Venous puncture pain on patients that Body mass index > 30kg / m2
16442058|NCT03689205||Patients that BMI< 30kg / m2 (Group B)|Venous puncture pain on patients that Body mass index < 30kg / m2
16442059|NCT03689192|Experimental|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
16442060|NCT03689179|Experimental|Treatment with Follow-up (Group A)|"After an initial orientation/control period (4 weeks), group A will receive access to the Time for Living & Caring (TLC) intervention for 8 weeks, followed by an optional 8-week control period where they can continue to use the TLC intervention if they choose."
16442061|NCT03689179|Experimental|Wait-List Control w/Treatment (Group B)|"After the initial 4-week orientation period, Group B will receive 8 weeks of waitlist (no treatment) control, followed by access to the Time for Living & Caring (TLC) intervention for 8 weeks."
16442062|NCT03689166|Active Comparator|Probiotics group|Probiotic drug
16442063|NCT03689166|Placebo Comparator|Control group|This group will receive placebo
16442064|NCT03689153|Experimental|Cohort 1: JNJ-63733657 or Placebo|Participants will receive a single intravenous (IV) low dose of JNJ-63733657 or matching placebo.
16442065|NCT03689153|Experimental|Cohort 2: JNJ-63733657 or Placebo|Participants will receive a single IV middle dose of JNJ-63733657 or matching placebo.
16442066|NCT03689153|Experimental|Cohort 3: JNJ-63733657 or Placebo|Participants will receive a single IV high dose of JNJ-63733657 or matching placebo.
16442067|NCT03689140|Experimental|App-only|The intervention will consist of participants will only use a smoking cessation app
16442068|NCT03689140|Experimental|Telemedicine counseling only|The intervention will consist of participants will only use telemedicine counseling
16442069|NCT03689140|Experimental|App + telemedicine counseling|The intervention will consist of participants will only use a smoking cessation app + telemedicine counseling
16442070|NCT03689140|No Intervention|Usual Care|The participants will continue with usual care
16442071|NCT03689127|Active Comparator|Control|Heated breathing circuit will be turned off.
16442072|NCT03689127|Experimental|Heat|Heated breathing circuit will be turned on.
16442073|NCT03689114|Experimental|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
16442106|NCT03688906||Cohort A|"Blood and stool specimen collection.
~Study samples must be collected prior to any treatment."
16442107|NCT03688906||Cohort B|"Blood and stool specimen collection.
~Samples must be collected prior to performing bowel preparation for the colonoscopy."
16442108|NCT03688906||Cohort C|"Blood and stool specimen collection.
~Study samples must be collected prior to any treatment."
16442282|NCT03687554|Experimental|Venglustat|Single dose of Venglustat is given, orally under fasting conditions
16442074|NCT03689114|Active Comparator|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
16442075|NCT03689101|Experimental|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
16442076|NCT03689088|Experimental|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
16442077|NCT03689088|Active Comparator|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
16442078|NCT03689075|No Intervention|Immediate release tacrolimus|Patients will continue on immediate release tacrolimus
16442079|NCT03689075|Active Comparator|Extended release tacrolimus|
16442080|NCT03689062|Active Comparator|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
16442081|NCT03689062|Experimental|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
16442082|NCT03689049|Experimental|SPIDER|QI Learning Collaboratives.
16442083|NCT03689049|Placebo Comparator|Usual Care|Standard primary care.
16442084|NCT03689023|Experimental|A controlled multimodal intervention|A uniform and systematic patient education about cardiovascular risk factors, physical activity and a healthy diet lifestyle starting early in the primary rehabilitation process with 6 months of follow up.
16442085|NCT03689010|Active Comparator|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
16442086|NCT03689010|Active Comparator|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
16442087|NCT03689010|Placebo Comparator|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
16442088|NCT03688997|Experimental|Experts|"For the novice group, the investigators recruited 30 residents within their first year of surgical residency (Post-Graduate Year [PGY]-1) in general surgery, vascular surgery, plastic surgery, orthopedic surgery, cardio-thoracic surgery, gynecology and urology.
~The intervention administered was the use of a simulator by the participants."
16442089|NCT03688997|Experimental|Novice|"The expert's group included 15 attending surgical faculty members in the general surgery, vascular surgery, cardio-thoracic surgery and gynecology services.
~The intervention administered was the use of a simulator by the participants."
16442090|NCT03688984|Experimental|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
16442091|NCT03688984|No Intervention|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
16442092|NCT03688971|Experimental|Omiganan Topical Gel|Omiganan 1.75%
16442093|NCT03688971|Active Comparator|Ketoconazole Topical Cream|Ketoconazole 2.0%
16442094|NCT03688971|Placebo Comparator|Vehicle|
16442095|NCT03688958|Placebo Comparator|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.
~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
16442096|NCT03688958|Experimental|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
16442097|NCT03688958|Placebo Comparator|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.
~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
16442098|NCT03688958|Experimental|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.
~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
16442099|NCT03688945|Experimental|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
16442100|NCT03688945|Active Comparator|Arm II (standard of care)|Participants receive standard of care for 2 years.
16442101|NCT03688932|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
16442102|NCT03688932|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
16442103|NCT03688932|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
16442104|NCT03688919|No Intervention|Comparison|Adolescents and their families in this group will not receive any of the interventions.
16442105|NCT03688919|Experimental|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
16442592|NCT03685565|Experimental|Dermabond with underlying steristrips|
16442109|NCT03688893|Experimental|Laser Application|35% Hydrogen Peroxide (Whitening HP, FGM SC Brazil) 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes Laser Application and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. Experimental
16442110|NCT03688893|No Intervention|No Laser Application|35% Hydrogen Peroxide (Whitening HP FGM SC Brazil), 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes waiting and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. No Laser Application No Intervention
16442111|NCT03688880|Active Comparator|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
16442112|NCT03688880|Experimental|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
16442113|NCT03688867|Experimental|At-home prehabilitation regimen|"Grip strength: Squeeze a stress ball in your hand, holding it squeezed for 5 seconds. Perform this at least thirty times with each hand over the course of a day.
~Lower body strength: Perform at least one hundred chair sit-stands in a day.
~Endurance: Walking at least 7,500 steps in a day."
16442114|NCT03688854|Placebo Comparator|Placebo|Placebo are capsules containing cellulose.
16442115|NCT03688854|Experimental|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
16442116|NCT03688854|Experimental|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
16442117|NCT03688841|Experimental|Bridged V.A.C.® with compression therapy|A vacuum assisted closure device will be placed on the ulcer. A compression dressing will be placed over the V.A.C.® device
16442118|NCT03688841|Active Comparator|Conventional compression therapy|A Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings will be applied and changed once to three times per week (dependant on exudate).
16442121|NCT03688815||Patients with ischemic heart disease|Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
16442122|NCT03688802|Active Comparator|OC-01|
16442123|NCT03688802|Placebo Comparator|Placebo|
16442124|NCT03688789|Experimental|Hydrocortisone supplementation|
16442125|NCT03688776|Experimental|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
16442126|NCT03688776|Experimental|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
16442127|NCT03688763|Other|Digital CBTi administered|Participants will receive 6 sessions of digitally administered CBTi using the Sleepio platform over the course of 12 weeks. Each session lasts on average 30-60 minutes, and is tailored to participant's progress and problems. During the treatment phase, between sessions, participants complete the Consensus Sleep Diary to track their progress.
16442128|NCT03688737|Placebo Comparator|control group|"A) Control group:
~Has Surgical procedures von Langenbeck technique  to repair cleft palate and will come for follow up visit at day of surgery, 1st day and 3rd day for placebo device like LLL and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
16442129|NCT03688737|Active Comparator|study group|"B) Study group:
~This group will be subjected to the same surgical procedure von Langenbeck technique to repair cleft palate but low level laser Therapy will be at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
16442130|NCT03688711|Experimental|Dasiglucagon|single fixed dose (subcutaneous injection) of dasiglucagon
16442131|NCT03688711|Placebo Comparator|Placebo|single fixed dose (subcutaneous injection) of placebo
16442132|NCT03688698||PAH|
16442133|NCT03688698||Controls|
16442134|NCT03688685|Experimental|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
16442135|NCT03688672|Other|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
16442136|NCT03688659|Other|vancomycin,gentamycin in endocarditis|patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks
16442137|NCT03688646|Experimental|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
16442138|NCT03688646|No Intervention|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
16442139|NCT03688633|Experimental|Candesartan|
16442140|NCT03688633|Active Comparator|Usual care|
16442141|NCT03688620|Other|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
16442142|NCT03688620|Other|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
16442222|NCT03687983|Experimental|Intervention arm|Participants will be treated with GoldenFlow Peripheral Stent System.
16442593|NCT03685565|Active Comparator|Dermabond|
16442143|NCT03688620|Other|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
16442144|NCT03688607||POKE|All babies in NICU at Intermountain Healthcare hospitals
16442145|NCT03688594|Experimental|couple : man and pregnant women|
16442146|NCT03688568|Experimental|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
16442147|NCT03688555|Experimental|ACT-774312|Subjects will receive ACT-774312 400 mg b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.
16442148|NCT03688555|Placebo Comparator|Placebo|Subjects will receive placebo b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.
16442149|NCT03688542|Experimental|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
16442150|NCT03688542|No Intervention|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
16442151|NCT03688516|Experimental|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
16442152|NCT03688516|Sham Comparator|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
16442153|NCT03688503|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
16442154|NCT03688503|Placebo Comparator|placebo|placebo supplement
16442155|NCT03688477|Experimental|iovera°|Patients will receive iovera° prior to stand of care ACL
16442156|NCT03688477|No Intervention|Standard of Care|Patients will receive standard of care ACL procedure without iovera° treatment.
16442157|NCT03688464|Active Comparator|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
16442158|NCT03688464|Active Comparator|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
16442159|NCT03688464|Placebo Comparator|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
16442160|NCT03688451|Experimental|Intrathecal rituximab|Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5
16442161|NCT03688438|No Intervention|Standard of Care|Standard of care wound closure and dressing No active interventions
16442162|NCT03688438|Experimental|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
16442163|NCT03688425|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
16442164|NCT03688425|Active Comparator|IOL implantation active comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
16442165|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
16442166|NCT03688399|Experimental|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
16442167|NCT03688399|Active Comparator|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
16442168|NCT03688386|Experimental|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback
~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
16442169|NCT03688386|Active Comparator|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings
~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
16442170|NCT03688373|Experimental|Exposure-in-big-steps|In the big steps exposure sessions the adolescent moves in three a set pace of big steps from bottom to top (1-5-10) in their fear hierarchy. From 0-5 in the first session and from 5-10 in the second session.
16442223|NCT03687970|Experimental|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
16442171|NCT03688373|Experimental|Exposure-in-small-steps|In the small steps exposure sessions the adolescent moves in a step-by-step pace of their own choice from bottom to top in their fear hierarchy, for example from 1 to 2 to 3 to in the first session and from 4 to 5 to 6 etc. in the second session.
16442172|NCT03688360|Experimental|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
16442173|NCT03688360|Experimental|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
16442174|NCT03688360|Experimental|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
16442175|NCT03688334|Active Comparator|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
16442176|NCT03688334|Sham Comparator|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
16442177|NCT03688321|Active Comparator|Probiotic capsule GR-1 and RC-14|The intervention for study group is taking 2 capsules containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
16442178|NCT03688321|Placebo Comparator|Placebo capsule|The intervention for placebo group is taking 2 capsules not containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
16442179|NCT03688308|Experimental|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
16442180|NCT03688308|Active Comparator|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
16442181|NCT03688295|Other|experimental group|no antibiotherapy post surgery for complicated acute appendicitis (CAA)
16442182|NCT03688295|Active Comparator|control group|antibiotherapy post surgery for complicated acute appendicitis (CAA)
16442183|NCT03688282|Sham Comparator|Sham Wearable belt|Device will be worn but not turned on for 30 minutes.
16442184|NCT03688282|Experimental|Wearable vibration belt (30)|Device will be worn and turned on for 30 minute treatment.
16442185|NCT03688269|Experimental|Intravenous dexamethasone|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.
~Intravenous injection of 8mg/2ml Dexamethasone during the regional anesthesia"
16442186|NCT03688269|Placebo Comparator|Intravenous saline|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.
~Intravenous injection of 2ml Saline 0.9% during the regional anesthesia"
16442187|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
16442188|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
16442189|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
16442190|NCT03688230|Experimental|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:
~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
~(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min
~(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
16442191|NCT03688230|Placebo Comparator|Placebo + Cetuximab + FOLFIRI|"Cetuximab:
~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
~(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min
~(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
16442192|NCT03688217|Experimental|Philani Intervention Model+MOVIE (PIM+M)|Participants will receive the standard PIM perinatal home visiting program together with the MOVIE intervention (13 entertainment-education videos about infant feeding). The PIM is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others. The MOVIE videos will be integrated into the regular home visiting program.
16442193|NCT03688217|Active Comparator|Philani Intervention Model (PIM)|Participants will receive the standard PIM perinatal home visiting program, which is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
16442194|NCT03688191|Experimental|Study Group|participants who received sirolimus treatment
16442195|NCT03688178|Experimental|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning.
16442224|NCT03687970|Active Comparator|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
16442328|NCT03687216|Active Comparator|Routing group|Routing therapy (EVL plus NSBB)
16442196|NCT03688178|Experimental|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
16442197|NCT03688178|Experimental|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (IV) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side.
16442198|NCT03688165||Treadmill-based Robotic Gait Training|The Treadmill-based Robotic Gait Training (TRGT) period will last 20 sessions, 3-5 days/week for at least 400' of exercise totally. The parameters to be respected for the robotic training will be the following for all patients: 0.9 km / h starting speed up to a maximum of 2.5 km / h; weight support not exceeding 40-45% of the body weight at the beginning and gradual progressive reduction depending on the case; for Lokomat: maximum assistance required at the start of treatment and gradual decrease during the treatment. The TRGT will always be associated with the traditional gait rehabilitation, and will be part of the Individual Rehabilitation Project which normally includes 3 hours of rehabilitation treatments for patients in the subacute phase, 60' of treatment for those in chronic phase.
16442199|NCT03688165||Traditional Over-ground Gait Training|"The Traditional Over-ground Gait Training (TOGT) period will last 20 sessions, 3-5 days / week for a total time that corresponds to the same total time of traditional overground gait training, or at least 400' totally at the end of the period.
~By Traditional Therapy we mean any technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids."
16442200|NCT03688152|Experimental|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
16442201|NCT03688139|Experimental|Engage Therapy|Participants receive Engage therapy for 9 weeks.
16442202|NCT03688139|Active Comparator|Supportive Therapy|Participants receive supportive therapy for 9 weeks.
16442203|NCT03688126|Experimental|Self-Guided Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
16442204|NCT03688126|Experimental|Structured Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
16442205|NCT03688113|Experimental|Treatment|
16442206|NCT03688113|Other|Wait list|
16442209|NCT03688087|Placebo Comparator|placebo|"Smartphone application placebo"
16442210|NCT03688087|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
16442211|NCT03688074|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
16442212|NCT03688074|Placebo Comparator|Placebo|Placebo subcutaneous injection
16442213|NCT03688061|Experimental|Group 1 (low dose/healthy volunteers)|5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10*7 pfu) IM at week 8
16442214|NCT03688061|Experimental|Group 2 (higher dose/healthy volunteers)|10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10*8 pfu) IM at week 8
16442215|NCT03688061|Experimental|Group 3 (higher dose/HCV cured volunteers)|10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10*8 pfu) IM at week 8
16442216|NCT03688048|Experimental|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
16442217|NCT03688048|Placebo Comparator|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
16442218|NCT03688022|Experimental|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
16442219|NCT03688022|Experimental|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
16442220|NCT03688009|Experimental|Mindfulness-Based Family Psycho-Education (MBFBE)|A programme focuses on non-judgmental attitudes, collaborative inquiry and self-care, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
16442221|NCT03688009|Active Comparator|Family Psycho-Education (FPE)|A programme focuses on information giving, problem-solving and mutual support, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
16442398|NCT03686735||Satisfaction measure 4|25% of the cohort
16442228|NCT03687931|Experimental|Arm 1|Dexamethasone suspension dose level 1
16442229|NCT03687931|Experimental|Arm 2|Dexamethasone suspension dose level 2
16442230|NCT03687905||Lupus nephritis III or IV/chloroquine|receiving chloroquine with daily dose 5 mg/kg
16442231|NCT03687905||Lupus nephritis III or IV/hydroxychloroquine|receiving hydroxycholorquine with daily dose 5 mg/kg
16442232|NCT03687905||Systemic lupus erythematosus|not received hydroxychloroquine nor chloroquine .
16442233|NCT03687892|Experimental|continuous Theta Burst Stimulation|The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
16442234|NCT03687892|Experimental|intermittent Theta Burst Stimulation|The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
16442235|NCT03687853|Experimental|Intrahepatic Arterial Infusion chemotherapy|chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.
16442236|NCT03687853|No Intervention|control|chemotherapy through Peripheral venous is one of the regularly used method.
16442237|NCT03687840|Other|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
16442238|NCT03687840|Other|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
16442239|NCT03687827|Experimental|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
16442240|NCT03687827|Active Comparator|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
16442241|NCT03687814|Experimental|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
16442242|NCT03687814|Sham Comparator|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
16442243|NCT03687801|Experimental|Online hearing support|The intervention group will have access to online hearing support for five weeks. The online hearing support will include a program that consists of three elements: 1) reading material; 2) reading instructions and weekly assignments related to the reading material; and 3) online and telephone interaction with a professional.
16442244|NCT03687801|Active Comparator|Standard care|"The control group will have access to traditional support that the Hearing Organization provides (standard care)."
16442245|NCT03687788|Experimental|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
16442246|NCT03687788|No Intervention|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
16442247|NCT03687775||DSG-Stabi|The group consists of patients with primary trapeziometacarpal osteoarthritis and an indication for trapeziectomy alone or in combination with the resection-suspension-interposition arthroplasty.
16442248|NCT03687762|Active Comparator|Cognitive Therapy (CT) Condition|"Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
16442279|NCT03687580|Sham Comparator|Sham laser|Subjects from the Sham laser group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
16442280|NCT03687567||HBA|alpha-Thalassemia
16442281|NCT03687567||HBB|beta-Thalassemia
16442249|NCT03687762|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
16442250|NCT03687762|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
16442251|NCT03687749||Women with breast cancer-related lymphedema|Individuals with upper limb lymphedema developed after breast cancer treatment
16442252|NCT03687749||Healthy control subjects|Healthy individuals without breast cancer-related lymphoedema.
16442253|NCT03687736|Other|AbobotulinumtoxinA|Open-label
16442254|NCT03687697|Experimental|Global vs. G-TL Media|Global medium will be compared with G-TL (Time-Lapse) medium.
16442255|NCT03687697|Experimental|Global vs. Cornell's C3 Media|Global medium will be compared with Cornell's C3 single step medium.
16442256|NCT03687697|Experimental|Global vs. Cornell's sequential Media|Global medium will be compared with Cornell's C1/C2 sequential medium.
16442257|NCT03687684|Experimental|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
16442258|NCT03687684|Experimental|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
16442259|NCT03687684|Experimental|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
16442260|NCT03687684|Experimental|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
16442261|NCT03687684|Experimental|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
16442262|NCT03687684|Experimental|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
16442263|NCT03687684|Experimental|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
16442264|NCT03687671|Experimental|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
16442265|NCT03687671|Active Comparator|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
16442266|NCT03687658|Experimental|Binge Eating Group|All participants in the study will be invited to use Laddr, described in the intervention section.
16442267|NCT03687658|Experimental|Smoking Group|All participants in the study will be invited to use Laddr, described in the intervention section.
16442268|NCT03687645|Experimental|Prostate Cancer|Patients with biopsy-proven prostate cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
16442269|NCT03687645|Experimental|Renal Cancer|Patients with biopsy-proven renal cell carcinoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
16442270|NCT03687645|Experimental|Breast Cancer|Patients with biopsy-proven breast cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
16442271|NCT03687645|Experimental|Lymphoma|Patients with biopsy-proven lymphoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
16442272|NCT03687632|Experimental|Single arm - active|ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
16442273|NCT03687619|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a top-down approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
16442274|NCT03687619|Experimental|Conductive Education|Conductive Education is a down-top approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
16442275|NCT03687606|Active Comparator|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for 3 years.
16442276|NCT03687606|Experimental|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for six months, then 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
16442277|NCT03687606|Experimental|hCG and hMG|Human Chorionic Gonadotropin 2000U~6000U and 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
16442278|NCT03687580|Experimental|B-Cure Laser Pro|Subjects from the B-Cure Laser Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
16442284|NCT03687515|Experimental|budesonide inhalation suspension|
16442285|NCT03687515|Active Comparator|budesonide aqueous nasal spray|
16442286|NCT03687515|Active Comparator|oral steroids|
16442287|NCT03687502|Experimental|Experimental|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, up to 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
16442288|NCT03687489|Experimental|Intervention arm|Participants will be treated with Abdominal Aortic Aneurysm Stent Graft System
16442289|NCT03687476|Experimental|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
16442290|NCT03687476|Experimental|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
16442291|NCT03687450|Experimental|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
16442292|NCT03687450|No Intervention|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
16442293|NCT03687424|Active Comparator|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16442294|NCT03687424|Active Comparator|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16442295|NCT03687424|Active Comparator|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16442296|NCT03687424|Experimental|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16442297|NCT03687424|Experimental|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16442298|NCT03687424|Experimental|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16442299|NCT03687411|Experimental|ULTRA-SINE (phases 1-4)|"There will be four phases in this proposed uSINE system. In first phase attending anaesthetist will use the automated spinal landmark system for neuraxial needle insertion to place the neuraxial anaesthesia in non-obese patients.
~For the second phase, obese patients will have ultrasound scan of their lumbar back and no needle insertion is involved.
~In third phase, conventional ultrasonography is used prior to the needle insertion, and needle insertion is conducted manually as per routine practice. The images collected in the system will be used for annotation and evaluation which serves as training material for uSINE to optimize its algorithm to improve landmark identification for obese patients. The fourth phase will have uSINE system used prior to the needle insertion, with the neuraxial needle insertion conducted manually as per routine practice. The identification accuracy and first-attempt puncture success rate of uSINE will be determined."
16442300|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
16442301|NCT03687398||patient|has laparoscopically proven endometriosis
16442302|NCT03687385|Active Comparator|ASA I / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16442303|NCT03687385|Active Comparator|ASA II / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16442304|NCT03687385|Active Comparator|ASA III / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
16442305|NCT03687385|Experimental|ASA I / HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16442306|NCT03687385|Experimental|ASA II/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16442307|NCT03687385|Experimental|ASA III/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
16442308|NCT03687372|Experimental|A-101|topical solution
16442309|NCT03687372|Other|Vehicle|topical solution
16442310|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
16442311|NCT03687346||High Risk Group|Parental history of eating pathology
16442312|NCT03687346||Low Risk Group|No parental history of eating pathology
16442313|NCT03687333|Experimental|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
16442314|NCT03687320|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
16442315|NCT03687320|Sham Comparator|Standard and Sham|Subjects from the Standard and sham group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
16442316|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
16442317|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
16442318|NCT03687281||Male patients living with HIV and having sex with men|Male patients living with HIV and having sex with men followed at Universitary Hospital Center of Reunion Island
16442319|NCT03687268|Placebo Comparator|Placebo|
16442320|NCT03687268|Experimental|Naloxone 24 mg|
16442321|NCT03687268|Experimental|Naloxone 48 mg|
16442322|NCT03687255|Experimental|cefepime/AAI101 combination|Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)
16442323|NCT03687255|Active Comparator|piperacillin/tazobactam|Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)
16442324|NCT03687242|Experimental|SPR001|SPR001 at Dose A
16442325|NCT03687229||Patient|"Chronic HCV patients before treatment & 3 months after starting of treatment. not known to be:
~Cirrhosis
~Diabetes Mellitus.
~Hemochromatosis
~HBV
~HIV.
~Hepatocellular carcinoma (HCC)
~Chemotherapy
~Organ transplantation"
16442326|NCT03687229||Control|Apparently healthy individuals
16442327|NCT03687216|Experimental|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
16442329|NCT03687190|Experimental|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
16442330|NCT03687190|Active Comparator|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
16442331|NCT03687177|Other|Control group|Nurses from intensive care informed on the prevention of VAP and without visual cue to estimate the angle of elevation of the head of intubated patients
16442332|NCT03687177|Other|Experimental group|Nurses from intensive care informed on the prevention of VAP with visual cue to estimate the angle of elevation of the head of intubated patients.
16442333|NCT03687164|Experimental|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
16442334|NCT03687164|No Intervention|Usual Care|Usual clinical office visits
16442335|NCT03687151||patients with a diagnosis of invasive or in situ cancer|patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005
16442336|NCT03687138||Control 1|This is the control population. The analysis will be done with a 24h urin sample. We will compare this population with the other two.
16442337|NCT03687138||Control 2|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
16442338|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the other two controls populations.
16442339|NCT03687125|Experimental|Tinostamustine 180 mg/m^2|Participants received single dose of tinostamustine 180 milligrams per meter square (mg/m^2) intravenous (IV) injection on Day -1 followed by autologous stem cell transplantation (ASCT) on Day 1.
16442340|NCT03687125|Experimental|Tinostamustine 220 mg/m^2|Participants received single dose of tinostamustine 220 mg/m^2 IV injection on Day -1 followed by ASCT on Day 1.
16442341|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
16442342|NCT03687086|Experimental|Program A|cognitive behavioral therapy type A plus medications in packaging type A
16442343|NCT03687086|Active Comparator|Program B|cognitive behavioral therapy type B plus medications in packaging type B
16442344|NCT03687073|Experimental|Single-dose PK study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
16442345|NCT03687073|Experimental|Multi-dose PK Study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
16442346|NCT03687073|Experimental|Safety Study|Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.
16442347|NCT03687073|Experimental|Cohort 4 PD Study|The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.
16442348|NCT03687060|Other|Organization Level|
16442349|NCT03687060|Other|Provider Level|
16442350|NCT03687060|Other|Patient Level|
16442351|NCT03687047|Experimental|New complete dentures|"Steps: 1) Preliminary impressions will be done using stock trays and impression compound; 2) primary casts will be fabricated to make custom trays for definitive impressions; 3) definitive impressions will be made using zinc oxide eugenol impression paste;4) definitive impressions will be poured with type III dental stone to obtain mastercasts; 5)jaw relations will be recorded, and the casts will be mounted on the articulator; 6) the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up. After denture insertion, post-denture insertion instructions such as oral hygiene will be explained to the patients.
~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and at 3, 6, 9, 12 and 18 months after treatment."
16442352|NCT03687034|Experimental|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
16442353|NCT03687021|No Intervention|endometriosis|tissue biopsy from patients (n=10) with endometriosis
16442354|NCT03687021|No Intervention|without endometriosis|tissue biopsy from patients (n=10) without endometriosis
16442355|NCT03687021|Experimental|Intramuscular progesterone|Intramuscular progestin(20mg)
16442356|NCT03687021|Experimental|vaginal progesterone|vaginal progestin (90mg)
16442357|NCT03687021|Experimental|oral progesterone|oral progestin(40mg)
16442358|NCT03687008|Experimental|Adolescents with SVHD|All adolescents will receive the intervention Cogmed. This is an in home, computer based, cognitive intervention to improve working memory, supervised by trained coaches, [25 sessions, each 30-45 minutes, 5 days a week / 5 week duration].
16442359|NCT03686982|Experimental|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
16442360|NCT03686982|Placebo Comparator|Placebo Bar|Containing no active ingredients
16442361|NCT03686969|Experimental|Octanorm|0.5g/kg/week octanorm 16.5%
16442362|NCT03686969|Placebo Comparator|Placebo|Placebo
16442399|NCT03686722|Active Comparator|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
16442363|NCT03686956|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
16442364|NCT03686956|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
16442365|NCT03686943||Elderly|Patient over 75 years seen with the mobile extra hospital geriatric team
16442366|NCT03686930|Active Comparator|Cohort 1 - FP-045 oral solution|FP-045 powder for oral solution, will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
16442367|NCT03686930|Placebo Comparator|Cohort 1 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
16442368|NCT03686930|Active Comparator|Cohort 2 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
16442369|NCT03686930|Placebo Comparator|Cohort 2 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
16442370|NCT03686930|Active Comparator|Cohort 3 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
16442371|NCT03686930|Placebo Comparator|Cohort 3 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
16442372|NCT03686917||CHAT-P|Survey
16442373|NCT03686904|Placebo Comparator|SOC GROUP [Cohort A]|Debridement, SOC irrigation & SOC topical gel
16442374|NCT03686904|Active Comparator|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation & SOC topical gel
16442375|NCT03686904|Active Comparator|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation & benzalkonium gel
16442376|NCT03686904|Active Comparator|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation & benzalkonium gel
16442377|NCT03686878|Experimental|Intervention Group|Lifitegrast 5% ophthalmic solution group
16442378|NCT03686865||dental implants|
16442379|NCT03686852|Active Comparator|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
16442380|NCT03686852|Active Comparator|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
16442381|NCT03686852|Active Comparator|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
16442382|NCT03686839|Experimental|SMR neurofeedback training to MCI|"Sensorimotor rhythm neurofeedback protocol consisted of 20 individual sessions, twice a week, during 11 weeks maximum. For each subject MCI, NF was planned and conducted by a neuropsychologist experienced in neurophysiology and neurofeedback. Each session lasted 1h10-15min and was conducted as follows:
~Preparation and installation of the electrodes, verification of the impedance, adjustment of the calibration and thresholds (15 minutes).
~NF training (tasks and video described below) (45 minutes).
~Feedback and debriefing about the session (15 minutes)."
16442383|NCT03686826||multiple sclerosis patients|
16442384|NCT03686826||healthy volunteers|
16442385|NCT03686813|Placebo Comparator|Placebo|Each participant will be studied with active drug and placebo.
16442386|NCT03686813|Active Comparator|Sildenafil|Sildenafil 50 mg orally one hour (once) before immersed exercise
16442387|NCT03686800|Experimental|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
16442388|NCT03686774|Experimental|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
16442389|NCT03686774|Other|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
16442390|NCT03686761|Experimental|Study|A Involvement with the osteotomy site of the surgery, osteotomy was performed then GCF were collected from teeth neighboring the
16442391|NCT03686761|Active Comparator|Control|Involvement with the osteotomy site of the surgery, surgical osteotomy was performed then GCF were collected from teeth away from the osteotomy site
16442392|NCT03686748|Experimental|Two-point intervention|Two point discrimination training.
16442393|NCT03686748|Active Comparator|One-point intervention|One point discrimination of size of probe
16442394|NCT03686748|No Intervention|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
16442395|NCT03686735||Satisfaction measure 1|25% of the cohort
16442396|NCT03686735||Satisfaction measure 2|25% of the cohort
16442397|NCT03686735||Satisfaction measure 3|25% of the cohort
16442400|NCT03686722|Experimental|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
16442401|NCT03686709|Experimental|SIR-Spheres Therapy Selection|Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
16442402|NCT03686709|Experimental|TheraSpheres Therapy Selection|Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
16442403|NCT03686696|No Intervention|No Beta blocker and no ACEI/ARB|No Beta blocker and no ACEI/ARB
16442404|NCT03686696|Experimental|Beta blocker and ACEI/ARB|Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
16442405|NCT03686696|Experimental|Beta blocker alone|Beta blocker alone
16442406|NCT03686696|Experimental|ACEI/ARB alone|Either ACE inhibitor or Angiotensin receptor blocker alone
16442407|NCT03686683|Experimental|Treatment Group: Sipuleucel-T|Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals.
16442408|NCT03686683|No Intervention|Control Arm: Active Surveillance|Subjects randomized to the control arm will be followed on Active Surveillance described in the schedule of events.
16442409|NCT03686657|No Intervention|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
16442410|NCT03686657|Active Comparator|Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin|Patients receive metformin once daily
16442411|NCT03686657|Experimental|RK-01 Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
16442412|NCT03686657|Experimental|RK-01 High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
16442413|NCT03686644|Experimental|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
16442414|NCT03686631|No Intervention|Passive Arm|This arm uses a passive tracking device to assess the number of times a patient uses their prescribed incentive spirometer.
16442415|NCT03686631|Experimental|Smartphone Arm|This arm uses a smartphone connected device and smartphone application to remind and encourage patients to use the spirometer as well as track the number of times they utilize the spirometer.
16442416|NCT03686618|No Intervention|Cohort X|no secretin administered. All observations
16442417|NCT03686618|Active Comparator|Cohort 1|32 mcg (<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
16442418|NCT03686618|Active Comparator|Cohort 2|32 mcg (<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
16442419|NCT03686618|Active Comparator|Cohort 3|32 mcg (<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
16442420|NCT03686605||Cancer pain patients|
16442421|NCT03686592|Experimental|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
16442422|NCT03686592|Active Comparator|Volunteers|
16442423|NCT03686579||chest trauma|"Early detection and diagnosis of associated thoracic injuries .
~decrease of costs required for investigations . 3- sensitivity and specificity of the investigations"
16442424|NCT03686566||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
16442425|NCT03686566||No 13C-glucose infusion|Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
16442426|NCT03686553||infected, with SSI|patients with SSI
16442427|NCT03686553||non-infected|patients without SSI
16442428|NCT03686527||Echocardiography|
16442429|NCT03686527||MRI Fibrosis|
16442430|NCT03686514|Experimental|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
16442431|NCT03686514|Experimental|H1N1 birth cohort|The H1N1 cohort consist of participants born between 1948-1957.
16442432|NCT03686501|Experimental|PF-06412562|To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.
16442433|NCT03686488|Experimental|TAS 102 and Ramucirumab|TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.
16442434|NCT03686475|Experimental|Biodentine pulpotomy|Biodentine (Septodont, France) Pulpotomy for primary molars Clinical and radiographic evaluation Follow up at 1,3,6 and 12 months
16442435|NCT03686475|Active Comparator|MTA pulpotomy|"MTA (Angelus- Londrina, Brazil) Pulpotomy for primary molars . it is fine hydrophilic powder consisting of tricalcium silicate, tricalicum aluminate, tricalcium oxide, silicate oxide and bismuth oxide11.
~It is currently being used in pulpotomy of primary molars with a high rate of success.
~Clinical and radiographic evaluation. Follow up at 1,3,6 and 12 months"
16442436|NCT03686462|Experimental|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
16442437|NCT03686462|Sham Comparator|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
16442438|NCT03686449|Experimental|study group 1|Non-cultured Autologous Keratinocyte Suspension
16442439|NCT03686449|Experimental|study group 2|Adipose-Derived Stem cell-Keratinocyte Suspension
16442440|NCT03686449|Active Comparator|Control group|Split skin graft
16442441|NCT03686410|Experimental|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.
~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
16442442|NCT03686410|Active Comparator|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
16442443|NCT03686397|Experimental|SVT-15652|1 vial twice daily
16442444|NCT03686397|Placebo Comparator|Placebo|1 vial twice daily
16442445|NCT03686384|Experimental|SVT-15652|1 vial twice daily
16442446|NCT03686384|Placebo Comparator|Placebo|1 vial twice daily
16442447|NCT03686345|Experimental|Core binding factor acute myeloid leukemia (CBF-AML)|Patients must have an unequivocal diagnosis of de novo-CBFL, prior to start midostaurin, documented by rearrangement of Core Binding Factor (CBF) genes, namely AML1-ETO and CBFB-MYH11. The experimental arm involves the administration of Midostaurin orally 50 mg (two 25 mg tablets) twice a day, from the end of induction chemotherapy, for 14 days. Patients should take Midostaurin at approximately 12 hours intervals. During all consolidation cycles, Midostaurin 50 mg (two 25 mg tablets) is administered orally twice a day, on days 8-21. Patients in complete remission after 3 cycles of remission consolidation therapy, will receive Midostaurin continuation therapy for 12 months. Midostaurin 50 mg (two 25 mg tablets) will be given orally twice a day for 12 months.
16442448|NCT03686332|Other|Arm A: Atezolizumab and Radiotherapy|"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.
~Drug: Arm A: Atezolizumab and Radiotherapy
~Atezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation."
16442449|NCT03686332|Other|Arm B: Atezolizumab|Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
16442450|NCT03686319|No Intervention|control groups|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).
~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
16442451|NCT03686319|Experimental|"intervention (foot reflexology)"|Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
16442452|NCT03686306|Experimental|Experimental group|Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks.
16442453|NCT03686306|Placebo Comparator|Control group|Placebo (single morning oral dose) for a total duration of 24 weeks.
16442454|NCT03686293|Experimental|Paracetamol and breakfast|One tablet of paracetamol (500 mg) and a standardized breakfast will be consumed within 15 minutes one morning upon 10 hours of fasting
16442455|NCT03686280|Experimental|Robot in combination with traditional reeducation|
16442456|NCT03686280|Active Comparator|Standard rehabilitation|
16442457|NCT03686267|Experimental|intervention (I1)|Lithium disilicate crowns over titanium abutments covered by a layer of opaque porcelain
16442458|NCT03686267|Experimental|Intervention (I2)|Lithium disilicate crowns over titanium abutments covered by lithium disilicate (high opacity) coping
16442459|NCT03686267|Active Comparator|Lithium disilicate crowns over uncovered titanium abutments|Lithium disilicate crowns over uncovered titanium abutments directly without masking
16442460|NCT03686254|Active Comparator|The control Arm|bevacizumab and second-line chemotherapy
16442461|NCT03686254|Experimental|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
16442462|NCT03686228|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb and Aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
16442463|NCT03686228|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
16442466|NCT03686202|Experimental|Group A: Safety Cohort|Subjects with advanced solid tumors already on ICI will receive treatment with MET-4 in addition to SOC ICI. MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until unacceptable toxicity, progression of disease
16442540|NCT03685786|Experimental|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
16442541|NCT03685773|Experimental|MRI: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
16442467|NCT03686202|Experimental|Group B|Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
16442468|NCT03686202|Experimental|Group C|In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
16442469|NCT03686189|Experimental|Intervention arm|Participants will be treated with Iliac Bifurcation Stent Graft System
16442470|NCT03686176|Experimental|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
16442471|NCT03686176|No Intervention|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
16442472|NCT03686176|No Intervention|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
16442473|NCT03686163|Experimental|IN-NGF group|Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly
16442474|NCT03686163|Placebo Comparator|Control group|Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly
16442475|NCT03686150|Experimental|Part 1, Cohort 1 Vitamin D3 oral regimen|Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
16442476|NCT03686150|Experimental|Part 1, Cohort 2 Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
16442477|NCT03686150|Experimental|Part 1, Cohort 3 Vitamin D3 oral regimen|Vitamin D: 6000 IU daily dose
16442478|NCT03686150|Active Comparator|Part 1, Cohort 4 Vitamin D3 oral regimen|Vitamin D: 600 IU daily dose
16442479|NCT03686150|Experimental|Part 2, Cohort A Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
16442480|NCT03686150|Active Comparator|Part 2, Cohort B Vitamin D oral regimen|Vitamin D: 600 IU daily dose
16442481|NCT03686137||Institut Paoli-Calmettes patients undergoing liver surgery|
16442482|NCT03686124|Experimental|Dose Escalation|Dose escalation of IMA203
16442483|NCT03686124|Experimental|Extension Cohort A|IMA203 at MTD
16442484|NCT03686124|Experimental|Extension Cohort B|IMA203 at MTD + atezolizumab
16442485|NCT03686111||infertile patientes with medical assistance to procreation|
16442486|NCT03686111||Infertile patientes with induction of ovulation to give their|
16442487|NCT03686098|Experimental|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
16442488|NCT03686098|Active Comparator|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
16442489|NCT03686098|No Intervention|Control Arm|No diet or supplement changes
16442490|NCT03686085|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
16442491|NCT03686085|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
16442492|NCT03686072|Other|Cataract surgery with goniosynechialysis|
16442493|NCT03686059|Experimental|punctal plug|SOFT PLUG® Preloaded Silicone Plugs by OASIS®
16442494|NCT03686059|Experimental|Combined|SOFT PLUG® Preloaded Silicone Plugs by OASIS® plus Daily intake of DHA (docosahexaenoic acid)
16442495|NCT03686059|No Intervention|control|no medication was given
16442496|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
16442497|NCT03686033|Experimental|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
16442498|NCT03686033|Experimental|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
16442499|NCT03686033|Experimental|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
16442500|NCT03686033|Experimental|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
16442542|NCT03685773|Placebo Comparator|MRI: Non-diabetic transplant (Placebo)|Taste-matched placebo for diazoxide
16442543|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
16442544|NCT03685773|Placebo Comparator|MRI: T2D transplant (Placebo)|Taste-matched placebo for diazoxide
16442545|NCT03685773|Experimental|Clamp: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
16442501|NCT03686033|Experimental|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
16442502|NCT03686033|Experimental|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
16442503|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
16442504|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
16442505|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
16442506|NCT03686007|Experimental|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
16442507|NCT03686007|Active Comparator|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
16442508|NCT03685994||the patients who will undergo TIPS|
16442509|NCT03685981|Experimental|Incentives information provided|
16442510|NCT03685981|No Intervention|No incentives information provided|
16442511|NCT03685968|Experimental|Glidescope AVL|
16442512|NCT03685968|Experimental|King Vision Channeled VL|
16442513|NCT03685968|Experimental|King Vision Non-Channeled (Standard) VL|
16442514|NCT03685955||Genitourinary Reconstruction with Amniotic Membranes|Patients who undergo genitourinary reconstruction with amniotic membranes
16442515|NCT03685942|Experimental|active light therapy|Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
16442516|NCT03685942|Placebo Comparator|placebo light therapy|People receive usual treatment and use a placebo light therapy device (175 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
16442517|NCT03685929||Pressure ulcers|Patients with pressure ulcers category II/III at sacrum or trochanter
16442518|NCT03685929||Incontinence-associated dermatitis|Patients with incontinence-associated dermatitis category IIA at sacrum (or trochanter)
16442519|NCT03685929||Combined lesion|Patients with pressure ulcer category II/III and incontinence-associated dermatitis category IIA at sacrum or trochanter
16442520|NCT03685916|Other|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
16442521|NCT03685916|Experimental|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
16442522|NCT03685916|Experimental|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
16442523|NCT03685916|Experimental|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
16442524|NCT03685916|Experimental|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
16442525|NCT03685916|Experimental|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
16442526|NCT03685916|Experimental|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
16442527|NCT03685916|Experimental|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
16442528|NCT03685916|Experimental|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
16442529|NCT03685903|Experimental|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
16442530|NCT03685890|Experimental|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
16442531|NCT03685890|Placebo Comparator|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
16442532|NCT03685864|Experimental|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
16442533|NCT03685864|Sham Comparator|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
16442534|NCT03685851||UT-DSAEK|With graft 6 months thick less than 100 µm
16442535|NCT03685851||DSAEK|With graft thicker than 100 µm
16442536|NCT03685838|Active Comparator|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
16442537|NCT03685838|No Intervention|No Compression|Patient will not receive any compression stockings.
16442538|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
16442539|NCT03685799||DHG on Barrett's esophagus|patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
16442546|NCT03685773|Placebo Comparator|Clamp: Non-diabetic transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
16442547|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
16442548|NCT03685773|Placebo Comparator|Clamp: T2D transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
16442549|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study
16442550|NCT03685773|Experimental|Clamp: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study
16442551|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg)
16442552|NCT03685773|Experimental|MRI: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide)
16442553|NCT03685760|Experimental|Reiki|Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
16442554|NCT03685760|Sham Comparator|Sham Reiki|Sham Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily sham Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
16442555|NCT03685760|No Intervention|Usual Care|Twice per day, 30 minutes apart, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data. Usual care will also involve a 5-day period.
16442556|NCT03685747|Experimental|Vancomycin|A single 20 mg/kg intraperitoneal dose in 1-liter of 7.5% icodextrin solution of vancomycin will be administered. Sparse blood sampling will be obtained during an overnight 12-hour dwell and during the exchange period.
16442560|NCT03685708|Experimental|Arm 1|Patients with CLL
16442561|NCT03685695|Experimental|Supportive care (physical activity)|Participants wear Fitbit Charge 2 to monitor physical activity for 3 courses (9-12 weeks). Participants then increase their activity minutes to 30 minutes, 5 times a week or by 30% for 6 additional months.
16442562|NCT03685682|Experimental|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
16442563|NCT03685669||Lung nodule group|
16442564|NCT03685669||Healthy Control group|
16442565|NCT03685656|Experimental|ANACA3|ANACA3 slimming gel
16442566|NCT03685656|Placebo Comparator|Placebo|Slimming gel contening no active ingredient
16442567|NCT03685643|Experimental|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
16442568|NCT03685643|Placebo Comparator|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
16442569|NCT03685630|Experimental|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
16442570|NCT03685617|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.
~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;
~Patients with acute myocardial infarction (AMI) and AVB:
~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
16442571|NCT03685617|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
16442572|NCT03685604|Active Comparator|Cardiothoracic surgery - PI disinfection|
16442573|NCT03685604|Active Comparator|Cardiothoracic surgery - CHX disinfection|
16442574|NCT03685604|Active Comparator|Abdominal surgery - PI disinfection|
16442575|NCT03685604|Active Comparator|Abdominal surgery - CHX disinfection|
16442594|NCT03685552|Experimental|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
16442595|NCT03685539|Experimental|Diagnostic (DECT)|Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
16442596|NCT03685526|Experimental|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
16442597|NCT03685513|Active Comparator|Metal ceramic single posterior crowns|Metal copings veneered with feldspathic porcelain
16442598|NCT03685513|Experimental|BioHPP PEEK-based single posterior crowns|BioHPP PEEK copings veneered with composite resin
16442599|NCT03685500|Active Comparator|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
16442600|NCT03685500|Experimental|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
16442601|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
16442602|NCT03685474|Experimental|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
16442603|NCT03685474|Active Comparator|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
16442604|NCT03685461|Other|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
16442605|NCT03685461|Experimental|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
16442606|NCT03685448|Experimental|Experimental: Cabozantonib|Cabozantinib 60 mg/day for up to 12 cycles (one cycle is 28 days), taken orally
16442607|NCT03685435||Non-fasting patients|We will examine non-fasting patients using bedside ultrasound. First we examine the gaster in a supine position. Then we repeat the procedure in a right lateral position.
16442608|NCT03685422|Experimental|Virtual Reality|Patient will be given a Samsung Gear VR3 headset fitted with a smartphone. She will choose the desired playlist on calming scenario and experience the Virtual Reality (VR) for about 10 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Patient will be asked on their satisfaction on the VR experience after the intervention. Questionnaires will be conducted during this period. During and after the gynecologic surgery, baseline demographic data and analgesia usage will be recorded. Patient will be sent to the recovery room after the surgery, and the study team members will collect their questionnaire scorings. All the headsets will be disinfected following the hospital's infection control guideline.
16442609|NCT03685409|Active Comparator|Metformin-Group|Metformin hydrochloride tablets 500 mg taken orally once daily for 3 months
16442610|NCT03685409|Placebo Comparator|Placebo-Group|Starch placebo tablets taken orally once daily for 3 months
16442611|NCT03685396|Experimental|Test Group|In the Test Group venous blood sampling was done in order to prepare PRF membranes used to cover the donor site of the connective tissue graft.
16442612|NCT03685396|Active Comparator|Control Group|In Control Group hemostatic agents with oxidized and regenerated cellulosa were used to cover the donor site.
16442613|NCT03685383|Experimental|intervention group: eCPR + CytoSorb|In addition to standard treatment in patients undergoing eCPR in the intervention group the CytoSorb removal column will be added to the ECLS-system (intervention: CytoSorb removal column in eCPR).
16442614|NCT03685383|Active Comparator|control group: eCPR - CytoSorb|Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
16442615|NCT03685370|Active Comparator|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
16442616|NCT03685370|Experimental|X-ray group|Patients randomized for X-ray placement of epidural catheter
16442617|NCT03685357||Idiopathic Parkinson's|"Oral glucose tolerance test
~The Unified Parkinson's Disease Rating Scale (UDPRS)."
16442618|NCT03685357||Diabetics receive sulphonylurea group|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
16442619|NCT03685357||Diabetics on sulphonylurea and metformin|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
16442620|NCT03685357||Healthy|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score
~Oral glucose tolerance test"
16443001|NCT03682796|Experimental|Expansion|Estimated to be <121 subjects across multiple centers
16442622|NCT03685331|Experimental|Phase I Level 0|"(28-day cycle)
~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
16442623|NCT03685331|Experimental|Phase I Level 1|"(28-day cycle)
~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1
~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
16442624|NCT03685331|Experimental|Phase I Level 2|"(28-day cycle)
~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1
~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
16442625|NCT03685331|Experimental|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21
~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
16442626|NCT03685318|Active Comparator|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
16442627|NCT03685318|Active Comparator|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
16442628|NCT03685305|Experimental|Hypocaloric diet with hunger reduction strategy|Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
16442629|NCT03685305|Active Comparator|Hypocaloric diet without hunger reduction strategy|Participants will only be prescribed a hypocaloric diet. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
16442630|NCT03685292||Group A|Subject(s): A Subgroup
16442631|NCT03685292||Group B|Subject(s): B Subgroup
16442632|NCT03685292||Group C|Subject(s): C Sub Group
16442633|NCT03685279|Experimental|NHA Group|"Six-week, online intervention with weekly, sequential, content knowledge and skills practice. Each week included recorded, slide presentations (narrated by the developer of the NHA, Howard Glasser); readings from The Transforming the Intense Child Workbook by Howard Glasser with Melissa Lowenstein; participants' skills practice, web postings, and live sessions with Howard Glasser and Advanced NHA Trainers."
16442634|NCT03685279|Other|Control Group|The Control Group received the same intervention after the collection of NHA Group post-intervention surveys.
16442635|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
16442636|NCT03685253|Placebo Comparator|Placebo|Participants randomized to placebo will take 2 capsules by mouth twice a day for 6 months. The placebo capsules are matched to the NR capsules.
16442637|NCT03685253|Experimental|Niagen®|Participants randomized to Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will take 250 mg capsules. Participants will take 2 capsules by mouth twice a day (1000 mg) for 6 months
16442638|NCT03685240|Experimental|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
16442639|NCT03685240|No Intervention|Control|No camera detection
16442640|NCT03685227|No Intervention|Control|Participant will lie quietly for 90 minutes. They will be allowed to sleep.
16442641|NCT03685227|Experimental|Yoga Nidra|Participant will practice yoga nidra (using a recording) during the first 30 minutes of the 90 minute measurement period. Then they will be allowed to sleep.
16442642|NCT03685214|Experimental|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
16442643|NCT03685214|Experimental|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
16442644|NCT03685201|Active Comparator|Orange Juice1|100% orange juice
16442645|NCT03685201|Experimental|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
16442646|NCT03685201|Placebo Comparator|Raw Orange|raw orange
16442647|NCT03685188|Experimental|Oxycodone group|PCIA is formulated at 0.4 mg/ml of oxycodone.
16442648|NCT03685188|Active Comparator|Sufentanil group|PCIA is formulated at 2 μg/ml of sufentanil.
16442651|NCT03685149|Active Comparator|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
16442652|NCT03685149|Placebo Comparator|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
16442653|NCT03685123|Experimental|PA-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the minimum physical activity recommendations
16442654|NCT03685123|Experimental|WM-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the weight maintenance recommendations
16442655|NCT03685110||CoreHip|Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up
16442656|NCT03685097||Cardiac surgery patients|Patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.
16442657|NCT03685084|Placebo Comparator|0.9% saline infusion|Saline 0.9% infusion
16442658|NCT03685084|Experimental|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.
~Drug-Drug Interaction:
~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.
~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
16442659|NCT03685084|Experimental|Piperacillin i.v.|Piperacillin 3 g
16442660|NCT03685084|Experimental|Cefepime i.v.|Cefepime 1 g
16442661|NCT03685058|Active Comparator|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
16442662|NCT03685058|Experimental|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
16442663|NCT03685045|Experimental|Campaign Days|All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
16442664|NCT03685032|Experimental|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.
~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
16442665|NCT03685032|Placebo Comparator|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.
~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
16442666|NCT03685019|Experimental|Valgus stress - lateral compartment|Valgus stress radiograph. Joint space width measured in lateral compartment.
16442667|NCT03685019|Experimental|Varus stress - medial compartment|Varus stress radiograph. Joint space width measured in medial compartment.
16442668|NCT03685019|Experimental|0 degree flexion - medial compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
16442669|NCT03685019|Experimental|0 degree flexion - lateral compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
16442670|NCT03685019|Experimental|20 degree flexion - medial compartment|20 degree flexion radiograph. Joint space width measured in medial compartment.
16442671|NCT03685019|Experimental|20 degree flexion - lateral compartment|20 degree flexion radiograph. Joint space width measured in lateral compartment.
16442672|NCT03685019|Experimental|45 degree flexion - medial compartment|45 degree flexion radiograph. Joint space width measured in medial compartment.
16442673|NCT03685019|Experimental|45 degree flexion - lateral compartment|45 degree flexion radiograph. Joint space width measured in lateral compartment.
16442674|NCT03684993|Experimental|Arabic gum extract|natural product Arabic gum (acacia gum) prepared as a mouthwash
16442675|NCT03684993|Experimental|Licorice root extract|natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash
16442676|NCT03684993|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
16442677|NCT03684980|Experimental|Arm A - Rituximab + MTX|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
16442678|NCT03684980|Experimental|Arm B - Rituximab + MTX|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
16442679|NCT03684980|Experimental|Arm C - HD-MTX|In Arm COVID-19, the primary endpoint is HD-MTX levels <100 nmol/L 48 hours post-MTX administration. This will be determined via mass spectrometry/HPLC drawn 48 hours after start of MTX infusion +/- 2 hours.
16442680|NCT03684980|Experimental|Arm D - MTX + Voraxaze|Participants will receive MTX 3.5 g/m2 followed by reduced-dose Voraxaze (2000u, determined in Arm A). MTX will be administered in both the inpatient and outpatient settings.
16442681|NCT03684967|Experimental|fruquintinib|Fruquintinib treatment: administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.
16442682|NCT03684954|Other|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
16442683|NCT03684954|No Intervention|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
16442684|NCT03684941|Experimental|Treatment Period One|LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.
16442685|NCT03684941|Active Comparator|Treatment Period Two|CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.
16442686|NCT03684928|Active Comparator|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
16442687|NCT03684928|Active Comparator|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
16442755|NCT03684538|Experimental|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
16442688|NCT03684915|Experimental|rotary files|"Pre-operative radiograph showing all roots and their apices.
~Local anaesthetic (to enable use of rubber dam clamp).
~Rubber dam isolation.
~Removal of caries.
~Removal of roof of pulp chamber.
~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece.
~Identify root canals.
~Irrigate with normal saline (0.9%)
~Estimate working lengths of root canals keeping 2 mm short of the radiographic apex.
~Insert rotary files into canals and debride the canals lightly and gently.
~Irrigate the root canals.
~Dry canals with pre-measured paper points, keeping 2 mm from root apices.
~Canals will be dried with paper points, obturated by injecting Metapex. (Meta Biomed - Metapex Root Canal Filling Material)
~Stainless steel crown will be performed"
16442689|NCT03684915|Active Comparator|manual files|All steps as that of intervention group are to be followed except step (j) instead of it; a manual files will be inserted into the canals for debridement lightly and gently
16442690|NCT03684902|Experimental|xpolration|women who underwent emergency midline laprotomy
16442691|NCT03684889|Experimental|SCRI-huCAR19v2|Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
16442692|NCT03684889|Experimental|SCRI-huCAR19v1 - [CLOSED]|Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
16442693|NCT03684863|No Intervention|Standard therapy|
16442694|NCT03684863|Experimental|capecitabine|
16442695|NCT03684850|Active Comparator|Exercise therapy group|(n = 40)
16442696|NCT03684850|Experimental|Knee brace and exercise group|(n = 40)
16442697|NCT03684850|Experimental|Footwear device group|(n = 40)
16442698|NCT03684837|Active Comparator|D vitamine|a dose for week
16442699|NCT03684837|Placebo Comparator|D vitamine placebo|a dose for week
16442700|NCT03684824|Other|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
16442701|NCT03684811|Experimental|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
16442702|NCT03684811|Experimental|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
16442703|NCT03684811|Experimental|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
16442704|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 2b)|
16442705|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 4b)|
16442706|NCT03684798|Experimental|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.
~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, & Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, & Gollwitzer, 2015)."
16442707|NCT03684798|Active Comparator|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
16442715|NCT03684772|Experimental|ICVT|Digoxin and Furosemide (0.125%)
16442716|NCT03684772|Experimental|Furosemide|Furosemide (0.125%)
16442717|NCT03684772|Experimental|Digoxin|Digoxin (0.125%)
16442718|NCT03684772|Placebo Comparator|Placebo|Vehicle Gel
16442719|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
16442720|NCT03684746||Care specialist|including nurses - before/after care staff
16442721|NCT03684733||Arm 1: Cohort 1 - Retrospective Analysis|Participants attending MRI & XRM for a clinical indication with at least one normal breast
16442722|NCT03684733||Arm 2: Cohort 2 - Retrospective Analysis|"BRCA1 or BRCA2 mutation carriers attending MRI & XRM for breast screening:
~Genetic risk of breast cancer"
16442723|NCT03684733||Arm 2: Cohort 3 - Retrospective Analysis|"Participants attending MRI & XRM for breast screening post mantle radiotherapy:
~Environmental risk of breast cancer"
16442724|NCT03684733||Arm 2: Cohort 4 - Prospective|"General population attending XRM for breast investigation:
~Population risk of breast cancer MRI"
16442725|NCT03684720|Experimental|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
16442726|NCT03684720|No Intervention|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
16442727|NCT03684707|Active Comparator|Metformin Hcl 500Mg 24Hr Sa Tab|Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
16442728|NCT03684707|Placebo Comparator|control|starch tablets
16442729|NCT03684694|Experimental|Phase 1: Dose-Escalation of ADCT-402|A standard 3+3 dose escalation design will be used. The dose-limiting toxicity (DLT) period will be the 21 days following the first dose of ibrutinib. The dose escalation cohort will receive loncastuximab tesirine for Cycle 1 and 2 (3 weeks each) with concurrent ibrutinib (concomitant therapy) daily. Participants may continue to receive treatment up to 1 year after Cycle 1 Day 1 (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a frozen liquid.
16442730|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL|Participants with non-germinal center B-cell diffuse large B-cell lymphoma (Non-GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
16442731|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL|Participants with germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
16442732|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in MCL|Participants with mantle cell lymphoma (MCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
16442733|NCT03684681|Other|Peer Navigator|Current standard of care
16442734|NCT03684681|Other|Social Worker|Current standard of care
16442735|NCT03684668|Experimental|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
16442736|NCT03684668|No Intervention|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
16442737|NCT03684655|Experimental|[18F]F-AraG|"radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
~Trade name: VisAcT"
16442738|NCT03684642|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (autoinjector) administered once weekly for 56 weeks
16442739|NCT03684642|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (autoinjector) administered once weekly for 56 weeks
16442740|NCT03684642|Active Comparator|Dulaglutide|Dulaglutide (pen) administered once weekly for 56 weeks
16442741|NCT03684629|Experimental|the response of KPI and corresponding suggestion|The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month. The multifaceted quality improvement interventions include: 1) implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols; 2) feedback system of performance measures; 3) expert online consultation.
16442742|NCT03684629|No Intervention|a control arm|The control group indicated that the hospitals will not be provided with the multifaceted quality improvement interventions. They just provide patients with routine care.
16442743|NCT03684616||Statin treatment prior to cardiac arrest|
16442744|NCT03684616||No Statin treatment prior to cardiac arrest|
16442745|NCT03684603|Active Comparator|Acoustic cueing|The melody will be played during training and during slow wave sleep.
16442746|NCT03684603|Sham Comparator|Control|The melody will be played during training.
16442747|NCT03684590|Active Comparator|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
16442748|NCT03684590|Experimental|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
16442749|NCT03684577|Experimental|Hypnotherapy for Agoraphobia|A total of 8-12 individual sessions of hypnotherapy over 12 weeks will be delivered. Hypnotherapy consists of hypnotic activation and reinforcement of the patient's own resources, the use of relevant positive and negative experiences from the biography, and the development of positive solution imagery. The central technique is the work with a symptom regression and the resolution of old and actual experiences. Furthermore, formal trance induction, utilisation techniques, indirect techniques such as the use of metaphors or the representative technique, or work with time progression will be used.
16442750|NCT03684577|No Intervention|Wait-list control group|Patients in the wait-list control group will receive 8-12 sessions of individual hypnotherapy after a waiting period for 12 weeks.
16442751|NCT03684564|Experimental|Rivaroxaban (Treatment Arm)|
16442752|NCT03684564|Active Comparator|Warfarin (Control Arm)|
16442753|NCT03684551|Active Comparator|No dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. The supervisory feedback session for CHWs in the control arm was not facilitated by a visual Dashboard tool or any personalised quantitative feedback on quantity, speed, or quality of care. CHW supervisors were instructed to continue providing CHWs in the control arm with feedback informed by patient perspectives and direct observation during the individual supervision visit.
16442754|NCT03684551|Experimental|Dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. For CHWs randomised to the intervention arm, a visual feedback tool, the CHW Performance Dashboard, was employed during individual supervision, starting in January 2016. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month. The feedback provided to CHWs in the intervention arm, therefore, was both quantitative, informed by the Dashboard, and qualitative, informed by patient perspectives and direct observation of CHW service provision during the individual supervision visit.
16443004|NCT03682770|Experimental|placebo matching dupilumab + AR101|Participant randomization of a ratio of 1 placebo arm
16442756|NCT03684538|Experimental|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
16442757|NCT03684538|Active Comparator|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
16442758|NCT03684525|Experimental|Extraction of primary canines only|"A total of 43 patients with unilateral mesioangular displaced maxillary canines Interceptive treatment: Extraction of both maxillary primary canines will be held at baseline visit At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan
~Treatment Plan :
~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department
~If Canine is emerged to oral cavity: No further CBCT scan will be taken
~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
16442759|NCT03684525|No Intervention|Control group- no extraction|"A total of 43 patients with unilateral mesioangular displaced maxillary canines At Baseline (T0): Clinical examinatiion + CBCT scan , no extraction At 6 month follow-up (T1): Clinical examination At 12 month follow-up: Clinical examination +/- CBCT scan
~Treatment Plan :
~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department
~If Canine is emerged to oral cavity: No further CBCT scan will be taken
~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
16442760|NCT03684512|Experimental|Adolescent Only|Remote based physical activity intervention delivered to adolescents only. Adolescents will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity.
16442761|NCT03684512|Active Comparator|Adolescent and Parent|Remote based physical activity intervention delivered to adolescents and their parent. Adolescents and a parent will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity. Parents will have access to a Parent Facebook group.
16442762|NCT03684499|Other|study group (1)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
16442763|NCT03684499|No Intervention|control group( 2)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
16442764|NCT03684486|Experimental|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
16442765|NCT03684473|Experimental|Yoga Intervention|Participants in the intervention condition will be assigned to an 8-week online delivered trauma-informed yoga protocol focused on home-based daily practice of yoga and mindfulness meditation.
16442766|NCT03684473|No Intervention|Waitlist Control|Participants in the wait list control condition will be invited to attend a 60-minute online mental health education session to learn how to recognize signs and symptoms of PTSD and outline potential strategies to alleviate stress to reduce the risk of heightened severity of mental health challenges. The materials used will be based on the Canadian Mental Health Association resource hub on understanding symptoms of mental illness. All participants in the wait list control condition will be offered the opportunity to participate in the intervention free of charge after completion of the study.
16442767|NCT03684460|Experimental|Bright Light|"Intervention: Daytime Bright Light
~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 09:00 to 13:00 starting on study day 2 and continuing through study day 5 or MICU discharge whichever is longer up to 30 days. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor, if the patient is transferred (prior to study day 5). Feasibility metrics will also be collected."
16442768|NCT03684460|Active Comparator|Usual Light|"Intervention: Usual Care
~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), but otherwise, have usual care."
16442769|NCT03684447|Experimental|Propofol High Dose|high propofol injectable, individually dosed, three times per week
16442770|NCT03684447|Experimental|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
16442771|NCT03684434|Experimental|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
16442772|NCT03684434|Active Comparator|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
16442773|NCT03684421||Long Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Long Antagonist Protocol for COS
16442774|NCT03684421||Classical Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Classical Antagonist Protocol for COS
16442775|NCT03684408|Other|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
16442776|NCT03684408|Experimental|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
16442777|NCT03684408|Active Comparator|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
16442778|NCT03684395||DOACs (Direct Oral Anticoagulants)|
16442779|NCT03684395||Standard of care|
16442780|NCT03684382|Experimental|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
16442781|NCT03684382|No Intervention|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
16442782|NCT03684369|Experimental|Augmented TENS|Transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions.
16442783|NCT03684369|Sham Comparator|Sham|Transient (10 s) application of transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions .
16442784|NCT03684356|Experimental|experimental|immediate implant with socket shield technique
16442785|NCT03684356|Active Comparator|control|immediate implant placement with filling the buccal gap with xenograft
16442786|NCT03684343|Other|Atopic Dermatitis patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
16442787|NCT03684343|Other|Healthy patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
16442788|NCT03684330|Active Comparator|Vitamin D supplementation|
16442789|NCT03684330|Placebo Comparator|Vitamin D placebo|
16442790|NCT03684304|No Intervention|Control / No Binder|Patients randomized to routine care / no abdominal binder use will not use an abdominal binder during their post operative course.
16442791|NCT03684304|Experimental|Abdominal binder|Patients randomized abdominal binder use will have an abdominal binder placed on them in the operating room once their surgery has been completed.
16442792|NCT03684291||Group V|The patients in this group are ventilated using VCV (Volume Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute, I/E ratio: 1/2, PEEP not applied)
16442793|NCT03684291||Group P|The patients in this group are ventilated using PCV-VG (Volume Guaranteed Pressure Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute (EtCO2 kept between 35-40 mmHg), Pressure limit: 30 cm H2O, I/E:1/2, PEEP not applied)
16442794|NCT03684278|Active Comparator|Infusion of 5 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 5 mg of Infliximab, per kg of patient body weight.
16442795|NCT03684278|Active Comparator|Infusion of 10 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 10 mg of Infliximab, per kg of patient body weight.
16442796|NCT03684278|Placebo Comparator|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) 0.9% Sodium Chloride to be administered as a one time intravenous infusion over a period of 2 hours.
16442797|NCT03684265|Experimental|Test to Reference|
16442798|NCT03684265|Experimental|Reference to Test|
16442799|NCT03684252|Other|Control|Treatment as usual
16442800|NCT03684252|Experimental|Intervention|CBT-based intervention
16443002|NCT03682783||Fundus Image|Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
16442801|NCT03684239|Experimental|G-CBT group|G-CBT group has 40 patients, maybe will be divided them into 4 groups. Every group has 8-10 patients. Every group receive 10 times CBT group therapy and 1 times a week for 120 minutes each time.
16442802|NCT03684239|Active Comparator|Conventional treatment group|Conventional treatment group has 40 patients, received routine outpatient treatment. Once every two weeks for 45 minutes each time, including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
16442803|NCT03684213|Active Comparator|Control (Norepinephrine)|Subjects will be administered norepinephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
16442804|NCT03684213|Experimental|Norepinephrine + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
16442805|NCT03684213|Experimental|Norepinephrine + L-NAME|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) at the same rate and for the same time as the control arm.
16442806|NCT03684213|Experimental|Norepinephrine + L-NAME + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and combined L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
16442807|NCT03684200|Experimental|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
16442808|NCT03684200|No Intervention|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
16442809|NCT03684187|Experimental|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
16442810|NCT03684161||Surgically closed VSDs|Patients born with a ventricular septal defect, which have been closed in early childhood.
16442811|NCT03684161||Small, persistent VSDs|Patients born with a small, hemodynamically insignificant ventricular septal defect.
16442812|NCT03684161||Healthy controls|Healthy control subjects.
16442813|NCT03684148|Experimental|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
16442814|NCT03684148|No Intervention|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
16442815|NCT03684135|Experimental|Use of cosmetics during chemotherapy and thermal cure|Use of cosmetics during chemotherapy and post-treatment thermal cure
16442816|NCT03684122|Experimental|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
16442817|NCT03684122|Experimental|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
16442818|NCT03684109|Experimental|IDH-Mutant Glioma Patients|Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain.
16442819|NCT03684096|Active Comparator|non-estrogenic pollen extract PCC-100|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
16442820|NCT03684096|Placebo Comparator|placebo|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
16442821|NCT03684083||Case|patients having received heterologous stem cell transplantation (HSCT)
16442822|NCT03684083||Control|patients without HSCT
16442823|NCT03684070|Experimental|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
16442824|NCT03684070|Active Comparator|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
16442825|NCT03684057|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
16442826|NCT03684057|Other|Wait list control|Individuals in the wait list group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control)
16442827|NCT03684044|Experimental|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
16442828|NCT03684044|Placebo Comparator|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
16442829|NCT03684031|Experimental|Cognitive Control Training|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
16442830|NCT03684031|Sham Comparator|Sham Cognitive Control Training Program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
16442831|NCT03684018|Experimental|IgPro10 (single dose)|
16442832|NCT03684018|Experimental|IgPro10 (multiple dose)|
16442833|NCT03684005|Other|Single-Arm Smartphone App Use|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
16442834|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
16442835|NCT03683979|Experimental|Interpretation bias modification program|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
16442836|NCT03683979|Sham Comparator|Control training program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
16442837|NCT03683953|Placebo Comparator|Placebo|0.9% sodium chloride intratracheal instillate on 14 days after birth
16442838|NCT03683953|Experimental|mesenchymal stem cells|mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg
16442839|NCT03683940|Other|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
16442840|NCT03683927|Experimental|Probiotics|Probiotics consist on Bacillus clausii in a plastic vial that will be administered to the infant 4 times a week
16442841|NCT03683927|Placebo Comparator|Placebo group|Sterile water contained in a plastic vial will be administered to the infant 4 times a week
16442842|NCT03683914|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
16442843|NCT03683914|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
16442844|NCT03683901|Experimental|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
16442845|NCT03683888|Experimental|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
16442846|NCT03683888|Active Comparator|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
16442847|NCT03683862|Experimental|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
16442848|NCT03683862|Active Comparator|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
16442849|NCT03683849|Experimental|Dancing group|Dance intervention group, inspired by the rhythm of Salsa. Training will be administered for an hour twice a week, for six months.
16442850|NCT03683849|Active Comparator|Strength training group|Strength training group. Training will be administered for an hour twice a week, for six months.
16442851|NCT03683849|No Intervention|Control|Control group
16442852|NCT03683836||Study Group|
16442853|NCT03683823|Experimental|Attention guidance|In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
16442854|NCT03683823|Active Comparator|Control intervention|"Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.
~On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.
~Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.
~Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.
~Between speeches participants will have a 1-minute break."
16442855|NCT03683810|Experimental|Lactoferrin|Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
16442856|NCT03683810|Active Comparator|Standard treatment|Participants will receive only the standard treatment for anemia
16442857|NCT03683797|Experimental|Post-discharge call|Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
16442858|NCT03683797|No Intervention|No post-discharge call|Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
16442859|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
16442860|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
16442861|NCT03683758|Experimental|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
16442862|NCT03683758|Active Comparator|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
16442863|NCT03683745||Maryland|Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute ~600 people (~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.
16442864|NCT03683732||Frenchteenagers|
16442865|NCT03683719|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
16442866|NCT03683719|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
16442867|NCT03683719|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
16442868|NCT03683719|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
16442869|NCT03683719|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 16 weeks.
16442870|NCT03683706|Active Comparator|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
16442871|NCT03683706|No Intervention|Treatment as Usual|Participants in this arm will be getting their usual treatment
16442872|NCT03683693|No Intervention|Standard of Care group|Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
16442873|NCT03683693|Experimental|Procalcitonin group|ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
16442874|NCT03683680|Experimental|MRiS|"The specimens to be collected will include at least five pleural biopsy samples
~MPT test and the CLDN15/VIM test will be performed"
16442875|NCT03683667|Placebo Comparator|Placebo & Control|Placebo / Nutrition education
16442876|NCT03683667|Experimental|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
16442877|NCT03683667|Placebo Comparator|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
16442878|NCT03683667|Experimental|Placebo & Egg|Placebo / Egg / Nutrition education
16442879|NCT03683667|Experimental|Azithromycin & Control|Azithromycin / Nutrition education
16442880|NCT03683667|Experimental|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
16442881|NCT03683667|Experimental|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
16442882|NCT03683667|Experimental|Azithromycin and Egg|Azithromycin Egg Nutrition education
16442883|NCT03683641|Active Comparator|Shock Wave group|Applying shock wave to patient's Achilles tendon insertion
16442884|NCT03683641|Sham Comparator|Sham Control group|Applying sham shock wave to patient's Achilles tendon insertion
16442885|NCT03683628|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
16442886|NCT03683628|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
16442887|NCT03683615|Other|patients with traumatic recent orbital blow out fractures|
16442888|NCT03683602|Experimental|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
16442889|NCT03683602|Active Comparator|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
16442890|NCT03683589||Study group|"Participants will receive deuterated water for 10 days before undergoing bariatric surgery.
~Liver biopsy collected, lipids extracted and DNL measured via GC/MS."
16442891|NCT03683576|Placebo Comparator|Placebo|Placebo once per day (QD) for 24 weeks
16442892|NCT03683576|Experimental|GB001 20 mg|GB001 20 mg QD for 24 weeks
16442893|NCT03683576|Experimental|GB001 40 mg|GB001 40 mg QD for 24 weeks
16442894|NCT03683576|Experimental|GB001 60 mg|GB001 60 mg QD for 24 weeks
16442895|NCT03683563|Active Comparator|4% citrate|dialysis catheter locked with 4% sodium citrate
16442896|NCT03683563|Experimental|30% citrate|dialysis catheter locked with 30% sodium citrate
16442897|NCT03683550|Experimental|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
16442898|NCT03683550|Active Comparator|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
16442899|NCT03683537||Delayed Neurocognitive decline|Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically. DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
16442900|NCT03683537||Normal postop neurocognitive function|Patients in whom there is no clinical signs of DNR, defined as in previous group.
16442901|NCT03683524|Experimental|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
16442902|NCT03683524|Active Comparator|Control group|continuation of their current stable ART
16443003|NCT03682770|Experimental|dupilumab + AR101|Participant randomization of a ratio of 2 active dupilumab arms
16442903|NCT03683498|Experimental|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:
~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
16442904|NCT03683485|Experimental|long duration EPBD group|Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.
16442905|NCT03683485|Active Comparator|endoscopic sphincterotomy (EST) group|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.
16442906|NCT03683472|No Intervention|Treatment as usual (TAU)|Individuals will receive treatment as usual
16442907|NCT03683472|Active Comparator|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
16442908|NCT03683459|Experimental|interventional arm|Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.
16442909|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
16442910|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
16442911|NCT03683433|Experimental|Treatment (azacitidine, enasidenib mesylate)|Patients receive azacitidine SC or IV over 30 minutes on days 1-7 and enasidenib mesylate PO QD beginning on day 1. Cycles repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
16442912|NCT03683420|Experimental|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
16442913|NCT03683420|No Intervention|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
16442914|NCT03683407||Chemotherapy Group|All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.
16442915|NCT03683394|Active Comparator|SMARRT Intervention|The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
16442916|NCT03683394|Active Comparator|Health Education Intervention|Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.
16442917|NCT03683381|Experimental|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
16442918|NCT03683381|Experimental|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
16442919|NCT03683368|Experimental|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
16442920|NCT03683368|Experimental|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
16442921|NCT03683355||Edwards Sapien 3|Patients who underwent transcatheter aortic valve replacement with the Edwards Sapien 3 valve
16442922|NCT03683355||Core Valve Evolut R|Patients who underwent transcatheter aortic valve replacement with the Core Valve Evolut R valve
16442923|NCT03683342|Active Comparator|Ankle Block|Ankle block will be performed under ultrasound guidance.
16442924|NCT03683342|Active Comparator|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
16442973|NCT03682991|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
16442974|NCT03682991|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
16442925|NCT03683329|Experimental|Antibiotic de-escalation|"According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens,
~Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible,
~Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture."
16442926|NCT03683329|Active Comparator|Standard treatment without de-escalation|"The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription,
~Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines,
~The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment."
16442927|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
16442928|NCT03683303|Experimental|mobile applications (APP)|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
16442929|NCT03683303|Active Comparator|oral education|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
16442930|NCT03683277|Experimental|Ixazomib/Pomalidomide/Dexamethasone|"Single arm treatment organized in 2 separate phases
~Induction phase : association of Ixazomib, Pomalidomide & Dexamethasone (IPD) 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years
~Maintenance phase : association of Ixazomib and Pomalidomide (IP) 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
16442931|NCT03683264|Other|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
16442932|NCT03683264|Other|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
16442933|NCT03683251|Experimental|PDS Implant Cohort 1 (US only)|"Participants with PDS implant from Study GX28228 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
16442934|NCT03683251|Experimental|PDS Implant Cohort 2 (US only)|"Participants with PDS implant from Study GR40548 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
16442935|NCT03683251|Experimental|PDS Implant Cohort 3 (US only)|"Participants in the intravitreal ranibizumab arm of Study GX28228 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
16442936|NCT03683251|Experimental|PDS Implant Cohort 4 (US only)|"Participants in the intravitreal ranibizumab arm of Study GR40548 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
16442937|NCT03683251|Experimental|PDS Implant Cohort 5 (ex-US only)|Participants from Study WR42221 who completed Week 24 but were not eligible to be randomized within WR42221 and who will be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
16442938|NCT03683251|Experimental|PDS Implant Cohort 6 (ex-US only)|Participants from Study WR42221 randomized to the Q24W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
16442939|NCT03683251|Experimental|PDS Implant Cohort 7 (ex-US only)|Participants from Study WR42221 randomized to the Q36W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q36W
16442940|NCT03683225|Experimental|CTC-413|Pramipexole with/with out aprepitant orally once daily
16442941|NCT03683212|Experimental|Intervention period : early and comprehensive care bundle|
16442942|NCT03683212|No Intervention|acute heart failure standard therapy|
16442943|NCT03683199|Experimental|Cleft lip nasal deformity|"•Anthropometric evaluation of the nose (will be measured pre and post-operative) This represents the objective evaluation. It will be done by measuring the angles and ratios of the nose and its relation to the face. Common parameters will be measured from the photos (frontal, oblique, lateral and basal views) for all the patients to compare the pre-operative measures with the post-operative ones.
~MSCT flesh mode will be used to measure nose related angels and ratios. It also gives idea about nasal skeleton pre-operative for proper design of the operative strategy, and it will be done post-operative for assessment and comparizon."
16442944|NCT03683186|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
16442945|NCT03683173|Experimental|Multilevel Intervention|Participants will receive the multilevel intervention consisting of community events, walking group formation, and short messaging service.
16442946|NCT03683173|No Intervention|Control|Does not receive the multilevel intervention.
16442947|NCT03683160|Experimental|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
16442948|NCT03683147|Experimental|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
16442949|NCT03683147|Experimental|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
16442950|NCT03683134|Experimental|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
16442951|NCT03683134|Active Comparator|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
16442952|NCT03683121||the traditional follow-up group|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding
16442953|NCT03683121||Non-traditional follow-up|The dose and notes for the use of the Non-selective beta blockers were informed during telephone or WeChat follow-ups for the patients with a history of esophageal variceal bleeding
16442954|NCT03683121||Combine of Group1 and Group2|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding,and the patients were followed up by telephone or WeChat again on the same day.
16442955|NCT03683108|Experimental|Resveratrol and Carbossimetyl Beta Glucan|
16442956|NCT03683108|Placebo Comparator|Saline solution|
16442957|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
16442958|NCT03683082|Active Comparator|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
16442959|NCT03683082|Sham Comparator|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
16442960|NCT03683069|Experimental|Epleronone Arm|
16442961|NCT03683069|Experimental|Amlodipine Arm|
16442962|NCT03683056|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
16442963|NCT03683056|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
16442964|NCT03683043|Active Comparator|Transabdominal guided transfer|In the trans-abdominal guided embryo transfer group, the patients' bladder were filled by 500-700 ml saline; in order to enhance the visualization. The trans-abdominal probe is applied on pelvis by an assistant nurse or the attending gynecologist intern
16442965|NCT03683043|Active Comparator|Transvaginal guided transfer|the trans-vaginal guided embryo transfer group had their bladder emptied by the gynecologist via catheter prior to transfer or else the patient was asked to void. The speculum is applied followed by insertion of the outer sheath of the transfer catheter. The speculum is removed with caution; to maintain the outer sheath in place. The TVUS probe is applied vaginally and endometrium is visualized before transfer. The transfer is done through an inner catheter applied to the already inserted outer sheath
16442966|NCT03683030|Experimental|Treatment Group|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
16442967|NCT03683017|Experimental|I-OP2.0|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
16442968|NCT03683017|Experimental|I-OP2.1|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.
16442969|NCT03683017|Experimental|F-OP2.0|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
16442970|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
16442971|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
16442972|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
16442975|NCT03682978|Experimental|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.
~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.
~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.
~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
16442976|NCT03682978|Placebo Comparator|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.
~Dosage level is n/a."
16442977|NCT03682965|Experimental|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
16442978|NCT03682965|Placebo Comparator|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
16442979|NCT03682952|Experimental|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
16442980|NCT03682952|No Intervention|Anemia control group|Anemia patients
16442981|NCT03682952|No Intervention|Control group|Healthy person
16442982|NCT03682939|Experimental|Single arm|Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.
16442983|NCT03682926|Experimental|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
16442984|NCT03682926|Active Comparator|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
16442985|NCT03682913|Experimental|P-CIT protocol|OCD patients who receive the P-CIT intervention.
16442986|NCT03682913|Placebo Comparator|Placebo|OCD patients who don't receive the P-CIT intervention.
16442987|NCT03682900|Experimental|Click City Tobacco Prevention Program|Click City program used as part of school curriculum
16442988|NCT03682900|No Intervention|Usual Tobacco Prevention Curriculum|Will vary by school district.
16442989|NCT03682887|Active Comparator|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.
~Esophageal temperature will be monitored to prevent esophageal injury.
~A 28mm cryoballoon catheter will be used.
~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.
~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.
~The procedure and ablation times will be evaluated.
~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16442990|NCT03682887|Experimental|Cryoballoon PV isolation w/ RA linear ablation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter as the same as cryoballoon PV isolation group.
~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.
~Additional SVC-right atrial septal linear ablation will be performed with a radiofrequency catheter.
~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local RF ablation will be followed.
~The procedure and ablation times will be evaluated.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
16442991|NCT03682861|Placebo Comparator|Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
16442992|NCT03682861|Experimental|Carbohydrate drinks|Sweet corn derived starch mixed in water at three different concentrations (6%, 12% and 18%) will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
16442993|NCT03682848|Experimental|Participants receiving DTG + 3TC FDC|Eligible participants will receive FDC of DTG + 3TC 50/300 milligrams, tablets, given orally once daily.
16442994|NCT03682835|Placebo Comparator|Placebo treatment arm|Placebo: 2 capsules per dose, 2 doses per study day.
16442995|NCT03682835|Experimental|POCO treatment arm|FDGard Capsule containing a combination of peppermint oil (41,5mg) and caraway oil (50mg); 2 capsules per dose, 2 doses per study day.
16442996|NCT03682822|Experimental|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
16442997|NCT03682822|Active Comparator|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
16442998|NCT03682809|Experimental|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
16442999|NCT03682809|No Intervention|No Treatment|Subjects randomized to this group will not receive a treatment.
16443000|NCT03682796|Experimental|Escalation|Estimated to be <31 subjects across multiple centers
16443005|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)>=25, and base deficit (BD)>=6.
16443006|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)<25, and base deficit (BD) <6.
16443007|NCT03682757||Healthy Controls|Uninjured healthy volunteers
16443008|NCT03682744|Experimental|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
16443009|NCT03682718|Experimental|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
16443010|NCT03682718|Active Comparator|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.
~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
16443011|NCT03682705|Placebo Comparator|ELS placebo/UPA placebo|Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
16443012|NCT03682705|Experimental|UPA 15 mg/ELS 60 mg|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
16443013|NCT03682705|Experimental|ELS 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
16443014|NCT03682705|Experimental|ELS 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
16443015|NCT03682705|Experimental|ELS 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
16443016|NCT03682705|Experimental|UPA 15 mg/ELS placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks
16443017|NCT03682692|Experimental|ACEI/CCB|
16443018|NCT03682692|Experimental|ACEI/DIU|
16443019|NCT03682666|Active Comparator|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
16443020|NCT03682666|Sham Comparator|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.
~And they will receive sham taping on the affected limb."
16443021|NCT03682666|Experimental|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
16443022|NCT03682653|Active Comparator|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
16443023|NCT03682653|Placebo Comparator|Placebo|a single dose of placebo will be administered to infants between their 8-27th days of life
16443024|NCT03682640|Experimental|AIDIT protocol|"Treatment as usual with the addition of:
~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight < 30 kg.
~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.
~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
16443025|NCT03682640|No Intervention|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
16443026|NCT03682627|Active Comparator|preventive fenestration|Fenestration is performed at the time of kidney transplantation
16443027|NCT03682627|Experimental|preventive fenestration and clipping|Fenestration and clipping of the edges are performed at the time of kidney transplantation
16443028|NCT03682614|Experimental|HCG group|All patients will accept HCG 500IU intrauterine injection 2 days before blastocyte transfer
16443029|NCT03682614|Placebo Comparator|control group|All patients will accept same dose of culture medium intrauterine injection 2 days before blastocyte transfer
16443030|NCT03682601|Placebo Comparator|Placebo|"15 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.
~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).
~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.
~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
16443054|NCT03682484|Experimental|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
16443055|NCT03682484|Experimental|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
16443056|NCT03682484|Placebo Comparator|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
16443031|NCT03682601|Active Comparator|5% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.
~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).
~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.
~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
16443032|NCT03682601|Active Comparator|10% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.
~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).
~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.
~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
16443033|NCT03682588|Experimental|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
16443034|NCT03682588|Active Comparator|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
16443035|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
16443036|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
16443037|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
16443038|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
16443039|NCT03682562||Normal Subjects|"Patients who give a history of:
~No smoking
~No alcohol
~No systemic disease; and who on conventional oral examination have:
~No visible oral lesions on conventional oral examination .
~Good oral hygiene."
16443040|NCT03682549||HCV positive Patients|"patients will be recruited from the outpatient's viral hepatitis clinic
~The patients will be diagnosed as HCV positive through (antiHCV-Ab) and (HCV-PCR) tests"
16443041|NCT03682549||Successfully treated former HCV patients|Patients formerly diagnosed as HCV positive who received DAA treatment successfully.
16443042|NCT03682549||Normal Individuals|healthy volunteers recruited from the outpatient clinic of the Faculty of Dentistry- Cairo University
16443043|NCT03682536|Experimental|Experimental Arm: luspatercept (ACE-536)|1.0 mg/kg subcutaneous (SC) every 3 weeks (Q3W)
16443044|NCT03682536|Active Comparator|Control Arm: epoetin alfa|450 IU/kg subcutaneous (SC) weekly
16443045|NCT03682523|No Intervention|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
16443046|NCT03682523|Experimental|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; real-time feedback on goal attainment provided on bedside tablet; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
16443047|NCT03682510|Active Comparator|stepwise devascularization|routine stepwise devascularization
16443048|NCT03682510|Active Comparator|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.
~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
16443049|NCT03682510|Experimental|N&H technique|"In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:
~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.
~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
16443050|NCT03682497|Active Comparator|Spironolactone|Spironolactone treatment for 28 days
16443051|NCT03682497|Experimental|AZD9977|AZD9977 treatment for 28 days
16443052|NCT03682484|Experimental|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
16443053|NCT03682484|Placebo Comparator|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
16443843|NCT03677297|Experimental|ROSUVASTATIN|1.2% Rosuvastatin Gel. Insertion in infrabony defects once
16443057|NCT03682471||Deoxycholic Acid Injection, 5 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 5 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
16443058|NCT03682471||Deoxycholic Acid Injection, 10 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 10 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
16443059|NCT03682471||Placebo|Non-treatment observational follow-up study: Participants were previously treated with placebo in studies ATX-101-10-16 or ATX-101-10-17.
16443060|NCT03682445|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
16443061|NCT03682445|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
16443062|NCT03682445|No Intervention|Control group|The participants in the control group will make stretching exercise at home
16443063|NCT03682419|Experimental|VKA Patients|Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy
16443064|NCT03682419|Experimental|non-Vka Patients|Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy
16443065|NCT03682406|Experimental|CAMS-G|CAMS-G is an group-based adaptation of the Collaborative Assessment and Management of Suicidality (CAMS) that has been developed to address perceived burdensomeness and thwarted belongingness, two drivers of suicide risk. Ongoing assessment and treatment planning are completed using the CAMS Suicide Status Form in the group modality, with involvement from group members and group facilitators. Driver-focused intervention strategies and group process also occur in the group based upon the unique needs of the group members. Groups are 90-minutes in length and occur on a weekly basis.
16443066|NCT03682406|Other|Care as Usual|Care as usual includes access to all existing forms of treatment that currently exist at the Robley Rex VAMC and affiliated CBOCs, such as individual and group psychotherapy, suicide prevention programming and case management, psychiatric care, social work services, and substance use disorder counseling. We will essentially track the control condition over time as they engage in the typical services provided to suicidal Veterans through the Robley Rex VAMC. The CAMS-G study participants will have access to the same services delivered as part of care as usual, with the only difference being their participation in the CAMS-G treatment for suicidality.
16443067|NCT03682393|Experimental|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
16443068|NCT03682393|Placebo Comparator|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
16443069|NCT03682380|Experimental|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
16443070|NCT03682380|Experimental|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
16443071|NCT03682380|Experimental|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
16443072|NCT03682367|Placebo Comparator|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
16443073|NCT03682367|Experimental|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
16443074|NCT03682354|Active Comparator|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
16443075|NCT03682354|Experimental|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
16443076|NCT03682341||Group A|Patients with ovarian endometriosis cyst
16443077|NCT03682341||Group B|Patients with ovarian teratoma cyst
16443078|NCT03682328|Active Comparator|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
16443079|NCT03682328|Active Comparator|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
16443080|NCT03682315|Active Comparator|Biphasic phycogenic biomaterial|Biphasic phycogenic biomaterial and Autogenous cortical bone
16443081|NCT03682315|Experimental|Xenograft bovine hydroxyapatite|Xenograft bovine hydroxyapatite and Autogenous cortical bone
16443082|NCT03682302|Experimental|Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
16443083|NCT03682302|Active Comparator|Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine|Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
16443084|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
16443085|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
16443086|NCT03682289|Experimental|Arm I (ATR kinase inhibitor AZD6738)|Participants who are BAF250a negative or ATM-Mutant receive ATR kinase inhibitor AZD6738 PO twice a day on days 1-14. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16443087|NCT03682289|Experimental|Arm II (ATR kinase inhibitor AZD6738, olaparib)|Participants who are BAF250a positive receive ATR kinase inhibitor AZD6738 PO every day on days 1-7 and olaparib PO twice a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16443088|NCT03682276|Experimental|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
16443089|NCT03682263|Experimental|Full Service Treatment|The Full Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services, as well as Medication Management Support (MMS) from a Nurse Care Coordinator (NCC).
16443090|NCT03682263|Experimental|Basic Service Treatment|The Basic Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services.
16443091|NCT03682263|No Intervention|Usual Services|Members of the Usual Service group seek services as they normally would (or would not) in their community. At the time of randomization, each Usual Services group member receives a comprehensive manual describing mental health and employment services in their local community, as well as state and national resources.
16443092|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
16443093|NCT03682237|No Intervention|A) Standard diabetes training (control)|"More specifically, group training in general diabetes health issues, how to do experienced based dosing, how to handle sick days, exercise etc. in general terms. The group will not be taught in carbohydrate counting or bolus calculation. They will be encouraged to measure SMBG at least 4 times daily with patients own preferred glucose meter.
~Patients will be offered 6 months treatment with FGM after study end."
16443094|NCT03682237|Active Comparator|B) Carbohydrate counting, automated bolus calculation|
16443095|NCT03682237|Active Comparator|C) Flash glucose monitoring (FGM)|Group training with same content as for group A.
16443096|NCT03682237|Active Comparator|D) Carbohydrate counting, automated bolus calculation, FGM|Group training as group B. A more sophisticated education concept will be developed for how FGM should be used to adjust settings and suggestions from the automated bolus calculator (MySugr app).
16443097|NCT03682224|Active Comparator|Exparel|
16443098|NCT03682224|Active Comparator|Marcaine|
16443099|NCT03682211|Experimental|Active Intranasal Fentanyl|Subjects will receive 50 μg/ml intranasal fentanyl citrate and a placebo matched to intravenous morphine (1 ml water for injection) at time 0
16443100|NCT03682211|Active Comparator|Active IV Morphine|Subjects will receive 10 mg/ml intravenous morphine sulphate and a placebo matched to intranasal fentanyl (2 ml water)
16443101|NCT03682198|Other|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
16443102|NCT03682185|Experimental|Timed Activity Intervention Protocol|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.
16443103|NCT03682185|Active Comparator|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
16443104|NCT03682172|Experimental|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
16443105|NCT03682172|Experimental|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
16443106|NCT03682172|Experimental|Placebo|A single four hour intravenous infusion with saline water (placebo)
16443107|NCT03682159|No Intervention|control|
16443108|NCT03682159|Experimental|intervention|
16443109|NCT03682146|Experimental|R-LRPE|robot-assisted laparoscopic prostatectomy
16443110|NCT03682146|Experimental|LRPE|conventional radical laparoscopic prostatectomy
16443111|NCT03682133||Prehabilitation|The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
16443112|NCT03682133||Usual care|Guideline based colon cancer surgery, without prehabilitation.
16443113|NCT03682120|Experimental|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
16443114|NCT03682120|Experimental|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
16443115|NCT03682120|Experimental|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
16443116|NCT03682120|Experimental|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
16443117|NCT03682107|Experimental|Arm 1 (2 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.
~11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
16443118|NCT03682107|Experimental|Arm 2 (2 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.
~11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
16443119|NCT03682107|Experimental|Arm 3 (4 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.
~11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
16443120|NCT03682107|Experimental|Arm 4 (4 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.
~11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
16443121|NCT03682094|Experimental|Probiotic|The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow.
16443122|NCT03682081|No Intervention|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
16443123|NCT03682081|Experimental|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
16443124|NCT03682081|Experimental|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
16443125|NCT03682081|Experimental|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
16443126|NCT03682068|Experimental|Durvalumab in Combination with SoC Chemotherapy|"Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks.
~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
~cisplatin+ gemcitabine
~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
16443127|NCT03682068|Experimental|Durvalumab in Combination with Tremelimumab+SoC Chemotherapy|"Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks
~Tremelimumab will be provided for 4 cycles.
~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
~cisplatin+ gemcitabine
~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
16443128|NCT03682068|Active Comparator|SoC Chemotherapy|"Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
~cisplatin+ gemcitabine
~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
16443129|NCT03682055|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC
16443130|NCT03682055|Experimental|Phase 1 Dose Escalation (Rolling Six)|VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.
16443131|NCT03682055|Experimental|Phase 1 Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.
16443132|NCT03682055|Experimental|Phase 2a Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.
16443133|NCT03682042|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
16443134|NCT03682042|No Intervention|Early Cord Clamping|The umbilical cord is clamped immediately after the delivery (within 60 seconds).
16443135|NCT03682029|Experimental|Vitamin C|Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.
16443136|NCT03682029|Placebo Comparator|Placebo|Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.
16443137|NCT03681990|Experimental|3M CHG/IPA Prep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
16443138|NCT03681977|Experimental|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
16443139|NCT03681977|Active Comparator|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
16443140|NCT03681977|No Intervention|Healthy Participants|The control group for the kinematic assessment
16443141|NCT03681951|Experimental|Part 1: Dose Escalation - GSK3145095 monotherapy|In Part 1, advanced or metastatic PDAC will be enrolled. Part 1 will be using escalating doses of GSK3145095 (total daily dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1600 mg) orally as monotherapy for up to 2 years. For each dose level, subjects will receive a single dose of half the total daily dose on Day 1; and as BID (total daily dose divided in two equal doses) starting from Day 2.
16443142|NCT03681951|Experimental|Part 2: Dose Escalation - GSK3145095 + pembrolizumab|In Part 2, subjects with selected solid tumors, including but not limited to, PDAC, NSCLC, TNBC and/or melanoma will be enrolled. Part 2 will be using GSK3145095 combination escalation to start at least one dose level below the highest dose of GSK3145095 shown to be safe in Part 1, orally BID for up to 2 years along with pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) for up to 2 years.
16443143|NCT03681951|Experimental|Part 3: Dose Expansion - GSK3145095 + pembrolizumab|In Part 3, subjects with selected solid tumors will be enrolled. Part 3 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with pembrolizumab 200 mg IV Q3W for up to 2 years.
16443144|NCT03681951|Experimental|Part 4: Dose Expansion - GSK3145095 + anticancer agent|In Part 4, subjects with selected solid tumors will be enrolled. Part 4 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with combination of additional anticancer agents.
16443145|NCT03681938||Intensification treatment: Autograft|
16443146|NCT03681938||Standard chemotherapy (without autograft)|
16443147|NCT03681925|Experimental|Intervention|Dietitians randomized to the intervention arm will have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and base their intervention on these results.
16443148|NCT03681925|No Intervention|Control|Dietitians randomized to the control arm will not have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and will provide the standard-of-care intervention for their patients.
16443149|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
16443150|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
16443151|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
16443152|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
16443153|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
16443154|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
16443155|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
16443156|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
16443157|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
16443158|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
16443159|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
16443160|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
16443161|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
16443162|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
16443163|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
16443164|NCT03681899||Subjects aged of 65 years or older|Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
16443165|NCT03681886|Experimental|Primary Implantation (Cohort 1)|Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
16443166|NCT03681886|Experimental|Optic Exchange (Cohort 2)|Subset of Cohort 1 with optic exchange at Month 1 post primary implantation, followed up to Month 1 post optic exchange
16443167|NCT03681873|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
16443168|NCT03681860|Other|Group 1 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
16443169|NCT03681860|Other|Group 2 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
16443170|NCT03681860|Other|Group 3 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
16443171|NCT03681860|Other|Group 4 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
16443172|NCT03681860|Experimental|Group 5/6 Randomised Comparison|30 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp followed by MVA85A boost versus 30 adolescents who are EMaBS participants, to receive BCG revaccination
16443173|NCT03681847|Active Comparator|normal saline|Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.
16443174|NCT03681847|Active Comparator|Hydroxyethyl starch|Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
16443175|NCT03681847|Active Comparator|Hypertonic saline|Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.
16443176|NCT03681821|Experimental|The intervention group|Patients in the intervention group receiving the follow-up TTM-based intervention sessions.
16443177|NCT03681821|No Intervention|The control group|No interventions except conventional care were performed for the control group.
16443178|NCT03681808|Experimental|Test|Soft Contact Lens
16443179|NCT03681808|Active Comparator|Control|Contact lens
16443180|NCT03681795|Experimental|patient|patients with Gilles de la Tourette syndrome
16443181|NCT03681795|Experimental|Control|healthy control
16443182|NCT03681769|Experimental|Intermittent Theta Burst Stimulation (iTBS) to the left dlPFC|For intermittent theta burst stimulation (iTBS) (Aim 1), participants will receive 20 trains of stimulation over the dlPFC (middle frontal gyrus) (F3) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P).
16443183|NCT03681769|Sham Comparator|Sham iTBS to the left dlPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
16443184|NCT03681769|Experimental|cTBS to the mPFC|For continuous theta burst stimulation (Aim 2), participants will receive 1 train of stimulation over the left frontal pole (FP1) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P). This protocol has been shown to attenuate the mPFC and striatum in cocaine dependent individuals in the past (61-63) and has been more effective than 1200 or 1800 pulses of cTBS in attenuating depression (The time between the end of the TBS procedures and the beginning of the behavioral assessments, as well as the scalp-to-cortex distance (which effects the actual TMS dose given to the cortex) will be compiled and used as covariates in subsequent analyses.
16443185|NCT03681769|Sham Comparator|Sham cTBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
16443186|NCT03681756|No Intervention|Group 1|Participants will receive an in-person session and an activity monitor
16443187|NCT03681756|Experimental|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
16443188|NCT03681743|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
16443189|NCT03681743|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors and/or parents.
16443190|NCT03681730|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
16443191|NCT03681730|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
16443192|NCT03681717|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during laceration repair with sutures.
16443193|NCT03681717|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
16443194|NCT03681704|Experimental|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
16443195|NCT03681704|Placebo Comparator|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
16443196|NCT03681691|Experimental|Post menopausal women with diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
16443197|NCT03681691|Experimental|Post menopausal women without diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
16443198|NCT03681678||fCO2 Laser Therapy Group|Women treated with the fCO2 laser
16443199|NCT03681665||Abscess|Patients group with abdominal abscess
16443200|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
16443201|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
16443688|NCT03678480|Experimental|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
16443202|NCT03681639|Experimental|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application with the Durom® Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
16443203|NCT03681626|Active Comparator|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
16443204|NCT03681626|Experimental|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
16443205|NCT03681613|Experimental|Exercise Therapy With CNS Treatment|NEMEX program combined with a CNS-focused protocol
16443206|NCT03681613|Experimental|Exercise Therapy alone|NEMEX program alone
16443207|NCT03681574|Experimental|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
16443208|NCT03681574|Experimental|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
16443209|NCT03681574|Experimental|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
16443210|NCT03681561|Experimental|Ruxolitinib and Nivolumab|
16443211|NCT03681548|Active Comparator|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
16443212|NCT03681548|Experimental|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
16443213|NCT03681535|Experimental|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
16443214|NCT03681522|Experimental|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
16443215|NCT03681522|Active Comparator|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
16443216|NCT03681509|Experimental|Pramipexole|Maximum daily dose: 1.0 mg of pramipexole salt
16443217|NCT03681509|Placebo Comparator|Placebo|Lactose
16443218|NCT03681483|Experimental|RO5126766 (CH5126766)|The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
16443219|NCT03681470|Experimental|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
16443220|NCT03681457|Other|Group 1 - Normal Hepatic Function|Normal hepatic function - Control - control group
16443221|NCT03681457|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment - Child-Pugh A (Score 5-6)
16443222|NCT03681457|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment - Child-Pugh B (Score 7-9)
16443223|NCT03681457|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment - Child-Pugh C (score 10-15)
16443224|NCT03681444|Experimental|Regular diet|no dietary restriction
16443225|NCT03681444|Placebo Comparator|Clear fluid diet|no solid material
16443226|NCT03681444|Experimental|Low residue diet|easy digestible food
16443227|NCT03681431|Experimental|Ceftriaxone 4g/ 24h|Single intravenous dose of Ceftriaxone 4g/ 24h
16443228|NCT03681431|Active Comparator|Ceftriaxone 2g/ 12h|Two intravenous doses of Ceftriaxone 2g/ 12h
16443229|NCT03681418|Other|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
16443230|NCT03681405|Experimental|Group I (eMMB)|Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
16443231|NCT03681405|Active Comparator|Group II (AC)|Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
16443232|NCT03681392|Experimental|Once daily then twice daily|One 6.5 cc scoop of S4S once a day for 7 days, then one 6.5 cc scoop of S4S twice a day for 7 days
16443233|NCT03681392|Experimental|Twice daily then once daily|One 6.5 cc scoop of S4S twice a day for 7 days, then one 6.5 cc scoop of S4S once a day for 7 days
16443234|NCT03681366|No Intervention|Single vision soft contact lens|single vision, spherical soft contact lens
16443235|NCT03681366|Experimental|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
16443274|NCT03681080|Experimental|crossed legs|cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)
16443236|NCT03681353|Experimental|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
16443237|NCT03681340|Experimental|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
16443238|NCT03681340|Active Comparator|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
16443239|NCT03681314|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
16443240|NCT03681314|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
16443241|NCT03681301|Experimental|Interventional|Additional self-directed learning and practice using virtual reality simulator, after conventional training session
16443242|NCT03681301|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
16443243|NCT03681288|Experimental|MSC|Mindful Self-Compassion Intervention
16443244|NCT03681275|Experimental|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
16443245|NCT03681275|Placebo Comparator|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
16443246|NCT03681262|Experimental|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
16443247|NCT03681262|Experimental|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
16443248|NCT03681249|Experimental|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
16443249|NCT03681249|Placebo Comparator|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
16443250|NCT03681236|No Intervention|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
16443251|NCT03681236|Active Comparator|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
16443252|NCT03681223|Active Comparator|Restorelle® Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
16443253|NCT03681223|Experimental|Vertessa® Lite Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
16443254|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
16443255|NCT03681197|Active Comparator|Metformin Group|Will receive metformin plus clomiphene citrate
16443256|NCT03681197|Placebo Comparator|Placebo|Will receive placebo plus clomiphene citrate.
16443259|NCT03681171|Experimental|Children with CP|Children with CP (9-15 years old) participated in a therapeutic dance program to improve physical, physiological and cognitive outcomes.
16443260|NCT03681158|Experimental|sodium valproate|Single oral dose of sodium valproate containing [14C]-sodium VPA
16443261|NCT03681145|Experimental|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
16443262|NCT03681145|Experimental|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
16443263|NCT03681132|Other|Low-threshold re-start|Re-start antiviral therapy if HBV DNA viral load >2000 IU/ml and ALT >80 U/L.
16443264|NCT03681132|Other|High-threshold re-start|"Re-start antiviral therapy if:
~ALT >100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR
~ALT >400 U/L persisting for more than 2 months in consecutive assays."
16443265|NCT03681119|Experimental|Advanced Demential Patients|
16443266|NCT03681119|Experimental|Hospice IDT Members|
16443267|NCT03681106|Experimental|Kinesiotape|Kinesio Tex taping treatment for 10 days + usual care
16443268|NCT03681106|No Intervention|Control|usual care
16443269|NCT03681093|Experimental|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily orally
16443270|NCT03681093|Experimental|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily orally
16443271|NCT03681093|Placebo Comparator|Placebo|Placebo once daily orally
16443272|NCT03681080|No Intervention|lying|cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)
16443273|NCT03681080|No Intervention|standing|cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)
16443277|NCT03681054|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
16443278|NCT03681054|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
16443279|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
16443280|NCT03681028|Other|Individualized therapy|Study treatment for a given patient will consist of a regimen chosen from agents implicated in critical molecular signaling pathways and/or from signature-based predictions of drug efficacy. All agents are listed in the current pharmacopoeia for human use, but will differ amongst individual subjects. The study treatment will consist of up to 4 FDA approved drugs that have known dosing. This study is not only looking at 4 drugs. It is selecting up to 4 drugs per patient but the drugs chosen can be any FDA-approved drug. Therefore, it is not possible to pre-specify the medications.
16443281|NCT03681015||Cohort 1 - Parkinson's Disease Participants|Volunteers will be women and men with early, untreated Parkinson disease.
16443282|NCT03681015||Cohort 2 - Control Participants|Participants will be women and men without PD.
16443283|NCT03681002|Other|structured lifestyle program|individual counseling focusing on Lifestyle habits
16443284|NCT03680989|Placebo Comparator|Natural Light|"Participants will use a therapy light that provides ~500 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
16443285|NCT03680989|Active Comparator|Bright Light|"Participants will receive Bright Light Exposure using a therapy light that provides ~10,000 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
16443286|NCT03680976|Experimental|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
16443287|NCT03680976|Placebo Comparator|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
16443288|NCT03680963|Experimental|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
16443289|NCT03680963|Other|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
16443290|NCT03680950|Experimental|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
16443291|NCT03680937||Immature oocytes vitrified before in vitro maturation|Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
16443292|NCT03680937||Immature oocytes vitrified after in vitro maturation|A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
16443293|NCT03680937||Fresh oocytes|The culture of immature oocytes will be performed during 36 hours
16443294|NCT03680911|Experimental|NAC Group|NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
16443295|NCT03680911|Placebo Comparator|Placebo Group|Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
16443296|NCT03680898|Experimental|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
16443297|NCT03680898|Active Comparator|Reference Method|The other swab will be used in the Reference Method.
16443298|NCT03680885|Active Comparator|Reports getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
16443299|NCT03680885|Active Comparator|Reports trouble getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
16443300|NCT03680872|Experimental|Spinal Cord Injury Participants|This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.
16443301|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
16443302|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
16443303|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
16443304|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
16443305|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
16443306|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
16443307|NCT03680846|Other|CMM|Conventional Medical Management
16443308|NCT03680846|Active Comparator|HF10 + CMM|Addition of HF10 therapy to CMM
16443309|NCT03680833|Other|prospective cohort study|"Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.
~The intervention is the detection and removal of sentinel lymph nodes"
16443310|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
16443311|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
16443312|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
16443313|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
16443314|NCT03680807||Older adults with knee osteoarthritis (>50 years)|
16443315|NCT03680807||Healthy older adults (> 50 years)|
16443316|NCT03680794|Experimental|Patients with ophthalmic surgery|
16443317|NCT03680781|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
16443318|NCT03680755|Experimental|Tr1 group|Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
16443319|NCT03680755|Experimental|Tr2 group|Participants assigned to Tr2 will complete the experimental dental anxiety management program, which will be facilitated by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
16443320|NCT03680755|No Intervention|Active control|Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
16443321|NCT03680742|Experimental|Treated|All eligible patients who underwent an attempt with the Contour device.
16443322|NCT03680729|Experimental|aBSB|aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.
16443323|NCT03680729|Active Comparator|Street Outreach|Standard street outreach was used as the control in the original BSB trial.
16443324|NCT03680716|Experimental|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
16443325|NCT03680716|Active Comparator|Local infiltration analgesia|Periarticular infiltration by surgeon
16443326|NCT03680703|Experimental|Internet|Guided self-help behavioral weight loss treatment delivered via the internet
16443327|NCT03680703|Experimental|Internet Plus Phone|Guided self-help behavioral weight loss treatment delivered via the internet with weekly phone consultations
16443328|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
16443329|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
16443330|NCT03680677||Cancer Directed Therapy or Best Supportive Care|Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
16443331|NCT03680677||Transplant|Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
16443332|NCT03680664|Experimental|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.
~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
16443333|NCT03680664|Sham Comparator|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
16443334|NCT03680638|Sham Comparator|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
16443335|NCT03680638|Experimental|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
16443336|NCT03680638|Experimental|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
16443337|NCT03680638|Experimental|Allopurinol|This site will only be infused with tempol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
16443338|NCT03680625|Active Comparator|Passive Distraction|The child will watch a video on an iPad® during the pin removal procedure and/or removal of sutures.
16443339|NCT03680625|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment using an Oculus Quest® head-mounted device throughout the pin removal procedure and/or removal of sutures.
16443340|NCT03680612|Experimental|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
16443341|NCT03680612|Active Comparator|cefepime monotherapy|cefepime 1 g or cefepime 2 g
16443342|NCT03680599|Experimental|Connection to Health for Smokers|Participants in this arm will participate in the Connection to Health for Smokers Arm of the study, wherein an electronic survey will be administered and participants will be guided through an evidence-based action planning sequence, taking into account each patient's unique social environment, health related behaviors, and behavioral health status, with multimodal follow up.
16443343|NCT03680599|Active Comparator|Enhanced Standard of Care|Participants in this arm will participate in Enhanced Standard Care, wherein participants will receive a brief electronic survey and receive standard smoking cessation program that does not include formal action planning and multimodal follow up.
16443344|NCT03680586|Experimental|Treatment (low-dose radiation therapy)|Patients undergo low-dose radiation therapy over 2 fractions for 2 consecutive days in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease at 12-16 weeks post-treatment, or persistent disease at 1 year may undergo higher-dose radiation therapy at the discretion of treating physician.
16443345|NCT03680573|Active Comparator|Control- Lactated Ringers|This site will serve as the control site and will receive lactated Ringer's (saline solution) at an infusion rate of 2 µl/min.
16443346|NCT03680573|Experimental|Apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone)|This site will receive 100 µM apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone) at an infusion rate of 2 µl/min.
16443347|NCT03680573|Experimental|Allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)|This site will receive 10 µM allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.
16443348|NCT03680573|Experimental|BH4 ((6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride)|This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.
16443349|NCT03680560|Experimental|ACTR T cell product in combination with trastuzumab|
16443350|NCT03680534|Experimental|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
16443351|NCT03680534|Experimental|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
16443352|NCT03680534|Experimental|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
16443353|NCT03680521|Experimental|Sitravatinib and nivolumab|Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
16443354|NCT03680508|Experimental|TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16443355|NCT03680495||AECOPD with Respiratory Failure|The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
16443356|NCT03680495||Stable COPD|The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
16443357|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
16443358|NCT03680482|No Intervention|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
16443359|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
16443360|NCT03680469|Active Comparator|standard early rehabilitation|The standard early rehabilitation program after acute stroke is an intervention regularly utilized in the stroke center of National Taiwan University Hospital.
16443361|NCT03680469|Experimental|adding early out-of-bed mobilization|The adding early out-of-bed mobilization treatment will be defined as the patients with acute ischemic stroke who receive out-of-bed mobilization treatment in addition to standard early rehabilitation care.
16443362|NCT03680456|Active Comparator|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
16443363|NCT03680456|Placebo Comparator|Placebo|Natriumchlorid is the placebo
16443364|NCT03680430|Experimental|limb soft tissue sarcoma|
16443365|NCT03680417|Active Comparator|Safety Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
16443366|NCT03680417|Active Comparator|Sub Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
16443367|NCT03680404|Active Comparator|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
16443368|NCT03680404|Experimental|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10^-4 M) at the same rate and for the same time as the control arm.
16443369|NCT03680404|Experimental|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10^-5 M) at the same rate and for the same time as the control arm.
16443370|NCT03680404|Experimental|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10^-5 M) at the same rate and for the same time as the control arm.
16443371|NCT03680391||early postoperative feeding|103 patients will have early postoperative oral fluids and semisolid food after 6 hours of cesarean section irrespective to intestinal sounds ,flatus or stool passage
16443372|NCT03680391||Late postoperative feeding|97 patient will start oral fluids 6 hours with no solid or semi solid until after passage of flatus or stool
16443373|NCT03680378|Experimental|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
16443374|NCT03680352|Experimental|cefepime/AAI101 combination|Investigational drug
16443375|NCT03680339|Active Comparator|Routine ecbolic group|100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
16443376|NCT03680339|Active Comparator|Misoprostol group|The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
16443377|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
16443378|NCT03680313||Hypertension group|"All adult patients (above 18 year of age) were recruited between May, 2016 and June 2017, at Duc Giang General Hospital. The inclusion criteria are as followed:
~Patients have never been diagnosed with hypertension.
~Has been diagnosed with primary hypertension, but not take any treatment."
16443379|NCT03680313||Control group|A group of normal people with the similar age to hypertension group was recruited as control group at the same time
16443380|NCT03680300|Experimental|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
16443381|NCT03680300|Experimental|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
16443382|NCT03680300|Experimental|Frictional Massage|Frictional massage will be given to 3rd group
16443383|NCT03680287|Active Comparator|Uninterrupted Sleep|Participants will be permitted to sleep without interruption for 8 hours.
16443384|NCT03680287|Experimental|Sleep Disruption|Participants will be repeatedly awakened throughout the night according to a standardized protocol.
16443385|NCT03680274|Experimental|Vitamin C|Vitamin C: 50 mg/kg every 6 hours for 96 hours.
16443386|NCT03680274|Placebo Comparator|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
16443387|NCT03680261|Experimental|Adjuvant chemoradiotherapy group|Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
16443388|NCT03680261|Active Comparator|Adjuvant chemotherapy group|Adjuvant chemotherapy (6 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
16443389|NCT03680248|Experimental|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
16443390|NCT03680248|Experimental|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
16443391|NCT03680248|Other|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
16443392|NCT03680248|Other|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
16443393|NCT03680248|Experimental|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
16443394|NCT03680248|Experimental|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
16443395|NCT03680248|Experimental|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
16443396|NCT03680248|Experimental|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
16443397|NCT03680248|Experimental|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
16443398|NCT03680248|Experimental|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
16443399|NCT03680248|Experimental|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
16443400|NCT03680248|Experimental|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
16443401|NCT03680235|Active Comparator|Group I: (standard information about pregnancy, breastfeeding)|Participants receive standard information about pregnancy and breastfeeding. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
16443402|NCT03680235|Experimental|Group II (information about breastfeeding and cancer)|Participants receive standard information about pregnancy and breastfeeding as well as information about breastfeeding and breast cancer. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
16443403|NCT03680222|No Intervention|Standard method|Standard method recommended by the guide
16443404|NCT03680222|Experimental|Reversed Tracking Method|Reversed Tracking Method
16443405|NCT03680196|Experimental|cerebral palsy patients|cerebral palsy patients who have GMFCS level3,4,5 and 2 years old and under 10 years old apply an A injection of medication Botulinum A injection
16443406|NCT03680183||Pre-exposure|Entecavir 1Mg Oral Tablet
16443407|NCT03680183||Post-exposure|Entecavir 1Mg Oral Tablet
16443408|NCT03680170|Experimental|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.
~Intervention Device: web-based cognitive training"
16443409|NCT03680170|Placebo Comparator|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).
~Intervention Device: Web-based cognitive training"
16443448|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
16443410|NCT03680144|Experimental|Diagnostic (MRI, DSC-MRI)|Participants undergo diagnostic magnetic resonance imaging (MRI) with and without contrast and treatment planning dynamic susceptibility contrast-MRI (DSC-MRI) series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.
16443415|NCT03680118|Experimental|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
16443416|NCT03680105|Experimental|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
16443417|NCT03680105|Experimental|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
16443418|NCT03680105|Experimental|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
16443419|NCT03680105|Experimental|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
16443420|NCT03680105|Experimental|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
16443421|NCT03680105|Experimental|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
16443422|NCT03680105|Experimental|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
16443423|NCT03680105|Experimental|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
16443424|NCT03680105|Experimental|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
16443425|NCT03680092|Experimental|Cyclophosphamide and abatacept|The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
16443426|NCT03680092|Active Comparator|methotrexate and tacrolimus|The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus
16443427|NCT03680079|Other|Youth with type 1 diabetes|A group of 16 teens (ages 13-18) with poorly -controlled type 1 diabetes will be recruited to participate in this study.
16443428|NCT03680066|Experimental|Foods with traces|Oral food challenge with foods with traces
16443429|NCT03680053|Experimental|PPOS group|Ovarian stimulation will use the progestin-primed ovarian stimulation (PPOS) protocol.Women will receive progesterone (oral duphaston 20mg) daily from Day 3 till the day of ovulation trigger.
16443430|NCT03680053|Active Comparator|Antagonist group|Ovarian stimulation will use the antagonist protocol. Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
16443431|NCT03680027|No Intervention|Control Group|In 'Control group' participants had 6 week follow-up without any intervention.
16443432|NCT03680027|Experimental|Interventional Group|In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
16443433|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
16443434|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
16443435|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
16443436|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
16443437|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
16443438|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
16443439|NCT03679975|Experimental|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
16443440|NCT03679962|Experimental|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
16443441|NCT03679962|Active Comparator|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
16443442|NCT03679949|Placebo Comparator|Placebo|Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
16443443|NCT03679949|Experimental|Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
16443444|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0)|Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
16443445|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
16443446|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
16443447|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
16443449|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
16443450|NCT03679936||Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
16443451|NCT03679936||Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
16443452|NCT03679936||Multiple primary lung cancer group|PET/CT dynamic scan,needle biopsy and gene detection
16443453|NCT03679936||Intrapulmonary metastases group|PET/CT dynamic scan,needle biopsy and gene detection
16443454|NCT03679923|Experimental|NEM® brand eggshell membrane|NEM, 500 mg, #0 capsule, once daily orally for 2 weeks
16443455|NCT03679923|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks
16443456|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
16443457|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
16443458|NCT03679897|Experimental|Ropivacaine group|BPB with 0.375% ropivacaine solution
16443459|NCT03679897|Active Comparator|Levobupivacaine group|BPB with 0.25% levobupivacaine solution
16443460|NCT03679884|Experimental|ACT-541468 10 mg|Tablets administered orally, once daily in the evening
16443461|NCT03679884|Experimental|ACT-541468 25 mg|Tablets administered orally, once daily in the evening
16443462|NCT03679884|Experimental|ACT-541468 50 mg|Tablets administered orally, once daily in the evening
16443463|NCT03679884|Placebo Comparator|Placebo|Tablets administered orally, once daily in the evening
16443464|NCT03679871|Other|Questionnaire validation|"22-items questionnaire Spiritual Resources and Distress"
16443465|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
16443466|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
16443467|NCT03679845|Experimental|Sarilumab Arm|200 mg of sarilumab every two weeks
16443468|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
16443469|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
16443470|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
16443471|NCT03679819||HR-TRUS|HR-TRUS for the detection of prostate cancer in men scheduled for radical prostatectomy for localized prostate cancer
16443472|NCT03679806|Experimental|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
16443473|NCT03679806|Experimental|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
16443474|NCT03679793|Active Comparator|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger.
16443475|NCT03679793|Experimental|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
16443476|NCT03679780|Active Comparator|Control|This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
16443477|NCT03679780|Experimental|Inhibitor of Endothelin Type B Receptor|This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
16443478|NCT03679780|Experimental|Inhibition of Endothelin Type A Receptor|This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
16443479|NCT03679780|Experimental|L-Arginine|This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
16443480|NCT03679767|Experimental|INCMGA00012|INCMGA00012 administered to cohorts of specific tumor types.
16443481|NCT03679754|Experimental|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
16443482|NCT03679741|Experimental|TEST/CONTROL/CONTROL|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
16443483|NCT03679741|Experimental|CONTROL/TEST/TEST|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
16443484|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
16443485|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
16443486|NCT03679715|Experimental|Intervention group|The participants in the Intervention group will be participants of the museum participatory art-based activity.
16443487|NCT03679715|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the museum participatory art-based activity.
16443488|NCT03679702|Other|Active treatment|
16443489|NCT03679689|No Intervention|Control group|no changes in their alimentary habits
16443490|NCT03679689|Experimental|intervention group|no intake of artificially sweetened beverages
16443491|NCT03679676|Other|Cohort A: Omalizumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo
16443492|NCT03679676|Other|Cohort B: Omalizumab/Dupilumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.
16443493|NCT03679676|Other|Cohort C: Dupilumab|Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.
16443494|NCT03679663|No Intervention|Palpation|Anesthesia performed without ultrasound
16443495|NCT03679663|Experimental|Ultrasound|Anesthesia performed after ultrasound
16443496|NCT03679650|Experimental|AML Patient who are undergoing allogeneic transplantation|"Patients will be vaccinated with DC/AML fusion cells
~Four days of GM-CSF given subcutaneously at the site of vaccination
~Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine
~Patients will be treated with 5 days of decitabine in the post-transplant setting"
16443497|NCT03679650|Experimental|AML Patient who are undergoing transplantation|"Patients will be vaccinated with DC/AML fusion cells
~Four days of GM-CSF given subcutaneously at the site of vaccination
~Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine"
16443498|NCT03679637|Experimental|Intervention group|Each participant will receive a tablet-based aphasia therapy
16443499|NCT03679624|Experimental|Cohort A - Ibrutinib naive|Cohort A will consist of subjects who are ibrutinib naïve and appropriate for ibrutinib based treatment. Treatment naïve subjects will be eligible to enroll in this cohort. All subjects in this cohort will receive ibrutinib plus daratumumab
16443500|NCT03679624|Experimental|Cohort B - Ibrutinib response plateau|Cohort B will consist of subjects who have had at least 6 months of exposure to single agent ibrutinib and who have demonstrated an IgM response plateau defined by two IgM measurements, at least 8 weeks apart that have changed <15% from the previous mark. All subjects in this cohort will receive ibrutinib plus daratumumab
16443503|NCT03679598|Active Comparator|Alvelestat (MPH966)|Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks
16443504|NCT03679598|Placebo Comparator|Placebo|4 Placebo tablets twice daily by mouth for 12 weeks
16443505|NCT03679585|Experimental|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
16443506|NCT03679572|Experimental|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
16443507|NCT03679572|Active Comparator|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
16443508|NCT03679559|Experimental|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
16443509|NCT03679559|Experimental|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
16443510|NCT03679559|Experimental|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
16443511|NCT03679559|Active Comparator|Arm IV (supervised moderate intensity walking program)|Participants wear Fitbit and attend supervised moderate intensity walking sessions weekly for 50-60 each over 12 weeks. Participants undergo resistance training as in Arm I.
16443512|NCT03679559|Active Comparator|Arm V (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
16443513|NCT03679546|Experimental|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
16443514|NCT03679546|Experimental|Vedolizumab|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
16443515|NCT03679533|Active Comparator|Active Cranberry Study Food|
16443516|NCT03679533|Placebo Comparator|Placebo Study Food|
16443517|NCT03679520|Experimental|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
16443518|NCT03679520|Active Comparator|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
16443519|NCT03679507|Active Comparator|Group A|The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
16443520|NCT03679507|Placebo Comparator|Group B|"Will be treated with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light."
16443521|NCT03679507|Active Comparator|Group B1|The first patient group will receive high CBD oil applied topically to the affected knee joint.
16443522|NCT03679507|No Intervention|Group B2|This group of patients will not receive high CBD oil to the affected joint.
16443523|NCT03679494|Experimental|SDM intervention group|Using shared decision making support tool for intervention
16443524|NCT03679494|No Intervention|Usual care group|No intervention, just continue using usual care
16443525|NCT03679481|Experimental|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
16443526|NCT03679481|Placebo Comparator|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
16443527|NCT03679468|Sham Comparator|Cognitive Rehab & Sham Exercise|Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
16443528|NCT03679468|Sham Comparator|Sham Cognitive Rehab & Sham Exercise|Sham cognitive Rehabilitation will consist of basic internet searches and learning to use a computer, and sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
16443529|NCT03679468|Sham Comparator|Sham Cognitive rehab & Aerobic Exercise|Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
16443530|NCT03679468|Active Comparator|Cognitive Rehab & Aerobic Exercise|Cognitive Rehabilitation by computer based brain tasks and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
16443531|NCT03679455|Experimental|Treatment arm|Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.
16443532|NCT03679442|Experimental|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
16443533|NCT03679429||Control group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
16443534|NCT03679429||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.
16443535|NCT03679403||ADHD Probands|Subjects with DSM-IV ADHD who received the same MRI and CANTAB+CPT assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at the estimated age of 15-25.
16443536|NCT03679403||Unaffected siblings of ADHD|The unaffected siblings received the MRI and CANTAB+CPT assessments during 2013.8-2015.7 (NCT01682915) will be recruited and assessed.
16443537|NCT03679403||Neurotypicals Follow-up|Subjects without any lifetime diagnosis of DSM-IV ADHD or other psychiatric disorders as the control group of the ADHDFU group around 4-8 years ago when they received the same MRI and neuropsychological assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at their estimated age of 15-25.
16443538|NCT03679390|Experimental|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
16443539|NCT03679390|Experimental|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
16443540|NCT03679390|Experimental|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
16443541|NCT03679377|Experimental|Mandibular slotplate|Mandibular slotplates are placed during BSSO surgery and their clinical usefullness is tested. Afterwards the plates are removed and the osteotomy is fixated by three bicortical screws.
16443542|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
16443543|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
16443544|NCT03679338|Other|Ablation Therapy With Bipolar Radio Frequency|
16443545|NCT03679325|Active Comparator|vitamine D|a dose once a week
16443546|NCT03679325|Placebo Comparator|vitamine D placebo|a dose once a week
16443547|NCT03679312|Experimental|COPD Group|COPD to receive either placebo or inhaled nitric oxide (40ppm)
16443548|NCT03679312|Experimental|Control Group|Control group to receive either placebo or inhaled nitric oxide (40ppm)
16443549|NCT03679299||Healthy Control|Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
16443550|NCT03679299||Asthma|Individuals experiencing an asthma exacerbation will be recruited from the University of Alberta Hospital Emergency Department. Once discharged, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity. Participants will complete the same assessments at a follow up date 48 hours and 14 days post-discharge, with the addition of a full pulmonary function test, physical activity assessment via a Fitbit, and the completion of two questionnaires: Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire.
16443551|NCT03679286||All subjects|No intervention
16443552|NCT03679273|Experimental|Abound supplement|The participant will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
16443553|NCT03679273|No Intervention|Traditional supplement|The participant will take traditional diabetes-specific formula as provided by dietitians.
16443554|NCT03679260|Experimental|Arm A|Carbohydrate restricted diet and phone counseling with dietitian. After 6 months, patients will crossover to a non-restricted diet.
16443598|NCT03679026||WCVRF|individuals without cardio-vascular risk factors and diseases
16443555|NCT03679260|Experimental|Arm B|Non-restricted diet and after 6 months, patients will crossover to a carbohydrate restricted diet and phone counseling with dietitian
16443556|NCT03679247|Experimental|Intervention|Intervention arm will receive guidance within electronic health record from clinical decision support system.
16443557|NCT03679247|Experimental|Control|The control arm will continue to provide usual care.
16443558|NCT03679234|Experimental|Intervention|Routine infant formula
16443559|NCT03679221||Group 45-54 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
16443560|NCT03679221||Group 54-64 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
16443561|NCT03679221||Group 65-74 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
16443562|NCT03679221||Group 75-85 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
16443563|NCT03679208|Experimental|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
16443564|NCT03679208|Experimental|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
16443565|NCT03679208|Active Comparator|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
16443566|NCT03679195|Experimental|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
16443567|NCT03679195|Placebo Comparator|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
16443568|NCT03679182|Experimental|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
16443569|NCT03679169|Experimental|Group RAMPS|Radical antegrade modular pancreatosplenectomy
16443570|NCT03679169|Active Comparator|Group SPS|standard pancreatosplenectomy
16443571|NCT03679143|Experimental|ZSP1273(single dose)-100 mg(Cohort 1)|ZSP1273 100 mg /Placebo
16443572|NCT03679143|Experimental|ZSP1273(single dose)-200 mg(Cohort 2)|"ZSP1273 200mg/Placebo
~Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1."
16443573|NCT03679143|Experimental|ZSP1273(single dose)-400 mg(Cohort 3)|"ZSP1273 400mg/Placebo
~Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2."
16443574|NCT03679143|Experimental|ZSP1273(single dose)-600 mg(Cohort 4)|"ZSP1273 600 mg/Placebo
~Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3."
16443575|NCT03679143|Experimental|ZSP1273(single dose)-900 mg(Cohort 5)|"Drug:ZSP1273 900 mg/Placebo 900mg；
~Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4."
16443576|NCT03679143|Experimental|ZSP1273(single dose)-1200 mg(Cohort 6)|"ZSP1273 1200 mg/Placebo
~Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5."
16443577|NCT03679143|Experimental|ZSP1273(Food Effect)-Cohort 7|"Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.
~Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8."
16443578|NCT03679143|Experimental|ZSP1273(multiple doses)-Low Dose(Cohort 8)|"while fasted or fed according to the results of Cohort FE
~ZSP1273 /Placebo for 5 Days."
16443579|NCT03679143|Experimental|ZSP1273(multiple doses)-Median Dose(Cohort 9)|"while fasted or fed according to the results of Cohort FE
~ZSP1273/Placebo for 5 Days."
16443580|NCT03679143|Experimental|ZSP1273(multiple doses)-High Dose(Cohort 10)|"while fasted or fed according to the results of Cohort FE
~ZSP1273/Placebo for 5 Days."
16443581|NCT03679130|Experimental|Structured exercise training (EXE)|Structured supervised exercise training (EXE) contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
16443582|NCT03679130|Experimental|Motivational counseling (MOT)|Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
16443583|NCT03679130|No Intervention|Control group (CON)|Control group receiving standard treatment.
16443584|NCT03679117|Experimental|Mindfulness Training|Phone-delivered mindfulness training
16443585|NCT03679117|No Intervention|Treatment as Usual|Prenatal care
16443586|NCT03679104|Active Comparator|Endoscopic clips|Closure of mucosotomy using endoscopic clips
16443587|NCT03679104|Active Comparator|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
16443588|NCT03679091|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
16443589|NCT03679091|Active Comparator|clopidogrel|To observe the safety and efficacy between low-dose ticagrelor and standard-dose clopidogrel.
16443590|NCT03679078|Experimental|IDDSI nutritional supplement drink|Single arm designed, 28day on IDDSI nutritional supplement drink
16443591|NCT03679065|Active Comparator|P (Paracetamol) group:(n=100)|
16443592|NCT03679065|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
16443593|NCT03679065|Placebo Comparator|Placebo|
16443594|NCT03679052|Active Comparator|Group I (Mirtazapine group): (n=100)|
16443595|NCT03679052|Active Comparator|Group II (Clonidine group): (n=100)|
16443596|NCT03679052|Placebo Comparator|Group III (Control group): (n=100)|
16443597|NCT03679026||CVRF|individuals with cardio-vascular risk factors and diseases
16443599|NCT03679013|Other|Opoid based standard of care regimen.|Inova Heart and Vascular Institute (IHVI) opioid based standard of care regimen given for post operative cardiac surgery pain.
16443600|NCT03679013|Experimental|Opioid sparing pain regimen.|Multimodal pain regimen consisting of PO Gabapentin paired with intravenous Acetaminophen given for post operative cardiac surgery pain.
16443601|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
16443602|NCT03678987||SSc on MMF|"Patients with systemic sclerosis using mycophenolate mofetil (mycophenolic acid, MMF) since >3 months.
~During a 6 hour time period, P-MPA concentration will be measured 4 times."
16443603|NCT03678974|Experimental|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
16443604|NCT03678961||Group N|Neutral position
16443605|NCT03678961||Group E|External rotation of leg by 45 degrees
16443606|NCT03678961||Group EF45|External rotation of leg by 45 degrees, hip flexion by 45 degrees, and knee flexion by 45 degrees
16443607|NCT03678961||Group EF15|External rotation of leg by 45 degrees, hip flexion by 15 degrees, and knee flexion by 15 degrees
16443608|NCT03678948|Active Comparator|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
16443609|NCT03678948|Active Comparator|Mechanical Debridement|
16443610|NCT03678935|Active Comparator|Low FODMAP diet (LFD)|The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
16443611|NCT03678935|No Intervention|Control|Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
16443612|NCT03678909||Hypoplastic Left Heart Disease|Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure
16443613|NCT03678896|Experimental|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.
~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.
~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
16443614|NCT03678896|Active Comparator|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.
~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.
~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
16443615|NCT03678883|Experimental|9-ING-41|Drug: 9-ING-41
16443616|NCT03678883|Experimental|9-ING-41 plus Gemcitabine|Drugs: Gemcitabine - 21 day cycle. 9-ING-41
16443617|NCT03678883|Experimental|9-ING-41 plus Doxorubicin|Drugs: Doxorubicin. 9-ING-41
16443618|NCT03678883|Experimental|9-ING-41 plus Lomustine|Drugs: Lomustine. 9-ING-41.
16443619|NCT03678883|Experimental|9-ING-41 plus Carboplatin|Drugs: Carboplatin. 9-ING-41.
16443620|NCT03678883|Experimental|9-ING-41 plus nab paclitaxel Gemcitabine|Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
16443621|NCT03678883|Experimental|9-ING-41 plus Paclitaxel/Carboplatin|Drugs: Paclitaxel. Carboplatin. 9-ING-41.
16443622|NCT03678883|Experimental|9-ING-41 plus Irinotecan|Drugs: Irinotecan. 9-ING-41.
16443623|NCT03678870|Experimental|Education|Opioid Education
16443624|NCT03678870|No Intervention|Control|standard discharge instructions, which lists medications prescribed at discharge
16443625|NCT03678857|Experimental|Creatine Before|Receives Creatine before and placebo after training.
16443626|NCT03678857|Experimental|Creatine After|Receives creatine after and placebo before training.
16443627|NCT03678844|Experimental|Taekwondo practice|
16443628|NCT03678844|Placebo Comparator|CONTROL|
16443629|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
16443630|NCT03678818|Experimental|Handling Medium Supplemented with Latrunculin A|
16443631|NCT03678818|No Intervention|Handling Medium as it is.|
16443632|NCT03678805|Experimental|Acceleration|The impacted canines will undergo acceleration by corticotomy accompanied with traditional traction techniques.
16443633|NCT03678805|Active Comparator|Traditional Traction|"Traditional traction will be employed in this group of patients with impacted canines.
~Traditional withdrawal techniques will be used."
16443634|NCT03678792|Other|Buprenorphine-Naloxone|Standard of Care
16443635|NCT03678792|Experimental|Morphine|
16443636|NCT03678792|Experimental|Tramadol|
16443637|NCT03678779|Experimental|Incentive|Each week parents received one $5 grocery store gift card per child in the household, intended for the purchase of healthy snacks, donated to the study by a partnering grocery store
16443687|NCT03678493|Placebo Comparator|AML Patients undergoing Allo-HCT Patients Control|
16443638|NCT03678779|Experimental|Education|Parents received brief weekly nutrition education videos (approximately one minute in length, uploaded on YouTube and viewable on most operating systems and on mobile devices
16443639|NCT03678779|Experimental|Combined|Parents received both the Incentive and Education arm interventions
16443640|NCT03678766|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experimental learning.
16443641|NCT03678766|Experimental|Cognitive Behavior Therapy (CBT)|CBT provides coping skills, self-monitoring, and goal setting.
16443642|NCT03678753|Experimental|Cenobamate|Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks
16443643|NCT03678753|Placebo Comparator|Placebo|Matching placebo
16443644|NCT03678714|Experimental|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
16443645|NCT03678714|Experimental|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
16443646|NCT03678714|No Intervention|Control|Resting control
16443647|NCT03678701|Experimental|Protein group|The protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
16443648|NCT03678701|No Intervention|Control group|Control group will not consume any protein supplements. They will continue the usual feeding habits
16443649|NCT03678688|Active Comparator|Stage 1 and Stage 2: RHEZ|
16443650|NCT03678688|Experimental|Stage 1 Cohort 1|
16443651|NCT03678688|Experimental|Stage 1 Cohort 2|
16443652|NCT03678688|Experimental|Stage 1 Cohort 3|
16443653|NCT03678688|Experimental|Stage 1 Cohort 4|
16443654|NCT03678688|Experimental|Stage 2: OPC-167832/Delamanid|
16443655|NCT03678688|Experimental|Stage 2: OPC-167832/Bedaquiline|
16443656|NCT03678688|Experimental|Stage 2: OPC-167832/Delamanid/Bedaquiline|
16443657|NCT03678675|No Intervention|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain.
16443658|NCT03678675|Experimental|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 5 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room.
16443659|NCT03678662|Experimental|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
16443660|NCT03678662|Experimental|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
16443661|NCT03678662|Active Comparator|Neutral|In this group the subjects expectations are not manipulated
16443662|NCT03678649|Experimental|the treatment arm|"1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
~it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
16443663|NCT03678649|No Intervention|the control arm|clinical observation
16443664|NCT03678636|Experimental|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
16443665|NCT03678636|Active Comparator|Control|The wound will be treated as per usual care.
16443666|NCT03678623||Office-based workers|Individuals working in an office environment with their main tasks involving use of a computer, reading, phoning, making presentations and participating in meetings, who perform more than 30 hours per week mostly sitting at a computer.
16443667|NCT03678610|Experimental|ICSI medium supplemented with Ionomycin and Latrunculin A|
16443668|NCT03678610|No Intervention|ICSI medium as it is|
16443669|NCT03678597|Experimental|Handling Medium Supplemented with Latrunculin B|
16443670|NCT03678597|No Intervention|handling Medium as it is.|
16443671|NCT03678584|Experimental|Handling Medium Supplemented with Chaetoglobosin A|
16443672|NCT03678584|No Intervention|handling Medium as it is.|
16443673|NCT03678571|Experimental|Latrunculin A supplemented vitrification medium|
16443674|NCT03678571|No Intervention|Vitrification medium with no supplementation|
16443675|NCT03678558|Experimental|Cytochalasin B supplemented vitrification medium|
16443676|NCT03678558|No Intervention|Vitrification medium with no supplementation|
16443679|NCT03678532|Experimental|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
16443680|NCT03678532|Experimental|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
16443681|NCT03678519||Exposed workers|Flour mills workers exposed to health hazards
16443682|NCT03678506|Experimental|Positive D-Dimer|At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
16443683|NCT03678506|No Intervention|Negative D-Dimer|Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.
16443684|NCT03678493|Experimental|AML Patients undergoing Intensive Chemothera|
16443685|NCT03678493|Placebo Comparator|AML Patients undergoing Intensive Chemotherapy Control|
16443686|NCT03678493|Experimental|AML Patients undergoing Allo-HCT Patients|
16443689|NCT03678480|Active Comparator|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
16443690|NCT03678467|Experimental|EB-CMF Implant|Subject receiving EB-CMF implant
16443691|NCT03678441|Experimental|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
16443692|NCT03678441|Active Comparator|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
16443693|NCT03678428|Experimental|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:
~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
16443694|NCT03678428|Active Comparator|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:
~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
16443695|NCT03678415|Experimental|Control|In the control arm, the community healthcare providers serve usual health education like counseling as they provided in perinatal period of enrolled mothers regular follow up basis. This health education is different from developed intervention. But service provider does not know. The investigators select community clinic before provide training regarding training manual. For this, the investigators selected 11 cluster randomly among the 23 community clinics' in the primary health care in study area and provide common health education instructions to the enrolled mothers. But service providers does not know the intervention package services that will provide in intervention arm's service providers.
16443696|NCT03678402|Experimental|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
16443697|NCT03678389|Experimental|1|ENDOSPHENOIDAL COIL
16443698|NCT03678376|Other|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
16443699|NCT03678363|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
16443700|NCT03678363|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
16443701|NCT03678350|Experimental|Treatment (porfimer sodium, IO-PDT)|Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.
16443702|NCT03678337||Observational cohort with plasma samples|
16443703|NCT03678324|Other|Fabry|Must be 18 or older and able to have an MRI.
16443704|NCT03678311|Other|Sleep Apnea ahi > 5|If Sleep Apnea index is > 5 and diagnosed with Long QT Syndrome
16443705|NCT03678285|Experimental|HIFRT Workout|Consecutive completion of; 1 mile run, 100 pull ups, 200 push-ups, 300 bodyweight squats, 1 mile run.
16443706|NCT03678272|Active Comparator|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
16443707|NCT03678272|Active Comparator|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
16443708|NCT03678272|Active Comparator|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
16443709|NCT03678272|Active Comparator|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
16443710|NCT03678259|Experimental|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
16443711|NCT03678246|Experimental|LSFOI (Ramped)|LSFOI (Ramped)
16443712|NCT03678246|Active Comparator|LSFOI (Supine)|LSFOI (Supine)
16443713|NCT03678233|Active Comparator|Intervention|AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
16443714|NCT03678233|No Intervention|Control|In the control group, AndroGel will not be administered.
16443715|NCT03678220|Experimental|Patients using LapAR system|
16443716|NCT03678207||Potential Undiagnosed HTN|
16443717|NCT03678194|Experimental|Smartphone application|This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
16443718|NCT03678194|No Intervention|Standard services|This group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.
16443719|NCT03678181|Active Comparator|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
16443720|NCT03678181|Experimental|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question & answer platform.
16443758|NCT03677960|Experimental|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
16443721|NCT03678181|Experimental|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
16443722|NCT03678168|Other|Control|Standard care (Throat pack) which will be used as a control.
16443723|NCT03678168|Experimental|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
16443724|NCT03678155|Active Comparator|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
16443725|NCT03678155|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
16443726|NCT03678129|Experimental|Placebo, AZD7325_10, AZD7325_20|Dose order: Placebo, AZD7325 10mg, AZD7325 20mg
16443727|NCT03678129|Experimental|Placebo, AZD7325_20, AZD7325_10|Dose order: Placebo, AZD7325 20mg, AZD7325 10 mg
16443728|NCT03678129|Experimental|AZD7325_20, Placebo, AZD7325_10|Dose order: AZD7325 20mg, Placebo, AZD7325 10mg
16443729|NCT03678129|Experimental|AZD7325_10, Placebo, AZD7325_20|Dose order: AZD7325 10mg, Placebo, AZD7325 20mg
16443730|NCT03678129|Experimental|AZD7325_10, AZD7325_20, Placebo|Dose order: AZD7325 10mg, AZD7325 20mg, Placebo
16443731|NCT03678129|Experimental|AZD7325_20, AZD7325_10, Placebo|Dose order: AZD7325 20mg, AZD7325 10mg, Placebo
16443732|NCT03678116|Placebo Comparator|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
16443733|NCT03678116|Experimental|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
16443734|NCT03678116|Experimental|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
16443735|NCT03678103|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
16443736|NCT03678090|Active Comparator|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
16443737|NCT03678090|Experimental|tPA low dosage|tPA dose of 2.5mg
16443738|NCT03678077||Mild traumatic brain injury|"Patients between 18-60 years, who were hospital admitted, emergency or outpatient treated with mild traumatic brain injury (ICD-10 S06.0). Data were extracted from the Danish national patient register from January 2003 - December 2007.
~Patients who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
16443739|NCT03678077||Matching controls|"Matching controls without concussion of the same age, from the same municipality and of same gender as the included cases. Controls were included during 2003 - 2007. Data were extracted from the population register.
~Controls who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
16443740|NCT03678064|Experimental|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
16443741|NCT03678051|Active Comparator|Treatment as Usual (TAU)|Standard of care
16443742|NCT03678051|Experimental|TAU+CBT4CBT|TAU with access to the CBT4CBT program
16443743|NCT03678038|Experimental|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
16443744|NCT03678038|Active Comparator|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
16443745|NCT03678025|Active Comparator|Arm I (SST)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.
16443746|NCT03678025|Experimental|Arm II (SST, prostatectomy or radiation therapy)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.
16443747|NCT03678025|Active Comparator|Step 1 (pre-randomization)|Standard treatment data collection prior to randomization
16443748|NCT03678012|Active Comparator|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
16443749|NCT03678012|Placebo Comparator|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
16443750|NCT03678012|Sham Comparator|Water|Sham solution (water; negative control)
16443751|NCT03677999||Brain tumor patients with Glioma|"Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.
~Passed the safety screen for MRI
~Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
16443752|NCT03677986|No Intervention|Usual Care|Participants in this group will be referred to receive office-based buprenorphine treatment
16443753|NCT03677986|Experimental|Video DOT+|Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
16443754|NCT03677973|Active Comparator|Active: Dose Escalation|Healthy volunteers will receive AB680 as a single intravenous (IV) infusion at 7 dose levels and as multiple IV infusions at 1 dose level. Assignment to receive AB680 or matching placebo will be random.
16443755|NCT03677973|Placebo Comparator|Placebo: Dose Escalation|Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
16443756|NCT03677960|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
16443757|NCT03677960|Experimental|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
16443844|NCT03677297|Placebo Comparator|placebo|No intervention used on control site
16443763|NCT03677921|Experimental|Investigational Group- Bio-Germanium|"Ingredient: Bio-Germanium
~Type: HPMC capsule
~Weight: 300mg/capsule
~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)
~Duration of use: 8 weeks"
16443764|NCT03677921|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Corn starch
~Type: HPMC capsule
~Weight: 300mg/capsule
~Directions: 2 capsules, twice a day
~Duration of use: 8 weeks"
16443765|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
16443766|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
16443767|NCT03677895|Experimental|patients with rotator cuff disorders|patients with rotator cuff disorders, including impingment, rotator cuff disorders and rotator cuff tear receiving hyaluronic acid injection over subacromial bursa
16443768|NCT03677882|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
16443769|NCT03677882|Experimental|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator.
16443770|NCT03677869|Experimental|Pneumatic vitreolysis (PVL)|Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.
16443771|NCT03677856|Experimental|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
16443772|NCT03677856|Active Comparator|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
16443773|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
16443774|NCT03677830|Active Comparator|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; >39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
16443775|NCT03677830|Placebo Comparator|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
16443776|NCT03677817|Active Comparator|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
16443777|NCT03677817|Placebo Comparator|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
16443778|NCT03677791|Experimental|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
16443779|NCT03677791|Active Comparator|Control group|counselling in accordance with current practice
16443780|NCT03677778|Placebo Comparator|Placebo group|This control group will have no normal saline injected into their nerve catheter (no intervention). This group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
16443781|NCT03677778|Active Comparator|Treatment group|This group will have 30ml normal saline injected into their nerve catheter. The treatment group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
16443782|NCT03677765|Active Comparator|Infraclavicular group|In the infraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle.
16443783|NCT03677765|Active Comparator|Supraclavicular group|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
16443784|NCT03677752|Experimental|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
16443785|NCT03677752|No Intervention|Control|Participants in the control arm will receive usual care.
16443842|NCT03677310|Sham Comparator|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
16443788|NCT03677726|Experimental|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
16443789|NCT03677726|Active Comparator|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
16443790|NCT03677713|Active Comparator|Nasal Packing|Nasal packing will be placed at the end of surgery.
16443791|NCT03677713|Experimental|No Nasal Packing|No nasal packing will be placed during or after the surgery.
16443792|NCT03677687|Experimental|Mindfulness for Physical Activity|A 6-week mindfulness programme (2 hours per week) aimed at increasing physical activity in underactive participants.
16443793|NCT03677674|Experimental|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
16443794|NCT03677674|No Intervention|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
16443795|NCT03677661|Active Comparator|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
16443796|NCT03677661|Experimental|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
16443801|NCT03677635|Experimental|Intervention|Guided autobiographical memory recall to enhance specificity and links to the future.
16443802|NCT03677635|No Intervention|Control|Recall without prompts or psychoeducation video.
16443803|NCT03677622|Experimental|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:
~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.
~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
16443804|NCT03677622|Active Comparator|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.
~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.
~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.
~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.
~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
16443805|NCT03677609|Experimental|Intervention|Physicians will receive a training or trainings to improve their communication and interaction with patients. The primary trainings will involve teaching physicians how to understand and leverage patient psychology as part of clinical care. Impact on patient health will then be assessed.
16443806|NCT03677609|No Intervention|Control|
16443807|NCT03677596|Experimental|Dose Level 2|Inotuzumab ozogamicin at starting dose 1.2 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
16443808|NCT03677596|Active Comparator|Dose Level 1|Inotuzumab ozogamicin at starting dose 1.8 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
16443809|NCT03677583|Experimental|Duckweed|daily lunch with 150-180g wet weight duck weed
16443810|NCT03677583|Active Comparator|Spinach|daily lunch with 150-180g wet weight spinach
16443811|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
16443812|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
16443813|NCT03677557|Other|Cutaquig Intervention|Participants with primary or secondary immunodeficiency disease who are currently on subcutaneous immunoglobulin treatment but have developed adverse events including allergic reaction and are willing to change the treatment product to 16.5% Cutaquig.
16443814|NCT03677544||exploratory cohort (A)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
16443815|NCT03677544||exploratory cohort (B)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
16443816|NCT03677531|Experimental|Other (radiation therapy, videos)|Participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.
16443817|NCT03677505|Experimental|KoMAC group|Orotracheal intubation with KoMAC videolaryngoscope
16443818|NCT03677505|Active Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscope
16443819|NCT03677492|Experimental|Handling Medium Supplemented with Cytochalasin D|
16443820|NCT03677492|No Intervention|Handling Medium as it is.|
16443821|NCT03677479|Experimental|socket preservation with camelline bone|natural hydroxyapatite derived from camels prepared by investigator
16443822|NCT03677479|Active Comparator|socket preservation with bovine bone|natural hydroxyapatite derived from cows (Bio-Oss)
16443823|NCT03677466|Experimental|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
16443824|NCT03677466|Active Comparator|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
16443825|NCT03677453|Active Comparator|IPTP|Patients will have access to the web-based interactive teaching tool.
16443826|NCT03677453|No Intervention|Non-IPTP|Patients will not have access to the web-based interactive teaching tool.
16443827|NCT03677440|Experimental|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.
~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
16443828|NCT03677440|Active Comparator|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
16443829|NCT03677427|Experimental|5 fractions|
16443830|NCT03677427|Experimental|15 fractions|
16443831|NCT03677401|Experimental|5 mg Serlopitant Tablets|
16443832|NCT03677401|Placebo Comparator|Matching Placebo Tablets|
16443833|NCT03677375|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
16443834|NCT03677362|Experimental|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
16443835|NCT03677349|Experimental|Resensitized group|Patients with resensitized free flap by neurorrhaphy
16443836|NCT03677349|Experimental|Non Resensitized group|Patients without resensitized free flap by neurorrhaphy.
16443837|NCT03677336|Other|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.
~1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.
~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
16443838|NCT03677336|Other|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.
~1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.
~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
16443839|NCT03677323|Experimental|Virtual reality|The virtual reality device will consist of the virtual reality headset and headphones for full immersion.
16443840|NCT03677323|Active Comparator|Drug sedation|The sedation group will benefit from drug sedation used in current practice, that is to say an association of Sufentanil, Droleptan and Propofol.
16443841|NCT03677310|Experimental|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
16443845|NCT03677284|Experimental|Intervention group|"Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
~Time assistive product. Time assistive products for time perception are products making the passage of time visible and understandable, to know for how long to perform an activity or how long to wait until the next activity starts e.g a time log.
~Time assistive products for time orientation includes the use of schedules, calendars and other visual aids to promote orientation to the time of the day, week, or year.
~Time assistive products for time management would compensate for deficits in time management and focus on self-scheduling skills."
16443846|NCT03677284|Active Comparator|Control group|Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
16443847|NCT03677271|Other|Physical Activity|
16443848|NCT03677258|Experimental|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
16443849|NCT03677258|Active Comparator|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
16443850|NCT03677245|Experimental|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
16443851|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
16443852|NCT03677219|No Intervention|Control|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, and do not view an educational video.
16443853|NCT03677219|Experimental|Video|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, then view a 2 minute educational video and respond to a second survey.
16443854|NCT03677206|Sham Comparator|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
16443855|NCT03677206|Experimental|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
16443856|NCT03677206|Other|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
16443857|NCT03677193|Experimental|Experimental arm|
16443858|NCT03677167|Experimental|walking on a treadmill barefoot group|26 Patients in this group will walk barefoot on the treadmill and will be asked to walk barefoot at home and report the time of barefoot walking at home
16443859|NCT03677167|Active Comparator|Walking on a treadmill with shoes group|26 Patients in this group will walk with shoes on the treadmill
16443863|NCT03677141|Experimental|Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding|Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
16443864|NCT03677141|Experimental|Phase Ib: M-CHP-Pola Dose-Finding|Participants will receive M-CHP-Pola up to the RP2D.
16443865|NCT03677141|Experimental|Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort|Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
16443866|NCT03677141|Experimental|Phase II: M-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
16443867|NCT03677141|Active Comparator|Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
16443868|NCT03677141|Experimental|Phase II: M-CHOP 1L DLBCL|Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.
16443869|NCT03677128|Experimental|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
16443870|NCT03677128|No Intervention|Historical controls|BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.
16443871|NCT03677115|Experimental|dexmedetomidine group|a combination of ropivacaine and dexmedetomidine
16443872|NCT03677102|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
16443873|NCT03677102|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
16443874|NCT03677089|Experimental|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
16443875|NCT03677076||Ancillary/Correlative|Patients will complete questionnaires and have research blood drawn.
16443876|NCT03677063|No Intervention|Dressing|"It is the historical cohort which is composed of patients over 18 years of age treated by peritoneal dialysis in the nephrology department of Universty Hospital of Caen Normandie. Patients with the same non-inclusion criteria as the experimental group will not be included. The data will be extracted from the Registry of Peritoneal Dialysis of French Language. The number of patients included from the register can not be fixed in advance; this number will correspond to the 4-year follow-up at the start date of the study to ensure at least two years of patient follow-up
~Usually care
~First dressing 5 or 10 days after the pose of the catheter :
~Cleaning emergence with antiseptic soap
~Rinsing with saline
~Drying
~Application of a hazelnut mupirocin on the exit-site
~Application of an occlusive dressing on the exit-site Then, care is the same. Exit-site care is performed daily if the patient takes a shower or twice a week."
16443877|NCT03677063|Experimental|No dressing|No application of sterile dressing at the exit-site of periotoneal dialysis catheter for all patients (30 days after the placement of the peritoneal dialysis catheter)
16443878|NCT03677050|No Intervention|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
16443986|NCT03676296|Experimental|Puerarin|Puerarin (90.2 mg daily) in granules
16443879|NCT03677050|Experimental|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
16443880|NCT03677037|Experimental|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
16443881|NCT03677037|Active Comparator|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
16443882|NCT03677024|Experimental|SLN arm|"Experimental:
~Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.
~Full bilateral laparoscopic lymphadenectomy and hysterectomy:
~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.
~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.
~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
16443883|NCT03677024|No Intervention|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
16443884|NCT03677011|Other|category 1|Low responder
16443885|NCT03677011|Other|category 2|Medium Responder and High Responder
16443886|NCT03676998|Other|Measurement of diaphragm function|Patients will be followed up from admission to weaning with twice a week a diaphragm function multimodal evaluation (ultrasound, phrenic nerves stimulation technique)
16443887|NCT03676985|Experimental|ZKAB001 5 mg/kg/time|Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
16443888|NCT03676985|Experimental|ZKAB001 10 mg/kg/time|Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
16443889|NCT03676985|Experimental|ZKAB001 15 mg/kg/time|Three or six patients will treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
16443890|NCT03676972|Experimental|LithoVue ureteroscope system|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
16443891|NCT03676959|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
16443892|NCT03676959|Experimental|ZKAB001 10 mg/kg|Three or six patients will be treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
16443893|NCT03676959|Experimental|ZKAB001 15 mg/kg|Three or six patients will be treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
16443894|NCT03676946|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
16443895|NCT03676946|Experimental|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
16443896|NCT03676946|Experimental|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
16443897|NCT03676933|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
16443898|NCT03676933|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
16443899|NCT03676920|Experimental|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
16443900|NCT03676907|No Intervention|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
16443901|NCT03676907|Experimental|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
16443902|NCT03676894|Sham Comparator|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
16443903|NCT03676894|Active Comparator|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
16443904|NCT03676894|Experimental|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
16443905|NCT03676881||Mild Cognitive Impairment (MCI)|30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
16443906|NCT03676881||Cognitively normal subjects (CN)|30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
16443907|NCT03676855|Active Comparator|bladder dissection before uterine incision|
16443908|NCT03676855|Experimental|bladder dissection after uterine incision|
16443909|NCT03676842|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
16443910|NCT03676829|Experimental|Arterial Embolization of the Shoulder (AES)|Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
16443911|NCT03676816|Experimental|Vaginal self-sampling and provider performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
16443912|NCT03676803|Experimental|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
16443913|NCT03676803|Placebo Comparator|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
16443914|NCT03676790|Experimental|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
16443915|NCT03676790|Experimental|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
16443916|NCT03676790|Experimental|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
16443917|NCT03676790|Experimental|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
16443918|NCT03676790|Experimental|Group V|(patients received only exercise sessions three times a week for eight weeks)
16443919|NCT03676777||Infection|Patients admitted or developed bacterial/fungal infection while hospitalization
16443920|NCT03676777||Non-infection|Patients without bacterial/fungal infection
16443921|NCT03676764|Active Comparator|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
16443922|NCT03676764|Placebo Comparator|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
16443923|NCT03676764|Placebo Comparator|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
16443924|NCT03676764|Active Comparator|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
16443925|NCT03676751|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
16443926|NCT03676751|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
16443927|NCT03676738||In-patient spine surgery|Scheduled for an in-patient, elective spine surgery where subject will receive general anesthesia
16443928|NCT03676738||Non-surgical spine care|Presenting to spine clinic and undergoing conservative, non-surgical management of spine disorder
16443929|NCT03676725|Experimental|All subjects|All subjects get the lidocaine taste test
16443930|NCT03676712|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
16443931|NCT03676686|Experimental|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
16443932|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
16443933|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
16443934|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
16443935|NCT03676647||Diagnostic (biospecimen collection)|Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay.
16443937|NCT03676621|Experimental|study group|patients will receive buccal misoprostol
16443938|NCT03676621|Active Comparator|control group|patients will receive intravenous oxytocin
16443939|NCT03676608|Experimental|Bee wax mammary areolae|"Usual educational care plus the product.
~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
16443940|NCT03676608|Active Comparator|Control|Usual educational care.
16443941|NCT03676595|Experimental|Group A|Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
16443942|NCT03676595|Experimental|Group B|Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
16443943|NCT03676569|Experimental|Experimental group|Autologous ADRC transplantation in autoimmune refractory epilepsy
16443944|NCT03676556|Active Comparator|Topical lidocaine|23 patients will recieve lidocaine solution before wound treatment
16443945|NCT03676556|Placebo Comparator|Saline serum|23 patients will recieve saline solution before wound treatment
16443946|NCT03676543|Experimental|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
16443947|NCT03676530|No Intervention|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
16443948|NCT03676530|Experimental|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
16443949|NCT03676517|Experimental|Preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
16443950|NCT03676504|Experimental|Stratum I|Adult patients with relapsed or refractory ALL
16443951|NCT03676504|Experimental|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
16443952|NCT03676504|Experimental|Stratum III|Pediatric patients with relapsed or refractory ALL
16443953|NCT03676491|Experimental|Experimental Group|"Music Intervention: Participants listen to music minimum 30 minutes at bedtime for a period of 4 weeks wearing accelerometer.
~Participants are monitored for a 4 week follow up period wearing accelerometer"
16443987|NCT03676296|Placebo Comparator|Placebo|Placebo in granules
16444078|NCT03675672|Active Comparator|Group 1|Misoprostol Oral tablet, 200mcg, QID
16443954|NCT03676491|No Intervention|Waitlist Control Group|"No intervention: Participants are monitored for a period of 4 weeks wearing accelerometer.
~Participants are monitored for a 4 week follow up period wearing accelerometer."
16443955|NCT03676478|No Intervention|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
16443956|NCT03676478|Active Comparator|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of 4.000 kCal in the immediate postoperative course.
16443957|NCT03676465|Experimental|Experimental Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will receive a weekly CloudConnect Report based on analysis of the weekly data gathered for each participant. The report will be sent via email once a week to both the subject and their parent(s). Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:
~the communication within the family about the information shared in this report
~how subjects feel when blood sugar is high or low
~who takes responsibility of how diabetes care is managed"
16443958|NCT03676465|Active Comparator|Control Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will not receive a CloudConnect Report. Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:
~the communication within the family about the information shared in this report
~how subjects feel when blood sugar is high or low
~who takes responsibility of how diabetes care is managed"
16443959|NCT03676452|Experimental|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
16443960|NCT03676452|No Intervention|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
16443961|NCT03676439|Active Comparator|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
16443962|NCT03676439|Placebo Comparator|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
16443963|NCT03676426|Experimental|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
16443964|NCT03676426|Active Comparator|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
16443965|NCT03676413|Experimental|Test (T)|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals
16443966|NCT03676413|Active Comparator|Reference (R)|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
16443967|NCT03676413|Placebo Comparator|Placebo|
16443968|NCT03676400|Experimental|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.
~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
16443969|NCT03676400|Placebo Comparator|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
16443970|NCT03676387|No Intervention|Aged based group (group AB) (n = 27)|ETT size was determined according to age
16443971|NCT03676387|Active Comparator|Ultrasound based group (group UB) (n = 27): ETT was determined|ETT was determined according to the subglottic transverse diameter that was estimated with ultrasonography.
16443972|NCT03676374|Experimental|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
16443973|NCT03676374|Placebo Comparator|Placebo|Placebo once a day as add-on for PPI 2x/d
16443974|NCT03676361|Experimental|Desmopressin|All ten subjects will be evaluated pre and post nephrectomy at 6 months.
16443975|NCT03676335|Experimental|0.3 g: 0.15 mg（1)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
16443976|NCT03676335|Experimental|0.3 g: 0.15mg（2)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
16443977|NCT03676335|Experimental|0.3 g: 0.3 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
16443978|NCT03676335|Active Comparator|0.4 ml: 0.2 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
16443979|NCT03676322|Experimental|Part A: M5049|
16443980|NCT03676322|Placebo Comparator|Part A: Placebo|
16443981|NCT03676322|Experimental|Part B: M5049|
16443982|NCT03676322|Placebo Comparator|Part B: Placebo|
16443983|NCT03676322|Experimental|Part C: M5049|
16443984|NCT03676309|Placebo Comparator|placebo|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
16443985|NCT03676309|Active Comparator|nutraceutical oral capsule|nutraceutical oral capsule 920 mg twice a day for 12 weeks
16443988|NCT03676283|Experimental|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
16443989|NCT03676244|Experimental|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
16443990|NCT03676231|Experimental|High-dose SGM-1019|
16443991|NCT03676231|Experimental|Low-dose SGM-1019|
16443992|NCT03676231|Placebo Comparator|Placebo|
16443993|NCT03676218||Elderly cancer patients|
16443994|NCT03676205|Experimental|Platelet-Rich Plasma|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 6-7 ml of PRP .
~After 4-5 days from the injury the patient starts physiotherapy adapted by stages, according to the muscular group affected.
~After 7 days from the first infiltration, the patient will recived the second infiltration of 6-7 ml of PRP."
16443995|NCT03676205|Other|Traumel ®|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 4 ml of a homeopathic product (Traumeel ®) After 4-5 days from the date of injury, the patient starts physiotherapy adapted by stages, according to the muscular group affected.
~After 7 days from the first infiltration, the patient will receive the second infiltration of 4 ml of a homeopathic product."
16443996|NCT03676192|Experimental|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
16443997|NCT03676192|Active Comparator|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
16443998|NCT03676179|Active Comparator|unicompartment knee arthroplasty and patella denervation|UKA and patella denervation
16443999|NCT03676179|Experimental|unicompartment knee arthroplasty and patella non-denervation|UKA and patella non-denervation
16444000|NCT03676166|Experimental|0mg THC smoked cannabis|placebo smoked cannabis
16444001|NCT03676166|Experimental|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
16444002|NCT03676166|Experimental|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
16444003|NCT03676166|Experimental|0mg THC vaporized cannabis|placebo vaporized cannabis
16444004|NCT03676166|Experimental|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
16444005|NCT03676166|Experimental|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
16444006|NCT03676153|Experimental|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
16444007|NCT03676153|Active Comparator|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
16444008|NCT03676140|Active Comparator|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
16444009|NCT03676140|Experimental|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
16444010|NCT03676127||Study Group|ultrasonographic dermal thickness measurements in patients with unilateral breast cancer related lymphedema
16444011|NCT03676114|Experimental|ketamine group|
16444012|NCT03676114|Placebo Comparator|normal saline group|
16444013|NCT03676101|Experimental|9-valent HPV Recombinant Vaccine|
16444014|NCT03676101|Placebo Comparator|Placebo|
16444015|NCT03676088|Experimental|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
16444016|NCT03676088|Active Comparator|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
16444017|NCT03676062|Active Comparator|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
16444018|NCT03676062|Active Comparator|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
16444019|NCT03676062|Active Comparator|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked&progressed in each control sessions.
16444020|NCT03676036|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
16444021|NCT03676036|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
16444022|NCT03676023||Pulmonary Hemorrhage|Patients treated for pulmonary hemorrhage with inhaled Transexamic Acid
16444023|NCT03676010||Sarcoma and GIST|
16444024|NCT03676010||Breast cancer|
16444025|NCT03676010||Pancreatic cancer|
16444026|NCT03676010||Renal cell carcinoma|
16444027|NCT03676010||Colon Cancer (adjuvant setting)|
16444028|NCT03676010||Solid tumours undergoing image-guided tumor ablation|
16444029|NCT03675997||Autografted patients|Patients hospitalized in the hematological department of the Institute will complete the first day of conditioning and then weekly HAD (Hospital Anxiety and Depression) scale.
16444030|NCT03675984|Experimental|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
16444031|NCT03675971|Experimental|Medical Cannabis|Drug: Cannabidiol
16444032|NCT03675971|Placebo Comparator|Placebo|Placebo comparator
16444076|NCT03675711|Active Comparator|Standard Peripheral venous Catheter|Pt. will receive a standard Peripheral venous catheter
16444033|NCT03675958|Experimental|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
16444034|NCT03675958|Active Comparator|GS|Control group (GS): Just Stretching in 4 different treatment postures.
16444035|NCT03675932|Experimental|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
16444036|NCT03675919|Active Comparator|Control group|The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.
16444037|NCT03675919|Experimental|TeLIPro group|The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.
16444038|NCT03675906||preoperative albumin levels <3.8|
16444039|NCT03675906||preoperative albumin level >3.8|
16444040|NCT03675906||postoperative Day 2 albumin level <2.9|
16444041|NCT03675906||postoperative Day 2 albumin level >2.9|
16444042|NCT03675893|Experimental|Cohort 1A|"Abemaciclib is administered by mouth twice daily
~Letrozole is administered by mouth once daily"
16444043|NCT03675880|Experimental|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
16444044|NCT03675880|Experimental|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
16444045|NCT03675880|Experimental|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
16444046|NCT03675880|Experimental|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
16444047|NCT03675880|Experimental|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
16444048|NCT03675880|Experimental|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
16444049|NCT03675867||Obese teenagers|
16444050|NCT03675854|Experimental|Extended Group|3 weeks of antibiotics
16444051|NCT03675854|Active Comparator|Conventional Group|2 weeks of antibiotics
16444052|NCT03675841|Experimental|0.1% single-dose pre|Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
16444053|NCT03675841|Experimental|0.1% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
16444054|NCT03675841|Experimental|0.3% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose
16444055|NCT03675841|Experimental|0.5% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose
16444056|NCT03675828|Experimental|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
16444057|NCT03675828|No Intervention|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
16444058|NCT03675815|Active Comparator|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
16444059|NCT03675815|Experimental|Dolutegravir + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC)|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
16444060|NCT03675815|Experimental|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
16444061|NCT03675802|Active Comparator|Arm number one ,misoprostol|
16444062|NCT03675802|Active Comparator|Arm number 2 dinoprostone|
16444063|NCT03675789||STEMI|50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
16444064|NCT03675789||Stable angina|50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
16444065|NCT03675789||Controls|50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
16444066|NCT03675776|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
16444067|NCT03675776|Experimental|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
16444068|NCT03675776|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration).
16444069|NCT03675763|Experimental|Craniosacral therapy|Craniosacral therapy and parent information on how to manage colic.
16444070|NCT03675763|No Intervention|Parent information|Parent information on how to manage colic.
16444071|NCT03675737|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
16444072|NCT03675737|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
16444073|NCT03675724|Experimental|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
16444074|NCT03675724|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
16444075|NCT03675711|Active Comparator|Midline Catheter|Pt. will receive midline catheters.
16444077|NCT03675685|Experimental|CCH (Collagenase clostridium histolyticum)|
16444079|NCT03675672|Placebo Comparator|Group 2|Placebo Oral Tablet, 1 tab, QID
16444080|NCT03675659|Active Comparator|intra-articular injection|intra-articular injection with magnesium sulfate at weekly interval for four weeks
16444081|NCT03675659|Placebo Comparator|control|intra-articular injection with saline
16444082|NCT03675646|Experimental|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
16444083|NCT03675646|No Intervention|Control group C|No intervention
16444084|NCT03675633||FEUrea in decompensated liver cirrhosis|FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS
16444085|NCT03675620|Active Comparator|Standard Rehabilitation (Control Group)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
16444086|NCT03675620|Experimental|Blood Flow Restriction (BFR)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to the BFR group will begin combining BFR with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for the first 6 weeks post-operative care. Standard rehabilitation will continue until discharge.
16444087|NCT03675607||Caregivers infants <2years old|Caregivers of infants under 2 years of age (parents or other), of any gender, who prepare complementary feeding regularly (more than once a week).
16444088|NCT03675594|Experimental|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
16444089|NCT03675594|Experimental|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
16444090|NCT03675581|Experimental|All subjects|
16444091|NCT03675568|Experimental|study group|Non-Cultured autologous keratinocyte suspension
16444092|NCT03675568|Active Comparator|Control group|Split skin Graft
16444093|NCT03675555|Active Comparator|M (Mirtazapine) (Merta) group:(n=100)|
16444094|NCT03675555|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
16444095|NCT03675555|Placebo Comparator|C (Control) group: (n=100)|
16444096|NCT03675542|Experimental|Study medication|HSP90 inhibitor (CUDC-305)
16444097|NCT03675529|Experimental|High Intensity Interval Training bout|Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
16444098|NCT03675529|No Intervention|Controls (usual care)|Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
16444099|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
16444100|NCT03675516||Controls|Age, gender and primary care practice-matched controls
16444101|NCT03675503|No Intervention|Control|No change in the standard of care.
16444102|NCT03675503|Experimental|Fall Prevention Decision Support|"Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.
~Decision support aimed at preventing hospital falls and empowering nurses."
16444103|NCT03675490|Experimental|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
16444104|NCT03675477|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 16.
16444105|NCT03675477|Active Comparator|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 16.
16444106|NCT03675477|Active Comparator|SHR0302 dose C|Participants randomized in this arm will receive dose D of SHR0302 until end of study at week 16.
16444107|NCT03675477|Placebo Comparator|palcebo|Participants randomized in this arm will receive placebo until week 8, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 16.
16444108|NCT03675451|Experimental|Interventional|"Injection of study drug followed by PET/CT imaging.
~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
~Followed by prostatectomy"
16444109|NCT03675438|Experimental|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
16444110|NCT03675425|Experimental|Group 1: non chest shielding|non chest shielding generic name: non dosage: non frequency and duration: in first 48 h eco with pad diameter will be measured in before and after phototherapy,
16444111|NCT03675425|Placebo Comparator|Group 2: chest shielding|chest shielding generic name: Phototrephy dosage: non frequency and duration: in first 48 h echo with pad diameter will be measured in before and after phototherapy,
16444112|NCT03675412|Active Comparator|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
16444113|NCT03675412|Active Comparator|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
16444114|NCT03675399|Experimental|Supra-threshold isometric exercise|Participants will perform 10 isometric external rotation supra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
16444115|NCT03675399|Experimental|Infra-threshold isometric exercise|Participants will perform 10 isometric external rotation infra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
16444116|NCT03675399|No Intervention|Control|Participants will remain resting.
16444117|NCT03675386|Active Comparator|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
16444118|NCT03675386|Experimental|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
16444119|NCT03675373|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
16444120|NCT03675373|Active Comparator|control group|Alcohol brief intervention
16444121|NCT03675360|Experimental|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.
~At baseline, participants will receive written information with standard physical activity recommendations."
16444122|NCT03675360|No Intervention|Usual Diet|"No dietary intervention.
~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
16444123|NCT03675334|Active Comparator|Test Group|"Active comparator: gingival recession
~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
16444124|NCT03675334|Placebo Comparator|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
16444125|NCT03675321|Experimental|Auricular Neurostimulation|Intervention: Active Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks
16444126|NCT03675321|Sham Comparator|Sham Auricular Neurostimulation|Intervention: Sham (Inactive) Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks.
16444127|NCT03675308|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
16444128|NCT03675308|Experimental|Risankizumab|Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
16444129|NCT03675295|Active Comparator|Comparator: Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
16444130|NCT03675295|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
16444131|NCT03675282|Experimental|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
16444132|NCT03675282|Experimental|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
16444133|NCT03675282|Experimental|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
16444134|NCT03675282|Experimental|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
16444135|NCT03675282|Experimental|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
16444136|NCT03675282|Experimental|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
16444137|NCT03675269|Experimental|Treatment|HBOT
16444138|NCT03675269|Active Comparator|Control|Standard wound care
16444139|NCT03675256|Experimental|Arm 1|immediate Cervarix, delayed MenVeo vaccine
16444140|NCT03675256|Experimental|Arm 2|immediate Gardasil 9, delayed MenVeo vaccine
16444141|NCT03675256|Active Comparator|Arm 3|immediate MenVeo, delayed Gardasil 9 vaccine
16444142|NCT03675230|Active Comparator|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
16444143|NCT03675230|Experimental|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
16444144|NCT03675217|Experimental|PE and PCFPC|Physical Exercise and primary care family caregivers program
16444145|NCT03675217|Active Comparator|Usual Care|Usual Care: PCFPC (primary care family caregivers program)
16444146|NCT03675191|Experimental|orlistat|Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
16444589|NCT03672474|Experimental|Photobiomodulation REGEnLIFE RGn530 device group|
16444147|NCT03675191|Placebo Comparator|placebo|placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
16444148|NCT03675178|Experimental|treatment group|Anerning particle +ceftriaxone sodium
16444149|NCT03675178|Placebo Comparator|control group|Anerning particle placebo+ceftriaxone sodium
16444150|NCT03675165|Experimental|Intervention|Participants receive a tailored version of Laura King's 'Best Possible Self' intervention: a brief, self-administered, psychological intervention. It is fundamentally a writing exercise, whereby recipients are asked to spend 10 minutes writing about their best possible future self and the steps they need to take to become that person. This helps the individual set goals while facilitating positive affect. Our version of the task has people focus on their health-related goals in particular.
16444151|NCT03675165|No Intervention|Waiting List Control|Participants are informed that they are on a waiting list and will receive the intervention at the end of the study.
16444152|NCT03675152|Experimental|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
16444153|NCT03675152|Active Comparator|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
16444154|NCT03675139|Experimental|Medroxyprogesterone Acetate|EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. All of the findings will be recorded.
16444155|NCT03675139|Experimental|dydrogesterone|EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium. All of the findings will be recorded.
16444156|NCT03675126|Experimental|SRP-5051|Patients will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.
16444157|NCT03675113|Experimental|upper extremity aerobic group|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
16444158|NCT03675113|Sham Comparator|control group|Deep breathing exercises combination with arm movements will be given as a home program in the control group. Training duration will be 3 day per a week through 6-weeks.
16444159|NCT03675100|Sham Comparator|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
16444160|NCT03675100|Active Comparator|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
16444161|NCT03675074|Experimental|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
16444162|NCT03675061|Other|Control group|Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
16444163|NCT03675061|Other|PartoSure group|"Each women have a biochemical test = PartoSure Test.
~PartoSure test negative : For a negative test, the patient will be able to benefit from a nifedipine tocolysis, if the uterine contractions require it, then she will return home with a control by a midwife at home twice a week up to 34 weeks of amenorrhea.
~PartoSure test positive : For a positive test, the patient will be hospitalized 7 days with a care identical to the control group."
16444164|NCT03675048|Experimental|Intervention group|The intervention group will receive 5 drops (10^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
16444165|NCT03675048|Placebo Comparator|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
16444166|NCT03675048|No Intervention|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
16444167|NCT03675035|Experimental|Endomina|Reduction trough sutures of the gastro-jejunal anastomosis
16444168|NCT03675022|Experimental|Dupilumab|Dupilumab injections every 2 weeks.
16444169|NCT03675009|Other|Early Intervention|Educational curriculum will be delivered earlier in the timeframe after IAQ monitoring has initiated.
16444170|NCT03675009|Other|Late Intervention|Educational curriculum will be delivered later in the timeframe after IAQ monitoring has initiated.
16444171|NCT03674996|Experimental|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
16444172|NCT03674996|Experimental|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
16444173|NCT03674996|Other|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
16444174|NCT03674983|Experimental|CEI Group|CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
16444175|NCT03674983|No Intervention|SOC Group|SOC Group will receive the standard of care only (information, prescription, free PrEP.)
16444176|NCT03674970|Experimental|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
16444177|NCT03674970|Active Comparator|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
16444178|NCT03674970|Placebo Comparator|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
16444179|NCT03674944|Experimental|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
16444180|NCT03674944|Active Comparator|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
16444181|NCT03674931|Experimental|musical practice|Intensive weekly musical keyboard training over 12 months
16444182|NCT03674931|Active Comparator|music education|Recreative weekly musical courses without practice over 12 months
16444183|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
16444184|NCT03674905|Other|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
16444185|NCT03674905|Other|Peripheral nerve block|Pre-operative peripheral nerve block.
16444186|NCT03674879|No Intervention|Phone Call|Follow up contact is attempted via phone call.
16444187|NCT03674879|Experimental|Text Message|Follow up contact is attempted via text message.
16444188|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
16444189|NCT03674853|Experimental|Wuling Capsule group|Patients who were treated with Wuling Caspule
16444190|NCT03674853|Active Comparator|Oryzanol group|Patients who were treated with oryzanol
16444191|NCT03674840|Other|control group|Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
16444192|NCT03674840|Experimental|design group|Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
16444193|NCT03674827|Experimental|Dose escalation (Part 1)|Participants with NSCLC or TNBC were enrolled at escalating dose levels s of the VBIR-2 regimen.
16444194|NCT03674827|Experimental|Dose Expansion (Part 2)|Participants with metastatic NSCLC will be enrolled at the expansion dose level identified during Part 1 of the study.
16444195|NCT03674814|Experimental|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
16444196|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
16444197|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
16444198|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
16444199|NCT03674775|Active Comparator|Intervention Group Providers|DART QI Program Participation
16444200|NCT03674775|No Intervention|Control Group Providers|Usual Care
16444201|NCT03674762|Experimental|dental implants|microgrooved dental implants submerged
16444202|NCT03674762|Experimental|dentale implants|microgrooved dental implants nonsubmerged
16444203|NCT03674749|Active Comparator|Hyperbaric Oxygen|Hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks
16444204|NCT03674749|Experimental|Meditation with Hyperbaric Oxygen|Meditation session combined with each hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks,
16444209|NCT03674723|Experimental|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
16444210|NCT03674710|Experimental|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
16444211|NCT03674710|Experimental|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
16444212|NCT03674710|Experimental|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
16444252|NCT03674476|Experimental|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
16444213|NCT03674710|Experimental|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
16444214|NCT03674710|Experimental|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
16444215|NCT03674710|Experimental|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
16444216|NCT03674697|Experimental|Active Treatment Group (Green LED)|Subjects will be exposed to a Green LED light for 3 weeks prior to surgery, during their hospital stay and for an additional 10 weeks after hospital discharge. Wattage: 8W; Voltage: 120V; Wavelength: 525 nm; Intensity: 4-100 Lux
16444217|NCT03674697|Placebo Comparator|Control Group (White LED)|Subjects will be exposed to a White LED light for 3 weeks prior to surgery, during their hospital stay and for an additional 10 weeks after hospital discharge. Wattage: 9.6W; Voltage: 120V. Intensity: 4-100 Lux
16444218|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
16444219|NCT03674684||gelatin|Patients who received gelatin
16444220|NCT03674684||crystalloids|Patients who received crystalloids
16444221|NCT03674671|Experimental|Intravenous Ketamine|
16444222|NCT03674671|Active Comparator|Electroconvulsive Therapy|
16444223|NCT03674658|Experimental|A drug|Rhynorm(A drug)
16444224|NCT03674658|Active Comparator|B drug|Rytmonorm (B drug)
16444225|NCT03674645|Experimental|MRI|MRI exam performed on 200 healthy volunteers
16444226|NCT03674632|Experimental|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
16444227|NCT03674632|No Intervention|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
16444228|NCT03674619|Active Comparator|Surgical treatment|Anterior discectomy
16444229|NCT03674619|Active Comparator|Conservative treatment|Patients will attend an experienced specialist in physical medicine and rehabilitation and a physiotherapist.
16444230|NCT03674606|Experimental|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
16444231|NCT03674606|No Intervention|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
16444232|NCT03674606|Active Comparator|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk > 1:8 must start low-dose aspirin treatment immediately. Participants with a risk < 1:8 will be excluded.
16444233|NCT03674593|Experimental|Mitral valve chordae prosthesis|"Patients of this group receive mitral valve chordae replacement performed in five stages:
~Measure the required length of the chordae.
~Forming loops.
~Fixation of the loop group to the papillary muscles.
~Fixation of chordal loops to the free edge of the valve.
~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse."
16444234|NCT03674593|Active Comparator|Mitral valve chordae translocation|"The technique of translocation of secondary chordae:
~The method consists essentially of three stages:
~Selection of the secondary chordae.
~Fixation of secondary chordae to the free edge of the valve.
~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
16444235|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
16444240|NCT03674554|Experimental|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
16444241|NCT03674554|Experimental|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
16444242|NCT03674541|Active Comparator|Study Drug - Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
16444243|NCT03674541|Placebo Comparator|Placebo|Placebo by mouth as a one time dose
16444244|NCT03674528||Control Group|Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.
16444245|NCT03674528||Patient Group|Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.
16444246|NCT03674515|Placebo Comparator|placebo|"Smartphone application placebo"
16444247|NCT03674515|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
16444248|NCT03674502|Experimental|ADU-1604|ADU-1604 administered as an IV infusion
16444249|NCT03674489|Active Comparator|Neurodynamic Slider Mobilization|
16444250|NCT03674489|Active Comparator|Neurodynamic Tensioner Mobilization|
16444251|NCT03674489|Sham Comparator|Sham Neurodynamic Mobilization|
16444590|NCT03672474|Sham Comparator|Sham REGEnLIFE RGn530 device group|
16444253|NCT03674476|Experimental|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
16444254|NCT03674476|Experimental|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
16444255|NCT03674476|Other|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
16444256|NCT03674463|Experimental|LCAR-B4822M treatment group|r/r multiple myeloma patients will be treated with LCAR-B4822M CAR-T cells with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
16444257|NCT03674450|Experimental|Interventional|
16444258|NCT03674437||Breast Cancer Survivors|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
16444259|NCT03674437||Healthy Controls|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
16444260|NCT03674437||Healthy 21-25 year olds|Healthy participants between the ages of 21 and 25 will be administered the Cogsuite Battery remotely. These participants will not be matched to any other groups and will not be asked for their full medical histories. They will only complete the assessment only once.
16444261|NCT03674424|Experimental|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.
~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.
~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
16444262|NCT03674424|Experimental|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.
~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
16444263|NCT03674424|Experimental|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.
~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
16444264|NCT03674424|Experimental|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.
~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
16444265|NCT03674411|Experimental|FLU, CY, TBI + MGTA-456 infusion|
16444266|NCT03674411|Experimental|BU/ FLU/ MEL + MGTA-456 infusion Suspended: No|
16444267|NCT03674398|Experimental|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
16444268|NCT03674398|Active Comparator|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
16444269|NCT03674385|Experimental|vitamin E group|30 patient
16444270|NCT03674385|Active Comparator|control group|clomiphene
16444271|NCT03674372|Experimental|Fetuses with Left CDH (O/E LHR < 25%)|Fetuses with Left CDH (O/E LHR < 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
16444272|NCT03674372|Experimental|Fetuses with L- sided CDH with O/E LHR <30%.|Fetuses with Left CDH (O/E LHR < 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
16444273|NCT03674372|Experimental|Fetuses with R- sided CDH with O/E LHR < 45%|Fetuses with Right CDH (O/E LHR < 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
16444274|NCT03674359||Cohort|Patients hospitalized in intensive care, meeting the inclusion criteria. BDG analysis
16444275|NCT03674346|Experimental|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
16444276|NCT03674346|Other|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
16444277|NCT03674333|Experimental|Group A|Folic acid 1mg daily will be given to the participants of Group A.
16444278|NCT03674333|Placebo Comparator|Group B|A Placebo (a sugar pill) will be given to the participants of the Group B.
16444279|NCT03674320|Placebo Comparator|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
16444280|NCT03674320|Active Comparator|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
16444281|NCT03674307|Experimental|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
16444282|NCT03674307|Active Comparator|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
16444283|NCT03674294|Experimental|Palonosetron/Dexamethasone/Aprepitant|
16444284|NCT03674294|Placebo Comparator|Palonosetron/Dexamethasone/Placebo|
16444285|NCT03674281|Experimental|Sensor Augmented Pump (SAP)-Closed-Loop Control (CLC)|"SAP: Subjects will be utilizing their own insulin pumps (without automated insulin delivery) plus Dexcom G6 CGM to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period.
~CLC with Control-IQ plus CGM: Following SAP, subjects will be utilizing the Tandem t:slim X2 with Control-IQ along with a Dexcom G6 continuous glucose monitor to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period."
16444404|NCT03673579|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
16445563|NCT03665753|Experimental|Ketorolac 10mg|Subjects will be administered 10 mg of Ketorolac.
16444286|NCT03674255||1|Participants in group 1 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained, in addition to venous blood samples obtained from the cannula inserted as part of the standard clinical procedure. These blood samples will be collected before and after the stress echocardiogram. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
16444287|NCT03674255||2|Participants in group 2 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
16444288|NCT03674255||3|Participants in group 3 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
16444289|NCT03674255||4|Participants in group 4 will be recruited at their stress echocardiogram appointment, regardless of the type of investigation. A simplified data set and an anonymised version of the stress echocardiography report will be collected as a part of this registry phase. Participants will be followed up over a 10-year period.
16444290|NCT03674242|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with
~Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.
~Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
16444291|NCT03674242|Active Comparator|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
16444292|NCT03674229|Active Comparator|Group I (information about weight management programs)|Participants receive information about commercially-available weight management programs and encouragement to participate in one of the programs for 6 months.
16444293|NCT03674229|Experimental|Group II (information, call from patient navigator)|Participants receive information about commercially-available weight management programs encouragement to participate in one of the programs for 6 months. Participants also receive 6 phone calls over 20-30 minutes each from an assigned patient navigator for 6 months.
16444294|NCT03674203|Experimental|Application of platelet-rich plasma|The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
16444295|NCT03674190|Experimental|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
16444296|NCT03674190|Active Comparator|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
16444297|NCT03674177|Experimental|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
16444298|NCT03674177|Experimental|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
16444299|NCT03674177|Experimental|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
16444300|NCT03674177|Placebo Comparator|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
16444301|NCT03674151|Active Comparator|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
16444302|NCT03674151|Active Comparator|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
16444303|NCT03674151|Active Comparator|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
16444304|NCT03674151|Active Comparator|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
16444305|NCT03674138|Active Comparator|DNA-guided choice of therapy|DNA-guided choice of antidepressant therapy
16444306|NCT03674138|Active Comparator|Clinical management|Clinical management
16444307|NCT03674125|Experimental|Group 1|GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
16444308|NCT03674125|Experimental|Group 2|GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
16444309|NCT03674125|Experimental|Group 3|GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
16444310|NCT03674125|Experimental|Group 4|GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
16444311|NCT03674112|Experimental|A: P+H IV Followed by PH FDC SC|In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
16445564|NCT03665753|Experimental|Ketorolac 20mg|Subjects will be administered 20 mg of Ketorolac
16444312|NCT03674112|Experimental|B: PH FDC SC Followed by P+H IV|In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
16444313|NCT03674099|Experimental|Imatinib|Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
16444314|NCT03674099|Active Comparator|Methylprednisolone|Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
16444315|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
16444316|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
16444317|NCT03674073|Experimental|Microwave Ablation + Neoantigen Vaccines|The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.
16444318|NCT03674073|Active Comparator|Microwave Ablation|The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.
16444319|NCT03674060|Experimental|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
16444320|NCT03674060|Experimental|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
16444321|NCT03674060|Experimental|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
16444322|NCT03674060|Active Comparator|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
16444323|NCT03674047|Experimental|newly-diagnosed BOS|-Participants will take ruxolitinib twice every day
16444324|NCT03674047|Experimental|Established BOS|-Participants will take ruxolitinib twice every day
16444325|NCT03674034||term|50 CTscan and MRI images of children aged at term
16444326|NCT03674034||one month|50 CTscan and MRI images of children aged one month
16444327|NCT03674034||two months|50 CTscan and MRI images of children aged two months
16444328|NCT03674021|Experimental|Intervention Arm|Patients in the intervention arm will receive the Chest Pain Choice visual aid prior to discussion with their primary physician regarding disposition.
16444329|NCT03674021|No Intervention|Control Arm|Patients in the control arm will not receive the Chest Pain Choice visual aid and will receive standard care.
16444330|NCT03674008|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
16444331|NCT03674008|Active Comparator|Propofol|1.5mg/kg/0.75mg/kg
16444332|NCT03673995|Experimental|Myo-inositol+L-tyrosine|One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.
16444333|NCT03673982|Experimental|iCASK Group|Materials and support to aid transitions.
16444334|NCT03673969|Active Comparator|MGB|Mini gastric bypass
16444335|NCT03673969|Active Comparator|Roux enY gastric bypass|Roux enY gastric bypass
16444336|NCT03673956|Experimental|Topical Antibiotic Nasal Saline Rinse|The topical antibiotics will prescribed to the patient in capsule form as compounded by the Mayo Clinic pharmacy, or suitable licensed 3rd party compounding pharmacy. One capsule will subsequently be added to a nasal saline irrigation bottle, and the patient will administer this irrigation to him or herself in the usual fashion twice per day.
16444337|NCT03673943|Experimental|PET/CT imaging with 64Cu-DOTATATE|64Cu-DOTATATE is an investigational radioactive drug that binds to somatostatin receptors on NETs cancer cells.
16444338|NCT03673930|Active Comparator|Zanthozylum armatum|fruit extract
16444339|NCT03673930|Placebo Comparator|Placebo|placebo
16444340|NCT03673917|Experimental|Educational video|The educational video on skin cancer for cosmetologists
16444341|NCT03673917|Active Comparator|Control video|A publicly accessible healthy lifestyle video on YouTube, which did not contain any information on skin cancer
16444342|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
16444343|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5%
16444344|NCT03673891|No Intervention|Control|After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
16444345|NCT03673891|Experimental|LifeFlow group|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
16444348|NCT03673852|Other|Peer Wellness Enhancement (WE Harambee)|This project employs a pragmatic, stepped wedge experimental design in which 60 BHH participants are randomly assigned to one of 3 waves of WE Harambee implementation (20 in each wave) during the 2 year study. Participants in this arm receive the WE Harambee Wellness Enhancement and are enrolled in a Behavioral Health Home. WE Harambee is a 6-month peer-delivered whole health intervention intended to address the 8 dimensions of wellness and the social determinants of health.
16444349|NCT03673852|Other|Behavioral Health Home enrollment|"In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a health home option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness."
16444350|NCT03673839|Active Comparator|Animal proteins (crossover)|
16444351|NCT03673839|Experimental|Plant-based protein blends type 1 (crossover)|
16444352|NCT03673839|Experimental|Plant-based protein blends type 2 (crossover)|
16444353|NCT03673839|Experimental|Plant-based protein blends type 3 (crossover)|
16444354|NCT03673826|Experimental|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
16444355|NCT03673826|Experimental|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
16444356|NCT03673800|Experimental|Cognitive Training|Online Cognitive training on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
16444357|NCT03673800|Sham Comparator|Online sensorial program|Online sensorial program on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
16444358|NCT03673787|Experimental|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
16444359|NCT03673787|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in six patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma; patients with melanoma; patients solid tumour types refractory to immune-checkpoint inhibitors; patients with gynaecological cancers.
16444361|NCT03673761||Cushing's syndrome|"a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.
~This group will under go the following procedures:
~muscle MRI
~dual-energy x-ray absorptiometry
~muscle ultrasounds
~blood testing"
16444362|NCT03673761||acromegaly|"b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.
~This group will under go the following procedures:
~muscle MRI
~dual-energy x-ray absorptiometry
~muscle ultrasounds
~blood testing"
16444363|NCT03673761||Healthy controls|"Controls: n = 40; normal healthy control paired by age, sex and BMI will be included.
~This group will under go the following procedures:
~muscle MRI
~dual-energy x-ray absorptiometry
~muscle ultrasounds
~blood testing"
16444364|NCT03673748|Experimental|Mesenchymal stromal cells (MSC)|Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid
16444365|NCT03673748|Placebo Comparator|Placebo|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups.
16444366|NCT03673735|Experimental|Experimental Arm|Patients will receive 1 infusion of 1500 mg Durvalumab within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with Durvalumab will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
16444367|NCT03673735|Placebo Comparator|Control arm|Patients will receive 1 infusion of placebo within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with placebo will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
16444368|NCT03673722|Experimental|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
16444369|NCT03673722|Experimental|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
16444370|NCT03673722|Placebo Comparator|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
16444472|NCT03673124|Other|Ribociclib and letrozole|Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
16444473|NCT03673111|Experimental|1.0 mg|Y14 single dose, subcutaneous
16444371|NCT03673709|No Intervention|Individual Antenatal Care (usual care)|Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
16444372|NCT03673709|Experimental|Group Antenatal Care (intervention)|Women have the same number of visits as those in individual care. Their first antenatal care (intake) and first postnatal visit is done individually (identical to individual care). Women in group care bypass the waiting area and have a 2-hour visit with the same provider in a group of 8-12 women at a similar stage of pregnancy. Women assess their blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
16444373|NCT03673696|Experimental|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
16444374|NCT03673696|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
16444375|NCT03673696|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
16444376|NCT03673696|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
16444377|NCT03673696|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
16444378|NCT03673696|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
16444379|NCT03673696|Experimental|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
16444380|NCT03673696|Experimental|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
16444381|NCT03673696|Experimental|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
16444382|NCT03673683|Active Comparator|Usual Care|Sedation and ventilation weaning that is non-protocol-based and primarily medically-driven.
16444383|NCT03673683|Experimental|SANDWICH protocol|A protocol-based intervention for managing sedation and ventilation weaning.
16444384|NCT03673670|Experimental|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
16444385|NCT03673670|Experimental|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
16444386|NCT03673670|Experimental|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
16444387|NCT03673657|Experimental|A|"ONS from the start of radiotherapy; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.
~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
16444388|NCT03673657|Experimental|B|"ONS from the time of grade 2 radiation esophagitis; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.
~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
16444389|NCT03673657|Experimental|C|ONS from the start of radiotherapy; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
16444390|NCT03673657|Experimental|D|ONS from the time of grade 2 radiation esophagitis; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
16444391|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:
~Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
~Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
16444392|NCT03673631||NFHC-O2 Group|NFHC-O2 therapy alone with gas flow at least 40L/min,
16444393|NCT03673631||NIV/Standard-O2 Group|NIV sessions with at least 30% FiO2 and standard oxygen therapy
16444394|NCT03673631||NFHC-O2/NIV Group|combination of NIV sessions and NFHC-O2 therapy,
16444395|NCT03673618|Experimental|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
16444396|NCT03673618|Placebo Comparator|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
16444397|NCT03673605|Experimental|Rivaroxaban|
16444398|NCT03673605|Active Comparator|Warfarin|
16444399|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
16444400|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (<50%). This embryos will be considered for transfer to the uterus.
16444401|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
16444402|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
16444403|NCT03673579|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.
~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
16444405|NCT03673579|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.
~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
16444406|NCT03673566|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.
~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
16444407|NCT03673566|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
16444408|NCT03673566|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.
~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
16444409|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
16444410|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
16444411|NCT03673540|Experimental|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
16444412|NCT03673527|Experimental|topical formulation of tacrolimus|
16444413|NCT03673514|Active Comparator|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
16444414|NCT03673514|Active Comparator|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
16444415|NCT03673501|Experimental|DCC-2618|150 mg QD DCC-2618
16444416|NCT03673501|Active Comparator|sunitinib|50 mg QD sunitinib
16444417|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
16444418|NCT03673475||fluid responsiveness|Assessment of fluid responsiveness using pleth variebility index and jugular vein distensibility in patients undergoing major abdominal surgery
16444419|NCT03673462|Experimental|MenACYW conjugate vaccine|MenACYW conjugate vaccine, 4 doses at 2, 4, 6, and 12 months of age, co-administered with routine vaccines
16444420|NCT03673462|Active Comparator|MENVEO®|MENVEO®, 4 doses at 2, 4, 6, and 12 months of age, co-administered with routine vaccines
16444421|NCT03673449|Experimental|SilkBridge treatment|Surgery for digital nerve reconstruction with SilkBridge
16444422|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
16444423|NCT03673410|Active Comparator|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
16444424|NCT03673410|Experimental|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
16444425|NCT03673397|Experimental|Aerobic exercise|Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
16444426|NCT03673397|No Intervention|Control|Individuals allocated to the control group will be placed in a room with analogous conditions to the exercise group concerning light, temperature and absence of music at the same time as individuals performing the exercise intervention. The control group will be asked to remain seated and read magazines.
16444427|NCT03673384|Experimental|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.
~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
16444428|NCT03673384|Placebo Comparator|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
16444429|NCT03673371||Women Veterans with Lower Limb Amputations|Questionnaire
16444430|NCT03673358|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
16444431|NCT03673358|No Intervention|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
16444432|NCT03673345|Experimental|Cohort 1A|0.25 mL dose of IIV-4 administered intramuscularly on days 0 and 28 of study year 1 and on day 0 of study year 2 in children 6-12 months of age who have not previously had an influenza infection or vaccination, n=20
16444474|NCT03673111|Experimental|2.0 mg|Y14 single dose, subcutaneous
16444475|NCT03673111|Experimental|6.0 mg|Y14 single dose, subcutaneous
16444433|NCT03673345|Experimental|Cohort 1B|0.25 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 after primary influenza infection in study year 1 in children 3-12 months of age, who have not previously had an influenza vaccination, n=20
16444434|NCT03673345|Experimental|Cohort 2A|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=60
16444435|NCT03673345|Experimental|Cohort 2B|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
16444436|NCT03673345|Experimental|Cohort 3A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2006 and 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=30
16444437|NCT03673345|Experimental|Cohort 3B|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2006 and 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
16444438|NCT03673345|Experimental|Cohort 4A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2003 and 2006, who have previously received 2 doses of influenza vaccine prior to the study, n=30
16444439|NCT03673345|Experimental|Cohort 4B|0.5 mL does of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2003 and 2006, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
16444440|NCT03673332|Experimental|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
16444441|NCT03673319|Experimental|Positive expectative|"Participants in the positive expectation group will be told that DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
16444442|NCT03673319|Experimental|Neutral expectatives|"Participants in the neutral expectation group will be told that DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
16444443|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
16444444|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
16444445|NCT03673280|Placebo Comparator|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
16444446|NCT03673280|Experimental|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
16444447|NCT03673280|Experimental|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
16444448|NCT03673267|Experimental|Nutricity|
16444449|NCT03673241|No Intervention|Control Group|The Control Group will receive the standard support surface mattresses/bed surfaces and recovery chairs without the non-invasive perfusion enhancement system (The Guardian System)
16444450|NCT03673241|Experimental|Study Arm|The Study Arm will have the non-invasive perfusion enhancement system placed on their beds and recovery chairs. Patients will be utilizing the systems while lying in bed or sitting in the chair.
16444451|NCT03673228|Experimental|Intervention Group|"Participants randomized to the Intervention Arm will receive counseling that includes:
~A Visit prior to discharge
~Follow up calls after discharge
~Text Messaging Support
~Caregiver Support"
16444452|NCT03673228|Active Comparator|Standard treatment|Patients will receive current usual care.
16444453|NCT03673215|Experimental|A|
16444454|NCT03673215|Experimental|B1|
16444455|NCT03673215|Placebo Comparator|B2|
16444456|NCT03673215|Experimental|C1-1|
16444457|NCT03673215|Placebo Comparator|C1-2|
16444458|NCT03673215|Experimental|C2-1|
16444459|NCT03673215|Placebo Comparator|C2-2|
16444460|NCT03673215|Experimental|C3-1|
16444461|NCT03673215|Placebo Comparator|C3-2|
16444462|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
16444463|NCT03673189|Experimental|Healthy volunteers|Sensors assigned for 3 weeks
16444464|NCT03673189|Experimental|Patients with arythmic disease or peripheral vascular disease|Sensors assigned for 3 weeks
16444465|NCT03673176|Experimental|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
16444466|NCT03673163|Experimental|Lidocaine|Lidocaine treatment
16444467|NCT03673163|Placebo Comparator|Control|Placebo treatment
16444468|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
16444469|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
16444470|NCT03673137|Experimental|Synchronous treatment group|Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
16444471|NCT03673137|Active Comparator|Traditional treatment group|The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
16444480|NCT03673111|Experimental|26.0 mg (B1)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 12mg on day 8, 16mg on day 15, 20mg on day 22 and 26mg on day 29.
16444481|NCT03673111|Experimental|36mg (B2)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
16444482|NCT03673111|Experimental|36mg (B3)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 12mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
16444483|NCT03673098|Experimental|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
16444484|NCT03673098|No Intervention|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
16444485|NCT03673085|Experimental|Group 1-1|The dose of CN128 is 2.5 mg/kg bw.
16444486|NCT03673085|Placebo Comparator|Group 1-2|The dose of placebo is 2.5 mg/kg bw.
16444487|NCT03673085|Experimental|Group 2-1|The dose of CN128 is 5 mg/kg bw.
16444488|NCT03673085|Placebo Comparator|Group 2-2|The dose of placebo is 5 mg/kg bw.
16444489|NCT03673085|Experimental|Group 3-1|The dose of CN128 is 10 mg/kg bw.
16444490|NCT03673085|Placebo Comparator|Group 3-2|The dose of placebo is 10 mg/kg bw.
16444491|NCT03673085|Experimental|Group 4-1|The dose of CN128 is 15 mg/kg bw.
16444492|NCT03673085|Placebo Comparator|Group 4-2|The dose of placebo is 15 mg/kg bw.
16444493|NCT03673085|Experimental|Group 5-1|The dose of CN128 is 20 mg/kg bw.
16444494|NCT03673085|Placebo Comparator|Group 5-2|The dose of placebo is 20 mg/kg bw.
16444495|NCT03673085|Experimental|Group 6-1|The dose of CN128 is 30 mg/kg bw.
16444496|NCT03673085|Placebo Comparator|Group 6-2|The dose of placebo is 30 mg/kg bw.
16444497|NCT03673085|Experimental|Group 7-1|The dose of CN128 is 45 mg/kg bw.
16444498|NCT03673085|Placebo Comparator|Group 7-2|The dose of placebo is 45 mg/kg bw.
16444499|NCT03673085|Experimental|Group 8-1|The dose of CN128 is 60 mg/kg bw.
16444500|NCT03673085|Placebo Comparator|Group 8-2|The dose of placebo is 60 mg/kg bw.
16444501|NCT03673072|Experimental|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
16444502|NCT03673072|Active Comparator|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
16444503|NCT03673059|Experimental|OTC Eczema Moisturizer Regimen|Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
16444504|NCT03673059|Experimental|Cosmetic Moisturizer Regimen|Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).
16444505|NCT03673046|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
16444506|NCT03673046|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
16444507|NCT03673020|Experimental|ASV® AGEN2017|ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine
16444508|NCT03673007|Experimental|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
16444509|NCT03673007|No Intervention|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
16444510|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
16444511|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
16444512|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
16444513|NCT03672994||Heart failure|Patients with confirmed heart failure
16444514|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
16444515|NCT03672981|Experimental|Supportive Care (aerobic exercise and resistance training)|Patients undergo moderately intense aerobic/cardiovascular exercise over 30-60 minutes and complete 1-2 sets of 8 to 10 resistance/strength training exercises, 8 to 12 repetitions of each exercise, 3 days per week for 12 weeks. Patients also participate in weekly phone calls with an exercise physiologist to ensure adherence to the program and to provide support.
16444516|NCT03672942|Experimental|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
16444517|NCT03672942|Experimental|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
16444518|NCT03672942|Placebo Comparator|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
16444519|NCT03672929|No Intervention|Full cohort|Prospective non Controlled to Document long term performance of Allofit IT Shell in combination with the Longevity® Liner when used in primary total hip arthroplasty.
16444520|NCT03672929|Other|Subgroup RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years and will only be conducted on 40 patients.
16444521|NCT03672916||Patients who received the Allofit IT with BIOLOX delta|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the BIOLOX delta Taper Liners
16444522|NCT03672903|Experimental|Intervention|Subjects in this arm will carry heavy weight vests for three weeks.
16446026|NCT03662607|No Intervention|Control|Standard pre-procedural education for cardiac catheterization.
16444523|NCT03672903|Placebo Comparator|Control|Subjects in this arm will carry light weight vests for three weeks.
16444524|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
16444525|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
16444526|NCT03672877|Experimental|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
16444527|NCT03672877|No Intervention|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
16444528|NCT03672864|Experimental|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
16444529|NCT03672864|No Intervention|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
16444530|NCT03672851|Experimental|anti-CD123 CAR-T treatment|
16444531|NCT03672838|Active Comparator|Cohort 1|Patients with NF1
16444532|NCT03672838|Active Comparator|Cohort 2|Patients with NF2
16444533|NCT03672825|Experimental|RECLAIM|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
16444534|NCT03672812|No Intervention|placebo|0,5ml
16444535|NCT03672812|Experimental|liraglutide|0,5ml
16444536|NCT03672799|Experimental|Rehabilitation Planning Consult (RPC)|"The RPC is a trans-disciplinary, consultative intervention. In the RPC, individualized rehabilitation needs are established, goals are set, strategies to achieve the goals are developed, and follow-through with strategies and goal attainment is facilitated by a rehabilitation professional who consults and collaborates with the survivor. The Rehabilitation Consultant does not provide hands-on treatment, but rather determines the survivors' priority individualized rehabilitation goals, and then helps devise a plan for the survivor to meet those goals independently.
~Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consultant and second consultation 2 to 12 weeks later."
16444537|NCT03672799|Active Comparator|Wait list control (WLC)|"There is no standard rehabilitation care for survivors of head and neck cancer at the Princess Margaret Cancer Centre.
~Participants allocated to WLC will enter a 12 week waiting period after which they will crossover to the RPC group."
16444538|NCT03672786|Active Comparator|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
16444539|NCT03672786|Experimental|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
16444540|NCT03672773|Experimental|Treatment (temozolomide, talazoparib)|Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16444541|NCT03672760|Active Comparator|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.
~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
16444542|NCT03672760|Placebo Comparator|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.
~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
16444543|NCT03672760|Active Comparator|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
16444544|NCT03672747|Active Comparator|Anodal|Participants will receive occipital anodal stimulation using high-definition tDCS
16444545|NCT03672747|Active Comparator|Cathodal|Participants will receive occipital cathodal stimulation using high-definition tDCS
16444546|NCT03672747|Placebo Comparator|Sham|Participants will receive occipital sham stimulation (placebo) using high-definition tDCS
16444547|NCT03672721|Experimental|IA Carbo + radiation|Intraarterial carboplatin + radiation
16444548|NCT03672708|Other|Cresyl violet|
16444549|NCT03672695|Experimental|S64315 and venetoclax administered in combination|
16444550|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
16444551|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
16444552|NCT03672682||Healthy patients|15 healthy patients
16444553|NCT03672669|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF was applied into the tooth socket after mandibular third molar surgery.
16444554|NCT03672669|Active Comparator|Leukocyte- and platelet-rich fibrin (L-PRF)|L-PRF was applied into the tooth socket after mandibular third molar surgery.
16444555|NCT03672656|Experimental|pattern scanning laser system Pascal|
16444556|NCT03672656|Active Comparator|conventional laser|
16444557|NCT03672643|Other|single arm|Crizotinib
16444558|NCT03672630|Active Comparator|2-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
16444616|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
16444559|NCT03672630|Active Comparator|3-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
16444560|NCT03672617||Children and adolescents|Children and adolescents, who administer growth hormone (GH) themselves (self-injections) will be asked to complete the questionnaire.
16444561|NCT03672617||Parents/legal guardians|Parents/legal guardians who administer the GH to their child will be asked to complete the questionnaire.
16444562|NCT03672604|Placebo Comparator|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01
~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
16444563|NCT03672604|Placebo Comparator|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.
~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
16444564|NCT03672604|Placebo Comparator|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.
~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
16444565|NCT03672591||HFpEF patients|Patients suffering from heart failure with preserved ejection fraction
16444566|NCT03672591||Control group|Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
16444567|NCT03672578|Experimental|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
16444568|NCT03672578|Experimental|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
16444569|NCT03672578|Experimental|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
16444570|NCT03672578|Experimental|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
16444571|NCT03672578|Experimental|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
16444572|NCT03672578|Experimental|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
16444573|NCT03672578|Experimental|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
16444574|NCT03672578|Experimental|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
16444575|NCT03672578|Placebo Comparator|No label|Participant will not see a label
16444576|NCT03672565|Active Comparator|Hospital setting|ERPs may be conducted in various settings on hospital grounds (e.g., cafeteria, hallways) but will not be conducted off property.
16444577|NCT03672565|Active Comparator|Community setting|Community ERP sessions will be conducted locations deemed most relevant to the child's symptom presentation such as in the home or at other community locations (e.g., church, downtown).
16444578|NCT03672552|Experimental|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
16444579|NCT03672552|No Intervention|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
16444580|NCT03672539|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.
~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.
~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16444581|NCT03672526|Experimental|device compuflo|
16444582|NCT03672513|Placebo Comparator|Placebo Supplemented Group|Placebo control
16444583|NCT03672513|Experimental|Magnesium Supplemented Group|Magnesium Group
16444584|NCT03672513|Experimental|Zinc Supplemented Group|Zinc Group
16444585|NCT03672500|Active Comparator|Bupivacaine arm|The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
16444586|NCT03672500|Sham Comparator|Control arm|Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.
16444591|NCT03672461|Experimental|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
16444592|NCT03672461|Active Comparator|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
16444593|NCT03672448||Neurocognitive disorder|Dementias
16444594|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
16444595|NCT03672435||proparacaine|Received topical proparacaine 0.5% with routine antibiotic-steroid ointment in operative eye(s) following strabismus surgery
16444596|NCT03672435||No proparacaine|Received no topical proparacaine 0.5% but did receive routine antibiotic-steroid ointment in the operative eye(s) following strabismus surgery
16444597|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month pain-free interval between episodes.
16444598|NCT03672422||Chronic Pancreatitis|"Children with at least:
~1) One irreversible structural change* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.
~*irreversible structural changes:
~Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).
~Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.
~Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.
~Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
16444599|NCT03672409|Other|Intervention in knowledge|All participants will be offered learning sessions to improve knowledge in diabetes
16444600|NCT03672396|Experimental|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour.
16444601|NCT03672383|Experimental|BAY987534 (Treated Arm)|Subjects with quiescent atopic dermatitis. Right or left volar forearm with test product applied.
16444602|NCT03672383|No Intervention|Untreated Arm|Subjects with quiescent atopic dermatitis. Right or left volar forearm without test product applied.
16444603|NCT03672370||Alloclassic® Variall® Cup|Subjects who received the Alloclassic® Variall® Cup Ceramic Bearing System
16444604|NCT03672357|Experimental|Laparoscopic liver resection|Laparoscopic hepatectomy
16444605|NCT03672357|Other|Open liver resection|Open hepatectomy
16444606|NCT03672344|Active Comparator|BioStream Training|
16444607|NCT03672344|Placebo Comparator|Alternative Game|
16444608|NCT03672331|Other|Standard arm|Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly.
16444609|NCT03672331|Experimental|Risk-based arm|Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer.
16444610|NCT03672318|Experimental|CAR138 T cells|The first 3 patients enrolled in the study will receive 5x10^6 CAR138 T-cells/m^2 via infusion. The number of cells for the infusion will be increased to 1x10^7 CAR138 T-cells/m^2 and then, 2.5x10^7 CAR138 T-cells/m^2, 5x10^7 CAR138 T-cells/m^2, 1x10^8 CAR138 T-cells/m^2 and 2x10^8 CAR138 T-cells/m^2 in subsequent cohorts of 3 patients provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each patient to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another patient is allowed to enroll in the cohort.
16444611|NCT03672305|Other|c-Met/PD-L1 CAR-T cells treating group|Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 * 10^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
16444612|NCT03672292|Experimental|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).
~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
16444613|NCT03672292|Placebo Comparator|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).
~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).
~Treatment duration = minimum 6 weeks/Max 13 weeks"
16444614|NCT03672279||Mild neurocognitive disorder|
16444615|NCT03672279||Major neurocognitive disorder|
16444617|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
16446120|NCT03662100|Experimental|LY3074828 Test 3|Solution formulation administered SC via an AI in abdomen
16444618|NCT03672253|Experimental|CAR-T Re-treatment group|Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
16444619|NCT03672240|Experimental|APL-1202|"APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).
~Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
16444620|NCT03672227|Experimental|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
16444621|NCT03672227|No Intervention|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
16444622|NCT03672214|Experimental|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
16444623|NCT03672214|Active Comparator|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
16444624|NCT03672201|Active Comparator|The Integrated Care Pathway (ICP) Arm|The ICP consists of 1) a cleanup phase during which a thorough assessment of pharmacotherapy to discontinue unnecessary medications, is performed; 2) Structured non-pharmacological interventions, which would have started as soon as randomization occurred and would continue before any pharmacological intervention for 2 weeks as stand-alone interventions; and 3) a pharmacological intervention phase: in this phase the medications algorithm for AD-AA is initiated.
16444625|NCT03672201|No Intervention|Treatment-As-Usual (TAU) Arm|Following eligibility and baseline assessments, half of the participants will be randomized to TAU. TAU will consist of the typical care that the interdisciplinary team provides at each site for AD-AA. No predetermined cleanup phase, non-pharmacological interventions, algorithmic pharmacological interventions will be systematically part of TAU.
16444626|NCT03672188|Experimental|VIR-2218|
16444627|NCT03672188|Placebo Comparator|Placebo|
16444628|NCT03672175|Experimental|SAGE-217 (low dose)|
16444629|NCT03672175|Experimental|SAGE-217 (high dose)|
16444630|NCT03672175|Placebo Comparator|Placebo|
16444631|NCT03672162|Active Comparator|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
16444632|NCT03672162|Active Comparator|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
16444633|NCT03672162|Placebo Comparator|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
16444634|NCT03672149|Other|Infection needing cefazolin|a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
16444635|NCT03672149|Other|Infection not needing cefazolin|b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
16444636|NCT03672149|Other|No infection|c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
16444637|NCT03672136|Experimental|Concurrent Chemoradiotherapy+Anlotinib|"Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.
~Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.
~Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1~14, day22~36.
~Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.
~During the course of study, it's not allowed to receive other anti-tumor therapy."
16444638|NCT03672123||APE with RVD|RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
16444639|NCT03672123||APE without RVD|RVD defined according to ESC criteria
16444640|NCT03672110|Active Comparator|Standard tacrolimus group|Control group: Advagraf will be administered as usual (0.2mg/kg bodyweight), trough levels will be measured every day in the first week after kidney transplantation (TX) and Advagraf dose will be adjusted accordingly.
16444641|NCT03672110|Experimental|Fixed dose tacrolimus group|Study group: Advagraf will be administered per fix dose 5mg/day, trough levels will be blinded during the first week, there will be no adjustments in the first week after TX.
16444642|NCT03672097|Experimental|Prasugrel|Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)
16444643|NCT03672071|Other|Group E|If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Ephedrine i.v. will be administered to patient will be performed. In the case of hypotension,
16444644|NCT03672071|Other|Group NE|.If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Noradrenaline, i.v. will be administered to patient will be performed. In the case of hypotension,
16444645|NCT03672071|Other|Group N|. If a 20% decrease in parameter compared to their baseline levels is sustained, necessary interventions mg Ephedrine + 2.5 mg Noradrenaline i.v. will be administered to patient will be performed. In the case of hypotension,
16444646|NCT03672058|Experimental|Fitbit plus personalised text messaging & Goal Setting|
16444647|NCT03672058|Active Comparator|Fitbit Only|
16444648|NCT03672045|Active Comparator|Carbetocin 10mcg|Patient is given 10 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16444649|NCT03672045|Active Comparator|Carbetocin 20mcg|Patient is given 20 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16444650|NCT03672045|Active Comparator|Carbetocin 40mcg|Patient is given 40 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16444651|NCT03672045|Active Comparator|Carbetocin 60mcg|Patient is given 60 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16444652|NCT03672045|Active Comparator|Carbetocin 80mcg|Patient is given 80 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16444653|NCT03672045|Active Comparator|Carbetocin 100mcg|Patient is given 100 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
16444654|NCT03672032|Active Comparator|Fork-tip Needle|
16444655|NCT03672032|Active Comparator|Franseen Needle|
16444656|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
16444657|NCT03672006|Experimental|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
16444658|NCT03672006|Active Comparator|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
16444659|NCT03671993|Experimental|EPNS group|Electrical pudendal nerve stimulation (EPNS) is a type of conservative treatment which can directly modulate the pudendal nerve and produce a regulation effects on both the sensory fibers and the motor fibers of pudendal nerve.
16444660|NCT03671993|Active Comparator|II group|Intravesical instillation (II) are mixture solution administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects.
16444661|NCT03671980|Experimental|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
16444664|NCT03671954|Experimental|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
16444665|NCT03671954|Active Comparator|TKA Control Group|The TKA control group will receive standard physical therapy alone.
16444666|NCT03671954|Active Comparator|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
16444667|NCT03671941|Active Comparator|Group A|D578 Tab. 1T
16444668|NCT03671941|Experimental|Group B|CKD-357 Tab. 1T
16444669|NCT03671928|Other|bowel ischemia|
16444670|NCT03671928|Other|non-digestive abdominal pain|
16444671|NCT03671915|Active Comparator|Usual System (Open-loop)|In open loop: sensor-augmented pump (SAP) therapy using standard insulin pump setting combined with the six-generation glucose sensor (Dexcom G6).
16444672|NCT03671915|Experimental|DIABELOOP System (Closed-loop)|"In the closed loop: Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.
~A remote monitoring system managed by specialized nurse on behalf diabetologist, is provided in closed-loop session."
16444673|NCT03671902|Other|Lower Body Negative/Positive Pressure|
16444674|NCT03671889|Experimental|Blood Brain Barrier (BBB) Disruption|ExAblate Model 4000 Type 2.0 System
16444675|NCT03671876|Active Comparator|Intervention plus therapy|"Case group:
~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.
~Intervention with the Selfit system include a set of mobility task exercises."
16444676|NCT03671876|No Intervention|Therapy and no intervention|"Control group:
~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
16444677|NCT03671863||Infants who are treated for clubfoot|Infants who are treated for clubfoot in the reference reeducation center
16444678|NCT03671850|Experimental|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
16444679|NCT03671850|Placebo Comparator|Placebo|Peripheral blood mononuclear cell, PBMC
16444680|NCT03671837|Experimental|Oyxgen|Nasal Insufflation with 15 L/min O2 and a nasopharyngeal airway
16444681|NCT03671837|Active Comparator|Air|Nasal Insufflation with 15 L/min air and a nasopharyngeal airway
16444682|NCT03671824||Lean|BMI ≤ 30 kg/m2
16444683|NCT03671824||Obese|BMI ≥30 kg/m2
16444684|NCT03671811|Experimental|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
16444685|NCT03671811|Experimental|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
16444686|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
16446233|NCT03661320|Active Comparator|Arm A|Chemotherapy alone followed by radical cystectomy
16444687|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
16444688|NCT03671785|Experimental|Active group treated with healthy fecal microbiota|
16444689|NCT03671785|Experimental|Placebo group|
16444690|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
16444691|NCT03671772||FDRs of controls|First-degree relatives of controls
16444692|NCT03671759|Experimental|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
16444693|NCT03671746|Placebo Comparator|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
16444694|NCT03671746|Experimental|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
16444695|NCT03671733|Experimental|Liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
16444696|NCT03671733|Experimental|Exenatide|Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
16444697|NCT03671733|Experimental|Exenatide Microspheres for Injection|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
16444698|NCT03671720|Experimental|personalized vaccine|
16444699|NCT03671707|Experimental|Intervention group|Brief AWARD advice + Nicotine replacement therapy sampling + Active referral
16444700|NCT03671707|Active Comparator|Control group|Very brief advice (VBA) + Leaflet
16444701|NCT03671694|Active Comparator|laser treatment|Erbium-YAG laser treatment to the vagina
16444702|NCT03671694|Placebo Comparator|sham treatment|sham treatment with laser placebo
16444703|NCT03671681|Experimental|MT group|Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and six group sessions of 45 minutes of mindfulness-based treatment.
16444704|NCT03671681|Other|MED group|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (i.e. clinical features, previous failures and contraindications)
16444705|NCT03671668|Active Comparator|Screw retained prosthesis on transmucosal abutments|
16444706|NCT03671668|Experimental|Screw retained prosthesis on titanium bases|
16444707|NCT03671655|Experimental|Drug-eluting stent|Drug-eluting stent is nitinol stent coated with Paclitaxel drug Other Names: Zilver PTX stent Zilver Paclitaxel stent
16444708|NCT03671655|Active Comparator|Bare metal stent|Bare metal stentis Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
16444709|NCT03671642|Experimental|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
16444710|NCT03671629|Experimental|Intervention group|In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.
16444711|NCT03671629|No Intervention|Control group|This group receives standard care, which might include a medication review at the hospital.
16444712|NCT03671616|Experimental|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
16444713|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
16444714|NCT03671590|Experimental|Arm 1|TG-1701 oral daily dose
16444715|NCT03671590|Experimental|Arm 2|TG-1701 + Ublituximab + Umbralisib
16444716|NCT03671577|Experimental|Active Treatment|four week computerized intervention designed to reduce fear of intimacy
16444717|NCT03671577|No Intervention|Wait List Control|Participants will continue as usual and will be given the option to receive the active treatment after completion of the study
16444718|NCT03671564|Experimental|Dose Escalation - Milademetan|All participants enrolled for dose escalation receive a single oral dose of 90 mg milademetan, followed by escalated doses, based on mCRM with EWOC
16444719|NCT03671551||Psychomotor/psychological evaluation|Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
16444720|NCT03671538|Experimental|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
16444721|NCT03671525|Experimental|Nimodipine|One 60mg capsule of nimodipine on first or second study visit
16444722|NCT03671525|Placebo Comparator|Placebo|One placebo capsule on first or second study visit
16444723|NCT03671512|Experimental|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
16444724|NCT03671512|Active Comparator|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
16444725|NCT03671499|Experimental|Social Cognitive Theory based text messages|The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
16444726|NCT03671486||GBS-negative pregnant women|One Hundred Healthy GBS-negative pregnant women will be follow-up since the first trimester of pregnancy until one month post-delivery
16444727|NCT03671473|Experimental|Focused|fESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
16444728|NCT03671473|Active Comparator|Radial|rESWT (2000shocks, 4 Bar, 5Hz)
16444729|NCT03671460|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
16444730|NCT03671447|Active Comparator|ICU usual care|control condition
16444731|NCT03671447|Experimental|"Intervention ERIC"|intervention condition
16446349|NCT03660527||6-17 year old|
16444736|NCT03671421|Active Comparator|Quads tendon|The graft tissue will be quadriceps tendon
16444737|NCT03671421|Active Comparator|Hamstring|Semitendinosus and gracilis will be used for graft
16444738|NCT03671421|Active Comparator|BPTB|Bone patellar tendon bone graft to be used.
16444739|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
16444740|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
16444741|NCT03671382|Experimental|Intervention Arm|Communication Training Program and Patient Prompt Sheet
16444742|NCT03671382|No Intervention|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
16444743|NCT03671369||Cervarix Group|The study group comprises of 9-25 year-old male and female subjects who will be administered 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects can be vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose is administered before 5 months after the first dose, the third dose vaccination is required. In the 3 doses schedule, if the vaccination schedule requires flexibility, the second dose can be administered between 1 and 2.5 months and the third dose can be administered between 5 and 12 months after the first dose.
16444744|NCT03671343|Experimental|Intervention : Physical rehabilitation|"The Arm Physical rehabilitation will benefit from the implementation of the Loss of Mobility Prevention program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY."
16444745|NCT03671343|No Intervention|Control : optimized medical treatment|"The Arm Optimized medical treatment will not benefit from the implementation of the Loss of Mobility Prevention program."
16444746|NCT03671330|Experimental|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.
~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.
~It is the investigators choice for NSAI based on patient's past medical history.
~Postmenopausal experimental arm:
~Letrozole + Ribociclib
~PK Cohort: Open-label ribociclib + Letrozole treatment combination.
~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
16444747|NCT03671330|Placebo Comparator|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.
~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.
~It is the investigators choice for NSAI based on patient's past medical history.
~Postmenopausal control arm:
~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
16444748|NCT03671317|Experimental|Intervention group|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
16444749|NCT03671317|No Intervention|Non-intervention group|This arm will continue usual care with no intervention from medical clowns. They will be asked to complete pre and post surveys about the blood draw process.
16444750|NCT03671304|Experimental|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
16444751|NCT03671291|Experimental|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
16444752|NCT03671278|Other|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
16444753|NCT03671265|Experimental|SHR-1210 + Chemotherapy + Radiotherapy|"Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.
~SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
~Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.
~Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )"
16444754|NCT03671252|Experimental|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
16446350|NCT03660527||18-44 year old|
16444755|NCT03671252|Active Comparator|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
16444756|NCT03671239|Other|Product Sequence A|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
16444757|NCT03671239|Other|Product Sequence B|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
16444758|NCT03671239|Other|Product Sequence C|Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.
16444759|NCT03671239|Other|Product Sequence D|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.
16444760|NCT03671239|Other|Product Sequence E|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
16444761|NCT03671239|Other|Product Sequence F|Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
16444762|NCT03671226|Experimental|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
16444763|NCT03671213|Experimental|Calypso|Calypso Knee System
16444764|NCT03671187|Experimental|Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
16444765|NCT03671187|Experimental|Ex- Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
16444766|NCT03671174|Experimental|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
16444767|NCT03671174|Experimental|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
16444768|NCT03671174|Active Comparator|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
16444769|NCT03671161|Experimental|Patients with poorly controlled diabetes type 1|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring
16444770|NCT03671148|Experimental|Risankizumab|Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
16444771|NCT03671148|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
16444772|NCT03671135|Experimental|TCA Intrastromal Inlay|A monocular intrastromal corneal inlay will be implanted.
16444773|NCT03671122||PREFERS main study|500 patients with new onset heart failure will be characterized into those with HFpEFand HFrEF at baseline and undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis
16444774|NCT03671122||CABG PREFERS|500 Patients undergoing elective by pass surgery with or without diastolic or systolic dysfunction as Proxy for HFpEF and HFrEF will undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis and cardiac biopsies
16444775|NCT03671109|Experimental|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
16444776|NCT03671109|Placebo Comparator|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
16444777|NCT03671096|Experimental|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
16444778|NCT03671083||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
16444779|NCT03671083||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
16444780|NCT03671070|Active Comparator|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
16444781|NCT03671070|Placebo Comparator|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
16444782|NCT03671057|Experimental|HospiAvontuur|Intervention group - Non-pharmacological (HospiAvontuur) preparation HospiAvontuur is a simple point and click adventure game on a I-pad. The game describes the pathway which a child and his parents will take before, during and just after a hospital admission for an elective otorhinolaryngeal procedure under general anaesthesia.
16446351|NCT03660527||45-59 year old|
16444783|NCT03671057|Active Comparator|Midazolam|control group: The children of the control group will not play the game HospiAvontuur as an at home preparation for surgery. These children will be prepared for surgery according to the current practice at the Jessa hospital. Children receive only the basic information during the consultation with the surgeon. There is no specific at home preparation required. When admitted at the hospital, children receive a pharmacological preparation, 45 - 60 minutes prior to the induction of the anaesthesia. The medication is administered orally by a small syringe in the mouth and contains Dormicum 0.3mg/kg body weight and atropine 0.02mg/kg body weight supplemented with raspberry syrup.
16444784|NCT03671044|Experimental|Nanosomal Docetaxel Lipid Suspension - 75 mg/m2|Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
16444785|NCT03671044|Experimental|T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
16444786|NCT03671044|Active Comparator|R, Taxotere® (100 mg/m2)|Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
16444787|NCT03671031||isolated roux loop|isolated roux loop reconstruction following pancreaticoduodenectomy as the first group.
16444788|NCT03671031||single loop|single loop reconstruction following pancreaticoduodenectomy as the second group.
16444789|NCT03671018|Experimental|Dose Finding|Participants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.
16444790|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL|Participants with at least one line of prior therapy (2L+) and that have relapsed or refractory (R/R) follicular lymphoma (FL) will receive mosunetuzumab + polatuzumab vedotin.
16444791|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL|2L+ participants with R/R diffuse large B-cell lymphoma will receive mosunetuzumab + polatuzumab vedotin.
16444792|NCT03671018|Experimental|Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL|Participants with at least 2 lines of prior therapy (3L+) will receive subcutaneous (SC) mosunetuzumab + polatuzumab vedotin.
16444793|NCT03671005|Experimental|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
16444794|NCT03671005|Active Comparator|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
16444795|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
16444796|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
16444797|NCT03670979|Experimental|bone swaging alone|xenograft alone
16444798|NCT03670979|Experimental|bone swaging plus EDTA|bone swaging with EDTA
16444799|NCT03670966|Experimental|Treatment (211At-BC8-B10, chemotherapy, TBI, MMF, G-CSF)|"PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion over 6-8 hours on day -8, fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on days -6 and -5. Patients also undergo TBI on day -1.
~TRANSPLANT: Patients undergo PBSC or bone marrow transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID on days 5-35, and tacrolimus IV over 1-2 hours (changed to PO once tolerated) on days 5-180 with taper beginning on day 84 per physician discretion. Patients also begin G-CSF IV or SC on day 5 to continue until ANC > 1000/mm^3 x 3 days."
16444800|NCT03670953|Experimental|IPX203 ER CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to investigational product IPX203 ER CD-LD and IR CD-LD placebo.
~IR CD-LD active and placebo are tablets and IPX203 ER CD-LD active is capsules. Dosage and frequency is patient specific."
16444801|NCT03670953|Active Comparator|IR CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to IPX203 placebo and IR CD-LD active comparator.
~IR CD-LD active is tablets and IPX203 active and placebo are capsules. Dosage and frequency is patient specific."
16444802|NCT03670940||COPD patients|COPD patients without bronchiectasis
16444803|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
16444804|NCT03670927||Cases|Cases (incident patients with a diagnosis of primary sarcoma and histologically confirmed by an expert pathologist of the RRePS or ResOs networks in the 15 districts of France participating to this study) Environmental, occupational and lifestyle-related exposures
16444805|NCT03670927||Controls|"Subjects never diagnosed with a primary sarcoma and individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list.
~Environmental, occupational and lifestyle-related exposures"
16444943|NCT03669965|Experimental|Part A Arm 2b|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
16444944|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
16444806|NCT03670914|Experimental|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
16444807|NCT03670901|Experimental|JHL1101|375 mg/m2 of JHL1101 is given intravenously on D1 of each cycle
16444808|NCT03670901|Active Comparator|MabThera|375 mg/m2 of Rituximab is given intravenously on D1 of each cycle
16444809|NCT03670888|Experimental|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
16444810|NCT03670888|Active Comparator|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
16444811|NCT03670875|Experimental|Agave inulin|Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
16444812|NCT03670875|Experimental|Curcumin|Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
16444813|NCT03670875|Experimental|Omega 3 Fatty Acids|O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
16444814|NCT03670875|Other|Control|Recommendations to decrease calories intake an do exercise.
16444815|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
16444816|NCT03670849|Experimental|Patients using LapAR system|
16444817|NCT03670836|Experimental|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
16444818|NCT03670836|Experimental|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
16444819|NCT03670823||Healthy subjects|50 healthy subjects for a control group
16444820|NCT03670823||Patients with Major Depression|50 patients with major depression for a research group
16444821|NCT03670810|Experimental|100 milligram (mg) Lasmiditan|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
16444822|NCT03670810|Experimental|200 mg Lasmiditan|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
16444823|NCT03670810|Placebo Comparator|Control 1 Sequence|"Control 1:
~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.
~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.
~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
16444824|NCT03670810|Placebo Comparator|Control 2 Sequence|"Control 2:
~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.
~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.
~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
16444825|NCT03670810|Experimental|100 mg Lasmiditan Maximum Extended Enrollment (MEE)|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
16444826|NCT03670810|Experimental|200 mg Lasmiditan MEE|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
16444827|NCT03670810|Placebo Comparator|Control 1 Sequence MEE|"Control 1:
~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.
~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.
~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
16444828|NCT03670810|Placebo Comparator|Control 2 Sequence MEE|"Control 2:
~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.
~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.
~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
16444829|NCT03670797||controlled diabetic patients|
16444830|NCT03670797||uncontrolled diabetic patients|
16444831|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
16444832|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
16444833|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
16444834|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
16445140|NCT03668613|Experimental|secukinumab high dose|secukinumab high dose
16444837|NCT03670732|Active Comparator|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
16444838|NCT03670732|Active Comparator|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
16444839|NCT03670719|Experimental|Manual Therapy and Exercise Group|Combination of manual therapy and exercises for chronic cervical pain
16444840|NCT03670719|Active Comparator|Exercise Group|Only exercises for chronic cervical pain
16444841|NCT03670706|Active Comparator|Group A|Exercise training, then crossover to analgesic optimisation
16444842|NCT03670706|Active Comparator|Group B|Analgesic optimisation, then crossover to exercise training
16444843|NCT03670706|No Intervention|Group C|Control group
16444844|NCT03670693|Experimental|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 >14, and a score of >4 in the Fatigue questionnaire.)
16444845|NCT03670693|Experimental|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 <14, and a score of <4 in the Fatigue questionnaire.)
16444846|NCT03670693|Experimental|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
16444847|NCT03670680|Experimental|Lina LibrataTM|Use of the Lina LibrataTM
16444848|NCT03670667||RA patients treated with abatacept|
16444849|NCT03670667||RA patients treated with anti-TNFi's|
16444850|NCT03670667||RA patients treated with other biologics|
16444851|NCT03670654|Active Comparator|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
16444852|NCT03670654|Sham Comparator|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
16444853|NCT03670641|Experimental|Insulin and CGM Intervention|10 individuals with newly diagnosed type 2 diabetes will be started on basal (glargine) bolus (lispro) insulin therapy for up to 4 weeks with titrations guided by continuous glucose monitor (Dexcom G6) to achieve euglycemia and then insulin stopped after 4 weeks with hopes of diabetes remission.
16444854|NCT03670628|Active Comparator|720 shockwave therapy|5 Daily sessions of shockwave therapy within a week.( Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shock of treatment energy will be applied in every session to each region ( left and right corpora cavernosa and crura)
16444855|NCT03670628|Sham Comparator|None shockwave therapy|5 Daily sessions of shockwave therapy within a week.( Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shock of treatment energy will be applied in every session to each region ( left and right corpora cavernosa and crura. The device probe, will be covered with a cap that will stopped the transmission of shockwaves.
16444856|NCT03670615|Experimental|Exercise and tDCS|Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
16444857|NCT03670615|Other|Exercise Education and tDCS|Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
16444858|NCT03670615|Other|Exercise and Sham tDCS|Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
16444859|NCT03670602|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
16444860|NCT03670602|Other|Control Thinking|Participants will generate or be provided with non-future cues.
16444861|NCT03670589||radiosurgery gammaknife group|Patient treated by radiosurgery gammaknife for a one side vestibular schwannoma
16444862|NCT03670589||microsurgery resection group|Patient treated by microsurgery resection for a one side vestibular schwannoma
16444863|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
16444864|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
16444865|NCT03670563|Experimental|Exercise 1|Short foot exercise protocol instructed utilizing verbal instruction, passive modeling, active-assisted modeling, and active modeling.
16444866|NCT03670563|Active Comparator|Exercise 2|Short foot exercises plus NMES. Short foot exercise protocol instructed utilizing verbal instruction, passive modeling assisted by neuromuscular electric stimulation (NMES), active-assisted modeling assisted by neuromuscular electric stimulation, and active modeling.
16444867|NCT03670563|No Intervention|Control|No exercise intervention; continue normal physical activity, but do not start any new exercise programs
16444868|NCT03670550|Experimental|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.
~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
16444869|NCT03670537||First trimester pregnant women|
16444870|NCT03670524|Experimental|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
16444871|NCT03670524|No Intervention|Control Group|No intervention
16444872|NCT03670511|Experimental|sit-to-stand|
16444873|NCT03670511|Active Comparator|six minute walking test|
16444874|NCT03670498|Experimental|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
16446352|NCT03660527||above 60 year old|
16444875|NCT03670498|Active Comparator|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
16444876|NCT03670485|Experimental|Revised sequential activation protocol|"Apply 4 channel electrical stimulation device with a revised sequential activation protocol.
~It sequentially activates Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device."
16444877|NCT03670485|No Intervention|control subject|Apply 4 channel electrical stimulation device without any stimulation
16444878|NCT03670459|Experimental|Group 1|Patients in G1 will receive traditional physical therapy program (balance exercises) for twelve sessions; day after day
16444879|NCT03670459|Experimental|Group 2|Patients in G2 will receive Cawthorne Cooksey Exercises in addition to traditional physical therapy program for twelve sessions; day after day .
16444880|NCT03670459|Experimental|Group 3|Patients in G3 will receive vestibular habituation exercises in addition to traditional physical therapy program for twelve sessions; day after day.
16444881|NCT03670446|Experimental|Pharmacists' intervention|A group of participants assigned to a pharmaceutical intervention
16444882|NCT03670446|No Intervention|Routine therapy|A group of participants assigned to a control (routine therapy)
16444883|NCT03670433||Patients admitted in the Polyvalent Internal Medical Unit|"Patients over 65 years old admitted in the Polyvalent Internal Medical Unit (UMIP) of Rennes University Hospital between 09/04/2017 and 10/31/2017 or going back home or to a rehabilitation service during the same period.
~Cost analysis of medication reconciliation."
16444884|NCT03670420|Experimental|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
16444885|NCT03670420|No Intervention|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
16444886|NCT03670407|No Intervention|Control group|Participants who opt not to go ahead with ovarian fragmentation.
16444887|NCT03670407|Experimental|Study group|Participants who opt for ovarian fragmentation.
16444888|NCT03670381||ASD group|ASD patients with HDAC4 CNVs
16444889|NCT03670381||TD group|Typically developing controls without lifetime ASD or a family history of ASD
16444890|NCT03670368|Experimental|Intervention (Mentor/Mentee)|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on social relationships, coping behaviors, and healthy lifestyles.
16444891|NCT03670368|Active Comparator|Comparison group - written materials|Youth in the comparator group will receive written versions of all materials covered in the mentoring sessions.
16444894|NCT03670329|Experimental|URGO2875|Dressing
16444895|NCT03670316|Experimental|Algorithm Treatment plus referral to quitline (AT)|will be assigned a pharmacotherapy treatment regimen recommended to their provider.
16444896|NCT03670316|Active Comparator|Quitline (eTAU)|will be referred to quitlines, telephone-based tobacco cessation services.
16444897|NCT03670303|Experimental|Intervention group|This group will include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance will be assessed at 6 months follow-up after baseline assessment than educational intervention will be given. Six months after intervention compliance will be assessed again.
16444898|NCT03670303|No Intervention|Control group|This group will also include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance towards spectacle use will be assessed at 6 months after baseline assessment. No intervention will be given in this group. Compliance will be assessed again at the same time when assessed in intervention group 6 months after the intervention.
16444899|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
16444900|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
16444901|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
16444902|NCT03670264|Experimental|Quitline Incentive|The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
16444903|NCT03670264|Experimental|Tobacco Cessation Incentive|The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
16444904|NCT03670264|Placebo Comparator|No Financial Incentive|No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.
16444905|NCT03670251|Other|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
16444906|NCT03670238|Experimental|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
16444907|NCT03670238|Active Comparator|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
16444908|NCT03670225|Other|Invia Motion Endure|
16446446|NCT03659864|Experimental|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
16444909|NCT03670212|Placebo Comparator|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
16444910|NCT03670212|Experimental|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
16444911|NCT03670199|Experimental|Experimental group|nutritional and functional management coordinated by dieticians and physiotherapists, with adapted nutritional and physical advice and support, realized with the use of Nutrimus booklet in order to facilitate coordination and delivration of cares proposed to the patients
16444912|NCT03670199|Active Comparator|Control group|usual preoperative advice for patients who undergoing surgical procedure concerning nutritional cares and physical activity
16444913|NCT03670186|Experimental|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
16444914|NCT03670186|Experimental|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
16444915|NCT03670173|Experimental|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
16444916|NCT03670160|Active Comparator|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
16444917|NCT03670160|Active Comparator|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
16444918|NCT03670147|Experimental|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
16444919|NCT03670147|Experimental|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
16444920|NCT03670134|Experimental|Volumetric laser Endomicroscopy (VLE)|Volumetric laser Endomicroscopy (VLE) is a second-generation optical coherence tomography platform that can image the human esophagus in cross-section at microscopic resolution this will performed by using the Nvision VLE Imaging System.
16444921|NCT03670121|Experimental|BTVA Treatment|All patients that will receive Bronchoscopic Thermal Vapor Ablation (BTVA) Treatment
16444922|NCT03670108||patients receiving an individualized SMS|
16444923|NCT03670108||patients receiving a standard SMS|
16444924|NCT03670095|Experimental|Lactose-free memantine tablet|(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
16444925|NCT03670095|Experimental|Lactose-containing memantine tablet (Ebixa®)|(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
16444926|NCT03670082|Experimental|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
16444927|NCT03670082|Experimental|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
16444928|NCT03670069|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16444929|NCT03670056|Experimental|Nivolumab and Ipilimumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
16444930|NCT03670043|Active Comparator|Metformin ER|The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
16444931|NCT03670043|Experimental|Psyllium|The subjects developing GI-related symptoms with metformin will be randomized to Psyllium
16444932|NCT03670030|Experimental|ABI-009|In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.
16444934|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
16444935|NCT03670004||Non-Impaired|Able-bodied controls
16444936|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.
~Creation of a bone and arterial panorama using EndoNaut® software."
16444937|NCT03669965|Experimental|Part A Arm 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
16444938|NCT03669965|Experimental|Part A Arm 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
16444939|NCT03669965|Experimental|Part A Arm 3|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
16444940|NCT03669965|Experimental|Part B KRT-232 Arm|Recommended KRT-232 dose and schedule from Part A
16444941|NCT03669965|Active Comparator|Part B Ruxolitinib Arm|Ruxolitinib per approved prescribing label
16444942|NCT03669965|Experimental|Part A Arm 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
16444945|NCT03669939||Communication strategy|Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
16444946|NCT03669939||Standard of Care|Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
16444947|NCT03669926|Other|DBT+SM|Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
16444948|NCT03669913|Experimental|Intervention|Intervention arm will receive a pre evaluation survey, 11 lessons on CSE sequentially in a period of one year and a post evaluation survey
16444949|NCT03669913|No Intervention|Control arm|This is a control arm that receives no intervention but will have and pre and post evaluation in one year
16444950|NCT03669900|Other|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
16444951|NCT03669887|Experimental|Lifestyle Modification Program|
16444952|NCT03669887|No Intervention|Control|
16444953|NCT03669861|Experimental|Abatacept|To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
16444954|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
16444955|NCT03669835|Experimental|Dietary supplement and standard therapy.|Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
16444956|NCT03669835|Other|Standard therapy only.|Patients would be given standard treatment for 1 month.
16444957|NCT03669822||Inpatient ulcerative colitis patients|Patients hospitalized for acute severe ulcerative colitis will be invited to enroll. Participants will be treated at the discretion of their treating physicians per standard of care. We expect some participants will be treated with standard versus accelerated infliximab dosing, permitting comparison, in addition to other treatment strategies.
16444958|NCT03669809||male, non-obese|male with BMI<28
16444959|NCT03669809||male, obese|male with BMI≥28
16444960|NCT03669809||female, non-obese|female with BMI<28
16444961|NCT03669809||female, obese|female with BMI≥28
16444962|NCT03669796|Experimental|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
16444963|NCT03669796|Placebo Comparator|control|20 mg powder per kg body weight of casein/maltodextrin
16444964|NCT03669783|Active Comparator|treatment VAD|Vincristin, Actinomycin-D and Doxorubicin
16444965|NCT03669783|Experimental|treatment VCE|Vincristin, Carboplatin and Etoposide
16444966|NCT03669757|Experimental|LEO 134310 Dose A|Once daily application
16444967|NCT03669757|Experimental|LEO 134310 Dose B|Once daily application
16444968|NCT03669757|Experimental|LEO 134310 Dose C|Once daily application
16444969|NCT03669757|Experimental|LEO 134310 Dose D|Once daily application
16444970|NCT03669757|Placebo Comparator|LEO 134310 vehicle|Once daily application
16444971|NCT03669757|Active Comparator|0.1% betamethasone valerate ointment (class III steroid)|Once daily application
16444972|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
16444973|NCT03669731|Experimental|Group 1|Urinary urea 24 hours and food diary
16444974|NCT03669731|Experimental|Group 2|Urinary urea 24 hours and food diary
16444975|NCT03669731|Experimental|Group 3|Urinary urea 24 hours and food diary
16444976|NCT03669718|Experimental|Active ISA101b and cemiplimab.|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
16444977|NCT03669718|Placebo Comparator|Placebo and cemiplimab|Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
16444978|NCT03669692|Active Comparator|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
16444979|NCT03669692|Experimental|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.
~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
16444980|NCT03669679|Active Comparator|Group A|"participants undergoing superomedial pedicle breast reduction Hall-Findlay technique"
16444981|NCT03669679|Active Comparator|Group B|"participants undergoing inferior pedicle breast reduction Robbins technique"
16444982|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
16444983|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
16444984|NCT03669653|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
16444985|NCT03669653|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
16444988|NCT03669627|Active Comparator|Group 1: aTIV primer, QIV booster|Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.
16444989|NCT03669627|Other|Group 2: QIV primer, QIV booster|"Standard of care control group:
~Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2."
16444990|NCT03669627|Experimental|Group 3: aTIV primer, aTIV booster|"This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.
~Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2."
16444991|NCT03669614|Experimental|AR-501 inhaled|Three doses (low, medium, high) of inhaled AR-501 will be used.
16444992|NCT03669614|Placebo Comparator|inhaled AR-501 Placebo|Three doses (low, medium, high) of inhaled placebo will be used
16444993|NCT03669601|Experimental|Continuous AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.
~Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg."
16444994|NCT03669601|Experimental|Intermittent AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.
~Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg."
16444995|NCT03669588|Experimental|ARGX-113|
16444996|NCT03669588|Placebo Comparator|Placebo|
16444997|NCT03669575|Experimental|omega 7 - placebo|Receiving the active first then switch to the placebo after three weeks
16444998|NCT03669575|Active Comparator|placebo - omega 7|Receiving the placebo first then switch to the active after three weeks
16444999|NCT03669562|Experimental|Alprostadil liposome|
16445000|NCT03669562|Placebo Comparator|Placebo|
16445001|NCT03669549|Experimental|Nevanimibe hydrochloride|Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID
16445002|NCT03669523|Experimental|Denosumab-nivolumab combination|Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years
16445003|NCT03669510|Active Comparator|computer gaiuded IAN|Computer guided surgical technique
16445004|NCT03669510|Experimental|Classical technique|Non computer guided surgical technique
16445005|NCT03669497|Experimental|Hypo fractionated radiotherapy|Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour
16445006|NCT03669484|Experimental|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.
~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.
~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
16445007|NCT03669484|Active Comparator|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.
~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.
~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.
~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
16445008|NCT03669471||FAIS group|Subjects who have had a hip arthroscopy for femoroacetabular impingement during the preceding 6-30 months
16445009|NCT03669458|Experimental|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
16445010|NCT03669458|Experimental|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
16445011|NCT03669458|Experimental|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
16445012|NCT03669445|Experimental|four drugs combination|21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
16445013|NCT03669432|Experimental|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.
~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.
~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
16445014|NCT03669432|Other|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
16445015|NCT03669406|Experimental|Autograft fat|Paraplegic patients with healed pelvic eschar
16445016|NCT03669393|Experimental|THR-317|
16445017|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
16445018|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
16445019|NCT03669367|Experimental|abatacept|abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
16445020|NCT03669367|Active Comparator|hydroxycloroquina|Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
16445021|NCT03669354||Cohort SMT|Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
16445022|NCT03669354||Cohort OAT|Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
16445023|NCT03669354||Cohort SMTX|Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
16445024|NCT03669354||Cohort OATX|Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
16445025|NCT03669341|Experimental|Deep Inspiration Breath Hold (DIBH)|DIBH extended by prior hyperventilation while breathing 100% O2
16445026|NCT03669341|Active Comparator|High Frequency Percussive Ventilation (HFPV)|passive Ventilation by a jet ventilator
16445027|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
16445028|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
16445029|NCT03669315|Active Comparator|Active cTBS treatment|Active cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. TBS consists of bursts of 3 pulses separated by 20ms (i.e. 50 Hz), with each triplet being repeated every 200 ms (i.e. 5 Hz). Stimulus intensities will be set at 80% of AMT. The investigators will use 2 trains of 600 pulses each separated by 1 minute (a total of 1200 pulses).
16445030|NCT03669315|Sham Comparator|Sham cTBS treatment|Sham cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same active cTBS configuration will be used.
16445031|NCT03669302|Sham Comparator|Robotic gait training|Robotic gait training only
16445032|NCT03669302|Experimental|Robotic gait training & low-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at low frequency (0.3 Hz).
16445033|NCT03669302|Experimental|Robotic gait training & high-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at high frequency (30 Hz).
16445034|NCT03669289|Experimental|Enhanced model of primary care|
16445035|NCT03669263|Experimental|Fentanyl buccal soluble film (FBSF)|Single arm
16445036|NCT03669250|Active Comparator|CVN058, low dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg or 75mg substitution of 15mg.
16445037|NCT03669250|Active Comparator|CVN058, high dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
16445038|NCT03669250|Placebo Comparator|Placebo|Matching placebo.
16445039|NCT03669237|Experimental|end-to-side anastomosis|
16445040|NCT03669237|No Intervention|end-to-end anastomosis|
16445041|NCT03669224|Experimental|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
16445042|NCT03669224|Active Comparator|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
16445043|NCT03669211|Experimental|Cardiac stress test|
16445044|NCT03669198|Active Comparator|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
16445045|NCT03669198|No Intervention|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
16445046|NCT03669185|Placebo Comparator|Placebos|Placebos, 2 times daily 1 tablet, intake max. 133 days
16445047|NCT03669185|Active Comparator|Pentalong|Pentalong, 2 times daily 1 tablet, intake max. 133 days
16445048|NCT03669172|Experimental|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
16445049|NCT03669146|Experimental|Hyperopic subjects receiving glasses|Randomized +5.00 to +7.00 diopter hyperopic subjects that will receive partial refractive correction and will be instructed to do accommodation exercises on a daily basis.
16445050|NCT03669146|No Intervention|Hyperopic subjects uncorrected|Randomized +5.00 to +7.00 diopter hyperopic subjects that will serve as the control to the experimental arm who will receive no correction but be observed for the duration of the study.
16445051|NCT03669146|Active Comparator|Highly hyperopic subjects corrected|If a subject is found to be greater than +7.00 diopters hyperopic during the screening phase of the study, they will receive glasses correction and be followed during the study period.
16445052|NCT03669133|Active Comparator|Group A|Vitamin E 800 IU/daily for 24 weeks
16445053|NCT03669133|Placebo Comparator|Group B|Matching placebo for 24 weeks
16445054|NCT03669120|Active Comparator|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
16445055|NCT03669120|Experimental|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
16445056|NCT03669107|Experimental|Gum chewing|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.
~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
16445057|NCT03669107|No Intervention|Control group|no gum
16446447|NCT03659851||Levosimendan before LVAD implantation|Levosimendan use 24 hrs. before LVAD implantation
16445058|NCT03669094|Active Comparator|L. salivarius V4II-90|Lactobacillus salivarius V4II-90; approximately 1*10E9 colony forming unit (CFU) of L. salivarius V4II-90 in 1 oral capsule per day for 12 weeks.
16445059|NCT03669094|Placebo Comparator|Control group|Placebo supplement in 1 oral capsule per day for 12 weeks.
16445060|NCT03669081|Experimental|Toradol and Lyrica|Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
16445061|NCT03669081|Placebo Comparator|Placebo and Standard of Care|Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
16445062|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
16445063|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
16445064|NCT03669055|Experimental|Pre-operative and post operative Magnetic Resonance Imaging|Realization of an angio-MRI with 4D phase contrast sequence before and after the endovascular treatment of the aortic dissection
16445065|NCT03669042|Experimental|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
16445066|NCT03669029|Experimental|Week 6 Responders|In patients with clinical response at week 6, serum golimumab levels and anti-golimumab antibody levels will be correlated with clinical response.
16445067|NCT03669029|Experimental|Week 6 Non Responders|In patients without clinical response at week 6, golimumab treatment will be optimized.
16445068|NCT03669016|Experimental|Face-to-face group-based mindfulness|8 weeks training.
16445069|NCT03669016|Experimental|Internet-based mindfulness|8 weeks training.
16445070|NCT03669016|No Intervention|Waiting-list control group|No training during the study.
16445071|NCT03669003|Experimental|Gelfoam|Gelfoam slurry will be injected at the end of the biopsy procedure.
16445072|NCT03669003|Active Comparator|Standard procedure|Standard procedure of lung biopsy
16445073|NCT03668990|Other|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
~Funcitonal-oriented upper limb movements are performed at two different test days."
16445074|NCT03668990|Other|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
~Funcitonal-oriented upper limb movements are performed at two different test days."
16445075|NCT03668990|Other|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
~Funcitonal-oriented upper limb movements are performed at two different test days."
16445076|NCT03668977|No Intervention|Routine care|"In all four groups, the following antenatal and post-natal interventions will be offered:
~Women encouraged to enroll in routine antenatal care at their local health post/center.
~A clean birthing kit consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump.
~Women encouraged to deliver at a certified birthing facility and participate in the government's incentive scheme.
~Nutritional, hygiene, and infant care counseling.
~Tetanus toxoid (if needed) and iron-folic acid supplements."
16445077|NCT03668977|Experimental|Supplementation-pregnancy|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing throughout pregnancy. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
16445078|NCT03668977|Experimental|Supplementation-lactation|A daily fortified balanced protein-energy nutritional supplement beginning after delivery and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
16445079|NCT03668977|Experimental|Supplementation-pregnancy & lactation|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
16445080|NCT03668964|Experimental|Vitamin B2|Daily dose of 75 mg Vitamin B2
16445081|NCT03668964|Experimental|Vitamin C|Daily dose of 500 mg Vitamin C
16445082|NCT03668964|Experimental|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
16445083|NCT03668964|Experimental|Vitamin A|Daily dose of 250 µg Vitamin A
16445084|NCT03668964|Experimental|Vitamin D3|Daily dose of 60 µg Vitamin D3
16445085|NCT03668964|Experimental|Vitamin E|Daily dose of 100 mg Vitamin E
16445086|NCT03668964|Placebo Comparator|Placebo|Daily dose of 575 mg microcrystalline cellulose
16445087|NCT03668951|Experimental|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
16445249|NCT03667898|Experimental|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
16445088|NCT03668951|Experimental|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
16445089|NCT03668951|Experimental|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
16445090|NCT03668938|Experimental|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
16445091|NCT03668938|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
16445092|NCT03668925|Experimental|"Group Case"|patient diagnosed with hidrosadenitis suppurativa
16445093|NCT03668925|Active Comparator|"Group control"|patient without hidrosadenitis suppurativa
16445094|NCT03668912|Experimental|Guided participation group|
16445095|NCT03668912|No Intervention|Usual care group|
16445096|NCT03668899|Experimental|Chitosan NPs group|irrigation with Chitosan nanoparticles (final flush)
16445097|NCT03668899|Experimental|Chlorhexidine group|irrigation with CHX (final flush)
16445098|NCT03668899|Experimental|Combination group|irrigation with CHX/ nano Chitosan combination (final flush)
16445099|NCT03668899|Active Comparator|Hypochlorite group|irrigation with NaOCL (final flush)
16445100|NCT03668886|Experimental|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
16445101|NCT03668886|No Intervention|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
16445102|NCT03668873|Experimental|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-weeks. In addition to the five sessions, there are three home visits conducted via Express Care Online (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
16445103|NCT03668873|Active Comparator|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
16445104|NCT03668860|Active Comparator|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
16445105|NCT03668860|Active Comparator|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
16445106|NCT03668860|Active Comparator|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
16445107|NCT03668860|Active Comparator|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
16445108|NCT03668860|Active Comparator|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
16445109|NCT03668860|Active Comparator|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
16445110|NCT03668860|Active Comparator|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)
~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
16445111|NCT03668860|Active Comparator|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)
~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
16445112|NCT03668847|Experimental|DM-CHOC-PEN|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 75 or 98.7 mg/m2 emulsion will be administered IV once every 21-days until relapse
16445113|NCT03668834|Active Comparator|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
16445114|NCT03668834|Active Comparator|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
16445115|NCT03668834|Active Comparator|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
16445116|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
16445117|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
16445118|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
16445119|NCT03668808|Experimental|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
16445120|NCT03668808|Active Comparator|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
16445121|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
16445122|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
16445123|NCT03668769|Experimental|Prevention (smoking reduction, Quitting Schedule mobile app)|"AIM I: Participants follow an individually tailored gradual reduction of smoking schedule for 5 weeks while MDACC eHealth adapts WebCASSI into a smartphone app: Quitting Schedule.
~AIM II: Participants pre-test the Quitting Schedule mobile smartphone app for 5 weeks."
16445124|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
16445125|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
16445126|NCT03668730|Experimental|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
16445127|NCT03668730|Experimental|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
16445128|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
16445129|NCT03668678|Experimental|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
16445130|NCT03668678|No Intervention|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
16445131|NCT03668665|Active Comparator|Conventionell Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):
~1st half: conventional treatment with moist dressings (mepilex and fixomull)"
16445132|NCT03668665|Experimental|Treatment with Ready Medical Post Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):
~2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment"
16445133|NCT03668652|Experimental|Focal prostate cancer treatment by HIFU|Patients with target lesion distance < 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion > 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
16445134|NCT03668652|Active Comparator|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
16445135|NCT03668639|Other|Akynzeo plus dexamethasone|Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
16445136|NCT03668626|No Intervention|Term infants|Healthy term infants
16445137|NCT03668626|No Intervention|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
16445138|NCT03668626|Experimental|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
16445139|NCT03668613|Experimental|secukinumab low dose|secukinumab low dose
16445141|NCT03668600|Experimental|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
16445142|NCT03668574|Experimental|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
16445143|NCT03668574|Placebo Comparator|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
16445144|NCT03668561|Experimental|Treatment (CALIGALOC)|Wearing of the Caligaloc orthosis
16445145|NCT03668548|Experimental|Leucine group|To receive leucine on a daily basis for 10 weeks
16445146|NCT03668548|Placebo Comparator|Control group|To receive a placebo supplement on a daily basis for 10 weeks
16445147|NCT03668535|Active Comparator|Bladder Filling arm|Group A have triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
16445148|NCT03668535|Active Comparator|Bladder deflation arm|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
16445149|NCT03668522||children|age<=17
16445150|NCT03668522||adult|age>17
16445151|NCT03668509|Experimental|Cohort 1|oral adminstration of SHR1459, dose 1
16445152|NCT03668509|Experimental|Cohort 2|oral adminstration of SHR1459, dose 2
16445153|NCT03668509|Experimental|Cohort 3|oral adminstration of SHR1459, dose 3
16445154|NCT03668496|Experimental|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
16445155|NCT03668496|Active Comparator|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
16445156|NCT03668483|Experimental|Pulmonary Rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
16445157|NCT03668470|Experimental|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
16445158|NCT03668470|Placebo Comparator|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
16445159|NCT03668457|Experimental|Intervention to Patients|Only patients receive intervention
16445160|NCT03668457|Experimental|Intervention to Psychiatrists|Psychiatrists receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
16445161|NCT03668457|Experimental|Mixed Intervention|Patients and Psychiatrists associated with these patients receive intervention
16445162|NCT03668457|Other|Control|Psychiatrists provide the usual care Patients receive usual care
16445163|NCT03668444|Experimental|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
16445164|NCT03668444|Placebo Comparator|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
16445165|NCT03668431|Experimental|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.
~After the screening procedures confirm participation in the research study:
~Dabrafenib will be taken twice a day for 28 consecutive days
~Trametinib will be taken once a day for 28 consecutive days
~PDR001 will be administered IV every 28 days."
16445166|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
16445167|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
16445168|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
16445169|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
16445170|NCT03668405|Experimental|Lu AF20513 high dose|
16445171|NCT03668392|Experimental|Patients on Oncospar|
16445172|NCT03668379|Active Comparator|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 & 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 & 5 will review progress, challenges & maintenance strategies."
16445250|NCT03667898|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
16445173|NCT03668379|Experimental|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
16445174|NCT03668366|Experimental|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
16445175|NCT03668353|Experimental|treatment 1|Recombinant SeV-hFGF2/dF Injection 2×10 8CIU
16445176|NCT03668353|Experimental|treatment 2|Recombinant SeV-hFGF2/dF Injection 1×10 9CIU
16445177|NCT03668353|Experimental|treatment 3|Recombinant SeV-hFGF2/dF Injection 5×10 9CIU
16445178|NCT03668353|Experimental|treatment 4|Recombinant SeV-hFGF2/dF Injection 1×10 10CIU
16445179|NCT03668340|Experimental|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
16445180|NCT03668340|Experimental|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
16445181|NCT03668340|Experimental|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
16445182|NCT03668314|Experimental|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
16445183|NCT03668314|Placebo Comparator|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
16445184|NCT03668314|Experimental|Cohort 2:1|Fed/Fast RDN-929
16445185|NCT03668314|Experimental|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
16445186|NCT03668314|Placebo Comparator|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
16445187|NCT03668301||Group CPB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery with cardiopulmonary bypass
16445188|NCT03668301||Group OPCAB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery without cardiopulmonary bypass
16445189|NCT03668301||Group CPB-C|Control patients undergoing cardiac surgery with cardiopulmonary bypass
16445190|NCT03668301||Group OPCAB-C|Control patients undergoing cardiac surgery without cardiopulmonary bypass
16445191|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
16445192|NCT03668275|Experimental|Intervention|(partial) oncological home-hospitalization
16445193|NCT03668275|No Intervention|Control|standard oncological ambulatory hospital care
16445194|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
16445195|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
16445196|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
16445197|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
16445198|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
16445199|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
16445200|NCT03668249||All Participants|Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.
16445279|NCT03667703|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
16445201|NCT03668236|Experimental|Fluid restriction group|"No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:
~In case of severe hypoperfusion or severe circulatory impairment defined by either:
~Lactate≥4 mmol/L
~MAP<50 mmHg (with or without vasopressor/inotrope)
~Mottling beyond the kneecap (mottling score >2) OR
~Urinary output<0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation
~A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation
~In case of overt fluid losses (e.g. vomiting, large aspirates,…) IV fluid may be given to correct for the loss, but not above the volume lost.
~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:
~Correct dehydration or electrolyte deficiencies
~Ensure a total fluid input of 1L per 24hrs
~IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible"
16445202|NCT03668236|Active Comparator|Standard-care|"There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:
~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.
~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid
~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
16445203|NCT03668223|Experimental|Promoting Resilience in Stress Management (PRISM)|Resilience Skills Training
16445204|NCT03668223|No Intervention|Usual Care|Standard psychosocial care
16445205|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.
~Isokinetic evaluation."
16445206|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.
~Isokinetic evaluation."
16445207|NCT03668171|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks
16445208|NCT03668171|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2
16445209|NCT03668158||recurrent HCC|recurrent HCC after LT
16445210|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
16445211|NCT03668145|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.
16445212|NCT03668145|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.
16445213|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
16445214|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
16445215|NCT03668132||Normal control|Not have the ischemic brain damage
16445216|NCT03668119|Experimental|Nivolumab + Ipilimumab Combination|
16445217|NCT03668119|Experimental|Nivolumab Monotherapy|
16445218|NCT03668106|Active Comparator|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
16445219|NCT03668106|Active Comparator|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.
~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
16445220|NCT03668106|Active Comparator|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.
~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.
~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
16445221|NCT03668093|Experimental|ICCMS|Intervention
16445222|NCT03668093|Active Comparator|CAMBRA|Comparator
16445223|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
16445280|NCT03667703|Active Comparator|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
16445224|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
16445225|NCT03668067||2WIN|Accommodation, refraction and ocular alignment are estimated by infrared photoscreener using the 2WIN photoscreener device. Photoscreener screening makes use of light crescent quantification from off-axis flash-to-lens in a camera.
16445226|NCT03668067||school bus skiascopy|Refractive error estimated by child-friendly skiascopy rack holding lenses from +1.00 D to +10.00 D and -5.00 D. Skiascopy is a common, old-fashioned form of retinoscopy.
16445227|NCT03668054|Experimental|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
16445228|NCT03668041|Active Comparator|Trazodone|Participants who are assigned to take trazodone, an active study medication.
16445229|NCT03668041|Active Comparator|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
16445230|NCT03668041|Active Comparator|Gabapentin|Participants who are assigned to take gabapentin, an active study medication.
16445231|NCT03668041|Placebo Comparator|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
16445232|NCT03668028|Experimental|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
16445233|NCT03668028|Placebo Comparator|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
16445234|NCT03668015|Experimental|Group A (Xylitol then sorbitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol"
16445235|NCT03668015|Experimental|Group B (Sorbitol then xylitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol"
16445236|NCT03668002|Placebo Comparator|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
16445237|NCT03668002|Active Comparator|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
16445238|NCT03667989|Other|123I-MIBG CZT SPECT|Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
16445239|NCT03667976|No Intervention|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
16445240|NCT03667976|Experimental|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
16445241|NCT03667963|Other|Low Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
16445242|NCT03667963|Other|High Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
16445243|NCT03667950|Experimental|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
16445244|NCT03667937|Experimental|CUTIMED|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.
~If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.
~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
16445245|NCT03667937|Active Comparator|AQUACEL silver|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.
~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
16445246|NCT03667924|Experimental|PorchLight Project Intervention Group|Participants in the intervention group will receive home-based support and respite services from PorchLight Project trained Senior Companion volunteers of the Lutheran Social Services of Minnesota.
16445247|NCT03667911|No Intervention|Control Group|Only routine patient education on bowel preparation of colonoscopy. Give oral instructions on bowel preparation(including definition, significance, correct steps as well as dietary limitations) by a well-trained nurses or doctors. Written instructions are offered, which have the some contents.
16445248|NCT03667911|Experimental|Virtual-reality Group|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
16445251|NCT03667885||Small renal Masses|patients with a renal mass of 4 cm or less. Typically incidentally found. Blood and urine samples will be collected from each patient at baseline before a biopsy of the tumor is collected and 14 days later. In addition, all patients will be offered a Multi planar MRI before the biopsy. Patients elected for curative treatment for malignant tumors will have another set of blood and urine samples collected at 1 month and 6 months after the intervention.
16445252|NCT03667872|Experimental|Device|MRI compatible and LFP recordable implantable stimulator
16445253|NCT03667859||Women undergoing Brachytherapy|Women with either uterine or cervical malignancy treated primarily by brachytherapy.
16445254|NCT03667859||Women undergoing Pelvic Radiation|Women with either uterine or cervical malignancy treated primarily by pelvic radiation.
16445255|NCT03667846|Placebo Comparator|Placebo|Placebo
16445256|NCT03667846|Experimental|Topiramate|Week 0-1: 25 mg qhs Week 1-2: 25 mg qAM, 25 mg qhs Week 2-3: 25 mg qAM, 50 mg qhs Week 3-4: 50 mg qAM, 50 mg qhs Week 4-5: 50 mg qAM, 75 mg qhs Week 5-6: 75 mg qAM, 75 mg qhs Week 6-7: 75 mg qAM, 100 mg qhs Week 7-8: 100 mg qAM, 100 mg qhs Week 8-10: 100 mg qAM, 100 mg qhs Week 10-12: 100 mg qAM, 100 mg qhs Week 12-14: 2-week taper
16445257|NCT03667833|Experimental|shoulder brace with comfortable tension|"Self-comfortable tension of strap will be adjusted by subject's feedback with comfortable feeling as please feel postural correction by shoulder brace without tight pressure."
16445258|NCT03667833|Experimental|shoulder brace with forced tension|Forced tension, the self-comfortable tension of strap will be increased till forced tension of strap using buckles.
16445259|NCT03667820|Experimental|Osimertinib|Osimertinib in combination with Stereotactic Ablative Radiation (SABR)
16445260|NCT03667807|Experimental|rTMS condition 1|
16445261|NCT03667807|Experimental|rTMS condition 2|
16445262|NCT03667807|Experimental|rTMS condition 3|
16445263|NCT03667794||PH patients|Patients with known or first diagnosis of PH
16445264|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
16445265|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
16445266|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
16445267|NCT03667781||Providers Interviewed|Providers in cardiology clinic
16445268|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
16445269|NCT03667768|Experimental|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
16445270|NCT03667768|Other|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
16445271|NCT03667755|Experimental|fast track recovery|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Subjects are given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3 hours prior to operation drink) of a lactose-free clear tea-colour fruit flavoured fluid contains 14% whey protein, 86% carbohydrates and 0% lipids. Participants fast for solids for 6 hours from the operation. Participants will be given clear fluid (2 packs Resource peach) within 24 hours post-surgery (without present of bowel sound) and reviewed by dietitian. Staff nurse in-charged will monitor anesthetic risk of drinking whey protein and ensure subject to finish specific drinks prior surgery. When they tolerated at least 500ml of clear fluids, they were given a regular solid diet.
16445272|NCT03667755|No Intervention|conventional|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
16445273|NCT03667729|Experimental|progressive muscle relaxation|The experimental group received PMR once a week for a total of 12 weeks. Subjects completed measures at baseline, 3-month, and 3-month follow-up.
16445274|NCT03667729|No Intervention|Control group|treatment-as-usual(TAU)
16445275|NCT03667716|Experimental|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
16445276|NCT03667716|Experimental|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
16445277|NCT03667716|Experimental|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
16445278|NCT03667716|Experimental|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).
16445281|NCT03667690|Experimental|Group 1: Rezafungin for Injection|"Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.
~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day."
16445282|NCT03667690|Active Comparator|Group 2: Caspofungin|"Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.
~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
16445283|NCT03667677|Experimental|Group 1|Tandospirone + Amlodipine
16445284|NCT03667677|Experimental|Group 2|Tandospirone placebo + Amlodipine
16445285|NCT03667677|Experimental|Group 3|Tandospirone + Amlodipine placebo
16445286|NCT03667677|Placebo Comparator|Group 4|Tandospirone placebo + Amlodipine placebo
16445287|NCT03667664|Other|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
16445288|NCT03667651|Active Comparator|Twice daily use treatment with EpiCeram|They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
16445289|NCT03667651|No Intervention|Standard skin care|Parents are to follow standard skin care practices
16445290|NCT03667638|Experimental|PRP Intervention|PRP injection into wound border
16445291|NCT03667625|Experimental|Aquatic group|Aquatic multidimensional mobility exercises were given in the treatment pool at Balcova Thermal Centre, Izmir, Turkey. Group of 6-7 patients was instructed by a specialized physiotherapist twice in a week for eight weeks. The water temperature was 33-340C and the depth was between 110-140 cm, patients were asked to keep T11 level submersion during vertical exercises. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
16445292|NCT03667625|Experimental|Land group|Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
16445293|NCT03667625|Active Comparator|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks.
16445294|NCT03667612||Patients with breast cancer|"Patients clinical data collection
~Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres
~Realization of tumor samples series of cuts and paraffin shavings for:
~Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)
~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)
~Characterization of lymphocyte populations
~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
16445295|NCT03667612||Patients with colorectal cancer|"Patients clinical data collection
~Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments
~Realization of series of cuts and paraffin shavings of the tumor samples for:
~Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)
~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)
~Characterization of lymphocyte populations
~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
16445296|NCT03667599|Experimental|Home care|This is the arm for patients who receive their transplant care in their homes.
16445297|NCT03667599|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
16445298|NCT03667599|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
16445299|NCT03667586|Experimental|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
16445300|NCT03667586|Placebo Comparator|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
16445301|NCT03667573|Experimental|tsDCS Dosage A and textured insoles|"tsDCS dosage A and textured shoe insoles"
16445302|NCT03667573|Experimental|tsDCS Dosage B and textured insoles|"tsDCS dosage B and textured shoe insoles"
16445303|NCT03667573|Experimental|tsDCS Dosage A and smooth insoles|"tsDCS dosage A and smooth shoe insoles"
16445304|NCT03667573|Experimental|tsDCS Dosage B and smooth insoles|"tsDCS dosage B and smooth shoe insoles"
16445305|NCT03667560|Experimental|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
16445306|NCT03667560|Active Comparator|FlexHD|FDA-approved FlexHD Pliable
16445307|NCT03667547|Experimental|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
16445308|NCT03667521||non-nerve-sparing laparaoscopic sacrocolpopexy.|
16445309|NCT03667521||nerve-sparing laparaoscopic sacrocolpopexy.|
16445310|NCT03667508|Experimental|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
16445311|NCT03667508|Active Comparator|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
16445312|NCT03667495||Relapse|Patients who suffered colorectal cancer or adenoma relapse after curative surgery
16445313|NCT03667495||Remission|Patients who get remission after curative surgery
16445314|NCT03667482|Experimental|Cabozantinib in Combination With Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week. Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
16445315|NCT03667469|Experimental|Stapleless one anastomosis gastric bypass|Laparoscopic stapleless-separated one anastomosis (mini-) gastric bypass procedures
16445316|NCT03667469|Active Comparator|Staple use mini-gastric bypass|Laparoscopic stapler-separated one anastomosis (mini-) gastric bypass procedures
16445317|NCT03667469|Active Comparator|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
16445318|NCT03667456|Experimental|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
16445319|NCT03667443|Active Comparator|Myo-inositol plus folic|
16445320|NCT03667443|Active Comparator|Myo-inositol + folic a. + α-lactalbumin|
16445321|NCT03667430|Experimental|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
16445322|NCT03667430|Experimental|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
16445323|NCT03667417||subjects carrying a BRCA gene mutation|subjects carrying a BRCA gene mutation
16445324|NCT03667404|Experimental|Resistant Maltodextrin|Resistant maltodextrin (RM) powder 25 g during days 1-7 and 50g during days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
16445325|NCT03667404|Placebo Comparator|Maltodextrin|Maltodextrin 25g for days 1-7 and 50 g for days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
16445326|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
16445327|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
16445328|NCT03667365|Experimental|aortic valve replacement|
16445329|NCT03667365|Active Comparator|strict clinical surveillance|
16445330|NCT03667352|Experimental|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
16445331|NCT03667352|Active Comparator|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
16445332|NCT03667339||outpatients group|Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
16445333|NCT03667339||inpatients group|Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty
16445334|NCT03667326|Active Comparator|Low-Dose Aspirin (LDA) Intervention Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
16445335|NCT03667326|Placebo Comparator|Placebo Control Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.
16445336|NCT03667313|Experimental|sirolimus-eluting balloon (SEB)|treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB
16445337|NCT03667313|Active Comparator|paclitaxel-eluting balloon (PEB)|treatment of BMS- or DES-ISR with PEB
16445338|NCT03667300|Active Comparator|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
16445339|NCT03667300|Active Comparator|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
16445340|NCT03667287|Experimental|Full-thickness skin graft|Repair of parastomal hernia with full-thickness skin graft, placed intraperitoneally, as reinforcement.
16445341|NCT03667287|Active Comparator|Synthethic mesh|Repair of parastomal hernia with best available conventional method, using synthetic mesh material as reinforcement
16445342|NCT03667261|Active Comparator|cover screw|extraction of hopeless mandibular molars followed by immediate implants that will be covered using cover screw
16445343|NCT03667261|Experimental|sealing socket abutment|extraction of hopeless mandibular molars followed by immediate implants that will be covered using sealing socket abutment
16445344|NCT03667222|Experimental|BPX-04 Active|BPX-04 1% minocycline topical gel
16445345|NCT03667222|Placebo Comparator|BPX-04 Vehicle|BPX-04 topical gel vehicle
16445346|NCT03667209|Experimental|Traditional exercise and pain neuroscience education|Will include exercises of the neck and scapular regions using traditional methods and pain neuroscience education
16445347|NCT03667209|Active Comparator|Suspension exercise and pain neuroscience education|Will include suspension exercises of the neck and scapular regions using traditional methods and pain education.
16445348|NCT03667196||Observational|
16445349|NCT03667183|Experimental|Pilates Group|Female adolescents with eating disorders who receive Pilates for 10 weeks.
16445350|NCT03667170|Experimental|Cohort1: MSI-H Colorectal Cancer|Cohort 1 patients receive KN035 150 mg Subcutaneously on Day 1, 8, 15, 22 of every 4-week cycle (Q4W)
16445351|NCT03667170|Experimental|Cohort2: dMMR Non-Colorectal Cancer|Cohort 1 patients receive KN035 150 mg Subcutaneously on Day 1, 8, 15, 22 of every 4-week cycle (Q4W)
16445352|NCT03667157|Active Comparator|moderate-to-severe Graves Orbitopathy|active, moderate-to-severe Graves Orbitopathy according to EUGOGO.
16445353|NCT03667157|Active Comparator|Dysthyroid Orbit Neuropathy|Dysthyroid Orbit Neuropathy according to EUGOGO
16445354|NCT03667131|Experimental|Enalapril Maleate|Enalapril Maleate 5 mg every 12 hrs for 90 days.
16445355|NCT03667131|Experimental|Placebo|Substance that lacks in itself therapeutic action.
16445356|NCT03667118|Experimental|Food Supplement|Infants who received the active food supplement powder
16445357|NCT03667118|Placebo Comparator|Placebo|Infants who received the placebo powder
16445358|NCT03667105|Experimental|CAF+XDM|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous dermal collagen matrix graft (AXDM - Mucoderm®, Botiss,) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
16445359|NCT03667105|Experimental|CAF+MC|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Mucograft®, Geistlich Pharma) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
16445360|NCT03667105|Active Comparator|CAF|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Then, the flap will be coronally positioned and sutured to completely cover the graft. This group will be the control group.
16445361|NCT03667092|Experimental|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.
~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
16445362|NCT03667079|Experimental|Integrated|Intervention 'integrated delivery of deworming and vaccination' will be delivered to this arm of the study
16445363|NCT03667079|Active Comparator|Deworming only|Intervention 'Mass deworming only' will be delivered to villages in this arm of the study
16445364|NCT03667079|Active Comparator|Rabies vaccination only|Villages assigned to this arm received mass vaccination of dogs against rabies only
16445365|NCT03667053|Experimental|dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
16445366|NCT03667053|Placebo Comparator|placebo|Single fixed dose (s.c.injection) of placebo
16445367|NCT03667053|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
16445368|NCT03667040|No Intervention|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
16445369|NCT03667040|Active Comparator|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
16445370|NCT03667027||Patients undergoing LTx with respiratory failure (cases)|Patients are receiving a respiratory support modality (mechanical ventilation and/or extracorporeal life support) as a bridge to lung transplantation (LTx).
16445371|NCT03667027||Patients undergoing LTx without prior respiratory support|Patients undergoing lung transplantation but do not require prior bridging respiratory support.
16445372|NCT03667027||Elective thoracic surgical patients|Patients undergoing elective thoracic surgery for planned lung or esophageal resection.
16445373|NCT03667014|Experimental|Dupilumab treatment|30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
16445374|NCT03667001|Experimental|Lidocaine Hydrochloride|"1.5 mg/kg lean body mass lidocaine (lidocaine 1%) bolus I.V. as general anesthesia steady state concentration is accomplished
~1.5 mg/kg lean body mass/h lidocaine I.V. with beginning of surgical procedures
~after completion of surgery: transfer to PACU, pain evaluation for 48 hours
~duration of intervention: lidocaine infusion up to four hours from completion of surgery, or till transfer to surgical ward"
16445454|NCT03666494|Active Comparator|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
16445455|NCT03666494|Active Comparator|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
16445375|NCT03667001|Placebo Comparator|Saline Solution|"0.15 ml/kg lean body mass saline 0.9% bolus I.V. as general anesthesia steady state concentration is accomplished
~0.15 ml/kg lean body mass/h saline 0.9% I.V. with beginning of surgical procedure
~after completion of surgery: transfer to PACU, pain evaluation for 48 hours
~duration of intervention: saline infusion up to four hours from completion of surgery, or till transfer to surgical ward"
16445376|NCT03666988|Experimental|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
16445377|NCT03666988|Experimental|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
16445378|NCT03666988|Experimental|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
16445379|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
16445380|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
16445381|NCT03666975|Experimental|LIV 30 Hz, 0.4 g|LIV 30 Hz, 0.4 g Low intensity vibration to short leg 3x / week x 10 wks
16445382|NCT03666975|Experimental|LIV 30 Hz, 1.0 g|LIV 30 Hz, 1.0 g Low intensity vibration to short leg 3x/week x 10 wks
16445383|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
16445384|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
16445385|NCT03666949|Other|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
16445386|NCT03666949|Other|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
16445387|NCT03666936|Experimental|Intervention|Social-health care intervention
16445388|NCT03666923|Experimental|THR-687 dose level 1|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
16445389|NCT03666923|Experimental|THR-687 dose level 2|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
16445390|NCT03666923|Experimental|THR-687 dose level 3|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
16445391|NCT03666910||children of rheumatic diseased mothers not on treatment|
16445392|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
16445393|NCT03666910||children of normal mothers|
16445394|NCT03666897|Other|DTI Outcomes and Biomarkers|Imaging and Lab Collection
16445395|NCT03666884|Active Comparator|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
16445396|NCT03666884|Active Comparator|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
16445397|NCT03666871|Experimental|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
16445398|NCT03666871|Active Comparator|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
16445399|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
16445400|NCT03666845||Sciatic nerve block|Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease
16445401|NCT03666832|Experimental|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
16445402|NCT03666819|Experimental|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16445403|NCT03666806|Experimental|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
16445404|NCT03666806|Placebo Comparator|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
16445405|NCT03666793|No Intervention|Control|Standard healthcare procedures
16445406|NCT03666793|Experimental|experimental: Reconciliation group|medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital
16445456|NCT03666481|Experimental|MPAI group|Patients in this group participated in a 6-months Motivational Physical Activity Intervention (MPAI) to explore its effects on different variables related to PA levels and psychosocial aspects of life of bariatric patients. Concretely, the fundamental goals of the MPAI group were three: to increase the self-determined forms of motivation of the patients towards exercise or reduce those related to non-self-determined motivation; to improve post-operative levels of PA with respect to pre-operative levels, and; transfer the benefits of the intervention on different variables related to the perceived health-related quality of life.
16445407|NCT03666780||Subject|"All patients who signed informed consent and are implanted with a LAmbre occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post implant:
~At discharge (+/- 1 day)
~1-3 months (+/- 1 week)
~6 months (+/- 2 weeks)
~12 months (+/- 1 month)
~2 years (+/- 3 month)
~3 years(+/- 3 month) Patients who have undergone a LAmbre explant should remain in the study and adhere to the above mentioned follow-up time point until completion of 3 years follow-up period.
~After the patient has completed the 3 years follow-up assessments, the patient is considered to have completed the study. A study exit eCRF needs to be completed and the patient will receive routine care."
16445408|NCT03666767||Oesophageal atresia (OA) +/- tracheo-oesophageal fistula (TOF)|
16445409|NCT03666767||Congenital diaphragmatic hernia (CDH)|
16445410|NCT03666767||Intestinal atresia (IA)|
16445411|NCT03666767||Gastroschisis|
16445412|NCT03666767||Exomphalos|
16445413|NCT03666767||Anorectal malformation (ARM)|
16445414|NCT03666767||Hirschsprung's disease|
16445415|NCT03666754|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
16445416|NCT03666754|Experimental|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
16445417|NCT03666728|Experimental|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
16445418|NCT03666715||Participants with Schizophrenia|Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
16445419|NCT03666702|Experimental|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
16445420|NCT03666702|Active Comparator|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
16445421|NCT03666689||MHV reconstruction|Both ends of middle hepatic vein tributaries V8 and/or V5 of modified right lobe graft will be anastomosed to side of a single synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice.
16445422|NCT03666689||Separate tributaries reconstruction|End of V8 middle hepatic vein tributary of modified right lobe graft; if present, will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice, and end of V5; if present; will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's Inferior Vena Cava directly.
16445423|NCT03666676|Active Comparator|Normal Hearing|Signal processing to improve intelligibility
16445424|NCT03666676|Active Comparator|Mild hearing loss|Signal processing to improve intelligibility
16445425|NCT03666676|Active Comparator|Moderate hearing loss|Signal processing to improve intelligibility
16445426|NCT03666663|Experimental|Lidocaine|Participants will receive SPG blocks with lidocaine.
16445427|NCT03666663|Experimental|Bupivacaine|Participants will receive SPG blocks with bupivacaine
16445428|NCT03666663|Experimental|Ropivacaine|Participants will receive SPG blocks with ropivacaine
16445429|NCT03666663|Placebo Comparator|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
16445430|NCT03666650|Other|Rotem|
16445431|NCT03666624|Experimental|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
16445432|NCT03666624|No Intervention|Routine medical care|No intervention
16445433|NCT03666598|No Intervention|No tourniquet|No use of tourniquet during surgery
16445434|NCT03666598|Experimental|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
16445435|NCT03666585|Active Comparator|mobile application actuated rehabilitation exercise guidance|
16445436|NCT03666585|Active Comparator|routine rehabilitation exercise guidance|
16445437|NCT03666572|Active Comparator|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
16445438|NCT03666572|Active Comparator|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose [LNnT] (Bif+prebiotic) in Severe Acute Malnourished infants
16445439|NCT03666572|Placebo Comparator|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
16445440|NCT03666572|Active Comparator|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
16445441|NCT03666559|Experimental|Azacitidine|Azacitidine is administered by sub-cutaneous injection at 75 mg/m2 per day for seven consecutive days every 4 weeks until progression, intolerance or end of the study.
16445442|NCT03666546|Experimental|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
16445443|NCT03666546|Experimental|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
16445444|NCT03666546|Experimental|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
16445445|NCT03666546|Experimental|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
16445446|NCT03666546|Active Comparator|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
16445447|NCT03666546|Placebo Comparator|Water|Still water, oral intake, 250 mL single dose
16445448|NCT03666533|Active Comparator|Active tDCS|active tDCS plus gait training
16445449|NCT03666533|Sham Comparator|Sham tDCS|sham tDCS plus gait training
16445450|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
16445451|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
16445452|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
16445453|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
16445536|NCT03665961||No central obesity|Controls with no central obesity
16445457|NCT03666481|No Intervention|Control group|Patients in this group did not participate in any intervention, but the same measurements were made in them as in the MPAI group in the same temporal spaces.
16445458|NCT03666468|Experimental|PlayMed|"PlayMed, a highly immersive role-playing computer game
~- Focus on Paediatric Asthma and Seizure management"
16445459|NCT03666468|Active Comparator|Online Package (OP)|"Online package (OP) of NSW Health Guidelines
~- Focus on Paediatric Asthma and Seizure management"
16445460|NCT03666468|Placebo Comparator|Paper Guidelines|"Paper NSW Health Guidelines
~- Focus on Paediatric Asthma and Seizure management"
16445461|NCT03666455|Experimental|Acceptance and Commitment Therapy|The intervention consists of eight individual (one-on-one) acceptance and commitment therapy sessions approximately one week apart over a 12-week period.
16445462|NCT03666442|Experimental|chemotherapy group|patients receive 4 cycles of Xelox
16445463|NCT03666429|Active Comparator|Bulb suction|Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.
16445464|NCT03666429|Experimental|NoseFrida|Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.
16445465|NCT03666416|Experimental|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
16445466|NCT03666403|Experimental|Patients|This prospective one-year study enrolled consecutive 30 children of ≤3 years-old with suspected major airway diseases and therefore scheduled for diagnostic FB. During FB, PIP measurements and associated lumen images were obtained at six airway locations using three studied NIV modes, including 1) NIV rate: 0/min, 2) NIV rate: 10-20/min, 3) NIV rate: 5-10/min.
16445467|NCT03666390|Experimental|0.5mg/kg Ketamine|Anesthesia
16445468|NCT03666390|Active Comparator|0.045mg/kg Midazolam|Benzodiazepine
16445469|NCT03666377|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
16445470|NCT03666377|Experimental|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
16445471|NCT03666364|Experimental|Magnetic nanoparticle selection for teratozoospermia|
16445472|NCT03666364|No Intervention|Density gradient centrifugation for teratozoospermia|
16445473|NCT03666351|Experimental|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.
~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
16445474|NCT03666351|Experimental|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.
~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
16445475|NCT03666338|Active Comparator|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
16445476|NCT03666338|No Intervention|Standard of Care|Standard of Care regarding mobilization
16445477|NCT03666325|Experimental|Pembrolizumab|Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
16445478|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all >18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
16445479|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
16445480|NCT03666299|Experimental|Lidocaine|Lidocaine treatment
16445481|NCT03666299|Placebo Comparator|Control|Placebo treatment
16445482|NCT03666286||Intensive Care Patients|Patients >24h on intensive care
16445483|NCT03666273|Experimental|Dose escalation_Monotherapy|Patients with solid tumor types considered immunosensitive
16445484|NCT03666273|Experimental|Dose escalation_Combination therapy|Patients with solid tumor types considered immunosensitive
16445485|NCT03666273|Experimental|Expansion HNSCC_Combination therapy|Patients with head and neck squamous cell carcinoma (HNSCC)
16445486|NCT03666260|Experimental|Quadratus Lumborum Block arm|
16445487|NCT03666260|Active Comparator|Femoral block arm|
16445488|NCT03666247|Experimental|HealthMindr Application|Participants in this study arm will have access to the mobile messaging platform (HealthMindr) for 3 months.
16445489|NCT03666247|Other|Waitlist|Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
16445490|NCT03666221|Experimental|Nimotuzumab plus IMRT|Patients with recurrent nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent intensity modulated radiation therapy(IMRT) , folowing weekly nimotuzumab (200 mg/week) for totally 8 weeks concurrent with IMRT.
16445491|NCT03666208|Experimental|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
16445492|NCT03666195|Active Comparator|Group A|complete dentures will be fabricated using poly methyl methacrylate resin denture base material modified with 5%wt titanium dioxide nanoparticles.
16445493|NCT03666195|No Intervention|Group B|complete dentures will be fabricated with poly methyl methacrylate resin denture base material.
16445494|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
16445495|NCT03666169||Whole Cohort|UK Citizens, aged 18-65 years
16445496|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
16445497|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC|
16445498|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody naïve NSCLC|
16445499|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant RCC|
16445500|NCT03666143|Experimental|Metastatic or advanced RCC without prior systemic therapy|
16445501|NCT03666143|Experimental|Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC|
16445502|NCT03666143|Experimental|Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC|
16445503|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody R/R melanoma|
16445504|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC|
16445505|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, sq NSCLC|
16445506|NCT03666130|Active Comparator|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
16445507|NCT03666130|Active Comparator|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
16445508|NCT03666117||Study group|children and adolescents with type 1 diabetes
16445509|NCT03666078||normal vaginal delivery|
16445510|NCT03666078||assisted vaginal delivery|
16445511|NCT03666078||elective cesarean delivery|
16445512|NCT03666078||emergency cesarean delivery|
16445513|NCT03666065|Active Comparator|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
16445514|NCT03666065|Experimental|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
16445515|NCT03666039|Experimental|Sensorimotor training|The participants will receive a tablet-based app for at home training that contains sensorimotor components.
16445516|NCT03666039|Active Comparator|Control training|The participants will receive a tablet-based app for at home training that contains relaxing components.
16445517|NCT03666026|No Intervention|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
16445518|NCT03666026|Experimental|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
16445519|NCT03666026|Experimental|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
16445520|NCT03666026|Experimental|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
16445521|NCT03666013||Young healthy subjects|20-30 years old, max 1h of exercise per week
16445522|NCT03666013||Elderly with a normal physical function|65-80 years old, max 1h of exercise per week
16445523|NCT03666013||Elderly with a decreased physical function|65-80 years old, max 1h of exercise per week, SPPB under 9 or frailty score lower then 10
16445524|NCT03666013||Active elderly|65-80 years old, minimal 3h of exercise per week
16445525|NCT03666000|Experimental|Dose Level 1|"PBCAR0191, 3 x 10^5 CAR T cells per kg body weight.
~In this study, PBCAR0191, allogeneic anti-CD19 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia.
~Route of Administration: Intravenous infusion.
~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR0191 infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16445526|NCT03666000|Experimental|Dose Level 2|PBCAR0191, 1 x 10^6 CAR T cells per kg body weight.
16445527|NCT03666000|Experimental|Dose Level 3a|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight.
16445528|NCT03666000|Experimental|Dose Level 3b|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight as 3 administrations of 1 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
16445529|NCT03666000|Experimental|Dose Level 4|PBCAR0191, 6 x 10^6 CAR T cells per kg body weight as 2 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
16445530|NCT03666000|Experimental|Dose Level 5|PBCAR0191, 9 x 10^6 CAR T cells per kg body weight as 3 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
16445531|NCT03665987||properative assessment clinic group|The treatment group will be seen in the preoperative clinic before hospitalization.
16445532|NCT03665987||Control group|The control group will get anesthetic consultation after hospitalization without clinic service.
16445533|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
16445534|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
16445535|NCT03665961||Central obesity|Cases with central obesity as defined by waist circumference cut-offs ≥ 90 cm in men and ≥ 80 cm in women for Asians
16445537|NCT03665948|Experimental|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
16445538|NCT03665948|Active Comparator|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about ~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
16445539|NCT03665922|Experimental|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
16445540|NCT03665922|Placebo Comparator|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
16445541|NCT03665909|Experimental|Remote activity monitoring|"Receive the remote activity monitoring system (i.e., eNeighbor; see intervention description) over an 18-month period."
16445542|NCT03665909|No Intervention|Control|Control participants do not receive the remote activity monitoring intervention.
16445543|NCT03665896|Active Comparator|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
16445544|NCT03665896|Placebo Comparator|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
16445545|NCT03665883|Active Comparator|Diathermy preferred|Monopolar energy is the preferred dissection approach in this group of patients undergo TEP. Total time of activation of monopolar machine will recorded by specially designed device
16445546|NCT03665883|Active Comparator|Blunt dissection preferred|Blunt dissection is the preferred dissection approach in this group of patients undergo TEP. Use of monopolar energy for haemostasis is still allowed upon surgeons' decision. Total time of activation of monopolar machine will recorded by specially designed device
16445547|NCT03665870|Experimental|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
16445548|NCT03665857|Experimental|multicomponent intervention|"Schools in the intervention arm will receive a multicomponent intervention at the school-, parent- and student-level, with a mobile application to promote the collaboration between investigators, school teachers, parents and students.
~The school-level intervention elements will include school policies and health education for teachers.
~The parent-level intervention elements will include health education for parents and promoting students' physical activity at home.
~The student-level intervention elements will include health education for students, promoting students' physical activity in school and monthly monitoring of weight and height."
16445549|NCT03665857|No Intervention|usual-care control|Schools assigned to the control group will have usual education provision throughout their participation in the trial, and after finishing the study they will be offered the health education package, policy suggestion and materials as the schools in the multicomponent intervention group.
16445550|NCT03665844|Placebo Comparator|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
16445551|NCT03665844|Active Comparator|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
16445552|NCT03665831|Experimental|Active H1 Coil deep rTMS active treatment|
16445553|NCT03665818|Experimental|Oral appliance intervention|
16445554|NCT03665818|No Intervention|Without oral appliance intervention|
16445555|NCT03665779|Experimental|isosorbide mono-nitrate group|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
16445556|NCT03665779|Placebo Comparator|placebo group|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.
16445557|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
16445558|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
16445559|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
16445560|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
16445561|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
16445562|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
16445565|NCT03665753|Experimental|Ketorolac 30mg|As a part of standard care, subjects will be administered 30 mg of Ketorolac.
16445566|NCT03665740|Experimental|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
16445567|NCT03665740|Placebo Comparator|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
16445568|NCT03665727|Experimental|Mindfulness|15 minute mindfulness session
16445569|NCT03665727|Experimental|Suggestion|15 minute therapeutic suggestion session
16445570|NCT03665727|Active Comparator|Psychoeducation|15 minute psychoeducation session
16445571|NCT03665727|No Intervention|Usual Care|The usual care comparison group was comprised of patients who underwent total joint arthroplasty of the hip or knee at the same academic medical center during the study period but who did not attend Joint Academy.
16445572|NCT03665714|Experimental|Impact Oral|"Preoperatively:
~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.
~Postoperatively:
~Patient should receive:
~1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.
~2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.
~3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.
~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
16445573|NCT03665714|Active Comparator|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:
~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.
~Postoperatively:
~Patient should receive:
~272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.
~544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.
~816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.
~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
16445574|NCT03665701|Experimental|Inhibitory effects of Fevipiprant|in vitro experiments: The reaction of the innate lymphoid cells by cytokine secretion in response to the stimulation by Prostagalandin D2 metabolites and the measurement of a potential suppressive effect of Fevipiprant will be assessed.
16445577|NCT03665675|Experimental|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with partial response, may receive up to 2 additional doses at monthly intervals.
16445578|NCT03665662|Experimental|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
16445579|NCT03665662|No Intervention|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
16445580|NCT03665649|Other|CD133+ human donors|CD133+ cells isolation
16445581|NCT03665636|Experimental|Triheptanoin|Open Label Study
16445582|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
16445583|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
16445584|NCT03665597|Experimental|Pembrolizumab Sequence 1|Participants receive a single dose of pembrolizumab (pembro) in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A subcutaneously (SC); Cycle 2 Day 1: pembro Dose B intravenously (IV); Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
16445585|NCT03665597|Experimental|Pembrolizumab Sequence 2|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A SC; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
16445586|NCT03665597|Experimental|Pembrolizumab Sequence 3|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
16445587|NCT03665597|Experimental|Pembrolizumab Sequence 4|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose B IV; Cycle 3 Day 1: pembro Dose A SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
16445588|NCT03665597|Experimental|Pembrolizumab Sequence 5|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose A SC: Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
16445684|NCT03664934|Experimental|Patients, Neck-specific exercises|Patients before and after neck-specific exercises, subgroup to NCT01528579 with additional measures
16445685|NCT03664934|No Intervention|Healthy controls|Healthy controls, no treatment
16445589|NCT03665597|Experimental|Pembrolizumab Sequence 6|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
16445590|NCT03665597|Experimental|Pembrolizumab Dose D|Participants receive a single dose of pembro Dose D IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
16445591|NCT03665584|Active Comparator|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
16445592|NCT03665584|Sham Comparator|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
16445593|NCT03665571||Conventional Activation method|NK cell was incubated with either K562 cells
16445594|NCT03665571||Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
16445595|NCT03665558|No Intervention|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
16445596|NCT03665558|Active Comparator|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
16445597|NCT03665545|Active Comparator|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
16445598|NCT03665545|Experimental|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
16445599|NCT03665532|Experimental|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
16445600|NCT03665532|Active Comparator|Passive text reminders|Automated weekly text message health care reminders
16445601|NCT03665519|Experimental|Dietary supplement and ursodeoxycholic acid therapy.|Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
16445602|NCT03665519|Other|Ursodeoxycholic acid therapy only.|Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
16445603|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications ON|Idiopathic Parkinson's patient's with Hoehn and Yahr score of 1.5- 2 i.e. in an early stage of the disease, under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
16445604|NCT03665493|Experimental|PD patients H&Y=3 Medications ON|Parkinson's patient's with Hoehn and Yahr score of 3, i.e. in moderate-to-advanced stages of the disease under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
16445605|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications OFF|Same as above described
16445606|NCT03665493|Experimental|PD patients H&Y=3 Medications OFF|Same as above described
16445607|NCT03665493|Experimental|Healthy age-matched controls|Healthy controls. Right-handed healthy subjects (it will be assessed by the Edinburgh handedness inventory) with normal or corrected-to-normal vision, without a history of neurological diseases. Age range: 40-70.
16445608|NCT03665480|Experimental|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
16445609|NCT03665480|No Intervention|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
16445610|NCT03665454|Experimental|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
16445611|NCT03665454|Active Comparator|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
16445612|NCT03665441|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with
~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:
~Abraxane (125 mg/m2) IV
~Gemcitabine (1000 mg/m2) IV
~Or
~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:
~Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1*28 is 50 mg/m2)
~Leucovorin 400 mg/m2 IV
~5 FU 2400 mg/m2
~Or
~FOLFIRI: Irinotecan 180 mg/m2 IV
~Leucovorin 400 mg/m² IV
~5 FU 400 mg/m² IV bolus
~5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
16445613|NCT03665441|Other|Chemotherapy alone|Standard treatment: Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
16445614|NCT03665428|Experimental|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
16445615|NCT03665428|Active Comparator|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
16445643|NCT03665246|No Intervention|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
16445616|NCT03665415|Other|Formative|This stage represents an initial formative phase to implement the NDGame Squad intervention with small samples of youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase. Three (n=3) participants from the school site only will participate in an initial 4-week Game Squad intervention in the first formative phase. Participant feedback including barriers to engagement and suggestions for improvements will be obtained via parent/caregiver and child interviews post-intervention.
16445617|NCT03665415|Experimental|Pilot Intervention|Participants in the pilot intervention arm will receive either 10 or 14 weeks of the NDGameSquad intervention. School site participants will receive 10 weeks during the school year, followed by another 4 weeks during summer vacation. Clinic site participants will receive 10 weeks only.
16445618|NCT03665415|Other|Pilot Waitlist Control|Participants at both sites randomized to the waitlist control arm will be asked to maintain current physical activity levels during the first 10-week period. They will then be provided the intervention equipment and training. School site control arm participants will then participate in a 4-week, unsupported summer NDGame Squad intervention. Clinic site control arm participants will not be required to participate in the NDGameSquad intervention.
16445619|NCT03665402|Active Comparator|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
16445620|NCT03665402|Active Comparator|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
16445621|NCT03665402|Experimental|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
16445622|NCT03665389|Other|Single Arm|Among patients who undergo TAVR at the kobe university hospital, those who are found to have moderate or severe stenosis on cCTA performed before surgery and judged to clinically require ischemia evaluation will be included in this study.
16445623|NCT03665376|Experimental|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
16445624|NCT03665376|No Intervention|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest… Pain control was managed with medication of choice by surgeon and anesthesiologist.
16445625|NCT03665363|Experimental|SCOPE|Participants allocated to SCOPE, will receive an internet-based psychoeducation intervention, eight weeks of ASD-theme modules with coaching.
16445626|NCT03665363|Active Comparator|Self-study|Participants allocated to self-study will receive eight weekly emails containing informative and relevant websites about ASD. The emails are accessed on the same platform as the experimental condition (SCOPE), no active contact with the coaches is available.
16445627|NCT03665363|No Intervention|Wait-list controls/Treatment as usual|Participants allocated to wait-list will receive prompts to answer outcome measures but otherwise no other contact with the study coordinators or coaches. Participants may receive treatment as usual.
16445628|NCT03665350|No Intervention|non insulin|standard care + antidiabetic therapy non insulin
16445629|NCT03665350|Experimental|Insulin|standard care including insulin
16445630|NCT03665337|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
16445631|NCT03665337|Active Comparator|Control|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
16445632|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) with documented paroxysmal supraventricular arrhythmias.
16445633|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) without documented supraventricular arrhythmia.
16445634|NCT03665311|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED and another 100 mL 0.9% Normal Saline after 4 hours of treatment
16445635|NCT03665311|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of SLED and another 100 mL 25% Albumin fluid after 4 hours of treatment
16445636|NCT03665298|Experimental|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
16445637|NCT03665285|Experimental|NC318|NC318 for IV infusion of various dose strengths administered in 14 day dosing cycles. Alternative dosing schedules may be explored once RP2D has been determined.
16445638|NCT03665272|Experimental|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
16445639|NCT03665272|Experimental|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
16445640|NCT03665259|Active Comparator|Pure oxygen group|The patients receive 100% oxygen therapy during the induction phase of induction
16445641|NCT03665259|Experimental|Lower oxygen group|The patients received 60% oxygen therapy during the induction phase of induction
16445642|NCT03665246|Experimental|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
16445644|NCT03665233|Sham Comparator|Sh-group|The patients in this arm get standard treatment, together with a sham version of a VR session.
16445645|NCT03665233|Active Comparator|VR-group|These patients get a VR session with the standard treatment
16445646|NCT03665220|Experimental|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
16445647|NCT03665220|Experimental|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
16445648|NCT03665220|Active Comparator|Healthcare education|A conservative intervention program for post-stroke patients
16445649|NCT03665207|Experimental|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
16445650|NCT03665207|Active Comparator|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
16445651|NCT03665194|Experimental|Cortexolone 17α-propionate 7.5% solution|
16445652|NCT03665194|Placebo Comparator|Vehicle solution|
16445653|NCT03665181||without modification of dose and without bismuth mask|The cranial CT imaging presrcibed in usual care will be performed without modification of dose and without bismuth mask
16445654|NCT03665181||with modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and with bismuth mask
16445655|NCT03665181||without modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed without modification of dose and with bismuth mask
16445656|NCT03665181||with modification of dose and without bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and without bismuth mask
16445657|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
16445658|NCT03665155|Experimental|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.
~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
16445659|NCT03665142|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
16445660|NCT03665142|Placebo Comparator|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
16445661|NCT03665129|Experimental|Dose escalation|IPH5401 at different doses and schedule + Durvalumab
16445662|NCT03665129|Experimental|Cohort expansion NSCLC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients
16445663|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 naive|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients
16445664|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients
16445665|NCT03665116|Experimental|Arginine|L-arginine 1.5 g capsule by mouth, once daily for 6 months
16445666|NCT03665116|No Intervention|No Intervention|no supplement for 6 months
16445667|NCT03665103|Experimental|Laser-assisted ICSI|
16445668|NCT03665103|No Intervention|conventional ICSI|
16445669|NCT03665077|Experimental|Participants|Patients with breast cancer who have completed all their primary treatments (surgery±radiation therapy) and are scheduled to start their adjuvant hormonal therapy.
16445670|NCT03665051|Other|Young adults|Obtain muscle biopsy specimens from young adults (ages 20-40) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
16445671|NCT03665051|Other|Older adults|Obtain muscle biopsy specimens from older adults (ages 60-80) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
16445672|NCT03665038|Experimental|Brexanolone|
16445673|NCT03665025|Experimental|immediate implant placement with xenograft|Immediate implant placement with the use of xenograft as grafting material
16445674|NCT03665025|Experimental|immediate implant using mixed allograft and xenograft|Immediate implant placement with using mixture of allograft and xenograft material
16445675|NCT03664999||Parturients physiologic pregnancy|Parturients undergoing caesarean delivery with physiologic pregnancy
16445676|NCT03664999||Parturients with risk pregnancy|Parturients undergoing caesarean with risk of complications (pre-eclampsia, HELLP syndrom, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
16445677|NCT03664986|Experimental|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
16445678|NCT03664986|No Intervention|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
16445679|NCT03664973|Experimental|continuous|continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.
16445680|NCT03664973|Active Comparator|single-shot|Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml
16445681|NCT03664960|Experimental|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
16445682|NCT03664947|Experimental|exercise|The exergaming training programs have included recent daily living activities in games. In our study we have planned the Nintendo Wii Fit Plus Game Console in the therapy training.
16445683|NCT03664947|No Intervention|control|No exercise training applied for the control group.
16445686|NCT03664921|Experimental|Omnitram|Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
16445687|NCT03664921|Placebo Comparator|Placebo|Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
16445688|NCT03664908|Experimental|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
16445689|NCT03664908|Experimental|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
16445690|NCT03664908|Experimental|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
16445691|NCT03664895|No Intervention|observation arm(TMX, MDR≥5%)|keep go on TMX
16445692|NCT03664895|No Intervention|control arm(TMX, MDR<5%)|keep go on TMX
16445693|NCT03664895|Active Comparator|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
16445694|NCT03664882|Experimental|Fexofenadine|Fexofenadine, single administration
16445695|NCT03664882|Placebo Comparator|Placebo|Placebo, single administration
16445696|NCT03664869|Active Comparator|Group A|"BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used."
16445697|NCT03664869|Experimental|Group B|"Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3
~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.
~Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water"
16445698|NCT03664856|Experimental|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
16445699|NCT03664843||The chemotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
16445700|NCT03664843||The radiotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
16445701|NCT03664843||The targeted therapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
16445702|NCT03664830|Experimental|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
16445703|NCT03664817|Experimental|social capital intervention|This group will receive intervention developed from Phase 1 study and based on photovoice project
16445704|NCT03664817|Active Comparator|group-based health promotion intervention|"The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)"
16445706|NCT03664791||Vanguard Rocc knee implant|Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant
16445707|NCT03664765|Active Comparator|Intervention exercise arm|daily oropharyngeal and respiratory muscle exercises
16445708|NCT03664765|Sham Comparator|Control arm|Daily sham exercises
16445709|NCT03664752|Experimental|IDP-120 Gel|Component A
16445710|NCT03664752|Placebo Comparator|IDP-120 vehicle gel|Vehicle
16445711|NCT03664739|Experimental|IDP-120 Gel|Component A
16445712|NCT03664739|Placebo Comparator|IDP-120 Vehicle Gel|Gel
16445713|NCT03664726|Experimental|Episodic Future Thinking (EFT)|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months)
16445714|NCT03664726|Active Comparator|Episodic Recent Thinking (ERT)|Participants will complete an episodic task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties). ERT participants will list positive recent events that have already happened and that they have enjoyed, at different general recent time points (e.g., a few hours ago, 1 day ago, 2-6 days ago, 7-12 days ago)
16445715|NCT03664713|Experimental|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
16446947|NCT03656718|Experimental|Part D, Group 5: nivolumab (dose 3) + rHuPH20|
16445716|NCT03664713|No Intervention|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
16445717|NCT03664700||LMA Protector|The LMA Protector will be used
16445718|NCT03664687|Active Comparator|Zoledronate one dose (4 mg)|One 4 mg dose of Zoledronate
16445719|NCT03664687|Active Comparator|Zoledronate 4 mg every 6 months x 3 years|One 4 mg dose of Zoledronate given every 6 months for 3 years
16445720|NCT03664674|Experimental|OTO-104|
16445721|NCT03664674|Placebo Comparator|placebo|
16445722|NCT03664661|Experimental|experimental group|BCMA nanobody CAR-T cells
16445723|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
16445724|NCT03664635|Experimental|Phase I - Safety Dose Level|In phase I three (3) + 3 patients will be treated with 1x10^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level
16445725|NCT03664635|Experimental|Phase I - Dose Level 1|In phase I six (6) + 3 patients will be treated with 1x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1
16445726|NCT03664635|Experimental|Phase I - Dose Level 2|In phase I six (6) + 3 patients will be treated with 3x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2
16445727|NCT03664635|Experimental|Phase II|The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I
16445728|NCT03664622|Experimental|group K|patients with a ketamine infusion intraoperative
16445729|NCT03664622|Experimental|group M|patients with a Morphine infusion intraoperative
16445730|NCT03664609||Parkinson's Disease|Subjects with Parkinson's disease, implanted with a Boston Scientific Deep Brain Stimulation System
16445731|NCT03664609||Essential Tremor|Subjects with Essential Tremor, implanted with a Boston Scientific Deep Brain Stimulation System
16445732|NCT03664609||Dystonia|Subjects with dystonia, implanted with a Boston Scientific Deep Brain Stimulation System
16445733|NCT03664596|Experimental|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
16445734|NCT03664596|Other|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
16445735|NCT03664596|Active Comparator|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
16445736|NCT03664583|Experimental|Intervention Group|Patients randomly assigned to the intervention group will be offered the ACHRU-Community Partnership Program (CPP) intervention in addition to usual primary care services offered by their local diabetes education centre or primary care setting. The CPP is a 6-month self-management intervention consisting of six core components: 1) home or virtual visits (up to 3) supported by phone calls by either a Registered Nurse (RN) or Registered Dietician (RD); 2) wellness sessions (up to 6, one per month) provided to patients and their caregivers at the location of the community partner or virtually; 3) monthly team case conferences with the provider team; 4) caregiver support; 5) collaboration with the primary care interprofessional team and other specialists; 6) nurse-led care coordination/system navigation.
16445737|NCT03664583|No Intervention|Control Group|Those who are randomly assigned to the control group will continue to be offered usual primary care services through their local diabetes education centre or primary care setting. The services that comprise usual diabetes care vary across the provinces e.g., length and focus of educational sessions, whether classes are strongly recommended versus optional (e.g., foot care, cardiac health, eating and exercise interventions), home visits, access to on-site professionals (e.g., endocrinologist, dietitian, physiotherapist, exercise specialist, pharmacist), connections with support services and community resources, and type of follow-up services available. Details of usual care provided at each site will be recorded.
16445738|NCT03664570|Experimental|Condition A|"Infusion rate = 25 ml/h
~Radiography: confirmation balloon position
~VIPUN Balloon Catheter
~13C-Octanoate Breath Test o"
16445739|NCT03664570|Experimental|Condition B|"Infusion rate = 75 ml/h
~Magnetic resonance imaging
~VIPUN Balloon Catheter
~13C-Octanoate Breath Test"
16445740|NCT03664570|Experimental|Condition C|"Infusion rate = 250 ml/h
~Magnetic resonance imaging
~VIPUN Balloon Catheter
~13C-Octanoate Breath Testt"
16445741|NCT03664557|Experimental|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
16445742|NCT03664544|Experimental|Subjects with severe hepatic impairment|HP PK MCI-186
16445743|NCT03664544|Experimental|Subjects with normal hepatic function|NHV PK MCI-186
16445744|NCT03664531|Experimental|Gluten, ATIs, nocebo|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
16445745|NCT03664531|Experimental|Gluten, nocebo, ATIs|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of nocebo muesli bars (with nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
16445746|NCT03664531|Experimental|ATIs, gluten, nocebo|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
16445747|NCT03664531|Experimental|ATIs, nocebo, gluten|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of nocebo muesli bars (containing nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
16445771|NCT03664362|Experimental|The BSHAPE Intervention|Participants in the BSHAPE intervention attend a 9 sessions program post-assessments which is a combination of individualized and group-based sessions.
16445748|NCT03664531|Experimental|Nocebo, ATIs, gluten|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars containing non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
16445749|NCT03664531|Experimental|Nocebo, gluten, ATIs|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
16445750|NCT03664518|Experimental|Eltrombopag|58 enrolled patients are picked up to take eltrombopag at the indicated dose.
16445751|NCT03664505|Active Comparator|Garment based on manual measurement|Garment based on manual measurement is used on burn scar
16445752|NCT03664505|Experimental|Garment based on scan measurement|Garment based on scan measurement is used on burn scar
16445753|NCT03664492|Other|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
16445754|NCT03664479|Experimental|classical electrical stimulation protocol|"apply 4 channel electrical stimulation device with protocol 1.
~It will simultaneously stimulate suprahyoid, thyrohyoid and sternothyroid m with 4 channel electrical stimulation device.
~during apply the device, we evaluate the manometry and videofluoroscopic swallowing study for evaluation of deglutition function."
16445755|NCT03664479|Experimental|revised sequential activation protocol|"apply 4 channel electrical stimulation device with protocol 2
~Is a revised sequential activation protocol, it sequentially stimulate bilateral suprahyoid m (channel 1), pharyngeal constrictors (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
~during apply the synchronized electrical stimulation device, we will evaluate the parameters same as group 1."
16445756|NCT03664466|Experimental|Astaxanthin|Astaxanthin 12mg twice daily by mouth
16445757|NCT03664466|Placebo Comparator|Placebo|Placebo twice daily by mouth
16445758|NCT03664453|Experimental|Food Effect (Fasted)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fasted state (Period 1) with a crossover and then in the fed state (Period 2).
~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
16445759|NCT03664453|Experimental|Effect (Fed)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fed state (Period 1) with a crossover and then in the fasted state (Period 2).
~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
16445760|NCT03664453|Experimental|Dose Proportionality|"Subjects will be randomly assigned to one of two omaveloxolone dosages. A single dose of omaveloxolone (in either 50 mg or 100 mg) will be administered to the subjects in 50 mg capsules in a fasted state.
~Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 6."
16445761|NCT03664440|Placebo Comparator|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
16445762|NCT03664440|Active Comparator|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
16445763|NCT03664427||Group 1: Patients with VOD|paediatric patients with Veno-Occlusive Disease (VOD) complicating haematological stem cell transplantation
16445764|NCT03664427||Group 2: matched controls|Paediatric patients defined as matched controls without veno-occlusive disease complicating haematological stem cell transplantation
16445765|NCT03664414|Placebo Comparator|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
16445766|NCT03664414|Active Comparator|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
16445767|NCT03664401|Experimental|Kerecis Oral™|The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
16445768|NCT03664401|Active Comparator|Autogenous Free Gingival Graft|"The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.
~The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed."
16445769|NCT03664375|Experimental|Experimental Group|The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients. It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
16445770|NCT03664375|Placebo Comparator|Control Group|The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
16445772|NCT03664362|No Intervention|Usual care or no treatment control|Participants in the control arm either are receiving no services or are engaged in usual care provided by community-based/health care organizations
16445773|NCT03664349||Older Adult Participants and Informal/Formal Caregiver Pairs|A sub-cohort of approximately 10 participant-caregiver pairs will utilize SE9000 and communication strategies over a 4-6-week period between LVR visits.
16445774|NCT03664349||Older Adult Participants|The pilot cohort of approximately 100 adults over age 60, with vision impairment, will complete the Hearing Handicap Inventory for the Elderly (HHIE), an assessment of perceived impact of hearing impairment, and an objective hearing evaluation.
16445775|NCT03664349||Formal/Informal Caregivers|Identified persons who assist willing and eligible older adult pilot participants with two or more ADLs/IADLs.
16445776|NCT03664323||Group 1 Sequential strategy|Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
16445777|NCT03664323||Group 2 Concomitant strategy|Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
16445778|NCT03664310|Experimental|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
16445779|NCT03664310|Active Comparator|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, & Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
16445780|NCT03664297|Experimental|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
16445781|NCT03664284|Active Comparator|intervention group|
16445782|NCT03664284|No Intervention|control group|
16445783|NCT03664271|Experimental|in-clinic video intervention|Intervention: Caregivers will watch an educational video in clinic, and also be given information about how to access the video from home (ideal condition). The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
16445784|NCT03664271|Active Comparator|at home video intervention|Intervention: Caregivers will be given information about how to watch the video at home, but will not watch it in clinic (real-world condition).The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
16445785|NCT03664271|No Intervention|usual care|Control: Caregivers will not watch the educational video, but will be given access to it at the conclusion of the study.
16445786|NCT03664245||experimental group|Critically ill patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
16445789|NCT03664219|Active Comparator|isolation of IAN nerve with collagen membrane|
16445790|NCT03664219|Experimental|without isolation of the IAN with collagen|
16445791|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS
~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
16445792|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS
~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
16445793|NCT03664193|Other|Single Arm|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
16445794|NCT03664180|Experimental|anticoagulation|
16445795|NCT03664180|Placebo Comparator|No anticoagulation|
16445796|NCT03664167|Experimental|intervention|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
16445797|NCT03664167|No Intervention|control|usual care
16445798|NCT03664154|Experimental|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
16445799|NCT03664141|Placebo Comparator|Placebo group|1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
16445800|NCT03664141|Experimental|Cannabis oil group|1 drop of 3% cannabis oil once a day during 3 months
16445801|NCT03664128||pregnant women positive for anxiety|"100 pregnant women who screen positive for anxiety symptoms (>21 on the Perinatal Anxiety Screening Scale). Participants are matched for age, parity, and gestational age at enrollment.
~Coping with Anxiety through Living Mindfully (CALM) Pregnancy: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants)"
16445802|NCT03664128||healthy pregnant controls|100 matched healthy pregnant women. Participants are matched for age, parity, and gestational age at enrollment.
16445803|NCT03664115|Experimental|Itraconazole Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.
~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
16445804|NCT03664115|Active Comparator|Control Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.
~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
16445805|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
16445806|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
16445807|NCT03664089|Experimental|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
16445808|NCT03664089|Placebo Comparator|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
16445809|NCT03664063|Active Comparator|Azithromycin for Yaws|Patients will receive standard treatment for yaws alone
16445810|NCT03664063|Active Comparator|IDA for Lymphatic Filariasis|Patients will receive standard IDA (Ivermectin & Diethylcarbamazine & Albendazole) treatment for Lymphatic Filariasis alone
16445811|NCT03664063|Experimental|Combination Therapy of Azithromycin for Yaws and IDA for LF|Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.
16445812|NCT03664050|Experimental|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
16445813|NCT03664050|Active Comparator|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
16445814|NCT03664037|Active Comparator|D group, (n=55)|
16445815|NCT03664037|Placebo Comparator|C group, (n=55)|
16445816|NCT03664024|Experimental|Pembrolizumab Standard of Care|Participants will receive standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then pembrolizumab plus pemetrexed maintenance for up to 31 additional cycles. The platinum doublet would be pemetrexed plus the investigator's choice of either cisplatin or carboplatin.
16445817|NCT03664011|Experimental|All Subjects|
16445818|NCT03663998|Active Comparator|A|CN54ENV IM EP 400 g
16445819|NCT03663998|Active Comparator|B|CN54ENV IM EP 1000 g
16445820|NCT03663998|Active Comparator|C|CN54ENV IM EP 4000 g
16445821|NCT03663998|Active Comparator|D|CN54ENV ID EP 600 g
16445822|NCT03663998|Active Comparator|E|CN54ENV ID EP 1200 g
16445823|NCT03663998|Active Comparator|F|CN54ENV ID EP 1800 g
16445824|NCT03663998|Active Comparator|G|"CN54ENV IM1 EP
~+ pIL-12 (500 g)"
16445825|NCT03663998|Active Comparator|H|"CN54ENV IM1 EP
~+ pIL-12 (1500 g)"
16445826|NCT03663998|Active Comparator|I|"CN54ENV IM1 EP
~+ ID2 EP"
16445827|NCT03663972|Active Comparator|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
16445828|NCT03663972|Active Comparator|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
16445829|NCT03663959||Vaginal Sacrospinous Fixation group|Women who had vaginal sacrospinous fixation procedure with Dr.Aksakal's Desta suture carrier in our clinic between January 2014 and June 2018.
16445830|NCT03663959||Laparoscopic Pectopexy Group|Women who had Laparoscopic Pectopexy procedure in our clinic between January 2014 and June 2018
16445831|NCT03663946||Patients taking combination therapy with Yervoy and Opdivo|Medical records will be reviewed for safety and treatments for specific ADR
16445834|NCT03663907|Experimental|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
16445835|NCT03663907|No Intervention|Usual Care|Patients with usual care follow-up in a heart failure program.
16445836|NCT03663881|Experimental|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
16445837|NCT03663868|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
16445838|NCT03663868|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
16445839|NCT03663868|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
16445840|NCT03663855|Experimental|Cystinuria Patients|
16445841|NCT03663842|Experimental|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
16445842|NCT03663829||Participants RA who have received a TNFi|
16445843|NCT03663829||Participants with RA who have received abatacept|
16445844|NCT03663816|Experimental|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
16445845|NCT03663803|Experimental|Intervention|Participants in the intervention group received the offer of four 2h group sessions during five weeks, and two further sessions after one and six months. The attendance rates of the sessions were 95%, 88%, 87%, 73%, 67% and 51%, respectively. The course was delivered by health care staff in the Holstebro Health Care Centre, including a dietitian and an occupational therapist, both with health pedagogic competences. It was delivered to seven intervention groups, which varied in size from 5 to 15 participants.
16445846|NCT03663803|No Intervention|Control|Usual practice
16445847|NCT03663790|No Intervention|Control|No intervention
16446948|NCT03656718|Experimental|Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20|
16445848|NCT03663790|Experimental|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
16445849|NCT03663790|Experimental|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
16445850|NCT03663777|Experimental|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
16445851|NCT03663777|Other|Control group|Control gorup will be recommended to increase daily physical activity level
16445852|NCT03663764|Experimental|Expeiment|Patients in experimental group received four cycles of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 66 Gy/22 fractions. Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
16445853|NCT03663751|Experimental|Treatment|The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (>98%).
16445854|NCT03663738|Active Comparator|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
16445855|NCT03663738|No Intervention|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
16445856|NCT03663725|Experimental|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
16445857|NCT03663725|Active Comparator|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
16445859|NCT03663699|Experimental|Exergaming|24 week access to the exergaming platform PlayPulse
16445860|NCT03663699|No Intervention|Control|Asked to continue with their normal daily routine
16445861|NCT03663686|Placebo Comparator|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445862|NCT03663686|Placebo Comparator|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445863|NCT03663686|Placebo Comparator|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445864|NCT03663686|Placebo Comparator|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445865|NCT03663686|Placebo Comparator|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445866|NCT03663686|Placebo Comparator|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445867|NCT03663686|Placebo Comparator|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
16445868|NCT03663673|Other|Clinical pilot study|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
16445869|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
16445870|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
16445871|NCT03663634|Experimental|Handling Medium Supplemented with Cytochalasin B|
16445872|NCT03663634|No Intervention|Handling Medium as it is.|
16445873|NCT03663621||Initial survey and interview (Aim 2)|Participants in Aim 2 will be asked to complete an initial 15-minute survey and 20-30 minute semi-structured interview. The purpose of this study is to learn the best ways to support healthful behaviors and weight loss prior to pregnancy. Researchers are also interested in what motivates or prevents women of reproductive age from engaging in a structured weight loss program.
16445874|NCT03663621||Formal weight loss program (Aim 3)|Participants in Aim 3 have expressed interest in referral to the Mass General Weight Center. The purpose of this study is to learn what motivates or prevents women of reproductive age from engaging in a structured weight loss program. Researchers will ask for no more than a half hour of participant's time to complete a 5- minute interview following Orientation at the Weight Center and another 10-minute interview after a participant has participated in a program offered at the Weight Center.
16445875|NCT03663595|No Intervention|Control Group|Females asymptomatic for patellofemoral pain syndrome
16445876|NCT03663595|Experimental|PFPS: Proximal factors - Model 1 (Hip and Knee)|Females symptomatic for PFPS with modification in proximal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
16445877|NCT03663595|Experimental|PFPS: Proximal factors - Model 2 (knee, foot and ankle)|Females symptomatic for PFPS with modification in proximal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in distal (foot and ankle) and local (knee) factors.
16447137|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
16445878|NCT03663595|Experimental|PFPS: Distal factors - Model 1(Hip and Knee)|Females symptomatic for PFPS with modification in distal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
16445879|NCT03663595|Experimental|AKP: Distal factors - Model 2 (knee, foot and ankle)|Females symptomatic for PFPS with modification in distal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in local (knee) and distal (foot and ankle) factors.
16445880|NCT03663582|Experimental|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
16445881|NCT03663569||subjects with COPD|
16445882|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
16445883|NCT03663543|Active Comparator|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
16445884|NCT03663543|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
16445885|NCT03663530|Experimental|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
16445886|NCT03663530|Active Comparator|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
16445887|NCT03663517||pregnant women|pregnant women in Hong Kong
16445888|NCT03663504|Active Comparator|No Preparation|No preparation before surgery
16445889|NCT03663504|Active Comparator|Oral Antibiotics|Oral antibiotics (neomycin and flagyl), to be taken the day before the surgery
16445890|NCT03663491|Experimental|Unsedated Nasal Gastroscopy|Transnasal Endoscopy. No sedation used. Use of local anesthesia.
16445891|NCT03663491|Active Comparator|Oral Gastroscopy, unsedated|Transoral Endoscopy. No sedation used. Use of local anesthesia.
16445892|NCT03663491|Active Comparator|Oral Gastroscopy, sedated|Transoral Endoscopy. Intravenous sedation used.
16445893|NCT03663478|Active Comparator|Intervention|Ropivacaine
16445894|NCT03663478|Placebo Comparator|Control|Isotonic saline
16445895|NCT03663465|Experimental|Hawthorn and SGAs|SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
16445896|NCT03663465|Active Comparator|Hawthorn|Hawthorn at a dose of 3 gm/day for six months.
16445897|NCT03663452|Active Comparator|Prolonged exposure training|
16445898|NCT03663452|Experimental|TACTICS|
16445899|NCT03663439|Experimental|modified shell technique|block of bone from the mandibular ramus divided into two shells ,grafting one shell in the anterior maxilla to increase width
16445900|NCT03663439|Active Comparator|onlay bone graft|grafting block of bone from the mandibular ramus in the atrophic anterior maxilla
16445901|NCT03663426|Active Comparator|control group opioid anesthesia|standard anesthesia using opioids
16445902|NCT03663426|Experimental|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
16445903|NCT03663413||BIS|Monitored with BIS (bispectral index) monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
16445904|NCT03663413||Narcotrend|Monitored with Narcotrend monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
16445905|NCT03663400||Patients Treated with Tofacitinib|Microbiota profiling by 16S sequencing RNA-seq transcriptional profiling of the blood and biopsy samples Immunological profiling by multi-parameter flow cytometry
16445906|NCT03663387||Normal subjects|70
16445907|NCT03663374|Experimental|Odelepan|One tablet once daily
16445908|NCT03663374|Placebo Comparator|Placebo|One tablet once daily
16445909|NCT03663361|Experimental|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
16445910|NCT03663361|Active Comparator|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
16445911|NCT03663335|Experimental|Arm 1/Cohort 1|CFZ533 dose A+ MMF + Corticosteroids
16445912|NCT03663335|Experimental|Arm 2/Cohort 1|CFZ533 dose B + MMF + Corticosteroids
16445913|NCT03663335|Active Comparator|Arm 3/Cohort 1|Control/Standard of Care: TAC + MMF + Corticosteroids
16445914|NCT03663335|Experimental|Arm 1/Cohort 2|CFZ533 dose C + MMF ± Corticosteroids
16445915|NCT03663335|Active Comparator|Arm 2/Cohort 2|Tac + MMF ± Corticosteroids
16445916|NCT03663322|Experimental|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
16445917|NCT03663322|Sham Comparator|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
16445918|NCT03663309||study group|"Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease
~Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year."
16445919|NCT03663309||control group|Healthy controls aged 2-17 years old matched for age and sex.
16445920|NCT03663296|Experimental|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
16445921|NCT03663296|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
16445952|NCT03663101|Experimental|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
16445922|NCT03663283|Experimental|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
16445923|NCT03663283|Active Comparator|Plain Bupivacaine|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
16445924|NCT03663270|Active Comparator|Intervention arm|HPI monitoring to predict hypotension
16445925|NCT03663270|No Intervention|Control arm|blinded HPI monitoring
16445926|NCT03663257||AneurysmFlow Observational Cohort|Subjects with unruptured, >5mm saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent enrolled at the centers participating in this CARO study.
16445927|NCT03663244|Experimental|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
16445928|NCT03663244|Experimental|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
16445929|NCT03663244|No Intervention|Wait-list|Usual practice
16445930|NCT03663231|Experimental|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
16445931|NCT03663231|Placebo Comparator|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
16445932|NCT03663218|Other|Single Arm|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
16445935|NCT03663179|Experimental|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
16445936|NCT03663179|Sham Comparator|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
16445937|NCT03663166|Experimental|Radiation and Chemotherapy|Thoracic Radiotherapy with cytotoxic platinum based chemotherapy with cytotoxic platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology) and Ipilimumab.
16445938|NCT03663166|Experimental|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) after completion of radiation and chemotherapy for up to 12 cycles until progression.
16445939|NCT03663153||SEMA4C high value follow-up group|Postoperative SEMA4C value is higher than 5.00 ng/ml.
16445940|NCT03663153||SEMA4C low value follow-up group|Postoperative SEMA4C value is lower than 5.00 ng/ml.
16445941|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
16445942|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
16445943|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
16445944|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
16445945|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
16445946|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
16445947|NCT03663127|Experimental|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage."
16445948|NCT03663127|Placebo Comparator|Placebo|Subjects receive two bottles placebo per day for 8 weeks of a stage.
16445949|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
16445950|NCT03663101|Experimental|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
16445951|NCT03663101|Experimental|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
16445953|NCT03663101|Experimental|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
16445954|NCT03663101|Placebo Comparator|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
16445955|NCT03663088|Active Comparator|GPR-A|The 6-months supervised GPR-A group will receive a 1-hour-long individual session once a week plus a home program (1 or 2 exercises, 2 times a week).
16445956|NCT03663088|Experimental|GPR-B|The 6-months supervised GPR-B group will receive a 1-hour long individual session once per two weeks alternately with a 1-hour-long class of exercises once per two weeks plus a home program (1 or 2 exercises, 2 times a week).
16445957|NCT03663075|Experimental|Group 1|This group will receive the intervention Group information (GI).
16445958|NCT03663075|Experimental|Group 2|This group will receive the intervention Group information (GI) followed by Structured person-centered support (PCS)
16445959|NCT03663075|Experimental|Group 3|This group will receive the intervention Structured person-centered support (PCS)
16445960|NCT03663075|No Intervention|Group 4|This is a control group.
16445961|NCT03663049|No Intervention|Usual care|These patients will continue as statins as usual.
16445962|NCT03663049|Experimental|Discontinue statin|Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.
16445963|NCT03663036|Experimental|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
16445964|NCT03662997|Active Comparator|Five-layer vs Hydropolymer|Bordered Five-layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks.
16445965|NCT03662997|Active Comparator|Hydropolymer vs Five-layer|Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
16445966|NCT03662997|Active Comparator|Five-layer vs Hydrocellular|Bordered Five-layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks.
16445967|NCT03662997|Active Comparator|Hydrocellular vs Five-layer|Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
16445968|NCT03662984|Active Comparator|Ciprofibrate|1dd100mg at breakfast
16445969|NCT03662984|Placebo Comparator|Placebo|1dd0mg at breakfast
16445970|NCT03662971|Experimental|0.0005% single-dose|Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.
16445971|NCT03662971|Experimental|0.001% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).
16445972|NCT03662971|Experimental|0.002% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).
16445973|NCT03662971|Experimental|0.004% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).
16445974|NCT03662971|Experimental|0.008% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).
16445975|NCT03662971|Experimental|0.002% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).
16445976|NCT03662971|Experimental|0.004% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).
16445977|NCT03662971|Experimental|0.008% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).
16445978|NCT03662958|Experimental|Lutrate|a novel leuprolide acetate 3.75mg depot
16445979|NCT03662958|Active Comparator|Enantone|market reference leuprolide acetate 3.75 mg depot
16445980|NCT03662945|Experimental|Intervention group|Mobile Geriatric Team intervention including physicians and nurses with the aim of developing person-centered, safe, sustainable and coordinated care plans. These care plans are developed in collaboration with the patient, his/her relatives and staff from the municipality. Among the main ambitions of this concept are improved communication flows between patients, their relatives and healthcare providers in combination with the delivery of medical as well as care measures. Other ambitions are to avoid unnecessary traditional healthcare utilization in the form of inpatient care and EMR visits, for example.
16445981|NCT03662945|No Intervention|Control group|Standard care including primary care units, home care and home help.
16445982|NCT03662932|Experimental|Early intensive mobilization|Progressed mobilization from postoperative day 0.
16445983|NCT03662919||Flixabi|Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
16445984|NCT03662919||Imraldi|Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.
16445985|NCT03662906|Experimental|Electroacupuncture|Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.30 mm in diameter, 75 mm in length or 0.40 mm diameter, 100 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
16445986|NCT03662906|Sham Comparator|Sham electroacupuncture|Sham Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.20 mm in diameter, 25 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
16445987|NCT03662893|Sham Comparator|Behavioural therapy with written guideline|Patients were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist over six-month period.
16445988|NCT03662893|Active Comparator|Behavioural therapy with checklist|Patients were instructed to apply behavioural therapy with a written checklist for patients to fully complete over six-month period.
16445989|NCT03662893|Active Comparator|antimuscarinic drug plus verbal behavioural therapy|Patients received medical treatment (once or twice per day) plus behavioural therapy without checklist over six-month period.
16445990|NCT03662893|Active Comparator|antimuscarinics plus checklist|Patients received medical treatment (once or twice per day) with a written checklist to fully complete over six-month period.
16445991|NCT03662880|Other|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
16445992|NCT03662867|Experimental|Family-based mindfulness intervention|Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
16445993|NCT03662867|Other|Wait-list control|Intervention group participants were assessed at baseline (T1) and after the intervention (T2). Control group participants were assessed at the same time with the intervention group, and would receive the same program after posttest of intervention groups.
16445994|NCT03662854|Experimental|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
16445995|NCT03662854|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
16445996|NCT03662841|Other|ACE for HCC of size >10cm|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
16445997|NCT03662815|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;
~Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
~GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01."
16445998|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
16445999|NCT03662789|Active Comparator|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
16446000|NCT03662789|Placebo Comparator|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
16446003|NCT03662763|Placebo Comparator|Placebo|
16446004|NCT03662763|Experimental|Extended-release Guanfacine Hydrochloride (SPD503)|
16446005|NCT03662750|Experimental|Acute stroke cohort|Acute stroke cohort
16446006|NCT03662737||Group 1 -Chronic cannabis use|Individuals between 18 and 50 years old who have been using at least 2 joints per day for at least 3 years. They should have used cannabis during the last 24h but not during the 3h prior to participation to the study and they should test positive for cannabis in their urine. Individuals with another substance use or severe mental disorder will be excluded (except tobacco use)
16446007|NCT03662737||Group 2 - Alcohol dependence|Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
16446008|NCT03662737||Control Group|Individuals matched in gender and age with the experimental groups and with no diagnosis of substance use or severe mental disorder (except tobacco use)
16446009|NCT03662711|Active Comparator|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
16446010|NCT03662711|Experimental|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
16446011|NCT03662698|Experimental|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
16446012|NCT03662698|Active Comparator|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to RT from the clinic nurse coordinator.
16446013|NCT03662685|Active Comparator|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
16446014|NCT03662685|Active Comparator|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
16446015|NCT03662685|Active Comparator|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
16446016|NCT03662672|Experimental|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
16446017|NCT03662672|Sham Comparator|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
16446020|NCT03662646||IBD patients|
16446021|NCT03662646||Healthy controls|
16446022|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
16446023|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
16446024|NCT03662620|Experimental|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
16446025|NCT03662620|Experimental|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
16446027|NCT03662607|Experimental|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
16446028|NCT03662594|Other|ECMO tube|
16446029|NCT03662581|Experimental|Mindfulness Group Program|A primary care mindfulness-based rolling admissions program where subjects must attend 4 of 8 consecutive group sessions, to be considered to have completed the program.
16446030|NCT03662568|Experimental|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
16446031|NCT03662568|Experimental|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
16446032|NCT03662568|Experimental|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
16446033|NCT03662568|Experimental|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
16446034|NCT03662555|Experimental|NMES and BFR (80%)|Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.
16446035|NCT03662555|Experimental|NMES and BFR (40%)|Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.
16446036|NCT03662555|Active Comparator|NMES alone|Group 3, participants will undergo NMES applied to the quadriceps for 25 min.
16446040|NCT03662529|Experimental|Mind Freedom Plan therapy sessions|The Four-Session Mind Freedom Plan (MFP) is cognitive behavioral therapy (CBT)-based, client-centered, manualized individual therapy that functions as part of intensive outpatient substance abuse treatment. The MFP model is based on efficacious brief interventions, with content and format driven from military veteran feedback. The four 60-minute MFP sessions were one-on-one private consultations with a therapist that were focused on identifying and changing unhealthy thinking and behavioral patterns as core elements of CBT, but with an emphasis on problem-solving, coping skills, goal setting, and psychosocial functioning. At each session, structured worksheets were utilized and homework was assigned to facilitate this CBT-based skill building.
16446041|NCT03662529|Active Comparator|Treatment as usual therapy|The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
16446042|NCT03662516|Other|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
16446043|NCT03662516|Other|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
16446044|NCT03662503||nutrition not aggressive group|"Children will be grouped according to their calorie and protein during the first week of life. The tertile 1 will represent the group of children with the lowest nutritional intake (called the nutrition not aggressive )"
16446045|NCT03662503||aggressive nutrition group|"Children will be grouped according to their calorie and protein during the first week of life. the tertile 3 will define the group of children presenting the contributions highest nutritional levels (called the aggressive nutrition group)"
16446046|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
16446047|NCT03662477|Experimental|EGFR+NK+|The EGFR mutation positive patients were with the principles of randomized and NK cells treatment.
16446048|NCT03662477|No Intervention|EGFR+NK-|The EGFR mutation positive patients were with the principles of randomized and without NK cells treatment .
16446049|NCT03662477|Experimental|EGFR-NK+|The EGFR mutation negative patients were with the principles of randomized and NK cells treatment .
16446050|NCT03662477|No Intervention|EGFR-NK-|The EGFR mutation negative patients were with the principles of randomized and without NK cells treatment.
16446051|NCT03662451|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
16446052|NCT03662451|Active Comparator|Robotic multi-site hysterectomy|Robotic multi-site hysterectomy is performed in this arm
16446053|NCT03662438|Other|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).
~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
16446054|NCT03662425|Experimental|schizophrenia with oxytocin|Participants self-administered the oxytocin twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of oxytocin.
16446055|NCT03662425|Placebo Comparator|schizophrenia with Placebo|Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.
16446056|NCT03662412|Experimental|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
16446057|NCT03662399|Experimental|Insole A|Investigational product - Insole A
16446058|NCT03662399|Experimental|Insole B|Investigational product - Insole B
16446059|NCT03662399|Experimental|Insole C|Investigational product - Insole C
16446060|NCT03662399|Experimental|Insole D|Investigational product - Insole D
16446061|NCT03662399|Experimental|Insole E|Investigational product - Insole E
16446062|NCT03662399|Experimental|Insole F|Investigational product - Insole F
16446063|NCT03662399|Experimental|Insole G|Non-Investigational product - Standard shoe
16446064|NCT03662386||Patients with suspicion of hereditary retinal dystrophy|
16446065|NCT03662373||carbon ions radiation therapy|the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
16446066|NCT03662373||protons radiation therapy|the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
16446067|NCT03662360|No Intervention|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
16446068|NCT03662360|Experimental|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy
16446069|NCT03662334|Experimental|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
16446070|NCT03662334|Sham Comparator|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
16446071|NCT03662321||sexual behavior on the internet|this group of teenagers use internet for sexuality
16446072|NCT03662321||not sexual behavior on the internet|this group of teenagers doesn't use internet for sexuality
16446073|NCT03662308|Other|Heated Vest Safety & Comfort (able-bodied subjects)|Able-bodied controls will be fitted with an appropriately sized heated vest, while wearing only a standard cotton T-shirt and shorts, and will remain seated in a wheelchair. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for 2 hours with the heated vest on full power. Outcome Variables for Visit 1: Skin thermocouple temperatures, subjective ratings of thermal sensation.
16446074|NCT03662308|Experimental|Heated Vest Efficacy (persons with tetraplegia)|Subjects with tetraplegia, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized heated vest. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the self-regulating heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
16446075|NCT03662308|Active Comparator|Non-Heated Vest control condition (persons with tetraplegia)|The same subjects with tetraplegia from the experimental arm, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized, similarly insulated, but non-heated vest (control condition). Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the non-heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
16446076|NCT03662282|Experimental|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
16446077|NCT03662269|Experimental|indomethacin treatment group|indomethacin (75mg, bid) + omeprazole (20mg, qd)
16446078|NCT03662269|Placebo Comparator|placebo treatment group|placebo (75mg, bid) + omeprazole (20mg, qd)
16446079|NCT03662256|Active Comparator|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
16446080|NCT03662256|Experimental|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
16446081|NCT03662243||Acquired brain injury participants|People with acquired alexia and/or agraphia secondary to brain injury who participate in the reading/writing intervention.
16446082|NCT03662217|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
16446083|NCT03662217|Other|ADA- based diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes
16446084|NCT03662204||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446085|NCT03662204||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446086|NCT03662204||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446087|NCT03662204||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446088|NCT03662204||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446089|NCT03662204||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446090|NCT03662204||Kidney & Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446091|NCT03662204||Pancreatic|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446092|NCT03662204||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446093|NCT03662204||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446094|NCT03662204||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446095|NCT03662204||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
16446096|NCT03662191|Experimental|Treatment A|4 × 20 mg commercial tafamidis meglumine administered as soft gelatin capsules under fasted conditions
16446097|NCT03662191|Experimental|Treatment B|10 mgA tafamidis free acid administered as a wet-milled suspension under fasted conditions
16446098|NCT03662191|Experimental|Treatment C|a dose of tafamidis free acid projected to be an equivalent of 4 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
16446099|NCT03662191|Experimental|Treatment D|a dose of tafamidis free acid projected to be an equivalent of 5 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
16446100|NCT03662165|Experimental|Intervention|"The primary intervention consisted of a text message informing participants that HIV self-test kits were available at all North Star Alliance clinics in Kenya. The message was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority."
16446101|NCT03662165|Experimental|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
16446102|NCT03662165|Active Comparator|Traditional Standard of Care|"Those randomized to the traditional SOC arm received the SOC message one time sent simultaneously in both Kiswahili and English. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
16446103|NCT03662152|Experimental|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
16446104|NCT03662152|Experimental|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
16446105|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
16446106|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
16446107|NCT03662126|Experimental|Part A Cohort 1|KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
16446108|NCT03662126|Experimental|Part A Cohort 2|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
16446109|NCT03662126|Experimental|Part A Cohort 3|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
16446110|NCT03662126|Experimental|Part A Cohort 4b|KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
16446111|NCT03662126|Experimental|Part B Arm 1 KRT-232|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
16446112|NCT03662126|Active Comparator|Part B Arm 2 Best Available Therapy|Best available therapy at the discretion of the investigator, on a 28-day cycle.
16446113|NCT03662113|Experimental|Experimental: Domperidone|5ml domperidone prior to VCE
16446114|NCT03662113|Other|Control: water|5ml warm water prior to VCE
16446115|NCT03662100|Experimental|LY3074828 Reference 1|Solution formulation in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm
16446116|NCT03662100|Experimental|LY3074828 Reference 2|Solution formulation in PFS administered as SC injection in thigh
16446117|NCT03662100|Experimental|LY3074828 Reference 3|Solution formulation in PFS administered as SC injection in abdomen
16446118|NCT03662100|Experimental|LY3074828 Test 1|Solution formulation administered SC via an auto-injector (AI) in arm
16446119|NCT03662100|Experimental|LY3074828 Test 2|Solution formulation administered SC via an AI in thigh
16446121|NCT03662087|Experimental|HMA+DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day +60 post-transplantation, HMA and DLI were given. DLI was given 48 hours after administration of HMA. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, HMA and DLI were given as shown above.
16446122|NCT03662087|Experimental|DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60 post-transplantation. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day+60 post-transplantation, DLI was given. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, DLI was given as shown above.
16446123|NCT03662074|Experimental|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
16446124|NCT03662048|Active Comparator|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
16446125|NCT03662048|Placebo Comparator|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
16446126|NCT03662035|Experimental|single-arm|Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2) until their disease have progressed.
16446127|NCT03662022|No Intervention|No PEP|No PEP will be distributed
16446128|NCT03662022|Other|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
16446129|NCT03662022|Experimental|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
16446130|NCT03662022|Other|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
16446131|NCT03662009||Parkinson Disease|Observation of individuals with idiopathic Parkinson disease performing a multilimb dual task using the arm and the leg.
16446132|NCT03662009||Control|Observation of healthy age-matched individuals will perform a multilimb dual task using the arm and the leg.
16446133|NCT03661996|Experimental|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
16446134|NCT03661996|Experimental|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
16446135|NCT03661996|Experimental|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
16446136|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
16446137|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
16446138|NCT03661983|Experimental|Open Label Stabilization Phase: Aripiprazole|Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.
16446139|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Full Dose|Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for <50 kg participants,and 10 mg or 20 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
16446140|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Half Dose|Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for <50 kg participants, and 5 mg or 10 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
16446141|NCT03661983|Placebo Comparator|Double Blind Phase: Placebo|Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.
16446142|NCT03661970||Normal subjects hearing group|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
16446143|NCT03661970||Cochlear implant subjects with good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
16446144|NCT03661970||Cochlear implant subjects without good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
16446145|NCT03661957|Active Comparator|Non grafted maxillary sinus floor elevation with implant pacem|
16446146|NCT03661957|Experimental|using short dental implants for posterior atrophic maxilla|
16446147|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
16446148|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
16446149|NCT03661931|Experimental|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a User Experience Questionnaire for each dietary assessment method.
16446150|NCT03661918|Other|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
16446151|NCT03661918|Other|Group 2|In-person first session, no second caregiver, wifi-enabled scale
16446152|NCT03661918|Other|Group 3|In-person first session, second caregiver, no wifi-enabled scale
16446153|NCT03661918|Other|Group 4|In-person first session, second caregiver, wifi-enabled scale
16446154|NCT03661918|Other|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
16446155|NCT03661918|Other|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
16446156|NCT03661918|Other|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
16446157|NCT03661918|Other|Group 8|No in-person first session, second caregiver, wifi-enabled scale
16446158|NCT03661905|Experimental|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
16446159|NCT03661905|Active Comparator|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
16446160|NCT03661892|Experimental|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
16446161|NCT03661879|Experimental|NNC9204-1706|Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period.
16446162|NCT03661879|Placebo Comparator|Placebo (NNC9204-1706)|Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period.
16446163|NCT03661853|Active Comparator|Control|This microintervention is intended to control for the effect of nonspecific therapy factors such as therapeutic alliance, time spent with a therapist, talking about alcohol, and/or effects related to assessment reactivity, and consists of 60 minutes of psycho-education on alcohol and drugs. The therapist will talk about historical and scientific information on different types of alcohol and drugs and will not overlap with CBT treatment. The participants will not be encouraged to personalize this information, make any behavioral changes, or do homework. The control does not have any active interventions that would specifically target or affect our outcome variables.
16446164|NCT03661853|Experimental|Functional Analysis|"Functional Analysis (FA) is a core intervention in Cognitive Behavioral Therapy (CBT) for AUD, and helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use. The FA microintervention teaches the patient to think and behave in new, more controlled ways in response to triggers, to identify maladaptive, impulsive behavior chains and to replace them with more deliberate ones."
16446165|NCT03661853|Experimental|Cognitive Restructuring|"Cognitive Restructuring of Thoughts About Alcohol (CR) is a core technique in CBT to help patients identify automatic (habituated) thoughts that happen quickly and are often not noticed, and change automatic thoughts occurring in response to alcohol triggers."
16446166|NCT03661853|Experimental|Dealing with Cravings|Dealing with Cravings (DC) is designed to directly target the reward and arousal systems, helping the patient accept the nature of cravings as time limited and deflated by continued abstinence so that craving is no longer associated with urgency. DC also teaches skills to reduce cravings by conjuring images such as a spider floating in a glass of wine, or of older versions of oneself sitting alone and dejected in a bar. Distraction techniques and breathing skills to reduce physiological arousal occurring in response to alcohol cues are also taught.
16446167|NCT03661840|Experimental|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
16446168|NCT03661840|Active Comparator|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
16446169|NCT03661827|Experimental|Patients with heart failure|Patients with heart failure
16446170|NCT03661814|Experimental|Prevena|This group will receive the negative pressure wound therapy device.
16446171|NCT03661814|No Intervention|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
16446172|NCT03661788|Experimental|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
16446173|NCT03661788|Experimental|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
16446174|NCT03661775|Experimental|controlled group|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour
16446175|NCT03661775|Experimental|Experimental group|group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
16446176|NCT03661762||Healthy Volunteers|All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
16446177|NCT03661749|Experimental|Clean catch|women in this group will collect urine for PR/CR using a clean catch technique
16446178|NCT03661749|Placebo Comparator|Non-clean catch|women in this group will not employ clean catch technique
16446179|NCT03661723|Experimental|Pembrolizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
16446180|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)
~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
16446181|NCT03661723|Experimental|Pembrolizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
16446182|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks
~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
16446183|NCT03661697|Experimental|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
16446184|NCT03661697|Active Comparator|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
16446185|NCT03661684|Experimental|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
16446186|NCT03661684|Experimental|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
16446187|NCT03661671|Experimental|LCI+white light|Using white light firstly to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
16446188|NCT03661671|No Intervention|White light|Using white light only.
16446189|NCT03661658|Active Comparator|Inferior alveolar nerve lateralization with implant placement|
16446190|NCT03661658|Experimental|Using short dental implant with atrophic mandible|
16446191|NCT03661645|Active Comparator|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone & 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
16446192|NCT03661645|Other|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
16446193|NCT03661632|Experimental|Dose Escalation|"Part 1: BMS-986310 + Nivolumab Combination Dose Escalation
~Sub-Study A: A cohort of Cisplatin Ineligible Muscle Invasive Bladder Cancer patients will receive either monotherapy BMS-986310, or BMS-986310 + Nivolumab, or Nivolumab monotherapy.
~Sub-Study B: A cohort of PD[L]1 relapsed / refractory tumor cancer patients will be treated with monotherapy BMS-986310 followed by BMS-986310 + nivolumab"
16446194|NCT03661632|Experimental|Cohort Expansion|"Part 2: Cohort Expansion will initiate upon consideration of the totality of data from Part 1.
~BMS-986310 + Nivolumab combination will be administered in specific patient populations."
16446195|NCT03661619|Experimental|Control Group|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
16446196|NCT03661619|Experimental|Test Group|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
16446197|NCT03661606|Experimental|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
16446198|NCT03661593|Experimental|Cataract guideline|In this patients we follow cataract guideline and correct the patients ametropia during the cataract surgery
16446199|NCT03661593|No Intervention|Standard refraction|The patients gets an IOL ensuring his preoperatively refraction
16446200|NCT03661580|Experimental|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
16446201|NCT03661580|Active Comparator|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
16446202|NCT03661567|Experimental|Methylprednisolone|Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
16446203|NCT03661567|Active Comparator|Observation|Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).
16446204|NCT03661554|Experimental|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
16446205|NCT03661541|Experimental|Group A|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:
~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.
~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.
~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
16446232|NCT03661333|Experimental|Adolescents with bipolar disorder|40 adolescents aged 13 to 19 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
16446206|NCT03661541|No Intervention|Group B|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:
~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
16446207|NCT03661541|No Intervention|Group C|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:
~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
16446208|NCT03661528|Experimental|Andexanet|
16446209|NCT03661528|Placebo Comparator|Usual Care|
16446210|NCT03661515|Experimental|Fludarabine-Idarubicine-Cytarabine- Selinexor|"fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:
~Level -1: Selinexor 40 mg/day, once weekly
~Level 1: Selinexor 60 mg/day, once weekly
~Level 2: Selinexor 80 mg/day, once weekly
~Level 3: Selinexor 100 mg/day, once weekly"
16446211|NCT03661502|Experimental|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
16446212|NCT03661502|Experimental|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
16446213|NCT03661489|Experimental|Intravenous Remimazolam 50 mg|"For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.
~For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
16446214|NCT03661489|Active Comparator|Intravenous Propofol 2%|"For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.
~For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
16446215|NCT03661476|Experimental|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
16446216|NCT03661463|Experimental|Aspirin|Aspirin (Acetylsalicylic Acid [ASA]) tablets, 300mg once a day, for 90 days.
16446217|NCT03661463|No Intervention|No Treatment|No medical treatment
16446218|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
16446219|NCT03661437|Experimental|Arm I (BWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
16446220|NCT03661437|Experimental|Arm II (DWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
16446221|NCT03661424|Experimental|Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)|Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
16446222|NCT03661411|Experimental|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
16446223|NCT03661411|Active Comparator|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
16446224|NCT03661398|Experimental|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
16446225|NCT03661385|Active Comparator|Intervention arm|• Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
16446226|NCT03661385|No Intervention|Control arm|Control arm will not receive nitric oxide, they will receive standard bypass as per local policy
16446227|NCT03661372|Active Comparator|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
16446228|NCT03661372|Active Comparator|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
16446229|NCT03661359|Experimental|Social Determinants of Health|Intervention will be the Social Determinants of Health Referrals.
16446230|NCT03661346|Experimental|Esmolol|Patients receiving esmolol when intra-operative MAP > 80 mmHg.
16446231|NCT03661346|Active Comparator|Labetalol|Patients receiving labetalol when intra-operative MAP > 80 mmHg
16446234|NCT03661320|Experimental|Arm B|BMS-986205 Placebo + Nivolumab + Chemotherapy followed by BMS-986205 Placebo + Nivolumab post radical cystectomy
16446235|NCT03661320|Experimental|Arm C|BMS-986205 + Nivolumab + Chemotherapy followed by Nivolumab plus BMS-986205 post radical cystectomy
16446236|NCT03661307|Experimental|Treatment (decitabine, quizartinib, venetoclax)|Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16446237|NCT03661294|Other|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
16446238|NCT03661281|Experimental|Simulated Thumb Arthrodesis|Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
16446239|NCT03661268|Experimental|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
16446240|NCT03661255|Experimental|PC CARES Intervention|Participants will attend 1-4 sessions of the PC CARES curriculum. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
16446241|NCT03661255|No Intervention|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
16446242|NCT03661242|No Intervention|Standard of care|No intervention
16446243|NCT03661242|Active Comparator|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
16446244|NCT03661229|Experimental|CVInsight Monitoring|Single group arm: All participants receive the same intervention/treatment CVInsight non-contact device and CVInsight contact device application.
16446245|NCT03661216|Placebo Comparator|Placebo|3g of non-GMO maltodextrin
16446246|NCT03661216|Active Comparator|Nephure|3g of Nephure
16446247|NCT03661203||Qualitative cohort|The cohort consists of MSM with late HIV diagnosis. The person from this cohort will participate to round table called also focus group or individual interview.
16446248|NCT03661203||Quantitative cohort|MSM community will be invited to participate to an online self questionnaire established from the information gathered from the previous cohort.
16446249|NCT03661190|Other|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
16446250|NCT03661190|Other|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
16446251|NCT03661177|Experimental|Diet intervention|
16446252|NCT03661177|No Intervention|Control|
16446253|NCT03661151||Antireflux surgery following PPI|A single cohort with the GERD patients who had acid suppressive medication with proton pump inhibitor (PPI) followed by laparoscopic antireflux surgery
16446254|NCT03661138|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
16446255|NCT03661138|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
16446256|NCT03661138|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
16446257|NCT03661138|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
16446258|NCT03661125|Experimental|Saracatinib or placebo|In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
16446259|NCT03661125|Experimental|Placebo or Saracatinib (Cross-over)|The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
16446260|NCT03661112||All of Us Research Program (AoURP) consortium members|
16446261|NCT03661086|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
16446262|NCT03661086|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.
16446263|NCT03661073|Experimental|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
16446264|NCT03661073|Sham Comparator|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
16446265|NCT03661047|Active Comparator|Omega-3 treatment|Daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl)
16446266|NCT03661047|Placebo Comparator|Placebo|Identical placebo
16446267|NCT03661034|Experimental|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
16446268|NCT03661034|Experimental|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
16446269|NCT03661034|Experimental|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
16446270|NCT03661034|Experimental|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
16446271|NCT03661008||Adolescents with paternal involvement|
16446272|NCT03661008||Adolescents without paternal involvement|
16446273|NCT03660995|Experimental|SLI children|
16446274|NCT03660995|Active Comparator|Control children|
16446275|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
16446276|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
16446277|NCT03660956|Experimental|Exercise and back counselling group|
16446278|NCT03660956|Active Comparator|Back counselling group|
16446279|NCT03660943|Placebo Comparator|Placebo|Intra-articular Placebo Injection
16446280|NCT03660943|Experimental|CNTX-4975-05 (trans-capsaicin)|Intra-articular 1.0 mg CNTX-4975-05 Injection
16446281|NCT03660930|Experimental|Treatment (ABI-009, pazopanib)|Participants receive nanoparticle albumin-bound rapamycin IV on days 1 and 8 and pazopanib hydrochloride PO daily on days 1-21. Courses repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
16446282|NCT03660917|Experimental|Riluzole|Riluzole 50 mg twice daily for 12 months in the treated group. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
16446283|NCT03660917|Placebo Comparator|Placebo + riluzole|Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
16446284|NCT03660904|Experimental|Home made media|home made vitrification & thawing kit
16446285|NCT03660904|Active Comparator|Commercial media|commercially available vitrification & thawing kit
16446286|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
16446287|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
16446288|NCT03660878|Placebo Comparator|Vehicle Ophthalmic Solution|
16446289|NCT03660865|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's primary eye will receive the light adjustable lens.
16446290|NCT03660865|Active Comparator|Control monofocal IOL|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's fellow eye will receive the control monofocal IOL.
16446291|NCT03660852||Before dedicated MRI|
16446292|NCT03660852||After dedicated MRI|
16446293|NCT03660839|Experimental|Ferroquine 400 milligram (mg)|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.
16446294|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 300 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.
16446295|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 600 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.
16446296|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 1000 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.
16446303|NCT03660813|Experimental|HCG triggering|Ovitrelle ( hCG 250 mcg)
16446304|NCT03660813|Experimental|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )
16446305|NCT03660800|Experimental|CTAP101 Capsules 450mcg/weekly fasted|
16446306|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fasted|
16446307|NCT03660800|Experimental|CTAP101 Capsules 1800mcg/weekly fasted|
16446308|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fed|
16446309|NCT03660787|Placebo Comparator|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
16446310|NCT03660787|Placebo Comparator|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
16446311|NCT03660787|Experimental|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
16446312|NCT03660787|Experimental|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
16446313|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
16446314|NCT03660761|Experimental|apatinib 500mg|
16446315|NCT03660748|Experimental|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
16446316|NCT03660748|Experimental|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
16446317|NCT03660735||Male Factor Subfertility|Participant is undergoing first or second cycle of IVF and ICSI for male factor subfertility
16446318|NCT03660735||Recurrent Implantation Failure|Participant is undergoing an IVF cycle to treat subfertility with a history of Recurrent Implantation Failure (RIF).
16446319|NCT03660735||Female Subfertility|Participant is undergoing an IVF cycle to treat at least 1 year of subfertility
16446320|NCT03660722|Other|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
16446321|NCT03660709|Experimental|Intervention|enhanced version of HIV testing and counseling
16446322|NCT03660709|Active Comparator|Control|standard-of-care HIV testing and counseling
16446323|NCT03660683|Experimental|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
16446324|NCT03660683|Active Comparator|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
16446325|NCT03660683|Placebo Comparator|Placebo|Placebo Oral Tablet
16446326|NCT03660670|Experimental|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
16446327|NCT03660670|Sham Comparator|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
16446328|NCT03660657|Experimental|Ozone Group:|Standard treatment + Ozone therapy (O3/O2)
16446329|NCT03660657|Placebo Comparator|Control Group:|Standard treatment + Oxygen (O2)
16446330|NCT03660644|Experimental|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
16446331|NCT03660644|No Intervention|Control|Usual care following pulmonary rehabilitation.
16446332|NCT03660631|Experimental|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
16446333|NCT03660631|Other|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
16446334|NCT03660618|Other|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
16446335|NCT03660605|Experimental|Rhythmic Auditory Stimulation|Participants will walk on treadmill to metronome set at 85% of typical cadence, followed by overground walking with metronome set at 115% of typical cadence.
16446336|NCT03660592||operator 1|ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
16446337|NCT03660592||operator 2|a different ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
16446338|NCT03660579|No Intervention|HIIT-CON|No intervention: Control
16446339|NCT03660579|Experimental|HIIT-AB Group|"Intake:
~330ml (women) or 2x300 ml (men) of beer with 5.4% alcohol. The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
16446340|NCT03660579|Experimental|HIIT-NAB Group|"Intake:
~330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%). The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
16446341|NCT03660579|Experimental|HIIT-SW Group|"Intake:
~330 ml (women) or 2x300 ml (men) of sparkling water. The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
16446342|NCT03660579|Experimental|HIIT-ASW Group|"Intake:
~330 ml (women) or 2x300 ml (men) of sparkling water with 5.4% alcohol.The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
16446343|NCT03660566|Experimental|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
16446344|NCT03660566|Active Comparator|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
16446345|NCT03660553|Active Comparator|Multiple Subcutaneous Injection (MSI)|MSI group will receive four insulin injections per day that will include a long acting and a short acting insulin. Short acting insulin will be either insulin aspart or insulin lispro.
16446346|NCT03660553|Experimental|Basal Insulin (BI)|BI group will receive only one injection of insulin glargine in the morning.
16446347|NCT03660540|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
16446348|NCT03660540|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
16446353|NCT03660514|No Intervention|Standard Family Planning|Counseling Clients receive standard FP counseling services.
16446354|NCT03660514|Experimental|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
16446355|NCT03660488|Active Comparator|Benzathine Penicillin G|"Patients of the Penicillin Group will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients."
16446356|NCT03660488|Experimental|Cefixime Group|"Patients of the Cefixime Group will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.
~The group will consist of 50 patients."
16446357|NCT03660475|Experimental|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
16446358|NCT03660475|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
16446359|NCT03660462|Active Comparator|FeSO4 fortified rice test meal|
16446360|NCT03660462|Experimental|FePO4 fortified rice test meal|
16446361|NCT03660462|Experimental|HiFePO4 1 fortified rice test meal|
16446362|NCT03660462|Experimental|HiFePO4 2 fortified rice test meal|
16446363|NCT03660449|Experimental|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
16446364|NCT03660436|Experimental|BMS-986165 + MMF|Oral administration
16446365|NCT03660423|Experimental|Dance Group|Dance group will participate in a 60 minute integrative dance class two times per week
16446366|NCT03660423|No Intervention|Control Group|The Control group will continue with normal activities, not participating in the dance intervention.
16446367|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
16446368|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
16446369|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
16446370|NCT03660397|Experimental|Intervention|Selective endovascular chemical ablation of adrenal gland after adrenal angiography.
16446371|NCT03660397|Active Comparator|Control|No intervention, but treated with standard antihypertensive drugs
16446372|NCT03660384|Experimental|SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
16446373|NCT03660384|Experimental|C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
16446374|NCT03660371|Experimental|PPV/MP|Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
16446375|NCT03660371|Active Comparator|PPV without MP|Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
16446376|NCT03660358|Experimental|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
16446377|NCT03660358|No Intervention|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
16446378|NCT03660345|Experimental|PPV/MP|Study Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo pars plana vitrectomy with internal limiting membrane peeling
16446379|NCT03660345|Active Comparator|Intravitreal Injection|Control Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo intravitreal ziv-aflibercept monotherapy according to a fixed treatment schedule
16446380|NCT03660332|Active Comparator|IL-6 infusion|Healthy young men will receive IL-6 infusion
16446381|NCT03660332|Placebo Comparator|Placebo infusion|Healthy young men will receive saline infusion
16446382|NCT03660319|Experimental|Environmental Music Therapy|Music Therapy Intervention (EMT)
16446383|NCT03660319|No Intervention|Control|Control - No Environmental Music Therapy. Does not experience Environmental Music Therapy during wait time in radiation oncology waiting room.
16446384|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
16446385|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
16446386|NCT03660293|No Intervention|diabetic- no cardioprotectives|25 child with type 1 diabetes mellitus will not receive any cardio protective drug
16446387|NCT03660293|Experimental|diabetic-Atorvastatin|25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
16446388|NCT03660293|Experimental|diabetic-Captopril|25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
16446389|NCT03660293|Experimental|diabetic-L-Carnitine|25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
16446390|NCT03660293|No Intervention|Controls|50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
16446391|NCT03660280|Experimental|Probiotics|
16446392|NCT03660280|Placebo Comparator|Placebo|
16446393|NCT03660267|Experimental|coffee group|caffeine coffee
16446394|NCT03660267|Experimental|decaffeinete coffee group|decaffeinete coffee group
16446395|NCT03660267|Experimental|water group|
16446396|NCT03660254|Experimental|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
16446397|NCT03660254|No Intervention|no intervention|no intervention
16446398|NCT03660241|Experimental|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
16446399|NCT03660228|Experimental|Peri-Transfusion QOL Assessment|"Participants will be given a study packet containing a paper copy of the QUALMS
~Study participants will fill out the survey on the day before their first/next pRBC transfusion.
~Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site
~The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results"
16446400|NCT03660215|No Intervention|control group|usual charge
16446443|NCT03659877|Experimental|Heart failure patients|Patients will be required to perform a number of physical activity tasks such as laying down, sitting and walking. During these activities, acceleration, oxygen consumption, rating of perceived exertion and heart rate will be recorded.
16446401|NCT03660215|Experimental|experimental group|"Mediation:
~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
16446402|NCT03660202|Experimental|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
16446403|NCT03660189|No Intervention|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
16446404|NCT03660189|Experimental|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
16446405|NCT03660176|Active Comparator|routine management|Children in the control group receive no additional treatment
16446406|NCT03660176|Experimental|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
16446407|NCT03660137|Experimental|MOLLI Localization|All patients will be implanted with a MOLLI magnetic seed in addition to the standard-of-care RSL seed. Both systems will be use to localize the respective seeds during the lumpectomy surgery.
16446408|NCT03660124|Experimental|Deep Brain Stimulation Treatment|
16446409|NCT03660111|Other|spirometry|single spirometry: only a routine diagnostic test
16446410|NCT03660085|Experimental|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
16446411|NCT03660085|Active Comparator|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
16446412|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
16446413|NCT03660059|Experimental|ASP015K dose-A|Participants will receive dose-A of ASP015K once daily after breakfast for 52 weeks.
16446414|NCT03660059|Experimental|ASP015K dose-B|Participants will receive dose-B of ASP015K once daily after breakfast for 52 weeks.
16446415|NCT03660059|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks, then either dose-A or dose-B of ASP015K for 28 weeks as determined randomly at Week 0 in advance.
16446416|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
16446417|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
16446418|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
16446419|NCT03660033|Experimental|With ECG|These teams will have access to ECG monitoring (intervention) during the scenario
16446420|NCT03660033|No Intervention|Without ECG|These teams will NOT have access to ECG monitoring during the scenario
16446421|NCT03660020|Sham Comparator|local anaesthetic group|
16446422|NCT03660020|Active Comparator|hyalorounidase group|
16446423|NCT03660007||Fresh embryo transfer|This exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
16446424|NCT03660007||Frozen embryo transfer|This exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
16446425|NCT03660007||Natural pregnancy|Spontaneous pregnancy without IVF
16446426|NCT03659994|Experimental|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
16446427|NCT03659994|Experimental|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
16446428|NCT03659994|Experimental|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
16446429|NCT03659994|Placebo Comparator|Placebo|3 Capsules of Placebo
16446430|NCT03659981|Experimental|MS Patients|Multiple sclerosis patients MRI 7T will be performed
16446431|NCT03659968|Experimental|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
16446432|NCT03659955|Experimental|Autologous blood|"Patients with severe dry eye and ocular surface disease who attend the corneal service within NHS Lanarkshire and who are unresponsive to conservative treatment measures will be considered for treatment of their condition with autologous blood.
~Intervention is application of autologous blood."
16446433|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
16446434|NCT03659929|Experimental|Arm 1: 20 mg/day|Amphetamine Sulfate
16446435|NCT03659929|Experimental|Arm 2: 40 mg/day|Amphetamine Sulfate
16446436|NCT03659929|Placebo Comparator|Arm 3: Placebo|Placebo, no active drug
16446437|NCT03659916|Experimental|A4250|Capsules for oral administration (120 ug/kg) once daily for 72 weeks
16446438|NCT03659903||younger patients (age < 80)|age < 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
16446439|NCT03659903||older patients (age≥ 80 )|age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
16446440|NCT03659890|Placebo Comparator|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
16446441|NCT03659890|Experimental|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
16446442|NCT03659890|Experimental|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
16446444|NCT03659864|Sham Comparator|Exposure 1|filtered air
16446445|NCT03659864|Experimental|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
16446448|NCT03659851||Dobutamine/milrinone before LVAD implantation|Dobutamine/milrinone use 24 hrs. before LVAD implantation
16446449|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
16446450|NCT03659825|Placebo Comparator|Placebo + Normoxia|Taste, volume and appearance matched drink given before cognitive testing in normoxia
16446451|NCT03659825|Placebo Comparator|Placebo + Hypoxia|Taste, volume and appearance matched drink given before cognitive testing in hypoxia
16446452|NCT03659825|Experimental|Ketone Ester + Normoxia|Ketone ester drink given before cognitive testing in normoxia
16446453|NCT03659825|Experimental|Ketone Ester + Hypoxia|Ketone ester drink given before cognitive testing in hypoxia
16446454|NCT03659812|Experimental|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
16446455|NCT03659812|No Intervention|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
16446456|NCT03659799|Active Comparator|Aspart - 60-minutes postprandial exercise|
16446457|NCT03659799|Active Comparator|Aspart - 120-minutes postprandial exercise|
16446458|NCT03659799|Active Comparator|FiAsp - 60-minutes postprandial exercise|
16446459|NCT03659799|Active Comparator|FiAsp - 120-minutes postprandial exercise|
16446460|NCT03659786|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
16446461|NCT03659786|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
16446462|NCT03659786|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
16446463|NCT03659773|Experimental|hematopoietic stem cell transplant (HSCT)|immune biomarkers to evaluate vaccine response in HSCT recipients
16446464|NCT03659760|Experimental|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
16446465|NCT03659760|No Intervention|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
16446466|NCT03659747|Experimental|Probiotic|"6 g sachet containing probiotic powder (1.8 x 10^12 colony forming units (CFU) Probiotic) in sachet
~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
16446467|NCT03659747|Active Comparator|Lactrase|"6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier
~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
16446468|NCT03659747|Placebo Comparator|Placebo|"6 g sachet containing placebo powder (maltodextrin) in sachet
~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
16446469|NCT03659734|Experimental|Motivational Interviewing and Gradual Opioid Weaning|
16446470|NCT03659734|Experimental|Enhanced Usual Care|
16446471|NCT03659734|No Intervention|Observation|
16446472|NCT03659721|Experimental|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
16446473|NCT03659721|Active Comparator|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
16446474|NCT03659708|Experimental|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :
~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:
~A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;
~A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);
~A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.
~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).
~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
16446475|NCT03659708|Experimental|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
16446476|NCT03659695|Experimental|Grape Powder|69 g/d freeze dried grape powder
16446477|NCT03659695|Placebo Comparator|Placebo powder|69 g/d placebo powder matched for taste and appearance
16446478|NCT03659682|Active Comparator|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
16446479|NCT03659682|Placebo Comparator|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
16446480|NCT03659669||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label.
16446481|NCT03659656|Other|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
16446482|NCT03659656|Experimental|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
16446483|NCT03659643||Retrospective MCI cohort|EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
16446484|NCT03659643||Prospective MCI cohort|New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
16446485|NCT03659630|Experimental|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
16446486|NCT03659630|Placebo Comparator|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
16446487|NCT03659617|Experimental|Implant placement 3 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 3 mo. after tooth ext.
16446488|NCT03659617|Active Comparator|Implant placement 6 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 6 mo. after tooth ext.
16446489|NCT03659617|Active Comparator|Implant placement 9 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 9 mo. after tooth ext.
16446490|NCT03659604|Experimental|Experimental with tailored feedback|'SmartLife' with tailored feedback: School classes will receive the developed 'SmartLife' intervention with tailored feedback, that is based on data from a sensors that is integrated in a T-shirt.
16446491|NCT03659604|Active Comparator|Active control without tailored feedback|'SmartLife' without tailored feedback: School classes will receive the developed 'SmartLife' intervention without tailored feedback.
16446492|NCT03659604|Other|Passive control|School classes will not receive any intervention, thus no game.
16446493|NCT03659591|Active Comparator|Cognitive Behaviour Therapy|10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
16446494|NCT03659591|Active Comparator|Adaptive Psychological Training|5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
16446495|NCT03659578|Experimental|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
16446496|NCT03659565|Experimental|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
16446497|NCT03659565|Active Comparator|Usual Care Control|Patients continue to receive usual care from their cardiologist.
16446498|NCT03659552|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
16446499|NCT03659539|Active Comparator|CLADS group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with propofol, with its administration controlled with CLADS tuned to consistent anesthetic depth (BIS-50) feedback from the patients.
16446500|NCT03659539|Active Comparator|Desflurane group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
16446501|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
16446502|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
16446503|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (>50%).
16446504|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
16446505|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
16446506|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
16446507|NCT03659487|Active Comparator|Nissen|Surgery of GERD with 360 degrees total fundoplication
16446508|NCT03659487|Active Comparator|Toupét|Surgery of GERD with 270 degrees partial fundoplication
16446509|NCT03659474|Experimental|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
16446510|NCT03659474|Experimental|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
16446511|NCT03659474|Experimental|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
16446512|NCT03659461|Experimental|low GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
16446513|NCT03659461|Active Comparator|normal GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
16446514|NCT03659448|Active Comparator|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
16446515|NCT03659448|No Intervention|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
16446646|NCT03658564|No Intervention|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
16446516|NCT03659435|Experimental|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
16446517|NCT03659435|Active Comparator|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
16446518|NCT03659422|Other|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
16446519|NCT03659409|Experimental|Mindfulness Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
16446520|NCT03659409|Other|Treatment Waitlist Group|Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
16446521|NCT03659396|Experimental|individualized Tai Chi|patient received individualized Tai Chi program training.
16446522|NCT03659396|Active Comparator|Entire Tai Chi|patient received Entire Tai Chi program training.
16446523|NCT03659396|Placebo Comparator|home-based program|patient received home-based program training.
16446524|NCT03659383|Experimental|Optimal hypoglycemic treatment|The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
16446525|NCT03659370|Active Comparator|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
16446526|NCT03659370|Active Comparator|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
16446527|NCT03659370|Active Comparator|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
16446528|NCT03659357||A-first CTE examination|
16446529|NCT03659357||B-first MRE examination|
16446530|NCT03659344|Active Comparator|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
16446531|NCT03659344|No Intervention|vicryl|In this group, vicryl sutures were used to close flaps
16446532|NCT03659331|Experimental|unexplained elevation of liver enzymes|patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again.
16446533|NCT03659318|Experimental|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
16446534|NCT03659318|Active Comparator|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
16446535|NCT03659305|Experimental|RPH-001|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
16446536|NCT03659305|Active Comparator|Avastin|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
16446537|NCT03659292|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
16446538|NCT03659292|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
16446539|NCT03659279|Experimental|Let's Get Organized|Group intervention with 10 weekly sessions, each lasting 1.5 hours.
16446540|NCT03659266|Active Comparator|Group 1|"D0: Injection of Botulinum toxin A in triceps surae, according to pre-established modalities (no influence of the experimental protocol on this stage) W2-W4: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization)"
16446541|NCT03659266|Active Comparator|group 2|"D0: Injection of Botulinum toxin A in triceps surae W2-W4: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization)"
16446542|NCT03659253|Experimental|Oral Fluid Based Self Testing|All study participants that received intervention and meet inclusion criteria intervention that will be offered OFT
16446543|NCT03659253|No Intervention|Control Group|All HIV Patients in the clinic that not received any intervention
16446544|NCT03659253|Experimental|Simplified ART Initiation|All study participants that received intervention and meet inclusion criteria intervention that will be offered SAI
16446545|NCT03659253|Experimental|CBO AND BROTHEL-BASED ART SERVICE|All patients coming to brothel or Community Based Organization services will be offered to get tested and received ART
16446546|NCT03659253|Experimental|SMS Reminder|"All patients that recently found HIV Positive HIV Naive offered to get SMS Reminder"
16446547|NCT03659253|Experimental|Motivational Interviewing|PWID in Jakarta and Bandung that recently found HIV Positive or lost to follow up ARV offered MI intervention
16446548|NCT03659240|Experimental|Cranberry beverage|
16446549|NCT03659240|Placebo Comparator|Placebo beverage|
16446550|NCT03659214||Treated group|Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
16446551|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
16446552|NCT03659201|Experimental|Neosil complete|"The patient will take the tablets, as follow:
~3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and
~2 tablets of Neosil Oral, per day - during the last 12 weeks."
16446553|NCT03659201|Experimental|Pantogar|"The patient wil take the tablets, as follow:
~3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and
~3 tablets of Pantogar, Oral, per day - during the last 12 weeks."
16447138|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
16446554|NCT03659201|Experimental|Neosil|"The patient will take the tablets, as follow:
~2 tablets of Neosil Oral, per day - during the 12 weeks."
16446555|NCT03659188|Experimental|Corticotomy with drills|Patients will undergo orthodontic treatment plus an acceleration procedure employing corticotomy with drills.
16446556|NCT03659188|Experimental|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
16446557|NCT03659188|No Intervention|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
16446558|NCT03659175||male elderly with SIBO|"male elderly who was diagnosed as SIBO via 'lactulose breath test' (LBT). At the same time, they meet the following criteria:
~no use of antibiotics in the past 1 month.
~no use of prokinetic drugs and probiotics in the past 1 week.
~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
16446559|NCT03659175||male elderly without SIBO|"male elderly without SIBO after 'lactulose breath test'. At the same time, they meet the following criteria:
~no use of antibiotics in the past 1 month.
~no use of prokinetic drugs and probiotics in the past 1 week.
~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
16446560|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
16446561|NCT03659149|Experimental|Group 1|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Test drug 2(CKD-333 formulation II) Period 3: Reference drug(CKD-330 + D086)
16446562|NCT03659149|Experimental|Group 2|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 2(CKD-333 formulation II)
16446563|NCT03659149|Experimental|Group 3|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 1(CKD-333 formulation I)
16446564|NCT03659149|Experimental|Group 4|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Reference drug(CKD-330 + D086)
16446565|NCT03659149|Experimental|Group 5|Period 1: Reference drug(CKD-330 + D086) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Test drug 2(CKD-333 formulation II)
16446566|NCT03659149|Experimental|Group 6|Period 1: Reference drug(CKD-330 + D086) Period 2: Test durg 2(CKD-333 formulation II) Period 3: Test drug 1(CKD-333 formulation I)
16446569|NCT03659123|Experimental|Intervention|"The intervention is designed to be implemented at different times of patients' care
~During the prehabilitation time:
~Nutritional care
~Total-body rehabilitation
~Pharmaceutical conciliation During peri-operative time
~Management of enhances rehabilitation of the elderly. During rehabilitation time
~Nutritional, medication conciliation and functional follow-up During hospital-home transition time
~Nutritional and functional follow-up
~Optimisation of symptoms management: abdominal pain, nausea, vomiting…"
16446570|NCT03659110||1000 subjects receive the HPV 4 vaccine|
16446571|NCT03659097|Experimental|Periodontally accelerated osteogenic orthodontics|Patients in this group will undergo orthodontic treatment plus periodontally accelerated osteogenic orthodontics in order to induce tooth movement.
16446572|NCT03659097|No Intervention|Traditional orthodontics|Patients in this group will undergo traditional orthodontics without any surgical interventions
16446573|NCT03659071|Experimental|DONORS|donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
16446574|NCT03659071|Other|NON DONORS|non-donor siblings. questionnaire VSP-A will be performed
16446575|NCT03659058|Active Comparator|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
16446576|NCT03659058|Placebo Comparator|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
16446577|NCT03659045|Experimental|Mifegyne® 600MG|Patients assigned to this group will receive three 200 mg tablets of Mifegyne® taken during the consultation Patients will answer to a scale of pain
16446578|NCT03659045|Placebo Comparator|Mifegyne® 200MG|"Patients assigned to this group will receive one 200 mg Mifegyne® tablet and two placebo tablets that will be taken during the consultation.
~Patients will answer to a scale of pain"
16446579|NCT03659032|Experimental|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
16446580|NCT03659032|Active Comparator|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
16446581|NCT03659019||ventilatory paralysis|dependence on mechanical ventilatory support
16446582|NCT03659019||central hypoventilation|documented permanent or nocturnal hypoventilation
16446583|NCT03659006|Experimental|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
16446584|NCT03658993|Active Comparator|Rifaxamine 550 mg|Study drug Oral Rifaximin 550 mg TID for 4 weeks .
16446585|NCT03658993|Placebo Comparator|Placebo|Placebo TID for 4 weeks
16446586|NCT03658980|Experimental|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
16446587|NCT03658980|No Intervention|Control Group|No Intervention will be conducted in this control group
16446588|NCT03658967|Active Comparator|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
16446589|NCT03658967|Placebo Comparator|Placebo (0.9% physiological saline)|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
16446590|NCT03658954|Active Comparator|Advice|Participants receive only web-based sleep hygiene advice
16446591|NCT03658954|Experimental|Advice + Self-monitoring|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring
16446592|NCT03658954|Experimental|Advice + Self-monitoring + Feedback|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback
16446593|NCT03658941|Experimental|No dural tenting sutures|No dural tenting techniques
16446594|NCT03658941|Active Comparator|Dural tenting sutures|Dural tenting techniques
16446595|NCT03658915||Osteoarthritis|"Thirty symptomatic knee with osteoarthritis will be recruited according to the following criteria:
~INCLUSION CRITERIA:
~Referred with a confirmed diagnosis of unilateral or bilateral OA of the knee based on the following criteria.
~1.1. Morning stiffness < 30 minutes, 1.2. Crepitus on active knee movement. 1.3. Bony enlargement either palpable or visible in radiographs. 1.4. Bony tenderness.
~Age 40-60 years old.
~EXCLUSION CRITERIA:
~Steroid injection within the past 2 months.
~Presence of neurologic disorders.
~Presence of of orthopedic diseases or trauma in the lower extremity or spine within the past year.
~6. Severe pain with active movement 7. Poor memory or cognitive function"
16446596|NCT03658915||Control|Thirty asymptomatic knee will be recruited for this study. Control group participants will be age-matched to the osteoarthritis group, and should have no pain or other relevant clinical symptoms in lower quadrant.
16446597|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
16446598|NCT03658876|Active Comparator|EPO group|
16446599|NCT03658876|Active Comparator|Iron group|
16446600|NCT03658863|Active Comparator|Endoscopy first|Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
16446601|NCT03658863|Active Comparator|Cholecystectomy first|Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).
16446602|NCT03658850|Active Comparator|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
16446603|NCT03658850|Placebo Comparator|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
16446604|NCT03658824|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
16446605|NCT03658824|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
16446606|NCT03658824|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
16446607|NCT03658824|Other|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
16446608|NCT03658824|Other|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
16446609|NCT03658824|Other|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
16446610|NCT03658811|Experimental|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
16446611|NCT03658798|Experimental|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
16446612|NCT03658785|Experimental|TIL,IL-2,Cyclophosphamide,Fludarabine|"Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).
~Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
~Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days."
16446615|NCT03658746|Experimental|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
16446616|NCT03658746|Active Comparator|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
16446647|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
16446617|NCT03658733|Experimental|Esomeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole,amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
16446618|NCT03658733|Active Comparator|Rabeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
~Drugs: 1. rabeprazole 20mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
16446619|NCT03658720|Experimental|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
16446620|NCT03658720|Experimental|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
16446621|NCT03658694|Experimental|rTMS high dose - stage 1|In stage 1 patients were randomly allocated to receive real repetitive transcranial magnetic stimulation.
16446622|NCT03658694|Experimental|rTMS sham - stage 1|In stage 1 patients were randomly allocated to receive sham repetitive transcranial magnetic stimulation.
16446623|NCT03658694|Experimental|high dose rTMS - stage 2|In stage 2, after the end of the first trial will be allocated to receive high dose of repetitive transcranial magnetic stimulation.
16446624|NCT03658694|Experimental|low dose rTMS - stage 2|In stage 2, after the end of the first trial will be allocated to receive low dose of repetitive transcranial magnetic stimulation.
16446625|NCT03658681|Experimental|Test meal 1: Saturated fat 14.9 E%|Test meal with saturated fat 14.9 E%
16446626|NCT03658681|Experimental|Test meal 2: Polyunsaturated fat 13.6 E%|Test meal with polyunsaturated fat 13,6 E%
16446627|NCT03658668|Experimental|active tDCS+PA|
16446628|NCT03658668|Sham Comparator|sham tDCS+PA|
16446629|NCT03658655|Experimental|Stem Cells From Human Exfoliated Teeth|According to the weight of 0.1IU /kg with Stem Cells From Human Exfoliated Teeth, three injections will be given respectively at the time of enrollment, one week and four weeks after enrollment.
16446630|NCT03658642|Experimental|Clinical Decision Support for BUP|The Clinical Decision Support (CDS) will be available for clinician use for Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) with referral for ongoing medication assisted treatment (MAT) if: ED chief complaint or urine drug screen indicate opioid use. The clinician will then be prompted to complete DSM-5 checklist for OUD. If DSM-5 OUD Score>5 and urine drug screen is positive for opioids, then the clinician is prompted to complete COWS scale. If COWS score >12, then the clinician is prompted to order BUP. Regardless of COWS score, the clinician will be prompted to schedule an MAT appointment with BUP provider. The CDS will interface with outside MAT facilities so that making an appointment is easy and to capture data on whether an appointment has been scheduled.
16446631|NCT03658642|No Intervention|Usual Care|The CDS will not be activated and patients will receive care as usual.
16446632|NCT03658629|Experimental|Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-1 (Day 0) and Placebo (Day 28)
16446633|NCT03658629|Experimental|Quad-NIV Preformulated with Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-2 (Day 0) and Placebo (Day 28)
16446634|NCT03658629|Experimental|Quad-NIV Preformulated with Adjuvant Dose B|Alternating deltoid injections of 2018-2019 Quad-NIV-3 (Day 0) and Placebo (Day 28)
16446635|NCT03658629|Experimental|Quad-NIV Preformulated with Increased B HA Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-4 (Day 0) and Placebo (Day 28)
16446636|NCT03658629|Experimental|Quad-NIV without Adjuvant|Alternating deltoid injections of 2018-2019 Quad-NIV-5 (Day 0) and Licensed 2018-2019 Influenza vaccine (Day 28)
16446637|NCT03658629|Active Comparator|Licensed High-Dose Trivalent Influenza Vaccine|Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine (Day 0) and Placebo (Day 28)
16446638|NCT03658629|Active Comparator|Licensed Quadrivalent Influenza Vaccine|Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine (Day 0) and Placebo (Day 28)
16446639|NCT03658616|Experimental|WO3970|Formulation containing WO3979 for topical application
16446640|NCT03658616|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
16446641|NCT03658603|Experimental|Study group|Thoracodorsal artery perforator flap
16446642|NCT03658603|Active Comparator|control group|Conventional free flaps
16446643|NCT03658590|Active Comparator|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
16446644|NCT03658590|Placebo Comparator|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
16446645|NCT03658564|Experimental|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
16446648|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
16446649|NCT03658538|Active Comparator|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
16446650|NCT03658538|Sham Comparator|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
16446651|NCT03658525|Experimental|MR LINAC RADIOTHERAPY|RADIOTHERAPY DELIVERED ON MR LINAC
16446652|NCT03658512||TUEDID cohort|
16446653|NCT03658499|Experimental|Experimental|"Those assigned to the experimental condition will be provided with treatment as usual (the two day skills group) and exposure to the video intervention adjuncts.
~two day skills group plus treatment adjuncts"
16446654|NCT03658499|Other|control|"Those in the control condition will be provided with treatment as usual (the two day skills group) without access to the video intervention adjuncts.
~two day skills group control group"
16446655|NCT03658486|Other|Exercise|12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
16446656|NCT03658473|Active Comparator|Treatment A|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
16446657|NCT03658473|Active Comparator|Treatment B|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole 1x daily over 7 days.
16446658|NCT03658473|Active Comparator|Treatment C|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
16446659|NCT03658473|Placebo Comparator|Treatment D|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
16446660|NCT03658447|Experimental|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
16446661|NCT03658434|Experimental|feasibilty|Palliative Radiotherapy
16446662|NCT03658421|Experimental|H group|H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
16446663|NCT03658421|Experimental|L group|L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
16446664|NCT03658421|Experimental|LD group|LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
16446665|NCT03658408|Experimental|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
16446666|NCT03658408|Placebo Comparator|Placebo|Participants with recent prostatectomies receiving placebo
16446667|NCT03658395|Active Comparator|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
16446668|NCT03658395|Active Comparator|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.
~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
16446669|NCT03658382|No Intervention|Telephone Results Disclosure|
16446670|NCT03658382|Experimental|Virtual Visit Results Disclosure|
16446671|NCT03658369|Active Comparator|Lanconone®|Lanconone®: 2 Capsules once a day after breakfast
16446672|NCT03658369|Placebo Comparator|Methyl Crystalline Cellulose|2 Capsules once a day after breakfast
16446673|NCT03658356|Placebo Comparator|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.
~Intervention: Pt will be given verbal instruction to collect urine"
16446674|NCT03658356|Active Comparator|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture
~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
16446675|NCT03658343|Experimental|T2* Imaging|Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
16446676|NCT03658330|Experimental|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
16446677|NCT03658317|Active Comparator|cases|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
16446678|NCT03658317|Active Comparator|controls|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
16446679|NCT03658304|Experimental|Mitomycin C|
16446680|NCT03658291|Experimental|Sanjin tablets group|Sanjin tablets+ levofloxacin simulants
16446681|NCT03658291|Placebo Comparator|Levofloxacin group|Sanjin tablets simulants +levofloxacin
16446682|NCT03658291|Active Comparator|Sanjin tablets+ Levofloxacin group|Sanjin tablets+ levofloxacin
16446683|NCT03658278|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
16446684|NCT03658278|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
16446685|NCT03658265|Active Comparator|7 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
16446686|NCT03658265|Experimental|7 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
16446687|NCT03658265|Experimental|3 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
16446688|NCT03658265|Experimental|3 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
16446689|NCT03658252|Experimental|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.
~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
16446690|NCT03658252|No Intervention|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
16446691|NCT03658239|Experimental|Experimental|"Subjects will undergo 4-5 visits total over the course of 6 months. There will be 3-4 visits that will be done at the Flaum Eye Institute. During these sessions the subject will be measured with a stationary topographer (GALILEI G4), with a rotatable topography measurement (Oculus Topographer) and a Tonometer. The subject's heart rate and blood pressure will also be measured (using a commercially available blood pressure and heart rate meter).
~The GALILEI measurement will only be done once. The rest of the measurements will be done up to 4 times. Once at the start of the study session then, after the subject has been inverted using a commercially available inversion table to first 135 degrees, then 150 degrees and finally to 165 degrees.
~The blood pressure and heart rate will be monitored to ensure subject safety.
~There will also be one visit at the Massachusetts General Hospital. The visit will be 2 hours and will involve a Brillouin Microscopy measurement."
16446692|NCT03658226|Experimental|Therapy|Psychodynamic Interpersonal Therapy (PIT)
16446693|NCT03658213|Experimental|ZOLADEX 10.8 mg depot group|• ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
16446694|NCT03658213|Active Comparator|ZOLADEX 3.6 mg depot group|• ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks
16446695|NCT03658200|Active Comparator|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
16446696|NCT03658200|Active Comparator|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
16446697|NCT03658187|Placebo Comparator|Placebo|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
16446698|NCT03658187|Experimental|IP|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
16446699|NCT03658174|Active Comparator|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
16446700|NCT03658174|Placebo Comparator|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
16446701|NCT03658161|Experimental|CASCADE|Oncology providers will receive the CASCADE coaching intervention.
16446702|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
16446703|NCT03658135|Experimental|BIIB092|The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
16446704|NCT03658135|Placebo Comparator|Placebo|Inactive ingredient
16446705|NCT03658122|Experimental|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
16446706|NCT03658122|Other|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
16446707|NCT03658109|Active Comparator|Lidocaine Bolus Infusion|"Patients will also undergo a loading dose of lidocaine, followed by continuous lidocaine infusion in the lidocaine group.
~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.
~Patients will undergo a simulated QL block."
16446708|NCT03658109|Active Comparator|QL Block & Saline Bolus Infusion|"Patients will undergo a posterior QL block.
~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.
~Patients will receive a saline bolus infusion."
16446753|NCT03657797|Experimental|NCX 470 0.021%|NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
16446709|NCT03658109|No Intervention|Intrathecal Morphine Alone|"Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.
~Patients will undergo a simulated QL block.
~Patients will receive a saline bolus infusion."
16446710|NCT03658096|Active Comparator|Healthy volunteer|
16446711|NCT03658096|Active Comparator|DRUJ instability patients|
16446712|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
16446713|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
16446714|NCT03658070|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
16446715|NCT03658070|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
16446716|NCT03658070|Experimental|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
16446717|NCT03658070|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
16446718|NCT03658070|Experimental|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
16446719|NCT03658070|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
16446720|NCT03658057|Active Comparator|ROC|Neuromuscular blockade is performed in the ROC group by administering rocuronium 0.4~0.8mg/kg before the insertion of laryngeal airway.
16446721|NCT03658057|No Intervention|Control|Neuromuscular blockade is not performed.
16446722|NCT03658044|Experimental|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
16446723|NCT03658044|Active Comparator|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
16446724|NCT03658031|Experimental|Dapagliflozin|Dapagliflozin 10mg per/day in prediabetes cases with MI before breakfast
16446725|NCT03658031|No Intervention|Placebo|Antiplatelet, ACEI and Betablockers
16446726|NCT03658018|Experimental|Intracept System Ablation|
16446727|NCT03658005||Study cohort|"Adult (>18 years, <90 years) patients admitted and treated for acute myocardial infarction, and whose treatment includes ticagrelor in association with aspirin.
~Blood samples will be taken at 3 timepoints between two doses of ticagrelor (taken at 12 hours interval)."
16446728|NCT03657979|Experimental|Ropivacaine|Conventional PCA morphine +TAP-block ropivacaine 0.2%
16446729|NCT03657979|Placebo Comparator|TAP-block with placebo|Conventional PCA morphine treatment with TAP-block with placebo
16446730|NCT03657966|Experimental|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
16446731|NCT03657953|Active Comparator|anterior (MI-A) surgical approach|The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
16446732|NCT03657953|Active Comparator|anterolateral (MI-AL) surgical approach|For the minimally invasive anterolateral surgical approach, a modified Watson-Jones approach according to Röttinger (Rottinger et al. 2006) was applied with the patient in supine position.
16446733|NCT03657953|Active Comparator|direct lateral (DLA) surgical approach|The direct lateral surgical approach was performed according to the technique described by Hardinge et al. (Hardinge et al. 1982) with the patient positioned supine
16446734|NCT03657940|Experimental|Exercise intervention|multicomponent exercise training program [VIVIFRAIL],
16446735|NCT03657940|No Intervention|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
16446736|NCT03657927|Active Comparator|C-MAC Videolaryngoscope|Morbidly obese patients intubated with C-MAC Videolaryngoscope
16446737|NCT03657927|Active Comparator|McGrath MAC Videolaryngoscope|Morbidly obese patients intubated with McGrath MAC Videolaryngoscope
16446738|NCT03657914|Experimental|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
16446739|NCT03657901|Experimental|Breathing|Guided slow breathing for 30 minutes before sleep onset
16446740|NCT03657901|Active Comparator|Music listening|Guided music listening for 30 minutes before sleep onset
16446741|NCT03657888|Experimental|Family Club Denmark (FCD)|Participation in FCD
16446742|NCT03657888|Other|Wait-list|Wait-list control
16446743|NCT03657862|Experimental|SDF treated|application of 38% silver diamine fluoride solution
16446744|NCT03657862|Placebo Comparator|Placebo|application of a placebo (tonic water)
16446745|NCT03657849|Experimental|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
16446746|NCT03657836|Experimental|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
16446747|NCT03657836|Other|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
16446748|NCT03657823||Fetal growth cohort|Longitudinal measurements of fetal growth, fetal circulation and maternal circulation
16446749|NCT03657823||Hypertensive cohort|Retrospective cohort of women with heart disease that underwent oregnancy and childbirth
16446750|NCT03657810|Experimental|CL-108 5 mg|Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
16446751|NCT03657810|Active Comparator|Norco|hydrocodone 5 mg/APAP 325 mg
16446752|NCT03657810|Placebo Comparator|Placebo|Placebo 0 mg matching CL-108
16446754|NCT03657797|Experimental|NCX 470 0.042%|NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
16446755|NCT03657797|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
16446756|NCT03657797|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks
16446757|NCT03657784|Experimental|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
16446758|NCT03657784|Experimental|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
16446759|NCT03657784|Experimental|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
16446760|NCT03657784|Experimental|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
16446761|NCT03657784|Experimental|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
16446762|NCT03657771|Active Comparator|DED|Diet eliminating dairy
16446763|NCT03657771|Active Comparator|FREE|Diet eliminating dairy and food additives
16446764|NCT03657758|Active Comparator|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
16446765|NCT03657758|Active Comparator|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
16446766|NCT03657758|No Intervention|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
16446767|NCT03657745||Participants who adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants adhere to the protocol if they exercise with AlzLife the minimum of 1hour/week.
16446768|NCT03657745||Participants who do not adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants do not adhere to the protocol if they exercise with AlzLife less than 1hour/week.
16446769|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
16446770|NCT03657732||Normal control group|Normal cognitive control people
16446771|NCT03657719|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
16446772|NCT03657719|Active Comparator|Active Comparator: GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
16446773|NCT03657706|Active Comparator|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
16446774|NCT03657706|Active Comparator|group B|tunnel procedure with modified free gingival graft (mFGG)
16446775|NCT03657693||BPD|Infants born premature requiring oxygen
16446776|NCT03657693||Controls|
16446777|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
16446778|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
16446779|NCT03657667|Other|Ureteroscopy (URS) (standard treatment)|Endoscopic procedure used to remove kidney stones
16446780|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
16446781|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
16446782|NCT03657641|Experimental|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16446783|NCT03657628|Experimental|Physical activity|"The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.
~Will receive social/behavioral support
~Will receive research staff contact time to encourage them to increase their physical activity level
~The participants will be given the option of a third supervised session each week"
16446784|NCT03657615|Active Comparator|Control|Hearing Aid Fitting Patients with hearing loss but no tinnitus paired by age and hearing loss degree Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
16446785|NCT03657615|Experimental|Tinnitus|Hearing Aid Fitting Patients with tinnitus and hearing loss associated Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
16446786|NCT03657602|Experimental|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
16446787|NCT03657602|Experimental|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
16446788|NCT03657589||patients with 1 missing tooth|Patients with 1 missing anterior or premolar tooth and planned for implant surgery were recruited. Gingiva and alveolar bone were ultrasound scanned and compared to CT scans and direct measures during implant surgery.
16446789|NCT03657576|Experimental|C134 Treatment|All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)
16446790|NCT03657563|Experimental|Intervention group|Nurses with burnout are recruited in the intervention group and participate in positive psychological intervention.
16446791|NCT03657563|No Intervention|Control group|Nurses with burnout are recruited in the control group and none interventions are conducted to them.
16446833|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 3 weeks|F520 200mg/times every 3 weeks
16447139|NCT03655353|Experimental|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
16446792|NCT03657550|Other|Test Drug - Reference Product - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
16446793|NCT03657550|Other|Reference Product - Test Drug - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
16446794|NCT03657537|Experimental|Hyperketonemia - Placebo|Participants are randomly assigned to initially receive ketone infusion and then saline infusion
16446795|NCT03657537|Experimental|Placebo - Hyperketonemia|Participants are randomly assigned to initially receive saline infusion and then ketone infusion
16446796|NCT03657524|Experimental|Resuscitation patients|
16446797|NCT03657524|Active Comparator|healthy volunteers|
16446798|NCT03657511|Other|Educational Interventions to Promote Tobacco Cessation|
16446799|NCT03657498|Experimental|Study group|Combined orthodontic-orthognathic treatment
16446800|NCT03657498|No Intervention|Control Group I|No intervention
16446801|NCT03657498|Active Comparator|Control Group II|Standard orthodontic treatment
16446802|NCT03657485|Experimental|interventional|In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFbaby, IBSS Biomed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
16446803|NCT03657485|No Intervention|control|No intervention. Feeding with mother milk
16446804|NCT03657485|No Intervention|comperative|Comparing stool composition of vaginally born newborns
16446805|NCT03657472|Experimental|Sequence 1(RTR)|
16446806|NCT03657472|Experimental|Sequence 2(RRT)|
16446807|NCT03657472|Experimental|Sequence 3(TRR)|
16446808|NCT03657459|No Intervention|usual care group|Usual care consists of patient's receiving a Heart Failure Handbook before hospital discharge + verbal education delivered by multiple care providers (including a group education class at 1 site). The handbook is consistent; however, verbal education may vary between care providers based on their knowledge and time available, and perceived patient needs
16446809|NCT03657459|Active Comparator|video education group|"Will receive usual care, plus will watch 2 short Wellflix, Inc. Danger Signs of Heart Failure videos (via iPAD) on dyspnea, fatigue + a Danger Sign edema video, when applicable. Each video describes how to recognize if the sign/symptom is new or worsening and how to self-manage at home (via diet, fluid management and activity instructions)"
16446810|NCT03657446|Experimental|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
16446811|NCT03657446|Experimental|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
16446812|NCT03657446|Experimental|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
16446813|NCT03657446|Experimental|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
16446814|NCT03657446|Experimental|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
16446815|NCT03657446|Experimental|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
16446816|NCT03657433|Experimental|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.
~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
16446817|NCT03657433|Active Comparator|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.
~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
16446818|NCT03657420|Experimental|ABI-009 + Pomalidomide + Dexamethasone|"Pomalidomide is given orally daily on days 1-21, 7 days off
~ABI-009 is given intravenously on days 1, 8, and 15
~Dexamethasone is given orally weekly on days 1, 8, 15, 22"
16446819|NCT03657407|Active Comparator|B&O|29 women randomized to Belladonna & Opium suppository
16446820|NCT03657407|Sham Comparator|Placebo|27 women randomized to Glycerin suppository
16446821|NCT03657394|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC.
16446822|NCT03657394|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
16446823|NCT03657381|Experimental|F520 0.2mg/kg single-dose|F520 0.2mg/kg single-dose
16446824|NCT03657381|Experimental|F520 1.0mg/kg single-dose|F520 1.0mg/kg single-dose
16446825|NCT03657381|Experimental|F520 3.0mg/kg single-dose|F520 3.0mg/kg single-dose
16446826|NCT03657381|Experimental|F520 200mg/times single-dose|F520 200mg/times single-dose
16446827|NCT03657381|Experimental|F520 10mg/kg single-dose|F520 10mg/kg single-dose
16446828|NCT03657381|Experimental|F520 1mg/kg multiple dosing, every 2 weeks|F520 1mg/kg every 2 weeks
16446829|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 2 weeks|F520 3mg/kg every 2 weeks
16446830|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 2 weeks|F520 200mg/times every 2 weeks
16446831|NCT03657381|Experimental|F520 10mg/kg multiple dosing, every 2 weeks|F520 10mg/kg every 2 weeks
16446832|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 3 weeks|F520 3mg/kg every 3 weeks
16446834|NCT03657368|Experimental|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
16446835|NCT03657368|Experimental|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
16446836|NCT03657368|Experimental|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
16446837|NCT03657368|Experimental|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
16446838|NCT03657355|Experimental|50 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
16446839|NCT03657355|Experimental|100 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
16446840|NCT03657355|Experimental|150 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
16446841|NCT03657355|Active Comparator|150 mg suvorexant|Suvorexant will be administered as tablets for oral use.
16446842|NCT03657355|Active Comparator|30 mg zolpidem|Zolpidem will be administered as tablets for oral use.
16446843|NCT03657355|Placebo Comparator|Placebo|Placebo will be administered as tablets for oral use.
16446844|NCT03657342|Experimental|L-CsA treatment plus SoC|L-CsA 5 mg twice daily for 48 weeks Standard of Care Therapy
16446845|NCT03657342|No Intervention|Standard of Care alone|Standard of Care Therapy
16446846|NCT03657329|Experimental|Suspicion of sleep-disordered breathing|Dreem
16446847|NCT03657316|Experimental|experimental school 1|"The experimental school 1 will receive the following:
~Nutritional and physical activity educational workshop
~Enhanced physical education
~Involvement of the morning broadcast
~Educational brochure will be sent to the parents
~A monthly telephone call or a text message will be sent to the parents
~Message to school administration to prevent selling of soft drinks and to sell healthy food
~A monthly session (3 months)"
16446848|NCT03657316|Experimental|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
16446849|NCT03657316|No Intervention|control|The control school will receive no intervention
16446850|NCT03657303||Healthy volunteers|
16446851|NCT03657303||Osteoarthritis patients|
16446852|NCT03657290|Active Comparator|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
16446853|NCT03657290|Active Comparator|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
16446854|NCT03657290|Active Comparator|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
16446855|NCT03657277|Other|Micropatch Application|This is the only study arm, which all participants complete. Five sites each on each the upper arm, forearm, and abdomen will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, hydration, and skin color will be made. Micropatches will be applied at three sites (at each body location). This only occurs on the first study day. Trans-epidermal water loss and electrical resistance are re-measured immediately after micropatch application. The sites will be covered with a small patch secured with medical tape. One site at each location will just be covered with a patch. The last site will not have micropatch application or patches. Electrical resistance will be re-measured at all sites for 3 days. Measurements from the 4th and 5th sites allow each subject to serve as their own control in data analysis.
16446856|NCT03657264|Experimental|Sequence 1|"The sequence of administration is: P/ScD/PC/CD
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
16446857|NCT03657264|Experimental|Sequence 2|"The sequence of administration is: CD/PC/ScD/P
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
16446858|NCT03657264|Experimental|Sequence 3|"The sequence of administration is: ScD/CD/P/PC
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
16446859|NCT03657264|Experimental|Sequence 4|"The sequence of administration is: PC/P/CD/ScD
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
16446860|NCT03657251||CureCloud Direct to Patient|
16446861|NCT03657238|Experimental|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
16446862|NCT03657238|Placebo Comparator|Placebo|
16446863|NCT03657225|Active Comparator|Mini CPB (ECCO, Sorin, Italy)|Utilization of the mini CPB circuit (Extra Corporeal Circuit Optimized; Phisio, Sorin Group, Italy)
16446864|NCT03657225|Placebo Comparator|Conventional|Use of conventional CPB circuit
16446865|NCT03657212|Active Comparator|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
16446866|NCT03657212|Placebo Comparator|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
16446867|NCT03657199||Bypass graft failure|Patients with at least one detected graft failure after routine cardiac computed tomography before discharge
16446868|NCT03657199||No bypass graft failure|Patients without occluded bypass grafts after routine cardiac computed tomography before discharge
16446869|NCT03657186|Experimental|ProbioSatys™|
16446870|NCT03657186|Placebo Comparator|Placebo|
16446871|NCT03657160|Experimental|Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background graft-versus-host disease (GvHD) prophylaxis regimen.
16446872|NCT03657160|Placebo Comparator|Placebo|Vedolizumab placebo-matching, intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background GvHD prophylaxis regimen.
16446873|NCT03657147|Experimental|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
16446874|NCT03657147|No Intervention|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
16446875|NCT03657134|Experimental|EP Procedure|Patient will continuously wear the CoVa-2 monitoring system until they are discharged. During this period, data from the sensor will be sent to the Gateway and Cloud-based System, and then analyzed retrospectively.
16446876|NCT03657108|Experimental|group 1 of 60 Gy dose|The first 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
16446877|NCT03657108|Experimental|group 2 of 60 Gy dose|The second 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
16446878|NCT03657108|Experimental|group 1 of 75 Gy dose|The third 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
16446879|NCT03657108|Experimental|group 2 of 75 Gy dose|The fourth 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
16446880|NCT03657095|Experimental|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
16446881|NCT03657095|Placebo Comparator|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
16446882|NCT03657082|Experimental|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
16446883|NCT03657082|Experimental|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
16446884|NCT03657069|Experimental|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
16446885|NCT03657056|Experimental|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
16446886|NCT03657043|Experimental|Safety Run-In (3Q4W Schedule)|28-day, 3 dose cycle
16446887|NCT03657043|Experimental|Part A: Tisotumab Vedotin|21-day, single dose cycle
16446888|NCT03657043|Experimental|Part A: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
16446889|NCT03657043|Experimental|Part B: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
16446890|NCT03657030|Active Comparator|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
16446891|NCT03657030|Active Comparator|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
16446892|NCT03657017|Other|PET/MR|Patients are examined with PET/MR.
16446893|NCT03656991|Experimental|0 month group|Receive the bicycle intervention at 0 months after enrollment.
16446894|NCT03656991|Experimental|2 month group|Receive the bicycle intervention at 2 months after enrollment.
16446895|NCT03656991|Experimental|4 month group|Receive the bicycle intervention at 4 months after enrollment.
16446896|NCT03656991|Experimental|6 month group|Receive the bicycle intervention at 6 months after enrollment.
16446897|NCT03656978|Active Comparator|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
16446898|NCT03656978|Placebo Comparator|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
16446899|NCT03656965|Experimental|Antiviral Drug with Chemoradiotherapy|Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.
16446900|NCT03656965|Other|Chemoradiotherapy|Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
16446901|NCT03656952|Experimental|Seq 1|PF-06700841-> placebo-> moxifloxacin
16446902|NCT03656952|Experimental|Seq 2|PF-06700841->moxifloxacin->placebo
16446903|NCT03656952|Experimental|Seq 3|Placebo->PF-06700841->moxifloxacin
16446904|NCT03656952|Experimental|Seq 4|Placebo->moxifloxacin->PF-06700841
16446905|NCT03656952|Experimental|Seq 5|Moxifloxacin->PF-06700841->placebo
16446906|NCT03656952|Experimental|Seq 6|Moxifloxacin->placebo->PF-06700841
16446907|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
16446908|NCT03656926|Experimental|L-CsA treatment plus SoC|L-CsA 10 mg twice daily for 48 weeks, plus Standard of Care Therapy
16446909|NCT03656926|No Intervention|Standard of Care alone|Standard of Care Therapy
16446910|NCT03656913|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose CT exams
16446911|NCT03656900|Experimental|BA9/BA46|
16446912|NCT03656900|Experimental|BA46/BA9|
16446913|NCT03656874|No Intervention|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
16446914|NCT03656874|Experimental|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
16446915|NCT03656861||Athletes|122 were athletes (41 females and 81 males). Of the 41 female athletes, 32 were endurance athletes, and 9 strength athletes. From 81 male athletes, 56 were endurance athletes, and 25 were strength athletes.
16446916|NCT03656861||Non-athletes|29 were non-athletes (14 females and 15 males)
16446917|NCT03656848|Experimental|QFR-guided PCI group|If the patient is assigned to QFR-guided PCI, QFR is first measured in all coronary arteries with DS% ≥ 50% and ≤ 90%. Then PCI treatment is performed in lesions with QFR ≤ 0.80, and optimal medicine treatment is prescribed to those with QFR > 0.80. It is strongly recommended to select the device size based on the 3D-QCA measurements in this group.
16446918|NCT03656848|Active Comparator|Angiography-guided PCI group|If the patient is assigned to angiography-guided PCI, then the investigator performs PCI according to the stenosis severity based on visual assessment of the angiogram. No other functional tests such as FFR/iFR can be used for further assessment of the lesion before PCI.
16446919|NCT03656835|Experimental|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
16446920|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
16446921|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
16446922|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
16446923|NCT03656796|Experimental|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
16446924|NCT03656796|Experimental|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
16446925|NCT03656796|Experimental|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
16446926|NCT03656783|Other|HIV patients on stable therapy|Open-label, multicenter, single-arm study
16446927|NCT03656770|No Intervention|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
16446928|NCT03656770|Experimental|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
16446929|NCT03656770|Experimental|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
16446930|NCT03656770|Experimental|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
16446931|NCT03656770|Experimental|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
16446932|NCT03656770|Experimental|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
16446933|NCT03656770|Experimental|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
16446934|NCT03656770|Experimental|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
16446935|NCT03656770|Experimental|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
16446936|NCT03656770|Experimental|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
16446937|NCT03656744|Experimental|500mg HTD1801, bid|
16446938|NCT03656744|Experimental|1000mg HTD1801, bid|
16446939|NCT03656744|Placebo Comparator|placebo, bid|
16446940|NCT03656731|Experimental|Intervention group (n=50)|Patients in the intervention group will receive standard care and a 12-week exercise-based intervention.
16446941|NCT03656731|No Intervention|Control group (n=50)|Patient in the control group will receive standard care.
16446942|NCT03656718|Experimental|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
16446943|NCT03656718|Experimental|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
16446944|NCT03656718|Experimental|Part B, Group 2: nivolumab (dose 1)|
16446949|NCT03656705|Experimental|CCCR-NK92 cells immunotherapy|Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
16446950|NCT03656692|Other|Acthar Gel|Participants received Acthar 1 mL (80 units [U]) subcutaneously (SC) 2 times per week for 36 weeks followed by a taper to Acthar 1 mL (80 U) SC once a week for 2 weeks, then 0.5 mL (40 U) SC once a week for 2 weeks.
16446951|NCT03656679|Active Comparator|Pectoralis Blockade(PECs)|Participants undergo pectoralis nerve block (PEC II) will received anesthesia between the pectoralis major and minor in the chest while lying flat.
16446952|NCT03656679|Active Comparator|Paravertebral Blockade (PVB)|Participants undergoing paravertebral nerve block (PVB) consisting of receiving anesthesia in the back while sitting upright.
16446953|NCT03656666|Active Comparator|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.
~Initial titration:
~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
16446954|NCT03656666|Placebo Comparator|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
16446955|NCT03656653|Experimental|Future-based recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future without cocaine use
16446956|NCT03656653|Experimental|Future-based cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future where cocaine is causing significant distress
16446957|NCT03656653|Experimental|Past recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event without cocaine use
16446958|NCT03656653|Experimental|Past cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event where cocaine use has caused significant distress
16446959|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
16446960|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:
~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis
~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
16446961|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:
~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.
~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
16446962|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
16446963|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
16446964|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
16446965|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
16446966|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
16446967|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
16446968|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
16446969|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
16446970|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
16446971|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
16446972|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
16446973|NCT03656601||Vaginal delivery|Women that had only vaginal delivery
16446974|NCT03656601||Cesarean-section|Women that had only cesarean-section
16446975|NCT03656601||Nulliparous|Women without delivery
16446976|NCT03656588|Active Comparator|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
16446977|NCT03656588|Active Comparator|b. Iodine scrub and ChloraPrep alone|
16446978|NCT03656575|Active Comparator|intra-articular alpha-2-macroglobulin|intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)
16446979|NCT03656575|Active Comparator|intra-articular Platelet-rich Plasma (PRP) injection|Standard of care PRP treatment
16446980|NCT03656575|Active Comparator|Intra-articular corticosteroid|Standard of Care steroid treatment
16446981|NCT03656562|Experimental|Cohort 1 VAY736|multiple doses of VAY736, s.c.
16446982|NCT03656562|Placebo Comparator|Cohort 1 VAY736 Placebo|multiple doses of matching placebo s.c. until week 29. Multiple doses of VAY736, s.c from week 29 until week 53.
16446983|NCT03656562|Experimental|Cohort 2 CFZ533|multiple doses of CFZ533, i.v.
16446984|NCT03656562|Placebo Comparator|Cohort 2 CFZ533 Placebo|multiple doses of matching placebo i.v. until week 29. Multiple doses of CFZ533, i.v. from week 29 until week 53.
16446985|NCT03656549|Experimental|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function.
16446986|NCT03656536|Experimental|Pemigatinib|
16446987|NCT03656536|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
16446988|NCT03656523||Acute Coronary Syndrome|Patients with Aute coronary syndrome trated with Percutaneous Coronary Intervention plus Stent implantation and Atrial Fibrillation
16447318|NCT03654222||Other|Any surgery that does not include the previous ones
16446992|NCT03656484|Active Comparator|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
16446993|NCT03656484|Experimental|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
16446994|NCT03656471||Clear aligner group|Patients receiving clear aligner treatments for their malocclusions
16446995|NCT03656471||Fixed appliance group|Patients receiving fixed appliance treatments for their malocclusions
16446996|NCT03656458|Active Comparator|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
16446997|NCT03656458|No Intervention|Control Group B|Control group. No intervention given to participants.
16446998|NCT03656458|Experimental|Experimental Group|Warm Up followed by Biodex Balance Training
16446999|NCT03656445|Active Comparator|Group A - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
16447000|NCT03656445|Active Comparator|Group B - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
16447001|NCT03656445|Active Comparator|Group C - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively
16447002|NCT03656432|Experimental|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
16447003|NCT03656432|Experimental|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
16447004|NCT03656432|Active Comparator|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
16447005|NCT03656419|Experimental|aPDT group|For photodynamic therapy will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² .One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points, considering the scattering halo and the effectiveness of aPDT. The LED apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
16447006|NCT03656419|Active Comparator|Tongue Scraper|Tongue scraper 10 times in the tongue, from the back to the front.
16447007|NCT03656419|Experimental|aPDT and tongue scraper|Tongue scraper 10 times in the tongue, from the back to the front. For aPDT will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² . One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points. Based on previous studies carried out with the aPDT for the treatment of halitosis the apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
16447008|NCT03656393|Experimental|Gefitinib therapy group|Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
16447009|NCT03656393|Active Comparator|Vinorelbine combination therapy group|Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
16447010|NCT03656380|Experimental|Mepolizumab 300 mg|Subjects will receive Mepolizumab 300 mg subcutaneously (SQ) monthly for 6 months
16447011|NCT03656380|Other|Placebo, followed by Mepolizumab 100 mg|This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
16447012|NCT03656367|Experimental|All subjects|"Cross-over study (all subjects receive all interventions)
~Cheddar cheese
~Blended and homogenized cheddar cheese
~An analog milk
~An analog cheese"
16447013|NCT03656367|Other|Healthy subjects only (subgroup)|"If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects.
~All subjects receive all interventions)
~Cheddar cheese
~Blended and homogenized cheddar cheese
~An analog milk
~An analog cheese"
16447014|NCT03656341|Experimental|2 Feet 4 Life|Intervention group will receive one hour intervention weekly for four consecutive weeks. Outcomes will be measured at baseline (before the intervention), immediately after the intervention (1 month), three months post-intervention, and six months post-intervention
16447015|NCT03656341|No Intervention|True control group|Will complete the same four assessment visits as the intervention group.
16447016|NCT03656341|No Intervention|Bias control group|Will complete outcome assessments at baseline and the final assessment.
16447017|NCT03656328|Experimental|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
16447018|NCT03656328|Placebo Comparator|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
16447019|NCT03656315|Other|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
16447020|NCT03656302||Case offspring|"Inclusion criteria:
~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form
~Exclusion criteria:
~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
16447021|NCT03656302||Control offspring|"Inclusion criteria:
~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.
~Exclusion criteria:
~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
16447022|NCT03656289|Experimental|Etonogestrel Contraceptive|Etonogestrel contraceptive implant; consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. The implant must be removed no later than by the end of the third year.
16447023|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
16447024|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
16447025|NCT03656263||High risk cardiac surgery patients|"Defined as either:
~Multiple surgical procedures planned and/or,
~EuroSCORE ≥ 5% and/or,
~Known pulmonary hypertension (mPAP>25 mmHg or sPAP > 40 mmHg)"
16447026|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
16447027|NCT03656237|Experimental|Usual training + Audits + LDHF training|"Usual training of health workers, in classroom, following standard curriculum
~+ Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits"
16447028|NCT03656237|Experimental|Audits + LDHF training|Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits
16447029|NCT03656237|Active Comparator|Usual Training|Control Arm exposed to usual training of health workers, in classroom, following standard curriculum
16447030|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
16447031|NCT03656211||Patients with UAVM|"All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination.
~Telephone interview"
16447032|NCT03656198|Experimental|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
16447033|NCT03656198|Placebo Comparator|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
16447034|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
16447035|NCT03656159|Active Comparator|Non-directive support group|This intervention will provide time and space to discuss the impact of AD. The objective will be to help participants feel less alone and better understood and to address the implications of AD in their daily life.
16447036|NCT03656159|Experimental|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
16447037|NCT03656146|Active Comparator|Tablet Screening|Food insecurity screening conducted via electronic tablet
16447038|NCT03656146|Active Comparator|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
16447039|NCT03656133|Active Comparator|Standard Fractionation|Standard Radiotherapy Fractionation
16447040|NCT03656133|Active Comparator|Hyperfractionation|Hyperfractionation
16447041|NCT03656120|Experimental|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
16447042|NCT03656120|Experimental|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
16447043|NCT03656120|Placebo Comparator|placebo control group|Participants only taking placebo once a day for 12 weeks.
16447044|NCT03656107|Experimental|Cognitive training|Participants selected to brain training will be given instructions on how to access and use the program at home for 15-30minutes, 3-5 times per week for 8-12 weeks.
16447045|NCT03656107|No Intervention|Waiting-list control|Control participants will be waiting listed to receive the brain training program at the end of the study. control participants will undergo usual care.
16447046|NCT03656094|Experimental|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
16447435|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
16447047|NCT03656094|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
16447048|NCT03656081|Placebo Comparator|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
16447049|NCT03656081|Experimental|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
16447050|NCT03656068|Experimental|Open label NTZ|Open label study. All patients will receive study drug.
16447051|NCT03656042|Experimental|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
16447052|NCT03656042|No Intervention|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
16447053|NCT03656029|Placebo Comparator|Placebo|Participants will smoke a single smoked placebo (<0.1% THC) cannabis cigarette
16447054|NCT03656029|Active Comparator|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
16447055|NCT03656029|Active Comparator|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
16447056|NCT03656029|Active Comparator|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
16447057|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
16447058|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
16447059|NCT03656003|Experimental|Procore needle|EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
16447060|NCT03656003|Active Comparator|Conventional needle|Conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
16447061|NCT03655990||Treatment with the JUVORA™ Dental Disc|Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
16447062|NCT03655977|Experimental|Cervical cancer patients|This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.
16447063|NCT03655964|Experimental|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
16447064|NCT03655964|Experimental|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
16447065|NCT03655964|Experimental|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
16447066|NCT03655951|Experimental|Resource 1|Web-based resource on adolescent sexual health
16447067|NCT03655951|Active Comparator|Resource 2|Alternate web-based resource on adolescent sexual health
16447068|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction <40
16447069|NCT03655912|Active Comparator|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
16447070|NCT03655912|Experimental|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
16447071|NCT03655912|Experimental|Red/Green Glasses|Red/green glasses and a electronic tablet
16447072|NCT03655886|Experimental|Radical prostatectomy|
16447073|NCT03655886|Experimental|Radiotherapy|
16447074|NCT03655873|Experimental|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .
~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
16447075|NCT03655873|Placebo Comparator|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .
~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
16447076|NCT03655860|Experimental|SIMEOX|
16447077|NCT03655847|Experimental|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
16447078|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
16447079|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
16447080|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
16447081|NCT03655808|Experimental|BBCs transplantation|Autologous Bronchial basal cells transplantation
16447082|NCT03655795|Experimental|Bronchial basal cells|Autologous transplantation of bronchial basal cells
16447083|NCT03655782|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether dim gray stripes in fish-shaped window move left or right relative to stationary background stripes. The subject reports which way center stripes move by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, 15 minutes, 3 times each week for 16 weeks. Fifteen minutes of working memory practice, recalling the correct sequence of digits, each presented for 500 msec, from 5 digits up to 10 digits will be completed for 15 minutes following PATH training.
16447140|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
16447084|NCT03655782|Sham Comparator|Orientation Discrimination training|The sham treatment will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings, see patterns in Fig. 4 below. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key component of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
16447085|NCT03655769|Sham Comparator|sham tDCS|tDCS delivered for only 30 sec to replicate tingling sensation and blind subject
16447086|NCT03655769|Experimental|cathodal tDCS|cathodal tDCS, 2 milliamps (mA), delivered to right parietal region
16447087|NCT03655756|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:
~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator
~Route of Administration:
~Intratumoral injection of cutaneous, subcutaneous or nodal lesions
~Mechanism of Action:
~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.
~Physiological Effect:
~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
16447088|NCT03655743||Patients after refractive surgery|Patients have had any type of corneal or lens refractive surgery.
16447089|NCT03655743||Patients before refractive surgery|Patients will have any type of corneal or lens refractive surgery.
16447090|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
16447091|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
16447092|NCT03655717|Experimental|Placebo Dronabinol + Ethanol|single dose of Placebo Dronabinol + Ethanol See protocol for dosing
16447093|NCT03655717|Experimental|Dronabinol + Placebo Ethanol|single dose of Dronabinol + Placebo Ethanol See protocol for dosing
16447094|NCT03655717|Experimental|Dronabinol + Ethanol|single dose of Dronabinol + Ethanol See protocol for dosing
16447095|NCT03655717|Placebo Comparator|Placebo Dronabinol + Placebo Ethanol|single dose of Placebo Dronabinol + Placebo Ethanol See protocol for dosing
16447096|NCT03655704|Experimental|Apabetalone|100mg BID for 16 weeks.
16447097|NCT03655691|Placebo Comparator|Vehicle|Vehicle / Placebo formulation
16447098|NCT03655691|Experimental|Dose 1|lower dose of ET-01
16447099|NCT03655691|Experimental|Dose 2|higher dose of ET-01
16447100|NCT03655678|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
16447101|NCT03655665|Experimental|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
16447102|NCT03655665|No Intervention|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
16447103|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
16447104|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
16447105|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
16447106|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
16447107|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
16447108|NCT03655600|No Intervention|Usual care|Usual care
16447109|NCT03655587|Experimental|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
16447110|NCT03655587|Active Comparator|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
16447111|NCT03655574|Experimental|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.
~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
16448489|NCT03646318|Placebo Comparator|Placebo|The placebo is a standard glucose 5% solution.
16447112|NCT03655574|Placebo Comparator|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
16447113|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
16447114|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
16447115|NCT03655535|Experimental|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
16447116|NCT03655535|Placebo Comparator|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
16447117|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
16447118|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
16447119|NCT03655509|Other|ACTH stimulation test|
16447120|NCT03655496|No Intervention|Control group|Subject to standard care.
16447121|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
16447122|NCT03655483|Experimental|GLS-010|GLS-010
16447123|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
16447124|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
16447125|NCT03655457|Experimental|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
16447126|NCT03655457|Active Comparator|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
16447127|NCT03655444|Experimental|Phase I: Abemaciclib + Nivolumab|"Abemaciclib (150 mg) will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle
~Nivolumab 480 mg will be given intravenously (IV) over 30 minutes on Day 1 of every 4-week cycle."
16447128|NCT03655444|Experimental|Phase II: Abemaciclib + Nivolumab|"Phase II Lead-in: Patients will be treated with abemaciclib monotherapy at the recommended phase II dose (150 mg) on Day -7 through Day -1 prior to starting Cycle 1 with the combination of abemaciclib and nivolumab. Patients will proceed directly from Day -1 to Cycle 1 Day 1 of combination abemaciclib + nivolumab, there is not a Day 0.
~Patients will be treated with abemaciclib at the RP2D (150 mg) (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle."
16447129|NCT03655431|Experimental|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
16447130|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
16447131|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
16447132|NCT03655405|Experimental|Individual Deprescribing Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
16447133|NCT03655405|No Intervention|Control|Participants allocated to the control group will receive usual care.
16447134|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
16447135|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
16447136|NCT03655379|Experimental|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
16447141|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
16447142|NCT03655327||stroke patients|stroke patients with upper limb paresis
16447143|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
16447144|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
16447145|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
16447146|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
16447147|NCT03655275|Active Comparator|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
16447148|NCT03655275|Active Comparator|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
16447149|NCT03655262|Experimental|1 Session|1 neuro-reinforcement session
16447150|NCT03655262|Experimental|3 Sessions|3 neuro-reinforcement sessions
16447151|NCT03655262|Experimental|5 sessions|5 neuro-reinforcement sessions
16447152|NCT03655249|Experimental|Asl + CPT|Aerosotherapy + Autogenic drainage
16447153|NCT03655249|Active Comparator|Asl|Aerosoltherapy alone
16447157|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
16447158|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
16447159|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
16447160|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
16447161|NCT03655197|No Intervention|Healthy Subjects|Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.
16447162|NCT03655197|Experimental|Ocular Rosacea Subjects|Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.
16447163|NCT03655197|Other|Cutaneous Rosacea Subjects|Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxycycline intervention.
16447164|NCT03655184||MOH group|Patients with medication overuse headache
16447165|NCT03655184||Episodic migraine group|Patients with episodic migraine
16447166|NCT03655184||Healthy group|No headache or other special medical history
16447167|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
16447168|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
16447169|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
16447170|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
16447171|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
16447172|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
16447173|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
16447174|NCT03655145|Experimental|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
16447175|NCT03655145|Active Comparator|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
16447176|NCT03655132|No Intervention|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
16447177|NCT03655132|Experimental|VACT-CP Group|Veterans randomized to VACT-CP will receive 8 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
16447201|NCT03654937|Active Comparator|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
16447202|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
16447178|NCT03655119|No Intervention|Baseline|Youth and parents will complete surveys at index PES visit regarding suicide related risk and protective factors. Parents and youth will complete a follow-up survey at 3 days (parents only) and 2 weeks (parents and youth) post discharge. At 3 days and 2 weeks, parents will complete a survey that evaluates adherence to safety recommendations. The 2-week follow-up survey for parents will also re-assess self-efficacy, parental distress, and mental health treatment stigma. The 2-week follow-up survey for youth assesses mood and suicidal thoughts, perceptions of parent support post discharge, and outpatient treatment. It reassesses suicidal risk, depression, connectedness, and alcohol use.
16447179|NCT03655119|Experimental|Phase I|Families will complete baseline measures, and receive enhanced usual care from PES clinical staff during their visit as well as a parent toolkit that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth. The same follow-up methodology as in Baseline will be utilized.
16447180|NCT03655119|Experimental|Phase II|Families will complete baseline measures and receive Phase I interventions (enhanced care and parent toolkit). Parents will receive caring contacts post discharge, which may occur by phone, text, or email. Caring follow-up messages will provide support, additional education, and problem solving assistance. The same follow-up methodology as in Baseline will be utilized.
16447181|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
16447182|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
16447183|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
16447185|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
16447186|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
16447187|NCT03655054|Experimental|eCoin Tibial Nerve Stimulation|
16447188|NCT03655041|Experimental|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
16447189|NCT03655041|Placebo Comparator|Placebo|6.4 g/day of maltodextrin for 24 weeks
16447190|NCT03655028|Experimental|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
16447191|NCT03655028|Active Comparator|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
16447192|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
16447193|NCT03654989|Experimental|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)
~Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².
~Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
16447194|NCT03654989|Placebo Comparator|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
16447195|NCT03654989|No Intervention|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests <1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
16447196|NCT03654976|Experimental|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
16447197|NCT03654976|Placebo Comparator|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
16447198|NCT03654963|No Intervention|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
16447199|NCT03654963|Experimental|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
16447200|NCT03654937|Active Comparator|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
16447203|NCT03654911||aMCI subjects|EEG recording, ApoE testing
16447204|NCT03654898|Active Comparator|VITAL Start|VITAL Start: Video-based pre-ART counseling
16447205|NCT03654898|Placebo Comparator|Standard of Care|pre-ART education as conducted via routine facility methods
16447206|NCT03654885|Active Comparator|XEN group|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation
16447207|NCT03654885|Active Comparator|Trabeculectomy|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.
16447208|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:
~verbal description of location
~telephone-assisted CPR"
16447209|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:
~automated geolocalisation
~video-assisted CPR"
16447210|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
16447211|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
16447212|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:
~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
16447213|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
16447214|NCT03654833|Experimental|MiST 5 Dostarlimab and Niraparib|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.
16447215|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
16447216|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
16447217|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
16447218|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
16447219|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.
~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.
~Cell pharmacokinetics of tacrolimus"
16447220|NCT03654781|Active Comparator|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
16447221|NCT03654781|Experimental|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
16447222|NCT03654768|Active Comparator|Arm I (dasatinib, nilotinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16447223|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16447224|NCT03654755|Experimental|ASN002 40 mg|ASN002 40 mg
16447225|NCT03654755|Experimental|ASN002 60 mg|ASN002 60 mg
16447226|NCT03654755|Experimental|ASN002 80 mg|ASN002 80 mg
16447227|NCT03654742|Active Comparator|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
16447228|NCT03654742|Experimental|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
16447229|NCT03654742|Experimental|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
16447230|NCT03654729|Experimental|PledOx (2 µmol/kg)|Calmangafodipir (2 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
16447231|NCT03654729|Experimental|PledOx (5 µmol/kg)|Calmangafodipir (5 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
16447232|NCT03654729|Placebo Comparator|Placebo|Placebo will be given to patients as an intravenous infusion, on top of mFOLFOX6 chemotherapy.
16447233|NCT03654716|Experimental|ALRN-6924 -- Cohort A|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.
~ALRN-6924 will be administered intravenously.
~Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
16447234|NCT03654716|Experimental|ALRN-6924 -- Cohort B|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.
~ALRN-6924 will be administered intravenously.
~Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
16447235|NCT03654716|Experimental|ALRN-6924 -- Cohort C|"Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.
~Cytarabine is administered intravenously.
~ALRN-6924 will be administered intravenously.
~Participants with TP53 wild type acute leukemia will participate in this cohort."
16447236|NCT03654703|Experimental|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
16447237|NCT03654703|Experimental|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
16447238|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
16447239|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
16447240|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
16447241|NCT03654677|Experimental|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
16447242|NCT03654677|Active Comparator|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
16447243|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
16447244|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
16447245|NCT03654651|Experimental|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
16447246|NCT03654651|Active Comparator|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
16447249|NCT03654625|Experimental|Standard Written Exposure|Four writing sessions at the laboratory
16447250|NCT03654625|Experimental|Enhanced Written Exposure|Four writing sessions at the laboratory
16447251|NCT03654625|Placebo Comparator|Control Condition|Four writing sessions at the laboratory
16447252|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
16447253|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
16447254|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
16447255|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
16447256|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
16447257|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
16447258|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
16447259|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
16447260|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
16447261|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
16447264|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
16447265|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
16447266|NCT03654521|Active Comparator|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
16447267|NCT03654521|Active Comparator|Control group|Women without gestational or pre-gestational diabetes mellitus.
16447268|NCT03654508|Active Comparator|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
16447269|NCT03654508|Active Comparator|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
16447270|NCT03654495|Experimental|Exergame Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.
16447271|NCT03654495|Active Comparator|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation.
16447272|NCT03654482|Experimental|SuperSeton arm|
16447273|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
16447274|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
16447275|NCT03654443|Experimental|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
16447276|NCT03654443|Experimental|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
16447277|NCT03654430|Other|Healthy Newborns|
16447278|NCT03654417|Active Comparator|EMLA|
16447279|NCT03654417|Active Comparator|Lidocaine|
16447280|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.
~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).
~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
16447281|NCT03654391|Active Comparator|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
16447282|NCT03654391|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
16447283|NCT03654365|Active Comparator|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
16447284|NCT03654365|Experimental|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
16447285|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
16447286|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
16447287|NCT03654339|Experimental|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach
~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
16447288|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
16447289|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
16447290|NCT03654313|Experimental|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
16447291|NCT03654313|Experimental|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
16447292|NCT03654313|Experimental|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
16447293|NCT03654313|Experimental|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
16447294|NCT03654313|Placebo Comparator|Part A Placebo|Part A Placebo
16447295|NCT03654313|Experimental|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
16447296|NCT03654313|Experimental|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
16447297|NCT03654313|Experimental|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
16447298|NCT03654313|Placebo Comparator|Part B Placebo|Part B Placebo
16447299|NCT03654313|Experimental|Part A MEDI6570 Cohort 5|Part A MEDI6570 Cohort 5 Dose level
16447300|NCT03654313|Experimental|Part A MEDI6570 Cohort 6|Part A MEDI6570 Cohort 6 dose level
16447301|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
16447302|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
16447303|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
16447304|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
16447305|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
16447306|NCT03654274|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 80 weeks.
16447307|NCT03654261|Experimental|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
16447308|NCT03654261|Experimental|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
16447309|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
16447310|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
16447311|NCT03654235|Experimental|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
16447312|NCT03654235|Active Comparator|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
16447313|NCT03654222||Cardiac surgery|Direct procedures in heart
16447314|NCT03654222||Organ preservation|Mainly renal autograft
16447315|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
16447316|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
16447317|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
16447319|NCT03654209|Experimental|Argon Plasma Coagulation|Following polyp removal using standard of care methods, Argon Plasma Coagulation (APC) will be applied to the perimeter of the resection site before any clips are added.
16447320|NCT03654209|Experimental|Snare Tip Soft Coagulation|Following polyp removal using standard of care methods, Snare Tip Soft Coagulation (STSC) will be applied to the perimeter of the resection site before any clips are added.
16447321|NCT03654209|No Intervention|No treatment|Following polyp removal using standard of care methods, neither APC nor STSC will be applied to the perimeter of the resection site. Clips may be added at the discretion of the PI.
16447322|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
16447323|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
16447324|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
16447325|NCT03654144|Experimental|Study group|women will receive dienogest
16447326|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
16447327|NCT03654131|Active Comparator|MWA|Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.
16447328|NCT03654131|Active Comparator|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
16447329|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points
~Phone follow-up"
16447330|NCT03654105|Experimental|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
16447331|NCT03654105|Experimental|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
16447332|NCT03654105|Experimental|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
16447333|NCT03654105|Other|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
16447334|NCT03654092|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
16447335|NCT03654092|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment decisions, including participation in other exercise training programs).
16447338|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
16447339|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
16447340|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
16447341|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
16447342|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells
~The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.
~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <90 x10^6 total cells will be included in intent-to-treat analysis."
16447343|NCT03654027|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
16447344|NCT03654027|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
16447345|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
16447346|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
16447347|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
16447348|NCT03654001|Experimental|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
~Balanced crystalloid solutions
~According to the preference and the standard use of the participating center:
~Ringer Lactate
~Ringer Acetate
~Crystalsol"
16447468|NCT03653208|Experimental|Group 2 (hzVSF-v13 20mg)|Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
16447349|NCT03654001|Experimental|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
16447350|NCT03654001|Experimental|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
16447351|NCT03654001|No Intervention|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
16447352|NCT03653988|Active Comparator|PEC I/II block - pre-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction case. The intervention administered to Group I will having the block performed by the anesthesiologist after induction of general anesthesia and prior to surgical incision.
16447353|NCT03653988|Experimental|PEC I/II block - intra-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction.
16447354|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria
~Major criteria
~Age 3 to 18 y at onset of head nodding
~Nodding frequency 5 to 20 times per min
~Minor criteria
~Other neurologic abnormalities
~Clustering in space or time with similar cases
~Triggering by eating or cold weather
~Delayed sexual or physical development
~Psychiatric manifestations
~As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions."
16447355|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)
~confirmed or suspected generalized and idiopathic epilepsy
~confirmed active infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
16447356|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)
~confirmed or suspected generalized and idiopathic epilepsy
~excluded active or past infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
16447357|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)
~no evidence for epilepsy or other neurological diseases
~confirmed active infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
16447358|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)
~no evidence for epilepsy or other neurological diseases
~excluded active or past infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
16447359|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)
~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
16447360|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
16447361|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
16447362|NCT03653949|Experimental|High Intensity Interval Training|The subjects will participate of an educational intervention and a High Intensity Interval Training.
16447363|NCT03653949|Active Comparator|Control Group|The subjects will participate of an educational intervention.
16447364|NCT03653923|Experimental|Waiting-List|
16447365|NCT03653923|Experimental|Treatment|
16447366|NCT03653923|No Intervention|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
16447367|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
16447368|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
16447369|NCT03653897|Experimental|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
16447370|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
16447371|NCT03653871|Experimental|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
16447372|NCT03653871|No Intervention|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
16447373|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.
~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.
~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
16447469|NCT03653208|Experimental|Group 3 (hzVSF-v13 50mg)|Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
16447374|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.
~2ND STAGE: See group A."
16447375|NCT03653845|Experimental|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
16447376|NCT03653845|Active Comparator|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
16447377|NCT03653832|Experimental|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7µg.kg-1.hour-1 titrated to a maximum dose 1.4µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
16447378|NCT03653832|Experimental|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
16447379|NCT03653832|Active Comparator|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
16447380|NCT03653819|Other|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
16447381|NCT03653819|Other|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
16447382|NCT03653793|Experimental|LivRelief Varicose Veins Cream|"Intervention:
~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
16447383|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
16447384|NCT03653767|No Intervention|Control Group|The control group will use conventional school furniture.
16447385|NCT03653767|Experimental|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
16447386|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
16447387|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
16447388|NCT03653741|Experimental|Healthy males|healthy males will undergo EEG, VEP, BAER, and SEP testing, then take a single dose of Perampanel 6 MG pill (intervention), then have blood drawn and undergo the 4 tests mentioned previously for a second time
16447389|NCT03653728||Traumatic brain injury with cerebral contusions|
16447390|NCT03653715|Experimental|Test Device|Within this arm the Clerio Vision LIRIC-modified Bifocal Contact Lens is administered.
16447391|NCT03653715|Active Comparator|Control Devices|Within this arm the Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, and Clerio Vision Single Vision Contact Lens are administered.
16447392|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
16447393|NCT03653689|Active Comparator|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
16447394|NCT03653689|Active Comparator|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
16447395|NCT03653689|Placebo Comparator|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
16447396|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
16447397|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
16447398|NCT03653663|Placebo Comparator|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
16447399|NCT03653663|Active Comparator|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
16447400|NCT03653650|Experimental|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
16447401|NCT03653650|Active Comparator|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
16447402|NCT03653650|Active Comparator|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
16447403|NCT03653637|Experimental|Project Life Force|"A novel, 10-session intervention to enhance currently mandated VA suicide safety planning in a group setting to support its implementation. PLF is a manualized, weekly 90-minute group treatment lasting 10 weeks coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. Session content is described in Table 1 (see appendix A). Six of the PLF sessions correspond to a step of the safety plan and teach skills to maximize the use of that particular step of the plan. The use of emotion regulation skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation, distraction and developing social support in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on physical health management, education pertaining to suicide risk, promoting positive emotion and suicide prevention mobile apps. PLF patients also receive usual care."
16447404|NCT03653637|Active Comparator|Treatment-As-Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Research team will track number of individual mental health appointments, SPC outreach contacts, and usage patterns of safety plans. Veterans in both randomized conditions will be receiving the mandated monitoring, outreach, and involvement of SPC staff and clinical team management that constitutes standard VA care for suicidal individuals.
16447407|NCT03653598||AF patients|Patients with Atrial Fibrillation
16447408|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
16447409|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
16447410|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:
~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
16447411|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
16447412|NCT03653559|Experimental|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and < 30% lipids.
16447413|NCT03653559|Active Comparator|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
16447414|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
16447415|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
16447416|NCT03653533|Other|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
16447417|NCT03653533|Other|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
16447418|NCT03653533|Other|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
16447419|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
16447420|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
16447421|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
16447422|NCT03653507|Experimental|Arm A (zolbetuximab plus CAPOX)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
16447423|NCT03653507|Placebo Comparator|Arm B (placebo plus CAPOX)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
16447424|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
16447425|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
16447426|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
16447427|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
16447428|NCT03653468|No Intervention|Control group|No-exercise
16447429|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
16447430|NCT03653455|Experimental|Pre-operative discussion group|At a pre-operative visit, patients and their care provider will discuss what assigned surveys are and why they are important. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
16447431|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
16447432|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
16447433|NCT03653455|Experimental|control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
16447434|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
16447436|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
16447437|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
16447438|NCT03653403|Experimental|IDP-126 Gel|Component A
16447439|NCT03653403|Active Comparator|Control Gel|Gel
16447440|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
16447441|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
16447442|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
16447443|NCT03653377||Patients with self-administered questionnaire|
16447444|NCT03653364|Experimental|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
16447445|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
16447446|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
16447447|NCT03653338|Experimental|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.
~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
16447448|NCT03653325|Experimental|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:
~Interventional arm (FiO2 adaptation every 2-3 min) :
~ORI >0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.2 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.1 ORI >0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1
~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
16447449|NCT03653325|Active Comparator|Observational arm|"Observational arm (adaptation every 2-3 min):
~oxygen saturation measurement SatO2>98% and FiO2>0.5 reduction of FiO2 by 0.1 SatO2>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1"
16447450|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.
~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
16447451|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
16447452|NCT03653299|Experimental|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
16447453|NCT03653299|Experimental|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
16447454|NCT03653299|Experimental|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
16447455|NCT03653299|Experimental|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
16447456|NCT03653286|Experimental|NMES and Run|NMES and run
16447457|NCT03653286|Other|Only Run|Only Run
16447458|NCT03653273|Experimental|DMT withdrawal|DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
16447459|NCT03653273|Active Comparator|DMT continuation|The previously established therapy will be continued at the same dose during two years.
16447460|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
16447461|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
16447462|NCT03653247|Experimental|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
16447463|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
16447464|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
16447465|NCT03653221|Experimental|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
16447466|NCT03653221|Placebo Comparator|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
16447467|NCT03653208|Experimental|Group 1 (hzVSF-v13 10mg)|Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
16447470|NCT03653208|Experimental|Group 4 (hzVSF-v13 100mg)|Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
16447471|NCT03653208|Experimental|Group 5 (hzVSF-v13 200mg)|Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
16447472|NCT03653208|Experimental|Group 6 (hzVSF-v13 400mg)|Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
16447473|NCT03653208|Experimental|Group 7 (hzVSF-v13 800mg)|Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
16447474|NCT03653208|Experimental|Group 8 (hzVSF-v13 1200mg)|Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
16447475|NCT03653208|Placebo Comparator|Placebo|Placebo group received a single placebo on Day 1.
16447476|NCT03653195|Other|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
16447477|NCT03653195|Active Comparator|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
16447478|NCT03653182||normal|A normal constitution condition in TCM.
16447479|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
16447480|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
16447481|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
16447482|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
16447483|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
16447484|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
16447485|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
16447486|NCT03653182||Special|One of an abnormal constitution condition in TCM.
16447487|NCT03653169|Experimental|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
16447488|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
16447489|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
16447490|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
16447491|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
16447492|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
16447493|NCT03653156||Non-Alzheimer degenerative dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
16447494|NCT03653143|Experimental|Treatment Group|Assessment #1 Baseline Visit >> 3 month JASPER intervention (weekly) >> Assessment #2 Research Visit >> 3 month treatment as usual >> Assessment #3 Research Visit
16447495|NCT03653143|Experimental|Control/Wait-list Group|Assessment #1 Baseline Visit >> 3 month treatment as usual >> Assessment #2 Research Visit >> 3 month JASPER intervention >> Assessment #3 Research Visit
16447496|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
16447497|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
16447498|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
16447499|NCT03653117|Experimental|TPLA|TPLA procedure
16447500|NCT03653104|Experimental|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
16447501|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
16447502|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
16447503|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
16447504|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
16447505|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
16447506|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
16447507|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
16447603|NCT03652363|Placebo Comparator|Placebo|Placebo administered via convection enhanced delivery
16447508|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
16447509|NCT03653039|Experimental|Tritube|
16447510|NCT03653039|Active Comparator|Standard endotracheal tube|
16447511|NCT03653026|Experimental|Upadacitinib|Administered once daily (QD)
16447512|NCT03653026|Experimental|Placebo|Administered once daily (QD)
16447513|NCT03653013|Active Comparator|Control Group|Usual standard of care from their diabetes care team
16447514|NCT03653013|Experimental|Neuropsychological Consultation Group|Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
16447515|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
16447516|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Drug: sodium valproate with Clozapine"
16447517|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
16447518|NCT03652974|Experimental|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Drug: amisulpride with Clozapine"
16447519|NCT03652974|Placebo Comparator|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Drug: placebo with Clozapine"
16447520|NCT03652961|Other|Open Label|Open Label abatacept for Intravenous Infusion Abatacept intravenous will be administered as a 30-minute intravenous infusion utilizing the weight range-based dosing. Following the initial intravenous administration, an intravenous infusion will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for a total of 7 doses.
16447521|NCT03652948|Experimental|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.
~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
16447522|NCT03652935|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
16447523|NCT03652935|Active Comparator|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
16447524|NCT03652922|Experimental|Propranolol|
16447525|NCT03652922|Placebo Comparator|Placebo|
16447526|NCT03652909||PSAD|Patients try the personal sound amplification device.
16447527|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
16447528|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
16447529|NCT03652883|Experimental|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
16447530|NCT03652883|Active Comparator|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
16447531|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
16447532|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
16448618|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
16447533|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
16447534|NCT03652857|Experimental|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
16447535|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
16447536|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
16447537|NCT03652831|Active Comparator|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.
~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
16447538|NCT03652831|Active Comparator|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.
~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
16447539|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;
~Post-op Placebo 1;
~Post-op Placebo 2"
16447540|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;
~Post-op Placebo 2;
~Post-op acetaminophen."
16447541|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;
~Post-op pregabalin;
~Post-op Placebo 2."
16447542|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;
~Post-op pregabalin
~Post-op acetaminophen."
16447543|NCT03652818|Experimental|Group E|"Pre-op pregabalin;
~Post-op Placebo 1;
~Post-op acetaminophen."
16447544|NCT03652805|Experimental|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
16447545|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
16447546|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
16447547|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
16447548|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
16447549|NCT03652779|Experimental|Tecarfarin 10mg|
16447550|NCT03652779|Experimental|Tecarfarin 20mg|
16447551|NCT03652779|Experimental|Tecarfarin 30mg|
16447552|NCT03652779|Experimental|Tecarfarin 40mg|
16447553|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
16447554|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
16447555|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
16447556|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
16447557|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
16447558|NCT03652727|Experimental|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance [Site~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)]
16447559|NCT03652727|Active Comparator|FX Guidance|PICC insertion using fluoroscopic guidance
16447560|NCT03652714|Experimental|Local anesthetic|
16447561|NCT03652714|Placebo Comparator|Isotonic NaCl|
16447562|NCT03652701|Experimental|Hair Up|
16447563|NCT03652701|Placebo Comparator|Placebo|
16447564|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
16447565|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
16447566|NCT03652675|Experimental|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
16447567|NCT03652675|No Intervention|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
16447568|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:
~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
16447569|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:
~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
16447570|NCT03652649|Experimental|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet
16447571|NCT03652636|Other|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
16447572|NCT03652623|Experimental|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
16447573|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
16447574|NCT03652610|Active Comparator|ACWY Group|Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
16447575|NCT03652597|Active Comparator|Left|Subjects are ascribed to left hemispheric stimulation
16447576|NCT03652597|Active Comparator|Right|Subjects are ascribed to right hemispheric stimulation
16447577|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
16447578|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
16447579|NCT03652571|Experimental|Nortriptyline|"Nortriptyline in an escalating dose regimen:
~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
16447580|NCT03652571|Placebo Comparator|Placebo|Placebo
16447581|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
16447582|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
16447583|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.
~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2
~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.
~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.
~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
16447584|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
16447585|NCT03652532|Experimental|Alternate Day Fasting|
16447586|NCT03652532|Experimental|Exercise|
16447587|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
16447588|NCT03652519|Experimental|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x one-and-a-half Minute high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 minutes with the aim to achieve 60% HRmax.
16447589|NCT03652519|Active Comparator|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
16447590|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
16447591|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
16447592|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
16447593|NCT03652493|Experimental|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
16447594|NCT03652467|Experimental|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
16447595|NCT03652467|Active Comparator|Conventional TACE|Patients are treated with conventional TACE.
16447596|NCT03652454|Experimental|micro-osteoperforation|Propel device (ABD)
16447597|NCT03652454|Other|conventional treatment|conventional fixed appliance treatment
16447598|NCT03652441|Experimental|Maintenance|Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
16447599|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:
~Gemcitabine + nab-paclitaxel:
~• Administered per institutional standard every 7 days for 3 weeks
~Part II:
~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.
~Part III:
~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy
~OR
~Chemo per discretion of MD if not resectable"
16447600|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
16447601|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
16447602|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
16447604|NCT03652363|Experimental|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
16447605|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
16447606|NCT03652337|Experimental|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
16447607|NCT03652337|Experimental|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
16447608|NCT03652324|Other|randomized|
16447609|NCT03652311|Experimental|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
16447610|NCT03652311|Sham Comparator|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
16447611|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
16447612|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
16447613|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
16447614|NCT03652272|Experimental|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:
~Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks
~Patients will receive a Medication Guide + Summary with their After Visit Summary
~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)
~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
16447615|NCT03652272|No Intervention|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
16447616|NCT03652259|Experimental|Cohort 1: SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.
16447617|NCT03652259|Experimental|Cohort 2: SRP-9003|Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.
16447618|NCT03652233|Experimental|Afatinib and Nivolumab|
16447619|NCT03652220|Experimental|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation
~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
16447620|NCT03652220|Active Comparator|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment
~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
16447621|NCT03652220|Active Comparator|Control 2|"Definitions 24 weeks Multimodal specific treatment
~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
16447622|NCT03652207|Placebo Comparator|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
16447623|NCT03652207|Experimental|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
16447624|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
16447625|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
16447626|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
16447628|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
16447629|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
16447630|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
16449473|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
16447631|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.
~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
16447632|NCT03652129|Experimental|Laser Group|Disinfection using biostimulating LASER
16447633|NCT03652129|Experimental|Nano irrigant Group|Disinfection using Nano irrigant
16447634|NCT03652129|Active Comparator|Conventional irrigation protocol group|disinfection using normal irrigation protocols
16447635|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
16447636|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
16447637|NCT03652103|No Intervention|GCont|Only dressing will be applied to patients without actually nerve catheter performed
16447638|NCT03652103|Experimental|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution* will be administered initially.
~20 ml Bupivacaine %0.25 Injectable Solution** will be administered 30 minutes before ambulation at postoperative day(POD) 0 and before removal of nephrostomy at POD 2
~*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
16447639|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
16447640|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
16447641|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
16447642|NCT03652077|Experimental|INCAGN02390|
16447643|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
16447644|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
16447649|NCT03652038|Experimental|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
16447650|NCT03652038|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
16447651|NCT03652038|Experimental|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
16447652|NCT03652038|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
16447653|NCT03652038|Experimental|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
16447654|NCT03652038|Placebo Comparator|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
16447655|NCT03652025|Experimental|Study group|perimenopausal women
16447656|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.
~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
16447657|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.
~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
16447658|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
16447659|NCT03651999||control|"No dream workshop"
16447660|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
16449474|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
16447661|NCT03651973|Experimental|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
16447662|NCT03651973|Other|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
16447663|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
16447664|NCT03651947|Experimental|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
16447665|NCT03651947|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
16447666|NCT03651934|Experimental|Normal iron|
16447667|NCT03651934|Experimental|Weak iron|
16447668|NCT03651934|Experimental|Normal selenium|
16447669|NCT03651934|Experimental|Weak selenium|
16447670|NCT03651921|No Intervention|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
16447671|NCT03651921|Experimental|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
16447672|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
16447673|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
16447674|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
16447675|NCT03651895|Placebo Comparator|Placebo Group|Placebo
16447676|NCT03651882|Active Comparator|Oxytocin|
16447677|NCT03651882|Active Comparator|Carbetocin|
16447678|NCT03651869|Experimental|Condition 1|
16447679|NCT03651869|Experimental|Condition 2|
16447680|NCT03651869|Experimental|Condition 3|
16447681|NCT03651869|Experimental|Condition 4|
16447682|NCT03651856|Experimental|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
16447683|NCT03651843||Healthy subjects|
16447684|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
16447685|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
16447686|NCT03651817|Active Comparator|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
16447687|NCT03651817|Active Comparator|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
16447688|NCT03651804|Active Comparator|Control Group|"The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks."
16447689|NCT03651804|Active Comparator|Treatment Group|The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
16447690|NCT03651804|Active Comparator|Crossover Group|This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.
16447691|NCT03651791|Experimental|USPIO labeled MSC injection|USPIO labeled MSC injection
16447692|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
16447693|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
16447694|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect during their knee classes at the Holland Centre
16447695|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:
~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
16447696|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:
~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
16447697|NCT03651713|Experimental|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
16447698|NCT03651713|Active Comparator|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
16447699|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
16447725|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
16447700|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
16447701|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
16447702|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
16447703|NCT03651661|Active Comparator|nasal insulin|160 U of human insulin as nasal spray
16447704|NCT03651661|Placebo Comparator|nasal placebo|placebo as nasal spray
16447705|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
16447706|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
16447707|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
16447708|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
16447709|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
16447710|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
16447711|NCT03651609|Experimental|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
16447712|NCT03651609|Active Comparator|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
16447713|NCT03651609|Experimental|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
16447714|NCT03651609|Active Comparator|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
16447715|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
16447716|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
16447717|NCT03651583|Other|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
16447718|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
16447719|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
16447720|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
16447721|NCT03651557|Experimental|Neu2000KWL high dose|
16447722|NCT03651557|Experimental|Neu2000KWL low dose|
16447723|NCT03651557|Placebo Comparator|saline|
16447724|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
16447835|NCT03650907|Experimental|Group exercise program by coach|
16447726|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
16447727|NCT03651531|Active Comparator|insulin|
16447728|NCT03651531|Active Comparator|insulin and metformin|
16447729|NCT03651518|Experimental|Kineret|
16447730|NCT03651518|Experimental|Humira|
16447731|NCT03651518|Experimental|Stelara|
16447732|NCT03651518|Experimental|Cosentyx|
16447733|NCT03651518|Experimental|Roactemra|
16447734|NCT03651518|Experimental|Rituximab|
16447735|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
16447736|NCT03651505||Not from Prior Burosumab Clinical Trial|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
16447737|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
16447738|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
16447739|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
16447740|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
16447741|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
16447742|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
16447743|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
16447744|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
16447745|NCT03651453|Active Comparator|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
16447746|NCT03651453|Experimental|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
16447747|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
16447748|NCT03651440|Experimental|PNF training|PNF training exercises
16447749|NCT03651440|Experimental|physical therapy|HP,TENS US
16447750|NCT03651440|Sham Comparator|control|NO APPLİCATİON
16447751|NCT03651427|Experimental|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.
~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.
~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
16447752|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
16447753|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
16447754|NCT03651401||Subacromial impingement syndrome|Participants were assessed for SME, pain (rest, activity, night, measurement), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
16447755|NCT03651401||partial rotator cuff tears|Participants were assessed for SME, pain (rest, activity, night, measurement), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
16447756|NCT03651401||age gender matched healthy controls|Participants were assessed for SME, shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
16447757|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
16447758|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
16447759|NCT03651375|Experimental|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
16447760|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447761|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447762|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447763|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447764|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447765|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447766|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447767|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
16447768|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
16447769|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
16447836|NCT03650907|Sham Comparator|Self exercise|
16447770|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
16447771|NCT03651297|Experimental|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
16447772|NCT03651297|Experimental|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
16447773|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
16447774|NCT03651284|Other|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
16447775|NCT03651271|Experimental|"Hot tumors for Advanced Metastatic Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
16447776|NCT03651271|Experimental|"Cold tumors for Advanced Metastatic Cancer"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
16447777|NCT03651271|Experimental|"Hot tumors for Advanced Prostate Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
16447778|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort A"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
16447779|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort B"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
16447780|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
16447781|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
16447782|NCT03651245||Participants with suspicion for Alpha-Mannosidosis|Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years
16447783|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
16447784|NCT03651232|Active Comparator|support|weekly group support class
16447785|NCT03651219|Experimental|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
16447786|NCT03651219|Active Comparator|controlled group|Patients use Irinotecan
16447787|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
16447788|NCT03651206|Experimental|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose
~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
16447789|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)
~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days
~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
16447790|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
16447791|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
16447792|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
16447793|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
16447794|NCT03651154|Experimental|Hypovolemic Phlebotomy|"Hypovolemic Phlebotomy will consist of the withdrawal of 7-10 mL/kg of whole blood from the patient, as tolerated (e.g. for a 70kg patient, 490 to 700 mL of whole blood will be removed) The volume of removed blood will not be replaced by the administration of intravenous fluids.
~Removed blood will be transfused back to participant at the end of surgery. The phlebotomized whole blood will be transfused back after liver transection regardless of blood loss."
16447795|NCT03651154|No Intervention|Control (Standard of Care)|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
16447796|NCT03651141|Experimental|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
16447797|NCT03651141|Experimental|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
16447798|NCT03651141|Sham Comparator|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
16447799|NCT03651128|Experimental|Arm A - Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
16447943|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
16447800|NCT03651128|Experimental|Arm B- standard regimens as per Investigator's discretion|"The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen:
~Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR
~DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR
~Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR
~Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR
~Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)"
16447801|NCT03651115||Neonates with gentamicin|
16447802|NCT03651115||Neonates with vancomycin|
16447803|NCT03651102|Experimental|Patients Receiving Thalidomide Therapy|All the study patients will be given thalidomide at an average dose of 2mg/kg/day (range 1-3mg/kg/day). The patients will be followed at 4 weeks interval by a haematologist for monitoring of potential side effects and for evaluation of clinical and laboratory response.
16447804|NCT03651089|Active Comparator|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
16447805|NCT03651089|Active Comparator|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
16447806|NCT03651089|Active Comparator|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
16447807|NCT03651089|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
16447808|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
16447809|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
16447810|NCT03651063|Experimental|social robot group|
16447811|NCT03651063|Active Comparator|computer group|
16447812|NCT03651063|Active Comparator|self-training group|
16447813|NCT03651063|No Intervention|contro: no intervention|This group will only be a follow up: clinical examination at the entrance and follow 5 weeks with clinical examination 5 weeks post, with no intervention.
16447814|NCT03651050|Experimental|intervention FBOs receive the P-MHDT|
16447815|NCT03651050|Experimental|control FBOs receive no P-MHDT|
16447816|NCT03651037|Experimental|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
16447817|NCT03651037|Experimental|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
16447818|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
16447819|NCT03651011|Active Comparator|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
16447820|NCT03651011|Active Comparator|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
16447821|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.
~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
16447822|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.
~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
16447823|NCT03650985|Experimental|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
16447824|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
16447825|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
16447826|NCT03650959|Experimental|Faculty-led|
16447827|NCT03650959|Experimental|Peer tutor-led|
16447828|NCT03650959|Experimental|Computer augmented self-directed learning|
16447829|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
16447830|NCT03650946||2|men with rising PSA after local definitive treatments
16447831|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
16447832|NCT03650933|Experimental|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
16447833|NCT03650933|Active Comparator|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
16447834|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
16447837|NCT03650894|Experimental|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
16447838|NCT03650881|Experimental|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
16447839|NCT03650881|Active Comparator|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
16447840|NCT03650868|No Intervention|Control Group|No intervention will be applied to control group
16447841|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
16447842|NCT03650842|Experimental|Laparoscopic pyloromyotomy|Infants undergoing laparoscopic pyloromyotomy.
16447843|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)
~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
16447844|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.
~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
16447845|NCT03650803|Experimental|3D MR Fingerprinting scan|Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.
16447846|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
16447847|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
16447848|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
16447849|NCT03650764|Experimental|Phase I: Ramucirumab + Pembrolizumab|-Ramucirumab will be administered IV over 1 hour on Day 1 of each 21-day cycle. Pembrolizumab will be administered as per standard of care (IV at a dose of 200 mg over 30 minutes on Day 1 of each 21-day cycle). On Day 1, pembrolizumab will be given after ramucirumab.
16447850|NCT03650764|Experimental|Phase II: Ramucirumab + Pembrolizumab|-Patients will be treated with ramucirumab at the RP2D on Day 1 and SOC pembrolizumab (200 mg IV over 30 minutes) on Day 1 of each 21-day cycle.
16447851|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
16447852|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
16447855|NCT03650712|Other|frequently sampled oral glucose tolerance testing|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit
16447856|NCT03650712|Other|Frequently sampled oral glucose tolerance testing anc CGM|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back
16447857|NCT03650712|Other|frequently sampled oral glucose tolerance testing and DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + a DXA scan will be done at the same visit
16447858|NCT03650712|Other|frequently sampled oral glucose tolerance testing, CGM & DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back + a DXA scan will be done at the same visit
16447859|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.
~Assessments will be taken during the beginning, middle, and end of each study arm."
16447860|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.
~Assessments will be taken during the beginning, middle, and end of each study arm."
16447861|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
16447862|NCT03650660||Patients with liver cirrhosis|
16449551|NCT03639012|No Intervention|No Carbohydrate loading|Current standard of care
16447863|NCT03650647|Active Comparator|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.
~Intervention: Total soft and leathery caries removal. Carious dentin removal"
16447864|NCT03650647|Experimental|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.
~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
16447865|NCT03650647|Experimental|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.
~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
16447866|NCT03650621|Experimental|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.
~Total duration of study 2.5-3 hours"
16447867|NCT03650621|Placebo Comparator|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.
~Total duration of study 2.5-3 hours"
16447868|NCT03650608|Experimental|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
16447869|NCT03650608|Experimental|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
16447870|NCT03650608|Experimental|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
16447871|NCT03650608|Placebo Comparator|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
16447872|NCT03650595|Experimental|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
16447873|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
16447874|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
16447875|NCT03650556|Experimental|Ablation|Pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the persistent AF population.
16447876|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
16447877|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 *1/*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 *1/*2 or *1/*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 *2/*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
16447878|NCT03650530|Experimental|The Family Talk Intervention|These families will participate in a psychosocial support program.
16447879|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.
~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
16447880|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.
~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
16447881|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.
~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
16447882|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.
~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
16447883|NCT03650504|Experimental|Above Artery Group|
16447884|NCT03650504|Active Comparator|Between Artery and Vein Group|
16447885|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
16447886|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
16447887|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
16447888|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
16447889|NCT03650465|Experimental|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck & Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
16447890|NCT03650465|Experimental|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden & DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
16447891|NCT03650465|Experimental|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
16447892|NCT03650452|Placebo Comparator|Placebo|TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
16447893|NCT03650452|Experimental|TAK-935|TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
16447894|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
16447895|NCT03650426|Experimental|Inlay patellar resurfacing technique|
16447896|NCT03650413|Experimental|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
16447897|NCT03650400|Experimental|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
16447898|NCT03650400|Experimental|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
16447899|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
16447900|NCT03650374|Active Comparator|Group 1|standard of care postoperative rehabilitation.
16447901|NCT03650374|Experimental|Group 2|experimental strength training
16447902|NCT03650361|Experimental|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
16447903|NCT03650361|Active Comparator|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
16447904|NCT03650361|Placebo Comparator|Placebo Control|Vehicle of the test product, applied for 84 days
16447905|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
16447906|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
16447907|NCT03650335||group II|with a total of 30 mL 0.25% bupivacaine injection to be administered
16447908|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
16447909|NCT03650322|Active Comparator|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
16447910|NCT03650322|Experimental|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
16447911|NCT03650309|Experimental|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
16447912|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
16447913|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
16447914|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
16447915|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
16447916|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
16447944|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
16447945|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
16447917|NCT03650257|Experimental|gp96 group|"Patients receive standard treatment with radiation and temozolomide after surgery.
~Then 6 times of autologous gp96 vaccination are administered via subcutaneous injection in 25μg doses at the 2nd week after the end of postoperative radiotherapy.
~( gp96 is administered once a week for the first 4 weeks, the 5th injection is administered 2 weeks after the 4th injection, and the 6th injection is administered 3 weeks after the 5th injection. )
~The first adjunctive temozolomide startes on the day of the fifth gp96 injection.
~(150-200 mg/m2/day for 5 days, then stop for 23 days, one cycle is 28 days for a total of 6 cycles)"
16447918|NCT03650257|Active Comparator|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
16447919|NCT03650244||Patients fitted with REMEEX|
16447920|NCT03650218|Experimental|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)
~THIODERM STRONG injected into nasolabial folds (cohort 2)"
16447921|NCT03650205|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
16447922|NCT03650205|Placebo Comparator|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
16447923|NCT03650192|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
16447924|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
16447925|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
16447926|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
16447927|NCT03650153|Active Comparator|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
16447928|NCT03650153|Active Comparator|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
16447929|NCT03650140|Active Comparator|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
16447930|NCT03650140|Active Comparator|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
16447931|NCT03650114|Experimental|Ofatumumab|Subcutaneous injection
16447932|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
16447933|NCT03650075|Placebo Comparator|Single Ascending Dose (SAD)|
16447934|NCT03650075|Placebo Comparator|Multiple Ascending Dose (MAD)|
16447935|NCT03650075|Experimental|Food Effect Part|
16447936|NCT03650036|Experimental|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
16447937|NCT03650036|Experimental|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
16447938|NCT03650023|Experimental|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
16447939|NCT03650023|Placebo Comparator|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
16447940|NCT03649997|Experimental|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
16447941|NCT03649997|Experimental|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
16447942|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
16448275|NCT03647813|Placebo Comparator|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
16447946|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
16447947|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
16447948|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
16447949|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
16447950|NCT03649997|Experimental|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
16447951|NCT03649997|Experimental|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
16447952|NCT03649984|Experimental|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
16447953|NCT03649984|No Intervention|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
16447954|NCT03649971|Experimental|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
16447955|NCT03649971|Experimental|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
16447956|NCT03649971|Placebo Comparator|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
16447957|NCT03649958|Active Comparator|HIRREM-SOP|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time..
16447958|NCT03649958|Placebo Comparator|random notes|Participants randomized to the control will be seated in a comfortable zero-gravity chair identical to those in the active arm, and will also listen to a pattern of musical notes, but they will be random, and not linked to their brain activity patterns.
16447959|NCT03649945|Active Comparator|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
16447960|NCT03649945|Active Comparator|Test Group 2|Docetaxel plus Nedaplatin
16447961|NCT03649945|No Intervention|Control Group|No medicine intervention
16447965|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
16447966|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
16447967|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
16447968|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
16447969|NCT03649906|Experimental|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
16447970|NCT03649893|No Intervention|Control Group|The control group will use conventional siiting-desk office.
16447971|NCT03649893|Experimental|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
16448009|NCT03649633|Experimental|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
16447972|NCT03649880|Experimental|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive ¹⁸F-fluoromisonidazole IV and 1.5 - 2 hours later undergo PET (Positron Emission Tomography) /CT (Computed Tomography) or PET/MRI (Magnetic Resonance Imaging) over 20-40 minutes and a retest examination within 7 days. Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks.
16447973|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
16447974|NCT03649841|Active Comparator|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
16447975|NCT03649841|Experimental|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
16447976|NCT03649828|Experimental|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
16447977|NCT03649828|Experimental|control group|control group (CG) that received only curd
16447978|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
16447979|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
16447980|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
16447981|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
16447982|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
16447983|NCT03649763|Active Comparator|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
16447984|NCT03649763|Active Comparator|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
16447985|NCT03649763|Active Comparator|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
16447986|NCT03649763|Active Comparator|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
16447987|NCT03649750|Experimental|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
16447988|NCT03649750|Experimental|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
16447989|NCT03649737|Experimental|Supportive care (exercise)|Participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. Participants also attend home-based unsupervised exercise sessions via an instructional DVD once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.
16447990|NCT03649724|Placebo Comparator|Placebo|0.25 ml of sterile normal saline administered subcutaneously / 12 weeks
16447991|NCT03649724|Experimental|Leuprolide|Eligard 22.5mg administered subcutaneously / 12 weeks
16447992|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
16447993|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
16447994|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
16447995|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
16447996|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
16447997|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
16447998|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
16447999|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
16448000|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
16448001|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
16448002|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
16448003|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
16448004|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
16448005|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
16448006|NCT03649659|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
16448007|NCT03649659|Placebo Comparator|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
16448008|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
16450559|NCT03632057|Active Comparator|Fixed Pulse Width|This is the Study group.
16448010|NCT03649633|Placebo Comparator|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
16448011|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
16448012|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
16448013|NCT03649607|Other|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
16448014|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
16448015|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
16448016|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
16448017|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
16448018|NCT03649581|Active Comparator|healthy volunteers|
16448019|NCT03649568|Experimental|Pork|1 ounce lean pork
16448020|NCT03649568|Active Comparator|Egg|1 large whole egg
16448021|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
16448022|NCT03649568|Experimental|Almonds|1 ounce almonds
16448023|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
16448024|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
16448025|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
16448026|NCT03649529|Experimental|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
16448027|NCT03649516|Experimental|iCKD APP Group|Use iCKD APP
16448028|NCT03649516|No Intervention|Traditional Care Group|Accept traditional care
16448029|NCT03649490||Smooth PEEK Interbody Implants in XLIF|Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth. Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence. Additionally, lordotic profiles are available to induce proper sagittal alignment.
16448030|NCT03649490||3D-Printed Titanium Interbody Implants in XLIF|3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging. The advanced microporous surface topography creates an ideal environment for bone in-growth.
16448031|NCT03649490||Porous PEEK Interbody Implants in XLIF|Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants. The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
16448032|NCT03649477|Placebo Comparator|Placebo|matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
16448033|NCT03649477|Experimental|3.2 mg of LV-101|3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
16448034|NCT03649477|Experimental|9.6 mg of LV-101|9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
16448035|NCT03649464|Experimental|OKN-007|Oral OKN-007
16448036|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
16448037|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
16448038|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
16448039|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
16448040|NCT03649399|Experimental|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
16448041|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
16448042|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
16448043|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
16448044|NCT03649347|Experimental|AR therapy intervention for spider phobia|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
16448045|NCT03649347|No Intervention|No treatment control group for spider phobia|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (1 months).
16448100|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
16448046|NCT03649347|Experimental|AR therapy intervention for fear of snakes|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
16448047|NCT03649347|No Intervention|No treatment control group for fear of snakes|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (1 months).
16448048|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
16448049|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
16448053|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
16448054|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
16448055|NCT03649295|Experimental|Functional Electrical Stimulation|"- Functional electrical stimulation device obeying the following steps: Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure. Conventional therapy should be performed in conjunction with functional electrostimulation
~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
16448056|NCT03649295|Placebo Comparator|Placebo|"Sham.The electrodes are placed at 0 Hz
~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
16448057|NCT03649282|Experimental|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
16448058|NCT03649282|Experimental|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
16448059|NCT03649269|Experimental|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
16448060|NCT03649269|Active Comparator|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
16448061|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
16448062|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
16448063|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
16448064|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
16448065|NCT03649217|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
16448066|NCT03649204|Experimental|HY-PAD|"People in the HY-PAD group will participate in the clinical on-site therapist-supervised exercise (3 times/week for weeks 1-4).
~At the end of week 4, participants in the HY-PAD group will receive an updated home exercise prescription for the duration of the program (weeks 5-12), following the same principles as above. The therapist will call the participants once a week (15min/call) for weeks 5-12."
16448067|NCT03649204|No Intervention|Wait List Control (WLC)|Participants assigned to the WLC will continue their usual care for the next 12 weeks. After completion of the 3-month follow-up data gathering, WLC participants will be offered the clinical PAD walking program.
16448068|NCT03649191|Other|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
16448069|NCT03649191|Other|Control ACP Group|Control group Advance Care Planning
16448070|NCT03649178|Other|low salt diet|low-sodium diet (50mmol/24hours x 8 weeks ) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
16448071|NCT03649178|Other|high salt diet|high-sodium diet (200mmol/24hours x 8weeks) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
16448072|NCT03649165|Experimental|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
16448073|NCT03649165|Experimental|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
16448074|NCT03649165|Experimental|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
16448075|NCT03649165|Experimental|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
16448076|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
16448077|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
16448078|NCT03649139|Active Comparator|artemisia annua (sweet sagewort) allergen extract drops|Drug: sublingual immunotherapy drops
16448079|NCT03649139|Placebo Comparator|Placebo drops|Drug: sublingual placebo drops
16448080|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
16448081|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
16448082|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
16448083|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
16448084|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
16448085|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
16448086|NCT03649113|Experimental|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
16448087|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
16448088|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
16448089|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
16448090|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
16448091|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
16448092|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
16448093|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
16448094|NCT03649009|Placebo Comparator|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.
~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
16448095|NCT03649009|Active Comparator|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.
~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
16448096|NCT03648996|Experimental|Low-fructose diet, isocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.
16448097|NCT03648996|Experimental|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)
16448098|NCT03648996|Placebo Comparator|Placebo|Subjects assigned to this arm will receive placebo
16448099|NCT03648996|Experimental|Low-fructose diet, hypocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.
16450589|NCT03631823||Healthy volunteer group|The volunteers for control group
16448101|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
16448102|NCT03648970|Experimental|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
16448103|NCT03648970|No Intervention|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
16448104|NCT03648957|Experimental|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
16448105|NCT03648957|Active Comparator|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
16448106|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
16448107|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
16448108|NCT03648931||Pregnant or Breastfeeding Women|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
16448109|NCT03648931||Male Partners|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
16448110|NCT03648931||Grandmothers|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
16448111|NCT03648931||Key Informants|No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures.
16448112|NCT03648905|Active Comparator|Control patients (iatrogenic CAF)|Patients with iatrogenic chronic autonomic failure (CAF) (e.g., status-post cardiac transplantation, pre/post renal sympathetic ablation, pre/post bilateral thoracic sympathectomies)
16448113|NCT03648905|Active Comparator|Control patients (PD No OH)|Patients with Parkinson's disease (PD) without orthostatic hypotension (PD no OH)
16448114|NCT03648905|Active Comparator|Healthy Volunteers|Despiramine
16448115|NCT03648905|Active Comparator|Healthy Volunteers as Controls|Healthy Volunteers
16448116|NCT03648905|Experimental|Healthy Volunteers with genetic risk of PD|Healthy Volunteers with genetic risk of PD
16448117|NCT03648905|Experimental|Patients with neurodegenerative chronic autonomic failure (CAF|Includes patients with orthostatic hypotension (OH) due to sympathetic neurocirculatory failure (nOH), and people with multiple system atrophy (MSA).
16448118|NCT03648892|Other|1|Healthy Volunteers with a BMI greater than or equal to 18.5 kg/m^2 and less than 25 kg/m^2
16448119|NCT03648892|Other|2|Healthy Volunteers with a BMI greater than or equal to 25 kg/m^2 and less than 35 kg/m^2
16448120|NCT03648892|Other|3|Healthy Volunteers with a BMI greater than or equal to 35 kg/m^2
16448121|NCT03648879|Experimental|1/Arm 1 - Upper white-light endoscopy and confocal endoscopic microscopy|Upper white-light endoscopy and confocal endoscopic microscopy
16448122|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
16448123|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
16448124|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
16448125|NCT03648866||Patients|interview patients who have participated in compassion rounds
16448126|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
16448127|NCT03648853|Experimental|intervention|all participants receive the same intervention
16448128|NCT03648840|Other|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
16448129|NCT03648840|Other|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
16448130|NCT03648840|Other|Resting state connectivity|Some participants will also complete a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All participants in this Arm will have completed both of the iv alcohol self-administration sessions (Aversive cue, Neutral cue).
16448131|NCT03648827|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
16448132|NCT03648814|Experimental|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
16448133|NCT03648814|Experimental|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
16448134|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
16448135|NCT03648762|Other|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
16448136|NCT03648749|Experimental|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
16448137|NCT03648736||HOCM patients|selected for routine TASH procedure
16448138|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
16448139|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
16448170|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
16448140|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
16448141|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
16448142|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
16448143|NCT03648697|Experimental|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.
~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
16448144|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
16448145|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
16448146|NCT03648684|No Intervention|Control|
16448147|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
16448148|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
16448149|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
16448150|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
16448151|NCT03648658|Experimental|Paracetamol 15mg/kg|
16448152|NCT03648645|Experimental|AH Telemonitoring|Self measurement of blood pressure
16448153|NCT03648632|Experimental|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
16448154|NCT03648619|Other|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
16448155|NCT03648593|Experimental|behavioral|work recovery intervention
16448156|NCT03648593|Experimental|waiting list control|work recovery intervention after 6 months
16448157|NCT03648580|Experimental|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
16448158|NCT03648580|Other|Control group|just give the verbal nutrition education.
16448159|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
16448160|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
16448162|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
16448163|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
16448164|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.
~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
16448165|NCT03648502|Experimental|dementia (D-HI)|hearing impaired dementia
16448166|NCT03648502|Other|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
16448167|NCT03648502|Active Comparator|normal (N-HI)|normal cognition with hearing loss
16448168|NCT03648489|Active Comparator|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
16448169|NCT03648489|Experimental|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
16448171|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
16448172|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
16448173|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
16448174|NCT03648450||Hailie Smart Inhaler EMD|All enrolled participants will be given the Hailie Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
16448175|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
16448176|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
16448177|NCT03648437|Experimental|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
16448178|NCT03648437|Placebo Comparator|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
16448179|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
16448180|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
16448181|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
16448182|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
16448183|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
16448184|NCT03648385|Experimental|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
16448185|NCT03648385|Placebo Comparator|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
16448186|NCT03648372|Experimental|Phase 1, Dose Escalation Cohort: TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. If clinical safety, pharmacokinetics, and pharmacodynamics are supportive, the dosing schedule may be modified to evaluate a less intensive administration of TAK-981 on Day 1, or Days 1 and 8, or Day 1, Day 8, and Day 15 in 21-day cycles in participants with advanced or metastatic solid tumors or lymphomas. Dose levels will be escalated based on the Bayesian logistic regression modeling (BLRM). The dose escalation phase will determine the RP2D of TAK-981.
16448187|NCT03648372|Experimental|Phase 2, Cohort A: Nonsquamous NSCLC|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with nonsquamous non-small cell lung cancer (NSCLC).
16448188|NCT03648372|Experimental|Phase 2, Cohort B: Cervical Cancer|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with cervical cancer.
16448189|NCT03648372|Experimental|Phase 2, Cohort C: MSS-CRC|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with microsatellite-stable colorectal cancer (MSS-CRC).
16448190|NCT03648372|Experimental|Phase 2, Cohort D: r/r DLBCL after CAR T-cells therapy|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after prior chimeric antigen receptor (CAR) T-cells therapy.
16448191|NCT03648372|Experimental|Phase 2, Cohort E: r/r DLBCL without prior cellular therapy|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory DLBCL that have not received prior cellular therapy.
16448192|NCT03648372|Experimental|Phase 2, Cohort F: r/r Follicular Lymphoma|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory follicular lymphoma (FL).
16448193|NCT03648359|Other|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
16448194|NCT03648346|Experimental|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
16448195|NCT03648346|Experimental|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
16448196|NCT03648346|Placebo Comparator|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
16448197|NCT03648333|Experimental|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
16448198|NCT03648333|Active Comparator|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
16448199|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
16448276|NCT03647800|Experimental|PART 1 Dose Escalation - 10 dose cohorts|CD123 and CD3 epsilon bispecific antibody
16448200|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
16448201|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
16448202|NCT03648281||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
16448203|NCT03648268|Active Comparator|Active DLPFC rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC at 80% of active motor threshold.
16448204|NCT03648268|Sham Comparator|Sham DLPFC rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC
16448205|NCT03648268|Active Comparator|Active cerebellum rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum at 100% of active motor threshold.
16448206|NCT03648268|Sham Comparator|Sham cerebellum rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum
16448207|NCT03648242|Experimental|Interruptive Clinical Decision Support|
16448208|NCT03648229|Experimental|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
16448209|NCT03648229|Active Comparator|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
16448210|NCT03648229|Active Comparator|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
16448211|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
16448212|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
16448213|NCT03648203|Experimental|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
16448214|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.
~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
16448215|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
16448216|NCT03648177|Active Comparator|Treatment as Usual|"Active Comparator: (n=15) Treatment as Usual
~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
16448217|NCT03648177|Experimental|IPGT|"Experimental: IPGT (n=15) Integrated Psychosocial Group Treatment
~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
16448218|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
16448219|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
16448220|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
16448221|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
16448222|NCT03648125|Other|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :
~with artificial occlusal disturbance and
~without artificial occlusal disturbance"
16448223|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
16448277|NCT03647800|Experimental|PART 2 Dose expansion - 5 cohorts|90 patients, 18/cohort in 5 dose expansion cohorts, will receive the recommended dose of APVO436 determined from Part 1
16448278|NCT03647774|Experimental|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
16450939|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
16448224|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~These oat flakes were roasted at 150°C for 20 minutes.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
16448225|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
16448226|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
16448227|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.
~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
16448228|NCT03648099|Experimental|Labor Dance and music groups|"Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.
~The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
16448229|NCT03648099|No Intervention|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
16448230|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
16448231|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
16448232|NCT03648073|Experimental|Untreated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
16448233|NCT03648073|Experimental|Previously treated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
16448234|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
16448235|NCT03648047|Experimental|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
16448236|NCT03648047|Active Comparator|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
16448237|NCT03648034|Experimental|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
16448238|NCT03648034|Placebo Comparator|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
16448239|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
16448240|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
16448241|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
16448242|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
16448243|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
16448244|NCT03647995|Active Comparator|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
16448245|NCT03647995|Placebo Comparator|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
16448246|NCT03647982|Experimental|botulinum toxin 1U|
16448247|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
16448248|NCT03647982|Experimental|botulinum toxin 5U|
16448249|NCT03647982|Experimental|botulinum toxin 10U|
16448250|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
16448251|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
16448252|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab A/A1|"Nivolumab 240mg Flatdose i.v. d1 over 30 min every 2 weeks followed by Ipilimumab 1mg/kg i.v. d1 over 30 min every 6 weeks followed by FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
16448274|NCT03647813|Active Comparator|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
16448253|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab sequential A2|"3 cycles of induction chemotherapy with FOLFOX: FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks followed by immunotherapy consisting of: 4 administrations of Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks and 2 administrations of Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks
~Sequence as described may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision. After discontinuation of chemotherapy, immunotherapy will be continued consisting of:
~Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks until disease progression or inacceptable toxicity or end of study treatment."
16448254|NCT03647969|Active Comparator|mFOLFOX B|FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
16448255|NCT03647969|Experimental|FLOT/Nivolumab C|"Nivolumab 240mg Flatdose i.v. d1 every 2 weeks followed by FLOT: Docetaxel 50mg/², Oxaliplatin 85 mg/m², leucovorin 200 mg/m² on day 1 and fluorouracil 2600 mg/m² IV continuous infusion over 24 hours every 2 weeks until disease progression or inacceptable toxicity or end of study treatment. After completion or discontinuation of chemotherapy, immunotherapy may be continued consisting of: Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks Chemotherapy can also be administered per local standard."
16448256|NCT03647956|Experimental|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
16448257|NCT03647943|Experimental|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
16448258|NCT03647943|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
16448259|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
16448260|NCT03647930|No Intervention|Control|No MPH
16448261|NCT03647917|Experimental|Platelet Rich Plasma, Left face and hands|"Subjects will receive PRP on left half of face and saline solution on right half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of left hand and saline solution on dorsal part of right hand through injections via filler injection technique. Microneedling will not be performed on the hands.
~Injections will take place every 4 weeks for a total of 3 treatments."
16448262|NCT03647917|Experimental|Platelet Rich Plasma, Right face and hands|"Subjects will receive PRP on right half of face and saline solution on left half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of right hand and saline solution on dorsal part of left hand, through injections via filler injection technique. Microneedling will not be performed on the hands.
~Injections will take place every 4 weeks for a total of 3 treatments."
16448263|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
16448264|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
16448265|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.
~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
16448266|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
16448267|NCT03647865|Experimental|Patients need genioplasty|
16448268|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
16448269|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
16448270|NCT03647839|Experimental|Arm 1|Nivolumab and BNC105
16448271|NCT03647839|Experimental|Arm 2|Nivolumab and BBI-608
16448272|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.
~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
16448273|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.
~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
16451271|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
16448279|NCT03647774|No Intervention|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
16448280|NCT03647761|No Intervention|Control|Standard of care
16448281|NCT03647761|Experimental|Treatment|Tetra-grip applied
16448282|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
16448283|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.
~Sham Device, or Placebo."
16448284|NCT03647735|Experimental|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
16448285|NCT03647735|Active Comparator|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
16448286|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
16448287|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
16448288|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
16448289|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
16448290|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
16448291|NCT03647683|Experimental|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
16448292|NCT03647683|Experimental|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
16448293|NCT03647683|Experimental|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
16448294|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
16448295|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
16448296|NCT03647657|Experimental|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
16448297|NCT03647657|Experimental|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
16448298|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
16448299|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
16448300|NCT03647631||Patients affected to porocarcinoma|
16448301|NCT03647631||patients affected to porocarcinoma in our centre|
16448302|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
16448303|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
16448304|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
16448305|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
16448306|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
16451303|NCT03627065|Experimental|Parsaclisib|
16451304|NCT03627052|Experimental|Itacitinib|
16448307|NCT03647605|Experimental|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
16448308|NCT03647592||Cohorts 1|patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
16448309|NCT03647579|Active Comparator|midazolam plus ketamine|
16448310|NCT03647579|Active Comparator|dexmedetomidine plus ketamine|
16448311|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
16448312|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
16448313|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
16448314|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
16448315|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
16448316|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
16448317|NCT03647501|Active Comparator|3D-printed titanium cage|Subjects enrolled in this arm will have the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
16448318|NCT03647501|Active Comparator|Poly-ether-ether-ketone (PEEK) cage|Subjects enrolled in this arm will have the HonourTM poly-ether-ether-ketone (PEEK) cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
16448321|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfilled the inclusion criteria and none of the exclusion criteria were treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal was evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
16448322|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.
~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
16448323|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
16448324|NCT03647449|Experimental|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
16448325|NCT03647449|Experimental|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
16448326|NCT03647449|Experimental|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
16448327|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.
~Intervention:
~Comprehensive Geriatric Assesment (CGA). Both groups.
~CGA includes measuring of:
~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
16448349|NCT03647306|Experimental|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
16448350|NCT03647293|Active Comparator|Control Group|Neonates who underwent a peripherally inserted central catheter
16448351|NCT03647293|Active Comparator|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
16448328|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission
~Intervention:
~Comprehensive Geriatric Assesment (CGA). Both groups.
~CGA includes measuring of:
~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
16448329|NCT03647423|Experimental|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
16448330|NCT03647423|Active Comparator|Controlled Arm - Radiation|SBRT
16448331|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
16448332|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
16448333|NCT03647397|Experimental|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
16448334|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
16448335|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
16448336|NCT03647371|Other|Macintosh laryngoscope|direct laryngoscope - laryngoscope with Macintosh blade
16448337|NCT03647371|Other|McGrath videolaryngoscope|McGrath Videolaryngoscope
16448338|NCT03647358|Experimental|Lesion Dosimetry With Iodine-124|Pts will be administered 124I & undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In a set of 10 pts, consent will be sought to obtain additional PET/CT scans during the week of 131I therapy. In this study group, patients will receive an additional 4 to 7 mCi 124I tracer dose, alongside the 131I radioiodine therapy dose, for the purpose of imaging radioiodine lesional uptake during therapy. This will be the first study to compare the predicted lesion radiation absorbed doses in Gray derived from a pre-therapy test imaging dose to an imaging dose administered concomitant with 131I radioiodine therapy. Pts will be taken off-treatment on day 8, as days 9 & 10 are standard of care intervention. Subjects receiving RAI therapy may remain on-study & be followed for up to 1.5 years with standard of care anatomical imaging, or until they receive their next standard of care anatomical imaging (PET, CT, MRI, ultrasound) or are deemed lost to follow up by the study doctor.
16448339|NCT03647345|Experimental|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
16448340|NCT03647345|Experimental|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
16448341|NCT03647345|Active Comparator|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
16448342|NCT03647332|Active Comparator|Cooled RFA treatment|
16448343|NCT03647332|Active Comparator|Steroid injection|
16448344|NCT03647319|Experimental|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
16448345|NCT03647319|Experimental|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
16448346|NCT03647319|Active Comparator|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
16448347|NCT03647306|Active Comparator|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
16448348|NCT03647306|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
16448352|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
16448355|NCT03647254|Experimental|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
16448356|NCT03647254|No Intervention|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
16448357|NCT03647241|Experimental|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
16448358|NCT03647241|Experimental|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
16448359|NCT03647241|Active Comparator|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
16448360|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
16448361|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
16448362|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy. CML patients must meet the ELN criteria for warning and failure ) or have high SOKAL score (>0.8) or presence of additional chromosomal abnormalities (ACAs) and have detectable BCR-ABL levels. Ph+ALL patients need detectable BCR-ABL levels only.
16448363|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
16448364|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
16448365|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
16448366|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
16448367|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
16448368|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
16448369|NCT03647189|Experimental|Treatment Arm|Subjects will be treated with hybrid fractional laser
16448370|NCT03647189|Placebo Comparator|Control Arm|
16448371|NCT03647176|Active Comparator|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
16448372|NCT03647176|Experimental|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
16448373|NCT03647163|Experimental|Safety Run-in Dose Level 1|Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
16448374|NCT03647163|Experimental|Safety Run-in Dose Level 2|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
16448375|NCT03647163|Experimental|Expansion NEC|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
16448376|NCT03647163|Experimental|Expansion NSCLC arm|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
16448377|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
16448378|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
16448379|NCT03647137||Parkinson's disease with FoG|Subjects with Parkinson's disease that have freezing of gait (FoG) who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
16448380|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
16448381|NCT03647124||Lenalidomide treated R/R-MCL patients in Denmark and Sweden|Retrospective data collection for Lenalidomide treated R/R-MCL patients from Nordic registries and national health databases
16448382|NCT03647124||Lenalidomide treated R/R-MCL patients in the rest of EU|Retrospective data collection for Lenalidomide treated R/R-MCL patients from sites in the rest of European Union
16448383|NCT03647111||Cohorts 1|
16448384|NCT03647098||Cohorts 1|Treatment plan
16448385|NCT03647098||Cohorts 2|brain metastases
16448386|NCT03647098||Cohorts 3|Concomitant KRAS mutation
16448387|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
16448388|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
16448389|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
16448390|NCT03647072|Active Comparator|CHOP|CHOP only
16448391|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
16448392|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
16448393|NCT03647059||LSCM examination|
16448394|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
16448395|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
16448396|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
16448397|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
16448398|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
16448399|NCT03646994||Cohorts 1|ROS1 fusion positive NSCLC patients who received crizotinib
16448400|NCT03646968|Experimental|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
16448401|NCT03646955|Active Comparator|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
16448402|NCT03646955|No Intervention|No partial breast irradiation|No radiation therapy
16448403|NCT03646942|Active Comparator|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
16448404|NCT03646942|Experimental|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
16448405|NCT03646929|Other|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
16448406|NCT03646929|Other|patients with multiple sclerosis|MEP in patients with multiple sclerosis are measured using modified facilitation technique
16448407|NCT03646916|Active Comparator|Dexamethasone|
16448408|NCT03646916|No Intervention|Non-treatment|
16448409|NCT03646903|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
16448410|NCT03646903|Placebo Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
16448411|NCT03646903|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
16448412|NCT03646877|Experimental|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
16448413|NCT03646877|Placebo Comparator|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
16448414|NCT03646864|Experimental|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
16448415|NCT03646864|Placebo Comparator|Treatment B|Placebo from Day 1 to Day 5 of Period B
16448416|NCT03646851|Experimental|COPD|COPD patients GOLD stage III and IV
16448417|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
16448418|NCT03646812|Other|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
16448419|NCT03646812|Other|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
16448420|NCT03646812|Other|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
16448421|NCT03646812|Experimental|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
16448422|NCT03646812|Experimental|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
16448423|NCT03646812|Experimental|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
16448424|NCT03646812|Experimental|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
16448425|NCT03646812|Experimental|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
16448426|NCT03646812|Experimental|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
16448427|NCT03646799|Experimental|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
16448428|NCT03646799|Experimental|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
16448429|NCT03646786|Experimental|visually impaired patients|
16448430|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
16448431|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
16448432|NCT03646747|Experimental|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.
~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
16448433|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
16448434|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
16448435|NCT03646721|Experimental|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
16448436|NCT03646721|Placebo Comparator|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
16448437|NCT03646721|Experimental|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
16448438|NCT03646721|Placebo Comparator|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
16448439|NCT03646721|Active Comparator|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
16448440|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
16448441|NCT03646695|Experimental|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
16448442|NCT03646695|Active Comparator|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
16448443|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
16448444|NCT03646682|Active Comparator|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
16448445|NCT03646669|Experimental|Asthma education and PEF feedback|Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
16448446|NCT03646669|Placebo Comparator|Asthma education|No PEF feedback arm
16448447|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
16448448|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
16448449|NCT03646643|Active Comparator|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
16448450|NCT03646643|Active Comparator|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
16448451|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
16448452|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
16448453|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks or every 4 weeks until disease progression.
16448454|NCT03646617|Experimental|HFRT|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
16448455|NCT03646604|Experimental|Part 1; Cohort 1|Participants, 6 to <12 years of age, will receive low dose of upadacitinib.
16448456|NCT03646604|Experimental|Part 1; Cohort 2|Participants, 6 to <12 years of age, will receive high dose of upadacitinib.
16448457|NCT03646604|Experimental|Part 1; Cohort 3|Participants, 2 to <6 years of age, will receive low dose of upadacitinib.
16448458|NCT03646604|Experimental|Part 1; Cohort 4|Participants, 2 to <6 years of age, will receive high dose of upadacitinib.
16448459|NCT03646604|Experimental|Part 1; Cohort 5|Participants, 6 months to <2 years of age, will receive low dose of upadacitinib.
16448460|NCT03646604|Experimental|Part 1; Cohort 6|Participants, 6 months to <2 years of age, will receive high dose of upadacitinib.
16448461|NCT03646591||Neoadjuvant chemotherapy|"FLOT Chemotherapy regimen
~A cycle consist of Day 1: 5-fluorouracil (5-FU) 2600mg/M2 intravenous Via peripherally inserted central catheter (PICC) for 24 hour Day 1: Leucovorin 200mg/M2 intravenous Day 1: Oxaliplatin 85mg/ M2 intravenous Day 1: Docetaxel 50mg/M2 intravenous Repeated every 15th day"
16448462|NCT03646552|Experimental|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
16448463|NCT03646539|Experimental|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
16448464|NCT03646539|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
16448465|NCT03646526|Experimental|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .
~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
16448466|NCT03646526|Experimental|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.
~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
16448467|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
16448468|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
16448469|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
16448470|NCT03646487|Experimental|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
16448471|NCT03646487|Placebo Comparator|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
16448472|NCT03646474|Active Comparator|tranexamic acid group|
16448473|NCT03646474|Placebo Comparator|placebo group|
16448474|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
16448475|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
16448478|NCT03646435|Experimental|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
16448479|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients > 18 years with esophageal cancer receiving neoadjuvant chemotherapy
16448480|NCT03646396|Experimental|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
16448482|NCT03646357|Active Comparator|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
16448483|NCT03646357|Experimental|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
16448484|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
16448485|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
16448486|NCT03646331|Experimental|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
16448487|NCT03646331|Experimental|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
16448488|NCT03646318|Experimental|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent [Dabire 1990]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
16448490|NCT03646305|Experimental|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
16448491|NCT03646305|Experimental|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
16448492|NCT03646305|No Intervention|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
16448493|NCT03646305|No Intervention|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
16448494|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
16448495|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
16448496|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
16448497|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
16448498|NCT03646266|No Intervention|Control|Standard of care
16448499|NCT03646253||Patients with proximal humerus fracture|
16448500|NCT03646240|Experimental|Dosing arm|
16448501|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
16448502|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
16448503|NCT03646201|Experimental|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
16448504|NCT03646201|No Intervention|Control Group|Data are collected at baseline and post intervention session.
16448505|NCT03646188|Placebo Comparator|Placebo-containing MNA|Placebo
16448506|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
16448507|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
16448508|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
16448509|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
16448510|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
16448511|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
16448515|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
16448516|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
16448517|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
16448521|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
16448522|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
16448523|NCT03646097|Active Comparator|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
16448524|NCT03646097|Active Comparator|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
16448525|NCT03646097|Experimental|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
16448526|NCT03646084|Experimental|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
16448527|NCT03646084|Active Comparator|Control|Rehabilitation according to current clinical practice.
16448528|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
16448529|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
16448530|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
16448531|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
16451305|NCT03627052|Placebo Comparator|Placebo|
16448532|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
16448533|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
16448534|NCT03646045||Control|Preterm infants receiving gastric feeding
16448535|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
16448536|NCT03646032|Active Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
16448537|NCT03646019||Normal coronary arteries|
16448538|NCT03646019||Non significant coronary artery disease|
16448539|NCT03646019||Significant coronary artery disease|
16448540|NCT03646006|Experimental|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
16448541|NCT03646006|Sham Comparator|Sham block|10 mL normal saline
16448542|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
16448543|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
16448544|NCT03645980|Experimental|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
16448545|NCT03645980|Experimental|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
16448546|NCT03645967|Other|ReadyCleanse for IUC|ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.
16448547|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
16448548|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.
~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.
~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
16448549|NCT03645941|No Intervention|Quitline/Treatment Referral|•Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)
16448550|NCT03645941|Experimental|Facebook+Quitline/Treatment Referral|"Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months
~Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement
~Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)"
16448586|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
16448587|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
16448558|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
16448559|NCT03645889|Experimental|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
16448560|NCT03645889|Placebo Comparator|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
16448561|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
16448562|NCT03645863|Experimental|Cohort 1|Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.
16448563|NCT03645863|Experimental|Cohort 2|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.
16448564|NCT03645863|Experimental|Cohort 3|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.
16448565|NCT03645850|Experimental|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
16448566|NCT03645850|Active Comparator|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
16448567|NCT03645837|Experimental|10 minutes|Compression clamp release start after 10 minutes
16448568|NCT03645837|Experimental|20 minutes|Compression clamp release start after 20 minutes
16448569|NCT03645837|Active Comparator|30 minutes|Compression clamp release start after 30 minutes
16448570|NCT03645824|Experimental|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
16448571|NCT03645811|Experimental|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
16448572|NCT03645811|Experimental|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.
~The content of each EFT session was as follows:
~Preparation
~Tapping Series
~The Nine Gamut Sequence and Eye Movements"
16448573|NCT03645811|No Intervention|Control|For the control group, 15 minutes of free time was given.
16448574|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
16448575|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
16448576|NCT03645785|Active Comparator|Normal Diet/Drinking|Baseline diet and drinking patterns for patients. This is the pre-intervention baseline for cross-over analysis
16448577|NCT03645785|Experimental|Increased fluid Intake and Citrate Supplementation|Patients will increase fluid (with goal to double their baseline) and further take a citrate supplement in the form of True Lemon (citric acid).
16448578|NCT03645772|Experimental|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
16448579|NCT03645772|Active Comparator|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
16448580|NCT03645772|Active Comparator|Walking|12-week progressive walking program.
16448581|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
16448582|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
16448583|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
16448584|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
16448585|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
16448588|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
16448589|NCT03645746|Experimental|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
16448590|NCT03645733|No Intervention|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
16448591|NCT03645733|Experimental|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
16448592|NCT03645733|No Intervention|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
16448593|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
16448594|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
16448595|NCT03645707|Experimental|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.
~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
16448596|NCT03645694|Experimental|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
16448597|NCT03645694|No Intervention|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
16448598|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
16448599|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
16448600|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
16448601|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
16448602|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
16448603|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
16448604|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
16448605|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
16448606|NCT03645629|Active Comparator|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
16448607|NCT03645629|Active Comparator|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
16448608|NCT03645629|Active Comparator|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
16448609|NCT03645616|Experimental|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
16448610|NCT03645603|Experimental|Dexmedetomidine|Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
16448611|NCT03645603|Placebo Comparator|Placebo|saline solution for IV infusion. The administration of infusion will follow the experimental drug.
16448612|NCT03645590|Experimental|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
16448613|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
16448614|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
16448615|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
16448616|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
16448617|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
16448619|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
16448620|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
16448621|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
16448622|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
16448623|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
16448624|NCT03645499|Experimental|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
16448625|NCT03645499|Experimental|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
16448626|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
16448627|NCT03645473|Experimental|Monarch device settings assessment group|"Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.
~The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures."
16448628|NCT03645460|Experimental|TYF-ADA-modified autologous stem cells|Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene
16448629|NCT03645447|Experimental|Taste test|Participants will be presented with a series of tastants of 4 different modalities (sweet, salt, sour, bitter) of 9 different concentrations in pseudo-random order. The threshold at which each participant reliably identifies the taste is determined for each tastant. Mood Questionnaires will be used to determine whether a participant is clinically depressed.
16448630|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
16448631|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:
~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
16448632|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:
~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
16448633|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
16448634|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
16448635|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
16448636|NCT03645421|Placebo Comparator|placebo|Placebo per day,SC injection on 48 days.
16448637|NCT03645421|Experimental|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
16448638|NCT03645421|Experimental|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
16448639|NCT03645421|Experimental|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
16448640|NCT03645408|Experimental|Exenatide injection|Subjects in this arm will receive a 5 mcg dose of immediate release exenatide on the day of the alcohol challenge. The 5mcg dose of exenatide is approved as the first dose to be administered to patients at the start of their treatment with this drug for FDA-approved indications.
16448641|NCT03645408|Placebo Comparator|Placebo|Subjects in this arm will receive a sham injection on the day of the alcohol challenge. The sham injection will be a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects will sense this volume of fluid (or lack thereof) during the injection. Subjects will be shielded from seeing the injection to maintain the blind.
16448642|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
16448643|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
16448644|NCT03645395|Experimental|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
16448848|NCT03643991|No Intervention|Control Cohort|Last 15 subjects enrolled receive treatment as usual while inpatient.
16448645|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
16448646|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
16448647|NCT03645382|Placebo Comparator|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
16448648|NCT03645382|Experimental|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
16448649|NCT03645369|Experimental|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
16448650|NCT03645369|Experimental|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
16448651|NCT03645369|No Intervention|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
16448652|NCT03645356|Active Comparator|fixed appliances|patients will be treated using fixed appliances in order to align their teeth after extraction of four premolars
16448653|NCT03645356|Experimental|clear aligners|patients will be treated using clear aligners in order to align their teeth after extraction of four premolars
16448654|NCT03645343|Active Comparator|Activator|Patients will be treated using the Activator appliance for one and a half year
16448655|NCT03645343|Experimental|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
16448656|NCT03645343|No Intervention|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
16448657|NCT03645317|Other|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
16448658|NCT03645304|Experimental|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
16448659|NCT03645304|Placebo Comparator|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
16448660|NCT03645291|Active Comparator|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
16448661|NCT03645291|Sham Comparator|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
16448662|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
16448663|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
16448664|NCT03645265|Experimental|Gestures|Use of hand gestures to improve speech rhythm and speech production
16448665|NCT03645265|Experimental|Auditory|Use of auditory cues to improve speech rhythm and speech production
16448666|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
16448667|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
16448668|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
16448669|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
16448670|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
16448671|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
16448672|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above
~Being capable of giving informed consent for participation of the study
~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.
~Onset of PD symptoms of <5 years
~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
16448849|NCT03643978|Experimental|Decision Aid Group|These patients review a decision aid.
16448850|NCT03643978|No Intervention|Control Group|These patients do not review a decision aid.
16448673|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects
~Chinese aged 50 or above
~Being capable of giving informed consent for participation of the study
~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
16448674|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;
~Age-and sex-matched with PD subjects
~Chinese aged 40 or above;
~Absence of dream enactment behaviors;
~Not cohabiting with proband"
16448675|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;
~Chinese aged 50 or above;
~Being capable of giving informed consent for participation of the study;
~Without a personal history or a family history of PD or RBD;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Absence of RSWA as measured by v-PSG."
16448676|NCT03645226||Spouses of patients with iRBD|"Spouses of patients with iRBD;
~Age-and sex-matched with PD subjects;
~Chinese aged 50 or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Cohabiting with proband."
16448677|NCT03645226||First degree relatives of healthy controls|"First degree relatives of healthy controls;
~Age-and sex-matched with PD subjects;
~Chinese aged 40 or above ;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;"
16448678|NCT03645226||Spouses of healthy controls|"Spouses of healthy controls;
~Age-and sex-matched with PD subjects;
~Chinese aged 50 or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Cohabiting with proband."
16448679|NCT03645213|Experimental|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
16448680|NCT03645213|Experimental|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
16448681|NCT03645213|No Intervention|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
16448682|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.
~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
16448683|NCT03645187|Active Comparator|FOLFERI|FOLFERI regien
16448684|NCT03645187|Active Comparator|FOLFERI and celecoxib|FOLFERI and celecoxib
16448685|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
16448686|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
16448687|NCT03645161|Active Comparator|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
16448688|NCT03645161|Active Comparator|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
16448689|NCT03645148|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;
~Peptides: 4 x 100 mcg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses;
~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses"
16448690|NCT03645135|No Intervention|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
16448691|NCT03645135|Experimental|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
16448692|NCT03645122|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneurlonal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be invited to participate.
16448693|NCT03645122|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
16448694|NCT03645109|Experimental|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
16448695|NCT03645109|Placebo Comparator|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
16448696|NCT03645096|Experimental|Pregnenolone 500 > Pregnenolone 800 > Placebo|"3 exposures in order:
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days."
16448697|NCT03645096|Experimental|Pregnenolone 500 > Placebo > Pregnenolone 800|"3 exposures in order:
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
16448851|NCT03643965|Experimental|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
16448852|NCT03643965|Placebo Comparator|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
16448698|NCT03645096|Experimental|Pregnenolone 800 > Pregnenolone 500 > Placebo|"3 exposures in order:
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days."
16448699|NCT03645096|Experimental|Pregnenolone 800 > Placebo > Pregnenolone 500|"3 exposures in order:
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
16448700|NCT03645096|Experimental|Placebo > Pregnenolone 500 > Pregnenolone 800|"3 exposures in order:
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
16448701|NCT03645096|Experimental|Placebo > Pregnenolone 800 > Pregnenolone 500|"3 exposures in order:
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
16448702|NCT03645083|Experimental|Telephone call|Participants receive a telephone call reminder three days after their initial visit
16448703|NCT03645083|Experimental|Text message|Participants receive a text message reminder three days after their initial visit
16448704|NCT03645083|No Intervention|Control|Participants do not receive any intervention after their initial visit
16448705|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
16448706|NCT03645070|Active Comparator|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
16448707|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
16448708|NCT03645057|Experimental|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
16448709|NCT03645057|Active Comparator|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
16448710|NCT03645031|Experimental|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
16448711|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
16448712|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.
~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
16448713|NCT03645005|Experimental|My Guide (psychoeducation & self-management program)|
16448714|NCT03645005|Active Comparator|My Health (health education program)|
16448715|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
16448716|NCT03644979|Experimental|Skydiving|Tandem skydiving
16448717|NCT03644979|No Intervention|Negative control|No skydiving
16448718|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
16448719|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
16448721|NCT03644940|Experimental|Subpopulation-specific Algorithm|
16448722|NCT03644940|No Intervention|Control Algorithm|
16448723|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual.."
16448724|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
16448725|NCT03644914|Experimental|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
16448726|NCT03644914|No Intervention|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
16448727|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
16448728|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
16448729|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
16448730|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
16448853|NCT03643952|Experimental|Daptomycin|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
16448731|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
16448732|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
16448733|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
16448734|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
16448735|NCT03644849|Sham Comparator|Sham laser intervention group|
16448736|NCT03644836|Experimental|Retraining with respiratory effort+ amino acids|
16448737|NCT03644836|Placebo Comparator|Retraining with respiratory effort+ placebo|
16448738|NCT03644823|Experimental|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
16448739|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed
~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
16448740|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale
~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
16448741|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
16448742|NCT03644784||Yamaguchi University Hospital|
16448743|NCT03644784||Erasmus Medical Center|
16448744|NCT03644784||Academic Medical Center - Amsterdam|
16448745|NCT03644784||Segeberger Kliniken Gruppe|
16448746|NCT03644784||McGill University - Montreal|
16448747|NCT03644758||professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
16448748|NCT03644745|Experimental|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
16448749|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
16448750|NCT03644719|Experimental|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
16448751|NCT03644719|No Intervention|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
16448752|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
16448753|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
16448754|NCT03644693|Experimental|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
16448755|NCT03644693|Placebo Comparator|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
16448756|NCT03644680|Experimental|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
16448757|NCT03644680|Placebo Comparator|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
16448758|NCT03644667|Experimental|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.
~Standard of care triple maintenance immunosuppression includes:
~a calcineurin inhibitor (tacrolimus),
~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and
~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.
~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
16448790|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
16448791|NCT03644433|Placebo Comparator|Single layer|Single layer closure
16448759|NCT03644667|Placebo Comparator|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.
~Standard of care triple maintenance immunosuppression includes:
~a calcineurin inhibitor (tacrolimus),
~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and
~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.
~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
16448760|NCT03644654|Active Comparator|Standard care group|Fluid management will be done according standard care
16448761|NCT03644654|Experimental|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
16448762|NCT03644641|Experimental|Desflurane Group|Induction and anesthesia will be held by using desflurane
16448763|NCT03644641|Experimental|Propofol Group|Induction and anesthesia will be held by using target-control anesthesia with propofol
16448764|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
16448765|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
16448766|NCT03644615|Experimental|Mindfluness and usual care|
16448767|NCT03644615|Other|Usual Care|
16448768|NCT03644602|Active Comparator|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI <150), and with Ulcerative colitis in clinical remission (defined in the presence of <3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.
~The low FODMAPs diet was administered for 3 months."
16448769|NCT03644602|Active Comparator|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
16448770|NCT03644602|Active Comparator|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
16448771|NCT03644589|Experimental|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).
~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
16448772|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
16448773|NCT03644576|Placebo Comparator|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
16448774|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
16448775|NCT03644550|Experimental|1/LMB- 100+pembrolizumab|LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles
16448776|NCT03644537|Other|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
16448777|NCT03644537|Other|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
16448778|NCT03644537|Other|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
16448779|NCT03644524|Experimental|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, ~4-5 weeks), and post (after all 30 heat sessions; ~8-10 weeks).
16448780|NCT03644524|No Intervention|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
16448781|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
16448782|NCT03644498||Adults treated with a CPI therapy for cancer|
16448785|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
16448786|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
16448787|NCT03644459|Experimental|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
16448788|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
16448789|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
16448792|NCT03644433|Active Comparator|Double layer with resection|Double layer closure after resection uterine scar
16453589|NCT03611075|No Intervention|TD Healthy Participant Adolescents|Participants will be 13-17 years old
16448793|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:
~Clinical evaluation
~Radiographic assessment of osteoarthritis
~Magnetic resonance imaging (MRI)
~Histological evaluation of the surgical piece"
16448794|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
16448795|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
16448796|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
16448797|NCT03644355|Experimental|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
16448798|NCT03644355|Active Comparator|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
16448799|NCT03644355|Active Comparator|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
16448800|NCT03644355|No Intervention|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
16448801|NCT03644342|Experimental|Niraparib Arm|For the purposes of this study, two dose levels of Niraparib (100 mg and 200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
16448802|NCT03644329|Other|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
16448803|NCT03644329|Experimental|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
16448804|NCT03644329|Experimental|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
16448805|NCT03644329|Experimental|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
16448806|NCT03644316|Experimental|BandGrip|Topical skin closure device
16448807|NCT03644303|Experimental|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
16448808|NCT03644290|Experimental|Cognitive training|Semantic categorization training sessions
16448809|NCT03644290|Active Comparator|Control condition|Five sessions of behavioral control condition with information and education
16448810|NCT03644277|Experimental|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
16448811|NCT03644277|Experimental|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
16448812|NCT03644277|Experimental|Rapael glove with dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
16448813|NCT03644277|Active Comparator|Rapael glove with Sham dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
16448846|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
16448847|NCT03643991|Experimental|Weighted Blanket Cohort|First 15 subjects enrolled have access to sleep with weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
16448814|NCT03644277|Placebo Comparator|No training with dAIH|"Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%.
~Hearth rate and pulse oximetry will be continuously monitored throughout, and recording will be taken at each alteration in sequence. Blood pressure will be taken upon completion of the total sequence"
16448815|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
16448816|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
16448817|NCT03644251|Experimental|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
16448818|NCT03644251|Experimental|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
16448819|NCT03644251|Experimental|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
16448820|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
16448821|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
16448822|NCT03644225|Other|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
16448823|NCT03644225|Other|Systemic sclerosis patients|"SSc patients who signed an Informed consent
~Age ≥18 years old
~Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria
~Skin thickening diagnosed by clinical expert"
16448824|NCT03644212|Active Comparator|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
16448825|NCT03644212|No Intervention|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
16448826|NCT03644199|Other|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
16448827|NCT03644199|Other|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
16448830|NCT03644173|Experimental|Study arm - PREP Intervention|Participants receiving the coaching intervention
16448831|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
16448832|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
16448833|NCT03644147|Experimental|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
16448834|NCT03644147|No Intervention|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
16448835|NCT03644134|Experimental|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
16448836|NCT03644134|No Intervention|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
16448837|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
16448838|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
16448839|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
16448840|NCT03644082|Experimental|Epilepsy Patients|
16448841|NCT03644069|Experimental|Nexvax2|
16448842|NCT03644069|Placebo Comparator|Placebo|
16448843|NCT03644056|Experimental|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
16448844|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
16448845|NCT03644017|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
16448854|NCT03643939|Experimental|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
16448855|NCT03643939|Active Comparator|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
16448856|NCT03643926|Experimental|Arthroscopic Brostrom|
16448857|NCT03643926|Active Comparator|Open Brostrom|
16448858|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.
~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.
~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
16448859|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
16448860|NCT03643900|Experimental|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
16448861|NCT03643900|Active Comparator|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
16448862|NCT03643887|Experimental|FMT Capsule DE|FMT Capsule DE
16448863|NCT03643887|Placebo Comparator|Placebo Oral Capsule|Placebo Capsule
16448864|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
16448865|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
16448866|NCT03643861|Experimental|5 Fraction Breast Stereotactic Body Radiation Therapy|This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fraction stereotactic body radiation therapy at a dose of 30 gy for treatment. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
16448867|NCT03643848|Experimental|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
16448868|NCT03643848|Sham Comparator|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
16448869|NCT03643835|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
16448870|NCT03643835|Active Comparator|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
16448871|NCT03643835|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
16448876|NCT03643796|Active Comparator|Remifentanil Group|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
16448877|NCT03643796|Active Comparator|Ketamine and Dexmedetomidine group|"dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
~Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation."
16448878|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
16448879|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
16448880|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
16448881|NCT03643770|Active Comparator|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
16448998|NCT03643042|Experimental|Restrictive group|Transfusion with: Hb < 80g/L and Hb maintain between 80 and 100g/L
16448882|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
16448883|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
16448884|NCT03643757|Active Comparator|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
16448885|NCT03643757|Active Comparator|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
16448886|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
16448887|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
16448888|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
16448889|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
16448890|NCT03643731|Experimental|HeatTens|"After baseline measurements and during 4 weeks of follow up
~Composition and dosing of the device:
~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
16448891|NCT03643731|No Intervention|Control group|No intervention
16448892|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
16448893|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
16448894|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
16448895|NCT03643679|Experimental|Kwit smartphone app|This arm will receive the Kwit smartphone app.
16448896|NCT03643666|Placebo Comparator|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
16448897|NCT03643666|Active Comparator|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
16448898|NCT03643666|Active Comparator|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
16448899|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
16448900|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
16448901|NCT03643627|Placebo Comparator|Placebo|
16448902|NCT03643627|Experimental|1 mg/kg|
16448903|NCT03643627|Experimental|3 mg/kg|
16448904|NCT03643627|Experimental|10 mg/kg|
16448905|NCT03643627|Experimental|30 mg/kg|
16448906|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
16448907|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
16448908|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
16448909|NCT03643588|Experimental|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
16448910|NCT03643588|Active Comparator|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
16448911|NCT03643575|Experimental|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
16448912|NCT03643575|Experimental|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
16448913|NCT03643575|Experimental|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
16448914|NCT03643562|Experimental|Adrabetadex|Participants receive prescribed adrabetadex by intra-thecal injection
16448915|NCT03643549|Experimental|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
16448916|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
16448917|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
16448918|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
16448919|NCT03643510|Experimental|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
16448920|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
16448921|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
16448922|NCT03643445|Experimental|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
16448923|NCT03643445|Active Comparator|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
16448924|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
16448925|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
16448926|NCT03643419|Sham Comparator|Laminectomy|
16448927|NCT03643419|Experimental|Laminectomy & Irradiation|
16448928|NCT03643406|Experimental|Mental Fatigue Condition|
16448929|NCT03643406|Placebo Comparator|Control Condition|
16448930|NCT03643393|Other|incarceration rectal prolapse|
16448931|NCT03643380|Experimental|Investigational SNS device|
16448932|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
16448933|NCT03643367|Active Comparator|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
16448934|NCT03643354|Experimental|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
16448935|NCT03643341|Experimental|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
16448936|NCT03643341|No Intervention|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
16448937|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
16448938|NCT03643315|Experimental|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
16448939|NCT03643315|Experimental|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
16448940|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
16448941|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
16448942|NCT03643289||Cohort A|Patients with stage 4 melanoma due to commence immunotherapy. Patients should be naïve to immunotherapy.
16448943|NCT03643289||Cohort B|Patients with stage 3 melanoma who are naïve to immunotherapy
16448944|NCT03643276|Active Comparator|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)
~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]
~Erwinase is given in case of allergy to pegaspargase."
16448996|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
16448997|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
16448945|NCT03643276|Experimental|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]
~Erwinase is given in case of allergy to pegaspargase."
16448946|NCT03643276|Experimental|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
16448947|NCT03643276|Experimental|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX
~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)
~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
16448948|NCT03643276|Active Comparator|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms
~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX
~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide
~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX
~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)."
16448949|NCT03643276|Experimental|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide
~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
16448950|NCT03643276|Experimental|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms
~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX
~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)
~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX
~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
16448951|NCT03643276|Experimental|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)
~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
16448952|NCT03643276|Other|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
16448953|NCT03643276|Active Comparator|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM
~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR
~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
16448954|NCT03643276|Experimental|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM
~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR
~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
16448955|NCT03643276|Other|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
16448956|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
16448957|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
16448958|NCT03643250|Experimental|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
16448959|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
16448960|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
16448961|NCT03643237|Experimental|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
16448962|NCT03643237|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
16448964|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
16448965|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
16448966|NCT03643159|Experimental|Abilify MyCite|Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
16448967|NCT03643159|Active Comparator|Virtual Matched Controls|Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.
16448968|NCT03643146|Experimental|Wedge 1- Step 1|
16448969|NCT03643146|Experimental|Wedge 1-Step 2|
16448970|NCT03643146|Experimental|Wedge 1-Step 3|
16448971|NCT03643146|Experimental|Wedge 1-Step 4|
16448972|NCT03643146|Experimental|Wedge 1-Step 5|
16448973|NCT03643146|Experimental|Wedge 2- Step 1|
16448974|NCT03643146|Experimental|Wedge 2-Step 2|
16448975|NCT03643146|Experimental|Wedge 2-Step 3|
16448976|NCT03643146|Experimental|Wedge 2-Step 4|
16448977|NCT03643146|Experimental|Wedge 2-Step 5|
16448978|NCT03643146|Experimental|Wedge 3-Step 1|
16448979|NCT03643146|Experimental|Wedge 3- Step 2|
16448980|NCT03643146|Experimental|Wedge 3- Step 3|
16448981|NCT03643146|Experimental|Wedge 3- Step 4|
16448982|NCT03643146|Experimental|Wedge 3- Step 5|
16448983|NCT03643146|Experimental|Wedge 4-Step 1|
16448984|NCT03643146|Experimental|Wedge 4- Step 2|
16448985|NCT03643146|Experimental|Wedge 4-Step 3|
16448986|NCT03643146|Experimental|Wedge 4-Step 4|
16448987|NCT03643146|Experimental|Wedge 4-Step 5|
16448988|NCT03643133|Active Comparator|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :
~M-API regimen (≤25 years) :
~Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2
~EI regimen (26-50 years) :
~Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4"
16448989|NCT03643133|Experimental|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
16448990|NCT03643120|Other|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
16448991|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.
~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
16448992|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
16448993|NCT03643081|Experimental|"use of camera Fluobeam"|
16448994|NCT03643081|No Intervention|"Without use of the camera Fluobeam"|
16448995|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
16448999|NCT03643042|Experimental|Liberal group|Transfusion with: Hb < 100g/L and Hb maintain between 100 and 120g/L
16449000|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
16449001|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
16449002|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
16449003|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
16449004|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
16449005|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
16449006|NCT03642964|Experimental|treatment|CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily
16449007|NCT03642964|Placebo Comparator|placebo|generic placebo tablets given orally twice daily
16449008|NCT03642951|Active Comparator|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.
~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
16449009|NCT03642951|Sham Comparator|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.
~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.
~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
16449010|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
16449011|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
16449012|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
16449013|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
16449014|NCT03642925|Experimental|Meal replacement diet|Obese subjects (BMI>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
16449015|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
16449016|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
16449017|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
16449018|NCT03642886|No Intervention|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
16449019|NCT03642886|Experimental|Prescribed Detraining|"Detraining period of 8-weeks which is defined as:
~a 75% decrease in the amount of exercise (from baseline)
~a 50% decrease in the intensity of exercise as measured in METS (from baseline)
~Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
16449020|NCT03642873|Experimental|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
16449021|NCT03642873|Experimental|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
16449022|NCT03642873|Experimental|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
16449023|NCT03642860|Experimental|Active treatment|Triheptanoin oil
16449024|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
16449025|NCT03642847|Active Comparator|Prevnar 13|13 valent Pneumococcal Conjugate
16449026|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
16449027|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
16449028|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
16449029|NCT03642808|Experimental|rehabilitation program|"Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week
~Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
16449031|NCT03642782|Experimental|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
16449032|NCT03642769|Active Comparator|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
16449033|NCT03642769|Experimental|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
16449034|NCT03642756|Placebo Comparator|20 gauge|
16449035|NCT03642756|Active Comparator|22 gauge|
16449036|NCT03642756|Active Comparator|24 gauge|
16449037|NCT03642743|Experimental|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
16449038|NCT03642743|Experimental|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
16449039|NCT03642730|Experimental|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
16449040|NCT03642730|Experimental|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
16449041|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
16449042|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
16449043|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.
~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
16449044|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
16449045|NCT03642665|Experimental|Natural cycle|no medication
16449046|NCT03642665|Active Comparator|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
16449047|NCT03642652|Experimental|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
16449048|NCT03642652|No Intervention|Control|Routine care
16449049|NCT03642639|Other|Coils|MICRUSFRAME and GALAXY coils
16449050|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)|
16449051|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)|
16449052|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)|
16449053|NCT03642626||Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)|
16449054|NCT03642600|Active Comparator|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
16449055|NCT03642600|Active Comparator|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
16449056|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
16449057|NCT03642574|Experimental|PMS group|Subjects in the PMS group will have blastocyst biopsy and whole genome bisulfate sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by DNA methylation level.The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
16449058|NCT03642574|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
16449059|NCT03642561|Experimental|RFA group|Patients in RFA group will accept RFA treatment
16449060|NCT03642561|Active Comparator|TACE group|Patients in TACE group will accept TACE treatment
16449061|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
16453590|NCT03611075|No Intervention|TD Healthy Participant Adults|Participants will be 18-45 years old
16449062|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
16449063|NCT03642535|Experimental|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
16449064|NCT03642535|Active Comparator|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
16449065|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
16449066|NCT03642509|Experimental|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
16449067|NCT03642509|Experimental|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
16449068|NCT03642496|Experimental|The low dose group|
16449069|NCT03642496|Experimental|The middle dose group|
16449070|NCT03642496|Experimental|The high dose group|
16449071|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
16449072|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
16449073|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
16449074|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
16449075|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
16449076|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
16449077|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
16449078|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
16449079|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
16449080|NCT03642366|Active Comparator|Active Arm 1|
16449081|NCT03642366|Active Comparator|Active Arm 2|
16449082|NCT03642366|Sham Comparator|Sham Arm|
16449083|NCT03642353|Experimental|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
16449084|NCT03642353|Placebo Comparator|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
16449085|NCT03642353|Experimental|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
16449086|NCT03642353|Placebo Comparator|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
16449087|NCT03642327|Active Comparator|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
16449088|NCT03642327|Experimental|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
16449089|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
16449090|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
16449091|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
16449092|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
16449093|NCT03642275|Experimental|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
16449094|NCT03642275|No Intervention|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
16449095|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
16449096|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
16449586|NCT03638778|Experimental|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
16449097|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);
~online learning delirium care activities (20 minutes in duration); and
~delirium care OSCE and reflective activity (30 minutes in duration)."
16449098|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);
~online learning delirium care activities (20 minutes in duration)"
16449099|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
16449100|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
16449101|NCT03642223|Active Comparator|normal-weight|
16449102|NCT03642223|Experimental|peripheral adiposity|
16449103|NCT03642223|Experimental|central adiposity|
16449104|NCT03642210|Experimental|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system, inserted for use up to 6 months
16449105|NCT03642197|Experimental|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
16449106|NCT03642197|No Intervention|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
16449107|NCT03642197|Experimental|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
16449108|NCT03642197|No Intervention|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
16449109|NCT03642184|Active Comparator|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
16449110|NCT03642184|Active Comparator|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
16449111|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
16449112|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
16449113|NCT03642145|Experimental|Arm A: Deflazacort 0.9 mg/kg|Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
16449114|NCT03642145|Experimental|Arm B: Deflazacort 0.45 mg/kg|Participants will receive approximately 0.45 mg/kg deflazacort once daily orally for 52 weeks in Period 1. Participants will either continue to receive 0.45 mg/kg deflazacort or escalated dose of deflazacort (0.9 mg/kg) once daily orally in Period 2 at the investigator's discretion and in consultation with the caregiver. The target dose could be varied +/- 20% depending upon the available tablet strengths and change in participant's weight.
16449115|NCT03642145|No Intervention|Natural History Control Group|Control participants matching to the study population as closely as possible, will be used as a comparator to characterize the safety and tolerability of deflazacort.
16449116|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
16449117|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
16449118|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
16449119|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
16449256|NCT03641053|Active Comparator|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
16449122|NCT03642093|Experimental|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
16449123|NCT03642093|Active Comparator|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
16449124|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
16449125|NCT03642067|Experimental|Cohort A/B: Nivolumab and Relatlimab|480mg/160mg (co-administered)
16449126|NCT03642067|Experimental|Cohort C: Nivolumab and Relatlimab|480mg/ 960mg (sequential administration)
16449127|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
16449128|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
16449129|NCT03642028|Experimental|Suvorexant|Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.
16449130|NCT03642028|Placebo Comparator|Identical Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
16449131|NCT03642015|Experimental|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
16449132|NCT03642015|No Intervention|Control|control group rested only by sitting on a comfortable chair
16449133|NCT03642002|Experimental|Toning|Vocal Tonal Holding
16449134|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
16449135|NCT03642002|Experimental|SOK|Song of kin with lyric content
16449136|NCT03642002|Experimental|Process|Processing of experience
16449137|NCT03642002|Experimental|Holding Harmonic Container|
16449138|NCT03641989|Active Comparator|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
16449139|NCT03641989|Placebo Comparator|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
16449140|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
16449141|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
16449142|NCT03641963|Experimental|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
16449143|NCT03641950|Experimental|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
16449144|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
16449145|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
16449146|NCT03641885|Experimental|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
16449147|NCT03641885|Experimental|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
16449148|NCT03641885|Active Comparator|active control|mothers and adolescents are in active control group and only receive the questionnaires
16449149|NCT03641872||Acute-on-Chronic Liver Disease|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.
~ALI(acute liver injury): including [ALT > 3 ULN(upper limited of normal),AST > 3 ULN or TB > 2 ULN within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB > 5 ULN) within 1 month before enrollment)].
~Standary therapy for chronic liver disease with ATI and/or AD"
16449150|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.
~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:
~- Arm 1 (usual care): the procedure of care will be the same as usual."
16449151|NCT03641859|Experimental|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.
~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:
~- Arm 2 (intervention): local anesthesia + virtual reality"
16449152|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
16449153|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
16449154|NCT03641807|Experimental|Acupuncture|
16449155|NCT03641807|Sham Comparator|Sham acupuncture|
16449156|NCT03641794|Experimental|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
16449157|NCT03641794|Placebo Comparator|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
16449158|NCT03641781|Active Comparator|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
16449159|NCT03641781|Active Comparator|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
16449160|NCT03641781|No Intervention|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
16449161|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
16449162|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
16449163|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
16449164|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
16449165|NCT03641755|Experimental|Olaparib + Sapacitabine|"Olaparib will be administered orally twice daily for each 28-day cycle
~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle
~Olaparib will be given at a predetermined dose
~Sapacitabine will be given at a predetermined dose"
16449166|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
16449167|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
16449168|NCT03641729|Other|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
16449169|NCT03641716|Experimental|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
16449170|NCT03641703|Experimental|FLT180a|Participants who have received gene therapy vector (FLT180a)
16449171|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
16449172|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
16449173|NCT03641677|Experimental|EVLP|
16449174|NCT03641677|Active Comparator|Control|
16449175|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
16449176|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
16449177|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
16449178|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 34-102 IU/ml.
16449179|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 103-204 IU/ml.
16449180|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb >205IU/ml.
16449181|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L.
16449182|NCT03641625|Experimental|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
16449183|NCT03641625|No Intervention|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
16449184|NCT03641612|Experimental|one shape|single file rotary system
16449185|NCT03641612|Active Comparator|protaper next|multiple file rotary system
16449186|NCT03641599||heart failure with preserved ejection fraction|
16449187|NCT03641599||heart failure with mid range ejection fraction|
16449188|NCT03641599||heart failure with reduced ejection fraction|
16449189|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
16449190|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
16449191|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
16449192|NCT03641573|Experimental|[14C] ASN002|[14C] ASN002
16449193|NCT03641560|Experimental|Enzalutamide group|Participants will receive Enzalutamide once daily in addition to continued androgen deprivation therapy until discontinuation criteria is met
16449194|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.
~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
16449195|NCT03641534||Sepsis|
16449196|NCT03641534||Severe malaria|
16449197|NCT03641534||Uncomplicated malaria|
16449198|NCT03641521|Experimental|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
16449199|NCT03641521|No Intervention|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
16449200|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
16449201|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
16449202|NCT03641495|Experimental|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler
~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
16449203|NCT03641495|Active Comparator|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
16449204|NCT03641482|Active Comparator|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
16449205|NCT03641482|Placebo Comparator|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
16449206|NCT03641469|Experimental|Green Sun Dynamic Brace|Historical measures of brace effectiveness (in- and out-of-brace Cobb angles), wear time, and brace-related quality of life will be compared to those measured after the subject is fit with a Green Sun dynamic brace.
16449207|NCT03641456|Experimental|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
16449208|NCT03641443|Experimental|Non-invasive measurement of intracranial pressure|Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement
16449209|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
16449210|NCT03641417|Experimental|GLWL-01|Oral administration of GLWL-01 300mg BD for 10 days
16449211|NCT03641417|Placebo Comparator|Placebo|Identical oral capsules with no active ingredient, administered BD for 10 days
16449212|NCT03641404|Experimental|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
16449213|NCT03641404|Placebo Comparator|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
16449214|NCT03641391|Experimental|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
16449215|NCT03641378|Experimental|Inpatient Palliative Care Intervention|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent
~Palliative Care Intervention
~Therapeutic Relationship
~--Develop a strong therapeutic relationship with patients and caregivers
~Assessment and Treatment of Patient Symptoms
~--Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms
~Managing Patients and Caregivers Expectations
~--Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects
~Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
16449216|NCT03641378|Experimental|Transplant Care Alone|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.
~Standard Transplant Care"
16449217|NCT03641365|Experimental|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
16449257|NCT03641053|Active Comparator|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
16449218|NCT03641365|Active Comparator|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
16449219|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
16449220|NCT03641352|Placebo Comparator|Placebo|Placebo
16449221|NCT03641339|Experimental|Cohort A: One vector feeding and three biopsies|Undergo one vector feeding and three biopsies on Day 0
16449222|NCT03641339|Experimental|Cohort B: Four vector feedings and three biopsies|Undergo 4 vector feedings over 8 weeks and 3 biopsy procedures after the 4th and final feeding
16449223|NCT03641326|Experimental|1|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest.Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
16449224|NCT03641313|Experimental|Treatment (irinotecan and M6620)|Patients receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16449225|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
16449226|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q
16449227|NCT03641287|Experimental|Arm I (aerobic exercise)|Participants meet with exercise physiologist for 1, 60 minute session. Participants then receive individualized exercise prescription with goal of moderate aerobic exercise over 150 minutes per week at home for up to 24 weeks. Participants also receive telephone-based motivational support by exercise physiologist weekly for 24 weeks.
16449228|NCT03641287|Active Comparator|Arm II (habitual level of physical activity)|Participants maintain habitual levels of physical activity and receive general education material about ovarian cancer and survivorship for 24 weeks. After 24 weeks, participants are offered exercise intervention.
16449229|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
16449230|NCT03641261|Experimental|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
16449231|NCT03641248|Experimental|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
16449232|NCT03641248|Active Comparator|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
16449233|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
16449234|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
16449235|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
16449236|NCT03641209|Experimental|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
16449237|NCT03641209|Placebo Comparator|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
16449238|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
16449239|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
16449240|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
16449241|NCT03641170|Experimental|Experimental intervention|Fixed diet and physical activity.
16449242|NCT03641170|Other|Control intervention|Fixed diet and inactivity.
16449243|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
16449244|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
16449245|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
16449246|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
16449247|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
16449248|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
16449249|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
16449250|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
16449251|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
16449252|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
16449253|NCT03641079|Experimental|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
16449254|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
16449255|NCT03641053|Experimental|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
16449258|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
16449259|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
16449260|NCT03641027|Experimental|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
16449261|NCT03641027|Other|Standard care|Standard care
16449262|NCT03641014|Experimental|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
16449263|NCT03641014|No Intervention|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
16449264|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
16449265|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
16449266|NCT03640988|Experimental|dermaPACE|Non-sterile, single, Benchtop System that is comprised of a dermaPACE Control Console, PACE Applicator and foot pedal. The PACE applicator uses shockwave technology on acute and chronic defects.
16449267|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
16449268|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
16449269|NCT03640949|Experimental|Vasopressin and methylprednisolone|The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
16449270|NCT03640949|Placebo Comparator|Placebo|"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl."
16449271|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
16449272|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronyssinus, tested by prick test or specific IgE
16449273|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronyssinus, with negative prick test or specific IgE
16449274|NCT03640923|Experimental|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
16449275|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
16449276|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
16449277|NCT03640897|Experimental|Liniderm|"Oleocalcareous liniment Liniderm:
~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
16449278|NCT03640897|Active Comparator|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
16449279|NCT03640897|Active Comparator|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
16449280|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
16449281|NCT03640871|Experimental|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
16449282|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
16449283|NCT03640845|Experimental|experimental group|Patient living in nursing homes a tele-expertise will be performed
16449284|NCT03640845|No Intervention|control group|Patient living in nursing homes will performed a normal care.
16449285|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
16449286|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
16449287|NCT03640819|Experimental|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
16449288|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
16449289|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
16449290|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
16449291|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
16449292|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
16449293|NCT03640767|Experimental|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
16449294|NCT03640767|No Intervention|Control|no intervention
16449297|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
16449298|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
16449299|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
16449300|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
16449301|NCT03640715|Other|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
16449302|NCT03640715|Other|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
16449303|NCT03640715|Other|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
16449304|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
16449305|NCT03640689|Experimental|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
16449306|NCT03640689|Active Comparator|Control Group|Endovenous ablation of Great Saphenous Vein
16449307|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
16449308|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
16449309|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
16449310|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
16449311|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
16449312|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
16449313|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
16449314|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
16449315|NCT03640624|Experimental|Intervention|Multidisciplinary treatment
16449316|NCT03640624|Active Comparator|Control|Treatment as usual
16449317|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
16449318|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
16449319|NCT03640585|Experimental|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
16449320|NCT03640585|Placebo Comparator|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
16449321|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
16449322|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
16449323|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
16449324|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
16449325|NCT03640533|Experimental|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
16449326|NCT03640533|No Intervention|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
16449391|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
16449392|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
16449327|NCT03640520|Experimental|Intervention|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
16449328|NCT03640520|Active Comparator|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
16449329|NCT03640507|Active Comparator|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
16449330|NCT03640507|Active Comparator|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
16449331|NCT03640507|Placebo Comparator|Saline|Subjects will receive vaginal preparation with sterile saline.
16449332|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
16449333|NCT03640481|Experimental|Arm A: belumosudil 200 mg QD|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
16449334|NCT03640481|Experimental|Arm B: belumosudil 200 mg BID|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
16449335|NCT03640468|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
16449336|NCT03640468|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
16449337|NCT03640455|Placebo Comparator|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; dummy stimulation will be given.
16449338|NCT03640455|Experimental|Anodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in anodal polarity.
16449339|NCT03640455|Experimental|Cathodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in cathodal polarity.
16449340|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
16449341|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
16449342|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
16449343|NCT03640403|Experimental|DP|Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
16449344|NCT03640403|Active Comparator|ASAQ|Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
16449345|NCT03640403|No Intervention|Control|No intervention drugs will be given, but normal routine standard of care will be provided.
16449346|NCT03640390|Experimental|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
16449347|NCT03640390|Active Comparator|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
16449348|NCT03640390|Placebo Comparator|Saline group|This group will receive normal saline infusion
16449349|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
16449350|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose only baseline treatment|150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
16449351|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
16449352|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose at baseline and 6 months|150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.
16449353|NCT03640351|Active Comparator|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
16449354|NCT03640351|Active Comparator|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
16449355|NCT03640351|Active Comparator|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
16449356|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
16449357|NCT03640338|No Intervention|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
16449358|NCT03640325|Experimental|PRISM (Promoting Resilience in Stress Management)|Resilience Skills Training
16449359|NCT03640325|No Intervention|Usual Care|Usual psychosocial care (control arm, no intervention)
16449393|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
16449394|NCT03640039|Experimental|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
16449360|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
16449361|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
16449362|NCT03640299|Experimental|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.
~Extensive preoperative counselling and education by surgeon and anesthetists.
~No Bowel preparation.
~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.
~Oral nonselective NSAIDs premedication.
~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).
~Minimally invasive surgery.
~Maintenance of normothermia.
~Avoidance of surgical drains and nasogastric tubes.
~Nonselective NSAIDs postoperative medication.
~Postoperative nausea and vomiting active control.
~Early oral feeding and ambulation.
~VTE prophylaxis postoperative."
16449363|NCT03640299|No Intervention|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.
~Conventional preoperative visits and education.
~Mechanical bowel preparation.
~Fasting overnight, and no fluids before surgery.
~No oral nonselective NSAIDs premedication.
~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.
~Minimally invasive surgery.
~No maintenance of normothermia.
~Drainage tube insertion if needed.
~Postoperative patient-controlled intravenous analgesia.
~Postoperative Nausea Control if needed.
~Conventional oral feeding and mobilization.
~No bowel routine.
~VTE prophylaxis postoperative."
16449364|NCT03640286|Active Comparator|VeSTAL - active device|The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
16449365|NCT03640286|Sham Comparator|Sham device|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
16449366|NCT03640273|Experimental|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
16449367|NCT03640273|Experimental|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
16449368|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
16449369|NCT03640260|No Intervention|controlled|
16449370|NCT03640247|Other|Narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with
~Ibuprofen tablet 800 mg by mouth every 8 hours
~Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
16449371|NCT03640247|Active Comparator|Non-narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with
~Ibuprofen tablet 800 mg by mouth every 8 hours"
16449372|NCT03640221|Experimental|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
16449373|NCT03640221|Active Comparator|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
16449374|NCT03640208|Experimental|Complete colorectal screening|11 step process divided into three phases: 1. Community Outreach Event; 2. Data Collection; 3. Navigation and Program Monitoring
16449375|NCT03640195|Experimental|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
16449376|NCT03640195|No Intervention|Control group|without intervention
16449377|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
16449378|NCT03640169|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
16449379|NCT03640156|Experimental|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
16449380|NCT03640156|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
16449381|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
16449382|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
16449383|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
16449384|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
16449385|NCT03640091|Experimental|Pre-extractive inter-radicular implant bed preparation|
16449386|NCT03640078|Experimental|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
16449387|NCT03640065|Experimental|freeze-dried probiotic sachets|
16449388|NCT03640065|Active Comparator|fermented dairy product (yogurt)|
16449389|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
16449390|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
16449395|NCT03640039|Active Comparator|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
16449396|NCT03640026|Experimental|Tacrolimus treatment|
16449397|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
16449398|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
16449399|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
16449400|NCT03639987|Experimental|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
16449401|NCT03639987|Experimental|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
16449402|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
16449403|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
16449404|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
16449405|NCT03639961|Experimental|Staff of facilities for intervention|Intervention: Participants have been trained two times in six months period with integrated leading, managing and governing for results model.
16449406|NCT03639961|Active Comparator|Staff of facilities for control|Intervention: Participants have been trained two times in six months period with traditional model.
16449407|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.
~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
16449408|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
16449409|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
16449410|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
16449411|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
16449412|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
16449413|NCT03639896|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
16449414|NCT03639896|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
16449415|NCT03639883|Placebo Comparator|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
16449416|NCT03639883|Placebo Comparator|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
16449417|NCT03639883|Placebo Comparator|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
16449418|NCT03639883|Placebo Comparator|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
16449419|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
16449420|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
16449421|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
16449422|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
16449423|NCT03639831|Experimental|Active group|Proprietary, standardized botanical extract
16449424|NCT03639831|Placebo Comparator|Placebo group|Placebo (maltodextrin)
16449425|NCT03639818|Experimental|experimental group|HIV patients
16449426|NCT03639805|Active Comparator|non interventional arm|Standard Of Care
16449427|NCT03639805|Experimental|interventional arm|Standard of Care + music therapy program MUSIC CARE®
16449428|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
16449429|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
16449430|NCT03639766|Experimental|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
16449431|NCT03639766|Placebo Comparator|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
16449432|NCT03639753|Experimental|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
16449434|NCT03639740|Other|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
16449435|NCT03639727|Active Comparator|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
16449436|NCT03639727|Active Comparator|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
16449437|NCT03639714|Experimental|Phase 1|"GRT-C901
~GRT-R902
~nivolumab
~ipilimumab"
16449438|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901
~GRT-R902
~nivolumab
~ipilimumab"
16449439|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
16449440|NCT03639688|Active Comparator|Left sided|
16449441|NCT03639688|Active Comparator|Right sided|
16449442|NCT03639675|Experimental|NVG patients|Japanese patients with neovascular glaucoma
16449443|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.
~Patients will also be able to share their feelings and ask questions"
16449444|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
16449445|NCT03639649|Experimental|STHLM3|
16449446|NCT03639649|Active Comparator|PSA|
16449447|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
16449448|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
16449449|NCT03639610|Experimental|Single arm|"Cohort 1A Melphalan flufenamide 40 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.
~Cohort 1B Melphalan flufenamide 30 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.
~Cohort 2A Melphalan flufenamide 20 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.
~Cohort 2B Melphalan flufenamide 30 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg."
16449450|NCT03639597|Experimental|Study device|VytronUS Ablation System
16449451|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
16449452|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
16449453|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
16449454|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
16449455|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
16449456|NCT03639571|Experimental|Test|Ibuprofen 200mg TEPI medicated plaster
16449457|NCT03639571|Placebo Comparator|Placebo|Placebo TEPI Plaster
16449458|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|
16449459|NCT03639558|Experimental|Haloperidol + Promethazine|
16449460|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
16449461|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
16449462|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
16449463|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
16449464|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
16449465|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
16449466|NCT03639519|Experimental|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
16449467|NCT03639519|Placebo Comparator|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
16449468|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
16449469|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
16449470|NCT03639493|Experimental|Sequence 1|"Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg
~Period 2: receive CJ-30060 10/160/20mg"
16449471|NCT03639493|Experimental|Sequence 2|"Period 1: receive CJ-30060 10/160/20mg
~Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
16449472|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
16449475|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.
~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.
~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
16449476|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16449477|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16449478|NCT03639441|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16449479|NCT03639441|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16449480|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
16449481|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
16449482|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
16449483|NCT03639415|Experimental|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.
~Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.
~Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
16449484|NCT03639402|Experimental|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).
~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
16449485|NCT03639402|No Intervention|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
16449486|NCT03639389|Active Comparator|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
16449487|NCT03639389|Experimental|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
16449488|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
16449489|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
16449490|NCT03639363|Experimental|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
16449491|NCT03639363|Active Comparator|Control Arm|daily bathing with standard soap
16449492|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
16449493|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
16449494|NCT03639337|Experimental|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.
~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
16449495|NCT03639337|No Intervention|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
16449496|NCT03639337|No Intervention|Controls|Healthy controls ages between 10 and 14 months
16449503|NCT03639311|Experimental|Participants receiving Injection CAB LA plus RPV LA|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
16449587|NCT03638778|Experimental|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
16449504|NCT03639311|Experimental|Participants receiving Oral DTG plus RPV|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available.
16449505|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
16449506|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
16449507|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
16449508|NCT03639246|Experimental|Phase 1b: AVB-S6-500+PLD|
16449509|NCT03639246|Experimental|Phase 1b: AVB-S6-500+Pac|
16449510|NCT03639246|Experimental|Phase 2: AVB-S6-500+PLD|
16449511|NCT03639246|Experimental|Phase 2: AVB-S6-500+Pac|
16449512|NCT03639246|Active Comparator|Phase 2: Placebo+PLD|
16449513|NCT03639246|Active Comparator|Phase 2: Placebo+Pac|
16449514|NCT03639233|Other|Arm 1|Intervention access
16449515|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
16449516|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
16449517|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
16449518|NCT03639194|Experimental|Part A: ABBV-011 Dose Escalation|ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.
16449519|NCT03639194|Experimental|Part B: ABBV-011 Dose Expansion|ABBV-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A.
16449520|NCT03639194|Experimental|Part C: ABBV-011 + Budigalimab Escalation and Expansion|ABBV-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of ABBV-011 for Part B plus Budigalimab via intravenous administration at fixed doses and various dosing regimens.
16449521|NCT03639194|Experimental|Part D: ABBV-011 Dose Evaluation for Japan|ABBV-011 via intravenous administration will be administered every 3 weeks (Q3wk), on Day 1 of each 21-day cycle or alternate dosing regimens.
16449522|NCT03639181|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
16449523|NCT03639168|Experimental|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
16449524|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
16449525|NCT03639155|Experimental|Regimen B|vadadustat test tablets
16449526|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
16449527|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
16449528|NCT03639129|Experimental|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
16449529|NCT03639116|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post first-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be recruited to participate.
16449530|NCT03639116|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
16449531|NCT03639077|Experimental|Allograft bone alone|
16449532|NCT03639077|Experimental|Allograft and xenograft mixture|
16449533|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
16449534|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
16449535|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
16449536|NCT03639051|Experimental|Active Treatment|Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
16449537|NCT03639051|Sham Comparator|Sham Control|Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
16449538|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
16449539|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
16449540|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
16449541|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
16449542|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
16449543|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
16449544|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
16449545|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
16449546|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
16449547|NCT03639025||Standard Donor Lungs Primary Analysis Population|The first 289 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
16449548|NCT03639025||Initially Unacceptable Donor Lung Primary Analysis Pop.|The first 266 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
16449549|NCT03639025||All Other Enrolled Patients|All OCS Lung transplanted patients that do not meet any of the above analysis populations.
16449550|NCT03639012|Active Comparator|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
16449552|NCT03638999|Active Comparator|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
16449553|NCT03638999|Placebo Comparator|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
16449554|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
16449555|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
16449556|NCT03638973|Experimental|Biopsy with Er: YAG|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
16449557|NCT03638973|Active Comparator|Biopsy with Scalpel|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
16449558|NCT03638960|Active Comparator|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
16449559|NCT03638960|Experimental|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
16449560|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
16449561|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
16449562|NCT03638934|Experimental|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
16449563|NCT03638934|Active Comparator|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
16449564|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
16449565|NCT03638908|Other|Fluoxetine|"Dosing will be
~Week 1-4: 20 mg daily
~Week 5-8: 40 mg daily
~Week 9-12: 60 mg daily
~Week 13-24: 80 mg daily"
16449566|NCT03638895|Active Comparator|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
16449567|NCT03638895|Placebo Comparator|SC group|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
16449568|NCT03638882|Experimental|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
16449569|NCT03638882|Active Comparator|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
16449570|NCT03638882|Placebo Comparator|Passive Control|No intervention.
16449571|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
16449572|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449573|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449574|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449575|NCT03638856|Experimental|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
16449576|NCT03638856|No Intervention|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
16449577|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
16449578|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
16449579|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
16449580|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
16449581|NCT03638817|Experimental|Eltrombopag|
16449582|NCT03638804|Experimental|89Zr-KN035 injection|
16449583|NCT03638791||Healthy controls|Matched Controls without treatment
16449584|NCT03638791||OCD|Exposure and response inhibition
16449585|NCT03638778|Active Comparator|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
16449588|NCT03638778|Experimental|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
16449589|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
16449590|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:
~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;
~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,
~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,
~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,
~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,
~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
16449591|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:
~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,
~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
16449592|NCT03638739|Experimental|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
16449593|NCT03638739|Experimental|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
16449594|NCT03638726|Experimental|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
16449595|NCT03638726|Other|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
16449596|NCT03638713|Experimental|colonoscopy first group|Patients received water-exchange colonoscopy first and followed by esophagogastroduodenoscopy
16449597|NCT03638713|Active Comparator|EGD first group|Patients received esophagogastroduodenoscopy first and followed by water-exchange colonoscopy
16449598|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
16449599|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
16449600|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
16449601|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
16449602|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
16449603|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
16449604|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
16449605|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
16449606|NCT03638674|Active Comparator|2nd lumbar spine acquisition in same position|spine and hip STRATOS DR + 2nd lumbar spine acquisition in same position (with template)
16449607|NCT03638674|Active Comparator|2nd lumbar spine acquisition|spine and hip STRATOS DR + 2nd lumbar spine acquisition (no template)
16449608|NCT03638674|Active Comparator|2nd hip acquisition in same position|spine and hip STRATOS DR + 2nd hip acquisition in same position (with template)
16449609|NCT03638674|Active Comparator|2nd hip acquisition|spine and hip STRATOS DR + 2nd hip acquisition (without template)
16449610|NCT03638661|Experimental|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).
~vegetable (canola, flaxseed) derived n-3 fatty acid"
16449611|NCT03638661|Placebo Comparator|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.
~soybean used formula"
16449612|NCT03638648|Active Comparator|Low risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk receiving capecitabine.
16449613|NCT03638648|No Intervention|Low risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk NOT receiving any additional chemotherapy.
16449614|NCT03638648|Experimental|High risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk receiving capecitabine.
16449615|NCT03638648|No Intervention|High risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk NOT receiving any additional chemotherapy.
16449616|NCT03638635|Active Comparator|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
16449617|NCT03638635|Experimental|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
16449618|NCT03638622|Experimental|Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)|Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
16449619|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
16449620|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
16449621|NCT03638596|Experimental|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
16449622|NCT03638596|Placebo Comparator|Control|Incentive delivery not contingent on transdermal alcohol concentration
16449623|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;
~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.
~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
16449624|NCT03638544|Active Comparator|Reduced Gluten-Normal Gluten|
16449625|NCT03638544|Active Comparator|Normal Gluten-Reduced Gluten|
16449626|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
16449627|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
16449628|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.
~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.
~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
16449629|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
16449630|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
16449631|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
16449632|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
16449633|NCT03638492|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
16449634|NCT03638492|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
16449635|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
16449636|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor or other Movement Disorders
16449637|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD, ET or other Movement Disorders
16449638|NCT03638466|Experimental|Single dose of SPN-810|Subjects will be treated with medium dose of SPN-810
16449639|NCT03638466|Placebo Comparator|Placebo|Subjects will be treated with a matching Placebo
16449640|NCT03638453|Experimental|PediCARE|"PediCARE Administered x6 mos
~Resource Provision: Monthly Groceries (delivery via Instacart)
~Resource Provision: Transport to/from home/hospital 8x per month (via RideHealth)"
16449641|NCT03638453|Active Comparator|Usual Care|The control group will receive usual supportive care
16449642|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
16449643|NCT03638414|Experimental|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
16449644|NCT03638414|No Intervention|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
16449645|NCT03638401|No Intervention|Standard treatment|
16449646|NCT03638401|Active Comparator|Intervention arm|
16449647|NCT03638388|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.
~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
16449648|NCT03638388|Active Comparator|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.
~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
16453763|NCT03609957|No Intervention|Control|Control (no exercise intervention) group
16449649|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.
~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion
~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
16449650|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.
~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion
~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion
~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
16449651|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
16449652|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
16449653|NCT03638336|Experimental|flexible ureteroscopy|
16449654|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
16449655|NCT03638310|Experimental|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
16449656|NCT03638310|Active Comparator|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
16449657|NCT03638297|Experimental|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
16449658|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
16449659|NCT03638271|Other|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
16449660|NCT03638258|Experimental|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% topically applied once daily
16449661|NCT03638258|Experimental|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% topically applied once daily
16449662|NCT03638258|Placebo Comparator|ARQ-151 Vehicle cream|Matching vehicle cream containing only excipients of ARQ-151 cream applied once daily
16449663|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
16449664|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
16449665|NCT03638232||Patients with multiple myeloma|"Data to be collected are :
~Drug exposition data
~Administrative data
~Medical data"
16449666|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
16449667|NCT03638193|Experimental|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10^7/m^2 CART positive cells(chort 1)or 1-3×10^8/m^2 CART positive cells(chort 2).
16449668|NCT03638180|Experimental|Single Ascending Doses|Single ascending doses, 6 dose levels
16449669|NCT03638180|Experimental|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
16449670|NCT03638167|Experimental|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
16449671|NCT03638167|Experimental|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
16449672|NCT03638154|Placebo Comparator|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
16449673|NCT03638154|Active Comparator|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.
~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
16449674|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort A dose)|"Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).
~Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted."
16449675|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort B dose)|Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.
16449676|NCT03638128|Experimental|Denosumab 3-Month Dosing Regimen|
16449677|NCT03638128|Active Comparator|Alternative Treatment|Alternative osteoporosis medication/s at the discretion of the investigator, including the commercially available denosumab on a 6-month dosing regimen.
16449678|NCT03638128|Active Comparator|No Intervention|Subjects who discontinue any osteoporosis medication when joining Study 20170534 for off-treatment observation.
16449679|NCT03638115|Experimental|VaSecure™ Drug Coated PTA Balloon Catheter|
16449680|NCT03638102|Experimental|Sleep intervention|Sleep extension
16449681|NCT03638102|Active Comparator|Healthy living|Health education
16449682|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
16449722|NCT03637816|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
16449683|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
16449684|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
16449685|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
16449686|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
16449687|NCT03638063||Control|healthy controls
16449688|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
16449689|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
16449690|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
16449691|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
16449692|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
16449693|NCT03638011|No Intervention|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
16449694|NCT03638011|Active Comparator|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
16449695|NCT03637998|Experimental|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
16449696|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
16449697|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
16449698|NCT03637972|Experimental|Ventilated cigarettes only|Filters with approximately 30-36% filter ventilation
16449699|NCT03637972|Experimental|Unventilated cigarettes only|Filters with approximately 3.0-4.6% filter ventilation
16449700|NCT03637972|Experimental|Ventilated cigarettes + alternative nicotine delivery systems|Filters with approximately 30-36% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
16449701|NCT03637972|Experimental|Unventilated cigarettes + ANDS|Filters with approximately 3.0-4.6% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
16449702|NCT03637959|Experimental|MR Elastography comparision study|Evaluate the efficacy of liver stiffness measured by ultrasound for fibrosis staging, using clinically indicated MRE as the gold standard.
16449703|NCT03637946|Experimental|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
16449704|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
16449705|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
16449706|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
16449707|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
16449708|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
16449709|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.
~The breastfeeding infants were the reference group"
16449710|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
16449711|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
16449712|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.
~The breastfeeding infants were the reference group."
16449713|NCT03637881||Other|Daily or non-daily Consumers
16449714|NCT03637868|Experimental|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
16449715|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
16449716|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
16449717|NCT03637829|Placebo Comparator|Control|250 mL of water
16449718|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
16449719|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
16449720|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
16449721|NCT03637816|Experimental|Arm I (anamorelin hydrochloride)|Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
16453877|NCT03609164|Active Comparator|single-row repair|
16449723|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
16449724|NCT03637790|Other|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
16449725|NCT03637790|Other|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
16449733|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
16449734|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
16449735|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.
~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
16449736|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
16449737|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
16449738|NCT03637712|Experimental|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
16449739|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
16449740|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
16449743|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
16449744|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
16449745|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
16449746|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
16449747|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
16449748|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
16449749|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.
~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
16449750|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
16449751|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
16449752|NCT03637556|Experimental|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
16449753|NCT03637556|Active Comparator|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
16449754|NCT03637556|Active Comparator|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
16449755|NCT03637543|Experimental|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
16449756|NCT03637543|Experimental|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
16449757|NCT03637530|Experimental|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
16449758|NCT03637530|No Intervention|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
16449759|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
16449760|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
16449761|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
16449762|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
16449763|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
16449764|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
16449765|NCT03637491|Experimental|Avelumab and binimetinib|Open label
16449766|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
16449767|NCT03637491|Experimental|Binimetinib and talazoparib.|Open label.
16449768|NCT03637478|Experimental|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
16449769|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
16449770|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
16449771|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
16449772|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
16449773|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
16449774|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
16449775|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
16449776|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
16449777|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.
~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
16449871|NCT03636854|Experimental|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
16449778|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
16449779|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
16449780|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
16449781|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
16449782|NCT03637387|Experimental|BIIB074|Administered orally three times daily (TID)
16449783|NCT03637387|Placebo Comparator|Placebo|Placebo matching BIIB074
16449784|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
16449785|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
16449786|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
16449787|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449788|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449789|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449790|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449791|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
16449792|NCT03637348|Other|TrueTear|Use of TrueTear device to stimulate tear production
16449793|NCT03637335|Experimental|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
16449794|NCT03637335|Placebo Comparator|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
16449795|NCT03637309|Experimental|BeReady2Smile Video and App|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
16449796|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
16449797|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
16449798|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
16449799|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
16449800|NCT03637270|Experimental|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
16449801|NCT03637270|Active Comparator|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
16449802|NCT03637257|Experimental|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
16449803|NCT03637257|Experimental|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
16449804|NCT03637244|Experimental|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
16449805|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
16449806|NCT03637218|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
16449807|NCT03637218|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16449808|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
16449809|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
16453878|NCT03609151|Active Comparator|group A|laparoscopic hepatectomy (surgery)
16449810|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
16449811|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16449812|NCT03637179|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
16449813|NCT03637179|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16449814|NCT03637166|Experimental|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
16449815|NCT03637166|Experimental|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
16449816|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
16449817|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
16449818|NCT03637140|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
16449819|NCT03637140|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16449820|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
16449821|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16449822|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
16449823|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16449824|NCT03637088|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
16449825|NCT03637088|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16449826|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
16449827|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
16449828|NCT03637062|Experimental|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
16449829|NCT03637062|Active Comparator|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
16449830|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
16449831|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
16449832|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
16449833|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
16449834|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
16449837|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
16449838|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
16449872|NCT03636854|Experimental|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
16449839|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
16449840|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
16449841|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
16449842|NCT03636971|Experimental|hyaluronic acid with mannitol|
16449843|NCT03636971|Experimental|hyaluronic acid with sorbitol|
16449844|NCT03636971|Active Comparator|saline|
16449845|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
16449846|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
16449847|NCT03636945|Experimental|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
16449848|NCT03636932|Active Comparator|N-acetylcysteine (NAC) group|
16449849|NCT03636932|Placebo Comparator|Placebo group|
16449850|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
16449851|NCT03636906|Experimental|1 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Bexsero vaccine
16449852|NCT03636906|Experimental|2 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Bexsero vaccine
16449853|NCT03636906|Active Comparator|Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive the Bexsero vaccine comparator and placebo
16449854|NCT03636906|Experimental|1 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Nimenrix vaccine
16449855|NCT03636906|Experimental|2 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Nimenrix vaccine
16449856|NCT03636906|Active Comparator|Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Nimenrix comparator vaccine and placebo.
16449857|NCT03636906|Experimental|1 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Menveo vaccine
16449858|NCT03636906|Experimental|2 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Menveo vaccine
16449859|NCT03636906|Active Comparator|Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Menveo comparator vaccine and placebo.
16449860|NCT03636906|Experimental|1 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive1 dose of the experimental GSK3389245A vaccine followed by placebo and Synflorix vaccine
16449861|NCT03636906|Experimental|2 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive2 doses of the experimental GSK3389245A vaccine followed by Synflorix vaccine
16449862|NCT03636906|Active Comparator|Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Synflorix comparator vaccine and placebo
16449863|NCT03636906|Experimental|1 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 1 dose of the GSK3389245A experimental vaccine followed by placebo.
16449864|NCT03636906|Experimental|2 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 2 doses of the GSK3389245A experimental vaccine followed by placebo.
16449865|NCT03636906|Placebo Comparator|Placebo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Placebo vaccine
16449866|NCT03636893|Experimental|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered
~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous
~Repeated every 15th day"
16449867|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered
~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)
~Repeated every 21st day"
16449868|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
16449869|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
16449870|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
16449992|NCT03635970|Placebo Comparator|conventional treatment|receive the best conventional therapy
16449873|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
16449874|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
16449875|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
16449876|NCT03636789|Experimental|Neurological consultation group|
16449877|NCT03636776|Experimental|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.
~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.
~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.
~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
16449878|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
16449879|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
16449880|NCT03636750|Experimental|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
16449881|NCT03636750|Experimental|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
16449882|NCT03636750|Experimental|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
16449883|NCT03636750|Experimental|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
16449884|NCT03636750|Experimental|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
16449885|NCT03636750|Experimental|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
16449886|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
16449887|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
16449888|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
16449889|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
16449890|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
16449891|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
16449892|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I
~Anlotinib combined with pemetrexed and carboplatin, phase II"
16449893|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I
~Anlotinib combined with paclitaxel and carboplatin, phase II"
16449894|NCT03636672|Experimental|experimental|Perturbation training during stationary bicycle riding
16449895|NCT03636672|Active Comparator|control|stationary bicycle riding training
16449896|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
16449897|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
16449898|NCT03636633|Active Comparator|Control Group|"Standard respiratory physiotherapy
~Patients in this group will receive standard respiratory physiotherapy two times a day, 7 days a week for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
16449899|NCT03636633|Experimental|Training Group|"Standard respiratory physiotherapy and inspiratory muscle train
~In addition to the standard respiratory physiotherapy program, patients in this group will receive 3 sets of inspiratory muscle training with 10 repetitions twice a day for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
16449900|NCT03636620|Active Comparator|TACE group|Transcatheter arterial chemoembolization
16449901|NCT03636620|Experimental|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
16449902|NCT03636607|Experimental|Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
16449903|NCT03636607|Experimental|Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
16449904|NCT03636594|Experimental|Dance|This was a single arm study with all participants receiving the same intervention.
16449905|NCT03636581|Experimental|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
16449906|NCT03636581|No Intervention|Control|This group will receive a smart watch to track activity only with no intervention.
16449907|NCT03636568|Experimental|Fluid restricted|Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg)
16449908|NCT03636568|No Intervention|Non Fluid Restricted|No fluid restriction
16449909|NCT03636555|Active Comparator|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
16449910|NCT03636555|Placebo Comparator|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
16449911|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
16449912|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
16449913|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
16449914|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
16449915|NCT03636516|Active Comparator|jj stent yes|
16449916|NCT03636516|Active Comparator|jj stent no|
16449917|NCT03636503|Experimental|Rituximab +Utomilumab+Avelumab|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
~Utomilumab is administered intravenously over 1 hour once every 4 weeks
~Avelumab is administered intravenously over 1 hour once every 2 weeks"
16449918|NCT03636503|Experimental|Rituximab+Utomilumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
~Utomilumab is administered intravenously over 1 hour once every 4 weeks
~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
16449919|NCT03636503|Experimental|Rituximab+Avelumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
~Avelumab is administered intravenously over 1 hour once every 2 weeks
~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
16449920|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
16449921|NCT03636477|Experimental|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
16449922|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
16449923|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
16449924|NCT03636399|Experimental|Standard GIST|Standard Group Interactive Structured Treatment.
16449925|NCT03636399|Other|Waitlist control/Intensive GIST|After a wait list control period of nine months the participants receive Intensive Group Interactive Structured Treatment.
16449926|NCT03636386|Experimental|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
16449927|NCT03636386|Active Comparator|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
16449928|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
16449929|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
16449930|NCT03636360|Experimental|LED - Sunlike|LED lighting with spectral pattern similar to that of sunlight
16449931|NCT03636360|Active Comparator|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
16449932|NCT03636360|Placebo Comparator|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
16449933|NCT03636360|Active Comparator|LED|Standard LED lighting
16449934|NCT03636347|Placebo Comparator|Placebo oral tablet|
16449935|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
16449936|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
16449937|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
16449938|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
16449939|NCT03636321|Experimental|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis with internal biliary stent
16449940|NCT03636321|Active Comparator|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without internal biliary
16449941|NCT03636308|Experimental|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.
~S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
16449942|NCT03636308|Active Comparator|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.
~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
16449943|NCT03636295|Experimental|Reduced INR Target|Warfarin therapy will be titrated to a target INR in the range of 1.5 to 2.5.
16449944|NCT03636295|Active Comparator|Standard INR Target|"Warfarin therapy will be titrated to a standard of care target INR range."
16449945|NCT03636282|Experimental|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
16449946|NCT03636282|No Intervention|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
16449947|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
16449948|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
16449949|NCT03636256|Experimental|Non-Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL and additional Induction (6 weekly NanoDoce intravesical instillations, followed by 6 weeks of rest) and Maintenance (3 weekly NanoDoce intravesical instillations, followed by 9 weeks of rest) instillations at 2.0 or 3.0 mg/mL.
16449950|NCT03636256|Experimental|Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.
16449951|NCT03636243|Other|Group of obese patients with type-2 diabetes|
16449952|NCT03636243|Other|Group of non-diabetic obese patients|
16449953|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
16449954|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
16449955|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
16449956|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
16449957|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
16449958|NCT03636204|Experimental|AL001|Up to six single ascending doses of AL001
16449959|NCT03636204|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
16449960|NCT03636191|Experimental|Probiotic|
16449961|NCT03636191|Placebo Comparator|Placebo|
16449962|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
16449963|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
16449966|NCT03636152|Active Comparator|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
16449967|NCT03636152|Placebo Comparator|Placebo Group|These patients will receive a matching placebo for 18 months
16449968|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
16449969|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
16449970|NCT03636126|Experimental|VR + TACS|"Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).
~Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
16449971|NCT03636126|No Intervention|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
16449972|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
16449973|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
16449974|NCT03636087|Active Comparator|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
16449975|NCT03636087|Experimental|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
16449976|NCT03636074||Hearth-valve surgery|
16449977|NCT03636074||Hearth bypass surgery|
16449982|NCT03636048|Experimental|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
16449983|NCT03636048|Active Comparator|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
16449984|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
16449985|NCT03636022|Experimental|VR System|Participants will then be assigned one week of daily exposure homework. Patients randomized to the intervention condition will take home the VR system for homework.
16449986|NCT03636022|Experimental|Control Condition|Participants will then be assigned one week of daily exposure homework. Participants assigned to control will be instructed to complete imaginal exposures.
16449987|NCT03636009|Experimental|Concurrent traction|Concurrent traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
16449988|NCT03636009|Active Comparator|Sequential traction|Sequential traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
16449989|NCT03635996|Experimental|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
16449990|NCT03635983|Experimental|Combination|NKTR-214 + Nivolumab
16449991|NCT03635983|Experimental|Monotherapy|Nivolumab
16449993|NCT03635970|Active Comparator|experimental treatment|The best medical treatment possible plus celular therapy
16449994|NCT03635957|Experimental|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.
~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
16449995|NCT03635944||Group A|Infants born in Lyon (France)
16449996|NCT03635944||Group B|Infants born in Stockholm (Sweden)
16449997|NCT03635931|Active Comparator|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
16449998|NCT03635931|No Intervention|Control Group|plaque control, scaling and root planing if required
16449999|NCT03635918|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
16450000|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
16450001|NCT03635905|Placebo Comparator|Placebo|
16450002|NCT03635892|Experimental|Cohort 1: Unclassified, papillary, and HL RCC|Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
16450003|NCT03635892|Experimental|Cohort 2: Chromophobe RCC|Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
16450004|NCT03635892|Experimental|Cohort 3: Unclassified, papillary, and HL RCC|Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
16450005|NCT03635892|Experimental|Cohort 4: Unclassified, papillary, and HL RCC|Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
16450006|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
16450007|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
16450008|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
16450009|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
16450010|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
16450011|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
16450012|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
16450013|NCT03635853|Experimental|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
16450014|NCT03635840|No Intervention|Control|Group of patients not receiving IABP
16450015|NCT03635840|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
16450016|NCT03635827|Active Comparator|NBTX-001|
16450017|NCT03635827|Placebo Comparator|Placebo|
16450018|NCT03635814|Experimental|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
16450019|NCT03635814|Placebo Comparator|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
16450020|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.
~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.
~An ECG is performed under controlled conditions."
16450023|NCT03635775|Experimental|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
16450024|NCT03635775|Experimental|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
16450025|NCT03635775|Experimental|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
16450026|NCT03635775|Sham Comparator|Sham tDCS|Sham tDCS applied in one of the above configurations
16450027|NCT03635762|Experimental|Be In Charge|behavioral + nutrition education program
16450028|NCT03635749|Active Comparator|DAPT + immediate high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
16450029|NCT03635749|Other|DAPT + delayed high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
16450030|NCT03635749|Other|Aspirin+immediate high-intensity statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
16450031|NCT03635749|Placebo Comparator|Aspirin+delayed high-intensity statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
16450032|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
16450033|NCT03635697|Experimental|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
16450034|NCT03635697|No Intervention|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
16450035|NCT03635684|Experimental|SC Acetaminophen|Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
16450036|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
16450037|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
16450038|NCT03635658|Active Comparator|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
16450039|NCT03635658|Experimental|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
16450040|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
16450041|NCT03635632|Experimental|Arm A: High-risk group of patients with lung metastases|"Patients will be treated at 4 dose levels. At dose level 0, patients will only receive C7R-GD2.CART cells without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
~Starting at dose level 1, the protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Starting with dose level 1, each arm will undergo separate dose escalation."
16450042|NCT03635632|Experimental|Arm B: Standard risk group of all other patients|"Patients will be treated at 4 dose levels. At the dose level 0, patients will only receive C7R-GD2.CART cells without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
~Starting at dose level 1, the protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Starting with dose level 1, each arm will undergo separate dose escalation."
16450043|NCT03635593|Active Comparator|CBD|10mg capsules Cannabidiol (CBD)
16450044|NCT03635593|Active Comparator|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
16450045|NCT03635593|Placebo Comparator|Placebo|10mg capsules placebo
16450046|NCT03635580|Experimental|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
16450047|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
16450048|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
16450049|NCT03635541||observational group of NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
16450050|NCT03635528|Experimental|Test 1\Test 2\Control 2\Test 3\Control 1\Test 4\Test 5|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450051|NCT03635528|Experimental|Test 2\Test 3\Test 1\Test 4\Control 2\Test 5\Control 1|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450052|NCT03635528|Experimental|Test 3\Test 4\Test 2\Test 5\Test 1\Control 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450053|NCT03635528|Experimental|Test 4\Test 5\Test 3\Control 1\Test 2\Control 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450054|NCT03635528|Experimental|Test 5\Control 1\Test 4\Control 2\Test 3\Test 1\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450055|NCT03635528|Experimental|Control 1\Control 2\Test 5\Test 1\Test 4\Test 2\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450056|NCT03635528|Experimental|Control 2\Test 1\Control 1\Test 2\Test 5\Test 3\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450057|NCT03635528|Experimental|Test 5\Test 4\Control 1\Test 3\Control 2\Test 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450058|NCT03635528|Experimental|Control 1\Test 5\Control 2\Test 4\Test 1\Test 3\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450136|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
16450059|NCT03635528|Experimental|Control 2\Control 1\Test 1\Test 5\Test 2\Test 4\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450060|NCT03635528|Experimental|Test 1\Control 2\Test 2\Control 1\Test 3\Test 5\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450061|NCT03635528|Experimental|Test 2\Test 1\Test 3\Control 2\Test 4\Control 1\Test 5|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450062|NCT03635528|Experimental|Test 3\Test 2\Test 4\Test 1\Test 5\Control 2\Control 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450063|NCT03635528|Experimental|Test 4\Test 3\Test 5\Test 2\Control 1\Test 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
16450064|NCT03635515|Active Comparator|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
16450065|NCT03635515|Active Comparator|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
16450066|NCT03635502||Stroke Group|
16450067|NCT03635502||Healthy Group|
16450068|NCT03635489|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab for a total of 21 cycles of bevacizumab in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
16450069|NCT03635489|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and placebo IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy placebo for a total of 21 cycles of placebo in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
16450070|NCT03635463|Experimental|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
16450071|NCT03635463|Experimental|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
16450072|NCT03635450|Experimental|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
16450073|NCT03635450|Experimental|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
16450074|NCT03635437|Experimental|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
16450075|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
16450076|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA) + Alprazolam|Oral Alprazolam treatment 0.5 mg daily combined with oral GABA treatment 600 mg daily for 3 months. Alprazolam treatment thereafter ended, and study subjects will continue with oral GABA treatment 600 mg daily only for another 3 months.
16450078|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
16450079|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
16450080|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
16450081|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
16450082|NCT03635398|Active Comparator|oral administration of midazolam|
16450083|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
16450084|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
16450085|NCT03635372|Experimental|Alginate|10 cc of Alginate peroral
16450086|NCT03635372|Experimental|Sucralfate|10 cc of Sucralfate peroral
16450087|NCT03635372|Experimental|Hydrotalcite|10 cc of Hydrotalcite peroral
16450088|NCT03635359||positive for fetal aneuploidy|
16450089|NCT03635359||negative for fetal aneuploidy|
16450090|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
16450091|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
16450092|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
16450093|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
16450094|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
16450095|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
16450096|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
16450097|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
16450098|NCT03635307||Operated patients with volume expansion|
16450099|NCT03635294|Experimental|Blood sample|Blood sample for analyses
16453879|NCT03609151|Experimental|group B|stereotactic body radiotherapy (SBRT)
16450100|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
16450101|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers
~set FIO2 at 1.0
~Ppeak limit at 45 cmH2O
~Respiratory rate set at 6
~I:E set at 1:1
~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O
~If the maximum VT is set without rasing the Pplat, raise PEEP
~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O
~End of RM
~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
16450102|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
16450103|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.
~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
16450104|NCT03635190|Experimental|Interventional|Orbital Circumferential Atherectomy
16450107|NCT03635164|Experimental|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.
~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.
~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
16450110|NCT03635138|Experimental|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
16450111|NCT03635138|Active Comparator|Adhesive control|Adhesive conventional
16450112|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
16450113|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
16450114|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
16450115|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
16450119|NCT03635099|Experimental|Dose group A|
16450120|NCT03635099|Experimental|Dose group B|
16450121|NCT03635099|Experimental|Dose group C|
16450122|NCT03635099|Experimental|Dose group D|
16450123|NCT03635099|Placebo Comparator|Placebo|
16450124|NCT03635099|Experimental|Dose group V|
16450125|NCT03635099|Experimental|Dose group U|
16450126|NCT03635099|Placebo Comparator|Placebo W|
16450132|NCT03635073|Experimental|TAK-935|Treatment: 0 to 2 Weeks Dose Optimization Period followed by 103 weeks Maintenance Period.
16450133|NCT03635060|Active Comparator|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
16450134|NCT03635060|Active Comparator|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
16450135|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
16453880|NCT03609138||Study Cohort|
16450137|NCT03635034|Experimental|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.
~Intervention: No catheter"
16450138|NCT03635034|Active Comparator|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.
~Intervention: bladder catheter inserted"
16450139|NCT03635021|Experimental|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
16450140|NCT03635021|Experimental|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
16450141|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.
~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
16450142|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.
~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
16450143|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
16450144|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
16450145|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
16450146|NCT03634982|Experimental|RMC-4630|RMC-4630 for oral administration
16450147|NCT03634969|Experimental|Normal Renal Function|
16450148|NCT03634969|Experimental|Mild Renal Impairment|
16450149|NCT03634969|Experimental|Moderate Renal Impairment|
16450150|NCT03634969|Experimental|Severe Renal Impairment|
16450151|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
16450152|NCT03634956|Experimental|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
16450153|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
16450154|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
16450155|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
16450156|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium
~oral use
~3 times / day (morning, noon, evening)
~666 mg per capsule
~14 - 19 days"
16450157|NCT03634917|Active Comparator|Calcium Carbonate|"1 capsule with Calcium Carbonate
~oral use
~3 times / day (morning, noon, evening)
~1500 mg Calcium Carbonate (= 600 mg Calcium 2+)
~14 - 19 days"
16450158|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,
~oral use
~3 times / day (morning, noon, evening)
~14 - 19 days"
16450159|NCT03634904|Experimental|Drug Blood sampling|"Drug Blood sampling
~Pharmacokinetic study measuring total and free ceftazidime concentrations"
16450160|NCT03634878|Experimental|Perineal ultrasound to visualize the strips and their position|
16450161|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
16450162|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
16450163|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet non-menthol|Nicotine 0 mg combined with sweet non-menthol flavor
16450164|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet non-menthol|Nicotine 3 mg combined with sweet non-menthol flavor
16450165|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet non-menthol|Nicotine 12 mg combined with sweet non-menthol flavor
16450166|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet menthol|Nicotine 0 mg combined with sweet menthol flavor
16450167|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet menthol|Nicotine 3 mg combined with sweet menthol flavor
16450168|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet menthol|Nicotine 12 mg combined with sweet menthol flavor
16450169|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco non-menthol|Nicotine 0 mg combined with tobacco non-menthol flavor
16450170|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco non-menthol|Nicotine 3 mg combined with tobacco non-menthol flavor
16450171|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco non-menthol|Nicotine 12 mg combined with tobacco non-menthol flavor
16450172|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco menthol|Nicotine 0 mg with tobacco menthol flavor
16450173|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco menthol|Nicotine 3 mg combined with tobacco menthol flavor
16450174|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco menthol|Nicotine 12 mg combined with tobacco menthol flavor
16450175|NCT03634813|Experimental|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
16450176|NCT03634813|Active Comparator|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
16450177|NCT03634800|Experimental|nivolumab/radiotherapy|"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.
~Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached
~Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab"
16450178|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
16450179|NCT03634787||Healthy|No major systemic illness
16450180|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
16450181|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
16450182|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
16450183|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
16450184|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
16450185|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
16450186|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
16450187|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
16450188|NCT03634722|No Intervention|The observational group|routine nursing
16450189|NCT03634709|Experimental|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
16450190|NCT03634709|No Intervention|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
16450191|NCT03634696|Experimental|Field test participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to participate in mPCL application field test
16450192|NCT03634696|Active Comparator|Control participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to serve as controls for mPCL field test
16450193|NCT03634683|Experimental|LioCyx|"This is a single-arm study.
~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
16450194|NCT03634657|Active Comparator|Plain X-ray protection shield|
16450195|NCT03634657|Experimental|Protection shield & X-ray protective strips|
16450196|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
16450197|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
16450198|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
16450199|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
16450200|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
16450201|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
16450202|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
16450203|NCT03634579|Experimental|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
16450204|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
16450205|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
16453966|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
16450206|NCT03634553|Experimental|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
16450207|NCT03634553|Active Comparator|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
16450208|NCT03634540|Experimental|Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)|Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
16450209|NCT03634540|Experimental|Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)|Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
16450210|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
16450211|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
16450212|NCT03634514|Experimental|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
16450213|NCT03634514|Active Comparator|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
16450214|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
16450215|NCT03634488|Experimental|Nutritional Supplement and Hydroxyurea|50 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive nutritional supplement and hydroxyurea (20mg/kg/day)
16450216|NCT03634488|Placebo Comparator|Nutritional Supplement alone|50 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive nutritional supplement alone
16450217|NCT03634488|Placebo Comparator|non-SCD AND severe malnutrition|To decrease the likelihood of sharing limited food resources, we will enroll 100 malnourished non-SCD siblings.
16450218|NCT03634475|Experimental|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
16450219|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
16450220|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
16450221|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
16450222|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
16450223|NCT03634436|Experimental|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
16450224|NCT03634436|Experimental|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
16450225|NCT03634436|Experimental|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
16450226|NCT03634436|Experimental|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
16450227|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
16450228|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
16450229|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
16450230|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
16450231|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
16450232|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
16450233|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
16450234|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
16450235|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
16450236|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
16450237|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
16450238|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
16450239|NCT03634410||Employed|people aged +50 and currently employed
16450240|NCT03634410||Unemployed|people aged +50 and currently unemployed
16450241|NCT03634410||Early retirement|people aged +50 and currently on early retirement
16450242|NCT03634410||Disability pension|people aged +50 and currently on disability pension
16450243|NCT03634397|Experimental|Less-Impaired Arm Training|Intervention condition includes therapy of the less-impaired (ipsilesional) arm.
16450244|NCT03634397|Sham Comparator|Contralesional Arm Comparison|Comparison control condition includes therapy of the paretic (contralesional) arm.
16450245|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).
~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
16450246|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).
~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
16450247|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
16450248|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
16450249|NCT03634358|Active Comparator|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
16450250|NCT03634358|Active Comparator|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
16450251|NCT03634345|Experimental|PF-04965842|investigational drug
16450252|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
16450253|NCT03634306|Active Comparator|ARM 1|Laparoscopic hysterectomy with use of the Ultravision System
16450254|NCT03634306|Placebo Comparator|ARM 2|Laparoscopic Hysterectomy per Standard of Care/no Ultravision System
16450255|NCT03634306|Active Comparator|ARM 3|Laparoscopic myomectomy with use of the Ultravision System.
16450256|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
16450257|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
16450258|NCT03634280|Placebo Comparator|Splinting|Splinting was applied to the patients' ankle in the second group(n=120). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
16450259|NCT03634280|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 120 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
16450260|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
16450261|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
16450262|NCT03634241|Active Comparator|Arm A (standard of care)|Participants receive standard of care.
16450263|NCT03634241|Experimental|Arm B (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16450264|NCT03634228|Experimental|Arm A (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10 and milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16450265|NCT03634228|Experimental|Arm B (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10, milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16450266|NCT03634215||Multiple Trauma patients|
16450267|NCT03634202|Experimental|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
16450268|NCT03634189|Experimental|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
16450269|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
16450270|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
16450271|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
16450272|NCT03634163|Experimental|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
16450273|NCT03634163|Active Comparator|Delayed|Quality of Life Assessment
16450477|NCT03632681|Placebo Comparator|Placebo|In this arm a single-dose intranasal placebo will be administrated
16450275|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
16450276|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
16450277|NCT03634124|Experimental|interventional group|
16450278|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
16450279|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
16450280|NCT03634098|Experimental|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:
~MRI
~Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
16450281|NCT03634098|Experimental|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :
~sample for analysis and biocollection
~MRI +/-Primovist
~Ultrasound AixPlorer +Sonovue"
16450282|NCT03634098|No Intervention|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
16450283|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
16450284|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
16450285|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
16450286|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
16450287|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
16450288|NCT03634046|Experimental|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 ~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
16450289|NCT03634046|Active Comparator|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
16450290|NCT03634033|Experimental|MiCAP with IF|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
16450291|NCT03634033|Experimental|MiCAP with IF and EF|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
16450292|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
16450293|NCT03634007|Experimental|Cohort I: 5.0 x 10^10 gc/mL CSF|Subjects will receive 5.0 x 10^10 gc/mL CSF of LX1001
16450294|NCT03634007|Experimental|Cohort II: 1.6 x 10^11 gc/mL CSF|Subjects will receive 1.6 x 10^11 gc/mL CSF of LX1001
16450295|NCT03634007|Experimental|Cohort III: 5.0 x 10^11 gc/mL CSF|Subjects will receive 5.0 x 10^11 gc/mL CSF of LX1001
16450296|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
16450297|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
16450298|NCT03633968|Active Comparator|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.
~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
16450299|NCT03633968|Active Comparator|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.
~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
16450300|NCT03633955|Active Comparator|Standard therapy|This Arm will accrue patients receiving standard therapy (e.g. chemotherapy for leukemia).
16450301|NCT03633955|Experimental|Immunotherapy|The other Arm will include patients receiving immunotherapy
16450302|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.
~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
16450303|NCT03633929||KIOS OUD|
16450304|NCT03633916|Experimental|Intervention|Classroom sensitization session (plus school-level sensitization activities)
16450305|NCT03633916|Active Comparator|Control|School-level sensitization activities only
16450306|NCT03633903|Active Comparator|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks. Surveys administered prior to each session.
16450307|NCT03633903|No Intervention|Control|Treatment as usual (i.e., pharmacotherapy, psychotherapy, etc.) for the four week duration with twice weekly surveys administered.
16450308|NCT03633890|Experimental|DaZhu Rhodiola Rosea Capsule|
16450309|NCT03633890|Placebo Comparator|DaZhu Rhodiola Rosea Simulation Capsule|
16450310|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
16450311|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
16450312|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
16450313|NCT03633851|Experimental|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
16450314|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
16450315|NCT03633825|No Intervention|Control|
16450316|NCT03633825|Experimental|Intervention|
16450317|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
16450318|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
16450319|NCT03633799|Experimental|VeraCept|VeraCept™ Intrauterine Contraceptive
16450320|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
16450321|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
16450322|NCT03633773|Experimental|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
16450323|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
16450324|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
16450325|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
16450326|NCT03633734|Experimental|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.
~Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m^2 + gemcitabine 1000mg/m^2 (days 1, 8, 15, 28)
~Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m^2 continuous intravenous drip 46h + calcium folinate 400 mg/m^2 + irinotecan 135 mg/m^2 + oxaliplatin 68 mg/m^2 (day 1, 15, a total of 28 days).
~Repeat the cycle above until progression or intolerance of toxicity."
16450327|NCT03633721|Active Comparator|HIV positive; cannabis|HIV positive women will be given cannabis and tested
16450328|NCT03633721|Active Comparator|HIV positive; placebo|HIV positive women will be given placebo and tested
16450329|NCT03633721|Active Comparator|HIV negative; cannabis|HIV negative women will be given cannabis and tested
16450330|NCT03633721|Active Comparator|HIV negative; placebo|HIV negative women will be given placebo and tested
16450331|NCT03633708|Experimental|Etelcalcetide|Randomized in a 3:1 ratio to receive etelcalcetide in addition to standard of care
16450332|NCT03633708|Active Comparator|Control|Randomized in a 3:1 ratio to receive etelcalcetide in addition standard of care alone (control arm)
16450333|NCT03633695|Experimental|IC-8 IOL|The AcuFocus IC-8 intraocular lens will be surgically implanted in one eye of each subject. A monofocal or monofocal toric intraocular lens will be surgically implanted in the fellow eye of each subject.
16450334|NCT03633695|Active Comparator|Monofocal|A monofocal or monofocal toric intraocular lens will be surgically implanted in both eyes of each subject.
16450335|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
16450336|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
16450337|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
16450338|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
16450339|NCT03633656|Experimental|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
16450340|NCT03633643|Placebo Comparator|Group A|Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
16453967|NCT03608397|Placebo Comparator|Placebo|Placebo Group
16450341|NCT03633643|Active Comparator|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
16450342|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
16450343|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
16450344|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
16450345|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
16450346|NCT03633617|Experimental|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
16450347|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
16450348|NCT03633578|Experimental|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
16450349|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
16450350|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
16450351|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
16450352|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
16450353|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
16450354|NCT03633539|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
16450355|NCT03633539|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
16450356|NCT03633526|Experimental|VX-659/TEZ/IVA|Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
16450357|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
16450358|NCT03633513||Caregivers|Environmentally matched healthy control subjects
16450359|NCT03633500|Placebo Comparator|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
16450360|NCT03633500|Experimental|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
16450361|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
16450362|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
16450363|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
16450364|NCT03633461|Active Comparator|OC-02|
16450365|NCT03633461|Placebo Comparator|Placebo|
16450366|NCT03633448|Experimental|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
16450367|NCT03633448|Experimental|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
16450368|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
16450369|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
16450370|NCT03633396|Placebo Comparator|Placebo|Placebo as subcutaneous (SC) injection every 4 weeks
16450371|NCT03633396|Experimental|Group 1|ANB019 subcutaneous (SC) injection every 4 weeks
16450372|NCT03633383||Transfemoral Approach|
16450373|NCT03633383||Transapical Approach|
16450374|NCT03633370|No Intervention|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
16450375|NCT03633370|Other|Test Group|"Multifaceted intervention
~Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone
~Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)
~Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
16450376|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
16450377|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
16450378|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
16450379|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
16450380|NCT03633331|Experimental|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16450381|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
16450382|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
16450383|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
16450384|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
16450385|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
16450386|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
16450387|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
16450388|NCT03633305|No Intervention|No additional treatment|
16450389|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
16450390|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month
~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
16450391|NCT03633279|Experimental|Branched Chain Amino Acid|Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.
16450392|NCT03633279|Placebo Comparator|Placebo|Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
16450393|NCT03633266|Experimental|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
16450394|NCT03633266|Active Comparator|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
16450395|NCT03633253||MCR syndroms|
16450396|NCT03633253||Non MCR syndroms|
16450397|NCT03633227|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|
16450398|NCT03633227|Placebo Comparator|Placebo|
16450399|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
16450400|NCT03633214|No Intervention|No training module (Control)|
16450401|NCT03633201|Active Comparator|Cruciate Retaining|
16450402|NCT03633201|Active Comparator|Medial Congruent|
16450403|NCT03633201|No Intervention|Healthy Controls|
16450404|NCT03633188|Experimental|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
16450405|NCT03633175|Active Comparator|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
16450406|NCT03633175|No Intervention|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
16450407|NCT03633149|Experimental|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
16450408|NCT03633149|Experimental|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
16450409|NCT03633149|Active Comparator|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
16450410|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
16450411|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
16450412|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
16450413|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
16450414|NCT03633110|Experimental|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).
~Part A will consist of approximately 9 participants."
16450415|NCT03633110|Experimental|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).
~Part B will consist of up to 90 participants."
16450416|NCT03633097|Experimental|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
16450417|NCT03633097|Active Comparator|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
16450418|NCT03633084|Experimental|RBM-007 Injectable Solution - 0.2 mg|No additional information.
16450419|NCT03633084|Experimental|RBM-007 Injectable Solution - 1.0 mg|No additional information.
16450420|NCT03633084|Experimental|RBM-007 Injectable Solution - 2.0 mg|No additional information.
16450425|NCT03633032|Other|UTE MRI|
16450426|NCT03633019|Experimental|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
16450427|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.
~A second blood draw will be collected at 12 months."
16450428|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.
~Diagnostic information will be collected to confirm the final diagnosis."
16450429|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.
~Subject will be enrolled and provide a blood sample."
16450430|NCT03632993|Active Comparator|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 mL aliquots (for a total injection volume of 0.3 mL).
~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
16450431|NCT03632993|Active Comparator|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.
~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
16450432|NCT03632993|Active Comparator|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.
~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
16450433|NCT03632993|Active Comparator|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).
~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
16450434|NCT03632993|Active Comparator|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).
~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2mL of CCH (4 aliquots of 0.3mL each). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
16450435|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).
~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices
~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
16450436|NCT03632967|Experimental|Device: TriCinch Coil System treatment|
16450437|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®
~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.
~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
16450476|NCT03632681|Active Comparator|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
16450441|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.
~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
16450442|NCT03632915||No study intervention|No study intervention
16450443|NCT03632889|No Intervention|Control Arm|Subjects randomized to the control group will receive a sleep hygiene handout .
16450444|NCT03632889|Other|Computerized Group|Subjects randomized to GoToSleep program will receive a sleep hygiene handout and a unique code for home access to the GoToSleep program.
16450445|NCT03632876|Active Comparator|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
16450446|NCT03632876|Active Comparator|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
16450447|NCT03632876|No Intervention|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
16450448|NCT03632863|Experimental|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
16450449|NCT03632863|Sham Comparator|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
16450450|NCT03632850||Doctors|This is a group of oncologists who have experience in treatment deliberations with patients of advanced cancer.
16450451|NCT03632850||Nurses|This is a group of clinical nurse specialists who have experience in treatment deliberations with patients of advanced cancer
16450452|NCT03632850||Patients|this is a group of adult patients who have been diagnosed with advanced pancreatic cancer
16450453|NCT03632850||Relatives|this is a group of adults who are involved in providing support for their loved ones who are diagnosed with advanced pancreatic cancer
16450454|NCT03632837|Experimental|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
16450455|NCT03632837|No Intervention|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
16450456|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
16450457|NCT03632824|Placebo Comparator|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
16450460|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
16450461|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
16450462|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
16450463|NCT03632759|Experimental|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
16450464|NCT03632759|Experimental|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
16450465|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
16450466|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
16450467|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
16450468|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
16450469|NCT03632720|Experimental|Group 1|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
16450470|NCT03632720|Experimental|Group 2|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2 and 4 months of age; routine pediatric vaccines
16450471|NCT03632720|Active Comparator|Group 3|Meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
16450472|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
16450473|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
16450474|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
16450475|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
16450478|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
16450479|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
16450480|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
16450481|NCT03632642|Active Comparator|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
16450482|NCT03632642|Active Comparator|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
16450483|NCT03632629|Active Comparator|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
16450484|NCT03632629|No Intervention|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
16450485|NCT03632603|Experimental|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
16450486|NCT03632603|Active Comparator|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
16450487|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
16450488|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
16450489|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
16450490|NCT03632590|Placebo Comparator|Placebo|
16450491|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
16450492|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
16450493|NCT03632564|Experimental|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
16450494|NCT03632551|Active Comparator|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
16450495|NCT03632551|Experimental|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
16450496|NCT03632551|Experimental|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
16450497|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
16450498|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
16450499|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
16450500|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
16450501|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
16450502|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
16450503|NCT03632473||clinically isolated syndrome (CIS)|"Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
16450504|NCT03632473||early relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting early disease course (RRMS) </= 10 years, Expanded Disability Status Scale (EDSS) </=3.5
~EDSS:
~1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
16450505|NCT03632473||late relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive
~EDSS:
~4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
16450556|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
16450626|NCT03631537|No Intervention|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
16450506|NCT03632473||primary progressive disease course (PPMS)|"MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive
~EDSS:
~6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
16450507|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
16450508|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
16450509|NCT03632447|Experimental|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
16450510|NCT03632447|Active Comparator|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
16450511|NCT03632434|Experimental|tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
16450512|NCT03632421|Experimental|Intervention group|
16450513|NCT03632421|Active Comparator|Control group|
16450514|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
16450515|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
16450516|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
16450517|NCT03632356|Experimental|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
16450518|NCT03632356|Active Comparator|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
16450519|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
16450520|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
16450521|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
16450522|NCT03632330||Dexmedetomidine|Dexmedetomidine group
16450523|NCT03632330||Midazolam|Midazolam group
16450524|NCT03632330||propofol|propofol group
16450525|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
16450526|NCT03632317|Experimental|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
16450527|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
16450528|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
16450529|NCT03632291|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
16450530|NCT03632291|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
16450531|NCT03632291|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
16450532|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
16450533|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
16450534|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
16450557|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
16454049|NCT03607890|Experimental|Cohort 1: Nivolumab and Relatlimab|480mg/160mg (co-administered)
16450535|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.
~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
16450537|NCT03632239||GAPP|Individuals undergoing phenotyping by GAPP
16450538|NCT03632226||1|Healthy Volunteers
16450539|NCT03632213|Active Comparator|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
16450540|NCT03632213|Placebo Comparator|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
16450541|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.
~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.
~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
16450542|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
16450543|NCT03632187|Experimental|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
16450544|NCT03632187|Placebo Comparator|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
16450545|NCT03632174|Experimental|Topical Ointment with L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
16450546|NCT03632174|Experimental|Topical Ointment without L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
16450547|NCT03632161|Active Comparator|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
16450548|NCT03632161|Other|Bupivacaine|Bupivacaine only in the paravertebral block
16450551|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
16450552|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
16450553|NCT03632096|Active Comparator|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
16450554|NCT03632096|Sham Comparator|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
16450555|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
16450558|NCT03632057|Active Comparator|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
16450560|NCT03632044|Experimental|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
16450561|NCT03632044|Sham Comparator|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
16450562|NCT03632031||Patients with chronic non-healing wounds|Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix
16450563|NCT03632018|Active Comparator|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
16450564|NCT03632018|Experimental|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
16450565|NCT03632005|Other|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
16450566|NCT03632005|Active Comparator|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
16450567|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
16450568|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
16450569|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
16450570|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
16450571|NCT03631966|Experimental|BTX-A injection|
16450572|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
16450573|NCT03631940|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
16450574|NCT03631940|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
16450575|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
16450576|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
16450577|NCT03631901|Active Comparator|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
16450578|NCT03631901|Active Comparator|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
16450579|NCT03631888||patients scheduled for elective laparoscopic surgery|
16450580|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
16450581|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
16450582|NCT03631862|Experimental|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
16450583|NCT03631862|Experimental|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
16450584|NCT03631849|Experimental|Peri implantitis patients|
16450585|NCT03631849|Active Comparator|not peri implantitis patient|
16450586|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
16450587|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
16450588|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
16450590|NCT03631797|Experimental|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.
~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
16450591|NCT03631784|Experimental|Cohort A|Participants will receive 1 cycle of pembrolizumab 200 mg on Day 1 with paclitaxel 200 mg/m^2, and carboplatin area under the curve (AUC) AUC6. Approximately 3 weeks later, participants will receive 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) and carboplatin AUC2 with paclitaxel 45 mg/m^2 administered weekly for 6 weeks in conjunction with standard thoracic radiotherapy (60 Gray [Gy]). To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
16450592|NCT03631784|Experimental|Cohort B|Participants will receive 3 cycles of pembrolizumab 200 mg on Day 1 of each 3-week cycle and 3 cycles of pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2. Treatment will be given in conjunction with standard thoracic radiotherapy (60 Gy) in Cycles 2 and 3. To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
16450593|NCT03631771|Experimental|Iodixanol, iohexol, iopromide, or ioversol|Investigational medicinal product administered intravascularly per usual clinical practice at each participating institution. Doses will be per usual practice. The dose of ICM, timing of ICM administration in relation to the diagnostic procedure, rate of ICM administration, and route of ICM administration will be determined by the physician performing the enhanced radiologic procedure per medical need and local clinical practice.
16450594|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
16450595|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
16450596|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
16450597|NCT03631745|Experimental|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
16450598|NCT03631745|No Intervention|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
16450599|NCT03631732|Experimental|B/F/TAF|Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
16450600|NCT03631732|Active Comparator|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
16450601|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
16450602|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
16450603|NCT03631706|Experimental|M7824|
16450604|NCT03631706|Active Comparator|Pembrolizumab|
16450605|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
16450606|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
16450607|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
16450608|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
16450609|NCT03631667|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
16450610|NCT03631667|Experimental|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene
16450613|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
16450614|NCT03631628|Experimental|MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + MT and 1 hour conventional training.
16450615|NCT03631628|Placebo Comparator|sham-MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + sham-MT and 1-hour conventional training.
16450616|NCT03631615|Experimental|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
16450617|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
16450618|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
16450619|NCT03631589|Experimental|MSCs treated|
16450620|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
16450621|NCT03631563|Experimental|Arm 1|ATG-F treated
16450622|NCT03631563|Active Comparator|Arm 2|ATG treated
16450623|NCT03631550|Active Comparator|Active|Relivion Active device
16450624|NCT03631550|Sham Comparator|Sham|Relivion Sham device
16450625|NCT03631537|Experimental|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
16450627|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
16450628|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
16450629|NCT03631511|Experimental|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
16450630|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
16450631|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
16450632|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
16450633|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
16450634|NCT03631485||parents having children with cancer|No intervention.
16450635|NCT03631472|Experimental|RheOx Treatment|RheOx Treatment (i.e., Bronchial Rheoplasty)
16450636|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
16450638|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
16450639|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
16450640|NCT03631420|Experimental|UMC119-01|UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product
16450641|NCT03631407|Experimental|Vicriviroc QD at Dose Level 1 + Pembrolizumab|Participants vicriviroc (dosed orally; once daily [QD]) at dose level 1 in combination with 200 mg pembrolizumab (intravenous [IV] infusion; every 3 weeks [Q3W]) for up to 35 cycles (cycle length: 3 weeks).
16450642|NCT03631407|Experimental|Vicriviroc QD at Dose Level 2 + Pembrolizumab|Participants receive vicriviroc (dosed orally; QD) at dose level 2 in combination with 200 mg pembrolizumab (IV infusion; Q3W) for up to 35 cycles (cycle length: 3 weeks).
16450643|NCT03631394|Experimental|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
16450644|NCT03631394|Placebo Comparator|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
16450645|NCT03631368|Experimental|Botox|
16450646|NCT03631355|Active Comparator|ACL Reconstruction w/ BTB Autograft + IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.
16450647|NCT03631355|No Intervention|ACL Reconstruction w/ BTB Autograft, no IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.
16450648|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
16450649|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
16450650|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
16450651|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
16450652|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
16450653|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
16450654|NCT03631316|Experimental|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
16450655|NCT03631316|Active Comparator|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
16450656|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who received appropriate ICD therapy during follow-up.
16450657|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who were free from appropriate ICD therapy during follow-up.
16450658|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF >50%).
16450659|NCT03631290|Experimental|Deprescribing Intervention|
16450660|NCT03631277|Experimental|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
16450661|NCT03631277|Active Comparator|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
16450662|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
16450663|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
16450664|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
16450665|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
16450666|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
16450667|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
16450668|NCT03631212|No Intervention|Waitlist control|Wait-list control group
16450669|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
16450672|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
16450673|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
16450674|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
16450675|NCT03631160|Experimental|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
16450676|NCT03631160|Sham Comparator|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
16450677|NCT03631147|Experimental|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
16450678|NCT03631147|No Intervention|The control group|
16450679|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
16450680|NCT03631121|Experimental|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
16450681|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.
~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
16450682|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.
~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
16450683|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.
~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
16450684|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.
~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
16450685|NCT03631082|Experimental|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.
~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.
~Patients will perform 10 repetitions of each exercise."
16450749|NCT03630666|Experimental|IADT+ radiotherapy|One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.
16454050|NCT03607890|Experimental|Cohort 2: Nivolumab and Relatlimab|480mg/960mg (sequential administration)
16450686|NCT03631082|Active Comparator|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.
~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.
~Patients will perform 10 repetitions of each exercise."
16450687|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
16450688|NCT03631069||Normal|
16450689|NCT03631043|Experimental|Stage I (personalized vaccine)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16450690|NCT03631043|Experimental|Stage II (personalized vaccine, lenalidomide)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16450691|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
16450692|NCT03631017|Experimental|[18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
16450693|NCT03631004|Experimental|olanzapine tablets|PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
16450694|NCT03631004|Placebo Comparator|Starch tablets|PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
16450695|NCT03630991|Experimental|Cohort I (edetate calcium disodium, multivitamin)|During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
16450696|NCT03630991|Experimental|Cohort II (succimer, multivitamin)|During standard of care chemotherapy, patients receive succimer PO daily for 8 or 21 days of each cycle beginning day 1. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
16450697|NCT03630978||Liver resection|
16450698|NCT03630965|No Intervention|Group A|No CPR video
16450699|NCT03630965|Experimental|Group B|CPR video
16450700|NCT03630952|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
16450701|NCT03630952|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
16450702|NCT03630952|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
16450703|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
16450704|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
16450705|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
16450706|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
16450707|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
16450708|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
16450709|NCT03630913|Experimental|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.
~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
16450710|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
16450711|NCT03630900|No Intervention|5% O2 culture|
16450712|NCT03630887|No Intervention|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
16450713|NCT03630887|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
16450714|NCT03630887|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
16450715|NCT03630887|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
16450716|NCT03630874|Experimental|Experimental arm|
16450717|NCT03630874|No Intervention|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
16450718|NCT03630861||GBM|Primary glioblastoma (GBM)
16450719|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
16450720|NCT03630861||Brain metastases|Brain metastases (BM)
16450721|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
16450722|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
16450723|NCT03630848|Experimental|10 mg/ml protein concentration in Embryo Culture Media|
16450724|NCT03630848|No Intervention|5 mg/ml protein concentration in Embryo Culture Media|
16450726|NCT03630822|Experimental|beneficiary of the advance directive program|
16450727|NCT03630822|Active Comparator|beneficiary of standard Support|
16450729|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.
~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.
~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.
~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
16450730|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.
~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.
~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.
~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
16450731|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
16450732|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
16450733|NCT03630770|No Intervention|Control|This group receives no feeding supplement.
16450734|NCT03630770|Experimental|MCT Oil|This group is supplemented with MCT oil
16450735|NCT03630757|Experimental|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
16450736|NCT03630757|Placebo Comparator|Group 2|reaching to the feet while sitting together with warming and cooling periods
16450737|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
16450738|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
16450739|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
16450740|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
16450741|NCT03630705|Experimental|Group 1 (Mexico)|MenACYW conjugate vaccine at 2, 6, and 12 months of age + routine pediatric vaccines at 2, 4, 6, and 12 months of age
16450742|NCT03630705|Active Comparator|Group 2 (Mexico)|Menveo® at 2, 4, 6, and 12 months of age + routine pediatric vaccines at 2, 4, 6, and 12 months of age
16450743|NCT03630705|Experimental|Group 3 (Russian Federation)|MenACYW conjugate vaccine at 3, 6, and 12 months of age + routine pediatric vaccines at 2, 3, 4.5, 6, and 12 months of age
16450744|NCT03630705|Other|Group 4 (Russian Federation)|Routine pediatric vaccines at 2, 3, 4, 5, 6, and 12 months of age
16450745|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
16450746|NCT03630679||Preterm|born at <37 weeks of gestation
16450747|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
16450748|NCT03630666|Active Comparator|IADT|one injection of IADT. The overall duration of IADT will be six months.
16450782|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
16450750|NCT03630653|Experimental|Sentinel LN in breast cancer recurrence|"Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.
~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.
~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND."
16450751|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
16450752|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
16450753|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
16450754|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
16450755|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
16450756|NCT03630614|Experimental|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
16450757|NCT03630614|Active Comparator|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
16450758|NCT03630614|Placebo Comparator|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
16450759|NCT03630601|Experimental|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
16450760|NCT03630588|Placebo Comparator|Placebo|
16450761|NCT03630588|Experimental|Surimi intervention|
16450762|NCT03630575|Experimental|Newborns exposed in-utero to psychoactive substances|
16450763|NCT03630562|Other|Patients with exudative AMD|
16450764|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation
~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing
~No SMS intervention"
16450765|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation
~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing
~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)
~Offer of Individually customized SMS
~Monthly reminder SMS: to pick up ART
~SMS communicating VL result"
16450766|NCT03630523|Other|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
16450767|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
16450768|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
16450769|NCT03630497|Experimental|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450770|NCT03630497|Experimental|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450771|NCT03630497|Experimental|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450772|NCT03630497|Experimental|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450773|NCT03630497|Experimental|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450774|NCT03630497|Experimental|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450775|NCT03630497|Experimental|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450776|NCT03630497|Experimental|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
16450777|NCT03630497|Experimental|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days
~Comparison of BN201 treatment with Placebo"
16450778|NCT03630497|Experimental|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days
~Comparison of BN201 treatment with Placebo"
16450779|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
16450780|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
16450781|NCT03630471|Active Comparator|Control|Enhanced usual care (problem-solving booklets only).
16450783|NCT03630458|Experimental|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
16450784|NCT03630458|Experimental|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
16450785|NCT03630458|Experimental|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
16450786|NCT03630458|Experimental|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
16450787|NCT03630458|Active Comparator|White rice|White rice - medium-grain prepared using a rice cooker
16450788|NCT03630445|Experimental|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.
~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
16450789|NCT03630445|Experimental|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.
~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
16450790|NCT03630445|Experimental|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
16450791|NCT03630445|Experimental|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.
~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
16450792|NCT03630445|Experimental|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.
~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
16450793|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
16450794|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
16450795|NCT03630419|Experimental|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
16450796|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
16450797|NCT03630393|Experimental|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
16450798|NCT03630393|Active Comparator|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
16450799|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
16450800|NCT03630367|Experimental|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
16450801|NCT03630367|Active Comparator|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
16450802|NCT03630354|Experimental|Arm I (supervised exercise together)|Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.
16450803|NCT03630354|Experimental|Arm II (supervised exercise separately)|Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.
16450804|NCT03630354|Experimental|Arm III (unsupervised exercise separately)|Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
16450805|NCT03630341|Experimental|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
16450806|NCT03630341|Active Comparator|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
16450807|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
16450808|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
16450809|NCT03630315|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
16450810|NCT03630315|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
16450811|NCT03630315|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
16450812|NCT03630315|Experimental|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
16450813|NCT03630315|Experimental|Cohort 4 (High Dose)|Subjects will receive a high dose of OTX-TKI.
16450814|NCT03630315|Experimental|Cohort 4 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
16450816|NCT03630276|Other|Neutrophil/lymphocyte ratio|
16450817|NCT03630276|Other|Platelet/lymphocyte ratio|
16450818|NCT03630276|Other|CRP|
16450819|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
16450820|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
16450821|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).
~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.
~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.
~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
16450822|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
16450823|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).
~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.
~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.
~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
16450824|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
16450825|NCT03630224|Experimental|Plasmalyte Viaflo|Intervention type: drug (Plasmalyte Viaflo) Intervention name: plasmalyte Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
16450826|NCT03630224|Active Comparator|NaCl 0.9%|Intervention type: drug (NaCl 0.9%) Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
16450827|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
16450828|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
16450829|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
16450830|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
16450831|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
16450832|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
16450833|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
16450834|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
16450835|NCT03630146|Experimental|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
16450836|NCT03630146|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
16450837|NCT03630133|Experimental|Intracept System Ablation|Single Arm
16450838|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
16450839|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
16450840|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
16450841|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
16450842|NCT03630107|Experimental|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
16450843|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
16450844|NCT03630081|Experimental|FEP-TAZ 4 g|FEP-TAZ Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
16450845|NCT03630081|Active Comparator|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
16450846|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
16450847|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
16450848|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
16450849|NCT03630042|Experimental|Pembrolizumab and Rituximab|
16450850|NCT03630029|Other|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.
16450851|NCT03630029|Other|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.
16450852|NCT03630029|Other|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.
16451168|NCT03627962|No Intervention|control|No intervention: participants in control read ordinary Chinese textbooks.
16450853|NCT03630029|Other|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.
16450854|NCT03630029|Other|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
16450855|NCT03630016|Active Comparator|Reference CO-Oximetry|Reference Co-Oximetry
16450856|NCT03630016|Experimental|Owlet BabySat v1.0|Owlet BabySat v1.0
16450857|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
16450858|NCT03630003|Experimental|Use of MOCS with post-use interview|"The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences.
~Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour.
~The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team."
16450859|NCT03629990|Experimental|Active ABM + CBT/MET|"Participants in the Active ABM condition will receive approach bias modification (ABM) training sessions aimed at reducing cognitive bias for cannabis cues.
~All participants will receive MET/CBT therapy."
16450860|NCT03629990|Sham Comparator|Sham ABM + CBT/MET|"Participants in the Sham ABM condition will undergo similar computerized tasks without the manipulation of response contingencies that target modification of approach bias.
~All participants will receive MET/CBT therapy."
16450861|NCT03629977||early RRT|A patient where initiation of RRT is started without the absolute indications
16450862|NCT03629977||late RRT|"CRRT based on absolute indications.
~Absolute indications:
~hyperkalemia (serum potassium≥6 mEq/L),
~severe acidosis (pH≤7.15),
~plasma urea>36 mmol/L (equals BUN=100.8 mg/dl),
~oliguria or anuria (urine output<0.3 ml/kg per hour for ≥24 hours or anuria for ≥12 hours), and
~fluid overload with pulmonary edema as defined by the presence of all the following factors: (a) >10% fluid accumulation (cumulative fluid balance/baseline weight>10%), (b) oliguria (urine output<0.5 ml/kg per hour for ≥12 hours), and (c) severely impaired oxygenation (PaO2/FiO2<200 indicated by respiratory Sequential Organ Failure Assessment [SOFA] score≥3)"
16450863|NCT03629977||never RRT|RRT is never started, matched against early RRT group.
16450864|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
16450866|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin
16450867|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin
16450868|NCT03629912|Experimental|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
16450869|NCT03629912|Active Comparator|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
16450870|NCT03629912|Active Comparator|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
16450871|NCT03629912|No Intervention|Bingo Only|Participants use the Bingocize app to play bingo only.
16450872|NCT03629899|Experimental|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
16450873|NCT03629886|No Intervention|Vacc-039 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received HPV vaccine in HPV-039 study (NCT00779766), underwent cervical sample collection and didn't receive any vaccine in the current study.
16450874|NCT03629886|Experimental|Vacc-092 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received placebo (control group) in HPV-039 study (NCT00779766), were intended to receive HPV vaccine in the current study and were to provide cervical samples before HPV vaccination.
16450875|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient
~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.
~A disc bur will be used to make a rectangular osteotomy
~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws
~Doner site flap is closed by using interrupted internal sutures.
~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done
~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
16450907|NCT03629600|Active Comparator|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin [Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA] just after the completion of ERCP procedure.
16454429|NCT03605199|Experimental|Denosumab active treatment|Denosumab active treatment
16450876|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient
~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.
~A disc bur will be used to make a rectangular osteotomy
~The block bone graft is removed from chin to recipient site the fixed by mini screws
~Doner site flap is closed by using interrupted internal sutures
~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done
~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
16450877|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
16450878|NCT03629821|Experimental|Ballet|Subjects who will receive the experimental protocol.
16450879|NCT03629821|No Intervention|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
16450880|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
16450881|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
16450882|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
16450883|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RDE will be determined in this part with escalating doses of etrumadenant in combination with a fixed dose of zimberelimab.
16450884|NCT03629756|Experimental|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RDE + zimberelimab
16450885|NCT03629756|Experimental|Dose Expansion-mCRPC|Etrumadenant at RDE + zimberelimab
16450886|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
16450887|NCT03629730|Experimental|High dose|Will receive the greatest duration of coordination intervention training.
16450888|NCT03629730|Experimental|Intermediate dose|Will receive a moderate duration of coordination intervention training.
16450889|NCT03629730|Experimental|Low dose|Will receive a short duration of coordination intervention training.
16450890|NCT03629730|Active Comparator|Active control|Will perform the same number and duration of physical exercises as the High Dose group, but while moving one body segment at a time.
16450891|NCT03629717|Experimental|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
16450892|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
16450893|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
16450894|NCT03629678|No Intervention|Control group (Booklets)|Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
16450895|NCT03629678|Active Comparator|mobile health application|Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
16450896|NCT03629665|Active Comparator|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
16450897|NCT03629665|Sham Comparator|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
16450898|NCT03629652|Experimental|Head down position|head-down position treatment combined with conventional rehabilitation.
16450899|NCT03629652|Sham Comparator|Conventional Rehabilitation|Conventional rehabilitation treatment
16450900|NCT03629639|Experimental|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
16450901|NCT03629639|Placebo Comparator|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
16450902|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
16450903|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
16450904|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.
~During baseline testing, no supplement or placebo intake will be used."
16450905|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.
~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
16450906|NCT03629600|Experimental|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) [COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
16450908|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
16450909|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
16450910|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
16450911|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
16450912|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
16450913|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix
16450914|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
16450915|NCT03629522|Active Comparator|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
16450916|NCT03629522|Placebo Comparator|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
16450917|NCT03629509|Other|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)
~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
16450918|NCT03629509|Experimental|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:
~We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.
~We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
16450919|NCT03629509|Other|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
16450920|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
16450921|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
16450922|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
16450923|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
16450926|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2 hours. Participants must practice at home for 15 minutes a day
16450927|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2 hours. Participants must practice at home for 30 minutes a day
16450928|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
16450929|NCT03629431|Active Comparator|postoperative standard care|Standard care after surgery in postoperative unit
16450930|NCT03629431|Experimental|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
16450931|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
16450932|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
16450933|NCT03629405|No Intervention|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
16450934|NCT03629405|No Intervention|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
16450935|NCT03629405|Experimental|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
16450936|NCT03629405|Experimental|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
16450940|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
16450941|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
16450942|NCT03629366|Experimental|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
16450943|NCT03629366|Active Comparator|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
16450944|NCT03629353|Experimental|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
16450945|NCT03629353|Experimental|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
16450946|NCT03629340|Experimental|Drug: Metformin|500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks
16450947|NCT03629340|Placebo Comparator|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
16450948|NCT03629327|Active Comparator|ASA 325mg|Daily uptake of 325mg ASA
16450949|NCT03629327|Active Comparator|No drug|no drug
16450950|NCT03629327|Active Comparator|ASA 81mg|daily uptake of 81mg ASA
16450952|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
16450953|NCT03629301|Other|Wait-list Group|
16450954|NCT03629288|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
16450955|NCT03629288|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
16450956|NCT03629275|Experimental|CTX0E03 Drug Product and delivery device|20 million neural stem cells
16450957|NCT03629275|Sham Comparator|Placebo|Sham Surgery
16450958|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
16450959|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
16450960|NCT03629249|Experimental|QAW039 150 mg|QAW039 150 mg once daily orally
16450961|NCT03629249|Experimental|QAW039 450 mg|QAW039 450 mg once daily orally
16450962|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
16450963|NCT03629236|Experimental|GrafixPL|
16450964|NCT03629236|Active Comparator|Control|
16450965|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
16450966|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
16450967|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
16450968|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
16450969|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
16450970|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
16450971|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
16450972|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
16452605|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
16450973|NCT03629210|Experimental|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
16450974|NCT03629210|Active Comparator|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
16450975|NCT03629197|Experimental|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
16450976|NCT03629197|Active Comparator|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
16450977|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
16450978|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
16450979|NCT03629171|Experimental|Treatment (CPX-351, venetoclax)|"INDUCTION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and on days 1 and 3 of cycle 2. Participants also receive venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
16450980|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
16450981|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
16450982|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
16450983|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
16450984|NCT03629132|Experimental|PRP|Platelet-rich plasma
16450985|NCT03629132|Sham Comparator|Gel|Self-crosslinking sodium hyaluronate gel
16450986|NCT03629119|Experimental|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
16450987|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
16450988|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
16450989|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
16450990|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
16450991|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
16450992|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
16450993|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
16450994|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
16450995|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
16450996|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
16450997|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)
~There will be a 14 washout of days between the each period."
16450998|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)
~There will be a 14 washout of days between the each period."
16450999|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)
~There will be a 14 washout of days between the each period."
16451000|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
16451001|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
16451002|NCT03629041|Experimental|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
16451003|NCT03629041|Sham Comparator|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
16451004|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
16451005|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
16451006|NCT03629015|Experimental|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
16451007|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
16451008|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
16451009|NCT03628989|Experimental|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
16451010|NCT03628989|Experimental|Allergy Patients|Participants will use technology based distraction during procedure
16451011|NCT03628989|No Intervention|Procedure-Only Patients|
16451012|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
16451013|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
16451014|NCT03628963|Experimental|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
16451015|NCT03628963|No Intervention|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
16451016|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
16451017|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
16451018|NCT03628937|Experimental|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.
~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
16451019|NCT03628937|Placebo Comparator|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
16451020|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
16451021|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
16451022|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
16451023|NCT03628898|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor
16451024|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
16451025|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
16451026|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
16451027|NCT03628872|Active Comparator|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
16451028|NCT03628872|Experimental|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
16451029|NCT03628846||Traumatically Injured Adolescent|
16451030|NCT03628846||Not Traumatically Injured Adolescent|
16451031|NCT03628833|Experimental|Incontinence Management system|
16452640|NCT03617536|Placebo Comparator|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
16451032|NCT03628820|Experimental|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
16451033|NCT03628820|Experimental|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
16451034|NCT03628820|No Intervention|No Intervention|This group is not exposed to the therapy dog or handler.
16451035|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
16451036|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
16451037|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
16451038|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
16451039|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
16451040|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
16451041|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
16451042|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
16451043|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
16451044|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
16451045|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
16451046|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
16451047|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
16451048|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
16451049|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.
~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
16451050|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
16451051|NCT03628729|Experimental|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
16451052|NCT03628729|Active Comparator|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
16451053|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
16451054|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
16451055|NCT03628690|Experimental|BandGrip|Topical skin closure device
16451056|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
16451063|NCT03628664|Active Comparator|CT planned total knee arthroplasty|Surgeon will follow the CT plan
16451064|NCT03628664|No Intervention|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
16451065|NCT03628651||HCC Surveillance|Approximately 1400 HCC surveillance subjects (controls) will be enrolled.
16451066|NCT03628651||HCC|Approximately 700 subjects with untreated clinically diagnosed HCC will be enrolled.
16451067|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
16451068|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
16451069|NCT03628625|Experimental|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
16451070|NCT03628625|Placebo Comparator|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
16451071|NCT03628612|Experimental|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
16451072|NCT03628599|Experimental|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
16451073|NCT03628599|Active Comparator|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
16451074|NCT03628573|Other|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
16451075|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
16451076|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
16451077|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
16451078|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
16451079|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
16451080|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
16451081|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
16451082|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
16451083|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
16451084|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
16451085|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
16451086|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
16451087|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
16451088|NCT03628534|Experimental|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
16451089|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
16451090|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
16451091|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
16451092|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
16451093|NCT03628495|Experimental|SSCP + SPMS|
16451094|NCT03628495|Active Comparator|PG|
16451095|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
16451096|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
16451097|NCT03628469|Experimental|Proactive Health Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
16451098|NCT03628469|No Intervention|Usual care|Usual care
16451099|NCT03628456|Experimental|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
16451100|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
16451101|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
16451102|NCT03628430|Placebo Comparator|Group C|"For patients of this group, the intervention was a Local Anesthesia with:
~10 mL of 2% lidocaine with epinephrine 0.005mg/ml
~and 5 mL of 0.9% NaCl"
16451103|NCT03628430|Active Comparator|Group A|"For patients of this group, the intervention was a Local Anesthesia with:
~10 mL of 2% lidocaine with epinephrine 0.005mg/ml
~and 5 mL of 4.2 % sodium bicarbonate"
16451104|NCT03628417|Experimental|Calcium Electroporation|"Calcium
~Calcium chloride 220 mmol/L (9 mg/ml):
~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume
~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
16451105|NCT03628417|Experimental|Bleomycin based electrochemotherapy|"Bleomycin
~Bleomycin 1000 IU/ml:
~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume
~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)
~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
16451106|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.
~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
16451107|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.
~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
16451108|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
16451109|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
16451110|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
16451111|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
16451112|NCT03628352|Experimental|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
16451113|NCT03628339|Experimental|Midazolam, then tepotinib followed by midazolam + tepotinib|Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
16451114|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
16451115|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
16451116|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
16451117|NCT03628300||piperacillin serum measurement|patient that underwent at least one piperacillin serum concentration monitoring
16451118|NCT03628300||included for analysis|patient that have been included for analysis according to previously described criteria
16451119|NCT03628287|Active Comparator|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
16451120|NCT03628287|Experimental|Revised Care Coordination Program|"The revised model includes the original intervention components without program track assignments or the three-month induction period of weekly visits. Program additions include a set of tools for assessment and counseling around client HIV self-management capacity; allowance of video chat for delivery of some services; and optional iART (immediate ART: ensuring the client has a filled prescription within 4 days of enrollment or diagnosis). Other changes include greater guidance on recruiting individuals with unsuppressed VL and a switch from per-member-per-day reimbursement to fee-for-service reimbursement that accounts for resource demands, such as staff travel to clients' homes, and offers higher rates for meeting performance standards."
16451121|NCT03628274|Experimental|Magnetic Resonance Imaging (RMI) 7 Tesla|
16451122|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
16451123|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
16451124|NCT03628248|Experimental|embolization|
16451125|NCT03628248|Other|No embolization|
16451132|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
16451133|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
16451169|NCT03627949|Experimental|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
16451134|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
16451135|NCT03628196||Quality Improvement Program Basic and Enhanced Phase|Patients that meet the eligibility criteria and participate in the QIP.
16451136|NCT03628196||Retrospective Group|Patients seen a year prior to the QIP period at the clinic but that did not participate in the QIP.
16451137|NCT03628196||Concurrent Group|Patients seen during the QIP period at the clinic but that did not participate in the QIP.
16451138|NCT03628183|Active Comparator|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
16451139|NCT03628183|Experimental|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
16451140|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
16451141|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
16451142|NCT03628157|Experimental|intervention|using a bio-oss bovine bone alone
16451143|NCT03628157|Active Comparator|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
16451144|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
16451145|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
16451146|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
16451147|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
16451148|NCT03628105|Experimental|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
16451149|NCT03628105|Experimental|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
16451150|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
16451151|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
16451152|NCT03628079|Experimental|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.
~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
16451153|NCT03628066|Experimental|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue
~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
16451154|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
16451155|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
16451156|NCT03628040|Sham Comparator|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
16451157|NCT03628040|Active Comparator|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane
16451158|NCT03628027|Experimental|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
16451159|NCT03628027|No Intervention|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
16451160|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
16451161|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
16451162|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
16451163|NCT03627988|Experimental|Patients with breast cancer|
16451164|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
16451165|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
16451166|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
16451167|NCT03627962|Experimental|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
16451170|NCT03627949|Experimental|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
16451171|NCT03627949|No Intervention|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
16451172|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
16451173|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
16451174|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
16451175|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
16451176|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
16451177|NCT03627897|Other|Control group|
16451178|NCT03627884|Active Comparator|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
16451179|NCT03627884|Active Comparator|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
16451180|NCT03627871|Experimental|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
16451181|NCT03627871|Experimental|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
16451182|NCT03627871|Experimental|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
16451183|NCT03627871|Experimental|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
16451184|NCT03627871|Experimental|Control|Participants receive information about exercise unrelated to social norms or recent trends.
16451185|NCT03627845|Experimental|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
16451186|NCT03627845|Placebo Comparator|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
16451187|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
16451188|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
16451189|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
16451190|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
16451191|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
16451192|NCT03627793|Active Comparator|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
16451193|NCT03627793|Active Comparator|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
16451194|NCT03627793|Experimental|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
16451195|NCT03627793|Experimental|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
16451196|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
16451197|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
16451198|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
16451199|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
16451200|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
16451201|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
16451202|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
16451203|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
16451204|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
16451205|NCT03627728|Experimental|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
16451206|NCT03627728|Placebo Comparator|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
16451268|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
16451207|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
16451208|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
16451209|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
16451210|NCT03627689|Experimental|Active air purifier arm|Active portable air purifier for 1 month at bedside
16451211|NCT03627689|Sham Comparator|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
16451212|NCT03627676|Experimental|Intervention|
16451213|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
16451214|NCT03627650|Experimental|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
16451215|NCT03627650|Experimental|Same group of 15 patients|procedure/surgery: placebo injection of scar
16451216|NCT03627637|Experimental|Experimental: Soy nuts|
16451217|NCT03627637|No Intervention|Control - no soy nuts|
16451218|NCT03627611|Active Comparator|T4|
16451219|NCT03627611|Experimental|T3|
16451220|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
16451221|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
16451222|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
16451223|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
16451224|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
16451225|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
16451226|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
16451227|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
16451228|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
16451229|NCT03627533|Experimental|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on MA-IC3 endocrine (ear points), GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
16451230|NCT03627533|Sham Comparator|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
16451231|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
16451232|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
16451233|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
16451234|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451235|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451269|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
16451236|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451237|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451238|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451239|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451240|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451241|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451242|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451243|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
16451244|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
16451245|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451246|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
16451247|NCT03627481|Experimental|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
16451248|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, q.d. for 48 weeks
16451249|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 48 weeks
16451250|NCT03627455||Male, with DM|
16451251|NCT03627455||Male, without DM|
16451252|NCT03627455||Female, with DM|
16451253|NCT03627455||Female, without DM|
16451254|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
16451255|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
16451256|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
16451257|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
16451258|NCT03627403|Experimental|Selinexor, all patients|Single Arm Study, all patients will get selinexor
16451259|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
16451260|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
16451261|NCT03627377|No Intervention|Control Phase|3-month initial control phase (no intervention, month 1-3)
16451262|NCT03627377|Experimental|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
16451263|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
16451264|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
16451265|NCT03627351||Healthy Women and Men|Group of healthy women and men
16451266|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
16451267|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
16451270|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
16451273|NCT03627273|Experimental|walker|'6 minutes walking test' with a walker
16451274|NCT03627273|Active Comparator|no walker|'6 minutes walking test' without walker
16451275|NCT03627247|Experimental|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
16451276|NCT03627247|No Intervention|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
16451277|NCT03627234|Experimental|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
16451278|NCT03627234|Experimental|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
16451279|NCT03627221|Experimental|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
16451280|NCT03627221|No Intervention|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
16451281|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
16451282|NCT03627195|Experimental|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
16451283|NCT03627195|Placebo Comparator|Placbo|placebo injection
16451284|NCT03627182|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
16451285|NCT03627182|Placebo Comparator|Placebo|Placebo
16451286|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
16451287|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
16451288|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
16451289|NCT03627143|Other|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
16451290|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
16451291|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
16451292|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
16451293|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
16451294|NCT03627104|Other|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
16451295|NCT03627104|Other|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
16451296|NCT03627104|Other|High-protein diet with animal protein|The patient will intake the diet assigned for a month
16451297|NCT03627104|Other|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
16451298|NCT03627091|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous (SC) injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
16451299|NCT03627091|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
16451300|NCT03627091|Placebo Comparator|Placebo|Participants will receive placebo matched with ontamalimab SC injection using prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
16451301|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
16451302|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
16451306|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
16451307|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
16451308|NCT03627013|Experimental|Kidney Custodiol-N|
16451309|NCT03627013|Active Comparator|Kidney Custodiol|
16451310|NCT03627013|Experimental|Liver Custodiol-N|
16451311|NCT03627013|Active Comparator|Liver Custodiol|
16451312|NCT03627013|Experimental|Kidney/Pancreas Custodiol-N|
16451313|NCT03627013|Active Comparator|Kidney/Pancreas Custodiol|
16451314|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
16451315|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
16451316|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
16451317|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
16451318|NCT03626961||discharge|patients discharged from icu
16451319|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
16451320|NCT03626948|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
16451321|NCT03626935|Experimental|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
16451322|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.
~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.
~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
16451323|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.
~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.
~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
16451324|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
16451325|NCT03626883|Experimental|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
16451326|NCT03626883|Active Comparator|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
16451329|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
16451330|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
16451331|NCT03626831|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
16451332|NCT03626831|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
16451333|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
16451334|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
16451335|NCT03626805||Healthy Controls|Age and sex matched
16451336|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
16451412|NCT03626181|Experimental|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
16451413|NCT03626168|Active Comparator|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
16451337|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
16451338|NCT03626779|Other|immediate placment and loading with prf|Immediat placment and loading with prf
16451339|NCT03626779|No Intervention|immediate implant placment and loading|Immediate implant placment and loading without prf
16451340|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
16451341|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
16451342|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
16451343|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
16451344|NCT03626753|Active Comparator|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
16451345|NCT03626753|Active Comparator|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
16451346|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
16451347|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
16451348|NCT03626727|Experimental|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
16451349|NCT03626714|Experimental|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
16451350|NCT03626701|Experimental|RECELL® Autologous Cell Harvesting Device|"RECELL + Telfa™ Clear and Xeroform™ dressings
~Conventional autografting (only when indicated)"
16451351|NCT03626701|Active Comparator|Mepilex® Ag Wound Dressing|"Mepilex® Ag Wound Dressing
~Conventional autografting (only when indicated)"
16451352|NCT03626688|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
16451353|NCT03626688|Placebo Comparator|Placebo|Matching placebo tablets (oral)
16451354|NCT03626675|Other|study group|"They will be subjected to:
~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS-OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.
~Surgery combined Phaco trabeculectomy
~Post operative:
~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.
~and biometric parameters measured with the AS-OCT before and after the surgery will be used to collect the data.
~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
16451355|NCT03626662|Placebo Comparator|Placebo|Single Ascending Dose Cohorts
16451356|NCT03626662|Experimental|AMG 890|Single Ascending Dose Cohorts
16451357|NCT03626649|Experimental|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
16451358|NCT03626636|Active Comparator|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
16451359|NCT03626636|Placebo Comparator|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
16451360|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
16451361|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
16451362|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
16451363|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
16451364|NCT03626597|Active Comparator|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
16451365|NCT03626597|Active Comparator|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
16451366|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
16451367|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
16451368|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
16451369|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
16451370|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
16451414|NCT03626168|Placebo Comparator|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
16451415|NCT03626155|Experimental|Seated Control|
16451371|NCT03626558|Experimental|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.
~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
16451374|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
16451375|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
16451376|NCT03626519|Experimental|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
16451377|NCT03626519|Placebo Comparator|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
16451378|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
16451379|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
16451380|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
16451381|NCT03626467|Experimental|Arm 1|Men infected by HIV who have sex with men
16451382|NCT03626454|Active Comparator|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
16451383|NCT03626454|Active Comparator|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
16451384|NCT03626441|Placebo Comparator|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
16451385|NCT03626441|Experimental|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
16451386|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
16451387|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
16451388|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
16451390|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
16451391|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
16451392|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
16451393|NCT03626363|Active Comparator|Stress Management Education|
16451394|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
16451395|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
16451396|NCT03626324|Experimental|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
16451397|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
16451398|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
16451399|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
16451400|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
16451401|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
16451402|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
16451403|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
16451404|NCT03626259|Other|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
16451405|NCT03626259|Active Comparator|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
16451406|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
16451407|NCT03626233||Vascular group|Pregnant women with vascular pathology
16451408|NCT03626233||Control group|"Pregnancy without any vascular complication
~Delivery before or after 37 weeks of gestation (GW)
~In case of delivery after 37GW: birth by cesarean delivery"
16451409|NCT03626220||acupuncture group|acupuncture with de-chi sensation
16451410|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
16451411|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
16451416|NCT03626155|Experimental|Morning Exercise (walking)|
16451419|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
16451420|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
16451421|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
16451422|NCT03626129|No Intervention|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
16451423|NCT03626129|Experimental|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
16451424|NCT03626103|Experimental|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
16451425|NCT03626103|Experimental|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
16451426|NCT03626103|Experimental|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
16451427|NCT03626103|No Intervention|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
16451428|NCT03626090|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
16451429|NCT03626077|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
16451430|NCT03626077|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
16451431|NCT03626077|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
16451432|NCT03626064|Other|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
16451433|NCT03626051|Active Comparator|rigid tape group|
16451434|NCT03626051|Experimental|fibular tape group|
16451435|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.
~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
16451436|NCT03626025|No Intervention|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
16451437|NCT03626025|Other|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
16451438|NCT03626012|Experimental|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
16451439|NCT03626012|Experimental|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
16451440|NCT03626012|Experimental|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
16451441|NCT03626012|Experimental|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
16451442|NCT03626012|Experimental|Cohort 5: BIIB078 Fifth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
16451443|NCT03626012|Experimental|Cohort 6: BIIB078 Sixth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
16451444|NCT03626012|Placebo Comparator|Cohorts 1-6: Placebo|Matching placebo will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days (Cohorts 1 through 3) and five maintenance doses on five later days (Cohorts 4 through 6).
16451445|NCT03625999|Experimental|Training Group|Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
16451483|NCT03625778|Placebo Comparator|Placebo Cohort 3|Participants will receive SC placebo matched to MEDI0382 Cohort 3 once daily for 18 weeks.
16451484|NCT03625778|Experimental|MEDI0382 Cohort 3|Participants will receive SC MEDI0382 titrated doses of Doses 1, 8, 4, and 7 once daily (4-step titration/ 4 week per dose) from Weeks 1 to 16 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 17 to 18.
16451446|NCT03625999|No Intervention|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on a loaned laptop), walked through the game's operation and controls, and encouraged to use it as often as they or their child like. If the child plays the game for a minimum of 20 minutes, 3 times per week, for 4 weeks, the family will be invited back to CARE for post-testing.
16451447|NCT03625986|Experimental|Nicotine-Containing Electronic Cigarette|The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 15 mg/ml nicotine for the duration of 6 weeks.
16451448|NCT03625986|Placebo Comparator|Non-Nicotine Electronic Cigarette|The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.
16451449|NCT03625973|Experimental|16 Weeks of 3D-RT|Participants will receive 16 weeks of Reminiscence Therapy using 3D printed objects as stimuli.
16451450|NCT03625973|Experimental|8 Weeks of 3D-RT|Participants will receive 8weeks of Reminiscence Therapy using 3D printed objects as stimuli and 8 weeks of RT using verbal stimuli.
16451451|NCT03625973|Active Comparator|16 Weeks of RT using Verbal Stimuli|Participants will receive 16 weeks of RT using verbal stimuli to reminiscence.
16451452|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
16451453|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
16451454|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
16451455|NCT03625934|Experimental|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
16451456|NCT03625934|Placebo Comparator|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
16451457|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
16451458|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
16451459|NCT03625908|Active Comparator|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
16451460|NCT03625908|Active Comparator|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
16451461|NCT03625895||Agrylin|Participants who received treatment with Agrylin will be evaluated for this study.
16451462|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
16451463|NCT03625869|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
16451464|NCT03625869|Experimental|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
16451465|NCT03625856|Experimental|Intervention|1500 mg Chlorella Vulgaris capsule
16451466|NCT03625856|Placebo Comparator|Control|1500 mg placebo (starch)
16451467|NCT03625843|Experimental|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
16451468|NCT03625843|No Intervention|Control|Sitting quietly in a room alone.
16451469|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
16451470|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
16451471|NCT03625817|No Intervention|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
16451472|NCT03625817|Experimental|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
16451473|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
16451474|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
16451475|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
16451476|NCT03625791||radiation-induced sarcomas|
16451477|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
16451478|NCT03625791||primary sarcomas|
16451479|NCT03625778|Placebo Comparator|Placebo Cohort 1|Participants will receive subcutaneous (SC) placebo matched to MEDI0382 Cohort 1 once daily for 9 weeks.
16451480|NCT03625778|Experimental|MEDI0382 Cohort 1|Participants will receive SC MEDI0382 titrated doses of Dose 1 to 7 once daily (7-step titration/ 1 week per dose) from Weeks 1 to 7 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 7 to 9.
16451481|NCT03625778|Placebo Comparator|Placebo Cohort 2|Participants will receive SC placebo matched to MEDI0382 Cohort 2 once daily for 14 weeks.
16451482|NCT03625778|Experimental|MEDI0382 Cohort 2|Participants will receive SC MEDI0382 titrated doses of Doses 1, 2, 3, 5, and 7 once daily (5-step titration/ 2 week per dose) from Weeks 1 to 10 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 11 to 14.
16451485|NCT03625765|Experimental|SmartGoggles|The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. Investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nanomolar (nM) concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with optical density (OD) 6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
16451486|NCT03625752|Active Comparator|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
16451487|NCT03625752|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
16451488|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
16451489|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
16451490|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
16451491|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation <94 % irrespective of supplemental oxygen
~Patients with chronic obstructive pulmonary disease: blood oxygen saturation <88% irrespective of supplemental oxygen"
16451492|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.
~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
16451493|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation >98% in combination with supplemental oxygen
~Patients with chronic obstructive pulmonary disease: blood oxygen saturation >92% in combination with supplemental oxygen"
16451494|NCT03625687|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
16451495|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
16451496|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
16451497|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
16451498|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
16451499|NCT03625661|Experimental|Arm with Ferinject|Ferinject will be administered once at inclusion
16451500|NCT03625648|Experimental|PTX|Active drug
16451501|NCT03625648|Placebo Comparator|Placebo|Placebo
16451502|NCT03625635|Experimental|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
16451503|NCT03625622|Placebo Comparator|Placebo|Placebo, orally administered once daily for 26 weeks.
16451504|NCT03625622|Active Comparator|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
16451505|NCT03625622|Active Comparator|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
16451506|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
16451507|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
16451508|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
16451509|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
16451510|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
16451511|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
16451512|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
16451513|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
16451514|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
16451515|NCT03625544|Active Comparator|Autograft|Autologous bone graft
16451516|NCT03625531|Experimental|Personalized acupuncture|Two sets of acupoints will be selected for the two types. The basic acupoint-prescription includes CV 4, CV 6, CV 12 and SP 6 bilaterally, ST 25 bilaterally, EX-CA 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points K 13, LR 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients special symptoms.
16451517|NCT03625531|Experimental|Fixed acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
16451588|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
16451518|NCT03625531|Active Comparator|Letrozole|Women in the letrozole group will be given letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
16451519|NCT03625531|Placebo Comparator|Placebo letrozole|Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
16451520|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
16451521|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
16451522|NCT03625505|Experimental|Dose Escalation Venetoclax + Gilteritinib|Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
16451523|NCT03625505|Experimental|Dose Expansion Venetoclax + Gilteritinib|Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.
16451524|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
16451525|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
16451526|NCT03625466|Experimental|Part 1: Double Blind Period|Subjects will receive LUM/IVA as FDC granules dependent upon weight or matched placebo at Day 1.
16451527|NCT03625466|Experimental|Part 2: Open Label Period|Subjects will receive LUM/IVA as FDC tablets or granules dependent upon weight at Day 1.
16451528|NCT03625453|Experimental|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
16451529|NCT03625453|Placebo Comparator|Placebo|Oral use of hard capsule
16451530|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.
~The Digit span test and PASAT with waterpipe smoking"
16451531|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.
~The Digit span test and PASAT without waterpipe smoking"
16451532|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
16451533|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
16451534|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
16451535|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
16451536|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
16451537|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
16451538|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
16451539|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
16451540|NCT03625401|Experimental|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
16451541|NCT03625401|Placebo Comparator|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
16451542|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
16451543|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
16451544|NCT03625375|Experimental|Treatment Group|Individuals will perform exercises 3 times a week.
16451545|NCT03625375|No Intervention|Control Group|Individuals will not perform exercises
16451546|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
16451547|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
16451548|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
16451549|NCT03625336||Prostate Calcifications|Men with prostate calcifications
16451550|NCT03625323|Experimental|1st line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).
~Pembrolizumab: 200 mg every 3 weeks."
16451551|NCT03625323|Experimental|2nd line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).
~Pembrolizumab: 200 mg every 3 weeks."
16451552|NCT03625323|Experimental|HNSCC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).
~Pembrolizumab: 200 mg every 3 weeks."
16451553|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
16451554|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
16451555|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
16451556|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
16451557|NCT03625297|No Intervention|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
16451558|NCT03625297|Experimental|shelter cat adoption|Families of children with autism will adopt a shelter cat
16451559|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
16451560|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
16451561|NCT03625271|No Intervention|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
16451562|NCT03625271|Experimental|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
16451563|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
16451564|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
16451565|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
16451566|NCT03625219|Active Comparator|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
16451567|NCT03625219|Placebo Comparator|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
16451568|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
16451569|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
16451570|NCT03625193||Ambulatory patients with SCI|"Age at least 18 years
~Body mass index (BMI) between 18.5 - 29.9 kg/m2
~Having an incomplete SCI from traumatic or non-traumatic causes
~Ability of independent standing up from a chair with or without hand support
~Ability of independent walking with or without walking device over at least 10 meters continuously.
~Ability to follow commands used in the studies"
16451571|NCT03625180||Treatment|NAMIC technique
16451572|NCT03625167|Experimental|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
16451573|NCT03625167|No Intervention|Control|The control forearm will remain untreated throughout the study.
16451574|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
16451575|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
16451576|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
16451577|NCT03625141|Experimental|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
16451578|NCT03625141|Experimental|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
16451579|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
16451580|NCT03625115|No Intervention|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
16451581|NCT03625115|Experimental|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
16451582|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
16451583|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
16451584|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
16451585|NCT03625089|Active Comparator|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Framingham Risk Score >10%
16451586|NCT03625089|Experimental|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
16451587|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
16451589|NCT03625063|Active Comparator|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
16451590|NCT03625063|Sham Comparator|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
16451591|NCT03625050|Experimental|Chuna + Usual care|
16451592|NCT03625050|Active Comparator|Usual care|
16451593|NCT03625037|Experimental|Epcoritamab (GEN3013, DuoBody®-CD3xCD20)|Open label, single arm trial where Epcoritamab will be administered.
16451594|NCT03625011|Placebo Comparator|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
16451595|NCT03625011|Active Comparator|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
16451596|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
16451597|NCT03624985|Experimental|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
16451598|NCT03624985|Placebo Comparator|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
16451599|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
16451600|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
16451601|NCT03624972|No Intervention|Clinician Arm|Clinicians were consented in order to have their clinic visits audio recorded. No outcomes data were collected from clinician participants.
16451602|NCT03624959|Experimental|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
16451603|NCT03624959|Experimental|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
16451604|NCT03624959|Experimental|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
16451605|NCT03624959|Experimental|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
16451606|NCT03624959|Experimental|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
16451607|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
16451608|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
16451609|NCT03624933|Experimental|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
16451610|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
16451611|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
16451612|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
16451613|NCT03624907|Other|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
16451614|NCT03624907|Other|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
16451615|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
16451616|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
16451617|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
16451618|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
16451619|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
16451620|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
16451621|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
16451622|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
16451623|NCT03624816|No Intervention|Control|no-treatment control
16451624|NCT03624790|Experimental|Group 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
16451625|NCT03624777|Experimental|Stroll Safe Program|
16451626|NCT03624777|Active Comparator|Outdoor Fall Prevention Brochure|
16451627|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
16451628|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
16451629|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
16451630|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
16451631|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
16451632|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
16451633|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
16451634|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
16451635|NCT03624686||healthy volunteer|
16451636|NCT03624686||luekemia patient|
16451637|NCT03624673|Experimental|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
16451638|NCT03624673|Active Comparator|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
16451639|NCT03624660|Experimental|HR-A (High-risk A)|"Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.
~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
16451640|NCT03624660|Experimental|HR-B (High-risk B)|"Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.
~Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.
~Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.
~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
16451641|NCT03624647|Experimental|Power toothbrush|
16451642|NCT03624647|Placebo Comparator|Manual toothbrush|
16451643|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
16451644|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
16451645|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
16451646|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
16451647|NCT03624595|Experimental|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
16451648|NCT03624595|Placebo Comparator|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
16451649|NCT03624569|Sham Comparator|Bagel diet|Bagel consumed daily for 2 weeks
16451650|NCT03624569|Experimental|Potato diet|Potato consumed daily for 2 weeks
16451651|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
16451652|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
16451653|NCT03624543|Experimental|Cohort 1: TNBC|N=9 to 24 patients
16451654|NCT03624543|Experimental|Cohort 2: PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
16451655|NCT03624543|Experimental|Cohort 3: Not PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
16451656|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
16451657|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
16451658|NCT03624517|Experimental|24-hour octreotide infusion|Patients will receive octreotide infusion over 24 hours
16451659|NCT03624517|Active Comparator|72-hour octreotide infusion|Patients will receive octreotide infusion over 72 hours
16451660|NCT03624504|Experimental|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
16455361|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
16451661|NCT03624491|No Intervention|Standard of care mechanical ventilation|Anesthesia and surgical procedures will be performed following standard of care for mechanical ventilation during surgery.
16451662|NCT03624491|Active Comparator|Transpulmonary pressure guided mechanical ventilation|Same treatment as the control group with the addition of esophageal pressure measurements used to guide mechanical ventilation during surgery.
16451663|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
16451664|NCT03624465|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
16451665|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
16451666|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
16451667|NCT03624439|Experimental|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
16451668|NCT03624439|Experimental|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
16451669|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
16451670|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
16451671|NCT03624413|Experimental|Social Media Intervention|Adolescent HIV-positive participants receiving the social media intervention.
16451672|NCT03624413|Active Comparator|Standard of Care|Adolescent HIV-positive participants receiving the standard of care.
16451673|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
16451674|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
16451675|NCT03624387|No Intervention|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
16451676|NCT03624387|Experimental|Intervention Group( Painting Session)|Painting sessions for participants
16451677|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.
~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
16451678|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
16451679|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
16451680|NCT03624335|Experimental|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.
~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
16451681|NCT03624335|Experimental|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
16451682|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
16451683|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
16451684|NCT03624309|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
16451685|NCT03624309|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
16451686|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
16451687|NCT03624283|Experimental|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
16451688|NCT03624283|Experimental|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
16451689|NCT03624283|Experimental|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
16451690|NCT03624270|Experimental|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:
~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days
~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)
~Hydroxyurea 2-4g per day if WBC > 5 x 10^9/L during the first 7 days of induction.
~Consolidation (for all patients):
~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles
~Maintenance (for all patients):
~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
16451691|NCT03624257|Experimental|Scaling and root planning + Laser treatment|
16451692|NCT03624257|Active Comparator|Mucosal flap surgery|
16451693|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
16451694|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
16452388|NCT03619239|Experimental|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
16451695|NCT03624231|Experimental|Arm 1|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.
~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
16451696|NCT03624231|Experimental|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.
~Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
16451697|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
16451698|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
16451699|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
16451700|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
16451701|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
16451702|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
16451703|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
16451704|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
16451705|NCT03624153|Experimental|Robotic-assisted intervention|70 minutes Robotic-assisted intervention.
16451706|NCT03624153|Active Comparator|Conventional intervention|70 minutes conventional rehabilitation.
16451707|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
16451708|NCT03624127|Experimental|BMS-986165|
16451709|NCT03624127|Placebo Comparator|Placebo|
16451710|NCT03624127|Active Comparator|Apremilast|
16451711|NCT03624101|Experimental|Trikafta|If the participant is not on a current modulator, they will take Trikafta for 28 days followed by a 28 day off period. This cycle will be continued for 168 days
16451712|NCT03624101|Experimental|Symdeko/Trikafta|If the participant currently takes Symdeko , they will take Trikafta for a 28 day period followed by Symdeko for a 28 day period. This cycle will be continued for 168 days
16451713|NCT03624101|Experimental|Ivacaftor/Trikafta|If the participant currently takes Ivacaftor , they will take Trikafta for a 28 day period followed by Ivacaftor for a 28 day period. This cycle will be continued for 168 days
16451714|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
16451715|NCT03624075|No Intervention|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
16451716|NCT03624075|Placebo Comparator|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
16451717|NCT03624075|Experimental|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
16451718|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
16451719|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
16451720|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
16451721|NCT03624062|Other|TBD ug IBC in 0.5 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the maximum safe IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.5 mL MAS-1 emulsion
16451722|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
16451723|NCT03624036|Experimental|brexucabtagene autoleucel (KTE-X19)|Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide), followed by the investigational treatment, brexucabtagene autoleucel (KTE-X19).
16451724|NCT03624023|Experimental|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
16451725|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
16451726|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
16451727|NCT03623984|Experimental|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
16451728|NCT03623971|Experimental|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
16451729|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
16451730|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
16451731|NCT03623945||Cohort A|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.
16451732|NCT03623945||Cohort B|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.
16451733|NCT03623945||Cohort C|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH).
16451734|NCT03623945||Cohort D|Patients who have had a normal screening mammogram within the last 6 months will be invited to participate.
16451735|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
16451736|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
16451737|NCT03623919|Experimental|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.
~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.
~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
16451738|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
16451739|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
16451740|NCT03623893|Other|Intervention group|Unilateral inguinal hernia repair with contralateral exploration.
16451741|NCT03623893|No Intervention|Control group|Unilateral inguinal hernia repair.
16451742|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
16451743|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
16451744|NCT03623867|Experimental|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
16451745|NCT03623867|Placebo Comparator|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 48
16451746|NCT03623854|Experimental|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16451747|NCT03623841|Experimental|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
16451748|NCT03623841|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
16451749|NCT03623828|Experimental|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.
~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
16452389|NCT03619239|Experimental|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
16451750|NCT03623815|Other|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
16451751|NCT03623815|Other|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
16451752|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
16451753|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
16451754|NCT03623789|Active Comparator|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
16451755|NCT03623789|Active Comparator|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
16451756|NCT03623789|Placebo Comparator|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
16451757|NCT03623776|Experimental|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
16451758|NCT03623776|Experimental|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
16451759|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
16451760|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
16451761|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
16451762|NCT03623750|Experimental|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
16451763|NCT03623737|Experimental|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
16451764|NCT03623737|Active Comparator|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
16451765|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
16451766|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
16451767|NCT03623711|Experimental|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
16451768|NCT03623711|Experimental|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
16451769|NCT03623711|Experimental|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
16451770|NCT03623711|Placebo Comparator|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
16451771|NCT03623698||Before treatment|Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
16451772|NCT03623698||After treatment|Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)
16451773|NCT03623685|Experimental|voluson 8|
16451774|NCT03623659|Active Comparator|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
16451775|NCT03623659|No Intervention|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
16451776|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
16451777|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
16451778|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
16451779|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
16451780|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
16451781|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
16451782|NCT03623594|Experimental|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
16451783|NCT03623581|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
16451784|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
16451785|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.
~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
16451786|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.
~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
16451787|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
16451788|NCT03623529|Experimental|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
16451789|NCT03623529|Placebo Comparator|Placebo Comparator: Placebo|0.9% sodium chloride solution
16451790|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
16451791|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
16451792|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
16451793|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
16451794|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
16451795|NCT03623477|Active Comparator|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
16451796|NCT03623477|Experimental|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
16451797|NCT03623464|Active Comparator|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
16451798|NCT03623464|Other|Standard of care|Participants will receive standard of care
16451799|NCT03623451|Experimental|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for three menstrual cycles.
16451800|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
16451801|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
16451802|NCT03623425|Experimental|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
16451803|NCT03623425|Experimental|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
16451804|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
16451805|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
16451806|NCT03623399|No Intervention|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
16451807|NCT03623399|Other|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.
~Low gas pressure laparoscopy"
16451808|NCT03623399|Other|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.
~Low gas pressure laparoscopy"
16451809|NCT03623386|Experimental|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
16451810|NCT03623386|Active Comparator|Patients with PD control|Patients will not receive neurofeedback training.
16451811|NCT03623373|Experimental|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"Patients will receive (6) 28 day cycles
~Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
~Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
~After Cycle 6, patients will undergo leukapheresis"
16451812|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.
~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
16451813|NCT03623334|Experimental|Dose Level A: IGRT 3.33Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks
16451814|NCT03623334|Experimental|Dose Level B: IGRT 3.67Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks
16451815|NCT03623334|Experimental|Dose Level C: IGRT 4.00Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks
16452390|NCT03619239|Experimental|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
16451816|NCT03623321|Experimental|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
16451817|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
16451818|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
16451819|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
16451820|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
16451821|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
16451822|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
16451823|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
16451824|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
16451825|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
16451826|NCT03623243|Experimental|Siponimod 2 mg|Siponimod 2mg tablets taken once daily after a 5 day titration
16451827|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
16451828|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.
~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
16451829|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.
~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
16451830|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
16451831|NCT03623204||Patients with bariatric surgery for obesity|
16451832|NCT03623191||Patients with erosive pustular dermatosis of the leg|
16451833|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.
~or (2) difficulties to attend their health care appointments, during the last 3 months."
16451834|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
16451835|NCT03623165||Arm|Cordella™ Heart Failure System
16451836|NCT03623139|Active Comparator|Standard nutritional education|Control group
16451837|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
16451838|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
16451839|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
16451840|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
16451841|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
16451842|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
16451843|NCT03623087|Experimental|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
16451844|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
16451845|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
16451846|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
16451847|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
16451848|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
16451849|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
16451850|NCT03623048|Experimental|Propolis extract|intervention
16451851|NCT03623048|Experimental|Pomegranate extract|intervention
16451852|NCT03623048|Active Comparator|Chlorhexidine|comparator
16451853|NCT03623048|Placebo Comparator|Saline|comparator
16451854|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
16451855|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
16451856|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
16451857|NCT03623009|Experimental|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
16451858|NCT03623009|Sham Comparator|Control|The control arm will receive a neutral article prior to completing the assessment.
16451859|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
16451860|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:
~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
16451861|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:
~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
16451862|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
16451863|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
16451864|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
16451865|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
16451866|NCT03622931|Experimental|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
16451867|NCT03622931|Placebo Comparator|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
16451868|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
16451869|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
16451870|NCT03622905|Experimental|DBS On|DBS system On
16451871|NCT03622905|Sham Comparator|DBS Off|DBS System Off
16451872|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
16451873|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
16451874|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
16451875|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
16451876|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
16451877|NCT03622866|Active Comparator|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
16451878|NCT03622853|Experimental|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
16451879|NCT03622840|Other|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
16451880|NCT03622827|Experimental|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：
~Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.
~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
16451881|NCT03622814|Experimental|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
16451882|NCT03622814|Placebo Comparator|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
16451883|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
16451884|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
16451885|NCT03622788|Experimental|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.
~TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
16451886|NCT03622775|Experimental|Treatment (daratumumab)|Beginning 60-120 days after transplant, participants receive daratumumab IV over 4-8 hours on days 1, 8, 15 and 22 of courses 1 and 2 and days 1 and 15 of courses 3-6, then on day 1 of subsequent courses. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
16451887|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
16451888|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
16451889|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
16451890|NCT03622749|No Intervention|Controls|Healthy controls
16451891|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
16451892|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
16451895|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
16451896|NCT03622671|Active Comparator|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
16451897|NCT03622671|Active Comparator|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
16451898|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeksx
16451899|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeksx
16451900|NCT03622645|Experimental|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
16451901|NCT03622619|Experimental|Manuka eye drops|
16451902|NCT03622619|Active Comparator|Systane Ultra|
16451903|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).
~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.
~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
16451907|NCT03622580|Experimental|A: Faricimab Q8W|
16451908|NCT03622580|Experimental|B: Faricimab As Specified in Protocol|
16451909|NCT03622580|Active Comparator|C: Aflibercept Q8W|
16451910|NCT03622567|Other|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
16451911|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
16451912|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists
~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
16451913|NCT03622541|Experimental|sorafenib|
16452071|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
16451914|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
16451915|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
16451916|NCT03622515|No Intervention|Group C|Bispectral index (BIS)/Sedline monitoring
16451917|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
16451918|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
16451919|NCT03622489|Experimental|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:
~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3
~IV Tramal 100 mg, once
~After Admitted to Maternity ward:
~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr
~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.
~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
16451920|NCT03622489|Experimental|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:
~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3
~IV Tramal 100 mg, once
~After Admitted to Maternity ward:
~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr
~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.
~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
16451921|NCT03622489|Experimental|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:
~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3
~IV Tramal 100 mg, once
~After Admitted to Mternity ward:
~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:
~Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.
~PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.
~Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
16451922|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
16451923|NCT03622463|Experimental|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
16451924|NCT03622463|Experimental|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
16451925|NCT03622463|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, once a day
16451926|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
16451927|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
16451928|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
16451929|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
16451930|NCT03622424|Active Comparator|Gelesis200|Subjects on this ARM will receive Gelesis200
16451931|NCT03622424|Placebo Comparator|Placebo|Subjects on this ARM will receive a placebo device
16451932|NCT03622424|Active Comparator|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
16451933|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
16451934|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
16451935|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
16451936|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
16451937|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
16451938|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.
~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
16452188|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
16451939|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.
~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
16451940|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
16451941|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
16451942|NCT03622359|Experimental|SPECT/CT perfusion imaging|Patients with peripheral arterial disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo SPECT/CT imaging as part of the research protocol.
16451943|NCT03622359|Experimental|PET/CT perfusion imaging|Patients with peripheral arterial disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo PET/CT imaging as part of the research protocol.
16451944|NCT03622333|Experimental|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
16451945|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
16451946|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
16451947|NCT03622307|Experimental|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
16451948|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.
~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.
~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.
~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
16451949|NCT03622281|Experimental|Colonoscopists who received quality intervention|
16451950|NCT03622281|No Intervention|Colonoscopists who did not received quality intervention|
16451951|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
16451952|NCT03622255|Other|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
16451953|NCT03622255|Active Comparator|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
16451954|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
16451955|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
16451956|NCT03622229|Active Comparator|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.
~Diagnostic Test: Histologic evaluation"
16451957|NCT03622229|Active Comparator|EUS-FNB with fork-tip needle|"Intervention: like above.
~Diagnostic Test: Histologic evaluation."
16451958|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
16451959|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
16451960|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
16451961|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
16451962|NCT03622203||STEMI|Patients with STEMI
16451963|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
16451964|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
16451965|NCT03622177||HIV+|
16451966|NCT03622177||HIV- STI+|
16451967|NCT03622177||HIV- STI-|
16451968|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
16451969|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
16451970|NCT03622151|Experimental|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
16451971|NCT03622151|No Intervention|Control group|"Treatment as usual:
~attention from the resources of the homeless network in Barcelona."
16451972|NCT03622138|Experimental|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
16451973|NCT03622138|Experimental|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
16451974|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
16451975|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
16451976|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
16451977|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
16451978|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
16451979|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
16451980|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
16451981|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
16451982|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
16451983|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
16451984|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
16451985|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
16451986|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
16451987|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
16451988|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
16451989|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
16451990|NCT03622047|Experimental|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
16451991|NCT03622047|Experimental|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
16451992|NCT03622047|Experimental|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
16451993|NCT03622021|Experimental|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
16451994|NCT03622021|Experimental|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
16451995|NCT03622021|Experimental|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
16451996|NCT03622021|Experimental|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
16451997|NCT03622021|Experimental|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
16451998|NCT03622021|Experimental|AK111 600mg|Single dose of 600mg AK111 or placebo is administered subcutaneously to healthy subjects
16451999|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
16452000|NCT03622008|Placebo Comparator|Placebo|placebo IV
16452001|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
16452002|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
16452003|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
16452067|NCT03621605|Placebo Comparator|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
16452068|NCT03621592|Experimental|Cutimed® Sorbact®|
16452069|NCT03621592|Active Comparator|Acticoat®|
16452007|NCT03621969|Experimental|Group 1|"Group 1 will receive:
~Medical History and Brief Physical Exam
~Diagnostic Assessments
~Patient Instruction and use of RePlay Device
~two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,
~then will rest for 2 weeks (weeks 3-4),
~then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
16452008|NCT03621969|Experimental|Group 2|"Group 2 will receive:
~Medical History and Brief Physical Exam
~Diagnostic Assessments
~Patient Instruction and use of RePlay Device
~two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,
~then will rest for 2 weeks (weeks 3-4),
~then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
16452009|NCT03621956|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
16452010|NCT03621956|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
16452011|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
16452012|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
16452013|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
16452014|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
16452015|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
16452016|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
16452017|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
16452018|NCT03621878|Active Comparator|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
16452019|NCT03621878|Experimental|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
16452020|NCT03621878|Experimental|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
16452021|NCT03621865|Experimental|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452022|NCT03621865|Experimental|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452023|NCT03621865|Experimental|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452024|NCT03621865|Experimental|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452025|NCT03621865|Experimental|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452026|NCT03621865|Experimental|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452027|NCT03621865|Experimental|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452028|NCT03621865|Experimental|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452029|NCT03621865|Experimental|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452030|NCT03621865|Experimental|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
16452031|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
16452032|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
16452033|NCT03621813|Other|Control|Participants maintain their current activity level.
16452034|NCT03621813|Active Comparator|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
16452035|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
16452036|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
16452070|NCT03621579|Other|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
16452037|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
16452038|NCT03621774|Experimental|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
16452039|NCT03621774|Placebo Comparator|Supportive Contact|An active group leader- and device-contact control group.
16452040|NCT03621761|Active Comparator|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
16452041|NCT03621761|Active Comparator|Modafinil|50-400 mg per day (oral)
16452042|NCT03621761|Active Comparator|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
16452043|NCT03621748|Active Comparator|Non-Awake Cohort|Cohort undergoing craniotomy utilizing general anesthesia protocol
16452044|NCT03621748|Experimental|Awake Cohort|Cohort undergoing craniotomy utilizing awake anesthesia protocol
16452047|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
16452048|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
16452049|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
16452050|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
16452051|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
16452055|NCT03621683|Experimental|ovarian bio-stimulation|"Intervention:
~ovarian bio-stimulation: blood rich plasma platelets"
16452056|NCT03621683|Active Comparator|Antioxidant therapy|"Intervention:
~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
16452059|NCT03621657|Experimental|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
16452060|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
16452061|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
16452062|NCT03621631|Experimental|optimized Tai Chi intervention|
16452063|NCT03621631|Active Comparator|traditional Tai Chi intervention|
16452064|NCT03621618|Other|dobutamine|Cardiac failure
16452065|NCT03621618|Other|norepinephrine|Sepsis
16452066|NCT03621605|Experimental|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.
~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
16452072|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.
~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
16452073|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.
~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
16452074|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.
~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
16452075|NCT03621540|Active Comparator|Verum arm|25 min anodal tDCS + adaptive working memory training
16452076|NCT03621540|Sham Comparator|Sham arm|sham tDCS + adaptive working memory training
16452077|NCT03621527|Active Comparator|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.
~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
16452078|NCT03621527|Experimental|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.
~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.
~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
16452079|NCT03621514|Other|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
16452080|NCT03621514|Other|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
16452081|NCT03621501|Placebo Comparator|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Control arm)
16452082|NCT03621501|Active Comparator|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Experimental arm)
16452083|NCT03621488|Experimental|Efficacy of Behavioral Self-Activation with virtual reality|"10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week
~+ virtual reality activities of the session 4 to 9 lasting half an hour."
16452084|NCT03621488|Sham Comparator|Efficacy of Behavioral Self-Activation without virtual reality|10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week.
16452085|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
16452086|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
16452087|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
16452088|NCT03621436|Experimental|TRVD Therapy|
16452089|NCT03621397|Experimental|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
16452090|NCT03621397|No Intervention|Control Group|Research participants in the control group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
16452091|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
16452092|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
16452093|NCT03621371|Experimental|Metacognitive therapy|
16452094|NCT03621371|Experimental|Intolerance of uncertainty therapy|
16452095|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
16452096|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
16452097|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
16452098|NCT03621345|Active Comparator|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.
~Interventions:
~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
16452189|NCT03620721|Experimental|M-Body|mindfulness group intervention
16452099|NCT03621345|Sham Comparator|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.
~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
16452100|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
16452101|NCT03621319|Active Comparator|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
16452102|NCT03621319|Active Comparator|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
16452103|NCT03621306||Men and women aged 18+|Men and women over the age of 18
16452104|NCT03621293|Active Comparator|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
16452105|NCT03621293|Experimental|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
16452106|NCT03621280|Experimental|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
16452107|NCT03621267|Experimental|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)
~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.
~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
16452108|NCT03621267|Active Comparator|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
16452109|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
16452110|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
16452111|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
16452112|NCT03621228|No Intervention|Control|Standard care only
16452113|NCT03621215|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
16452114|NCT03621215|Placebo Comparator|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).
~once per day (250 mL total volume per day)"
16452115|NCT03621202|Experimental|Saranas Early Bird Bleed Monitoring System (EBBMS)|
16452116|NCT03621189|Active Comparator|Active-Active|"Participants received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 8 weeks (2 days/week).
~*iTBS = intermittent theta burst stimulation"
16452117|NCT03621189|Sham Comparator|Sham-Active|"Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the posterior superior temporal sulcus for 4 weeks (2 days/week) and then received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 4 weeks (2 days/week).
~*iTBS = intermittent theta burst stimulation"
16452118|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
16452119|NCT03621163|Experimental|bleaching agent|intervention : bleaching agent ( Boost 40%)
16452120|NCT03621163|Active Comparator|laminate veneers|laminate veneers ( monolithic lithium - silicate)
16452121|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
16452122|NCT03621137||Patients with moderate-to-severe atopic eczema|Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
16452123|NCT03621124|Other|Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
16452124|NCT03621124|Other|Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
16452190|NCT03620721|No Intervention|Usual Care|treatment as usual
16452191|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
16452192|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
16452125|NCT03621111|Experimental|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
16452126|NCT03621111|No Intervention|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
16452127|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
16452128|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.
~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
16452129|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
16452130|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
16452131|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
16452132|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
16452133|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
16452134|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
16452135|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
16452136|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
16452137|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
16452138|NCT03621033|Other|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
16452139|NCT03621033|Other|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
16452140|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
16452141|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
16452142|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
16452143|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
16452144|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
16452145|NCT03621007||POMC deficiency obesity|
16452146|NCT03621007||LEPR deficiency obesity|
16452147|NCT03621007||PCSK1 deficiency obesity|
16452148|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
16452149|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
16452150|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
16452151|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
16452152|NCT03620968|No Intervention|Group 1|Control, no intervention
16452153|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
16452154|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
16452155|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after three courses of chemo therapy.
16452156|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
16452157|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
16452158|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
16452159|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
16452160|NCT03620916|Experimental|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
16452161|NCT03620916|Active Comparator|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
16452162|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:
~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;
~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;
~Maintenance I (1 cycle = 56 days):
~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);
~Maintenance II (1 cycle = 84 days):
~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
16452163|NCT03620890|Active Comparator|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
16452164|NCT03620890|Active Comparator|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
16452165|NCT03620877|Experimental|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
16452166|NCT03620864|Active Comparator|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
16452167|NCT03620864|Experimental|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
16452168|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
16452169|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
16452170|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period
16452171|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period
16452172|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment
16452173|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
16452174|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
16452175|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
16452176|NCT03620825|No Intervention|Negative control|No intervention is performed
16452177|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
16452178|NCT03620812|Active Comparator|soy protein|
16452179|NCT03620812|Placebo Comparator|no protein|
16452180|NCT03620799|Experimental|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
16452181|NCT03620799|No Intervention|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
16452182|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
16452183|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.
~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
16452184|NCT03620760|Experimental|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg once daily.
16452185|NCT03620760|Active Comparator|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
16452186|NCT03620747|Experimental|Dupilumab|One dose administered every two weeks. A loading dose may be administered at the start of treatment for some patients (e.g., due to previous Dupilumab treatment discontinuation for more than 6 weeks).
16452187|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
16452193|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
16452194|NCT03620682|Experimental|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
16452195|NCT03620669|Experimental|Durvalumab|Durvalumab until progression or unacceptable toxicity
16452196|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
16452197|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
16452198|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] monotherapy|Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule [Xalkori] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
16452199|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection|Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule [Xalkori] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe [Faslodex or generic] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
16452200|NCT03620630|No Intervention|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
16452201|NCT03620630|Active Comparator|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
16452202|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
16452203|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
16452204|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
16452205|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.
~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
16452206|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
16452207|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
16452208|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
16452209|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
16452210|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
16452211|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
16452212|NCT03620552|Experimental|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
16452213|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
16452214|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
16452215|NCT03620526|Experimental|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
16452216|NCT03620526|Placebo Comparator|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
16452217|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
16452218|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
16452219|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
16452220|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
16452221|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
16452249|NCT03620266|Experimental|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
16452601|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
16452222|NCT03620474|Experimental|PRI-724|"Dose: 140, 280, 380 mg / m 2/4 hr
~Administration method:
~【Phase I Phase】 (Level 1) 140 mg / m 2/4 hr (Level 2) 280 mg / m 2/4 hr (Level 3) 380 mg / m 2/4 hr Twice weekly, continuous 4-hour intravenous administration (tolerance of administration time: ± 15 minutes). This is one cycle and 12 cycles (12 weeks in total) are carried out. However, in Phase I phase, single dose is administered on Day - 7 (tolerance: - 7 days).
~【Phase IIa phase】 Continuous intravenous administration for 4 hours twice a week at the recommended dose determined in Phase I. This is one cycle and 12 cycles (12 weeks in total) are carried out."
16452223|NCT03620448|Experimental|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:
~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
16452224|NCT03620448|Other|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
16452225|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
16452226|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
16452227|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
16452228|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
16452229|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection
16452230|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
16452231|NCT03620409||Healthy subjects|Healthy controls
16452232|NCT03620396|Experimental|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
16452233|NCT03620396|Experimental|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
16452234|NCT03620383|Experimental|Heat|Distal topical heat application
16452235|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
16452236|NCT03620370|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
16452237|NCT03620370|No Intervention|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
16452238|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
16452239|NCT03620357|Active Comparator|SMBG Group|
16452240|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
16452241|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
16452242|NCT03620331|Active Comparator|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
16452243|NCT03620331|Experimental|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
16452244|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
16452245|NCT03620292|Experimental|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma
~IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.
~Peroperative open air NIR fluorescence imaging
~Ex vivo endoscopic and histopathological NIR fluorescence imaging"
16452246|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
16452247|NCT03620266|Experimental|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
16452248|NCT03620266|Placebo Comparator|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
16452602|NCT03617770|Active Comparator|Healthy Living|Health education
16452250|NCT03620266|Experimental|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
16452251|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
16452252|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
16452253|NCT03620240|Experimental|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
16452254|NCT03620240|No Intervention|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
16452255|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
16452256|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
16452257|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
16452258|NCT03620201|Experimental|Treatment (M7824)|Participants receive anti-PD-L1/TGFbetaRII fusion protein M7824 IV over 1 hour on days 1 and 15. During days 28-56 participants receive planned neoadjuvant chemotherapy.
16452259|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
16452260|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
16452261|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
16452262|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
16452263|NCT03620162|Active Comparator|Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
16452264|NCT03620162|Experimental|Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
16452265|NCT03620162|Experimental|Group 3: Prevnar 13™-Prevnar 13™-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
16452266|NCT03620162|Experimental|Group 4: Prevnar 13™-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
16452267|NCT03620162|Experimental|Group 5: V114-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
16452268|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
16452269|NCT03620136|Experimental|locoregional analgesia by a block on the adductor channel|
16452270|NCT03620136|Experimental|locoregional analgesia by periarticular local infiltrations|
16452271|NCT03620123|Experimental|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
16452272|NCT03620123|Other|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
16452273|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
16452274|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
16452275|NCT03620084|Experimental|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
16452276|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
16452277|NCT03620071|Experimental|Control|Standard Care
16452278|NCT03620058|Experimental|CART22-65s monotherapy|
16452279|NCT03620058|Experimental|CART22-65s in combination with huCART19|
16452280|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
16452281|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
16452313|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
16452314|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
16452315|NCT03619720|Experimental|Participants|
16452282|NCT03620032|Other|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
16452283|NCT03620032|Experimental|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
16452284|NCT03620019|Experimental|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
16452285|NCT03619993|Experimental|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
16452286|NCT03619993|Experimental|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
16452287|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
16452288|NCT03619967|Experimental|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
16452289|NCT03619954|Experimental|NK cells infusion|
16452290|NCT03619941|Placebo Comparator|Placebo|
16452291|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
16452292|NCT03619928|Experimental|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
16452293|NCT03619928|Active Comparator|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
16452294|NCT03619915||Greater dependence|
16452295|NCT03619915||Less dependence|
16452296|NCT03619915||Independent|
16452297|NCT03619902|Experimental|ANB019 Biological/Vaccine|ANB019 subcutaneous (SC) injection every 4 weeks
16452298|NCT03619889|Sham Comparator|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
16452299|NCT03619889|Experimental|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
16452300|NCT03619876|Active Comparator|Non-TNF inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
16452301|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
16452302|NCT03619850|Experimental|Ferumoxytol|
16452303|NCT03619850|Active Comparator|Iron sucrose|
16452304|NCT03619837|Experimental|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir
~Dosage: 400mg/100mg. Once daily for 12 weeks."
16452305|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
16452306|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
16452307|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
16452308|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
16452309|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
16452310|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
16452311|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
16452312|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15~20mg intravenous, at the end of surgery, before extubation
16452387|NCT03619239|Experimental|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
16452316|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
16452317|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
16452318|NCT03619681|Experimental|KN026|
16452319|NCT03619655|Experimental|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
16452320|NCT03619655|Experimental|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
16452321|NCT03619655|Experimental|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
16452322|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
16452323|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
16452324|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
16452325|NCT03619629|Experimental|Kinesio-taping|Kinesiotape will be applied both ankles.
16452326|NCT03619629|Experimental|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
16452327|NCT03619629|Sham Comparator|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
16452328|NCT03619629|Sham Comparator|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
16452329|NCT03619616|Experimental|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
16452330|NCT03619616|Experimental|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.
~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
16452331|NCT03619616|Experimental|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.
~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
16452332|NCT03619616|Experimental|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.
~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
16452333|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
16452334|NCT03619577|Experimental|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
16452335|NCT03619577|Experimental|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
16452336|NCT03619564||No protein restriction|No protein restriction
16452337|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
16452338|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
16452341|NCT03619538|Placebo Comparator|control group|
16452342|NCT03619538|Experimental|Nefopam group|
16452343|NCT03619525|Active Comparator|recruitment group|will receive intermittent lung recruitment during CPB
16452344|NCT03619525|No Intervention|control group|will recieve no intervention
16452345|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
16452346|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
16452347|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
16452348|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
16452349|NCT03619499|Experimental|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
16452350|NCT03619499|No Intervention|invasive|infants who were connected to invasive mechanical ventilation
16452351|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
16452352|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
16452731|NCT03616886|Active Comparator|Phase II Arm B|Patients are treated with paclitaxel, carboplatin and durvalumab.
16452353|NCT03619473|Experimental|intervention|"the group
~assessed for proper helmet usage (type, chinstrap, standard helmet usage)
~evaluated for the behavioral of helmet usage
~underwent the educational session under helmet initiative program
~received one standard motorcycle child safety helmet per family
~assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet
~evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
16452354|NCT03619473|No Intervention|control|"the group
~assessed for proper helmet usage (type, chinstrap, standard helmet usage)
~evaluated for the behavioral of helmet usage
~assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months
~do not receive any educational session or standard motorcycle child safety helmet"
16452355|NCT03619460|Experimental|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
16452356|NCT03619460|Active Comparator|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
16452357|NCT03619447|Active Comparator|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
16452358|NCT03619447|Active Comparator|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
16452359|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
16452360|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
16452361|NCT03619421|Experimental|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
16452362|NCT03619421|Experimental|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
16452363|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
16452364|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.
~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
16452365|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
16452366|NCT03619369|Active Comparator|Early Circumcision|
16452367|NCT03619369|Placebo Comparator|Routine Circumcision|
16452368|NCT03619369|Active Comparator|Delayed Circumcision|
16452369|NCT03619343|Experimental|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
16452370|NCT03619343|Active Comparator|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
16452371|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
16452372|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
16452373|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
16452374|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
16452375|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
16452376|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
16452377|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
16452378|NCT03619291|Experimental|High-intensity functional training|all-out exercise
16452379|NCT03619291|Active Comparator|Aerobic exercise|walking
16452380|NCT03619291|Sham Comparator|control|sitting
16452381|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
16452382|NCT03619278|Placebo Comparator|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
16452383|NCT03619265|Experimental|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
16452384|NCT03619265|Placebo Comparator|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
16452385|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
16452386|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
16452732|NCT03616873||Adults aged 60 or older|
16452391|NCT03619239|Experimental|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
16452392|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
16452393|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
16452394|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
16452395|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
16452396|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
16452397|NCT03619187|Experimental|Single Arm|Study Product
16452398|NCT03619174|Active Comparator|Active Treatment|Treatment dose
16452399|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
16452400|NCT03619161|No Intervention|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
16452401|NCT03619161|Experimental|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
16452402|NCT03619161|Active Comparator|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
16452403|NCT03619148|Other|High-Flow Humidified Nasal Oxygen - TOE participants|High-Flow Humidified Nasal Oxygen - standard care
16452404|NCT03619148|Active Comparator|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
16452405|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
16452406|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
16452407|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
16452408|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
16452409|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
16452410|NCT03619096|Active Comparator|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
16452411|NCT03619096|Placebo Comparator|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
16452412|NCT03619083||Breast cancer patients treated with chemotherapy|
16452413|NCT03619083||patients not exposed to chemotherapy|
16452414|NCT03619083||healthy controls|
16452415|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
16452416|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
16452417|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
16452418|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
16452419|NCT03619057||> 18 years|
16452420|NCT03619057||10 to 18 years|
16452421|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
16452422|NCT03619031|Experimental|LONG LEAVENING|Acute test meal
16452423|NCT03619031|Experimental|SHORT LEAVENING|Acute test meal
16452424|NCT03619031|Active Comparator|TRADITIONAL|Acute test meal
16452425|NCT03619005|Placebo Comparator|Placebo|
16452426|NCT03619005|Active Comparator|Prasterone|
16452427|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
16452428|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
16452603|NCT03617757|Experimental|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
16452429|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
16452430|NCT03618979|Experimental|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
16452431|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
16452432|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
16452433|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
16452434|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
16452435|NCT03618953|Experimental|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.
~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
16452436|NCT03618953|Experimental|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 & 29.
~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
16452437|NCT03618940|Experimental|School-based educational intervention|"assessed for knowledge and attitude on burn injury prevention
~underwent the School-based educational intervention
~impact evaluation
~Output evaluation 3 months after School-based educational intervention"
16452438|NCT03618927|Experimental|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
16452439|NCT03618927|No Intervention|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
16452440|NCT03618914||Non-anemic women|
16452441|NCT03618914||anemic women|anemia due to iron deficiency
16452442|NCT03618901|Experimental|Rock Steady Boxing|Non-contact boxing program.
16452443|NCT03618901|Active Comparator|PD SAFEx|Sensory attention focused exercise.
16452444|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
16452445|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
16452446|NCT03618875|Active Comparator|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
16452447|NCT03618875|Placebo Comparator|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
16452448|NCT03618849|Experimental|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments and EEG recording.
16452449|NCT03618849|Experimental|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current (for head circumference >52 cm; children with head circumference 43-52cm will receive 0.5-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
16452450|NCT03618849|Experimental|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current (if head circumference >52cm; children with head circumference 43-52cm will receive 1-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
16452451|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
16452452|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
16452453|NCT03618823|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary.
16452879|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
16452454|NCT03618823|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
16452455|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
16452456|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
16452457|NCT03618797|Experimental|HL-PIF cap.160/2mg + Placebo|"Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
~once a day"
16452458|NCT03618797|Active Comparator|Livalo tab. 2mg + Placebo|"Pitavastatin ca 2mg
~once a day"
16452459|NCT03618784|Experimental|FURESTEM-RA Inj.|
16452460|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
16452461|NCT03618771|Experimental|Medacta GMK Sphere|Half of the patients will be implanted with the Medacta GMK Sphere total knee arthroplasty
16452462|NCT03618771|Experimental|DePuy Synthes Attune|Half of the patients will be implanted with the DePuy Attune total knee arthroplasty
16452463|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
16452464|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
16452465|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
16452466|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
16452467|NCT03618719||Control|Healthy controls without OSA
16452468|NCT03618706|Experimental|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
16452469|NCT03618693|Experimental|spinal analgesia SSS|"Patients will receive a spinal analgesia (group SSS) with a single shot of bupivacaine 0.5% combined with fentanyl intrathecally during induction of anaesthesia. The technique used is referred to daily practice.
~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.
~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).
~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
16452470|NCT03618693|Experimental|TAP block|"Patients will receive a TAP block with a single shot of ropivacaine 0.375% combined with clonidine bilaterally. The technique used is referred to daily practice. The blocks will be performed under ultrasound guidance.
~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.
~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).
~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
16452471|NCT03618693|Active Comparator|Standard|"Standard care for prostatectomy in the investigators institution consists in the concomitant systemic administration of lidocaine to standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.
~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets.
~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
16452472|NCT03618667|Experimental|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
16452473|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.
~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
16452474|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
16452475|NCT03618641|Experimental|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 10 mg will be administered Weeks 2 -7.
~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
16452880|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
16452476|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
16452477|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
16452478|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
16452479|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
16452480|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
16452481|NCT03618589|Placebo Comparator|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
16452482|NCT03618589|Experimental|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
16452483|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
16452484|NCT03618550|Experimental|pembrolizumab plus GVD|"Part 1: Patients will receive 2-4 cycles of pembrolizumab plus GVD
~Part 2: an additional 25 patients will be enrolled onto an expansion cohort. On the expansion, patients who achieve CR to 4 cycles of pembro-GVD will receive 13 cycles of pembrolizumab maintenance (instead of HDT/ASCT)."
16452485|NCT03618537|Experimental|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days
~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
16452486|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
16452487|NCT03618511|Experimental|Financial Incentive Group|
16452488|NCT03618511|Experimental|Reminders Group|
16452489|NCT03618511|Experimental|Financial Incentive and Reminders Group|
16452490|NCT03618511|No Intervention|Control Group|
16452491|NCT03618511|Experimental|Information Group|
16452492|NCT03618511|Experimental|Stigma-relieving Group|
16452493|NCT03618511|Experimental|Information and Stigma-relieving Group|
16452494|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
16452495|NCT03618472|Experimental|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
16452496|NCT03618472|Placebo Comparator|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
16452497|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
16452498|NCT03618446||Survivors|Patients whose pelvic fracture and survived till time of discharge from the hospital.
16452499|NCT03618446||Non-Survivors|Patients whose pelvic fracture and died while in hospital.
16452500|NCT03618433|Experimental|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy
~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
16452501|NCT03618433|Active Comparator|Control group|"Standart exercise protocol and Upper extremity rehabilitation
~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
16452502|NCT03618420|Other|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
16452503|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
16452504|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
16452505|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
16452506|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
16452507|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
16452508|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
16452509|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
16452510|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
16452511|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
16452512|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
16452513|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
16455362|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
16452514|NCT03618355|Experimental|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
16452515|NCT03618355|Experimental|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
16452516|NCT03618355|Experimental|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
16452517|NCT03618355|Experimental|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
16452518|NCT03618342||PCOS|PCOS women
16452519|NCT03618342||Healthy controls|Healthy control women
16452520|NCT03618329|Active Comparator|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
16452521|NCT03618329|No Intervention|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
16452522|NCT03618316|Experimental|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
16452523|NCT03618303|Experimental|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
16452524|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
16452525|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
16452526|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
16452527|NCT03618277|Other|Intra individual|Before and after being treated by a product (outside the study)
16452528|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
16452529|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
16452530|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
16452531|NCT03618238|Experimental|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
16452532|NCT03618225|Active Comparator|duloxetine group|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
16452533|NCT03618225|Placebo Comparator|placebo pill group|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
16452534|NCT03618212||Myeloma patients|
16452535|NCT03618199|Experimental|Efficacy of vibrating system on healthy volunteers|
16452536|NCT03618199|Experimental|Efficacy of vibrating system on vestibular patients|
16452537|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
16452538|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
16452539|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
16452540|NCT03618173|Experimental|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
16452541|NCT03618173|Placebo Comparator|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
16452542|NCT03618160|Experimental|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
16452543|NCT03618160|Experimental|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
16452544|NCT03618160|Experimental|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
16452545|NCT03618134|Experimental|Cohort I (SBRT, durvalumab, TORS, neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16452604|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
16452546|NCT03618134|Experimental|Cohort II (SBRT, durvalumab,tremelimumab,TORS,neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive tremelimumab IV and durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16452547|NCT03618121|Experimental|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
16452548|NCT03618121|Active Comparator|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
16452549|NCT03618121|Active Comparator|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
16452550|NCT03618121|Active Comparator|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
16452551|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
16452552|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
16452553|NCT03618095|Experimental|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
16452554|NCT03618095|Experimental|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
16452555|NCT03618095|Experimental|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
16452556|NCT03618082|Active Comparator|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
16452557|NCT03618082|Experimental|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.
~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
16452558|NCT03618069|No Intervention|routine investigation|
16452559|NCT03618069|Active Comparator|study protocol CCI (CTA, cardiac CT) and MRI scans|
16452560|NCT03618056|Experimental|AIDSVAX® B/E|Participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.
16452561|NCT03618043|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
16452562|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
16452563|NCT03618030|Placebo Comparator|Placebo Treatment|Matched placebo
16452564|NCT03618017|Experimental|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
16452565|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
16452566|NCT03618004|Experimental|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.
~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
16452567|NCT03618004|Active Comparator|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.
~The subjects in the control group did not use pressure cuffs."
16452568|NCT03617991|Experimental|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
16452569|NCT03617991|No Intervention|Control Group|The control group will be contacted weekly to check on health status.
16452570|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
16452571|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
16452572|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
16452573|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
16452574|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
16452575|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
16452576|NCT03617965||Severe thrombocytopenia|Patients with a platelet count<50 × 10e9/L
16452577|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
16452578|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.
~The P3 Bio Intervention is implemented in this group."
16452579|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.
~The P3 Bio Intervention is implemented in this group."
16452580|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
16452581|NCT03617926|Experimental|Test product|Water-based lotion (internal code (X92001666)
16452582|NCT03617926|Active Comparator|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
16452583|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
16452584|NCT03617900|Placebo Comparator|Placebo|
16452585|NCT03617900|Experimental|Ginger|
16452586|NCT03617900|Active Comparator|Paracetamol|
16452587|NCT03617887|Experimental|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
16452588|NCT03617887|Experimental|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
16452589|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
16452590|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
16452591|NCT03617861|Experimental|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
16452592|NCT03617861|Experimental|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
16452593|NCT03617861|Experimental|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
16452594|NCT03617861|Experimental|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
16452595|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
16452596|NCT03617835|Experimental|Spesolimab|
16452597|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
16452598|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
16452599|NCT03617783|Active Comparator|Prebiotin|
16452600|NCT03617783|Placebo Comparator|Placebo|
16452606|NCT03617731|Active Comparator|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
16452607|NCT03617731|Experimental|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
16452608|NCT03617731|Active Comparator|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
16452609|NCT03617731|Experimental|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
16452610|NCT03617718|Experimental|Glycine Buffer|All participants will be asked to inhale a glycine buffer at visit 2 prior to the research bronchoscopy that is performed at visit 3.
16452611|NCT03617705|Active Comparator|HIV+ drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
16452612|NCT03617705|Active Comparator|HIV- drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
16452613|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
16452614|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
16452615|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
16452616|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
16452617|NCT03617653|Other|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
16452618|NCT03617653|Other|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis & End of 3 month assessment.
16452619|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
16452620|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
16452621|NCT03617627|Experimental|Experimental group|Patients will be included in a self-management intervention.
16452622|NCT03617627|No Intervention|Control group|Patients will receive a booklet with information.
16452623|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
16452624|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
16452625|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
16452626|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
16452627|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
16452628|NCT03617575|Placebo Comparator|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1
16452629|NCT03617575|Placebo Comparator|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1
16452630|NCT03617575|Placebo Comparator|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
16452631|NCT03617575|Placebo Comparator|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
16452632|NCT03617575|Placebo Comparator|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
16452633|NCT03617575|Placebo Comparator|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
16452636|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
16452637|NCT03617536|Experimental|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
16452638|NCT03617536|Experimental|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
16452639|NCT03617536|Experimental|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
16452641|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to <36 months|Participants (aged 6 to <36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16452642|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to <9 years|Participants (aged 3 to <9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
16452643|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 3: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
16452644|NCT03617523|Experimental|Flublok Quadrivalent vaccine Group 4: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.
16452645|NCT03617523|Experimental|Fluzone High-Dose vaccine Group 5: >=65 years|Participants (aged >=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
16452646|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
16452647|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
16452648|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
16452649|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
16452650|NCT03617497|Active Comparator|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
16452651|NCT03617497|Active Comparator|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
16452652|NCT03617497|Experimental|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
16452653|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
16452654|NCT03617471|Experimental|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
16452655|NCT03617471|Experimental|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
16452656|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
16452657|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
16452658|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.
~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
16452659|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
16452660|NCT03617445|Active Comparator|FMT oral capsules/ oral vancomycin placebo|FMT plus placebo vancomycin
16452661|NCT03617445|Active Comparator|Placebo FMT capsules/ Active oral vancomycin|Vancomycin plus FMT enema placebo
16452662|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
16452663|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
16452664|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System
~The following post-market products will be used on label:
~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
16452665|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
16452666|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
16452667|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
16452668|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose > 8 mmol/L.
16452669|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
16452670|NCT03617380|Experimental|PHARMD-TOC i|PharmD Follow-Up Post Discharge
16452671|NCT03617380|Active Comparator|USUAL CARE|Usual Post Discharge Procedures
16452672|NCT03617367|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
16452881|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
16452673|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;
~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).
~Will be able to attend each of the 10 training days."
16452674|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
16452675|NCT03617328|Experimental|Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.
16452676|NCT03617328|Experimental|Arm B: 6MHP/Montanide ISA-51 + polyICLC|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.
16452677|NCT03617315|Experimental|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
16452678|NCT03617315|Experimental|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
16452679|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
16452680|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
16452681|NCT03617289|Experimental|Treatment|Receiving Magnesium Sulfate
16452682|NCT03617289|Placebo Comparator|Placebo|Receiving D5W
16452683|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
16452684|NCT03617263|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
16452685|NCT03617263|Placebo Comparator|Placebo|Placebo tablet once daily in the morning before breakfast
16452686|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
16452687|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
16452688|NCT03617224|Experimental|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
16452689|NCT03617224|Experimental|Radiation: TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
16452690|NCT03617198|Experimental|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
16452691|NCT03617198|Experimental|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
16452692|NCT03617185|Active Comparator|Bariatric Surgery/HIIT|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
16452693|NCT03617185|Active Comparator|Bariatric Surgery/Routine Exercise|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
16452694|NCT03617185|Active Comparator|No Bariatric Surgery/HIIT|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
16452695|NCT03617185|Active Comparator|No Bariatric Surgery/Routine Exercise|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
16452696|NCT03617172|Experimental|Study Drug (Misoprostol)|
16452697|NCT03617172|Placebo Comparator|Placebo|
16452698|NCT03617146|Experimental|Intervention Arm|"Participants in the intervention arm will receive the following interventions:
~Month 1: Diabetes Distress-specific Education.
~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.
~Month 3: Follow up distress-specific education.
~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
16452699|NCT03617146|Active Comparator|Control Arm|"Participants in the control arm will receive the following interventions:
~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).
~Month 3: Follow up distress-specific education (same as for the intervention arm)."
16452733|NCT03616860|Experimental|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
16452734|NCT03616847|Experimental|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
16452735|NCT03616847|Experimental|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
16452700|NCT03617133|Other|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
16452701|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.
~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
16452702|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
16452703|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
16452704|NCT03617081|Experimental|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
16452705|NCT03617081|Placebo Comparator|Placebo|Participants will receive placebo (NNC0113-2023)
16452706|NCT03617068|Active Comparator|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
16452707|NCT03617068|Placebo Comparator|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
16452708|NCT03617029|Experimental|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
16452709|NCT03617029|Active Comparator|Contrast|Needle localization for deep-seated lung nodules with contrast injection
16452710|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
16452711|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
16452712|NCT03617003|Experimental|phototherapy with WST11|Patients with urothelial cancer that includes involvement of the upper urinary tract and have failed prior endoscopic treatment, refuse standard treatment, or are ineligible for curative surgical resection of the kidney or ureter will be offered WST11 VTP treatment to be provided at the time of scheduled endoscopic procedure. At the time of endoscopy, patients will be treated with VTP therapy applied to the site of the tumor.
16452713|NCT03616990|Active Comparator|Usual Care (Control)|"Usual care. These individuals will receive linkages to community-based services only. These linkages will be made while in the Discharge Area of the Cook County Jail. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.
~Receives: TASC Service Linkages - Discharge Area Only"
16452714|NCT03616990|Experimental|Supportive Release Center (Treatment)|"These individuals will receive SRC services: an overnight stay at the SRC, linkages to community-based services made at the SRC or in the discharge area of the CCJ if they choose not to visit the SRC facility, and access to an Advanced Practice Nurse. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.
~Receives: TASC Service Linkages - Discharge Area Only -OR- SRC Overnight Stay, TASC Services Linkages - SRC Onsite, APN Appointment"
16452715|NCT03616977|Experimental|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
16452716|NCT03616977|Experimental|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
16452720|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
16452721|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
16452722|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
16452723|NCT03616925|Experimental|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
16452724|NCT03616925|Active Comparator|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
16452728|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
16452729|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
16452730|NCT03616886|Experimental|Phase I and Phase II Arm A|Patients are treated with paclitaxel, carboplatin, durvalumab and oleclumab.
16452736|NCT03616834|Experimental|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
16452740|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
16452741|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
16452742|NCT03616795|Experimental|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and [14C]-LY3154207administered orally.
16452743|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
16452744|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
16452745|NCT03616756|Experimental|Intervention group|
16452746|NCT03616756|Active Comparator|Control group|
16452747|NCT03616743|Experimental|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
16452748|NCT03616743|Active Comparator|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
16452751|NCT03616717|Active Comparator|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
16452752|NCT03616717|Active Comparator|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
16452753|NCT03616717|Placebo Comparator|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
16452754|NCT03616691|Experimental|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
16452755|NCT03616691|Experimental|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
16452756|NCT03616678|Experimental|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
16452757|NCT03616665|Other|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
16452758|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
16455363|NCT03598322|Active Comparator|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
16452759|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
16452760|NCT03616639|Experimental|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
16452761|NCT03616639|Active Comparator|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
16452762|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
16452763|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
16452764|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
16452765|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
16452766|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
16452767|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
16452768|NCT03616600|No Intervention|Control|Not wearing any contact lenses
16452779|NCT03616574|Experimental|Dose Escalation - CA102N Monotherapy|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
16452780|NCT03616574|Experimental|Dose Escalation - CA102N plus LONSURF|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
16452781|NCT03616574|Experimental|Dose Expansion - CA102N plus LONSURF|The preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
16452782|NCT03616561||Apremilast|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
16452783|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
16452784|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
16452785|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
16452786|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
16452787|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
16452788|NCT03616509|Experimental|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
16452789|NCT03616496|Experimental|ATTR amyloidosis patients|Intervention by this arm: PET/CT with injection of Neuraceq [4 MegaBecquerel /Kilogram (MBq/kg)], blood and urine sampling for protein electrophoresis, bone scintigraphy
16452790|NCT03616496|Experimental|AL amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq (4 MBq/kg), blood and urine sampling for protein electrophoresis, bone scintigraphy
16452791|NCT03616496|Active Comparator|Control subjects with aortic stenosis|"Intervention by this arm: PET with injection of Neuraceq (4 MBq/kg), blood and urine sampling for protein electrophoresis, bone scintigraphy.
~Control subjects are patients with aortic stenosis and left ventricular hypertrophy treated by surgery or by Transcatheter Aortic Valve Implantation (TAVI)"
16452792|NCT03616470|Experimental|Uproleselan (GMI-1271)|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
16452793|NCT03616470|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
16452794|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
16452795|NCT03616444|Experimental|TCM-Xiaoai Jiedu Decoction|Xiaoai Jiedu Decoction：Oldenlandia 20g,kuh-seng 9g,Codonopsis pilosula 15g,bighead atractylodes rhizome 12g,smoked plum 9g,the rhizome of Chinese goldthread 3g,RHIZOMA ZINGIBERIS PREPARATA 6g,Semen Coicis 20g. Take one pack a day, divided into twice one day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year， last two years.
16452796|NCT03616444|Placebo Comparator|TCM-Xiaoai Jiedu Decoction Placebo|The control group took placebo twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year，last two years.
16452797|NCT03616431||Demographic cohort|A prospective cross-sectional assessment of the prevalence of PEI-related symptoms in up to n=150 patients with pancreatic malignancy.
16453040|NCT03614767||Successes|Patients with >50% improvement during test procedure of sacral neuromodulation.
16452798|NCT03616431||Diagnosis cohort|"A sub-set (up to n=50) of the Demographic cohort patients will be tested to elucidate the most efficient diagnostic panel for PEI in pancreatic malignancy.
~An extra assessment for PEI diagnosis consisting of a breath test (Pancreo-KIT breath test) will be carried out during the following 1-2 weeks after the first appointment (which takes around six hours to complete and involves the administration of bread spread with 13C butter followed by collection of the patient's breath in small plastic vials at timed intervals. The vials will subsequently be analyzed for 13C quantity; details in Appendix 6). Following these diagnostic tests, patients will complete an acceptability questionnaire to assess their opinion regarding the burden that these diagnostic tests may add."
16452799|NCT03616431||Follow-up cohort|Validation of the diagnostic panel designed and tested in Step-1 of this study and evaluation of dietician intervention (including Pancreatic Enzyme Replacement Therapy; PERT) and its impact in weight loss, symptom evolution, chemotherapy receiving rate, quality of life and overall survival.
16452800|NCT03616405|Experimental|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
~Drugs: 1. rabeprazole 10mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
16452801|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
16452802|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
16452803|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
16452804|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
16452805|NCT03616379|Placebo Comparator|Psychoeducational Control|
16452806|NCT03616379|Experimental|Affect Regulation Condition|
16452807|NCT03616379|Experimental|Affect Labelling Condition|
16452808|NCT03616353|Experimental|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
16452809|NCT03616353|Experimental|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
16452810|NCT03616340|Experimental|Ketorolac|
16452811|NCT03616340|Experimental|Kenalog|
16452812|NCT03616327|Other|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
16452813|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
16452814|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
16452815|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
16452816|NCT03616301|Experimental|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
16452817|NCT03616301|Active Comparator|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
16452818|NCT03616288|Placebo Comparator|Negative Control|placebo; 0 mg thiamine
16452819|NCT03616288|Experimental|EAR Group|1.2 mg thiamine as thiamine hydrochloride
16452820|NCT03616288|Experimental|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
16452821|NCT03616288|Experimental|Positive Control|10 mg thiamine as thiamine hydrochloride
16452822|NCT03616275|Experimental|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
16452823|NCT03616275|No Intervention|control group|1 session of healthy lifestyle education
16452824|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
16452825|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
16452826|NCT03616249|Experimental|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
16452827|NCT03616249|Experimental|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
16452828|NCT03616249|Active Comparator|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
16452829|NCT03616249|Active Comparator|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
16452830|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
16452875|NCT03615885|Placebo Comparator|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
16452831|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
16452832|NCT03616223|Experimental|FX-322 Low Dose|Single intratympanic injection of a hydrogel formulation
16452833|NCT03616223|Experimental|FX-322 High Dose|Single intratympanic injection of a hydrogel formulation
16452834|NCT03616223|Placebo Comparator|Placebo|Single intratympanic injection of a hydrogel formulation
16452835|NCT03616210|Experimental|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
16452836|NCT03616210|No Intervention|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
16452837|NCT03616197|Active Comparator|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.
~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
16452838|NCT03616197|Active Comparator|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.
~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
16452839|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
16452840|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:
~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)
~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
16452841|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
16452842|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
16452843|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
16452844|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
16452845|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
16452846|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
16452876|NCT03615885|Experimental|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
16452877|NCT03615885|Experimental|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
16452878|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
16452847|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
16452848|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
16452849|NCT03616132|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
16452850|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
16452851|NCT03616093|Experimental|Test Beet shot|Active supplement containing 6.2 mmol nitrate
16452852|NCT03616093|Placebo Comparator|Placebo beverage|Placebo supplement containing negligible nitrate
16452853|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
16452854|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
16452855|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
16452856|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
16452857|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
16452858|NCT03616028|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the CLAAS device will be performed according to the device Instructions for Use, based on TEE, ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
16452859|NCT03616015|Experimental|Patient|"For all patients included in the study, the following interventions will be performed :
~several blood samples (quantity collected requiring classification of this study as interventional according to French law)
~several fecal samples
~anxiety tests
~stress tests"
16452860|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
16452861|NCT03615989|Placebo Comparator|Exercise and Carbohydrate (CHO)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, 50g of carbohydrate (maltodextrin) + water was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 50g of carbohydrate was consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
16452862|NCT03615989|Experimental|Exercise and Milk (Milk)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, ~500 ml of skim milk was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 500 ml of skim milk was consumed 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
16452863|NCT03615976|Active Comparator|group A|group A with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done for all patients with arthroscopic patellar denervation will be done
16452864|NCT03615976|Active Comparator|GROUP B|operative group B with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done without arthroscopic patellar denervation
16452865|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
16452866|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
16452867|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
16452868|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
16452869|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:
~Child interactive intervention (dialogic reading and play intervention)
~Family Empowerment (positive parenting and grandparenting)
~Access to Community Hub and its services
~Enhancement to the kindergartens
~Health education, screening, and support"
16452870|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.
~1. Health education, screening, and support"
16452871|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:
~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day
~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day
~>48 kg: Ticagrelor 45 mg, twice a day."
16452872|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:
~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day
~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day
~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
16452873|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28
~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
16452874|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28
~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
16452882|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
16452883|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.
~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
16452884|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.
~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
16452885|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
16452886|NCT03615833|Experimental|Patients with Vitamin D deficiency|Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
16452887|NCT03615820|Experimental|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
16452888|NCT03615820|Placebo Comparator|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
16452889|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
16452890|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
16452891|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
16452892|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
16452893|NCT03615781|Experimental|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
16452894|NCT03615781|Active Comparator|Four week's arm - surgery|The investigators surgically remove the infected implant.
16452895|NCT03615781|Experimental|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
16452896|NCT03615781|Active Comparator|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
16452897|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
16452898|NCT03615768|Active Comparator|Adapalene Gel|
16452899|NCT03615768|Active Comparator|Clindamycin Gel|
16452900|NCT03615755|No Intervention|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
16452901|NCT03615755|Active Comparator|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
16452902|NCT03615742|Placebo Comparator|Placebo and Filtered Air|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
16452903|NCT03615742|Active Comparator|Budesonide and Filtered Air|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to HEPA filtered air for 2 hours.
16452904|NCT03615742|Active Comparator|Placebo and Diesel Exhaust|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
16452905|NCT03615742|Experimental|Budesonide and Diesel Exhaust|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
16452906|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
16452907|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
16452908|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
16452909|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
16452910|NCT03615690|Experimental|Fasting Mimicking Diet|Three cycles of a 5-day reduced calorie diet
16452911|NCT03615690|Placebo Comparator|Regular Diet Control Arm|
16452912|NCT03615677|Experimental|LXI-15028 50mg group (n=130)|
16452913|NCT03615677|Active Comparator|Esomeprazole 40mg group (n=130)|
16452914|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
16452915|NCT03615651|Placebo Comparator|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
16452916|NCT03615651|Experimental|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
16452917|NCT03615638|Experimental|Fall prevention group|Fall prevention program
16452918|NCT03615638|No Intervention|Usual care group|Usual postoperative care
16452919|NCT03615638|No Intervention|Asymptomatic control|No intervention
16452920|NCT03615625|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 40 min
16452921|NCT03615625|Experimental|Power Training Session|The power training session lasted 40 min, in which the participants performed a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
16452922|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
16452923|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
16452924|NCT03615599||Seventh-day Adventists|This is a prospective cohort study of 96,000 members of the Seventh-day Adventists Church in the United States and Canada age 30 and older at the time of enrollment who are proficient in English language.
16452925|NCT03615586|Active Comparator|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
16452926|NCT03615586|Active Comparator|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
16452927|NCT03615560||Preeclampsia (mild)|
16452928|NCT03615560||Preeclampsia (severe)|
16452929|NCT03615560||Gestational hypertension|
16452930|NCT03615560||Control group|
16452931|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
16452932|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
16452933|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
16452934|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
16452935|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
16452936|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
16452937|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
16452938|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.
~3 Session for 6 weeks."
16452939|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.
~3 session for 6 weeks."
16452940|NCT03615508|Other|10% phenylephrine|All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
16452941|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
16452942|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
16452943|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
16452944|NCT03615469|Active Comparator|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
16452945|NCT03615469|Sham Comparator|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
16452946|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
16452947|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
16452948|NCT03615443||Treatment-naive metastatic non-squamous NSCLC|
16452949|NCT03615430|Placebo Comparator|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
16452950|NCT03615430|Experimental|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
16452951|NCT03615417|Experimental|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
16452952|NCT03615417|Active Comparator|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
16455364|NCT03598322|Experimental|Dextrose 2mL|Dextrose injection, Dextrose 2mL
16452953|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
16452954|NCT03615378|Placebo Comparator|Placebo|
16452955|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
16452956|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
16452957|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.
~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
16452958|NCT03615352|Experimental|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
16452959|NCT03615352|Experimental|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
16452960|NCT03615339|Experimental|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening).
~Total duration was 6 weeks."
16452961|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
16452962|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
16452963|NCT03615313|Experimental|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
16452964|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
16452965|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
16452966|NCT03615287||Group A|40 subjects undergoing Medical Treatment
16452967|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
16452968|NCT03615287||Group C|40 control subjects
16452969|NCT03615274|Experimental|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
16452970|NCT03615274|Active Comparator|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
16452971|NCT03615261|Experimental|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
16452972|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.
~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
16452973|NCT03615235||Recipients of a Kidney Transplant|APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.
16452974|NCT03615235||Living Kidney Donors|APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.
16452975|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
16452976|NCT03615209|Active Comparator|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
16452977|NCT03615209|Sham Comparator|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
16452978|NCT03615196|Experimental|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
16452979|NCT03615196|Experimental|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
16452980|NCT03615196|Experimental|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
16453041|NCT03614767||Failures|Patients with <50% improvement during test procedure of sacral neuromodulation.
16452981|NCT03615196|Experimental|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
16452982|NCT03615196|Placebo Comparator|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
16452983|NCT03615183|Experimental|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
16452984|NCT03615183|Experimental|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
16452985|NCT03615183|Experimental|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
16452986|NCT03615183|Experimental|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
16452987|NCT03615183|Experimental|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
16452988|NCT03615157|Experimental|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
16452989|NCT03615157|Active Comparator|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
16452990|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
16452991|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
16452992|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
16452993|NCT03615118|Experimental|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
16452994|NCT03615118|Active Comparator|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
16452995|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
16452996|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
16452997|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
16452998|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion
~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
16452999|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
16453000|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
16453001|NCT03615066|Experimental|Selgantolimod 3 mg + TAF|Participants with hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
16453002|NCT03615066|Experimental|Selgantolimod 1.5 mg + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16453003|NCT03615066|Placebo Comparator|Placebo + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16453004|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
16453005|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
16455365|NCT03598322|Experimental|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
16453006|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
16453007|NCT03615027|Experimental|Intervention|see detailed description
16453008|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
16453009|NCT03615001|Experimental|Urodynamics Arm|
16453010|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
16453011|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
16453012|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
16453013|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
16453014|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
16453015|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
16453016|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
16453017|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
16453018|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
16453019|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
16453020|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
16453021|NCT03614923|Active Comparator|Dose 1|SC administration, Q4W
16453022|NCT03614923|Active Comparator|Dose 2|SC administration, Q8W
16453023|NCT03614923|Placebo Comparator|Placebo|SC administration, Q4W
16453024|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:
~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein
~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery
~abutment or encasement of the celiac axis
~involvement of lymph nodes outside the area of resection"
16453025|NCT03614897|Experimental|Education|Providers participating in education related to guidelines for treating patients at risk of falling
16453026|NCT03614884|Experimental|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
16453027|NCT03614884|Active Comparator|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
16453028|NCT03614871||No arms|There are no interventions
16453029|NCT03614858|Experimental|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
16453030|NCT03614845|Active Comparator|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
16453031|NCT03614845|Active Comparator|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
16453032|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
16453033|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
16453034|NCT03614819|Experimental|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
16453035|NCT03614819|Active Comparator|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
16453036|NCT03614806|Experimental|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
16453037|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
16453038|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
16453039|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
16453042|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
16453043|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
16453044|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
16453045|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
16453046|NCT03614728|Experimental|Part 1: Participants receiving GSK3326595|
16453047|NCT03614728|Experimental|Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine|
16453048|NCT03614728|Experimental|Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine|
16453049|NCT03614715|Experimental|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
16453050|NCT03614715|Active Comparator|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
16453051|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
16453052|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
16453053|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
16453054|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
16453055|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
16453056|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose
~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
16453057|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
16453058|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
16453059|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
16453060|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
16453090|NCT03614533|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
16453091|NCT03614533|Active Comparator|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
16453061|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
16453062|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose
~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
16453063|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age and with pre-pregnancy body mass index (BMI) ≥18.5 and ≤ 39.9 kg/m2 enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV). Collection of maternal blood samples and cord blood samples at delivery are planned for determination of antibody titers.
16453064|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-40 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization
16453065|NCT03614663|Experimental|ZYN002 - CBD transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg CBD Q12H or placebo.
~Patients weighing greater than 35 kg will be randomized to receive 250 mg CBD Q12H or placebo."
16453066|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
16453067|NCT03614650|Experimental|EIE cells to treat cancer|EIE cells to treat cancer
16453068|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
16453069|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
16453070|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
16453071|NCT03614611|Experimental|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
16453072|NCT03614598|Active Comparator|LMA-UNIQUE™|
16453073|NCT03614598|Active Comparator|LMA-SUPREME™|
16453074|NCT03614598|Active Comparator|I-GEL®|
16453075|NCT03614585|Experimental|High-intensity interval training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The protocol will involve 10 60-second intervals of high intensity interspersed with 9 60-second low-intensity intervals. The initial high intensity intervals will start at 80% of the HRR (RPE=14-17) and progress by 10% every 4 weeks. Low intensity intervals will be performed at 30% of HRR (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% of HRR. Total HIIT time including warm-up and cool-down is 24 minutes.
16453076|NCT03614585|Experimental|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
16453077|NCT03614572|Experimental|Group MI|The structure and content of the active intervention programme will be developed and adopted on the basis of previous research on sleep educational programme and motivational interviewing techniques. The whole treatment package consists of 4 sessions of group therapy (n=6-8) followed by 3 week daily text reminders.
16453078|NCT03614572|No Intervention|Control group|Control group will no receive any intervention
16453079|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
16453080|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
16453081|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
16453082|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
16453083|NCT03614546|Other|A（surgery） group|Hepatectomy
16453084|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
16453085|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
16453086|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
16453087|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
16453088|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
16453089|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
16453204|NCT03613740|Placebo Comparator|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
16453092|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
16453093|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
16453094|NCT03614507|Experimental|FreeO2 group|Automatic oxygen flow titration
16453095|NCT03614507|Active Comparator|Manual group|Manual oxygen flow titration
16453096|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
16453097|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
16453098|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.
~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
16453099|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.
~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
16453100|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
16453101|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
16453102|NCT03614455|Experimental|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
16453103|NCT03614455|Other|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
16453104|NCT03614455|Other|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
16453105|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
16453106|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
16453107|NCT03614429|No Intervention|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)
~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.
~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
16453108|NCT03614429|Experimental|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)
~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.
~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
16453109|NCT03614416|Experimental|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
16453110|NCT03614403|Experimental|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
16453111|NCT03614403|No Intervention|control|Control patients will not be received any intervention
16453112|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.
~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.
~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
16453113|NCT03614377||Patients with low burden of sleep-disordered breathing|
16453114|NCT03614377||Patients with high burden of sleep-disordered breathing|
16453115|NCT03614364|Experimental|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
16453116|NCT03614351|Experimental|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
16456482|NCT03590561|No Intervention|Control diet|Participants will eat regular diet.
16453117|NCT03614351|Active Comparator|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
16453118|NCT03614338|Experimental|Core Participants Weight Loss Program|Small changes weight loss program
16453119|NCT03614325|Experimental|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.
~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
16453120|NCT03614325|No Intervention|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
16453121|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
16453122|NCT03614299||pSS cohort|Patients with pSS included in the study
16453123|NCT03614273|Active Comparator|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
16453124|NCT03614273|Active Comparator|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
16453125|NCT03614260|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (Paradise Renal Denervation System)
16453126|NCT03614260|Sham Comparator|Sham Control|Renal Angiogram
16453127|NCT03614247|Active Comparator|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
16453128|NCT03614247|Active Comparator|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size <10 F) for lower calyceal stone between 1cm and 2cm in size
16453129|NCT03614247|Active Comparator|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size <15 F) for lower calyceal stone between 1cm and 2cm in size
16453130|NCT03614247|Active Comparator|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size <20 F) for lower calyceal stone between 1cm and 2cm in size
16453131|NCT03614247|Active Comparator|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size >25 F) for lower calyceal stone between 1cm and 2cm in size
16453132|NCT03614234|Experimental|Experimental open label|Pegunigalsidase alfa
16453133|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
16453134|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
16453135|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.
~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
16453136|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
16453137|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
16453138|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
16453139|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
16453140|NCT03614182|Experimental|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
16453141|NCT03614182|Active Comparator|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
16453142|NCT03614182|Active Comparator|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
16453143|NCT03614169|Experimental|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
16453241|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
16456648|NCT03589430||3 child C|child C liver cirrhosis
16453144|NCT03614169|Active Comparator|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold)
16453145|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
16453146|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
16453147|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
16453148|NCT03614130|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
16453149|NCT03614130|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
16453150|NCT03614117|Active Comparator|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
16453151|NCT03614117|Active Comparator|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
16453152|NCT03614117|Placebo Comparator|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
16453153|NCT03614104|Active Comparator|mobile health technology|Health education with mobile health technology
16453154|NCT03614104|Sham Comparator|Without mobile health technology|Health education without mobile health technology
16453155|NCT03614091|Active Comparator|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
16453156|NCT03614091|Active Comparator|Erector spinae plane block group|the transducer will be placed in a transverse orientation to identify the spinous process, lamina,and transverse process.The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superfacial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudad Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process.following which a total of 20 mL of 0.5%bupivacaine will be injected.
16453157|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
16453158|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
16453159|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
16453160|NCT03614065|Placebo Comparator|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
16453161|NCT03614065|Experimental|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
16453162|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
16453163|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
16453164|NCT03614039|Active Comparator|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
16453165|NCT03614039|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
16453166|NCT03614026|Experimental|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
16453167|NCT03614026|No Intervention|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
16453168|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
16453169|NCT03614000|Experimental|positive screenings|
16453170|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
16453171|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
16453242|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
16457437|NCT03583957|Experimental|Entire Study|Each patient is eligible for all interventions in the study.
16453172|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
16453173|NCT03613935|Placebo Comparator|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
16453174|NCT03613935|Active Comparator|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
16453175|NCT03613935|Active Comparator|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
16453176|NCT03613935|Active Comparator|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
16453177|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
16453178|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
16453179|NCT03613909|Experimental|CP950|CP950 Off The Ear (OTE) sound processor
16453180|NCT03613909|Active Comparator|BTE|Behind the Ear (BTE) sound processor (either a CP810 or CP900 series)
16453181|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
16453182|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
16453183|NCT03613883|Experimental|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
16453184|NCT03613883|Experimental|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
16453185|NCT03613870|Active Comparator|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
16453186|NCT03613870|Active Comparator|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
16453187|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
16453188|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
16453189|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
16453190|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
16453191|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
16453192|NCT03613818|No Intervention|Control|Assessment only
16453193|NCT03613805|Active Comparator|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
16453194|NCT03613805|Experimental|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
16453195|NCT03613792|Active Comparator|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
16453196|NCT03613792|Active Comparator|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
16453197|NCT03613779|Experimental|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.
~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
16453198|NCT03613779|Active Comparator|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).
~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
16453199|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
16453200|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
16453201|NCT03613753|Experimental|Arm A|Chemotherapy:irinotecan plus lobaplatin
16453202|NCT03613753|Active Comparator|Arm B|Chemotherapy:irinotecan
16453203|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
16457558|NCT03583177||undergoing chronic hemodialysis patients|
16453205|NCT03613727|Experimental|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
16453206|NCT03613714|Active Comparator|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
16453207|NCT03613714|No Intervention|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
16453208|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
16453209|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
16453210|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
16453211|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
16453212|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
16453213|NCT03613675|Experimental|Video games|All participants will be asked to play 4 video games.
16453214|NCT03613662|Experimental|SP-102|SP-102
16453215|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
16453216|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
16453217|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
16453218|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
16453219|NCT03613636||CAP cohort|"Children of age 3 to 16 years;
~In- and outpatients;
~Clinically diagnosed community-acquired pneumonia (CAP)."
16453220|NCT03613636||Healthy control cohort|"Healthy asymptomatic children of age 3 to 16 years;
~undergoing an elective surgical procedure."
16453221|NCT03613636||Family control cohort|- Family members of index CAP patients.
16453222|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
16453223|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
16453224|NCT03613610|Active Comparator|Three needles group|
16453225|NCT03613610|Active Comparator|Single needle group|
16453226|NCT03613597|Experimental|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
16453227|NCT03613597|Active Comparator|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
16453228|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
16453229|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
16453230|NCT03613571|Experimental|ILB|ILB treatment
16453231|NCT03613558|Experimental|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
16453232|NCT03613558|Placebo Comparator|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
16453233|NCT03613545|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
16453234|NCT03613545|Sham Comparator|placebo fecal microbiota transplantation|Infusion of sham
16453235|NCT03613545|Sham Comparator|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
16453236|NCT03613532|Experimental|Venetoclax|"This study has three periods: 1) Screening, 2) Treatment including venetoclax + FluBu2 conditioning chemotherapy and transplantation; and 3) Post-Transplant follow up. For Part 1, the post-transplant period will include routine follow-up. For Part 2, the post-transplant period will include investigational therapy with azacitidine and venetoclax and follow-up.
~Dose escalation in Part 1 will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation/de-escalation.
~Venetoclax: 6-7 total doses depending on dose level assigned
~FLuBu2
~Busulfan: given twice daily for 4 days
~Fludarabine: given once daily for 4 days
~Dose escalation in Part 2 will occur using a 10+10 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation/de-escalation.
~Venetoclax: 14 doses for 8-12 cycles depending on dose level assigned
~Azacitidine: 5 doses for 8-12 cycles depending on dose level assigned"
16453237|NCT03613519|Placebo Comparator|Usual care (sleep hygiene)|A web-based program that presents ways to improve behaviors and environments that can affect sleep.
16453238|NCT03613519|Active Comparator|SHUTi (Sleep Healthy Using the Internet)|SHUTi is web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
16453239|NCT03613519|Active Comparator|modified SHUTi (SHUTi modified for Black women)|The CBT-I instrument tailored for Black women.
16453240|NCT03613506|Experimental|Peripheral blood TGF-β content before and after radiotherapy|
16453243|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
16453244|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
16453245|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
16453246|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
16453247|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
16453248|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
16453249|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
16453250|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
16453251|NCT03613441|Experimental|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
16453252|NCT03613441|No Intervention|Control|Waitlist control (intervention will be available to this group at the end of the study period)
16453253|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
16453254|NCT03613415|Experimental|Expansion by Densah bur|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.
~A mid crestal flap will be reflected.
~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.
~Sequential use of Densah bur under copious irrigation.
~An implant of 3.9*10 mm will be inserted.
~Smart peg will be placed on implant and Osstell will be used to record ISQ.
~Healing collars will be placed on implants.
~Flap will be prepared for closure and suturing."
16453255|NCT03613415|Active Comparator|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.
~A mid crestal flap will be reflected.
~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.
~Sequential use of screw expanders.
~An implant of 3.9*10 mm will be inserted.
~Smart peg will be placed on implant and Osstell will be used to record ISQ.
~Healing collars will be placed on implants.
~Flap will be prepared for closure and suturing."
16453256|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
16453257|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
16453258|NCT03613389|Experimental|oral topical vitamin E|
16453259|NCT03613389|No Intervention|voriconazole and levofloxacin|
16453260|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
16453261|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
16453262|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
16453263|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
16453264|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
16453265|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
16453266|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
16453267|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
16453268|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
16453269|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was <12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
16453270|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was <12 mL/s and PdetQmax was <10 cmH2O during voiding cystometry.
16453271|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
16453272|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
16453273|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
16453274|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
16453275|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:
~Evaluate its ability to locate and assess the volume of the endometriosic lesion
~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.
~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
16453276|NCT03613285|Active Comparator|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
16453277|NCT03613285|Active Comparator|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
16453278|NCT03613285|Active Comparator|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
16453279|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
16453280|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
16453281|NCT03613259|Experimental|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
16453282|NCT03613233|Active Comparator|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
16453283|NCT03613233|Active Comparator|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
16453284|NCT03613207|Experimental|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.
~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.
~Each subject will have 9 test sites in total which are treated with:
~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)
~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)
~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)
~test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)
~2 test sites: untreated test site"
16453285|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.
~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:
~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal
~Peritoneal liquid
~none tumoral peritoneum
~Portal blood
~Peripheral blood
~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.
~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
16453286|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
16453287|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
16453288|NCT03613168|Experimental|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
16453289|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
16453290|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
16453291|NCT03613129|Active Comparator|D0.20|Subcutaneous infusion of CT38 at 0.20 μg/kg/hour, for 3 hours on each of 2 days
16453292|NCT03613129|Active Comparator|D0.03|Subcutaneous infusion of CT38 at 0.03 μg/kg/hour, for 3.5 hours on each of 3 days
16453293|NCT03613129|Active Comparator|D0.06|Subcutaneous infusion of CT38 at 0.06 μg/kg/hour, for 3.5 hours on each of 3 days
16453294|NCT03613129|Active Comparator|D0.01|Subcutaneous infusion of CT38 at 0.01 μg/kg/hour, for 3.5 hours on each of 3 days
16453295|NCT03613116|Experimental|High Dose Vitamin D3|Receives 4000 IU daily Vitamin D3 tablets.
16453296|NCT03613116|Active Comparator|Standard Dose Vitamin D3|Receives 600 IU Vitamin D3 tablets.
16453297|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
16453298|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
16453299|NCT03613090|Experimental|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
16453300|NCT03613090|Active Comparator|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
16453301|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
16453302|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
16453303|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
16453304|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
16453305|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
16453306|NCT03613038|Other|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
16453307|NCT03613025|Other|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
16453308|NCT03613025|Other|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
16453309|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
16453310|NCT03612999|Experimental|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
16453311|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)
~1 tablet/day, oral administration"
16453312|NCT03612986|Placebo Comparator|B: Placebo|"Placebo
~1 tablet/day, oral administration"
16453313|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture
~Liver and renal function tests
~Prothrombin time and concentration
~HCV quantitative polymerase chain reaction
~Hepatitis B surface Ag
~lipid profile
~fasting blood glucose level
~fasting insulin level
~homeostasis model for the assessment of insulin resistance (HOMA-IR)
~fibrosis (FIB- 4) index
~Aspartate aminotransferase (AST)/platelet ratio index (APRI)
~Abdominal ultrasound to assess liver and spleen
~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
16453314|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture
~Liver and renal function tests
~Prothrombin time and concentration
~HCV quantitative polymerase chain reaction
~Hepatitis B surface Ag
~lipid profile
~fasting blood glucose level
~fasting insulin level
~homeostasis model for the assessment of insulin resistance (HOMA-IR)
~Fibrosis (FIB- 4) index
~Aspartate aminotransferase (AST)/platelet ratio index (APRI)
~Abdominal ultrasound to assess liver and spleen
~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
16453315|NCT03612960|Experimental|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
16453316|NCT03612960|Placebo Comparator|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
16453317|NCT03612947|Active Comparator|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
16453318|NCT03612947|Placebo Comparator|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
16453319|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
16453320|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
16453321|NCT03612921|Active Comparator|oral group|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline
16453322|NCT03612921|Active Comparator|I.V group|the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery
16453323|NCT03612921|Placebo Comparator|control group (group C)|the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery
16453324|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
16453325|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
16453326|NCT03612895|Experimental|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
16453327|NCT03612895|Experimental|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
16453328|NCT03612895|Other|Usual Care|Passive referral to quitline and referral to primary care physician.
16453329|NCT03612882||Western University Students|Online questionnaire
16453330|NCT03612869|Experimental|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
16453331|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 1|Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
16453332|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 2|Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
16453333|NCT03612856|Placebo Comparator|placebo|Participants will receive a single dose of placebo.
16453334|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
16453335|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
16453336|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
16453337|NCT03612817|Active Comparator|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
16453338|NCT03612817|Active Comparator|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
16453339|NCT03612804|No Intervention|Unstructured care|Providers in this arm will continue to provide care as usual during lung cancer screening, with no intervention from the study team.
16453340|NCT03612804|Experimental|Proactive care|Providers in this arm will receive guidance from the study team about offering lung cancer screening patients proactive cessation care, including cessation medications and behavioral telephone counseling.
16453341|NCT03612791|Active Comparator|Standard Treatment Arm|"Radiotherapy (RT):
~Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).
~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a minimal total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).
~Total duration of RT (including brachytherapy) should be ≤ 55 days.
~Chemotherapy:
~- Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5)."
16453342|NCT03612791|Experimental|Experimental Treatment Arm|"Same treatment as described above (CRT, followed by uterovaginal brachytherapy), plus
~atezolizumab administered IV 1200 mg Q3W, starting on the same week as EBRT (Week 1) and continued as an adjuvant for a total maximum of 20 cycles (approximately 14 months total of treatment)."
16453343|NCT03612778|Experimental|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
16453344|NCT03612778|Active Comparator|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
16453345|NCT03612765|Experimental|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
16453346|NCT03612765|No Intervention|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
16453347|NCT03612752|Experimental|Active arm|CMI-168
16453348|NCT03612752|Placebo Comparator|Placebo arm|Placebo
16453349|NCT03612739|Experimental|Cohort 1|5-azacytidine + 1x10^8 NKR-2 CAR-T Cells
16453350|NCT03612739|Experimental|Cohort 2|5-azacytidine + 3x10^8 NKR-2 CAR-T Cells
16453351|NCT03612739|Experimental|Cohort 3|5-azacytidine + 1x10^9 NKR-2 CAR-T Cells
16453352|NCT03612713|Active Comparator|Oxycodone Medication First|one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
16453353|NCT03612713|Placebo Comparator|Placebo First|one hour before fMRI scan participants will be given a single dose placebo.
16453354|NCT03612700|Experimental|CPFA-rich diet|Free living diet controlled in CPFA intake
16453355|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
16453356|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
16453357|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
16453358|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
16453359|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
16453360|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
16453361|NCT03612661|Experimental|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
16453362|NCT03612661|Experimental|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have ~20 minute weekly phone call with a study interventionist.
16453363|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR
~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
16453364|NCT03612622|Active Comparator|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
16453365|NCT03612622|Placebo Comparator|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
16453366|NCT03612609|Other|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
16453367|NCT03612596|Experimental|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
16453368|NCT03612596|Active Comparator|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
16453369|NCT03612583|Experimental|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
16453370|NCT03612583|Experimental|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
16453371|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
16453372|NCT03612557|Experimental|active treatment arm|penicillin G benzathine treatment
16453373|NCT03612544|Experimental|Intervention group|
16453374|NCT03612544|Active Comparator|Control group|
16453375|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
16453376|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
16453377|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
16453378|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
16453379|NCT03612505|Active Comparator|Intervention|
16453380|NCT03612505|No Intervention|Control|
16453381|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
16453382|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
16453383|NCT03612479|Experimental|KIDFIT Healthy|
16453384|NCT03612479|Active Comparator|KIDFIT Safe|
16453385|NCT03612466|Experimental|Dose Escalation Arm|"Dose Levels 1-3 will consist of treatment with radiopharmaceutical (153Sm-DOTMP) alone. If the maximally tolerated dose (MTD) has not been reached at Level 3, external beam radiotherapy will be added to each of Levels 4-6. Participants enrolled on Dose Levels 4-6 will be treated with external beam radiotherapy to all radiographically evident sites of disease. If an MTD has not been determined at Level 6, the study will end and Dose Level 6 will be declared the Recommended Phase 2 Dose.
~Participants will be given prophylactic / supportive treatment protocols including Calcium Carbonate, mozobil, and neupogen injectable product."
16453386|NCT03612453|Experimental|Intervention group|
16453387|NCT03612453|Active Comparator|Control group|
16453388|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
16453389|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
16453390|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
16453391|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
16453392|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
16453393|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
16453394|NCT03612401|Other|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
16453395|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
16453396|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
16453397|NCT03612375|Experimental|Intervention group|
16453398|NCT03612375|Active Comparator|Control group|
16453399|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
16453400|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
16453401|NCT03612349|Other|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
16453450|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^3)|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
16453402|NCT03612349|Other|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
16453403|NCT03612336|Experimental|Intervention group|
16453404|NCT03612336|Active Comparator|Control group|
16453405|NCT03612323|Experimental|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
16453406|NCT03612323|Active Comparator|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
16453407|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
16453408|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
16453409|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN
~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC
~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
16453410|NCT03612271|Experimental|mGlide Intervention|Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
16453411|NCT03612271|No Intervention|Clinical Care Comparison|Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
16453412|NCT03612258|Experimental|Functional Magnetic Resonance Imaging|
16453413|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
16453414|NCT03612219|Experimental|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
16453415|NCT03612219|Active Comparator|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
16453416|NCT03612193||Study A: Chronic >1 year|
16453417|NCT03612193||Study A: Acute <1 year|
16453418|NCT03612193||Study A: Household Control|
16453419|NCT03612193||Study B: Newly Diagnosed <6 months|
16453420|NCT03612193||Study B: Household Controls|
16453421|NCT03612167|Experimental|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
16453422|NCT03612167|Active Comparator|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
16453423|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
16453424|NCT03612128|Other|control group|Children continued their traditional physiotherapy
16453425|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
16453426|NCT03612115|Experimental|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
16453427|NCT03612115|No Intervention|Control|No additional intervention
16453428|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
16453429|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
16453430|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
16453431|NCT03612089||Healthy control group|Healthy individuals without low back pain
16453432|NCT03612076||Global cost of management of PJI|
16453433|NCT03612063|Experimental|Fitbit Iconic HR and Garmin Vivosmart HR|
16453434|NCT03612063|Experimental|Fitbit Iconic HR and TomTom Spark 3|
16453435|NCT03612063|Experimental|Garmin Vivosmart HR and TomTom Spark 3|
16453436|NCT03612063|Experimental|Fitbit Iconic HR and Apple Watch III|
16453437|NCT03612063|Experimental|Apple Watch III and Garmin Vivosmart HR|
16453438|NCT03612063|Experimental|Apple Watch III and TomTom Spark 3|
16453439|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
16453440|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
16453441|NCT03612037|Placebo Comparator|Control Phase|cellulose (600 mg)
16453442|NCT03612037|Experimental|Experimental Phase|alpha lipoic acid (600 mg)
16453443|NCT03612024||request for organ donation approved|
16453444|NCT03612024||request for organ donation rejected|
16453445|NCT03612011|Experimental|Onco-Repair|Onco-Repair tube of 150 ml
16453446|NCT03612011|Placebo Comparator|Placebo|Placebo tube of 150 ml
16453447|NCT03611998|Experimental|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
16453448|NCT03611985|Experimental|Epidiferphane + taxane chemotherapy|
16453449|NCT03611972|Experimental|Sugar-sweetened beverage (SSB)|SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks
16453451|NCT03611946|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16453452|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^4)|Participants will receive a single dose of rZIKV/D4Δ30-713 or placebo at study entry (Day 0).
16453453|NCT03611933|No Intervention|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
16453454|NCT03611933|Experimental|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
16453455|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
16453456|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
16453457|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
16453458|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
16453459|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
16453460|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
16453461|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
16453462|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
16453463|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
16453464|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
16453465|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
16453466|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
16453467|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
16453468|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
16453469|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
16453470|NCT03611868|Experimental|APG-115+Pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
16453471|NCT03611855|Experimental|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
16453472|NCT03611855|Active Comparator|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
16453473|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
16453474|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
16453475|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
16453476|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
16453477|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
16453478|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
16453479|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
16453480|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
16453481|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
16453482|NCT03611803|Experimental|Ekso Group|
16453483|NCT03611803|Active Comparator|Control|
16453484|NCT03611790|Experimental|Intervention|NeVa VS
16453485|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
16453518|NCT03611556|Experimental|Arm B2|oleclumab (MEDI9447) and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
16453519|NCT03611556|Experimental|Arm B3|oleclumab (MEDI9447), durvalumab (MEDI4736), and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
16453556|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
16453486|NCT03611764|Experimental|Arm 1: Body Scan|"The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes
~Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.
~Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
16453487|NCT03611751|Experimental|BMS-986165|BMS-986165 oral administration
16453488|NCT03611751|Placebo Comparator|Placebo|Placebo oral administration
16453489|NCT03611751|Active Comparator|Active comparator|Active comparator oral administration
16453490|NCT03611738|Experimental|Phase I Dose Escalation|"The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).
~Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m^2 docetaxel"
16453491|NCT03611738|Experimental|Phase Ib Dose Expansion|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
16453492|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
16453493|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
16453494|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
16453495|NCT03611712|No Intervention|CCRT alone arm|
16453496|NCT03611699|Active Comparator|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
16453497|NCT03611699|Placebo Comparator|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
16453498|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
16453499|NCT03611673|Experimental|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
16453500|NCT03611673|Active Comparator|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
16453501|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
16453502|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
16453503|NCT03611647|Active Comparator|Probiotic|
16453504|NCT03611647|Placebo Comparator|Placebo|
16453505|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
16453506|NCT03611608|Experimental|LY3316531 Dose 1|LY3316531 administered IV
16453507|NCT03611608|Experimental|LY3316531 Dose 2|LY3316531 administered IV
16453508|NCT03611608|Placebo Comparator|Placebo|Placebo administered IV
16453509|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
16453510|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
16453511|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
16453512|NCT03611569|Experimental|Lu AF82422|"Part A:
~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)
~Part B:
~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
16453513|NCT03611569|Placebo Comparator|Placebo|"Part A:
~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)
~Part B:
~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
16453514|NCT03611556|Active Comparator|Arm A1|gemcitabine and nab-paclitaxel
16453515|NCT03611556|Experimental|Arm A2|oleclumab (MEDI9447), gemcitabine and nab-paclitaxel
16453516|NCT03611556|Experimental|Arm A3|oleclumab (MEDI9447), durvalumab (MEDI4736), and gemcitabine/nab-paclitaxel
16453517|NCT03611556|Active Comparator|Arm B1|mFOLFOX (oxaliplatin, leucovorin, 5-FU)
16453520|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
16453521|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
16453522|NCT03611530|Experimental|CoQun®|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
16453523|NCT03611530|Placebo Comparator|Placebo|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
16453524|NCT03611517|Experimental|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
16453525|NCT03611517|No Intervention|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
16453526|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
16453527|NCT03611491|Experimental|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
16453528|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
16453529|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
16453530|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
16453531|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients scheduled for a cardiac defibrillator implantation in primary prevention.
16453532|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
16453533|NCT03611452|Experimental|Simple continuous|the sutures will be taken continuously by simple method
16453534|NCT03611452|Active Comparator|subcuticular|the sutures will be taken subcuticular
16453535|NCT03611452|Active Comparator|interrupted|the sutures will be taken interrupted method
16453536|NCT03611439|Active Comparator|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
16453537|NCT03611439|Placebo Comparator|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
16453538|NCT03611426|Experimental|rhThrombin ( Topical )|Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
16453539|NCT03611426|Placebo Comparator|placebo|Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;
16453540|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
16453541|NCT03611413||conventional care|Patients who have been treated under an conventional care
16453542|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
16453543|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
16453544|NCT03611387||Normal|Patients without any type of glaucoma
16453545|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
16453546|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
16453547|NCT03611374|Experimental|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
16453548|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
16453549|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
16453550|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
16453551|NCT03611335||Site 2 H+H|Bellevue Hospital
16453552|NCT03611335||Site 3 H+H|Metropolitan Hospital
16453553|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
16453554|NCT03611335||Site 5 H+H|Coney Island Hospital
16453557|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
16453558|NCT03611309|Experimental|Surgeon-palliative care team co-management|In the Surgeon-palliative care team co-management arm, all patients receive the surgical care of surgeon alone management, which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will also be provided by a specialist team. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed for 12 weeks following surgery.
16453559|NCT03611309|Other|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery. The surgeon team is given guidelines published by the National Cancer Coalition Network as to when palliative care specialist consultation is recommended
16453560|NCT03611283|Experimental|Test group|"Patients had to use:
~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.
~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
16453561|NCT03611283|Placebo Comparator|Placebo group|"Patients had to use:
~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.
~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
16453562|NCT03611257|Experimental|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
16453563|NCT03611257|Active Comparator|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
16453564|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
16453565|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
16453566|NCT03611231|Experimental|Experimental|chidamide
16453567|NCT03611218|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
16453568|NCT03611205|Experimental|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
16453569|NCT03611192|Experimental|Multicomponent exercise group|
16453570|NCT03611192|Active Comparator|Home-program exercise group|
16453571|NCT03611179|Experimental|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 & Carboplatin AUC 5 every 21 days)
16453572|NCT03611153|Experimental|Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
16453573|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
16453574|NCT03611140|Experimental|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
16453575|NCT03611140|Placebo Comparator|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
16453576|NCT03611127|Experimental|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
16453577|NCT03611127|No Intervention|Usual care (UC)|No pulmonary rehabilitation for this group
16453578|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
16453579|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
16453580|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
16453581|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
16453582|NCT03611075|Experimental|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
16453583|NCT03611075|Experimental|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
16453584|NCT03611075|Experimental|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
16453585|NCT03611075|Experimental|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
16453586|NCT03611075|Experimental|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
16453587|NCT03611075|Experimental|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
16453588|NCT03611075|No Intervention|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
16453591|NCT03611062|Experimental|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
16453592|NCT03611062|Placebo Comparator|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
16453593|NCT03611049|Placebo Comparator|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
16453594|NCT03611049|Active Comparator|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
16453595|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
16453596|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
16453597|NCT03611010|Experimental|10 mg oral atorvastatin|Subjects taking 10 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
16453598|NCT03611010|Experimental|20 mg oral atorvastatin|Subjects taking 20 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
16453599|NCT03611010|Experimental|40 mg oral atorvastatin|Subjects taking 40 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
16453600|NCT03611010|Experimental|80 mg oral atorvastatin|Subjects taking 80 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
16453601|NCT03610997|Other|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
16453602|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
16453603|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
16453604|NCT03610971|Experimental|Combination Therapy + Remission Phase|"Combination therapy followed by treatment free remission (TFR) phase.
~Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).
~All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. For cycle 2 and beyond, if day 1 of a cycle is delayed, day 1 procedures should be repeated if out of the specified window and day 1 of the cycle is considered the day study drug is restarted. They will continue combination therapy for a total of 12 cycles. Each cycle will be approximately 28 days.
~At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment."
16453605|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.
~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
16453606|NCT03610945|Experimental|EDP-305 and fluconazole interaction (Part 1)|
16453607|NCT03610945|Experimental|EDP-305 and quinidine interaction (Part 2)|
16453608|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
16453609|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
16453610|NCT03610919|Experimental|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
16453611|NCT03610919|Experimental|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
16453612|NCT03610919|Placebo Comparator|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
16453613|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
16453614|NCT03610893|Active Comparator|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
16453615|NCT03610893|Active Comparator|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
16453616|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
16453617|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
16453618|NCT03610867|Experimental|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
16453619|NCT03610867|Placebo Comparator|Placebo (SAD)|"Single ascending oral dose of Furaprevir similar capsule.
~."
16453620|NCT03610867|Experimental|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
16453621|NCT03610867|Placebo Comparator|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
16453622|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
16453623|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
16453624|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
16453625|NCT03610815|Experimental|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
16453626|NCT03610815|Active Comparator|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
16457863|NCT03581019|Experimental|Uterus transplantation|Uterus transplantation
16453629|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems, monolithic sleeved stems and/or Acetabular Components or modular shells and/or augments
16453630|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
16453631|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
16453632|NCT03610763|Active Comparator|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
16453633|NCT03610763|Active Comparator|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
16453634|NCT03610763|No Intervention|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
16453635|NCT03610750|Active Comparator|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
16453636|NCT03610750|Experimental|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
16453637|NCT03610750|Experimental|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
16453638|NCT03610737|Active Comparator|MILD with CMM|The MILD procedure is an image-guided minimally-invasive lumbar decompression with conventional medical managment
16453639|NCT03610737|Active Comparator|CMM alone|Patient in the CMM alone group can have physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
16453640|NCT03610724|Experimental|Tisagenlecleucel|CAR-positive viable T cells infusion
16453641|NCT03610711|Experimental|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
16453642|NCT03610711|Experimental|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
16453643|NCT03610698|Experimental|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
16453644|NCT03610698|Experimental|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
16453645|NCT03610698|Active Comparator|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
16453646|NCT03610685|Placebo Comparator|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
16453647|NCT03610685|Active Comparator|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
16453648|NCT03610672|Active Comparator|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
16453649|NCT03610672|Experimental|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
16453650|NCT03610646|Experimental|MYL-1701P|MYL-1701P
16453651|NCT03610646|Active Comparator|Eylea|Eylea
16453652|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
16453653|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
16453654|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
16453655|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
16453656|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
16453657|NCT03610594|Experimental|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
16453658|NCT03610594|No Intervention|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
16453659|NCT03610581|Experimental|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
16453660|NCT03610581|Experimental|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
16453661|NCT03610581|Experimental|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
16453662|NCT03610581|Placebo Comparator|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
16453663|NCT03610568|Experimental|Growing up GREAT! Intervention|
16453664|NCT03610568|No Intervention|Control|
16453665|NCT03610555||Current website|Show patient one of the website
16453666|NCT03610555||New patient centered website|Show patient another (different) of the website
16453667|NCT03610542|Experimental|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
16453668|NCT03610542|Experimental|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
16453669|NCT03610542|No Intervention|Control|This is a no intervention control arm
16453670|NCT03610529|Experimental|ECG monitoring system CardioSenseSystem group|
16453671|NCT03610529|Active Comparator|ECG monitoring system Philips Intellivue|
16453674|NCT03610503|Experimental|Music|Patients listen to music during EMG test
16453675|NCT03610503|No Intervention|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
16453676|NCT03610490|Experimental|Treatment (autologous tumor infiltrating lymphocytes MDA-TIL)|"LYMPHODEPLETION REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, and fludarabine IV over 15-30 minutes on days -5 to -1 in the absence of disease progression or unacceptable toxicity.
~T-CELL INFUSION: Patients receive autologous tumor infiltrating lymphocytes MDA-TIL IV over 45 minutes on day 0. Patients then receive IL-2 IV over 30 minutes on days 1-4 for up to 6 doses in the absence of disease progression or unacceptable toxicity."
16453677|NCT03610477|Active Comparator|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
16453678|NCT03610477|Placebo Comparator|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
16453679|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
16453680|NCT03610451|Experimental|Floatation-REST|Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.
16453681|NCT03610451|Other|Usual care|Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
16453682|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
16453683|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
16453684|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
16453685|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
16453686|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
16453687|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
16453688|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
16453689|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
16453690|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
16453691|NCT03610386|Active Comparator|Control|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours and then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes .
16453692|NCT03610386|Experimental|Treatment with menthoxypropanediol|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. Thy will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours. Then the menthoxypropanediol (200 µM) will be applied topically on this explant and left for 6 hours. Then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes.
16453693|NCT03610373|Experimental|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
16453694|NCT03610373|Active Comparator|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
16453695|NCT03610360|Active Comparator|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
16453696|NCT03610360|No Intervention|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
16453697|NCT03610347|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
16453698|NCT03610347|Active Comparator|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
16453699|NCT03610334|Experimental|IFB-088|"IFB-088 oral capsule:
~In SAD phase: single daily dose of IFB-088 will be administered to 6 successive cohorts while increasing dose exposure.
~In MAD phase: multiple doses of IFB-088 will be administered daily during 14 days to 3 succesive cohorts while increasing dose exposure."
16453700|NCT03610334|Placebo Comparator|Placebo|"Placebo oral capsule:
~In SAD phase: single daily dose of placebo (cellulose microcrystalline) will be administered in equivalent-weight.
~In MAD phase: multiple doses of placebo (cellulose microcrystalline) will be administered daily during 14 days."
16453701|NCT03610321|Active Comparator|Statin group|Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.
16453702|NCT03610321|Experimental|Gefarnate group|Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.
16453703|NCT03610295|Experimental|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
16453704|NCT03610295|Active Comparator|historical control group|cataract extraction surgery
16453705|NCT03610282|Experimental|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
16453706|NCT03610282|Placebo Comparator|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
16453707|NCT03610269|Experimental|INVSENSOR00026|All enrolled subjects receive INVSENSOR00026 Pulse CO-Oximeter and sensor for the noninvasive measurement of hemoglobin (SpHb).
16453708|NCT03610256|Experimental|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).
~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
16453709|NCT03610256|Active Comparator|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).
~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
16453710|NCT03610243|Experimental|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).
~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
16453711|NCT03610243|No Intervention|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
16453712|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
16453713|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
16453714|NCT03610217|Experimental|Interstitial lung disease induction|
16453715|NCT03610217|Experimental|Pulmonary arterial hypertension|
16453716|NCT03610217|Experimental|Raynaud's phenomenon|
16453717|NCT03610217|Experimental|Digital ulcers|
16453718|NCT03610217|Experimental|Inflammatory arthritis|
16453719|NCT03610217|Experimental|Gastroesophageal reflux|
16453720|NCT03610217|Experimental|Bacterial overgrowth|
16453721|NCT03610217|Experimental|Constipation|
16453722|NCT03610217|Experimental|Skin involvement|
16453723|NCT03610217|Experimental|Pain|
16453724|NCT03610204|Experimental|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end with a higher force against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
16453725|NCT03610204|Active Comparator|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. By pressuring the rod end with a lower force against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
16453726|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
16453727|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
16453728|NCT03610178|Active Comparator|very tight glycemic targets|
16453729|NCT03610178|Active Comparator|tight-moderate glycemic targets|
16453730|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
16453731|NCT03610165|Placebo Comparator|Arterial line - Control|Arterial line waveform and pressure
16453732|NCT03610165|Experimental|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
16453733|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
16453734|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
16453735|NCT03610139|Active Comparator|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
16453736|NCT03610139|Experimental|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.
~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
16453737|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
16453738|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
16453739|NCT03610113|No Intervention|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
16453740|NCT03610113|Experimental|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.
~It is followed by the same rehabilitation protocol than conservative treatment"
16453741|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.
~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
16453742|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.
~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
16453743|NCT03610087|Other|Low Intensity Intervention|The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
16453744|NCT03610087|Experimental|High Intensity Intervention|The intervention group (high intensity) receives a technology-enabled CCM intervention. Participants receive access to an online platform and infographic modules to learn more about nutrition, physical activity, and smoking cessation. Also, they are assigned a personal health coach who collaboratively schedules weekly virtual sessions via the platform to discuss the educational materials, goal setting and motivation, and provide support in the 12-week program. The participant's health coach reviews the participant's concerns and goals weekly with a virtual care team (VCT; including a psychiatrist, addictions specialist, nutrition specialist, peer mentor, and recreational therapist), who provides individualized recommendations to include in the participant's treatment plan. Participants have access to online resources and online webinars about nutrition, physical activity and smoking.
16453745|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.
~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
16453746|NCT03610061|Experimental|Radiotherapy plus Durvalumab|"A minimum of 3 patients will initially be enrolled in each cohort of this arm. Patients will be allocated to a radiotherapy dose and site cohort from the schedule at registration. There will be no intra-patient dose or site escalations.
~Cohorts will escalate in number of anatomical sites of radiotherapy and dose of radiotherapy given subject to safety. Durvalumab will be administered at a fixed dose every 4 weeks IV."
16453747|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
16453748|NCT03610035|Experimental|Experimental|NPT189
16453749|NCT03610035|Placebo Comparator|Placebo Comparator|Placebo
16453750|NCT03610022|Experimental|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
16453751|NCT03610009|Active Comparator|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
16453752|NCT03610009|Active Comparator|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
16453753|NCT03609996||PDR treated with Laser|
16453754|NCT03609996||PDR treated with Lucentis|
16453755|NCT03609983|Experimental|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
16453756|NCT03609983|Experimental|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
16453757|NCT03609983|No Intervention|No Weighing|Participants will refrain from weighing themselves.
16453758|NCT03609970|No Intervention|Control|No intervention
16453759|NCT03609970|Experimental|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
16453760|NCT03609970|Experimental|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
16453761|NCT03609957|Experimental|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
16453762|NCT03609957|Experimental|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
16453764|NCT03609944|Sham Comparator|EUS + Sham|Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
16453765|NCT03609944|Experimental|EUS + ERCP with miES|Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
16453766|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
16453767|NCT03609905|Experimental|Intervention group|interventions: The MSCs of 5×10*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
16453768|NCT03609905|Other|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
16453769|NCT03609892|Experimental|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
16453770|NCT03609892|Active Comparator|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
16453771|NCT03609879|No Intervention|without cervical collar|baseline - without cervical collar
16453772|NCT03609879|Experimental|with cervical collar|scenarios with cervical collars
16453773|NCT03609866|Active Comparator|control|will be performed metatarsophalangeal joint passive mobilization
16453774|NCT03609866|Experimental|experimental|rapid thoracic compression technique will be applied
16453775|NCT03609853|Placebo Comparator|Placebo|Placebo (5mL distilled water)
16453776|NCT03609853|Experimental|Vaporized low THC|15mg of pure THC
16453777|NCT03609853|Experimental|Vaporized high THC|30mg of pure THC
16453778|NCT03609853|Experimental|Vaporized low d-limonene|1mg of d-limonene
16453779|NCT03609853|Experimental|Vaporized high d-limonene|5mg of d-limonene
16453780|NCT03609853|Experimental|Low THC and low d-limonene|15mg of THC paired with 1mg of d-limonene
16453781|NCT03609853|Experimental|High THC and low d-limonene|30mg of THC paired with 1mg of d-limonene
16453782|NCT03609853|Experimental|Low THC and high d-limonene|15mg of THC paired with 5mg of d-limonene
16453783|NCT03609853|Experimental|High THC and high d-limonene|30mg of THC paired with 5mg of d-limonene
16453784|NCT03609840||Pediatric Hematopoietic Stem Cell Transplant Recipients|Children undergoing hematopoietic stem cell transplant (HCT) at University of California, San Francisco Benioff Children's Hospital
16453785|NCT03609827||Pediatric patients undergoing Hematopoietic Stem Cell Transplant|Children undergoing allogeneic hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco Benioff Children's Hospital.
16453786|NCT03609814||Pediatric Bone Marrow Transplantation Recipients|Children undergoing alloHCT at UCSF Benioff Children's Hospital.
16453789|NCT03609775|Experimental|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
16453790|NCT03609775|Experimental|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
16453791|NCT03609775|Experimental|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
16453792|NCT03609775|Experimental|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
16453793|NCT03609762|Experimental|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
16453794|NCT03609762|No Intervention|Control group|usual care. All subjects attending the control clinics will not need to complete the electronic EQ-5D-5L before seeing the doctor during their follow-up visits. The doctor will manage the patient as usual, based on the usual clinical information. The doctor will complete the clinician-reported follow-up clinical data form (CRF) for each subject at the end of the consultation.
16453795|NCT03609749|Experimental|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
16453881|NCT03609125|Experimental|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
16453796|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
16453797|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
16453798|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
16453799|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
16453802|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
16453803|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
16453804|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
16453805|NCT03609671|Experimental|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
16453806|NCT03609671|Other|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
16453807|NCT03609658|Experimental|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
16453808|NCT03609658|Sham Comparator|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
16453809|NCT03609645|Active Comparator|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
16453810|NCT03609645|Experimental|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
16453811|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
16453812|NCT03609619|Experimental|AEVI-001|
16453813|NCT03609619|Placebo Comparator|Placebo|
16453814|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7
~Period 2: Treatment of D013 on Day22~Day28"
16453815|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7
~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
16453816|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7
~Period 2: Treatment of D326 and D337 on Day22~Day28"
16453817|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7
~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
16453818|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
16453819|NCT03609567|Experimental|Aromatherapy|Aromatherapy using essential oils
16453820|NCT03609567|Placebo Comparator|Placebo|Aromatherapy using odorless placebo
16453821|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
16453822|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
16453823|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
16453824|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
16453825|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
16453826|NCT03609515|Experimental|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
16453827|NCT03609502|Experimental|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
16453828|NCT03609502|Experimental|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
16453829|NCT03609489|Experimental|Test Group|Apatinib combined with Capetabine
16453830|NCT03609489|Active Comparator|Control Group|Capecitabine
16453831|NCT03609476|Active Comparator|Standard of care group|No saline instillation
16453832|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
16453833|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
16453834|NCT03609463|Experimental|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
16453835|NCT03609463|Active Comparator|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
16453836|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
16453837|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
16453838|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
16453839|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
16453840|NCT03609424|Experimental|PDR001 plus Imatinib|
16453841|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
16453842|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
16453843|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
16453844|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
16453845|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
16453846|NCT03609359|Experimental|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
16453847|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
16453848|NCT03609333|Experimental|Internal arm|
16453849|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
16453850|NCT03609307|Active Comparator|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
16453851|NCT03609307|Active Comparator|injection Intravitreal bevacizumab|patients receive only Bevacizumab
16453852|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)
~There will be a washout of 35 days between the each period."
16453853|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)
~There will be a washout of 35 days between the each period."
16453854|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)
~There will be a washout of 35 days between the each period."
16453855|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
16453856|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
16453857|NCT03609268|Active Comparator|MWA|Patients receive microwave ablation (MWA)
16453858|NCT03609268|Experimental|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
16453859|NCT03609255|Active Comparator|Control group (C)|
16453860|NCT03609255|Experimental|Sedentary behavior group (SB)|
16453861|NCT03609255|Experimental|Stress management group (SR)|
16453862|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
16453863|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
16453864|NCT03609229|Experimental|Study group|Abdominal Sacrocolpopexy with burch technique
16453865|NCT03609229|Active Comparator|control group|Abdominal Sacrocolpopexy without burch technique
16453866|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
16453867|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
16453868|NCT03609203||Patients|
16453869|NCT03609203||Controls|
16453870|NCT03609190|Experimental|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
16453871|NCT03609190|Placebo Comparator|Placebo|i.v. infusion of NaCl over 40 min
16453872|NCT03609177|Experimental|Advance Care Planning|"-Survey:
~A group of older patients with advanced cancer (N=450) will have a survey over the course of the 36 months of recruitment.
~Participants will be provided written copies of the questions to follow along during the interviews"
16453873|NCT03609177|Experimental|Advance Care Planning-Video Declaration|"Video Declaration:
~From among this group of 450 participants, the video declaration of preferences activity will be conducted with 240 patients.
~For those participants that agree to the video declaration, they will proceed with recording of their video declarations
~The RA will begin by reading a standardized introduction to aid the subject do the video"
16453874|NCT03609177|Other|Comprehensive Record Review of ACP|"A review of Medical orders for resuscitation preferences in the electronic health record
~A review of Medical orders for Palliative care consultations preferences in the electronic health record
~A review of Medical orders for Hospice use preferences in the electronic health record"
16453875|NCT03609177|Experimental|Main Study Arm|Patients with cancer being seen at the 36 oncology clinics will be exposed to clinicians who have had communication skills training (Vital Talk) and who are using video decision aids (ACP Decisions). Our main outcome is advance care planning documentation.
16453876|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
16453882|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
16453883|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
16453884|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.
~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
16453885|NCT03609099|Active Comparator|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
16453886|NCT03609099|Experimental|Placebo|Placebo treatment to patients treated during the 5 previous days.
16453887|NCT03609073|Experimental|Intervention|
16453888|NCT03609060|Experimental|DEXAML|"Induction therapy:
~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.
~Post remission therapy:
~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).
~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
16453889|NCT03609047|Experimental|experimental palbociclib arm|Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
16453890|NCT03609047|Active Comparator|control chemotherapy arm|"Adjuvant chemotherapy:
~4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w
~Followed by standard adjuvant endocrine therapy for a duration of at least 5 years."
16453891|NCT03609021||Observational (bilateral screening mammogram)|Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
16453892|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
16453893|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
16453894|NCT03608995|Experimental|Premaquick©|
16453895|NCT03608995|Other|Quikcheck|
16453896|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
16453897|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
16453898|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
16453899|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:
~hydrocortisone to prednisolone or;
~prednisolone to hydrocortisone"
16453900|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
16453933|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
16453934|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
16453968|NCT03608371|Experimental|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
16453901|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
16453902|NCT03608917|Experimental|Treatment group|"Drug:Total Glucosides of Paeony (TGP)
~Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)
~Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
16453903|NCT03608917|Placebo Comparator|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue
~Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)
~Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
16453904|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
16453905|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
16453906|NCT03608891|Active Comparator|Control Arm|Conventional titanium miniplates
16453907|NCT03608891|Experimental|Intervention arm|Patient specific 3D plates
16453908|NCT03608878|Active Comparator|TACE alone arm|TACE (Transarterial Chemoembolization)
16453909|NCT03608878|Experimental|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
16453910|NCT03608865|Experimental|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
16453911|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
16453912|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
16453913|NCT03608839|Experimental|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
16453914|NCT03608839|Experimental|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
16453915|NCT03608839|Experimental|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
16453916|NCT03608826|Experimental|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
16453917|NCT03608813||Controls|Healthy subjects
16453918|NCT03608813||Case|PCOS affected subjects
16453919|NCT03608800|Experimental|Intermittent fasting|two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
16453920|NCT03608800|No Intervention|Control diet|maintain the energy intake as usual
16453921|NCT03608787|Experimental|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
16453922|NCT03608787|Experimental|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
16453923|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
16453924|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
16453925|NCT03608761|Experimental|Rebamipide 2%|"- wash-out: 2 weeks
~- rebamipide 2% four times a day for 3 months
~- controls will be taken at day zero, 30 and 90.
~- wash-out: 2 weeks
~- autologous serum for 3 months"
16453926|NCT03608761|Experimental|Autologous serum|"- wash-out: 2 weeks
~- autologous serum four times a day for 3 months
~- controls will be taken at day zero, 30 and 90.
~- wash-out: 2 weeks
~- rebamipe 2% for 3 months"
16453927|NCT03608761|Experimental|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
16453928|NCT03608722|Experimental|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
16453929|NCT03608722|Experimental|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
16453930|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution
~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
16453931|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
16453932|NCT03608657||Psoriatic Arthritis patients treated with Apremilast|Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
16453935|NCT03608618|Experimental|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
16453936|NCT03608618|Experimental|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
16453937|NCT03608618|Experimental|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
16453938|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
16453939|NCT03608579|Experimental|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
16453940|NCT03608579|Experimental|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
16453941|NCT03608553|Experimental|ExAblate|ExAblate MR Guided Focused Ultrasound
16453942|NCT03608540|Experimental|Intervention|Suturing system with suture apposition then bulging formation then cutting the lesion
16453943|NCT03608527|Experimental|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
16453944|NCT03608527|Active Comparator|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
16453945|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.
~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.
~Patients will be followed for 48 hours."
16453946|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.
~Patients will be followed for 48 hours."
16453947|NCT03608501|Experimental|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
16453948|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement|Vitamin D replacement (50.000 IU/per week, for 8 weeks)
16453949|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|Vitamin D replacement (50.000 IU/per week, for 8 weeks) and Core and balance exercises for 8 weeks.
16453950|NCT03608488|Experimental|Vitamin D<10 ng/ml; exercise|Core and balance exercises for 8 weeks.
16453951|NCT03608488|Active Comparator|Vitamin D>30ng/ml; exercise|Core and balance exercises for 8 weeks.
16453952|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
16453953|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
16453954|NCT03608462|Sham Comparator|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
16453955|NCT03608462|Sham Comparator|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
16453956|NCT03608462|No Intervention|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
16453957|NCT03608449|Active Comparator|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
16453958|NCT03608449|Placebo Comparator|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
16453961|NCT03608423|Experimental|Surgical treatment|Minimally-invasive endoscopy-guided surgery or hematoma aspiration, additional to standard medical treatment.
16453962|NCT03608423|No Intervention|Standard medical management|Standard medical treatment (treatment of bloodpressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration)
16453963|NCT03608410|Experimental|PRO intervention|Weekly PRO questionnaires Quality of life every 2 months
16453964|NCT03608410|No Intervention|Standard of care|Quality of life every 2 months
16453965|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
16453969|NCT03608371|Experimental|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
16453970|NCT03608371|Experimental|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
16453971|NCT03608371|Placebo Comparator|Placebo Cohorts 1-3|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
16453972|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
16453973|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
16453974|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
16453975|NCT03608332|No Intervention|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-
~Resolution of acute phase of disease for which patient was intubated
~Adequate cough
~Absence of excessive tracheobronchial secretions
~B) Objective criteria:-
~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200
~Respiratory rate <30
~PH and PaCO2 appropriate for patients' baseline respiratory status
~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia
~HR<140 beats/minute
~Patient is arousable or Glasgow coma scale (GCS)>13"
16453976|NCT03608332|Experimental|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-
~Resolution of acute phase of disease for which patient was intubated
~Adequate cough
~Absence of excessive tracheobronchial secretions
~B) Objective criteria:-
~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200
~Respiratory rate <30
~PH and PaCO2 appropriate for patients' baseline respiratory status
~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia
~HR<140 beats/minute
~Patient is arousable or Glasgow coma scale (GCS)>13
~C) Ultrasound criteria:-
~• Diaphragmatic excursion >11 mm"
16453977|NCT03608319|Experimental|Single dose following overnight fast|
16453978|NCT03608319|Experimental|Single dose following high fat breakfast|
16453979|NCT03608319|Experimental|Single dose sprinkled on applesauce following overnight fast|
16453980|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
16453981|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
16453982|NCT03608293|Experimental|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
16453983|NCT03608293|Active Comparator|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
16453984|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
16453985|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).
~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
16453986|NCT03608267|Experimental|Intervention|
16453987|NCT03608241|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
16453988|NCT03608241|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
16453989|NCT03608228||Parkinson's Disease|
16453990|NCT03608215|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
16453991|NCT03608215|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
16453992|NCT03608202|Experimental|POCUS protocol group|"POCUS protocol group
~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:
~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
16453993|NCT03608202|Active Comparator|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
16453994|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
16453995|NCT03608176|Experimental|PASO diet group|
16453996|NCT03608176|Active Comparator|Low-fat diet group|
16453997|NCT03608176|Other|Waiting list group|
16453998|NCT03608163|No Intervention|No intervention (Susceptibility to HAAF evaluation)|Susceptibility to HAAF evaluation: No intervention medication will be given during episodes of hypoglycemia.
16453999|NCT03608163|Experimental|Naloxone|Naloxone evaluation: Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
16454000|NCT03608163|Placebo Comparator|Placebo (for Naloxone)|Naloxone evaluation: Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
16454001|NCT03608163|Experimental|Naloxone + diazoxide|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
16454002|NCT03608163|Active Comparator|Diazoxide + placebo (for naloxone)|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
16454003|NCT03608163|Active Comparator|Naloxone + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
16454004|NCT03608163|Placebo Comparator|Placebo (for naloxone) + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
16454005|NCT03608150|Experimental|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
16454006|NCT03608150|Active Comparator|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
16454007|NCT03608137|Experimental|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
16454008|NCT03608137|Active Comparator|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
16454009|NCT03608111|Active Comparator|single task balance training|
16454010|NCT03608111|Active Comparator|dual task balance training|
16454011|NCT03608098|Active Comparator|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
16454012|NCT03608098|Active Comparator|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
16454013|NCT03608085|Experimental|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
16454014|NCT03608085|Experimental|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
16454015|NCT03608072|Experimental|Dose group 1|
16454016|NCT03608072|Experimental|Dose group 2|
16454017|NCT03608072|Experimental|Dose group 3|
16454018|NCT03608059|Experimental|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
16454019|NCT03608059|Active Comparator|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
16454020|NCT03608059|Active Comparator|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
16454021|NCT03608046|Experimental|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.
~Irinotecan: administrated every 2 weeks (180 mg/m2)."
16454022|NCT03608033|Experimental|OMS721|Administration of OMS721
16454023|NCT03608033|Placebo Comparator|Placebo|Administration of Vehicle (D5W or Saline Solution)
16454024|NCT03608020|Active Comparator|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
16454025|NCT03608020|No Intervention|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
16454026|NCT03608007|Experimental|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
16454029|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline [i.e., 100 * (postoperative pad weight - baseline pad weight)/baseline pad weight].
16454030|NCT03607955|Experimental|AVB-S6-500 + Paclitaxel + Carboplatin|"Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle
~Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy
~AVB-S6-500 will be given at doses based on the dose escalation schema
~The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
16454031|NCT03607942|Experimental|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
16454032|NCT03607942|Placebo Comparator|Control Formula|The control group will receive a liquid placebo
16454033|NCT03607929|Experimental|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
16454034|NCT03607929|Active Comparator|variability and hydration|Other Solutions >o < 300 ml/h AND uncontrolled drink during labor
16454035|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454036|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454037|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454038|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454039|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454040|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454041|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454042|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454043|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454044|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
16454045|NCT03607903|Active Comparator|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
16454046|NCT03607903|Active Comparator|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
16454047|NCT03607903|Experimental|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
16454048|NCT03607903|Experimental|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
16454051|NCT03607877|Active Comparator|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
16454052|NCT03607877|Active Comparator|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
16454053|NCT03607877|Experimental|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
16454054|NCT03607864|Experimental|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
16454055|NCT03607851|Active Comparator|Conventional titration group|
16454056|NCT03607851|Experimental|Rapid titration group 1|
16454057|NCT03607851|Experimental|Rapid titration group 2|
16454058|NCT03607838|Experimental|SI-6603|
16454059|NCT03607838|Sham Comparator|Sham injection|
16454060|NCT03607825|Experimental|Neurapheresis System|CSF filtration
16454061|NCT03607799|Experimental|Dietary Intervention|"A dietitian develops personalized diet advice for each intervention group participant. She sets 2-4 SMART goals according to the following principles: 1) Replace fried foods and meat with vegetable protein, raw and cooked vegetables; 2) Reduce refined carbohydrate intake; 3) Improve carbohydrate quality (replace high glycemic index, refined grain foods with lower glycemic index, whole-grain foods; 4) Reduce trans fats; 5) Schedule regular mealtimes, 3-4 hours apart; 6) Reduce high-carbohydrate snacks; 7) Reduce desserts and/or drinks high in starch and sugar. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
16454062|NCT03607799|Active Comparator|Control|"Control group participants will be provided with paper copies and website links to The Sensible Guide to a Healthy Pregnancy, which provides advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the SA community. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
16454063|NCT03607786|Active Comparator|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
16454064|NCT03607786|Active Comparator|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
16454065|NCT03607773|Active Comparator|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
16454066|NCT03607773|No Intervention|Control group|Standard of care.
16454067|NCT03607760||ECMO|severe respiratory failure with ECMO
16454068|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
16454069|NCT03607734|Other|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:
~50mg amoxicillin (10% total dose)
~250mg amoxicillin (50% total dose)
~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
16454070|NCT03607721|Experimental|DBS Patients Group|Body Motion Evaluation DARI
16454071|NCT03607721|Active Comparator|Control Group|Body Motion Evaluation DARI
16454072|NCT03607708|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
16454073|NCT03607708|Active Comparator|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
16454075|NCT03607682|Experimental|Prevention (TTF therapy, NovoTTF-200A device)|
16454076|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
16454077|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
16454078|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
16454079|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
16454080|NCT03607656|Experimental|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.
~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
16454112|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
16454113|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
16454114|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
16454081|NCT03607656|Active Comparator|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
16454082|NCT03607643|Placebo Comparator|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
16454083|NCT03607643|Experimental|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
16454084|NCT03607643|Placebo Comparator|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
16454085|NCT03607643|Experimental|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
16454086|NCT03607643|Placebo Comparator|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
16454087|NCT03607643|Experimental|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
16454088|NCT03607643|Placebo Comparator|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
16454089|NCT03607643|Experimental|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
16454090|NCT03607643|Placebo Comparator|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
16454091|NCT03607643|Experimental|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
16454092|NCT03607630|No Intervention|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
16454093|NCT03607630|Experimental|Imagery Rescripting|3 Sessions of Imagery Rescripting
16454094|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
16454095|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
16454096|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
16454097|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
16454098|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
16454099|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
16454100|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)
~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
16454101|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus
~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
16454102|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
16454103|NCT03607591|Active Comparator|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
16454104|NCT03607591|Placebo Comparator|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
16454105|NCT03607578|Other|Control Group - Minimal Intervention|Minimal intervention
16454106|NCT03607578|Experimental|Protection Routine 1|
16454107|NCT03607578|Experimental|Protection Routine 2|
16454108|NCT03607578|Experimental|Protection Routine 1+2|
16454109|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(good perfusion)
16454110|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(middle perfusion)
16454111|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(poor perfusion)
16454115|NCT03607539|Experimental|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
16454116|NCT03607539|Placebo Comparator|Sitilimab Placebo Comparator|placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
16454117|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
16454118|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
16454119|NCT03607513|Experimental|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.
16454120|NCT03607513|Experimental|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
16454121|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
16454122|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
16454123|NCT03607487|Experimental|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
16454124|NCT03607487|Experimental|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
16454125|NCT03607487|Experimental|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
16454126|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.
~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
16454127|NCT03607461|Experimental|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
16454128|NCT03607461|Active Comparator|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
16454129|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
16454130|NCT03607435|Experimental|Test Article Scanning|Spectroscopy for Analyte Quantification
16454131|NCT03607422|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
16454132|NCT03607422|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
16454133|NCT03607422|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
16454134|NCT03607422|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
16454135|NCT03607383|Experimental|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
16454136|NCT03607383|Active Comparator|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
16454137|NCT03607370|No Intervention|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
16454138|NCT03607370|Experimental|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
16454139|NCT03607357|Experimental|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
16454140|NCT03607357|Placebo Comparator|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
16454141|NCT03607331|Experimental|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
16454142|NCT03607331|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
16454178|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
16454143|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
16454144|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
16454145|NCT03607305|Active Comparator|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
16454146|NCT03607305|Experimental|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
16454147|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
16454148|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
16454149|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
16454150|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
16454151|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
16454152|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
16454153|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
16454154|NCT03607253|Other|Men|Healthy young men aged between 18-25 years
16454155|NCT03607253|Other|Women|Healthy young women aged between 18-25 years
16454156|NCT03607240|Experimental|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
16454157|NCT03607240|Active Comparator|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
16454158|NCT03607227|Active Comparator|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
16454159|NCT03607227|Placebo Comparator|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
16454160|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
16454161|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
16454162|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
16454163|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
16454164|NCT03607188|Experimental|ZG0418 200mg QD|ZG0418 200mg/day,oral
16454165|NCT03607188|Experimental|ZG0418 300mg QD|ZG0418 300mg/day,oral
16454166|NCT03607188|Experimental|ZG0418 400mg QD|ZG0418 400mg/day,oral
16454167|NCT03607188|Experimental|ZG0418 500mg QD|ZG0418 500mg/day,oral
16454168|NCT03607188|Experimental|ZG0418 600mg QD|ZG0418 600mg/day,oral
16454169|NCT03607175|Active Comparator|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
16454170|NCT03607175|Experimental|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
16454171|NCT03607162|No Intervention|Usual care|Local usual management of FWS (pragmatic approach)
16454172|NCT03607162|Experimental|DIAFEVER algorithm|New DIAFEVER sequential algorithm PCT rapid test-based will be applied
16454173|NCT03607149|Active Comparator|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
16454174|NCT03607149|Experimental|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
16454175|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
16454176|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
16454177|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
16454179|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
16454180|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
16454181|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
16454182|NCT03607110||ketamine|ketamine used
16454183|NCT03607110||fentanyl|fentanyl used
16454184|NCT03607097|Experimental|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
16454185|NCT03607097|No Intervention|Usual care (control group)|The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit
16454186|NCT03607084|Experimental|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
16454187|NCT03607084|No Intervention|Control|The control group receives regular school programming.
16454188|NCT03607071|Experimental|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
16454189|NCT03607058|Active Comparator|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 10 weeks washout period only exercise training will be applied for 8 weeks.
16454190|NCT03607058|Active Comparator|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 10 weeks washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
16454191|NCT03607045|Placebo Comparator|control group|bouquet technique
16454192|NCT03607045|Active Comparator|test group|headless screw
16454193|NCT03607032|Experimental|RespinPad and usual treatment|
16454194|NCT03607032|Active Comparator|only usual treatment|
16454195|NCT03607006|Experimental|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
16454196|NCT03607006|Active Comparator|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
16454197|NCT03606993|Experimental|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one ~ 200g iron ingot.
16454198|NCT03606993|No Intervention|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
16454199|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
16454200|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
16454201|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
16454202|NCT03606967|Experimental|Arm I (neoantigen vaccine, durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 for 2 cycles at the discretion of the treating physician.
~PART B: Patients receive personalized synthetic long peptide vaccine and poly-ICLC SC on days 1, 4, 8, 15, 22, 50, and 78 in the absence of disease progression or unacceptable toxicity. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16454231|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
16454320|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
16454203|NCT03606967|Active Comparator|Arm II (durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each remaining cycle.
~PART B: Patients receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16454204|NCT03606954|Active Comparator|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.
~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
16454205|NCT03606954|Active Comparator|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.
~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
16454206|NCT03606941|Experimental|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
16454207|NCT03606941|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
16454208|NCT03606928|Experimental|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
16454209|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
16454210|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
16454211|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
16454212|NCT03606902|Active Comparator|(Group f):|"Intervention:
~Procedure: Epidural catheter insertion
~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
16454213|NCT03606902|Active Comparator|(Group Lf):|"Intervention:
~Procedure:Epidural catheter insertion
~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
16454214|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
16454215|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
16454216|NCT03606876|Experimental|BAT1806 injection|BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
16454217|NCT03606876|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
16454218|NCT03606876|Active Comparator|Actemra(US-licensed)|Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min
16454219|NCT03606863|Experimental|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
16454220|NCT03606863|No Intervention|Standard fluid therapy|Standard fluid therap
16454221|NCT03606850|Experimental|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
16454222|NCT03606837|Experimental|PET/CT Imaging|
16454223|NCT03606824|Placebo Comparator|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
16454224|NCT03606824|Experimental|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
16454225|NCT03606811|Active Comparator|fluroscopic guided block|
16454226|NCT03606811|Experimental|double modality guided block|
16454227|NCT03606798|Experimental|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
16454228|NCT03606798|No Intervention|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
16454229|NCT03606785|Active Comparator|tranexamic acid group|
16454230|NCT03606785|Placebo Comparator|placebo group|
16454232|NCT03606759|Experimental|Traitment as usual adjusted on ATI information|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
16454233|NCT03606759|Active Comparator|Traitment as usual|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
16454234|NCT03606746|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
16454235|NCT03606733|Experimental|A custom made Suprachoroidal needle for macular diseases|A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
16454236|NCT03606720|Experimental|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
16454237|NCT03606720|Active Comparator|group(B) pelvic stabilization exercises only|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
16454238|NCT03606720|Active Comparator|group (C) low level laser therapy only|composed of 30 patients who low level laser therapy only For 12 sessions over six week's period by 2 sessions per week.
16454239|NCT03606707|Experimental|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
16454240|NCT03606707|No Intervention|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
16454241|NCT03606694|Experimental|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
16454242|NCT03606694|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
16454243|NCT03606681|Active Comparator|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
16454244|NCT03606681|Experimental|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
16454245|NCT03606681|Experimental|Theracal LC|Indirect pulp capping treatment with Theracal LC
16454246|NCT03606668|Experimental|Virtual Reality Therapy|eligible participants will receive a full session of VR therapy that may extend as long as an hour in length.
16454247|NCT03606655|Experimental|Kava|This is a single-arm pre- and post- Phase 0/1 study with one primary goal to explore the feasibility of recruitment of participants, adherence rate, acceptability of treatment and completion rate with 14 day dietary supplement kava treatment in head and neck cancer patients who continue to smoke. The other primary goal is to evaluate distribution of change in nicotine and NNK metabolism after 14 day kava treatment..
16454248|NCT03606642|Experimental|PCI with 30 day DAPT Therapy|Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose [if applicable] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
16454249|NCT03606629||Endoprosthesis implantation|Device implantation
16454250|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
16454251|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
16454252|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
16454253|NCT03606577|Experimental|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
16454254|NCT03606564||paediatric patients undergoing day care surgery|
16454255|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.
~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
16454256|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
16454257|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
16454258|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
16454259|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
16454290|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
16454263|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
16454264|NCT03606473|Experimental|Prenatal cocaine exposed subjects|[C-11]NPA PET at baseline and post d-amphetamine
16454265|NCT03606473|Experimental|Comparison subjects|[C-11]NPA PET at baseline and post d-amphetamine
16454266|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
16454267|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
16454268|NCT03606447|Experimental|Single IV administration of [14C]-Uproleselan|
16454269|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
16454270|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
16454271|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
16454272|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
16454273|NCT03606395|Experimental|Single ascending dose_healthy subjects|"NV-5138:
~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
16454274|NCT03606395|Experimental|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
16454275|NCT03606369|Experimental|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.
~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
16454276|NCT03606369|Active Comparator|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.
~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
16454277|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
16454278|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
16454279|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
16454280|NCT03606304|Experimental|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
16454281|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:
~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
16454282|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
16454283|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
16454284|NCT03606265|Experimental|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
16454285|NCT03606265|Active Comparator|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
16454286|NCT03606252|Other|pneumocystosis with favourable evolution|patients with a favourable pneumocystosis outcome
16454287|NCT03606252|Other|pneumocystosis with unfavourable outcome|patients with unfavourable pneumocystosis outcome
16454288|NCT03606252|Other|Pneumocystis colonization|subject colonized by Pneumocystis jirovecii
16454289|NCT03606239|Experimental|isotoxic hypofractionated group|"Hypofractionated radiation:
~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:
~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy.
~Chemotherapy:
~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.
~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
16454291|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
16454292|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
16454293|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
16454294|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
16454295|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
16454296|NCT03606174|Experimental|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454297|NCT03606174|Experimental|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454298|NCT03606174|Experimental|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454299|NCT03606174|Experimental|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454300|NCT03606174|Experimental|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454301|NCT03606174|Experimental|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454302|NCT03606174|Experimental|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454303|NCT03606174|Experimental|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
16454304|NCT03606174|Experimental|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
16454305|NCT03606161|Experimental|Supportive care (nrTMS)|Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
16454306|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.
~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
16454307|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.
~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
16454308|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
16454309|NCT03606135||The Control Group|Healthy subjects
16454310|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
16454311|NCT03606109|Active Comparator|TTO + IV TXA|
16454312|NCT03606109|No Intervention|TTO, no IV TXA|
16454313|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
16454314|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
16454315|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
16454316|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
16454317|NCT03606070|Other|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.
~Patients will realize:
~a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)
~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
16454318|NCT03606057|Experimental|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
16454319|NCT03606057|Active Comparator|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
16454321|NCT03606018|Experimental|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
16454322|NCT03606018|Active Comparator|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
16454323|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea [Modified Medical Research Council dyspnea scale (MMRC)], submaximal exercise capacity [6-minute walk test (6-MWT)], physical activity level [metabolic holter], quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] and pulmonary functions [spirometry] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
16454324|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
16454325|NCT03605992|Experimental|Home-based Rehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
16454326|NCT03605992|Active Comparator|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
16454327|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
16454328|NCT03605940|Experimental|Experimental group|corticosteroids + ECP
16454329|NCT03605940|Active Comparator|Contrôl group|corticosteroids alone
16454330|NCT03605927|Experimental|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.
~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
16454331|NCT03605914|Experimental|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
16454332|NCT03605914|Active Comparator|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
16454333|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
16454334|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 4 breaths/min, induction of general anesthesia and intubation will proceed.
16454335|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
16454336|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
16454337|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
16454338|NCT03605875|Experimental|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
16454339|NCT03605875|Active Comparator|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
16454340|NCT03605862|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
16454341|NCT03605862|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
16454342|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
16454346|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
16454347|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.
~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
16454348|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
16454349|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
16454350|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
16454351|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:
~Disease onset as metastatic or unresectable disease.
~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
16454352|NCT03605758|Active Comparator|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
16454353|NCT03605758|Active Comparator|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
16454354|NCT03605745|Experimental|Treatment|Prostatic Vapor Ablation with Rezum
16454355|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
16454356|NCT03605732|Active Comparator|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
16454357|NCT03605719|Experimental|Arm 1|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16454358|NCT03605719|Experimental|Arm 2|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16454359|NCT03605719|Experimental|Arm 3 (expansion)|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16454360|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
16454361|NCT03605706|Experimental|CONTROL|SHR-1210+Placebo
16454362|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
16454363|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
16454364|NCT03605680|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
16454365|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
16454366|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
16454367|NCT03605680|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
16454370|NCT03605654|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
16454371|NCT03605654|Active Comparator|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
16454372|NCT03605654|Experimental|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
16454373|NCT03605641|Experimental|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
16454374|NCT03605641|Active Comparator|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
16454375|NCT03605641|Active Comparator|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
16454376|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
16454377|NCT03605615|No Intervention|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
16454378|NCT03605615|Experimental|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
16454379|NCT03605589|Experimental|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).
~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)
~Cycle 1 (Days 1-7):
~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day
~Cycle 1(Days 8-28):
~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day
~Cycle 2 (Days 1-28):
~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day
~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
16454380|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16454381|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16454382|NCT03605563|Experimental|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16454383|NCT03605563|Active Comparator|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
16454384|NCT03605550|Experimental|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with radiotherapy. One cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 25 cycles.
16454427|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
16454428|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
16454385|NCT03605537|Experimental|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).
~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
16454386|NCT03605537|No Intervention|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).
~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
16454387|NCT03605524|Other|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.
~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
16454388|NCT03605485|Experimental|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
16454389|NCT03605472|Experimental|Patients|
16454390|NCT03605459|Experimental|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
16454391|NCT03605446|Experimental|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
16454392|NCT03605446|Experimental|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
16454393|NCT03605446|Experimental|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
16454394|NCT03605446|Experimental|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
16454395|NCT03605446|Placebo Comparator|Wheat biscuit|
16454396|NCT03605433|Experimental|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
16454397|NCT03605433|Experimental|Oral Anticoagulation|Rivaroxaban 20 mg once daily
16454398|NCT03605433|Active Comparator|Antiplatet|Aspirin 100 mg once daily
16454399|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
16454400|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
16454401|NCT03605407|Experimental|Experimental group|Patient receiving one visit prior to hospital admission
16454402|NCT03605407|No Intervention|Control group|Patient without receiving one visit prior to hospital admission
16454403|NCT03605368|Active Comparator|Video Modeling|
16454404|NCT03605368|Experimental|Virtual Reality Intervention|
16454405|NCT03605342|Active Comparator|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
16454406|NCT03605342|Active Comparator|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
16454407|NCT03605329|Other|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
16454408|NCT03605303|Active Comparator|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
16454409|NCT03605303|Experimental|TEST- etafilcon A novel molding|Investigational Contact Lens
16454410|NCT03605290|Active Comparator|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
16454411|NCT03605290|Experimental|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
16454412|NCT03605277|Experimental|Normal renal function|healthy volunteers with normal renal function
16454413|NCT03605277|Experimental|Severe renal impairment|subjects with severe renal impairment
16454414|NCT03605277|Experimental|Moderate renal impairment|subject with moderate renal impairment
16454415|NCT03605277|Experimental|Mild renal impairment|subjects with mild renal impairment
16454418|NCT03605251|Experimental|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
16454419|NCT03605251|Experimental|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
16454420|NCT03605251|Placebo Comparator|Placebo group|Placebo and Methotrexate as specified
16454421|NCT03605238|Experimental|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
16454422|NCT03605225|Experimental|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
16454423|NCT03605225|Active Comparator|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
16454424|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
16454425|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
16454426|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
16454430|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).
~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.
~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.
~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
16454431|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.
~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.
~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.
~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
16454432|NCT03605173|Experimental|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
16454433|NCT03605173|Experimental|total vitamin d|Total vitamin d is measured routinely from blood serum
16454434|NCT03605160|Active Comparator|traditional group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents. All operations are videotaped during the whole operation. The total polish time is recorded as the time of all polish procedures.
16454435|NCT03605160|Experimental|fluid-jet group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.
16454436|NCT03605147|Experimental|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
16454437|NCT03605147|Active Comparator|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
16454438|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
16454439|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:
~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
16454440|NCT03605108|Placebo Comparator|Placebo|Rice flour only
16454441|NCT03605095|Active Comparator|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
16454442|NCT03605095|Active Comparator|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
16454443|NCT03605082|Experimental|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
16454444|NCT03605082|Placebo Comparator|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
16454445|NCT03605069|Other|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.
~In the first arm; randomization of the first selected TWA to active treatment or placebo"
16454446|NCT03605069|Other|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
16454447|NCT03605056|Experimental|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
16454448|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
16454449|NCT03605030|Active Comparator|Novel Lead Based Armboard|
16454450|NCT03605030|Placebo Comparator|Standard Armboard|
16454453|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
16454454|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
16454459|NCT03604978|Experimental|Cohort A (nivolumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
16454460|NCT03604978|Experimental|Cohort B (nivolumab, ipilimumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
16454461|NCT03604965|Experimental|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
16454462|NCT03604965|Active Comparator|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
16454463|NCT03604926||chemo-naive patients|
16454464|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
16454465|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
16454466|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
16454467|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
16454468|NCT03604874|Active Comparator|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
16454469|NCT03604874|Experimental|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
16454470|NCT03604848|Experimental|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
16454471|NCT03604848|Experimental|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
16454472|NCT03604848|Experimental|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
16454473|NCT03604848|Active Comparator|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
16454474|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
16454475|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
16454476|NCT03604822|Experimental|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
16454477|NCT03604809|Experimental|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
16454478|NCT03604809|No Intervention|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
16454479|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
16454480|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
16454481|NCT03604783|Experimental|Single Arm TP-1287|TP-1287 by oral administration
16454482|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
16454483|NCT03604757|Experimental|PET/CT Imaging|
16454484|NCT03604744|Experimental|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16454485|NCT03604744|Placebo Comparator|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16454486|NCT03604744|Placebo Comparator|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16454487|NCT03604744|Placebo Comparator|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16454488|NCT03604744|Placebo Comparator|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16454489|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
16454490|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
16454491|NCT03604705|Experimental|APX001 Treatment|
16454492|NCT03604692|Experimental|Cohorts of escalating dose levels of SNDX-6352|"Escalating dose levels of SNDX-6352 to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).
~IV infusion; SNDX-6352 at a dose of 0.15 mg/kg to 3 mg/kg."
16454493|NCT03604692|Experimental|Phase 2 Dose Expansion|"Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size.
~IV infusion; SNDX-6352 at a dose of 1 mg/kg."
16454494|NCT03604679|Experimental|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.
~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
16454675|NCT03603327|Other|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
16454495|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:
~Be present at the announcement consultation
~Give information on the outpatient circuit
~Offer assistance for patients over 75 years
~Complete onco-geriatric orientation questionnaires
~Take care of patients on the ambulatory circuit"
16454496|NCT03604666||Health care process|Health care process
16454497|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
16454498|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
16454499|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
16454500|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
16454501|NCT03604640|No Intervention|standard care|
16454502|NCT03604640|Experimental|Physical and educational program|
16454503|NCT03604627|Other|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg / m²)
16454504|NCT03604614|Experimental|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
16454505|NCT03604614|Sham Comparator|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
16454506|NCT03604588|Other|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.
~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
16454507|NCT03604575|Experimental|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
16454508|NCT03604575|Active Comparator|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
16454509|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
16454510|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
16454511|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
16454512|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
16454513|NCT03604510|Experimental|Electroencephalographic recordings|Electroencephalographic recordings
16454514|NCT03604497|Experimental|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
16454515|NCT03604497|No Intervention|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
16454516|NCT03604497|Other|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
16454517|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
16454518|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
16454519|NCT03604471|Other|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
16454520|NCT03604445|Experimental|BI 905677|Schedule A: 3 week cycle (treatment every 3 weeks). Schedule B: 4 week cycle (treatment every 2 weeks). Recruitment into Schedule B will start after the MTD of Schedule A is reached.
16454521|NCT03604419|Experimental|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
16454522|NCT03604419|Experimental|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
16454523|NCT03604419|Experimental|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
16454524|NCT03604419|Placebo Comparator|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
16454525|NCT03604406|Experimental|Varicella Zoster Vaccine (Zostavax)|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
16454526|NCT03604406|Placebo Comparator|Placebo Injection (Zostavax Comparator)|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
16454527|NCT03604406|Experimental|Varicella Zoster Vaccine (Shingrix)|Non-live zoster vaccine injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
16454528|NCT03604406|Placebo Comparator|Placebo Injection (Shingrix Comparator)|Saline injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
16454529|NCT03604393|Experimental|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
16454530|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
16454531|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
16454532|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
16454533|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
16454534|NCT03604380|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
16454535|NCT03604380|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
16454536|NCT03604367||GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
16454537|NCT03604354|Active Comparator|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
16454538|NCT03604354|Experimental|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
16454539|NCT03604341|Experimental|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
16454540|NCT03604341|Placebo Comparator|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
16454541|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
16454542|NCT03604315|Experimental|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.
16454543|NCT03604302|Experimental|Functional Magnetic Resonance Imaging (fMRI)|The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
16454544|NCT03604289|Experimental|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
16454545|NCT03604289|Placebo Comparator|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
16454546|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
16454547|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
16454548|NCT03604237|Experimental|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
16454549|NCT03604237|No Intervention|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
16454550|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
16454551|NCT03604198|Experimental|relacorilant (CORT125134)|
16454552|NCT03604185|Experimental|Choir Singing Group|Choir participants will take part in weekly two-hour group choral sessions over the course of fourteen weeks, during which time they will receive pitch training and vocal direction. In addition to the weekly group choir sessions, participants will be offered optional individual online musical and vocal training exercises (up to one hour weekly).
16454553|NCT03604185|Active Comparator|Music Appreciation Group|Participants assigned to the music appreciation class will take part in a fourteen week course which will emphasize analytic listening to musical excerpts, which will match the choir class in terms of duration, homework demands, and instructor - both classes will be taught by the same person.
16454554|NCT03604185|No Intervention|Do-Nothing Control Group|The do-nothing control group will not receive any active training.
16454555|NCT03604172|Experimental|Cognitive behavioral therapy|16-week cognitive behavioral therapy intervention for binge eating disorder
16454556|NCT03604172|Other|Waitlist control|16-weeks on waitlist then participants will be provided with 16-weeks of cognitive behavioral therapy
16454557|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
16454596|NCT03603834|Experimental|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:
~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection
~each 14 day cycle, for 6 cycles"
16454597|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
16454558|NCT03604159|Active Comparator|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
16454559|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
16454560|NCT03604146||Intervention group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
16454561|NCT03604133||Patients receiving ICD devices|
16454562|NCT03604120|Experimental|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
16454563|NCT03604120|Active Comparator|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
16454564|NCT03604094||Group I|0-1 month old newborns
16454565|NCT03604094||Group II|1 month-2 year-old pediatric patients
16454566|NCT03604081|Experimental|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
16454567|NCT03604081|Placebo Comparator|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
16454568|NCT03604068|Active Comparator|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
16454569|NCT03604068|Sham Comparator|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
16454570|NCT03604055|Other|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
16454571|NCT03604042|Active Comparator|Weight-driven protein fortification|Individualized protein fortification based on weight gain
16454572|NCT03604042|Experimental|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
16454573|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
16454574|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
16454575|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
16454576|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
16454577|NCT03604003|Experimental|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
16454578|NCT03604003|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
16454579|NCT03603990|Experimental|Vitrectomy|"Patient with standard pars plana vitrectomy
~During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.
~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
16454580|NCT03603990|Active Comparator|Usual care|"Patients with usual care according to the investigator choice :
~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.
~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
16454581|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
16454582|NCT03603964|Experimental|Guadecitabine|Subjects will receive guadecitabine treatment at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol. Treatment may continue as long as the subject continues to benefit based on investigator judgment.
16454583|NCT03603951|Experimental|SHR2554 treated group|treated with escalated doses of EZH2 inhibitor SHR2554 respectively
16454584|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
16454585|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
16454586|NCT03603925||PET/MR + PET/CT|The interventions for participating in this research are centered around steps needed to safely and ethically collect a research PET/MR scan following a standard-of-care PET/CT scan. The patient will be imaged in at least one of several standard anatomic areas: head/neck, thorax, abdomen, pelvis or whole-body.
16454587|NCT03603912|No Intervention|Control|Written educational literature on healthy eating and exercise guideline
16454588|NCT03603912|Experimental|Metformin|Metformin ER up to 750 mg twice daily
16454589|NCT03603912|Experimental|Lifestyle/Risk Factor Modification|Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
16454590|NCT03603912|Experimental|Metformin + LRFM|Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
16454591|NCT03603912|No Intervention|No Atrial Fibrillation|Written educational literature on healthy eating and exercise guideline
16454592|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
16454593|NCT03603886|Experimental|Telemedicine Pain Management|
16454594|NCT03603886|Other|Waitlist Control|Treatment as usual comparator
16454595|NCT03603873||Patients|
16454598|NCT03603808|Experimental|Treatment (VGX-3100, electroporation)|Patients receive HPV DNA plasmids therapeutic vaccine VGX-3100 IM and then undergo electroporation over 10 seconds for 4 doses in week 0, 4, 12, and 24 in the absence of disease progression or unacceptable toxicity.
16454599|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.
~Chemotherapy administration would be performed among standard practice:
~Daunorubicin: 60 mg/m² D1 to D3
~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
~Lomustine (CCNU): 200 mg/m² per os, at D1.
~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.
~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
16454600|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)
~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.
~Chemotherapy administration would be performed among standard practice:
~Daunorubicin: 60 mg/m² D1 to D3
~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
~Lomustine (CCNU): 200 mg/m² per os, at D1."
16454601|NCT03603782|Experimental|1|
16454602|NCT03603782|Experimental|2|
16454603|NCT03603782|Experimental|3|
16454604|NCT03603782|Experimental|4|
16454605|NCT03603769|Experimental|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)
~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.
~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
16454606|NCT03603769|Placebo Comparator|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.
~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.
~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
16454607|NCT03603756|Experimental|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
16454608|NCT03603756|Experimental|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
16454609|NCT03603743|Experimental|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
16454610|NCT03603743|Active Comparator|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
16454611|NCT03603730|Experimental|taVNS|Active or inactive taVNS
16454612|NCT03603717|Experimental|CBT-I|Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
16454613|NCT03603717|Active Comparator|SH|Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
16454614|NCT03603704|Experimental|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.
~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
16454615|NCT03603704|Active Comparator|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
16454616|NCT03603691|Active Comparator|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
16454617|NCT03603691|Active Comparator|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
16454618|NCT03603691|Active Comparator|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
16454619|NCT03603678|Experimental|Part A single dose BAY2253651|Single dose BAY2253651
16454620|NCT03603678|Placebo Comparator|Part A single dose Placebo|Single dose matching placebo
16454621|NCT03603678|Experimental|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
16454622|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
16454623|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
16454624|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
16454625|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
16454670|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
16454626|NCT03603639|Experimental|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
16454627|NCT03603639|Experimental|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
16454628|NCT03603639|Experimental|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
16454629|NCT03603639|Experimental|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
16454630|NCT03603639|Experimental|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
16454631|NCT03603639|Experimental|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
16454632|NCT03603626|Experimental|Preemptive pregabalin|
16454633|NCT03603626|Placebo Comparator|Placebo|
16454634|NCT03603613|Experimental|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
16454635|NCT03603613|Experimental|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
16454636|NCT03603613|No Intervention|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
16454637|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
16454638|NCT03603600|Sham Comparator|enVista MX60E|enVista MX60E monofocal IOL
16454639|NCT03603587|Experimental|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.
~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
16454640|NCT03603574|Experimental|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
16454641|NCT03603574|Experimental|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
16454642|NCT03603561|Active Comparator|Active cTBS|
16454643|NCT03603561|Sham Comparator|Sham cTBS|
16454644|NCT03603548|Active Comparator|Advagraf|
16454645|NCT03603548|Experimental|Envarsus|
16454646|NCT03603522|Experimental|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
16454647|NCT03603522|Placebo Comparator|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
16454648|NCT03603509|Active Comparator|Fluad vaccine|Subjects receive a single dose of the Fluad influenza vaccine.
16454649|NCT03603509|Active Comparator|Fluzone vaccine|Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.
16454671|NCT03603353|Experimental|Intervention group|
16454672|NCT03603353|Active Comparator|Control group|
16454673|NCT03603340|Experimental|Intervention group|
16454650|NCT03603496|Experimental|Personalized Tobacco Care Management|PTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call +/- text messaging +/- email. At each contact the patient is offered a return call from the hospital-based tobacco coach forcounseling, medication advice, and coordination of care with the patient's outpatient health care team.
16454651|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the quitline will be included in the patient's medical chart.
16454652|NCT03603483|Active Comparator|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
16454653|NCT03603483|Active Comparator|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
16454654|NCT03603470|Other|Patients with previous prothesis instability|
16454655|NCT03603470|Other|Patients without prothesis instability|
16454656|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.
~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
16454657|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.
~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
16454658|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.
~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
16454659|NCT03603431|Experimental|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
16454660|NCT03603431|Placebo Comparator|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
16454661|NCT03603431|Experimental|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
16454662|NCT03603431|Placebo Comparator|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
16454663|NCT03603418|Experimental|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
16454664|NCT03603418|Placebo Comparator|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
16454665|NCT03603405|Experimental|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)
~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol.
~Patient can receive second treatment of HSV-tk after 6 months."
16454666|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
16454667|NCT03603379|Experimental|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
16454668|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.
~Subgroups:
~Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD
~Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
16454669|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.
~Subgroups:
~Patients eligible for and using low-dose aspirin for secondary prevention of CVD
~Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
16454676|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
16454677|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
16454678|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
16454679|NCT03603288|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
16454680|NCT03603275||Patient/caregiver of Kovaltry or Jivi|Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
16454681|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
16454682|NCT03603262|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
16454683|NCT03603249|Experimental|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
16454684|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
16454685|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
16454686|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
16454687|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.
~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
16454688|NCT03603197|Experimental|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
16454689|NCT03603197|Placebo Comparator|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
16454690|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
16454691|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
16454692|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
16454693|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
16454694|NCT03603145|Experimental|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
16454695|NCT03603145|No Intervention|Standard Insertion|Insertion at 2-4 weeks post medical abortion
16454696|NCT03603132|Active Comparator|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
16454697|NCT03603132|Active Comparator|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
16454698|NCT03603132|Active Comparator|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
16454699|NCT03603119|Active Comparator|Group A|Dexamethasone-ondansetron
16454700|NCT03603119|Experimental|Group B|Midazolam
16454701|NCT03603106|Experimental|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
16454702|NCT03603106|Experimental|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
16454703|NCT03603080|Experimental|Medication arm|
16454704|NCT03603080|No Intervention|No medication arm|
16454705|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
16454706|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
16454707|NCT03603054|Active Comparator|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
16454774|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16454775|NCT03602573||pre-menopause|
16454708|NCT03603054|Experimental|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
16454709|NCT03603041|No Intervention|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
16454710|NCT03603041|Experimental|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
16454711|NCT03603041|Experimental|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
16454712|NCT03603041|Experimental|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
16454713|NCT03603041|Placebo Comparator|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
16454714|NCT03603028|Experimental|Exergaming|
16454715|NCT03603015|Other|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
16454716|NCT03603002|Experimental|Stage I NSCLC with SABR Therapy|Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
16454717|NCT03602976|No Intervention|Observation|
16454718|NCT03602976|Experimental|UDCA at Month 6|
16454719|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
16454720|NCT03602950|No Intervention|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
16454721|NCT03602950|Active Comparator|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
16454722|NCT03602937|Experimental|Renastep|All participants to incorporate Renastep into their usual dietary regime.
16454723|NCT03602911|Other|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
16454724|NCT03602898|Experimental|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
16454725|NCT03602898|Experimental|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
16454726|NCT03602898|Experimental|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
16454727|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
16454728|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
16454729|NCT03602872|Experimental|Group 1|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
16454730|NCT03602872|Experimental|Group 2|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
16454731|NCT03602872|Experimental|Group 3|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
16454732|NCT03602859|Placebo Comparator|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+bevacizumab) in cycle 1 followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab along with niraparib placebo and dostarlimab placebo.
16454733|NCT03602859|Active Comparator|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab with niraparib and dostarlimab placebo.
16454734|NCT03602859|Experimental|Participants receiving SOC+dostarlimab|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of bevacizumab with niraparib and dostarlimab.
16454735|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
16454736|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
16454737|NCT03602833|Experimental|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
16454738|NCT03602807|Experimental|Active treatment|
16454776|NCT03602573||post-menopause|
16454777|NCT03602560|Experimental|Seladelpar 5-10 mg|
16454739|NCT03602794|Active Comparator|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%
~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
16454740|NCT03602794|Placebo Comparator|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
16454741|NCT03602781|Placebo Comparator|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:
~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day
~Long Term Open Label Extension Period:
~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
16454742|NCT03602781|Active Comparator|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:
~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day
~Long Term Open Label Extension Period:
~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
16454743|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
16454744|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
16454745|NCT03602768|Placebo Comparator|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
16454746|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
16454747|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
16454748|NCT03602742|Other|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
16454749|NCT03602729|No Intervention|Group 1|No study related education given
16454750|NCT03602729|Experimental|Group 2|Written BF education
16454751|NCT03602729|Experimental|Group 3|Verbal BF education
16454752|NCT03602729|Experimental|Group 4|Video BF education
16454753|NCT03602716|Experimental|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
16454754|NCT03602716|Sham Comparator|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
16454755|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
16454756|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
16454757|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
16454758|NCT03602703||Control group|Healthy subjects
16454759|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:
~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
16454760|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
16454761|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
16454762|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
16454763|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
16454764|NCT03602638|Experimental|Sitagliptin|
16454765|NCT03602638|Active Comparator|CONTROL|Acarbose
16454766|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
16454767|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
16454768|NCT03602612|Experimental|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
16454769|NCT03602612|Experimental|2/Conditioning chemotherapy plus CAR T-cells expansion phase|6.0x10^6 dose (maximum feasible dose) of CAR T Cells + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
16454778|NCT03602560|Experimental|Seladelpar 10 mg|
16454779|NCT03602560|Placebo Comparator|Placebo|
16454780|NCT03602547|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
16454781|NCT03602534||cases with variable acne severity scores|"group will include 50 females
~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)
~Assessment of body mass index (BMI)
~blood serum samples will be collected from all patients to do thyroid function test"
16454782|NCT03602534||healthy controls|"group will include 29 females
~Assessment of body mass index (BMI)
~blood serum samples will be collected from all healthy controls to do thyroid function test"
16454783|NCT03602521|Experimental|BPD|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
16454784|NCT03602521|Active Comparator|HC|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
16454785|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
16454786|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
16454787|NCT03602495|Experimental|Donafenib|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
16454788|NCT03602495|Placebo Comparator|Placebo|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
16454789|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
16454790|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
16454791|NCT03602469|Experimental|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
16454792|NCT03602469|Active Comparator|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
16454793|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
16454794|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
16454795|NCT03602443|Experimental|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
16454796|NCT03602443|Other|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
16454797|NCT03602430|Experimental|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
16454798|NCT03602430|Placebo Comparator|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
16454799|NCT03602417|Experimental|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
16454800|NCT03602417|Active Comparator|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
16454801|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
16454802|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
16454803|NCT03602404||Marrakesh: School aged children|Generally healthy 9 to 12 years old children
16454804|NCT03602404||Marrakesh: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
16454805|NCT03602391|Experimental|SCP Plus|
16454806|NCT03602391|No Intervention|Services as usual|
16454807|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
16454808|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
16454809|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
16454810|NCT03602365|Experimental|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
16454811|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
16454812|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
16454864|NCT03602001|Experimental|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
16454865|NCT03602001|Active Comparator|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
16454813|NCT03602326|Experimental|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
16454814|NCT03602326|Active Comparator|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
16454815|NCT03602313|Active Comparator|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
16454816|NCT03602313|Experimental|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
16454817|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
16454818|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
16454819|NCT03602287|Active Comparator|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
16454820|NCT03602287|Placebo Comparator|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
16454821|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
16454822|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
16454823|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
16454824|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
16454825|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
16454826|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
16454827|NCT03602248|Experimental|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:
~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
16454828|NCT03602248|Experimental|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
16454829|NCT03602248|No Intervention|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
16454830|NCT03602235|Experimental|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.
~HDAA + Melphalan:
~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.
~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
16454831|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
16454832|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
16454833|NCT03602209|Experimental|4 weeks of treatment|
16454834|NCT03602209|Active Comparator|6 weeks of treatment|
16454835|NCT03602196|Experimental|pregnant women|"pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)
~For the ancillary study: non-pregnant nulliparous women"
16454836|NCT03602183|Experimental|Normal airway scenario|intubation in normal airway scenario
16454837|NCT03602183|Experimental|Tongue edema scenario|intubation in the tongue edema scenario. Tongue edema was obtain using simulator indicators
16454838|NCT03602183|Experimental|Spinal immobilization with normal airway scenario|intubation in spinal immobilization with normal airway scenario
16454839|NCT03602183|Experimental|Spinal immobilization with tongue edema scenario|endotracheal intubation with immobilized cervical spine and tongue edema scenario
16454840|NCT03602170|Experimental|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
16454841|NCT03602170|Active Comparator|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
16454866|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
16454867|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
16455069|NCT03600454|Experimental|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
16454842|NCT03602157|Experimental|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 5 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
16454843|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
16454844|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
16454845|NCT03602131|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
16454846|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
16454847|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
16454848|NCT03602105|Active Comparator|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
16454849|NCT03602105|No Intervention|Control group|Care as usual
16454850|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
16454851|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
16454852|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
16454853|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
16454854|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
16454855|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
16454856|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
16454857|NCT03602053|Experimental|ROTAVAC 5D|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
16454858|NCT03602053|Experimental|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
16454859|NCT03602053|Active Comparator|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
16454860|NCT03602040|Experimental|PISICC group|Psychoeducational intervention
16454861|NCT03602027|Experimental|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
16454862|NCT03602014|Experimental|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
16454863|NCT03602014|Placebo Comparator|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
16455102|NCT03600220|Experimental|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
16454868|NCT03601975|Experimental|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
16454869|NCT03601975|Placebo Comparator|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
16454870|NCT03601962|Experimental|Aqualief® tablets|oral mucoadesive tablets
16454871|NCT03601962|Placebo Comparator|Placebo tablets|oral mucoadesive tablets
16454872|NCT03601949|Experimental|SInergy Cooled Radiofrequency|Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management
16454873|NCT03601949|Active Comparator|Medical Management|Standard Medical Management
16454874|NCT03601936|Other|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
16454875|NCT03601923|Experimental|Niraparib|"Niraparib will be administered orally once daily
~Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment"
16454876|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T
~Period 2: CKD-380 10mg Tab. 1T"
16454877|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T
~Period 2: D308 10mg Tab. 1T"
16454878|NCT03601897|Experimental|Part 1 - Completed|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
16454879|NCT03601897|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel
~Triple-negative and Stage IV inflammatory breast cancer
~Ovarian cancer
~Endometrial cancer
~Gynecological Carcinosarcoma"
16454880|NCT03601884|Experimental|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.
~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.
~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.
~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
16454881|NCT03601884|Other|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.
~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
16454882|NCT03601871|Active Comparator|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
16454883|NCT03601871|Experimental|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
16454884|NCT03601845|Other|MRE-IA (no stimuli)|Additional sequencing only
16454885|NCT03601845|Active Comparator|MRE-IA with stimuli|Visual stimulation while using additional sequencing
16454886|NCT03601832|Experimental|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
16454887|NCT03601819|Experimental|Pacritinib|200 mg twice daily (with possible dose reduction to 100 mg twice daily)
16454888|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16454889|NCT03601793|Experimental|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
16454890|NCT03601793|Active Comparator|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
16454891|NCT03601780|Active Comparator|Local wound infiltration|local wound infiltration plus usual care
16454892|NCT03601780|Placebo Comparator|Control|usual care only
16454893|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
16454894|NCT03601741|Active Comparator|Antimicrobial Stethoscope Diaphragm Covers|
16454895|NCT03601741|Active Comparator|Uncovered Stethoscopes|
16454896|NCT03601728|Experimental|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
16454897|NCT03601728|No Intervention|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
16454898|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
16454899|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
16454900|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
16454901|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
16454902|NCT03601676|Active Comparator|Intervention|
16454903|NCT03601676|No Intervention|Control|
16454967|NCT03601104|Experimental|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
16454904|NCT03601663|Experimental|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
16454905|NCT03601663|Active Comparator|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
16454906|NCT03601663|Active Comparator|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
16454907|NCT03601650|Experimental|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
16454908|NCT03601650|Active Comparator|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
16454909|NCT03601650|No Intervention|No strategy control|Participants will simply complete the measures
16454910|NCT03601637|Experimental|Part A Cohort 1 [aged 18 to <24 months]|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
16454911|NCT03601637|Experimental|Part A Cohort 2 [12 to <18months]|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
16454912|NCT03601637|Experimental|Part B|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
16454913|NCT03601624|Experimental|Experimental|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle
~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.
~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
16454914|NCT03601611|Experimental|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
16454915|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
16454916|NCT03601585|Experimental|Rolly Brush|Chew for 1 minute
16454917|NCT03601585|Experimental|Chewing gum|Chew for 1 minute
16454918|NCT03601585|Experimental|Apple|Chew for 1 minute
16454919|NCT03601585|Active Comparator|Brush|brush for 1 minute
16454920|NCT03601559|Active Comparator|Lactobacillus paracasei Lpc-37|Probiotic
16454921|NCT03601559|Placebo Comparator|Placebo|Inert placebo
16454922|NCT03601546||Patients with HCV infection|
16454923|NCT03601533|Other|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
16454924|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
16454925|NCT03601494|Active Comparator|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
16454926|NCT03601494|Placebo Comparator|Control|medical treatment only
16454927|NCT03601455|Experimental|Regimen A (radiation therapy and durvalumab)|Participants receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo EBRT for 5 fractions beginning on day 8 of course 1.
16454928|NCT03601455|Experimental|Regimen B (radiation therapy, durvalumab, tremelimumab)|Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1.
16454929|NCT03601429|Experimental|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
16454930|NCT03601429|Placebo Comparator|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
16454931|NCT03601416|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.
16454932|NCT03601416|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.
16454933|NCT03601403|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
16454934|NCT03601403|Experimental|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
16454935|NCT03601390||PET/CT and EBV DNA|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT protocol 12 weeks after the end of IMRT (primary endpoint).Plasma EBV DNA test will be performed 4, 12, 24 weeks after the end of IMRT. In patients with negative PET/CT results, 2 follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA test in the frist year. All patients will undergo annual PET/CT or traditional follow-up examination and plasma EBV DNA test 1 year after completing chemoradiation unless recurrent/residual disease is histopathologically-confirmed.
16454968|NCT03601104|Experimental|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
16454936|NCT03601377|Experimental|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (< or >) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.
~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
16454937|NCT03601377|Experimental|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.
~Experiment 2: received 4 times (2 times for 2 weeks)"
16454938|NCT03601377|Placebo Comparator|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.
~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
16454939|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
16454940|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),
~FIO2 50%, Flow: 2L / min,
~Frequency; 10-12 applied group."
16454941|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,
~Tidal Voltage 3-4ml / kg (TV),
~FIO2 50%, Flow: 2L / min,
~Frequency; 10-12 applied group."
16454942|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
16454943|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
16454944|NCT03601338|Active Comparator|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery
~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
16454945|NCT03601338|Placebo Comparator|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
16454946|NCT03601312|Active Comparator|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
16454947|NCT03601312|Experimental|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
16454948|NCT03601299|Experimental|Traditional food arm|Traditional food-focused menu
16454949|NCT03601299|No Intervention|Non-intervention arm|Standard RurAL CAP menu
16454950|NCT03601286|Experimental|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
16454951|NCT03601260|Other|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
16454952|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
16454953|NCT03601234|Experimental|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
16454954|NCT03601234|Experimental|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
16454955|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
16454956|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
16454957|NCT03601169|Experimental|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: ~22mg/kg LBM/day) for 6 weeks
16454958|NCT03601169|Experimental|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: ~33mg/kg LBM/day) for 6 weeks
16454959|NCT03601169|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 6 weeks
16454960|NCT03601156|Experimental|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
16454961|NCT03601156|Active Comparator|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
16454962|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
16454963|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
16454964|NCT03601117|Experimental|Dorsolateral Prefrontal Cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC), for 10 sessions per day for up to 5 days.
16454965|NCT03601117|Experimental|Anterior Cingulate Cortex|The accelerated theta burst stimulation protocol will be applied to the left anterior cingulate cortex (ACC), for 10 sessions per day for up to 5 days.
16454966|NCT03601104|Active Comparator|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
16454969|NCT03601104|Active Comparator|LIET (n= 15)|Low intensity eccentric training: A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
16454970|NCT03601091|Active Comparator|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
16454971|NCT03601091|Active Comparator|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
16454972|NCT03601078|Experimental|bb2121 in relapsed and refractory multiple myeloma patients|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
16454973|NCT03601065||Routine colonoscopy Cohort|
16454974|NCT03601052|Experimental|Remlarsen - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
16454975|NCT03601052|Placebo Comparator|Placebo - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
16454976|NCT03601039|Experimental|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
16454977|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
16454978|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
16454979|NCT03601000|Experimental|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
16454980|NCT03601000|Placebo Comparator|Placebo|Placebo given three times every day for 16 weeks.
16454981|NCT03600987|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
16454982|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
16454983|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
16454984|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
16454985|NCT03600974||Acid-A(-)|Subjects with DeMeester scores<14.72
16454986|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number > 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
16454987|NCT03600974||impedance-I（-）|Subjects with total reflux number < 80 in 24h pH-impedance monitoring.
16454988|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
16454989|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
16454990|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
16454991|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
16454992|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
16454993|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
16454994|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
16454995|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
16454996|NCT03600935|Experimental|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
16454997|NCT03600922|Experimental|Intervention group|
16454998|NCT03600909|Experimental|Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
16454999|NCT03600909|Experimental|Intermediate risk patients|Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
16455000|NCT03600909|Experimental|High risk patients|Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
16455065|NCT03600480|Experimental|NNC0174-0833+Semaglutide|Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
16455066|NCT03600480|Active Comparator|Placebo (NNC0174-0833)+Semaglutide|Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
16455067|NCT03600467|Experimental|Adrogen Postive Solid Tumours|
16455001|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.
~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
16455002|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
16455009|NCT03600870|Experimental|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
16455010|NCT03600857|Experimental|Home administration|Home administration of 0.8 mg misoprostol pv
16455011|NCT03600857|No Intervention|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
16455012|NCT03600844|Experimental|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
16455013|NCT03600844|Active Comparator|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
16455014|NCT03600831|Experimental|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
16455015|NCT03600831|Active Comparator|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
16455016|NCT03600818|Experimental|Group 1|Sarilumab once every 2 weeks plus prednisone taper regimen of 14 weeks
16455017|NCT03600818|Placebo Comparator|Group 2|Placebo matching sarilumab once every 2 weeks plus prednisone taper regimen of 52 weeks
16455018|NCT03600805|Experimental|Group A|Sarilumab dose 1, once every 2 weeks plus 26-week prednisone taper regimen
16455019|NCT03600805|Experimental|Group B|Sarilumab dose 2, once every 2 weeks plus 26-week prednisone taper regimen
16455020|NCT03600805|Placebo Comparator|Group C|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 26 weeks
16455021|NCT03600805|Placebo Comparator|Group D|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 52 weeks
16455022|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
16455023|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
16455024|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
16455025|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
16455026|NCT03600766|Active Comparator|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
16455027|NCT03600766|Active Comparator|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
16455028|NCT03600753|Experimental|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
16455029|NCT03600753|Active Comparator|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.
~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
16455030|NCT03600753|Other|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
16455068|NCT03600454|Experimental|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
16455103|NCT03600207|Active Comparator|Control group -complex training|complex training
16455031|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
16455032|NCT03600727|Experimental|Propofol group|Patients in this arm will be sedated by propofol.
16455033|NCT03600727|Experimental|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
16455034|NCT03600714|Experimental|Treatment|Treatment with Lonafarnib, Ritonavir, and Peginterferon lambda
16455036|NCT03600675||South Asian Indians|No intervention will be applied for any group
16455037|NCT03600675||Caucasians|No intervention will be applied for any group
16455038|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
16455039|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
16455040|NCT03600649|Experimental|Myxoid Liposarcoma|Twice-daily administration of oral seclidemstat
16455041|NCT03600649|Experimental|Sarcomas with FET-family translocations, including demoplastic small round cell tumors|Twice-daily administration of oral seclidemstat
16455042|NCT03600649|Experimental|Ewing sarcoma, combination therapy|Twice daily administration of seclidemstat in combination with cyclophosphamide and topotecan
16455043|NCT03600636|Other|Control|
16455044|NCT03600636|Other|antiphospholipid syndrome patients|
16455045|NCT03600623|Experimental|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
16455046|NCT03600623|Experimental|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
16455047|NCT03600610|Experimental|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
16455048|NCT03600610|Active Comparator|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
16455049|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
16455050|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
16455051|NCT03600571|Experimental|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
16455052|NCT03600571|Experimental|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
16455053|NCT03600571|Experimental|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
16455054|NCT03600571|Experimental|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
16455055|NCT03600545|Experimental|Active|4 weeks daily practice of the brain exercises
16455056|NCT03600545|No Intervention|control|no brain exercises
16455057|NCT03600532|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
16455058|NCT03600532|No Intervention|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
16455059|NCT03600532|No Intervention|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
16455060|NCT03600519||AMD Patients|OCT scan
16455061|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
16455062|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
16455063|NCT03600493|Active Comparator|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
16455064|NCT03600493|Active Comparator|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
16455104|NCT03600207|Active Comparator|Experimental group -diaphragm training|diaphragm training
16455070|NCT03600454|Experimental|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
16455071|NCT03600454|Experimental|Colectomy: general anesthesia|Patients will receive general anesthesia.
16455072|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
16455073|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
16455074|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
16455075|NCT03600415|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
16455076|NCT03600415|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16455077|NCT03600402|Experimental|Experimental Group|
16455078|NCT03600402|Other|Control Group|
16455079|NCT03600389|Experimental|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
16455080|NCT03600389|No Intervention|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
16455081|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
16455082|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
16455083|NCT03600363|Experimental|metformin arm|
16455084|NCT03600363|Placebo Comparator|control arm|
16455085|NCT03600350|Experimental|Treatment Group|"Nivolumab 240 mg IV every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12
~pTVG-HP (100 µg) administered intradermally (i.d.) every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12
~rhGM-CSF (208 µg) administered intradermally (i.d.) every two weeks x 4 beginning week 4, then every four weeks x 9 beginning week 12 NOTE: Only administered to patients for whom serum PSA obtained week 4 > serum PSA obtained at day 1."
16455086|NCT03600337|Experimental|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
16455087|NCT03600337|No Intervention|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
16455088|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
16455089|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
16455090|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
16455091|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
16455092|NCT03600311|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
16455093|NCT03600311|Active Comparator|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
16455094|NCT03600311|Experimental|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
16455095|NCT03600298|Other|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.
~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
16455096|NCT03600285|Experimental|TB1-K|TB1-K preservation arm
16455097|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
16455098|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
16455099|NCT03600259||Acute Myocardial Infarction|
16455100|NCT03600233|Experimental|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
16455101|NCT03600220|No Intervention|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
16455169|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
16455105|NCT03600194|Active Comparator|PowerSleep Stim|In this arm soft audio tones (below 65dB) will be administered by the PowerSleep Stim Device during deep sleep as determined by the functionality of the device.
16455106|NCT03600194|Placebo Comparator|PowerSleep Sham|This PowerSleep Sham device is the same as the PowerSleep Stim device, however, it can be configured in a mode that does not play audio tones
16455107|NCT03600194|Active Comparator|Northwestern Stim|The NorthWestern Stim device is set up will function similarly to the PowerSleep prototype. Acoustic stimulation provided by headphones with an audible soft volume that do not result in arousals will be used.
16455108|NCT03600194|Placebo Comparator|Northwestern Sham|The Northwestern Sham device will be the same as the Northwestern Stim set up, however no audio tones will be played.
16455109|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
16455110|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16455111|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16455112|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16455113|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
16455114|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
16455115|NCT03600129|Experimental|QLB with 0,375% ropivacaine|
16455116|NCT03600129|Placebo Comparator|QLB with 0,9% NaCl|
16455117|NCT03600116|Other|Study Visit|Subjects will arrive to the study visit having fasted the night before. Subjects will be given an insulin injection based on their meal to carbohydrate ratio for their breakfast meal as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL. Following the insulin injection, subjects will eat breakfast. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
16455118|NCT03600103|No Intervention|Control|Participants will receive standard of care.
16455119|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
16455120|NCT03600090|Experimental|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).
~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.
~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
16455121|NCT03600064|Other|Misoprostol group|
16455122|NCT03600064|No Intervention|NO intervention|
16455123|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
16455124|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
16455125|NCT03600025|Other|non-randomized|Responses will be compared before and after vaccination
16455126|NCT03600012|Experimental|intervention group|"intervention group: Cycling Functional Electrical Stimulation & Physiotherapy
~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
16455127|NCT03600012|Active Comparator|control group|"control group: Physiotherapy
~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
16455128|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
16455129|NCT03599960|Experimental|Chemotherapy|
16455130|NCT03599934|Experimental|LiFE training and home safety assessment|The participants will receive Lifestyle Integrated Functional Exercise Program and Home safety assessment
16455131|NCT03599934|No Intervention|Control group|The control group will continue their usual daily routine.
16455132|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
16455133|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
16455134|NCT03599921||Family-based Treatment for ARFID|Participants will receive family-based treatment modified for Avoidant/Restrictive Food Intake Disorder (ARFID).
16455135|NCT03599921||FBT + UP for ARFID|Participants will receive family-based treatment with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents, named FBT + UP for ARFID.
16455136|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
16455137|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
16455138|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
16455139|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
16455140|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
16455141|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
16455142|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
16455143|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
16455144|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
16455145|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
16455146|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
16455147|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
16455148|NCT03599765|Experimental|Arm I (LCT, routine therapy)|Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.
16455149|NCT03599765|Experimental|Arm II (routine therapy)|Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.
16455150|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
16455151|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
16455152|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
16455153|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
16455154|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
16455155|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
16455156|NCT03599726|Experimental|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
16455157|NCT03599726|Placebo Comparator|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
16455159|NCT03599700||myeloproliferative neoplasms|"history taking
~physical examination
~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
16455160|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
16455161|NCT03599661||Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
16455162|NCT03599648|Experimental|BPT-E|"Behavioral parent training (BPT) plus a psychoeducation program.
~Includes a 10-week standard BPT, plus a 6-week psychoeducation program delivered prior to the standard BPT."
16455163|NCT03599648|Experimental|BPT-M|"Behavioral parent training (BPT) plus mindfulness-based stress reduction (MBSR).
~Includes a 10-week standard BPT, plus a 6-week MBSR delivered prior to the standard BPT."
16455164|NCT03599635|Experimental|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
16455165|NCT03599635|Active Comparator|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
16455166|NCT03599622|Experimental|BMS-986165 Dose 1|
16455167|NCT03599622|Experimental|BMS-986165 Dose 2|
16455168|NCT03599622|Placebo Comparator|Placebo|
16455170|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
16455171|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
16455172|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
16455173|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
16455174|NCT03599570|Experimental|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
16455175|NCT03599570|No Intervention|Control|Arm 2 will receive standard of care
16455176|NCT03599557|Experimental|Intervention|Arm 1 will receive the STOP-HPV communication intervention
16455177|NCT03599557|No Intervention|Control|Arm 2 will receive standard of care
16455178|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
16455179|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
16455180|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 250 mg oral dose of gefitinib
16455181|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
16455182|NCT03599479|Experimental|Virtual reality group|"After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.
~After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).
~After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.
~Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
16455183|NCT03599479|No Intervention|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
16455184|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
16455185|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
16455186|NCT03599453|Experimental|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16455187|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
16455188|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
16455189|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
16455190|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
16455191|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
16455192|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
16455193|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)
~Fitbit 24/7
~Phone/videoconference (weekly with study team)
~Epworth Sleepiness Scale (weekly)
~PROMIS fatigue scale-morning (weekly)
~PROMIS fatigue scale-evening (weekly)"
16455194|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
16455196|NCT03599349|Experimental|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 0.75 joules for the 7-4.5mm transducer)
16455197|NCT03599336|Other|Nonoperative Treatment|Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
16455198|NCT03599336|Other|Operative Course for rTSA|Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.
16455199|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
16455200|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
16455328|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
16455201|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
16455202|NCT03599297|Experimental|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
16455203|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
16455204|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
16455205|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
16455206|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
16455207|NCT03599271|Experimental|Drug-Coated Device|Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.
16455208|NCT03599271|Active Comparator|Control Sinus Dilation Device|Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.
16455209|NCT03599271|Experimental|PK cohort- Drug-Coated Device|PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.
16455210|NCT03599258|Other|Arm 1|Skylife device
16455211|NCT03599258|Active Comparator|Arm 2|Standard therapy
16455213|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).
~assessed at end of the module(7 weeks) through summative OSCE"
16455214|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
16455215|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
16455216|NCT03599219|Other|control|donors with an hemorrhagic score <2.
16455217|NCT03599206|Experimental|Ozone|
16455218|NCT03599206|Placebo Comparator|Filtered Air|
16455219|NCT03599193|Experimental|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
16455220|NCT03599193|Active Comparator|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for ~12 hours. 29 subjects will be enrolled into this arm.
16455221|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
16455222|NCT03599180||Control group|Heathly volunteers
16455223|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
16455224|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
16455225|NCT03599128|Placebo Comparator|Placebo|Placebo
16455226|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
16455227|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
16455228|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
16455229|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
16455230|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
16455231|NCT03599102|Experimental|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
16455232|NCT03599102|No Intervention|Standard Care|Standard interaction with transplant center and physician care.
16455233|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 0.7 mg (0.05 mg/mL concentration)|Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
16455329|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
16455234|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 2.1 mg (0.15 mg/mL concentration)|Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
16455235|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 4.2 mg (0.3 mg/mL concentration)|Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
16455236|NCT03599089|Placebo Comparator|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
16455237|NCT03599076||Manifest HD|
16455238|NCT03599076||Premanifest HD|
16455239|NCT03599076||Control|
16455240|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
16455241|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
16455242|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
16455243|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
16455244|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
16455245|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
16455246|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
16455247|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
16455248|NCT03599050|Experimental|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
16455249|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
16455250|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
16455251|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
16455252|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
16455253|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
16455254|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
16455255|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
16455256|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16455257|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.
~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
16455258|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.
~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
16455259|NCT03598972||control|teeth of children of non vitamin taking mother
16455260|NCT03598972||intervention|children teeth of vitamin taking mother
16455261|NCT03598959|Experimental|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
16455262|NCT03598946|Experimental|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
16455263|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
16455264|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
16455265|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
16455266|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
16455267|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP >145mmHg at baseline and a decline of <10% between mean day time and night time systolic pressures)
16455268|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP <120mmHg)
16455269|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP >145mmHg and a decline of >10% between mean day time and night time systolic pressures)
16455270|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
16455271|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
16455272|NCT03598868|Experimental|Vortioxetine|Vortioxetine 5-20 mg
16455273|NCT03598868|Placebo Comparator|Placebo|Placebo augmentation
16455274|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
16455275|NCT03598855|No Intervention|Control|
16455276|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
16455277|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
16455278|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
16455279|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
16455280|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses
~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles
~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab
~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
16455281|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses
~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
16455282|NCT03598790|Experimental|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 or dose regimen 2, those on dose regimen 1 will switch to dose regimen 2 at Week 24 or later.
~Intervention Name: Bimekizumab"
16455283|NCT03598790|Experimental|Bimekizumab dose regimen 2|Subjects will receive bimekizumab dose regimen 2. Intervention Name: Bimekizumab
16455284|NCT03598777|Experimental|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
16455285|NCT03598777|Placebo Comparator|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
16455286|NCT03598777|Active Comparator|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
16455287|NCT03598764|Other|Classic head extraction group|
16455288|NCT03598764|Other|External Pop out group|
16455289|NCT03598751|Experimental|BCD-085|"Blinded period:
~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22
~Open-label period:
~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
16455290|NCT03598751|Placebo Comparator|Placebo|"Blinded period:
~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14
~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22
~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22
~Open-label period:
~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
16455291|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
16455292|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
16455293|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
16455294|NCT03598712|Experimental|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.
~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.
~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.
~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
16455295|NCT03598712|Active Comparator|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.
~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
16455296|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
16455297|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
16455298|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
16455299|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
16455300|NCT03598686|No Intervention|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:
~For present household members: blood-based HIV testing
~For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
16455301|NCT03598686|Experimental|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:
~For present household members: blood-based HIV testing
~a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)
~For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
16455302|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
16455303|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.
~The followings markers must be estimated:
~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
16455304|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.
~The followings markers must be estimated:
~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
16455305|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.
~The followings markers must be estimated:
~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
16455306|NCT03598647|Active Comparator|Physical activity information - for non-exercisers only|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
16455307|NCT03598647|Experimental|Affect and physical activity - for non-exercisers only|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
16455308|NCT03598647|No Intervention|Exercisers|Engaging in >=150 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
16455309|NCT03598647|No Intervention|Non-exercisers|Engaging in <30 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
16455310|NCT03598634|Active Comparator|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
16455311|NCT03598634|Active Comparator|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
16455312|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
16455313|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
16455314|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
16455315|NCT03598608|Experimental|Part A: Favezelimab Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
16455316|NCT03598608|Experimental|Part A: Favezelimab Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
16455317|NCT03598608|Experimental|Part A: Favezelimab Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
16455318|NCT03598608|Experimental|Part B: cHL|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
16455319|NCT03598608|Experimental|Part B: DLBCL|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
16455320|NCT03598608|Experimental|Part B: iNHL|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
16455321|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16455322|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
16455323|NCT03598569||lung cancer|
16455324|NCT03598569||other lung diseases|
16455325|NCT03598556|Experimental|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
16455326|NCT03598556|Placebo Comparator|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
16455327|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
16455330|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
16455331|NCT03598504|Active Comparator|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
16455332|NCT03598504|Active Comparator|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.
~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
16455333|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
16455334|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
16455335|NCT03598478|Experimental|TC-MPT group|Tai Chi-muscle power training group
16455336|NCT03598478|Active Comparator|TC group|Tai Chi group
16455337|NCT03598478|Active Comparator|MPT group|Muscle power training group
16455338|NCT03598478|No Intervention|Control group|Usual medical care is allowed.
16455339|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
16455340|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
16455341|NCT03598452|Experimental|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
16455342|NCT03598439|Experimental|Recombinant (RIV4) Influenza Vaccine|A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
16455343|NCT03598439|Experimental|Cell-culture (ccIIV4) Influenza Vaccine|A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20
16455344|NCT03598439|Active Comparator|Standard (IIV4) Influenza Vaccine|A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
16455345|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
16455346|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
16455347|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
16455348|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
16455349|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
16455350|NCT03598400|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
16455351|NCT03598400|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
16455352|NCT03598400|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
16455353|NCT03598387|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
16455354|NCT03598387|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
16455355|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.
~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
16455356|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.
~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
16455357|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
16455358|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
16455359|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
16455360|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
16455366|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza®|"Group A:
~4 grams Lovaza®, 2 grams twice a day (BID). 2 grams by mouth daily, AM and PM 8,000 mgs CUR Curcumin C3 complex® tablets, divided into 2 doses. 4 grams by mouth, twice a day, AM and PM."
16455367|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:
~2 grams Lovaza®, 1 gram twice a day, AM and PM. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs twice a day, AM and PM.
~1 placebo capsule twice a day, AM and PM."
16455368|NCT03598309|Active Comparator|Placebo only|Placebo: Two matching placebo capsules twice a day (BID), taken by mouth, AM and PM
16455369|NCT03598296|Experimental|Group A:Group Tube|Patients are inserted the large size tube (28F).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
16455370|NCT03598296|Experimental|Group B:Group Ball|Patients are inserted the small size tube connects with a negative pressure ball(drainage ball).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
16455371|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
16455372|NCT03598270|Placebo Comparator|Arm A (Control Arm)|"Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:
~Carboplatin (AUC = 5, d1) plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks
~Carboplatin (AUC = 4, d1) plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.
~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks."
16455373|NCT03598270|Experimental|Arm B (experimental arm)|"Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:
~Carboplatin (AUC = 5, d1) plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.
~Carboplatin (AUC = 4, d1) plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.
~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks."
16455376|NCT03598244|Experimental|Treatment (volitinib)|Patients receive volitinib PO QD. Treatment repeats every 28 days for up to 39 cycles in the absence of disease progression or unacceptable toxicity.
16455377|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.
~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.
~Specific scales will be passed after each sequence crossing."
16455378|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.
~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.
~Specific scales will be passed after each sequence crossing."
16455379|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
16455380|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
16455381|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
16455382|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
16455383|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.
~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
16455384|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
16455409|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
16455437|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
16455387|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
16455388|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
16455389|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
16455390|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
16455391|NCT03598114|Experimental|Program Sustainability Training|"Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.
~The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
16455392|NCT03598114|No Intervention|Control Condition|"In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training
~The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
16455393|NCT03598101|Experimental|Test group|
16455394|NCT03598088|Other|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya PCT cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
16455395|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
16455396|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
16455397|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
16455398|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
16455399|NCT03598036|Experimental|Voclosporin|"Cohort 1:
~Maximum dose of 3 capsules (7.9mg) BID
~Cohort 2
~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
16455400|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
16455401|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
16455402|NCT03598010|Experimental|Lenodiar Pediatric in Acute/Prolonged Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.
~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:
~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;
~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
16455403|NCT03598010|Experimental|Lenodiar Pediatric in Chronic Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.
~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:
~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;
~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
16455404|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
16455405|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
16455406|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
16455407|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases
~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:
~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
16455408|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
16455410|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.
~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.
~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
16455411|NCT03597945|Placebo Comparator|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:
~15 ml of lidocaine with epinephrine (300 mg)
~and 3 ml of normal saline as adjuvant."
16455412|NCT03597945|Active Comparator|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:
~15 ml of lidocaine with epinephrine (300 mg)
~and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
16455413|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
16455414|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
16455415|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
16455416|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
16455417|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
16455418|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
16455419|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
16455420|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
16455421|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
16455422|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
16455423|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
16455424|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
16455425|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
16455426|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
16455427|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
16455428|NCT03597841||Patients with CRKp BSI:Combination therapy|
16455429|NCT03597841||Patients with CRKp BSI: Monotherapy|
16455430|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
16455431|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
16455432|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
16455433|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
16455434|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
16455435|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
16455436|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
16457957|NCT03580343|Experimental|Tofacitinib Treatment|11mg extended-release tofacitinib, once daily, oral
16455438|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
16455439|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
16455440|NCT03597776|Experimental|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
16455441|NCT03597776|Placebo Comparator|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
16455442|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
16455443|NCT03597750|Experimental|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:
~Repose® Mattress
~Repose® Cushion
~Repose® Wedge or Foot Protectors
~The frequency of repositioning remains unchanged."
16455444|NCT03597750|No Intervention|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.
~The frequency of repositioning remains unchanged."
16455445|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
16455446|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
16455447|NCT03597711|Active Comparator|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
16455448|NCT03597711|Active Comparator|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
16455449|NCT03597711|Active Comparator|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
16455450|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).
~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.
~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
16455451|NCT03597646|Experimental|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
16455452|NCT03597646|Active Comparator|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
16455453|NCT03597646|No Intervention|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
16455454|NCT03597620|Experimental|Patients with plaque psoriasis 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions.
16455455|NCT03597620|Experimental|Patients with stable dose of biologic treatment & 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
16455456|NCT03597620|Experimental|Patients with Scalp Psoriasis|For the subgroup for scalp psoriasis, patient will use the shampoo Head & Shoulders formula with 1% Pyrithione Zinc as the active ingredient
16455457|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
16455458|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
16455459|NCT03597607|No Intervention|Usual care group|The usual care group will be given a package of independent resources that could aid them to quit smoking on their own. They will not receive intervention by a clinic pharmacist.
16455460|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System
~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD
~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0
~Regimen 2 - RAG1, RAG2 (Haplocompatible)
~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0
~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)
~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
16455461|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:
~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0
~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.
~Phase II:
~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.
~Cells for infusion are prepared using the CliniMACS System."
16455713|NCT03595826|Experimental|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
16455465|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening
16455466|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
16455467|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.
~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.
~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
16455468|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
16455469|NCT03597542|Experimental|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
16455470|NCT03597542|Experimental|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
16455471|NCT03597529|Experimental|Low-Dose Melatonin (mg)|melatonin 2mg (equal to or over 40kg) melatonin 1mg (under 40kg) Melatonin: melatonin
16455472|NCT03597529|Experimental|High-Dose Melatonin (mg)|melatonin 8mg (equal to or over 40kg) melatonin 4mg (under 40kg) Melatonin: melatonin
16455473|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
16455474|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
16455475|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects will be treated with flexible dose of SPN-810
16455476|NCT03597503|Placebo Comparator|Placebo|Subjects will be treated with Placebo
16455477|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
16455478|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
16455479|NCT03597477||Control|Patients with no developmental diagnoses
16455482|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
16455483|NCT03597451||Control|Healthy individuals of similar age and sex to patients
16455484|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
16455485|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
16455486|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
16455487|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
16455488|NCT03597386||All Participants|
16455489|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
16455490|NCT03597373||not reintubation|Favourable respiratory function
16455491|NCT03597360|Experimental|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
16455495|NCT03597334||critical ill patients|critical ill patients who admit to ICU
16455496|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
16455497|NCT03597321|No Intervention|Arm B- No intervention|
16455498|NCT03597308|Active Comparator|Opioid Group|
16455499|NCT03597308|Active Comparator|NSAID group|
16455500|NCT03597308|Active Comparator|Acetaminophen|
16455501|NCT03597295|Experimental|INCMGA00012|
16457958|NCT03580330|Experimental|Intervention Group|
16455502|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
16455503|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
16455504|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
16455505|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
16455506|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
16455507|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
16455508|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
16455509|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
16455510|NCT03597256|No Intervention|Control Group|No treatment
16455511|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
16455512|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
16455513|NCT03597230|Experimental|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
16455514|NCT03597217|Experimental|Cohort A_Active|3 single doses treatment of PF-05221304
16455515|NCT03597217|Experimental|Cohort B_Active|Repeated doses of PF-05221304
16455516|NCT03597217|Placebo Comparator|Cohort B_Placebo|Repeated doses of placebo
16455517|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
16455518|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.
~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
16455519|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
16455520|NCT03597178|Experimental|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
16455521|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
16455522|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
16455523|NCT03597152|Experimental|Treatment|WelTract
16455524|NCT03597152|Placebo Comparator|Control|Inert Placebo
16455525|NCT03597139|Experimental|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twice Daily (BID), both eyes for 28 days
16455526|NCT03597139|Active Comparator|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
16455527|NCT03597126|Active Comparator|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
16455528|NCT03597126|Active Comparator|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
16455529|NCT03597100|Experimental|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
16455530|NCT03597087|Experimental|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
16455531|NCT03597087|Experimental|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
16455532|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
16455714|NCT03595826|Experimental|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
16455533|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
16455534|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
16455535|NCT03597061|Experimental|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
16455536|NCT03597061|No Intervention|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
16455537|NCT03597048|Experimental|Curriculum|Participants received only the curriculum intervention
16455538|NCT03597048|Active Comparator|Contact|Participants received only the contact intervention
16455539|NCT03597048|Active Comparator|Materials|Participants received only the materials intervention
16455540|NCT03597048|Experimental|Curriculum and Contact|Participants received both curriculum and contact interventions
16455541|NCT03597048|Experimental|Curriculum and Materials|Participants received curriculum and materials interventions
16455542|NCT03597048|Active Comparator|Contact and Materials|Participants received contact and materials intervention
16455543|NCT03597048|Active Comparator|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
16455544|NCT03597048|No Intervention|No intervention|Participants received no intervention
16455545|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
16455546|NCT03597022|Experimental|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
16455547|NCT03597022|Experimental|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
16455548|NCT03597022|Experimental|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
16455549|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
16455550|NCT03596996|Experimental|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
16455551|NCT03596996|Placebo Comparator|Placebo|
16455552|NCT03596983|Experimental|Short Sleep Patients|
16455553|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
16455554|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
16455555|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
16455556|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
16455557|NCT03596944||Statin|History of statin use for primary prevention
16455558|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
16455559|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
16455560|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
16455561|NCT03596918|Experimental|Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16455562|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
16455563|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
16455564|NCT03596905|Experimental|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
16455565|NCT03596905|Experimental|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
16455566|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
16455567|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16455568|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16455569|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
16455570|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
16455573|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
16455574|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
16455715|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
16455716|NCT03595800|Experimental|haploidentical related donors|
16455717|NCT03595800|Active Comparator|Matched unrelated donor|
16455575|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
16455576|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
16455577|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
16455578|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
16455579|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
16455580|NCT03596801|Experimental|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
16455581|NCT03596801|Experimental|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
16455582|NCT03596801|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
16455583|NCT03596801|Experimental|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
16455584|NCT03596801|Experimental|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
16455585|NCT03596801|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
16455586|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
16455587|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
16455588|NCT03596775|Experimental|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
16455589|NCT03596775|Placebo Comparator|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
16455590|NCT03596762|Experimental|160 mg BAY3427080|
16455591|NCT03596762|Experimental|120 mg BAY3427080|
16455592|NCT03596762|Experimental|80 mg BAY3427080|
16455593|NCT03596762|Experimental|40 mg BAY3427080|
16455594|NCT03596762|Placebo Comparator|Placebo|
16455595|NCT03596749|Experimental|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
16455596|NCT03596749|No Intervention|Control|blank-control
16455597|NCT03596736|Experimental|Elbow Hemiarthroplasty|
16455598|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
16455599|NCT03596723|Experimental|KPI-121 1% BID (twice daily)|
16455600|NCT03596723|Active Comparator|Prednisolone acetate QID (four times daily)|
16455601|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
16455602|NCT03596697|Experimental|CRV431|Either single or multiple doses of varying dose levels
16455603|NCT03596697|Placebo Comparator|Placebo|
16455604|NCT03596697|Experimental|TDF|300 mg TDF
16455605|NCT03596684|Experimental|citrulline|citrulline 5g/d
16455606|NCT03596684|Placebo Comparator|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
16455607|NCT03596671|Experimental|Treatment arm|RENOVA iStim™ System implanted patients
16455608|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
16455611|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
16455612|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
16455613|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
16455719|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
16455614|NCT03596606|Experimental|Myofunctional Motor Control Exercises|"Both groups will be treated with Osteopathic treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.
~The patient will receive five sessions, one session every week."
16455615|NCT03596606|Active Comparator|Osteopathic Treatment|The control group will receive only osteopathic treatment (TO). The patient will receive five sessions, one session every week.
16455616|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
16455617|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
16455618|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
16455619|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
16455620|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
16455621|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
16455622|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
16455623|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
16455624|NCT03596528|Other|Lung biopsy|Lung biopsy
16455625|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
16455626|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
16455627|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
16455628|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
16455629|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
16455630|NCT03596463||Group A|Patients treated according to suggestions of tumor board
16455631|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
16455634|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
16455635|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
16455636|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
16455637|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
16455638|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
16455639|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
16455640|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.
~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
16455641|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
16455642|NCT03596372|Experimental|Patients with Solid tumors|Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.
16455643|NCT03596372|Experimental|Patients with Gastric cancer|"Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:
~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
16455644|NCT03596372|Experimental|Patients with Colorectal cancer|"Expansion with patients having colorectal cancer:
~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
16455645|NCT03596372|Experimental|Patients with Non-small-cell-lung cancer|"Expansion with patients having adeno Non-small-cell-lung cancer:
~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
16455646|NCT03596372|Experimental|Low-dose expansion|Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).
16455647|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
16455648|NCT03596359|Active Comparator|Control group|The control group received routine treatment
16455649|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
16455650|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
16455651|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
16455652|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
16455653|NCT03596294|Experimental|Treatment sequence AB|"Period A:
~Saline + clazosentan
~Period B:
~Rifampicin + clazosentan"
16455654|NCT03596294|Experimental|Treatment sequence BA|"Period B:
~Rifampicin + clazosentan
~Period A:
~Saline + clazosentan"
16455655|NCT03596281|Experimental|Cohort A|
16455656|NCT03596281|Experimental|Cohort B|
16455657|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
16455658|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
16455659|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
16455660|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
16455661|NCT03596242|Experimental|High Blood Pressure Monitoring by SMS|Will receive the text message intervention and will be provided with a blood pressure cuff in addition to standard blood pressure control education received at clinic visits
16455662|NCT03596242|Active Comparator|Usual Care Plus Standard Blood Pressure Monitoring|Will receive standard blood pressure care and education, as well as a blood pressure cuff at their clinic visits
16455663|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.
~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
16455664|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.
~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
16455665|NCT03596203|Experimental|Treatment group|
16455666|NCT03596190|Other|Assessment arm|
16455667|NCT03596177|Experimental|MEDI0382|Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
16455668|NCT03596177|Placebo Comparator|Placebo|Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.
16455669|NCT03596164|Experimental|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
16455670|NCT03596151|Experimental|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
16455671|NCT03596125|Experimental|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.
~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
16455672|NCT03596125|Placebo Comparator|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.
~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
16455673|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
16455674|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
16455675|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
16455676|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
16455718|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
16457959|NCT03580330|No Intervention|Control Group|
16455677|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.
~Patient can receive second treatment of HSV-tk after 6 months"
16455678|NCT03596073|Experimental|Topical Calcipotriene Ointment|-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
16455679|NCT03596073|Placebo Comparator|Topical Vaseline|-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
16455680|NCT03596060|Active Comparator|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
16455681|NCT03596060|Active Comparator|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
16455682|NCT03596047|Experimental|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
16455683|NCT03596047|Placebo Comparator|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
16455684|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
16455685|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
16455686|NCT03596008|Placebo Comparator|Placebo|Placebo drink
16455687|NCT03595995|Experimental|Cohort 1|"Placebo (volume equivalent to 2.5 mg/kg UB-621)
~2.5 mg/kg UB-621"
16455688|NCT03595995|Experimental|Cohort 2|"Placebo (volume equivalent to 5 mg/kg UB-621)
~5 mg/kg UB-621"
16455689|NCT03595982|Experimental|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
16455690|NCT03595982|Active Comparator|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
16455691|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
16455692|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
16455693|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
16455694|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
16455695|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
16455696|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
16455697|NCT03595917|Experimental|ABL001, Dasatinib, Prednisone|"- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)
~Dasatinib-Fixed doses oral once a day per cycle
~ABL001 is administered orally daily per cycle
~Prednisone-Fixed doses oral once a day per cycle. --- Prednisone will be tapered and stop during cycle 2."
16455698|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
16455699|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
16455700|NCT03595891||Adult with acute PE before the introduction of apixaban|
16455701|NCT03595891||Adult with acute PE after the introduction of apixaban|
16455702|NCT03595878|Active Comparator|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
16455703|NCT03595878|Experimental|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
16455704|NCT03595878|No Intervention|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
16455705|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
16455706|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
16455707|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
16455708|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
16455709|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
16455710|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
16455711|NCT03595826|Experimental|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
16455712|NCT03595826|Experimental|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
16455720|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*
~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
16455721|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate
~Other names:Beet It Sport Nitrate 400"
16455722|NCT03595748|Experimental|Peer mentorship intervention|This arm of mentees will be assigned to weekly telephone calls with a matched mentor over a period of 3 months.
16455723|NCT03595748|No Intervention|Usual Care|This arm of mentees will not get a telephone intervention by an assigned mentee
16455724|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
16455725|NCT03595722|Experimental|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
16455726|NCT03595722|Experimental|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
16455727|NCT03595709|Experimental|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
16455728|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
16455729|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
16455730|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
16455731|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
16455732|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist
~standardized questionnaires and interview will be performed"
16455733|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
16455734|NCT03595644|Experimental|SBRT plus TKI group|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
16455735|NCT03595644|Active Comparator|TKI treatment group|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
16455736|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
16455737|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
16455738|NCT03595618|Experimental|GLPG1972 75 mg|Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
16455739|NCT03595618|Experimental|GLPG1972 150 mg|Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
16455740|NCT03595618|Experimental|GLPG1972 300 mg|Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.
16455741|NCT03595618|Placebo Comparator|Placebo|Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.
16455742|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
16455743|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
16455744|NCT03595592|Active Comparator|HPCT|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin and paclitaxel as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8. Paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 12 additional cycles as adjuvant therapy.
16455745|NCT03595592|Experimental|ACy followed by HPCT and atezolizumab|Patients will receive a combination of doxorubicin (A, 60 mg/m2 i.v.), cyclophosphamide (C, 600 mg/m2 i.v.) and atezolizumab (1200 mg i.v.) on day 1 every 3 week for 3 cycles. Subsequently they will be given trastuzumab on day 1 (H, at the loading dose of 8 mg/kg i.v. then 6 mg/kg i.v.), pertuzumab on day 1 (P, at the loading dose of 840 mg .v., then 420 mg i.v.), carboplatin (C) at AUC 2 i.v. on day 1 and day 8, paclitaxel (T) at 90 mg/m2 i.v. on day 1 and day 8, and atezolizumab 1200 mg i.v. on day 1 for 3 cycles every 3 weeks. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 15 additional cycles and atezolizumab for 12 additional cycles as adjuvant therapy.
16455778|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
16458249|NCT03578367|Active Comparator|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
16455746|NCT03595592|Experimental|HPCT and atezolizumab|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin, paclitaxel and atezolizumab as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8; paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8; atezolizumab at the dose of 1200 mg i.v. on day 1. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab, pertuzumab and atezolizumab will then be delivered for 12 additional cycles as adjuvant therapy.
16455747|NCT03595579|Experimental|AXS-05|
16455748|NCT03595579|Active Comparator|Bupropion|
16455749|NCT03595566|Experimental|ridinilazole|
16455750|NCT03595566|Active Comparator|vancomycin|
16455751|NCT03595553|Experimental|ridinilazole|
16455752|NCT03595553|Active Comparator|vancomycin|
16455753|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
16455754|NCT03595527|Experimental|Patients consulting in the emergency room|Patients consulting in the emergency room.
16455755|NCT03595514|Active Comparator|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
16455756|NCT03595514|Experimental|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
16455757|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
16455758|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
16455759|NCT03595488|Experimental|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.
~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
16455760|NCT03595475||Psychiatric RBD cases|"Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);
~The onset of mental symptoms preceded the onset of RBD:
~Onset of RBD symptom was younger than 50 years old (as most patients with pRBD tended to be younger at mid-40s with an earlier age onset than typical iRBD)."
16455761|NCT03595475||Psychiatric cases|"Age- and sex- matched with pRBD proband;
~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);
~Free of narcolepsy and other neurological diseases;
~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG;
~Free of neurodegenerative diseases."
16455762|NCT03595475||Age- & sex-matched health control|"Age- and sex- matched with pRBD proband;
~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);
~Free of narcolepsy and other neurological diseases;
~Absence of any RBD features as based on RBDQ-HK and v-PSG;
~Free of neurodegenerative diseases."
16455763|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
16455764|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
16455765|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
16455766|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
16455767|NCT03595436|Experimental|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to ~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
16455768|NCT03595436|Placebo Comparator|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
16455769|NCT03595436|Active Comparator|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
16455770|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
16455771|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
16455772|NCT03595410||Recurrence laryngeal cancer|
16455773|NCT03595410||No recurrence laryngeal cancer|
16455774|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
16455775|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
16455776|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
16455777|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Participants taking part in a 24 week soccer program as part of diabetes prevention.
16455779|NCT03595358|Experimental|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test
~Upper respiratory tract samples from participants will be tested with:
~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
16455780|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
16455781|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
16455782|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
16455783|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
16455784|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
16455785|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
16455786|NCT03595319|Experimental|Elder patients|Older than 65
16455787|NCT03595306|Experimental|Prebiotic A|
16455788|NCT03595306|Experimental|Prebiotic B|
16455789|NCT03595306|Experimental|Prebiotic C|
16455790|NCT03595293|Experimental|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
16455791|NCT03595293|Sham Comparator|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
16455792|NCT03595293|Experimental|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
16455793|NCT03595293|Sham Comparator|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
16455797|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
16455798|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
16455799|NCT03595254|No Intervention|Waitlist Control|Wait 8 weeks before receiving program access
16455800|NCT03595241|Experimental|Group A - active treatment|
16455801|NCT03595241|No Intervention|Group B - conservative management|
16455802|NCT03595228|Experimental|BN-Brachyury plus radiation|MVA-BN-Brachyury then treatment of the tumor(s) with radiation followed by FPV-Brachyury
16455803|NCT03595215|Experimental|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
16455804|NCT03595202|Other|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
16455805|NCT03595202|Other|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
16455806|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
16455807|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
16455808|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
16455809|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
16455810|NCT03595176|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
16455980|NCT03594006|Other|Cancer patients on active therapy|
16455981|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
16455811|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
16455812|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
16455813|NCT03595150|Active Comparator|Diclofenac|100 mg Diclofenac rectally prior to the ERCP
16455814|NCT03595150|No Intervention|No prophylaxis|No prophylaxis
16455815|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
16455816|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
16455820|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
16455821|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
16455822|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
16455823|NCT03595085|Experimental|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
16455824|NCT03595085|Active Comparator|systemic thrombolysis|Those patients will receive systemic streptokinase
16455825|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
16455826|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
16455827|NCT03595059|Experimental|Escalation 1a: ABBV-155|Participants will be administered ABBV-155 (various doses).
16455828|NCT03595059|Experimental|Escalation 1b: ABBV-155 + paclitaxel or docetaxel|Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .
16455829|NCT03595059|Experimental|Expansion 2a: ABBV-155 in SCLC|Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
16455830|NCT03595059|Experimental|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
16455831|NCT03595059|Experimental|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
16455832|NCT03595046|Experimental|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
16455833|NCT03595046|Active Comparator|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
16455834|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
16455835|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
16455836|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
16455837|NCT03595007||Phase 1|
16455838|NCT03595007||Phase 2|
16455839|NCT03595007||Phase 3|
16455840|NCT03594994|No Intervention|Control|Normal sleep habits < 6h
16455841|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed to 8 hours
16455842|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
16455843|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:
~oligomenorrhea and/or anovulation
~Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
16455844|NCT03594968||healthy|healthy patients who had no polycystic ovary
16455982|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
16458250|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
16455845|NCT03594955|Experimental|SAR440234|SAR440234 as weekly intravenous injection; a cycle is defined as 6 weeks of study treatment; (Additionally infusion on day 4 is planned for dose level ≥ 3). One dose escalation scheme will be used. Treatment may be continued as long as it is clinically beneficial.
16455846|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
16455847|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
16455848|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
16455849|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
16455850|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
16455851|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations
~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
16455852|NCT03594890|Experimental|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.
~3 Dose levels tested: 30µg, 90 µg and 180 µg."
16455853|NCT03594890|Placebo Comparator|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
16455854|NCT03594890|Experimental|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.
~3 Dose levels tested: 30µg, 90 µg and 180 µg."
16455855|NCT03594890|Placebo Comparator|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
16455856|NCT03594877|Experimental|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
16455857|NCT03594877|No Intervention|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
16455858|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
16455859|NCT03594851|Experimental|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :
~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living
~& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
16455860|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
16455861|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
16455862|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
16455863|NCT03594825|Experimental|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
16455864|NCT03594825|Active Comparator|daytime group|patients with nocturnal hypertension taking valsartan at daytime
16455865|NCT03594812|Experimental|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
16455866|NCT03594812|Placebo Comparator|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
16455867|NCT03594799|Experimental|Bed Rest Control Group|60 days of strict head-down tilt bed rest
16455868|NCT03594799|Experimental|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
16455869|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
16455870|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
16455984|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
16455871|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
16455872|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
16455873|NCT03594747|Experimental|Tislelizumab combined with carboplatin and paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
16455874|NCT03594747|Experimental|Tislelizumab combined with carboplatin and nab-paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Nab-paclitaxel 100 mg/m2, D1, D8, and D15 of each cycle, administered as an IV infusion over 30 minutes, for 4 to 6 cycles
16455875|NCT03594747|Active Comparator|Carboplatin and paclitaxel|Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
16455876|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
16455877|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
16455878|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
16455879|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
16455880|NCT03594708|Placebo Comparator|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
16455881|NCT03594708|Active Comparator|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
16455882|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
16455883|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
16455884|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
16455885|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
16455886|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).
~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
16455887|NCT03594656|Experimental|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
16455888|NCT03594656|Placebo Comparator|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
16455889|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
16455890|NCT03594643||control|patient not smoking nor using electronic cigarette
16455891|NCT03594630|Active Comparator|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
16455892|NCT03594630|Experimental|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
16455893|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
16455894|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
16455895|NCT03594604|Experimental|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
16455896|NCT03594604|Active Comparator|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
16455897|NCT03594578|Experimental|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
16455898|NCT03594578|Sham Comparator|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
16455899|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.
~Dosage: 2 puffs."
16455900|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
16455901|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
16455902|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
16455903|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
16455904|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
16455905|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
16455906|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
16455907|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
16455908|NCT03594526|Experimental|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:
~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.
~Four Educational sessions and support sessions for maternal empowerment in each home visit.
~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
16455909|NCT03594526|Active Comparator|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
16455910|NCT03594513|Active Comparator|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
16455911|NCT03594513|Experimental|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
16455912|NCT03594500|Experimental|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
16455913|NCT03594500|Other|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
16455914|NCT03594487|Experimental|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.
~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
16455915|NCT03594487|Active Comparator|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.
~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
16455985|NCT03593954|Experimental|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
16455916|NCT03594474|No Intervention|control group|Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
16455917|NCT03594474|Experimental|experimental group|"The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth.
~The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group."
16455918|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
16455919|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
16455920|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
16455921|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
16455922|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
16455923|NCT03594422|Experimental|HQP1351 30mg|30 mg QOD
16455924|NCT03594422|Experimental|HQP1351 40mg|40 mg QOD
16455925|NCT03594422|Experimental|HQP1351 50mg|50 mg QOD
16455926|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.
~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.
~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
16455927|NCT03594370||control|Limbal image by OCT in normal subjects.
16455928|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
16455929|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
16455930|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
16455931|NCT03594357||Control|Healthy individuals without chronic disease
16455932|NCT03594344|Experimental|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
16455933|NCT03594344|No Intervention|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
16455934|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
16455935|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
16455936|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
16455937|NCT03594305|Experimental|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
16455938|NCT03594305|No Intervention|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
16455939|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
16455940|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
16455941|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
16455983|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
16455942|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
16455943|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
16455944|NCT03594266|Experimental|Therapy A Spinal Cord Stimulation Parameter Set|
16455945|NCT03594266|Experimental|Therapy B Spinal Cord Stimulation Parameter Set|
16455946|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
16455947|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
16455948|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
16455949|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
16455950|NCT03594227|Active Comparator|400mg BID (Low dose)|ATI-501 low dose - oral administration
16455951|NCT03594227|Active Comparator|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
16455952|NCT03594227|Active Comparator|800mg BID (High dose)|ATI-501 high dose - oral administration
16455953|NCT03594227|Placebo Comparator|Placebo|Placebo - oral administration
16455954|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
16455955|NCT03594201||group1|A+B grade sperm count after treatment=0
16455956|NCT03594201||group2|0<A+B grade sperm count after treatment≤10^6
16455957|NCT03594201||group3|10^6<A+B grade sperm count after treatment<2*10^6
16455958|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
16455959|NCT03594188|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
16455960|NCT03594188|Active Comparator|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
16455961|NCT03594175|Experimental|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants will receive the first dose at minute (min) 0, and the second dose, if needed, at min 90.
16455962|NCT03594175|Placebo Comparator|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
16455963|NCT03594175|Active Comparator|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
16455964|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
16455965|NCT03594149|No Intervention|control|No levofloxacin will be given.
16455966|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
16455967|NCT03594123|Experimental|Brexpiprazole Arm 1|Oral tablet; taken once daily. Total daily dose of 2 mg/day
16455968|NCT03594123|Experimental|Brexpiprazole Arm 2|Oral tablet; taken once daily. Total daily dose of 3 mg/day
16455969|NCT03594110|Experimental|Empagliflozin|
16455970|NCT03594110|Placebo Comparator|Placebo|
16455971|NCT03594097|Experimental|Treatment cookies|
16455972|NCT03594097|Active Comparator|Control cookies|
16455973|NCT03594058|Experimental|Solabegron modified release tablets low dose|
16455974|NCT03594058|Experimental|Solabegron modified release tablets high dose|
16455975|NCT03594058|Placebo Comparator|Placebo Comparator|
16455976|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
16455977|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
16455978|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
16455979|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
16455986|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents >65y No interventions as this is a pilot project
16455987|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents >65y No interventions as this is a pilot project
16455988|NCT03593941||Older adults without dementia|Care home residents >65y No interventions as this is a pilot project
16455990|NCT03593902|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
16455991|NCT03593889|Experimental|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
16455992|NCT03593889|Other|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
16455993|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
16455994|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
16455995|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
16455996|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
16455997|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
16455998|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
16455999|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
16456000|NCT03593824|Experimental|dense cataract group|
16456001|NCT03593824|Experimental|non-dense nuclear cataract group|
16456002|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
16456003|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
16456004|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
16456005|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
16456006|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.
16456007|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
16456008|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
16456009|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
16456010|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
16456011|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
16456042|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
16458251|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
16456012|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
16456013|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
16456016|NCT03593746|Experimental|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
16456017|NCT03593746|Sham Comparator|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
16456018|NCT03593746|Experimental|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
16456019|NCT03593746|Sham Comparator|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
16456020|NCT03593733|Experimental|Cold Water Immersion|Cold Water Immersion
16456021|NCT03593733|Experimental|Photobiomodulation Therapy|Photobiomodulation Therapy
16456022|NCT03593720||Hypospadias|Patients with hypospadias
16456023|NCT03593720||Control|Patients without hypospadias
16456024|NCT03593707|Experimental|Metformin Alone|Metformin alone
16456025|NCT03593707|Experimental|Metformin + PF-06865571|Co-administer metformin and PF-06865571
16456026|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
16456027|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
16456028|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
16456029|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
16456030|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
16456031|NCT03593655|Experimental|Sequence A: Dapivirine vaginal ring + FTC/TDF|Participants will receive one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
16456032|NCT03593655|Experimental|Sequence B: FTC/TDF + Dapivirine vaginal ring|Participants will receive one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
16456033|NCT03593642|Placebo Comparator|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
16456034|NCT03593642|Experimental|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
16456038|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
16456039|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
16456041|NCT03593564|Experimental|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
16458252|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
16456043|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
16456044|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
16456045|NCT03593538|Placebo Comparator|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
16456046|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
16456047|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
16456048|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
16456049|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
16456050|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
16456051|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
16456052|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
16456053|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
16456054|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
16456055|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
16456056|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
16456057|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
16456058|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
16456059|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
16456060|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
16456061|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
16456062|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
16456063|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
16456064|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
16456065|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
16456066|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
16456067|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
16456068|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
16456069|NCT03593408||Pediatric Patients on ECMO Support|
16456070|NCT03593395|Active Comparator|Arm 1-A|Small sized Program Structured Education Based Transition Program [STE]
16456071|NCT03593395|Experimental|Arm 1-B|Small sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
16456072|NCT03593395|Active Comparator|Arm 2-A|Large sized program Structured Education Based Transition Program [STE]
16456073|NCT03593395|Experimental|2-B|Large sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
16456074|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
16456075|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
16456076|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
16456077|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
16456078|NCT03593356|Experimental|Monthly cash gift payments of $333|These subjects receive $333 each month for 52 months via debit card.
16456079|NCT03593356|Active Comparator|Monthly cash gift payments of $20|These subjects receive $20 each month for 52 months via debit card.
16456080|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
16456081|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
16456082|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
16456083|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
16456084|NCT03593317|Experimental|Spironolactone group|
16456085|NCT03593317|Placebo Comparator|Placebo group|
16456086|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
16456087|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
16456088|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
16456089|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
16456090|NCT03593252|Experimental|Combination bowel prep|Patients will received mechanical bowel preparation (age appropriate dose, starting 2 days before surgery) and prophylactic oral antibiotics (3 doses, 1 day before surgery). The standard care will also be delivered (NPO for anesthesia and intravenous antibiotics on induction) Patients/parents will be provided with stool diary to document the adequacy of preparation. This will include frequency and character of stool according to Bristol grade.
16456091|NCT03593252|Active Comparator|Oral antibiotics|The patients will receive prophylactic oral antibiotics (3 doses, 1 day before surgery)as well as standard care (NPO for anesthesia and intravenous antibiotics on induction).
16456092|NCT03593252|Placebo Comparator|No prep|Patients will receive no pre-operative bowel prep. The will receive the standard care only.
16456093|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
16456094|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
16456095|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
16456096|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
16456097|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
16456098|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
16456099|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
16456100|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
16456101|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
16456102|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
16456103|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
16456104|NCT03593213|Experimental|Cariprazine 3.0 mg/day|Cariprazine capsules, oral administration, once daily.
16456105|NCT03593213|Experimental|Cariprazine 4.5 mg/day|Cariprazine capsules, oral administration, once daily.
16456106|NCT03593213|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
16456107|NCT03593200|Experimental|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364*
16456108|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
16456109|NCT03593174|Experimental|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
16456110|NCT03593174|Active Comparator|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
16456111|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
16456112|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
16456113|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
16456114|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
16456115|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
16456152|NCT03592862|Experimental|HTL0018318 low dose|oral capsule, once daily
16456116|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
16456117|NCT03593109|Experimental|LCAR-L10D treatment group|In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 5.0×10^6 CAR-T cells/kg.
16456118|NCT03593096|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
16456119|NCT03593096|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16456120|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
16456121|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16456122|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
16456123|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
16456124|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, one every 15 days.
16456125|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
16456126|NCT03593044|Experimental|One Week Atropine|0.01% concentration atropine drops
16456127|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
16456128|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
16456129|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
16456130|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
16456131|NCT03593018|Experimental|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
16456132|NCT03593018|Active Comparator|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
16456133|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
16456134|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
16456135|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
16456136|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
16456137|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16456138|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
16456139|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
16456140|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
16456141|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
16456142|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
16456143|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
16456144|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
16456145|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16456146|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
16456147|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
16456148|NCT03592888|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
16456149|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
16456150|NCT03592862|Experimental|HTL0018318 high dose|oral capsule, once daily
16456151|NCT03592862|Experimental|HTL0018318 mid dose|oral capsule, once daily
16456154|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
16456155|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
16456156|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
16456157|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
16456158|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
16456159|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
16456160|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
16456161|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
16456162|NCT03592784|Experimental|Food Order Therapy + Medical Nutrition Therapy|
16456163|NCT03592784|Active Comparator|Medical Nutrition Therapy Alone|
16456164|NCT03592771|No Intervention|Usual Care|Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication.
16456165|NCT03592771|Active Comparator|App|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.
~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
16456166|NCT03592771|Active Comparator|App+Feedback|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.
~In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase.
~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
16456167|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
16456168|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
16456169|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
16456170|NCT03592732||A|Patients with atrial fibrillation
16456171|NCT03592732||B|Patients without atrial fibrillation
16456172|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
16456173|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
16456174|NCT03592706|Experimental|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
16456175|NCT03592706|Active Comparator|TACE|TACE (Transcatheter Arterial Chemoembolization)
16456176|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
16456177|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
16456178|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
16456179|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
16456180|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
16456181|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
16456182|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
16456183|NCT03592641|Experimental|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16456184|NCT03592628|Placebo Comparator|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
16456185|NCT03592628|Experimental|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
16456186|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
16456187|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
16456188|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
16456189|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
16456190|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
16456191|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions
~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
16456192|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:
~family history (first degree relative) one or more neurological and/or psychiatric conditions;
~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.
~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
16456193|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.
~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
16456194|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
16456195|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
16456196|NCT03592537|Active Comparator|fentanyl|Group F: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + (5ug) of fentanyl intrathecally
16456197|NCT03592537|Active Comparator|midazolam|Group M: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + 0.5 mg of midazolam intrathecally
16456198|NCT03592537|Placebo Comparator|Bupivacaine|Group B:intrathecal 0.5% bupivacaine (0.3 mg/kg)
16456199|NCT03592511|Experimental|Intervention|WGPF-burger group
16456200|NCT03592511|Placebo Comparator|Control|Control-burger group
16456201|NCT03592498|Active Comparator|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
16456202|NCT03592498|Experimental|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
16456203|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
16456204|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
16456205|NCT03592472|Experimental|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
16456206|NCT03592472|Placebo Comparator|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
16456207|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
16456208|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
16456209|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
16456210|NCT03592433|Experimental|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
16456211|NCT03592433|No Intervention|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
16456212|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions
~On-site supervised group exercise program (11 weeks)
~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)
~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards
~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.
~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
16456213|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
16456214|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
16456215|NCT03592394|Active Comparator|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
16456216|NCT03592394|Active Comparator|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
16456217|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
16456218|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
16456219|NCT03592368|Active Comparator|Active IBT, Out of MRI|
16456220|NCT03592368|Sham Comparator|Sham IBT, Out of MRI|
16456221|NCT03592368|Active Comparator|Active IBT, In MRI|
16456222|NCT03592368|Sham Comparator|Sham IBT, In MRI|
16456223|NCT03592355|Experimental|Intervention|"If enrolled in the intervention arm, the following steps will occur:
~The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.
~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
16456224|NCT03592355|No Intervention|Control|"If enrolled in the control arm, the following steps will occur:
~Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.
~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
16456225|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
16456226|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
16456227|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
16456228|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
16456229|NCT03592329|Experimental|active tVNS + SRT A|active tVNS and Stress Reduction Training A
16456230|NCT03592329|Experimental|active tVNS + SRT B|active tVNS and Stress Reduction Training B
16456231|NCT03592329|Other|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
16456232|NCT03592329|Other|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
16456233|NCT03592316|Experimental|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
16456234|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
16456235|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
16456236|NCT03592277|Experimental|Intervention Arm|Patients in this arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
16456237|NCT03592277|No Intervention|Control Arm|Patients in the control arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
16456238|NCT03592264|Experimental|Dose escalation phase|OBI-3424 (1.0 mg/m^2 to 14.0 mg/m^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle or Day 1 of each 21-day cycle to determine the MTD and RP2D with a classic 3+3 dose escalation design.
16456239|NCT03592264|Experimental|Cohort expansion phase|Once the MTD and RP2D is determined then OBI-3424 (dosage TBD) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
16456240|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
16456241|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
16456242|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
16456243|NCT03592238|Experimental|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
16456244|NCT03592238|Active Comparator|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
16456245|NCT03592238|Placebo Comparator|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
16456246|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
16456247|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
16456248|NCT03592199|Experimental|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
16456249|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
16456250|NCT03592186|Active Comparator|Treatment as Usual|"The active comparator is defined as residential treatment services as usual.
~At short-term facility, average length of stay was 6-10 days. At long-term facility, average length of stay was 30-45 days."
16456251|NCT03592173|Experimental|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
16456413|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
16456252|NCT03592173|Active Comparator|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
16456253|NCT03592173|Active Comparator|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
16456254|NCT03592160|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
16456255|NCT03592160|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
16456256|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
16456257|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
16456258|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
16456259|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
16456260|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
16456261|NCT03592108|Experimental|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
16456262|NCT03592095|Experimental|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
16456263|NCT03592095|Placebo Comparator|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
16456264|NCT03592082|Active Comparator|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
16456265|NCT03592082|Experimental|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
16456266|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:
~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
16456267|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:
~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
16456268|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
16456269|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
16456270|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
16456271|NCT03592004||Guangdong General Hospital|
16456272|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
16456273|NCT03592004||Beijing Friendship Hospital|
16456274|NCT03592004||Yunnan Cancer Hospital|
16456275|NCT03592004||Liaoning Cancer Hospital|
16456276|NCT03592004||The First Hospital Of China Medical University|
16456277|NCT03592004||Affiliated Hospital Of Hebei University|
16456278|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
16456279|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
16456280|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
16456281|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
16456282|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
16456414|NCT03591042|Experimental|cervical length screening|cervical length screening
16456415|NCT03591042|No Intervention|no screening|no screening
16456283|NCT03591965|Experimental|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
16456284|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
16456285|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
16456286|NCT03591939||1|cases of Diabetic type two nephropathy
16456287|NCT03591939||2|controls of normal subjects
16456288|NCT03591926|Experimental|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
16456289|NCT03591926|Experimental|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
16456290|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
16456291|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
16456292|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:
~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).
~B-Therapeutic intervention:
~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
16456293|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:
~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et
~B-Therapeutic intervention:
~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
16456294|NCT03591887|Experimental|ABY-035 2 mg|2 mg ABY-035 SC
16456295|NCT03591887|Experimental|ABY-035 20 mg|20 mg ABY-035 SC
16456296|NCT03591887|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
16456297|NCT03591887|Experimental|ABY-035 160 mg|160 mg ABY-035 SC
16456298|NCT03591887|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
16456299|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
16456300|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
16456301|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)
~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months
~Laboratory studies prior to hospital admission and then at each follow-up visit
~Hospital admission (3-5 day) to start the ketogenic diet
~Standard of care chemotherapy with BCNU for up to 2 years
~Ketogenic diet can continue for up to 2 years"
16456302|NCT03591848|Experimental|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
16456303|NCT03591848|Active Comparator|IRIS|Exposed to a standard oral information
16456304|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
16456305|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
16456306|NCT03591822|Other|Arm AB : Intervention under study x Control intervention|Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
16456307|NCT03591822|Other|Arm BA: Control intervention x Intervention under study|Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
16456308|NCT03591809|Experimental|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
16456309|NCT03591809|No Intervention|Control group|The patients in the control group will not apply an exercise training.
16456310|NCT03591796|Experimental|HFOV|Ventilated infants were randomized to HFOV.
16456311|NCT03591796|Active Comparator|CMV|Ventilated infants were randomized to CMV.
16456312|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
16456313|NCT03591770|Experimental|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
16456314|NCT03591770|Active Comparator|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
16456315|NCT03591770|Active Comparator|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
16456316|NCT03591770|Active Comparator|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
16456317|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
16456318|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
16456319|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
16456320|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
16456321|NCT03591718|Experimental|BI 456906|
16456322|NCT03591718|Experimental|Placebo|
16456323|NCT03591705|Experimental|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
16456324|NCT03591705|Active Comparator|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
16456325|NCT03591692|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
16456326|NCT03591692|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
16456327|NCT03591679|Experimental|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
16456328|NCT03591679|Active Comparator|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
16456329|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16456330|NCT03591653|Experimental|LXI-15028 50mg group|
16456331|NCT03591653|Placebo Comparator|Placebo group|
16456332|NCT03591640|Active Comparator|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
16456333|NCT03591640|Active Comparator|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
16456334|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
16456335|NCT03591614|Experimental|Dendritic cell DKK1 vaccine|5-10x106 DKK1 loaded dendritic cells. Three doses will be given two weeks apart, followed by 11 months of observations.
16456336|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
16456337|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
16456338|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
16456339|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
16456340|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
16456341|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
16456342|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
16456343|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
16456344|NCT03591549|Experimental|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
16456345|NCT03591536|Other|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
16456346|NCT03591536|Placebo Comparator|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
16456347|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
16456348|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|"In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.
~In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy."
16456349|NCT03591497|Experimental|Intervention Group|"Instrument to be used:
~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.
~Programme schedule:
~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
16456350|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
16456351|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
16456352|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
16456353|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
16456354|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
16456355|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.
~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
16456356|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.
~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
16456357|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
16456358|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
16456359|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
16456360|NCT03591432|Experimental|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
16456361|NCT03591432|Active Comparator|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
16456362|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
16456363|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
16456364|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
16456365|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
16456366|NCT03591393|Experimental|Pregnant women|"questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum
~pelvic floor ultrasound at 1st trimester and at 3rd trimester"
16456367|NCT03591380|Experimental|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
16456368|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
16456369|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 3 months.
~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)
~Objective 2: This arm is participants who had 6 months of SAP in the primary trial (DCLP3 Pivotal Trial)
~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
16456370|NCT03591354|Active Comparator|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ & Dexcom G6 CGM for 3 months.
~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)
~Objective 2: This arm is not applicable to objective 2
~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
16456371|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
16456372|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
16456373|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
16456374|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
16456375|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
16456416|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
16456417|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
16456418|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
16456376|NCT03591302|Experimental|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
16456377|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
16456378|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
16456379|NCT03591276|Experimental|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.
~Reduced Dose Cohort (R1)*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.
~*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
16456380|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
16456381|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
16456382|NCT03591224|Active Comparator|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
16456383|NCT03591224|Placebo Comparator|Control|Pharmacist optimizing antidepressant therapy based on standard of care
16456384|NCT03591211|Experimental|Qigong Training|
16456385|NCT03591211|Active Comparator|Cognitive Training|
16456386|NCT03591198|Experimental|Qigong Training|
16456387|NCT03591198|Active Comparator|Cognitive Training|
16456388|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
16456389|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
16456390|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
16456391|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
16456392|NCT03591159|Active Comparator|Membrane Sweeping Group|
16456393|NCT03591159|No Intervention|Control Group|
16456394|NCT03591146|Experimental|TLC590 190mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16456395|NCT03591146|Experimental|TLC590 380mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16456396|NCT03591146|Experimental|TLC590 570mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16456397|NCT03591146|Experimental|TLC590 475mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
16456398|NCT03591146|Active Comparator|Naropin 150mg|Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
16456399|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
16456400|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
16456401|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
16456402|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
16456403|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
16456404|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
16456405|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
16456406|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
16456407|NCT03591094|Active Comparator|PTI-428 dose level 1|
16456408|NCT03591094|Active Comparator|PTI-428 dose level 2|
16456409|NCT03591094|Placebo Comparator|Placebo PTI-428|
16456410|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
16456411|NCT03591068|Experimental|OPN-375 186 mcg BID|
16456412|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
16456419|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
16456420|NCT03590964|Active Comparator|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
16456421|NCT03590964|Experimental|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
16456422|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
16456423|NCT03590912|No Intervention|Wait and watch (Group D)|Wait and watch for 1 month
16456424|NCT03590912|Experimental|Mometasone spray (Group B)|Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given
16456425|NCT03590912|Experimental|antibiotic + histaminic + oxymetazoline drops (Group A)|This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given
16456426|NCT03590912|Experimental|Oral steroid (Group C)|Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week
16456427|NCT03590899||Healthy patients|
16456428|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
16456429|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
16456430|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
16456431|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.
~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
16456432|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
16456433|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
16456434|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
16456435|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
16456436|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
16456437|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
16456438|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
16456439|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
16456440|NCT03590834|Active Comparator|Active Control|Active comparison group
16456441|NCT03590821|Experimental|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
16456442|NCT03590821|Experimental|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
16456443|NCT03590808|Experimental|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients
~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
16456444|NCT03590808|Active Comparator|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy
~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
16456445|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
16456446|NCT03590769|Experimental|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
16456447|NCT03590756|Experimental|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
16456448|NCT03590756|Other|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
16456449|NCT03590743|Active Comparator|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
16456450|NCT03590743|Placebo Comparator|Placebo|Patients will receive matching placebo.
16456451|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
16456452|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
16456453|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
16456454|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
16456477|NCT03590600|Experimental|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
16456478|NCT03590600|Placebo Comparator|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
16456479|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
16456480|NCT03590574|Experimental|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
16456481|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
16456455|NCT03590704|Experimental|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
16456456|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
16456457|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.
~PLUS
~Three selected enhancements integrated into routine clinical care:
~expanded community health worker services;
~home blood pressure self-monitoring; and
~a storytelling intervention."
16456458|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
16456459|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
16456460|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
16456461|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
16456462|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
16456463|NCT03590626|Experimental|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
16456464|NCT03590626|No Intervention|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
16456465|NCT03590613|Experimental|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
16456466|NCT03590613|Experimental|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
16456467|NCT03590613|Experimental|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
16456468|NCT03590613|Experimental|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
16456469|NCT03590600|Experimental|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
16456470|NCT03590600|Placebo Comparator|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
16456471|NCT03590600|Experimental|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
16456472|NCT03590600|Placebo Comparator|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
16456473|NCT03590600|Experimental|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
16456474|NCT03590600|Placebo Comparator|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
16456475|NCT03590600|Experimental|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
16456476|NCT03590600|Placebo Comparator|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
16456483|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
16456484|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
16456485|NCT03590522||Group I:|Thirty heart failure patients
16456486|NCT03590522||Group II:|Twenty healthy controls
16456487|NCT03590509|Experimental|Telemedicine Program*|"Integrated Telemedicine-Home Visitation* Program.
~*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
16456488|NCT03590509|Active Comparator|Control|Usual Comprehensive Care
16456489|NCT03590496|Active Comparator|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
16456490|NCT03590496|Placebo Comparator|Arm 2|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
16456491|NCT03590470|Experimental|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
16456492|NCT03590470|No Intervention|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
16456493|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
16456494|NCT03590444|Active Comparator|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).
~Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
16456495|NCT03590444|Active Comparator|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).
~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
16456496|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
16456497|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
16456498|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
16456499|NCT03590418||Intestinal stoma output|No interventions.
16456500|NCT03590418||Colonic feaces|No interventions.
16456501|NCT03590418||Healthy Control|No interventions.
16456502|NCT03590405|Experimental|uterus transplantation|uterus transplantation from living donor with the donor being close relative
16456503|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
16456504|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
16456505|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
16456506|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
16456507|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
16456508|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
16456509|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle
~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
16456510|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle
~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
16456511|NCT03590353|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.
~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;
~Patients with acute myocardial infarction (AMI) and AVB:
~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
16456512|NCT03590353|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
16456513|NCT03590340|Experimental|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 113.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
16456514|NCT03590340|Experimental|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
16456515|NCT03590340|Experimental|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
16456516|NCT03590340|Experimental|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
16456517|NCT03590340|Placebo Comparator|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
16456518|NCT03590340|Placebo Comparator|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
16456519|NCT03590340|Placebo Comparator|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
16456520|NCT03590340|Placebo Comparator|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
16456521|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
16456522|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
16456523|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
16456524|NCT03590314|Experimental|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
16456525|NCT03590314|Active Comparator|Control group|The control group was treated using a conventional training, without end effector robot.
16456526|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
16456527|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
16456528|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
16456529|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
16456530|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
16456531|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
16456532|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
16456533|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
16456534|NCT03590236|No Intervention|Control group|Waiting list patients
16456535|NCT03590210|Experimental|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
16456536|NCT03590210|Experimental|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
16456537|NCT03590197|Placebo Comparator|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
16456538|NCT03590197|Experimental|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
16456539|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
16456540|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
16456541|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
16456542|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
16456543|NCT03590158|Experimental|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
16456544|NCT03590145||Qatari athletes|Participants meeting general inclusion criteria.
16456545|NCT03590132|Experimental|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
16456546|NCT03590132|Experimental|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
16456547|NCT03590132|Experimental|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
16456548|NCT03590132|No Intervention|Control|These participants receive no interventions.
16456549|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
16456550|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
16456551|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:
~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.
~Demonstrate negative drug screens done randomly during their hospitalization.
~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).
~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.
~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
16456552|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
16456553|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
16456554|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
16456555|NCT03590067||Heamodialysis group|
16456556|NCT03590067||Kidney transplantation group|
16456557|NCT03590054|Experimental|Treatment (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days 1-21 and pembrolizumab IV on over 30 minutes day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16456560|NCT03590028|Experimental|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
16456561|NCT03590028|Active Comparator|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
16456562|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
16456563|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
16456564|NCT03590002|Experimental|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
16456565|NCT03590002|No Intervention|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
16456566|NCT03589989|Experimental|Intervention group|
16456567|NCT03589989|Active Comparator|Control group|
16456568|NCT03589976|Experimental|Sirolimus|2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).
16456569|NCT03589976|Placebo Comparator|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
16456570|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
16456571|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
16456572|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
16456573|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
16456574|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
16456575|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
16456576|NCT03589898|Experimental|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
16456577|NCT03589885|Placebo Comparator|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
16456578|NCT03589885|Placebo Comparator|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 * 1 ml prefilled syringe form
16456579|NCT03589885|Experimental|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
16456580|NCT03589885|Active Comparator|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
16456581|NCT03589872||Study Group|patients with parkinson disease
16456582|NCT03589859||Normal Volunteers|Testing motor learning
16456583|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
16456585|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
16456586|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
16456587|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
16456588|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
16456589|NCT03589820|Active Comparator|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
16456590|NCT03589820|No Intervention|Control group|30 patients will receive treatment of internal medicine.
16456591|NCT03589807|Experimental|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
16456592|NCT03589807|Experimental|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
16456593|NCT03589807|Experimental|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
16456594|NCT03589807|Experimental|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
16456595|NCT03589807|Experimental|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
16456596|NCT03589807|Experimental|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
16456597|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
16456598|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
16456599|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
16456600|NCT03589794|Experimental|Group 4|9 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
16456601|NCT03589794|Experimental|Group 4B|10 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
16456602|NCT03589794|Experimental|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
16456603|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
16456604|NCT03589781|Experimental|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
16456605|NCT03589781|Placebo Comparator|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
16456606|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).
~N=133"
16456607|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.
~N=67"
16456608|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
16456609|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
16456610|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
16456611|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
16456612|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
16456613|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
16456614|NCT03589703|Active Comparator|APA|Patients with active points related to cLBP. Will receive acupressure within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain.
16456615|NCT03589703|Sham Comparator|Comparison Group (CG-1)|"The same procedure for APA will be applied but the tapes/seeds will be placed on five different ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.
~These points are chosen for the sham APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group."
16456616|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|Participants in the enhanced educational control group will be given the cLBP educational booklet and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA groups.
16456617|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
16456618|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
16456619|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:
~quality of life evaluation
~exam of neuroimaging
~study of myomiRNAs before and after rehabilitation"
16456620|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
16456621|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
16456622|NCT03589651|Experimental|Group A|INCMGA00012 with epacadostat.
16456623|NCT03589651|Experimental|Group B|INCMGA00012 with INCB050465.
16456624|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
16456625|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
16456626|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
16456627|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
16456628|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
16456629|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
16456630|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
16456631|NCT03589586|Experimental|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
16456632|NCT03589586|No Intervention|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
16456633|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
16456634|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
16456635|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).
~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors
~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
16456636|NCT03589534|Other|pregnancy test|pregnancy tests
16456637|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
16456638|NCT03589508|Experimental|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
16456639|NCT03589508|Experimental|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
16456640|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
16456641|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
16456642|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
16456643|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
16456644|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
16456645|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
16456646|NCT03589430||1 child A|child A liver cirrhosis
16456647|NCT03589430||2 child B|child B liver cirrhosis
16456649|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
16456650|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
16456651|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
16456652|NCT03589378|Experimental|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
16456653|NCT03589378|No Intervention|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
16456654|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
16456655|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
16456656|NCT03589339|Experimental|NBTXR3 activated by SABR|
16456657|NCT03589326|Experimental|Cohort A: Ponatinib 30 milligram (mg)|Ponatinib 30 mg, tablets, orally, once daily (QD), with vincristine 1.4 mg/m^2 intravenous(IV), on Days 1 and 14 and dexamethasone 40 mg(<60 years [yrs]) and 20 mg (>=60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 for up to 3 cycles (each cycle will be of 28-days) in induction phase followed by ponatinib last dose of induction phase tablets, orally, QD, with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour IV infusion (<60 yrs) and 250 mg/m^2 every 12 hours (>=60 yrs), IV on Days 1, 3, and 5 of Cycles 2, 4, and 6, (cytarabine dose will be reduced/ discontinued in case of impaired renal function) and methotrexate, 1000 mg/m^2 (<60 yrs) and 250 mg/m^2 (>=60 yrs), IV infusion, on Day 1 of cycles 1, 3, and 5 in consolidation phase followed by ponatinib last dose of consolidation phase, tablets, orally, QD, with vincristine 1.4 mg/m^2, IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (>=60-69 yrs) and 50 mg(>=70 yrs) on Days 1 to 5 for up to 11 cycles in maintenance phase.
16456658|NCT03589326|Active Comparator|Cohort B: Imatinib 600 mg|Imatinib 600 mg,tablets, orally,QD,along with vincristine 1.4 mg/m^2 (max 2 mg),IV,on Days 1 and 14 and dexamethasone 40 mg (<60 yrs) and 20 mg (≥60 yrs),orally,once on Days 1 through 4 and Days 11 through 14 in each 28-day cycle up to 3 cycles in induction phase followed by imatinib 600 mg,tablets,orally,QD, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (<60 yrs) and 250 mg/m^2 every 12 hours (≥60 yrs), IV on Days 1,3, and 5 of each 28-day even cycles (Cycles 2,4,and 6), (cytarabine dose reduced/discontinued for participant with impaired renal function) and methotrexate, 1000 mg/m^2 (<60 yrs) and 250 mg/m^2 (≥60 yrs),IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1,3,and 5) in consolidation phase followed by imatinib 600 mg,tablets,orally,QD, along with vincristine 1.4 mg/m^2 (max 2 mg),IV,on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each 28-day cycle up to 11 cycles in maintenance phase.
16456659|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
16456661|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
16456662|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
16456663|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
16456664|NCT03589274|Experimental|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
16456665|NCT03589274|Experimental|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
16456666|NCT03589261|Other|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
16456667|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
16456668|NCT03589248||US score|assess the AGI by ultrasonography(US) score
16456669|NCT03589235|Experimental|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
16456670|NCT03589235|Experimental|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
16456734|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
16456735|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
16456736|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
16456906|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
16456671|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
16456672|NCT03589196|Active Comparator|Photoselective Vaporization|
16456673|NCT03589196|Active Comparator|Plasma Kinetic Vaporization|
16456674|NCT03589196|Active Comparator|Transurethral Resection Of The Prostate|
16456675|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
16456676|NCT03589157|Experimental|Drug-coated balloon group|
16456677|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
16456678|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
16456679|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.
~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
16456680|NCT03589118|Experimental|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
16456681|NCT03589118|No Intervention|Control|Usual well defined medical and psychological support
16456682|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
16456683|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.
~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
16456684|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).
~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
16456685|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
16456686|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
16456687|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
16456688|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
16456689|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
16456690|NCT03589040|Other|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
16456691|NCT03589040|Other|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
16456692|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
16456693|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
16456694|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
16456695|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
16456696|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
16456697|NCT03588988|Experimental|Dexmedetomidine group|
16456698|NCT03588988|Placebo Comparator|Control group|
16456701|NCT03588962|Experimental|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
16456737|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
16456798|NCT03588260||Idiopathic pulmonary fibrosis|The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
16456702|NCT03588962|Placebo Comparator|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
16456703|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
16456704|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
16456705|NCT03588936|Experimental|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).
~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
16456706|NCT03588936|Experimental|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).
~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
16456707|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
16456708|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
16456709|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
16456710|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
16456711|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
16456712|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
16456713|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
16456714|NCT03588884|Active Comparator|CTAP101|CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
16456715|NCT03588884|Experimental|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
16456716|NCT03588884|Experimental|Cholecalciferol|Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
16456717|NCT03588884|Active Comparator|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
16456718|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
16456719|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
16456720|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
16456721|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.
~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
16456722|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
16456723|NCT03588819|Experimental|2-fraction SABR|
16456724|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
16456725|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
16456726|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
16456727|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
16456728|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
16456729|NCT03588741|Experimental|Turoctocog alfa|
16456730|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
16456731|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
16456732|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
16456733|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
16456738|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.
~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
16456739|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
16456740|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
16456741|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
16456742|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
16456743|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
16456744|NCT03588650|Experimental|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
16456745|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
16456746|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
16456747|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
16456748|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
16456749|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
16456750|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
16456751|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
16456752|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
16456753|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
16456754|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
16456755|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
16456756|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
16456757|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)
~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks
~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
16456758|NCT03588520|Experimental|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
16456759|NCT03588520|No Intervention|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
16456760|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
16456761|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
16456762|NCT03588494|Active Comparator|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
16456799|NCT03588260||Healthy subjects|The healthy adults without additional disease
16456763|NCT03588494|Experimental|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
16456764|NCT03588494|Experimental|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
16456765|NCT03588481||Coronary stenosis|
16456766|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
16456767|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.
~Electrophysiological biomarkers and MRI biomarkers will be performed"
16456768|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.
~Electrophysiological biomarkers and MRI biomarkers will be performed"
16456769|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
16456770|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
16456771|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
16456772|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
16456773|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
16456774|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
16456775|NCT03588390|Experimental|Dose Group 1|
16456776|NCT03588390|Experimental|Dose Group 2|
16456777|NCT03588390|Experimental|Dose Group 3|
16456778|NCT03588390|Experimental|Dose Group 4|
16456779|NCT03588390|Experimental|Dose Group 5|
16456780|NCT03588390|Experimental|Dose Group 6|
16456781|NCT03588390|Experimental|Dose Group 7|
16456782|NCT03588390|Experimental|Dose Group 8|
16456783|NCT03588377|Active Comparator|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
16456784|NCT03588377|No Intervention|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
16456785|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
16456786|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
16456787|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
16456788|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
16456789|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
16456790|NCT03588338|Active Comparator|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
16456791|NCT03588338|Other|Control|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
16456792|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
16456793|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
16456794|NCT03588299|Experimental|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
16456795|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).
~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.
~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
16456796|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
16456797|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
16456850|NCT03587987|Active Comparator|Neopuff|neopuff
16456800|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
16456801|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
16456802|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
16456803|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
16456804|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
16456805|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
16456806|NCT03588208|Experimental|Intervention Group|
16456807|NCT03588208|Active Comparator|Control Group|
16456808|NCT03588195|Experimental|Education Group|
16456809|NCT03588195|Active Comparator|Control Group|
16456810|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
16456811|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
16456812|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
16456813|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
16456814|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
16456815|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
16456816|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
16456817|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
16456818|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
16456819|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
16456820|NCT03588130|Active Comparator|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
16456821|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
16456822|NCT03588104|Experimental|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
16456823|NCT03588104|Active Comparator|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
16456824|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
16456825|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
16456826|NCT03588078|Experimental|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
16456827|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
16456851|NCT03587987|Experimental|r PAP|rPap device
16456852|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
16456853|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
16456828|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.
~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
16456829|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
16456830|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin
~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
16456831|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
16456832|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456833|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456834|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456835|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456836|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456837|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456838|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456839|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456840|NCT03588039|Experimental|Dose expansion-Urothelial cancer|The dose expansion period will enroll subjects with advanced/metastatic urothelial to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
16456841|NCT03588026|Experimental|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
16456842|NCT03588026|Experimental|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
16456843|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
16456844|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
16456845|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
16456846|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
16456847|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
16456848|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
16456849|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
16456854|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
16456855|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
16456856|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
16456857|NCT03587948||Case group|Children and adolescents with diabetes mellitus
16456858|NCT03587948||Control group|Children and adolescents without diabetes mellitus
16456859|NCT03587922|Experimental|Treatment Arm|Single arm study with treatment of Fantom scaffold
16456860|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
16456861|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
16456862|NCT03587896|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
16456863|NCT03587896|No Intervention|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
16456864|NCT03587883|Experimental|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
16456865|NCT03587883|Placebo Comparator|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
16456866|NCT03587870|Experimental|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
16456867|NCT03587870|Active Comparator|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
16456868|NCT03587857|Experimental|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
16456869|NCT03587844|Experimental|not been previously treated with brentuximab vedotin.|Patients with MF/SS who have not been previously treated with brentuximab vedotin. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. As of October 2020, the Simon two stage design for Cohort 1 has restarted at the 1.2 mg/kg dose.
16456870|NCT03587844|Experimental|treated with reduced dose brentuximab vedotin|Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. The 0.9mg/kg dose did not meet the primary endpoint for response, therefore 1.2 mg/kg has been chosen as the dose for Cohort 2. As of October 2020, enrollment on our exploratory Cohort 2 has opened at the 1.2 mg/kg dose.
16456871|NCT03587844|Experimental|Patients with LyP|Patients with LyP patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1. Treatment may be held if felt to be in patient's best interest (for example: for toxicity or no active disease). Treatment can be reinitiated after discussion with MSK PI as long as the study is still open and patient has not received alternate systemic therapy.
16456872|NCT03587831|Experimental|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.
~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
16456873|NCT03587831|Active Comparator|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
16456874|NCT03587818|No Intervention|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.
~Communication between patients and professionals during consultations occurred according to conventional care practice."
16456902|NCT03587558|Active Comparator|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
16456903|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
16456904|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
16456875|NCT03587818|Experimental|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:
~generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility
~arena of dialogues between patient and professionals; voicing concerns, share perspectives
~for the patient to personally reflect on generic information.
~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:
~professionals guiding the patient through the care process
~communicating an introduction, agenda and closing
~being sensitive to the patient's questions, beliefs, experiences and resources
~dialogue based on story, posing open-ended questions, and following up."
16456877|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
16456878|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
16456879|NCT03587766|Experimental|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
16456880|NCT03587766|Experimental|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
16456881|NCT03587766|Experimental|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
16456882|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
16456883|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
16456885|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
16456886|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
16456887|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
16456888|NCT03587675|Other|EVH in high-school elite athletes|EVH-test, skin prick test, sputum induction in all subjects Interventional but no drug or device tested
16456889|NCT03587662|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Patients receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ixazomib PO and gemcitabine IV over 90 minutes. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
16456890|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
16456891|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
16456892|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
16456893|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date
~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
16456894|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date
~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
16456895|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
16456896|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
16456897|NCT03587584|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
16456898|NCT03587584|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
16456899|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
16456900|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
16456901|NCT03587558|Experimental|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
16456905|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.
~Placebo nasal spray."
16457696|NCT03582176|Active Comparator|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
16456907|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
16456908|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
16456909|NCT03587532|Experimental|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
16456910|NCT03587519|Experimental|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
16456911|NCT03587519|Active Comparator|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
16456912|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
16456913|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
16456914|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
16456915|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
16456917|NCT03587480|Other|TME+LLND group|Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
16456918|NCT03587480|Other|TME+nCRT group|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
16456919|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~smooth and soft stool like sausage or snake
~Voluntary participate in this study"
16456920|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
16456921|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
16456922|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
16456923|NCT03587454|Experimental|Tele-Glaucoma arm|Subjects enrolled in tele-glaucoma arm for remote assessment
16456924|NCT03587441|Active Comparator|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
16456925|NCT03587441|Placebo Comparator|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
16456926|NCT03587428|Experimental|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
16456927|NCT03587428|Experimental|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
16456928|NCT03587428|Other|Mineral Water|In this arm, participants received mineral water.
16456929|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
16456930|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
16456931|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
16456932|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
16456933|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.
~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.
~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
16456934|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
16456935|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
16456936|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
16456937|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
16457697|NCT03582176|Active Comparator|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
16456938|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
16456939|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
16456940|NCT03587350|Active Comparator|Interventional Treatment|
16456941|NCT03587350|No Intervention|Usual care|
16456942|NCT03587337||Prophylaxis|
16456943|NCT03587337||Antibiotic tp|
16456944|NCT03587324|Experimental|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
16456947|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
16456948|NCT03587298||Group 2|Control group: matched age; no NAFKL
16456949|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
16456950|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
16456951|NCT03587272|Experimental|SUN regimen|"Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
16456952|NCT03587259|Active Comparator|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
16456953|NCT03587259|Experimental|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
16456954|NCT03587246||Pregnant women|
16456955|NCT03587246||non-pregnant women|
16456956|NCT03587233|Active Comparator|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
16456957|NCT03587233|Active Comparator|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
16456958|NCT03587233|Active Comparator|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
16456959|NCT03587233|Active Comparator|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
16456960|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
16456961|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
16456962|NCT03587207|Experimental|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
16456963|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
16456964|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
16456965|NCT03587207|Active Comparator|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
16456966|NCT03587207|Active Comparator|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
16456967|NCT03587194|Experimental|Otezla|Otezla BID
16456968|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
16456969|NCT03587168||Healthy Controls|Healthy People
16456970|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
16456971|NCT03587155||Control|Embryo or infant without ASNS mutation.
16456972|NCT03587142|Active Comparator|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
16456973|NCT03587142|Placebo Comparator|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
16456974|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
16456977|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
16456978|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
16456979|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
16456980|NCT03587077|Experimental|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
16456981|NCT03587077|Placebo Comparator|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
16456982|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
16456983|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
16456984|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
16456985|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
16456986|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
16456987|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
16456988|NCT03587025|Active Comparator|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
16456989|NCT03587025|Placebo Comparator|Placebo|Patients who will be take placebo 30min before surgery.
16456990|NCT03587012|Experimental|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
16456991|NCT03587012|Experimental|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD combined with simultaneous transcranial alternating current stimulation (tACS)
16456992|NCT03586999|Experimental|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
16456993|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
16456994|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
16456995|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
16456996|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state. Participants received first/second line anticancer therapy with sorafenib before this study were assigned to Cohort A.
16456997|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Cabozantinib 60 mg, tablet orally, once daily in the fasted state. Participants who did not receive first/second line anticancer therapy with sorafenib before this study were assigned to Cohort B.
16457016|NCT03586843|Experimental|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
16456998|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
16456999|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
16457000|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
16457001|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
16457002|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.
~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
16457003|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
16457004|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
16457005|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
16457006|NCT03586895|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
16457007|NCT03586882|Experimental|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
16457008|NCT03586882|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
16457009|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
16457010|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
16457011|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
16457012|NCT03586843|Experimental|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
16457013|NCT03586843|Experimental|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
16457014|NCT03586843|Experimental|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
16457015|NCT03586843|Experimental|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
16457017|NCT03586843|Experimental|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
16457018|NCT03586843|Experimental|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
16457019|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
16457020|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
16457021|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
16457022|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
16457023|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
16457024|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
16457025|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
16457026|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
16457027|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
16457028|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
16457029|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
16457030|NCT03586778|Experimental|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
16457031|NCT03586778|Active Comparator|MTEX|manual therapy and therapeutic exercise
16457032|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
16457033|NCT03586752|Experimental|On-line group|On-line program course
16457034|NCT03586752|Active Comparator|Standard group|Standard program course
16457035|NCT03586739|Experimental|"Covered stents strategy"|
16457036|NCT03586739|Active Comparator|"Bare metal stents strategy"|
16457037|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
16457038|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
16457039|NCT03586700|Experimental|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
16457040|NCT03586700|Placebo Comparator|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
16457041|NCT03586687|Active Comparator|20 mg|20mg Triamcinolone with 3cc of 1% Lidocaine
16457042|NCT03586687|Active Comparator|40 mg|40mg Triamcinolone with 3cc of 1% Lidocaine
16457043|NCT03586687|Active Comparator|80 mg|80mg Triamcinolone with 3cc of 1% Lidocaine
16457044|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
16457045|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
16457046|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16457047|NCT03586648|Experimental|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
16457048|NCT03586648|Experimental|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
16457049|NCT03586635||Patients with Multiple Sclerosis|
16457050|NCT03586622|Experimental|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
16457084|NCT03586388|Experimental|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
16457698|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
16457051|NCT03586622|Experimental|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
16457052|NCT03586609|Experimental|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
16457053|NCT03586596|Experimental|The Decídetext program|Participants will receive a tablet-based interactive educational session, 6 months of text-messaging based counseling, which includes prompts to access free pharmacotherapy.
16457054|NCT03586596|Active Comparator|Standard Care Control|Participants will receive an adapted version of standard printed smoking cessation educational materials from the American Cancer Society and, the National Cancer Institute, which include information about the health risks of smoking, benefits & strategies for quitting and access to free pharmacotherapy by calling a free number.
16457055|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
16457056|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
16457057|NCT03586570|Experimental|Aprocitentan|
16457058|NCT03586570|Placebo Comparator|Placebo|
16457059|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
16457060|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
16457061|NCT03586544|Experimental|Albuterol first|Order albuterol and then interval warm up (IWU)
16457062|NCT03586544|Experimental|Interval warm-up first|Order is interval warm up (IWU) and then albuterol
16457063|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.
~Inclusion:
~Prevalent haemodialysis patient (more than 3 months)
~Active on the supportive care register with anticipated death in the subsequent 12 months
~Able to give informed consent
~Consent to donation of heart for research following death
~Able to understand written and verbal explanations in English
~Exclusion:
~Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)
~Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)
~Unable to give informed consent
~Unable to understand written and verbal explanations in English"
16457064|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.
~The patients switch off the light when the discomfort is too elevated"
16457065|NCT03586492|Other|Patient with myocardial ischemia|
16457066|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
16457067|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
16457068|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
16457069|NCT03586466|Experimental|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
16457070|NCT03586466|Active Comparator|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
16457071|NCT03586466|Active Comparator|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
16457072|NCT03586453|Experimental|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
16457073|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
16457074|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree
~distance between on table and acromion ≥ 2.5 cm"
16457075|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree
~distance between on table and acromion < 2.5 cm"
16457076|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
16457077|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
16457078|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
16457079|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
16457080|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
16457081|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
16457082|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
16457083|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
16457085|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
16457086|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
16457087|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
16457088|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
16457089|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
16457090|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
16457091|NCT03586310|Other|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
16457092|NCT03586310|Other|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.
~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
16457093|NCT03586284|Active Comparator|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
16457094|NCT03586284|Active Comparator|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
16457095|NCT03586284|Placebo Comparator|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
16457096|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
16457097|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
16457098|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
16457099|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
16457100|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
16457101|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
16457102|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.
~57FePP (95.8%) 3.49 mg
~Aspergillus oryzae (unenriched) 0.025 mg
~FePP natural abundance 0.685 mg.
~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
16457103|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.
~ASP-p (8% Fe; natural abundance) 3.516 mg
~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg
~4.2 total mg of Fe"
16457104|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .
~Aspergillus oryzae (unenriched) 0.027 mg
~57FeSO4 (95.4%) 3.18 mg
~4.2 total mg of Fe"
16457105|NCT03586232|Placebo Comparator|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
16457106|NCT03586232|Experimental|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
16457107|NCT03586232|Experimental|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
16457108|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
16457109|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
16457110|NCT03586206||Mild-moderate C.difficile infection|
16457111|NCT03586206||severe C.difficile infection|
16457112|NCT03586206||severe complicated/fulminant C.difficile infection|
16457113|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
16457114|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
16457115|NCT03586180||Dr. Clowns|they will perform shows for children and parents
16457116|NCT03586167|Experimental|LID014341|LID014341 contact lenses worn bilaterally (in both eyes) for 30 days on a daily wear basis
16457117|NCT03586167|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally for 30 days on a daily wear basis
16457118|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
16457119|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
16457120|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
16457121|NCT03586128||HIV serodiscordant couples|
16457122|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
16457176|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
16457699|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
16457123|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
16457124|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
16457125|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
16457126|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
16457127|NCT03586076|Experimental|JHL1922|
16457128|NCT03586076|Active Comparator|Pulmozyme|
16457129|NCT03586050|Experimental|Microwave Ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
16457130|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
16457131|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
16457132|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
16457133|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
16457134|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
16457135|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
16457136|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
16457137|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
16457138|NCT03585998|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
16457139|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
16457140|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
16457141|NCT03585972|Experimental|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
16457142|NCT03585972|No Intervention|Educational materials|Participants receive publicly available educational materials
16457143|NCT03585959|Experimental|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
16457144|NCT03585946||Cyclosporine|
16457145|NCT03585946||Intravenous Immunoglobulin|
16457146|NCT03585946||Etanercept|
16457147|NCT03585946||Steroids|
16457148|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
16457149|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
16457150|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
16457151|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
16457152|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
16457153|NCT03585894|Other|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
16457154|NCT03585894|Active Comparator|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
16457155|NCT03585881|Experimental|window bracket positioning tray|
16457156|NCT03585881|No Intervention|conventional indirect boning tray|
16457157|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
16457158|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
16457159|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
16457160|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
16457161|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
16457162|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
16457163|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
16457164|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
16457165|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
16457166|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
16457167|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
16457168|NCT03585803|Other|KMRC011 15μg or Placebo|Cohort 3
16457169|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 4
16457170|NCT03585803|Other|KMRC011 25μg or Placebo|Cohort 5
16457171|NCT03585790|Other|Multifocal Optics first, then Single Vision Optics|First Intervention (1 week) Second Intervention (1 week)
16457172|NCT03585790|Other|Single Vision Optics first, then Multifocal Optics|First Intervention (1 week) Second Intervention (1 week)
16457173|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
16457174|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
16457175|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
16457700|NCT03582150|Experimental|Receiving Soberlink Device|
16457177|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
16457178|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
16457179|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
16457180|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
16457181|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
16457182|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
16457183|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
16457184|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
16457185|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
16457186|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg
16457187|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg
16457188|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
16457189|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
16457190|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
16457191|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.
~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
16457192|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
16457193|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
16457194|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.
~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
16457195|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
16457196|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
16457197|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
16457200|NCT03585582||PARDS survivors|"Children <18 years
~diagnosed with PARDS, as defined by PALICC
~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
16457201|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
16457202|NCT03585543|Experimental|Single group intervention arm|
16457203|NCT03585530|Experimental|treatment group|
16457204|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
16457205|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
16457206|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
16457207|NCT03585491|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
16457208|NCT03585491|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
16457209|NCT03585478|Active Comparator|Latiglutenase|IMGX003
16457210|NCT03585478|Placebo Comparator|Placebo|Placebo
16457211|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|This arm was applicable to first stage, and is closed
16457212|NCT03585465|Experimental|B: Capecitabine Nivolumab|This arm was applicable to first stage, and is closed
16457213|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|This arm was applicable to first stage, and is closed
16457214|NCT03585465|Experimental|"Metronomic CT "|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)
~This arm is applicable to second stage, and 43 patients are expected"
16457215|NCT03585465|Experimental|"Metronomic CT + Nivolumab"|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab
~This arm is applicable to second stage, and 43 patients are expected"
16457216|NCT03585452||Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
16457217|NCT03585452||Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
16457218|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
16457219|NCT03585426|Experimental|Vancomycin 1g q12h|
16457220|NCT03585426|Experimental|Vancomycin 1g q8h|
16457221|NCT03585413|Active Comparator|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.
~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
16457222|NCT03585413|Placebo Comparator|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.
~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
16457223|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
16457224|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
16457225|NCT03585374|Experimental|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
16457226|NCT03585374|Active Comparator|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.
~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.
~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.
~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .
~Maximum time of infusion 10 minutes."
16457227|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
16457228|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
16457701|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
16457702|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
16457229|NCT03585348||Study cohort|The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
16457230|NCT03585322|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a escalation scheme at the dose escalation phase.
16457231|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
16457232|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
16457233|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
16457234|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
16457235|NCT03585270|Experimental|Clazosentan|Participants will receive clazosentan for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
16457236|NCT03585270|Placebo Comparator|Placebo|Participants will receive clazosentan matching-placebo for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
16457237|NCT03585257|Experimental|IV albumin|25% IV albutein (albumin) formulation will be infused 1.5g/kg IV over one hour weekly for 4 weeks
16457238|NCT03585257|Placebo Comparator|Placebo|Normal saline will be infused 1.5g/kg IV over one hour weekly for 4 weeks
16457239|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
16457240|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
16457241|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
16457242|NCT03585231|Active Comparator|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
16457243|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
16457244|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
16457245|NCT03585205|Experimental|Stress and cognitive load Induction|Participants will engage in a computerized task which induces cognitive load. Each participant will perform the task once under a stress condition and once under a neutral (non-stress) condition.
16457246|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
16457247|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
16457248|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
16457249|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
16457250|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
16457251|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
16457252|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
16457253|NCT03585153||T1D|Individuals with type 1 diabetes
16457254|NCT03585153||Control|Individuals without type 1 diabetes
16457255|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
16457256|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
16457257|NCT03585140|Active Comparator|Normal Diet|Participants will receive a normal diet according to their metabolic status.
16457258|NCT03585140|Experimental|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
16457259|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
16457260|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
16457261|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
16457262|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
16457263|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
16457264|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
16457265|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure
~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
16457266|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure
~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
~."
16457267|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
16457268|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
16457269|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
16457270|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
16457271|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
16457272|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
16457273|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
16457274|NCT03584984|Experimental|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
16457275|NCT03584984|Active Comparator|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
16457276|NCT03584984|Active Comparator|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
16457277|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
16457278|NCT03584971||control group|random sample of male students
16457279|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
16457280|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
16457281|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
16457282|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
16457283|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
16457284|NCT03584945|Experimental|Obsessive Compulsive Disorder|
16457285|NCT03584945|Other|Subclinical Obsessive-Compulsive symptoms (OCS)|
16457286|NCT03584945|No Intervention|Healthy Control|
16457287|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
16457288|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
16457289|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
16457290|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
16457291|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
16457292|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
16457293|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.
~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
16457294|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.
~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
16457295|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.
~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
16457296|NCT03584893||Epidemiologic observational study cohort|All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
16457297|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
16457298|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
16457299|NCT03584867|Experimental|study Group|refresher CPR
16457300|NCT03584867|No Intervention|control|NO refresher
16457301|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
16457302|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
16457303|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
16457304|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
16457305|NCT03584841|Active Comparator|Healthy volunteers|
16457306|NCT03584828|Experimental|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
16457307|NCT03584828|No Intervention|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
16457308|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:
~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
16457309|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.
~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
16457310|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
16457311|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
16457312|NCT03584789|No Intervention|Standard Practice|
16457313|NCT03584789|Experimental|Clinical Decision Support|
16457314|NCT03584789|Experimental|Clinical Decision Support + Education|
16457315|NCT03584776|Experimental|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
16457316|NCT03584776|No Intervention|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery. This will include 15-30 minutes of movie viewing during research visits.
16457317|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
16457318|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
16457319|NCT03584750|Active Comparator|Intervention group|Floating
16457320|NCT03584750|Placebo Comparator|Control group|Placebo floating
16457321|NCT03584750|No Intervention|No-treatment group|Waiting list
16457322|NCT03584737||Symptomatic for bacterial sinusitis|Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
16457323|NCT03584737||Healthy - no symptoms of sinusitis|Samples from healthy participants showing no symptoms of sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
16457324|NCT03584724|Experimental|Norflo Oro|Box of 30 packets of Norflo Oro. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
16457325|NCT03584724|Placebo Comparator|Placebo for Norflo Oro|Box of 30 packets of Placebo. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
16457326|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours
~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
16457327|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
16457328|NCT03584698|Active Comparator|control group|Misoprostol only group
16457329|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
16457330|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
16457331|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score < 7)
16457332|NCT03584672||Healthy Controls|Healthy people
16457333|NCT03584659|No Intervention|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
16457334|NCT03584659|Experimental|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
16457335|NCT03584646|Experimental|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
16457336|NCT03584646|Experimental|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
16457337|NCT03584633|Other|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with Indocyanine Green Lymphography.
16458033|NCT03579914|Experimental|Intravenous metoprolol group|Patients receive intravenous metoprolol injection.
16457338|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
16457339|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
16457340|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
16457341|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
16457342|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
16457343|NCT03584581|Experimental|Olive polyphenols|
16457344|NCT03584581|Placebo Comparator|Control|
16457345|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
16457346|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
16457347|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
16457348|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
16457349|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
16457350|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
16457351|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
16457352|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
16457353|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
16457354|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
16457355|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
16457356|NCT03584516|Experimental|Part 1 : Dose determination of itacitinib|itacitinib administered in combination with corticosteroids.
16457357|NCT03584516|Experimental|Part 1 : Dose expansion of itacitinib|itacitinib administered in combination with corticosteroids or corticosteroids alone.
16457358|NCT03584516|Placebo Comparator|Part 2 : itacitinib recommended dose from part 1|itacitinib or placebo administered in combination with corticosteroids
16457359|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
16457360|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
16457361|NCT03584490|Active Comparator|Pen-and-paper format|Based on randomization, participants in this group will receive traditional pen-and-paper questionnaires about health.
16457362|NCT03584490|Experimental|Computerized Talking Touchscreen|"This group will receive the Computerized Talking Touchscreen intervention.
~Based on randomization, participants in this group will receive a computerized talking touchscreen version of our health questionnaires, which allows the participant to have questions and answer choices read aloud to them by the computer."
16457363|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
16457364|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
16457365|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
16457366|NCT03584464|Other|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
16457367|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
16457368|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
16457369|NCT03584438|Experimental|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
16457370|NCT03584438|Experimental|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
16457371|NCT03584438|Experimental|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
16457372|NCT03584438|Experimental|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
16457373|NCT03584438|Sham Comparator|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
16457374|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
16457375|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
16457376|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
16457377|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
16457378|NCT03584386|Experimental|V-CAMS (aka Jaspr)|"In Phase I (formative), participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.
~Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants in the Telehealth RCT will be randomly assigned to receive the V-CAMS/Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups.
~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as completing setup of JAH on their personal mobile phone."
16457379|NCT03584386|No Intervention|Care As Usual|"Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups.
~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as setting up the control condition crisis stability plan."
16457380|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).
~Acetaminophen - Oral; patient directed as needed. Not prescribed.
~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
16457381|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).
~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
16457382|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
16457383|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
16457384|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
16457385|NCT03584334|Other|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
16457386|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
16457387|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
16457388|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
16457389|NCT03584295|Active Comparator|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
16457390|NCT03584295|Experimental|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (22-24Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-1.75 L/min.
16457391|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
16457392|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
16457393|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
16457394|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
16457395|NCT03584269|Experimental|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
16457396|NCT03584269|Active Comparator|LTOT|standard treatment, without NIV
16457397|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
16457398|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
16457399|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.
~The intervention administrated is a cross-linking with oxygen treatment"
16457400|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.
~Intervention: Assigned to positive group"
16457434|NCT03583996|Experimental|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
16457435|NCT03583983|Other|Personalized Health Recommendations|
16457401|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.
~Intervention: Assigned to negative group"
16457402|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
16457403|NCT03584217|Other|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
16457404|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
16457405|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
16457406|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
16457407|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
16457408|NCT03584165||BIIB111|Participants previously treated with sub-retinal injection of BIIB111 in the antecedent study 273CH301 (NCT03496012) will be enrolled.
16457409|NCT03584165||BIIB112|Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled.
16457410|NCT03584165||Untreated|Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled.
16457411|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
16457412|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
16457413|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
16457414|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
16457415|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
16457416|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
16457417|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
16457418|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
16457419|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
16457420|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
16457421|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
16457422|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
16457423|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
16457424|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
16457425|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
16457426|NCT03584061|Experimental|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
16457427|NCT03584048||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, residing in the Charlotte Metropolitan Area and with at least a single entry in the EHR in the last 2 years.
16457428|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
16457429|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
16457430|NCT03584022|Experimental|Biopsy + Nerve Repair|Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.
16457431|NCT03584022|Sham Comparator|Biopsy Only|Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.
16457432|NCT03584009|Experimental|Venetoclax + Fulvestrant|Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
16457433|NCT03584009|Active Comparator|Fulvestrant|Participants were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
16457436|NCT03583983|Other|No Health Recommendations|
16457438|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
16457439|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
16457440|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
16457441|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
16457442|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
16457443|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
16457444|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
16457445|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
16457446|NCT03583892||Group B|In the group B gabapentin was not administered.
16457447|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
16457448|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
16457449|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
16457450|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
16457451|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
16457452|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
16457453|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
16457454|NCT03583840|No Intervention|Control group|Participants who will not be directed to the ScreenMen website
16457455|NCT03583840|Experimental|Intervention group|Participants who will be directed to the ScreenMen website
16457456|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
16457457|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
16457458|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
16457459|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
16457460|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
16457461|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :
~sweet orange (Citrus sinensis L. Persoon)
~fine lavender (Lavandula angustifolia P. Miller)
~little seed from the mandarin tree (Citrus reticulata blanco)"
16457462|NCT03583801|Placebo Comparator|without aromatherapy|
16457463|NCT03583788|Experimental|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson's (permissive) hypnosis (17). It began with a conversation about patient's past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
16457464|NCT03583788|Active Comparator|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
16457465|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
16457466|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
16457467|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
16457468|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
16457469|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
16457470|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
16457739|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
16457471|NCT03583736|Active Comparator|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
16457472|NCT03583736|Placebo Comparator|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
16457473|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
16457474|NCT03583710|Experimental|Arm A (mitotane)|Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
16457475|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16457476|NCT03583697|Experimental|Active BMN111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111 daily
16457477|NCT03583697|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
16457478|NCT03583684|Experimental|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
16457479|NCT03583684|No Intervention|Delayed Treatment Group (DTG)|Child continues stable treatments as usual in the community.
16457480|NCT03583658|Active Comparator|Ambroxol hydrochloride (BIH1526)|One lozenge 20 mg on as-needed basis, up to 6 times per day
16457481|NCT03583658|Placebo Comparator|Placebo|One lozenge on as-needed basis, up to 6 times per day
16457482|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
16457483|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
16457484|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
16457485|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
16457486|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
16457487|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
16457488|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
16457489|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
16457490|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
16457491|NCT03583580|Experimental|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
16457492|NCT03583567|Placebo Comparator|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
16457493|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
16457494|NCT03583554|Placebo Comparator|Placebo|Placebo
16457495|NCT03583554|Active Comparator|AV-101 720 mg|One time 720 mg L-4-Chlorokynurenine
16457496|NCT03583554|Active Comparator|AV-101 1440 mg|One time 1440 mg L-4-Chlorokynurenine
16457497|NCT03583541|Experimental|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
16457498|NCT03583541|Experimental|Treatment arm: HIVRR+S+FL|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate). They will also receive 6 financial literacy (FL) sessions provided twice a week for 3 weeks
16457499|NCT03583541|Experimental|Treatment arm: HIVRR+S+FLM|"Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.
~*Revision note: Following COVID-19, with approval from NIMH (on record if requested), the HIVRR+S+FLM treatment of the study has been combined with the HIVRR+S+FL treatment arm. The total sample size has been revised to 532 participants, with approval from NIMH."
16457500|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
16457501|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
16457502|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
16457503|NCT03583502|Experimental|Supplemented|krill oil and fish oil supplement
16457504|NCT03583502|No Intervention|Controls|The control group did not receive any supplementation.
16457505|NCT03583489|Placebo Comparator|Placebo|
16457506|NCT03583489|Experimental|APD421|
16457507|NCT03583489|Experimental|APD421 + ondansetron|
16457508|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
16457509|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
16457510|NCT03583476||Concomitant therapy|Patients with concomitant therapy
16457511|NCT03583476||Sequential therapy|Patients with sequential therapy
16457512|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
16457513|NCT03583450|No Intervention|Control|Routine anesthetic care
16457514|NCT03583437|Experimental|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
16457515|NCT03583437|Experimental|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
16457516|NCT03583424|Experimental|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
16457517|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
16457518|NCT03583398||TAVI TAo|
16457519|NCT03583398||TAVI TF|
16457520|NCT03583398||AVR|
16457521|NCT03583385|Experimental|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
16457522|NCT03583385|Experimental|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
16457523|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
16457524|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
16457525|NCT03583359|Experimental|Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
16457526|NCT03583359|Other|Delayed Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
16457527|NCT03583346|Experimental|M6495|
16457528|NCT03583346|Placebo Comparator|Placebo|
16457531|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
16457559|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
16457560|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
16457561|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
16457703|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
16457532|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.
~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
16457533|NCT03583307|Experimental|Sirolimus|
16457534|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
16457535|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
16457536|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
16457537|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
16457538|NCT03583281|Active Comparator|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid [ALA] per day) for 4 weeks
16457539|NCT03583281|Active Comparator|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
16457540|NCT03583268|Active Comparator|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
16457541|NCT03583268|Experimental|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
16457542|NCT03583268|Experimental|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
16457543|NCT03583268|Experimental|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
16457544|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Participants receive dexamethasone PO BID for 7 days. Participants also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
16457545|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Participants receive placebo PO BID for 7 days. Participants also complete resistance training and moderate intensity walking as in Arm I.
16457546|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
16457547|NCT03583229|Other|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
16457548|NCT03583229|Experimental|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
16457549|NCT03583229|No Intervention|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
16457550|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
16457551|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
16457552|NCT03583203|Experimental|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
16457553|NCT03583203|No Intervention|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
16457554|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
16457555|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
16457556|NCT03583177||healthy volunteers|
16457557|NCT03583177||cancer patients|
16457562|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
16457563|NCT03583138||No buprenorphine|No buprenorphine
16457564|NCT03583125|Experimental|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.
~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
16457565|NCT03583112|Active Comparator|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
16457566|NCT03583112|Placebo Comparator|Placebo|In this group, patients received placebo tablet before MRI scan.
16457567|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
16457568|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
16457569|NCT03583086|Experimental|Treatment (vorolanib, nivolumab)|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
16457570|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
16457571|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
16457572|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
16457573|NCT03583060|No Intervention|Control|
16457574|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
16457575|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
16457576|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
16457577|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
16457578|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
16457579|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
16457580|NCT03582982|Experimental|Eccentric overload exercise|
16457581|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
16457582|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
16457583|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
16457584|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
16457585|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
16457586|NCT03582943|Experimental|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
16457587|NCT03582943|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
16457588|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
16457589|NCT03582917|No Intervention|No treatment|
16457590|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
16457591|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
16457592|NCT03582891|Other|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
16457593|NCT03582891|Other|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
16457594|NCT03582891|Other|Dystonia patients|Isolated dystonia patients
16457595|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
16457596|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
16457691|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
16457704|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
16457597|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
16457598|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
16457599|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
16457600|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
16457601|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
16457602|NCT03582839|Experimental|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
16457603|NCT03582826|Experimental|MEBO/PATM cohort|"Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes.
~The following subcohorts were formed for analyses of different outcomes: MEBO and PATM subcohorts, TMAU positive and negative subcohorts, Active MEBO, Active PATM, Regression and Remission; MEBO/PATM Cohort that Submitted Gut Samples, MEBO/PATM cohort that answered QoL survey, MEBO/PATM Subcohort that observed and documented both flareups and improvements."
16457604|NCT03582826|No Intervention|non-MEBO cohort|Data volunteers that never experienced episodes of uncontrollable socially debilitating metabolic body odor (MEBO) or PATM
16457605|NCT03582813|Experimental|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
16457606|NCT03582813|Active Comparator|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
16457607|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
16457608|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
16457609|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
16457610|NCT03582774|Active Comparator|Arm I (standard of care)|Participants receive standard of care SRT.
16457611|NCT03582774|Experimental|Arm II (68Ga-PSMA-11 PET/CT)|Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.
16457612|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
16457613|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
16457614|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
16457615|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
16457616|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
16457617|NCT03582735|No Intervention|Control|No intervention according to current practice.
16457618|NCT03582722|Experimental|Weight loss aid|One-month supply of orlistat capsules (60mg) to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
16457619|NCT03582722|Placebo Comparator|Placebo|One-month supply of placebo capsules to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
16457620|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
16457621|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
16457622|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
16457623|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
16457624|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
16457625|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
16457626|NCT03582644|Experimental|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
16457692|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
16457693|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
16457627|NCT03582618|Experimental|Sorafenib + CVM-1118|"Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)
~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.
~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)
~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
16457628|NCT03582605|Placebo Comparator|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
16457629|NCT03582605|Experimental|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
16457630|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
16457631|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
16457632|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
16457633|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
16457634|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
16457635|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
16457636|NCT03582566|Experimental|Phonological Awareness|Children will play games to practice their rhyming, sound sequencing, and letter-sound knowledge. These games are all implemented in the Earobics program.
16457637|NCT03582566|Experimental|Working Memory|Children will play games designed to help them hold and manipulate objects in memory. These games are implemented in Cogmed.
16457638|NCT03582566|Experimental|Phonological Awareness + Working Memory|Children will practice both their sound skills (Earobics) and their memory skills (Cogmed).
16457639|NCT03582566|Active Comparator|Active Control|Children will play games to practice their addition and subtraction skills (Splashmath).
16457640|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
16457641|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
16457642|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
16457643|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
16457644|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
16457645|NCT03582540|Active Comparator|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
16457646|NCT03582540|Active Comparator|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
16457647|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
16457648|NCT03582514|Experimental|Dose or volume radiation escalation|"Patients with a new radiological diagnosis of GBM (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.
~This study arm will use 5 radiotherapy doses (6 Gy, 8 Gy, 10 Gy, 12 Gy and 14 Gy) and three treatment volumes (<30 cm3, 30-60 cm3 and >60 cm3). The study will use 6 dosing levels based on a combination of radiotherapy dose and treatment volume. The stepwise inclusion process allows for variation in tumour volume and location. The study will commence with dosing level 1: 8 Gy to <30 cm3 and 6 Gy to 30-60 cm3. In collaboration with the Clinical Trials Unit, the Trial Management Group will enter outcome data for patients at a given dose level into the CRM model. The model output will then guide dose escalation to determine the next dose level. After the single fraction of radiotherapy, patients will receive the standard treatment."
16457649|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
16457650|NCT03582488|Experimental|Dementia with Lewy Bodies|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
16457694|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
16457695|NCT03582176|Placebo Comparator|Lactose Placebo|Lactose Placebo by mouth twice per day
16457651|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16457652|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
16457653|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
16457654|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
16457655|NCT03582436||Prospective cohort|Kidney transplantation
16457656|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
16457657|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
16457658|NCT03582410|Active Comparator|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
16457659|NCT03582410|Active Comparator|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
16457660|NCT03582397|Experimental|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
16457661|NCT03582384|Experimental|Treatment|
16457664|NCT03582358||Verrine|Patients served verrines
16457665|NCT03582358||CNO|Patients served wrapped supplements
16457666|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
16457667|NCT03582332|Active Comparator|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
16457668|NCT03582332|Active Comparator|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
16457669|NCT03582332|Active Comparator|Group A in phase 2|Etoricoxib 90 mg once daily
16457670|NCT03582332|Active Comparator|Group B in phase 2|Etoricoxib 60 mg once daily
16457671|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
16457672|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
16457673|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
16457674|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
16457675|NCT03582293|Active Comparator|Tranexamic Acid|Tranexamic acid 500mg two times a day orally for a total of 28 days
16457676|NCT03582293|Placebo Comparator|PLACEBO|Placebo capsules two times a day orally for a total of 28 days
16457677|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:
~Amor powder, each eppendorf contains 200mg Calcium
~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
16457678|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
16457679|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
16457680|NCT03582254|Experimental|[18F]-FDG PET/MR|[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
16457681|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).
~Weekly sessions will follow a standardized format:
~15 minutes- Social support group (guided discussion of experiences related to weekly topic)
~20 minutes- Didactic instruction
~15 minutes- Role playing
~10 minutes- Debriefing and group feedback"
16457682|NCT03582215|Experimental|Part 1: Cream|"Part 1: Cream
~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
16457683|NCT03582215|Experimental|Part 1: Lotion|"Part 1: Lotion
~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
16457684|NCT03582215|Experimental|Part 1: Spray 1|"Part 1: Spray 1
~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
16457685|NCT03582215|Experimental|Part 1: Spray 2|"Part 1: Spray 2
~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
16457686|NCT03582215|Experimental|Part 2: Lotion|"Part 2: Lotion
~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
16457687|NCT03582215|Experimental|Part 2: Aerosol Spray|"Part 2: Aerosol Spray
~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
16457688|NCT03582215|Experimental|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray
~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
16457689|NCT03582215|Experimental|Part 2: Pump Spray|"Part 2: Pump Spray
~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
16457690|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
16457705|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
16457706|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
16457707|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
16457708|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
16457709|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
16457710|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
16457711|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
16457712|NCT03582046|No Intervention|Monitoring Group|Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
16457713|NCT03582046|Active Comparator|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
16457714|NCT03582046|Experimental|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
16457715|NCT03582033|Experimental|SEA-BCMA Monotherapy|SEA-BCMA
16457716|NCT03582033|Experimental|SEA-BCMA + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone
16457717|NCT03582033|Experimental|SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone + pomalidomide
16457718|NCT03582033|Experimental|SEA-BCMA + Nirogacestat + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone + nirogacestat
16457719|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
16457720|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
16457721|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
16457722|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
16457723|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
16457724|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
16457725|NCT03581994|No Intervention|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
16457726|NCT03581994|Experimental|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
16457727|NCT03581994|Experimental|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
16457728|NCT03581981|Experimental|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
16457729|NCT03581981|Active Comparator|Treatment as Usual (TAU)|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
16457730|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
16457731|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
16457732|NCT03581955|Experimental|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
16457733|NCT03581955|Experimental|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
16457734|NCT03581955|Experimental|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
16457735|NCT03581942|Experimental|Copanlisib in combination with Ibrutinib|"The 3+3 design will be applied in the phase Ib portion of the trial. Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off). Phase II: (Simon two-stage design: 14 patients will be treated at the MTD (including 6 patients from the phaseIb portion) If at least 11 patients respond then an additional 19 patients will be accrued to the second stage. If 10 or less patients respond the study will be terminated and declared negative)."
16457736|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
16457737|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
16457738|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
16457796|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
16457740|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
16457741|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
16457742|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
16457743|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
16457744|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16457745|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
16457746|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
16457747|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
16457748|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
16457749|NCT03581825|Experimental|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
16457750|NCT03581825|Experimental|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
16457751|NCT03581812|Active Comparator|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
16457752|NCT03581812|Active Comparator|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
16457753|NCT03581812|Placebo Comparator|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
16457754|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
16457755|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|
16457756|NCT03581786|Experimental|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|
16457757|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
16457758|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
16457759|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
16457760|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
16457761|NCT03581747||Subjects with atopic dermatitis|
16457762|NCT03581747||Controls|
16457763|NCT03581734|Active Comparator|OPV only|The vaccine will be available in prefilled vials containing 10 doses. Each vial will be labelled with the study ID of the participant. Therefore, for participants randomized to arm A and arm C, there will be 3 vials per participant for the 3 doses of the bOPV vaccine to be given 28 weeks apart. Any remaining, non-used doses of vaccine in the vial will be discarded.
16457764|NCT03581734|Active Comparator|Shanchol only|Each dose of vaccine is 1.5ml in volume. Each vial will be labelled with the study ID of the participant. One vial will be used per participant per study visit. OCV was studied in a double-blind, randomized, placebo-controlled trial in Kolkata, India. Participants were 1 year and above in age. In these studies, 100 children aged 1-17 were administered 2-doses of OCV or placebo separated by an interval of two weeks, with 80% of vaccinated showing over 4 fold rise in serum V. cholerae O1 antibody titers, showing that the 2-dose regimen was well-tolerated, safe and immunogenic
16457797|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
16457765|NCT03581734|Experimental|OPV-OCV co-administered|"Our primary analysis will be to compare seroconversion (defined as a change of status from seronegative to seropositive titers, or a ≥4-fold rise in antibody titer) for OPV1 and OPV 3 antibodies between Arm A and Arm C, to determine whether seroconversion to bOPV when administered with Shanchol is non-inferior to seroconversion to bOPV when bOPV is administered alone.
~Our second objective will be to compare vibriocidal antibody seroconversion (also, ≥4-fold rise in antibody titers) to Shanchol when co-administered with OPV or when Shanchol is administered alone, Arm B compared to Arm C"
16457766|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
16457767|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
16457768|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
16457769|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
16457770|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
16457771|NCT03581695||Healthy Controls|Healthy Controls
16457772|NCT03581682|Experimental|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
16457773|NCT03581669||THA + cerclage acetabulum|
16457774|NCT03581656|Experimental|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
16457775|NCT03581630|Experimental|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
16457776|NCT03581630|Experimental|Breast cancer subjects-Mediterranean Diet|
16457777|NCT03581630|Active Comparator|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
16457778|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
16457779|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
16457780|NCT03581604|Other|Patients labeled as penicillin allergic|Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples and Microbiological samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.
16457781|NCT03581604|Other|Healthy Controls|Healthy Controls, blood samples and microbiological samples.Clinical history
16457782|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
16457783|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown
~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
16457784|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown
~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
16457785|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown
~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
16457786|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
16457787|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
16457788|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
16457789|NCT03581513|Experimental|IMR<40 and defer PCI|Patients whose IMR<40 undergo stent implantation after an interval of 7±2 days.
16457790|NCT03581513|Active Comparator|IMR<40 and immediately PCI|Patients whose IMR<40 undergo immediately stent implantation.
16457791|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.
16457792|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation.
16457793|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
16457794|NCT03581487|Experimental|Arm I (intermittent selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16457795|NCT03581487|Experimental|Arm II (continuous selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16457798|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.
~The intervention Sensory Restoration During Prosthesis Control will be used."
16457799|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
16457800|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
16457801|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
16457802|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
16457803|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
16457804|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
16457805|NCT03581383|No Intervention|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
16457806|NCT03581383|Experimental|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
16457807|NCT03581383|Experimental|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
16457808|NCT03581383|Experimental|Telemedicine Arm|The telemedicine Model will track outcomes and record patient experiences with HCV management and treatment with telemedicine.
16457809|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.
~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
16457810|NCT03581370|Experimental|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.
~."
16457811|NCT03581357|Active Comparator|Control/Waitlist (Anxiety Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
16457812|NCT03581357|Active Comparator|Mindfulness App (Anxiety Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
16457813|NCT03581357|Active Comparator|Control/Waitlist (Neuropathy Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
16457814|NCT03581357|Active Comparator|Mindfulness App (Neuropathy Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
16457815|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
16457816|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
16457817|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
16457818|NCT03581318|Other|1|MRI
16457862|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
16457822|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
16457823|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
16457824|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
16457825|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
16457826|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
16457827|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
16457828|NCT03581214|Active Comparator|Room air|Room air (no mask)
16457829|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
16457830|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
16457831|NCT03581201||No contraception|Healthy females without any contraception at all.
16457832|NCT03581188|Experimental|Self-examination of the skin|Participants will perform self-surveillance of the skin using a dermatoscope device. They will receive guidance from the ASICA skin checker and receive reminders every 2 months to perform self-examination. They will receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
16457833|NCT03581188|No Intervention|Control|Participants will receive an educational booklet 'Your guide to early melanoma'and scheduled visits to their clinician as required.
16457834|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
16457835|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
16457836|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
16457837|NCT03581162||Controls|Healthy, age-and sex-matched controls
16457838|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
16457839|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
16457840|NCT03581136|Experimental|Prescription Isodose Surface Coverage|"The dose fractionation to the CTV (1cm expansion on cavity) will be 40Gy/ 5 fractions and the PTV (3 mm expansion of CTV) will be a minimum dose of 30Gy/5 fractions.
~If PTV >100cc or if dose constraints cannot be met on higher dose prescribe CTV (1.0cm) to 35Gy/5 fractions and PTV (3mm) to 30Gy/5 fractions. This is to potentially reduce risk of fat necrosis."
16457841|NCT03581123|Experimental|Supported-Self management (SSM)|Supported-Self management
16457842|NCT03581123|Experimental|Spinal Manipulation Therapy (SMT)|Spinal Manipulation Therapy
16457843|NCT03581123|Experimental|SMT + SSM|Spinal Manipulation Therapy + Supported Self-Management
16457844|NCT03581123|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care
16457845|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
16457846|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
16457847|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
16457848|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
16457849|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
16457851|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
16457852|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
16457853|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
16457854|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
16457855|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
16457856|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
16457857|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
16457858|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
16457859|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
16457860|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
16457861|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
16457864|NCT03581006||Intervention Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.
~This intervention group will undergo technology based monitoring and behavioral participation in a dietary and exercise program with the intent of weight loss and compliance with a low-calorie Mediterranean diet."
16457865|NCT03581006||Control (Usual care) Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.
~This group will receive no dietary or behavioral intervention. They will continue usual care with their home physicians."
16457866|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
16457867|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
16457868|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
16457869|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
16457870|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
16457871|NCT03580967|Other|Drug: Vortioxetine|
16457872|NCT03580954|Experimental|Repetitive TMS (estimulation)|
16457873|NCT03580954|Active Comparator|Repetitive TMS (inhibition)|
16457874|NCT03580928|Experimental|Acalabrutinib/Venetoclax/Obinutuzumab|"Acalabrutinib will be administered orally twice daily at 100 mg bid
~Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg
~Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
16457875|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
16457876|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
16457877|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
16457878|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
16457879|NCT03580889|Active Comparator|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
16457880|NCT03580889|Active Comparator|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
16457881|NCT03580889|Active Comparator|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
16457882|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)
~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
16457883|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine
~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR
~Loss of response under Adalimumab: 40mg EW SC Randomization to:
~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
16457884|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm).
16457885|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
16457960|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
16458034|NCT03579914|Experimental|RIPC group|Patients receive RIPC treatment.
16458615|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
16457886|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
16457887|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
16457888|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
16457889|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
16457890|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
16457891|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
16457892|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
16457893|NCT03580772||Control participants|Patients will not have recieved a primary TKR
16457894|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
16457895|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
16457896|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
16457897|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
16457898|NCT03580733|Placebo Comparator|placebo|placebo
16457899|NCT03580733|Experimental|antifungal therapy|caspofungin
16457900|NCT03580720|Experimental|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
16457901|NCT03580707|Active Comparator|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) & brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
16457902|NCT03580707|Active Comparator|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose & BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
16457903|NCT03580694|Experimental|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
16457904|NCT03580694|Experimental|Combination Therapy|"Dose Escalation cohorts:
~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.
~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.
~Dose Expansion cohorts:
~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
16457905|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
16457906|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
16457907|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
16457908|NCT03580655|Experimental|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
16457909|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
16457910|NCT03580642|No Intervention|Control|Habitual treatment.
16457911|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
16457912|NCT03580616|Experimental|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
16457913|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
16457914|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
16457915|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
16457916|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
16457917|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
16457996|NCT03580161||99mTc MDP Bone Scan|Patients receiving routine diagnostic scan
16458035|NCT03579914|Experimental|Intravenous metoprolol and RIPC group|Patients receive intravenous metoprolol injection and RIPC treatment.
16457918|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).
~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.
~Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.
~Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
16457919|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.
~- Protein C, protein S and antithrombin III level will be assessed at baseline."
16457920|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
16457921|NCT03580551|Experimental|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
16457922|NCT03580551|Active Comparator|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
16457923|NCT03580538|Experimental|elastic tube group|
16457924|NCT03580525|Experimental|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
16457925|NCT03580525|Experimental|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
16457926|NCT03580525|Experimental|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
16457927|NCT03580525|Experimental|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
16457928|NCT03580525|Experimental|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
16457929|NCT03580512||Group 1|- 800 existing clients who already received PrEP
16457930|NCT03580512||Group 2|"800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP
~600 clients who will refuse PrEP
~200 clients who will receive PrEP"
16457931|NCT03580512||Group 3|- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive
16457932|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
16457933|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
16457934|NCT03580486||Healthy controls|Healthy people
16457935|NCT03580473|Experimental|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
16457936|NCT03580473|Active Comparator|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
16457937|NCT03580460|No Intervention|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
16457938|NCT03580460|Experimental|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
16457939|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
16457940|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
16457941|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
16457944|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)
~Consolidation treatment:
~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :
~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.
~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)
~In case of progressive disease , patients will be considered in treatment failure."
16457945|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
16457946|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
16457947|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
16457948|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
16457961|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
16457962|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
16457963|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
16457964|NCT03580304|Experimental|industrial-physical-cognitive|
16457965|NCT03580304|Experimental|industrial- cognitive-physical|
16457966|NCT03580304|Experimental|physical- industrial- cognitive|
16457967|NCT03580304|Experimental|physical-cognitive- industrial|
16457968|NCT03580304|Experimental|cognitive- industrial-physical|
16457969|NCT03580304|Experimental|cognitive-physical-industrial|
16457970|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.
~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.
~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
16457971|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
16457972|NCT03580278|Experimental|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
16457973|NCT03580278|Experimental|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
16457974|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
16457975|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
16457976|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.
~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
16457977|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
16457978|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
16457979|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
16457980|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
16457981|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.
~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
16457982|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.
~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
16457983|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.
~No treatment after the collagenase injection and extension treatment."
16457984|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.
~No treatment after the collagenase injection and extension treatment."
16457985|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
16457986|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
16457987|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.
~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
16457988|NCT03580174|Active Comparator|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
16457989|NCT03580174|Active Comparator|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
16457990|NCT03580161||18-F FDG PET/CT|Patients receiving routine diagnostic scan
16457991|NCT03580161||Ga-68 PSMA PET/CT|Patients receiving routine diagnostic scan
16457992|NCT03580161||68-Ga Dotatate PET/CT|Patients receiving routine diagnostic scan
16457993|NCT03580161||99mTc Pertechnetate Thyroid Scan|Patients receiving routine diagnostic scan
16457994|NCT03580161||99mTc DMSA(III) Renal Scan|Patients receiving routine diagnostic scan
16457995|NCT03580161||99mTc MAG3 Renal Scan|Patients receiving routine diagnostic scan
16457997|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
16457998|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
16457999|NCT03580135|Experimental|Propolis powder|"resin (50%),
~vegetable Balsam, wax
~essential aromatic oils (30%)
~salivary secretions (10%)
~pollen(5%)
~other substances (5%) including amino acids
~,ethanol vitamin A, B complex, and E, minerals, steroids
~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.
~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
16458000|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.
~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
16458001|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
16458002|NCT03580109|Active Comparator|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
16458003|NCT03580109|Sham Comparator|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
16458004|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
16458005|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
16458006|NCT03580083|Experimental|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
16458007|NCT03580083|Experimental|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
16458008|NCT03580057|Experimental|Breastfeeding promotion intervention (BPI)|
16458009|NCT03580057|Experimental|Diet- and weight loss intervention (D)|
16458010|NCT03580057|Experimental|BPI and D|Both interventions.
16458011|NCT03580057|No Intervention|Control|
16458014|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
16458015|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
16458016|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
16458017|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
16458018|NCT03580005|Active Comparator|Quillichew ERCT|Quillichew ERCT
16458019|NCT03580005|Placebo Comparator|Placebo to match Quillichew ERCT|Placebo to match Quillichew ERCT
16458020|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
16458021|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
16458022|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
16458023|NCT03579979|Experimental|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.
~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
16458024|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
16458025|NCT03579953|Experimental|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
16458026|NCT03579953|Sham Comparator|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
16458027|NCT03579940|Experimental|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
16458028|NCT03579940|Placebo Comparator|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
16458029|NCT03579940|Experimental|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
16458030|NCT03579940|Placebo Comparator|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
16458031|NCT03579927|Experimental|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10^9/L per 3 consecutive days.
16458032|NCT03579914|Placebo Comparator|Placebo group|Patients receive intravenous placebo injection.
16458036|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
16458037|NCT03579901|Other|Primary Breast Reconstruction|Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
16458038|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
16458039|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
16458040|NCT03579888|Experimental|Treatment (fludarabine, cyclophosphamide, CD19 T cell)|"CHEMOTHERAPY: Patients receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.
~T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0."
16458041|NCT03579875|Experimental|Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP|"Given to:
~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR
~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia"
16458042|NCT03579875|Experimental|Treatment Plan 2: CY, FLU and MP|"Given to:
~• HLA-identical sibling donor recipients with aplastic anemia"
16458043|NCT03579875|Experimental|Treatment Plan 3: BU, Cy, FLU, MP and Rituximab|"Given to:
~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI
~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia who cannot tolerate TBI
~Per treating physician preference"
16458044|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
16458045|NCT03579862||Pulmonary Embolism (PE)|
16458046|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
16458047|NCT03579849|Experimental|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.
~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
16458048|NCT03579836|Experimental|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
16458049|NCT03579836|Experimental|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
16458050|NCT03579836|Experimental|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
16458051|NCT03579823|Experimental|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
16458052|NCT03579823|Active Comparator|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) [HUMIRA]
16458053|NCT03579810|Experimental|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.
~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).
~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).
~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
16458054|NCT03579810|Active Comparator|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.
~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.
~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
16458055|NCT03579784|Experimental|Durvalumab+Olaparib+Paclitaxel|"st cycle : Paclitaxel+Olaparib
~Olaparib 150mg bid on D1-28
~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15
~nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :
~Olaparib 150mg bid on D1-28
~Durvalumab 1.5 g iv on D1
~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
16458056|NCT03579771|Experimental|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
16458057|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
16458058|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
16458059|NCT03579745|Active Comparator|Conventional lingual mechanics|
16458060|NCT03579745|Experimental|Lever arm lingual mechanics|
16458061|NCT03579732||Long-term users|Adults using low-dose aspirin for > 3 years
16458062|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but < 3 years
16458063|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
16458064|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
16458065|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
16458094|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
16458066|NCT03579706|Experimental|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
16458067|NCT03579706|Placebo Comparator|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
16458068|NCT03579693|Active Comparator|CoQ10|Coenzyme Q10, 2 - 250 mg tablets twice a day (1000 mg total daily dose) for 6 weeks
16458069|NCT03579693|Active Comparator|Nicotinamide riboside|Nicotinamide riboside, 1 - 600 mg tablet twice a day (1200 mg total daily dose) for 6 weeks
16458070|NCT03579693|Placebo Comparator|Placebo|Placebo, inactive sugar pill for 6 weeks
16458071|NCT03579680||Providers|Urologists and other providers who have experience caring for more than 10 prostate cancer patients on ADT and express interest in prostate cancer care for prostate cancer will be eligible to participate. Providers will engage in a 30-45 minute interview to identify key preferences and de-implementation barriers, as well as facilitators, for reducing low value ADT as prostate cancer (PC) treatment.
16458072|NCT03579680||Patients|Patients receiving ADT as primary prostate cancer treatment will engage in a 30-45 minute interview regarding to better understand patient perspectives into not initiating or stopping castration with ADT
16458073|NCT03579680||cRCT Facility|We will conduct a 6-month cluster randomized clinical trial of Or vs. Sc de-implementation strategies across 40 facilities with high rates of low value ADT.
16458076|NCT03579654|Experimental|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
16458077|NCT03579654|No Intervention|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
16458078|NCT03579641||Implantable Cardiac device with HeartLogic feature|Patients with Heart Failure, implanted with Boston Scientific Implantable Cardioverter Defibrillator or Defibrillator with Cardiac Resynchronization device with HeartLogic feature
16458079|NCT03579628|Experimental|AsiDNA|"Part A: AsiDNA as a single agent:
~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).
~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.
~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):
~Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.
~Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
16458080|NCT03579615|Experimental|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
16458081|NCT03579615|Active Comparator|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
16458082|NCT03579602|Active Comparator|Arm 1 (no tozuleristide)|Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
16458083|NCT03579602|Experimental|Arm 2 (tozuleristide treated)|Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
16458084|NCT03579589|Active Comparator|Sugammadex|"If spontaneous recovery has reached second twitch after TOF: 2 mg/kg
~If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg
~When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
16458085|NCT03579589|Active Comparator|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
16458086|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
16458087|NCT03579563|Active Comparator|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide hearing aids.
16458088|NCT03579563|Experimental|OTC (over-the-counter)|In this group, the over-the-counter fitting will be used to provide hearing aids.
16458089|NCT03579563|Experimental|OTC-Plus|In this group, the hybrid fitting will be used to provide hearing aids.
16458090|NCT03579550|Active Comparator|Intervention arm: Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception Intervention arm for hysteroscopy group
16458091|NCT03579550|No Intervention|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
16458092|NCT03579537|Experimental|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
16458093|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
16458095|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
16458096|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
16458097|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
16458098|NCT03579472|Experimental|Treatment (bintrafusp alfa, eribulin mesylate)|Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16458099|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
16458100|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
16458101|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
16458102|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
16458103|NCT03579446|Experimental|Supportive care (levorphanol, opioid regimen)|Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine sulfate, hydromorphone hydrochloride, oxycodone, and oxymorphone hydrochloride for breakthrough pain.
16458104|NCT03579433|Experimental|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
16458105|NCT03579433|Active Comparator|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
16458106|NCT03579420|Experimental|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
16458107|NCT03579420|Active Comparator|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
16458108|NCT03579407|Active Comparator|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
16458109|NCT03579407|Experimental|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
16458110|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
16458111|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
16458112|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
16458113|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
16458114|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
16458115|NCT03579355|Experimental|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
16458116|NCT03579355|No Intervention|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
16458117|NCT03579342|Experimental|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
16458118|NCT03579342|Experimental|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
16458119|NCT03579342|No Intervention|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
16458120|NCT03579316|Active Comparator|Arm I (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16458121|NCT03579316|Experimental|Arm II (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16458122|NCT03579303|Active Comparator|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
16458123|NCT03579303|Active Comparator|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
16458124|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:
~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
16458125|NCT03579277|Active Comparator|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
16458126|NCT03579277|Active Comparator|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
16458127|NCT03579264|No Intervention|Standard Arm|No use of My Viva Plan.
16458128|NCT03579264|Experimental|Intervention Arm|Use of My Viva Plan.
16458129|NCT03579251|Other|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
16458130|NCT03579238|No Intervention|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
16458131|NCT03579238|No Intervention|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
16458132|NCT03579238|Sham Comparator|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
16458133|NCT03579238|Experimental|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
16458134|NCT03579225||MATRx plus test|
16458135|NCT03579199|Experimental|exploration of abdominal cavity using a NIR/ICG camera|
16458136|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
16458137|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
16458138|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
16458139|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
16458140|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed
~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft
~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
16458141|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC
~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
16458142|NCT03579147|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
16458143|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
16458144|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
16458145|NCT03579121|Experimental|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
16458146|NCT03579121|Active Comparator|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
16458147|NCT03579095|Experimental|American ginseng|200mg Cereboost and Maltodextrin
16458148|NCT03579095|Placebo Comparator|Placebo|Placebo
16458149|NCT03579082|Experimental|Arm A|"R±DHAP + decitabine:
~decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle."
16458150|NCT03579082|No Intervention|Arm B|R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.
16458151|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
16458152|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
16458153|NCT03579043|Experimental|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
16458154|NCT03579043|Experimental|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
16458155|NCT03579043|Experimental|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
16458156|NCT03579030|Experimental|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.
~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
16458157|NCT03579030|Experimental|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.
~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
16458158|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
16458159|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
16458160|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
16458161|NCT03579004|Experimental|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).
~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
16458162|NCT03578991|No Intervention|Arm 1|"Control group - Treatment as usual:
~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
16458163|NCT03578991|Experimental|Arm 2|"Intervention - Smart pillbox:
~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
16458164|NCT03578991|Experimental|Arm 3|"Intervention - Smart pillbox & Interactive digital platform:
~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
16458165|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
16458166|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
16458167|NCT03578965|Experimental|Arm 1: Antibiotic prophylaxis prior to skin incision|-Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
16458168|NCT03578965|No Intervention|Arm 1: No antibiotic prophylaxis prior to skin incision|-Women randomized to no antibiotic prophylaxis will not receive any antibiotics prior to skin incision.
16458169|NCT03578952|Experimental|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
16458170|NCT03578926|Experimental|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
16458171|NCT03578926|Active Comparator|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
16458172|NCT03578913|Active Comparator|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
16458173|NCT03578913|Experimental|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
16458174|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.
~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
16458175|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.
~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
16458176|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.
~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
16458177|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.
~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
16458178|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.
~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
16458179|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
16458180|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
16458181|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
16458182|NCT03578874|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
16458216|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
16458217|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
16458218|NCT03578575|Experimental|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
16458219|NCT03578575|Placebo Comparator|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
16458183|NCT03578861|Experimental|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.
~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
16458184|NCT03578848|Active Comparator|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
16458185|NCT03578848|Experimental|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
16458186|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
16458187|NCT03578822|Experimental|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
16458188|NCT03578822|Other|Group B|rhPro-UK simulation agent and Aspirn
16458189|NCT03578809|Experimental|Cohort A|MEDI6012
16458190|NCT03578809|Experimental|Cohort B|MEDI6012
16458191|NCT03578809|Placebo Comparator|Placebo|
16458192|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
16458193|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
16458194|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
16458195|NCT03578757|Experimental|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
16458196|NCT03578757|Active Comparator|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
16458197|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
16458198|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
16458199|NCT03578731||Consilium-APP|Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies.
16458200|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
16458201|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
16458202|NCT03578679|Experimental|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
16458203|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
16458204|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
16458205|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
16458206|NCT03578653|Experimental|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
16458207|NCT03578640|Experimental|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
16458208|NCT03578627|No Intervention|Assessment-only|
16458209|NCT03578627|Experimental|Intervention|
16458210|NCT03578614|No Intervention|Control Group|There is no intervention for Control Group
16458211|NCT03578614|Experimental|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
16458212|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
16458213|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
16458214|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
16458215|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
16458220|NCT03578562|Experimental|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
16458221|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.
~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
16458222|NCT03578536|Experimental|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.
~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
16458223|NCT03578536|No Intervention|Standard of Care|As part of standard care, participants will receive a minimum of daily OT, PT and Speech for a total of three hours. Current occupational therapy intervention options for inpatient stroke rehab patients with UE neuromotor impairments include active assisted range of motion exercise, morning bedside ADL sessions, high-repetition task-specific training, mirror therapy, Digi-flex, theraputty, theraband, free weights, weighted therapy bars for strengthening exercises in clinic and use with home exercise programs (HEP). Additional tools used as determined by therapist include FES modalities to assist with upper extremity neuromotor re-education, unweighted reaching tasks via the ArmeoSpring, and functional work task training/strengthening. They also participate in recreation therapy as appropriate.
16458224|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).
~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.
~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.
~Iohexol clearance to measure GFR within 1 week of the scan session"
16458225|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).
~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.
~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.
~Iohexol clearance to measure GFR within 1 week of the scan session"
16458226|NCT03578510|Active Comparator|SHD|Standard hemodialysis
16458227|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
16458228|NCT03578497|Experimental|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
16458229|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
16458230|NCT03578471|Active Comparator|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
16458231|NCT03578471|Experimental|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
16458232|NCT03578471|Experimental|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
16458233|NCT03578458|Other|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
16458234|NCT03578458|Other|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
16458235|NCT03578458|Other|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
16458236|NCT03578445|Experimental|Patients with a pancreatic cystic lesion|
16458237|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
16458238|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
16458239|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
16458240|NCT03578406|Experimental|HPV TCR-T|HPV E6-specific TCR-T cell
16458241|NCT03578406|Experimental|HPV TCR-T with anti-PD1|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element
16458244|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
16458245|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
16458246|NCT03578367|Experimental|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
16458247|NCT03578367|Experimental|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
16458248|NCT03578367|Active Comparator|Imatinib 400mg QD|Imatinib 400 mg taken once daily
16458253|NCT03578341|Experimental|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
16458254|NCT03578341|Placebo Comparator|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
16458255|NCT03578328||Cardiac arrest with targeted temperature management|
16458256|NCT03578315|Experimental|Solar lentigo|25 Patients with Solar lentigo
16458257|NCT03578315|Experimental|Nevus zygomaticus|25 Patients with Nevus zygomaticus
16458258|NCT03578289|Experimental|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
16458259|NCT03578289|Experimental|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
16458260|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
16458261|NCT03578276|Active Comparator|Standard of Care|"Gatifoxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.
~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
16458262|NCT03578263|Experimental|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
16458263|NCT03578263|Active Comparator|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
16458264|NCT03578250|Experimental|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.
~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
16458265|NCT03578250|Experimental|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.
~During training the robotic device will not apply any perturbations on the participant's arm."
16458266|NCT03578237|Experimental|Treatment (active cryoneurolysis)|Receiving active cryoneurolysis
16458267|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
16458268|NCT03578224|Experimental|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
16458269|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
16458270|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
16458271|NCT03578198|Experimental|Rituximab + MG4101|"Drug: Rituximab + MG4101
~Induction phase:
~Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase
~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)"
16458272|NCT03578172|Experimental|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
16458273|NCT03578172|Active Comparator|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
16458274|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
16458275|NCT03578146|Experimental|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (~30 mg/min)
16458276|NCT03578146|Experimental|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (~30 mg/min)
16458277|NCT03578146|Experimental|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (~30 mg/min)
16458278|NCT03578146|Experimental|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes [~30 mg/min] followed by 240 mg continuous IV infusion [4 mg/min over 60 min)
16458279|NCT03578146|Experimental|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes [~30 mg/min] followed by 960 mg continuous IV infusion [8 mg/min over 120 min]
16458280|NCT03578146|Experimental|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
16458281|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
16458282|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
16458283|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
16458284|NCT03578107|Other|Improvement intervention1|receive the following improvement intervention for 18 months：
16458285|NCT03578107|Other|Improvement intervention2|receive the following improvement intervention for 12 months：
16458286|NCT03578107|Other|Improvement intervention3|receive the following improvement intervention for 6 months：
16458382|NCT03577353|Active Comparator|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
16458289|NCT03578055|Active Comparator|BDD with UDCA|Postoperative BDD with UDCA treatment
16458290|NCT03578055|Placebo Comparator|Placebo|Placebo
16458291|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
16458292|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
16458293|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
16458294|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
16458295|NCT03578016|Experimental|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
16458296|NCT03578016|Other|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
16458297|NCT03578003|Experimental|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
16458298|NCT03578003|No Intervention|Control|Subjects who do not engage in morning bright light therapy
16458301|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
16458302|NCT03577951|Experimental|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
16458303|NCT03577951|Experimental|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
16458304|NCT03577938|Experimental|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
16458305|NCT03577938|Other|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
16458306|NCT03577925||HSIL|the patients with HSIL
16458307|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
16458308|NCT03577912|Active Comparator|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
16458309|NCT03577912|Active Comparator|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
16458310|NCT03577899|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
16458311|NCT03577899|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
16458312|NCT03577899|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
16458313|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
16458314|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
16458315|NCT03577873|Placebo Comparator|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
16458316|NCT03577873|Experimental|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
16458317|NCT03577860|Active Comparator|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
16458318|NCT03577860|Active Comparator|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
16458319|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
16458320|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
16458321|NCT03577834|Experimental|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
16458322|NCT03577834|Placebo Comparator|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
16458323|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
16458475|NCT03576703|Experimental|EX+SSB|Exercise and diet that includes SSB
16458324|NCT03577782|Experimental|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
16458325|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
16458326|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
16458327|NCT03577743|Experimental|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
16458328|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
16458329|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
16458330|NCT03577717|Experimental|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
16458331|NCT03577717|Active Comparator|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
16458332|NCT03577704|Experimental|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).
~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
16458333|NCT03577704|Experimental|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).
~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
16458334|NCT03577704|Experimental|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).
~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
16458335|NCT03577691|Experimental|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
16458336|NCT03577691|Placebo Comparator|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
16458337|NCT03577678|Experimental|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
16458338|NCT03577665|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
16458339|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
16458340|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
16458341|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
16458342|NCT03577626|Experimental|Hemay005 Fast|
16458343|NCT03577626|Experimental|Hemay005 Fed|
16458344|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
16458345|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
16458346|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
16458347|NCT03577600|Experimental|QMRT using the Cytotron®|Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
16458348|NCT03577587|Experimental|Verum|Silitidil for 21 days
16458349|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
16458350|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
16458351|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
16458352|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
16458353|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
16458354|NCT03577561|No Intervention|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
16458355|NCT03577561|Active Comparator|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
16458356|NCT03577561|Active Comparator|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.
~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
16458357|NCT03577535|Experimental|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
16458358|NCT03577535|No Intervention|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
16458359|NCT03577522|Active Comparator|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
16458360|NCT03577522|Active Comparator|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
16458361|NCT03577509|Experimental|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
16458362|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
16458363|NCT03577483|Other|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
16458364|NCT03577483|Other|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
16458365|NCT03577483|Other|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
16458366|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
16458367|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
16458368|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
16458369|NCT03577457|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
16458370|NCT03577457|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
16458371|NCT03577457|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
16458372|NCT03577457|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
16458373|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
16458374|NCT03577431|Experimental|arTreg-CSB|"arTreg CSB: alloantigen-reactive T regulatory cells costimulatory blockade per protocol.
~The investigational product is donor alloantigen-specific T regulatory cells (arTreg-CSB). Supportive regimen for receipt of arTregs-CSB includes everolimus, leukapheresis, cyclophosphamide, and mesna.
~Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes.
~Note: Participants who receive at least the minimum Treg product (arTreg-CSB) dose of 1 to < 2.5 x 10^6 cells will be included in intent-to-treat analysis."
16458375|NCT03577418|Experimental|Clinician-facilitated educational intervention|
16458376|NCT03577418|Active Comparator|Enhanced usual care|
16458377|NCT03577392|Experimental|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
16458378|NCT03577392|Active Comparator|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
16458379|NCT03577379|No Intervention|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
16458380|NCT03577379|Experimental|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
16458381|NCT03577353|Experimental|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
16458383|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
16458384|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
16458385|NCT03577327||Adults with vitiligo|
16458386|NCT03577327||Healthy adults|
16458387|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
16458388|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
16458389|NCT03577301|Active Comparator|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
16458390|NCT03577301|Active Comparator|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
16458391|NCT03577301|Active Comparator|Multi-modal Delivery|A 4 session MI intervention. Session 1 is always delivered in person immediately after baseline. Session 2-4 can be delivered in person or remotely based upon youth preference. This arm is open to enrollment as of 11/15/2019.
16458392|NCT03577301|No Intervention|Treatment as Usual|Treatment as usual control = individual HIV testing with referrals and link age to care as provided by the sites under routine circumstances. This arm is open to enrollment as of 11/15/2019.
16458393|NCT03577288|Experimental|Experiment 1 A, B - Level of realism of EVR|Participants (50 children and 50 young adults for part A, and 50 other children and 50 other young adults) will be exposed to virtual experience having different level of realism. In one condition the realism will be high (very close to the real word) and in the second condition the realism will be low (comparable to cartoon). The stimuli of interest included in virtual experience will be of three emotional categories : negative, positive and neutral.
16458394|NCT03577288|Experimental|Experiment 2 - Presence and size of avatar|"Participants (50 children and 100 young adults) will be exposed to virtual experiences in which in one condition they will be part of the virtual environment in a body of an avatar and in another condition the avatar will not be present.
~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar."
16458395|NCT03577288|Experimental|Experiment 3 - Interaction in virtual experience|Participants (50 children and 50 young adults) will be submitted to two conditions of virtual experience, one condition in which it is possible to interact with the stimuli presented in the virtual environment and another condition in which it is not possible to interact. In addition, the stimuli of interest will be of one of three emotional categories : negative, positive and neutral. Thus participants will be exposed to six short virtual experiences.
16458396|NCT03577288|Experimental|Experiment 4 - Animate/Inanimate nature of interactive objects|Participants (30 children and 30 young adults) will be exposed to the virtual experience during which they will be able to interact in one condition with animated (e.g., dog, bird) stimuli and in another condition with inanimate (e.g., book, jacket) stimuli. The animate and inanimate stimuli of interest will be of three emotional categories : negative, positive and neutral.
16458397|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
16458398|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
16458399|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
16458400|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
16458401|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
16458402|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
16458403|NCT03577249|Experimental|Single arm|
16458404|NCT03577236|Experimental|Zenflow Spring System|Receives treatment with the investigational device
16458405|NCT03577223|Experimental|Whole Eggs|
16458406|NCT03577223|Active Comparator|Egg White-Based Egg Substitute|
16458407|NCT03577210|Other|computer-guided augmentation genioplasty|patient-specific PEEK implant
16458408|NCT03577171|Experimental|ABI-H0731 + SOC ETV|Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
16458409|NCT03577171|Experimental|Placebo + SOC ETV|Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
16458410|NCT03577158|Experimental|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.
~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
16458411|NCT03577158|Experimental|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
16458412|NCT03577158|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
16458413|NCT03577145|Experimental|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) & lovage (20g) with 10g inulin will be given to subjects in the form of a soup
16458414|NCT03577145|Experimental|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) & lovage (20g) will be given to subjects in the form of a soup
16458415|NCT03577145|Experimental|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
16458416|NCT03577132|Experimental|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
16458417|NCT03577132|Experimental|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
16458418|NCT03577119|Experimental|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
16458419|NCT03577119|Experimental|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
16458420|NCT03577106|Experimental|Transcranial magnetic stimulation (TMS)|
16458421|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
16458422|NCT03577093||control|healthy controls
16458423|NCT03577080|Active Comparator|ET+RT+ NMES|neuromuscular electrical training NMES
16458424|NCT03577080|Placebo Comparator|ET+RT|placebo neuromuscular electrical training NMES
16458425|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
16458426|NCT03577054|Experimental|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.
~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.
~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
16458427|NCT03577054|Placebo Comparator|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.
~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
16458428|NCT03577028|Experimental|Experimental: HPN424-1001|"In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.
~In Part 2 (Dose Expansion), patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added."
16458429|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
16458430|NCT03577002|Active Comparator|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
16458431|NCT03577002|Active Comparator|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
16458432|NCT03576989|Experimental|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (three opaque softgels to provide a total daily intake of 1.87 g of EPA + 1.0 g of DHA)
16458433|NCT03576989|Placebo Comparator|Placebo Group|12 weeks of daily oral therapy with placebo (three opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
16458434|NCT03576976|Active Comparator|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
16458435|NCT03576976|Experimental|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
16458436|NCT03576963|Experimental|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
16458437|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
16458438|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
16458439|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
16458440|NCT03576924|Active Comparator|Imposed-MICT|Continuous exercise for 30 minutes per session at 60-65% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
16458441|NCT03576924|Active Comparator|Imposed-HIIT|Five repeated vigorous intervals of 1-min duration at 85-90% of heart rate max with 1-min recovery periods, with 3-min warm-up and 2-min cool-down, making the total session duration 15 min for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
16458476|NCT03576703|No Intervention|CONTROL|No exercise and diet that did not include SSB
16458442|NCT03576924|Experimental|CHOICE|Participants will always self-select the exercise type that they will do, either the IM-HIIT or the IM-MICT protocols, which will be matched to the parallel imposed conditions.
16458443|NCT03576911|Experimental|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
16458444|NCT03576911|Placebo Comparator|Placebo|Placebo capsule taken orally three times per day for 6 months
16458445|NCT03576885|Active Comparator|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
16458446|NCT03576885|Placebo Comparator|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
16458447|NCT03576885|No Intervention|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
16458448|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.
~Teach session will occur prior and during administration of chemo
~A small quiz will be conducted to asses understanding of the educational binder"
16458449|NCT03576859|Other|cirrhotic patients with chronic liver failure|
16458450|NCT03576859|Other|cirrhotic patients without chronic liver failure|
16458451|NCT03576846|Experimental|Intervention|Stretching and Spinal Manipulative Therapy
16458452|NCT03576846|Active Comparator|Comparator|Stretching
16458453|NCT03576833|Experimental|Balloon|
16458454|NCT03576820|Experimental|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
16458455|NCT03576820|Placebo Comparator|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
16458456|NCT03576807|Experimental|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
16458457|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
16458458|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
16458459|NCT03576781|Experimental|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
16458460|NCT03576781|Sham Comparator|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
16458461|NCT03576781|Experimental|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
16458462|NCT03576781|Sham Comparator|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
16458463|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
16458464|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
16458465|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
16458466|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
16458467|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
16458468|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
16458469|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
16458470|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
16458471|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
16458472|NCT03576729||Healthy Controls|Age-matched healthy controls
16458473|NCT03576716|Experimental|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
16458474|NCT03576703|Experimental|EX+H2O|Exercise and diet that did not include SSB
16458477|NCT03576677|Active Comparator|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
16458478|NCT03576677|Placebo Comparator|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
16458479|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
16458480|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
16458481|NCT03576651|Experimental|JHL1149|
16458482|NCT03576651|Active Comparator|US-sourced-Avastin™|
16458483|NCT03576651|Active Comparator|EU-sourced Avastin™|
16458484|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
16458485|NCT03576638|Experimental|AP CD/LD|
16458486|NCT03576625|Placebo Comparator|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
16458487|NCT03576625|Experimental|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
16458488|NCT03576612|Experimental|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
16458489|NCT03576612|Experimental|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
16458490|NCT03576599|Active Comparator|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
16458491|NCT03576599|Placebo Comparator|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
16458492|NCT03576586|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
16458493|NCT03576586|Placebo Comparator|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
16458494|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
16458495|NCT03576547|Experimental|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
16458496|NCT03576534|No Intervention|Control|Standard of care
16458497|NCT03576534|Active Comparator|Study|PBUF used prior to Cardiopulmonary bypass
16458498|NCT03576521|Experimental|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
16458499|NCT03576521|Placebo Comparator|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
16458500|NCT03576508|Experimental|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
16458501|NCT03576508|Active Comparator|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
16458502|NCT03576495|Experimental|Early Intervention / Retention Group|"The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).
~Follow-up testing will be conducted after one year to evaluate learner retention.
~Further, the investigators will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
16458503|NCT03576495|Active Comparator|Delayed Intervention Group|"The investigators will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.
~Both between- and within-group differences will be examined based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
16458504|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
16458505|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
16458506|NCT03576469|Experimental|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:
~6 - 8 weeks - subjects will receive 2 infusions of IVIG
~9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion"
16458507|NCT03576456|Active Comparator|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
16458508|NCT03576456|Placebo Comparator|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
16458509|NCT03576443|Experimental|Treatment arm|Idelalisib 150 mg x 2 p o, until progression
16458510|NCT03576430|Active Comparator|active|active stress handling
16458511|NCT03576430|No Intervention|control|no stress handling
16458512|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
16458513|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"240 mg of nivolumab 3 weeks before RT-Cisplatin
~360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin
~480 mg of nivolumab for maintenance"
16458514|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
16458515|NCT03576391|Experimental|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
16458616|NCT03575858|Active Comparator|Tapered interdental brushes|control group
16458516|NCT03576391|Experimental|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
16458517|NCT03576391|Experimental|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
16458518|NCT03576378|Experimental|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
16458519|NCT03576365|Experimental|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
16458520|NCT03576365|Sham Comparator|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
16458521|NCT03576352|Experimental|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
16458522|NCT03576352|Experimental|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
16458523|NCT03576352|Experimental|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
16458524|NCT03576352|Experimental|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
16458525|NCT03576339|Sham Comparator|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
16458526|NCT03576339|Experimental|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
16458527|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
16458528|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
16458529|NCT03576313|Experimental|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
16458530|NCT03576313|Active Comparator|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
16458531|NCT03576300||control|subjects without dry eye and diabetes
16458532|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
16458533|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
16458534|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
16458535|NCT03576287|Experimental|apremilast|apremilast standard doses
16458536|NCT03576274|Experimental|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
16458537|NCT03576274|Experimental|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.
~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).
~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
16458538|NCT03576274|Experimental|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.
~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.
~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
16458712|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
16458539|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
16458540|NCT03576274|Active Comparator|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.
~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).
~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
16458541|NCT03576261|Experimental|Preoperative echo + fluids|20 individuals investigated by preoperative transthoracic echocardiography. Preoperative colloid fluid bolus (Gelofusine, Fresenius Kabi AB, Sweden) 6 ml/kg lean body weight, is infused intravenously immediately before anesthesia induction.
16458542|NCT03576261|Active Comparator|Preoperative echo, control|20 individuals investigated by preoperative transthoracic echocardiography. No intravenous fluids are infused before anesthesia induction.
16458543|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
16458544|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
16458545|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
16458546|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
16458547|NCT03576235|Experimental|a treatment group|PG102P 1.5 g/day
16458548|NCT03576235|Placebo Comparator|a control group|placebo
16458549|NCT03576222|Active Comparator|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
16458550|NCT03576222|Placebo Comparator|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
16458551|NCT03576209|Active Comparator|Intervention Group|12 week intervention
16458552|NCT03576209|No Intervention|Control Group|No walking program
16458553|NCT03576196|Experimental|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.
~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
16458554|NCT03576196|Other|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.
~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
16458555|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
~The vaccine is administered orally in 2 doses about 1 week apart."
16458556|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.
~The vaccine is administered orally in 2 doses about 1 week apart."
16458557|NCT03576170|Active Comparator|aromatherapy-scent|
16458558|NCT03576170|Active Comparator|aromatherapy-touch|
16458559|NCT03576170|No Intervention|wait-list control|
16458560|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
16458561|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
16458562|NCT03576144|Experimental|BI 1265162|
16458563|NCT03576144|Placebo Comparator|Placebo|
16458564|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|Open label, single arm trial where GEN1029 will be administered
16458565|NCT03576118|Experimental|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
16458566|NCT03576118|Active Comparator|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
16458567|NCT03576105|Experimental|experimental group|G1 - 32 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
16458610|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
16458611|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
16458612|NCT03575871|Experimental|PF-04965842 100 mg|
16458568|NCT03576105|Active Comparator|positive control group|G2 - 32 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
16458569|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
16458570|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
16458571|NCT03576079|Experimental|Laser therapy|12 laser sessions over 3 months
16458572|NCT03576079|Active Comparator|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
16458573|NCT03576079|Placebo Comparator|inactive laser therapy|placebo laser for 12 sessions over 3 months
16458574|NCT03576066|Experimental|ABI-H0731 + SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
16458575|NCT03576066|Active Comparator|Placebo + SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
16458576|NCT03576053|Experimental|Histamine+cowhage+heat|
16458577|NCT03576053|Experimental|Histamine+cowhage+serotonin+pre-heating|
16458578|NCT03576053|Placebo Comparator|lidocaine and saline+heat|
16458579|NCT03576027|Experimental|Hyperbaric oxygen therapy|
16458580|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).
~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
16458581|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
16458582|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
16458583|NCT03575988||Diabetes group|
16458584|NCT03575988||Control group|
16458585|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
16458586|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
16458587|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
16458588|NCT03575962|Experimental|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
16458589|NCT03575962|Experimental|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
16458590|NCT03575949|Experimental|Diagnostic (FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard CRT completion.
16458591|NCT03575936|Active Comparator|Standard of Care Group|Standard of Care arm. Pharmacist intervention in clinic
16458592|NCT03575936|Experimental|Home Monitoring Group|Pharmacist intervention with home INR monitoring
16458593|NCT03575923||Intervention site 1|2 planted trees; bulb planting
16458594|NCT03575923||Comparison site 1A|
16458595|NCT03575923||Comparison site 1B|
16458596|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
16458597|NCT03575923||Comparison site 2A|
16458598|NCT03575923||Comparison site 2B|
16458599|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
16458600|NCT03575923||Comparison site 3A|
16458601|NCT03575923||Comparison site 3B|
16458602|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
16458603|NCT03575923||Comparison site 4A|
16458604|NCT03575923||Comparison site 4B|
16458608|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
16458609|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
16458613|NCT03575871|Experimental|PF-04965842 200 mg|
16458614|NCT03575871|Placebo Comparator|Placebo|
16458617|NCT03575845|Experimental|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
16458618|NCT03575832|Experimental|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
16458619|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
16458620|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
16458621|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
16458622|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
16458623|NCT03575793|Experimental|Phase I (Dose Escalation): nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).
~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.
~Plinabulin escalation is as follows:
~Level -1 : 13.5mg/m^2
~Level 1 (start) : 20mg/m^2
~Level 2 : 30mg/m^2"
16458624|NCT03575793|Experimental|Phase II: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).
~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
16458625|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
16458626|NCT03575754|Experimental|Interventional|This arm utilizes the investigational device, as specified in protocol.
16458627|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
16458628|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
16458629|NCT03575728|Other|Mood disorder|Participants who screen positive for a history of mood disorders
16458630|NCT03575728|Other|Other|Participants who do not screen positive for a history of mood disorders
16458631|NCT03575715|Experimental|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
16458632|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
16458633|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
16458634|NCT03575689|Experimental|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
16458635|NCT03575689|No Intervention|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
16458636|NCT03575676|Experimental|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
16458637|NCT03575676|Experimental|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
16458638|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
16458639|NCT03575637|Experimental|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
16458640|NCT03575637|No Intervention|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
16458641|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
16458642|NCT03575611|Experimental|Treatment (SBRT)|Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist.
16458643|NCT03575598|Experimental|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.
~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
16458644|NCT03575585|Experimental|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
16458645|NCT03575585|Experimental|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
16458646|NCT03575585|Experimental|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
16458647|NCT03575585|Experimental|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
16458648|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
16459562|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
16458649|NCT03575559|Experimental|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
16458650|NCT03575559|Experimental|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
16458651|NCT03575559|Active Comparator|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
16458652|NCT03575559|Active Comparator|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
16458653|NCT03575520|Experimental|Peg group|
16458654|NCT03575507|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
16458655|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
16458656|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
16458657|NCT03575481||Post stroke patients|
16458658|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
16458659|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
16458660|NCT03575455|Experimental|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.
~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
16458661|NCT03575455|No Intervention|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.
~Healthy participants will participate in a single 20' treatment session of seated rest."
16458662|NCT03575442|Other|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
16458663|NCT03575429|Active Comparator|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
16458664|NCT03575429|Active Comparator|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
16458665|NCT03575403|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules one time daily.
16458666|NCT03575403|Experimental|Low Dose Duloxetine|Subjects will receive 30 mg oral duloxetine one time daily.
16458667|NCT03575403|Experimental|High Dose Duloxetine|Subjects will receive 60 mg oral duloxetine one time daily.
16458668|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
16458669|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
16458670|NCT03575377|Experimental|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
16458671|NCT03575377|No Intervention|Control|These families will receive routine postoperative instructions only.
16458672|NCT03575364||Primary Analytic|Patients with unilateral acute or subacute DVT of less than 6 weeks' duration.
16458673|NCT03575364||Registry|Patients with proximal lower extremity DVT.
16458674|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
16458675|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
16458676|NCT03575338|Active Comparator|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
16458677|NCT03575338|Experimental|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
16458678|NCT03575325|Experimental|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.
~This may be followed by consolidation with CPX-351 at a dose of 65 u/m^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
16458679|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
16458680|NCT03575299|Experimental|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
16458681|NCT03575299|Placebo Comparator|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
16458682|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
16458683|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
16458684|NCT03575273|Experimental|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
16458685|NCT03575273|Experimental|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
16458686|NCT03575273|Active Comparator|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
16458687|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
16458688|NCT03575260||Exemestane|Exemestane 25mg per day
16458689|NCT03575234|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
16458690|NCT03575221||Enrollees|Individuals with Osteogenesis Imperfecta
16458693|NCT03575195|Experimental|Intervention|Rifaximin
16458694|NCT03575195|Placebo Comparator|Placebo|Matching placebo
16458695|NCT03575182|Experimental|Gait retraining program|
16458696|NCT03575182|No Intervention|Physical therapy standard care|
16458697|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
16458698|NCT03575156|Experimental|Systemic lupus erythematosus (SLE)|
16458699|NCT03575156|Experimental|systemic scleroderma (SSc)|
16458700|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea
16458701|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea
16458702|NCT03575130|Experimental|Glanatec|
16458703|NCT03575130|Placebo Comparator|Placebo|
16458704|NCT03575117|Experimental|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
16458705|NCT03575117|Other|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
16458706|NCT03575104|Experimental|ACT-541468 10 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
16458707|NCT03575104|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
16458708|NCT03575104|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
16458709|NCT03575091|No Intervention|control group|The infants will receive the standard care at the ward.
16458710|NCT03575091|Experimental|Non-individualized|The parents will be guided manually by the nursing staff and receive written information about how to change body positions of their child regularly throughout the hospital stay.
16458711|NCT03575091|Experimental|Individualized|The infant will receive frequent changes of body positions, stimulation to physical activity, and stimulation to deep breathing while bouncing on a large ball in the arms of an adult. Additional light chest compressions and inhalations may be given. A physiotherapist will perform the intervention at least once daily, and the parents will be manually guided and receive written information about how to change body positions of their child regularly in a similar way throughout the hospital stay.
16458713|NCT03575065|Experimental|Cohort 1: Triple-negative breast cancer (TNBC)|Locally advanced or metastatic TNBC
16458714|NCT03575065|Experimental|Cohort 2: HR(+)/HER2(-) breast cancer|Locally advanced or metastatic HR(+)/HER2(-) breast cancer
16458715|NCT03575052|Experimental|Drug - Pimavanserin|
16458716|NCT03575052|Placebo Comparator|Placebo|
16458717|NCT03575039|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
16458718|NCT03575026|Experimental|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
16458719|NCT03575026|Placebo Comparator|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
16458720|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:
~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles
~Maintenance phase:
~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
16458721|NCT03575000|Experimental|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
16458722|NCT03574987|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
16458723|NCT03574987|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
16458724|NCT03574987|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
16458725|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
16458726|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
16458727|NCT03574961|Experimental|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
16458728|NCT03574961|Placebo Comparator|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
16458729|NCT03574948|Experimental|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
16458730|NCT03574948|Placebo Comparator|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
16458731|NCT03574935|Experimental|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:
~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
16458732|NCT03574935|Active Comparator|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
16458733|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
16458734|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
16458735|NCT03574922|No Intervention|Control|Assessments only
16458736|NCT03574909|Experimental|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).
~There is no requirement for the first dose to be administered in the clinic under observation.
~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.
~No specific precautions are required in relation to concomitant food intake."
16458737|NCT03574909|Placebo Comparator|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.
~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.
~No specific precautions are required in relation to concomitant food intake."
16458738|NCT03574883|Experimental|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
16458739|NCT03574883|Active Comparator|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
16458740|NCT03574883|Sham Comparator|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
16458741|NCT03574883|Experimental|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
16458742|NCT03574883|Sham Comparator|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
16458743|NCT03574870|Experimental|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):
~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
16458861|NCT03574194|Experimental|Methionine-restricted diet|6-10 weeks methionine-restricted diet (MRD) curative intent radiation therapy course of 6 weeks or less.
16458744|NCT03574870|Experimental|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)
~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery
~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)
~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
16458745|NCT03574857|Active Comparator|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
16458746|NCT03574857|Active Comparator|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
16458747|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
16458748|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
16458749|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
16458750|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
16458751|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).
~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).
~The regimen will be given for a total of 3 cycles.
~The regimen will be given for a total of 3 cycles."
16458752|NCT03574805|Active Comparator|PRS-060|PRS-060 or Placebo
16458753|NCT03574805|Placebo Comparator|Placebo|PRS-060 or Placebo
16458754|NCT03574792|Active Comparator|Arm I (gabapentin, methadone, oxycodone)|Participants receive gabapentin PO daily or TID. Participants may also receive methadone PO TID and oxycodone PO every 8 hours as needed. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
16458755|NCT03574792|Experimental|Arm II (gabapentin, methadone, oxycodone, venlafaxine)|Participants receive gabapentin, methadone, and oxycodone as in Arm I and venlafaxine PO BID or venlafaxine hydrochloride extended release daily for up to 12 months in the absence of disease progression or unacceptable toxicity.
16458756|NCT03574779|Experimental|Cohort A: 1-2 prior lines of therapy|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered every 3 weeks for 4 cycles (each cycle is 21 days), followed by every 6 weeks beginning on cycle 5 day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
16458757|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
16458758|NCT03574766|No Intervention|Control Group|Routine lactation support.
16458760|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
16458761|NCT03574701|Experimental|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
16458762|NCT03574701|Experimental|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
16458763|NCT03574701|No Intervention|C: Standard of Care|Group C: This study group will receive only standard of care .
16458764|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
16458765|NCT03574675|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
16458766|NCT03574675|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
16458767|NCT03574662|Experimental|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
16458768|NCT03574649|Experimental|NANT NSCLC Combination Immunotherapy regimen|
16458769|NCT03574649|Active Comparator|Standard of Care|
16458770|NCT03574636|Active Comparator|OCT guidance|"Firehawk stent implantation will be performed with Optical Coherence Tomography guidance.
~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.
~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
16458771|NCT03574636|Active Comparator|IVUS guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.
~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.
~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
16458772|NCT03574636|Active Comparator|QCA guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.
~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.
~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
16458862|NCT03574168|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
16459563|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
16458773|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
16458774|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
16458775|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
16458776|NCT03574610|Experimental|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
16458777|NCT03574597|Experimental|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
16458778|NCT03574597|Placebo Comparator|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
16458779|NCT03574584|Experimental|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
16458780|NCT03574584|Experimental|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
16458783|NCT03574558|Experimental|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for personalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
16458786|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
16458787|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
16458788|NCT03574519|Experimental|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
16458789|NCT03574519|Experimental|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
16458790|NCT03574519|Experimental|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
16458791|NCT03574519|Experimental|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
16458792|NCT03574493||Open laparotomy|A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.
16458793|NCT03574493||Laparoscopic surgery|A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.
16458794|NCT03574493||Robot-assisted surgery using the da Vinci® Surgical System|A minimally-invasive approach that allows good precision, flexibility, and control.
16458795|NCT03574493||Transanal surgery through the anus|Where the protectomy is performed down to up until the Douglas pouch
16458796|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
16458797|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations
~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
16458798|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
16458799|NCT03574467||Bobath Approach Applied to Patient with Stroke|
16458800|NCT03574454|Other|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
16459623|NCT03569007|Active Comparator|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
16458801|NCT03574454|Other|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
16458802|NCT03574454|Other|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
16458803|NCT03574441|Active Comparator|TegadermTM only|
16458804|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
16458805|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
16458806|NCT03574428|Active Comparator|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
16458807|NCT03574428|Active Comparator|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
16458808|NCT03574428|Active Comparator|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
16458809|NCT03574428|Active Comparator|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
16458810|NCT03574415|Experimental|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
16458811|NCT03574415|Experimental|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
16458812|NCT03574415|Experimental|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
16458813|NCT03574415|Experimental|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
16458814|NCT03574415|Experimental|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
16458815|NCT03574415|Experimental|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
16458816|NCT03574415|Experimental|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
16458817|NCT03574415|Placebo Comparator|Placebo|DWP14012 placebo-matching tablets
16458818|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
16458819|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.
~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
16458820|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16458821|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16458822|NCT03574402|Experimental|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
16458823|NCT03574402|Experimental|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
16458824|NCT03574402|Experimental|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
16458825|NCT03574402|Experimental|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
16458826|NCT03574402|Experimental|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.
~This arm was divided into three groups:
~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
16458827|NCT03574402|Experimental|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.
~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
16458828|NCT03574402|Experimental|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1.
~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
16458829|NCT03574402|Experimental|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.
~This arm was divided into two groups:
~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
16458830|NCT03574402|Experimental|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
16458831|NCT03574402|Experimental|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
16458832|NCT03574402|Experimental|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1<50% without EGFR mutation or ALK rearrangement.
~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
16458954|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
16458833|NCT03574402|Experimental|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement.
~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
16458834|NCT03574402|Experimental|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.
~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
16458835|NCT03574402|Experimental|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.
~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
16458836|NCT03574389|Experimental|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|"Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.
~Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).
~Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.
~Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age."
16458837|NCT03574389|Active Comparator|Haemophilus influenzae type b (Hib)|"No participants in cohort 1 will receive Hib vaccine.
~Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.
~Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age."
16458838|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
16458839|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.
~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
16458840|NCT03574363|Experimental|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
16458841|NCT03574363|Experimental|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
16458842|NCT03574363|Placebo Comparator|Placebo tablet|Placebo tablet QD orally, 84 days
16458843|NCT03574350|Experimental|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
16458844|NCT03574350|Active Comparator|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
16458845|NCT03574337|Active Comparator|Sugammadex|Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
16458846|NCT03574337|Active Comparator|Neostigmine/glycopyrrolate|Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
16458847|NCT03574337|No Intervention|No reversal administered|No reversal administered at the end of the case
16458848|NCT03574324|Experimental|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
16458849|NCT03574324|Other|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
16458850|NCT03574311|Experimental|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
16458851|NCT03574311|Placebo Comparator|Placebo|Preoperative 100 ml saline as 30 minute infusion
16458852|NCT03574285|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
16458853|NCT03574285|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
16458854|NCT03574272|Experimental|Patient Transfer Monitoring System|
16458855|NCT03574246|Experimental|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
16458856|NCT03574246|Active Comparator|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
16458857|NCT03574233||patients who are ready to wean ventilator off|
16458858|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.
~Adjuvant Therapy:
~Pembrolizumab 200mg IV every 21 days for 6 months"
16458859|NCT03574207|Other|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
16458860|NCT03574207|Other|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
16458863|NCT03574155|No Intervention|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.
~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
16458864|NCT03574155|Experimental|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.
~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
16458865|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
16458866|NCT03574129|Experimental|Adolescent transition package|Adolescent transition package
16458867|NCT03574129|No Intervention|Standard of care|Standard of care adolescent services
16458868|NCT03574103|Active Comparator|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
16458869|NCT03574103|Experimental|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
16458870|NCT03574103|Experimental|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
16458871|NCT03574090|Experimental|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
16458872|NCT03574090|Active Comparator|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
16458873|NCT03574077|Experimental|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
16458874|NCT03574077|Active Comparator|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
16458875|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
16458876|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
16458877|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
16458878|NCT03574064|Placebo Comparator|Placebo|Placebo
16458879|NCT03574051|Experimental|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
16458880|NCT03574038|Active Comparator|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
16458881|NCT03574038|Sham Comparator|Sham Stimulation|Sham Stimulation
16458882|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
16458883|NCT03574012|Active Comparator|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
16458884|NCT03574012|Experimental|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
16458885|NCT03573999|Active Comparator|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
16458886|NCT03573999|Experimental|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
16458887|NCT03573986|Experimental|Arm A|
16458888|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
16458889|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
16458890|NCT03573960|Experimental|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
16458891|NCT03573947|Experimental|nivolumab, ipilimumab and paclitaxel|
16458892|NCT03573934|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
16458893|NCT03573934|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
16458894|NCT03573934|Experimental|GLP-2+GIP|GLP-2+GIP injection
16458895|NCT03573934|Placebo Comparator|Placebo|Placebo injection
16458896|NCT03573921|Experimental|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
16458897|NCT03573921|Experimental|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
16458898|NCT03573908|Experimental|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
16458955|NCT03573518|Experimental|BTX 1503 Dose 1 BID|BTX 1503 Dose 1 twice daily
16458956|NCT03573518|Experimental|BTX 1503 Dose 1 QD|BTX 1503 Dose 1 once daily
16458899|NCT03573908|Placebo Comparator|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
16458900|NCT03573895|Experimental|Foam-Roller|
16458901|NCT03573895|Experimental|Neuromuscular Stretching|
16458902|NCT03573895|Experimental|Pasive stretching|
16458903|NCT03573895|No Intervention|Control|
16458904|NCT03573882|Other|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
16458905|NCT03573869|Experimental|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
16458906|NCT03573869|No Intervention|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
16458909|NCT03573843|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
16458910|NCT03573843|Experimental|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
16458911|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
16458912|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
16458913|NCT03573817|Experimental|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
16458914|NCT03573817|Experimental|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
16458915|NCT03573817|Placebo Comparator|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
16458916|NCT03573817|Placebo Comparator|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
16458917|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
16458918|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
16458919|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
16458920|NCT03573778|Experimental|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
16458921|NCT03573778|Active Comparator|Usual Care|Information about Community Services
16458922|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
16458923|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
16458924|NCT03573726|Other|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
16458925|NCT03573713|Experimental|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
16458926|NCT03573713|Other|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
16458957|NCT03573518|Experimental|BTX 1503 Dose 2 QD|BTX 1502 Dose 2 once daily
16458958|NCT03573518|Placebo Comparator|Vehicle BID|Vehicle twice daily
16458959|NCT03573518|Placebo Comparator|Vehicle QD|Vehicle once daily
16458927|NCT03573700|Experimental|SJCAR19 Therapy|"Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.
~Cells for infusion are prepared using the CliniMACS System."
16458928|NCT03573687|Experimental|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
16458929|NCT03573687|Experimental|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
16458930|NCT03573687|Experimental|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
16458931|NCT03573674|Experimental|Cognitive ergonomics Intervention|
16458932|NCT03573674|Active Comparator|Stress management Intervention|
16458933|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
16458934|NCT03573661|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
16458935|NCT03573648|Active Comparator|Endocrine Therapy|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
16458936|NCT03573648|Active Comparator|Endocrine Therapy with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
16458937|NCT03573635|Other|Supratube|Patient with orotracheal intubation and supratube device
16458938|NCT03573622|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
16458939|NCT03573622|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
16458940|NCT03573609|No Intervention|Control|Usual respiratory care
16458941|NCT03573609|Active Comparator|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
16458942|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
16458943|NCT03573583|Experimental|Resistance Training group (RT)|"The resistance training intervention will include a full body, resistance training performed three days per week.
~The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines"
16458944|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
16458945|NCT03573570|Experimental|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
16458946|NCT03573570|No Intervention|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
16458947|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
16458948|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
16458949|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
16458950|NCT03573544|Experimental|OBI-888 Escalation Phase|Part A: Three cohorts of escalating dose levels of OBI-888 5, 10, and 20 mg/kg liquid form for intravenous infusion to establish maximum tolerated dose (MTD).
16458951|NCT03573544|Experimental|OBI-888 Expansion Phase|Part B: Five cohorts at dose level 20 mg/kg of liquid form OBI-888 for intravenous infusion.
16458952|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
16458953|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
16459032|NCT03572972||Patients prescribed dabigatran|
16458960|NCT03573505|Experimental|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
16458961|NCT03573505|Placebo Comparator|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
16458962|NCT03573492|Active Comparator|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
16458963|NCT03573492|Active Comparator|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
16458964|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
16458965|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
16458966|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
16458967|NCT03573453|Experimental|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
16458968|NCT03573453|Experimental|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
16458969|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.
~They will inform the investigator verbally when they are feeling full.
~After they have decided to end their meal, they will be asked to fill out a questionnaire"
16458970|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.
~They will inform the investigator verbally when they are feeling full.
~After they have decided to end their meal, they will be asked to fill out a questionnaire"
16458972|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).
~Photodynamic therapy (PDT)"
16458973|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
16458974|NCT03573388||Optical coherence tomography (OCT)|
16458975|NCT03573375|Experimental|Cancer Patients in Supportive Care Clinic (SCC)|
16458976|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
16458977|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
16458978|NCT03573349|Other|Ketamine|Open-label, non-randomized
16458979|NCT03573336|Experimental|Vilaprisan (BAY1002670) 2 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
16458980|NCT03573336|Experimental|Vilaprisan (BAY1002670) 4 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
16458981|NCT03573336|Placebo Comparator|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
16458982|NCT03573323|Experimental|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.
~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
16458983|NCT03573323|Experimental|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.
~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
16458984|NCT03573310|Experimental|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
16458985|NCT03573310|Experimental|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
16458986|NCT03573297|Experimental|Cariprazine 3 mg/day|Cariprazine capsules, oral administration, once daily
16458987|NCT03573297|Experimental|Cariprazine 1.5 mg/day|Cariprazine capsules, oral administration, once daily
16458988|NCT03573297|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily
16458989|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
16458990|NCT03573271|Experimental|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
16458991|NCT03573258|Experimental|Fiber|"300 ml of orange juice plus Intervention
~6 g of oat beta glucan = FIBER (study A) or
~25 g inulin/FOS = FIBER (study B)"
16458992|NCT03573258|Placebo Comparator|Placebo|"300 ml of orange juice plus Placebo:
~13.5 g maltodextrin = PLACEBO (study A) or
~15.5 g maltodextrin = PLACEBO (study B)"
16458993|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
16458994|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
16458995|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
16458996|NCT03573219|Experimental|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
16458997|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
16458998|NCT03573193|Active Comparator|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
16458999|NCT03573193|Other|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
16459000|NCT03573167|Active Comparator|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
16459001|NCT03573167|Experimental|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
16459002|NCT03573167|No Intervention|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
16459003|NCT03573154|Other|e-liquid 1|
16459004|NCT03573154|Other|e-liquid 2|
16459005|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
16459006|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
16459007|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
16459008|NCT03573115|Experimental|Acne patients|
16459009|NCT03573102|Active Comparator|control|ACE inhibitor , aspirin , statins will be given once daily
16459010|NCT03573102|Experimental|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
16459011|NCT03573089|Active Comparator|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
16459012|NCT03573089|Experimental|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
16459013|NCT03573076|Experimental|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
16459014|NCT03573076|Experimental|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
16459015|NCT03573076|Active Comparator|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
16459016|NCT03573076|Active Comparator|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
16459017|NCT03573076|No Intervention|Control|Control receiving no intervention
16459018|NCT03573063|Other|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
16459019|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
16459020|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
16459021|NCT03573037|Experimental|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
16459022|NCT03573037|Active Comparator|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
16459023|NCT03573024|Experimental|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
16459024|NCT03573011|Experimental|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal [18F]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.
~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.
~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
16459025|NCT03573011|Experimental|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of [18F]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
16459026|NCT03572998|Other|Breast cancer patients|study subject
16459027|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
16459028|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
16459029|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
16459030|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
16459031|NCT03572972||Patients prescribed apixaban|
16459036|NCT03572959|Active Comparator|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
16459037|NCT03572959|Experimental|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.
~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
16459038|NCT03572946|Experimental|target biopsy group|Targeted prostate biopsy
16459039|NCT03572946|Active Comparator|standard biopsy group|Standard prostate biopsy
16459040|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
16459041|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
16459042|NCT03572920||Patients with hip/knee arthroplasty.|RAR description by actgraphy Objective sleep evaluation by actigraphy. Subjective sleep quality with sleep diary Pittsburgh Sleep Quality Index (PSQI).
16459043|NCT03572881|Experimental|Asymptomatic|
16459044|NCT03572881|Experimental|Symptomatic|
16459045|NCT03572855|Experimental|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
16459046|NCT03572842|Other|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
16459047|NCT03572829|Experimental|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
16459048|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)
~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
16459049|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)
~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
16459050|NCT03572803|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
16459051|NCT03572803|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
16459052|NCT03572803|Sham Comparator|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
16459053|NCT03572790|Experimental|Prucalopride|
16459054|NCT03572790|Placebo Comparator|Placebo|
16459055|NCT03572777|Active Comparator|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
16459056|NCT03572777|Active Comparator|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
16459057|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction
~If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3
~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
16459058|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.
~Bed-, wrist- and ECG-sensor monitoring"
16459059|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.
~Bed-, wrist- and ECG-sensor monitoring"
16459060|NCT03572738||Patients with HS|The set of all Hidradenitis Suppurativa patients (ICD-10 code: L73.2) who visited Wake Forest Baptist Medical Center's dermatology clinic during the last 5 years will either be recruited in person or be mailed the HS Severity Self-Assessment tool and a survey about their demographics, symptoms, treatments, psychological aspects, and lifestyle.
16459061|NCT03572725|Active Comparator|Gas tamponade|Gas as intraocular tamponade.
16459062|NCT03572725|Experimental|Air tamponade|Air as intraocular tamponade.
16459063|NCT03572686|Sham Comparator|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
16459064|NCT03572686|Placebo Comparator|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
16459065|NCT03572686|Experimental|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
16459066|NCT03572673|Active Comparator|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
16459067|NCT03572673|Experimental|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
16459068|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
16459069|NCT03572647|Experimental|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
16459070|NCT03572647|Active Comparator|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
16459071|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:
~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
16459072|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:
~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
16459073|NCT03572621|Experimental|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
16459074|NCT03572621|Sham Comparator|Control group|Patient without therapeutic education.
16459075|NCT03572621|Other|Partner|Patient's partner.
16459076|NCT03572608|Experimental|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
16459077|NCT03572608|No Intervention|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
16459078|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
16459079|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.
~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.
~comparing the results with histopathology ."
16459080|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
16459081|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
16459082|NCT03572569||First-degree family members|Parents and siblings of index patients
16459083|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
16459084|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
16459085|NCT03572543|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
16459086|NCT03572543|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
16459090|NCT03572517|Active Comparator|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.
~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.
~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
16459091|NCT03572517|Active Comparator|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.
~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
16459117|NCT03572335||HIV positive with mild DLco impairment|HIV positive with mild DLco impairment DLco <80% predicted after adjustments for Hgb and Co.
16459118|NCT03572322||Doctors|
16459119|NCT03572322||Patients|
16459120|NCT03572296|Placebo Comparator|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
16459092|NCT03572491|Experimental|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
16459093|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
16459094|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
16459095|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
16459096|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
16459097|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:
~Acoustic Radiation Force Impulse (ARFI)
~Magnetic Resonance Elastography (MRE)"
16459098|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:
~Acoustic Radiation Force Impulse (ARFI)
~Magnetic Resonance Elastography (MRE)"
16459099|NCT03572452|Experimental|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
16459100|NCT03572452|Active Comparator|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
16459101|NCT03572439|Active Comparator|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
16459102|NCT03572439|Active Comparator|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
16459103|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
16459104|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
16459105|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
16459106|NCT03572413|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
16459107|NCT03572413|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
16459108|NCT03572400|Experimental|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab
~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
16459109|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
16459110|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
16459111|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
16459112|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
16459113|NCT03572361|Experimental|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
16459114|NCT03572348|Active Comparator|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
16459115|NCT03572348|Active Comparator|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
16459116|NCT03572335||HIV positive with normal PFT's|HIV positive with normal baseline DLco. Subjects with DLco>80% predicted after adjustments for Hgb and Co
16459257|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
16459121|NCT03572296|Experimental|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
16459122|NCT03572296|Experimental|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
16459123|NCT03572283|Experimental|Bethanechol|Patients with pancreatic adenocarcinoma will receive bethanechol prior to pancreatic surgery
16459124|NCT03572270|Experimental|case|PLWH
16459125|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
16459126|NCT03572257|Experimental|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
16459127|NCT03572257|Placebo Comparator|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
16459128|NCT03572244|Experimental|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
16459129|NCT03572244|Active Comparator|Machine|A machined implant will be placed.
16459130|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
16459131|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
16459132|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
16459133|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
16459134|NCT03572205|Experimental|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
16459135|NCT03572205|Experimental|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
16459136|NCT03572205|Experimental|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
16459137|NCT03572205|Experimental|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
16459138|NCT03572179|Active Comparator|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
16459139|NCT03572179|No Intervention|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
16459140|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
16459141|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
16459142|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
16459143|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
16459144|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
16459145|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
16459146|NCT03572127|Experimental|Non-animal derived diet|High protein diet derived from non-animal sources.
16459147|NCT03572127|Active Comparator|Animal derived diet|High protein diet derived from animal sources.
16459148|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
16459149|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
16459150|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
16459151|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
16459152|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
16459153|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
16459258|NCT03571464|Experimental|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
16459154|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
16459155|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
16459156|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
16459157|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
16459158|NCT03572088|Active Comparator|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
16459159|NCT03572088|Placebo Comparator|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
16459160|NCT03572075|Experimental|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
16459161|NCT03572075|Experimental|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
16459162|NCT03572062|Experimental|Arm 1|Low dose formulation A and SIIV
16459163|NCT03572062|Experimental|Arm 2|Low dose formulation B and SIIV
16459164|NCT03572062|Experimental|Arm 3|Mid dose formulation A and SIIV
16459165|NCT03572062|Experimental|Arm 4|Mid dose formulation B and SIIV
16459166|NCT03572062|Experimental|Arm 5|High dose formulation A and SIIV
16459167|NCT03572062|Experimental|Arm 6|High dose formulation B and SIIV
16459168|NCT03572062|Experimental|Arm 7|High dose formulation C and SIIV
16459169|NCT03572062|Placebo Comparator|Arm 8|Placebo and SIIV
16459170|NCT03572062|Experimental|M0M2 Arm 1|High dose formulation B
16459171|NCT03572062|Placebo Comparator|M0M2 Arm 2|Placebo
16459172|NCT03572049|Experimental|SUBA itraconazole|"Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.
~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food"
16459173|NCT03572049|Active Comparator|Conventional itraconazole|"Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.
~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food"
16459174|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
16459175|NCT03572023|Active Comparator|MINOCA|"This group will include patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).
~Integrative characterization of MINOCA patients:
~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
16459176|NCT03572023|Active Comparator|MI with coronary obstruction|"This group will include patients with myocardial infarction and obstructive coronary arteries.
~Characterization of MI patients with coronary obstruction:
~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
16459177|NCT03572010|Placebo Comparator|FeFum fortified maize test meal|
16459178|NCT03572010|Placebo Comparator|FeSO4 fortified LNS|
16459179|NCT03572010|Placebo Comparator|FeSO4 supplement|
16459180|NCT03572010|Placebo Comparator|FeSO4 fortified fruit juice|
16459181|NCT03571984|Experimental|Moving on ABC Plus|Moving on ABC Plus is combination of two interventions. The culturally adapted CBT and Moving on ABC. CBT will be integrated with The Moving on After Breast Cancer (ABC), which has been developed by Dr Anneela Saleem who suffered from breast cancer. The integrated intervention will consist of 12 sessions (60-90 minutes). The first 8 sessions will be delivered weekly and the last four sessions will be delivered fortnightly
16459182|NCT03571984|No Intervention|Routine Care|This will consist of routine assessment and management as usually conducted by oncology clinics and general practice. GP's will be informed about the psychiatric diagnosis.
16459183|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
16459184|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
16459185|NCT03571958|No Intervention|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
16459186|NCT03571958|Experimental|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
16459187|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
16459188|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
16459189|NCT03571932||Intervention Facilities|Includes 18 health facilities
16459190|NCT03571932||Comparison facilities|Infludes 18 health facilities
16459191|NCT03571919|Placebo Comparator|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
16459192|NCT03571919|Active Comparator|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
16459259|NCT03571464|Active Comparator|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
16459193|NCT03571906|Experimental|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.
~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
16459194|NCT03571906|No Intervention|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up
~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
16459195|NCT03571893|Experimental|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
16459196|NCT03571893|Active Comparator|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
16459197|NCT03571880|Experimental|CNSLBP group|
16459198|NCT03571880|Active Comparator|Healthy control group|
16459199|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
16459200|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
16459201|NCT03571854|Experimental|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
16459202|NCT03571854|Active Comparator|Group VCV|Volume controlled ventilation
16459203|NCT03571841|Experimental|Educational Intervention|"For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.
~Group Session
~Telephone Booster Session"
16459204|NCT03571828|Experimental|Part 1: Dose Exploration|Dose exploration cohorts to estimate the MTD, safety, tolerability, and PK of different doses of AMG 562 in subjects with relapsed/refractory DLBCL, MCL or FL using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
16459205|NCT03571828|Experimental|Part 2: Dose Expansion|dose expansion part to gain further clinical experience, safety and efficacy data for AMG 562 in subjects with relapsed / refractory DLBCL. The dose to be evaluated will be at or below the MTD estimated in the dose exploration cohorts.
16459206|NCT03571815|Experimental|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
16459207|NCT03571815|Placebo Comparator|control group|application of water on teeth in the control group
16459208|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
16459209|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
16459210|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
16459211|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
16459212|NCT03571763||acute ischemic stroke patient|acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months
16459213|NCT03571750|Experimental|Building Stronger Allies Condition|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
16459214|NCT03571750|Placebo Comparator|Health Education Training Condition|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
16459215|NCT03571737|Active Comparator|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
16459216|NCT03571737|Experimental|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
16459217|NCT03571724|Experimental|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
16459218|NCT03571724|Experimental|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
16459219|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
16459220|NCT03571698|No Intervention|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
16459221|NCT03571698|Active Comparator|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
16459222|NCT03571698|Active Comparator|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
16459223|NCT03571685|Experimental|Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting.
16459224|NCT03571672|Experimental|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
16459225|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
16459226|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
16459227|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
16459228|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
16459229|NCT03571633|Experimental|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).
~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
16459230|NCT03571633|Active Comparator|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).
~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
16459231|NCT03571620|Placebo Comparator|Vehicle|
16459232|NCT03571620|Experimental|1.0% Q301 Cream|
16459233|NCT03571620|Experimental|1.4% Q301 Cream|
16459234|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
16459235|NCT03571594|Experimental|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
16459236|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
16459237|NCT03571594|Experimental|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
16459238|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
16459239|NCT03571594|Experimental|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
16459240|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
16459241|NCT03571594|Experimental|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
16459242|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
16459243|NCT03571594|Experimental|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
16459244|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
16459245|NCT03571594|Active Comparator|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
16459246|NCT03571581|Experimental|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
16459247|NCT03571568|Experimental|BI-1206|BI-1206 IV Standard 3+3 Dose-Escalation Design
16459248|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
16459249|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
16459250|NCT03571529|Active Comparator|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation
~Protocol with EMG-driven hand exoskeleton (Hand of Hope):
~Warm-up: 10 min passive mode 2 min resting
~Training: According to residual muscle power:
~10 min active-assistive, 2 min resting, 10 min Active-assistive or
~5 min active, 2 min resting, 15 min active assistive or
~10 min active, 2 min resting, 10 min active and
~10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
16459251|NCT03571529|Active Comparator|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).
~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
16459252|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
16459253|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
16459254|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
16459255|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
16459256|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
16459260|NCT03571438|Experimental|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
16459261|NCT03571438|Active Comparator|Sunitinib|Treatment of cell culture with Sunitinib
16459262|NCT03571438|Active Comparator|Pazopanib|Treatment of cell culture with Pazopanib
16459263|NCT03571438|Active Comparator|Temsirolimus|Treatment of cell culture with Temsirolimus
16459264|NCT03571425|Placebo Comparator|Oral Placebo|Placebo drink
16459265|NCT03571425|Active Comparator|Oral Protein|Protein drink, ingested orally
16459266|NCT03571425|Active Comparator|Enteral Protein|Protein drink, administered via enteral tube
16459267|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
16459268|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
16459269|NCT03571386||Mild to Moderate Depression|Patients who currently have mild to moderate severity of depression symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
16459270|NCT03571386||Mild to Moderate Anxiety|Patients who currently have mild to moderate severity of anxiety symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
16459271|NCT03571386||High Stress|Patients with a history of reported stress who are receiving Mindfulness-Based Stress Reduction (MBSR) in a group setting as standard of care will be recruited for this study. All patients are eligible.
16459272|NCT03571360|Other|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
16459273|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
16459274|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
16459275|NCT03571334|Experimental|IncobotulinumtoxinA|"IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.
~Study participants in this arm will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)
~Hands: INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).
~Feet: INA will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
16459276|NCT03571334|Placebo Comparator|saline control|"Study participants in this arm will 2.5mL normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)
~Hands: saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).
~Feet: Saline will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
16459277|NCT03571321|Experimental|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.
~Standard Chemotherapy Consists of:
~Remission consolidation therapy (lasting 8 weeks)
~Interim Maintenance (lasting 8 weeks)
~Delayed Intensification (lasting 8 weeks
~Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)
~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
16459278|NCT03571308|Experimental|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.
~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
16459279|NCT03571295|Experimental|videolaryngoscopy|
16459280|NCT03571295|Experimental|direct laryngoscopy|
16459281|NCT03571282|Experimental|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
16459282|NCT03571269|Experimental|OCT-guided group|Detailed methods of OCT examination are the same as above. Whether stenting or not will be decided by the operators according to the underlying mechanisms of culprit lesions. If stenting, OCT will be used to guide and optimize the whole process of PCI. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
16459283|NCT03571269|No Intervention|Angiography-guided group|Detailed methods of angiography examination are the same as above. Whether stenting or not and the whole process of PCI will be decided by the operators according to the current treatment standard of angiography. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
16459284|NCT03571256|Experimental|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
16459285|NCT03571256|Experimental|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
16459286|NCT03571256|Placebo Comparator|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
16459287|NCT03571243||smokers|no intervention
16459288|NCT03571243||never-smokers|no intervention
16459319|NCT03571061|Experimental|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
16459289|NCT03571230|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
16459290|NCT03571230|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
16459291|NCT03571230|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
16459292|NCT03571230|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
16459293|NCT03571217||Diabetic retinopathy cohort|
16459294|NCT03571217||Mild visual impairment cohort|
16459295|NCT03571204|Active Comparator|Group-1 active treatment|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with 3BNC117 plus 10-1074. Study staff and participants will be blinded to Group 1 treatment assignments.
16459296|NCT03571204|Placebo Comparator|Group-1 placebo|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with normal saline placebo. Study staff and participants willbe blinded to Group 1 treatment assignments.
16459297|NCT03571204|Experimental|Group-2 active treatment|Group 2, up to 15 viremic individuals not taking ARTwill receive 3BNC117 combined with 10-1074.
16459298|NCT03571191|Experimental|1|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
16459299|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
16459300|NCT03571165|Experimental|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
16459301|NCT03571152|Experimental|Educational videos|Subjects allocated in this arms will receive the educational videos.
16459302|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
16459303|NCT03571126|Placebo Comparator|Placebos group|"Patients will be administered with dexamethasone plus tropisetron from D1 to D3.
~Patients will also be administrated with placebos from D1-D4"
16459304|NCT03571126|Experimental|Experimental group|Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
16459305|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
16459306|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
16459307|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
16459308|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
16459309|NCT03571087|Experimental|HL140 5/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
16459310|NCT03571087|Experimental|HL140 10/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
16459311|NCT03571087|Experimental|HL140 20/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
16459312|NCT03571087|Experimental|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg
~Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
16459313|NCT03571087|Experimental|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg
~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
16459314|NCT03571087|Experimental|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg
~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
16459315|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen.
~If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen."
16459316|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen.
~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen."
16459317|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen.
~If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen."
16459318|NCT03571061|Active Comparator|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
16459320|NCT03571061|Placebo Comparator|carbon dioxide (CO2) insufflation|carbon dioxide (CO2) insufflation group: carbon dioxide (CO2) was insufflated through out the whole procedure for advancement and inspection when needed.
16459321|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
16459322|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
16459323|NCT03571035|Experimental|Example|Mandibular movements recordings by a mono vision system.
16459324|NCT03571022|Experimental|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
16459325|NCT03571009|Experimental|utilization of PAAS|conventional treatment utilization of PAAS
16459326|NCT03571009|No Intervention|Conventional care|conventional treatment only
16459327|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
16459328|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
16459329|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
16459330|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
16459331|NCT03570970|Experimental|Banapenem C1 group|250mg Once daily for 7
16459332|NCT03570970|Experimental|Banapenem C2group|500mg Once daily for 7
16459333|NCT03570970|Experimental|Banapenem C3group|1000mg Once daily for 7
16459334|NCT03570957|Experimental|MT-2990, Low dose|Single intravenous dose
16459335|NCT03570957|Experimental|MT-2990, Low-middle dose|Single intravenous dose
16459336|NCT03570957|Experimental|MT-2990, High-middle dose|Single intravenous dose
16459337|NCT03570957|Experimental|MT-2990, High dose|Single intravenous dose
16459338|NCT03570957|Placebo Comparator|Placebo|Single intravenous dose
16459339|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
16459340|NCT03570931|Experimental|RT001|RT001, oral, 3.84 g/day
16459342|NCT03570905|Experimental|Sugartong Splint|
16459343|NCT03570905|Experimental|Clam Shell Splint|
16459346|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
16459347|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
16459348|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
16459349|NCT03570853|Experimental|Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
16459350|NCT03570853|No Intervention|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
16459351|NCT03570840||obese children and adolescents|
16459352|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
16459353|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
16459354|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
16459355|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
16459356|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
16459387|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures
~o Spinal cage filling"
16459388|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:
~Filling bone defects after cyst removal
~Filling distal radius fractures
~Filling defects such as tibial plateau fractures
~Filling defects created by osteotomy procedures"
16459357|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.
~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
16459358|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
16459359|NCT03570775|Experimental|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
16459360|NCT03570775|Active Comparator|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
16459361|NCT03570749|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16459362|NCT03570749|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16459363|NCT03570749|Placebo Comparator|Placebo|Placebo administered orally.
16459364|NCT03570736|Experimental|Minimal Invasive Surgical Technique|
16459365|NCT03570736|Active Comparator|Open Flap Debridement|
16459366|NCT03570723|Active Comparator|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
16459367|NCT03570723|Experimental|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
16459368|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
16459369|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
16459370|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
16459371|NCT03570697|Experimental|Evolucumab|Participants receive Evolocumab subcutaneous injection once every month (QM=every 4 weeks + 3 days) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy and not expected to change for the duration of the study participation.
16459372|NCT03570697|Placebo Comparator|Placebo|Participants receive placebo subcutaneous injection once every month (QM=every 4 weeks + 3 days) for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy and not expected to change for the duration of the study participation.
16459373|NCT03570684|Experimental|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
16459374|NCT03570684|No Intervention|non-tie group|
16459375|NCT03570671|Experimental|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
16459376|NCT03570671|Placebo Comparator|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
16459377|NCT03570658|Experimental|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
16459378|NCT03570658|Experimental|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
16459379|NCT03570658|Placebo Comparator|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
16459380|NCT03570645|Experimental|dexmedetomidine group|thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time
16459381|NCT03570645|Experimental|dexamethasone Group|thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time
16459382|NCT03570645|Sham Comparator|control group|thoracic paravertebral blocks using only ropivacaine
16459383|NCT03570632|No Intervention|Usual care|
16459384|NCT03570632|Experimental|Metformin|
16459385|NCT03570619|Experimental|Metastatic CRPC|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
16459386|NCT03570619|Experimental|Solid Tumors (non-prostate)|Patients with all other metastatic subtypes will be enrolled in cohort B
16459389|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures
~o Spinal cage filling"
16459390|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:
~Filling bone defects after cyst removal
~Filling distal radius fractures
~Filling defects such as tibial plateau fractures
~Filling defects created by osteotomy procedures"
16459391|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures
~o Spinal cage filling"
16459392|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:
~Filling bone defects after cyst removal
~Filling distal radius fractures
~Filling defects such as tibial plateau fractures
~Filling defects created by osteotomy procedures"
16459393|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:
~o High tibial osteotomies with fixation"
16459394|NCT03570593|No Intervention|Retrospective Group|
16459395|NCT03570593|Experimental|Prospective Group|
16459396|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
16459397|NCT03570567|Other|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
16459398|NCT03570554|Experimental|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
16459399|NCT03570554|Experimental|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
16459400|NCT03570554|Experimental|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
16459401|NCT03570554|Experimental|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
16459402|NCT03570541|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.
~Every six hours postoperative, all patients are administered 1 g of acetaminophen.
~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.
~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.
~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.
~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
16459403|NCT03570541|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.
~Every six hours postoperative, all patients are administered 1 g of acetaminophen.
~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.
~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.
~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.
~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
16459404|NCT03570528||Maxillary Retrusion|CT
16459405|NCT03570528||Healthy Patients|
16459406|NCT03570515|Experimental|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
16459407|NCT03570515|Active Comparator|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
16459408|NCT03570489|Active Comparator|Exercise|Use of an ergometric bicycle where patients will bicycle 5 Days a week for 20 minutes at a predetermine level
16459409|NCT03570489|Sham Comparator|Relaxation|Patients will listen to a relaxation exercise involving muscle relaxation. This takes about 20 minutes and will be performed 5 Days/week
16459410|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
16459411|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
16459412|NCT03570450|Experimental|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10^6cells/kg
16459413|NCT03570450|Experimental|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10^6cells/kg
16459414|NCT03570450|Experimental|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10^6cells/kg
16459415|NCT03570450|Experimental|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10^6cells/kg
16459416|NCT03570450|Placebo Comparator|placebo|Placebo
16459417|NCT03570437|Active Comparator|Arm 1: Paclitaxel|Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.
16459418|NCT03570437|Experimental|Arm 2: Cediranib and paclitaxel|Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue cediranib once daily until disease progression.
16459419|NCT03570437|Experimental|Arm 3: Cediranib and olaparib|Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue with olaparib and cediranib until disease progression.
16459420|NCT03570424|Placebo Comparator|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
16459421|NCT03570424|Experimental|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
16459422|NCT03570424|Experimental|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
16459423|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.
~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.
~The amount of blood collected at each visit will be based on age."
16459424|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol
~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
16459425|NCT03570398|Other|Abdominal CT|
16459426|NCT03570398|Other|Abdominal Ultrasound|
16459427|NCT03570385|Experimental|Patient with Optic Neuritis|
16459428|NCT03570372|Experimental|Intervention group|36 week internet-based CBT with therapist support. Regular online group discussions.
16459429|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
16459430|NCT03570359|Active Comparator|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation
~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
16459431|NCT03570359|Placebo Comparator|Placebo|"Part 1- placebo once a day for 3 days via inhalation
~Part 2 - placebo once a day for 14 days via inhalation"
16459432|NCT03570346|Experimental|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
16459433|NCT03570346|Placebo Comparator|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
16459434|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
16459435|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
16459436|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
16459437|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
16459438|NCT03570307|Other|drug treatment|Misoprostol for uterine evacuation
16459439|NCT03570307|Other|surgical treatment|dilatation and curettage for uterine evacuation
16459440|NCT03570294|Other|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
16459441|NCT03570281|Experimental|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
16459442|NCT03570281|Active Comparator|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
16459443|NCT03570268|Experimental|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
16459444|NCT03570268|Active Comparator|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
16459445|NCT03570255|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
16459446|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
16459447|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
16459448|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
16459449|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
16459450|NCT03570216|Experimental|Exercise|All participants will perform 3 exercise sessions: one session to assess their cardiorespiratory fitness, one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
16459451|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of admission.
16459452|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of recruitment.
16459453|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
16459454|NCT03570177||all subject|the all population (described in eligibility criteria)
16459455|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
16459456|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
16459457|NCT03570138|Experimental|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
16459458|NCT03570138|Active Comparator|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
16459459|NCT03570125|Experimental|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).
~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
16459460|NCT03570125|No Intervention|no intervention|Control/Placebo with multivitamin supplementation
16459461|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
16459462|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
16459463|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
16459464|NCT03570086||migraineurs without aura|
16459465|NCT03570086||health controls|
16459466|NCT03570073|Active Comparator|Manual vitrification|
16459467|NCT03570073|Experimental|Automatic vitrification|
16459468|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
16459469|NCT03570021|Active Comparator|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].
16459470|NCT03570021|Experimental|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
16459471|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
16459472|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
16459473|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
16459474|NCT03569995|Experimental|Induction+Consolidation chemotherapy|"[Induction phase]
~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation
~Complete, partial response or stable disease-> next step
~Progressive disease-> eliminated
~② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation
~Complete response -> consolidation therapy(Rituximab-Cytarabine) progress
~Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations
~Progressive disease-> eliminated
~③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation
~Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)
~Progressive disease-> eliminated"
16459475|NCT03569982|No Intervention|Control|Patients receiving best supportive care
16459476|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
16459477|NCT03569969|Experimental|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
16459478|NCT03569969|Experimental|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
16459479|NCT03569956|Active Comparator|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
16459480|NCT03569956|Experimental|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
16459481|NCT03569943|Experimental|Robotol|
16459482|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
16459483|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
16459484|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
16459485|NCT03569917|Experimental|patient under Ceftriaxone treatment|
16459486|NCT03569891|Experimental|AMT-061|"Single infusion of AMT-061
~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
16459487|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
16459488|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
16459489|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
16459490|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
16459491|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
16459492|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
16459493|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
16459494|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
16459495|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
16459496|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
16459497|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
16459498|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (>500mU/L).
16459499|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
16459500|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
16459501|NCT03569761|Experimental|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
16459502|NCT03569761|Active Comparator|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
16459503|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
16459504|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
16459505|NCT03569722||Older adults|Older adults, ages 65+
16459506|NCT03569709|Active Comparator|Aerobic Exercise|Sub-threshold aerobic exercise.
16459507|NCT03569709|Placebo Comparator|Stretching|Stretching program that will not raise heart rate.
16459508|NCT03569709|Placebo Comparator|Rest|Relative rest. Avoid all structured exercise.
16459509|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
16459510|NCT03569683|Experimental|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.
~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.
~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
16459511|NCT03569670|Experimental|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
16459512|NCT03569670|Active Comparator|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
16459513|NCT03569657|Other|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
16459514|NCT03569644|Other|qualitative study|heterogeneous group of patients
16459515|NCT03569631|Experimental|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
16459516|NCT03569631|Placebo Comparator|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
16459517|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
16459518|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
16459519|NCT03569605|Active Comparator|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
16459520|NCT03569605|Experimental|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
16459521|NCT03569592|Experimental|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
16459522|NCT03569579|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.
~Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.
~Each treatment period was separated by a washout period of at least 21 dyas."
16459523|NCT03569579|Experimental|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.
~Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.
~Each treatment period was separated by a washout period of at least 21 dyas."
16459524|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
16459525|NCT03569553||AIGIV|Inhalational anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
16459526|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
16459527|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
16459528|NCT03569527|Active Comparator|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
16459529|NCT03569527|Active Comparator|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
16459530|NCT03569527|Active Comparator|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
16459531|NCT03569514||AIGIV|Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
16459532|NCT03569501|No Intervention|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
16459533|NCT03569501|Active Comparator|oat grains|90 mg oat, per day.
16459534|NCT03569501|Experimental|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
16459535|NCT03569501|Active Comparator|DHA tablets|500 mg DHA oral tablets, per day.
16459536|NCT03569475|Experimental|Levomilnacipran ER|patients will take levomilnacipran 10 mg/day on Days 1-3, 20 mg/day on Days 4-7, and 40 mg/day during weeks 2 through 8 of the double blinded treatment and 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days in the down-taper period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day is permitted at Week 3 through 8 of the double blinded treatment. in the down-taper period. the patient will take levomilnacipran 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days
16459537|NCT03569475|Active Comparator|Fluoxetine 20 mg|Patients randomized to the Fluoxetine 20 mg arm will take Week 1, 10mg/day; week 2 through week 8, 20 mg/day
16459538|NCT03569475|Placebo Comparator|Placebo|Patients randomized to the placebo arm will take placebo capsules once daily through week 8
16459539|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
16459540|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
16459541|NCT03569449|Experimental|Group 1- Goat|Clinic-based visit, usual care, standard pediatric surveillance, and structured visits
16459542|NCT03569449|Experimental|Group 2- Cow|Clinic-based visit, usual care, enhanced pediatric surveillance, and structured visits
16459543|NCT03569449|Experimental|Group 3- Horse|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and structured visits
16459544|NCT03569449|Experimental|Group 4- Pig|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and structured visits
16459545|NCT03569449|Experimental|Group 5- Sheep|Clinic-based visit, usual care, standard pediatric surveillance, and individually-tailored visits
16459546|NCT03569449|Experimental|Group 6- Llama|Clinic-based visit, usual care, enhanced pediatric surveillance, and individually-tailored visits
16459547|NCT03569449|Experimental|Group 7- Cat|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and individually-tailored visits
16459548|NCT03569449|Experimental|Group 8- Dog|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and individually-tailored visits
16459549|NCT03569449|Experimental|Group 9- Donkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and structured visits
16459550|NCT03569449|Experimental|Group 10- Bear|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and structured visits
16459551|NCT03569449|Experimental|Group 11- Tiger|Clinic and community visits, technology enhanced care coordination, standard pediatric surveillance, and structured visits
16459552|NCT03569449|Experimental|Group 12- Lion|Clinic and community visits, technology enhanced care coordination, enhanced pediatric surveillance, and structured visits
16459553|NCT03569449|Experimental|Group 13- Monkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and individually-tailored visits
16459554|NCT03569449|Experimental|Group 14- Zebra|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and individually-tailored visits
16459555|NCT03569449|Experimental|Group 15- Elephant|Clinic and community visits, technology-enhanced care, standard pediatric surveillance, and individually-tailored visits
16459556|NCT03569449|Experimental|Group 16- Giraffe|Clinic and community visits, technology-enhanced care, enhanced pediatric surveillance, and individually-tailored visits
16459557|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
16459558|NCT03569423|Experimental|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
16459559|NCT03569423|Active Comparator|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
16459560|NCT03569410|Active Comparator|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
16459561|NCT03569410|Experimental|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
16459564|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):
~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
16459565|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
16459566|NCT03569371|Experimental|INCB054707|
16459567|NCT03569358|Experimental|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
16459568|NCT03569358|Active Comparator|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
16459569|NCT03569358|Active Comparator|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
16459570|NCT03569345|Experimental|Arm|Basal cell carcinoma (BCC) patients Patients (>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on face/scalp, <50 mm on trunk/extremities)
16459571|NCT03569332|Experimental|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
16459572|NCT03569332|No Intervention|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
16459573|NCT03569319|Experimental|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
16459574|NCT03569319|Experimental|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
16459575|NCT03569319|Placebo Comparator|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
16459576|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
16459577|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
16459578|NCT03569293|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
16459579|NCT03569293|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
16459580|NCT03569293|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
16459581|NCT03569293|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
16459582|NCT03569280|Experimental|KPG-121|Safety and Antitumor Activity of KPG-121 capsules 1.5, 2.5, 5.0, 10, 20, and 30 mg/day daily for 21 days
16459583|NCT03569267|Experimental|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
16459584|NCT03569267|Placebo Comparator|Placebo|placebo
16459585|NCT03569254|Experimental|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
16459586|NCT03569254|Active Comparator|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
16459587|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
16459588|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
16459589|NCT03569228|Experimental|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
16459590|NCT03569228|Experimental|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
16459591|NCT03569228|No Intervention|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
16459624|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID
16459592|NCT03569228|Active Comparator|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
16459593|NCT03569228|Active Comparator|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
16459594|NCT03569228|Experimental|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
16459595|NCT03569228|Experimental|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
16459596|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
16459597|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
16459598|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
16459599|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
16459600|NCT03569189|Experimental|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
16459601|NCT03569176|Experimental|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
16459602|NCT03569176|Other|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
16459603|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
16459604|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
16459605|NCT03569124||Training group|
16459606|NCT03569124||Non-Training group|
16459607|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
16459608|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
16459609|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
16459610|NCT03569085|Experimental|Sevoflurane then isoflurane|
16459611|NCT03569072|Experimental|Dose escalated functionally adapted radiation therapy|This is a single arm study
16459612|NCT03569059|Experimental|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
16459613|NCT03569059|Experimental|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
16459614|NCT03569059|No Intervention|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
16459615|NCT03569059|Experimental|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
16459616|NCT03569046|Active Comparator|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
16459617|NCT03569046|Placebo Comparator|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
16459618|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
16459619|NCT03569033|Placebo Comparator|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
16459620|NCT03569020|Experimental|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
16459621|NCT03569020|No Intervention|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
16459622|NCT03569007|Active Comparator|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
16459627|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
16459628|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
16459629|NCT03568968|Experimental|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is tablets.
16459630|NCT03568968|Placebo Comparator|Placebo Comparator|Placebo tablets, no active ingredients.
16459631|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
16459632|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
16459633|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
16459634|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
16459636|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
16459637|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
16459638|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
16459639|NCT03568903|Experimental|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
16459640|NCT03568903|No Intervention|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it's dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
16459641|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.
16459642|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.
16459643|NCT03568877|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
16459644|NCT03568877|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
16459645|NCT03568864|Placebo Comparator|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (~ 2% nucleotides)
16459646|NCT03568864|Experimental|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (~ 10% nucleotides)
16459647|NCT03568838|Experimental|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
16459648|NCT03568838|No Intervention|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
16459649|NCT03568825|Experimental|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
16459650|NCT03568825|Experimental|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
16459651|NCT03568812|Experimental|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
16459652|NCT03568812|Placebo Comparator|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
16459653|NCT03568799|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
16459654|NCT03568786|Experimental|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
16459681|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:
~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended
~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
16459706|NCT03568474|Experimental|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
16459655|NCT03568786|Experimental|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
16459656|NCT03568773|Experimental|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.
~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
16459657|NCT03568773|Experimental|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
16459658|NCT03568773|Experimental|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
16459659|NCT03568760|Experimental|SFA treatment|Semantic feature analysis
16459660|NCT03568760|Placebo Comparator|Comprehension training|Comprehension training
16459661|NCT03568747|Experimental|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
16459662|NCT03568747|Experimental|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
16459663|NCT03568734|Experimental|Transplant arm|Fecal transplant sample given to child at delivery
16459664|NCT03568721|Experimental|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
16459665|NCT03568721|Experimental|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
16459666|NCT03568721|Experimental|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
16459667|NCT03568721|No Intervention|control|control (no reliever for orthodontic pain)
16459668|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
16459669|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
16459670|NCT03568695|Other|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
16459671|NCT03568682|Experimental|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
16459672|NCT03568682|No Intervention|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
16459678|NCT03568643|Experimental|Azithromycin|children in this arm will receive one dose of azithromycin
16459679|NCT03568643|Active Comparator|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
16459680|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:
~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician
~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
16459682|NCT03568630||Inherited Risk|"Must meet one of the following criteria:
~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)
~One 1st degree relative with PDAC diagnosed before age 60
~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR
~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
16459683|NCT03568617|Experimental|rTMS group|
16459684|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
16459685|NCT03568591|Experimental|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
16459686|NCT03568591|No Intervention|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
16459687|NCT03568578|Active Comparator|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
16459688|NCT03568578|Experimental|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
16459689|NCT03568565|Experimental|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
16459690|NCT03568565|Experimental|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
16459691|NCT03568565|Experimental|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
16459692|NCT03568565|Experimental|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
16459693|NCT03568565|No Intervention|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
16459694|NCT03568552|Experimental|Patient Decision Aid|Participating clinics (and their patients) will be randomly selected to implement the intervention, at which time their patients will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
16459695|NCT03568552|No Intervention|Prior to intervention|All participating clinics will start with a baseline period without the intervention. The clinics and their patients will remain in the no intervention condition until randomly selected to crossover to receive the intervention.
16459696|NCT03568539|Experimental|IBI308|
16459697|NCT03568526|Experimental|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
16459698|NCT03568513|Experimental|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
16459699|NCT03568513|Placebo Comparator|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
16459700|NCT03568500|Experimental|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
16459701|NCT03568500|Experimental|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
16459702|NCT03568500|Experimental|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
16459703|NCT03568500|Experimental|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
16459704|NCT03568487|Experimental|Intensive scapula-focused approach|
16459705|NCT03568487|Active Comparator|Control therapy|
16459834|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
16459707|NCT03568474|Active Comparator|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
16459708|NCT03568461|Experimental|CTL019|tisagenlecleucel infusion
16459709|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
16459710|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
16459711|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
16459712|NCT03568409|Placebo Comparator|Group B: Placebo|
16459713|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
16459714|NCT03568383|Experimental|Arm A: Delamanid (DLM)|HHCs will receive delamanid (DLM) for 26 weeks.
16459715|NCT03568383|Experimental|Arm B: Isoniazid (INH)|HHCs will receive isoniazid (INH) and pyridoxine (vitamin B6) for 26 weeks.
16459716|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
16459717|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
16459718|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
16459719|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
16459720|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
16459721|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
16459722|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
16459723|NCT03568331|Experimental|Tradipitant|
16459724|NCT03568331|Placebo Comparator|Placebo|
16459725|NCT03568318|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical corticosteroids (TCS).
16459726|NCT03568318|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical corticosteroids (TCS).
16459727|NCT03568318|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
16459728|NCT03568318|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
16459731|NCT03568279|Active Comparator|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
16459732|NCT03568279|Experimental|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
16459733|NCT03568266||Biospecimen Collection|Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
16459734|NCT03568253|Active Comparator|Bulk fil composite|
16459735|NCT03568253|Active Comparator|High viscosity glass ionomer|
16459736|NCT03568240||30 men suffering from apnea|
16459737|NCT03568240||15 men defined as snorers|
16459738|NCT03568240||15 men without complaints|
16459739|NCT03568227|Experimental|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 & 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:
~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2
~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2
~Volunteers will be randomly allocated to the two sequence types."
16459740|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)
~4 days per week of MICT for 50 minutes per session
~1 day per week of HIIT for 35 minutes per session
~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)
~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
16459741|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT
~5 days per week of MICT for 50 minutes per session
~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
16459742|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
16459743|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
16459744|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
16459835|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
16459836|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
16459745|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
16459746|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
16459747|NCT03568162|Experimental|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
16459748|NCT03568162|Experimental|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
16459749|NCT03568162|Experimental|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
16459750|NCT03568162|Placebo Comparator|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
16459751|NCT03568162|Experimental|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
16459752|NCT03568162|Placebo Comparator|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
16459753|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
16459754|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
16459755|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
16459756|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
16459757|NCT03568123|Experimental|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
16459758|NCT03568123|Active Comparator|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
16459759|NCT03568097|Experimental|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
16459762|NCT03568071|Experimental|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
16459763|NCT03568071|Experimental|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
16459764|NCT03568071|Experimental|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
16459765|NCT03568071|Experimental|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
16459766|NCT03568071|Experimental|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen E) will be administered on Day 1.
16459767|NCT03568071|Placebo Comparator|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
16459768|NCT03568058|Experimental|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
16459769|NCT03568058|Experimental|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
16459770|NCT03568058|Experimental|anti-PD1 and vaccine|anti-PD-1 antibody followed by personalized vaccine therapy
16459771|NCT03568058|Experimental|vaccine|personalized vaccine therapy
16459772|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
16459773|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.
~Feasibility metrics will be collected."
16459837|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
16459838|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
16460412|NCT03563755|No Intervention|Treatment as usual|Participants will continue to receive their usual treatment.
16459774|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.
~Feasibility metrics will be collected."
16459775|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
16459776|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
16459777|NCT03568006|Experimental|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.
~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
16459778|NCT03568006|Active Comparator|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
16459779|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
16459780|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
16459782|NCT03567967|Experimental|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
16459783|NCT03567967|Active Comparator|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
16459784|NCT03567941|Placebo Comparator|Placebo|Single dose
16459785|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
16459786|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
16459787|NCT03567941|Active Comparator|Reference|Single dose
16459788|NCT03567928|Active Comparator|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
16459789|NCT03567928|Experimental|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
16459790|NCT03567915||Rice|Group that healthy volunteers eat rice.
16459791|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
16459792|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
16459793|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
16459794|NCT03567889|Experimental|Daromun plus Surgery and Adjuvant therapy (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
16459795|NCT03567889|Active Comparator|Surgery and adjuvant therapy (Arm 2)|Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
16459796|NCT03567876|Experimental|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.
~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
16459797|NCT03567863|Active Comparator|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
16459798|NCT03567863|Active Comparator|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
16459799|NCT03567850|Experimental|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
16459800|NCT03567850|Active Comparator|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
16459801|NCT03567837|Active Comparator|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
16459802|NCT03567837|Experimental|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
16459803|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
16459804|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
16459866|NCT03567369|Experimental|Dexamethasone|Dexamethasone 4,0 mg / mL
16459805|NCT03567811|Other|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
16459806|NCT03567811|Other|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
16459807|NCT03567798|Experimental|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract
~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
16459808|NCT03567798|Placebo Comparator|B|"Placebo
~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
16459809|NCT03567772|Experimental|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
16459810|NCT03567772|Active Comparator|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
16459811|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
16459812|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
16459813|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
16459814|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)
16459815|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab with chemotherapy|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab and nab-paclitaxel chemotherapy
16459816|NCT03567707|Experimental|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.
~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
16459817|NCT03567707|Experimental|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.
~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
16459818|NCT03567707|Active Comparator|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .
~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
16459819|NCT03567694|Experimental|Single Ascending Dose and Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
16459820|NCT03567694|Experimental|Multiple Ascending Dose|For the MAD portion, 3 dose levels will be selected based on SAD results.
16459821|NCT03567681|Experimental|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
16459822|NCT03567681|Experimental|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
16459823|NCT03567655|Experimental|Single group|Farlutal tab. 500mg/ Pfizer to be administered
16459824|NCT03567642|Experimental|Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide|Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)
16459825|NCT03567629|Experimental|Irinotecan-based chemotherapy|
16459826|NCT03567629|Active Comparator|Oxaliplatin-based chemotherapy|
16459827|NCT03567616|Experimental|Part 1: Dose Escalation|Venetoclax (400 mg oral [PO], once daily [QD]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly [qw]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
16459828|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) positive|Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
16459829|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) negative|Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
16459830|NCT03567603||opioid exposed neonates|prenatal opioid exposure
16459831|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
16459867|NCT03567369|Experimental|Traumeel S|Traumeel 2,2 mg / mL
16459839|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
16459840|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
16459841|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: <140/90
16459842|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
16459843|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
16459844|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
16459845|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
16459846|NCT03567499|Experimental|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
16459847|NCT03567499|Experimental|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
16459848|NCT03567499|Experimental|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
16459849|NCT03567499|Experimental|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
16459850|NCT03567499|Experimental|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
16459851|NCT03567499|Experimental|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
16459852|NCT03567499|Experimental|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
16459853|NCT03567499|Experimental|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
16459854|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
16459855|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI
16459856|NCT03567473|Placebo Comparator|Control Arm|"Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.
~OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI."
16459857|NCT03567460|Experimental|10,000 Steps/day for Pediatric Marfan Patients|Participants will be given a Garmin VivoFit and asked to take at least 10,000 steps per day. A study coordinator will reach out at least once per week to check in on progress made and help make weekly goals.
16459858|NCT03567447|Experimental|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
16459859|NCT03567447|Placebo Comparator|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
16459860|NCT03567408|Experimental|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
16459861|NCT03567408|Placebo Comparator|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
16459862|NCT03567395|Active Comparator|Melatonin|Melatonin (5 mg sublingual tablet)
16459863|NCT03567395|Experimental|Honey|raw honey (1.5 tablespoons)
16459864|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
16459865|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
16459868|NCT03567356|No Intervention|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
16459869|NCT03567356|Experimental|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
16459870|NCT03567343|Active Comparator|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
~A subset of this group will undergo 2 overnight polysomnography studies"
16459871|NCT03567343|Placebo Comparator|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
~A subset of this group will undergo 2 overnight polysomnography studies"
16459872|NCT03567343|Active Comparator|Proprietary Blend And Melatonin|Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the proprietary spearmint extract blend and 1 Mg of melatonin by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
16459873|NCT03567343|Active Comparator|Melatonin|Subjects randomized into the active treatment group will be asked to consume 1 Mg of melatonin by mouth every night 30 mins before bed and complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
16459874|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
16459875|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
16459876|NCT03567317|No Intervention|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
16459877|NCT03567317|Experimental|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
16459878|NCT03567304|No Intervention|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.
~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
16459879|NCT03567304|Experimental|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.
~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
16459880|NCT03567291|Experimental|TEV-50717- Part A|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
16459881|NCT03567291|Experimental|TEV-50717- Part B RW|TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
16459882|NCT03567291|Placebo Comparator|Placebo- Part B RW|Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.
16459883|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
16459884|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
16459885|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
16459886|NCT03567239|Experimental|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
16459887|NCT03567226|Experimental|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
16459888|NCT03567226|Active Comparator|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
16459890|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
16459891|NCT03567187|Experimental|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (cryoprobe) and disposable nitrous oxide (N2O) cartridges (cryogen). The smart tip is composed of closed-tip stainless steel needles, thereby fully enclosing the cryogen. There are 2 types of smart tips that will be utilized during this study, depending on the depth of the nerves being treated. The shorter smart tip comes in 2 variants - three X 6.9 mm or 8.9 mm, 27-gauge needles, with an attached skin warmer to prevent damage to the underlying skin. The longer smart tip also comes in 2 variants - 55 mm 22-gauge needle or a 90 mm 20G needle.
~The effect is by initiation of a cooling cycle, by fully inserting the smart tip into the procedure site and activating the cryogen flow. As the gas travels through the length of the needle, an ice ball develops around the needle freezing the surrounding tissue."
16459892|NCT03567174|Experimental|Integrated care van (ICV)|ICV visits neighborhoods served by the mobile syringe service program weekly. ICV provides a range of services targeted to people who inject drugs - HIV testing, HCV testing, PrEP, MAT, wound care, case work services, on-site medical management and linkage.
16459893|NCT03567174|No Intervention|Control|No additional services provided.
16459894|NCT03567161|Experimental|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.
~Inclusion criteria:
~Having received a diagnosis of chronic periodontitis (Armitage 1999)
~Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)
~Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm
~Exclusion criteria:
~Smoking more than ten cigarettes per day
~Pregnancy
~Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
16459895|NCT03567148|Active Comparator|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
16459896|NCT03567148|Active Comparator|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
16459897|NCT03567148|Active Comparator|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
16459898|NCT03567148|Active Comparator|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
16459899|NCT03567148|Active Comparator|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
16459900|NCT03567148|No Intervention|Control group|Palatal wounds were left for spontaneous healing
16459901|NCT03567135||Experimental 1|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
16459902|NCT03567135||control|concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
16459903|NCT03567135||Experimental 2|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
16459904|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
16459905|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
16459906|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
16459907|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
16459908|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
16459909|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
16459910|NCT03567109||control|healthy subjects
16459911|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
16459912|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
16459913|NCT03567083|Experimental|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
16459914|NCT03567083|No Intervention|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
16459915|NCT03567070|Other|qualitative study based on an individual clinical interview|
16459916|NCT03567057|Experimental|ADS-5102|
16459917|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
16459918|NCT03567031|Experimental|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
16459919|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
16459920|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
16459991|NCT03566550||Control|people without cystic fibrosis
16459921|NCT03567005|Other|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
16459922|NCT03567005|Other|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
16459923|NCT03566992|Active Comparator|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
16459924|NCT03566992|Experimental|Small bowel|Nasoenteric tube placed in the small bowel.
16459925|NCT03566979|Experimental|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
16459926|NCT03566979|Active Comparator|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
16459927|NCT03566979|Active Comparator|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
16459928|NCT03566979|Placebo Comparator|Placebo tablet|Single dose of two Placebo tablets
16459929|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
16459930|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
16459931|NCT03566940|Experimental|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
16459932|NCT03566940|Experimental|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
16459933|NCT03566940|Experimental|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
16459934|NCT03566940|Active Comparator|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
16459935|NCT03566927|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
16459936|NCT03566914|Experimental|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
16459937|NCT03566914|Placebo Comparator|Placebo|Tablet placebo once daily per oral for 3 months
16459938|NCT03566901|Experimental|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
16459939|NCT03566901|Active Comparator|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
16459940|NCT03566888||Single Group|85 eligible study participants
16459941|NCT03566875|Experimental|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
16459942|NCT03566875|Active Comparator|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
16459943|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
16459944|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
16459945|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
16459946|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
16459947|NCT03566849|Experimental|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
16459948|NCT03566849|Experimental|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
16459949|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
16459950|NCT03566823|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
16459951|NCT03566823|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
16459952|NCT03566823|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
16459953|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
16459992|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
16459993|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
16459954|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
16459955|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
16459956|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
16459957|NCT03566797||SC-CIP|Patients developing SC-CIP
16459958|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
16459959|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
16459960|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
16459961|NCT03566771|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 12 months
16459962|NCT03566771|Active Comparator|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 12 months
16459963|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
16459964|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
16459966|NCT03566719|Experimental|Intervention group|
16459967|NCT03566719|No Intervention|Control group|
16459968|NCT03566706|Experimental|Unhealthy Eating|
16459969|NCT03566706|Experimental|Marijuana Use|
16459970|NCT03566706|Experimental|Sedentary Behavior|
16459971|NCT03566693|Experimental|Continous Glucose Monitor|
16459972|NCT03566693|Active Comparator|Self Monitoring Blood Glucose|
16459973|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
16459974|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
16459975|NCT03566667|Other|Standard care|Usual standard care
16459976|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
16459977|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
16459978|NCT03566641|Experimental|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
16459979|NCT03566641|Active Comparator|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
16459980|NCT03566628|Experimental|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
16459981|NCT03566628|Active Comparator|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
16459982|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
16459983|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
16459984|NCT03566615|Experimental|CAP-daisy|A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
16459985|NCT03566602|Other|Dura Sealant Patch|Application of Dura Sealant Patch after closure of the dura mater
16459986|NCT03566589|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
16459987|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
16459988|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
16459989|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
16459990|NCT03566550||CF|people with cystic fibrosis
16460314|NCT03564431||T2DM patients|
16459994|NCT03566524|Experimental|Arginine|In this experimental arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary arginine for 21 days. Arginine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The arginine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
16459995|NCT03566524|Active Comparator|Citrulline|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 21 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
16459996|NCT03566524|Placebo Comparator|alanine|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 21 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
16459997|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
16459998|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
16459999|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
16460000|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
16460001|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
16460002|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
16460003|NCT03566485|Experimental|Phase 2 (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16460004|NCT03566485|Experimental|Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO|
16460005|NCT03566459||Veterans with opioid use disorder (OUD)|Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
16460006|NCT03566446|Experimental|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
16460007|NCT03566433|Active Comparator|Endoscopic TEP surgery|Routine total extraperitoneal technique surgery for inguinal hernia
16460008|NCT03566433|Active Comparator|Open Lichtenstein hernioplasty|Routine lichtenstein surgery for inguinal hernia
16460009|NCT03566407|Other|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
16460010|NCT03566394|Experimental|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
16460011|NCT03566394|No Intervention|Observation|
16460012|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
16460013|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
16460014|NCT03566355|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
16460015|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
16460016|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
16460017|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
16460018|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
16460019|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
16460020|NCT03566329|Active Comparator|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
16460021|NCT03566329|Active Comparator|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
16460022|NCT03566329|Placebo Comparator|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
16460023|NCT03566316|Experimental|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
16460024|NCT03566316|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
16460025|NCT03566316|Active Comparator|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
16460026|NCT03566303|Active Comparator|Rivaroxaban|Rivaroxaban 15mg BID
16460027|NCT03566303|Placebo Comparator|Warfarin|Warfarin dose adjusted
16460028|NCT03566290|Experimental|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
16460029|NCT03566277|Experimental|Single-arm trial|All participants will undergo each of three conditions during the study.
16460030|NCT03566264||Participants hospitalized with ADHF|
16460031|NCT03566251|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
16460032|NCT03566251|No Intervention|Healthy individuals|29 healthy volunteers with matching ages and genders
16460033|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
16460034|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
16460035|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
16460036|NCT03566225|Active Comparator|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
16460037|NCT03566225|Placebo Comparator|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
16460038|NCT03566212|Experimental|conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
16460039|NCT03566212|Experimental|camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
16460040|NCT03566199|Experimental|Treatment (MTX110)|Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16460041|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
16460042|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
16460043|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
16460044|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
16460045|NCT03566147|Experimental|low dose group|300,000 HuRPE cells
16460046|NCT03566147|Experimental|middle dose group|500,000 HuRPE cells
16460047|NCT03566147|Experimental|high dose group|1,000,000 HuRPE cells
16460048|NCT03566134|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
16460049|NCT03566134|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
16460050|NCT03566134|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
16460051|NCT03566134|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
16460052|NCT03566121|Other|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
16460053|NCT03566121|Experimental|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
16460054|NCT03566108|Experimental|VISTA|VISTA incision with CAF and ADM
16460055|NCT03566108|Active Comparator|Sulcular Tunnell access|Sulcular tunnel surgery with CAF and ADM
16460056|NCT03566095|Active Comparator|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
16460057|NCT03566095|Sham Comparator|Voices for Food Kit|The comparison community received the Voices for Food kit.
16460058|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.
~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
16460059|NCT03566069|Experimental|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
16460060|NCT03566069|Placebo Comparator|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
16460065|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
16460066|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
16460067|NCT03566017|Experimental|Experimental open label|pegunigalsidase alfa
16460068|NCT03566004|Other|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
16460069|NCT03565991|Experimental|Combination of avelumab and talazoparib|Single arm open label
16460070|NCT03565978|Experimental|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
16460071|NCT03565978|No Intervention|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
16460072|NCT03565965|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
16460073|NCT03565965|Active Comparator|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
16460074|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
16460075|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
16460076|NCT03565939|Active Comparator|Trichuris suis ova (TSO)|7500 TSO suspension, orally every second week for 24 weeks.
16460077|NCT03565939|Placebo Comparator|Placebo|Solution without TSO orally every second week for 24 weeks
16460078|NCT03565926|Active Comparator|Manual Therapy|"Manual Therapy Protocol
~Articulation technique L4-S1
~Lumbar neuromuscular technique
~Fascial technique of crossed hands
~Posteroanterior mobilizations of the lumbar vertebrae"
16460079|NCT03565926|Experimental|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
16460080|NCT03565913|Experimental|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
16460081|NCT03565913|Active Comparator|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
16460082|NCT03565900|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
16460083|NCT03565900|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.
16460084|NCT03565887|Experimental|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
16460085|NCT03565887|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
16460086|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
16460087|NCT03565861|Placebo Comparator|Placebo|Placebo intravenous 30 minute infusion on day 1
16460088|NCT03565861|Experimental|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
16460089|NCT03565861|Experimental|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
16460090|NCT03565861|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
16460091|NCT03565861|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
16460092|NCT03565861|Experimental|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
16460093|NCT03565861|Experimental|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
16460094|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
16460095|NCT03565835|Experimental|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
16460096|NCT03565822|Other|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
16460097|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
16460098|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
16460099|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
16460100|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
16460101|NCT03565783|Experimental|Treatment (cemiplimab)|Participants receive cemiplimab IV over 30 minutes every 3 weeks. Courses repeat every 3 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
16460102|NCT03565770|Experimental|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
16460103|NCT03565770|Sham Comparator|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
16460104|NCT03565757|Experimental|SMART intervention|90-minute SMART small group session
16460105|NCT03565744|Experimental|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
16460106|NCT03565744|No Intervention|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
16460107|NCT03565744|No Intervention|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
16460315|NCT03564431||depression patients|
16460316|NCT03564431||T2DM with depression patients|
16460108|NCT03565731|Experimental|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
16460109|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
16460110|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.
~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
16460111|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
16460112|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
16460113|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients treated by LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) Patients over 6 years who are currently able to benefit from LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) according the mutation eligibility criteria and for whom conventional microbiological analysis of sputum samples and stool will be collected during their follow-up after the treatment onset.
16460114|NCT03565679|Experimental|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
16460115|NCT03565679|Sham Comparator|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
16460116|NCT03565666|Active Comparator|Adult RCT: Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule
16460117|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
16460118|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet using Fiasp|Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
16460119|NCT03565653|Experimental|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
16460120|NCT03565653|Experimental|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
16460121|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
16460122|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
16460123|NCT03565627|Experimental|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
16460124|NCT03565627|Experimental|Running App|One You Couch to 5K by Public Health England
16460125|NCT03565614|Experimental|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
16460126|NCT03565614|Active Comparator|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
16460127|NCT03565601||CTD patients with anti-Ro52 antibodies|Connective tissue disease patients with anti-Ro52 antibodies at diagnosis
16460128|NCT03565601||CTD patients without anti-Ro52 antibodies|Connective tissue disease patients without anti-Ro52 antibodies at diagnosis
16460129|NCT03565588|Experimental|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
16460130|NCT03565588|Experimental|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
16460131|NCT03565588|No Intervention|Control arm|No intervention will be administered to the control arm
16460132|NCT03565575|Experimental|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
16460133|NCT03565575|No Intervention|Control arm|No intervention will be administered to the control arm
16460134|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
16460135|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
16460136|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
16460137|NCT03565549|Experimental|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
16460138|NCT03565549|Active Comparator|CCHR rule|The control group will receive the CCHR only
16460139|NCT03565536|Experimental|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
~then External radiation therapy after surgery."
16460140|NCT03565523|Experimental|Test Beet shot|Containing 385 mg nitrate
16460141|NCT03565523|Placebo Comparator|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
16460142|NCT03565510|No Intervention|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
16460143|NCT03565510|Experimental|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based total diet replacement.
16460144|NCT03565497|Placebo Comparator|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
16460145|NCT03565497|Experimental|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
16460146|NCT03565497|Experimental|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
16460147|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
16460148|NCT03565484|Experimental|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
16460149|NCT03565484|Other|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
16460150|NCT03565484|Other|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
16460151|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.
~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
16460152|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.
~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
16460153|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.
~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
16460154|NCT03565458|Experimental|gemigliptin|gemigliptin single dose
16460155|NCT03565458|Experimental|dapagliflozin|dapagliflozin single dose
16460156|NCT03565458|Experimental|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
16460157|NCT03565458|Experimental|empagliflozin|empagliflozin single dose
16460158|NCT03565458|Experimental|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
16460165|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
16460166|NCT03565419|No Intervention|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
16460167|NCT03565419|Experimental|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
16460168|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
16460169|NCT03565393|Placebo Comparator|Fibersol-2|Receive Fibersol-2 twice daily
16460170|NCT03565393|Placebo Comparator|Placebo|Receive placebo twice daily
16460171|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
16460172|NCT03565380|Experimental|Patients without intervention|usual post-operative care
16460173|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
16460174|NCT03565367|Experimental|Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
16460175|NCT03565354|Active Comparator|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: > 50kg: 1000mg; <50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
16460176|NCT03565354|No Intervention|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
16460177|NCT03565341|Experimental|Melasma|Treatment of Melasma Using PiQo4 Laser System
16460178|NCT03565328|Experimental|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
16460179|NCT03565315|Experimental|Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group|10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)
16460180|NCT03565315|Experimental|Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)
~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
16460181|NCT03565315|Experimental|Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group|10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)
16460182|NCT03565315|Experimental|Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)
~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
16460183|NCT03565302|Placebo Comparator|Control|Subjects receive placebo treatment
16460184|NCT03565302|Experimental|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
16460185|NCT03565302|Experimental|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
16460186|NCT03565289||All patients|All
16460187|NCT03565276|Experimental|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
16460188|NCT03565263||FGID-IBD|"Patients aged 9-18 years
~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)
~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy
~followed for IBD for at least 1 year
~with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
16460868|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
16460189|NCT03565263||No FGID-IBD|"Patients aged 9-18 years
~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)
~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy
~followed for IBD for at least 1 year
~not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
16460190|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
16460191|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
16460192|NCT03565237|Experimental|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
16460193|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
16460194|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
16460195|NCT03565185|Active Comparator|End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.
~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
16460196|NCT03565185|Active Comparator|Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.
~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
16460197|NCT03565185|Placebo Comparator|conventional treatment|conventional treatment methods for stroke rehabilitation 5 days a week Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level.
16460198|NCT03565172|Experimental|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:
~Baseline: 4, 5 or 6 evaluations
~Intervention: 9 evaluations before and after every stretching session
~Follow-up: 4, 5 or 6 evaluations
~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
16460199|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
16460200|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
16460201|NCT03565146|Experimental|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
16460202|NCT03565133|Experimental|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
16460203|NCT03565133|Experimental|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
16460204|NCT03565133|Experimental|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
16460205|NCT03565133|Placebo Comparator|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
16460206|NCT03565120|Experimental|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
16460207|NCT03565107||Female Patients|ICSI treatment because of male subfertility
16460208|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose
~Part A:
~Cohort 1: single oral dose of Lu AF28996
~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between
~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects
~Part B: 8 subjects (randomised to one of four treatment sequences)"
16460209|NCT03565081|Experimental|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
16460210|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg|Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
16460211|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo Monotherapy|Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
16460212|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
16460213|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
16460214|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg|In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
16460215|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
16460761|NCT03561181|Experimental|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
16460216|NCT03565068|Experimental|Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
16460217|NCT03565068|Placebo Comparator|Panel D (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
16460218|NCT03565055|Experimental|IPCST|Intervention = Patients that participate in IPCST programme
16460219|NCT03565055|Active Comparator|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
16460220|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
16460221|NCT03565029|Experimental|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
16460222|NCT03565003|Experimental|JAB-3068 (SHP2 inhibitor)|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
16460223|NCT03564990|Experimental|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
16460224|NCT03564990|Sham Comparator|conventional approach|conventional follow-up with oral healthy education
16460225|NCT03564977|Experimental|CD19-targeted CAR-T cells|
16460226|NCT03564951|Active Comparator|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
16460227|NCT03564951|Experimental|Isochrone|ablation of concordance zones using isochrone and voltage maps
16460229|NCT03564925|Active Comparator|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
16460230|NCT03564925|Experimental|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
16460231|NCT03564912|Experimental|2 week group|
16460232|NCT03564912|Active Comparator|3 week group|
16460233|NCT03564899|No Intervention|control|Receive no physical activity intervention (maintain baseline physical activity participation)
16460234|NCT03564899|Experimental|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
16460235|NCT03564899|Active Comparator|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
16460236|NCT03564886|Experimental|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
16460237|NCT03564886|Placebo Comparator|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
16460240|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
16460241|NCT03564847|Experimental|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
16460242|NCT03564847|No Intervention|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
16460243|NCT03564834|Experimental|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
16460244|NCT03564834|Active Comparator|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
16460247|NCT03564808|Experimental|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
16460248|NCT03564808|Experimental|Fat graft only|Fat graft withiut enrichment with MSCs
16460249|NCT03564795|Experimental|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
16460408|NCT03563781|Other|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
16460250|NCT03564795|Active Comparator|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
16460251|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
16460252|NCT03564769|Experimental|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
16460253|NCT03564769|Experimental|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
16460254|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
16460255|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
16460256|NCT03564730|Active Comparator|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
16460257|NCT03564730|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
16460258|NCT03564717|Experimental|Segmented Three dimensionally printed transfer tray|
16460259|NCT03564717|No Intervention|Full arch three dimensionally printed transfer tray|
16460260|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
16460261|NCT03564691|Experimental|Dose Escalation, Part A: MK-4830 Monotherapy|MK-4830 monotherapy (with MK-4830 doses determined by an accelerated titration design [ATD]) will be administered intravenously (IV), every 3 weeks (Q3W), starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pancreatic adenocarcinoma.
16460262|NCT03564691|Experimental|Dose Escalation, Part B: MK-4830 Monotherapy|MK-4830 monotherapy (with MK 4830 doses determined by a modified toxicity probability interval [mTPI] method) will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes,
16460263|NCT03564691|Experimental|Dose Escalation, Part C: MK-4830 and Pembrolizumab|Combination therapy with MK-4830 and pembrolizumab (with MK-4830 doses determined by an mTPI design). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460264|NCT03564691|Experimental|Dose Expansion, Arm A: Pancreatic Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed pancreatic adenocarcinoma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460265|NCT03564691|Experimental|Dose Expansion, Arm B: Glioblastoma (GBM)|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed GBM. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460266|NCT03564691|Experimental|Dose Expansion, Arm C: R/M HNSCC|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease progressed on an anti-programmed cell death 1/programmed cell death ligand 1 (PD1/L1) therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460267|NCT03564691|Experimental|Dose Expansion, Arm D: PD-L1 positive HNSCC, Dose A|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed advanced programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (HNSCC). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460268|NCT03564691|Experimental|Dose Expansion, Arm E: First-Line Advanced NSCLC, Dose A|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460411|NCT03563755|Experimental|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
16460269|NCT03564691|Experimental|Dose Expansion, Arm F: First-Line Advanced NSCLC, Dose B|Combination therapy with the preliminary recommended phase 2 dose (RP2D) B of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460270|NCT03564691|Experimental|Dose Expansion, Arm G: NSCLC, +Carboplatin/Pemetrexed|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, pembrolizumab, and carboplatin/pemetrexed in participants with advanced non-squamous non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Carboplatin and pemetrexed will be administered IV Q3W, starting with Cycle 1, Day 1, for 4 cycles, followed by pemetrexed Q3W continuous with MK-4830 and pembrolizumab, up to 35 cycles. Each cycle is 21 days.
16460271|NCT03564691|Experimental|Dose Expansion, Arm H: RCC, +Lenvatinib|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, pembrolizumab, and lenvatinib in participants with advanced renal cell carcinoma (RCC). MK-4830 will be administered IV, Q3W, starting with Cycle 1 following pembrolizumab infusion, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Lenvatinib will be administered orally once daily for up to 35 cycles of 21 days.
16460272|NCT03564691|Experimental|Dose Expansion, Arm I: R/M Gastric/GE Junction Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic (R/M) gastric or gastroesophageal (GE) junction adenocarcinoma and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
16460273|NCT03564691|Experimental|Dose Expansion, Arm J: Ovarian Cancer|Triple combination therapy with pembrolizumab plus preliminary recommended phase 2 dose (RP2D) A of MK-4830 plus paclitaxel in participants who have histologically confirmed, ovarian cancer. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles. Each cycle is 21 days. Paclitaxel will be administered by IV, once every week (QW) on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity.
16460274|NCT03564691|Experimental|Dose Expansion, Arm K: Triple negative Breast Cancer (TNBC)|Triple combination therapy with pembrolizumab plus preliminary recommended phase 2 dose (RP2D) A of MK-4830 plus paclitaxel in participants who have histologically confirmed TNBC. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles. Each cycle is 21 days. Paclitaxel will be administered by IV on Days 1, 8, and 15 every 4 weeks (Q4W) until disease progression or prohibitive toxicity.
16460275|NCT03564691|Experimental|Dose Expansion, Arm L: Mesothelioma|Triple combination therapy with pembrolizumab plus preliminary recommended phase 2 dose (RP2D) A of MK-4830 plus pemetrexed plus cisplatin in participants who have histologically confirmed advanced mesothelioma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles. Each cycle is 21 days. Pemetrexed will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days. Cisplatin will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days.
16460276|NCT03564678|Experimental|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
16460277|NCT03564665|Experimental|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
16460278|NCT03564665|Placebo Comparator|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
16460279|NCT03564652|No Intervention|Arm A|Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
16460280|NCT03564652|Experimental|Arm B|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
16460281|NCT03564652|Experimental|Arm C|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
16460282|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
16460283|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
16460284|NCT03564626|Experimental|Health IT only|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline and at 30 days.Follow-up will be for 30 days
16460285|NCT03564626|Experimental|Health IT + Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
16460286|NCT03564613||HIV positive pregnant women|Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.
16460287|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
16460288|NCT03564600||UC Group|Veterans with back pain for at least the past 6 months.
16460289|NCT03564587|Experimental|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
16460290|NCT03564587|No Intervention|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
16460291|NCT03564574|Experimental|Study group|"Inclusion criteria
~History of consumption of OP compound.
~Symptom complex consistent with OP poisoning
~Age > 18 years
~Informed consent from the patient or next kin.
~Exclusion criteria
~History of combined poisoning with a non OP compound.
~All other patients not fitting in the organophosphate symptom complex.
~Patients with underlying liver and kidney disease.
~History suggestive of acute pancreatitis in the past.
~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.
~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
16460292|NCT03564574|No Intervention|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
16460293|NCT03564548|Experimental|PPP001|Inhaled cannabinoids (PPP001)
16460294|NCT03564548|Active Comparator|Morphine sulfate or Hydromorphone or Oxycodone|Oral morphine sulfate or hydromorphone or oxycodone at the previous stabilized dosage
16460295|NCT03564535|Experimental|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
16460296|NCT03564535|Active Comparator|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
16460297|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
16460298|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
16460299|NCT03564509|Experimental|FE 999302 (dose 1) and follitropin delta|
16460300|NCT03564509|Experimental|FE 999302 (dose 2) and follitropin delta|
16460301|NCT03564509|Experimental|FE 999302 (dose 3) and follitropin delta|
16460302|NCT03564509|Experimental|FE 999302 (dose 4) and follitropin delta|
16460303|NCT03564509|Experimental|FE 999302 (dose 5) and follitropin delta|
16460304|NCT03564509|Placebo Comparator|Placebo and follitropin delta|
16460305|NCT03564496|Active Comparator|Healthy Controls|20 Healthy Controls
16460306|NCT03564496|Experimental|MS Patients|40 individuals diagnosed with MS recruited from the MS Center/ Neurology Department at NYULMC
16460307|NCT03564483||Registry Observational Study|All women presenting for evaluation of Extramammary Paget's Disease (EMPD) at Mayo Clinic in Rochester MN.
16460308|NCT03564470|Experimental|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
16460309|NCT03564470|Experimental|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
16460310|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
16460311|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
16460312|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
16460313|NCT03564431||controls|
16460317|NCT03564418|Active Comparator|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
16460318|NCT03564418|Active Comparator|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
16460319|NCT03564405|Experimental|UNI-DEB|
16460320|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
16460321|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
16460322|NCT03564379|Experimental|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
16460323|NCT03564379|Experimental|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
16460324|NCT03564353|Experimental|memory task with tDCS location 1|memory task paired with tDCS targeting C2 nerve (anode left c2; cathode right C2)
16460325|NCT03564353|Experimental|memory task with tDCS location 2|memory task paired with tDCS targeting C2 nerve (anode right c2; cathode left C2)
16460326|NCT03564353|Experimental|memory task with tDCS location 3|memory task paired with tDCS targeting C5/6 nerve
16460327|NCT03564353|Experimental|memory task with tDCS location 4|memory task paired with tDCS targeting trigeminal nerve dermatomes (left and right temple/jaw)
16460330|NCT03564327||Patients with sinus rhythm|
16460331|NCT03564327||patients with atrial fibrillation|
16460332|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
16460333|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
16460334|NCT03564301|Active Comparator|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
16460335|NCT03564301|Placebo Comparator|Placebo|Placebo: same shape, size and dosis as test
16460336|NCT03564288|Experimental|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
16460337|NCT03564275|Experimental|Prospective Treatment Group|Proton Boost
16460338|NCT03564275|No Intervention|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
16460339|NCT03564262|Experimental|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.
~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
16460340|NCT03564262|Experimental|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
16460341|NCT03564249|Experimental|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
16460342|NCT03564249|Experimental|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
16460343|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:
~oral prednisolone 40 mg/day for 5 days;
~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;
~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.
~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
16460409|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
16460410|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
16460344|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:
~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.
~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.
~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
16460345|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.
~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
16460346|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.
~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
16460347|NCT03564210|Active Comparator|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
16460348|NCT03564210|Active Comparator|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
16460349|NCT03564197|Other|Nivolumab|nivolumab containing treatment according to label
16460350|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
16460351|NCT03564184|Experimental|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
16460352|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
16460353|NCT03564184|Experimental|No MT|Consists of standard care.
16460354|NCT03564171|No Intervention|Standard of Care|Patients will receive standard treatment without added intervention.
16460355|NCT03564171|Experimental|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :
~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
16460356|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
16460357|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
16460358|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
16460359|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
16460360|NCT03564145|Experimental|S5G4T-1|Topical cream
16460361|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
16460362|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
16460363|NCT03564119|Experimental|S5G4T-1|topical cream
16460364|NCT03564119|Placebo Comparator|S5G4T-2|topical cream
16460365|NCT03564106|Experimental|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
16460366|NCT03564106|Experimental|group C|receive intraarticular methylprednisolone (30 mg)
16460367|NCT03564093|Experimental|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
16460368|NCT03564093|Placebo Comparator|Placebo|0,01ml/kg intranasal 4,5% saline
16460369|NCT03564080|No Intervention|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
16460370|NCT03564080|Experimental|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
16460371|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
16460372|NCT03564054|Experimental|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
16460373|NCT03564054|Experimental|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
16460374|NCT03564041|Experimental|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
16460375|NCT03564041|Other|Health Enhancement Program (HEP)|"Arm type: Active control group
~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
16460376|NCT03564028|Experimental|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
16460377|NCT03564028|Other|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
16460378|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
16460379|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
16460380|NCT03564002||obese subjects|
16460381|NCT03564002||lean subjects|
16460382|NCT03563989|Experimental|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
16460383|NCT03563989|Active Comparator|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
16460384|NCT03563963|Active Comparator|Lidocaine 2% in Endotracheal Tube cuff|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
16460385|NCT03563963|Experimental|Ropivacaine 0.5% Endotracheal Tube cuff|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
16460386|NCT03563963|Active Comparator|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
16460387|NCT03563950|Experimental|Rifampin + BMS-986224|Oral administration
16460388|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
16460389|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
16460390|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
16460391|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
16460392|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
16460393|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
16460394|NCT03563911|Experimental|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
16460395|NCT03563911|Active Comparator|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
16460396|NCT03563885|Experimental|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
16460397|NCT03563885|No Intervention|Lean|Lean control subjects doing baseline testing only.
16460398|NCT03563872|Active Comparator|Active Comparator|Team-based care
16460399|NCT03563872|Experimental|Intervention|Enhanced team-based care
16460400|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
16460401|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
16460402|NCT03563833|Other|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.
~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
16460403|NCT03563833|Other|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.
~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
16460404|NCT03563807|Experimental|Golf|Group golf lessons will be led by professional golf instructors.
16460405|NCT03563807|Active Comparator|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
16460406|NCT03563794|Experimental|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
16460407|NCT03563794|Active Comparator|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
16460413|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
16460414|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
16460415|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
16460416|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
16460417|NCT03563729|Experimental|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
16460418|NCT03563716|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
16460419|NCT03563716|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
16460420|NCT03563703|Experimental|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
16460421|NCT03563703|Experimental|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
16460422|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
16460423|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
16460424|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
16460425|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
16460426|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
16460427|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
16460428|NCT03563677|No Intervention|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
16460429|NCT03563677|Experimental|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
16460430|NCT03563664|Experimental|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
16460431|NCT03563651||Ancillary-Correlative (biospecimen collection, biopsy)|Participants undergo collection of blood and urine at baseline, on day 1 of courses 1, 2, and 3, at restaging, and at disease progression. Participants may undergo collection of stool at baseline, on day 1 of course 2, and at disease progression. Participants also undergo biopsy within 4 weeks of disease progression.
16460432|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
16460864|NCT03560479|Experimental|alpha1H, 74 mg/mL|alpha1H (74 mg/mL), solution for instillation, 30 mL
16460433|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
16460434|NCT03563625|Active Comparator|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
16460435|NCT03563625|Active Comparator|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
16460436|NCT03563612|Active Comparator|cpap first, differential ventilation later|
16460437|NCT03563612|Active Comparator|differential ventilation first, cpap late|
16460438|NCT03563599|Experimental|Telacebec (Q203) tablet|
16460439|NCT03563599|Active Comparator|Rifafour e-275|
16460440|NCT03563586|Active Comparator|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
16460441|NCT03563586|Other|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
16460442|NCT03563573|Active Comparator|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
16460443|NCT03563573|Placebo Comparator|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
16460444|NCT03563573|Active Comparator|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
16460445|NCT03563573|Placebo Comparator|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
16460446|NCT03563560|Experimental|ACM regimen|ACM regimen is for Japanese patients with relapsed or refractory AML.
16460447|NCT03563560|Experimental|A+7+3 regimen|A+7+3 regimen is for Japanese newly diagnosed AML patients.
16460448|NCT03563547|Active Comparator|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
16460449|NCT03563547|Experimental|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
16460450|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
16460451|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
16460452|NCT03563521||Atopic, eosinophilic|
16460453|NCT03563521||Atopic, non-eosinophilic|
16460454|NCT03563521||Non-atopic, eosinophilic|
16460455|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
16460456|NCT03563521||Non-atopic, non-eosinophilic|
16460457|NCT03563521||Control|Without asthma, atopy and eosinophilia
16460458|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
16460459|NCT03563495|Active Comparator|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
16460460|NCT03563495|Active Comparator|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
16460461|NCT03563482|Experimental|Experimental|Biopsy and PET scan
16460462|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
16460463|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
16460464|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
16460465|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
16460466|NCT03563430|Experimental|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
16460467|NCT03563430|Experimental|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
16460468|NCT03563430|Experimental|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
16460471|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
16460472|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
16460869|NCT03560427|Experimental|duloxetine+morphine|
16460870|NCT03560427|Placebo Comparator|placebo+morphine|
16460473|NCT03563391|Experimental|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
16460474|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
16460475|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
16460476|NCT03563365|Experimental|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
16460477|NCT03563365|Experimental|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
16460478|NCT03563365|Active Comparator|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
16460479|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
16460480|NCT03563339|Experimental|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
16460481|NCT03563326|Experimental|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
16460482|NCT03563326|Active Comparator|chemotherapy|Chemotherapy: determined by medical Oncologist
16460483|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
16460484|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
16460485|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
16460486|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
16460487|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs before surgery|
16460488|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
16460489|NCT03563261|Active Comparator|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
16460490|NCT03563261|Placebo Comparator|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
16460491|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~SBRT should be administered 2-6 weeks after completing chemotherapy
~All participants will undergo an attempt at definitive surgical resection following SBRT"
16460492|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~Losartan will be administered orally as a tablet to be taken by the patient at home every day
~SBRT should be administered 2-6 weeks after completing chemotherapy
~All participants will undergo an attempt at definitive surgical resection following SBRT"
16460493|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~Losartan will be administered orally as a tablet to be taken by the patient at home every day
~SBRT should be administered 2-6 weeks after completing chemotherapy
~Participants will receive nivolumab during SBRT
~All participants will undergo an attempt at definitive surgical resection following SBRT"
16460494|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~SBRT should be administered 2-6 weeks after completing chemotherapy
~Participants will receive nivolumab during SBRT
~All participants will undergo an attempt at definitive surgical resection following SBRT"
16460495|NCT03563235|Experimental|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
16460496|NCT03563235|Active Comparator|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
16460497|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
16460498|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
16460499|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
16460500|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
16460501|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
16460502|NCT03563170|Experimental|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.
16460503|NCT03563170|Active Comparator|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.
16460504|NCT03563157|Experimental|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
16460505|NCT03563157|Active Comparator|Regorafenib|In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.
16460506|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1
~A combination of agents will be administered to subjects in this study:
~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
16460507|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
16460508|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
16460509|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
16460510|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
16460511|NCT03563118||Group OSAS|We included 56 with OSAS [13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
16460512|NCT03563118||control group|simple snoring
16460513|NCT03563105|Experimental|Desaturation|Vascular Occlusion Test
16460514|NCT03563092|Experimental|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
16460515|NCT03563092|Active Comparator|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
16460516|NCT03563079|Experimental|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
16460517|NCT03563079|Active Comparator|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
16460520|NCT03563053|Experimental|active drug|~14-22 mg dexamethasone sodium phosphate (DSP)
16460521|NCT03563040|Experimental|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
16460522|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
16460523|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
16460524|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
16460525|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
16460526|NCT03563001|Experimental|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
16460527|NCT03563001|Experimental|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
16460528|NCT03562988|Other|Vitamin C gummy, Then Vitamin C Caplet|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
16460529|NCT03562988|Other|Vitamin C tablet, Then Vitamin C gummy|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.
16460592|NCT03562507|Experimental|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
16460593|NCT03562507|Experimental|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
~Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle"
16460594|NCT03562494|Experimental|VY-AADC02 (NBIb-1817)|Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02
16460595|NCT03562494|Placebo Comparator|Sham (Placebo) Surgery|Sham surgical procedure
16460530|NCT03562962|Other|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland & Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).
~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
16460531|NCT03562949|Experimental|Test Product|Test Product, 40 mcg, 2 x daily
16460532|NCT03562949|Active Comparator|Reference Product|Reference Product, 40 mcg, 2 x daily
16460533|NCT03562949|Placebo Comparator|Placebo|Placebo Product 2 x daily
16460534|NCT03562923|Experimental|Test Product|Test Product, 100/50 mcg, 2 x daily
16460535|NCT03562923|Active Comparator|Reference Product|Reference Product, 100/50 mcg, 2 x daily
16460536|NCT03562923|Placebo Comparator|Placebo|Placebo Product 2 x daily
16460537|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
16460539|NCT03562884|Experimental|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
16460540|NCT03562884|Active Comparator|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
16460541|NCT03562871|Experimental|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
16460542|NCT03562871|Active Comparator|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
16460543|NCT03562871|Experimental|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
16460544|NCT03562871|Active Comparator|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
16460545|NCT03562858|Active Comparator|Delayed dentine sealing|
16460546|NCT03562858|Experimental|Immediate dentin sealing|
16460547|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:
~Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved
~Patients with a good and stable clinical evolution
~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
16460548|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
16460549|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
16460550|NCT03562819||NSCLC|Non-small cell lung cancer
16460551|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
16460552|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
16460553|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
16460554|NCT03562780|Experimental|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
16460555|NCT03562780|Active Comparator|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
16460556|NCT03562767|Experimental|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
16460557|NCT03562767|Experimental|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
16460558|NCT03562767|Placebo Comparator|Usual Care|Subjects receiving usual care from their primary care providers
16460559|NCT03562754|Active Comparator|Control|
16460560|NCT03562754|Experimental|Prometheus System|
16460561|NCT03562741|Experimental|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
16460562|NCT03562728|Active Comparator|ECMO- Bridge to Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
16460563|NCT03562728|Other|ECMO- Bridge to Transplant Control Group|"Interventions: standard of care
~Patients are not going to receive any additional intervention."
16460564|NCT03562728|Active Comparator|Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
16460565|NCT03562728|Other|Transplant Control Group|"Interventions: standard of care.
~Patients are not going to receive any additional intervention."
16460566|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
16460567|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
16460568|NCT03562702|Active Comparator|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
16460569|NCT03562702|Experimental|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
16460570|NCT03562676|Experimental|weightlessness|
16460571|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
16460572|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
16460573|NCT03562650|Experimental|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
16460574|NCT03562650|Active Comparator|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
16460575|NCT03562637|Experimental|Adagloxad simolenin + OBI-821 in conjunction with SOC|"Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks.
~Patient will also receive standard of care (SOC) treatment."
16460576|NCT03562637|Active Comparator|Standard of Care treatment|"Study visit intervals will be identical to those in Arm 1.
~Patient will receive standard of care (SOC) treatment."
16460577|NCT03562624|Experimental|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
16460578|NCT03562624|Experimental|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
16460579|NCT03562624|Experimental|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
16460580|NCT03562624|Active Comparator|Marketed comparator|Marketed comparator IUS
16460581|NCT03562611|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
16460582|NCT03562611|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
16460583|NCT03562611|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
16460584|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
16460585|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
16460586|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
16460587|NCT03562559||TKA Patients|
16460588|NCT03562546|Experimental|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
16460589|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve [AUC] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
16460590|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
16460591|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
16460691|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
16460596|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
16460597|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
16460598|NCT03562468|Placebo Comparator|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
16460599|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
16460600|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
16460601|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
16460602|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
16460603|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).
~Intervention: Smoking cessation"
16460604|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
16460605|NCT03562429|Experimental|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
16460606|NCT03562429|Placebo Comparator|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
16460607|NCT03562416|Experimental|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
16460608|NCT03562416|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 24 months
16460609|NCT03562403|Experimental|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
16460610|NCT03562390|Experimental|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
16460611|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >
~> Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
16460612|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections. >
~> Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
16460613|NCT03562364|No Intervention|Standard of Care|The standard of care group will remain non-weight bearing for 10-12 weeks following definitive fixation and receive physical therapy in accordance with standard practice at the treating center.
16460614|NCT03562364|Experimental|Early Advanced Weight Bearing (EAWB)|The Early Advanced Weight Bearing (EAWB) group will receive early weight-bearing treatment using the antigravity AlterG treadmill. These sessions will begin 14-28 days following definitive fixation and last for a total of 10 weeks
16460615|NCT03562351|Experimental|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
16460616|NCT03562351|Experimental|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
16460617|NCT03562351|Experimental|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
16460618|NCT03562338|Experimental|Manual Therapy and Exercise|
16460619|NCT03562338|Active Comparator|Usual Care|
16460620|NCT03562325|Other|ACT|Acceptance & Commitment Therapy (ACT)
16460621|NCT03562312|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
16460622|NCT03562312|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
16460623|NCT03562299|Experimental|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
16460624|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
16460625|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
16460626|NCT03562260|Experimental|children who had bipolar release|children who had bipolar release are included
16460627|NCT03562247|Active Comparator|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
16460628|NCT03562247|Experimental|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
16460629|NCT03562247|Experimental|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
16460630|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.
~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
16460631|NCT03562221|Experimental|Gluten free diet|Gluten free diet
16460632|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
16460633|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
16460634|NCT03562195|Experimental|Subjects receiving Mepolizumab|Eligible subjects will randomized in 1:1 ratio to Mepolizumab group or Placebo group. Subjects in Mepolizumab group will receive Mepolizumab 100mg subcutaneously into the upper arm or thigh every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC of asthma treatment. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an needed basis in this study.
16460635|NCT03562195|Placebo Comparator|Subjects receiving Placebo|Eligible subjects in placebo group will receive placebo (0.9 percent sodium chloride) matching to Mepolizumab administered subcutaneously into the upper arm or thigh every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC of asthma treatment. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an as needed basis in this study.
16460636|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
16460637|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
16460638|NCT03562169|Active Comparator|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
16460639|NCT03562169|Experimental|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
16460640|NCT03562156|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
16460641|NCT03562156|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
16460642|NCT03562143|Experimental|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
16460643|NCT03562143|Active Comparator|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
16460644|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
16460645|NCT03562117|Experimental|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
16460646|NCT03562117|Experimental|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
16460647|NCT03562117|Experimental|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
16460648|NCT03562117|Experimental|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
16460649|NCT03562117|Experimental|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
16460650|NCT03562104|Experimental|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
16460651|NCT03562078|Experimental|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
16460652|NCT03562078|No Intervention|Control Group for Type 2 Diabetes|diabetic patients care education
16460653|NCT03562065|Experimental|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:
~1.10^6 CSM / kg
~2.10^6 CSM / kg
~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
16460654|NCT03562039|Experimental|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
16460655|NCT03562039|Active Comparator|M-MIST (group B)|conventional M-MIST.
16460656|NCT03562000|Experimental|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
16460931|NCT03560011|No Intervention|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
16460657|NCT03562000|Other|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
16460658|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.
~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.
~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
16460659|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.
~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.
~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
16460660|NCT03561974|Experimental|Humidification|
16460661|NCT03561974|No Intervention|Control group without humidification|
16460662|NCT03561961|Active Comparator|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. All patients will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
16460663|NCT03561961|Experimental|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. All patients will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
16460664|NCT03561948|Experimental|Experimental group|Surgery and Intraperitoneal Chemotherapy
16460665|NCT03561948|Placebo Comparator|Control group|only surgery
16460666|NCT03561935|Experimental|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
16460667|NCT03561935|Active Comparator|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
16460668|NCT03561922|Experimental|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
16460669|NCT03561909|Other|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
16460670|NCT03561896|Experimental|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
16460671|NCT03561896|Experimental|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
16460672|NCT03561883|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
16460673|NCT03561883|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
16460674|NCT03561870|Experimental|Olaparib|
16460675|NCT03561857|Experimental|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
16460676|NCT03561844|Active Comparator|aromatherapy-scent|
16460677|NCT03561844|Active Comparator|aromatherapy-touch|
16460678|NCT03561844|No Intervention|waiting-list control|
16460679|NCT03561831|Active Comparator|propofol group|patients who anesthesized by propofol
16460680|NCT03561831|Active Comparator|sevoflurane group|patients who anesthesized by sevoflurane
16460681|NCT03561818|Experimental|Hospital-based group|2 months hospital-based pulmonary rehabilitation program
16460682|NCT03561818|Experimental|Home-based group|2 months home-based pulmonary rehabilitation program
16460683|NCT03561805|Other|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
16460684|NCT03561792|No Intervention|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI < 105 predicts successful weaning)
16460685|NCT03561792|Experimental|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI < 1.3 predicts successful weaning)
16460686|NCT03561779|Experimental|YYD302|YYD302 (2ml)
16460687|NCT03561779|Active Comparator|Synovian Inj.|Synovian Inj. (3ml)
16460688|NCT03561753|Active Comparator|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
16460689|NCT03561753|Experimental|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ [high dose] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
16460690|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
16460692|NCT03561727|Experimental|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
16460693|NCT03561727|Active Comparator|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
16460694|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
16460695|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
16460696|NCT03561701|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
16460697|NCT03561701|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
16460698|NCT03561688|Sham Comparator|Standard insole|a flat insole
16460699|NCT03561688|Experimental|Foot orthotics|Custom-made foot orthoses
16460700|NCT03561675|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16460701|NCT03561675|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
16460702|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
16460703|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
16460704|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
16460705|NCT03561649|Experimental|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.
~The patients will be seen as part of their follow-up consultation in Rheumatology.
~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.
~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
16460706|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
16460707|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
16460708|NCT03561610|Active Comparator|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
16460709|NCT03561610|Experimental|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
16460710|NCT03561597|Experimental|Mobile health application|Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
16460711|NCT03561584|Active Comparator|Active Drug (Sulfasalazine)|
16460712|NCT03561584|Placebo Comparator|Placebo|
16460713|NCT03561571|Active Comparator|Butter based breakfast|
16460714|NCT03561571|Active Comparator|Chocolate spread based breakfast|
16460715|NCT03561558|Experimental|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
16460716|NCT03561558|Active Comparator|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
16460717|NCT03561545|Experimental|Functional capillary density|Functional capillary density during weightlessness
16460718|NCT03561532|Active Comparator|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
16460719|NCT03561532|Placebo Comparator|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
16460720|NCT03561519|Active Comparator|FMT|IBS patients randomized to receive FMT from a healthy donor.
16460721|NCT03561519|Placebo Comparator|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
16460722|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
16460723|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
16460724|NCT03561493|Experimental|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
16460725|NCT03561493|No Intervention|non zumba exercise group|The participants in the control group did not receive any intervention.
16460726|NCT03561480|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
16460727|NCT03561480|Active Comparator|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
16460728|NCT03561454|Other|XOFT-Intra-Operative Radiation Therapy|XOFT-Intra-Operative Radiation Therapy
16460729|NCT03561441|Active Comparator|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
16460730|NCT03561441|Experimental|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
16460731|NCT03561415|Experimental|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
16460732|NCT03561415|Experimental|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
16460733|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
16460734|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
16460735|NCT03561376|Other|Single arm - split scar study|Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
16460736|NCT03561363|Experimental|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.
~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.
~Carbohydrate comprise 20 E% and protein 15 E%."
16460737|NCT03561363|Experimental|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
16460738|NCT03561337|Experimental|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
16460739|NCT03561337|Placebo Comparator|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
16460740|NCT03561324|Experimental|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
16460741|NCT03561311|Experimental|Remote ischemic conditioning group|
16460742|NCT03561311|Sham Comparator|Sham remote ischemic conditioning group|
16460743|NCT03561298|Experimental|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
16460744|NCT03561285||Stroke with antiphospholipid|
16460745|NCT03561285||stroke without antiphospholipid|
16460746|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
16460747|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
16460748|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
16460749|NCT03561259|Experimental|131I-MIBG|131I-MIBG
16460750|NCT03561259|Experimental|131I-MIBG + Vorinostat|131I-MIBG + Vorinostat
16460751|NCT03561246|Active Comparator|Personalized training effect on SSWS|"Determine the efficacy of motor control deficit guided personalized training on SSWS compared to non-personalized and CONTROL interventions.
~Incline treadmill walking Decline treadmill walking"
16460752|NCT03561246|Active Comparator|Personalized training effect on Pp|"Determine the efficacy of motor control deficit guided personalized training on increasing symmetry of Pp compared to non-personalized and CONTROL interventions.
~Incline treadmill walking Decline treadmill walking"
16460753|NCT03561246|Active Comparator|Positive response|"Determine if the personalized intervention increase the positive response rate compared to non-personalized and CONTROL interventions, and to further advance personalize interventions by identifying factors that predict response.
~Incline treadmill walking Decline treadmill walking"
16460754|NCT03561233|Experimental|proton pump inhibitor|omeprazole 20 mg twice daily
16460755|NCT03561220|Active Comparator|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
16460756|NCT03561220|Active Comparator|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
16460757|NCT03561220|Experimental|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
16460758|NCT03561220|Experimental|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
16460759|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.
16460760|NCT03561181|Experimental|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
16460762|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
16460763|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
16460764|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
16460765|NCT03561155|Experimental|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
16460766|NCT03561155|Active Comparator|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
16460767|NCT03561142|Experimental|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
16460768|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
16460769|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
16460770|NCT03561103|Experimental|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
16460771|NCT03561103|No Intervention|RCT: Control|Participants in the RCT control group will receive the standard of care.
16460772|NCT03561103|Experimental|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
16460773|NCT03561103|No Intervention|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
16460774|NCT03561090|Experimental|1500 mg IW-3718 BID + PPI|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
16460775|NCT03561090|Placebo Comparator|Placebo + PPI|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
16460776|NCT03561077|Experimental|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
16460777|NCT03561064|Experimental|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
16460778|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
16460779|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
16460780|NCT03561025|Active Comparator|18F-FDG-PET/MRI|
16460781|NCT03561025|Experimental|18F-GE180-PET/MRI|
16460782|NCT03561012|Experimental|Intervention arm|
16460783|NCT03561012|Active Comparator|Control Arm|
16460784|NCT03560986|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
16460785|NCT03560986|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
16460786|NCT03560973|Experimental|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
16460787|NCT03560973|Placebo Comparator|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
16460788|NCT03560960|Experimental|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
16460789|NCT03560960|Active Comparator|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
16460790|NCT03560960|Active Comparator|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
16460791|NCT03560947|Experimental|Manual Therapy and Exercise|
16460792|NCT03560947|Active Comparator|Usual Care|
16460793|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.
~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
16460794|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
16460795|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
16460796|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
16460797|NCT03560908|Experimental|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
16460798|NCT03560895|Active Comparator|Group I|Patients will be anesthetized using low-volume cuffed Kimberly-Clark * MICROCUFF * endotracheal tube (Microcuff, Halyard Health Inc., Atlanta, GA, USA), with its outer diameter determined by ultrasonography.
16460799|NCT03560895|Active Comparator|Group II|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
16460800|NCT03560895|Active Comparator|Group III|Patients will be anesthetized using uncuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
16460801|NCT03560882|Experimental|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
16460802|NCT03560869|Experimental|Normal hydration then dehydration|Participants will consume water to maintain proper hydration for three days prior to testing (visit 1). Seven to 60 days later, participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 2).
16460803|NCT03560869|Experimental|Dehydration than normal hydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 1). Seven to 60 days later, participants will consume water to maintain proper hydration for three days prior to testing (visit 2).
16460804|NCT03560856|Other|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
16460805|NCT03560843|Experimental|MBSR treatment|MBSR will be administered over 8 week period.
16460806|NCT03560843|No Intervention|Control group|Usual care will continue for this group.
16460807|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
16460808|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
16460809|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.
~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
16460810|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.
~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
16460811|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
16460812|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
16460813|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
16460814|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
16460815|NCT03560765|Experimental|Using MED assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen to purchase an MED following training
16460816|NCT03560765|Active Comparator|Using MED training only|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen to purchase an MED following training
16460817|NCT03560765|Active Comparator|No MED, assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen not to purchase an MED following training
16460818|NCT03560765|No Intervention|No MED, no buddy|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen not to purchase an MED following training
16460819|NCT03560752|Experimental|Prevention(multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
16460820|NCT03560739|Other|OMB 20mg PFS abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen
16460821|NCT03560739|Other|OMB 20mg AI abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen
16460822|NCT03560739|Other|OMB 20mg PFS thigh|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh
16460823|NCT03560739|Other|OMB 20mg AI thigh|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh
16460824|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
16460825|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).
~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
16460866|NCT03560453|No Intervention|Control|Attend assigned high school for 9 months
16460867|NCT03560453|Experimental|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
16460826|NCT03560713|Experimental|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
16460827|NCT03560713|Sham Comparator|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
16460828|NCT03560700|Experimental|lactobacillus probiotic strain|60 billion CFU/day
16460829|NCT03560700|Placebo Comparator|placebo|
16460830|NCT03560687|Experimental|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
16460831|NCT03560687|No Intervention|Control|
16460832|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
16460833|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
16460834|NCT03560661||Kennedy's disease (KD) patients|
16460835|NCT03560648|Other|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
16460836|NCT03560648|Other|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
16460837|NCT03560635|Active Comparator|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
16460838|NCT03560635|Experimental|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
16460839|NCT03560622|Active Comparator|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
16460840|NCT03560622|Experimental|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
16460841|NCT03560609|Active Comparator|Subjects With Keratoconus|
16460842|NCT03560609|Active Comparator|Subjects with Glaucoma|
16460843|NCT03560596|Experimental|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
16460844|NCT03560596|Active Comparator|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
16460845|NCT03560583|Experimental|Metoclopramide 10 mg BID|
16460846|NCT03560583|Placebo Comparator|Placebo 10 mg BID|
16460847|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
16460848|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
16460849|NCT03560570||Control|Healthy subject
16460850|NCT03560544|Experimental|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
16460851|NCT03560544|No Intervention|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
16460852|NCT03560531|Experimental|ZN-c5 monotherapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.
16460853|NCT03560531|Experimental|ZN-c5 + palbociclib combination therapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 in combination with palbociclib as well as a Phase 2 cohort.
16460854|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
16460855|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
16460856|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
16460857|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.
~Intervention: Ultrasound protocol."
16460858|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.
~Intervention: Ultrasound protocol."
16460859|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
16460860|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
16460861|NCT03560479|Experimental|alpha1H, 7.4 mg/mL|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
16460862|NCT03560479|Placebo Comparator|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
16460863|NCT03560479|Experimental|alpha1H, 37 mg/mL|alpha1H (37 mg/mL), solution for instillation, 30 mL
16460871|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
16460872|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
16460873|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
16460874|NCT03560401|Experimental|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor [chairback] brace) full-time for 12 weeks, except when bathing or lying in bed.
16460875|NCT03560401|No Intervention|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
16460876|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
16460877|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
16460878|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
16460879|NCT03560375|Experimental|Circuit resistance training (CRT)|2-3 circuits * 10 exercises * 3 times per week
16460880|NCT03560375|Experimental|Empagliflozin 10 MG|10 mg once daily
16460881|NCT03560375|Experimental|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
16460882|NCT03560362|Active Comparator|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
16460883|NCT03560362|Experimental|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
16460884|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
16460885|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
16460886|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
16460887|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
16460888|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
16460889|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
16460890|NCT03560310|Experimental|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75-100 mg daily for 12 months
16460891|NCT03560310|Active Comparator|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
16460892|NCT03560297|Experimental|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
16460893|NCT03560297|Experimental|Delayed/Waitlist Program|Participants do not participate in the program for a time period
16460894|NCT03560271|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
16460895|NCT03560271|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
16460896|NCT03560271|Placebo Comparator|Dose C|Placebo
16460897|NCT03560258|Experimental|Arm 1: p24CE1/2 pDNA + full-length p55^gag pDNA vaccine|Participants will receive p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24.
16460898|NCT03560258|Experimental|Arm 2: Full-length p55^gag pDNA vaccine|Participants will receive full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
16460899|NCT03560258|Placebo Comparator|Arm 3: Placebo|Participants will receive placebo at Weeks 0, 4, 12, and 24.
16460900|NCT03560245|Experimental|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
16460901|NCT03560245|Placebo Comparator|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
16460928|NCT03560037|Experimental|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
16460929|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
16460930|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
16460902|NCT03560232|Active Comparator|Cefazolin + Gentamicin|"[Cefazolin]
~Initial dose:
~Cefazolin 2g IV x1 dose (patient weight < 120kg)
~Cefazolin 3g IV x1 dose (patient weight >/= 120kg)
~Subsequent dose:
~Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min)
~Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)
~Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min)
~Duration:
~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first
~[Gentamicin]
~Initial dose:
~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)
~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)
~Subsequent dose:
~Pharmacy Consult to dose gentamicin
~Duration:
~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
16460903|NCT03560232|Active Comparator|Ceftriaxone|"Initial dose:
~Ceftriaxone 2g IV x1 dose
~Subsequent dose:
~Ceftriaxone 2g IV every 24 hours
~Duration:
~One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
16460904|NCT03560232|Active Comparator|Ampicillin/Sulbactam|"Initial dose:
~Ampicillin/Sulbactam 3g IV x1 dose
~Subsequent dose:
~Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min)
~Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)
~Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min)
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
16460905|NCT03560232|Active Comparator|Piperacillin/Tazobactam|"Initial dose:
~Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes
~Subsequent dose:
~Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min)
~Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min)
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
16460906|NCT03560232|Other|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:
~[Clindamycin]
~Initial dose:
~Clindamycin 900mg IV x1 dose
~Subsequent dose:
~Clindamycin 600mg IV every 8 hours
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
~[Gentamicin]
~Initial dose:
~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)
~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)
~Subsequent dose:
~Pharmacy Consult to dose gentamicin
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
16460907|NCT03560206|Experimental|Family SWaP intervention with mini iPad|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
16460908|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
16460909|NCT03560193|Experimental|Chlorhexidine Group|
16460910|NCT03560193|Active Comparator|Povidone Iodine Group|
16460911|NCT03560167|Experimental|AccuCinch® Ventricular Restoration System|
16460912|NCT03560154|Experimental|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
16460913|NCT03560154|No Intervention|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
16460914|NCT03560141|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
16460915|NCT03560141|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
16460916|NCT03560128|Experimental|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
16460917|NCT03560128|Experimental|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
16460919|NCT03560089|Active Comparator|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
16460920|NCT03560089|Placebo Comparator|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
16460921|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
16460922|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
16460923|NCT03560063|Experimental|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
16460924|NCT03560063|Active Comparator|Standard care arm|Total hip replacement with standard templating to guide implant positioning
16460925|NCT03560050|Experimental|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
16460926|NCT03560050|Experimental|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
16460927|NCT03560037|No Intervention|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
16460932|NCT03560011|Experimental|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
16460933|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
16460934|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
16460935|NCT03559972|Experimental|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.
~SkinMedica Facial Cleanser
~Hulk (cosmetic investigational)
~Marvel AM (cosmetic investigational)
~Marvel PM (cosmetic investigational)
~SkinMedica HA5 Rejuvenating Hydrator
~SkinMedica Rejuvenative Moisturizer
~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
16460936|NCT03559972|Experimental|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.
~SkinMedica Facial Cleanser
~SkinMedica TNS Essential Serum
~Marvel AM (cosmetic investigational)
~Marvel PM (cosmetic investigational)
~SkinMedica HA5 Rejuvenating Hydrator
~SkinMedica Rejuvenative Moisturizer
~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
16460937|NCT03559959|Experimental|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
16460938|NCT03559959|Experimental|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
16460939|NCT03559959|Experimental|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
16460940|NCT03559959|Experimental|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
16460941|NCT03559959|Experimental|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
16460942|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
16460943|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
16460944|NCT03559933|Experimental|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
16460945|NCT03559920|Experimental|Sevoflurane group|Patients who are sedated using sevoflurane
16460946|NCT03559920|Active Comparator|Intravenous sedation group|Patients who are sedated using propofol
16460947|NCT03559907|Experimental|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
16460948|NCT03559907|Experimental|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
16460949|NCT03559907|Experimental|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
16460950|NCT03559881|No Intervention|Observation|Participants with a habitual protein intake >1.2 g/kg body weight/day will be allocated to the observational arm of the study
16460951|NCT03559881|Experimental|Intervention|Participants with a habitual protein intake <1.2 g/kg body weight/day will be allocated to the interventional arm of the study
16460952|NCT03559868|Active Comparator|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
16460953|NCT03559868|Active Comparator|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
16460954|NCT03559868|Placebo Comparator|Placebo|oral placebo
16460955|NCT03559855|Experimental|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
16460956|NCT03559855|No Intervention|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
16460957|NCT03559842||Surgery patients|Obese patients undergoing laparoscopic sleeve gastrectomy
16460958|NCT03559842||Non-surgery patients|Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)
16460959|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
16460960|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
16460961|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
16460962|NCT03559803|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
16460990|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
16460991|NCT03559504||Group 1|Infant period: 1 month-1 year old
16460992|NCT03559504||Group 2|Toddler period:1-3 years old
16460993|NCT03559504||Group 3|Preschool age period:3-6 years old
16460994|NCT03559504||Group 4|School age period:7-18 years old
16460963|NCT03559777|Active Comparator|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally
~A full thickness flap will be elevated
~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.
~The widening drills can be sequentially used to widen the osteotomy site to the same level
~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.
~The osteotome will be tapped gently to fracture up the sinus floor.
~Xenograft will be added to the osteotomy as the grafting material.
~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.
~Smart peg will be placed on implant and Ostell will be used to record ISQ.
~Healing collar will be placed on implant.
~Suturing the flab around healing collar."
16460964|NCT03559777|Experimental|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally
~A full thickness flap will be elevated
~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.
~Change the drill motor to reverse- densifying Mode
~Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.
~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.
~densah burs (3.5mm) advance in the osteotomy.
~Xenograft will be added to the osteotomy .
~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.
~Smart peg will be placed on implant and Ostell will be used to record ISQ.
~Healing collar will be placed on implant.
~Suturing the flab around healing collar."
16460965|NCT03559764|Experimental|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
16460966|NCT03559751|Experimental|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
16460967|NCT03559751|Experimental|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
16460968|NCT03559751|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
16460969|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
16460970|NCT03559725|Experimental|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
16460971|NCT03559725|Experimental|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
16460972|NCT03559725|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
16460973|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
16460974|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
16460975|NCT03559699|Experimental|Part 1: Dose Optimization AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for up to 16 weeks.
~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual participant's transfusion cycle and response to AG-348 in Part 1."
16460976|NCT03559647||Cohort 1|Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
16460977|NCT03559647||Cohort 2|Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab
16460978|NCT03559634|Experimental|Intervention group|Using an electronic application, participants answer survey questions about their sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception. Then, based on survey answers, they will be able to watch more in-depth educational videos on methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to survey screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. Participants will then be given the opportunity to initiate contraception in the ED. All participants will be referred for follow up outpatient health services. Subjects who have medical contraindications to certain contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s) while in the ED.
16460979|NCT03559634|Other|Control Group|Using an electronic application, participants answer survey questions about their background, sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants medical history and contraceptive preferences they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. After these videos they will be given information on where they will be able to follow up to receive these contraceptive methods if they wish to start a method. Subjects who have medical contraindications to certain hormonal contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s), should this come up in future discussions with their providers.
16460980|NCT03559621|No Intervention|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
16460981|NCT03559621|Other|intervention group|A mobile-based lifestyle intervention
16460982|NCT03559595|Experimental|Intervention group|All study participants will be exposed to the intervention
16460983|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
16460984|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
16460985|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
16460987|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
16460988|NCT03559517|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
16460989|NCT03559517|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
16460995|NCT03559504||Group 5|Adults:18-65 years old
16460997|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
16460998|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
16460999|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
16461000|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
16461001|NCT03559465|Sham Comparator|healthy subject|
16461002|NCT03559452|No Intervention|Control|Immobilisation without prior exercise
16461003|NCT03559452|Experimental|Muscle damage|300 bilateral knee extensor eccentric contraction performed immediately prior to immobilisation
16461004|NCT03559439|Experimental|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
16461005|NCT03559426|Active Comparator|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
16461006|NCT03559426|Experimental|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
16461007|NCT03559413|Experimental|Intervention group|
16461008|NCT03559400|Experimental|gentamicin injection at fracture site|Subjects with an open tibia fracture who receive gentamicin in saline solution administered after closure at the time of initial debridement.
16461009|NCT03559400|Placebo Comparator|placebo saline injection at fracture site|Subjects with an open tibia fracture who receive placebo saline solution administered after closure at the time of initial debridement.
16461010|NCT03559387|Experimental|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
16461011|NCT03559387|Active Comparator|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
16461012|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
16461013|NCT03559361|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
16461014|NCT03559361|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
16461015|NCT03559361|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
16461016|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
16461017|NCT03559335||Patients after colorectal cancer surgery|
16461018|NCT03559309|Other|Alirocumab|Medical Treatment (Clinical Routine)
16461019|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
16461020|NCT03559283|Experimental|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
16461021|NCT03559270|Experimental|Baricitinib|Baricitinib administered orally.
16461022|NCT03559257|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
16461023|NCT03559257|Placebo Comparator|Placebo|Placebo administered SC.
16461024|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
16461025|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
16461026|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
16461027|NCT03559231|Experimental|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
16461028|NCT03559231|Active Comparator|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
16461029|NCT03559218|Other|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
16461030|NCT03559218|Experimental|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
16461031|NCT03559205|No Intervention|MSK-Tracker (before)|Usual Care in clinic consultations
16461032|NCT03559205|Active Comparator|MSK-Tracker (after)|Use of the MSK-Tracker in clinic consultations
16461033|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
16461034|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
16461035|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
16461036|NCT03559179|Experimental|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
16461067|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
16461037|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
16461038|NCT03559179|Experimental|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
16461039|NCT03559166|Experimental|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
16461040|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
16461041|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
16461042|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
16461043|NCT03559166|Placebo Comparator|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
16461044|NCT03559166|Placebo Comparator|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
16461045|NCT03559166|Placebo Comparator|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
16461046|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
16461047|NCT03559166|Placebo Comparator|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
16461048|NCT03559166|Placebo Comparator|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
16461049|NCT03559166|Placebo Comparator|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
16461050|NCT03559153|No Intervention|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
16461051|NCT03559153|Experimental|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
16461052|NCT03559153|Active Comparator|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
16461053|NCT03559140|Experimental|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.
~After the procedure cryotherapy will be applied as follows:
~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
16461054|NCT03559140|Experimental|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)
~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:
~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
16461055|NCT03559140|Experimental|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).
~The group will receive the irrigant solution at room temperature. as follows:
~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
16461056|NCT03559127|Experimental|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.
~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
16461057|NCT03559127|Experimental|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution
~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
16461058|NCT03559127|Experimental|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution
~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
16461059|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
16461060|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
16461061|NCT03559101|Active Comparator|Beverage 1 - Control|Distilled Water
16461062|NCT03559101|Experimental|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
16461063|NCT03559101|Experimental|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
16461064|NCT03559101|Experimental|Beverage 4|Pedialyte
16461065|NCT03559101|Experimental|Beverage 5|Gatorade
16461066|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
16461068|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461069|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461070|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461071|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461072|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461073|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461074|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461075|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
16461076|NCT03559062|Other|Placebo|Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
16461077|NCT03559062|Experimental|TEZ/IVA|Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
16461078|NCT03559062|Experimental|Ivacaftor|Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
16461079|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).
~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
16461080|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
16461081|NCT03559023|Active Comparator|Ultrasound Only|Ultrasound assisted epidural placement
16461082|NCT03559023|Active Comparator|Manometry Only|Manometry confirmation in epidural placement
16461083|NCT03559023|Active Comparator|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
16461084|NCT03559023|Sham Comparator|Usual Care/Management|Usual epidural technique placement
16461085|NCT03559010|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
16461086|NCT03558997|Experimental|Placebo|Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
16461087|NCT03558997|Experimental|Dupilumab|Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
16461088|NCT03558997|Experimental|SCIT|Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
16461089|NCT03558997|Experimental|Dupilumab + SCIT|Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
16461090|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
16461091|NCT03558984|Other|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
16461092|NCT03558971|Experimental|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
16461093|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
16461094|NCT03558945|Experimental|Personalized neoantigen vaccine|"Patients will receive radical surgery and at least one circle of post-operative chemotherapy.
~Personalized neoantigen vaccines will be injected on day 1 of weeks 1, 3, 5, 7, 9, short interval or 1-2 months after the end of their post-operative chemotherapy, and two boosts will be on day 1 of weeks 12, 20.
~Vaccines will be given in a total volume of up to 1.0ml/shot consisting of 0.3mg peptide+0.5mg ployICLC injected subcutaneously into two to four separate sites of the subject's thighs.
~Patients will be called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
16461095|NCT03558945|No Intervention|Conventional treatment|Patients will receive radical surgery and conventional post-operative chemotherapy.
16461096|NCT03558919|Experimental|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
16461097|NCT03558919|Active Comparator|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
16461150|NCT03558581|Experimental|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
16461151|NCT03558568|Active Comparator|DBS off|
16461152|NCT03558568|Active Comparator|DBS on 60 Hz.|
16461098|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
16461099|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.
16461100|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.
16461101|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was <15% in the whole mouth.
16461102|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
16461103|NCT03558880|Active Comparator|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
16461104|NCT03558880|Active Comparator|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
16461105|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
16461106|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
16461107|NCT03558854|Active Comparator|ASA group|Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
16461108|NCT03558854|Placebo Comparator|Placebo oral capsule group|Identical pill containing placebo, taken once daily for 04 weeks
16461109|NCT03558841|Experimental|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
16461110|NCT03558841|Active Comparator|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
16461111|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
16461112|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).
~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
16461113|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
16461114|NCT03558815||Adults with mild, moderate, severe or profound ID|Adults with mild, moderate, severe or profound ID in contact with either a sheltered workshop and/ or sheltered living Institution in Saxony.
16461117|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
16461118|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
16461119|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
16461120|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
16461121|NCT03558763|Active Comparator|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
16461122|NCT03558763|Active Comparator|Telemonitoring|"Twice a week subject will perform additional vital functions:
~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.
~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And
~Complete two PRO´s (integrated in the application):
~CAT MRC All this is estimated to take approximately 20-30 min each time.
~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.
~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
16461123|NCT03558750|Experimental|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
16461124|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
16461125|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
16461153|NCT03558568|Active Comparator|DBS on 99 Hz.|
16461154|NCT03558568|Active Comparator|DBS on 130 Hz.|
16461155|NCT03558568|Active Comparator|DBS on 230 Hz.|
16461126|NCT03558724|Experimental|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.
~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.
~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
16461127|NCT03558724|Experimental|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.
~IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.
~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
16461128|NCT03558724|Experimental|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.
~IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.
~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
16461129|NCT03558711|Experimental|study group|
16461130|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
16461131|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
16461132|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
16461133|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
16461134|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
16461135|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
16461136|NCT03558685|Experimental|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
16461137|NCT03558659|Experimental|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
16461138|NCT03558659|No Intervention|Standard Care|No positional therapy belt provided for use during sleep.
16461139|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand -> one hand with an endoscopic bite block -> held by two hands
16461140|NCT03558620|Experimental|Group 12O|A fitting mask is held by one hand -> held by two hands-> one hand with an endoscopic bite block
16461141|NCT03558620|Experimental|Group O12|A fitting mask is held by one hand with an endoscopic bite block->by one hand -> by two hands
16461142|NCT03558620|Experimental|Group O21|A fitting mask is held by one hand with an endoscopic bite block -> by two hands-> one hand
16461143|NCT03558620|Experimental|Group 21O|A fitting mask is held by two hands -> one hand -> one hand with an endoscopic bite block
16461144|NCT03558620|Experimental|Group 2O1|A fitting mask is held by two hands ->one hand with an endoscopic bite block-> by one hand
16461145|NCT03558607|Experimental|Experimental arm|
16461146|NCT03558594|Experimental|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
16461147|NCT03558594|Experimental|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
16461148|NCT03558594|No Intervention|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
16461149|NCT03558581|No Intervention|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
16461250|NCT03557814|Active Comparator|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
16461156|NCT03558555|Active Comparator|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
16461157|NCT03558555|Active Comparator|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
16461158|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
16461159|NCT03558516|Experimental|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
16461160|NCT03558516|Placebo Comparator|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
16461161|NCT03558503|Experimental|UGN-102|75 mg Mitomycin C (MMC) in 56 mL admixture (1.33 mg MMC per 1 mL of admixture).
16461162|NCT03558490|Experimental|ZEMY software|
16461163|NCT03558477|Experimental|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 & Nexium
16461164|NCT03558477|Experimental|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 & Nexium
16461165|NCT03558477|Experimental|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 & Nexium
16461166|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package
~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
16461167|NCT03558464|Active Comparator|Control|(agriculture-focused package)
16461168|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
16461169|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
16461170|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
16461171|NCT03558425|Experimental|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
16461172|NCT03558425|Experimental|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
16461173|NCT03558412|Experimental|Arm A|Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.
16461174|NCT03558399|Experimental|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
16461175|NCT03558399|Active Comparator|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
16461176|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:
~6 months to 1 year ago
~1 year to 3 years ago
~3 years ago or more"
16461177|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:
~6 months to 1 year ago
~1 year to 3 years ago
~3 years ago or more"
16461178|NCT03558360||Bariatric surger|Bariatric surgery and impedance measurement
16461179|NCT03558347|Experimental|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
16461180|NCT03558347|Experimental|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
16461181|NCT03558334|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
16461182|NCT03558334|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
16461183|NCT03558321|Experimental|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
16461184|NCT03558308|Experimental|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
16461185|NCT03558308|Experimental|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
16461186|NCT03558308|Experimental|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
16461187|NCT03558308|Sham Comparator|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
16461188|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
16461189|NCT03558269|Experimental|Study group|This group will receive UCB after the first palliative surgery
16461190|NCT03558269|No Intervention|Control group|This group will not receive any treatment
16461191|NCT03558256|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
16461192|NCT03558256|Active Comparator|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
16461193|NCT03558243|Active Comparator|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
16461194|NCT03558243|Experimental|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
16461195|NCT03558243|Experimental|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
16461196|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
16461197|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.
~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
16461200|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
16461201|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
16461202|NCT03558191|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
16461203|NCT03558178|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
16461204|NCT03558178|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
16461205|NCT03558165||Stage IV Lung Adenocarcinoma|
16461206|NCT03558152|Experimental|Arm 1a: UTTR1147A Dose Level 1 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.
~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
16461207|NCT03558152|Experimental|Arm 1b: UTTR1147A Dose Level 1 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.
~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
16461208|NCT03558152|Experimental|Arm 2a: UTTR1147A Dose Level 2 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.
~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
16461209|NCT03558152|Experimental|Arm 2b: UTTR1147A Dose Level 2 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.
~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
16461210|NCT03558152|Experimental|Arm 3a: UTTR1147A Dose Level 3 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.
~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
16461211|NCT03558152|Experimental|Arm 3b: UTTR1147A Dose Level 3 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.
~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
16461212|NCT03558152|Active Comparator|Arm 4: Vedolizumab|Parts A and B: Vedolizumab and UTTR1147A Placebo.
16461213|NCT03558152|Placebo Comparator|Arm 5: Placebo|Parts A and B: UTTR1147A Placebo and Vedolizumab Placebo.
16461214|NCT03558139|Experimental|Magrolimab + Avelumab (Part 1, Safety Run-in)|"Dose Level 1: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 30 mg/kg weekly for 4 doses (Cycle 1). Starting in Cycle 2, magrolimab 30 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.
~Based on Dose Limiting Toxicities (DLTs) assessment in Dose Level 1 Cycle 1; additional participants will be enrolled and administered Dose Level 2.
~Dose Level 2: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 45 mg/kg on Days 8,11,15, 22 and 29 for Cycle 1, continuing weekly in Cycle 2 on Days 1, 8, 15 and 22. Starting in Cycle 3, magrolimab 45 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.
~Additional lower or higher dose levels may be explored after reviewing all available clinical data."
16461251|NCT03557814|Active Comparator|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
16461252|NCT03557814|Sham Comparator|Control|Conventional non-surgical periodontal therapy without LED light irradiation
16461215|NCT03558139|Experimental|Magrolimab + Avelumab (Part 2, Ovarian Cancer Expansion)|After Part 1 Safety Run-in has completed and the recommended expansion dose(s) for magrolimab is determined, participants with ovarian cancer will be administered the recommended magrolimab dose(s) combined with avelumab 800 mg given once every 2 weeks.
16461216|NCT03558113|Other|visual tactile method|visual tactile method using the modified USHPS critiria
16461217|NCT03558100|Experimental|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
16461218|NCT03558087|Experimental|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy.
16461219|NCT03558074|Experimental|Active|ALK4290 800 mg daily
16461220|NCT03558061|Experimental|Active|ALK4290 800 mg daily
16461221|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
16461222|NCT03558035|Experimental|Induction chemotherapy and concurret chemoradiotherapy group|Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
16461223|NCT03558035|Active Comparator|Concurrent chemoradiotherapy group|Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy
16461224|NCT03558022|Experimental|Salt Pills|One week on low salt diet plus salt pills
16461225|NCT03558022|Placebo Comparator|Placebo Pills|One week on low salt diet plus placebo pills
16461226|NCT03558009||Participants with abdominal pain attacks|Participants experiencing recurrent abdominal pain attacks without a clear etiolgy aged between 2-60 years
16461227|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
16461228|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
16461229|NCT03557983|Experimental|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
16461230|NCT03557983|Placebo Comparator|Saline|Saline is topically spread three times per day for one week.
16461231|NCT03557970|Experimental|Treatment (JNJ-40346527)|Participants receive JNJ-40346527 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16461232|NCT03557957|Experimental|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
16461233|NCT03557957|Active Comparator|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
16461234|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:
~Medication reconciliation
~Identification of patient priorities for care
~Identification of medications that are potentially appropriate for discontinuation/dose reduction
~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
~Identification of medications for trial of discontinuation/dose reduction (shared decision making)
~Pause of medication and clinical monitoring"
16461235|NCT03557931|Experimental|ASP4345 50 milligram (mg)|Participants on stable doses of antipsychotic medication received ASP4345 50 mg, capsules, orally, once daily for 12 weeks.
16461236|NCT03557931|Experimental|ASP4345 150 mg|Participants on stable doses of antipsychotic medication received ASP4345 150 mg, capsules, orally, once daily for 12 weeks.
16461237|NCT03557931|Placebo Comparator|Placebo|Participants on stable doses of antipsychotic medication received ASP4345 placebo matching capsules, orally, once daily for 12 weeks.
16461238|NCT03557918|Experimental|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
16461239|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
16461240|NCT03557905|Active Comparator|Group II|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.5.
16461241|NCT03557892|Experimental|CSII+CGM|
16461242|NCT03557892|Active Comparator|MDI with degludec|
16461243|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
16461244|NCT03557866|Experimental|pronated group|individuals with pronated foot
16461245|NCT03557866|Active Comparator|control group|individuals with normal foot posture
16461246|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
16461247|NCT03557840|Experimental|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
16461248|NCT03557827|Sham Comparator|control|Mechanical debridement by periodontal curets alone
16461249|NCT03557827|Active Comparator|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
16461253|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
16461254|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
16461255|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
16461256|NCT03557788|Experimental|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
16461257|NCT03557775|Experimental|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).
~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
16461258|NCT03557775|Experimental|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).
~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
16461259|NCT03557775|Active Comparator|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
16461260|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
16461261|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
16461262|NCT03557749||Immune and Microbial Reconstitution|
16461263|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
16461264|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
16461265|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
16461266|NCT03557749||Immune Response Triggered by Relapse|
16461267|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
16461268|NCT03557749||Allogeneic Related Donor Samples|
16461269|NCT03557749||Cellular Therapy Products|
16461270|NCT03557736|Experimental|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
16461271|NCT03557736|Experimental|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
16461272|NCT03557736|Experimental|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
16461273|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
16461274|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
16461275|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
16461276|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
16461277|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
16461278|NCT03557684|Experimental|PO leucine & IV LPS|Oral (PO) leucine 6 g twice a day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
16461279|NCT03557684|Experimental|PO placebo & IV LPS|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of LPS 0.8 ng/kg of body weight
16461280|NCT03557684|Experimental|PO leucine & IV placebo|PO leucine 6 g twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
16461281|NCT03557684|Placebo Comparator|PO placebo & IV placebo|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
16461282|NCT03557671|Experimental|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
16461283|NCT03557671|Placebo Comparator|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
16461284|NCT03557658|Experimental|Hepatic Impaired|Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)
16461285|NCT03557658|Experimental|Healthy Volunteer|Subjects with normal hepatic function
16461286|NCT03557645|Sham Comparator|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
16461287|NCT03557645|Experimental|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
16461288|NCT03557645|Experimental|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
16461289|NCT03557632|Experimental|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
16461290|NCT03557632|Active Comparator|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
16461292|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
16461293|NCT03557580|Active Comparator|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
16461294|NCT03557580|Experimental|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
16461295|NCT03557580|Experimental|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
16461296|NCT03557567||MO patients|
16461297|NCT03557567||OI patients|
16461298|NCT03557554|Experimental|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
16461299|NCT03557541|Experimental|Sardine group|
16461300|NCT03557541|Active Comparator|Control group|
16461301|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
16461302|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
16461303|NCT03557515|Experimental|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
16461304|NCT03557515|Experimental|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
16461305|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
16461306|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
16461307|NCT03557489|Experimental|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
16461308|NCT03557489|No Intervention|Control group|patients use gel pad(in usual) during surgery.
16461309|NCT03557476|Experimental|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
16461310|NCT03557476|Placebo Comparator|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
16461311|NCT03557463|Active Comparator|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
16461312|NCT03557463|Experimental|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
16461313|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
16461314|NCT03557437|Active Comparator|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
16461315|NCT03557437|Experimental|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
16461316|NCT03557424|Experimental|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
16461317|NCT03557424|Experimental|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
16461318|NCT03557424|Placebo Comparator|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
16461319|NCT03557411|Experimental|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
16461320|NCT03557398|Experimental|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
16461322|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
16461323|NCT03557359|Experimental|Nivolumab|Nivolumab 240 mg will be given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg will be given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab will be administered as a 30-minute infusion. A finite treatment duration with immune therapies in this participant population remains an area of ongoing research; therefore the treatment duration chosen was 2 years.
16461324|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
16461325|NCT03557307|Experimental|Benralizumab|Benralizumab subcutaneous injection
16461326|NCT03557294|Experimental|1.0mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.
16461327|NCT03557294|Experimental|0.5mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study
16461328|NCT03557294|Placebo Comparator|0.0mg placebo varenicline b.i.d.|Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.
16461329|NCT03557281|Experimental|Subjects receiving GSK3036656|Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
16461330|NCT03557281|Active Comparator|Subjects receiving RIFAFOUR e-275|Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
16461331|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
16461332|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
16461333|NCT03557255|Active Comparator|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of > 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP < 80 mmHg) or tachycardia (heart rate > 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
16461334|NCT03557255|Active Comparator|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
16461335|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
16461336|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
16461337|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
16461338|NCT03557229|Experimental|Melatonin|
16461339|NCT03557229|Experimental|Vitamin C|
16461340|NCT03557229|Experimental|Vitamin E|
16461341|NCT03557229|Experimental|N-acetylcysteine|
16461342|NCT03557229|No Intervention|Control|
16461343|NCT03557216|Experimental|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
16461344|NCT03557216|Experimental|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
16461405|NCT03556657|No Intervention|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
16461345|NCT03557151|Active Comparator|Usual Care|Usual Care participants will receive the same excellent multidisciplinary care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
16461346|NCT03557151|Experimental|Transdisciplinary Care-In Person & Telehealth|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person or by telehealth at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
16461347|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
16461348|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
16461349|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
16461350|NCT03557112|Experimental|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
16461351|NCT03557112|Active Comparator|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
16461352|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
16461353|NCT03557086|Experimental|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
16461354|NCT03557086|Active Comparator|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
16461355|NCT03557073|Experimental|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
16461356|NCT03557073|No Intervention|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
16461357|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
16461358|NCT03557034|No Intervention|Standard of Care Monitoring|Standard of Care
16461359|NCT03557034|Experimental|Kardia Monitoring|Kardia Mobile/Kardia Pro
16461360|NCT03557021|Experimental|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
16461361|NCT03557021|Active Comparator|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
16461362|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
16461363|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
16461364|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
16461365|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
16461366|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
16461367|NCT03556956|Experimental|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).
~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
16461368|NCT03556956|No Intervention|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
16461369|NCT03556930|Experimental|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
16461370|NCT03556917|Active Comparator|group 1|topical gel base + caffeine.
16461371|NCT03556917|Active Comparator|group 2|iontophoresis + caffeine
16461372|NCT03556917|Active Comparator|Group 3|iontophoresis
16461375|NCT03556891|Experimental|eCoin Tibial Nerve Stimulation|
16461376|NCT03556878|Experimental|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
16461377|NCT03556852|Active Comparator|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
16461378|NCT03556852|Active Comparator|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
16461379|NCT03556839|Active Comparator|Arm A|Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
16461380|NCT03556839|Experimental|Arm B|cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
16461381|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
16461382|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
16461383|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
16461384|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
16461385|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
16461386|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
16461387|NCT03556800|Active Comparator|1.25 EstroGel|
16461388|NCT03556787|Experimental|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
16461389|NCT03556774|Experimental|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
16461390|NCT03556774|No Intervention|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
16461391|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
16461392|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
16461393|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),
~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
16461394|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)
~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
16461395|NCT03556735|Other|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
16461396|NCT03556722|Active Comparator|repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
16461397|NCT03556722|Sham Comparator|Sham repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
16461398|NCT03556709|Experimental|Treadmill Ankle Robot Training|
16461399|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
16461400|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
16461401|NCT03556683|Experimental|7% Hypertonic Saline|Subjects will inhale 4 mL of 7% hypertonic saline before having a Mucociliary Clearance (MCC) scan
16461402|NCT03556670|Experimental|Total Worker Health Intervention|
16461403|NCT03556670|Active Comparator|Control|
16461404|NCT03556657|Experimental|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
16461406|NCT03556644|Other|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
16461407|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
16461408|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
16461409|NCT03556618|Experimental|Whole Person Care (WPC) Reentry Program|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24)."
16461410|NCT03556618|No Intervention|Control|Participants in the control arm will receive usual care reentry healthcare planning, including correctional health provider and court-referred SUD and mental health treatment recommendations, medication prescriptions, written instructions for reinstating Medicaid, and written health discharge summaries. Participants in this branch will include youth exiting the adult justice system (ages 18-24) and youth exiting the juvenile justice system (ages 16-18).
16461411|NCT03556605|Other|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
16461412|NCT03556605|Other|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
16461413|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:
~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.
~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.
~CYP substrates - non-investigational medicinal products:
~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
16461414|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
16461415|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
16461416|NCT03556566|Experimental|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
16461417|NCT03556553|Experimental|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
16461418|NCT03556553|Experimental|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
16461419|NCT03556540|Placebo Comparator|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
16461420|NCT03556540|Experimental|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
16461421|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
16461422|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=90)
16461423|NCT03556475||Disease type 2-1)|Patients with Mild/moderate AECOPD (n=60)
16461424|NCT03556475||Disease type 2-2)|Patients with Severe AECOPD( n=60)
16461425|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=90)
16461426|NCT03556462|Experimental|Sleep Health Interventions|"Sleep Health Interventions:
~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.
~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
16461427|NCT03556462|No Intervention|Control Period|No Intervention, but data collection
16461428|NCT03556449||Patients|High resolution ultrasound
16461429|NCT03556449||Healthy subjects|High resolution ultrasound
16461430|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
16461431|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
16461432|NCT03556410|Placebo Comparator|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
16461433|NCT03556410|Experimental|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
16461434|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
16461435|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
16461436|NCT03556397|Experimental|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
16461437|NCT03556397|Experimental|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
16461466|NCT03556189|Experimental|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
16461467|NCT03556189|No Intervention|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
16461438|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.
~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.
~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
16461439|NCT03556371|Experimental|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
16461440|NCT03556371|Placebo Comparator|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
16461441|NCT03556358|Experimental|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles
~Followed by:
~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
16461442|NCT03556358|Active Comparator|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles
~Followed by:
~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
16461443|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
16461445|NCT03556319|Placebo Comparator|Placebo|Placebo
16461446|NCT03556319|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
16461447|NCT03556319|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
16461448|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
16461449|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
16461450|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
16461451|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
16461452|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
16461453|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
16461454|NCT03556267|Other|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
16461455|NCT03556267|Other|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
16461456|NCT03556254|Experimental|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
16461457|NCT03556254|Active Comparator|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
16461458|NCT03556241|Experimental|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
16461459|NCT03556241|No Intervention|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
16461460|NCT03556228|Experimental|VMD-928 300 mg Tablet or 100 mg Capsule|
16461461|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
16461462|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
16461463|NCT03556215|Experimental|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
16461469|NCT03556176|Active Comparator|Control ( without 5-HTTLPR or BDNF polymorphisms )|
16461470|NCT03556163|Experimental|Test Group|Modified vertical internal mattress sutures + MWF surgery.
16461471|NCT03556163|Active Comparator|Control Group|Simple loop interrupted sutures + MWF surgery.
16461472|NCT03556150|Experimental|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
16461473|NCT03556150|Active Comparator|Effleurage|Superficial massage in the most painful joint.
16461474|NCT03556137|Experimental|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
16461475|NCT03556137|Experimental|Healthy Volunteers|Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
16461476|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
16461477|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
16461478|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
16461479|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
16461480|NCT03556111|Experimental|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.
~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
16461481|NCT03556111|Experimental|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.
~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.
~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.
~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
16461482|NCT03556098|Active Comparator|GIP|Infusion of Glucose-dependent insulinotropic peptide
16461483|NCT03556098|Active Comparator|GIP[3-30]|Infusion of GIP[3-30]
16461484|NCT03556098|Placebo Comparator|Saline|Infusion of saline
16461485|NCT03556085|Experimental|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
16461486|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
16461487|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
16461488|NCT03556059|Active Comparator|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
16461489|NCT03556059|Active Comparator|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
16461490|NCT03556059|Active Comparator|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
16461491|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
16461492|NCT03556033|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
16461493|NCT03556033|Placebo Comparator|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
16461494|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
16461495|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
16461496|NCT03556007|Experimental|Cohort 1 - 3 μg/kg LY3471851|Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.
16461497|NCT03556007|Experimental|Cohort 1 - 6 μg/kg LY3471851|Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
16461498|NCT03556007|Experimental|Cohort 1 - 12 μg/kg LY3471851|Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
16461499|NCT03556007|Experimental|Cohort 1 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
16461500|NCT03555994|Experimental|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
16461501|NCT03555994|Placebo Comparator|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
16461502|NCT03555994|Active Comparator|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
16461503|NCT03555994|Experimental|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
16461504|NCT03555994|Placebo Comparator|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
16461505|NCT03555981|Experimental|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
16461506|NCT03555981|Active Comparator|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at >24h of hospital admission until hospital discharge with encouragement of KMC at home
16461507|NCT03555968|Placebo Comparator|THC 0 + BAC 0|Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%.
16461508|NCT03555968|Experimental|THC 5 + BAC 0|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%.
16462355|NCT03550170|Active Comparator|I-to-1, in-person|1-to-1, in-person intervention arm
16461509|NCT03555968|Experimental|THC 10 + BAC 0|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%.
16461510|NCT03555968|Experimental|THC 5 + BAC .025|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%.
16461511|NCT03555968|Experimental|THC 10 + BAC .025|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%.
16461512|NCT03555968|Experimental|THC 0 + BAC .049|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%.
16461513|NCT03555968|Experimental|THC 5 + BAC .049|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%.
16461514|NCT03555968|Experimental|THC 10 + BAC .049|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%.
16461515|NCT03555968|Experimental|THC 0 + BAC .025|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%.
16461516|NCT03555955|Experimental|Cohort 1|Normal renal function
16461517|NCT03555955|Experimental|Cohort 2|Moderate renal impairment
16461518|NCT03555955|Experimental|Cohort 3|Severe renal impairment
16461519|NCT03555942|Active Comparator|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
16461520|NCT03555942|Experimental|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
16461521|NCT03555929|Experimental|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
16461522|NCT03555929|Placebo Comparator|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
16461523|NCT03555916|Experimental|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
16461524|NCT03555916|Placebo Comparator|Placebo|2 mL of saline solution (0.9% NaCl) treatment
16461525|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
16461526|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
16461527|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
16461528|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
16461529|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
16461530|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
16461531|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
16461532|NCT03555864||Obese|Patients need two intravenous access with infra red
16461533|NCT03555851||Recipient|Cyclophosphamide
16461534|NCT03555851||Donor|Specimen collection
16461535|NCT03555838|Experimental|Active tDCS|Participants in this arm will receive 20 minutes of 2 mA transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
16461536|NCT03555838|Sham Comparator|Sham tDCS|Participants in this arm will receive 20 minutes of sham transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
16461537|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
16461538|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
16461539|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
16461540|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
16461541|NCT03555812|Experimental|Healthy volunteers|"a medical examination
~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
16461542|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:
~a medical examination
~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
16462594|NCT03548441||Non-surgical management|Non-exposed
16461543|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
16461544|NCT03555773|Experimental|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
16461545|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
16461546|NCT03555747|Other|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
16461547|NCT03555747|Other|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
16461548|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
16461549|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
16461550|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
16461551|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
16461552|NCT03555695|Experimental|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
16461553|NCT03555682|Placebo Comparator|Placebo|Placebo
16461554|NCT03555682|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
16461555|NCT03555682|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
16461556|NCT03555669|No Intervention|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
16461557|NCT03555669|Experimental|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
16461558|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
16461559|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
16461560|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
16461561|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
16461562|NCT03555630||Post-cesarean preeclampsia|
16461563|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
16461564|NCT03555617|Experimental|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
16461565|NCT03555617|Experimental|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
16461566|NCT03555617|Experimental|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
16461567|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
16461568|NCT03555591||Trelagliptin 100 mg|Trelagliptin 100 mg tablet, orally, once weekly for up to 36 months. Participants received interventions as part of routine medical care.
16461569|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
16461570|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
16461571|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
16461572|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
16461573|NCT03555539|Experimental|Part 1: Healthy Match|Single 200-milligram (mg) dose of danicopan on Day 1 in healthy participants (matched control group with normal hepatic function).
16461574|NCT03555539|Experimental|Part 1: Moderate HI|Single 200-mg dose of danicopan on Day 1 in participants with moderate HI.
16461575|NCT03555526|Experimental|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
16461576|NCT03555526|Active Comparator|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
16461577|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
16461578|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
16461579|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
16461580|NCT03555487|Experimental|18F-choline PET|PET/CT
16461581|NCT03555474|Experimental|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.
~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
16461582|NCT03555474|Experimental|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 [Grasp/Flexion/Extension, PATT (pattern movement)] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10~50 mA.
~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
16461583|NCT03555474|Active Comparator|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.
~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
16461584|NCT03555448|Active Comparator|Once daily regimen|Once daily medication regimen (Envarsus and azathioprine)
16461585|NCT03555448|Active Comparator|Twice daily regimen|Twice daily medication regimen (Tacrolimus and mycophenolic acid)
16461586|NCT03555435|Experimental|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
16461587|NCT03555435|Experimental|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
16461588|NCT03555435|Placebo Comparator|Wait|Participants in this group will wait 6 weeks.
16461591|NCT03555396|Experimental|Intervention|Subjects will receive an intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
16461592|NCT03555396|Active Comparator|Standard of Care|Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
16461593|NCT03555370|Experimental|Standard of Care Group|"Standard of Care:
~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
16461594|NCT03555370|Experimental|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
16461595|NCT03555357|Active Comparator|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
16461596|NCT03555357|Experimental|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
16461597|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
16461598|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
16461599|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
16461600|NCT03555318|Experimental|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
16461601|NCT03555318|Active Comparator|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
16461602|NCT03555305|Experimental|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
16461603|NCT03555305|Active Comparator|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
16461604|NCT03555292|Experimental|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
16461605|NCT03555292|Experimental|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
16461606|NCT03555292|Experimental|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
16461607|NCT03555292|Experimental|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
16461608|NCT03555292|Experimental|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
16461609|NCT03555279|Experimental|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
16461610|NCT03555279|Experimental|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
16461611|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
16461612|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
16461613|NCT03555253|Experimental|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
16461614|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
16461615|NCT03555227|Active Comparator|Group X|"PECS group
~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
16461616|NCT03555227|Active Comparator|Group Y|"LA (local anaesthetic) infiltration group
~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
16461617|NCT03555214|Experimental|Manual Therapy based on soft tissue|
16461618|NCT03555214|Placebo Comparator|Control Group|
16461619|NCT03555214|Experimental|Manual Therapy based on structural techniques|
16461620|NCT03555214|Experimental|Manual Therapy based on soft tissue and structural techniques|
16461621|NCT03555201|Experimental|Manual therapy|Protocol of soft tissue techniques
16461622|NCT03555201|Active Comparator|Regular treatment control.|Regular treatment control.
16461623|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
16461624|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
16461625|NCT03555175|Other|Group one|This participants group must do eccentric exercise for 12 weeks
16461626|NCT03555175|Other|Group two|This participants group must do proprioception exercise for 12 weeks
16461627|NCT03555175|Other|Group 3|This participants group mustn't do exercise extra
16461628|NCT03555162|Other|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
16461629|NCT03555162|Other|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
16461638|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
16461639|NCT03555123|Experimental|SIMDAX|Levosimendan2.5mg/mL
16461640|NCT03555123|Placebo Comparator|SIMDAX Placebo|Water for injection
16461641|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
16461642|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:
~Three evaluation and preparation sessions,
~Eight EMDR sessions weekly with variable length of 60 minutes and
~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
16461643|NCT03555097|Experimental|COPD Group|incremental pressure support
16461644|NCT03555084|Experimental|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
16461645|NCT03555084|Active Comparator|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
16461646|NCT03555071|Experimental|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.
~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
16461647|NCT03555071|Experimental|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.
~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
16461648|NCT03555071|Experimental|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.
~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
16461649|NCT03555071|Active Comparator|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.
~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
16461650|NCT03555058|Other|High risk- TDM|Treatment escalation per TDM and physician's decision.
16461651|NCT03555058|No Intervention|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
16461652|NCT03555058|No Intervention|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
16461653|NCT03555045|Active Comparator|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
16461654|NCT03555045|Active Comparator|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
16461655|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
16461656|NCT03555019|Experimental|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
16461657|NCT03555019|Active Comparator|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
16461658|NCT03555006|Other|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
16461659|NCT03555006|Other|Local vs local group|The examination will be interpreted by two department's radiologists
16461660|NCT03554993|Experimental|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
16461661|NCT03554993|Experimental|Placebo|Placebo under fasted conditions
16461662|NCT03554993|Experimental|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
16461663|NCT03554980|Experimental|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.
~SDF is a brush-on liquid."
16461664|NCT03554980|Active Comparator|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
16461665|NCT03554941|Experimental|noise stimulation|noise stimulation
16461666|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
16461667|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
16461668|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
16461669|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
16461670|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
16461671|NCT03554889|Experimental|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
16461672|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
16461673|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
16461674|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
16461675|NCT03554863|Active Comparator|Facial mask|
16461676|NCT03554863|Experimental|Optiflow anesthesia|
16461677|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
16461678|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
16461679|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
16461680|NCT03554811|Experimental|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
16461681|NCT03554811|Active Comparator|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
16461682|NCT03554798|Experimental|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.
~6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
16461683|NCT03554798|Experimental|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.
~Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
16461684|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)
~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)
~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
16461685|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)
~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)
~CHC staff leadership key informant interviews (up to 5 at each site)
~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
16461686|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Single dose containing 62.5 mg of celecoxib in 10 ml solution
16461687|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 125 mg|Single dose containing 125 mg of celecoxib in 10 ml solution
16461688|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 250 mg|Single dose containing 250 mg of celecoxib in 10 ml solution
16461689|NCT03554772|Placebo Comparator|Placebo|Single dose containing 0 mg of celecoxib in 10 ml solution
16461690|NCT03554746|Experimental|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
16461691|NCT03554746|Experimental|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
16461692|NCT03554733|Experimental|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
16461693|NCT03554733|No Intervention|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
16461694|NCT03554720|Active Comparator|Standard implants|ATTUNE PS Knee
16461695|NCT03554720|Active Comparator|Enhanced-Fixation|ATTUNE S+ PS Knee
16461696|NCT03554707|Experimental|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.
~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
16461697|NCT03554694|Experimental|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
16461698|NCT03554694|Experimental|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
16461699|NCT03554668||1|Post total knee replacement patients
16461700|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
16461701|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
16461702|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
16461703|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
16461704|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
16461705|NCT03554629|Other|Capnography CO2 Sampling Filterline Performance|Adult volunteer exhaled gas was sampled by 8 different CO2 cannula sampling filterline (CCSF) designs connected to a Capnostream 35 for measurement of CO2 during patient simulated scripted activities in order to assess patient interface design performance to provide a quality gas sample for CO2 partial pressure measurement.
16461706|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
16461707|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
16461708|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
16461709|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
16461710|NCT03554603|Experimental|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
16461711|NCT03554603|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
16461712|NCT03554590|Experimental|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
16461713|NCT03554590|Active Comparator|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
16461714|NCT03554577|Active Comparator|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
16461715|NCT03554577|Experimental|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
16461716|NCT03554577|Experimental|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
16461717|NCT03554577|Experimental|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
16461718|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
16461719|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
16461720|NCT03554551||Patients with Parkinsons disease|Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
16461721|NCT03554551||Healthy controls|50-85 years
16461722|NCT03554538|Experimental|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
16461723|NCT03554538|Active Comparator|Exercises|An evidence based exercise program for the shoulder pain.
16461724|NCT03554525|Experimental|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
16461725|NCT03554525|Placebo Comparator|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
16461726|NCT03554512|No Intervention|Standard of Care|No Intervention
16461727|NCT03554512|Experimental|Telehealth|Telehealth virtual appointment
16461728|NCT03554499|Experimental|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
16461729|NCT03554499|Active Comparator|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
16461730|NCT03554486|Experimental|Fiasp then Novolog|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
16461731|NCT03554486|Experimental|Novolog then Fiasp|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Novolog insulin for 2 weeks, followed by Fiasp insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
16462595|NCT03548428|Experimental|A|SBRT + Atezolizumab
16461735|NCT03554460|Experimental|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
16461736|NCT03554447|Experimental|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
16461737|NCT03554447|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
16461738|NCT03554421|Experimental|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
16461739|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
16461740|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
16461741|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
16461742|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
16461743|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
16461744|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
16461745|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
16461746|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
16461747|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
16461748|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
16461749|NCT03554408|Experimental|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
16461750|NCT03554408|Experimental|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
16461751|NCT03554408|Experimental|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
16461752|NCT03554408|Experimental|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
16461753|NCT03554395|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16461754|NCT03554395|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16461755|NCT03554395|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16461756|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
16461757|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
16461758|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
16461759|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)
16461760|NCT03554330|Active Comparator|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
16461761|NCT03554330|Experimental|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
16461762|NCT03554330|Experimental|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
16461796|NCT03554083|Experimental|Arm B - CLOSED (cobimetinib, atezolizumab)|Patients receive cobimetinib as in Arm A and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16462596|NCT03548428|Active Comparator|B|SBRT
16461763|NCT03554317|Experimental|Bipolar Androgen Therapy + Nivolumab|All participants must have a rising PSA and/or radiographic progression and prior treatment with at least one novel androgen receptor (AR) targeted therapy (i.e. abiraterone acetate, enzalutamide). Up to one taxane agent for metastatic castration-resistant prostate cancer is permitted. Patients will be treated with testosterone cypionate 400mg IM every 4 weeks for a lead-in period of 12 weeks. After the lead-in period, all patients will be treated with nivolumab 480mg IV every 4 weeks and maintained on testosterone cypionate 400mg IM every 4 weeks. Treatment [with a minimum drug exposure of 12 weeks] will be continued until PSA progression (PCGW3 criteria) or clinical/radiographic progression (whichever comes first), or until unmanageable toxicity requiring drug cessation.
16461764|NCT03554304|Experimental|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
16461765|NCT03554304|Placebo Comparator|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
16461766|NCT03554304|Active Comparator|Moxifloxacin 400-mg|positive control
16461767|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily
~Other names: Pepcid"
16461768|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
16461769|NCT03554278||Anemia|Stool samples from infants with anemia. Severe anemia defined as hematocrit less than 25%. Anemia defined as hematocrit greater than or equal to 25% and less than 30%.
16461770|NCT03554278||No Anemia|Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
16461771|NCT03554265|Experimental|mTBI subjects|"mTBI subjects will receive recombinant human growth hormone replacement therapy daily for 6 months.
~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin
~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 6 will be dosed at 0.6 mg / day"
16461772|NCT03554265|No Intervention|Household Control Subjects|household control subjects will not receive any intervention.
16461773|NCT03554252|Experimental|Frequencies|
16461774|NCT03554252|Experimental|Percentages|
16461775|NCT03554239|Other|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
16461776|NCT03554226|Experimental|AD Patients with NeuroPsychiatric Inventory Clinician (NPI-C)|The investigation aims to study the natural evolution of type A / A SPCDs in patients with AD. In this study, patients will receive optimized management based on existing best practice recommendations (HAS Recommendations 2009). It will therefore be a standard care study, since this survey applies the current recommendations on tools for the evaluation of SPCDs and the management of behavioral disorders in Alzheimer's disease (Recommendations HAS 2009).
16461777|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
16461778|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
16461779|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
16461780|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
16461781|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)
~Interventions :
~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
16461782|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)
~Intervention(s) :
~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
16461783|NCT03554174|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
16461784|NCT03554174|Experimental|Placebo/Medium Dose Psilocybin|Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
16461785|NCT03554174|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
16461786|NCT03554174|Experimental|Medium Dose Psilocybin/Placebo|Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
16461787|NCT03554161|Experimental|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
16461788|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
16461789|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
16461790|NCT03554122|Active Comparator|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
16461791|NCT03554122|Placebo Comparator|Placebo Group|Patients spinal injections were performed without Shotblocker
16461792|NCT03554109|Experimental|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine
~A combination of agents will be administered to subjects in this study:
~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
16461793|NCT03554109|Active Comparator|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
16461794|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
16461795|NCT03554083|Experimental|Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab)|"Patients receive vemurafenib PO BID on days 1-28 and cobimetinib PO QD on days 1-21. Patients also receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15 of cycles 2 and 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
16461797|NCT03554083|Experimental|Arm C (atezolizumab, tiragolumab)|"Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
16461798|NCT03554070|Experimental|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS > 20, Qmax < 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
16461799|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
16461800|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
16461801|NCT03554044|Experimental|Cohort I (talimogene laherparepvec, chemotherapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with one of the following chemotherapies: paclitaxel (IV), nab-paclitaxel IV, or gemcitabine / carboplatin IV.
~Cycles repeat every 21 days until disease progression or unacceptable toxicity"
16461802|NCT03554044|Experimental|Cohort II (talimogene laherparepvec, endocrine therapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-21 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.
~Cycles repeat every 28 days until disease progression or unacceptable toxicity"
16461803|NCT03554031|Experimental|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
16461804|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
16461805|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
16461806|NCT03554005|Experimental|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
16461807|NCT03554005|Experimental|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
16461808|NCT03554005|Experimental|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
16461809|NCT03554005|Experimental|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
16461810|NCT03554005|Experimental|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
16461811|NCT03554005|Experimental|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
16461812|NCT03553992|Experimental|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
16461813|NCT03553992|Experimental|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
16461814|NCT03553979|Experimental|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
16461815|NCT03553979|Experimental|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
16461849|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
16463088|NCT03545230|Experimental|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
16461816|NCT03553979|No Intervention|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
16461817|NCT03553966|Experimental|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).
~Procedure: Tooth Brushing HA"
16461818|NCT03553966|Active Comparator|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).
~Intervention:
~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
16461819|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
16461822|NCT03553927|Other|Low Energy Diet|Commercially available diet products
16461823|NCT03553927|Other|NHS advice on healthy eating|Dietary / lifestyle advice programme
16461824|NCT03553914|Experimental|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m^2 dose.
16461825|NCT03553914|Experimental|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m^2 dose.
16461826|NCT03553914|Experimental|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m^2 dose.
16461827|NCT03553901|Experimental|Acupressure|Acupressure is applied before injection
16461828|NCT03553901|No Intervention|Control group|acupressure is not applied before injection
16461829|NCT03553888||HS patient|patients with HS
16461830|NCT03553888||no HS patients|patients without HS
16461831|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
16461832|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
16461833|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
16461834|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
16461835|NCT03553849|Experimental|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
16461836|NCT03553849|No Intervention|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
16461837|NCT03553836|Experimental|Pembrolizumab|Pediatric participants receive 2 mg/kg (200 mg maximum) pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Adult participants receive 200 mg pembrolizumab by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of pembrolizumab and experience disease recurrence may be eligible to receive additional cycles of pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for unresectable disease recurrence. Participants with distant metastasis who undergo complete resection will receive 17 cycles (up to ~1 year) of pembrolizumab but can receive up to 35 cycles (up to ~2 years) of pembrolizumab under certain circumstances.
16461838|NCT03553836|Placebo Comparator|Placebo|Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of placebo and experience disease recurrence may be eligible to receive pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for disease that cannot be resected or metastatic disease.
16461839|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
16461840|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
16461841|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
16461842|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
16461843|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
16461844|NCT03553784|No Intervention|Control Group|No intervention.
16461845|NCT03553758|Experimental|Ketamine|15 subjects undergoing ketamine general anesthesia.
16461846|NCT03553745|Experimental|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
16461847|NCT03553745|Experimental|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
16461848|NCT03553745|Experimental|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
16461850|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
16461851|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.
~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
16461852|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
16461853|NCT03553693|Experimental|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
16461854|NCT03553693|No Intervention|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
16461855|NCT03553680|Experimental|Emotion-Focused CBT|Ten CBT sessions with a therapist.
16461856|NCT03553680|No Intervention|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
16461857|NCT03553667|Active Comparator|Standard group|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
16461858|NCT03553667|Experimental|ClearSight|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
16461859|NCT03553654|Experimental|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
16461860|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
16461861|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
16461862|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
16461863|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
16461864|NCT03553615|Experimental|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
16461865|NCT03553602|Experimental|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.
~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.
~6 months hormonal therapy(LHRH agonist and antiandrogen [until the end of radiotherapy])"
16461866|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
16461867|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
16461868|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
16461869|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
16461870|NCT03553563|Experimental|Group1|Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
16461871|NCT03553563|Experimental|Group2|Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
16461872|NCT03553563|Experimental|Group3|D961H 10 mg once-daily (32 or 52 weeks)
16461873|NCT03553563|Experimental|Group4|D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
16461874|NCT03553537|Experimental|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
16461875|NCT03553537|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
16461876|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.
~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
16461877|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.
~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
16461878|NCT03553511|Experimental|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
16461879|NCT03553511|Active Comparator|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
16461880|NCT03553498|Experimental|IV Acetaminophen|1000 mg IV acetaminophen administered over 5-10 minutes
16461881|NCT03553498|Placebo Comparator|IV hydromorphone and placebo|100 ml IV normal saline administered over 5-10 minutes
16461882|NCT03553485|Experimental|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
16461883|NCT03553485|Sham Comparator|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
16461884|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
16461885|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
16461886|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
16461887|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
16461888|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.
~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
16461889|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
16461890|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
16461891|NCT03553459|Experimental|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
16461892|NCT03553446|Experimental|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
16461893|NCT03553433|Experimental|Verum|Apremilast 30mg bd
16461894|NCT03553433|Placebo Comparator|Placebo Oral Tablet|Excipiens
16461895|NCT03553407|Experimental|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
16461896|NCT03553407|Experimental|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
16461897|NCT03553407|Placebo Comparator|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
16461898|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
16461899|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
16461900|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
16461901|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
16461902|NCT03553368|Experimental|Step 1: Healthy volunteers|"Experimental intervention:
~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).
~Control intervention:
~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
16461903|NCT03553368|Experimental|Step 2: Patients (arm A)|"Experimental intervention:
~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).
~Control intervention:
~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
16461904|NCT03553368|Experimental|Step 2: Patients (arm B)|"Experimental intervention:
~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).
~Control intervention:
~Data from the clinically indicated PET/CT acquisition will be used as reference.
~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
16461905|NCT03553368|Experimental|Step 1 bis: Healthy volunteers|"Experimental intervention:
~MRI data will be acquired with the use of CPAP (CPAP-MR).
~Control intervention:
~MRI data will be acquired without the use of CPAP, as a reference (MR)."
16461906|NCT03553355|Experimental|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
16461907|NCT03553355|Sham Comparator|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
16461908|NCT03553355|No Intervention|Waitlist Controls|The patients maintain their usual treatment and self-care,
16461909|NCT03553342|Experimental|Corticoids|
16461910|NCT03553342|Placebo Comparator|Placebo|
16461911|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24
~Wash out Period: over 7 days (between each period)
~Investigators Products(IPs) for Period1: A (Single)= PK101-002
~IPs for Period2: B (Combination)= PK101-001, PK101-002"
16461912|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24
~Wash out Period: over 7 days (between each period)
~IPs for Period1: B (Combination)= PK101-001, PK101-002
~IPs for Period2: A (Single)= PK101-002"
16461913|NCT03553303|Experimental|Intervention|Increasing doses of Sacubitril/Valsartan
16461914|NCT03553290|Sham Comparator|control|Mechanical debridement alone
16461915|NCT03553290|Active Comparator|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy
~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
16461916|NCT03553277|Experimental|Transfluthrin|transfluthrin
16461917|NCT03553277|Placebo Comparator|Placebo|inert ingredients
16461918|NCT03553264|Experimental|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
16461947|NCT03553043|Experimental|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
16461948|NCT03553043|Placebo Comparator|Unlabelled|Alcohol beverage displayed unlabelled.
16461949|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
16461950|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
16463089|NCT03545217|Experimental|intervention group|
16461919|NCT03553264|Active Comparator|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
16461920|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
16461921|NCT03553225|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
16461922|NCT03553225|Active Comparator|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
16461923|NCT03553225|Active Comparator|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
16461924|NCT03553212|Experimental|High dose external beam Radiotherapy|Image-guided tomotherapy
16461925|NCT03553199|Experimental|TRS|TRS, Tissue resection system
16461926|NCT03553186|Experimental|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
16461927|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
16461928|NCT03553173|Active Comparator|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.
~Prescribed treatments:
~Bupropion pills + Psychological advice
~Varenicline pills + Psychological advice"
16461929|NCT03553173|Experimental|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.
~Prescribed treatments:
~Bupropion pills + Psychological advice + So-Lo-Mo
~Varenicline pills + Psychological advice + So-Lo-Mo"
16461930|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
16461931|NCT03553147|Experimental|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
16461932|NCT03553121|Active Comparator|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
16461933|NCT03553121|Active Comparator|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
16461934|NCT03553108|Experimental|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
16461935|NCT03553108|Experimental|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
16461936|NCT03553108|Experimental|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
16461937|NCT03553108|Experimental|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
16461938|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
16461939|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
16461940|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
16461941|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
16461942|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
16461943|NCT03553056|Experimental|Intervention|NZ Step Away app
16461944|NCT03553056|Active Comparator|Control|Modified NZ Step Away app
16461945|NCT03553043|Experimental|Energy Label 1|Alcoholic beverage displayed with Energy label 1
16461946|NCT03553043|Experimental|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
16461951|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
16461952|NCT03553004|Experimental|Niraparib Treatment|"Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)
~(Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL))."
16461953|NCT03552991|Other|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
16461954|NCT03552978|Experimental|Tech-facilitated IC intervention|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.
~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.
~Receive 8 video or telephone counseling sessions for smoking cessation. The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min.
~Be asked to use the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation.
~Be asked to use the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The Covita mobile app (compatible with iOS and Android) is used with the iCO Smokerlyzer to display CO readings."
16461955|NCT03552978|Active Comparator|Treatment as usual (VA Quitline)|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.
~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.
~Receive weekly proactive telephone sessions through the VA telephone Quitline, a proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor."
16461956|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
16461957|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
16461958|NCT03552952||Preterm infants|100 preterm infants
16461959|NCT03552952||Term infants|100 term healthy infants
16461960|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
16461961|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
16461962|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
16461963|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
16461964|NCT03552900|Active Comparator|App 1 Study group (7cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7cups) which allows participants access to direct online social support via the app."
16461965|NCT03552900|Active Comparator|App 2 Study Group (Bliss|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app ( Bliss ) which provides participants an informational app about mental health resources at Harvard."
16461966|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
16461967|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
16461968|NCT03552874||Healthy Group|Healthy peers
16461969|NCT03552861|Active Comparator|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
16461970|NCT03552861|Active Comparator|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
16461971|NCT03552861|Active Comparator|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
16461972|NCT03552861|Sham Comparator|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
16463090|NCT03545217|No Intervention|control group|
16461973|NCT03552848|Experimental|Mesenchymal stem cell|Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
16461974|NCT03552848|No Intervention|Control|Patients in the control arm will not be given MSC.
16461975|NCT03552835|Experimental|no caries removal|mandibular occlusal caries were treated with placement of stainless steel crown with no caries removal
16461976|NCT03552835|Experimental|partial caries removal upto soft dentin|mandibular occlusal caries were treated by partial caries removal upto soft dentin
16461977|NCT03552835|Experimental|partial caries removal upto firm dentin|mandibular occlusal caries were treated by partial caries removal upto firm dentin
16461978|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
16461979|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
16461980|NCT03552809|Active Comparator|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
16461981|NCT03552809|Experimental|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
16461982|NCT03552809|Experimental|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
16461984|NCT03552783|Active Comparator|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
16461985|NCT03552783|Experimental|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
16461986|NCT03552770|Active Comparator|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
16461987|NCT03552770|Active Comparator|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
16461988|NCT03552757|Experimental|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
16461989|NCT03552757|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
16461990|NCT03552757|Placebo Comparator|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
16461991|NCT03552744|Experimental|Intervention group|
16461992|NCT03552744|No Intervention|Control group|
16461993|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
16461994|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
16461995|NCT03552718|Experimental|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
16461996|NCT03552705|Experimental|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
16461997|NCT03552705|Placebo Comparator|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
16461998|NCT03552692|Experimental|ARM1 - Venetoclax (ABT-199)|"Venetoclax (ABT-199) will be administered orally at the dose of 800 mg once daily.
~Response evaluation will be performed initially after 3 cycles from the beginning of treatment with ABT-199 and then every 3 cycles during the first 12 cycles, every 4 cycles from cycle 13 to 24; for those patients still on therapy after 24 cycles, the response evaluation, after this time, will be performed every 6 cycles."
16462036|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
16463146|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
16461999|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
16462000|NCT03552666|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
16462001|NCT03552666|Active Comparator|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
16462002|NCT03552653|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
16462003|NCT03552653|Active Comparator|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
16462004|NCT03552627|Active Comparator|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
16462005|NCT03552627|Active Comparator|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
16462006|NCT03552627|Experimental|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
16462007|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
16462008|NCT03552601|Other|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
16462009|NCT03552601|Other|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
16462010|NCT03552575|Experimental|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
16462011|NCT03552575|Experimental|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
16462012|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
16462013|NCT03552562|Other|30 patients with mild diabetic retinopathy|
16462014|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
16462015|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
16462016|NCT03552549|Experimental|PEG-Intron|Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
16462017|NCT03552549|Experimental|INTRON A|Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks post-surgery.
16462018|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
16462019|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
16462020|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
16462021|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
16462022|NCT03552523|Experimental|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
16462023|NCT03552510|Active Comparator|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.
~Then, infants will receive regular gavage feeding only for the next 24 hours."
16462024|NCT03552510|Active Comparator|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.
~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
16462025|NCT03552484|Active Comparator|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.
~[Completion of Home Visit Program]"
16462026|NCT03552484|Active Comparator|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.
~[Completion of Usual Care/Online Survey]"
16462027|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16462028|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
16462029|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
16462030|NCT03552445|Active Comparator|Tetanus-diphtheria (Td) and PCV13|
16462031|NCT03552445|Active Comparator|PCV13 alone|
16462032|NCT03552445|Active Comparator|Td alone|
16462033|NCT03552432|Experimental|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
16462034|NCT03552432|No Intervention|standard statin therapy group|start with only rosuvastatin 10mg per day
16462035|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
16462131|NCT03551769|Experimental|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
16462037|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
16462038|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
16462039|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
16462040|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
16462041|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
16462042|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
16462043|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
16462044|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 1: Monotherapy)|ISU104 20 mg/kg to be administered every three weeks (Q3W) as monotherapy
16462045|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 2: Combination therapy)|ISU104 20 mg/kg (or decreased dose) Q3W in combination with cetuximab* 250 mg/m2 QW (*Initial dose: 400 mg/m2)
16462047|NCT03552380|Experimental|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1
~Each cycle is 21 days"
16462048|NCT03552367|Experimental|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.
~Intervention: Non-personalized non-structured exercise"
16462049|NCT03552367|Active Comparator|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
16462050|NCT03552354|Experimental|Argatroban combined with antiplatelet|
16462051|NCT03552328|Experimental|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
16462052|NCT03552328|Placebo Comparator|Control|Seniors receiving daily meals from Meals on Wheels
16462053|NCT03552315|Active Comparator|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
16462054|NCT03552315|Placebo Comparator|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
16462055|NCT03552302||Cases|Yoga exercise for 12 weeks
16462056|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
16462057|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
16462058|NCT03552276|Experimental|SUNPG18_07 q4 weeks, high dose|
16462059|NCT03552276|Experimental|SUNPG18_07 q12 weeks, high dose|
16462060|NCT03552276|Experimental|SUNPG18_07 q12 weeks, low dose|
16462061|NCT03552263|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.
~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
16462062|NCT03552263|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.
~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
16462063|NCT03552263|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
16462064|NCT03552250|Other|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
16462065|NCT03552237|Experimental|dietary fiber intervention group|
16462066|NCT03552224|Experimental|Subjects with no hearing loss|Subjects referred for cerebellopontine angle surgery with no hearing loss with recording of auditory nerve activity by contact electrode
16462067|NCT03552224|Experimental|Subjects with hearing loss|Subjects referred for cerebellopontine angle surgery with hearing loss with recording of auditory nerve activity by contact electrode
16462068|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
16462069|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
16463147|NCT03544801||control group,100|community population
16462074|NCT03552172||Prescription physical activity|
16462075|NCT03552172||No prescription for physical activity or suspension|
16462076|NCT03552159|Experimental|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
16462077|NCT03552159|Active Comparator|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
16462078|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
16462079|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
16462080|NCT03552133|Experimental|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
16462081|NCT03552133|No Intervention|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
16462082|NCT03552120|Experimental|Mindfulness-Oriented Recovery Enhancement|
16462083|NCT03552120|Active Comparator|Supportive Psychotherapy|
16462084|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
16462085|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
~Blood bag (volume of blood: from 450 to 500 mL)."
16462086|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
16462087|NCT03552081|Experimental|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
16462088|NCT03552068|Placebo Comparator|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
16462089|NCT03552068|Active Comparator|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
16462090|NCT03552042|Experimental|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
16462091|NCT03552042|Active Comparator|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
16462092|NCT03552042|No Intervention|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
16462093|NCT03552029|Experimental|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
16462094|NCT03552029|Experimental|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
16462095|NCT03552029|Experimental|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
16462096|NCT03552016|Experimental|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
16462097|NCT03552016|Experimental|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
16462098|NCT03552016|Placebo Comparator|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
16462099|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
16462100|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
16462101|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
16462102|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
16462103|NCT03551977|Experimental|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
16462104|NCT03551977|Active Comparator|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
16462105|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
16462106|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
16462107|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
16462108|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.
~Lung cancer screening subjects"
16462109|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
16462110|NCT03551938|No Intervention|Control|Receive only the standard HIV Counseling, Testing, and Referral or Couples HIV Testing and Counseling (CHTC) Session.
16462111|NCT03551938|Experimental|Intervention|Receive one 45-minute Relationship skills session for YMSM individuals and couples (the intervention) as an addition to the standard HIV Counseling, Testing, and Referral (CTR) or Couples HIV Testing and Counseling (CHTC) Session.
16462112|NCT03551925|Experimental|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
16462113|NCT03551925|Active Comparator|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
16462114|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
16462115|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
16462116|NCT03551860|Experimental|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
16462117|NCT03551860|Active Comparator|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
16462118|NCT03551847|Experimental|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
16462119|NCT03551847|Active Comparator|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
16462120|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
16462121|NCT03551834|Active Comparator|Using short tunnel small flap technique|
16462122|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
16462123|NCT03551808|Active Comparator|installation of Ketorolac Tromethamine Eye Drop|
16462124|NCT03551808|No Intervention|not receiving placebo|
16462125|NCT03551795|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells.
16462126|NCT03551782|Experimental|Cohort 1|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer [t-SCNC]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
16462127|NCT03551782|Experimental|Cohort 2|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.
16462128|NCT03551782|Experimental|Cohort 3|Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
16462129|NCT03551782|Experimental|Cohort 4|Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
16462130|NCT03551782|Experimental|Cohort 5|Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
16463148|NCT03544788|Experimental|Cirvo™ Therapy|
16462132|NCT03551769|Experimental|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
16462133|NCT03551769|Experimental|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
16462134|NCT03551769|Experimental|Cohort 1, Period 4|Study drug administered after an overnight fast
16462135|NCT03551769|Experimental|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
16462136|NCT03551769|Experimental|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
16462137|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
16462138|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
16462139|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
16462140|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
16462141|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
16462142|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
16462143|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
16462144|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
16462145|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
16462146|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
16462147|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
16462148|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.
~The age balance of the patients included in the two groups will be checked regularly."
16462149|NCT03551704|Active Comparator|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.
~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
16462150|NCT03551704|Experimental|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
16462151|NCT03551691|Active Comparator|Treatment Arm|Subjects will take omeprazole 40mg daily for 28 days, then undergo assessments of fat absorption.
16462152|NCT03551691|Placebo Comparator|Placebo Arm|Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
16462153|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
16462154|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
16462155|NCT03551652||Young patients|Patients aged 18 - 50 years
16462156|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
16462157|NCT03551626|Experimental|Dabrafenib and trametinib combination therapy|Subjects will receive dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
16462158|NCT03551613|Active Comparator|honey group|malnourished children supplemented with honey in dose of 2ml/kg
16462159|NCT03551613|Placebo Comparator|malnourished control group|no honey supplementation only nutrition rehabilitation
16462160|NCT03551613|No Intervention|healthy children|healthy children with no suplementation
16462161|NCT03551600||Preterm, no PDA|"Babies </= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA
~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
16462162|NCT03551600||Preterm, moderate to large PDA|Babies </= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
16462163|NCT03551600||>/= 34 wk infants, no CHD|"Babies >/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)
~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
16462164|NCT03551600||>/= 34 week infants, CHD|"Babies >/= to 34 weeks gestation at birth with ductal dependent CHD
~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
16462165|NCT03551587|Experimental|Irrigant delivered by the Vibringe|"Experimental group:
~The irrigant will be delivered and sonically activated with the Vibringe system."
16462166|NCT03551587|No Intervention|Irrigation by Conventional needle|"Control group:
~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
16462167|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
16462220|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
16462168|NCT03551561|Active Comparator|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
16462169|NCT03551561|Active Comparator|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
16462170|NCT03551548|Placebo Comparator|Reference treatment|
16462171|NCT03551548|Experimental|experimental treatment|Spironolactone 25 mg
16462172|NCT03551535|Experimental|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
16462173|NCT03551535|No Intervention|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
16462174|NCT03551522|Experimental|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
16462175|NCT03551522|Experimental|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
16462176|NCT03551522|Experimental|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
16462177|NCT03551522|Placebo Comparator|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
16462178|NCT03551509|No Intervention|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
16462179|NCT03551509|Active Comparator|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
16462180|NCT03551509|Other|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
16462181|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
16462182|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
16462183|NCT03551483|Experimental|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
16462184|NCT03551483|Active Comparator|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
16462185|NCT03551483|Other|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
16462186|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
16462187|NCT03551444|Active Comparator|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:
~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.
~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
16462188|NCT03551444|Experimental|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
16462189|NCT03551431|Experimental|Video EEG with verbal suggestion|
16462190|NCT03551431|Experimental|video EEG with verbal suggestion and tuning fork|
16462191|NCT03551431|Experimental|video EEG with verbal suggestion and cotton swab|
16462192|NCT03551418|Experimental|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
16462193|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.
~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
16462194|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
16462195|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
16462196|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
16462197|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
16462198|NCT03551379||Endoscopic procedure|A double balloon endoscopic platform will be used during an ESD procedure
16462199|NCT03551366|No Intervention|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
16462221|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
16462200|NCT03551366|Experimental|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
16462201|NCT03551366|Experimental|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
16462202|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
16462203|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
16462204|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
16462205|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
16462206|NCT03551327|Experimental|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
16462207|NCT03551327|Other|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
16462208|NCT03551314|Active Comparator|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.
~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
16462209|NCT03551314|Active Comparator|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.
~CPAP: Continuous Positive Airway Pressure"
16462210|NCT03551288|Experimental|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
16462211|NCT03551288|Experimental|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
16462212|NCT03551288|Experimental|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
16462213|NCT03551275|Experimental|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.
~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.
~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
16462214|NCT03551275|Experimental|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.
~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.
~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
16462215|NCT03551275|Experimental|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.
~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.
~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
16462216|NCT03551275|Experimental|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.
~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
16462217|NCT03551262|Experimental|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
16462218|NCT03551262|Active Comparator|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
16462219|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
16462222|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.
~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
16462223|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.
~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
16462224|NCT03551197|Experimental|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
16462225|NCT03551184|Active Comparator|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
16462226|NCT03551184|Placebo Comparator|Placebo|Saline injection
16462227|NCT03551171|Experimental|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
16462228|NCT03551158|Other|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
16462229|NCT03551145|Experimental|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
16462230|NCT03551145|Active Comparator|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
16462231|NCT03551132|Experimental|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).
~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
16462232|NCT03551132|No Intervention|Group 2|Control group The CG not participated in the RTC program.
16462233|NCT03551119|Experimental|Exercise|"Personnel experienced in training people with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be prescribed based on the most recent exercise test.
~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.
~Phase 2: a 16-week home-based exercise program overseen by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.
~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.
~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
16462234|NCT03551119|Other|Enhanced usual care|Participants in the control group will perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
16462235|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
16462236|NCT03551093|Experimental|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
16462237|NCT03551080|Active Comparator|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
16462238|NCT03551080|Placebo Comparator|Placebo|Saline injection
16462239|NCT03551067|Active Comparator|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
16462240|NCT03551067|Active Comparator|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
16462241|NCT03551054|Experimental|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
16462242|NCT03551054|Active Comparator|Pregnancy Health Education|Single health education visit with study staff member
16462243|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
16462244|NCT03551015|Experimental|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
16462245|NCT03551015|No Intervention|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
16462246|NCT03551002||Retrospective|
16462247|NCT03551002||Prospective|
16462248|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.
~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.
~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
16462597|NCT03548415|Experimental|IONIS-GHR-LRx|Single Dose of IONIS GHR-LRx administered subcutaneously once every 28 days for 16 weeks
16462249|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.
~Used at least 100 cigarettes
~Smokes cigarettes daily > 1/day
~Uses IQOS less than daily
~Uses less than 30 HeatSticks/month
~Cigarette is > 95% of tobacco/nicotine product (all product use)"
16462250|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.
~Used at least 100 HeatSticks
~Uses IQOS daily > 1/day
~Smokes a cigarette less than daily
~Smokes less than 30 cigarettes/month
~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
16462251|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.
~Used at least 100 HeatSticks
~Uses IQOS daily > 1/day
~Smokes a cigarette less than daily
~Smokes less than 30 cigarettes/month
~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
16462252|NCT03550976|Experimental|High risk intervention group|
16462253|NCT03550976|No Intervention|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
16462254|NCT03550976|No Intervention|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
16462255|NCT03550963|Other|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
16462256|NCT03550963|Other|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
16462257|NCT03550950|Experimental|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
16462258|NCT03550950|Experimental|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
16462259|NCT03550924|Active Comparator|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
16462260|NCT03550924|Experimental|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
16462261|NCT03550898|Other|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
16462262|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
16462263|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
16462264|NCT03550872|No Intervention|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
16462265|NCT03550872|Experimental|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
16462266|NCT03550859|Experimental|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
16462267|NCT03550859|Active Comparator|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
16462268|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
16462269|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)
16462270|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
16462271|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
16462272|NCT03550781|Experimental|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
16462273|NCT03550781|No Intervention|Control group|No intervention
16462274|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
16462275|NCT03550755|Experimental|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
16462276|NCT03550742|Experimental|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
16462277|NCT03550729|Experimental|Training|12-weeks of supervised endurance training program.
16462278|NCT03550716|Active Comparator|mTESE|Patients randomized to mTESE
16462279|NCT03550716|Active Comparator|TESA|Patients randomized to TESA
16462280|NCT03550703|Experimental|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
16462281|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
16462282|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
16462351|NCT03550209|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
16463201|NCT03544359|Active Comparator|Active tES|
16462283|NCT03550677|Experimental|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
16462284|NCT03550677|Experimental|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
16462285|NCT03550664|Experimental|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
16462286|NCT03550651|Experimental|Licorice extract mouthrinse|10ml twice a day for 4 Days.
16462287|NCT03550651|Experimental|Hypertonic salt solution|10ml twice a day for 4 Days.
16462288|NCT03550651|Active Comparator|Essential oil mouthrinse|10ml twice a day for 4 Days.
16462289|NCT03550651|Active Comparator|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
16462290|NCT03550651|Placebo Comparator|Distilled water|10ml twice a day for 4 Days.
16462291|NCT03550638|Experimental|group A|Coil system(Ton-bridgeMT)
16462292|NCT03550638|Active Comparator|group B|Axium Detachable Coil(Medtronic)
16462293|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
16462294|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
16462295|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
16462296|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
16462297|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
16462298|NCT03550573|Experimental|hypertrophic cardiomyopathy without sudden death history|
16462299|NCT03550573|Experimental|hypertrophic cardiomyopathy with sudden death history|
16462300|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
16462301|NCT03550547|Experimental|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :
~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
16462302|NCT03550547|Active Comparator|spa therapy|Approved Spa therapy
16462303|NCT03550534|Experimental|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
16462304|NCT03550534|Placebo Comparator|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
16462305|NCT03550521|Experimental|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
16462306|NCT03550521|No Intervention|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
16462307|NCT03550508|Experimental|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
16462308|NCT03550495|No Intervention|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
16462309|NCT03550495|Experimental|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
16462310|NCT03550482|Experimental|Oncoxin®|
16462311|NCT03550482|No Intervention|Control|
16462312|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
16462313|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
16462352|NCT03550183|Experimental|mesenchymal stem cells|Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
16462353|NCT03550170|Active Comparator|Teleconference|Teleconference Intervention arm
16462354|NCT03550170|Active Comparator|Internet|Internet Intervention arm
16462314|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).
~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).
~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.
~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.
~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
16462315|NCT03550443|Experimental|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
16462316|NCT03550443|Placebo Comparator|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
16462317|NCT03550430|Experimental|ADR neurofeedback|Ten ADR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions consists of five training blocks each. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
16462318|NCT03550430|Active Comparator|BTR neurofeedback|Ten BTR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions each consists of five training blocks. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
16462319|NCT03550430|Active Comparator|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
16462320|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
16462321|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011, 2013 cohorts & July16/June17.
16462322|NCT03550417||July2016/Jun17 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010 & 2014. Comparison of 2011, 2013 cohorts & July16/June17.
16462323|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
16462324|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
16462325|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
16462326|NCT03550391|Experimental|Hippocampal-avoidant (HA-WBRT) plus Memantine|WBRT 30Gy in 10 fractions + memantine
16462327|NCT03550391|Experimental|Stereotactic Radiosurgery (SRS)|SRS 18-20 or 22Gy in single fraction
16462328|NCT03550378|Experimental|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
16462329|NCT03550378|Placebo Comparator|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
16462330|NCT03550365|Experimental|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
16462331|NCT03550365|Experimental|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
16462332|NCT03550365|Active Comparator|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
16462333|NCT03550352|Experimental|1) THC and CBD combined|TN-TC11M2 oral capsules (THC 2.5 mg / CBD 2.5 mg)
16462334|NCT03550352|Experimental|2) CBD alone|TN-C200M2 oral capsules (CBD 200 mg)
16462335|NCT03550339|Active Comparator|SURG|subjects attending bariatric surgery
16462336|NCT03550339|Active Comparator|DIET|subjects attending dietary weight loss program
16462337|NCT03550339|Active Comparator|HAES|subjects attending Health At Every Size weight management program
16462338|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
16462339|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
16462340|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
16462341|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
16462342|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
16462343|NCT03550300||Control participants|Control participants
16462344|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
16462345|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
16462346|NCT03550274|Experimental|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
16462347|NCT03550248|Other|Intervention group|Participants will receive the intervention - Healthy Together (HT).
16462348|NCT03550209|Experimental|LCPUFA Oil Supplement, Low Dose|25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
16462349|NCT03550209|Experimental|LCPUFA Oil Supplement, Medium Dose|50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
16462350|NCT03550209|Experimental|LCPUFA Oil Supplement, High Dose|75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
16462356|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
16462357|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
16462358|NCT03550131|Active Comparator|Standard intervention|"Reducing Disabilities in Alzheimer's Disease (RDAD):
~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
16462359|NCT03550131|Experimental|Personalized intervention|"Innovations in Dementia Empowerment and Action (IDEA):
~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
16462360|NCT03550118|Experimental|Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
16462361|NCT03550118|Experimental|Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
16462362|NCT03550118|Experimental|Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
16462363|NCT03550118|Experimental|Stress-Sensing Liner|An adjustable socket is tested in addition to a prosthetic liner with embedded stress sensors to measure mechanical stresses as the socket is adjusted.
16462364|NCT03550118|Experimental|Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
16462365|NCT03550118|Experimental|Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
16462366|NCT03550105|Experimental|GJ-Only|Study Subjects with Baseline Glucose of > 150mg/dl, will have Gentle Jogger Only for 7 days
16462367|NCT03550105|Experimental|GJ-OGTT|Study Subjects with Baseline Glucose of < 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
16462368|NCT03550092|Experimental|Aphasia|Abstract Semantic Association Network Training (AbSANT) Each session will be 2 hours long and will occur twice each week for a total of 20 sessions.
16462369|NCT03550079|Experimental|three screws fixation|femoral neck fractures were fixed with three converted screws
16462370|NCT03550079|Experimental|four screws fixation|femoral neck fractures were fixed with four screws
16462371|NCT03550066|Experimental|Values affirmation|In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.
16462372|NCT03550066|Active Comparator|No affirmation|"In the no affirmation condition, the health outreach message appeared alone, with no values affirmation."
16462373|NCT03550053|Active Comparator|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
16462374|NCT03550053|Active Comparator|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
16462375|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
16462376|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
16462377|NCT03550027|Experimental|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
16462378|NCT03550027|Experimental|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
16462379|NCT03550014|Active Comparator|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
16462380|NCT03550014|Active Comparator|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
16462381|NCT03550001|Experimental|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
16462382|NCT03550001|No Intervention|No injection|Do not inject carbon nanoparticle during the treatment.
16462383|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.
~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
16462384|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.
~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
16462385|NCT03549975|Experimental|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
16462386|NCT03549936|Active Comparator|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
16462387|NCT03549936|Active Comparator|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
16462388|NCT03549923|Experimental|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
16462389|NCT03549923|Experimental|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (> 6.5 mmol/L), metabolic acidosis (pH < 7.2), pulmonary edema, blood urea nitrogen level >112 mg/dL, or oliguria (urine output < 200 mL/12 h) for more than 72 hours.
16462390|NCT03549923|Experimental|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
16462391|NCT03549923|Experimental|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
16462392|NCT03549910|Experimental|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
16462393|NCT03549910|Other|Low tidal volume ventilation|Low tidal volume lung protective ventilation
16462394|NCT03549897|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
16462395|NCT03549897|Active Comparator|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
16462396|NCT03549897|Active Comparator|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
16462397|NCT03549897|Experimental|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
16462398|NCT03549884|Experimental|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
16462399|NCT03549884|Active Comparator|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
16462400|NCT03549871|Experimental|Fitusiran|Fitusiran sub-cutaneous injection for 7 months
16462401|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
16462402|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
16462403|NCT03549832|Active Comparator|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
16462404|NCT03549832|Active Comparator|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
16462405|NCT03549819|Experimental|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
16462406|NCT03549819|Placebo Comparator|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
16462407|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
16462408|NCT03549793|Experimental|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
16462409|NCT03549793|Active Comparator|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
16462410|NCT03549780|Other|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
16462411|NCT03549767|Experimental|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
16462412|NCT03549767|Active Comparator|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
16462413|NCT03549741|Experimental|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
16462414|NCT03549741|Active Comparator|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
16462415|NCT03549728|Experimental|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
16462416|NCT03549728|Placebo Comparator|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
16462419|NCT03549702|Active Comparator|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
16462420|NCT03549702|No Intervention|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
16462421|NCT03549689|Experimental|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
16462422|NCT03549689|Active Comparator|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
16462423|NCT03549676|Experimental|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
16462424|NCT03549663|Experimental|Tacrolimus monotherapy|
16462425|NCT03549663|Active Comparator|Tacrolimus combined with hormone therapy|
16462426|NCT03549650|Experimental|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
16462427|NCT03549650|Placebo Comparator|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
16462428|NCT03549637|Experimental|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).
~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.
~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
16462429|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.
~Patients will be treated with an perioperative regime/protocol consisting of:
~Early so called NEWS-monitoring (measuring of standard physiological parameters);
~Early start of antibiotics;
~Rapid (within 6 hours) start of operation;
~Goal-directed fluid therapy;
~Intensified post-operative monitoring;
~The presence of both surgical and anesthesiological specialists in the early care of the patients."
16462430|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
16462431|NCT03549611|Experimental|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia
~Tylenol, 975mg (3 tabs)
~800mg Gabapentin
~400mg Celecoxib
~10mg Oxycodone"
16462432|NCT03549611|Active Comparator|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia
~1. Tylenol, 975mg (3 tabs)"
16462433|NCT03549598|Experimental|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan, 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed on each subject
16462434|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
16462435|NCT03549559|Active Comparator|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
16462436|NCT03549559|Active Comparator|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
16462437|NCT03549559|Experimental|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
16462438|NCT03549546|Other|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
16462439|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
16462440|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
16462443|NCT03549468|Experimental|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
16462444|NCT03549455|Experimental|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
16462445|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
16462446|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
16462447|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
16462448|NCT03549442|Experimental|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
16462449|NCT03549429|Experimental|TegadermTM on R eye, EyeGard® on L eye|Patients will get TegadermTM on Right eye, EyeGard® on Left eye
16462450|NCT03549429|Experimental|TegadermTM on L eye, EyeGard® on R eye|Patients will get TegadermTM on Left eye, EyeGard® on Right eye
16462451|NCT03549403|Experimental|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
16462452|NCT03549403|No Intervention|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
16462453|NCT03549390|Experimental|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A & B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A & B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
16462454|NCT03549390|Experimental|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
16462455|NCT03549390|No Intervention|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
16462456|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
16462457|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
16462458|NCT03549364|Experimental|Endurance race|"baseline investigations with CT and lab tests
~the same CT and lab tests < 24h after an endurance race
~CT and lab tests again about 1-2weeks after the race"
16462459|NCT03549338|Experimental|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.
~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
16462460|NCT03549338|Experimental|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
16462461|NCT03549338|Experimental|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
16462462|NCT03549325|Experimental|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.
~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.
~Follow up visits occur on Days 5, 14 and 32."
16462463|NCT03549325|Experimental|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.
~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.
~Follow up visits occur on Days 15, 24 and 42."
16462464|NCT03549312|Experimental|Switch to Genvoya Followed By HCV Therapy Then Start Biktarvy|Oral Genvoya 150/150/200/10 mg & Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
16462465|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
16462466|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
16462467|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
16462468|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
16462469|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
16462471|NCT03549260|Experimental|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
16462472|NCT03549260|Experimental|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
16462473|NCT03549260|Experimental|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
16462474|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
16462475|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
16462476|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
16462477|NCT03549234|Experimental|Erector Spinae (single injection)|
16462478|NCT03549234|Active Comparator|Paravertebral (single injection)|
16462479|NCT03549221|Experimental|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
16462480|NCT03549221|No Intervention|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
16462481|NCT03549208|Experimental|LBVE01|Multivalent pneumococcal conjugate vaccine
16462482|NCT03549208|Experimental|LBVE02|Multivalent pneumococcal conjugate vaccine
16462483|NCT03549208|Active Comparator|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
16462484|NCT03549195|Active Comparator|ICG|
16462485|NCT03549195|Active Comparator|ICG-CP|CP, control peptide
16462486|NCT03549195|Experimental|ICG-TMTP1|also named as TMTP1-ICG
16462487|NCT03549182|Experimental|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
16462488|NCT03549182|Experimental|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
16462489|NCT03549182|Experimental|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
16462490|NCT03549182|Experimental|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
16462491|NCT03549169|Experimental|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
16462492|NCT03549169|Other|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
16462493|NCT03549156|Active Comparator|C-RUSF|Control/Standard RUSF
16462494|NCT03549156|Active Comparator|HIPRO RUSF|New RUSF product
16462495|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
16462496|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
16462497|NCT03549117|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
16462498|NCT03549117|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
16462499|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
16462500|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
16462501|NCT03549091|Experimental|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
16462502|NCT03549078|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
16462503|NCT03549065|Active Comparator|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
16462504|NCT03549065|Active Comparator|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
16462505|NCT03549065|Active Comparator|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
16462506|NCT03549065|Sham Comparator|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
16462507|NCT03549026|Experimental|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
16462508|NCT03549026|Placebo Comparator|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
16462509|NCT03549000|Experimental|NZV930 Monotherapy|Single Agent NZV930
16462510|NCT03549000|Experimental|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
16462511|NCT03549000|Experimental|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
16462512|NCT03549000|Experimental|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
16462513|NCT03548987|Experimental|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.
~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).
~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
16462514|NCT03548987|Placebo Comparator|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.
~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).
~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
16462515|NCT03548974|Active Comparator|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
16462516|NCT03548974|Active Comparator|Interventiongroup2|intermittent active and passive training followed by no intervention
16462517|NCT03548961|Experimental|Neoadjuvant chemotherapy|
16462518|NCT03548948|Other|High heme iron diet|
16462519|NCT03548948|Other|Low iron diet|
16462520|NCT03548948|Other|Plant-based high non-heme iron diet|
16462521|NCT03548935|Experimental|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
16462522|NCT03548935|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
16462523|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
16462524|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
16462525|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
16462526|NCT03548896|Experimental|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
16462527|NCT03548896|Experimental|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
16462528|NCT03548896|Experimental|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
16462529|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
16462530|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
16462531|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
16462532|NCT03548870|Experimental|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
16462533|NCT03548870|Sham Comparator|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
16462534|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
16462535|NCT03548844|Experimental|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
16462536|NCT03548844|Active Comparator|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
16462537|NCT03548831||MLH|Minilaparotomy Hysterectomy
16462538|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
16462539|NCT03548805|Experimental|Trabeculectomy with Ologen|ologen® Collagen Matrix
16462540|NCT03548805|Active Comparator|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC (0.02%)
16462541|NCT03548792|Other|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
16462542|NCT03548792|Other|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
16462543|NCT03548779|Experimental|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.
~Participants will receive usual care and will be offered research exome sequencing."
16462544|NCT03548779|Experimental|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.
~Participants will receive usual care."
16462545|NCT03548779|Experimental|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.
~Participants will receive usual care and will be offered research exome sequencing."
16462546|NCT03548779|No Intervention|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.
~Participants will receive usual care."
16462547|NCT03548766|Experimental|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
16462548|NCT03548766|Experimental|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
16462549|NCT03548753||Patients with Agatston score > 399|"Coronary computed tomography angiography with FFR-CT
~Invasive coronary angiography with FFR"
16462550|NCT03548740||Group A|
16462551|NCT03548740||Group B|
16462552|NCT03548727|Experimental|Repeatability of FLT kinetics|Radiotracer: 18F-FLT Dose: 10 mCi Frequency: Two baseline PET/CT at baseline up to 3 days apart.
16462553|NCT03548727|Experimental|Pseudo-Simultaneous FMISO/FLT PET/CT Imaging|Radiotracer: 18F-FLT and 18F-FLT Dose and Frequency: 8 mCi 18F-FLT and 8 mCi 18F-FLT on Day1, the 8mCi 18F-FLT on Day2
16462554|NCT03548714|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
16462555|NCT03548714|Placebo Comparator|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
16462556|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
16462557|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
16462558|NCT03548675|Experimental|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
16462559|NCT03548675|Active Comparator|Standard TCA treatment|Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
16462560|NCT03548662|Experimental|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
16462561|NCT03548662|Active Comparator|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
16462562|NCT03548649|Experimental|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
16462563|NCT03548636|Experimental|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
16462564|NCT03548610|Experimental|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical & local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film & 3 layers of dressings. Topical application creates a fine <1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 & 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours & suture removal (if not absorbed) at 7 days.
16462565|NCT03548610|No Intervention|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
16462566|NCT03548584|Experimental|Low Dose Brexpiprazole Arm|Tablet
16462567|NCT03548584|Experimental|High Dose Brexpiprazole Arm|Tablet
16462568|NCT03548584|Placebo Comparator|Placebo|Tablet
16462569|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
16462570|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
16462571|NCT03548558|Experimental|"Arm 1 (group sessions)"|Group meetings only with some booster sessions
16462572|NCT03548558|Experimental|"Arm 2 (group+home sessions)"|Group meetings with a limited number of individual home visits and booster sessions
16462573|NCT03548558|No Intervention|Arm 3|This arm will serve as the control group to identify the effects of a parenting intervention and the most effective mode of delivery, as well as the sustained impacts from the intervention
16462574|NCT03548558|Experimental|Arm B (Father villages)|In one half of Arm 1 and Arm 2 villages above, fathers will be invited to attend the ECD sessions along with mothers.
16462575|NCT03548558|Other|Arm A (Mother-only villages)|In the other half of Arm 1 and Arm 2 villages, only mothers will be invited.
16462576|NCT03548545|Experimental|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
16462577|NCT03548545|Sham Comparator|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
16462578|NCT03548532|Active Comparator|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
16462579|NCT03548532|Experimental|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
16462580|NCT03548519|Experimental|Attention Training|MCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
16462581|NCT03548519|Active Comparator|Active placebo training|MCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
16462582|NCT03548519|Experimental|PSE and Attention Training|MCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
16462583|NCT03548506|Active Comparator|STN_O|Omnidirectional Deep Brain Stimulation of STN
16462584|NCT03548506|Experimental|STN_D|Directional Deep Brain Stimulation of STN
16462585|NCT03548493|Experimental|Magnesium (M) group|Magnesium (M) group (n=17) , in which magnesium sulphate is given as adjuvant to propofol for sedation
16462586|NCT03548493|Active Comparator|Fentanyl (F) group|Fentanyl (F) group (n=17), in which fentanyl is given as adjuvant to propofol for sedation
16462587|NCT03548480|Placebo Comparator|Placebo|
16462588|NCT03548480|Experimental|Probiotic|
16462589|NCT03548467|Experimental|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
16462590|NCT03548467|Experimental|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
16462591|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
16462592|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
16462593|NCT03548441||Surgery|Exposed
16462598|NCT03548415|Placebo Comparator|Placebo|Placebo (sterile saline 0.9%) Calculated volume to match active comparator administered subcutaneously every 28 days for 16 weeks
16462599|NCT03548389|Experimental|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
16462600|NCT03548389|No Intervention|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
16462601|NCT03548376|Experimental|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
16462602|NCT03548363|Active Comparator|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
16462603|NCT03548363|Active Comparator|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
16462604|NCT03548363|Placebo Comparator|Placebo|200 mg/d maltodextrin for 4-weeks
16462605|NCT03548350|Experimental|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:
~A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).
~'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week
~After schools club (not compulsory) featuring mind-set component delivered by external facilitators
~Healthy kidz app with reward system"
16462606|NCT03548350|No Intervention|Control|The control group will continue doing physical activity including physical education as is normal for their school
16462607|NCT03548337|Active Comparator|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
16462608|NCT03548337|Active Comparator|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
16462609|NCT03548324|Active Comparator|HHHFNC|Heated Humidified High Flow Nasal Cannulae
16462610|NCT03548324|Active Comparator|NCPAP|Nasal Continuous Positive Air Pressure
16462611|NCT03548311|Placebo Comparator|Placebo|intramuscular injection of saline solution
16462612|NCT03548311|Active Comparator|methylcobalamin|intramuscular injection of methylcobalamin
16462613|NCT03548298|Experimental|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
16462614|NCT03548285|Experimental|patient with low risk|"Low-risk is defined by:
~Planning target volume (PTV) less than 10 cc, AND
~No reported smoking within 1 month from registration
~Radiation Therapy will be delivered twice per week for 5 fractions (total 42.5 Gy)"
16462615|NCT03548285|Experimental|patient with moderate risk|"Moderate-risk is defined by:
~Planning target volume (PTV) greater than or equal to 10 cc, OR
~Smoking within 1 month from registration (no more than 1 pack per day)
~Radiation Therapy will be delivered daily for 16 fraction (total 58.08 Gy)"
16462616|NCT03548272|Experimental|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.
~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
16462617|NCT03548272|Active Comparator|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).
~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
16462618|NCT03548259|Experimental|Experimental|Platelet-rich plasma
16462619|NCT03548259|Placebo Comparator|Platelet-poor plasma|Platelet-poor plasma
16462620|NCT03548246|Placebo Comparator|Placebo|Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
16462621|NCT03548246|Experimental|Abiraterone acetate|Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
16462622|NCT03548233|Other|bcg vaccinated|children under five year vaccinated by bcg vaccine
16462623|NCT03548220|Experimental|AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.
~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual's response in Part 1."
16462624|NCT03548220|Placebo Comparator|Placebo|"Part 1 (Dose Optimization Period): Participants will receive placebo matching AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.
~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of placebo matching AG-348 as determined by the individual's response in Part 1."
16462625|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
16462626|NCT03548194|Experimental|BNC210|Administered orally b.i.d. for 5 days.
16462627|NCT03548194|Placebo Comparator|Placebo|Administered orally b.i.d. for 5 days.
16462653|NCT03548090|Experimental|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
16462654|NCT03548090|Experimental|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
16462683|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
16462628|NCT03548181|Experimental|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.
~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
16462629|NCT03548181|Active Comparator|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
16462630|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
16462631|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
16462632|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
16462633|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
16462634|NCT03548155|Experimental|berberine group|
16462635|NCT03548155|Placebo Comparator|control group|
16462636|NCT03548129|Active Comparator|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.
~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.
~Response to treatment will be assessed by post-treatment urine culture."
16462637|NCT03548129|Active Comparator|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.
~Response to treatment will be assessed by post-treatment urine culture."
16462638|NCT03548116|Sham Comparator|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
16462639|NCT03548116|Experimental|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
16462640|NCT03548116|Experimental|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
16462641|NCT03548116|Sham Comparator|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
16462642|NCT03548116|Experimental|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
16462643|NCT03548116|Experimental|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
16462644|NCT03548116|Sham Comparator|Group 7|Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
16462645|NCT03548103|Experimental|Green Tea Extract|Green Tea Extract 500 mg per capsule
16462646|NCT03548103|Placebo Comparator|Placebo|Identical Placebo capsule
16462647|NCT03548090|Experimental|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
16462648|NCT03548090|Experimental|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
16462649|NCT03548090|Experimental|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
16462650|NCT03548090|Experimental|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
16462651|NCT03548090|Experimental|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
16462652|NCT03548090|Experimental|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
16462684|NCT03548025|Experimental|Treatment Group|Treated group of subjects, serves as its own control
16462655|NCT03548090|Experimental|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
16462656|NCT03548090|Experimental|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
16462657|NCT03548090|Experimental|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
16462658|NCT03548090|Experimental|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
16462659|NCT03548090|Experimental|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
16462660|NCT03548090|Experimental|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
16462661|NCT03548090|Experimental|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
16462662|NCT03548090|Experimental|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
16462663|NCT03548090|Experimental|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
16462664|NCT03548090|Experimental|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
16462665|NCT03548090|Experimental|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
16462666|NCT03548090|Experimental|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
16462667|NCT03548090|Experimental|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
16462668|NCT03548090|Experimental|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
16462669|NCT03548090|Experimental|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
16462670|NCT03548090|Experimental|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
16462671|NCT03548077|Experimental|Intervention group|Powerplay, a workplace wellness program designed for male-dominated work sites, is the intervention. The program focuses on physical activity, healthy eating, mental wellness, and smoking cessation as well as promoting changes in workplace environments to support employee health and wellness. Program delivery is supported with a detailed program manual and web-based resources. More information about the intervention is available here: http://www.powerplayatwork.com/
16462672|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
16462673|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
16462674|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
16462675|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
16462676|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
16462677|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
16462678|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
16462679|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
16462680|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
16462681|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
16462682|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
16462685|NCT03548012|Experimental|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
16462686|NCT03548012|No Intervention|Control|('Standard' basic palliative care). No intervention offered.
16462687|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
16462688|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
16462689|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
16462690|NCT03547986|Experimental|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
16462696|NCT03547960|Experimental|Guar gum in women with early GDM|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
16462697|NCT03547960|Placebo Comparator|Control/Cellulose in women with early GDM|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
16462698|NCT03547934|Experimental|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
16462699|NCT03547921||operative|operative
16462700|NCT03547921||non operative|non operative
16462701|NCT03547908|Experimental|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF
16462702|NCT03547908|Experimental|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF
16462703|NCT03547895|Active Comparator|cases|"patients with decompensated cirrhosis
~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
16462704|NCT03547895|Placebo Comparator|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
16462705|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
16462706|NCT03547882||Patients|Ten interviews were conducted with VA patients receiving ORT.
16462707|NCT03547869|Experimental|Active tDCS|Active tDCS
16462708|NCT03547869|Sham Comparator|Sham tDCS|Sham tDCS
16462709|NCT03547843|Experimental|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
16462710|NCT03547843|Active Comparator|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
16462711|NCT03547830|Experimental|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
16462712|NCT03547817|Experimental|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
16462713|NCT03547804|Experimental|experimental arm|apatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
16462714|NCT03547791|Active Comparator|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
16462715|NCT03547791|Placebo Comparator|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
16462716|NCT03547778|Experimental|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
16462717|NCT03547778|Placebo Comparator|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
16462718|NCT03547752|Active Comparator|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
16462719|NCT03547752|Experimental|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
16462720|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
16462721|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
16462722|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
16462723|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
16462724|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
16462725|NCT03547713|Experimental|Study group|social feedback and neuropsychological assessment
16462726|NCT03547700|Experimental|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
16462727|NCT03547687|Experimental|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
16462728|NCT03547674|Active Comparator|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
16462729|NCT03547674|Active Comparator|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
16462730|NCT03547674|Active Comparator|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
16462731|NCT03547674|Experimental|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
16462732|NCT03547661|No Intervention|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
16462733|NCT03547661|Active Comparator|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.
~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
16462734|NCT03547661|Active Comparator|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.
~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
16462735|NCT03547648|Active Comparator|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
16462736|NCT03547648|Active Comparator|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
16462737|NCT03547648|Active Comparator|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
16462738|NCT03547635|Experimental|AMNIOEXCEL Plus Amniotic Membrane|
16462739|NCT03547635|Active Comparator|A Marketed Comparator|
16462740|NCT03547635|Other|Standard of Care|
16462741|NCT03547622|Active Comparator|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
16462742|NCT03547622|Placebo Comparator|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
16462743|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
16462744|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
16462745|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
16462746|NCT03547570|Experimental|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
16462747|NCT03547557|Experimental|ExAblate MRgFUS|
16462748|NCT03547531|Active Comparator|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
16462749|NCT03547531|Experimental|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
16462750|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
16462751|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
16462752|NCT03547505|Experimental|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
16462753|NCT03547505|Experimental|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
16462754|NCT03547505|Experimental|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
16462755|NCT03547492|Experimental|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback
~Assessments:
~Ages and Stages Questionnaire at 4 and 12 months
~Maternal Peabody Picture Vocabulary test at 4 months
~Edinburgh Post-partum Depression Scale at 4 months
~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12
~Participants receive a book at each interaction."
16462756|NCT03547492|Active Comparator|Motor Control|"Baseline LENA recording
~Review motor curriculum with study personnel
~2nd LENA recording completed and analyzed
~4- monthly text messages
~4 month LENA recording
~12 month LENA recording with mailed linguistic feedback of all recordings
~Assessments:
~Ages and Stages Questionnaire at 4 and 12 months
~Maternal Peabody Picture Vocabulary test at 4 months
~Edinburgh Post-partum Depression Scale at 4 months
~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12
~Participants receive a toy at each interaction."
16462757|NCT03547479|No Intervention|Control|Participants receive current standard of care (DOTS)
16462758|NCT03547479|Experimental|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
16462759|NCT03547479|Experimental|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
16462760|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
16462761|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
16462762|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
16462763|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
16462764|NCT03547427|Experimental|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
16462765|NCT03547427|Active Comparator|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
16462766|NCT03547427|Experimental|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
16462767|NCT03547427|Active Comparator|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
16462768|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
16462769|NCT03547388|Experimental|Single Arm|Additional application of weekly moderate whole-body hyperthermia concurrent to re-irradiation plus chemotherapy
16462770|NCT03547375|Experimental|treatment group|Apatinib 500mg/d po,28 days as one cycle
16462771|NCT03547362|Experimental|Casein|Single oral administration
16462772|NCT03547362|Experimental|Dairy protein blend 1|single oral administration
16462773|NCT03547362|Experimental|Whey protein|Single oral administration
16462774|NCT03547362|Experimental|Dairy protein blend 2|Single oral administration
16462775|NCT03547362|Experimental|Dairy protein blend 3|Single oral administration
16462776|NCT03547362|Experimental|Dairy protein blend 4|Single oral administration
16462777|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
16462778|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
16462779|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
16462780|NCT03547336|Experimental|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
16462781|NCT03547336|Active Comparator|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
16462782|NCT03547323|Experimental|Theranova 400 Dialyzer|One treatment session in an in-center setting.
16462783|NCT03547323|Active Comparator|FX80 Dialyzer|One treatment session in an in-center setting.
16462784|NCT03547310|Experimental|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
16462785|NCT03547284|Active Comparator|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
16462786|NCT03547284|No Intervention|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool)
16463202|NCT03544359|Sham Comparator|Sham/Inactive tES|
16462791|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
16462792|NCT03547245|Active Comparator|HIV-uninfected, healthy adults|
16462793|NCT03547245|Placebo Comparator|HIV-uninfected, healthy adults - placebo|
16462794|NCT03547232|Experimental|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
16462795|NCT03547232|Sham Comparator|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
16462796|NCT03547219|Experimental|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
16462797|NCT03547206|Experimental|RPh201 Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
16462798|NCT03547206|Placebo Comparator|Placebo Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
16462799|NCT03547206|Experimental|RPh201 Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
16462800|NCT03547206|Placebo Comparator|Placebo Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the vehicle control.
16462801|NCT03547180|Active Comparator|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
16462802|NCT03547180|Active Comparator|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
16462803|NCT03547180|Other|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
16462804|NCT03547167|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
16462805|NCT03547167|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
16462806|NCT03547154|Experimental|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
16462807|NCT03547154|Active Comparator|Interferon alfa-2b|Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
16462808|NCT03547141|Experimental|botulinum toxin 1U|
16462809|NCT03547141|Experimental|botulinum toxin 5U|
16462810|NCT03547141|Experimental|botulinum toxin 15U|
16462811|NCT03547141|Experimental|botulinum toxin 30U|
16462812|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
16462813|NCT03547115|Experimental|voruciclib|Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)
16462814|NCT03547102|Active Comparator|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
16462815|NCT03547102|Placebo Comparator|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
16462816|NCT03547089|Experimental|Viveve treatment|Group of women who receive Viveve treatment
16462817|NCT03547076|Experimental|Focused ultrasound diagnostics|"Intervention: Focused ultrasound Diagnostics
~All participants will first be examined twice with handheld ultrasound, With separate examinations performed by general practioners and nurses (random order). Both will utilize automatic analyses of left ventricular function and telemedicine support for best possible diagnosis of heart failure. Subsequently, reference imaging and diagnostics will be performed by experts (cardiologists). Handheld ultrasound examinations will be compared to Reference."
16462818|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
16462819|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
16462820|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
16462821|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
16462822|NCT03547050||Controls|People without a lifetime history of seizures.
16462823|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
16462824|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
16462825|NCT03547024|Experimental|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
16462826|NCT03547024|Experimental|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
16462827|NCT03547024|Experimental|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
16462828|NCT03547011|Active Comparator|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
16462829|NCT03547011|Active Comparator|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
16462830|NCT03546985|Experimental|Group A|
16462831|NCT03546985|Active Comparator|Group B|
16462832|NCT03546972|Active Comparator|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
16462833|NCT03546972|Experimental|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
16462834|NCT03546959|Experimental|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
16462835|NCT03546959|Active Comparator|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
16462836|NCT03546946|Experimental|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
16462837|NCT03546946|Placebo Comparator|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
16462838|NCT03546946|No Intervention|No-Train Group|No active training.
16462839|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
16462840|NCT03546920|No Intervention|Control Phase|Usual care for patients admitted to the SNF.
16462841|NCT03546920|Experimental|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
16462842|NCT03546907|Experimental|SAR440340|Administration of SAR440340 monotherapy injection
16462843|NCT03546907|Placebo Comparator|Placebo|Administration of matching placebo for injection of SAR440340
16462844|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
16462845|NCT03546894||Any FDA Approved ALK Inhibitor|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
16462846|NCT03546881|Experimental|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
16462847|NCT03546881|Active Comparator|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
16462848|NCT03546868|Experimental|Ulcerative Colitis|Patients with ulcerative colitis undergoing [18F]FSPG PET/CT scan
16462849|NCT03546868|Experimental|Crohn's disease|Patients with Crohn's disease undergoing [18F]FSPG PET/CT scan
16462850|NCT03546855|Experimental|treatment group|apatinib 500mg/d po.28d as one cycle
16462851|NCT03546842|Experimental|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
16462852|NCT03546829|Experimental|Arm 1 - Experimental|
16462853|NCT03546829|Active Comparator|Arm 2 - Control Arm|
16462854|NCT03546816|Experimental|5 mg Serlopitant Tablets|
16462855|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
16462856|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
16462857|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
16462858|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
16462859|NCT03546790|Experimental|Flavor 1|Grape flavored tobacco cigar wrapper
16462860|NCT03546790|Experimental|Flavor 2|Chocolate flavored tobacco cigar wrapper
16462861|NCT03546790|Experimental|Flavor 3|Tobacco flavored tobacco cigar wrapper
16462862|NCT03546764|Experimental|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
16462863|NCT03546764|Active Comparator|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
16462864|NCT03546751|Experimental|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
16462907|NCT03546465|Experimental|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
16462865|NCT03546751|Active Comparator|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
16462866|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
16462867|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
16462868|NCT03546725|Experimental|Leg with compression stocking|Leg wearing compression stocking during the flight
16462869|NCT03546725|No Intervention|Leg without compression stocking|Leg not wearing compression stocking during the flight
16462870|NCT03546686|Experimental|Treatment Arm|Ipilimumab + Nivolumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery Nivolumab
16462871|NCT03546673|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
16462872|NCT03546673|Experimental|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
16462873|NCT03546673|Experimental|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
16462874|NCT03546660|Experimental|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
16462875|NCT03546647|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
16462876|NCT03546647|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
16462877|NCT03546634|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
16462878|NCT03546634|Experimental|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
16462879|NCT03546621|Experimental|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
16462880|NCT03546621|Experimental|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
16462881|NCT03546621|Experimental|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
16462882|NCT03546621|Active Comparator|Arm D|tenofovir treatment for 48 weeks
16462883|NCT03546608|Experimental|Part 1, Child-Pugh Class A: Tepotinib|
16462884|NCT03546608|Experimental|Part 1, Child-Pugh Class B: Tepotinib|
16462885|NCT03546608|Experimental|Part 1, Healthy Participants: Tepotinib|Healthy participants matched to Child-Pugh Class B participants.
16462886|NCT03546595|Experimental|Auricular acupoints acupressure|
16462887|NCT03546595|Sham Comparator|Sham auricular acupoints acupressure|
16462888|NCT03546582|Experimental|Arm I|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.
16462889|NCT03546582|Other|Arm II|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.
16462890|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
16462891|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
16462892|NCT03546543|Experimental|Supine|
16462893|NCT03546543|Experimental|Prone|
16462894|NCT03546530|Experimental|Interferon|Interferon 1.5ug/kg/week, 48weeks
16462895|NCT03546530|Experimental|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
16462896|NCT03546517|Experimental|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
16462897|NCT03546517|Sham Comparator|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
16462898|NCT03546504|Experimental|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
16462899|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
16462900|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
16462901|NCT03546478|Experimental|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
16462902|NCT03546465|Experimental|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
16462903|NCT03546465|Experimental|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
16462904|NCT03546465|Experimental|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
16462905|NCT03546465|Experimental|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
16462906|NCT03546465|Experimental|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
16462908|NCT03546465|Experimental|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
16462909|NCT03546465|Experimental|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
16462910|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
16462911|NCT03546426|Experimental|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
16462915|NCT03546400|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
16462916|NCT03546374|Experimental|Primary Cohort|Patients with a history of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) who are undergoing concomitant cardiac surgery
16462917|NCT03546361|Experimental|Treatment (Ad-CCL21-DC vaccine, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by autologous dendritic cell-adenovirus CCL21 vaccine by CT-guided or bronchoscopic IT injection on days 0, 21, and 42. Patients then receive pembrolizumab every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
16462918|NCT03546335|Experimental|1mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
16462919|NCT03546335|Experimental|0.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
16462920|NCT03546335|Experimental|1.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
16462921|NCT03546335|Experimental|2mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
16462922|NCT03546322||Registry|Head and neck cancer patients monitored on registry
16462923|NCT03546309|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
16462924|NCT03546309|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
16462925|NCT03546283|Placebo Comparator|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
16462926|NCT03546283|Experimental|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
16462927|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
16462928|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
16462929|NCT03546257||EUS|group using conventional WLE and EUS
16462930|NCT03546257||ME-NBI|group using WLE and ME-NBI.
16462931|NCT03546244|Experimental|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
16462932|NCT03546244|Active Comparator|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
16462933|NCT03546218|Experimental|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
16462934|NCT03546218|Active Comparator|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
16462935|NCT03546205|Experimental|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter/minute [mL/min]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
16462936|NCT03546205|Experimental|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than [<] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
16462937|NCT03546205|Experimental|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to <60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
16462938|NCT03546205|Experimental|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR <30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
16462939|NCT03546205|Experimental|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
16462940|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
16462941|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
16462943|NCT03546153|Experimental|Aerobic exercise program|Participants will complete 12 week exercise program.
16462944|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
16462945|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
16462946|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age>18 years, first visit at osteopathic clinic (Centro di Medicina Osteopatica)
16462947|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
16462948|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
16462949|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
16462950|NCT03546088|Experimental|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam and 3 mcg/kg fentanyl. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
16462951|NCT03546075|Experimental|500 mg Resveratrol|
16462952|NCT03546075|Experimental|250 mg Resveratrol|
16462953|NCT03546075|Placebo Comparator|Placebo|
16462954|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant.
16462955|NCT03546049|Active Comparator|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
16462956|NCT03546049|Experimental|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
16462957|NCT03546036|Experimental|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
16462958|NCT03546036|Sham Comparator|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
16462959|NCT03546010|Experimental|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
16462960|NCT03545997|Experimental|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
16462961|NCT03545997|Placebo Comparator|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
16462962|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
16462963|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
16462964|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
16462965|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
16462966|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
16462967|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
16462968|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
16462969|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
16462970|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
16462971|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
16462972|NCT03545958|Experimental|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
16462973|NCT03545958|Active Comparator|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
16462974|NCT03545945|Experimental|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
16462975|NCT03545945|Other|Control arm|Patients having only endometrial biopsy
16462976|NCT03545932|Experimental|Hydrogymnastics|Hydrogymnastics Program
16462977|NCT03545906|Experimental|TEAM-UP Intervention Group|
16462978|NCT03545906|Active Comparator|Enhanced Care Comparison Group|
16462979|NCT03545893|Active Comparator|Ibuprofen|
16462980|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
16462981|NCT03545880|Experimental|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
16462982|NCT03545880|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
16462983|NCT03545867|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
16462984|NCT03545867|Experimental|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and ~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
16462985|NCT03545867|Experimental|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
16462986|NCT03545867|Experimental|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
16462987|NCT03545854|Experimental|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
16462988|NCT03545854|Experimental|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
16462989|NCT03545854|Experimental|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
16462990|NCT03545854|Experimental|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
16462991|NCT03545854|Experimental|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
16462992|NCT03545854|Experimental|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
16462993|NCT03545854|Experimental|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
16462994|NCT03545854|Experimental|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
16462995|NCT03545854|Experimental|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
16462996|NCT03545841|Experimental|HIT training|6 weeks of high-intensity interval training (HIT)
16462997|NCT03545841|Experimental|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
16462998|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
16462999|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
16463000|NCT03545815|Experimental|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.
~Patients receive anti-mesothelin-CAR T cells on day 0."
16463001|NCT03545802|Experimental|Training|6 weeks of home-based high intensity interval training
16463002|NCT03545789|Experimental|[18F]MNI-958|To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
16463003|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.
~Training will be followed by an online teaching consisting on additional questions and answers quizzes based on the 10 educational goals already described elsewhere.
~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
16463004|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
16463005|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
16463006|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
16463007|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
16463008|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
16463009|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.
~The depth of intubation = 0.1977* height-4.2423"
16463010|NCT03545724|Experimental|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
16463011|NCT03545711|Experimental|Anlotinib plus Irinotecan|
16463012|NCT03545698|Active Comparator|Telehealth Intervention|
16463013|NCT03545698|No Intervention|Non-Telehealth Intervention|
16463014|NCT03545685|Experimental|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
16463015|NCT03545685|Other|Control group|Participants in this group will serve as control group
16463016|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
16463017|NCT03545672||Control group|The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
16463018|NCT03545646|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
16463019|NCT03545633|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
16463020|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
16463021|NCT03545607|Experimental|MultiStem|1.2 billion cells
16463022|NCT03545607|Placebo Comparator|Placebo|
16463023|NCT03545594|Experimental|Patient-centered in home rehabilitation|Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
16463024|NCT03545594|Active Comparator|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
16463025|NCT03545581|Other|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
16463026|NCT03545581|Other|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
16463027|NCT03545568|Other|Experimental: sialic acid|
16463028|NCT03545555|Experimental|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
16463029|NCT03545555|Experimental|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
16463030|NCT03545555|Experimental|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
16463031|NCT03545555|Placebo Comparator|Placebo|"5 capsules with placebo per day for 8 weeks"
16463032|NCT03545542|Experimental|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.
~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).
~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
16463033|NCT03545542|Other|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.
~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).
~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
16463034|NCT03545529|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
16463035|NCT03545529|No Intervention|conventional supported|Patients benefit from usual care
16463036|NCT03545516|Placebo Comparator|Placebo|Wound infiltration with a placebo
16463037|NCT03545516|Experimental|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
16463038|NCT03545516|Experimental|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
16463039|NCT03545503|Active Comparator|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
16463040|NCT03545503|Active Comparator|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
16463041|NCT03545490|Experimental|Intervention oral or tube feeding group|Ensure 3 times/day
16463042|NCT03545490|No Intervention|Control oral or tube feeding group|Only nutrition education
16463043|NCT03545477|Experimental|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
16463044|NCT03545477|Active Comparator|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
16463045|NCT03545464|Experimental|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.
~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally
~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).
~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
16463046|NCT03545464|Active Comparator|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.
~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.
~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).
~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
16463047|NCT03545451|Experimental|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
16463048|NCT03545438|Placebo Comparator|cohort 1|LIB003 dose 1 SC
16463049|NCT03545438|Placebo Comparator|cohort 2|LIB003 dose 2 SC
16463050|NCT03545438|Placebo Comparator|cohort 3|LIB003 dose 4 SC
16463051|NCT03545438|Placebo Comparator|cohort 4|LIB003 dose 4 SC
16463052|NCT03545438|Placebo Comparator|cohort 5|LIB003 dose 5 SC
16463053|NCT03545438|Placebo Comparator|cohort 6|LIB003 dose 4 IV
16463054|NCT03545438|Placebo Comparator|cohort 7|LIB003 dose 5 IV
16463055|NCT03545438|Placebo Comparator|cohort 8|LIB003 dose 3 SC - statin treated
16463056|NCT03545438|Placebo Comparator|cohort 9|LIB003 dose 4 SC - statin treated
16463057|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
16463058|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
16463059|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
16463060|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
16463061|NCT03545412|Experimental|Microfocused ultrasound with visualization|
16463062|NCT03545399|Experimental|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
16463063|NCT03545399|Placebo Comparator|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
16463064|NCT03545386|Experimental|FMT|
16463065|NCT03545386|Placebo Comparator|Placebo|
16463066|NCT03545373|Experimental|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
16463067|NCT03545373|Experimental|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
16463068|NCT03545373|No Intervention|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
16463069|NCT03545360|Experimental|Treatment Group|Treated group of subjects, serves as its own control
16463070|NCT03545347|Experimental|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
16463071|NCT03545347|Placebo Comparator|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
16463072|NCT03545334|Experimental|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.
~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
16463073|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
16463074|NCT03545295|Experimental|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
16463075|NCT03545295|Experimental|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
16463076|NCT03545295|Experimental|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
16463077|NCT03545295|Experimental|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
16463078|NCT03545295|Experimental|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
16463079|NCT03545295|Experimental|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
16463080|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
16463081|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
16463082|NCT03545269|Experimental|CartiLife®|
16463083|NCT03545269|Active Comparator|Microfracture|
16463084|NCT03545256|Other|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
16463085|NCT03545243|Other|Pantoprazole 40mg in healthy volunteers|Peroral Pantoprazole 40mg once daily for 4 weeks
16463086|NCT03545243|Other|Pantoprazole 40mg in functional dyspepsia|Peroral Pantoprazole 40mg once daily for 4 weeks
16463087|NCT03545243|Other|PPI-withdrawal in functional dyspepsia|no PPI for 8 weeks
16463091|NCT03545204|Other|Intervention Clusters|Community based Kangaroo Mother Care,KMC package in low birth weight infants of randomly selected union councils.
16463092|NCT03545204|Other|Control clusters|Essential newborn and routine standard care in low birth weight infants of randomly selected union councils.
16463093|NCT03545191|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
16463094|NCT03545191|Experimental|ACT-541468 50 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
16463095|NCT03545191|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
16463096|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
16463097|NCT03545165|Experimental|All Subjects|"177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration
~177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration
~68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
16463098|NCT03545152|No Intervention|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
16463099|NCT03545152|Experimental|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
16463100|NCT03545152|Experimental|cognitive training group|Consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
16463101|NCT03545139|Experimental|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
16463102|NCT03545139|Active Comparator|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
16463103|NCT03545126||Progressive Supranuclear Palsy (PSP)|N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
16463104|NCT03545126||Corticobasal Degeneration (CBD)|N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
16463105|NCT03545126||Frontotemporal Dementia: MAPT|N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
16463106|NCT03545113|Experimental|Upper extremity arteriovenous graft (AVG) - first|Participants randomized to receive an AVG will undergo surgery to have an AVG placed.
16463107|NCT03545113|Active Comparator|Upper extremity arteriovenous fistula (AVF) - first|Participants randomized to receive an AVF will undergo surgery to have an AVF created.
16463108|NCT03545100|Experimental|experimental group|motor control therapy
16463109|NCT03545100|Active Comparator|control group|regular physical therapy
16463110|NCT03545087|Experimental|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
16463111|NCT03545087|Experimental|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
16463112|NCT03545074|Experimental|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston & Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
16463113|NCT03545074|Experimental|Mindfulness English|The MAPs program was developed at UCLA (Winston & Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
16463114|NCT03545074|Active Comparator|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
16463115|NCT03545074|Active Comparator|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
16463116|NCT03545048|Experimental|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.
~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.
~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
16463117|NCT03545048|No Intervention|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
16463118|NCT03545035||Study group|All patients being observed during the study duration.
16463119|NCT03545022|Active Comparator|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
16463120|NCT03545022|Placebo Comparator|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
16463121|NCT03545009|Experimental|Beetroot Juice|
16463122|NCT03545009|Active Comparator|Beetroot Juice no Nitrate|
16463123|NCT03545009|Active Comparator|Sodium Nitrate|
16463124|NCT03545009|No Intervention|Control|
16463125|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
16463126|NCT03544983|Experimental|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Counseling
16463127|NCT03544983|No Intervention|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
16463128|NCT03544944|Experimental|TJP-008-1|
16463129|NCT03544944|Experimental|TJP-008-2|
16463130|NCT03544944|Active Comparator|Coolprep powder|
16463131|NCT03544931|Experimental|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
16463132|NCT03544931|Active Comparator|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
16463133|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
16463134|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
16463135|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
16463136|NCT03544892|Experimental|Experimental: Low carbohydrate diet|
16463137|NCT03544892|Active Comparator|Experimental: Standard of care diet|
16463138|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
16463139|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
16463140|NCT03544853|Experimental|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
16463141|NCT03544840|Experimental|Dynamic Standing Device|Home program using the Upsee
16463142|NCT03544827|Experimental|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
16463143|NCT03544827|Experimental|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
16463144|NCT03544814|Experimental|Concurrent therapy group|Icotinib combined with pemetrexed plus cisplatin.
16463145|NCT03544814|Experimental|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
16463149|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
16463150|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
16463151|NCT03544762|Experimental|18F-FES PET|PET/CT
16463152|NCT03544749|Experimental|Ambu® AuraGain™ group|
16463153|NCT03544749|Active Comparator|I-gel group|
16463154|NCT03544736|Experimental|Cohort A|"Subjects having palliative radiotherapy towards esophageal tumor will receive concomitant therapy With Nivolumab i.v. 240mg Q2W: first 6 patients, 360mg Q3W: Next 6 patients or 480mg Q4W: Last 6 patients, treatment to progression or up to 2 years of treatment.
~Radiotherapy: 2 Gy / day, (5 fx/week) to a total of 20 - 50 Gy in 25fx (2-4Gy/fx) at the decision of the responsible physician."
16463155|NCT03544736|Experimental|Cohort B|"Subjects receiving definitive chemoradiotherapy for esophageal cancer will receive concomitant therapy with Nivolumab 240mg Q2W, during RT, and continued with 480mg Q4W, treatment to progression or up to 1 year after completion of radiotherapy. 6 patients in total.
~Chemotherapy: Paclitaxel i.v. 175mg/m2 and Carboplatin AUC5, then after 21 days Radiotherapy 1,8 Gy / day (5 fx/week) up to 50,4 Gy in 28fx and concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Nivolumab as described above."
16463156|NCT03544736|Experimental|Cohort C|"Subjects with operable esophageal cancer eligible for neoadjuvant chemoradiotherapy will receive Nivolumab 240mg Q2W, concomitantly with RT Then surgery 4-12 weeks after RT. Within 6-12 months after surgery: Adjuvant Nivolumab 480mg Q4W, for 12 months. 6 patients in total.
~Neoadjuvant chemotherapy: Concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Radiotherapy: 41,4 Gy in 23 fractions."
16463157|NCT03544723|Experimental|Ad-p53 with anti-PD-1/anti-PD-L1 100% of patients|Up to 40 patients, all patients treated with intra-tumoral Ad-p53 (dose determined by tumor size) in combination with IV physician's choice of approved immune checkpoint inhibitor
16463158|NCT03544710|Experimental|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
16463159|NCT03544710|No Intervention|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.
~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
16463160|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
16463161|NCT03544684|Experimental|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
16463162|NCT03544684|Experimental|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
16463163|NCT03544684|Experimental|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
16463164|NCT03544671|Experimental|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
16463165|NCT03544671|Experimental|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
16463166|NCT03544671|Experimental|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
16463167|NCT03544671|Placebo Comparator|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
16463168|NCT03544658|Experimental|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
16463169|NCT03544645|Active Comparator|control group|"This group received a printed material brochure as an educational material"
16463170|NCT03544645|Experimental|intervention group|"This group received an audiovisual material video as an educational material"
16463171|NCT03544632|Experimental|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
16463172|NCT03544606|Experimental|isosorbide mononitrate group|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
16463173|NCT03544606|Placebo Comparator|placebos group|70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction
16463251|NCT03543917|Experimental|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
16463174|NCT03544580|Experimental|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments & scraping all enamel & cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant & thin buccal bone
16463175|NCT03544580|Active Comparator|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
16463176|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
16463177|NCT03544554|Experimental|Intervention group and control group|This research is planned with semi experimental design
16463178|NCT03544528|Experimental|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
16463179|NCT03544528|No Intervention|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
16463180|NCT03544515|Sham Comparator|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
16463181|NCT03544515|Experimental|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
16463182|NCT03544502|Experimental|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
16463183|NCT03544502|Experimental|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.
~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
16463184|NCT03544502|Placebo Comparator|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.
~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
16463185|NCT03544489|Experimental|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Digi-walker, Borg scale, and exercise logs), and 3) telephone coaching by clinic RNs. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months. Participants will record walking sessions each week in the exercise logs that will be collected again at 6 months.
16463186|NCT03544489|No Intervention|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3 and 6 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3 and 6 months."
16463187|NCT03544476|Experimental|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
16463188|NCT03544476|Active Comparator|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
16463189|NCT03544463|Experimental|Treated|iNAP® Sleep Therapy System Treatment Intervention
16463190|NCT03544463|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline condition
16463191|NCT03544450|Experimental|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
16463192|NCT03544450|Active Comparator|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
16463193|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
16463194|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
16463195|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
16463196|NCT03544398|Active Comparator|exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
16463197|NCT03544398|Active Comparator|end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
16463198|NCT03544398|Placebo Comparator|conventional physiotherapy|
16463199|NCT03544385|Experimental|Treatment Group|
16463200|NCT03544385|Placebo Comparator|Placebo Group|
16463203|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.
~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
16463204|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.
~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
16463205|NCT03544333|Experimental|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
16463206|NCT03544333|Placebo Comparator|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
16463207|NCT03544320|Active Comparator|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
16463208|NCT03544320|Active Comparator|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
16463209|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
16463210|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
16463211|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
16463212|NCT03544281|Experimental|Arm A: Belantamab mafodotin+lenalidomide +dexamethasone|"Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion.
~SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle.
~STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, & 22 of each cycle."
16463213|NCT03544281|Experimental|Arm B: Belantamab mafodotin+bortezomib+dexamethasone|Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 & 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 & 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 & so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, & so on). Bortezomib will be administered at 1.3 mg/m^2 SC/IV on Days 1,4,8, & 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, & 12 of every 21-day cycle.
16463214|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
16463215|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 30 participants will be recruited to aid in optimizing the imaging parameters.
16463216|NCT03544242|Active Comparator|Control group|
16463217|NCT03544242|Experimental|Pre-Isolation Infusion|
16463218|NCT03544242|Experimental|Post-Isolation Infusion|
16463219|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, twice daily (BID) for up to 12 weeks.
16463220|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, twice daily for up to 12 weeks.
16463221|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, twice daily for up to 12 weeks.
16463222|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily for up to 12 weeks.
16463223|NCT03544216|Experimental|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
16463224|NCT03544216|Experimental|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.
16463225|NCT03544177|Experimental|BFR-Walking|Interval walking training with blood flow restriction.
16463226|NCT03544177|Active Comparator|Conventional therapy|Conventional therapy
16463227|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
16463252|NCT03543904|Experimental|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
16463253|NCT03543904|Experimental|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
16463228|NCT03544125|Experimental|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
16463229|NCT03544112||ED and OUD treatment providers and staff|"ED patients will be recruited to participate in interviews or focus groups.
~ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.
~Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
16463230|NCT03544112||Community Stakeholders|"Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.
~Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
16463231|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
16463232|NCT03544099|Experimental|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
16463233|NCT03544086||test group|First group is the first 10 patients
16463234|NCT03544086||study group|following 150 patients
16463235|NCT03544073|Placebo Comparator|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
16463236|NCT03544073|Experimental|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
16463237|NCT03544047|Experimental|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
16463238|NCT03544034|No Intervention|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
16463239|NCT03544034|Experimental|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
16463240|NCT03544021|Experimental|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
16463241|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
16463242|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
16463243|NCT03543982|Experimental|Oral probiotic product|
16463244|NCT03543969|Experimental|BRAF-MEK Inhibitor Therapy|"Vemurafenib twice a day and cobimetinib daily, 3 weeks on / 2 weeks off / 3 weeks on, for an 8-week cycle.
~After 8 week cycle, response to these study drugs will be analyzed based on several parameters to determine if participants will proceed in the study.
~Participants will be invited for post-treatment follow-up visits for up to 5 years."
16463245|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
16463246|NCT03543943|Experimental|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
16463247|NCT03543943|Active Comparator|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
16463248|NCT03543943|Active Comparator|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
16463249|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
16463250|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
16463254|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
16463255|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
16463256|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
16463257|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
16463258|NCT03543865|Experimental|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days.
~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
16463259|NCT03543865|Experimental|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days
~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
16463260|NCT03543865|Other|Control Condition|"The control condition will only receive Case Management (CM) (n=76).
~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
16463261|NCT03543865|Experimental|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
16463262|NCT03543852|Experimental|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
16463263|NCT03543852|No Intervention|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
16463264|NCT03543839|Active Comparator|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
16463265|NCT03543839|Experimental|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
16463266|NCT03543839|Placebo Comparator|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
16463267|NCT03543826|Other|Protocol|Patients will have perioperative nuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed subjectively at adductor pollicis with standard train-of-four stimulation of the ulnar nerve.
16463268|NCT03543813|Experimental|CX-2029 Escalation|Dose Escalation and Determination
16463269|NCT03543813|Experimental|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
16463270|NCT03543813|Experimental|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
16463271|NCT03543800|Experimental|ABP|(test treatment)
16463272|NCT03543800|Active Comparator|PRP|(active control)
16463273|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
16463274|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
16463275|NCT03543774|Active Comparator|simvastatin treatment|
16463276|NCT03543774|Sham Comparator|EZE/simvastatin 10/20 mg treatment|
16463277|NCT03543774|Sham Comparator|EZE/simvastatin 10/40 mg treatment|
16463278|NCT03543761|Sham Comparator|A|Sham group
16463279|NCT03543761|Active Comparator|B|LiST active treatment group
16463280|NCT03543761|Active Comparator|C|LiST active treatment group
16463281|NCT03543748|Experimental|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
16463282|NCT03543748|Sham Comparator|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
16463283|NCT03543735|Experimental|Wisepill+SMS|
16463284|NCT03543735|Active Comparator|Wisepill-only|
16463285|NCT03543735|No Intervention|Disulfiram-only|
16463318|NCT03543475|Active Comparator|No Pessary|standard care, no pessary
16463319|NCT03543462|Sham Comparator|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
16463286|NCT03543722|Experimental|National Career Coach Program|This program has four main components: a 4-day in-person introductory seminar held in Alpharetta, GA, up to 18 months of job coaching provided by telephone and Skype, a human capital fund to pay for expenses of securing a job (e.g., travel, clothing, computers, professional organization fees), and an opportunity for two years to earn a bonus for employment earnings above a certain level.
16463287|NCT03543722|Active Comparator|Local Community Resources Program|Consists of referral to three local face-to-face service providers offering veterans training, financial assistance, and paid work experiences: The Department of Veterans Affairs Compensated Work Therapy Program, the state Vocational Rehabilitation program, and the Department of Labor America's Job Center.
16463288|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
16463289|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
16463290|NCT03543696|Experimental|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
16463291|NCT03543683||osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
16463292|NCT03543683||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
16463293|NCT03543670|Experimental|Oncoxin-Viusid|
16463294|NCT03543657|Experimental|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
16463295|NCT03543657|Active Comparator|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
16463296|NCT03543644|Active Comparator|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
16463297|NCT03543644|Experimental|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
16463298|NCT03543644|Experimental|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
16463299|NCT03543618|Sham Comparator|Control|Installation of conventional design dental implant
16463300|NCT03543618|Active Comparator|Sloped|Installation of sloped design dental implant
16463301|NCT03543605|Experimental|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.
~The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.
~These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.
~They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.
~The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
16463302|NCT03543605|Other|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:
~Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.
~Presentation of the project by the local team in its own center.
~Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.
~Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).
~Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
16463303|NCT03543592|Other|3 dimensional power Doppler|100 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study and 3 dimensional ultrasonography and Doppler will be done for them
16463304|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
16463305|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
16463306|NCT03543553||HC|Healthy control participants
16463307|NCT03543540|Experimental|Nexvax2 (Arm A)|
16463308|NCT03543540|Experimental|Nexvax2 (Arm B)|
16463309|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm C)|
16463310|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm D)|
16463311|NCT03543527||Takayashu|
16463312|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
16463313|NCT03543501|Experimental|Real-time ultrasound imaging group|See intervention
16463314|NCT03543501|Experimental|PBU group|See intervention
16463315|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
16463316|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
16463317|NCT03543475|Experimental|Pessary|Silicon device applied on the cervix
16463320|NCT03543462|No Intervention|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
16463321|NCT03543436|Experimental|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)
16463322|NCT03543436|Active Comparator|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
16463323|NCT03543423|Experimental|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
16463324|NCT03543423|Experimental|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
16463325|NCT03543410|Experimental|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
16463326|NCT03543410|Experimental|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
16463327|NCT03543410|Placebo Comparator|Placebo|Placebo (supplied in two tablets/day
16463328|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
16463329|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
16463330|NCT03543358|Experimental|Arm A: Post-Treatment Follow-Up/Optional Retreatment|Arm A includes participants who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per participant per retreatment period.
16463331|NCT03543358|Experimental|Arm B: Continued Treatment|Arm B includes participants who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
16463332|NCT03543332||Cardiac arrest|
16463333|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
16463334|NCT03543267|Experimental|epileptic Patients|
16463335|NCT03543254|Experimental|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
16463336|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
16463337|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
16463338|NCT03543202|Experimental|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
16463339|NCT03543202|Active Comparator|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
16463340|NCT03543202|Sham Comparator|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
16463341|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
16463342|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
16463343|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
16463344|NCT03543163|Active Comparator|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
16463345|NCT03543163|Experimental|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
16463346|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
16463347|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
16463348|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
16463349|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
16463350|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
16463351|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
16463352|NCT03543111|No Intervention|Control|No intervention
16463353|NCT03543098|Experimental|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
16463354|NCT03543098|Experimental|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
16463355|NCT03543098|Experimental|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
16463356|NCT03543098|Experimental|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
16463357|NCT03543098|Experimental|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
16463358|NCT03543098|Experimental|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
16463394|NCT03542877|Experimental|Stage 2|Up to 28 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks.
16463359|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
16463360|NCT03543072||exposure group|exposed to some factors
16463361|NCT03543072||control group|not exposed to some factors
16463362|NCT03543059||exposure group|exposed to some factors
16463363|NCT03543059||control group|not exposed to some factors
16463364|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
16463365|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
16463366|NCT03543033|Experimental|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
16463367|NCT03543033|No Intervention|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
16463368|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
16463369|NCT03542994|Other|Cohort 1|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days
16463370|NCT03542994|Other|Cohort 2|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days
16463371|NCT03542994|Other|Cohort 3|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days
16463372|NCT03542994|Other|Cohort 4|12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days
16463373|NCT03542994|Other|Cohort 5|24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days
16463374|NCT03542994|Other|Cohort 6|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
~Dose=up to a maximum of 660 mg, capsule, once daily, 29 days"
16463375|NCT03542994|Other|Cohort 7|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
16463376|NCT03542994|Other|Cohort 8|up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days
16463377|NCT03542994|Other|Cohort 9|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
16463378|NCT03542981|Active Comparator|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
16463379|NCT03542981|Sham Comparator|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
16463380|NCT03542968|Experimental|4D magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
16463381|NCT03542968|Sham Comparator|2D magnetic resonance imaging|MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI
16463382|NCT03542955|Active Comparator|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
16463383|NCT03542955|Placebo Comparator|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
16463384|NCT03542942|Other|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
16463385|NCT03542929|Active Comparator|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
16463386|NCT03542929|Experimental|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
16463387|NCT03542916|Experimental|CJ-40001|CJ-40001 60ug SC, IV injection
16463388|NCT03542916|Active Comparator|NESP|NESP 60ug SC, IV injection
16463389|NCT03542903|Active Comparator|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
16463390|NCT03542903|Active Comparator|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
16463391|NCT03542890||Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
16463392|NCT03542890||I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
16463393|NCT03542877|Experimental|Stage 1|Up to 16 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
16463480|NCT03542253||Sex|
16463481|NCT03542253||triglyceride|
16463395|NCT03542864|Experimental|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
16463396|NCT03542864|Active Comparator|Controls|Change from Baseline Body Composition values at 1 and 3 months
16463397|NCT03542864|Other|Data analysis|Analysis and publication of data
16463398|NCT03542851|Experimental|Subject Receives BTD001 first|
16463399|NCT03542851|Experimental|Subject Receives Placebo first|
16463400|NCT03542838|Experimental|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at a dose level of 5ug, 12.5ug, 20ug, 25ug, or 30ug.
16463401|NCT03542838|Placebo Comparator|Saline|Saline is administered as a one-time dose, intra-articularly.
16463402|NCT03542825|Active Comparator|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
16463403|NCT03542825|Active Comparator|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
16463404|NCT03542825|Active Comparator|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
16463405|NCT03542812|Experimental|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.
~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
16463406|NCT03542812|Experimental|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
16463407|NCT03542799|Experimental|3|anti-tumor response of EGFR IL12 CART
16463408|NCT03542786|Experimental|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
16463409|NCT03542786|Experimental|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
16463410|NCT03542786|Placebo Comparator|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
16463411|NCT03542773|Experimental|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
16463412|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels > 30%.
16463413|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
16463414|NCT03542747|Experimental|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
16463415|NCT03542747|Experimental|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
16463416|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
16463417|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
16463418|NCT03542721|Placebo Comparator|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
16463419|NCT03542721|Experimental|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
16463420|NCT03542708|Experimental|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma.
16463421|NCT03542708|No Intervention|Control|The contralateral ovary will not be injected.
16463422|NCT03542695|Experimental|Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)|Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.
16463423|NCT03542682|Active Comparator|Individuals given Standard Bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
16463424|NCT03542682|Active Comparator|Individuals given Quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
16463426|NCT03542656|Experimental|amyloid PET|PET/CT
16463427|NCT03542643|Active Comparator|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
16463428|NCT03542643|Placebo Comparator|Placebo|olive oil ethyl esters
16463429|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.
~Interventions:
~salivary MMP8 test; periodontal examination; blood tests"
16463430|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.
~Interventions:
~salivary MMP8 test;periodontal examination;blood tests"
16463482|NCT03542253||Lipoprotein|
16463483|NCT03542253||CT|Target Reconstruction
16463484|NCT03542253||micorRNA-A Plasma exocrine|
16463431|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.
~Interventions:
~salivary MMP8 test; periodontal examination;blood tests"
16463432|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.
~Interventions:
~salivary MMP8 test; periodontal examination; blood tests"
16463433|NCT03542617|Placebo Comparator|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
16463434|NCT03542617|Active Comparator|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
16463435|NCT03542617|Active Comparator|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
16463436|NCT03542604|Experimental|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
16463437|NCT03542604|Placebo Comparator|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
16463438|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
16463439|NCT03542552|Active Comparator|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
16463440|NCT03542552|Experimental|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
16463441|NCT03542500|No Intervention|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
16463442|NCT03542500|Experimental|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
16463443|NCT03542500|Experimental|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
16463444|NCT03542487|No Intervention|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
16463445|NCT03542487|Experimental|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
16463446|NCT03542487|Experimental|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
16463447|NCT03542487|Experimental|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
16463485|NCT03542253||micorRNA-A Paracancerous tiusse|
16463486|NCT03542253||pathologic diagnosis|
16463487|NCT03542253||hemolysis|
16463488|NCT03542253||ct-DNA|
16463489|NCT03542253||micorRNA-A in plasma|
16463490|NCT03542253||Sample quality control|
16463491|NCT03542253||positive|
16463492|NCT03542253||negative|
16463448|NCT03542487|Experimental|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
16463449|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
16463450|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
16463451|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
16463452|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:
~Age into 3 groups:
~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: > 40 years old
~Axial length into 3 groups:
~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: > 26 mm
~Spherical equivalent of refractive error into :
~Group A : from zero to - 2 D Group B : from - 2 to > - 4 D Group C : from - 4 to > - 6 D Group D: from - 6 to - 8 D
~Minimum corneal thickness (MCT) into 3 groups:
~Group i: < 500 um Group ii: from 500 to 540 um Group iii: > 540 um
~Refractive power of cornea (Mean K) into 3 groups:
~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: > 46 D"
16463453|NCT03542435|Experimental|SXC-2023|Dose Escalation
16463454|NCT03542435|Placebo Comparator|Placebo|Dose Escalation
16463455|NCT03542422|Experimental|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
16463456|NCT03542409|Experimental|Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
16463457|NCT03542409|Experimental|Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
16463458|NCT03542396|Experimental|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
16463459|NCT03542396|No Intervention|Control|Participants do not receive any intervention. Participants receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual psychotherapeutic treatment
16463460|NCT03542383|Active Comparator|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
16463461|NCT03542383|Sham Comparator|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
16463462|NCT03542357|Active Comparator|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
16463463|NCT03542357|Placebo Comparator|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
16463464|NCT03542344|Experimental|BI 1015550|
16463465|NCT03542344|Placebo Comparator|Placebo|
16463466|NCT03542331|Other|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
16463467|NCT03542331|Experimental|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
16463468|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
16463469|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
16463470|NCT03542305|Experimental|Mild|Mild renal impairment
16463471|NCT03542305|Experimental|Moderate|Moderate renal impairment
16463472|NCT03542305|Experimental|Severe|Severe renal impairment
16463473|NCT03542305|Other|Normal|Normal renal function
16463474|NCT03542292|Experimental|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
16463475|NCT03542292|Active Comparator|no placental drainage group|In control group the umblical cord was clamped both sides.
16463476|NCT03542279|Experimental|Early PE group|PE (3-5 times in each course) combined with high-dose glucocorticoid, and IVIG after PE.
16463477|NCT03542279|Active Comparator|Non-early PE group|IVIG (0.4 g/kg/d for each course for 5 d) combined with high-dose glucocorticoid, and PE after IVIG 2 weeks.
16463478|NCT03542266|Experimental|CC486 +CHOP|CC486 +CHOP
16463479|NCT03542253||Age|
16463497|NCT03542214|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
16463498|NCT03542201|Experimental|PLS|Plain abstract about the Cochrane systematic review.
16463499|NCT03542201|Experimental|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
16463503|NCT03542162|Experimental|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
16463504|NCT03542149|Experimental|A|"200mg of OZ439 and 480 mgPQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
16463505|NCT03542149|Experimental|B|"200mg of OZ439 and 640 mg PQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
16463506|NCT03542149|Experimental|C|"400mg of OZ439 and 480 mg PQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
16463507|NCT03542149|Experimental|D|"400mg of OZ439 and 640 mg PQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
16463508|NCT03542136|Other|Patients receiving chemotherapy treatment with oxaliplatin.|
16463509|NCT03542123|Experimental|NeuroTronik CANS Therapy® System|
16463510|NCT03542110|Active Comparator|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
16463511|NCT03542110|Placebo Comparator|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
16463512|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
16463513|NCT03542084|Experimental|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
16463514|NCT03542084|No Intervention|Control|Control arm patients will receive usual care
16463515|NCT03542071|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
16463516|NCT03542071|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
16463517|NCT03542058|Experimental|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
16463518|NCT03542058|No Intervention|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
16463519|NCT03542032|Other|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.
~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.
~Patients' postoperative sore throat will be questioned and recorded."
16463520|NCT03542032|No Intervention|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.
~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.
~Patients' postoperative sore throat will be questioned and recorded."
16463521|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
16463522|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
16463523|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
16463524|NCT03542006|Experimental|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
16463525|NCT03541993|Experimental|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
16463526|NCT03541993|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
16463527|NCT03541993|Experimental|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
16463528|NCT03541993|Placebo Comparator|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
16463529|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
16463530|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
16463531|NCT03541967|Other|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
16463532|NCT03541967|Other|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
16463533|NCT03541954|Other|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria > 5)
16463534|NCT03541954|Other|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria < 5)
16463535|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
16463536|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
16463537|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
16463538|NCT03541928|Experimental|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.
~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).
~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).
~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
16463539|NCT03541915|Experimental|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
16463540|NCT03541915|Placebo Comparator|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
16463541|NCT03541902|Experimental|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16463542|NCT03541902|Experimental|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16463543|NCT03541889|Experimental|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
16463544|NCT03541889|Experimental|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
16463545|NCT03541876||children with H. pylori infection|
16463546|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
16463547|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
16463549|NCT03541837|Other|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
16463550|NCT03541824|Experimental|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
16463551|NCT03541824|No Intervention|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
16463552|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
16463553|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
16463554|NCT03541798|Active Comparator|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
16463555|NCT03541798|Experimental|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.
~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
16464036|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
16463556|NCT03541798|Experimental|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .
~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
16463557|NCT03541772|Experimental|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
16463558|NCT03541772|Placebo Comparator|Placebo|Radiotherapy + Chemotherapy + Placebo
16463559|NCT03541759|Active Comparator|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) > 5.
16463560|NCT03541759|Active Comparator|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) > 5.
16463561|NCT03541746|Experimental|Study Group|Platelet Rich Plasma
16463562|NCT03541746|Active Comparator|Control Group|Intrauterine Foley's Catheter
16463563|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
16463564|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
16463565|NCT03541720|Experimental|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
16463566|NCT03541707|Active Comparator|Active Therapy|
16463567|NCT03541707|Sham Comparator|"As if Stimulation"|
16463568|NCT03541681|Active Comparator|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
16463569|NCT03541681|Active Comparator|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
16463570|NCT03541668|Experimental|Group A|Recombinant human urokinase (rhPro-UK)
16463571|NCT03541668|Active Comparator|Group B|Alteplase(rt-PA)
16463572|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
16463573|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
16463574|NCT03541642|Experimental|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
16463575|NCT03541642|Active Comparator|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
16463576|NCT03541616||Enrolled Patients|
16463577|NCT03541603|Experimental|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
16463578|NCT03541603|Placebo Comparator|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
16463579|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
16463580|NCT03541564|Experimental|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
16463581|NCT03541564|Experimental|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
16463582|NCT03541564|Active Comparator|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
16463583|NCT03541564|Placebo Comparator|Placebo Dose 4 oral administration|Placebo single dose
16463584|NCT03541551|Experimental|CTT with ologen® Collagen Matrix|Experimental: Trabeculotomy with trabeculectomy with ologen implant
16463585|NCT03541551|Active Comparator|Trab Trab|Active Comparator: Trabeculotomy with trabeculectomy
16463586|NCT03541538|Active Comparator|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
16463587|NCT03541538|Experimental|Especific manipulation|manual therapy performed specifically on the C6-7 segment
16463588|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
16463589|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
16463590|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
16463591|NCT03541512|Active Comparator|Education only|Educational materials only
16463592|NCT03541499|Experimental|Group 1|800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
16463593|NCT03541499|Experimental|Group 2|800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
16463594|NCT03541499|Placebo Comparator|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
16463595|NCT03541499|Experimental|Group 4|800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
16463596|NCT03541486|Experimental|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
16463597|NCT03541486|Active Comparator|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
16463598|NCT03541473|Active Comparator|Peptamen® 1.5 Vanilla|
16463599|NCT03541473|Placebo Comparator|Boost Plus® Vanilla|
16463600|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
16463601|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
16463602|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
16463603|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
16463604|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
16463605|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
16463606|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
16463607|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
16463608|NCT03541421|Experimental|Intervention|The patients administers own drugs during hospital stay.
16463609|NCT03541421|No Intervention|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
16463610|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
16463611|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable
~Minimized fentanyl usage intraoperatively
~Intubation + GA adjunct total: 1-2 mcg/kg
~Sedation: 0-0.25 mcg/kg
~Post-op: 0.5-1 mcg/kg
~Avoid morphine
~Avoid ketamine
~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine
~Avoid H2-blockers (cimetidine, ranitidine, famotidine)
~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)
~Fluid repletion based on maintenance and losses"
16463612|NCT03541395|Other|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
16463613|NCT03541382|Active Comparator|HIVST campaign arm|Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.
16463614|NCT03541382|No Intervention|SOC arm|Standard HTS will be provided by MoH at health facilities.
16463615|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
16463616|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
16463617|NCT03541356|Placebo Comparator|Placebo|
16463618|NCT03541356|Active Comparator|L-dopa 35 mg|
16463619|NCT03541356|Active Comparator|L-dopa 70 mg|
16463620|NCT03541356|Active Comparator|L-dopa 140 mg|
16463621|NCT03541356|Active Comparator|L-dopa 70 mg/carbidopa 7 mg|
16463622|NCT03541343|Experimental|GreenBone|All patients will receive the GreenBone implant instead of bovine xenograft.
16463623|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
16463624|NCT03541317|Experimental|Stage 1: Optimal First Line Implementation Strategy|"All schools enrolled will first be randomized to an optimal first line treatment in order to compare REP vs. REP + Coaching. Schools assigned to Stage 1 treatment REP will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation. Schools assigned to Stage 1 treatment REP + Coaching will receive the REP components plus weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
16463625|NCT03541317|Experimental|Stage 2: Added Value of Providing Facilitation|"After 2 months, schools will be assessed to determine whether they could benefit from augmenting their current strategy with a step-up strategy called Facilitation. Schools identified as potentially benefiting will be re-randomized to compare the added value of augmenting their current strategy with Facilitation, compared to continuing with their same strategy. Stage 2 treatment strategy: step-up will include provision of an additional implementation strategy called Facilitation. A full-time Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support school professionals in strategic thinking and leadership skills to address organizational barriers. Sites receiving Facilitation will receive regular calls for up to a minimum of 10 weeks from the Facilitator. All schools will also continue to receive their first line treatment (i.e. REP or REP + Coaching)."
16463626|NCT03541291|Experimental|SMART-SYNC LM03|All participants
16463627|NCT03541278|Experimental|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
16463628|NCT03541265|Experimental|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
16463677|NCT03540888|Active Comparator|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
16463629|NCT03541265|Active Comparator|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
16463630|NCT03541252|Experimental|Basal Cell Carcinoma Patients|Patients (>18 years) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on the face/scalp, <50mm on the trunk/extremities)
16463631|NCT03541239|Active Comparator|non-ischemic preconditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation by the Single Cuff Tourniquet 8000 to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
16463632|NCT03541239|Experimental|ischemic preconditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Single Cuff Tourniquet 8000, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
16463633|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.
~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
16463634|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.
~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
16463635|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).
~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
16463636|NCT03541200|Experimental|Open Label|MT-8554
16463637|NCT03541187|Experimental|G. cockroach allergenic extract|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.
~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
16463638|NCT03541187|Placebo Comparator|Placebo|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.
~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
16463645|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
16463646|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
16463647|NCT03541148|Experimental|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
16463648|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
16463649|NCT03541109|Experimental|Polypill|Polypill group will receive a fixed dose combinations of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg), prescribed once daily by moth for 34 months
16463650|NCT03541109|No Intervention|Control|The usual care arm will receive regular drug order at the time of discharge from the hospital.
16463651|NCT03541096|Experimental|Winter Swimmers|4 Months of supervised winter swimming.
16463652|NCT03541096|Placebo Comparator|Control group|No winter swimming activities.
16463653|NCT03541083|Experimental|Blinatumomab|After a 5-day steroid prephase patients will receive two weeks continuous infusion of blinatumomab. Then the first remission-induction course will be given after one week interruption. Subsequent therapy with 4 cycles of chemotherapy and two 4-week courses of blinatumomab will follow, and subsequently depending on risk group, eligibility and a suitable donor either allogeneic stem cell transplantation or 2 year maintenance treatment.
16463716|NCT03540680|Other|Child between 7 and 15 years old with BPD|Blood punction
16463717|NCT03540680|Other|Child between 7 and 15 years old without BPD|Blood punction
16464037|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
16463654|NCT03541070|Experimental|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
16463655|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
16463656|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
16463657|NCT03541031|Experimental|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
16463658|NCT03541031|Placebo Comparator|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
16463659|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
16463660|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
16463663|NCT03540979|Active Comparator|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
16463664|NCT03540979|Experimental|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
16463665|NCT03540966|Experimental|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
16463666|NCT03540966|Placebo Comparator|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
16463667|NCT03540953|Other|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
16463668|NCT03540940|Experimental|zero positive end expiratory pressure|
16463669|NCT03540940|Experimental|Positive end expiratory pressure|
16463670|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
16463671|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
16463672|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16463673|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
16463674|NCT03540901|Active Comparator|ACETAZOLAMIDE oral capsule|375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m
16463675|NCT03540901|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m.
16463676|NCT03540888|Experimental|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
16463718|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
16463678|NCT03540888|Active Comparator|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
16463679|NCT03540875|Experimental|Full automation group|Full automation control of propofol and remifentanil
16463680|NCT03540875|Other|Control group|Manual control of of propofol and remifentanil using TCI system
16463681|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging -20 to -30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
16463682|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
16463683|NCT03540849|Experimental|BV after allogeneic hematopoietic stem cell transplantation|
16463684|NCT03540836|Experimental|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
16463685|NCT03540836|Experimental|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
16463686|NCT03540836|Experimental|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
16463687|NCT03540823|Experimental|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
16463688|NCT03540823|Other|Healthy controls|Healthy children and adults
16463689|NCT03540810|Active Comparator|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
16463690|NCT03540810|Placebo Comparator|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
16463691|NCT03540797||Intensive care unit (ICU) patients with sepsis|
16463692|NCT03540784|No Intervention|Control group|usual care treatment
16463693|NCT03540784|Experimental|Nutrition|high-protein nutrition therapy
16463694|NCT03540784|Experimental|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
16463695|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
16463696|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
16463703|NCT03540745|Experimental|TES Treatment|Where subject is randomized to TES.
16463704|NCT03540745|Placebo Comparator|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
16463707|NCT03540706|Experimental|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
16463708|NCT03540706|No Intervention|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
16463709|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
16463710|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
16463711|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
16463712|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
16463713|NCT03540693||Weight-loss failure|Subjects who lost <25% body weight (or lost more but then regain weight so that now are at <25%) by 2-5 years post-surgery
16463714|NCT03540680|Other|Term newborns (≥37GA)|Blood punction on the cordon
16463715|NCT03540680|Other|Premature newborns|Blood punction on the cordon
16463720|NCT03540641|Active Comparator|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
16463721|NCT03540641|Sham Comparator|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
16463722|NCT03540641|Active Comparator|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
16463723|NCT03540641|Sham Comparator|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
16463724|NCT03540628|No Intervention|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
16463725|NCT03540628|Experimental|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
16463726|NCT03540615|Experimental|BAY1830839|Single Dose escalations
16463727|NCT03540615|Placebo Comparator|Placebo|Matching Placebo
16463728|NCT03540602|Placebo Comparator|Placebo|Rice flour capsule
16463729|NCT03540602|Active Comparator|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
16463730|NCT03540589|Experimental|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
16463731|NCT03540589|Experimental|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
16463732|NCT03540589|Experimental|Distraction plus vibration|Combination of the two interventions described above
16463733|NCT03540589|No Intervention|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
16463734|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
16463735|NCT03540550|Experimental|Dietary intervention|
16463736|NCT03540537|Other|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
16463737|NCT03540537|Experimental|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
16463738|NCT03540537|Experimental|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
16463739|NCT03540537|Other|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
16463740|NCT03540537|Experimental|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
16463741|NCT03540537|Experimental|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
16463742|NCT03540524|Experimental|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
16463743|NCT03540524|Experimental|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
16463744|NCT03540524|Experimental|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
16463745|NCT03540498|Experimental|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
16463746|NCT03540498|Placebo Comparator|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
16463747|NCT03540485|Experimental|Melatonin|Daily administration of 300 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
16463748|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
16463814|NCT03540082|No Intervention|Control|Written instructions will be provided on the correct way to fall without physical practice.
16463749|NCT03540472|Experimental|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.
~Medication time should last at least 6 months."
16463750|NCT03540446|Experimental|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
16463751|NCT03540446|Experimental|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
16463752|NCT03540446|Experimental|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)
16463753|NCT03540433||Study group|Surgical patients aged ≥70 years
16463754|NCT03540433||Control group|Healthy subjects, aged ≥70 years, American Society of Anesthesiologists (ASA) I+II+III, no surgery
16463755|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
16463756|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
16463757|NCT03540407|Experimental|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
16463758|NCT03540407|Placebo Comparator|Placebo|will receive a Placebo concomitant to the onco-specific treatment
16463759|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
16463760|NCT03540381||Not-identified neoatherosclerosis group|
16463761|NCT03540368|Experimental|Tranexamic acid injection|Group with tranexamic acid injection
16463762|NCT03540368|Placebo Comparator|Placebo|Group with Placebo
16463763|NCT03540355|Experimental|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:
~1 tablet Cipros 20 association; and
~1 tablet crestor placebo. Oral, once a day"
16463764|NCT03540355|Active Comparator|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:
~1 tablet Crestor 20 mg; and
~1 tablet cipros association placebo. Oral, once a day"
16463765|NCT03540342|Experimental|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
16463766|NCT03540342|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
16463767|NCT03540329|Active Comparator|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
16463768|NCT03540329|Active Comparator|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
16463769|NCT03540329|Active Comparator|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
16463770|NCT03540329|Active Comparator|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
16463771|NCT03540329|Active Comparator|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
16463772|NCT03540329|Active Comparator|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
16463773|NCT03540329|Active Comparator|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
16463774|NCT03540329|Active Comparator|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
16463775|NCT03540316|Active Comparator|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
16463776|NCT03540316|Active Comparator|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
16463777|NCT03540316|Active Comparator|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
16463778|NCT03540316|Active Comparator|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
16463779|NCT03540303|Experimental|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
16463780|NCT03540290|Active Comparator|Mechanical instrumentation and oral hygiene instructions|
16463781|NCT03540290|Experimental|Modification of the implant supported prostheses|
16463782|NCT03540277|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
16463783|NCT03540277|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
16463784|NCT03540277|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
16463785|NCT03540264|Active Comparator|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Clearfil Majesty will be used in the present study.
16463786|NCT03540264|Active Comparator|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
16463787|NCT03540251|Active Comparator|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
16463788|NCT03540251|Sham Comparator|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
16463789|NCT03540225|Experimental|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
16463790|NCT03540225|Experimental|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
16463791|NCT03540225|Experimental|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
16463792|NCT03540225|Experimental|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
16463793|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir
~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
16463794|NCT03540199|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16463795|NCT03540199|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16463796|NCT03540199|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16463797|NCT03540186|Experimental|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
16463798|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p<0.1) were included in multivariate analysis.
16463799|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
16463800|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
16463801|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
16463802|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
16463803|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
16463804|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
16463805|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
16463806|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
16463807|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
16463808|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
16463809|NCT03540108|Experimental|Experimental: L. plantarum ECGC 13110402 (LPLDL®)|Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 4 x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
16463810|NCT03540108|Placebo Comparator|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
16463811|NCT03540095|Experimental|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
16463812|NCT03540095|Experimental|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
16463813|NCT03540082|Active Comparator|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
16464038|NCT03538639||3|Healthy adult volunteers
16463815|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
16463816|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
16463817|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
16463818|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
16463819|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
16463820|NCT03540043|Placebo Comparator|Placebo|Administration of Placebo
16463821|NCT03540043|Experimental|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
16463822|NCT03540043|Experimental|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
16463823|NCT03540043|Experimental|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
16463824|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
16463825|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
16463826|NCT03540017|Experimental|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
16463827|NCT03539991|Experimental|Supportive care (online course, virtual meeting)|Participants complete an online course focusing on different aspects of tobacco prevention and cessation over 1 hour each per week for 4 weeks. They also engage in 6 virtual meetings over 1 hour about tobacco use once per month.
16463828|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
16463829|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
16463830|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
16463831|NCT03539952|Experimental|TETA 4HCL|Active Treatment
16463832|NCT03539952|Experimental|Penicillamine|Comparator: Penicillamine
16463833|NCT03539939|Experimental|Smoker Group|This group included smoker gingival recession patients.
16463834|NCT03539939|Active Comparator|Non-smoker Group|This group included non-smoker gingival recession patients.
16463835|NCT03539926|Experimental|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
16463836|NCT03539926|Placebo Comparator|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
16463837|NCT03539913|Active Comparator|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
16463838|NCT03539913|Active Comparator|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
16463839|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
16463840|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
16463841|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
16463842|NCT03539887|Experimental|Intranasal ketamine in alcohol abuse|Intranasal ketamine
16463843|NCT03539887|Placebo Comparator|Placebo|non-active placebo
16463844|NCT03539887|Placebo Comparator|Placebo in alcohol abuse|non-active placebo
16463845|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
16463846|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
16463847|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
16464039|NCT03538626|Experimental|1|5 mg/kg IV x 1
16463848|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:
~Treatment 1 will be standard hemodialysis (no device).
~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
16463849|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
16463850|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
16463851|NCT03539835|Experimental|Resistance training|
16463852|NCT03539835|Active Comparator|Cognitively-based compassion training|
16463854|NCT03539809|Experimental|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
16463855|NCT03539796|Experimental|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
16463856|NCT03539796|Active Comparator|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
16463857|NCT03539796|Active Comparator|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
16463858|NCT03539783||PARDS|Children <18 years of age with PARDS and expected duration of hospitalization seven days or greater.
16463859|NCT03539783||Control|Children <18 years of age without PARDS or other lung disease and expected duration of hospitalization 7 days or greater.
16463860|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
16463861|NCT03539770||Control|Children without scoliosis
16463862|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
16463865|NCT03539731|Active Comparator|Group I ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
16463866|NCT03539731|Experimental|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
16463867|NCT03539731|Experimental|Group III ([18F]DASA-23, PET)|Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one [18F]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final [18F]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
16463868|NCT03539731|Active Comparator|Group IV ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins
16463869|NCT03539718|Experimental|cases|Cases, taurolidine heparin 500 will be used at end of session
16463870|NCT03539718|Active Comparator|control|Controls, Heparin Sodium 5000 will be given at end of session
16463871|NCT03539679|Experimental|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
16463872|NCT03539679|No Intervention|CONTROL GROUP|No intervention.
16463873|NCT03539666|Experimental|Pork|Standard American Diet with meat source: lean pork. Diet adheres to 2015-2020 Guidelines for Americans.
16463874|NCT03539666|Experimental|Poultry|Standard American Diet with meat source: chicken. Diet adheres to 2015-2020 Guidelines for Americans.
16463875|NCT03539640|Active Comparator|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
16463876|NCT03539640|Active Comparator|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
16463877|NCT03539640|Active Comparator|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
16463878|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
16463879|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
16463880|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
16463881|NCT03539601|Experimental|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
16463882|NCT03539601|Active Comparator|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
16463883|NCT03539601|Active Comparator|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
16463884|NCT03539601|Placebo Comparator|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
16463885|NCT03539588|Active Comparator|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
16463886|NCT03539588|Active Comparator|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
16463888|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
16463889|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
16463890|NCT03539549|Experimental|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
16463892|NCT03539510|Experimental|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
16463893|NCT03539510|No Intervention|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
16463894|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
16463895|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
16463896|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
16463897|NCT03539471||psychiatric resident in NTUH|
16463898|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
16463899|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
16463900|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
16463903|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
16463904|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
16463905|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
16463906|NCT03539367|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16463907|NCT03539367|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16463908|NCT03539354|Active Comparator|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
16463940|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
16463909|NCT03539354|Experimental|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
16463910|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
16463911|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
16463912|NCT03539328|Other|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
16463913|NCT03539328|Experimental|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
16463914|NCT03539315|Experimental|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
16463915|NCT03539315|No Intervention|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
16463916|NCT03539302|Experimental|Repeat dose inhaled flecainide acetate|One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.
16463917|NCT03539289|Other|MUFA Diet|Monounsaturated Fatty Acids Diet
16463918|NCT03539289|Other|SFA Diet|Saturated Fatty Acids Diet
16463919|NCT03539276|No Intervention|Pre-intervention|Usual care
16463920|NCT03539276|Experimental|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
16463921|NCT03539263|Experimental|Group 1|the subjects are treated with probiotics: Bifihappy
16463922|NCT03539263|Placebo Comparator|Group 2|the subjects are treated with a placebo
16463923|NCT03539250|Experimental|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
16463924|NCT03539237|Experimental|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
16463925|NCT03539237|No Intervention|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
16463926|NCT03539224|Experimental|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
16463927|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
16463928|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
16463929|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
16463930|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
16463931|NCT03539185|Active Comparator|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
16463932|NCT03539185|Active Comparator|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
16463933|NCT03539172|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
16463934|NCT03539159|Experimental|Allogeneic conventional sized serum eye drops|
16463935|NCT03539159|Experimental|Allogeneic micro sized serum eye drops|
16463936|NCT03539146|Active Comparator|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
16463937|NCT03539146|Experimental|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
16463938|NCT03539107|Experimental|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
16463939|NCT03539107|Active Comparator|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
16463941|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
16463942|NCT03539081|Experimental|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.
~Intervention: Use of epidural spinal cord stimulation."
16463943|NCT03539081|Other|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.
~Intervention: Use of epidural spinal cord stimulation."
16463944|NCT03539081|Other|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.
~Intervention: Use of epidural spinal cord stimulation."
16463945|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
16463946|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:
~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.
~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.
~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
16463947|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.
~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
16463948|NCT03539029||Control group|age and sex matched healthy control persons
16463949|NCT03539029||Surgery|patients with ankle fracture treated surgically
16463950|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
16463951|NCT03539003|Experimental|sevoflurane (Group S)|general anesthesia with sevoflurane
16463952|NCT03539003|Active Comparator|desflurane (Group D)|general anesthesia with desflurane
16463953|NCT03539003|Active Comparator|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
16463954|NCT03538990|Experimental|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
16463955|NCT03538977|Active Comparator|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
16463956|NCT03538977|Experimental|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
16463957|NCT03538964|Active Comparator|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
16463958|NCT03538964|Sham Comparator|Non toric intraocular lens (IOL)|non toric intraocular lens
16463959|NCT03538951|Experimental|Cohort 1|10% VDA-1102
16463960|NCT03538951|Experimental|Cohort 2|20% VDA-1102
16463961|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
16463962|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
16463963|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
16463964|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
16463965|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
16463966|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
16463967|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
16463968|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
16463969|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
16463970|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
16463987|NCT03538860|Other|Method B first then Method A|Asynchronous telepsychiatry - that is, video-recorded interviews that are subsequently processed with automated speech recognition and machine translation technologies, with crossover to conventional in-person interview with a psychiatrist with a live human interpreter
16463988|NCT03538834|Experimental|Cod meal from residual material|Dietary supplement: cod meal from residual material, 8 g protein daily for 8 weeks
16463971|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
16463972|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
16463973|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
16463974|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
16463975|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
16463976|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
16463977|NCT03538925|Experimental|Treatment Group|AAC Generative Language Intervention
16463978|NCT03538925|Active Comparator|Business as Usual|Standard of Care / Business as Usual
16463979|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
16463980|NCT03538912|Other|Routine group|patient follow the routine strategy
16463982|NCT03538886|Active Comparator|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
16463983|NCT03538886|Experimental|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
16463984|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:
~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
16463985|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
16463986|NCT03538860|Other|Method A first then Method B|Conventional in-person interview with a psychiatrist with a live human interpreter with crossover to asynchronous telepsychiatry
16463989|NCT03538834|Placebo Comparator|Control|Control group receive tablet containing fillers and no protein
16463990|NCT03538821|Experimental|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
16463991|NCT03538821|Experimental|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
16463992|NCT03538821|Experimental|Control|Control group receive tablet containing fillers and no proteins
16463993|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
16463994|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
16463995|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
16463996|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
16463997|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
16463998|NCT03538769|No Intervention|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
16463999|NCT03538769|Other|Alert group|This will be the phase when e-alerts will be sent to the provider
16464000|NCT03538756|Experimental|Group A--Walkasins On Then Off|"Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.
~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
16464001|NCT03538756|Experimental|Group B--Walkasins Off Then On|"Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.
~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
16464002|NCT03538743|Placebo Comparator|Placebo|
16464003|NCT03538743|Experimental|PF-06882961 30 mg|
16464004|NCT03538743|Experimental|PF-06882961 100 mg|
16464005|NCT03538743|Experimental|PF-06882961 300 mg|
16464006|NCT03538743|Experimental|PF-06882961 600 mg|
16464007|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 5|
16464008|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 6|
16464009|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 7|
16464010|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 8|
16464011|NCT03538730|No Intervention|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
16464012|NCT03538730|Experimental|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
16464013|NCT03538704|Experimental|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
16464014|NCT03538704|No Intervention|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
16464015|NCT03538691|Experimental|Brexpiprazole & Citalopram Hydrobromide|Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
16464016|NCT03538691|Placebo Comparator|Placebo & Citalopram Hydrobromide|Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
16464017|NCT03538691|Experimental|Brexpiprazole & Escitalopram|Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
16464018|NCT03538691|Placebo Comparator|Placebo & Escitalopram|Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
16464019|NCT03538691|Experimental|Brexpiprazole & Fluoxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
16464020|NCT03538691|Placebo Comparator|Placebo & Fluoxetine|Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
16464021|NCT03538691|Experimental|Brexpiprazole & Paroxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
16464022|NCT03538691|Placebo Comparator|Placebo & Paroxetine|Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
16464023|NCT03538691|Experimental|Brexpiprazole & Sertraline|Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
16464024|NCT03538691|Placebo Comparator|Placebo & Sertraline|Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
16464025|NCT03538691|Experimental|Brexpiprazole & Duloxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
16464026|NCT03538691|Placebo Comparator|Placebo & Duloxetine|Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
16464027|NCT03538691|Experimental|Brexpiprazole & Venlafaxine extended-release (XR)|Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
16464028|NCT03538691|Placebo Comparator|Placebo & Venlafaxine extended-release (XR)|Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
16464029|NCT03538678|Experimental|Kwit app|Use of Kwit smartphone app
16464030|NCT03538678|No Intervention|Standard of care|Patient initiated follow-up post discharge
16464031|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
16464032|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
16464048|NCT03538587|Active Comparator|1/EMI Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions
16464049|NCT03538587|Active Comparator|2/Control Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
16464050|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
16464051|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
16464052|NCT03538548|Experimental|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
16464053|NCT03538535|Experimental|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
16464054|NCT03538522|Experimental|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
16464055|NCT03538522|Experimental|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
16464056|NCT03538522|Experimental|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
16464057|NCT03538522|Placebo Comparator|Placebo|Oral administration of placebo per day for 24 weeks
16464058|NCT03538496|Active Comparator|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
16464059|NCT03538496|Active Comparator|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
16464060|NCT03538483|Active Comparator|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
16464061|NCT03538483|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
16464062|NCT03538470|Experimental|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
16464063|NCT03538444|Experimental|Active rTMS|Participants will receive 18 sessions of active repetitive Transcranial Magnetic Stimulation over a period of three days. TMS consists of 3000 pulses of 10Hz stimulation applied to the left DLPFC using the beam F3 method
16464064|NCT03538444|Placebo Comparator|Sham rTMS|Participants will receive 18 sessions of sham rTMS over a period of three days.
16464065|NCT03538431|Experimental|Buspirone|These subjects will receive buspirone prior to engaging in the driving simulation.
16464066|NCT03538431|Experimental|Unmedicated|These subjects will take no medication prior to engaging in the driving simulation
16464067|NCT03538418|Experimental|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
16464068|NCT03538418|No Intervention|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
16464069|NCT03538405|Experimental|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
16464070|NCT03538392||PAD|
16464071|NCT03538392||AV Fistula|
16464072|NCT03538392||AV Graft|
16464073|NCT03538379|Active Comparator|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
16464074|NCT03538379|Active Comparator|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
16464075|NCT03538379|Active Comparator|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
16464076|NCT03538379|Active Comparator|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
16464077|NCT03538379|Active Comparator|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
16464078|NCT03538366|Experimental|Donor FMT|Fecal transplant from unrelated, healthy volunteers
16464079|NCT03538353|Other|Pain Education Video|Participants will watch a pain education video and then answer several questions.
16464080|NCT03538340|Active Comparator|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
16464081|NCT03538340|Experimental|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
16464082|NCT03538327|Experimental|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.
16464083|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
16464084|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 1)|
16464085|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 2)|
16464087|NCT03538288|Experimental|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
16464088|NCT03538275||Unipolar depression cohort|
16464089|NCT03538275||Bipolar depression cohort|
16464090|NCT03538275||Healthy Control cohort|
16464091|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
16464092|NCT03538249|Experimental|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
16464093|NCT03538249|Experimental|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
16464094|NCT03538249|Experimental|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
16464095|NCT03538249|No Intervention|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
16464096|NCT03538249|Experimental|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
16464097|NCT03538249|Experimental|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
16464098|NCT03538236|Active Comparator|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
16464099|NCT03538236|Experimental|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
16464100|NCT03538223|Experimental|"Radioterapy+Melomics-Health Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
16464101|NCT03538223|Experimental|Radiotherapy+Individualized Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
16464102|NCT03538223|Other|Radiotherapy+No Music Listening|Patients will undergo the standard treatment (radiotherapy) without music support.
16464103|NCT03538197|Other|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
16464104|NCT03538184|Experimental|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
16464105|NCT03538184|Active Comparator|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
16464106|NCT03538171|Active Comparator|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16464107|NCT03538171|Placebo Comparator|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16464108|NCT03538158|Experimental|Intervention condition - Fittle Senior|Participants will have access to the Fittle Senior System which will provide guided exercises and social support.
16464109|NCT03538158|Placebo Comparator|Control condition - paper and pencil|Participants will have a written booklet with exercises that they may do it on their own.
16464110|NCT03538119|Experimental|HIIT program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
16464111|NCT03538119|Experimental|Moderate continuous training program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
16464112|NCT03538119|No Intervention|Control Group|Usual care. The patients will receive nutritional counseling as well as physical activity.
16464113|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
16464114|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
16464115|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
16464116|NCT03538080|Experimental|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
16464117|NCT03538080|Sham Comparator|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
16464118|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
16464119|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
16464120|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
16464121|NCT03538041|Experimental|Cohort 1|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period, with a dose-increase option at Week 6 for participants who fulfill dose increase criteria.
16464122|NCT03538041|Experimental|Cohort 2|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period.
16464123|NCT03538028|Experimental|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
16464124|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
16464125|NCT03538015|Experimental|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
16464126|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
16464127|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
16464128|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
16464129|NCT03537989|Experimental|Restricted group|"Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.
~Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.
~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.
~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.
~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
16464130|NCT03537989|Active Comparator|Standard group|"Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.
~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.
~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.
~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
16464131|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
16464132|NCT03537963|Other|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
16464133|NCT03537963|Experimental|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
16464134|NCT03537963|Active Comparator|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
16464176|NCT03537703|Experimental|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
16464135|NCT03537963|Experimental|mHealth Stepped-care Intervention + virtual reality relaxation|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention + virtual reality relaxation component, post-intervention questionnaire and interview.
16464136|NCT03537950|Experimental|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
16464137|NCT03537950|Experimental|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
16464138|NCT03537950|Experimental|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
16464139|NCT03537950|Experimental|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
16464140|NCT03537950|Experimental|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
16464141|NCT03537950|Experimental|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
16464142|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
16464143|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
16464144|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
16464145|NCT03537924|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464146|NCT03537924|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464147|NCT03537911|Experimental|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
16464148|NCT03537898|Active Comparator|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
16464149|NCT03537898|Active Comparator|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
16464150|NCT03537885|Experimental|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.
~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
16464151|NCT03537872|Experimental|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.
~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
16464152|NCT03537872|Active Comparator|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.
~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
16464153|NCT03537859|Experimental|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
16464154|NCT03537859|Other|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
16464155|NCT03537846||Osteoporosis and women|Patient women over thirty years old
16464156|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
16464157|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
16464158|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
16464159|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
16464160|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
16464161|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
16464162|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
16464163|NCT03537781|Experimental|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
16464164|NCT03537781|Experimental|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
16464165|NCT03537781|Experimental|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
16464166|NCT03537781|Experimental|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
16464167|NCT03537768|Active Comparator|UPA 30mg|
16464168|NCT03537768|Active Comparator|LNG 1.5 mg|
16464169|NCT03537768|Active Comparator|LNG 3.0|
16464170|NCT03537742|Experimental|alirocumab|alirocumab 150mg subcutaneous every other week for one year following start of study drug
16464171|NCT03537742|Placebo Comparator|placebo|placebo to match alirocumab every other week for one year following start of study drug
16464172|NCT03537729|No Intervention|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
16464173|NCT03537729|Experimental|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
16464174|NCT03537729|Experimental|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
16464175|NCT03537716|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
16464177|NCT03537703|Active Comparator|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
16464178|NCT03537703|Active Comparator|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
16464179|NCT03537690|Experimental|Treatment (FID-007)|Participants receive FID-007 IV over 60 minutes on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16464180|NCT03537677|Experimental|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
16464181|NCT03537664|Experimental|Total bacteria analysis after 1rst- and 2nd-visit procedures|DNA levels and activity (RNA/DNA ratio) of total bacteria after the first-visit procedures (root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation) and the second-visit protocol (intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation). Additionally, the composition of the active microbiome will be assessed by Next Generation Sequencing (NGS) analysis of the root canal samples, and the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
16464182|NCT03537664|Other|Bacterial species analysis after root canal preparation|DNA levels and activity (RNA/DNA ratio) of Bacteroidaceae sp. 272 , Cutibacterium acnes, Selenomonas spp., and Enterococcus faecalis after root canal preparation.Additionally, the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
16464183|NCT03537651|Experimental|TEZ + IVA|"Subjects <30 kg will receive 50 mg TEZ/ 75 mg IVA as a FDC tablet in the morning and 75 mg IVA as a mono tablet in the evening.
~Subjects >=30 kg will receive 100 mg TEZ/ 150 mg IVA FDC tablet in the morning and 150 mg IVA as a mono tablet in the evening."
16464184|NCT03537638|Experimental|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
16464185|NCT03537638|No Intervention|Control|Rheumatologist and internist provide the usual care
16464186|NCT03537625|Experimental|Green tea|Green tea extract 2 gram per day
16464187|NCT03537625|Experimental|Fermented green tea|Fermented green tea extract 2 gram per day
16464188|NCT03537625|Placebo Comparator|Placebo|Placebo
16464189|NCT03537612|Experimental|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
16464190|NCT03537612|Experimental|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
16464191|NCT03537612|Active Comparator|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
16464192|NCT03537612|Active Comparator|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
16464193|NCT03537599|Experimental|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
16464194|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells. Evaluation of the sublingual microvasculature with a side stream dark field imaging video microscope will be performed.
16464195|NCT03537573|Active Comparator|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
16464196|NCT03537573|Experimental|Guideline + Opioid Justification (OJ)|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
16464197|NCT03537573|Experimental|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
16464198|NCT03537573|Experimental|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
16464199|NCT03537547|Experimental|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
16464263|NCT03537157|Experimental|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
16464264|NCT03537157|Placebo Comparator|Placebo|Two placebo tablets twice a day for 26 weeks
16464200|NCT03537547|Active Comparator|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
16464201|NCT03537534|Experimental|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
16464202|NCT03537534|Placebo Comparator|Placebo|Surgilube 5mL x 1 dose only
16464203|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
16464204|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
16464205|NCT03537508|Experimental|Group 1a|MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
16464206|NCT03537508|Experimental|Group 1b|MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
16464207|NCT03537508|Active Comparator|Group 2a|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
16464208|NCT03537508|Active Comparator|Group 2b|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
16464209|NCT03537495|No Intervention|Control arm|"Subjects in this arm will only receive high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (>37 kg: two 600 mg tablets) to reach ~35 mg/kg rifampicin in total."
16464210|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
16464211|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
16464212|NCT03537482|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
16464213|NCT03537469|Experimental|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
16464214|NCT03537469|Sham Comparator|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
16464215|NCT03537456|Experimental|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:
~Hypotrophic tissues
~Tissue hypotonicity
~Crow's feet
~Glogau III - IV
~Fiztpatrick I - VI
~WSRS (Wrinkle Severity Ranking Scale): 2-5"
16464216|NCT03537443|Placebo Comparator|Group A (Placebo)|Children whose mothers were randomized to receive a weekly dose of placebo from 17-24 weeks of gestation to 26 weeks postpartum.
16464217|NCT03537443|Experimental|Group B (4200:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 4200 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
16464218|NCT03537443|Experimental|Group C (16800:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 16800 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
16464219|NCT03537443|Experimental|Group D (28000:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
16464220|NCT03537443|Experimental|Group E (28000:28000 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by the same dose (28000 IU/week vitamin D3) from delivery to 26 weeks postpartum.
16464221|NCT03537430|Other|TNT Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent TNT uniportal VATS mediastinal tumor resection
16464222|NCT03537430|Other|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent traditional uniportal VATS mediastinal tumor resection
16464223|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
16464224|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
16464225|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
16464226|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
16464227|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
16464228|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
16464265|NCT03537144|Active Comparator|Indomethacin|Indomethacin as drug to treat PDA.
16464266|NCT03537144|Experimental|Acetaminophen|Acetaminophen as drug to treat PDA.
16464267|NCT03537131|Active Comparator|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
16464268|NCT03537131|Active Comparator|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
16464229|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:
~Traditional imaging (clinical standard imaging);
~Whole-body contrast enhanced computer tomography
~Planar bone scintigraphy
~Novel imaging (investigational imaging);
~SPECT/CT (investigational imaging)
~18F-PSMA-PET/CT (investigational imaging)
~Whole-body MRI (investigational imaging)
~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
16464230|NCT03537378|Experimental|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung neoplasms (severe dysplasia, carcinoma in situ, microinvasive carcinoma，mucoepidermoid carcinoma.etc.) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
16464231|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
16464232|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
16464233|NCT03537352||Surgical Disorders|"A. Surgical Disorders:
~Current Hospitalization at the Surgical Inpatient Department or at the Inpatient Department of Otorhinolaryngology or at the Inpatient Department of Cardiology OR
~Current Follow-up at the Surgical Outpatient Department or at the Outpatient Department of Otorhinolaryngology or at the Outpatient Department of Cardiology due to a disorder for which any appropriate surgical treatment (surgery) is a treatment option."
16464234|NCT03537352||Non-Surgical General Medical Disorders|"Current Hospitalization at the Internal Medicine Inpatient Department or at the Inpatient Department of Cardiology OR
~Current Follow-up at the Internal Medicine Outpatient Department or at the Outpatient Department of Cardiology due to a disorder for which surgery is not a treatment option and any appropriate drug or non-drug treatment excluding surgery is a treatment option."
16464235|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
16464236|NCT03537326|Experimental|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
16464237|NCT03537313|No Intervention|Control-douching group|No preoperative vagina douching
16464238|NCT03537313|No Intervention|Control-painting group|No intra-operative vagina painting
16464239|NCT03537313|Experimental|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
16464240|NCT03537313|Experimental|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
16464241|NCT03537300|Experimental|experimental group|
16464242|NCT03537300|Active Comparator|control group|
16464243|NCT03537287|Active Comparator|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
16464244|NCT03537287|Active Comparator|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
16464245|NCT03537287|Active Comparator|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
16464246|NCT03537274|Experimental|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
16464247|NCT03537274|Experimental|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
16464248|NCT03537274|Experimental|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
16464249|NCT03537274|Active Comparator|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
16464250|NCT03537261|Experimental|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
16464251|NCT03537261|No Intervention|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.
~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
16464252|NCT03537248|Experimental|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
16464253|NCT03537248|Active Comparator|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
16464254|NCT03537235|Experimental|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
16464255|NCT03537235|Placebo Comparator|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
16464256|NCT03537222||MyPOS|
16464257|NCT03537196|Other|All patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
16464258|NCT03537196|Other|HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (sofosbuvir 400 mg and daclatasvir 90 mg)
16464259|NCT03537196|Other|Cirrhosis|In case of cirrhosis : ribavirin will be added to sofosbuvir / daclatasvir 12 weeks
16464260|NCT03537196|Other|Cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : sofosbuvir and daclatasvir for 24 weeks
16464261|NCT03537183|No Intervention|Usual activity level|12 weeks of usual activity level
16464262|NCT03537183|Active Comparator|Exercise training|12 weeks of moderate intensity exercise training, 3 hours a week
16464271|NCT03537105|Experimental|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
16464272|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
16464273|NCT03537079|Placebo Comparator|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
16464274|NCT03537079|Active Comparator|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
16464275|NCT03537079|Active Comparator|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
16464276|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
16464277|NCT03537053|Experimental|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.
~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
16464278|NCT03537040|Other|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
16464279|NCT03537027|Experimental|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
16464280|NCT03537014|Experimental|MDMA-assisted therapy|Administration of 80 or 120 mg MDMA (with a supplemental dose offered 1.5 to 2 hours later of 40 or 60 mg MDMA respectively) in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.
16464281|NCT03537014|Placebo Comparator|Placebo with therapy|Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart
16464282|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
16464283|NCT03536988|Experimental|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
16464284|NCT03536988|Active Comparator|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
16464285|NCT03536975|Other|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
16464286|NCT03536975|No Intervention|Control|Group without any access to the web platform
16464287|NCT03536949|Experimental|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
16464288|NCT03536949|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
16464289|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
16464290|NCT03536910|Other|General anesthesia|
16464291|NCT03536910|Other|Spinal anesthesia|
16464292|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
16464293|NCT03536884|Experimental|Bimekizumab dosage regimen 1|Subjects randomized to this arm will receive bimekizumab dosage regimen 1. At Week 16 subjects will be re-randomized and continue to receive bimekizumab regimen 1 or to switch to bimekizumab regimen 2. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
16464294|NCT03536884|Experimental|Bimekizumab dosage regimen 2|Subjects randomized to this arm will receive bimekizumab dosage regimen 2 starting at Week 16 after initial treatment on bimekizumab regimen 1 for 16 weeks. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
16464295|NCT03536884|Active Comparator|Secukinumab|Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
16464296|NCT03536871|Active Comparator|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
16464297|NCT03536871|No Intervention|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
16464298|NCT03536871|No Intervention|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
16464299|NCT03536871|Experimental|Exercise - home based programme|Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
16464300|NCT03536858|Active Comparator|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
16464327|NCT03536676|Active Comparator|Traditional School Breakfast Program|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
16464328|NCT03536676|Experimental|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
16464301|NCT03536858|Active Comparator|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
16464302|NCT03536845|Active Comparator|400 IU|
16464303|NCT03536845|Active Comparator|1000 IU|
16464304|NCT03536832|Active Comparator|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
16464305|NCT03536832|Active Comparator|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
16464306|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
16464307|NCT03536806|Placebo Comparator|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
16464308|NCT03536806|Experimental|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
16464309|NCT03536793||Pancreatic cysts|Samples (urine, serum, whole blood and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM). Some of the cystic fluid and the whole blood sample will either be analysed at the University of Hull or a commercial laboratory for proteomic and genomic data. Collection will occur on the same day of the participants' routinely indicated procedure.
16464310|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
16464311|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing investigations for dyspepsia (normal control subgroup). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
16464312|NCT03536780|Experimental|Avelumab and Gemcitabine|
16464313|NCT03536767|Experimental|Open-Label|
16464314|NCT03536754|Placebo Comparator|Group A|Placebo (N=10)
16464315|NCT03536754|Experimental|Group B|CCX140-B 5 mg once daily (N=10)
16464316|NCT03536754|Experimental|Group C|CCX140-B 10 mg twice daily (N=10)
16464317|NCT03536754|Experimental|Group D|CCX140-B 15 mg twice daily (N=10)
16464318|NCT03536741|Experimental|ALR|
16464319|NCT03536741|Active Comparator|EV|
16464323|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
16464324|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
16464325|NCT03536689|Experimental|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
16464326|NCT03536689|Experimental|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
16464329|NCT03536663|Other|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
16464330|NCT03536650|Experimental|DMR procedure|
16464331|NCT03536637|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
16464332|NCT03536637|Experimental|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
16464333|NCT03536637|Experimental|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
16464334|NCT03536637|Placebo Comparator|Control|Placebo powder mixed with Placebo Diluent
16464335|NCT03536624|Experimental|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
~After the program, participants will be followed for 12 months."
16464336|NCT03536611|Experimental|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
16464337|NCT03536611|Active Comparator|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
16464338|NCT03536598|Experimental|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
16464339|NCT03536598|Active Comparator|Reference 1|Amlodipine 10mg + Valsartan 160mg
16464340|NCT03536598|Active Comparator|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
16464341|NCT03536585|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments; External mons pubis treatment monthly for 3 treatments; External labia treatment monthly for 3 treatments.
16464342|NCT03536585|No Intervention|Baseline|Subject's baseline photograph to act as their own control for the one-month and four-month post-treatment photograph of the mons pubis and labia.
16464343|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
16464344|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
16464345|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
16464346|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
16464347|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
16464348|NCT03536546|Experimental|Alcohol Peer-Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
16464349|NCT03536546|Active Comparator|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
16464350|NCT03536533|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
16464351|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464352|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464353|NCT03536507|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464354|NCT03536507|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464355|NCT03536494|Experimental|Mirabegron intervention|Review the use of mirabegron and its discontinuation
16464356|NCT03536494|No Intervention|Control group|Usual care
16464357|NCT03536481|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
16464358|NCT03536481|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
16464359|NCT03536481|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
16464360|NCT03536481|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
16464393|NCT03536260|Active Comparator|Immediate implant with Xenograft|
16464361|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
16464362|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464363|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464364|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
16464365|NCT03536429|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464366|NCT03536429|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
16464367|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
16464368|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
16464369|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
16464370|NCT03536403|Experimental|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
16464371|NCT03536390|Placebo Comparator|Placebo|one chewable tablet once daily in morning.
16464372|NCT03536390|Experimental|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
16464373|NCT03536377|Experimental|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
16464374|NCT03536364|Experimental|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
16464375|NCT03536351|Experimental|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
16464376|NCT03536338|Active Comparator|Control|Sit-to-stand training alone
16464377|NCT03536338|Experimental|Treatment|Sit-to-stand training combined with Spinal Stimulation
16464378|NCT03536325|Experimental|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
16464379|NCT03536325|Experimental|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
16464380|NCT03536325|Experimental|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
16464381|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
16464382|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
16464383|NCT03536299|Active Comparator|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
16464384|NCT03536299|Experimental|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
16464385|NCT03536286|Experimental|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.
~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
16464386|NCT03536286|No Intervention|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
16464387|NCT03536286|Experimental|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.
~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
16464388|NCT03536286|No Intervention|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
16464389|NCT03536273|Experimental|Functional Movement Screen|
16464390|NCT03536273|Experimental|Posture Analysis|
16464391|NCT03536273|Experimental|Depression Level|
16464392|NCT03536273|Experimental|Quality of Life|
16464395|NCT03536247|Active Comparator|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
16464396|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
16464397|NCT03536234|Experimental|Triptorelin (GnRH analogue)|
16464398|NCT03536234|No Intervention|Control group|
16464399|NCT03536208|Experimental|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
16464400|NCT03536182|Active Comparator|Arm A: Carbon ion radiotherapy|"The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency
~Japan : 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of each CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose.
~European: . Patients treated in Europe should receive 57.6 GyE in 4.8 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose. This evaluation will occur in the LEM system"
16464401|NCT03536182|Active Comparator|Arm B: Photon radiotherapy|50.4-56 Gy in 1.8-2.0 Gy per fraction in 28 fractions delivered 5 days a week. The plan should be normalized such that 100% of the PTV receives at least 48.9 Gy (i.e. 97% of 50.4 Gy). In addition, 100% of the GTV should receive at least 50.4 Gy. The maximum dose allowed to a point volume (0.03 mL) is 115% of the prescribed dose.
16464402|NCT03536143|Experimental|Topical beremagene geperpavec|HSV1-COL7A1 vector (KB103)
16464403|NCT03536130|Experimental|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
16464404|NCT03536130|No Intervention|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
16464405|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
16464406|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
16464407|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
16464408|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
16464409|NCT03536104||Controls|"This group will include healthy person."
16464410|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
16464411|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
16464412|NCT03536078|No Intervention|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
16464413|NCT03536078|Experimental|Home phototherapy|Newborns with icterus receiving phototherapy at home.
16464414|NCT03536065|Active Comparator|Pre-Intervention|Current practice (unchanged)
16464415|NCT03536065|Experimental|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
16464416|NCT03536052|Experimental|Virtual Heart Guided Ablation|
16464417|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
16464418|NCT03536026|Experimental|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
16464419|NCT03536013|Experimental|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
16464420|NCT03536013|No Intervention|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
16464421|NCT03536000||Healthy women|"200 Pregnant women
~Over 18 years
~Healthy
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
16464422|NCT03536000||Intrauterine Growth restriction|"Pregnant women
~Over 18 years
~Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth <p3 or <p10 with vascular Doppler alteration.
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
16464423|NCT03536000||Preeclampsia|"Pregnant women
~Over 18 years
~Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine> 30 mg / mmol creatinin
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
16464450|NCT03535792|Active Comparator|Fentanyl/Hyperbaric Bupivacaine|"Group F:
~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
16464424|NCT03536000||Diabetes Mellitus type 1|"Pregnant women
~Over 18 years
~Diabetes mellitus type1
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
16464425|NCT03535987||Observational|To determine the feasibility of using myocardial PET imaging
16464426|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
16464427|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
16464428|NCT03535961|Other|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
16464429|NCT03535935|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
16464430|NCT03535935|Experimental|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
16464431|NCT03535922|Experimental|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the ESAS-r:Renal or the IPOS-Renal.
16464432|NCT03535922|Experimental|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
16464433|NCT03535922|Experimental|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
16464434|NCT03535922|No Intervention|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
16464435|NCT03535896|Experimental|HSR and injection|HSR and corticosteroid injection
16464436|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
16464437|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
16464438|NCT03535870|Experimental|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
16464439|NCT03535870|Active Comparator|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
16464440|NCT03535870|Placebo Comparator|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
16464441|NCT03535857|Active Comparator|Unilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
16464442|NCT03535857|Experimental|Bilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
16464443|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
16464444|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
16464445|NCT03535831|Experimental|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.
~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
16464446|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
16464447|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
16464448|NCT03535805|Experimental|Mind My Mind (MMM)|Mind My Mind (MMM)
16464449|NCT03535805|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU)
16464451|NCT03535792|Active Comparator|Nalbuphine/Hyerbaric Bupivacaine|"Group N:
~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
16464452|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
16464453|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
16464454|NCT03535753|Experimental|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
16464456|NCT03535727|Experimental|Cohort 1|(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
16464457|NCT03535727|Experimental|Cohort 2|(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
16464458|NCT03535714|Active Comparator|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.
~Patients who who have already an existing psychotherapy are attached to the control group."
16464459|NCT03535714|No Intervention|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
16464460|NCT03535701|Active Comparator|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
16464461|NCT03535701|Experimental|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
16464462|NCT03535688|Experimental|D-cycloserine|D-cycloserine 200 mg BID (twice daily)
16464463|NCT03535688|Placebo Comparator|Placebo|Placebo BID (twice daily)
16464464|NCT03535675|Experimental|Muscadine Plus|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
16464465|NCT03535675|Experimental|Placebo|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
16464466|NCT03535662|Experimental|Orvepitant|Orvepitant single 20mg dose
16464467|NCT03535662|Experimental|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
16464468|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
16464469|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.
~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.
~A BMI under 35 and no pregnancy."
16464470|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
16464471|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
16464472|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
16464473|NCT03535610|Experimental|Embolization|Uterine Embolization with PVA Microspheres
16464474|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
16464475|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
16464476|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
16464477|NCT03535584|Experimental|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
16464478|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
16464479|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
16464699|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
16464480|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
16464481|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
16464482|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
16464483|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
16464484|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
16464485|NCT03535545|Experimental|Pulmonary Fibrosis Subjects|Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive [68Ga]CBP8 and undergo PET imaging.
16464486|NCT03535532|Experimental|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
16464487|NCT03535532|Active Comparator|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
16464488|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
16464489|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
16464490|NCT03535493|Active Comparator|Acceptance and Commitment Therapy (ACT)|
16464491|NCT03535493|Active Comparator|Float REST|
16464492|NCT03535493|Experimental|ACT + Float REST|
16464493|NCT03535480|Experimental|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
16464494|NCT03535480|Experimental|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
16464495|NCT03535467||Conventional Rehabilitation|
16464496|NCT03535467||Robotic Therapy|
16464497|NCT03535454||Factory workers|
16464498|NCT03535454||Nurses|
16464499|NCT03535454||Janitors|
16464500|NCT03535454||Data automation employees|
16464501|NCT03535441||voluteer group|No treatment, only blood sample collection
16464502|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, <15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
16464503|NCT03535428||VENOUS exploration|
16464504|NCT03535415|Experimental|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
16464505|NCT03535415|No Intervention|Non-treatment control group|Only follow-up without treatment
16464506|NCT03535402|Other|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
16464507|NCT03535389|Experimental|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
16464508|NCT03535389|Active Comparator|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).
~Does not have any clinical PFI syndrome
~Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
16464509|NCT03535363|Experimental|Maximum Tolerated Dose of Osimertinib with standard of care|For patients with 1-10 brain metastases, begin daily Osimeritinib 0-7 days prior to stereotactic radiosurgery (SRS), provide daily Osimeritinib concurrently with radiotherapy, followed by maintenance Osimeritinib until disease progression, withdrawal, or unacceptable toxicity. Dose Level 1: 80mg daily. Dose Level -1: 40mg daily
16464510|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
16464511|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
16464512|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
16464513|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
16464916|NCT03532620|Experimental|pitavastatin|Pitavastatin Calcium + lifestyle modification
16464514|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
16464515|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
16464516|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
16464517|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
16464518|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
16464519|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
16464520|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
16464521|NCT03535324|Other|Control|There will be no intervention.
16464522|NCT03535298|Experimental|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment.
~Interventions: one of the highly effective MS therapies
~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
16464523|NCT03535298|Experimental|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.
~Interventions: one of the MS therapies NOT in the highly effective group
~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
16464524|NCT03535298|No Intervention|OBS: Observational|"Participants will not be restricted to a group of MS therapies.
~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
16464525|NCT03535285|Experimental|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
16464526|NCT03535285|Active Comparator|Conventional surgery|Periodontal ligament distraction
16464527|NCT03535272|Active Comparator|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
16464528|NCT03535272|Placebo Comparator|Placebo|Placebo oral tablet 4 bid
16464529|NCT03535259|Experimental|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
16464530|NCT03535246|Experimental|Single arm|EIE cells to treat cancer.
16464531|NCT03535233|Active Comparator|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
16464532|NCT03535233|Active Comparator|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
16464533|NCT03535220||Observational/ Interventional|Hematologic Disease
16464534|NCT03535207|Experimental|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
16464535|NCT03535194|Experimental|250mg Q4W/250mg Q8W Mirikizumab|Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
16464536|NCT03535194|Experimental|250mg Q4W/125mg Q8W Mirikizumab|Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
16464537|NCT03535194|Experimental|Placebo/250mg Mirikizumab|Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
16464538|NCT03535194|Active Comparator|300mg Secukinumab|Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
16464539|NCT03535194|Experimental|Japan GPP/EP|Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.
16464540|NCT03535168|Experimental|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
16464541|NCT03535168|Experimental|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
16464542|NCT03535168|Experimental|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
16464609|NCT03534713|Active Comparator|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
16464543|NCT03535168|Experimental|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
16464544|NCT03535168|Experimental|BAY1902607+Matching Placebo|"Part 2:
~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
16464545|NCT03535168|Experimental|Matching Placebo+BAY1902607|"Part 2:
~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
16464546|NCT03535142|Experimental|Intervention|The intervention is bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
16464547|NCT03535142|No Intervention|Control|Age, BMI and co-morbidity matched group who do not undergo surgery.
16464548|NCT03535129|No Intervention|Stage 1|Pilot portion to optimize intervention and achievecorrelational research aims
16464549|NCT03535129|Experimental|Stage 2|Main Clinical Trial with random assignment
16464550|NCT03535116|Experimental|Patients receiving ketorolac|Patient receives 30mg IV ketorolac(single dose) towards the end of the operation.
16464551|NCT03535116|Placebo Comparator|Control|Patients receive saline intravenously towards the end of the operation.
16464552|NCT03535103|Experimental|ARM A|Gonal-F®
16464553|NCT03535103|Experimental|ARM B|LM001
16464554|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
16464555|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
16464556|NCT03535064|Experimental|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
16464557|NCT03535064|No Intervention|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
16464558|NCT03535051|Experimental|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
16464559|NCT03535051|Active Comparator|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
16464560|NCT03535038|Experimental|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
16464561|NCT03535038|Active Comparator|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
16464562|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
16464563|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
16464564|NCT03534999|Experimental|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
16464565|NCT03534999|No Intervention|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
16464566|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
16464567|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
16464568|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
16464569|NCT03534973|Active Comparator|Caffeine intake|Caffeine is given orally prior to cataract surgery
16464570|NCT03534973|Sham Comparator|No caffeine intake|Caffeine is not given orally prior to cataract surgery
16464571|NCT03534960|Other|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
16464572|NCT03534960|Other|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
16464573|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
16464574|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
16464575|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
16464634|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
16464576|NCT03534934|Experimental|Baseline|"Smokers, defined has having at least a 10 pack-year lifetime history, with and without COPD will participate in the following interventions:
~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
16464577|NCT03534934|Experimental|3 year follow-up|"All subjects who completed a baseline visit will return for a follow-up visit and participate in the following interventions:
~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
16464578|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged >=18 years with a record of severe mental illness so that at least one event occurs in the study period.
16464579|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
16464580|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
16464581|NCT03534908||NAFLD group|those with NAFLD
16464582|NCT03534908||Control group|those without NAFLD
16464583|NCT03534895|Placebo Comparator|PC1|5mL normal saline intravenous, single-administration, as pre-medication
16464584|NCT03534895|Experimental|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
16464585|NCT03534895|Experimental|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
16464586|NCT03534882|Experimental|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
16464587|NCT03534882|No Intervention|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
16464588|NCT03534869|Experimental|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.
~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
16464589|NCT03534869|Active Comparator|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
16464590|NCT03534856|Experimental|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
16464591|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
16464592|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
16464593|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
16464594|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
16464595|NCT03534817|Experimental|Early Access CR|Participants begin cardiac rehabilitation (CR) after 1-week following discharge post-MI.
16464596|NCT03534817|No Intervention|Standard Access CR|Participants begin CR after 7-weeks following discharge post-MI, similar to the average Canadian wait time.
16464597|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
16464598|NCT03534791|Experimental|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
16464599|NCT03534791|No Intervention|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
16464600|NCT03534778||patients undergoing neck dissection|all patients undergoing neck dissection
16464601|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
16464602|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
16464603|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
16464604|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
16464605|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
16464606|NCT03534726||Patients|Patients with cardiomyopathy
16464607|NCT03534726||Normal subjects|No prior history of heart disease.
16464608|NCT03534713|Experimental|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
16464635|NCT03534453|Experimental|Olaparib 300mg tablets|Taken orally twice daily
16464610|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
16464611|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
16464612|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
16464613|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
16464614|NCT03534674|Experimental|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
16464615|NCT03534674|No Intervention|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
16464616|NCT03534661|Placebo Comparator|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
16464617|NCT03534661|Active Comparator|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
16464618|NCT03534661|Placebo Comparator|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
16464619|NCT03534648|Experimental|Effect of PF-05221304 on PF-06865571 PK|
16464620|NCT03534648|Experimental|Effect of PF-06865571 on PF-05221304 PK|
16464621|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.
~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
16464622|NCT03534622|Experimental|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a
~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
16464623|NCT03534609|Experimental|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
16464624|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 3 consecutive days for 1.5-3 hours. There will then be a a gap of 4 days where participants will practice what they have learned, followed by 3 consecutive days of 1.5-3 hours of instruction. Starting the following week participants will attend once weekly follow up sessions (60-90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes, HEP will be delivered by a trained social worker (or equivalent).
16464625|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (6-8 participants). During the first week participants will attend three 2.5-3 hour sessions on three consecutive days. There will then be a gap of 4 days where participants can apply the tools provided, followed by three more consecutive days of 1.5-3 hours of instruction. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency.
16464626|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
16464627|NCT03534518|Active Comparator|SCI-patients receiving overground training|
16464628|NCT03534518|Active Comparator|SCI-patients receiving treadmill training|
16464629|NCT03534505|Experimental|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
16464630|NCT03534505|Active Comparator|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
16464631|NCT03534492|Experimental|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
16464632|NCT03534479|Experimental|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
16464633|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
16464637|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
16464638|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
16464639|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
16464640|NCT03534401|No Intervention|Standard Family Planning Counseling|Clients receive standard FP counseling services.
16464641|NCT03534401|Experimental|ARCHES Kenya Intervention in FP Counseling|Clients receive the ARCHES Kenya intervention in addition to standard FP counseling services.
16464642|NCT03534388|Other|Prospective Subjects|
16464645|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
16464646|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
16464647|NCT03534336|No Intervention|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.
~No financial incentives are given for losing weight or passing quizzes."
16464648|NCT03534336|Experimental|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.
~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
16464649|NCT03534336|Experimental|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.
~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
16464650|NCT03534323|Experimental|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.
~Duvelisib will be administered orally twice daily
~Venetoclax will be administered orally daily
~All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
16464651|NCT03534310|Active Comparator|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
16464652|NCT03534310|Experimental|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
16464653|NCT03534310|Active Comparator|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
16464654|NCT03534297|Experimental|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:
~Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days
~Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days
~Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days"
16464655|NCT03534297|Placebo Comparator|Placebo Capsules|"A total of 2 patients in each cohort will receive placebo capsules:
~Cohort 1 will receive 5 placebo capsules QD for 14 days
~Cohort 2 will receive 5 placebo capsules BID for 14 days
~Cohort 3 will receive 5 placebo capsules QID for 14 days"
16464656|NCT03534284|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
16464657|NCT03534284|Active Comparator|Medication- Trazodone|Trazodone (50-100 mg):
16464658|NCT03534284|Placebo Comparator|Medication- Placebo|Placebo (for trazodone)
16464659|NCT03534245||1|Healthy children aged 2 - 9 years
16464660|NCT03534219|Experimental|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.
~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6
~Administration:
~Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.
~Push button to start the airflow and swallow while the device is running.
~Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.
~Telephone call survey:
~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
16464661|NCT03534219|No Intervention|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)
~Telephone call survey:
~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
16464662|NCT03534193|Other|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
16464663|NCT03534193|Experimental|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
16464664|NCT03534180|Experimental|Treatment (venetoclax, romidepsin)|Patients receive venetoclax PO QD on days 1-28 and romidepsin IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
16464665|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
16464666|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
16464667|NCT03534154||TBI - MRI / bloods / cognitive / clinical outcomes|Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months
16464668|NCT03534154||TBI - Advanced MRI / bloods / cognitive / clinical outcomes|Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.
16464669|NCT03534154||TBI - microdialysis / adv. MRI / cognitive / clinical|Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.
16464670|NCT03534154||Healthy volunteer|Single assessment using MRI, bloods and cognitive testing.
16464671|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
16464672|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
16464673|NCT03534128|Experimental|Spatial navigation evaluation|
16464674|NCT03534115|Placebo Comparator|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
16464675|NCT03534115|Experimental|Experimental Arm|solution containing NAC with buffers
16464676|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
16464677|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
16464678|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
16464679|NCT03534089|Placebo Comparator|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
16464680|NCT03534089|Experimental|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
16464681|NCT03534089|Experimental|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
16464682|NCT03534063|Active Comparator|genotype-guided opioid therapy|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
16464683|NCT03534063|No Intervention|usual care|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
16464684|NCT03534050|Experimental|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
16464685|NCT03534037|Experimental|Febuxostat 40mg|Febuxostat 40mg orally per day
16464686|NCT03534037|Active Comparator|Benzbromarone 50mg|Benzbromarone 50mg orally per day
16464687|NCT03534037|Other|Control|Dietary control only
16464688|NCT03534024|Active Comparator|nanomicielle curcumin|
16464689|NCT03534024|Placebo Comparator|plecebo|
16464690|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
16464691|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
16464692|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
16464693|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
16464694|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
16464695|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
16464696|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
16464697|NCT03533972|Experimental|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
16464698|NCT03533972|Placebo Comparator|Control group|subjects will be provided with placebo capsules.
16464700|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
16464701|NCT03533946|Experimental|Rucaparib, all patients|Single Arm study, all patients will get rucaparib
16464702|NCT03533933|Active Comparator|Autologous connective tissue graft|Soft tissue harvesting from patient palate
16464703|NCT03533933|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
16464704|NCT03533920|Experimental|UNI-DEB|
16464705|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
16464706|NCT03533881|Active Comparator|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
16464707|NCT03533881|Active Comparator|Nutritional changes|Subjects only follow minimal nutritional changes
16464708|NCT03533868|No Intervention|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1® v2 (Roche) assay.
16464709|NCT03533868|Experimental|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
16464710|NCT03533855|Experimental|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
16464711|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
16464712|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
16464713|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
16464714|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
16464715|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
16464716|NCT03533803|Active Comparator|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
16464717|NCT03533803|Placebo Comparator|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
16464718|NCT03533790|Experimental|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
16464719|NCT03533777|Active Comparator|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
16464720|NCT03533777|Experimental|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
16464721|NCT03533764|Experimental|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
16464722|NCT03533764|No Intervention|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
16464723|NCT03533751|Placebo Comparator|Placebo|Placebo
16464724|NCT03533751|Experimental|Group 1|etokimab (ANB020)
16464725|NCT03533751|Experimental|Group 2|etokimab (ANB020)
16464726|NCT03533751|Experimental|Group 3|etokimab (ANB020)
16464727|NCT03533751|Experimental|Group 4|etokimab (ANB020)
16464728|NCT03533738|Experimental|Food selection 1|To consume vegetables followed by meat & rice together
16464729|NCT03533738|Experimental|Food selection 2|To consume meat followed by vegetables & rice together
16464730|NCT03533738|Experimental|Food selection 3|To consume as follows: vegetables, meat, rice
16464731|NCT03533738|Experimental|Food selection 4|To consume vegetables followed by meat and rice together
16464732|NCT03533738|Experimental|Food selection 5|To consume rice followed by vegetables & meat together
16464733|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
16464734|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
16464735|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
16464736|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
16464737|NCT03533699|Active Comparator|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
16464738|NCT03533699|Placebo Comparator|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
16464739|NCT03533686|Experimental|Single-Sided Deafness Adult (Aim1) Group|Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
16464740|NCT03533686|Experimental|Conductive Hearing Loss Adult (Aim 2) Group|Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
16464741|NCT03533686|Experimental|Adhear followed by BAHA (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
16464742|NCT03533686|Experimental|BAHA followed by Adhear (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
16464743|NCT03533686|Experimental|Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group|Pediatric participants (aged 2-17 years) with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
16464744|NCT03533686|Experimental|Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group|Pediatric participants (aged 2-17 years) with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
16464745|NCT03533673|Experimental|Cohort 1|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 1)
16464746|NCT03533673|Experimental|Cohort 2|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 2)
16464747|NCT03533673|Experimental|Cohort 3|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 3)
16464748|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
16464749|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
16464750|NCT03533647||entire cohort (observational)|none (observational study)
16464751|NCT03533634|Experimental|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
16464752|NCT03533634|Experimental|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
16464753|NCT03533621|Experimental|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
16464754|NCT03533621|Placebo Comparator|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
16464755|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
16464756|NCT03533595|No Intervention|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
16464757|NCT03533595|Active Comparator|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
16464758|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
16464759|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
16464760|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity.
16464761|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity.
16464762|NCT03533582|Experimental|GROUP B2 (UNRESECTABLE)|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (4 pre-surgery, 2 post-surgery).
16464763|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
16464764|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
16464819|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
16464820|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
16464765|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
16464766|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16464767|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16464768|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
16464769|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
16464770|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment.
16464771|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment.
16464772|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
16464773|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
16464774|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
16464775|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
16464776|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
16464777|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
16464778|NCT03533530|Active Comparator|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
16464779|NCT03533530|Experimental|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
16464780|NCT03533530|Experimental|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
16464781|NCT03533517|Experimental|AccuCinch® Ventricular Restoration System|
16464782|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
16464783|NCT03533491|Experimental|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
16464784|NCT03533478|Experimental|Group I|32 patients with mild or moderate diabetic macular edema.
16464785|NCT03533478|Placebo Comparator|Group II|32 patients with mild or moderate diabetic macular edema
16464786|NCT03533465|Experimental|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
16464787|NCT03533452|Active Comparator|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
16464788|NCT03533452|Sham Comparator|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
16464789|NCT03533426|Active Comparator|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg & the pump is sufficient for about 60 hours according to patient response."
16464821|NCT03533192|Experimental|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
16464822|NCT03533192|No Intervention|Usual care|Students received their regular health education.
16464790|NCT03533426|Active Comparator|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
16464791|NCT03533413|Active Comparator|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
16464792|NCT03533413|Active Comparator|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
16464793|NCT03533400|Active Comparator|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
16464794|NCT03533400|Experimental|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
16464795|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
16464796|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
16464797|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
16464798|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation
~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
16464799|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation
~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
16464800|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
16464801|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
16464802|NCT03533335|Active Comparator|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
16464803|NCT03533335|Experimental|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
16464804|NCT03533335|Placebo Comparator|Sterile water spray|Placebo
16464805|NCT03533309|Experimental|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.
~."
16464806|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
16464807|NCT03533296|Experimental|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
16464811|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
16464812|NCT03533257|Active Comparator|Active (AMX0035)|AMX0035--a combination of TUDCA and Phenylbutyrate
16464813|NCT03533257|Placebo Comparator|Placebo|Taste-matched Placebo
16464814|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
16464815|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
16464816|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
16464817|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
16464818|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
16464917|NCT03532620|Active Comparator|atorvastatin|Atorvastatin Calcium + lifestyle modification
16464823|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.
~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
16464824|NCT03533179|Experimental|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.
~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
16464825|NCT03533179|Experimental|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.
~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
16464826|NCT03533179|Experimental|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.
~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
16464827|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.
~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
16464828|NCT03533166|Experimental|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
16464829|NCT03533166|Placebo Comparator|Placebo|Mechanical treatment + Placebo mouth rinse
16464830|NCT03533153|Experimental|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
16464831|NCT03533153|Placebo Comparator|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
16464832|NCT03533140|Active Comparator|DUCEST Neurostimulator V Group A|
16464833|NCT03533140|Sham Comparator|DUCEST Neurostimulator V Group B|
16464834|NCT03533127|Experimental|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
16464835|NCT03533127|Experimental|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
16464836|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
16464837|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
16464838|NCT03533101|Experimental|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
16464839|NCT03533101|Active Comparator|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
16464840|NCT03533088|Experimental|Hospitalized rehabilitation|Patients in this group will recieve rehabilitation program twice in a week at our clinic after the surgical procedure until post-operative 12 weeks.
16464841|NCT03533088|Experimental|Home-based rehabilitation|Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
16464842|NCT03533075|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
16464843|NCT03533075|No Intervention|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
16464844|NCT03533062|Active Comparator|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
16464845|NCT03533062|Active Comparator|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
16464846|NCT03533049|Experimental|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.
~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
16464871|NCT03532906|Active Comparator|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
16465005|NCT03532009|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
16464847|NCT03533049|Active Comparator|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
16464848|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
16464849|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
16464850|NCT03533023|Experimental|TRE + SOC|Time Restricted Eating + Standard of Care
16464851|NCT03533023|Other|SOC|Standard of Care
16464852|NCT03533010|Active Comparator|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
16464853|NCT03533010|Placebo Comparator|Placebo|Dietary Supplement: Placebo
16464854|NCT03532997|Experimental|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
16464855|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
16464856|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
16464857|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
16464858|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
16464859|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
16464860|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
16464861|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
16464862|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
16464863|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
16464864|NCT03532958|Placebo Comparator|Placebo|Normal saline
16464865|NCT03532958|Experimental|Low Dose BNZ-1|0.5 mg/kg QW
16464866|NCT03532958|Experimental|Moderate Dose BNZ-1|2 mg/kg QW
16464867|NCT03532945|Experimental|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
16464868|NCT03532945|Active Comparator|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
16464869|NCT03532932||UC Participants|Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
16464870|NCT03532932||CD Participants|Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.
16464872|NCT03532906|Other|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
16464874|NCT03532867|Experimental|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.
~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.
~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :
~Examination of pressures before stopping the exercise
~Examination of pressure during the exercise
~Examination of pressures after stopping the exercise"
16464875|NCT03532854|Experimental|Sequence A|Ezetimibe/Rosuvastatin -> Valsartan -> Valsartan and Ezetimibe/Rosuvastatin
16464876|NCT03532854|Experimental|Sequence B|Valsartan -> Valsartan and Ezetimibe/Rosuvastatin-> Ezetimibe/Rosuvastatin
16464877|NCT03532854|Experimental|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -> Ezetimibe/Rosuvastatin -> Valsartan
16464878|NCT03532854|Experimental|Sequence D|Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin-> Valsartan
16464879|NCT03532854|Experimental|Sequence E|Valsartan -> Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin
16464880|NCT03532854|Experimental|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -> Valsartan -> Ezetimibe/Rosuvastatin
16464881|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
16464882|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
16464883|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
16464884|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
16464885|NCT03532815|Active Comparator|Lifestyle Modification group|
16464886|NCT03532815|No Intervention|Control group|
16464887|NCT03532802|Active Comparator|Metoprolol Succinate|Metoprololsuccinat
16464888|NCT03532802|Placebo Comparator|Placebo oral capsule|Placebo
16464889|NCT03532789|Experimental|herbal patch group|using herbal patch as an intervention
16464890|NCT03532789|Placebo Comparator|placebo patch group|using placebo patch as an intervention
16464891|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
16464892|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
16464893|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
16464894|NCT03532763|Experimental|Tocotrienol-rich fraction|
16464895|NCT03532763|Placebo Comparator|Placebo|
16464896|NCT03532750|No Intervention|Control|This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.
16464897|NCT03532750|Experimental|Particle|Randomized to receive either the Embozene or Embosphere particles
16464898|NCT03532750|Experimental|Coil|Randomized to receive either Ruby or Interlock detachable coils
16464899|NCT03532737|Experimental|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.
~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 21 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses
~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
16464900|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
16464901|NCT03532698||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
16464902|NCT03532698||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
16464903|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
16464904|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
16464905|NCT03532685|No Intervention|Severe Obese Patients|usual care
16464906|NCT03532672|Experimental|Acute Fasting|Eutrophic and obese women will fast 10 hours during daily activities after a standardized breakfast.
16464907|NCT03532659|Experimental|Active video game|The adolescents will be submitted to physical activity with active video game for 50 minutes, 3 times a week, for a period of eight weeks. The XBOX360® platform will be used with the Kinect accessory (Microsoft®) and Just Dance will be the selected game. The music used for intervention will be previously selected, including those that can lead to moderate intensity, and assembled in blocks of 10. For each week, a new block and challenges must be elaborated to increase the motivation to carry out the physical activity.
16464908|NCT03532659|No Intervention|control|A follow-up will be done for eight weeks to compare the variables. The adolescents in this group will be interviewed monthly to detect changes in eating habits and lifestyle.
16464909|NCT03532646|Other|group 1: RYGB|All patients who underwent RYGB and were readmitted to upper endoscopy are getting observed
16464910|NCT03532646|Other|group 2:MGB/OAGB|All patients who underwent MGB/OAGB and were readmitted to upper endoscopy are getting observed
16464911|NCT03532633||23-27w|preterm infants 23+0-27+6SSW
16464912|NCT03532633||28-31w|preterm infants 28+0-31+6SSW
16464913|NCT03532633||32-34w|preterm infants 32+0 - 34+6SSW
16464914|NCT03532633||35-36w|preterm infants 35+0-36+6 SSW
16464915|NCT03532633||37-42w|term infants 37+0-42+6
16464918|NCT03532607|Experimental|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
16464919|NCT03532607|No Intervention|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
16464920|NCT03532594|Other|Standard Care|At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
16464921|NCT03532594|Experimental|Algorithm|For patients in the intervention group, protamine will be administered according to the PRODOSE algorithm, which has been incorporated into an Excel spread sheet for ease of use (Microsoft Corporation).
16464922|NCT03532581|Experimental|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
16464923|NCT03532568|Experimental|CKD-aP patients|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue and their response to narrow band ultraviolet B
16464924|NCT03532568|Experimental|CKD patients without pruritis|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
16464925|NCT03532568|Experimental|normal healthy participants|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
16464926|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
16464927|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
16464928|NCT03532542|Experimental|Casimersen|Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
16464929|NCT03532542|Experimental|Golodirsen|Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
16464930|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:
~death within 30 days from VA ECMO liberation
~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation
~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal
~heart transplantation within 30 days from VA ECMO liberation"
16464931|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:
~death within 30 days from VA ECMO liberation
~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation
~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal
~heart transplantation within 30 days from VA ECMO liberation"
16464932|NCT03532503|Active Comparator|Foley catheter filled with 30 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 30 ml saline. A gentle traction will be applied.
16464933|NCT03532503|Active Comparator|Foley catheter filled with 50 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 50 ml saline. A gentle traction will be applied.
16464934|NCT03532490|Active Comparator|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
16464935|NCT03532490|Placebo Comparator|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
16464936|NCT03532464|Experimental|Patient treated by doxycycline|"The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
16464937|NCT03532464|Active Comparator|Patients treated by azithromycin|"The patients in the azithromycin group take 4 tablets of 250 mg in the morning as a single dose.
~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
16464938|NCT03532451|Experimental|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
16464939|NCT03532451|Experimental|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
16464940|NCT03532438||NTM patient group|NTM lung disease patients living together
16464941|NCT03532425|Experimental|B/F/TAF|"B/F/TAF + Atripla Placebo
~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
16464942|NCT03532425|Active Comparator|Atripla|"Atripla + B/F/TAF Placebo
~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
16464943|NCT03532412||HF+CSA+PB|Systolic heart failure with predominant central sleep apnea and periodic breathing
16464944|NCT03532399||Pediatric Cardiac Catheterization|
16464945|NCT03532399||Pediatric Cardiac Surgery|
16464946|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
16464947|NCT03532386||Study group|Infertile men with oligoasthenospermia with non-tense vaginal hydrocele subjected to ICSI
16464948|NCT03532386||Control group|infertile men with oligoasthenospermia without hydrocele subjected to ICSI
16464949|NCT03532373|No Intervention|Control|None- normal care
16464950|NCT03532373|Experimental|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
16465006|NCT03532009|Placebo Comparator|Placebo|Powder for oral suspension
16464951|NCT03532360|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
16464952|NCT03532360|Active Comparator|Low-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
16464953|NCT03532360|Active Comparator|High-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
16464954|NCT03532347|Experimental|EUS tissue sampling|"Device: EUS-FNA needle (Beacon) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail
~Device:EUS-FNB needle (Beacon Sharkcore) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail"
16464955|NCT03532321||Caregivers|Caregivers in the participating hospital departments : medical (doctors, midwives) and paramedical (nurses' aides, registered nurses, specialized nurses and head nurses) staff, working in hospital departments drawn at random among five volunteer hospital centers in Paris, and who will be present at the time of investigator's passage, at a date drawn at random during the inclusion phase.
16464956|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
16464957|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
16464960|NCT03532282|Active Comparator|ONLINE ONLY|Online cognitive behavioral therapy for insomnia
16464961|NCT03532282|Experimental|STEPPED CARE|Cognitive behavioral therapy for insomnia online or therapist-led or sequentially both
16464962|NCT03532269|Experimental|A: 3rd night with acoustic stimulation|Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
16464963|NCT03532269|Experimental|B: 2nd night with acoustic stimulation|Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
16464964|NCT03532256||Treated Patients|This prospective, observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients treated for an acute injury and prescribed an opioid from the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
16464965|NCT03532256||Treated patients randomized to receive survey|A subset of patients (described above) will receive an automated SMS text message with a link to an online survey. This survey contains the script questions about pain management and opioid use.
16464966|NCT03532256||Treated patients randomized to receive text script|A subset of patients (described above) will receive an automated questionnaire conducted via text message. Questions will be about pain management and opioid use.
16464967|NCT03532243|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the threshold loading device with incremental inspiratory load.
16464968|NCT03532243|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the threshold loading device with incremental inspiratory load.
16464969|NCT03532230||Experimental Group|90 new patients seeking treatment for chronic low back pain. This group will receive standard care plus osteopathic manipulative treatment (OMT) for low back pain.
16464970|NCT03532230||Control Group|90 new patients seeking treatment for chronic low back pain. This group will receive only standard care without osteopathic manipulative treatment (OMT) for low back pain.
16464971|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.
~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
16465004|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
16464972|NCT03532204|Experimental|Chemotherapy + SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.
~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.
~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
16464973|NCT03532204|Active Comparator|Chemotherapy|Patients will receive chemotherapy as initially scheduled
16464974|NCT03532191|Experimental|PrEP-OI Intervention|All clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
16464975|NCT03532191|No Intervention|Control until randomized for intervention|All clinics that have not yet initiated the intervention at this time (i.e., control clinics). A new clinic will cross over to receive the intervention each month, with the order of clinic crossover determined at random, until all clinics are receiving the intervention.
16464976|NCT03532178|Experimental|Group A|rocuronium + sugammadex / succinylcholine + normal saline
16464977|NCT03532178|Experimental|Group B|succinylcholine + normal saline / rocuronium + sugammadex
16464978|NCT03532165|Other|Positive lower extremity ultrasound|This group found to to have a deep venous thrombosis on lower extremity ultrasound will not have a CT of the chest ordered from the emergency department, and will be treated for the DVT and presumed PE.
16464979|NCT03532165|Other|Negative lower extremity ultrasound|This group that does not have a deep venous thrombosis on lower extremity ultrasound will proceed to get the CT of the chest .
16464980|NCT03532152|Active Comparator|Pure Purr VR technology|"The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.
~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
16464981|NCT03532152|Sham Comparator|Sham VR technology|"The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
16464982|NCT03532139|Experimental|Enoxaparin|-Enoxaparin is administered subcutaneous daily
16464983|NCT03532139|Experimental|Enoxaparin + Rosuvastatin|"Enoxaparin is administered subcutaneous daily.
~Rosuvastatin is administered daily orally starting on day 15"
16464984|NCT03532139|Experimental|Thromboprophylaxis|-Thromboprophylaxis is administered per clinician discretion
16464985|NCT03532126||Dermal filler for midface deficit|There will be one group in this study, the actual treatment group.
16464986|NCT03532113|Experimental|Updating|The Updating intervention aims to improve the ability to monitor and quickly add or delete of content of working memory.
16464987|NCT03532113|Experimental|Inhibition|The Inhibition intervention aims to improve the ability to supersede responses that are prepotent or automatic for a given situation.
16464988|NCT03532113|Active Comparator|General Knowledge|The General knowledge intervention allows the learning of information on various topics. It does not involve attentional control but semantic knowledge.
16464989|NCT03532100|Experimental|Straight line walking|All participants will walk in a straight line while wearing the study prosthesis.
16464990|NCT03532100|Experimental|Circle walking with prosthesis inside|All participants will walk around a 1-meter radius circle with their prosthesis on the inside of the circle.
16464991|NCT03532100|Experimental|Circle walking with prosthesis outside|All participants will walk around a 1-meter radius circle with their prosthesis on the outside of the circle.
16464992|NCT03532087|No Intervention|No denosumab|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are not additionally treated with denosumab.
16464993|NCT03532087|Experimental|Denosumab 120 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 120 mg every 3 weeks. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
16464994|NCT03532087|Experimental|Denosumab 60 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 60 mg every 6 months. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
16464995|NCT03532074|Other|laparoscopic approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a laparoscopic approach; follow up and assessment of bowel symptoms after surgery
16464996|NCT03532074|Other|robot-assisted approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a robot-assisted approach; follow up and assessment of bowel symptoms after surgery
16464997|NCT03532061|Experimental|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
16464998|NCT03532061|Active Comparator|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
16464999|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
16465000|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
16465001|NCT03532035|Experimental|Brincidofovir (BCV)|"Cohort 1: BCV 10 mg twice weekly via IV infusion over 2 hours
~Cohort 2: BCV 15 mg twice weekly via IV infusion over 2 hours
~Cohort 3: BCV In Cohort 3, the actual dose may be higher or lower than doses administered in previous cohorts; the maximum dose of IV BCV will be ≤ 25 mg."
16465002|NCT03532035|Active Comparator|Standard of Care (SoC)|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV Cidofovir (CDV), ganciclovir, or ribavirin."
16465003|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
16465008|NCT03531970|Placebo Comparator|Non-dexamethasone|lidocaine & Placebo
16465009|NCT03531957|Experimental|ASN002 40 mg|40 mg ASN002
16465010|NCT03531957|Experimental|ASN002 60 mg|60 mg ASN002
16465011|NCT03531957|Experimental|ASN002 80 mg|80 mg ASN002
16465012|NCT03531957|Experimental|Placebo Oral Tablet|Matching placebo for ASN002 doses
16465013|NCT03531944|Experimental|Community pharmacist-involved care|Community pharmacist-involved collaborative care in the management of type 2 diabetes mellitus
16465014|NCT03531944|Placebo Comparator|Usual care|Usual care with physician and as needed referral to nurses
16465015|NCT03531918|Experimental|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first cycle of induction are eligible for a second cycle, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.
~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during cycle 1, and cytarabine IV every 12 hours on days 1-6 of cycles 2-3. Treatment repeats every month for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
16465016|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
16465017|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
16465018|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsule
16465019|NCT03531892|Experimental|AJM300 960mg/dose|Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
16465020|NCT03531892|Placebo Comparator|Placebo|Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
16465021|NCT03531879||subject with plaques and without plaques|Subject with plaques and without plaques
16465022|NCT03531866|Experimental|Intervention Version A|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version A will include an additional topic area.
16465023|NCT03531866|Experimental|Intervention Version B|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version B will include an additional topic area (different than in Version A).
16465024|NCT03531866|No Intervention|Wait-List Control|Youth will not have access to DigiKnowIt News until after the post-test timepoint.
16465026|NCT03531840|Experimental|Arm 1/Olaparib|Twice daily oral olaparib
16465027|NCT03531827|Experimental|1/Lead-In Safety|Combination treatment of increasing dose of CRLX101 with enzalutamide
16465028|NCT03531827|Experimental|2/Efficacy|Tolerable dose of CRLX101 in combination with enzalutamide (8 patients, expandable to 21 total patients)
16465029|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
16465030|NCT03531801||Recovered fracture group|The interventions will be conducted on both groups, on two experimental (approximately 45 minutes per session) sessions separated by 24 hours.Pressure algometry consists of measuring pressure pain thresholds at three bilateral muscle sites.Mapping referred pain areas consists of recording on an electronic body chart the area of pain induced by 60s pressure stimulation at 1.2 times the force needed to reach the pressure pain threshold, exerted on the extensor carpi radialis and the infraspinatus muscles.As group-differences can be attenuated at baseline but emerge on a sensitized (exercise-induced soreness) state, these procedures are performed at baseline and 24 hours after evoking exercise-induced muscle soreness. For further clarification see our recent publication PMID:29608510
16465031|NCT03531801||Control group|This group will receive the same intervention than the recovered fracture group
16465032|NCT03531788|Experimental|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
16465033|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
16465034|NCT03531775|Other|Upright MRI|All participants will be scanned using an upright MRI in seated/standing position and supine position. They will also be scanned supine using a conventional MRI.
16465035|NCT03531762|Experimental|Sequence 1: Treatment A-B-C|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
16465036|NCT03531762|Experimental|Sequence 2: Treatment A-C-B|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
16465037|NCT03531762|Experimental|Sequence 3: Treatment B-A-C|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
16465038|NCT03531762|Experimental|Sequence 4: Treatment B-C-A|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days between.
16465039|NCT03531762|Experimental|Sequence 5: Treatment C-A-B|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
16465040|NCT03531762|Experimental|Sequence 6: Treatment C-B-A|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days.
16465041|NCT03531749|Experimental|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
16465042|NCT03531749|Experimental|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
16465043|NCT03531749|Experimental|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
16465044|NCT03531749|Experimental|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
16465045|NCT03531749|No Intervention|HIV- Control|Unsupplemented
16465046|NCT03531749|No Intervention|HIV+ Control|Unsupplemented
16465047|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
16465048|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
16465049|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
16465050|NCT03531697|Experimental|Generic Loteprednol Etabonate - RLD|Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
16465051|NCT03531697|Active Comparator|RLD - Generic Loteprednol Etabonate|Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate
16465052|NCT03531684|Experimental|MMFS-205-SR|Oral MMFS-205-SR twice daily (2,000, 3,000, or 4,000 mg/day total, depending on lean body mass and response to initial dose at Week 12) for 24 weeks
16465053|NCT03531684|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 24 weeks
16465054|NCT03531671|Experimental|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
16465055|NCT03531645|Experimental|Fulvestrant + Abemaciclib|
16465056|NCT03531632|Experimental|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
16465057|NCT03531619||Dizziness|Patients referred to a neuro-otological clinic due to dizziness who answer that they do not suffer from neck pain
16465058|NCT03531619||Dizziness and neck pain|Patients referred to a neuro-otological clinic due to dizziness who answer that they suffer from neck pain
16465059|NCT03531619||Neck pain|Patients referred to a rehabilitation center due to neck pain who answer that they do not suffer from dizziness
16465060|NCT03531619||Neck pain and dizziness|Patients referred to a rehabilitation center due to neck pain who answer that the suffer from dizziness
16465061|NCT03531619||Healthy Control|Healthy Controls without neck pain or dizziness
16465062|NCT03531606|Experimental|Experimental|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
~(1 week before surgery and 3 weeks after surgery)
~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
16465063|NCT03531606|Placebo Comparator|Placebo comparator|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
~The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
~(1 week before surgery and 3 weeks after surgery)
~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
16465064|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
16465065|NCT03531580|Experimental|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
16465066|NCT03531567|Experimental|Virtual Reality Mystic Isle Game|"Subjects in the treatment arm will complete a prescribed 2-month treatment using the virtual reality program Mystic Isle. The OT will follow the Treatment Arm Intervention Protocol, which provides standardized guidelines for grading the intensity, level of challenge, and types of games/activities of the intervention up or down. The OT will complete weekly phone calls with participant to discuss progress, answer any questions, and remotely make updates to the game as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the intervention will be 7 hours/week. The minimum amount of time spent on the intervention will be 3.5 hours/week."
16465067|NCT03531567|Active Comparator|Standard Home Exercise Program|"Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the Control Arm Intervention Protocol to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week."
16465068|NCT03531554|Experimental|ketone ester drink|Oral intake of ketone ester drink muscle biopsy exercise muscle biopsy Magnetic Resonance imaging
16465069|NCT03531554|Placebo Comparator|carbohydrate drink|Oral intake of isocaloric carbohydrate drinkmuscle biopsy exercise muscle biopsy Magnetic Resonance imaging
16465070|NCT03531541|Active Comparator|active TENS and CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.
~After application of TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust)."
16465159|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
16465071|NCT03531541|Placebo Comparator|placebos TENS and CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.
~Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies[42-44]. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect"
16465072|NCT03531541|Active Comparator|placebo TENS and active CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.
~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
16465073|NCT03531541|Active Comparator|active TENS and placebo CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.
~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
16465074|NCT03531528|Experimental|Experimental|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
16465078|NCT03531489|Experimental|Part 1: Feasibility|Patients will perform 6-minute walk test with AIR-AD to allow for observation and real-time feedback.
16465079|NCT03531489|Experimental|Part 2: Crossover|Crossover design where investigator will compare wearing of AIR-AD during exercise to compare distance walked with and without it.
16465080|NCT03531476|Experimental|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
16465081|NCT03531463|Active Comparator|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.
~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
16465082|NCT03531463|No Intervention|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
16465083|NCT03531450|Experimental|Cognitive Behavioral Therapy|Patients in the cognitive behavioral therapy group will be asked to undergo a 8-week CBT trial. An online videoconferencing link will be used to deliver CBT virtual sessions that will be approximately 60 minutes in length. Each session will be conducted by a clinical psychology doctoral student, supervised by a licensed psychologist. Patients will also undergo careful phenotyping pre- and post intervention with brain MRI, AFT, WMC, and NDT.
16465084|NCT03531437|Active Comparator|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
16465085|NCT03531437|Active Comparator|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
16465086|NCT03531424|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
16465087|NCT03531424|Experimental|CTA guided PCI|CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
16465088|NCT03531398|Experimental|High fat meal|Muffin containing 30g fat
16465089|NCT03531398|Experimental|Medium fat meal|Muffin containing 20g fat
16465090|NCT03531385||Behcet|Patients diagnosed with Behcet disease
16465091|NCT03531385||Healthy controls|Individuals without any chronic disease
16465092|NCT03531372|Experimental|Mipolixin®|Mipolixin® (Advanced Natural Antacid - AdNA)
16465093|NCT03531372|Active Comparator|Poliprotect®|Poliprotect® (Neobianacid)
16465094|NCT03531359|Experimental|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
16465095|NCT03531359|Active Comparator|Midazolam|Children will be premedicated with usual treatmente (midazolam)
16465096|NCT03531346|Experimental|Hyperosmolarity group|Healthy, young, habitual contact lens wearers with initial increased tear osmolarity (hyperosmolarity)
16465097|NCT03531346|Experimental|Normal osmolarity|Healthy, young, habitual contact lens wearers with initial tear osmolarity reported as normal
16465098|NCT03531333|Experimental|Ultrasound|ultrasound navigation guided surgery.
16465099|NCT03531333|No Intervention|Non-ultrasound|standard surgery without ultrasound guidance.
16465100|NCT03531320|Experimental|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
16465101|NCT03531320|Experimental|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
16465160|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
16465102|NCT03531307||Lactate and Ki 67 levels|Neurosurgical patients between June 2017 and February 2018 for tumoral and non-tumoral craniectomy with lactate levels at the beginning of surgery and Ki-67 index in biopsies.
16465103|NCT03531294|Experimental|Group 1|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.
16465104|NCT03531294|Experimental|Group 2|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.
16465105|NCT03531281|Experimental|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell infusion on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
16465106|NCT03531281|Active Comparator|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell infusion on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
16465107|NCT03531268|Active Comparator|PGx testing has clinical utility|These are subjects whose PGx testing is judged to have clinical utility and whose clinical care may be modified. Modifications may include altering doses or types of drugs given based on metabolic profile of the patient.
16465108|NCT03531268|No Intervention|PGx testing has no clinical utility|"These are subjects whose PGx testing is judged to have no clinical utility. Care as usual is provided, and there are no changes in drug selection or dosing based on the results of PGx testing."
16465109|NCT03531255|Experimental|1,080 mg pegcetacoplan administered subcutaneously|1,080mg pegcetacoplan administered subcutaneously twice weekly or every three days.
16465110|NCT03531242|Experimental|Cohort A: Initial Non-responders to VEE TC-83 vaccinations|Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, to be administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area.
16465111|NCT03531242|Experimental|Cohort B: Responders to TC-83 or previous C-84 vaccinations|"Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.
~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
16465112|NCT03531229|Placebo Comparator|Placebo|Placebo to Lu AF76432
16465113|NCT03531229|Experimental|Lu AF76432|Lu AF76432
16465114|NCT03531216|Active Comparator|Topical application of rosemary oil|Rosemary essential oil (10% )
16465115|NCT03531216|Placebo Comparator|Placebo|Pharmaceutical quality olive oil
16465116|NCT03531203|Experimental|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
16465117|NCT03531203|Placebo Comparator|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
16465118|NCT03531190|Experimental|Nutritional supplement (Protein + MIX)|Patients are given: Nutritional Supplement of protein 2-3 times a day + MIX once daily for 35 days
16465119|NCT03531190|Active Comparator|Nutritional supplement (Protein)|Nutritional Supplement of protein as needed 2-3 times a day for 35 days
16465120|NCT03531177|Experimental|Intervention|HEAL-D diet and lifestyle education and behavioural change intervention, 7 sessions over 14 weeks.
16465121|NCT03531177|Active Comparator|Control|Usual care.
16465122|NCT03531164|Experimental|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
16465123|NCT03531164|Active Comparator|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
16465124|NCT03531138|Experimental|Pulmonary rehabilitation group|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week.
16465125|NCT03531112|Experimental|Appetite Awareness Treatment|Participants will receive an 8-week Appetite Awareness Training (AAT) program using a group format, will be provided a smart scale (with bluetooth connection) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessment will be conducted at 0, 2, and 6 months.
16465126|NCT03531112|No Intervention|Control|Control group participants will receive no intervention in months 1-6, but will be offered the chance to receive an abbreviated form of AAT (4 weeks) following the 6-month assessment.
16465127|NCT03531099|Experimental|HIFU treatment|"65 patients will receive the immediate treatment with focal HIFU in order to destroy the cancer without causing side effects. HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
16465128|NCT03531099|Active Comparator|Active surveillance|"65 patients will be randomized to active surveillance and will have exactly the same follow-up as treated patients excepting the HIFU treatment.
~Active surveillance is a therapeutic option that shifts the eventual moment of curative treatment while remaining within a window of curability of the disease.
~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
16465161|NCT03530917|Experimental|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
16465129|NCT03531086||Ioflupane I123|Participants will receive Ioflupane I123 as an adjunct diagnostic tool in combination with single photon emission computer tomography (SPECT) to evaluate striatal dopamine transporter. Patients will serve as their own control longitudinally.
16465130|NCT03531073||Standard care cohort|This study is observational. Patients will receive standard treatment as given in usual clinical practice with no intervention as part of the study. As per current clinical practice guidelines and UK reimbursement rules for biologics in PsA, patients will receive a pragmatic treat to target approach using step up standard therapies. Patients will usually receive methotrexate first line, initially 15mg ow increasing to 25mg ow as tolerated. In case of non-response, an additional DMARD will be used (sulfasalazine up to 3g daily or leflunomide 20mg od). If two DMARDs are failed and patients are eligible for biologic therapy under UK National Institute of Health and Clinical Excellence (NICE) guidance, then biologics will be used.
16465131|NCT03531060|Experimental|IRL790|IRL790 Capsule 10 mg, oral administration
16465132|NCT03531060|Placebo Comparator|Placebo|Placebo capsule, identical appearance, oral administration
16465133|NCT03531047|Experimental|Refractive CXL|Tomography-customised CXL
16465134|NCT03531034|Experimental|Hypertensive Women|Group of hypertensive and controlled women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
16465135|NCT03531034|Active Comparator|Normotensive Women|Group of normotensive women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities.
16465136|NCT03531021|Experimental|Heart healthy intervention|The intervention group will receive 2 modules (one in in person and one by video conference) and will receive follow-up phone calls/emails by study staff 3 weeks following each visit to review education and strategies for and barriers to reaching goals. Intervention sessions must include teen; parents may attend if they wish. Participants will be placed on teams and encouraged to complete behavioral challenges to earn points towards a cash reward.
16465137|NCT03531021|No Intervention|Attention Control|There will be a delayed intervention for the control group with study handouts after 3 months. The control group will meet with the RAs for demographic and survey completion and receive reminder phone calls/emails in order to match for attention.
16465138|NCT03531008||Treatment-resistant focal epilepsy|Individuals with treatment-resistant focal epilepsy
16465139|NCT03530995|Experimental|Part 1, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
16465140|NCT03530995|Experimental|Part 1, Period 2|"Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.
~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9"
16465141|NCT03530995|Experimental|Part 1, Period 3|"Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.
~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4."
16465142|NCT03530995|Experimental|Part 1, Period 4|"Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.
~Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10."
16465143|NCT03530995|Experimental|Part 2, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
16465144|NCT03530995|Experimental|Part 2, Period 2|"Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.
~Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4."
16465145|NCT03530982|Experimental|Intervention group|Intensive goal training of relevant activities reported by adolescents in the beginning of the study. Therapists will grade the level of complexity of the proposed activities, considering the relevant movements, task demands and contextual factors involved in the performance of each task. Adolescents will be asked to practice these activities at home (1 hour/daily) and to discuss their difficulties and improvements with the therapists. The intervention will be provided in a day-camp model.
16465146|NCT03530969|Experimental|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
16465147|NCT03530969|Active Comparator|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
16465148|NCT03530969|Active Comparator|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
16465149|NCT03530956|Active Comparator|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis
16465150|NCT03530956|Experimental|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis
16465151|NCT03530943|Active Comparator|Academic Stress Management|Students assigned to the Academic Stress Management (ASM) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks during which time they will receive 100% exposure to various evidence-based academic stress management tools.
16465152|NCT03530943|Experimental|Human Animal Interaction Enhanced|Students assigned to the Human Animal Interaction - Enhanced (HAI-E) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group receives 50% exposure to structured and unstructured animal assisted activities and 50% exposure to various evidence-based academic stress management tools.
16465153|NCT03530943|Experimental|Human Animal Interaction only|Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
16465154|NCT03530930|Experimental|Comarum Palustre|Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
16465155|NCT03530917|Experimental|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
16465156|NCT03530917|Experimental|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
16465157|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
16465158|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
16465162|NCT03530917|Experimental|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
16465163|NCT03530904|Active Comparator|early mobilization after cardiac device implantation|mobilization after 4 hours
16465164|NCT03530904|Active Comparator|Late mobilization after cardiac device implantation|Mobilization after 24 hours
16465165|NCT03530891|Experimental|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
16465166|NCT03530891|Active Comparator|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
16465167|NCT03530878|Experimental|Hip Arthroscopy (HA)|This approach addresses intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH 3. Furthermore, capsular plication can be performed through HA to reduce instability of the joint.
16465168|NCT03530878|No Intervention|Periacetabular Osteootmy (PAO)|The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization.
16465169|NCT03530852|Experimental|Relizorb treatment|Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition
16465170|NCT03530839|Experimental|Arthrodesis|Arthrodesis of the proximal interphalangeal joint by using a threaded K-wire
16465171|NCT03530839|Active Comparator|Resection arthroplasty|Resection arthroplasty of the proximal interphalangeal joint using a normal K-wire
16465172|NCT03530813|Active Comparator|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
16465173|NCT03530813|Experimental|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
16465174|NCT03530800|Active Comparator|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final six weeks. Dose escalations will only be done if the investigator deems necessary.
16465175|NCT03530800|Placebo Comparator|Placebo|Subjects will receive placebo for 10 weeks weeks.
16465176|NCT03530787|Active Comparator|Acetyl Zingerone Group|This group was given the topical with the active acetyl zingerone agent.
16465177|NCT03530787|Placebo Comparator|Control Group|This group was given the topical without the active acetyl zingerone agent and just the carrier lotion.
16465178|NCT03530774|Experimental|Egg while protein supplement|25 g of powdered egg white protein supplement daily for 6 months. Total of 20.6 g of protein in 25 g of supplement.
16465179|NCT03530774|Placebo Comparator|Maltodextrin supplement|25 g of powdered maltodextrin supplement daily for 6 months. Total 23.5 g of carbohydrate in 25 g of supplement.
16465180|NCT03530761||Acute kidney injury|Increase in serum creatinine more than 0.3 mg/dl within 48 hours or a percentage increase serum creatinine more than 50% from baseline.
16465181|NCT03530761||Hepatorenal syndrome|"Diagnosis of cirrhosis and ascites,
~Diagnosis of AKI according to ICA-AKI criteria
~No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight
~Absence of shock
~No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs, aminoglycosides, iodinated contrast media, etc.)
~No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (> 50 RBCs per high power field), normal findings on renal ultrasonography."
16465182|NCT03530748||Patients with Renal Artery Stenosis|Patients with simple renal artery stenosis or aortic dissection with renal artery obstruction
16465183|NCT03530735|Experimental|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.
~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
16465184|NCT03530709|Experimental|Experimental|videoconferencing
16465185|NCT03530709|No Intervention|Control|Usual care
16465186|NCT03530696|Experimental|T-DM1 with palbociclib|T-DM1 is given IV every 21 days Palbociclib is administered days 5-18
16465187|NCT03530696|Active Comparator|T-DM1|T-DM1 is given IV every 21 days
16465188|NCT03530683|Experimental|TTI-622 Monotherapy|
16465189|NCT03530683|Experimental|Cohort A: TTI-622 + Azacitidine|
16465190|NCT03530683|Experimental|Cohort B: TTI-622 + Azacitidine and Venetoclax|
16465191|NCT03530683|Experimental|Cohort C: TTI-622 + Carfilzomib and Dexamethasone|
16465192|NCT03530670|Active Comparator|oral midazolam (demizolam)|"To prevent preoperative anxiety patient premedicated by 0.5 mg/kg oral midazolam.
~In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale"
16465193|NCT03530670|Active Comparator|http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|To prevent preoperative anxiety by watching a short movie ( at http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
16465194|NCT03530670|Active Comparator|playing smartphone game|To prevent preoperative anxiety by playing smartphone game ( angry birds, subway surfers, snail Bob) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
16465195|NCT03530644|Experimental|RSP-14|"Comparative study of two Investigational Medical Devices (WM3.4NR and P0.1)
~Optical data will be obtained from T1D over a dynamic glycemic range. Data will be paired with references."
16465196|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
16465197|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
16465198|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
16465199|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
16465200|NCT03530618|Experimental|Flexible tip straight guidewire|
16465201|NCT03530618|Experimental|J-tip guidewire|
16465202|NCT03530605|Experimental|Optune TTF Device|Optune TTF treatment
16465203|NCT03530605|No Intervention|Historical matched control|age-matched historical controls
16465204|NCT03530592|Experimental|Seated Ankle Robot Training|
16465205|NCT03530579|Experimental|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
16465206|NCT03530579|Active Comparator|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
16465207|NCT03530566||Pnk group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
16465208|NCT03530566||Control group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
16465209|NCT03530553|Experimental|Treatment arm|The treatment arm will receive the HMS as well as standard of care of the weight management program.
16465210|NCT03530553|No Intervention|Control arm|The control arm will not receive the HMS and will receive standard of care.
16465211|NCT03530540|Experimental|Intervention|Active shockwaves
16465212|NCT03530540|Placebo Comparator|Placebo|Placebo shockwaves
16465213|NCT03530527|Active Comparator|ERCP with biliary stenting|Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.
16465214|NCT03530527|Active Comparator|EUS guided biliary drainage|Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.
16465215|NCT03530514|Experimental|Part A: Single dose cohort 1|Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
16465216|NCT03530514|Experimental|Part A: Single dose cohort 2|Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
16465217|NCT03530514|Experimental|Part A: Single dose cohort 3|Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
16465218|NCT03530514|Experimental|Part A: Single dose cohort 4|Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
16465219|NCT03530514|Experimental|Part A: Single dose cohort 5|Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
16465220|NCT03530514|Experimental|Part A: Single dose cohort 6|Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
16465221|NCT03530514|Experimental|Part A: Single dose cohort 7|Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
16465222|NCT03530514|Experimental|Part A: Single dose cohort 8|Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
16465223|NCT03530514|Experimental|Part A: Single dose cohort 9|Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
16465224|NCT03530514|Experimental|Part B: Repeated dose cohort 10|Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
16465225|NCT03530501|Placebo Comparator|Placebo|Very low calorie ketogenic diet followed by low calorie diet
16465226|NCT03530501|Experimental|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
16465227|NCT03530501|Experimental|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
16465228|NCT03530488|Active Comparator|Lidocaine group|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline 5 minutes before hystroscopy
16465229|NCT03530488|Placebo Comparator|control group|intrauterine and intracervical instillation of 19 ml normal saline 5 minutes before hystroscopy
16465230|NCT03530475|Active Comparator|placenta previa|cases diagnosed as placenta previa diagnosed by ultrasound and doppler
16465231|NCT03530475|Active Comparator|placenta accreta|placenta previa diagnosed as placenta accreta by ultrasound and doppler
16465232|NCT03530462||patient with first-line and second-line|patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)
16465233|NCT03530462||patients with first-line only|patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only
16465234|NCT03530462||healthy control|healthy individuals without a history of psychiatric or neurologic disease
16465235|NCT03530449||Subjects with Normal Eyes|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
16465236|NCT03530449||Subjects with Retinal Vascular Pathology|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology
16465237|NCT03530436|Other|Native turmeric extract|6 capsules of native curcumin (207 mg curcumin)
16465238|NCT03530436|Experimental|Native turmeric extract with 7-9% volatile turmeric oils|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465239|NCT03530436|Experimental|Turmeric extract plus mixture of phytochemicals|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465240|NCT03530436|Experimental|Cyclodextrin complex of curcuminoids|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465241|NCT03530436|Experimental|Turmeric oleoresin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465242|NCT03530436|Experimental|Liposomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465243|NCT03530436|Experimental|Phytosomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465244|NCT03530436|Experimental|Micellar turmeric extract|6 capsules of the formulation; dosage normalized to 207 mg curcumin
16465245|NCT03530410||Patients with intragastric balloon|Patients who will receive an intragastric balloon placement for weight loss
16465246|NCT03530397|Experimental|Arm A: MEDI5752|MEDI5752
16465247|NCT03530397|Experimental|Arm B: MEDI5752 and chemotherapy|MEDI5752, pemetrexed and carboplatin.
16465248|NCT03530397|Active Comparator|Arm C: Pembrolizumab and chemotherapy|pembrolizumab, pemetrexed, and carboplatin
16465249|NCT03530384|Experimental|Cognitive training|Computerized cognitive training program targeting inhibitory control
16465250|NCT03530384|Sham Comparator|Control Training|A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
16465251|NCT03530371|Experimental|Dexmedetomidine Hydrochloride|sedation of patients to perform auditory test
16465252|NCT03530358|Experimental|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
16465253|NCT03530358|Active Comparator|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
16465254|NCT03530345|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
16465255|NCT03530345|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
16465256|NCT03530332|Experimental|Treatment|
16465257|NCT03530332|No Intervention|Control|
16465258|NCT03530319|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
16465259|NCT03530319|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
16465260|NCT03530306|Active Comparator|PS1-PS4|
16465261|NCT03530306|Active Comparator|PS6-PS10|
16465262|NCT03530306|Active Comparator|PS7-PS4|
16465263|NCT03530306|Active Comparator|PS9-PS6|
16465264|NCT03530293|Experimental|Valbenazine|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
16465265|NCT03530293|Placebo Comparator|Placebo|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
16465266|NCT03530280|Active Comparator|pregabalin (lyrica)|pregabalin (lyrica) 150 mg preoperative 1 hour before and the postoperative sham block will perform.
16465267|NCT03530280|Placebo Comparator|placebo group|a placebo capsule 1 hour before surgery and the postoperative sham block will perform.
16465268|NCT03530280|Active Comparator|adductor channel block group|A preoperative placebo capsule will be given.This group will receive postoperative adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
16465269|NCT03530267|Active Comparator|Arm A (mFOLFOX7)|"Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
~This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study."
16465270|NCT03530267|Experimental|Arm B (Aflibercept + mLV5FU2)|"Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
~The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7."
16465271|NCT03530254|Other|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
16465272|NCT03530254|Other|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
16465273|NCT03530241|Experimental|MRCP positive|
16465274|NCT03530241|Active Comparator|MRCP negative|
16465275|NCT03530228|Experimental|Treatment A: Tegoprazan (C1)|Tegoprazan QD, oral administration
16465276|NCT03530228|Experimental|Treatment B: Tegoprazan (C1)|Tegoprazan QD, oral administration
16465277|NCT03530228|Experimental|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
16465278|NCT03530228|Experimental|Group 1: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
16465279|NCT03530228|Experimental|Group 2: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
16465280|NCT03530228|Active Comparator|Group 3: Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days
16465281|NCT03530228|Experimental|Tegoprazan (C3)|Tegoprazan QD, oral administration
16465282|NCT03530215||Adverse Events with Antineoplastic and immunomodulating agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Antineoplastic and immunomodulating agents, with a chronology compatible with the drug toxicity
16465283|NCT03530202|Experimental|HVRT + Creatine Monohydrate|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume creatine monohydrate powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
16465312|NCT03529981|Experimental|TVS in response to participant initiation or stress detection|The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
16465335|NCT03529799|Active Comparator|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
16465376|NCT03529617||Hematology patients|Patients admitted on the hematology ward.
16465284|NCT03530202|Placebo Comparator|HVRT + Maltodextrin Powder|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume maltodexterin powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
16465285|NCT03530189||Normoglycemic group|"The infant will enter this group if a single blood glucose concentration is between 2.1 and 2.5 mmol/l (38-45 mg/dL), or a single blood glucose concentration is between 8.6 - 10 mmol/l (155-180 mg/dL) with all other measures between 2.6 and 8.5 mmol/l (47-153 mg/dL).
~To all premature infants intravenous 10% dextrose at 60-90 mL/kg/day will be started as soon as possible after birth."
16465286|NCT03530189||Group with impaired glucose|"The infant can be hypoglycemic, hyperglycemic or unstable. The infant will be hypoglycemic if blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration is≤2,0 mmol/l (36 mg/dL). Hypoglycemia will be treated with intravenous bolus of 10% dextrose.
~The infant will be hyperglycemic if blood glucose concentration is ≥8,6 mmol/l (155 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration ≥10,1 mmol/l (182 mg/dL). Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.
~The infant will be unstable if at least 1 blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) and ≥1 blood glucose concentration is ≥8,6 mmol/l (155 mg/dL)."
16465287|NCT03530176|Experimental|single arm|18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms. Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer. Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability. Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest. After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes. A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
16465288|NCT03530163|Experimental|Respiratory Muscle Training|
16465289|NCT03530163|Sham Comparator|Sham Breathing Training|
16465290|NCT03530150|Active Comparator|Pirfenidone 600 mg|Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
16465291|NCT03530150|No Intervention|Usual Care|Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
16465292|NCT03530137|Other|families living at Families Moving Forward (FMF)|
16465293|NCT03530124|Other|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from randomization to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
16465294|NCT03530124|No Intervention|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
16465295|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving < 75 minutes of moderate-intensity or < 37 minutes of vigorous-intensity aerobic physical activity per week.
16465296|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving > 225 minutes of moderate-intensity or > 112 minutes of vigorous-intensity aerobic physical activity per week.
16465297|NCT03530098|No Intervention|Control (Without-AI)|This is the control arm where no intervention is provided; represents current standard of care.
16465298|NCT03530098|Experimental|Experiment (With-AI)|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
16465299|NCT03530085|Experimental|Dec+Flu+Bu Conditioning Regimen|For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -9 to -7；Fludarabine(Flu) 30mg/m2/day on days -6 to -3；Busulfan (BU) 3.2 mg/kg/day on days -5 to -4).
16465300|NCT03530072||Cases|Subjects with Fever and Neutropenia
16465301|NCT03530046|Experimental|High SID fluid|Group 1: half-normal saline with addition of 75mEq/L sodium bicarbonate
16465302|NCT03530046|Active Comparator|Hartmann's solution|Group 2: Hartmann's Solution
16465303|NCT03530033|No Intervention|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
16465304|NCT03530033|Experimental|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
16465305|NCT03530020|Active Comparator|monolithic zirconia crowns|Monolithic zirconia attracts many dentists worldwide due to its excellent mechanical properties, biocompatibility and appreciate aesthetics
16465306|NCT03530020|Experimental|lithium silicate crowns|A lithium silicate glass ceramic is newly introduced to the market. After crystallization, it exhibits an ideal combination of aesthetics and strength with translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns.
16465307|NCT03530007|Active Comparator|normal saline|patients received normal saline for prevention of shivering during spinal anesthesia
16465308|NCT03530007|Active Comparator|ondansetron 4MG|patients received 4 mg of ondansetron for prevention of spinal shivering
16465309|NCT03530007|Active Comparator|ondansetron 8MG|patients received 8 mg of ondansetron for prevention of spinal shivering
16465310|NCT03529994||Enrollment|
16465311|NCT03529981|Active Comparator|Stress incidents without TVS|a fraction of physiological detected stress incidents will not trigger TVS
16465313|NCT03529968||Italian Siewert I-II adenocarcinoma|Patients with Siewert type I adenocarcinoma underwent subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Patients with Siewert type II adenocarcinoma underwent total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy. A right anterolateral thoracotomy and an upper midline laparotomy were performed as previously described. Lymphadenectomy included chest stations classified according to the AJCC TNM 7th edition (L/R = left/right; 3, 4R, 7, 2R, 8 and 9 and abdominal stations classified according to the Japanese Classification of Gastric Carcinoma (stations 1-12)
16465314|NCT03529968||Finnish Siewert I-II adenocarcinoma|All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
16465315|NCT03529955|Experimental|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
16465316|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
16465317|NCT03529929|Experimental|Methylprednisolone|"Methylprednisolone glucocorticoid Medrol Dose Pack
~Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively)."
16465318|NCT03529916||CVD subjects|CVD will be defined as >50% stenosis of one or more coronary arteries as assessed by coronary angiography.
16465319|NCT03529916||healthy controls|healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.
16465320|NCT03529903|No Intervention|Control Group|*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. *Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). *Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. *Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
16465321|NCT03529903|Experimental|Experimental Group|*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. *Wear a Fitbit to track their daily physical activity and weight *Set a weekly active minutes goal and record their weight weekly. *Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). *Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. *Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
16465323|NCT03529877|Experimental|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)
16465324|NCT03529864|Experimental|Exercise therapy|The participants took part in a progressive exercise therapy program for 9 consecutive weeks, once a week. This consisted of group sessions with 8 or 9 students, with each session lasting 60 minutes, supervised by the principal researcher
16465325|NCT03529864|No Intervention|Control|The CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form
16465326|NCT03529851|Experimental|PRO intervention|Patients included will weekly fill in a 12 item questionaire via the internet during the 3 week study period.
16465327|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
16465328|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
16465329|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
16465330|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
16465331|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
16465332|NCT03529812|Experimental|Early-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education during the first unit of their year-long residency.
16465333|NCT03529812|Active Comparator|Delayed-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education midway through their year-long residency.
16465334|NCT03529799|Experimental|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
16465336|NCT03529786||Retrospective|An observational medical records review study (data collected retrospectively) in subjects with the severe form of MPS II.
16465337|NCT03529773|Experimental|Sentinel Arm 1|Low dose formulation A
16465338|NCT03529773|Experimental|Sentinel Arm 2|Mid dose formulation A
16465339|NCT03529773|Experimental|Sentinel Arm 3|High dose formulation A
16465340|NCT03529773|Experimental|Sentinel Arm 4|Low dose formulation B
16465341|NCT03529773|Experimental|Sentinel Arm 5|Mid dose formulation B
16465342|NCT03529773|Experimental|Sentinel Arm 6|High dose formulation B
16465343|NCT03529773|Placebo Comparator|Sentinel Arm 7|Placebo
16465344|NCT03529773|Experimental|Expanded Arm 8|Low dose formulation A and SIIV
16465345|NCT03529773|Experimental|Expanded Arm 9|Mid dose formulation A and SIIV
16465346|NCT03529773|Experimental|Expanded Arm 10|High dose formulation A and SIIV
16465347|NCT03529773|Experimental|Expanded Arm 11|Low dose formulation B and SIIV
16465348|NCT03529773|Experimental|Expanded Arm 12|Mid dose formulation B and SIIV
16465349|NCT03529773|Experimental|Expanded Arm 13|High dose formulation B and SIIV
16465350|NCT03529773|Experimental|Expanded Arm 14|Low dose formulation A and placebo
16465351|NCT03529773|Experimental|Expanded Arm 15|Mid dose formulation A and placebo
16465352|NCT03529773|Experimental|Expanded Arm 16|High dose formulation A and placebo
16465353|NCT03529773|Experimental|Expanded Arm 17|Low dose formulation B and placebo
16465354|NCT03529773|Experimental|Expanded Arm 18|Mid dose formulation B and placebo
16465355|NCT03529773|Experimental|Expanded Arm 19|High dose formulation B and placebo
16465356|NCT03529773|Placebo Comparator|Expanded Arm 20|placebo and placebo
16465357|NCT03529747|Experimental|Online self-help|A website providing information and psycho-education aimed at parents and carers of children with food allergies.
16465358|NCT03529747|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help once the RCT is complete.
16465359|NCT03529734|Experimental|12 min running group|This group will perform a 12 min high intensity running with the goal to cover maximal possible distance.
16465360|NCT03529734|Experimental|Local strengthening exercise group|This group will perform local strengthening exercises (curl-ups, left side trunk flexion, trunk extension, right side trunk flexion). Each participant will have to perform three sets of each exercise with the maximal possible number of repetitions with a slow tempo (1s concentric phase and 2 s eccentric phase). Between sets, minimal rest (15 s) will be administered.
16465361|NCT03529721|Experimental|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
16465362|NCT03529721|Placebo Comparator|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
16465363|NCT03529708|Experimental|SBRT boost|Standard radiotherapy (3D conformal, urgent palliative radiotherapy) plus stereotactic body radiotherapy (SBRT) boost
16465364|NCT03529695|Active Comparator|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
16465365|NCT03529695|Experimental|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
16465366|NCT03529682|Experimental|Circuit Training Group|Circuit exercise training will be given to the experimental group participants during 10 weeks, 60 minutes in a day and 3 times a week.
16465367|NCT03529682|Other|Control Group|The control group participants will continue to their own previous physiotherapy approaches as the same as minimum 3 times a week and total 3 hours.
16465368|NCT03529669|Experimental|Cytosponge™|All participants will receive the Cytosponge™ device.
16465369|NCT03529656|No Intervention|Pre-ERP|A group of patients who underwent liver transplantation surgery before the early rehabilitation program
16465370|NCT03529656|Experimental|Post-ERP|A group of immediate liver transplant patients who had an early rehabilitation program in ICU care
16465371|NCT03529643|Experimental|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine
~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
16465372|NCT03529643|Placebo Comparator|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil
~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
16465373|NCT03529630|Experimental|Inverted syringe|Participants in this arm will use of the inverted syringe before each breastfeeding starting from the first feed after delivery and continued as long as needed by the mother.
16465374|NCT03529630|No Intervention|Standard of care|Participants in the control group will receive standard medical care as dictated by their obstetricians. Any advice regarding infant nutrition or treatment of inverted nipples will be left to the primary physician, including possible use of the inverted syringe technique. .
16465375|NCT03529617||Critically ill patients|Patients admitted on ICU.
16465377|NCT03529604||Oral Cancer group|Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
16465378|NCT03529604||PMOD group|Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
16465379|NCT03529604||Control|Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
16465380|NCT03529591|Active Comparator|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
16465381|NCT03529591|Active Comparator|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
16465382|NCT03529578|Experimental|dHACM|Standard of Care plus Weekly Application of dHACM
16465383|NCT03529565||Ancillary-Correlative (biospecimen collection)|Participants undergo collection of blood samples for histamine level analysis via ELISA.
16465384|NCT03529552|Experimental|Patients with anterior cruciate ligament rupture|
16465385|NCT03529526|Experimental|KN046|
16465386|NCT03529513||Depressed|Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
16465387|NCT03529513||Control|Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
16465388|NCT03529500||Adequate nutritional status|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
16465389|NCT03529500||Mild malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
16465390|NCT03529500||Moderate malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
16465391|NCT03529500||Severe malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
16465392|NCT03529487|Experimental|Oxymetazoline applied intra analy|
16465393|NCT03529474|Experimental|Psychology and Physiotherapy group|The psychological program consists of 4 sessions (2 hours each) comprising psychoeducation, training techniques of psychological management of pain and kinesiophobia resources The physiotherapy program consists of 3 domiciliary sessions per week, including physical exercise and stretching
16465394|NCT03529474|Placebo Comparator|Placebo Comparator: Control group|Usual daily activities
16465395|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
16465396|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
16465397|NCT03529448|Experimental|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)
~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
16465398|NCT03529435|Active Comparator|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
16465399|NCT03529435|Experimental|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
16465400|NCT03529422|Other|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments
16465434|NCT03529149|Active Comparator|Guideline blood pressure control|Control blood pressure according to guidelines
16465435|NCT03529136|Experimental|MSC group 1|Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
16465401|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
16465402|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
16465403|NCT03529396|Experimental|1a: Chloroquine + 5th-day Primaquine|[ARM HALTED PREMATURELY DUE TO SAFETY CONCERNS]
16465404|NCT03529396|Experimental|1b: Chloroquine + 8-week Primaquine|26 G6PD deficient patients. Directly observed therapy.
16465405|NCT03529396|Active Comparator|1c: Chloroquine + 12-week Chloroquine|26 G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
16465406|NCT03529396|Active Comparator|2: Standard chloroquine + primaquine|52 G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
16465407|NCT03529383|Experimental|Connected device|"Women randomized to the connected device arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity."
16465408|NCT03529383|Experimental|Therapeutic education|"Women randomized to the therapeutic education arm will follow a 6-month program of therapeutic patient education. They will also receive international recommendations on physical activity."
16465409|NCT03529383|Experimental|Combined|"Women will benefit from both the connected device intervention and the therapeutic education intervention and receive international recommendations on physical activity."
16465410|NCT03529383|No Intervention|Control|Women will receive standard care, i.e., international recommendations on physical activity, without further intervention.
16465411|NCT03529344|Active Comparator|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
16465412|NCT03529344|Placebo Comparator|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
16465413|NCT03529331|Active Comparator|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
16465414|NCT03529331|Active Comparator|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
16465415|NCT03529331|Active Comparator|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
16465416|NCT03529305|Experimental|Low frequency rTMS|Patients receive low frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the unaffected side for two weeks, 5 consecutive days each week.
16465417|NCT03529305|Experimental|High frequency rTMS|Patients receive high frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the affected side for two weeks, 5 consecutive days each week.
16465418|NCT03529305|Active Comparator|Physical therapy|Patients receive physical therapy for two weeks.
16465419|NCT03529292|Experimental|Modified matrix obtained by the AmeaCell® device|
16465420|NCT03529279|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive CNG staging and CNG chemotherapy strategy and CNG radiation strategy
16465421|NCT03529279|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive the eighth edition of UICC/AJCC staging and NCCN chemotherapy strategy and NCCN radiation strategy
16465422|NCT03529266|Experimental|A(Surgery+PFS)|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal or coloesophageal anastomosis during Mckeown surgery .
16465423|NCT03529253|Experimental|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
16465424|NCT03529253|Active Comparator|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
16465425|NCT03529240|Experimental|Kinesiology taping|After performing the baseline assessments, kinesiology taping with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles of children. In both applications, the first and last 5 cm section of the bands were used as anchor and no tension was applied.
16465426|NCT03529214|Other|Implemented Health Facility|"Health facility that has piloted the Team Birth Project"
16465427|NCT03529201|Experimental|QLB|At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
16465428|NCT03529201|Experimental|Control|Standard care. No regional blocks.
16465429|NCT03529175|Active Comparator|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
16465430|NCT03529175|Active Comparator|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
16465431|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
16465432|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
16465433|NCT03529149|Experimental|Accurate blood pressure control|Implementing accurate blood pressure management under TCD monitoring
16465436|NCT03529136|Experimental|MSC group 2|Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
16465437|NCT03529136|Experimental|Control group|Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
16465438|NCT03529123|Experimental|Tested Drug|Insulin glargine/lixisenatide fixed ratio combination (FRC)
16465439|NCT03529123|Active Comparator|Control Drug|Insulin glargine (Lantus®)
16465440|NCT03529110|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with DS-8201a
16465441|NCT03529110|Active Comparator|Ado-trastuzumab emtansine (T-DM1)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with T-DM1
16465442|NCT03529097|Active Comparator|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
16465443|NCT03529097|Placebo Comparator|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
16465444|NCT03529084|Experimental|EGF816|Investigational treatment arm of EGF816 (nazartinib).
16465445|NCT03529084|Active Comparator|Investigator's Choice|Investigator's Choice (erlotinib or gefitinib).
16465446|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
16465447|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
16465448|NCT03529045||VNS Therapy|Any approved VNS Therapy System (according to local regulations) may be used in this registry.
16465449|NCT03529032|No Intervention|Fentanyl group|Drug: Fentanyl Fentanyl group 3µg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
16465450|NCT03529032|Experimental|methadone group|Drug: methadone methadone group 0.2mg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
16465451|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
16465452|NCT03529006|Active Comparator|Sequent Please Drug Coated Balloon Group|For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery. This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice. For bailout situation Xience stent implantation is possible.
16465453|NCT03529006|Active Comparator|Absorb Stent Group|Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb). Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
16465454|NCT03528993|Experimental|Exercise by hippotherapy device group|The experimental group receive conventional rehabilitation for 45 min/day following by use of a hippotherapy device for 15 min/day, 5 times/week for 4 weeks
16465455|NCT03528993|Other|Control group|The control group will receive conventional rehabilitation for 45 min/day, following by postural control exercises 15 min/day 5 times/week for 4 weeks.
16465456|NCT03528980||Bariatric surgery|
16465457|NCT03528980||standard nutritional management|
16465458|NCT03528967|Experimental|Arm 1|"Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:
~Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily
~Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily
~Start treatment from inclusion visit
~Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)"
16465459|NCT03528967|Other|Arm 2|"Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:
~Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily
~Administer orally
~Start treatment from inclusion visit
~Maintain treatment until 35 Weeks of Amenorrhea (WA)"
16465460|NCT03528954|Active Comparator|Propofol|Received intravenous 0.5mg/kg propofol
16465461|NCT03528954|No Intervention|Control|Do not received intravenous 0.5 mg/kg propofol
16465462|NCT03528941||Lamivudine|Patients who received lamivudine
16465463|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
16465464|NCT03528928|Experimental|Surface electrical stimulation|Each subject did a Kegel pelvic floor contraction, had the surface electrical stimulation turned on at highest comfortable intensity, did a Kegel contraction with surface electrical stimulation on, and had second electrical stimulation turned on.
16465465|NCT03528915||Prophylaxis group|Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
16465466|NCT03528915||no-antibiotic group|Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
16465467|NCT03528902|Experimental|Tamoxifen|20 mg po TID for 24 weeks
16465468|NCT03528902|Placebo Comparator|Placebo|Placebo arm
16465469|NCT03528889|Active Comparator|Goniometer|Extension FDO: classic procedure with goniometer controlled extension and derotation
16465470|NCT03528889|Experimental|EMT|Extension FDO: procedure with electromagnetic tracking (EMT) controlling extension and derotation
16465471|NCT03528876|Other|Single arm intervention study|Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)
16465472|NCT03528863|Experimental|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
16465519|NCT03528499|Experimental|Scapular Movement Training|Orientation and scapular exercises, performed twice a week, for 8 weeks.
16465473|NCT03528850|Experimental|Telehealth|The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
16465474|NCT03528850|No Intervention|Standard of Care|The Standard of Care will receive no interventions but will conduct surveys at enrollment and at the end of 30 days.
16465475|NCT03528837||Diagnosed as acute kidney injury|Sure diagnosed as acute kidney injury
16465476|NCT03528824|Experimental|Fenugreek wraps|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
16465477|NCT03528824|Active Comparator|Diclofenac gel|Daily application of diclofenac gel, 4 weeks application
16465478|NCT03528824|No Intervention|Usual care|no specific intervention
16465479|NCT03528811|Other|Five points test of Tongji university|"We established the evaluatation and follow-up system of diabetes vascular disease based on the method called Five points test of Tongji university ."
16465480|NCT03528785|Experimental|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
16465481|NCT03528772|Active Comparator|Minoxidil|Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
16465482|NCT03528772|Active Comparator|Glyceryl trinitrate|Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
16465483|NCT03528746|Experimental|Isometric exercise|Participants will complete isometric quadriceps exercise
16465484|NCT03528746|Active Comparator|Isotonic exercise|Participants will complete dynamic leg extension
16465485|NCT03528733|Experimental|Multi-Energy Detector|Multi-Energy Digital Radiography Detector System
16465486|NCT03528707|Active Comparator|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
16465487|NCT03528707|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
16465488|NCT03528694|Experimental|Durvalumab plus BCG (induction + maintenance)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
16465489|NCT03528694|Experimental|Durvalumab plus BCG (induction only)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
16465490|NCT03528694|Active Comparator|BCG treatment (Standard of care therapy)|Bacillus Calmette-Guerrin (BCG) standard of care treatment
16465491|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the open label initial phase.
16465492|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the open label initial phase.
16465493|NCT03528681|Placebo Comparator|Matching Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase.
16465494|NCT03528655|Experimental|Decision aid group|Shared decision making using decision aid
16465495|NCT03528655|No Intervention|Controlled group|Standard oral explanation with booklet.
16465497|NCT03528629|Experimental|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
16465498|NCT03528629|Experimental|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
16465499|NCT03528629|Experimental|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
16465500|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
16465501|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
16465502|NCT03528590|Active Comparator|size 3 i-gel®|size 3 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
16465503|NCT03528590|Experimental|size 4 i-gel®|size 4 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
16465504|NCT03528577|Experimental|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
16465505|NCT03528577|Active Comparator|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
16465506|NCT03528577|Placebo Comparator|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
16465507|NCT03528577|Placebo Comparator|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
16465508|NCT03528564|Experimental|Epoetin alfa|Preoperative treatment of anemia with iron sucrose (Venofer) plus Epoetin Alfa (Eprex)
16465509|NCT03528564|Placebo Comparator|Intravenous Iron|Preoperative treatment of anemia with iron sucrose (Venofer) plus placebo (saline)
16465510|NCT03528551|Experimental|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
16465511|NCT03528551|Experimental|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
16465512|NCT03528551|Experimental|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
16465513|NCT03528538|Placebo Comparator|Placebo|
16465514|NCT03528538|Active Comparator|AlphaFen fenugreek 400 mg|This group received 400 mg of fenugreek to be ingested daily for 60 days.
16465515|NCT03528538|Active Comparator|AlphaFen fenugreek 500 mg|This group received 500 mg of fenugreek to be ingested daily.
16465516|NCT03528525||Monogenic diseases cases|
16465517|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
16465518|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
16465520|NCT03528499|Active Comparator|General Exercises|Scapulothoracic muscle stretching and strengthening exercises, performed twice a week, for 8 weeks.
16465521|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
16465522|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
16465523|NCT03528473|Experimental|Exercise|Patients involved in the 6 months-physical training group.
16465524|NCT03528473|No Intervention|Control|Patients in control group carry on their usual follow-up programme.
16465526|NCT03528434|Experimental|Zinc|Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet
16465527|NCT03528434|Placebo Comparator|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
16465528|NCT03528421|Experimental|IM19 CAR-T cells|3*10^5/kg，1*10^6/kg，3*10^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
16465530|NCT03528395|Experimental|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
16465531|NCT03528395|Active Comparator|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
16465532|NCT03528382|Experimental|period I group|
16465533|NCT03528382|Experimental|period II group|
16465534|NCT03528382|Experimental|period III group|
16465535|NCT03528369|Experimental|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
16465536|NCT03528369|Experimental|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
16465537|NCT03528369|Sham Comparator|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
16465538|NCT03528356|Placebo Comparator|Regular diet|
16465539|NCT03528356|Experimental|White diet|
16465540|NCT03528343|Experimental|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
16465541|NCT03528343|No Intervention|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
16465542|NCT03528330|Active Comparator|Internal hexagon connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.
~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.
~The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm."
16465543|NCT03528330|Experimental|Conical connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.
~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.
~The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm."
16465544|NCT03528317|Experimental|Alternate day fasting|Alternate day fasting with a high protein diet
16465545|NCT03528304|Experimental|Smoking arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking.
16465546|NCT03528304|Experimental|Weight loss arm|As part of the CM intervention women attend visits for smoking and weight loss assessment and are rewarded with prizes for losing some weight.
16465547|NCT03528304|Experimental|Smoking and weight loss arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking and for losing some weight.
16465548|NCT03528304|No Intervention|Control|Women attended clinic visits for smoking status and weight loss assessment.
16465549|NCT03528291||Cardiogenic shock treated with medical treatment|Patients with cardiogenic shock treated only by medical treatment
16465550|NCT03528291||Cardiogenic shock treated with transient circulatory support|Patients where transient circulatory support was implanted: veno-arterial extracorporeal circulatory life support (ECLS), Impella
16465551|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
16465552|NCT03528252|Active Comparator|LDL Cholesterol|Will receive dietary advice effective for reducing LDL cholesterol.
16465553|NCT03528252|Sham Comparator|Triglycerides|Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.
16465554|NCT03528226|Experimental|Exercise Training|
16465555|NCT03528226|Other|Control|
16465556|NCT03528213|Sham Comparator|Normal saline|at physician discretion
16465557|NCT03528213|Experimental|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
16465558|NCT03528213|Experimental|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
16465559|NCT03528200|Other|Dyna Embo|Contrast dye injected through the IV in their arm which helps to see the blood in the arteries using x-ray pictures
16465595|NCT03527953|Active Comparator|everX fiber-reinforced resin|Randomly applied
16465596|NCT03527940||Patients with STEMI|
16466037|NCT03524963|Experimental|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
16465560|NCT03528187||Patient Cohort 1|"Age 18 or over
~BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)
~Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications [dietary change, behavioural therapy, increased physical activity], surgical intervention or pharmacological treatment) as part of their usual clinical care
~Informed written consent
~Able to tolerate MRI"
16465561|NCT03528187||Patient Cohort 2|"Age 18 or over
~Attending weight management service at UCLH
~Informed written consent
~Able to tolerate MRI"
16465562|NCT03528187||Controls|"Age 18 or over
~BMI less than 25
~Informed written consent
~Able to tolerate MRI"
16465563|NCT03528174|Experimental|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
16465564|NCT03528148|Experimental|active cycling group|effect of combine cycling and conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
16465565|NCT03528148|Active Comparator|control group|effect of combine conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
16465566|NCT03528135|Experimental|Project PRIDE|"Those in the Project PRIDE condition will receive 8 weekly sessions, each lasting 2.5 hours and consisting of approximately 10 men (estimated number given expected attrition). Each session will be co-led by two trained group facilitators. The intervention sessions are described in the Detailed Description section. The will complete a pre-test, post-test, and follow-up assessment."
16465567|NCT03528135|No Intervention|Wait-list|Those in the wait-list arm will wait approximately 5 months before receiving the intervention. They will complete the same pre-test, post-test, and follow-up assessments as those in the PRIDE arm. After they have completed the follow-up assessment, they will be offered the intervention.
16465568|NCT03528122|Experimental|Recurrent opened macular hole|Pars plana vitrectomy with internal limiting membrane peel if not peeled in the first surgery and application of amniotic membrane graft
16465569|NCT03528109|Experimental|patient-centered home CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
16465570|NCT03528109|Active Comparator|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
16465571|NCT03528109|Experimental|patient-centered telehealth CBT|60 minute telehealth exposure therapy with a PhD psychologist once per month and a 90 minute telehealth CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week). Patient-centered telehealth was closed when the recruitment goal was met in May 2021.
16465572|NCT03528096|Experimental|Intervention night|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed. Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms. The stimulation frequency is in the range of 0.25-2 Hz.
16465573|NCT03528096|Sham Comparator|Baseline night|The sound of the moving bed is played back to the participant at the right sound intensity level.
16465574|NCT03528083|No Intervention|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
16465575|NCT03528083|Experimental|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
16465576|NCT03528070|Experimental|Tranilast|
16465577|NCT03528057|Active Comparator|Group 1|Patients undergoing RALPN with the use of HAs by a surgeon.
16465578|NCT03528057|No Intervention|Group 2|Patients undergoing RALPN without the use of HAs by a surgeon
16465579|NCT03528044|Experimental|Patients undergoing bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
16465580|NCT03528044|No Intervention|Control group|Healthy controls with normal BMI.
16465581|NCT03528031|Experimental|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
16465582|NCT03528031|No Intervention|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
16465583|NCT03528018|Other|Control|Conventional physical therapy
16465584|NCT03528018|Experimental|Experimental|Combined tDCS and VR-based intervention
16465585|NCT03528005|No Intervention|Control|A regular health education program was provided by case managers only.
16465586|NCT03528005|Experimental|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
16465587|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
16465588|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
16465589|NCT03527979|Active Comparator|PCOS women with history of LOD before IVF/ICSI|
16465590|NCT03527979|Active Comparator|PCOS women without history of drilling|
16465591|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
16465592|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
16465593|NCT03527953|Active Comparator|Tetric EvoCeram BulkFill resin|Randomly applied
16465594|NCT03527953|Active Comparator|Surefil SDR Flowable bulk-fill resin|Randomly applied
16465597|NCT03527927|Experimental|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
16465598|NCT03527914|Active Comparator|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
16465599|NCT03527914|Experimental|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
16465600|NCT03527901||Chronic periodontitis|This groups participant has radiographically moderate alveolar bone loss, CAL > 5 mm and PD >6 mm in several sites of each quadrant
16465601|NCT03527901||Generalized aggressive periodontitis|This demonstrated a generalized pattern of severe breakdown and CAL > 5 mm and PD > 6 mm on 8 > teeth; minimum three of those were other than first incisors or first molars
16465602|NCT03527901||Gingivitis|This group has varying degrees of gingival inflammation, with CAL < 2 mm, without any radiographical bone loss due to periodontitis
16465603|NCT03527901||Implant|Implants classified PD < 5 mm, no bleeding on probing, no suppuration and no radiographic bone loss > 0.5 mm
16465604|NCT03527901||Health|Probing depth (PD) < 3mm, no gingival recession due to periodontal disease, and clinical attachment level (CAL) < 2 mm, BOP in < 10% of full-mouth score examination
16465605|NCT03527888|Other|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16465606|NCT03527875|Experimental|PTBD group|Percutaneous Transhepatic Biliary Drainage
16465607|NCT03527875|Experimental|ENBD group|Endoscopic Nasobiliary Biliary Drainage
16465608|NCT03527875|Experimental|EBS group|Endoscopic Biliary Stenting
16465609|NCT03527875|No Intervention|Without PBD group|receive surgery without PBD
16465610|NCT03527862|No Intervention|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
16465611|NCT03527862|Experimental|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
16465612|NCT03527849|Experimental|In-Person MBSR Course|
16465613|NCT03527849|Experimental|Online MBSR Course|
16465614|NCT03527849|Active Comparator|In-Person HEP|
16465615|NCT03527836|Active Comparator|Lidocaine|Lidocaine brachial plexus block 0.4 ml/kg of 0.66% solution
16465616|NCT03527836|Active Comparator|Bupivacaine|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
16465617|NCT03527836|Active Comparator|Mixture|Mixture brachial plexus block 0.4 ml/kg of 0.33% bupivacaine and 0.33% lidocaine solution
16465618|NCT03527823||LH supplementation|luteinizing hormone administrated microdose flare up GnRH analog protocol in poor ovarian responders undergoing in vitro fertilization.
16465619|NCT03527823||without LH supplementation|microdose flare up GnRH analog protocol in poor ovarian responders
16465620|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
16465621|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
16465622|NCT03527797|No Intervention|Control|Standard of care
16465623|NCT03527797|Experimental|Intervention|Titration of support level
16465624|NCT03527784|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh.
16465625|NCT03527784|Active Comparator|Parietex Parastomal|Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.
16465626|NCT03527784|Active Comparator|Dynamesh IPST|Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.
16465627|NCT03527771|No Intervention|unassisted CPR|unassisted CPR
16465628|NCT03527771|Active Comparator|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
16465629|NCT03527771|Experimental|V-CPR|video-assisted CPR according to ERC Guidelines 2015
16465630|NCT03527758|No Intervention|Standard Invasive intraoperative monitoring|
16465631|NCT03527758|Experimental|Flo TracIQ with HPI software|
16465632|NCT03527745|Experimental|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
16465633|NCT03527745|Experimental|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
16465634|NCT03527745|Experimental|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
16465635|NCT03527745|Experimental|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
16465636|NCT03527745|Placebo Comparator|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
16465637|NCT03527732|Placebo Comparator|Arm A: albendazole|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
16465638|NCT03527732|Experimental|Arm B: albendazole and ivermectin|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally
16465639|NCT03527719|Experimental|Experimental Group|"All participants of intervention groups will receive a new comprehensive evidence-based medicine (EBM) management program including nine intervention measures.
~Strengthen the performance appraisal system for primary hypertension management.
~Establishing a chronic disease management system.
~Simulating medical insurance reform.
~Enhancing village doctors'ability for standardized diagnosis and treatment of hypertension.
~Establishing a supervision mechanism for the effect of hypertension management.
~Establishing a hierarchical management system for patients.
~Enhancing the awareness of blood pressure self-management.
~Establishing a self-management group for patients.
~Establishing patient encouragement system."
16465640|NCT03527719|No Intervention|Control Group|All participants in the routine management groups will receive the current management program.
16465641|NCT03527680|Experimental|Lactobacillus rhamnosus|received daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus
16465642|NCT03527680|Placebo Comparator|Placebo|received one placebo capsule per day Infant formula after meal for 28 days
16465643|NCT03527667|Experimental|Short term incentives|usual quit smoking treatment (counseling + medication) plus 6-weeks of payments for proof of smoking abstinence
16465644|NCT03527667|Experimental|Long term incentives|usual quit smoking treatment (counseling + medication) plus 12-weeks of payments for proof of smoking abstinence
16465645|NCT03527667|No Intervention|No incentives|usual quit smoking treatment (counseling + medication)
16465646|NCT03527654||Hispanic Immigrants|
16465647|NCT03527641|Experimental|Salud sin Barreras, Health without Barriers|"Salud sin Barreras is a manualized community-delivered program tailored for Latino families and their adolescent children at-risk for type 2 diabetes. Salud sin Barreras is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions that include parent education on nutrition, fitness, goal-setting, parenting, and a brief mindfulness curriculum, a teen group physical fitness class, and a teen mindfulness curriculum called Learning 2 BREATHe. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
16465648|NCT03527641|Active Comparator|La Vida Saludable, Healthy Living|The Health Living Program (HeLP) is a manualized community-delivered program tailored specifically for Latino families and children at-risk for adult obesity. HeLP includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions, that include parent education on nutrition, fitness, goal-setting, and parenting, a teen group physical fitness class, and a teen health knowledge curriculum derived from a health education curriculum called Hey DURHAM.
16465649|NCT03527628|Other|Patients with PET-2 Negative Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results
~PET-2 negative patients will be treated with 4 cycles of ACVD (Adriamycin, Cyclophosphamide, Vinblastine And Dacarbazine)"
16465650|NCT03527628|Other|Patients with PET-2 Positive Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results
~PET-2 positive patients will be treated with 4 cycles of ACVD with addition of Brentuximab Vedotin"
16465651|NCT03527602|Experimental|Intervention|Endodontic treatment will be performed in maxillary anterior teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with rotary files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
16465652|NCT03527602|No Intervention|Control|In the control group, no foraminal enlargement will be performed.
16465653|NCT03527589||Treated with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).
16465654|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
16465655|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
16465656|NCT03527563|Other|Internet Medical Model|Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
16465657|NCT03527563|No Intervention|Conventional Medical Model|Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
16465658|NCT03527550|Experimental|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
16465659|NCT03527550|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
16465660|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
16465661|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
16465662|NCT03527524|Experimental|exercise with ball|The participant in core stabilization exercise with ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
16466038|NCT03524963|Experimental|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
16465663|NCT03527524|Other|exercise without ball|The participant in core stabilization exercise without ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
16465664|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
16465665|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
16465666|NCT03527485|Other|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
16465667|NCT03527485|Other|Cocaine Use Disorder (CUD)|30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
16465668|NCT03527485|Other|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
16465669|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
16465670|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
16465671|NCT03527459|Active Comparator|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
16465672|NCT03527459|Experimental|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
16465673|NCT03527446|Experimental|Normal Weight|BMI ≥ 18.5 < 25.0 km/m2 Sprint Interval Training
16465674|NCT03527446|Experimental|Individuals living with Obesity|BMI ≥ 30.0 km/m2 Sprint Interval Training
16465675|NCT03527433|No Intervention|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
16465676|NCT03527433|Experimental|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
16465677|NCT03527420|Active Comparator|Exercising|12 weeks of aerobic exercise training
16465678|NCT03527420|No Intervention|Non-exercising|standard of care
16465679|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.
~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include ~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
16465680|NCT03527381|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
16465681|NCT03527381|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
16465682|NCT03527368|Experimental|Time-restricted feeding|
16465683|NCT03527368|Other|Usual feeding pattern|Comparison
16465684|NCT03527355|Experimental|A (Single dose)|"One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).
~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).
~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months."
16465685|NCT03527355|Active Comparator|B (Two dose)|"Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).
~MMR for age group at 9-12 months."
16465686|NCT03527355|Placebo Comparator|C (Placebo/Comparator)|"One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).
~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).
~MMR for age group at 9-12 months."
16465687|NCT03527342||Dilated Cardiomyopathy|
16465688|NCT03527342||Myocarditis|
16465689|NCT03527342||Sarcoidosis Heart|
16465690|NCT03527342||Giant Cell Myocarditis|
16465691|NCT03527342||Amyloidosis Heart|
16465692|NCT03527342||Hypertrophic Cardiomyopathies|
16465693|NCT03527342||Left Ventricular Myocardial Noncompaction Cardiomyopathy|
16465694|NCT03527342||Arrhythmogenic Right Ventricular Cardiomyopathies|
16465695|NCT03527329||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
16465696|NCT03527329||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
16465697|NCT03527316|Experimental|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
16465698|NCT03527316|Experimental|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
16465699|NCT03527303|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
16465700|NCT03527303|No Intervention|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
16465701|NCT03527290|Experimental|Time Restricted Eating|Participants will be instructed and counseled to incorporate a 12-hour Time Restricted Eating (TRE) regimen that begins upon waking and concludes within a 12-hour period (e.g. if wake at 6:30 AM then all caloric intake occurs between 6:30 AM and 6:30 PM). Water and non-caloric beverages (e.g. herbal tea) outside the period are encouraged as desired. There are no specific content or energy intake changes to the diet counseled or recommended as the focus of the counseling in this arm is timing of eating with innate circadian patterns and developing plans and approaches to follow this plan.
16465702|NCT03527290|Active Comparator|Standard Cardiometabolic Health Diet|Participants will be instructed and counseled with standard clinical dietary guidance for improving cardiometabolic health, where the focus is on the content, specifically a dietary pattern that emphasizes vegetables, fruits, whole grains, legumes, nuts/seeds, low fat dairy, seafood, lean poultry and meat and avoidance of foods with high levels of sodium, added sugars, saturated fats, and trans fats. There is no prescription to reduce energy intake.
16465703|NCT03527277|Experimental|Naturally-sweetened orange juice|Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
16465704|NCT03527277|Active Comparator|Sugar-sweetened beverage|Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
16465705|NCT03527264|Experimental|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
16465706|NCT03527264|Experimental|Cohort 1B|Nivolumab during Chemo/RT with extended field
16465707|NCT03527264|Experimental|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
16465708|NCT03527264|Experimental|Cohort 3|Nivolumab during chemoradiation and then as maintenance
16465709|NCT03527251|Experimental|Sequential group|intravenous ipilimumab following by intravenous SHR-1210
16465710|NCT03527238|Active Comparator|Standard of Care|Standard of Care Tacrolimus Drug Dosing
16465711|NCT03527238|Experimental|Phenotypic Precision Medicine (PPM)|PPM-based Computation Assisted Drug Dosing
16465712|NCT03527225|Experimental|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
16465713|NCT03527225|No Intervention|No Music|These patient's will have no music playing during the first radiotherapy session.
16465714|NCT03527212|Experimental|SJP-0035 0.001% (ophthalmic solution)|
16465715|NCT03527212|Placebo Comparator|Placebo (ophthalmic solution)|
16465716|NCT03527186|Experimental|Risperidone ISM 100 mg|A single intramuscular (IM) dose of 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. A total of 4 IM doses will be given; each dose will be separated by 4 weeks
16465717|NCT03527173|Experimental|S. sonnei Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
16465718|NCT03527173|Placebo Comparator|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
16465719|NCT03527147|Experimental|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
16465720|NCT03527147|Experimental|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
16465721|NCT03527147|Experimental|Hu5F9-G4 + rituximab + Acalabrutinib|Hu5F9-G4/rituximab in combination with acalabrutinib
16465722|NCT03527147|Experimental|AZD5153 + Acalabrutinib|AZD5153 in combination with acalabrutinib
16465723|NCT03527134|Experimental|Amantadine treatment|To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.
16465724|NCT03527134|No Intervention|No-treatment|Patients will not receive any treatment.
16465725|NCT03527121|Experimental|R.I.C.E.+ (ESP physiotherapy)|Participants will receive a single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
16465726|NCT03527121|Active Comparator|R.I.C.E.(Usual care)|A single session with advice and instructions from a physician in rest, ice, compression and elevation.
16465727|NCT03527108|Experimental|Patients with prior IO therapy|
16465728|NCT03527095|Experimental|Regimen A|FDL169 200 mg reference tablet
16465729|NCT03527095|Experimental|Regimen B|FDL169 200 mg testing tablet 1
16465730|NCT03527095|Experimental|Regimen C|FDL169 200 mg testing tablet 2
16465731|NCT03527095|Experimental|Regimen D|FDL169 200 mg testing tablet 1 or 2 with high fat diet
16465732|NCT03527095|Experimental|Regimen E|FDL169 200 mg testing tablet 1 or 2, fasted
16465733|NCT03527095|Experimental|Regimen F|FDL169 200 mg testing tablet 1 or 2, with standard diet
16465734|NCT03527082||Women attending gynaecology clinics|"150 women attending gynaecology clinics that fulfil inclusion criteria
~Inclusion criteria:
~Inclusion criteria
~Over the age of 18
~attending gynaecology clinics
~Able to read and comprehend the details of the study in patient information sheet.
~Mentally competent at signing the consent form.
~English -speaking, if not then translator available"
16465735|NCT03527069|Experimental|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:
~1 tablet Cipros 10 association; and
~1 tablet crestor placebo Oral, once a day."
16465736|NCT03527069|Active Comparator|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:
~1 tablet Crestor 10mg; and
~1 tablet Cipros association placebo Oral, once a day."
16465815|NCT03526536|Other|Patients with diabetes and no ESRD|Patients with diabetes and no end stage renal disease (ESRD)
16465816|NCT03526523|Experimental|Active Treatment|Mindfulness-based stress reduction
16465737|NCT03527056|Experimental|Oral capsule fecal transplantation|Enrolled patients who have screened positive for CRE in the stool will receive fecal transplant via OpenBiome oral capsules. The patient is given 90 minutes to swallow all capsules and does not require any anesthesia or sedation. Stool samples to test for CRE will be taken 10 days and 30 days after the fecal transplant.
16465738|NCT03527056|No Intervention|Observation|Enrolled patients who have screened positive for CRE in the stool will have stool samples to test for CRE taken 10 days and 30 days after initial enrollment.
16465739|NCT03527043|Experimental|Escitalopram|10mg by mouth daily for 6 weeks
16465740|NCT03527043|Placebo Comparator|Placebo|Matched placebo control by mouth for 6 weeks.
16465741|NCT03527030||General Population|Adults living in a registered household in the Greater London area.
16465742|NCT03527030||IQOS users|Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.
16465743|NCT03527017||General Population|Adults living in Germany.
16465744|NCT03527017||IQOS Users|Adult current IQOS users (at the time of survey) living in Germany who are registered in the Germany IQOS User Database and agreed to be contacted for research purposes at the time of registration.
16465745|NCT03527004||General Population|Survey on use of tobacco products in the general population of adults living in Italy.
16465746|NCT03527004||IQOS Users|Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
16465747|NCT03526991|Experimental|Spinal Cord Stimulation (SCS) Tonic stimulation|Tonic stimulation
16465748|NCT03526991|Experimental|Spinal Cord Stimulation (SCS) Burst stimulation|Burst stimulation.
16465749|NCT03526978|Experimental|Experimental Group|"The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
~Intervention: investigational sIPV"
16465750|NCT03526978|Active Comparator|Control Group|The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
16465751|NCT03526965|Experimental|Yoga Chikitsa|YC group were given traditional combination of yoga therapy including loosening movements, physical postures, breathing, relaxation and yoga counselling.
16465752|NCT03526965|Active Comparator|Usual Care|Usual care were given exercise moves of necks, pain medications prescribed by physicians.
16465753|NCT03526952|Experimental|Intervention Group|Couples in this group will receive the Internet-Delivered Intervention for Sexual Re-Adjustment
16465754|NCT03526952|Active Comparator|Educational Comparison Group|Couples in this group will receive only written educational material about sexuality and intimacy with an ostomy.
16465755|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
16465756|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
16465757|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
16465758|NCT03526926||Vyxeos|A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.
16465759|NCT03526913|Experimental|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
16465760|NCT03526913|Active Comparator|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
16465761|NCT03526900|Experimental|Atezolizumab|Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
16465762|NCT03526887|Experimental|Cohort 1|Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
16465763|NCT03526887|Experimental|Cohort 2|Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
16465764|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.
~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
16465765|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.
~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
16465817|NCT03526523|No Intervention|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
16466039|NCT03524950|No Intervention|no dexmedetomidine|
16466040|NCT03524950|Experimental|high dose dexmedetomidine|
16465774|NCT03526848|Experimental|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
16465775|NCT03526848|Experimental|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
16465776|NCT03526835|Experimental|MCLA-158|In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.
16465777|NCT03526822|Experimental|patients with newly diagnosed glioblastoma|
16465778|NCT03526809||Ovarian cancer patients|MRI and FDG-PET imaging
16465779|NCT03526796|Experimental|Hyperbaric oxygen therapy|Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
16465780|NCT03526783|Other|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
16465781|NCT03526783|Other|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
16465782|NCT03526770|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink."
16465783|NCT03526770|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
16465784|NCT03526770|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
16465785|NCT03526770|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the tooth paste as an intervention."
16465786|NCT03526770|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
16465818|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
16466041|NCT03524950|Experimental|low dose dexmedetomidine|
16465787|NCT03526770|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
16465788|NCT03526757|Experimental|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
16465789|NCT03526757|Active Comparator|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
16465790|NCT03526744|Experimental|marine protein hydrolysate 1234|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
16465791|NCT03526744|Experimental|marine protein hydrolysate 2134|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
16465792|NCT03526744|Experimental|marine protein hydrolysate 3124|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with with up to 7 days-out in between. Random sequence of arms.
16465793|NCT03526744|Experimental|marine protein hydrolysate 4123|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
16465794|NCT03526731|Experimental|Group A (original QLB-2):|Local anesthetic will be injected between the quadratus lumborum muscle and the latissimus dorsi muscle guided by ultrasound.
16465795|NCT03526731|Experimental|Group B (trans-muscular OLB-3)|Local anesthetic will be injected between quadratus lumborum and psoas major after passing through the quadratus lumborum muscle guided by ultrasound.
16465796|NCT03526705|Experimental|nb-uvb|psoriasis patients will receive 26 sessions of nb-uvb phototherapy
16465797|NCT03526692|Experimental|Sensorimotor/delta NF training group|"Three interventions will be administered:
~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.
~The third intervention is the neurofeedback training sensorimotor/delta ratio that will be recorded at channel Cz according to the International 10-20 system."
16465798|NCT03526692|Experimental|Beta1/theta NF training group|"Three interventions will be administered:
~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.
~The third intervention is the neurofeedback training Beta1/theta ratio that will be recorded at channel Fz according to the International 10-20 system."
16465799|NCT03526692|No Intervention|Control group|"Three interventions will be administered:
~An electroencephalography recording for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.
~The psychopedagogical care : Each session will be organized using the same video material than for the NF training sessions."
16465800|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
16465801|NCT03526666||AML, MDS, and CMML patients|Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
16465802|NCT03526653|Other|Intervention 1|exercise on an ergometer or motomed in an environment without other visual stimuli
16465803|NCT03526653|Other|Intervention 2|exercise on an ergometer or motomed while watching the National Geografics channel on television
16465804|NCT03526653|Other|Intervention 3|exercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
16465805|NCT03526653|No Intervention|Control group|Rest during 30 minutes
16465806|NCT03526640|Experimental|Plug Arm|Participants randomized for plug arm will be treated with a plug after CT guided is conducted.
16465807|NCT03526640|No Intervention|Non Plug arm|No Intervention, i.a. CT guided biopsy without plug.
16465808|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.
16465809|NCT03526588|Experimental|Autologous umbilical cord blood|
16465810|NCT03526575|Placebo Comparator|10 mg Zolpidem and 10 mg Zaleplon|Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
16465811|NCT03526575|Placebo Comparator|5 mg Zolpidem and 10 mg Zaleplon|Experiment 2, which will involve N=20 subjects randomized to placebo, 5 mg zolpidem and 10 mg zaleplon. All females will be placed in experiment 2. Subjects are nested into group.
16465812|NCT03526562|Experimental|Single arm phase I trial with 3 exercise dose-escalation arms|exercise dose-escalation: aerobic, resistance and flexibility training
16465813|NCT03526549|Experimental|EN3835 Active|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
16465814|NCT03526536|Other|Patients with diabetes and ESRD|Patients with diabetes and end stage renal disease (ESRD)
16465819|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
16465820|NCT03526484|Active Comparator|Standard of Care|The control group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will be reported to the doctor performing the procedure. The provider may require participants to take antibiotics and/or delay their procedure as a result of the urinalysis.
16465821|NCT03526484|Experimental|Experimental|The experimental group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will NOT be reported to the doctor performing the procedure. Instead, the provider will conduct the procedure without looking at or acting upon the results of the urinalysis. The urinalysis and urine culture results will be monitored by the research team, and the participant will be informed if the urine culture results are positive for an infection.
16465822|NCT03526471|Experimental|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
16465823|NCT03526458|Active Comparator|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser.
16465824|NCT03526458|Experimental|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser.
16465825|NCT03526445|Active Comparator|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
16465826|NCT03526445|Placebo Comparator|Saline|3 hours i.v. infusion of saline
16465827|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
16465828|NCT03526406|Experimental|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
16465829|NCT03526406|Placebo Comparator|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
16465830|NCT03526393|Experimental|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
16465831|NCT03526380|Experimental|Treatment|Participants receive the OPT-IN Brief Intervention.
16465832|NCT03526380|No Intervention|Control|Participants will only complete the baseline and follow-up surveys.
16465833|NCT03526367|Experimental|hydration plus rosuvastatin therapy|"After randomized，hydration（3ml/kg/h, if patients had LVEF<40%, 1.5 ml/kg/h）last 12 hours;
~After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
16465834|NCT03526367|Active Comparator|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
16465835|NCT03526354|Experimental|Experimental|Brexpiprazole 4mg daily for 12 weeks
16465836|NCT03526354|Active Comparator|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
16465837|NCT03526328||DCLK1 post BE treatment|Effects of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
16465838|NCT03526315|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
16465839|NCT03526315|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
16465840|NCT03526315|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
16465841|NCT03526289|Active Comparator|GIP infusion|5 hours of continuously GIP1-42 infusion
16465842|NCT03526289|Placebo Comparator|Saline|5 hours of continuously saline infusion
16465843|NCT03526276|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
16465844|NCT03526276|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
16465845|NCT03526276|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
16465846|NCT03526263|Experimental|Gastric mucosal devitalization arm|"Patients will be enrolled into the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care at Johns Hopkins Bayview. The cost of the surgery will be covered by the patient's insurance and there will no extra procedural element that would add time to surgery.
~The intervention will occur on the excised specimen ex vivo (outside the body) and will involve devitalization of the gastric mucosa using Argon Plasma Coagulation."
16465848|NCT03526237|Experimental|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
16465849|NCT03526237|Other|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
16465850|NCT03526224||Aubagio|Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).
16465851|NCT03526224||Tecfidera|Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level
16465853|NCT03526198|Experimental|Group 1 (adult)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
16465854|NCT03526198|Experimental|Group 2 (elderly)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
16465855|NCT03526185|Experimental|Cohort 1|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.
~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400
~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)."
16465856|NCT03526185|Experimental|Cohort 2|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.
~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400
~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses).
~Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment."
16465857|NCT03526172||Control|Patients undergoing HTO without the inclusion of any bone wedge
16465858|NCT03526172||Allograft|Patients undergoing HTO with the inclusion of an allograft bone wedge
16465859|NCT03526159|Experimental|Gentamicin Sulfate|"IV Arm:
~7.5 mg/kg gentamicin once daily for 14 days.
~Topical Arm:
~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
16465860|NCT03526146|Experimental|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
16465861|NCT03526146|No Intervention|Usua Care|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the senior center, which include a combination of daily physical, mental and social activities.
16465862|NCT03526120|Experimental|Pistachio diet|Incorporates 44 g (1 serving) of pistachios into a daily diet
16465863|NCT03526120|No Intervention|Control|No pistachio consumption
16465864|NCT03526107|Active Comparator|CF Control|CF Control: 583 mg of cocoa flavanols, <1 mg caffeine and <1 mg theobromine
16465865|NCT03526107|Experimental|CF-Theobromine|CF-Theobromine: 566 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
16465866|NCT03526107|Experimental|CF-Caffeine|CF-Caffeine: 583 mg of cocoa flavanols, 112 mg caffeine and <1 mg theobromine(Experimental)
16465867|NCT03526094|Active Comparator|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
16465868|NCT03526094|Experimental|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
16465869|NCT03526094|Experimental|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
16465870|NCT03526094|Experimental|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
16465871|NCT03526094|Experimental|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
16465872|NCT03526094|Experimental|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
16465873|NCT03526094|Experimental|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
16465874|NCT03526094|Experimental|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
16465875|NCT03526094|Active Comparator|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
16465876|NCT03526094|Experimental|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
16465877|NCT03526081|Experimental|Chamomile Tea|Chamomile Tea in 300mL hot water
16465878|NCT03526081|Experimental|Parsley based drink|3.2 g dried parsley in 300mL hot water
16465879|NCT03526081|Experimental|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
16465880|NCT03526081|Experimental|Apigenin|Apigenin capsule mixed with 300mL hot water
16465881|NCT03526081|Experimental|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
16465882|NCT03526068|Experimental|SafeZoneUVC|Patients were subjected to 90s UV light therapy of 540 mW/cm2 sessions 2 times a week for 2 weeks for a total of 4 sessions. Pre and post UV light therapy swabs were taken after standard wound irrigation
16466042|NCT03524937|Experimental|MELATONIN (LOW DOSE)|Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.
16465883|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
16465884|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
16465885|NCT03526042|Experimental|Losartan|AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.
16465886|NCT03526042|Active Comparator|Enalapril|Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.
16465887|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
16465888|NCT03525990|Active Comparator|Intervention Arm|Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
16465889|NCT03525990|Placebo Comparator|Control Arm|Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
16465890|NCT03525977|No Intervention|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
16465891|NCT03525977|Experimental|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
16465892|NCT03525964|Experimental|Individualized treatment|"The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast after surgery. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.
~The patient will follow standard functional rehabilitation and the follow-up evaluations."
16465893|NCT03525964|Active Comparator|Control group 1|"For the patients allocated to non-operative treatment the injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.
~The patient will follow standard functional rehabilitation and the follow-up evaluations."
16465894|NCT03525964|Active Comparator|Control group 2|"The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.
~The patient will follow standard functional rehabilitation and the follow-up evaluations."
16465895|NCT03525951|Other|Typically Developing Children Study 2 (TD2)|No-intervention comparison group measured over time.
16465896|NCT03525951|Experimental|Children with Dev Language Disorder Study 2 (DLD2)|Enhanced Milieu Teaching
16465897|NCT03525951|Experimental|Children with Autism Spectrum Disorders Study 2 (ASD+DLD 2)|Enhanced Milieu Teaching
16465898|NCT03525951|Other|Typically Developing Children Study 1 (TD1)|No-intervention group for observational data comparison.
16465899|NCT03525951|Other|Children with Dev Language Disorder Study 1 (DLD1)|No-intervention group for observational data comparison.
16465900|NCT03525938|Active Comparator|TAP group|
16465901|NCT03525938|Sham Comparator|SHAM group|
16465902|NCT03525925|Experimental|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16465903|NCT03525912|Experimental|Ketamine infusion|postoperative pain in adult population after abdominal, thoracic and orthopedic surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 24 to 48 hours in postoperative period.
16465904|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
16465905|NCT03525886|Experimental|NBI-74788 Dose Group 1|NBI-74788 administered orally for 14 consecutive days.
16465906|NCT03525886|Experimental|NBI-74788 Dose Group 2|NBI-74788 administered orally for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 2 will be dosed in parallel with Group 3.
16465907|NCT03525886|Experimental|NBI-74788 Dose Group 3|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 3 will be dosed in parallel with Group 2.
16465908|NCT03525886|Experimental|NBI-74788 Dose Group 4|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days.
16465909|NCT03525873|Experimental|ARM I (methylphenidate, physical activity)|Patients receive methylphenidate PO BID for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete physical activity consisting of walking and resistance exercise over 25-40 minutes QD 4 days a week. After 2 weeks, patients may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
16465910|NCT03525873|Placebo Comparator|ARM II (placebo, physical activity)|Patients receive a matched placebo PO BID and complete physical activity as in Arm I. Treatment continues for up to 2 weeks in the absence of disease progression or unacceptable toxicity.
16465911|NCT03525860|Experimental|Acupuncture Treatment|"20 subjects will be treated with standard of care and acupuncture.
~Will complete Symptom and Pain questionnaire (VAS) and a Was It Worth It (WIWI) questionnaire each day of study participation (3 days)."
16465912|NCT03525860|No Intervention|No Intervention|"20 subjects will be treated with standard of care only.
~Will complete Symptom and Pain questionnaire (VAS) each day of study participation (3 days)."
16465913|NCT03525847|Active Comparator|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
16465914|NCT03525847|Active Comparator|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
16465915|NCT03525834|Experimental|Everolimus|Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.
16465916|NCT03525821|Experimental|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
16465917|NCT03525808|Experimental|AXIOS|Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
16465918|NCT03525795|Experimental|CPI-1205 Combination with ipilimumab|
16465919|NCT03525782|Experimental|CAR-T|Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.
16465920|NCT03525782|Experimental|CAR-T combining PD-1 knockout|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
16465921|NCT03525782|Experimental|PD-1 knockout|PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
16465922|NCT03525782|Active Comparator|PD-1 mAb|Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.
16465923|NCT03525782|Placebo Comparator|Sham Control|Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.
16465924|NCT03525769||Type 2 Diabetes Mellitus|
16465925|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
16465926|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
16465927|NCT03525730|No Intervention|Control|This group receives no intervention.
16465928|NCT03525730|Experimental|Valproic acid|This group receives valproic acid (enteric) for 14 days.
16465929|NCT03525730|Experimental|Pyrimethamine|This group receives pyrimethamine for 14 days.
16465930|NCT03525730|Experimental|Valproic acid and Pyrimethamine|This group receives valproic acid and pyrimethamine for 14 days.
16465931|NCT03525717|Active Comparator|Routine Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at routine dinner time (18:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from late dinner. This arm will cross-over to late dinner in random order."
16465932|NCT03525717|Experimental|Late Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (22:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from routine dinner. This arm will cross-over to routine dinner in random order."
16465933|NCT03525704|Experimental|Saline Solution Enriched|Saline Solution enriched with electrolytes and PH balanced to mimic normal tears
16465934|NCT03525704|Active Comparator|Saline Rinse Solution|Saline Solution .9% NaCL
16465935|NCT03525691|Experimental|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
16465936|NCT03525691|Experimental|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
16465937|NCT03525691|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
16465938|NCT03525678|Experimental|Participants receiving frozen 2.5 mg/kg belantamab mafodotin|Participants will receive 2.5 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
16465939|NCT03525678|Experimental|Participants receiving frozen 3.4 mg/kg belantamab mafodotin|Participants will receive 3.4 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
16465940|NCT03525678|Experimental|Participants receiving lyophilized belantamab mafodotin|Participants in lyophilized arm will receive lyophilized belantamab mafodotin once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
16465941|NCT03525652|Active Comparator|Therapeutic vaccine|Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.
16466034|NCT03524989|Active Comparator|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
16465942|NCT03525652|Experimental|Therapeutic vaccine plus PD-1 knockout|Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
16465943|NCT03525652|Active Comparator|PD-1 knockout T cells|PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
16465944|NCT03525639|Experimental|Patients with Acute Myocarditis|Patients undergoing Cardiac Magnetic Resonance at baseline, 2 month, 1 year.
16465945|NCT03525626|Experimental|Online Mindfulness-based Tic Reduction|
16465946|NCT03525613|Experimental|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
16465947|NCT03525613|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
16465948|NCT03525613|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
16465949|NCT03525613|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
16465950|NCT03525600|Experimental|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
16465951|NCT03525600|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
16465952|NCT03525600|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
16465953|NCT03525600|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
16465954|NCT03525587|Active Comparator|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.
~Intervention: Use of MAGHD App/MAGHD Framework"
16465955|NCT03525587|Active Comparator|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).
~Intervention: Use of MAGHD App/MAGHD Framework"
16465956|NCT03525587|Active Comparator|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).
~Intervention: Use of MAGHD App/MAGHD Framework"
16465957|NCT03525574|Experimental|Open-label Triple Combination|"Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.
~Parent studies are Phase 3 Vertex studies investigating VX-445 in combination with TEZ and IVA. This includes Studies VX17-445-102 and VX17-445-103."
16465958|NCT03525561|Active Comparator|acetazolamide arm|This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill.
16465959|NCT03525561|Placebo Comparator|placebo arm|This is the arm of the study in which volunteers will take the placebo.
16465960|NCT03525548|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
16465961|NCT03525548|Experimental|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
16465962|NCT03525535||Pulmonary embolism|data from routine care will be collected for patient eligible and willing to participate
16465963|NCT03525522|Experimental|Nd:YAG Laser|Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)
16465964|NCT03525522|Active Comparator|Topical Corticosteroid Diprosone|Topical corticosteroid betamethasone (Diprosone, Merck Sharp & Dohme, d.o.o.) for 3 months.
16465965|NCT03525509|Experimental|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
16465966|NCT03525509|Active Comparator|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
16465967|NCT03525483|Experimental|Patients with ECMO|"Patients with circulatory assistance by ECMO Patients are included 48 hours after ECMO VA or VV therapy and after hemodynamic stabilization defined by blood pressure stability and cardiac output for at least 12 hours without significant changes in amine flow.
~When stable they will have an Ultrasound for renal resistivity index measurement"
16465968|NCT03525470|Experimental|Water|Subjects consumed water
16465969|NCT03525470|Experimental|No water|Subjects did not consume water
16465970|NCT03525457|Experimental|Experimental|Non surgical periodontal therapy
16465971|NCT03525444|Placebo Comparator|Placebo|Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
16465972|NCT03525444|Experimental|VX-445/TEZ/IVA TC|Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
16465973|NCT03525431|Experimental|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
16465974|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
16466035|NCT03524989|Sham Comparator|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
16466043|NCT03524937|Experimental|MELATONIN (HIGH DOSE)|Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.
16466044|NCT03524937|Placebo Comparator|PLACEBO|Daily administration of identical placebo up to 14 days.
16465975|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
16465976|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
16465977|NCT03525405|Experimental|Single Dose|
16465978|NCT03525392|Experimental|177Lu-3BP-227|"Screening: 177Lu-IPN01087 - 25 µg 3BP-227 (IPN01087) per 1 GBq of 177Lu. 1 GBq in a total volume of 10 mL.
~Treatment phase: 177Lu-IPN01087 - 2.5 to 7.5 GBq escalation dose of 177Lu-3BP-227 (IPN01087) in a total volume of 20 mL for each cycle of administration (2 cycles plus 4 optional additional)."
16465979|NCT03525379|Experimental|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
16465980|NCT03525379|Placebo Comparator|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
16465981|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
16465982|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
16465983|NCT03525340|No Intervention|Standard of Care|Participants in the standard of care arm will receive no navigation assistance to remain in care. They will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation, but no additional services to remain engaged in care other than what is provided as standard by the clinic.
16465984|NCT03525340|Experimental|Peer Navigation|Participants in the peer navigation arm will meet with a peer navigator at least once per month for nine months in-person, and have at least one other navigator contact per month. Like the standard of care arm, they will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation.
16465985|NCT03525327||Line Dance Class participants|The group will be participating in line dance classes as intervention.
16465986|NCT03525301|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
16465987|NCT03525301|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16465988|NCT03525288|Experimental|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
16465989|NCT03525288|Active Comparator|Standard|Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
16465990|NCT03525275|Experimental|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
16465991|NCT03525275|Active Comparator|Physical Therapy alone|Intervention = Post-surgical protocol
16465992|NCT03525262|No Intervention|SAbR WITHOUT Neurovascular sparing|"GTV represents MR defined gross radiographic disease, if identifiable.
~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.
~PTV1_30Gy will not be used or created on this arm
~PTV2_SAbR will be generated by a 3mm expansion on the CTV. PTV2_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
16465993|NCT03525262|Experimental|SAbR WITH Neurovascular sparing|"GTV represents MR defined gross radiographic disease, if identifiable.
~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.
~PTV1_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
~PTV2_SAbR will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries. PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
16465994|NCT03525249|Experimental|Comparator Membraflex 500mg|experimental product one dose
16465995|NCT03525249|Experimental|Comparator Membraflex 300mg|experimental product two doses
16465996|NCT03525249|Placebo Comparator|Placebo Comparator|placebo product
16465997|NCT03525236|Experimental|Taste of 5 flavors|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.
~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)
~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.
~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
16465998|NCT03525223|Active Comparator|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate [Na+] from 138 mmol/l to 142 mmol/l The dialysate [Na+] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
16466036|NCT03524976||Embolization with Squid|All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The
16466119|NCT03524339|Experimental|Tamsulosin|
16465999|NCT03525223|Active Comparator|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate [Na+] from 142 mmol/l to 135 mmol/l The dialysate [Na+] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate [Na+] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
16466000|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
16466001|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
16466002|NCT03525197|Experimental|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
16466003|NCT03525197|Active Comparator|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
16466004|NCT03525184|Placebo Comparator|Normal sleep|A normal sleep condition and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; NS)
16466005|NCT03525184|Placebo Comparator|72-h Sleep restriction with placebo beverage|Sleep restriction (72-h with 2-h of sleep per night) and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; SR),
16466006|NCT03525184|Experimental|72-h Sleep restriction with multi-nutrient beverage|Sleep restriction (72-h with 2-h of sleep per night) and the experimental treatment (1.5 g protein/kg body weight/day + multi-nutrient beverage; SR+).
16466007|NCT03525171|Active Comparator|GHD children|23 prepubertal children with isolated GHD consecutively admitted to the Section of Endocrinology of the University of Palermo during treated with GH for at least 12 months underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
16466008|NCT03525171|Placebo Comparator|controls|12 prepubertal healthy subjects with short stature recruited among children referred for assessment of short stature as a control group at baseline underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
16466009|NCT03525158|Other|Baseline phase ('A') and Intervention phase ('B')|"Baseline phase ('A'): Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
~Intervention phase ('B'): A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma)."
16466010|NCT03525132|Experimental|Healthy subjects|120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
16466011|NCT03525132|Experimental|Glaucoma|60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
16466012|NCT03525132|Experimental|Retinal vein occlusion|80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
16466013|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
16466014|NCT03525119|Experimental|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
16466015|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
16466016|NCT03525106|Experimental|Participants: Positive Psychology Intervention|Participants receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
16466017|NCT03525106|Experimental|Caregivers: Positive Psychology Intervention|Caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
16466018|NCT03525093|Active Comparator|Hypnosis + health education|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home plus health education booklet on coping with stress
16466019|NCT03525093|Other|Health education alone|Patients receive a health education booklet to improve coping with stress
16466020|NCT03525080|Experimental|PET Arm|
16466021|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
16466022|NCT03525041|Active Comparator|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
16466023|NCT03525041|Active Comparator|CABG|Participants will undergo CABG only.
16466024|NCT03525028|Experimental|Metformin group|Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
16466025|NCT03525028|Placebo Comparator|Placebo group|Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
16466026|NCT03525015|Experimental|A decision aid booklet|A decision aid booklet about cataract surgery choice
16466027|NCT03525015|Active Comparator|An usual booklet|An usual booklet about cataract and cataract surgery
16466028|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (AA), Placebo|Participants with FTO SNP rs8050136 AA receiving matching Placebo
16466029|NCT03525002|Active Comparator|FTO SNP rs8050136 (AA), Bromocriptine|Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg
16466030|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CA), Placebo|Participants with FTO SNP rs8050136 CA receiving matching Placebo
16466031|NCT03525002|Active Comparator|FTO SNP rs8050136 (CA), Bromocriptine|Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg
16466032|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CC), Placebo|Participants with FTO SNP rs8050136 CC receiving matching Placebo
16466033|NCT03525002|Active Comparator|FTO SNP rs8050136 (CC), Bromocriptine|Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg
16466045|NCT03524924||non-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: < 0.3151361243 Male: < 1.211878526
16466046|NCT03524924||pre-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 0.3151361243 to < 2.1301121973 Male: 1.211878526 to < 3.0052612772
16466047|NCT03524924||frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 2.1301121973 to < 6 Male: 3.0052612772 to < 7
16466048|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
16466049|NCT03524898|Experimental|nab-paclitaxel and gemcitabine|Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
16466050|NCT03524885|Active Comparator|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
16466051|NCT03524885|Experimental|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).
~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).
~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
16466052|NCT03524872|Active Comparator|Original CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and original (Sweden&Martina) CAD/CAM abutments.
16466053|NCT03524872|Experimental|Compatible CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and compatible (New Ancorvis) CAD/CAM abutments.
16466054|NCT03524859||Cystic fibrosis|Cystic fibrosis participants without experience on endurance or resistance training will be analyzed through a test battery and lung function test.
16466055|NCT03524859||Healthy Subjects|Healthy matched control group without experience on endurance or resistance training will be analyzed through a test battery.
16466056|NCT03524846|Active Comparator|Ascorbic acid 300 mg|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
16466057|NCT03524846|Active Comparator|Ascorbic acid 600 mg|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
16466058|NCT03524846|Placebo Comparator|Placebo|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
16466059|NCT03524833|Other|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
16466060|NCT03524833|Other|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
16466061|NCT03524820|Experimental|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
16466062|NCT03524807|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
16466063|NCT03524807|No Intervention|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
16466064|NCT03524768||patients presenting with Chagas cardiomyopathy|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
16466065|NCT03524768||control group|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
16466066|NCT03524755|Experimental|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (~6 weeks).
16466067|NCT03524755|No Intervention|Control Group|The control group received usual care.
16466068|NCT03524742|Experimental|Avocado-Mediterranean Diet|Avocado based Mediterranean diet with intake of ½ portion of a Hass avocado per day, during 3 months.
16466069|NCT03524742|Active Comparator|Control-Group Diet|Control-Group Diet consists of a low fat-high complex carbohydrate diet, during 3 months.
16466070|NCT03524729|Active Comparator|Ankle osteoarthritis patients|Ambulatory adult patients (18+) with ankle osteoarthritis.
16466071|NCT03524729|Other|Healthy control subjects|Ambulatory adults (18+) with no known ankle osteoarthritis.
16466072|NCT03524716|Experimental|Fitbit and Text Messages|Participants randomized to this arm receive print materials and a Fitbit Flex 2 at baseline and daily text messages for 12 weeks.
16466073|NCT03524716|No Intervention|Usual Care|Participants randomized to usual care receive print materials at baseline.
16466074|NCT03524703|Experimental|Chewing Gum Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
16466075|NCT03524703|No Intervention|Control Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Control Group receive standard cares and are asked not to chew gum within 5 days after surgery. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
16466076|NCT03524690|Active Comparator|SUSOPS Balance|Volunteers provided sufficient food to maintain energy balance.
16466077|NCT03524690|Experimental|SUSOPS Negative Balance|Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
16466078|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
16466079|NCT03524664|No Intervention|"Delayed tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
16466080|NCT03524664|Experimental|"Tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
16466081|NCT03524651|Active Comparator|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
16466082|NCT03524651|Active Comparator|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
16466083|NCT03524638|Active Comparator|ARM A|Colorectal surgery with administration of Visbiome
16466084|NCT03524638|Active Comparator|ARM B|Colorectal Surgery alone
16466085|NCT03524612|Other|eltrombopag|Participants will be treated with eltrombopagto to induce sustained remission to reach a target platelet count of ≥ 100×109/L (CR), after 1st line steroids have failed.
16466086|NCT03524599|Experimental|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
16466087|NCT03524599|No Intervention|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
16466088|NCT03524586|Experimental|Ipsilateral rotation of head|Head was laterally rotated to the same side against fixed tube
16466089|NCT03524586|Active Comparator|Contralateral rotation of head|Head was laterally rotated to the opposite side against fixed tube
16466090|NCT03524573|Experimental|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0530 - 0900.
16466091|NCT03524573|Active Comparator|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2000 - 0400.
16466092|NCT03524547|Experimental|J-shaped|Endotracheal tube will be molded into a J-shape that is similar to that of Macintosh type blade of a McGrath MAC® videolaryngoscope.
16466093|NCT03524547|Active Comparator|60-degrees|Endotracheal tube will be bent 60 degrees.
16466094|NCT03524534|Active Comparator|Telephone Follow-Up Intervention|
16466095|NCT03524534|Active Comparator|In-person follow-up intervention|
16466096|NCT03524521|Active Comparator|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
16466097|NCT03524521|Experimental|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
16466098|NCT03524508|Experimental|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
16466099|NCT03524508|Active Comparator|5FU/LV|dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
16466100|NCT03524482|Experimental|Path2Quit|Culturally specific text message intervention
16466101|NCT03524482|Active Comparator|SmokeFreeText|The National Cancer Institute's publicly available, standard text messaging program for tobacco cessation
16466102|NCT03524469||Normal weight|"Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test."
16466103|NCT03524469||Insulin resistant|"Insulin Resistance will be defined as meeting any of the following:
~pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test
~pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth.
~pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy
~pre-pregnant BMI ≥ 30, and unmediated."
16466104|NCT03524456|Experimental|Home blood pressure monitoring|
16466105|NCT03524456|No Intervention|Usual monitoring|
16466106|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
16466107|NCT03524430|Experimental|Single Interventional Study Arm|There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.
16466108|NCT03524417|Experimental|RIG injection|RIG injection on day 7
16466109|NCT03524404|Active Comparator|Diabetes Prevention Program (DPP)|Live stream the first six sessions of the Diabetes Prevention Program (DPP) curriculum to Senior Planet on a weekly basis, The webinars will be about 1 hour long, led by a certified DPP educator, and live-streamed to the senior center. Participants will have weekly weigh-ins and meet with a research assistant led focus group following two out of the six sessions to discuss program acceptability.
16466110|NCT03524391|Experimental|Yoga Counselling Group|Yoga based psychological counselling delivered individually and in group along with conventional care
16466111|NCT03524391|Active Comparator|Usual Care Group|Usual care provided to patients
16466112|NCT03524378|Other|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
16466113|NCT03524365|Active Comparator|RYGB plus LM counselling|96 subjects with NASH
16466114|NCT03524365|Active Comparator|SG plus LM counselling|96 subjects with NASH
16466115|NCT03524365|Sham Comparator|ILM|96 subjects with NASH
16466116|NCT03524352|Experimental|fecal microbiota|
16466117|NCT03524352|Placebo Comparator|placebo|
16466118|NCT03524339|Placebo Comparator|Placebo|
16466121|NCT03524300|Experimental|Robotic Assisted Total Gastrectomy|Robotic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
16466122|NCT03524300|Active Comparator|Laparoscopic Assisted Total Gastrectomy|Laparoscopic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
16466123|NCT03524287|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
16466124|NCT03524274|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16466125|NCT03524274|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16466126|NCT03524274|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16466127|NCT03524261|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16466128|NCT03524261|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16466129|NCT03524261|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16466130|NCT03524235|Experimental|Subjects|Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion
16466131|NCT03524235|No Intervention|Controls|Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.
16466132|NCT03524222|Experimental|Home Hospitalization|Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
16466133|NCT03524209|Other|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
16466134|NCT03524209|Other|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
16466135|NCT03524196|Experimental|MYLO|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.
~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
16466136|NCT03524183|Active Comparator|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
16466137|NCT03524183|Experimental|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
16466138|NCT03524170|Experimental|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
16466139|NCT03524157|Experimental|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
16466140|NCT03524157|Active Comparator|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
16466141|NCT03524157|Active Comparator|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
16466142|NCT03524144|Other|adult patients with Crohn's disease|All adult patients(18 years old or older) with Crohn's disease underwent gastroscopy; patients with diagnosed and treated Crohn's disease had gastroscopy performed during the re-examination, and patients diagnosed with Crohn's disease for the first time had gastroscopy performed during the initial consultation.
16466143|NCT03524131|Experimental|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
16466144|NCT03524131|Experimental|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
16466145|NCT03524131|Active Comparator|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
16466154|NCT03524105|Active Comparator|Thrive Professional Learning plus ParentCorps|
16466155|NCT03524105|Active Comparator|Thrive Professional Learning track|
16466159|NCT03524079||BrS Group|Ajmaline 17-(Chloroacetate) Monohydrochloride
16466160|NCT03524079||No BrS group|Ajmaline 17-(Chloroacetate) Monohydrochloride
16466161|NCT03524066|Experimental|Inhaled + Bronchoscopy|One-time Inhalation of Salbutamol 200 µg, Salmeterol 50µg and Fluticasone 500µg. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and bronchoalveolar lavage (BAL) samples will be taken from each site.
16466162|NCT03524066|Experimental|Systemic + Bronchoscopy|One-time Salbutamol (8 mg) and Propranolol (40mg) administered orally. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples will be taken from each site.
16466163|NCT03524053|Experimental|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
16466164|NCT03524053|Active Comparator|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
16466165|NCT03524053|No Intervention|Control|Participants will attend the laboratory but no exercise trial will be performed.
16466166|NCT03524040|Experimental|Acne patients|Application of gold microparticles to 2-3 facial areas
16466167|NCT03524040|Experimental|Heatlhy volunteers|Application of gold microparticles to 2 facial areas
16466168|NCT03524027|Experimental|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
16466169|NCT03524014||HEV-infected patients with hepatitis|
16466170|NCT03524014||HEV-infected patients with neurological features|
16466171|NCT03524014||HEV-infected patients with kidney features|
16466172|NCT03524001|Active Comparator|Bifocal stimulation|Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
16466173|NCT03524001|Placebo Comparator|VVI 40|Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).
16466174|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
16466175|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
16466176|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
16466177|NCT03523975|Experimental|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
16466210|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
16466211|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
16466178|NCT03523962|Experimental|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
16466179|NCT03523962|Experimental|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
16466180|NCT03523949|Experimental|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
16466181|NCT03523936|Active Comparator|Prebiotic|
16466182|NCT03523936|Placebo Comparator|Placebo|
16466183|NCT03523923|No Intervention|Usual Care|If assigned to the Usual Care (UC) arm, participants receive the same care as they would normally received from the HMC or UWMC outpatient TBI clinics, which could include similar types of treatment (medication changes, referral to specialists, etc.).
16466184|NCT03523923|Active Comparator|Collaborative Care|If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
16466185|NCT03523910|Experimental|Patient|A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
16466186|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
16466187|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
16466188|NCT03523884|Experimental|Exercise Program plus Education.|Rotator cuff stretching and strengthening exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
16466189|NCT03523884|Active Comparator|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
16466190|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
16466192|NCT03523845||Test group|Test group (patients diagnosed with early apical peri-implantitis diagnosed)
16466193|NCT03523845||Control group|Control group (patients whose implants had not developed any inflammatory/infectious process and were osseointegrated)
16466194|NCT03523832|Active Comparator|Group 1|celecoxib 400mg and pregabaline 150mg 1 hour before operation
16466195|NCT03523832|Active Comparator|Group 2|celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
16466196|NCT03523832|Placebo Comparator|Group 3|No treatment given
16466197|NCT03523819|Experimental|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
16466198|NCT03523819|Experimental|CS1003|Participants will receive CS1003 intravenously at fixed dose on specified days.
16466199|NCT03523806|Experimental|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
16466200|NCT03523806|No Intervention|Control Group|Half of the participants (n=15) will not be receiving coaching
16466201|NCT03523793|Experimental|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
16466202|NCT03523793|Active Comparator|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
16466203|NCT03523767|Experimental|Typhoid Vaccine, then Normal Saline|0.5 ml of S.typhi injection, then 0.5 ml of normal saline injection
16466204|NCT03523767|Placebo Comparator|Normal Saline, then Typhoid Vaccine|0.5 ml of normal saline injection, then 0.5 ml of S.typhi injection
16466205|NCT03523754|Other|Misoprostol only|This group will receive Intravaginal Misoprostol only.
16466206|NCT03523754|Other|Isosorbide Mononitrate & Misoprostol|This group will reveive intravaginal Isosorbide Mononitrate & Misoprostol.
16466207|NCT03523728|Experimental|Venglustat dose 1|Patients will receive venglustat dose 1 once daily for 24 months
16466208|NCT03523728|Experimental|Venglustat dose 2|Patients will receive venglustat dose 2 once daily for 24 months
16466209|NCT03523728|Placebo Comparator|Placebo|Placebo will be given once daily (Stage 1 and Stage 2) for 24 months
16466626|NCT03520959|Experimental|CMB305|A sequential regimen of LV305 and G305.
16466212|NCT03523702|Experimental|PembroRT Cohort|Subjects with PD-L1 expression ≥ 50% Combination of pembrolizumab and dose-painted radiotherapy for locally advanced NSCLC patients with high (≥ 50%) PD-L1 expression.
16466213|NCT03523702|Active Comparator|ChemoRT Cohort|Subjects with PD-L1 expression < 50% Subjects with PD-L1 expression below 50% will be enrolled and treated with standard concurrent chemoradiotherapy.
16466214|NCT03523689||Observational (bronchoscopy, RP-EBUS)|Patients undergo bronchoscopy per standard of care, RP-EBUS of the left and right lungs during bronchoscopy procedure, and RP-imaging over 3-5 minutes at the end of the bronchoscopy procedure.
16466215|NCT03523676||Group A|sepsis patients who did not develop atrial fibrillation during ICU stay
16466216|NCT03523676||Group B|sepsis patients with newly developed atrial fibrillation during ICU stay
16466217|NCT03523663||Control|healthy children without ADHD or other mental health issues
16466218|NCT03523663||ADHD|children diagnosed with ADHD
16466219|NCT03523650|Experimental|Group 1: Propranolol Group|Group 1: Propranolol - group of randomized patients will receive one propranolol pill tid for 36 months.
16466220|NCT03523650|Placebo Comparator|Group 2: Placebo Group|Group 2: Placebo - group of randomized patients will receive one placebo pill tid for 36 months.
16466221|NCT03523637|Experimental|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
16466222|NCT03523611||lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
16466223|NCT03523598|Placebo Comparator|Placebo gel + Normal Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
16466224|NCT03523598|Experimental|Placebo Gel + Potassium Nitrate Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the Potassium nitrate toothpaste (Sensodyne).
16466225|NCT03523598|Experimental|Potassium Nitrate Gel + Normal Toothpaste|The patient will receive the application of 5% Potassium nitrategel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
16466226|NCT03523585|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
16466227|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
16466228|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
16466229|NCT03523572|Experimental|Dose Escalation|"Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle.
~The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles."
16466230|NCT03523572|Experimental|Dose Expansion - Cohort 1|"Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) [as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines]. These participants have received prior ado-trastuzumab emtansine (T-DM1).
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
16466231|NCT03523572|Experimental|Dose Expansion - Cohort 2|"Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive).
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
16466232|NCT03523572|Experimental|Dose Expansion - Cohort 3|"Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression.
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
16466233|NCT03523572|Experimental|Dose Expansion - Cohort 4|"Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression.
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
16466234|NCT03523559||Interstitial Cystitis|
16466235|NCT03523559||normal|
16466236|NCT03523546|Experimental|Cancer Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
16466237|NCT03523546|No Intervention|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
16466238|NCT03523533|Experimental|Peripherally-inserted internal jugular catheter|All enrolled patients will receive a peripheral angiocatheter in the internal jugular vein, under dynamic ultrasound guidance.
16466239|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection
~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
16466268|NCT03523260|Active Comparator|Tunneled dialysis Split-tip catheter|High-flow tunneled Split-tip catheter for hemodialysis will be inserted by standard interventional technique
16466622|NCT03520972|Experimental|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
16466240|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet
~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
16466241|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection
~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
16466242|NCT03523507|Experimental|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
16466243|NCT03523507|Sham Comparator|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
16466244|NCT03523494||Normal limb|Normal
16466245|NCT03523494||Abnormal limb|Lymph Edema
16466246|NCT03523481||NHF use|
16466249|NCT03523455|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment) Taken once each day after breakfast, but before lunch.
16466250|NCT03523455|Active Comparator|Iron Aid IPS (Iron Protein Succinylate)|IronAid Iron Protein Succinylate 30 mg Taken once each day after breakfast, but before lunch.
16466251|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days.
16466252|NCT03523429|Experimental|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD < 0.1% (< 1×10-3) after induction therapy.
16466253|NCT03523416|Experimental|Edwards Transcatheter Atrial Shunt System|
16466254|NCT03523403|Experimental|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
16466255|NCT03523403|No Intervention|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
16466256|NCT03523403|Experimental|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
16466257|NCT03523403|No Intervention|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
16466258|NCT03523390|Experimental|Avelumab|
16466260|NCT03523351|Active Comparator|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
16466261|NCT03523351|Experimental|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement.
16466263|NCT03523299|Experimental|Cryoablation|Participants in this arm will receive cryoablation of their breast tumor two weeks before their routine lumpectomy. They will undergo two blood draws: one before cryoablation (at the time of consent) and one after cryoablation (at the time of surgery).
16466264|NCT03523299|No Intervention|Control|Participants in this arm will undergo a blood draw at the time of consent and then will continue with their scheduled lumpectomy (standard of care).
16466265|NCT03523286|Experimental|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
16466266|NCT03523273|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
16466267|NCT03523273|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
16467251|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
16466269|NCT03523260|Active Comparator|Tunneled dialysis Step-tip catheter|High-flow tunneled Step-tip catheter for hemodialysis will be inserted by standard interventional technique
16466270|NCT03523260|Active Comparator|Tunneled dialysis Symmetric tip catheter|High-flow tunneled Symmetric tip catheter for hemodialysis will be inserted by standard interventional technique
16466271|NCT03523247|Experimental|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
16466272|NCT03523234|Experimental|surgery group|
16466273|NCT03523234|Placebo Comparator|control group|
16466274|NCT03523221|Active Comparator|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
16466275|NCT03523221|Placebo Comparator|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
16466276|NCT03523195|Active Comparator|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
16466277|NCT03523195|Experimental|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
16466278|NCT03523182|Experimental|Spirulina (SP)|Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.
16466279|NCT03523182|Active Comparator|Control (CON)|Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.
16466280|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
16466281|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
16466282|NCT03523143|Experimental|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
16466283|NCT03523143|Active Comparator|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
16466284|NCT03523130||HIV-infected|
16466285|NCT03523130||non-HIV-infected|
16466286|NCT03523117|Active Comparator|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
16466287|NCT03523117|Active Comparator|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants <12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to <4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to <12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
16466288|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
16466289|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
16466290|NCT03523039|Experimental|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
16466291|NCT03523039|No Intervention|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
16466292|NCT03523026|Experimental|NMES and Peripheral Muscle Training|"Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training
~NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week.
~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
16466293|NCT03523026|Experimental|IMT and Peripheral Muscle Training|"Inspirator Muscle Training (IMT) and Peripheral Muscle Training
~IMT will be applied 7 days per week, twice a day for 15 minutes.
~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks."
16466294|NCT03523026|Experimental|Peripheral Muscle Training|"Peripheral Muscle Training
~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
16466295|NCT03523013|Experimental|CPAP pressure (determied by DISE)|
16466296|NCT03523013|Active Comparator|CPAP pressure (determined by physician)|
16466297|NCT03523000|Active Comparator|Active Solution|Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml
16466298|NCT03523000|Placebo Comparator|Inactive Placebo Solution|Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline
16466344|NCT03522805|Experimental|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
16466345|NCT03522792|Experimental|Saline + ad libitum meal|This will serve as the placebo / control day for the NT + ad libitum meal study day.
16466346|NCT03522792|Experimental|NT + ad libitum meal|Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
16466367|NCT03522714|Active Comparator|Fluid Immersion Simulation System (FIS)|Pressure ulcer patients are assigned to Fluid Immersion Simulation System (Dolphin) after operative debridement and closure.
16466299|NCT03522987|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
16466300|NCT03522974|Placebo Comparator|Placebo|40 g/d placebo powder
16466301|NCT03522974|Experimental|Strawberry powder (high dose)|40 g/d freeze dried strawberry powder
16466302|NCT03522974|Active Comparator|Strawberry powder (low dose)|13 g/d freeze dried strawberry powder
16466303|NCT03522961|Active Comparator|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
16466304|NCT03522961|Active Comparator|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
16466305|NCT03522948|Experimental|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
16466306|NCT03522935|Experimental|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
16466307|NCT03522935|Experimental|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
16466308|NCT03522935|Experimental|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
16466309|NCT03522935|Experimental|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
16466310|NCT03522935|Experimental|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
16466311|NCT03522935|Placebo Comparator|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
16466312|NCT03522922|Active Comparator|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
16466313|NCT03522922|Active Comparator|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
16466314|NCT03522922|Active Comparator|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
16466315|NCT03522909||Study|We will be reviewing records of parturients seen at Johns Hopkins Hospital in the Center for Peripartum Optimization (CPO) clinic between January 2017 to January 2018
16466316|NCT03522909||Control|A matched controlled group patients not seen at the CPO clinic
16466317|NCT03522896|Placebo Comparator|control meal|glucose, fructose, sucrose, malic acid and citric acid in water
16466318|NCT03522896|Experimental|test meal 1|orange juice with added hesperidin (low dose)
16466319|NCT03522896|Experimental|test meal 2|orange juice with added hesperidin (high dose)
16466320|NCT03522896|Experimental|test meal 3|diluted orange juice with added hesperidin
16466321|NCT03522883|Placebo Comparator|group control|the subjects will not take any type of nutrient intake
16466322|NCT03522883|Experimental|experimental group 1|carbohydrate intake prior to exercise
16466323|NCT03522883|Active Comparator|experimental group 2|carbohydrate intake prior to exercise
16466324|NCT03522870|Experimental|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
16466325|NCT03522870|Active Comparator|SMBG|People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
16466326|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
16466327|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
16466328|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
16466329|NCT03522857||University of Nottingham|Physiotherapy, nursing and midwifery
16466330|NCT03522857||Curtin University|Physiotherapy
16466331|NCT03522857||Notre Dame University|Physiotherapy
16466332|NCT03522857||University College Dublin|Physiotherapists
16466333|NCT03522857||Leeds Beckett University|Physiotherapists
16466334|NCT03522857||University College Cork|Physiotherapists
16466335|NCT03522857||Robert Gordon University|OT, Physio, Midwifery, Nursing, Diagnostic radiography
16466336|NCT03522857||University of Ulster|Physiotherapy
16466337|NCT03522857||University of Limerick|OT, Physio, Midwifery, Nursing, Diagnostic radiography, paramedic
16466338|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
16466339|NCT03522844|Active Comparator|Escitalopram|
16466340|NCT03522831|Active Comparator|Salbutamol meter-dose inhaler|Inhalation of 400 μg salbutamol
16466341|NCT03522831|Placebo Comparator|Placebo meter-dose inhaler|Inhalation of 400 μg placebo
16466342|NCT03522818|Active Comparator|Normal|Group will use the alarm as provided by the manufacture.
16466343|NCT03522818|Experimental|Manual trigger|Group will use the same model but will be instructed to manually trigger the alarm 1-2 hours after the child falls asleep.
16467252|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
16466347|NCT03522792|Experimental|Saline + liquid meal + ad libitum meal|Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
16466348|NCT03522792|Experimental|NT + liquid meal + ad libitum meal|NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
16466349|NCT03522792|Experimental|Neurotensin|Acclimatization day
16466350|NCT03522779|Placebo Comparator|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
16466351|NCT03522779|Experimental|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
16466352|NCT03522779|Placebo Comparator|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
16466353|NCT03522779|Experimental|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
16466354|NCT03522766||Healthy volunteers with no urinary tract infections|people who don't experience urinary tract infections
16466355|NCT03522766||Healthy volunteers with urinary tract infections|people who frequently experience urinary tract infections
16466356|NCT03522766||Intermittent catheter users with neurogenic bladder|
16466357|NCT03522766||Intermittent catheter users with enlarged prostate|
16466358|NCT03522753|Experimental|Staples|For short single incisions, these patients will receive superficial closure using only metal skin staples. Closure will be performed by resident or fellow involved in the case.
16466359|NCT03522753|Active Comparator|Suture|For short single incisions, these patients will receive superficial closure using only nylon sutures. No metal skin staples will be used. Closure will be performed by resident or fellow involved in the case.
16466360|NCT03522753|Other|Half Staple Half Suture|Some patients will receive both nylon sutures and metal skin staples for superficial closure. If multiple incisions are involved, each incision will count as 1 in the alternation method (i.e. toe 1 will be all sutures, then toe 2 will be all staples). For long incisions, closure will alternate between nylon sutures and metal skin staples on the part of the incision which is closer (more proximal) or farther away (more distal) from the rest of the body.
16466361|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
16466362|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
16466363|NCT03522727|No Intervention|Control|Participants will be asked to complete a questionnaire.
16466364|NCT03522727|Experimental|Intervention 1|"Single self-incentivising implementation intention
~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:
~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.
~Please complete the following sentence with a reward of your own choosing.
~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…
~**Drop down menu**
~Learning a new skill..."
16466365|NCT03522727|Experimental|Intervention 2|"Multiple self-incentivising implementation intentions
~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:
~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.
~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by… and/or…
~**Drop down menu**
~Learning a new skill..."
16466366|NCT03522727|Experimental|Intervention 3|"Self-generated self-incentivising implementation intentions
~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:
~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.
~Please complete the following sentence with a reward of your own choosing.
~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…"
16466460|NCT03522090||Neck CT|Cohort of patients with suspected lung cancer where the lower neck is routinely included in CT
16466368|NCT03522714|Active Comparator|Air Fluidized Bed System (AFB)|Pressure ulcer patients are assigned to Air Fluidized Bed (Clinitron) after operative debridement and closure
16466369|NCT03522701|Experimental|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
16466370|NCT03522701|Active Comparator|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
16466371|NCT03522701|No Intervention|Waiting-list control|Participants will not receive any active treatment.
16466372|NCT03522688|No Intervention|control group|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
16466373|NCT03522688|Active Comparator|treatment group|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
16466374|NCT03522675|Other|NeoMatriX and Two Comparators|NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
16466375|NCT03522649|Experimental|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours. For patients who have failed bevacizumab with irinotecan-based chemotherapies, bevacizumab may be administered with FOLFIRI. FOLFIRI infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks, starting on C1D1. If bevacizumab is added to FOLFIRI, bevacizumab infusion should start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion. 5-FU 400 mg/ m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/ m^2/day continuous infusion. For patients who could not tolerate FOLFIRI at the full dose previously, FOLFIRI should be started at the same dose level the patient tolerated FOLFIRI previously.
16466376|NCT03522649|Other|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
16466377|NCT03522636||Treatment|Prehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
16466378|NCT03522636||Historic control|No prehospital blood products available
16466379|NCT03522623||IBD|Children and families with IBD will be surveyed
16466380|NCT03522610|Experimental|ADAPT|Parents participate in a 14-week in person group based version of ADAPT with web-enhanced online ADAPT materials.
16466381|NCT03522610|No Intervention|Comparison Group|Parents receive services as usual (pamphlets, brochures, etc) on parenting typically found at a VA or Dr.'s office.
16466382|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
16466383|NCT03522597||Obese|Obese (BMI) women and their infants
16466384|NCT03522597||Diabetic|Women with gestational diabetes and their infants
16466385|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
16466386|NCT03522571|Experimental|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
16466387|NCT03522571|Active Comparator|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
16466388|NCT03522558|Experimental|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
16466389|NCT03522558|Active Comparator|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
16466390|NCT03522545|Experimental|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
16466391|NCT03522545|Placebo Comparator|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
16466392|NCT03522532|Experimental|Amalgam (Amg)|Amalgam was sealed in 8-K2 patients and 6-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
16466393|NCT03522532|Experimental|Tetric EvoCeram (TEC)|Tetric EvoCeram was sealed in 12-K2 patients and 5-K5 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
16466394|NCT03522532|Experimental|Beautifil (BF)|Beautifil was sealed in 15-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
16466395|NCT03522532|Experimental|Zinc phosphate cement (ZPhC)|"Zinc phosphate cement was sealed in 7-K2 patients, 4-K3 patients, 1-K4 patients and 2-K5 patients.
~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
16466396|NCT03522532|Experimental|Zinc polycarboxylate cement (ZPoC)|"Zinc polycarboxylate cement was sealed in 5-K2 patients, 4-K3 patients and 5-K4 patients.
~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
16467254|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
16466397|NCT03522532|Experimental|Glass ionomer cement (GIC)|"Glass ionomer cement was sealed in 11-K2 patients, 2-K3 patients and 1-K5 patients.
~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
16466398|NCT03522519||Assessment of real world performance|
16466399|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
16466400|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
16466401|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
16466402|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
16466403|NCT03522493|Active Comparator|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
16466404|NCT03522493|Experimental|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
16466405|NCT03522480|Other|Group A: Education & Gaming|Children will participate in 1 initial training session where they will be taught by a RT to use autogenic drainage (AD). Patients will be sent home & prescribed to practice the technique 15 minutes 3 times / week. At week 8 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform the AD sequence (percent accuracy). At the 8 week visit, the Jamboxx gaming device will be introduced, which will contain a game to guide them through the proper sequence of breathing for the AD technique. Patients will be sent home with a Jamboxx device and requested to do 15 minutes of AD training 3 times / week. Patients will return at week 16 and again will be tested via software program for ability to perform the AD technique.
16466406|NCT03522480|Experimental|Group B: Gaming Only|Children will participate in an initial training session at Albany Med where they will be taught by a RT to use the Jamboxx respiratory therapy device to guide them through autogenic drainage (AD): a series of controlled breathing exercises that mobilizes mucous without inducing wheezing in patients with reactive airways. Patients will be sent home and prescribed to use the Jamboxx respiratory therapy device 15 minutes three times per week. At week 8 and week 16 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform AD sequence (percent accuracy).
16466407|NCT03522467|Experimental|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
16466408|NCT03522454|Experimental|Intervention group|Intervention group: Combination of a protein-rich oral nutritional supplement consumed twice daily for 4 weeks pre-TAVR and 12 weeks after the patient is discharged home post-TAVR, and a home-based supervised exercise program that combines walking and weight-bearing exercises to build strength and balance performed for 12 weeks after the patient is discharged home post-TAVR.
16466409|NCT03522454|No Intervention|Lifestyle counselling group|Lifestyle counselling group: Recommendation to perform moderate-intensity aerobic activity at least 30 minutes 5 days per week as tolerated and eat a balanced diet based on the AHA/ACC Guideline on Lifestyle Management.
16466410|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
16466411|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
16466412|NCT03522441|Placebo Comparator|Placebo|
16466413|NCT03522428|Active Comparator|Receiving treatment|Adding vitamin B12 at a dose of 5 μg / 100 days, custom folic acid therapy and iron supplements
16466414|NCT03522428|No Intervention|Control group|Standard prenatal care (custom folic acid therapy and iron supplements)
16466415|NCT03522415|Experimental|HLX01+MTX|
16466416|NCT03522415|Placebo Comparator|Placebo+MTX|
16466417|NCT03522402|Experimental|30 degree rotated lateral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
16466623|NCT03520972|Experimental|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
16466418|NCT03522402|Active Comparator|neutral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in the neutral position.The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
16466419|NCT03522389|Experimental|AOT with gait training group|Action observation training with gait training
16466420|NCT03522389|Active Comparator|Gait training group|Gait training
16466421|NCT03522389|Other|Control group|Education
16466422|NCT03522376||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic obstructive pulmonary disease, stable clinically, has no infection or acute exacerbation in the previous four weeks, and can cooperate with the measurements of this study, loaded inspiratory muscle test.
16466423|NCT03522363|Experimental|Monodose group|1 vial with 4E10 CFU/g Total dose treatment: 4E10 CFU
16466424|NCT03522363|Experimental|Multidose group|7 vials with 5,5E09 CFU/g Total dose treatment: 4E10 CFU
16466425|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
16466426|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
16466427|NCT03522337|Placebo Comparator|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
16466428|NCT03522337|Experimental|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
16466429|NCT03522298|Experimental|Dose Escalation and Expansion Cohorts|"This is an open-label study.
~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.
~The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).
~In stage 1, dose escalation will occur for QD dosing.
~In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.
~Patients will be randomized in a 1:1 ratio to fed or fasted schedules."
16466430|NCT03522272|Experimental|Ultrasonic cleaning with cetylpyridinium chloride|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with 0.07% cetylpyridinium chloride mouthrinse
16466431|NCT03522272|Active Comparator|Ultrasonic cleaning with water|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with distilled water
16466432|NCT03522272|Active Comparator|Conventional denture hygiene|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent (Control group)
16466433|NCT03522259|Active Comparator|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
16466434|NCT03522259|Active Comparator|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
16466435|NCT03522246|Experimental|Arm A|oral rucaparib + intravenous (IV) nivolumab
16466436|NCT03522246|Experimental|Arm B|oral rucaparib+IV placebo
16466437|NCT03522246|Experimental|Arm C|oral placebo+ IV nivolumab
16466438|NCT03522246|Placebo Comparator|Arm D|Oral placebo + IV placebo
16466439|NCT03522220|Experimental|3D Super Mario Game Condition|3D navigation video game intervention
16466440|NCT03522220|Active Comparator|2D Super Mario Game Condition|Video game intervention without 3D navigation
16466441|NCT03522220|Active Comparator|Kindle Device|No 3D navigation
16466442|NCT03522207|Experimental|Trazo1|After a baseline polysomnography (PSG), subject will receive 100 mg of trazodone 30 minutes prior to their 2nd PSG and will receive 100mg Placebo 30 minutes prior to their 3rd PSG.
16466443|NCT03522207|Experimental|Trazo2|After a baseline polysomnography (PSG), subject will receive 100 mg of placebo 30 minutes prior to their 2nd PSG and will receive 100mg trazodone 30 minutes prior to their 3rd PSG.
16466444|NCT03522194||Sevoflurane|Anesthesia maintenance
16466445|NCT03522194||Propofol|Anesthesia maintenance
16466446|NCT03522181|Placebo Comparator|control group|saline
16466447|NCT03522181|Experimental|GIK group|glucose-Insulin-Potassium(GIK) infusion
16466448|NCT03522168||Risperidone group|Rispridone, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have <90 days of prior treatment with any antipsychotic.
16466449|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
16466450|NCT03522155|Experimental|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
16466451|NCT03522155|No Intervention|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
16466452|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
16466453|NCT03522142|Experimental|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
16466454|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
16466455|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
16466456|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
16466457|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
16466458|NCT03522116||No intervention|
16466459|NCT03522090||No neck CT|Cohort of patients with suspected lung cancer where the lower neck is not routinely included in CT
16467255|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
16466461|NCT03522077|Experimental|RadAR EasyCLik plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
16466462|NCT03522077|Active Comparator|TR BAND® plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
16466463|NCT03522077|Experimental|SoftSeal®-STF hemostatic|Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.
16466464|NCT03522077|Active Comparator|VascBand™ Hemostat|Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.
16466467|NCT03522051|Experimental|Patients with carious teeth|female or male patients with permanent teeth and deep caries will receive pulpotomy treatment and dressing with calcium silicate based material (Neo MTA plus material) followed by restoration.
16466468|NCT03522025|Active Comparator|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
16466469|NCT03522025|Experimental|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
16466470|NCT03522012|Experimental|LusiNex|4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)
16466471|NCT03522012|Active Comparator|RoActemra|4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )
16466472|NCT03522012|Active Comparator|Actemra|4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)
16466473|NCT03521999|Active Comparator|AboutFace|Veterans in the AboutFACe arm will receive access to an online peer-to-peer digital storytelling resource for Veterans with PTSD
16466474|NCT03521999|Placebo Comparator|Enhanced Usual Care (eUC)|Veterans in the Enhanced Usual Care (eUC) arm will receive an education brochure for PTSD
16466475|NCT03521986|Experimental|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
16466476|NCT03521986|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
16466477|NCT03521973|Experimental|Group 1- PfSPZ-Vaccine|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.
~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
16466478|NCT03521973|Placebo Comparator|Group 2|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.
~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
16466479|NCT03521973|Experimental|Group 3|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.
~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 1."
16466480|NCT03521973|Placebo Comparator|Group 4|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.
~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 2."
16466481|NCT03521973|Experimental|Group 5|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.
~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 3."
16466482|NCT03521973|Placebo Comparator|Group 6|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.
~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 4."
16466483|NCT03521960|Active Comparator|Buspirone oral capsule|Buspirone (15 milligrams) administered orally three times per day
16466484|NCT03521960|Placebo Comparator|Placebo oral capsule|Placebo administered orally three times per day
16466485|NCT03521947||One group of children below 18 years old|
16466486|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin dose 1, once daily with possible uptitration in the first 8 months to dose 2
16466487|NCT03521934|Placebo Comparator|Placebo|Placebo dose 1, once daily with possible uptitration in the first 8 months to dose 2
16466488|NCT03521908||Participants treated with apixaban|
16466489|NCT03521908||Participants treated with warfarin|
16466490|NCT03521895||Treatment naïve wAMD|Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW
16466491|NCT03521882||Stroke Symptom Participants|
16466492|NCT03521882||Healthy Controls|
16466493|NCT03521869|Active Comparator|Compression bandage group|
16466494|NCT03521869|Active Comparator|Standard gauze group|
16466495|NCT03521856|Experimental|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
16466624|NCT03520972|Placebo Comparator|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
16466496|NCT03521856|Active Comparator|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
16466497|NCT03521843|Experimental|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
16466498|NCT03521843|Experimental|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
16466499|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Arm A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
16466500|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A) and Cohort C|Arm B: ipilimumab 1mg/kg IV q4 weeks x 4 doses + nivolumab 480mg IV q4weeks followed by nivolumab 480mg IV q4weeks for up to 48 total weeks of therapy.
16466501|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A)|Arm C: nivolumab 480 mg IV q4 weeks plus relatlimab 960 mg IV q4wks.
16466502|NCT03521817|Experimental|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the ~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
16466503|NCT03521817|Active Comparator|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
16466504|NCT03521804|Other|SoundBite™ Crossing System-Coronary|Crossing of coronary chronic total occlusions.
16466505|NCT03521791|Experimental|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
16466506|NCT03521791|Placebo Comparator|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
16466507|NCT03521778|Experimental|Fascial Distortion Model group|Patients will receive manual treatment complies with Fascial Distortion Model method.
16466508|NCT03521778|Experimental|Mulligan Concept group|Patients will receive manual treatment complies with Mulligan Concept method.
16466509|NCT03521778|Experimental|Traditional physiotherapy group|Patients will receive traditional physiotherapy.
16466510|NCT03521765|Experimental|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
16466511|NCT03521765|No Intervention|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
16466512|NCT03521752|Experimental|Experimental|Performed a specific program exercises (resistance training, balance, coordination and flexibility) during 4 weeks.
16466513|NCT03521752|No Intervention|Control|The control group wasn't subjected to any intervention
16466514|NCT03521726|Other|Intraluminal Amoxicillin eradication|20 Patients receive intraluminal Amoxicillin eradication of H. pylori.
16466515|NCT03521726|Other|Rabeprazole, Amoxicillin dual therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole and Amoxicillin) for 14 days.
16466516|NCT03521713|Experimental|EPORON|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.
~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
16466517|NCT03521713|Active Comparator|EPREX|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.
~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
16466518|NCT03521700|Experimental|Intensive lipid lowering group|10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L
16466519|NCT03521700|Other|Conventional lipid lowering group|5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L
16466520|NCT03521687|Experimental|Apremilast|Patients with CCCA
16466521|NCT03521674|Other|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
16466522|NCT03521674|Other|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
16466523|NCT03521661||Kyphoplasty|Patients underwent kyphoplasty with an intravertebral expander
16466524|NCT03521648||PAE|Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study.
16466525|NCT03521648||TURP|Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study.
16466526|NCT03521648||Other|Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study.
16466527|NCT03521635|Experimental|Pramipexole SR|
16466528|NCT03521635|Active Comparator|Pramipexole IR|
16466529|NCT03521622|Experimental|brief counseling interventions|"For smoking patients the brief intervention is 5 As model for motivated patients and 5Rs for not motivated patients.
~For risky alcohol drinkers the brief intervention is simple advise for motivated patients and brief intervention for not motivated patients."
16466530|NCT03521622|Placebo Comparator|Control group|written informative material about healthy lifestyles
16466531|NCT03521609|Experimental|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
16466532|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
16466533|NCT03521570|Experimental|Treatment (nivolumab, IMRT)|Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
16466534|NCT03521557|Experimental|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.
~Gaze stability exercise will consist of progressive Vestibular-occular training.
~Postural stability exercises will consist of progressive static and dynamic postural training."
16466535|NCT03521557|Active Comparator|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
16466536|NCT03521544|Experimental|Plantar Fascia|Self-myofascial release in the plantar fascia.
16466537|NCT03521544|Experimental|Tricep surae fascia|Self-myofascial release in the triceps surae fascia.
16466538|NCT03521544|Experimental|Hamstrings fascia|Self-myofascial release in the hamstrings fascia.
16466539|NCT03521544|Experimental|Spine erectors and lumbar fascia|Self-myofascial release in the spine erectors and lumbar fascia.
16466540|NCT03521544|Experimental|Occipital and suboccipital fascia|Self-myofascial release in the occipital and suboccipital fascia.
16466541|NCT03521544|No Intervention|Control group|Lay on a stretcher.
16466542|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
16466543|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
16466544|NCT03521492|Experimental|caries group|
16466545|NCT03521492|Experimental|free caries group|
16466546|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
16466547|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
16466548|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
16466549|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
16466550|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
16466551|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
16466552|NCT03521453||Before|Conventionnel written information
16466553|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
16466554|NCT03521440|Experimental|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
16466555|NCT03521440|Experimental|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
16466556|NCT03521440|No Intervention|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
16466557|NCT03521427|Experimental|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
16466558|NCT03521427|Active Comparator|Neurodevelopmental treatment|Ninety hours of intensive neurodevelopmental therapy
16466559|NCT03521414|Active Comparator|Group I=13-15 mildly injured|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.
~Group I (n=15)=13-15 mildly injured"
16466560|NCT03521414|Active Comparator|Group 2 =9-12 moderately damaged|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery.use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.
~Group 2 (n=15)=9-12 moderately damaged"
16466561|NCT03521414|Active Comparator|Group 3=3-8 severely damaged.|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.
~Group 3 (n=15)=3-8 severely damaged."
16466562|NCT03521401|Experimental|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
16466563|NCT03521401|No Intervention|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
16466564|NCT03521401|No Intervention|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
16466591|NCT03521206|No Intervention|Control group|The staff of nursing homes in the control group will receive no additional training next to any standard education or continuous training. After the intervention and follow-up measures are finished, all nursing homes in the control group will be offered a shortened version of the ACP+ training programme as well as all ACP+ training materials.
16466625|NCT03520959|Placebo Comparator|Placebo|A sequential regimen of LV305-matching placebo and G305-matching placebo.
16466565|NCT03521388|Experimental|Intervention group|"The intervention consists of an Internet-based program. The program will last 3 months, with subsequent monthly reinforcement sessions for other 3 months.
~The program is stepped, so that the more depressive symptomatology the more intensive program and consists of more components.
~The students will interact with the program via a monitoring and feedback e-mail with 3 questions of the PHQ--9- adolescent version (1st, 2nd & 9th question) that they will receive every 2 weeks and a Website that will allow them to access to psycho-educational videos and information. There will also in the Website sections that will provide emergency information, the possibility of a contact via e-mail, and group chats. Adolescents with more depressive symptoms or suicidal risk will be invited to participate in an online counselling appointment or a face to face assessment with a mental health professional of the program."
16466566|NCT03521388|Other|Control group|The comparison group will receive general psychoeducation of depression in adolescents and will be on the waiting list to receive the intervention in the event that its efficacy is demonstrated.
16466567|NCT03521375|Experimental|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
16466568|NCT03521375|Active Comparator|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
16466569|NCT03521362|Experimental|MyT1DHero App|Participants in this group will receive use of the MyT1DHero app.
16466570|NCT03521362|Active Comparator|"Other T1D App"|Participants in this group will receive use of a different app with less capabilities.
16466571|NCT03521349|Placebo Comparator|Egg White Snacks|Egg white-based snacks
16466572|NCT03521349|Experimental|Whole Egg Snacks|Whole egg-based snacks
16466573|NCT03521336|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
16466574|NCT03521336|Placebo Comparator|Control|Placebo: Sham operation, 10ml saline, once a month for 4 months
16466575|NCT03521323|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
16466576|NCT03521323|Placebo Comparator|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
16466577|NCT03521310|Experimental|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
16466578|NCT03521310|Active Comparator|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
16466579|NCT03521297|Placebo Comparator|Placebo group|Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months
16466580|NCT03521297|Experimental|Probiotics group|Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months
16466581|NCT03521284||Mothers with education program during their mat|
16466582|NCT03521284||Mothers without education program during their mat|
16466583|NCT03521258|Experimental|Human Amnion/Chorion Membrane + skin graft|Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
16466584|NCT03521258|Active Comparator|Flap Reconstruction (Standard of Care)|A negative pressure wound dressing (NPWD) will be applied at the time of debridement until the wound is clean and adequate for flap reconstruction. Flap-based reconstruction is performed. Following flap reconstruction,patient will have 5 days of bed rest to allow proper healing and coverage of the wounds. If flaps are successful, patients starts a limb dangle protocol which gradually increases the dependent position and allows the flap to acclimate to new physiologic demands. Following dangle protocol patient will require inpatient physical and occupational therapy prior to discharge.
16466585|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
16466586|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
16466587|NCT03521232|Experimental|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
16466588|NCT03521232|Experimental|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
16466589|NCT03521219|Experimental|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
16466590|NCT03521206|Experimental|Intervention group|"The ACP+ programme aims to improve or establish advance care planning (ACP) in the day-to-day routine of staff working in nursing homes.
~The intervention implementation period has a total duration of 8 months and is divided into:
~a four-month preparation and training phase. During this phase the ACP reference persons will attend a two-day training given by the ACP trainers. Other staff will receive training by the reference persons on conducting ACP conversation or recognizing triggers for an ACP conversation in nursing home residents.
~A four-month follow-up phase in which ACP conversations are held with residents. Additional training sessions will be organized to give more in-depth knowledge to the ACP reference persons."
16466621|NCT03520972|Experimental|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
16466593|NCT03521180||Subjects with Celiac Disease|"Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses.
~Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once.
~The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes."
16466594|NCT03521167|No Intervention|T|traditional opioid based regimen
16466595|NCT03521167|Active Comparator|MD|multimodal group with dexmedetomidine
16466596|NCT03521167|Placebo Comparator|M|multimodal with saline placebo
16466599|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
16466600|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
16466601|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
16466602|NCT03521128|Experimental|the radiological tubal blockage group|
16466603|NCT03521128|Active Comparator|the laparoscopic salpingectomy group|
16466604|NCT03521115|Experimental|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component. Numbers are provided for the number of families
16466605|NCT03521115|No Intervention|Control condition|This group was provided with websites where information was available regarding the same topics.
16466606|NCT03521102|Experimental|Acetaminophen 1000mg IV|NRS pain scores will be obtained at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
16466607|NCT03521102|Active Comparator|Hydromorphone 0.5mg IV|NRS score will be checked at 5 minutes and every 15 minutes for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
16466608|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
16466609|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
16466610|NCT03521076|Experimental|Virtual Reality for distraction|The application of VR during the putative painful treatment (botulinum toxin injections) will provide a) active and engaging distraction during the procedure, and will b) block the view and auditory noise related to the procedure.
16466611|NCT03521076|No Intervention|Standard of Care|Patients will receive the standard of care for the putative painful treatment (botulinum toxin injections).
16466612|NCT03521063|Experimental|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
16466613|NCT03521063|Active Comparator|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
16466614|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
16466616|NCT03521024|Active Comparator|lithium disilicate crowns|lithium disilicate crowns are well documented in the literatures as successful restoration modality.
16466617|NCT03521024|Experimental|poly ether ketone ketone crowns|pekkton
16466618|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
16466619|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
16466620|NCT03520985|Experimental|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
16467373|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
16466627|NCT03520946|Experimental|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
16466628|NCT03520946|Active Comparator|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
16466629|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
16466632|NCT03520907|Experimental|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
16466633|NCT03520907|Active Comparator|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
16466634|NCT03520894|Experimental|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
16466635|NCT03520881|Experimental|Pediatric ASTHMA-Educator arm|This arm corresponds to the pediatric version of the ASTHMA-Educator mobile application.
16466636|NCT03520868||Coumadin|Coumadin patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 70 U/kg
16466637|NCT03520868||Dabigatran|Dabigatran patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
16466638|NCT03520868||Rivaroxiban|Rivaroxiban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
16466639|NCT03520868||Apixaban|Apixaban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 10 U/kg
16466640|NCT03520855|Experimental|ETP + Serious game|patients receiving the serious game additionally to the classic therapeutic education
16466641|NCT03520855|Active Comparator|ETP|patients under classic therapeutic education
16466642|NCT03520842|Experimental|Treatment (regorafenib, methotrexate)|Participants receive regorafenib PO QD on days 1-21, and methotrexate PO twice weekly with 2-3 days apart on a 3 week on/ 1 week off cycle. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16466643|NCT03520829||Patient treated for Gamma Knife|
16466644|NCT03520816|Experimental|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
16466645|NCT03520816|No Intervention|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
16466646|NCT03520803|Experimental|Experimental|ERAS protocol
16466647|NCT03520803|No Intervention|Control|Standard of care
16466648|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine and Nab-paclitaxel is administered intravenously 3 times a cycle.
~Placebo is administered orally on a daily basis"
16466649|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.
~Paricalcitol is administered intravenously 3 times/week."
16466650|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.
~Paricalcitol is administered orally on a daily basis"
16466651|NCT03520777|Other|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
16466652|NCT03520764|Experimental|New infant formula with synbiotics|pHP infant formula with synbiotics (test product)
16466653|NCT03520764|Active Comparator|Standard infant formula with prebiotics|Standard (commercial) infant formula with prebiotics (control product)
16466654|NCT03520764|No Intervention|human milk|Full breastfeeding for at least 17 weeks
16466655|NCT03520751|Experimental|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
16466656|NCT03520738|Other|Chronic Kidney Disease|"Blood and urinary samples on the following patients:
~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
16466657|NCT03520738|Other|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:
~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
16466658|NCT03520738|Other|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:
~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
16466659|NCT03520725|Experimental|No Intervention|This group did not have an intervention
16466660|NCT03520725|Experimental|Intervention pineapple|Daily consumption of 30 g of pineapple snack bar for 4 weeks.
16466661|NCT03520725|Experimental|Intervention mango|Daily consumption of 30 g of mango snack bar for 4 weeks.
16466662|NCT03520712|Experimental|valoctocogene roxaparvovec Open Label|Single administration of BMN270 at a dose of 6E13 vg/kg
16466663|NCT03520686|Experimental|Cohort A (Experimental)|
16466664|NCT03520686|Experimental|Cohort B (Experimental)|
16466665|NCT03520686|Experimental|Cohort C (Experimental)|
16466666|NCT03520686|Active Comparator|Cohort A (Control)|
16466667|NCT03520686|Active Comparator|Cohort B (Control)|
16466668|NCT03520686|Active Comparator|Cohort C (Control)|
16466803|NCT03519854|Experimental|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466669|NCT03520673|Other|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
16466670|NCT03520660|Experimental|Phase I|Phase I treatment
16466671|NCT03520660|No Intervention|Phase II after Phase I|Participants who achieved SVR12 in Phase I
16466672|NCT03520660|No Intervention|Phase II without Phase I|Participants who achieved SVR 24 previously
16466673|NCT03520647|Experimental|Treatment Arm|G-CSF mobilized peripheral stem cells and post haplo-identical transplantation cyclophosphamide
16466674|NCT03520634|Experimental|PD-L1 PET imaging in melanoma patients|The main intervention of this study is a [18F]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
16466675|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
16466676|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
16466677|NCT03520595|Active Comparator|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
16466678|NCT03520595|Active Comparator|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
16466679|NCT03520595|Placebo Comparator|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
16466680|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
16466681|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
16466682|NCT03520569|Active Comparator|Octreotide- Euglycemia|octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min
16466683|NCT03520569|Active Comparator|Octreotide - Euglycemia- insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min
16466684|NCT03520569|Active Comparator|Octreotide- hyperglycemia|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
16466685|NCT03520569|Active Comparator|Octreotide- hyperglycemia - insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
16466686|NCT03520556||docosahexaenoic acid (DHA)|Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
16466687|NCT03520556||eicosapentaenoic acid (EPA)|Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
16466688|NCT03520556||control|Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
16466689|NCT03520543|Experimental|Part A : Imput function|Compartmental model of the volume of distribution of [11C]Yohimbine in Brain by PET
16466690|NCT03520543|Experimental|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of [11C]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
16466691|NCT03520530|Experimental|Mouth Guard|Patients will push in the second stage of labor without use of mouth guard
16466692|NCT03520530|No Intervention|Control|Patients will push in the second stage of labor without use of mouth guard
16466693|NCT03520517|Experimental|BHV-0223|riluzole 40 mg sublingual tablet
16466694|NCT03520504|Experimental|Proton Radiation|"Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
~The first 3 patients will be enrolled at dose level 30Gy (RBE) in 3Gy(RBE) fractions. If 1 or fewer patients develop dose-limiting toxicity (DLT), 3 additional patients will be enrolled. If 1 or fewer of the 6 patients experiences a DLT, the trial will proceed to the dose expansion cohort at 30Gy (RBE) . In contrast, if 2 or more patients experience a treatment DLT, 3 patients will be enrolled at dose level 25Gy (RBE) in 2.5Gy(RBE) fractions. If 1 or fewer patients develop a DLT, an additional three patients will be enrolled. If 2 or more patients experience a DLT at 25Gy, the study will be stopped. If 1 or fewer patients develop a DLT in these 6 patients, the trial will proceed to the dose expansion cohort at 25Gy (RBE) and the 6 patients who were treated in Phase Ib will be included in full assessment of safety and efficacy."
16466695|NCT03520491|Experimental|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
16466696|NCT03520491|Experimental|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
16466697|NCT03520491|Experimental|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
16466698|NCT03520491|Experimental|Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.
16466699|NCT03520478|Experimental|SHR3680|Participants will receive SHR3680 orally
16466700|NCT03520478|Active Comparator|bicalutamide|Participants will receive bicalutamide orally
16466846|NCT03519646|Experimental|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
16466701|NCT03520465|Experimental|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.
~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.
~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
16466702|NCT03520465|No Intervention|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
16466703|NCT03520452|Placebo Comparator|Placebo|Placebo
16466704|NCT03520452|Experimental|302 mg green coffee extract|Green coffee extract
16466705|NCT03520452|Experimental|604 mg green coffee extract|Green coffee extract
16466706|NCT03520452|Experimental|906 mg green coffee extract|Green coffee extract
16466707|NCT03520439|Experimental|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
16466708|NCT03520439|Placebo Comparator|control group|placebo，10mg，One tablet daily, oral treatment
16466709|NCT03520426|Experimental|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
16466710|NCT03520426|Sham Comparator|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
16466711|NCT03520413|Experimental|PRACTICE-DM|PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
16466712|NCT03520413|Active Comparator|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
16466713|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
16466714|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
16466715|NCT03520387|Experimental|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
16466716|NCT03520387|Active Comparator|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
16466717|NCT03520387|Experimental|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
16466718|NCT03520387|Active Comparator|TBSCE|Telephone-based self-directed CBT and education (TBSCE)
16466719|NCT03520374|Other|Ultrasonography- Novices|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. These results will be compared to the evaluation of experts in ultrasonography i.e interventional radiologists.
16466720|NCT03520374|Other|Ultrasonography-Expert Interventional Radiologists|Physician assessment i.e interventional radiologist evaluation of gastric contents using ultrasonography.
16466721|NCT03520361|Experimental|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
16466722|NCT03520361|Active Comparator|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
16466723|NCT03520348|Experimental|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
16466724|NCT03520348|Active Comparator|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
16466725|NCT03520322|Experimental|Mastoid Oscillator|patients with Menieres Disease
16466726|NCT03520322|Placebo Comparator|Control device|patients with Menieres Disease
16466729|NCT03520296||Patients hospitalized in the cardiology unit|
16466730|NCT03520296||Patients hospitalized in the orthopedic surgery unit|
16466731|NCT03520296||Patients hospitalized in the endocrinology unit|
16466732|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
16466733|NCT03520257|Experimental|Apatinib Plus Radiotherapy|
16466734|NCT03520257|Other|Apatinib|
16466735|NCT03520244|Experimental|Exercise + Holistic Education|A 12-week exercise program with 6 bi-weekly education sessions.
16466736|NCT03520244|No Intervention|Wait list control|Participants in the control group will be offered the exercise + education sessions after the study is complete.
16466847|NCT03519633|Experimental|SUG|
16466848|NCT03519633|Active Comparator|NEO|
16466737|NCT03520231|Experimental|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.
~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.
~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~Calcium, orally at a dose of 1000 mg, once daily.
~Vitamin D, orally at a dose of 400 IU, once daily."
16466738|NCT03520231|Placebo Comparator|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.
~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.
~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~Calcium, orally at a dose of 1000 mg, once daily.
~Vitamin D, orally at a dose of 400 IU, once daily."
16466739|NCT03520218|Experimental|Performance of R-PEM|"5miCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection.
~These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI"
16466740|NCT03520205|Active Comparator|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
16466741|NCT03520205|Active Comparator|Continuous Epidural|Patient will receive epidural anesthesia
16466742|NCT03520179||SMA TYPE 1|genetically confirmed SMA
16466743|NCT03520179||SMA TYPE 2|genetically confirmed SMA
16466744|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
16466745|NCT03520166|Placebo Comparator|Group-A|No treatment
16466746|NCT03520166|Experimental|Group-B|Medium frequency electrotherapy (interferential currents)
16466747|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
16466748|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
16466749|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
16466750|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
16466751|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
16466752|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
16466753|NCT03520114|Experimental|RP sling group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
16466754|NCT03520114|Experimental|SIS group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
16466755|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
16466756|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
16466757|NCT03520088|Experimental|Inferior mesenteric Vein dissection|To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis
16466758|NCT03520088|Active Comparator|Inferior mesenteric Artery dissection|As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis
16466759|NCT03520075|Experimental|Phase 1 Regimen 1|"Dose escalation and expansion:
~Regimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle."
16466760|NCT03520075|Experimental|Phase 1 Regimen 2|"Dose escalation and expansion:
~Regimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle."
16466761|NCT03520075|Experimental|Phase 2|ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.
16466762|NCT03520062|Experimental|GLP-1 Receptor Agonist (Liraglutide)|3.0mg daily dose
16466763|NCT03520049|Experimental|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
16466764|NCT03520049|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
16466765|NCT03520036|Experimental|MT-7117 low dose|
16466766|NCT03520036|Experimental|MT-7117 high dose|
16466767|NCT03520036|Placebo Comparator|Placebo|
16466768|NCT03520023|No Intervention|Standard Care|Standard care with consultant discretion regarding consult of palliative care medicine
16466769|NCT03520023|Experimental|Experimental|Early palliative care consult based upon meeting study inclusion criteria
16466770|NCT03520010|Active Comparator|Internally-driven implementation|
16466771|NCT03520010|Experimental|Externally-facilitated implementation|
16466772|NCT03519997|Experimental|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
16466773|NCT03519984|Experimental|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16466774|NCT03519984|Experimental|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16467374|NCT03516227|No Intervention|Control|Usual Care
16466775|NCT03519971|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy and radiation|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:
~cisplatin/etoposide
~carboplatin/paclitaxel
~pemetrexed/cisplatin
~pemetrexed/carboplatin
~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
16466776|NCT03519971|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy and radiation|"Placebo in concurrence with platinum-based chemo-radiation therapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:
~cisplatin/etoposide
~carboplatin/paclitaxel
~pemetrexed/cisplatin
~pemetrexed/carboplatin
~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment."
16466777|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
16466779|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
16466780|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
16466781|NCT03519919|Experimental|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
16466782|NCT03519880|Experimental|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
16466783|NCT03519867|Experimental|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
16466784|NCT03519867|Experimental|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466785|NCT03519867|Experimental|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466786|NCT03519867|Experimental|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466787|NCT03519867|Experimental|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466788|NCT03519867|Experimental|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466789|NCT03519867|Experimental|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466790|NCT03519867|Experimental|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466791|NCT03519867|Experimental|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466792|NCT03519867|Experimental|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
16466793|NCT03519854|Placebo Comparator|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466794|NCT03519854|Experimental|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466795|NCT03519854|Experimental|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466796|NCT03519854|Experimental|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466797|NCT03519854|Experimental|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466798|NCT03519854|Experimental|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466799|NCT03519854|Placebo Comparator|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466800|NCT03519854|Experimental|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466801|NCT03519854|Experimental|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466802|NCT03519854|Experimental|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466804|NCT03519854|Experimental|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466805|NCT03519854|Placebo Comparator|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466806|NCT03519854|Experimental|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466807|NCT03519854|Experimental|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466808|NCT03519854|Experimental|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466809|NCT03519854|Experimental|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466810|NCT03519854|Experimental|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
16466811|NCT03519841|Experimental|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
16466812|NCT03519841|Experimental|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
16466813|NCT03519828||Patients with post-stroke cognitive impairment|
16466814|NCT03519828||Patients without post-stroke cognitive impairment|
16466815|NCT03519815|Active Comparator|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device
~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
16466816|NCT03519815|Active Comparator|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days
~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
16466817|NCT03519789||Post-Traumatic Stress Disorders (PTSD)|30 patients with PTSD (diagnosis based on the standard DSM criteria)
16466818|NCT03519789||Controls|30 healthy controls without any psychiatric or neurological diagnosis
16466819|NCT03519763||Control group|Fifteen patients without isthmocele
16466820|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
16466821|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
16466822|NCT03519750|Active Comparator|Intravenous melatonin|Intravenous administration, making it possible to calculate bioavailability for other routes of administration
16466823|NCT03519750|Experimental|Rectal melatonin|Rectal administration of melatonin
16466824|NCT03519750|Experimental|Intravesical melatonin|Intravesical administration of melatonin
16466825|NCT03519750|Experimental|Vaginal melatonin|Vaginal administration of melatonin
16466826|NCT03519750|Experimental|Transdermal melatonin|Transdermal administration of melatonin
16466827|NCT03519737|Sham Comparator|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
16466828|NCT03519737|Active Comparator|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
16466829|NCT03519724|Experimental|SUG|
16466830|NCT03519724|Active Comparator|NEO|
16466831|NCT03519711|Experimental|Cohort 1: CNSA-001 2.5 mg/kg/day or 10 mg/kg/day|Participants will receive CNSA-001 suspension 2.5 milligrams (mg)/kilogram (kg)/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 10 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
16466832|NCT03519711|Experimental|Cohort 2: CNSA-001 5 mg/kg/day or 20 mg/kg/day|Participants will receive CNSA-001 suspension 5 mg/kg/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 20 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
16466833|NCT03519698|Placebo Comparator|Warm water|12 l footbath with warm water (40 °C)
16466834|NCT03519698|Experimental|Warm water & Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour
16466835|NCT03519698|Experimental|Warm water & Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour
16466836|NCT03519685|Experimental|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
16466837|NCT03519685|Placebo Comparator|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
16466838|NCT03519672||Participants with cTTP - adolescents|Adolescents aged 12 to 17 years
16466839|NCT03519672||Participants with cTTP - adults|Adults aged ≥18 years
16466840|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
16466841|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
16466842|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
16466843|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
16466844|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
16466845|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
16468194|NCT03511040|Experimental|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
16466849|NCT03519620|Experimental|SWWSV|Spirometric Values: Forced Vital Capacity; Forced Expiratory Volume in 1 second; Peak Expiratory Flow
16466850|NCT03519607|Active Comparator|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
16466851|NCT03519607|No Intervention|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
16466852|NCT03519594||Embolization group|The group that underwent embolization after pelvic injury.
16466853|NCT03519594||Non-embolization group|The observed group of pelvic injuries without embolization
16466854|NCT03519581|Active Comparator|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:
~Confirmation of the subject's identity and eye to be treated
~Subject's eye will be dilated
~Subject will be positioned at the slit lamp for treatment
~Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
16466855|NCT03519581|Placebo Comparator|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:
~Confirmation of the subject's identity and eye to be treated
~Subject's eye will be dilated
~Subject will be positioned at the slit lamp for treatment
~No Actual laser treatment will occur"
16466856|NCT03519568|Experimental|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
16466857|NCT03519568|Active Comparator|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
16466858|NCT03519568|Active Comparator|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
16466859|NCT03519542||Metastatic clear cell renal carcinoma (mRCC) patients|Metastatic clear cell renal carcinoma (mRCC) patients cadidates to receive Sunitinib 50 mg/day 4/2 schedule or Pazopanib 800mg/day until unaccetable toxicity or progression or death under standar clinical practice.
16466860|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%
~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
16466861|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
16466862|NCT03519490|Placebo Comparator|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
16466863|NCT03519490|Experimental|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
16466864|NCT03519477|Experimental|Heart failure care with Sano test|Scheduled outpatient care for patients at high risk of admission for heart failure, supplemented with the Sano Patient Medication Profile
16466865|NCT03519477|No Intervention|Heart failure care as-usual|Scheduled outpatient care for patients at high risk of admission for heart failure, care as-usual (i.e. without the Sano Patient Medication Profile).
16466866|NCT03519464|Other|ICL and Healthy Volunteers|Biological/Vaccine
16466867|NCT03519451|Experimental|Group I (KickAsh smartphone mobile application)|Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
16466868|NCT03519451|Experimental|Group II (Breathe2Relax smartphone mobile application)|Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
16466869|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
16466870|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
16466871|NCT03519425|No Intervention|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:
~Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.
~Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.
~Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.
~Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
16466872|NCT03519425|Active Comparator|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.
~HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.
~HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
16466913|NCT03519191|Other|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
16466873|NCT03519425|Active Comparator|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:
~A digital chest x-ray using the study MinXray unit.
~Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.
~Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.
~Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
16466874|NCT03519412|Experimental|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is > 20 Muts/Mb
16466875|NCT03519412|Other|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
16466876|NCT03519399||Cases and Controls|"Cases - Pregnant women with ICP defined as pruritus in pregnancy in association with raised serum bile acids (using hospital threshold for diagnosis), and in the absence of an alternative cause.
~Controls - Pregnant women not affected by ICP, or other liver, cardiac or hypertensive disorders."
16466877|NCT03519386|Experimental|Implant Group 1|G2TR intraocular implant containing travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
16466878|NCT03519386|Experimental|Implant Group 2|G2TR intraocular implant containing travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
16466879|NCT03519386|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
16466880|NCT03519373||PER001|HIV 1-infected pregnant women
16466881|NCT03519373||PER002|HIV 1-uninfected pregnant women
16466882|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
16466883|NCT03519360|Experimental|Restricted ultrafiltration rate (UFR)|UFR ≤10 ml/kg/hr
16466884|NCT03519360|Experimental|Standard of Care/ Unrestricted UFR|UFR as needed
16466885|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
16466886|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
16466887|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
16466888|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
16466889|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back & Neck Pain, Cancer, Ischemic Heart Disease
16466890|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
16466891|NCT03519321|Experimental|Treatment|MID-C EOS implant will be implanted for the correction of the spine deformity in children found eligible for the study
16466892|NCT03519308|Experimental|Arm A|
16466893|NCT03519308|Experimental|Arm B|
16466894|NCT03519295|Experimental|ARM A - mDCF + Atezolizumab|"MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.
~Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
16466895|NCT03519295|Active Comparator|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
16466896|NCT03519282|Experimental|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
16466897|NCT03519282|Active Comparator|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
16466898|NCT03519269|No Intervention|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
16466899|NCT03519269|Experimental|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
16466900|NCT03519256|Experimental|Nivolumab monotherapy|
16466901|NCT03519256|Experimental|Nivolumab + BCG|
16466902|NCT03519256|Experimental|Nivolumab + BMS-986205|
16466903|NCT03519256|Experimental|Nivolumab + BMS-986205 + BCG|
16466904|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
16466905|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
16466906|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
16466907|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
16466908|NCT03519230|Experimental|Treatment arm|
16466909|NCT03519230|Placebo Comparator|Placebo arm|
16466910|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
16466911|NCT03519204|Experimental|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
16466912|NCT03519204|Experimental|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
16466914|NCT03519191|Other|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
16466923|NCT03519165|No Intervention|Control group (Group C)|"Conventional Fluid therapy guided by clinical parameter
~Intraoperative fluid therapy will include maintenance fluid and replacement of the surgical loss. Aim to maintain MAP > 65 mmHg, CVP 8-12 cm H2O and urine output > 0.5 ml/kg/h."
16466924|NCT03519165|Active Comparator|Goal directed group (Group G)|"Intervention: Machine guided fluid therapy using EV1000 (FloTrac System 4.0 Edward Lifesciences, Irvine, CA, USA)
~Intraoperative fluid therapy will be targeted to SVV <13%, SVI > 35ml/m2/ beat, SVRI more than equal to 1900 dynes-sec/cm-5/m2 using EV1000 floTrac monitor in addition to clinical parameters like MAP, CVP and urine output"
16466925|NCT03519152|Experimental|study group one side|All patients were scheduled for open flap debridement surgery on at least two quadrants ≥1 weeks apart.One group will receive Low Dose Diclofenac tablets (25mg Diclofeanc and 325 mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis will be included in study. For each quadrant, a flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure will be recorded in the patient file. Patients will be instructed to complete a pain diary chart for 3 days.
16466926|NCT03519152|Placebo Comparator|study group second side|Other group will receive Diclofeanc (50mg Diclofenac and 325mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis were included in study. For each quadrant, aperiodontal flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure was recorded in the patient file. Patients were instructed to complete a pain diary chart for 3 days.
16466927|NCT03519139|Experimental|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
16466928|NCT03519139|No Intervention|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
16466929|NCT03519126|Experimental|vaginal|Group of volunteers who will be treated with vaginal electrostimulation
16466930|NCT03519126|Experimental|posterior tibial nerve|Group treated with transcutaneous electrostimulation of the posterior tibial nerve
16466931|NCT03519126|No Intervention|control|Group of volunteers who will not be treated
16466932|NCT03519113|Experimental|Test group 1|GC1102 80,000 IU
16466933|NCT03519113|Experimental|Test group 2|GC1102 100,000 IU
16466934|NCT03519113|Active Comparator|Control group|I.V HBIG
16466935|NCT03519087|Experimental|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
16466936|NCT03519087|No Intervention|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
16466937|NCT03519087|Experimental|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
16466938|NCT03519087|No Intervention|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
16466939|NCT03519087|Other|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
16466940|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
16466941|NCT03519061|Experimental|Treatment|This is the group of enrollees who receive budesonide
16466942|NCT03519048|Active Comparator|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of > 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
16466943|NCT03519048|Experimental|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
16467063|NCT03518125|Experimental|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
16466944|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.
~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
16466945|NCT03519022|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16466946|NCT03519022|Active Comparator|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
16466947|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
16466948|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
16466949|NCT03518996|Experimental|TMS/tACS|Subjects will receive 5 days of 3x daily rTMS (intermittent theta burst stimulation) or tACS (transcranial alternating current stimulation) targeted over the cerebellum.
16466950|NCT03518996|Sham Comparator|Sham TMS/tACS|Subjects will receive 5 days of 3x daily sham stimulation of the cerebellum.
16466951|NCT03518983|Sham Comparator|Sham Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) by the sham probe.
16466952|NCT03518983|Active Comparator|Active Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) at energy level 7.
16466953|NCT03518970|Experimental|Nursing intervention|The experimental group will receive the Nursing intervention to reduce uncertainty in illness and increase quality of life in family caregivers of patients with cancer in palliative care
16466954|NCT03518970|No Intervention|Conventional care|The control group will receive the nursing care conventionally given in the health care institution
16466955|NCT03518957|Experimental|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
16466956|NCT03518957|No Intervention|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
16466957|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion >4 weeks apart
16466958|NCT03518931|No Intervention|Control|This arm included individuals randomized to receiving fitness information only.
16466959|NCT03518931|Experimental|Intervention|This arm included individuals randomized to having fitness assessments performed.
16466960|NCT03518905|Sham Comparator|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
16466961|NCT03518905|Active Comparator|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
16466962|NCT03518892||Spinal Cord Injury Group|Body Composition, Resting Metabolic Rate, and dietary assessment
16466963|NCT03518892||Healthy Controls|Body Composition, Resting Metabolic Rate, and dietary assessment
16466964|NCT03518879|Experimental|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
16466965|NCT03518853|Experimental|Short-course Radiation Therapy|Short-course Hypofractionated Once-weekly Radiation Therapy: 35Gy in 5 fractions delivered once a week.
16466966|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
16466967|NCT03518827||Athletes|For Asymmetry measurement, the group will consist of 200 athletes of different sports (the proportion not strictly predefined) - track and field, racket sports, ball sports, other team sports, swimming, running, cycling, dancing, ice skating, etc.
16466968|NCT03518814||Multimetastatic melanoma in remission|Questionnaires
16466969|NCT03518801|Experimental|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
16466970|NCT03518801|Active Comparator|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
16466971|NCT03518788|Experimental|Pleur-X|Placement of a permanent drainage under local anesthesia
16466972|NCT03518788|Experimental|pleurodesis|Pleurodesis with talc in VATS
16466973|NCT03518775||Normal Eyes|Eyes with best-corrected visual acuity of 20/20 or better, and lens opacities of 1.0 or less in the study eye using the LOCS III system, and no prior Laser Vision Correction.
16466974|NCT03518775||Cataract Eyes|Cataract in the study eye greater than Grade 1 using the LOCS III system for one or more: nuclear opacity, nuclear color, cortical opacity, or PSC.
16466975|NCT03518775||Post LVC Eyes|History of Laser Vision Correction (LVC)
16466976|NCT03518762|Experimental|Sustained lung inflation|"Participants in this arm (n=80) received:
~Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.
~Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;
~Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.
~Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.
~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
16466977|NCT03518762|Other|Control|"Participants in this arm (n=80) received:
~Resuscitation according to the American academy of pediatrics guidelines.
~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
16466978|NCT03518749|Active Comparator|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
16467064|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
16466979|NCT03518749|Active Comparator|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
16466980|NCT03518749|Placebo Comparator|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
16466981|NCT03518736|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
16466982|NCT03518736|Experimental|SPEEDI_Early|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting in the hospital and lasting for 4 months. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.
~In addition they will continue with any intervention in the community recommended by their health care team."
16466983|NCT03518736|Experimental|SPEEDI_Late|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting at 4 months post baseline or approximately 3 months after discharge from the hospital. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.
~In addition they will continue with any intervention in the community recommended by their health care team."
16466984|NCT03518723|Experimental|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.
~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).
~All exercises will be performed using exercise equipment that are available at each included center.
~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
16466985|NCT03518723|Active Comparator|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.
~Progression of exercise is performance dependent and will be based on the previous 2 sessions.
~All exercises will be performed using exercise equipment that are available at each included center.
~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
16466986|NCT03518710|Experimental|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :
~Neuropsychological evaluation
~Evaluation of the reading assistance technique"
16466987|NCT03518697|Experimental|Exercise Group|"First 6 months supervised exercise program with telephone contact every two weeks
~Second 6 months exercise program without telephone contact
~Patients should increase habitual daily physical activity for 10-20 minutes per day 5 times per week
~Activities were chosen according to the preferences, interests, and severity of disease of the patients
~Activites should improve endurance, strength, coordination and flexibility
~Every three month regular vistit at the CF care center (medical examination, lung function, exercise testing, counselling and evaluation of activities by acceleometry and if appropirate adaption of exercise program)"
16466988|NCT03518697|No Intervention|Control-Group|"12 months usual routine care and habitual exercise in daily life.
~At start and after 12 month assessment of habitual exercise with accelerometry (Actigraph GTX3)"
16466989|NCT03518684|No Intervention|Group 1|Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel
16466990|NCT03518684|Experimental|Group 2|Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous [never delivered beyond 20 weeks of gestation in a previous pregnancy] or primiparous or more)
16466991|NCT03518671|Experimental|CBT (face to face)|"Self-limited cognitive behavioral therapy (CBT) delivered via 5 weekly sessions, face-face
~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 5 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT."
16466992|NCT03518671|Experimental|CBT (telemedicine)|"Self-limited cognitive behavioral therapy (CBT) delivered via 5 weekly sessions, via tablet-based telemedicine platform
~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 5 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT. To overcome the expected travel distance-related barrier to receipt of CBT, patients will receive the intervention via tablet-based telemedicine delivery platform"
16466993|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
16466994|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
16466995|NCT03518645|Experimental|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016'' lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
16466996|NCT03518645|Active Comparator|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
16466997|NCT03518632|Active Comparator|Control group|
16466998|NCT03518632|Experimental|Interval training 1|
16466999|NCT03518632|Experimental|Interval training 2|
16467065|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
16467000|NCT03518619|Experimental|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
16467001|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
16467002|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
16467003|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
16467004|NCT03518606|Experimental|Prostate cohort|Patients presenting advanced refractory prostate cancer
16467005|NCT03518606|Experimental|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
16467006|NCT03518593|Experimental|Intervention|Additional cash transfer and nutritional counselling
16467007|NCT03518593|No Intervention|Control|Existing cash transfer only
16467008|NCT03518567|Experimental|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
16467009|NCT03518554|Experimental|JAB-3068 (SHP2 inhibitor)|Daily oral administration of JAB-3068
16467010|NCT03518541|Active Comparator|Goniometer|FDO: classic procedure with goniometer controlled derotation
16467011|NCT03518541|Experimental|EMT|FDO: procedure with electromagnetic tracking (EMT) controlling derotation
16467012|NCT03518528||transdermal|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
16467013|NCT03518528||vaginal|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
16467014|NCT03518515|Experimental|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
16467015|NCT03518515|Experimental|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
16467016|NCT03518515|Active Comparator|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
16467017|NCT03518502|Active Comparator|Sorafenib monotherapy arm|The sorafenib monotherapy group receives sorafenib immediately after randomization.
16467018|NCT03518502|Experimental|TACE-sorafenib sequential therapy arm|TACE(transarterial chemoembolization )-sorafenib group receives 2~4 times of TACE before starting sorafenib.
16467019|NCT03518489|Experimental|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
16467020|NCT03518489|Active Comparator|Control|Patients will be given standard care when oral pain is reported
16467021|NCT03518476|Experimental|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
16467022|NCT03518476|Active Comparator|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
16467023|NCT03518463|Experimental|Intervention|"ERAS arm received;
~Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg
~Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat
~Postoperative:
~Feeding within 1 hour
~urethral catheter removal at 6-8 hours
~Mobilization at 8-10 hours
~A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly
~Tablets Amoxicillin-clavulunate 850mg 12 hourly"
16467024|NCT03518463|Active Comparator|Control|"Standard care arm received;
~IV ceftriaxone 2g or ampiclox 2g
~Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.
~Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.
~Urethral catheters were removed between 12-24 hours after surgery.
~Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight."
16467025|NCT03518450|Active Comparator|Femoral Nerve Block|Ultrasound guided femoral nerve block, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
16467026|NCT03518450|Active Comparator|Adductor Canal Block|Ultrasound guided adductor canal block, at the proximal third of the canal, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
16467027|NCT03518450|Experimental|Apex Femoral Triangle Block|Ultrasound guided femoral triangle block, at the distal third of the triangle, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
16467028|NCT03518411|Experimental|Medical Students|Cognitive Behavioral Therapy Protocol
16467029|NCT03518398|Experimental|IPL group|IPL 9-13 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
16467030|NCT03518398|Sham Comparator|sham-IPL group|IPL 0 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
16467031|NCT03518385||Patients with intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, this group patients will have intracavitary fluid.
16467032|NCT03518385||Patients without intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, in this group patients will not have intracavitary fluid.
16467035|NCT03518346|Experimental|Virtual Reality Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. For the VR group, we are using the Samsung VR Go (VR head set), Samsung S7 (phone) and programmed distraction (Spaceburgers, Pebbles the Penguin, and/or Happy Place). Spaceburgers and Pebbles the Penguin were designed by the Department of Anesthesiology at Lucile Packard Children's Hospital Stanford through the Stanford Chariot Program (Childhood Anxiety Reduction Through Innovation and Technology). Happy Place is a nongame immersive experience that will be offered to children uninterested in the previously mentioned game. Happy Place was designed by a Swedish Pharmacy Chain, Apotek Hjartat, aimed to distract patients from their pain with a peaceful, interactive environment. Each of the video games runs for the length of time needed to complete the venipuncture.
16467036|NCT03518346|Active Comparator|Standard of Care Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. The standard of care group will use various distractions. Distraction tools include books and movies using a wall mounted TV as standard practice.
16467037|NCT03518333|Experimental|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
16467038|NCT03518333|Experimental|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
16467039|NCT03518320|Experimental|TAR-200 and Nivolumab Combination|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. In combination, subjects are dosed intravenously with a Nivolumab Injection [Opdivo] within 3 days of TAR-200 placement. Subjects will receive four consecutive 21-day dosing cycles of the combination of TAR-200 and Nivolumab prior to radical cystectomy.
16467040|NCT03518294|No Intervention|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
16467041|NCT03518294|Experimental|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
16467042|NCT03518281|Placebo Comparator|Placebo|
16467043|NCT03518281|Experimental|Treatment|Whole Cell Euglena delivering βeta Glucan
16467044|NCT03518268|Active Comparator|Dietary supplement Vivomixx|Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731
16467045|NCT03518268|Placebo Comparator|Placebo|The placebo sachets contain the inactive ingredients maltose and silicon dioxides
16467046|NCT03518255|No Intervention|Control group|This control group will not receive an intervention.
16467047|NCT03518255|Experimental|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
16467048|NCT03518242|Experimental|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.
~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
16467049|NCT03518229|Experimental|Intervention|Microsoft Band 2 application with UV messaging activated
16467050|NCT03518229|Active Comparator|Control|Microsoft Band 2 application (UV messaging not active)
16467051|NCT03518216|Experimental|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT), a remotely delivered tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are interactive with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist support.
16467052|NCT03518216|No Intervention|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
16467053|NCT03518203|Experimental|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
16467054|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
16467055|NCT03518177|Experimental|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
16467056|NCT03518177|Experimental|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
16467057|NCT03518164|Other|Allograft|Bone graft
16467058|NCT03518164|Other|Autograft|Bone from iliac crest
16467059|NCT03518151|Experimental|Intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section at store entrance; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
16467060|NCT03518151|Sham Comparator|Control|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
16467061|NCT03518138|Experimental|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
16467062|NCT03518138|Placebo Comparator|Group 2, placebo|65 patients treated with placebo
16467066|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
16467067|NCT03518125|Active Comparator|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
16467068|NCT03518125|Active Comparator|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
16467069|NCT03518112|Experimental|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
16467070|NCT03518099|Experimental|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
16467071|NCT03518099|Experimental|witness|
16467077|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
16467078|NCT03518047|Placebo Comparator|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
16467079|NCT03518047|Experimental|Risankizumab|Risankizumab by subcutaneous (SC) injection.
16467080|NCT03518034|Active Comparator|Arm A|Participants receiving topical testosterone
16467081|NCT03518034|Placebo Comparator|Arm B|Participants receiving placebo
16467082|NCT03518021|Experimental|Naloxone, intranasal|
16467083|NCT03518021|Active Comparator|Naloxone, intramuscular|
16467084|NCT03518021|Placebo Comparator|placebo, intranasal|
16467085|NCT03518021|Placebo Comparator|placebo, intramuscular|
16467086|NCT03518008|Other|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
16467087|NCT03518008|Other|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
16467088|NCT03517995|Active Comparator|Sulforaphane Plus Surgery|Sulforaphane Administration prior to bladder cancer surgery.
16467089|NCT03517995|Placebo Comparator|Placebo Plus Surgery|Placebo Administration prior to bladder cancer surgery.
16467090|NCT03517969|Active Comparator|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
16467091|NCT03517969|Experimental|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16467092|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:
~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.
~Dose expansion (urothelial cancer):
~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
16467093|NCT03517943|Experimental|Test treatment|Healthy adult subjects under fed conditions
16467094|NCT03517943|Active Comparator|Reference treatment|Healthy adult subjects under fed conditions
16467095|NCT03517930|Experimental|Test treatment|Healthy adult subjects under fasted conditions
16467096|NCT03517930|Active Comparator|Reference treatment|Healthy adult subjects under fasted conditions
16467097|NCT03517917||Arm 1|Tumour tissue collection and blood collection to enable a manufacturing process for immunotherapies to be developed.
16467098|NCT03517904|Experimental|IVUS-guided group|Intravascular ultrasound-guided intervention group
16467099|NCT03517904|Active Comparator|Angiography-guided group|Angiography-guided intervention group
16467100|NCT03517891|Experimental|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.
~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
16467101|NCT03517891|No Intervention|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
16467102|NCT03517878||Comprehensive CHW Cohort|Pregnant women who become mothers and their infants living in areas served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Control Cohort clinic areas.
16467103|NCT03517878||Control Cohort|Pregnant women who become mothers and their infants living in areas that are not served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Comprehensive CHW Cohort clinic areas.
16467104|NCT03517852|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
16467105|NCT03517839|Experimental|Training Group|
16467106|NCT03517839|Sham Comparator|Control Group|
16467177|NCT03517319|Experimental|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
16467178|NCT03517319|Experimental|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
16467179|NCT03517306||Beijing|No interventions
16467107|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.
~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
16467108|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.
~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
16467109|NCT03517787|Experimental|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
16467110|NCT03517787|Active Comparator|TE|Participants receiving only therapeutic exercise
16467111|NCT03517787|Other|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
16467112|NCT03517787|Other|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
16467113|NCT03517774|Experimental|3D Printed Socket|All participants will received a 3D Printed Prosthetic
16467114|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
16467115|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
16467116|NCT03517748|Experimental|the investigational device: DM05|DM05 eye drops, multidose sterile emulsion, will be administered in the DM05 Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
16467117|NCT03517748|Active Comparator|The comparative device : Optive™|Optive™ eye drops, multidose sterile solution, will be administered in the Optive Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
16467118|NCT03517735|Experimental|Automated postoperative sedation|Automated administration of Propofol and Remifentanil.
16467119|NCT03517735|Active Comparator|Manual postoperative sedation|Manual administration of Propofol and Remifentanil.
16467120|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
16467121|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
16467122|NCT03517709|Other|Conventional|
16467123|NCT03517709|Other|Blood Pressure Monitor|
16467124|NCT03517696|Active Comparator|Membrane Sweeping|Membrane sweeping
16467125|NCT03517696|No Intervention|Control|Routine vaginal exam
16467126|NCT03517683|Experimental|Low speed|Patients will receive intrathecal injection of the anesthetic mixture in a slow speed (1ml in 15 seconds)
16467127|NCT03517683|Active Comparator|High speed|Patients will receive intrathecal injection of the anesthetic mixture in a high speed (1ml in 5 seconds)
16467128|NCT03517657|Experimental|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
16467129|NCT03517657|Active Comparator|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
16467130|NCT03517644|Experimental|Deceptive Placebo (DP)|After pretreatment heat pain assessment, participants are informed that they are about to receive an effective analgesic cream. In fact, they receive a placebo cream. Next, the posttreatment pain assessment is conducted.
16467131|NCT03517644|Experimental|OLP with Hope (OLP Hope)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect. Next, the posttreatment pain assessment is conducted.
16467132|NCT03517644|Experimental|OLP with Expectations (OLP Expectation)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to raise expectations among the participants that the cream will have a positive effect. Next, the posttreatment pain assessment is conducted.
16467133|NCT03517644|Experimental|Control|After pretreatment heat pain assessment, this group does not receive an intervention targeting pain sensation prior to the posttreatment pain assessment.
16467134|NCT03517631|Experimental|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
16467135|NCT03517631|Experimental|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
16467136|NCT03517631|Experimental|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
16467137|NCT03517618|Experimental|S-1 + leucovorin|Single arm
16467138|NCT03517605|Experimental|Exercise for cardiac rehabilitation|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
16467139|NCT03517592|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
16467180|NCT03517306||Ningxia|No interventions
16467140|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
16467141|NCT03517579|Experimental|Pilot Project|It is a Pilot study of 10 persons
16467142|NCT03517566|Placebo Comparator|placebo|Placebo
16467143|NCT03517566|Experimental|ZPL389 3mg|ZPL389 3 mg oral powder
16467144|NCT03517566|Experimental|ZPL389 10 mg|ZPL389 10 mg oral powder
16467145|NCT03517566|Experimental|ZPL389 30mg|ZPL389 30 mg oral powder
16467146|NCT03517566|Experimental|ZPL389 50mg|ZPL389 50 mg oral powder
16467147|NCT03517553|Experimental|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
16467148|NCT03517540|Experimental|Arm A: Tropifexor (LJN452) - Dose 1|tropifexor 140 mcg, once daily; given orally
16467149|NCT03517540|Experimental|Arm B: Cenicriviroc (CVC)|CVC 150 mg, once daily; given orally
16467150|NCT03517540|Experimental|Arm C: Tropifexor (LJN452) Dose 1 + CVC|tropifexor 140 mcg + CVC 150 mg, once daily; given orally
16467151|NCT03517540|Experimental|Arm D: Tropifexor Dose 2 + CVC|tropifexor 90 mcg + CVC 150 mg, once daily; given orally
16467152|NCT03517527|No Intervention|Control|
16467153|NCT03517527|Experimental|Intervention|
16467154|NCT03517501|Active Comparator|ART-123|
16467155|NCT03517501|Placebo Comparator|Placebo|
16467156|NCT03517488|Experimental|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
16467157|NCT03517475|Experimental|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
16467158|NCT03517475|Placebo Comparator|Services as Usual|Clients will receive home visiting services from Head Start
16467159|NCT03517462|Experimental|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
16467160|NCT03517449|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
16467161|NCT03517449|Active Comparator|Treatment of Physician's Choice|Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m^2 OR paclitaxel 80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
16467162|NCT03517436|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
16467163|NCT03517410||Smart phone Use Experimental group|Patients with CLBP
16467164|NCT03517397|Experimental|Mobile Contingency Management|
16467165|NCT03517384|Experimental|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
16467166|NCT03517371|Experimental|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
16467167|NCT03517371|Active Comparator|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
16467168|NCT03517358|Active Comparator|Pharmacy|service of care: pharmacy
16467169|NCT03517358|Active Comparator|Case management|service of care: case management
16467170|NCT03517345|Experimental|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
16467171|NCT03517345|Experimental|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
16467172|NCT03517332||Cohort 1|"Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma
~Subjects of cohort 1 must not:
~• Have been treated for above diagnosed malignancy"
16467173|NCT03517332||Cohort 2|"Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).
~Subjects of cohort 2 must:
~• Meet the listed matching criteria
~Subjects of cohort 2 must not:
~• Have been diagnosed/treated for a malignancy previously"
16467174|NCT03517319|Placebo Comparator|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
16467175|NCT03517319|Experimental|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
16467176|NCT03517319|Experimental|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
16467181|NCT03517306||Wenzhou|No interventions
16467183|NCT03517293|Experimental|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from ~16-40 weeks of pregnancy
16467184|NCT03517293|No Intervention|Control|usual daily activities - not exercise, not elevating heart rate
16467185|NCT03517280||Children with Neuroblastoma|Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
16467186|NCT03517254|Experimental|Glutamine and strength training program|Three times per week, standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks of follow up. At the beginning and at the end of the training session, the experimental group will receive by mouth 10 grams of glutamine dissolved in 120 milliliters of water, all participants and team of researchers will not be aware of the supplement.
16467187|NCT03517254|Placebo Comparator|Placebo and strength training program|Three times per week a standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks after discharge. At the beginning and at the end of the training session, the placebo group will receive by mouth10 grams of maltodextrin dissolved in 120 milliliters of water. All participants and team of researchers will not be aware of the supplement content.
16467188|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
16467189|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
16467190|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
16467191|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
16467192|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
16467193|NCT03517228|Experimental|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
16467194|NCT03517215|Experimental|Enhanced CB-ASP|If a site is randomized to the enhanced CB-ASP, prescribers at that site will be required to attend an education session. In the four months following the initial session, prescribers will be asked to complete one on-line eModule for each target condition (acute sinusitis, sore throat, acute bronchitis and acute uncomplicated cystitis) each month. Each module will take approximately 15 minutes to complete. Two audit and feedback reports (every 3 months) of their clinic's prescriptions for these conditions will be provided where they will be asked to review and discuss with their colleagues and study staff.
16467195|NCT03517215|Active Comparator|Standard CB-ASP|If a site is randomized to the standard CB-ASP strategy arm, prescribers will be offered the opportunity to attend the 1 hour introductory seminar by a web-link, provided with access to the short e-learning modules each month by email, and sent their clinic's audit and feedback reports by email for review two times during the study.
16467196|NCT03517215|No Intervention|Control|If a site is randomized to the control arm, the site will not receive any active interventions. Prescribers at the site will be offered access to the eModules at the completion of the study and provided with one audit and feedback report of their clinic's antibiotic prescribing patterns for local quality improvement needs as desired.
16467197|NCT03517189|Experimental|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
16467198|NCT03517176|Experimental|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m^2) / gemcitabine (1000mg/m^2) combination given on Days 1, 8, 15.
16467199|NCT03517176|Experimental|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m^2) and gemcitabine (1000mg/m^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
16467200|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
16467201|NCT03517150|Experimental|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
16467202|NCT03517150|Active Comparator|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
16467203|NCT03517137|Experimental|Treatment|
16467204|NCT03517124|Experimental|Zirconia restorations|Dental restorations in surface modified zirconia bonded to tooth substance by dual cure resin cement
16467205|NCT03517124|Active Comparator|e.max|Restorations in e.max bonded to tooth substance by dual cure resin cement
16467206|NCT03517111|Experimental|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
16467207|NCT03517111|Active Comparator|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
16467208|NCT03517111|Sham Comparator|Academic success program|Control program focused only on academic success.
16467209|NCT03517098|Experimental|The ERAS group|Patients will be treated with the ERAS pathway
16467210|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
16467211|NCT03517085|Experimental|DTX401 Dose 1|DTX401 solution for intravenous (IV) infusion
16467212|NCT03517085|Experimental|DTX401 Dose 2|DTX401 solution for intravenous (IV) infusion
16467213|NCT03517085|Experimental|DTX401 Dose 3|DTX401 solution for intravenous (IV) infusion
16467214|NCT03517085|Experimental|DTX401 Dose 4|DTX401 solution for intravenous (IV) infusion
16467215|NCT03517059||PD patients|30 PD patients in ON and OFF levodopa conditions
16467216|NCT03517059||Healthy control subjects|30 age matched healthy control subjects
16467217|NCT03517059||Neurological control subjects|10 patients with defined supra nuclear palsy
16467253|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
16467218|NCT03517046|Experimental|CartiLife (low-dose group)|Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
16467219|NCT03517046|Experimental|CartiLife (high-dose group)|Total defect volume in High-dose group is 2 ~ 4 ㎤.
16467220|NCT03517033|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
16467221|NCT03517033|Active Comparator|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
16467222|NCT03517020|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
16467223|NCT03517020|Active Comparator|Reference|Forest Pharmaceuticals Inc.'s Bystolic® Tablets 20 mg
16467224|NCT03517007|Experimental|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
16467225|NCT03517007|No Intervention|Standard of Care|Provider continues routine, standard of care on the patient.
16467226|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
16467227|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
16467240|NCT03516968|Experimental|Monthly bolus arm|
16467241|NCT03516968|Active Comparator|Daily arm|
16467242|NCT03516968|Other|Control group|Group of obese patients without vitamin D deficiency
16467243|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
16467244|NCT03516929|Active Comparator|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
16467245|NCT03516929|Sham Comparator|low risk group|No history or stroke,TIA. NO left main stem disease
16467246|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
16467247|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
16467248|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
16467249|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
16467250|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
16467256|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
16467257|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
16467258|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
16467259|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
16467260|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
16467261|NCT03516903|Active Comparator|Methotrexate & Folic acid|ddMTX-LDE 40mg/m2 (100mL total volume) IV and Folic acid 5mg by mouth (the day after ddMTX-LDE) weekly for 6 weeks
16467262|NCT03516903|Placebo Comparator|Placebo & folic acid|Placebo-LDE IV 100mL and Folic acid 5mg by mouth (the day after Placedo-LDE) weekly for 6 weeks
16467264|NCT03516851|Active Comparator|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
16467265|NCT03516851|No Intervention|Empirical group|choosing the recipient vessel by the surgeon's own experience
16467266|NCT03516838|Experimental|ACTIVA™ BioACTIVE|Restoring cavity using ACTIVA filling material
16467267|NCT03516838|Active Comparator|Compomer|Restoring cavity using compomer filling material
16467268|NCT03516825|Experimental|Musical Neglect Training (MNT)|A single-subject design was used. All participants took Musical Neglect Training.
16467269|NCT03516812|Experimental|Treatment (olaparib, testosterone enanthate or cypionate)|Patients receive olaparib PO BID on days 1-28 and testosterone enanthate or cypionate IM on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16467270|NCT03516799|Experimental|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
16467271|NCT03516799|No Intervention|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
16467272|NCT03516773|Experimental|Treatment A|Intervention: EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID) (approximately 5 hours apart) for 4 doses, for a total dose of 9 mg per day
16467273|NCT03516773|Experimental|Treatment B|Intervention: EB612 (EBP05) 2.25 mg PO twice a day (BID) (approximately 10 hours apart) for 2 doses, for a total dose of 4.5 mg per day
16467274|NCT03516773|Active Comparator|Treatment C|Intervention: NATPARA/NATPAR PTH(1-84) 100 μg subcutaneous injection once daily (single dose)
16467275|NCT03516773|Experimental|Treatment D|Intervention: EB612 (EBP05) 2.25 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 6.75 mg per day
16467276|NCT03516773|Experimental|Treatment E - EB612 (EBP05)|Intervention: EB612 (EBP05) 0.75 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 2.25 mg per day
16467277|NCT03516760|Experimental|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
16467278|NCT03516747|Experimental|investigation group|participants that suffer hypercalcemia due to primary hyperparathyroidism. include all participants in the trial
16467279|NCT03516734|Experimental|Iron fortified lentils|Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
16467280|NCT03516734|Active Comparator|Non iron-fortified lentils|It will be the same Saskatchewan (province of Canada) grown small cotyledon color lentil (Iron content 75-90ppm) without the iron fortification.
16467281|NCT03516734|Placebo Comparator|Usual Intake (no intervention)|It will be the usual intake of lentil- no additional lentil will be provided. However, participants will be free to consume lentils from anywhere (homemade or restaurants) if they want to, except our fortified lentils.
16467282|NCT03516721|Other|Obese adolescents|
16467283|NCT03516721|Other|Lean adolescents|
16467286|NCT03516682|No Intervention|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
16467287|NCT03516682|Experimental|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
16467288|NCT03516669|Other|Intraluminal Clarithromycin eradication|20 Patients receive intraluminal Clarithromycin eradication of H. pylori.
16467289|NCT03516669|Other|Oral standard triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.
16467290|NCT03516656|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
16467291|NCT03516656|Active Comparator|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged
16467292|NCT03516643|Experimental|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
16467293|NCT03516630|Experimental|TRZ 20|Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
16467294|NCT03516630|Experimental|TRZ 60|Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
16467295|NCT03516630|Experimental|TRZ 140|Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
16467296|NCT03516630|Placebo Comparator|Placebo|Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
16467297|NCT03516630|Active Comparator|Moxifloxacin|Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
16467298|NCT03516617|Experimental|Arm A (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
16467299|NCT03516617|Experimental|Arm B (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
16467300|NCT03516617|Active Comparator|Arm C (observation)|Patients will be observed every 6 months for up to 2 years.
16467301|NCT03516604|Experimental|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
~+ 1 placebo capsule, once daily for 7-9 days"
16467302|NCT03516604|Active Comparator|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days
~+ 3 placebo tablets, once daily for 7-9 days"
16467303|NCT03516604|Placebo Comparator|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
16467304|NCT03516591|Experimental|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
16467305|NCT03516591|Experimental|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
16467306|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
16467307|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
16467308|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
16467309|NCT03516552||Hemoglobin content on blood loss|Hemoglobin content on blood loss, to assess ratio hemoglobin/volume.
16467310|NCT03516539|Experimental|Group ML|Mcgrath videolaryngoscopy
16467311|NCT03516539|Active Comparator|Group DL|direct Macintosh laryngoscope
16468672|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=40 group
16467312|NCT03516526|Other|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
16467313|NCT03516513|Active Comparator|Problem Solving Therapy as Usual|"Clinicians in this arm of care will have access to the Case Management Tracking System which is already in use.
~Intervention: unguided PST"
16467314|NCT03516513|Experimental|Assisted Problem Solving Therapy|"This arm will be designed and finalized in Phase 1 and 2 of the project. We anticipate that the intervention will leverage clinical notes required to be completed by clinicians and will provide information to clinicians to help patients improve over time, as well as help clinicians implement PST to high quality.
~Intervention: guided PST"
16467315|NCT03516500|Experimental|Iron Sucrose injection group|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.
16467316|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^10 colony-forming units [CFU]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467317|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467318|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467319|NCT03516487|Experimental|SAD HV SB: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.
16467320|NCT03516487|Experimental|SAD HV: SYNB1618 (2 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (2 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467321|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467322|NCT03516487|Placebo Comparator|SAD HV: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467323|NCT03516487|Experimental|SAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467324|NCT03516487|Placebo Comparator|SAD PKU: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
16467325|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive oral SYNB1618 (1 x 10^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).
16467326|NCT03516487|Experimental|MAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive oral SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
16467327|NCT03516487|Experimental|MAD HV: SYNB1618 (7 x 10^10 CFU)|HV subjects receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
16467328|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive oral SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
16467329|NCT03516487|Placebo Comparator|MAD HV: Placebo|HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
16467330|NCT03516487|Experimental|MAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
16467331|NCT03516487|Placebo Comparator|MAD PKU: Placebo|Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
16467332|NCT03516474||St. Michael's Hospital|"St. Michael's Hospital is an Acute care centre for the diabetic lower extremity.
~n=100"
16467333|NCT03516474||South Riverdale Community Health Centre|South Riverdale is a Community Health Centre focused on prevention. n=100
16467334|NCT03516474||Westpark|Westpark is a rehabilitation site focused on post-operative/amputation care and preservation of the opposite limb. n=100
16467335|NCT03516474||Women's College Hospital|Women's College Hospital is an outpatient wound clinic focused on the management of DFUs. n=100
16467336|NCT03516461|Experimental|Selective Microbiota Transplant (SMT)|Patients undergo once SMT a day for three consecutive days.
16467337|NCT03516461|Experimental|Fecal Microbiota Transplantation (FMT)|Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.
16467338|NCT03516448|Active Comparator|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
16467339|NCT03516448|Placebo Comparator|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
16467340|NCT03516435|Experimental|Parasacral transcutaneous ES|20min./session, 2 sessions/week ,12 sessions of Parasacral transcutaneous electrical stimulation.
16467341|NCT03516435|Active Comparator|Intravaginal electrical stimulation|20min./session, 2 sessions/week ,12 sessions of Intravaginal electrical stimulation.
16467342|NCT03516422|Placebo Comparator|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
16467375|NCT03516214|Experimental|EGF816 (nazartinib) and trametinib|Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
16467376|NCT03516201||obese patients after bariatric surgery|obese adults (≥ 18 years) who underwent bariatric surgery
16467377|NCT03516201||obese adultes without bariatric surgery|obese adults (≥ 18 years) who did not underwent bariatric surgery at the time of the examination
16467343|NCT03516422|Experimental|ULTRASOUND DEBRIDEMENT GROUP:|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
16467344|NCT03516409|Active Comparator|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
16467345|NCT03516409|Placebo Comparator|Placebo|1 sachet once a day mixed with milk, water or food.
16467346|NCT03516396|Experimental|Training Plus|"Intervention: Community Development
~Training plus enhanced community development activities"
16467347|NCT03516396|Active Comparator|Control|No inputs
16467348|NCT03516396|Experimental|Training Only|"Intervention: Training
~Training Only (livestock management and child nutrition)"
16467349|NCT03516383||Experimental|"ABI < 0.6, confirmed PAD
~50 - 90 years of age
~In-patients or out-patients
~Participants who understand the study and are able to give consent
~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
16467350|NCT03516383||Control|"ABI of 0.9 < ABI < 1.2
~50 - 90 years of age
~Participants who understand the study and are able to give consent
~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
16467351|NCT03516370|Experimental|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
16467352|NCT03516370|Placebo Comparator|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
16467353|NCT03516357||low myopia|-3.00D < spherical equivalent refractive error < -0.50D
16467354|NCT03516357||moderate myopia|-6.00D < spherical equivalent refractive error ≤ -3.0D
16467355|NCT03516357||high myopia|spherical equivalent refractive error ≤ -6.0D
16467356|NCT03516344|No Intervention|Control|Subjects will remain at rest in supine position for one minute.
16467357|NCT03516344|Experimental|Iliac psoas muscle|In supine position with a high-density foam cushion under the subject's feet, they will be asked to make a push in the caudal direction, against the cushion, alternating between both feet with their knees stretched out, for one minute
16467358|NCT03516344|Experimental|Diaphragmatic Breathing|Subjects perform five cycles of diaphragmatic breathing in the supine position.
16467359|NCT03516344|Experimental|Liver pumping|A technique of hepatic supine pumping is performed by simultaneous compression in the right hypochondrium and epigastrium, in the opposite direction, during the inspiratory phase, stopping during the expiratory phase and repeating the maneuver for five respiratory cycles.
16467360|NCT03516344|Experimental|Spinal manipulation|A semi-direct vertebral manipulation, type Dog Technique in extension, will be performed on level D8
16467361|NCT03516331|Experimental|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
16467362|NCT03516331|Experimental|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
16467363|NCT03516318|Experimental|SMART Connections|"The intervention components include:
~Informational messages that reflect the content of the structured group counseling curriculum and are posted to the Facebook group wall on a regular basis for approximately 4 to 5 months
~Moderated, closed group chats in a secret Facebook group where YLHIV can interact with their peers and with a trained support group facilitator
~Access to a trained facilitator via Facebook Messenger for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
16467364|NCT03516318|No Intervention|Control|All study participants, in both study arms, will receive standard services currently available to YLHIV in these facilities and communities. The services currently include: routine clinical care for HIV treatment including laboratory testing (CD4, viral load tests); active case management by community volunteers with intensive adherence support during the first 4 weeks of ART; adherence support through phone calls and SMS (short messaging service) reminders; and enhanced adherence counseling for patients with unsuppressed viral loads.
16467365|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
16467366|NCT03516292||OAB-POP group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
16467367|NCT03516292||POP only group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
16467368|NCT03516279|Experimental|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
16467369|NCT03516253|Experimental|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
16467370|NCT03516253|No Intervention|Control group|Dietary Supplement: Mineral oil (5 gel capsules, each 1g mineral oil), 3 months with lunch.
16467371|NCT03516240|Experimental|Experimental|Participants receive the topical analgesic, Biofreeze.
16467372|NCT03516240|Placebo Comparator|Placebo|Participants receive a placebo cream.
16467378|NCT03516188|Experimental|Alginate-antacid group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
16467379|NCT03516188|Experimental|Non antacid alginate group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.
16467380|NCT03516175|Active Comparator|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
16467381|NCT03516175|Experimental|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
16467382|NCT03516162||Patients With Brain Tumors/AVMs|"Patients with a brain tumour/AVM scheduled for maximum safe resection via craniotomy.
~Participants fulfilling all of the following inclusion criteria are eligible for the study:
~Consent of the patient
~Age: ≥18
~Fluent language skills in German
~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months
~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
16467383|NCT03516162||Patients With Hydrocephalus|"Patients with hydrocephalus scheduled for VP-shunting
~Participants fulfilling all of the following inclusion criteria are eligible for the study:
~Consent of the patient
~Age: ≥18
~Fluent language skills in German
~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months
~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
16467384|NCT03516149|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
16467385|NCT03516149|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
16467386|NCT03516123|Experimental|CS3006|Participants will receive CS3006 orally at specified dose on specified days
16467387|NCT03516110||Prostate cancer subjects 60-<70 years|
16467388|NCT03516110||Prostate cancer subjects 70-<75 years|
16467389|NCT03516110||Prostate cancer subjects ≥ 75 years|
16467390|NCT03516097|Experimental|Experimental Group A|Structured school based intervention + mobile app usage
16467391|NCT03516097|Experimental|Experimental Group B|mobile app usage
16467392|NCT03516097|Active Comparator|Control Group|Structured school based intervention
16467393|NCT03516084|Experimental|ZL-2306(nirapairb)|
16467394|NCT03516084|Placebo Comparator|Placebo|
16467395|NCT03516071|Experimental|Brivanib 800 mg, QD + BSC|
16467396|NCT03516071|Experimental|Brivanib 400 mg, BID + BSC|
16467397|NCT03516045|Experimental|18F-AlF-NOTA-neurotensin PET/CT|One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
16467398|NCT03516032|Experimental|walking exercises|walking in the hospital corridor
16467399|NCT03516032|Experimental|balance exercises|heel rise exercises
16467400|NCT03516019|Experimental|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
16467401|NCT03516019|Experimental|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
16467402|NCT03516019|Experimental|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
16467403|NCT03516019|Experimental|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
16467404|NCT03516019|Experimental|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
16467405|NCT03516019|Experimental|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
16467406|NCT03516019|Experimental|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
16467407|NCT03516019|Experimental|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
16467408|NCT03516006|Experimental|UCMSC|infusion of aUCMSC and Ursodeoxycholic acid therapy
16467409|NCT03516006|Active Comparator|UDCA|Ursodeoxycholic acid therapy 15mg/kg/d
16467410|NCT03515980|Experimental|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
16467411|NCT03515980|Experimental|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
16467412|NCT03515980|Experimental|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
16467413|NCT03515980|Experimental|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
16467414|NCT03515967|Experimental|Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) after injury using the I-PAS goggles
16467415|NCT03515967|Active Comparator|Non-Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) with no injury using the I-PAS goggles
16467416|NCT03515941|Experimental|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 or 1000 mg/m2 by PO (BID) on 21 day-cycle or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
16467417|NCT03515941|Experimental|Arm 2: Adjuvant Chemoradiation|Three cycles of chemo with Capecitabine: 750 mg/m2 by PO BID on days 1-14 of a 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on days 1 and 15 of a 28 day cycle After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above.
16467418|NCT03515928|Active Comparator|Noise Exposed Group|
16467419|NCT03515928|Placebo Comparator|Control Group|
16467420|NCT03515902|Experimental|mouthguard|Mouthguard arm is application of mouthguard while swimming
16467421|NCT03515902|Experimental|mouthguard with desensitizing toothpaste|Mouthguard with desensitizing toothpaste arm is application of mouthguard with desensitizing toothpaste containing 8% arginine and calcium carbonate while swimming
16467422|NCT03515889|Experimental|Ideal Protein Weight Loss Protocol|This arm will follow the Ideal Protein method as documented in the Ideal Protein Clinic Manual and in the Ideal Protein Coaches Manual.
16467423|NCT03515889|Active Comparator|Standard Weight Loss|This arm utilizes evidence-based, low fat, low calorie strategies that have been shown to be effective for long-term weight loss and weight loss maintenance.
16467424|NCT03515876||Control|Patients will receive intravenous propofol infusion.
16467425|NCT03515876||Dexmedetomidine 0.5 microgram/kg group|Patients will receive dexmedetomidine 0.5 microgram/kg and then intravenous propofol infusion.
16467426|NCT03515876||Dexmedetomidine 1 microgram/kg group|Patients will receive dexmedetomidine 1 microgram/kg and then intravenous propofol infusion.
16467427|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
16467428|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
16467429|NCT03515837|Experimental|Pembro+Pemetrexed+Chemo|Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve [AUC] 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
16467430|NCT03515837|Active Comparator|Placebo+Pemetrexed+Chemo|Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
16467431|NCT03515824|Experimental|Part A: MK-1696 20 mg|Participants received 20 mg of MK-1697 by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
16467432|NCT03515824|Experimental|Part A: MK-1697 65 mg|Participants received 65 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
16467433|NCT03515824|Experimental|Part A: MK-1697 200 mg|Participants received 200 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
16467434|NCT03515824|Experimental|Part B: Expansion Cohort|Participants with select tumor types were to receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
16467435|NCT03515811||Abdominal|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.
~Abdominal (approximately 53 subjects)."
16467436|NCT03515811||Thoracic|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.
~Thoracic (approximately 74 subjects)."
16467437|NCT03515798|Experimental|Pembrolizumab|EC Paclitaxel + Pembrolizumab Injection
16467438|NCT03515798|Active Comparator|Standard neoadjuvant chemotherapy|EC Paclitaxel alone
16467439|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
16467440|NCT03515772||Amlodipine with Dolutegravir|"This is the control group regarding HIV drug interaction potential on amlodipine"
16467441|NCT03515772||Amlodipine with Darunavir|"This is the case group regarding HIV drug interaction potential on amlodipine"
16467442|NCT03515772||Atorvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on atorvastatin"
16467443|NCT03515772||Atorvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on atorvastatin"
16467444|NCT03515772||Rosuvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on rosuvastatin"
16467445|NCT03515772||Rosuvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on rosuvastatin"
16467446|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
16467447|NCT03515746|Active Comparator|Exergaming2D|The participants will practise grab and grasp through exergaming in virtual environment (VE) on a laptop computer. During the task, they will sit in a comfortable chair in front of the screen.
16467448|NCT03515746|Active Comparator|Exergaming3D|The participants will practise grab and grasp through exergaming in virtual environment (VE) in 3D VE using Oculus Rift CV1 3D goggles. During the task, they will sit in a comfortable chair with head-mounted 3D display.
16467449|NCT03515733|Experimental|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
16467450|NCT03515733|Placebo Comparator|Placebo|3 placebo tablets, once daily for 7-9 days
16467451|NCT03515720|Experimental|Study group|Painful points will be located in the path of the sensory nerves of the knee in which asepsis and antisepsis will be performed, and then 0.5-1 ml of 5% dextrose solution will be applied subcutaneously at a 45º angle along the way. of the nerve with a 27 gauge needle of ½ inch. The number of injections will vary according to the symptoms to be treated. The application will be made once a week for 6 weeks. After the first application of neuroprolotherapy, the patient will be trained to perform a rehabilitation therapy program based on thermotherapy, kinesitherapy and knee strengthening exercises. At the end of the 6 sessions, a new assessment will be made with the WOMAC, EVA and measurement of movement arcs to assess the evolution after treatment.
16467452|NCT03515720|No Intervention|Control group|Physical therapy consisting of 10 sessions based on thermotherapy, kinesitherapy and muscle strengthening exercises to the knee. Subsequently, the patient will perform this therapy home until completing 6 weeks. At the end a new assessment will be made with measurement of movement arcs, WOMAC scale and EVA to assess the evolution after treatment.
16467453|NCT03515707|Experimental|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
16467454|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF1|
16467455|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF2|
16467456|NCT03515694|Experimental|Dose of 0 ,5mg/kg TOF1|
16467457|NCT03515694|Active Comparator|Dose of 0,5mg/kg TOF2|
16467458|NCT03515694|Experimental|Dose of 1mg/kg TOF1|
16467459|NCT03515694|Active Comparator|Dose of 1mg/kg TOF2|
16467460|NCT03515694|Experimental|Dose of 2mg/kg TOF1|
16467461|NCT03515694|Active Comparator|Dose of 2mg/kg TOF2|
16467462|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
16467463|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
16467464|NCT03515668|Experimental|Ritalin|20 mg Ritalin, 90 min before testing
16467465|NCT03515668|Placebo Comparator|Control|Identical size/taste placebo pill, 90 min before testing
16467466|NCT03515642|Experimental|HIIT group|The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max). Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6-weeks.
16467467|NCT03515642|Active Comparator|SIT group|The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
16467468|NCT03515629|Active Comparator|Pembrolizumab|Pembrolizumab
16467469|NCT03515629|Experimental|REGN2810/ipi|REGN2810/ipi
16467470|NCT03515629|Experimental|REGN2810/chemo/ipi|REGN2810/chemo/ipi
16467471|NCT03515603|Active Comparator|microsurgical technique|
16467472|NCT03515603|Active Comparator|endoscopic technique|
16467473|NCT03515590|Experimental|Emulsion with solid droplets|Emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
16467474|NCT03515590|Experimental|Emulsion with liquid droplets|Emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
16467475|NCT03515577|Experimental|Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)|Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.
16467476|NCT03515564|Experimental|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga
~60 minutes once weekly for 8 weeks"
16467477|NCT03515564|No Intervention|No Intervention|No Intervention
16467478|NCT03515551|Experimental|IMCnyeso dose Escalation Phase with approximately 4-10 cohorts|Phase (Arm 1) n=approximately 27 patients to establish the MTD/RP2D
16467479|NCT03515551|Experimental|IMCnyeso expansion with 3 cohorts|n=9-24/cohort treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso
16467480|NCT03515538|Experimental|RRx-001 Pre-Treatment plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
16467481|NCT03515538|Experimental|RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
16467482|NCT03515538|Experimental|RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
16467483|NCT03515538|Active Comparator|Standard of Care|No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
16467484|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
16467485|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
16467486|NCT03515512|Experimental|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
16467487|NCT03515499|Active Comparator|Control|The control arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use.
16467488|NCT03515499|Experimental|Treatment arm|The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
16467489|NCT03515486|Experimental|Post-stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.
16467490|NCT03515473||CI532|Patients with CI532 cochlear implant
16467491|NCT03515473||CI522|Patients with CI522 cochlear implant
16467492|NCT03515473||CI512|Patients with CI512 cochlear implant
16467493|NCT03515460|Experimental|sugar oral load|oral ingestion of a high carbohydrate meal
16467494|NCT03515460|Experimental|fat oral load|oral ingestion of a high fat meal
16467495|NCT03515460|Experimental|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
16467496|NCT03515447||Before period|During this period no patient received Romiplostim.
16467497|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.
~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
16467498|NCT03515434|Active Comparator|ESP Block|Ultrasound-guided Erector spinae plane (ESP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
16467596|NCT03514745|Active Comparator|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
16467499|NCT03515434|Active Comparator|TAP Block|Ultrasound-guided Transversus abdominis plane (TAP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
16467500|NCT03515434|Sham Comparator|Control|The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16467501|NCT03515421|Experimental|Blood Glucose monitoring System (BGMS)|"Intervention: Blood Glucose monitoring Systems (BGMSs): Frazier 3 Verio and Frazier 3 UltraPLus.
~Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)"
16467502|NCT03515408|Experimental|Real rTMS (motor area)|Real rTMS targeting motor area for 30 min
16467503|NCT03515408|Experimental|Real rTMS (parietal gyrus)|Real rTMS targeting parietal gyrus for 30 min
16467504|NCT03515408|Experimental|Real rTMS (both brain area)|Real rTMS targeting motor area and parietal gyrus for 15 min, separately
16467505|NCT03515408|Sham Comparator|Sham rTMS|Sham rTMS targeting motor area and parietal gyrus for 15 min, separately
16467506|NCT03515382|Experimental|Treatment A|single dose GLPG1690.
16467507|NCT03515382|Experimental|Treatment B|Single dose itraconazole + single dose GLPG1690.
16467508|NCT03515382|Experimental|Treatment C|Single dose voriconazole + single dose GLPG1690.
16467509|NCT03515369|Experimental|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
16467510|NCT03515369|Placebo Comparator|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
16467511|NCT03515356|Experimental|MI-Walk Intervention|"Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T1), 2 weeks (T3), and 4 weeks (T4)."
16467512|NCT03515356|Active Comparator|PA Education Alone|Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
16467513|NCT03515343||Optical diagnosis with Optivista|Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
16467514|NCT03515343||Optical diagnosis with iScan|Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
16467515|NCT03515330|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressant medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth application.
16467516|NCT03515330|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to aid in immunosuppressant medication adherence post-transplant.
16467517|NCT03515317|Experimental|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
16467518|NCT03515317|Experimental|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
16467519|NCT03515317|No Intervention|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
16467520|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
16467521|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
16467522|NCT03515291|Experimental|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
16467523|NCT03515291|Placebo Comparator|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
16467524|NCT03515278|Experimental|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.
~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
16467525|NCT03515278|Active Comparator|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.
~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
16467526|NCT03515265|Experimental|Fiber resin composite|Fiber reinforced resin composite restoration used as dentin substitute covered by conventional resin composite
16467527|NCT03515265|Active Comparator|Microhybrid resin composite|Microhybrid resin composite restoration with lower strength compared to Fiber reinforced resin composite restoration
16467528|NCT03515252|Experimental|Late stage lung cancer and liver cancer|Immune Killer Cells (IKC)
16467529|NCT03515226|Active Comparator|Traditional Training|24 hours of didactic and simulated case role play training in CBT principles, depression assessment and cultural competency.
16467530|NCT03515226|Experimental|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
16467531|NCT03515213|Active Comparator|Active|
16467532|NCT03515213|Placebo Comparator|Placebo|
16467533|NCT03515200|Experimental|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.
~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability. If our highest dosing of 100mg/m2/day is tolerated, we will have a final dose level that receives an additional 10 days of palbociclib (Days 1-5, 11-15, and 21-30).
~For patients that are Ph+ or have Ph-like ALL that are also receiving dasatinib or ruxolitinib: palbociclib, initially at 75mg/m2/day, 60% of the adult MTD, will be administered on Days 1-5 and 11-15 and escalated based on tolerability.
~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
16467534|NCT03515187|Experimental|A1 Medicine treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
16467535|NCT03515187|Experimental|A2 Combined treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days
16467536|NCT03515187|Placebo Comparator|B1 Control group|Placebo
16467537|NCT03515187|Experimental|B2 Experiment group|0.3%sodium hyaluronate ophthalmic solution, 12 months
16467538|NCT03515174|Experimental|Interventional Program|Patients will participate in a structured supportive care program.
16467539|NCT03515174|Active Comparator|Control Group|Patients in the control group will receive usual care.
16467540|NCT03515161|Experimental|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
16467541|NCT03515148|Experimental|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
16467542|NCT03515148|Experimental|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
16467543|NCT03515135|Experimental|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
16467544|NCT03515135|No Intervention|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
16467545|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
16467546|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
16467547|NCT03515109|Active Comparator|group A|Altis tape surgical placement
16467548|NCT03515109|Placebo Comparator|group B|TVT transobturator tape placement
16467549|NCT03515096|Experimental|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
16467550|NCT03515096|Placebo Comparator|rhTPO|Recombinant human thrombopoietin (rhTPO)
16467553|NCT03515057|Experimental|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
16467554|NCT03515057|No Intervention|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
16467555|NCT03515044|Experimental|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
16467556|NCT03515044|Experimental|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
16467557|NCT03515044|Experimental|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
16467558|NCT03515044|Experimental|Cohort 4 80 mg Rifaximin SSD twice daiy|Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose
16467559|NCT03515044|Experimental|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
16467597|NCT03514745|Experimental|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
16467560|NCT03515031|Experimental|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula Oxygenation with a minimum flow ≥ 60L / min, and an FiO2 such as to maintain a SpO2 ≥ 92% for at least 48 hours until clinical stability
16467561|NCT03515031|Active Comparator|Venturi Mask Oxygenation|Venturi Mask Oxygenation, with an FiO2 such as to maintain an SpO2 ≥ 92% for at least 48 hours until clinical stability
16467562|NCT03515018|Experimental|Hydroxyurea|Drug: hydroxyurea, pulse therapy
16467563|NCT03515018|Active Comparator|imatinib|Drug: imatinib, 400mg PO per day
16467564|NCT03515005|Experimental|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
16467565|NCT03515005|No Intervention|Usual Care|Control patients will receive usual care from their doctors.
16467566|NCT03514979|Experimental|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
16467567|NCT03514979|Experimental|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
16467568|NCT03514979|Experimental|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
16467569|NCT03514966|No Intervention|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
16467570|NCT03514966|Experimental|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
16467571|NCT03514953|Experimental|Reduced Physical Activity|Participants will reduce their physical activity level by >5000 steps per day for two weeks.
16467572|NCT03514927|Experimental|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.
~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
16467573|NCT03514914|Experimental|CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by female providers.
16467574|NCT03514914|No Intervention|Control|Control clusters will receive standard of care.
16467575|NCT03514901|Experimental|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
16467576|NCT03514901|Active Comparator|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
16467577|NCT03514888|Experimental|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
16467578|NCT03514875|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
16467579|NCT03514875|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
16467580|NCT03514862|Experimental|Intervention|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then will be invited to continue to participate in 4 additional Mindfulness Booster Training.
16467581|NCT03514862|Active Comparator|Control|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then continue to Self-Practice for 4 weeks.
16467582|NCT03514849|Experimental|PCI group|
16467583|NCT03514849|Placebo Comparator|Control group|
16467584|NCT03514836|Experimental|DCVac and ONCOS-102|ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
16467585|NCT03514823|Experimental|IMT Group|
16467586|NCT03514823|Sham Comparator|No IMT Group|
16467587|NCT03514810|Placebo Comparator|Sertralin & Ketoprofen in MDD|To compare the median of Beck Depression Inventory-II (BDI-II) score of MDD patients after treatment with sertralin (50mg) daily+placebo and after treatment with combination of (sertralin & ketoprofen) for two months.
16467588|NCT03514810|Experimental|Interleukins in MDD after treatment|Some Interleukines level were estimated before and after treatment with sertralin 50 mg in combination with either placebo or ketoprofen 100mg daily.
16467589|NCT03514797|Experimental|Combined technique|A single session of in-office tooth bleaching will be performed with 35% hydrogen peroxide for 45 minutes. Following, the teeth will be further bleached with customized trays filled with 10% carbamide peroxide and used for 1h per day.
16467590|NCT03514797|Active Comparator|At-home bleaching|The teeth will be bleached only with customized trays filled with 10% carbamide peroxide and used for 1h per day.
16467591|NCT03514784|Active Comparator|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs
16467592|NCT03514784|Placebo Comparator|Placebo|Maltodextrin
16467593|NCT03514784|Active Comparator|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
16467594|NCT03514771|Other|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
16467595|NCT03514758|Experimental|normal hearing participants|normal hearing participants with and without hearing aids
16467598|NCT03514732|Experimental|Novanuit® Triple Action|2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
16467599|NCT03514719|Experimental|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-avelumab PET
16467600|NCT03514706|Experimental|Volume controlled ventilation|Group V: Patients will receive volume controlled mechanical ventilation. (Vt 7ml/kg ideal body weight).
16467601|NCT03514706|Experimental|Pressure controlled ventilation|Group P: Patients will receive pressure controlled mechanical ventilation. (to achieve Vt 7 ml/kg ideal body weight, Pmax 30 cmH2O)
16467602|NCT03514693|Active Comparator|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
16467603|NCT03514693|Placebo Comparator|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
16467604|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
16467605|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.
~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
16467606|NCT03514667|Active Comparator|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
16467607|NCT03514667|Placebo Comparator|control group|placebo capsules once a day for 12 weeks
16467608|NCT03514654|Active Comparator|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
16467609|NCT03514654|Active Comparator|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
16467610|NCT03514641|Other|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
16467611|NCT03514641|Other|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
16467612|NCT03514641|Other|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
16467613|NCT03514641|Other|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
16467614|NCT03514628|Experimental|Valsalva Assist Device (VAD)|Intervention is the use of Valsalva Assist Device (VAD) to deliver the Valsalva strain
16467615|NCT03514628|Active Comparator|Standard Care|Intervention is the use of Standard technique to deliver Valsalva strain eg blowing on empty syringe
16467616|NCT03514615|Placebo Comparator|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
16467617|NCT03514615|Experimental|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
16467618|NCT03514602|Experimental|Multicomponent behavioral intervention|The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support.
16467619|NCT03514602|Active Comparator|Control|The control group will receive smoking cessation education only.
16467620|NCT03514589|Active Comparator|Arm 1|250 mcg IV synacthen
16467621|NCT03514589|Experimental|Arm 2|Nasal Synacthen
16467622|NCT03514576|Experimental|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
16467623|NCT03514576|Experimental|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
16467624|NCT03514563||Group A|MRI imaging, Optical scan and 3D photography for patients with Class I (non-skeletal) malocclusion with no facial asymmetry or other pathology.
16467625|NCT03514563||Group B|MRI imaging, Optical scan and 3D photography for patients with Class III (skeletal-based) malocclusion with maxillary deficiency and normal vertical facial relationships, with no facial asymmetry or other pathology
16467626|NCT03514563||Group C|MRI imaging, Optical scan and 3D photography for patients with Cleft lip and/or palate and a Class III malocclusion and no other pathology
16467627|NCT03514550|Experimental|total intravenous anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia
16467628|NCT03514550|Active Comparator|Volatile anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia
16467629|NCT03514537|Experimental|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
16467630|NCT03514537|Experimental|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
16467631|NCT03514537|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
16467632|NCT03514524|Experimental|healthy ageing|
16467633|NCT03514524|Experimental|TBI|
16467634|NCT03514524|Experimental|CTE|
16467635|NCT03514524|Experimental|Ischemic stroke|
16467637|NCT03514511|Experimental|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
16467638|NCT03514511|Experimental|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
16467639|NCT03514511|Experimental|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
16467640|NCT03514511|Experimental|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
16467641|NCT03514511|Experimental|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
16467642|NCT03514511|Experimental|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
16467643|NCT03514511|Experimental|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
16467644|NCT03514511|Experimental|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
16467645|NCT03514511|Experimental|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
16467646|NCT03514498||Autism Spectrum Disorder|Children aged 4-12 years with a clinical diagnosis of mild-to-moderate Autism Spectrum Disorder undergoing dental surgery
16467647|NCT03514498||Typically Developed Controls|Children with no neurodevelopmental delays matched to Autism Spectrum Disorder participants according to age (within 6 months), gender, and ASA physical status level, scheduled to undergo dental surgery
16467648|NCT03514485|Active Comparator|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
16467649|NCT03514485|Active Comparator|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
16467650|NCT03514485|Active Comparator|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
16467651|NCT03514485|No Intervention|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
16467652|NCT03514485|Active Comparator|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
16467653|NCT03514485|No Intervention|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
16467654|NCT03514472|Active Comparator|Group A (Below 18 years)|Dried Moringa oleifera leaves (15g/recipe)
16467655|NCT03514472|Active Comparator|Group B (Above 18)|Dried Moringa oleifera leaves (15g/recipe)
16467656|NCT03514459|No Intervention|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
16467657|NCT03514459|Experimental|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
16467658|NCT03514446|Experimental|Antibiotic therapy duration for 7 days|
16467659|NCT03514446|No Intervention|Antibiotic therapy duration for 14 days|
16467660|NCT03514433|No Intervention|Historical Control|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
16467661|NCT03514433|Experimental|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
16467662|NCT03514420|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.
16467663|NCT03514407|Experimental|INCB059872|INCB059872
16467664|NCT03514394|Active Comparator|Problem Solving Therapy (PST)|6 weekly sessions to teach patients seven steps of problem solving (problem orientation, problem definition, goal setting, brain storming, decision making, action planning, solution evaluation).
16467665|NCT03514394|Experimental|Modified PST|This intervention will be a modification of PST, based on clinician feedback. It will be developed in phase 1 and 2 of this study. It will include elements of cognitive processing therapy, behavioral activation and distress tolerance. Anticipated number of sessions is 6.
16467666|NCT03514381|Other|Patients starting a treatment with Doxorubicin and Ifosfamide|
16467667|NCT03514368|Other|Patients treated with immune checkpoint blockade|
16467668|NCT03514355|Experimental|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
16467669|NCT03514355|No Intervention|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
16467670|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
16467672|NCT03514316|Active Comparator|Scalpel Gingivectomy|Patients treated with Scalpel Gingivectomy on the labial side of the anterior maxillary teeth
16467673|NCT03514316|Active Comparator|Laser Gingivectomy|Patients treated with Laser Gingivectomy on the labial side of the anterior maxillary teeth
16467674|NCT03514316|Active Comparator|Nonsurgical periodontal treatment|Patients treated with a full-mouth periodontal debridement
16467675|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
16467676|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
16467677|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
16467678|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
16467679|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
16467680|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
16467681|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
16467682|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
16467683|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
16467684|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
16467685|NCT03514290|Placebo Comparator|GPLACEBO|the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP).
16467686|NCT03514290|Experimental|GLASER|treated with Low-lever laser + tooth bleaching with 35% hydrogen peroxide (HP).
16467687|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
16467688|NCT03514277|Active Comparator|Local infiltration of Exparel|
16467689|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
16467690|NCT03514264|Experimental|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
16467691|NCT03514264|Experimental|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
16467692|NCT03514251|No Intervention|Control group|Routine thyroidectomy and central lymph node dissection
16467693|NCT03514251|Experimental|Parathyroid marker group|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker.
16467694|NCT03514238|Experimental|Adults (BMI: ≥30 kg/m2)|"Obese individuals will participate to three conditions:
~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
16467695|NCT03514238|Experimental|Adults (BMI: 18.5-24.9 kg/m2)|"Normal weight individuals will participate to three conditions:
~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
16467696|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
16467697|NCT03514212|Experimental|ProActiveS|As this was a feasibility study, all participants received the intervention.
16467698|NCT03514199|Experimental|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
16467699|NCT03514199|Active Comparator|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
16467700|NCT03514186|Experimental|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
16467701|NCT03514186|Active Comparator|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
16467702|NCT03514160|Active Comparator|Group exercise|Group exercise training at a community site. Exercises included supervised upper and lower-body strength and balance exercises twice per week. Hand-made, weighted bars were used for resistance props and balance. The exercises included: chair squats; standing single leg hip abduction; hip extension; balance heal-to-toe walking; seated hip adduction and knee extension; wall push-ups; bent-over rows; shoulder press; elbow flexion and extension).
16467703|NCT03514160|No Intervention|Attention-Control group|Attendance to community site usual activities offered to older adults. Participants in this group were offered the exercise routine after completing the 12-week study.
16467704|NCT03514147|Experimental|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
16468056|NCT03511833|Active Comparator|Morphine group|Morphine group will receive IV medication and IN saline.
16467705|NCT03514147|Active Comparator|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
16467706|NCT03514134|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
16467707|NCT03514134|Active Comparator|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
16467708|NCT03514121|Experimental|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
16467709|NCT03514108|Active Comparator|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.
~Average treatment period 4 years."
16467710|NCT03514108|Placebo Comparator|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
16467711|NCT03514108|Active Comparator|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
16467712|NCT03514108|Placebo Comparator|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
16467713|NCT03514095|No Intervention|Control Group|The control group shall participate in the usual home-based care provided by their carer.
16467714|NCT03514095|Experimental|Individual Cognitive Stimulation Therapy|The experimental group shall participate in the Making a Difference 3 program (Yates et al., 2015) is aimed at elderly people with mild or major neurocognitive disorder, where informal caregiver (family, friend or neighbour) assume a partnering role in an one-to-one approach. The program is composed by a range of stimulating activities (sessions), each with two levels of difficulty. The carers are introduced to a set of key principles that guides them during individual cognitive stimulation sessions, tailoring the interventions to the needs and reality of the elderly participants.
16467715|NCT03514082||Adolescent Idiopathic Scoliosis|Subjects with AIS who are beginning to the conservative treatment.
16467716|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
16467717|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.
~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.
~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
16467718|NCT03514056||1|group Behcet
16467719|NCT03514056||2|group fibromyalgia
16467720|NCT03514043||Ambulatory care surgical patients|Patients who have attended the surgical assessment unit with an emergency general surgical condition and have their care completed without an inpatient stay.
16467721|NCT03514043||Surgical assessment unit staff|Staff who are involved in the care of patients on the surgical assessment unit. This includes senior and junior doctors, nurses, healthcare assistants and ward receptionists.
16467722|NCT03514030||positive|serum AQP4-antibody is positive
16467723|NCT03514030||negtive|serum AQP4-antibody is negtive
16467724|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.
~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
16467725|NCT03514004|Experimental|Intervention|"The ICT-based intervention is known as Project Clan. Each participant randomized to the intervention group will have access to the web platform and mobile applications of Project Clan - a virtual community that seeks to promote adolescent mental health and wellbeing as students interact, express themselves, and resolve concerns, with the support of peers and mental health professionals. During the three-month intervention, participants will have complete anonymity, unless trained psychologists supervising the platform as community counselors identify behaviors associated with suicide risk and proceed to follow an established emergency protocol. The counselors will be available to answer community questions and provide support on an individual basis."
16467726|NCT03514004|No Intervention|Control|Participants in the control group will also be assigned a username and password to access the website, but they will be met with a user interface that only displays a space to answer the corresponding assessments. In addition to the introductory presentation, they will be given a brochure with information regarding adolescent suicide and wellbeing and tips with regard to seeking help and assisting others. This will include the contact information for a telephone hotline, to ensure they can receive professional help if needed.
16467727|NCT03513991|Experimental|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
16467728|NCT03513991|Other|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
16467729|NCT03513991|Other|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
16467730|NCT03513991|No Intervention|HM (human milk)|Participants were exclusively breastfed
16467731|NCT03513978|Experimental|IAI Protocol|A progressive exercises with transference to sport protocol, oriented to improve the proprioception.
16467732|NCT03513978|Active Comparator|FIFA 11+ Protocol|A typical exercises protocol to soccer
16467757|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
16467758|NCT03513770|Experimental|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
16467759|NCT03513770|Placebo Comparator|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
16467733|NCT03513965|Experimental|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
16467734|NCT03513965|Experimental|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
16467735|NCT03513952|Experimental|Group 1 (CYT107, atezolizumab)|Patients receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16467736|NCT03513952|Experimental|Group 2 (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16467737|NCT03513939|Experimental|T1DM Cell Pouch™ Recipients|Eligible Type 1 Diabetes Mellitus (T1DM) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch™ intervention
16467738|NCT03513926||Non-OSA group|Patients with out sleep apnea.
16467739|NCT03513926||OSA group|Patients with OSA, without cardiovascular comorbidities who could be treated with Continuous Positive Airway Pressure
16467740|NCT03513926||OSA with hypertension group|Patients with OSA, with hypertension who could be treated with Continuous Positive Airway Pressure
16467741|NCT03513926||OSA with CVE group|Patients with OSA, with a previous ictus or stroke who could be treated with Continuous Positive Airway Pressure
16467742|NCT03513913|Experimental|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
16467743|NCT03513913|Experimental|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
16467744|NCT03513900||cirrhosis|In this cross-sectional study , we will collect all patients with cirrhosis who meet the inclusion and exclusion criteria criteria coming to The Second Affiliated Hospital, Xi'an Jiaotong University since March 2018 to December 2018.
16467745|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
16467746|NCT03513874|Experimental|Metformin + Insulin|
16467747|NCT03513874|Active Comparator|Insulin alone|
16467748|NCT03513861|Experimental|Aim 1: Parental FASTER tool training|The goal is to see whether the child's parent/ guardian can be trained in overall severity of illness assessment using the FASTER Tool, to match the performance of a professional.
16467749|NCT03513861|Active Comparator|Aim 2: Intervention group|The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
16467750|NCT03513861|No Intervention|Aim 2: Control Group|The control group parents will not be taught the FASTER assessment tool. Hence they will not be involved in monitoring their child, nor signaling severity of their child's illness per color-coded flag system. Control group parents will record the frequency of healthcare provider assessments of their child over the 24 hrs enrollment period.
16467751|NCT03513848|Experimental|Bright Light|
16467752|NCT03513848|Placebo Comparator|Dim Light|
16467753|NCT03513822|Active Comparator|Chronic neuropathic pain and bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).
~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.
~Maximum 100mg. One and only perfusion."
16467754|NCT03513822|Placebo Comparator|Chronic neuropathic pain and bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).
~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.
~One and only perfusion."
16467755|NCT03513822|Active Comparator|Chronic neuropathic pain without bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).
~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.
~Maximum 100mg. One and only perfusion."
16467756|NCT03513822|Placebo Comparator|Chronic neuropathic pain without bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).
~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.
~One and only perfusion."
16467834|NCT03513302|Active Comparator|nitrate|
16468057|NCT03511833|Experimental|Ketamine group|Ketamine group will receive IV saline and IN medication.
16467760|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
16467761|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
16467762|NCT03513744|Experimental|infant formula containing five HMOs|
16467763|NCT03513744|No Intervention|infant formula|
16467764|NCT03513744|No Intervention|breast milk group|
16467765|NCT03513731|Experimental|Adipose-derived stem cell injection|ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
16467766|NCT03513731|Active Comparator|Corticosteroid injection|The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
16467767|NCT03513705|Experimental|Best practice|Enhanced implementation of best practices in pancreatic cancer care
16467768|NCT03513705|No Intervention|Current practice|Pancreatic cancer care according to current practice
16467769|NCT03513692|Active Comparator|Fill-Up composite resin|"In this arm of the study, participants will have the dental restoration completed with FillUp from Coltene, a composite resin a CE marked and licensed restorative material."
16467770|NCT03513692|Active Comparator|Conventional; composite|In this arm of the study, participants will have the dental restoration completed with a conventional composite resin using a CE marked and licensed restorative material.
16467771|NCT03513679|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
16467772|NCT03513679|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
16467773|NCT03513666|Experimental|treatment arm|Toripalimab 240 mg or 360 mg Q3W in combination with chemotherapy
16467774|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
16467775|NCT03513627||Implant|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at a dental implant born crown in the front region of the jaw
16467776|NCT03513627||Tooth|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at the contralateral natural tooth
16467779|NCT03513601|Experimental|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
16467780|NCT03513601|Experimental|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
16467781|NCT03513588|Placebo Comparator|Placebo|
16467782|NCT03513588|Experimental|PF-06865571 100 mg|
16467783|NCT03513588|Experimental|PF-06865571 600 mg|
16467784|NCT03513575|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
16467785|NCT03513575|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
16467786|NCT03513575|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
16467835|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
16467836|NCT03513276|Experimental|Multimodal analgesia + Local Infiltration Anesthesia|100cc of 2% ropivacaine + Adrenaline 10mcg/ml + 20cc saline solution
16467837|NCT03513276|Active Comparator|Multimodal analgesia + saline solution|120cc of saline solution
16467787|NCT03513575|Experimental|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
16467788|NCT03513575|Experimental|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
16467789|NCT03513575|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
16467790|NCT03513562|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
16467791|NCT03513549||Loxapine 10 MG|ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
16467792|NCT03513536|Experimental|Intervention 1|The women in this arm will receive the Citrus-Based Aromatherapy product to apply regularly for 6 days.
16467793|NCT03513536|Experimental|Intervention 2|The women in this arm will receive the Mint-Based Aromatherapy product to apply regularly for 6 days.
16467794|NCT03513536|Experimental|Intervention 3|The women in this arm will receive the Spice-Scented Aromatherapy product to apply regularly for 6 days.
16467795|NCT03513536|Placebo Comparator|Control|The women in this arm will receive a vegetable oil roll-on product to apply regularly for 6 days.
16467796|NCT03513523|Experimental|Group 1: 1X dose of NRPT|250 mg of NR and 50 mg of PT
16467797|NCT03513523|Experimental|Group 2: 2X dose of NRPT|500 mg of NR and 100 mg of PT
16467798|NCT03513523|Placebo Comparator|Group 3: Placebo|Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate
16467799|NCT03513510|Experimental|iChoose|6 biweekly family sessions, 6 biweekly telephone support calls to parents, 6 biweekly newsletters for children, and 3 supervised exercise sessions per week/3 months; delivers intervention to parents and children only
16467800|NCT03513497|Experimental|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
16467801|NCT03513497|Experimental|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
16467802|NCT03513484|Experimental|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
16467803|NCT03513471|Experimental|Anakinra then Placebo Treatment|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to the Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
16467804|NCT03513471|Experimental|Placebo then Anakinra Treatment|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
16467805|NCT03513458|Experimental|Anakinra then Placebo|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
16467806|NCT03513458|Experimental|Placebo then Anakinra|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
16467807|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
16467808|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
16467809|NCT03513432|Experimental|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day
16467810|NCT03513432|Experimental|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day
16467811|NCT03513432|Experimental|Non-alcoholic beer with 0.00 % alcohol|330 ml non-alcoholic beer (0.00 % alcohol)/day
16467985|NCT03512145|Experimental|VIPUN Balloon Catheter|Recording of gastric motility with the investigational medical device. Gastric emptying rate of a liquid meal is assessed with the 13C-octanoate breath test.
16467986|NCT03512132||control|
16467812|NCT03513419|Experimental|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
16467813|NCT03513419|No Intervention|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
16467814|NCT03513406|Active Comparator|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
16467815|NCT03513406|Active Comparator|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
16467816|NCT03513393|Experimental|A: Epclusa + omeprazole + Coca Cola (test 1)|Day 1 - 6 40mg omeprazole QD; on Day 5 a single-dose of SOF/VEL with 250 mL of Coca Cola Classic is administered (test 1).
16467817|NCT03513393|Experimental|B: Epclusa + omeprazole + water (test 2)|Day 8 - 13: 40mg omeprazole QD; on Day 12 a single-dose of SOF/VEL is administered (test 2).
16467818|NCT03513393|Active Comparator|C: Epclusa + water (Reference)|Day 15 - 21: no treatment with omeprazole; on Day 19 a single-dose of SOF/VEL is administered (reference).
16467819|NCT03513380|Experimental|Exergaming|free access to the exergame PedalTanks
16467820|NCT03513380|No Intervention|Control|recommended to continue with their normal daily routine
16467821|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.
~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
16467822|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
16467823|NCT03513354|No Intervention|Control group|The control group did not perform any of the interventions.
16467824|NCT03513354|Experimental|Soil group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
16467825|NCT03513354|Experimental|Pool group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
16467826|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
16467827|NCT03513328|Experimental|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
16467828|NCT03513328|Experimental|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
16467829|NCT03513328|Active Comparator|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
16467830|NCT03513328|Active Comparator|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
16467831|NCT03513315|Experimental|Intervention Community Clusters|For the community-based arm of the study, 16 clusters will be randomized into intervention and control groups. Those in the intervention group will receive implementation of community-based Home Heat Bundle. This Bundle includes education from community health workers on the signs and symptoms of heat-related illness, how to prevent the illness, and when to seek treatment. In addition, the intervention group will receive SMS messaging with information about heatwaves. The education and Short Message Service (SMS) messaging will occur in March and April via meetings in households and in public spaces. There will be a total of 40 activities, each lasting approximately two hours.
16467832|NCT03513315|Experimental|Control Community Clusters|Eight community clusters of 1000 population each where regular community-based healthcare services will be provided without focused interventions on identification and management of heat-related illnesses. These clusters will receive regular community healthcare provision.
16467833|NCT03513302|Placebo Comparator|placebo|
16467838|NCT03513263|Active Comparator|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
16467839|NCT03513263|Sham Comparator|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
16467840|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
16467841|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
16467842|NCT03513237|Experimental|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
16467843|NCT03513237|No Intervention|no cervical dilation group|No cervical dilation will be done.
16467844|NCT03513224|Experimental|eDosette|
16467845|NCT03513211|Experimental|Dose escalation arm|Suba-itraconazole in combination dose escalating hydroxychloroquine H
16467846|NCT03513211|Experimental|Phase II: Dose expansion arm|Suba-itraconazole with recommended phase II dose of hydroxychloroquine as determined by phase I arm.
16467847|NCT03513198||Non-resectable pancreatic cancer|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months.
~Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included.
~Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment"
16467848|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
16467849|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
16467850|NCT03513172|Active Comparator|Brimonidine Pre-Administration During First Visit|
16467851|NCT03513172|Active Comparator|Brimonidine Pre-Administration During Second Visit|
16467852|NCT03513159|Experimental|Pathfinder support|Pathfinder support with development of an individual care plan for the intervention patients and their informal caregivers, with the hospital physicians already inside the hospital setting. This will then be developed and improved further during up to twelve months after hospital release with the primary physician. The pathfinders will coordinate the ambulatory care team services and closely involve the primary physicians. The patients and their informal caregivers will be empowered and educated to achieve a stabilization or improvement in functionality, independence, quality of life, coping with disease, nutritional status and wound healing process. In the regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
16467853|NCT03513159|No Intervention|Control without pathfinder support|Control patients will not be supported by pathfinders. In regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
16467854|NCT03513146|Experimental|OPAMM group|"During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours.
~When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol.
~This practice will be continued till the infants reach full oral feeding."
16467855|NCT03513146|No Intervention|Control Group|"During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol.
~This practice will be continued till the infants reach full oral feeding."
16467856|NCT03513133|Experimental|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
16467857|NCT03513094|Experimental|Without and With Transversus Abdominis|"Without:
~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.
~With:
~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
16467858|NCT03513081|Experimental|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
16467859|NCT03513081|No Intervention|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
16467860|NCT03513068|No Intervention|Standard Of Care (SOC)|Standard of care long-term oxygen therapy
16467861|NCT03513068|Experimental|SOC + POC (Portable Oxygen Concentrator)|Standard of care long-term oxygen therapy + POC
16467862|NCT03513055|Experimental|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
16467987|NCT03512132||T1D with normal albumin levels|
16467988|NCT03512132||T1D with macroalbuminuria|
16467989|NCT03512132||T1D with microalbuminuria|
16467863|NCT03513042||Cohort|"Intervention:
~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.
~Baseline measurements:
~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.
~Interim measurements conventional):
~FDG PET-CT will be repeated at the end of the second week of IMPT.
~FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.
~A subcohort will also undergo activation PET imaging three times during IMPT."
16467864|NCT03513029|Experimental|Study Device|VytronUS Ablation System
16467865|NCT03513016|Experimental|Part A: UBX0101|Part A: UBX0101, single intra-articular injection, ascending dose
16467866|NCT03513016|Placebo Comparator|Part A: Placebo|Part A: Placebo, single intra-articular injection, ascending dose
16467867|NCT03513016|Experimental|Part B: UBX0101|Part B: UBX0101, single intra-articular injection, fixed dose
16467868|NCT03513016|Placebo Comparator|Part B: Placebo|Part B: Placebo, single intra-articular injection, fixed dose
16467869|NCT03513003|Experimental|Functional pacifier|Swap from the habitual pacifier to a functional pacifier
16467870|NCT03513003|Active Comparator|Stop habit|Stop the use of the habitual pacifier and or baby bottle
16467871|NCT03512990|Experimental|Bupivacaine - Superior Trunk Block|"Patients scheduled for rotator cuff surgery received 6 mL of 0,5% bupivacaine in the superior Trunk.
~6 mL of methylene blue will be injected into cadavers with the same technique."
16467872|NCT03512977|Experimental|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
16467873|NCT03512977|Active Comparator|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
16467874|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
16467875|NCT03512951|Experimental|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
16467876|NCT03512951|Experimental|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
16467877|NCT03512951|Experimental|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
16467878|NCT03512938|Active Comparator|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
16467879|NCT03512938|Experimental|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
16467880|NCT03512925|Experimental|Standardized post-coercion review|Intervention: Standardized post-coercion review session. Patients allocated to this arm receive a standardized post-coercion review of the coercive measure they experienced using the developed guidelines.
16467881|NCT03512925|No Intervention|Control group|Patients allocated to this arm are treated following usual standards and routine. This might include some form of post-coercion review that doesn't follow the developed standardized guidelines.
16467882|NCT03512899|Active Comparator|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
16467883|NCT03512899|Active Comparator|Axillary vein access|Axillary vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
16467884|NCT03512886|Active Comparator|Single task training|The exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
16467885|NCT03512886|Experimental|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
16467886|NCT03512886|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
16467887|NCT03512873|Experimental|Tranilast|
16467888|NCT03512860|Experimental|E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)|Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.
16467889|NCT03512860|Experimental|E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)|Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
16467890|NCT03512834|Experimental|Paclitaxel+Avelumab|Paclitaxel combination with Avelumab for inoperable angiosarcoma
16467891|NCT03512821|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
16467892|NCT03512821|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
16467893|NCT03512808|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
16467894|NCT03512808|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
16467895|NCT03512782|No Intervention|CONTROL|
16467896|NCT03512782|Experimental|INTERVENTION|
16467897|NCT03512756|Experimental|Part 1 and Part 2 SM-88 Arm|"(Part 1 enrollment complete) SM-88 used with MPS (methoxsalen, phenytoin and sirolimus)
~(Part 2 actively enrolling) SM-88 (920 mg per day) used with MPS (methoxsalen, phenytoin and sirolimus) will be administered to 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met."
16467898|NCT03512756|Experimental|Physician's Choice|Physician's Choice therapy will be administered for a total of 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
16467899|NCT03512730|Experimental|Titanium brush, H2O2 3%, plastic curettes|
16467900|NCT03512730|Active Comparator|H2O2 3%, plastic curettes|
16467901|NCT03512717|Experimental|Potenfill|
16467902|NCT03512717|Active Comparator|Powerfill|
16467903|NCT03512691|Experimental|Information on CVD risk|Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
16467904|NCT03512691|Experimental|Lottery Incentive|Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage.
16467905|NCT03512691|No Intervention|Control|No intervention will be introduced to the participants in this arm.
16467906|NCT03512665|Experimental|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
16467907|NCT03512665|Experimental|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
16467908|NCT03512665|Other|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
16467909|NCT03512652|Other|Patello|
16467910|NCT03512639|Active Comparator|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
16467911|NCT03512639|Placebo Comparator|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
16467912|NCT03512626|Experimental|Multifocal IOL (OptiVis)|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.
~The randomly assigned IOL (in this arm: a hybrid (refractive-diffractive) multifocal IOL (OptiVis, Aaren Scientific) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
16467913|NCT03512626|Active Comparator|Monofocal IOL|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.
~The randomly assigned IOL (in this arm: a monofocal IOL (AR40e, AMO) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
16467914|NCT03512600|Experimental|Study group|"All patients will follow four different dietary interventions (with or without cacao) for 1 day prior to the taking of a urine sample.
~After the sample is taken the patient will follow a washout period of 6 days before following a different diet and this process will be repeated for each patient until they have followed the four diets.
~."
16467915|NCT03512587|Experimental|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
16467916|NCT03512587|Placebo Comparator|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
16467917|NCT03512574|Experimental|Group PD|combination of pregabalin and dexmedetomidine
16467918|NCT03512574|Active Comparator|Group P|pregabalin +placebo
16467919|NCT03512574|Active Comparator|Group D|placebo + dexmedetomidine
16467920|NCT03512574|Placebo Comparator|Group C|placebo + placebo
16467921|NCT03512548|Experimental|Part 1 Period 1|Part 1 Period 1: Relacorilant 350mg will be given once on Day 1
16467922|NCT03512548|Experimental|Part 1 Period 2|Part 1 Period 2: Itraconazole 200mg will be given for three days
16467923|NCT03512548|Experimental|Part 1 Period 3|Part 1 Period 3: Relacorilant 350mg will be given once with concomitant itraconazole and itraconazole will continue for three additional days
16467924|NCT03512548|Experimental|Part 2 Period A|Part 2 Period A: Relacorilant 300mg will be given once daily for 10 days
16467925|NCT03512548|Experimental|Part 2 Period B|Part 2 Period B: Relacorilant 300mg will be given once daily in combination with itraconazole 200mg once daily for 10 days
16467926|NCT03512535||Stage 1|Samples from up to 20 participants will be used to finalise the analytical methods
16467927|NCT03512535||Stage 2|Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders
16467928|NCT03512522|Experimental|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
16467990|NCT03512132||T1D with microalbuminuria and statins|
16467991|NCT03512119||Patient|Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
16467992|NCT03512106|Experimental|Acupuncture group|Chinese traditional acupuncture
16467929|NCT03512522|Experimental|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Workbook Group will receive access to the course in a printed (workbook) format. A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
16467930|NCT03512522|No Intervention|Wait List Control Group|Participants who are randomly allocated to the wait list control group will be provided access to the course after the twelve-week period has passed.
16467931|NCT03512509|Experimental|A|Low glycaemic potato
16467932|NCT03512509|Experimental|B|High glycaemic potato
16467933|NCT03512496|Placebo Comparator|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
16467934|NCT03512496|Active Comparator|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
16467935|NCT03512496|Sham Comparator|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
16467936|NCT03512483|No Intervention|Usual Care|Control group participants will be notified of their assignment and will continue their usual care with the AF clinic receiving onsite care. Participants will be contacted at 3 time points (baseline, 3 months, and 6 months)
16467937|NCT03512483|Experimental|Virtual Atrial Fibrillation Clinic|Participants in the intervention group can expect to receive between 1 and 4 telehealth appointments over a 6 month period, as well as being contacted by the research team at 3 time points for data collection (baseline, 3 months, and 6 months). Telehealth appointments will consist of remote interactions with clinicians. Telehealth appointments will take place in participants' homes, using their personal computer/tablet/smartphone. Participants will also receive an orientation to the website and will be encouraged to visit often and utilize the resources. To promote and encourage website interaction, emails will be sent to participants once semi-monthly for the duration of the intervention with highlights and important messages from the website.
16467938|NCT03512470|Experimental|Sistema Prevena ™ (TVAC)|Negative topical pressure system (Sistema Prevena ™).
16467939|NCT03512470|Active Comparator|Standard medication|Standard medication with sterile gauzes and a TNT patch or medicated patch
16467940|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
16467941|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
16467942|NCT03512444|Experimental|Negative pressure|"Negative pressure system is applied with negative pressure (Active)
~at a participant's unilateral arm"
16467943|NCT03512444|No Intervention|No negative pressure|"Negative pressure system is applied without negative pressure (Inactive)
~at a participant's contralateral arm"
16467944|NCT03512431||Study group|Only one arm in the present study
16467945|NCT03512418|Experimental|PrEPsteps|Participants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
16467946|NCT03512418|Active Comparator|Control|Participants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
16467947|NCT03512405|Experimental|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16467948|NCT03512392|Experimental|Conservative fluid and deresuscitation|"Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)
~Daily assessment of eligibility for deresuscitation for 3 days (eligible if oedema in more than 1 site and cumulative fluid balance > 2 litres)
~Deresuscitation to target negative daily fluid balance of 1 to 3 litres:
~5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
16467949|NCT03512392|Active Comparator|Usual care|Usual care at the discretion of the treating team
16467950|NCT03512379|Experimental|Robot assisted surgery group|Spinal surgery using TIANJI Robot system.
16467951|NCT03512379|Active Comparator|Free hand surgery group|Spinal surgery using fluoroscopy-based free hand technique
16467952|NCT03512379|Active Comparator|Navigation-assisted surgery group|Spinal surgery using Navigation-assisted technique
16467953|NCT03512366|Experimental|Desarsda's technique|"These patients wil be operated by the Desarda's technique without using any prosthetic mesh. A strip of external oblique aponeurosis will be used to strengthen the defect.
~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia
~Intervention:
~A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the muscle arch or conjoint tendon above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure it to the inguinal ligament inferiorly , and will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures."
16467954|NCT03512366|Active Comparator|Lichtenstein's technique|"These patients will be operated using prosthetic mesh described as Lichtenstein's tension free mesh hernioplasty.
~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia.
~Intervention :
~A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring. Laterally, 2 cm silt will be made through the mesh to accommodate the cord. while the two tails will be sutured to create a new deep ring made of mesh."
16467993|NCT03512106|Placebo Comparator|Sham group|Sham
16467994|NCT03512093||Retrospective chart review|
16467995|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
16467996|NCT03512093||Interviews of mothers|
16468058|NCT03511807|Experimental|Electrical/ Acoustic stimulation|
16467955|NCT03512353|Experimental|Carfilzomib Plus Dexamethasone|"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.
~Participants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12."
16467956|NCT03512340|Experimental|Part A|Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SRF231 as a monotherapy in patients with advanced solid tumors and lymphoma/Chronic lymphocytic leukemia.
16467957|NCT03512340|Experimental|Part B Cohort 1|Depending upon the results from Part A of the study and the decision from the Safety Review Committee, 1 or 2 doses or dosing frequencies of SRF231 in select advanced solid and hematologic malignancies.
16467958|NCT03512327|Experimental|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
16467959|NCT03512314|Experimental|Tadekinig alfa|Active drug treatment during 26 weeks
16467960|NCT03512301|Experimental|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
16467961|NCT03512301|Experimental|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
16467962|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
16467963|NCT03512288|Active Comparator|Control|13vPnC
16467964|NCT03512275|Experimental|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
16467965|NCT03512275|Experimental|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
16467966|NCT03512262|Experimental|Abaloparatide (BA058)|Abaloparatide is an active synthetic peptide of parathyroid hormone
16467967|NCT03512262|Placebo Comparator|Placebo|Placebo with no peptide of parathyroid hormone
16467968|NCT03512249|Experimental|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.
~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
16467969|NCT03512249|Placebo Comparator|Placebo|Sterile saline for injection
16467970|NCT03512236|Experimental|BC Pram Ins|Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy
16467971|NCT03512236|Active Comparator|Symlin® and Humulin®|Simultaneous subcutaneous injections avec pramlintide and human insulin
16467972|NCT03512236|Active Comparator|Humalog®|Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy
16467976|NCT03512210|Experimental|MINMON 24 weeks with SOF/VEL 12 Weeks|Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks
16467977|NCT03512197|Experimental|Midostaurin + chemotherapy|Participants will receive Midostaurin 50mg twice a day until not achieving CR nor CRi without adequate hematologic recovery for continuation of treatment, intolerable toxicity, relapse or consent withdrawal plus chemotherapy whichever occurs first during induction and consolidation followed by midostaurin monotherapy for 12 cycles of 28 days cycle duration.Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
16467978|NCT03512197|Placebo Comparator|Midostaurin Placebo + chemotherapy|Participants will receive matching placebo to midostaurin with same dose, plus chemotherapy. Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation
16467979|NCT03512184|Other|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
16467980|NCT03512171|Experimental|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in [18F]fallypride binding relative to baseline.
16467981|NCT03512171|Placebo Comparator|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
16467982|NCT03512171|Experimental|[18F]-FE-PE2I|[18F]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
16467983|NCT03512158|Experimental|High NCPAP|Administration of high NCPAP (> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
16467984|NCT03512158|Active Comparator|NIPPV|Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
16468053|NCT03511846|Sham Comparator|Cold water irrigation and Medical Air|
16468054|NCT03511846|Experimental|Cold water irrigation and Low Flow Oxygen|
16467997|NCT03512080||Stable International Normalised Ratio|Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
16467998|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
16467999|NCT03512054|Experimental|Experimental procedure|
16468000|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
16468001|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
16468002|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
16468003|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
16468004|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
16468005|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
16468006|NCT03512015|Experimental|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.
~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
16468007|NCT03512015|Active Comparator|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
16468008|NCT03512002|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
16468009|NCT03512002|Other|Continued Current Care|Participants will continue their current care.
16468010|NCT03511989|Active Comparator|Bone Borne distractor|The device being investigated, Boneborne distraction appliance
16468011|NCT03511989|Other|Tooth borne distractor|The control device Toothborne distraction appliance
16468012|NCT03511989|No Intervention|Segmental LF1 osteotomy group 1|Control Group, no stabilization of palatal vault
16468013|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 2|Testgroup, biodegradable plate at osteotomy site in palate
16468014|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 3|Testgroup, autologous bonegraft at palatal osteotomy site
16468015|NCT03511976|No Intervention|Business as Usual (BAU)|One-third of participants will be assigned to this condition and will receive academic accommodations and interventions as deemed appropriate by their teachers, school personnel, and parents. This condition is intended to mirror current standard procedures for youth with ADHD. Thus, the specific accommodations and interventions are expected to vary across students. Some students' parents and physicians may choose to start stimulant medication with a goal of improving classroom performance.
16468016|NCT03511976|Experimental|Response to Intervention (RTI): Tier 1|Two-thirds of participants will be assigned to the RTI Tier 1 Arm. Teachers of students in this arm will receive consultation in RTI Tier 1 Classroom Management strategies.
16468017|NCT03511976|Experimental|RTI: Daily Report Card (DRC)|Students assigned to the RTI Tier 1 Arm, who do not respond to the initial RTI Tier 1 Classroom Management strategies, will move to the RTI DRC Arm of the study. Teachers of students in this arm of the study will receive consultation to implement a daily report card.
16468018|NCT03511976|Experimental|RTI: Enhanced|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the RTI: Enhanced Arm. Students in this arm will receive a more intensive classroom behavioral intervention directed at individual target behaviors through an enhanced DRC.
16468019|NCT03511976|Experimental|Medication|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the Medication arm and will receive stimulant medication as an additional intervention.
16468020|NCT03511963|Experimental|HLX04|
16468021|NCT03511963|Active Comparator|Bevacizumab|
16468022|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
16468023|NCT03511937|Other|Neutral Label|
16468024|NCT03511924|Experimental|Intradialytic resistance training|During the 12-week intradialytic training plan subjects will be performed 3 to 5 sets of 3 different lower extremities exercises, each set will consist of 12 up to 18 repetitions of a single exercise. Subjects will take 1 to 2 minutes rest between each set. The resistance training will be realized 3 times per week and will be performed during haemodialysis therapy.
16468025|NCT03511924|No Intervention|Control programme|Control subjects will receive no intervention during the 12-weeks of the experiment. Through the 12-week control period, all participants will be instructed to maintain a standard treatment regimen and to maintain their customary dietary and physical activity patterns.
16468026|NCT03511911|Experimental|GROUP A1|In GROUP A1, participants are all healthy women.A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group A1 will be tested by inspector B twice in the same way as what they have done the first day.
16468027|NCT03511911|Experimental|GROUP A2|In GROUP A2,participants are all healthy women.A gynecological physician evaluates participant's pelvic floor muscle strength by vaginal palpation without telling the participant her result, and records it on a unique paper other than in the Case Report Form as what GROUP A1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group A2 will be tested by inspector A twice in the same way as what they have done the first day.
16468028|NCT03511911|Experimental|GROUP B1|In GROUP B1,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the patient her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,patients in group B1 will be tested by inspector B twice in the same way as what they have done the first day.
16468029|NCT03511911|Experimental|GROUP B2|In GROUP B2,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP B1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,patients in group B2 will be tested by inspector A twice in the same way as what they have done the first day.
16468030|NCT03511911|Experimental|GROUP C1|In GROUP C1,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group C1 will be tested by inspector B twice in the same way as what they have done the first day.
16468031|NCT03511911|Experimental|GROUP C2|In GROUP C2,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP C1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group C2 will be tested by inspector A twice in the same way as what they have done the first day.
16468032|NCT03511898|Experimental|THR-149 dose level 1|
16468033|NCT03511898|Experimental|THR-149 dose level 2|
16468034|NCT03511898|Experimental|THR-149 dose level 3|
16468035|NCT03511885||high cardiovascular risk patients|"Coronary patients
~Elective coronary artery bypass surgery (CABG).
~Elective percutaneous coronary intervention (PCI) .
~Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).
~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
16468036|NCT03511872|Experimental|Peers' group|"36 Medical students are allocated randomly to Peers' group where they are trained on BLS skills by senior students.
~Four students from the latest three years of study in medical schools in Syria (4th, 5th, and 6th) are randomly selected and enrolled to be instructors for basic life support training course to transfer the resuscitation skills to medical students from pre-clinical years."
16468037|NCT03511872|Experimental|Professionals' group|36 students are allocated randomly to professionals' group where they are trained on BLS skills by professional trainers in emergency. Four professionals (2 emergency doctors, cardiologist and anesthesiologist) are leading training to the control group to deliver the basic life support training course with the same duration and content as the intervention group.
16468038|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
16468039|NCT03511859||Cancer Group|The biopsy result is breast cancer.
16468040|NCT03511846|Experimental|Oral capsaicin|
16468041|NCT03511846|Sham Comparator|Oral capsaicin and Medical Air|
16468042|NCT03511846|Experimental|Oral Capsaicin and Low Flow Oxygen|
16468043|NCT03511846|Experimental|Oral capsaicin and High Flow Oxygen|
16468044|NCT03511846|Experimental|Topical capsaicin|
16468045|NCT03511846|Sham Comparator|Topical capsaicin and Medical Air|
16468046|NCT03511846|Experimental|Topical capsaicin and Low Flow Oxygen|
16468047|NCT03511846|Experimental|Topical capsaicin and High Flow Oxygen|
16468048|NCT03511846|Experimental|Intranasal capsaicin|
16468049|NCT03511846|Sham Comparator|Intranasal capsaicin and Medical Air|
16468050|NCT03511846|Experimental|Intranasal capsaicin and Low Flow Oxygen|
16468051|NCT03511846|Experimental|Intranasal capsaicin and High Flow Oxygen|
16468052|NCT03511846|Experimental|Cold water irrigation|
16468059|NCT03511794||hep B vaccine|1. Patient must have received at least one dose of the hepatitis B vaccine
16468060|NCT03511781|Experimental|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
16468061|NCT03511768|Experimental|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
16468062|NCT03511755|Experimental|TEN 1-11 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-11 kHz)
16468063|NCT03511755|Active Comparator|TEN 1-3 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-3 kHz)
16468064|NCT03511729||A single exposure to general anesthesia|Participants who have surgery under general anesthesia (without anesthesia/surgery before)
16468065|NCT03511729||Multiple exposures to general anesthesia|Participants who have surgery under general anesthesia (had anesthesia/surgery before)
16468066|NCT03511703|Experimental|Apatinib|
16468067|NCT03511703|Other|TACE|
16468068|NCT03511690|Experimental|Immediate BRCA-Gist Intervention|Participants randomized to immediate BRCA-gist will complete the adapted intervention and immediately complete a baseline survey. They will be asked to complete a second survey two weeks after completion of the first one. BRCA-gist is a web-based tutoring system that emulates one-to-one human tutoring via avatars to communicate risk of BRCA1/2. We estimate a completion time of 90 minutes.
16468069|NCT03511690|Experimental|Delayed BRCA-Gist Intervention|Participants randomized to delayed BRCA-gist will initially complete a baseline survey. Two weeks after completion of that survey, they will complete the adapted intervention and immediately complete a second survey.
16468070|NCT03511677|Experimental|Intervention Group|Customized insole with metatarsal support
16468071|NCT03511677|Placebo Comparator|Control Group|Placebo flat insole
16468072|NCT03511664|Experimental|177Lu-PSMA-617 plus BS/BSC|Patients randomized to receive the investigational product will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) may be used
16468073|NCT03511664|Other|BS/BSC alone|Patients randomized to this arm will receive best supportive/best standard of care (BS/BSOC) as determined by the investigator
16468074|NCT03511651|Other|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
16468075|NCT03511651|Experimental|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
16468078|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
16468079|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
16468080|NCT03511612|Other|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
16468081|NCT03511612|Other|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
16468082|NCT03511599|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
16468083|NCT03511599|Active Comparator|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
16468084|NCT03511560|Active Comparator|Tacrolimus, Immediate release|Tacrolimus (immediate-release) will be administered twice daily per clinical judgment of supervising physician (dosing and monitoring in accordance with center protocol) to a minimum whole blood tacrolimus concentration of at least 8 ng/mL.
16468085|NCT03511560|Experimental|Envarsus XR|Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
16468086|NCT03511547|Active Comparator|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
16468087|NCT03511547|Active Comparator|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
16468088|NCT03511547|No Intervention|Control|
16468089|NCT03511534|Active Comparator|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
16468090|NCT03511534|Active Comparator|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
16468091|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:
~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
16468122|NCT03511274|No Intervention|Treatment as usual (TAU)|Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.
16468124|NCT03511261|Active Comparator|Curcumin capsules 500mg|"Group 2 patients:
~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
16468092|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:
~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
16468093|NCT03511508|Active Comparator|ChroPreg|The participants in the intervention Group receive the midwife-coordinated, individualized and specialized intervention plus standard care
16468094|NCT03511508|No Intervention|Standard care alone|"Participants in the control group receive the standard care for pregnant women with chronic disease.
~The standard care is given to the participants in the control group. The standard care for pregnant women with chronic disease include five routine visits at a non-specialized midwife and an individually scheduled number of visits with an obstetrician, depending on the type and severity of the chronic Medical disease and possible pregnancy complications.
~The women in the control Group have the same amount of ultrasound examinations as do the women in the intervention Group.
~Women in the control Group can attend auditorium antenatal classes at the hospital."
16468095|NCT03511495||Keratoconic Patients|
16468096|NCT03511482|Experimental|MyAsthma Application and Lloyds Pharmacy Online Doctor|Web based applications to support people with Asthma management
16468097|NCT03511482|Experimental|MyAsthma Application and Usual care|Web based application to support people with Asthma Management
16468098|NCT03511482|No Intervention|Usual care only (control)|Usual care of asthma management
16468099|NCT03511469|Experimental|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
16468100|NCT03511469|Experimental|Isokinetic Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
16468101|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
16468102|NCT03511443|Other|Diagnostic performance of hsRDT|Comparing diagnostic power of two diagnostics
16468104|NCT03511404|Experimental|Chronical LBP|Patients with chronic low back pain to be measured with Numeric Pain Rating Scale (NPRS).
16468105|NCT03511391|Experimental|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:
~Nivolumab or Pembrolizumab or Atezolizumab + SBRT"
16468106|NCT03511391|Active Comparator|Control arm|"Checkpoint inhibitor treatment only:
~Nivolumab or Pembrolizumab or Atezolizumab monotherapy"
16468107|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
16468108|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
16468109|NCT03511365|Experimental|Probiotic administration|After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
16468110|NCT03511352|No Intervention|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
16468111|NCT03511352|Experimental|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
16468112|NCT03511352|Experimental|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
16468113|NCT03511339|No Intervention|Control|Brain rest
16468114|NCT03511339|Experimental|TecTraum Device|Treatment with study device
16468115|NCT03511326|Experimental|Luxerm®|
16468116|NCT03511313|Experimental|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
16468117|NCT03511313|Sham Comparator|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
16468118|NCT03511300|Placebo Comparator|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
16468119|NCT03511300|Experimental|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
16468120|NCT03511287|Experimental|IMT group|"Group intervention: home-based interval inspiratory muscle training:
~during 8 weeks (two sessions per day, daily)
~two times 30 breaths with one-minute rest between them in each session
~training resistance set to the highest tolerable load according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher adjusted in the supervised weekly session"
16468121|NCT03511274|Experimental|Hygiene based educational film|Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
16468123|NCT03511261|Active Comparator|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel
~Group 1 patients:
~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
16468125|NCT03511261|Active Comparator|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:
~Drug: 5% Curcumin mucoadhesive gel & Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
16468126|NCT03511261|Placebo Comparator|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
16468127|NCT03511248|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
16468128|NCT03511248|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
16468129|NCT03511222|Experimental|Dose Escalation: Vorolanib + Nivolumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.
~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle
~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
16468130|NCT03511222|Experimental|Dose Escalation: Vorolanib + Pembrolizumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level
~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle
~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
16468131|NCT03511222|Experimental|Vorolanib + Nivolumab (Small Cell Lung Cancer)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at 300 mg daily
~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle
~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
16468132|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
16468133|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
16468134|NCT03511196|Experimental|Adaptive ADT+ Standard of Care|Participants will undergo 12-16 weeks of GnRH analog, along with 8-12 weeks of combinational therapy with GnRH analog and abiraterone plus prednisone. 14 participants who achieve >75% PSA decline after the run-in period will be enrolled. GnRH analog and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 4 weeks during the run-in period, then every 6 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
16468135|NCT03511183|Experimental|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.
~The second stage: continue to apply another plan until there is progress or intolerance."
16468136|NCT03511183|Placebo Comparator|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
16468137|NCT03511170|Experimental|alternative regiment|The first stage:XELOX chemotherapy and XELIRI chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.
16468138|NCT03511170|Placebo Comparator|classical regiment|Use the XELOX chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI chemotherapy until there is progress or intolerance.
16468141|NCT03511144|Active Comparator|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
16468142|NCT03511144|Active Comparator|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
16468192|NCT03511066|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
16468151|NCT03511118||Tranexamic acid (TXA)|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468152|NCT03511118||labetalol|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468153|NCT03511118||metformin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468154|NCT03511118||nifedipine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468155|NCT03511118||clindamycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468156|NCT03511118||oxycodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468157|NCT03511118||azithromycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468158|NCT03511118||escitalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468159|NCT03511118||sertraline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468160|NCT03511118||ondansetron|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468161|NCT03511118||Ciprofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468162|NCT03511118||Doxycycline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468163|NCT03511118||Levofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468164|NCT03511118||Methylphenidate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468165|NCT03511118||Sumatriptan|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468193|NCT03511053|Experimental|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
16468166|NCT03511118||Citalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468167|NCT03511118||Cyclobenzaprine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468168|NCT03511118||Furosemide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468169|NCT03511118||Gabapentin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468170|NCT03511118||Hydrochlorothiazide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468171|NCT03511118||Hydroxyurea|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468172|NCT03511118||Rosuvastatin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468173|NCT03511118||Topiramate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468174|NCT03511118||Trazodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468175|NCT03511118||Valganciclovir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468176|NCT03511118||Venlafaxine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468177|NCT03511118||Verapamil|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468178|NCT03511118||Remdesivir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468179|NCT03511118||Anakinra|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468180|NCT03511118||Tocilizumab|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468181|NCT03511118||Fluvoxamine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
16468182|NCT03511105|Experimental|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
16468183|NCT03511105|Placebo Comparator|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
16468184|NCT03511092|Experimental|HMB-FA|
16468185|NCT03511092|Experimental|HMB-Ca|
16468186|NCT03511092|Experimental|alfa-HICA|
16468187|NCT03511092|Placebo Comparator|Placebo|
16468188|NCT03511079|Experimental|Music|This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
16468189|NCT03511079|No Intervention|Control|This group will not listen to music each night for the duration of the study.
16468190|NCT03511066|Experimental|CT-P27 Dose1|CT-P27 will be administrated once in IV infusion.
16468191|NCT03511066|Experimental|CT-P27 Dose2|CT-P27 will be administrated once in IV infusion.
16468195|NCT03511027|Experimental|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
16468196|NCT03511027|Active Comparator|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
16468197|NCT03511014|Experimental|microcurrent|
16468198|NCT03511014|Sham Comparator|control|
16468199|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
16468200|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
16468202|NCT03510975|Sham Comparator|Verbal Behavioral Therapy|All children and their parents were instructed only a verbal behavioral therapy
16468203|NCT03510975|Experimental|Check-list|All participants were instructed a behavioral therapy with a written formed check-list for parents to complete
16468204|NCT03510975|Active Comparator|Desmopressin plus verbal therapy|All children in Group III received desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) plus verbal behavioral therapy.
16468205|NCT03510962|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice."
16468206|NCT03510962|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
16468207|NCT03510962|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
16468208|NCT03510962|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will Brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the brushing as an intervention."
16468209|NCT03510962|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
16468210|NCT03510962|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
16468211|NCT03510949|Other|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
16468212|NCT03510949|Other|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
16468213|NCT03510936|No Intervention|blue light phototherapy|the patients in this arm will not receive probiotics.
16468214|NCT03510936|Experimental|probiotics concurrent with phototherapy|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks
16468215|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
16468216|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
16468217|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
16468218|NCT03510910|Experimental|Percocet only|
16468219|NCT03510897|Active Comparator|QPI-1002|QPI-1002 Injection, Single dose
16468220|NCT03510897|Placebo Comparator|Placebo|isotonic saline
16468221|NCT03510884|Experimental|Alirocumab|Alirocumab (one of 4 doses, depending on body weight and Q2W or Q4W dose regimens) will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
16468222|NCT03510884|Placebo Comparator|Palcebo|Alirocumab Placebo will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose
16468223|NCT03510871|Experimental|nivolumab plus ipilimumab|nivolumab plus ipilimumab
16468224|NCT03510858|Experimental|Intervention group|
16468225|NCT03510858|Other|Control group with crossover|Participants in the control group will receive the intervention after 12 months, cross-over design
16468226|NCT03510845|Experimental|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
16468227|NCT03510845|Other|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
16468228|NCT03510832||STEMI patients undergoing Emergent PCI|
16468229|NCT03510806|Placebo Comparator|Placebo|taste, color, and calorie-matched to supplement
16468230|NCT03510806|Experimental|Supplement|Proprietary protein and fruit extract blend
16468231|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
16468232|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
16468233|NCT03510780|Active Comparator|EMD treated patients|"Periodontal surgery with Enamel Matrix Derivative is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers EMD will be applied to the entire root surfaces ; then, ABG will be applied alternatively with EMD into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositionated and sutures completed by interrupted sutures."
16468234|NCT03510780|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
16468235|NCT03510767|Experimental|TQ-B3525|
16468236|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
16468237|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
16468238|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
16468239|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
16468240|NCT03510728|No Intervention|No single-session intervention-EMA|Participants will be assessed both using a computer and using their phone. However, they will not receive an intervention at the start of the study and will only be using their phone for ecological assessment only data collection.
16468241|NCT03510728|Active Comparator|Standard single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will interact with their phone only for assessment purposes.
16468242|NCT03510728|Experimental|Augment single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will interact with their phone only for assessment purposes.
16468243|NCT03510728|Experimental|No single-session intervention-EMI|Participants in this group will not take a single-session intervention at baseline, but will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
16468244|NCT03510728|Experimental|Standard single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
16468245|NCT03510728|Experimental|Augment single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
16468246|NCT03510715|Experimental|Alirocumab|"Participants with BW less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to [>=] 50 kg.
~Participants with BW >=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks."
16468247|NCT03510702||Periodontal patients.|Taking gingival Crevicular fluid.
16468248|NCT03510702||Periodontally healthy patients.|Taking gingival Crevicular fluid.
16468249|NCT03510689||Group 1|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
16468250|NCT03510689||Group 2|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer does not include anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
16468251|NCT03510689||Group 3|Subjects with genetic testing confirming no mutation in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
16468252|NCT03510676|Experimental|NiTiDES|Single arm
16468253|NCT03510663|Experimental|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
16468254|NCT03510663|Experimental|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
16468255|NCT03510663|Active Comparator|Moxifloxacin|400mg tablet will be administrated once a week.
16468256|NCT03510663|Placebo Comparator|Placebo|Placebo will be intravenously administered once a week.
16468257|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH [anticipated]
16468258|NCT03510624|Experimental|First rebaudioside A and then placebo|
16468259|NCT03510624|Experimental|First placebo and then rebaudioside A|
16468260|NCT03510611|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
16468261|NCT03510611|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
16468262|NCT03510598|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental area with a new applicator design.
16468263|NCT03510598|Experimental|Drug Treatment for Fat Reduction|Kybella will be used after two treatments with the ZELTIQ applicator.
16468264|NCT03510585|Experimental|saline and sniffing|This RRC is the combination of positioning (laying down), sniffing (only one side), throat vibration and saline instillation. And then the other side.
16468265|NCT03510585|Placebo Comparator|sniffing|Pacient will be in a lay down condition and will perform sniffing with throat vibration several times each side (but with no saline instillation)
16468266|NCT03510572|Experimental|Healthy volunteer|Cognitively healthy subjects will receive a single IV injection of [18F]PI-2620.
16468267|NCT03510572|Experimental|Alzheimer's Disease|Alzheimer's Disease Subjects will receive a single IV injection of [18F]PI-2620.
16468268|NCT03510572|Experimental|Frontotemporal dementia|frontotemporal dementia Subjects will receive a single IV injection of [18F]PI-2620.
16468269|NCT03510572|Experimental|Parkinson's disease|Parkinson's disease Subjects will receive a single IV injection of [18F]PI-2620.
16468270|NCT03510559|Active Comparator|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
16468271|NCT03510559|Experimental|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
16468272|NCT03510546|Experimental|Active|"De-novo: Each capsule contains 60 mg. pyridostigmine. 1 capsule is administered twice within 4 hours.
~Chronic: Each capsule contains 60 mg. pyridostigmine. Number of administered capsules per dosage depend on the patient's usual dosage. Study drug is administered twice within 4 hours.
~Patients are examined/rated before 1st dose, 1 hour after 1st dose, 1 hour after 2nd dose (Visit 1). After cross-over (Visit 2), patients will be rated open-label at 1 month (Visit 3) and 3 months (Visit 4)."
16468273|NCT03510546|Placebo Comparator|Placebo|"Same as Active, however capsules contain placebo."
16468274|NCT03510533|Experimental|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
16468275|NCT03510533|Other|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
16468276|NCT03510520|Experimental|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
16468277|NCT03510520|Active Comparator|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
16468278|NCT03510494|Experimental|Intervention|Trebling of weekly curricular physical education (270 minutes per week)
16468279|NCT03510494|No Intervention|Control|Standard curriculum physical education (90 minutes per week)
16468280|NCT03510481|Experimental|Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
16468411|NCT03509545|Active Comparator|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
16468673|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=40 group
16468281|NCT03510481|Experimental|Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
16468282|NCT03510481|Placebo Comparator|Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks|Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
16468283|NCT03510481|Placebo Comparator|Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks|Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
16468284|NCT03510468|Experimental|1|(1) TAF once daily alone (days 1-14) and (2) TAFonce daily + weight-based RPT + INH (withpyridoxine) once weekly (days 15-31)
16468285|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
16468291|NCT03510429|Active Comparator|Routine post-op care|Routine post-op care (N=20)
16468292|NCT03510429|Experimental|Routine post-op care with Nutritional supplement|Routine post-op care + Nutritional supplement by specific product (N=20)
16468293|NCT03510416|Experimental|apatinib combined with TACE|Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.
16468294|NCT03510403|Experimental|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
16468295|NCT03510390|Experimental|Metformin|Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
16468296|NCT03510377|Experimental|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
16468297|NCT03510377|Experimental|On-land physical intervention|On-land physical intervention: Tai-Chi
16468298|NCT03510377|Experimental|Non physical intervention|Non physical intervention: Guided imagery
16468299|NCT03510364|Experimental|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
16468300|NCT03510351||Treated subjects|All patients with Pseudomonas infections treated with ceftolozane-taezobactam who meet the inclusion criteria
16468301|NCT03510338|Experimental|Sublingual sildenafil (fasted)|Subjects receive a single dose of 100 mg sildenafil
16468302|NCT03510338|Active Comparator|Oral sildenafil (fed)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
16468303|NCT03510338|Experimental|Sublingual sildenafil (fed)|Subjects receive a single dose of 100 mg sildenafil
16468304|NCT03510338|Active Comparator|Oral comparator (fasted)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
16468305|NCT03510325|Experimental|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
16468306|NCT03510325|Experimental|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
16468307|NCT03510325|Experimental|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
16468308|NCT03510325|Experimental|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
16468309|NCT03510325|Experimental|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
16468310|NCT03510312||Long-term follow up, observational|This cohort does not involve interventions, just follow up of prognosis of ischemic stroke/transient ischemic attack patients.
16468311|NCT03510299|Placebo Comparator|Control group|
16468312|NCT03510299|Experimental|McGrath group|
16468732|NCT03507413|Active Comparator|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: Glucophage 500mg Tablet (2-0-2) daily for 1 year
16468313|NCT03510286||Pregnant women|Pregnant women attending ANC clinics in Techiman Holy Family Hospital and Kintampo North and South districts (all hospitals and clinics inclusive where ANC services are provided) are the primary participant group- primarily women of reproductive age. Pregnant women attending routine ANC will be enrolled. In addition to routine ANC, pregnant women will be tested with the Test-it™ PrCr Urinalysis Strips. Pregnant women are a potentially vulnerable population whose participation in this research is necessary given the target use case for this diagnostic tool: providing reliable and accurate point of care screening of proteinuria in ANC settings. The legal age of consent in Ghana is 18 years and women under the age of 18 will not be recruited for this study.
16468314|NCT03510273|Other|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
16468315|NCT03510260|Placebo Comparator|Control Group|Subject will undergo regular consenting only. At our unit consent for an elective cesarean delivery occurs in the same day of surgery, few hours before the procedure in a private room in labor and delivery while awaiting surgery. The COMRADE questionnaire (our primary outcome) will be obtained after the completion of the paper consent form.
16468316|NCT03510260|Experimental|Study Group I|Subject will receive an electronic invitation to complete the consent process electronically and will proceed through the Confirmed Consent system prior to arrival to labor and delivery on day of surgery, which is the routine patient flow at this time. The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group) before the completion of the paper consent form, in order to assess satisfaction and understanding of the e-confirmed consenting process completed before the procedure. After completion of the survey, the subject will sign the regular paper consent for the procedure as standard in our institution.
16468317|NCT03510260|Experimental|Study Group II|Subject will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent is obtained in order to assess whether both methods combined together improve the subjects' satisfaction of the consenting methods and better understanding of the surgical procedure.
16468318|NCT03510221|Active Comparator|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
16468319|NCT03510221|Placebo Comparator|Placebo|Subjects received 3 placebo capsules during 4 weeks.
16468320|NCT03510208|Experimental|Cohort 1 -50mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
16468321|NCT03510208|Experimental|Cohort 2 -100mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
16468322|NCT03510208|Experimental|Cohort 3 -100mg panitumumab-IRDye800|Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery
16468323|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
16468324|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
16468325|NCT03510169|Experimental|NeoVest|Negative pressure ventilation using NeoVest
16468326|NCT03510156|Experimental|Treatment|
16468327|NCT03510156|No Intervention|Observation|
16468328|NCT03510143|No Intervention|Control|No use of Neoveil in the neck node dissection area
16468329|NCT03510143|Experimental|Neoveil|Use of Neoveil in the neck node dissection area
16468330|NCT03510130|Experimental|Routine leg movement|Intervention group- In the second stage of labor, attending physician or nurse will help the participant in routine leg movements every 20-30 minutes.
16468331|NCT03510130|No Intervention|Control group|Control group which includes women during the second stage of labor with no intervention (routine leg movement).
16468332|NCT03510117|Other|Mindfulness|Mindfulness
16468333|NCT03510104|Experimental|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
16468334|NCT03510091|Experimental|Video-Assisted Counseling|Patients receiving video-assisted counseling
16468335|NCT03510078|Experimental|Intensive glycemic control|With a target of blood glucose range of 130 mg/dL or less
16468336|NCT03510078|Experimental|Conventional glycemic control|With a target of blood glucose range of 130-180 mg/dL
16468337|NCT03510052|Other|Diet Modification Pilot Program|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
16468338|NCT03510039|Active Comparator|"Before Group"|35 Thirds benefiting from the usual care
16468339|NCT03510039|Experimental|"After Group"|"Recruit 35 Thirds for the phase phase After : Early device / Follow up by nurses"
16468340|NCT03510026|Other|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
16468341|NCT03510013|Experimental|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
16468342|NCT03510000|Experimental|Main arm|Single arm open-label cross-over study with random order of SGLT-2 inhibitor intervention (Empagliflozin 25mg po qd), in which each cross-over phase includes different meal strategies (carbohydrate counting, meal announcement, no meal announcement) on separate days in the setting of single hormone artificial pancreas
16468343|NCT03509987|Other|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
16468412|NCT03509519|Experimental|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
16468345|NCT03509961|Other|Observational Arm|"Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.
~If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome."
16468346|NCT03509961|Other|Treatment Arm|Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.
16468347|NCT03509948|Experimental|Schedule A: Fed Then Fasted|"Schedule A (6 participants):
~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)
~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
16468348|NCT03509948|Experimental|Schedule B: Fasted Then Fed|"Schedule B (6 participants):
~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)
~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
16468349|NCT03509935|Experimental|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:
~In the first 6 to 12 hours of admission to ICU
~Second US after 12-24 hours of inclusion.
~Third US after 24-48 hours of inclusion.
~Protocol:
~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.
~US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.
~Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.
~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
16468350|NCT03509935|No Intervention|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
16468351|NCT03509922|Experimental|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
16468352|NCT03509922|Experimental|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
16468353|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
16468354|NCT03509909|Active Comparator|Supportive physical activity|12-week group-based stretching and strengthening class
16468355|NCT03509896||Participants newly diagnosed with CML-CP|
16468356|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
16468357|NCT03509883|Active Comparator|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
16468358|NCT03509870|Other|mesenchymal stromal cells|mesenchymal stromal cells in collagen scaffold
16468359|NCT03509857|Placebo Comparator|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
16468360|NCT03509857|Experimental|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
16468361|NCT03509844|Experimental|Prolonged Exposure|Psychotherapy: 10 weeks, Prolonged Exposure (individual sessions) according to the manual developed by Foa et al., adapted for a residential care setting
16468362|NCT03509844|Experimental|STAIR|Psychotherapy: 10 weeks, Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting
16468363|NCT03509844|Experimental|STAIR/NT|Psychotherapy: 16 weeks, 10 weeks Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), followed by 6 weeks of Narrative Therapy (NT) (individual sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting.
16468364|NCT03509831|Other|INT2150-A|
16468365|NCT03509831|Other|INT2150-B|
16468366|NCT03509818|Experimental|Plyometric|Effects of plyometric acute exercise
16468367|NCT03509818|Experimental|Aerobic|Effects of aerobic acute exercise
16468368|NCT03509805|Experimental|OSA in obese patient during pregnancy|OSA in polysomnography
16468369|NCT03509805|Experimental|no OSA in obese patient during pregnancy|no OSA in polysomnography
16468370|NCT03509792|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
16468371|NCT03509792|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
16468372|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
16468373|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
16468374|NCT03509753|Experimental|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
16468375|NCT03509753|Active Comparator|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
16468376|NCT03509740|Experimental|tramadol|Intravenous 100 mg tramadol in 100 ml saline with slow infusion over 10 minutes.
16468377|NCT03509740|Active Comparator|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion over 10 minutes.
16468378|NCT03509714|Active Comparator|Experimental: Part 1 Oxaloacetate Random|Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
16468379|NCT03509714|Active Comparator|Experimental: Part 2 Oxaloacetate Second|Participants take 2 capsules of 250 mg rice flour (Placebo) per day during their entire menstrual cycle (approximately 28 days). After one menstrual cycle, they cross-over to 2 capsules of Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend.
16468473|NCT03509181|Active Comparator|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
16468380|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
16468381|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
16468382|NCT03509688|Experimental|entecavir|drug:entecavir 0.5mg/day, one time/day,144weeks
16468383|NCT03509688|Experimental|entecavir+resveratrol|entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks
16468384|NCT03509688|Experimental|entecavir+thymosin α1|entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks
16468385|NCT03509675|Placebo Comparator|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
16468386|NCT03509675|Active Comparator|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
16468387|NCT03509662|Placebo Comparator|Placebo group|Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
16468388|NCT03509662|Active Comparator|Vitamin C - 3 gr/day|Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
16468389|NCT03509662|Active Comparator|Vitamin C - 10 gr/day|Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
16468390|NCT03509649|Experimental|Experienced - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from an experienced clinician
16468391|NCT03509649|Experimental|Experienced - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from an experienced clinician
16468392|NCT03509649|Active Comparator|Novice - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from a novice clinician
16468393|NCT03509649|Active Comparator|Novice - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from a novice clinician
16468395|NCT03509623|Experimental|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
16468396|NCT03509610|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
16468397|NCT03509610|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
16468398|NCT03509610|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
16468399|NCT03509597|Experimental|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
16468400|NCT03509597|Experimental|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
16468401|NCT03509597|Sham Comparator|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
16468402|NCT03509584|Experimental|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
16468403|NCT03509584|Experimental|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
16468404|NCT03509584|Experimental|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
16468405|NCT03509584|Experimental|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
16468408|NCT03509558|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
16468409|NCT03509558|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
16468410|NCT03509545|Experimental|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
16468413|NCT03509519|Sham Comparator|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
16468414|NCT03509506|No Intervention|Non-App Group|"The participants will be instructed to continue their daily routine, track their daily steps with a pedometer, and record their daily steps on the Activity Log paper form."
16468415|NCT03509506|Experimental|App Group|The participants will be trained how to use the mobile application (Heart Failure Health Storyline (HFHS)) to track their health status, physical activity, manage their medications schedule, and explore the other features that the application has. Additionally, they will receive a pedometer to track their daily steps and record their data on the mobile application.
16468416|NCT03509493||Patients without structural heart disease|
16468417|NCT03509493||Patients with structural heart disease|
16468418|NCT03509493||Patients with high risk parameters for AF development|
16468419|NCT03509493||Patients post-cryptogenic stroke|
16468420|NCT03509493||Patients post-cardioversion therapy|
16468421|NCT03509493||Patients post-ablation therapy|
16468422|NCT03509480|Active Comparator|Curettage with Vitoss|ultraporous beta-tricalcium phosphate mixed with autologous bone marrow aspirate for patients undergoing surgical curettage for benign bone lesions
16468423|NCT03509480|Active Comparator|Curettage with Prodense|ultraporous beta-tricalcium phosphate mixed with calcium sulfate for patients undergoing surgical curettage for benign bone lesions
16468428|NCT03509454||Type 1 DM, Normo albuminuric|Type 1 diabetics with no history of albumnuria (UACR < 30 mg/g in 2 out of 3 consecutive samples)
16468429|NCT03509454||Type 1 DM, Micro albuminuric|Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
16468430|NCT03509454||Type 1 DM, Macro albuminuric|Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
16468431|NCT03509454||Healthy subjects|Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.
16468432|NCT03509441||South Asians with Insulin Resistance|125 patients (anticipated)
16468433|NCT03509441||South Asians without Insulin Resistance|125 patients (anticipated)
16468434|NCT03509428|No Intervention|Control|Usual care plus additional monitoring
16468435|NCT03509428|Experimental|SRETP|Structured Responsive Exercise Training Programme (SRETP) prior to surgery
16468436|NCT03509428|Experimental|Psychological support|Psychological support prior to surgery
16468437|NCT03509428|Experimental|SRETP and psychological support|Structured Responsive Exercise Training Programme (SRETP) and psychological support prior to surgery
16468438|NCT03509402|Experimental|Short implants|A full-arch screw-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6mm)
16468439|NCT03509402|Active Comparator|Long implants|A full-arch srew-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
16468440|NCT03509376|Experimental|Suture repair|Diastasis recti is repaired using nylon suture for the plication
16468441|NCT03509376|Experimental|Rolled mesh repair|Diastasis recti is repaired with self gripping mesh to reinforce the suture line
16468474|NCT03509168|Active Comparator|Misoprostol Pfizer Brand arm|participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy
16468475|NCT03509168|Other|No misoprostol arm|standard of care
16468476|NCT03509155|No Intervention|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
16468733|NCT03507413|Placebo Comparator|COMPARATIVE DRUG|Placebo matching M90 Oral Tablet treatment twice daily (2-0-2) for 1 year
16468442|NCT03509363|Experimental|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
16468443|NCT03509363|No Intervention|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
16468444|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
16468445|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
16468446|NCT03509324|Other|duration of disease|different duration of disease receive insulin LISPRO
16468447|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.
~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
16468448|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
16468449|NCT03509298|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16468450|NCT03509298|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16468451|NCT03509298|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16468452|NCT03509285|Placebo Comparator|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
16468453|NCT03509285|Active Comparator|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
16468454|NCT03509285|Placebo Comparator|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
16468455|NCT03509285|Active Comparator|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
16468456|NCT03509285|Active Comparator|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
16468457|NCT03509285|Experimental|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
16468458|NCT03509285|Experimental|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
16468459|NCT03509272|No Intervention|Control Group|
16468460|NCT03509272|Experimental|remote monitoring group|
16468461|NCT03509259||Asthma|"If the doctor has been diagnosed with asthma and one or more of the following criteria is met;
~FEV1 (Forced expiratory volume in 1 second) increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)
~Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)
~FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer.
~They can have concomittent COPD or not"
16468462|NCT03509259||Healthy control|Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)
16468463|NCT03509246|Experimental|Pegylated liposomal doxorubicin plus Bortezomib combination|At BRCA wild-type platinum-resistant recurrent ovarian cancer patients, Pegylated liposomal doxorubicin and Bortezomib combination therapy for six cycles.
16468464|NCT03509233|Active Comparator|Q-SRP|Quadrant scaling and root planing
16468465|NCT03509233|Experimental|FMS|Full mouth scaling and root planing
16468466|NCT03509233|Experimental|FMD|Full mouth disinfection
16468467|NCT03509233|Experimental|FMDP|Full mouth disinfection with periopolishing
16468468|NCT03509220|Experimental|PBK-1701TC|2-Day Split-Dosing Regimen
16468469|NCT03509220|Active Comparator|Standard oral preparation|2-Day Split-Dosing Regimen
16468470|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
16468471|NCT03509194||Pediatric liver disease patients|Comparison of outcome of pediatric liver disease and prognostic functional liver test results and gene expression in liver biopsies.
16468472|NCT03509181|Experimental|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
16468477|NCT03509155|Active Comparator|National portion & IYCF counseling|The second arm as the national portion & IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
16468478|NCT03509155|Experimental|Adjusted portion & local food counseling|the third arm as the adjusted portion & local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
16468479|NCT03509142|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).
16468480|NCT03509129|Active Comparator|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
16468481|NCT03509129|Experimental|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
16468482|NCT03509116||Patient group 1|Observations only
16468483|NCT03509116||Patient group 2|Qualitative interview, key stakeholders, documentary analysis
16468484|NCT03509103|Experimental|Electronic partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.
~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
16468485|NCT03509103|Active Comparator|Paper Partograph|An standard training on how to use and fill out partograph was conducted
16468486|NCT03509090|Active Comparator|ESP block group|Unilateral ESP block will be applied as postoperative regional analgesia technique in addition to the multimodal therapy. Then she is positioned in a right lateral position to perform ESP blocks. The skin will be disinfected and ESP block at one side will be performed in the lateral decubitus position and at T4 transverse process level by using 10-MHz linear ultrasound probe (Logic Ebook XP General Electrics, USA). The probe will be located 3 cm lateral to T4 spinous process in longitudinal parasagittal orientation. An 8 cm 21 gauge needle (BRAUN Stimuplex A®, Germany) will be inserted by using out of the plane technique. The ESP blocks proceed with 15 ml of 0,25% bupivacaine, 7,5 ml 1 % lidocaine, ,7,5 ml 0,9 % NaCl as total 30 ml . The injections will be applied after the confirmation of location by hidrodisection developed anterior to erector spinae muscle with 1-2 ml of local anesthetic solution.
16468487|NCT03509090|Active Comparator|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia prepared with tramadol. Patient-controlled analgesia (PCA) with tramadol at 3mg/cc concentration is programmed with no basal infusion, demand dose 10 mg and 20-minute lock-out interval. Also, patients received 1 gr paracetamol in every 6 hours.
16468488|NCT03509064||1: Patients with small fiber neuropathy|patients with Sjogren syndrome have a definite small fiber neuropathy
16468489|NCT03509064||2: Patients without peripheral neuropathy|patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)
16468490|NCT03509051|Experimental|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
16468491|NCT03509038|Experimental|Urinary incontinence before bariatric surgery|All patients with urinary incontinence before bariatric surgery will be addressed for a urodynamic exam
16468492|NCT03509025|Experimental|Long Term Follow-up after Jointstem Transplantation|
16468493|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
16468494|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
16468495|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
16468496|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
16468497|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
16468498|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
16468499|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
16468500|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
16468501|NCT03508999|Experimental|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
16468587|NCT03508453|Placebo Comparator|Placebo|Placebo intravenously twice weekly for 12 weeks
16468502|NCT03508999|Other|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
16468503|NCT03508999|Placebo Comparator|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
16468504|NCT03508973|Experimental|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
16468505|NCT03508947|Experimental|WVE-210201 (Dose A) or placebo|
16468506|NCT03508947|Experimental|WVE-210201 (Dose B) or placebo|
16468507|NCT03508947|Experimental|WVE-210201 (Dose C) or placebo|
16468508|NCT03508947|Experimental|WVE-210201 (Dose D) or placebo|
16468509|NCT03508947|Experimental|WVE-210201 (Dose E) or placebo|
16468510|NCT03508934|Active Comparator|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
16468511|NCT03508934|Placebo Comparator|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
16468512|NCT03508921|Experimental|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
16468513|NCT03508921|Experimental|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
16468514|NCT03508908|No Intervention|Observation Period|HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
16468515|NCT03508908|Active Comparator|Intervention Period|Combination intervention with HIV-1 RNA testing followed by rapid tests if positive for HIV diagnosis, immediate ART if diagnosed, assisted partner notification with HIV-1 RNA testing of partners, and PrEP for uninfected partners in discordant relationships.
16468516|NCT03508895|Experimental|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
16468517|NCT03508895|Experimental|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
16468518|NCT03508895|Active Comparator|Casein protein|25 grams of protein powder, twice a day
16468519|NCT03508882|Active Comparator|Preseptal-pretarsal|The Preseptal-pretarsal group will receive injections of Botulinum Toxin Type A 100Unit/Vial (Product) in the preseptal site (Injection pattern A) and Saline Solution for Injection (placebo control) in the pretarsal site for 2 cycles at 3 months apart. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
16468520|NCT03508882|Active Comparator|Pretarsal-preseptal|The Pretarsal-preseptal group will initially receive injections Botulinum Toxin Type A 100Unit/Vial (Product) in the reverse with the intervention at the pretarsal site (Injection pattern B) for 2 cycles at 3 months apart. Groups 1 and 2 will crossover and receive the alternative intervention. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
16468521|NCT03508869|Active Comparator|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
16468522|NCT03508869|Active Comparator|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
16468523|NCT03508869|Active Comparator|Dysport® in conjunction with Mirvaso|Dysport® in conjunction with Mirvaso
16468524|NCT03508856|Experimental|Picato 0.015% gel|Picato 0.015% gel, is a topical treatment for actinic ketatoses.
16468525|NCT03508843|Experimental|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
16468526|NCT03508830|Experimental|Liposomal Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
~Drug Preparation: 266mg (20cc) Liposomal Bupivacaine admixed with 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) and varied 0.9% normal saline volume for total volume of 60cc."
16468527|NCT03508830|Active Comparator|Standard Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
~Drug Preparation - 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) admixed with varied 0.9% normal saline volume for total volume of 60cc."
16468528|NCT03508817|Experimental|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
16468529|NCT03508817|No Intervention|Control group|Control group will not receive any medication.
16468530|NCT03508804|Experimental|Lidocaine-prilocaine cream|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the lidocaine-prilocaine cream vaginally using a syringe
16468531|NCT03508804|Placebo Comparator|Placebo cream (pain lucubrating gel)|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the placebo cream vaginally using a syringe
16468532|NCT03508791|Active Comparator|Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the Trendelenberg position
16468533|NCT03508791|Active Comparator|reverse Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the reverse Trendelenberg position
16468588|NCT03508440|Active Comparator|Standard of Care|Oral steroids (prednisone or prednisolone) 60mg per day for 10 days or 60mg/day for 5 days followed by a 5 day taper
16468534|NCT03508778|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
16468535|NCT03508778|Active Comparator|PanOptix|Commercially available trifocal IOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
16468536|NCT03508765|Experimental|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
16468537|NCT03508752|Experimental|Radiation|Stereotactic Radiosurgery
16468538|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
16468539|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
16468540|NCT03508726|Experimental|Phase I dose escalation/Phase II portion|"Phase 1 dose escalation:
~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
~Phase II portion:
~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation."
16468541|NCT03508713||early RA patients|patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
16468542|NCT03508700|Experimental|TNX-102 SL 5.6 mg|2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
16468543|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
16468544|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
16468545|NCT03508674|Experimental|Intervention|Levita Magnetic Surgical System
16468546|NCT03508661|Experimental|SPIN-SSLED Program|13-session SPIN-SSLED Program
16468547|NCT03508648|Placebo Comparator|Matching Placebo|Subjects previously enrolled in the placebo arm of study G201002.
16468548|NCT03508648|Active Comparator|1 mg GTx-024|Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
16468549|NCT03508648|Active Comparator|3 mg GTx-024|Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
16468550|NCT03508635|Experimental|SAD Cohorts 1 through 6|Participants will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
16468551|NCT03508635|Placebo Comparator|SAD Cohorts 1 through 6 Placebo|Participants will receive single doses of Matching Placebo of CORT125134 (capsule).
16468552|NCT03508635|Experimental|Food Effect Cohort 7|Participants will receive a single dose of CORT125134 (capsule) with a standard high fat breakfast. The dose will be chosen such that it has been previously administered in a prior SAD cohort.
16468553|NCT03508635|Experimental|Pharmacological Effect Cohort 8|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
16468554|NCT03508635|Experimental|Proof of Concept (POC) Cohort 9|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg of prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. An oral glucose tolerance test will be administered on each study day. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
16468555|NCT03508635|Experimental|MAD Cohorts 10 and 11|Participants will receive the selected dose of CORT125134 (capsule) following receipt of data from Cohorts 1-9 up to a maximum frequency of twice a day for a total of 14 days.
16468556|NCT03508635|Placebo Comparator|MAD Cohorts 10 and 11 Placebo|Participants will receive Matching Placebo of CORT125134 (capsule) up to a maximum frequency of twice a day for a total of 14 days.
16468589|NCT03508440|Experimental|SOC + injection|Oral steroids as described above + intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks.
16468590|NCT03508440|Other|Injection only|Only Intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks
16471499|NCT03488186|Experimental|Lansoprazole Capsules|Lansoprazole Capsules of Beijing Sihuan Pharm, 30 mg
16468557|NCT03508635|Experimental|MAD of PoPE Cohorts 12 and 13|Proof of Pharmacological Effect (PoPE+POC). Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the selected dose of CORT125134 (capsule) for a total of 13 days. Participants may either receive a higher dose level than previously administered or a repeat of a dose level given in 1 of the previous 2 MAD Cohorts. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
16468558|NCT03508635|Placebo Comparator|MAD of PoPE Cohort 12 and 13 Placebo|Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the Matching Placebo of CORT125134 (capsule) for a total of 13 days. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
16468559|NCT03508622|Experimental|Telehealth|This group will receive weight management treatment via 12 online group sessions, over 6 months. They will have Bluetooth-enabled scales that will allow them to transmit their weight data to the PI in between research visits. They will answer questionnaires and have research visits at baseline, 3 months, and 6 months.
16468560|NCT03508622|Other|Empower|This retrospective control group received standard in-clinic individualized weight management with a multi-disciplinary group of providers, via 6 monthly clinic visits, over 6 months.
16468561|NCT03508609|Experimental|Autologous CD34 cells|Open label active treatment arm. Subjects receive autologous CD34 cells.
16468562|NCT03508596|Experimental|Intervention|"Intervention group (IG)
~An educational intervention for the supervisors"
16468563|NCT03508596|No Intervention|Control|control group (CG)
16468564|NCT03508596|No Intervention|Non-Intervention|group without intervention (GWI)
16468565|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary
~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
16468566|NCT03508570|Experimental|Group I (nivolumab)|Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16468567|NCT03508570|Experimental|Group II (nivolumab and ipilimumab)|Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16468568|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
16468569|NCT03508544|Active Comparator|Lumbar ESP block|Ultrasound-guided lumbar Erector spinae plane (ESP) block performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
16468570|NCT03508544|Active Comparator|QLB Block|Ultrasound-guided transmuscular quadratus lumborum block (QLB) performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
16468571|NCT03508544|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16468572|NCT03508531|Active Comparator|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16468573|NCT03508531|Active Comparator|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16468574|NCT03508531|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
16468575|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
16468576|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :
~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
16468577|NCT03508492|Active Comparator|Knee surgeons|Four knee surgeons
16468578|NCT03508492|Active Comparator|Hip surgeons|Six hip surgeons
16468579|NCT03508492|Active Comparator|Cardiac surgeons|6 cardiac surgeons
16468580|NCT03508492|Active Comparator|Colon surgeons|6 colon surgeons
16468581|NCT03508479|Experimental|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
16468582|NCT03508466||Group 1|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject)
16468583|NCT03508466||Group 2|adult participants from 18-65 years of age previous intravenous ferric carboxymaltose (Ferinject) and no hypersensitivity reaction
16468584|NCT03508466||Group 3|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to iron sucrose (Venofer)
16468585|NCT03508466||Group 4|adult participants from 18-65 years of age previous intravenous iron sucrose (Venofer) and no hypersensitivity reaction
16468586|NCT03508453|Active Comparator|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
16468591|NCT03508427|Experimental|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
~Tool: Toi Même mobile app"
16468592|NCT03508414|Experimental|Ketogenic diet|
16468593|NCT03508414|Experimental|Intermittent therapeutical fasting|
16468594|NCT03508414|Active Comparator|Control group|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
16468595|NCT03508401|Experimental|ICU intubated patients|"After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR
~Patients will be classified in two groups according to the hemodynamic response to PLR :
~Patients are responders if LVOT VTI increases of at least 10% after PLR
~patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR."
16468596|NCT03508375|Experimental|SSc without ILD|
16468597|NCT03508375|Experimental|SSc with ILD|
16468598|NCT03508375|Active Comparator|patients with idiopathic pulmonary fibrosis|
16468599|NCT03508362|Experimental|Drug user|Regular use of cocaine
16468600|NCT03508362|Active Comparator|Healthy volunteers|non-drug user
16468601|NCT03508349|Experimental|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
16468602|NCT03508349|No Intervention|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
16468603|NCT03508336||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
16468604|NCT03508323|Experimental|Teneligliptin|
16468605|NCT03508323|Placebo Comparator|Placebo|
16468606|NCT03508310|Experimental|Intervention|29-minute clinic waiting room video intervention that includes three vignettes and a 2-part animation sequence about main characters who model overcoming challenges to optimal HIV care. The video was played on continuous loop in recognition of typically short patient wait times. Waiting room posters used images from the video to direct patients' attention to the video and reinforce prevention messages.
16468607|NCT03508310|No Intervention|Comparison|Historical comparison condition. Patients were exposed to standard waiting room environment (absent of intervention video and posters).
16468608|NCT03508284||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
16468609|NCT03508284||Healthy group|Healthy individuals without chronic disease
16468610|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
16468611|NCT03508258||Participants with NVAF starting Apixaban|
16468612|NCT03508258||Participants with NVAF starting Warfarin|
16468613|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength light therapy
16468614|NCT03508232|Placebo Comparator|Placebo control|Two placebo capsules upon enrollment, followed by one placebo capsule p.o. every 12 hours for 7 days
16468615|NCT03508232|Experimental|Doxycycline hyclate|Two 100mg doxycycline capsules (200 mg) p.o. upon enrollment, followed by one 100 mg capsule p.o. every 12 hours for 7 days
16468616|NCT03508219|Experimental|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
16468617|NCT03508206|Experimental|SBRP arm|Food supplement in hard gelatin capsule form containing a Standardized botanical blend rich in polyphenols (SBRP)
16468618|NCT03508206|Placebo Comparator|Placebo arm|Hard gelatin capsule form containing maltodextrin, with the same appearance as SBRP capsules
16468619|NCT03508193|Experimental|Intervention|Whole-foods based smoothie as nutritional therapy
16468620|NCT03508180|Experimental|foot reflexology|patients WITH foot reflexology session during chemotherapy treatments
16468621|NCT03508180|Placebo Comparator|platinum-based treatment|Patients WITHOUT ANY foot reflexology session during chemotherapy treatments
16468622|NCT03508167|Experimental|Thermal Band plus Dorilax®|
16468623|NCT03508167|Other|Thermal Band plus Placebo|
16468624|NCT03508154|Active Comparator|Control Meal 1|Control carbohydrate solution
16468625|NCT03508154|Active Comparator|Control Meal 2|Control carbohydrate solution
16468626|NCT03508154|Experimental|Experimental Nutritional Product|Study nutritional formulation
16468627|NCT03508141|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
16468628|NCT03508141|Active Comparator|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
16468629|NCT03508128||Micra subjects|Surgical procedure
16468630|NCT03508102|Experimental|Remifentanil 1 μg kg-1 (R1)|Received remifentanil 1μg/kg when induction of general anesthesia
16468631|NCT03508102|Experimental|Remifentanil 0.5 μg kg-1 (R0.5),|Received remifentanil 0.5μg/kg when induction of general anesthesia
16468632|NCT03508102|No Intervention|saline (control)|Injected the equal volume normal saline when induction of general anesthesia
16468633|NCT03508089|Other|Control Arm|
16468634|NCT03508089|Active Comparator|Multiple Sclerosis Arm|
16468671|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=40 group
16468635|NCT03508076|Sham Comparator|Sham Capsule|Patients swallowed 1 sham Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
16468636|NCT03508076|Experimental|Vibration Capsule of low level|Patients swallowed 1 low level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
16468637|NCT03508076|Experimental|Vibration Capsule of high level|Patients swallowed 1 high level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
16468638|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
16468639|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
16468640|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
16468641|NCT03508037|Experimental|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
16468642|NCT03508037|Active Comparator|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
16468643|NCT03508011|Experimental|IMP4297|
16468644|NCT03507998|Experimental|CGX1321 Dosing|"Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned.
~Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321"
16468645|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
16468646|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.
~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
16468647|NCT03507972|Other|Ankle ultrasound & ankle MRI|Ankle ultrasound performed on the day of emergency consultation member MRI (without injection of contrast products) performed within 7 days following the trauma
16468648|NCT03507959|Experimental|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
16468649|NCT03507959|Experimental|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
16468650|NCT03507959|Experimental|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
16468651|NCT03507959|Experimental|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
16468652|NCT03507959|No Intervention|Control group|This group does not take the nasal spray.
16468653|NCT03507946|Experimental|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
~Plaque 2: No Intervention"
16468654|NCT03507920|Experimental|Neck passive mobilizations|
16468655|NCT03507920|Placebo Comparator|Manual contact|
16468656|NCT03507907|Experimental|Study Group|Mulligan mobilization techniques were applied to the older adults.
16468657|NCT03507907|Other|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
16468658|NCT03507894||m-health stroke rehabilitation|8-week multimodal exercise rehabilitation program (MERP) based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
16468659|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
16468660|NCT03507868||Group 1|Periodontally healthy individuals
16468661|NCT03507868||Group 2|Chronic periodontitis patients
16468662|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
16468663|NCT03507855|Active Comparator|Control|Normal operating room environment.
16468664|NCT03507842|Experimental|High-dose cytarabine|High-dose cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
16468665|NCT03507842|Experimental|high-dose daunorubicin|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7) plus high-dose daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
16468666|NCT03507829|Active Comparator|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
16468667|NCT03507829|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
16468668|NCT03507829|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
16468669|NCT03507803|Experimental|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
16468670|NCT03507803|No Intervention|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
16468674|NCT03507777|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.
~At the end of the procedure, a final OCT imaging run must be performed."
16468675|NCT03507777|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with angiography guidance according to local standard practice.
~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
16468676|NCT03507764|No Intervention|Control Group|"During the randomized study phase (6 months),subjects will perform their usual activity without access to the treadmill workstation in the dispatch center.
~After six months, all subjects will continue to be assessed with free access to the treadmill workstation at the workplace."
16468677|NCT03507764|Experimental|Experimental Group|"During the randomized study phase, subjects will have an open access to the treadmill workstation with the indication to use it for at least one hour (continuous or split) on working days.
~After six months, all subjects will continue to be assessed with free access to the treadmill workstation."
16468678|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
16468679|NCT03507738|Experimental|Adult MT-5625 middle dose|Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo
16468680|NCT03507738|Experimental|Adult MT-5625 high dose|Adult receiving intramuscular injection with either high dose of MT-5625 or placebo
16468681|NCT03507738|Experimental|Toddler MT-5625 middle dose|Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo
16468682|NCT03507738|Experimental|Toddler MT-5625 high dose|Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo
16468683|NCT03507738|Experimental|Infant MT-5625 low dose|Infant receiving intramuscular injection with either low dose of MT-5625 or placebo
16468684|NCT03507738|Experimental|Infant MT-5625 middle dose|Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo
16468685|NCT03507738|Experimental|Infant MT-5625 high dose|Infant receiving intramuscular injection with either high dose of MT-5625 or placebo
16468686|NCT03507738|Active Comparator|Rotarix|Infant receiving oral administration with Rotarix
16468687|NCT03507725|Experimental|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
16468688|NCT03507725|Active Comparator|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
16468689|NCT03507712|Active Comparator|Symmetrical IO weakening.|Same surgery in both eyes
16468690|NCT03507712|Active Comparator|Asymmetrical IO weakening.|Different amounts or different surgery in each eye
16468691|NCT03507699|Experimental|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
16468692|NCT03507699|Experimental|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.
~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
16468693|NCT03507686|Experimental|BIIB111|Participants will receive a single dose of sub-retinal injection of BIIB111 in each eye at Day 0 separated by an interval of <6 months, 6-12 months, or >12 months.
16468694|NCT03507673||Progynova/Dydrogesterone|
16468695|NCT03507673||Spontaneous cycle|
16468696|NCT03507673||Progynova/Crinone|
16468697|NCT03507673||Others Medication|
16468698|NCT03507660|Experimental|verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~squeeze the pelvic floor muscles.
~squeeze and lift the pelvic floor muscles as if stopping the flow of urine
~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.
~squeeze the anus
~shorten the penis
~elevate the scrotum"
16468701|NCT03507634|Active Comparator|Opioid Based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl and Sevoflurane.
16468702|NCT03507634|Active Comparator|Opioid Free Anesthesia|General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine and Sevoflurane.
16468703|NCT03507621||Propofol Group|1- Propofol Group: Propofol group will use 1 mg / kg propofol for the patient.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete .
16468734|NCT03507400|Experimental|non-waiting list group|Intervention: Introvision: mental and emotional self-regulation
16468735|NCT03507400|Experimental|waiting list group|"Intervention: Introvision: mental and emotional self-regulation
~Introvision is teached to participants of the waiting-list group at least 6 weaks or more after first group"
16468835|NCT03506750|Experimental|IVC-4day|patients with proliferative diabetic retinopathy receiving IVC 4 days before surgery
16468704|NCT03507621||Sevoflurane Group|1- Sevofluran Group: sevoflurane was administered at one minimum alveolar concentration (MAC) to end-tidal concentrations of 3% to 5%.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete.
16468705|NCT03507608|Experimental|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
16468706|NCT03507608|Placebo Comparator|placebo|placebo prior to brachytherapy and prostatic biopsy
16468707|NCT03507595||Patients with initial diagnosis of PCa|"T2 stage: PSA>20ng/ml, Gleason Score >= 8;
~T3 or T4 stage;
~The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
16468708|NCT03507595||Patients with biochemical recurrent PCa|"After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;
~After the radiotherapy: the lowest PSA is up to 2 ng/ml."
16468709|NCT03507595||Patients with CRPC|"The serum testosterone is in the castration level (< 50 ng/dL or < 1.7 nmol/L);
~The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA > 2ng/mL(the interval is one week);
~The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;
~Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
16468710|NCT03507582|Active Comparator|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
16468711|NCT03507582|Active Comparator|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
16468712|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
16468713|NCT03507556|Experimental|Triple paste and induced bleeding|The triple paste is a mixture of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol will be used and next visit intracanal bleeding will be induced
16468714|NCT03507543|Experimental|IMP4297|
16468715|NCT03507504||care pathway with SCU-B|250 patients with dementia and behavioural and psychological symptoms of dementia (BPSD) followed up by six clinical centres with a Special Care Unit for BPSD (SCU-B)
16468716|NCT03507504||care pathway without SCU-B|250 patients with dementia and BPSD followed up by six clinical centres without SCU-B
16468717|NCT03507491|Experimental|Gemcitabine + Nab-paclitaxel|Participants receiving gemcitabine and nab-paclitaxel for refractory and/or relapsed solid tumors of childhood.
16468718|NCT03507478|Experimental|BPI1000013|Subjects suffering from pain associated with plantar fasciitis or general heel pain
16468719|NCT03507465|Experimental|Letrozole Plus Low-Dose Metronomic Capecitabine|
16468720|NCT03507465|Active Comparator|EC-T|
16468721|NCT03507452|Experimental|Dose escalation cohort a|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg."
16468722|NCT03507452|Experimental|Dose escalation cohort b|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg."
16468723|NCT03507452|Experimental|Dose Expansion Cohort 1|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options
~Dose / Regimen 1 (to be determined after completion of the dose escalation)"
16468724|NCT03507452|Experimental|Dose Expansion Cohort 2|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options
~Dose / Regimen 2 (to be determined after completion of the dose escalation)"
16468725|NCT03507452|Experimental|Dose expansion Cohort 3 (optional)|"Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma
~Dose / Regimen to be determined"
16468726|NCT03507452|Experimental|Dose escalation cohort c|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg."
16468727|NCT03507452|Experimental|Dose escalation cohort d|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg."
16468728|NCT03507439|Experimental|Heart failure patients|Patients with worsening heart failure (HF) and recent hospitalization for the treatment of HF or patients with chronic stable HF with either preserved (EF ≥ 45%) or reduced ejection fraction (EF ≤ 35%)
16468729|NCT03507426|Active Comparator|Retrobulbar group|Retrobulbar block
16468730|NCT03507426|Active Comparator|Ketamine group|Intravenous analgesia
16468731|NCT03507426|No Intervention|Control group|General anesthesia alone
16468736|NCT03507387|Experimental|Intramuscular phenylephrine group|Patients in intramuscular phenylephrine group will receive spinal anesthesia with bupivacaine. 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
16468737|NCT03507387|Active Comparator|Intravenous phenylephrine group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed.
16468738|NCT03507387|Placebo Comparator|Placebo group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia. 1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
16468739|NCT03507374|Placebo Comparator|Placebo Comparator|After review of eligibility criteria, 20 patients will be randomized to the placebo arm of the study where patient will administer one subcutaneous injection of placebo every two weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg.
16468740|NCT03507374|Active Comparator|Active Comparator|After review of eligibility criteria, 20 patients will be randomized to receive the investigational treatment of alirocumab 150mg which will be administered subcutaneously with a single-dose pre-filled pen syringe every 2 weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg
16468741|NCT03507361|Experimental|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
16468742|NCT03507361|No Intervention|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
16468743|NCT03507348|Other|Desensitization with Tocilizumab and rituximab (MFI >15000)|
16468744|NCT03507348|Other|Desensitization with Rituximab only (MFI<15000)|
16468745|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
16468746|NCT03507335||Sinus|Patients with sinus rhythm during measurements
16468747|NCT03507322||Ultrasound texturization|Application of ultrasound texturization (2D/3D ultrasound scanning)
16468748|NCT03507309||To be specified by Steering Committee.|
16468749|NCT03507296||Chronic low back pain patients|
16468750|NCT03507296||Asymptomatic subjects|
16468751|NCT03507270|Other|FABP group|Coronary angiography and PCI (according to indications).
16468752|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia
~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)
~CDR score ≤ 1.0
~flortaucipir (18F-AV-1451) PET scanning"
16468753|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living
~Mini-Mental State Exam score between 26-30
~CDR score = 0
~flortaucipir (18F-AV-1451) PET scanning"
16468754|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia
~Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)
~CDR score ≤ 1.0
~flortaucipir (18F-AV-1451) PET scanning"
16468755|NCT03507244|Experimental|Group 1,Intra-pemetrexed, radiotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.
16468756|NCT03507231|Active Comparator|Control|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination.
16468757|NCT03507231|Experimental|Direct Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for Vaccination ($5 Amazon Gift Card).
16468758|NCT03507231|Experimental|Indirect Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
16468759|NCT03507218||1|Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
16468760|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
16468761|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
16468762|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
16468763|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
16468764|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
16468765|NCT03507192|No Intervention|Arm 1|30 subjects In arm 1, no intervention is performed.
16468766|NCT03507192|Active Comparator|Arm 2|30 patients In arm 2 , active comparators, Muscle relaxation using full body massage machine is performed every morning and evening for 30 minutes.
16468767|NCT03507179|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
16468768|NCT03507179|Active Comparator|3d printed dentures|a complete denture made through 3D printing
16468907|NCT03506230|No Intervention|Standard group|Will buy their medications as usual
16468769|NCT03507166|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
16468770|NCT03507153|Active Comparator|Bre-fllex group|Maxillary class III modification I edentulous patients that will recieve Bre-flex partial denture
16468771|NCT03507153|Experimental|PEEK group|Maxillary class III modification I edentulous patients that will recieve PEEK partial denture
16468772|NCT03507127|Active Comparator|Varenicline|
16468773|NCT03507127|Placebo Comparator|Placebo|
16468774|NCT03507114|Experimental|Rumination-Focused CBT (RFCBT)|RFCBT seeks to change the process of thinking as opposed to the content of thoughts as in standard CBT. The underlying idea is that shifting individuals repetitive negative thinking into the concrete mode will reduce unconstructive ruminations and worries.
16468775|NCT03507114|No Intervention|Wait List Control Group|This arm represents the wait-list comparison group.
16468777|NCT03507088|Experimental|fulvestrant|500mg fulvestrant on days 0, 14, 28 and every 28 days thereafter Fluoroestradiol-PET is performed at baseline and after 28 days
16468778|NCT03507075|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
16468779|NCT03507075|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
16468780|NCT03507062|Experimental|Chloride-rich solution|Patients will receive two boluses of 10 and 20 ml/kg of the 0.9% saline in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
16468781|NCT03507062|Experimental|Low-chloride solution A|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's lactate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
16468782|NCT03507062|Experimental|Very low-chloride solution|Patients will receive two boluses of 10 and 20 ml/kg of a plasmalyte-like solution (namely soluzione elettrolitica reintegrante [SER]) in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
16468783|NCT03507049|Active Comparator|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure.
16468784|NCT03507049|Sham Comparator|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.
~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.
~An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure."
16468785|NCT03507049|Other|Functional MRI study|The Swedish patients will also undergo quantitative sensory testing at inclusion and at 6 month follow-up. At the same time they will undergo a cerebral MRI and a Functional MRI looking at activation of the CNS from pain in the sacroiliac joints induced by one leg lift. The purpose of this study is to look at contributing factors in treatment response. One hopes to map which CNS mechanisms are involved in causing the chronic pain these patients experience as well as how they respond to treatment.
16468786|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.
~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
16468787|NCT03507023|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
16468788|NCT03507023|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
16468789|NCT03507010|Experimental|Radiotherapy|Patients assigned to the Radiotherapy group are treated with electrons and will receive a total dose of 30 Gy.
16468790|NCT03507010|Placebo Comparator|Sham Radiotherapy|Patients assigned to the sham-radiotherapy group will not actually receive radiation. For these patients the radiation is simulated.
16468791|NCT03506997|Experimental|Pembrolizumab|Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years
16468792|NCT03506984|Experimental|Group A|the participant will do a program of inspiratory muscle training for 10-15 minutes once daily using Threshold Inspiration Muscle Training Device
16468834|NCT03506750|Experimental|IVC-3day|patients with proliferative diabetic retinopathy receiving IVC 3 days before surgery
16468793|NCT03506984|Experimental|Group B|the participant will start cycling slowly for five minutes without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down using Electronic Bicycle Ergometer
16468796|NCT03506958||General Practice|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the general practice Zorgplein Lemmer.
16468797|NCT03506958||Hospital|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the Antonius Hospital Sneek.
16468798|NCT03506945|Experimental|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities
16468799|NCT03506945|Active Comparator|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills
16468800|NCT03506932|Experimental|Untreated|Bread containing 20% yellow pea flour.
16468801|NCT03506932|Experimental|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
16468802|NCT03506932|Experimental|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
16468803|NCT03506932|Active Comparator|Wheat|Bread made with 100% wheat flour
16468804|NCT03506919|Experimental|Arthitec 1|
16468805|NCT03506919|Experimental|Arthitec 2|
16468806|NCT03506906|Active Comparator|Conventional-approach|The non-invasive ventilation therapy will be optimized according to routine tests (blood gas analysis, lung function, ventilator's built-in software analysis)
16468807|NCT03506906|Experimental|Sleep studies-based approach|Additionally to the routine tests, the results of a nocturnal polysomnography and transcutaneous capnometry under the non-invasive ventilation therapy will be considered for the therapy optimization.
16468808|NCT03506893|Experimental|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
16468809|NCT03506893|Active Comparator|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
16468810|NCT03506880|Experimental|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
16468811|NCT03506880|Active Comparator|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
16468812|NCT03506880|No Intervention|Control|TAU
16468813|NCT03506867|Active Comparator|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
16468814|NCT03506867|Active Comparator|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
16468815|NCT03506854|Experimental|Normal Renal Function|Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
16468816|NCT03506854|Experimental|Moderate Renal Impairment|Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
16468817|NCT03506841|Active Comparator|Cerbrolysin|Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
16468818|NCT03506841|No Intervention|Control|Preterm infants with gestational age less than 32 weeks at birth will receive routine care.
16468819|NCT03506828|Active Comparator|Surgical sympathectomy|All patients in this group will have standard surgical procedure
16468820|NCT03506828|Active Comparator|Radiofrequency ablation with phenol injection|patient will receive radiofrequency ablation of T2 and T3 sympathetic ganglia + phenol 6% (0.5ml) injection
16468821|NCT03506815|Experimental|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
16468822|NCT03506815|No Intervention|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
16468823|NCT03506802|Experimental|Treatment (Genetically engineered PBMC and PBSC)|Refer to outline
16468824|NCT03506789|Active Comparator|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
16468825|NCT03506789|Active Comparator|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
16468826|NCT03506789|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
16468827|NCT03506776|Active Comparator|Education Only Group|The education only group will receive foot self-management education.
16468828|NCT03506776|Experimental|Education and Thermometer Group|The intervention group will receive foot self-management education. Additionally, the intervention group will receive a Commercially Available Infrared Thermometer (CAIT). Education on use of the CAIT will be provided through demonstration using a foot model and CAIT.
16468829|NCT03506763|Placebo Comparator|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
16468830|NCT03506763|Active Comparator|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
16468831|NCT03506763|Active Comparator|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
16468832|NCT03506750|Experimental|IVC-1day|patients with proliferative diabetic retinopathy receiving IVC 1 days before surgery
16468833|NCT03506750|Experimental|IVC-2day|patients with proliferative diabetic retinopathy receiving IVC 2 days before surgery
16468836|NCT03506750|Experimental|IVC-5day|patients with proliferative diabetic retinopathy receiving IVC 5 days before surgery
16468837|NCT03506750|Experimental|IVC-6day|patients with proliferative diabetic retinopathy receiving IVC 6 days before surgery
16468838|NCT03506750|Experimental|IVC-7day|patients with proliferative diabetic retinopathy receiving IVC 7 days before surgery
16468839|NCT03506750|Sham Comparator|IVC-sham|patients with proliferative diabetic retinopathy receiving sham IVC
16468840|NCT03506750|Placebo Comparator|non-DR|patients with other retinopathy (idiopathic macular hole or epiretinal membrane)
16468841|NCT03506737|Experimental|Conventional exercise protocol|Conventional global exercise
16468842|NCT03506737|Experimental|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
16468843|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
16468844|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
16468845|NCT03506711|Active Comparator|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
16468846|NCT03506711|Active Comparator|Healthy Children and adolescents|Healthy community-dwelling children on no medication
16468847|NCT03506685|No Intervention|control group Standard ACL protocol|This group will receive the standard ACL protocol rehab
16468848|NCT03506685|Experimental|Dry needling and STM group|This group will also receive the standard ACL protocol in addition to STM and DN
16468849|NCT03506672|Experimental|Experimental group|Approach based on the meanings of vocal behaviours
16468850|NCT03506672|Active Comparator|Control group|Usual practices of formal caregivers regarding vocal behaviours
16468851|NCT03506659|Active Comparator|Test|2000 patients healthy in anesthesiology consultation
16468852|NCT03506659|Experimental|Patients|2000 patients in pain clinic consultation
16468853|NCT03506646|Experimental|Beetroot juice-Placebo|Subjects will be tested on two different days. The first day will be beetroot juice and the second day will be a placebo. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
16468854|NCT03506646|Experimental|Placebo-Beetroot juice|Subjects will be tested on two different days. The first day will be a placebo and the second day will be beetroot juice. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
16468855|NCT03506633|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.
16468856|NCT03506633|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.
16468857|NCT03506620|Placebo Comparator|Control|Subjects will be randomized to receive a single-injection QL block with normal saline (Saline Solution for Injection).
16468858|NCT03506620|Experimental|QL Block|Subjects will be randomized to receive a single-injection QL block with either local anesthetic (0.25% Ropivacaine injection).
16468859|NCT03506607|Experimental|Exercise in hypoxia 1500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%.
16468860|NCT03506607|Experimental|Exercise in hypoxia 2500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%.
16468861|NCT03506607|Placebo Comparator|Exercise in normoxia|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
16468862|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
16468863|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.
~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
16468864|NCT03506568|No Intervention|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
16468865|NCT03506568|Experimental|Integrated daily reminder using the D3 app|For Group 2, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
16468866|NCT03506555|Active Comparator|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
16468867|NCT03506555|Active Comparator|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
16468868|NCT03506542|Experimental|Ologen (OLO)|Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy
16468869|NCT03506542|Active Comparator|Mitomycin C (MMC)|Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)
16468870|NCT03506516|Experimental|single type|Restricted to drinking only one type of alcohol
16468871|NCT03506516|Active Comparator|mixed type|Drinking and mixing different types of alcohols freely
16468872|NCT03506503|Experimental|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
16468873|NCT03506490|Experimental|Experimental|The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
16468874|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
16468875|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
16468876|NCT03506464|Experimental|plantar fasciitis group|Myofascial release technique
16468877|NCT03506464|No Intervention|control group|None of the control group received the treatment
16468878|NCT03506451|Other|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
16468879|NCT03506438|Experimental|Mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
16468880|NCT03506438|Placebo Comparator|Usual care|Usual ICU care
16468881|NCT03506425|Experimental|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
16468882|NCT03506425|Experimental|Group 2|Standard care and Triheptanoin for 6 months.
16468883|NCT03506425|No Intervention|Group 3|Healthy controls for biomarkers
16468884|NCT03506412|Experimental|Entresto™|HFpEF patients will be given Entresto™
16468885|NCT03506399|Experimental|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
16468886|NCT03506399|Experimental|Lanabecestat|Single oral dose of lanabecestat
16468887|NCT03506399|Experimental|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
16468888|NCT03506386||Multiple Myeloma Participants|Participants with multiple myeloma (MM) were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
16468889|NCT03506373|Experimental|Treatment (ixazomib citrate, ibrutinib)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16468890|NCT03506360|Experimental|Treatment (ixazomib citrate, pembrolizumab, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16468891|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
16468892|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
16468893|NCT03506334|Experimental|Pediatric Scoliosis Patients|Tether group
16468894|NCT03506334|Active Comparator|Pediatric Scoliosis Control Patients|Fusion (control) group
16468895|NCT03506321|Other|LANS|Lesions are assessed with chromoendoscopy, HD-WL & NBI
16468896|NCT03506308|Other|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
16468897|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
16468898|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
16468899|NCT03506282|No Intervention|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
16468900|NCT03506282|Active Comparator|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
16468901|NCT03506282|Experimental|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
16468902|NCT03506282|Experimental|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
16468903|NCT03506256|Experimental|Norofloxacin|The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones. Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system. The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
16468904|NCT03506243|Experimental|Test group|Follitrope PFS
16468905|NCT03506243|Active Comparator|Control group|Gonal-F pen
16468906|NCT03506230|Experimental|Incentives group|a bonus to buy their medications if they improve their HbA1c
16468908|NCT03506217||mitral valve prolaps|Hemodynamic recovery and anesthesia revealed by invasive arterial cardiac output (CO) measurement (Vigileo Flo-trac device) in 13 cases who underwent mitral valve (MV) repair with the transapical off-pump minimally invasive method in our clinic.
16468909|NCT03506178|Experimental|Obstructive sleep apnea patients|
16468910|NCT03506178|Other|Healthy controls|
16468911|NCT03506165|Experimental|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
16468912|NCT03506165|No Intervention|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
16468913|NCT03506152||Culture positive|
16468914|NCT03506152||Culture negative|
16468915|NCT03506139|Experimental|Radiation Therapy|External beam radiation therapy delivered to target volume.
16468916|NCT03506126|Experimental|Leucine Adults > 60|In this arm, all subjects will receive all 8 of the leucine test levels, assigned in random order.
16468917|NCT03506113|Active Comparator|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
16468918|NCT03506113|Active Comparator|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
16468919|NCT03506100|Other|water walking in spirometric values|Experimental: practice swimming complemented with water walking
16468920|NCT03506087|Experimental|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
16468921|NCT03506087|Active Comparator|Enhanced Control|Receives printed advance care planning materials only.
16468922|NCT03506074||General population|"Adult volunteers (≥18 years of age) selected as part of a project to investigate the role of lifestyle in preventing chronic diseases supported by the Campus Salute association (www.campussalute.it).
~All volunteers performed the flavor test as described in Maione et al, Endocrine, 2016 (doi:10.1007/s12020-015-0690-y)."
16468923|NCT03506061|Experimental|Trikafta|Participants will receive Trikafta for 28 days
16468924|NCT03506048|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
16468925|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
16468926|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
16468927|NCT03506035||Healthy controls|From health blood donors
16468928|NCT03506022|Other|patients with type 1 mellitus diabetes|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters
16468929|NCT03506009|Experimental|Argatroban combined with rt-PA|
16468930|NCT03506009|Active Comparator|rt-PA|
16468931|NCT03505996|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
16468932|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
16468933|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
16468934|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
16468935|NCT03505970|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
16468936|NCT03505970|Placebo Comparator|Placebo|Individuals will ingest 0.3 g/kg maltodextrin before undergoing exercise
16468937|NCT03505957|Experimental|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
16468938|NCT03505944|Experimental|Treatment|Venetoclax+lenalidomide+rituximab
16468939|NCT03505931||Eluvia|Patients treated with Eluvia stent
16468940|NCT03505918|No Intervention|Standard municipal rehabilitation|Standard care with postoperative rehabilitation at the municipal facility.
16468941|NCT03505918|Experimental|No referral for rehabilitation|No referral for supervised postoperative rehabilitation. Only standard information booklet and advice during hospitalization.
16468942|NCT03505905|Experimental|Pregnenlone (phase 1 and 2)|Participants will receive pregnenolone at phase 1 (baseline-WK 7) and 2 (WK 8-16). The titration schedule is as follows: at baseline a 50 mg (BID, 7 days). WK 1=150 mg (BID, 7 days); WK 2=250 mg (BID, 14 days) and WK 4=250 mg (BID, 14 days) (BID, 14 days). At phase 2 (WK 8) to maintain the double blind of rerandomization, treatment in all conditions recommence at a dosage frequency similar to phase 1. At WK 8=250 mg (BID, 7 days); at WK 9=250 mg (BID, 7 days); WK 10=250 mg (BID, 14 days) and WK 12=250 mg (BID, 14 days) . During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (BID, 4 days) and 50 mg (BID, 4 days), discontinue.
16472024|NCT03484585|Experimental|Rogaratinib (BAY1163877)|Healthy male subjects
16468943|NCT03505905|Placebo Comparator|Placebo rerandom to placebo|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1= placebo (7 days); at WK 2=placebo (14 days) and WK 4=placebo (14 days). Placebo nonresponders rerandomized to placebo: At WK 8=placebo (7 days);WK 9=placebo (7 days);WK 10=placebo (14 days) and WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo (4 days) and placebo (4 days), discontinue.
16468944|NCT03505905|Experimental|Placebo rerandom to pregnenolone|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo nonresponders who are rerandomized to pregnenolone: At WK 8=250 mg (7 days);WK 9=250 mg (7 days);WK 10=250 mg (14 days) & WK 12=250 mg (14 days). During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (4 days) and 50 mg (4 days), discontinue.
16468945|NCT03505905|Placebo Comparator|Placebo responsive cont placebo|Participants will placebo throughout phase 1 (baseline- WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Responders continue to receive placebo at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo responders remain on placebo: At WK 8, placebo (7 days); WK 9=placebo (7 days); WK 10=placebo (14 days) & WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo= 4 days) and placebo=4 days, discontinue.
16468946|NCT03505892||Participants receiving adalimumab|Participants with AS receiving adalimumab
16468947|NCT03505866|Other|Mutual support groups of HIV|HIV-positive people who did not enroll in a community home-based care intervention and receiving regular HIV services and support from mutual support groups of HIV
16468948|NCT03505853|Experimental|Givosiran with 5-probe cocktail|
16468949|NCT03505840||antiphospholipid group|pregnant ladies in the third trimester who have antiphospholipid syndrome
16468950|NCT03505840||control group|pregnant ladies in the third trimester who have no medical disorders with pregnancy
16468951|NCT03505827||TECNIS Monofocal|This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
16468952|NCT03505827||TECNIS Symfony|This group of patients has chosen to undergo implantation of a TECNIS Symfony extended depth of focus lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 SITA standard Humphrey visual field test prior to surgery, and a 24-2 Humphrey visual field test after surgery at 1 month post-operatively.
16468953|NCT03505814|Experimental|Optiflow Group|high flow (6l/min), humidified oxygen administred into nasal cannula for post-extubation new born ventilated patients.
16468954|NCT03505814|Active Comparator|Control Group|Conventional oxygen therapy for post extubation care
16468955|NCT03505788|Placebo Comparator|high-dose loop diuretics+placebo|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of placebo.
~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of placebo. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
16468956|NCT03505788|Experimental|high-dose loop diuretics+acetazolamide|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of acetazolamide.
~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of acetazolamide. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
16468957|NCT03505775|Other|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
16468958|NCT03505762|Experimental|Arm I (tailored prednisone dose)|Participants receive rituximab IV, vincristine sulfate IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16468959|NCT03505762|Active Comparator|Arm II (usual care prednisone dose)|Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16468960|NCT03505749|Experimental|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
16468989|NCT03505541||Control group|Healthy, term, non-obese (BMI < 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
16472025|NCT03484559||1|
16468961|NCT03505749|Active Comparator|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
16468962|NCT03505736||Diagnostic (stress test)|Within 2 years of initiating anti-estrogen therapy or 2 years after completing chemotherapy, participants undergo a stress test which consists of receiving adenosine IV over 1-5 minutes or regadenoson IV over 2 minutes and then undergoing CMR imaging over 45-60 minutes at baseline, and again 3-6 months later.
16468963|NCT03505723|Active Comparator|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
16468964|NCT03505723|Placebo Comparator|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
16468965|NCT03505723|Active Comparator|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
16468966|NCT03505723|Placebo Comparator|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
16468967|NCT03505710|Experimental|Cohort 1: HER2 Overexpressing|Cohort 1 will enroll participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
16468968|NCT03505710|Experimental|Cohort 1a: HER2 Overexpressing|Cohort 1a will enroll participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
16468969|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Cohort 2 will enroll participants with HER2-mutated, unresectable and/or metastatic NSCLC to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
16468970|NCT03505697|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
16468971|NCT03505697|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
16468972|NCT03505684|Experimental|CTP group|1,000 mg of collagen tripeptide (CTP) was orally administered per day for 12 weeks.
16468973|NCT03505684|Placebo Comparator|Control group|1,000 mg of placebo (starch) was orally administered per day for 12 weeks
16468974|NCT03505671|Experimental|Group 1 (acupuncture)|Participants undergo 8 45-minute acupuncture treatments over 10 weeks.
16468975|NCT03505671|Active Comparator|Group 2 (usual care)|Participants receive usual care.
16468976|NCT03505658|Experimental|Intervention|The Intervention is educational with 6 workshops for 2 hrs a week. Data/ assessments are collected, pre and post the 6 weeks intervention and 6 months post follow-up.
16468977|NCT03505658|No Intervention|Control|One or two non-intervention related workshop talks are given; 1 hr each during the same 6 weeks as the intervention arm. Pre and post assessment/ data collection and 6 months follow-up are completed.
16468978|NCT03505645|Active Comparator|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
16468979|NCT03505645|Active Comparator|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
16468980|NCT03505632|Experimental|Recruitment with low PEEP|Recruitment maneuver ( RM) will carried out during 2 minutes with increasing PEEP in stepwise manner.PEEP increase from 5 to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths), PEEP to 20 cmH2O (10 breaths).Then decrease by 5 cmH2O every 3 breaths till back to preset PEEP 5 cmH2O .Recruitment carried out at the following times: post intubation(T1) , after insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O .
16468981|NCT03505632|Active Comparator|High PEEP without RM|"Patients will receive from the start during anesthesia high PEEP (15 cmH2O) with maintaining the peak airway pressure below 40 cm H2O.
~Monitoring times: after intubation(T1), post-insufflation(T2), after desuflation (T3) and before extubation(T4)."
16468982|NCT03505619|Experimental|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
16468983|NCT03505619|No Intervention|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
16468984|NCT03505606|Active Comparator|Control|Visual acuity tests on control participants
16468985|NCT03505606|Experimental|Amblyopic|Visual acuity tests on amblyopic participants.
16468986|NCT03505593|Experimental|EFT placement using ENVUE System|Placement of the ENvizion Medical™ Enteral Feeding Tube (EFT) in the stomach or small intestine of adult patients who require feedings via the oro/ nasoenteric route, using the ENVUE™ System.
16468987|NCT03505567|Other|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
16468988|NCT03505554|Experimental|Lorlatinib|100 mg QD
16469055|NCT03505112|No Intervention|Control group|The patients in control group will be managed according to standard perioperative care.
16468990|NCT03505541||Study group 1|Term pregnant, non-obese (BMI <30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
16468991|NCT03505541||Study group 2|Term pregnant, obese (BMI >30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
16468992|NCT03505528|Experimental|Cohort Group|There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D & E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
16468993|NCT03505515||Lung Cancer Patricipants in China|Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
16468994|NCT03505502|Placebo Comparator|placebo arm|group receive i/v saline plus irrigation of the myoma bed with normal saline
16468995|NCT03505502|Experimental|IV tranexamic acid group|group received IV tranexamic 1gm in normal saline
16468996|NCT03505502|Active Comparator|topical tranexamic acid group|group received topical tranexamic 2gm in normal saline
16468997|NCT03505489|Experimental|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
16468998|NCT03505489|Experimental|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
16468999|NCT03505489|Experimental|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
16469000|NCT03505489|Experimental|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
16469001|NCT03505476|Experimental|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
16469002|NCT03505463||Injured participants|
16469003|NCT03505463||Healthy participants|
16469004|NCT03505450||Population sample|
16469005|NCT03505450||Purposive Sample|
16469006|NCT03505437|Experimental|Stress + Exposure|Stress Condition: Cold water condition of the socially evaluated cold pressor test (SECPT; Schwabe et al, 2008).
16469007|NCT03505437|Active Comparator|Control + Exposure|Control condition: Warm water condition of the SECPT.
16469008|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
16469009|NCT03505424|Active Comparator|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
16469010|NCT03505424|Active Comparator|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
16469011|NCT03505411|Experimental|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
16469012|NCT03505398|Experimental|central vision disorder|
16469013|NCT03505398|Experimental|peripheral vision disorder|
16469014|NCT03505398|Other|control|
16469015|NCT03505385|Experimental|Co-created intervention|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:
~The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).
~The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).
~The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
16469016|NCT03505385|No Intervention|Usual care|
16469017|NCT03505372|Experimental|Contrast enhanced mammography|"The CESM images will be performed according to clinical protocol
~Images will be acquired within approximately 2-12 minutes of contrast injection
~A total of four images per breast will be acquired with low and high energy
~Two radiologists will prospectively review the CESM, and will use a third as tie-breaker
~The CESM will be evaluated for the biopsy site and up to two additional findings in either breast
~The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
16469018|NCT03505359|Experimental|Experimental group|Group treated by the new protocol with partial knee immobilization
16469019|NCT03505359|Active Comparator|Control group|Group treated by a standard protocol for ACL reconstruction.
16469020|NCT03505346|Experimental|percutanous coronary intervention(PCI)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
16469021|NCT03505346|Experimental|Coronary artery bypass-graft(CABG)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
16469022|NCT03505333|Experimental|conventional suture ligature|use of conventional sutures for hysterectomy
16469023|NCT03505333|Active Comparator|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
16469024|NCT03505320|Experimental|zolbetuximab (Cohort 1A)|Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met.
16469056|NCT03505099|Experimental|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10^14 vg/kg
16469057|NCT03505086||cohort|All patients fulfilling the eligibility criteria who can be asked for consent. Basic register of only patient diagnosis, treatment and bleeding yes or no (without identifiable information).
16469058|NCT03505086||cases|Patient with clinically relevant bleeding, defined as major and clinically relevant non-major bleeding that leads to substantial additional medical care: WHO score 3-4 and part of the WHO score 2 bleedings (depending on the need for additional care).
16469025|NCT03505320|Experimental|mFOLFOX6 plus zolbetuximab (Cohort 2)|Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive up to 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous [IV] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.
16469026|NCT03505320|Experimental|Pembrolizumab plus zolbetuximab (Cohort 3A)|Participants will be treated with zolbetuximab and pembrolizumab on a 21-day cycle. Loading dose of zolbetuximab will be administered at cycle 1, day 1 followed by maintenance dose of zolbetuximab once every 3 weeks (Q3W). Pembrolizumab will be administered to 3 to 6 subjects at a intravenously on day 1 of every 21-day cycle and will be infused 1 hour after the zolbetuximab infusion is completed. Tolerability and safety of zolbetuximab in combination with pembrolizumab will be evaluated during the 3-week dose-limiting toxicity (DLT) assessment period. If this cycle 1 dose is not tolerable, a lower dose of zolbetuximab in combination with pembrolizumab will subsequently be evaluated.
16469027|NCT03505320|Experimental|Zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4A/4B)|Participants will be treated with zolbetuximab and mFOLFOX6, nivolumab on a 42-day cycle. Cohort 4A: Loading dose of zolbetuximab in combination with nivolumab and mFOLFOX6 on cycle 1 day 1, followed by zolbetuximab in combination with nivolumab and mFOLFOX6 q2w [days 15 and 29] (1 cycle = 6 weeks). Tolerability and safety of zolbetuximab in combination with nivolumab, mFOLFOX6 will be evaluated during the 3-week DLT assessment period. If cycle 1 dose is not tolerable, a lower dose of dose zolbetuximab in combination with nivolumab and mFOLFOX6 will be subsequently evaluated. Cohort 4B: Subjects will be treated with the combination of zolbetuximab, mFOLFOX6 and nivolumab at the dose deemed tolerable in Cohort 4A. Subjects will receive up to 12 mFOLFOX6 treatments (4 cycles). For Cohorts 4A and 4B, beginning at cycle 5, subjects may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab and nivolumab for the remainder of the study per investigator's discretion.
16469028|NCT03505294|Experimental|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks will be applied."
16469029|NCT03505294|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform.
16469030|NCT03505268|Experimental|telemedicine intervention|The intervention group, in addition to usual care, will get 10 telemedicine interventions by a certified nurse and dietitian who both specialize in treatment of type 1 diabetes.
16469031|NCT03505268|No Intervention|usual care|Usual care consisted of visits to the diabetes center every three months and communication with their doctor by phone when needed.
16469032|NCT03505255|Active Comparator|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
16469033|NCT03505255|Active Comparator|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
16469034|NCT03505255|Active Comparator|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
16469035|NCT03505255|Placebo Comparator|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
16469036|NCT03505242|Experimental|BB|
16469037|NCT03505242|Experimental|DLT|
16469038|NCT03505229|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.
~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
16469039|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
16469040|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
16469041|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
16469042|NCT03505190|Experimental|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
16469043|NCT03505190|Experimental|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
16469044|NCT03505190|Experimental|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
16469045|NCT03505190|Experimental|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
16469046|NCT03505190|Placebo Comparator|Placebo|Participants will receive matching placebo.
16469047|NCT03505177|Experimental|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
16469048|NCT03505151|Experimental|All subjects|
16469049|NCT03505138|Experimental|Group intervention|Conventional management for COPD will take place in our health care system more telematics intervention.
16469050|NCT03505138|Active Comparator|Group control|Is performed only conventional management of COPD in our health care system.
16469051|NCT03505125||PKU Patients|Adults with PKU will be interviewed about the symptoms and impacts of PKU.
16469052|NCT03505125||Observers|Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
16469053|NCT03505125||Clinical Experts|Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
16469054|NCT03505112|Experimental|Goal-directed therapy group|The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
16469059|NCT03505086||controls|Patient without clinically relevant bleeding matched to a case patient based on diagnosis and therapy.
16469060|NCT03505060|Experimental|Group 1: DNA CON-S env + IHV01|Participants will receive 4 mg of DNA CON-S env at Months 0 and 1. They will receive 4 mg of DNA CON-S env and 150 mcg of IHV01 at Months 3 and 6.
16469061|NCT03505060|Placebo Comparator|Group 2: Placebo|Participants will receive placebo at Months 0, 1, 3, and 6.
16469062|NCT03505047|Experimental|Immediate group:|The Copper Intrauterine device will be inserted within 24 hours of the expulsion of the fetus and placenta or after surgical evacuation for placental remains, and prior to discharge from the facility.
16469063|NCT03505047|No Intervention|Delayed Group|The Copper Intrauterine device will be inserted at a local community health centre 14-28 days after discharge.
16469064|NCT03505034|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
16469065|NCT03505021|Experimental|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
16469066|NCT03505021|Placebo Comparator|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
16469067|NCT03505008|Experimental|MTX-Monotherapy Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
16469068|NCT03505008|Experimental|ADA/MTX-Maximum Tolerated Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
16469069|NCT03505008|Experimental|ADA/MTX-Reduced Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.
16469070|NCT03504995|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
16469071|NCT03504982|Experimental|Treatment 1|Treatment sequences: A*-B-C-D
16469072|NCT03504982|Experimental|Treatment 2|Treatment sequences: D-A-B-C*
16469073|NCT03504956|Other|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
16469074|NCT03504956|Other|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
16469075|NCT03504943|Active Comparator|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
16469076|NCT03504943|Experimental|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
16469077|NCT03504930||Impact of biotherapy on postoperative morbidity|Impact of biotherapy on postoperative morbidity in ulcerative colitis
16469080|NCT03504904|Experimental|Internet-delivered ACT and CFT|8 week, guided internet- delivered acceptance and commitment therapy (ACT) and compassion focused therapy (CFT)
16469081|NCT03504904|No Intervention|Wait list control group|Wait list control group, received treatment at later point.
16469082|NCT03504891|Experimental|MRI Prior to CRT for Upgrades|MRI will be performed prior to CRT upgrade.
16469083|NCT03504891|Active Comparator|MRI Prior to de novo CRT Implants|MRI will be performed prior to de novo CRT implants.
16469084|NCT03504878||Patients undergoing laparoscopic appendectomy|Appendix removal via scope.
16469085|NCT03504878||Patients undergoing open appendectomy|Open operation for removal of appendix
16469086|NCT03504865|Experimental|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
16469087|NCT03504865|Active Comparator|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
16469088|NCT03504865|Placebo Comparator|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
16469089|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks (Q2W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
16469090|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks (Q4W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
16469091|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)|2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
16469093|NCT03504826|Experimental|Locomotor training using adaptive robot|The intervention will consist of 60 sessions of locomotor training using the HAL adaptive robot. The training sessions will be scheduled 5 days per week for 12 weeks. A physical therapist with expertise in SCI walking rehabilitation and use of the HAL will oversee all intervention sessions. The intervention sessions will include up to a total of 40 minutes of stepping time, which may take up to 2 hours to complete due to set up time and rest breaks.
16469094|NCT03504813|Experimental|Urinary Incontinence|"The involuntary loss of urine through the urethra, objectively demonstrable and constituting for the person who suffers it a social and hygienic problem.
~In this arm, participants will receive the following interventions: physical activities program, training of the pelvic floor and counseling about occupational performance"
16469095|NCT03504813|Experimental|Insomnia|"A condition characterized by an unsatisfactory amount or quality of sleep which persists for a considerable period. This disorder includes difficulties for the falling and/or staying asleep and early awakening in the final phase of sleep.
~In this arm, participants will receive the following interventions: physical activities program, relaxation training and counseling about occupational performance."
16469096|NCT03504813|Experimental|Risk of falls|"Involuntary events that cause people to lose balance and find themselves on the ground or other firm surfaces. The factor of falls can be intrinsic (related to the person) or extrinsic (derived from the activity or environment of the individual).
~In this arm, participants will receive the following interventions: physical activities program, and counseling about occupational performance"
16469097|NCT03504800||Group A: Classification of Corneal Irregularities|This group will consist of participants >14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
16469098|NCT03504800||Group B: Detection of Keratoconus Progression|Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
16469099|NCT03504800||Group C: OCT-and-Topography Guided PTK|Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
16469100|NCT03504774|Experimental|Cashew or Shrimp Oral Immunotherapy|Participants, ages 7 to 55 years, inclusive, with an allergy to Cashew or Shrimp.
16469101|NCT03504761|Experimental|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
16469102|NCT03504748|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
16469103|NCT03504748|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
16469104|NCT03504735|Placebo Comparator|Therapeutic Lifestyle Change+Placebo|Therapeutic Life-style change intervention with Placebo pills.
16469105|NCT03504735|Active Comparator|Therapeutic Lifestyle Change+Caduet|Therapeutic Lifestyle Change intervention with Caduet pills.
16469106|NCT03504722|Experimental|RESCUE+PE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area Society for the Prevention of Cruelty to Animals (SPCA) facilities.All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
16469107|NCT03504722|Active Comparator|PE+delayed RESCUE|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
16469108|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
16469109|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
16469110|NCT03504696||Patients with Advanced Melanoma|RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)
16469111|NCT03504683|Experimental|Early Time-Restricted Feeding|
16469112|NCT03504683|Experimental|Mid-day Time-Restricted Feeding|
16469113|NCT03504683|Placebo Comparator|Control Schedule|
16469114|NCT03504670|Experimental|Early amniotomy|Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
16469115|NCT03504670|Experimental|Late amniotomy|Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
16469116|NCT03504657|Experimental|Drug-coated balloon angioplasty|
16469117|NCT03504657|Active Comparator|stenting angioplasty|
16469118|NCT03504644|Experimental|Treatment (venetoclax, vincristine liposomal)|Patients receive venetoclax PO QD on days 1-42 of course 1 and days 43-70 of course 2. Patients also receive vincristine liposomal IV weekly for 4 weeks starting on day 14 of course 1.
16469119|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
16469120|NCT03504618||Metastatic colon cancer patients|Colon cancer patients with metastase at the diagnostic time, impossibility of radical resection, adenocarcinoma, treated by at least 3 cycles of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department
16469179|NCT03504150|Experimental|PRISM|It is an online self-guided brief cognitive-behavioural therapy program that offers a headache diary and helps users discover their headache triggers and non-triggers. Then the program provides the users with a few personalized recommendations to help them to cope with their triggers.
16469121|NCT03504605|Experimental|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
16469122|NCT03504605|No Intervention|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
16469123|NCT03504592|Experimental|Glooko App|Glooko application and meter compatibility device (if required)
16469124|NCT03504592|Active Comparator|Traditional Care|Traditional clinic reporting system: paper/MyChart/emailed glucose logs
16469125|NCT03504579|Experimental|rt-fMRI neurofeedback aimed at STG|One session of rt-fMRI neurofeedback from the patient's STG.
16469126|NCT03504579|Sham Comparator|sham rt-fMRI|One session of rt-fMRI neurofeedback from the patient's motor cortex.
16469127|NCT03504566|Other|Intervention|All patients recieve, in randomomized order a four way treatment schedule. Due to the nature of the study, the individual patient will serve as his/hers own comparator.
16469128|NCT03504553|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
16469129|NCT03504553|No Intervention|Control|Normal operating room environment.
16469130|NCT03504540||Case (with pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits"
16469131|NCT03504540||Control (without pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, without pseudo-drusen-like deposits"
16469132|NCT03504527|Experimental|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
16469133|NCT03504527|Active Comparator|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
16469134|NCT03504514|No Intervention|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
16469135|NCT03504514|Experimental|Adapted mechanical ventilation|Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions
16469136|NCT03504501|Experimental|Exp. I: Noonan Syndrome - Lovastatin|200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
16469137|NCT03504501|Experimental|Exp. II: Noonan Syndrome - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
16469138|NCT03504501|Experimental|Exp. III: Neurofibromatosis Type 1 - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
16469139|NCT03504488|Experimental|Monotherapy - CAB-ROR2-ADC (BA3021) alone|BA3021 alone
16469140|NCT03504488|Experimental|Combination Therapy|CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
16469141|NCT03504475|Experimental|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
16469142|NCT03504475|Active Comparator|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
16469143|NCT03504462|Experimental|Distal tibial nerve block|Patient receiving a specific block of medial and lateral plantar nerves in order to preserve the calcaneal nerve
16469144|NCT03504449|Experimental|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
16469145|NCT03504449|Experimental|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
16469146|NCT03504423|Experimental|CPI-613, mFolfirinox|"CPI-613, mFolfirinox
~CPI-613 at 500 mg/m2 IV infusion at a rate of 4mL/min via a central venous port on day 1 and 3 of a 14-day cycle.
~mFolfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
16469147|NCT03504423|Active Comparator|Folfirinox|"Folfirinox
~Folfirinox: Oxaliplatin (Eloxatin) at 85 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 180mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
16469148|NCT03504410|Experimental|CPI-613 + HD Cytarabine and Mitoxantrone|"CPI-613 + High Dose Cytarabine and Mitoxantrone
~CPI-613 at 2,000 mg/m2/day from day 1 to 5.
~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine."
16469149|NCT03504410|Active Comparator|Control (HAM) and control sub-groups (MEC and FLAG)|"High Dose Cytarabine and Mitoxantrone
~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.
~Mitoxantrone, Etoposide and Cytarabine
~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6
~Fludarabine, Cytarabine and Filgrastim
~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
16469180|NCT03504150|No Intervention|Usual care|
16469150|NCT03504397|Experimental|Arm A (zolbetuximab plus mFOLFOX6)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
16469151|NCT03504397|Placebo Comparator|Arm B (Placebo plus mFOLFOX6)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
16469152|NCT03504371|Active Comparator|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
16469153|NCT03504371|Sham Comparator|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
16469154|NCT03504358||Analysis before liver resection|Multivariate analysis of predictive factors associated with survival
16469155|NCT03504358||Different risk group|Low-risk group, moderate-risk group, high-risk group
16469156|NCT03504358||Model comparison|Comparison of models in predicting survival
16469157|NCT03504345|Active Comparator|Control Group|This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
16469158|NCT03504345|Experimental|Experimental Group|This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
16469159|NCT03504332|Experimental|Calcium Hydroxide in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Pure Calcium Hydroxide powder mixed with saline will be placed as intra-canal medication in the 1st visit of dental pulp revascularization.
16469160|NCT03504332|Active Comparator|Di-antibiotic paste in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Mix 1:1 ciprofloxacin: metronidazole to a final concentration of 0.1 mg/ml, placed as intra-canal medication in the 1st visit of dental pulp revascularization.
16469161|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
16469162|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
16469163|NCT03504280|Active Comparator|high dose IM|cholecalciferol 600,000 IU given intramuscularly
16469164|NCT03504280|Active Comparator|high dose oral|cholecalciferol 600,000 IU given orally
16469165|NCT03504280|Active Comparator|low dose oral|cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU
16469166|NCT03504267|Experimental|Physical Activity Group|The PAG (physical activity) group will receive evidence-based educational information as well as a list of local resources for pursuing physical activity.
16469167|NCT03504267|No Intervention|Standard of Care Group|The SOC (standard of care) group will receive no additional information beyond standard-of-care brochures and information
16469168|NCT03504254||CSM|A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
16469169|NCT03504241|Experimental|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
16469170|NCT03504241|Experimental|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
16469171|NCT03504241|Experimental|MSCs 10^6 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks.
16469172|NCT03504215|Experimental|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
16469173|NCT03504202|Experimental|Trimetazidine|
16469174|NCT03504189|Experimental|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
16469175|NCT03504176||Intervention|Patients will be ventilated according to the bundle; including ventilation targets, tidal volume, end expiratory pressure-fraction of inspired oxygen titration.
16469176|NCT03504176||Control|Standard of care prior to implementation of the ventilation bundle
16469177|NCT03504163|Experimental|Pembrolizumab (MK-3475)|Patients will receive Pembrolizumab (MK-3475) administered after TUR as single agent initial therapy. Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur.
16469178|NCT03504150|Experimental|SPHERE|It is an online self-guided comprehensive cognitive-behavioural therapy program that offers a headache diary, learning modules that teach a variety of cognitive and behavioural skills to cope better with their headaches, and a discussion forum where users may interact.
16472479|NCT03481400|Experimental|Placebo|Infusion with placebo (isotonic saline)
16469183|NCT03504124|Experimental|Intervention group|Patients will receive a multicomponent intervention.
16469184|NCT03504124|No Intervention|Control group|Patients will receive the usual care.
16469185|NCT03504111|Active Comparator|Needle Tenotomy|1 group will be assigned to get the standard treatment for chronic tendinopathy, percutaneous needle tenotomy (PNT). It is currently considered a standard treatment option. Ultrasound guided PNT with approximately 25 passes through the tendon and enthesis with approximately an 18 gauge needle with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used
16469186|NCT03504111|Active Comparator|Platelet Rich Plasma|1 group will be assigned to the PRP arm. Investigators will have a trained provider draw the blood, and prepare the PRP according to manufacturer and departmental (KP) protocol. Ultrasound guided injection of this PRP using approximately an 18 gauge needle with a single pass through the tendon into affected area as demonstrated on ultrasound. Adequate amount of anesthetic will be given in a separate syringe with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of amount and type of anesthetic used. The amount of anesthesia will be the same in both arms of the study
16469187|NCT03504098||Lung cancer patients tumor|Using to analysis metabolomic markers, one carbon folate nutrition levels in lung cancer patients.
16469188|NCT03504098||Lung cancer patients blood|Using to analysis folate, B12, homocysteine levels in plasma and RBC. Using to analysis cDNA gene test in buffy coat.
16469189|NCT03504098||Lung cancer patients|Supply nutrition counseling
16469190|NCT03504085|Experimental|Hatha Yoga|This arm will receive the active Hatha yoga intervention. Instructors lead participants through various yoga poses for 60-minutes, 1-2x weekly for 12 weeks, and daily home practice is recommended.
16469191|NCT03504085|Active Comparator|Restorative Yoga|This arm will receive a restorative yoga intervention. Instructors guide participants through relaxation exercises, typically with eyes closed, laying down, and minimal movement 60-minutes, 1-2x weekly for 12 weeks.
16469192|NCT03504072|Active Comparator|Tofacitinib 5mg|tofacitinib 5 mg 12 hourly daily for 9 months. Evaluation schedule will be baseline, 1st month, 3rd months and 3 monthly for 9 months. relevant investigations will be done at each visit. occurrence of tuberculosis and infections will be recorded at follow up visits.
16469193|NCT03504072|Active Comparator|Etanercept 50 mg|Etanercept 50 mg subcutaneously every 7 days interval for 1st month then, Etanercept 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval for 9 months. Occurrence of tuberculosis and infections will be recorded at follow up visits.
16469194|NCT03504059|No Intervention|Control|The usual educational program is applied
16469195|NCT03504059|Active Comparator|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
16469196|NCT03504059|Active Comparator|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
16469197|NCT03504046|Experimental|Artificial Pancreas App|After completing a 1 week open-loop run in period, subjects will use the APS APP for a 48-hour period in an observed transitional environment.
16469198|NCT03504033|Experimental|Xenon|Xenon concentration of 50-60 % will be used for maintenance of general anesthesia and will be adjusted to maintain Bispectral index (BIS) value between 40 and 60.
16469199|NCT03504033|Active Comparator|Desflurane|Desflurane concentrations of 4-5%/0.8 minimum alveolar concentration (MAC) respectively will be used for maintenance of general anesthesia and will be adjusted to maintain BIS index value between 40 and 60.
16469200|NCT03504020|Experimental|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
16469201|NCT03504020|No Intervention|Control Arm|Standard CRT through 6 months follow-up.
16469202|NCT03503994|Other|Drug|"Patients receiving inhaled beclomethasone diproprionate in four escalating doses:
~200 mcg bid
~400 mcg bid
~600 mcg bid
~800 mcg bid"
16469203|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
16469204|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
16469205|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
16469206|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
16469207|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
16469208|NCT03503968|Experimental|Phase I - 3 disease entities|MDG1011 administration of escalating doses
16469209|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 1|MDG1011 administration of Phase II recommended dose
16469210|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 1|Investigator Choice therapy
16469211|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 2|MDG1011 administration of Phase II recommended dose
16469212|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 2|Investigator Choice therapy
16469213|NCT03503955|Experimental|study group|fine motor skills activities and Leap-Motion virtual reality games
16469214|NCT03503955|Experimental|control group|fine motor skills activities
16469251|NCT03503656||CompuFlo|All the consecutive patients undergoing to an epidural catheter placement in Gynecological and Obstetric setting
16469215|NCT03503942|Experimental|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
16469216|NCT03503942|No Intervention|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
16469217|NCT03503929|Other|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
16469218|NCT03503903|Experimental|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
16469219|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
16469220|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
16469221|NCT03503864|Experimental|ATO-combined chemotherapy|Patients receive combined induction chemotherapy with arsenic trioxide.
16469222|NCT03503851|Active Comparator|One CLIP|Implantation of single MitraClip
16469223|NCT03503851|Active Comparator|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
16469224|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
16469225|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
16469226|NCT03503825|Experimental|Healthy Volunteers|Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
16469227|NCT03503825|Experimental|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.
16469228|NCT03503812|No Intervention|No intervention to DDS exposure - Asthma in Children|
16469229|NCT03503812|Experimental|Intervention 1 - Asthma in Children|
16469230|NCT03503812|Experimental|Intervention 2 - Asthma in Children|
16469231|NCT03503812|No Intervention|No intervention to DDS exposure - Atrial Fibrillation|
16469232|NCT03503812|Experimental|Intervention 1 - Atrial Fibrillation|
16469233|NCT03503812|Experimental|Intervention 2 - Atrial Fibrillation|
16469234|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
16469235|NCT03503786|Active Comparator|Chemotherapy|Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab
16469236|NCT03503786|Experimental|Chemotherapy and avelumab|Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
16469237|NCT03503773|Experimental|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
16469238|NCT03503773|Sham Comparator|Sham Control Arm|Only renal angiography performed
16469239|NCT03503760|Experimental|true-sham|"Patients first received the true LIMFA Therapy® treatment for 3 weeks followed by 3 weeks of washout and then six sham sessions for 3 weeks more."
16469240|NCT03503760|Experimental|sham-true|"Patients first received the sham treatment for 3 weeks followed by 3 weeks of washout and then six true LIMFA Therapy® sessions for 3 weeks more."
16469241|NCT03503734||Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.
~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.
~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.
~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
16469242|NCT03503721|Experimental|BipolEP|includes all patients undergoing BipolEP surgery
16469243|NCT03503721|Active Comparator|TURP|includes all patients undergoing TURP surgery
16469244|NCT03503708|Experimental|Intervention Group|All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
16469245|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
16469246|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
16469247|NCT03503682|Active Comparator|standard treatment|Patients in this group are treated with 3000 cGy in 10 daily fractions
16469248|NCT03503682|Experimental|short course treatment|Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
16469249|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
16469250|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
16472480|NCT03481387|Other|PERCEVAL S valve|patients to be treated with PERCEVAL S valve
16469252|NCT03503630|Experimental|Locally advanced rectal cancer patients|"Week 1: D1-5: radiotherapy 25 Gy in 5 fractions
~mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)
~Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
16469253|NCT03503617|Experimental|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
16469254|NCT03503617|Active Comparator|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
16469255|NCT03503604|Experimental|group 1|hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin)
16469256|NCT03503604|Experimental|group 2|hPV19 mAb plus paclitaxel/carboplatin
16469257|NCT03503604|Experimental|group 3|hPV19 mAb plus gemcitabine/carboplatin
16469258|NCT03503604|Experimental|group 4|hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
16469259|NCT03503578|Experimental|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
16469260|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
16469261|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
16469262|NCT03503539|Experimental|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
16469263|NCT03503539|Active Comparator|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
16469264|NCT03503526|Experimental|Music therapy treatment|"An intervention consisting of 12 weekly sessions of trauma-focused treatment in form of group music and imagery therapy.
~Receptive music therapy."
16469265|NCT03503526|No Intervention|Wait List Control|No treatment for approximately 12 weeks.
16469266|NCT03503513|Experimental|Gentamicin sulfate|
16469267|NCT03503500|Experimental|Laid-back breastfeeding|Women will breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves, without following particular procedure to breastfed.
16469268|NCT03503500|Active Comparator|Standard care|Staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast,
16469269|NCT03503487|No Intervention|Control|Patients receiving standard informed consent procedure before intervention
16469270|NCT03503487|Experimental|Planner 1|Patients receiving 3D informed consent procedure before intervention with Surgical Theater
16469271|NCT03503487|Experimental|Planner 2|Patients receiving 3D informed consent procedure before intervention with Vesalius
16469272|NCT03503474||CDI cases|
16469273|NCT03503474||CDI negative controls|
16469274|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
16469275|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
16469276|NCT03503448|Other|space between 11/21|Osteotomy between the maxillary central incisors
16469277|NCT03503448|Other|space between 12/13 and 22/23|Osteotomy between the maxillary lateral incisors and canines
16469278|NCT03503435|Other|Art therapy intervention|Participants will then take part in six-weeks of group art therapy with a goal of increasing self-awareness and expression. During the intervention sessions, participants will have access to a wide range of materials conventionally used in art therapy excluding materials that may be abrasive or powdery and unsuitable around people wearing a stoma.
16469279|NCT03503422|Experimental|tDCS (anodal) + therapeutic exercises|"Real transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
16469280|NCT03503422|Sham Comparator|tDCS (sham) + therapeutic exercises|"Sham transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
16469281|NCT03503409|Experimental|AG-120|Subjects enrolled will receive continuous 28-day cycles of AG-120 - 500 mg. AG-120 will be dispensed on Day 1 of each treatment cycle
16469282|NCT03503396|Experimental|BAC feedback|Participants will receive a warning when their BAC is above a set limit (cutpoint is not disclosed by well below legal limit). Warning will notify them that their results indicate it is not safe for them to drive.
16472919|NCT03478319|Experimental|Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
16469283|NCT03503396|Active Comparator|No Feedback|Participants will not receive any information on their BAC from their device.
16469284|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
16469285|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
16469286|NCT03503370|Experimental|chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
16469287|NCT03503370|Placebo Comparator|placebo|Participants randomized to the placebo will wash their feet using bath CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
16469288|NCT03503357|Experimental|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
16469289|NCT03503357|Experimental|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
16469290|NCT03503357|Experimental|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
16469291|NCT03503357|Experimental|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
16469292|NCT03503344|Experimental|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
16469293|NCT03503344|Active Comparator|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
16469294|NCT03503331|Experimental|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system. The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
16469295|NCT03503318|Placebo Comparator|Placebo|Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
16469296|NCT03503318|Experimental|TV-46000 q1m|Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
16469297|NCT03503318|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
16469298|NCT03503305|Experimental|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
16469299|NCT03503305|Active Comparator|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
16469300|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
16469301|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
16469302|NCT03503279|No Intervention|Macintosh Laryngoscope|
16469303|NCT03503279|Active Comparator|McGrath MAC® Video Laryngoscope|
16469304|NCT03503266|Experimental|[14C] MT-7117|14-C MT-7117
16469305|NCT03503253|Other|Single-arm|LAA leak closure using detachable coils; Interlock-35 Fibered IDC Occlusion System, Concerto Helix Detachable Coil System
16469306|NCT03503227|Active Comparator|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
16469307|NCT03503227|Active Comparator|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
16469308|NCT03503214||Septic patients|Patients with sepsis or septic shock according to the SEPSIS-III (Singer M Jama 2016) admitted to the general Intensive Care Unit
16469309|NCT03503214||Healthy volunteers|Subjects without known respiratory, cardiovascular, hepatic, renal or hematologic diseases.
16469310|NCT03503201|Active Comparator|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
16469311|NCT03503201|No Intervention|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
16469312|NCT03503188|Experimental|All participants|
16469313|NCT03503175|Experimental|Novel urinary access system|Participants randomized to this arm will receive the novel urinary access system (CystoSureTM).
16469314|NCT03503175|Active Comparator|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and rigid cystoscopy.
16469315|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
16469316|NCT03503136|Experimental|A (TPF+P-RT)|Induction docetaxel, cisplatin, and fluorouracil plus concurrent chemoradiotherapy with cisplatin
16469317|NCT03503136|Experimental|B (TNF+N-RT)|Induction docetaxel, nedaplatin, and fluorouracil plus concurrent chemoradiotherapy with nedaplatin
16469318|NCT03503136|Experimental|C (TPX+P-RT)|Induction docetaxel, cisplatin, and capecitabine plus concurrent chemoradiotherapy with cisplatin
16469319|NCT03503136|Experimental|D (TNX+N-RT)|Induction docetaxel, nedaplatin, and capecitabine plus concurrent chemoradiotherapy with nedaplatin
16469320|NCT03503123||COPD patients with deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV with severe symptoms of deventilation dyspnoea (Borg Dyspnoea Scale ≥ 5)
16469321|NCT03503123||COPD patients without deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV without symptoms of deventilation dyspnoea, matched with the first cohort/group with regard to the degree of static lung hyperinflation and NIV settings.
16469322|NCT03503110|Experimental|dMRI and electrocorticography|Direct measurements of cortical electrical properties of patients operated on awake surgery for a brain tumor, using electrocorticography (ECoG), based on the dMRI tractography data previously acquired for each patient.
16469323|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
16469324|NCT03503084|Experimental|TCC group|Classical Yang's TCC exercise
16469325|NCT03503058|Experimental|Group 1|N=140 will receive PfSPZ Vaccine; three doses of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals.
16469326|NCT03503058|Placebo Comparator|Group 2|N=70 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals.
16469327|NCT03503058|Experimental|Group 3|"N=140 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10^5 PfSPZ of PfSPZ Challenge administered by DVI at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.
~CQ will first be given as a loading dose of 620 mg base two days before the first administration of PfSPZ Challenge, followed by weekly 310 mg doses of CQ with the last dose 5 days after the last dose of PfSPZ Challenge."
16469328|NCT03503058|Placebo Comparator|Group 4|"N=70 will receive normal; three doses of NS administered by DVI given at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.
~CQ will first be given as a loading dose of 620 mg base two days before the first administration of NS, followed by weekly 310 mg doses of CQ with the last dose 5 days after the last dose of NS."
16469329|NCT03503032||Fenestrated|Standard extracardiac fontan undergoing Fontan fenestration creation
16469330|NCT03503032||Non fenestrated|Standard extracardiac fontan without fenestration
16469331|NCT03503019||Diabetic|
16469332|NCT03503019||Non-diabetic|
16469333|NCT03502993||MOFICHE|This is an observational study assessing the management and outcome of children presenting to Emergency Departments (ED) with fever across Europe. This study will use large departmental datasets to collect information on at least 50,000 febrile episodes . This study will use large-scale, pseudo-anonymized departmental data, and will not involve consented patient recruitment; nor will it use patient samples. Data included in MOFICHE will be based on that collected as part of routine clinical care. Antibiotic prescription, hospitalisation and number/type of investigations, re-attendance at ED within 5 days of the first hospital presentation will be recorded.
16469334|NCT03502993||BIVA studies|A minimum of 3,000 children will be recruited to the BIVA-ED study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
16469335|NCT03502980|Active Comparator|Peripherally inserted central venous catheters|Bard PowerPICC
16469336|NCT03502980|Active Comparator|Midline|Bard PowerMidline catheter
16469337|NCT03502967|Experimental|Hyperpolarized [1-13C] Pyruvate|Injection with hyperpolarized [1-13C] Pyruvate during MRI.
16469338|NCT03502967|Experimental|Hyperpolarized [2-13C] Pyruvate|Injection with hyperpolarized [2-13C] Pyruvate during MRI.
16469339|NCT03502954|Experimental|ABY-039 IV|
16469340|NCT03502954|Experimental|ABY-039 SC|
16469341|NCT03502954|Placebo Comparator|Placebo IV|
16469342|NCT03502954|Placebo Comparator|Placebo SC|
16469343|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
16469344|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
16469345|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
16469346|NCT03502928|Active Comparator|Conventional Treatment|Motor Control + Manual Therapy
16469347|NCT03502928|Experimental|Experimental Treatment|Motor Control + Manual Therapy + Dry Needling
16469348|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
16469349|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
16469350|NCT03502902|Experimental|HEC68498|administered once on first day in each Treatment Period， HEC68498 VS placebo 3:1 ratio
16469351|NCT03502902|Placebo Comparator|placebo|administered once on first day in each Treatment Period
16469352|NCT03502889|Active Comparator|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
16469353|NCT03502889|Experimental|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
16469354|NCT03502863|Experimental|Digital refraction|Web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone
16469355|NCT03502863|Active Comparator|Manual Refraction|Manual manifest refraction is performed by an eyesore specialist using a phoropter.
16469356|NCT03502850|Experimental|ASK120067|patients take ASK120067 orally once per day at different dose
16469357|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
16469358|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
16469359|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
16469360|NCT03502824|Active Comparator|PuraPly® AM plus Standard of Care|
16469361|NCT03502824|Active Comparator|Standard of Care (SOC) for Pressure Ulcers|
16469362|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
16469363|NCT03502798|Experimental|scanning a/LCI|
16469364|NCT03502785|Experimental|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
16469365|NCT03502785|Experimental|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
16469366|NCT03502772|Experimental|Pilates exercises group|
16469367|NCT03502772|Active Comparator|Home exercise program group|
16469368|NCT03502759|No Intervention|Pre-intervention|Seizure patients receive usual care.
16469369|NCT03502759|Experimental|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
16469370|NCT03502746|Experimental|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
16469371|NCT03502733|Experimental|Treatment (copanlisib, nivolumab, ipilimumab)|"DOUBLET TREATMENT PLAN: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~TRIPLET TREATMENT PLAN: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Beginning cycle 2, patients also receive ipilimumab IV over 90 minutes on day 1 for a total of 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16469372|NCT03502720||Control Patients|"Data obtained retrospectively from Scaphoid fixation surgeries performed at our center using the standard procedure (no device for guide wire positioning).
~This control group should have registered al parameters and variables to be studied."
16469373|NCT03502720||Case Patients|Prospective series of ten patients on which the external 3D guide system will be used.
16469395|NCT03502694|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
16469396|NCT03502694|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
16469397|NCT03502694|Placebo Comparator|Regimen C (Placebo)|Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
16469398|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.
~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
16469399|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
16469400|NCT03502668|Experimental|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
16469401|NCT03502668|Experimental|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
16469402|NCT03502655|Other|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
16469403|NCT03502655|Active Comparator|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
16469404|NCT03502655|Other|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
16469405|NCT03502655|Active Comparator|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
16469406|NCT03502642|Placebo Comparator|Placebo (P)|Placebo group parturients will receive spinal anesthesia with intrathecal morphine and will have continuous normal saline wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
16469407|NCT03502642|Active Comparator|Ropivacaine (R)|Ropivacaine group parturients will receive spinal anesthesia without intrathecal morphine and will have continuous ropivacaine (Ropivacaina Molteni®) wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
16469408|NCT03502629|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
16469409|NCT03502616|Experimental|Tofacitinib|
16469410|NCT03502616|Placebo Comparator|Placebo|
16469411|NCT03502603|Active Comparator|Cerebral neurological illness (CNI) participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
16469412|NCT03502603|Active Comparator|Non-CNI participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
16469413|NCT03502590|Experimental|IGEL arm|
16469414|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
16469415|NCT03502564|Active Comparator|CBT for ED only|In this arm, participants will receive CBT for ED following intensive ED treatment (see intervention section for description).
16469416|NCT03502564|Experimental|Concurrent CBT for ED and PTSD|In this arm, participants will receive concurrent CBT for ED and PTSD following intensive treatment. (see intervention section for description).
16469417|NCT03502551|Experimental|Treatment with Ketamine|In this arm an IV infusion of 0.5 mg/kg of ketamine will be administered over 40 minutes.
16469418|NCT03502538|Experimental|Curaprox 5460 Ultra Soft|Brushing with a Curaprox Ultra Soft 5460 toothbrush for one minute timed without orientations about brushing techniques and without supervision
16469419|NCT03502538|Active Comparator|Oral-B Indicator Plus|Brushing with a Oral-B Indicator Plus toothbrush for one minute timed without orientations about brushing techniques and without supervision
16469420|NCT03502525|Experimental|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
16472920|NCT03478319|Experimental|Cohort 4|ACE-2494 or placebo 1.0 mg/kg SC Day 1
16469421|NCT03502512|Experimental|Arm I (REVOLVE technique)|Patients undergo reconstructive surgery with REVOLVE technique.
16469422|NCT03502512|Experimental|Arm II (PureGraft technique)|Patients undergo reconstructive surgery with PureGraft technique.
16469423|NCT03502499|Experimental|Half-normal saline|
16469424|NCT03502499|Active Comparator|Normal saline|
16469425|NCT03502486|Experimental|Moderate exercise|20 minutes of cycle ergometry at 50 - 60% of heart rate max.
16469426|NCT03502486|Experimental|Intense Exercise|20 minutes of cycle ergometry at 70 - 80% of heart rate max.
16469427|NCT03502486|Active Comparator|Rest|20 minutes of seated reading.
16469428|NCT03502473|Experimental|One pass/no treatment arm|One random flank will be treated with UltraShape Power device with one pass or remained as a control (no treatment)
16469429|NCT03502473|Experimental|Multiple passes treatment arm|Second flank will be treated with UltraShape Power device with multiple passes.
16469430|NCT03502460|Other|ORFALU|"Lung ultrasound consists of the application of a high-frequency ultrasound probe type Trans Thoracic Echography (ETT) on the anterior and lateral chest of the patient. Since air and bone do not pass through the US, it is the artefacts due to these structures that constitute ultrasound lung semiology.
~Esophageal Doppler is a means of monitoring cardiac output measuring stroke volume (SV)."
16469431|NCT03502447|Experimental|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
16469432|NCT03502447|Active Comparator|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
16469433|NCT03502434|Experimental|90 mg/mL SM04755 in water|90 mg/mL SM04755 in water applied via patches
16469434|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle|90 mg/mL SM04755 in aqueous Vehicle applied via patches
16469435|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches
16469436|NCT03502434|Other|Vehicle|Aqueous Vehicle applied via patches
16469437|NCT03502434|Other|White petrolatum|White petrolatum (Negative control) applied via patches
16469438|NCT03502434|Other|Sodium lauryl sulfate|Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches
16469439|NCT03502421|Experimental|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
16469440|NCT03502421|No Intervention|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
16469441|NCT03502408|Experimental|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
16469442|NCT03502395|Active Comparator|Group I|Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
16469443|NCT03502395|Placebo Comparator|Group II|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
16469444|NCT03502382|Other|radilogical|Radiological: standing antero-posterior full-length digital images of the lower extremities
16469445|NCT03502369|Experimental|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
16469446|NCT03502369|No Intervention|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
16469447|NCT03502356|Active Comparator|Control Group|This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
16469448|NCT03502356|No Intervention|Study Group|This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)
16469449|NCT03502343|Experimental|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
16469450|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
16469451|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
16469452|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
16469453|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
16469454|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
16469455|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
16469456|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
16469457|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
16469458|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
16469459|NCT03502317|Experimental|Prehabilitation Study Arm|Patients will participate in a two-pronged prehabilitation strategy - physical prehabilitation and psychological prehabilitation. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before a patient's clinically indicated surgery.
16469481|NCT03502135|Experimental|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
16469482|NCT03502122|Experimental|VR rehabilitation|Virtual Reality based rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
16469460|NCT03502317|No Intervention|Usual Care Study Arm|No specific exercises or stress reduction techniques are prescribed and the patient will be counseled to continue their current level of activity, and will be given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in the Usual Care arm will also be given the same Fitbit activity tracker as patients in the Prehabilitation arm in order to eliminate the activity tracker as an intervention itself and to be able to track the activity (steps) for comparison. Patients in the Usual Care arm will be required to wear their Fitbit activity tracker from the day of randomization to 90 days post-surgery. Patients will record their steps in the diary provided.
16469461|NCT03502304|Active Comparator|Control group|No-exercise
16469462|NCT03502304|Experimental|Endurance training plus resistant training|To concurrent training (endurance training plus resistant training, RT) program will be use cycle ergometers adapted for obese adults (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Prior to the CT intervention, all subjects were familiarized (during 3 sessions) with the training protocols. The CT intervention included 3 weekly sessions of both ET and RT. The core part of each session included RT followed by ET exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
16469463|NCT03502291|Active Comparator|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
16469464|NCT03502291|Placebo Comparator|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
16469465|NCT03502291|Active Comparator|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
16469466|NCT03502291|Placebo Comparator|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
16469467|NCT03502278|Active Comparator|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
16469468|NCT03502278|No Intervention|Waitlist|Waitlist
16469470|NCT03502252|Experimental|Treatment Group|Semillas de Apego is a group-based psychosocial program for victimized caregivers with children 2 to 5 in Colombia, a country devastated by violence. The program's builds upon scientific evidence on (i) the way in which violence hinders early childhood development and erodes mothers' mental health and their capacity to form nurturing relationships with their children, and (ii) the effectiveness of promoting healthy child-parent attachments to mitigate the effects of toxic stress on toddlers (Lieberman and Van Horn, 2011).
16469471|NCT03502252|No Intervention|Control Group|Centers and participants assigned to the this group continue to have access to the regular early childhood programs offered through the centers to which children are affiliated.
16469472|NCT03502239|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
16469473|NCT03502239|No Intervention|Control- wait list group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
16469474|NCT03502226|Experimental|Intervention group|Received tailored feedback regarding sexual health risks
16469475|NCT03502226|No Intervention|Control group|Did not receive tailored feedback.
16469476|NCT03502187|Active Comparator|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
16469477|NCT03502187|Experimental|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
16469478|NCT03502187|Experimental|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
16469479|NCT03502161||All subjects|Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.
16469480|NCT03502148|Experimental|Open-Label, Single Arm Study of PRV111|In Stage 1, subjects will receive 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery. Following review of Stage 1 subject data, additional subjects will be enrolled in Stage 2 and will receive 2, 3 or 5 treatment applications dependent on the results of Stage 1 at each of the 4 visits prior to their tumor surgery.
16469547|NCT03501641|Active Comparator|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
16469483|NCT03502122|Active Comparator|control- conventional rehabilitation|conventional rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
16469484|NCT03502109|Experimental|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
16469485|NCT03502109|No Intervention|Control group|Usual care by physicians, nurses and dietitians.
16469486|NCT03502096|Experimental|100% portion size|100% portion sizes of all foods served (baseline). To-go container and controls received this meal.
16469487|NCT03502096|Experimental|125% portion size|125% of baseline portions served. To-go container and controls received this meal.
16469488|NCT03502096|Experimental|150% portion size|150% of baseline portions served. To-go container and controls received this meal.
16469489|NCT03502096|Experimental|175% portion size|175% of baseline portions served. To-go container and controls received this meal.
16469490|NCT03502070|Other|Open-Label Placebo|One dose (4 capsules) of placebo
16469491|NCT03502044|Active Comparator|Arm 1, active KOS treatment|Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
16469492|NCT03502044|Placebo Comparator|Arm 2, 8 inactive KOS treatments then 8 active KOS treatments|Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
16469493|NCT03502031|Experimental|Renin-Angioten (RAAombination with Spironolactone|Patients with overt Type II diabetic nephropathy and >5 mg/gm UP/Cr ratio that wi to maximal RAAS blockade (ACE/ARB-such as Lisinopril 2000mg, Losartan in combination with Spironolactone (25 m Qday) for 24 months. The determination of maximum tolerwill be left to the discretion anyone at the site
16469494|NCT03502018|Placebo Comparator|Saline|This arm will receive Saline along with Bupivacaine
16469495|NCT03502018|Experimental|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
16469496|NCT03502005|Experimental|BIKTARVY®|initiation of single pill once daily bictegravir/emtricitabine/tenofovir alafenamide from prior efavirenz/emtricitabine/tenofovir DF
16469497|NCT03501992|Other|Practice A|Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
16469498|NCT03501992|Other|Practice B|Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
16469499|NCT03501992|Other|Practice C|Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
16469500|NCT03501992|Other|Practice D|Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
16469501|NCT03501992|Other|Practice E|Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
16469502|NCT03501992|Other|Practice F|Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
16469503|NCT03501979|Experimental|Tucatinib + Trastuzumab + Capecitabine|Tucatinib will be taken orally at 300 mg twice a day starting with Cycle 1, Day 1. A cycle consists of 21 days. Capecitabine will be taken orally at 1000 mg/m2 twice a day on Days 1-14 starting with cycle 1. Trastuzumab is given intravenously as a loading dose of 8 mg/kg on Cycle 1, Day 1 and then at 6 mg/kg for all subsequent cycles.
16469504|NCT03501966|Active Comparator|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).
~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
16469505|NCT03501966|Active Comparator|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).
~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.
~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
16469548|NCT03501628|Placebo Comparator|Placebo|"2 servings daily
~Serving information:
~204 kcal
~2.8 g fat
~44.4 g carbohydrate
~0.4 g protein (0 g L-leucine)"
16469549|NCT03501628|Experimental|L-leucine + maltodextrin|"2 servings daily
~Serving information:
~200 kcal
~2.0 g fat
~43.1 g carbohydrate
~2.8 g protein (2.8 g L-leucine)"
16472921|NCT03478319|Experimental|Cohort 5|ACE-2494 or placebo 2.0 mg/kg SC Day 1
16469506|NCT03501966|Active Comparator|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).
~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.
~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
16469507|NCT03501953|Experimental|Nature Exposure|6-week physical activity course in a natural environment
16469508|NCT03501953|Active Comparator|Urban Exposure|6-week physical activity course in an urban environment
16469509|NCT03501927|Active Comparator|FOCUS (focused cardiac ultrasound)|Patients allocated to FOCUS will receive a preoperative FOCUS examination in conjunction with a standard anesthetic preoperative evaluation.
16469510|NCT03501927|No Intervention|Control|Patients allocated til control arm will receive a standard anesthetic preoperative evaluation according to hospitals' standards.
16469511|NCT03501914|Experimental|Mindfulness Based Intervention|Mindfulness principles based manualized intervention will be provided to the participants which is developed by colleagues in Manchester. This intervention will be adapted to be accessible for people having intellectual disability (ID) in Pakistan.Sessions will take place once-weekly for 12 weeks including an initial orientation session. It will include breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking
16469512|NCT03501888|Active Comparator|Cognitive Behavior Therapy (CBT)|CBT: individually, ca 18 weeks.
16469513|NCT03501888|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT: given in a group setting: ca 18 weeks.
16469514|NCT03501875|Experimental|CAC Score|CAC Score evaluated by the Agatston method
16469515|NCT03501862|Experimental|Mindfulness-based intervention|Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
16469516|NCT03501862|Active Comparator|Psychoeducation|Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
16469517|NCT03501849|Experimental|Polypectomy using a cold snare|Polypectomy by cold-snare technique
16469518|NCT03501836|Experimental|Rapid Rhythm Handheld 8-lead ECG Device|Participants will have measurements taken with the 8 lead ECG system, which will be compared to the conventional standard care 12 lead ECG.
16469519|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.
~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.
~Photoacoustic tomography to be performed after ultrasound"
16469520|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.
~Photoacoustic tomography to be performed after ultrasound"
16469521|NCT03501797|Experimental|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
16469522|NCT03501797|Experimental|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
16469523|NCT03501784|Experimental|Novidia Dental bonding and flow|Nobio particles incorporated within Novidia Dental Bonding and Flow.
16469524|NCT03501784|Active Comparator|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
16469525|NCT03501771|Experimental|Acupuncture|Acupuncture needle will be administered.
16469526|NCT03501758||Remission with treatment|Patients randomized to continue medical treatment with biologics
16469527|NCT03501758||Remission without treatment|Patients randomized to stop medical treatment with biologics
16469528|NCT03501745|Other|Management Group|
16469529|NCT03501745|Other|control group|
16469530|NCT03501732|Experimental|Values Affirmation plus Risk Feedback|Values Affirmation with Risk Feedback in substance use and HIV domains of risk
16469531|NCT03501732|Active Comparator|Risk Feedback|Sham Values Affirmation with Risk Feedback in substance use and HIV domains of risk
16469532|NCT03501732|No Intervention|Sleep Control|Description of sleep habits in lieu of values affirmation/sham values affirmation. No risk feedback
16469533|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
16469534|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
16469535|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
16469536|NCT03501706|Experimental|Active Training (AT) Group|Participants will complete four computerized training programs to improve executive function (EF), including Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Words - Visual, Verbal Memory - Visual.
16469537|NCT03501706|No Intervention|Control Training (CT) Group|Participants will complete the four computerized programs relating to executive function (EF), but without memory requirements for control.
16469538|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
16469539|NCT03501693||FFDM alone|FFDM alone images
16469540|NCT03501680|Experimental|Group A: intensive insulin|Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)
16469541|NCT03501680|Active Comparator|Group B: standard insulin|Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),
16469542|NCT03501680|Active Comparator|Group C: plasmapheresis|Group C: plasmapheresis
16469543|NCT03501667|Active Comparator|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
16469544|NCT03501667|Active Comparator|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
16469545|NCT03501654|Experimental|TecnisSymfony intraocular lens insertion group|
16469546|NCT03501641|Experimental|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
16469550|NCT03501628|Experimental|Whey protein concentrate|"2 servings daily
~Serving information:
~184 kcal
~3.5 g fat
~12 g carbohydrate
~26.3 g protein (2.8 g L-leucine)"
16469551|NCT03501628|Experimental|Hydrolyzed whey protein concentrate|"2 servings daily
~Serving information:
~192 kcal
~4.6 g fat
~12.2 g carbohydrate
~25.4 g protein (2.9 g L-leucine)"
16469552|NCT03501628|Experimental|Soy protein concentrate|"2 servings daily
~Serving information:
~266 kcal
~4.5 g fat
~17.2 g carbohydrate
~39.2 g protein (2.9 g L-leucine)"
16469553|NCT03501602|Active Comparator|LMA protector group|The LMA Protector is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts
16469554|NCT03501602|Active Comparator|I-gel LMA group|The I-gel is an alternative supraglottic device which provides the seal over the airway versus an inflatable cuff.
16469555|NCT03501576|Experimental|Inactivated Influenza Vaccine|Patients receive seasonal inactivated influenza vaccine IM at day 0.
16469556|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.
~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
16469557|NCT03501550|Experimental|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
16469558|NCT03501537|Experimental|Surgical treatment with free gingival graft|Free gingival graft harvested from the palate will be placed around the diseased implant
16469559|NCT03501524|Experimental|VATS evacuation|patients selected for VATS after failure of first thoracostomy tube drainage
16469560|NCT03501524|Experimental|thoracostomy tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube
16469561|NCT03501511|Active Comparator|IDF modules|Diabetes educations using IDF Arabic translated modules
16469562|NCT03501511|Experimental|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
16469563|NCT03501498|Experimental|loperamide|Slows intestinal transit time
16469564|NCT03501498|Experimental|senna|Speeds up intestinal transit time
16469565|NCT03501472|Experimental|Text-only PWL, immediate post|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
16469566|NCT03501472|Experimental|Text-only PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
16469567|NCT03501472|Experimental|Low-emot PWL, immed post|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
16469568|NCT03501472|Experimental|Low-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
16469569|NCT03501472|Experimental|High-emot PWL, immed posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
16469570|NCT03501472|Experimental|High-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
16469571|NCT03501459|Experimental|Rituximab|
16469572|NCT03501433|Experimental|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
16469573|NCT03501433|Placebo Comparator|Placebo|7 days of placebo supplementation (2/day)
16469574|NCT03501420||Physicians|A sample of 230 to 325 rheumatologists actively involved in management and treatment decisions of pSS subjects in France, Italy, Spain, Germany and the United States will be included in the survey.
16469575|NCT03501420||Subjects with pSS|Subjects with a confirmed diagnosis of pSS under consultation of the rheumatologists enrolled in the study will be included.
16469576|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
16469577|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:
~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
16469578|NCT03501394|Experimental|Single Arm|25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited. During the study, patients will receive the standard care and the current study will not alter the care plan offered to them. All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions. Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery. Health questionnaire will be completed by each patient.
16469579|NCT03501381|Active Comparator|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
16469612|NCT03501225|Experimental|ozone|tooth extraction under irrigation with ozonated water
16469580|NCT03501381|Experimental|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
16469581|NCT03501368|Experimental|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
16469582|NCT03501355|Active Comparator|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
16469583|NCT03501355|Active Comparator|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
16469584|NCT03501342|Experimental|Virtual reality group|In virtual reality group, 30 minutes of Pilates training, 10 minutes of rest and then 20 minutes of virtual reality will be applied.
16469585|NCT03501342|Active Comparator|Dynamic Balance Training|"In the Dynamic Balance Training group, 20 minutes of dynamic balance exercises will be applied after Pilates training."
16469586|NCT03501342|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
16469587|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.
~Treatment was not changed as a result of the investigation in itself."
16469588|NCT03501316|Active Comparator|Hand Instrumentation|Root surface debridement using hand instruments.
16469589|NCT03501316|Active Comparator|Ultrasonic Instrumentation|Root surface debridement using ultrasonic scaler.
16469590|NCT03501303|Experimental|No touch|No touch technique. Patients are randomized to no touch vein harvesting. The technique is used as routine in Medical care by some hospitals.
16469591|NCT03501303|Other|Control|Control technique. Patients are randomized to Control vein harvesting. The technique is used as routine in Medical care.
16469592|NCT03501290|Other|Oral Nutritional Supplement Group|All patients will be in one group, receiving the active product, Oral Nutritional Supplement with 'Fortimel® Protein supplementation'
16469593|NCT03501277|Experimental|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 [milligram] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Regimen D).
16469594|NCT03501277|Experimental|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen A).
16469595|NCT03501277|Experimental|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Regimen B).
16469596|NCT03501277|Experimental|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen C).
16469597|NCT03501264|Experimental|Intervention group|This group receives the game
16469598|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
16469599|NCT03501251|Experimental|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
16469600|NCT03501251|Experimental|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
16469601|NCT03501251|Experimental|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
16469602|NCT03501251|Experimental|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
16469603|NCT03501251|Experimental|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
16469604|NCT03501251|Experimental|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
16469605|NCT03501251|Placebo Comparator|Placebo|A single tablet of placebo
16469606|NCT03501238|Experimental|BSG|Participant receives bovine milk, then milk substitute, then milk substitute treated with gelatin
16469607|NCT03501238|Experimental|BGS|Participant receives bovine milk, then milk substitute with gelatin, then milk substitute
16469608|NCT03501238|Experimental|SBG|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin.
16469609|NCT03501238|Experimental|SGB|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin
16469610|NCT03501238|Experimental|GSB|Participant receives milk substitute with gelatin, then milk substitute, then bovine milk.
16469611|NCT03501238|Experimental|GBS|Participant receives milk substitute with gelatin, then bovine milk, then milk substitute.
16469613|NCT03501225|Experimental|water|tooth extraction under irrigation with ozonated water or doubly distilled water
16469614|NCT03501212|Active Comparator|Interventional|EMLA group layer of 2.5 gr EMLA cream (standard adult dose) was applied to both wrists
16469615|NCT03501212|Placebo Comparator|Placebo|Placebo cream was applied to both wrists
16469616|NCT03501199|Experimental|PRF Group|PRF is will be used in immediate dental implant placement.
16469617|NCT03501199|Experimental|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
16469618|NCT03501199|Experimental|Control Group|No extra material is will be used in immediate dental implant placement.
16469619|NCT03501186|Experimental|Group 1|forward walking on leveled surface
16469620|NCT03501186|Active Comparator|Group 2|forward walking on sand.
16469621|NCT03501186|Experimental|Group 3|Backward walking on leveled surface
16469622|NCT03501186|Active Comparator|Group 4|Backward walking on sand.
16469623|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
16469624|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
16469625|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
16469626|NCT03501173||mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)|Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7nmol/L]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.
16469627|NCT03501147|Experimental|Intervention|15 minutes of resistance training at the work place every day
16469628|NCT03501147|No Intervention|Control|Usual work
16469629|NCT03501134||Tumor treating fields|Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device
16469630|NCT03501108|No Intervention|Control|Patients in the control arm receive usual pharmaceutical care in hospital i.e. daily medication review by the attending physicians and ward-assigned pharmacist.
16469631|NCT03501108|Experimental|Intervention|Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
16469632|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
16469633|NCT03501082|Experimental|L. Reuteri PB-W1 Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
16469634|NCT03501082|Experimental|L. Reuteri DSM20016T Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
16469635|NCT03501082|Placebo Comparator|Placebo Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
16469636|NCT03501082|Experimental|L. Reuteri PB-W1 Non-Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period.The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
16469637|NCT03501082|Experimental|L. Reuteri DSM20016T Non-West Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
16469638|NCT03501082|Placebo Comparator|Placebo Non-Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
16469719|NCT03500549|Experimental|1,080mg APL-2 administered subcutaneously|1,080mg APL-2 administered subcutaneously twice weekly or every three days.
16469720|NCT03500549|Active Comparator|Eculizumab|Complement (C5) Inhibitor
16469639|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
16469640|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
16469641|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
16469642|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
16469643|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
16469644|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
16469645|NCT03501056|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16469646|NCT03501056|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16469647|NCT03501056|No Intervention|conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16469648|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
16469649|NCT03501030|Experimental|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
16469650|NCT03501030|No Intervention|No activity restriction|Women in the control group will not receive any reccomandation regarding activity restriction. Bed rest and abstain from sexual intercourse will also not recommended.
16469651|NCT03501017|Experimental|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
16469652|NCT03501017|Active Comparator|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
16469653|NCT03501004|Experimental|The Acupuncture Group|Sterile acupuncture needles for single use will be used.The intervention is going to be executed using the acupuncture points GV14（Dazhui）and GB20 (Fengchi) for 20 minutes.The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14（Dazhui）and GB20 (Fengchi).
16469654|NCT03501004|Sham Comparator|The Sham Acupuncture Group|Sterile acupuncture needles for single use will be used.The sham acupuncture group's acupuncture needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points for 20 minutes.
16469655|NCT03500991|Experimental|ARM A (Tumor Cavity Infusion)|"patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
16469656|NCT03500991|Experimental|ARM B (Ventricular System Infusion)|"patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
16469657|NCT03500978|Experimental|Peer CBT Intervention|Women allocated to the peer-specialist delivered CBT intervention group will be mailed an intervention workbook (CBT exercises) and have their first telephone-based intervention session scheduled. The CBT intervention group will receive 8 telephone-based CBT intervention sessions (over 9 weeks) delivered by peer specialists. Each session will last up to 30 minutes.
16469658|NCT03500978|No Intervention|Control|Women allocated to the observation-only control group will not receive any intervention.
16469659|NCT03500965|Experimental|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
16469660|NCT03500965|Experimental|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
16469661|NCT03500965|Experimental|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
16469662|NCT03500965|Experimental|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
16469663|NCT03500952|Experimental|Patient Decision Aid|Birth Control After Pregnancy patient decision aid and supporting document
16469664|NCT03500952|Active Comparator|Patient Information Leaflet|Postpartum Birth Control patient information leaflet
16469690|NCT03500770|Experimental|Transcranial Direct Current Stimulator|The Transcranial Direct Current Stimulator device (tDCS) is a safe technique which poses a non-significant risk to study subjects. This technique uses weak current which is applied by using two electrodes. In the literature, no undesirable or long-lasting side effects due to device have been reported, nor have any participants reportedly abandoned a study due to discomfort.
16469665|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
16469666|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
16469667|NCT03500926|Active Comparator|hype standard|total hip replacement with standard femoral stem
16469668|NCT03500926|Experimental|hype mini|total hip replacement with short uncemented femoral stem
16469669|NCT03500913||Adults with growth hormone deficiency|Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
16469670|NCT03500913||Control group|Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
16469671|NCT03500900|Experimental|Vildagliptin|DPP-4 inhibitor, acute administration (50 mg.)
16469672|NCT03500900|Placebo Comparator|Placebo|Placebo treatment, acute administration
16469673|NCT03500887|Other|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
16469674|NCT03500887|Other|2. Bag inflated to ¾ volume of 1|
16469675|NCT03500874|Experimental|Systematic Chemotherapy + HAI(FUDR)|"Patients will receive Systemic FOLFOX + HAI (FUDR) every 28 days:
~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15.
~floxuridine (FUDR) 0.12mg/Kg/d,d1-14 and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
16469676|NCT03500874|Active Comparator|Systematic Chemotherapy|"Patients will receive FOLFOX every every 28 days:
~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15."
16469677|NCT03500861|Experimental|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
16469678|NCT03500861|Sham Comparator|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
16469679|NCT03500848|Active Comparator|Tacrolimus-based group|Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids
16469680|NCT03500848|Experimental|Sirolimus-based group|Sirolimus-based immunosuppression regimen: Tacrolimus (Tacrolimus elimination 30 (± 5) days post LT)+Sirolimus+MMF and/or steroids
16469681|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
16469682|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
16469683|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
16469684|NCT03500822|Experimental|Metronome-paced tachypnea|Dynamic hyperinflation by the method of metronome-paced tachypnea.
16469685|NCT03500822|Experimental|Exspiratory-stenosis breathing|Dynamic hyperinflation by the method of expiratory-stenosis breathing.
16469686|NCT03500809|Experimental|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).
~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
16469687|NCT03500796|Other|Corneal perforation patients|"Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention.
~Patients will undergo:
~Platelet rich plasma clot implantation Wound closure with amniotic membrane"
16469688|NCT03500783|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
16469689|NCT03500783|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
16469691|NCT03500757||360-degree Display of solid tumors|Evaluate the feed back of using the HoloLens headset to have a 360 degree visualization of patient tumors during percutaneous liver tumor ablation
16472922|NCT03478319|Experimental|Cohort 6|ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1
16469692|NCT03500744|Experimental|Erector spinae plane block|"The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.
~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
16469693|NCT03500744|Sham Comparator|Shame block|"A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.
~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
16469694|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.
~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
16469695|NCT03500718|Experimental|Pediatric patients with bilateral sensorineural hearing loss|One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.
16469696|NCT03500705|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
16469697|NCT03500705|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
16469698|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
16469699|NCT03500679|Experimental|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram [mcg]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
16469700|NCT03500679|Placebo Comparator|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
16469701|NCT03500666|Experimental|Robot lateral neck lymph node dissection|Robot neck lateral lymph node dissection was performed in patients with thyroid cancer and lateral cervical lymph node metastasis.
16469702|NCT03500666|Experimental|Total endoscopic lateral cervical lymph node dissection|Patients with thyroid cancer and lateral cervical lymph node metastases underwent total endoscopic neck dissection.
16469703|NCT03500653|Active Comparator|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
16469704|NCT03500653|Placebo Comparator|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
16469705|NCT03500640|Active Comparator|DPP Plus: 30-minute calls|Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
16469706|NCT03500640|Placebo Comparator|DPP Minimal: 15-minute calls|Following the 6-month, 16-session, DPP core program, 15-minute group telephone calls will be implemented. Social-support sessions occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
16469707|NCT03500627|Experimental|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
16469708|NCT03500627|Experimental|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
16469709|NCT03500627|Experimental|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
16469710|NCT03500614|Experimental|Cohort 1|Participants (n=57) will receive either true or sham air cleaner treatment for 1 week and then alternate the treatment after a wash out interval (Air cleaner use method 1). Exposure monitoring for PM2.5 will continue throughout the treatment period and air and fine particle phase phthalates samples will be collected during the last day (24 hours) of the treatment period; and health variables will be measured and biological samples will be collected immediately after the completion of each intervention period.
16469711|NCT03500614|Experimental|Cohort 2|Participants (n=32) will undergo extended treatment period covering the start, peak and end phases of smog episodes in Beijing, with either true or sham air cleaner treatment and then alternate the treatment after a wash out interval (Air cleaner use method 2). Exposure monitoring for PM2.5 will continue throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes.
16469712|NCT03500601|Experimental|Active treatment|Nut components
16469713|NCT03500601|Placebo Comparator|Placebo|Placebo
16469714|NCT03500588||normotensive pregnant women more than 20 weeks gestation.|One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.
16469715|NCT03500588||Pregnant women after 20 weeks with preeclampsia.|One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.
16469716|NCT03500575|Experimental|photopheresis|
16469717|NCT03500575|No Intervention|control|
16469718|NCT03500562||HCV participant population in China|
16469721|NCT03500536|No Intervention|Waitlist Control|8 weeks of treatment as usual followed by 8 weeks of IntelliCare treatment.
16469722|NCT03500536|Experimental|Experimental|8 weeks of IntelliCare treatment followed by 8 weeks of treatment as usual.
16469723|NCT03500523|Experimental|1-study group|study group: pregnant women
16469724|NCT03500523|Experimental|2-control group|control group: healthy non pregnant women
16469725|NCT03500484|Experimental|obese subjects|Subjects will self-administer Liraglutide once daily for 12 weeks.
16469726|NCT03500484|No Intervention|lean subjects|no intervention
16469729|NCT03500458|No Intervention|Typical Sleep|All participants will sleep for 6 nights (Sunday - Thursday) in the home environment per their usual school schedule.
16469730|NCT03500458|Experimental|Sleep Extension|Participants will be prescribed a sleep schedule that allows them to obtain 1 hour more time in bed compared to Typical Sleep.
16469731|NCT03500445|Experimental|Treatment Arm (D-KRd)|
16469732|NCT03500432|Active Comparator|periprostatic group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periprostatic block
16469733|NCT03500432|Active Comparator|PAT group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periapical triangle (PAT) block
16469734|NCT03500432|Experimental|TPA switch group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+TPA switch (transperineal prostate biopsy local anesthesia switch) block
16469738|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
16469739|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
16469740|NCT03500393|Active Comparator|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
16469741|NCT03500393|Experimental|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
16469742|NCT03500380|Experimental|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
16469743|NCT03500380|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
16469744|NCT03500367|Experimental|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
16469745|NCT03500354|Experimental|Nutrient|Nutrient drink
16469746|NCT03500341|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00014 sensor
16469747|NCT03500328|Active Comparator|Early Aggressive Therapy|"Higher efficacy disease-modifying therapy (Early Aggressive Therapy) for treatment of multiple sclerosis
~Early Aggressive Therapy choices and maximum allowable doses:
~Natalizumab (Tysabri), 300 mg intravenously (IV) every 4 weeks
~Alemtuzumab (Lemtrada), 12 mg IV daily for 5 days; 1 year later: 12 mg IV daily for 3 days
~Ocrelizumab (Ocrevus), 300 mg IV every 2 weeks (for 2 doses) at initiation; subsequently, 600 mg IV every 6 months
~Rituximab (Rituxan), 1000 mg IV every 2 weeks (for 2 doses); may repeat every 16-24 weeks
~Cladribine (Mavenclad), 3.5 mg per kg body weight PO divided into 2 yearly treatment courses (1.75 mg per kg body weight each year); each yearly treatment course is divided into 2 treatment cycles; administer cycle dosage as 1 or 2 tablets once daily over 4-5 consecutive days
~Ofatumumab (Kesimpta), 20 mg SC weekly for weeks 0, 1 and 2; 20 mg SC monthly starting at week 4"
16469748|NCT03500328|Active Comparator|Traditional Therapy|"First-line disease-modifying therapy (Traditional Therapy) for treatment of multiple sclerosis
~Traditional Therapy choices and maximum allowable doses:
~Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg subcutaneously (SC) daily, or 40 mg SC three times a week
~Intramuscular interferon (Avonex), 30 mcg intramuscularly (IM) weekly
~Subcutaneous interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC three times a week (Rebif)
~Pegylated interferon (Plegridy), 125 mcg SC every 14 days
~Teriflunomide (Aubagio), 14 mg orally (PO) daily
~Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day
~Diroximel fumarate (Vumerity), 462 mg PO twice a day
~Monomethyl fumarate (Bafiertam), 190 mg PO twice a day
~Fingolimod (Gilenya and generics), 0.5 mg PO daily
~Siponimod (Mayzent), 1 mg PO daily or 2 mg PO daily
~Ozanimod (Zeposia), 0.92 mg PO daily
~Ponesimod (Ponvory), 20 mg PO daily"
16469749|NCT03500315|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 80
16469750|NCT03500315|No Intervention|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 80
16470105|NCT03497884|Sham Comparator|Sham rTMS|Sham rTMS session includes low frequency and high frequency stimulations.
16469751|NCT03500315|No Intervention|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
16469752|NCT03500302|Experimental|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
16469753|NCT03500289|Experimental|Ketamine|
16469754|NCT03500289|Placebo Comparator|Midazolam|
16469755|NCT03500276|Experimental|Yoga program|"12 weeks of Yoga in daily life practice, 2x weekly for 90 minutes including physical exercises (asanas), breathing exercises (pranayama), relaxation and meditation exercises."
16469756|NCT03500276|Active Comparator|Arthritis-education control|12 weeks of arthritis - education classes, consisting of 1x weekly sessions for 120 minutes including lectures on arthritis and related issues followed by group discussion.
16469757|NCT03500263|Active Comparator|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
16469758|NCT03500263|Placebo Comparator|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
16469759|NCT03500263|Active Comparator|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
16469760|NCT03500263|Placebo Comparator|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
16469761|NCT03500263|Active Comparator|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
16469762|NCT03500263|Placebo Comparator|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
16469763|NCT03500250||Nurses|Nurses working on the neurological wards of three hospitals (one university hospital and two general hospitals)
16469766|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
16469767|NCT03500211|Experimental|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
16469768|NCT03500211|Sham Comparator|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
16469769|NCT03500198|Experimental|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
16469770|NCT03500198|Active Comparator|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
16469771|NCT03500185|Experimental|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
16469772|NCT03500185|Active Comparator|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
16469773|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|
16469774|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|
16469775|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|
16469776|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|
16469777|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|
16469778|NCT03500172|Active Comparator|ICM, SoC if Responsive|
16469779|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|
16469780|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|
16469781|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
16469782|NCT03500159|Placebo Comparator|Placebo|Matching placebo
16469783|NCT03500146||Normal sexual function|Patients with an overall FSFI score equal to or above 26.5 will be in the normal sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
16469882|NCT03499405|No Intervention|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
16469784|NCT03500146||Low sexual function|Female sexual dysfunction is defined as an overall FSFI score below 26.5, patients meeting this criteria will be in the low sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
16469785|NCT03500133|Experimental|Group A|"Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
~No radiotherapy if CR at the end of chemotherapy."
16469786|NCT03500133|Experimental|Group B|"Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
~No radiotherapy if CR at the end of chemotherapy"
16469787|NCT03500133|Experimental|Group B2|"Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
16469788|NCT03500133|Experimental|Group C|"Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
~No radiotherapy if CR at the end of chemotherapy."
16469789|NCT03500133|Experimental|Group D|"Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
16469790|NCT03500133|Experimental|Group E|"High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
~No radiotherapy if CR at the end of chemotherapy"
16469791|NCT03500133|Experimental|Group F|"High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
16469792|NCT03500120||Primary Aldosteronism|Aldosterone/renin concentration ratio(ARR)≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST≥6 ng/dl
16469793|NCT03500120||non Primary Aldosteronism|1. ARR≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST<6 ng/dl
16469794|NCT03500107|Experimental|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
16469795|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl (herein referred to as migalastat) will be administered with water every other day for 12 months."
16469796|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy.
16469797|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
16469798|NCT03500055|Experimental|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
16469799|NCT03500055|No Intervention|Control|Normal operative procedure. The abdominal closure bundle will not be used.
16469800|NCT03500042|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
16469801|NCT03500042|Experimental|normal respiratory muscle|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
16469802|NCT03500029|Experimental|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
16469803|NCT03500029|Active Comparator|medication group|In the medication group patients with severe depression are treated with anti-depressants.
16469804|NCT03500029|No Intervention|healthy control group|The control group don't accept intervention and treatment.
16469805|NCT03500016|Experimental|Acute exercise and exercise training|"Euglycemic-hyperinsulinemic clamp before and after 8 weeks supervised exercise training. Before exercise training the participants will also do an acute exercise on 1 hour with muscle biopsies taken before and after exercise and then again 4 hours into recovery."
16469806|NCT03500003|Experimental|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
16469807|NCT03500003|Experimental|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
16469808|NCT03499977|Experimental|Sitting|The participant will be asked to sit for 10 min (not increasing their heart rate) then do the anti-saccade task
16469809|NCT03499977|Experimental|Low-Intensity Cycling|Participant will be asked to cycle for 10 min (<40% VO2R) and then perform the anti-saccade task
16469810|NCT03499977|Experimental|Moderate-Intensity Cycling|The participant will be asked to do 10 min of cycling (40-59% VO2R) followed but the anti-saccade task
16469811|NCT03499977|Experimental|High-Intensity Cycling|The participant will be asked to do 10 min of cycling (60%-84% VO2R) followed but the anti-saccade task
16469812|NCT03499964|Experimental|Optilume Treatment|The treatment arm will be the Urotronic Optilume Drug Coated Balloon (DCB).
16469813|NCT03499964|Active Comparator|Control Treatment|The control arm will be treated by a urethral dilation method considered to be best standard of care for the study site and subject. A control treatment may be either a rod, uncoated balloon or DVIU.
16469846|NCT03499665|Experimental|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|This group of patients received patients with bruxism. It was applied proprioceptive neuromuscular facilitation (PNF), myofascial releasing maneuvers and home exercises.
16469814|NCT03499951|Other|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
16469815|NCT03499951|Other|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
16469816|NCT03499925|Experimental|Test Group|Telephone consultation effectiveness and cognitive behaviors
16469817|NCT03499925|No Intervention|Comparison Group|Routine product inspection
16469821|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/1mL|"In the intervention group, Ketamine Hydrochloride 50Mg/1mL was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention."
16469822|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/mL|in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
16469823|NCT03499873|Experimental|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
16469824|NCT03499873|Active Comparator|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
16469825|NCT03499873|Placebo Comparator|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
16469826|NCT03499847|Active Comparator|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
16469827|NCT03499847|Active Comparator|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
16469828|NCT03499847|No Intervention|Control|
16469829|NCT03499834|Experimental|Study Group|26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment
16469830|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
16469831|NCT03499808|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
16469832|NCT03499795|Experimental|VGX-3100|Adult participants, who are HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, will receive VGX-3100 administered by IM injection followed immediately by EP using the CELLECTRA™ 5PSP device. Participants will receive at least 3 doses of VGX-3100 at Day 0, Week 4 and Week 12. For partial responders at Week 36, a fourth dose may be administered at Week 40. All participants are scheduled to be followed to Week 88.
16469833|NCT03499769|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
16469834|NCT03499769|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
16469837|NCT03499743|Experimental|group1 (hyoscine Butyl-bromide group)|group1 will receive hyoscine butyl bromide 10 mg (BUSCOPAN tablets, produced by Chemical Industries Development (CID), Giza - A.R.E. under licence of Boehringer Ingelheim International GmbH - Germany) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
16469838|NCT03499743|Placebo Comparator|group 3 (PLACEBO GROUP)|will receive a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
16469839|NCT03499743|Experimental|group 2(celecoxib group)|group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide 2 hours before IUD insertion.
16469840|NCT03499704|Experimental|Pioglitazone + Alogliptin + Metformin (PAM)|Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (>=) 500 mg, tablet, orally, twice a day for up to 52 weeks. At Week 12, if participants has HbA1c >=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 52.
16469841|NCT03499704|Active Comparator|Dapagliflozin + Alogliptin + Metformin (DAM)|Dapagliflozin 10 mg, tablet, orally, once daily with alogliptin 25 mg, tablet, orally, once daily, and metformin >=500 mg, tablet, orally, twice a day, for up to Week 52.
16469842|NCT03499691|Experimental|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
16469843|NCT03499691|Active Comparator|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
16469844|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
16469845|NCT03499678||Control|Age and sex matched control individuals
16469847|NCT03499665|Active Comparator|Myofascial Releasing Maneuvers and Home Exercises Group|This group of patients received patient with bruxism. It was applied myofascial releasing maneuvers and home exercises.
16469848|NCT03499665|Active Comparator|Control Group|This group of patients received patient with bruxism. It was applied conventional treatment and no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
16469849|NCT03499652||derivation cohort|The data of derivation cohort are used to derive the neonatal bacterial meningitis risk score
16469850|NCT03499652||validation cohort|The data of validation cohort are used to validate the neonatal bacterial meningitis risk score
16469851|NCT03499639|Other|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
16469852|NCT03499626|Experimental|ASLAN001|A 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdrawal of consent.
16469853|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
16469854|NCT03499600|Experimental|Clinical Assessment and CFI|CA and CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
16469855|NCT03499600|Active Comparator|Clinical Assessment Only|CA families will receive a standard Clinical Assessment during intake.
16469856|NCT03499587||Obese pregnant women|BMI >30 with early OB visit medical records accessible
16469857|NCT03499587||Normal weight pregnant women|BMI 18.5-25 with early OB visit medical records accessible.
16469858|NCT03499574|Experimental|Biofeedback group|Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.
16469859|NCT03499574|Other|Control group|This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education
16469860|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
16469861|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
16469862|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
16469863|NCT03499548|Experimental|Intervention|10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
16469864|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
16469865|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
16469866|NCT03499535|Experimental|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
16469867|NCT03499535|Experimental|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
16469868|NCT03499535|Experimental|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
16469869|NCT03499535|Other|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
16469870|NCT03499535|Active Comparator|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
16469871|NCT03499522||Observational group|"80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.
~The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.
~On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments."
16469872|NCT03499509|Experimental|Low Glycemic Diet|
16469873|NCT03499509|Placebo Comparator|High Glycemic Diet|
16469874|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
16469875|NCT03499470|Active Comparator|Intervention|"The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.
~Actions in structured discharge and follow up protocol:
~Patient education for disease severity and medications
~Education of family/relatives about medications and types of equipment
~Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)
~Preparation of home environment for patients needs
~Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed
~Outpatient control for the first month"
16469876|NCT03499470|No Intervention|Control|Control patients will receive usual care
16469877|NCT03499457|Experimental|treatment|penicillin chalange test, as descibed.
16469878|NCT03499444|Experimental|Oral Rucaparib monotherapy|Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)
16469879|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
16469880|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
16469881|NCT03499405|Experimental|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
16469884|NCT03499379||Women initiating use of an intrauterine device|"Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.
~A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion."
16469885|NCT03499353|Experimental|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
16469886|NCT03499340|Experimental|Text-only PWL, absolute risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
16469887|NCT03499340|Experimental|Text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
16469888|NCT03499340|Experimental|Low arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
16469889|NCT03499340|Experimental|Low arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
16469890|NCT03499340|Experimental|High arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
16469891|NCT03499340|Experimental|High arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
16469892|NCT03499327|Active Comparator|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
16469893|NCT03499327|Placebo Comparator|Wheat germ oil (untreated)|Wheat germ oil (untreated)
16469894|NCT03499327|No Intervention|Control|no study products
16469895|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
16469896|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
16469897|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
16469898|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
16469899|NCT03499288||Children and youth with cerebral palsy|Subjects between 1 month and 18 years of age with Cerebral Palsy who visited the coordinating HCP within the past 12 months.
16469900|NCT03499275|Sham Comparator|Sham NMES|Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
16469901|NCT03499275|Experimental|Active NMES|Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
16469902|NCT03499262|Experimental|Group Social ABcs|Participants receiving Group Social ABCs intervention
16469903|NCT03499249|Experimental|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
16469907|NCT03499223|Experimental|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
16469908|NCT03499223|Active Comparator|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
16469909|NCT03499210|Experimental|Investigational group|All subjects will participate in study procedures involving use of the ReWalk ReStore device.
16469910|NCT03499184|Experimental|Local Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be delivered locally every 12 hours for 12 weeks
16469911|NCT03499184|Experimental|Systemic Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be administered every 12 hours for 12 weeks
16469912|NCT03499184|Active Comparator|Systemic Antibiotics|Amoxil 500 mg capsule and Flagyl 400 mg tablet by mouth, will be given every 8 hours for 5 days
16469913|NCT03499171|Experimental|Citalopram|20mg, once a day
16469914|NCT03499171|Placebo Comparator|Placebo|Once a day
16469915|NCT03499158||1|affected arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome
16469916|NCT03499158||2|healthy arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome in the other arms
16469917|NCT03499145||Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
16469918|NCT03499132||General anesthesia (with opioids)|orthopedic surgery plus general anesthesia
16469919|NCT03499132||Epidural anesthesia (without opioids)|orthopedic surgery plus epidural anesthesia (without opioids use)
16469920|NCT03499132||Subarachnoid anesthesia (with opioids)|orthopedic surgery plus subarachnoid anesthesia (plus intrathecal opioid)
16469921|NCT03499132||Regional anesthesia (without opioids)|orthopedic surgery plus regional anesthesia (peripheral nerve block, continous or single shot, without opioid use)
16469922|NCT03499119|Other|Cohort 1|Subjects with a body weight at Day 1 of less than weight threshold.
16469923|NCT03499119|Other|Cohort 2|Subjects with a body weight at Day 1 of weight threshold or more.
16469924|NCT03499106|Experimental|Healthy Volunteers|Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.
16469925|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
16469926|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
16469927|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
16469928|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
16469929|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
16469930|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
16469931|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
16469932|NCT03499067|Experimental|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
16469933|NCT03499067|Active Comparator|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
16469934|NCT03499054|No Intervention|control group|Hemodialysis patients in the control group who receive only routine nursing care during hemodialysis
16469935|NCT03499054|Experimental|exercise group|The exercise group are asked to perform breathing exercises during hemodialysis for the study period of 3 months.
16469936|NCT03499041|Experimental|LY3314814 Control|LY3314814 administered orally to participants with normal hepatic function
16469937|NCT03499041|Experimental|LY3314814 Mild|LY3314814 administered orally to participants with mild hepatic impairment
16469938|NCT03499041|Experimental|LY3314814 Moderate|LY3314814 administered orally to participants with moderate hepatic impairment
16469939|NCT03499041|Experimental|LY3314814 Severe|LY3314814 administered orally to participants with severe hepatic impairment
16469940|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
16469941|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
16469942|NCT03499015|No Intervention|Ear without BET|ear without BET treatment works as control
16469943|NCT03499015|Experimental|BET ear|ear with BET treatment works as intervention arm
16469944|NCT03499002|Experimental|Simulation Lab|
16469945|NCT03499002|Experimental|ER in situ Simulation|
16469946|NCT03498989|Experimental|preterm formula milk neoborn|will be given preterm formula milk
16469947|NCT03498989|Experimental|exclusive breast milk|will be given exclusive breast milk
16469948|NCT03498976|Other|Pulsed radiofrequency on SE nerve|Single technic
16469949|NCT03498976|Other|Pulsed radiofrequency on SE + CF nerves|Combinated technic
16469950|NCT03498963|Other|bronchoalveolar lavage|
16469951|NCT03498950|No Intervention|Placebo Group|submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae
16469952|NCT03498950|Experimental|Test Group|submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.
16469953|NCT03498937|Experimental|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
16469954|NCT03498937|Experimental|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
16469955|NCT03498924||CASES|Patients with endometrial cancer
16469956|NCT03498924||CONTROLS|Matched controls without neoplasm disease
16469957|NCT03498911|Active Comparator|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
16469958|NCT03498911|Experimental|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
16469959|NCT03498898|Active Comparator|Group A|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
16469960|NCT03498898|No Intervention|Group B|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
16469961|NCT03498898|Active Comparator|Group C|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement.
16469962|NCT03498898|No Intervention|Group D|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement
16469963|NCT03498885|Experimental|Low ligation|Left colic artery (LCA) is identified, tie the sigmoid artery and superior rectal artery,Apical lymph node dissection with the left colic artery preservation is performed.
16469964|NCT03498885|Active Comparator|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
16469965|NCT03498872|Active Comparator|Able-bodied individuals|
16469966|NCT03498872|Experimental|Transtibial amputee|
16469967|NCT03498872|Experimental|Transfemoral amputee|
16469968|NCT03498859|Other|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
16469969|NCT03498859|Other|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
16469970|NCT03498846|Experimental|Modified EA and AMLK|Modified corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe corneal burn.
16469971|NCT03498846|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe corneal burn.
16469972|NCT03498833|Other|Test-retest reliability testing|Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
16469973|NCT03498820|Experimental|Analgesia Nociception Index|Intraoperative remifentanil administration guided by the Analgesia Nociception Index
16469974|NCT03498820|Active Comparator|Usual practice|Intraoperative remifentanil administration managed in standard practice
16469975|NCT03498807|Experimental|Control group_Use Ventilator P/V tool|Use the Pressure/Volume Loop
16469976|NCT03498807|Active Comparator|Study group_Use EIT|Use the Electrical Impedance Tomography
16469977|NCT03498794|Active Comparator|Ureteral stent|"Technique of ureteral stent insertion:
~All patients will be in lithotomy position, and an endoscopy operating table with fluoroscopic imaging capability will be used. Before the procedures, all patients will have retrograde ureteropyelography. Then, a 0.035-inch hydrophilic guide wire will be placed into the renal pelvis under the guidance of flexible cystoscope.
~The ureteral stent will be inserted retrograde by using flexible cystoscope, under mild sedation or local anesthesia by instilling 2% xylocain gel per urethra. Patients will be covered by specific antimicrobial therapy according to urine and/or blood culture. This treatment will be continued until there was no fever and any evidence of infection disappeared. A Foley's catheter will be left in the bladder for 2 hours in all patients. In each case the type of stent will be that of 5 or 6 F, with side-holes and remain in place until definitive treatment of stone."
16469978|NCT03498794|Active Comparator|Percutaneous nephrostomy tube|"Technique of PCN insertion:
~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively. The patients will be placed on the ultrasound table with fluoroscopic imaging capability in prone position and a pillow placed under the abdomen on the affected side to support the kidney. Then the initial puncture site will be chosen, cleaned and draped. Local anesthesia was injected and a stab incision was given at the puncture site. The 18-gauge Chiba needle will be inserted at the renal angle or at the posterior axillary line under ultrasound guidance into dilated pelvicalyceal system. Urine or pus drained out spontaneously or will be sucked with a disposable syringe and sample was sent to the laboratory for culture and sensitively."
16469979|NCT03498781|Experimental|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
16469980|NCT03498781|Sham Comparator|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
16469981|NCT03498768||Inpatients with lung nodules|All inpatients in our department are invited to finish the questionnaire at inpatient education on the first day of hospitalization as the baseline date, then they are followed up by phone call to reevaluate their psychosocial status at 6 months and 1 year after the surgery.
16469982|NCT03498755|Experimental|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
16469983|NCT03498755|Experimental|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
16469984|NCT03498755|Experimental|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
16469985|NCT03498742||No SABA users|Asthmatic subjects that did not use short acting beta2 agonists in the last 3 months and being using none agent or ICS, systemic corticosteroids of combined ICS/LABA as relief symptoms agent.
16469986|NCT03498742||SABA users|Most of the asthmatic subjects usually inhale SABA as rescue medication and many times SABA is the only one prescribed treatment for asthma.
16469987|NCT03498729||Persistent AF|
16469988|NCT03498729||Paroxysmal AF|
16469989|NCT03498729||Psoriasis|
16469990|NCT03498729||Healthy Controls|
16469991|NCT03498716|Experimental|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose
~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
16469992|NCT03498716|Active Comparator|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
16469993|NCT03498703|Experimental|Azathioprine|
16469994|NCT03498703|Placebo Comparator|Control|
16469995|NCT03498690|Active Comparator|Integrative|
16469996|NCT03498690|Active Comparator|Role Specific|
16469997|NCT03498690|Active Comparator|Consecutive|
16469998|NCT03498677|Active Comparator|Method of presentation one|
16470000|NCT03498664|Experimental|EMR-C group|"A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.
~After submucosal injection, the cap will be applied against the lesion which will be aspirated by controlled suction, avoiding excessive protrusion of tissue in order not to trap the muscular layer.
~The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan)."
16470001|NCT03498664|Active Comparator|EMR-S group|The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
16470002|NCT03498651|Experimental|CBM-I, low attrition|Computer- or phone-based Cognitive Bias Modification - Interpretation training
16470003|NCT03498651|Experimental|CBM-I, high attrition, coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training + Coaching
16470004|NCT03498651|Experimental|CBM-I, high attrition, no coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training
16470005|NCT03498651|Active Comparator|Psychoeducation|Online psychoeducation about anxiety
16470006|NCT03498638|Experimental|Couples Therapy|Couples Therapy
16470007|NCT03498638|Placebo Comparator|Control|Couples Therapy after an 8 week waiting period
16470008|NCT03498625|Other|Clinical remission CD|
16470009|NCT03498612|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
16470010|NCT03498599|Experimental|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
16470011|NCT03498599|Other|Standard extinction|The shock is omitted during standard extinction
16470012|NCT03498586|Experimental|Half-normal saline|
16470013|NCT03498586|Active Comparator|Normal saline|
16470014|NCT03498573|Experimental|tunneling surgical technique|
16470015|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
16470016|NCT03498547|Active Comparator|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
16470017|NCT03498547|Active Comparator|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
16470018|NCT03498534|Active Comparator|Patients with a -TST|In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
16470019|NCT03498534|Active Comparator|Patients with a +TST|In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
16470020|NCT03498534|Active Comparator|HIV positive patients|The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
16470023|NCT03498508||Healthcare professionals in Dalarna County Council|Healthcare professionals working in-hospital at the hospitals in Mora, Avesta and Falun, Sweden, n=1473.
16470024|NCT03498508||Healthcare professionals in Region Västmanland|Healthcare professionals working in-hospital at the hospital in Västerås, Region Västmanland, Sweden, n=1571.
16470025|NCT03498495|Experimental|SMART Intervention|
16470026|NCT03498495|No Intervention|Usual Care|
16470027|NCT03498482|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
16470028|NCT03498469|Active Comparator|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
16470029|NCT03498469|Experimental|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
16470030|NCT03498456|Experimental|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
16470031|NCT03498456|Active Comparator|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
16470032|NCT03498430|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle
16470033|NCT03498417||Graves' diseases|Patients with Graves' disease. No interventions foreseen
16470034|NCT03498417||Autoimmune thyroiditis|Patients with autoimmune thyroiditis. No interventions foreseen
16470035|NCT03498417||Healthy Subjects|Normal healthy subjects. No interventions foreseen
16470036|NCT03498404|Experimental|Photodynamic Therapy and SRP|"Procedure/Surgery: Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
~Treatment with TFDa in the Test Group maintained the protocol of applications in the periods of 2, 7 and 14 days post-surgical intervention."
16470037|NCT03498404|Sham Comparator|SRP and Sham Photodynamic Therapy|Procedure/Surgery: Sham Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
16470038|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
16470039|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
16470040|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
16470041|NCT03498365|Experimental|Online MCDA|
16470042|NCT03498365|Active Comparator|Online Delphi|
16470043|NCT03498326|Experimental|gemcitabine|one group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection.
16470044|NCT03498326|Experimental|gemcitabine plus celecoxib|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection, and receive additional celecoxib every days during chemotherapy period.
16470045|NCT03498313|Experimental|Transdermal Estradiol + Placebo|.1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
16470046|NCT03498313|Experimental|Oral Micronized Progesterone + Placebo|100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
16470047|NCT03498313|Placebo Comparator|Placebos|Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
16470048|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
16470049|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
16470050|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
16470051|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
16470052|NCT03498274|Experimental|Fitting System|a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
16470053|NCT03498274|Active Comparator|Traditional Fitting System|A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.
16470054|NCT03498261|Active Comparator|Gabapentin|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
16470055|NCT03498261|Placebo Comparator|Placebo|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
16470056|NCT03498248|Experimental|Neutropenia in chemotherapy|Neutropenia after cytotoxic chemotherapy
16470057|NCT03498235|Experimental|Team Sevoflurane|
16470058|NCT03498235|Experimental|Team Propofol|
16470059|NCT03498222|Experimental|Dose Level -1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2
16470060|NCT03498222|Experimental|Dose Level 1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 18mg/m2
16470061|NCT03498222|Experimental|Dose Level 2|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 36mg/m2
16470062|NCT03498196|Experimental|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
16470063|NCT03498183|Experimental|ARM experimental|All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.
16470064|NCT03498170|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1
~Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7"
16470065|NCT03498157|Experimental|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
16470106|NCT03497884|Experimental|Real rTMS (high frequency)|Real rTMS (high frequency) is 10Hz.
16470066|NCT03498157|Active Comparator|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
16470067|NCT03498157|Active Comparator|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
16470068|NCT03498157|No Intervention|Comparison group- women too active|Added comparison group: Women who are ineligible on the basis of 'engaging in systematic intense exercise training (at least 1h twice a week) will be recruited to complete measures only, with no randomization
16470069|NCT03498144||Patients with acquired punctal stenosis|Patients with acquired punctal stenosis with epiphora
16470070|NCT03498144||Control subjects|normal subjects, without evidence of any punctal abnormalities.
16470071|NCT03498131|Experimental|3 mg Melatonin|Subjects will receive 3 mg melatonin once a day.
16470072|NCT03498131|Experimental|5 mg Melatonin|Subjects will receive 5 mg melatonin once a day.
16470073|NCT03498118|Experimental|Transversus Abdominis Plane Block group|after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
16470074|NCT03498118|Active Comparator|Wound Infiltration group|at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure
16470075|NCT03498105||Emergency Department (ED)|"450-500 participants who will;
~self present to the Emergency Department (ED) will chest pain
~be brought in by ambulance to ED with acute chest pain
~be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
16470076|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
16470077|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
16470078|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
16470079|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
16470080|NCT03498092|Experimental|Bupivacaine-Dexmedetomidine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline and 1mcg/kg dexmedetomidine in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
16470081|NCT03498092|Active Comparator|Bupivacaine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
16470082|NCT03498092|Placebo Comparator|Saline group|This group will serve as a control and blinding group and will receive saline infiltration in the same manner.
16470083|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
16470084|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
16470085|NCT03498053|Other|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.
~The content of an experimental day is described in the study design."
16470086|NCT03498040||Patients with or at risk of carcinoid heart disease|"Adult patients with well-differentiated metastatic ileum or bronchial neuroendocrine tumor
~Adult patients with carcinoid syndrome or elevated urinary 5HIAA regardless of primary site"
16470087|NCT03498027||Data Collection|
16470088|NCT03498014|Active Comparator|Prescription as standard|
16470089|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
16470090|NCT03498001|Experimental|Patients|
16470091|NCT03497988|Experimental|Syntocinon (=Oxytocin), then Placebo|"Single-Dose Intranasal Oxytocin
~Single-Dose Placebo"
16470092|NCT03497988|Experimental|Placebo, then Syntocinon (=Oxytocin)|"Single-Dose Placebo
~Single-Dose Intranasal Oxytocin"
16470093|NCT03497975|Active Comparator|Active|162 mg nalbuphine ER tablets, BID
16470094|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
16470095|NCT03497962||ITU patients|25 patients will be recruited from the Intensive Care Unit/ High dependency unit Inclusion- Adults (>18years) with community acquired pneumonia (CAP).
16470096|NCT03497962||Healthy volunteer|24 healthy adult volunteers will be recruited to establish a comparison data set and to extend the laboratory observations to include other bacterial pathogens.
16470097|NCT03497936|Experimental|Women's Stories|Participants in this group will be randomly assigned to use the Women's Stories intervention.
16470098|NCT03497936|No Intervention|Programming as usual|Participants in this group will be randomly assigned participate in their usual programming.
16470099|NCT03497923|Active Comparator|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
16470100|NCT03497923|Experimental|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
16470104|NCT03497884|Experimental|Real rTMS (low frequency)|Real rTMS (low frequency) is 1Hz.
16470107|NCT03497871|Experimental|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).
~They use the HeartMan system in addition to receiving standard care."
16470108|NCT03497871|No Intervention|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).
~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
16470109|NCT03497858|Experimental|coconut water|participants will complete the simulated basketball game with coconut water supplementation
16470110|NCT03497858|Placebo Comparator|Placebo - water|participants will complete the simulated basketball game with water supplementation
16470111|NCT03497858|Experimental|Sports drink|participants will complete the simulated basketball game with sports drink supplementation
16470112|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
16470113|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
16470114|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
16470115|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
16470116|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
16470117|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
16470118|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
16470119|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
16470120|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
16470121|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
16470122|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
16470123|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
16470124|NCT03497819|Experimental|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
16470125|NCT03497806|Experimental|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
16470126|NCT03497793|Experimental|Skin-to-skin care with SNUBY|Mothers providing skin-to-skin care with the use of SNUBY
16470127|NCT03497780||ACL Tear|Patients with ACL tears
16470128|NCT03497780||Healthy Subjects|Healthy subjects
16470129|NCT03497767|Experimental|Osimertinib|80mg Osimerinib taken once daily
16470130|NCT03497767|Experimental|Stereotactic Radiosurgery + Osimertinib|Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily
16470131|NCT03497754|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient
16470132|NCT03497715|Experimental|Experimental 1|Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)
16470133|NCT03497715|Experimental|Experimental 2|Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules
16470134|NCT03497715|Experimental|Experimental 3|Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine
16470135|NCT03497715|Experimental|Experimental 4|Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium
16470136|NCT03497702|Experimental|Experimental|Patients receive neoadjuvant chemotherapy (doxorubicin 60mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 every 3 weeks for 4 cycles followed by docetaxel 75mg/m2 IV on day 1 every 3 weeks for 4 cycles) plus letrozole with or without leuproelin depending on menopausal status
16470137|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Intravenous (IV) or subcutaneous (SC) treprostinil induction followed by transition to oral treprostinil
16470138|NCT03497676|Experimental|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.
~Step 2: CAB LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (600 mg/3 mL), and at Week 8 (600 mg/3 mL)."
16473065|NCT03477292|Experimental|Long duration of antibiotics|14 days of Colistin
16470139|NCT03497676|Experimental|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.
~Step 2: RPV LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (900 mg/3 mL), and at Week 8 (900 mg/3 mL)."
16470140|NCT03497676|Experimental|Cohort 2: CAB + RPV|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.
~Step 4: First injection: CAB LA administered as one 600 mg (3 mL) IM injection AND RPV LA administered as one 900 mg (3 mL) IM injection, at Week 4b (Step 4 Entry) and at Week 8. Subsequent injections: starting at Week 16, CAB LA administered as a 600 mg (3 mL) IM injection AND RPV LA administered as a 900 mg (3 mL) IM injection, every eight weeks through Week 96."
16470141|NCT03497663|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
16470142|NCT03497663|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
16470143|NCT03497650|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb while observing the reflection of the exercising limb in the mirror which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
16470144|NCT03497650|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
16470145|NCT03497637|Active Comparator|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
16470146|NCT03497637|Active Comparator|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
16470147|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
16470148|NCT03497598|Experimental|mannose|"2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.
~rUTI diary"
16470149|NCT03497598|Placebo Comparator|placebo|"2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.
~rUTI diary"
16470150|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
16470151|NCT03497559|Experimental|Music|Patients will received 30 minutes of classical music 3 times per day . Music will be delivered with noise cancellation headphones.
16470152|NCT03497559|Sham Comparator|Noise cancellation|Patients will received 30 minutes of silent recording 3 times per day . Music will be delivered with noise cancellation headphones.
16470153|NCT03497559|No Intervention|Control|Patients will receive standard of care.
16470154|NCT03497546|Experimental|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
16470155|NCT03497546|No Intervention|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
16470156|NCT03497533|Experimental|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
16470157|NCT03497520|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 10 degree perform asymmetric spinal stabilization exercise
16470160|NCT03497494|Active Comparator|Without hiatal suture|the different distance of pylorus without hiatal suture
16470161|NCT03497494|Active Comparator|With hiatal suture|the different distance of pylorus without hiatal suture
16470162|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
16470163|NCT03497468|Active Comparator|Control group|Patients in this group will receive combined exercise training included aerobic and strengthening exercises, 3 times a week for 6 weeks. All exercise sessions will be performed under the supervision of a physiotherapist.
16470164|NCT03497468|Experimental|Training group|Patients in this group will receive task-oriented training additional to combined exercise training 3 times a week for 6 weeks. Task-oriented training included more functional daily life mobility activities like reaching, obstacle walking, stairs climbing. All exercise sessions will be performed under the supervision of a physiotherapist.
16470165|NCT03497442|Experimental|Treatment Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
16470198|NCT03497195|Active Comparator|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
16470199|NCT03497182|Experimental|Breath sample collection|
16473066|NCT03477292|Active Comparator|Short duration of antibiotics|7 days of Colistin
16470166|NCT03497442|Placebo Comparator|Placebo Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
16470167|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
16470168|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
16470169|NCT03497416||Anemic|
16470170|NCT03497416||Non-anemic|
16470171|NCT03497403|Active Comparator|Control|Socket preservation control. After tooth extraction, bone graft is applied to socket and a non-cross-linked membrane is used in primary intentional healing.
16470172|NCT03497403|Experimental|Experimental|Socket preservation experimental. After tooth extraction, bone graft is applied to socket and a cross-linked membrane is used in secondary intention healing.
16470173|NCT03497390|Active Comparator|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 3 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
16470174|NCT03497390|Placebo Comparator|Usual care|Usual management without any workshop or program
16470175|NCT03497377|Experimental|18F-DCFPyL Injection & 18F-NaF|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
16470176|NCT03497364|Experimental|Bupivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. The dose of bupivacaine depended on height of subjects.
16470177|NCT03497364|Experimental|Ropivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting ropivacaine. The dose of ropivacaine depended on height of subjects).
16470178|NCT03497364|No Intervention|Control group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. 2ml bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection for all subjects.
16470179|NCT03497351|Experimental|Group N|the group treated with nicardipine
16470180|NCT03497351|Experimental|Group U|the group treated with Urapidil
16470181|NCT03497325|Experimental|PRP|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
16470182|NCT03497325|Placebo Comparator|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
16470183|NCT03497299|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
16470184|NCT03497299|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
16470185|NCT03497286|Experimental|Treatment|Participants in the treatment condition will be enrolled in the text-based mentorship program and will be able to engage with their assigned mentor as much or as little as they choose.
16470186|NCT03497286|Active Comparator|Control|Participants in the control condition will receive periodic informational texts related to the growth and development of their new baby.
16470187|NCT03497273|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
16470188|NCT03497260|Experimental|Fructose in water first, water only second|Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
16470189|NCT03497260|Experimental|Water only first, Fructose in water second|Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
16470190|NCT03497247|Experimental|Mindfulness-Based Cognitive-Behavioral Therapy|
16470191|NCT03497247|Active Comparator|Cognitive-Behavioral Therapy|
16470192|NCT03497234|Experimental|All women eligible to participate|All women presenting who sign the consent and found eligible will have a VF and AF sample taken and analyzed on the Perilynx Analyzer to measure AF and VF fluid. This does not affect their regular standard of care and diagnosis
16470193|NCT03497221|Other|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
16470194|NCT03497221|Other|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
16470195|NCT03497208|Experimental|Microneedling+cell susp+phototherapy|Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
16470196|NCT03497208|Active Comparator|Microneedling and phototherapy|Technique involves only the abrasion with dermaroller equipped with 0,25mm on the lesion of vitiligo.
16470197|NCT03497195|Active Comparator|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
16470200|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
16470201|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.
~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
16470202|NCT03497117|Other|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.
~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.
~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
16470203|NCT03497091||Enteral Tube fed children|Enteral Formula
16470204|NCT03497078|Other|Refered patients for scintigraphy|
16470205|NCT03497052||Group 1|Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
16470206|NCT03497052||Group 2|Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
16470207|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
16470208|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
16470209|NCT03497026|Experimental|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
16470210|NCT03497013|Experimental|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
16470211|NCT03497013|Sham Comparator|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
16470212|NCT03497000|Experimental|OCTA group|Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
16470213|NCT03497000|Active Comparator|ICGA group|Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
16470214|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
16470215|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
16470216|NCT03496974|Experimental|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
16470217|NCT03496974|Experimental|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
16470218|NCT03496961|Experimental|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
16470219|NCT03496961|Placebo Comparator|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
16470220|NCT03496961|No Intervention|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
16470221|NCT03496948|Experimental|TeGeCoach|Home-based exercise program consisting of telephone health coaching, remote walking exercise monitoring based on wearable monitors and intensified primary care.
16470222|NCT03496948|No Intervention|Usual care group (TAU)|Patients randomized to TAU receive written information about courses offered by their statutory health insurance. Health insurance companies offer a variety of courses to encourage regular exercise and to promote lifestyle changes, including SEPs (vascular and cardio exercise), physical therapy, nutritional assistance programs, smoking cessation programs, weight loss programs, and patient education programs for obesity and diabetes.
16470223|NCT03496935|Active Comparator|Tunneled dialysis catheter|In this arm, patients will be randomized to undergo tunneled dialysis catheter insertion.
16470224|NCT03496935|Active Comparator|Non-tunneled dialysis catheter|In this arm, patients will be randomized to undergo non-tunneled dialysis catheter insertion.
16470225|NCT03496922|Experimental|Tobacco Products|Participants will be asked to sample ventilated and unventilated cigarettes (and possibly alternative nicotine products such as cigarillos). During the experimental sessions, they will be given the opportunity to purchase ventilated and unventilated cigarettes (and possibly alternative nicotine products) using an account balance in the Experimental Tobacco Marketplace. However, besides the required sampling session, participants will not be required to purchase any nicotine products.
16470226|NCT03496909|Active Comparator|Standard OT|
16470227|NCT03496909|Experimental|PhysioTouch|
16470228|NCT03496896|Experimental|"TARGET intervention"|The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.
16470229|NCT03496896|No Intervention|Control|The group control will receive usual care without additional intervention.
16470230|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
16470231|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
16470232|NCT03496870|Experimental|Opicapone once daily with Carbidopa/Levodopa|Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 & 15
16470277|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
16470233|NCT03496857|Experimental|Photobiomodulation analgesia|"LED therapy sessions will be held in the pre-labor room. The patient who will undergo analgesia and the professional responsible for placing the LED plate on the patient's back, between T10 and L2, will be present at the time of the intervention. The LED plate will be covered with clear disposable plastic (PVC) to avoid cross-contamination and ensure hygiene. During the interventions, the patient will be allowed to choose the position that is the most comfortable for her.
~Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention."
16470234|NCT03496857|Active Comparator|bath therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
16470235|NCT03496844|No Intervention|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
16470236|NCT03496844|Active Comparator|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
16470237|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
16470238|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
16470239|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
16470240|NCT03496818||Crohn's Disease|Participants age 18-80 years old, diagnosed with Crohn's disease with active disease based on MR enterography or CT enterography confirmed within the prior 90 days.
16470241|NCT03496818||Healthy controls|Participants age 18-80 years old, with no diagnosis of inflammatory bowel disease.
16470242|NCT03496805|Experimental|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
16470243|NCT03496805|Placebo Comparator|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
16470244|NCT03496792|Experimental|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
16470245|NCT03496792|Placebo Comparator|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
16470246|NCT03496792|Experimental|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
16470247|NCT03496792|Placebo Comparator|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
16470248|NCT03496779|Experimental|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.
~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.
~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
16470249|NCT03496766|Experimental|Experimental Arm|Tipifarnib 600 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months
16470250|NCT03496753|Experimental|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
16470251|NCT03496753|No Intervention|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
16470252|NCT03496740|Active Comparator|Penile Block|"Ultrasound guided dorsal penile nerve block will be administered after general anesthesia.
~0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks"
16470253|NCT03496740|Active Comparator|Pudendal Block|Nerve stimulator-guided pudendal block. 0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks
16470254|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
16470255|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
16470256|NCT03496714|Active Comparator|PSYED-T|In PSYED-T (psychoeducation on trauma symptoms), participants will receive a psychoeducation handout and watch a related video on common reactions to trauma. Participants in this condition will also receive a rationale stating that both learning about the nature of trauma reactions and monitoring symptoms are important for preventing development of PTSD.
16470402|NCT03495765|Active Comparator|Well controlled|Eligibile people with diabetic macular oedema and HBA1C < 7.5
16470257|NCT03496714|Experimental|PSYED-T+SB|Participants in PSYED-T+SB (Combined psychoeducation on trauma reactions and safety behaviors) will receive psychoeducation handouts and videos on the nature of trauma symptoms and the nature of safety behaviors and how to fade them. Participants in this condition will also receive a rationale stating that learning about the nature of trauma reactions and safety behaviors, learning to fade safety behaviors, and monitoring symptoms are important in the prevention of PTSD.
16470258|NCT03496714|No Intervention|Monitoring-only control|The third condition will be a monitoring-only control and thus will receive no psychoeducation information. Participants in the control condition will receive a rationale that monitoring symptoms is important in the prevention of PTSD development.
16470259|NCT03496701|Experimental|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
16470260|NCT03496688|Active Comparator|bone substitute material MCBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using mineralized sol-vent-dehydrated bone allograft material.
16470261|NCT03496688|Active Comparator|bone substitute material FDBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using freeze-dried mineralized bone allograft material.
16470262|NCT03496688|Active Comparator|bone substitute material ABB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using anorganic bovine bone material.
16470263|NCT03496688|Active Comparator|bone substitute material EB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using equine-derived bone material.
16470264|NCT03496688|Active Comparator|bone substitute material HA-β-TCP 30/70|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using synthetic micromacroporous bi-phasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hy-droxyapatite material.
16470265|NCT03496688|Active Comparator|bone substitute material BC|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using bioapatite-collagen material.
16470266|NCT03496675|Other|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
16470267|NCT03496675|Experimental|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
16470268|NCT03496675|Experimental|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
16470269|NCT03496675|Experimental|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
16470270|NCT03496662|Experimental|Part A - Experimental|"BMS-813160 daily oral pill
~Nivolumab will be given as a 30-minute intravenous infusion at a flat dose of 480 mg on Day 1 (+/- 2 days) of each 28-day cycle
~Gemcitabine will be given as a 30-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle
~Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle
~Post-treatment biopsy at the end of cycle 2
~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
16470271|NCT03496662|Active Comparator|Part A - Control|"Gemcitabine will be given as a 30-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle
~Post treatment biopsy at the end of cycle 2
~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
16470272|NCT03496662|Experimental|Part B - Dose expansion|"BMS-813160 daily oral pill
~Nivolumab will be given as a 30-minute intravenous infusion at a flat dose of 480 mg on Day 1 (+/- 2 days) of each 28-day cycle
~Gemcitabine will be given as a 30-minute intravenous infusion at the maximum tolerated dose on Days 1, 8, and 15 of each 28-day cycle
~Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the maximum tolerated dose on Days 1, 8, and 15 of each 28-day cycle
~Post-treatment biopsy at the end of cycle 2
~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
16470273|NCT03496649|Experimental|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.
~At least 2 of the 4 muscles below will be injected, depending on which muscles are affected:
~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle 200 IU for the adductor brevis muscle
~These injections will be uni or bilateral, it will depend on clinical diagnosis.
~If necessary, the 4 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
16470274|NCT03496636|Experimental|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
16470275|NCT03496623|Experimental|Inhaled Treprostinil|Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms [mcg]) 4 times daily (QID)
16470276|NCT03496623|Placebo Comparator|Placebo|Placebo delivered via an ultrasonic nebulizer for QID administration
16470531|NCT03494842|Active Comparator|the active TENS group|Transcutaneous nerve stimulation (TENS)
16470278|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 166 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
16470282|NCT03496584|Active Comparator|Pomegranate Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Pomegranate Juice , followed by 12 weeks of pomegranate juice consumption.
16470283|NCT03496584|Placebo Comparator|Placebo Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Placebo Juice , followed by 12 weeks of pomegranate juice consumption.
16470284|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
16470285|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
16470286|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
16470287|NCT03496558|Experimental|150 pregnant women with a history of risk|
16470288|NCT03496558|No Intervention|150 healthy pregnant women|
16470289|NCT03496545|Active Comparator|Acetaminophen|Standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
16470290|NCT03496545|Experimental|Bromocriptine and Acetaminophen|Bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
16470291|NCT03496532|Experimental|Pulse generator change under sedation|"The efficacy of every set will be measured on induced changes in LFP recorded from the STN electrodes.LFP will be compared between before, during and right after each stimulation conditions. The stimulation order will be randomized. All other stimulation parameters will be the same (macrocontact with most beta-oscillations, 1 minute, 1.5mA) .
~Hence 4 sets of 1 minutes of STN stimulation will be performed, for:
~Symmetrical biphasic pulses versus standard pseudo monophasic pulses (study I; 2 sets).
~Pseudorandom uniform distribution stimulation paradigms versus pseudorandom Poisson distribution stimulation paradigms (study II: 2 sets)."
16470292|NCT03496532|Experimental|First pulse generator implantation under general an|The depth of anesthesia will be documented, recording the BIS spectral analysis index. The difference in spectral amplitude density of LFP, in particular in beta band oscillations will be correlated with the depth of anesthesia as measured with the BIS index.
16470293|NCT03496519|Experimental|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.
~Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2
~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2
~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2
~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2
~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
16470294|NCT03496519|Experimental|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
16470295|NCT03496506|Experimental|Sequential treatment arm|Subjects receive 1 tablet of selexipag twice daily from Day 1 to Day 9 and 1 tablet in the morning of Day 10. In the morning of Day 4 and 1 hour before the administration of selexipag, they receive 4 tablets of clopidogrel. Then from Day 5 to Day 10, 1 hour before the morning administration of selexipag, they receive 1 tablet of clopidogrel .
16470296|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
16470297|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
16470298|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
16470299|NCT03496454|Other|PfSPZ Challenge|this is a basic sciences protocol designed to study the effect of pre-exposure to Plasmodium falciparum (Pf) on malaria parasite kinetics, clinical symptoms and immunity after Controlled Human Malaria Infection by administration of an injection PfSPZ Challenge in Gambian adults. Based on a well-defined serological profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection. The classification as a clinical trial results from the administration of the PfSPZ Challenge to the healthy volunteers
16470300|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
16470301|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
16470302|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
16470303|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
16470370|NCT03496012|Experimental|BIIB111 Low Dose|Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
16470371|NCT03496012|No Intervention|Untreated Control Group|Participants will receive no sham surgery or study medication.
16470372|NCT03495999||Normouricemia|Serum uric of 7mg/dl or less in men or 6mg/dl or less in women
16470373|NCT03495999||Hyperuricemia|Serum uric of 7mg/dl or more in men or 6mg/dl or more in women
16470304|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.
~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
16470305|NCT03496415|Experimental|Remote ischemic conditioning|
16470306|NCT03496415|Sham Comparator|Sham remote ischemic conditioning|
16470307|NCT03496402|Experimental|High risk Cohorts|Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
16470308|NCT03496402|Experimental|Low risk Cohort|Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
16470309|NCT03496389|Experimental|Gabapentin + panadol|
16470310|NCT03496389|Active Comparator|Tramadol + panadol|
16470311|NCT03496376|Experimental|Kinesio Taping Group|Kinesio Taping Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set plus thoracic kinesio taping application.
16470312|NCT03496376|Active Comparator|Control Group|Control Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
16470313|NCT03496363||CHD with Hypothyroidism|
16470314|NCT03496350|Experimental|Internet CBT|Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.
16470315|NCT03496350|No Intervention|Wait-list|Wait-list control
16470316|NCT03496324|Active Comparator|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
16470317|NCT03496324|Active Comparator|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
16470318|NCT03496324|Experimental|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
16470319|NCT03496324|Experimental|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
16470320|NCT03496311||Pregnant Women|Pregnant women with gestational age > 35 weeks undergoing spinal anesthesia for elective cesarean section.
16470321|NCT03496311||Control Group|Fertile, non-pregnant women undergoing spinal anesthesia for elective surgery.
16470322|NCT03496298|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
16470323|NCT03496298|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
16470324|NCT03496298|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
16470325|NCT03496259|Experimental|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
16470326|NCT03496259|Active Comparator|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
16470327|NCT03496246|Active Comparator|Group A|patients with vitamin D deficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
16470328|NCT03496246|Active Comparator|Group B|patients with vitamin D insufficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
16470329|NCT03496246|Active Comparator|Group C|patients with normal vitamin D level normal are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
16470330|NCT03496233|Experimental|All patients included|All patients included will be treated with Elbasvir/grazoprevir for 8 weeks
16470331|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
16470332|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
16470333|NCT03496207|Placebo Comparator|Placebo|Placebo SC every 21 days plus SOC for 24 weeks
16470334|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks
16470335|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks
16470336|NCT03496194||Head of Post Anaesthesia Care Unit|The chief physician of PACUs at all Danish Anaesthesia departments will receive electronic survey on postoperative pain treatment
16470374|NCT03495986|Experimental|Home-Based Exercise & Diet Group|16-week home based functional electrical stimulation leg cycle ergometry exercise program and diet intervention
16470375|NCT03495986|Placebo Comparator|Home-Based Diet Alone Group|Diet intervention
16470397|NCT03495804|Experimental|polyethylene glycol|Participants are given a minimum of 1500 mL of a preparation of polyethylene glycol as oral contrast agent over an hour prior to the examination.
16470398|NCT03495791|Experimental|EI development phase.|
16470399|NCT03495791|No Intervention|Pilot-testing phase.|
16470337|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.
~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
16470338|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
16470339|NCT03496168|Experimental|mavacamten (MYK-461)|
16470340|NCT03496155|Experimental|Intervention Group (Arm 1- Main)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
16470341|NCT03496155|No Intervention|Control Group (Arm 1- Main)|Will receive usual care at well-child visit.
16470342|NCT03496155|Experimental|Intervention Group (Arm 1-asthma subgroup)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
16470343|NCT03496155|No Intervention|Control Group (Arm 1-asthma subgroup)|Will receive usual care at well-child visit.
16470344|NCT03496155|No Intervention|Control Group (Arm 2)|Convenience sample used for a post-hoc, exploratory analysis. Will receive usual care at well-child visit.
16470345|NCT03496142|Active Comparator|Transperineal prostate biopsy|Patient will have a transperineal prostate biopsy.
16470346|NCT03496142|Active Comparator|Transrectal prostate biopsy|Patient will have a transrectal prostate biopsy.
16470347|NCT03496129|Experimental|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
16470348|NCT03496129|Experimental|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
16470349|NCT03496129|Active Comparator|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
16470350|NCT03496116|Experimental|ECIG Session: 0.5 Ohms, 3 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
16470351|NCT03496116|Experimental|ECIG Session 0.5 Ohms, 8 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
16470352|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 3 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
16470353|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 8 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
16470354|NCT03496103|Other|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
16470355|NCT03496103|Other|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
16470356|NCT03496090|Experimental|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
16470357|NCT03496090|Active Comparator|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
16470358|NCT03496077|Experimental|Flavored LCCs|Half of the group will start with a flavored little cigar/cigarillo (LCC) and cross over to unflavored LCC. The LCCs will be a popular brand already available for sale on the market.
16470359|NCT03496077|Experimental|Unflavored LCCs|Half of the group will start with an unflavored little cigar/cigarillo (LCC) and cross over to flavored LCC. The LCCs will be a popular brand already available for sale on the market.
16470360|NCT03496064||Anterior circulation LVO patients with ASPECTS <6|
16470361|NCT03496064||Anterior circulation LVO patients with NIHSS<8|
16470362|NCT03496064||Posterior versus anterior circulation LVO patients|
16470363|NCT03496064||LVO patients with isolated PCA or ACA occlusions|
16470364|NCT03496064||Tandem lesions versus non-tandem lesion|
16470365|NCT03496064||Bridging vs Direct MT|
16470366|NCT03496038|Experimental|Leukocyte and Platelet Rich Fibrin (L-PRF)|"For the test group the sub-sinus cavity will be filled with Leukocyte en Platelet Rich Fibrin (L-PRF).
~Before starting the surgery, 8 tubes (9 ml) of venous blood will be collected from the patients. A centrifugation standard L-PRF protocol will be followed followed (12 minutes centrifugation, 2700 rpm/408g RCF).
~After full centrifugation of the tubes, the L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA)."
16470367|NCT03496038|Active Comparator|Deproteinized Bovine Bone Mineral (DBBM)|For the test group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland).
16470368|NCT03496025|Experimental|Electrical stimulation|
16470369|NCT03496012|Experimental|BIIB111 High Dose|Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
16470376|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
16470377|NCT03495960|Experimental|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:
~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.
~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.
~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
16470378|NCT03495960|Active Comparator|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:
~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.
~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.
~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
16470379|NCT03495960|Other|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive
~whole-brain radiotherapy (2340 cGy in 5 weekly fractions)
~temozolomide 75 mg/m2/d during radiotherapy
~4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.
~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
16470380|NCT03495934|Experimental|single oral administration of 14C-pracinostat in the fas|
16470383|NCT03495908|Experimental|VGo with Regular Human Insulin|U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go
16470384|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go
16470385|NCT03495895|Experimental|Minding the Baby|Families are visited weekly beginning in the mother's third trimester of pregnancy up through the child's first birthday, at which point visits take place biweekly up through the child's second birthday.
16470386|NCT03495895|Other|Control|Usual care control condition. Families in the control Group receive the usual care that is offered to families in the target group
16470387|NCT03495882|Experimental|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
16470388|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).
~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
16470389|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
16470390|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
16470391|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
16470392|NCT03495856|Experimental|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
16470393|NCT03495830||Carotid endarterectomy|Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.
16470394|NCT03495830||Optimal medical therapy group|Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.
16470395|NCT03495817|Experimental|ATI-50002 Topical Solution|"This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia.
~Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks."
16470396|NCT03495804|Active Comparator|mannitol|Participants are given a minimum of 1500 mL of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
16470403|NCT03495765|Active Comparator|Poorly controlled|eligible people with Diabetic macular oedema and HBAIC >10.0
16470404|NCT03495752|Experimental|Pre/Post Repeated Measures|Performance on the forward-step-down test (FSDT) before and at one, five, and ten minutes following the Bruce Fatigue Protocol
16470405|NCT03495739|Experimental|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
16470406|NCT03495739|Active Comparator|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
16470407|NCT03495726|Experimental|Headspace app|Participants randomized to use the mindfulness app for 6 weeks.
16470408|NCT03495726|No Intervention|Waitlist control group|This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
16470409|NCT03495713|Experimental|Single Arm|Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
16470410|NCT03495700|Experimental|L-PRF block|"For the test group the sub-sinus cavity will be filled with L-PRF block and the window will be closed with L-PRF membranes.
~Eight tubes (9 ml) of venous blood will be collected from the patients. For 6 tubes (red cap) a 12 min centrifugation at 2700 rpm/408g RCF will be followed. Two tubes (white cap) will be centrifuged (IntraSpin, Intra-Lock, Florida, USA) for 3 minutes only to form the Liquid Fibrinogen.
~The L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA).
~To prepare the L-PRF Block, L-PRF membranes will be cut into small pieces and mixed with DBBM (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The Liquid Fibrinogen will be added to the homogeneous mix, and stirred gently for ± 10 seconds while shaping it to the L-PRF block"
16470411|NCT03495700|Active Comparator|DBBM|For the control group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The window will be closed with a collagen membrane (Bio-Gide, Geistlich AG, Wolhusen, Switzerland).
16470412|NCT03495674|Experimental|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
16470413|NCT03495674|Active Comparator|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
16470414|NCT03495661|Active Comparator|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
16470415|NCT03495661|No Intervention|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
16470416|NCT03495648|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
16470417|NCT03495648|Active Comparator|Non-walking Group|Subjects will drive themselves to the farmer's market.
16470418|NCT03495635|Experimental|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
16470419|NCT03495635|No Intervention|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
16470420|NCT03495622|Experimental|Motivational Interviewing/Text messaging|Home visits by community health worker to deliver motivational interviewing and set up a structured text messaging strategy designed around a pre-determined quit date for smoking cessation.
16470421|NCT03495622|No Intervention|Control|All participants will receive brief verbal advice about the hazards of smoking and the benefits of smoking cessation.
16470422|NCT03495609|Experimental|Ovitrelle|
16470423|NCT03495596||Videolaryngoscopy patients|The patients who were attempted to be intubated with videolaryngoscopy
16470424|NCT03495583|Experimental|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
16470425|NCT03495583|No Intervention|Standard introduction|Infants followed UK DoH standard advice for weaning
16470426|NCT03495570||A|HIV-infected (chronic or acute infection) with a HIV viral load of >1000 copies/mL in the 6 months prior to study entry and not (yet) in receipt of combination antiretroviral therapy (cART) at study entry.
16470427|NCT03495570||B|HIV-infected on cART with HIV viral load <50 copies/mL within the 6 months prior to study entry, at least one measure of HCV (chronic or acute infection) showing a detectable HCV viral load and not in receipt of HCV treatment at study entry.
16470428|NCT03495570||C|HCV mono-infected (chronic or acute infection) with detectable HCV viral load (>lower limit of quantification) in the prior 6 months and not in receipt of HCV treatment at study entry.
16470429|NCT03495570||D|HBV mono-infected (chronic or acute infection) patients with detectable HBV viral load in the prior 6 months and not in receipt of HBV treatment at study entry.
16470430|NCT03495557|Sham Comparator|Control|Simple closure
16470431|NCT03495557|Experimental|Experimental|Simple closure + mesh
16470432|NCT03495544||Hereditary BC|Pathogenic germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
16470433|NCT03495544||Sporadic BC|Without germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
16470434|NCT03495531|No Intervention|Standard of Care|Standard of Care
16470435|NCT03495531|Experimental|VR Use|Obstetrics patients who use virtual reality
16470436|NCT03495518|Active Comparator|Symptom feedback to Health Care Provider|"For those randomized to the intervention arm, symptom screening using SPARK will be completed once daily for 5 days on an iPad using the approach refined in aim 2. Daily SSPedi reports will be printed and provided in the patient chart. On days 1 and 3±1, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical care"
16470437|NCT03495518|Active Comparator|Standard of care|For those randomized to the control arm, a clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
16470438|NCT03495505|Experimental|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
16470439|NCT03495492|Experimental|Participants|Group receiving dermal chelation and nutritional therapy
16470441|NCT03495466|Active Comparator|Local only Anesthesia|The patient will receive local only anesthesia during the first surgery and local with sedation anesthesia for their second surgery.
16470442|NCT03495466|Active Comparator|Local with sedation anesthesia|The patient will receive local with sedation anesthesia during the first surgery and local only anesthesia for their second surgery.
16470443|NCT03495453|Active Comparator|CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)|OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
16470444|NCT03495453|Active Comparator|Medtronic's Hawkone Directional Atherectomy system (DAS)|DAS (using the Hawkone device) followed by DCB
16470445|NCT03495440|Experimental|Center Sessions|Treatment condition in which participants receive psychoeducation and communication coaching.
16470446|NCT03495440|Active Comparator|At-home|Active, self-study control condition in which participants receive regular communication with study personnel and self-study materials to review on their own.
16470447|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
16470448|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
16470449|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010)
16470450|NCT03495401|Experimental|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
16470451|NCT03495401|Placebo Comparator|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
16470452|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
16470453|NCT03495375|Experimental|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
16470454|NCT03495375|Placebo Comparator|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
16470455|NCT03495362|Experimental|Intervention group|"Ingredients: yeast beta-glucan, and capsule shell Capsule, per capsule with 500mg insoluble beta-glucan, twice a day, 1 capsule each time.
~The intervention period is about 3 months."
16470456|NCT03495362|Placebo Comparator|Placebo group|Ingredients: starch, and capsule shell Capsule, per capsule with 500mg starch, twice a day, 1 capsule each time. The intervention period is about 3 months.
16470457|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
16470458|NCT03495336|Experimental|Washout period|Coffee abstention phase for 2 weeks.
16470459|NCT03495336|Experimental|Light roast coffee (LR)|Participants will follow LR Coffee consumption procedure and consume at least 3 cups of Light (LR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
16470460|NCT03495336|Experimental|Second washout period|coffee abstention phase for 2 weeks
16470461|NCT03495336|Experimental|Dark roast coffee (DR)|Participants will follow DR Coffee consumption procedure and consume at least 3 cups of Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
16470462|NCT03495323|Experimental|Prexasertib + LY3300054|"Prexasertib is administered intravenously twice per cycle
~LY3300054 is administered intravenously twice per cycle"
16470463|NCT03495310|Experimental|Mindfulness|"In this group, children and their parents will receive a mindfulness session once a week, with a duration of 90 minutes, during 8 weeks (sessions will be separated for children and parents). Mindfulness sessions will be coordinated by experts in mindfulness techniques in children and adults respectively from the collaborator Institution Spanish School of Transpersonal Development Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan if necessary. Also a 60-minute walk 3 times a week will be recommended"
16470464|NCT03495310|No Intervention|Control|In this group, children and their parents will receive information regarding what is a healthy diet and physical activity attached to the World Health Organization recommendations. The session will be coordinated by a pediatric endocrinologist. Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan when necessary. Also a 60-minute walk 3 times a week will be recommended
16470465|NCT03495297|No Intervention|S-ICD Implant with defibrillation test|Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant
16470466|NCT03495297|Experimental|S-ICD Implant without defibrillation test|Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant
16470532|NCT03494842|Placebo Comparator|the placebo TENS group|Placebo Transcutaneous nerve stimulation (TENS)
16470533|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
16470467|NCT03495284|Experimental|Potato treatment|Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet. The potato-based side dish will be prepared at the Penn State Metabolic Kitchen. The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium. French fries will not be provided. The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
16470468|NCT03495284|Active Comparator|Refined grain treatment|Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
16470469|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:
~Patient's undergoing hemodialysis.
~Male and female of any race
~18 years/ older.
~Those with dysphagia were excluded.
~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.
~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.
~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
16470470|NCT03495271||Healthy Controls|"Inclusion Criteria
~No tongue, lip, or cheek piercings
~Over 18 years of age
~Normal taste and smell function
~No known issues with salivation or dry mouth
~Willing to comply with study protocol (taste samples and provide saliva)
~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
16470471|NCT03495258|Experimental|Clarion Evolve Laser Vaporization System|Clarion Evolve Laser Vaporization System
16470472|NCT03495258|Experimental|Olympus TURis Plasma Vaporization|Olympus TURis Plasma Vaporization
16470473|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
16470474|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
16470475|NCT03495219||Esophageal Manometry|Esophageal manometry is a test to assess motor function of the upper esophageal sphincter, esophageal body and lower esophageal sphincter
16470476|NCT03495206|Experimental|Y-2(Edaravone And Borneol) sublingual tablet|
16470477|NCT03495193|Active Comparator|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
16470478|NCT03495193|Active Comparator|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
16470479|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
16470480|NCT03495167|Experimental|SyB C-1101|
16470481|NCT03495154|Experimental|Parietene DS Composite Mesh|Patients treated with Parietene DS Composite Mesh
16470482|NCT03495141|Active Comparator|Supervised|Participants first take part in supervised/coached colonoscopy module session twice (case one and case two) and then transition to performing an unassisted colonoscopy module twice (case three and case four).
16470483|NCT03495141|Active Comparator|Unsupervised|Participants will either first partake in an unsupervised colonoscopy module twice (case one and case two) and then transition to a supervised/coached colonoscopy module session twice (case three and case four).
16470484|NCT03495128|Experimental|Bed rest|Three days of bed rest at -6 degrees of head-down tilt
16470485|NCT03495128|Experimental|Reconditioning|Three days of one-legged knee extension contractions to recondition one leg
16470486|NCT03495115|Active Comparator|SCREENING MRI|Standard MRI procedure will be used.
16470487|NCT03495115|Experimental|SCREENING MG BI-RADS 4/5|"RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.
~RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .
~The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
16470488|NCT03495102|Active Comparator|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
16470489|NCT03495102|Experimental|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
16470490|NCT03495102|Experimental|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
16470491|NCT03495089|Experimental|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.
~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
16470492|NCT03495089|Experimental|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.
~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
16470534|NCT03494803||Control|
16470493|NCT03495089|Experimental|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
16470494|NCT03495076|Experimental|Saline injection|In the saline condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline solution.
16470495|NCT03495076|Sham Comparator|Sham injection|In the sham injection condition, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
16470496|NCT03495076|No Intervention|Control|Participants in the control condition will not receive any kind of pain or pinprick sensation.
16470497|NCT03495063|Experimental|Natural Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
16470498|NCT03495063|Experimental|Synthetic Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
16470499|NCT03495037|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
16470500|NCT03495037|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
16470501|NCT03495024|Other|Smoking cessation with varenicline|FDA-approved indication of varenicline for smoking cessation
16470502|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
16470503|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
16470504|NCT03494998||Children and young people|Aged 0-16 years
16470505|NCT03494985|Experimental|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
16470506|NCT03494985|Experimental|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
16470507|NCT03494985|Experimental|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
16470508|NCT03494985|Sham Comparator|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
16470509|NCT03494972|Active Comparator|drain|Tetracyclin drain
16470510|NCT03494972|Sham Comparator|No-drain|No drain
16470511|NCT03494959|Experimental|Treatment with Pentaglobin|Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days.
16470512|NCT03494946|Experimental|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
16470513|NCT03494946|Active Comparator|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
16470516|NCT03494920|Other|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
16470517|NCT03494920|Other|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
16470518|NCT03494907|Experimental|Seltorexant (Low and high dose)|Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
16470519|NCT03494907|Experimental|Moxifloxacin|Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
16470520|NCT03494907|Experimental|Placebo Matched to Seltorexant|Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
16470521|NCT03494907|Experimental|Placebo Matched to Moxifloxacin|Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
16470522|NCT03494894||patients with Cystic Fibrosis and Primary Ciliary Dyskinesia|
16470523|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
16470524|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
16470525|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
16470526|NCT03494855||Neonates|<1 month of age SyMRI software used for brain imaging and radiological interpretation
16470527|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
16470528|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
16470529|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
16470530|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
16470536|NCT03494777|Experimental|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.
~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.
~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
16470537|NCT03494777|Experimental|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.
~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
16470538|NCT03494777|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
16470539|NCT03494764|Active Comparator|5 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
16470540|NCT03494764|Active Comparator|3 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
16470541|NCT03494751|Experimental|Heart Monitor|We used the device (heart monitor) in the patients with myocardial infarction.
16470542|NCT03494751|Active Comparator|No Heart Monitor|No heart monitor device in the patients with myocardial infarction (control).
16470543|NCT03494738||Newborn infants|Neonates born from consented women at the study hospital
16470544|NCT03494725|Active Comparator|Lpc-37|"Lacticaseibacillus paracasei Lpc-37 (Lpc-37), formerly Lactobacillus paracasei Lpc-37
~1x 1 capsule in the morning for 5 weeks"
16470545|NCT03494725|Placebo Comparator|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule
~1x 1 capsule in the morning for 5 weeks"
16470546|NCT03494712|Experimental|S 95010|Increasing single doses of S 95010 to 5 subjects.
16470547|NCT03494712|Placebo Comparator|Placebo|Increasing single doses of Placebo to 2 subjects.
16470548|NCT03494699|Experimental|Intervention group|
16470549|NCT03494699|No Intervention|Control group|
16470550|NCT03494686|Experimental|LLETZ under local anaesthesia|The LLETZ procedure will be performed under local anaesthesia
16470551|NCT03494686|Active Comparator|LLETZ under general anaesthesia|The LLETZ procedure will be performed under general anaesthesia
16470552|NCT03494673||Control|Normal controls without headaches will undergo BOLD MRI with prospective CO2 targeting
16470553|NCT03494673||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo BOLD MRI with prospective CO2 targeting
16470554|NCT03494647|Active Comparator|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
16470555|NCT03494647|Active Comparator|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
16470556|NCT03494634|Experimental|Chidamide|
16470557|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
16470558|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
16470559|NCT03494595||Thrombosis|Patients who will develop thrombosis perioperatively
16470560|NCT03494595||No thrombosis|Patients who will not develop thrombosis perioperatively
16470561|NCT03494582|Experimental|Sacral Hysteropexy|Abdominal approach for uterine suspension
16470562|NCT03494582|Experimental|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
16470563|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
16470564|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
16470565|NCT03494530|Other|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
16470566|NCT03494530|Other|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
16470567|NCT03494517||Preeclampsia|"Women aged 18-45 years
~Confirmed pregnancy > 30 weeks of gestation
~Singleton or multiple pregnancies
~Admission in maternity of the Women's hospital with clinically suspected signs of severe preeclampsia:
~Systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg and
~Proteinuria > 0.3 grams in a 24-hour urine or protein:creatinine ratio >0.3 or
~Signs of end-organ dysfunction (platelet count < 100'000G/l, serum creatinine >110 mg/l, or doubling of the serum creatinine, elevated serum transaminases to twice normal concentration)"
16470568|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
16470569|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
16470571|NCT03494478|Experimental|Cohort group|All participants will have evaluations at inclusion and 12 months. Neuropsychological testing Actimetry Selfquestionnaires on emotional topics
16470572|NCT03494465|Active Comparator|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.
~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
16470573|NCT03494465|Experimental|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.
~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
16470574|NCT03494452||Low back pain - no intervention|Patients who perform sitting occupational activities for at least 4 hours/day and have had low back pain for at least the previous 6 months
16470575|NCT03494452||Healthy - no intervention|Healthy persons who perform sitting occupational activities for at least 4 hours/day
16470576|NCT03494426|Experimental|interventional group|patients will receive Radiofrequency thoracic sympathectomy then will receive pregabalin ,tramadol,and tricyclic antidepressants
16470577|NCT03494426|Active Comparator|control group|patients will receive pregabalin ,tramadol,and tricyclic antidepressants
16470578|NCT03494413|Experimental|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
16470579|NCT03494413|Experimental|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
16470580|NCT03494400|Experimental|Presential Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform presential aerobic training.
16470581|NCT03494400|Active Comparator|Presential Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform presential aerobic training.
16470582|NCT03494400|Experimental|Home-based Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform home-based aerobic training.
16470583|NCT03494400|Active Comparator|Home-based Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform aerobic training home-based.
16470584|NCT03494387|Experimental|1|
16470585|NCT03494387|Experimental|2|
16470586|NCT03494374|Experimental|treatment group|Treatment with UCBL and exercise therapy
16470587|NCT03494361||Young normal group|normal participants below 60 years
16470588|NCT03494361||Old normal group|normal participants above 60 years
16470589|NCT03494348|No Intervention|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
16470590|NCT03494348|Active Comparator|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
16470592|NCT03494322|Experimental|Avelumab + cetuximab|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.
~Avelumab + cetuximab combination therapy:
~Cycle 1
~Day 1: Cetuximab 500* mg/m2 given IV over approx 3 hrs
~Day 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr
~All other cycles:
~- Days 1 and 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr
~*Cetuximab dose will be dependent on outcome of safety run-in.
~There must be a 60 minute break between the administration of cetuximab and avelumab."
16470593|NCT03494322|Other|Avelumab monotherapy|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.
~Avelumab monotherapy will be given as follows:
~All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour"
16470594|NCT03494309|Experimental|ORIF|Open Reduction & Internal Fixation
16470595|NCT03494309|Active Comparator|CREF|Closed Reduction & External Fixation
16470596|NCT03494296||Open, multi-center, prospective|All enrolled and relapsed patients received D-COP regimen chemotherapy
16470597|NCT03494283||CrossFit injuries|
16470598|NCT03494270|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
16470599|NCT03494270|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
16470600|NCT03494257|Active Comparator|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
16470601|NCT03494257|No Intervention|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
16470602|NCT03494244||ADM|Patients having undergone direct-to-implant breast reconstruction using acellular dermal matrix.
16470603|NCT03494244||Non-ADM (Vicryl)|Patients having undergone direct-to-implant breast reconstruction using non-acellular dermal matrix mesh (Vicryl mesh).
16470604|NCT03494231|Experimental|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
16470605|NCT03494218|Experimental|vegetative state|patients with vegetative state lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
16470606|NCT03494218|Experimental|minimally conscious state|Patients with minimally conscious state display inconsistent, but reproducible and discernible signs of awareness using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
16470640|NCT03493971|Active Comparator|Carotid artery stenting (CAS)|Carotid revascularization performed using CAS
16470607|NCT03494205|Experimental|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.
~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.
~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
16470608|NCT03494205|Active Comparator|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
16470609|NCT03494192|Experimental|scapula based|"Cold pack
~Stretching Exercises
~Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week"
16470610|NCT03494192|Experimental|scapula&rotator cuff based|"Cold pack
~Stretching Exercises
~Exercise training focus on scapulothoracic muscles
~Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week"
16470611|NCT03494179|Experimental|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
16470612|NCT03494179|Experimental|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
16470613|NCT03494166|No Intervention|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, they will receive baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone will assess symptoms. Approximately 35% of all participants will be in this group.
16470614|NCT03494166|Experimental|High Need A-SMH or TIP-C|Participants will be mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant will be called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. Calls will last approximately 10 minutes. After 4 weeks, participants will be re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIP-C) Intervention for the subsequent 8 weeks. If the TIP-C is added, the counselor will call the participant once per week for about 35-40 minutes to assess and discuss strategies for managing symptoms, provide survivorship education, and discuss interpersonal relationships, communication, and social support. At week 13, the participant will complete the second assessment.
16470615|NCT03494166|Experimental|High Need B-TIP-C+SMH|Participant will be called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor will assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls will focus be the SMH protocol. At week 13, the second assessment will be conducted.
16470616|NCT03494127|Experimental|Group A|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
16470617|NCT03494127|Experimental|Group B|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
16470618|NCT03494114|Experimental|COPD Patients|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ. In addition, PET imaging data will be compared with disease severity, based on pulmonary function testing.
16470619|NCT03494114|Experimental|Individuals without COPD|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ.
16470620|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
16470621|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
16470622|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
16470623|NCT03494088||Children with Autism with gastrointestinal (GI) symtpoms|
16470624|NCT03494088||Children with Autism without gastrointestinal (GI) symtpoms|
16470625|NCT03494088||Healthy Children|
16470626|NCT03494062|Experimental|Exercise|Home-based exercise intervention
16470627|NCT03494062|No Intervention|Control|Usual care
16470628|NCT03494049|Active Comparator|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.
~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
16470629|NCT03494049|Active Comparator|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
16470630|NCT03494036|Experimental|Synbiotic|Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days
16470631|NCT03494036|Placebo Comparator|Placebo|Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days
16470632|NCT03494010||prospective cohort|Patients will be followed to determine the impact of the hybrid closed-loop (HCL) system that was prescribed at part of clinical care.
16470633|NCT03494010||historical controls|Medical record data of these patients, who did not use the HCL system, will be compared with patients in the HCL cohort.
16470634|NCT03493997|Experimental|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
16470641|NCT03493971|Active Comparator|Carotid endarterectomy (CEA)|Carotid revascularization performed using CEA
16470651|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
16470656|NCT03493906|Experimental|Intervention|Patient Ambassador Support
16470657|NCT03493893||Affixus|To compare Affixus to PFNA and TFNA
16470658|NCT03493893||PFNA|To compare PFNA to Affixus and TFNA
16470659|NCT03493893||TFNA|To compare TFNA toPFNA and Affixus
16470660|NCT03493880||naCT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
16470661|NCT03493880||naCRT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
16470662|NCT03493867|Other|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
16470663|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
16470664|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
16470665|NCT03493841|Experimental|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
16470666|NCT03493841|Experimental|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
16470667|NCT03493828|Active Comparator|TAP using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
16470668|NCT03493828|Active Comparator|TAP using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
16470669|NCT03493828|Placebo Comparator|Placebo|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
16470670|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
16470671|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
16470672|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
16470673|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
16470674|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
16470675|NCT03493776|Active Comparator|Pre-Transplant Group|VZV Subunit vaccine will be administered
16470676|NCT03493776|Experimental|Post-Transplant Group|VZV Subunit vaccine will be administered
16470677|NCT03493763||serum AFP negative HCC patients|"Patients who received liver resection within 3 months;
~Hepatocellular carcinoma confirmed pathologically;
~Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
16470678|NCT03493750|No Intervention|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.
~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.
~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.
~If care are indicated, they will be organized but outside this trial."
16470679|NCT03493750|Experimental|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.
~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.
~If care are indicated, they will be organised but outside this trial."
16470680|NCT03493737||HaH (Hospital-at-Home)|Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
16470681|NCT03493737||OH (Outpatient Hospital)|Bortezomib is always injected at Outpatient hospital
16470682|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
16470683|NCT03493711||Milk-based fomula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
16470684|NCT03493698|Experimental|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
16470685|NCT03493698|Experimental|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
16470686|NCT03493698|Experimental|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
16470687|NCT03493685|Experimental|sparsentan for double-blind and open-label extension|Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
16470688|NCT03493685|Active Comparator|Irbesartan|Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
16470689|NCT03493659|No Intervention|Sit-Sit|The participants will sit during the tutorials, and sit during the concept tests given to measure their learning.
16470690|NCT03493659|Active Comparator|Sit-Stand|The participants will sit during the tutorials. Intervention: Behavioral: Standing during Concept Test will be administered
16470691|NCT03493659|Active Comparator|Stand-Stand|The participants will stand during the tutorials, and stand during the concept tests given to measure their learning. Intervention: Behavioral: Standing during Concept Test and regular tutorial session will be administered.
16470692|NCT03493659|Active Comparator|Stand-Sit|"The participants will stand during the tutorials. Intervention: Behavioral: Standing during regular tutorial session will be administered.
~However, participants will sit during the concept tests given to measure their learning."
16470693|NCT03493646|Active Comparator|Azacitidine|6 cycles of azacitidine (28 day cycle)
16470694|NCT03493646|Experimental|CC 486|6 cycles CC 486 (28 day cycle)
16470695|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
16470696|NCT03493620|Experimental|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
16470697|NCT03493620|Sham Comparator|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
16470698|NCT03493607|Experimental|AMO-01|Intravenous Infusion
16470699|NCT03493594|No Intervention|Control|"Control group will receive standard health care.
~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
16470700|NCT03493594|Experimental|Nutrition education program|"The intervention group will receive an early nutrition program for 12 months. Workshops format will be mainly in form of talks and experience sharing groups which run by lactation consultants, nutritionists / dietitians. All classes and workshops will be run for 4-6 times to cater for subjects recruited in different phases.
~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
16470701|NCT03493581|Experimental|NSCLC patients|
16470702|NCT03493568|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Table|switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
16470703|NCT03493568|Active Comparator|Dolutegravir 50 mg plus one RTI (at label dose)|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
16470704|NCT03493555|Experimental|Intervention Development|Peer Health Navigator for PrEP
16470705|NCT03493542|Experimental|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
16470706|NCT03493542|Active Comparator|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
16470707|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
16470708|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
16470709|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
16470710|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
16470711|NCT03493503|Experimental|Salbutamol loading dose|Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.
16470712|NCT03493503|Placebo Comparator|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes.
16470713|NCT03493490|Experimental|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
16470714|NCT03493490|Active Comparator|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
16470715|NCT03493490|Placebo Comparator|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
16470716|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
16470717|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
16470718|NCT03493464|Experimental|Treatment|Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
16470719|NCT03493451|Experimental|NK/T cell lymphoma and with other mature T-cell neoplasms|"In this cohort, participants will be treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle.BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
~Cohort 1: Participants with relapsed or refractory extranodal NK/T cell lymphoma (nasal or non-nasal type)
~Cohort 2: other mature T-cell neoplasms (limited to the following histologies: peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, or anaplastic large-cell lymphoma)
~Cohort 3: cutaneous T-cell lymphoma (limited to mycosis fungoides and Sèzary syndrome)"
16470720|NCT03493438|Experimental|Relaxation Group|Patients performed Jacobson relaxation technique in supine position. Respiration control and various visual imaging techniques were used during the technique. Relaxation exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
16470721|NCT03493438|Experimental|Proprioceptive Neuromuscular Facilitation Group|Patients exercised with proprioceptive neuromuscular facilitation technique for trunk muscles using chopping and lifting patterns with ritmic initiation PNF exercises were made by the physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
16470722|NCT03493438|Experimental|Core stabilization group|Patients had core stabilization exercises that involved spinal mobility. The patients performed the drawing-in maneuver within various visual imaging techniques during all exercises, especially with respiratory control. Exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
16470723|NCT03493438|Other|control group|Patients in the control group were told the importance of a single session exercise
16470724|NCT03493425|Active Comparator|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
16470725|NCT03493425|Experimental|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
16470726|NCT03493412|Experimental|BH4-Placebo|Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
16470727|NCT03493412|Experimental|Placebo-BH4|Subjects will be tested on two different days, first day will be baseline and placebo and second day will be Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin). Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
16470728|NCT03493399|Experimental|Problem Gamblers|Interference
16470729|NCT03493386|Experimental|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
16470796|NCT03492866|Active Comparator|Gentamicin Sulfate|All subjects will be treated with topical gentamycin applied twice daily (1 fingertip unit (FTU)) to the right half of the scalp. Total study period: 6 months.
16470730|NCT03493386|Experimental|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
16470731|NCT03493386|Experimental|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
16470732|NCT03493386|Experimental|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
16470733|NCT03493373|Experimental|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
16470734|NCT03493373|Experimental|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
16470735|NCT03493360|Experimental|Visual feedback|Participants will be asked to perform movements of the low back while looking at a mirror for visual feedback.
16470736|NCT03493360|Active Comparator|No visual feedback|Participants will be asked to perform movements of the low back while the mirrors are covered and no visual feedback is provided.
16470737|NCT03493347|Experimental|Equine-assisted Occupational Therapy|All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
16470738|NCT03493334|Experimental|Visual feedback|Participants in this group will receive visual feedback of their neck when performing 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation).
16470739|NCT03493334|Active Comparator|No visual feedback|Participants in this group will perform 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation) without feedback.
16470740|NCT03493321|Experimental|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
16470741|NCT03493308|Experimental|Pain neuroscience and exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines, covering the neurophysiology of pain, transition from from acute to chronic pain and the nervous system ability to modulate the pain experience. exercise will include general exercise and dance.
16470742|NCT03493295||Levonogestrel IntraUterine System (LNG-IUS)|Women in childbearing age between 18 to 30 years old and who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at the routine clinical practice setting in Spain
16470743|NCT03493282|Active Comparator|Active Treatment- CT1812 100 mg|7 subjects randomized to 100 mg CT1812
16470744|NCT03493282|Active Comparator|Active Treatment- CT1812 300 mg|7 subjects randomized to 300 mg CT1812
16470745|NCT03493282|Placebo Comparator|Placebo|7 subjects randomized to matching placebo
16470746|NCT03493269|Experimental|BAY1834845|"Part 1 in healthy male subjects:
~Dose Groups 1-4 : orally administered multiple ascending doses. The treatment will last 10 consecutive days (treatment period1) and 1 day (treatment period 2) Dose Group 5: The treatment will last 1 day (treatment period 1) and 10 consecutive days (treatment period 2)"
16470747|NCT03493269|Placebo Comparator|Matching Placebo|Part 1: Matching placebo in healthy male subjects.
16470748|NCT03493269|Experimental|Chosen dose of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with psoriasis
16470749|NCT03493269|Placebo Comparator|Placebo|Part 2: The placebo will be adminstered in female and male patients with psoriasis
16470750|NCT03493256||type 2 neurological complications present|The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
16470751|NCT03493256||type 2 neurological complications absent|The group of patients without neurological complications.
16470752|NCT03493243||Adolescents exposed|Only clinical questionnaires
16470753|NCT03493230|Experimental|Patient with malignant melanoma|Patient with advanced or metastatic malignant melanoma (stage IIIB inoperable or IIIC or stage IV) will have a first blood test before any treatment, then at day 15 or 30 after initiation of therapy, and every two months until recurrence or progression for a maximum of 22 months.
16470754|NCT03493217|Experimental|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
16470755|NCT03493204|Experimental|Home-delivered, salt restricted|Meal description: salt-restricted (1500 mg to 2000 mg daily), > 2100 kilocalorie, high protein (>80 g daily) in addition to receiving standard pamphlet receipt
16470756|NCT03493204|Active Comparator|Dietary Advice|Standard of care, advice on salt-restriction using standard pamphlet receipt
16470757|NCT03493191|Experimental|0.5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)
16470758|NCT03493191|Experimental|1 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)
16470759|NCT03493191|Experimental|2 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)
16470760|NCT03493191|Experimental|5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)
16470761|NCT03493191|Experimental|10 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
16470762|NCT03493191|Experimental|20 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
16470763|NCT03493178|Active Comparator|MCI-active|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
16470797|NCT03492866|No Intervention|No treatment|The medication won't be applied to the left half of the scalp.
16470764|NCT03493178|Placebo Comparator|MCI-placebo|30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks
16470765|NCT03493139|Experimental|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
16470766|NCT03493139|Experimental|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
16470767|NCT03493126|Experimental|Estradiol|Estrace: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
16470768|NCT03493126|Placebo Comparator|Placebo|Placebo: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
16470769|NCT03493100|Experimental|oral nutritional supplementation|This group receives optimized nutritional support, by ONS for a period of four weeks.
16470770|NCT03493100|Other|Control|The control group will receive treatment according to usual care.
16470771|NCT03493087|Active Comparator|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
16470772|NCT03493087|Active Comparator|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
16470773|NCT03493061|Experimental|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:
~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
16470774|NCT03493048|Experimental|Cetuximab Plus FOLFOXIRI|Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
16470775|NCT03493048|Active Comparator|Cetuximab Plus FOLFOX|Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
16470776|NCT03493035||MCA aneurysm group|All patients with unruptured MCA aneurysm diagnosed on three-dimensional computed tomography angiography (3D CTA) and transcranial color-coded sonography (TCCS) .
16470777|NCT03493035||non-MCA aneurysm group|All patients with no evidence of intracranial pathologies on 3D CTA and diagnosed on transcranial color-coded sonography (TCCS).
16470778|NCT03493022|Experimental|Test Granola|50.5 g Test Granola
16470779|NCT03493022|Placebo Comparator|Control Granola|54.3 Control Granola
16470780|NCT03493009|Experimental|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
16470781|NCT03493009|Experimental|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
16470782|NCT03492996|Experimental|LCB01-0371 dose with a [14C]-LCB01-0371-tracer|A mass balance study to investigate the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose in healthy male subjects
16470783|NCT03492983|No Intervention|Control group|No intervention
16470784|NCT03492983|Experimental|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
16470785|NCT03492970|Other|10 adult patients with SMS|Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
16470786|NCT03492957|Experimental|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change. There is no control group ion this feasibility study.
16470787|NCT03492944||Ultrasound Microbubble Contrast Agent|All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results
16470788|NCT03492931|Experimental|Treatment arm|Single dose of ticagrelor based on age
16470789|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
16470790|NCT03492905|Experimental|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
16470791|NCT03492892|Experimental|Acupuncture|Use real acupuncture treatment for blood pressure management in patients with hypertension
16470792|NCT03492892|Sham Comparator|Sham Acupuncture|Use non-acupoint as the stimulating site in acupuncture for the treatment of hypertension
16470793|NCT03492879|Experimental|Biopsy: Routine tests & EIT Technology|The patients will undergo a routine liver biopsy and also routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
16470794|NCT03492879|Experimental|Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
16470795|NCT03492879|Experimental|NASH : Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and quantification of liver steatosis using the Electrical Impedance Technology (EIT).
16474159|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
16470798|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
16470799|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
16470800|NCT03492840|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into the subcutaneous fat.
~Dercum's disease - dosing according to nodule size:
~Nodule of 2-2.9cm - 2 injections (0.1 mL each); total of 10 mg RZL-012.
~Nodules of 3-3.9cm - 3 injections (0.1 mL each); total of 15 mg RZL-012.
~Nodules of 4-8cm - 4 injections (0.1 mL each); total of 20 mg RZL-012.
~Lipedema -
~2 subjects will receive 20mg RZL-012 in 4 injections in each leg adding up to 8 injections of 40mg RZL-012.
~2 subjects will receive 30mg RZL-012 in 6 injections in each leg adding up to 12 injections of 60mg RZL-012.
~2 subjects will receive 40mg RZL-012 in 8 injections in each leg adding up to 16 injections of 80mg RZL-012."
16470801|NCT03492827|Experimental|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
16470802|NCT03492827|No Intervention|Control group|Control group will not be interventioned with gargle
16470803|NCT03492814|Experimental|Partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
16470804|NCT03492814|Active Comparator|Total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
16470805|NCT03492801||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
16470806|NCT03492788|Active Comparator|ECGI-optimized VV-offset|
16470807|NCT03492788|Placebo Comparator|Zero VV-offset|
16470808|NCT03492775|Active Comparator|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1
~If at least 'stable disease':
~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
16470809|NCT03492775|Active Comparator|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles
~If at least 'stable disease':
~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
16470810|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
16470811|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
16470812|NCT03492736|Experimental|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
16470813|NCT03492736|Placebo Comparator|Placebo|30 days placebo taken nightly 1 hour before bed
16470814|NCT03492723|Experimental|garlic groupe|Concentrated Aged Garlic Extract Microcrystalline Cellulose 133 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
16470815|NCT03492723|Placebo Comparator|placebo groupe|Microcrystalline Cellulose 258.55 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Coloring Agent 0.45 mg Details: Gardenia Extractive 44.5%, Corn Syrup 55% Potassium pyrophosphate 0.5% Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
16470816|NCT03492710|Experimental|IGIV-SN|Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
16470817|NCT03492697|Experimental|PF-06882961|
16470818|NCT03492671|Experimental|Chemotherapy and SBRT|"Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.
~Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.
~Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy."
16470819|NCT03492658|Experimental|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
16470820|NCT03492658|Active Comparator|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
16470821|NCT03492645|Active Comparator|Office Group|
16470822|NCT03492645|Experimental|Telephone Group|
16470823|NCT03492632||Women with Psoriasis|Reproductive age women newly diagnosed with psoriasis
16470824|NCT03492632||Women without Psoriasis|Reproductive age women without psoriasis to serve as control
16470825|NCT03492619|Active Comparator|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
16470826|NCT03492619|Experimental|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
16470827|NCT03492606||multiple sclerosis patients|
16470828|NCT03492593|Experimental|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
16470856|NCT03492463|Active Comparator|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
16470959|NCT03491787||Not ultrasound guidance|The ultrasound guidance was not used to obtain intraosseous access
16470829|NCT03492593|Experimental|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
16470830|NCT03492593|Placebo Comparator|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
16470831|NCT03492580||Cohort 1: Canagliflozin|A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
16470832|NCT03492580||Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)|A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470833|NCT03492580||Cohort 3: Empagliflozin|A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470834|NCT03492580||Cohort 4: Empagliflozin with CVD|A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470835|NCT03492580||Cohort 5: Dapagliflozin|A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470836|NCT03492580||Cohort 6: Dapagliflozin with CVD|A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470837|NCT03492580||Cohort 7: Empagliflozin or Dapagliflozin|A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470838|NCT03492580||Cohort 8: Empagliflozin or Dapagliflozin with CVD|A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470839|NCT03492580||Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA|A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470840|NCT03492580||Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470841|NCT03492580||Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470842|NCT03492580||Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
16470843|NCT03492567|Experimental|Blood monocyte precursors/osteoclasts|Blood test
16470844|NCT03492554|Other|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
16470845|NCT03492554|Other|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
16470846|NCT03492541|Experimental|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
16470847|NCT03492528|Experimental|Cardiovascular patients treated for a cancer|
16470848|NCT03492515|Experimental|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
16470849|NCT03492515|Active Comparator|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
16470850|NCT03492515|No Intervention|healthy control group|Healthy pregnant women and no use of any medicine。
16470851|NCT03492502|Experimental|Allo-SCT patients with GI related GVHD|"Allo-SCT patients above 18 years of age with acute steroid-resistant GI-related GVHD grade III-IV.
~The diagnosis of GVHD will be made on clinical grounds (in line with the major associations' recommendations) - the appearance of characteristic mucoid diarrhea within 100 days after Allo-SCT, with or without associated skin/liver involvement. In cases of atypical presentation - we will recommend biopsy or endoscopy for diagnosis. Patients suspected to have Clostridium difficille associated diarrhea will be tested for toxin (CDT).
~Steroid-resistant GI-related GVHD will be defined as lack of improvement (same stage) or worsening of GI symptoms after 7 days of steroid therapy (≥ 2 ml/kg of IV methylprednisolone)."
16470852|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
16470853|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
16470854|NCT03492463|Active Comparator|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
16470855|NCT03492463|Active Comparator|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
16470857|NCT03492463|Placebo Comparator|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
16470858|NCT03492450|No Intervention|Control Group|All subjects continue participating in their normal daily and physical activities.
16470859|NCT03492450|Experimental|Treadmill training Group|16 sessions (2 sessions/week for 8 weeks) of treadmill training as recommended in a review on this subject (Langeskov-Christensen, 2015) aimed at the reduction/stabilization of gait and balance disturbances.
16470860|NCT03492437|Experimental|Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib|Dabigatran etexilate in treatment period 1 followed by tepotinib alone for 7 days and then tepotinib co-administered with Dabigatran in treatment period 2. Two treatment periods will be separated by a 3-day wash-out period.
16470861|NCT03492424||Focal therapy for prostate cancer|"All men >18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.
~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
16470862|NCT03492411|Experimental|eHealth Intervention|This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
16470863|NCT03492411|No Intervention|Usual Care|This group will not receive any intervention. They will receive emails for 6 weeks reminding them that they are in the study.
16470864|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
16470865|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
16470866|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
16470867|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
16470868|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
16470869|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
16470870|NCT03492398|Experimental|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
16470871|NCT03492385|Experimental|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
16470872|NCT03492385|Experimental|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
16470873|NCT03492385|Experimental|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
16470874|NCT03492385|Experimental|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
16470875|NCT03492385|Experimental|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
16470876|NCT03492385|Experimental|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
16470877|NCT03492385|Experimental|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
16470878|NCT03492385|Experimental|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
16470879|NCT03492385|Experimental|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
16470880|NCT03492385|Experimental|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
16470881|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
16470882|NCT03492359|Active Comparator|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
16470883|NCT03492359|Active Comparator|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
16470884|NCT03492346||LGMD2E Subject Population|"Individuals:
~Confirmed LGMD2E diagnosis by genetic testing or
~Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types"
16470885|NCT03492333|Experimental|Gluten free diet|Single arm
16470886|NCT03492307|Active Comparator|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
16470887|NCT03492307|Experimental|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
16470888|NCT03492294||patients with disorders of consciousness|patients with disorders of consciousness from several brain injury have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state. These patients were scaned by functional magnetic resonance imaging.
16470889|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
16470890|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
16470891|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
16470892|NCT03492268|Experimental|BCMA-CART|Autologous T cells transduced to express anti-BCMA chimeric antigen receptor (CAR)
16470917|NCT03492112|Experimental|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
16470893|NCT03492255|Active Comparator|Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC|The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
16470894|NCT03492255|Experimental|Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC|CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
16470895|NCT03492242||Adverse drug reaction induced by immune checkpoint inhibitors|Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity
16470896|NCT03492229|Experimental|tDCS+AMT|TDCS in combination with movement training before treadmill training
16470897|NCT03492229|Active Comparator|tDCS|tDCS only before treadmill training
16470898|NCT03492229|Active Comparator|AMT|Movement training only before treadmill training
16470899|NCT03492229|Sham Comparator|Control|No priming before treadmill training
16470900|NCT03492216|No Intervention|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
16470901|NCT03492216|Experimental|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
16470902|NCT03492216|Experimental|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
16470903|NCT03492216|Experimental|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
16470904|NCT03492203|Experimental|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
16470905|NCT03492203|Active Comparator|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
16470906|NCT03492203|Placebo Comparator|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
16470907|NCT03492190||adults|"Select the individual:
~Healthy, non-pregnant adults 18-65 years of age, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range and stable weight.
~Exclusion criteria: children and elderly (over 65), pregnancy, diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, adults will be eat the bean enrichment of deuterium for availability protein, collected urine, saliva and blood."
16470908|NCT03492190||Children|"Fifty children will be recruited from ages varying from 1 to 3 years and of both sexes. Children who use medications, who do not habitually consume beans, will be excluded and when there is no explicit written authorization from the parents or guardians.
~All the children with different status of nutrition will be eaten the beans. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, children will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult)."
16470909|NCT03492190||Elderly|Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
16470912|NCT03492138|Experimental|Participants with relapsed/refractory multiple myeloma|ONC201, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Run-in phase of ONC201 and dexamethasone weekly until progression at 4 weeks, lack of response at 8 weeks, or progression followed by the addition of weekly ixazomib.
16470913|NCT03492125|Experimental|low dose|MS-533
16470914|NCT03492125|Experimental|mid low dose|MS-533
16470915|NCT03492125|Experimental|mid high dose|MS-533
16470916|NCT03492125|Experimental|high dose|MS-533
16470918|NCT03492099|Experimental|Buprenorphine Arm|This is the main and only arm of the study. All patients in this arm will undergo the steps outlined in the protocol to convert to buprenorphine treatment.
16470919|NCT03492086|Experimental|Rosemary and alkylglycerol capsules|
16470920|NCT03492086|Placebo Comparator|Control capsules|
16470921|NCT03492073|Experimental|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.
~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
16470922|NCT03492073|Active Comparator|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.
~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
16470924|NCT03492047|Active Comparator|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
16470925|NCT03492047|Experimental|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
16470926|NCT03492047|Experimental|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
16470927|NCT03492034|Active Comparator|IUD during CS|
16470928|NCT03492034|Active Comparator|IUD after puerperium|
16470929|NCT03492021|Experimental|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy [AP-CPT]
16470930|NCT03492021|Experimental|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy [OP-PPT]
16470931|NCT03492008|Active Comparator|Conventional technique|Nasogastric tube
16470932|NCT03492008|Experimental|Contralateral cricothyroid pressure|Nasogastric tube
16470933|NCT03492008|Experimental|Ipsilateral head turning|Nasogastric tube
16470934|NCT03491995|Experimental|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
16470935|NCT03491995|Active Comparator|Classic treatment|Omeprazole, clarithromycin, amoxicillin
16470936|NCT03491969|Experimental|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
16470937|NCT03491969|Placebo Comparator|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
16470938|NCT03491956|Other|DFPP group|self contrast (before and after DFPP)
16470939|NCT03491943|Experimental|Midline group|Preprocedural ultrasound-assisted midline approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
16470940|NCT03491943|Active Comparator|Paramedian group|Preprocedural ultrasound-assisted paramedian approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
16470941|NCT03491930|Experimental|Interventional Cohort|"VA MOVE! Coach app: Weight loss using the VA MOVE! Coach weight loss app which presents positive feedback, education in nutrition and portion sizes, coping mechanisms, charts and graphs. App will be used for three months.
~Telephone Coaching: Weekly phone coaching will provide further support and assist with problem solving and goal setting for a three month period.
~Standard of care for weight loss (the 2013 AHA/ACC/TOS guidelines). Followed for three months.
~Pre and post weight loss metabolic measurements will be obtained."
16470942|NCT03491930|Active Comparator|Control Cohort|"Standard of care for weight loss (2013 AHA/ACC/TOS guidelines). Followed for three months.
~Pre and post weight loss metabolic measurements will be obtained."
16470943|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
16470944|NCT03491917||FFDM alone|Breast images using FFDM alone only
16470945|NCT03491904|Experimental|Auto-injector (AI)|
16470946|NCT03491904|Experimental|Prefilled syringe (PFS)|
16470947|NCT03491891||derivation cohort|no interventions will be administrated
16470948|NCT03491891||validation cohort|no interventions will be administrated
16470949|NCT03491878|Experimental|3D approach|Three dimensional laparoscopic cholecystectomy including segments IVB and V
16470950|NCT03491878|Active Comparator|open approach|Open cholecystectomy including segments IVB and V
16470951|NCT03491865|Experimental|REAL media Plus|Participants in this group will be assigned to use the REAL media Plus curriculum.
16470952|NCT03491865|No Intervention|programming as usual|Participants in this group will participate in their usual school curriculum. They will have the opportunity to use the REAL media Plus curriculum at the conclusion of the study.
16470953|NCT03491852|Experimental|BOOST Intervention|"The BOOST intervention consists of 8 group-based, weekly one-hour sessions. While every BOOST session is different, in general they will focus on helping participants fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment. BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support worker to provide unique insights on living with and overcoming self-stigma. Content of sessions involve group discussions, exercises conducted in session, and between-session missions (i.e., home practice activities)."
16470954|NCT03491852|Active Comparator|Waitlist Controls|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis. Frequency of contact largely depends on the individual needs of patients. Waitlist controls will be offered the BOOST intervention 3 months post-enrollment.
16470955|NCT03491826||ROM before 34 weeks (A)|premature rupture of membrane before 34 weeks
16470956|NCT03491826||ROM after 34 weeks (B)|premature rupture of membrane after 34 weeks
16470957|NCT03491800|Other|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
16470958|NCT03491787||Ultrasound guidance|The ultrasound guidance was used to establish intraosseous access
16470960|NCT03491774|Experimental|Montessori Intervention|Participants will receive Montessori intervention for three months,twice weekly sessions over the period of three months.
16470961|NCT03491761|Experimental|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
16470962|NCT03491761|Active Comparator|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Euflexxa will be prepared according to the package insert.
16470963|NCT03491748|Experimental|Part A (SAD): Cohort 1, 100 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 milligrams (mg) ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
16470964|NCT03491748|Experimental|Part A (SAD): Cohort 2, 200 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
16470965|NCT03491748|Experimental|Part A (SAD): Cohort 3, 400 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
16470966|NCT03491748|Experimental|Part A (SAD): Cohort 4, 800 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 800 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
16470967|NCT03491748|Experimental|Part A (SAD): Cohort 5, 600 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
16470968|NCT03491748|Experimental|Part A (SAD): Cohort 6 (Elderly), 300 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Elderly participants (aged 65 years or older) will be treated with a single oral dose of 300 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
16470969|NCT03491748|Experimental|Part B (Food Effect): Cohort 7, 100 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 100 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
16470970|NCT03491748|Experimental|Part C (MAD): Cohort 9, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed three times a day (TID) beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
16470971|NCT03491748|Experimental|Part C (MAD): Cohort 10, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed TID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
16470972|NCT03491748|Experimental|Part D: Cohort 12, ETX0282/Placebo plus Cefpodoxime Proxetil|Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fed state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fed state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fed state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fed state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
16470973|NCT03491748|Experimental|Part B (Food Effect): Cohort 14, 300 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 300 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 300 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
16470974|NCT03491748|Experimental|Part G: Cohort 17, 300 mg ETX0282/Placebo|Part G of the study will explore the tolerability and PK profile of oral ETX0282 when administered either as a single dose (i.e., 300 mg as a single dose) or in 4 equal, divided doses over a 6 hour period (i.e., 75 mg every 2 hours for 4 doses [a 300 mg total dose]) when administered in a fasted state. Participants will receive the 2 treatments in a cross-over design according to one of 2 randomized sequences: AB or BA. Treatment A: 0 hours, 4 × 75 mg ETX0282/placebo; 2, 4, and 6 hours, 1 × 75 mg placebo. Treatment B: 0 hours, 1 × 75 mg ETX0282/placebo and 3 × 75 mg placebo; 2, 4, and 6 hours, 1 × 75 mg ETX0282/placebo. Participants will be confined to the Study Unit from Day -1 and discharged following collection of the 24 hours post Day 4 dose assessments (Day 5).
16471071|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
16470975|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
16470976|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
16470977|NCT03491709|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
16470978|NCT03491709|Active Comparator|Cetuximab injection|Cetuximab,Erbitux 250mg/m2 single administration
16470979|NCT03491696|Experimental|Patients|It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
16470980|NCT03491683|Experimental|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
16470981|NCT03491683|Experimental|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
16470982|NCT03491657|Experimental|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
16470983|NCT03491657|Active Comparator|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
16470984|NCT03491644|Active Comparator|Liberal oxygen|"Liberal oxygen administration (to mimic current practice) for the first 24 hours without interruption.
~In the trauma bay and during intrahospital transportation this implies administration of a FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the operating room, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."
16470985|NCT03491644|Experimental|Titrated oxygen|"Titrated oxygen administration for the first 24 hours without interruption. Lowest dosage of oxygen possible in order to achieve a saturation of at least 94%, either using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing.
~A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.
~The intervention will only be interrupted in case the saturation becomes unmeasurable - if this happens, the treating physician shall treat the patient as he/she judges best fit. As soon as the saturation is measurable again, the intervention will resume. The treating physician must document and explain the situation."
16470986|NCT03491631|Experimental|2 drugs combination group|
16470987|NCT03491631|Experimental|3 drugs combination group|
16470988|NCT03491618|Active Comparator|PARALLEL|Thick canulae (18 gauge) placed parallel to Medial Branch under fluoroscopy.
16470989|NCT03491618|Active Comparator|PERPENDICULAR|Thin canulae (22 gauge) placed perpendicular to Medial Branch under fluoroscopy.
16470990|NCT03491605||peripheral EBV-DNA load|subjects with high load (>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
16470991|NCT03491592|Experimental|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
16470992|NCT03491592|Active Comparator|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
16470993|NCT03491579|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
16470994|NCT03491566|Experimental|Clinic Pilates Group|Initial assessments of participants were made and they were taught key components of the Clinical Pilates exercises. Exercises were administered for 4 weeks, 3 days/week, 40-50 minutes/session under the supervision of a physiotherapist. Groups of 9-10 people with similar physical characteristics and fitness level for session times were created. The sessions were started with level 1 exercises requiring more support and less control. Each exercise was repeated 8-10 times; as the physical level of the participants increased, exercises progressed towards level 3 exercises requiring more attention, concentration and control. Each session consisted of an average of 10 minutes warm-up, 20 to 30 minutes of matt and 10 minutes cooling of of Clinical Pilates exercises.
16470995|NCT03491566|Experimental|Aerobic Exercise Group|"Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 4 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the 220-years. For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min."
16470996|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-positive CHB Participants|Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
16474160|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
16470997|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16470998|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16470999|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16471000|NCT03491553|Experimental|Placebo: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16471001|NCT03491553|Experimental|Placebo: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
16471002|NCT03491540|Experimental|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
16471003|NCT03491540|Placebo Comparator|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
16471004|NCT03491527|Active Comparator|Conventional Resin Cement|Resin cement without MTA
16471005|NCT03491527|Active Comparator|MTA Resin Cement|Resin cement with MTA
16471006|NCT03491514|Experimental|Test Granola|51 g of Test Granola
16471007|NCT03491514|Placebo Comparator|Control Granola|54.1 Control Granola
16471008|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
16471009|NCT03491488|Experimental|Intervention Group|"300 children in the randomly selected crèche classrooms receiving the Brain Games intervention.
~The Brain Games intervention we propose in this project is designed to complement and improve current government efforts. Given the importance of executive functioning skills and the high plasticity around age three, early programs like the ones proposed here may be the most effective tool to reduce socioeconomic and intergenerational disparities, and thus nicely complement current social protection policies."
16471010|NCT03491488|No Intervention|Control Group|300 children in the randomly selected creches classrooms receiving the regular Brazilian curriculum.
16471011|NCT03491475||Negative Ajmaline test|No appearance of a type 1 ECG during Ajmaline test
16471012|NCT03491475||Positive Ajmaline test|Appearance of a type 1 ECG during Ajmaline test
16471013|NCT03491462|Experimental|Arimoclomol|Arimoclomol, capsule
16471014|NCT03491462|Placebo Comparator|Placebo|Placebo oral capsule (matching to experimental Arm)
16471015|NCT03491449|Experimental|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
16471016|NCT03491449|Active Comparator|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure <185 mm Hg for 72 hours.
16471017|NCT03491436|Experimental|Remote monitoring group|Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
16471018|NCT03491423|Experimental|Patients|
16471019|NCT03491410|Placebo Comparator|1|Arm 1: standard Unit´s protocol + placebo
16471020|NCT03491410|Experimental|B|Arm 2: standard Unit´s protocol + aspirin
16471021|NCT03491397|Experimental|GAE OA|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
16471022|NCT03491371|Experimental|osteosarcoma|all patients had been given apatinib alone
16471023|NCT03491371|Experimental|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
16471024|NCT03491371|Experimental|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
16471025|NCT03491371|Experimental|Chondrosarcoma|Patients were given apatinib alone
16471026|NCT03491358|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
16471027|NCT03491358|Experimental|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
16471028|NCT03491345|Experimental|avelumab|
16471029|NCT03491332|Placebo Comparator|group C|general circuit group
16471030|NCT03491332|Active Comparator|group H|warm circuit group
16471031|NCT03491332|Experimental|group SH|new warm circuit group
16471032|NCT03491319|Placebo Comparator|Group C Control|spinal anaesthesia was given with table in neutral positon. Same position was maintained after spinal anaesthesia
16471033|NCT03491319|Active Comparator|Group X|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal
16471177|NCT03490474|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
16471034|NCT03491319|Active Comparator|Group Y|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
16471035|NCT03491306|Active Comparator|Group 1|patients will receive partial denture constructed from breflex material
16471036|NCT03491306|Experimental|Group 2|patients will receive partial denture constructed from PEEK material
16471037|NCT03491293|Active Comparator|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
16471038|NCT03491293|Experimental|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
16471039|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
16471040|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
16471041|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
16471042|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
16471043|NCT03491254||Group A/exposure group|Huaier Granule & biliary drainage
16471044|NCT03491254||Group B/non-exposure group|biliary drainage.
16471045|NCT03491241|Experimental|pre-diabetics obese patients|These pre-diabetic obese patients will be treated by hypocaloric diet therapy. these patients were under metformine therapy at enrollment.
16471046|NCT03491241|Placebo Comparator|pre-diabetics patients|These pre-diabetic patients will be treated by hypocaloric diet therapy alone.
16471047|NCT03491241|Active Comparator|obese patients|These obese patients will be treated by hypocaloric diet therapy.
16471048|NCT03491215|Experimental|Ruxolitinib|All patients will receive ruxolitinib in addition to corticosteroids +/-calcineurin inhibitor (CNI)
16471049|NCT03491202||atrial fibrillation|Patients with a diagnosis of atrial fibrillation will be eligible for enrollment
16471050|NCT03491189|Active Comparator|Lag screw fixation|Lag screw fixation
16471051|NCT03491189|Active Comparator|Helical Blade fixation|Helical Blade fixation
16471053|NCT03491163||Patients|Syndecan-1 concentration evaluation
16471054|NCT03491150|Placebo Comparator|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
16471055|NCT03491150|Experimental|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
16471056|NCT03491124|Sham Comparator|Sham Treatment|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will also receive a sham intervention, pointing a laser pointer to the ear without turning the laser on.
16471057|NCT03491124|Experimental|Auricular Acupuncture|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
16471058|NCT03491111|Experimental|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
16471059|NCT03491111|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
16471060|NCT03491111|Experimental|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
16471061|NCT03491098|Placebo Comparator|momestone furoate spray first group: will be given|Nasonex spray one puff in each nostril daily for 8 weeks
16471062|NCT03491098|Placebo Comparator|prednisolone sodium phosphate 15mg second group: will be given|Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks
16471063|NCT03491098|Placebo Comparator|hypertonic sea water solution spray third group: will be given|Nasal spray one puff in each nostril daily for 8 weeks
16471064|NCT03491085|Active Comparator|tonsillictomy with antibiotics|
16471065|NCT03491085|No Intervention|tonsillictomy Without Antibiotics|
16471066|NCT03491072|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
16471067|NCT03491072|Active Comparator|Fentanyl|Patients will receive IV fentanyl 1µg /Kg. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
16471068|NCT03491059|Experimental|Full Study - Radiation|
16471069|NCT03491059|No Intervention|Dress Rehearsal Only - No Radiation|
16471070|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
16471072|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
16471073|NCT03491020||Respiratory syncytial virus (RSV)|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify RSV.
16471074|NCT03491020||Enteroviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify enterovirus.
16471075|NCT03491020||Adenoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify adenovirus.
16471076|NCT03491020||Coronaviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify coronavirus.
16471077|NCT03491020||Metapneumoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify metapneumovirus.
16471078|NCT03491020||Chlamydia pneumoniae|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify chlamydia pneumoniae.
16471079|NCT03491020||Mycoplasma|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify mycoplasma.
16471080|NCT03491020||Parainfluenza|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify parainfluenza.
16471081|NCT03491020||Neisseria meningitides|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify neisseria meningitides.
16471082|NCT03491020||Bordetella pertussis|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify bordetella pertussis.
16471083|NCT03491020||Rhinovirus|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify rhinovirus.
16471084|NCT03491007|No Intervention|Placebo|Subjects will receive a one-time oral dose of PBO prior to initial brain imaging followed by sustained administration of PBO for 6 weeks.
16471085|NCT03491007|Placebo Comparator|DHEA|Subjects will receive a one-time oral dose of DHEA prior to initial brain imaging followed by sustained administration of DHEA for 6 weeks.
16471086|NCT03490994|Experimental|Rivaroxaban|Rivaroxaban
16471087|NCT03490994|Active Comparator|Warfarin|warfarin + enoxaparin
16471088|NCT03490981|Other|Treatment as usual (TAU) only|Primary care treatment as usual
16471089|NCT03490981|Experimental|Treatment as usual (TAU) plus Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Primary care treatment as usual and Brief CBT-CP
16471090|NCT03490968|Other|Healthy Subjects|
16471091|NCT03490968|Experimental|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
16471092|NCT03490968|Active Comparator|PAD Subjects Who Undergo Revascularization of the Leg|This group of subjects are receiving leg revascularization as part of standard of care.
16471093|NCT03490955|Sham Comparator|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
16471094|NCT03490955|Active Comparator|Salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
16471095|NCT03490955|Active Comparator|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
16471096|NCT03490955|Active Comparator|Salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with dressing (canola oil) and with black pepper one time in the morning
16471097|NCT03490955|Active Comparator|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with dressing (olive oil) and with black pepper one time in the morning
16471098|NCT03490955|Active Comparator|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with dressing (corn oil) and with black pepper one time in the morning
16471099|NCT03490955|Active Comparator|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with dressing (sunflower oil) and with black pepper one time in the morning
16471100|NCT03490955|Active Comparator|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with dressing (flaxseed oil) and with black pepper one time in the morning
16471101|NCT03490942|Experimental|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
16471102|NCT03490942|Experimental|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
16471103|NCT03490942|Placebo Comparator|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
16471104|NCT03490942|Placebo Comparator|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
16471105|NCT03490929|Experimental|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
16471106|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
16471107|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
16471138|NCT03490734|Active Comparator|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage with added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
16474161|NCT03469921||patients included in clinical trials|patients included in clinical trials
16471108|NCT03490903|Experimental|VR with or without Moderate Sedation|"Patients randomized to receive a Virtual Reality Intervention will be fitted with a VR headset and headphones and undergo a continuous immersive meditation experience. This will begin immediately prior to the start of the procedure, and continue until the procedure is completed.
~Patient pain and anxiety levels will be frequently assessed by procedure operator and circulating nurse, and pain medication or anxiolytic medications will be administered in the absence of contraindications. Baseline amounts of sedation pre-procedurally will not be used in either arm. Pain and Anxiety Scores will be assessed pre, intra, and post-procedurally. If no contraindications, the operator will decide upon how much sedation medication to administer if indicated or requested. This is the usual manner in which pain and anxiety is treated in the cath lab."
16471109|NCT03490903|Active Comparator|Moderate Sedation without VR|Subjects randomized to the comparison arm will not undergo the Virtual Reality Intervention. Baseline amounts of sedation pre-procedurally will not be used in either arm. Subjects will be assessed periodically by physicians and/or circulating nurses for their pain and anxiety levels. The patient may also prompt the staff that they are anxious or in pain, and if no contraindications, the operator will decide upon how much medication to administer. This is the usual manner in which pain and anxiety is treated in the cath lab.
16471110|NCT03490890|Experimental|Microwave ablation in the GGO|Patients with GGO were treated with microwave ablation.
16471111|NCT03490864|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
16471112|NCT03490864|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
16471113|NCT03490864|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
16471114|NCT03490864|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
16471115|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 1|2g β-glucan
16471116|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 2|4g β-glucan
16471117|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 3|4g β-glucan plus β-glucanase
16471118|NCT03490851|Placebo Comparator|Cream of Rice|27 grams of cream of rice
16471126|NCT03490825|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
16471127|NCT03490825|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
16471128|NCT03490825|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
16471129|NCT03490825|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
16471130|NCT03490812|Experimental|Prospective population|
16471131|NCT03490812|Experimental|Retrospective population|
16471132|NCT03490786|Experimental|Dose escalation|Single arm dose escalation.
16471133|NCT03490760|Experimental|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
16471134|NCT03490747|Experimental|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
16471135|NCT03490747|Active Comparator|Usual care referral scheme|Comparative, usual care exercise referral scheme.
16471136|NCT03490747|No Intervention|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
16471137|NCT03490734|Active Comparator|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
16471175|NCT03490474|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
16471176|NCT03490474|Active Comparator|Pain Free Massage|Participants will receive light touch applied to one myofascial trigger point.
16471139|NCT03490734|Active Comparator|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
16471140|NCT03490734|Active Comparator|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage no added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
16471141|NCT03490721|Experimental|Intervention|Clustering care for 20 minutes.
16471142|NCT03490721|No Intervention|Control|Standard care non clustered.
16471143|NCT03490708|Experimental|Tranilast|Subjects who were treated with tranilast
16471144|NCT03490695|Experimental|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
16471145|NCT03490695|Experimental|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.
~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.
~During this 12 months period, practice facilitation will end in the Group A arm."
16471146|NCT03490682|Active Comparator|Non-pregnant control|adult females aged less than 40 years, not currently pregnant, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and 1 hour for clear fluids.
16471147|NCT03490682|Active Comparator|Pregnant control|adult females aged less than 40 years, pregnant in the third trimester (gestation greater than 32 weeks on the day of the study) according to dates and the calculation of term established at the start of the pregnancy by an obstetrician, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and I hour for clear fluids.
16471148|NCT03490682|Experimental|Analgesia|adult females aged less than 40 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, with a working epidural, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
16471149|NCT03490682|Experimental|Parturient|adult females aged less than 35 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, without any epidural analgesia, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
16471150|NCT03490669|Experimental|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
16471151|NCT03490669|Experimental|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
16471152|NCT03490656|Experimental|Healthy volunteer population|
16471153|NCT03490656|Experimental|Patient population|
16471154|NCT03490643|Other|TMD Group|people who has TMD
16471155|NCT03490643|Other|Control Group|individuals who dont have healthy temporomandibular joint
16471156|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
16471157|NCT03490617|Active Comparator|Vaginal Misoprostol Group|Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion
16471158|NCT03490617|Placebo Comparator|Placebo group|Vaginal placebo tablets 4 hours prior to IUD insertion
16471159|NCT03490591|Experimental|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
16471160|NCT03490578|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
16471161|NCT03490578|Active Comparator|Intensive treadmill training|Intensive treadmill training using an usual treadmill
16471162|NCT03490565|Active Comparator|EX group|Exercise training
16471163|NCT03490565|No Intervention|CON-group|Usual Care
16471164|NCT03490552|Sham Comparator|group A|include clots which have been extracted by mechanical thrombectomy and with definite stroke etiology and submitted to the RNA analysis in blinded coded label .
16471165|NCT03490552|Experimental|group B|include all clots which have been extracted by mechanical thrombectomy and with unknown stroke etiology and submitted to RNA analysis in cryptogenic label.
16471166|NCT03490539||azathioprine (AZT)|Patients with MG who are receiving azathioprine as part of routine clinical care
16471167|NCT03490539||mycophenolate mofetil (MMF)|Patients with MG who are receiving mycophenolate mofetil as part of routine clinical care
16471168|NCT03490526|Experimental|Root canal disinfection with XP-endo Finisher|
16471169|NCT03490526|Active Comparator|Root canal disinfection with passive ultrasonic irrigation|
16471170|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
16471171|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
16471172|NCT03490500||S100B protein dosage|Biological
16471173|NCT03490487|Active Comparator|A antiepileptic|will receive conventional antiepileptic drugs only
16471174|NCT03490487|Experimental|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
16471178|NCT03490461||Statin group|Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
16471179|NCT03490461||Non-statin group|the administration of statins for less than 30 days after liver transplantation
16471180|NCT03490448|Other|intervention group|aerobic exercise and appropriate caloric control
16471181|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
16471182|NCT03490422|Experimental|Pulpotomy|Pulpotomy is performed in carious-exposed pulp in mature permanent teeth
16471183|NCT03490409|Experimental|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
16471184|NCT03490409|No Intervention|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
16471185|NCT03490396|Experimental|Arm 1 (Gelclair at time of conditioning)|All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
16471186|NCT03490396|Active Comparator|Arm 2 (Gelclair when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
16471187|NCT03490396|Active Comparator|Arm 3 (MMW when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.
16471188|NCT03490383||patients without CBD calculi|patients without CBD calculi
16471189|NCT03490383||CBD calculi without ERCP history|patients with CBD calculi without ERCP history
16471190|NCT03490383||CBD calculi with ERCP history|patients with CBD calculi and ERCP history
16471191|NCT03490370|Experimental|Electronic Muscle Stimulation Activity|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
16471192|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
16471193|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
16471194|NCT03490344|Experimental|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
16471195|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.
~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
16471196|NCT03490318||Patients with DMO and/or PDR|
16471197|NCT03490305||Combatants|Men 16-50 years old or combatants by own admission.
16471198|NCT03490305||Civilians|Children <16 years, all women and men ≥50 years.
16471199|NCT03490292|Experimental|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) [intravenous infusion on days 1, 8, 15, 22, & 29] while undergoing radiation therapy [23 fractions, M-F, estimated completion day 35].
~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.
~Trial enrollment will resume after at least 5 patients do not have a DLT during the DLT evaluation period or until all 6 patients are seen for post-operative evaluation. If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
16471200|NCT03490292|Experimental|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation & Avelumab combined with Chemoradiation).
16471201|NCT03490279|Experimental|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
16471202|NCT03490279|Placebo Comparator|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
16471203|NCT03490266|Active Comparator|Laparoscopic Repair|The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
16471204|NCT03490266|Experimental|Robotic Repair|Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
16471234|NCT03490123|Active Comparator|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.
~Study interventions are:
~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
16471205|NCT03490253|Active Comparator|Static Messaging|We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
16471206|NCT03490253|Experimental|Adaptive Messaging|Patients in the adaptive messaging arm will receive the daily messages of the static arm, and additionally receive daily messages within different categories of feedback and motivational messages that are chosen using a reinforcement learning (RL) algorithm. Physical activity (step-count/day) will be actively monitored via the app on their smartphone.
16471207|NCT03490253|No Intervention|Control Condition|Control patients will only install the app on their phone and will not receive any feedback messages. They will receive one message a week, on a fixed day, asking them to assess their mood in the previous week on a scale of 1 to 9. The message will be sent daily at 10:00 am. Non-responders will receive reminders to submit their mood self-assessments in two hour intervals.
16471208|NCT03490240|Experimental|BIPAMS|The behavioral intervention consists of two primary components, a dedicated Internet website and one-on-one video chats with a behavioral coach via Skype. The behavioral intervention focuses on the skills, techniques, resources, and strategies for becoming and staying physically active with MS, but it does not provide a prescription for exercise or physical activity itself.
16471209|NCT03490240|Active Comparator|WELLMS|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
16471210|NCT03490214|Experimental|Muscular Dystrophia|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
16471211|NCT03490214|Active Comparator|Healthy Volunteer|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
16471212|NCT03490201|Active Comparator|Randomized - Control|
16471213|NCT03490201|Active Comparator|Randomized - Treatment|
16471214|NCT03490201|Experimental|Non-randomized - Treatment|
16471215|NCT03490188|Experimental|Treatment Arm|Patients assigned to treatment arm will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center. In addition, they will be matched with a mentor who will conduct 5 meetings with the patients (which includes one video chat meeting, 4 30-minute phone calls) and discuss the following topics related to post-discharge: Medications, Lab Work, Fluid Intake and Adherence to doctor's appointment
16471216|NCT03490188|No Intervention|Control Arm|Control arm recipient will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center
16471217|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
16471218|NCT03490162|Experimental|Food Effect|300 mg of DM1157 (2 capsules of 150 mg) orally with high fat diet, n=6, and matching placebo (2 capsules) orally with high fat diet, n=2
16471219|NCT03490162|Experimental|MAD 1|150 mg of DM1157 (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=2
16471220|NCT03490162|Experimental|MAD 2|300 mg of DM1157 (2 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (2 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
16471221|NCT03490162|Experimental|MAD 3|600 mg of DM1157 (4 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (4 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
16471222|NCT03490162|Experimental|MAD 4|900 mg of DM1157 (6 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (6 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
16471223|NCT03490162|Experimental|SAD 1|9 mg of DM1157 (1 capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
16471224|NCT03490162|Experimental|SAD 2|27 mg of DM1157 (3 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (3 capsules) orally with 240 ml of water after an overnight fast, n=2
16471225|NCT03490162|Experimental|SAD 3|81 mg of DM1157 (9 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (9 capsule) orally with 240 ml of water after an overnight fast, n=2
16471226|NCT03490162|Experimental|SAD 4|150 mg of DM1157 (1capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
16471227|NCT03490162|Experimental|SAD 5|300 mg of DM1157 (2 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (2 capsules) orally with 240 ml of water after an overnight fast, n=2
16471228|NCT03490162|Experimental|SAD 6|600 mg of DM1157 (4 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (4 capsules) orally with 240 ml of water after an overnight fast, n=2
16471229|NCT03490162|Experimental|SAD 7|900 mg of DM1157 (6 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (6 capsules) orally with 240 ml of water after an overnight fast (n=2)
16471230|NCT03490149||ECT|
16471231|NCT03490149||Medication - Treatment as usual|
16471232|NCT03490149||Healthy controls|
16471233|NCT03490123|Experimental|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).
~Study interventions are:
~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
16471264|NCT03489928|Experimental|Low dose vaginal misoprostol|25-50ug q6h, vaginally, as needed
16471265|NCT03489928|Experimental|Usual vaginal dinoprostone|1-2mg q6h, vaginally as needed
16474162|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
16471235|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
16471236|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
16471237|NCT03490097|Experimental|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.
16471238|NCT03490097|Active Comparator|Group II|sofosbuvir plus daclatasvir
16471239|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
16471240|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
16471241|NCT03490058||Young women|Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
16471242|NCT03490045|Experimental|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
16471243|NCT03490045|Active Comparator|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will receive a conditional cash transfer of equivalent value of the diapers provided to the intervention group.
16471244|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
16471245|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
16471246|NCT03490032|Experimental|Metastatic Prostate Cancer (mPCa) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
16471247|NCT03490019|Experimental|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
16471248|NCT03490006|Active Comparator|Paravertebral Block|For this arm, the initial level will be at T3-4 and an out-of-plane technique to guide the needle tip to a point between the costotransverse ligament and the parietal pleura between the visualized transverse processes. Then, a few milliliters of 0.5% ropivacaine will be injected slowly to displace the pleura ventrally as the paravertebral space fills with local anesthetic. After negative aspiration, the rest of 0.5% ropivacaine (total 10 ml) will be injected in 5 ml increments to further fill the paravertebral space. The procedure will then be repeated in the same exact fashion at the T5-6 level. We will observe local anesthetic spread under real-time ultrasound imaging.
16471249|NCT03490006|Experimental|Erector Spinae Plane Block|For this arm, the needle tip will be directed under ultrasound guidance using an in-plane technique towards the T5 transverse process until the needle tip contacts os. Then, a few milliliters of ropivacaine will be injected slowly to separate the plane between the erector spinae muscle and the transverse process. After negative aspiration, the rest of the 0.5% ropivacaine will be injected (total 20ml)
16471250|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
16471251|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
16471252|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
16471253|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
16471254|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
16471255|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
16471256|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
16471257|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
16471258|NCT03489954||Non-specific chronic neck pain group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
16471259|NCT03489954||Healthy group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
16471260|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
16471261|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
16471262|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
16471263|NCT03489928|Experimental|Oral Misoprostol|50ug po q4h orally, as needed
16471266|NCT03489915||Patients with macular edema due to RVO|assessment of visual acuity using Landolt chart and follow up of macular edema using OCT
16471267|NCT03489902|Experimental|Transobturator arm|Transobturator Paravaginal Repair
16471268|NCT03489902|Experimental|Transvaginal arm|traditional transvaginal Paravaginal Repair
16471269|NCT03489889|Experimental|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
16471270|NCT03489889|Experimental|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
16471271|NCT03489876|Experimental|Synthetic Cartilage Implant|Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.
16471272|NCT03489876|Active Comparator|Osteochondral Autograft Transfer|Participants receive the current standard osteochondral autograft transfer procedure.
16471273|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
16471274|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
16471275|NCT03489850|Active Comparator|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
16471276|NCT03489850|Placebo Comparator|Placebo|Matched to active
16471277|NCT03489837|Experimental|Levotuss CR tab|oral taken
16471278|NCT03489837|Active Comparator|Levotuss syrup|oral taken
16471279|NCT03489824|Experimental|modified-WIM colonoscopy in RLP|Modified-water immersion method colonoscopy is performed to patients with right-lateral starting position (RLP). Patients will lie in the right lateral position with both hips and knees flexed at the beginning and change the position into supine and at last left-lateral position when it is needed.
16471280|NCT03489824|Active Comparator|modified-WIM colonoscopy in LLP|Modified-water immersion method (WIM) colonoscopy is performed to patients with left-lateral starting position (LLP). Patients will lie in the left lateral position with right hip and knee flexed and left leg straight at the beginning and change the position into supine and at last right lateral position when it is needed.
16471281|NCT03489811|Experimental|Test Essential Oil Blend|Participants in this arm receive the test essential oil inhaler to administer during the 4-week intervention.
16471282|NCT03489811|Active Comparator|Active Essential Oil Blend|Participants in this arm receive an active essential oil inhaler to administer during the 4-week intervention.
16471283|NCT03489811|Placebo Comparator|Control|Participants in this arm receive a control inhaler to administer during the 4-week intervention.
16471284|NCT03489798|Experimental|6 Misoprostol|Up to six doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
16471285|NCT03489798|Active Comparator|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
16471286|NCT03489785||Movement|If there is unexpected movement
16471287|NCT03489785||No movement|If there is no unexpected movement
16471288|NCT03489772|Experimental|1 mg ITI-214|Single dose
16471289|NCT03489772|Experimental|10 mg ITI-214|Single dose
16471290|NCT03489772|Placebo Comparator|Placebo|Single dose
16471291|NCT03489759|Experimental|ViE15-A|The patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using ViE15-A hemofilter
16471292|NCT03489759|Active Comparator|REXEED-15A|TThe patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using REXEED-15A
16471293|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
16471294|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
16471295|NCT03489733|Experimental|Intervention Group|Infant Formula with hydrolyzed protein and breast milk until at least 120 days of life
16471296|NCT03489733|Experimental|Control Group|Infant Formula with intact protein and breast milk until at least 120 days of life
16471297|NCT03489733|No Intervention|Breast Fed Group|Exclusively breast ilk until at least 120 days of life
16471298|NCT03489720|Experimental|Arm A: Exercise intervention then usual exercise program|8 weeks of exercise intervention followed by 8 weeks of usual exercise program
16471299|NCT03489720|Active Comparator|Arm B: Usual Exercise Program then exercise intervention|8 weeks of usual exercise program followed by 8 weeks of exercise intervention
16471300|NCT03489707|Experimental|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
16471301|NCT03489707|Active Comparator|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
16471302|NCT03489694||Subjects|Each subject will undergo skin test endpoint titrations with three different testers.
16471303|NCT03489681|Experimental|Acupuncture, low dosage|treat as six acupoints
16471304|NCT03489681|Experimental|Acupuncture, high dosage|treat as 18 acupoints
16471305|NCT03489681|No Intervention|Control group|no acupuncture treatment, healthy control
16471306|NCT03489668|Active Comparator|PCOS|Metformin administration 1500mg/day
16471307|NCT03489668|No Intervention|Control|
16471308|NCT03489655|Experimental|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
16471309|NCT03489655|No Intervention|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
16471310|NCT03489642|Experimental|COPD Telehealth Program|Participants will take part in a structured telehealth program for 12 weeks. Web-based educational tools will be made available to participants. Study participants will meet with a registered respiratory therapist two times per week.
16471350|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
16471351|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
16471311|NCT03489629|Experimental|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.
~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
16471312|NCT03489616|Experimental|Radiotherapy+chemotherapy+ rhGM-CSF|Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be> 4Gy per time（or BED >45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
16471313|NCT03489616|Experimental|Single agent maintenance therapy|Maintenance treatment by single agent in a cycle of 21 days.
16471314|NCT03489590|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.
16471315|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
16471316|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
16471317|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
16471318|NCT03489538||RYGB Patients|Laparoscopic long limb roux-en-Y gastric bypass group. All consecutive patients eligible for bariatric surgery.
16471319|NCT03489525|Experimental|Dose Escalation, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
16471320|NCT03489525|Experimental|Dose Expansion, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
16471321|NCT03489512|Experimental|A (Chloraprep)|2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
16471322|NCT03489512|Active Comparator|B (Clorhexidine 2%)|2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
16471323|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
16471324|NCT03489460|Active Comparator|Receive sleep health messages + GAD|Procedures will be delivered to users of the GAD, individuals who have opted in via their smartphone application, to receive messages about various areas of health.
16471325|NCT03489460|Active Comparator|Sleep message No GAD|For two weeks participants agree to receive sleep health messages and wear the GAD
16471326|NCT03489447||Sepsis group|All adult (>= 18 years) patients with a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
16471327|NCT03489447||Non-sepsis group|All adult (>=18 years) patients without a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
16471328|NCT03489434|Experimental|Intervention Group|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
16471329|NCT03489434|No Intervention|Control|Assessment only control.
16471330|NCT03489421||HIV Infected|
16471331|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
16471332|NCT03489395|Experimental|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
16471335|NCT03489369|Experimental|Sym022|Sym022 will be administered at up to 4 planned dose levels.
16471336|NCT03489356|Experimental|Intervention|Addressing Behavior Change (ABC) intervention delivery method
16471337|NCT03489356|No Intervention|Control|Control
16471338|NCT03489343|Experimental|Sym023 0.03 mg/kg|Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion
16471339|NCT03489343|Experimental|Sym023 0.1 mg/kg|Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion
16471340|NCT03489343|Experimental|Sym023 0.3 mg/kg|Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion
16471341|NCT03489343|Experimental|Sym023 1.0 mg/kg|Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion
16471342|NCT03489343|Experimental|Sym023 3.0 mg/kg|Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion
16471343|NCT03489343|Experimental|Sym023 10.0 mg/kg|Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion
16471344|NCT03489343|Experimental|Sym023 20.0 mg/kg|Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion
16471345|NCT03489330||Northwestern Memorial Hospital data|Inpatient intravenous vancomycin use
16471346|NCT03489330||Henry Ford Hospital data|Inpatient intravenous vancomycin use
16471347|NCT03489330||University of Michigan Hospital data|Inpatient intravenous vancomycin use
16471348|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
16471349|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
16471418|NCT03488836|Active Comparator|reciproc|reciprocal endodontic treatment group
16471352|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
16471354|NCT03489265|Other|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
16471355|NCT03489265|Other|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
16471357|NCT03489239|Experimental|Single Arm|SingleArm: TAF 25 mg
16471358|NCT03489226|Active Comparator|Capsimax 2 mg|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
16471359|NCT03489226|Placebo Comparator|Placebo|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
16471360|NCT03489226|Active Comparator|Capsimax 4 mg plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
16471361|NCT03489226|Placebo Comparator|Placebo plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
16471362|NCT03489213|Active Comparator|Arm I (DGA/AICR)|Patients receive DGA/AICR-based dietary intervention for 6 months consisting of 12 education sessions (60 minutes each) every other week. Lectures will take place in an urban garden where fruit, vegetable, and herb harvesting 1-2 times per week is encouraged. All participants will be given a FitBit and regular physical activity will be encouraged. Finally, remote health coaching is offered to all study subjects for the duration of the intervention (12 weeks).
16471363|NCT03489213|Experimental|Arm II (DGA/AICR plus Beef)|Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
16471364|NCT03489200|Experimental|EH301|
16471365|NCT03489200|Placebo Comparator|Placebo|
16471366|NCT03489187||VTTS as standard of care|VTTS as standard of care.
16471367|NCT03489174|Experimental|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
16471368|NCT03489174|Active Comparator|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
16471369|NCT03489161|Experimental|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
16471370|NCT03489148|Experimental|Tamarkoz®|A Sufi method to focus, called Tamarkoz®. Participants had met in class twice a week for two and a half hours total for three months. One day of the week, they met for theoretical teachings of Sufism, and for the second day in the week they met with a Tamarkoz® instructor to learn meditation techniques.
16471371|NCT03489148|Active Comparator|Stress Management Resources|The self-care stress management group used the campus resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, and online reading materials for stress management as needed for themselves.
16471372|NCT03489148|No Intervention|Waitlist|The waitlist control group did not receive Tamarkoz® and did not use the stress management resources on campus for the duration of the study.
16471373|NCT03489135|Experimental|Intervention using the ReVene Thrombectomy Catheter|Open label, prospective, non-randomised, multi-centre first-in-human evaluation of the Vetex ReVene Thrombectomy Catheter for treatment of acute iliofemoral deep vein thrombosis (DVT).
16471374|NCT03489122|Experimental|Iyengar yoga and coherent breathing|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
16471375|NCT03489122|Active Comparator|Walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
16471376|NCT03489109|Experimental|Intermittent Fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet.
16471377|NCT03489109|Active Comparator|Standard of Care|Standard of care dietary and healthy lifestyle counseling
16471378|NCT03489096|Experimental|Cryoballoon Ablation|Cryoballoon Ablation: PVI + substrate modification. Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
16471379|NCT03489083|Experimental|Trained Group|Subjects performing strength training three times per week for twelve weeks.
16471380|NCT03489083|Placebo Comparator|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
16471381|NCT03489070|Active Comparator|Traumastem®|Oxidized nonregenerated cellulose hemostatic agents.Traumastem® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
16471382|NCT03489070|Active Comparator|Surgicel®|Oxidized regenerated cellulose hemostatic agents.Surgicle® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
16471383|NCT03489057|Experimental|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
16471384|NCT03489057|Active Comparator|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
16471385|NCT03489044|Experimental|Active treatment arm (Levetiracetam)|When in the active arm, after a baseline visit, participants will up-titrate Levetiracetam in 250mg steps at intervals of one week to Levetiracetam 500mg twice daily (two tablets twice daily). Participants will be maintained on Levetiracetam 500mg bd for four weeks and have a further full assessment at 8 weeks after being on Levetiracetam. Participants will then down-titrate Levetiracetam by 250mg every week until weaned to nil.
16471386|NCT03489044|Placebo Comparator|Control arm (placebo oral tablets)|When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
16471387|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
16471388|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
16471389|NCT03489005|Other|Treatment Period 1|"Interventions to be administered:
~Schema 1:
~400 mg BIA 5-1058
~1200 mg BIA 5-1058
~Placebo
~Moxifloxacin
~Schema 2:
~1200 mg BIA 5-1058
~Placebo
~400 mg BIA 5-1058
~Moxifloxacin"
16471390|NCT03489005|Other|Treatment Period 2|"Interventions to be administered:
~Schema 1
~1200 mg BIA 5-1058
~Moxifloxacin
~400 mg BIA 5-1058
~Placebo
~Schema 2:
~Placebo
~Moxifloxacin
~1200 mg BIA 5-1058
~400 mg BIA 5-1058"
16471391|NCT03489005|Other|Treatment Period 3|"Interventions to be administered:
~Schema 1
~Placebo
~400 mg BIA 5-1058
~Moxifloxacin
~1200 mg BIA 5-1058
~Schema 2
~400 mg BIA 5-1058
~1200 mg BIA 5-1058
~Moxifloxacin
~Placebo"
16471392|NCT03489005|Other|Treatment Period 4|"Interventions to be administered:
~Schema 1
~Moxifloxacin
~Placebo
~1200 mg BIA 5-1058
~400 mg BIA 5-1058 Schema 2
~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
16471393|NCT03488992|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
16471394|NCT03488992|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
16471395|NCT03488979||Educational Interventional Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
16471396|NCT03488979||Attention Control Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
16471397|NCT03488966|Experimental|MB-EAT|Behavioral: group psychotherapy. Eight weekly sessions, each session is 2 hours in duration.
16471398|NCT03488966|No Intervention|Waitlist Control|Wait list control.
16471399|NCT03488953|Other|Transplantation Arm|
16471400|NCT03488940|Active Comparator|24-hours group|"The septic patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
16471401|NCT03488940|Experimental|16-hours group|"The septic patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
16471402|NCT03488940|Experimental|intermittent group|"The septic patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
16471403|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
16471404|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
16471405|NCT03488914|Other|Intervention|
16471406|NCT03488914|Other|Enhanced Treatment as Usual|
16471407|NCT03488901||methotrexate sensitive|patients with gestational choriocarcinoma cured with methotrexate alone
16471408|NCT03488901||methotrexate resistant|patients with gestational choriocarcinoma not cured with methotrexate alone
16471409|NCT03488901||polychemotherapy sensitive|patients with gestational choriocarcinoma cured with polychemotherapy
16471410|NCT03488901||polychemotherapy resistant|patients with gestational choriocarcinoma not cured with polychemotherapy
16471411|NCT03488901||hydatidiform moles without malignant transformation|patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)
16471412|NCT03488901||placental site trophoblastic tumors|patients with placental site trophoblastic tumors not cured with polychemotherapy
16471413|NCT03488888|Sham Comparator|Normal Saline|"General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9%
~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles
~Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery.
~Visualization of Pectoralis menor and Serratil Muscles
~3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution"
16471414|NCT03488888|Experimental|Bupivacaine|"General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine
~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles
~Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery.
~Visualization of Pectoralis minor and Serratil Muscles
~3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution"
16471415|NCT03488875|Experimental|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
16471416|NCT03488875|No Intervention|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
16471417|NCT03488836|Active Comparator|race|race rotation protocol
16471419|NCT03488823|Experimental|Young with Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
16471420|NCT03488823|Placebo Comparator|Young without Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
16471421|NCT03488823|Experimental|Old with Flavanol|Old patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
16471422|NCT03488823|Placebo Comparator|Old without Flavanol|Young patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
16471423|NCT03488810|Active Comparator|Arm A: ADT + radiation therapy|"Patient will receive 2 injections of a three-monthly LHRH agonist depot plus non-steroidal anti-androgen (rescue treatment) (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection.
~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
16471424|NCT03488810|Experimental|Arm B: ADT + radiation therapy + Apalutamide|"Patients will receive 2 injections of a three-monthly LHRH agonist depot. Apalutamide treatment: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months.
~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
16471425|NCT03488797|Experimental|Experimental|Supervised web- and home-based exercise intervention
16471426|NCT03488797|No Intervention|No Intervention|"Control group - Standard of Care
~Re-assessment 24 weeks (6 month) after enrolment.
~Afterwards crossover into experimental group"
16471427|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
16471428|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
16471429|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
16471430|NCT03488758|Active Comparator|CMF|infant formula based on cow milk protein fractions
16471431|NCT03488758|Experimental|GMF|infant formula based on whole goat milk
16471432|NCT03488745|Experimental|IntelliCare + Phone Coaching|Participants will receive IntelliCare apps with phone coaching for 7 weeks. In this arm, participants will pick two IntelliCare apps to use every week. Participants will receive a phone coaching call before they use the apps, for approximately 30 minutes, as well as 3 weeks after initiating app use (10 minute call).
16471433|NCT03488732||Patients undergonig transcatheter valvular interventions|
16471434|NCT03488719|Experimental|Cohort 1|Tesofensine 0.25mg
16471435|NCT03488719|Experimental|Cohort 2|Tesofensine 0.50mg
16471436|NCT03488719|Experimental|Cohort 3|Tesofensine 0.75mg
16471437|NCT03488706||Gray Zone Group|The gray zone group PSA between 4.00 to 10.99 ng/ml.
16471438|NCT03488693|Active Comparator|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
16471439|NCT03488693|Active Comparator|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
16471440|NCT03488680|Experimental|Intervention group|Behavior change communication
16471441|NCT03488680|No Intervention|Control group|No Behavior change communication
16471442|NCT03488667|Experimental|mFOLFOX6 (Leucovorin-Fluorouracil-Oxaliplatin) + Pembrolizumab|"Drug: Pembrolizumab Dose: 200 mg Dose Frequency: Every three weeks (Q3W) Route: Intravenous (IV) infusion
~Drug: Oxaliplatin Dose: 85 milligrams per meter squared (mg/m2) Dose Frequency: Every 2 weeks (Q2W) Route: IV infusion
~Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion
~Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus
~Drug: Fluorouracil Dose: 2,400 mg/m2 Dose Frequency: Q2W Route: IV continuous 46-hour infusion
~Pembrolizumab will be administered at a fixed dose of 200 mg IV over 30 minutes every 3 weeks. Participants will receive 3 doses of the drug on Days 1, 22, 43 during the neoadjuvant phase of the study, and 12 doses of the drug on Days 1, 22, 43 during the adjuvant phase of the study (total 15 doses). Participants will receive 4 doses of mFOLFOX6 regimen on Days 1, 15, 29, 43 during the neoadjuvant phase of the study, and 4 doses during the adjuvant phase of the study (total 8 doses)."
16471445|NCT03488602|Experimental|F-SPS Intervention|This group will receive the F-SPS intervention.
16471446|NCT03488602|Active Comparator|Enhanced Usual Care (EUC)|This group will receive Enhanced Usual Care (EUC)
16471447|NCT03488576|Active Comparator|Complete Peeling|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with complete macular peeling of the internal limiting membrane.
16471448|NCT03488576|Experimental|Foveal Sparing|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with partial peeling the internal limiting membrane (foveal sparing).
16471449|NCT03488563|Experimental|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
16471450|NCT03488563|Experimental|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
16471451|NCT03488563|Placebo Comparator|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
16471452|NCT03488550|Experimental|ANX007-GLA-01|
16471453|NCT03488537|Other|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
16471454|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
16471496|NCT03488212|Experimental|Online Treatment; Refresher Courses for Maintenance|
16471497|NCT03488199|Active Comparator|Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)|50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
16471498|NCT03488199|Experimental|Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))|50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
16471455|NCT03488511|Experimental|Intervention group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of six small protein and energy enriched meals and snacks that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
16471456|NCT03488511|No Intervention|Control group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
16471457|NCT03488498||Receiving NSAID medication|Receiving NSAID medication
16471458|NCT03488498||Receiving NSAID medication and weight bath therapy,|
16471459|NCT03488498||Receiving weight bath therapy,|
16471460|NCT03488485|Other|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).
~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks
~Cirrhotics:
~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
16471461|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
16471462|NCT03488459|Other|Routine preoperative information from a nurse|
16471463|NCT03488459|Experimental|Additional information support from a psychologist|
16471464|NCT03488433|Active Comparator|Antirotation sling|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
16471465|NCT03488433|Active Comparator|abduction brace|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
16471466|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
16471467|NCT03488394|Experimental|Treatment|Gene therapy (autologous, CD34+ cell enriched cells fraction containing HSCs, transduced with the IDUA LV encoding for the human IDUA gene and cryopreserved in cryoformulation medium)
16471468|NCT03488381|Experimental|Soccer Heading|
16471469|NCT03488381|Sham Comparator|Kicking-Control|
16471470|NCT03488368||Supportive-care group|Observation of IgAN patients who received supportive care measures (without additional immunosuppression) during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
16471471|NCT03488368||Immunosuppression group|Observation of IgAN patients who received supportive care measures and additional immunosuppression during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
16471472|NCT03488355|Experimental|Modified Reporting|Modified laboratory report
16471473|NCT03488355|No Intervention|Standard Reporting|Standard laboratory report
16471474|NCT03488342|Other|Rives technique|Rives technique for primary inguinal hernia
16471475|NCT03488342|Other|Lichtenstein repair|Lichtenstein repair for primary inguinal hernia
16471476|NCT03488329|Experimental|Intervention|"Intervention group
~Individual nutritional therapy"
16471477|NCT03488329|No Intervention|Control|"Control group
~Standard treatment"
16471478|NCT03488316|Active Comparator|Calcium Hydroxide temporary filling material|Temporary filling with Ca(OH)2
16471479|NCT03488316|Active Comparator|MTA temporary filling material|Temporary filling with MTA
16471480|NCT03488303||Main group|Study has only one group
16471481|NCT03488290|Experimental|LTP Plus TF CBT|LTP Plus TF CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
16471482|NCT03488290|Other|Treatment as Usual|TAU group will receive routine care consisting of routine follow ups
16471483|NCT03488277|Experimental|LE: leg elevation group|the patients of this group will be positionned in supine with 15° left tilt and will have a leg elevation with a 30 cm pillow positionned under the heels. this position will be hold immediately after spinal anesthesia until fetal extraction
16471484|NCT03488277|No Intervention|CG: Control group|The patients of this group will be positiooned in supine with 15° left tlit after spinal anesthesia. no leg elevation
16471485|NCT03488264||United States|50 participants will be recruited from the United States.
16471486|NCT03488264||Jamaica|50 participants will be recruited from Jamaica.
16471487|NCT03488251|Experimental|MT-3724 10mcg/kg-GEMOX|MT-3724 10 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 10 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
16471488|NCT03488251|Experimental|MT-3724 25mcg/kg-GEMOX|MT-3724 25 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 25 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
16471489|NCT03488251|Experimental|MT-3724 50mcg/kg- GEMOX|MT-3724 50 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 50 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
16471490|NCT03488238|Experimental|ORi sensor|All subjects are enrolled in the test group and receive an ORi sensor during their scheduled, general surgery procedure
16471491|NCT03488225|Experimental|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
16471492|NCT03488212|Active Comparator|Basic Implementation Intervention|
16471493|NCT03488212|Experimental|Enhanced Implementation Intervention|
16471494|NCT03488212|Active Comparator|Online Treatment; Control Maintenance Intervention|
16471495|NCT03488212|Experimental|Online Treatment; Monthly Lessons & Feedback for Maintenance|
16471500|NCT03488186|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules of Takeda Pharmaceutical Company Limited, 30 mg
16471501|NCT03488173|Experimental|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
16471502|NCT03488173|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
16471503|NCT03488160|Experimental|Single arm|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:the first day,the second day Duration:total two times
16471504|NCT03488147|Experimental|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
16471505|NCT03488147|Active Comparator|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
16471506|NCT03488147|Placebo Comparator|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
16471507|NCT03488121|Experimental|Poster Only|This arm will only receive motivational posters.
16471508|NCT03488121|Experimental|Thank-you Letter Only|This arm will only receive thank-you letters.
16471509|NCT03488121|Experimental|Double Incentive|This arm will receive both motivational posters and thank-you letters.
16471510|NCT03488121|No Intervention|Control|This arm will not receive any intervention.
16471511|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
16471512|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
16471513|NCT03488095|Other|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
16471514|NCT03488095|No Intervention|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
16471515|NCT03488082|Experimental|Measurement of the bold signal|
16471516|NCT03488056|Experimental|Test - ICCMS|"The dentists will perform clinical examination on children following the ICCMS sequence:
~The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.
~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
16471517|NCT03488056|Active Comparator|Control - Standard care SESC|"The clinical sequence in this group will be:
~Caries Diagnosis Operative and non-operative treatments Indication of recall interval according to the dentist However, dentists will do that without a schematic guide to follow. They will do as they usually do in their practices."
16471518|NCT03488043||Retrospective cohort|All patients having a CT-guided transthoracic biopsy from September 2012 and September 2017.
16471519|NCT03488043||Prospective cohort|All patients having a CT-guided transthoracic biopsy from April 2018.
16471520|NCT03488030||All Participants|Participants diagnosed with moderate to severe UC or CD from the 7 participating sites will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years from the date of UC or CD diagnosis until Day 1 to assess the IBD treatments, medical history and comorbidities, treatment patterns and use of health resources.
16471521|NCT03488017|Experimental|Placebo Ocular Coil (left eye)|Left eye
16471522|NCT03488017|Experimental|Placebo Ocular Coil (right eye)|Right eye
16471523|NCT03487991|Experimental|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
16471524|NCT03487991|No Intervention|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
16471525|NCT03487978||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo 3-tesla resting-state functional MRI.
16471526|NCT03487978||Control|Normal controls without headaches will undergo 3-tesla resting-state functional MRI.
16471527|NCT03487965|Experimental|Low dose Polyphenol|130 mg of Aronia Extract with 120 mg of licorice root combination blend provided to subjects once per day for 16 weeks.
16471528|NCT03487965|Experimental|High dose Polyphenol|200 mg of Aronia extract provided to subjects once per day for 16 weeks
16471529|NCT03487965|Placebo Comparator|Placebo control|Inert tablet provided to subjects once per day for 16 weeks
16471530|NCT03487952||LDCT screening group|People receive questionnaire administration at baseline, then subsequent yearly chest LDCT scan and follow up.
16471531|NCT03487939|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
16471532|NCT03487926||Group 1 (IBD primary diagnosis)|Participants have active IBD
16471533|NCT03487926||Group 2( IBD + comorbid MDE)|1 [18F]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE
16471534|NCT03487926||Group 3-Controls|"Matched for Level of Depressive Symptoms and Otherwise Healthy
~-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available)."
16471535|NCT03487913|Experimental|High dose|Oral lixivaptan
16471536|NCT03487913|Experimental|Low dose|Oral lixivaptan
16471537|NCT03487900|Other|Clinical remission CD|
16471538|NCT03487874|Experimental|Interscalene block with C8 root block|The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
16471539|NCT03487874|Active Comparator|Conventional interscalene block|The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
16471540|NCT03487848|Experimental|Daclatasvir with Sofosbuvir|Specified dose on specified days for specified duration
16471541|NCT03487835|Experimental|Kinesiotape group|
16471542|NCT03487835|Experimental|Control group|
16471543|NCT03487822|Experimental|Path Pain|Path Pain participants will be receiving 8 weekly therapy session by license clinicians trained in the Path Pain intervention. They will also receive 4, 15-minute phone booster sessions, on a monthly basis after their final therapy session. They will also be invited to monthly group educational sessions. Both intervention and usual care participants will be receiving a pain educational booklet.
16471544|NCT03487822|No Intervention|Usual Care with Education|Usual Care with Education (UCE) will receive a pain educational booklet. Following completion of their 24 weeks in the study, they will also be invited to attend the monthly group educational sessions.
16471545|NCT03487822|No Intervention|Provider Feedback|Providers of patients in the study will take part in a short interview on their impressions of the intervention.
16471546|NCT03487809||NTUH|National Taiwan University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
16471547|NCT03487809||FJUH|Fu Jen University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
16471548|NCT03487809||CGH|Cathay General Hospital, all participants receive Alvesco (Ciclesonide, 160mcg/puff)
16471549|NCT03487796|Experimental|MySTYLE|MySTYLE is online, brief and encourages parent-adolescent communication about sex and HIV prevention. Participants (non-heterosexual Black adolescent males and parents/caregivers) will receive two texts per week (for eight weeks) with links to intervention content that includes video, games and graphics to improve knowledge, motivation and skills for HIV prevention. Topics include assertive communication, sexual safety, goal setting, and resilience.
16471550|NCT03487796|Other|Waitlist Control|Participants randomized to the waitlist control will be eligible to receive the eight-week MySTYLE intervention after the completion of the 4-month follow-up assessment. During their first four months of participation, waitlist control participants will not receive any intervention materials.
16471551|NCT03487783|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
16471552|NCT03487783|Placebo Comparator|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
16471553|NCT03487770|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
16471554|NCT03487770|Placebo Comparator|Placebo Oral Solution|2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
16471555|NCT03487757|Active Comparator|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
16471556|NCT03487757|Experimental|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
16471557|NCT03487744|Active Comparator|Promote without fiber|Lower osmolality enteral tube feed formulation
16471558|NCT03487744|Active Comparator|Osmolite 1.5|Higher osmolality enteral tube feed formulation
16471559|NCT03487731|Placebo Comparator|Group 1 - Placebo|Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.
16471560|NCT03487731|Experimental|Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.
16471561|NCT03487731|Experimental|Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.
16471562|NCT03487731|Placebo Comparator|Group B - Placebo|Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator.
16471563|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
16471564|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
16471565|NCT03487705|Other|child essential tremor|electromyogram with accelerometer
16471566|NCT03487692|Experimental|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
16471597|NCT03487484||No stoma|"Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.
~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied."
16471567|NCT03487692|Other|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
16471568|NCT03487679|Experimental|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
16471569|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
16471570|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
16471571|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
16471572|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
16471573|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
16471574|NCT03487627|Experimental|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
16471575|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
16471576|NCT03487614|Experimental|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
16471577|NCT03487614|No Intervention|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children <3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
16471578|NCT03487601|Active Comparator|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
16471579|NCT03487601|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
16471580|NCT03487588|Experimental|A-101 Topical Solution|Open Label Arm
16471582|NCT03487562|Experimental|Sequence 1|Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
16471583|NCT03487562|Experimental|Sequence 2|Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
16471584|NCT03487562|Experimental|Sequence 3|Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
16471585|NCT03487562|Experimental|Sequence 4|Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
16471586|NCT03487562|Experimental|A|Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
16471587|NCT03487562|Experimental|B|Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
16471588|NCT03487562|Experimental|C|Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
16471589|NCT03487549|Experimental|VP-102|Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.
16471590|NCT03487523|Active Comparator|Intervention 1|Text message (SMS Message)
16471591|NCT03487523|Active Comparator|Intervention 2|Text message (SMS Message)
16471592|NCT03487523|No Intervention|Intervention 3|no intervention
16471593|NCT03487510||NO groups|no groups apply.
16471594|NCT03487497||Patients|Patients who underwent lateral column lengthening osteotomy
16471595|NCT03487497||Healthy subjects|Healthy subjects without intervention
16471596|NCT03487484||With protective stoma|Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
16474357|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
16471598|NCT03487471|Active Comparator|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
16471599|NCT03487471|Active Comparator|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
16471600|NCT03487458|No Intervention|Control|participants receive no surgical treatment
16471601|NCT03487458|Experimental|Rib Fixation Surgery|participants receive surgical treatment
16471602|NCT03487445|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
16471603|NCT03487445|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
16471604|NCT03487432|Experimental|OPN NC|Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)
16471605|NCT03487432|Experimental|NSE Alpha|Patients receiving a Scoring PTCA Balloon (NSE Alpha)
16471606|NCT03487419||patients develop atrial fibrillation|patients post coronary artery bypass grafting who develop atrial fibrillation post operative
16471607|NCT03487419||patients who not develop atrial fibrillation|patients post coronary artery bypass grafting who don't develop atrial fibrillation post operative
16471608|NCT03487406|Placebo Comparator|Placebo Ticagrelor & placebo Aspirin|Placebo Ticagrelor 90 mg- one tablet, twice daily. Placebo Aspirin 75 mg- one tablet, once a day.
16471609|NCT03487406|Active Comparator|Aspirin & Placebo Ticagrelor|Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
16471610|NCT03487406|Active Comparator|Placebo Aspirin & Ticagrelor|Placebo Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
16471611|NCT03487406|Experimental|Aspirin & Ticagrelor|Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
16471612|NCT03487393|Experimental|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
16471613|NCT03487380|Experimental|Alzheimer with rapid DCR|
16471614|NCT03487380|Experimental|Alzheimer without rapid DCR|
16471615|NCT03487380|Sham Comparator|Control|
16471616|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
16471617|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
16471618|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
16471619|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
16471620|NCT03487354|Active Comparator|Single daily dose|
16471621|NCT03487354|Active Comparator|Multiple daily doses|
16471622|NCT03487341|Active Comparator|Cord drainage|
16471623|NCT03487341|Active Comparator|Cord clamping|
16471624|NCT03487328|Active Comparator|Modified technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
16471625|NCT03487328|Active Comparator|Conventional technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
16471626|NCT03487315|Experimental|specific IgE|Different level of specific IgE and immunoblot
16471627|NCT03487302||cCHD|
16471628|NCT03487302||CONTROLS|
16471629|NCT03487289|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
16471630|NCT03487289|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
16471631|NCT03487276|Placebo Comparator|Cohort 1|Placebo
16471632|NCT03487276|Experimental|Cohort 2|Minimum Dose IFX-1 (400 mg Q4W)
16471633|NCT03487276|Experimental|Cohort 3|Low dose IFX-1 (800 mg Q4W)
16471634|NCT03487276|Experimental|Cohort 4|Medium Dose IFX-1 (800 mg Q2W)
16471635|NCT03487276|Experimental|Cohort 5|High Dose IFX-1 (1200 mg Q2W)
16471636|NCT03487263|Experimental|IC14 dose level 1|For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses
16471637|NCT03487263|Experimental|IC14 dose level 2|For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4
16471638|NCT03487250||TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
16471639|NCT03487237|Experimental|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
16471640|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
16471641|NCT03487224||Healthy Controls|Adults without mental illness
16471642|NCT03487211|Active Comparator|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
16471643|NCT03487211|Experimental|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
16471644|NCT03487198|Experimental|Brexpiprazole|2-3 mg/day, once daily for 6 weeks, oral administration
16471645|NCT03487198|Placebo Comparator|Placebo|2-3 mg/day, once daily for 6 weeks, oral administration
16471646|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
16471647|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
16471648|NCT03487172|Other|Right Side Treated|Subjects will be randomized to have their right side treated with PLLA and their left side treated with normal saline.
16471649|NCT03487172|Other|Left Side Treated|Subjects will be randomized to have their left side treated with PLLA and their right side treated with normal saline.
16471650|NCT03487159|Other|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
16471651|NCT03487159|Other|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
16471652|NCT03487146|No Intervention|HD(hemodialysis) group|HD group as conventional control arm
16471653|NCT03487146|Active Comparator|HD+HP(hemodialysis+hemoperfusion) group|HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.
16471654|NCT03487133|Experimental|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
16471655|NCT03487120|No Intervention|lumbar laminectomy|
16471656|NCT03487120|Active Comparator|lumbar laminectomy with denervation of the facet joint|
16471657|NCT03487107|Experimental|SOF 400 mg+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.
16471658|NCT03487094|Active Comparator|Growth, Tolerance of Infants-Exp|Infant Formula
16471659|NCT03487094|Active Comparator|Growth,Tolerance of Infants-Com|Infant Formula
16471660|NCT03487081|Experimental|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
16471661|NCT03487081|Active Comparator|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
16471662|NCT03487068|Other|Patients with NAFLD|
16471663|NCT03487055|Experimental|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
16471664|NCT03487042|Experimental|Generalized vitiligo patients|"Each patient with generalized vitiligo will be subjected to the following:
~One side will be treated by narrow band ultraviolet rays sessions twice weekly for 3 months + topical bimatoprost 0.03% ophthalmic solution solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% ophthalmic solution twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months."
16471665|NCT03487029|Experimental|short duration group|30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
16471666|NCT03487029|Experimental|long duration group|4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
16471667|NCT03487016|Active Comparator|A: Gemcitabine/nab-Paclitaxel (Standard)|"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.
~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
16471668|NCT03487016|Experimental|B: NAPOLI regimen|"On Day 1 of a 14-day cycle:
~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)
~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
16471669|NCT03487016|Experimental|C: seq-NAPOLI-FOLFOX|"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.
~NAPOLI:
~On Day 1 of a 14-day cycle:
~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)
~mFOLFOX6:
~On Day 1 of a 14-day cycle:
~Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)
~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
16471670|NCT03487003|Active Comparator|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
16471671|NCT03487003|Experimental|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
16471672|NCT03486990|Experimental|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
16471673|NCT03486990|Experimental|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
16471674|NCT03486990|Experimental|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
16471675|NCT03486990|Experimental|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
16471676|NCT03486990|Experimental|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
16471677|NCT03486990|Experimental|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
16471678|NCT03486990|Experimental|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
16471679|NCT03486990|Experimental|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
16471680|NCT03486990|Experimental|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
16471681|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
16472026|NCT03484546||folicular|Women who will undergo endometrioma cystectomy in her follicular phase of menstrual period.
16471682|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.
~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
16471683|NCT03486964||DPP-4 plus other therapies|Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
16471684|NCT03486964||Other therapies|Patients in therapy with other hypoglycemic classes, such as sulphonylureas and/or biguanides and/or thiazolidinediones and/or insulin.
16471685|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
16471686|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
16471687|NCT03486925|Experimental|oxytocin group|
16471688|NCT03486925|Placebo Comparator|placebo group|
16471689|NCT03486912|Experimental|BMS-986036 Dose Level 1|
16471690|NCT03486912|Experimental|BMS-986036 Dose Level 2|
16471691|NCT03486912|Experimental|BMS-986036 Dose Level 3|
16471692|NCT03486912|Placebo Comparator|Placebo|
16471693|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
16471694|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
16471695|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
16471696|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection.
16471697|NCT03486886|Experimental|PSMA -PET/CT scanning|
16471703|NCT03486860|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
16471704|NCT03486860|Other|Waitlist Control|Untreated comparison group during the study, received parent psychoeducation intervention after the active treatment group.
16471705|NCT03486847|Experimental|Repetitive recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
16471706|NCT03486847|Active Comparator|One recruitment with PEEP|One alveolar recruitment at before surgery
16471707|NCT03486834|Experimental|V160 3-Dose Regimen|Participants will receive V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
16471708|NCT03486834|Experimental|V160 2-Dose Regimen|Participants will receive V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.
16471709|NCT03486834|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 3, and Month 6.
16471710|NCT03486821|Experimental|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.
~Each treatment should take about 10-20 minutes."
16471711|NCT03486808|Experimental|Dual stimulation|i) anodal stimulation of left inferior frontal cortex ii) anodal stimulation on left dorsolateral prefrontal cortex
16471712|NCT03486808|Active Comparator|IFG stimulation|anodal stimulation of left inferior frontal cortex
16471713|NCT03486808|Active Comparator|DLPFC stimulation|anodal stimulation on left dorsolateral prefrontal cortex
16471714|NCT03486808|Sham Comparator|Sham stimulation|sham stimulation
16471715|NCT03486795|Experimental|Dual stimulation|"anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
~anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area"
16471716|NCT03486795|Experimental|M1 stimulation|anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
16471717|NCT03486795|Experimental|PMC stimulation|anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
16471718|NCT03486795|Sham Comparator|Sham stimulation|Sham stimulation
16471719|NCT03486782|Active Comparator|Dual stimulation|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex and cathodal stimulation of contralesional supraorbital area
16471720|NCT03486782|Active Comparator|Single stimulation 1|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional inferior frontal cortex
16471721|NCT03486782|Active Comparator|Single stimulation 2|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area
16471722|NCT03486769|Experimental|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
16471723|NCT03486769|Experimental|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
16471724|NCT03486769|Experimental|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
16471725|NCT03486756|Experimental|Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
16471726|NCT03486743|Experimental|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
16471727|NCT03486743|No Intervention|Control arm|Participants in the intervention arm will only be asked to complete a survey.
16471728|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
16471729|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
16471730|NCT03486717|Experimental|Control|Study group that does not wear the virtual reality goggles. This group will serve as a control.
16471731|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
16471732|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
16471733|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
16471734|NCT03486704|Experimental|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
16471735|NCT03486704|Active Comparator|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
16471736|NCT03486691|Experimental|preoperative left lobe measurement|routine preoperative left lobe measurement
16471737|NCT03486691|Active Comparator|Control group|Control group without routine measurement of left lobe
16471739|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
16471740|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
16471741|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
16471742|NCT03486639||Patients undergoing urodynamic|All patients older than 18 who are refered for Urodynamics examination
16471743|NCT03486626|Experimental|Patients|
16471744|NCT03486613|Other|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
16471745|NCT03486613|Other|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
16471746|NCT03486600|Other|fluid resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
16471747|NCT03486587|Experimental|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
16471748|NCT03486574||Gastric cancer|Pathologically proven diseases after upper gastroendoscopy and biopsy. Previous pathological reports and endoscopic image can be used.
16471749|NCT03486574||non-gastric cnacer|Rull out gastric cancer by upper gastroendoscopy. The results 3 moths before enrollment is available.
16471750|NCT03486561|Other|Ranolazine|Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
16471751|NCT03486548|Sham Comparator|control group|adductor canal block with sham block
16471752|NCT03486548|Experimental|sciatic group|adductor canal block with popliteal sciatic nerve block
16472550|NCT03480893|Experimental|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
16471753|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
16471754|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
16471755|NCT03486509|Experimental|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
16471756|NCT03486496|Experimental|Gefitinib and Berberine|Experimental: Gefitinib and Berberine Patients will be treated with Gefitinib and Berberine. Gefitinib: 250 mg p.o., daily. Berberine: 50 mg p.o., tid.
16471757|NCT03486483|Experimental|Supervised Slackline Training|Supervised Slackline training in children and teenagers with spastic cerebral palsy (grade I and II of the Gross Motor Function Classification System). Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
16471758|NCT03486483|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine.
16471759|NCT03486457|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
16471760|NCT03486457|Placebo Comparator|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
16471761|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
16471762|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
16471763|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
16471764|NCT03486431|Experimental|Level I|5 x 7 Gy SABR
16471765|NCT03486431|Experimental|Level II|3 x 10 Gy SABR
16471766|NCT03486431|Experimental|Level III|1 x 20 Gy SABR
16471767|NCT03486405|Experimental|Intervention group|The experimental group will have no in person education by researchers. All education and running modification will be performed via video. Education on running form, a home exercise program, and a 4 week return to run program will be provided to the subjects through e-mail. They will also receive the same in person video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
16471768|NCT03486405|Active Comparator|Control group|This group will have the same 4 week return to run program, home exercise program, and video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
16471769|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
16471770|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
16471771|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
16471772|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
16471773|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
16471774|NCT03486366|Other|Workpackage1 WP1|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.
16471775|NCT03486366|Other|Workpackage2 WP2|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach criteria: Roach 1998) and epilepsy, aged up to 16 years, seizure free, in whom a decision to withdraw antiepileptic drugs was made. We plan to enroll 60 TSC patients into WP2 to Epimarker in 12 months. The data obtained in children seizure free at the end of follow-up and patients with recurrent seizures will be compare.
16471776|NCT03486353|Experimental|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
16471777|NCT03486353|Experimental|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
16471778|NCT03486340|Experimental|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
16471779|NCT03486340|No Intervention|Standard treatment|Standard chemotherapeutic treatment
16471780|NCT03486327|Experimental|0.03mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
16471781|NCT03486327|Experimental|0.05mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
16471782|NCT03486327|Experimental|0.08mL/kg Dose Group|A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
16471783|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
16471784|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 intravenously in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin +paclitaxel 175 mg/m^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
16471785|NCT03486301|Experimental|Single Agent BDB001|"A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.
~Then dosage escalation will follow a traditional 3+3 dose escalation design.
~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached."
16471786|NCT03486301|Experimental|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.
~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
16471787|NCT03486288||Delirium|
16471788|NCT03486288||No Delirium|
16471789|NCT03486275|Active Comparator|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
16471790|NCT03486275|Active Comparator|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
16471791|NCT03486262||Lung carcinoma on IPF|Lung carcinoma on IPF
16471792|NCT03486249|Experimental|Patient difficult to wean|Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.
16471793|NCT03486236|Experimental|Cohort C1|
16471794|NCT03486236|Placebo Comparator|Cohort C1: Triple Placebo|
16471795|NCT03486236|Experimental|Cohort C2|
16471796|NCT03486236|Placebo Comparator|Cohort C2: Triple Placebo|
16471797|NCT03486223|Experimental|Placebo, GSK2256294|Subjects will receive placebo oral capsule daily by mouth for 7 days, then seven week washout and then GSK2256294 daily by mouth for 7 days.
16471798|NCT03486223|Experimental|GSK2256294, Placebo|Subjects will receive GSK2256294 daily by mouth for 7 days, then seven week washout and then placebo oral capsule daily by mouth for 7 days.
16471799|NCT03486223|Other|Genotype only, no study medication|New participants will receive genotyping only, no study medication
16471800|NCT03486210||Phase 1 Group 1|Healthy volunteers
16471801|NCT03486210||Phase 1 Group 2|Health professionals
16471802|NCT03486210||Phase 2 Group 1|Control group : patients obese without surgery
16471803|NCT03486210||Phase 2 Group 2|Patients who have underwent a sleeve gastrectomy
16471804|NCT03486210||Phase 2 Group 3|Patients who have underwent a gastric bypass
16471805|NCT03486197|Experimental|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
16471806|NCT03486158|Experimental|CalproSmart application|In addition to regular outpatient clinic visits and a routine CalproSmart test every 3 months, patients are instructed to obtain fecal samples if they experience symptoms suspect of recurrent IBD and to perform home analysis with CalproSmart™ system test kit
16471807|NCT03486158|No Intervention|Standard follow-up|In addition to regular outpatient clinic visits and a routine calprotectin test in the same week as the visit date, patients bring home an Fecal-calprotectin tube and envelope and are instructed to obtain fecal samples and send these to local lab if they experience symptoms suspect of recurrent IBD
16471808|NCT03486145|Experimental|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
16471809|NCT03486145|Placebo Comparator|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained <0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
16471810|NCT03486132|Other|interrupted repair of mediolateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.
~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut"
16471837|NCT03485937|Experimental|Pre-Operative Videos + verbal/written instructions|This video contains the same instructions that the patient receives when they arrive at the clinic, as well as a video walk through of the clinic/patient room. Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions.
16471811|NCT03486132|Other|continous repair of mediolateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
16471812|NCT03486132|Other|interrupted repair of lateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.
~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity"
16471813|NCT03486132|Other|continuous repair of lateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
16471814|NCT03486106|Placebo Comparator|Headphones without music|Participants in the control group will receive noise-cancelling wireless headphones that will not play any noise throughout the procedure. They will also receive propofol for sedation as needed.
16471815|NCT03486106|Experimental|Headphones with music|Participants in the experimental group will receive the same noise-cancelling wireless headphones but will be permitted to listen to the music of their choice while in the operating room. They will also receive propofol for sedation as needed.
16471816|NCT03486093|Experimental|CVC managed by healthcare workers|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.
16471817|NCT03486093|Experimental|CVC managed by healthcare workers plus port protector|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices.
16471818|NCT03486080|Active Comparator|Dutogliptin/filgrastim combination|Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
16471819|NCT03486080|Placebo Comparator|Placebo control|Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
16471820|NCT03486067|Experimental|Administration of CC-93269|CC-93269 will be administered to each patient on a 28-day cycle
16471821|NCT03486054|Experimental|Experimental Arm A|Whole blood treated with amustaline and glutathione, a pathogen reduction technology (PRT), ordered and administered to study patients by their treating physicians
16471822|NCT03486054|Active Comparator|Control Arm B|Standard of Care (either red blood cells or whole blood)
16471823|NCT03486041|Experimental|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
16471824|NCT03486041|Placebo Comparator|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB [as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model].
16471825|NCT03486028||ASAM Counties/non-computerized|Pre- and 1115-waived counties that are implementing the ASAM. Intervention is adherence to ASAM protocols.
16471826|NCT03486028||ASAM Counties/computerized|Counties using a computerized system to assist in intervention determination according to ASAM protocols. Intervention is adherence to ASAM protocols.
16471827|NCT03486028||Non-ASAM Counties|"Pre- and non-waived control counties that are not implementing the ASAM. Intervention is non-adherence to ASAM protocols."
16471828|NCT03486015|Experimental|30% glucose|This group will be given 2 ml of 30% glucose in the mouth before the physical examination of the infant.
16471829|NCT03486015|Placebo Comparator|Sterile water|This group will be given 2 ml of sterile water in the mouth before the physical examination of the infant.
16471830|NCT03486002|Other|Cleansweep closed suction system|
16471831|NCT03486002|Other|Halyard closed suction system|
16471832|NCT03485989|Experimental|Hazelnuts|Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
16471833|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
16471834|NCT03485963|Experimental|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
16471835|NCT03485950|Experimental|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
16471836|NCT03485950|Active Comparator|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
16471838|NCT03485937|Active Comparator|verbal/written instructions|This arm will receive the standard-of-care verbal/written instructions and the pre-operative video explanation. These instructions contain the same content as in the pre-operative videos
16471839|NCT03485924|Active Comparator|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
16471840|NCT03485924|Active Comparator|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
16471841|NCT03485911|Experimental|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
16471842|NCT03485911|Experimental|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
16471843|NCT03485911|Placebo Comparator|Placebo|Matching placebo administered as oral capsules once daily
16471844|NCT03485885||Maqui Berry Extract (MBE)|To be tested for the extracts bioavailability
16471845|NCT03485872|Experimental|Self-Screening and Referral Information|The intervention will include a combination of self-screening and UI specific information and resources. Older adults in the intervention group will complete a gender specific UI Self-Screening tool. Men will complete the International Consultation on Incontinence Modular Questionnaire (ICIQ) for Males and women will complete the ICIQ for Females. In addition, the intervention group will receive a fact sheet with UI specific information, contact information to the local incontinence clinic and a link to a website with patient incontinence resources and education.
16471846|NCT03485872|Active Comparator|Control Group|Older adults assigned to the control group will receive standard care from their physicians. Standard care may differ from general practitioner to general practitioner. Usual care for urinary incontinence (UI) from general practitioners is generally minimal. Most patients do not tell their physicians about UI, and most physicians do not ask about UI. If this topic does come up during a GP appointment, a patient may be offered no treatment, lifestyle advice (e.g., do not drink before bed), told to do Kegels (but likely not instructed how to do these properly) or in some cases, offered pharmacological therapies (which will be captured in our questionnaire with the participants). But standard of care is unfortunately very often no care.
16471847|NCT03485859|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
16471848|NCT03485859|Placebo Comparator|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
16471849|NCT03485846|Experimental|Narlaprevir + Ritonavir + Daclatasvir|All of enrolled patients receive equal study therapy with Narlaprevir/Ritonavir/Daclatasvir daily for 12 weeks
16471850|NCT03485833|Experimental|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
16471851|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
16471852|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
16471853|NCT03485807|Experimental|Mindfulness Training (MT)|
16471854|NCT03485807|Experimental|Active Coping Training (CT)|
16471855|NCT03485794||Diagnostic (biospecimen collection)|Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.
16471856|NCT03485768|Experimental|percutaneous disc decompression with coblation nucleoplasty|PDCN will be performed in patients who are allocated to this group by using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA)
16471857|NCT03485768|Active Comparator|Manual Therapy|Participants who are allocated to this group will undergo manual therapy treatments containing two kinds: sustained natural apophyseal glides (SNAGs) plus passive joint mobilisations (PJMs)
16471858|NCT03485755||Children|Children 8-10 years of age
16471859|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
16471860|NCT03485729|Experimental|Biopsy-mandated|
16471861|NCT03485729|Experimental|Biopsy-optional|
16471862|NCT03485729|Experimental|Dosing twice per week on two consecutive days|
16471863|NCT03485716|Experimental|running under hypoxia - first|running under hypoxia (first day) and normoxia (second day)
16471864|NCT03485716|Active Comparator|running under normoxia - first|running under normoxia (first day) and hypoxia (second day)
16471865|NCT03485703|Experimental|azithromycin group|A control group composed of 40 newborns receiving azithromycin
16471866|NCT03485703|Placebo Comparator|placebo group|comparative group composed of 40 newborns who would receive saline 0.9%
16471867|NCT03485690||COPD|COPD patients with no restrictions. The study protocol does not consider ad-hoc different patient groups. Prospective follow-up will be equally done in all recruited patients
16471868|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.
~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.
~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
16471869|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for two years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
16471870|NCT03485664||Study Group|Severe pain on percussion of the relevant tooth was considered as basic criteria when deciding on acute infection phase. The acutely infected teeth were labelled as the study group
16471871|NCT03485664||Control Group|The asymptomatic teeth were labelled as the control group
16471872|NCT03485638||Cetuximab administration|
16471873|NCT03485625|Experimental|Lidocaine|Patients in group C will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
16471874|NCT03485625|Experimental|Lidocaine+ Ketorolac|Patients in group K receive 3 mg/kg of lidocaine 2% + 20 mg ketorolac diluted with saline to a total volume of 40 ml.
16471875|NCT03485625|Experimental|Lidocaine+Paracetamol|Patients in group P will receive 3 mg/kg of lidocaine 2% + 300 mg paracetamol diluted with saline to a total volume of 40 ml.
16471876|NCT03485612||change of the optic nerve sheath diameter|The test group will be male and female patients, aged over 18 and below 90 years of age. Each patient will be operated for urological reasons in the position for lithotomy.
16471877|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
16471878|NCT03485586||Group:Traditional ultrasonic biological|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use traditional ultrasonic biological combined with cornea curvimeter to measure the ocular parameter.
16471879|NCT03485586||Group:Lenstar|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use lenstar to measure the ocular parameter.
16471880|NCT03485560|Experimental|internvention of Chrinic skin conditions|All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
16471881|NCT03485547|Experimental|Venetoclax|"Venetoclax is administered on a daily basis orally.
~The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax."
16471882|NCT03485534|Experimental|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
16471883|NCT03485534|Placebo Comparator|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
16471884|NCT03485521|Active Comparator|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
16471885|NCT03485521|Experimental|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
16471886|NCT03485495|Experimental|Divaza|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
16471887|NCT03485495|Placebo Comparator|Placebo|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
16471888|NCT03485482|Experimental|Group Ivabradine|six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
16471889|NCT03485482|Experimental|Group Bisoprolol|six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
16471890|NCT03485482|Experimental|Group combination|six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
16471891|NCT03485469|Other|Usual Care|The control group will benefit from a standard care dietary consultation in the service and 9 dietary consultations by phone every 15 days.
16471892|NCT03485469|Other|Hypnosis|The experimental group will benefit from a dietary consultation in the service, 9 dietary consultations by telephone every 15 days to which will be associated 7 individual sessions of hypnosis and 3 individual sessions of learning to autohypnosis. A recording containing the induction of a self-hypnosis session will be given to the subject at the end of the 10 sessions, in order to promote the continuation of home-made autohypnosis.
16471893|NCT03485456|Experimental|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
16471894|NCT03485443|Active Comparator|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.
~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
16471895|NCT03485443|Active Comparator|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.
~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
16471896|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
16471897|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
16471898|NCT03485417|Active Comparator|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
16471899|NCT03485417|Active Comparator|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
16471900|NCT03485417|Other|Treatment as Usual Arm|Treatment as Usual arm
16471901|NCT03485404|Experimental|VB12+FA|Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
16471902|NCT03485404|Placebo Comparator|Placebo|Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
16471903|NCT03485404|Other|Non-surgical controls|Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.
16471904|NCT03485391|Experimental|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
16471905|NCT03485391|Active Comparator|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
16471906|NCT03485378|Experimental|Treatment Arm: Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
16471907|NCT03485365|Experimental|Part A: Cohort 1: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
16471908|NCT03485365|Experimental|Part A: Cohort 2: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
16471909|NCT03485365|Experimental|Part A: Cohort 3: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
16471910|NCT03485365|Experimental|Part A: Cohort 4: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
16471911|NCT03485365|Experimental|Part A: Cohort 5: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
16471912|NCT03485365|Experimental|Part A: Cohort 6: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
16471913|NCT03485365|Placebo Comparator|Part A: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.
16471914|NCT03485365|Experimental|Part B: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
16471915|NCT03485365|Placebo Comparator|Part B: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC route.
16471916|NCT03485352||Bariatric Surgery patients|Patients attending a private clinic specialized in the treatment of obesity and bariatric surgery. Patients to be analyzed should have a medical indication for bariatric surgery.
16471917|NCT03485339||Case|Ketamine user with psychotic disorders
16471918|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
16471919|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
16471920|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
16471922|NCT03485300||Patients with chronic liver or kidney diseases|"Patients with chronic liver diseases may affect warfarin therapeutic outcome as liver is the site of metabolism of the drug by cytochrome p 450 enzymes so it decrease warfarin absorption
~Kidney diseases also affect the clearance of the drug these patients will undergo liver function tests and kidney function tests"
16471923|NCT03485300||Non compliance of the patient|Missed dose of the warfarin or intermittent drug intake may affect drug therapeutic outcome as well as changing time of drug administration during the day
16471924|NCT03485300||Drugs or food interactions|Administration of other drugs beside warfarin may affect its therapeutic outcome either by inhibition or synergism certain food may also interfere with warfarin especially vitamin k and c rich food so patients will be followed up for drug or food interactions
16471925|NCT03485287|Experimental|MDMA and Psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
16471926|NCT03485274|Active Comparator|Vortioxetine Arm|Oral: 5-20mg daily
16471927|NCT03485274|Active Comparator|Treatment as Usual|Any medication or Rx other than vortixoetine
16471928|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR <15ml/min/1.7m2 )
16471929|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
16471930|NCT03485248|Active Comparator|Beetroot juice|Beetroot Juice cotaining on average 9mmol of nitrate per dose
16471931|NCT03485248|Placebo Comparator|Placebo beet juice (Nitrate depleted)|Beetroot juice nitrate depleted
16471932|NCT03485235|Experimental|D&C|
16471933|NCT03485235|Other|No D&C|
16471934|NCT03485222|Experimental|Empagliflozin|10mg once a day
16471935|NCT03485222|Placebo Comparator|Placebos|placebo once a day
16471939|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When two antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
16471940|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status. When one antibodies show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite unstable low (MSI-L).
16471941|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
16471978|NCT03484936|Placebo Comparator|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
16471942|NCT03485183|Experimental|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
16471943|NCT03485183|Other|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
16471944|NCT03485170|Other|PET|Hemophilia patients receive PET evaluation
16471945|NCT03485157|Experimental|Micronized dHACM|Injection of micronized dHACM
16471946|NCT03485157|Placebo Comparator|Saline|Injection of 0.9% Sodium Chloride Injection, USP
16471947|NCT03485144|Experimental|TV003|Live Attenuated Virus Vaccine-TetraVax-DV
16471948|NCT03485144|Placebo Comparator|Placebo for TV003|Placebo
16471949|NCT03485131|Experimental|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
16471950|NCT03485131|Sham Comparator|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
16471951|NCT03485118|Experimental|HS006+Chemotherapy|"Participants received six 21-day cycles of HS006(375 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
~Participants received six 21-day cycles of HS006(500 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles)."
16471952|NCT03485118|Active Comparator|Rituxan+Chemotherapy|Participants received six 21-day cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
16471953|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
16471954|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
16471955|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
16471956|NCT03485092|Active Comparator|Empagliflozin|Empagliflozin 10mg tablets for oral self-administration once daily
16471957|NCT03485092|Placebo Comparator|Placebo Oral Tablet|placebo tablets for oral self-administration once daily
16471958|NCT03485066|Experimental|Training|20 healthy participants, 4 week training of a challenging cognitive task (Tetris) between PET/MR measurements
16471959|NCT03485066|No Intervention|Control|20 healthy participants, no training between PET/MR measurements
16471961|NCT03485027|Experimental|XELOX regimen|oxaliplatin 130mg/m2，intravenous，on Day1 capecitabine 1000mg/m2，oral，bid，on Day1-14 every three weeks
16471962|NCT03485027|Experimental|FOLFOX regimen|oxaliplatin 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
16471963|NCT03485027|Experimental|FOLFIRI regimen|irinotecan 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
16471964|NCT03485027|Experimental|IRI regimen|irinotecan single agent 180mg/m2，intravenous，on Day1 every two weeks
16471965|NCT03485014|Experimental|Experimental: EXPAREL 4 mg/kg|Single dose of EXPAREL 4 mg/kg
16471966|NCT03485001|Sham Comparator|Sham of Argon Laser Treatment|Slit lamp light exposure
16471967|NCT03485001|Experimental|Argon Laser Treatment|Argon Laser Treatment
16471968|NCT03484988|Placebo Comparator|Placebo oil|Ingredients: Corn oil, 500mg per capsule
16471969|NCT03484988|Experimental|Echium oil|Ingredients: Echium oil,500mg per capsule
16471970|NCT03484988|Experimental|Mixed oil|Ingredients:Mixed oil(Echium oil,camelina oil,safflower oil) 500mg per capsule
16471971|NCT03484975|Other|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
16471972|NCT03484962|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
16471973|NCT03484962|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
16471974|NCT03484962|No Intervention|No intervention|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16471975|NCT03484949|Experimental|pre-endoscopic screening risk assessment|
16471976|NCT03484949|No Intervention|routine screening|
16471977|NCT03484936|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
16471979|NCT03484923|Experimental|Arm 1: LAG525 + Spartalizumab in unselected patients|Spartalizumab and LAG525 will be administered intravenously
16471980|NCT03484923|Experimental|Arm 2: Capmatinib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Capmatinib will be administered orally.
16471981|NCT03484923|Experimental|Arm 3: Canakinumab+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously.
16471982|NCT03484923|Experimental|Arm 4: Ribociclib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Ribociclib will be administered orally.
16471983|NCT03484923|Experimental|Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients|Spartalizumab and LAG525 will be administered intravenously
16471984|NCT03484910|Experimental|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
16471985|NCT03484910|Active Comparator|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
16471986|NCT03484897|Experimental|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
16471987|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
16471988|NCT03484858|Other|High glycaemic index meal and exercise|
16471989|NCT03484858|Other|High glycaemic index meal and rest|
16471990|NCT03484858|Other|Low glycaemic index meal and exercise|
16471991|NCT03484858|Other|Low glycaemic index meal and rest|
16471992|NCT03484845|Active Comparator|Oral lactoferrin|women who take oral lactoferrin sachets 100 mg twice daily for one month.
16471993|NCT03484845|Active Comparator|Oral ferrous fumarate|women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month.
16471994|NCT03484845|Active Comparator|Combined lactoferrin & ferrous fumarate|women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month.
16471995|NCT03484832|Experimental|Spray group|Using Walter Ritter Ethyl Chloride Spray and placebo cream
16471996|NCT03484832|Experimental|EMLA group|Using EMLA cream and placebo spray
16471997|NCT03484832|Placebo Comparator|Placebo group|Using placebo cream and placebo spray
16471998|NCT03484819|Experimental|Treatment (copanlisib hydrochloride, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16471999|NCT03484793|Experimental|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
16472000|NCT03484793|No Intervention|Non AESOP|19 were assigned to the traditional CPOE system
16472001|NCT03484780|Experimental|VisONE ADS|Patients implanted with a VisONE stimulator and leads for receiving continual Synchronized Diaphragmatic Stimulation
16472002|NCT03484767||Methylmalonic Acidemia Participants|Individuals with isolated MMA (mut0 and mut-)
16472003|NCT03484767||Propionic Acidemia Participants|Individuals with isolated PA
16472004|NCT03484754|Experimental|corrugator|single injection of 10 Units of botulinum toxina in the corrugator and procerus
16472005|NCT03484754|Active Comparator|orbicularis oculi|single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)
16472006|NCT03484741|Experimental|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
16472007|NCT03484728|Placebo Comparator|High-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
16472008|NCT03484728|Other|Low-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
16472009|NCT03484715|Experimental|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
16472010|NCT03484715|No Intervention|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
16472011|NCT03484702|Experimental|Administration of JCAR017|JCAR017 will be infused at a dose of 100 x 10^6 JCAR017-positive transfected viable T cells (50 × 10^6 CD8+ CAR+ T cells and 50 × 10^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of lymphodepleting chemotherapy (LD) chemotherapy)
16472012|NCT03484689|Other|MBCT arm|8-week MBCT program
16472013|NCT03484676|Other|Unilateral Non comminuted zygomatic complex fracture|Patient undergo treatment no control group
16472014|NCT03484663|Experimental|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
16472015|NCT03484663|No Intervention|Chest tube only after uniport vats|After uniport vats we put chest tube only
16472016|NCT03484650|Placebo Comparator|Control|Patients will receive standard care plus infusion of placebo
16472017|NCT03484650|Experimental|Lidocaine|Patients will receive lidocaine infusions peri-operatively
16472018|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
16472019|NCT03484624|Experimental|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
16472020|NCT03484611|Active Comparator|AMH < 0.3 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH < 0,3 ng/ml
16472021|NCT03484611|Active Comparator|AMH 0.3 to 0.7 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
16472022|NCT03484611|Active Comparator|AMH > 0.7 to 1 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
16472023|NCT03484598|Experimental|SPEAC Treatment Arm|All study participants will be provided with a SPEAC System to use in their home environment.
16472027|NCT03484546||ovulatory|Women who will undergo endometrioma cystectomy in her ovulatory phase (12-14th day of mestrual period cycle for women regular period) of menstrual cycle.
16472028|NCT03484546||luteal|Women who will undergo endometrioma cystectomy in her luteal phase of menstrual period.
16472029|NCT03484533|Active Comparator|HIV Self-test kit|
16472030|NCT03484533|Active Comparator|Invitation letter-standard of care|
16472031|NCT03484520|Experimental|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
16472032|NCT03484507|Active Comparator|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
16472033|NCT03484507|Experimental|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
16472034|NCT03484507|Experimental|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
16472035|NCT03484507|Experimental|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
16472036|NCT03484507|Placebo Comparator|Placebo|Artificial tears for weeks 4-11
16472037|NCT03484494|Other|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
16472038|NCT03484494|Other|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
16472039|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
16472040|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
16472041|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
16472042|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
16472043|NCT03484468||femtosecond_laser|participants had there lasik corneal flap creation using femtosecond laser
16472044|NCT03484468||moria_microkeratome|participants had there lasik corneal flap creation using moria microkeratome
16472045|NCT03484455|Experimental|Hypothermic Machine Perfusion|Hypothermic Machine Perfusion with Organ Recovery Systems LLT system
16472046|NCT03484455|Active Comparator|Static Cold Storage|Standard of Care - Static Cold Storage
16472047|NCT03484429|Experimental|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
16472048|NCT03484429|Active Comparator|Group 2|Standard medical therapy only
16472049|NCT03484416|Active Comparator|Routine calcium|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day
16472050|NCT03484416|No Intervention|control|Patients in the control group did not receive calcium or cholecalciferol for 2 weeks
16472051|NCT03484403|Active Comparator|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
16472052|NCT03484403|Experimental|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
16472053|NCT03484390|Experimental|Mindfulness-based stress reduction|The MBSR program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
16472054|NCT03484390|Active Comparator|Wellness Group|The Wellness control group uses a health education manual that provides information on various aspects of health, including diet, physical activity, sleep, stress management, and communication. The manual is used during weekly check-in phone calls for an 8-week period.
16472055|NCT03484377|Experimental|Anodal tDCS|The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
16472056|NCT03484377|Sham Comparator|Sham tDCS|The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
16472057|NCT03484364|Experimental|Intervention Group|The ENACTS intervention is eight weeks of peer-facilitated educational classes about hypertension self-management and autonomous support from family or friend enrolled as support person.
16472058|NCT03484364|No Intervention|Waitlist Group|Usual care and $30 in groceries each week for 8 weeks.
16472059|NCT03484351|Experimental|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
16472060|NCT03484338|Experimental|Intervention|
16472061|NCT03484338|Active Comparator|Wait list controlled|
16472062|NCT03484299|Other|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
16472063|NCT03484286|Other|Control group|Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.
16472064|NCT03484286|Experimental|Intervention group|Device: OPTILOGG
16472069|NCT03484260||Case group: Testosterone Product|Male subjects prescribed testosterone in UK
16472070|NCT03484260||Control group|Matched male subjects not prescribed testosterone in the UK
16472551|NCT03480893|Active Comparator|Laminectomy|Patients will undergo laminectomy
16472071|NCT03484247|Active Comparator|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
16472072|NCT03484247|Active Comparator|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
16472073|NCT03484234|Experimental|Ultimaster stent|
16472074|NCT03484234|Active Comparator|Xience alpine stent|
16472075|NCT03484221|Experimental|FOLFOXIRI+short-course radiation+XELOX|Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
16472076|NCT03484195|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
16472077|NCT03484182|Active Comparator|Standard Home Exercise Program|
16472078|NCT03484182|Experimental|Web-based Home Exercise Program|
16472079|NCT03484169|No Intervention|Control group|No intervention
16472080|NCT03484169|Experimental|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:
~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
16472081|NCT03484156|Experimental|Volunteers|"The Installation of 3PEGASE Sensor in elders volunteers to monitor clinical indicators at home.The instrument is for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home.
~The volunteers will have 70 years old or more, living alone at home, frail of disable (ADL> or =3) and able to walk by themselves."
16472084|NCT03484130||High-Risk Normotensives|These high-risk normotensives are considered to be enriched for subclinical autonomous aldosterone secretion and have a high risk for developing incident hypertension
16472085|NCT03484117|No Intervention|Treatment as Usual|Participants in this arm will receive bilingual written materials on healthy living with HIV at the baseline visit. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants.
16472086|NCT03484117|Experimental|Community Health Worker|Participants in the intervention arm will receive 5 one-on-one sessions over 24 weeks with a Spanish-speaking CHW. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants
16472087|NCT03484104||Hypothermic circulatory arrest|Patients undergoing cardiac surgery with hypothermic circulatory arrest and selective antegrade cerebral perfusion
16472088|NCT03484091|Experimental|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
16472089|NCT03484091|Active Comparator|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
16472090|NCT03484091|Placebo Comparator|N group|Single dose of normal saline 6 mL intra-articular knee injection.
16472091|NCT03484078|Experimental|Vibration Platform|The vibration group will stand on a platform that emits a mild vibration 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
16472092|NCT03484078|Placebo Comparator|Placebo Platform|The placebo group will stand on a placebo platform 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
16472093|NCT03484065||Afibrinogenemia|
16472094|NCT03484052|Other|Jugular ultrasound|
16472095|NCT03484039|Experimental|Epilepsy Patients|The group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
16472096|NCT03484026|Experimental|BioFe Medical Food|Consumption of BioFe Medical Food in a single cohort of up to 8 female subjects with iron deficiency.
16472097|NCT03484000|Experimental|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
16472098|NCT03484000|Other|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
16472099|NCT03483987|Experimental|Sof+Ledi+R arm|"Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination
~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks
~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks
~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
16472100|NCT03483987|Experimental|Sof+Ledi+R+Peg-IFN arm|Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
16472101|NCT03483987|Experimental|Sof+Dacla+R arm|"Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin
~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks
~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks
~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
16472481|NCT03481374|Active Comparator|subjects with Type 1 Diabetes mellitus|Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
16472102|NCT03483987|Experimental|Sof+Dacla+R+Peg-IFN arm|Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
16472103|NCT03483987|Experimental|Sof+Velpa+R arm|"Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination
~who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or
~who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon"
16472104|NCT03483987|Experimental|Sof+Velpa+R+Peg-IFN arm|Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination
16472105|NCT03483974||neoplasm|neoplasm found in follow up
16472106|NCT03483974||non-neoplasm|non-neoplasm patients in follow up
16472107|NCT03483961|Experimental|Group 1: 20 mcg/unadjuvant (Day 1 & 29)|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
16472108|NCT03483961|Experimental|Group 2: 6 mcg/adjuvant (Day 1 & 29)|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
16472109|NCT03483961|Experimental|Group 3: 10 mcg/adjuvant (Day 1 & 29)|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
16472110|NCT03483961|Experimental|Group 4: 20mcg/adjuvant(Day 1 & 29);40mcg/adjuvant (Day 547)|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
16472111|NCT03483961|Experimental|Group 5: 6 mcg/adjuvant (Day 15 & 29)|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
16472112|NCT03483961|Experimental|Group 6: 10 mcg/adjuvant (Day 15 & 29)|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
16472113|NCT03483961|Experimental|Group 7: 20 mcg/adjuvant (Day 15 & 29)|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
16472114|NCT03483961|Experimental|Group 8: 40 mcg/adjuvant (Day 29)|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
16472115|NCT03483961|Experimental|Group 9: 20 mcg/adjuvant (Day 1 & 29)|20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
16472116|NCT03483961|Experimental|Group 10: 40 mcg/adjuvant (Day 1)|40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
16472117|NCT03483948|Experimental|HMPL-523 & Azacitidine|HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
16472118|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
16472119|NCT03483935|No Intervention|Control|No treatment will be given.
16472120|NCT03483922||chronic hepatitis B|This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline.
16472121|NCT03483922||HCC Cases|"This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma.
~HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"
16472122|NCT03483922||Healthy|This group will include 50 healthy sex and age matched controls.
16472123|NCT03483909|Experimental|left IFG iTBS|intermittent theta burst stimulation over the left inferior frontal gyrus
16472124|NCT03483909|Active Comparator|right IPL cTBS|continuous theta burst stimulation over the right inferior parietal cortex
16472125|NCT03483909|Placebo Comparator|placebo|Placebo TMS stimulation over the left inferior parietal cortex
16472126|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
16472127|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
16472128|NCT03483883|Experimental|Single Arm|
16472129|NCT03483870|Placebo Comparator|Morphine sulphate & Placebo|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of normal saline 0.9% (placebo) IV injection preoperative.
16472130|NCT03483870|Active Comparator|Morphine sulphate & Granisetron|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of 2 mg granisetron IV injection preoperative.
16472131|NCT03483857|Experimental|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
16472235|NCT03483129|No Intervention|Control|All participants will receive an information leaflet detailing pre-diabetes, the associated risks and steps that can be taken to avoid developing diabetes.
16472132|NCT03483857|No Intervention|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
16472133|NCT03483831|Experimental|Intervention group|Students of 5 secondary school classes aged 12-14
16472134|NCT03483831|No Intervention|Control group|Students of 5 secondary school classes aged 12-14
16472135|NCT03483818|Active Comparator|Pharmacist-Led Pathway|Assessment & Treatment of HCV infection with oral antivirals in a community pharmacy pathway
16472136|NCT03483818|Active Comparator|Conventional Care Pathway|Assessment & Treatment of HCV infection with oral antivirals in a conventional care pathway
16472137|NCT03483805|Experimental|Treatment|Protalsafe product, daily, 12 weeks
16472138|NCT03483805|Placebo Comparator|Placebo|Placebo product, daily, 12 weeks
16472139|NCT03483792||PCOS group|
16472140|NCT03483792||Control group|
16472141|NCT03483779|Experimental|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
16472142|NCT03483779|Placebo Comparator|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
16472143|NCT03483766|No Intervention|Baseline before robotic functional rehabilitation|Baseline spinal cord MRI scan
16472144|NCT03483766|Experimental|post rehabilitation|Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
16472145|NCT03483753|Experimental|Vasopressin group|Blinded vasopressin
16472146|NCT03483753|Active Comparator|Norepinephrine group|Blinded norepinephrine
16472147|NCT03483740|Experimental|Cognitive remediation group therapy|8 weekly 3-hour sessions of CRGT
16472148|NCT03483740|Active Comparator|Mutual aid support group|8 weekly 3-hour sessions of HIV group therapy
16472149|NCT03483727|Experimental|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
16472150|NCT03483727|Experimental|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
16472151|NCT03483714||Healthy Participants|Spinal manipulation
16472152|NCT03483714||Acute Low back pain participants|Spinal Manipulation
16472153|NCT03483714||Chronic low back pain participants|Spinal Manipulation
16472154|NCT03483701|Experimental|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
16472155|NCT03483701|No Intervention|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
16472156|NCT03483688|Experimental|CD19-directed CAR-T cells|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
16472157|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
16472158|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
16472159|NCT03483662|Experimental|Multicomponent Intervention|Protocol-based treatment using the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification
16472160|NCT03483662|Active Comparator|Enhanced Usual Care|Webinar education session for providers on the new ACC/AHA hypertensive clinical guideline and the SPRINT study findings
16472161|NCT03483649|Experimental|HLX04|
16472162|NCT03483649|Active Comparator|United States (US) Avastin®|
16472163|NCT03483649|Active Comparator|European Union (EU) Avastin®|
16472164|NCT03483649|Active Comparator|China (CN) Avastin®|
16472165|NCT03483636|Experimental|Lemborexant|Participants will be randomized to receive a 10 milligram (mg) lemborexant tablet administered with 50 milliliter (mL) water followed by a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
16472166|NCT03483636|Experimental|Lemborexant Plus Alcohol|Participants will be randomized to receive a 10 mg lemborexant tablet administered with 50 mL water followed by alcohol (0.6 grams per kilogram [g/kg] of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
16472167|NCT03483636|Experimental|Alcohol|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol (0.6 g/kg of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
16472482|NCT03481374|Placebo Comparator|Healthy controls|healthy people without known disease undergo autonomic function testing
16472168|NCT03483636|Placebo Comparator|Placebo|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
16472169|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
16472170|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
16472171|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
16472172|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
16472173|NCT03483610|Active Comparator|screening and referral|
16472174|NCT03483610|Active Comparator|behavioral intervention|
16472175|NCT03483597||rheumatologists|Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
16472176|NCT03483597||patients|Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
16472177|NCT03483558|Experimental|Control|Participants were fed a standardized diet (without any vegetables) in this experiment.
16472178|NCT03483558|Experimental|Spinach|Participants were fed a standardized diet with 200g spinach in this experiment.
16472179|NCT03483558|Experimental|Celery|Participants were fed a standardized diet with 200g celery in this experiment.
16472180|NCT03483558|Experimental|Onion|Participants were fed a standardized diet with 200g onion in this experiment.
16472181|NCT03483558|Experimental|Mixed Vegetables|Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
16472182|NCT03483545|Experimental|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
16472183|NCT03483532||Lit Control pH Up without cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract without cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
16472184|NCT03483532||Lit Control pH Up with dry cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract with cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
16472185|NCT03483519|Experimental|Prehabilitation|Patients in the Prehabilitation Group and are randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
16472186|NCT03483519|Active Comparator|Standard of Care|Patients in the Standard of Care will not receive an additional an exercise program, patients will receive the usual care received by all orthopaedic patients.
16472187|NCT03483506|Experimental|All subjects|
16472188|NCT03483493|Experimental|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
16472189|NCT03483493|Active Comparator|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
16472190|NCT03483480|Experimental|Non powered-NPWT|
16472191|NCT03483480|Active Comparator|Open Technique|
16472192|NCT03483467|Experimental|1|Application of Omnigen
16472193|NCT03483467|Placebo Comparator|2|Dummy Omnigen Packaging
16472194|NCT03483454|Experimental|Exercise classes|This group of children and their parents will participate in an exercise class for 8 weeks.
16472195|NCT03483454|Experimental|Home exercise|"This group of children and their parents will participate in exercise at home for 8 weeks. This is currently the standard of care in the weight management clinic (advise to continue increasing activity at home). This group is considered the control group."
16472196|NCT03483428|Experimental|Parent Coaches|"Parent coaches will complete interventionist training and supervision in the Family Check-Up, an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads."
16472197|NCT03483428|Experimental|Parent-Child Dyads|"Parents and children will receive the adapted Family Check-Up behavioral parent training (BPT) intervention delivered by parent coaches."
16472198|NCT03483415|Experimental|Grup L|"IV patient-controlled analgesia (PCA) morphine
~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
16472199|NCT03483415|Active Comparator|Group P|IV patient-controlled analgesia (PCA) morphine
16472200|NCT03483402|Experimental|PEXG treated with MLT|Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)
16472201|NCT03483389|Experimental|Alcohol, placebo|Alcohol, ethyl - Placebo
16472202|NCT03483389|Experimental|Alcohol, low dose|Alcohol, ethyl - Low dose
16472203|NCT03483389|Experimental|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
16472204|NCT03483376|Active Comparator|Dental prophylaxis|Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste.
16472236|NCT03483116|Experimental|High dose RV3-BB neonatal schedule|High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
16472205|NCT03483376|Experimental|Dental prophylaxis + aPDT|"Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning, followed by antimicrobial photodynamic therapy (aPDT) to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste. The aPDT protocol is as follows:
~Patient will rinse the oral cavity with 20 ml of an aqueous solution of curcumin (photosensitizer; 1.5 g/L) for 30 seconds.
~Blue light from a Bluephase 20i curing lamp will be applied perpendicularly for 1 min per tooth (30 seconds on the vestibular side and 30 seconds on the palatal side).
~Remaining photosensitizer will be removed using the prophylaxis brush. The aPDT protocol is repeated following a rest period of 10 days."
16472206|NCT03483363|Experimental|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure. All groups with receive standard parenteral intravenous (IV) prophylactic antibiotic.
16472207|NCT03483363|Active Comparator|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
16472208|NCT03483350|Experimental|1- 1st group|1- 1st group will include 30 patients will receive intravenous granisetron 10 μg/kg after induction of anesthesia and before start of surgery
16472209|NCT03483350|Experimental|2- 2nd|2- 2nd group will include 30 patients will receive intravenous midazolam 50 μg/kg after induction of anesthesia and before start of surgery
16472210|NCT03483350|Experimental|3- 3rd group|3- 3rd group will include 30 patients will receive combination intravenous granisetron 5 μg/kg with midazolam 25 μg/kg after induction of anesthesia and before start of surgery
16472211|NCT03483337||recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
16472212|NCT03483337||head and neck cancer or thyroid cancers|All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies at two months (60 days) and four months (120 days) after completion of all treatments, including systemic therapy if (+/- 2 weeks or 14 days). Imaging on or immediately after systemic therapy treatment (+/- 2 weeks or 14 days) to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed. Patients who will be receiving radiation therapy treatment will also have recommended weekly imaging during their course of treatment.
16472213|NCT03483324|Experimental|Experimental|Unmanipulated umbilical cord blood plus AB-110
16472214|NCT03483311|Experimental|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
16472215|NCT03483311|Experimental|controls|Tissue levels of resolvin D1 in controls
16472216|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
16472217|NCT03483285|Active Comparator|heart rate|Effects of İntubation with Airtraq or Storz to heart rate
16472218|NCT03483285|Active Comparator|mean arterial pressure|Effect of intubation with Airtraq or Storz to mean arterial pressure
16472219|NCT03483259|Experimental|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
16472220|NCT03483259|Experimental|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
16472223|NCT03483233|Experimental|fMRI and EEG study|
16472224|NCT03483220||cases|patients with substance use disorder
16472225|NCT03483207|Experimental|MVT with anticoagulation therapy(heparin &warfarin)|patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively with anticoagulation(heparin &warfarin) while other cases will be for surgical management and not included in the study.
16472226|NCT03483207|Experimental|MVT with failure of anticoagulation therapy(heparin &warfarin)|patients who underwent conservative therapy with anticoagulation (heparin &warfarin) but showed no improvement .
16472227|NCT03483194|Active Comparator|Kalinox®|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
16472228|NCT03483194|Experimental|Virtual Reality|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
16472229|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
16472230|NCT03483168|Experimental|Culturally sensitive pain education|
16472231|NCT03483168|Active Comparator|Standard pain education|
16472232|NCT03483142|Experimental|misoprostol group|misoprostol group ( study group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
16472233|NCT03483142|Placebo Comparator|placebo group|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.
16472234|NCT03483129|Experimental|Consultation|The consultation will provide the participant with one to one information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide (Eatwell Guide, 2016). Furthermore, participants will have the opportunity to discuss pre-diabetes with a trained practice nurse and ask any questions they may have.
16472622|NCT03480321|Active Comparator|Cilostazol 100 mg|
16472237|NCT03483116|Experimental|Mid dose RV3-BB neonatal schedule|Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
16472238|NCT03483116|Experimental|Low dose RV3-BB neonatal schedule|Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
16472239|NCT03483116|Experimental|High dose RV3-BB infant schedule|High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)
16472240|NCT03483103|Experimental|Treatment|Lisocabtagene maraleucel at a dose of 100×10^6 CAR+ T cells (50×10^6 CD8+ CAR+ T cells and 50×10^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
16472241|NCT03483090|Experimental|Treatment A|4000mg Swisse High Strength Deep Sea Krill Oil (Superba BOOST) (4 capsules containing 1000mg each)
16472242|NCT03483090|Placebo Comparator|Treatment B|4 capsules of matching Placebo orally daily (1000mg each of mixed vegetable Oil)
16472243|NCT03483077|Experimental|BI 730460|
16472244|NCT03483077|Placebo Comparator|Placebo|
16472245|NCT03483064|No Intervention|Control group|Subjects without low back pain to whom the electric current is put but it is not activated.
16472246|NCT03483064|Experimental|Healthy group|Subjects without low back pain to whom the electric current is put but it is activated.
16472247|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
16472248|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
16472249|NCT03483038|Experimental|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
16472250|NCT03483025|Other|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
16472251|NCT03483025|Other|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
16472252|NCT03483025|Other|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
16472253|NCT03483025|Other|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
16472254|NCT03483025|Other|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
16472255|NCT03483025|Other|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
16472256|NCT03483012|Experimental|Atezolizumab + Stereotactic radiosurgery (SRS)|"Atezolizumab administered intravenously once every 3 weeks
~Stereotactic radiosurgery (SRS) begin within 14 days after brain MRI obtained"
16472257|NCT03482999||Control|Standard Wound Closure with drains
16472258|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
16472259|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
16472260|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
16472261|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
16472262|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
16472263|NCT03482960|Experimental|129Xe MRI|Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
16472264|NCT03482960|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
16472265|NCT03482947|Experimental|TAP|ultrasonography-guided transversus abdominis plane block administration of (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
16472266|NCT03482947|Experimental|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% &1 μ/kg dexmedetomidine
16472267|NCT03482934||hypertensive patients|
16472268|NCT03482908|Experimental|Responsive parenting treatment|Early Healthy Lifestyles (EHL) screening tool reported by participants to identify potentially obesogenic parenting practices and child behaviors; data sharing/coordination into electronic health records to inform counseling by trained providers; responsive parenting curriculum delivered by trained WIC nutritionists.
16472269|NCT03482908|No Intervention|Standard Care Control|Standard of pediatric and WIC care
16472270|NCT03482895||Patient: Blood sampling & Feces sampling|"Blood samplings at different times after a meal test: 0, 15, 30, 60, 90 and 120 minutes.
~Feces sampling: collection during 24 hours"
16472271|NCT03482882|Experimental|Drug - pimavanserin|
16472304|NCT03482596|Experimental|Intervention|All participants will follow the personalised multifaceted intervention to reducing/breaking prolonged sitting.
16472623|NCT03480321|Experimental|PMR 150 mg|
16472272|NCT03482869|Experimental|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
16472273|NCT03482856|Experimental|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
16472274|NCT03482856|Active Comparator|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
16472275|NCT03482843||Vitamin D Deficiency|25-Vitamin D level <25 ng/ml
16472276|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level >=25-70 ng/ml
16472277|NCT03482817|Experimental|Probe drug cocktail / Ze 117|One-sequence, Probe drug cocktail alone and in combination with Ze 117.
16472278|NCT03482791|Experimental|Arm 1: Resectable (proton beam therapy)|"Proton beam therapy: total dose of 50 or 50.4 Gy
~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision
~Surgery should ideally be performed no later than 8 to 10 weeks after completing chemoradiation
~Patient-reported outcome measures (PROs) performed at several time points"
16472279|NCT03482791|Experimental|Arm 2: Unresectable (proton beam therapy)|"Proton beam therapy: total dose of 59.4 or 60 Gy
~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision
~Patient-reported outcome measures (PROs) performed at several time points"
16472283|NCT03482765|Experimental|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
16472284|NCT03482765|Experimental|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
16472285|NCT03482765|Placebo Comparator|Placebo|The Placebo contains MCC.
16472286|NCT03482726|Other|Cycling Cadence Modulation|3 initial visits to collect baseline information; 6-week HIIT indoor cycling program at the individual prescribed cadence; final study visit for post-intervention measures.
16472287|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
16472288|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
16472289|NCT03482700|Other|Intervention|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
16472290|NCT03482700|Other|Control|Usual standard of care
16472291|NCT03482687|Experimental|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
16472292|NCT03482687|No Intervention|Comparison Group|No intervention was provided, only usual care.
16472293|NCT03482674|No Intervention|Control Group|The control group will receive standard care as provided by the German statutory health insurance.
16472294|NCT03482674|Experimental|Intervention group|The intervention group receives the DIMINI lifestyle intervention for a period of three months.
16472295|NCT03482661|No Intervention|Control|The patients swallowed the capsule with water in the supine position. When the capsule reached the stomach, the capsule was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After completing the stomach examination, the capsule moved automatically without magnetic control and entered the duodenum under physiological conditions. The position of the capsule was verified through real-time viewer.
16472296|NCT03482661|Experimental|Magnetic steering|After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis.
16472297|NCT03482648|Experimental|Single Ascending Doses|
16472298|NCT03482648|Experimental|Multiple Ascending Doses|
16472299|NCT03482635|Experimental|Group 1- Placebo Group|
16472300|NCT03482635|Experimental|Group 2- Small Dose Group|
16472301|NCT03482635|Experimental|Group 3- Medium Dose Group|
16472302|NCT03482635|Experimental|Group 4 - High Dose Group|
16472303|NCT03482622||Patients undergoing Mohs surgery|Skin samples excised during Mohs surgery will be measured by the Fast Raman device. The Fast Raman measurements will be compared to gold standard histopathology to determine measurement accuracy.
16472376|NCT03482154||Without Malglycemia|
16472305|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
16472306|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
16472307|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.
~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
16472309|NCT03482544|Active Comparator|Pregabalin Group|We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
16472310|NCT03482544|Active Comparator|Control Group|In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
16472311|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.
~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
16472312|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.
~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
16472313|NCT03482518|Experimental|Intervention Group|The intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover with elements in insoles. They will be advised to wear the slipper for 4 hours in the first week and up to 8 hours after that period. Should any part of you feel uncomfortable, the participant should return immediately so that the appropriate adjustments are made in the slipper
16472314|NCT03482518|Sham Comparator|Control group|"The control (sham) group volunteers will receive a pair of custom slippers with perforated synthetic leather cover as those used by GI.
~The difference will be that these slippers will not have the elements in the insoles."
16472315|NCT03482505|Experimental|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
16472316|NCT03482492|Active Comparator|Tramadol|Group Tramadol patients received tramadol 1 mg kg-1 iv
16472317|NCT03482492|Active Comparator|Tramadol-Paracetamol|Group Tramadol-Paracetamol patients received paracetamol 1 gr iv in addition to tramadol 1 mg kg-1 iv 30 minutes before the end of the operation and after the operation at 6 hour intervals for 24 hours
16472318|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
16472319|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
16472320|NCT03482466|Experimental|PTSD patients|12 PTSD patients will be recruited to undergo neurofeedback training .
16472321|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
16472322|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
16472323|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
16472324|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
16472325|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
16472377|NCT03482141|Other|WES|Whole exome sequencing (WES) will take place.
16472378|NCT03482128||preAlgorithm|Standard coagulation management of patients undergoing cardiac surgery
16472379|NCT03482128||postAlgorithm|Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery
16472326|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
16472327|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
16472328|NCT03482453|Experimental|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
16472329|NCT03482453|Experimental|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
16472330|NCT03482440|Placebo Comparator|Placebo|
16472331|NCT03482440|Experimental|Salsalate|
16472332|NCT03482427|Experimental|Intervention|After completion of the Healthy Hear Score assessment, participants will receive a lifestyle intervention based on the Healthy Heart Score results for 12-weeks by trained dietetic interns on-site. Participants will receive a check-in email or phone 6 weeks after the initial visit. A Registered Dietitian is also available to speak with patients. The intervention will consist on educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors
16472333|NCT03482427|No Intervention|Control|Participants in the control group will follow their usual care protocol after taking the Healthy Heart Score assessment. Researchers will provide the Healthy Heart Score survey results, but will not discuss or interpret the results with them. Participants can discuss any concern they have with their usual physician if they choose. After the follow-up visit and upon completion of the study, all participants in the control group may also receive the educational handouts and will be granted access to the Healthy Heart Score application if they wish.
16472334|NCT03482414|Active Comparator|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
16472335|NCT03482414|Experimental|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
16472336|NCT03482414|Experimental|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
16472337|NCT03482401|Experimental|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
16472338|NCT03482401|No Intervention|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
16472339|NCT03482388|Experimental|Crowdsourced intervention|A multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images.
16472340|NCT03482388|Other|Control|No images or videos will be viewed, and suggestions for improving hepatitis testing materials will not be collected.
16472341|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
16472342|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
16472343|NCT03482362|Experimental|Cohort A; KRASmt, BRAFwt, BRAF-like CC|Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
16472344|NCT03482362|Experimental|Cohort B; KRASwt, BRAFmt, BRAF-like CC|Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
16472345|NCT03482349|Experimental|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
16472346|NCT03482349|No Intervention|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
16472347|NCT03482336|Other|Uninstructed Group|"For the first block of participants recruited (39, one of which withdrew from boredom), no overt reference was made regarding the FOP labels that were present on the images that participants viewed during the course of the video game. Participants comprising this block were referred to as uninstructed."
16472348|NCT03482336|Other|Minimally trained|"Realizing that subjects might not use the FOP during decision making when not informed that it contained nutrition information, we conducted a second experiment (N= 41) which provided minimal information about the FOP. These subjects (the minimally instructed group) were provided with further instruction. At the beginning of the experiment, in addition to being shown the basic premise of the game and told that Munchy preferred to eat healthy options, the researcher pointed to one of the FOPs and told children this information might be helpful when you decide what's healthy."
16472380|NCT03482115|Experimental|Comatose patient|Subject with coma of traumatic or anoxic aetiology : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
16472381|NCT03482115|Other|control volunteers|subject control : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
16472624|NCT03480321|Experimental|PMR 200 mg|
16472349|NCT03482323|Experimental|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
16472350|NCT03482323|Experimental|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
16472351|NCT03482323|No Intervention|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
16472352|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
16472353|NCT03482297|Experimental|Automated Abdominal Binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (~40 mmHg) every time the participant stands up throughout the study day.
16472354|NCT03482297|Sham Comparator|Sham binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the sham binder combined with placebo pill t.i.d. The sham binder will be placed during the morning orthostatic trial on the active/sham binder study day. The sham binder will inflate automatically (~5 mmHg) every time the participant stands up throughout the study day.
16472355|NCT03482284|Experimental|Monosaccharide 1|Participants receive standardized meals with a defined amount of monosaccharide 1.
16472356|NCT03482284|Experimental|Monosaccharide 2|Participants receive standardized meals with a defined amount of monosaccharide 2.
16472357|NCT03482258|Experimental|Treatment Prebiotic|3 week daily dose of Vivinal-GOS (galacto-oligosaccharide)
16472358|NCT03482258|Placebo Comparator|Placebo|3 week daily dose of Maltodextrin
16472359|NCT03482245|Experimental|Pneumonia: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
16472360|NCT03482245|Experimental|Diverticulitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
16472361|NCT03482245|Experimental|Appendicitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
16472362|NCT03482245|No Intervention|Pneumonia: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
16472363|NCT03482245|No Intervention|Diverticulitis: Ambient Light|Standard ambient hospital lighting (~300 lux)for an initial 24 hour photoperiod after surgery for diverticulitis.
16472364|NCT03482245|No Intervention|Appendicitis: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod after surgery for diverticulitis.
16472365|NCT03482232||Patients visiting GP|All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
16472366|NCT03482232||Patient visiting pediatricians|All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
16472367|NCT03482219|Experimental|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:
~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations
~Application of the Physiotouch (a low-intensity negative pressure device)
~Passive Range of Motion
~Active Range of Motion
~Functional Activities"
16472368|NCT03482219|Active Comparator|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
16472369|NCT03482206|Experimental|Healthy subjects|Healthy adult volunteers (age 18 or greater) that are not claustrophobic, do not have hyperventilation or panic disorders, not pregnant, have no metal implants and can pass the MRI screening questions.
16472370|NCT03482193||Adolescents|Adolescents in 2nd or 4th year in secondary school, from 9 different schools in Liège, Belgium.
16472371|NCT03482180|Experimental|Investigational Group- KI1106|KI1106 tablet - daily administration
16472372|NCT03482180|Active Comparator|Control Group - Atorvastatin|Atorvastatin Calcium 20mg - daily administration
16472373|NCT03482167|Placebo Comparator|Placebo|placebo
16472374|NCT03482167|Experimental|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
16472375|NCT03482154||With Malglycemia|
16472382|NCT03482102|Experimental|Tremelimumab + Durvalumab + Radiation|"Durvalumab via IV infusion every 28 days for up to 4 doses/cycles
~Tremelimumab via IV infusion every 28 days for up to 4 doses/cycles, and then continue durvalumab monotherapy every 4 weeks starting on Week 16 for up to 8 months.
~Radiation therapy will only be given during cycle 2"
16472383|NCT03482089|Experimental|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
16472384|NCT03482089|Active Comparator|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
16472385|NCT03482076|Other|transferrin receptor concentration|Prevelance of iron deficiency in this patients
16472386|NCT03482063|Experimental|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
16472387|NCT03482063|Placebo Comparator|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
16472388|NCT03482050|Experimental|AstroRx|
16472389|NCT03482037|Experimental|Rec 0/0438|Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks
16472390|NCT03482037|Placebo Comparator|Placebo|Placebo, to be administered by intravesical instillation once daily for four weeks
16472391|NCT03482024|Experimental|Tirzepatide - Healthy|Group 1 - Tirzepatide administered subcutaneously (SC) to healthy participants with normal renal function.
16472392|NCT03482024|Experimental|Tirzepatide - Mild Renal Impairment|Group 2 - Tirzepatide administered SC to participants with mild renal impairment.
16472393|NCT03482024|Experimental|Tirzepatide - Moderate Renal Impairment|Group 3 - Tirzepatide administered SC to participants with moderate renal impairment.
16472394|NCT03482024|Experimental|Tirzepatide - Severe Renal Impairment|Group 4 - Tirzepatide administered SC to participants with severe renal impairment.
16472395|NCT03482024|Experimental|Tirzepatide - End Stage Renal Disease (ESRD)|Group 5 - Tirzepatide administered SC to participants with ESRD.
16472396|NCT03482011|Experimental|Mirikizumab|"Induction Period:
~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).
~Maintenance Period:
~Participants received one of the four options below:
~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).
~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).
~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).
~250 mg mirikizumab administered SC Q8W for non-responders (<PASI 90)."
16472397|NCT03482011|Placebo Comparator|Placebo|"Induction Period: Participants received placebo administered SC Q4W.
~Maintenance Period:
~Participants received one of the two options below:
~Placebo administered SC Q8W for responders (≥PASI 90).
~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (< PASI 90)."
16472398|NCT03481998|Experimental|Cohort 1 (Part 1)|Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
16472399|NCT03481998|Experimental|Cohort 2 (Part 1)|SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
16472400|NCT03481998|Experimental|SHR6390 + Letrozole or anastrozole (Part 2)|SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
16472401|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 3 (Part 1)|SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
16472402|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 4 (Part 1)|SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
16472403|NCT03481972|Experimental|Doxy/TUDCA|"doxycicline (100 mg / BID)
~tauroursodeoxycholic acid (250 mg / TID)"
16472404|NCT03481972|Active Comparator|Standard of care|Standard of care therapies.
16472405|NCT03481959|Experimental|Methylphenidate|Methylphenidate delay shape, 10 and 30 mg capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).
16472406|NCT03481959|Placebo Comparator|Matching Placebo|
16472407|NCT03481946|Experimental|BAY1093884 in subjects with Hemophilia|Single dose of BAY1093884 over 30 minutes administered in subjects with severe congenital Hemophilia A or B, with inhibitors or without inhibitors
16472408|NCT03481933|Experimental|1:left-excitatory tDCS|20 SD patients who receive left-excitatory trans cranial stimulation
16472409|NCT03481933|Active Comparator|2:right-inhibitory tDCS|20 SD patients who receive right-inhibotory trans cranial stimulation
16472410|NCT03481933|Sham Comparator|3:sham tDCS|20 SD patients who receive sham stimulation
16472411|NCT03481920|Experimental|PEGPH20 + Avelumab|PEGPH20, a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K/B or PEG) and recombinant human hyaluronidase (rHuPH20). PEGPH20 has a half-life of approximately 2 days, thereby enabling systemic activity and sustained duration of action to degrade HA. In many different tumor types tested in murine xenograft models, response to PEGPH20 has been shown to be more robust for tumors characterized by higher HA expression.
16472412|NCT03481907|Other|Internalized Control|Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
16472413|NCT03481894|Experimental|Kabiven®|Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
16472548|NCT03480906|Experimental|Microdose administration|Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD
16472414|NCT03481894|Active Comparator|Compounded standard parenteral nutrition|"The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) <797> Pharmaceutical Compounding-Sterile Preparations."
16472415|NCT03481868||Chronic Myeloid Leukemia|Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
16472416|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
16472417|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
16472421|NCT03481816|Experimental|Arm 1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts.
16472422|NCT03481816|Experimental|Arm 2/Dose expansion|Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.
16472423|NCT03481790|Experimental|Lactoferrin|100mg of bovine lactoferrin (Pravotin sachets, Hygint, Egypt) twice a day.
16472424|NCT03481790|Experimental|ferrous sulphate + folic acid (vitamin B9)|150mg of dried ferrous sulphate + folic acid (vitamin B9) 0.50mg (Ferrofol, E.I.P.I.C.O, Egypt) three capsules per day.
16472425|NCT03481777|Active Comparator|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.
~Initial remote ischemic conditioning: prehospital phase, all included patients
~Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres
~Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital
~Usual care with or without acute reperfusion therapy"
16472426|NCT03481777|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.
~Initial Sham remote ischemic conditioning: prehospital phase, all included patients
~Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres
~Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital
~Usual care with or without acute reperfusion therapy."
16472427|NCT03481764||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 5-14 years
16472428|NCT03481764||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
16472429|NCT03481764||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
16472430|NCT03481764||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
16472431|NCT03481764||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed epilepsia
16472432|NCT03481764||EFS: group of individuals with epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
16472433|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
16472434|NCT03481738||PKD Diagnosed|Participants diagnosed with PK deficiency by the presence of 2 or more PKLR gene mutations as well as clinical features.
16472435|NCT03481725|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
16472436|NCT03481725|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
16472437|NCT03481699|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
16472438|NCT03481699|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
16472439|NCT03481686|Experimental|Patients with injections of ESA|Patients with injections of ESA
16472476|NCT03481426|Experimental|Workplace intervention group|Workers with back problems receive both information/advice and participatory workplace intervention organized by Occupational Health Physioterapist.
16472477|NCT03481426|No Intervention|Information and advice group|Workers with back problems receive only information / advice by Occupational Health Physiotherapist, not the workplace intervention.
16472478|NCT03481400|Experimental|Calcitonin gene-related peptide|Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)
16472440|NCT03481673|Experimental|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
16472441|NCT03481660|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
16472442|NCT03481660|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
16472443|NCT03481647|Active Comparator|Intervention|The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
16472444|NCT03481647|No Intervention|Control|Professional oral care once a week according to existing routine
16472448|NCT03481621|Active Comparator|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
16472449|NCT03481621|Active Comparator|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
16472450|NCT03481621|Active Comparator|Group2, Standard care or waiting lists|Standard care without acupuncture
16472451|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid
~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
16472452|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid
~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
16472453|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
16472454|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
16472455|NCT03481582|Active Comparator|Group without nitroglycerin|They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
16472456|NCT03481582|Experimental|Group with nitroglycerin|They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
16472457|NCT03481569|Experimental|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
16472458|NCT03481556|Experimental|A (melflufen+bortezomib+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
16472459|NCT03481556|Experimental|B (melflufen+daratumumab+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Dexamethasone p.o. 40 mg weekly (20 mg weekly for patients age ≥ 75 years).
16472460|NCT03481543|Experimental|In-line nebulization through NIV mask|Bronchodilator nebulization is given through NIV circuit.
16472461|NCT03481543|Active Comparator|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished.
16472462|NCT03481530||Blinded|Continuing Glucose Monitoring System will be blinded
16472463|NCT03481530||Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
16472464|NCT03481517|Experimental|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
16472465|NCT03481517|No Intervention|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
16472466|NCT03481504|Experimental|ACT-ETP|Cognitive behavioral treatment
16472467|NCT03481504|No Intervention|Usual care|no intervention
16472468|NCT03481491|Sham Comparator|Sham cerebellar stimulation|Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.
16472469|NCT03481491|Active Comparator|Real cerebellar stimulation|Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.
16472470|NCT03481478||Patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
16472471|NCT03481478||Dislocation patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
16472472|NCT03481452|Experimental|psychotherapy intervention group|NBO behavioral intervention would be used to improve mother-infant dyad interaction and infants' disorders of regulation of states.
16472473|NCT03481452|No Intervention|control group|No behavioral intervention would be used.
16472474|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
16472475|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
16472483|NCT03481348|Experimental|Pharyngeal Electrical Stimulation|PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
16472484|NCT03481348|No Intervention|Control|Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
16472485|NCT03481335|Experimental|Intervention Community|Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
16472486|NCT03481335|No Intervention|Control Community|Control communities (barangays) will receive care as usual.
16472487|NCT03481322|Active Comparator|Cooked diet with controlled amount of salt|Patients will receive intervention diet (cooked with controlled amount of salt)
16472488|NCT03481322|Placebo Comparator|Cooked without salt|Patients will receive the standard diet (cooked without salt and 2 grams of salt separated will be added by the patient)
16472489|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
16472490|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
16472491|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
16472492|NCT03481296|Active Comparator|Advanced Control|The advanced control group receives a set of standard materials regarding colorectal cancer screening.
16472493|NCT03481296|Experimental|Culturally Adapted Decision Support Navigation Intervention|The culturally adapted decision support navigation intervention group receives everything advanced group receives as well as decision support and navigation contacts.
16472494|NCT03481270|Placebo Comparator|Discordant|Does not receive the concordant provider.
16472495|NCT03481270|Experimental|Concordant|The intervention is that the subject receives the concordant provider.
16472496|NCT03481257||Ticagrelor|ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
16472497|NCT03481257||Clopidogrel + very low dose rivaroxaban|ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
16472498|NCT03481218||Patients with type 1 diabetes|Young adults (male and female) between the ages of 18 and 35, who have type 1 diabetes for at least one year.
16472499|NCT03481218||Individuals without chronic diseases|Young adults (male and female) between the ages of 18 and 35, without chronic diseases.
16472500|NCT03481205|Experimental|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
16472501|NCT03481192|Experimental|A group using amnesic substances|"A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates.
~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
16472502|NCT03481192|Active Comparator|A control group|"A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant.
~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
16472503|NCT03481179|Experimental|Experimental: hf rTMS and Physical therapy|High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
16472504|NCT03481179|Sham Comparator|Control: Sham hf rTMS and Physical theraphy|In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
16472505|NCT03481166|Experimental|Education on breastfeeding pain|Both the experimental and control groups will receive usual prenatal education offered through our regional public health program. In addition to usual prenatal education, the experimental group will also receive a one-hour, nurse led (a Registered Nurse specially trained in perinatal care), small group-based education session with specific focus on breastfeeding pain. The goals of this educational intervention are to provide pregnant women with anticipatory guidance around pain which is commonly experienced while breastfeeding in the first two weeks postpartum. Education will include the prevalence, etiology and management of various types of breastfeeding-related pain experienced postpartum.
16472506|NCT03481166|No Intervention|Usual prenatal education|Women allocated to the usual prenatal education group will receive prenatal classes through their local public health unit. Women enrolled in classes will receive approximately 12 hours of combined in-class and online prenatal content. Topics include: discomforts of pregnancy, labor and birth, medical interventions, adjustment to parenting, breastfeeding, and caring for the newborn. Breastfeeding-related material includes basic mechanisms of milk production, benefits of breastfeeding, benefits of skin-to-skin, correct breastfeeding latch, breastfeeding positions, timing of feeds, responding to infant cues, and caring for nipples. Women in the usual prenatal education group will not receive education on the prevalence and etiology of nipple pain, nor specific pain management strategies.
16472507|NCT03481153|Placebo Comparator|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
16472549|NCT03480906|Active Comparator|Eyedrop administration|Latanoprost ophthalmic solution administered as an eyedrop
16472508|NCT03481153|Active Comparator|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
16472509|NCT03481140||Control|donor site DIEP flap breast reconstruction procedure with standard wound closure with drains
16472510|NCT03481140||TissuGlu Surgical Adhesive|donor site DIEP flap breast reconstruction procedure with standard wound closure with TissuGlu Surgical Adhesive and no drains
16472511|NCT03481127|Active Comparator|Arm 1: Usual Care|-No psychosocial care in clinic
16472512|NCT03481127|Experimental|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
16472513|NCT03481114|Active Comparator|Standard chemoradiotherapy|Patients receiving standard radiotherapy will receive a total dose of 60 Gy in 30 fractions over 6 weeks, delivered to all involved lesions (tumors and lymph nodes).
16472514|NCT03481114|Experimental|PET-based, dose-painted, accelerated chemoradiotherapy,|For patients receiving PET-based, dose-painted, accelerated chemoradiotherapy, lesions with MTV exceeding 20 cc will be treated with 55 Gy in 20 fractions over 4 weeks, while lesions with MTV below 20 cc will receive 44 Gy in 20 fractions over the same 4 weeks.
16472515|NCT03481101|Other|All patients|Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
16472516|NCT03481088|Other|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.
~Stage- I (pre-treatment),
~Stage- II (after pre-functional therapy)
~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
16472517|NCT03481075|Experimental|Rigid and Elastic registration softwares|
16472518|NCT03481062||Neutral|
16472519|NCT03481062||abduction|
16472520|NCT03481062||pad|
16472521|NCT03481062||combination|
16472522|NCT03481049|Experimental|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
16472523|NCT03481049|Experimental|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
16472524|NCT03481049|Experimental|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
16472525|NCT03481036|Active Comparator|Non cirrhotic|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg), LDV (90 mg) and DCV (60 mg) per day
16472526|NCT03481036|Active Comparator|Genotype 1,4,5 and 6 with cirrhosis|Sofosbuvir (SOF)+ Ledipasvir (LDV) for 12-weeks + weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and LDV (90 mg) per day
16472527|NCT03481036|Active Comparator|Genotype 2 and 3 with Cirrhosis|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks+ weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and DCV (60 mg) per day
16472528|NCT03481023|Experimental|Esophageal thermal regulation device|
16472529|NCT03481023|Active Comparator|LET monitoring|
16472530|NCT03481010|Experimental|PAO with hip arthroscopy|"Patient's in the Scope PAO group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the Scope-PAO group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy."
16472531|NCT03481010|Active Comparator|PAO without hip arthroscopy|"Patient's in the PAO-only group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the PAO-only group have been randomized to receive a periacetabular osteotomy only."
16472532|NCT03480997|Experimental|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
16472533|NCT03480997|Active Comparator|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
16472534|NCT03480997|Experimental|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
16472535|NCT03480984|Active Comparator|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
16472536|NCT03480984|Active Comparator|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
16472537|NCT03480971|Active Comparator|Active 1000 mg Tempol Solution|Patients will take 1000 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
16472538|NCT03480971|Placebo Comparator|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
16472539|NCT03480958|Active Comparator|ESP group|Erector Spinae Plane Block administered group
16472540|NCT03480958|Active Comparator|TPVB group|Thoracic Paravertebral Block administered group
16472541|NCT03480958|Other|Control Group|No regional anesthesia technique will be applied to control group; but will be provided with iv PCA
16472542|NCT03480932|Active Comparator|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
16472543|NCT03480932|Active Comparator|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
16472544|NCT03480932|Active Comparator|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
16472545|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
16472546|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
16472547|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
16472552|NCT03480880|Experimental|Group BIS|Thiopentone dosing during induction of anaesthesia based on guidance of Bispectral Index values.
16472553|NCT03480880|No Intervention|Group Clinical|Thiopentone dosing during induction of anaesthesia based on clinical guidance targeted to loss of eyelash reflex or loss of response to noxious stimulus.
16472554|NCT03480867|Experimental|Pre-operative RT and TMZ|Single Arm: Pre-operative Radiation +Temozolomide followed by Surgery plus six cycles of Temozolomide
16472555|NCT03480854|No Intervention|Baseline Analysis|To conduct studies of variation in performance across microsystems and to utilize benchmarking analyses to identify top performers.
16472556|NCT03480854|Experimental|The effect of continuous quality improvements (CQI)|To study the comparative improvement of selected primary process performance indicators (DMT and MRI process measures) over a 3 year period (Years 2-3) in microsystems receiving CQI interventions versus those not receiving CQI intervention, and between two different CQI intervention types (IHI Breakthrough Series and Patient Centered Medical Home).
16472557|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
16472558|NCT03480815|Active Comparator|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
16472559|NCT03480815|Placebo Comparator|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
16472560|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
16472561|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
16472562|NCT03480789|Experimental|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
16472563|NCT03480789|Experimental|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
16472564|NCT03480789|Experimental|eye patch + DEX|given dexmedetomidine to meet RASS -1 and wearing the eye patch from 22:00 to 6:00 of the next day
16472565|NCT03480789|No Intervention|usual treatment|treatment as usual
16472566|NCT03480776|Active Comparator|Acetylsalicylic Acid (ASA)|
16472567|NCT03480776|Sham Comparator|Placebo|
16472568|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
16472569|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
16472570|NCT03480750|Experimental|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
16472571|NCT03480737|Experimental|10 Hz rTMS|
16472572|NCT03480737|Sham Comparator|Sham rTMS|
16472573|NCT03480737|Experimental|iTBS rTMS|
16472574|NCT03480724|Active Comparator|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
16472575|NCT03480724|Active Comparator|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
16472576|NCT03480724|No Intervention|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group
16472577|NCT03480711|Experimental|Group (A)|20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
16472578|NCT03480711|Experimental|group (B)|20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
16472579|NCT03480698||Cerebrolysin and standard stroke care|
16472580|NCT03480698||Standard stroke care|
16472581|NCT03480685|Other|IVUS Imaging vs. OCT Imaging|A vessel segment will be imaged with intravascular ultrasound (IVUS). The same vessel segment will be imaged with optical coherence tomography (OCT).
16472582|NCT03480672|Experimental|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
16472583|NCT03480672|Active Comparator|aRCH|adjuvant radio-chemotherapy (aRCH)
16472584|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
16472585|NCT03480659||Control|Age matched control females
16472586|NCT03480646|Experimental|CPI-1205 Combination with Enzalutamide|
16472587|NCT03480646|Experimental|CPI-1205 Combination with Abiraterone/Prednisone|
16472588|NCT03480633||Control|Defined as patients without a history of heart failure
16472589|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 50%.
16472590|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 50%.
16472625|NCT03480308|Active Comparator|Bupivacaine fentanyl group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
16472626|NCT03480308|Active Comparator|Bupivacaine dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
16472591|NCT03480620|Experimental|Telerehabilitation|Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
16472592|NCT03480620|Active Comparator|Usual care|Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
16472593|NCT03480607|Active Comparator|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
16472594|NCT03480607|Active Comparator|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
16472595|NCT03480594|Experimental|Fatty Liver Patients|Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients
16472596|NCT03480594|Experimental|Healthy Control Subjects|Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects
16472597|NCT03480581|Experimental|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
16472598|NCT03480581|Experimental|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
16472599|NCT03480568|Experimental|alirocumab|Alirocumab 150 mg q 2 weeks for 12 weeks
16472600|NCT03480555|Active Comparator|Replenish Protein group|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
16472601|NCT03480555|Other|Standard Protein group|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
16472602|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
16472603|NCT03480516|Experimental|SDF arm|SDF arm is application of 38% silver diamine fluoride solution (SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained.
16472604|NCT03480516|Experimental|Fluoride varnish arm|Fluoride varnish arm is application of 5% sodium fluoride varnish on all surface of every tooth.
16472605|NCT03480516|Experimental|Combination arm|Combination arm is application of 38% silver diamine fluoride solution(SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained and then apply of 5% sodium fluoride varnish on all surface of every tooth.
16472606|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
16472607|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
16472608|NCT03480477||Pelvic Floor Disorders Group|Will collect patient information from new patients who present to the Urogynecology Clinic
16472609|NCT03480477||Control Group|Will collect patient information from patients who present to Gynecologic Clinic for their annual examination
16472610|NCT03480477||Chronic Pelvic Pain Group|Will collect patient information from patients who present to their Chronic Pelvic Pain Clinic appointment
16472611|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
16472612|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
16472613|NCT03480451|Other|Single Arm|"This project is being withdrawn. No revisions to ARM is available.
~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
16472614|NCT03480438|Experimental|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.
~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
16472615|NCT03480425|Experimental|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to >30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to >30cm water pressure, and force of extubation recorded.
16472616|NCT03480412||Follicular Phase|
16472617|NCT03480412||Luteal Phase|
16472618|NCT03480386|Experimental|Intervention|Patients randomized in this arm will start with the home based pulmonary rehabilitation program.
16472619|NCT03480386|Active Comparator|Control|Patients randomized in this arm will start the intervention after 12 weeks of usual care.
16472620|NCT03480360|Other|Johns Hopkins' conditioning regimen|Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant
16472621|NCT03480334|Experimental|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
16472627|NCT03480308|Active Comparator|Bupivacaine fentanyl dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
16472628|NCT03480295|Experimental|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
16472629|NCT03480295|Active Comparator|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
16472630|NCT03480282|Experimental|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
16472631|NCT03480256|Experimental|SHR6390 combined with pyrotinib|Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
16472632|NCT03480243|Experimental|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):
~Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4
~Padsevonil 100 mg single dose on Day 5
~1 week of wash-out (from evening of Day 5 to Day 11)
~Treatment Period 2 (Day 12 to 22):
~Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15
~Padsevonil 100 mg single dose on Day 16
~1 week of wash-out (from evening of Day 16 to Day 22)
~Treatment Period 3 (Day 23 to Day 38):
~Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25
~Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32
~Padsevonil 100 mg single dose on Day 33
~Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36
~Erythromycin 500 mg single dose on Day 37"
16472633|NCT03480230|Experimental|Treatment arm|"Non-squamous histology:
~Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.
~Compound 565994 500 mg/m2 administered over 10 minutes, and
~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.
~Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.
~Squamous histology:
~Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.
~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.
~Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.
~Platinum and Compound 343782 will be given for 3 cycles."
16472634|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
16472635|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
16472636|NCT03480191|Experimental|Patients|
16472637|NCT03480165|Experimental|20 mg Parecoxib + 0.75% Ropivacaine|1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine
16472638|NCT03480165|Active Comparator|0.75% Ropivacaine only|19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline
16472639|NCT03480152|Experimental|1/Phase - Escalating doses of mRNA vaccine|Escalating doses of messenger ribonucleic acid (mRNA) vaccine
16472640|NCT03480152|Experimental|2/Phase II -MTD of mRNA vaccine established in Phase I|Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I
16472641|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
16472642|NCT03480126|Placebo Comparator|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
16472643|NCT03480126|Experimental|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
16472644|NCT03480126|Experimental|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
16472645|NCT03480126|Experimental|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
16472646|NCT03480113|Experimental|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
16472647|NCT03480113|Active Comparator|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
16472648|NCT03480100||Xylometazoline Nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
16472649|NCT03480100||Xylometazoline + Ectoin Nasal Douche|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
16472650|NCT03480087||Chemotherapy alone|Patient treated with anthracycline containing chemotherapy
16472651|NCT03480087||Chemotherapy plus radiotherapy|Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
16472652|NCT03480074|Active Comparator|Staple Ligation|Arm 1: Staple Ligation
16472653|NCT03480074|Active Comparator|Selective Suture Ligation|Arm 2: Selective Suture Ligation
16472654|NCT03480074|Active Comparator|Single Suture Ligation|Arm 3: Single Suture Ligation
16472655|NCT03480061|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
16472656|NCT03480061|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
16472657|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
16472658|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
16472795|NCT03479190|Active Comparator|Platelet rich plasma|ultrasound guided injection of Platelet rich plasma
16472659|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
16472660|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
16472661|NCT03480009|Experimental|Dextromethorphan, opted for narcotic prescription|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
16472662|NCT03480009|Placebo Comparator|Placebo, opted for narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)
16472663|NCT03480009|Experimental|Dextromethorphan, declined narcotic prescription|Dextromethorphan hydrobromide and patient declines narcotic
16472664|NCT03480009|Placebo Comparator|Placebo, declined narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
16472665|NCT03479996|Experimental|Anesthetic|
16472666|NCT03479996|No Intervention|Control|
16472667|NCT03479983|Experimental|AMX160|500 mg (one capsule) x 2 times daily for 90 days
16472668|NCT03479983|Placebo Comparator|Placebo|500mg (one capsule) x 2 times daily for 90 days.
16472669|NCT03479970|Experimental|GNPT + Social Cognition|"Experimental Group: will undertake a rehabilitation treatment integrated by a set of tasks aimed at working attention, memory and executive functions together with a computerized treatment for the rehabilitation of the Social Cognition. The treatment will be carried out through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT).
~The treatment will consist of the carrying out of 24 treatment sessions"
16472670|NCT03479970|Active Comparator|GNPT (only N-SC measures)|Control Group: will only conduct a cognitive rehabilitation treatment through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT) focused on attention, memory and executive functions.
16472671|NCT03479957|Experimental|REMOTE-CR|Remotely monitored and coached exercise training in real time using the REMOTE-CR system. The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link.
16472672|NCT03479957|Other|Usual care|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care).
16472673|NCT03479944|Experimental|FLACS|Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
16472674|NCT03479944|Active Comparator|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
16472675|NCT03479931|Experimental|Without placement of a catheter|Without preoperatively placement of an indwelling catheter during Caesarean section
16472676|NCT03479931|Active Comparator|With placement of a catheter|Normal pre-operative routines with placement of an indwelling catheter during Caesarean section
16472677|NCT03479918|Active Comparator|R-DA-EPOCH-21|The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.
16472678|NCT03479918|Active Comparator|R-BL-M-04|"Course A:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.
~Course C:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.
~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
16472679|NCT03479918|Active Comparator|R-DA-EPOCH-21 + auto-SCT|"The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.
~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
16472680|NCT03479918|Active Comparator|R-BL-M-04 + auto-SCT|"The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.
~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
16472681|NCT03479905|Sham Comparator|Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 36%
16472682|NCT03479905|Sham Comparator|Face mask group|A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
16472683|NCT03479905|Experimental|High Floow Oxygen delivery|Oxygen will be delivered by using high flow nasal cannula
16472684|NCT03479892|Experimental|NNC0194-0499|Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
16472685|NCT03479892|Placebo Comparator|Placebo|Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
16472686|NCT03479879|Experimental|Estradiol + Misoprostol|
16472687|NCT03479879|Placebo Comparator|Placebo + Misoprostol|
16472688|NCT03479866|Experimental|Dietary intervention|2 week dietary intervention using standardized test meals
16472689|NCT03479853||Cases : suffering from ocular or oculo-cutaneous rosacea|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
16472796|NCT03479190|Placebo Comparator|Normal saline|ultrasound guided injection of Normal saline
16472690|NCT03479853||Witnesses|"Without any present or past palpebral meibomian Gland Dysfunction
~Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device."
16472691|NCT03479840||Patients undergoing PCI|all-comer population undergoing PCI
16472692|NCT03479827|Experimental|Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
16472693|NCT03479814|Experimental|IMRT-SIB plus sequential IG-RT boost|45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET
16472694|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
16472695|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
16472696|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
16472697|NCT03479788||DM|Observational study. NO intervention
16472698|NCT03479788||non-DM|Observational study. NO intervention
16472699|NCT03479775||Youth female athletes with poor muscle function|Youth female athletes (floorball, football and handball) with assessed poor muscle function at baseline.
16472700|NCT03479775||Youth female athletes with good muscle function|Youth female athletes (floorball, football and handball) with assessed good muscle function at baseline.
16472701|NCT03479762||Liraglutide|Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
16472702|NCT03479749|Experimental|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
16472703|NCT03479749|Experimental|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
16472704|NCT03479749|Placebo Comparator|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
16472705|NCT03479749|Placebo Comparator|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
16472706|NCT03479736||Cohort 1: Participants with Achilles Tendon Rupture (ATR)|Participants will be defined as having ATR if they receive a diagnosis for ATR as well as one of the following procedures: tenotomy or primary ruptured Achilles Tendon (AT) repair (with or without graft) within 7 days of diagnosis. Index will be based on the earlier date of diagnosis or procedure. Participants with ATR, and exposures to Fluoroquinolone (FQ) or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
16472707|NCT03479736||Cohort 2: Participants with Retinal Detachment (RD)|Participants will be defined as having a RD if they received a diagnosis of RD and a procedure for RD, e.g.: sclera buckle, vitrectomy, retinopexy, retinal cryotherapy, silicone oil fill, air gas fluid exchange or pneumatic retinopexy, within 14 days of index. Index will be defined as the earlier date of diagnosis or procedure. Participants with RD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
16472708|NCT03479736||Cohort 3: Participants with Aortic Aneurysm & Dissection (AAD)|Participants will be defined as having AAD if they received a primary diagnosis for aortic aneurysm, aortic rupture or dissection and have also received an aortic repair surgical procedure concurrently to the AAD diagnosis, in an inpatient or emergency department (ED) setting. Index will be defined as the earlier date of diagnosis or procedure. Participants with AAD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
16472709|NCT03479710|Experimental|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
16472710|NCT03479710|No Intervention|Control|No FMT infusion.
16472711|NCT03479697|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
16472712|NCT03479697|Other|Continued Current Care|Participants will continue their current care.
16472713|NCT03479684|Experimental|Gene-directed group|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
16472714|NCT03479684|Active Comparator|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
16472715|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
16472716|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
16472717|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
16472718|NCT03479658|Experimental|HIIT two sessions|Two sessions per week of HIIT + nutritional education (1 session/week)
16472719|NCT03479658|Experimental|HIIT one session|One session per week of HIIT + nutritional education (1 session/week)
16472720|NCT03479658|Active Comparator|Nutritional education|Nutritional education (1 session/week)
16472721|NCT03479645|No Intervention|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
16472722|NCT03479645|Experimental|Intervention|Serial text messages and mailed FIT kit
16472723|NCT03479632|Experimental|Intervention Group|The intervention group will undergo an aerobic walking program using a treadmill, a body-weight support system, and an assistive device.
16472724|NCT03479632|Active Comparator|Control Group|The control group will receive standard physical therapy (PT).
16472725|NCT03479619|Experimental|A/28/1|Lancing device A with personal lancet of size 28 G and minimum puncture depth.
16472726|NCT03479619|Experimental|A/28/5|Lancing device A with personal lancet of size 28 G and maximum puncture depth.
16472727|NCT03479619|Experimental|A/30/1|Lancing device A with personal lancet of size 30 G and minimum puncture depth.
16472728|NCT03479619|Experimental|A/30/5|Lancing device A with personal lancet of size 30 G and maximum puncture depth.
16472729|NCT03479619|Experimental|A/33/1|Lancing device A with personal lancet of size 33 G and minimum puncture depth.
16472730|NCT03479619|Experimental|A/33/5|Lancing device A with personal lancet of size 33 G and maximum puncture depth.
16472731|NCT03479619|Experimental|B/28/1|Lancing device B with personal lancet of size 28 G and minimum puncture depth.
16472732|NCT03479619|Experimental|B/28/5|Lancing device B with personal lancet of size 28 G and maximum puncture depth.
16472733|NCT03479619|Experimental|B/30/1|Lancing device B with personal lancet of size 30 G and minimum puncture depth.
16472734|NCT03479619|Experimental|B/30/5|Lancing device B with personal lancet of size 30 G and maximum puncture depth.
16472735|NCT03479619|Experimental|B/33/1|Lancing device B with personal lancet of size 33 G and minimum puncture depth.
16472736|NCT03479619|Experimental|B/33/5|Lancing device B with personal lancet of size 33 G and maximum puncture depth.
16472737|NCT03479619|Experimental|C/28/1|Lancing device C with personal lancet of size 28 G and minimum puncture depth.
16472738|NCT03479619|Experimental|C/28/5|Lancing device C with personal lancet of size 28 G and maximum puncture depth.
16472739|NCT03479619|Experimental|C/30/1|Lancing device C with personal lancet of size 30 G and minimum puncture depth.
16472740|NCT03479619|Experimental|C/30/5|Lancing device C with personal lancet of size 30 G and maximum puncture depth.
16472741|NCT03479619|Experimental|C/33/1|Lancing device C with personal lancet of size 33 G and minimum puncture depth.
16472742|NCT03479619|Experimental|C/33/5|Lancing device C with personal lancet of size 33 G and maximum puncture depth.
16472743|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
16472744|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
16472745|NCT03479593||CMR and OCT in NSTEMI patients with MVD|NSTEMI patients with multi vessel disease
16472746|NCT03479567|Other|HC|Healthy controls, i.e. older adults without cognitive impairment
16472747|NCT03479567|Other|MiD|older adults with mild dementia
16472748|NCT03479567|Other|MoD|older adults with moderate dementia
16472749|NCT03479554|Experimental|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
16472750|NCT03479554|Active Comparator|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
16472751|NCT03479541|Experimental|Physical Therapy (Early)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
16472752|NCT03479541|Experimental|Physical Therapy (Standard of Care)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
16472753|NCT03479528||Dyspepsia|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an jiaotong university,Xijing Hospital, Tangdu Hospital, Xi'an No.3 Hospital, and received investigation.
16472754|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
16472755|NCT03479502|Active Comparator|Methylprednisolone|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.
16472756|NCT03479502|Active Comparator|Doxycycline|Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.
16472757|NCT03479489|Experimental|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
16472758|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
16472819|NCT03478995|Experimental|GX-I7|Determined dose of GX-I7 on Day1 of each cycle
16472820|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
16472821|NCT03478982|Experimental|Staccato Alprazolam 2.0 mg|single dose for inhalation
16472822|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
16472759|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
16472760|NCT03479463||Treatment with Dehydrated Human Amnion Chorion Allograft|
16472761|NCT03479463||Standard of Care|
16472762|NCT03479424||Training Set|n = 333
16472763|NCT03479424||Validation Set|n = 167
16472764|NCT03479411|Experimental|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
16472765|NCT03479411|Experimental|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
16472766|NCT03479411|Active Comparator|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
16472767|NCT03479398||App Condition|Although we will be mostly observing routine practice, we will randomize patients into either an App condition or paper condition. The App condition refers to patients completing routine Cognitive Behavioral Therapy (CBT) worksheets on a mobile application during session. Everything else that occurs in treatment sessions will be consistent with routine care practices.
16472768|NCT03479398||Paper Condition|Although we will be mostly observing routine practice, we do randomize patients into either an App condition or paper condition. The paper condition refers to patients completing routine CBT worksheets on paper (the current standard) during session.
16472769|NCT03479385|Experimental|Integrative Medicine Intervention|Study participants randomized to the Integrative Medicine intervention will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months potentially followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
16472770|NCT03479385|Experimental|Health Education Intervention|Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
16472771|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 1|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
16472772|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 2|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
16472773|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 3|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
16472774|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
16472775|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
16472776|NCT03479346|Experimental|GGT group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
16472777|NCT03479346|Placebo Comparator|Placebo group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
16472778|NCT03479333|Experimental|Short implant|
16472779|NCT03479333|Active Comparator|standard implant with sinus lift|
16472780|NCT03479320|Experimental|Lidocaine group|Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery
16472781|NCT03479320|Placebo Comparator|Placebo|They will receive the same volume of 0.9% of normal saline as calculated for the experimental group
16472782|NCT03479307|Experimental|Bilastine Ophthalmic Solution 0.6%|
16472783|NCT03479307|Active Comparator|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|
16472784|NCT03479307|Placebo Comparator|Vehicle of Bilastine Ophthalmic Solution|
16472785|NCT03479294||Exposure group|Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
16472786|NCT03479294||Control group|Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.
16472787|NCT03479268|Experimental|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
16472788|NCT03479255|Experimental|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.
~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
16472789|NCT03479255|Active Comparator|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
16472790|NCT03479229|Experimental|Geneveve Treatment|Active Treatment
16472791|NCT03479229|Placebo Comparator|Sham Treatment|Sham Treatment
16472792|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
16472793|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
16472794|NCT03479203|Experimental|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
16472797|NCT03479177|Experimental|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
16472798|NCT03479177|No Intervention|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
16472799|NCT03479164|Experimental|Ultra Low-Dose CT|One non-contrast gated aortic (NCGA) computer tomography scan, a low radiation, non-contrast, low cost CT based study
16472800|NCT03479151|Experimental|MR-HIFU of painful bone metastases|Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
16472801|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with long acting beta agonists (LABA) + high doses inhaled corticosteroids (ICS) with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
16472802|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
16472803|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
16472804|NCT03479112|Experimental|Flashcards|Study participants in this arm of the trial received bleeding control flashcards that contain diagrams and figures to correctly identify the severity of the injury and visual instructions on the appropriate application of pressure dressing, hemostatic packing, and tourniquet.
16472805|NCT03479112|Experimental|Audio-kit|Study subjects in this arm received a commercially available audio bleeding control kit. The kit included a diagram and visual aids to identify the correct severity of the injury and determine the appropriate method of bleeding control. The kit also had buttons on it to play stepwise audio instructions on the application of compression dressing, hemostatic packing and tourniquet application in two languages (English and Spanish). The audio kits were bought at the market price and the name of the manufacturer was not mentioned in the manuscript to avoid conflict of interest.
16472806|NCT03479112|Experimental|Bleeding Control (B-Con) training|Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
16472807|NCT03479112|No Intervention|Control|Study subjects in this arm of the trial received no intervention (no training or access to point-of-care prompts) to assess baseline competence in hemorrhage control.
16472808|NCT03479112|Experimental|Retention of B-Con course|Control, Audio-kit, and flashcard arms undergo B-Con training at the completion of the initial evaluation, and the B-Con arm completed training prior to testing in order that all participants obtain training and then can be evaluated at retention testing. a. 3-9 months after the trial, investigators planned to test all study subjects with a simulated mass causality scenario for retention of knowledge and skills. This test will be the same as the initial test for competence at tourniquet placement in the trial and the same evaluation form will be used to evaluate the study subjects.
16472809|NCT03479086|Experimental|Topiramate|Topiramate 200mg/day
16472810|NCT03479086|Experimental|Naltrexone|Naltrexone 50mg/day
16472811|NCT03479073||Stroke group|Patients who experienced stroke or systemic embolic event following catheter ablation for AF.
16472812|NCT03479073||Control group|Patients who did not experienced stroke or systemic embolic event following catheter ablation for AF.
16472813|NCT03479060|Active Comparator|Continue WCT Application|From the 3rd month to the 12th month Wet cupping applied as an intervention MIDAS was applied at the end of the 6th and 12th months.
16472814|NCT03479060|No Intervention|Discontinue WCT Application|No intervention in this arm.Only MIDAS applied
16472815|NCT03479047|Experimental|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
16472816|NCT03479034||Group 1|"Ages 18-85
~Cognitively able to understand instructions and care for themselves
~Lives in the community (not institutionalised)
~Owner of a smartphone and able to use Apps
~On 3 or more chronic prescription medications
~Has had experience with prescriptions in Australia for at least 1 year
~Current patient attending Holdsworth House Medical Practice
~Willing to use the ScalaMed ePrescription application"
16472817|NCT03479008||Phase I|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. Volunteers will be randomized to receive alternating 5 minute episode of various vibration frequencies.
16472818|NCT03479008||Phase 2|Based on data collected from Phase I used to determine optimal vibration strategies, the investigators will recruit critically ill patients from the Intensive Care unit who are expected to be immobilized for a prolonged period of time due to the nature of their illness. these patient subjects will undergo up to three 5-10 minute vibration sessions a day for 5 days. Similar physiologic responses will be measured in these patients. Baseline blood values will be taken at prior to the first day of vibration and then additional samples taken at the end of each day of vibration. No randomization will take place in this phase.
16472823|NCT03478969|Experimental|Group A: Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
16472824|NCT03478969|Experimental|Group B: MDI, then Accu-Chek® Solo|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
16472825|NCT03478969|Experimental|Group C: mylife™ OmniPod®, then Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
16472826|NCT03478956|Experimental|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
16472827|NCT03478956|Experimental|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
16472828|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
16472829|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
16472830|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
16472831|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
16472833|NCT03478904|Experimental|4x40mg Enzalutamide Capsule Followed by 160mg Enzalutamide Liquid|Enzalutamide capsule (Treatment A) followed by enzalutamide liquid (Treatment B)
16472834|NCT03478904|Experimental|160mg Enzalutamide Liquid Followed by 4x40mg Enzalutamide Capsule|Enzalutamide liquid (Treatment B) followed by enzalutamide capsule (Treatment A)
16472835|NCT03478891|Experimental|Group 1: 5 mg/kg IV|Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
16472836|NCT03478891|Experimental|Group 2: 25 mg/kg IV|Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
16472837|NCT03478891|Experimental|Group 3: 50 mg/kg IV|Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.
16472838|NCT03478878|Experimental|Participants|Participants with reticular pseudodrusen
16472839|NCT03478865|Experimental|Participants|Participants with age-related macular degeneration
16472840|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
16472841|NCT03478839||CRF completion|Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.
16472842|NCT03478826||ILD|250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
16472843|NCT03478826||Healthy|100 healthy participants as a control group.
16472844|NCT03478826||Pneumonia|25 patients with pneumonia as a control group.
16472845|NCT03478813|Experimental|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
16472846|NCT03478813|No Intervention|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
16472847|NCT03478800|Experimental|High school football players and acupuncture|50 healthy high school football players without active musculoskeletal injury
16472848|NCT03478787|Experimental|Risankizumab|Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
16472849|NCT03478787|Active Comparator|Secukinumab|Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.
16472850|NCT03478774|Active Comparator|Control|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, continuous videolaryngoscopy will be performed.
16472851|NCT03478774|Experimental|High flow|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
16472852|NCT03478774|Experimental|medium flow|These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
16472853|NCT03478774|Experimental|low flow|These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
16472854|NCT03478774|Experimental|minimal flow|These patients will receive a standard tracheal tubes after induction of general anesthesia, with 100% Oxygen and Minimum-flow 0.25l/min. The measurement period is 15 or 30 minutes.
16472855|NCT03478748|Active Comparator|one-to-one dental health education|Conventional oral health education programme that mainly focuses at child level, which has been the normal practice at the Ministry of Health, were provided to the control participants.
16472856|NCT03478748|Experimental|anticipatory guidance technique|Anticipatory guidance technique were applied where appropriate dental health education (according to the children's milestones) were provided to mothers and their children.
16472857|NCT03478735|Experimental|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
16472858|NCT03478735|Active Comparator|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
16472859|NCT03478722||Maintenance Hemodialysis Patients|Protein meal, stable isotope amino acid infusion
16472860|NCT03478722||Control Subjects|Protein meal, stable isotope amino acid infusion
16472861|NCT03478709||Volume expansion|
16472862|NCT03478709||norepinephrine|
16472863|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
16472864|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
16472865|NCT03478683|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
16472866|NCT03478683|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
16472867|NCT03478670||ADA-SCID subjects treated with Strimvelis|Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy
16472868|NCT03478657|Experimental|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
16472869|NCT03478644|Experimental|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
16472870|NCT03478644|Placebo Comparator|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
16472871|NCT03478631|Experimental|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
16472872|NCT03478631|Active Comparator|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
16472873|NCT03478618|Active Comparator|Group R|30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative.
16472874|NCT03478618|Active Comparator|Group L|30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative.
16472875|NCT03478605|Experimental|Olanzapine|Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;
16472876|NCT03478605|Active Comparator|Aprepitant|Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;
16472879|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
16472880|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
16472881|NCT03478553||People with IPF|
16472882|NCT03478553||Family members without IPF|
16472883|NCT03478527|Experimental|verum condition probiotics|The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
16472884|NCT03478527|Placebo Comparator|placebo condition|In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
16472885|NCT03478514|Experimental|Single Arm|"All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.
~Ibrutinib will be administered at 560 mg oral continuously."
16472886|NCT03478501|Experimental|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
16472887|NCT03478501|No Intervention|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
16472888|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.
~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
16472889|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
16472890|NCT03478475|Experimental|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
16472891|NCT03478475|Placebo Comparator|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
16472892|NCT03478462|Experimental|CLR 131|CLR 131 intravenous administration
16472893|NCT03478449|Experimental|Fine sorting lymph node group|
16472894|NCT03478449|No Intervention|Regional sorting lymph node group|
16472895|NCT03478436|Other|fed group|14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
16472896|NCT03478436|Other|fasting group|14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
16472897|NCT03478423|Experimental|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.
~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
16472898|NCT03478423|Experimental|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.
~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
16472899|NCT03478423|Experimental|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.
~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
16472900|NCT03478410|Other|Atrial fibrillation|An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
16472901|NCT03478410|Other|Control|An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
16472902|NCT03478397|Active Comparator|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
16472903|NCT03478397|No Intervention|Usual Care|Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
16472904|NCT03478384|Experimental|Coaching group|Patient coaching
16472905|NCT03478384|No Intervention|Control group|Control group - no additional coaching provided
16472906|NCT03478371|Sham Comparator|Marketed Tampon D|Regular absorbency tampon
16472907|NCT03478371|Sham Comparator|Marketed Tampon M|Regular absorbency tampon
16472908|NCT03478371|Sham Comparator|Marketed Tampon T|Regular absorbency tampon
16472909|NCT03478371|Sham Comparator|Marketed Tampon V|Regular absorbency tampon
16472910|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
16472911|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
16472912|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
16472913|NCT03478358|Experimental|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
16472914|NCT03478345|Experimental|THRIVE Study|
16472915|NCT03478332|Active Comparator|Treatment group|The aim of the arm is to test if the addition of Yangxinshi pills to the conventional coronary heart disease medicine will improve the exercise tolerance of the coronary heart disease
16472916|NCT03478332|Placebo Comparator|Control group|The patients of the control group are treated with conventional coronary heart disease medicine plus the placebos-Yangxinshi simulant
16472917|NCT03478319|Experimental|Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
16472918|NCT03478319|Experimental|Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
16472923|NCT03478306|Active Comparator|Arm 1|Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
16472924|NCT03478306|Placebo Comparator|Arm 2|Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
16472925|NCT03478293|Experimental|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
16472926|NCT03478280|Active Comparator|Brodalumab|Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
16472927|NCT03478280|Placebo Comparator|Placebo|Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
16472928|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
16472929|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
16472930|NCT03478254||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
16472931|NCT03478241|Active Comparator|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
16472932|NCT03478241|Active Comparator|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
16472933|NCT03478241|Active Comparator|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
16472934|NCT03478228|Experimental|Multi-Sensory Training (MST)|Multi-Sensory Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
16472935|NCT03478228|Active Comparator|Wrist Stabilisation Training (WT)|Wrist Stabilisation Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
16472936|NCT03478215|Experimental|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.
~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
16472937|NCT03478215|Placebo Comparator|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
16472938|NCT03478202|Experimental|Open Label RELEASE Supplement|
16472939|NCT03478176||Patients|
16472940|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
16472941|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
16472942|NCT03478150|Experimental|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol and applied in the cavity, where the ethanol evaporates, while the zinc oxide nano-particles infiltrate into the carious floor of the cavity.
16472943|NCT03478150|Experimental|laser diode|Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
16472944|NCT03478137|Experimental|CPAP intervention|Over the course of 4-7 months, participants will have to wear the CPAP every night, at least 4 hours per night.
16472945|NCT03478137|No Intervention|Control 1|Eligible participants who declined to participate in the study. Their main study visit data will be used to compare with the intervention group.
16472946|NCT03478137|No Intervention|Control 2|Eligible participants who were not approached, hence not given the opportunity to accept or decline. Their main study visit data will be used to compare with the intervention group.
16472947|NCT03478124||PSP patients|Patients suffering from Progressive Supranuclear Palsy (PSP)
16472948|NCT03478124||PD Patients|Patients suffering from Parkinson's disease (PD)
16472949|NCT03478111|Experimental|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.
~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
16472950|NCT03478111|Active Comparator|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.
~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
16472951|NCT03478098|Experimental|10 Roux-en-Y Gastric Bypass patients|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
16472952|NCT03478098|Experimental|10 control subjects|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
16472953|NCT03478085|Active Comparator|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
16472954|NCT03478085|Experimental|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by >50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
16472955|NCT03478085|Placebo Comparator|Control|Patients will be advised to walk independently.
16472956|NCT03478059|Experimental|Mild Traumatic Brain Injury|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.
~Subjects with mTBI residuals will be gently progressed through exercise stations in an individually tailored fashion."
16472957|NCT03478059|Other|Healthy Control|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.
~In addition to providing comparison data, the healthy control, athletic 18-34 year old subjects will be used to identify levels and intensity of progressions of dual-task training stations appropriate for highly trained athletes and military personnel recovering from concussion."
16472958|NCT03478046|Experimental|Obese individuals|Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
16472959|NCT03478033|Active Comparator|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.
~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
16472960|NCT03478033|Experimental|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.
~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W<50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
16472961|NCT03478020|Experimental|Pre-Treatment, Treatment Cycles A & B|"Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.
~Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.
~Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days"
16472962|NCT03478007|No Intervention|Usual Treatment|Usual standard of care (exercises)
16472963|NCT03478007|Experimental|Intervention Technology Only|Exercises with technology alone
16472964|NCT03478007|Experimental|Intervention Technology Plus Coaching|Exercises with technology plus coaching
16472965|NCT03477994|Active Comparator|dexmedetomidine group|"Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
~+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur."
16472966|NCT03477994|Sham Comparator|clonidine group|In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
16472967|NCT03477981|Other|Study cohort|Participants will receive standard white bread for two weeks and then alginate bread for two weeks. All participants will receive the bread in the same order.
16472968|NCT03477968||PE|"Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.
~Enrolment completed for this group : 13th February 2020"
16472969|NCT03477968||DVT|"Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.
~Enrolment on going"
16472970|NCT03477955|Active Comparator|Peek Group|Patients that received PEEK interspinous spacer
16472971|NCT03477955|Active Comparator|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
16472972|NCT03477955|Active Comparator|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
16472973|NCT03477942|Experimental|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
16472974|NCT03477942|Experimental|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
16472975|NCT03477929|Experimental|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
16472976|NCT03477929|Experimental|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
16472977|NCT03477916|Other|Control (Placebo FMT and cellulose)|
16472978|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
16472979|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
16472980|NCT03477916|Experimental|FMT + prebiotic fiber|
16472981|NCT03477903|Experimental|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
16472982|NCT03477903|Experimental|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
16472983|NCT03477903|Experimental|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
16472984|NCT03477903|Active Comparator|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
16472985|NCT03477890|Active Comparator|Intervention group (coronary function test results disclosed)|Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter >=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
16472986|NCT03477890|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored.
16472987|NCT03477877|Experimental|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
16472988|NCT03477877|Active Comparator|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
16472989|NCT03477864|Experimental|Arm A (REGN2810, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
16472990|NCT03477864|Experimental|Arm B (ipilimumab, SBRT, surgery)|Participants receive ipilimumab via intraprostatic injection on day 1 of week 1, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
16472991|NCT03477864|Experimental|Arm C (REGN2810, ipilimumab, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 as in Arm A and ipilimumab as in Arm B. Participants also undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
16472994|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
16472995|NCT03477825|Placebo Comparator|Placebo|"Group A: Placebo group (n = 10)
~Supplement appearing similar to Herbal formulations
~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.
~Dose: subjects in this group will take 4 placebo tablets per day"
16472996|NCT03477825|Experimental|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)
~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)
~Each tablet contains 500 mg of R. cordifolia per tablet."
16472997|NCT03477825|Experimental|Triphala|"Group C: Triphala group (n= 10)
~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)
~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula
~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
16472998|NCT03477812||Healthy children|Healthy children 7-14 years of age.
16472999|NCT03477812||Nocturnal enuresis with polyuria|Children with nocturnal enuresis and polyuria aged 7-14 years.
16473000|NCT03477812||Nocturnal enuresis without polyuria|Children without nocturnal enuresis and polyuria aged 7-14 years.
16473001|NCT03477799|Active Comparator|Active|anodal stimulation over the right dlPFC
16473002|NCT03477799|Placebo Comparator|Sham|sham stimulation over the right dlPFC
16473003|NCT03477786|Active Comparator|tight BP|"Interventions: anti-hypertension drug prescription by physician and case management by health educator.
~Blood pressure is targeted at 120/80 mmHg in the tight BP control group."
16473004|NCT03477786|Placebo Comparator|usual BP|"Interventions: The physicians follow their usual care patterns to prescribe anti-HT drugs.
~Blood pressure is targeted at < 140/90 mmHg in the usual BP control group."
16473005|NCT03477773|Experimental|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
16473006|NCT03477773|No Intervention|Control|Continue with their normal habitual lifestyle over the 6-week intervention
16473007|NCT03477747|Experimental|Resistance Training Microcurrent|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of microcurrent after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
16473008|NCT03477747|Sham Comparator|Resistance Training Shadow|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of sham comparator after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
16473009|NCT03477747|Experimental|Endurance Training Microcurrent|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
16473010|NCT03477747|Sham Comparator|Endurance Training Shadow|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
16473011|NCT03477734|Experimental|CS1 & heart monitor - AF patients|Males and females diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
16473012|NCT03477734|Active Comparator|CS1 & heart monitor -Healthy volunteers|Males and females not diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
16473013|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
16473014|NCT03477721||Group without cancer cachexia (TB)|
16473015|NCT03477708||Study group|TCCO2 monitoring
16473016|NCT03477708||Control group|Routine monitoring
16473017|NCT03477695|Experimental|Upright device|Ambulatory use of the Upright device
16473018|NCT03477682|Experimental|Early Ambulation Group|The patient will remain on bed rest for one day following surgery and will be encouraged to be out of bed and ambulating on the second day following surgery.
16473019|NCT03477682|No Intervention|Standard Group|The patient will remain on bed rest for five days following surgery and will be encouraged to be out of bed and ambulating on the sixth day following surgery.
16473020|NCT03477669|Experimental|chamomile/probiotic arm|Infant will receive 5 drops of the study product once per day with a feeding at midday.
16473021|NCT03477669|Placebo Comparator|Placebo of chamomile/probiotic arm|Infant will receive 5 drops of a placebo product once a day at midday.
16473022|NCT03477656|Experimental|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption according to the initial isoagglutinin titer.
16473023|NCT03477656|Experimental|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis according to the initial isoagglutinin titer.
16473024|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between 01/01/2015 to 01/04/2018
16473025|NCT03477630|Experimental|Platelet Rich Plasma|Infiltration injected 8 cc per session, 4 sessions, 1 session every 15 days.
16473026|NCT03477630|Active Comparator|Hyaluronic Acid|Infiltration, injected 6 cc per session, 1 sessions.
16473027|NCT03477617|Experimental|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
16473028|NCT03477617|Active Comparator|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
16473029|NCT03477604|Experimental|MicroStent and Standard PTA|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
16473030|NCT03477604|Active Comparator|Standard PTA|
16473031|NCT03477591|Experimental|Evidence + PDA|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
16473032|NCT03477591|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
16473033|NCT03477591|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
16473034|NCT03477578||FoG+|Parkinsonian patients with Freezing of Gait
16473035|NCT03477578||FoG-|Parkinsonian patients withou Freezing of Gait
16473036|NCT03477565|Experimental|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.
~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
16473037|NCT03477565|No Intervention|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
16473038|NCT03477552|Experimental|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
16473039|NCT03477552|Active Comparator|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
16473040|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT.
~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
16473041|NCT03477526|Experimental|COPD patients (GOLD stage III-IV)|
16473042|NCT03477526|Active Comparator|IPF patients|
16473043|NCT03477513|Experimental|Single Arm|Dose-escalated radiation therapy
16473044|NCT03477500|Experimental|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.
~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.
~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.
~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
16473045|NCT03477500|Active Comparator|Alemtuzumab|Alemtuzumab 12 mg iv daily on 5 consecutive days at first alemtuzumab treatment cycle, followed by 3 consecutive days at the second alemtuzumab treatment cycle 12 months later.
16473046|NCT03477487|Experimental|Lowest dose|The lowest dose of XT-150 in the escalation schedule
16473047|NCT03477487|Experimental|Second dose|The 2nd dose of XT-150 in the escalation sequence
16473048|NCT03477487|Experimental|Third dose|The 3rd dose of XT-150 in the escalation sequence
16473049|NCT03477487|Experimental|Highest dose|The highest dose of XT-150 in the escalation sequence
16473050|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
16473051|NCT03477448|Active Comparator|PPD group|"This group will include 20 patients who will be treated with IL injection of PPD at a dose of 10 IU (0.1 ml) supplied an insulin syringe in the largest wart.
~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions"
16473052|NCT03477448|Active Comparator|Bleomycin group|"This group will include 20 patients who will be treated with IL injection of bleomycin.
~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions, if needed."
16473053|NCT03477435|Experimental|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
16473054|NCT03477435|Experimental|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
16473055|NCT03477422|Experimental|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|"CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was an Experimental drug in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. It was administered twelve hourly through intravenous route as infusion over 30 minutes. The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the Principal Investigator (PI).
~Interventions:
~Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)
~Drug: Matching Placebo"
16473056|NCT03477422|Active Comparator|Meropenem|"Meropenem was the active comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg. It was administered eight hourly through intravenous route as infusion over 30 minutes.The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the PI.
~Interventions:
~Drug: Meropenem
~Drug: Matching Placebo"
16473057|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
16473058|NCT03477396|Experimental|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16473061|NCT03477344|Active Comparator|Dexmédétomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
16473062|NCT03477344|Placebo Comparator|Sodium Chloride 0,9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
16473063|NCT03477318||Patients undergoing screening colonoscopy|Patients undergoing first-time colonoscopy using white light with at least 1 polyp resected.
16473064|NCT03477305|Experimental|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
16473067|NCT03477279|No Intervention|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
16473068|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
16473069|NCT03477279|No Intervention|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
16473070|NCT03477266|Experimental|Mouth dissolving mosapride|Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
16473071|NCT03477266|Placebo Comparator|Placebo mouth dissolving tablets|Dummy identical tablets taken in the same way
16473072|NCT03477253|Active Comparator|LC within 72 hours of disease onset|Immediate laparoscopic cholecystectomy within 72 hours of the onset of symptoms was performed in these patients
16473073|NCT03477253|Active Comparator|LC after 72 hours of disease onset|Late laparoscopic cholecystectomy after 72 hours of the onset of symptoms was performed in these patients
16473074|NCT03477227|Experimental|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
16473075|NCT03477227|Active Comparator|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
16473076|NCT03477214||Normal|No UI, no OAB conditions. Transvaginal biomechanical and electromyography mapping will be completed.
16473077|NCT03477214||Urinary incontinence|Urinary incontinence conditions. Transvaginal biomechanical and electromyography mapping will be completed.
16473078|NCT03477214||Overactive bladder|Overactive bladder conditions
16473079|NCT03477201|Experimental|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Intervention: 30 patients will undergo a robotic assisted laparoscopic inguinal hernia repair. This will be done using the DaVinci Robotic Platform by Intuitive Surgical. This an accepted safe method of repairing inguinal hernia. This platform uses special robotic ports produced and supplied by Intuitive Surgical required to dock the machine to the patient. Monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
16473080|NCT03477201|Active Comparator|Standard Laparoscopic inguinal hernia repair|Intervention: 30 patients will undergo a laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia. This platform uses standard laparoscopic ports. In our institution we use plastic ports made by Covidien, Boulder, CO. The operation will require two 5mm VersaPort (Covidien) and a Hassan Port. As in the robotic arm, monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
16473081|NCT03477188|Experimental|Somatosensorial and Vestibular Exercises Group|This group of patients received patients with acute stroke. It will be applied somatosensorial and vestibular rehabilitation additional conventional therapy
16473082|NCT03477188|Active Comparator|Conventional Group|This Group patients received patient with acute stroke. It will be applied classical physiotherapy and conventional exercises.
16473083|NCT03477175|Experimental|Cohort A : Lenvatinib|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
16473084|NCT03477175|Experimental|Cohort B: Lenvatinib plus Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
16473085|NCT03477175|Experimental|Cohort C: Comparator drug|"The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo.
~For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo."
16473086|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
16473087|NCT03477149|Experimental|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
16473088|NCT03477136||First group: semen parameter showing normospermic|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
16473089|NCT03477136||second group: semen parameter asthenozoospermic|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
16473090|NCT03477136||Third group: semen parameter oligozoospermic|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
16473091|NCT03477136||Forth groupsemen parameter: astheno-teratozoospermic,|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
16473092|NCT03477136||Fifth group semen parameter: oligo asthenoteratozoospermia|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
16473093|NCT03477123|Experimental|Intervention|Walking therapy with Exo-H2 exoskeleton
16473094|NCT03477123|No Intervention|Control|Group receiving conventional walking therapy without robotic exoskeleton
16473095|NCT03477110|Experimental|Treatment (temozolomide, radiation, NovoTTF-200A device)|Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16473096|NCT03477097|No Intervention|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
16473097|NCT03477097|Experimental|Control group w/ social network intervention|Subjects only received the intervention of social network.
16473098|NCT03477097|Experimental|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
16473099|NCT03477097|Experimental|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
16473100|NCT03477097|Experimental|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
16473101|NCT03477097|Experimental|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
16473102|NCT03477097|Experimental|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
16473103|NCT03477097|Experimental|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
16473104|NCT03477097|Experimental|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
16473105|NCT03477097|Experimental|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
16473106|NCT03477097|Experimental|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
16473107|NCT03477097|Experimental|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
16473108|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
16473109|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
16473110|NCT03477058|Experimental|WO 3308 cosmetic product for topical use|WO 3308 is used to treat acute or chronic pruritus
16473111|NCT03477045|Active Comparator|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
16473112|NCT03477045|Experimental|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
16473113|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
16473114|NCT03477019|Other|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
16473115|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
16473116|NCT03477019|Other|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
16473117|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
16473118|NCT03477006|No Intervention|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
16473119|NCT03476993|Experimental|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
16473120|NCT03476980|Active Comparator|Randomized to Umbilical Cord Milking at birth|Milking the umbilical cord towards the infant at a speed of 20cm/2seconds at birth.
16473121|NCT03476980|Active Comparator|Randomized to Delayed Cord Clamping at birth|Delayed clamping of the umbilical cord at birth.
16473122|NCT03476967||Pretreatment x Posttreatment|The group was evaluated through non-invasive complementary examinations before laser therapy and at the 1-year follow-up visit to analyze possible optical disc alterations that may occur after retinal panretinal photocoagulation in patients with proliferative diabetic retinopathy.
16473123|NCT03476941|Experimental|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
16473124|NCT03476941|Placebo Comparator|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
16473125|NCT03476928|Experimental|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
16473126|NCT03476928|Experimental|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
16473127|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
16473128|NCT03476902|Experimental|Integrated Mobile Treatment|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
16473129|NCT03476889|Experimental|Intervention|Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
16473130|NCT03476889|Active Comparator|Control|Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
16473131|NCT03476889|No Intervention|Breastfed reference|Exclusively breastfed from birth to study completion
16473132|NCT03476876|Experimental|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
16473133|NCT03476876|Active Comparator|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
16473134|NCT03476863|Experimental|Alveolar Recruitment Maneuver|
16473135|NCT03476863|Active Comparator|Conventional mechanical ventilation|
16473136|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
16473137|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
16473138|NCT03476837|Experimental|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample and WCG's carbon monoxide.
16473139|NCT03476837|Active Comparator|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
16473140|NCT03476811|No Intervention|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
16473141|NCT03476811|Active Comparator|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
16473142|NCT03476811|Placebo Comparator|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
16473143|NCT03476798|Experimental|Bevacizumab + Rucaparib|
16473144|NCT03476785|Experimental|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
16473145|NCT03476785|Placebo Comparator|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
16473146|NCT03476772|No Intervention|A|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % via caudal route to achieve post operative analgesia
16473147|NCT03476772|Active Comparator|B|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % plus 0.1 mg nalbuphine via caudal route to achieve post operative analgesia
16473148|NCT03476759|Active Comparator|Tubal adhesiolysis|laparoscopic tubal adhesiolysis and\or tuboplasty
16473149|NCT03476759|Active Comparator|IVF/ICSI|These patients will undergo IVF/ICSI
16473150|NCT03476746|Experimental|LEO 90100 foam|"LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g).
~Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total).
~Pivotal part: To be decided based on the result of the pilot part"
16473151|NCT03476746|Active Comparator|Dovobet® ointment|"Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total).
~Pivotal part: To be decided based on the result of the pilot part"
16473152|NCT03476733||patient with drug related problem|patient with drug related problem
16473153|NCT03476733||patient without drug related problem|patient without drug related problem
16473154|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
16473155|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
16473156|NCT03476694|Experimental|20ml of 0.75% Ropivacine|
16473157|NCT03476694|Experimental|25ml of 0.75% Ropivacine|
16473159|NCT03476668|Active Comparator|RPD PD patients|Right-side affected PD patients. Intervention: MIRT
16473160|NCT03476668|Active Comparator|LPD PD patients|Left-side affected (LPD) PD patients. Intervention: MIRT
16473161|NCT03476655||Participants with Chronic Lymphocytic Leukemia (CLL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
16473162|NCT03476655||Participants with Mantle Cell Lymphoma (MCL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
16475079|NCT03463837|Sham Comparator|Smoking cessation (no smoking)|Smoking cessation (no smoking).
16473163|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
16473164|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
16473165|NCT03476629|Experimental|Combined Training|Combined Training with 2 types of physical activity
16473166|NCT03476629|Experimental|Standard Training|Physical activity with aerobic exercise
16473167|NCT03476629|Experimental|Respiratory Muscle Training|Respiratory muscle performance
16473168|NCT03476616|Active Comparator|Eplerenone (-based therapy) arm|"Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.
~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.
~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
16473169|NCT03476616|Active Comparator|Valsartan (-based therapy) arm|"Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.
~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.
~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
16473170|NCT03476590|No Intervention|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
16473171|NCT03476590|Experimental|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -> (7') summary visit (12th month after the enrolment) performed by physician.
~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
16473172|NCT03476564|Experimental|intervention group|intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
16473173|NCT03476564|No Intervention|comparison group|. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
16473174|NCT03476499|Experimental|Planned skin flap procedure|"Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent.
~Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure.
~The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care.
~The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.
~One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery.
~One set of intra-operative Images that will be taken intra-operatively following the mastectomy.
~One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care."
16473175|NCT03476486|Experimental|Treatment|The hand that was subject to thread carpal tunnel release surgery
16473176|NCT03476486|No Intervention|Control|The hand that was not treated
16473177|NCT03476460|Experimental|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
16473178|NCT03476460|Active Comparator|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
16473179|NCT03476447|Active Comparator|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
16473180|NCT03476447|Active Comparator|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
16473181|NCT03476447|Active Comparator|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
16473182|NCT03476447|Placebo Comparator|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
16473183|NCT03476434|No Intervention|group A (HR-WLE)|Two tandem colonoscopies: first inspection was on high-resolution white-light endoscopy from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection also on HR-WLE.
16473184|NCT03476434|Experimental|group B (HR_CE)|two tandem colonoscopies: first inspection was on HR-WLE from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection with panchromoendoscopy on indigo carmine.
16473185|NCT03476421||R0 hepatectomy|Those HCC patients operated with standard R0 hepatectomy
16473186|NCT03476421||R1par hepatectomy|Those HCC patients operated with R1par hepatectomy
16473187|NCT03476421||R1vasc hepatectomy|Those HCC patients operated with R1vasc hepatectomy
16473188|NCT03476421||R1par+R1vasc hepatectomy|Those HCC patients operated with both R1par and R1vasc hepatectomy
16473189|NCT03476408|Experimental|Single Group Correlation|Correlation between these topics.
16473190|NCT03476382|Experimental|Experimental Group|Participants use active Ultrasound Bone Growth Stimulator device according to Investigational Protocol.
16473191|NCT03476369|Experimental|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
16473192|NCT03476369|Active Comparator|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
16473193|NCT03476356|Experimental|Group L|This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.
16473194|NCT03476356|Active Comparator|Group C|This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.
16473195|NCT03476343|Experimental|MRI for Neonates|MRI
16473197|NCT03476317|Experimental|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
16473198|NCT03476317|Placebo Comparator|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
16473199|NCT03476317|No Intervention|Group 2|Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.
16473200|NCT03476304|Experimental|Semi-direct composite endocrown restorations|
16473201|NCT03476304|Active Comparator|Post retained direct composite restoration|
16473202|NCT03476304|Active Comparator|Post retained ceramic restoration|
16473203|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
16473204|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
16473205|NCT03476278||regional, questionnaire|patients who underwent surgery under regional anesthesia.
16473206|NCT03476265|Experimental|Ineffective Esophageal Motility and GERD|Patients with gastroesophageal reflux disease (GERD) refractory to proton pump inhibitors (PPI) and ineffective esophageal motility (IEM) according to the Chicago classification v3.0.
16473207|NCT03476252|Experimental|patients|ST elevation myocardial infarction
16473208|NCT03476239|Experimental|Blinatumomab|"Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders.
~In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment.
~In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks."
16473209|NCT03476226|Experimental|Group 1|"The research team will provide the intervention to subjects. Intervention: The nursing-driven Cognitive Dysfunction Coping Strategy Teaching Sheet and provide education as to its use.
~QOL survey administered"
16473210|NCT03476226|No Intervention|Group 2|Provide current standard of education for cognitive dysfunction. QOL survey administered
16473211|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
16473212|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
16473213|NCT03476200|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy consisting of fourteen weekly group sessions, one hour and a half each, directed by two clinical psychologist.
16473214|NCT03476200|No Intervention|Control Group|Control Group with no intervention.
16473215|NCT03476187|Experimental|µCor wearers|Wear the µCor device
16473216|NCT03476174|Experimental|Pembrolizumab and HD Interleukin 2|Pembrolizumab 200 mg IV over 30 minutes; Day 1 of each cycle 3 weeks (21 days) for 2 cycles. IL-2 600,000 IU/kg2 IV over 15 minutes every 8 hours for up to 14 doses over 5 days; Days 1-5 = Cycle 1; 9 days of rest in between; Days 15-19 = Cycle 2
16473217|NCT03476161|Other|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive
~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
16473218|NCT03476161|Other|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive
~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
16473219|NCT03476148|Experimental|Interactive Device Rehabilitation|
16473220|NCT03476148|Active Comparator|Inpatient Rehabilitation|
16473221|NCT03476135|Experimental|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
16473222|NCT03476135|Experimental|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
16473223|NCT03476122||Disease Group|The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
16473224|NCT03476122||Control Group|The control group will receive Colonoscopy
16473225|NCT03476109|Active Comparator|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).
~Non responders will be switched to mepolizumab arm."
16473226|NCT03476109|Active Comparator|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).
~Non responders will be switched to omalizumab arm."
16473227|NCT03476096||Control|healthy pregnant women
16473228|NCT03476096||Pre-eclampsia|high-risk pregnant women
16473229|NCT03476083|Experimental|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
16473230|NCT03476083|Active Comparator|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
16473231|NCT03476070||AYA cancer patients|Patients (aged between 15-39) diagnosed with breast cancer, lymphoma or germ cell tumor
16473232|NCT03476070||Healthy controls|Healthy controls
16473233|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
16473234|NCT03476044|Active Comparator|Group Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
16473235|NCT03476044|Active Comparator|Group Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
16473236|NCT03476031||study group|patients with hepatitis c nephropathy detected by lab and renal biopsy
16473237|NCT03476018|Placebo Comparator|Placebo|
16473238|NCT03476018|Experimental|0.2 microgram Z-100|
16473239|NCT03476018|Experimental|2 microgram Z-100|
16473240|NCT03476018|Experimental|20 microgram Z-100|
16473241|NCT03476005|Active Comparator|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
16473242|NCT03476005|No Intervention|Historical controls|no extra training provided
16473243|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.
~Core needle biopsy performed ≥14 days before the microwave breast investigation"
16473244|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.
~No prior biopsy"
16473245|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.
~Core needle biopsy performed ≥14 days before the microwave breast investigation"
16473246|NCT03475966|Experimental|Prehabilitation|Exercise, nutrition and relaxation techniques all beginning four weeks prior to surgery date.
16473247|NCT03475966|Active Comparator|Rehabilitation|Exercise, nutrition and relaxation techniques all beginning immediately after surgery.
16473248|NCT03475953|Experimental|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473249|NCT03475953|Experimental|Phase 2 : cohort A Regorafenib + Avelumab|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473250|NCT03475953|Experimental|Phase 2 : cohort B Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473251|NCT03475953|Experimental|Phase 2 : cohort C Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473252|NCT03475953|Experimental|Phase 2 : cohort D Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473253|NCT03475953|Experimental|Phase 2 : cohort E Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473254|NCT03475953|Experimental|Phase 2 : cohort F Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473255|NCT03475953|Experimental|Phase 2 : cohort G Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473256|NCT03475953|Experimental|Phase 2 : cohort H Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473257|NCT03475953|Experimental|Phase 2 : cohort I Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473258|NCT03475953|Experimental|Phase 2 : cohort A' Regorafenib low-dose + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
16473259|NCT03475914||Psoriasis vulgaris|Pathological conditions stable for at least 1 month before collection. One punch biopsy from each patient, was taken from a big reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
16473260|NCT03475914||Psoriasis guttate|One punch biopsy from each patient, was taken from a small reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
16473261|NCT03475914||Healthy skin of psoriasis vulgaris|Healthy skin area of 2mm2 belonging to the left gluteus from patients affected by psoriasis vulgaris
16473262|NCT03475914||Healthy skin of psoriasis guttate|Healthy skin area of 2mm2 belonging to the left gluteus rom patients affected by psoriasis guttate
16473263|NCT03475901|Experimental|Virtualy Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
16473264|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
16473265|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization
16473266|NCT03475888|Active Comparator|Group C|Patients with an untreated CTO
16473267|NCT03475875|Experimental|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
16473268|NCT03475875|Experimental|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
16473269|NCT03475862|Experimental|PTI-821 Manipulated|oxycodone 40 mg capsule
16473270|NCT03475862|Active Comparator|Oxycodone|Oxycodone 40 mg IR tablet crushed
16473271|NCT03475862|Active Comparator|OxyContin|Oxycodone ER 40 mg tablet crushed
16473272|NCT03475862|Placebo Comparator|Placebo|Matching placebos for experimental and active comparator arms
16473273|NCT03475862|Experimental|PTI-821 Non-manipulated|Oxycodone 40 mg non-manipulated
16473274|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
16473275|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
16473276|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
16473277|NCT03475836|Placebo Comparator|Placebo|Vegetable oil
16473278|NCT03475836|Active Comparator|High-dose mint essential oil|100 μL Mentha piperita essential oil (in vegetable oil)
16473279|NCT03475836|Active Comparator|Low-dose mint essential oil|50 μL Mentha piperita essential oil (in vegetable oil)
16473280|NCT03475823|Placebo Comparator|Placebo control|Inert comparator indistinguishable from active interventions
16473281|NCT03475823|Active Comparator|Active control|240 mg ginkgo biloba
16473282|NCT03475823|Experimental|Low dose sideritis scardica|475 mg sideritis scardica
16473283|NCT03475823|Experimental|High dose sideritis scardica|950 mg sideritis scardica
16473284|NCT03475810|Experimental|VR GROUP|Patients watches 3D documentary videos on virtual reality glasses
16473285|NCT03475810|Active Comparator|midazolam|Patients do not watch virtual reality videos but will be administered iv sedative drugs before spinal attempt.
16473286|NCT03475797|Experimental|Occipital Nerve Stimulation (ONS)|Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
16473287|NCT03475797|Active Comparator|Optimal Medical Management (OMM)|Optimal Medical Management according to what is done in routine clinical practice
16473288|NCT03475784|Experimental|Restricted fluid therapy group|Restrictive fluid therapy: this group will not receive fluid pre-load, and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2mL/Kg/hour.
16473289|NCT03475784|Active Comparator|Liberal fluid therapy group|Liberal fluid therapy: this group will receive fluid pre-load (5 mL/Kg), and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
16473290|NCT03475758|No Intervention|chemotherapy without goserelin|these patients will receive their chemotherapy without addition of Goserelin
16473291|NCT03475758|Experimental|chemotherapy with goserelin|these patients will receive their chemotherapy with addition of Goserelin
16473292|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
16473293|NCT03475745||Control|Healthy controls
16473294|NCT03475732|Experimental|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
16473295|NCT03475719|Active Comparator|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
16473296|NCT03475719|Experimental|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
16473297|NCT03475706|Experimental|Solabegron immediate release tablets low dose|
16473298|NCT03475706|Experimental|Solabegron immediate release tablets high dose|
16473299|NCT03475706|Placebo Comparator|Placebo Comparator|
16473300|NCT03475693|Experimental|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
16473301|NCT03475693|Placebo Comparator|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
16473302|NCT03475680|Experimental|"1)  MBP and oral antibiotics  group"|"Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
~Sennosides colonic preparation (X-PREP) :
~1 per day, on day -2 and day -1.
~Gentamycin :
~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.
~Ornidazole :
~g per day (2 tablet per day), on day -2 and day -1; In tablets."
16473303|NCT03475680|Placebo Comparator|"2)  MBP alone  group"|"Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
~Sennosides colonic preparation (X-PREP) :
~1 per day, on day -2 and day -1.
~Placebo for oral gentamycin:
~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole
~1g per day (2 tablet per day) on day -2 and day -1."
16473304|NCT03475680|Experimental|"3)  Oral antibiotics alone  group"|"Oral Gentamycin Oral Ornidazole
~Gentamycin :
~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.
~Ornidazole :
~g per day (2 tablet per day), on day -2 and day -1; In tablets."
16473305|NCT03475680|Placebo Comparator|"4)  No preparation  group"|"Oral placebo Gentamycin Oral placebo Ornidazole
~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1
~- Placebo for oral ornidazole : Same presentation as oral ornidazole
~1g per day (2 tablet per day) on day -2 and day -1"
16473306|NCT03475654|Experimental|technology-assisted rehabilitation|The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
16473307|NCT03475654|Active Comparator|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
16473308|NCT03475641|Active Comparator|The current standard anesthesia|Standard treatment during procedure
16473309|NCT03475641|Experimental|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
16473310|NCT03475628|Experimental|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
16473311|NCT03475615|Experimental|SOXP|
16473312|NCT03475615|Active Comparator|SOX|
16473313|NCT03475602||Cyclophosphamide|Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
16473314|NCT03475602||Cyclosporin|Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
16473315|NCT03475589|Other|single group|
16473316|NCT03475576|Other|all participants|The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian.
16473317|NCT03475563||Patients with coronary artery disease|(coronary artery disease)
16473318|NCT03475550|Active Comparator|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
16473319|NCT03475550|Active Comparator|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
16473320|NCT03475537|Experimental|the treatment of transcranial direct current stimulation|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
16473321|NCT03475524|Experimental|study Metformin 1000 mg|
16473322|NCT03475524|Experimental|study Metformin 500 mg|
16473323|NCT03475524|Placebo Comparator|control group|
16473324|NCT03475485|Experimental|ID-Capsules- Active|"Randomly-assigned ingestions of ID-Capsules containing ingestible sensors (ID-Capsule- Active) while wearing the ID-Cap Reader (Wearable Sensor) under direct observation
~• Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded."
16473325|NCT03475485|Placebo Comparator|ID-Capsules- Inactive|"Randomly-assigned ingestions of ID-Capsules containing no ingestible sensors while wearing the ID-Cap Reader under direct observation
~• Subjects will also ingest empty placebo capsules that do not contain ingestible sensors. In the absence of an ingested sensor, no signal is received by the Reader after the capsule is ingested, and the ingestion event is not recorded."
16473326|NCT03475459|Experimental|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
16473327|NCT03475446|Placebo Comparator|sham tES healthy elderly|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
16473328|NCT03475446|Placebo Comparator|sham tES MCI|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
16473329|NCT03475446|Placebo Comparator|sham tES AD|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
16473330|NCT03475446|Experimental|real anodal tDCS healthy elderly|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16473331|NCT03475446|Experimental|real anodal tDCS MCI|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16473332|NCT03475446|Experimental|real anodal tDCS AD|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16473333|NCT03475446|Experimental|real tACS healthy elderly|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16473334|NCT03475446|Experimental|real tACS MCI|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16473399|NCT03475056|Experimental|Group 2: cAd3-Marburg vaccine (1x10^11 PU)|cAd3-Marburg vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
16473335|NCT03475446|Experimental|real tACS AD|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16473336|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
16473337|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
16473338|NCT03475420||National Cancer Database|Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
16473339|NCT03475407|Experimental|Treatment Group|Ozurdex intravitreal injection
16473340|NCT03475394|Active Comparator|Group 1 (Chlorhexidine gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 1% chlorhexidine gel administered in subsequent visits.
16473341|NCT03475394|Experimental|Group 2 (Morus alba gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 16% Morus alba gel administered in subsequent visits.
16473342|NCT03475394|Placebo Comparator|Group 3 (Placebo)|Non surgical periodontal treatment at baseline and no gel is applied.
16473343|NCT03475381||Orkambi treated patients|All patients with CF who started ivacaftor+lumacaftor outside of a clinical trial between January 22nd 2016 and January 22nd 2017.
16473344|NCT03475368|Experimental|Vegetarian diet|People randomized to interventional groups will take a vegetarian diet (i.e. without animal products, except milk and eggs)
16473345|NCT03475368|Experimental|Low carbs|People randomized to interventional groups will take a low carbs diet (i.e. with a limited amount of carbohydrates).
16473346|NCT03475368|Active Comparator|Mediterranean diet|People randomized to interventional groups will take a mediterranean diet (i.e. with low glycemic index carbohydrates and vegetables).
16473347|NCT03475355|Experimental|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
16473348|NCT03475355|Experimental|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
16473349|NCT03475355|Experimental|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
16473350|NCT03475355|Experimental|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
16473351|NCT03475355|Active Comparator|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.
~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
16473352|NCT03475355|Active Comparator|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.
~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
16473353|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
16473354|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
16473355|NCT03475329||adenoidectomy with bilateral partial tonsillectomy|
16473356|NCT03475329||adenoidectomy with complete unilateral tonsillectomy|
16473357|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
16473358|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
16473359|NCT03475303|Experimental|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
16473360|NCT03475290|Experimental|Self-Efficacy and Perceived Social Support|
16473361|NCT03475290|Experimental|Perceived Social Support and Self-Efficacy|
16473362|NCT03475290|Active Comparator|Self-Efficacy|
16473363|NCT03475290|Active Comparator|Perceived Social Support|
16473364|NCT03475277||Volunteers|"Participants will receive an IV infusion of ketamine (~.05mg/kg and 0.5mg/kg) or placebo.
~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.
~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives)."
16473365|NCT03475264||Healthy|Healthy Participants
16473366|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
16473367|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
16473368|NCT03475251|Experimental|CS1003|
16473369|NCT03475251|Experimental|CS1003 + regorafenib|
16473370|NCT03475238||Cohort for nursing care|Patients in ICU under oxygen and/or mechanical ventilation and/or vasoactive drugs and/or non-invasive ventilation
16473473|NCT03474575|Other|COPD patient|Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation
16473371|NCT03475225|Experimental|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
16473372|NCT03475225|Placebo Comparator|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
16473373|NCT03475212|Experimental|Virus specific T cell lines (VSTs) against three viruses|The study will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, activated using overlapping peptide libraries spanning immunogenic antigens from CMV, adenovirus and EBV, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy.
16473374|NCT03475199|Experimental|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
16473375|NCT03475199|No Intervention|Control group|General dietary recommendations.
16473376|NCT03475186|Experimental|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
16473377|NCT03475173|Experimental|Laser Speckle Blood Flow Group|
16473378|NCT03475160|Active Comparator|Sildenafil Citrate|Sildenafil Citrate vaginal suppositories: 25 mg every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
16473379|NCT03475160|Placebo Comparator|Placebo|Placebo vaginal suppositories: every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
16473380|NCT03475147|Active Comparator|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
16473381|NCT03475147|Experimental|eyeFusion Patients|Scotoma subjects aged 18-80.
16473382|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
16473383|NCT03475121|Experimental|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
16473384|NCT03475121|Experimental|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
16473385|NCT03475121|Experimental|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
16473386|NCT03475121|Experimental|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
16473387|NCT03475108|Experimental|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
16473388|NCT03475108|Other|Standard Diabetes Care Group|Patients receive standard diabetes care for one year. They receive a community health worker for the second year (as part of a crossover trial).
16473389|NCT03475095|Experimental|LDH patients|"ribs and bones Tuina therapy According to the diagnostic criteria ofvertebral dislocation,determine the position,degree and direction of the dislocation,assess the activity of the affected vertebrae.Treated with combining Tuina of muscle-loosing and bone-setting such as reinforcing ribs，kneading and plucking method,20 min every treatment,twice a week for a total time of 4 weeks."
16473390|NCT03475082|Placebo Comparator|Placebo TENS|30 minute TENS treatment where the stimulation ramps slowly to zero after 45 seconds. The lights/display on the unit are identical to the Active unit.
16473391|NCT03475082|Active Comparator|High Frequency TENS|30 minute TENS treatment at 100 Hertz (HZ). Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
16473392|NCT03475082|Active Comparator|Alternating frequency TENS|30 minute TENS treatment with a pre programed mode alternating from 4 Hz and 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
16473393|NCT03475082|Active Comparator|Modulated frequency TENS|30 minute TENS treatment at a pre programmed mode that ramps between 4 and 125 HZ over 12 seconds. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
16473394|NCT03475082|Active Comparator|High frequency TENS - increasing intensity|30 minute TENS treatment at 100 HZ. Intensity set at initial strong but comfortable setting on day one as above, then subjects asked for possible increases in intensity every 5 minutes on all five days.
16473395|NCT03475069|Experimental|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
16473396|NCT03475069|Experimental|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
16473397|NCT03475069|Experimental|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
16473398|NCT03475056|Experimental|Group 1: cAd3-Marburg vaccine (1x10^10 PU)|cAd3-Marburg vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
16473400|NCT03475043|Experimental|Auditory training: temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.
~Aim 2: Listeners will hear sentences that vary in speech rate for 6, 1-hour training sessions and will receive correct-answer feedback."
16473401|NCT03475043|Active Comparator|Auditory training: non-temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.
~Aim 2: Listeners will hear speech in varying levels of noise during 6, 1-hour training sessions and will receive correct-answer feedback."
16473402|NCT03475043|No Intervention|Passive control group (Aims 1 and 2)|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
16473403|NCT03475030|No Intervention|Usual Care|Patients receive usual care and can continue using their existing pharmacy.
16473404|NCT03475030|Experimental|Smart Pillbox|Patients receive pre-filled medication trays from Curant Health Pharmacy or the Brigham and Women's Hospital Outpatient Pharmacy. The smart pillbox in which pre-filled medication trays are housed provide automated medication reminders.
16473405|NCT03475017|Active Comparator|Supplement A|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
16473406|NCT03475017|Placebo Comparator|Supplement B|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
16473407|NCT03475004|Experimental|Combination Therapy|"Cohort A: Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.
~Cohort B: Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles."
16473408|NCT03474991|Active Comparator|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
16473409|NCT03474991|Placebo Comparator|Placebo|oral placebo matched to the product described above
16473410|NCT03474978|Experimental|Upper Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity
16473411|NCT03474978|Experimental|Lower Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity
16473412|NCT03474965|Experimental|Crizanlizumab|SEG101 (crizanlizumab) administered on Week 1 Day 1, Week3 Day 1 and Day 1 of every 4-week cycle
16473413|NCT03474952|Experimental|Remote ischemic preconditioning (RIPC)|Intervention is remote ischemic preconditioning (RIPC) consists of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) and subsequent 5-min reperfusion applied to upper arm.
16473414|NCT03474952|Sham Comparator|Control (Sham-RIPC)|Intervention is Sham-RIPC (ischemia pressure < 10 mmHg) applied to upper arm.
16473415|NCT03474939|Active Comparator|MIDAZOLAM|Patients receive midazolam 7,5mg night before and 60 minutes prior to surgery as part of preanesthetic medication
16473416|NCT03474939|Placebo Comparator|PLACEBO|Patients receive 1000mg Glucose tablets night before and 60 minutes prior to surgery during premedication
16473417|NCT03474926|Experimental|Routine lymph node dissection (LND) during nephroureterectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
16473418|NCT03474926|Active Comparator|LND for lymph nodes enlargement found before or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery.
16473419|NCT03474913||Standard MRI first|Patients will have a standard of care MRI, then consent to study participation and have an upright MRI.
16473420|NCT03474913||MRIs in random order|Patients will consent to participate in the study, then do two MRIs in random order.
16473421|NCT03474900|Experimental|PLGA implant, Bioretec ltd. Finland|Treatment with biodegradable elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
16473422|NCT03474900|Active Comparator|Titanium elastic stable nail|Treatment with titanium elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
16473423|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
16473424|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
16473425|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
16473426|NCT03474887||PHYSI-Throat+CONTROL-Throat|"Patients choosing to seek primary care through physical consultation with chief complaint sore throat.
~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat."
16473427|NCT03474887||PHYSI-Resp+CONTROL-Resp|"Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.
~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza."
16473428|NCT03474887||PHYSI-Dysuria+CONTROL-Dysuria|"Patients choosing to seek primary care through physical consultation with chief complaint dysuria
~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria."
16473429|NCT03474874|Other|Collagen Dressing and Comparator|NeoMatriX Collagen Dressing and Comparators - positive control and normal saline will be applied to the absorbent pad portion of the exclusive dressing.
16473430|NCT03474861|Experimental|Combination therapy|The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).
16473431|NCT03474848|Experimental|HABIT|Protocol of 90-hour of Hand-Arm Bimanual Intensive Training - 6 hours/day; 5 days/week, for 3 weeks
16473432|NCT03474848|Active Comparator|Conventional Occupational Therapy (OT)|Provision of 2 sessions/week (45 minutes), for 3 weeks
16473433|NCT03474835|Other|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
16473434|NCT03474835|No Intervention|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
16473474|NCT03474562|Experimental|Duowell Tab|Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks
16473435|NCT03474822|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 30 patients in each type cancer and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
16473436|NCT03474796|Experimental|Novice|
16473437|NCT03474796|Experimental|Expert|
16473438|NCT03474783|Experimental|multidisciplinary intervention|
16473439|NCT03474770|Experimental|BIS-001ER|Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
16473440|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
16473441|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
16473442|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
16473443|NCT03474744|Experimental|Experimental Arm|Copanlisib 60 mg i.v. fixed dose days 1,8,15 Rituximab 375 mg/m2 day 1 i.v.
16473444|NCT03474731|Experimental|Diabetes Self Management Program only|group education classes of the Diabetes Self-Management Program, (DSMP)
16473445|NCT03474731|Experimental|Tailored Patient Navigation (PN) only|assisting patients in navigation to physician offices, allowing for standard of care to follow.
16473446|NCT03474731|Experimental|DSMP AND Tailored Patient Navigation|Both group education classes and patient navigation
16473447|NCT03474718|Experimental|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
16473448|NCT03474718|Experimental|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
16473449|NCT03474705|Experimental|Eccentric Training Group|Eccentric training of the upper trapezius muscles. The intervention will consist of ten sessions of 25-30 minutes (twice a week over 5 consecutive weeks) of eccentric exercises of the shoulder muscles, as neural activation increases after 4 weeks of eccentric training. The total duration of the intervention will be 2 hours and a half.
16473450|NCT03474679|Experimental|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
16473451|NCT03474666|Active Comparator|Strict Glycemic Control Group|Intravenous insulin as described by Keegan and Cols. 2010.
16473452|NCT03474666|Active Comparator|Standard Glycemic Control Group|Subcutaneous insulin as instititional protocol.
16473453|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
16473454|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
16473455|NCT03474640|Experimental|Toripalimab 80 mg repeat dose every 14 days|3-6 subjects (Part A)
16473456|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 14 days|3-6 subjects (Part A)
16473457|NCT03474640|Experimental|Toripalimab 480 mg repeat dose every 14 days|3-6 subjects (Part A)
16473458|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 21 days|240 subjects (Part B)
16473459|NCT03474627|Active Comparator|Non-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
16473460|NCT03474627|Experimental|PLGA-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
16473461|NCT03474614|Experimental|treatment group|A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
16473462|NCT03474614|Other|Control Group|A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
16473463|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
16473464|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
16473465|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
16473466|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
16473467|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
16473468|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
16473469|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
16473470|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
16473471|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:
~Teaching about the treatment program
~Teaching important ideas about recovery
~Increasing knowledge about specific problems about addiction
~Demonstrating new ways of coping with skills designed to fit each participant"
16473472|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:
~Teaching about the treatment program
~Teaching important ideas about recovery
~Increasing knowledge about specific problems about addiction
~Demonstrating new ways of coping with skills designed to fit each participant PLUS
~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
16473475|NCT03474562|Active Comparator|Monorova Tab + Amlopin Tab|Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks
16473476|NCT03474549|Experimental|Tigertriever revascularization device|Mechanical thrombectomy with Tigertriever
16473477|NCT03474523|Experimental|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
16473478|NCT03474523|Active Comparator|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
16473479|NCT03474510|Experimental|EXPAREL|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
16473480|NCT03474510|Active Comparator|interscalene nerve block|Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
16473482|NCT03474484||np-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
16473483|NCT03474484||p-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission
16473484|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
16473485|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
16473486|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
16473487|NCT03474458|Experimental|Experimental intervention|doxycycline (100 mg bid)
16473488|NCT03474458|Active Comparator|Control intervention|Standard of care therapy
16473489|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
16473490|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
16473491|NCT03474432|Other|Optical Coherence Tomography|Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.
16473492|NCT03474393|No Intervention|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
16473493|NCT03474393|Experimental|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
16473494|NCT03474380|Experimental|Intervention|"Implementation of iHI-FIVES program
~Intervention: Behavioral: iHI-FIVES"
16473495|NCT03474380|No Intervention|Usual Care|Pre-implementation before iHI-FIVES program
16473496|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
16473497|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
16473498|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.
~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
16473499|NCT03474328|Experimental|Treatment arm|
16473500|NCT03474315||CHF and CIED patients|600 CHF patients with ICD or CRT admitted to regulatory ambulatory visit.
16473501|NCT03474302|Experimental|Physical Activity|The intervention will be a 12-week community-based physical activity promotion program
16473502|NCT03474302|Active Comparator|Successful Aging|Those randomized to the successful aging group will receive health information pertinent to African Americans over the 12 weeks
16473503|NCT03474289|Experimental|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
16473504|NCT03474289|Experimental|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
16473505|NCT03474276|Active Comparator|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).
~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
16473506|NCT03474276|Active Comparator|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
16473507|NCT03474276|Active Comparator|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
16473508|NCT03474263|Experimental|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
16473509|NCT03474237||Non-functioning adrenal incidentaloma|patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
16473510|NCT03474237||Pheochromocytoma|patients who were diagnosed with pheochromocytoma biochemically or histologically
16473511|NCT03474237||Primary aldosteronism|patients who were diagnosed with primary aldosteronism by saline loading test
16473512|NCT03474237||Adrenal cushing syndrome|patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
16473513|NCT03474237||Adrenocortical carcinoma|patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
16473514|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
16473515|NCT03474211||vaccinated|
16473516|NCT03474211||non vaccinated|
16473517|NCT03474198|Active Comparator|Standard TB Management Strategy|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only
16473518|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen B|"TRUNCATE-TB Management Strategy: 8 weeks* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment.
~*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment.
~Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid"
16473519|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen C|"TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B.
~Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine"
16473520|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen D|"TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B.
~Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin"
16473521|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen E|"TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B.
~Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline"
16473522|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
16473523|NCT03474172|Experimental|Genuine Tuina|Participants will receive genuine tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
16473524|NCT03474172|Sham Comparator|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
16473525|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
16473526|NCT03474146|Experimental|Ocimum sanctum extract as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
16473527|NCT03474146|Active Comparator|Chlorhexidine Gluconate as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
16473528|NCT03474146|Placebo Comparator|Propylene Glycol as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
16473529|NCT03474133|Experimental|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
16473530|NCT03474120||IVF treatment group|Patients treated with IVF. IVF promotion process, ovulation, fertilization, embryo quality, transplantation and final outcome were collected after the treatment cycle was completed.
16473531|NCT03474120||No IVF treatment group|the patients who did not have received IVF treatment .Patients were followed up to collect hormone levels, ultrasound results.
16473534|NCT03474094|Experimental|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
16473535|NCT03474094|Experimental|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
16473597|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
16473536|NCT03474094|Active Comparator|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
16473537|NCT03474081|Experimental|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI at a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
16473538|NCT03474081|Experimental|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium at a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
16473539|NCT03474055|Experimental|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
16473540|NCT03474055|Experimental|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
16473541|NCT03474055|Experimental|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
16473542|NCT03474055|Active Comparator|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
16473543|NCT03474042|Experimental|GLPG2737|GLPG2737 will be provided as capsules for oral use.
16473544|NCT03474042|Placebo Comparator|Placebo|Placebo will be provided as capsules for oral use.
16473545|NCT03474029|Experimental|6 weeks of daily rifapentine (6wP)|Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks
16473546|NCT03474029|Active Comparator|12-16 week rifamycin-based regimen|"A 12-16 week rifamycin-based regimen available at the participant's site:
~Rifapentine and Isoniazid weekly for 12 weeks (3HP) or Rifampin and Isoniazid daily for 12 weeks (3HR) or Rifampin daily for 16 weeks (4R)"
16473547|NCT03474016||Patients with early breast cancer(30)|
16473548|NCT03474016||Patients with advanced breast cancer(30)|
16473549|NCT03474016||Patients with benign breast diseases(20)|
16473550|NCT03474016||Apparently healthy females as a control group(36)|
16473551|NCT03473990|Active Comparator|Laboratory HIT|Supervised (Laboratory HIT) exercise in the lab up to 4 times per week for 4 weeks
16473552|NCT03473990|Active Comparator|Home HIT|Unsupervised (Home HIT) exercise at home up to 4 times per week for 4 weeks
16473553|NCT03473990|No Intervention|Control Group|No intervention
16473556|NCT03473964||Treatment|The study intervention is the observation of study subjects who have received H.P. Acthar® Gel (adrenocorticotrophic hormone), 40 units twice weekly injections in patients who have sarcoid uveitis and to assess it's effectiveness by measuring changes the degree of aqueous and vitreous inflammatory cells present, the degree of aqueous flare, and changes in visual acuity, macular thickness, intraocular pressure and quality of life measures assessed by using the National Eye Institute Visual Function Questionnaires (VFQ-25)
16473557|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
16473558|NCT03473938||Spatz3 AIGB|Patients with implanted Spatz3 AIGB balloon.
16473559|NCT03473925|Experimental|Navarixin Dose A + Pembrolizumab|Participants receive navarixin Dose A via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
16473560|NCT03473925|Experimental|Navarixin Dose B + Pembrolizumab|Participants receive navarixin Dose B via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
16473561|NCT03473912||RA patients|before or after medication
16473562|NCT03473912||Systemic sclerosis patients|before or after medication
16473563|NCT03473912||IgG4 RD patients|before or after medication
16473564|NCT03473912||Lupus patients|before or after medication
16473565|NCT03473899|Active Comparator|rESWT + RP|Device: rESWT
16473566|NCT03473899|Placebo Comparator|sham-rESWT + RP|Device: sham-rESWT
16473567|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
16473568|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
16473569|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.
~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:
~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).
~There will be a break of about 30 minutes.
~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
16473598|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
16473599|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
16473600|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
16473601|NCT03473652|Other|Adapted walking platform|
16473662|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473570|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.
~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:
~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).
~There will be a break of about 30 minutes.
~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
16473571|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.
~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
16473572|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.
~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
16473573|NCT03473834|Experimental|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
16473574|NCT03473834|Active Comparator|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
16473575|NCT03473821|No Intervention|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
16473576|NCT03473821|Experimental|MOTIFS|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS). In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
16473577|NCT03473808|Experimental|therapy + vibration|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
16473578|NCT03473795||healthy participants and participants diagnosed with NCDs|This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls.
16473579|NCT03473782||Voiding Diary|
16473580|NCT03473782||Urodynamics Correlation Study|
16473581|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
16473582|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
16473583|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.
~Patients will receive rogaratinib plus atezolizumab combination treatment."
16473584|NCT03473756|Placebo Comparator|Placebo + Atezolizumab|Part B:Patients will receive placebo in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
16473585|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part B|Part B:Patients will receive rogaratinib in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
16473586|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
16473587|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
16473588|NCT03473730|Experimental|Cohort 1 Renal (daratumumab, biopsy, surgery)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter during weeks 1-8. Treatment repeats every week for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo biopsy, nephrectomy, or metastasectomy during weeks 10-12. Patients may then restart treatment with daratumumab beginning 2 weeks after biopsy or 4-6 weeks after nephrectomy or metastasectomy. Cycles repeat every 2 weeks for 4 months and then monthly for 1 year in the absence of disease progression or unacceptable toxicity.
16473589|NCT03473730|Experimental|Cohort 2 Bladder (daratumumab)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter beginning at week 1. Cycles repeat every week for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
16473590|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
16473591|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
16473592|NCT03473704|Experimental|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
16473593|NCT03473704|Placebo Comparator|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
16473594|NCT03473691|Experimental|Glembatumumab vedotin (GV)|
16473595|NCT03473678|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
16473596|NCT03473678|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
16473602|NCT03473639|Experimental|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.
~The dose combinations include:
~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine
~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
16473603|NCT03473626|Experimental|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
16473604|NCT03473626|Experimental|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
16473605|NCT03473613|Active Comparator|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
16473606|NCT03473613|Active Comparator|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
16473607|NCT03473600|Experimental|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
16473608|NCT03473600|Active Comparator|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
16473609|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
16473610|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
16473611|NCT03473574|Experimental|Arm A|Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
16473612|NCT03473574|Experimental|Arm B|Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
16473613|NCT03473574|Other|Arm C|Gemcitabine in combination with Cisplatin
16473614|NCT03473574|Experimental|Arm D|Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
16473615|NCT03473574|Experimental|Arm E|Durvalumab in combination with Gemcitabine and Cisplatin
16473616|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|
16473617|NCT03473548|Experimental|Portable Sleep Monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
16473618|NCT03473535|Active Comparator|PST Alone|Participants will receive six sessions of face-to-face PST.
16473619|NCT03473535|Experimental|Blended-Therapy|Participants with receive six sessions of face-to-face PST supplemented by the BEACON platform.
16473620|NCT03473522|Experimental|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
16473621|NCT03473522|Sham Comparator|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
16473622|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
16473623|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
16473624|NCT03473496|Experimental|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
16473625|NCT03473483|Experimental|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
16473626|NCT03473483|Experimental|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
16473627|NCT03473483|Experimental|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
16473628|NCT03473470|No Intervention|not warmed|Not warming system
16473629|NCT03473470|Active Comparator|warmed group 1|forced air warming and warmed intravenous fluids
16473630|NCT03473470|Active Comparator|warmed group 2|warmed intravenous fluids
16473734|NCT03472846|Active Comparator|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
16473631|NCT03473457|Experimental|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
16473632|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
16473633|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
16473634|NCT03473418|Experimental|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
16473635|NCT03473418|Active Comparator|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
16473636|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
16473637|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
16473638|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
16473639|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
16473640|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
16473641|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
16473644|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
16473645|NCT03473340|Experimental|Pirfenidone Capsule|"Method of Administration: Oral (capsule)
~Dosing:
~Days 1 through 7, 267 mg three times daily;
~Days 8 through 14, 534 mg three times daily;
~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
16473646|NCT03473340|Placebo Comparator|Placebo Capsule|"Method of Administration: Oral (capsule)
~Dosing:
~Days 1 through 7, 267 mg three times daily;
~Days 8 through 14, 534 mg three times daily;
~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
16473647|NCT03473314|Experimental|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
16473648|NCT03473301|Experimental|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
16473649|NCT03473301|Experimental|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
16473650|NCT03473301|Active Comparator|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
16473651|NCT03473288|Active Comparator|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
16473652|NCT03473288|Placebo Comparator|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
16473653|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
16473654|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).
~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
16473655|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.
~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
16473656|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
16473657|NCT03473262||EMPA|Empagliflozin 25 mg/day
16473658|NCT03473262||INS|Insulin Glargine dose-titrated
16473659|NCT03473249|No Intervention|Retrospective Review|Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).
16473660|NCT03473249|No Intervention|Prospective Observation|Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.
16473661|NCT03473249|Other|Contrast-Enhanced Ultrasound using Lumason|Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.
16473735|NCT03472846|Active Comparator|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
16473663|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473664|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473665|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473666|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473667|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473668|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473669|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
16473672|NCT03473210|Active Comparator|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
16473673|NCT03473210|Active Comparator|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
16473674|NCT03473197|Other|Single Cohort (Healthy Volunteers)|Diacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
16473675|NCT03473184|Experimental|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
16473676|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
16473677|NCT03473158|Active Comparator|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
16473678|NCT03473158|Active Comparator|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
16473679|NCT03473145|Active Comparator|Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive one in-person health coaching sessions and 6 phone counseling sessions.
16473680|NCT03473145|Experimental|Reduce Sitting|Participants in the Reduce Sitting condition will receive an intervention aimed at reducing daily sitting time. This group will receive five in-person health coaching sessions and two phone counseling sessions.
16473681|NCT03473145|Experimental|Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive five in-person health coaching sessions and two phone counseling sessions.
16473682|NCT03473132|Experimental|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
16473683|NCT03473119||Control|Healthy individuals
16473684|NCT03473119||Asthma|Asthma acute exacerbations
16473685|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
16473686|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
16473687|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
16473688|NCT03473119||CAP|Community-acquired pneumonia
16473689|NCT03473106|Experimental|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
16473690|NCT03473106|No Intervention|Non Surgical Side|Contralateral side (Control Thigh).
16473691|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
16473692|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
16473693|NCT03473080|Other|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
16473694|NCT03473067|Experimental|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
16473695|NCT03473067|Active Comparator|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
16473696|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
16473697|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
16473698|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
16473699|NCT03473028|Active Comparator|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
16473700|NCT03473028|Active Comparator|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
16473701|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
16473702|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
16473703|NCT03473002|Placebo Comparator|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
16473704|NCT03473002|Experimental|SeVRSV|1 x 10^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
16473705|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
16473706|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
16473707|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
16473708|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
16473709|NCT03472976|Experimental|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
16473710|NCT03472976|Experimental|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
16473711|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
16473712|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
16473713|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
16473714|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
16473715|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
16473716|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
16473717|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
16473718|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
16473719|NCT03472950|Experimental|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
16473720|NCT03472950|Experimental|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
16473721|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
16473722|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
16473723|NCT03472924|Experimental|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
16473724|NCT03472924|No Intervention|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
16473725|NCT03472885|Experimental|Group 1: 100 mg Danicopan TID + Eculizumab|Starting dose of 100 mg danicopan TID in combination with eculizumab.
16473726|NCT03472885|Experimental|Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab|Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
16473727|NCT03472885|Experimental|Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab|Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
16473728|NCT03472885|Experimental|Group 4: Optimal Dose of Danicopan TID + Eculizumab|Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.
16473729|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
16473730|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
16473731|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
16473732|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
16473733|NCT03472846|Active Comparator|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
16473736|NCT03472846|Active Comparator|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
16473737|NCT03472833|Experimental|High-dose|"Intervention with high dose oral vitamin D3 supplementation.
~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
16473738|NCT03472833|Active Comparator|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.
~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
16473739|NCT03472820|Experimental|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
16473740|NCT03472820|No Intervention|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
16473741|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva
~Collection of a tumor sample taken before the participation of the patient in study
~Collection of blood sample if tumor sample is not available"
16473742|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
16473743|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
16473744|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
16473745|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
16473746|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
16473747|NCT03472755|Other|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
16473748|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
16473749|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
16473750|NCT03472716||Samples|Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).
16473751|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
16473752|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
16473753|NCT03472690|Experimental|Active|0.1 mL, self-administered subcutaneous injection, every second day
16473754|NCT03472690|Placebo Comparator|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
16473755|NCT03472677|Experimental|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
16473756|NCT03472677|Experimental|Cohort 2|Controlled cooling wrap versus ice pack cooling.
16473757|NCT03472677|Experimental|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
16473758|NCT03472677|Experimental|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
16473759|NCT03472664|Experimental|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of <20 grams total carbohydrates per day.
~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
16473760|NCT03472664|Experimental|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
16473761|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
16473762|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
16473763|NCT03472638|Experimental|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
16473764|NCT03472638|Experimental|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
16473797|NCT03472430|Active Comparator|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
16473765|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
16473766|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
16473769|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.
~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16473770|NCT03472560|Experimental|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
16473771|NCT03472547|Experimental|Single cohort (Healthy Volunteers)|diacerein 1% ointment
16473772|NCT03472534|Other|study in healthy volunteers|diacerein 1% ointment
16473773|NCT03472521|Experimental|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
16473774|NCT03472521|Placebo Comparator|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
16473775|NCT03472508|Sham Comparator|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
16473776|NCT03472508|Active Comparator|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
16473777|NCT03472508|Active Comparator|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
16473778|NCT03472508|Active Comparator|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
16473779|NCT03472508|Active Comparator|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
16473780|NCT03472508|Active Comparator|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
16473781|NCT03472508|Active Comparator|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
16473782|NCT03472508|Active Comparator|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
16473783|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
16473784|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
16473785|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
16473786|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
16473787|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
16473788|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
16473789|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
16473790|NCT03472482||LBD patients|"patients with Lewy Body Dementia
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
16473791|NCT03472469|Active Comparator|Original MMPR - descending dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
16473792|NCT03472469|Active Comparator|MAST MMPR - escalating dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
16473793|NCT03472456||Articaïne|
16473794|NCT03472456||Eugénol|
16473795|NCT03472443|Experimental|Sinew Acupuncture|
16473796|NCT03472443|No Intervention|Waitlist|
16473798|NCT03472430|Sham Comparator|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
16473799|NCT03472417|Active Comparator|Active partial rebreathing device|
16473800|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
16473801|NCT03472404|Experimental|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
16473802|NCT03472404|Active Comparator|Control Group|Brostrom-Gould ankle Ligament reconstruction
16473803|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
16473804|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
16473805|NCT03472378|Experimental|Active Treatment Group|DFN-15
16473806|NCT03472378|Placebo Comparator|Placebo Group|
16473807|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd.
16473808|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continous oral. Study treatment will be started on Day 1 of each 3-week cycle.
16473809|NCT03472352|Experimental|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
16473810|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
16473811|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
16473812|NCT03472326|Experimental|Part 1 Sentinel Cohort 1: GS-9131 60 mg|Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
16473813|NCT03472326|Experimental|Part 1 Sentinel Cohort 2: GS-9131 180 mg|Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
16473814|NCT03472326|Experimental|Part 1: Randomized Cohort|Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
16473815|NCT03472326|Experimental|Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV|Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
16473816|NCT03472326|Experimental|Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF|Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
16473817|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
16473818|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
16473819|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
16473820|NCT03472287|Experimental|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
16473821|NCT03472274|Active Comparator|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:
~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
16473822|NCT03472274|Experimental|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
16473823|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
16473824|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
16473825|NCT03472248|Experimental|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
16473826|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
16473827|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
16473828|NCT03472222|Experimental|Arsha Vidya Program|Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays.
16473829|NCT03472209||Group A|ETCO2=26-35 mmHg
16473830|NCT03472209||Group B|ETCO2=36-45 mmHg
16473831|NCT03472196|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.
~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
16473832|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
16473833|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
16473834|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
16473835|NCT03472170|Experimental|Experimental Arm|"The nutritional supplement used will be bovine lactoferrin, a product marketed according to the regulations of the European Union, and approved by the European Food Safety Agency (EFSA) in 2012, and by the American Agency for Food and Drug Administration ( FDA) in 2013. It will be acquired after purchase from Dicofarm® (Rome, Italy).
~The Hospital Pharmacy Service will provide the established dose of lactoferrin, according to the administration schedule of 150 mg / kg / day (maximum 300 mg / day).
~The treatments will be administered in liquid form, in the least amount possible. The administration of lactoferrin will be carried out enterally, orally or by nasogastric tube.
~The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
16473836|NCT03472170|Placebo Comparator|Control Arm|"Placebo with similar visual and taste characteristics to the nutritional supplement of bovine lactoferrin.
~It will be administered in liquid form, in the least amount possible. The administration of placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
16473837|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.
~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
16473838|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
16473839|NCT03472144|Experimental|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
16473840|NCT03472144|Experimental|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
16473841|NCT03472144|Experimental|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
16473842|NCT03472144|Experimental|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
16473843|NCT03472144|Experimental|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
16473844|NCT03472144|Experimental|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
16473845|NCT03472144|Active Comparator|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
16473846|NCT03472144|Active Comparator|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
16473847|NCT03472144|Active Comparator|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
16473848|NCT03472144|Active Comparator|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
16473849|NCT03472144|Active Comparator|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
16473850|NCT03472144|Active Comparator|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
16473851|NCT03472131|Experimental|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
16473852|NCT03472118|Experimental|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
16473853|NCT03472105|Other|Habitual diet|18 participants were on a habitual diet for 7 days
16473854|NCT03472105|Active Comparator|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
16473855|NCT03472092|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
16473856|NCT03472092|Placebo Comparator|Placebo|The placebo pill will be administered once a day at home, to be taken by mouth.
16473857|NCT03472092|Active Comparator|Amitriptyline|Amitriptyline will be administered once a day at home, to be taken by mouth. Dosage will be weight-based.
16473858|NCT03472092|Active Comparator|Biofeedback-Assisted Relaxation Training (BART)|Biofeedback-Assisted Relaxation Training (BART) is a mind and body based intervention that focuses specifically on mind and body techniques such as deep breathing, muscle relaxation, and guided imagery skills to manage pain.
16473969|NCT03471208|Experimental|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
16473859|NCT03472092|Active Comparator|Cognitive Retraining (CR)|Cognitive Retraining (CR) is a mind and body based intervention that focuses on the use of tests of evidence and other cognitive strategies such as positive coping statements and pleasant activities and mindfulness to manage pain.
16473860|NCT03472066||a group of women who have been conized|Previous conization
16473861|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
16473862|NCT03472053|Experimental|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
16473863|NCT03472053|Experimental|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
16473864|NCT03472040|Experimental|BCX7353 150 mg once daily|
16473865|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 1|
16473866|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 2|
16473867|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 3|
16473868|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 4|
16473869|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 5|
16473870|NCT03472014|Experimental|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
16473871|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
16473872|NCT03472001|Active Comparator|Lecture group|1-hour lecture
16473873|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
16473874|NCT03471988|Experimental|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
16473875|NCT03471988|Active Comparator|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
16473876|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
16473877|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.
~Trainer and Trainee both see the monitor."
16473878|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
16473879|NCT03471936|Other|Acquisition of pressure-volume loops|
16473880|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
16473881|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
16473882|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
16473883|NCT03471910|Experimental|Diosmin|Diosmin 600mg, one tablet once daily
16473884|NCT03471910|Active Comparator|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
16473885|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
16473886|NCT03471897||Controls|Subjects self-reported as healthy
16473887|NCT03471884|Experimental|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
16473888|NCT03471884|Active Comparator|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
16473889|NCT03471871|Experimental|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
16473890|NCT03471871|Experimental|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
16473891|NCT03471871|Experimental|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
16473892|NCT03471871|Experimental|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
16473965|NCT03471247|Experimental|In-Bed Cycle Ergometer + Routine PT|Patients will receive 30 minutes of in-bed cycling once per day, 5 days per week, while they remain in the ICU, for up to a maximum of 28 days. They will also receive routine physiotherapy.
16473970|NCT03471208|Active Comparator|Freehand|Dental implant surgery via conventional freehand
16473893|NCT03471871|Experimental|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
16473894|NCT03471858|Active Comparator|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline [1]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
16473895|NCT03471858|Active Comparator|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
16473896|NCT03471845|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
16473897|NCT03471832|Experimental|stenfilcon A lens|MyDay contact lens
16473898|NCT03471832|Active Comparator|narafilcon A lens|1-Day Acuvue TruEye
16473899|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
16473900|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
16473901|NCT03471806|Experimental|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
16473902|NCT03471806|Experimental|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
16473903|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
16473904|NCT03471767|Experimental|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
16473905|NCT03471767|Active Comparator|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
16473906|NCT03471754|Experimental|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
16473907|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
16473908|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
16473909|NCT03471728||Irritable Bowel Syndrome|Patients with Irritable Bowel Syndrome with Constipation (IBS-C) who have used linaclotide for the first time
16473910|NCT03471728||Chronic Constipation|Patients with Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time
16473911|NCT03471702|Experimental|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
16473912|NCT03471689|Experimental|Mindfulness|
16473913|NCT03471689|Active Comparator|Positive reappraisal|
16473914|NCT03471676||Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
16473915|NCT03471663|Experimental|D-0502|D-0502
16473916|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
16473917|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
16473918|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
16473919|NCT03471624|Experimental|Tenofovir Alafenamide for 24 months|Subjects on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
16473920|NCT03471611|Experimental|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
16473921|NCT03471585|Placebo Comparator|Placebo oral capsule|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the THC arm.
16473966|NCT03471247|Active Comparator|Routine PT|Patients will receive routine physiotherapy interventions per current institutional practice
16473967|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.
~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.
~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
16473968|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
16473922|NCT03471585|Experimental|THC|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the placebo arm.
16473923|NCT03471572||1|Ovarian Cancer
16473924|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
16473925|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
16473926|NCT03471546|Experimental|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
16473927|NCT03471533|Experimental|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.
~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
16473928|NCT03471533|Placebo Comparator|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
16473929|NCT03471520|Experimental|Earplugs and eye masks|
16473930|NCT03471507|Experimental|Bonipar|
16473931|NCT03471507|Active Comparator|Diclofenac topical solution 1.5%|
16473932|NCT03471494||Breast cancer|
16473933|NCT03471494||Gastric cancer|
16473934|NCT03471494||Colon cancer|
16473935|NCT03471468|Experimental|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
16473936|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
16473937|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
16473938|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
16473939|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
16473940|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
16473941|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
16473942|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
16473943|NCT03471429||No Dog|Patient receives standard of care
16473944|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
16473945|NCT03471403||FAP|FAP patients with duodenal adenomas
16473946|NCT03471390|Experimental|ProQuaS 2- Intervention|
16473947|NCT03471377||standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
16473948|NCT03471377||assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
16473949|NCT03471364|Experimental|Arm I (ketoconazole)|Participants apply ketoconazole topically BID on days 1-28.
16473950|NCT03471364|Placebo Comparator|Arm II (placebo)|Participants apply placebo topically BID on days 1-28.
16473951|NCT03471351|Experimental|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
16473952|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
16473953|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
16473954|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
16473955|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
16473956|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
16473957|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
16473958|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
16473959|NCT03471312||treated with placebo drug|will receive placebo drug
16473960|NCT03471286|Experimental|Sub-Protocol A|Epacadostat
16473961|NCT03471273|Other|endoscopic management|
16473962|NCT03471273|Other|follow up|
16473963|NCT03471273|Other|surgery|
16473964|NCT03471260|Experimental|Treatment (venetoclax, ivosidenib, azacitidine)|Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16473971|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
16473972|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
16473973|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
16473974|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
16473975|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
16473976|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
16473977|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
16473978|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
16473979|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
16473980|NCT03471143|Experimental|IV VTS-270 for NPC1 infants|"Phase 1: Dosing frequency will be twice a week administered via a peripherally inserted central catheter (PICC) for six weeks for a total of 12 administrations. Doses 3-12 will occur as an outpatient.
~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6 will receive 500 mg/kg Cohort 2: Subjects 7-12 will receive 1000 mg/kg Subjects who demonstrate significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin:total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open-label phase of six months duration. In the this phase of the study, dosing frequency will be monthly with IV VTS-270 administered via peripheral IV access for six months for a total of six administrations."
16473981|NCT03471130|Experimental|Low dose MT-8554 or placebo to match|Low dose MT-8554
16473982|NCT03471130|Experimental|High dose MT-8554 or placebo to match|High dose MT-8554
16473983|NCT03471117|Active Comparator|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
16473984|NCT03471117|Placebo Comparator|Placebo|Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills
16473985|NCT03471104|Experimental|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
16473986|NCT03471104|No Intervention|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
16473987|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.
~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
16473988|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
16473989|NCT03471078|Experimental|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
16473990|NCT03471078|Placebo Comparator|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
16473991|NCT03471065|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
16473992|NCT03471052|Experimental|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
16473993|NCT03471052|No Intervention|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
16473994|NCT03471039|Active Comparator|Active|PACAP-27
16473995|NCT03471039|Placebo Comparator|Placebo|Saline
16473996|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
16473997|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
16473998|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
16473999|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
16474061|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
16474062|NCT03470545|Experimental|mavacamten (MYK-461)|
16474000|NCT03471000|Experimental|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed without sinus lift and augmentation procedure.
16474001|NCT03471000|Active Comparator|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® [Geistlich AG, Wolhusen, Switzerland]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
16474002|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
16474003|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
16474004|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
16474005|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
16474006|NCT03470974|Experimental|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
16474007|NCT03470974|No Intervention|Control Group|The control group receives usual care and lifestyle education.
16474008|NCT03470961|Experimental|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
16474009|NCT03470961|Active Comparator|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
16474010|NCT03470922|Experimental|Arm A: Relatlimab + Nivolumab|Combination
16474011|NCT03470922|Experimental|Arm B: Nivolumab|Monotherapy
16474012|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
16474013|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
16474014|NCT03470896|Active Comparator|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
16474015|NCT03470896|Active Comparator|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
16474016|NCT03470896|Other|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
16474017|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
16474018|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
16474019|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
16474020|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
16474021|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
16474022|NCT03470844||5-10 years post severe burn injury|"Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
16474023|NCT03470844||2-5 years post severe burn injury|"Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
16474024|NCT03470844||1-2 years post severe burn injury|"Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
16474025|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.
~Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
16474063|NCT03470545|Placebo Comparator|Placebo|
16474064|NCT03470532|Experimental|Group A|buccal infiltration of 4% Articaine with epinephrine
16474065|NCT03470532|Active Comparator|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
16474066|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Neurologist
16474067|NCT03470493|Experimental|Participants|ApneaLink Air
16474358|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
16474026|NCT03470818|Experimental|Intervention group|"Preparatory instructional videos (flipped classroom model)
~32 participants
~Application of a flipped classroom model
~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.
~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
16474027|NCT03470818|Sham Comparator|Control group|"Sham videos
~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.
~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
16474028|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
16474029|NCT03470792|Experimental|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
16474030|NCT03470792|Active Comparator|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
16474031|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
16474032|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
16474033|NCT03470766|Active Comparator|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
16474034|NCT03470766|Sham Comparator|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
16474035|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
16474036|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
16474037|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
16474038|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
16474039|NCT03470740|Other|intervention group|An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
16474040|NCT03470740|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
16474041|NCT03470727|Experimental|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
16474042|NCT03470714|Experimental|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
16474043|NCT03470714|Active Comparator|Control group|The group in which the participants only perform the the force irradiation experiment.
16474044|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
16474045|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
16474046|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
16474047|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
16474048|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
16474049|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
16474050|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
16474051|NCT03470662|Experimental|experimental group|Care bundle
16474052|NCT03470662|No Intervention|control group|routine care
16474053|NCT03470649|Experimental|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
16474054|NCT03470649|No Intervention|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
16474055|NCT03470636|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
16474056|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
16474057|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
16474058|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
16474059|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
16474060|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
16474150|NCT03469947|No Intervention|Matched Controls|Retrospective matched controls
16474068|NCT03470480|Experimental|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
16474069|NCT03470480|Active Comparator|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
16474070|NCT03470480|Sham Comparator|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
16474071|NCT03470480|Sham Comparator|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
16474072|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
16474073|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
16474074|NCT03470441|Experimental|FDY-5301 Low Dose|Anticipated n=20
16474075|NCT03470441|Experimental|FDY-5301 Intermediate Dose|Anticipated n=20
16474076|NCT03470441|Experimental|FDY-5301 High Dose|Anticipated n=20
16474077|NCT03470441|Placebo Comparator|Placebo|Anticipated n=20
16474078|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
16474079|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
16474080|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
16474081|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
16474082|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
16474083|NCT03470402|Experimental|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
16474084|NCT03470402|Active Comparator|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
16474085|NCT03470389|Experimental|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
16474086|NCT03470376|Experimental|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
16474087|NCT03470376|Active Comparator|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
16474088|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia
~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
16474089|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia
~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
16474090|NCT03470350|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
16474091|NCT03470337|Experimental|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
16474092|NCT03470337|Placebo Comparator|Placebo|Placebo equates Phlogenzym but without active ingredients
16474093|NCT03470324|Active Comparator|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
16474094|NCT03470324|Experimental|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
16474095|NCT03470311|Active Comparator|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
16474096|NCT03470311|Placebo Comparator|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
16474097|NCT03470298|Active Comparator|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
16474098|NCT03470298|Active Comparator|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
16474099|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
16474100|NCT03470272|Experimental|Active Device|"Active Device: The FB Professional LED red light therapy system
~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.
~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
16474151|NCT03469934|Experimental|ANB020|ANB020, administration of ANB020
16474152|NCT03469934|Placebo Comparator|Placebo|Placebo, administration of Placebo
16474153|NCT03469921||15-17 years old|15-17 years old
16474101|NCT03470259|Experimental|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
16474102|NCT03470259|Experimental|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
16474103|NCT03470259|Experimental|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
16474104|NCT03470259|Experimental|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.
~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
16474105|NCT03470246|No Intervention|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
16474106|NCT03470246|Experimental|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
16474107|NCT03470246|No Intervention|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
16474108|NCT03470246|Experimental|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
16474109|NCT03470246|No Intervention|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
16474110|NCT03470246|Experimental|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
16474111|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
16474112|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
16474113|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
16474114|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
16474115|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
16474116|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
16474117|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
16474118|NCT03470168|Experimental|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
16474119|NCT03470168|Placebo Comparator|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
16474120|NCT03470155||functional mitral insufficiency op|Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)
16474154|NCT03469921||18-25 years old|18-25 years old
16474155|NCT03469921||26-30 years old|26-30 years old
16474121|NCT03470142|Active Comparator|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
16474122|NCT03470142|Experimental|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
16474123|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
16474124|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
16474125|NCT03470116|Experimental|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
16474126|NCT03470116|Active Comparator|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
16474127|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
16474128|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
16474129|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
16474130|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
16474131|NCT03470090|Experimental|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
16474132|NCT03470090|Active Comparator|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
16474133|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
16474134|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
16474135|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
16474136|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
16474137|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.
~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.
~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
16474138|NCT03470038|Experimental|NGF condition + Control condition|"All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg
~After 4 weeks:
~All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
16474139|NCT03470038|Experimental|Control condition + NGF condition|"All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg
~After 4 weeks:
~All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
16474140|NCT03470025|Experimental|Psychological Intervention|A weekly combined face to face & telephone-based PI (F-TPI); Psychological Intervention and medical therapy
16474141|NCT03470025|Experimental|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
16474142|NCT03470025|No Intervention|Optimal medical therapy|Patients will receive optimal medical therapy
16474143|NCT03470012|Experimental|Treatment Arm|Investigational tape
16474144|NCT03469999|Experimental|Dysport Injectable Product|All participants will participate in baseline data collection of energy expenditure, gait analysis, and lower limb spasticity assessment. All participants will receive single event multi level chemoneurolysis with Dysport and will have repeat data collection at 4 weeks and 12 weeks post injection.
16474145|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
16474146|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
16474147|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
16474148|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
16474149|NCT03469947|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
16474163|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.
~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
16474164|NCT03469882|Experimental|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.2 g/kg/day of protein and in-bed cycle ergometry exercise.
16474165|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
16474166|NCT03469869|Experimental|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
16474167|NCT03469869|Active Comparator|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
16474168|NCT03469856|Other|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
16474169|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
16474170|NCT03469830|Experimental|SSCP & SPMS|"The smart scar care pad (SCCP):
~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.
~The smart pressure monitored suit(SPMS):
~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
16474171|NCT03469830|Active Comparator|SPMS|"The smart pressure monitored suit(SPMS):
~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
16474172|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
16474173|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
16474174|NCT03469804|Experimental|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
16474175|NCT03469791|Active Comparator|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
16474176|NCT03469791|Active Comparator|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
16474177|NCT03469778|Experimental|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
16474178|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
16474179|NCT03469752|Experimental|Intervention group|8 weekly education sessions 2.5 hours
16474180|NCT03469752|No Intervention|Wait-list control group|No education sessions
16474181|NCT03469726|Other|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.
~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
16474182|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .
~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
16474183|NCT03469700|Experimental|GA+PVB|Patients will receive general anesthesia with paravertebral block
16474184|NCT03469700|Active Comparator|GA+placebo PVB|Patients will receive general anesthesia with placebo block
16474185|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
16474186|NCT03469674|Experimental|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
16474187|NCT03469674|Active Comparator|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
16474188|NCT03469661||Immune Thrombocytopenia Diagnosis|
16474189|NCT03469661||Myelodysplastic Syndrome Diagnosis|
16474190|NCT03469622|Active Comparator|EndoRings|Colonoscopy is performed with the EndoRings attached
16474191|NCT03469622|Active Comparator|Standard Colonoscopy|Standard colonoscopy without any additional devices
16474192|NCT03469609|Experimental|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
16474193|NCT03469609|No Intervention|No mucous fistula refeeding|No perioperative mucous fistula refeeding
16474194|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
16474195|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
16474196|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
16474197|NCT03469570|Experimental|Assisted Fluid Management|
16474198|NCT03469557|Experimental|Esophageal Squamous Cell Carcinoma (ESCC)|
16474199|NCT03469557|Experimental|Gastric (GC) and Gastroesophageal Junction (GEJ) Carcinoma|
16474200|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .
~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
16474201|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .
~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
16474202|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .
~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
16474203|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
16474204|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
16474205|NCT03469518|Sham Comparator|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
16474206|NCT03469518|Active Comparator|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
16474207|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
16474208|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
16474209|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
16474210|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
16474211|NCT03469479|Experimental|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
16474212|NCT03469479|Active Comparator|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
16474213|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
16474214|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
16474215|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
16474216|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
16474217|NCT03469440|Active Comparator|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
16474218|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy.
16474219|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
16474220|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
16474221|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
16474222|NCT03469388|Experimental|elective EVAR patients|Elective EVAR patients will be included in one arm only
16474223|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
16474224|NCT03469362|Experimental|Extracorporeal Urinary Diversion (ECD)|Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
16474225|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
16474226|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
16474227|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
16474228|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
16474229|NCT03469323|Experimental|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
16474230|NCT03469323|Placebo Comparator|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
16474231|NCT03469310|Experimental|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
16474232|NCT03469310|Active Comparator|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
16474233|NCT03469297|Experimental|Brown Glaucoma Implant|
16474234|NCT03469284|Experimental|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
16474235|NCT03469284|Experimental|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
16474236|NCT03469284|Experimental|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
16474237|NCT03469284|Active Comparator|Group 4 (standard of care)|Patients receive standard of care therapy.
16474238|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
16474239|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
16474240|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
16474241|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
16474242|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.
~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
16474243|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
16474244|NCT03469232|Experimental|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
16474245|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
16474246|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
16474247|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
16474248|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
16474249|NCT03469206|Sham Comparator|Direct MT|Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
16474250|NCT03469206|Active Comparator|IVT combine with MT|Intravenous thrombolysis before mechanical thrombectomy
16474251|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
16474252|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
16474253|NCT03469180|Active Comparator|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
16474254|NCT03469180|Experimental|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
16474255|NCT03469167|Experimental|CEGP003|
16474256|NCT03469167|Active Comparator|Injection Tx|
16474257|NCT03469154|Experimental|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
16474258|NCT03469154|Active Comparator|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.
~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
16474259|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
16474260|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
16474261|NCT03469128|Active Comparator|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
16474262|NCT03469128|Active Comparator|Sertraline|Patients with co-occurrence PTSD & SUD disorders were treated by Sertraline.
16474263|NCT03469128|Placebo Comparator|Control group|Placebo Control group
16474264|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
16474265|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
16474266|NCT03469089|Placebo Comparator|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
16474267|NCT03469089|Experimental|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
16474268|NCT03469089|Experimental|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
16474269|NCT03469089|Experimental|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
16474270|NCT03469076|Experimental|ACN Cream|Patients with mild to moderate acne using ACN Cream
16474271|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
16474272|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
16474276|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
16474277|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
16474278|NCT03469024|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
16474279|NCT03469024|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
16474280|NCT03469011|Experimental|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.
~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
16474281|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
16474282|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
16474283|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
16474284|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
16474285|NCT03468985|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16474286|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib s-malate)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16474287|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib s-malate, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16474288|NCT03468985|Experimental|Arm T (nivolumab, cabozantinib s-malate, ipilimumab)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16474289|NCT03468972|Experimental|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
16474290|NCT03468972|Active Comparator|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
16474291|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
16474292|NCT03468946|Other|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
16474293|NCT03468946|Other|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
16474359|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
16474294|NCT03468946|Other|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
16474295|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
16474296|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
16474297|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
16474298|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
16474299|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
16474300|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
16474301|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
16474302|NCT03468894|No Intervention|Control|The control group will continue to work as usual at their regular workstations.
16474303|NCT03468894|Experimental|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
16474304|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
16474305|NCT03468868|Active Comparator|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
16474306|NCT03468868|Active Comparator|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
16474307|NCT03468855|Experimental|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
16474308|NCT03468842|Placebo Comparator|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
16474309|NCT03468842|Active Comparator|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
16474310|NCT03468829|Experimental|ALX-0171 Dose 1|
16474311|NCT03468829|Experimental|ALX-0171 Dose 2|
16474312|NCT03468829|Placebo Comparator|Placebo|
16474313|NCT03468816|Experimental|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
16474314|NCT03468816|Experimental|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
16474315|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
16474316|NCT03468790|Experimental|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
16474317|NCT03468790|Placebo Comparator|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
16474318|NCT03468777|Experimental|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474319|NCT03468777|Experimental|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474360|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
16474320|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474321|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474322|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474323|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474324|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474325|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
16474326|NCT03468751|Experimental|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
16474327|NCT03468751|Experimental|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
16474328|NCT03468725|Experimental|XPF-008|Single oral dose
16474329|NCT03468725|Active Comparator|Placebo|Single oral dose
16474330|NCT03468712|Experimental|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
16474331|NCT03468699|Experimental|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
16474332|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
16474333|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
16474334|NCT03468686|Active Comparator|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
16474335|NCT03468660|Experimental|Experimental group|Auditory training with feedback
16474336|NCT03468660|No Intervention|Passive control group|Pre-post testing only; no training
16474337|NCT03468660|Active Comparator|Active Control group|Listening task with no feeback
16474338|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
16474339|NCT03468634|Experimental|Adenocarcinoma|patients diagnosed with adenocarcinoma
16474340|NCT03468634|Experimental|Squamous cell cancer|patients diagnosed with squamous cell cancer
16474341|NCT03468634|Experimental|Other|patients diagnosed with another condition
16474342|NCT03468634|Experimental|Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
16474343|NCT03468634|Experimental|Low-grade dysplasia|patients diagnosed with low-grade dysplasia
16474344|NCT03468634|Experimental|High-grade dysplasia|patients diagnosed with high-grade dysplasia
16474345|NCT03468634|Experimental|Indefinite for dysplasia|patients where the diagnosis is unclear
16474346|NCT03468634|Experimental|no dysplasia|patients not diagnosed with any cancer
16474347|NCT03468621|Other|Intradermal wound closure|Intradermal wound closure of the groin wound
16474348|NCT03468621|Other|Transdermal wound closure|Wound closure of the groin wound with metal staples
16474349|NCT03468608||Phase 1: Instrument Development|An initial set of questionnaire items will be created based on the questionnaires noted in the literature review as well as the semi-structured interviews conducted with parents and healthcare team members in our facility.
16474350|NCT03468608||Phase 2: Pre-Test Evaluation|Parents and healthcare team members will be asked to comment on the quality of the draft questionnaire created in phase 1 of this study.
16474351|NCT03468608||Phase 3: Pilot|"Parents will be asked to complete the questionnaire developed during phase 2 of this study. Upon completing the questionnaire, parents will be asked to rate the overall face validity of the tool using a 5-point Likert scale.
~Healthcare team members will be asked to rate the content validity of each item on the questionnaire."
16474352|NCT03468608||Phase 4: Validation|Parents will be asked to complete the questionnaire developed during phase 3 of this study.
16474353|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
16474354|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
16474355|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
16474356|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
16474361|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
16474362|NCT03468556|Experimental|test drug|2 tabs of SNP-610
16474363|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
16474364|NCT03468543|Experimental|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
16474365|NCT03468543|Experimental|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
16474366|NCT03468543|Experimental|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
16474367|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
16474368|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
16474369|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.
~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
16474370|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.
~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
16474371|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
16474372|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
16474373|NCT03468478|Experimental|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
16474374|NCT03468478|Experimental|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
16474375|NCT03468478|Active Comparator|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
16474376|NCT03468465|Experimental|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
16474377|NCT03468465|Active Comparator|Solifenacin|10 mg tablet daily during 75 days maximum
16474378|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
16474379|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.
~The catheter is inserted again within 48h."
16474380|NCT03468439|Other|femoral nerve block|
16474382|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
16474383|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
16474384|NCT03468387|Active Comparator|Primary realignment|
16474385|NCT03468387|Active Comparator|Suprapubic cystostomy|
16474386|NCT03468374|Active Comparator|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
16474387|NCT03468374|Active Comparator|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
16474388|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
16474389|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
16474390|NCT03468348|Placebo Comparator|placebo group|
16474391|NCT03468348|Active Comparator|duloxetine 30|
16474392|NCT03468348|Active Comparator|duloxetine 60|
16474393|NCT03468348|Active Comparator|duloxetine 90|
16474394|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:
~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion
~5-FU 2400 mg/m2 as 46 hour infusion
~Folinic acid 400 mg/m2 as 0.5 hour infusion
~all on D1 of each cycle; Cycle q2w ± 5 days
~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
16474395|NCT03468322|Experimental|AC-203 1% ointment|AC-203 1% ointment, QD
16474396|NCT03468322|Placebo Comparator|Vehicle ointment|Vehicle ointment, QD
16474397|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
16474398|NCT03468296|Experimental|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
16474399|NCT03468296|Active Comparator|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
16474400|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
16474500|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
16474401|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
16474402|NCT03468257|Active Comparator|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
16474403|NCT03468257|Experimental|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
16474404|NCT03468244|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
16474405|NCT03468231|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
16474406|NCT03468231|Experimental|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
16474407|NCT03468218|Experimental|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16474408|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
16474409|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
16474410|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
16474411|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
16474412|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
16474413|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
16474414|NCT03468153|Experimental|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
16474415|NCT03468140|Experimental|Current end stage liver disease patients|Eculizumab
16474416|NCT03468140|Other|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
16474417|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
16474418|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
16474419|NCT03468101||Dairy farmers COPD|
16474420|NCT03468101||Non farmers COPD|
16474421|NCT03468088|Experimental|Hand grip strengthening|This group will receive handgrip strengthening exercises.
16474422|NCT03468088|Active Comparator|Conventional treatment|This group will receive conventional exercises.
16474423|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
16474424|NCT03468062|Experimental|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
16474425|NCT03468062|Placebo Comparator|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
16474426|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
16474427|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
16474428|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
16474457|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
16474458|NCT03467932|Placebo Comparator|Excipient matched placebo once daily - QHS|Excipient matched placebo once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
16474429|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
16474430|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
16474431|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
16474432|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
16474433|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
16474434|NCT03468010|Active Comparator|The control group (Group A)|In Group A, observation is given after chemoradiation
16474435|NCT03468010|Experimental|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
16474436|NCT03467997|No Intervention|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
16474437|NCT03467997|Active Comparator|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
16474438|NCT03467997|Active Comparator|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
16474439|NCT03467997|Active Comparator|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
16474440|NCT03467984|Experimental|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
16474441|NCT03467984|Active Comparator|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
16474442|NCT03467971|Experimental|Metformin-Gliclazide (fasted), Then Metformin-Gliclazide (fed)|Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
16474443|NCT03467971|Experimental|Metformin-Gliclazide (fed), Then Metformin-Gliclazide (fasted)|Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
16474444|NCT03467958|Experimental|Administration of oral Ozanimod|Subjects will receive a single 0.92 mg capsule [equivalent to ozanimod HCl 1 mg] once daily x 48 weeks
16474445|NCT03467945|Experimental|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
16474446|NCT03467945|Experimental|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
16474447|NCT03467945|Experimental|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
16474448|NCT03467945|Experimental|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
16474449|NCT03467932|Active Comparator|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
16474450|NCT03467932|Active Comparator|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
16474451|NCT03467932|Active Comparator|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
16474452|NCT03467932|Placebo Comparator|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
16474453|NCT03467932|Placebo Comparator|Cohort A: Excipient-Matched Placebo three times daily-TID|Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
16474454|NCT03467932|Active Comparator|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
16474455|NCT03467932|Active Comparator|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
16474456|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
16474499|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
16474459|NCT03467919|Experimental|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
16474460|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
16474461|NCT03467906||Weight loss < median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
16474462|NCT03467906||Weight loss > median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
16474463|NCT03467880||Healthy subjects|Healthy subjects.
16474464|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
16474465|NCT03467880||Asthma|Patience with asthma.
16474466|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
16474467|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
16474468|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
16474469|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
16474470|NCT03467828|Experimental|Study Group|Infants diagnosed with BPD.
16474471|NCT03467828|No Intervention|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
16474472|NCT03467789|Experimental|Group A: D3 prior to first PDT|"In both groups, one PDT session is preceded by neoadjuvant PDT while the other PDT session has no pretreatment.
~Group A will take dietary D3 pills prior to the first PDT treatment (day 1), and placebo pills prior to the second PDT treatment (at 2 months). Both Group A and Group B will take continuous serum D3 prior to the third PDT visit (Month 4). A final assessment of lesion clearance will be performed at 6 months"
16474473|NCT03467789|Experimental|Group B: D3 prior to second PDT visit|"In both groups, one PDT session is preceded by neoadjuvant PDT while the other PDT session has no pretreatment.
~Group B will receive placebo prior to their first PDT visit (day 1), and Vitamin D3 prior to their second PDT visit (at 2 months). Both Group A and Group B will take continuous D3 prior to the third PDT visit (Month 4). A final assessment of lesion clearance will be performed at 6 months"
16474474|NCT03467776||healthy|healthy control, 5 months to 3 years
16474475|NCT03467776||wheezing with atopy|suspected asthma with wheezing (>3 episodes per year) and atopy
16474476|NCT03467776||wheezing without atopy|wheezing without atopy
16474477|NCT03467763|Active Comparator|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
16474478|NCT03467763|Placebo Comparator|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
16474479|NCT03467750|Experimental|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
16474480|NCT03467750|Active Comparator|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
16474481|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
16474482|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
16474483|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
16474484|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
16474485|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
16474486|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
16474487|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
16474488|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
16474489|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
16474490|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
16474491|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
16474492|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
16474493|NCT03467672||Infected patients|
16474494|NCT03467672||Control group|
16474495|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
16474496|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
16474497|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
16474498|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
16474501|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
16474502|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
16474503|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
16474504|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
16474505|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
16474506|NCT03467620|Experimental|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
16474507|NCT03467620|Placebo Comparator|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
16474508|NCT03467607|Active Comparator|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
16474509|NCT03467607|Active Comparator|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
16474510|NCT03467607|Active Comparator|control|15 patients ventilated using the anaesthetists usual ventilation strategy
16474511|NCT03467594|Experimental|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.
~Outcome measures assessed at baseline and follow-up (8 weeks)"
16474512|NCT03467594|No Intervention|Control|Outcome measures only at baseline at follow-up (8 weeks)
16474513|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
16474514|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
16474515|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
16474516|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
16474517|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
16474518|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
16474519|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
16474520|NCT03467503|No Intervention|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
16474521|NCT03467503|Experimental|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
16474522|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
16474523|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
16474524|NCT03467477|Experimental|Flortaucipir PET Scan|
16474525|NCT03467464|Experimental|Intervention|EMDR treatment
16474526|NCT03467438|Experimental|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
16474527|NCT03467438|Placebo Comparator|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
16474528|NCT03467425|Experimental|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
16474529|NCT03467425|Active Comparator|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
16474530|NCT03467412|Experimental|0.00625 μg FOL-005|50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.
16474531|NCT03467412|Experimental|0.025 μg FOL-005|50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.
16474532|NCT03467412|Experimental|0.050 μg FOL-005|50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.
16474533|NCT03467412|Experimental|0.100 μg FOL-005|50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.
16474534|NCT03467412|Placebo Comparator|Placebo|50 μl solution (placebo) injected intradermally three times per week for 12 weeks.
16474535|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
16474536|NCT03467386|Experimental|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.
16474537|NCT03467373|Experimental|Part 1: Dose Escalation r/r NHL|"Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.
~The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts."
16474538|NCT03467373|Experimental|Part 2: Dose Expansion r/r NHL|Participants with r/r NHL will be assigned to an expansion cohort to further explore glofitamab at the MTD/OBD determined in Part I.
16474539|NCT03467373|Experimental|Part 2: DLBCL G/R-CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
16474540|NCT03467373|Experimental|Part 2: DLBCL CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
16474541|NCT03467360|Experimental|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
16474542|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
16474543|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
16474544|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
16474545|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
16474546|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
16474547|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
16474548|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
16474549|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
16474550|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
16474551|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
16474552|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
16474553|NCT03467282|Experimental|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
16474554|NCT03467282|Placebo Comparator|Placebo|1g polydextrose/maltodextrin - twice day
16474555|NCT03467256|Experimental|experimental|Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.
16474556|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
16474557|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
16474558|NCT03467243|Other|Treatment as usual|Veterans receive treatment as usual
16474559|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
16474599|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
16474562|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
16474563|NCT03467191|Placebo Comparator|Placebo Beverage|
16474564|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
16474565|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
16474566|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
16474567|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
16474568|NCT03467152|Experimental|E2027|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of E2027 for 12 weeks.
16474569|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of E2027-matched placebo for 12 weeks.
16474570|NCT03467139|Experimental|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
16474571|NCT03467139|No Intervention|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
16474572|NCT03467113|Experimental|ZX008 0.2 to 0.8 mg/kg/day|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)
16474573|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
16474574|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
16474575|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
16474576|NCT03467061|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
16474577|NCT03467061|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
16474578|NCT03467061|Other|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
16474579|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
16474580|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
16474581|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test
~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
16474582|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test
~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
16474583|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.
~Eight-week longitudinal tailored CBT-based text-message program."
16474584|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
16474585|NCT03467009|Experimental|iPACT Intervention- App|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.
~Eight-week longitudinal tailored CBT-based message program delivered via app."
16474588|NCT03466983|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
16474589|NCT03466983|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
16474590|NCT03466970||IgG4 patient|20 samples of IgG4 patients
16474591|NCT03466970||healthy donors|20 healthy donors
16474592|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
16474593|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
16474594|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
16474595|NCT03466931|No Intervention|Historical cohort|Standard care
16474596|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
16474597|NCT03466905|Active Comparator|Intervention|Assessment of Ambulance Medical Service
16474598|NCT03466905|No Intervention|Control|Local treatment guidelines
16474600|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
16474601|NCT03466866|Experimental|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
16474602|NCT03466866|Active Comparator|Intensive Diabetes Education|In-home diabetes education
16474603|NCT03466840|Experimental|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
16474604|NCT03466840|Active Comparator|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
16474605|NCT03466814||JIA participants|
16474606|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
16474607|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
16474608|NCT03466788|Other|Patients treated with chemotherapy|
16474609|NCT03466788|Other|Patients not treated with chemotherapy|
16474610|NCT03466749|Experimental|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
16474611|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with [18F]flutemetamol
16474612|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with [18F]flutemetamol
16474613|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with [18F]flutemetamol
16474614|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
16474615|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
16474616|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
16474617|NCT03466697|Other|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
16474618|NCT03466684|Experimental|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL > 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
16474619|NCT03466684|Active Comparator|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
16474620|NCT03466671|Other|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
16474621|NCT03466671|Other|Low dose twice per day and placebo|Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
16474622|NCT03466671|Other|High dose once per day and placebo|"Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
16474623|NCT03466671|Other|High dose twice per day and placebo|Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
16474624|NCT03466671|Other|Placebo and low dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
16474625|NCT03466671|Other|Placebo and low dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
16474626|NCT03466671|Other|Placebo and high dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
16474627|NCT03466671|Other|Placebo and high dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.
16474628|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
16474629|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
16474630|NCT03466645|Active Comparator|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
16474631|NCT03466645|Active Comparator|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
16474632|NCT03466632|Active Comparator|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
16474633|NCT03466632|Active Comparator|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
16474634|NCT03466619|Experimental|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
16474635|NCT03466606|Experimental|Prehabilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
16474636|NCT03466606|No Intervention|Control|Conventional treatment
16474637|NCT03466593|Experimental|Prospective cohort-prehabilitation|A prehabilitation program including advice about diet, increased physical activity and cessation of smoking and drinking alcohol.
16474638|NCT03466593|Active Comparator|Retrospective cohort|Routine care before the prehabilitation program was introduced
16474639|NCT03466593|Experimental|Extra early mobilization|Mobilization the day of surgery
16474640|NCT03466593|Active Comparator|Traditional mobilization|Routine care with mobilization the day after surgery
16474641|NCT03466580|Experimental|Intervention|('Standard' specialized palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
16474642|NCT03466580|No Intervention|Control|('Standard' specialized palliative care). No intervention offered.
16474643|NCT03466567|Experimental|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
16474644|NCT03466567|Experimental|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
16474645|NCT03466567|Experimental|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
16474646|NCT03466554|Experimental|hyperbaric oxygen therapy (HBOT) active treatment|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
16474647|NCT03466554|No Intervention|Control-follow up|"The standard of care of psychological and mediational support .
~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
16474648|NCT03466541|Experimental|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
16474649|NCT03466541|Experimental|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
16474650|NCT03466541|No Intervention|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
16474651|NCT03466528|Active Comparator|Standard treatment - Pabrinex alone|Pabrinex alone
16474652|NCT03466528|Active Comparator|Pabrinex + magnesium sulphate|standard treatment and magnesium sulphate
16474653|NCT03466528|Experimental|Magnesium sulphate alone|This group receives the study intervention and delayed Pabrinex
16474654|NCT03466515|Experimental|intervention|Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
16474655|NCT03466502|No Intervention|No oral vancomycin|
16474656|NCT03466502|Experimental|Oral vancomycin 125 mg twice daily|
16474657|NCT03466502|Experimental|Oral vancomycin 125 mg daily|
16474658|NCT03466489|Experimental|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
16474659|NCT03466489|No Intervention|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
16474660|NCT03466476|Experimental|Wearable Technology|Patients in this arm will be provided with their own Consensus TracPatch wearable device as well as instructions on its use.
16474661|NCT03466476|No Intervention|Current Standard|Patients in this arm will not be provided with any wearable device.
16474662|NCT03466463|Experimental|GNT0003|2 doses of the IMP assessed in a dose escalation, open-label, phase 1/2 study
16474663|NCT03466450|Experimental|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.
~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
16474664|NCT03466437|Experimental|Glass-fiber post + composite resin restoration|
16474665|NCT03466437|Experimental|Glass-fiber post + metalceramic crown|
16474666|NCT03466437|Active Comparator|Cast-metal post + metalceramic crown|
16474667|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
16474668|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
16475230|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
16474669|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
16474670|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
16474671|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
16474672|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
16474673|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
16474674|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
16474675|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
16474676|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
16474677|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
16474678|NCT03466398|Experimental|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
16474679|NCT03466398|No Intervention|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
16474680|NCT03466385|Experimental|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min-1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
16474681|NCT03466385|Active Comparator|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
16474682|NCT03466372|Experimental|biofeedback 1|biofeedback training with progression of targets
16474683|NCT03466372|Active Comparator|biofeedback 2|biofeedback training with progression of targets and speeds
16474684|NCT03466359|Experimental|DEF-EI|these adolescents will follow a dietary restriction of 10% of their daily energy intake.
16474685|NCT03466359|Experimental|DEF-EX|these adolescents will increase their physical activity-induced energy expenditure by 10% per day.
16474691|NCT03466333|Experimental|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
16474692|NCT03466333|Placebo Comparator|Placebo|Oral placebo once daily for 6 months postpartum
16474693|NCT03466333|No Intervention|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
16474694|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.
~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
16474695|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.
~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
16474696|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.
~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
16474697|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL3|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.
~Dose 3: 1x109 NKR-2 (adjusted at 1.5x107 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
16474698|NCT03466320|Experimental|Phase I Dose Escalation - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
16474699|NCT03466320|Experimental|Phase II Segment 1|This extension segment will enroll more patients (to reach 13 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
16474700|NCT03466320|Experimental|Phase II Segment 2|Enrollment in the Phase II part of the study will be divided in 2 consecutive segments, with 13 patients in total in the segment 1 and 30 new patients in segment 2 (43 patients in total) if the study is not terminated due to futility, according a Simon's two-stage optimal design
16474701|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
16474702|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
16474703|NCT03466307||Group C|Healthy controls
16474704|NCT03466294|Experimental|Azacitidine and Venetoclax|On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
16474705|NCT03466281|Active Comparator|IBS School|Patient education provided in a group setting
16474706|NCT03466281|Active Comparator|Internet patient education|Patient education provided via the internet
16474707|NCT03466268|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
16474708|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
16474709|NCT03466242|Experimental|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
16474710|NCT03466242|Active Comparator|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
16474711|NCT03466229|Active Comparator|Antioxidant|Androferti - 1 twice per day
16474712|NCT03466229|Placebo Comparator|Placebo|Placebo - 1 twice per day
16474713|NCT03466216|Experimental|AlphaMedix|There is only a single treatment arm.
16474714|NCT03466203|Experimental|LLF580|LLF580 every 28 days * 3
16474715|NCT03466203|Placebo Comparator|Placebo|Placebo to LLF580 every 28 days * 3
16474716|NCT03466190|Experimental|Custom made PEEK plate fixation|Open Reduction Internal Fixation using Custom made PEEK plates.
16474717|NCT03466190|Active Comparator|Titanium plate fixation|Open Reduction Internal Fixation using conventional titanium plating system.
16474718|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients
~Venous blood sampling Hematology and chemistry
~Genotyping: apolipoprotein E (apoE) polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
16474719|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients
~Venous blood sampling Hematology and chemistry
~Genotyping: apoE polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
16474720|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers
~Venous blood sampling Hematology and chemistry
~Genotyping: apoE polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
16474721|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers
~Venous blood sampling Hematology and chemistry
~Genotyping: apoE polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
16474722|NCT03466164|Experimental|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
16474723|NCT03466164|No Intervention|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
16474724|NCT03466151|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
16474725|NCT03466151|Active Comparator|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
16474726|NCT03466138||General Anesthesia|subjects requiring a surgical procedure under general anesthesia. monitored by PMD-200
16474727|NCT03466125||Adult patients who underwent cardiac surgery in Massachusetts|No interventions. A retrospective cohort study of patients who underwent cardiac surgery in Massachusetts in calendar years 2012 - 2016.
16474728|NCT03466112|Experimental|endurance training|endurance training with stationary bicycles
16474729|NCT03466112|Active Comparator|balance and tone program|flexibility, core strength, balance, relaxation
16474730|NCT03466099|Experimental|KVD001 Injection (high dose)|
16474731|NCT03466099|Experimental|KVD001 Injection (low dose)|
16474732|NCT03466099|Sham Comparator|Sham Procedure|
16474733|NCT03466086|Experimental|Test/Control|Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
16474734|NCT03466086|Experimental|Control/Test|Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
16474735|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
16474736|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
16474737|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
16474738|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
16474739|NCT03466060|Active Comparator|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
16474740|NCT03466060|Active Comparator|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
16474741|NCT03466060|Active Comparator|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
16474742|NCT03466047|Experimental|Protein stomach|Encapsulated protein released in the stomach
16474743|NCT03466047|Experimental|Protein distal small intestine|Encapsulated protein released in the distal small intestine
16474744|NCT03466047|Experimental|CHO stomach|Encapsulated CHO released in the stomach
16474745|NCT03466047|Experimental|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
16474746|NCT03466047|Experimental|Fat stomach|Encapsulated Fat released in the stomach
16474747|NCT03466047|Experimental|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
16474748|NCT03466034||Endometriod|Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
16474749|NCT03466034||Serous|Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
16474750|NCT03466021|Active Comparator|Liraglutide|Liraglutide injection 3.0 mg daily
16474751|NCT03466021|Placebo Comparator|Placebo|Placebo, matching injection pen
16474752|NCT03466008|Experimental|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
16474753|NCT03466008|No Intervention|Usual treatment arm|usual care
16474754|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
16474757|NCT03465969|Other|Liver or kidney transplant participants of Advagraf|Transplant participants will provide 1 whole blood venepuncture sample and 1 whole blood finger prick MITRA sample at pre-dose of participant's usual oral dose of commercial Advagraf and at approximately 1 and 3 hours post-dose.
16474758|NCT03465956|Other|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy for patients with morbid obesity using the gastro-intestinal anastomosis stapler.
16474759|NCT03465943|Active Comparator|Ringer|This group will receive 1 L of Ringer's solution as a preload
16474760|NCT03465943|Active Comparator|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
16474761|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
16474762|NCT03465917|Experimental|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
16474763|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
16474764|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
16474765|NCT03465891|Experimental|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
16474867|NCT03465163|No Intervention|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
16474766|NCT03465891|Experimental|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
16474767|NCT03465878|Experimental|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
16474768|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
16474769|NCT03465878|Experimental|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
16474770|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
16474771|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
16474772|NCT03465852|Experimental|Intervention arm|"Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.
~."
16474773|NCT03465852|Other|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
16474774|NCT03465839|Experimental|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
16474775|NCT03465839|Active Comparator|Control|Education for improving handovers quality
16474776|NCT03465826|Experimental|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
16474777|NCT03465826|Active Comparator|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
16474778|NCT03465813|Experimental|CaringGuidance Intervention|Three months of web-based CaringGuidance psychoeducational program use, independently on home computer in addition to usual care.
16474779|NCT03465813|No Intervention|Usual Care|Three months of care as usual from subjects' clinics and community as the subject chooses.
16474780|NCT03465800|Active Comparator|Self-Monitoring|Participants self-monitor their physical activity
16474781|NCT03465800|Experimental|Daily Incentives|daily payments for physical activity
16474782|NCT03465800|Experimental|Delayed Lump Sum Incentives|lump sum payments for physical activity
16474783|NCT03465787|Experimental|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
16474784|NCT03465787|Active Comparator|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
16474785|NCT03465774||Group 2 (IPC alone)|Patients undergo IPC placement.
16474786|NCT03465774||Group I (IPC, doxycycline)|Patients undergo IPC placement and receive doxycycline via IPC 5 days later.
16474787|NCT03465761|Experimental|ExAblate 4000 System|ExAblate treatment of Bilateral Essential Tremor
16474788|NCT03465748|Experimental|Experimental-OrthoK|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles or soft contact lenses (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
16474789|NCT03465748|No Intervention|Control|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
16474790|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
16474791|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:
~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
16474794|NCT03465709|Experimental|Pegcetacoplan Study Drug|
16474795|NCT03465696|No Intervention|Group #1 (Control)|"Group #1 (Control)
~Oral survey 1 will be administered and patients will be asked:
~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis.
~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
16474868|NCT03465163|No Intervention|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
16474901|NCT03464955|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
16474796|NCT03465696|Experimental|Group #2 (Intervention)|"Group #2 (Intervention)
~Survey 2 will be administered, and patients will be asked the following primer:
~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.
~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
16474797|NCT03465696|Experimental|Group #3 (Intervention)|"Group #3 (Intervention)
~Survey 3 will be administered, and patients will be asked the following primer:
~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.
~What do you think would be the best way to describe this to a patient?
~Stelara® acts in an almost all-natural way to help control psoriasis.
~Stelara® blocks one of the genetic causes of psoriasis.
~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance
~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis
~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
16474798|NCT03465670|Active Comparator|CHX|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse (10 ml for 1 minute, t.i.d. for 21 days)
16474799|NCT03465670|Experimental|CHX+HA+ADS|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) (10 ml for 1 minute, t.i.d. for 21 days)
16474800|NCT03465644|Experimental|Tailored arm|early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy
16474801|NCT03465644|Active Comparator|Conventional arm|clopidogrel + aspirin for 12months
16474802|NCT03465631|Experimental|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
16474803|NCT03465631|Sham Comparator|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
16474804|NCT03465618|Experimental|surgical patients|Patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans will be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.
16474805|NCT03465618|Experimental|non-surgical patients|Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging
16474806|NCT03465592|Experimental|Nivolumab|"Adults: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.
~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks.A maximum of 24 cycles will be given on study."
16474807|NCT03465579|Other|Cohort 1|Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
16474808|NCT03465579|Other|Cohort 2|Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
16474809|NCT03465579|Other|Cohort 3a|Men with high-risk PCa (HR-PCa) prior to radical surgery.
16474810|NCT03465579|Other|Cohort 3b|Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
16474811|NCT03465566||Children with BECTS|"Children with active BECTS according to state-of-the-art diagnostic criteria of ILAE (International League Against Epilepsy). Eligible subjects will be recruited at their first clinical observation in the epilepsy centers involved in the study.
~All subjects will perform five diagnostic evaluations named:
~IDS (Intelligence and Development Scale) MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
16474812|NCT03465566||Healthy children|"Healthy controls matched for sex, age range, and education with no family history for epilepsy or other neuropsychiatric disorders.
~All subjects will perform the following tests:
~MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
16474813|NCT03465553|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
16474814|NCT03465540|Experimental|Part 1A: AMG 397 Dose Escalation|This arm includes subjects with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL).
16474815|NCT03465540|Experimental|Part 1B: AMG 397 Dose Escalation|This arm includes subjects with acute myeloid leukemia (AML).
16474816|NCT03465540|Experimental|Part 2A: AMG 397 Monotherapy|This arm includes subjects with AML or myelodysplastic syndrome (MDS).
16474817|NCT03465540|Experimental|Part 2B: AMG 397 Monotherapy|This arm includes subjects with AML in Japan only.
16474818|NCT03465540|Experimental|Part 2C: AMG 397 Monotherapy|This arm includes subjects with MM.
16474819|NCT03465540|Experimental|Part 3A: AMG 397 + Azacitidine Combotherapy|This arm includes subjects MDS.
16474820|NCT03465540|Experimental|Part 3B: AMG 397+ Azacitidine Combotherapy|This arm includes subjects AML.
16474821|NCT03465540|Experimental|Part 3C: AMG 397+ Dexamethasone Combotherapy|This arm includes subjects MM.
16474822|NCT03465527|Experimental|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
16474823|NCT03465501||Low Dose Rate|Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
16474824|NCT03465501||High Dose Rate|Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
16474869|NCT03465163|Experimental|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.
~We require a minimum of 5 seizures to occur during this phase."
16474825|NCT03465488|Experimental|Subjects|All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.
16474826|NCT03465475||Group 1|The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
16474827|NCT03465475||Group 2|The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
16474828|NCT03465475||Group 3|The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
16474829|NCT03465462|Active Comparator|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
16474830|NCT03465462|Active Comparator|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
16474831|NCT03465462|Active Comparator|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
16474832|NCT03465449|Active Comparator|usual care|
16474833|NCT03465449|Experimental|CKD-EDU arm|
16474834|NCT03465436|Experimental|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
16474835|NCT03465436|Experimental|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
16474836|NCT03465436|Placebo Comparator|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
16474837|NCT03465436|Active Comparator|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
16474838|NCT03465423||patients with nonfunctioning pituitary tumor|patients with nonfunctioning pituitary tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
16474839|NCT03465423||patients with pituitary somatotroph tumor|patients with pituitary somatotroph tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
16474840|NCT03465410|Active Comparator|GROUP I Standard adjustment|Standard dosage of Tacrolimus
16474841|NCT03465410|Experimental|GROUP II Bayesian prediction adjustment|Bayesian prediction Tacrolimus dosage
16474842|NCT03465397|Experimental|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
16474843|NCT03465397|No Intervention|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
16474844|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
16474845|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
16474846|NCT03465371|Experimental|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
16474847|NCT03465371|Active Comparator|InPerson Intervention|Participants receiving the InPerson Intervention
16474848|NCT03465345|Experimental|Metformin + OPC dose escalation|
16474849|NCT03465332||Lung specialist|Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
16474850|NCT03465332||Subjects with COPD|Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
16474851|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
16474852|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
16474853|NCT03465306|Experimental|Intensive digital CBT|
16474854|NCT03465306|Active Comparator|Standard digital CBT|
16474855|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
16474856|NCT03465267|Experimental|Armeo power|Armeo power robot for upper extremity
16474857|NCT03465267|Experimental|Armeo spring|Armeo spring robot for upper extremity
16474858|NCT03465254||Cohort|Recruited members of the cohort are children aged 9-14 years old and eligible to receive the dengue vaccine at the time of the initiation of community-based dengue immunization program of the Department of Health.
16474859|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
16474860|NCT03465228|Experimental|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
16474861|NCT03465228|Experimental|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
16474862|NCT03465228|Experimental|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
16474863|NCT03465215|Experimental|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
16474864|NCT03465202|Experimental|Capecitabine|
16474865|NCT03465176|Experimental|Intervention|The women in this arm will receive an essential oil blend to inhale each afternoon for two weeks.
16474866|NCT03465176|Placebo Comparator|Control|The women in this arm will receive an odorless vegetable based oil to inhale each afternoon for two weeks as a control/placebo.
16474900|NCT03464968|Experimental|mFOLFIRI|D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
16475003|NCT03464266|Active Comparator|Condoms only and no PrEP|
16474870|NCT03465163|Experimental|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
16474871|NCT03465163|Experimental|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
16474872|NCT03465137|Experimental|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
16474873|NCT03465137|No Intervention|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
16474874|NCT03465124|Active Comparator|Femtosecond Laser assisted Cataract Surgery|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.
16474875|NCT03465124|Active Comparator|Manual Cataract Surgery|Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.
16474876|NCT03465111|Experimental|Twice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U twice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.
16474877|NCT03465111|Experimental|Thrice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U thrice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 16, the treatment will be administered on as needed basis, based on the retreatment criteria.
16474878|NCT03465098|Experimental|enrolled patients|All enrolled patients will be received a strict low carbohydrate (< 3gr/day of carbohydrate) and 12h fasting before 18F-FDG PET/CT exam and 24h after a 18F-FDG PET/CT preceded by a low carbohydrate diet with 12h fasting
16474879|NCT03465085|Experimental|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
16474880|NCT03465085|Experimental|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
16474881|NCT03465085|No Intervention|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
16474882|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
16474883|NCT03465059|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
16474884|NCT03465059|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
16474885|NCT03465059|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
16474886|NCT03465059|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
16474887|NCT03465046|Experimental|low performance group 1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
16474888|NCT03465046|Experimental|low performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
16474889|NCT03465046|Experimental|moderate-high performance group1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
16474890|NCT03465046|Experimental|moderate-high performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
16474891|NCT03465033|No Intervention|Usual Care|Patients will receive basic indications of rehabilitation consisting of daily mobilization of the jaw (perform several movements a day opening movements, laterotrusion and mouth protrusion).
16474892|NCT03465033|Experimental|Early Physiotherapy|
16474893|NCT03465020||ITP patients|On active treatment
16474894|NCT03465007|Active Comparator|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
16474895|NCT03465007|Placebo Comparator|Placebo|100mg normal saline will be administered prior to hemodialysis
16474896|NCT03464994|Other|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
16474897|NCT03464994|Other|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
16474898|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
16474899|NCT03464968|Experimental|mFOLFOX|D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
16475004|NCT03464240|Active Comparator|Glucose|50 grams glucose in 50 ml water
16474902|NCT03464955|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
16474903|NCT03464955|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
16474904|NCT03464942|Active Comparator|Single Dose|SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
16474905|NCT03464942|Active Comparator|Fractionated Dose|SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
16474906|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
16474907|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
16474908|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
16474909|NCT03464890|Experimental|LICHTENA DermAD|"Comparison within subjects of P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO versus placebo and versus untreated control area. Study products were applied once, on experimentally induced erythema by repeated tape stripping on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side)"
16474910|NCT03464877|Experimental|Intervention group|Standardized six-week duration multi-station full-body supervised exercise program. The frequency was 2-3 sessions per week. The duration of each session was 60 minutes.
16474911|NCT03464864|Experimental|Treprostinil Inhalation Powder 30 mcg|
16474912|NCT03464864|Experimental|Treprostinil Inhalation Powder 60 mcg|
16474913|NCT03464864|Experimental|Treprostinil Inhalation Powder 90 mcg|
16474914|NCT03464864|Experimental|Treprostinil Inhalation Powder 120 mcg|
16474915|NCT03464864|Experimental|Treprostinil Inhalation Powder 150 mcg|
16474916|NCT03464864|Experimental|Treprostinil Inhalation Powder 180 mcg|
16474917|NCT03464864|Experimental|Treprostinil Inhalation Powder 240 mcg|
16474918|NCT03464864|Experimental|Treprostinil Inhalation Powder 300 mcg|
16474919|NCT03464851||Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV <= 125 cm/sec)
16474920|NCT03464851||Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
16474921|NCT03464851||Known ICA Fibromuscular Dysplasia|
16474922|NCT03464838|Experimental|Real Stimulation tDCS with CBT|16 participants will attend to one weekly tDCS stimulation session with intensity 1.8 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
16474923|NCT03464838|Sham Comparator|Sham tDCS with CBT|16 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
16474924|NCT03464825|Other|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
16474925|NCT03464825|No Intervention|Control|Care as usual
16474926|NCT03464812|Other|DSMES Group|Patients with type 2 diabetes will undergo a diabetes education program (DSMES) and evaluated for outcomes before and after completing the program.
16474927|NCT03464786|Experimental|absorbable collagen membrane|Subjects randomized in this arm will receive Lando® absorbable collagen membrane after tooth extraction.
16474928|NCT03464786|Active Comparator|Bio-Gide resorbable bilayer membrane|Subjects randomized in this arm will receive Bio-Gide resorbable bilayer membrane after tooth extraction.
16474929|NCT03464773|Other|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
16474930|NCT03464773|No Intervention|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
16474931|NCT03464760|Placebo Comparator|Placebo|
16474932|NCT03464760|Experimental|Spirulina-Silicon supplementation|
16474933|NCT03464734|Experimental|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
16474934|NCT03464721||Surgery Outpatients|
16474935|NCT03464708|Experimental|HMB|HMB 3 g/day until hospital discharge or 28-days (whichever comes first). HMB to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
16474936|NCT03464708|Placebo Comparator|Placebo|Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
16474937|NCT03464695|Active Comparator|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
16474938|NCT03464695|No Intervention|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
16474939|NCT03464682|Experimental|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
16474940|NCT03464682|Experimental|HS-25 20mg|HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
16474941|NCT03464682|Experimental|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks
16474942|NCT03464682|Experimental|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks
16474943|NCT03464682|Active Comparator|Aorvastatin 10mg|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks
16474944|NCT03464682|Placebo Comparator|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks
16474945|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
16475005|NCT03464240|Placebo Comparator|Water|50 ml water
16474946|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
16474947|NCT03464669||Control group|Absence of prenatal education
16474948|NCT03464656|Experimental|Patients|"Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study.
~Interventions:
~Patients will be given Fairhaven Pro for Men as antioxidant in a dose of 3 tablets twice daily for 3 months.
~Full assessment of fertility will be done."
16474949|NCT03464643|Other|Single embryo culture|Embryo is cultured individually in 25 ul media
16474950|NCT03464643|Other|Group embryo culture|2-3 Embryos are group cultured in 50 ul media
16474951|NCT03464630|Experimental|Mom & Baby Net|Skills based maternal depression treatment and targeted infant social-communication promotion
16474952|NCT03464630|Active Comparator|Developmental Awareness System|Depression and infant develop awareness
16474953|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
16474954|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:
~Sign an Information and Authorization form
~Demographic data: gender, date of birth, ethnicity
~Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
16474955|NCT03464565||Patients with acute ischemic stroke secondary to LVO|
16474956|NCT03464552|Active Comparator|Celecoxib group|will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy
16474957|NCT03464552|Placebo Comparator|Placebo group|will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy
16474958|NCT03464539|Other|CD patients|PG low molecular weight chitosan 3 times per day
16474959|NCT03464526|Active Comparator|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
16474960|NCT03464526|Active Comparator|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
16474961|NCT03464526|Active Comparator|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
16474962|NCT03464526|Placebo Comparator|Placebo|Placebo tablet, once daily for 12 weeks
16474963|NCT03464513|Other|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
16474964|NCT03464500|Active Comparator|AMAZ-02 Low dose|
16474965|NCT03464500|Active Comparator|AMAZ-02 High Dose|
16474966|NCT03464500|Active Comparator|Placebo|
16474967|NCT03464487|Active Comparator|Daily LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy diet everyday along with the antiepileptic drugs.
16474968|NCT03464487|Active Comparator|Intermittent LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy Diet on five days of each week along with antiepileptic drugs. Rest of the two days, they will receive a liberal diet.
16474969|NCT03464474|Experimental|Assessment of inflammation grade|Colonic biopsies will be acquired. Biopsies from all patients will be examined using digital holographic microscopy as well as performing a histopathological analysis using the Nancy-score (Goldstandard).
16474970|NCT03464461|Placebo Comparator|0 mg|0 mg ketorolac - placebo
16474971|NCT03464461|Active Comparator|10 mg|10 mg ketorolac - low dose ketorolac
16474972|NCT03464461|Active Comparator|30 mg|30 mg ketorolac - usual dose ketorolac
16474973|NCT03464448||1|Patients with RRMS who have been newly prescribed Teriflunomide.
16474974|NCT03464448||2|Healthy Controls
16474975|NCT03464435|Experimental|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
16474976|NCT03464422|Experimental|Young gay and bisexual men of color|Approximately 30 young MSM of color will take part in weekly 90-minute group treatment sessions over 10 weeks. All participants will complete outcome assessments at baseline and three months post-treatment, as well as an exit interview.
16474977|NCT03464409|Active Comparator|SCI Patient - Nerve Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking nerve transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
16474978|NCT03464409|Active Comparator|SCI Patient - Tendon Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking tendon transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
16474979|NCT03464409|Active Comparator|SCI Patient - No Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury who did not chose to have surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline, Early Followup (1 month later), and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
16474980|NCT03464396||Preterm infant study visits|"Preterm infants Study Visits
~Bedside Physiology Study at 28, 32, 36, 40, and 52 weeks GA.
~Respiratory tests:
~Carotid Body Function Test will be completed at 32, 36, 40 and 52 weeks GA
~Room Air Challenge (RAC) or Hypoxia Challenge Test (HCT) will be completed at 36 weeks GA
~Effects of nasal cannula flow be completed at 28, 32, 36, 40 and 52 weeks GA
~Magnetic Resonance Imaging (MRI): Completed on a subset of infants between 37-40 weeks GA or before discharge, whichever comes first.
~Echocardiogram (Echo): Completed at 32, 36 and 52 weeks GA
~Blood sample: Obtained at 32, 36 and 52 weeks GA"
16475006|NCT03464227|Experimental|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
16475007|NCT03464227|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
16475008|NCT03464214|Active Comparator|Vibration Group|Local vibration on neck muscles
16474981|NCT03464383|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
16474982|NCT03464383|Active Comparator|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
16474983|NCT03464383|Other|Survey Arm|This option will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are found to be ineligible for intervention arms of the study, or those who are eligible for the intervention arm but decline to participate in the intervention.
16474984|NCT03464370|Experimental|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
16474985|NCT03464370|Active Comparator|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
16474986|NCT03464370|Active Comparator|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
16474987|NCT03464370|Active Comparator|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
16474988|NCT03464357|Active Comparator|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
16474989|NCT03464357|Active Comparator|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.
~The fMRI will be carried out following the inclusion visit after all the necessary checks"
16474990|NCT03464344|Other|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
16474991|NCT03464344|Other|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
16474992|NCT03464331|Experimental|EXP group|Participants in EXP group (EXP) will be asked to practise Zero-time exercises (ZTE) at least 20-30 minutes per day, and on most and preferably all days of the week.
16474993|NCT03464331|Placebo Comparator|CON group|Participants in CON group (CON) will be asked to practise relaxation exercises (RE) and deep-breathing exercises (DBE) at least 30 mins every day.
16474994|NCT03464305|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
16474995|NCT03464305|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
16474996|NCT03464292|Placebo Comparator|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
16474997|NCT03464292|Active Comparator|Capsaicin Patch 8% or 0.1% Capsaicin Cream|8% capsaicin topical patch or 0.1% capsaicin cream. The patch will applied to the hand for 30 - 60 min. The cream will be applied similarly on a 3 cm2 area of the arm. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
16474998|NCT03464279|Experimental|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
16474999|NCT03464279|Active Comparator|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
16475000|NCT03464266|Active Comparator|DMPA and PrEP|
16475001|NCT03464266|Active Comparator|DMPA and no PrEP|
16475002|NCT03464266|Active Comparator|Condoms only and PrEP|
16475009|NCT03464214|Active Comparator|Stabilization Group|Cervical stabilization exercises on cervical region
16475010|NCT03464214|No Intervention|Control Group|Individuals performed only daily living activities
16475011|NCT03464201|Experimental|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
16475012|NCT03464188|No Intervention|Usual Care|Usual care family caregiver participants will be informed of the UAB Comprehensive Cancer Center Patient and Family Resources webpage.
16475013|NCT03464188|Experimental|Project Cornerstone|The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician. Regular caregiver distress thermometer screening and problem support and self-care coaching. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions.
16475014|NCT03464175|Active Comparator|Heated-humidifier left on during nebulization|
16475015|NCT03464175|Active Comparator|Heated-humidifier turned off 30 minutes before nebulization|
16475016|NCT03464175|Active Comparator|Use of a heat and moisture exchanger (HME) filter|
16475017|NCT03464175|Active Comparator|Use of a dry ventilator circuit specific for aerosol therapy|
16475018|NCT03464162|Experimental|Social Network Meetings Group|"This arm will receive Social Network Meetings for a 6 month period. Meetings may occur as often as 3 times a week when there is a crisis or more commonly would occur once every other week. These meetings will last between 60 and 90 minutes and will take place for however long the clients and their social networks would like within the project period. Ideally, each client and his/her Social Network would participate in 4 meetings during the 6 month period. This group would continue to receive care as usual with the addition of these meetings.
~*Final sample in this arm was N=3."
16475019|NCT03464162|No Intervention|No Social Network Meetings Group|"This arm will not receive the Social Network Meetings intervention. Clients in this arm will participate in the study for 6 months and receive care as usual during this time.
~*Final sample in this arm was N=1."
16475020|NCT03464162|Other|Social Network Members|"This arm is comprised of individuals who are social network members of clients who are receiving the Social Network Meetings intervention.
~*Final sample in this arm was N=3 (social network members of arm 1)."
16475021|NCT03464149||Study Arm|"One armed study, blood from each patient is analysed by the following assays:
~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
16475022|NCT03464136|Experimental|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram [mg/kg]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
16475023|NCT03464136|Active Comparator|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
16475024|NCT03464110|No Intervention|Standard of Care|Investigator will compare patients randomized into the intervention group to those who receive standard of care.
16475025|NCT03464110|Experimental|Communication Intervention|The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
16475026|NCT03464097|Experimental|Administration of oral Ozanimod 0.92mg|Subjects will receive a single 0.92 mg capsule [equivalent to ozanimod HCl 1 mg] once daily x 52 weeks
16475027|NCT03464097|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally once daily x 52 weeks
16475028|NCT03464097|Experimental|Administration of oral Ozanimod 0.46mg|Subjects will receive a single 0.46 mg capsule [equivalent to ozanimod HCl .5 mg] once daily x 52 weeks
16475029|NCT03464084|Other|bright light placebo|
16475030|NCT03464084|Other|bright light melatonin|
16475031|NCT03464084|Other|dim light|
16475032|NCT03464071|Experimental|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
16475033|NCT03464071|Experimental|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
16475034|NCT03464058|Experimental|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
16475035|NCT03464058|Experimental|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
16475036|NCT03464058|Experimental|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
16475037|NCT03464058|Experimental|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
16475038|NCT03464058|Experimental|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
16475039|NCT03464058|Experimental|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
16475040|NCT03464058|Experimental|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
16475041|NCT03464058|Experimental|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
16475042|NCT03464058|Experimental|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
16475043|NCT03464058|Experimental|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
16475044|NCT03464058|Experimental|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
16475045|NCT03464058|Experimental|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
16475046|NCT03464058|Experimental|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
16475047|NCT03464045||type 2 diabetes patients|
16475048|NCT03464032|Experimental|BCD-135|Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)
16475049|NCT03464019|Experimental|Etripamil 70 mg Single Dose|Self- administration of a single dose of 70 mg of etripamil.
16475050|NCT03464019|Placebo Comparator|Placebo Single Dose|Self- administration of a single dose of placebo.
16475051|NCT03464019|Experimental|Etripamil 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of etripamil 70 mg
16475052|NCT03464019|Placebo Comparator|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo.
16475053|NCT03464006|Experimental|Online Support Module|Patients in the online support module group will receive a tablet which has the developed peripheral arterial disease platform installed on it. The platform helps the patient to monitor factors related to their peripheral arterial disease such as exercise, smoking, and diet and helps them to track and modify these behaviours.
16475054|NCT03464006|Active Comparator|Standard of Care|Patients in this arm will receive the standard of care as provided by the institution.
16475055|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
16475056|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
16475057|NCT03463980|Experimental|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
16475058|NCT03463980|Active Comparator|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
16475059|NCT03463967|Active Comparator|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
16475060|NCT03463967|Sham Comparator|Calories Restricted|Energy-restricted diet
16475061|NCT03463954|Experimental|Novilase Laser Ablation and excision|Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
16475062|NCT03463941|Experimental|African American church members|
16475063|NCT03463915|Active Comparator|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
16475064|NCT03463915|Placebo Comparator|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
16475065|NCT03463902|Experimental|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
16475066|NCT03463902|Active Comparator|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
16475067|NCT03463902|Active Comparator|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
16475068|NCT03463902|Active Comparator|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
16475069|NCT03463902|Placebo Comparator|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
16475070|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
16475071|NCT03463876|Experimental|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
16475072|NCT03463850|Experimental|Non-fracture|subjects without a lumbar fracture will have a Dexa scan and Dual Energy CT (DECT) scan for observation/evaluation
16475073|NCT03463850|Experimental|Fracture|subjects with one or more lumbar fractures will have a Dexa scan andDual Energy CT (DECT) scan for observation/evaluation
16475074|NCT03463837|Experimental|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco [5 days] in confinement.
16475075|NCT03463837|Experimental|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint [5 days] in confinement.
16475076|NCT03463837|Experimental|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango [5 days] in confinement.
16475077|NCT03463837|Experimental|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele [5 days] in confinement.
16475078|NCT03463837|Active Comparator|Combustible cigarette|Exclusive use of combustible cigarette [5 days] in confinement.
16475080|NCT03463824|Experimental|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
16475081|NCT03463824|Experimental|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
16475082|NCT03463798||Patients|Patients with a suspicion of diaphragmatic dysfunction
16475083|NCT03463798||Healthy volunteers|Subjects without any medical condition
16475084|NCT03463785||Chinese|Chinese mild or moderate OSA patients
16475085|NCT03463785||Dutch|Dutch mild or moderate OSA patients
16475086|NCT03463772|Active Comparator|standard IVF|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group A will receive standard IVF procedure. Other standard assisted reproductive treatments are similar and parallel between two groups.
16475087|NCT03463772|Active Comparator|In vitro maturation|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
16475088|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
16475089|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
16475090|NCT03463746|Experimental|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
16475091|NCT03463746|Active Comparator|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
16475092|NCT03463733|Experimental|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.
~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
16475093|NCT03463720||Extremity wound|Patients with extremity wounds. Infected and not infected patients will be compared.
16475094|NCT03463707|Experimental|Treatment with BP101|
16475095|NCT03463707|Placebo Comparator|Treatment with placebo|
16475096|NCT03463694|Experimental|Hypertonic Saline ~2.6% NaCl|3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
16475097|NCT03463694|No Intervention|Standard Care|Control arm of standard symptomatic care only
16475098|NCT03463681|Experimental|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
16475099|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
16475100|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
16475101|NCT03463642|Experimental|Vitamin D3 pill|100 pills = 100,000IU + Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
16475102|NCT03463642|Placebo Comparator|Pill placebo|100 pills = Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
16475103|NCT03463642|Experimental|Vitamin D3 oral liquid|100 drops = 100,000IU in orange syrup
16475104|NCT03463642|Placebo Comparator|Oral liquid placebo|100 drops orange syrup
16475105|NCT03463642|Experimental|Skin oil + Vitamin D3 + penetrator|100,000IU + mineral oil+ Tangerine essential oil (10ml)
16475106|NCT03463642|Experimental|Skin oil + Vitamin D3|100,000IU + mineral oil
16475107|NCT03463642|Placebo Comparator|Skin oil placebo|Skin application: 100ml of mineral oil coloured with food colourant to match active oil sample
16475108|NCT03463629|Experimental|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.
~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.
~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
16475109|NCT03463629|Active Comparator|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services. Data for this arm will be collected through retrospective chart review.
16475110|NCT03463616||CT abdomen|Patients who had a CT abdomen as primary work-up before treatment planning for rectal cancer.
16475111|NCT03463616||MRI Abdomen|Patients who had a MRI abdomen as primary work-up before treatment planning for rectal cancer.
16475112|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
16475113|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
16475114|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
16475115|NCT03463590|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
16475116|NCT03463577||Exposed Group|Pregnant women vaccinated with Boostrix on or after the 1st day of the 27th week of pregnancy; who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy are in scope of this study.
16475117|NCT03463577||Unexposed Group|Women matched to the exposed cohort and pregnant sometime during the approximate estimated period between 1/1/2012-12/31/2013 who did not receive any Tdap vaccine during the pregnancy are in scope of this study.
16475118|NCT03463564|Active Comparator|Insulin pump|Insulin Pump with rapid acting insulin analog lispro
16475119|NCT03463564|Active Comparator|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection at bed-time of basal insulin glargine or degludec
16475120|NCT03463551|Experimental|ABL-101 IV as per dosing cohort + Supplementary O2 for 24h|"Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.
~In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.
~Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.
~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
16475121|NCT03463551|Placebo Comparator|IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h|"Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.
~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
16475122|NCT03463538|Active Comparator|Arthroscopic capsular release|Surgical release performed under general anesthetic
16475123|NCT03463538|Active Comparator|Hydro-dilatation|injection of water under local anesthetic in to shoulder joint
16475124|NCT03463525|Experimental|[11C]osimertinib + oral osimertinib|IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.
16475125|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
16475126|NCT03463512|Active Comparator|ORS (standard treatment)|
16475127|NCT03463499|Experimental|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
16475128|NCT03463473|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 0.3 mg/kg and may be escalted to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
16475129|NCT03463460|Experimental|Treatment (pembrolizumab, sunitinib malate)|Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
16475130|NCT03463447|Experimental|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
16475131|NCT03463434|Experimental|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
16475132|NCT03463434|Active Comparator|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
16475133|NCT03463408|Experimental|Immunotherapy arm|"Cohort A will comprise adult soft tissue sarcoma patents who consent to and receive ipilimumab + nivolumab concurrently with standard of care radiation. Ipilimumab will be given at a dose of 1 mg/kg every 6 weeks (total two doses) and nivolumab given as a flat dose of 240 mg every 2 weeks (total four doses).
~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
16475134|NCT03463408|No Intervention|no immunotherapy arm|"Cohort B will comprise patients eligible for the trial who do not wish to receive immunotherapy but consent to the same blood draws, surveys, and specimen analysis as Cohort A. Cohort B will serve as a non-randomized but pragmatic and clinically relevant control group.
~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
16475135|NCT03463395|No Intervention|Standard of Care|Group A will receive standard of care
16475136|NCT03463395|Experimental|Reza band use|Group B will receive standard care plus the Reza band (worn as recommended by the manufacturer)
16475137|NCT03463382|Active Comparator|ESP Group|"Erector Spinae Plane Block Group
~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
16475138|NCT03463382|Active Comparator|QLB Group|"Quadratus Lumborum Block Group
~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
16475139|NCT03463369|Experimental|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
16475140|NCT03463369|Experimental|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
16475141|NCT03463356|Experimental|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
16475142|NCT03463343|Experimental|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
16475143|NCT03463343|Active Comparator|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
16475144|NCT03463343|Placebo Comparator|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
16475145|NCT03463343|No Intervention|Control|The subjects stayed in supine position and no intervention occurred.
16475146|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
16475147|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
16475148|NCT03463317|Experimental|LAA closure group|Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)
16475149|NCT03463317|Active Comparator|Best medical care group|No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)
16475150|NCT03463291||Study group|All patients with bony lesions
16475151|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
16475152|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
16475153|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of >7 blastocysts vitrified
16475154|NCT03463265|Experimental|ABI-009|
16475155|NCT03463265|Experimental|ABI-009 + bevacizumab|
16475156|NCT03463265|Experimental|ABI-009 + temozolomide|
16475157|NCT03463265|Experimental|ABI-009 + lomustine|
16475158|NCT03463265|Experimental|ABI-009 + temozolomide + radiotherapy|
16475159|NCT03463265|Experimental|ABI-009 + marizomib|
16475160|NCT03463252|Active Comparator|MPA for EC without progesterone contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
16475161|NCT03463252|Experimental|MPA+Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
16475162|NCT03463252|Experimental|Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
16475163|NCT03463252|Active Comparator|GnRH agonist+Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
16475164|NCT03463252|Experimental|Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
16475165|NCT03463252|Active Comparator|Mirena® for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
16475166|NCT03463252|Experimental|MPA for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
16475231|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
16475232|NCT03462862|Experimental|Group 1|patients will receive partial denture constructed from PEEK material
16475233|NCT03462862|Active Comparator|Group 2|patients will receive partial denture constructed from breflex material
16475234|NCT03462849|Other|Patients with EFL at PEP 5|Patients with EFL at PEP 5 at the time of inclusion either in supine or semi-recumbent position
16475167|NCT03463252|Active Comparator|Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
16475168|NCT03463252|Experimental|GnRH-a+Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
16475169|NCT03463239|Experimental|Autologous tissue engineered corpora|All subjects enrolled will undergo a corpora cavernosum biopsy. Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
16475170|NCT03463226||Low testosterone|"Patients with HF and testosterone deficiency.
~Cardiopulmonary exercise test
~Muscle Sympathetic Nerve Activity
~Dual-energy X-ray absorptiometry
~Venous occlusion plethysmography
~Blood sample collection
~Dynamometers for Handgrip Strength"
16475171|NCT03463226||Normal testosterone|"Patients with HF and normal plasma levels of testosterone.
~Cardiopulmonary exercise test
~Muscle Sympathetic Nerve Activity
~Dual-energy X-ray absorptiometry
~Venous occlusion plethysmography
~Blood sample collection
~Dynamometers for Handgrip Strength"
16475172|NCT03463213|Experimental|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
16475173|NCT03463200|No Intervention|Control group|It will not apply any tape.
16475174|NCT03463200|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
16475175|NCT03463200|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
16475176|NCT03463200|Experimental|Experimental group 3|Apply Micropore tape in the erector spine muscles.
16475177|NCT03463187|Experimental|80mg SHR-1314-Part A|SHR-1314 80mg, subcutaneously
16475178|NCT03463187|Experimental|160mg SHR-1314-Part A|SHR-1314 160mg, subcutaneously
16475179|NCT03463187|Experimental|240mg SHR-1314-Part A|SHR-1314 240mg, subcutaneously
16475180|NCT03463187|Experimental|40mg SHR-1314 (Part B)|SHR-1314 40mg, subcutaneously
16475181|NCT03463187|Experimental|80mg SHR-1314 (Part B)|SHR-1314 80mg, subcutaneously
16475182|NCT03463187|Experimental|160mg SHR-1314 (Part B)|SHR-1314 160mg, subcutaneously
16475183|NCT03463187|Experimental|240mg SHR-1314 (Part B)|SHR-1314 240mg, subcutaneously
16475184|NCT03463187|Experimental|SHR-1314 Placebo (Part B)|SHR-1314 Placebo, subcutaneously
16475185|NCT03463174|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have a dental implant placed in the mandibular midline followed by the immediately insertion of a ball attachment and the incorporation of a retention matrix to the mandibular denture.
16475186|NCT03463174|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment besides the new set of conventional complete dentures. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
16475187|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.
~Participants will receive Pembrolizumab and Epacadostat."
16475188|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.
~Participants will receive Pembrolizumab and Epacadostat."
16475189|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
16475190|NCT03463135|Experimental|SAR439794 [PE SLIT + GLA)]|GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
16475191|NCT03463135|Experimental|Placebo for GLA + SLIT PE|Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
16475192|NCT03463135|Placebo Comparator|Placebo for GLA + Placebo for SLIT PE|Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks
16475193|NCT03463122|Other|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
16475194|NCT03463122|Other|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
16475195|NCT03463109|Other|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
16475235|NCT03462849|Other|Patients with no EFL at PEP 5|Patients with no EFL at PEP 5 at the time of inclusion in both supine and semi-recumbent positions
16475236|NCT03462836|Experimental|IV ketamine/lidocaine/IV PCA (MA) group|In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
16475196|NCT03463109|Other|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.
~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
16475197|NCT03463096|Experimental|Centrifuge study|High G acceleration on a long-arm human centrifuge
16475198|NCT03463083|Active Comparator|Bupivacaine dexmedetomidine group|Group 1 (bupivacaine + dexmedetomidine (BD) group); will Receive an epidural study solution of 18 ml of 0.25% of bupivacaine hydrochloride plus 1 ml of dexmedetomidine (1 mcg/kg) plus 1 ml normal saline keeping the total volume of 20 ml in a syringe pump .
16475199|NCT03463083|Active Comparator|Bupivacaine fentanyl group|Group 2 (bupivacaine + fentanyl (BF) group) ; will Receive an epidural study solution of 18 ml of 0.25% bupivacaine plus 2 ml fentanyl (1 mcg/kg) keeping the total volume of 20 ml in a syringe pump .
16475200|NCT03463070|Active Comparator|preoperative misoprostol group|70 women who received 600 mg misoprostol rectally preoperatively before cesarean section
16475201|NCT03463070|Active Comparator|postoperative misoprostol group|70 women who received 600 mg misoprostol postoperatively at operating theatre after cesarean section
16475202|NCT03463057|Other|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
16475203|NCT03463044|Placebo Comparator|Placebo|
16475204|NCT03463044|Experimental|MOTREM 1|
16475205|NCT03463044|Experimental|MOTREM 2|
16475206|NCT03463044|Experimental|MOTREM 3|
16475207|NCT03463044|Experimental|MOTREM 4|
16475208|NCT03463044|Experimental|MOTREM 5|
16475209|NCT03463044|Experimental|MOTREM 6|
16475210|NCT03463044|Experimental|MOTREM 7|
16475211|NCT03463044|Experimental|MOTREM 8|
16475212|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
16475213|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
16475214|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
16475215|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
16475216|NCT03463005|Experimental|Royal jelly|The study subjects included healthy women who had husbands with male-factor infertility problems.
16475217|NCT03463005|Active Comparator|IUI group|The study subjects included in IUI group were healthy women who had husbands with male-factor infertility problems.
16475218|NCT03462992||FIT-positive individuals|Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
16475219|NCT03462979|Experimental|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
16475220|NCT03462979|No Intervention|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 8 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
16475221|NCT03462966|Experimental|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
16475222|NCT03462953|Placebo Comparator|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
16475223|NCT03462953|Placebo Comparator|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
16475224|NCT03462940|Experimental|TUDCA Group|All subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period of of the nutritional supplement Tauroursodeoxycholic acid (TUDCA).
16475225|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
16475226|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
16475227|NCT03462901|Experimental|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
16475228|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
16475229|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
16475237|NCT03462836|Active Comparator|IV PCA only (CA) group|In addition to basic anesthetic methods, only IC PCA apply for pain control
16475238|NCT03462823|Active Comparator|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
16475239|NCT03462823|Experimental|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
16475240|NCT03462784||Cases|
16475241|NCT03462771|Experimental|Group exercise fish oil|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive omega-3 fatty acid supplements to be ingested 2g in the main meals, totaling 4g daily.
16475242|NCT03462771|Placebo Comparator|Group exercise placebo|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive sunflower oil to be ingested 2g in the main meals, totaling 4g daily.
16475243|NCT03462758|Other|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
16475244|NCT03462758|Experimental|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
16475245|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
16475246|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
16475247|NCT03462732|Active Comparator|Group I|Endotracheal tube plus Nelaton catheter
16475248|NCT03462732|Active Comparator|Group II|Endotracheal tube
16475251|NCT03462706|Experimental|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
16475252|NCT03462706|Experimental|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
16475253|NCT03462706|Experimental|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
16475254|NCT03462706|Experimental|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
16475255|NCT03462693||Group 1|Dry needling plus standard physiotherapy treatment
16475256|NCT03462693||Group 2|Standard physiotherapy treatment
16475257|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
16475258|NCT03462680|Placebo Comparator|placebo|placebo
16475259|NCT03462667|Experimental|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
16475260|NCT03462667|Active Comparator|Regular Care|Participants will receive normal standard of care prior to surgery.
16475261|NCT03462654|Active Comparator|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
16475262|NCT03462654|Experimental|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
16475263|NCT03462641|Active Comparator|Flumazenil|Flumazenil 1mg in 10cc normal saline will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
16475264|NCT03462641|Placebo Comparator|Placebo|10 cc of normal saline placebo will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
16475265|NCT03462628|Experimental|Study Group|PVI with additional low-voltage substrate modification
16475266|NCT03462628|Active Comparator|Control Group|PVI
16475267|NCT03462602|Experimental|NGT group|NGT group
16475268|NCT03462602|Experimental|non-NGT group|non-NGT group
16475269|NCT03462589|Experimental|SY-008 dose 1|A single dose of SY-008 (2~30mg) taken orally.
16475270|NCT03462589|Experimental|SY-008 dose 2|A single dose of SY-008 (2~30mg) taken orally.
16475271|NCT03462589|Experimental|SY-008 dose 3|A single dose of SY-008 (2~30mg) taken orally.
16475272|NCT03462589|Experimental|SY-008 dose 4|A single dose of SY-008 (2~30mg) taken orally.
16475273|NCT03462589|Experimental|SY-008 dose 5|A single dose of SY-008 (2~30mg) taken orally.
16475274|NCT03462589|Placebo Comparator|SY-008 matching placebo|from 6mg to 30mg
16475275|NCT03462576|Experimental|Emricasan 25mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
16475276|NCT03462576|Experimental|Emricasan 5mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
16475277|NCT03462576|Placebo Comparator|Placebo|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
16475278|NCT03462563|Experimental|INTERCEED™|patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen).
16475279|NCT03462563|Placebo Comparator|standard of care treatment|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
16475280|NCT03462550|Active Comparator|LMA Supreme|
16475281|NCT03462550|Experimental|LMA Protector|
16475282|NCT03462537|Experimental|Experimental group 1|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line.
16475283|NCT03462537|Experimental|Experimental group 2|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line, but low level laser therapy device was switched off.
16475284|NCT03462537|Placebo Comparator|Placebo group|Low level laser therapy without power. This group performed the low level laser therapy protocol, but low level laser therapy device was switched off.
16475285|NCT03462524||Neoadjuvant chemotherapy|
16475286|NCT03462524||Neoadjuvant chemoradiation|
16475287|NCT03462511|No Intervention|Control Group|Dyads randomized to the control group will receive standard care and education handouts.
16475288|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
16475289|NCT03462498|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
16475290|NCT03462498|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
16475291|NCT03462485|Experimental|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
16475292|NCT03462485|No Intervention|Control|Control participants will continue their normal activities.
16475293|NCT03462472|Experimental|15 minute lower leg heating|
16475294|NCT03462472|Experimental|45 minute lower leg heating|
16475295|NCT03462472|No Intervention|Control|
16475296|NCT03462472|Experimental|15 minute lower leg TENS|
16475297|NCT03462472|Experimental|45 minute lower leg TENS|
16475298|NCT03462459|Experimental|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
16475299|NCT03462459|Placebo Comparator|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
16475300|NCT03462446||Treatment group with Rivaroxaban|Patients treated with Rivaroxaban
16475301|NCT03462446||Control group with VKAs|Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
16475302|NCT03462420|Experimental|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
16475303|NCT03462420|Active Comparator|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
16475304|NCT03462407|Experimental|DAID|Trained assistants will help participants train their dog to engage in imitation based dog training, using positive reinforcement training (operant conditioning) focused on physical activities.
16475305|NCT03462407|Active Comparator|Dog walking|Trained assistants will help children train their dog to walk on a loose leash (eliminate pulling behavior) during this period using positive training techniques. The focus of this group will be on appropriate walking behavior to facilitate enjoyable independent dog-walking at home.
16475306|NCT03462407|No Intervention|Control|This group will all own family dogs but will not participate in either intervention during year 1. All participants assigned to the waitlist will be offered the DAID intervention the subsequent summer.
16475307|NCT03462394||Current Script Version|This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health.
16475308|NCT03462394||Script Iterations|This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script.
16475309|NCT03462381|Experimental|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
16475310|NCT03462381|Placebo Comparator|Carbohydrate|Three endurance training sessions weekly with carbohydrate supplementation post-exercise and before sleep.
16475311|NCT03462368|Active Comparator|Control|Root surface treatment by scaling and root planing
16475312|NCT03462368|Experimental|antimicrobial photodynamic therapy|Root surface treatment by antimicrobial photodynamic therapy
16475313|NCT03462368|Active Comparator|Photobiomodulation|Treatment of the whole surgical site with laser
16475314|NCT03462342|Experimental|A. Olaparib Pill + AZD6738.|"Cohort A: Recurrent platinum-sensitive ovarian cancer (progression greater than 6 months from last receipt of platinum-based chemotherapy), approximately 37 patients could be treated with an interim analysis after 17 subjects.
~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.
~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
16475352|NCT03462173|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
16475353|NCT03462173|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
16475315|NCT03462342|Experimental|B. Olaparib Pill + AZD6738.|"Cohort B: Recurrent platinum-resistant ovarian cancer (progression less than or equal to 6 months of the last receipt), approximately 37 patients could be treated with an interim analysis after 12 subjects.
~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.
~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
16475316|NCT03462342|Experimental|C. Olaparib Pill + AZD6738.|"Cohort C: PARP inhibitor (PARPi) resistant (subjects who have progressed on a PARPi), patients must be platinum-sensitive, and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 subjects could be treated.
~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.
~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
16475317|NCT03462342|Experimental|D-1. Olaparib Pill + AZD6738.|"Cohort D Part I: Patients will be platinum sensitive/platinum resistant ovarian cancer. Patient may or may not have received prior PARPi and will be enrolled irrespective of their BRCA status. The number of subjects treated will depend on the number of dose levels explored with a minimum of 12 subjects up to 30 subjects.
~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
16475318|NCT03462342|Experimental|D-2 Olaparib Pill + AZD6738.|"Cohort D Part II: Patients with ovarian cancer who are PARP inhibitor (PARPi) resistant (patients who have progressed on a PARPi). Patients must be platinum-sensitive and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 patients will be treated.
~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
16475319|NCT03462329|Active Comparator|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
16475320|NCT03462329|No Intervention|controls|Control subjects will not be given antibiotics.
16475321|NCT03462316|Experimental|NY-ESO-1 TCR Specific T cell Therapy|NY-ESO-1 TCR specific T cells are prepared by lentiviral infection. Seven days before TCR-T cell reinfusion, the subjects received low-dose cyclophosphamide (15mg/kg/d x 3 days) and low-dose fludarabine (15mg/m2/d x 3 days) lymphocyte clearance. Four days later, TCR-T cells were transfused back (1 x 109-5 x 1010 was administered once or in stages). Then interleukin (IL)-2 subcutaneous injections (250,000 IU/twice/day) will be subcutaneously administered for 14 days concomitantly to each subject within 15-30 minutes after cell reinfusion. If the first three patients had no severe bone marrow suppression side effects (CTCAE was above grade 3) on low-dose lymphocyte clearance therapy, the dosage of cyclophosphamide (20 mg/kg/d x 3 days) and fludarabine (25 mg/m2/d x 3 days) could be increased for follow-up patients.
16475322|NCT03462303|Placebo Comparator|tDCS sham + balanced drink|
16475323|NCT03462303|Experimental|tDCS sham + tyrosine depleted drink|
16475324|NCT03462303|Experimental|tDCS anodal + balanced drink|
16475325|NCT03462303|Experimental|tDCS anodal +tyrosine depleted drink|
16475326|NCT03462290|Experimental|Botulinum toxin|
16475327|NCT03462290|Placebo Comparator|placebo|
16475328|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
16475329|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
16475330|NCT03462264|No Intervention|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
16475331|NCT03462264|Experimental|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
16475332|NCT03462264|Experimental|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
16475333|NCT03462251|Experimental|Arm A|Combination of ribociclib and aromatase inhibitor or fulvestrant
16475334|NCT03462251|Active Comparator|Arm B|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
16475335|NCT03462238|Other|Kidney transplant patients|Group of renal transplant patients for 24 months
16475336|NCT03462238|Other|Dialysis patients|Group of dialysis patients for 24 months
16475337|NCT03462212|Other|Standard treatment|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
16475338|NCT03462212|Experimental|Carboplatin + Paclitaxel + Bevacizumab + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
16475339|NCT03462212|Experimental|Carboplatin + Paclitaxel + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
16475340|NCT03462199|Placebo Comparator|Placebo|
16475341|NCT03462199|Experimental|Actazin High Dose|
16475342|NCT03462199|Experimental|Actazin Low Dose|
16475343|NCT03462199|Active Comparator|Control Formula|
16475344|NCT03462199|Experimental|Livaux High Dose|
16475345|NCT03462199|Experimental|Livaux Low Dose|
16475346|NCT03462186|Experimental|Intervention|Invitation to use healthfinder website
16475347|NCT03462186|No Intervention|Control|No intervention
16475348|NCT03462173|Experimental|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
16475349|NCT03462173|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
16475350|NCT03462173|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
16475351|NCT03462173|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
16475354|NCT03462173|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
16475355|NCT03462160|Placebo Comparator|Placebo supply for 90 days|Patients will receive placebo (in blinded sachets)
16475356|NCT03462160|Experimental|Probiotic supply for 90 days|Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).
16475357|NCT03462147|Sham Comparator|SHAM|No stimulation will be given
16475358|NCT03462147|Experimental|High Density Stimulation|New way of spinal cord stimulation
16475359|NCT03462147|Active Comparator|Conventional stimulation|the most used stimulation of the spinal cord
16475360|NCT03462134||Survey amongst orthopaedic surgeons|Selected of 20 patients from the Escape trial (NCT01850719)
16475361|NCT03462121|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
16475362|NCT03462121|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
16475363|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Adult|1 doses of 1 ml of Rotavirus vaccine per oral
16475364|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Children|1 doses of 1 ml of Rotavirus vaccine per oral
16475365|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
16475366|NCT03462108|Placebo Comparator|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
16475367|NCT03462095|No Intervention|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
16475368|NCT03462095|Experimental|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
16475369|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
16475370|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
16475371|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
16475372|NCT03462069|Experimental|Treatment A (Test)|Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
16475373|NCT03462069|Active Comparator|Treatment B (Reference)|Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
16475374|NCT03462056|Experimental|CF Ready to Use Supplemental Food.|Participants will receive Cystic Fibrosis Ready to Use Supplemental Food sufficient to provide approximately 20% of estimated daily caloric needs up to 500kcal of total calories, 18.5 grams of protein and 28g of fat. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition
16475375|NCT03462043|Active Comparator|Sequence A|
16475376|NCT03462043|Active Comparator|Sequence B|
16475377|NCT03462043|Active Comparator|Sequence C|
16475378|NCT03462043|Active Comparator|Sequence D|
16475379|NCT03462030|Experimental|Baked Milk Immunotherapy|Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
16475380|NCT03462030|Placebo Comparator|Placebo|Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
16475381|NCT03462017|Experimental|SAR247799|SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design
16475382|NCT03462017|Placebo Comparator|Placebo|Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days
16475383|NCT03462017|Active Comparator|Sildenafil|Sildenafil once daily in the morning under fasted condition for 28 days
16475384|NCT03462004|Experimental|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
16475385|NCT03462004|Placebo Comparator|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
16475386|NCT03462004|Experimental|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
16475387|NCT03462004|Placebo Comparator|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
16475388|NCT03461991|Other|Patients scheduled for corneal transplantation|
16475389|NCT03461978|Other|10 patients with meibomian gland dysfunction|
16475390|NCT03461978|Other|10 patients with cataract|
16475391|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
16475392|NCT03461978|Other|10 patients after partial corneal transplantation|
16475393|NCT03461978|Other|5 patients with demodicosis|
16475394|NCT03461978|Other|5 patients with conjunctival pathologies|
16475395|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
16475396|NCT03461978|Other|5 patients with aniridia|
16475397|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
16475398|NCT03461965|Active Comparator|Verbal Counselling|Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
16475399|NCT03461952|Experimental|Nivolumab|240mg Q2W
16475400|NCT03461952|Experimental|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
16475401|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.
~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
16475402|NCT03461926|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
16475403|NCT03461926|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
16475404|NCT03461913|Active Comparator|normal pregnancy|women at full term healthy pregnancy who underwent elective Cesarean section
16475405|NCT03461913|Active Comparator|pregnancy hypertension|women at full term pregnancy associated with hypertension who underwent elective Cesarean section
16475406|NCT03461900|Experimental|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
16475407|NCT03461900|Experimental|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
16475408|NCT03461887|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
16475409|NCT03461887|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment or treatment decisions, including participation in other exercise training programs or rehabilitation programs)
16475410|NCT03461874|Active Comparator|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
16475411|NCT03461874|Experimental|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.
~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
16475412|NCT03461861|Experimental|AGB101 220 mg, then Placebo|AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
16475413|NCT03461861|Experimental|Placebo, then AGB101 220 mg|Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.
16475414|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
16475415|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
16475416|NCT03461835|Active Comparator|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
16475417|NCT03461835|Active Comparator|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
16475418|NCT03461822||SRT in primary-inoperable solid tumors|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
16475419|NCT03461822||Classic radiotherapy in primary-inoperable solid tumors|Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
16475420|NCT03461822||SRT in oligometastatic cancer|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
16475421|NCT03461822||Classic radiotherapy in oligometastatic cancer|Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
16475422|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
16475423|NCT03461783|Experimental|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
16475424|NCT03461783|Active Comparator|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
16475425|NCT03461770|No Intervention|Control group|Patients will receive anesthesia induction with Sevoflurane using a circular circuit without CPAP. Protective ventilation with 5 cmH20 of positive end-expiratory pressure (PEEP) will be initiated after induction. At the end of surgery, mechanical ventilation will stop allowing spontaneous ventilation. Patients will be extubated without CPAP. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
16475426|NCT03461770|Experimental|CPAP group|Patients will receive anesthesia induction using 5 cmH20 of CPAP until the moment of intubation. After induction patients will receive the same protective ventilation than the control group. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery. At the end of surgery, patients will be extubated under the modality of CPAP with 5 cmH20. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
16475427|NCT03461757|Experimental|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
16475428|NCT03461757|Placebo Comparator|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
16475429|NCT03461731|Sham Comparator|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
16475430|NCT03461731|Experimental|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
16475431|NCT03461731|Experimental|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
16475432|NCT03461731|Experimental|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
16475433|NCT03461718|Experimental|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
16475434|NCT03461718|Active Comparator|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
16475435|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
16475436|NCT03461679|Experimental|Intervention|Adductor canal block Femoral triangle block
16475437|NCT03461679|Active Comparator|Standard|Femoral triangle block
16475438|NCT03461666|Active Comparator|Cognitive Behavior Therapy-Insomnia|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
16475439|NCT03461666|Active Comparator|Focus Of Attention|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
16475440|NCT03461666|Active Comparator|Combined-CBT-I and FOA Group|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
16475441|NCT03461666|Active Comparator|Sleep Hygiene|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
16475442|NCT03461653|Other|Telemedicine counselling|intervention group Women who will receive telemedicine counselling
16475443|NCT03461653|No Intervention|Standard care|Women who will receive standard face-to-face counselling
16475444|NCT03461640|Experimental|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.
~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.
~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
16475445|NCT03461640|Active Comparator|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.
~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
16475446|NCT03461627|Experimental|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
16475447|NCT03461627|Active Comparator|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
16475448|NCT03461614|Experimental|Exercise Group|In addition to the service routine rehabilitation program, in this group all participant receive as group training with instructor supervising 5-6 participants. The specific days of the week and time of day in which the participants trained remained constant throughout each training protocol. Training programs lasted 6 weeks and comprised 2 training sessions per week with a total of 12 training sessions. A 45-60 min training sessions per week with a 2 day gap between each session.
16475449|NCT03461614|Other|Control Group|In addition to the service routine rehabilitation program, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
16475450|NCT03461601|Active Comparator|HCG uterine flushing group|Uterine flushing was done one day before Intrauterine insemination (IUI) with HCG (500 IU) in 10 ml of saline followed by Intrauterine insemination (IUI).
16475451|NCT03461601|Placebo Comparator|IUI alone group|Intrauterine insemination alone plus vaginal flushing with 10 ml normal saline
16475452|NCT03461588|Active Comparator|Free-breathing|standard treatment
16475453|NCT03461588|Experimental|Deep inspiratory breath-holding|new technique
16475454|NCT03461575|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%
~1 drop b.i.d at 12hr interval for 12 weeks"
16475455|NCT03461575|Active Comparator|Restasis|"Cyclosporine 0.05%
~1 drop b.i.d at 12hr interval for 12 weeks"
16475456|NCT03461575|Active Comparator|Moisview|"trehalose 3%
~1 drop b.i.d at 12hr interval for 12 weeks"
16475457|NCT03461562|Experimental|Experimental|
16475458|NCT03461562|Active Comparator|Control|
16475459|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
16475460|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
16475461|NCT03461536|Active Comparator|Clinical Decision Support|Participants in this arm will receive the study intervention, the clinical decision support.
16475462|NCT03461536|No Intervention|Usual care|Participants in this arm will not receive the the clinical decision support tool.
16475463|NCT03461510|Experimental|Type 2 Diabetes|Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
16475464|NCT03461510|No Intervention|Lean Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
16475465|NCT03461510|No Intervention|Obese Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
16475466|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
16475467|NCT03461471|Experimental|Intervention Group|Exercise intervention
16475468|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
16475469|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
16475470|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
16475471|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
16475472|NCT03461432|Experimental|Personalised Cognitive Remediation Therapy (pCRT)|A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
16475473|NCT03461419|Experimental|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
16475474|NCT03461419|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
16475475|NCT03461419|Experimental|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
16475478|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
16475479|NCT03461380|Experimental|Menopause Relief EP-40|Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients
16475480|NCT03461380|Active Comparator|High Dose Black Cohosh|Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient
16475481|NCT03461380|Placebo Comparator|Placebo|Placebo capsule 600 mg excipients orally twice daily
16475482|NCT03461380|Active Comparator|Low Dose Black Cohosh|Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient
16475485|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
16475486|NCT03461328|Experimental|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
16475487|NCT03461328|No Intervention|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
16475488|NCT03461315|No Intervention|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
16475489|NCT03461315|Experimental|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
16475490|NCT03461302|Experimental|Topical Coal Tar treatment|
16475491|NCT03461302|Active Comparator|Topical Corticosteroids treatment|
16475492|NCT03461289|Experimental|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
16475493|NCT03461276|Experimental|ABvac40|Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
16475494|NCT03461276|Placebo Comparator|Placebo|Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
16475495|NCT03461263|Active Comparator|Group A|phonophoresis treatment using pumpkin seeds oil
16475496|NCT03461263|No Intervention|Group B|Low intensity Ultrasound
16475497|NCT03461263|No Intervention|Group C|Placebo Low intensity Ultrasound
16475498|NCT03461250||HCV serology negative in HD|Risk factors
16475499|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
16475500|NCT03461224||MARA-1: accelerated hypofractionated RT|A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
16475501|NCT03461224||CG: conventional fractionated RT|In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
16475502|NCT03461211|Experimental|Teprotumumab|Eight infusions of teprotumumab every 3 weeks (q3W) for a total of 21 weeks: teprotumumab 10 mg/kg administered on Day 1 and teprotumumab 20 mg/kg administered q3W for the remaining 7 infusions.
16475503|NCT03461198|Experimental|Treatment|Restylane® Silk to a defined area of mid to low cheeks.
16475504|NCT03461185|Experimental|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
16475505|NCT03461185|Active Comparator|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
16475506|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
16475507|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
16475508|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
16475509|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
16475510|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
16475511|NCT03461146|Experimental|MT-6548|
16475512|NCT03461133||Reference|All patients admitted to the participating surgical wards from 2015-01-01 to 2015-12-31
16475513|NCT03461133||Intervention|All patients admitted to the participating surgical wards from 2016-07-01 to 2017-06-30
16475514|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% [or ropivacaine 0.5%] infusion for 7 days via femoral and sciatic perineural catheters
16475631|NCT03460249|Active Comparator|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
16475515|NCT03461120|Other|Control|Bupivacaine 0.1% [or ropivacaine 0.2%] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
16475516|NCT03461107||patients with heart failure|
16475517|NCT03461081|Experimental|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
16475518|NCT03461081|Experimental|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
16475519|NCT03461068|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
16475520|NCT03461068|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
16475521|NCT03461055|Experimental|Lavender|Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
16475522|NCT03461055|Placebo Comparator|Water|1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
16475523|NCT03461042|Experimental|Arm R|Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
16475524|NCT03461042|Placebo Comparator|Arm PL|Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
16475525|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
16475526|NCT03461016|Experimental|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
16475527|NCT03461016|No Intervention|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
16475528|NCT03461003|Experimental|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
16475529|NCT03461003|Active Comparator|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
16475530|NCT03460990|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
16475531|NCT03460990|Experimental|VX-659/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
16475532|NCT03460977|Experimental|Dose Escalation (Part 1A)|Participants with SCLC, CRPC and FL will receive PF-06821497 at escalating dose levels
16475533|NCT03460977|Experimental|Dose Escalation (Part 1B)|Participants with FL will receive PF-06821497 at escalating dose levels
16475534|NCT03460977|Experimental|Dose Escalation (Part 1C)|Participants with CRPC will receive PF-06821497 at escalating dose levels.
16475535|NCT03460977|Experimental|Dose Escalation (Part 2A)|Participants with CRPC and SCLC will receive PF-06821497 at escalating dose levels in combination with SOC.
16475536|NCT03460977|Experimental|Dose Expansion (Part 2B)|Participants with CRPC will receive PF-06821497 in combination with SOC or SOC alone.
16475537|NCT03460964|Experimental|Patients with Diabetes|All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.
16475538|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
16475539|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
16475540|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
16475541|NCT03460938|Experimental|RIPC|
16475542|NCT03460938|No Intervention|Control|
16475543|NCT03460925|Experimental|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
16475544|NCT03460912||All participants|
16475545|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
16475546|NCT03460886|Experimental|Bihemispheric stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
16475547|NCT03460886|Experimental|Ipsilesional stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Sham on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
16475548|NCT03460886|Experimental|Contralesional stimulation|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
16475632|NCT03460249|Active Comparator|as above|as above
16475549|NCT03460886|Active Comparator|Sham|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Sham stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
16475550|NCT03460860|Experimental|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
16475551|NCT03460860|Placebo Comparator|Placebo|
16475552|NCT03460834||Obese asthmatic patients|Observational Cohort
16475553|NCT03460821||Employees|Male and female employees (≥ 18 years of age) of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin experienced in the field of neurocognitive testing: residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects
16475554|NCT03460808|Experimental|atorvastatin, acetylcysteine & danazol|atorvastatin 20mg qd po plus acetylcysteine 400mg tid po plus danazol 200mg bid po for 12 weeks
16475555|NCT03460795|Experimental|Conventional plus MSC and Tregs treatment|
16475556|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
16475557|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
16475558|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
16475559|NCT03460756|Experimental|Ganaxolone|Oral
16475560|NCT03460756|Placebo Comparator|Placebo|Oral
16475561|NCT03460743|Experimental|Study group|single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine
16475562|NCT03460743|Active Comparator|Control group|single or two doses of quadrivalent inactivated influenza vaccine.
16475563|NCT03460730|Experimental|Immunised children|Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)
16475564|NCT03460717|Experimental|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
16475565|NCT03460717|No Intervention|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
16475566|NCT03460704|Experimental|Drug: Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45% Other Name: Promixin
16475567|NCT03460704|Placebo Comparator|Drug: Saline Solution|1 ml saline solution 0.45%
16475568|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
16475569|NCT03460678|Other|Pemetrexed Arm|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
16475570|NCT03460678|Other|Erlotinib Arm|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)
16475571|NCT03460665|Experimental|Microparticles|arteriography and an injection of inert microparticles of 75 µm in neovessels
16475572|NCT03460665|Placebo Comparator|Placebo|knee arteriography and injection of saline solution in neovessels
16475573|NCT03460652|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:
~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
16475574|NCT03460639|Active Comparator|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
16475575|NCT03460639|Sham Comparator|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
16475576|NCT03460639|Other|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
16475577|NCT03460626|Placebo Comparator|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
16475578|NCT03460626|Experimental|Group-II (Treated group)|This group will be administered lavender oil.
16475579|NCT03460626|No Intervention|Group-III (Untreated group)|No intervention will be provided in this group.
16475580|NCT03460613|Other|FGID Patients|
16475581|NCT03460613|No Intervention|Hepatology Control Group|
16475582|NCT03460613|No Intervention|Healthy Volunteers|
16475583|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
16475584|NCT03460574|Experimental|INFORMATION|"Participants in this condition receive a manipulation suggesting that the performance test TEMINT, they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted."
16475585|NCT03460574|Experimental|SALIENCE|Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
16475586|NCT03460574|Experimental|ATTENTION|Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
16475587|NCT03460574|Experimental|CONTROL|Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
16475588|NCT03460561|Active Comparator|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
16475589|NCT03460561|Active Comparator|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
16475590|NCT03460548|Experimental|Remogen|
16475591|NCT03460548|Active Comparator|Cationorm|
16475592|NCT03460522|Experimental|Induction Therapy with Inotuzumab Ozogamicin|Patients will receive up to 3 cycles Inotuzumab with applications on day 1, 8 and 15 in each cycle. First dose will be 0.8 mg/m² on Day 1. All subsequent doses will be 0,5 mg/m².
16475593|NCT03460509|Placebo Comparator|Sugammadex 0 mg/kg|Placebo NaCl 0,9%
16475594|NCT03460509|Active Comparator|Sugammadex 0,25 mg/kg|Sugammadex 0.25 mg/kg IBW
16475595|NCT03460509|Active Comparator|Sugammadex 0,5 mg/kg|Sugammadex 0.50 mg/kg IBW
16475596|NCT03460509|Active Comparator|Sugammadex 1mg/kg|Sugammadex 1.0 mg/kg IBW
16475597|NCT03460509|Active Comparator|Sugammadex 2mg/kg|Sugammadex 2 mg/kg IBW
16475598|NCT03460496|Experimental|APN-led Intervention|"Intervention group being provided with the interventions described below.
~Advanced practice nurses' interventions
~Neonatologists: neonatal outpatient consultation
~psychological support
~lactation consultant
~physiotherapeutic interventions
~collaboration with social workers
~music therapy
~close collaboration with other health care professionals
~interprofessional roundtable meetings"
16475599|NCT03460496|No Intervention|Control, Standard Care|Control group receiving standard care
16475600|NCT03460483|Experimental|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
16475601|NCT03460470|Active Comparator|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
16475602|NCT03460470|Placebo Comparator|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
16475603|NCT03460457|Experimental|TQB2450|
16475604|NCT03460444|Experimental|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days while consuming a diet similar to the recommended health guidelines (40-50% carbohydrate; 30-40% fat; 20-25% protein).
16475605|NCT03460431|Experimental|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm one session every month for 4 months
16475606|NCT03460431|Experimental|Nd YAG laser 1064nm|Nd YAG laser 1064nm
16475607|NCT03460431|Experimental|combined two laser types|combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
16475608|NCT03460418||Multiloc nail|Fracture treated with a Multiloc nail (patients treated between 2012 and 2017)
16475609|NCT03460418||Philos plate|Fracture treated with a Philos plate (patients treated between 2012 and 2017)
16475610|NCT03460418||arthroplasty|Fracture treated by arthroplasty (patients treated between 2012 and 2017)
16475611|NCT03460405|Experimental|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
16475612|NCT03460405|Active Comparator|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
16475613|NCT03460405|Experimental|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
16475614|NCT03460405|Active Comparator|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
16475615|NCT03460405|Experimental|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
16475616|NCT03460405|Active Comparator|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
16475617|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
16475618|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
16475619|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
16475620|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
16475621|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
16475622|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
16475623|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
16475624|NCT03460340|Experimental|FM group|patients diagnosed with Fibromyalgia receiving dTMS treatment.
16475625|NCT03460340|Sham Comparator|placebo group|patients diagnosed with Fibromyalgia receiving sham- treatment.
16475626|NCT03460288|Experimental|Intervention Group|The training-program includes ten pictures related to slot-machine gambling and 10 neutral pictures that need to be either pushed (i.e., avoidance) or pulled (i.e., approach) with the computer mouse or finger (when a tablet is used) according to a non-affective dimension (color of the frame). Pictures are presented in random order.
16475627|NCT03460288|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive the retraining intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including pharmacological treatment. Participants in the wait-list control condition receive full access to the training program after completion of the post-assessment.
16475628|NCT03460275|Other|single group|Osimertinib Mesylate Tablets 80 mg, one time a day until disease progression
16475629|NCT03460262|Active Comparator|Standard dressing-Cutiplast®|
16475630|NCT03460262|Experimental|Negative pressure wound therapy-PICO®|
16475635|NCT03460184||G.A Group A|Group A: n= 30 Parturiant patients will receive general anesthesia. General anesthesia will be conducted After pre-oxygenation for 3-5 minutes. 5% thiopental (5 mg/kg) will be administered intravenously over 30s, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium as needed. After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by intravenous infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake, the anesthesia is adequately reversed, and the patient is following commands
16475636|NCT03460184||Spinal A Group B|"Group B: n= 30 Parturiant patients will receive spinal anesthesia. In the sitting position and after complete aseptic precaution are taken, 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, either via midline or paramedian approaches using 22 guage Quinke needle with the bevel directed laterally. 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl (0.5 ml) will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.
~The patient will be put flat in the supine position with left uterine displacement using wedge under the right loin and the surgeon will be allowed to sterilize and wrap the field after confirmation of the solidity of the block its level.
~All patiens will be observed for cardiac complications in the form of non-fatal MI, arrhythmias and sudden cardiac death until discharged after at least 72h."
16475637|NCT03460158|Experimental|Restylane-L®, Restylane-L® Lyft, and Restylane Silk®|Hyaluronic acid
16475638|NCT03460145|Experimental|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.
~VAS- Anxiety scores pre and post inhalation."
16475639|NCT03460145|Placebo Comparator|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
16475640|NCT03460132|Experimental|Extraction cases|patients receive Tomas orthodontic miniscrew implant as a mean of anchorage augmentation
16475641|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
16475642|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
16475643|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
16475644|NCT03460080||Hepatic hemangioma patients|
16475645|NCT03460067|Experimental|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
16475646|NCT03460067|No Intervention|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
16475647|NCT03460067|No Intervention|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
16475648|NCT03460054||IgA Nephropathy (IgAN)|Biopsy-Proven IgAN
16475649|NCT03460054||Focal Segmental Glomerulosclerosis (FSGS)|Biopsy-Proven FSGS
16475650|NCT03460054||Membranous Nephropathy (MGN)|Biopsy-Proven MGN
16475651|NCT03460054||Mesangioproliferative Glomerulonephritis (MPGN)|Biopsy-Proven MPGN
16475652|NCT03460054||Minimal Change Disease (MCD)|Biopsy-Proven MCD
16475653|NCT03460041|Placebo Comparator|Control|
16475654|NCT03460041|Active Comparator|Magnesium|
16475655|NCT03460041|Active Comparator|Dexmetedomedine|
16475656|NCT03460028|Experimental|Yoga Condition|Participants randomized to the Yoga Condition will participate in a specialized yoga intervention.
16475657|NCT03460028|No Intervention|Wait-List Control Condition|Participants randomized to the Wait-List Control Condition will participate in a specialized yoga intervention once the Yoga Condition has completed their assigned intervention.
16475658|NCT03460015|Experimental|Sevoflurane group|
16475659|NCT03460015|Active Comparator|Propofol group|
16475660|NCT03460002|Experimental|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
16475661|NCT03460002|Experimental|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
16475662|NCT03460002|No Intervention|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
16475663|NCT03460002|No Intervention|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
16475664|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
16475665|NCT03459976||2 groups|control group case group
16475666|NCT03459963|Experimental|group C|indwelling urinary catheter
16475667|NCT03459963|No Intervention|group N|Non cathetrized patients
16475668|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
16475669|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
16475670|NCT03459937|Experimental|Hatha Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Hatha Yoga.
16475671|NCT03459937|Experimental|Vinyasa Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Vinyasa Yoga.
16475672|NCT03459911|Experimental|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
16475673|NCT03459911|Active Comparator|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
16475674|NCT03459898|Other|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
16475675|NCT03459898|Other|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
16475676|NCT03459885|Experimental|PAS|The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
16475677|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
16475678|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
16475679|NCT03459859|Experimental|Pevonedistat 10 LDAC 20|Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
16475680|NCT03459859|Experimental|Pevonedistat 15 LDAC 20|Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
16475681|NCT03459859|Experimental|Pevonedistat 20 LDAC 20|Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
16475682|NCT03459859|Experimental|Pevonedistat 25 LDAC 20|Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
16475683|NCT03459846|Experimental|Arm 1: Durvalumab/Placebo|Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1.
16475684|NCT03459846|Experimental|Arm 2: Durvalumab/Olaparib|Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
16475685|NCT03459833|Experimental|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
16475686|NCT03459833|Placebo Comparator|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
16475687|NCT03459820|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
16475688|NCT03459807|Experimental|Home systolic blood pressure (SBP) <140 mmHg|"Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.
~Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.
~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
16475689|NCT03459807|Active Comparator|Pre-dialysis SBP <140 mmHg|"Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.
~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
16475690|NCT03459794|Active Comparator|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
16475691|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
16475692|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
16475693|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
16475694|NCT03459755|Experimental|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
16475695|NCT03459755|No Intervention|Usual care|Patients will complete questionnaires and have research blood drawn.
16475696|NCT03459742|Experimental|Intervention|Gamification strategy. In 2018, the intervention group are 15 schools from Municipality of Santiago. In 2019, the intervention will cover all eligible schools in the Municipality of Santiago.
16475697|NCT03459742|No Intervention|Control|In 2018, the control group will be 5 randomly selected schools from Municipality of Santiago and 4 schools from Municipality of Estación Central. In 2019, the control group will be 4000 participants chosen from neighboring municipalities
16475698|NCT03459729|Experimental|Antitumor B|ATB will be administered on an outpatient basis.
16475699|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
16475700|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
16475701|NCT03459703|Experimental|Early Time-Restricted Feeding|
16475702|NCT03459703|Active Comparator|Control Schedule|
16475703|NCT03459690|Experimental|Experienced meditators|Meditation ≥ 30 min per day for at least 5 days per week over the past 1 year
16476182|NCT03456232|Active Comparator|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
16475704|NCT03459690|Experimental|Novice meditators|No meditation practice in the previous year and < 20 entire lifetime hours
16475705|NCT03459677|Experimental|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.
~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
16475706|NCT03459677|Active Comparator|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.
~The TAU condition will last for 4 months."
16475707|NCT03459664|Experimental|RECOVER|The intervention in the RECOVER stepped-care model includes specific evidence-based treatment options for severity grade 1 to 4.
16475708|NCT03459664|Active Comparator|Treatment As Usual|The active comparator is treatment as usual (TAU) and provides all common care options within the German health care system, depending on the severity grade 1 to 4.
16475709|NCT03459651|Experimental|ANS training|
16475710|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
16475711|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
16475712|NCT03459625|Experimental|Mindfulness-Based Stress Reduction (MSBR)|MSBR (Kabat-Zinn, 1990), 8-week group-based intervention where participants learn mindfulness skills to help alleviate parenting stress among parents of young children with Autism Spectrum Disorder.
16475713|NCT03459625|Active Comparator|Psychoeducational Support Group (PE)|PE is a 8-week group-based intervention to provide psychosocial support and resources for parents of young children with Autism Spectrum Disorder.
16475714|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
16475715|NCT03459612|Experimental|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
16475716|NCT03459612|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
16475717|NCT03459612|Active Comparator|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
16475718|NCT03459599|Active Comparator|Prophylaxis|Current protocol of administering antibiotics maintained
16475719|NCT03459599|Active Comparator|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
16475720|NCT03459586|Experimental|9zest app facilitated exercise|App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
16475721|NCT03459573|Active Comparator|T2D: One Drop with Fitbit Ionic|
16475722|NCT03459573|Active Comparator|T2D: One Drop without Fitbit Ionic|
16475723|NCT03459573|No Intervention|T2D: Waitlist Control|
16475724|NCT03459573|Active Comparator|T1D: One Drop with Fitbit Ionic|
16475725|NCT03459573|Active Comparator|T1D: One Drop without Fitbit Ionic|
16475726|NCT03459573|Active Comparator|PD: One Drop with Fitbit Charge 2|
16475727|NCT03459573|Active Comparator|PD: One Drop without Fitbit Charge 2|
16475728|NCT03459560|Experimental|PolyPill|Single daily dose of PolyPill and minimal care.
16475729|NCT03459560|No Intervention|Control|Only minimal care
16475730|NCT03459547|Experimental|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
16475731|NCT03459547|Active Comparator|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
16475732|NCT03459547|Active Comparator|dental implant + zirconia (control)|dental implant insertion, material zirconia
16475733|NCT03459547|Active Comparator|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
16475734|NCT03459534|Experimental|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.
~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
16475735|NCT03459521|Experimental|Fendrix HBV vaccine|Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 0.5 ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline, 1, 2 and 6 months.
16475736|NCT03459508||Primary antiphospholipid syndrome women|"Informed consent
~Detailed history emphasizing on
~a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis
~Revision of diagnosis of primary antiphospholipid syndrome:
~Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies.
~Ophthalmological examination:"
16475737|NCT03459495|Active Comparator|Group A|Group A: ultrasound group
16475738|NCT03459495|Placebo Comparator|Group P|Group P: placebo ultrasound group
16475739|NCT03459482|Experimental|Group 1 - True Food Elimination Diet|Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
16475740|NCT03459482|Sham Comparator|Group 2 - Sham Food Elimination Diet|"Group 2 (control group): Subjects will be given a Sham elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates."
16475741|NCT03459469|Experimental|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
16475860|NCT03458611|Experimental|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
16475742|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:
~Provocation OC task (Provoc)
~Trier Social Stress Test (TSST)
~Exposure provocation task"
16475743|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:
~Provocation OC task (Provoc)
~Trier Social Stress Test (TSST)
~Exposure provocation task"
16475744|NCT03459430|Experimental|Low Intensity training group|Low Intensity training group will complete a 6 week core stability training program with low intensity/oscillation exercises
16475745|NCT03459430|Experimental|High Intensity training group|High Intensity training group will complete a 6 week core stability training program with high intensity/oscillation exercises
16475746|NCT03459430|No Intervention|Control group|Control group will have 6 weeks with no intervention before post-test
16475747|NCT03459417|Active Comparator|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
16475748|NCT03459417|Active Comparator|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
16475749|NCT03459417|Active Comparator|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
16475750|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg
~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
16475751|NCT03459391|Experimental|XC221 60 mg|Cohort 1:16 subjects were randomized in a 3:1 ratio to be treated either with 60 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
16475752|NCT03459391|Experimental|XC221 200 mg|Cohort 2: 16 subjects were randomized in a 3:1 ratio to be treated either with 200 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
16475753|NCT03459391|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (4 subjects from each cohort).
16475754|NCT03459365|Experimental|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
16475755|NCT03459352|Experimental|ePRO|There is no therapeutic intervention. Patients will use ePRO system to report systems. We will describe use in patients to determine compliance in reporting symptoms.
16475756|NCT03459339|Experimental|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
16475757|NCT03459326||control group|men in relation
16475758|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
16475759|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
16475760|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
16475761|NCT03459313|Experimental|Active group|The active group will be provided the intervention program, i.e. access to a website.
16475762|NCT03459313|No Intervention|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
16475763|NCT03459287|Experimental|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
16475764|NCT03459287|Active Comparator|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
16475765|NCT03459274||VR-Biofeedback Feedback Sharers|These participants would express either interest or a lack of interest in trying biofeedback/virtual reality therapy. They will be instructed on how to use the virtual reality equipment and program. Then, they will have the option to participate in the biofeedback/virtual reality experience, if they choose to do so, before sharing their feedback.
16475766|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
16475767|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
16475768|NCT03459248|Experimental|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
16475769|NCT03459248|Active Comparator|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
16475770|NCT03459235|Experimental|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
16475771|NCT03459222|Experimental|Arm A|Relatlimab + Nivolumab + BMS-986205
16475772|NCT03459222|Experimental|Arm B|Relatlimab + Nivolumab + Ipilimumab
16475773|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
16475774|NCT03459183|Experimental|Infrasound - verum|In this condition, participants are exposed with non-audible infrasound from the Infrasound (85dB; 6Hz) source, for 8 constant hours during their night sleep. The source is placed close to the participant's bed (approximately 1-2 meters).
16475775|NCT03459183|Placebo Comparator|Infrasound - placebo|In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
16475776|NCT03459183|Experimental|Ultrasound - verum|In this condition, participants are exposed to non-audible ultrasound, emitted by the Ultrasound (10dB below hearing threshold; 22.4 kHz) source for 8 constant hours during their night sleep. The source is placed close to the participant's bed (1-2 meters), at the level of the participant's head (for instance on a nightstand).
16475777|NCT03459183|Placebo Comparator|Ultrasound - placebo|In this condition, participants are not exposed to any sound. The Ultrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Ultrasound dummy source looks exactly like the active ultrasound source, but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
16475778|NCT03459170|Experimental|BPX-501 T cells and rimiducid|"All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).
~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
16475779|NCT03459157|Other|HIV prevention package including PrEP|
16475780|NCT03459144|Experimental|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
16475781|NCT03459144|Experimental|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
16475782|NCT03459144|Experimental|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
16475783|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
16475784|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
16475785|NCT03459118|Experimental|Function Focused Care|FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the champion and stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
16475786|NCT03459118|Placebo Comparator|Education Only|Education only sites are exposed to Step II of the Four step approach described under the treatment arm. They receive baseline education of staff.
16475787|NCT03459105|Experimental|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
16475788|NCT03459105|Active Comparator|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
16475789|NCT03459092|Experimental|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
16475790|NCT03459092|Active Comparator|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
16475791|NCT03459079|Active Comparator|lanifibranor arm|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
16475792|NCT03459079|Placebo Comparator|Placebo|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
16475793|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
16475794|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
16475795|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
16475796|NCT03459053|Experimental|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
16475797|NCT03459053|No Intervention|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
16475798|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
16475799|NCT03459027|Active Comparator|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
16475800|NCT03459027|Placebo Comparator|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
16475801|NCT03459014|Experimental|Stimulus rich VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
16475802|NCT03459014|Active Comparator|Stimulus poor VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
16477502|NCT03447080|Experimental|Rice bran soybean milk|White Bread with 195ml of rice bran soybean mil
16475803|NCT03459001||Tube Fed Malnourished Outpatients|Outpatients that are malnourished or at risk of malnutrition and have been placed on a nutritional care plan, which includes a complete tube feeding formula as sole source nutrition
16475804|NCT03458988|Other|All patients|Nellcor™ Adult SpO2 Sensor
16475805|NCT03458975|Active Comparator|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
16475806|NCT03458975|Placebo Comparator|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
16475807|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
16475808|NCT03458923|Active Comparator|Group A|15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.
16475809|NCT03458923|Active Comparator|Group B|15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.
16475810|NCT03458910|Experimental|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
16475811|NCT03458910|Experimental|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
16475812|NCT03458897|Experimental|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
16475813|NCT03458884|Experimental|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
16475814|NCT03458884|No Intervention|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
16475816|NCT03458858|Other|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
16475817|NCT03458858|Other|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
16475818|NCT03458858|Other|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
16475819|NCT03458858|Other|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
16475820|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
16475821|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
16475822|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
16475823|NCT03458819||Control|Patients on neither active Vitamin D or a statin
16475824|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
16475825|NCT03458819||Statin|Patients on a statin but not active Vitamin D
16475826|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
16475827|NCT03458806||Control|Subjects with echocardiographically confirmed valvular disease of less than moderate-to-severe grading with regards to aortic stenosis (AS) and mitral regurgitation (MR). Note that within this cohort will be a sub cohort consisting of subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
16475828|NCT03458806||AS Case|Subjects with echocardiographically confirmed aortic stenosis (AS) of moderate-to-severe or greater grading.
16475829|NCT03458806||MR Case|Subjects with echocardiographically confirmed mitral regurgitation (MR) of moderate-to-severe or greater grading.
16475830|NCT03458806||Control Subgroup|Subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
16475831|NCT03458793|Experimental|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
16475832|NCT03458793|No Intervention|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
16475833|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
16475834|NCT03458767|Experimental|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
16475835|NCT03458767|No Intervention|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
16476132|NCT03456648|Experimental|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
16475836|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
16475837|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
16475843|NCT03458715|Experimental|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
16475844|NCT03458715|Active Comparator|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
16475845|NCT03458702|Experimental|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
16475846|NCT03458702|Experimental|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
16475847|NCT03458689|Other|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
16475848|NCT03458689|Active Comparator|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
16475849|NCT03458689|Active Comparator|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
16475850|NCT03458676|Experimental|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.
~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
16475851|NCT03458663|Experimental|Prevena|Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
16475852|NCT03458663|No Intervention|Conentional postoperative care|patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.
16475853|NCT03458650|Experimental|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
16475854|NCT03458650|Experimental|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
16475855|NCT03458650|Experimental|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
16475856|NCT03458637|Experimental|LITE Program with usual care.|LITE Program with usual care. LITE program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. The key aspects covered in the LITE program are in keeping with Health Promotion Board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. The parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes.
16475857|NCT03458637|Active Comparator|Usual Care|Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
16475858|NCT03458624||Not applicable-observational study|Not applicable-observational study
16475859|NCT03458611|Experimental|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
16475861|NCT03458598|Experimental|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
16475862|NCT03458598|Sham Comparator|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
16475863|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
16475864|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
16475865|NCT03458572|Experimental|Intervention|1.5mm Seirin Pyonex needle at LI11 point
16475866|NCT03458572|Sham Comparator|Control|0.3mm Seirin Pyonex needle at TB10 point
16475867|NCT03458559|Active Comparator|Radium-223-chloride|Radium-223-chloride 50kBg/kg, every 4 weeks intravenously, for a total of 6 administrations.
16475868|NCT03458559|Experimental|Rhenium-188-HEDP|Rhenium-188-HEDP 40MBq/kg, every 8 weeks intravenously, for a total of 3 administrations.
16475869|NCT03458546|Experimental|Roflumilast and R-CHOP|
16475870|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
16475871|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
16475872|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
16475873|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
16475874|NCT03458507|Active Comparator|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.
~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
16475875|NCT03458507|Active Comparator|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.
~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
16475876|NCT03458494|Experimental|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
16475877|NCT03458494|Experimental|Low-fat diet|during one week participants will receive food products low in fat content
16475878|NCT03458481|Experimental|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
16475879|NCT03458481|Experimental|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
16475880|NCT03458468|Experimental|Group A|Tranexamic Acid 1g IV
16475881|NCT03458468|Placebo Comparator|Group B|Saline injection
16475882|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
16475883|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
16475884|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
16475885|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
16475886|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
16475887|NCT03458442|Experimental|Intervention Arm|Standard surgical training + simulation-based surgical training
16475888|NCT03458442|Active Comparator|Control Arm|Standard surgical training
16475889|NCT03458429|Experimental|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
16475890|NCT03458416|Experimental|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
16475891|NCT03458403|Experimental|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
16475892|NCT03458390|Experimental|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
16475893|NCT03458377|Experimental|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
16475894|NCT03458377|No Intervention|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
16475895|NCT03458364|Experimental|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
16475896|NCT03458364|Active Comparator|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
16475897|NCT03458351|Active Comparator|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction
~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
16475898|NCT03458351|Sham Comparator|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
16475929|NCT03458117|Experimental|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
16475899|NCT03458325|Experimental|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
16475900|NCT03458325|No Intervention|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
16475901|NCT03458312|No Intervention|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.
~Test time points:
~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
16475902|NCT03458312|Experimental|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
16475903|NCT03458299|Experimental|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
16475904|NCT03458299|Experimental|Psychoeducation|The Psychoeducation session will consist of therapist assisted viewing and discussion of four educational DVDs about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
16475905|NCT03458286|No Intervention|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
16475906|NCT03458286|Experimental|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
16475907|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
16475908|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.
~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
16475909|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.
~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
16475910|NCT03458260|Experimental|Experimental|Pixantrone plus rituximab, ifosfamide and etoposide.
16475911|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
16475912|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
16475913|NCT03458234|Experimental|Focal SBRT with intra-urethral radiotransponder|This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
16475914|NCT03458221|Experimental|itraconazole / tamoxifen|In case of HedgeHog pathway positivity itraconazole will be administered in case of ER pathway positivity tamoxifen will be adminisered
16475915|NCT03458208|Experimental|Metformin|"First aIntervention Period:
~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition
~Third Intervention Period:
~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
16475916|NCT03458208|Active Comparator|Glucophage®|"Second Intervention Period:
~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition
~Fourth Intervention Period:
~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
16475917|NCT03458195|Experimental|Crohn's disease patients|Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.
16475918|NCT03458182|Experimental|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
16475919|NCT03458182|No Intervention|No intervention|No added exercise period (normal exercise test).
16475920|NCT03458169|Experimental|LEAP usability|"Therapist LEAP session feedback
~Participant LEAP session feedback
~LEAP risk control validation"
16475921|NCT03458156|Experimental|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
16475922|NCT03458156|Experimental|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
16475923|NCT03458156|Experimental|the control group|The patients will be assigned to the control group.
16475924|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
16475925|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
16475926|NCT03458130|Active Comparator|AG10 Low Dose|Low dose group
16475927|NCT03458130|Active Comparator|AG10 High Dose|High dose group
16475928|NCT03458130|Placebo Comparator|Placebo|
16475930|NCT03458104|Experimental|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
16475931|NCT03458104|Active Comparator|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
16475932|NCT03458091|Active Comparator|Intubation|The patients will be intubated and ventilated
16475933|NCT03458091|Experimental|THRIVE|The patients will be oxygenated during apnea using THRIVE
16475934|NCT03458078|Placebo Comparator|Group C|Control group
16475935|NCT03458078|Active Comparator|Group Mg|Magnesium sulfate group
16475936|NCT03458078|Active Comparator|Group MDZ|Midazolam group
16475937|NCT03458065||S-ICD|
16475938|NCT03458065||T-ICD|
16475939|NCT03458039|Experimental|In-person CETA|This is the in-person delivery method of the Common Elements Treatment Approach (CETA).
16475940|NCT03458039|Experimental|Telephone CETA (T-CETA)|This is the technology-based delivery method for the Common Elements Treatment Approach (CETA).
16475941|NCT03458039|Active Comparator|Treatment As Usual|This is the treatment as usual control condition who will engage with their usual care in the community and will receive CETA, if desired, following completion of the study.
16475942|NCT03458026|Experimental|connected object + SMS of physical activity reminders|"The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises.
~At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks.
~At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.
~In 36 week, they return the watch and finish the study."
16475943|NCT03458026|Other|Without connected object|"The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks.
~At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.
~In 36 week, the study will be finished."
16475944|NCT03458013|Experimental|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
16475945|NCT03458013|No Intervention|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
16475946|NCT03458000|Active Comparator|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
16475947|NCT03458000|Experimental|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
16475948|NCT03457974|Experimental|congenital heart disease|42 patients
16475949|NCT03457974|Other|helathy children|42 children
16475950|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
16475951|NCT03457948|Experimental|Group I [pembrolizumab, 177Lu DOTATATE]|Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index > 20% (well-differentiated grade 3) and any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor < 75%. Patients who achieve progressive or stable disease response after cycle 4 may receive an additional 4 cycles of pembrolizumab and lutetium Lu-177 DOTATATE in the absence of disease progression or unacceptable toxicity.
16475952|NCT03457948|Experimental|Group II [pembrolizumab, TAE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
16475953|NCT03457948|Experimental|Group III [pembrolizumab, yttrium-90 microsphere RE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
16475954|NCT03457935||Control|No lung diseases
16475955|NCT03457935||Non-IPF ILD|non-IPF ILD diagnosis
16475956|NCT03457935||IPF|Naive patients with no IPF treatment
16475957|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
16475958|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
16475959|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.
~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:
~• Neratinib daily + Trastuzumab weekly until disease progression"
16475960|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:
~• Neratinib daily + Cetuximab weekly until disease progression"
16475961|NCT03457883|Experimental|group A|accepted herniamesh mesh
16475962|NCT03457883|Experimental|group B|accepted biological graft of cook
16475963|NCT03457870|Experimental|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
16475965|NCT03457870|Experimental|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
16475966|NCT03457870|No Intervention|Control|No intervention: Control
16475967|NCT03457857|Other|Group 1 - Cleanser|Regimen with Baby Cleanser Only
16475968|NCT03457857|Other|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
16475969|NCT03457844|Experimental|Anlotinib|
16475970|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
16475971|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
16475972|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
16475973|NCT03457805|Other|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
16475974|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
16475975|NCT03457779|Experimental|Non Glucose Arm|4 patients without glucose infusion
16475976|NCT03457779|Experimental|Glucose Arm|12 Patients with glucose infusion
16475977|NCT03457766|Experimental|Patients with skin lesions|Using HIFU in identification of safety margins of lesions clinically apparent locally malignant, or malignant
16475978|NCT03457753|Experimental|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
16475979|NCT03457740|Experimental|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
16475980|NCT03457740|Experimental|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
16475981|NCT03457740|Placebo Comparator|Placebo|Placebo, 4 capsules daily, 6 weeks
16475982|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
16475983|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
16475984|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
16475985|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
16475986|NCT03457701|Experimental|rhEPO+57Fe followed by Daprodustat+58Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
16475987|NCT03457701|Experimental|rhEPO+58Fe followed by Daprodustat+57Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
16475988|NCT03457701|Experimental|Daprodustat+57Fe followed by rhEPO+58Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
16475989|NCT03457701|Experimental|Daprodustat+58Fe followed by rhEPO+57Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
16475990|NCT03457688|Active Comparator|prebiotic inulin-type fructans|
16475991|NCT03457688|Placebo Comparator|placebo maltodextrin|
16475992|NCT03457675|Experimental|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
16475993|NCT03457675|Experimental|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
16477503|NCT03447080|Experimental|Soybean milk|White Bread with 195ml of soybean milk
16475994|NCT03457662|Active Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
16475995|NCT03457662|Experimental|OMC and SDT|OMC and SDT are administrated in this arm.
16475996|NCT03457649|Active Comparator|ARGX-113|SAD and MAD with test product at different increasing doses
16475997|NCT03457649|Placebo Comparator|Placebo|SAD and MAD with placebo at different increasing doses
16475998|NCT03457636|Experimental|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
16475999|NCT03457623|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
16476000|NCT03457623|No Intervention|conventional supported|Patients benefit from usual care
16476001|NCT03457610|Experimental|Speech and language intervention|
16476002|NCT03457597|Experimental|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
16476003|NCT03457597|Experimental|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
16476004|NCT03457597|Experimental|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
16476005|NCT03457584|Active Comparator|BSS arm|BSS is given at the end of surgery
16476006|NCT03457584|Experimental|air arm|air-tamponade is given at the end of surgery
16476007|NCT03457545|Experimental|Intervention|Eligible participants will take part in the home-based pulmonary rehabilitation using the Aidcube platform in-person assessment and training with a research coordinator (i.e. physical exercise capacity assessment, SPPB, disability survey, exercise prescription determination, exercise training, dyspnea control techniques) and complete an follow-up assessment at the 8th week.
16476008|NCT03457545|No Intervention|No Intervention|Ineligible participants will receive standard of care
16476009|NCT03457532|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
16476010|NCT03457519|Active Comparator|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.
~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
16476011|NCT03457519|Active Comparator|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.
~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
16476012|NCT03457519|No Intervention|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
16476013|NCT03457506|Other|Patients undergo a digital PET/CT|Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner.
16476014|NCT03457493|Experimental|Healthy Controls, DPA-714-PET/MRI|
16476015|NCT03457493|Experimental|Early Parkinson's Disease, DPA-714-PET/MRI|
16476016|NCT03457480|Experimental|Prevention (text messages, computer messages)|"PHASE I: Participants attend focus group over 2 hours.
~PHASE II: Participants receive 2 text messages per day for 30 days at baseline and after 3 months.
~PHASE III: Participants read 64 computer messages with or without images over 30 minutes and have their facial expressions assessed."
16476017|NCT03457467|Experimental|SBRT+apatinib group|Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.
16476018|NCT03457454||Primary Care Provider/Staff Participants Interviews|"Up to two primary care providers and at least one staff person at each of the 16 clinics, with approximately 5 interviewees per clinic. Eligible providers and staff include physicians, nurse practitioners, nurses, case managers, medical assistants, administrative staff, or other employees of the clinic involved in the cancer screening and follow-up process.
~If the participant verbally consents, the research team member will conduct an interview with the provider to learn about the current processes used to support and monitor colorectal cancer screening (CRC) from screening initiation through follow-up; assess capacity and interest in implementing Evidence Based Practices for supporting and monitoring CRC screening, including any ideas interviewees have or find appealing; and engage the organizations as partners to build interest, capacity, and infrastructure for future intervention trial and other future studies."
16476019|NCT03457454||Patient Participants Interviews|"10 patients across 5 clinics will be recruited for interviews, which will address the patient experience with screening and follow-up.
~If the participant verbally consents, the research team member will conduct an interview with the patient participant to gain a deeper understanding of the CRC screening process from the patient's perspective; the gaps, challenges, or road blocks/speed bumps to completing CRC screening steps; and what organizations can do better or differently to help people complete the CRC screening process."
16476020|NCT03457454||Patient Participants Anonymous Survey|-Patient participants will be recruited to take an anonymous mailed survey, which will address patient level barriers to screening and follow-up focusing on out of pocket costs.
16476049|NCT03457246|Placebo Comparator|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
16476050|NCT03457233|Active Comparator|Normal weight|18.5- 24.9 kg/m2
16476021|NCT03457454||Colonoscopy Provider/Staff Participants Interviews|"Colonoscopy providers and a staff or mid-level provider in each office will be recruited for interviews.
~If the participant consents, the research team member will conduct an interview to learn about current processes used to support and monitor colorectal cancer screening from the perspective of gastroenterology/colonoscopy sites and to learn about how gastroenterology/colonoscopy sites communicate and coordinate care with other healthcare organizations and patients to support and monitor colorectal cancer screening."
16476022|NCT03457441|Other|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
16476023|NCT03457441|Other|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
16476024|NCT03457441|Other|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
16476025|NCT03457415||Healthy Cohort|Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
16476026|NCT03457415||High-risk Cohort|High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
16476027|NCT03457415||Cancer Cohort|Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
16476028|NCT03457402|Experimental|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
16476029|NCT03457402|Active Comparator|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
16476030|NCT03457389|Experimental|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
16476031|NCT03457389|Active Comparator|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
16476032|NCT03457363|Experimental|Double Trunk Mask|DTM will be add above nasal cannula
16476033|NCT03457363|Active Comparator|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
16476034|NCT03457350|Experimental|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
16476035|NCT03457350|Experimental|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
16476036|NCT03457337|Experimental|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA <1.25 m2, 80 mg / day; BSA 1.25 m2 to <1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.
~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
16476037|NCT03457337|Active Comparator|Gefitinib|Gefitinib 250 mg/day oral daily
16476038|NCT03457324|Experimental|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
16476039|NCT03457324|Placebo Comparator|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
16476040|NCT03457311|Other|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
16476041|NCT03457298|Experimental|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
16476042|NCT03457298|Active Comparator|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
16476043|NCT03457285|Experimental|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.
~This will continue for the 6-month duration of the intervention."
16476044|NCT03457272|Experimental|New risk assessment|New risk assesment
16476045|NCT03457272|No Intervention|Standard|Standard risk assessment
16476046|NCT03457259|Active Comparator|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
16476047|NCT03457259|Active Comparator|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
16476048|NCT03457246|Experimental|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
16476053|NCT03457207|Experimental|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
16476054|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.
~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.
~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.
~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
16476055|NCT03457181|Active Comparator|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
16476056|NCT03457181|Active Comparator|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
16476057|NCT03457168|Active Comparator|Intensive asleep SBP control|To reduce the asleep SBP mean up to a target <110 mmHg. Treatment of elevated asleep SBP mean
16476058|NCT03457168|Active Comparator|Conventional asleep SBP control|To reduce the asleep SBP mean up to a target <120 mmHg. Treatment of elevated asleep SBP mean
16476059|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16476060|NCT03457129|Active Comparator|Fycompa 2 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
16476061|NCT03457129|Experimental|Fycompa 3 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
16476062|NCT03457116|Active Comparator|Test Arm|400mg of Ibuprofen or
16476063|NCT03457116|Active Comparator|Control Arm|Norco( hydrocodone 5mg- acetaminophen 325mg)
16476064|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
16476065|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
16476066|NCT03457090|Experimental|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
16476067|NCT03457077|Experimental|Brief Intervention|Participants will receive a brief intervention at week 0
16476068|NCT03457077|Other|Delayed Intervention|Participants will receive a brief intervention at 6 months
16476069|NCT03457064|No Intervention|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
16476070|NCT03457064|Active Comparator|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
16476071|NCT03457051|Active Comparator|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
16476072|NCT03457051|Experimental|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
16476073|NCT03457038|Experimental|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
16476074|NCT03457025|Active Comparator|Standard of Care Therapy|Reference Therapy
16476075|NCT03457025|Experimental|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
16476076|NCT03457012||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
16476077|NCT03456999|Active Comparator|MAU868|BKV-specific, pan-serotype neutralizing antibody
16476078|NCT03456999|Placebo Comparator|Placebo|Matching placebo
16476079|NCT03456986|Experimental|PATH neurotraining (treatment)|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
16476133|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
16476134|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
16476135|NCT03456609|Experimental|shenqifuzheng|
16476080|NCT03456986|Active Comparator|Orientation Discrimination (control)|Subject looks at computer screen to determine whether bars in center circular window are tilted left or right relative to vertically oriented background bars. The subject reports which way center pattern is tilted by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes orientation of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern colored or black and white, and by increasing pattern's complexity level. This Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
16476081|NCT03456973|Experimental|Nurse AMIE|
16476082|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
16476083|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
16476084|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
16476085|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
16476086|NCT03456960|Experimental|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
16476087|NCT03456960|Experimental|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
16476088|NCT03456947|No Intervention|control group|the patients receive routine preoperative preparation without having Pregabalin
16476089|NCT03456947|Experimental|Pregabalin150mg group|the patients receive 150mg pregabalin 60 minutes prior to the surgery
16476090|NCT03456947|Experimental|Pregabalin300mg group|the patients receive 300mg pregabalin 60 minutes prior to the surgery
16476091|NCT03456934|Experimental|Experimental Group|Modified infant formula given from 3 to 12 months of age, as per standard requirement.
16476092|NCT03456934|Active Comparator|Control Group|Standard infant formula given from 3 to 12 months of age, as per standard requirement.
16476093|NCT03456934|No Intervention|Breast-fed Reference Group|Non-randomized infants who are predominantly breast-fed at time of enrollment.
16476094|NCT03456921|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
16476095|NCT03456908|Experimental|myeloma before MV-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
16476096|NCT03456908|Experimental|endometrial cancer before VSV-hINF-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
16476097|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:
~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)
~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
16476098|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
16476099|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
16476100|NCT03456882|Active Comparator|RNS60|RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
16476136|NCT03456609|Placebo Comparator|0.9%sodium chloride|
16476137|NCT03456596||Institution|Community cancer centers implementing ENABLE
16476183|NCT03456219|Experimental|Shift workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the normal protein diet.
16476184|NCT03456219|Experimental|Night workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the high-protein diet.
16476101|NCT03456882|Placebo Comparator|NORMAL SALINE|"Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months.
~RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site)."
16476102|NCT03456869|Experimental|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
16476104|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
16476105|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
16476106|NCT03456830|Experimental|ALLN-177|ALLN-177 3,750 units per capsule
16476107|NCT03456830|Placebo Comparator|Placebo|Placebo capsule
16476110|NCT03456804|Experimental|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
16476111|NCT03456791||endometrial carcinoma( cases)|42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
16476112|NCT03456791||benign diseases(control)|42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
16476114|NCT03456752|Experimental|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
16476115|NCT03456752|Placebo Comparator|Control|Normal Saline 1.6ml intravenously prior to anesthesia induction
16476116|NCT03456739||suppurative otitis media with effusion|
16476117|NCT03456739||non suppurative otitis media with effusion|
16476118|NCT03456726|Experimental|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
16476119|NCT03456726|Experimental|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
16476120|NCT03456713|Experimental|LY3074828 Formulation A|LY3074828 solution formulation in two prefilled syringes, administered as subcutaneous (SC) injection
16476121|NCT03456713|Experimental|LY3074828 Formulation B|LY3074828 solution formulation in a prefilled syringe, administered as a SC injection
16476122|NCT03456713|Experimental|LY3074828 Formulation C|LY3074828 solution formulation in an auto-injector
16476123|NCT03456713|Experimental|LY3074828 Formulation D|LY3074828 solution formulation in an auto-injector
16476124|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16476125|NCT03456687|Experimental|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
16476126|NCT03456674|Experimental|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
16476127|NCT03456661|Active Comparator|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
16476128|NCT03456661|Active Comparator|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
16476129|NCT03456648|Experimental|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
16476130|NCT03456648|Experimental|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
16476131|NCT03456648|Experimental|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
16476138|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
16476139|NCT03456570|Active Comparator|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
16476140|NCT03456570|Placebo Comparator|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
16476141|NCT03456557|Experimental|Computed tomography.|
16476142|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
16476143|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
16476144|NCT03456531|Active Comparator|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
16476145|NCT03456531|Placebo Comparator|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
16476146|NCT03456505|Experimental|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
16476147|NCT03456505|Active Comparator|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
16476148|NCT03456492||case|Hyponatremic elderly patients (>70 years) with hip fractures
16476149|NCT03456492||control|Normonatremic elderly patients(>70 years) undergoing joint replacement
16476150|NCT03456466|Experimental|TQB2303|
16476151|NCT03456466|Active Comparator|Rituximab|
16476152|NCT03456453|Experimental|NIDA Standard via Facebook|30 participants will receive the NIDA Standard via Facebook
16476153|NCT03456453|No Intervention|Re-entry services as usual|30 participants will receive re-entry services as usual
16476154|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
16476155|NCT03456440||normal individuals|controls cases are examined with MRI
16476156|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
16476157|NCT03456414|Experimental|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
16476158|NCT03456414|No Intervention|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
16476159|NCT03456401|Other|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
16476160|NCT03456388|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
16476161|NCT03456388|Active Comparator|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
16476162|NCT03456362|Active Comparator|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
16476163|NCT03456362|Sham Comparator|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
16476164|NCT03456349|Experimental|Low dose|HTL0018318
16476165|NCT03456349|Experimental|Medium dose|HTL0018318
16476166|NCT03456349|Experimental|High dose|HTL0018318
16476167|NCT03456349|Placebo Comparator|Placebo|Placebo
16476168|NCT03456336|Active Comparator|Active Treatment Group|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other.
16476169|NCT03456336|Active Comparator|Expectant Management Group|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
16476170|NCT03456323|Experimental|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
16476171|NCT03456323|Placebo Comparator|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
16476172|NCT03456310|Experimental|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
16476173|NCT03456297|Experimental|Experimental cluster|The Web-based clinical pedagogy program (WCP) will be provided to the participants in the experimental cluster.
16476174|NCT03456297|No Intervention|Control cluster|The participants in the control cluster will receive the current face-to-face preceptorship course.
16476175|NCT03456284|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device
16476176|NCT03456271||fracture group|
16476177|NCT03456271||non-fracture group|
16476178|NCT03456258|Experimental|Lactoferrin|To measure hemoglobin difference and serum ferritin
16476179|NCT03456258|Experimental|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
16476180|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
16476181|NCT03456232|Experimental|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
16476185|NCT03456206||"Diet, Cancer and Health cohort"|"Participants from the Diet, Cancer and Health (DCH) cohort with no CID diagnosis at entry to the DCH study. The number of persons developing a CID (defined as at least one of the mentioned CIDs) during follow up (1993/1997 - 2018) and the number of persons not developing a CID will be investigated.
~Based on the participants reporting of dietary habits in the Food Frequency Questionnaire (FFQ) from the DCH study, the exposure intake of red and processed meat and fibres will be investigated in both CID cases and non-cases.
~Other exposure variables are Lifestyle factors independently or combined and are also obtained from the data in the DCH cohort."
16476186|NCT03456193|Experimental|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
16476187|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
16476188|NCT03456167|Experimental|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op & weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 & 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory & surgeon.
16476189|NCT03456167|No Intervention|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 & 6 weeks post-op and attend all scheduled follow up appointments.
16476190|NCT03456154|Experimental|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
16476191|NCT03456154|Active Comparator|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
16476192|NCT03456128|Experimental|Intervention|The experimental group will receive CAPABLE services. These include ≤10 sessions: ≤ 6 with an Occupational Therapist (OT) and ≤ 4 sessions with a Registered Nurse (RN) and up to ≤ $1,500 of home safety and home modifications from a licensed handyman who is guided by the OT. The OT and RN sessions will target participants' self-identified functional goals (e.g., getting safely into the tub, getting upstairs to sleep in own bed).
16476193|NCT03456128|No Intervention|Usual Care|Participants in the usual care group will not receive visit from study clinicians and will continue to receive their usual VNSNY CHOICE benefits and healthcare.
16476194|NCT03456115|Experimental|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
16476195|NCT03456102|Other|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
16476196|NCT03456102|Other|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
16476197|NCT03456102|Other|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
16476198|NCT03456102|Other|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 80 mg is not tolerated as specified in protocol.
16476199|NCT03456089|Other|Neurogenic Bladder Patients|Patients with neurogenic bladder undergoing urodynamics testing
16476202|NCT03456063|Experimental|Arm A: Atezolizumab + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy
~Platinum-based chemotherapy may include:
~carboplatin + pemetrexed
~carboplatin + nab-paclitaxel
~cisplatin + pemetrexed
~cisplatin + gemcitabine
~Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab"
16476203|NCT03456063|Placebo Comparator|Arm B: Placebo + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy
~Platinum-based chemotherapy may include:
~carboplatin + pemetrexed
~carboplatin + nab-paclitaxel
~cisplatin + pemetrexed
~cisplatin + gemcitabine
~Participants will receive best supportive care and monitoring after surgery"
16476204|NCT03456050|Experimental|FRC group|This group will receive FRC exercise.
16476205|NCT03456050|Experimental|Conventional treatment|This group will receive conventional exercise.
16476206|NCT03456011|Other|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.
~Intervention: BFA"
16476207|NCT03456011|No Intervention|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider
~No interventions"
16476208|NCT03455998||post surgery|Patienst consultation Questionnaires
16476209|NCT03455998||pre and post surgery|Patient consultation Questionnaires
16476210|NCT03455985|Experimental|Discharge Order Set (DOS)|Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.
16476211|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
16476212|NCT03455972|Experimental|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (on d0) and anti-BCMA CAR T cells as split-dose (40% on d1 and 60% on d2)
16476213|NCT03455959|Experimental|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
16476214|NCT03455946|Experimental|Interventional|DASH Cloud with Alexa
16476215|NCT03455933|Experimental|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
16476216|NCT03455933|Experimental|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
16476217|NCT03455933|Other|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
16476218|NCT03455920|Experimental|Multidisciplinary arm|Patients randomized in this group will have their first sleep clinic evaluation with the clinical nurse. She will then discuss each case with the pulmonologist and validate the diagnostic and therapeutic avenue.
16476219|NCT03455920|Active Comparator|Pulmonologist arm|Patients randomized in this group will have their first sleep clinic evaluation with the pulmonologist.
16476220|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
16476221|NCT03455894|Experimental|Smart carpet|
16476222|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
16476223|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
16476224|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
16476225|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
16476226|NCT03455868||Sleeve gastrectomy diabetes|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Sleeve gastrectomy
16476227|NCT03455868||Roux-in-Y gastric bypass diabetes|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Roux-in-Y gastric bypass
16476228|NCT03455868||Sleeve gastrectomy no diabetes|35 Men and women without type 2 diabetes and with obesity undergoing bariatric surgery : Sleeve gastrectomy
16476229|NCT03455868||Control|30 Men and women with a normal BMI and normoglycemia matched for age and sex with bariatric groups
16476230|NCT03455855|Experimental|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
16476231|NCT03455842|Experimental|BCD-089 weekly|
16476232|NCT03455842|Experimental|BCD-089 biweekly|
16476233|NCT03455842|Placebo Comparator|Placebo|
16476234|NCT03455829|Experimental|Part 1: G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
16476235|NCT03455829|Experimental|Part 2: G1T38 + Osimertinib|Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.
16476236|NCT03455829|Active Comparator|Part 2: Osimertinib|"Patients will be randomized to receive osimertinib 80 mg once-daily.
~At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib."
16476237|NCT03455816|Experimental|Group that uses the Social Diabetes App (research group)|This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month
16476238|NCT03455816|Active Comparator|Usual clinical monitoring group (control group)|This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
16476239|NCT03455790|Experimental|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
16476240|NCT03455790|Experimental|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
16476269|NCT03455621|Experimental|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
16476241|NCT03455790|Other|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
16476242|NCT03455790|Other|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
16476243|NCT03455790|Other|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
16476244|NCT03455790|Other|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
16476245|NCT03455790|Other|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
16476246|NCT03455777|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
16476247|NCT03455764|Experimental|MCS110+ Trametinib + Dabrafenib|"For Phase 1 MCS110 will be administered intravenously every 3 weeks.
~Dabrafenib is given orally every 12 hours.
~Trametinib is given orally daily"
16476248|NCT03455764|Experimental|MCS110 + Trametinib + Dabrafenib Phase 2|"MCS110 will be administered intravenously every 3 weeks.
~The Dosage will be determine by the DLT of Phase 1
~Dabrafenib is given orally every 12 hours.
~Trametinib is given orally daily"
16476249|NCT03455751|No Intervention|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
16476250|NCT03455751|Experimental|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
16476251|NCT03455725|Active Comparator|CardiAMP cell therapy system|"Roll-in phase:
~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.
~In the subsequent randomized phase:
~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
16476252|NCT03455725|Sham Comparator|Sham procedure control|"Randomized phase:
~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
16476253|NCT03455712|Experimental|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
16476254|NCT03455712|No Intervention|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
16476255|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
16476256|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
16476257|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
16476258|NCT03455686|Experimental|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
16476259|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
16476260|NCT03455660||Pre-January 2015|Patients who underwent cesarean delivery between February 2013 and December 2014.
16476261|NCT03455660||Post-January 2016|Patients who underwent cesarean delivery between February 2016 and December 2017.
16476262|NCT03455647|Experimental|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
16476263|NCT03455647|No Intervention|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
16476264|NCT03455647|No Intervention|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
16476265|NCT03455634|Active Comparator|Twin Block|Twin Block functional appliance
16476266|NCT03455634|Active Comparator|Sander|Sander bite jumping appliance
16476267|NCT03455634|No Intervention|Control|no intervention
16476268|NCT03455621|Placebo Comparator|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
16479445|NCT03433911|Experimental|FemBloc|Investigational device and procedure
16476270|NCT03455621|Experimental|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
16476271|NCT03455621|Experimental|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
16476272|NCT03455621|Active Comparator|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
16476273|NCT03455608|Active Comparator|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
16476274|NCT03455608|Active Comparator|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
16476275|NCT03455608|Active Comparator|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
16476276|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
16476277|NCT03455582|Active Comparator|Control|40 Healthy controls
16476278|NCT03455569|Experimental|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
16476279|NCT03455569|Experimental|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
16476280|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16476281|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
16476282|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
16476283|NCT03455530|Experimental|Intervention Group|The intervention group will receive the IH-enhanced CHW intervention before (~3 months) the other arm (Delayed Intervention Group).
16476284|NCT03455530|Other|Delayed Intervention Group|The delayed intervention group will receive the IH-enhanced CHW intervention after (~3 months) the other arm (Intervention Group).
16476285|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.
~Step 2. All patients will receive 6 courses of the VR combination.
~Step 3. After 6 courses of VR combination:
~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
16476286|NCT03455504|Experimental|Cohort 1|FLAI + V400 mg
16476287|NCT03455504|Experimental|Cohort 2|FLAI + V600 mg
16476288|NCT03455491|Experimental|XC221 100 mg|"XC221 100 mg orally.
~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
16476289|NCT03455491|Experimental|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
16476290|NCT03455491|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
16476291|NCT03455478|Experimental|corrected refractive error|
16476292|NCT03455478|No Intervention|uncorrected refractive error|
16476293|NCT03455465||No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
16476294|NCT03455465||Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
16476295|NCT03455452||Cohort 1: Nivolumab|Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
16476296|NCT03455452||Cohort 2: Nivolumab + Ipilimumab|Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC
16476297|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
16476298|NCT03455426|Experimental|letrozole group|letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days
16476299|NCT03455426|No Intervention|natural cycle group|
16476300|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
16476301|NCT03455374|Experimental|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
16476302|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
16476303|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
16476304|NCT03455348|No Intervention|cathete to less than 4 four centimeters to the wrist joint|
16476305|NCT03455348|Active Comparator|catheter to more than four centimeters to the wrist joint|
16476306|NCT03455335|Experimental|low dose cohort|20 million hMSCs .
16476307|NCT03455335|Experimental|mid dose cohort|40 million hMSCs
16476308|NCT03455335|Experimental|high dose cohort|80 million hMSCs .
16476309|NCT03455322|Active Comparator|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days.
16476310|NCT03455322|Active Comparator|midodrine & octreotide|midodrine 5mg three times/day orally & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6hS.C. for 7-10 days
16476311|NCT03455309|Active Comparator|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
16476312|NCT03455309|Placebo Comparator|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
16476313|NCT03455296|Active Comparator|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
16479446|NCT03433911|Active Comparator|Control|Laparoscopic bilateral tubal sterilization
16476314|NCT03455296|Active Comparator|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
16476315|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
16476316|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
16476317|NCT03455270|Experimental|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.
~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
16476318|NCT03455270|Experimental|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.
~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
16476319|NCT03455270|Experimental|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
16476320|NCT03455270|Experimental|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
16476321|NCT03455257|No Intervention|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
16476322|NCT03455257|Experimental|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
16476323|NCT03455231|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
16476324|NCT03455218|Experimental|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
16476325|NCT03455218|Placebo Comparator|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
16476326|NCT03455205|Experimental|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:
~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
16476327|NCT03455205|Placebo Comparator|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
16476328|NCT03455192|Experimental|Synbiotic supplements|One synbiotic tablet, per day, during 30 days
16476329|NCT03455192|Placebo Comparator|Placebo Oral Tablet|One placebo tablet , per day, during 30 days
16476330|NCT03455179|Experimental|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
16476331|NCT03455179|Experimental|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (''as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
16476332|NCT03455179|Experimental|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
16476333|NCT03455179|No Intervention|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
16476334|NCT03455166|Other|Psoriasis|
16476335|NCT03455166|Other|Psoriatic arthropathy|
16476336|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
16476337|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
16476338|NCT03455140|Experimental|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
16476339|NCT03455140|Experimental|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
16476340|NCT03455140|Experimental|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
16476341|NCT03455140|Experimental|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
16476342|NCT03455127|No Intervention|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
16476381|NCT03454893|Experimental|Single Assignment AVR-RD-01|AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
16479447|NCT03433898|Experimental|Part 1|
16476343|NCT03455127|Experimental|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
16476344|NCT03455114|Experimental|capsular fixation surgery|patients required capsule centration safely undergo capsular fixation surgery with AssiAnchor under local anesthesia .
16476345|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
16476346|NCT03455088|Experimental|DBT group|DBT group has 55 patients, maybe will be divided them into 6 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
16476347|NCT03455088|Active Comparator|Drug therapy group|Drug therapy group has 55 patients, and the investigator may use fluoxetine as treatment drug.
16476348|NCT03455088|Experimental|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe the investigator can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, the investigator use fluoxetine as treatment drug.
16476349|NCT03455075|Experimental|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
16476350|NCT03455075|Experimental|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
16476351|NCT03455075|Experimental|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
16476352|NCT03455075|Experimental|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
16476353|NCT03455075|Placebo Comparator|Placebo|Placebo administered orally capsules.
16476354|NCT03455049|Experimental|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
16476355|NCT03455049|Placebo Comparator|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
16476356|NCT03455049|Experimental|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
16476357|NCT03455049|Placebo Comparator|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
16476358|NCT03455036|Experimental|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
16476359|NCT03455023|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
16476360|NCT03455023|No Intervention|control group|Patients will receive usual medical care.
16476361|NCT03455010|No Intervention|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
16476362|NCT03455010|Experimental|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
16476363|NCT03455010|Experimental|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
16476364|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
16476365|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
16476366|NCT03454984|Experimental|SGI-110|"SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.
~Initial dose will be 30/m2/day SQ for 5 days
~total 10 cycles of SGI-110"
16476367|NCT03454971|Experimental|MinOS arm|Patients are followed according to MinOS protocol:
16476368|NCT03454958||Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
16476369|NCT03454945|Experimental|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
16476370|NCT03454945|Active Comparator|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
16476371|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
16476372|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
16476373|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
16476374|NCT03454919|Other|Palbociclib|single arm
16476375|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
16476376|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
16476377|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
16476378|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
16476379|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
16476380|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
16476423|NCT03454594|Experimental|low level laser hemotherapy|Watch laser acupuncture and nasal irradiation
16476382|NCT03454867|Experimental|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
16476383|NCT03454867|Active Comparator|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
16476384|NCT03454854|Experimental|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
16476385|NCT03454841||Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
16476386|NCT03454841||Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
16476387|NCT03454828|Experimental|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) >95th percentile.
16476388|NCT03454828|Active Comparator|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) <85th percentile.
16476389|NCT03454815|Experimental|Patency Group|apical patency was maintained during chemomechanical preparation
16476390|NCT03454815|No Intervention|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
16476391|NCT03454802|Active Comparator|Normal subjects|Normal subjects 'Passive Leg Raising'
16476392|NCT03454802|Active Comparator|ICU patients|ICU patients 'Passive Leg Raising'
16476393|NCT03454802|Active Comparator|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
16476394|NCT03454789|Active Comparator|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
16476395|NCT03454789|Active Comparator|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
16476396|NCT03454789|Active Comparator|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
16476397|NCT03454789|Active Comparator|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
16476398|NCT03454776|Active Comparator|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
16476399|NCT03454776|Placebo Comparator|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
16476400|NCT03454763|Experimental|Arm A, Intensive|Arm A, Intensive every 5 weeks
16476401|NCT03454763|Experimental|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
16476402|NCT03454750|Experimental|177Lu-PSMA|177Lu PSMA
16476403|NCT03454737|Experimental|mesenchymal stem cells|
16476404|NCT03454737|Active Comparator|Pure platelet-rich plasma|
16476405|NCT03454724|Experimental|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
16476406|NCT03454724|Active Comparator|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
16476407|NCT03454711|Experimental|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.
~Three clinical visits will be realized in less than two months"
16476408|NCT03454711|Experimental|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.
~Three clinical visits will be realized in less than two months"
16476409|NCT03454698|Other|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
16476410|NCT03454685||NCSLC group|NSCLC patients,including stage I to stage IV.
16476411|NCT03454685||Healthy subjects|healthy subjects
16476412|NCT03454672|Experimental|Tixel|Tixel Treatment.
16476413|NCT03454672|Active Comparator|Laser|Laser Treatment.
16476414|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
16476415|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
16476416|NCT03454646|Experimental|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.
~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
16476417|NCT03454646|No Intervention|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
16476418|NCT03454633|Experimental|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
16476419|NCT03454633|Active Comparator|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
16476420|NCT03454620|Experimental|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
16476421|NCT03454620|Experimental|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
16476422|NCT03454607|Experimental|FREE robot|Patients undergoing sinus surgery with the FREE robot
16476424|NCT03454594|No Intervention|control|all the participants in this group did not receive low level laser irradiation during the study period
16476425|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.
~18 individuals"
16476426|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.
~16 individuals."
16476427|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
16476428|NCT03454555|Active Comparator|Arm 1|Arm 1 patients will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision-Making (SDM) intervention.
16476429|NCT03454555|Active Comparator|Arm 2|Arm 2 patients will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT+CP) Intervention.
16476430|NCT03454542|Experimental|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
16476431|NCT03454542|Active Comparator|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
16476432|NCT03454529|Experimental|Treatment (simvastatin)|Patients receive simvastatin PO daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
16476433|NCT03454516|No Intervention|Standard Care|This group is the usual standard treatment group
16476434|NCT03454516|Other|Telemonitoring group|This group will followed up with telemonitoring
16476435|NCT03454503||First cohort|Newly diagnosed patients
16476436|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
16476437|NCT03454477|Experimental|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
16476438|NCT03454477|Experimental|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
16476439|NCT03454477|Experimental|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
16476440|NCT03454464|Sham Comparator|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
16476441|NCT03454464|Experimental|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
16476442|NCT03454451|Experimental|Cohort 1a|CPI-006
16476443|NCT03454451|Experimental|Cohort1b|CPI-006 + ciforadenant
16476444|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
16476445|NCT03454451|Experimental|Cohort 2a|CPI-006
16476446|NCT03454451|Experimental|Cohort 2b|CPI-006 + ciforadenant
16476447|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
16476448|NCT03454438|Experimental|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
16476449|NCT03454438|Experimental|Triage|Triage by rheumatologist in a primary care setting.
16476450|NCT03454438|No Intervention|Usual care|Control group consisting of usual care.
16476451|NCT03454425|Experimental|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
16476452|NCT03454425|Sham Comparator|Sham ExAblate Subthalamotomy|
16476453|NCT03454399|No Intervention|TEE image before suction|Suction orogastric tube which is attached to TEE probe
16476454|NCT03454399|Experimental|TEE image after suction|Suction orogastric tube which is attached to TEE probe
16476455|NCT03454386|Active Comparator|Active Treatment|"Stress Management and Resilience Training Program
~This group will be initially enrolled in the program."
16476456|NCT03454386|Other|Control|"Self-Management Stress Reduction Program
~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
16476457|NCT03454373|Experimental|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
16476458|NCT03454373|No Intervention|Comparator|Standard of care HIV primary care services, including counseling to return to care.
16476459|NCT03454347|Experimental|Protein Supplementation Group|Participants in this group will complete two weeks of lower limb suspension and receive 75g/day of supplemental protein in addition to education aimed at increasing protein intake through their diet.
16476460|NCT03454347|Active Comparator|Non-Supplemental Group|Participants in this group will complete two weeks of lower limb suspension and will receive no supplementation or nutritional education.
16476461|NCT03454334|Active Comparator|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic
~-0.20
~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
16476462|NCT03454334|Active Comparator|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).
~6.0mm Silicone
~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
16476552|NCT03453762|Active Comparator|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
16476463|NCT03454334|Active Comparator|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
16476464|NCT03454334|Active Comparator|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic
~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
16476465|NCT03454308|Experimental|SMASH|Automated reminder functions activated on pill monitoring device, motivational text messages, at home BP monitoring
16476466|NCT03454308|Other|Enhanced SC|No reminder functions on the pill monitoring device, attention control text messages
16476467|NCT03454295|Experimental|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
16476468|NCT03454295|Experimental|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
16476469|NCT03454282|Experimental|FMD Arm|The intervention consists in 5-day FMD (Fasting Mimicking Diet) to be followed for one cycle (Cohorts A and B) or for 4 consecutive every-four week cycles postoperatively.
16476470|NCT03454269|Active Comparator|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
16476471|NCT03454269|Active Comparator|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
16476472|NCT03454269|Active Comparator|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
16476473|NCT03454256|Experimental|Virtual Reality Group (VRG)|The Virtual Reality Group (VRG) will perform the rehabilitation trough the Virtual Reality Rehabilitation system (VRRS, Khymeia,Italy). The patient standing upright on a balance board will practice exercises of vertical position control with a visual biofeedback received from the VRRS and interacting with the serious video-games. The difficulty level of the exercises will increase gradually session by session. Every session will last 45 minutes with a frequency of at least 5 times a week.
16476474|NCT03454256|No Intervention|Control Group (CG)|The Control Group (CG) will perform the traditional treatment consisting of the exercises of rehabilitation of gait and postural passages, exercises for postural control, and proprioceptive exercises in a vertical position according to the method chosen by the physiotherapist. Every session will last 45 minutes with a frequency of at least 5 times a week.
16476475|NCT03454243|Experimental|RXDX-106|
16476476|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.
~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
16476477|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
16476478|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
16476479|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
16476480|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
16476481|NCT03454191|Experimental|Erector spinae plane block|
16476482|NCT03454191|Placebo Comparator|Placebo|
16476483|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
16476484|NCT03454165|Experimental|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
16476485|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
16476486|NCT03454139|Active Comparator|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
16476553|NCT03453762|Experimental|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
16476487|NCT03454139|No Intervention|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
16476488|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
16476489|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
16476490|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
16476491|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
16476492|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
16476493|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
16476494|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
16476495|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
16476496|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
16476497|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
16476498|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
16476499|NCT03454100|Experimental|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
16476500|NCT03454100|No Intervention|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
16476501|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
16476502|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
16476503|NCT03454074|Experimental|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
16476504|NCT03454074|Active Comparator|Education Only|Provide group education about healthy behavior changes without problem-solving component.
16476505|NCT03454074|No Intervention|Wait-list|No intervention administered. Will be offered intervention following a delay.
16476506|NCT03454061|Experimental|Intervention|Physical activity intervention
16476507|NCT03454061|No Intervention|Control|Keep usual activities in kindergarten
16476508|NCT03454048|Experimental|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
16476509|NCT03454048|Experimental|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
16476587|NCT03453476|Experimental|SRP and Fotosan 630|Scaling and root planing, photodynamic therapy using Fotosan 630
16476510|NCT03454048|Experimental|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
16476511|NCT03454048|Experimental|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
16476512|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
16476513|NCT03454022|Active Comparator|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
16476514|NCT03454022|Experimental|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
16476515|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.
~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
16476516|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
16476517|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
16476518|NCT03453996|Other|Control|Usual care.
16476519|NCT03453983|Experimental|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
16476520|NCT03453983|Sham Comparator|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
16476521|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:
~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).
~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.
~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
16476522|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
16476523|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
16476524|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
16476525|NCT03453944|Experimental|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
16476526|NCT03453944|Sham Comparator|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
16476527|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
16476528|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
16476529|NCT03453905|Experimental|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
16476530|NCT03453905|Other|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
16476531|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
16476554|NCT03453749|Other|Salovum|Patients will be given Salovum 1g/kg body weight/24 hours, divided into 6 dosages and given during 5 consecutive days.
16479448|NCT03433898|Experimental|Part 2|
16476532|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
16476533|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
16476534|NCT03453866|Experimental|Warmed Arthroscopic Fluids|Arthroscopic Fluids will be warmed to 38 degrees Celsius during procedure with active warming device. Temperature will be measured in real time.
16476535|NCT03453866|Active Comparator|Room Temperature Arthroscopic Fluids|Arthroscopic fluids will be kept at room temperature and will not be warmed per current standard of care. Temperature will be measured in real time.
16476536|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
16476537|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
16476538|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
16476539|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
16476540|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
16476541|NCT03453827||PEX|Patients after Cataract surgery with PES
16476542|NCT03453827||Control|Patients after Cataract surgery without PES
16476543|NCT03453814|Experimental|Interventional|Music therapy.
16476544|NCT03453814|No Intervention|Comparison|No music therapy.
16476545|NCT03453801|Experimental|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
16476546|NCT03453801|Experimental|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
16476547|NCT03453801|Experimental|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
16476548|NCT03453788|Experimental|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
16476549|NCT03453788|No Intervention|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
16476550|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
16476551|NCT03453775|Active Comparator|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
16476588|NCT03453476|No Intervention|Control|Scaling and root planing only
16476555|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
16476556|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.
~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
16476557|NCT03453723|Experimental|magic glove hypnosis|Magic glove hypnosis technique use before propofol infusion
16476558|NCT03453723|Active Comparator|lidocaine|extemporaneous mixture with lidocaine for propofol infusion
16476559|NCT03453710|Active Comparator|Bankart Repair and Remplissage|Patients randomized to the all-arthroscopic group (Bankart repair and remplissage) will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
16476560|NCT03453710|Active Comparator|Latarjet Coracoid Transfer|Patients randomized to the open Latarjet coracoid transfer will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
16476561|NCT03453697|Experimental|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
16476562|NCT03453684|Experimental|Administration of Vancomycin|Administration of Vancomycin 15 mg/kg over 1 hour prior to surgical incision
16476563|NCT03453671|Experimental|Mindfulness|Participants will use the strategy of mindfulness, i.e., present moment awareness with nonjudgment and acceptance, while exercising.
16476564|NCT03453671|Experimental|Distraction|Participants will use the strategy of distraction, i.e., directing their attention to something other than exercise (specifically a podcast) while exercising.
16476565|NCT03453671|Active Comparator|Self-Monitoring|Participants will monitor their internal experience while exercising, without distraction and without being taught mindfulness skills of nonjudgment and acceptance.
16476566|NCT03453658|Active Comparator|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
16476567|NCT03453658|Experimental|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
16476568|NCT03453632|Experimental|Botulinic toxin|Injections of botulinic toxin (Dysport®, Allergan) 200 UI
16476569|NCT03453632|Placebo Comparator|Placebo|Injections of physiological serum
16476570|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
16476571|NCT03453606|Active Comparator|home group|
16476572|NCT03453606|Active Comparator|center group|
16476573|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
16476574|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
16476575|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
16476576|NCT03453554|Experimental|DMN/Smart Home Partnership|Participants will learn how to use a digital memory notebook partnered with smart environment prompting technology to support everyday activities of daily living and reduce problems associated with memory deficits.
16476577|NCT03453554|Active Comparator|Digital Memory Notebook app|Participants will learn how to use a Digital Memory Notebook app to support everyday activities of daily living and reduce problems associated with memory deficits.
16476578|NCT03453541|Experimental|Ketorolac Tromethamine|This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
16476579|NCT03453541|Placebo Comparator|0.9% Normal Saline|This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.
16476580|NCT03453528|Experimental|68Ga-PSMA|68Ga-PSMA
16476581|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
16476582|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
16476583|NCT03453502|No Intervention|Before-intervention phase|All the very low birth weight (VLBW) and extremely low birth weight (ELBW) infants who were admitted from January 2017 to December 2017 to the NICUs of different hospitals.
16476584|NCT03453502|Experimental|Intervention phase|All the VLBW and ELBW infants who were admitted from January 2018 to December 2018 to the NICUs.During this phase,multiple intervention bundles of quality improvement will be implemented.
16476585|NCT03453502|Experimental|Sustainability intervention phase|All the VLBW and ELBW infants who were admitted from January 2019 to December 2019to the NICUs.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
16476586|NCT03453489|Experimental|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
16479449|NCT03433898|Experimental|Part 3|
16476589|NCT03453463|Experimental|exercise and protein supplementation|Predominately resistance exercise training 2-3x week for 18 months; 1.5-1.7 g/kg/d total protein supplementation, Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
16476590|NCT03453463|No Intervention|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
16476591|NCT03453450||Health TAPESTRY volunteers|Volunteers in a primary care setting connecting with Health TAPESTRY clients
16476592|NCT03453450||Health TAPESTRY Volunteer Coordinators|The coordinators of volunteers
16476593|NCT03453437|No Intervention|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
16476594|NCT03453437|Experimental|Active group|Receiving Mindful Self-Compassion intervention
16476595|NCT03453424|Active Comparator|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.
~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
16476596|NCT03453424|Active Comparator|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.
~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
16476597|NCT03453411||Non interventional study|
16476598|NCT03453398|Experimental|Group 1|Shifts over 24-hours, shift cycle of 5 days (morning, afternoon, night, night off, rest).
16476599|NCT03453398|Experimental|Group 2|Shifts over 24-hours, shift cycle of 10 days (morning, morning, afternoon, afternoon, rest, night, night, night off, rest, rest).
16476600|NCT03453398|Active Comparator|Group 3|Only diurnal shifts, shift cycle of 5 days (morning, afternoon, morning, afternoon, morning, rest, rest).
16476601|NCT03453385|No Intervention|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
16476602|NCT03453385|Experimental|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
16476603|NCT03453372|Experimental|Active|MRgFUS treatment of pain caused by knee osteoarthritis
16476604|NCT03453372|Placebo Comparator|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
16476605|NCT03453359|Experimental|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
16476606|NCT03453359|Active Comparator|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
16476607|NCT03453346|Experimental|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for <75 kg, and 1200 mg for >=75 kg) twice daily with meal, orally given, for 12 successive weeks
16476608|NCT03453333|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
16476609|NCT03453333|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
16476610|NCT03453320|Experimental|Rapid - Slow|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.
~First time rapid (30 minutes), second time slow (120 minutes). Albumin solution"
16476611|NCT03453320|Experimental|Slow - Rapid|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.
~First time rapid (120 minutes), second time slow (30 minutes). Albumin solution"
16476612|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
16476613|NCT03453294|Experimental|Apnoeic oxygenation using THRIVE|Oxygenation by apnoea oxygenation using THRIVE
16476614|NCT03453294|Active Comparator|Endotracheal intubation and mechanical ventilation|Ventilation and oxygenation by an endotracheal tub and mechanical ventilation
16476615|NCT03453281|Experimental|Aflibercept Injection [Eylea]|Intravitreal injection of 2 mg in 0.05 ml Aflibercept. Frequency: once Duration: 10-15 minutes
16476616|NCT03453268|Other|1: Interventional (drug reduction)|"STEP DOWN strategy.
~Proposition of reduction of the number of antihypertensive medication according to:
~the systolic blood pressure levels,
~co-morbidities"
16476617|NCT03453268|Other|2: Control|Usual treatment
16476618|NCT03453255|Experimental|t(8;21)AML|chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(<60 year old) 500mg/m2(>60 year old) IV q12h d1,3,5
16476619|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
16476620|NCT03453203|Placebo Comparator|Control|"Both arms with be diagnosed using tenderpoints In the control arm the tenderpoint will Be palpated for 90 secs with no counterstrain treatment applied.
~Both treatment and control groups will remain on their current migraine medication regiment."
16476621|NCT03453203|Other|Treatment (conterstrain)|Both arms with be diagnosed using tenderpoints. Treatment arm will be treated with counterstrain technique. Counterstrain is a passive manipulative technique which the tissue being treated is positioned at a point of balance, or ease, AWAY from the restrictive barrier (The most thought of form of manipulative technique is high velocity low amplitude which is typically performed by chiropractors in spinal manipulation which goes TOWARD the restrictive barrier and actually pass through the restrictive barrier). Once a tenderpoint is found in the muscles the area of treatment is placed in a (three dimensional) position that will eliminate the sensation (tenderness).The treatment position is held for 90 seconds or until a release is felt (a decrease in muscle tension). Both treatment and control groups will remain on their current migraine medication regiment.
16476622|NCT03453190|Other|Psoriasis Patients on Comb. Treatment|Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
16476684|NCT03452748|Experimental|FTIR arm|all excised membranes are examined with FTIR spectroscopy
16476623|NCT03453177|No Intervention|Standard of Care|ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).
16476624|NCT03453177|Experimental|Standard of Care plus Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
16476625|NCT03453164|Experimental|Radiotherapy + Nivolumab|Localized short-term radiotherapy (22.5 Gy/5 fractions/5 days, Day 1-5) + nivolumab (starting on Day 15-22, a dose of 3 mg/kg (body weight), every 2 weeks to a total of 6 courses)
16476626|NCT03453151|Experimental|Regional nerve anesthesia|
16476627|NCT03453138|Experimental|LMA Protector Group|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
16476628|NCT03453138|Experimental|Tracheal Intubation Group|Patients will be intubated after standart anesthesia induction and we will record heamodynamic variables. including mean blood pressure and heart rate
16476629|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
16476630|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
16476631|NCT03453112|Experimental|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)
16476632|NCT03453112|Active Comparator|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.
16476633|NCT03453099||Study Cohort|Any ASA I or II patients scheduled for elective day case general anaesthesia at Chelsea & Westminster Hospital, involving a standard propofol-fentanyl induction regimen, aged between 18-65 years . See specific exclusion criteria below.
16476634|NCT03453086|Active Comparator|Group I:|These patients will receive single ipsilateral Ultrasound TPVB which performed with the patient in the sitting position at the level of the T4 with the probe in a vertical position 2.5-3 cm lateral to the midline. The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes which visualized with the superior costo-transverse ligament and the pleura visible in between . After this, 15-20 cc of bupivacaine 0.25% will be injected
16476635|NCT03453086|Active Comparator|Group II :|These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
16476636|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate <1 time/month
16476637|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and <1.5 times/month
16476638|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and <3.5 times/month,
16476639|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and <3 times/week
16476640|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate >3 times/week
16476641|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
16476642|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
16476643|NCT03453073||Younger|Age<65 years at follow-up baseline
16476644|NCT03453073||Older|Age>=65 years at follow-up baseline
16476645|NCT03453060|Experimental|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
16476646|NCT03453060|Experimental|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
16476647|NCT03453060|Experimental|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
16476648|NCT03453060|Experimental|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
16476649|NCT03453060|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
16476650|NCT03453047||1|Healthy volunteers. Liver donor groups; Course of the research: Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
16476651|NCT03453047||2|Liver transplant groups;Course of the research Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
16476652|NCT03453034|Experimental|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
16476921|NCT03451084|Experimental|Part 1: Dose Level 1|
16476653|NCT03453021||mepolizumab|Patients will receive a subcutaneous injection of mepolizumab 100 mg every 4 weeks for one year, for a total of 12 injections
16476654|NCT03452995|Active Comparator|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
16476655|NCT03452995|Active Comparator|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
16476656|NCT03452995|Experimental|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
16476657|NCT03452982|Experimental|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
16476658|NCT03452956||FTD Cohort|No intervention-observation only
16476659|NCT03452943|Experimental|TEV-50717|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 12 weeks
16476660|NCT03452943|Placebo Comparator|Placebo|Placebo matched to TEV-50717 BID for a total of 12 weeks
16476661|NCT03452930|Experimental|Stage 1A (tinostamustine)|Patients receive tinostamustine IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16476662|NCT03452930|Experimental|Stage 1B (tinostamustine)|Patients receive tinostamustine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16476663|NCT03452930|Experimental|Stage 2 (RT, tinostamustine)|Patients undergo RT 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive tinostamustine IV on day 1 or days 1 and 15 (to be determined following stage 1). Treatment repeats every 21 days (day 1) or 28 days (days 1 and 15) for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16476664|NCT03452917|Placebo Comparator|Placebo|2 ml of normal saline (n=500)
16476665|NCT03452917|Experimental|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
16476666|NCT03452904|Experimental|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
16476667|NCT03452904|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
16476668|NCT03452891|Experimental|SIM-MCL|
16476669|NCT03452891|Placebo Comparator|MCL|
16476670|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
16476671|NCT03452865|Experimental|Esomeprazole|Patients randomized to Esomeprazole Group will receive a bolus of 160 mg of esomeprazole (diluted in 100 ml of 0.9% sodium chloride for intravenous use and administered over 60 minutes) and an intravenous infusion of 12 mg/hr (diluted in 0.9% sodium chloride at a concentration of 8 mg/ml will be injected at a rate of 1.5 ml/hr) for 72 hours .
16476672|NCT03452865|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive a bolus of 100 ml of 0.9% sodium chloride for intravenous use administered over 60 minutes with no active principle and an intravenous infusion of 0.9% sodium chloride at a rate of 1.5 ml/hr with no active principle for 72 hours .
16476673|NCT03452852|Other|NPWT (PICO device)|In this arm, investigators will use the PICO system (Smith and Nephew) for compression therapy after split thickness skin graft of leg ulcers.
16476674|NCT03452852|Other|Compression bandaging (Coban 2 lite)|In this arm, investigators will use the Coban 2 lite compression bandaging for compression therapy after split thickness skin graft of leg ulcers.
16476675|NCT03452839|Experimental|Continuous infusion|"Patient randomized to continuous infusion group, will receive a continuous infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula and study day
~for ClCr > 50 ml/min: 3 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 12,5 ml/h.
~for ClCr < 50 ml/min: 2 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 8,3 ml/h.
~This solution will be replaced every time its duration exceeds the stability in use stated by the producer"
16476676|NCT03452839|Active Comparator|Bolus|"Patient randomized to bolus group, will receive a bolus infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula):
~for Cl-Cr > 50 ml/min 1 g every 6 hours on first 24 hours, every 8 hours after
~for Cl-Cr < 50 ml/min 1 g every 8 hours on first 24 hours, every 12 hours after"
16476677|NCT03452826|Experimental|Antibiotic therapy according to the result of mPCR|Combined use of a respiratory broad panel Multiplex polymerase chain reaction (mPCR) (performed on a lower respiratory tract sample : bronchoalveolar lavage fluid or tracheal aspirate, otherwise sputum) and procalcitonin.
16476678|NCT03452826|No Intervention|Antibiotic therapy at discretion of ICU physicians|Antibiotic therapy at discretion of ICU physicians
16476680|NCT03452787||Boston Puerto Rican Health Study (NCT01231958)|40 with CC and 40 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
16476681|NCT03452787||GOLDN (NCT00083369)|107 participants with CC genotype and 272 with TT genotype for APOA2 rs5082.
16476682|NCT03452787||Framingham Heart Study (NCT00005121)|73 with CC and 170 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
16476683|NCT03452774||Study Group|Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
16476685|NCT03452735||patients diagnosed before age 40|Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
16476686|NCT03452735||Control Group|Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility
16476687|NCT03452722||Study group|Applied rtPA
16476688|NCT03452722||Control study|rtPA not applied
16476689|NCT03452709|No Intervention|Control group: no intervention|Only the normal practise
16476690|NCT03452709|Experimental|therapeutic exercise|In this group the intervention is the prescription of physical activity. The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
16476691|NCT03452709|Experimental|ABPM|In this group the arterial pressure is evaluated with ABPM.
16476692|NCT03452709|Experimental|therapeutic exercise + ABPM|
16476693|NCT03452696|Experimental|Calcium supplement 10/90|Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
16476694|NCT03452696|Experimental|Calcium supplement 5/95|Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element
16476695|NCT03452696|Active Comparator|Calcium carbonate supplement|1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.
16476696|NCT03452696|Active Comparator|Calcium citrate supplement|1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element
16476697|NCT03452683|No Intervention|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
16476698|NCT03452683|Experimental|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
16476699|NCT03452670|Experimental|Active Group|Participants in this group will use a contemplative wellness application for 8 weeks.
16476700|NCT03452670|Other|Waitlist Group|The waitlist group will receive no intervention during the study but will be able to use the wellness application after completion of the study.
16476701|NCT03452657|Experimental|Ranibizumab|Participants received 0.5mg intravitreal ranibizumab injection
16476702|NCT03452657|Sham Comparator|Sham-injection|No drug involved in the sham procedure; patient's eye is anesthetized and a syringe without needle gently pressed on the conjunctival surface to simulate the force of an actual injection
16476703|NCT03452618|Experimental|patients with a NIV equipment|Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
16476704|NCT03452618|Active Comparator|patients without a NIV equipment|Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
16476705|NCT03452605|Experimental|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
16476706|NCT03452605|Placebo Comparator|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
16476707|NCT03452592|Experimental|The way patients take Alflutinib|patients take Alflutinib orally once per day at dose of 80mg or160mg
16476708|NCT03452579|Active Comparator|Nivolumab + Standard Dose Bevacizumab|"nivolumab 240 mg IV and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
16476709|NCT03452579|Experimental|Nivolumab + Low Dose Bevacizumab|"nivolumab 240 mg IV and low dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity
~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
16476710|NCT03452566|Experimental|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
16476711|NCT03452553|Experimental|Open Label Treatment|Chemoembolization using LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
16476712|NCT03452540|Experimental|DS102|Participants in this group will receive 2000mg DS102 capsules daily.
16476713|NCT03452540|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules daily.
16476714|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
16476715|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
16476716|NCT03452514||Cohort 1 - Low Dose CT (LDCT) Scan|Individuals undergoing their first or subsequent annual LDCT screening study
16476717|NCT03452514||Cohort 2 - Diagnostic CT Scan|Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
16476718|NCT03452501||Naïve group|Newly diagnosed patients
16476719|NCT03452501||Switched group|Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®
16476720|NCT03452488|Placebo Comparator|Arm 1 - Placebo oral capsule|"4 capsules taken twice a day: in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.
~Component : Microcrystalline cellulose, Colloidal anhydrous silica"
16476721|NCT03452488|Experimental|Arm 2 - BIO101 - Half daily dose 350 mg|"4 capsules taken twice a day (2 placebo and 2 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.
~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20-hydroxyecdysone (20E) containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
16476922|NCT03451084|Experimental|Part 1: Dose Level 2|
16476722|NCT03452488|Experimental|Arm 3 - BIO101 - Full daily dose 700 mg|"4 capsules taken twice a day (4 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.
~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
16476723|NCT03452475|Active Comparator|Arterolane-piperaquine|Arterolane-piperaquine for 3 days
16476724|NCT03452475|Active Comparator|Arterolane-piperaquine+mefloquine|Arterolane-piperaquine + mefloquine for 3 days
16476725|NCT03452475|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine for 3 days
16476726|NCT03452462|Experimental|Direct His Bundle Pacing|Pacing from the His bundle lead
16476727|NCT03452462|Active Comparator|Biventricular Pacing|Pacing from the right ventricular and coronary sinus leads
16476728|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
16476729|NCT03452436||Testicular cancer patients|Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
16476730|NCT03452436||Prostate cancer patients|Forty prostate cancer patients included prior to medical castration and radiotherapy.
16476731|NCT03452436||Healthy controls|Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
16476732|NCT03452423|Experimental|ACRFP|Patient suffering from osteoarthritis of knee joints, and planning to receive ACRFP, are enrolled into this study. Gait pattern is obtained preoperatively, 3 months, and 6 months postoperatively.
16476733|NCT03452397|Active Comparator|OC-02 Low Dose|
16476734|NCT03452397|Active Comparator|OC-02 Mid Dose|
16476735|NCT03452397|Active Comparator|OC-02 High Dose|
16476736|NCT03452397|Placebo Comparator|Placebo|
16476737|NCT03452384|Experimental|acupucture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface.
16476738|NCT03452384|Sham Comparator|control|For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
16476739|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
16476740|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
16476741|NCT03452345|Experimental|MEDITOXIN|
16476742|NCT03452345|Placebo Comparator|Placebo|
16476743|NCT03452332|Experimental|Treatment (tremelimumab, durvalumab, SABR)|Participants receive tremelimumab IV over 1 hour followed by durvalumab IV over 1 hour on day 1 of each cycle. Participants also undergo SABR over 30-45 minutes on days 8, 10, and 12 of cycle 1. Treatment with tremelimumab repeats every 4 weeks for up to 4 cycles, and treatment with durvalumab repeats every 4 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16476744|NCT03452319|Experimental|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
16476745|NCT03452319|Active Comparator|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
16476746|NCT03452306|Experimental|Metformin|"First aIntervention Period:
~Single administered dose of Metformin (750 mg tablet extended-release in a fasting condition
~Third Intervention Period:
~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
16476747|NCT03452306|Active Comparator|Glucophage® Long|"Second Intervention Period:
~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fasting condition
~Fourth Intervention Period:
~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fed condition"
16476748|NCT03452267|Experimental|Metformin|
16476749|NCT03452267|Experimental|Pioglitazone|
16476750|NCT03452267|Placebo Comparator|Placebo|
16476751|NCT03452254|Active Comparator|Experimental Group|Active bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
16476752|NCT03452254|Sham Comparator|Control Group|Sham bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
16476753|NCT03452241|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
16476754|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use
16476755|NCT03452241|Experimental|Intervention Group 1|The medical staffs who received the training will use the manual of brief intervention twice to deliver it and other materials about the harm of substance use.
16476756|NCT03452228|Experimental|evinacumab|
16476757|NCT03452228|Experimental|Placebo|
16476758|NCT03452215|Experimental|Study|
16476759|NCT03452215|Sham Comparator|Control|
16476760|NCT03452202|Experimental|Active Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
16476761|NCT03452202|Sham Comparator|Sham Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
16476762|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
16476763|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
16476764|NCT03452176|Experimental|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
16476765|NCT03452176|Sham Comparator|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
16476766|NCT03452163|Experimental|Anesthesia, General|Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
16476767|NCT03452150|Experimental|Daily oral dose of D-0316|
16476770|NCT03452124|Active Comparator|IQOS|I quit ordinary smoking (IQOS) assistes cessation program
16476771|NCT03452124|Active Comparator|Smoker control|Conventional cigarette smoking continuation
16476772|NCT03452111|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day). This daily gel volume will contain approximately 62 mg of T that will deliver 6 mg T to the body per day and will also contain 8 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/day + T 62 mg/day (NES-8/T-62) gel).
16476773|NCT03452085|Active Comparator|artificial saliva spray (AS)|"The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.
~After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment."
16476774|NCT03452085|Placebo Comparator|maritime throat spray (TT)|"The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.
~After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment."
16476775|NCT03452072|Experimental|0.25% Timolol gel under the paraffin gauzes|"Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied
~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
16476776|NCT03452072|Active Comparator|Standard of Care dressings|"Vaseline will be applied to wound bed immediately after surgery before dressing is applied
~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
16476777|NCT03452059|Experimental|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
16476778|NCT03452059|Active Comparator|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
16476779|NCT03452046||PS 10 mmHg, PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
16476780|NCT03452046||PS 10 mmHg PEEP 0 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
16476781|NCT03452046||PS 0 mmHg PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
16476782|NCT03452046||t tube (PS 0 mmHg PEEP 0mmHg)|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
16476783|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
16476784|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
16476785|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
16476786|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
16476787|NCT03452020|Other|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:
~Tyto Thermometer
~Standard of Care thermometer
~Predicate IR thermometer"
16476788|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
16476789|NCT03451994||Body odor|individuals self-reporting idiopathic body odor with or without bad breath
16476790|NCT03451994||Breath odor|individuals self-reporting idiopathic bad breath but no body odor
16476791|NCT03451981|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine.
16476792|NCT03451981|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant surface.
16476793|NCT03451981|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant surface.
16476794|NCT03451968|Experimental|critically ill|"amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive).
~it is a single bolus, no other elements or drug will be administered."
16476795|NCT03451968|Active Comparator|control|amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive) it is a single bolus, no other elements or drug will be administered.
16476796|NCT03451955|Experimental|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
16476797|NCT03451955|No Intervention|Control group|Patients in the control group follow their usual diet for six months
16476798|NCT03451942|Experimental|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
16476799|NCT03451942|Placebo Comparator|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
16476923|NCT03451084|Experimental|Part 1: Dose Level 3|
16476924|NCT03451084|Experimental|Part 1: Dose Level 4|
16476800|NCT03451916|Experimental|PLX-PAD|• Arm 1 - PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.
16476801|NCT03451916|Placebo Comparator|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
16476802|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
16476803|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
16476804|NCT03451890|Experimental|Cohort 1: E2730 40 mg|Participants will receive a single oral dose of E2730 40 milligrams (mg) under fasted conditions.
16476805|NCT03451890|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
16476806|NCT03451890|Experimental|Cohort 2: E2730 80 mg|Participants will receive a single oral dose of E2730 80 mg under fasted conditions.
16476807|NCT03451890|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
16476808|NCT03451890|Experimental|Cohort 3: E2730 120 mg|Participants will receive a single oral dose of E2730 120 mg under fasted conditions.
16476809|NCT03451890|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
16476810|NCT03451890|Experimental|Cohort 4: E2730 160 mg|Participants will receive a single oral dose of E2730 160 mg under fasted conditions.
16476811|NCT03451890|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
16476812|NCT03451877|Active Comparator|Study group|Children with cycloplegia refractive error more than -6 D TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
16476813|NCT03451877|Other|Control group|Emmetropic children TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
16476814|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
16476815|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
16476820|NCT03451838||Diabetes mellitus|Pregnant women with diabetes mellitus will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
16476821|NCT03451838||control group|Pregnant women with no medical disorders will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
16476822|NCT03451825|Experimental|Phase 1: Avelumab|
16476823|NCT03451825|Experimental|Phase 2, Cohort 1: Avelumab|
16476824|NCT03451825|Experimental|Phase 2, Cohort 2: Avelumab|
16476825|NCT03451812||prostate cancer|The newly diagnostic number for the high-risk PCa patients in our hospital annually is ~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.
16476826|NCT03451799|Experimental|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
16476827|NCT03451786|Experimental|Treatment group|
16476828|NCT03451773|Experimental|1/ Arm 1-Gemcitabine + de-escalating dose of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + de-escalating dose of M7824
16476829|NCT03451773|Experimental|2/ Arm 2-Gemcitabine + Recommended Phase 2 Dose (RP2D) of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + RP2D of M7824
16476830|NCT03451760|Experimental|Feru-guard|Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
16476831|NCT03451760|Placebo Comparator|Placebo|Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
16476832|NCT03451747||postmenopausal hypertensive women|
16476833|NCT03451747||mached hypertensive men|
16476834|NCT03451734||treatment cohort|in sub-project 1, participants are randomized into olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups, we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
16476835|NCT03451734||adjunctive group|Patients who do not have an ideal response to antipsychotics treatment (reduction rate of Positive and Negative Symptom Scale (PANSS) score less than 25%) in sub-project 2 are recruited in this trial. They are randomly assigned to antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups, and the antipsychotic drugs used at this stage are still consistent with the first trial of sub-project 2. At baseline, 4 weeks and 8 weeks after treatment, all participants receive evaluations.
16476836|NCT03451734||metformin and lifestyle intervention for MetS|Participants who develop MetS at the last visit in sub-project 1 and sub-project 2 are recruited in this trial. Patients are randomized into low-dose metformin (1000 mg/d), high-dose metformin (1500 mg/d), low dose metformin plus lifestyle intervention group (1000 mg/d), high dose metformin plus lifestyle intervention (1500 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
16476837|NCT03451734||metformin and lifestyle prevention for high risk of MetS|Participants who are at a high risk of MetS are recruited in this trial. Participants are randomized into low dose metformin (750 mg/d), high dose metformin (1000 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
16476838|NCT03451734||validation cohort|in sub-project 2, there are1,800 first-episode schizophrenia patients recruited from 19 hospitals, and six groups as with sub-project 1. The assessments (timepoint and content) are conducted as in sub-project 1.
16476839|NCT03451721||ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology
~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
16476840|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
16476841|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
16476842|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
16476843|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
16476844|NCT03451695|Experimental|Morphine group|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
16476845|NCT03451695|Placebo Comparator|Placebo group|Placebo group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1 ml).
16476846|NCT03451682|Experimental|procyanidine group|
16476847|NCT03451682|No Intervention|Control group|
16476848|NCT03451669||Shunt suspected to be functioning|
16476849|NCT03451669||Shunt suspected to not be functioning|
16476850|NCT03451643|Experimental|Endoscopic Expandable Stent|Procedure/Surgery. Endeosocpically a self-expandable metal stent will be placed in the colon rectum. Chemotherapy will be added
16476851|NCT03451643|Active Comparator|Colorectal Resection|Procedure/Surgery. A standard open or laparoscopic surgery will be performed to remove the colorectal cancer. Chemotherapy will be added
16476852|NCT03451630|Active Comparator|High-Touch|Delivered primarily via face-to-face interactions, with telephonic interactions and information sharing that does not require access to mobile devices or the Internet. In-person support and/or telephonic interactions to occur at least four times over at least a four-month period.
16476853|NCT03451630|Active Comparator|High-Tech|Delivered via a remote care management platform and digital health tools. Remote care support interactions to occur for at least a four-month period.
16476854|NCT03451630|Active Comparator|Usual Care|Delivered via Health Plan support and resources within 14 days of an initial home or telephonic visit.
16476855|NCT03451617|Other|Xpedition stent delivery system|
16476856|NCT03451617|Other|Alpine stent delivery system|
16476857|NCT03451591|Active Comparator|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning & evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
16476858|NCT03451591|Active Comparator|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning & evening. Day 11-15 / 50mg daily morning dose & 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning & evening. Week 53 / 50mg twice daily morning & evening. Week 54 / NIL dose.
16476859|NCT03451591|Active Comparator|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning & evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning & 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning & evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning & evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning & evening. Week 54 / NIL dose
16476860|NCT03451591|Placebo Comparator|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
16476861|NCT03451578|Other|Advanced Dry macular degeneration|
16476925|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
16476862|NCT03451552|No Intervention|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
16476863|NCT03451552|Experimental|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
16476864|NCT03451526||Surgeries+adjuvant chemotherapies|Patients who received radical resection of lung cancer + adjuvant chemotherapies
16476865|NCT03451526||Perioperative chemotherapies|Patients who received perioperative chemotherapies
16476866|NCT03451513|Experimental|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
16476867|NCT03451513|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
16476868|NCT03451500|Experimental|Carbidopa-levodopa 2 tablets daily|carbidopa-levodopa 25-100 mg 2 tablets daily hs
16476869|NCT03451500|Experimental|carbidopa-levodopa 6 tablets daily|carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
16476870|NCT03451500|Placebo Comparator|Placebo|Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
16476871|NCT03451487|Placebo Comparator|Reference drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.
~Panadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
16476872|NCT03451487|Experimental|Test drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.
~SafeTynadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
16476873|NCT03451487|Placebo Comparator|Reference drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.
~Panadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
16476874|NCT03451487|Experimental|Test drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.
~SafeTynadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study"
16476876|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
16476877|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
16476878|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
16476879|NCT03451435|No Intervention|Control|No intervention will be administered in this group as it serves as a control group.
16476880|NCT03451435|Experimental|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
16476883|NCT03451409|Active Comparator|OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
16476884|NCT03451409|Active Comparator|OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
16476885|NCT03451409|Active Comparator|Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
16476886|NCT03451396|Active Comparator|Mild Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
16476887|NCT03451396|Active Comparator|Moderate to Severe Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
16476888|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
16476889|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
16476926|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
16476927|NCT03451071|Experimental|Gardasil9|
16476928|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
16476890|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
16476891|NCT03451344|Experimental|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
16476892|NCT03451344|Active Comparator|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
16476893|NCT03451331|Experimental|Arm A|Gemcitabine plus carboplatin plus nivolumab
16476894|NCT03451331|Experimental|Arm B|Gemcitabine plus oxaliplatin plus nivolumab
16476895|NCT03451318|Active Comparator|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
16476896|NCT03451318|Active Comparator|tonsillar adenoidectomy|tonsillar adenoidectomy
16476897|NCT03451318|Active Comparator|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
16476898|NCT03451318|Active Comparator|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
16476899|NCT03451305|Experimental|Pillow group|Before surgery, with the patient lying in the supine position, a soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position. 12 hours duration suggested from 11:00 pm 1 night before the surgery till next day.
16476900|NCT03451305|No Intervention|No pillow group|No intervention was given in this group before surgery.
16476901|NCT03451292|Experimental|Standard Medical Treatment + Albutein 20%|Standard Medical Treatment plus Albutein 20% administrations
16476902|NCT03451292|Active Comparator|Standard Medical Treatment|The sites will follow the Standard Medical Treatment as per their Standard of Care.
16476903|NCT03451266|Experimental|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
16476904|NCT03451266|Placebo Comparator|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
16476905|NCT03451253|Experimental|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
16476906|NCT03451253|Active Comparator|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
16476907|NCT03451240|Experimental|Intervention|
16476908|NCT03451227|Experimental|Dexmedetomidine Group|The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
16476909|NCT03451227|Active Comparator|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)
16476910|NCT03451214|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 11 mg/d and 25 mg supplemental zinc/d
16476911|NCT03451201|Experimental|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
16476912|NCT03451201|Active Comparator|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
16476913|NCT03451201|Other|Non-exercise|Sedentary Type 1 Diabetes Controls.
16476914|NCT03451162|Experimental|Dose Escalation Cohort: DHES0815A|Participants will receive DHES0815A in escalating doses in the dose-escalation cohort of the study. Participants will receive additional infusions of DHES0815A on Day 1 of subsequent cycles provided that they meet the protocol specified criteria for acceptable toxicity and ongoing clinical benefit.
16476915|NCT03451162|Experimental|Dose Expansion Cohort: DHES0815A|Participants will be treated at or below the Maximum Tolerated Dose (MTD) of DHES0815A (based on the review of the totality of the data) to obtain additional safety, tolerability, PK, and anti-tumor activity data.
16476916|NCT03451149|Experimental|Intervention|Undergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
16476917|NCT03451123|Experimental|FET-PET/MRI|O-(2-[F-18]FET)-L-tyrosine (FET) for brain PET/MRI
16476918|NCT03451110|Experimental|Part 1: Lemborexant plus Loestrin|Healthy female participants will receive a single oral dose of Loestrin 1.5/30 (containing ethinyl estradiol [EE] 0.030 milligrams [mg] and norethindrone [NE] 1.5 mg) in the evening of Day 1 after a fast of at least 3 hours. After a washout period of at least 4 days, participants will receive 10 mg lemborexant orally for 10 days. Lemborexant will continue to be administered in the evening on Days 15 through 18, followed by a single oral dose of Loestrin on Day 15 when administered with lemborexant after fasting in the evening for at least 3 hours.
16476919|NCT03451110|Experimental|Part 2: Lemborexant plus Famotidine|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. On Day 15, participants will receive a single oral dose of 40 mg famotidine, followed at least 2 hours later by a single dose of 10 mg lemborexant. After a washout period of up to 14 days participants will receive 10 mg lemborexant orally for 10 days.
16476920|NCT03451110|Experimental|Part 3: Lemborexant plus Fluconazole|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. After a washout interval of approximately 10 days, on Day 11, participants will be administered 400 mg fluconazole followed by 200 mg fluconazole once daily from Days 12 to 26. During this time a single dose of 10 mg lemborexant will be administered following an overnight fast of at least 10 hours along with fluconazole on Day 15 only.
16476929|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
16476930|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
16476931|NCT03451045|Experimental|Lenabasum 20 mg BID|
16476932|NCT03451045|Experimental|Lenabasum 5 mg BID|
16476933|NCT03451045|Placebo Comparator|Placebo BID|
16476934|NCT03451019|Active Comparator|sevelamer hydrochloride|the subject receive a single dose of 2,4 g
16476935|NCT03451019|Active Comparator|lanthanum carbonate|the subject receive a single dose of 1.0 g
16476938|NCT03450993|Experimental|Immediate SMART Program Intervention|Subjects will receive the SMART-3RP intervention following study enrollment.
16476939|NCT03450993|Other|Delayed SMART Program Intervention|Subjects will record symptoms following enrollment and receive the SMART-3RP intervention approximately 3 months following study enrollment.
16476940|NCT03450980|Other|EyeTurn App|All participants will have their eye alignment measured with both the experimental device (EyeTurn app) and the clinical gold standard tests or ground truth (simulated strabismus gaze angles).
16476941|NCT03450967|Experimental|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
16476942|NCT03450954||Case(AMT patients)|patients who have undergone amniotic membrane transplant in our unit up till 2016.
16476943|NCT03450954||Control(Patients without AMT)|bullous keratopathy patients awaiting endothelial keratoplasty
16476944|NCT03450928|Active Comparator|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
16476945|NCT03450928|Active Comparator|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
16476946|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
16476947|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
16476948|NCT03450902|Experimental|Chinese herb & acupuncture|Participants will take Yiqi Suoquan granule and receive acupuncture.
16476949|NCT03450902|Active Comparator|Chinese herb & sham acupuncture|Participants will take Yiqi Suoquan granule and receive sham acupuncture.
16476950|NCT03450902|Active Comparator|Placebo & acupuncture|Participants will take placebo granule and receive acupuncture.
16476951|NCT03450902|Placebo Comparator|Placebo & sham acupuncture|Participants will take placebo granule and receive sham acupuncture.
16476952|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
16476953|NCT03450876||Healthy Control|Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
16476954|NCT03450876||24 to < 36 months post-ipilimumab treatment|24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
16476955|NCT03450876||≥ 36 to < 48 months post-ipilimumab treatment|36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
16476956|NCT03450876||≥ 48 months post-ipilimumab treatment|Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
16476957|NCT03450863||Fast-acting insulin aspart|Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.
16476958|NCT03450850|Other|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
16476959|NCT03450837||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.
~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
16476960|NCT03450837||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.
~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
16476961|NCT03450837||Sedentary control|"This group were sedentary men without cardiovascular disease.
~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
16476962|NCT03450824||The study group|The participants with patellofemoral pain.
16476963|NCT03450824||The control group|The participants without patellofemoral pain.
16476964|NCT03450811|Active Comparator|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
16476965|NCT03450811|No Intervention|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
16476995|NCT03450564|Experimental|Male Involvement|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, model who allows his wife to use FP, religious leader, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
16477169|NCT03449368||Cohort 3|Includes age group 16-20 with a cap of 40 subjects. This is a retrospective, observational study.
16476966|NCT03450798|Active Comparator|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
16476967|NCT03450798|Sham Comparator|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
16476968|NCT03450772|Experimental|Creon® 25000 then Creon® 10000|Pancreatic enzyme
16476969|NCT03450772|Active Comparator|Creon® 10000 then Creon® 25000|Pancreatic enzyme
16476970|NCT03450759|Experimental|Treatment sequence 1|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate)"
16476971|NCT03450759|Experimental|Treatment sequence 2|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 oral suspension (reference)"
16476972|NCT03450759|Experimental|Treatment sequence 3|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule"
16476973|NCT03450759|Experimental|Treatment sequence 4|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate)"
16476974|NCT03450746||Healthy patients for orthopaedic surgery|Standard general anaesthesia and ventilation with FiO2 0.50 for at least 45 minutes following the standard settings in our department.
16476975|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
16476976|NCT03450733||Control (Group 2)|Control, non-implanted subjects
16476977|NCT03450720|Experimental|GLPG2737 single dose.|Single dose of GLPG2737 oral suspension.
16476978|NCT03450707|Experimental|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
16476979|NCT03450707|Placebo Comparator|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
16476980|NCT03450681|Placebo Comparator|No pulsed radiofrequency|Procedure consists of a mock incision at the pulsed radiofrequency needle insertion site and standard perioperative pain management by the pain clinic (femoral catheter and PCA)
16476981|NCT03450681|Experimental|Pulsed Radiofrequency|Procedure consists in pre-operative pulsed radiofrequency under ultrasound guidance of the saphenous nerve and standard postoperative pain management by the pain clinic (femoral catheter and PCA)
16476982|NCT03450668|Active Comparator|standard incubator|routinely used standard incubator already used in the neonatal unit
16476983|NCT03450668|Experimental|mOm incubator|new test incubator
16476984|NCT03450655|Experimental|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
16476985|NCT03450655|Experimental|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
16476986|NCT03450642||Observation|Patients presenting with right Iliac Fosse pain
16476987|NCT03450629|Experimental|Brimonidine Tartrate Ophthalmic Suspension|
16476988|NCT03450629|Active Comparator|Brimonidine Tartrate Ophthalmic Solution|
16476989|NCT03450616|Experimental|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
16476990|NCT03450616|Active Comparator|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
16476991|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
16476992|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
16476993|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
16476994|NCT03450564|Experimental|Women Education|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
16476996|NCT03450564|Other|Control group|The third arm in this community-based intervention was following the community without provision of male and married women education. In this arm, there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
16476997|NCT03450551|Experimental|Twin Block|61 patients will receive the Twin Block appliance (one of the three appliances being studied)
16476998|NCT03450551|Active Comparator|Herbst|61 patients will receive the Herbst appliance (one of the three appliances being studied)
16476999|NCT03450551|Active Comparator|Frog distalising appliance|61 patients will receive the Frog distalising appliance (one of the three appliances being studied)
16477000|NCT03450499|Experimental|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
16477001|NCT03450499|Placebo Comparator|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
16477002|NCT03450486|Experimental|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
16477003|NCT03450486|Active Comparator|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
16477004|NCT03450473|Other|SurgiMend® MP|Patients will not be randomized as this is a case series study involving the evaluation of only 1 type of mesh (SurgiMend MP®).
16477005|NCT03450460|Experimental|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
16477006|NCT03450460|No Intervention|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
16477007|NCT03450434|Experimental|XC8 2 mg|XC8 2mg orally
16477008|NCT03450434|Experimental|XC8 10 mg|XC8 10 mg orally
16477009|NCT03450434|Experimental|XC8 100 mg|XC8 100 mg orally
16477010|NCT03450434|Placebo Comparator|Placebo|Placebo 2 mg, 10 mg or 100 mg orally
16477011|NCT03450421|Experimental|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
16477012|NCT03450421|No Intervention|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
16477013|NCT03450408|Active Comparator|Placement with gloved hand|The Foley bulb transcervical dilator will be placed blindly with a gloved hand.
16477014|NCT03450408|Active Comparator|Placement with sterile speculum|The cervix will be directly visualized using a sterile speculum, and an instrument will be used to advance the Foley bulb transcervical dilator into the cervical os.
16477015|NCT03450395|Placebo Comparator|Cereal - Cream of Rice|40 g cream of rice
16477016|NCT03450395|Experimental|Cereal - Oats containing beta-glucan|40 g oats
16477017|NCT03450382|Experimental|Hans Kai Participant|Participants receiving Hans Kai intervention
16477018|NCT03450382|No Intervention|Control|Participants not enrolled in Hans Kai
16477019|NCT03450369|Experimental|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.
~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
16477020|NCT03450343|Experimental|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
16477021|NCT03450330|Experimental|daily dose of AZD4205|daily dose of AZD4205
16477022|NCT03450317|Experimental|Aspirin|Aspirin 80mg once daily
16477023|NCT03450317|No Intervention|Non-treatment group|No intervention
16477024|NCT03450291|Experimental|Recovered from anorexia nervosa|Those who have a past diagnosis of AN (defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria) but are currently recovered, as shown by BMI over 18.5 throughout the last 12 months (self-report and current weight measured). Defined as either 'fully recovered'and: score must be within the 'normal range' of the Eating Disorders Examination Questionnaire (EDE-Q) global mean scores for young women, below 20 on the EAT-26 and below 16 on the Clinical Impairment Assessment for Eating Disorders (CIA); or partially recovered where one or more of these scores may be above the above-mentioned cutoffs.
16477025|NCT03450291|Experimental|High scoring on the EAT-26|Those who score above 20 on the EAT-26, but who do not declare a former diagnosis of an eating disorder (though they may meet criteria for a current diagnosis during the Structured Clinical Interview for the DSM-5).
16477026|NCT03450291|Experimental|Healthy controls|No history of or current diagnosis of any psychiatric disorder (especially eating disorders) which could impact study results.
16477027|NCT03450278|No Intervention|control|canine retraction without any means of acceleration.
16477028|NCT03450278|Experimental|micro-osteoperforation|canine retraction accelerated with micro-osteoperforation
16477029|NCT03450265|Experimental|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
16477030|NCT03450265|Active Comparator|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
16477031|NCT03450252|Experimental|Active pacing|Active ventricular pacing. The pacemaker is set-up with a short atrio-ventricular delay to allow for appropriate pacing capture of the ventricle.
16477032|NCT03450252|Sham Comparator|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
16477033|NCT03450239|Experimental|Recovered from anorexia nervosa|Women who have recovered from Anorexia Nervosa for over a year. BMI over 18.5, aged 18-40, scores on Eating Disorder Examination (EDE) within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
16477034|NCT03450239|Experimental|Healthy controls|Healthy control women. BMI over 18.5, aged 18-40, scores on EDE within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
16477035|NCT03450226|Experimental|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
16477036|NCT03450226|No Intervention|control|patients will be controlled
16477037|NCT03450213|Active Comparator|Patients with keratoconus|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
16477038|NCT03450213|Placebo Comparator|Normal people at the same age and sex|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
16477039|NCT03450200|Experimental|Exercises Group|three times daily exercises of hands and fingers exercises and foot exercises which last for 10 minutes in eight weeks, and health education about diabetic foot care
16477040|NCT03450200|Other|Control Group|health education about diabetic foot care
16477041|NCT03450187|Active Comparator|Cohort A|50 mg TP-271 q24 (n=6), a novel, broad-spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
16477042|NCT03450187|Active Comparator|Cohort B|100 mg TLP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
16477043|NCT03450187|Active Comparator|Cohort C|200 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
16477044|NCT03450187|Active Comparator|Cohort D|300 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
16477045|NCT03450187|Active Comparator|Cohort E|400 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
16477046|NCT03450174|Placebo Comparator|Control|this group, only placebo product will be given
16477047|NCT03450174|Experimental|Formative messages|this group will be received only daily formative messages on diet diversity, healthy and best nutrition practices
16477048|NCT03450174|Experimental|Fortified product|this group will be received only fortified product on alternate day up to 6 months
16477049|NCT03450174|Experimental|Fortified product plus|this group will receive fortified product along with daily messages on diet diversity and healthy nutrition practices
16477050|NCT03450161|Experimental|High-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 20 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.
~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
16477051|NCT03450161|Experimental|Low-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 3 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.
~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
16477052|NCT03450161|Experimental|Continuous Dose of Fentanyl|"5 minutes prior to sternotomy, patients will receive a NaCl 0.9% bolus (placebo) and a perfusion pump with fentanyl (verum) will be begun according to the Shibutani dosing scheme.
~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
16477053|NCT03450148|Experimental|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
16477054|NCT03450148|Placebo Comparator|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
16477055|NCT03450135||Mid-pubertal girls|Adolescent girls (ages 11-14) who are undergoing a healthy pubertal transition (Tanner developmental stage 3 or 4) will perform Trier Social Stress Test and Emotional go/no-go task.
16477056|NCT03450122|Experimental|Cohort 0 (cyclophosphamide, T cells, aldesleukin)|Participants receive cyclophosphamide IV over 30-60 minutes on day -2 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV over 60 minutes on day 0. Then, 6 hours later and twice a day for 14 days, receive aldesleukin SC in the absence of disease progression or unacceptable toxicity.
16477057|NCT03450122|Experimental|Cohort 1 (cyclophosphamide, T cells, aldesleukin, LV305)|Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes, and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 ID on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
16477058|NCT03450109|Experimental|LY01005|One LY01005 3.6 mg gluteal IM injection.
16477059|NCT03450109|Active Comparator|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
16477062|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
16477063|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
16477064|NCT03450070|Experimental|Test Panel|Light Therapy Mask Cream
16477065|NCT03450057|Experimental|Daratumumab + Dexamethasone|"Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
~Dexamethasone 40 mg (20 mg for patients>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle"
16477066|NCT03450044|Experimental|Vaccinated|Transfer of autologous dendritic cells interspersed with chemotherapy doses
16477067|NCT03450044|No Intervention|Control|Control patients who follow their basic treatment with chemotherapy with the A/C scheme
16477068|NCT03450031|Experimental|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
16477069|NCT03450031|Experimental|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
16477070|NCT03450018|Experimental|SLC-0111 + Gemcitabine|"Dose Level 1 - SLC-0111 (500 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)
~Dose Level 2 - SLC-0111 (750 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)
~Dose Level 3 - SLC-0111 (1000 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)"
16477071|NCT03450005||emerging Candida isolates|Web-based registry of invasive infections by Candida species
16477072|NCT03449992|Experimental|Intervention group|Participants in this group ingested nitrate-rich beetroot juice for 15 days
16477073|NCT03449992|Placebo Comparator|Placebo group|Participants in this group ingested a placebo drink for 15 days
16477074|NCT03449979|Experimental|alpha stimulation in participants in a depressive episode|Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
16477075|NCT03449979|Placebo Comparator|sham stimulation in participants in a depressive episode|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.
16477076|NCT03449979|Experimental|alpha stimulation in healthy participants|Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
16477077|NCT03449979|Placebo Comparator|sham stimulation in healthy participants|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.
16477078|NCT03449966|Experimental|Target biopsy under pCLE|(Cellvisio® with confocal minoprobe™, Mauna Kea Technologies, France)
16477079|NCT03449966|Active Comparator|Random biopsy at cancer lesion under WLE|WLE (GIF-HQ290, Olympus, Japan) group
16477080|NCT03449940|Active Comparator|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.
~1g Ceftriaxone IV was given.
~Incision-- Subcoronal, circumferential & degloving.
~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.
~All patients were discharged from hospital within 24 hours."
16477081|NCT03449940|Active Comparator|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.
~In an ambulatory setting, surgery was done 7 - 10 days later.
~1g Ceftriaxone IV was given.
~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.
~Incision--- 2 - 3cm localized incision over the site of the rolling sign.
~Repair--- Continuous technique with inverted knots using 3-0 polyglactin suture."
16477082|NCT03449927|Active Comparator|Control Arm: Regular menu|"Calorie count initiated on day +1 of transplant and ending upon count recovery
~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)
~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea
~Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
16477083|NCT03449927|Experimental|Intervention Arm: Specialized Menu|"Calorie count and tool provided on day +1 and ending upon count recovery
~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)
~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea
~Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
16477084|NCT03449901|Experimental|Cohort 1: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.
~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level
~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.
~Treatment may continue for up to 34 cycles (103 weeks)"
16477085|NCT03449901|Experimental|Cohort 2: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.
~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level
~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.
~Treatment may continue for up to 34 cycles (103 weeks)"
16477086|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
16477087|NCT03449862|Experimental|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
16477168|NCT03449368||Cohort 2|Includes age group 11-15 with a cap of 50 subjects. This is a retrospective, observational study.
16477088|NCT03449862|Active Comparator|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
16477089|NCT03449849|Other|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
16477090|NCT03449849|Other|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
16477091|NCT03449836|Experimental|Streptococcus salivarius 24SMBc + Strept.oralis 89a|spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
16477092|NCT03449836|Active Comparator|fluticasone + mometasone|spray with fluticasone and mometasone
16477093|NCT03449836|Placebo Comparator|placebo|spray with isotonic solution
16477094|NCT03449823||TTTS Cases|Cases of monochorionic / diamniotic twin pregnancies diagnosed with twin-twin transfusion syndrome.
16477095|NCT03449823||MCDA Controls|Controls of monochorionic / diamniotic twin pregnancies without a diagnosis of twin-twin transfusion syndrome.
16477096|NCT03449810|Experimental|DSE plus MET (group A)|"The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.
~The MET procedure will involve a total of 5-10 contralateral isometric voluntary contractions that will be resisted by force equal to the participant's for 30 seconds with 5 seconds rest between contractions (corresponding to 20-30%)."
16477097|NCT03449810|Active Comparator|DSE only (group B)|The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.
16477098|NCT03449810|Active Comparator|Standard Physiotherapy Treatment (group C)|This group will involve classical massage, therapeutic exercises (strengthening spinal and abdominal muscles) and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region. The participants will be asked to perform the therapeutic exercises once a day at home.
16477099|NCT03449797|Sham Comparator|Group A|AAVS performed with no intraprocedural rapid cortisol assay
16477100|NCT03449797|Experimental|Group B|AVS performed plus intraprocedural rapid cortisol assay
16477101|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
16477102|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
16477103|NCT03449771|Experimental|Single Arm|To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.
16477104|NCT03449758|Experimental|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
16477105|NCT03449732|Experimental|PDR measurement group A|Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)
16477106|NCT03449732|Experimental|PDR measurement group B|Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)
16477107|NCT03449732|Experimental|PDR measurement group C|Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)
16477108|NCT03449719|Active Comparator|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
16477109|NCT03449719|Experimental|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.
~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.
~Considering an Alfa/beta of 3, a BED3 > 100 Gy is recommended"
16477110|NCT03449693|Experimental|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
16477111|NCT03449693|No Intervention|No Supplement|No Intervention
16477114|NCT03449667|Active Comparator|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
16477115|NCT03449667|Sham Comparator|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
16477116|NCT03449654|Other|Liraglutide|
16477117|NCT03449654|Other|placebo|
16477118|NCT03449641|Other|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
16477119|NCT03449628|Experimental|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)
~1 capsule, b.i.d. for 12 weeks"
16477120|NCT03449628|Placebo Comparator|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.
~1 capsule, b.i.d. for 12 weeks"
16477202|NCT03449199|Experimental|TMX-049 dose 2|
16477121|NCT03449602|Experimental|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
16477122|NCT03449602|Active Comparator|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
16477123|NCT03449589||Smokers|RA patients currently smoking
16477124|NCT03449589||Former smokers|RA patients who previously smoked
16477125|NCT03449589||Non smokers|Non smoking RA patients
16477126|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
16477127|NCT03449576|Active Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
16477128|NCT03449563|Placebo Comparator|Placebo group (group G)|
16477129|NCT03449563|Active Comparator|Ultrasound-guided TPVB group (group U)|
16477130|NCT03449563|Experimental|open TPVB group(group E)|
16477131|NCT03449550|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
16477132|NCT03449550|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
16477133|NCT03449537|Experimental|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
16477134|NCT03449537|Active Comparator|AAF|hypoallergenic formula based on amino acid-based formula
16477135|NCT03449524|Active Comparator|75mg CXA-10|Once daily dosing of 75mg CXA-10 in the morning
16477136|NCT03449524|Active Comparator|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
16477137|NCT03449524|Placebo Comparator|Placebo|Once daily dosing in the morning
16477138|NCT03449511|Active Comparator|Ginger aromatherapy|Ginger essential oil (GIN-106) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
16477139|NCT03449511|Active Comparator|Orange aromatherpy|Orange essential oil (ORG-114) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
16477140|NCT03449511|Active Comparator|Lavender aromatherapy|Lavender essential oil (LAV-110) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
16477141|NCT03449511|Placebo Comparator|Jojoba aromatherapy|"Jojoba oil in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles. One drop of jojoba oil is on the other three aromatherapy inhalers. Jojoba oil is a carreir oil for essential oils which will be used as a comparator and placebo in this study."
16477142|NCT03449498|Experimental|study group|Intensive qualitative functional therapy
16477143|NCT03449498|Experimental|control group|Intensive functional therapy
16477144|NCT03449459|Experimental|oral probiotics|
16477145|NCT03449459|Experimental|aerosol inhaled amikacin|
16477146|NCT03449459|Experimental|combined vaccination|
16477147|NCT03449459|No Intervention|conventional therapy (blank control)|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.
16477148|NCT03449446|Experimental|Selonsertib (SEL)|Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
16477149|NCT03449446|Experimental|Firsocostat (FIR)|Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
16477150|NCT03449446|Experimental|Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
16477151|NCT03449446|Experimental|Selonsertib (SEL) + Firsocostat (FIR)|Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
16477152|NCT03449446|Experimental|Selonsertib (SEL) + Cilofexor (CILO)|Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
16477153|NCT03449446|Experimental|Firsocostat (FIR) + Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
16477154|NCT03449446|Experimental|Placebo|Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
16477155|NCT03449433|Experimental|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
16477156|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
16477157|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
16477158|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
16477159|NCT03449433|No Intervention|Healthy Participants|Healthy participants who received no study drug.
16477160|NCT03449420||Post Partum Hemorrhage|Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge
16477161|NCT03449394|Active Comparator|Delusions (Tx)|
16477162|NCT03449394|No Intervention|Delusions (TAU)|
16477163|NCT03449394|Active Comparator|Depression (Tx)|
16477164|NCT03449394|No Intervention|Depression (TAU)|
16477167|NCT03449368||Cohort 1|Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.
16477170|NCT03449368||Cohort 4|Includes age group 21-30 with a cap of 40 subjects. This is a retrospective, observational study.
16477171|NCT03449368||Cohort 5|Includes age group 31-40 with a cap at 40 subjects. This is a retrospective, observational study.
16477172|NCT03449368||Cohort 6|Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
16477173|NCT03449368||Cohort 7|Includes age group 51-70 with a cap at 40 subjects. This is a retrospective, observational study.
16477174|NCT03449355||vaginal group|
16477175|NCT03449355||cesarean section group|
16477176|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
16477177|NCT03449329|Placebo Comparator|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
16477178|NCT03449329|Active Comparator|Locoregional SIP block|"This group will receive a SIP block using:
~3mg/kg Ropivacain 1%
~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
16477179|NCT03449316|Experimental|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
16477180|NCT03449316|No Intervention|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.
~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
16477181|NCT03449303|Active Comparator|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
16477182|NCT03449303|Placebo Comparator|Placebo|Simmondsia chinensis
16477183|NCT03449290|Experimental|Kinesio taping group|Kinesio taping was applied on trunk muscles
16477184|NCT03449290|Sham Comparator|Control group|Sham Kinesio taping was applied on trunk muscles
16477185|NCT03449277|Active Comparator|take oral nifedipine tablets|Women who take the oral tablets of nifedipine till discharge of hospital
16477186|NCT03449277|Active Comparator|take oral labetalol tablets|Women who take the oral tablets of labetalol till discharge of hospital
16477187|NCT03449264|Experimental|Biological collection|"samples of different natures:
~Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.
~Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
~In parallel to this biological collection, standardized clinical data will be entered into a database"
16477188|NCT03449251|Experimental|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
16477189|NCT03449251|Experimental|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
16477190|NCT03449251|Experimental|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
16477191|NCT03449251|Experimental|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
16477192|NCT03449251|Experimental|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
16477193|NCT03449251|Experimental|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
16477194|NCT03449251|Experimental|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
16477195|NCT03449238|Other|pembrolizumab and SRS|Pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
16477196|NCT03449225|No Intervention|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
16477197|NCT03449225|Experimental|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
16477198|NCT03449212||SOD1 ALS|
16477199|NCT03449212||Sporadic ALS|
16477200|NCT03449212||Asymptomatic SOD1 gene carriers|
16477201|NCT03449199|Experimental|TMX-049 dose 1|
16477204|NCT03449186||Pregnancy group|Women, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
16477205|NCT03449186||Postpartum group|Postpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
16477206|NCT03449173|Experimental|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
16477207|NCT03449160|Active Comparator|Physical Therapy|Receive standard physical therapy
16477208|NCT03449160|Experimental|posture training device|Receive a posture training device in addition to standard physical therapy
16477209|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.
16477210|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.
16477211|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.
16477212|NCT03449134|Placebo Comparator|Placebo|Participants receive dose-matched placebo tablets twice daily (BID) during the 12-week main study period and 40-week extension period.
16477213|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants receive a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 12-week main study period and 40-week extension period.
16477214|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants receive a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 12-week main study period and 40-week extension period.
16477215|NCT03449121|Experimental|Slow breathing|Slow breathing techniques with exhale greater than inhale
16477216|NCT03449108|Experimental|ICI Ovarian Cancer and Sarcomas (LN-145-S1, nivolumab)|Ipilimumab will be administered as a single dose prior to tumor resection. Nivolumab will be administered once prior to tumor resection. Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, LN-145-S1 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses. Within 12 weeks after receiving LN-145-S1, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks and continued until unacceptable toxicity, progression, or start of another cancer therapy.
16477217|NCT03449108|Experimental|Ovarian Cancer and Sarcomas (LN-145-S1)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, LN-145-S1 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses.
16477218|NCT03449108|Experimental|Thyroid Cohort (LN-145)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, autologous tumor infiltrating lymphocytes LN-145 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses.
16477219|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
16477220|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
16477221|NCT03449082|Experimental|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
16477222|NCT03449082|Experimental|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
16477223|NCT03449082|Placebo Comparator|Placebo Comparator (Fibrin) group|Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
16477224|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
16477225|NCT03449056|Experimental|TREATMENT|salbutamol nebulization
16477226|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
16477227|NCT03449030|Experimental|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
16477228|NCT03449030|Experimental|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
16477229|NCT03449017|Experimental|E-cig use condition|Participants self-administer their own electronic cigarette device
16477230|NCT03448978|Experimental|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
16477231|NCT03448939|Experimental|S5G4T-1|topical cream
16477232|NCT03448939|Placebo Comparator|S5G4T-2|topical cream
16477233|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
16477234|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
16477235|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
16477272|NCT03448575|Sham Comparator|Control - Medication Alert Only|The control arm medication alert is a simple text pop-up in the EMR that will inform the prescriber of Choosing Wisely® recommendations developed the American Psychiatric Association regarding antipsychotic medication use in children and adolescents.
16477236|NCT03448900|Experimental|Multicomponent intervention|The intervention group consisted in face-to-face 50-minute meeting [motivational interviewing (MI)]; online self-help material focused on: (1) decisions; (2) moods; (3) social life; (4) smoking health effects; and (5) quitting; e-mail 15 days before the MI, group therapy 2 months after the MI (60 minutes), a second follow-up visit 4 months after the MI (20 minutes).
16477237|NCT03448900|Active Comparator|Brief advice|The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
16477238|NCT03448887|Experimental|Study group|Extended HD with MCO dialyzer
16477239|NCT03448887|Active Comparator|Control group|Online hemodiafiltration
16477240|NCT03448874|Experimental|Seal-G MIST System|Seal-G MIST System is a surgical sealant that will be applied adjunctively to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
16477241|NCT03448874|No Intervention|Standard of care|Patients in the control arm will receive the standard of care [SOC] for colorectal resection surgery with primary anastomosis (no additional intervention)
16477242|NCT03448861|Experimental|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
16477243|NCT03448848|Experimental|study|
16477244|NCT03448848|Placebo Comparator|control|
16477245|NCT03448835|Experimental|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
16477246|NCT03448822||sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure.
16477247|NCT03448809|Experimental|MMM (Mind My Mind training)|Mind My Mind training
16477248|NCT03448809|Active Comparator|TAU (Treatment as Usual)|Treatment as Usual
16477249|NCT03448796|Active Comparator|HTO-group|Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
16477250|NCT03448796|Active Comparator|FT -group|Group receives only supervised physiotherapeutic rehabilitation.
16477251|NCT03448770|Active Comparator|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
16477252|NCT03448770|Experimental|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
16477253|NCT03448757|Experimental|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.
~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.
~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
16477254|NCT03448744|Experimental|combiantion therapy group|thymosin alpha 1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
16477255|NCT03448744|Placebo Comparator|entecavir group|ETV (0.5 mg orally, daily) at least for 72 weeks
16477256|NCT03448731|Experimental|Doxycycline|Doxycycline 50 mg p.o. daily during 6 weeks
16477257|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
16477258|NCT03448705|Experimental|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
16477259|NCT03448705|Experimental|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
16477260|NCT03448705|Active Comparator|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
16477261|NCT03448692|Experimental|PF-06730512 Cohort 1|Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
16477262|NCT03448692|Experimental|PF-06730512 Cohort 2|Subjects in cohort 2 will receive dose 2 IV infusion.
16477263|NCT03448666|Experimental|pembrolizumab and elettrochemiotherapy|drug: Pembrolizumab 200 mg flat dose every three weeks procedure: elettrochemiotherapy once after first pembrolizumab dose
16477264|NCT03448653|Experimental|Colonoscopy with NBI|
16477265|NCT03448627||Group 1: HSCT recipients|Pulmonary functions [spirometry], maximal exercise capacity [Modified-Incremental Shuttle Walk Test (ISWT)], inspiratory and expiratory muscle strength (MIP and MEP, respectively) [mouth pressure device] and peripheral muscle strength [hand-held dynamometer] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of Modified-ISWT.
16477266|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
16477267|NCT03448601|No Intervention|Non-tailored control group|Participates will read the standard Alzheimer's disease and Precision Medicine brochure with standard text-based content NOT specifically tailored for AI/ANs.
16477268|NCT03448601|Experimental|Culturally tailored video intervention group|Participants will view a short 5-minute culturally-tailored video.
16477269|NCT03448601|Experimental|Culturally tailored brochure intervention group|Participants will read a culturally-tailored educational brochure on Alzheimer's disease and Precision Medicine.
16477270|NCT03448588||group with normal T4 level or T4/T3|participants with T4 within 4.3-12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ≤7.52, which are considered to be normal T4 level and T4/T3.
16477271|NCT03448588||group with elevated T4 level or T4/T3|participants with T4 more than 12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) > 7.52, which are considered to be elevated T4 level and T4/T3.
16480018|NCT03429972|Other|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
16477273|NCT03448575|Experimental|Intervention - Alert + CAP Review AND Enhanced BH Access|"The intervention alert prompts the prescriber to keep/remove the antipsychotic order, and/or order any study services: behavioral health navigation, expedited psychotherapy access, virtual consult with a child and adolescent psychiatrist (CAP). Passive case review by the study CAP will occur for all intervention arm cases. A virtual consult will be scheduled if the prescriber ordered it or the CAP needs to discuss the case. The CAP will provide the prescriber with a written summary of his/her review.
~Following review by the CAP, a navigator reaches out to the eligible intervention arm patient/family to offer extra support. The navigator's role is to (a) provide extra support to facilitate access and engagement in appropriate psychosocial therapies; (b) coordinate short-duration bridging therapy sessions for teens/families not engaged in psychotherapy, when appropriate; and (c) keep the prescriber informed of any clinically relevant updates."
16477274|NCT03448562|Experimental|Study Group|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR)
16477275|NCT03448562|Active Comparator|Control Group|CPVI alone
16477276|NCT03448549|Experimental|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
16477277|NCT03448549|Active Comparator|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
16477278|NCT03448536|Experimental|Naproxen Sodium : Acetaminophen|Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2
16477279|NCT03448536|Experimental|Acetaminophen : Naproxen Sodium|Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2
16477280|NCT03448523|Experimental|Right To Play's Positive Child and Youth Development program|Behavioural intervention
16477281|NCT03448523|No Intervention|Control|No intervention; intervention to be offered after end line assessment
16477282|NCT03448510|Experimental|Irreversible electroporation treatment|Subjects will receive irreversible electroporation of the prostate
16477283|NCT03448510|Active Comparator|standard medication group|Subjects will receive either α-blocker or 5α reductase monotherapy or combination therapy.
16477284|NCT03448497||Advanced Melanoma patients who intiated first-line therapy|patients who initiated any first-line therapy for advanced melanoma and had not previously received treatment for their advanced disease
16477285|NCT03448484|Experimental|Intervention|Intervention (agriculture-focused package + nutrition-sensitive and nutrition-specific interventions=integrated package)
16477286|NCT03448484|Other|Control|Control (agriculture-focused package)
16477287|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
16477288|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
16477289|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
16477290|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
16477291|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
16477292|NCT03448419|Experimental|Empagliflozin|
16477293|NCT03448419|Placebo Comparator|Placebo|
16477294|NCT03448406|Experimental|Empagliflozin|
16477295|NCT03448406|Active Comparator|Placebo|
16477296|NCT03448393|Experimental|Dose escalation|CD19/CD22-CAR-transduced T cells at escalating doses
16477297|NCT03448393|Experimental|Dose expansion|CD19/CD22-CAR-transduced T cells at MTD or highest dose administered
16477298|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
16477299|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
16477300|NCT03448354|Experimental|NAC-IDS-HIPEC|Under the clinicians' decision, HIPEC procedures will be performed at the time of IDS.
16477301|NCT03448354|No Intervention|NAC-IDS|Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS.
16477302|NCT03448328|Experimental|Pea Protein|NUTRALYS pea protein supplement
16477303|NCT03448328|Experimental|Whey Protein|Whey protein supplement
16477304|NCT03448328|Active Comparator|Apple juice|Apple juice
16477305|NCT03448315|Active Comparator|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
16477306|NCT03448315|Sham Comparator|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
16477307|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
16477308|NCT03448289|No Intervention|Control|This group will not receive the RLPT.
16477309|NCT03448289|Experimental|Intervention|This group will receive the RLPT.
16477310|NCT03448276|Experimental|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
16477311|NCT03448276|Active Comparator|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
16477312|NCT03448263|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
16477313|NCT03448263|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
16477314|NCT03448263|Experimental|Reciproc instruments|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
16477315|NCT03448250|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
16477316|NCT03448250|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
16477317|NCT03448237|Active Comparator|Speech therapy|Speech therapy adapted to the child,
16477318|NCT03448237|Experimental|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
16477319|NCT03448224|Experimental|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
16477320|NCT03448224|Active Comparator|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
16477321|NCT03448211|Experimental|Para-toluenesulfonamide Injection (PTS)|Investigational product
16477322|NCT03448198|Other|Knee arthritis|Total knee replacement
16477323|NCT03448185|Placebo Comparator|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
16477324|NCT03448185|Experimental|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
16477325|NCT03448185|Active Comparator|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
16477326|NCT03448185|Active Comparator|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
16477327|NCT03448172|Experimental|Investigational Product|[14C]PF-05221304
16477328|NCT03448159|Experimental|Fluoxetine Hydrochloride|Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).
16477329|NCT03448159|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks)."
16477330|NCT03448146|Experimental|Para-Toluenesulfonamide|".The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.
~. In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.
~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
16477331|NCT03448133|Experimental|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
16477332|NCT03448133|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
16477333|NCT03448120|No Intervention|Control Group|The volunteers who will remain in prolonged rest (10 minutes for homeostasis plus 30 minutes of no intervention).
16477334|NCT03448120|Experimental|Acupuncture Group|The volunteers will receive six needles in six acupoints in the non-dominant upper limb for 30 minutes.
16477335|NCT03448120|Experimental|Dry needling Group|The volunteers will receive application of six needles arranged in the non-dominant biceps brachialis for 30 minutes.
16477336|NCT03448107|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
16477337|NCT03448107|Active Comparator|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
16477338|NCT03448094|Experimental|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
16477339|NCT03448094|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
16477340|NCT03448081|Active Comparator|SNA-120 + Calcipotriene|
16477341|NCT03448081|Placebo Comparator|Placebo + Calcipotriene|
16477342|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.
~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.
~Ketamine infusion will not be titrated.
~Remaining care will be identical to standard therapy group."
16477379|NCT03447834|Experimental|Selective intracoronary hypothermia + PPCI|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation myocardial infarction with total ST-segment deviation of at least 5 mm. If the patient has TIMI grade flow 0 or 1, the experimental arm will be treated by selective intracoronary hypothermia just before and after reperfusion, in addition to routine PPCI.
16477380|NCT03447834|Other|Standard PPCI|The control group will receive routine PPCI.
16477343|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)
~Pre-op dexamethasone
~Pre-op midazolam at discretion of anesthesiologist
~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.
~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.
~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.
~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac
~Other post-op care as per usual surgical routine"
16477344|NCT03448055|Other|Interventional|Immunocal 20gm daily
16477345|NCT03448042|Experimental|Dose Escalation|Participants will be assigned sequentially to escalating doses of BTRC4017A, up to the maximum tolerated dose (MTD).
16477346|NCT03448042|Experimental|Dose Expansion|Participants will receive BTRC4017A based on the MTD or maximum allowed dose (MAD) identified during dose escalation.
16477347|NCT03448029||Endovascular Patients|Patients undergoing endovascular interventions for symptomatic PAD
16477348|NCT03448016|Experimental|Alcohol use disorders|[C-11]NOP-1A PET Scan
16477349|NCT03448016|Experimental|Controls|[C-11]NOP-1A PET Scan
16477350|NCT03448003|Experimental|Group I (IO prevention program)|Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
16477351|NCT03448003|Active Comparator|Group II (no intervention)|Patients receive no intervention. After 26 weeks, patients may crossover to Group I.
16477352|NCT03447990|Other|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo
~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
16477353|NCT03447990|Other|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo
~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
16477354|NCT03447977|Experimental|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
16477355|NCT03447977|Experimental|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
16477356|NCT03447977|Experimental|exercise group|exercises, 2 session for 6 weeks
16477357|NCT03447964||Type 1 diabetes|dosing of sphingolipids
16477358|NCT03447964||Type 2 diabetes|Dosing of sphingolipids
16477359|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 20%TTV|Group 1: total dose = 20% total tumor volume
16477360|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 30%TTV|Group 2: total dose = 30% total tumor volume
16477361|NCT03447938|Active Comparator|CABG with sternotomy|Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).
16477362|NCT03447938|Experimental|Minimally-invasive CABG|Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.
16477363|NCT03447925|Experimental|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
16477364|NCT03447925|Experimental|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
16477365|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
16477366|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
16477367|NCT03447899|Experimental|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
16477368|NCT03447899|No Intervention|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
16477369|NCT03447886||Quality Of Life|"This study uses qualitative research methods, specifically semi-structured interviews.
~This will include moderator guide development,
~Phone interviews with breast cancer survivors will be conducted
~Qualitative data analysis of the phone interviews will be conducted"
16477370|NCT03447873|Active Comparator|Triple therapy|To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
16477371|NCT03447873|Experimental|Switch to dual therapy A|Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
16477372|NCT03447873|Experimental|Switch to dual therapy B|Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
16477373|NCT03447860|Active Comparator|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress.
16477374|NCT03447860|Experimental|PAACC|A mindfulness-based multi-component caregiver intervention to reduce caregiver stress.
16477375|NCT03447847|Experimental|Phase 1|A=oligomineral water, B=oligomineral water
16477376|NCT03447847|Experimental|Phase 2|A=oligomineral water, B=bicarbonate-rich water
16477377|NCT03447847|Experimental|Phase 3|A=bicarbonate-rich water, B=oligomineral water
16477378|NCT03447847|Experimental|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
16477381|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
16480602|NCT03425968||Knee hyperextension group|athletes who has knee hyperextension
16477382|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
16477383|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
16477384|NCT03447808|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16477385|NCT03447795|Experimental|autogenous tooth grafted sites|
16477386|NCT03447795|Active Comparator|autogenous demineralised dentin grafted sites|
16477387|NCT03447782|Experimental|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).
~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
16477390|NCT03447756|Experimental|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
16477391|NCT03447756|Placebo Comparator|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
16477392|NCT03447743|Other|XR-NTX services as usual|60 participants will receive on-going XR-NTX injections in a local community clinic
16477393|NCT03447730|Experimental|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
16477394|NCT03447730|Experimental|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10^11 CFU TID given immediately after meals from Days 1 through 6.
16477395|NCT03447730|Placebo Comparator|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
16477396|NCT03447717|Experimental|ActiGait|Patients who get the ActiGait implant
16477397|NCT03447704|Experimental|BCD-085 (netakimab)|
16477398|NCT03447704|Placebo Comparator|Placebo|
16477399|NCT03447691|Experimental|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min
~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
16477400|NCT03447691|Active Comparator|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.
~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
16477401|NCT03447678|Experimental|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
16477402|NCT03447665|No Intervention|Control|Infant sleep monitoring and parental surveys only
16477403|NCT03447665|Experimental|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
16477404|NCT03447665|Experimental|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
16477405|NCT03447652|No Intervention|Control Group|Each patient in the control group did not perform any rehabilitation exercises. Over the intervention time frame, the patient was required to check in with a member of the research team each week to discuss any changes in their ankle or report any injury incidence.
16477406|NCT03447652|Experimental|Resistance Band Group|Each session, patients completed resistance training using a resistance band in 4 directions of ankle motion (plantarflexion, dorsiflexion, inversion and eversion). Patients would complete 3 sets of 10 repetitions during each session. Every 3 sessions, the band resistance would increase.
16477407|NCT03447652|Experimental|Biomechanical Ankle Platform System|The Biomechanical Ankle Platform System board is an oval shaped board that utilizes a half-sphere on the bottom of the board to allow the patient to train on an unstable surface. A one legged stance on their involved limb was performed on the Biomechanical Ankle Platform System board while clockwise and counterclockwise circles were completed. The initial rotation of direction was selected by the patient and changed every 10 seconds of the 40-second trial. Five 40-second trials were completed with 1-minute rest intervals in between the trials. Progression was determined by the supervising clinician and was based on the patient's ability to make smooth transitions between direction changes and completion of smooth circular rotations in both directions.
16477408|NCT03447652|Experimental|Combination Group|Patients completing the combination protocol completed both the resistance band and Biomechanical Ankle Platform System board protocols during each session. The order of exercise completion was counterbalanced for each session.
16477495|NCT03447106|Experimental|Robotic|
16477409|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
16477410|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
16477411|NCT03447626||Prospective Group- Robotic UKA Arm|Robotic UKA with the MAKO machine.
16477412|NCT03447626||Control- Fixed and Mobile UKA Arm|Patients who have received fixed or mobile bearing UKA
16477413|NCT03447626||Control-Total Knee Arthroplasty|Patients who have had cemented or cementless total knee arthroplasty
16477414|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
16477415|NCT03447600|Experimental|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at >/=5% weight loss which is an average of 12 weeks.
16477416|NCT03447600|Active Comparator|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at >/=5% weight loss which is an average of 12 weeks.
16477417|NCT03447587|Experimental|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
16477418|NCT03447587|Placebo Comparator|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
16477419|NCT03447574|Experimental|Aim 1|The ethanol dilution is, in essence, a non-invasive dilution method. It is of interest because of how ethanol readily dissolves itself exclusively into the water space of the body[4], is non-toxic in reasonable concentrations, is metabolized in a 0th order reaction above concentrations of 0.015 g/dL[4], and there are non-invasive methods for determining blood alcohol concentration[5, 6]. Thus, by drinking a known amount of ethanol, total body water can be calculated after a few hours of periodic breathalyzer analyses. Ethanol has been validated against deuterium oxide, the invasive gold standard for determining total body water[4]. The ethanol dose will be 0.5g/kg body weight.
16477420|NCT03447574|Active Comparator|Aim 2|30mL/kg body weight of saline will be rapidly infused after the baseline measurements completed in Aim 1. Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated. To determine if non-invasive fluid volume techniques can accurately determine fluid changes in healthy participants.Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated.
16477421|NCT03447561|Experimental|Anticipatory + consummatory food reward|PET-MR scan session with a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (viewing neutral images and drinking sips of water) and the fourth block the 'food reward condition' (viewing high-calorie food images and drinking sips of chocolate milkshake).
16477422|NCT03447561|Experimental|Consummatory food reward|PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
16477423|NCT03447548|Experimental|Processing speed training|Neurofeedback processing speed training
16477424|NCT03447548|Active Comparator|Active control|Computer games
16477425|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder
~SDQ total difficulties score and the parents report SDQ total difficulties score:
~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
16477426|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder
~SDQ total difficulties score and the parents report SDQ total difficulties score:
~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (<12), parents report SDQ total difficulties score abnormal (>16)"
16477427|NCT03447509|Active Comparator|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
16477428|NCT03447509|Active Comparator|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
16477429|NCT03447509|Active Comparator|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
16477430|NCT03447496||Closed reduction|The children were treated with closed reduction.
16477431|NCT03447496||Open reduction|The children were treated with open reduction.
16477432|NCT03447483|Other|Cohort of patients starting a treatment by ICI|
16477433|NCT03447470|Other|Monotherapy RXC004 - Module 1|Patients will be given RXC004 at a specified dose level and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD
16477496|NCT03447093||Control group|30 healthy volunteers were included in the healthy control group
16477434|NCT03447470|Other|Combination RXC004 plus Nivolumab - Module 2|Patients will be given RXC004 at specific doses in combination with a standard dose of Nivolumab and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD
16477435|NCT03447457|Other|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
16477436|NCT03447457|Other|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
16477437|NCT03447444|Other|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
16477438|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
16477439|NCT03447418|Other|no treatment, open label|
16477440|NCT03447405|Experimental|Dino Egg Safety and useability|Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.
16477441|NCT03447405|No Intervention|Standard of Care|
16477442|NCT03447392|Experimental|patient education and Chinese medicine|1-hour, one-on-one teaching session with a educator to the standard discharge education of Integrated Traditional and Western Medicine
16477443|NCT03447392|No Intervention|patient education|no discharge education
16477444|NCT03447379|Active Comparator|P2Y12 monotherapy after 3 months of DAPT|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)
16477445|NCT03447379|Active Comparator|Dual-antiplatelet therapy for a year|DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year
16477446|NCT03447366|Experimental|Mitral doppler|Mitral doppler before and after vascular filling
16477447|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
16477448|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
16477449|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
16477450|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
16477451|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
16477452|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
16477453|NCT03447327|Other|operated group|patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia
16477454|NCT03447314|Experimental|Part 1a: 50ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 50 nanogram (ng) intravenously (IV) on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3174998 24 milligram (mg) administered at 3-week intervals (Q3W) via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
16477455|NCT03447314|Experimental|Part 1a: 100ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
16477456|NCT03447314|Experimental|Part 1a: 150ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
16477457|NCT03447314|Experimental|Part 1a: 200ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
16477458|NCT03447314|Experimental|Part 1a: 250ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
16477459|NCT03447314|Experimental|Part 1b: 50ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
16477460|NCT03447314|Experimental|Part 1b: 100ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
16477461|NCT03447314|Experimental|Part 1b: 150ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
16477462|NCT03447314|Experimental|Part 1b: 200ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
16477497|NCT03447093||Drug treatment group|30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill
16477498|NCT03447093||Incipient group|30 untreated GD patients
16477463|NCT03447314|Experimental|Part 1b: 250ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
16477464|NCT03447314|Experimental|Part 1c: 50ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
16477465|NCT03447314|Experimental|Part 1c: 100ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
16477466|NCT03447314|Experimental|Part 1c: 150ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
16477467|NCT03447314|Experimental|Part 1c: 200ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
16477468|NCT03447314|Experimental|Part 1c: 250ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
16477469|NCT03447314|Experimental|Part 2a: GSK1795091 + 24 mg GSK3174998|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
16477470|NCT03447314|Experimental|Part 2b: GSK1795091 + 80 mg GSK3359609|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
16477471|NCT03447314|Experimental|Part 2c: GSK1795091 + 200 mg Pembrolizumab|Participants will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
16477472|NCT03447301|Experimental|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
16477473|NCT03447301|No Intervention|Control|No consumption of extra virgin olive oil
16477474|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
16477475|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
16477476|NCT03447262|Experimental|Open-label triple combination|"Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.
~Parent studies are Phase 3 Vertex studies investigating VX-659 in combination with TEZ and IVA. This includes Studies VX17-659-102 and VX17-659-103."
16477477|NCT03447249|Placebo Comparator|Placebo|Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
16477478|NCT03447249|Experimental|VX-659/TEZ/IVA TC|Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
16477479|NCT03447236|Experimental|Feuerstein Program|All subjects participating in the Feuerstein Program will be evaluated by anatomical and functional MRI as well as computerized cognitive assessment prior to and following intervention as outlined in the protocol.
16477480|NCT03447223||ADHD-patients|The children and adolescent 6-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
16477481|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 6-15 years old children and adolescent.
16477482|NCT03447210|Experimental|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
16477483|NCT03447197|Active Comparator|On-Pump|Use of extracorporeal circulation
16477484|NCT03447197|No Intervention|Off-Pump|
16477485|NCT03447184||Androgen priming|Eight weeks prior to stimulation for IVF - at the onset of menses, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor will commence, concomitantly with GnRHa down-regulation with a depot GnRHa (28days). After 8 weeks, a standard rFSH stimulation with either 300 IU rFSH or 300 IU rFSH+rLH will start. The androgen priming (hCG and aromatase inhibitor) will stop on the first day of stimulation.
16477486|NCT03447171||Refractive Error|
16477487|NCT03447158|Experimental|15% Dextrose group|4.5cc 15% dextrose and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
16477488|NCT03447158|Placebo Comparator|control group|4.5cc normal saline and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
16477489|NCT03447145|Experimental|TQ-B3203|
16477490|NCT03447132|Active Comparator|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
16477491|NCT03447132|Placebo Comparator|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
16477492|NCT03447119|Experimental|Living Well with a Disability|The parents will work together with the project directors to deliver the adapted curriculum to participating families. With bi-weekly meetings for 10 weeks between parent facilitators and family participants in the home or another desired location. The project directors have already participated in the facilitator training and will serve as mentors to newly trained facilitators. At the end of the online training session, the parent facilitators will be equipped to successfully implement the Living Well curriculum.
16477493|NCT03447106|Experimental|Open|
16477494|NCT03447106|Experimental|Laparoscopic|
16477504|NCT03447067|Experimental|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.
~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
16477505|NCT03447067|Experimental|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.
~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
16477506|NCT03447054|Experimental|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
16477507|NCT03447054|Active Comparator|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
16477508|NCT03447054|Active Comparator|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
16477509|NCT03447054|Sham Comparator|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
16477510|NCT03447041||the keratoplasty group|Patients who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
16477511|NCT03447015|Experimental|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
16477512|NCT03447015|No Intervention|Standard Maternity care|women will receive usual maternity care.
16477513|NCT03446989|Experimental|Case management|
16477514|NCT03446976|Experimental|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
16477515|NCT03446976|Experimental|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
16477516|NCT03446963|Experimental|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
16477517|NCT03446950|Active Comparator|Candy Cane|Participants in this arm will be positioned with their legs in candy cane stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
16477518|NCT03446950|Active Comparator|Boot Stirrups|Participants in this arm will have their feet placed in boot stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
16477519|NCT03446937|Experimental|Dexamethasone sodium phosphate injection|Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
16477520|NCT03446937|Experimental|Betamethasone sodium phosphate injection|Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
16477521|NCT03446937|Placebo Comparator|Water for injection|Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.
16477522|NCT03446924|Placebo Comparator|Control|The control group will be given a single dose of 1.5 g rice flour in capsule form (250 mg / capsule). The gelatine capsules (MyProtein, Northwich, UK) used are identical to those used in the treatment group. Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
16477523|NCT03446924|Active Comparator|Treatment|"The treatment group will be given a single dose of 1.5g phosphatidic acid in capsule form (250 mg / capsule). Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
~PA is considered a dietary supplement ingredient according to the US FDA. The source of PA will be a commercial available soy-derived PA (Mediator®, Chemi Nutra, White Bear Lake, MN). The safety of Mediator® Soy-PA has been thoroughly demonstrated in humans. Mediator® Soy-PA does not contain any compounds with narcotic, psychotropic or pharmaceutical effects and is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Mediator® Soy-PA is not a medicinal product."
16477524|NCT03446911|Active Comparator|SABR|Patients receive prior to surgery (lobectomy) SABR.
16477525|NCT03446911|Active Comparator|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
16477526|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
16477527|NCT03446885|Experimental|Lab visit 1|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
16477528|NCT03446885|Experimental|Lab visit 2|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
16477529|NCT03446872||All Study Participants|Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE
16477530|NCT03446859|Experimental|TENS|It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
16477531|NCT03446859|No Intervention|Control|These are 25 subjects which were not in any intervention. These were subjects that were not placed on TENS and were not used to drug taken for the amelioration of the dysmenorrhea. They were educated on the purpose of research and their inform consent was obtained. Their pain intensity was measured firs, third and 5th days
16477532|NCT03446846|Experimental|5.0 mg MIN-117|MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks
16477533|NCT03446846|Experimental|2.5 mg MIN-117|MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks
16477534|NCT03446846|Placebo Comparator|Placebo|Placebo (consisting of two placebo capsules) orally daily for 6 weeks
16477535|NCT03446833|Experimental|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
16477536|NCT03446820|Other|Sleep participants|Crossover from standard sheets to hygro cotton sheets
16477537|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
16477538|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
16477539|NCT03446794||patients with NVAF and ESCKD on HD|
16477540|NCT03446781|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
16477541|NCT03446781|Placebo Comparator|Placebo|Placebo
16477542|NCT03446768|Active Comparator|Reactive Care (RC)|Participants in the RC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support.
16477543|NCT03446768|Active Comparator|Proactive Care (PC)|Participants in the PC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support. Additionally, the PC group will also receive access to an online study portal which houses an educational health curriculum covering topics related to COPD and OSA. The portal allows participants to send online messages to peer coaches and respiratory therapist coaches. PC group will also receive weekly updates.
16477544|NCT03446755|Experimental|Intrauterine balloon (Cook medical)|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
16477545|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
16477546|NCT03446729|Experimental|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
16477547|NCT03446729|Active Comparator|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
16477548|NCT03446716|Experimental|EXTENSION|During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.
16477549|NCT03446716|No Intervention|CONTROL|Children followed their normal bedtime routine for five consecutive nights.
16477550|NCT03446703|Experimental|SCIT Social cognition interactive|Psychosocial intervention based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs & Penn; Lahera & Benito, in press).
16477551|NCT03446703|Active Comparator|TAR Training in affect recognition|Training in Affect Recognition it is a 12-session training on facial affect recognition over a period of 6 weeks.
16477552|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
16477553|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
16477554|NCT03446677|Experimental|Asymptomatic persons with HIV|
16477555|NCT03446664|Experimental|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
16477556|NCT03446651|Experimental|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
16477557|NCT03446651|Placebo Comparator|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
16477590|NCT03446391||Kinematic alignment with GMK Sphere®|Patients enrolled prospectively with surgeries planned to get kinematic alignment
16477558|NCT03446638|Experimental|Computational Biology-Informed Treatment|Patients randomized to this arm will receive an FDA-approved drug or combination of drugs predicted to have a therapeutic effect based on their individual MDS disease genetic profile by a computational biology simulation software program. The specific drug or combination of drugs that a patient on this arm will receive will be decided jointly by a molecular oncology board comprised of physicians, pharmacists, and nurse coordinators and the treating physician. Patients will receive a minimum of 2 months and a maximum of 4 months of treatment with the selected drug or combination of drugs.
16477559|NCT03446638|Active Comparator|Standard of Care Treatment|Patients randomized to this arm will receive either one of three standard of care treatment regimens of the treating physician's choice (low-dose cytarabine, 7 + 3 induction, or FLAG induction) or supportive care alone. Patients will receive a minimum of 2 months and a maximum of 4 months of the selected treatment regimen or of supportive care alone.
16477560|NCT03446625|Experimental|Resveratrol|Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
16477561|NCT03446625|Placebo Comparator|Control|Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
16477562|NCT03446612|Experimental|Participants receiving Daprodustat|Participants will receive 2 milligram (mg) daprodustat tablets once daily via oral route for a period of 41 days.
16477563|NCT03446612|Active Comparator|Participants receiving Darbepoetin alfa|Participants will receive Darbepoetin alfa solution for injection, administered as a single subcutaneous injection, once every two weeks (Days 1, 14 and 28).
16477564|NCT03446599|Experimental|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
16477565|NCT03446599|Experimental|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
16477566|NCT03446599|Placebo Comparator|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
16477569|NCT03446560|Active Comparator|CPAP, conventional follow up|Follow up of patients after initiation of treatment according to clinical routine at the study site.
16477570|NCT03446560|Active Comparator|CPAP, telemedicine based follow up|Follow up of patients after initiation of treatment according to a telemedicine based routine.
16477571|NCT03446547|No Intervention|Arm A|SBRT and follow-up
16477572|NCT03446547|Experimental|Arm B|SBRT followed by Durvalumab
16477573|NCT03446534|Experimental|Amoxicillin|Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.
16477574|NCT03446534|Placebo Comparator|Placebo|Placebo mixture 0.25ml/kg every 8 hours for 7 days
16477575|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
16477576|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
16477577|NCT03446508|Experimental|Active frontal|Active HD-tDCS
16477578|NCT03446508|Experimental|Active parietal|Active HD-tDCS
16477579|NCT03446508|Sham Comparator|Sham control|Sham HD-tDCS
16477580|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
16477581|NCT03446469|Experimental|Individuals with Chronic Ankle instability|Individuals with history of ankle sprains will be screened using the inclusion criteria before being included in the study
16477582|NCT03446456|Placebo Comparator|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.
~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
16477583|NCT03446456|Experimental|Arginine vasopressin|"Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).
~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment. Participants will be first stratified for sex and then randomized to saline (0.4 mL) or vasopressin (40 IU) group, respectively."
16477584|NCT03446443|Experimental|Honghe Fujie lotion group|
16477585|NCT03446443|Active Comparator|Metronidazole Suppositories group|
16477586|NCT03446430|Experimental|Hypertensives|PWV measurement by LDV
16477587|NCT03446417|Experimental|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
16477588|NCT03446417|Experimental|Phase 2|"MTD/RP2D in subjects:
~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.
~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
16477589|NCT03446404||MOST Cohort|"One portion of the cohort will be age 62-92 years, average age approximately 71 years, at the start of this study. This cohort will consist of participants who already have symptomatic knee OA, in many cases advanced disease, or who had risk factors at the start of the Multicenter Osteoarthritis Study but have not developed symptomatic knee OA. All of the existing cohort who have 1 or 2 native knees will be approached providing native knees are not considered to be Kellgren-Lawrence grade 4 (bone on bone). The other portion of the cohort will consist of subjects with knee pain, aching or stiffness at baseline and participants without any knee symptoms in the previous 30 days. Both knees with Kellgren-Lawrence grades of radiographic OA of 0, 1, or 2 in the tibiofemoral (TF) and patellofemoral (PF) compartments."
16477591|NCT03446391||Mechanical alignment with GMK Sphere®|Historical group who had mechanical alignment, match-paired with the prospective group
16477592|NCT03446378|Experimental|Anodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
16477593|NCT03446378|Experimental|Cathodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where cathodal electrode will be on the affected hemisphere and the anodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
16477594|NCT03446378|Sham Comparator|Sham tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
16477595|NCT03446365|Experimental|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
16477596|NCT03446365|Active Comparator|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
16477597|NCT03446365|No Intervention|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
16477598|NCT03446352|Experimental|Psychomotor exercise program|The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
16477599|NCT03446352|Experimental|Combined exercise program|The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
16477600|NCT03446352|No Intervention|Control Group|Usual care. After the study, control group (CG) participants will be offered the opportunity to integrate a similar fall prevention program.
16477601|NCT03446326|Experimental|Stroke volume and cardiac output|"Pacing runs will occur at the following rates:
~50 beats per minute (bpm)
~60 bpm
~70 bpm
~80 bpm
~90 bpm
~100 bpm
~110 bpm
~120 bpm
~130 bpm
~The finger blood pressure cuff will be calibrated between pacing runs.
~Following the final pacing run while supine, the patient will be given 10 minutes to rest prior to the upright portion of the study. They will then be strapped into the table (so they will not fall) and then they will be tilted up to >70 degrees (almost standing up). They will stand for ~10 minutes prior to commencing the next pacing trains."
16477602|NCT03446313|Experimental|MVN Group|Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
16477603|NCT03446313|No Intervention|Usual Care|Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
16477604|NCT03446300||college student population|
16477605|NCT03446300||working population|
16477606|NCT03446300||aged more than 50 years old population|
16477607|NCT03446261|Experimental|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
16477608|NCT03446261|Active Comparator|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
16477609|NCT03446248|Active Comparator|Fetal Acoustic Stimulator|Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
16477610|NCT03446248|Experimental|Mobile Phone Application|Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.
16477611|NCT03446235|Experimental|Connected Health|This group will get 2 interviews about physical exercise (exercise instruction with motivational interview) and 6 communications with individualized instruction and counseling of their physical exercise (investigators can access activity data and exercise log) including the usage of the monitoring device.
16477612|NCT03446235|Active Comparator|Self-Monitoring|This group will do physical exercise following the initial instruction and self-monitor them. Investigators can access activity data and exercise log but will not discuss with the subjects about the data.
16477613|NCT03446222|Active Comparator|Catheter Ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
16477614|NCT03446222|Active Comparator|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
16477615|NCT03446209|Experimental|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
16477616|NCT03446209|Placebo Comparator|Placebo|0,9% physiological Saline
16477617|NCT03446196|Experimental|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
16477618|NCT03446196|No Intervention|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
16477619|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
16477620|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
16477621|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
16477622|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
16477623|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
16477624|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
16477625|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
16477626|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
16477627|NCT03446144|Experimental|IONIS-FB-Lrx|
16477628|NCT03446144|Placebo Comparator|Placebo (sterile saline 0.9%)|
16477629|NCT03446118|Experimental|MRI to detect inflammation and fibrosis in EoE patients|To assess through MRI the existence of an inflammatory and fibrotic component in strictures of eosinophilic esophagitis patients and to determine if this component is responsive to a therapeutic course of budesonide.
16477630|NCT03446105|Experimental|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
16477631|NCT03446105|Active Comparator|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
16477632|NCT03446092|Experimental|Mindfulness group|Group will receive mindfulness intervention
16477633|NCT03446079|Experimental|Primary Subjects|Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
16477634|NCT03446066||case group|20 cases suffering from excessive daytime sleepiness (4 females and 16 males) with their age range 32-58yrs and BMI range is 24.97-39.06 kg/m2
16477635|NCT03446066||control group|20 healthy subjects (5 females and 15 males) with their age range 31-55yrs and BMI range is 23.40-43.0 kg/m2
16477638|NCT03446040|Experimental|Part A Dose Escalation: BMS-986258|
16477639|NCT03446040|Experimental|Part A1: BMS-986258 + Recombinant human hyaluronidase PH20 (rHuPH20)|
16477640|NCT03446040|Experimental|Part B Dose Escalation: BMS-986258 + nivolumab|
16477641|NCT03446040|Experimental|Part C Cohort Expansion: BMS-986258 + nivolumab|
16477642|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
16477643|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
16477644|NCT03446014||Control Group for Fitbit Sub-Study|Patient will be given Fitbit device, but will have no access to Fitbit website or interface. The coordinator will set up the patient's Fitbit on the office computer and will have access to the fitbit's associated username and password (this will be generated by the coordinator). The patient will be instructed to walk as much as they can each day, and to check the Fitbit wrist band periodically throughout the day to view their walking progress. At the end of the three month intervention, the patient will complete questionnaires and undergo a repeat 6 minute walk test.
16477645|NCT03446014||Intervention Group for Fitbit Sub-Study|Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
16477646|NCT03446001|Experimental|TRx0237 16 mg/day|
16477647|NCT03446001|Placebo Comparator|Placebo|
16477648|NCT03446001|Experimental|TRx0237 8 mg/day|
16477649|NCT03445988|Active Comparator|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
16477650|NCT03445988|Active Comparator|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Peers are people with chronic pain who live in the communities in which they teach. For this project, at least one peer facilitator per workshop will have had experience with prescription opioid use. Intervention fidelity is determined by having a trained observer with a checklist attend random workshop sessions. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session.
16477651|NCT03445988|Placebo Comparator|Taper Only (Usual Care)|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
16477652|NCT03445988|No Intervention|Observational Arm|Participants that do not wish to reduce their opioid medications but are otherwise eligible and interested in the research study will be offered participation in the observational arm. The observational arm of the study will not include interventions of any kind and will only collect survey data for the year following consent.
16480603|NCT03425968||Control group|athletes who doesn't have knee hyperextension
16477653|NCT03445975|Experimental|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
16477654|NCT03445975|No Intervention|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
16477655|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
16477656|NCT03445949|Other|30 days DAPT|short postimplantation dual antiplatelet therapy
16477657|NCT03445949|Other|6 months DAPT|extended postimplantation dual antiplatelet therapy
16477658|NCT03445936|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
16477659|NCT03445936|Active Comparator|Permacol|Permacol is a acellular porcine dermal implant used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
16477662|NCT03445910|Experimental|Human chorionic gonadotrophin|The hCG Group included 50 patients who had an intrauterine injected of 500 IU of hCG on the day of ovum pick-up
16477663|NCT03445910|No Intervention|control|The Control Group included 50 patients who went through the ICSI conventional protocol without intrauterine injection.
16477664|NCT03445897|Experimental|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
16477665|NCT03445884|Experimental|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
16477666|NCT03445884|Active Comparator|Control group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.
16477667|NCT03445871|Active Comparator|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
16477668|NCT03445871|Active Comparator|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
16477669|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
16477670|NCT03445845|Experimental|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.
~Blood specimen at each visits"
16477671|NCT03445845|Active Comparator|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:
~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:
~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,
~etanercept: 50mg per week in subcutaneous injection,
~adalimumab: 40mg every other week in subcutaneous injection,
~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,
~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.
~Blood specimen at each visits"
16477672|NCT03445819|Other|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
16477673|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
16477674|NCT03445780|Experimental|First Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection
16477675|NCT03445780|Experimental|Second Group|The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection
16477676|NCT03445780|Experimental|Third Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease
16477677|NCT03445780|Experimental|Fourth Group|Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.
16477678|NCT03445767|No Intervention|Standard Care|All patients will receive perioperative care per the standards of TOH. Standard care relevant to our study consists of a history by a nurse or physician; a best possible medication history performed by a pharmacy technician; and standardized perioperative-specific medication recommendations (e.g., anticoagulant, diabetes agent, and ACE-inhibitor management) based on medical directives. Medication recommendations beyond these medical directives do not occur as standard care in our clinics. Participants will be informed that their medical care will proceed as usual and that they are being recruited for a study to evaluate medication recommendations before surgery
16477679|NCT03445767|Experimental|Intervention|In addition to standard care, the intervention will include a structured preoperative polypharmacy management strategy that consists of: a) input of best possible medication history and comorbidities into our polypharmacy management tool (MedSafer); b) communication of the prioritized deprescribing plan (if indicated) to the patient's active treating physicians (automatically via fax), to the perioperative team (surgeon, anesthesiologist), and to the electronic medical record. During the pre-operative visit, the patient will receive a generalized information flyer about deprescribing. As in the usual care phase, patients will continue to receive usual recommendations from the perioperative team based on medical directives relevant to the perioperative period.
16477750|NCT03445312||study cohort|All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered
16477680|NCT03445754|Experimental|Interventional Arm|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
16477681|NCT03445754|Sham Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
16477682|NCT03445741|Active Comparator|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
16477683|NCT03445741|Experimental|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
16477684|NCT03445741|Experimental|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
16477685|NCT03445728|Experimental|Treatment arm|Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
16477686|NCT03445728|Placebo Comparator|Placebo arm|Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.
16477687|NCT03445715|Experimental|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
16477688|NCT03445715|Experimental|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
16477689|NCT03445715|Experimental|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
16477690|NCT03445702|Experimental|Metformin intolerant & metformin|Metformin 1000mg once
16477691|NCT03445702|Placebo Comparator|Metformin intolerant & placebo|Placebo 1000mg once
16477692|NCT03445702|Active Comparator|Metformin tolerant & metformin|Metformin 1000mg once
16477693|NCT03445702|Placebo Comparator|Metformin tolerant and placebo|Placebo 1000mg once
16477694|NCT03445676|No Intervention|Usual Care|Study personnel silently observe and record what the healthcare worker does at each hand hygiene opportunity without direction to the healthcare worker
16477695|NCT03445676|Experimental|ABHR directly on gloves|Healthcare worker will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
16477696|NCT03445676|Placebo Comparator|Ideal Standard|Healthcare worker will be directed by study personnel to remove gloves, perform hand hygiene and replace gloves at each hand hygiene opportunity
16477697|NCT03445663|Experimental|AMG 424|Comparison of different dosages of AMG 424
16477698|NCT03445650|Experimental|ADX-102 1% Topical Dermal Cream (reproxalap)|
16477699|NCT03445650|Placebo Comparator|Vehicle of ADX-102 Topical Dermal Cream|
16477700|NCT03445624||patient on traditional therapy|Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
16477701|NCT03445624||patient on infliximab|drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
16477702|NCT03445611|Experimental|Group 1|These patients will receive a corticosteroid solution with lidocaine containing parabens.
16477703|NCT03445611|Active Comparator|Group 2|These patients will receive corticosteroid solution with paraben free lidocaine.
16477704|NCT03445598|Experimental|Interactive CCBT group|This group receives Interactive and Personalized CCBT
16477705|NCT03445598|Active Comparator|Limited CCBT control group|This group receives Feature-limited CCBT
16477706|NCT03445598|Other|Waitlist control group|This group receives waitlist control
16477707|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
16477708|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
16477709|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
16477710|NCT03445585||Control group 2|Patients without liver disease.
16477711|NCT03445572|Experimental|Group I (MSB)|Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.
16477712|NCT03445572|Experimental|Group II (IK meditation)|Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.
16477713|NCT03445572|Active Comparator|Group III (waitlist)|Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.
16477714|NCT03445559|No Intervention|Control|No intervention
16477715|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
16477716|NCT03445546||oral P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)
16477717|NCT03445546||intravenous P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)
16477718|NCT03445533|Experimental|Arm A: ipilimumab|ipilimumab 3 mg/kg intravenous
16477719|NCT03445533|Experimental|Arm B: IMO-2125 plus ipilimumab|IMO-2125 by intratumoral injection plus ipilimumab 3 mg/kg intravenous
16477720|NCT03445520|No Intervention|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
16477751|NCT03445299|Experimental|Music|Daily music listening for 30 minutes at bedtime
16477752|NCT03445286|Experimental|Silver Diamine Fluordie Application|This group will receive Silver Diamine Fluoride (SDF) application once every week within three weeks period
16477753|NCT03445286|Placebo Comparator|Normal Saline|This control group will receive normal saline application once a week within a a three-week period
16480629|NCT03425812|Experimental|Non- NSAIDS group|To withdraw NSAIDS therapy
16477721|NCT03445520|Experimental|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
16477722|NCT03445507|Experimental|Intervention|Use of an evidence-based chat bot for smoking cessation
16477723|NCT03445507|Active Comparator|Control|Usual care (Madrid Health System Portfolio).
16477724|NCT03445494|Experimental|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
16477725|NCT03445494|Experimental|Normal sling|After surgery the patient must wear the normal sling for two weeks
16477726|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
16477727|NCT03445468|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The vaccine contains both B strain (Yamagata, Victoria)
16477728|NCT03445468|Active Comparator|IL-YANG Flu Vaccine Pre-filled Syringe|The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
16477729|NCT03445455||De novo AHRF|"Acute hypoxemic non hypercapnic respiratory failure with a PaO2/FiO2 ratio < 200.
~The following oxygenation devices are used and assessed during routine care:
~High concentration mask, High flow nasal canula, NIV using buco-nasal mask or Helmet.
~Electro impedence tomography signal will be recorded throughout this assessement for tidal volume measurement"
16477730|NCT03445442||Group 1|Sacrocolpopexy (SCP)
16477731|NCT03445442||Group 2|Native tissue repair surgery (NTR)
16477732|NCT03445442||Group 3|Vaginal mesh repair surgery (VMR)
16477733|NCT03445429|Experimental|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
16477734|NCT03445429|Experimental|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
16477735|NCT03445416|Experimental|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
16477736|NCT03445416|Active Comparator|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
16477737|NCT03445403|Experimental|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
16477738|NCT03445403|Active Comparator|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
16477739|NCT03445390|Experimental|Acetaminophen First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive acetaminophen first.
16477740|NCT03445390|Experimental|Placebo First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive placebo first.
16477741|NCT03445377|Active Comparator|Real-time continuous glucose monitoring|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
16477742|NCT03445377|Placebo Comparator|Self-monitoring of blood glucose|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. During the Control Period, masked CGM will be applied for one week, during Week 1, 4 and 8. At the end of this, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
16477743|NCT03445364|Active Comparator|Low coronary injection-pressure, 200 psi|"Patients with STEMI who undergo Primary PCI with the use of low intracoronary dye injection pressure (of 200 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.
~Use of different injection pressure during primary PCI"
16477744|NCT03445364|Active Comparator|High coronary injection-pressure,550 psi|"Patients with STEMI who undergo Primary PCI with the use of higher intracoronary dye injection pressure (of 500 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.
~Use of different injection pressure during primary PCI"
16477745|NCT03445351|Experimental|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
16477746|NCT03445338|Experimental|Cohort 1|
16477747|NCT03445338|Experimental|Cohort 2|
16477748|NCT03445338|Experimental|Cohort 3|
16477749|NCT03445325|Experimental|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
16480630|NCT03425812|Active Comparator|NSAIDS group|To continue NSAIDS therapy
16477754|NCT03445260|Placebo Comparator|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
16477755|NCT03445260|Experimental|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
16477756|NCT03445247|Sham Comparator|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
16477757|NCT03445247|Experimental|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
16477758|NCT03445234|Experimental|Blueberry|Freeze-dried blueberry powder
16477759|NCT03445234|Placebo Comparator|Placebo|Placebo powder
16477760|NCT03445234|Experimental|Banana|Acute banana ingestion
16477761|NCT03445234|Experimental|No banana|No banana ingestion
16477762|NCT03445221|Active Comparator|Group I|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 5 days before surgery.
16477763|NCT03445221|Active Comparator|Group II|patients will continue preoperative oral conventional diet.
16477764|NCT03445208|Experimental|Cohort 1|BMI 18.0 to ≤ 25.0
16477765|NCT03445208|Experimental|Cohort 2|BMI >25.0 to ≤ 30.0
16477766|NCT03445208|Experimental|Cohort 3|BMI >30.0 ≤ 40.0
16477767|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
16477768|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
16477769|NCT03445182|Active Comparator|Control group|Local anaesthesia with conventional syringe
16477770|NCT03445182|Active Comparator|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
16477771|NCT03445169|Experimental|Fasting|Belzutifan tablets taken after fasting
16477772|NCT03445169|Experimental|Non-Fasting|Belzutifan taken after eating a high calorie meal
16477773|NCT03445156|Experimental|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
16477774|NCT03445156|Experimental|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
16477775|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
16477776|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
16477777|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
16477778|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
16477779|NCT03445117|Experimental|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
16477780|NCT03445117|No Intervention|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
16477781|NCT03445104|Experimental|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
16477782|NCT03445104|Placebo Comparator|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
16477783|NCT03445091|Experimental|Patients using investigational product|Open-label use of SANKOM Patent Socks
16477784|NCT03445078|Active Comparator|A|Participants will be administered firstly selenium-rich corn powder 20g/d for 1 month and ordinary corn powder 20g/d for another month subsequently with a month washout period.
16477785|NCT03445078|Placebo Comparator|B|Participants will be administered firstly ordinary corn powder 20g/d for 1 month and selenium-rich corn powder 20g/d for another month subsequently with a month washout period.
16477786|NCT03445065|Experimental|Cohort 1, Enabled - Eversense XL CGM System|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
16477787|NCT03445065|Active Comparator|Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
16477788|NCT03445065|Experimental|Cohort 2, Enabled - Eversense XL CGM System|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
16477812|NCT03444922|Experimental|BPA 4 ug/kg BW|Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
16477813|NCT03444922|Experimental|BPA 50 ug/kg BW|Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
16477814|NCT03444909|Experimental|cardiotocograph and Toconaute|monitoring with cardiotocograph and next with the Toconaute of Bioserenity
16477815|NCT03444909|Experimental|Cardiotocograph and Toconaute and Electrophysiological device|monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
16477789|NCT03445065|Active Comparator|Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
16477790|NCT03445052|Experimental|2018 XPAND Intervention Arm|This group will receive the personalised adherence intervention in 2018 in addition to routine clinical care.
16477791|NCT03445052|No Intervention|2018 XPAND Control Arm|This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
16477792|NCT03445039|Experimental|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
16477793|NCT03445039|Experimental|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
16477794|NCT03445039|Experimental|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
16477795|NCT03445039|Experimental|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
16477796|NCT03445013|Experimental|SB414 6%|SB414 6% topically twice daily
16477797|NCT03445013|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
16477798|NCT03445000|Experimental|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.
~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
16477799|NCT03444987||patients group|"include 35 pre-menopausal women (age ˂ 50 years) enrolled to undergo hysterectomy for symptomatic UF at the women health hospitals, Assiut University.
~The protein expression of the followings markers will be estimated in tumor tissue samples:
~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.
~Phosphorylated protein kinase B (pAKT ) by ELISA (protein level). analysis.
~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
~Reduced glutathione, an antioxidant marker by a colorimetric method
~."
16477800|NCT03444987||Control group|"include 35 normal myometrial tissue samples obtained 1 cm away from the fibroid capsule from the same patients.
~The protein expression followings markers will be estimated in normal myometrial tissue samples
~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.
~Phosphorylated protein kinase B (pAKT) by ELISA (protein level).
~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
~Reduced glutathione, an antioxidant marker by a colorimetric method
~."
16477801|NCT03444974|Active Comparator|Patient therapy group|"Adolescents with substance use disorders
~Receiving an adapted treatment according to the MATRIX-A therapy"
16477802|NCT03444974|Active Comparator|Parental therapy group|"Parents of adolescents with substance use disorders
~Receiving an adapted treatment according to the MATRIX-A therapy"
16477803|NCT03444974|No Intervention|Patient waiting list group|"Adolescents with substance use disorders
~On the waiting list for receiving a MATRIX-A therapy"
16477804|NCT03444974|No Intervention|Parental waiting list group|"Parents of adolescents with substance use disorders
~On the waiting list for receiving a MATRIX-A therapy"
16477805|NCT03444974|No Intervention|control group|"Adolescents with no history of substance use disorders
~no other intake of psychotropic substances such as psychotropic medication"
16477806|NCT03444961|Experimental|CAREN system training|CAREN training
16477807|NCT03444948|Experimental|3 radiofrequency ablation procedures|Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
16477808|NCT03444948|Active Comparator|standard medical care|Subject will receive standard medical care, including pain relief drugs
16477809|NCT03444935|Experimental|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
16477810|NCT03444935|Other|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
16477811|NCT03444922|Placebo Comparator|Placebo|Participants consume Vanilla Wafer cookie
16477816|NCT03444909|Experimental|Cardiotocograph and electrophysiological device|monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
16477817|NCT03444896|Experimental|Acupuncture group|
16477818|NCT03444896|Placebo Comparator|Sham acupuncture group|
16477819|NCT03444883|Active Comparator|Treatment Group|10mg Ilaprazole x 2 tablets
16477820|NCT03444883|Placebo Comparator|Control Group|10mg placebo of Ilaprazole x 2 tablets
16477821|NCT03444870|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
16477822|NCT03444870|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
16477823|NCT03444857|Experimental|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
16477824|NCT03444857|No Intervention|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
16477825|NCT03444844|Experimental|Biochemical recurrent prostate cancer|"IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by whole body PET/CT scanning (pelvis to shoulders) for ~ 60 min (~150 min for first 10 patients/dosimetry) starting immediately after injection.
~A contrast CT scan follows PET scan."
16477826|NCT03444844|Experimental|Intermediate/High Risk primary prostate cancer|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by list mode PET/CT scanning using a fixed FOV including the pelvis area for ~ 50 min.
16477827|NCT03444831|Experimental|Buspirone plus Omeprazole|
16477828|NCT03444831|Placebo Comparator|Placebo plus Omeprazole|
16477829|NCT03444818|Experimental|[14C]-E6007|Participants will receive a single oral dose of 60 milligrams (mg) of [14C]-E6007.
16477830|NCT03444805||NISSC-2|SSC patients treated with AHSCT
16477831|NCT03444792|Experimental|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
16477832|NCT03444792|No Intervention|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
16477833|NCT03444779|Active Comparator|Control group|The patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.
16477834|NCT03444779|Experimental|Experimental group|"The patients will be treated with the Tibial Tuberoplasty technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique."
16477835|NCT03444766|Experimental|Monotherapy|administering nivolumab only
16477836|NCT03444753|Experimental|Arm A|BMS-986299
16477837|NCT03444753|Experimental|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
16477838|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
16477839|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
16477840|NCT03444714|Experimental|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
16477843|NCT03444688|Active Comparator|CT, Control Group|Conventional Gait Training
16477844|NCT03444688|Experimental|WT, Experimental Group|Gait rehabilitation with walker
16477845|NCT03444662|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
16477846|NCT03444662|Experimental|Cognizin and Omega-3|Intervention: Dietary Supplement: Citicoline and Omega-3 supplement
16477847|NCT03444662|Experimental|Omega-3|Intervention: Dietary Supplement: Omega-3 supplement
16477848|NCT03444649|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
16477849|NCT03444636|Experimental|Ropivacaine/Fentanyl|
16477850|NCT03444636|Active Comparator|Bupivacaine/Fentanyl|
16477851|NCT03444610|Other|Arm (blood transfusion escalation rate)|The intervention for the arm (blood transfusion escalation rate) will be about giving blood transfusion with escalating rate as described in intervention part to Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases.
16477852|NCT03444584|Experimental|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
16477884|NCT03444389||Study group|Patients with hemorrhoids
16477885|NCT03444389||Control group|Healthy participants without hemorrhoids
16477853|NCT03444584|Placebo Comparator|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
16477854|NCT03444571|No Intervention|Control|
16477855|NCT03444571|Experimental|DNA based diagnosis|
16477856|NCT03444558|Experimental|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
16477857|NCT03444558|Placebo Comparator|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
16477858|NCT03444532|Experimental|12-week aerobic exercise and cognitive-behavioral therapy|12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions
16477859|NCT03444532|No Intervention|Control group|Patients assigned to the control group will receive usual care
16477860|NCT03444519|Experimental|Mannitol A|in this group, Mannitol (1.0g/kg) is given just after the induction of general anesthesia
16477861|NCT03444519|Active Comparator|Mannitol B|in this group, Mannitol (1.0g/kg) is given at the time of skin incision
16477862|NCT03444506|Placebo Comparator|Placebo nasal spray|Placebo nasal spray - 2 sprays per nostril, BID
16477863|NCT03444506|Experimental|Molo 1 (also referred as GSP 301-2 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
16477864|NCT03444506|Experimental|Molo 2 (also referred as GSP 301-1 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
16477865|NCT03444506|Active Comparator|DYMISTA nasal spray|Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
16477866|NCT03444506|Active Comparator|PATANASE nasal spray|Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID
16477867|NCT03444493|Experimental|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
16477868|NCT03444493|No Intervention|Control|Control group was informed about protecting for biomechanics of lumbar spine.
16477869|NCT03444480|Experimental|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
16477870|NCT03444480|Experimental|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
16477871|NCT03444467|Experimental|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
16477872|NCT03444467|Active Comparator|Glucagon|Participants will receive a single fixed dose of glucagon.
16477873|NCT03444454|Experimental|VRRS Khymeia|"The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).
~The exercise program will be remotely charged by therapist on the patient's computer.
~Each patient's performed session will be reviewed remotely by the therapist."
16477874|NCT03444454|Active Comparator|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
16477875|NCT03444454|Experimental|VRRS Khymeia plus active tDCS|The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
16477876|NCT03444454|Active Comparator|VRRS Khymeia plus placebo tDCS|The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
16477877|NCT03444428||Non Invasive Ventilation|"Age, height, weight
~History and Physical Examination
~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)
~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
~24h Blood Pressure monitor
~Spirometry - FEV1 and FVC
~Respiratory muscle strength - MIP, MEP, and SNIP
~Arterial Blood Gases
~Carotid-femoral pulse wave velocity
~Breath CO exhale"
16477878|NCT03444428||Without Non Invasive Ventilation|"Age, height, weight
~History and Physical Examination
~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)
~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
~24h Blood Pressure monitor
~Spirometry - FEV1 and FVC
~Respiratory muscle strength - MIP, MEP, and SNIP
~Arterial Blood Gases
~Carotid-femoral pulse wave velocity
~Breath CO exhale"
16477879|NCT03444415|Experimental|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
16477880|NCT03444415|Other|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.
~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
16477881|NCT03444402|Experimental|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
16477882|NCT03444402|Experimental|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
16477883|NCT03444402|Experimental|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
16477886|NCT03444376|Experimental|GX-188E, Keytruda|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
16477887|NCT03444363|Experimental|Study group|SRP plus diode laser (810 nm wavelength, 1 W power)
16477888|NCT03444363|Active Comparator|Control group|SRP plus placebo
16477889|NCT03444350|Active Comparator|Control group|SRP plus placebo
16477890|NCT03444350|Experimental|Gaseous ozone group|SRP plus gaseous ozone [1 W (100 mJ, 10 Hz)]
16477891|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
16477892|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
16477893|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)|Standard of Care
16477894|NCT03444311|Active Comparator|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
16477895|NCT03444311|Active Comparator|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
16477896|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Safflower Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
16477897|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
16477898|NCT03444285|Active Comparator|Warm Up|
16477899|NCT03444285|Active Comparator|Hot Pack|
16477900|NCT03444272|Experimental|Hepatitis C Treatment|HCV Treatment (Sofosbuvir and Daklatasuvir)
16477901|NCT03444272|No Intervention|Supportive treatment|supportive liver therapy
16477902|NCT03444259||Atrial fibrillation|Patients with atrial fibrillation
16477903|NCT03444259||Coronary bypass|Patients undergoing coronary bypass
16477904|NCT03444259||Aortic valve replacement|Patients undergoing aortic valve replacement
16477905|NCT03444259||Mitral valve repair|Patients undergoing mitral valve repair
16477906|NCT03444259||Other|Patients undergoing cardiac surgery for indication other than above
16477907|NCT03444246|Experimental|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
16477908|NCT03444246|Active Comparator|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
16477909|NCT03444233|Experimental|low f1 diet|low fructose diet week 1
16477910|NCT03444233|Experimental|fruit rich diet|fruit rich diet week 2
16477911|NCT03444233|Experimental|low f2 diet|low fructose diet week 3
16477912|NCT03444233|Experimental|HFCS rich diet|HFCS rich diet week 4
16477913|NCT03444220|Active Comparator|ACHIM|Anaerobically Cultivated Human Intestinal Microbiota
16477914|NCT03444220|Placebo Comparator|Placebo|Anaerobically Cultivated medium
16477915|NCT03444207|Experimental|Group A|Endurance training
16477916|NCT03444207|Experimental|Group B|Endurance-strength training
16477917|NCT03444194|Experimental|Biopsi arm|
16477918|NCT03444181|Experimental|Music lessons|
16477919|NCT03444181|Active Comparator|Training intervention|
16477920|NCT03444181|No Intervention|No intervention|
16477921|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
16477922|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
16477923|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
16477924|NCT03444155|Active Comparator|Natural Panmol-B-Complex first, then synthetic Vitamin B-complex|Participants first received a Natural Vitamin B-complex, i.e., Panmol-B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
16477925|NCT03444155|Active Comparator|Synthetic Vitamin B-complex first, then Natural Panmol-B-Complex|Participants first received a Synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a natural Vitamin B-complex, i.e., Panmol-B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
16477926|NCT03444142|Active Comparator|Drug: Exenatide LAR|Exenatide LAR 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
16477927|NCT03444142|Active Comparator|Drug: Dulaglutide|Dulaglutide .75 mg, once weekly subcutaneously Before breakfast during 4 weeks.
16477928|NCT03444129|Active Comparator|Control|This group will participate in a health education workshop with weekly sessions (control group)
16477929|NCT03444129|Experimental|Game|This group will participate in the health education workshop plus the interactive health game (intervention group).
16477930|NCT03444116||Cases (+FDO)|Patients who underwent an FDO
16477931|NCT03444116||Controls (-FDO)|Same as cases but did not undergo an FDO
16477932|NCT03444103|Active Comparator|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
16477933|NCT03444103|Placebo Comparator|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
16477964|NCT03443856|Other|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
16477934|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
16477935|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
16477936|NCT03444077|Active Comparator|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
16477937|NCT03444077|Experimental|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.
~TICCS < 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.
~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
16477938|NCT03444064|No Intervention|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
16477939|NCT03444064|Experimental|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
16477940|NCT03444051||20-gauge Procore®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:
~34 punctures were performed with a 20-gauge Procore® during the period study"
16477941|NCT03444051||22-gauge Acquire®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:
~34 punctures were performed with a 22-gauge Acquire® during the period study"
16477942|NCT03444038|Experimental|NBI-98854|NBI-98854 administered once daily for up to 24 weeks
16477943|NCT03444025|Experimental|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
16477944|NCT03444025|No Intervention|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
16477945|NCT03443986|Experimental|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes.
16477946|NCT03443986|Sham Comparator|Resistance training associated with sham|"The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment."
16477947|NCT03443986|No Intervention|Control group|Will not be submitted to any physical intervention. It continues in your daily life with only monitoring via phone callings. Guidelines about foot care.
16477948|NCT03443973|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
16477949|NCT03443973|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
16477950|NCT03443960|Experimental|Treatment A (TNX-102 SL)|2 x TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg once daily for 20 consecutive days
16477951|NCT03443960|Active Comparator|Treatment B (AMRIX)|1 x AMRIX ER capsule 30 mg once daily for 20 consecutive days
16477952|NCT03443947|Experimental|D group|
16477953|NCT03443921|Experimental|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
16477954|NCT03443921|Active Comparator|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
16477955|NCT03443908||CPAP therapy|CPAP therapy (minimum of 3-4 weeks)
16477956|NCT03443895|Active Comparator|Experimental: AEF0117|Subjects in cohorts 1 through 3 receive active treatments. Subjects in Cohorts 1 through 3 will receive a single dose of 0.6, 2 and 6mg respectively of AEF0117 on Day 1 to Day 7.
16477957|NCT03443895|Placebo Comparator|Placebo|Subjects in Cohorts1 through 3 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
16477958|NCT03443882|Active Comparator|Astaxanthin formulation #1|capsules
16477959|NCT03443882|Active Comparator|Astaxanthin formulation #2|tablets
16477960|NCT03443882|Active Comparator|Astaxanthin formulation #3|powder
16477961|NCT03443882|Experimental|Astaxanthin formulations|fast condition
16477962|NCT03443869|Experimental|Letermovir|Letermovir (LET) 480mg (or 240 mg when co-administered with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
16477963|NCT03443869|Active Comparator|Valganciclovir|900 mg Valganciclovir (VGCV) tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
16477965|NCT03443856|Experimental|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
16477966|NCT03443843|Experimental|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
16477967|NCT03443843|Experimental|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
16477968|NCT03443843|Experimental|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
16477969|NCT03443843|Experimental|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
16477970|NCT03443830|Experimental|0.2 mg/kg|Subject will be administered with 0.2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16477971|NCT03443830|Experimental|0.5 mg/kg|Subject will be administered with 0.5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16477972|NCT03443830|Experimental|1 mg/kg|Subject will be administered with 1 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16477973|NCT03443830|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16477974|NCT03443830|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16477975|NCT03443830|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
16477976|NCT03443817|No Intervention|Control group|There is no conventional rehabilitation follow up program, but all patients are encouraged to continue training
16477977|NCT03443817|Experimental|Intervention group|The intervention group will obtain telerehabilitation
16477978|NCT03443804|Experimental|Test(DW1401)|tid PO, DW1401+Placebo of Stillen tab.
16477979|NCT03443804|Active Comparator|Reference(Stillen tab.)|tid PO, Stillen tab.+Placebo of DW1401
16477980|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
16477981|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
16477982|NCT03443778|Active Comparator|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
16477983|NCT03443778|Active Comparator|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
16477984|NCT03443778|Active Comparator|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
16477985|NCT03443765||Patients with Pityriasis alba|
16477986|NCT03443765||Healthy participants (control group)|
16477987|NCT03443752|Experimental|Shotokan-Karate|The protocol for Shotokan-karate training will involve a one hour training session which will be broken down into 3 major components. The training program will consist of warm-up exercises, katas (choreographed karate movements), and cool-down exercise.
16477988|NCT03443752|Experimental|Tai-Chi|The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre.The following program will be held three times per week.
16477989|NCT03443726|Experimental|Infiltrative technique|Patients in this arm will have buccal and lingual infiltrative anesthesia with 4% articaine 1:100.000 epinephrine for third molar extraction.
16477990|NCT03443726|Active Comparator|Nerve block technique|Patients in this arm will have inferior alveolar nerve and buccal nerve block with 4% articaine 1:100.000 epinephrine for third molar extraction.
16477991|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
16477992|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
16477993|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
16477994|NCT03443700|Active Comparator|sLT|Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
16477995|NCT03443700|Experimental|sLT + EX-T|Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
16477996|NCT03443687|Active Comparator|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo the intervention of 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
16477997|NCT03443687|Experimental|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months and their intervention will be to perform daily exercises with the device in place. At 3 months they will return for a follow up visit and complete questionnaires.
16477999|NCT03443661|Experimental|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
16478000|NCT03443635|Experimental|Treatment|Subjects receiving hands-on cooking and nutrition education classes
16478001|NCT03443635|No Intervention|Control|Subjects not receiving any additional nutrition education aside from that contained in their curricula (for trainees) or medical care (for patients)
16478002|NCT03443622|Experimental|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
16478003|NCT03443622|Experimental|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
16480841|NCT03424278|Experimental|Resistance Training|
16478004|NCT03443622|Experimental|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
16478005|NCT03443622|Experimental|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
16478006|NCT03443622|Experimental|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
16478007|NCT03443622|Experimental|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
16478008|NCT03443609|Other|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
16478009|NCT03443596|Active Comparator|Early intensive BP control|BP in participants in this arm is treated aggressively, lowered and maintained at systolic blood pressure between 140-160mmHg, within 6 hours of stroke onset and maintained in this range for first 72 hours.
16478010|NCT03443596|No Intervention|Guidelined based BP control|Participants are treated according to the current international guidelines in thrombolysed acute ischemic stroke patients, i.e., less than 180/105mmHg
16478011|NCT03443570|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rituximab in combination with bortezomib at the indicated dose
16478012|NCT03443570|Active Comparator|control group|100 enrolled patients are randomly picked up to take rituximabalone at the indicated dose
16478013|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
16478014|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
16478015|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
16478016|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
16478017|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
16478018|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
16478019|NCT03443531|Experimental|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
16478020|NCT03443531|Placebo Comparator|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
16478021|NCT03443518|Experimental|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical land mark for psoas plexus, also normal saline 0.9% IV infusion will be in the same rate of the Remifentanil infusion for the other group.
16478022|NCT03443518|Experimental|L.A infiltration /Remifentanil infusion|L.A infiltration (lidocaine) 5 ml of 2% will be injected subcutaneous as L.A infiltration then Remifentanil infusion with rate 0.03-0.1 μg / kg / min to achieve Visual Analog Scale 3 or less.
16478023|NCT03443492|Experimental|SLOG|800 mg/m2 gemcitabine at a fixed rate of 10 mg/m2/min followed by a 2-hour intravenous infusion of oxaliplatin on day 1 plus twice daily oral S-1 80-120 mg/day (based on BSA) and oral leucovorin 30 mg twice a day on day 1 to day 7, every 14 days as a cycle
16478024|NCT03443492|Experimental|mFOLFIRINOX|oxaliplatin at a dose of 85 mg/m2, given as a 2-hour infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute infusion. The treatment was immediately followed by a continuous intravenous infusion via central venous catheter of leucovorin 400 mg/m2 given as a 2-hour infusion and 5-FU 2400 mg/m2 over a 46-hour period on day 1 every 14 days/cycle.
16478025|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
16478026|NCT03443466|Experimental|Epidural electrical stimulation (EES)|n=20
16478027|NCT03443466|Active Comparator|Loss of resistance (LOR)|n=20
16478028|NCT03443453|Experimental|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
16478029|NCT03443453|Experimental|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
16478030|NCT03443427|Experimental|Schedule 0-2-6 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).
16478031|NCT03443427|Experimental|Schedule 0-2-12 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).
16478032|NCT03443414|Experimental|0.75 mg RPL554|
16478033|NCT03443414|Experimental|1.5 mg RPL554|
16478034|NCT03443414|Experimental|3 mg RPL554|
16478035|NCT03443414|Experimental|6 mg RPL554|
16478036|NCT03443414|Placebo Comparator|Placebo|
16478037|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
16478038|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
16478065|NCT03443206|Active Comparator|Control|This condition will include access to a website that includes psychoeducation and access to resources.
16478066|NCT03443193|Experimental|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
16478039|NCT03443388|Active Comparator|Part 2: Helmet|"After a screening period, 10 patients with drug resistant epilepsy will first be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. After experiencing a seizure resulting in a fall or any helmet deployment, patients will crossover to the no helmet group. If no seizure resulting in fall occurs in 3 months, participation will end."
16478040|NCT03443388|No Intervention|Part 2: No Helmet|"After a screening period, 10 subjects with drug resistant epilepsy will first be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. After approximately 3 months, patients will crossover to the helmet group."
16478041|NCT03443375|Experimental|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
16478042|NCT03443375|Experimental|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
16478043|NCT03443375|No Intervention|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
16478044|NCT03443362||Chronic urticaria|50 consecutive chronic urticaria patients receiving medical care within the CHU Brugmann Hospital. Diagnose according to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
16478045|NCT03443362||Control|20 healthy control patients, without chronic urticaria. Patients coming to the CHU Brugmann hospital for the excision of atypical naevi.
16478046|NCT03443349|Other|Use of the medical Device: Vibwife One|"The medical device will be used according to its market authorization.
~Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:
~First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.
~Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.
~All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.
~During the intervention period, position and module might be changed once if required."
16478047|NCT03443323|Experimental|OST-S Intervention group|
16478048|NCT03443323|No Intervention|Treatment as usual control group|
16478049|NCT03443310|Other|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
16478050|NCT03443297|Experimental|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight <1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
16478051|NCT03443297|No Intervention|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
16478052|NCT03443284|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of an iPhone or iPod Touch Operating System (iOS) mobile application (app) and a health care provider (HCP) portal.
16478053|NCT03443284|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
16478054|NCT03443271|Experimental|Group T (TAP Block with Bupivicaine)|Ultrasound guided TAP block will be performed in this group. Bupivicaine 0.25 % 20 ml will be administered in the block on either side.
16478055|NCT03443271|Placebo Comparator|Group C (TAP Block with Placebo drug)|Ultrasound guided TAP block will be performed in this group. 0.9 % Saline 20 ml will be administered in the block on either side.
16478056|NCT03443258|Experimental|Intervention Group (IG)|Patients receive needs assessment tool integrated in nursing consultation in accordance with requirements by Danish Health and Medicine Board follow-up program for HNC patients. The consultation consists of 6 steps 1. Welcoming patient; 2. Introducing patient to assessment tool; 3. Discuss symptoms and concerns patient wishes to discuss; 4. Follow up on patients symptoms, concerns and emotional reactions/problems; 5. Accompany/support patient during appointment with surgeon and in cooperation with patient and surgeon ensure that problems arising from the tool needing medical attention are focused on; 6. Continue the consultation after appointment with surgeon; refer patient to multi-disciplinary team members when needed
16478057|NCT03443258|No Intervention|Control Group (CG)|CG will receive standard care according to the Danish Health and Medicine Board's follow-up program for HNC patients. At present this is done by a staff nurse interviewing the patient, who is a member of the rehabilitation team who perform nursing consultations. The interview takes place after the appointment with the surgeon. The nurse refers the patient to physical rehabilitation if needed
16478058|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
16478059|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
16478060|NCT03443232|Experimental|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
16478061|NCT03443232|Other|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
16478062|NCT03443219|Experimental|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
16478063|NCT03443219|Active Comparator|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
16478064|NCT03443206|Experimental|Intervention|This condition will include access to a website that includes a social component, in addition to psychoeducation and access to resources.
16478067|NCT03443193|Experimental|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
16478068|NCT03443180|Other|Dietary intervention|Participants will be asked to remove food containing gluten and ATI from their diets for 4 weeks.
16478069|NCT03443167|Active Comparator|Intervention group|Training on emergency telephone numbers and mnemonics
16478070|NCT03443167|Sham Comparator|Control group|Sham generic formation on the cardiopulmonary arrest.
16478071|NCT03443141|Experimental|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
16478072|NCT03443141|Sham Comparator|Standard dressing|Patients will receive a standard dressing over the wound
16478073|NCT03443128|Experimental|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
16478074|NCT03443102||SARS survivors|First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results.
16478075|NCT03443102||Controls|"Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results.
~Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus."
16478076|NCT03443089|Experimental|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
16478077|NCT03443089|Active Comparator|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
16478078|NCT03443076|Experimental|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
16478079|NCT03443076|Active Comparator|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
16478080|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
16478081|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
16478082|NCT03443050|Experimental|Experimental|Balance training on unstable surfaces
16478083|NCT03443050|Active Comparator|Control|Balance training on stable surface
16478084|NCT03443037||Amantadine group|Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
16478085|NCT03443037||Control group|Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
16478086|NCT03443024|Experimental|125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W)|"125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.
~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).
~Week 2: Four 1-mL SC injections placebo.
~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.
~Weeks 6, 10, 14: Two 1-mL SC placebo."
16478087|NCT03443024|Experimental|250 mg Lebrikizumab - Q4W|"250 mg Lebrikizumab administered SC once Q4W.
~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).
~Week 2: Four 1-mL SC injections of placebo.
~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).
~Weeks 6, 10, 14: Two 1-mL injections of placebo."
16478088|NCT03443024|Experimental|250 mg Lebrikizumab - Every 2 Weeks (Q2W)|"250 mg Lebrikizumab administered SC once Q2W.
~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).
~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab)."
16478089|NCT03443024|Placebo Comparator|Group 4 - Placebo|"Placebo administered SC once Q2W.
~Baseline and Week 2: Four 1-mL SC injections of placebo.
~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo."
16478090|NCT03443011|Experimental|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
16478091|NCT03442998|Other|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
16478092|NCT03442998|Other|Nature|Study participants will wall on a nature path setting for 50 minutes.
16478093|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
16478094|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
16478095|NCT03442985|Placebo Comparator|Placebo regimen|
16478096|NCT03442972|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
16478097|NCT03442972|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
16478098|NCT03442959||patient with primary resection of the Small Intestinal TNE|
16478099|NCT03442959||patient without primary resection of the Small Intestinal TNE|
16478100|NCT03442946||INS|Patients in need of a cardiovascular surgery will be included in this observational study. The focus is on the nutrition therapies provided to these critically ill patients according to institutional or international nutrition guidelines, what ever applies for the participating sites.
16478101|NCT03442933|Active Comparator|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
16478102|NCT03442933|Active Comparator|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
16478103|NCT03442920|Experimental|Obese women|Obese women who participated exercise programme.
16478104|NCT03442920|No Intervention|Normal weighted|Normal weighted women with non-periodontitis
16478105|NCT03442907|Experimental|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.
~To achieve the blood pressure target, fluid or vasoactive substances will be used."
16479112|NCT03436251|Experimental|Local Hyperthermia at 44℃ for CIN2/HPV+|Local hyperthermia at 44℃ for 30 mins at days of 1,2,3 and 17, 18. HPV+ and CIN2.
16478106|NCT03442907|Active Comparator|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
16478107|NCT03442894|Active Comparator|Standard PT Treatment|"This group will receive manual therapy and exercise interventions provided by their physical therapist. The treatment will occur for 10 sessions over 6 weeks.
~Interventions: Manual therapy interventions including mobilization and manipulation of the shoulder girdle spine and ribcage. Exercise interventions will include strengthening and flexibility exercises for rotator cuff and shoulder girdle musculature."
16478108|NCT03442894|Experimental|Standard PT Treatment plus DN|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits.
16478109|NCT03442894|Sham Comparator|Standard PT Treatment plus Sham DN|In addition to the standard PT treatment, patients in the sham DN group will receive 6 sessions of sham DN intervention.
16478110|NCT03442881||benign adnexal mass|pathological examination of the specimen after excision reveals benign criteria
16478111|NCT03442881||Malignant adnexal mass|pathological examination of the specimen after excision reveals malignant criteria
16478112|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
16478113|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
16478114|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
16478115|NCT03442816|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
16478116|NCT03442803|Experimental|Propofol TCI|Delivery of Propofol via a Target-controlled infusion pump for procedural sedation.
16478117|NCT03442790|Experimental|Agitated Saline Method|The proper placement of the central venous line will be confirmed using agitated saline under ultrasound vision
16478118|NCT03442790|Active Comparator|Chest X-Ray Confirmation|The proper placement of the central venous line will be compared with chest x-ray obtained in supine position after central line placement
16478119|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings
~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
16478120|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings
~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
16478121|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
16478122|NCT03442764|Experimental|Group 1|Active Treatment for participants with base target trough concentration
16478123|NCT03442764|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
16478124|NCT03442764|Placebo Comparator|Placebo|Placebo Group
16478125|NCT03442751|Active Comparator|Epithelium-on CXL Treatment Group|Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)
16478126|NCT03442751|Sham Comparator|Sham Treatment/Control Group|Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)
16478127|NCT03442738||Group I Endocuff group|Group I Endocuff cap use
16478128|NCT03442738||Group II standard colonoscope|Group II standard colonoscope, no further device used
16478129|NCT03442725|Experimental|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
16478130|NCT03442725|Active Comparator|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
16478131|NCT03442725|Experimental|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
16478132|NCT03442725|Experimental|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
16478133|NCT03442712|Active Comparator|Treatment arm 1|"Auricular acupressure (AA) plus smartphone App:
~Semen Vaccaria laccaria will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear. Subjects will be requested to apply pressure on the acupoints thrice per day. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. The total treatment period will be 8 weeks."
16478134|NCT03442712|Active Comparator|Treatment arm 2|The participants will only receive AA treatment and are required to perform daily self-administered seeds pressing.
16478135|NCT03442712|No Intervention|Treatment arm 3|The participants in the waitlist control group will maintain their usual dietary and exercising patterns.
16479200|NCT03435705|No Intervention|control arm|usual care after the end of the recommended initial program
16478136|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
16478137|NCT03442686|Experimental|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
16478138|NCT03442686|No Intervention|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
16478139|NCT03442673|Active Comparator|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
16478140|NCT03442673|Experimental|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
16478141|NCT03442660|Other|Data collection|An electronic data capture (EDC) system will be used to collect data in electronic format. Data will be collected at the enrolment visit, at the follow-up visit (8 weeks +/-2 weeks) and 1 to 4 days after the follow-up visit.
16478142|NCT03442647|Active Comparator|Living donors|sinistrin clearance dynamic measurement
16478143|NCT03442647|Active Comparator|ADPKD patients|sinistrin clearance dynamic measurement
16478144|NCT03442647|Active Comparator|Patients with primary renal tumor|sinistrin clearance dynamic measurement
16478145|NCT03442634|Experimental|Early Hydration Group|this study group will get 200 ml of sugar free water within 1 hour after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Early Oral Hydration
16478146|NCT03442634|Active Comparator|Traditional Hydration Group|this study group will get 200 ml of sugar free water after 6 hours after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Traditional Oral Hydration
16478147|NCT03442621|Experimental|Relacorilant Fasted|Relacorilant Fasted
16478148|NCT03442621|Experimental|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
16478149|NCT03442621|Experimental|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
16478150|NCT03442608|Experimental|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
16478151|NCT03442608|Placebo Comparator|northermia|normal physical cooling methods,like ice bag, conditionally required.
16478152|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
16478153|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
16478154|NCT03442582||Afluria|Afluria exposure in pregnancy
16478156|NCT03442556|Experimental|Treatment (docetaxel, carboplatin, rucaparib camsylate)|"INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16478157|NCT03442543|Experimental|charcoal|
16478158|NCT03442543|Experimental|silver wire|
16478159|NCT03442530|Active Comparator|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
16478160|NCT03442530|Experimental|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
16478161|NCT03442517|Experimental|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
16478162|NCT03442517|Active Comparator|Usual prenatal care|Participants will continue their usual prenatal care.
16478163|NCT03442504|Other|FES PET/CT|"The images will be made immediately after the injection of the FES in a dynamic acquisition, of 30 minutes, centered on a positive FDG lesion. The imaging will then be completed 1 hour after the injection, after obtaining a urination, by an acquisition whole body (from the top of the skull to the root of the thighs or more if element on FDG or conventional imaging) which will be performed in the supine position with arms around the body. During the PET / CT scan, patients will breathe spontaneously. The acquisition will last 30 minutes."
16478164|NCT03442491||Hayman's Haemostatic Suture|Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.
16478165|NCT03442478|Experimental|2D/3D Tomosynthesis|2D/3D Tomosynthesis images will be obtained in addition to standard mammographic images.
16478166|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone sarcoma
16478167|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone sarcoma
16478168|NCT03442452|Other|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
16478169|NCT03442439|Active Comparator|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
16478170|NCT03442439|Experimental|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
16478171|NCT03442426|Experimental|Intervention Cohort|Integrated model of primary care
16478172|NCT03442413|Experimental|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
16478173|NCT03442400|Experimental|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
16478174|NCT03442387|Experimental|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
16478175|NCT03442387|Experimental|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
16478176|NCT03442374|Experimental|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
16478177|NCT03442374|No Intervention|Non-exercise|No exercise intervention.
16478178|NCT03442361||Intralipid|Standard soybean oil-based therapy
16478179|NCT03442361||Clinoleic|Olive oil based therapy
16478180|NCT03442348|Experimental|Omega 3 fatty acid supplements|Participants in this arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
16478181|NCT03442348|Active Comparator|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (inulin fibre) per day for a period of 6 weeks.
16478182|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
16478183|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
16478184|NCT03442322|Active Comparator|transdisciplinary approach|The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
16478185|NCT03442322|Active Comparator|multidisciplinary approach|The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
16478186|NCT03442309|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
16478187|NCT03442309|Active Comparator|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
16478188|NCT03442296|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
16478189|NCT03442296|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
16478190|NCT03442283||Supplementation|
16478191|NCT03442283||No Supplementation|
16478192|NCT03442257|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
16478193|NCT03442257|No Intervention|Control|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
16478194|NCT03442244|Experimental|LEO 90100 foam|Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g
16478195|NCT03442244|Placebo Comparator|Vehicle foam|"Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner.
~Foam vehicle does not contain active ingredients"
16478196|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
16478197|NCT03442218|Experimental|Clorhexidine|Vaginal wash with clorhexidine solution
16478198|NCT03442218|Placebo Comparator|Saline solution|Vaginal wash with saline solution
16478199|NCT03442205|Experimental|Group A|
16478200|NCT03442205|Experimental|Group B|
16478201|NCT03442205|Experimental|Group C|
16478202|NCT03442192|Other|PrEP Care Anywhere Services|The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.
16478203|NCT03442179|Active Comparator|Treatment Group|Anesthesiologists in the treatment group use the unprocessed EEG waveforms and EEG spectrogram to maintain appropriate levels of unconsciousness for general anesthesia while avoiding burst suppression.
16478204|NCT03442179|No Intervention|Control Group|Anesthesiologists managing patients assigned to the control group will manage each anesthetic based on their clinical judgment, using standard monitoring required by American Society of Anesthesiologists (ASA), which include cardiac and respiratory monitoring, but not EEG monitoring.
16478262|NCT03441867|Experimental|(CBT-Sz) - PNES|Participants with history of a head injury and confirmed Psychogenic Non-Epileptic Seizures will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
16480842|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
16478205|NCT03442166|Active Comparator|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
16478206|NCT03442166|Sham Comparator|Sham group|Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
16478207|NCT03442153|Experimental|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
16478208|NCT03442153|Placebo Comparator|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
16478209|NCT03442140|Experimental|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
16478210|NCT03442127|Other|Patient Group|Program users
16478211|NCT03442114|Experimental|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients & Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
16478212|NCT03442114|Active Comparator|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
16478213|NCT03442101||Treatment group|These participants are newly diagnosed with psychosis.
16478214|NCT03442088|Experimental|Apremilast for Treatment of Psoriasis with the AM-endotype|Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
16478215|NCT03442088|No Intervention|Untreated healthy control|Untreated healthy controls will also be enrolled and will provide two blood draws. These are needed to maintain quality control of the normal levels of the biomarkers being tested.
16478216|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
16478217|NCT03442075||Group 2|Group 2 was administered analgesic orally
16478218|NCT03442075||Group 3|Group 3 was given trans rectal gel
16478219|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
16478220|NCT03442075||Group 5|Group was performed by placebo oral
16478221|NCT03442062|Experimental|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes ~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
16478222|NCT03442062|Experimental|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
16478223|NCT03442062|Experimental|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
16478224|NCT03442062|Other|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
16478225|NCT03442049|Experimental|Study group|Spinal stabilization exercises in addition to home exercise program
16478226|NCT03442049|Active Comparator|Control Group|Home exercise program
16478227|NCT03442036|Active Comparator|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.
~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
16478228|NCT03442036|Experimental|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.
~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
16478229|NCT03442023|Experimental|Chlorhexidine 2%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 2% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 2%
16478230|NCT03442023|Active Comparator|Chlorhexidine 0.12%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 0.12% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 0.12%
16478231|NCT03442010||People with adverse drug event|People with adverse drug event
16478232|NCT03442010||People without adverse drug event|People without adverse drug event
16478233|NCT03441997|Experimental|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
16478234|NCT03441997|Active Comparator|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
16478235|NCT03441997|No Intervention|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
16479225|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
16478236|NCT03441984|Experimental|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478237|NCT03441984|Experimental|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478238|NCT03441984|Experimental|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478239|NCT03441984|Experimental|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478240|NCT03441984|Experimental|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478241|NCT03441984|Experimental|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478242|NCT03441984|Experimental|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478243|NCT03441984|Experimental|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478244|NCT03441984|Experimental|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478245|NCT03441984|Experimental|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478246|NCT03441984|Experimental|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478247|NCT03441984|Experimental|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
16478248|NCT03441971|Experimental|Single Arm|Participants will receive the device on Day 1.
16478249|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.
~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.
~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
16478250|NCT03441945|No Intervention|control|"The patients swallowed the capsule with water in the lying position.After finishing the stomach examination, the operation of the capsule is adjusted to small bowel mode without magnetic control. Capsule entered the duodenum under physiological peristalsis. The position of the capsule was established using a real-time viewer. If the capsule failed to enter the duodenum after one hour, domperidone (10 mg) was orally administered."
16478251|NCT03441945|Experimental|magnetic steering|"After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis. After reaching the duodenal bulb, capsule was held to the maximum position of Z, then the capsule would scan the duodenal bulb automatically with the mode 360° automatic scanning."
16478252|NCT03441932|Active Comparator|Dysphagia screening failed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
16478253|NCT03441932|Active Comparator|Dysphagia screening passed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
16478254|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"Diagnosis based on clinical criteria
~Duration of diabetes ≥10 years
~Age ≥20 years, ≤ 60 years
~HbA1c >64 mmol/mol"
16478255|NCT03441919||Patients with type 1 diabetes, good glycemic control|"Diagnosis based on clinical criteria
~Duration of diabetes ≥10 years
~Age ≥20 years, ≤ 60 years
~HbA1c <64 mmol/mol"
16478256|NCT03441919||Healthy subjects|"Absence of disease, no use of medication
~Matched for age, gender and BMI
~HbA1c <42 mmol/mol"
16478257|NCT03441893|Experimental|Patients with ulcerative colitis|
16478258|NCT03441893|Experimental|Participants (control group)|
16478259|NCT03441893|Active Comparator|UC patients (cohort 1)|
16478260|NCT03441893|Active Comparator|UC patients (cohort 2)|
16478261|NCT03441893|Active Comparator|UC patients (cohort 3)|
16478263|NCT03441867|Experimental|(CBT-Sz) - PTE|Participants with history of a head injury and confirmed Post-Traumatic Epilepsy (PTE) will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
16478264|NCT03441867|Active Comparator|TBI Control|Participants with TBI will complete 2 brain fMRI scans.
16478265|NCT03441867|Active Comparator|Healthy Volunteer|Healthy control volunteers will complete 2 brain fMRI scans.
16478266|NCT03441854||HFNC group|The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.
16478267|NCT03441854||Control Group|For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.
16478268|NCT03441841|Experimental|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
16478269|NCT03441841|Active Comparator|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
16478270|NCT03441841|Active Comparator|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
16478271|NCT03441828|Experimental|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.
~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
16478272|NCT03441828|Active Comparator|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.
~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
16478273|NCT03441815|Experimental|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
16478274|NCT03441815|Experimental|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
16478275|NCT03441815|Experimental|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
16478276|NCT03441815|Experimental|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
16478277|NCT03441815|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
16478278|NCT03441802|Active Comparator|Cases|
16478279|NCT03441802|Other|Controls|
16478280|NCT03441789|Experimental|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
16478281|NCT03441789|Placebo Comparator|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
16478282|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
16478283|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
16478284|NCT03441763|Experimental|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
16478285|NCT03441763|Experimental|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
16478286|NCT03441763|Experimental|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
16478287|NCT03441750|Experimental|metformin plus standard lifestyle intervention|Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
16478288|NCT03441750|Other|Standard lifestyle intervention|Standard lifestyle advice will be united for all subjects by providing special booklet.
16478289|NCT03441737|Experimental|Exercise|Aerobic exercise intervention
16478290|NCT03441737|Active Comparator|Non-Exercise|Non-aerobic exercise intervention
16478291|NCT03441724||STEMI before PCI|ST-segment elevation, recording acquired before coronary intervention
16478292|NCT03441724||STEMI after PCI|ST-segment elevation, recording acquired from the same patients after coronary intervention
16478293|NCT03441711||Group 1|elevated sFlt-1/PlGF ratio
16478294|NCT03441711||Group 2|normal sFlt-1/PlGF ratio
16478295|NCT03441698|Experimental|Genuine acupuncture (A)|Genuine acupuncture (A) with neutral communication (A1) or positive communication (A2)
16478296|NCT03441698|Placebo Comparator|Sham Acupuncture (B)|Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
16478297|NCT03441698|Active Comparator|Rest (C)|Rest (C) with neutral communication (C1) or positive communication (C2)
16478298|NCT03441685|Experimental|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
16478299|NCT03441672|Experimental|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
16478300|NCT03441672|No Intervention|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
16478301|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.
~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~1b. patients who previously have been treated with VKA in the 12 months before index date."
16478302|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.
~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~2b. patients who previously have been treated with VKA in the 12 months before index date."
16478303|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.
~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~3b. patients who previously have been treated with VKA in the 12 months before index date."
16478304|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.
~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~4b. patients who previously have been treated with VKA in the 12 months before index date."
16478305|NCT03441620|Placebo Comparator|Control|Calorie and fiber-matched control powder
16478306|NCT03441620|Experimental|Strawberry one serving|Freeze-dried powder equivalent to one serving fresh strawberries per day.
16478307|NCT03441620|Experimental|Strawberry two-half servings|Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
16478308|NCT03441607|Active Comparator|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
16478309|NCT03441607|Placebo Comparator|Placebo|Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
16478310|NCT03441581|Experimental|Eluxadoline 100 mg with BAM|IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.
16478311|NCT03441581|Experimental|Eluxadoline 100 mg without BAM|IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.
16478312|NCT03441568|Experimental|BAY987534|Infants and children with quiescent atopic dermatitis
16478313|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
16478314|NCT03441542|Experimental|Data-assisted Case Navigation|Patients are recruited and consented into the study by the patient navigator after which the navigator provides assistance with scheduling, reminders, and transportation. The navigator is also charged with responding to patient questions, and monitoring and documenting if and when patients achieve HCV care milestones. Each month, the project will update the Grady Liver Clinic HCV patient registry, to generate information about the patient's HCV care progress and use this information to develop instructions sheets regarding the expected care milestones to be achieved that month for each patient. During the month, the navigator will participate in project meetings and report on milestone achievement and barriers for patients assigned to the experimental arm of the study.
16478315|NCT03441542|Active Comparator|Standard of Care|Patients are recruited and consented into the study by the patient navigator at which time they will be reminded of their infection, consequences of untreated disease, and the availability of study sponsored antiviral treatment should they seek it. Patients will not be subsequently contacted by the study. Patients who seek treatment without patient navigation services will receive the same study provided HCV pre-treatment care and study provided treatment drugs when indicated. Self-referral to care and antiviral therapy when indicated are known to be effective in curing HCV among some patients, this arm is classified as an active comparator.
16478316|NCT03441529|Experimental|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
16478317|NCT03441529|Experimental|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
16478318|NCT03441516|Experimental|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
16478319|NCT03441516|Active Comparator|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
16478320|NCT03441503|Experimental|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey
~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:
~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.
~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
16478321|NCT03441503|No Intervention|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
16478322|NCT03441490|Active Comparator|ICBT standard|Internet-based cognitive behavioural therapy with therapeutic guidance through mail
16478323|NCT03441490|Experimental|ICBT chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat
16478324|NCT03441490|Experimental|ICBT learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail
16478325|NCT03441490|Experimental|ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat
16478326|NCT03441464|Experimental|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
16478327|NCT03441464|Experimental|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
16478328|NCT03441464|Experimental|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
16478329|NCT03441464|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
16478330|NCT03441438|Active Comparator|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
16478331|NCT03441438|Active Comparator|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
16478332|NCT03441438|Active Comparator|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
16478333|NCT03441425|No Intervention|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
16478334|NCT03441425|Experimental|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
16478335|NCT03441412|Experimental|Ticagrelor/Epinephrine/Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.
~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
16478336|NCT03441399|Experimental|Escalating Incentives|Participants assigned to the escalating financial incentives will receive an increasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
16478337|NCT03441399|Experimental|De-escalating Incentives|Participants assigned to the de-escalating financial incentives will receive a decreasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
16478338|NCT03441399|No Intervention|Control|Participants in this condition will receive usual care.
16478339|NCT03441386|Experimental|Cognitive Study|Cognitive Responses was analyzed after different intensities physical exercise sessions.
16478340|NCT03441373|Experimental|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
16478341|NCT03441373|Experimental|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.
~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
16478342|NCT03441373|Experimental|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
16478343|NCT03441373|Placebo Comparator|Placebo (Group D)|Placebo orally.
16478347|NCT03441347|Experimental|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
16478348|NCT03441347|Other|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
16478349|NCT03441334|Experimental|High Frequency rTMS|The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
16478350|NCT03441334|Sham Comparator|Sham rTMS|The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.
16478351|NCT03441321|Experimental|Group I (focusing on indoor tanning and healthy body image)|Participants periodically read the content on the study-specific secret Facebook group related to living a healthy lifestyle including avoiding indoor tanning and excessive ultraviolet exposure, managing stress, healthy eating, promoting physically active lifestyles, and promoting a healthy body image, and participate in the group by providing reactions, commenting on the posts, or by sharing study relevant information within the group for 8 weeks.
16478352|NCT03441321|Active Comparator|Group II (focusing on other health topics)|Participants participate in secret Facebook groups that utilize content from the intervention content library related to other health topics of interest (e.g., physical activity, healthy eating, alcohol misuse prevention, stress reduction, sleep) for 8 weeks.
16478353|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
16478354|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
16478355|NCT03441295|Experimental|Study 1 Ligamys|Repair Surgery.
16478356|NCT03441295|Experimental|Study 1 Internal Bracing|Repair Surgery.
16478357|NCT03441295|Experimental|Study 2 Internal Bracing|Repair Surgery.
16478358|NCT03441295|Active Comparator|Study 2 Reconstruction|Reconstructive Surgery.
16478359|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.
~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
16478360|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.
~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents."
16478361|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
16478362|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
16478363|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
16478364|NCT03441256|Experimental|Intervention|All participant in the intervention group will undergo the LION procedure and subsequent neurostimulation.
16478365|NCT03441256|Active Comparator|Control|All participants in the control group will be issued with a device for neuromuscular electrical stimulation.
16478366|NCT03441243||Case group:Cesarean section urgently|- 43 patients had an emergency caesarean section between 01/01/2015 and 31/12/2016.
16478367|NCT03441243||Case group:Hemorrhage of deliverance|- 85 patients had haemorrhage of the delivery with need for a transfusion between 01/01/2015 and 31/12/2017.
16478368|NCT03441243||Control group: delivery physiological low path|- A control group will consist of 128 patients who had a physiological low birth delivery over the same period.
16478369|NCT03441230|Active Comparator|Circumference of 13 cm, sphere form (diameter of 4 cm)|
16478370|NCT03441230|Active Comparator|Circumference of 13 cm, cylinder form, length 11 cm|
16478371|NCT03441230|Active Comparator|Circumference of 16 cm, sphere form (diameter of 5 cm)|
16478372|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 11 cm|
16478373|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 18 cm|
16478374|NCT03441230|Active Comparator|Circumference of 19 cm, sphere form (diameter of 6 cm)|
16478375|NCT03441230|Active Comparator|Circumference of 19 cm, cylinder form, length 11 cm|
16478376|NCT03441230|Active Comparator|Circumference of 22 cm, sphere form (diameter of 7 cm)|
16478377|NCT03441230|Active Comparator|Circumference of 25 cm, sphere form (diameter of 8 cm)|
16478378|NCT03441230|Active Comparator|Circumference of 28 cm, sphere form (diameter of 9 cm)|
16478379|NCT03441217|Experimental|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
16478380|NCT03441217|Placebo Comparator|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
16478381|NCT03441204|Active Comparator|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
16478382|NCT03441204|Active Comparator|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
16478383|NCT03441191|Experimental|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
16478384|NCT03441191|Placebo Comparator|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
16478385|NCT03441178|Experimental|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
16478386|NCT03441152|Experimental|tDCS+CT|application of tDCS in combination with CT
16478387|NCT03441152|Sham Comparator|Sham tDCS|application of sham tDCS in combination with CT
16478388|NCT03441152|Active Comparator|CT|application of CT
16478391|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
16478416|NCT03440970|Placebo Comparator|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
16478396|NCT03441100|Experimental|Experimental: IMA202 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.
~Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
16478397|NCT03441087|Other|Transvaginal ultrasound|Transvaginal ultrasound was applied 216 women with abnormal uterine bleeding.The transvaginal ultrasound diagnoses were compared with the received endometrial samples.
16478398|NCT03441087|Other|Hysteroscopy|Hysteroscopy was also performed under general anesthesia.Hysteroscopy was performed by a single operator (NNY).The operator and two supervising endoscopists were blinded to the ultrasound results.After the hysteroscopy, endometrial sampling was also done. The diagnoses were compared with the received endometrial samples.
16478399|NCT03441074|Experimental|Intervention Group|Patients randomly assigned to intervention group will get enhanced olfactory stimuli during the perioperative period
16478400|NCT03441074|No Intervention|Non-intervention Group|Patients randomly assigned to non-intervention group will not get any olfactory stimuli during the perioperative period
16478401|NCT03441061|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8. Treatment repeats every 21-28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16478402|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
16478403|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
16478404|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
16478405|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
16478406|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
16478407|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
16478408|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
16478409|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
16478410|NCT03441022|Experimental|Cardioversion|Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
16478411|NCT03440996|Experimental|Clinpro™ 5000|Participants will use Clinpro™ 5000 to brush their teeth for two minutes twice daily for 4 months.
16478412|NCT03440996|Experimental|Clinpro™ Tooth Crème|Participants will use Clinpro™ Tooth Crème to brush their teeth for two minutes twice daily for 4 months.
16478413|NCT03440996|Active Comparator|MI-Paste Plus|Participants will use MI-Paste Plus to brush their teeth for two minutes twice daily for 4 months.
16478414|NCT03440983|Experimental|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
16478415|NCT03440970|Experimental|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
16478418|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
16478419|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
16478420|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
16478421|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
16478422|NCT03440892||1|
16478423|NCT03440879|Experimental|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
16478424|NCT03440879|No Intervention|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
16478425|NCT03440866|Experimental|Intervention|Administration of drugs concomitantly.
16478426|NCT03440866|No Intervention|Control|Administration of oral Mifepristone 600 mg and after interval of 48 hours administration of oral Misoprostol 400 mcg.
16478427|NCT03440853|Experimental|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
16478428|NCT03440853|Other|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
16478429|NCT03440840|Experimental|Computer Training with active tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with active transcranial direct current stimulation (tDCS).
16478430|NCT03440840|Active Comparator|Computer Training with sham tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with sham transcranial direct current stimulation (tDCS).
16478431|NCT03440840|Placebo Comparator|Computer Training with or without tDCS|Participants in this arm will watch educational videos as a comparator to computer training with the car racing game (watching educational videos).
16478432|NCT03440827|Other|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.
~Phase 2 : Administration of the scale of life's quality for validation."
16478433|NCT03440814|Experimental|DCCR|75 - 450 mg DCCR
16478434|NCT03440814|Placebo Comparator|Placebo|75 - 450 mg placebo for DCCR
16478435|NCT03440801|Experimental|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
16478436|NCT03440801|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
16478437|NCT03440775|Experimental|Experimental|
16478438|NCT03440775|Sham Comparator|Comparator|
16478439|NCT03440762|Other|AF awareness education|AF awareness education face to face
16478440|NCT03440749|Experimental|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
16478441|NCT03440749|Active Comparator|Control Group|Serial reaction time task: of movements according to the luminous stimuli
16478442|NCT03440736|Active Comparator|Secukinumab 300 mg s.c.|Patients in arm A receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
16478443|NCT03440736|Experimental|Secukinumab 300 mg s.c. and lifestyle intervention|Arm B: Patients in arm B receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24). In addition they participate in a lifestyle intervention program.
16478444|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
16478445|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
16478446|NCT03440710|Experimental|with BET|with BET and Tympanoplast
16478447|NCT03440710|Other|without BET|with Tympanoplast only
16478448|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
16478449|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)
~•positive genetic testing and/or a previous cardiac study required to be eligible"
16478450|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
16478451|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
16478452|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects
~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
16478453|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
16478454|NCT03440684|Experimental|Healthy individuals|Forty-one healthy individuals were volunteer to participate in the study and 39 of them had no neurological disease, were from 18 to 65 years old, and had no upper extremity injuries. And they have joined to exercise training during 6 weeks.
16478455|NCT03440671|Experimental|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
16478456|NCT03440671|Active Comparator|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
16478458|NCT03440632|Other|FES start|"Start: 4 weeks 'adaptation phase' and 8 weeks 'FES phase'. Adaption phase: the stimulus (in Volt) will gradually be increased up to an effective level and the wear time has to be increased from 30 minutes to 6 hours a day. FES phase: the participants have to wear the FES device for minimal 6 hours a day during walking. Usual physiotherapy can be continued during the FES phase.
~Second: after the FES phase, this group will enter the 'wash-out' period of 6 weeks for fading of the therapeutic effects, in which they return to their conventional therapy. Afterwards, 12 weeks of conventional therapy (orthoses/shoes and usual physiotherapy) with measurements at start and end will follow."
16478459|NCT03440632|Other|Conventional start|"Start: wearing usual orthoses/shoes on a daily basis for the first 12 weeks of the study. Usual physiotherapy can be continued.
~Second: after 12 weeks this group will enter a 6 week watch out phase, and next be switched to FES treatment for 12 weeks, consisting of: 4 weeks 'adaptation phase' with gradual increase of the treatment and 8 weeks 'FES phase'."
16478460|NCT03440619|Experimental|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
16478461|NCT03440606|Experimental|MCAT Supervision Group|The 6-week 3-hour Mindful-Compassion Art Therapy (MCAT) supervision will include intervention elements of brief psycho-education, weekly mindfulness mediation that serve as a foundation to foster creative art making, reflective writing, group sharing and discussion.
16478462|NCT03440606|Experimental|Waitlist Control Group|Those assigned to the waitlist control group will not receive Mindful-Compassion Art Therapy (MCAT) supervision until approximately 1.5 month later; equivalent intervention and assessment procedures will be administered.
16478463|NCT03440593|Experimental|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
16478464|NCT03440593|No Intervention|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
16478465|NCT03440580|Active Comparator|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
16478466|NCT03440580|No Intervention|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
16478467|NCT03440567|Experimental|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
16478468|NCT03440567|Experimental|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. (Closed as of 12/12/2019)
16478469|NCT03440554|Experimental|Whole Body Non-Contrast MRI|
16478470|NCT03440541|Experimental|treated|Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
16478471|NCT03440515|Experimental|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop
16478472|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
16478473|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
16478474|NCT03440489|Other|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
16478475|NCT03440476|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
16478476|NCT03440476|Active Comparator|Intervention plus feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-only booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The content is clearly automatically generated.
16478477|NCT03440476|Active Comparator|Intervention plus feedback and personal contact booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-plus-personal-contact booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The email is sent from a member of the research staff.
16478478|NCT03440463|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
16478479|NCT03440463|Experimental|Intervention plus Norms-only booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use.
16478480|NCT03440463|Experimental|Intervention plus Norms-plus-Strategies booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use. It also includes reported harm reduction strategies, and other strategies they might consider.
16478481|NCT03440450|Experimental|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16478482|NCT03440450|Experimental|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16478483|NCT03440450|Experimental|Cohort 3: Treatment at 4.8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16478484|NCT03440450|Experimental|Cohort 4: Treatment at 8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
16478486|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
16478487|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
16478488|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index [BMI]) will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
16478489|NCT03440411|Active Comparator|ARM pom-dex Early (A-I)|Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
16478490|NCT03440411|Experimental|ARM pom-cyclo-dex Early(B-I)|Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
16478491|NCT03440411|Experimental|ARM pom-dex Late (A-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.
~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
16478492|NCT03440411|Active Comparator|ARM pom-cyclo-dex Late (B-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.
~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
16478493|NCT03440398|Active Comparator|Open NSM|Conventional Nipple Sparing Mastectomy
16478494|NCT03440398|Experimental|Robotic NSM|Robotic Nipple-Sparing Mastectomy
16478495|NCT03440385|Experimental|Administration of oral Ozanimod|Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation
16478496|NCT03440385|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally starting with a 7-day dose escalation
16478497|NCT03440372|Experimental|Administration of oral Ozanimod|Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation
16478498|NCT03440372|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally starting with a 7-day dose escalation
16478499|NCT03440359|Other|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
16478500|NCT03440359|Active Comparator|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
16478501|NCT03440346|Experimental|Few-foods diet intervention|
16478502|NCT03440320|Experimental|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
16478503|NCT03440320|Active Comparator|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
16478504|NCT03440307|Placebo Comparator|Email Only|Participants received weekly email about health and fitness education. No face-to-face intervention, and not provided any other information about bisphenol exposure.
16478505|NCT03440307|Experimental|Face-to-Face Meetings|Participants met with a counselor once per week for 3-weeks to reduce bisphenol exposure. Intervention included same weekly email about health and fitness education as Email only group, and a weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Women provided with bisphenol-free cosmetics, hygiene, and glass food/water containers.
16478506|NCT03440294|Other|with neoprene suit and life jacket|"Realization of the following examinations WITH neoprene suit and life jacket :
~resting standard spirometry
~maximum exercise testing. No drug and no placebo will be used in this arm."
16478507|NCT03440294|Other|without neoprene suit and life jacket|"Realization of the following examinations WITHOUT neoprene suit and life jacket :
~resting standard spirometry
~maximum exercise testing. No drug and no placebo will be used in this arm."
16478508|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
16478509|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
16478510|NCT03440268|Experimental|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
16478511|NCT03440268|Placebo Comparator|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
16478512|NCT03440255|Experimental|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
16478513|NCT03440242||JJVC Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
16478514|NCT03440242||JJVC Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
16478515|NCT03440242||Marketed Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
16478516|NCT03440242||Marketed Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
16478519|NCT03440216|Experimental|Sampling if GFR = or > 30 mL/min|"Note: GFR = Glomerular Filtration Rate
~Patients with a normal of moderately decreased renal function
~Temocillin: 6 g in continuous infusion over 24 h;
~Ceftriaxone: bolus 2 g (in 30 min) every 12h
~Meropenem: prolonged infusion (3 h) of 2 g every 8h
~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content when possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration when possible"
16478520|NCT03440216|Experimental|Sampling if GFR < 30 mL/min|"Patients with severe renal insufficiency or hemodialysis:
~Temocillin: 6 g in continuous infusion over 24 h;
~Ceftriaxone: bolus 2 g (in 30 min) every 12h
~Meropenem: prolonged infusion (3 h) of 2 g every 8h
~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content if possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration if possible"
16478521|NCT03440203||no Diabetic neuropathy|
16478522|NCT03440203||Diabetic peripheral neuropathy|
16478523|NCT03440203||Diabetic peripheral neuropathic pain|
16478524|NCT03440151|Experimental|contralateral submental flap for tongue cancer defect|
16478525|NCT03440151|Active Comparator|primary closure for tongue cancer defect|
16478526|NCT03440138||University Hospital Zurich|
16478527|NCT03440138||St Pierre University Hospital, Brussels, Belgium|
16478528|NCT03440138||Sana Klinikum, Offenbach, Germany|
16478529|NCT03440138||Complutense University of Madrid, Spain|
16478530|NCT03440138||Musgrove Park Hospital, Taunton, UK|
16478531|NCT03440138||University of Gothenburg, Sweden|
16478532|NCT03440138||AZ Sint-Jan Hospital in Bruges, Belgium|
16478533|NCT03440138||Bristol|
16478534|NCT03440138||Cleveland Clinic, Weston, Florida, USA|
16478535|NCT03440138||Oswaldo Cruz German Hospital, Sao Paolo, Brazil|
16478536|NCT03440138||Clínica Las Condes, Santiago, Chile|
16478537|NCT03440138||Brown University, Providence Rhode Island|
16478538|NCT03440138||Fresno Bariatric, CA, USA|
16478539|NCT03440138||Rijnstate Hospital, Arnhem, The Netherlands|
16478540|NCT03440138||CHU Nice, France|
16478541|NCT03440138||Claraspital Basel, Switzerland|
16478542|NCT03440138||Gastro-Obeso-Center Advanced Med Inst, Brazil|
16478543|NCT03440138||Hospital Dipreca Santiago Región Metropolitana , Chile|
16478544|NCT03440138||Medical University Wien, Austria|
16478545|NCT03440125|Experimental|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
16478546|NCT03440125|Experimental|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
16478547|NCT03440125|Experimental|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
16478548|NCT03440112|Active Comparator|Clarithromycin (Not used anymore as of 4/2020)|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
16478549|NCT03440112|Placebo Comparator|Placebo (Not used anymore as of 4/2020)|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
16478550|NCT03440112|Active Comparator|Transdermal flumazenil (added 4/2020)|Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
16478551|NCT03440112|Placebo Comparator|Placebo cream (added 4/2020)|Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
16478552|NCT03440099|Other|Training|All participants will participate in the 16-week resistance exercise training program.
16478553|NCT03440086|Experimental|Abdominal Jackson-Pratt drain|Patients in this arm will undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
16478554|NCT03440086|No Intervention|Controls|Patients in this arm will not undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
16478555|NCT03440073|Experimental|Mulligan Concept Intervention|Mulligan Concept Intervention, including Mobilizations with Movement intervention is administered. Up to 30 minutes total treatment time.
16478556|NCT03440073|Sham Comparator|Sham Mulligan Concept Treatment|Assessment procedures of the Mulligan Concept are followed, but no manual pressure is applied to the participant during treatment to provide a sham Mulligan Concept Treatment.
16478557|NCT03440060|No Intervention|standard group|participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy
16478558|NCT03440060|Active Comparator|Procalcitonin group|participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml
16478560|NCT03440034|Experimental|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
16478561|NCT03440021|Experimental|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
16478562|NCT03440021|Experimental|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
16478563|NCT03440021|Placebo Comparator|Placebo|6 x placebo capsules in a single dose
16478564|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
16478565|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
16478566|NCT03439995|Experimental|Open Lung Protective Ventilation|Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
16478567|NCT03439995|Active Comparator|Conventional Ventilation|Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect
16478568|NCT03439982|Experimental|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
16478569|NCT03439969|No Intervention|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
16478570|NCT03439969|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
16478571|NCT03439969|Experimental|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
16478572|NCT03439969|Experimental|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
16478573|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
16478574|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
16478575|NCT03439943|Experimental|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
16478576|NCT03439943|Placebo Comparator|Placebo|Placebo: once daily subcutaneous injection
16478577|NCT03439930|Active Comparator|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
16478578|NCT03439930|Active Comparator|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
16478579|NCT03439917|Experimental|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
16478580|NCT03439917|Placebo Comparator|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
16478581|NCT03439904|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care
16478582|NCT03439904|No Intervention|control group|Patients will receive usual medical care
16478583|NCT03439891|Experimental|Lead-in Arm I (Part 2: nivolumab, sorafenib)|After determination of MTD [Part 1] participants receive nivolumab IV over 30 minutes on days 1 and 15, and sorafenib PO beginning on day 15 of course 1, then on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16478584|NCT03439891|Experimental|Lead-in Arm II (Part 2: sorafenib, nivolumab)|After determination of MTD [Part 1] participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16479226|NCT03435523|Experimental|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
16478585|NCT03439891|Experimental|Part 1: Dose Escalation (CLOSED TO ENROLLMENT)|Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
16478586|NCT03439878|Experimental|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
16478587|NCT03439878|Active Comparator|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
16478588|NCT03439865|Experimental|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
16478589|NCT03439865|Placebo Comparator|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
16478590|NCT03439852|Experimental|Light to Moderate Physical Activity/Sedentary Time|The telephone counseling plus group cohesion intervention is designed to increase Light-to-Moderate intensity physical activity (LMPA) and reduce Sedentary time (ST). The 12-wk intervention includes group discussions during 3 regular monthly club meetings when clubs' accumulated milestones for LMPA/ST min/wk will be identified and future cumulative club goals for PA/ST set. In addition, each member will receive 12 weekly personalized phone calls from health coaches who will use motivational interviewing to set individualized LMPA/ST goals setting, reduce barriers, and facilitate social support for LMPA/ST change.
16478591|NCT03439852|No Intervention|Delayed Treatment/Healthy Aging|Delayed Treatment (DT) / Healthy Aging materials Condition is for 12 weeks and participants receive 12 phone calls using a previously developed contact-matched protocol that uses mailed healthy aging information and telephone calls to assess symptom ratings. After the initial 12 weeks they then receive the LMPA/ST intervention
16478592|NCT03439839|Experimental|Arm 1|10 patients receiving LNP023 high dose daily over up to approximately 3 years
16478593|NCT03439839|Experimental|Arm 2|5 patients receiving LNP023 low dose daily over up to approximately 3 years
16478594|NCT03439813|Experimental|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
16478595|NCT03439813|Active Comparator|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
16478596|NCT03439800|Experimental|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.
~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.
~Physical Practice: is the execution of the motor action."
16478597|NCT03439800|Active Comparator|Physical Practice|Physical Practice: is the execution of the motor action.
16478598|NCT03439787|Active Comparator|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
16478599|NCT03439787|Placebo Comparator|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
16478600|NCT03439774|Other|Adults 18 years old or older|
16478601|NCT03439761|Experimental|PT-112 Injection|PT-112 Injection alone
16478602|NCT03439748|Experimental|Positive Affect Treatment|Sessions 1-7: Planning for engagement in pleasurable activities and reinforcement of positive mood effects of those activities Sessions 8-10: Exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention
16478603|NCT03439748|Active Comparator|Negative Affect Treatment|Sessions 1-7: Exposures to avoided scenarios Sessions 8-10: Cognitive restructuring Sessions 11-14: Normalization of arousal response to exposure Session 15: Relapse prevention
16478604|NCT03439735|Experimental|Cohort A: Participants with untreated metastatic disease receiving ET and a CDK 4/6|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
16478605|NCT03439735|Experimental|Cohort B: Participants initiating a CDK 4/6 i after progression on ET.|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
16478606|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
16478607|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
16478608|NCT03439709|Experimental|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
16478609|NCT03439709|Active Comparator|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
16478610|NCT03439696|Experimental|Needlescopic-assisted|Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
16478611|NCT03439696|Active Comparator|Uniportal|Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
16478612|NCT03439683||Physicians|"Definition: Physicians working in the ICU for at least 50% of their time in the hospital
~Intervention: Survey about patient-ventilator asynchrony"
16478613|NCT03439683||Nurses|"Definition: Nurses working in the ICU for at least 20 hours/week
~Intervention: Survey about patient-ventilator asynchrony"
16478614|NCT03439683||Respiratory Therapists|"Definition: Respiratory Therapists working in the ICU for at least 20 hours/week
~Intervention: Survey about patient-ventilator asynchrony"
16478615|NCT03439670|Experimental|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
16478616|NCT03439670|Experimental|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
16478617|NCT03439670|Active Comparator|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
16478618|NCT03439670|Active Comparator|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
16478619|NCT03439670|Placebo Comparator|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
16478620|NCT03439670|Placebo Comparator|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
16478621|NCT03439657|Experimental|Co-Ad Group|Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
16478622|NCT03439657|Active Comparator|Control Group|Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
16478623|NCT03439631|Active Comparator|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
16478624|NCT03439631|Other|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
16478625|NCT03439618|Other|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
16478626|NCT03439618|Other|time-restricted feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 6h (7:00-9:00,11:00-13:00,17:00-19:00).
16478627|NCT03439592||hyperglycemic patients|diabetic patients admitted for STEMI and with hyperglycemia at hospital admission.
16478628|NCT03439592||normoglycemic patients|diabetic patients admitted for STEMI and with normoglycemia at hospital admission.
16478629|NCT03439579|Experimental|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
16478630|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
16478631|NCT03439553|Experimental|Intervention|People shown ads with referral to target websites.
16478632|NCT03439553|Active Comparator|Intervention with control websites|People shown ads with referral to control websites.
16478633|NCT03439553|No Intervention|Control|People who make target queries, but are not shown the ads.
16478634|NCT03439540|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 12 weeks.
16478635|NCT03439540|Experimental|Plantago major|Individuals receive Plantago major daily, for 12 weeks.
16478636|NCT03439527|Experimental|MPC-group|All patients are treated by the same product: Autologous MPCs
16478637|NCT03439527|Other|NMES+MPC-group|After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy (Neuromuscular Electromagnetic Stimulation, NMES)
16478638|NCT03439514|Experimental|Part 1 Double-blind Treatment|ARRY-371797 (PF-07265803) tablet orally OR matching placebo tablet orally
16478639|NCT03439514|Experimental|Part 2 Open-label Treatment|ARRY-371797 (PF-07265803) tablet orally
16478640|NCT03439501|Other|avelumab|"1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)
~Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
16478641|NCT03439488|Experimental|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ-440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
16478642|NCT03439488|Experimental|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily or twice daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
16478643|NCT03439488|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ-440/placebo once daily or twice daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
16479312|NCT03434860|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
16478644|NCT03439436|Experimental|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
16478645|NCT03439436|Active Comparator|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
16478646|NCT03439423||Patients who underwent EVAR|
16478647|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
16478648|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
16478649|NCT03439397|Experimental|Ballon Technique group|Intervention：Ballon Technique
16478650|NCT03439397|Active Comparator|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
16478651|NCT03439384|Experimental|Experimental: Home Telemonitoring|Patients will receive home telemonitoring equipment and monitor their health for 60 days post-enrollment. A monitoring nurse will receive and review the patients health data on a daily basis for the 60 day duration and provide remote care, counseling and education.
16478652|NCT03439384|No Intervention|Control: No Home Telemonitoring|The patient will not receive any home telemonitoring once enrolled and will continue to receive the usual care he/she can expect as part of his/her care plan.
16478653|NCT03439371|Experimental|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
16478654|NCT03439358|Experimental|Magnesium sulfate|Magnesium sulfate (MgSO4) infusion will be commenced prior to epidural top-up.
16478655|NCT03439358|Placebo Comparator|Normal saline|Normal saline infusion will be commenced prior to epidural top-up.
16478656|NCT03439345|Experimental|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
16478657|NCT03439345|Placebo Comparator|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
16478658|NCT03439319|Active Comparator|MyndMove® therapy|Non-invasive Functional Electrical Stimulation (FES) technique with surface electrodes to stimulate from 3 to 8 muscles to create purposeful movements in one or both hands/arms
16478659|NCT03439319|Active Comparator|Intensive Conventional therapy|Using Conventional therapy which focuses exclusively on the purposeful movements in one or both hands/arms
16478660|NCT03439306||healthy adult volunteer|"Subject is 18 to 50 years of age.
~Subject is a non-smoker or who has not smoked within 2 days prior to the study."
16478661|NCT03439293|Experimental|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 milligram per kilogram (mg/kg), intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), have an unacceptable toxicity, or withdraw consent, or when the study has completed or until the sponsor terminates the study.
16478662|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: TAK-079|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. Dose escalation of TAK-079 will range from 45 milligram (mg) to 1800 mg and may be done using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
16478663|NCT03439280|Experimental|Phase 1 Dose Confirmation Cohort: TAK-079|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD. TAK-079 dose will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the previous cohort of Phase 1.
16478664|NCT03439280|Experimental|Phase 1 Combination Cohort: TAK-079 + PomDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, orally, once daily on Days 1 to 21 and dexamethasone, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD. TAK-079 dose will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1.
16478665|NCT03439280|Experimental|Phase 2a: TAK-079 TBD|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study.
16478666|NCT03439267|Active Comparator|Proactive Current National Guidelines Group|Standard Interventional Control Group. Will receive treatment recommendation according to the current National guidelines for statin initiation and follow-up.
16478667|NCT03439267|Experimental|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin recommendation based on the cardiovascular risk algorithm.
16478668|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
16478669|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
16478670|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 18 months
16478671|NCT03439241|Experimental|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
16478672|NCT03439241|Experimental|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
16478673|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
16478674|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
16478675|NCT03439215|Experimental|Lorlatinb Arm|Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.
16478676|NCT03439202|Other|No arm used|No drug use for this study. No arm used in this study. Subjects are exposed to hypoxic conditions (clinical study).
16478677|NCT03439189|Experimental|Emricasan 5mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
16478678|NCT03439189|Experimental|Emricasan 25mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
16478679|NCT03439189|Experimental|Emricasan 50mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
16478680|NCT03439189|Placebo Comparator|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
16478681|NCT03439176|Experimental|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:
~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
16478682|NCT03439163||PD patients|the entire group underwent MRI scan
16478683|NCT03439150|Other|Study arm|The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery
16478684|NCT03439137|Experimental|MT-6548|
16478685|NCT03439137|Active Comparator|Darbepoetin alfa|
16478686|NCT03439124|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
16478687|NCT03439124|Active Comparator|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.
~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.
~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
16478688|NCT03439111|Placebo Comparator|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
16478689|NCT03439111|Experimental|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
16478690|NCT03439098|Experimental|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
16478691|NCT03439098|Experimental|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
16478692|NCT03439098|Placebo Comparator|Placebo|Placebo
16478693|NCT03439085|Experimental|Treatment (INO-3112, durvalumab)|Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
16478694|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
16478695|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
16478696|NCT03439059|Experimental|intervention- reducing SB|prompted to do 10min of light physical activity 3x/day
16478697|NCT03439059|No Intervention|Control|go about their normal daily living
16478698|NCT03439046|Experimental|ribociclib+letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
16478699|NCT03439046|Experimental|alpelisib+fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
16478700|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
16478701|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
16478702|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
16478703|NCT03439020|Experimental|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.
~(Plastic stent anchoring)"
16478704|NCT03439020|Active Comparator|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
16478705|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
16478706|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
16478707|NCT03438994|Active Comparator|Participants diagnosed with ASD|
16478708|NCT03438994|Experimental|Participants diagnosed with OND|
16478709|NCT03438994|Active Comparator|Typically developing participants|
16478710|NCT03438968|Experimental|High-Intensity aerobic training|Individuals will exercise using a high-intensity interval exercise training protocol
16478711|NCT03438968|Active Comparator|Standard Moderate continuous training|Individuals will exercise using a standard moderate intensity continuous exercise training protocol
16478712|NCT03438955|Experimental|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
16478713|NCT03438955|Experimental|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
16478714|NCT03438942|Experimental|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
16478715|NCT03438942|Active Comparator|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
16478716|NCT03438903||Normal group|Healthy subjects without any ocular problems Repeat exams of OCT device (SD and SS-OCT)
16478717|NCT03438903||Retinal diseases group|Patients with various macular diseases Repeat exams of OCT device (SD and SS-OCT)
16478718|NCT03438890|Experimental|Warm saline group|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
16478719|NCT03438890|Experimental|anti-fog agent group|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
16478720|NCT03438890|Experimental|chlorhexidine group|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
16478721|NCT03438890|No Intervention|control group|In the control group, the lens was not wiped gauze or applied any solution before use of the laparoscope. When occurred the event of each laparoscopic lens fogging (LLF) that splatter of irrigation fluid, blood, and body fluids affected visual clearance, the laparoscopic lens was manually rubbed with clean gauze by a scrub nurse.
16478722|NCT03438877|Experimental|Intervention group|Intervention group is intensive dosage of PD.
16478723|NCT03438877|Active Comparator|Control group|Control group is regular dosage of PD.
16478724|NCT03438864|Experimental|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
16478725|NCT03438864|Experimental|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
16478726|NCT03438864|Sham Comparator|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
16478727|NCT03438851|Experimental|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
16478728|NCT03438851|Experimental|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
16478729|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
16478730|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
16478731|NCT03438812|Experimental|Poor ovarian responders with DHEA|Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.
16478732|NCT03438812|No Intervention|Poor ovarian responders|Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA
16478733|NCT03438812|No Intervention|Normal ovarian responders|Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.
16478734|NCT03438799||Cordio|Cordio R&D database to develop the Cordio System
16478735|NCT03438786|Experimental|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
16478736|NCT03438786|Experimental|group B|Patients undergoing lichtnestein's hernioplasty
16478737|NCT03438773|Other|Envarsus|Study group - Envarsus once daily in addition to standard of care.
16478738|NCT03438773|Other|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
16478739|NCT03438760|Placebo Comparator|Science + Phonological Awareness|In all conditions, science is taught via the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) Journal/Reflection, and 4) dialogic reading centered around a given theme such as plant life. In the control condition, a minimum of six phoneme identifications and five rhymes will be incorporated into each lesson of this curriculum. While these activities are likely to improve the children's awareness of the sounds of the language (a foundational skill for learning to read), they are not likely to improve their access to the science being taught. Therefore, this intervention constitutes a placebo.
16478740|NCT03438760|Experimental|Science + Grammar Intervention|In the science + grammar condition, focused stimulation, an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities. The approach is incidental, rather than explicit. The active ingredients are models and recasts of the target structure. Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Recasts and/or models will be provided at an average rate of one per minute, an accepted therapeutic dose.
16478998|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
16478741|NCT03438760|Experimental|Science + Vocabulary Intervention|This arm involves Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 20 words that pertain to scientific practices applicable to the FOSS lessons. The children receive a cumulative exposure of at least 20 times per word (a minimum of 5 times per each of four lessons) and at least 4 chances to produce the word (a minimum of 1 chance per each of four lessons).
16478742|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
16478743|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
16478744|NCT03438734|Active Comparator|Low flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 0.75 L/min. Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
16478745|NCT03438734|Sham Comparator|Normal flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 1.5 L/min.Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
16478746|NCT03438721|Experimental|Infant Obesity Prevention|The infant obesity prevention arm will provide parents with education on optimal infant feeding, sleep, and screen time practices.
16478747|NCT03438721|Experimental|Financial Coaching|The financial coaching arm will provide parents with education on basic financial literacy topics and coaching to help parents achieve financial goals.
16478748|NCT03438708|Experimental|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
16478749|NCT03438695|Experimental|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
16478750|NCT03438682||Essure Hysteroscopic Sterilization|Women who have undergone Essure hysteroscopic sterilization
16478751|NCT03438682||Laparoscopic Sterilization|Women who have undergone laparoscopic sterilization
16478752|NCT03438682||Intrauterine device (IUD) placement|Women who have undergone IUD placement
16478753|NCT03438656|Experimental|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
16478754|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
16478755|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
16478756|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
16478757|NCT03438617|Experimental|First Cohort|The first cohort of 3 CHCs will receive the peer support intervention for the full duration of the study period (12 months).
16478758|NCT03438617|Other|Second Cohort|The second cohort of 3 CHCs will serve as a control group for the first 3 months of the study. After 3 months, the second cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 9 months.
16478759|NCT03438617|Other|Third Cohort|The third cohort of 4 CHCs will serve as a control group for the first 6 months of the study. After 6 months, the third cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 6 months.
16478760|NCT03438604|Other|Donepezil TDS with Heat Applied|Corplex Donepezil TDS 5 mg/day with heat applied
16478761|NCT03438604|Other|Donepezil TDS without Heat|Corplex Donepezil TDS 5 mg/day with no heat applied
16478762|NCT03438604|Other|Donepezil TDS Extension Study with Heat|Corplex Donepezil TDS 5 mg/day with heat. Two skin sensors will be placed underneath the TDS and adjacent to the TDS.
16478763|NCT03438591|Experimental|Cerclage-CRT (medtronic 4196 lead)|trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing'
16478764|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
16478765|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
16478766|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
16478767|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
16478768|NCT03438552|Experimental|SBRT at a total dose of 30 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
16478769|NCT03438552|Experimental|SBRT at a total dose of 25 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
16478770|NCT03438552|Experimental|SBRT at a total dose of 36 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
16478771|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
16478772|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
16478773|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
16478774|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
16478775|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
16478776|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
16478777|NCT03438526|Experimental|Melatonin (Circadin ®)|
16478778|NCT03438526|Placebo Comparator|Placebo|
16478779|NCT03438513||Problem Solving Therapy|This program is intended for caregivers to acquire techniques to manage stressful situations encountered in everyday life.
16478780|NCT03438513||Speaking group|The group will be led by a psychologist.
16478781|NCT03438513||Standard medical care|Occupational Therapy Assessment Psychological assessment
16478782|NCT03438500|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
16478783|NCT03438487||Flucelvax Trivalent or Quadrivalent Influenza Vaccine|Flucelvax Trivalent or Quadrivalent exposure in pregnancy
16478784|NCT03438474|Active Comparator|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:
~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
16478785|NCT03438474|Experimental|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:
~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
16478786|NCT03438461|Experimental|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
16478787|NCT03438461|Experimental|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
16478788|NCT03438435|Experimental|QRH-882260 Heptapeptide|Five mL of reconstituted (with sterile 0.9% NaCl) QRH-882260 Cy-5-labeled heptapeptide
16478789|NCT03438422|Experimental|GROUP A|1 tablet a day of pollen A extract containing (140 mg aqueous extract and 8mg lipid purified pollen, aqueous extract pumpkin seed 300mg, 10mg Vitamin E)
16478790|NCT03438422|Active Comparator|GROUP B|1 tablet a day of pollen B extract containing (140 mg aqueous extract and lipid 8 mg of purified pollen)
16478791|NCT03438422|Active Comparator|GROUP C|1 tablet a day of pollen extract C containing (Pollen extract 160 mg, pumpkin seed extract, 300 mg and Vitamin E 10 mg)
16478792|NCT03438422|Placebo Comparator|PLACEBO|1 tablet a day of placebo
16478793|NCT03438409|Experimental|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
16478794|NCT03438396|Experimental|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
16478887|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
16478795|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
16478796|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
16478797|NCT03438370|No Intervention|Three monthly ART supply at facilities|Sites at which patients will be provided three monthly ART supply at health facilities.
16478798|NCT03438370|Experimental|Three monthly ART supply at CAGs|Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
16478799|NCT03438370|Experimental|Six monthly ART supply at outreaches|Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
16478800|NCT03438357||Patients with multiple sclerosis|
16478801|NCT03438344|Experimental|Arm I (CMV-MVA triplex vaccine)|Patients receive multi-antigen CMV-modified vaccinia Ankara vaccine via injection on days 28 and 56 post-HCT.
16478802|NCT03438344|Placebo Comparator|Arm II (placebo)|Patients receive placebo via injection on days 28 and 56 post-HCT.
16478803|NCT03438331|Experimental|CBT-I|
16478804|NCT03438331|Active Comparator|CBT-D|
16478805|NCT03438331|No Intervention|Waiting-list control|
16478806|NCT03438318|Experimental|Part A (CMP-001, Atezolizumab and Optional Radiation Therapy)|Participants will receive CMP-001 5 milligrams (mg) SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by every 3 weeks thereafter until discontinuation of treatment in combination with atezolizumab SC every 3 weeks starting at Week 2. Route of administration (IT/SC) for CMP-001 beyond Week 5 will be determined by Investigator. Participants enrolled in Part A who progressed per RECIST v1.1 on combination of CMP-001 and atezolizumab have opportunity to enroll in Part A optional radiation therapy add-on after documented disease progression per CT/MRI or PET scan. After CMP-001 washout period of 10 days, participants will be treated with radiation consisting of 20 grays in 5 fractions for 5 days then resume CMP-001 treatment.
16478807|NCT03438318|Experimental|Part B (Radiation Therapy, CMP-001 and Atezolizumab)|Participants will be treated with radiation therapy consisting of 20 grays in 5 fractions for 5 days, then participants will receive CMP-001 5 mg SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by dosing every 3 weeks thereafter until discontinuation of treatment. The route of administration (that is, IT or SC) for CMP-001 beyond Week 5 will be determined by the Investigator. First dose of CMP-001 will be administered within 2 days of radiation therapy. Atezolizumab will be administered SC in combination with CMP-001 every 3 weeks starting at Week 2.
16478808|NCT03438305||Group D|
16478809|NCT03438305||Group N|
16478810|NCT03438292|Experimental|Group A - TPGS emulsified with berberine|After an 8-10 hour overnight fast, Group A will receive two soft capsules of TPGS (400mg) emulsified berberine. Following a 7 day wash out period, Group A participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Following another 7 day wash out period, Group A participants will then receive two hard shell capsules of the berberine reference powder 400mg. Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
16478811|NCT03438292|Experimental|Group B - Quillaja extract emulsified with Berberine|After an 8-10 hour overnight fast, Group B will receive four soft capsules of Quillaja extract emulsified berberine (400mg). Following a 7 day wash out period, Group B participants will then receive two hard shell capsules of the berberine reference powder (400mg). Following another 7 day wash out period, Group B participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
16478812|NCT03438292|Experimental|Group C - Berberine reference powder|After an 8-10 hour overnight fast, Group C will receive two hard shell capsules of the berberine reference powder (400mg). Following a 7 day wash out period, Group C participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Following another 7 day wash out period, Group C participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
16478813|NCT03438279||First-Line Ipilimumab|patients who received ipilimumab as their first-line treatment
16478814|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
16478815|NCT03438266|Other|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
16478816|NCT03438240|Active Comparator|Group BF|Bupivacaine plus Fentanyl
16478817|NCT03438240|Active Comparator|Group BD|Bupivacaine plus Dexmedetomidine
16478818|NCT03438227|Experimental|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
16478819|NCT03438227|Active Comparator|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
16478820|NCT03438214|Active Comparator|Vancomycin continuous infusion|Continuous infusion of vancomycin
16478821|NCT03438214|Active Comparator|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
16478822|NCT03438201|Active Comparator|High-protein diet|High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol
16478823|NCT03438201|Active Comparator|Normoproteic diet|Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol
16478961|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
16478824|NCT03438188|Experimental|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
16478825|NCT03438188|No Intervention|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
16478826|NCT03438175|No Intervention|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
16478827|NCT03438175|Experimental|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
16478828|NCT03438162|No Intervention|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
16478829|NCT03438162|Experimental|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
16478830|NCT03438136|Experimental|Intervention arm|This arm will be enrolled in the intervention.
16478831|NCT03438136|No Intervention|No intervention arm|This arm will be enrolled in a no contact control group.
16478832|NCT03438123|Experimental|CZT SPECT|CZT SPECT imaging with/without the addition of CT on the Spectrum Dynamics camera
16478833|NCT03438084|Experimental|Interesterified|Commercially available interesterifed fat spread. 50g fat.
16478834|NCT03438084|Active Comparator|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
16478835|NCT03438084|Active Comparator|Control|Rapeseed oil. 50 g fat.
16478836|NCT03438084|Active Comparator|Saturated fat control|Butter. 50g fat
16478837|NCT03438071||Control group|
16478838|NCT03438071||Videoconference group|
16478839|NCT03438058||With complement-activating anti-HLA DSAs|Patients with complement-activating anti-HLA DSAs either C1q, C3d, C4d and IgG subclass
16478840|NCT03438058||Without complement-activating anti-HLA DSAs|Patients with anti-HLA DSAs but without the ability to activate the complement (either C1q, C3d, C4d and IgG subclass)
16478841|NCT03438058||Without DSAs and without complement-activating DSAs|Matching group of patients without DSAs and without complement-activating DSAs
16478842|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
16478845|NCT03438019|Experimental|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
16478846|NCT03438019|Experimental|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
16478847|NCT03438019|Sham Comparator|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
16478848|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 45 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
16478849|NCT03437993|Experimental|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
16478850|NCT03437993|Sham Comparator|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
16478851|NCT03437980|Experimental|propofol spinal acceptance|"The surgeon and the anesthetist will discuss the exclusion criteria. Then they will discuss the information's about spinal and general anesthesia with the illegible patients, also reply the patient's questions in a preoperative visit. The primary decision for the patient; either spinal or general anesthesia will be recorded.
~The patients refusing spinal anesthesia will be discussed again to detect the rate of acceptance of spinal anesthesia if propofol sedation is ensured during the procedure to provide a painless spinal injection. The final decision will be applied; either spinal with procedural sedation, or general anesthesia."
16478997|NCT03436992|Experimental|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
16478852|NCT03437967|Other|ABAB|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).
~ABAB initial period is active treatment - LASER.
~Active Treatment:
~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation."
16478853|NCT03437967|Other|BABA|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).
~BABA initial period is sham treatment - LOW LEVEL LASER.
~LOW LEVEL LASER treatment:
~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels."
16478854|NCT03437954|Other|Standard soft diet|
16478855|NCT03437954|Other|Non-restricted diet|
16478856|NCT03437941|Experimental|Dose Determination Segment 1|Patients will be treated with enzalutamide monotherapy once daily for 28 days followed by combination treatment with CORT125281 at escalating dose levels and enzalutamide once daily in 28-day dosing cycles.
16478857|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort|Patients who have progressed during treatment with abiraterone and no other AR-blocking therapies will be treated with CORT125281 and enzalutamide.
16478858|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort Food Effect|Sub-Cohort (first 10 patients enrolled into Cohort A). Patients enrolled into this subcohort will receive a single dose of CORT125281 at Cycle 1 Day -7 and a single dose of CORT125281 at Cycle 1 Day 1 30 minutes after a standard breakfast to assess the effect of food on PK parameters. Patients will then begin CORT125281 in combination with enzalutamide on Cycle 1 Day 2 and continue in 28-day dosing cycles.
16478859|NCT03437941|Experimental|Dose Expansion - ARant-Resistant Cohort|Patients who progressed during treatment with enzalutamide or second-generation AR-blocking therapies will be treated with a daily dose of CORT125281 and enzalutamide.
16478860|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm A|Patients randomized to this cohort will receive enzalutamide and a titrated dose of CORT125281. Enzalutamide will be continued at the dose currently tolerated by the patient at screening.
16478861|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm B|Patients randomized to this cohort will receive enzalutamide, placebo, and CORT125281.
16478862|NCT03437928|Experimental|Directional Deep Brain Stimulation|
16478863|NCT03437915|Experimental|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
16478864|NCT03437902|Experimental|Rutin C group|patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
16478865|NCT03437902|Experimental|Vitamin C group|patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
16478866|NCT03437902|No Intervention|Control group|patients will receive their usual antidiabetic treatment only for 8 weeks.
16478867|NCT03437889|Experimental|Epidural analgesia/anesthesia for childbirth|
16478868|NCT03437876|Experimental|patients with HBV induced cirrhosis|patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times intestinal microbiota transplant and the time interval is generally 2 weeks.
16478869|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
16478870|NCT03437850||South African cohort|
16478871|NCT03437850||Swedish Cohort|
16478872|NCT03437824|Experimental|Cyanocobalamin|Vitamin B12, 1,000 mg, Once
16478873|NCT03437824|Placebo Comparator|Placebo|Normal Saline Solution (0.9% Sodium Chloride), Once
16478874|NCT03437811||Active Treatment|Active arm, Electro Flo Percussor, Model 5000 airway clearance system for daily basis as needed (pro re nata).
16478875|NCT03437785|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
16478876|NCT03437785|Experimental|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
16478877|NCT03437785|Placebo Comparator|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
16478878|NCT03437785|Active Comparator|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
16478879|NCT03437785|Active Comparator|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
16478880|NCT03437772||CBT with mindfulness|
16478881|NCT03437772||Treatment as Usual: Barkley therapy|
16478882|NCT03437759|Experimental|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
16478883|NCT03437759|No Intervention|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
16478884|NCT03437733|Experimental|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
16478885|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
16478886|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
16478999|NCT03436953|Experimental|CX-8998 T-type calcium channel blocker|
16478888|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
16478889|NCT03437707|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
16478890|NCT03437707|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
16478891|NCT03437707|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
16478892|NCT03437694|Experimental|Medication Optimization Intervention|This group will represent those participants whose medical records have been provided to the pharmacist.
16478893|NCT03437694|Active Comparator|Medication Optimization Control|This group will represent those participants whose medical records have not been provided to the pharmacist.
16478894|NCT03437681|Experimental|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
16478895|NCT03437668|Experimental|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
16478896|NCT03437668|Placebo Comparator|Placebo tablets|Placebo oral tablet bid for 12 weeks
16478897|NCT03437655|Active Comparator|Zinc oxide and eugenol|Temporary direct restoration with zinc oxide and eugenol.
16478898|NCT03437655|Active Comparator|Mineral trioxide aggregate|Temporary direct restoration with Mineral trioxide aggregate.
16478899|NCT03437642||Tako-Tsubo - STP|Short term psychotherapy + Classic cardiological therapy
16478900|NCT03437642||Tako-Tsubo - Control|Classic cardiological therapy only
16478901|NCT03437642||Oncologic - STP|Short term psychotherapy + Classic oncological therapy
16478902|NCT03437642||Oncologic - Control|Classic oncological therapy only
16478903|NCT03437642||AMI - STP|Short term psychotherapy + Classic cardiological therapy
16478904|NCT03437642||AMI - Control|Classic cardiological therapy only
16478905|NCT03437642||Healthy Subjects|No therapy
16478906|NCT03437629|Active Comparator|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
16478907|NCT03437629|Active Comparator|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
16478908|NCT03437616|Experimental|Tulppa rehabilitation|8-10 weekly 3-hour group sessions and two follow-up sessions (6 and 12 months).
16478909|NCT03437616|No Intervention|Control group|Control group does not receive Tulppa rehabilitation during the study.
16478910|NCT03437603|Experimental|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
16478911|NCT03437590|Experimental|Part 1: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with [18F]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram [mg]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of [18F]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.
16478912|NCT03437590|Experimental|Part 2: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline PET/MR scan with [18F]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
16478913|NCT03437577|Active Comparator|immediate-release tacrolimus|This is standard of care
16478914|NCT03437577|Experimental|extended release tacrolimus|replace standard of care
16478915|NCT03437564|Experimental|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
16478916|NCT03437564|Experimental|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
16478917|NCT03437551||no intervention|Cross-sectional Observation study
16478918|NCT03437538|Active Comparator|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
16478919|NCT03437538|Active Comparator|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
16478920|NCT03437525|Experimental|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
16478921|NCT03437525|No Intervention|Control|Usual care
16478922|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
16479000|NCT03436953|Placebo Comparator|Comparator|
16478923|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
16478924|NCT03437499|Active Comparator|Positive Pressure Ventilation|Positive Pressure Ventilation ( peak pressure set at 25 cmH20 and PEEP set at 5 cmH2O, with 40 inflations per minute)
16478925|NCT03437499|Experimental|Sustained Inflation|Prolonged inflation ( 25 cmH20 for 15 seconds) followed by PEEP set at 5 cmH2O
16478926|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
16478927|NCT03437473|Active Comparator|Active stimulation QD|
16478928|NCT03437473|Active Comparator|Active stimulation QID|
16478929|NCT03437473|Sham Comparator|No stimulation|
16478930|NCT03437460|Active Comparator|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
16478931|NCT03437460|Placebo Comparator|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
16478932|NCT03437460|No Intervention|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
16478933|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
16478934|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
16478935|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
16478936|NCT03437434||BunnyLens and Gore-Tex suture|All patients Underwent 4 point PC-IOL scleral fixation with Gore-Tex sutures
16478937|NCT03437421|Experimental|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
16478938|NCT03437421|Experimental|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
16478939|NCT03437408|Experimental|Mapping and ablation|Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
16478940|NCT03437395|Other|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
16478941|NCT03437382|Other|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
16478942|NCT03437369|Experimental|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
16478943|NCT03437369|Other|Standard of Care|The study drug will be compared with standard of Care treatment
16478944|NCT03437356|Active Comparator|ADT ON Group|'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.
16478945|NCT03437356|Active Comparator|ADT OFF Group|'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation
16478948|NCT03437317|Experimental|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
16478949|NCT03437317|Sham Comparator|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
16478950|NCT03437317|Experimental|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
16478951|NCT03437317|Experimental|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
16478952|NCT03437317|Sham Comparator|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
16478953|NCT03437304|Experimental|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
16478954|NCT03437304|Experimental|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
16478955|NCT03437304|Experimental|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
16478956|NCT03437304|Experimental|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
16478957|NCT03437304|Placebo Comparator|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
16478958|NCT03437304|Experimental|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
16478959|NCT03437304|Active Comparator|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
16478960|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
16478962|NCT03437278|Experimental|Ligelizumab 120 mg|Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
16478963|NCT03437278|Experimental|Ligelizumab 24 mg|Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
16478964|NCT03437278|Placebo Comparator|Placebo + Ligelizumab 120 mg|Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial.
16478965|NCT03437265|Experimental|NER1006 powder for oral solution|"Oral administration of 1 sachet (115.96 g) NER1006 Dose 1 (containing PEG 3350, sodium sulfate and electrolytes), to be reconstituted with water and made up to 500 mL, consumed over approximately 30 min, followed by 500 mL water, consumed over approximately 30 min. Additional water may be drunk ad libitum after the dose.
~Following 1 hour rest period, oral administration of 2 sachets (101.91 g) NER1006 Dose 2 (containing sodium ascorbate, PEG 3350, ascorbic acid and electrolytes), to be reconstituted with water and made up to 500 mL, consumed over approximately 30 min, followed by 500 mL water, consumed over approximately 30 min. Additional water may be drunk ad libitum after the dose."
16478966|NCT03437239|Experimental|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
16478967|NCT03437239|No Intervention|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
16478968|NCT03437226|Experimental|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
16478969|NCT03437226|Placebo Comparator|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
16478970|NCT03437213|Experimental|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
16478971|NCT03437213|Active Comparator|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
16478972|NCT03437200|Experimental|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.
~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
16478973|NCT03437200|Experimental|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
16478974|NCT03437187|Other|Cholecystectomy without nerve blocks|Cholecystectomy, enteral and parenteral analgesics
16478975|NCT03437187|Placebo Comparator|Cholecystectomy with placebo nerve block|Cholecystectomy, NaCl as a placebo Quadratus lumborum block
16478976|NCT03437187|Active Comparator|Cholecystectomy with naropin nerve block|Cholecystectomy, Quadratus lumborum block with naropin
16478977|NCT03437161|Experimental|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
16478978|NCT03437148|Experimental|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
16478979|NCT03437135||Witness patients|Healthy Volunteers
16478980|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
16478981|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
16478982|NCT03437122|Experimental|All|
16478983|NCT03437096|Other|venipuncture pain|pain during venipuncture
16478984|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
16478985|NCT03437070|Experimental|TDO Dose Level|Trabectedin [T], Doxorubicin [D], and Olaratumab [O]
16478986|NCT03437057|Experimental|Patients treated with acethylsalicylic acid 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
16478987|NCT03437044|Experimental|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
16478988|NCT03437044|Active Comparator|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
16478989|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
16478990|NCT03437031|Experimental|Latent-VR|Patients in the latent phase of labor who will receive the VR intervention.
16478991|NCT03437031|No Intervention|Active-Control|Patients in the active phase of labor who will receive no intervention.
16478992|NCT03437031|Experimental|Active-VR|Patients in the active phase of labor who will receive the VR intervention.
16478993|NCT03437005|Experimental|Desonide 0.05%|Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
16478994|NCT03437005|Experimental|Ketoconazole 2%|Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
16478995|NCT03436992|Experimental|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
16478996|NCT03436992|No Intervention|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
16479001|NCT03436940|Active Comparator|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
16479002|NCT03436940|Experimental|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
16479003|NCT03436927|Experimental|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
16479004|NCT03436927|Experimental|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
16479005|NCT03436927|No Intervention|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
16479006|NCT03436914|Experimental|PPI|Esomezol®
16479007|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
16479008|NCT03436875||FH+|FH+ = having at least 1 parent with type 2 diabetes
16479009|NCT03436875||FH-|FH- = having no history of type 2 diabetes for two generations (parents and grandparents)
16479011|NCT03436849|Experimental|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
16479012|NCT03436849|Experimental|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
16479013|NCT03436849|Placebo Comparator|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
16479014|NCT03436849|Experimental|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
16479015|NCT03436849|Experimental|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
16479016|NCT03436849|Experimental|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
16479017|NCT03436849|Placebo Comparator|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
16479018|NCT03436849|Placebo Comparator|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
16479019|NCT03436849|Placebo Comparator|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
16479020|NCT03436836|Experimental|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.
~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
16479021|NCT03436836|Active Comparator|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
16479022|NCT03436823|Experimental|R.TMS + nurse semi-structured interview|Repeated Transcranial Magnetic Stimulation sessions associated with nurse semi-structured interview
16479023|NCT03436823|Sham Comparator|R.TMS + Music & Relaxation|Repeated Transcranial Magnetic Stimulation sessions associated with music listening & relaxation with eyes closed
16479024|NCT03436810|Experimental|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
16479025|NCT03436810|Active Comparator|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
16479026|NCT03436784|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
16479027|NCT03436784|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
16479028|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
16479029|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
16479032|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
16479033|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
16479034|NCT03436719|Experimental|Oral with Intravenous|Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
16479035|NCT03436719|Active Comparator|Intravenous|Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
16479036|NCT03436706||Participants|The cohort will consist of male and female children ages 11-12 accompanied by a participating parent over the age of 18 years. The family income of participants in this cohort cannot exceed 200% of the federal poverty level established in 2018.
16479037|NCT03436693|Experimental|Canagliflozin 100mg|
16479038|NCT03436693|Placebo Comparator|Placebo|
16479039|NCT03436680|Experimental|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
16479040|NCT03436680|Active Comparator|Group II (standard of care)|Participants receive standard of care.
16479041|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
16479042|NCT03436654|Experimental|ADT + Apalutamide|
16479043|NCT03436654|Experimental|ADT + Apalutamide + Abiraterone Acetate + Prednisone|
16479044|NCT03436628|Experimental|App Use|Kids (10-15 years old) with type 1 diabetes and one of their parents will receive the MyT1DHero app to use for a 3-month period. Participants are urged to use the app four times each day.
16479045|NCT03436615|Experimental|SB206 4%|SB206 4% topically twice daily
16479046|NCT03436615|Experimental|SB206 8%|SB206 8% topically twice daily
16479047|NCT03436615|Experimental|SB206 12%|SB206 12% topically once or twice daily
16479048|NCT03436615|Placebo Comparator|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
16479049|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
16479050|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
16479051|NCT03436589|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
16479052|NCT03436589|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
16479053|NCT03436576|Active Comparator|Autologous Serum 20%|Treatment with Autologous Serum 20% for 2 months
16479054|NCT03436576|Active Comparator|Autologous Serum 50%|Treatment with Autologous Serum 50% for 2 months
16479055|NCT03436563|Experimental|Treatment (M7824)|Patients receive M7824 IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity (Cohorts A,B, and C) or for six doses in patients with detectable circulating tumor DNA (ctDNA) following resection of all known liver metastases (Cohort D).
16479056|NCT03436550||Patients with Chronic Liver Disease|
16479057|NCT03436550||Control Group|
16479058|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
16479059|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
16479060|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
16479061|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
16479062|NCT03436524||Validation cohorts|Cohorts of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
16479063|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
16479064|NCT03436498|Experimental|SAR341402/NovoLog|SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.
16479065|NCT03436498|Experimental|NovoLog/SAR341402|Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.
16479068|NCT03436472|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
16479069|NCT03436472|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
16479070|NCT03436459|Active Comparator|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
16479111|NCT03436251|Active Comparator|coniztion of the cervix treatment|coniztion of cervix for HPV+/CIN2, including LEEP or cold knife coniztion
16479071|NCT03436459|Active Comparator|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
16479072|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
16479073|NCT03436433|Active Comparator|Lacosamide|Enrolled subjects will be randomized to receive Lacosamide.
16479074|NCT03436433|Active Comparator|Levetiracetam|Enrolled subjects will be randomized to receive Levetiracetam.
16479075|NCT03436433|No Intervention|No anti-epileptic|Enrolled subjects will be randomized to not receive anti-epileptic drugs.
16479076|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
16479077|NCT03436407||PrEP Group|Subject offered to start PrEP treatment in routine clinical practice
16479078|NCT03436407||Control Group|"Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study.
~Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2)
~Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort."
16479079|NCT03436394|Experimental|Evobrutinib: Normal Renal Function|Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) will receive a single oral dose of evobrutinib under fasting conditions.
16479080|NCT03436394|Experimental|Evobrutinib: Severe Renal Impairment|Subjects with eGFR less than (<) 30 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
16479081|NCT03436394|Experimental|Evobrutinib: Moderate Renal Impairment|Subjects with eGFR >= to 30 mL/min/1.73 m^2 and < 60 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
16479082|NCT03436394|Experimental|Evobrutinib: Mild Renal Impairment|Subjects with eGFR >= to 60 mL/min/1.73 m^2 and < 90 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
16479083|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
16479084|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
16479085|NCT03436368|Active Comparator|GA group|General Anesthesia
16479086|NCT03436355|Experimental|Physical activity|60 minutes of daily physical activity (see intervention)
16479087|NCT03436342|Experimental|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
16479088|NCT03436329|Experimental|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
16479089|NCT03436329|Active Comparator|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
16479090|NCT03436316|Experimental|SAD Cohort 1 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 1) and 2 participants will receive placebo.
16479091|NCT03436316|Experimental|SAD Cohort 2 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 2) and 2 participants will receive placebo.
16479092|NCT03436316|Experimental|SAD Cohort 3 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 3) and 2 participants will receive placebo.
16479093|NCT03436316|Experimental|SAD Cohort 4 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 4) and 2 participants will receive placebo.
16479094|NCT03436316|Experimental|SAD Cohort 5 (Part 1)|"6 Participants will receive AZD8154 (single inhaled small particle dose 5) and 2 participants will receive placebo.
~Participants in this Cohort will return for a second Treatment Period after a minimum washout period of 7 to 14 days. All 6 subjects will receive an inhaled dose of AZD8154 (large particle size)."
16479095|NCT03436316|Experimental|SAD Cohort 6 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 6) and 2 participants will receive placebo.
16479096|NCT03436316|Experimental|Cohort 1 (Part 2)|All participants in this cohort will receive single IV dose of AZD8154 in Treatment Period 1 and then after washout period, will receive inhaled AZD8154 (small particle size) in Treatment Period 2.
16479097|NCT03436316|Experimental|MAD Cohort 1 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 8) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 8) or placebo once daily from Day 4 to Day 12.
16479098|NCT03436316|Experimental|MAD Cohort 2 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 9) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (Inhaled dose 9) or placebo once daily from Day 4 to Day 12.
16479099|NCT03436316|Experimental|MAD Cohort 3 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 10) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 10) or placebo once daily from Day 4 to Day 12.
16479100|NCT03436303|Experimental|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
16479101|NCT03436303|Experimental|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
16479102|NCT03436303|Experimental|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
16479103|NCT03436290|Experimental|Palliative Care Intervention|
16479104|NCT03436290|No Intervention|Standard of Care|
16479105|NCT03436277|Placebo Comparator|Placebo|Sucralose 1,5 g
16479106|NCT03436277|Experimental|L-Carnitine|L- Carnitine 1,5 g
16479107|NCT03436264||high sensitivity to pain|
16479108|NCT03436264||low sensitivity to pain|
16479109|NCT03436251|Experimental|Local Hyperthermia at 44℃ for HPV+/CIN-1|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18. HPV+ and normal cytology or HPV+/CIN-1
16479110|NCT03436251|Sham Comparator|local hyperthermia at 37℃ for 30 mins|HPV+/CIN-1
16479114|NCT03436225|Other|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
16479115|NCT03436225|Other|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
16479116|NCT03436225|Other|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
16479117|NCT03436225|Other|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
16479118|NCT03436212|Other|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
16479119|NCT03436199|Experimental|ADS-5102 137 mg|
16479120|NCT03436199|Experimental|ADS-5102 274 mg|
16479121|NCT03436199|Other|Placebo|placebo capsules
16479122|NCT03436186||no arm|no arm
16479123|NCT03436173|Experimental|Fluoxetine|Fluoxetine 10 mg/2.5 ml
16479124|NCT03436173|Placebo Comparator|Placebo|Peppermint syrup measured to equivalent volume
16479125|NCT03436160|Experimental|WR826647|100 mcg Carbon-14 radio labeled WR826647 administered via IV
16479126|NCT03436160|Experimental|WR909388|100 mcg Carbon-14 radio labeled WR909388 administered via IV
16479127|NCT03436160|Experimental|WR909390|100 mcg Carbon-14 radio labeled WR909390 administered via IV
16479128|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
16479129|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
16479130|NCT03436134|Active Comparator|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
16479131|NCT03436134|Experimental|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
16479132|NCT03436121|Experimental|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
16479133|NCT03436121|Active Comparator|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
16479134|NCT03436108||PCOS group|patients who have PCOS
16479135|NCT03436108||control group|patients who donnot have PCOS
16479136|NCT03436095||research group|bundle measures to help patient to weaning ventilator
16479137|NCT03436095||historical control group|retrospect the patients who were difficult to wean from ventilator and collect some materials to compare.
16479138|NCT03436095||External control group|contrast other same level hospitals measures to patients who are difficult to wean ventilator.
16479139|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
16479140|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
16479141|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
16479142|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
16479143|NCT03436056|Other|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
16479144|NCT03436043|Experimental|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
16479145|NCT03436043|No Intervention|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
16479146|NCT03436030|Experimental|Single arm, breathing manuevers|All subjects perform/undergo Valsalva, Muller, CPAP, hand grip, and passive leg raise, with ultrasound examination of heart recorded before and during the manoeuvre.
16479147|NCT03436017||ADHD|Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach
16479148|NCT03436017||non ADHD|"Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.
~The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach."
16479149|NCT03436004|Experimental|Experimental|Colonoscopy with specific device with CE marking (Endocuff Vision)
16479150|NCT03436004|Active Comparator|Active Comparator|Colonoscopy with standard device of the center
16479151|NCT03435991||OAB patients|
16479152|NCT03435991||Healthy volunteers|
16479153|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
16479154|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
16479155|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
16479156|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
16479157|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
16479158|NCT03435952|Experimental|Pembrolizumab + Clostridium novyi-NT|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months.
~Clostridium novyi-NT injected into the tumor on Day 8.
~Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT"
16479159|NCT03435939|Experimental|losartan|a daily dose of 50 mg losartan for 7 days (for tolerability). Then, the losartan dose will be increased to 100 mg daily for 12 weeks.
16479160|NCT03435913|Experimental|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
16479161|NCT03435913|Experimental|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).
~1 mmHg = 1,36 cmH20.
~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
16479162|NCT03435900|Experimental|Intervention group|
16479163|NCT03435900|Active Comparator|Control group|
16479164|NCT03435887|Active Comparator|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
16479165|NCT03435887|Active Comparator|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
16479166|NCT03435874|Experimental|Group 1 Active|n=6. Age 18-35 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 at D56.
16479167|NCT03435874|Placebo Comparator|Group 1 Comparator|n=3. Age 18-35 years. Rabies vaccine at D0 and D56.
16479168|NCT03435874|Experimental|Group 2a Active|n=6. Age 1-6 years. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
16479169|NCT03435874|Placebo Comparator|Group 2a Comparator|n=3. Age 1-6 years. Rabies vaccine at D0 and D56.
16479170|NCT03435874|Experimental|Group 2b Active|n=12. Age 1-6 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
16479171|NCT03435874|Placebo Comparator|Group 2b Comparator|n=6. Age 1-6 years. Rabies vaccine at D0 and D56.
16479172|NCT03435874|Experimental|Group 3a Active|n=6. Age 6-11 months. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
16479173|NCT03435874|Placebo Comparator|Group 3a Comparator|n=3. Age 6-11 months. Rabies vaccine at D0 and D56.
16479174|NCT03435874|Experimental|Group 3b Active|n=12. Age 6-11 months. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
16479175|NCT03435874|Placebo Comparator|Group 3b Comparator|n=6. Age 6-11 months. Rabies vaccine at D0 and D56.
16479176|NCT03435861|Experimental|VX-745|In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
16479177|NCT03435861|Placebo Comparator|placebo|In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
16479178|NCT03435848|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
16479179|NCT03435835|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 33ºC will be circulated through the pants for 80 minutes.
16479180|NCT03435835|Active Comparator|Heat Therapy|Participants will be dressed in water circulating trousers that are connected to. Warm water (42-43ºC) will be circulated through the pants for 80 minutes.
16479181|NCT03435822|Other|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
16479182|NCT03435822|Other|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
16479183|NCT03435809|Active Comparator|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
16479184|NCT03435809|Active Comparator|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
16479185|NCT03435796|Other|Subjects exposed to Gene-modified (GM) T cell therapy|Subjects will be followed for 15 years from the last GM T cells infusion until withdrawal of consent, lost to follow-up, or death, whichever occurs first. Annual safety assessments will be conducted every 6 months during the first 5 years from the date of last GM T cell infusion. Laboratory evaluations and safety assessments will be conducted during this period. After 5 years, subjects will continue to be followed yearly. During the trial, pediatric subjects will be monitored for growth, development and sexual maturity. Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.
16479186|NCT03435783|Experimental|Intervention|
16479187|NCT03435783|Active Comparator|Attention-matched control|
16479188|NCT03435770|Experimental|EUSRA RFA needle|This procedure is very similar to the standard technique of EUS-guided fine needle aspiration. All patients would undergo EUS with a linear array or therapeutic echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the EUSRA RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue.
16479189|NCT03435757|Experimental|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
16479190|NCT03435757|Active Comparator|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
16479191|NCT03435744|Experimental|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
16479192|NCT03435744|Placebo Comparator|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
16479193|NCT03435731|Experimental|Treatment Group|This group will undergo 1 month Dual Therapy.
16479194|NCT03435718|Experimental|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
16479195|NCT03435718|Experimental|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
16479196|NCT03435718|Experimental|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
16479197|NCT03435718|Experimental|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
16479198|NCT03435718|Active Comparator|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
16479199|NCT03435705|Experimental|intervention arm|maintaining of occupational therapy for a 4 months period
16479201|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.
~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
16479202|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.
~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
16479203|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.
~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
16479204|NCT03435679|Experimental|one-stage|one-stage surgical treatment of the infected knee arthroplasty
16479205|NCT03435679|Active Comparator|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
16479206|NCT03435666|Experimental|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
16479207|NCT03435666|Active Comparator|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
16479208|NCT03435653|Active Comparator|Control group|Control group OFD with DFDBA
16479209|NCT03435653|Experimental|Test group|Test group OFD with decortication and DFDBA
16479210|NCT03435640|Experimental|Doublet: NKTR-262 + bempegaldesleukin|"Phase 1 Doublet: NKTR-262 in escalating doses, will be combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a safe and tolerable RP2D for NKTR-262 in combination with bempegaldesleukin (Every Three Week [Q3W] fixed dose) in select tumor indications.
~Phase 2 Doublet: NKTR-262 RP2D will be combined with a Q3W dose of bempegaldesleukin in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.
~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
16479211|NCT03435640|Experimental|Triplet: NKTR-262 + bempegaldesleukin + Nivolumab|"Phase 1 Triplet: The RP2D of NKTR-262 RP2D will be combined with a Q3W dose regimen of bempegaldesleukin plus nivolumab. The goal is to establish the safety and tolerability of the triplet regimen.
~Phase 2 Triplet: The RP2D of NKTR-262 will be combined with a Q3W dose regimen of bempegaldesleukin plus nivolumab in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.
~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
16479212|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
16479213|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
16479214|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
16479215|NCT03435601|Experimental|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
16479216|NCT03435601|Placebo Comparator|Placebo|Placebo IV administration Q4W, a total of 6 doses
16479217|NCT03435588|Active Comparator|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
16479218|NCT03435588|Experimental|EUS-FNB alone|EUS-FNB is performed with a 22 or 25 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
16479219|NCT03435575|Active Comparator|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
16479220|NCT03435575|No Intervention|Control group|Standard care
16479221|NCT03435562|Experimental|electronic cigarette vs own brand use|Participants will come in for three session. During one session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (the session will be approximately 3 hours). The order of the sessions will be determined randomly and data about session will not be recorded or used in the analysis.
16479222|NCT03435549|No Intervention|Arm 1: Control Arm (Usual care)|If Patient is randomized to Arm 1, no contact will occur, patient will receive standard and routine clinical care
16479223|NCT03435549|Experimental|Arm 2a: Remote monitoring|If Patient is randomized to Arm 2a they will remote monitoring for 6 weeks post-surgery
16479224|NCT03435549|Experimental|Arm 2b: Remote monitoring plus goal setting and social support|If Patient is randomized to Arm 2b, they will receive a remote monitoring plus social support and nudge messaging for 6 weeks post-surgery
16479227|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
16479228|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
16479229|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
16479230|NCT03435484|Active Comparator|Arm A|Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
16479231|NCT03435484|Active Comparator|Arm B|Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
16479232|NCT03435471|Experimental|G1 - Clinician-Directed Therapy|"Clinician-Directed Weekly Swallowing Therapy: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises and review the home swallowing exercise program. Each session will last 30 minutes +/- ten minutes. Other assessments include:
~Clinician-Directed Prophylactic Swallowing Exercises
~Prophylactic Swallowing Home Exercise Program
~Penetration/Aspiration Scale (PAS)
~Functional Oral Intake Scale (FOIS)
~Eating Assessment Tool-10 (EAT-10)
~University of Washington Quality of Life (UW-QOL)
~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)
~DIGEST Safety Grade"
16479233|NCT03435471|Active Comparator|G2 - Patient-Directed Home Therapy|"Patient-Directed Home Swallowing Therapy: One face-to-face meeting with a study speech pathologist prior to initiation of treatment. During that session, they will be encouraged to practice the given exercises independently on a specific daily schedule regime throughout their treatment. Other assessments include:
~Prophylactic Swallowing Home Exercise Program
~Penetration/Aspiration Scale (PAS)
~Functional Oral Intake Scale (FOIS)
~Eating Assessment Tool-10 (EAT-10)
~University of Washington Quality of Life (UW-QOL)
~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)
~DIGEST Safety Grade"
16479234|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
16479235|NCT03435458|Active Comparator|Oral misoprostol alone|
16479236|NCT03435445|Experimental|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
16479237|NCT03435445|Experimental|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
16479238|NCT03435445|Active Comparator|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
16479239|NCT03435432|Active Comparator|Glucose|50 grams of glucose in 50 ml water
16479240|NCT03435432|Placebo Comparator|Water|50 ml water
16479241|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria & Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.
~These will be tested by diagnostic tests under evaluation:
~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
16479242|NCT03435406||cirrhosis with HPS|Diagnosed as HPS
16479243|NCT03435406||cirrhosis without HPS|Not Diagnosed as HPS
16479244|NCT03435380|Experimental|Control (C)|Targeted mailed educational materials (C).
16479245|NCT03435380|Experimental|Patient activation (PA)|C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.
16479246|NCT03435380|Active Comparator|Patient activation + primary care provider activation (PA+PCP)|C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.
16479247|NCT03435367|Experimental|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for ~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
16479248|NCT03435367|Active Comparator|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for ~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
16479249|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
16479250|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
16479251|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
16479252|NCT03435328|Experimental|TENS intervention|"one group receiving TENS:
~- The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area."
16479253|NCT03435315|Active Comparator|Treadmill exercise|
16479254|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
16479255|NCT03435302|Experimental|Temozolomide Plus Cisplatin|per os 200 mg/m^2/d temozolomide on days 1 to 5 plus i.v. 75 mg/m^2 cisplatin divided into 3 days,which was repeated every 3 weeks for six cycles
16479313|NCT03434847|No Intervention|Control|Standard preoperative assessment
16479256|NCT03435302|Active Comparator|High-Dose IFN-a2b|Participants will be treated with i.v. 15×10^6U/m^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10^6U IFN- a2b three times per week for 48 weeks.
16479257|NCT03435289|Other|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
16479258|NCT03435276|Experimental|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
16479259|NCT03435276|Experimental|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
16479260|NCT03435276|Experimental|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
16479261|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
16479262|NCT03435263||home management group A|home management
16479263|NCT03435250|Experimental|AG-270|AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
16479264|NCT03435250|Experimental|AG-270/docetaxel|AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion [IV]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.
16479265|NCT03435250|Experimental|AG-270/nab-paclitaxel/gemcitabine|AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.
16479266|NCT03435224|Experimental|INVSENSOR00012|All subjects consented are enrolled into the test group and will receive the INVSENSOR00012.
16479267|NCT03435211|Experimental|INVSENSOR00006|All subjects consented are enrolled into the test group and received the INVSENSOR00006.
16479268|NCT03435185|Active Comparator|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
16479269|NCT03435185|Placebo Comparator|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
16479270|NCT03435172|Experimental|Treatment Group|Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness meshed skin graft (STSG) will be used.
16479271|NCT03435172|No Intervention|Usual Care|Standard care of split thickness meshed skin graft (STSG) will be used.
16479272|NCT03435159|Experimental|Manual Chiropractic Spinal Manipulation|Demographic informations, pain, previous trauma, diseases, current medicine, past surgical operations, pregnancy, smoking use and cervical artery dissection history in family are questioned. Cervical flexion, extension, right and left rotations, right and left lateral flexions are measured by physiotherapist, in sitting position and with goniometer.Upper extremity muscle strength was measured with manual muscle testing in sitting position by physical therapist. The muscles innervated by C4, C5, C6, C7, C8 and T1 cervical nerves were examined bilaterally. Cervical foraminal compression test was used to eliminate cervical root compression.Vertebrobasilar artery was assessed by premanipulative vertebrobasilar insufficiency test.Neck Disability Index was used to evaluate the functional neck status of the participants. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after manual manipulative intervention.
16479273|NCT03435159|Experimental|Instrumental Chiropractic Spinal Manipulation|The same assessments were applied to determine the eligibility of participants for this study. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after instrumental manipulative intervention.
16479274|NCT03435146|Experimental|Groups 1,2,3 and 4|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.
~3HP plus DTG +2NRTIs
~Group 2: The next 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.
~3HP plus DTG +2NRTIs
~Group 3: The next 25 (Group 3) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.
~IPT plus DTG +2NRTIs
~Group 4: The next 50 (Group 4) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.
~3HP plus DTG +2NRTIs"
16479275|NCT03435133|Active Comparator|Prasugrel|
16479276|NCT03435133|Active Comparator|Ticagrelor|
16479277|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
16479278|NCT03435107|Experimental|Durvalumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were refractory to fluoropyrimidines, irinotecan and oxaliplatin with or without targeted agents will be accrued.
~After checking the eligibility for the study entry, patients will be entered into the study treatment with durvalumab monotherapy."
16479279|NCT03435094||Fosamax®|1 group will be treated with alendronate 70 mg tablets (Fosamax®)
16479280|NCT03435094||Binosto®|1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)
16479281|NCT03435081|Experimental|2 milligram (mg) Baricitinib|2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
16479282|NCT03435081|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
16479283|NCT03435081|Placebo Comparator|Placebo|Placebo administered orally every day.
16479284|NCT03435068|Experimental|Ceramic rotary bur|For the ceramic bur group(Meisenger gingivectomies, ceramic rotary burs were used with 400-rpm rotary systems and with no serum irrigation, per the manufacturer's recommendation.
16479285|NCT03435068|Experimental|Diode laser|In the laser group (LG), a diode laser was applied to the operation sites in accordance with the manufacturer's guidelines (2.8 W continuous wave mode, wavelength 980 nm). The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power. The laser never made contact with the gingival tissue. The practice distance did not affect the laser spot size, which was 0.5 cm-1 cm. Smoke associated with the laser application was aspirated from the surgical site.
16479286|NCT03435068|Active Comparator|Scalpel|In the scalpel group following the local anesthetic administration, the gingivectomy was performed with a #15 scalpel. Subsequent to the operation, the borderline of gingiva was determined via the use of a pointer dental tweezers, and excessive gingival tissue was then removed with Gracey curettes
16479287|NCT03435055|Experimental|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
16479288|NCT03435042|Experimental|Children with cancer + their siblings|
16479289|NCT03435042|Experimental|Parents of children with cancer|
16479290|NCT03435029|Experimental|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
16479291|NCT03435029|Active Comparator|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
16479292|NCT03435016|Other|Diagnosis|
16479293|NCT03435003|Experimental|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.
~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.
~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
16479294|NCT03435003|Active Comparator|Control Arm|"A) Pre-operatively: No intervention
~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.
~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
16479295|NCT03434990|Experimental|Spinal manipulation/myofascial release|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. Myofascial release will be done on paravertebral muscle (Erector spinae, quadratus lumborum) and on gluteus maximus and piriform muscles, the pressure will depend of pain tolerance of each subject. After this procedure, the spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
16479296|NCT03434990|Active Comparator|Spinal manipulation|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. The spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
16479297|NCT03434977|Experimental|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligram (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
16479298|NCT03434977|Experimental|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
16479299|NCT03434951|Experimental|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
16479300|NCT03434951|Active Comparator|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
16479301|NCT03434938|Experimental|MI Intervention|Standard geriatric rehabilitation combined with 4 MI sessions (within 72 hours from admission, within 6 days, at 1 week from the second session and pre-discharge, respectively). MI will be delivered by nurses trained through a certified MI course and additional group coaching sessions will be offered them throughout the study. Quality control of the MI sessions will be carried out using Motivational Interviewing Treatment Integrity (MITI) Code 3.1.1 through random video recording.
16479302|NCT03434938|No Intervention|Standard rehabilitation|Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
16479303|NCT03434899|Experimental|Intervention group|Health care plan including physical exercise and online support during the entire study
16479304|NCT03434899|Active Comparator|Control Group|Health care plan including physical exercise
16479305|NCT03434886|Experimental|CF View|
16479306|NCT03434886|Active Comparator|CF Educational videos|
16479307|NCT03434886|Active Comparator|CF View and videos|
16479308|NCT03434886|No Intervention|Usual standard of care|
16479309|NCT03434873|Active Comparator|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
16479310|NCT03434873|Active Comparator|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
16479311|NCT03434860|Active Comparator|probiotic|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
16479314|NCT03434847|Active Comparator|Education|Pre-operative education regarding post-operative pain expectations
16479315|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
16479316|NCT03434782|Experimental|G1- Negative Control|Group with no desensitizing treatment. Prior to bleaching therapy, a water-soluble placebo gel, with non-active agent will be applied to dental vestibular surfaces. After bleaching therapy, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
16479317|NCT03434782|Experimental|G2- LASER (Positive Control)|Group treated with placebo gel before bleaching and with LLLT after in-office bleaching.
16479318|NCT03434782|Experimental|G3- KNO3 (Positive Control)|Group treated with desensitizing gel before bleaching and after in-office bleaching, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
16479319|NCT03434782|Experimental|G4- KNO3 + LASER|Group treated with desensitizing gel before bleaching and with LLLT after in-office bleaching.
16479320|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
16479321|NCT03434756|Experimental|Propioceptive Training|
16479322|NCT03434743|Experimental|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
16479323|NCT03434743|Active Comparator|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
16479324|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
16479325|NCT03434717|Experimental|Control (high distress)|Control group receiving care as usual
16479326|NCT03434717|Experimental|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
16479327|NCT03434717|Experimental|Control group (low distress)|Control group receiving care as usual
16479328|NCT03434704|Experimental|Single Arm Treatment|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis."
16479329|NCT03434691|Experimental|DEX group|continuous infusion of Dexmedetomidine at 0.4 μg/kg per hour and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
16479330|NCT03434691|Active Comparator|MDZ group|continuous infusion of a Midazolam at 0,1 mg/kg/h and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
16479331|NCT03434678|Experimental|Epidural-General Anesthesia|
16479332|NCT03434678|Active Comparator|General Anesthesia|
16479333|NCT03434665|Other|Recruited patients|Transradial celiac artery angiography
16479334|NCT03434652|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
16479335|NCT03434652|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
16479336|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
16479337|NCT03434639||2a - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
16479338|NCT03434639||2b - Healthy subjects (gastric emptying)|A subset of healthy volunteers will be recruited to take part in experiments to help in understanding the impact of gastric emptying rate as a confounding factor in measurements of gut permeability.
16479339|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
16479340|NCT03434626|Experimental|ACP Education|Eligible patients in the experimental group will receive an educational intervention from an advance care planning navigator consisting of a 4-item values tool, a Goals of Care Designation form and, if applicable, watch a cardiopulmonary resuscitation video.
16479341|NCT03434626|Active Comparator|Usual care|Patients in the usual care group will complete a Goals of Care Designation form with the family physician.
16479342|NCT03434613|Active Comparator|Rosuvastatin monotherapy|Rosuvastatin 5mg 1T daily for 6 months
16479343|NCT03434613|Experimental|Rosuvastatin + ezetimibe combination therapy|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
16479344|NCT03434600|Active Comparator|Oxford|Patients receiving an Oxford UKA, which is the standard treatment for patients with medial osteoarthritis of the knee at our department.
16479345|NCT03434600|Experimental|Sigma|Patients receiving a Sigma UKA, which is the experimental treatment.
16479346|NCT03434587|Experimental|Syndactyly|Syndactyly
16479347|NCT03434587|Active Comparator|Reduction and inmobilization|Closed reduction and splint inmobilization
16479348|NCT03434574|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
16479349|NCT03434574|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
16479350|NCT03434548||Cohort 1|Healthy Controls
16479351|NCT03434548||Cohort 2|Huntington's Disease Gene Expansion Carriers (HDGECs: premanifest near-onset, peri-manifest, and manifest), and Healthy Controls
16479352|NCT03434535|Experimental|Intervention|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months. They will also receive an activity sensor and weight scale. Health state data from this group will be generated over a 3-6 month period and remotely monitored. These data will be used to provide personalized feedback regarding the participant's progress towards established goals.
16479353|NCT03434535|No Intervention|Control|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months.
16479354|NCT03434509|Experimental|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
16479355|NCT03434496|Experimental|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
16479356|NCT03434496|Active Comparator|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
16479357|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
16479358|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.
~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .
~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
16479359|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
16479360|NCT03434457||Prenatal and 3 to 72 months|
16479361|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
16479362|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
16479363|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
16479364|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
16479365|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
16479366|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
16479367|NCT03434418|Experimental|osimertinib|
16479368|NCT03434405|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
16479369|NCT03434392|Active Comparator|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
16479370|NCT03434392|Active Comparator|Suspected CP|"Suspected Chronic Pancreatitis patients.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
16479371|NCT03434392|Active Comparator|Definite CP|"Definite Chronic Pancreatitis patients.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires.
~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3 and questionnaires."
16479372|NCT03434392|Active Comparator|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
16479373|NCT03434379|Experimental|Atezolizumab + Bevacizumab|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator
16479374|NCT03434379|Active Comparator|Sorafenib|Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator
16479375|NCT03434366|Experimental|ketamine and dexmedetomidine group|intranasal ketamine and dexmedetomidine was treated in the children
16479376|NCT03434366|Experimental|ketamine group|intranasal ketamine was treated in the children
16479377|NCT03434366|Placebo Comparator|control group|intranasal insaline was used in the children
16479378|NCT03434353|Experimental|Group 1 (Inarigivir Soproxil 50 mg + TAF)|Inarigivir Soproxil 50 mg (2 x 25 mg capsule) plus TAF for 12 weeks, followed by TAF for 36 weeks
16479379|NCT03434353|Experimental|Group 2 (TAF)|TAF for 48 weeks
16479380|NCT03434353|Experimental|Group 3 (Inarigivir Soproxil 200 mg + TAF)|Inarigivir Soproxil 200 mg (2 x 100 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks
16479381|NCT03434353|Experimental|Group 4 (Inarigivir Soproxil 100 mg)|Inarigivir Soproxil 100 mg tablet for 12 weeks in virally suppressed participants currently being treated with a commercially available NUC
16479382|NCT03434353|Experimental|Group 5 (Inarigivir Soproxil 200 mg + TAF)|Inarigivir Soproxil 400 mg (2 x 200 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks (Group 5 applies to Hong Kong only)
16479383|NCT03434340|Experimental|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
16479384|NCT03434340|Active Comparator|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
16479385|NCT03434327|Experimental|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
16479386|NCT03434327|Experimental|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
16479387|NCT03434314|Experimental|MISACE arm|"Minimally-Invasive Segmental Artery Coil-Embolization
~MISACE procedure prior to aneurysm repair
~segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)"
16479388|NCT03434314|No Intervention|control arm|receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
16479389|NCT03434301|Active Comparator|Mesh with absorbable tack fixation|Mesh with absorbable tack (ReliaTack™) fixation
16479390|NCT03434301|Active Comparator|Mesh with non-absorbable fixation|Mesh with non-absorbable (Protack™) fixation
16479391|NCT03434288||Diabetic patients with foot osteomyelitis|Biological and MRI signs of foot osteomyelitis
16479392|NCT03434275|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
16479393|NCT03434275|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
16479394|NCT03434262|Experimental|A: ribociclib + gemcitabine|Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.
16479395|NCT03434262|Experimental|B: ribociclib + trametinib|Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.
16479396|NCT03434262|Experimental|C: ribociclib + sonidegib|Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.
16479397|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
16479398|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
16479399|NCT03434236|Placebo Comparator|Placebo|Patients will be taking placebo twice daily for 5 days prior to surgery. The placebo has a similar taste and smell as the active supplement.
16479400|NCT03434236|Experimental|low dose Lipinova (30mL)|Patients will take 15 mL Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
16479401|NCT03434236|Experimental|high dose Lipinova (60mL)|Patients will take 30mL of Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
16479402|NCT03434223||Single Cohort|
16479403|NCT03434210|Experimental|LAT-treated Community Model|The subjects in experimental group are on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
16479404|NCT03434210|Other|Care as usual|"The subjects in control group are on  cared as usual Which means Patients will be managed follow the request of National Continuing Management and Intervention Program for Psychoses. Patients will managed by community mental health professionals, get education information and rehablitation guidence from them."
16479405|NCT03434197|Experimental|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
16479406|NCT03434197|Active Comparator|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
16479407|NCT03434171|Active Comparator|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
16479444|NCT03433937|Active Comparator|Control|Micropore tape
16479408|NCT03434171|Active Comparator|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
16479409|NCT03434158|Experimental|Olaparib|600 mg/day
16479410|NCT03434145||patients with chronic kidney diseases|patients with end stage retinal disease undergoing hemodialysis underwent various ophthalmologic exams before and after hemodialysis.
16479411|NCT03434132|Active Comparator|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
16479412|NCT03434132|Experimental|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
16479413|NCT03434119|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine/lixisenatide) once daily in the morning within 1 hour before breakfast, on top of oral anti-diabetic drug (OAD) therapy for 26 weeks.
16479414|NCT03434119|Active Comparator|Lantus|Lantus (Insulin glargine) once daily at any time of the day but at about the same time every day on top of OAD therapy for 26 weeks.
16479415|NCT03434106|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
16479416|NCT03434106|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
16479417|NCT03434106|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
16479418|NCT03434106|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
16479419|NCT03434093|Active Comparator|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
16479420|NCT03434093|Active Comparator|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
16479424|NCT03434067||Primary hyperthyroidism|Patients diagnosed with primary hyperparathyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
16479425|NCT03434067||Secondary hyperthyroidism|Patients diagnosed with Secondary hyperthyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
16479426|NCT03434067||Unilateral thyroidectomy|Patients diagnosed with unilateral thyroid benign tumor were prepared for unilateral thyroidectomy. PTH test paper is used addtional at postoperation
16479427|NCT03434067||thyroidectomy and bilateral CCD|Patients diagnosed with bilateral thyroid carcinoma were prepared to undergo total thyroidectomy and bilateral central clearing.PTH test paper is used addtional at postoperation
16479428|NCT03434054|Experimental|Losartan|single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally
16479429|NCT03434054|Placebo Comparator|Placebo|single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally
16479430|NCT03434041|Experimental|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
16479431|NCT03434041|Active Comparator|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
16479432|NCT03434028|Other|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
16479433|NCT03434028|Other|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
16479434|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.
~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
16479435|NCT03434002|Experimental|Arm-A|Randomized 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation
16479436|NCT03434002|Experimental|Arm-B|Randomized other 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation
16479437|NCT03433989|Experimental|Diagnosis and follow up arm|
16479438|NCT03433976|Other|Hyperbaric Bupivacaine|spinal anesthesia for planned cesarean sections control group
16479439|NCT03433976|Active Comparator|Hyperbaric Prilocaïne|spinal anesthesia for planned cesarean sections
16479440|NCT03433963|Experimental|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
16479441|NCT03433963|Placebo Comparator|Control group|Study participants in the group will take placebo during the trial.
16479442|NCT03433950||Fluctuator|Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
16479443|NCT03433937|Experimental|Negative pressure wound therapy|
16479450|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
16479451|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
16479452|NCT03433872|Other|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
16479453|NCT03433859|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
16479454|NCT03433859|Active Comparator|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
16479455|NCT03433846||Preterm Infants|Blood samples will be obtained from preterm and former preterm infants at birth and then monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
16479456|NCT03433846||Term Infants|Blood samples will be obtained from term control infants admitted to the NICU monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
16479457|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
16479458|NCT03433820|Experimental|randomized repeated biopsy|"The study will entail 1 cohort with a randomized repeated biopsy collection time. Three skin punch biopsies (3 mm) of the lower back will be taken from each volunteer on day 0. One biopsy sample taken on day 0 will serve as a baseline measurement for the repeated samples regarding the histology, immunohistochemistry, and RNA sequencing (RNA-seq) or real-time reverse transcription polymerase chain reaction (qRT-PCR) assessments.
~Repeated biopsies of the same location as on day 0 will be taken on day 7, 14 or 21 (biopsy lesion and day randomized), and day 28, 42 or 56 (biopsy lesion and day randomized) for all subjects. The observation biopsy (biopsy lesion randomized) will serve as primary biopsy and followed for all measurements."
16479459|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
16479460|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
16479461|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
16479462|NCT03433781|Experimental|Absorbic Acid|All patients will receive at least 1 cycle of treatment (4 weeks). Patients with clinical benefit (CR,PR, or SD) then will undergo a second 4-week cycle of treatment.
16479463|NCT03433768||poor responders|
16479464|NCT03433768||normal responders|
16479465|NCT03433755|Placebo Comparator|Placebo Q2W|Placebo subcutaneous (SC) Q2W for 12 weeks
16479466|NCT03433755|Placebo Comparator|Placebo QM|Placebo SC QM for 12 weeks
16479467|NCT03433755|Experimental|Evolocumab 140 mg Q2W|Evolocumab 140 mg SC Q2W for 12 weeks
16479468|NCT03433755|Experimental|Evolocumab 420 mg QM|Evolocumab 420 mg SC QM for 12 weeks
16479469|NCT03433742|Other|Preoperative Group|This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
16479470|NCT03433742|Other|1 year Postoperative Group|This is the same group of 30 patients who are now one year post op after having a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at their one year visit.
16479471|NCT03433729|Experimental|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
16479472|NCT03433729|No Intervention|Usual care|Patients' appointment continues as usual.
16479583|NCT03432949|No Intervention|Standard of Care Radium-223|Radium-223 treatment will be administered as per standard of care.
16479584|NCT03432949|Experimental|Radium-223 with oral Dexamethasone 0.5 mg|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
16479585|NCT03432936|Experimental|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
16479473|NCT03433716|Experimental|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
16479474|NCT03433716|No Intervention|Control group|the subects of the control group received no any treatment
16479475|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
16479476|NCT03433690|Experimental|High Intensity Interval Training|Twelve weeks of High Intensity Interval Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
16479477|NCT03433690|Active Comparator|Moderate training|Twelve weeks of Moderate Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
16479478|NCT03433677|Experimental|LY900014|100 units per milliliter (U/mL) LY900014 administered by individualized, continuous, subcutaneous insulin infusion (CSII)
16479479|NCT03433677|Experimental|Insulin Lispro|100 U/mL insulin lispro (Humalog®) administered by individualized CSII
16479480|NCT03433664|Experimental|Treatment|Each treatment half of the scar received three standardised CO2 laser treatments using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping. Post-operatively all laser treatment and control zones had emollient applied and silicone dressings which were removed at 48 hours. Further emollient was applied twice daily for 2 weeks to all areas of the scar. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
16479481|NCT03433664|No Intervention|Control|Each control half of the scar received emollient applied twice daily for 2 weeks to all areas of the scar after each treatment. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
16479482|NCT03433651|Experimental|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
16479483|NCT03433651|Placebo Comparator|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
16479484|NCT03433625|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
16479485|NCT03433625|No Intervention|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
16479486|NCT03433612|Other|All Patients|"Estimates of the location of the L4-L5 intervertebral space will be done by the classic intercristal line technique and novel SAIL technique. Each technique will be performed by different randomly assigned investigators.
~* Both techiques will be assessed on all patients"
16479487|NCT03433599|Active Comparator|rAIH + training by research staff|Participants will receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by research staff.
16479488|NCT03433599|Sham Comparator|sham rAIH + training|Participants will sham receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by the research staff.
16479489|NCT03433586|Placebo Comparator|Placebo|Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days
16479490|NCT03433586|Active Comparator|Aspirin|Aspirin (81mg) will be taken orally daily for 10-14 days.
16479491|NCT03433573|Experimental|Intervention|Abbott Sensor Based Glucose Monitoring System
16479492|NCT03433560||Korean female breast cancer patients|
16479493|NCT03433547|Experimental|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
16479494|NCT03433547|Active Comparator|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
16479495|NCT03433534||Pharmacokinetic of Nivolumab|Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
16479496|NCT03433508|Experimental|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
16479497|NCT03433508|Active Comparator|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
16479498|NCT03433495|Active Comparator|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
16479499|NCT03433495|No Intervention|Waiting list|No intervention
16479500|NCT03433482|Experimental|GSK3536820A ACWY_Liq24 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
16479501|NCT03433482|Active Comparator|ACWY_1 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
16479502|NCT03433482|Experimental|GSK3536820A ACWY_Liq30 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
16479503|NCT03433482|Active Comparator|ACWY_2 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
16479737|NCT03431805|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
16479504|NCT03433469|Experimental|Treatment (osimertinib)|Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.
16479505|NCT03433456|Experimental|Home visitation + HABITS Program|The HABITS module will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children. Participants will receive the HABITS module in addition to their standard home visitation services.
16479506|NCT03433456|Active Comparator|Standard home visitation program|Participants will receive the standard of care home visitation regularly delivered through the existing home visitation program without the HABITS module.
16479507|NCT03433443|Active Comparator|Control group|Usual physical rehabilitation group
16479508|NCT03433443|Experimental|Intervention group|Case manager assisted rehabilitation
16479509|NCT03433430|Other|truSculpt|truSculpt treatment
16479510|NCT03433417|Other|Cutera truSculpt|One truSculpt treatment
16479511|NCT03433404|Experimental|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
16479512|NCT03433404|Active Comparator|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
16479513|NCT03433404|No Intervention|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
16479514|NCT03433391|Other|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
16479515|NCT03433391|Other|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
16479516|NCT03433378|Active Comparator|Tretinoin cream, 0.05%|Apply once a day application, under at-home use conditions.
16479517|NCT03433378|Active Comparator|RETIN-A® (tretinoin) cream, 0.05%|Apply once a day application, under at-home use conditions.
16479518|NCT03433378|Placebo Comparator|Vehicle of the test product|Apply once a day application, under at-home use conditions.
16479519|NCT03433365||1|Potential study subjects will sign an informed consent prior undergoing any study related procedure. Patients enrolled in this study will receive Lenalidomide-based regimen as maintenance therapy according to their previous decided therapeutic schedule. All consecutive patients treated with Lenalidomide-based regimen as maintenance therapy and with inclusion criteria will be asked to participate to this study.
16479520|NCT03433352||Control group|30 healthy volunteers were included in the healthy control group
16479521|NCT03433352||Recrudescence group|30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
16479522|NCT03433352||No recrudescence group|30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
16479523|NCT03433339|Experimental|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5mA for 20 min/ three times per week for 8 weeks.
16479524|NCT03433339|Sham Comparator|Sham Treatment|Thoracic anodal transcutaneous spinal direct current sham stimulation session of 20min/ three times per week for 8 weeks.
16479525|NCT03433313|Experimental|EG12014|Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
16479526|NCT03433313|Active Comparator|Herceptin|Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
16479527|NCT03433300|Experimental|Microprocessor Knee|Ottobock Kenevo/Ottobock C-Leg
16479528|NCT03433300|Active Comparator|Nonmicroprocessor knee|Ottobock 3R60 for K3 participants, Ottobock 3R62 for K2 participants.
16479529|NCT03433287|Experimental|18F-NaF-PET/MRI|Eligible patients who give informed consent will be offered a NaF -PET/MRI scan
16479530|NCT03433274|Experimental|Randomized Cohort - Treatment Group|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
16479531|NCT03433274|Active Comparator|Randomized Cohort - Control Group|Treatment of mitral regurgitation within commercially approved MitraClip system indications
16479532|NCT03433274|Experimental|Non-Randomized Cohort|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
16479533|NCT03433274|Experimental|Mitral Annular Calcification (MAC) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Mitral Valve System
16479534|NCT03433261|No Intervention|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
16479535|NCT03433261|Experimental|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
16479536|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
16479537|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
16479538|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
16479539|NCT03433235|Experimental|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
16479540|NCT03433235|Active Comparator|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
16479586|NCT03432923|Experimental|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
16479541|NCT03433222|Experimental|HF-LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
16479542|NCT03433222|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
16479543|NCT03433209|Active Comparator|Ligasure device|This group of women undergoing hysterectomy were randomized to the Ligasure energy device
16479544|NCT03433209|Active Comparator|Articulating Enseal|This group of women undergoing hysterectomy were randomized to the articulating Enseal energy device
16479545|NCT03433196|Experimental|HS-25 and Atorvastatin|HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
16479546|NCT03433196|Active Comparator|Atorvastatin|Atorvastatin 20mg, Placebo of HS-25 2 tablets
16479547|NCT03433183|Experimental|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
16479548|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
16479549|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
16479550|NCT03433157|Experimental|Hall technique|SSCs placed on primary teeth using Hall technique
16479551|NCT03433157|Active Comparator|Traditional technique|SSCs placed on primary teeth using Traditional technique
16479552|NCT03433144|Experimental|Intervention TXA|patients receiving TXA10mg/kg IV pre-operatively
16479553|NCT03433144|Placebo Comparator|Placebo|patients will receive an equivalent amount of normal saline 0.9% IV pre-operatively
16479554|NCT03433118|Experimental|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers to patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
16479555|NCT03433118|No Intervention|Standard care|Standard care for patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
16479556|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
16479557|NCT03433092||Jing Huang et. al, 2017|
16479558|NCT03433092||Max Leenders et. al,2014|
16479559|NCT03433092||Yusuke Okuyama et. al,2014|
16479560|NCT03433092||GC Kabat et. al,2012|
16479561|NCT03433092||Christina Persson et. al,2008|
16479562|NCT03433092||M Jenab et. al,2006|
16479563|NCT03433092||Kenji Wakai et. al,2005|
16479564|NCT03433092||Christian C. Abnet et. al,2003|
16479565|NCT03433092||N Malila et. al,2002|
16479566|NCT03433092||G Pappalardo et. al,1997|
16479567|NCT03433079||Acute Kidney Injury|Patients > 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
16479568|NCT03433066|Experimental|group I (Test)|Advanced platelet-rich fibrin mixed with biphasic alloplast
16479569|NCT03433066|Active Comparator|Group II (control)|Biphasic alloplast mixed with saline
16479570|NCT03433053|Placebo Comparator|Control|Participants will be exposed to a generic HIV testing message.
16479571|NCT03433053|Experimental|Experiment|Participants will be exposed to a targeted HIV testing message, developed specifically for African American women.
16479572|NCT03433040|Other|non obese|250mg 17 OHP-C
16479573|NCT03433040|Other|obese - control|250mg 17 OHP-C
16479574|NCT03433040|Experimental|obese|500mg 17 OHP-C
16479575|NCT03433027|Experimental|BB-401|BB-401 Intratumoral injection
16479576|NCT03433014|Active Comparator|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
16479577|NCT03433014|Other|Control|The control group will not receive any local infiltrative agent.
16479578|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants will take ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone will not be defined by the protocol but according to the package insert of each drug.
16479579|NCT03432988|Experimental|nurses in the hemodialysis service|Nursing Solution-Focused: Two two-hour training modules were designed by two recognized solution-focused therapy experts. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays.
16479580|NCT03432975|Experimental|Povidone Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine.
16479581|NCT03432975|Placebo Comparator|Sterile saline solution|The other side of the mouth will be irrigated with a sterile saline solution.
16479582|NCT03432962||Food code group|The participants freely selected foods from the online dietary assessment tool to record what they had eaten over the last 24h. They then provided information on brand details. The recalls were recoded to take into account all branded items and then recoded again to take represent all generic (ie. no brands) foods.
16479587|NCT03432923|Placebo Comparator|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
16479588|NCT03432910|Other|treatment group|Participants of the study undergo the standard stages of the clinical routine within a PAP therapy setting: a diagnostic night followed by one or two treatment nights.
16479589|NCT03432897|Experimental|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.
~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
16479590|NCT03432884|Experimental|Part A: BGB-3111|
16479591|NCT03432884|Placebo Comparator|Part A: Placebo|
16479592|NCT03432884|Experimental|Part B: BGB-3111, Placebo, and Moxifloxicin|
16479593|NCT03432871|Experimental|Nicotinamide Riboside|"This is an open-label experimental medicine study.
~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
16479594|NCT03432858|Active Comparator|Vancomycin|
16479595|NCT03432858|Active Comparator|Cefazolin|
16479596|NCT03432858|Placebo Comparator|Saline|
16479597|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
16479598|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
16479599|NCT03432832|Experimental|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions focused on mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement and practice sessions in the youth's community. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community."
16479600|NCT03432832|Active Comparator|Supportive Therapy|Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The intervention will not involve mindfulness or other emotion regulation strategies used in EASE. The therapy will be tailored to the individual's needs and will include aspects common in supportive therapy such as reflective listening, antecedent management, and problem-solving. This program does not have an online component.
16479601|NCT03432819|Experimental|Siempre Seguiré|We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
16479602|NCT03432819|No Intervention|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
16479603|NCT03432806||presumptive Stage II or III colon cancer|
16479604|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
16479605|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
16479606|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
16479607|NCT03432793|Experimental|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
16479608|NCT03432793|Experimental|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
16479609|NCT03432780|Experimental|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
16479610|NCT03432780|Active Comparator|Hormone and radiation therapy|Radiation therapy and hormone therapy
16479611|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
16479612|NCT03432754|Experimental|Mindfulness-Based Attention Training|Four weekly group mindfulness attention training sessions of a 1.5-hour duration. Participants provided with audio recordings, readings, and homework assignments consisting of various mindfulness practices.
16479613|NCT03432754|Active Comparator|Lifestyle Education Group|Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
16479614|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.
16479615|NCT03432728||S-ECC|Children in their fifth year of life with severe early childhood caries Children selected will require complete dental rehabilitation under general anesthesia All enrolled children will receive treatment of all dental carious lesions under general anesthesia
16479616|NCT03432728||Control|Children age and sex matched with the S-ECC group who are free of dental caries
16479617|NCT03432715|Experimental|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
16479618|NCT03432715|Experimental|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
16479619|NCT03432715|No Intervention|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
16479620|NCT03432702|Active Comparator|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
16479621|NCT03432702|Experimental|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
16479622|NCT03432689|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
16479623|NCT03432689|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
16479624|NCT03432676|Experimental|Treatment (pembrolizumab, epacadostat)|Participants receive pembrolizumab IV over 30 minutes on day 1 and epacadostat PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unaccepted toxicity.
16479625|NCT03432663|Experimental|24h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)
16479626|NCT03432663|Experimental|72h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)
16479627|NCT03432650|Experimental|QLB Block + Standard of Care|"Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
~Patients will receive a single shot anterior QLB (30cc 0.5% Bupivacaine with 2mg preservative free dexamethasone)."
16479628|NCT03432650|No Intervention|Standard of Care|Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
16479629|NCT03432637|Experimental|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
16479630|NCT03432637|Active Comparator|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
16479631|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
16479632|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
16479633|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
16479634|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
16479635|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
16479636|NCT03432611|Experimental|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
16479637|NCT03432611|Active Comparator|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
16479638|NCT03432611|Active Comparator|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
16479639|NCT03432598|Experimental|Non-squamous NSCLC|"Day 1 of each 21-day (3 weeks) cycle: Tislelizumab + pemetrexed + cisplatin 75 mg/m²/day IV (or carboplatin AUC 5).
~Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted."
16479640|NCT03432598|Experimental|Squamous NSCLC Cohort A|"Tislelizumab every 3 weeks (Q3W) + paclitaxel + cisplatin (or carboplatin), Q3W.
~Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
16479641|NCT03432598|Experimental|Squamous NSCLC Cohort B|"Tislelizumab Q3W on Day 1 + gemcitabine on Day 1 and Day 8 + cisplatin IV (or carboplatin) on Day 1.
~Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
16479642|NCT03432598|Experimental|SCLC|"Tislelizumab Q3W on Day 1, etoposide on Days 1, 2, and 3 + cisplatin (or carboplatin) on Day 1.
~Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
16479643|NCT03432585||Family Support Grant applicants|Participants include applicants for the Family Support Grants that will be provided for the American Society for Nutrition annual meeting who are willing to complete the applicant survey.
16479644|NCT03432572|Experimental|pyridium|Group A will take 200 mg of oral Pyridium 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
16479645|NCT03432572|Active Comparator|riboflavin|Group B will take 400 mg of riboflavin 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
16479646|NCT03432572|Placebo Comparator|thiamine|Group C will take the placebo (50 mg of thiamine) 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
16479647|NCT03432559|Other|endoscopy|endoscopy of the upper GI tract
16479648|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
16479649|NCT03432533|Active Comparator|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
16479650|NCT03432533|Active Comparator|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
16479651|NCT03432507||disc herniation|patients suffering from disc herniation
16479652|NCT03432507||spinal stenosis|patients suffering from spinal stenosis
16479653|NCT03432494|Experimental|Study Arm 1|Subjects undergoing transcaval access for TAVR
16479654|NCT03432481|Experimental|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
16479655|NCT03432468|Active Comparator|postmenopausal hypertensive women|
16479656|NCT03432468|Placebo Comparator|age-matched hypertensive male patients|
16479657|NCT03432442|Experimental|Group 1 (6 dengue patients)|Volunteers weighed > 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
16479658|NCT03432442|Experimental|Group 2 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
16479659|NCT03432442|Experimental|Group 3 (6 dengue patients)|Volunteers weighed > 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
16479660|NCT03432442|Experimental|Group 4 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
16479661|NCT03432416|Experimental|Regimen 1: Continuous Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.
16479662|NCT03432416|Experimental|Regimen 2: Cyclical Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).
16479663|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
16479664|NCT03432390|Experimental|CPAP|
16479665|NCT03432390|Active Comparator|Control|
16479666|NCT03432364|Experimental|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
16479667|NCT03432351||Children: 0-36mo|EEG sensor will be placed on the subject's forehead to observe and record EEG activity. No other applicable intervention.
16479668|NCT03432338||idiopathic parkinson|Classical Parkinson´s disease, idiopathic
16479669|NCT03432338||secondary parkinsonism|parkinsonism due to other reasons than idiopathic
16479670|NCT03432338||controls|persona matched by age and gender, non parkinsonism
16479671|NCT03432325|Experimental|Neural Enabled Prosthesis|Neural Enabled Prosthesis Treatment Group
16479672|NCT03432312|Experimental|Nicotine 4 mg mint lozenges|
16479673|NCT03432312|Active Comparator|NiQuitin 4 mg mint lozenges|
16479674|NCT03432299|Experimental|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
16479677|NCT03432273|Experimental|Nicotine 2 mg mint lozenges|
16479678|NCT03432273|Active Comparator|NiQuitin 2 mg mint lozenges|
16479679|NCT03432260|Experimental|DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
16479680|NCT03432260|Experimental|DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
16479681|NCT03432260|Experimental|DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
16479682|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
16479683|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
16479684|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
16479685|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
16479686|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
16479687|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
16479688|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
16479689|NCT03432208|Active Comparator|ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)|GI consult Procedure performed is EGD
16479690|NCT03432208|Experimental|ENDOSCOPIC ULTRASOUND (EUS)|GI consult Procedure performed is EUS
16479691|NCT03432195|Experimental|Donepezil TDS Back|Corplex Donepezil TDS 10 mg/day applied to the Back for 1 week (7 days)
16479692|NCT03432195|Experimental|Donepezil TDS Buttock|Corplex Donepezil TDS 10 mg/day applied to the Buttock for 1 week (7 days)
16479693|NCT03432195|Experimental|Donepezil TDS Leg|Corplex Donepezil TDS 10 mg/day applied to the Leg for 1 week (7 days)
16479694|NCT03432182|Other|very premature infants|Electroencephalography allowing sleep observation
16479695|NCT03432169|Active Comparator|Yoga|Stretching with mindfulness
16479696|NCT03432169|Active Comparator|Stretching|Stretching exercises without mindfulness
16479697|NCT03432156|Experimental|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
16479698|NCT03432156|No Intervention|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
16479736|NCT03431805|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
16479699|NCT03432143|Experimental|Community Reviewers|24 community members will receive training and mentoring in reviewing manuscripts. Approximately 284 manuscripts will be randomized into the intervention group over the duration of the study. Manuscripts will be reviewed by both a community member and scientific reviewers.
16479700|NCT03432143|No Intervention|Scientific Reviewers Only|Approximately 284 manuscripts will be randomized into the control group over the duration of the study. Manuscripts will be reviewed by multiple scientific reviewers. Community reviewers will not be involved in reviewing these manuscripts.
16479701|NCT03432130|Experimental|Experimental group|Performing a structural training program twice a week, 30 minutes each.
16479702|NCT03432130|No Intervention|Control group|
16479703|NCT03432117|Experimental|Fixed respiratory rehabilitation program(A)|respiratory rehabilitation program for 12 weeks
16479704|NCT03432117|Experimental|Mixed respiratory rehabilitation program(B)|Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks
16479705|NCT03432117|No Intervention|Control(C)|Ordinary rehabilitation service of the site for 12 weeks
16479706|NCT03432104|Experimental|Verum|This arm receives 1 x 450 mg-capsule of Oxxynea®, a blend of polyphenol-rich fruit and vegetable extracts
16479707|NCT03432104|Placebo Comparator|Placebo|This arms receives 1 x 450 mg-capsule of Placebo, containing maltodextrin only
16479708|NCT03432078|Active Comparator|Individual hypnotherapy|Treatment given on a individual basis, face to face.
16479709|NCT03432078|Active Comparator|Group hypnotherapy|Treatment given in a group setting, face to face.
16479710|NCT03432065|Experimental|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
16479711|NCT03432039|Placebo Comparator|Psychoeducation arm|This arm will provide information about admission procedures, story telling and a follow-up phone call
16479712|NCT03432039|Experimental|Behavioral intervention|This arm will provide information about what invasive procedures maybe given to the child, the emotional and behavioral reactions of the child while on the ward, games and stories that the child can engage with the mother and a follow-up phone call
16479713|NCT03432026||Non-smoker COPD patients|stable non-smoker COPD patients diagnosed by a previous spiromtery to have FEV1/FVC less than 70
16479714|NCT03432013|Active Comparator|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
16479715|NCT03432013|Experimental|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
16479716|NCT03432000|Experimental|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
16479717|NCT03432000|Sham Comparator|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
16479718|NCT03431987||Marijuana Users|
16479719|NCT03431974|Experimental|Aminopterin oral capsule|LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
16479720|NCT03431974|Placebo Comparator|Placebo oral capsule|Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
16479721|NCT03431961|Placebo Comparator|Placebo|0.9% normal saline administered twice daily for 14 days
16479722|NCT03431961|Experimental|Intranasal Corticosteroid|Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
16479723|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
16479724|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
16479725|NCT03431922|Experimental|endovascular denervation|endovascular denervation
16479726|NCT03431909|Experimental|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
16479727|NCT03431909|Sham Comparator|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
16479728|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.
~Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development
~Describe the levels longitudinally
~Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
16479729|NCT03431870|Other|Aorta dilated|Patients with aorta of 40mm or more who undergo a cardiac surgery. The intervention include: Trans-Esophageal Echocardiography
16479732|NCT03431831|Active Comparator|Intervention Control|All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
16479733|NCT03431831|Experimental|Counselling|These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
16479734|NCT03431831|Experimental|Contrave|These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
16479735|NCT03431831|Experimental|Contrave and counseling|These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
16479738|NCT03431792|Experimental|Long-Tail-FETO|"Fetus with severe CDH and o/e TFLV Ratio of < 25% or < 35% with liver herniation. The Long tail FETO will performed between 26 and 30 weeks of gestation.
~The MRI control will be perfirmed ar 32-34 weeks of gestation. Long Tail FETO: fetal i.m. application of 0.1 mg/kg Pancuronium, 1 µg/kg Fentanyl® and 0.01 mg/kg atropine. (Long-Tail Goldbal 5, 2,5 ml, BALT Extrusion, Montmorency, France). The fetoscope (Karl Storz, Tuttlingen, Germany) with a diameter of 1.3 mm, will be percutaneously inserted through a sheath into the uterus and then into the fetal trachea. The fetoscope will be removed and the balloon will be inserted under 4-D ultrasound guidance into the fetal trachea. The position of the balloon and suture will be visualized using the fetoscopy.
~The Long tail ballon will be removed by a second FETO after 34 weeks' gestation or bei the fetus itself with or without of the long tail balloon puncture with 22 gauge needle. The EXIT procedure is also possible."
16479739|NCT03431779|Experimental|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
16479740|NCT03431779|Active Comparator|Surgical excision|Excision of painful areas
16479741|NCT03431766|Placebo Comparator|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
16479742|NCT03431766|Experimental|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
16479743|NCT03431753|Experimental|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
16479744|NCT03431714|Experimental|single arm|Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight
16479745|NCT03431701|Experimental|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
16479746|NCT03431701|Active Comparator|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
16479747|NCT03431688|Active Comparator|PAM|treatment with PPI, metonidazole, amoxicillin
16479748|NCT03431688|Active Comparator|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
16479749|NCT03431675|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
16479750|NCT03431675|Active Comparator|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
16479751|NCT03431675|Active Comparator|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
16479752|NCT03431662|Experimental|Ellipse IM HTO Nail|In this arm, the subjects varus malalignment is corrected with Ellipse Intramedullary High Tibial Osteotomy Intramedullary Nail, which is a CE device. The device achieves the correction via progressive distraction osteogenesis.
16479753|NCT03431662|Active Comparator|TomoFix|In this arm, the subjects varus malalignment is corrected with Synthes TomoFix system, which is a CE device. The device achieves the correction via fixating an accute intraoperative correction of the varus malalignment.
16479754|NCT03431649|Experimental|Beraprost Sodium|"Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.
~22 patients"
16479755|NCT03431649|Active Comparator|Sildenafil citrate|"Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.
~20 patients"
16479756|NCT03431636|Experimental|Immersion in cold water|"The athlete will remain submerged in a Cryo Control - Ice Bath Systems® bathtub, which allows filtration and maintenance of constant water temperature, and shoulder blade water (Getto and Golden, 2013) for 15 minutes in the 15 degrees Celsius (Machado et al, 2016)."
16479757|NCT03431636|Active Comparator|Ice pack|The athlete will remain for 20 minutes with plastic packets of 500 grams of ice each, in the region of the evaluated muscles.
16479758|NCT03431636|Sham Comparator|Control|Group in which the athlete will be instructed to remain seated in a comfortable position, at rest, for 20 minutes.
16479759|NCT03431623|Experimental|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
16479760|NCT03431623|Active Comparator|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
16479761|NCT03431610|Experimental|SB414 2%|SB414 2% topically twice daily
16479762|NCT03431610|Experimental|SB414 6%|SB414 6% topically twice daily
16479763|NCT03431610|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
16479764|NCT03431597|Experimental|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
16479765|NCT03431597|Active Comparator|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
16479766|NCT03431597|No Intervention|control|no treatment will be given to this group observation only (no placebo)
16479767|NCT03431584|Active Comparator|Infiltration of corticosteroids|
16479768|NCT03431584|Experimental|Infiltration of corticosteroids and hyaluronic acid|
16479769|NCT03431571|Other|Single arm|ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group
16479770|NCT03431558|Experimental|Group 1|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).
~Duration: 1 month"
16479771|NCT03431558|Experimental|Group 2|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 300mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).
~Duration: 1 month"
16479772|NCT03431558|Placebo Comparator|Group 3|"Placebo: Only Glucan-D (99.4% glucoseDose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).
~Duration: 1 month"
16479773|NCT03431545|Experimental|PALS and BEECH|Play and Learning Strategies (PALS) and Beginning Education: Early Childcare at Home (BEECH) include web-based parent and teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.
16479774|NCT03431545|Active Comparator|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
16479775|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
16479776|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
16479777|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
16479778|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
16479779|NCT03431506|Active Comparator|non-training group|
16479780|NCT03431506|Experimental|training group|
16479781|NCT03431493|Experimental|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
16479782|NCT03431493|No Intervention|Usual Care Control|Usual Care Control
16479783|NCT03431480|Experimental|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
16479784|NCT03431467|No Intervention|Control|VA-ECMO alone per standard clinical protocol.
16479785|NCT03431467|Experimental|Experimental|VA-ECMO with early institution of Impella CP LV venting
16479786|NCT03431454|Active Comparator|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
16479787|NCT03431454|Active Comparator|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
16479788|NCT03431454|Active Comparator|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
16479789|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
16479790|NCT03431428|Experimental|transanal surgery|"To ensure the complete cutting edge with no residual tumor, the tumor with corresponding mesorectal excision was removed by the distance edge of 1cm.
~The intestinal wall was sutured to ensure the integrity of the bowel."
16479791|NCT03431428|Placebo Comparator|Miles surgery|According to the total mesorectal excision(TME) principle, complete mesorectum, lymph node and the anus was excised. A sigmoid colostomy was finally performed.
16479792|NCT03431415|Active Comparator|Surgery|Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
16479793|NCT03431415|Active Comparator|SBRT (Stereotactic Body Radiation Therapy)|Patients that will undergo SBRT as primary lung cancer treatment
16479794|NCT03431402|Other|Acute stroke receive hyperbaric oxygen|
16479795|NCT03431402|No Intervention|Acute stroke receive only conventional treatment|
16479796|NCT03431389|Active Comparator|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
16479797|NCT03431389|Active Comparator|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
16479798|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
16479799|NCT03431350|Experimental|Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
16479833|NCT03431155|No Intervention|Control Group|- Receive routine nursing care
16480076|NCT03429556|Placebo Comparator|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
16479800|NCT03431350|Experimental|Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
16479801|NCT03431350|Experimental|Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)|Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
16479802|NCT03431350|Experimental|Combination 3: Niraparib + AA-P|Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
16479803|NCT03431337|Experimental|High dose|Amoxicillin/clavulanate 875mg/125mg & amoxicillin 875 mg twice a day x 7 days
16479804|NCT03431337|Active Comparator|Standard dose|Amoxicillin/clavulanate 875 mg/125mg & placebo (lactase) twice a day x 7 days.
16479805|NCT03431324|Experimental|Mating-EFT Intervention Effectiveness|"Study 1: 90 participants will attend an initial session, at which point they will provide demographic information as well as their relationship status. They will then be randomly assigned to complete either the Episodic Future Thinking about Mating Opportunities intervention, a general-EFT intervention, or an unrelated questionnaire (yoked control condition).
~All participants will submit daily reports of the number of cigarettes smoked for a period of one week. Participants will then complete a series of questionnaires measuring individual differences in fundamental social motives (including mate-seeking motives), self-efficacy, and nicotine dependence."
16479806|NCT03431324|Experimental|Message Tailoring for Smoking Cessation|Study 2: A quasi-experimental design will be employed in order to determine whether targeting individuals who are single and highly motivated to seek a mate with a Targeted Mating-EFT Intervention is a more effective means of reducing cigarette consumption than presenting all individuals with a general-EFT intervention. A total of 180 smokers who intend to quit or reduce smoking will be recruited as participants. These individuals will be selected from a larger pool of participants based upon responses to screening questions. The screening questions will measure relationship status and mate seeking motivation.
16479807|NCT03431311|Experimental|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.
~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
16479808|NCT03431298|Experimental|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.
~Individualized functional movement control training is 60 min/week
~Aerobic exercise is 60 min/week"
16479809|NCT03431298|Active Comparator|Aerobic exercise|"The duration of intervention is 8 weeks.
~Frequency: 2 times/ week
~Duration: 60min/ time"
16479810|NCT03431285|Active Comparator|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
16479811|NCT03431285|Active Comparator|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
16479812|NCT03431272|Experimental|Treatment|lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day
16479813|NCT03431259|Experimental|Enrollment group|
16479814|NCT03431259|No Intervention|Information group|
16479815|NCT03431246|Experimental|Gardasil and Gardasil-9|
16479816|NCT03431233|Experimental|Group 1|protein enriched bar->commercial cereal bar->water
16479817|NCT03431233|Experimental|Group 2|protein enriched bar->water->commercial cereal bar
16479818|NCT03431233|Experimental|Group 3|commercial cereal bar->protein enriched bar->water
16479819|NCT03431233|Experimental|Group 4|commercial cereal bar->water->protein enriched bar
16479820|NCT03431233|Experimental|Group 5|water->protein enriched bar->commercial cereal bar
16479821|NCT03431233|Experimental|Group 6|water->commercial cereal bar->protein enriched bar
16479822|NCT03431220|Experimental|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
16479823|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.
~The referenced range could be found in the following publication:
~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
16479824|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
16479825|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
16479826|NCT03431194|Active Comparator|midodrine group|Patients will receive midodrine tablets
16479827|NCT03431194|Placebo Comparator|placebo group|Patients receive sugary oral tablets therapy
16479828|NCT03431181|Experimental|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
16479829|NCT03431181|Active Comparator|Usual Care|Patients in the control arm will receive usual care (as per local practices).
16479830|NCT03431168|Active Comparator|Azithromycin/TMPS|"Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.
~TMPS double strength 1 tablet po daily."
16479831|NCT03431168|Placebo Comparator|Placebo/TMPS|"Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.
~TMPS double strength 1 tablet po daily."
16479832|NCT03431155|Experimental|Experimental group|Nursing intervention
16479834|NCT03431142|Experimental|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
16479835|NCT03431142|Active Comparator|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
16479836|NCT03431116||Low implanted placenta group|
16479837|NCT03431103|Other|After home exercise program|"Patients will be instructed to use the Wii Fit for 20 minutes at least twice a week for 12 weeks using specific Wii Fit exercises while on the Wii pressure sensor floor mat. The Wii Fit exercises will be as follows: 1. Basic Run (warm-up exercise by walking in place); 2.Bird's Eye, Bull's-Eye (mostly arms, requires arm flipping); 3.Free Step (lower extremity exercise); 4.Hula Hoop (gyration exercise)"
16479838|NCT03431090|Experimental|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
16479839|NCT03431077|Experimental|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
16479840|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
16479841|NCT03431051|Active Comparator|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
16479842|NCT03431051|No Intervention|Control Arm|No change in beverages or education at two hospital campuses.
16479843|NCT03431025|No Intervention|Control|Participants in the Control Arm will wear sensors to monitor their upper limb movement but will not receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
16479844|NCT03431025|Experimental|Intervention|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
16479845|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
16479846|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
16479847|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
16479848|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
16479849|NCT03430999|Experimental|Group 1 (Japanese) Calmangafodipir|
16479850|NCT03430999|Placebo Comparator|Group 1 (Japanese) Placebo|
16479851|NCT03430999|Experimental|Group 2 (Caucasian) Calmangafodipir|
16479852|NCT03430999|Placebo Comparator|Group 2 (Caucasian) Placebo|
16479853|NCT03430986|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants were treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel during the 24-week Control Period. Participants were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable. Follow-up continued in the 24-week Post-Control period.
16479854|NCT03430986|Experimental|No-treatment Control|Participants received no treatment during the 24-week Control Period. After 24 weeks, participants had the option of treatment with JUVÉDERM® VOLUMA® with Lidocaine Injectable Gel in the nose area during the 24-week Post-Control period and were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable.
16479855|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
16479856|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
16479880|NCT03430830|Experimental|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
16479881|NCT03430830|Experimental|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
16479857|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
16479858|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
16479859|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=60) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) case of beer on passenger seat, or (2) case of water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
16479860|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
16479861|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
16479862|NCT03430960|Other|Group A - Standard of Care|
16479863|NCT03430960|Experimental|Group B - mCare group|
16479864|NCT03430947|Experimental|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
16479865|NCT03430934|Experimental|NAVI mapping with Indocyanine green|Participants will undergo their scheduled Mohs surgery with the addition of the NAVI mapping with ICG dye
16479866|NCT03430921|Other|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
16479867|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
16479868|NCT03430895|Experimental|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
16479869|NCT03430882|Experimental|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16479870|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
16479871|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
16479872|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
16479873|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
16479874|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
16479877|NCT03430830|Experimental|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
16479878|NCT03430830|Experimental|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
16479879|NCT03430830|Experimental|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
16480250|NCT03428438|Other|Controlled group hospital based|Physical rehabilitation in the ward physiotherapist
16479882|NCT03430830|Experimental|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
16479883|NCT03430817|Experimental|Group C|Citicholine Drug
16479884|NCT03430817|Experimental|Group A|Amantadine Drug
16479885|NCT03430817|Experimental|Group D|Both Citocholine and Amantadine
16479886|NCT03430804||Single gruop320 parturients|Measurement of cervical length and digital examination of Bishop score in 320 women undergoing induction of labour will be carried out in ain shams university maternity hospital.
16479887|NCT03430791|Experimental|Nivolumab Monotherapy|Nivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months
16479888|NCT03430791|Experimental|Nivolumab+Ipilimumab|"Nivolumab 3 mg/kg IV with ipilimumab then 240 mg every 2 weeks for maximum of 24 months.
~Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. NovoTTF200A (Optune) TTF for maximum 24 months"
16479889|NCT03430778|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
16479890|NCT03430778|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
16479891|NCT03430765|Experimental|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
16479892|NCT03430765|No Intervention|Treatment as Usual|Standard breast cancer treatment.
16479893|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
16479894|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
16479895|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
16479896|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
16479897|NCT03430726|Experimental|Healthy Kids Probiotic Yogurt Drink Group|Healthy children will be given a commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.
16479898|NCT03430713|Experimental|Dental colour measurement|Comparison of dental colour measurement between two shade guides VITA Classical and VITA Toothguide 3D-Master and two spectrophotometers VITA Easyshade and Spectroshade Micro
16479899|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
16479900|NCT03430687|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
16479901|NCT03430674|Experimental|Exercise Intervention|Clinic and at home exercise sessions.
16479902|NCT03430661|Experimental|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
16479903|NCT03430661|Experimental|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
16479904|NCT03430661|Experimental|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
16479905|NCT03430661|Experimental|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
16479906|NCT03430661|Experimental|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
16479907|NCT03430661|Experimental|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
16479908|NCT03430661|Experimental|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
16479909|NCT03430661|Experimental|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
16479910|NCT03430661|Experimental|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
16479911|NCT03430648||Cognitively and metabolically normal|This group has been defined as being cognitively and metabolically normal.
16479912|NCT03430648||Cognitively normal with prediabetes|This group has been defined as being cognitively normal but showing signs of prediabetes.
16479913|NCT03430648||Persons with Mild Cognitive Impairment|This group has been defined as being mildly cognitively impaired.
16479914|NCT03430648||Persons with early Alzheimer's disase|This group has been defined as having early Alzheimer's disease.
16479915|NCT03430622|Experimental|LTP Plus|LTP Plus group participants will receive intervention over the telephone for 3 months one session per week for 2 months and rest of the sessions fortnightly by trained graduates, expert in delivering LTP plus intervention.
16479916|NCT03430622|Active Comparator|Treatment as Usual (TAU)|TAU group will receive routine care and their follow up will be done after completion of the intervention and then at 6-month post randomization.
16479917|NCT03430609|Active Comparator|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
16479918|NCT03430609|Active Comparator|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
16479952|NCT03430349|Experimental|Novel OPV2 Candidate 1|Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
16479919|NCT03430609|Active Comparator|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
16479920|NCT03430596|Experimental|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
16479921|NCT03430596|Active Comparator|Antan|Antan,flexible dose (2-4mg/d)
16479922|NCT03430583||MZ101|Dosing per treatment regimen
16479923|NCT03430570|Experimental|Tablet TRAC Emotion Regulation Intervention|
16479924|NCT03430570|No Intervention|Waitlist Control|Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 3-month follow-up
16479925|NCT03430557|Experimental|Periapical surgery with PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and PRP will be filled in the lesion before closure of flap
16479926|NCT03430557|Active Comparator|Periapical surgery without PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and flap will be closed without placement of PRP
16479927|NCT03430544|Placebo Comparator|Placebo|
16479928|NCT03430544|Experimental|1.5 mg/d cariprazine|
16479929|NCT03430544|Experimental|3.0 mg/d cariprazine|
16479930|NCT03430531|Experimental|Sphenopalatine ganglion block|Sphenopalatine ganglion block: this block will be performed by inserting swabs, with lidocaine squirted on them, into each nostril and reaching the nasopharyngeal wall.
16479931|NCT03430518|Experimental|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
16479932|NCT03430505|Active Comparator|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
16479933|NCT03430505|Active Comparator|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
16479934|NCT03430479|Experimental|Cohort A|
16479935|NCT03430479|Experimental|Cohort B|
16479936|NCT03430466|Experimental|Durvalmab&Tremelimumab&Fulvestrant|Durvalmab&Tremelimumab&Fulvestrant
16479937|NCT03430453|Experimental|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
16479938|NCT03430440|Experimental|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
16479939|NCT03430440|Active Comparator|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
16479940|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
16479941|NCT03430414||Therapy Responders|
16479942|NCT03430414||Non-Responders|
16479943|NCT03430401|Experimental|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
16479944|NCT03430401|Experimental|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
16479945|NCT03430401|Active Comparator|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, & Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
16479946|NCT03430388|Active Comparator|Rheumatic diseases patients|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
16479947|NCT03430388|Active Comparator|Healthy controls|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
16479948|NCT03430375|Active Comparator|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
16479949|NCT03430375|Active Comparator|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted.
16479950|NCT03430362|Active Comparator|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
16479951|NCT03430362|Placebo Comparator|Control group|Group B, will receive 2 ml of normal saline single intravenous dose
16480251|NCT03428425|Experimental|apatinib paclitaxel S-1|
16479953|NCT03430349|Experimental|Novel OPV2 Candidate 2|Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
16479954|NCT03430336|Experimental|Computer-assisted medication management|"Family physician adds, modifies and optimizes medication in patient's with polypharmacy assisted by an user-initiated computerized decision support system (CDSS) which provides drug-therapy relevant information about patients (e.g. diagnoses and treatments) and alerts in case of drug-drug, drug-disease, drug-age interactions to systematically assess the appropriateness of medication:
~CDSS provides drug-therapy relevant information
~modification of medication
~assessment of medication appropriateness
~medication plan
~Guidance in medication process"
16479955|NCT03430336|No Intervention|Control arm|Patients will receive the usual clinical care based on current clinical practice guidelines during intervention period. After completion of trial, the patients in the control group will be invited to participate after written informed consent to receive the intervention.
16479956|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
16479957|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
16479958|NCT03430297|Experimental|JS001 240mg Q2W|
16479959|NCT03430297|Active Comparator|Dacarbazine 1000mg/m2 Q3W|
16479960|NCT03430284|Experimental|Integrated Treatment|
16479961|NCT03430284|Other|General Treatment|
16479962|NCT03430271|Active Comparator|Physical Activity (PA) Intervention|
16479963|NCT03430271|Placebo Comparator|Health Education (HE) Intervention|
16479964|NCT03430258|Placebo Comparator|conventional oxygen therapy|oxygen was delivered by a nasal cannula or nonrebreather mask
16479965|NCT03430258|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
16479966|NCT03430245|Experimental|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
16479967|NCT03430232|Experimental|Part I (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
16479968|NCT03430232|Experimental|Part I (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
16479969|NCT03430232|Experimental|Part II (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
16479970|NCT03430232|Experimental|Part II (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
16479971|NCT03430232|Experimental|Part II (Panel 3): STR-324 or placebo|Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
16479972|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
16479973|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
16479974|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
16479975|NCT03430193|Experimental|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
16479976|NCT03430193|Active Comparator|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
16479977|NCT03430193|No Intervention|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
16479978|NCT03430180|Placebo Comparator|placebo nasal spray|Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
16480017|NCT03429972|Experimental|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
16479979|NCT03430180|Active Comparator|Naloxone hydrochloride 40mg/ml nasal spray|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
16479980|NCT03430167|Other|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
16479981|NCT03430167|Other|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
16479982|NCT03430154||Adults with hemophilia and obesity/overweight|Adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
16479983|NCT03430154||Caregivers identified with obesity/overweight|Caregivers of children (any gender) currently aged <18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight
16479984|NCT03430154||Spouses or partners self-identified with obesity/overweight|Spouses or partners of adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
16479985|NCT03430154||Healthcare profs. managing hemophilia and obesity/overweight|Healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight.
16479986|NCT03430141|Experimental|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
16479987|NCT03430128|Experimental|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
16479988|NCT03430128|Active Comparator|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
16479989|NCT03430115||Weight loss plus exercise (WL+EX)|This group was randomized and previously assigned to weight loss plus exercise.
16479990|NCT03430115||Exercise alone (EX)|This group was randomized and previously assigned to exercise alone.
16479991|NCT03430115||Weight loss alone (WL)|This group was randomized and previously assigned to weight loss alone.
16479992|NCT03430115||Control|This group was randomized and previously assigned to control.
16479993|NCT03430102||LeftHeartCath|Patients scheduled for LV catheterization for direct measurement of LVEDP
16479994|NCT03430089|Experimental|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
16479995|NCT03430089|Experimental|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
16479996|NCT03430089|Experimental|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
16479997|NCT03430089|Experimental|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
16479998|NCT03430089|Experimental|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
16479999|NCT03430076|Experimental|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
16480000|NCT03430076|Active Comparator|Revascularization by Crude PTFE|
16480001|NCT03430063|Experimental|SDREGN2810|
16480002|NCT03430063|Experimental|SDREGN2810/ipi|
16480003|NCT03430063|Experimental|HDREGN2810|
16480004|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
16480005|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
16480006|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
16480007|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
16480008|NCT03430024||Cases|"We will enrol 100 women who have been newly diagnosed with T2 (>2cm) palpable invasive breast cancer having primary surgical treatment at Maidstone Hospital. We will exclude all patients with a metabolic disorder, significant co-morbidities and locally advanced or metastatic disease as well as those with a previous history of cancer treatment. We will collect data on tumour size, grade and phenotype as well as ER, progesterone receptor (PR) and Her-2 expression status and patient demographic information.
~We will investigate the Association of Myosin VI with oestrogen receptor."
16480009|NCT03430024||Controls|A cohort of control breast tissue will be obtained from 20 patients undergoing benign surgical breast procedures. For those control patients having reduction mammoplasties the excised tissue will be core biopsied but patients having other types of benign surgery will have an extra core biopsy taken from breast tissue surrounding the lesion being excised.
16480010|NCT03430011|Experimental|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
16480011|NCT03430011|Experimental|JCARH125 + anakinra|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
16480012|NCT03429998|Placebo Comparator|LDL apheresis|LDL apheresis during at least one year
16480013|NCT03429998|Active Comparator|Evolocumab|140 mg evolocumab biweekly
16480014|NCT03429998|Active Comparator|LDL apheresis and evolocumab|LDL-apheresis monthly evolocumab 140 mg biweekly
16480015|NCT03429985|Experimental|FRRM Intervention|The experimental arm will receive the FRRM intervention.
16480016|NCT03429985|No Intervention|Control|The control arm will not receive the FRRM intervention.
16480019|NCT03429959|Experimental|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
16480020|NCT03429959|Active Comparator|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
16480021|NCT03429946|Active Comparator|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
16480022|NCT03429946|Active Comparator|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
16480023|NCT03429946|Placebo Comparator|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
16480024|NCT03429933|Experimental|Single Ascending Dose|BMS-986278 or placebo
16480025|NCT03429933|Experimental|Multiple Ascending Dose|BMS-986278 or placebo
16480026|NCT03429920|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER:2 pouches per day, each pouch contains(12-15gms of fermented soy powder)
16480027|NCT03429920|Placebo Comparator|placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
16480028|NCT03429907|Experimental|Mind-Body Exercises|"Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are presented on an online application (app) that runs on participant's personal electronic device (such as a mobile phone or tablet).
~Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy."
16480029|NCT03429907|Other|Standard of Care|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
16480030|NCT03429894|Experimental|Treatment|All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.
16480031|NCT03429881|Active Comparator|Laparoscopic stripping ovarian endometriomas|
16480032|NCT03429881|Active Comparator|Laser CO2 treatment ovarian endometriomas|
16480033|NCT03429868|Experimental|integrated PET/MRI|The enrolled subjects receive an integrated 18F-FDG PET/MRI during tumor staging.
16480034|NCT03429855|Experimental|study group|Bobath based trunk exercises
16480035|NCT03429855|Other|control group|conventional physiotherapy approaches
16480036|NCT03429829|Experimental|Flairesse varnish|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as fluoridated toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. In addition, fluoride varnish (22.600 ppm, DMG, Hamburg, Germany) was applied in 3-monthly intervals by the local non-professional assistants who had been trained beforehand and supervised at the first application.
16480037|NCT03429829|No Intervention|Control|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. Beyond that, the children in this arm were left untreated.
16480038|NCT03429816|Experimental|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.
~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
16480039|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA </= 1.5m^2|"Phase I Part B BSA </= 1.5m^2
~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1
~Study treatment cycle lasts 28 days, oral, once a week"
16480040|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA > 1.5m^2|"Phase I Part B BSA > 1.5m^2
~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1
~Study treatment cycle lasts 28 days, oral, once a week"
16480041|NCT03429790|Experimental|group intra-operative cell salvage|"The theoretical amount of blood transfusion should be based on the following formula:
~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether the experimental group or the no intervention group."
16480042|NCT03429790|Active Comparator|group allogeneic blood transfusion|"The theoretical amount of blood transfusion should be based on the following formula:
~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether group intra-operative cell salvage or group allogeneic blood transfusion."
16480043|NCT03429777|Experimental|Hearing Loss Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in patients with hearing loss.
16480044|NCT03429777|Active Comparator|Control Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in control subjects without any prior or current hearing loss.
16480045|NCT03429764|Active Comparator|Control group (CG),CISS|continuous independent sling sutures (CISS) will be placed with minimum two intact contact points at the surgical site,
16480046|NCT03429764|Experimental|Test group (TG),VIMS|internal mattress suture (VIMS) will be placed with minimum two intact contact points at the surgical site,
16480047|NCT03429751|Experimental|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
16480048|NCT03429751|Active Comparator|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
16480049|NCT03429738|Experimental|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
16480050|NCT03429738|Active Comparator|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
16480051|NCT03429725|Experimental|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
16480052|NCT03429725|Experimental|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
16480053|NCT03429712|Experimental|Dose Split CT|
16480054|NCT03429699|Experimental|Intervention group|
16480055|NCT03429699|Other|Control group|
16480056|NCT03429686|Experimental|DRT Intervention|Intervention: Individual digital reminiscence therapy programme.
16480057|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
16480058|NCT03429660||Cohort|"Data to be collected are :
~- Medical information on Immune Thrombocytopenia treatment"
16480059|NCT03429647|Other|Sigmoid perfusion|Measured by visible light spectroscopy
16480060|NCT03429634|Experimental|Balloon-Stent Kissing technique|randomly, patients with bifurcation lesion treated by Balloon-Stent Kissing intervention technique in this group.For procedure,stent in main vessel and balloon protect of side branch,final kiss-balloon was performed.
16480061|NCT03429634|Sham Comparator|Jailed Wire technique|randomly,patients with bifurcation lesion treated by Jailed Wire intervention technique in this group.For procedure,stent in main vessel and only wire protect of side branch.If need,post-stent rewire of branch,and balloon dilation of side branch was performed.
16480062|NCT03429621|Experimental|Simethicone|Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
16480063|NCT03429621|No Intervention|No simethicone|The women will not be given Simethicone.
16480064|NCT03429608||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
16480065|NCT03429608||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
16480066|NCT03429595|Experimental|Group 1: ATx201 GEL 2%|
16480067|NCT03429595|Experimental|Group 2: ATx201 GEL 4%|
16480068|NCT03429595|Experimental|Group 3: ATx201 GEL 4% plus vehicle|
16480069|NCT03429595|Experimental|Group 4: ATx201 GEL 4% plus vehicle|
16480070|NCT03429595|Placebo Comparator|Group 5: Vehicle|
16480071|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
16480072|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
16480073|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
16480074|NCT03429569|Sham Comparator|accelerated conventional technique|"Pachymetry greater than 400μm
~Topographic criteria for keratoconus evolution:
~Variation over a 6-month period of the following changes:
~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
16480075|NCT03429569|Sham Comparator|iontophoresis|"Pachymetry greater than 400μm
~Topographic criteria for keratoconus evolution:
~Variation over a 6-month period of the following changes:
~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
16480403|NCT03427385|Experimental|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
16480077|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
16480078|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
16480079|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
16480083|NCT03429530||Group1|20 patients with chronic HCV
16480084|NCT03429530||GroupII|20 patient with chronic HCV related liver cirrhosis
16480085|NCT03429530||GroupIII|40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
16480086|NCT03429530||group IV|20 healthy blood donors will also be included as a control group
16480087|NCT03429517||Patients|ACS Lipogram
16480088|NCT03429517||Controls|Normal LDL-C level Lipogram
16480089|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
16480090|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
16480091|NCT03429491|Placebo Comparator|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
16480092|NCT03429491|Experimental|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
16480093|NCT03429491|Experimental|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
16480094|NCT03429478|Experimental|Music|Preoperative application of a Bluetooth enabled headphones with standard music played for atleast 2 hours preoperatively.
16480095|NCT03429478|Active Comparator|No Music|Preoperative application of a Bluetooth enabled headphones with no music played and headphones will just mask the surrounding noise.
16480096|NCT03429465|Experimental|EVO|All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
16480097|NCT03429439|Experimental|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.
~Interventions:
~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
16480098|NCT03429439|Other|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.
~Interventions:
~Procedure: antiviral therapy"
16480099|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.
~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
16480100|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
16480101|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
16480102|NCT03429413|Active Comparator|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
16480103|NCT03429413|Active Comparator|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
16480104|NCT03429413|No Intervention|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
16480105|NCT03429413|No Intervention|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
16480106|NCT03429413|No Intervention|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
16480107|NCT03429400|Other|Morphine Sulfate|oral morphine sulfate tablets oral morphine sulfate oral solution
16480108|NCT03429387|Experimental|FDG-PET/CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
16480109|NCT03429387|Active Comparator|Conventional CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
16480110|NCT03429374|Active Comparator|Liquiband Fix8 glue mesh fixation|
16480111|NCT03429374|Active Comparator|Mesh fixation with absorbable tacks|
16480112|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
16480113|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
16480114|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
16480115|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
16480116|NCT03429322|Experimental|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
16480289|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
16480117|NCT03429322|Active Comparator|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
16480118|NCT03429309|Other|Anesthesia-induction with propofol|
16480119|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
16480120|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
16480121|NCT03429270|Experimental|Urodynamics Arm|
16480122|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
16480123|NCT03429244|Experimental|Low and intermediate risk prostate cancer|
16480124|NCT03429231||Active Group|Women who are taking coenzyme Q and who will continue taking it for 3 months
16480125|NCT03429231||Control Group|Women who are not taking coenzyme Q and who will not take it in the next 3 months
16480127|NCT03429205|Experimental|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
16480128|NCT03429205|Other|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
16480129|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
16480130|NCT03429179|Experimental|High anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were >10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
16480131|NCT03429179|Placebo Comparator|High anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were >10, and received an infusion of the same volume of 0.9% saline
16480132|NCT03429179|Experimental|Low anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
16480133|NCT03429179|Placebo Comparator|Low anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline
16480134|NCT03429166|Experimental|STAIR|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
16480135|NCT03429166|Active Comparator|PCT|PCT stands for Present Centered Therapy, a non-trauma-focused treatment
16480136|NCT03429140|Experimental|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
16480137|NCT03429140|Placebo Comparator|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
16480138|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
16480139|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
16480140|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
16480141|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
16480142|NCT03429101|Experimental|Poziotinib|"Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.
~Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
16480143|NCT03429088|Experimental|Telephone counseling|Participants were provided with approximately 7 telephone-based motivational interviewing over a 24-week period to increase their physical activity.
16480144|NCT03429088|No Intervention|Usual care|Participants in the usual care arm received a packet of places near their home in which they could engage in physical activity if they chose.
16480145|NCT03429075|Experimental|Psilocybin|Patients receive Psilocybin
16480146|NCT03429075|Active Comparator|Escitalopram|Patients receive Escitalopram
16480147|NCT03429062||personal training|Individuals with a diagnosis of MS and any level of function will be recruited to participate in exercise two times per week with trained personal trainers. Exercise consists of strengthening, stretching, balance, endurance and gait when able. Equipment to be used include treadmill, stationary bike, weight equipment.
16480148|NCT03429062||Whole Body Platform|Individuals with a diagnosis of MS and able to walk with or without an assistive device will be recruited to participate in whole body platform training two times per week with a physical therapist. The exercise on the whole body platform includes strengthening, balance, stretching, and endurance for 30 second bouts. The whole body platform is on for 30 seconds then off. Each exercise will use the 30 seconds to complete.
16480149|NCT03429049|Placebo Comparator|Placebo|Single intra-articular 1.0 mg Placebo Injection
16480150|NCT03429049|Experimental|CNTX-4975-05|Single intra-articular 1.0 mg CNTX-4975-05 (trans-capsaicin) injection
16480152|NCT03429010|Experimental|"New guideline"|"New guideline anesthesia strategy team (Group A)"
16480153|NCT03429010|No Intervention|Current strategy|Current anesthesia strategy team (Group B)
16480154|NCT03428997|Experimental|Lotion|Test sites were patched with the lotion F #13451-131.
16480155|NCT03428997|Other|Negative Control|Test sites were patched with undosed occlusive patch.
16480156|NCT03428984|Experimental|EXPAREL 20 + 20|20 mL EXPAREL with 20 mL normal saline
16480157|NCT03428984|Experimental|EXPAREL 20 + 10|20 mL EXPAREL with 10 mL normal saline
16480404|NCT03427372||group 1: patients with headache|the patients who have post spinal puncture headache after spinal anesthesia
16480158|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) fortnightly|Arm 1a: NUC-3373 administered IV followed by a 2-week washout period. The next dose of NUC-3373 administered in combination with LV at 400 mg/m2. All subsequent doses of NUC-3373 administered in combination with LV every 2 weeks in 28-day cycles.
16480159|NCT03428958|Experimental|NUC-3373 fortnightly|Arm 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks without LV in 28-day cycles.
16480160|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) weekly|Arm 1c: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV weekly on Days 1, 8, 15 and 22 of 28-day cycles.
16480161|NCT03428958|Experimental|NUC-3373 + leucovorin (LV); combination chemotherapy ineligible|Arm 1d: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV on Days 1, 8, 15 and 22 of 28-day cycles.
16480162|NCT03428958|Experimental|NUC-3373 + oxaliplatin weekly|Arm 2a: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
16480163|NCT03428958|Experimental|NUC-3373 + irinotecan weekly|Arm 2b: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
16480164|NCT03428958|Experimental|NUC-3373 + oxaliplatin (NUFOX) expansion|Arm 2c: At the completion of Arm 2a, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
16480165|NCT03428958|Experimental|NUC-3373 + irinotecan (NUFIRI) expansion|Arm 2d: At the completion of Arm 2b, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
16480166|NCT03428958|Experimental|NUFOX + bevacizumab weekly|Arm 3a: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c will be combined with bevacizumab. NUC-3373+LV will be administered weekly, oxaliplatin will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
16480167|NCT03428958|Experimental|NUFOX + bevacizumab fortnightly|Arm 3b: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c will be combined with bevacizumab. NUC-3373+LV+oxaliplatin will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
16480168|NCT03428958|Experimental|NUFIRI + bevacizumab weekly|Arm 3c: NUC-3373, LV and irinotecan at dose levels used in Arm 2d will be combined with bevacizumab. NUC-3373+LV will be administered weekly, irinotecan will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
16480169|NCT03428958|Experimental|NUFIRI + bevacizumab fortnightly|Arm 3d: NUC-3373, LV and irinotecan at dose levels used in Arm 2d will be combined with bevacizumab. NUC-3373+LV+irinotecan will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
16480170|NCT03428958|Experimental|NUC-3373 + LV + bevacizumab; maintenance patients|Arm 3e: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with bevacizumab and bevacizumab will be administered in accordance with standard local practice.
16480171|NCT03428958|Experimental|NUFOX + cetuximab|Arm 3f: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or fortnightly, oxaliplatin will be administered fortnightly and cetuximab will be administered in accordance with standard local practice.
16480172|NCT03428958|Experimental|NUFIRI + cetuximab|Arm 3g: NUC-3373, LV and irinotecan at dose levels used in Arm 2d may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or fortnightly, irinotecan will be administered fortnightly and cetuximab will be administered in accordance with standard local practice.
16480173|NCT03428945|Experimental|Hydroxychloroquine|Hydroxychloroquine compound for oral use
16480174|NCT03428945|Placebo Comparator|Placebo|Placebo tablet matching active drug
16480175|NCT03428932|Active Comparator|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
16480176|NCT03428932|Active Comparator|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
16480177|NCT03428919|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.
~Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
16480178|NCT03428919|Active Comparator|In Vitro Fertilization (IVF)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.
~Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium.
~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen."
16480179|NCT03428906|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .
16480180|NCT03428906|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.
16480405|NCT03427372||group 2: patients without headache|the patients who do not have post spinal puncture headache after spinal anesthesia
16480181|NCT03428893|Experimental|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
16480182|NCT03428893|No Intervention|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
16480183|NCT03428880|Active Comparator|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
16480184|NCT03428880|Active Comparator|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.
~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
16480185|NCT03428841||Patients with dural puncture at epidural|Patients who sustained an accidental dural puncture during the epidural procedure.
16480186|NCT03428841||Patients with no dural puncture|Patients with no dural puncture during epidural procedure, to serve as a control group.
16480187|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
16480188|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
16480189|NCT03428815|Experimental|PCM liner|Willowwood Smart Temp Liner
16480190|NCT03428815|Active Comparator|regular liner|User's regular prescribed liner
16480191|NCT03428802|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
16480192|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
16480193|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
16480194|NCT03428776|Sham Comparator|Controls|Self returns
16480195|NCT03428776|Active Comparator|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives
16480196|NCT03428776|Active Comparator|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives
16480197|NCT03428763|Experimental|Homebased disease monitoring (eHealth)|Participants allocated to the intervention group will be trained in self-monitoring of their RA
16480198|NCT03428763|Active Comparator|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
16480199|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
16480200|NCT03428750|Placebo Comparator|Placebo|
16480201|NCT03428737|Other|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
16480202|NCT03428737|Other|Nocturnal pressure support ventilation|Use of a pressure support level identical during the night to the pressure support level at the end of the day.
16480203|NCT03428724|Active Comparator|standard group|standard polyethylene glycol preparation for colonoscopy
16480204|NCT03428724|Experimental|individualized group|either a low or a high volume bowel preparation according to patient characteristics
16480205|NCT03428711|Placebo Comparator|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
16480206|NCT03428711|Experimental|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.
~50 mg, twice-a-day, for 12 months"
16480207|NCT03428698|Experimental|experimental device|The extraction was completed, the socket was filled with a topical amino acid + sodium hyaluronate gel (Aminogam®, sterile syringe 2 ml).
16480208|NCT03428698|Placebo Comparator|control no device|The extraction was completed, socket was flushed, using a 2ml sterile syringe similar to one utilized to apply the gel, with sterile physiological solution.
16480209|NCT03428685|Active Comparator|Intervention group|
16480210|NCT03428685|Placebo Comparator|Placebo group|
16480211|NCT03428672|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
16480212|NCT03428672|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
16480213|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
16480214|NCT03428633|Active Comparator|Group A|Thoracic paravertebral block using ropivacaine
16480215|NCT03428633|Active Comparator|Group B|Morphine IV
16480216|NCT03428620|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints that will be manipulated include proximal tibiofibular, the distal tibiofibular, and talocrural joints and will be mobilized the first three sessions prior to the participants performing the exercise protocol.
16480217|NCT03428620|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
16480218|NCT03428607|Experimental|AZD6738+Olaparib|AZD6738 160mg QD per os administered for 7 days and olaparib 300mg BID per os administered daily. One cycle is considered of 28 days.
16480290|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
16480219|NCT03428594|Experimental|CKD-11101|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
16480220|NCT03428594|Active Comparator|NESP|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
16480221|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
16480222|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
16480223|NCT03428568|Experimental|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
16480224|NCT03428568|Active Comparator|Nexium|omeprazole 40 mg once per day for one month.
16480225|NCT03428568|Experimental|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
16480226|NCT03428568|Active Comparator|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.
~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
16480227|NCT03428568|Experimental|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
16480228|NCT03428568|Experimental|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
16480229|NCT03428555|Experimental|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.
~Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.
~Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.
~Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
16480230|NCT03428555|Active Comparator|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
16480231|NCT03428542|No Intervention|Control arm|Instructed not to practice any yoga or mindfulness during the five-week study period.
16480232|NCT03428542|Active Comparator|Yin yoga intervention arm|"The Yin yoga intervention arm will receive Yin yoga, a calm-paced practice that uses seated and lying down positions.
~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
16480233|NCT03428542|Active Comparator|YOMI program intervention arm|"The YOMI intervention arm will receive stress education + yoga, and bring together education about stress, mindfulness and yoga practice. It will involve weekly group meetings, homework, and yoga postures. Stress education and mindfulness will make up one portion of the intervention. This will take place in a group lecture format and shall be conducted by a mental health professional(s). Yoga practice in a group format will make up the second portion of the intervention.
~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
16480234|NCT03428529|Experimental|Capecitabine|Neoadjuvant capecitabine plus RT
16480235|NCT03428529|Active Comparator|5-Flourouracil|Neoadjuvant 5-Fluorouracil plus RT
16480236|NCT03428516|Experimental|Fixed CPAP|CPAP always deliver air with the same pressure
16480237|NCT03428516|Active Comparator|Auto-adjusting CPAP|Auto-CPAP changes the pressure delivered depending on events detected at any time (apnea, hypopnea …) and applies the lowest pressure required to eliminate events.
16480238|NCT03428503|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
16480239|NCT03428503|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
16480240|NCT03428490|Experimental|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
16480241|NCT03428490|Active Comparator|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
16480242|NCT03428477|Experimental|Icosapent Ethyl (EPA-EE)|Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
16480243|NCT03428477|Placebo Comparator|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
16480244|NCT03428464|Experimental|Sodium bicarbonate|During the treatment period, participants will receive 0.5 mEq/kg-lean body weight (LBW)/day of oral sodium bicarbonate for 8 weeks.
16480245|NCT03428464|Placebo Comparator|Placebo|During the control period, participants will take the same number of placebo capsules as if they were assigned 0.5 mEq/kg-LBW/day of sodium bicarbonate.
16480246|NCT03428451|Active Comparator|Group A (Hypertonic saline )|patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.
16480247|NCT03428451|Active Comparator|Group B (Hypertonic saline)|patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.
16480248|NCT03428451|Active Comparator|Group C (Normal saline)|patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.
16480249|NCT03428438|Other|Study group SMS to home phone|A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E.
16480252|NCT03428412|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
16480253|NCT03428412|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
16480254|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
16480255|NCT03428386|Experimental|Gastric plication ileal bypass|single-anastomosis plication ileal bypass
16480256|NCT03428373|Experimental|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
16480257|NCT03428373|Active Comparator|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
16480258|NCT03428360|Experimental|Subjects with Epilepsy|Male or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.
16480259|NCT03428347|Experimental|Group 1|1.4 mg/kg body weight
16480260|NCT03428347|Experimental|Group 2|7 mg/kg body weight
16480261|NCT03428347|Experimental|Group 3|14 mg/kg body weight
16480262|NCT03428334|Experimental|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
16480263|NCT03428308|Experimental|Individualized treatment of detected somatic disease(s)|
16480264|NCT03428295|Experimental|Experimental: Single Cohort in CRC|This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
16480265|NCT03428282|Experimental|VR Box|Inferior alveolar nerve block will be performed with the aid of VR box as a means of distracting patients' attention.
16480266|NCT03428282|Experimental|Tablet device|Inferior alveolar nerve block will be performed with the aid of a tablet device as a means of distracting patients' attention.
16480267|NCT03428282|Active Comparator|Anesthesia|Inferior alveolar nerve block will be performed in the normal manner without any specific intervention to distract patients' attention. Classic anesthesia will be applied.
16480268|NCT03428269|Experimental|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
16480269|NCT03428269|Active Comparator|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
16480270|NCT03428256|Active Comparator|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
16480271|NCT03428256|Experimental|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
16480272|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
16480273|NCT03428230|Experimental|30 mg Paracetamol 3% (1 mL)|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
16480274|NCT03428230|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
16480275|NCT03428230|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
16480276|NCT03428230|Placebo Comparator|Placebo, 0.9% saline solution|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
16480277|NCT03428217|Experimental|CB-Cabo|CB-839 orally twice daily + cabozantinib orally once daily
16480278|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo orally twice daily + cabozantinib orally once daily
16480279|NCT03428204|Other|180 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 180 seconds for percutaneous treatment of femoropopliteal artery stenosis
16480280|NCT03428204|Other|300 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 300 seconds for percutaneous treatment of femoropopliteal artery stenosis
16480281|NCT03428178|Experimental|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
16480282|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
16480283|NCT03428165|No Intervention|spontaneous|
16480284|NCT03428152||Hypo|The participants with a superior hypogastric block
16480285|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
16480286|NCT03428139|Active Comparator|Group I|Each patient in this group was treated with pulsed radiofrequency on the affected dorsal root ganglion at 42°C for 120 seconds
16480287|NCT03428139|Active Comparator|Group II|Each patient in this group was treated with pulsed radiofrequency as in group I plus oral alpha lipoic acid (ALA) 600 mg.
16480288|NCT03428126|Experimental|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.
~Participants receive Durvalumab by vein every 4 weeks.
~Each cycle is 28 days."
16480291|NCT03428100|Experimental|4 mg Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
16480292|NCT03428100|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
16480293|NCT03428100|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
16480294|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with topical corticosteroids.
16480295|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
16480296|NCT03428074||Patients with the surgery of Ivor-Lewis|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Ivor-Lewis
16480297|NCT03428074||Patients with the surgery of Mckeown|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Mckeown
16480298|NCT03428061||Intervention group|The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
16480299|NCT03428061||Control group|Usual care will be based on the Dutch CVRM guideline, describing how to calculate the CVR and advices to lower this risk by lifestyle intervention and/or medication. However systematic identification of patients eligible for CVRM, actively inviting patients for a visit, regular follow-up and standardized collaboration with other disciplines in the health care chain are not necessarily part of usual care.
16480300|NCT03428048||Adults diagnosed with paroxysmal and persistent Afib|Adults diagnosed with paroxysmal and persistent Afib who are identified as candidates for an intervention either surgical (epicardial) known as the hybrid approach or an endocardial ablation with either laser, radio frequency or cryoablation energy source.
16480301|NCT03428035|Experimental|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
16480302|NCT03428035|No Intervention|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
16480303|NCT03428035|Active Comparator|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
16480304|NCT03428022|Experimental|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
16480305|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
16480306|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
16480307|NCT03427996||Coronary disease|
16480308|NCT03427983|Other|US-guided regular injection|US in-plane injection with corticosteroid and 1cc of lidocaine. Total of 2cc.
16480309|NCT03427983|Other|US-guided hydrodissection|US in-plane injection with corticosteroid and 1cc of lidocaine, and 3cc of saline. Total of 5cc.
16480310|NCT03427970|Active Comparator|control group|Control subjects will receive observation for 6 months.
16480311|NCT03427970|Experimental|experimental group|Experimental group will perform three-dimensionally integrated exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 20-min period per day under the supervision of the parents at home.The treatment regimens lasted for 6 months.
16480312|NCT03427957|Experimental|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
16480313|NCT03427957|Active Comparator|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
16480314|NCT03427957|Active Comparator|Classic alligator grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic alligator grasper.
16480315|NCT03427944|Active Comparator|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
16480316|NCT03427944|Placebo Comparator|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
16480317|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
16480318|NCT03427918|Experimental|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
16480319|NCT03427918|Experimental|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
16480320|NCT03427918|No Intervention|Control group|The control group will receive a routine counseling
16480321|NCT03427905|Active Comparator|GROUP I|lipoaspiration and transplantation of ADSVCs (for adipose-derived stromal vascular cells/primary fresh cells without culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
16480322|NCT03427905|Active Comparator|GROUP II|lipoaspiration and transplantation of ADSCs (for adipose-derived mesynchymal stem cells/after culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
16480323|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
16480324|NCT03427879|Placebo Comparator|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
16480325|NCT03427879|Active Comparator|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
16480326|NCT03427866|Experimental|Ruxolitinib Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day
~Dosing will be continuous, with a new cycle scheduled to start every 28 days.
~There will be no break in dosing between cycles
~Ruxolitinib can be administered with or without food."
16480327|NCT03427866|Experimental|Ruxolitinib Not Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day after transplant
~Dosing will be continuous, with a new cycle scheduled to start every 28 days.
~There will be no break in dosing between cycles
~Ruxolitinib can be administered with or without food."
16480328|NCT03427853|Experimental|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
16480329|NCT03427853|Placebo Comparator|Placebo|Placebo subcutaneous injection
16480330|NCT03427840||Hypo|The participants with a superior hypogastric block
16480331|NCT03427840||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)
16480332|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
16480333|NCT03427827|No Intervention|Best supportive care|Patients randomized to this arm will receive best supportive care after chemoradiation
16480334|NCT03427814|Experimental|Pamiparib|Approximately 64 participants to receive pamiparib orally.
16480335|NCT03427814|Placebo Comparator|Placebo|Approximately 64 participants to receive placebo orally.
16480336|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
16480337|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
16480338|NCT03427788|Experimental|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
16480339|NCT03427788|Placebo Comparator|Placebo|Study group 1-11 of Placebo
16480340|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
16480341|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
16480342|NCT03427762|Experimental|Healthy cycling group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then there is a bicycle every 1 hour.
16480343|NCT03427762|Experimental|Healthy xbox group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then they will train 1 hour every day on an xbox program.
16480344|NCT03427762|No Intervention|Healthy controll group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
16480345|NCT03427762|Experimental|PD groupe|"Patients with PD have already been evaluated and compared to the results of a healthy group within a separate experiment.
~The study and the results have been completed. Clinical trial number:NCT03193268"
16480346|NCT03427736||Drug of Interest|Individuals receiving anesthetics or analgesics per standard of care
16480347|NCT03427723|Active Comparator|Standard care|visualization and palpation
16480348|NCT03427723|Experimental|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
16480349|NCT03427710|Experimental|Cohort A1|CiVi007 dose 1
16480350|NCT03427710|Experimental|Cohort A2|CiVi007 dose 2
16480351|NCT03427710|Experimental|Cohort A3|CiVi007 dose 3
16480352|NCT03427710|Experimental|Cohort A4|CiVi007 dose 4
16480353|NCT03427710|Experimental|Cohort A5|CiVi007 dose 5
16480354|NCT03427710|Placebo Comparator|Combined placebo group|group response from placebo subsets of dosing cohorts
16480355|NCT03427697|Experimental|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
16480356|NCT03427697|No Intervention|Control group|No intervention will be performed in the control group
16480357|NCT03427684|Experimental|Hypo-fractionated radiotherapy|Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer
16480358|NCT03427671|Experimental|Occlusin 500 microspheres|Uterine fibroid embolization
16480359|NCT03427658|Experimental|Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and additional sweet food consumption recommended.
16480360|NCT03427658|Active Comparator|Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and substitutions for sweet food consumption will be recommended.
16480361|NCT03427645|No Intervention|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
16480362|NCT03427645|Experimental|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
16480363|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
16480365|NCT03427606|Experimental|Continuous Suture|
16480366|NCT03427606|Active Comparator|Single 5-points Suture|
16480367|NCT03427593|Experimental|Patients|Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
16480368|NCT03427593|Other|relatives (parents)|
16480369|NCT03427593|Sham Comparator|Controls|
16480370|NCT03427580|Experimental|treatment group|
16480371|NCT03427580|Experimental|delayed treatment control group|
16480372|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
16480373|NCT03427554|Experimental|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
16480374|NCT03427554|Active Comparator|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
16480375|NCT03427554|Placebo Comparator|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
16480376|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
16480377|NCT03427528|Experimental|FAB Pilot Study (Male Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.
~Male partners will receive Fathers and Babies (FAB Intervention) while his female partner will receive MB 1-on-1 plus MB-TXT."
16480378|NCT03427528|Experimental|MB 1-on-1 Plus TEXT (Female Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.
~Female clients will receive the Mothers and Babies with -Text Messages intervention (i.e., MB 1-on-1 plus MB-TXT) while her male partner will receive FAB."
16480379|NCT03427515|Experimental|Lactobacillus|Lactobacillus rhamnosus GG (ATCC 53103) - encapsulated
16480380|NCT03427515|Placebo Comparator|Placebo|Placebo - encapsulated mixture of maltodextrins
16480381|NCT03427515|Experimental|Saccharomyces|Saccharomyces boulardii (CNCM I-1079) - encapsulated
16480382|NCT03427502|Experimental|Study Group|"Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve.
~Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose.
~Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel."
16480383|NCT03427502|Placebo Comparator|Control Group|"At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron.
~Injection technique remains the same as in Study group."
16480384|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
16480385|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
16480386|NCT03427476|Experimental|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
16480387|NCT03427476|Experimental|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions > 7 cm (may also have metastatic disease) (N = 5)
16480388|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
16480389|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
16480390|NCT03427450||Healthy Volunteers (Controls)|A control population of healthy volunteers (HVs) consisting of women with no prior/current history of cancer and no known history of breast disease (the information obtained from the HVs may be 'self-reports', as complete medical records may not be available at the enrolling site for these control subjects), and with a broadly similar age range to the cancer patient study population. All eligible and consenting subjects will have blood draw.
16480391|NCT03427450||MBC Patients (Cancers)|Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrollment into the cancer population. All eligible and consenting subjects will have blood draw.
16480392|NCT03427437|Active Comparator|Conventional Group|Caudal block was performed by conventional method with %0,25 bupivacaine plus 1/200.000 adrenalin
16480393|NCT03427437|Active Comparator|Ultrasound Group|Caudal block was performed by ultrasound method with %0,25 bupivacaine plus 1/200.000 adrenalin
16480394|NCT03427424||AUD-E|Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP within 2 months of starting treatment (AUD-E)
16480395|NCT03427424||AUD-L|Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (AUD-L)
16480396|NCT03427424||Characterization|substance use disorder participants currently enrolled in PHP, not eligible for main imaging study
16480397|NCT03427424||CON|healthy, non-drug using control participants (CON)
16480398|NCT03427424||POAUD-E|Early-in-treatment, healthy dual prescription opioid and alcohol and use disorder participants currently enrolled in PHP within 2 months of starting treatment (POAUD-E)
16480399|NCT03427424||POAUD-L|Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POAUD-L)
16480400|NCT03427424||POUD-E|Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health program (PHP) within 2 months of starting treatment (POUD-E)
16480401|NCT03427424||POUD-L|Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POUD-L)
16480406|NCT03427372||group 3: patients with backache|the patients who have post spinal puncture backache after spinal anesthesia
16480407|NCT03427372||group 4: patients without backache|the patients who do not have post spinal puncture backache after spinal anesthesia
16480408|NCT03427359|Experimental|experimental arm|Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
16480409|NCT03427346|Active Comparator|EMR|Endoscopic mucosal resection
16480410|NCT03427346|Active Comparator|ESD|Endoscopic submucosal dissection
16480411|NCT03427333|Experimental|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
16480412|NCT03427320|Experimental|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
16480413|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
16480414|NCT03427281|Experimental|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
16480415|NCT03427268|Experimental|PM060184|PM060184
16480416|NCT03427255|Active Comparator|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
16480417|NCT03427255|Other|Waiting list|Six months waiting-list control condition.
16480418|NCT03427242|Experimental|treatment arm|oral apatinib
16480419|NCT03427229|Experimental|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
16480420|NCT03427229|Active Comparator|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
16480421|NCT03427216|Active Comparator|Vaginal Baclofen/diazepam supp|Insert vaginal suppository once daily
16480422|NCT03427216|Placebo Comparator|Vaginal Placebo supp|Insert vaginal suppository once daily
16480423|NCT03427203|Experimental|Arm 1|"The subjects test the products in the following order
~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 2 Coloplast Ostomy device 3"
16480424|NCT03427203|Experimental|Arm 2|"The subjects test the products in the following order
~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 3 Coloplast Ostomy device2"
16480425|NCT03427190|Active Comparator|Control|Phone contact with patient will be made by a professional psychologist within 21 days of hospital discharge. If contact cannot be made after 9 attempts, post-cards will be sent monthly at M2, M3, M4 and M5, asking the participant to establish contact with the designated psychologist. The phone call will determine whether or not the participant is in a state of suicidal crisis. If yes, steps will be taken to attend the crisis within 24 hours.
16480426|NCT03427190|Other|APSOM|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
16480427|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
16480428|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
16480429|NCT03427164|Experimental|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
16480430|NCT03427151|Experimental|IPP-201101|every 4 weeks
16480431|NCT03427138|Experimental|Jasper|JASPER (Joint Attention Symbolic Play Engagement Regulation) is a targeted intervention that focusses on early communication skills.
16480432|NCT03427138|Experimental|Parent Education|Parent education intervention focusses on parenting a child with autism.
16480433|NCT03427125|Experimental|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
16480434|NCT03427125|Placebo Comparator|Placebo|Placebo
16480435|NCT03427125|Active Comparator|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
16480436|NCT03427099|Active Comparator|Control group|usual care
16480437|NCT03427099|Experimental|Intervention group|Rehabilitation with a biopsychosocial focus
16480438|NCT03427086|Active Comparator|Interventional|Patient will received high dose of biotin (300 mg/day)
16480439|NCT03427086|Placebo Comparator|Placebo|Patients will receive placebo
16480440|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours
~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
16480441|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer
~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
16480442|NCT03427060|Experimental|Coversin treatment|Coversin - 22.5mg followed by 45mg for 6 months.
16480495|NCT03426761|Experimental|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
16480445|NCT03427034|Experimental|Cystoscopic surveillance|Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
16480446|NCT03427034|Experimental|Haematuria group|Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
16480447|NCT03427034|No Intervention|Longitudinal group|Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.
16480448|NCT03427021|Experimental|Arm A|will be treated with consistent exposure to oral ice
16480449|NCT03427021|Active Comparator|Arm B|Will not be treated with consistent exposure to oral ice.
16480450|NCT03427008|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
16480451|NCT03427008|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
16480452|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
16480453|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
16480454|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
16480455|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
16480456|NCT03426995|Experimental|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
16480457|NCT03426995|Experimental|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
16480458|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
16480493|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480494|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480459|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
16480460|NCT03426982|Experimental|Anti-Xa group|- Heparin was monitored by Anti-Xa activity, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 0.30 and 0.70 IU/mL
16480461|NCT03426982|Experimental|APTT group|- Heparin was monitored by APTT, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 1.5 and 2.5 time the basiline.
16480462|NCT03426969|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on days -5, fludarabine phosphate IV over 1 hour on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously for approximately 2 weeks, then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 100, and filgrastim SC daily from day 7 until continued until ANC > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
16480463|NCT03426956|Experimental|Glucose|
16480464|NCT03426956|Experimental|Glucose + Canagliflozin|
16480465|NCT03426943|Experimental|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.
~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
16480466|NCT03426943|Active Comparator|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).
~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
16480467|NCT03426930|Active Comparator|The reference treatment of dysmorphophobia used|
16480468|NCT03426930|Experimental|The reference treatment with the virtual reality|
16480469|NCT03426904|Experimental|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
16480470|NCT03426904|Active Comparator|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
16480472|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
16480473|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
16480474|NCT03426865||Axumin PET scan|Only one arm is being evaluated--the arm receiving PET scan
16480475|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
16480476|NCT03426852||Control Group|Individuals with lumbar back pain
16480477|NCT03426839|Active Comparator|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
16480478|NCT03426839|Active Comparator|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
16480479|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
16480480|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
16480481|NCT03426813|Other|Early mobilization|Historical control group for early mobilization
16480482|NCT03426800|Experimental|Migraine_acupuncture and training|Migraine acupuncture and training
16480483|NCT03426800|Experimental|Migraine training|Migraine training
16480484|NCT03426800|Experimental|Tension_acupuncture and training|Tension headache acupuncture and training
16480485|NCT03426800|Experimental|Tension headache training|Tension headache training
16480486|NCT03426787|Experimental|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
16480487|NCT03426774|Experimental|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480488|NCT03426774|Experimental|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480489|NCT03426774|Experimental|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480490|NCT03426774|Experimental|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480491|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480492|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
16480496|NCT03426761|Active Comparator|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
16480497|NCT03426748|Active Comparator|Low dose rate brachytherapy|Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
16480498|NCT03426748|Experimental|High dose rate brachytherapy|"Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.
~HDR brachytherapy is also accomplished as an out-patient."
16480499|NCT03426735|Experimental|Dry heat|Dry heat application with a termal bag
16480500|NCT03426735|Active Comparator|Dry cold|Dry cold application with a termal bag
16480501|NCT03426722|Active Comparator|L-carnitine|L-carnitine 500mg three times daily (per oral)
16480502|NCT03426722|Placebo Comparator|Placebo|Placebo 500mg three times daily (per oral)
16480503|NCT03426709|Experimental|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies) in groups of 8-12 people.
16480504|NCT03426709|No Intervention|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
16480505|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
16480506|NCT03426683|Experimental|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
16480507|NCT03426683|No Intervention|traditional drugs|The patients will receive traditional medicine treatment as usual.
16480508|NCT03426670|Active Comparator|OraQuick HIV Self-Test|Sex workers in the intervention arm will be instructed to self-test before starting each monthly course of PrEP. HIV Self-testing will be performed during the months between scheduled quarterly visits.
16480509|NCT03426670|No Intervention|In-clinic testing|All study participants will receive quarterly in-clinic HIV testing as standard-of-care.
16480510|NCT03426657|Experimental|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W / since Amendment 3: 300 mg absolute dose d5) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
16480511|NCT03426644|Active Comparator|Group A|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.
16480512|NCT03426644|Experimental|Group B|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
16480513|NCT03426644|Experimental|Group C|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
16480514|NCT03426644|Experimental|Group D|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group D.
16480515|NCT03426631|Placebo Comparator|Placebo|Placebo before sleep
16480516|NCT03426631|Experimental|DAW1033B2 oral capsule|DAW1033B2 before sleep
16480517|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
16480518|NCT03426605|Experimental|LAM-003|Open label LAM-003 at three increasing dose levels of 200, 300 and 450 mg.
16480519|NCT03426592|Active Comparator|Vitamin D3, 10000 Intl Units Oral Capsule|Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months
16480520|NCT03426592|Placebo Comparator|Placebo oral capsule|Oleic acid capsule by mouth, daily for 6 months
16480521|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
16480522|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
16480523|NCT03426553|Experimental|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
16480524|NCT03426553|Active Comparator|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
16480525|NCT03426540|Experimental|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
16480526|NCT03426540|No Intervention|control group|Pars plana vitrectomy alone
16480527|NCT03426527|Placebo Comparator|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
16480528|NCT03426527|Active Comparator|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
16480529|NCT03426514|Experimental|Three-port Laparoscopic Surgery|Patients with colorectal cancer undergo three-port laparoscopic surgery.
16480530|NCT03426514|Experimental|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（4 or more ports）.
16480560|NCT03426241||smoking chronic periodontitis|
16480561|NCT03426241||non-smoking periodontitis|
16480531|NCT03426488||Västerbotten Intervention Programme|"The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.
~The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.
~The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.
~A large part is fasting samples.
~Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300"
16480532|NCT03426488||Mammography Screening Project|"Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).
~Survey data can be linked to the blood samples.
~Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000"
16480533|NCT03426488||The Northern Swedish MONICA Project|"The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.
~Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)"
16480534|NCT03426475|No Intervention|Control Group|Care of nursing home residents as usual.
16480535|NCT03426475|Experimental|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
16480536|NCT03426462|Experimental|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.
~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
16480537|NCT03426462|Experimental|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.
~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
16480538|NCT03426449|Active Comparator|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
16480539|NCT03426449|Active Comparator|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
16480540|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
16480541|NCT03426423|Experimental|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
16480542|NCT03426423|Active Comparator|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
16480543|NCT03426397||Study population|
16480544|NCT03426384|Active Comparator|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.
~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
16480545|NCT03426384|No Intervention|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
16480546|NCT03426371|Experimental|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
16480547|NCT03426371|Placebo Comparator|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
16480548|NCT03426358|Experimental|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
16480549|NCT03426345|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
16480550|NCT03426345|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.
16480551|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
16480552|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
16480553|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
16480554|NCT03426280|Experimental|Apple Watch|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
16480555|NCT03426280|No Intervention|Usual Care|Usual care.
16480556|NCT03426267|Experimental|SDN-037|
16480557|NCT03426267|Placebo Comparator|vehicle|
16480562|NCT03426241||smoking healthy|
16480563|NCT03426241||non-smoking healthy|
16480564|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
16480565|NCT03426202|Experimental|modafinil group|a single dose of p.o. modafinil (200mg)
16480566|NCT03426202|Experimental|placebo group|a single dose of p.o. placebo (200mg)
16480567|NCT03426189||HIV infected individuals on long term ART|"Leukapheresis
~Lymph node biopsy"
16480568|NCT03426176|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
16480569|NCT03426176|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
16480570|NCT03426176|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
16480571|NCT03426176|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
16480572|NCT03426163|Experimental|VR group|Application of virtual reality 12 hours before arthroscopic surgery
16480573|NCT03426163|No Intervention|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
16480574|NCT03426150|Experimental|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
16480575|NCT03426150|Placebo Comparator|Deionized water|Deionized water application on the specimen surface for 3 min
16480576|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
16480577|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
16480578|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
16480579|NCT03426124||Retrospective|Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
16480580|NCT03426124||Prospective|Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
16480581|NCT03426111|Placebo Comparator|Placebo|Diagnostic upper endoscopy plus lifestyle modification.
16480582|NCT03426111|Active Comparator|Treatment|Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
16480583|NCT03426098|Experimental|Treatment|After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
16480584|NCT03426085|Placebo Comparator|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
16480585|NCT03426085|Experimental|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
16480586|NCT03426072|Experimental|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
16480587|NCT03426072|No Intervention|Control|The control units (propensity matched) have no intervention and form a naturalistic control
16480588|NCT03426059||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
16480589|NCT03426046|Experimental|Biodentine|Partial pulpotomy treatment with Biodentine
16480590|NCT03426046|Active Comparator|Calcium Hydroxide|Partial pulpotomy treatment with Calcium Hydroxide
16480591|NCT03426046|Experimental|Mineral Trioxide Aggregate|Partial pulpotomy treatment with Mineral Trioxide Aggregate
16480592|NCT03426033|Experimental|Single dose of warfarin|Single dose of warfarin administered to obtain pharmacokinetic information.
16480593|NCT03426033|Experimental|Warfarin in combination with ISIS 681257|ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.
16480594|NCT03426020|Active Comparator|Oral midazolam (Demizolam®)|To prevent emergence agitation patient premedicated by 0.5 mg oral midazolam At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
16480595|NCT03426020|Active Comparator|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|To prevent emergence agitation patient premedicated by watching a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
16480596|NCT03426020|Active Comparator|Play game (PC fishing game)|To prevent emergence agitation patient premedicated by playing a simple PC game (fishing game) At the end of sugery patients postoperatif emergence agitation evaluated PAED(pediatric anesthesia emergence delirium scale).
16480597|NCT03426007|Experimental|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
16480598|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
16480599|NCT03425981|Experimental|WB-EMS-SRT|Training with basic global electrostimulation
16480600|NCT03425981|Experimental|WB-EMS-WT|Training with specific global electrostimulation for runners
16480601|NCT03425981|Placebo Comparator|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
16480604|NCT03425955|Experimental|GROUP 1|Normotypic or overweight subjects with rounded, oval or squared face (aged 35-50 years)
16480605|NCT03425955|Experimental|GROUP 2|"Thin subjects with oval or triangular face and sagging skin (aged 45-60 years)"
16480606|NCT03425942|Experimental|Internet CBT for insomnia|The intervention consists of Internet-based Cognitive Behavioral Therapy for insomnia (ICBT-i) (the main components are sleep restriction and stimulus control) for five consecutive weeks.
16480607|NCT03425942|Active Comparator|Internet ART for insomnia|The intervention consists of internet-based applied relaxation exercises/techniques (ART) (different and commonly used) for five consecutive weeks.The acronyme for this intervention is (IART-i).
16480608|NCT03425929|Active Comparator|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
16480609|NCT03425929|Active Comparator|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
16480610|NCT03425929|Placebo Comparator|Placebo|Placebo nasal spray for six days
16480611|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
16480612|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
16480613|NCT03425903|Active Comparator|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
16480614|NCT03425903|No Intervention|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
16480615|NCT03425890|Experimental|SURE Program Group|The intervention group will receive a SURE program booklet and will perform individualized daily self-exercise and functional use of the arm and hand on their own outside of therapy for 60 minutes/day, 6 days/week for 4 weeks. These self-exercises and upper limb functional use will be performed in addition to usual care. Three SURE program booklets have been developed which relate to the affected upper limb motor capability using individual Fugl Meyer (ULFM) score. Each SURE program booklet consists of warm-up exercises, strengthening exercises and motor tasks. The SURE program booklet also includes selected functional motor tasks to be performed by the participants using their affected upper limb. The performance of the exercises and functional motor tasks will be reviewed three times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.
16480616|NCT03425890|Experimental|Education Group|The control group will receive an education booklet with 10 modules. The education booklet will contain information on stroke, recovery and management strategies after stroke. Participants are to complete 2-3 modules per week and answer 1-2 simple questions after each module. Each module including answering questions takes approximately 5-10 minutes to complete. CPI will review the information with the participants 3 times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.The participants in the control group will continue with their usual care in the hospital.
16480617|NCT03425877|Experimental|Parkinson's disease Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.
~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
16480618|NCT03425877|Experimental|Stroke Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.
~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
16480619|NCT03425877|Experimental|Healthy Subjects Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.
~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
16480620|NCT03425864|Other|immediate implant|patient will receive immediate implant alone.
16480621|NCT03425864|Active Comparator|immediate implant with connective tissue graft|patient will receive immediate implant and connective tissue gaft
16480622|NCT03425851|Experimental|Intervention Group|Receive 600 diapers.
16480623|NCT03425851|Active Comparator|Control Group|Receive resources of diaper banks as requested.
16480624|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
16480625|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
16480626|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
16480627|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
16480628|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
16480631|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
16480632|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
16480633|NCT03425786|Experimental|Early BPPV Management|Diagnostic and treatment training for BPPV.
16480634|NCT03425786|Active Comparator|Late BPPV Management|Diagnostic training for BPPV. Sports Medicine providers will refer patients positive for BPPV to an Otolaryngologist at our institution for treatment.
16480635|NCT03425773|Experimental|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
16480636|NCT03425747|Active Comparator|Calcium Carbonate|Calcium Carbonate
16480637|NCT03425747|Active Comparator|calcium Citrate|Calcium Citrate
16480638|NCT03425734|Experimental|D group|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
16480639|NCT03425734|Experimental|S group|50 ml saline
16480640|NCT03425721||All Participants|
16480641|NCT03425708|Active Comparator|Treatment group1|Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
16480642|NCT03425708|Active Comparator|Treatment group2|Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
16480643|NCT03425708|No Intervention|Control group|Treatment of CKD patients with hyperuricaemia with conventional methods.
16480644|NCT03425695|Experimental|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination
~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
16480645|NCT03425695|Placebo Comparator|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination
~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
16480646|NCT03425682||Cervical Fusion - ACDF|Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
16480647|NCT03425682||Lumbar Interbody Fusion|Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
16480648|NCT03425669|Active Comparator|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
16480649|NCT03425669|Active Comparator|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
16480650|NCT03425669|Sham Comparator|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
16480651|NCT03425669|Active Comparator|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
16480652|NCT03425669|Sham Comparator|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
16480653|NCT03425656|Experimental|Trastuzumab (AryoTrust)|Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
16480654|NCT03425656|Active Comparator|Trastuzumab (Herceptin)|Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
16480657|NCT03425630|Experimental|Argicolina (cross-over vs Normolip)|Argicolina is a dietary supplement containing monacolin (sachets)
16480658|NCT03425630|Active Comparator|Normolip (cross-over vs Argicolina)|Normolip is a dietary supplement containing monacolin (tablets)
16480659|NCT03425617|Experimental|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
16480660|NCT03425617|Experimental|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
16480661|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
16480662|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
16480663|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
16480664|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
16480665|NCT03425578|Experimental|MSG + CHO|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
16480666|NCT03425578|Active Comparator|MSG + placebo B|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
16480667|NCT03425578|Active Comparator|Placebo A + CHO|Participants will ingest placebo capsules followed by 75 g dextrose.
16480669|NCT03425552|Experimental|Test treatment|Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)
16480670|NCT03425552|Active Comparator|Reference treatment|Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension
16480673|NCT03425526|Experimental|Treatment (allogeneic adenovirus-specific CTLs)|Within two weeks of enrollment, patients receive allogeneic adenovirus-specific CTLs IV over 30 minutes. Patients may receive additional allogeneic adenovirus-specific CTL infusions at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.
16480674|NCT03425513||Hepatitis B group|
16480675|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
16480676|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
16480677|NCT03425487|Experimental|MBSR+TAU|Mindfulness based Intervention (MBSR) + Usual specialized treatment in mental health. MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
16480678|NCT03425487|Experimental|ABCT+TAU|Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
16480679|NCT03425487|Active Comparator|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
16480680|NCT03425474|Experimental|Remimazolam Tosilate|Remimazolam Tosilate at 5mg for initial dose
16480681|NCT03425474|Active Comparator|Propofol|Propofol at 1.5mg/kg for initial dose
16480682|NCT03425461|Experimental|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16480683|NCT03425461|Experimental|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
16480684|NCT03425448|Active Comparator|Heparin group|
16480685|NCT03425448|Experimental|Neotrolin Group|
16480686|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
16480687|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
16480688|NCT03425409|Other|Continuous Flow|Oxygen delivery at 4 liters per minute is the standard method
16480689|NCT03425409|Other|Pneumatic Pulsed Flow|Oxygen delivery using test method
16480690|NCT03425396|Experimental|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
16480691|NCT03425396|Experimental|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
16480692|NCT03425396|Experimental|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
16480693|NCT03425396|Experimental|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
16480694|NCT03425396|Active Comparator|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
16480695|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
16480696|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
16480697|NCT03425370|Experimental|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
16480698|NCT03425370|Experimental|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
16480843|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
16480699|NCT03425357|Experimental|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
16480700|NCT03425344|Other|Diagnostic|All participants will be exposed to shoulder- MRI, ultrasound and sonoelastography.
16480701|NCT03425331|Experimental|Nivolumab+Ipilimumab|Nivolumab will be administered once every 2 weeks intravenously Ipilimumab will be administered once every 6 weeks intravenously
16480702|NCT03425318|Experimental|Single arm|Patients with ARDS will be placed inside of a Continuous Negative Abdominal Pressure Device. Negative pressure will be applied to the abdomen as an adjunct to positive pressure ventilation
16480703|NCT03425292|Active Comparator|1 SOC (closed to enrollment)|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
16480704|NCT03425292|Experimental|2 Nivo|Nivolumab
16480705|NCT03425292|Experimental|3 Nivo-Ipi (closed to enrollment)|Nivolumab plus Ipilimumab
16480706|NCT03425292|Experimental|4 Nivo-Ipi-CCNU-TMZ|Nivolumab plus Ipilimumab plus Lomustine (CCNU) plus 5-day Temozolomide
16480707|NCT03425292|Experimental|5 Nivo-Ipi-TMZ|Nivolumab plus Ipilimumab plus metronomic Temozolomide
16480708|NCT03425292|Experimental|6 Nivo-Ipi-Bev-TMZ|Nivolumab plus Ipilimumab plus Bevacizumab plus metronomic Temozolomide
16480709|NCT03425279|Experimental|BA3011|Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.
16480710|NCT03425279|Experimental|Combination Therapy|Phase 2: BA3011 in combination with PD-1 inhibitor.
16480711|NCT03425266|Experimental|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
16480712|NCT03425266|No Intervention|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
16480713|NCT03425253|Experimental|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® was injected into subcutaneous preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart). When the investigator and participant agreed that no further intervention was required to achieve the desired result, participants were eligible to receive VOLUMA™ treatment. VOLUMA™ was injected along the mandibular border, with an optional touch-up visit 2 weeks later if applicable.
16480714|NCT03425240|Experimental|Nerve Stimulation|Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.
16480715|NCT03425227|Experimental|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.
~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
16480716|NCT03425214|Experimental|NC with RBD|fMRI and video polysmnography
16480717|NCT03425214|Experimental|NC without RBD|fMRI and video polysomnography
16480718|NCT03425214|Experimental|control group (healthy subjects)|fMRI
16480719|NCT03425201|Experimental|Niraparib plus Cabozantinib|"Patients will receive niraparib and cabozantinib p.o. once daily in 28-day cycles.
~In phase I, patients will be accrued to each dose level in cohorts of 6 patients. Escalation will continue until a dose-limiting toxicity (DLT) is observed or the highest dose-level is reached.
~In phase II study patients will receive niraparib p.o. once daily and cabozantinib p.o. once daily in 28-day cycles at doses recommended in the phase I study.
~If niraparib or cabozantinib need to be interrupted due to toxicity, patient can continue only with the other drug."
16480720|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
16480721|NCT03425175|No Intervention|Control group|Standard care with recording of video but no audio-recording
16480722|NCT03425175|Experimental|Intervention group|Standard care with the addition of simultaneous audio-recording during the operation.
16480723|NCT03425162|Active Comparator|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+PCA (morphine)
16480724|NCT03425162|Sham Comparator|Group P|Group P:PCA (morphine)
16480725|NCT03425149|Experimental|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
16480726|NCT03425149|Experimental|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
16480727|NCT03425149|Experimental|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
16480728|NCT03425149|Experimental|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
16480729|NCT03425149|Placebo Comparator|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
16480730|NCT03425136|Experimental|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
16480731|NCT03425136|No Intervention|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
16480732|NCT03425123|Experimental|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
16480733|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
16480734|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
16480735|NCT03425084|Experimental|Morphine|Intravenous morphine (0,15 mg/kg) will be given as a single dosis at the end of the surgery followed by morphine administrated by patient-controlled analgesia (PCA) as single boluses (0,04mg/kg)
16480736|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
16480737|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
16480738|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
16480739|NCT03425045|Experimental|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
16480740|NCT03425045|Sham Comparator|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
16480741|NCT03425045|Active Comparator|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
16480742|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
16480743|NCT03425006|Experimental|Itacitinib and Pembrolizumab|
16480744|NCT03424993|Experimental|Dietary Sodium Restriction|Daily habitual dietary sodium intake < 2000mg
16480745|NCT03424993|Sham Comparator|Control|Routine habitual dietary sodium intake >3400mg
16480746|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
16480747|NCT03424967|Experimental|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
16480748|NCT03424954|Experimental|EpxOstomy|Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.
16480749|NCT03424941|Experimental|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
16480750|NCT03424941|Active Comparator|CABG and SAVR|CABG and SAVR
16480751|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
16480752|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
16480755|NCT03424902||group1|patients with no or mild paravalular leakage
16480756|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
16480757|NCT03424889|Experimental|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
16480758|NCT03424889|Placebo Comparator|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
16480759|NCT03424876||Arm A|Imatinib 400 mg/day or 600mg/day, and within 6 weeks after surgery, continuous treatment was not tolerated until tumor progression, recurrence or adverse reactions were not tolerated.
16480760|NCT03424876||Arm B|Sunitinib 37.5 mg/day, continuous taking, or 50 mg/day (4/2), began within 6 weeks after surgery, and was continuously administered until tumor progression, recurrence or adverse reactions were not tolerated
16480761|NCT03424863|Experimental|Aortic stent graft patients|Patients who have received an aortic stent graft who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
16480762|NCT03424863|Experimental|Healthy volunteers|Healthy volunteers in general good health with no history of heart disease who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
16480763|NCT03424850|Experimental|HDR brachytherapy - 21 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
16480764|NCT03424850|Experimental|HDR brachytherapy - 23 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
16480765|NCT03424850|Experimental|HDR brachytherapy - 25 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.
16480766|NCT03424837|Experimental|Intervention Arm: SoC (standard of care) and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
16480767|NCT03424837|No Intervention|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise & diet, and lived experiences modules.
16480768|NCT03424824|Experimental|BP1.3656 low dose|
16480769|NCT03424824|Experimental|BP1.3656 intermediate dose|
16480770|NCT03424824|Placebo Comparator|Placebo|
16480771|NCT03424811|Experimental|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
16480772|NCT03424811|No Intervention|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
16480773|NCT03424772||Patients with unexplained DD/ID|Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.
16480774|NCT03424759|Experimental|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
16480775|NCT03424746|Experimental|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
16480776|NCT03424733|Active Comparator|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
16480777|NCT03424733|Experimental|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
16480778|NCT03424720|Experimental|Comparison of PLE and BIS|Investigators assess PLE and BIS values as indicators of the depth of anesthesia during induction and emergence of anesthesia and facial nerve integrity monitoring
16480779|NCT03424707|Experimental|combination|
16480780|NCT03424707|Active Comparator|single|
16480781|NCT03424707|Placebo Comparator|placebo|
16480782|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.
~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
16480783|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.
~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
16480784|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
16480785|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
16480786|NCT03424655|Experimental|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
16480787|NCT03424655|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
16480788|NCT03424655|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
16480789|NCT03424655|Experimental|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
16480790|NCT03424642|Experimental|Interactive 4D-ultrasound examination|Pregnant women who are randomized to 4D-ultrasound intervention group will receive additional 4D-ultrasound examinations 2-3 times between gestational weeks 25-32. Patients in this group will also receive psychologist's interview twice and fill out questionaries.
16480791|NCT03424642|No Intervention|Control group|Pregnant women who are randomized to control group will receive psychologist's interview twice twice and fill out questionaires.
16480792|NCT03424629|Experimental|Low-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection
16480793|NCT03424629|Experimental|High-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection
16480794|NCT03424629|Active Comparator|Methotrexate|5-25mg Methotrexate orally
16480795|NCT03424616|Experimental|Postoperative immediate Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.
16480796|NCT03424616|Sham Comparator|Postoperative delayed Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.
16480797|NCT03424603|Experimental|STRO-001|intravenous
16480798|NCT03424590|Active Comparator|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
16480799|NCT03424590|No Intervention|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
16480800|NCT03424577|Experimental|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
16480801|NCT03424564|Experimental|Perampanel single-dose Part: 2 mg group|Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
16480802|NCT03424564|Experimental|Perampanel single-dose Part: 4 mg group|Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
16480803|NCT03424564|Experimental|Perampanel single-dose Part: 8 mg group|Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
16480844|NCT03424252|Experimental|FDL169 Dose Level 1,sublingual to oral|Dose level 1 sublingual first and oral second.
16480804|NCT03424564|Experimental|Perampanel multiple-dose Part|Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
16480805|NCT03424551|Experimental|Vibrator|Local or Whole body vibration was applied at six different frequencies to Healthy control and spastic spinal cord injury. For local vibration, vibration frequencies were 50, 85, 140, 185, 235 and 265 Hz . For whole body vibration, vibration frequencies were 35, 37, 39, 41, 43 and 45 Hz
16480806|NCT03424538|Experimental|MSt|The MSt group that received 5 weeks of intensive therapy.
16480807|NCT03424538|No Intervention|MSc|The MS controll group that did not receive treatment.
16480808|NCT03424538|Experimental|MStp|The MStp Group performs a traditional physiotherapy for 5 weeks.
16480809|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
16480810|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
16480811|NCT03424512|Experimental|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
16480812|NCT03424499|Active Comparator|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.
~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.
~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
16480813|NCT03424499|Experimental|Reused catheter|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.
~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soup after each catheterization and stored in a container with 0.5% benzalkonium chloride.
~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
16480814|NCT03424486||Adolescents (14 to 17 years old)|Patients with CF
16480815|NCT03424486||Parents|Parents of adolescents (14 to 17 years old with CF (father, mother and other)
16480816|NCT03424460|Experimental|population 1-A1 : DM1 with VTE|Myotonic dystrophy type 1 patients with a history of venous thromboembolism (pulmonary embolism and/or deep vein thrombosis)
16480817|NCT03424460|Active Comparator|population 1-B1 : DM1 without VTE|Myotonic dystrophy type 1 patients without a history of venous thromboembolism
16480818|NCT03424460|Active Comparator|population 1-C1 : Healthy volunteers|Healthy volunteers without any medical history or treatment
16480819|NCT03424460|Experimental|population 2-A2 : DM1 liver samples|Liver samples of patients with myotonic dystrophy type 1
16480820|NCT03424460|Active Comparator|population 2-B2 : Healthy liver samples|Liver samples from patients without any medical history
16480821|NCT03424447|No Intervention|Non stimulated|Prospective data obtained from non stimulated patients
16480822|NCT03424447|Experimental|Stimulated|Prospective data obtaied from stimulated patients
16480823|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
16480824|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
16480825|NCT03424408|Other|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
16480826|NCT03424395|Other|Personalized dietary and wellness program|An integrated personalized nutrition program which includes a combination of dietary and wellness advice/counseling on wellness and meals, or dietary and wellness advice/counseling alone, each for 10 weeks.
16480827|NCT03424382||Phase I|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
16480828|NCT03424382||Phase II|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
16480829|NCT03424369||Eustachian tube unobstructed|
16480830|NCT03424369||Eustachian tube dysfunction|
16480831|NCT03424356|Experimental|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
16480832|NCT03424356|Active Comparator|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
16480833|NCT03424343||cancer survivor, parents, sibling|
16480834|NCT03424330|Experimental|Arm1 - ReX first|Subjects begin with the ReX-C Intervention stage followed by Standard of Care stage.
16480835|NCT03424330|Experimental|Arm 2- Standard of Care first|Subjects start with Standard of Care stage followed by ReX-C Intervention.
16480836|NCT03424317|Active Comparator|Sodium intake reduction and exercise|education of sodium intake reduction and regular exercise
16480837|NCT03424317|Placebo Comparator|Exercise|education of regular exercise only
16480838|NCT03424304|Other|Excel V™ Laser With Green Genesis|Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
16480839|NCT03424291|Experimental|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
16480840|NCT03424278|Active Comparator|Motor Control|
16480845|NCT03424252|Experimental|FDL169 Dose Level 1 dosing,oral to sublingual|Dose level 1 oral first and sublingual second.
16480846|NCT03424252|Experimental|FDL169 Dose Level 2 sublingual to oral,Optional|Dose level 2 sublingual first and oral second.
16480847|NCT03424252|Experimental|FDL169 Dose Level 2 oral to sublingual,Optional|Dose level 2 oral first and sublingual second.
16480848|NCT03424239|Experimental|Drug: Zoledronic Acid, Calcium+Vitamin D|Subjects will receive a single intravenous infusion of zoledronic acid (5 mg). Supplemental calcium citrate + vitamin D (500mg+500IU) and vitamin D3 (1000 IU) will be dispensed throughout the study to fit individual needs.
16480849|NCT03424226|Experimental|day of acetazolamide|acetazolamide 125mg twice a day, started morning of ascent
16480850|NCT03424226|Active Comparator|night before acetazolamide|acetazolamide 125mg twice a day, started evening before ascent
16480851|NCT03424213||white low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
16480852|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
16480853|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
16480854|NCT03424213||AA low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
16480855|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
16480856|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
16480857|NCT03424200|Other|Coaching plus Routine Care|Participants will receive coaching plus routine care
16480858|NCT03424200|Other|Routine Care|Participants will receive the routine care
16480859|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
16480860|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
16480861|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
16480862|NCT03424174|Experimental|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
16480863|NCT03424174|Active Comparator|Standard Total Knee Arthroplasty|Implantation Standard Total Knee Arthroplasty
16480864|NCT03424161|Other|Secret RF|Treatment with Secret RF for skin quality
16480865|NCT03424148|Other|Excel V™ Laser & Micro-Lens Array Attach|Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
16480866|NCT03424135|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
16480867|NCT03424135|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
16480868|NCT03424122|Experimental|Treatment A|Parsaclisib + Rituximab
16480869|NCT03424122|Experimental|Treatment B|Parsaclisib + Bendamustine + Rituximab
16480870|NCT03424122|Experimental|Treatment C|Parsaclisib + Ibrutinib
16480871|NCT03424109||Beneficiaries with a one-year mortality of at least 30%|The patient cohort will be extracted via the Centers for Medicare and Medicaid Services (CMS) Research Data Assistance Center (ResDAC) using a two-step process to maximize diversity, and minimize intentional or unintentional exclusions based on risk, age, health literacy, demographics, or expected adherence.
16480872|NCT03424083||1 cohort|adult patients of both sexes (>18 and <80 years) with no previous diagnosis or follow up by a pulmonologist, send by a general practitioner to the lung function lab
16480873|NCT03424070|Active Comparator|Laryngoscopy view with a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy with and then without the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
16480874|NCT03424070|Placebo Comparator|Laryngoscopy without a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy without and then with the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
16480875|NCT03424057|Experimental|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).
~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
16480876|NCT03424057|Active Comparator|Group 2|Group 2 were treated with the standard Karydakis technique.
16480877|NCT03424044|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
16480878|NCT03424044|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
16481432|NCT03420547|Experimental|Intervention group|Group of participants receiving the RISE intervention
16480879|NCT03424044|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
16480880|NCT03424031|Experimental|Verticalization|the patient will be placed in the most vertical position possible.
16480881|NCT03424031|No Intervention|Passive mobilization|Passive mobilization of the lower limb deficit
16480882|NCT03424018|Experimental|BMN 111|
16480883|NCT03424005|Active Comparator|Atezolizumab + Nab-Paclitaxel|1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab + nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16480884|NCT03424005|Experimental|Atezolizumab + Nab-Paclitaxel + Tocilizumab|1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16480885|NCT03424005|Experimental|Atezolizumab + Sacituzumab Govitecan|1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16480886|NCT03424005|Active Comparator|Capecitabine|"2L CIT-naive participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.
~Enrollment is closed."
16480887|NCT03424005|Experimental|Atezolizumab + Ipatasertib|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab + ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.
~Enrollment is closed."
16480888|NCT03424005|Experimental|Atezolizumab + SGN-LIV1A|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.
~Enrollment is closed."
16480889|NCT03424005|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"2L-CIT-naive participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.
~Enrollment is closed."
16480890|NCT03424005|Experimental|Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)|2L CIT-naive participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naive participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemotherapy (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
16480891|NCT03423992|Experimental|Biological: Chimeric antigen receptor T cells|
16480892|NCT03423979|Experimental|Optilume™ BPH Prostatic DCB Dilation Catheter|Optilume™ BPH Prostatic DCB treatment procedure
16480893|NCT03423966|Experimental|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
16480894|NCT03423966|No Intervention|Usual Care (UC)|Usual Care of obesity
16480895|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
16480896|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
16480897|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
16480898|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
16480899|NCT03423927|Experimental|Intervention group : hypnosis + self-care|Groupal intervention combining self-care techniques and self-hypnosis exercises
16480900|NCT03423927|No Intervention|Control group : no intervention|Control group receiving usual care but not the intervention
16480901|NCT03423914|Experimental|Writing Intervention Group|Expressive writing The participant will write four days about her deepest thoughts and feelings in relation to the experience of hospitalization of the premature newborn and how this experience is related to your current life and to your future.
16480902|NCT03423914|Active Comparator|Control Group|Only Writing The participants will write about situations not related to the subjective human experience of their preterm birth, but about general aspects.
16480903|NCT03423901|Experimental|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
16480904|NCT03423901|Experimental|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
16480905|NCT03423901|Experimental|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
16480906|NCT03423888|Experimental|High-flow nasal oxygen|
16480907|NCT03423875|No Intervention|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
16480908|NCT03423875|Experimental|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
16480909|NCT03423849|Experimental|The original program (NG/NP)|Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）
16480910|NCT03423849|Experimental|One of the original program (N)|Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.
16480911|NCT03423849|Experimental|Capecitabine monotherapy|Capecitabine oral 1250mg/m2,bid,for 6 cycles
16480912|NCT03423836||High Risk Infants|Motor infants born prior to 35 weeks gestational age, or, infants small (<10th percentile) for gestational age.
16480913|NCT03423836||Low Risk Infants|Motor infants born after the completion of the 37th week of gestation and appropriate for gestational age.
16480914|NCT03423823|Experimental|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
16480915|NCT03423823|Other|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
16480916|NCT03423810|Experimental|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
16480917|NCT03423797|Active Comparator|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
16480918|NCT03423797|Experimental|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
16480919|NCT03423784|Experimental|HA BPX V3.3|A HMWHA gel available in a formulation specificaly designed for use in infants
16480920|NCT03423784|Active Comparator|Dentinox-Gel N|Gold standard for teething symptoms
16480921|NCT03423771|Experimental|NPF-08 Low dose （1-day treatment）|
16480922|NCT03423771|Experimental|NPF-08 Medium dose （2-day split dose）|
16480923|NCT03423771|Experimental|NPF-08 High dose （2-day split dose）|
16480924|NCT03423771|Experimental|NPF-08 Medium dose （1-day treatment）|
16480925|NCT03423771|Experimental|NPF-08 High dose （1-day treatment）|
16480926|NCT03423771|Experimental|NPF-08 Low～High dose （1-day treatment）|
16480927|NCT03423771|Experimental|NPF-08 Medium～High dose （2-day split dose）|
16480928|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
16480929|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
16480930|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
16480931|NCT03423758||Primary open-angle Glaucoma|Already diagnosed primary open-angle glaucoma with age more than 30 years
16480932|NCT03423732|Active Comparator|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
16480933|NCT03423732|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
16480934|NCT03423719|Experimental|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
16480935|NCT03423719|Placebo Comparator|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
16480936|NCT03423706|Experimental|new model of haplo-HSCT|use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
16480937|NCT03423693||Asthma with SAO+|Asthmatic patients with RV/TLC > or = 40
16480938|NCT03423693||Asthma with SAO-|Asthmatic patients with RV/TLC < 40
16480939|NCT03423693||ACO|Asthmatic patients with smoking > or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC < 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 > or = 200 ml and FEV1% > or =12% after BD)
16480940|NCT03423693||COPD|Patients with history of smoking > or = 10 pack year with post-BD FEV1/FVC < 0.7 and negative BD reversibility (absolute increase in FEV1 < 200 ml and FEV1% <12% after BD)
16480943|NCT03423667|Experimental|N-acetylcysteine|
16480944|NCT03423667|Placebo Comparator|Lactose powder|
16480945|NCT03423654|Experimental|Training Group|Spatial training
16480946|NCT03423654|Other|Control Group|Letter number matching
16480947|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
16480948|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
16480950|NCT03423615|Experimental|CHHIP Arm|"All enrolled students in schools in the CHHIP Arm were eligible to receive the CHHIP intervention. The CHHIP intervention was delivered by lay fieldworkers (SHAs). Intervention activities included:
~Health Education: activity-based curriculum with lessons delivered once per week. Units include hygiene, nutrition, safety, disease prevention& management, and social, emotional, and behavior development.
~Basic Primary Health Services: school-based treatment including deworming and iron supplementation; screening and referral programs including growth monitoring, well-child exam, vision screening, epilepsy screening, and oral health; psychosocial and counseling support for students with atypical behaviors.
~Health School Environment: improvements to physical infrastructure including latrines and water systems; modeling of positive behavior reinforcement, inclusive learning environment, and avoidance of corporal punishment."
16480951|NCT03423615|No Intervention|Comparison Arm|All enrolled students in schools in the Comparison Arm received school health activities as were routinely available in their school, through their curriculum, or through special events.
16480952|NCT03423602|Experimental|Investigational device|PerQseal® closure system
16480953|NCT03423589|Experimental|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
16480954|NCT03423576|Experimental|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
16480955|NCT03423576|No Intervention|Control|Standard care
16480956|NCT03423563|Experimental|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
16480957|NCT03423563|Experimental|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
16480959|NCT03423537|Experimental|Group 1 [HCG (+) group]|"Group 1 will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH"
16480960|NCT03423537|Placebo Comparator|Group 2 [placebo]|"Group 2 will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead"
16480961|NCT03423524|Experimental|Arm: Investigational Device|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. consisting of hydrophobic material"
16480962|NCT03423511|Experimental|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
16480963|NCT03423511|Active Comparator|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
16480964|NCT03423498|Experimental|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
16480965|NCT03423498|No Intervention|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
16480966|NCT03423485|Experimental|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
16480967|NCT03423472|Experimental|Full intervention|Healthy Baby Toolkit (HBT) in addition to Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
16480968|NCT03423472|Active Comparator|Partial intervention|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
16480969|NCT03423472|Other|Control|Government standard of care for nutrition education through the Health Development Army
16480970|NCT03423459||CT Cohort|"Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.
~Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.
~Determine how the Evolut PRO conforms to LVOT calcification.
~Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.
~Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.
~Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
16480971|NCT03423459||Non-CT Cohort|"Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.
~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.
~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
16480972|NCT03423446|Experimental|Severe Hepatic Impairment|Up to 8 subjects with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15 points)
16480973|NCT03423446|Experimental|Healthy Control|Up to 8 healthy control subjects with normal hepatic function
16480992|NCT03423329|Experimental|Group A|"Intervention:Drug: Brufen & Placebo
~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
16480993|NCT03423329|Experimental|Group B|"Intervention: Drug: Cital and Placebo
~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
16480994|NCT03423329|Placebo Comparator|Group C|"Intervention: Drug: Placebo
~Other names:
~(Placebo for Brufen) (Placebo for Cital)
~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
16480995|NCT03423316|No Intervention|Healthy Controls|
16480996|NCT03423316|No Intervention|Age-Matched Controls|Subjects without PAD who have the same average age as the PAD patients
16481171|NCT03422237|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16480974|NCT03423433|No Intervention|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.
~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.
~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
16480975|NCT03423433|Experimental|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.
~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
16480976|NCT03423407||PET/MR|"Participants will be scanned on a PET-MRI scanner which is FDA-approved and will operate within FDA-approved guidelines.
~Participants will be asked to lie still within the scanner for up to 90 minutes"
16480977|NCT03423394|Experimental|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment.
16480978|NCT03423394|Active Comparator|Treatment as Usual|The treatment as usual (TAU) condition was selected to mirror the existing process in the military for identifying and encouraging treatment for personnel who screen positive for PTSD.
16480979|NCT03423381|Experimental|Cereal product 1|Cereal based müsli no. 1, made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df). The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
16480980|NCT03423381|Experimental|Cereal product 2|Cereal based muesli no. 2 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
16480981|NCT03423381|Experimental|Cereal product 3|Cereal based muesli no.3 made from typical Swedish cereals. All experimental products have different types and amounts of df.The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
16480982|NCT03423381|Experimental|Cereal product 4|Cereal based muesli no. 4 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
16480983|NCT03423381|Experimental|Cereal product 5|Cereal based muesli no. 5 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
16480984|NCT03423381|Placebo Comparator|Control product|A cereal based product with low concentrations of df. The control portion is consumed as a single evening meal prior to determinations of test variables in the morning.
16480985|NCT03423368|Experimental|Libramed|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of Libramed for 30 days
16480986|NCT03423368|Placebo Comparator|Placebo|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of placebo for 30 days
16480987|NCT03423355|Active Comparator|Dapagliflozin|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. The study will be performed under double-blinded conditions with respect to treatment with dapagliflozin or matching placebo.
~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
16480988|NCT03423355|Placebo Comparator|Placebo dapagliflozin|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. The study will be performed under double-blinded conditions with respect to treatment with dapagliflozin or matching placebo.
~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
16480989|NCT03423355|Other|Hydrochlorothiazide|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. However, treatment in the reference group will not be blinded.
~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
16480990|NCT03423342|Experimental|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
16480991|NCT03423342|Placebo Comparator|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
16481205|NCT03422016||control|age 4-25yrs no eye disorder
16480997|NCT03423316|Experimental|PAD Patients|Patients with PAD. Approximately 75% of PAD patients will be enrolled in the 12-week exercise therapy program.
16480998|NCT03423303|Experimental|Screening arm|Invitation to prostate cancer screening and questionnaires.
16480999|NCT03423303|No Intervention|Control arm|Registry-based follow-up and a questionnaire.
16481000|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
16481001|NCT03423264|Experimental|Gabapentin|Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
16481002|NCT03423264|No Intervention|Supportive Care Only|Participants will receive standard best supportive care medications as per their treating physician's recommendation.
16481003|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
16481004|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
16481005|NCT03423225|Experimental|ADVAGRAF®|One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
16481006|NCT03423212|Experimental|Experimental Condition|Participants assigned to the experimental arm will be enrolled in the 2-session Just Do You intervention described elsewhere.
16481007|NCT03423212|No Intervention|Treatment as Usual Condition|Participants assigned to treatment as usual will receive the PROS program that is standard in the agencies without any additional intervention.
16481008|NCT03423212|Active Comparator|Active Control Condition|Participants assigned to the active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
16481009|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
16481010|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
16481011|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
16481012|NCT03423186|Experimental|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
16481013|NCT03423173|Placebo Comparator|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
16481014|NCT03423173|Experimental|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
16481015|NCT03423173|Experimental|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
16481016|NCT03423173|Experimental|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
16481019|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
16481020|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
16481021|NCT03423134|Experimental|Test of new adhesive strip|A new adhesive strip will be tested in this investigation
16481022|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
16481023|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
16481024|NCT03423108|No Intervention|Control|Participants randomized to this group will perform monthly cohabitation meetings.
16481025|NCT03423108|Experimental|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
16481026|NCT03423108|Experimental|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
16481027|NCT03423095|Placebo Comparator|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
16481028|NCT03423095|Active Comparator|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
16481105|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
16481029|NCT03423095|Experimental|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
16481030|NCT03423095|Experimental|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
16481031|NCT03423082|Experimental|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
16481032|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
16481033|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
16481034|NCT03423056|Experimental|Preoperative exercise program|"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks.
~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:
~Week 1: heart rate target: 50% of maximum heart rate Week 2: heart rate target: 60% of maximum heart rate Week 3: heart rate target: 70% of maximum heart rate Week 4: heart rate target: 60% of maximum heart rate The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist."
16481035|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
16481036|NCT03423030|Experimental|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
16481037|NCT03423030|Placebo Comparator|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
16481038|NCT03423030|Experimental|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
16481039|NCT03423030|Placebo Comparator|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
16481040|NCT03423030|Experimental|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
16481041|NCT03423030|Active Comparator|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
16481042|NCT03423030|Experimental|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
16481043|NCT03423030|Active Comparator|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
16481044|NCT03423017|Other|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate
~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
16481045|NCT03423017|Other|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
16481046|NCT03423017|Other|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
16481047|NCT03423004|Experimental|Patient with lesional skin|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
16481048|NCT03423004|No Intervention|Patients with healthy skin|the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed
16481049|NCT03422991|Other|Congestive Heart Failure patients Cohort|Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) > 500 ng/l. Will be followed during 18 months.
16481050|NCT03422978|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
16481051|NCT03422978|Experimental|Dexmedetomidine 0.25 mcg/kg|0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
16481052|NCT03422978|Experimental|Dexmedetomidine 0.50 mcg/kg|0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
16481053|NCT03422978|Experimental|Dexmedetomidine 1.00 mcg/kg|1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
16481054|NCT03422965|Active Comparator|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
16481055|NCT03422965|Sham Comparator|Healthy controls|Cohort of Healthy controls
16481056|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
16481057|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
16481058|NCT03422926|Experimental|Intervention|Social marketing messaging campaign
16481059|NCT03422926|No Intervention|Control|No messaging campaign
16481060|NCT03422913|Experimental|CLCVP Group|Controlled low central venous pressure(CLCVP) will be performed combined with intraoperative combined hilar intermittent (Pringle method)
16481061|NCT03422913|No Intervention|Control Group|Only intraoperative combined hilar intermittent (Pringle method) will be performed
16481062|NCT03422900|Experimental|Specific Diabetes Formula|"Diabetes-Specific Enteral Formula:
~Caloric density: 1,0 kcal/ml
~Energy: 100 kcal
~Carbohydrates: 10,1 g/100 ml;
~Fat: 4,5 g/100 ml
~Prot: 3,8 g/100 ml
~Osmolarity: 345 mOsm/l
~Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble)."
16481063|NCT03422900|Active Comparator|Standard Formula|"Standard Enteral Formula:
~Caloric density: 1,0 kcal/ml
~Energy: 100 kcal
~Carbohydrates: 13,8 g/100 ml;
~Fat: 3,4 g/100 ml
~Prot: 3,8 g/100 ml
~Osmolarity: 220 mOsm/l
~Fiber: 0 g/100 ml"
16481064|NCT03422887|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
16481065|NCT03422887|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
16481066|NCT03422887|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
16481106|NCT03422640|Experimental|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
16481067|NCT03422874|Experimental|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.
~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts [1250mg, 1875mg, 2500mg, 3125mg]) will be administered orally twice daily in the dose cohorts listed."
16481068|NCT03422861|Active Comparator|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
16481069|NCT03422861|Placebo Comparator|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
16481070|NCT03422848|Active Comparator|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
16481071|NCT03422848|Other|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
16481072|NCT03422835|Active Comparator|R-TME|Robotic total mesentery excision surgery for rectal cancer.
16481073|NCT03422835|Experimental|R-TaTME|Robotic transanal total mesentery excision surgery for rectal cancer.
16481076|NCT03422796|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
16481077|NCT03422796|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
16481078|NCT03422783|Experimental|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
16481079|NCT03422770|Other|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
16481080|NCT03422770|Other|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
16481081|NCT03422770|Other|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
16481082|NCT03422770|Other|Controls|100 subjects, all undergoing echocardiography and blood test, 30 undergoing MRI.
16481083|NCT03422757|Experimental|adaptive DBS|adaptive Deep Brain Stimulation, by AlphaDBSvext.
16481084|NCT03422757|Active Comparator|conventional DBS|conventional Deep Brain Stimulation, by AlphaDBSvext.
16481085|NCT03422744|Experimental|patient with peripheral lung lesion|"Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.
~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.
~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control"
16481086|NCT03422731|Experimental|Cohort I (TMLI+FLT/TMLI)|Patients may undergo optional fluorothymidine F-18 PET scan over 2 hours at baseline, on days 30 and 100, at 1 year, and at time of relapse. Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline, on days 30 and 100, at year 1, and at time of relapse. Patients also undergo collection of bone marrow and blood samples at baseline, on days 30 and 100, and at 1 year. Patients undergo fluorothymidine F-18 PET, DECT, and water-fat MRI as in TMLI+FLT.
16481087|NCT03422731|Active Comparator|Cohort II (TBI)|Patients undergo collection of bone marrow at baseline, day 30, time of relapse, and at 1 year.
16481088|NCT03422718|Experimental|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
16481089|NCT03422718|Experimental|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
16481090|NCT03422718|Experimental|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
16481091|NCT03422718|Experimental|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
16481092|NCT03422718|Experimental|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
16481093|NCT03422718|Experimental|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
16481094|NCT03422718|Experimental|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
16481095|NCT03422718|Experimental|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
16481096|NCT03422705|Sham Comparator|Standard of care|No intervention - no programming, no medical intervention.
16481097|NCT03422705|Experimental|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
16481098|NCT03422705|Experimental|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
16481099|NCT03422692|Experimental|BioXlude memebrane|Subjects in this arm will receive demineralized freeze dried bone allograft covered with BioXclude amnion-chorion membrane following tooth extraction
16481100|NCT03422692|Active Comparator|Mem-Lok|subjects in this arm will receive demineralized freeze dried bone allograft covered with Mem-Lok collagenous membrane following tooth extraction
16481101|NCT03422679|Experimental|CB-103|CB-103 capsules will be administered orally as a continuous once daily (QD) dosing during the treatment period of Part A (escalation) and Part B (expansion).
16481102|NCT03422666|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
16481103|NCT03422666|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
16481104|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
16481109|NCT03422614||Patient|Patients with Primary Immunodeficiency
16481110|NCT03422614||Control|Healthy Controls
16481111|NCT03422601||3 months treatment|FOLFOX or CAPOX
16481112|NCT03422601||6 months treatment|FOLFOX or CAPOX
16481113|NCT03422588|Experimental|Intracorporeal|Totally laparoscopic right colectomy with intracorporeal anastomosis
16481114|NCT03422588|Active Comparator|Extracorporeal|Laparoscopic assisted right colectomy with extracorporeal anastomosis
16481115|NCT03422575|Experimental|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
16481116|NCT03422575|Active Comparator|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
16481117|NCT03422562|Active Comparator|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
16481118|NCT03422562|No Intervention|Control|Standard of care arm
16481119|NCT03422549|Active Comparator|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
~Intervention: Device: Drager VN500 Ventilator"
16481120|NCT03422549|Active Comparator|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.
~Intervention: Device: Drager VN500 Ventilator"
16481121|NCT03422536|Experimental|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16481122|NCT03422536|Experimental|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16481123|NCT03422523|Active Comparator|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
16481124|NCT03422523|Experimental|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.
~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
16481125|NCT03422510|Experimental|Regimen 1 - CXA-10 75 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.
16481126|NCT03422510|Experimental|Regimen 1 - CXA-10 150 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.
16481127|NCT03422510|Experimental|Regimen 2 - CXA-10 150 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
16481128|NCT03422510|Experimental|Regimen 2 - CXA-10 300 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.
16481129|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
16481130|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
16481131|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
16481132|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
16481133|NCT03422471|Experimental|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
16481134|NCT03422458|No Intervention|natural healing|no treatment and the coagulum within the socket is left open for spontaneous healing
16481135|NCT03422458|Experimental|Alveolar Ridge Preservation|A bone substitute material (BioOss Collagen) is placed within the bony envelope at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mucograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
16481136|NCT03422458|Experimental|Immediate Implant + Alveolar Ridge Preservation|An immediate implant (Winsix) placement is performed. After implant insertion, a bone substitute material (BioOss Collagen) is placed in the gap occurred between the implant surface and the hard tissue walls of the extraction socket at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mugograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
16481137|NCT03422445|Experimental|Apatinib plus Temozolomide|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.
16481138|NCT03422432|Experimental|Group 1|Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
16481139|NCT03422432|Experimental|Group 2|Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
16481140|NCT03422419|Experimental|TIPS+Anticoagulation|
16481141|NCT03422419|Active Comparator|Anticoagulation|
16481142|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
16481143|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
16481144|NCT03422393|Experimental|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
16481145|NCT03422380||Weight Loss Maintainers (WLM)|Individuals maintaining ≥13.6 kg (30 lb) weight loss for ≥1 year
16481146|NCT03422380||Normal Weight Controls (NC)|Individuals with normal weight whose BMI was matched to the current BMI of the WLM. NC had to be weight stable and not maintaining a weight loss of ≥13.6kg
16481147|NCT03422380||Controls with Overweight/Obesity (OC)|Individuals with overweight/obesity whose BMI was matched to the pre-weight loss maximum BMI of WLM. OC had to be weight stable and not maintaining a weight loss of ≥13.6kg
16481148|NCT03422367|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
16481149|NCT03422367|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
16481150|NCT03422367|No Intervention|Control|Participants who are unable to complete JASPER due to age or time/distance commitment can enroll for single-time point participation
16481151|NCT03422354|Active Comparator|Paravertebral block Group|Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
16481152|NCT03422354|Active Comparator|General anesthesia Group|"Patients will receive only GA All patients in the study will receive GA in the form of propofol 2mg/kg , atracurium 0.5ml/kg ,fentanyl 100 microgram in induction with ETT and mechanical ventilation , full monitoring with ECG , NIBP and puls oximetry will be applied.
~To control intraoperative BP,fentanyl will be used as well as,hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
~To achieve post operative analgesia, intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed"
16481153|NCT03422341|Experimental|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.
~Intervention will be the Comparison between GenePOC CR and Reference Method."
16481154|NCT03422341|Active Comparator|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.
~Intervention will be the Comparison between GenePOC CR and Reference Method."
16481156|NCT03422315|Experimental|External control|propofol;injection;2mg/kg;single-dose
16481157|NCT03422302|Experimental|Treatment (CT simulation, CPAP, DIBH, SBRT, BiPAP)|Patients undergo free-breathing, DIBH, and CPAP CT simulation scans. If patient has difficulty exhaling on CPAP, then patient undergo BiPAP CT simulation. The attending physician then compares all 3 simulation treatment plans (free-breathing, DIBH, and CPAP/BiPAP) and determines which method to use during SBRT. If CPAP/BiPAP is chosen as preferred method, patients wear CPAP/BiPAP over 1 hour prior to SBRT, then again during SBRT over 30-60 minutes. All other patients complete free-breathing or DIBH during SBRT over 30-60 minutes.
16481158|NCT03422289|Experimental|Myo-inositol + folic acid|2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation.
16481159|NCT03422289|Experimental|Myo-inositol + folic a. + α-lactalbumin|2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation
16481160|NCT03422276|Active Comparator|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
16481161|NCT03422276|Active Comparator|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
16481162|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
16481163|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
16481164|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
16481165|NCT03422250|Experimental|Arm 1|Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)
16481166|NCT03422250|Experimental|Arm 2|Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)
16481167|NCT03422250|Experimental|Arm 3|Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)
16481168|NCT03422250|Experimental|Arm 4|Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)
16481169|NCT03422237|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
16481170|NCT03422237|Experimental|RSV 276 vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
16481172|NCT03422224||Good transplant function|Kidney transplant recipients without histological signs of rejection.
16481173|NCT03422224||Transplant Rejection|Kidney transplant recipinets experiencing a T cell mediated rejection episode.
16481174|NCT03422211||Sports orthopaedic surgery|Patients that recently underwent orthopaedic sports surgery performed by two separate surgeons
16481175|NCT03422198|Experimental|Short course vaginal cuff brachytherapy|Patients undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
16481176|NCT03422198|Active Comparator|Vaginal cuff brachytherapy|Patients undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
16481177|NCT03422172|Experimental|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
16481178|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
16481179|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
16481180|NCT03422146|Experimental|Cliradex® eyelid hygiene|Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.
16481181|NCT03422146|Other|I-Lid 'n Lash® Hygiene|Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,
16481182|NCT03422133||Pre-Implementation Phase|"Participants in this group (before the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
~Patients will be recruited using standardized procedures, and process and outcome measures will be recorded using the same tools and methods in both study phases to decrease the risk of measurement and selection bias."
16481183|NCT03422133||Post-Implementation Phase|Participants in this group (after the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
16481184|NCT03422120||Healthy Donors|Healthy patients, without a diagnosis of cancer and age>40. The Natural Killer Cell Activity Assay (NKA) will be measured with a blood test.
16481185|NCT03422120||Colorectal Cancer Surgery Patients|Patients >40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
16481186|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
16481187|NCT03422107||cAVR|Conventional Valve Replacement
16481188|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
16481189|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
16481195|NCT03422081||growth hormone deficiency|
16481196|NCT03422081||small for gestational age|
16481197|NCT03422081||matched controls|
16481198|NCT03422068|Experimental|BI 1015550|
16481199|NCT03422068|Placebo Comparator|Placebo|
16481200|NCT03422055|Experimental|99mTc-Fucoidan SPECT|
16481201|NCT03422042|Active Comparator|Short duration of antibiotic|group A: will received intravenous antibiotic until the temperature is less than 37.8 c for 72 hours, then antibiotic is discontinued
16481202|NCT03422042|Active Comparator|Standard treatment of antibiotic|group B: will received intravenous antibiotic for 7 days, and followed by oral antibiotic for 7 days, regardless of body temperature
16481203|NCT03422029|Experimental|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
16481204|NCT03422016||autistic spectrum disorder|intelligence quotient IQ>85 age 4-25yrs
16481206|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
16481207|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
16481208|NCT03421990||Group A|General anesthesia technique
16481209|NCT03421990||Group B|Regional anesthesia technique
16481210|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
16481211|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
16481212|NCT03421938|Experimental|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
16481213|NCT03421938|Experimental|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
16481214|NCT03421925|Other|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
16481215|NCT03421925|Other|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
16481216|NCT03421912|Experimental|Arm A : Cicaplast balm B5|Use of Cicaplast balm B5, 2 to 3 applications per day, since the first day of iEGFR treatment initiation for 30 days to avoid or limit appearance of cutaneous toxicities related to iEGFR treatment.
16481217|NCT03421912|Active Comparator|Arm B : Dexeryl|Use of Dexeryl, 2 to 3 applications per day, since de first day of iEGFR treatment initiation for 30 days to avoid or limit appearence of cutaneous toxicities related to iEGFR treatment.
16481218|NCT03421899||Genetic Parkinson's group|Those participants with Parkinson's disease and a genetic mutation known to cause or increase risk of Parkinson's disease (e.g. Parkin, PINK1, GBA or LRRK2)
16481219|NCT03421899||Idiopathic Parkinson's group|Those participants with Parkinson's disease but without a known genetic mutation known to cause or increase risk of Parkinson's disease
16481220|NCT03421899||Healthy control group|Those participants unaffected by Parkinson's disease
16481221|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
16481222|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
16481223|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
16481224|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
16481225|NCT03421860|Active Comparator|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
16481226|NCT03421860|Active Comparator|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
16481227|NCT03421860|Active Comparator|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
16481228|NCT03421860|Active Comparator|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
16481229|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
16481230|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
16481231|NCT03421834|Experimental|Prophylactic VT ablation prior to ICD implantation|
16481232|NCT03421834|Active Comparator|ICD implantation and optimal medical treatment|ICD implantation and optimal medical care until at least 2 appropriate ICD shock occurs or an arrhythmic storm and catheter ablation thereafter.
16481233|NCT03421821|Experimental|Subfascial Injection Group|30 ml of 0.33% ropivacaine was injected to subfascial.
16481234|NCT03421821|Active Comparator|Extrafascial Injection Group|30 ml of 0.33% ropivacaine was injected to extrafascial.
16481235|NCT03421808|Experimental|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
16481236|NCT03421808|Active Comparator|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
16481237|NCT03421795|Experimental|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
16481238|NCT03421795|Sham Comparator|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum & Gorter, 2012) .
16481239|NCT03421782|Experimental|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
16481240|NCT03421782|Experimental|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
16481241|NCT03421769|Experimental|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
16481242|NCT03421769|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
16481243|NCT03421756|Experimental|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
16481244|NCT03421743|Experimental|Inhaled molgramostim/antimycobacterials|Inhaled molgramostim administered in subjects who remain sputum culture positive while currently on a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen, which has been ongoing for at least 6 months prior to the Baseline Visit
16481245|NCT03421743|Experimental|Inhaled molgramostim|Inhaled molgramostim administered in subjects who remain sputum culture positive but have stopped a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance, or who never started such treatment
16481246|NCT03421730|Experimental|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481247|NCT03421730|Experimental|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481248|NCT03421730|Experimental|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
16481249|NCT03421730|Experimental|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481250|NCT03421730|Experimental|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481251|NCT03421730|Experimental|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
16481252|NCT03421730|Experimental|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481253|NCT03421730|Experimental|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481254|NCT03421730|Experimental|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
16481255|NCT03421730|Experimental|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481256|NCT03421730|Experimental|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481257|NCT03421730|Experimental|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
16481258|NCT03421717|Experimental|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
16481259|NCT03421717|Active Comparator|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
16481260|NCT03421691|Other|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
16481261|NCT03421678||Japanese American|Two parents of Japanese descent
16481262|NCT03421678||Non-Hispanic Whites|Two parents of non-Hispanic white descent
16481263|NCT03421678||Native Hawaiians|At least one parent of Hawaiian descent
16481264|NCT03421665||Titan 3-D Wedge System|Subjects who receive one or more Titan 3D wedge(s).
16481265|NCT03421652|Experimental|Treatment (nivolumab, radiation therapy)|Given IV
16481266|NCT03421639|Active Comparator|Ulipristal acetate|control group treated with Ulipristal acetate as control
16481267|NCT03421639|Experimental|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
16481268|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
16481269|NCT03421613|Experimental|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
16481392|NCT03420781|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 46 weeks.
16481270|NCT03421613|Placebo Comparator|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
16481271|NCT03421600|Active Comparator|Blue laser imaging|Blue laser imaging
16481272|NCT03421600|Experimental|White light imaging|White light imaging
16481273|NCT03421587||Individuals exposed to an intentional/non-intentional trauma|
16481274|NCT03421587||Healthy controls without trauma-exposure|
16481275|NCT03421574|Experimental|MR-Guided Focused Ultrasound|
16481276|NCT03421561|Experimental|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
~Basic Catheter Specifications
~Guidewire: 0.035
~Balloon Length: 40/80/120 mm
~Sheath Compatibility: greater than or equal to 6 French
~Balloon Diameter: 4/5/6 mm
~Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
16481277|NCT03421561|Placebo Comparator|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
~Basic Catheter Specifications
~Guidewire: 0.035
~Balloon Length: 40/80/120 mm
~Sheath Compatibility: greater to or equal to 6 French
~Balloon Diameter: 4/5/6 mm
~Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
16481278|NCT03421548|Experimental|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
16481279|NCT03421548|No Intervention|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
16481280|NCT03421535|Active Comparator|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
16481281|NCT03421535|Experimental|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
16481282|NCT03421522|Experimental|Intervention - ICBN preservation|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved.
16481283|NCT03421522|No Intervention|Control - Usual Care|For participants allocated to the usual surgical care arm, attending surgeons will perform a standard Level 1 and 2 axillary node dissection (sacrifice of the ICBN), either alone or with mastectomy or breast conserving surgery.
16481284|NCT03421496|Experimental|Cannabidiol Oral Solution (CBD)|"Cannabidiol Oral Solution, up to 40 milligrams per kilogram per day (mg/kg/day), participants will be dosed approximately every 12 hours with food.
~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
16481285|NCT03421496|Placebo Comparator|Placebo|"Matching CBD placebo, up to 40 mg/kg/day, participants will be dosed approximately every 12 hours with food.
~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
16481286|NCT03421483|Active Comparator|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
16481287|NCT03421483|Placebo Comparator|No supplementation|Participants only receive an adult multivitamin supplement
16481288|NCT03421457|Experimental|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
16481289|NCT03421457|Experimental|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
16481290|NCT03421431|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
16481291|NCT03421431|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
16481292|NCT03421431|Placebo Comparator|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
16481293|NCT03421405|Experimental|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
16481294|NCT03421392||Idiopathic thrombocytopenic purpura|
16481295|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
16481296|NCT03421392||without thrombocytopenia|
16481297|NCT03421379|Experimental|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
16481298|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
16481299|NCT03421366||Cystic Fibrosis on Posaconazole|"Able to provide written informed consent
~Greater than 18 years of age or older
~Have a diagnosis of cystic fibrosis
~No known azole hypersensitivity
~To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus
~Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care
~Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily."
16481307|NCT03421340|Other|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
16481308|NCT03421340|Other|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
16481309|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
16481310|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
16481311|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
16481312|NCT03421314|Experimental|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
16481313|NCT03421314|Experimental|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
16481314|NCT03421314|Experimental|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
16481315|NCT03421314|No Intervention|Control|Participants in this arm will not take supplementation as a control.
16481316|NCT03421301|Experimental|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
16481317|NCT03421301|Placebo Comparator|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
16481318|NCT03421288|Experimental|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
16481319|NCT03421288|Active Comparator|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
16481320|NCT03421275|Experimental|Esketamine|intravenous anaesthetic and analgetic
16481321|NCT03421275|Active Comparator|Fentanyl Citrate|intravenous opioid analgetic
16481322|NCT03421275|Placebo Comparator|Saline Nasal|"intravenous Natriumklorid b. Braun 9 mg/ml"
16481323|NCT03421262|Experimental|One-step:IADPSG Criteria|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gr oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
16481324|NCT03421262|Active Comparator|Two-step:NDDG Criteria|"Step 1: Perform a 1h 50-g glucose load test (nonfasting. If the plasma glucose level measured 1 h after the load is 140 mg/dL, proceed to a 100-g OGTT.
~Step 2: 100-g OGTT. The diagnosis of GDM is made if at least two of the following four plasma glucose levels(measured fasting and 1 h, 2 h, 3 h after the OGTT) are met or exceeded: 105mg/dl, 190mg/dl, 165mg/dl and 145mg/dl respectively"
16481325|NCT03421249|Active Comparator|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
16481326|NCT03421249|Active Comparator|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
16481327|NCT03421249|Placebo Comparator|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
16481328|NCT03421249|Active Comparator|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
16481329|NCT03421236|Experimental|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
16481330|NCT03421223||Case|Individuals diagnosed with chronic pain
16481331|NCT03421223||Control|Individuals without chronic pain
16481332|NCT03421210|Other|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
16481333|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
16481334|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
16481335|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
16481336|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
16481337|NCT03421184|Experimental|Patient with Systemic Lupus Erythematosus|30 women with SLE
16481338|NCT03421184|Active Comparator|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
16481339|NCT03421184|Active Comparator|Healthy control|30 healthy control women
16481340|NCT03421158|No Intervention|Control|Newborns received no pain interventions during the procedure
16481341|NCT03421158|Experimental|Breastfeeding|Newborns were breastfed during the procedure
16481342|NCT03421158|Experimental|Oral Sucrose|Newborns were given oral sucrose during the procedure
16481343|NCT03421158|Experimental|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
16481344|NCT03421158|Experimental|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
16481345|NCT03421119|Experimental|CinnaGen-liraglutide|CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
16481346|NCT03421119|Active Comparator|Victoza®|Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
16481347|NCT03421106|Experimental|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
16481348|NCT03421106|Active Comparator|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
16481349|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
16481350|NCT03421080|Active Comparator|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
16481351|NCT03421080|Experimental|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
16481352|NCT03421054|Other|nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
16481353|NCT03421041|Experimental|Dexamethasone group|
16481354|NCT03421041|No Intervention|control group|
16481355|NCT03421028|Active Comparator|Control group|Patients with masticatory muscle pain treated with occlusal splint, physiotherapy and counseling
16481356|NCT03421028|Experimental|Experimental group 1|Patients diagnosed with masticatory muscle pain treated with 4 meetings of EMG-biofeedback assisted training
16481357|NCT03421028|Experimental|Experimental group 2|Patients diagnosed with masticatory muscle pain treated with 8 meetings of EMG-biofeedback
16481358|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
16481359|NCT03421015||Control Group|patients without biochemical recurrence (control group)
16481360|NCT03421002|Experimental|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour. Micafungin will be administered for a minimum of 14 days until 1 of the following conditions applied: •Negative results (absence of Candida growth) from at least 2 consecutive blood cultures and/or resolution of clinical and laboratory symptoms and reduction of mannan antigen blood level (< 125 pg/mL) are obtained. •In case of meningitis, hydrocephalus and external ventricular derivation, negative results (absence of Candida growth) from at least 2 consecutive cerebral spinal fluid (CSF) cultures associated with resolution of clinical and laboratory symptoms. •Interruption (including addition or switch to another antifungal agent or dosage change of micafungin) due to demonstration of therapy failure.
16481361|NCT03420989|Active Comparator|Active snack food|snack food with carob and seaweeds 50 gr per day
16481362|NCT03420989|Placebo Comparator|Control snack food|snack food without carob and seaweeds 50 gr per day
16481390|NCT03420794|Active Comparator|Control Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once just prior to surgery.
16481391|NCT03420794|Experimental|Study Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once 3-4 hours prior to surgery.
16481363|NCT03420976|Experimental|Novel Supplement-based Therapy|"Low FODMAP diet + supplements outlined below:
~Product Name: Liver-G.I. Detox Active Ingredients: Alpha lipoic acid, n-acetyl-l-cystine, turmeric root extract, milk thistle seed extract, broccoli sprout concentrate, artichoke leaf extract, taurine, glycine, l-glutamine, l-methionine, and chlorella.
~Product Name: l-Glutamine Active Ingredients: l-glutamine
~Product Name: MicroDefense Active Ingredients: berberine sulfate, olive leaf extract, sweet wormwood, clove bud powder, and grapefruit seed and fruit extract.
~Product Name: A.C. Formulla II Active Ingredients: calcium and magnesium undecylenate, calcium and magnesium caprylate, bromelain, grapefruit seed and fruit extract, and berberine sulfate
~Product Name: Probiotic-5 (Pure Encapsulations) Active Ingredients: Probiotic blend
~Product Name: Digestive Enzymes Ultra with Betaine HCl Active Ingredients: Digestive enzyme blend and betaine HCl"
16481364|NCT03420963|Experimental|Treatment (cyclophosphamide, etoposide, NK cells)|Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
16481365|NCT03420950|Other|Sedative first|Rapid sequence intubation: sedative first
16481366|NCT03420950|Other|Paralytic agent first|Rapid sequence intubation: paralytic first
16481367|NCT03420937|Experimental|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.
~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).
~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.
~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
16481368|NCT03420937|Experimental|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
16481369|NCT03420924|Experimental|Thermal suit|
16481370|NCT03420924|Active Comparator|Conventional hospital clothes|
16481371|NCT03420911|Active Comparator|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
16481372|NCT03420911|Active Comparator|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
16481373|NCT03420898||1|General Medicine in Hospital Unit 70 Bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
16481374|NCT03420898||2|General Medicine in Hospital 38 Bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
16481375|NCT03420898||3|Cardiovascular Surgery in Hospital Unit 36 bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
16481376|NCT03420898||4|General Surgery in Hospital 24 bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
16481377|NCT03420898||5|Cardiac 36-bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
16481378|NCT03420898||6|General Medicine 26 Bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
16481379|NCT03420885|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
16481380|NCT03420885|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
16481381|NCT03420872||Subset from PROGRESS cohort|Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City
16481382|NCT03420846|Experimental|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
16481383|NCT03420846|No Intervention|Control arm|Standard MMS is performed
16481384|NCT03420833|Experimental|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
16481385|NCT03420833|Experimental|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
16481386|NCT03420820|Experimental|5% Betadine, Ocular Surface only|Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
16481387|NCT03420820|Experimental|10% Betadine, Ocular Surface only|Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
16481388|NCT03420820|Experimental|10% Betadine, Ocular Surface and Adnexa|Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
16481389|NCT03420807|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
16481393|NCT03420781|Experimental|Relamorelin 10 μg, followed by Placebo|Relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo injected twice daily for 6 weeks.
16481394|NCT03420781|Experimental|Placebo, followed by Relamorelin 10 μg|Placebo injected subcutaneously twice daily for 40 weeks, followed by Relamorelin 10 μg injected twice daily for 6 weeks.
16481395|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
16481396|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
16481397|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
16481398|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
16481399|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
16481400|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
16481401|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
16481402|NCT03420755|Experimental|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
16481403|NCT03420755|Experimental|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
16481404|NCT03420742|Experimental|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
16481405|NCT03420729|Experimental|magnetic assisted capsule endoscopy|All participants will undergo magnetic assisted capsule endoscopy at the sloan medical centre
16481406|NCT03420729|Active Comparator|gastroscopy|All participants will undergo gastroscopy as standard of care at sheffield teaching hospitals
16481407|NCT03420716|Experimental|functional yogurt|Participants are given the symbiotic yogurt daily (180 ml)
16481408|NCT03420716|Experimental|control yogurt|Participants are given the control yogurt daily (180 ml)
16481409|NCT03420703|Active Comparator|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
16481410|NCT03420703|Sham Comparator|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
16481411|NCT03420690||Family of patient|
16481412|NCT03420677|Active Comparator|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
16481413|NCT03420677|Sham Comparator|No application of tones|During NREM sleep no short tones will be played
16481414|NCT03420664|Experimental|Cast immobilisation|A below knee cast is applied in order to achieve ankle immobilisation for one hour
16481415|NCT03420664|Experimental|Orthosis (VACOped) immobilisation|A below knee orthosis which allows for ankle movement is applied for one hour.
16481416|NCT03420651|Experimental|PEFR Guided Management|Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
16481417|NCT03420651|Experimental|Non-PEFR Guided Management|Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
16481418|NCT03420638|Experimental|Adjunct Exparel|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL], i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension on each side.
16481419|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
16481420|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
16481421|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
16481422|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
16481423|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
16481424|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
16481425|NCT03420612||validation|The validation cohort was used to verify the IDS
16481426|NCT03420599||health control|healthy controls are all from normal volunteers
16481427|NCT03420599||splenectomy|Traumatic patients after total splenectomy
16481428|NCT03420586|Active Comparator|Nitrous oxide Group|The nitrous oxide group (GN2O) will receive air in 30% O2 during general anesthesia until the last 30 min of surgery, when 70% N2O in 30% O2 will be administered.
16481429|NCT03420586|No Intervention|Oxygen Group|The Oxygen group will receive gas carrier mixture consisting of air in 30% O2 during general anesthesia.
16481430|NCT03420560|Experimental|warmer temperature|To compare the incidence and intensity of pain on injection that is caused by propofol in warm temperature（27℃） versus normal temperature(23℃).
16481431|NCT03420560|Placebo Comparator|normal temperature|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol in different room temperature(27 VS 23).
16481433|NCT03420547|No Intervention|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
16481434|NCT03420534|Experimental|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
16481435|NCT03420534|Active Comparator|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
16481436|NCT03420534|Active Comparator|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
16481437|NCT03420534|Experimental|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
16481438|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab-240 mg IV over 60 minutes Q2W Ipilimumab 1mg/kg IV over 30 minutes Q6W
16481439|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
16481440|NCT03420495|Experimental|OCD Group|Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for principal OCD. These participants will complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
16481441|NCT03420495|Experimental|Non-psychiatric Control Group|No current DSM-5 diagnosis. These participants will also complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
16481442|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
16481443|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
16481444|NCT03420469|Experimental|Baseline CYP2D6 activity|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
16481445|NCT03420469|Experimental|CYP2D6 activity with single dose of bupropion|The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
16481446|NCT03420469|Experimental|CYP2D6 activity after treatment with bupropion to steady sate|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
16481447|NCT03420456|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
16481448|NCT03420443|Experimental|Oat bran|45 g oat bran
16481449|NCT03420443|Experimental|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
16481450|NCT03420443|Other|No oral supplementation|No oral supplementation.
16481451|NCT03420417|Experimental|Assessement of respiratory mechanics|Measurement of respiratory mechanics characteristics
16481452|NCT03420404|Experimental|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
16481453|NCT03420404|No Intervention|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
16481454|NCT03420391|Placebo Comparator|Placebo PBMT|Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
16481455|NCT03420391|Active Comparator|5 Minutes|"Participants will be performed the eccentric exercise protocol 5 minutes after PBMT.
~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
16481456|NCT03420391|Active Comparator|3 Hours|"3 hours: Participants will be performed the eccentric exercise protocol 3 hours after PBMT.
~Assessments will be performed before at baseline, 1 minute, 1 hour and 24, 48 hours after the end of exercise protocol."
16481457|NCT03420391|Active Comparator|6 Hours|"6 hours: Participants will be performed the eccentric exercise protocol 6 hours after PBMT.
~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
16481458|NCT03420391|Active Comparator|24 hours|24 hours: Participants will be performed the eccentric exercise protocol 24 hours after PBMT. Assessments will be performed before at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
16481459|NCT03420391|No Intervention|Control|Participants will not receive intervention. Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
16481460|NCT03420378|Experimental|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
16481461|NCT03420365|Experimental|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
16481462|NCT03420352|Other|butterfly needle with valve|thromboelastography
16481463|NCT03420352|Other|Standard hypodermic needle|thromboelastography
16481464|NCT03420339|Experimental|Subjects on stimulant medication|All participants: Children and adolescents diagnosed with AD/HD, displaying disruptive behavior, and taking stimulant medication.
16481465|NCT03420326||Atria fibrillation (AF) group|"Detection of AF during 30 seconds ECG assessment
~Once diagnosed with atrial fibrillation before
~Undergo the frailty status assessment"
16481466|NCT03420326||Non-AF group|"No detection of AF during 30 seconds ECG assessment
~Undergo the frailty status assessment"
16481503|NCT03420079|Experimental|Dose expansion cohort of FCN-411|"FCN-411 will be orally administrated at MTD.
~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
16481467|NCT03420313|Experimental|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).
~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad. (e) monthly follow-up assessments"
16481468|NCT03420313|No Intervention|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same monthly assessments.
16481469|NCT03420300|Experimental|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
16481470|NCT03420287|Experimental|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
16481471|NCT03420287|Active Comparator|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
16481472|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
16481473|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
16481474|NCT03420261|Active Comparator|Crystalloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of 0.9% saline (up to a maximum of 30 ml/kg)
16481475|NCT03420261|Experimental|Colloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of HES 130/0.4 (up to a maximum of 30 ml/kg, VOLUVEN ®, Fresenius Kabi)
16481476|NCT03420248|Experimental|Non-spherical polyvinyl alcohol particle|For embolic material, non-spherical polyvinyl alcohol particle is used.
16481477|NCT03420248|Experimental|Tris-acryl gelatin microsphere|For embolic material, Tris-acryl gelatin microsphere is used.
16481478|NCT03420235|No Intervention|Control group|Control group will receive standard care alone.
16481479|NCT03420235|Experimental|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
16481480|NCT03420222|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
16481481|NCT03420222|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
16481482|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
16481483|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
16481484|NCT03420196|Experimental|Supervised Rehabilitation program|It will be consist in a supervised exercise program by physical therapist, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility
16481485|NCT03420196|Active Comparator|Nonsupervised rehabilitation program|It will consist in an exercise program for home, nonsupervised, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility. The patients will perform an exercise program at home.
16481486|NCT03420170|Experimental|Graded Exercise Integrated Education|"The graded exercise (8 weeks)
~Strengthening exercise
~Aerobic Exercise
~Educational session to increase exercise self-efficacy and physical activity level (16 weeks)"
16481487|NCT03420170|Active Comparator|Conventional physical therapy|Normal routine of physical therapy (8 weeks)
16481488|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
16481489|NCT03420144|Active Comparator|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
16481490|NCT03420144|Active Comparator|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
16481491|NCT03420131||FFR-iFR-QFR group|
16481492|NCT03420118|Experimental|Tumor tissue and blood samples collection|
16481493|NCT03420105|Other|Group A|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
16481494|NCT03420105|Other|Group B|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
16481495|NCT03420105|Other|Healthy volunteers|Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
16481496|NCT03420092|Experimental|Treatment A|The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
16481497|NCT03420092|Experimental|Treatment B|The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
16481498|NCT03420092|Experimental|Treatment C|The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
16481499|NCT03420092|Experimental|Treatment D|The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
16481500|NCT03420092|Experimental|Treatment E|The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
16481501|NCT03420092|Experimental|Treatment F|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
16481502|NCT03420079|Experimental|Dose escalation cohort of FCN-411|"FCN-411 will be orally administrated at five sequential dose levels, which are 4 mg, 8 mg, 16 mg, 24 mg, and 32 mg.
~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
16481504|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
16481505|NCT03420053|Experimental|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.
~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
16481506|NCT03420053|Placebo Comparator|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.
~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
16481507|NCT03420053|Experimental|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
16481508|NCT03420053|Experimental|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.
~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
16481509|NCT03420053|Placebo Comparator|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.
~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
16481510|NCT03420040|Experimental|QS-M Needle Free Injector group|To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.
16481511|NCT03420040|Active Comparator|Glargine pen group|To observe the amount of insulin used by the Glargine pen group under good blood glucose control.
16481512|NCT03420014|Active Comparator|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
16481513|NCT03420014|Experimental|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.
~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
16481514|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
16481515|NCT03420001||controls|women after one vaginal delivery
16481516|NCT03419988|Experimental|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
16481517|NCT03419988|No Intervention|Control|8-weeks control: asked not to change anything or start exercising.
16481518|NCT03419975|Experimental|TJO-002|
16481519|NCT03419975|Active Comparator|latanoprost|
16481520|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
16481521|NCT03419936||Helicobacter pylori(HP) positive|Participants who are diagnosed with gastric cancer and Helicobacter Pylori infection will be treated with subtotal gastrectomy.
16481522|NCT03419923|Placebo Comparator|saline flushes|saline flushes with 250 mL were carried out every 30 min.
16481523|NCT03419923|Active Comparator|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
16481524|NCT03419923|Experimental|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
16481525|NCT03419910|Experimental|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
16481526|NCT03419897|Experimental|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
16481527|NCT03419871||monitoring sleep effects on toddlers|Monitoring the sleep characteristics of toddlers living in economically stressed communities.
16481528|NCT03419858|Experimental|Mindfulness Meditation Group|"Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are momentary and fleeting and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and simply let go of discursive thoughts."
16481529|NCT03419858|Active Comparator|Placebo Meditation Group|The purpose of this intervention was to lead subjects to attend to one's breathing in a non-evaluative manner. Subjects were instructed to sit with a straight posture, closed eyes, and to take a deep, slow breaths every 2-3 minutes.
16481530|NCT03419858|Active Comparator|Slow-Breathing Group|A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
16481531|NCT03419845|Experimental|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
16481532|NCT03419832|Experimental|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
16481533|NCT03419832|Active Comparator|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
16481534|NCT03419819|Experimental|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.
~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
16481535|NCT03419806|Experimental|Infudopa i.v.|"Infudopa i.v. in 75% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion.
~From patient 6 and onwards:
~Infudopa i.v. in 81% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion."
16481536|NCT03419806|Experimental|Infudopa s.c.|"Infudopa s.c. in the same dosage as the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion.
~From patient 6 and onwards:
~Infudopa s.c. in 86% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion."
16481537|NCT03419806|Active Comparator|LCIG (Duodopa)|Individually optimized dosing of LCIG (Duodopa) (delivered directly to the proximal small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable infusion pump) will be delivered over a 16-h period, administered as a morning rapid constant rate administration followed by continuous infusion.
16481538|NCT03419793|Experimental|physical therapy intervention and segmental muscle vibration|physiotherapy intervention and segmental muscle vibration device
16481539|NCT03419793|Sham Comparator|physical therapy intervention|physical therapy intervention alone
16481540|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
16481541|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
16481542|NCT03419767|Active Comparator|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
16481543|NCT03419767|Sham Comparator|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
16481544|NCT03419754|Experimental|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
16481545|NCT03419754|Placebo Comparator|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
16481546|NCT03419741|Active Comparator|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
16481547|NCT03419741|Sham Comparator|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
16481548|NCT03419728|Experimental|Healthy Families, Healthy Futures|Family coaches meet with participating pregnant and parenting females, the woman's partner, and the child. Visit frequency varies from once per week to once per month, depending on the length of time in the program, the client's needs, and the accomplishment of program milestones. In the short term, the program seeks to increase the use of Long-Acting Reversible Contraception (LARC), enhance family functioning including improving father involvement, and to meet the baby's child development needs. In the long term, the program aims to delay subsequent pregnancies, ensure positive child development, and increase parents' self-sufficiency.
16481549|NCT03419728|No Intervention|Control group|"No active treatment for control group. Control group has access to business as usual services in community."
16481550|NCT03419715|Experimental|Bimatoprost Topical Solution|0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
16481551|NCT03419715|Placebo Comparator|Control|Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks
16481552|NCT03419702|No Intervention|Control|No almonds
16481553|NCT03419702|Experimental|Experimental|Almonds
16481554|NCT03419689|Experimental|Sample Collection|"The following samples may be collected during the study:
~Tumour tissue samples
~Blood samples
~Ascites samples
~Other fluids requiring drainage"
16481555|NCT03419676|No Intervention|Control|No reinforcement.
16481556|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
16481557|NCT03419663||gastric cancer|
16481558|NCT03419650|Other|Treatment arm|treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
16481559|NCT03419637|No Intervention|Control - Standard of Care|The standard of care consists of in-clinic counseling, informational handouts, and access to patient medical records
16481560|NCT03419637|Experimental|Intervention - Mobile app|The mobile app, or app, is used to document before and after photos of the excised skin areas and to document related diagnoses. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
16481561|NCT03419624|Experimental|Dapagliflozin plus Exenatide|Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
16481562|NCT03419624|Placebo Comparator|Placebo plus Placebo|Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
16481563|NCT03419624|Active Comparator|Placebo plus Exenatide|Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
16481564|NCT03419611|Experimental|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
16481565|NCT03419611|Experimental|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
16482200|NCT03415321|Experimental|Intervention group|Postpartum Mobile Support Application
16481566|NCT03419611|Placebo Comparator|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
16481567|NCT03419611|Experimental|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
16481568|NCT03419611|Experimental|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
16481569|NCT03419598||All study participants|All virtual participants who received a virtual opening wedge high tibial osteotomy. The baseline information was the individual CT-based geometry of tibia.
16481570|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
16481571|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
16481574|NCT03419559|Experimental|LN-145 in combination with durvalumab|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
16481575|NCT03419546||Bronchoscopic procedures|Bronchoscopies performed in different sites to evaluate the level of satisfaction of the operators with the device Ambu® aScope™ 4
16481576|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
16481577|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
16481578|NCT03419520|Experimental|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
16481579|NCT03419520|No Intervention|Control group|Schools monitored along the study but won't receive any healthy action.
16481580|NCT03419507|Active Comparator|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
16481581|NCT03419507|Active Comparator|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
16481582|NCT03419494||VDCLD regimen containing PLD|PLD 36mg/㎡.d d1、d15，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
16481583|NCT03419494||VDCLD regimen containing DNR|DNR 45mg/㎡.d d1～3，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
16481585|NCT03419468|Experimental|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
16481586|NCT03419468|Active Comparator|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
16481587|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
16481588|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
16481589|NCT03419429|Experimental|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
16481590|NCT03419429|Experimental|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
16481591|NCT03419429|Experimental|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
16481592|NCT03419429|Experimental|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
16481593|NCT03419403|Experimental|Standard Steroids|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days
16481594|NCT03419403|Experimental|Standard Steroids + Vasoconstrictor + Cold Compress|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
16481595|NCT03419403|Experimental|Enhanced Steroids + Vasoconstrictor + Cold Compress|Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).
16481596|NCT03419390|Other|Healthy subjects|One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
16481597|NCT03419390|Other|Diseased groups|lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
16481598|NCT03419390|Other|Diseased subgroups|"Every second subject will be allocated to the subgroup.
~Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
~Thickness measurement with reference medical device."
16481599|NCT03419377|Experimental|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
16481600|NCT03419377|No Intervention|Standard care|Standard care including gynecological examination.
16481601|NCT03419364|Experimental|Nicotinamide|All participants will receive study agent
16481602|NCT03419351|Other|Main group|Main study group including all individuals that underwent the study procedures
16481603|NCT03419338|Experimental|Test group|Surgical alveolus + maxillary sinus lift with inorganic bovine bone + newly forming bone + collagen membrane
16481604|NCT03419338|Active Comparator|Control group|Maxillary sinus lift with inorganic bovine bone + collagen membrane
16481605|NCT03419325|Experimental|HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:
~An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
16481606|NCT03419325|Experimental|HTPR/no-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Presence of HTPR, but no CYP2C19 LOF allele found:
~An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
16481607|NCT03419325|Experimental|no-HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Presence of a CYP2C19 LOF allele, but no HTPR:
~An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
16481608|NCT03419325|Experimental|No-HTPR/No-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Absence of both HTPR and CYP2C19 LOF alleles:
~Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
16481609|NCT03419312|Experimental|Study sequence A|"Proclaim™ Elite 5: Burst - Washout - Sham
~14 days of burst stimulation.
~7 days washout.
~14 days of sham stimulation."
16481610|NCT03419312|Experimental|Study sequence B|"Proclaim™ Elite 5: Sham - Washout - Burst
~14 days of sham stimulation.
~7 days washout.
~14 days of burst stimulation."
16481611|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
16481612|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
16481613|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
16481614|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
16481615|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
16481616|NCT03419247|Experimental|Tumor tissue and blood sample collection|
16481617|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
16481618|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
16481619|NCT03419221|Active Comparator|A: Patients with PET/CT performs at day 14 after the drawing|Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture
16481620|NCT03419221|Placebo Comparator|B : Patients' routine care with performance of explorations|Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
16481621|NCT03419208|Experimental|SPIN-HAND Program|Offered the SPIN-HAND program
16481622|NCT03419208|No Intervention|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
16481623|NCT03419195|Experimental|Type 2 diabetes|Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C <9%).
16481624|NCT03419195|Experimental|Healthy overweight controls|Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.
16481625|NCT03419182|Active Comparator|RCT - ORIF|A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
16481626|NCT03419182|Active Comparator|RCT - (THA) + ORIF|A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
16481627|NCT03419182|No Intervention|OBS - ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
16481628|NCT03419182|No Intervention|OBS (THA) + ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
16481666|NCT03418935|Experimental|Remaxol 800 ml|Group II: treatment with Remaxol 800 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
16481667|NCT03418935|Placebo Comparator|Control|Group III: Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
16482201|NCT03415321|No Intervention|Control Group|Routine care
16481629|NCT03419169|Experimental|Light load BFR resistance training|This arm of the clinical trial will involve eight weeks of twice weekly light load resistance training with BFR. Patients in this arm will complete four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press exercise at 30% of predicted one repetition maximum. BFR will be applied at 80% of total limb arterial occlusive pressure. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum. Both legs will be trained with BFR.
16481630|NCT03419169|Active Comparator|Heavy load resistance training|This arm of the clinical trial will involve eight weeks of twice weekly heavy load resistance training. Patients in this arm will complete three sets of ten repetitions of unilateral leg press exercise at 70% of predicted one repetition maximum. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum.
16481631|NCT03419156|Experimental|Text Message Arm|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
16481632|NCT03419143||Cohort 1|naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)
16481633|NCT03419143||Cohort 2|"naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs"
16481634|NCT03419143||Cohort 3|naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents** other than a single TNFi
16481635|NCT03419130|Experimental|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
16481636|NCT03419130|Experimental|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
16481637|NCT03419117|Experimental|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
16481638|NCT03419117|Placebo Comparator|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
16481639|NCT03419104|Experimental|Preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
16481640|NCT03419091|Active Comparator|Reusable Ureteroscope|Standard ureteroscope.
16481641|NCT03419091|Experimental|single-use flexible digital ureteroscope (LithoVue)|Disposable ureteroscope being tested.
16481642|NCT03419065|Other|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
16481643|NCT03419052|Experimental|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
16481644|NCT03419052|Active Comparator|MIND food and training control|Consumption of foods high in polyphenols (i.e., MIND foods) AND online (inert) games
16481645|NCT03419052|Active Comparator|Control foods and speed of processing training|Consumption of low polyphenol foods AND speed of processing training
16481646|NCT03419052|Sham Comparator|Double Control|Consumption of low polyphenol foods AND online (inert) games
16481647|NCT03419039|Experimental|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
16481648|NCT03419039|Placebo Comparator|Placebo|2 identically appearing placebo capsules daily
16481649|NCT03419026||breast cancer|
16481650|NCT03419026||control|
16481651|NCT03419013|Experimental|Test of new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation
16481652|NCT03419000|Experimental|Patient|Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
16481653|NCT03419000|Active Comparator|healthy volunteers|Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
16481654|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
16481655|NCT03418974|Experimental|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
16481656|NCT03418974|Experimental|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
16481657|NCT03418974|Experimental|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
16481658|NCT03418961|Experimental|Arm I (carvedilol)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
16481659|NCT03418961|Active Comparator|Arm II (no intervention)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
16481660|NCT03418961|Active Comparator|Arm III (observation)|Patients undergo observation for up to 108 weeks.
16481661|NCT03418948|Active Comparator|2 x CC|2 x conventional colonoscopy (CC), back-to-back design
16481662|NCT03418948|Active Comparator|CC followed by EC|Conventional colonoscopy followed by Endocuff Vision- assisted colonoscopy, back-to-back design
16481663|NCT03418948|Active Comparator|EC followed by CC|Endocuff Vision-assisted colonoscopy followed by conventional colonoscopy, back-to-back design
16481664|NCT03418948|Active Comparator|2 x EC|2 x Endocuff Vision-assisted colonoscopy
16481665|NCT03418935|Experimental|Remaxol 400 ml|Group I: treatment with Remaxol 400 ml IV + Ringer solution 400 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
16481668|NCT03418922|Experimental|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
16481669|NCT03418922|Experimental|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
16481670|NCT03418909||Oropharyngeal carcinoma (excluding M+ stage)|"Eligible patients with histologically verified early stage squamous cell carcinoma of the oropharynx.
~Patients will be treated in accordance with current hospital protocols with transoral robotic surgery (T1-2, N1, M0) or radio(chemo)therapy (any T-stage, any N-stage, M0)."
16481671|NCT03418896|Experimental|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
16481672|NCT03418883|Experimental|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
16481673|NCT03418883|Sham Comparator|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
16481674|NCT03418870|Experimental|Family Integrated Care (mFI-Care)|Parents of infants assigned to the Family Integrated Care (mFI-Care) intervention will be treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches. Parent training on the Canadian FI-Care Parent Curriculum will be provided during small group sessions facilitated by the study team. Parents will receive peer support from mFI-Care-trained alumni parents and can interact with other mFI-Care parents through the We3Health App secure online parent forum. mFI-Care parents will be expected to track time spent with their infant; record infant activity, feeds and output; track learning and skills acquisition; and keep a journal of the NICU experience using the We3Health app.
16481675|NCT03418870|No Intervention|Family-Centered Care (FCC)|Infants assigned to usual FCC will have NICU nurses as primary caregivers per standard NICU protocol. FCC provides parents with orientation to the NICU; individualized teaching and support; and encouragement to participate in infant care under nursing supervision. Individualized support from social workers, lactation consultants and other specialists will be offered. As part of the study, parents will be asked to use the We3Health mobile app track their time in the NICU, time learning and time spent in infant caregiving activities and to keep of a journal of their NICU experience.
16481676|NCT03418857|Experimental|Experimental|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains 3.16 × 109 colony forming units (CFU) bifidobacterium animalis subsp. lactis BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
16481677|NCT03418857|Placebo Comparator|Control|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains no BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
16481678|NCT03418844|Other|Interest group (patients treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
16481679|NCT03418844|Other|Patient control group (patients not treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
16481680|NCT03418844|Other|Healthy volunteers|Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.
16481681|NCT03418831|Active Comparator|Raloxifene|Raloxifene Hydrochloride
16481682|NCT03418831|Placebo Comparator|Placebo|placebo tablet
16481683|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
16481684|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
16481685|NCT03418805|Active Comparator|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
16481686|NCT03418805|Active Comparator|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
16481687|NCT03418792|Experimental|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head & neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
16481688|NCT03418779|Experimental|Control Group|Optimized supportive care, YQF placebo (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
16481689|NCT03418779|Experimental|YQF Group|Optimized supportive care, YQF (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
16481690|NCT03418766||Normal|Normal healthy individual without migraine.
16481691|NCT03418766||Magraine|Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.
16481692|NCT03418753||single|subjects with abnormal intracranial pressure
16481693|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
16481694|NCT03418727|Experimental|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
16481695|NCT03418727|Experimental|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
16481696|NCT03418727|Placebo Comparator|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
16481697|NCT03418714|Experimental|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
16481729|NCT03418480|Experimental|RNA Vaccine A|Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.
16481698|NCT03418701|Active Comparator|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
16481699|NCT03418701|Active Comparator|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
16481700|NCT03418688|Active Comparator|COR388|Increasing doses of COR388 will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
16481701|NCT03418688|Placebo Comparator|Placebo|Matching placebo capsules will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
16481702|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
16481703|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
16481704|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
16481705|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
16481706|NCT03418649|Experimental|Experimental|Eplerenone 50 Mg Tab
16481707|NCT03418649|Placebo Comparator|Control|Placebo Oral Tablet
16481708|NCT03418636|Experimental|Staying Safe (Ssafe)|"Ssafe is delivered in a small group format (consisting of approximately 10-12 participants) by a trained facilitator over 4 2.5-hour sessions (10 hours total). To help promote the maintenance of risk reduction over the trial's 12-month follow-up period, Ssafe participants will be provided with a novel interactive, smartphone-delivered booster application based on core Ssafe principles and risk reduction strategies."
16481709|NCT03418636|Active Comparator|Healthy Living|Healthy Living is a time- and attention-matched control intervention of equivalent session structure and duration as Ssafe (4 2.5-hour sessions; 10 hours total), also delivered in a small group format (10-12 participants). Healthy Living participants will be provided with a publicly available, sleep hygiene-focused smartphone app to promote healthy sleep habits over the trial's follow-up period.
16481710|NCT03418623|Experimental|GET73|GET73 is administered at the dose of 300 mg t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of GET73: 3 capsules of GET73 on the first day of the related phase, according to randomization, and 2 capsules on the second day of each phase.
16481711|NCT03418623|Placebo Comparator|Placebo|Placebo is administered t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of Placebo: 3 capsules of Placebo on the first day of the related phase, according to randomization, and 2 capsules on the second day.
16481712|NCT03418610|Other|Open Label Single Arm|Azelaic Acid Foam 15% applied twice daily
16481713|NCT03418597|Experimental|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
16481714|NCT03418597|Active Comparator|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
16481715|NCT03418584|Experimental|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
16481716|NCT03418571|Experimental|ALX-0171 1.5 mg/kg|
16481717|NCT03418571|Placebo Comparator|Placebo|
16481718|NCT03418558|Experimental|HERACLES RESCUE|Patients will receive trastuzumab-emtansine, iv 3,6 mg/kg every 21 days. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first
16481719|NCT03418532|Experimental|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
16481720|NCT03418519|Experimental|CIMT group|"Two-hour mCIMT per day for 15 days (dosage = 30 hours)
~24-hour restraint for 3 weeks"
16481721|NCT03418519|No Intervention|Control group|no CIMT
16481722|NCT03418506|Experimental|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
16481723|NCT03418506|No Intervention|Control|No specific education will be given to the control group.
16481724|NCT03418493|Experimental|LY3316531 (Part A)|LY3316531 administered IV and/or SC.
16481725|NCT03418493|Placebo Comparator|Placebo (Part A)|Placebo matching LY3316531 administered IV.
16481726|NCT03418493|Experimental|LY3316531 (Part B)|LY3316531 administered IV and/or SC.
16481727|NCT03418493|Placebo Comparator|Placebo (Part B)|Placebo matching LY3316531 administered IV and/or SC.
16481728|NCT03418493|Experimental|LY3316531 (Part C)|LY3316531 administered IV and/or SC.
16482374|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
16481730|NCT03418480|Experimental|RAN Vaccine B|Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.
16481731|NCT03418467||tachycardiomyopathy|Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.
16481732|NCT03418467||dilated cardiomyopathy|Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.
16481733|NCT03418454||Oral Squamous Cell Carcinoma|Buccal mucosa samples for Extraction of BACTERIAL DNA
16481734|NCT03418454||Oral Epithelial Dysplasia|Buccal mucosa samples for Extraction of BACTERIAL DNA
16481735|NCT03418454||Control: Healthy age matched patients|Buccal mucosa samples for Extraction of BACTERIAL DNA
16481736|NCT03418454||Osteonecrosis of the Jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
16481737|NCT03418454||Underlying disease, no necrosis of the jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
16481738|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
16481739|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
16481740|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
16481741|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
16481742|NCT03418415|Experimental|Renal denervation|Procedure: Renal denervation
16481743|NCT03418402|Experimental|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
16481744|NCT03418402|Active Comparator|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
16481745|NCT03418389||Pediatric-onset Hypophosphatasia|
16481746|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
16481747|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
16481748|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
16481749|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
16481750|NCT03418363|Active Comparator|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
16481751|NCT03418363|Placebo Comparator|Placebo Oral Capsule|
16481752|NCT03418337|Experimental|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
16481753|NCT03418337|Active Comparator|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
16481754|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
16481755|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
16481756|NCT03418311|No Intervention|Control-Group|Control-group-women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications.
16481757|NCT03418311|Experimental|Cervical Pessary-Group|placement of the cervical pessary (non-invasive) at enrollment; removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37.
16481758|NCT03418298|Experimental|Prehabilitation group|Subjects will carry out a preoperative internet-based program including aerobic and resistance training three sessions per week
16481759|NCT03418272||Ventilated Pediatric Intensive Care Unit patient Group|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
16481760|NCT03418272||Intubated OR patient Control Group|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
16481761|NCT03418259|Experimental|Active KCS Medical Device|
16481762|NCT03418259|Placebo Comparator|Inactive KCS Medical Device|
16481763|NCT03418246|Sham Comparator|GIC filling|"Intervention/treatment One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer).
~Placebo Comparator: GIC
~Participants will have a restoration placed with GIC in the lesion near the gum line. Device: GIC Application of a tooth colored filling in the cavitated dental lesion. Other Name: Resin modified glass ionomer"
16481764|NCT03418246|Experimental|Biodentine filling|"Intervention/treatment The second group will be treated with Biodentine that will be placed near the gum line.Experimental: Biodentine
~Participants will have a restoration placed with Biodentine in the lesion near the gum line. Device: Biodentine Application of a white colored filling in dental lesion."
16481765|NCT03418233|Active Comparator|Active Group|"Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.
~The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
16481766|NCT03418233|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
16481767|NCT03418220|Other|AMD early / intermediate|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD early / intermediate
16481768|NCT03418220|Other|AMD exudative|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD exudative
16481769|NCT03418220|Other|AMD atrophic|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD atrophic
16481770|NCT03418220|Other|control group|A blood and aqueous humor sample will be taken during cataract surgery in patients with cataract (control group)
16481771|NCT03418207|Other|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
16481772|NCT03418194|Experimental|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
16481773|NCT03418194|Placebo Comparator|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
16481774|NCT03418181|Other|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
16481775|NCT03418181|Experimental|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.
~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
16481776|NCT03418168|Experimental|Molidustat (BAY85-3934)|Molidustat group
16481777|NCT03418155|Experimental|Treatment of TongBi Capsule|
16481778|NCT03418155|Placebo Comparator|Treatment of TongBi Placebo|
16481779|NCT03418142|Experimental|Priovi|Priovi is an Internet-administered intervention for people with BPD.
16481780|NCT03418142|Active Comparator|Care-as-Usual (CAU) / wait list|Additionaly, they will be informed about helpful and free available online self-help-proposals for BPD patients immediately after randomization.
16481781|NCT03418129|Experimental|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
16481782|NCT03418129|Experimental|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
16481783|NCT03418129|Experimental|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
16481784|NCT03418116|Experimental|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
16481785|NCT03418090|Active Comparator|Arm 1|Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy
16481786|NCT03418090|Active Comparator|Arm 2|Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI
16481787|NCT03418077|Experimental|energy drink|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
16481788|NCT03418077|Placebo Comparator|Placebo-control|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
16481789|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
16481790|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
16481791|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
16481792|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
16481793|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
16481794|NCT03418038|Experimental|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16481795|NCT03418038|Active Comparator|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16481827|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
16481828|NCT03417817|Other|Healthy subjects|Bravo wireless pH monitoring over 96 hours
16481829|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
16482375|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
16481796|NCT03418038|Experimental|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.
16481797|NCT03418038|Experimental|Arm D (ascobic acid)|Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16481798|NCT03418025|Experimental|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
16481799|NCT03418025|Active Comparator|Group II (pre and post testing)|Questionnaire Administration & Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
16481800|NCT03418012|Experimental|Cervical Pessary-Group|Cervical Pessary Group: placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37
16481801|NCT03418012|Other|Control-Group|Control-Group women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
16481802|NCT03417999|Experimental|Cohort 1|"Cohort 1A:
~Dexmedetomidine 2 μg/kg
~Under general oral endotracheal anesthesia
~7 subjects age >2 yo and ≤ 6 yo
~7 subjects age ≥1 mo and ≤2 yo
~Cohort 1B:
~Dexmedetomidine 2 μg/kg
~Under sedation with a natural airway
~7 subjects age >2 yo and ≤ 6 yo
~7 subjects age ≥1 mo and ≤2 yo"
16481803|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg
~Under general oral endotracheal anesthesia
~7 subjects age >2 yo and ≤ 6 yo"
16481804|NCT03417999|Experimental|Cohort 3|Currently analyzing data. May perform a 3 μg/kg pending review.
16481805|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
16481806|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
16481807|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
16481808|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
16481809|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
16481810|NCT03417960|Experimental|iTBS|accelerated iTBS to Left DLPFC
16481811|NCT03417947|Placebo Comparator|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
16481812|NCT03417947|Experimental|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
16481813|NCT03417921|Experimental|ARM A|ABTL0812 (starting 1,300 mg tid orally) in combination with gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer
16481814|NCT03417921|Active Comparator|ARM B|Gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer as standard pattern
16481815|NCT03417908|Active Comparator|COPD - PNF|COPD - PNF
16481816|NCT03417908|Sham Comparator|COPD - sham|COPD - sham
16481817|NCT03417908|Active Comparator|Individuals Without COPD - PNF|Individuals Without COPD - PNF
16481818|NCT03417908|Sham Comparator|Individuals Without COPD - sham|Individuals Without COPD - sham
16481819|NCT03417895|Experimental|A(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
16481820|NCT03417895|Experimental|B(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（5 Days on, 2 Days off）
16481821|NCT03417895|Experimental|C(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（7 Days on, 7 Days off）
16481822|NCT03417882|Experimental|Cohort 1|All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
16481823|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
16481824|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
16481825|NCT03417843|Experimental|EUSRA RF electrode|new ablation catheter RFA (RADIOFREQUENCY under EUS), developed by TAEWOONG company for the treatment of pancreatic premalignant and early malignant cystic lesion.
16481826|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
16481952|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
16481830|NCT03417778|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
16481831|NCT03417778|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
16481832|NCT03417778|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
16481833|NCT03417765|Experimental|Cohort A: 5 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
16481834|NCT03417765|Experimental|Cohort B: 10 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
16481835|NCT03417765|Experimental|Cohort C: 25 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
16481836|NCT03417752|Experimental|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
16481837|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
16481838|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
16481839|NCT03417739|Experimental|BVD-523|BVD-523 is to be taken twice daily orally for 28 consecutive days
16481840|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
16481841|NCT03417700|Experimental|Training NW|exercise and supplementation
16481842|NCT03417700|Experimental|Training HICT and vitamin D|Training HICT plus vitamin D
16481843|NCT03417700|Experimental|Placebo|placebo Vitamin D
16481844|NCT03417687|Active Comparator|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
16481845|NCT03417687|Active Comparator|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
16481846|NCT03417674|Experimental|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
16481847|NCT03417674|No Intervention|Control group|Routine care.
16481848|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
16481849|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
16481850|NCT03417661|Experimental|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
16481851|NCT03417648|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
16481852|NCT03417648|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
16481853|NCT03417635|Experimental|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.
~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
16481854|NCT03417635|Active Comparator|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.
~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
16481855|NCT03417622|Experimental|Post-treatment volume-resection margin|Lumpectomy is performed with resection margin of the clinically / radiologically identifiable post-treatment tumor.
16481856|NCT03417622|Active Comparator|Pre-treatment volume-resection margin|Lumpectomy is performed with resection margin of the bracketed tissue.
16481857|NCT03417609||Sarcopenia|Elderly patients with sarcopenia
16481858|NCT03417609||Control|Elderly patients without sarcopenia
16481859|NCT03417596|Experimental|Vestibular Rehabilitation|"Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day.
~Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around.
~Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides.
~The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit."
16481860|NCT03417596|Experimental|Vestibular Rehabilitation+Pharmacological Therapy|"Same exercises that were applied in first group were also applied to this group.
~For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated."
16481861|NCT03417596|Other|Pharmacological Therapy only|Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.
16481862|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
16481863|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
16481864|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap.
16481865|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap
16481866|NCT03417557|Experimental|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
16481867|NCT03417557|Active Comparator|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
16481868|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:
~Atezolizumab (IV) every 3 weeks (q3w)]
~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)
~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
16481869|NCT03417531|Active Comparator|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
16481870|NCT03417531|Active Comparator|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
16481871|NCT03417531|Active Comparator|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
16481872|NCT03417531|Sham Comparator|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
16481873|NCT03417518|Active Comparator|Desflurane Inhalant Product Group|general anesthesia with desflurane
16481874|NCT03417518|Experimental|Propofol Group|general anesthesia with propofol
16481875|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
16481876|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
16481877|NCT03417492|Experimental|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
16481878|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
16481879|NCT03417466|Experimental|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
16481880|NCT03417453|Active Comparator|Eye Drop Dispenser TYPE Opticare|subject will assess TYPE 1 dispenser
16481881|NCT03417453|Active Comparator|Eye Drop Dispenser Autodrop|subject will assess Autodrop dispenser
16481882|NCT03417440|Other|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
16481883|NCT03417440|Other|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
16481884|NCT03417440|Other|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
16481885|NCT03417440|Other|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
16481886|NCT03417440|Other|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
16481887|NCT03417440|Other|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
16481888|NCT03417440|Other|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
16481889|NCT03417440|Other|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
16481890|NCT03417427|Active Comparator|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
16481891|NCT03417427|Placebo Comparator|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
16481892|NCT03417414||B-CLL|Patients with B-Cell CLL
16481893|NCT03417414||B-NHL|Patients with B-Cell NHL
16481894|NCT03417401|Experimental|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
16481895|NCT03417388|Experimental|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
16481896|NCT03417388|Active Comparator|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
16481897|NCT03417375|Experimental|Osteocel Plus|Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
16481898|NCT03417375|Active Comparator|alloOss|The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
16481899|NCT03417362|Other|Animation|Animation describing process of early medical abortion, what to expect, how to take medicines. This is prior to consultation.
16481900|NCT03417362|No Intervention|Standard|Standard of Care - no animation ,standard consultation only.
16481901|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
16481902|NCT03417336|Experimental|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
16481903|NCT03417336|Active Comparator|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
16481904|NCT03417323|Experimental|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
16481905|NCT03417323|No Intervention|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
16481906|NCT03417310|Experimental|"H joystick"|"Patients are treated with the H joystick on a traction table"
16481907|NCT03417310|Active Comparator|Common reduction methods|Patients are treated with common reduction methods on a traction table
16481908|NCT03417297|Experimental|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
16481909|NCT03417284|Experimental|Group 1 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.
~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
16481910|NCT03417284|Experimental|Group 2 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.
~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
16481911|NCT03417271|Active Comparator|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
16481912|NCT03417271|Active Comparator|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
16481913|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
16481914|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
16481915|NCT03417245|Experimental|fitusiran|Fitusiran administered subcutaneously (SC) as prophylaxis once monthly, with use of on-demand factor concentrates for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months
16481916|NCT03417245|Experimental|On demand factor concentrates|On-demand factor concentrates for treatment of breakthrough bleeding episodes. On-demand use of factor concentrates is defined as the use of these agents, as needed, for episodic bleeding, and not on a regular regimen intended to prevent spontaneous bleeding. All patients will be treated for a total of 9 months.
16481917|NCT03417232|Experimental|Split Full Split Elevation of CAF|The central portion of the flap apical to the recession was elevated full thickness by the use of a small periostium elevator inserted into the probable sulcus
16481918|NCT03417232|Sham Comparator|Split Elevation of CAF|The flap was fully elevated with a split thickness approach: the blade of the knife was inserted into the sulcus
16481999|NCT03416660|Active Comparator|High density|Fractional carbon dioxide laser : Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).
16481919|NCT03417219|Experimental|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
16481920|NCT03417219|Active Comparator|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
16481921|NCT03417206|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE between 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
16481922|NCT03417206|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
16481923|NCT03417206|Experimental|TIVA USING PROPOROL|Infusion of propofol will be adjusted at target of SE 40,remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
16481924|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
16481925|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
16481926|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
16481927|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
16481928|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
16481929|NCT03417154|Experimental|Stage 1 Arms 1&2: Nivolumab and Cyclophosphamide|
16481930|NCT03417154|Experimental|Stage 2: Nivolumab and Cyclophosphamide|
16481931|NCT03417141|Experimental|Valchor treatment of Lichen Planopilaris|Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
16481932|NCT03417128|No Intervention|Control|Participants in the control group will receive a one-time personalised nutrition and lifestyle advised based from the Malaysian Dietary Guideline 2010. They will be assured to be followed up twice for the next six month.
16481933|NCT03417128|Experimental|Peer support|This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering.
16481934|NCT03417115||Advanced breast cancer - Her2 positive|Patients with HER2-positive advanced breast cancer
16481935|NCT03417115||Advanced breast cancer - triple negative|Patients with triple negative advanced breast cancer
16481936|NCT03417115||Advanced breast cancer - HR positive, Her2 negative|Patients with HR positive, Her2 negative advanced breast cancer
16481937|NCT03417115||Early breast cancer - HER2 positive|Patients with HER2 positive early breast cancer
16481938|NCT03417115||Early breast cancer - triple negative|Patients with triple negative early breast cancer
16481939|NCT03417115||Early breast cancer - HR positive, HER2 negative|Patients with HR positive, HER2 negative early breast cancer
16481940|NCT03417102|Experimental|Fitusiran|Fitusiran administered subcutaneously (SC) as prophylaxis once monthly, with use of on-demand BPAs for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months
16481941|NCT03417102|Active Comparator|On demand bypassing agents|On-demand bypassing agents (BPAs) for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months.
16481942|NCT03417089|Experimental|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
16481943|NCT03417089|Active Comparator|No suspension|working without suspension of the falciform ligament
16481944|NCT03417076|Experimental|Bexagliflozin|Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of < 30 ug 14C-bexagliflozin in 0.9% saline solution).
16481945|NCT03417050||Randomized CABG patients|Patients which were randomized to undergo CABG.
16481946|NCT03417050||Randomized PCI patients|Patients which were randomized to undergo PCI.
16481947|NCT03417050||Registry CABG|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
16481948|NCT03417050||Registry PCI|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
16481949|NCT03417037|Experimental|Arm A|BMS-986205 and Nivolumab administered in combination
16481950|NCT03417037|Experimental|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
16481951|NCT03417037|Active Comparator|Arm C|Chemotherapy administered alone
16482000|NCT03416647|Experimental|SMAS patients|
16481953|NCT03416998|Active Comparator|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
16481954|NCT03416998|Placebo Comparator|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
16481955|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
16481956|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
16481957|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
16481958|NCT03416972||Stage I-III NSCLC patients|Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
16481959|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
16481960|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
16481961|NCT03416933|Experimental|Biological|
16481962|NCT03416920|Experimental|Wellframe|Subjects in this arm will use the Wellframe application for 90 days
16481963|NCT03416907|Active Comparator|Original|Participants will review the full-length, original consent form for the clinical trial.
16481964|NCT03416907|Experimental|Shortened|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
16481965|NCT03416907|Experimental|Reordered|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
16481966|NCT03416907|Experimental|Highlighted|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
16481967|NCT03416907|Experimental|Interactive|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
16481968|NCT03416894|Experimental|Deep Brain Stimulation|
16481969|NCT03416868|Experimental|Week 3 start|"For the first two weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In the following 3 weeks of voice therapy (weeks 3 through 5), patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
16481970|NCT03416868|Experimental|Week 4 start|"For the first three weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy weeks 4 and 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
16481971|NCT03416868|Experimental|Week 5 start|"For the first four weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy week 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
16481972|NCT03416855||Overall population|Participants will be decided to be treated with Ryzodeg® FlexTouch® by physicians before the enrolment in the study based on clinical judgement in the diabetes management.
16481973|NCT03416842|Experimental|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
16481974|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
16482001|NCT03416634|Active Comparator|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
16482002|NCT03416634|Experimental|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
16482494|NCT03413332|Experimental|E-Talkcare Group|use the web-based patient education tool
16481975|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
16481976|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
16481977|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
16481978|NCT03416803|Experimental|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
16481979|NCT03416803|No Intervention|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
16481980|NCT03416777|Active Comparator|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
16481981|NCT03416777|Experimental|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
16481982|NCT03416777|Experimental|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
16481983|NCT03416764|Experimental|EFP-NF (participants without steady menstrual cycle).|EFP-NF training, twice a week for a total of 10 sessions .
16481984|NCT03416764|No Intervention|TAU|Participant will receive no EFP-NF training, and continue their treatment as usual (TAU).
16481985|NCT03416764|Experimental|EFP-NF during HIGH estrogen phase|EFP-NF training, twice a week, during high-estrogen phases only (days 7-21 of a 28-day cycle), for a total of 10 sessions.
16481986|NCT03416764|Experimental|EFP-NF during LOW estrogen phase|EFP-NF training, twice a week, during low-estrogen phases only (days 21-28 of a cycle and days 1-7 of the following cycle,based on a 28-day cycle), for a total of 10 sessions.
16481987|NCT03416751|Experimental|Fecal Microbial transplantation|Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor
16481988|NCT03416751|Placebo Comparator|Placebo|Patients will get one-dose of 90ml of saline enema on day 1
16481989|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
16481990|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
16481991|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
16481992|NCT03416712|No Intervention|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).
~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
16481993|NCT03416712|Experimental|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
16481994|NCT03416686|Experimental|Radiofrequency|
16481995|NCT03416673|Active Comparator|CTG+CAF|The surgical procedure will include a connective tissue graft harvested from the palate and used under a coronally advanced flap
16481996|NCT03416673|Experimental|peCTG+CAF|A papillary extended connective tissue graft reshaped after harvested from the palate will be used under a coronally advanced flap
16481997|NCT03416660|Active Comparator|Low density|Fractional carbon dioxide laser: Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).
16481998|NCT03416660|Active Comparator|Medium density|Fractional carbon dioxide laser : Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).
16482003|NCT03416634|Experimental|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
16482004|NCT03416634|Active Comparator|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
16482005|NCT03416634|Experimental|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
16482006|NCT03416634|Experimental|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
16482007|NCT03416621|Active Comparator|Experimental: Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
16482008|NCT03416621|Placebo Comparator|Placebo Comparator: Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
16482009|NCT03416621|Experimental|Active Comparator: Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
16482010|NCT03416595|Active Comparator|N1115 Probiotic Supplement|A probiotic supplement containing Lactobacillus paracasei N1115 [Junlebao Lp. N1115] Participators, who met inclusion criteria, will receive following product during 8 weeks: N1115 Probiotic Supplement in the form of powder packaged in sachet (one sachet containing 10^9 CFU Lp. N1115).
16482011|NCT03416595|Placebo Comparator|Placebo control|Dietary Supplement: Placebo Participators, who met inclusion criteria, will receive an identical N1115 Probiotic Supplement looking and tasting placebo.
16482012|NCT03416582|Experimental|SMENC Group|"The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.
~During the telephone call, the patient will report the use of the Drinks Diary."
16482013|NCT03416569|Experimental|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
16482014|NCT03416556|Experimental|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
16482015|NCT03416556|Sham Comparator|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
16482016|NCT03416556|No Intervention|No-contact condition|There was no manual contact between the therapist and the participant
16482017|NCT03416543||Puncture|Patient with RA or gout or osteoarthritis and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.
16482018|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
16482019|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
16482020|NCT03416530|Experimental|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
16482021|NCT03416530|Experimental|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
16482022|NCT03416530|Experimental|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
16482023|NCT03416530|Experimental|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
16482024|NCT03416530|Experimental|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
16482025|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 1b)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
16482026|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 2)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15 mg/m^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. The final dose of anlotinib and irinotecan depends on the result from previous phase Ib study. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
16482027|NCT03416504|Experimental|Gradual Exposure Group|The gradual exposure group received the Gradual Exposure (EXP-G) Intervention.
16482028|NCT03416504|Experimental|Variable Exposure Group|The variable exposure group received the Variable Exposure (EXP-V) Intervention.
16482029|NCT03416491|Experimental|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
16482030|NCT03416491|Experimental|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
16482031|NCT03416491|Experimental|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
16482032|NCT03416478||ctDNA test group|
16482033|NCT03416452|Experimental|PD patients no|PD patients without freezing of gait
16482034|NCT03416452|Placebo Comparator|Healthy|HV using Mobile Gait Trainer
16482035|NCT03416452|Experimental|PD patients|pd patients using vibratory cueing device
16482036|NCT03416452|Experimental|PD patients 1|PD patients with freezing of gait
16482037|NCT03416452|Experimental|Healthy Volunteers|Age and gender matched healthy volunteers.
16482038|NCT03416439|Experimental|intervention arm|lifestyle intervention program carried out by trained professionals
16482039|NCT03416439|No Intervention|control arm|standard, unstructured information given by the family physicians
16482040|NCT03416426||patients undergone PFO closure|patients with ischemic stroke and PFO documented by bubble contrast TEE with no other identifiable cause of the ischemic event who undergone PFO closure using Amplatzer® PFO occluder or Gore® Septal Occluder
16482041|NCT03416413|Active Comparator|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
16482042|NCT03416413|Active Comparator|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
16482043|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
16482044|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
16482045|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
16482046|NCT03416387|Other|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
16482047|NCT03416374|Experimental|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
16482048|NCT03416361|Experimental|Vitamin D|4000IU Vitamin D3 as two 50mcg tablets per day
16482049|NCT03416361|Placebo Comparator|Control|Placebo - two chewable blackcurrant flavoured tablets per day
16482050|NCT03416348|Placebo Comparator|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
16482051|NCT03416348|Active Comparator|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
16482052|NCT03416335|Experimental|Monotherapy Arm - Part A|Dose Escalation Drug DSP-0509
16482053|NCT03416335|Experimental|Combination arm - Part B|Dose Escalation Drug DSP-0509, Pembrolizumab
16482054|NCT03416335|Experimental|Combination arm - Part C|Dose Expansion, Drug DSP-0509, Pembrolizumab
16482055|NCT03416322|No Intervention|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
16482056|NCT03416322|Experimental|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
16482057|NCT03416296||normal placenta|TA , TV ,TP us
16482058|NCT03416296||placenta previa and MAP|TA,TV.TP us
16482059|NCT03416283|Experimental|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
16482060|NCT03416283|Experimental|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
16482061|NCT03416283|No Intervention|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
16482062|NCT03416270|Experimental|Ertuglifozin Treatment Arm|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
16482063|NCT03416270|Placebo Comparator|Placebo Arm|Placebo Matching Ertugliflozin Tablet for 12 weeks
16482064|NCT03416257||WIHS|Women's Interagency HIV Study
16482065|NCT03416257||MACS|Multicenter AIDS Cohort Study
16482066|NCT03416244|Experimental|A: Nivolumab / Ipilimumab combination treatment|Nivolumab 240 mg fixed dose IV every 2 weeks; Additionally, after 7 week safety assessment Ipilimumab 1mg/kg IV every 6 weeks
16482067|NCT03416244|Experimental|B. Nivolumab monotherapy|Nivolumab 240 mg fixed dose IV every 2 weeks
16482068|NCT03416231|Experimental|apatinib plus docetaxel|apatinib combine with docetaxel， 4~6 cycles
16482069|NCT03416218|Experimental|Intervention|All participants enrolled in the study will play Prognosis, the intervention being assessed in this study.
16482103|NCT03415984||Exposed patients|Patients with Parkinson's disease treated with L-DOPA
16482104|NCT03415984||Non exposed patients|Patients with Parkinson's disease not treated with L-DOPA
16482105|NCT03415971|Active Comparator|ASTRA TECH implants|implant restoration(replace of a missing tooth) - 35 patients
16482106|NCT03415971|Active Comparator|CROWN|to fixed denture restorations in own teeth - 32 patients
16482107|NCT03415971|Placebo Comparator|non-edontulos|control group will consist 38 non-edotulos patients
16482070|NCT03416205|Experimental|EST|EST is an operation using the Erbao electric knife and Three-cavity incision knife to make a large incision to the duodenal nipples，and the incision scope is the nipple mouth uplift length of 4/5. It has been used since 1974. The technique is intuitive and intact. However, EST cut too small to achieve the purpose of treatment and will affect the next step, and if the incision is too large it may be easier to occur gastrointestinal perforation and bleeding.The EST will also damage the anatomy of the Oddi sphincter structure,which causes bacterial reflux to the bile duct, the recurrence of CBD.Some surgeons prefer it because it's postoperative pancreatitis rate is lower and it may be easier to find the lesion position if bleeding or perforation occurs.
16482071|NCT03416205|Experimental|EPBD|EPBD is an operation using the Columnar expansion balloon to expand duodenal to achieve the purpose of using the basket and other instruments to take stone out. Balloon expansion may retain part of the sphincter not destroyed, and basically retain the normal physiological function of the nipple sphincter.Thus it may reduce the risk of recurrence of stones and bacterial reflux. However,the postoperative pancreatitis rate is high(4.8% -19.5% ), and nipple sphincter tear is uncontrollable in EPBD.If the digestive tract perforation or bleeding occur after EPBD,it is hard to accurately find the lesion position.Some surgeons prefer it for it's lower bleeding and perforation rate.
16482072|NCT03416205|Experimental|sEST+EPBD|sEST+EPBD is an operation combining EST and EPBD. Investigators use the Erbao electric knife and Three-cavity incision knife to make a small incision to the duodenal nipples, and the incision length is less than 5mm while the incision scope is less than the nipple mouth uplift length of 1/2. Then, Investigators match the appropriate Columnar expansion balloon according to the diameter of the common bile duct and gradually expand the duodenal nipples.This method allows the nipple sphincter to be cut in a small range, then the balloon can guide the direction of the nipple sphincter tearing after the expansion , so that the digestive tract bleeding, perforation may be smaller and more controllable. Besides,it may reduce postoperative pancreatitis rate and the recurrence rate of stones.
16482073|NCT03416192|Experimental|MCO-HD|Hemodialysis with Medium Cut-Off filter
16482074|NCT03416192|Active Comparator|High-flux HDF|Hemodiafiltration with standard high-flux filter
16482075|NCT03416179|Experimental|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
16482076|NCT03416179|Placebo Comparator|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
16482077|NCT03416179|Experimental|Arm A (Non-intensive study)|Glasdegib + azacitidine
16482078|NCT03416179|Placebo Comparator|Arm B (Non-intensive study)|Placebo + azacitidine
16482079|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
16482080|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
16482081|NCT03416140|Experimental|Therapeutic exercise|
16482082|NCT03416140|No Intervention|Control|
16482083|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
16482084|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
16482085|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
16482086|NCT03416088|Experimental|Liquid volume|Drink 300ml wine (alcohol concentration:13%) or 300ml coffee (caffeine concentration 1.2%).
16482087|NCT03416062|Experimental|Remaxol® 400 ml + Placebo 400 ml|Treatment with Remaxol® 400 ml IV + Ringer solution 400 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
16482088|NCT03416062|Experimental|Remaxol® 800 ml|Treatment with Remaxol® 800 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
16482089|NCT03416062|Placebo Comparator|Control|Treatment with Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
16482090|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
16482091|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
16482092|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
16482093|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
16482094|NCT03416036|Experimental|Arm 1: TV003 + rDEN2Δ30-7169|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
16482095|NCT03416036|Experimental|Arm 2: TV003 + rDEN3Δ30|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN3Δ30 on Day 28.
16482096|NCT03416036|Placebo Comparator|Arm 3: Placebo + rDEN2Δ30-7169|Participants will receive placebo at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
16482097|NCT03416036|Placebo Comparator|Arm 4: Placebo + rDEN3Δ30|Participants will receive placebo at study entry (Day 0) and rDEN3Δ30 on Day 28.
16482098|NCT03416023|Experimental|Single|
16482099|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
16482100|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
16482101|NCT03415997|Active Comparator|Total Body Weight|
16482102|NCT03415997|Active Comparator|Lean Body Weight|
16482108|NCT03415958||Open reduction internal fixation|Patients with displaced midshaft clavicle fractures will be offered operative treatment which involves open reduction and internal fixation.
16482109|NCT03415958||Conservative care|Patients will be treated in a sling for the acute phase of two weeks with progressive physiotherapy.
16482110|NCT03415945|Experimental|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
16482111|NCT03415932|Experimental|Health education|Assessment of healt care Contacts Before and after intervention
16482112|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
16482113|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
16482114|NCT03415919||Control patients|Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
16482115|NCT03415906|Experimental|sacubitril+valsartan|Combined angiotensin receptor and neprilysin inhibition
16482116|NCT03415906|Active Comparator|valsartan|Angiotensin receptor inhibition alone
16482117|NCT03415880|Other|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
16482118|NCT03415880|Experimental|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
16482119|NCT03415867|Experimental|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
16482120|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
16482121|NCT03415841|Experimental|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
16482122|NCT03415841|No Intervention|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
16482123|NCT03415828|Experimental|Ethanol gel|CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
16482124|NCT03415828|Active Comparator|Steroid infiltration|Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
16482125|NCT03415815||T1-T3 esophageal cancer|Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries
16482126|NCT03415802|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
16482127|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.
~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.
~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
16482128|NCT03415776|Experimental|Twice weekly|Two sessions of hemodialysis per week
16482129|NCT03415776|Experimental|Thrice weekly|Three sessions of hemodialysis per week
16482130|NCT03415763|No Intervention|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
16482131|NCT03415763|Experimental|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
16482132|NCT03415763|Experimental|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
16482133|NCT03415763|Experimental|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
16482134|NCT03415750|Experimental|Everolimus arm|Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'
16482135|NCT03415750|Active Comparator|Mycophenolate arm|Patients will remain in Tacrolimus + Mycophenolate mofetil combination
16482136|NCT03415724|Active Comparator|1.8 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
16482172|NCT03415516|Experimental|Single Bond2, etch&rinse (SBU)|
16482137|NCT03415724|Active Comparator|3.6 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
16482138|NCT03415724|Active Comparator|1.8 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
16482139|NCT03415724|Active Comparator|3.6 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
16482140|NCT03415711|Experimental|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
16482141|NCT03415711|Experimental|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
16482142|NCT03415711|Active Comparator|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
16482143|NCT03415698|Active Comparator|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
16482144|NCT03415698|Active Comparator|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
16482145|NCT03415685|Active Comparator|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
16482146|NCT03415685|Active Comparator|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
16482147|NCT03415672|Active Comparator|Group 1|Subjects included in Group 1 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine. They will receive three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
16482148|NCT03415672|Experimental|Group 2|"Subjects included in Group 2 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine). They will receive three doses of HBAI20 at 0, 1, and 2 months.
~The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly."
16482149|NCT03415659|Experimental|HWH340 monotherapy|HWH340 tablet, oral administration
16482150|NCT03415646|Active Comparator|Block Group|Erector Spinae Plane Block administered group
16482151|NCT03415646|Sham Comparator|Control Group|Control group
16482152|NCT03415633|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
16482153|NCT03415633|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
16482154|NCT03415620|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres. Patient will choose the desired playlist and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.
~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
16482155|NCT03415594|Experimental|FE203799 5 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
16482156|NCT03415594|Placebo Comparator|Placebo|Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration
16482157|NCT03415594|Other|FE203799 10 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
16482158|NCT03415581|Placebo Comparator|Doxazosin (Placebo First)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
16482159|NCT03415581|Active Comparator|Doxazosin (Active First)|Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
16482160|NCT03415568|Placebo Comparator|LCT consumption|Muffin that contains 15g of long-chain triglyceride (LCT) oils were provided to conduct 6-h meal tolerance test.
16482161|NCT03415568|Experimental|MCDG consumption|Muffin that contains 15g of the mixture of medium-chain triglyceride and diacylglycerol (MCDG) oils were provided to conduct 6-h meal tolerance test.
16482162|NCT03415555|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
16482163|NCT03415555|Experimental|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
16482164|NCT03415542|Other|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
16482165|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
16482166|NCT03415516|Experimental|Gluma Universal, self-etch mode (GSE)|
16482167|NCT03415516|Experimental|Gluma Universal, selective etching (GSL)|
16482168|NCT03415516|Experimental|Gluma Universal, etch&rinse (GER)|
16482169|NCT03415516|Experimental|All Bond Universal, self-etch (ASE)|
16482170|NCT03415516|Experimental|All Bond Universal, selective etching (ASL)|
16482171|NCT03415516|Experimental|All Bond Universal, etch&rinse (AER)|
16482173|NCT03415503|Placebo Comparator|placebo|The placebo capsules only contained pullulan and maltodextrin.During the trial period, the participants were instructed to consume 2 Medox® placebo capsules twice daily (30 min after breakfast or supper).
16482174|NCT03415503|Experimental|40mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (40 mg anthocyanins per capsule) will provid a total daily intake of 40 mg anthocyanins.
16482175|NCT03415503|Experimental|80mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule) will provid a total daily intake of 80 mg anthocyanins.
16482176|NCT03415503|Experimental|320mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,4 per day) will provid a total daily intake of 320 mg anthocyanins.
16482177|NCT03415490|Active Comparator|Classic technique of self-adherent wrap|"over 16 years old
~free of any symptoms in the eyes
~classic technique of self-adherent wrap after surgery"
16482178|NCT03415490|Experimental|Folded technique of self-adherent wrap|"over 16 years old
~free of any symptoms in the eyes
~folded technique of self-adherent wrap after surgery"
16482179|NCT03415477|Experimental|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
16482180|NCT03415464|Experimental|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
16482181|NCT03415464|No Intervention|Regular army training|Regular military training.
16482182|NCT03415451|Experimental|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
16482183|NCT03415438||Group 1|Assessments will be done for 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of Baskent University.
16482184|NCT03415438||Group 2|Assessments will be done for 30 healthy volunteers
16482185|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
16482186|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
16482187|NCT03415412|Experimental|Group CU (Clearfil Universal)|Clearfil Univesal Bond (Kuraray Dental, New York, United States of America), adhesive system
16482188|NCT03415412|Experimental|Group IU (Ibond Universal)|IBond Universal (Heraeus Kulzer GmbH, Hanau, Germany), adhesive system
16482189|NCT03415412|Experimental|Group GP (G-Premio)|G-Premio Bond (GC Coorporation, Tokyo, Japan), adhesive system
16482190|NCT03415399|Experimental|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
16482191|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
16482192|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
16482193|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
16482194|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
16482195|NCT03415373|Experimental|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
16482196|NCT03415360|Other|cryoablation|peripheral nerve cryoablation
16482197|NCT03415347|Active Comparator|Abscess de-roofing and curettage|Abscess de-roofing and curettage. The patient will be placed in the lateral position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. A spindle-shaped (elliptical) excision will be performed to the lateral aspect of the abscess formation with a scalpel staying away from the midline. Once the pus has been drained through this lateral incision the wound cavity will then be curetted and washed out with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
16482198|NCT03415347|Active Comparator|Abscess wide local excision|Wide local excision. Patients will be placed in the prone position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. Diluted methylene blue will be injected in all visible pits and a wide spindle-shaped (elliptical) midline excision of the skin and the underlying subcutaneous tissue down to the coccygeal (pre-sacral) fascia including all sinuses will be performed with electrocautery. The specimen will be sent for histology as per routine surgical practice. The wound will be washed with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
16482199|NCT03415334|Other|behavioral change|two approaches for behavior changes : social marketing and behavioral development
16482202|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
16482203|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
16482204|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
16482205|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
16482206|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
16482207|NCT03415282|Experimental|Open-label treatment arm|Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
16482208|NCT03415269|Experimental|20 mg ambroxol|20 mg ambroxol lozenge delivered once on one day
16482209|NCT03415256|Experimental|passive vibration group|The passive vibration group patients will receive passive vibration (50 Hz, one cycle= 60 seconds working time with 2 seconds rest time) on their calf in supine position for ten minutes. The total number of sessions will be nine. Passive vibration will be given to the treatment group twice a week for four weeks (eight sessions) and the ninth session will be the follow up. At every session, the skin blood flow will be measured before, immediately, and 15 minutes after passive vibration.
16482210|NCT03415256|Active Comparator|no passive vibration group|The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
16482211|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
16482212|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
16482213|NCT03415230|Experimental|Therapeutic massage|Women will undertake sessions of therapeutic massage
16482214|NCT03415230|Sham Comparator|Sham massage|Women will undertake sessions of sham massage
16482215|NCT03415217|Other|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
16482216|NCT03415204|Experimental|acupuncture|
16482217|NCT03415204|No Intervention|no acupuncture|
16482218|NCT03415191|Experimental|Ketamine Group|Five minutes before thoracotomy incision, Ketamine Group received a bolus dose of ketamine 1 mg/kg intravenously
16482219|NCT03415191|Placebo Comparator|Placebo Group|Five minutes before thoracotomy incision, Placebo Group received a bolus dose of normal saline 1 mg/kg intravenously
16482220|NCT03415178|Experimental|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
16482221|NCT03415178|Experimental|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
16482222|NCT03415165|Active Comparator|green tea buccal tablet|buccal tablet 3 times aday
16482223|NCT03415165|Sham Comparator|corticosteroids topical|topical steroids 3 times aday
16482224|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
16482225|NCT03415139||Arm 1 for MRD HCT Recipients|Patients undergo an Oral Glucose Tolerance Test (OGTT) and 1 hyperglycemic clamp will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
16482226|NCT03415139||Arm 2 for MRD HCT Recipients|Patients undergo 2 Oral Glucose Tolerance Test (OGTTs) (with and without GLP-1 infusion) will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
16482227|NCT03415126|Experimental|ASN007 ascending doses|Patients will receive escalating doses of ASN007 to identify the best dose.
16482228|NCT03415126|Experimental|ASN007 RD: KRAS mutant Melanoma|Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
16482229|NCT03415126|Experimental|ASN007 RD: NRAS mutant Melanoma|Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
16482230|NCT03415126|Experimental|ASN007 RD: KRAS mutant metastatic CRC|Patients with KRAS mutant CRC will receive the recommended dose from Part A
16482231|NCT03415126|Experimental|ASN007 RD: KRAS mutant NSCLC|Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
16482232|NCT03415126|Experimental|ASN007 RD: Metastatic Pancreatic Cancer|Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
16482233|NCT03415126|Experimental|ASN007 RD: MEK, All BRAF, BRAF-fusion cancers|Patients with solid tumors will receive the recommended dose from Part A
16482234|NCT03415100|Experimental|CAR-NK cells targeting NKG2D ligands|
16482235|NCT03415087|Active Comparator|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
16482495|NCT03413332|Placebo Comparator|Usual Care Group|receive usual care
16482236|NCT03415087|Experimental|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
16482237|NCT03415074|Active Comparator|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
16482238|NCT03415074|Active Comparator|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
16482241|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
16482242|NCT03415022|Experimental|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
16482243|NCT03415022|Experimental|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
16482244|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
16482245|NCT03414996|Experimental|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
16482246|NCT03414996|Active Comparator|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
16482249|NCT03414970|Active Comparator|Group I (radiation therapy)|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
16482250|NCT03414970|Experimental|Group II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
16482251|NCT03414957||Malay PCOS women|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who fulfilled these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria
16482252|NCT03414957||Malay women without PCOS|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who did not fulfill these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria.
16482253|NCT03414944|Experimental|SMART-Brain|selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.
16482254|NCT03414931|Experimental|NMDAE|An NMDA enhancer
16482255|NCT03414931|Active Comparator|SSRI|Sertraline
16482256|NCT03414931|Placebo Comparator|Placebo|Placebo
16482257|NCT03414918|Experimental|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
16482258|NCT03414905|Experimental|Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1
~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
16482259|NCT03414892|Experimental|Globalagliatin Hydrochloride (SY-004)|If subjects tolerate 20mg of Globalagliatin Hydrochloride (SY-004) for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
16482260|NCT03414892|Placebo Comparator|Placebo|If subjects tolerate 20mg of Placebo for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
16482261|NCT03414879|Active Comparator|Ketamine group|Nebulization with ketamine
16482262|NCT03414879|Active Comparator|Lidocaine group|Nebulization with with lidocaine
16482263|NCT03414866||Acute thoracic aortic syndrome|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
16482264|NCT03414866||Subacute/chronic dissection of the aorta|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
16482265|NCT03414866||Aortic aneurysm|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
16482266|NCT03414853||With algorithm use|
16482267|NCT03414853||No algorithm use|
16482268|NCT03414814|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
16482269|NCT03414801|Active Comparator|Cohort 1|Cat Allergic Subjects
16482270|NCT03414801|Active Comparator|Cohort 2|Non-Allergic Subjects will
16482271|NCT03414788|Experimental|Treatment Arm - PF 06687234 and [124I]IB PF 06687234|PF 06687234 and [124I]IB PF 06687234
16482272|NCT03414775|Active Comparator|Pediasure|Patients assigned to this arm will receive Pediasure
16482273|NCT03414775|Active Comparator|Nourish|Patients assigned to this arm will receive Nourish
16482302|NCT03414593|Experimental|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
16482303|NCT03414593|Active Comparator|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
16482274|NCT03414762|Experimental|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
16482275|NCT03414762|Active Comparator|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
16482276|NCT03414749|Experimental|Lower Extremity First (LEF)|The treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
16482277|NCT03414749|Experimental|Upper Extremity First (UEF)|The treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
16482278|NCT03414736|Experimental|Cohort 1|Daily dose escalation (click-by-click): Starting at dose 1 in the morning with daily increments to dose 2. During the escalation phase, the dose will only be increased if the patient is feeling fine.
16482279|NCT03414736|Experimental|Cohort 2|Weekly dose escalation in 6 escalation steps (7 dose levels): Starting at dose 1 injected in the morning with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
16482280|NCT03414736|Experimental|Cohort 3|Weekly dose escalation in 4 escalation steps (5 dose levels): Starting at dose 3 with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
16482281|NCT03414723|Experimental|SAR439954 with or without ramipril|"On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing.
~On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing."
16482282|NCT03414710|Experimental|Intervention group|"Health education booklet plus video plus brief counseling
~In addition to the educational booklet received by the control group, the intervention group will receive the following health promotion:
~Watch a 10-minute video promoting VMMC
~Receive a brief counseling promoting VMMC If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
16482283|NCT03414710|Active Comparator|Control group|"Health education booklet only After randomization took place, the control group will receive an education booklet introducing voluntary medical male circumcision.
~If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
16482284|NCT03414697|Other|Control group|Routine rehabilitation treatments
16482285|NCT03414697|Experimental|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
16482286|NCT03414697|Experimental|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
16482287|NCT03414697|Experimental|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
16482290|NCT03414671||historical control|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
16482291|NCT03414671||Standardized|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
16482292|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle
~Vinorelbine is administered intravenously 3 times per cycle"
16482293|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle
~Vinorelbine is administered intravenously 3 times per cycle
~Avelumab is administered intravenously twice per cycle
~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
16482294|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle
~Vinorelbine is administered intravenously 3 times per cycle
~Avelumab is administered intravenously twice per cycle
~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab
~Utomilumab is administered intravenously once per cycle"
16482295|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm
~Avelumab is administered intravenously twice per cycle
~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab
~Utomilumab is administered intravenously once per cycle
~Trastuzumab is administered intravenously twice per cycle"
16482296|NCT03414645|Experimental|CAM-101 10%|FD hPL 10 vol/vol %
16482297|NCT03414645|Experimental|CAM-101 30%|FD hPL 30 vol/vol %
16482298|NCT03414645|Placebo Comparator|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
16482299|NCT03414632|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
16482300|NCT03414619|Experimental|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
16482301|NCT03414619|Experimental|Non-psychiatric Control Group|A score 1 SD below the community mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
16482304|NCT03414580||Ulcerative colitis|Patients with ulcerative colitis whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
16482305|NCT03414580||Crohn's disease|Patients with crohn's disease whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
16482306|NCT03414580||Healthy control|Subject with no intestinal symptoms or no known gastrointestinal disorders. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
16482307|NCT03414567||Control Group|Non-smoker
16482308|NCT03414567||Study Group|Smoker
16482309|NCT03414554||HCV patients receiving DAAs|Patients with HCV-related liver cirrhosis (eligible for treatment) who will recieve DAAs therapy with one year follow up.markers: miR121, miR122, miR124will be assessed in both groups before and after DAAs
16482310|NCT03414541|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
16482311|NCT03414541|Experimental|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
16482312|NCT03414541|Experimental|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
16482313|NCT03414528||Patients with PID|
16482314|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
16482315|NCT03414502|Other|Single arm Methotrexate|"This study is a 16-week, open-label study designed to identify the subset of RA patients that respond to methotrexate monotherapy. All patients will receive methotrexate at a starting dose of 15 mg once weekly plus folic acid 1 mg daily. If a patient is not in remission by 8 weeks, then the dose will be escalated as tolerated to 20 mg once weekly. Both oral and injectable methotrexate are acceptable.
~If the patient is unable to tolerate the Methotrexate at 15 mg, it is allowed to titrate the dose as tolerated as long as patient remains on Methotrexate."
16482316|NCT03414476|Experimental|ET group|Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium
16482317|NCT03414476|Experimental|Control group|Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium
16482318|NCT03414463|Experimental|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
16482319|NCT03414463|Experimental|Waitlist Control|After Time 1 testing in Week 1, participants randomized to WLC will not receive any treatment during Weeks 2-5. The only staff interaction during this no treatment time period will be to schedule Time 2 testing appointment for week 6. After Time 2 testing, WLC will receive TREAT (weeks 14-17), followed up with testing.
16482320|NCT03414450|Experimental|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
16482321|NCT03414450|Experimental|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
16482322|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
16482323|NCT03414398||Experimental|Qualitative interview
16482324|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
16482325|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
16482326|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
16482327|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
16482328|NCT03414359|Active Comparator|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
16482329|NCT03414359|Experimental|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
16482330|NCT03414346|Experimental|Exclusively ice pack:|Ice pack application: 500 grams of crushed ice.
16482331|NCT03414346|Experimental|Ice pack added 10% of water:|Wetted ice pack application: 500 grams of crushed ice added to 50 mL of water at room temperature.
16482332|NCT03414346|Experimental|Ice pack added 100% of water:|Wetted ice pack application: 500 grams of crushed ice added to 500 mL of water at room temperature.
16482333|NCT03414333|Experimental|Roux-en- Y gastric bypass (RYGB)|Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
16482334|NCT03414333|Active Comparator|GLP-1|GLP-1 is an intestinal hormone secreted in response to nutrients.
16482335|NCT03414320|Experimental|Study Arm|We will gather data from this group of patients.
16482336|NCT03414307|Experimental|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
16482337|NCT03414294|Experimental|K-755 Part A (SAD)|
16482338|NCT03414294|Placebo Comparator|Placebo Part A (SAD)|
16482339|NCT03414294|Experimental|K-755 Part B (MAD)|
16482340|NCT03414294|Placebo Comparator|Placebo Part B (MAD)|
16482341|NCT03414294|Experimental|K-755 Part C (FE)|
16482342|NCT03414294|Experimental|K-755 Part D (FE)|
16482343|NCT03414294|Experimental|K-755 Part E (MAD)|
16482344|NCT03414294|Placebo Comparator|Placebo Part E (MAD)|
16482345|NCT03414281|Experimental|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
16482346|NCT03414281|Experimental|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
16482347|NCT03414281|Active Comparator|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
16482348|NCT03414268|Experimental|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
16482349|NCT03414268|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
16482350|NCT03414255|Experimental|Micronized DHACM|1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
16482351|NCT03414255|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
16482352|NCT03414242|Experimental|Cervical spine musculature|
16482353|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
16482354|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
16482355|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
16482356|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
16482357|NCT03414216|Experimental|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:
~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.
~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
16482358|NCT03414216|Active Comparator|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.
~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
16482359|NCT03414203|Active Comparator|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
16482360|NCT03414203|Experimental|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
16482361|NCT03414203|Sham Comparator|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
16482362|NCT03414190|Experimental|Experimental|Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
16482363|NCT03414190|No Intervention|No Intervention|Usual Care
16482364|NCT03414177|Active Comparator|Telemedicine Group|Telemedicine participants will have asthma subspecialty follow-up visits conducted via real-time audio and video conferencing in conjunction with electronic examination peripherals and remote pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
16482365|NCT03414177|Active Comparator|In-Person Group|In-Person participants will have asthma subspecialty follow-up visits at a subspecialty clinic. They will receive pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
16482366|NCT03414164|Experimental|procyanidine group|
16482367|NCT03414164|No Intervention|control group|
16482368|NCT03414151||Observational - Case Arm|All participants will be placed in this arm or group if they have an eligible psychiatric diagnosis as a case (there is no randomization procedure)
16482369|NCT03414151||Observational - Healthy Control Arm|All participants will be placed in this arm if they are healthy controls (there is no randomization procedure)
16482370|NCT03414138|Experimental|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
16482371|NCT03414138|Active Comparator|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
16482372|NCT03414125|Active Comparator|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).
~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.
~Centralized processes to promote guideline-based follow-up."
16482373|NCT03414125|Experimental|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.
~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.
~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).
~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.
~Centralized processes to promote guideline-based follow-up."
16482376|NCT03414099|Experimental|Ketum|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
16482377|NCT03414099|Placebo Comparator|Placebo|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
16482378|NCT03414086||Myositis in Remission|Subjects who are in remission with their myositis diagnosis.
16482379|NCT03414086||Healthy Controls|Subjects who do not have a myositis diagnosis.
16482380|NCT03414073|Sham Comparator|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
16482381|NCT03414073|Active Comparator|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
16482382|NCT03414073|Sham Comparator|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
16482383|NCT03414073|Active Comparator|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
16482384|NCT03414073|Sham Comparator|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
16482385|NCT03414073|Sham Comparator|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
16482386|NCT03414073|Sham Comparator|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
16482387|NCT03414073|Sham Comparator|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
16482388|NCT03414073|Active Comparator|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
16482389|NCT03414060|Experimental|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
16482424|NCT03413865|No Intervention|In person Visits|Patients are followed in person at the cancer clinic based on standard of care guidelines
16482496|NCT03413319|Experimental|ABBV-8E12|ABBV-8E12 administered by intravenous (IV) infusion.
16482394|NCT03414034|Experimental|Arm A: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.
16482395|NCT03414034|Experimental|Arm B: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
16482396|NCT03414034|Experimental|Arm C: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
16482397|NCT03414021||Thyroid Diseases|SPECT-CT Scan
16482398|NCT03414021||Heart Diseases|SPECT-CT Scan
16482399|NCT03414021||Bone Diseases|SPECT-CT Scan
16482400|NCT03414021||Brain Diseases|SPECT-CT Scan
16482401|NCT03414021||Kidney Diseases|SPECT-CT Scan
16482402|NCT03414008|Experimental|Active Drug Group|Single dose
16482403|NCT03414008|Placebo Comparator|Placebo Group|
16482404|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
16482405|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
16482406|NCT03413969|Experimental|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
16482407|NCT03413956||NSCLC patients with lymph metastases|Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
16482408|NCT03413943|Experimental|explicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
16482409|NCT03413943|Experimental|implicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
16482410|NCT03413943|Sham Comparator|sham gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
16482411|NCT03413930|Experimental|TaTME|Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
16482412|NCT03413930|Active Comparator|LaTME|Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
16482413|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
16482414|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
16482415|NCT03413904|Experimental|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
16482416|NCT03413904|Active Comparator|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
16482417|NCT03413891|Placebo Comparator|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
16482418|NCT03413891|Experimental|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
16482419|NCT03413878|Experimental|Wet snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a small air pocket
16482420|NCT03413878|Experimental|Dry snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a small air pocket
16482421|NCT03413878|Experimental|Wet snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a large air pocket
16482422|NCT03413878|Experimental|Dry snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a large air pocket
16482423|NCT03413865|Experimental|OTN virtual clinic|Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
16482425|NCT03413839|Experimental|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
16482426|NCT03413839|Other|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
16482427|NCT03413826|Experimental|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
16482428|NCT03413826|Experimental|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
16482429|NCT03413826|No Intervention|control|This group will remain sedentary for 12 weeks
16482430|NCT03413800|Experimental|Lenalidomide-Dexamethasone-DLI|"Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each
~For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg
~In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg
~If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg
~Patient will be followed for 5 years post relapse."
16482431|NCT03413774||Abortion group|910 women attended Fayoum University hospital outpatient gynecology clinic with recent first trimesteric spontaneous miscarriage
16482432|NCT03413774||Control group|940 women attended Fayoum University hospitalpresented for any other gynecological complaint
16482433|NCT03413748|Active Comparator|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
16482434|NCT03413748|Active Comparator|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
16482435|NCT03413735|Placebo Comparator|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
16482436|NCT03413735|Experimental|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
16482437|NCT03413722||Conversion Group|Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
16482438|NCT03413722||Control Group|Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
16482439|NCT03413709|Active Comparator|Treatment Group (n=350)|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour Family Formation Program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships,and economic stability and mobility. In addition, participants will receive case management and a variety of employment, legal and support services for up to one year following the completion of the curriculum.
16482440|NCT03413709|No Intervention|Comparison Group (n=350)|The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
16482441|NCT03413696||Not referred for HCV therapy|
16482442|NCT03413696||Referred for HCV therapy,did not show up|
16482443|NCT03413696||Referred,attended HCV therapy evaluation|
16482444|NCT03413657|Other|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
16482445|NCT03413657|Other|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
16482446|NCT03413631|Experimental|Prenatal mentalization intervention|The intervention group participants were offered three mentalization-focused 4D interactive ultrasounds at 24, 30 and 34 gestational weeks and a mentalization-focused week-by-week pregnancy diary combined with three prenatal sessions and option for one session after delivery in addition to obstetric care as usual (see Prenatal obstetric treatment as usual).
16482447|NCT03413631|Active Comparator|Prenatal obstetric treatment as usual|The control group received obstetric care as usual in a tertiary setting. The comprehensive treatment as usual was conducted at the hospital antenatal outpatient clinic, including regular obstetric ultrasounds. The multidisciplinary treatment team, consisting of an obstetrician, a midwife, a social worker and a psychiatric nurse, assess and support health and psychosocial situation of the pregnant woman. The pregnant woman was referred to addiction and psychiatric treatment when needed.
16482448|NCT03413618|Experimental|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
16482449|NCT03413618|Active Comparator|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
16482450|NCT03413605|Experimental|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
16482451|NCT03413605|No Intervention|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
16482452|NCT03413592|Other|Driving test|
16482491|NCT03413358|Experimental|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
16482492|NCT03413345||subjects without a history of cardiac disease|
16482453|NCT03413579|Experimental|Nimotuzumab|"Injection of 200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.
~The objective of the present study is to assess the overall survival of patients after administration of Nimotuzumab hR3 monoclonal antibodies (combined with a chemotherapy) in the treatment of patients with cervix epithelial tumors as first-line treatment.
~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.
~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
16482454|NCT03413579|Placebo Comparator|Placebo|"Injection of the Placebo in the same procedures (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.
~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.
~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
16482455|NCT03413566||Children with clinical diagnosis of CP|All children residing in Norway with a validated diagnosis of cerebral palsy.
16482456|NCT03413566||Children without CP|All children residing in Norway without a diagnosis of cerebral palsy.
16482457|NCT03413553|Active Comparator|control group|patient will receive immediate implant alone.
16482458|NCT03413553|Other|intervention group|"immediate implant combined with connective tissue graft and platelet rich fibrin .
~."
16482459|NCT03413540|Experimental|Group 1|10-cm step, 10 reps
16482460|NCT03413540|Experimental|Group 2|10-cm step, 50 reps
16482461|NCT03413540|Experimental|Group 3|10-cm step, 100 reps
16482462|NCT03413540|Experimental|Group 4|20-cm step, 10 reps
16482463|NCT03413540|Experimental|Group 5|20-cm step, 50 reps
16482464|NCT03413540|Experimental|Group 6|20-cm step, 100 reps
16482465|NCT03413540|Experimental|Group 7|30-cm step, 10 reps
16482466|NCT03413540|Experimental|Group 8|30-cm step, 50 reps
16482467|NCT03413540|Experimental|Group 9|30-cm step, 100 reps
16482468|NCT03413540|No Intervention|Group 10|Control
16482469|NCT03413527|Experimental|rTMS Treatment|
16482470|NCT03413514|Experimental|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
16482471|NCT03413501|No Intervention|Treatment as usual|Receives treatment as usual at the clinic
16482472|NCT03413501|Experimental|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
16482473|NCT03413488|Experimental|Kinesio taping|subject with shoulder impingement syndrome
16482474|NCT03413488|Active Comparator|Exercise|subject with shoulder impingement syndrome
16482475|NCT03413462|Active Comparator|HS-25|20mg, QD, 12 weeks
16482476|NCT03413462|Placebo Comparator|Placebo of HS-25|20mg, QD, 12 weeks
16482477|NCT03413449||Resections|Frailty model for patients undergoing esophagectomy and pneumonectomy/lobectomy for cancer
16482478|NCT03413436|Experimental|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
16482479|NCT03413436|Active Comparator|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
16482480|NCT03413423|Experimental|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
16482481|NCT03413423|Active Comparator|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
16482482|NCT03413410|Experimental|Metoprolol interventional group|"This is a multi-center, prospective, open label, single-arm interventional study.
~Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study."
16482483|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone
~Dosage form: crystalline powder for intramuscular injection
~Dose(s): 1 g
~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
16482484|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
16482485|NCT03413371|Experimental|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
16482486|NCT03413371|Experimental|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
16482487|NCT03413371|Experimental|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
16482488|NCT03413371|Experimental|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
16482489|NCT03413371|Experimental|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
16482490|NCT03413358|Experimental|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
16482493|NCT03413345||subjects with a history of cardiac disease|
16482500|NCT03413280|Experimental|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml Before surgical incision
16482501|NCT03413280|Active Comparator|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml After surgical incision
16482502|NCT03413267|Experimental|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
16482503|NCT03413267|Experimental|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
16482504|NCT03413267|Experimental|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
16482505|NCT03413267|Experimental|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
16482506|NCT03413254|Active Comparator|2nd look DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up according to the Dutch colorectal cancer guideline until 5 years.
16482507|NCT03413254|Experimental|2nd and 3rd DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up and third look DLS after negative CT abdomen at 18 months and normal CEA. Third look DLS is not performed in patients with evidence of disease that is not curable, or in those already diagnosed with PM in the preceding period.
16482508|NCT03413228||Influenza-like illness group|
16482509|NCT03413215|No Intervention|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
16482510|NCT03413215|Experimental|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
16482511|NCT03413202|Experimental|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
16482512|NCT03413202|Placebo Comparator|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
16482513|NCT03413189||PREDICT participants|This cohort is obtained from the PREDICT study enrolment (approx. 500) and a review of their medical records will be conducted
16482514|NCT03413189||PREDITCABLE participants|This is a nested cohort of patients recruited into PREDICT (approx. 40) that consent for a physiotherapist home visit to assess their physical and cognitive function and perform and interview to obtain themes regarding recovery
16482515|NCT03413163|Sham Comparator|control|"Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
~Intervention: Other: Standard Pain Followup and Monitorization"
16482516|NCT03413163|Experimental|ESP block|"In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
~Interventions:
~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
16482517|NCT03413150||severely ill patients receiving amiodarone for ATs|cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital.Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent atrial tachycardia during their hospitalization in the ICU.
16482518|NCT03413137|Active Comparator|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
16482519|NCT03413137|Active Comparator|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
16482520|NCT03413124|Active Comparator|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
16482521|NCT03413124|Active Comparator|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
16482522|NCT03413111|Experimental|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
16482523|NCT03413111|No Intervention|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
16482524|NCT03413098|Experimental|Trial nasal Continuous Positive Airway Pressure (CPAP) mask|Trial nasal CPAP mask
16482525|NCT03413085|Other|Group A|"Intervention name: multifocal soft contact lens/single vision soft contact lens
~Left eye: multifocal soft contact lens Right eye: single vision soft contact lens"
16482956|NCT03409627|Experimental|Group 2|Single infusion of INXN-4001, Dose 2
16482526|NCT03413085|Other|Group B|"Intervention name: multifocal soft contact lens/single vision soft contact lens
~Left eye: single vision soft contact lens Right eye: multifocal soft contact lens"
16482527|NCT03413059|Active Comparator|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
16482528|NCT03413059|Active Comparator|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
16482529|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
16482530|NCT03413046||Control|30 healthy children
16482531|NCT03413033||Group 1|43 participants will produce the vowel /a:/ three times as baseline during 5 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce series of a semi-occluded vocal tract exercises (resonance tube or lip trill). Afterwards, subjects will produce the vowel /a:/ three times once again. Electroglottographic signals will be captured before and after each exercise. A 15 minutes voice rest will be taken between exercises by all subjects.
16482532|NCT03413020|Experimental|Tailored Therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
16482533|NCT03412994|Experimental|Apatinib group|"Apatinib combined with second-line chemotherapy (5-Fu combined with irinotecan or oxaliplatin standard regimen ) Apatinib tablets: 500 mg po qd . Continuous medication, the cycle is consistent with the chemotherapy cycle.
~Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）"
16482534|NCT03412994|Placebo Comparator|Control group|Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）
16482535|NCT03412968|Experimental|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
16482536|NCT03412968|Active Comparator|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
16482537|NCT03412955|Experimental|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
16482538|NCT03412942|Other|Treatment with FISH device|Vascular closure to be performed with FISH device.
16482539|NCT03412929|Experimental|Honey Impregnated Dressing|Honey Impregnated Dressing
16482540|NCT03412916|Experimental|GetActive|The GetActive program uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The GetActive sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is a 10-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions.
16482541|NCT03412916|Experimental|GetActive with Fitbit|The GetActive with Fitbit is identical to that of the p3RP with the addition of a digital monitoring device (i.e., Fitbit) for recording of physical activity.
16482542|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
16482543|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
16482544|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
16482545|NCT03412890|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 28 weeks.
16482546|NCT03412877|Experimental|1/iTCR|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high or low-dose aldesleukin
16482547|NCT03412877|Experimental|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
16482548|NCT03412851||A Direct Aspiration First Pass Technique|
16482549|NCT03412851||Stentriever Thrombectomy|
16482550|NCT03412838|Active Comparator|Cortico-Cancellous|Graft surgery with cortico-cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
16482551|NCT03412838|Active Comparator|Cancellous|Graft surgery with cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
16482552|NCT03412825|Experimental|Nutrition Supplementation|
16482553|NCT03412825|No Intervention|Control|
16482554|NCT03412812|Experimental|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
16482555|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
16482556|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
16482557|NCT03412773|Experimental|Arm A: Tislelizumab & Safety Run-In Substudy [Japan Only]|
16482558|NCT03412773|Active Comparator|Arm B: Sorafenib|
16482786|NCT03410888|Experimental|popliteal approach|Blockade of the sciatic nerve at the level of the popliteal fossa.
16482957|NCT03409614|Other|Chemo|Part 1: Chemotherapy
16482559|NCT03412760|Experimental|Exome sequencing|There is only one arm of this study. All enrolled participants with unexplained NIHF or other birth defect will be offered exome sequencing for the affected fetus or neonate. Please refer to the Study Design section for further details.
16482560|NCT03412747|Experimental|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
16482561|NCT03412747|Experimental|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
16482562|NCT03412747|Active Comparator|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
16482563|NCT03412734|Experimental|Chlorhexidine group|
16482564|NCT03412734|Active Comparator|Iodine group|
16482565|NCT03412721|Experimental|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
16482566|NCT03412721|Placebo Comparator|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
16482567|NCT03412708|Active Comparator|Vestibular Rehabilitation|"Vestibular Rehabilitation Program Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking
~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
16482568|NCT03412708|Experimental|Vestibular Rehabilitation supported with Virtual Reality|"Patients will perform the exercises in a virtual reality environment using a virtual reality goggle and a smartphone.The virtual environments consist of 2 media provided by the videos taken with a 360 camera . 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full. Exercises conducted while sitting and standing on a soft ground will happen in the 1st environment, and the ones on the treadmill will happen in the 2nd environment.
~Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking
~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
16482569|NCT03412695|Experimental|Arm A|Use of the MyFood tool among patients and nurses (intervention group)
16482570|NCT03412695|No Intervention|Arm B|No intervention. Regular hospital routines
16482571|NCT03412682|Experimental|Budesonide (6 mg)|
16482572|NCT03412682|Experimental|Budesonide (9 mg)|
16482573|NCT03412682|Active Comparator|Mesalazine (3,600 mg)|
16482574|NCT03412669|Experimental|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
16482575|NCT03412669|Active Comparator|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
16482576|NCT03412656|Experimental|Patient|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing the subjects' own prosthetic sockets. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
16482577|NCT03412656|Other|Control|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing an adapter simulating a prosthetic socket. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
16482578|NCT03412643|Experimental|Arm 1|"Celcuity CELx HSF Test on tumor material obtained from research core biopsy to select patients with abnormal HER2 signaling tumors
~Doxorubicin + cyclophosphamide followed by Weekly Paclitaxel +Trastuzumab+Pertuzumab"
16482579|NCT03412630|Experimental|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
16482598|NCT03412487|Active Comparator|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
16482599|NCT03412474|Active Comparator|Bupivacaine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
16482600|NCT03412474|Active Comparator|Dexmedetomidine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
16482580|NCT03412604|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
16482581|NCT03412591|Other|Open label trial of suvorexant in SUDs|It is an open label trial to study the efficacy of suvorexant in a group of opioid use and alcohol use disorder subjects.
16482582|NCT03412578|No Intervention|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
16482583|NCT03412578|Active Comparator|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
16482584|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
16482585|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
16482586|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
16482587|NCT03412565|Experimental|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
16482588|NCT03412552||severe preeclampsia without HELLP syndrome|severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure >160 mm/ Hg or diastolic blood pressure >110 mm/Hg, headache, epigastric or right-upper-quadrant pain, visual disturbances,pulmonary edema, and proteinuria (urinary protein level >5 g/24 h).Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/ mm3, serum lactate dehydrogenase <600 IU /dL, serum total bilirubin <1.2 mg/dL and serum aspartate aminotransferase <70IU/L
16482589|NCT03412552||eclampsia without HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded
16482590|NCT03412552||eclampsia with HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded.HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
16482591|NCT03412552||HELLP syndrome without eclampsia|HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
16482592|NCT03412526|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day
~Preparation and administration of unselected or 4-1BB enriched TIL
~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
16482593|NCT03412513|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
16482594|NCT03412513|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
16482595|NCT03412500|Active Comparator|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
16482596|NCT03412500|Experimental|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
16482597|NCT03412487|Active Comparator|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level >20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
16482698|NCT03411551|Experimental|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
16482699|NCT03411538||Hospital-acquired bacterial infection|
16482601|NCT03412461|Experimental|Thought Spot Application|Participants randomly assigned to the experimental arm will have access to the Thought Spot application. The Thought Spot application is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area. This group will continue to have access to usual care.
16482602|NCT03412461|Active Comparator|Resource pamphlet|Participants randomly assigned to the active comparator will receive a pamphlet that outlines mental health services and wellness services across the Greater Toronto Area. This group will continue to have access to usual care.
16482603|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
16482604|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
16482605|NCT03412409|Experimental|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.
~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
16482606|NCT03412396|Experimental|Treatment (apalutamide, radical prostatectomy)|Patients receive apalutamide PO daily for 24 weeks in the absence of disease progression or unacceptable toxicity. Within 2 weeks of completing apalutamide, patients undergo radical prostatectomy.
16482607|NCT03412370||Observational (questionnaires, cognitive assessment)|Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.
16482608|NCT03412357|Experimental|pleurectomy/decortication|
16482609|NCT03412357|Experimental|indwelling pleural catheter|
16482610|NCT03412331|Active Comparator|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
16482611|NCT03412331|Experimental|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
16482612|NCT03412318|Experimental|Twisted file|Use of twisted file during cleaning and shaping of root canals
16482613|NCT03412318|Active Comparator|Mpro|Use of Mpro file during cleaning and shaping of root canals
16482614|NCT03412305|Active Comparator|Amoxicillin oral tablets|2 g amoxicillin tablets orally 1 hour before implant placement
16482615|NCT03412305|Placebo Comparator|Placebo|Placebo tablets orally 1 hour before implant placement
16482616|NCT03412292|Experimental|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).
~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
16482617|NCT03412266|Other|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.
~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
16482618|NCT03412240|Experimental|Anti tachycardia pacing|
16482619|NCT03412227|Other|Principal Anxiety Disorder|Youth with a principal anxiety disorder
16482620|NCT03412227|Other|Principal Depressive Disorder|Youth with a principal unipolar depressive disorder
16482621|NCT03412201|Active Comparator|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
16482622|NCT03412201|Experimental|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
16482625|NCT03412175|Experimental|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
16482626|NCT03412175|No Intervention|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
16482627|NCT03412162|Experimental|Ethnic and Racial Identity Promotion|Students will participate in 8, 1 hour and 15 minute classroom based intervention sessions at their local high school, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to promote a positive ethnic and racial identity (positive feelings about ones' ethnic and racial heritage and ethnic and racial group membership).
16482628|NCT03412162|Active Comparator|Academic Skills Promotion|Students in this active comparison group will participate in an 8-week, 1 hour and 15 minute classroom based intervention, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to provide information regarding college and career planning, and promote college and career planning as well as study skills and strategies. This condition receives the same amount of facilitator time and attention as the Experimental condition.
16482629|NCT03412149|Active Comparator|Mini Gastric Bypass|Mini Gastric Bypass: The gastric pouch will be performed starting below the incisura angularis (transverse resection 4 cm) on the lesser curvature (18).Then the stomach will be transected against a 36 Fr bougie up to the gastro-esophageal junction Then 1/3 of the small bowel will be excluded (approximately 200cms) and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler.
16482630|NCT03412149|Active Comparator|Roux en Y Gastric Bypass|Roux en Y Gastric Bypass: The steps of the standard double loop RYGB technique will be followed (17). The gastric pouch will be created 7 cm from the gastro-esophageal junction to obtain a volume of 30-40 ml, and the length of the alimentary limb will be 150 cm and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler. The length of the biliopancreatic limb will be from 65 to 75 cm beyond the ligament of Treitz. The lengths of both limbs should carefully measured with a graduated instrument. The mesenteric defects will be closed.
16482631|NCT03412136|Experimental|Control|
16482632|NCT03412136|Experimental|Glucose|
16482633|NCT03412136|Experimental|Protein|
16482634|NCT03412123|Experimental|gLiFE pilot group|
16482635|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
16482636|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
16482637|NCT03412071|No Intervention|Control group|25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.
16482638|NCT03412071|Active Comparator|Oral tinidazole group|25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.
16482639|NCT03412071|Active Comparator|Topical metronidazole (0.75%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.
16482640|NCT03412071|Active Comparator|Topical clindamycin (2%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.
16482641|NCT03412071|Active Comparator|Topical hydrogen peroxide (1%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.
16482642|NCT03412058|Experimental|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
16482643|NCT03412058|Experimental|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
16482644|NCT03412058|Experimental|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
16482645|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
16482646|NCT03412032|Other|ERC|Assessment as used by the European Resuscitation Council
16482647|NCT03412032|Other|AHA|Assessment as used by the American Heart Association
16482648|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
16482649|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
16482650|NCT03412006|Experimental|Fulacimstat (BAY1142524)|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
16482651|NCT03412006|Placebo Comparator|Placebo|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
16482652|NCT03411980|Experimental|Subjects with moderately decreased renal function|Subjects with moderate renal impairment with an estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m*2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
16482653|NCT03411980|Experimental|Subjects with severely decreased renal function|Subjects with severe renal impairment not on dialysis with an eGFR <30 mL/min/1.73 m*2 (CKD-EPI formula).
16482654|NCT03411980|Experimental|Control subjects with normal renal function|Subjects with an eGFR ≥90 mL/min/1.73 m*2 (CKD-EPI formula) who are matched based on sex, age, race and weight.
16482655|NCT03411967|Experimental|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
16482656|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
16482756|NCT03411148|Experimental|Exercise Group A|Weekly exercise sessions with physical therapist and psychologist
16482757|NCT03411148|Placebo Comparator|Exercise Group B|Home-based exercises
16482657|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
16482658|NCT03411928|Experimental|Tracheolator|Tracheal dilatation using the study device as per the protocol.
16482659|NCT03411915|Experimental|XmAb18087|XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles
16482660|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
16482661|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
16482662|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
16482663|NCT03411876|Experimental|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
16482664|NCT03411876|Experimental|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
16482665|NCT03411863|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
16482666|NCT03411850|Active Comparator|Orencia (Abatacept)|Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
16482667|NCT03411850|Placebo Comparator|Placebo|Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
16482668|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
16482669|NCT03411811|Active Comparator|Usual Care|
16482670|NCT03411811|Experimental|Dextrose|
16482671|NCT03411798|Experimental|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
16482672|NCT03411785|Experimental|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
16482673|NCT03411785|No Intervention|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
16482674|NCT03411772|Active Comparator|TAP block|Patients undergoing bariatric surgery having TAP block upon completion of the procedure
16482675|NCT03411772|Sham Comparator|Non TAP block|Patients undergoing bariatric surgery without having TAP block
16482676|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
16482677|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
16482678|NCT03411720|Experimental|FES-row-training|Subjects will perform 4 months of FES-row-raining
16482679|NCT03411720|Other|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
16482680|NCT03411720|Active Comparator|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
16482681|NCT03411707||Mutiple screening test group|
16482682|NCT03411681|Active Comparator|Normal Weight|
16482683|NCT03411681|Experimental|Obese|
16482684|NCT03411668|Experimental|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
16482685|NCT03411668|No Intervention|Usual Educational Programme|Without intervention. The participants in this group will be maintain usual educational programme.
16482686|NCT03411655|Active Comparator|Ambu® Aura-ITM|
16482687|NCT03411655|Active Comparator|Ambu Aura GainTM|
16482688|NCT03411603||INCA2 2006-07|"French National Dietary Intake Survey, conducted in 2006-2007 by the French Agency for Food, Environmental and Occupational Health Safety.
~Adults aged 18y and over, n=1918 included in the analyses."
16482689|NCT03411603||NHANES 2011-12|Wave 2011-12 of the National Health and Nutrition Examination Survey, the US national dietary intake Survey, conducted by the Centers for Disease Control and Prevention (CDC) Adults aged 18y and over, n=5073 included in the analyses.
16482690|NCT03411590|Other|200ml|Toddlers will be allocated to the 200 ml group
16482691|NCT03411590|Other|400ml|Toddlers will be allocated to the 400 ml group
16482692|NCT03411590|Other|600ml|Toddlers will be allocated to the 600 ml
16482693|NCT03411577|Experimental|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
16482694|NCT03411577|No Intervention|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
16482695|NCT03411564|Experimental|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
16482696|NCT03411564|No Intervention|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
16482697|NCT03411551|Active Comparator|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
16482700|NCT03411525|Experimental|Commitment invitation at time 1|In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
16482701|NCT03411525|Experimental|Commitment invitation at time 2|In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
16482702|NCT03411525|Experimental|Commitment invitation at time 3|In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
16482703|NCT03411525|Experimental|Commitment invitation at time 4|In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
16482704|NCT03411525|Experimental|Commitment invitation at time 5|In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
16482705|NCT03411525|Experimental|Commitment invitation at time 6|In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
16482706|NCT03411525|Experimental|Commitment invitation at time 7|In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
16482707|NCT03411525|Experimental|Commitment invitation at time 8|In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
16482708|NCT03411512||CHD|Newborns with structural congenital heart defects. The exclusion criteria were pulmonary or neurological disease, perinatal asphyxia, acute illness, prematurity and congenital abnormality other than CHD.
16482709|NCT03411512||Healthy controls|The control group comprised of healthy matched newborns without a diagnosed CHD.
16482710|NCT03411499|Experimental|Early surgery|Surgery within 72 hours from endocarditis diagnosis
16482711|NCT03411499|Active Comparator|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
16482712|NCT03411473|Experimental|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
16482713|NCT03411460|Experimental|Interstitial glucose|Glucose level tested by continuous monitoring device
16482714|NCT03411460|Active Comparator|Blood glucose|Glucose level tested on glucose monitor using standard finger prick
16482715|NCT03411447|Active Comparator|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
16482716|NCT03411447|Active Comparator|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
16482717|NCT03411434|Experimental|ADHD patients|90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
16482718|NCT03411421|Experimental|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
16482719|NCT03411421|Experimental|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
16482720|NCT03411408|Experimental|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
16482721|NCT03411395|Placebo Comparator|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
16482722|NCT03411395|Experimental|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
16482723|NCT03411395|Experimental|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
16482724|NCT03411395|Experimental|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
16482725|NCT03411382|Experimental|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
16482726|NCT03411382|Experimental|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
16482727|NCT03411382|Experimental|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
16482728|NCT03411382|Placebo Comparator|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
16482958|NCT03409614|Experimental|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
16482729|NCT03411369|Experimental|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
16482730|NCT03411369|Placebo Comparator|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
16482731|NCT03411356|Active Comparator|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
16482732|NCT03411356|Experimental|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
16482733|NCT03411343|Active Comparator|Interscalene Block|Patients randomized to receive an intesrcalene block.
16482734|NCT03411343|Experimental|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
16482735|NCT03411330|Active Comparator|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.
~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
16482736|NCT03411330|Active Comparator|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.
~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
16482737|NCT03411291||Diet: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.
16482738|NCT03411291||Statin: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.
16482739|NCT03411278|Experimental|Deep Oscillation (DO) self treatment|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2). The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
16482740|NCT03411278|No Intervention|No intervention, control|No intervention
16482741|NCT03411265|Experimental|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
16482742|NCT03411252|Experimental|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
16482743|NCT03411252|Placebo Comparator|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
16482744|NCT03411239|Other|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
16482745|NCT03411226||re-TREPP|Patients who presented with a recurrent inguinal hernia after previous TREPP repair.
16482746|NCT03411213|Experimental|Vascular function|Diffuse optical tomography detection of differences in vascular function between healthy volunteers and patients with proven heart disease or diabetes.
16482747|NCT03411213|Experimental|Coronary artery disease|Diffuse optical tomography prediction of presence or severity of coronary artery disease on angiography.
16482748|NCT03411200|Experimental|Intervention group (n=50)|Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.
16482749|NCT03411200|No Intervention|Control group (n=50)|Participants in the control group will receive usual care.
16482750|NCT03411187|Active Comparator|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
16482751|NCT03411187|Placebo Comparator|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
16482752|NCT03411174|Experimental|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
16482753|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously every two weeks at different doses on D1 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
16482754|NCT03411161|Active Comparator|paclitaxel phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.
~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m² during a 28-day cycle."
16482755|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.
~S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
16482758|NCT03411122|Experimental|Single-sequence 3-period|Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9
16482759|NCT03411109||Opioid Only Intrathecal|
16482760|NCT03411109||Opioid + Local Anesthetic Intrathecal|
16482761|NCT03411096|Experimental|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
16482762|NCT03411096|Placebo Comparator|Placebo|Quadratus lumborum block with normal saline
16482763|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
16482764|NCT03411070|Experimental|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
16482765|NCT03411057||Mindfulness Based Stress Reduction (MBSR)|Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) and scleroderma participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
16482766|NCT03411057||Control|Rheumatoid Arthritis, Psoriatic Arthritis, and scleroderma participants in this group will watch an educational stress reduction video (10 minutes).
16482767|NCT03411044||Subjects with a Fitmore Hip Stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem
16482768|NCT03411031|Active Comparator|A: Elotuzumab + Lenalidomide at 25 mg|"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.
~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule."
16482769|NCT03411031|Active Comparator|B: Elotuzumab + Lenalidomide at 10 mg|"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.
~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule."
16482770|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
16482771|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
16482772|NCT03411005|Experimental|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.
~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
16482773|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
16482774|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
16482775|NCT03410992|Experimental|Bimekizumab Escape arm|Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
16482776|NCT03410979|Experimental|GLPG2737 single dose|Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
16482777|NCT03410979|Placebo Comparator|Placebo single dose|Single doses of Placebo oral suspension
16482778|NCT03410979|Experimental|GLP2737 multiple dose|Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
16482779|NCT03410979|Placebo Comparator|GLPG2737 multiple dose|Multiple doses of Placebo oral suspension
16482780|NCT03410966|Experimental|Intervention group|All patients affected by paroxysmal symptomatic atrial fibrillation, and anti-arrhythmic drug refractory atrial fibrillation will receive a trans catheter ablation therapy (intervention).
16482781|NCT03410953|Experimental|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:
~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
16482782|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
16482783|NCT03410927|Experimental|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
16482784|NCT03410914|Experimental|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
16482785|NCT03410901|Experimental|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
16482787|NCT03410888|Active Comparator|infragluteal approach|Blocking the sciatic nerve at the subgluteal level.
16482788|NCT03410875|Experimental|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
16482789|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
16482790|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
16482791|NCT03410849|Active Comparator|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
16482792|NCT03410849|Active Comparator|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
16482793|NCT03410836|Experimental|intravenous lidocaine (IVL)|Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
16482794|NCT03410836|Placebo Comparator|Placebo|Will receive the same volume of normal saline for the entire duration of anesthesia.
16482795|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
16482796|NCT03410810||Infant Control Group|The control arm (term born Infants) will receive an MRI at neonatal age and neurodevelopmental follow-up assessments, investigators will then compare significant morphological and diffusion properties within the brain to those of a Preterm brain.
16482797|NCT03410810||Infant Preterm Group|The experimental group will consist of preterm infants, who will receive an MRI at neonatal age and neurodevelopmental assessments. This groups scans will then be compared to those of the control arm. Significant biomarkers will then be identified.
16482798|NCT03410810||Childhood Control Group|The experimental group will consist of preterm born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children control arm. Significant biomarkers will then be identified.
16482799|NCT03410810||Childhood Preterm Group|The experimental group will consist of term born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children preterm group. Significant biomarkers will then be identified.
16482800|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
16482801|NCT03410784|Other|First-line chemotherapy with pembrolizumab|"Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles
~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
16482802|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
16482803|NCT03410771||ICU patients on piperacillin/tazobactam|
16482804|NCT03410771||ICU patients on meropenem|
16482805|NCT03410771||ICU patients on vancomycin|
16482806|NCT03410745|Experimental|Exercise group|
16482807|NCT03410745|No Intervention|Control group|
16482808|NCT03410732|Experimental|Radical surgery plus activated DCs|In 21 days after a radical surgery, activated DCs are iv infused
16482809|NCT03410732|Active Comparator|Radical surgery only|Radical surgery only group as a control group
16482810|NCT03410719|Experimental|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
16482811|NCT03410719|Experimental|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
16482812|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
16482813|NCT03410693|Experimental|Rogaratinib|"Rogaratinib treatment study arm, comprising
~Pre-treatment period, including FGFR testing and screening,
~Treatment period, and
~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
16482843|NCT03410472|Experimental|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
16482814|NCT03410693|Active Comparator|Chemotherapy|"Chemotherapy treatment study arm, comprising
~Pre-treatment period, including FGFR testing and screening,
~Treatment period, and
~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
16482815|NCT03410680|No Intervention|Control arm|Patients will receive the standard of care at the clinic. Questionnaires will be applied 4 times in a period of 10 months
16482816|NCT03410680|Experimental|Intervention arm|"Each participant will receive FUERTES for a period of 4 months. It consists of receiving a habit-formation kit, which include an information and habit-formation tool that can be accessed through a web platform, a mobile app and a booklet; b) pill cases; c) a fidget cube; and f) a notebook. Patients will have the option of contacting a MD though WhatsApp regarding questions related to their treatment.
~After completing baseline a questionnaire, patients with a score of 2 for barriers that might affect their ART adherence will be assigned a coach. The coach will have 7 one-on-one sessions with the patient in a period of 4 months in order to catalyze ART adherence. MSM living with HIV who have been taking ART for >3 years will provide a one-time one-on-one peer support session"
16482817|NCT03410667|Other|Standard Care|Standard of care arm
16482818|NCT03410667|Experimental|Intervention Arm|Intervention arm
16482819|NCT03410654|Experimental|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
16482820|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
16482821|NCT03410641||Control|No intervention
16482822|NCT03410628|Experimental|gammaCore Active Device|open label
16482823|NCT03410615|Active Comparator|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
16482824|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).
~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
16482825|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|ARM CLOSED TO ACCRUAL WITH AMENDMENT #1
16482826|NCT03410602|Placebo Comparator|Supragingival and subgingival scaling|Supragingival and subgingival scaling group comprised of 15 orthodontic patients treated with routine full-mouth supragingival scaling and subgingival scaling only around all banded first molars. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
16482827|NCT03410602|Active Comparator|Subgingival irrigation|Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
16482828|NCT03410589||Single arm|
16482829|NCT03410576||Carotid artery stenting|Patients undergo carotid artery stenting.
16482830|NCT03410576||Carotid endarterectomy|Patients receive elective carotid endarterectomy.
16482831|NCT03410563||Healthy participants|
16482832|NCT03410550|Experimental|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
16482833|NCT03410537|Experimental|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
16482834|NCT03410537|Placebo Comparator|Placebo|Placebo 2.4mg/d for 12 weeks
16482835|NCT03410524|Active Comparator|Simethicone with PEG-3350 bisacodyl preparation|"Treatment arm:
~200 mg Simethicone in 3 mL of liquid formulation mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
16482836|NCT03410524|Placebo Comparator|Placebo with PEG-3350 bisacodyl preparation|"Placebo arm:
~3 mL of water mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
16482837|NCT03410511|Experimental|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
16482838|NCT03410511|Experimental|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake.
16482839|NCT03410511|Experimental|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
16482840|NCT03410498|Other|MS group|This group will perform walking trials in various conditions, i.e. normal walking, walking whilst performing an attention demanding task and walking while being physically tired.
16482841|NCT03410485|Active Comparator|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
16482842|NCT03410485|Experimental|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
16482844|NCT03410472|No Intervention|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
16482845|NCT03410459|Active Comparator|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
16482846|NCT03410459|Active Comparator|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
16482847|NCT03410446|Experimental|Ketamine|"Three doses of ketamine will be given intranasal:
~Dose 1 will be 50 mg on Day 1
~Dose 2 will be between 50-100 mg on Day 4
~Dose 3 will be between 50-150 mg on Day 7"
16482848|NCT03410433|Active Comparator|Silk 4.0|Silk suture
16482849|NCT03410433|Active Comparator|PG910 4.0|Vicryl Rapid suture
16482850|NCT03410433|Experimental|PP 4.0|Non-absorbable polypropylene monofilament
16482851|NCT03410433|Active Comparator|Silk 5.0|Silk suture
16482852|NCT03410433|Active Comparator|PG910 5.0|Vicryl suture
16482853|NCT03410433|Experimental|PP 5.0|Non-absorbable polypropylene monofilament
16482854|NCT03410433|Experimental|APG 5.0|Antibacterial Vicryl suture
16482855|NCT03410433|Experimental|ePTFE 5.0|expanded polytetrafluoroethylene
16482856|NCT03410420|Active Comparator|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
16482857|NCT03410420|Experimental|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
16482858|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
16482859|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.
~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23
~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24
~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
16482860|NCT03410381|Experimental|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
16482861|NCT03410368|Experimental|autologous natural killer cells|Infusion of 1-2×10^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.
16482862|NCT03410368|No Intervention|routine follow-up|According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.
16482863|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
16482864|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
16482865|NCT03410342|Placebo Comparator|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.
~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
16482866|NCT03410342|Experimental|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
16482867|NCT03410342|Experimental|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
16482868|NCT03410329|Experimental|High weekly training frequency|three sessions a week of resistance training
16482869|NCT03410329|Experimental|Low weekly training frequency|one workouts per week
16482870|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
16482871|NCT03410303|Other|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
16482872|NCT03410290||Group 1|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
16482873|NCT03410277|Experimental|All Subjects|Experimental hypoglycemia
16482874|NCT03410264|Experimental|CR-EXP|Cognitive restructuring before exposure with response prevention (45 minute intervention).
16482875|NCT03410264|Experimental|EXP-CR|Exposure with response prevention before cognitive restructuring (45 minute intervention).
16482876|NCT03410264|Active Comparator|Stress Management|Stress management skills.
16482877|NCT03410238|Experimental|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
16482878|NCT03410238|No Intervention|Control|Participants receive a brochure containing psycho-education and resources only.
16482879|NCT03410225|Experimental|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
16482880|NCT03410225|Active Comparator|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
16482881|NCT03410212|Active Comparator|Ketorolac Tromethanine|In the experimental group, 30mg/mL, ketorolac tromethamine will be injected as same as the first IANB and 5 minutes following it.
16482882|NCT03410212|Sham Comparator|No injection|In the control group, 5 minutes following the IANB, the sham injection will be provided at the same place of the first injection.
16482885|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
16482886|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
16482887|NCT03410147|Other|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
16482888|NCT03410147|Other|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
16482889|NCT03410147|Other|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
16482890|NCT03410134|Experimental|NeoMTA|Vital pulp therapy with NeoMTA
16482891|NCT03410121|Other|Standard 1 : Thoracic location|The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location
16482892|NCT03410121|Other|Standard 2 : Humeral location|The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location
16482893|NCT03410108|Experimental|Brigatinib 90 mg + Brigatinib 180 mg|90 mg of Brigatinib tablets, once daily for 7 days, followed by 180 mg of Brigatinib tablets, once daily in a 28-days cycle.
16482894|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
16482895|NCT03410082|Active Comparator|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
16482896|NCT03410082|Active Comparator|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
16482897|NCT03410069|Experimental|IKORUS UP|
16482898|NCT03410056|Placebo Comparator|Phase 1b: Placebo|Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).
16482899|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 1|A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
16482900|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 2|A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
16482901|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 3|A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
16482902|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 4|A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
16482903|NCT03410056|Placebo Comparator|Phase 2a: Placebo|Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.
16482904|NCT03410056|Experimental|Phase 2a: Efavaleukin alfa|Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.
16482905|NCT03410043|Experimental|Group I (LCT)|Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16482906|NCT03410043|Experimental|Group II (no LCT)|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16482907|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
16482909|NCT03410004|Experimental|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
16482912|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
16482913|NCT03409965|Experimental|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
16482914|NCT03409952|Active Comparator|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
16482915|NCT03409952|Active Comparator|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
16482916|NCT03409939|Experimental|Aromatic Amino Acid Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
16482917|NCT03409926|Active Comparator|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
16482918|NCT03409926|Experimental|Acacia Gum 5 grams/day|fermentable dietary fiber
16482919|NCT03409926|Experimental|Acacia Gum 10 grams/day|fermentable dietary fiber
16482959|NCT03409614|Experimental|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
16482920|NCT03409913||GCA cases|In a cohort of patients suspected of GCA based on the following inclusion criteria were 1) age ≥50 years, 2) CRP>15mg/l or ESR>40mm/h, 3) either a) cranial symptoms, b) new-onset extremity claudication or c) weight loss >5 kilograms or fever>38oC for >3 weeks, patients with a clinical diagnosis of GCA is identified.
16482921|NCT03409913||controls|Age-(+/- 3 years) and sex-matched malignant melanoma (MM) patients who had a follow-up metastatic-disease-free FDG PET/CT ≥6 months after MM resection
16482922|NCT03409900|Experimental|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
16482923|NCT03409900|Experimental|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
16482924|NCT03409887|Experimental|Intraorifice Group|Intraorifice barrier of GIC.
16482925|NCT03409887|Experimental|Base Group|Base of GIC
16482926|NCT03409887|Active Comparator|Control Group|Direct composite restoration
16482927|NCT03409874|Experimental|Dry Needling and Spinal Manipulation|
16482928|NCT03409874|Active Comparator|Interocclusal Appliance, NSAIDs and TMJ Mobs|
16482929|NCT03409848|Experimental|A: Chemo-free immunotherapy|Week 1-12 Trastuzumab 6mg/kg d1 every 3 weeks (loading dose 8mg/kg) Nivolumab 1mg/kg i.v. d1 every 3 weeks Ipilimumab 3mg/kg i.v. d1 every 3 weeks Week 13 till EOT (max treatment period 12 months) Trastuzumab 4mg/kg d1 every 2 weeks Nivolumab 240mg i.v. d1 every 2 weeks
16482930|NCT03409848|Experimental|B: Chemo- / immunotherapy|"Trastuzumab 4mg/kg d1 every 2 weeks (loading dose 6mg/kg) Nivolumab 240mg i.v. d1 every 2 weeks mFOLFOX6 every 2 weeks Oxaliplatin at a dose of 85 mg/m2 IV over two hours (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv over two hours (day 1) 5-FU at a dose of 2400 mg/m2 IV over 46 hours (day 1-3)
~Max Treatment period 12 months"
16482931|NCT03409835|Experimental|Ramosetron|
16482932|NCT03409835|Placebo Comparator|Control|
16482933|NCT03409822|Other|Placenta previa|
16482934|NCT03409809|Experimental|Training Alone|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website.
16482935|NCT03409809|Experimental|Training and Technical Assistance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies, and communication.
16482936|NCT03409809|Experimental|Training, Tech. Assist., Qual. Assurance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies and communication. Furthermore, this condition will have 1 year of technical assistance, coaching, and quality assurance to enhance implementation skills and sustainability.
16482937|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
16482938|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
16482939|NCT03409783|Active Comparator|Active or ENSO Group|Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
16482940|NCT03409783|Sham Comparator|Sham Group|Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
16482941|NCT03409770|No Intervention|Usual care|Usual care (normothermia) arm
16482942|NCT03409770|Experimental|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
16482943|NCT03409770|Experimental|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
16482944|NCT03409757||hemodialysis patients with hyperphosphatemia|"dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
~Velphoro® medication"
16482945|NCT03409757||control group|- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
16482946|NCT03409744|Experimental|evinacumab|
16482947|NCT03409731|Other|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
16482948|NCT03409718||Biomet Comprehensive Shoulder System|Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.
16482949|NCT03409705|Experimental|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
16482950|NCT03409705|Placebo Comparator|Control group|2,000 mg of placebo was orally administered per day for 12 weeks.
16482951|NCT03409679|Experimental|Murepavadin|Murepavadin IV + one anti-pseudomonal antibiotic
16482952|NCT03409679|Active Comparator|Two anti-pseudomonal antibiotics|Association of 2 anti-pseudomonal antibiotics
16482953|NCT03409666|Experimental|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
16482954|NCT03409666|Active Comparator|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
16482955|NCT03409627|Experimental|Group 1|Single infusion of INXN-4001, Dose 1
16482961|NCT03409614|Experimental|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
16482962|NCT03409601|Experimental|100% Portion Size|Test meal consists of baseline (100%) portion size of meal.
16482963|NCT03409601|Experimental|125% Portion Size|Test meal consists of food portion size that is 125% the size of baseline portion.
16482964|NCT03409601|Experimental|150% Portion Size|Test meal consists of food portion size that is 150% the size of baseline portion.
16482965|NCT03409601|Experimental|175% Portion Size|Test meal consists of food portion size that is 175% the size of baseline portion.
16482966|NCT03409588|Experimental|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
16482967|NCT03409575|Other|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
16482968|NCT03409575|Other|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
16482969|NCT03409562|Experimental|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
16482970|NCT03409562|Active Comparator|motor control training alone|This group will only perform motor control training.
16482971|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
16482972|NCT03409510|Experimental|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
16482973|NCT03409497|Active Comparator|Concord Grape Juice|Concord Grape Juice
16482974|NCT03409497|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
16482975|NCT03409497|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
16482976|NCT03409484|Active Comparator|Concord Grape Juice|100% Concord Grape Juice
16482977|NCT03409484|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
16482978|NCT03409484|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
16482979|NCT03409458|Experimental|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion
~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study."
16482980|NCT03409432|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
16482981|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
16482982|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
16482983|NCT03409406|Experimental|Caregiver Intervention + ST Intervention|Parents/caregivers receive web-based tablet protocol containing sequenced communication information for working with their child at home in addition to the Standard of Care Intervention.
16482984|NCT03409406|Active Comparator|ST Intervention|This intervention is the once monthly standard of care intervention 30-minutes speech therapy (ST) session that the child receives at the hospital.
16482985|NCT03409393|Experimental|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
16482986|NCT03409393|Other|Control Group|Usual care (OPUS treatment).
16482987|NCT03409380|Experimental|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
16482988|NCT03409380|Placebo Comparator|Placebo|Placebo drink provided 1 time.
16482989|NCT03409367|Experimental|Daily Emollient|Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
16482990|NCT03409367|No Intervention|Natural Skin|Parents assigned to the control arm will receive educational materials promoting general infant skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
16482991|NCT03409354|Experimental|Tele-rehabilitation|Tele-rehabilitation via iPad.
16482992|NCT03409354|Active Comparator|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
16482993|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
16482994|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
16482995|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
16482996|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
16482997|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
16482998|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
16483034|NCT03409016||Immune Checkpoint Inhibitor Therapy|Patients starting treatment with ipilimumab, nivolumab, pembrolizumab, or atezolizumab, alone or in combination, for treatment of a metastatic solid tumor cancer will be enrolled. Patients will receive checkpoint inhibitor therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
16483035|NCT03409016||Control|An additional 18 patients starting standard chemotherapy will be enrolled as a control population. Patients will receive chemotherapy per standard protocol
16482999|NCT03409302|Experimental|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla & Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
16483000|NCT03409302|Active Comparator|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
16483001|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
16483002|NCT03409276|Experimental|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
16483003|NCT03409276|Placebo Comparator|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
16483004|NCT03409276|Experimental|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
16483005|NCT03409276|Placebo Comparator|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
16483006|NCT03409276|Experimental|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
16483007|NCT03409276|Placebo Comparator|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
16483008|NCT03409250|Other|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
16483009|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
16483010|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
16483011|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
16483012|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
16483013|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
16483014|NCT03409211|Active Comparator|Pso|with or without PsA
16483015|NCT03409211|Active Comparator|Healthy Subjects|Without PsA
16483016|NCT03409198|Active Comparator|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
16483017|NCT03409198|Experimental|Arm B|Chemo + ipilimumab + nivolumab
16483018|NCT03409185|Experimental|Alcon lens group|Alcon 1 piece SA60AT lens
16483019|NCT03409185|Active Comparator|AMO lens group|AMO 1 piece Sensar AABOO lens
16483020|NCT03409172|Experimental|Control group (CTr)|No counseling or nutritional therapy and no exercise
16483021|NCT03409172|Experimental|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).
~MICT:
~3 sessions per week
~intensity at 65-75% HRmax
~time-effort per session: 50 min"
16483022|NCT03409172|Experimental|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).
~HIIT:
~3 sessions per week
~10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax
~time-effort per session: 25 min"
16483023|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton >37 week pregnancy.
~Subjects will be recruited for the study in the following groups :
~At least 10 patients with Body Mass Index (BMI) < 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
16483024|NCT03409133|Experimental|Multi contact electrode implant|"Ten subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.
~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
16483025|NCT03409120|Experimental|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
16483026|NCT03409107|Experimental|Daprodustat receivers|Participants will receive oral daprodustat once daily
16483027|NCT03409107|Placebo Comparator|Placebo receivers|Participants will receive oral placebo once daily
16483028|NCT03409068|Experimental|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
16483029|NCT03409068|Active Comparator|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
16483030|NCT03409055||Group 0|patients without pleural effusion
16483031|NCT03409055||Group 1|patients with pleural effusion
16483032|NCT03409055||Group 2|patients with pleural Effusion and need of drainage
16483033|NCT03409029|Experimental|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
16483036|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
16483037|NCT03408990||Healthy|Healthy children, no relevant pathologies
16483038|NCT03408977|Experimental|Men|
16483040|NCT03408964||Group 0 (set-up)|Patients with known diagnosis of CSPC (Group 0a) and CRPC (Group 0b) irrespective of the PC treatment (not first diagnosis)
16483041|NCT03408964||Group 1a (control)|Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer
16483042|NCT03408964||Group 1|Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery and / or radical radiotherapy
16483043|NCT03408964||Group 2|Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy
16483044|NCT03408964||Group 3|Patients with recurrent/progressive/metastatic CRPC planned to receive chemotherapy
16483045|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
16483046|NCT03408938||Continuous Hb monitoring with Masimo Radical|"Plethysmography Variability Index (PVI) is a measure of the dynamic changes in the perfusion index (PI) that occur during the respiratory cycle . PVI = ﴾PI Max - PI Min﴿ ÷ PI Maxx 100 %.
~PVI has the potential to provide useful information concerning changes in the balance between intrathoracic airway pressure and intravascular fluid volume. Trending of PVI may be useful in monitoring surgical patients, both intraoperatively and postoperatively, for appropriate hydration states. For example, a rising PVI may indicate developing hypovolemia and gives an alarm for the need of appropriate fluid and or blood products transfusion supported by the patient hemoglobin level"
16483047|NCT03408925|Experimental|Intervention|The intervention consists of an exercise program developed by the medical team of the National Federation of Orienteering. Specifically, it consists of four exercises targeting strength, flexibility and coordination of the lower extremity. The orienteerers are asked to perform the exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function (online supplement). Each second week the exercises' difficulty level is increased.
16483048|NCT03408925|No Intervention|Control|Normal training, no intervention
16483049|NCT03408912|Other|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
16483050|NCT03408899|Experimental|PC-1005|All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
16483051|NCT03408886|Experimental|Group A|Group A receives treatment in Part 1 and Part 2
16483052|NCT03408886|Other|Group B|Group B receives no treatment in Part 1, but does receive treatment in Part 2
16483053|NCT03408873|Experimental|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
16483054|NCT03408860|Other|2-week baseline|Patients complete assessment only for a duration of 2-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
16483055|NCT03408860|Other|4-week baseline|Patient complete assessment only for a duration of 4-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
16483056|NCT03408847|Active Comparator|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
16483057|NCT03408847|Placebo Comparator|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
16483058|NCT03408834|Active Comparator|pulse variability index|fluid management performed by pulse variability index
16483059|NCT03408834|Placebo Comparator|conventional fluid management|fluid management performed by conventional fluid management
16483060|NCT03408821|Experimental|Problem Solving Therapy|All participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.
16483061|NCT03408808|Active Comparator|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
16483062|NCT03408808|Experimental|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
16483063|NCT03408795|Other|JORS-LDG Group|Participants in JORS-LDG Group score the performance of procedure after LDG.
16483064|NCT03408782||No drainage|Those patients that underwent surgery and no drain was inserted at the end of the procedure
16483065|NCT03408782||Drainage|Those patients that underwent surgery and one or several drains were inserted at the end of the procedure.
16483066|NCT03408756|Active Comparator|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
16483067|NCT03408756|Active Comparator|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
16483068|NCT03408743|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
16483069|NCT03408743|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
16483070|NCT03408743|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks. *Also referred to as 'benefits' in other arm descriptions**
16483071|NCT03408743|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus perceived benefits and self-efficacy modules for a period up to 3 weeks.
16483072|NCT03408743|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
16483073|NCT03408743|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus injunctive norms and self-efficacy modules for a period up to 3 weeks.
16483074|NCT03408743|Experimental|Injunctive norms and benefits|Participants will have access to the knowledge module plus injunctive norms and perceived benefits modules for a period up to 3 weeks.
16483075|NCT03408743|Experimental|Injunctive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483076|NCT03408743|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms modules for a period up to 3 weeks.
16483077|NCT03408743|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
16483078|NCT03408743|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
16483079|NCT03408743|Experimental|Descriptive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483080|NCT03408743|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
16483081|NCT03408743|Experimental|Descriptive and injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
16483082|NCT03408743|Experimental|Descriptive and injunctive norms, and benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
16483083|NCT03408743|Experimental|Descriptive & injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483084|NCT03408743|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
16483085|NCT03408743|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
16483086|NCT03408743|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
16483087|NCT03408743|Experimental|Expectancies, benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483088|NCT03408743|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
16483089|NCT03408743|Experimental|Expectancies, injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
16483090|NCT03408743|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
16483091|NCT03408743|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483092|NCT03408743|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
16483093|NCT03408743|Experimental|Expectancies, descriptive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
16483094|NCT03408743|Experimental|Expectancies, descriptive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
16483095|NCT03408743|Experimental|Expectancies, descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483096|NCT03408743|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies , descriptive norms, and injunctive norms modules for a period up to 3 weeks.
16483097|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, efficacy|Participants will have access to the knowledge module plus the expectancies , descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
16483098|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
16483099|NCT03408743|Experimental|Expectancies, descriptive & injunctive, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16483100|NCT03408730|Experimental|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
16483101|NCT03408730|Experimental|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
16483102|NCT03408730|Experimental|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
16483103|NCT03408730|Active Comparator|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
16483104|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
16483105|NCT03408704|Experimental|ASP-arm|This group of primary health care centers get the internal education (ASP).
16483106|NCT03408704|No Intervention|Control-arm|No intervention at all.
16483107|NCT03408691|Active Comparator|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
16483108|NCT03408691|Placebo Comparator|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
16483109|NCT03408691|No Intervention|No product|no product
16483113|NCT03408639|Experimental|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
16483114|NCT03408639|Active Comparator|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
16483115|NCT03408626|Experimental|papain chemomechenical caries removal agent (brix 3000)|papain chemomechenical caries removal agent (Birx 3000) and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action
16483116|NCT03408626|Placebo Comparator|conventional|conventional 330 bur
16483117|NCT03408613|Experimental|Positive Airway Pressure (PAP)|A registered polysomnographic technologist will perform a titration starting at 4 cm water (H2O) and adjust this value as needed to identify the optimal pressure to achieve an Apnea Hypopnea Index (AHI) <5 (including rapid eye movement sleep in the supine position). After PAP titration, subjects will be instructed to use the machine at the optimal pressure every night for 3 months. Compliance will be defined as: ≥4 hours use on 70% of nights and average use ≥6 hours per night.
16483118|NCT03408613|Experimental|Supplemental Oxygen (O2)|Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
16483119|NCT03408613|Sham Comparator|Sham|Subjects in the sham treatment group will complete the oxygen titration protocol described for the night-time supplemental oxygen group, except that their oxygen concentrator will have been covertly modified to deliver room air at a rate of 0.5 l/min.
16483120|NCT03408613|No Intervention|Controls|Subjects without OSA will be recruited and complete all testing for primary outcome measures, but will not undergo any intervention.
16483121|NCT03408587|Experimental|CVA21 / Ipilimumab|Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
16483122|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
16483123|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
16483124|NCT03408561|Experimental|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
16483125|NCT03408548|Placebo Comparator|Placebo|Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.
16483126|NCT03408548|Experimental|Probiotic|Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.
16483127|NCT03408535|Other|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
16483128|NCT03408509|Experimental|Cognitive training|
16483129|NCT03408496|Experimental|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
16483130|NCT03408496|Experimental|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
16483131|NCT03408496|Active Comparator|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
16483132|NCT03408483|Experimental|quadratus lumborum block (QLB)|"Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.
~Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.
~After QLB is placed, patients will have THA under spinal anesthesia."
16483162|NCT03408262|Experimental|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
16483133|NCT03408483|Active Comparator|Standard of Care|"Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.
~Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
16483134|NCT03408470|Experimental|TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus|Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
16483135|NCT03408470|Experimental|[14C]-TD-1473 Oral Capsule|Cohort 2 - One oral dose
16483136|NCT03408431|Experimental|Group E|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neck extension positioning.
16483137|NCT03408431|Active Comparator|Group C|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neutral head and neck position.
16483138|NCT03408418|Experimental|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
16483139|NCT03408418|No Intervention|Control|Conventional tooth extraction without any bone substitute.
16483140|NCT03408405|Experimental|Acthar Gel treatment group|Participants will be treated with 'Acthar Gel 80 UNT/ML Injectable Solution'. Initial dose for week 1 will be 50% of 80 units, injected twice per week. Week 2 is 75% of 80 units, week 3 and throughout treatment period (6 months in total) will be 80 units/ml twice per week.
16483141|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
16483142|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
16483143|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
16483144|NCT03408353||Observational (mammography, questionnaires, blood collection)|Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
16483145|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
16483146|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
16483147|NCT03408327|Experimental|Experimental group|"Wearable technology (fitness wristband & App)
~4 times group activities (2 hr / each times)
~LINE group interaction
~Reminder and feedback form researcher"
16483148|NCT03408327|Active Comparator|Control group|"Wearable technology (fitness wristband + App)
~Health promotion manual"
16483149|NCT03408314|Experimental|PediQUEST Response|"Weekly PediQUEST surveys are automatically assigned to parents and children (if 5 years old or older) and sent 48 hours prior to participant's usual clinic day
~Once a PediQUEST survey is assigned, automated email reminders/app notifications are sent daily for two days
~After 48 hours, unanswered or incomplete surveys are auto-submitted
~PQ-feedback report generated automatically after a PQ Survey is answered
~A pdf of the report is automatically emailed/available on mobile App to designated recipients
~Will also receive oncology-PC integrated care through the Response team
~Duration of follow-up: 18 weeks (2-week run-in period, followed by a 16-week post-randomization follow-up)"
16483150|NCT03408314|Other|Usual Cancer Care|"Will receive the usual cancer care provided at the participating sites
~Will complete weekly PQ-Surveys (no feedback reports will be generated)
~Can receive regular palliative care consultations following the site's usual referral procedures
~Same follow-up (18 weeks)"
16483151|NCT03408301||Tourniquet deflation|Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia
16483152|NCT03408288||Nurses|
16483153|NCT03408288||Urologists|
16483154|NCT03408275||Pregnant women|Pregnant women enrolled in ALSPAC
16483155|NCT03408262|Active Comparator|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
16483156|NCT03408262|Experimental|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
16483157|NCT03408262|Experimental|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
16483158|NCT03408262|Experimental|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
16483159|NCT03408262|Active Comparator|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
16483160|NCT03408262|Experimental|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
16483161|NCT03408262|Experimental|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
16483163|NCT03408249|Experimental|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
16483164|NCT03408236|Experimental|Botulax|Single dose
16483165|NCT03408236|Active Comparator|Botox|Single dose
16483166|NCT03408223|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
16483167|NCT03408223|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12-20 Gy on Days -8 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
16483168|NCT03408210|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
16483169|NCT03408210|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
16483170|NCT03408197|Experimental|EasyWarm|
16483171|NCT03408197|Active Comparator|BairHugger|
16483172|NCT03408184|Active Comparator|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
16483173|NCT03408184|Active Comparator|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
16483174|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
16483175|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
16483176|NCT03408158|No Intervention|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
16483177|NCT03408158|No Intervention|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
16483178|NCT03408158|Experimental|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
16483179|NCT03408145|Placebo Comparator|Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml and 1ml of Saline) comprising a total volume of 8.5ml fluid during one procedure.
16483180|NCT03408145|Active Comparator|Hyaluronic Acid & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Saline) comprising a total of 8.5mL fluid during one procedure.
16483181|NCT03408145|Active Comparator|Amniotic Tissue & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Saline and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
16483182|NCT03408145|Experimental|Amniotic Tissue & Hyaluronic Acid|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
16483183|NCT03408132|Experimental|FE203799 5 mg|FE203799 5 mg subcutaneous injection
16483184|NCT03408119|Experimental|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
16483185|NCT03408119|Experimental|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
16483186|NCT03408119|Placebo Comparator|Group C|800 IU vitamin D and 450 mg elemental calcium
16483187|NCT03408093||Interferon beta-1b|Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
16483188|NCT03408080|Experimental|Open Arm|All subjects will receive the same dosage throughout the study.
16483189|NCT03408054|No Intervention|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
16483190|NCT03408054|Active Comparator|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
16483191|NCT03408054|Active Comparator|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
16483192|NCT03408054|Active Comparator|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
16483193|NCT03408041||Alzheimer Disease|Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
16483194|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
16483195|NCT03408015|Experimental|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
16483196|NCT03408015|Experimental|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
16483197|NCT03408015|Experimental|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
16483198|NCT03408002|No Intervention|control group|no intervention
16483199|NCT03408002|Experimental|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
16483200|NCT03407976|Experimental|Apatinib and Pembrolizumab, all patients|
16483201|NCT03407963|Experimental|Prostate cancer patients|
16483202|NCT03407950|Other|Group IPT+|2 sessions of IPT+ by week during 6 months
16483203|NCT03407950|Other|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
16483204|NCT03407937|Other|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
16483205|NCT03407924|Experimental|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
16483206|NCT03407924|Active Comparator|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
16483207|NCT03407924|No Intervention|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
16483208|NCT03407911||Peri-implant microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
16483209|NCT03407911||Periodontal pocket microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
16483210|NCT03407911||healthy teeth|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
16483211|NCT03407898||C-mac D blade used for intubation|
16483212|NCT03407898||mcgrath X blade used for intubation|
16483213|NCT03407885|Experimental|Experimental|Bundled payments for knee and hip replacement
16483214|NCT03407885|No Intervention|Control|No intervention
16483215|NCT03407872|Experimental|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
16483216|NCT03407872|Experimental|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
16483217|NCT03407872|Experimental|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
16483218|NCT03407872|Placebo Comparator|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
16483219|NCT03407859|Experimental|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.
16483220|NCT03407846|Active Comparator|Total laparscopic hystrectomy|
16483221|NCT03407846|Experimental|Total abdominal hystrectomy|
16483222|NCT03407833||Obese, surgery|Obese subjects recruited from the Center for Surgical Weight loss who are undergoing weight loss surgery as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at surgical visits.
16483223|NCT03407833||Obese, nonsurgery|Obese subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
16483224|NCT03407833||Lean control|Lean control subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
16483225|NCT03407833||Liver transplant|Lean or obese subjects who are undergoing liver transplantation as part of their standard of care. Excised liver tissue will be collected the day of procedure.
16483226|NCT03407820|Active Comparator|1st random 50% of cohort|Absorbable Chromic gut sutures
16483227|NCT03407820|Active Comparator|2nd random 50% of cohort|Non-absorbable Nylon sutures
16483228|NCT03407794|No Intervention|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
16483229|NCT03407794|Experimental|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
16483230|NCT03407794|Active Comparator|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
16483231|NCT03407781|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
16483232|NCT03407768|Other|Individualized interventions|Exercise, Yoga, massage therapy, acupuncture, and others
16483233|NCT03407755|Active Comparator|Air|Intraocular 100% atmospheric air (anterior chamber).
16483234|NCT03407755|Experimental|SF6|Intraocular 20% sulphur hexaflouride (anterior chamber).
16483235|NCT03407742|Experimental|Intervention|CAPAS Youth Parenting Intervention
16483375|NCT03406689|Active Comparator|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
16483236|NCT03407742|No Intervention|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
16483237|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=20).Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
16483238|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
16483239|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16483240|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
16483241|NCT03407690||PIN2 study participants|All those giving swabs for the study
16483242|NCT03407677|Other|ROTO Track|The individual patient will serve as his/her own control before intervention with ROTO Track
16483243|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
16483244|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
16483245|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
16483246|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
16483247|NCT03407638|Active Comparator|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems-not investigators-implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
16483248|NCT03407638|No Intervention|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
16483249|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
16483250|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
16483251|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
16483252|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
16483253|NCT03407599|Experimental|Faster aspart followed by insulin aspart (NovoRapid®)|Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
16483254|NCT03407599|Experimental|Insulin aspart (NovoRapid®) followed by faster aspart|Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
16483255|NCT03407586|Other|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
16483256|NCT03407573|Active Comparator|Restrictive|Restrictive transfused when Hb at or below 70
16483257|NCT03407573|Active Comparator|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
16483258|NCT03407560|Experimental|SintLife|Use of SintLife putty as bone substitute for spinal fusion in lumbar spine surgery for degenerative diseases.
16483259|NCT03407521|Active Comparator|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
16483260|NCT03407521|Placebo Comparator|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
16483261|NCT03407508|Placebo Comparator|Baseline|No dietary changes.
16483262|NCT03407508|Placebo Comparator|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
16483264|NCT03407482|Experimental|GDC-0853 (200mg) BID|Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
16483265|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
16483266|NCT03407443|Experimental|Exposure to Make the Connection messages|
16483267|NCT03407443|Active Comparator|Active Control group|
16483268|NCT03407443|No Intervention|No exposure control group|
16483269|NCT03407430|Experimental|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.
~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
16483376|NCT03406689|Placebo Comparator|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
16483270|NCT03407430|Experimental|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.
~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
16483271|NCT03407417|Experimental|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
16483272|NCT03407417|Active Comparator|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
16483273|NCT03407404|Experimental|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
16483274|NCT03407404|Active Comparator|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
16483275|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
16483276|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
16483277|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
16483278|NCT03407378|Experimental|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
16483279|NCT03407378|Experimental|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
16483280|NCT03407365|Experimental|Home Exercises|Patients will be given a set of home exercises to perform as part of their rehabilitation home exercise program. They will be initially trained by a research team member and will be given a DVD home exercise video with instructions on how to perform the exercises.
16483281|NCT03407365|Active Comparator|DVD Program|Weeks 1-10, subjects will not be prescribed exercise at home. If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
16483282|NCT03407352|Active Comparator|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
16483283|NCT03407352|Experimental|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
16483284|NCT03407339|Active Comparator|Shared Oral Care Intervention|
16483285|NCT03407339|No Intervention|Control|
16483286|NCT03407326|Experimental|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
16483287|NCT03407326|Active Comparator|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
16483288|NCT03407313|Experimental|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
16483289|NCT03407300|Active Comparator|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
16483290|NCT03407300|Active Comparator|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
16483291|NCT03407287||Cardiac Catheterization|
16483292|NCT03407287||Distributive shock|
16483293|NCT03407287||Vasoactive and inotropic agents|
16483294|NCT03407287||Congestive heart failure|
16483295|NCT03407287||Atrial fibrillation|Patients with atrial fibrillation undergoing elective direct current cardioversion
16483296|NCT03407287||Patients undergoing surgery|Patients undergoing surgery requiring positive pressure ventilation and arterial line placement
16483297|NCT03407261|Experimental|Micro-osteoperforations|Minimally invasive micro-osteoperforations procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice
16483298|NCT03407261|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (sliding mechanics)
16483299|NCT03407235|Other|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.
~Time to completion is recorded."
16483300|NCT03407222|Active Comparator|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
16483301|NCT03407222|No Intervention|Control group|Control group does not receive text message
16483302|NCT03407209|Sham Comparator|PEIB - Use of local levobupivacaine anesthetics: 0.625 mg / ml|"automatic hourly bolus: 8ml (5mg) on 3 min
~patient controlled bolus: 8ml (5mg) on 3 min
~refractory period: 8min
~continuous infusion: 0
~maximum dose: 65mg/4h"
16483303|NCT03407209|Experimental|FREE programming - levobupivacaine anesthetics: 0.625 mg / ml|"Epidural analgesia totally controlled by the patient
~automatic hourly bolus: 0
~patient controlled bolus: 8ml (5mg) on 3 min
~refractory period: 8min
~continuous infusion: 0
~maximum dose: 65mg/4h"
16483304|NCT03407183||spastic neurogenic bladder|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.
16483305|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
16483306|NCT03407157|Experimental|Intervention|Probiotic supplementation
16483307|NCT03407157|Placebo Comparator|Control|Placebo
16483377|NCT03406676|Experimental|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
16483310|NCT03407131|Experimental|Joint replacement|Intertrochanteric fracture patients were treated with joint replacement surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
16483311|NCT03407131|Active Comparator|Intramedullary nail fixation|Intertrochanteric fracture patients were treated with intramedullary nail fixation surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
16483312|NCT03407118|Experimental|LY900014|Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).
16483313|NCT03407118|Active Comparator|Insulin Lispro (Humalog)|Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.
16483314|NCT03407105|Experimental|Arm 2|Specified dose on specified days
16483315|NCT03407092||Stentriever Cohort|
16483316|NCT03407092||ADAPT cohort|
16483317|NCT03407079|Experimental|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
16483318|NCT03407079|Placebo Comparator|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
16483319|NCT03407066||In-person|200 in-person healthy volunteers.
16483320|NCT03407066||On-line|10,000 online healthy volunteers
16483321|NCT03407053|Active Comparator|Ultra-processed diet then unprocessed diet|Participants assigned to this arm will consume ultra-processed diet for two weeks followed by unprocessed diet for two weeks
16483322|NCT03407053|Active Comparator|Unprocessed diet then ultra-processed diet|Participants assigned to this arm will consume unprocessed diet for two weeks followed by ultra-processed diet for two weeks
16483324|NCT03407027|Experimental|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
16483325|NCT03407027|Experimental|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
16483326|NCT03407027|Active Comparator|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
16483327|NCT03407001|Experimental|Screening (US, CEUS, Lumason)|Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.
16483328|NCT03406988|Experimental|Autologous fat grafting|Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
16483329|NCT03406988|Placebo Comparator|Sham procedure|False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
16483330|NCT03406975|Placebo Comparator|Control Group|Participants randomized to the control group (lifestyle intervention only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. Control group participants who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI >30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program for 12 months.
16483331|NCT03406975|Active Comparator|Treatment Group|Participants randomized to the treatment group will proceed to have the Overstitch ESG at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved >25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
16483333|NCT03406949|Experimental|MGD009 + MGA012|B7-H3 x CD3 DART protein + anti-PD-1 antibody
16483334|NCT03406936|Active Comparator|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
16483335|NCT03406936|No Intervention|No Sedation|No sedation will be given after initiation of mechanical ventilation
16483336|NCT03406923|No Intervention|Usual care|Receive usual care only.
16483337|NCT03406923|Experimental|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
16483338|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
16483339|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
16483340|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
16483341|NCT03406884|Experimental|Open label C-kit+ cells Group A|Group A is an open-label treatment group determining safety and feasibility. Participants enrolled in this group will be receiving previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
16483342|NCT03406884|Active Comparator|C-kit+ cells Group B|Participants randomized to Group B Treatment Group will receive previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
16483343|NCT03406884|No Intervention|No Intervention Group|Participants randomized to Group B Control Group will receive only their standard of care (SOC) Stage II BDCPA operation without the injection of harvested c-kit+ cells.
16483344|NCT03406871|Experimental|Nivolumab + Regorafenib|Nivolumab and Regorafenib
16483345|NCT03406858|Experimental|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
16483346|NCT03406845|Experimental|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
16483347|NCT03406845|Active Comparator|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
16483348|NCT03406832|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
16483349|NCT03406832|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
16483350|NCT03406832|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
16483351|NCT03406819|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
16483352|NCT03406819|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
16483353|NCT03406819|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
16483354|NCT03406806|Experimental|GaitBox|
16483355|NCT03406806|Active Comparator|Sprint System device|
16483356|NCT03406806|Active Comparator|NIH Toolbox 4 meter test|
16483357|NCT03406793|Experimental|1. Standard MNP|
16483358|NCT03406793|Experimental|2. High zinc, low iron MNP|
16483359|NCT03406793|Experimental|3. High zinc, low/no iron|
16483360|NCT03406793|Active Comparator|4. Dispersible zinc supplement|
16483361|NCT03406793|Experimental|5. Intermittent zinc supplement|
16483362|NCT03406793|Placebo Comparator|6. Placebo powder|
16483363|NCT03406780|Experimental|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
16483364|NCT03406780|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
16483365|NCT03406767|Experimental|GLA:D Canada Program|GROUP 1: GLA:DTM CANADA GROUP (STANDARDIZED EXERCISE PROGRAM)
16483366|NCT03406767|Experimental|JointEffort Program|GROUP 2: JOINTEFFORT GROUP (INDIVIDUALIZED EXERCISE PROGRAM)
16483367|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
16483368|NCT03406741|Experimental|Child with Hirschsprung's disease|Neuropsychological assessment at elementary school
16483369|NCT03406728|Active Comparator|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
16483370|NCT03406728|Active Comparator|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
16483371|NCT03406728|Experimental|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
16483372|NCT03406715|Experimental|Combination Immunotherapy Plus Vaccine|Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.
16483373|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
16483374|NCT03406689|Active Comparator|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
16483378|NCT03406676|No Intervention|saline|50ml of saline is administrated I.V before anesthesia induction.
16483379|NCT03406663|Experimental|Group 1|"In group 1, the dose of Gla-300 will be titrated by the patients by 1 unit per day until achieving a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (INSIGHT algorithm).
~Titration algorithms:
~Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.
~Fasting SMPG in the range of
~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose
~> 4.4 and ≤ 5.6 mmol/L, no change
~< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
16483380|NCT03406663|Active Comparator|Group 2|"In group 2, the dose of Gla-300 will be titrated by the patients based on the SMPG values of the last 3 days at least weekly, but no more often than every 3 days to achieve a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (EDITION algorithm).
~Fasting SMPG (median of the last 3 days including current day) in the range of
~≥ 7.8 mmol/L, increase 6 units of Gla-300 dose
~> 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose
~> 4.4 and ≤ 5.6 mmol/L, no change
~≥ 3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose
~< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
16483381|NCT03406650|Experimental|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
16483382|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
16483383|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
16483384|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
16483385|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
16483386|NCT03406611|Active Comparator|Pegtibatinase|
16483387|NCT03406611|Placebo Comparator|Placebo|
16483388|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
16483389|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 1)|
16483390|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 2)|
16483391|NCT03406585|Placebo Comparator|Sham transplantation (placebo)|
16483392|NCT03406572|Experimental|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
16483393|NCT03406572|Active Comparator|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
16483394|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
16483395|NCT03406546|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
16483396|NCT03406546|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
16483397|NCT03406533|Experimental|Group F|Sedated with midazolam and fentanyl
16483398|NCT03406533|Experimental|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
16483399|NCT03406533|Experimental|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
16483400|NCT03406533|Experimental|Group PR|Sedated with midazolam, propofol and remifentanil
16483401|NCT03406520|Experimental|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
16483402|NCT03406507|Experimental|ALXN1210|
16483403|NCT03406494|Experimental|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
16483404|NCT03406494|No Intervention|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
16483405|NCT03406468|Experimental|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
16483406|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
16483407|NCT03406442|Other|patients|The patient who have lesions affecting pterygopalatine fossa, lateral recess of the sphenoid sinus, petrous apex, Meckel's cave, cavernous sinus, infratemporal fossa and lateral nasopharynx and can be treated by endonasal endoscopic transptergoid approaches
16483408|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
16483409|NCT03406416|Experimental|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
16483410|NCT03406403|Active Comparator|Laryngeal mask airway group|20 slips of papers will be taken and labeled as group L (LMA) These slips will be placed in an envelope and one slip will be raised for each patient.
16483411|NCT03406403|Active Comparator|Magensium sulphate group|20 slips of papers will be taken and labeled as group M (Mgso4) These slips will be placed in an envelope and one slip will be raised for each patient
16483412|NCT03406403|Active Comparator|Control group (closure of anesthetics)|20 slips of papers will be taken and labeled as group C (Control) These slips will be placed in an envelope and one slip will be raised for each patient.
16483413|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
16483414|NCT03406377|Placebo Comparator|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
16483415|NCT03406377|Experimental|OPK-88003|70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
16483416|NCT03406364|Experimental|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours); 8:00 PM (±2 hours)]
16483417|NCT03406351||Asthma|
16483418|NCT03406351||Healthy|Matched controls
16483419|NCT03406338|Active Comparator|Surgical fasciectomy|Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures
16483420|NCT03406338|Experimental|Collagenase Clostridium Histolyticum|Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures
16483421|NCT03406325||urticaria|Patients with this condition
16483422|NCT03406325||asthma|Patients with this condition
16483423|NCT03406325||eczema|Patients with this condition
16483424|NCT03406325||food allergy|Patients with this condition
16483425|NCT03406325||anaphylaxis|Patients with this condition
16483426|NCT03406325||mastocytosis|Patients with this condition
16483427|NCT03406325||mast cell activating syndrome|Patients with this condition
16483428|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
16483429|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
16483430|NCT03406299|Experimental|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
16483431|NCT03406299|Active Comparator|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
16483432|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
16483433|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
16483434|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
16483435|NCT03406260|Experimental|Lasmiditan 200 mg (milligrams)|Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
16483436|NCT03406260|Experimental|Lasmiditan 100 mg|Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
16483437|NCT03406260|Placebo Comparator|Placebo|Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
16483438|NCT03406247|Experimental|Nivolumab|Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months
16483439|NCT03406247|Experimental|Nivolumab + Ipilimumab|"Patients in cohorts 2 and 2bis will be administered
~nivolumab 240 mg every 2 weeks during 6 months
~ipilimumab 1mg/kg IV every 6 weeks during 6 months"
16483440|NCT03406234||A group of participants|
16483441|NCT03406221|Experimental|Intervention arm|
16483442|NCT03406221|Active Comparator|Control Arm|
16483443|NCT03406208|Experimental|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
16483444|NCT03406208|Experimental|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
16483445|NCT03406195|Experimental|healthy older adults|Healthy older adults who will receive TMS
16483446|NCT03406169|Active Comparator|Sildenafil 25mg Oral Tablet|25mg sildenafil citrate twice daily
16483447|NCT03406169|Active Comparator|Pentoxifylline|400mg pentoxifylline twice daily
16483448|NCT03406169|Placebo Comparator|Placebo|placebo twice daily
16483518|NCT03405675||SLAS 1|The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).
16483449|NCT03406156|Experimental|Obinutuzumab +/- bendamustine then obinutuzumab + venetoclax|"Debulking Period: Obinutuzumab with or without bendamustine (bendamustine administered in participants with high tumor load as described in the protocol) during the debulking period (up to 6 cycles).
~Treatment Period: Venetoclax + obinutuzumab regimen initiated when participant achieves low tumor burden during debulking period, or if the participant has not achieved low tumor burden status after 6 cycles of debulking, the participant may proceed to venetoclax per the discretion of the treating provider after discussion with the study physician. During this regimen period, participants to receive obinutuzumab in combination with venetoclax for 5 months then venetoclax therapy alone to continue for a total duration of up to 53 weeks."
16483450|NCT03406143|Experimental|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
16483451|NCT03406143|Sham Comparator|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
16483452|NCT03406130|Active Comparator|Insignia orthodontic treatment|
16483453|NCT03406130|Experimental|Piezocision-assisted Insignia orthodontic treatment|
16483454|NCT03406117|Experimental|HAT1-EPBF2|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.
~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.
~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
16483455|NCT03406117|Experimental|HAT1-HMF3|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.
~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.
~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
16483456|NCT03406117|Active Comparator|Saline Solution: Sodium Chloride|Saline, Sodium Chlorine (NaCl; 0.9%), was used as the negative irritant control in the CIT portion of the study
16483457|NCT03406104|Experimental|GS010|Lenadogene nolparvovec Intravitreal occular unilateral Injection
16483458|NCT03406104|Sham Comparator|Sham|Sham Intravitreal occular unilateral Injection
16483459|NCT03406091||Poor Mobilizer (PM) in Multiple Myeloma (MM) patients|
16483460|NCT03406078|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
16483461|NCT03406078|Placebo Comparator|Placebo|Placebo subcutaneous injection
16483462|NCT03406065|Experimental|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
16483463|NCT03406065|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
16483464|NCT03406052|Experimental|Smartphone-Assisted MB-CBT|Online intervention accessed through smartphone or online accessed computer comprised of Mindfulness-Based Cognitive Behaviour content
16483465|NCT03406052|No Intervention|Control|Standard psychiatric care
16483466|NCT03406039|Experimental|Integrated Online CBT and MI|Participants in this arm will be given access to the online integrated treatment.
16483467|NCT03406039|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about alcohol and mental illness.
16483468|NCT03406026|Experimental|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
16483469|NCT03406026|Active Comparator|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
16483470|NCT03406013|Active Comparator|Group I|Written Information
16483471|NCT03406013|Experimental|Group II|Written Information Prescription
16483472|NCT03406013|Experimental|Group III|Written Information Prescription Technology
16483473|NCT03406013|Experimental|Group IV|Written Information Prescription Technology Coaching
16483474|NCT03406000|Experimental|Insulin glargine (U300)|Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
16483475|NCT03405987||ECV < median|
16483476|NCT03405987||ECV ≥ median|
16483477|NCT03405974|Experimental|Aspirin|"Aspirin 100 mg
~1 tablet/ day for 2 years"
16483478|NCT03405974|Placebo Comparator|Placebo|"Placebo
~1 tablet/ day for 2 years"
16483479|NCT03405961||Manual PAR score|Patient will receive upper and lower impressions, which will be cast to produce plaster models. A calibrated individual will PAR score the casts in the traditional manner (regular care pathway)
16483480|NCT03405961||Direct digital PAR score|Patient will receive upper and lower intra-oral scans which will be PAR scored directly by the computer
16484064|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
16483481|NCT03405961||Indirect digital PAR score|Patient will receive upper and lower impressions which will be cast to produce plater models (regular care pathway). The casts will be scanned with Carestream 3600 intra oral scanner and scored digitally by the computer.
16483482|NCT03405948|Experimental|botulinum toxin|injection of Botulinum toxin
16483483|NCT03405948|Placebo Comparator|placebo|Injection of saline serum (placebo)
16483484|NCT03405935|Experimental|B/F/TAF|B/F/TAF FDC for at least 96 weeks.
16483485|NCT03405922|Placebo Comparator|Placebo|Placebo 40 mL Saline 0.9%
16483486|NCT03405922|Active Comparator|Ropivacain|40 mL Ropivacain 0.5%
16483487|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:
~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis
~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
16483488|NCT03405896|Experimental|Normal subjects|
16483489|NCT03405883||RIF (women with repeated implantation failure)|Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy
16483490|NCT03405883||NF (normal fertile women)|Spontaneous conception or conception after max 9 IUI cycles
16483491|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
16483492|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
16483493|NCT03405857|Experimental|Group 1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
16483494|NCT03405857|No Intervention|Group 2|No intervention will be administered
16483495|NCT03405831|Active Comparator|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
16483496|NCT03405831|Placebo Comparator|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
16483497|NCT03405818|Experimental|Tavaborole 5% Topical Solution|All study participants apply study drug
16483498|NCT03405805||3+1|Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
16483499|NCT03405805||3+0|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
16483500|NCT03405805||2+1|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
16483503|NCT03405753|Active Comparator|Aroia|
16483504|NCT03405753|Placebo Comparator|Placebo|
16483505|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
16483506|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
16483507|NCT03405727|No Intervention|Standard treatment|
16483508|NCT03405727|Experimental|Oral dietary supplements|
16483509|NCT03405714|Experimental|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects >=12 to <16 years; Cohort 2: Subjects >=6 to <12 years; Cohort 3: Subjects >=2 to <6 years; Cohort 4: Subjects 1 month to <2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
16483510|NCT03405701|Active Comparator|IVM (in vitro maturation)|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
16483511|NCT03405701|Active Comparator|IVF (in vitro fertilization)|Undergoing controlled ovarian hyperstimulation for in vitro Fertilization (IVF) with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist triggering will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
16483512|NCT03405688|Experimental|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
16483513|NCT03405688|Other|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
16483514|NCT03405688|Experimental|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
16483515|NCT03405688|Other|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
16483516|NCT03405688|Experimental|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
16483517|NCT03405688|Other|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
16483519|NCT03405675||SLAS 2|An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).
16483520|NCT03405662|Active Comparator|Acitve PBM|This arm will receive active photobiomodulation (PBM), delivered with the Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
16483521|NCT03405662|Sham Comparator|Sham PBM|This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
16483522|NCT03405649|Experimental|Group A|Participants train 60 min per session for 10 weeks on non-consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and weights, elastic bands and balls will be used. Babies less than 20 weeks of age will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
16483523|NCT03405649|Experimental|Group B|Participants train 60 min per session for 10 weeks on non consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and different equipment such as weights, elastic bands and balls will be used. Babies older than 20 weeks will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
16483524|NCT03405636|Experimental|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
16483525|NCT03405623|Active Comparator|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
16483526|NCT03405623|Active Comparator|Conventional long-axis|
16483527|NCT03405610|Experimental|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
16483528|NCT03405610|No Intervention|Usual Care|The Usual Care (UC) group will continue with their current medical care.
16483529|NCT03405597|Experimental|Healthy control|Commercial Hepatitis B vaccine
16483530|NCT03405597|Experimental|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
16483531|NCT03405597|Active Comparator|Chronic hepatitis B without vaccination|Standard treatment
16483532|NCT03405584|Experimental|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
16483533|NCT03405584|Active Comparator|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
16483534|NCT03405545|Experimental|HIIT|This group of subjects will perform High Intensity Interval training 3x/week for 12 weeks
16483535|NCT03405519|Other|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
16483536|NCT03405493|Experimental|Wake and Light Therapy|This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Light Therapy is given daily
16483537|NCT03405493|Active Comparator|Sleep and Light Therapy|Participants will be given information on sleep hygiene and getting a good night's sleep. They are then given Light Therapy daily for 1 week.
16483538|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
16483539|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
16483540|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
16483541|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
16483542|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
16483543|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
16483544|NCT03405454|Active Comparator|standard chemotherapy|Patients on physician's choice of chemotherapy are allowed to receive any systemic chemotherapy either as a single agent or in combination. However, biologics( including bevacizumab) and oral tyrosine kinase inhibitors will not be allowed for patients on this arm
16483545|NCT03405454|Experimental|durvalumab|Patients on durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months
16483546|NCT03405441|Experimental|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
16483547|NCT03405441|Experimental|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
16483548|NCT03405441|Experimental|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
16483549|NCT03405428|Other|All patients|
16483550|NCT03405402|Experimental|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
16483551|NCT03405402|Other|Control group|Allo-immunization not detected
16483552|NCT03405389||Patients|Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks
16483553|NCT03405376|Experimental|Branch retinal vein occlusion|Aflibercept 2mg is injected into the vitreous cavity. Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
16483554|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
16483555|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
16483556|NCT03405350|Active Comparator|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
16483557|NCT03405350|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
16483558|NCT03405337||FVIII products (prospective)|"Qualitative patient/caregiver study:
~Hemophilia A patients/caregivers (N=30) having initiated a FVIII products with improved half-life"
16483559|NCT03405337||Conventional FVIII replacement therapies|"Qualitative patient/caregiver study:
~Hemophilia A patients/caregivers (N=30) receiving conventional FVIII replacement therapy for at least 6 months who are considering switching to a FVIII product with improved half-life within the next 1 year"
16483560|NCT03405337||FVIII products (retrospective)|"Quantitative physician interview/ chart review study:
~Hemophilia A patients (N=100) who have switched from conventional FVIII replacement therapy to FVIII products with improved half-life."
16483561|NCT03405324|Active Comparator|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
16483562|NCT03405324|Sham Comparator|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
16483563|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
16483564|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
16483565|NCT03405298|Active Comparator|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
16483566|NCT03405298|Active Comparator|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
16483567|NCT03405285|Experimental|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
16483568|NCT03405272|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
16483569|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
16483570|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
16483571|NCT03405246|Active Comparator|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
16483572|NCT03405246|Experimental|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
16483573|NCT03405233|Experimental|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
16483574|NCT03405233|Active Comparator|Group B|Single vein cuffed PTFE graft at the outflow end
16483575|NCT03405233|Active Comparator|Group C|PTFE graft without vein cuff will be used
16483576|NCT03405220|Experimental|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
16483577|NCT03405220|Active Comparator|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
16483578|NCT03405220|Experimental|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
16483579|NCT03405220|No Intervention|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
16483580|NCT03405220|No Intervention|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
16483581|NCT03405220|No Intervention|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
16483582|NCT03405220|Experimental|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
16483583|NCT03405220|Experimental|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
16483584|NCT03405220|Experimental|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
16483585|NCT03405220|Active Comparator|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
16483586|NCT03405220|Experimental|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
16483587|NCT03405220|Experimental|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
16483588|NCT03405220|Experimental|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
16483589|NCT03405220|Experimental|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
16483590|NCT03405220|Experimental|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
16483591|NCT03405207|Active Comparator|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
16483592|NCT03405207|Placebo Comparator|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
16483593|NCT03405194|Experimental|Elvitegravir-Cobicistat-TAF-FTC|Elvitegravir 150mg po QD Cobicistat 150 mg po QD TAF 10 mg po QD FTC 200 mg QD
16483594|NCT03405194|Active Comparator|EFV-TDF-3TC|EFV 600 mg po QD TDF 300 mg po QD 3TC 300 mg po QD
16483595|NCT03405181|Experimental|Training with additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet with an additional weight characterized by 20% of the total mass of the upper limb placed on both wrists. This training will be adopted for the adequate weight intervention group and low weight intervention group.
16483596|NCT03405181|Placebo Comparator|Training without additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet without additional weight, placed on both wrists. This training will be adopted for the adequate weight placebo group and low weight placebo group.
16483597|NCT03405168|Experimental|routine therapy plus moxifloxacin|Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.
16483598|NCT03405155|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16483599|NCT03405142|Experimental|T1 or T2 stage and node negative|T1 or T2 stage primary tumor and node negative (i.e., cN0)
16483600|NCT03405142|Experimental|Any T stage and node positive|Any T stage tumor and node positive (i.e., cN+)
16483601|NCT03405129|Active Comparator|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
16483602|NCT03405129|Experimental|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
16483603|NCT03405129|Experimental|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
16483604|NCT03405103|Experimental|Striving|Striving vs Boning-up & Personal Choice
16483605|NCT03405103|Active Comparator|Boning-up Standard Education|Boning-up vs Striving and Personal Choice
16483606|NCT03405103|Sham Comparator|Personal Choice|Personal Choice vs Striving & Boning-up
16483607|NCT03405090|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
16483608|NCT03405090|Active Comparator|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
16483609|NCT03405077|Experimental|IPT Online Training|"Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from gold-standard training."
16483610|NCT03405064|Experimental|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
16483611|NCT03405064|Active Comparator|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
16483612|NCT03405025|Other|Safety and Feasibility|All patients will undergo endoscopic US guided radiofrequency ablation, to assess safety and feasibility.
16483613|NCT03404999|Experimental|clinical decision support activated|"TWO MED ASSIST ALERTS
~Enter height (when missing)
~Repeat BP (when high)
~ONE PROVIDER ALERT
~BP high & prior BP/BP%s
~Defines elev. BP, HTN stage 1-2 with button to enter diagnosis
~Link to tailored ordersets
~TAILORED ORDERSETS
~Elevated BP
~Button to schedule f-up <6 m
~Button for diet/lifestyle counseling/check-out instructions
~HTN stage 1
~Buttons to order labs/studies pre-checked for stage 1 recs
~Button for nephrology referral
~Button to schedule f-up in 1-2 wk/<1 m
~Button for diet/lifestyle counseling/check-out instructions
~HTN stage 2
~Buttons to order labs/studies for stage 2
~Button for nephrology referral (pre-checked)
~Button to f-up 1 wk
~Button for diet/lifestyle counseling/check-out instruction"
16483614|NCT03404986|Other|Standardized ureteroscopy group|
16483615|NCT03404986|Other|Ultrasonography ureteroscopy group|
16483616|NCT03404960|Experimental|Arm A|Niraparib + Nivolumab
16483617|NCT03404960|Experimental|Arm B|Niraparib + Ipilimumab
16483618|NCT03404947|Experimental|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
16483619|NCT03404947|No Intervention|No Ethanol|Participants will ingest a volume matched beverage of water only.
16483620|NCT03404934|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
16483621|NCT03404921|Experimental|ESTD group|Use tunnelling method during ESD operation
16483622|NCT03404921|Other|ESD group|Use traditional method during ESD operation
16483623|NCT03404908|Experimental|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
16483624|NCT03404908|Experimental|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
16483625|NCT03404895|Sham Comparator|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
16483626|NCT03404895|Active Comparator|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
16483627|NCT03404882|Experimental|text messaging plus peer support arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. In addition to peer support, participants in this arm of the study will receive daily supportive text messages from an automated online application and reminder text messages for their community clinic/program appointments.
16483628|NCT03404882|Active Comparator|supportive/reminder text message only arm|Patients in the supportive/reminder text message only arm of the study will receive daily supportive text messages from the automated online application and reminder text messages for their community clinic/program appointments.
16483629|NCT03404882|No Intervention|Control arm|Patients in the control arm of the study will receive the usual follow-up appointment offered to all patients who are discharged from acute care. However, they will not receive peer support or supportive/reminder text messages.
16483630|NCT03404882|Active Comparator|peer support only arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. Patients will not receive daily supportive/reminder text messages
16483631|NCT03404869|Other|Treatment with ORL-1M - D-mannose|
16483632|NCT03404856|Other|Treatment with ORL-1G - D-galactose|
16483633|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
16483634|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
16483635|NCT03404830|Experimental|HIIT group|This group receives physical training based on HIIT
16483636|NCT03404830|Experimental|MICT group|This group receives physical training based on MICT
16483637|NCT03404830|No Intervention|No intervention group|This group does not receive any treatment.
16483638|NCT03404817|Active Comparator|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
16483639|NCT03404817|Active Comparator|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
16483640|NCT03404817|Active Comparator|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
16483641|NCT03404804|Experimental|Oral Challenge|Patients getting amoxicillin
16483642|NCT03404791|Experimental|Participants Ineligible for Radical Cystectomy|Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.
16483643|NCT03404778||Biomet Comprehensive Reverse Shoulder|Subjects in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Shoulder System.
16483644|NCT03404765|Experimental|Tai Chi group|The Tai Chi group (i.e. the intervention group) received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long.
16483645|NCT03404765|No Intervention|Ususal care group|The control group received the usual care offered by the respective centers. No intervention had been arranged for the control group during the study period. Participants in the control group were advised to attend different kinds of recreational activities provided by their community centers and to continue with their daily activities, including their usual general physical mobility and social activities.
16483646|NCT03404752|Experimental|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
16483647|NCT03404752|Active Comparator|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
16483648|NCT03404739|Experimental|Single-dose group|Ceftazidime 2g at the start of POEM
16483649|NCT03404739|Active Comparator|Multiple-dose group|Ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure
16483650|NCT03404726|Experimental|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
16483651|NCT03404726|Experimental|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
16483652|NCT03404726|Experimental|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
16483653|NCT03404713|Active Comparator|Standard Behavioral Weight Loss (BWL) Treatment|All participants will participate in 4 weeks of group based behavioral weight lost treatment in the intervention called Pathways to Health. Based on early treatment response (improvement in binge eating), participants will be assigned to either continue in this arm for the remaining 12 weeks of treatment (early strong responders) or be assigned to the 2nd arm of this study.
16483654|NCT03404713|Experimental|Acceptance-Based Binge Eating Treatment|After 4 weeks of standard BWL treatment, early weak responders will be assigned to individual acceptance-based treatment for the remaining 12 weeks of treatment.
16483655|NCT03404700|Experimental|Group 1:Test breakfast A and B|"*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.
~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
16483656|NCT03404700|Experimental|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
16483657|NCT03404700|Experimental|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
16483658|NCT03404700|Experimental|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
16483659|NCT03404700|Experimental|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
16483660|NCT03404700|Experimental|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
16483661|NCT03404687||Patients with adnexal masses|
16483662|NCT03404674|Experimental|Group A1: CssBA 5 ug|Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.
16483663|NCT03404674|Experimental|Group A2: DmLT 100 ng|Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.
16483664|NCT03404674|Experimental|Group B: CssBA 5 ug + DmLT 100 ng|Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.
16483665|NCT03404674|Experimental|Group C: CssBA 5 ug + DmLT 500 ng|Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
16483666|NCT03404674|Experimental|Group D: CssBA 15 ug + DmLT 500 ng|Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
16483667|NCT03404674|Experimental|Group E: CssBA 45 ug + DmLT 500 ng|Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
16483668|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
16483669|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
16483670|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
16483671|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
16483672|NCT03404635||Apixaban for VTE|
16483673|NCT03404635||Rivaroxaban for VTE|
16483674|NCT03404622|Active Comparator|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
16483675|NCT03404622|Active Comparator|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
16483711|NCT03404362|Active Comparator|EBRT|Patient would undergo single fraction of external beam radiation to a dose of 8Gy or a session of 10 fractions of external beam radiations at 3Gy per fraction for two weeks.
16484026|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
16483676|NCT03404609|Experimental|Accelerated course of modified continuous theta-burst stimulation (cTBSmod)|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
16483677|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
16483678|NCT03404583|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform
16483679|NCT03404583|No Intervention|Usual Care|Evidence-based care
16483680|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
16483681|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
16483682|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
16483683|NCT03404557||Crohn's Disease patients group|44 patients
16483684|NCT03404557||Ulcerative Colitis patients group|22 patients
16483685|NCT03404557||Healthy volunteers group|22 patients
16483686|NCT03404544|Active Comparator|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
16483687|NCT03404544|Experimental|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
16483688|NCT03404531|Experimental|Social Media Messages Intervention Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
16483689|NCT03404531|Active Comparator|Website Only Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.
16483690|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.
~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
16483691|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.
~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
16483692|NCT03404505|Experimental|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
16483693|NCT03404505|Experimental|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
16483694|NCT03404492|Other|Patients with pulmonary hypertension|
16483695|NCT03404479|Experimental|Co-administration group|Co-administration of Diacerein 50mg, Celecoxib 100mg.
16483696|NCT03404479|Active Comparator|Single administration group 1|Single administration of Diacerein 50mg and placebo.
16483697|NCT03404479|Active Comparator|Single administration group 2|Single administration of Celecoxib 100mg and placebo.
16483698|NCT03404466|Experimental|experimental group one|10 mg of Hypidone Hydrochloride tablets
16483699|NCT03404466|Experimental|experimental group two|20 mg of Hypidone Hydrochloride tablets
16483700|NCT03404453||Paediatric patients at preanaesthetic visi|Difficult airway incidence and prediction:Paediatric patients at preanaesthetic visit scheduled for surgery under general anaesthesia
16483701|NCT03404440|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
16483702|NCT03404440|Placebo Comparator|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
16483703|NCT03404427|Sham Comparator|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
16483704|NCT03404427|Experimental|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
16483705|NCT03404414|Experimental|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
16483706|NCT03404401|Experimental|BLI4700 Bowel Preparation|
16483707|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
16483708|NCT03404388|Experimental|Experimental|Balance Training
16483709|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
16483710|NCT03404362|Active Comparator|MRgFUS|"The treatment process begins with the physician acquiring a set of MR images, identifying target volume(s) of tissue to ablate, and then drawing the treatment contours.
~The therapy planning software computes the type and number of sonications required to treat the defined region while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment"
16484324|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
16483712|NCT03404349|Experimental|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
16483713|NCT03404336|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
16483714|NCT03404336|Placebo Comparator|Control condition|The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.
16483715|NCT03404310|Experimental|Treatment|Zinc Sulfate 220mg twice daily for three months.
16483716|NCT03404310|Placebo Comparator|Placebo|Gelatin Placebo tablet twice daily for three months.
16483717|NCT03404297|Experimental|Immediate Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
16483718|NCT03404297|Placebo Comparator|Delayed Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy after completing ~ 14 weeks of chemotherapy.
16483719|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
16483720|NCT03404271|Placebo Comparator|Normal Diet|Participants in the normal diet (ND) group will follow a traditional dietary pattern, consisting of eating breakfast and continuing to eat throughout the day until the evening. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
16483721|NCT03404271|Experimental|Time-Restricted Feeding|Participants in the time-restricted feeding (TRF) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
16483722|NCT03404271|Experimental|Time-Restricted Feeding plus HMB|Participants in the time-restricted feeding plus HMB (TRF+HMB) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive HMB capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
16483723|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
16483724|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
16483725|NCT03404245|Active Comparator|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered PT, and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
16483726|NCT03404245|Placebo Comparator|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a PT. In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
16483727|NCT03404232|Active Comparator|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
16483728|NCT03404232|Active Comparator|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
16483729|NCT03404232|Active Comparator|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
16483730|NCT03404219|Experimental|Intervention|Mobile intervention (i.e., Ecological momentary intervention [EMI]) addressing social motivation and social skills. Twice daily notifications sent to deliver EMI content. Social goal reminders and steps provided to support goal attainment. Social Skills Training content delivered via brief video clips.
16483731|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
16483732|NCT03404206|Active Comparator|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
16483733|NCT03404206|Placebo Comparator|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
16483734|NCT03404193|Experimental|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16483735|NCT03404180|Experimental|Peripheral nerve block|"Prospectively evaluate peripheral nerve blocks as a primary anesthetic in the setting of above-the-knee amputations.
~All enrollees will be administered Intravenous sedatives using propofol or dexmedetomidine and have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator nerve blocks and lateral femoral cutaneous nerve blocks will also be performed."
16483736|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
16483737|NCT03404141|Experimental|Experimental group|"The intervention administered to the experimental group will be a cognitive-behavior therapy applied by two specifically trained psychologists.
~Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions)."
16483738|NCT03404141|Active Comparator|Control group|The intervention administered to the control group will consist on a regular parent craft classes offered by the community midwife Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions).
16483739|NCT03404128||Questionnaires|Questionnaire for patient Questionnaire for neurologist
16483740|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
16483741|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
16483742|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
16483743|NCT03404102||university clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion
~Informed Consent: All participants will give their informed consent prior to enrollment.
~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).
~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
16483744|NCT03404102||primary healthcare unit clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion
~Informed Consent: All participants will give their informed consent prior to enrollment.
~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).
~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
16483745|NCT03404089|Experimental|pharmacokinetic device|MON4STRAT system
16483746|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
16483747|NCT03404063|Experimental|Active Group|Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
16483748|NCT03404063|Placebo Comparator|Control Group|Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.
16483749|NCT03404050|Experimental|Music and dance movement therapy group|Music and dance movement therapy group
16483750|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
16483751|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
16483752|NCT03404024|Experimental|Stage 1-Low dose VM202RY|Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)
16483753|NCT03404024|Experimental|Stage 1-Middle dose VM202RY|Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)
16483754|NCT03404024|Experimental|Stage 1-High dose VM202RY|Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)
16483755|NCT03404024|Placebo Comparator|Stage 2-Placebo|Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)
16483756|NCT03404024|Experimental|Stage 2-Low dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)
16483757|NCT03404024|Experimental|Stage 2-High dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)
16483758|NCT03404011|Experimental|Propylene glycol and Glycerol intake|One gram intake of a Propylene glycol/Glycerol mix (50:50)
16483759|NCT03404011|Placebo Comparator|Mimicking intake|Mimicking Propylene glycol/Glycerol intake with the device turns off
16483760|NCT03403998|Experimental|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
16483761|NCT03403998|Placebo Comparator|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
16483762|NCT03403985|Experimental|calcium hydroxide direct pulp capping|calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group
16483763|NCT03403985|Experimental|MTA direct pulp capping|Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group
16483764|NCT03403972|Experimental|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
16483765|NCT03403959|Experimental|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
16483766|NCT03403959|No Intervention|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
16483767|NCT03403946|Experimental|Intervention|"All patients received the same treatment.
~Laryngscopy with C-MAC PM + Macintosh blade
~Laryngscopy with C-MAC PM + D-Blade
~Intubation with C-MAC PM + D-Blade"
16483768|NCT03403933|Experimental|cardiopathic patients in hypovitaminosis|Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D > 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study
16483769|NCT03403907|Experimental|Probiotic|Probiotic administration
16483770|NCT03403881|Active Comparator|Physical activity promotion + TAU|"Physical activity promotion based on:
~Pedometers use;
~Weekly contact (telephone or face-to-face);
~Contact based on a self-determination theory.
~TAU:
~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
16483771|NCT03403881|Placebo Comparator|Control|"Weekly calls with general health content.
~TAU:
~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
16483772|NCT03403868|Other|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
16483773|NCT03403855|Experimental|Rocket® IPC- Long External Length|"Intervention Rocket® IPC- Long External Length: a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.
~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.
~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate their product."
16483774|NCT03403855|Experimental|Rocket® IPC- Short External Length|"Intervention Rocket® IPC- Short External Length : a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.
~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.
~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate Rocket's product."
16483775|NCT03403842|Active Comparator|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
16483776|NCT03403842|Active Comparator|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
16483777|NCT03403842|Experimental|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
16483778|NCT03403829|Experimental|maintenance arm|Gemcitabine maintenance treatment
16483779|NCT03403829|Sham Comparator|control arm|observe and follow-up
16483780|NCT03403816|Active Comparator|Intervention|"Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.
~."
16483781|NCT03403816|No Intervention|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
16483782|NCT03403803||Control Group|
16483783|NCT03403803||Optune Only|
16483784|NCT03403803||Optune and TMZ|
16483785|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
16483786|NCT03403777|Experimental|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
16483787|NCT03403764|Experimental|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.
~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
16483788|NCT03403764|No Intervention|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
16483789|NCT03403751|Experimental|Reltecimod 0.5 mg/kg|Single IV infusion of Reltecimod 0.5 mg/kg
16483790|NCT03403751|Placebo Comparator|Placebo|Single IV infusion of 0.9% Sodium Chloride Injection (Normal Saline)
16483791|NCT03403738|Active Comparator|Enhanced usual Care|usual care plus comprehensive resource list
16483792|NCT03403738|Experimental|BBN|Bounce Back Now intervention
16483793|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.
~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
16483794|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.
~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
16483795|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
16483796|NCT03403699||nondiabetics|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must be a healthy control and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
16483797|NCT03403699||Diabetic|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) carry the diagnosis of diabetes and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
16483798|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
16483799|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
16483800|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
16483801|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
16483802|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
16483803|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
16483804|NCT03403660|Experimental|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
16483805|NCT03403660|Placebo Comparator|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
16483806|NCT03403647|Experimental|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
16483807|NCT03403647|No Intervention|No vitamin D deficiency|Regular and routine monitoring
16483811|NCT03403595|Experimental|177Lu-EB-PSMA-617 dosimetry calculation|All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
16483812|NCT03403582|No Intervention|Control arm|A high-fat break fast meal with no raspberries.
16483813|NCT03403582|Experimental|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
16483814|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
16483815|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
16483816|NCT03403556|Experimental|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
16483817|NCT03403556|Active Comparator|Monorova ® Tab.|Rosuvastatin 20mg
16483818|NCT03403543||1|This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.）
16483819|NCT03403530|Active Comparator|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
16483820|NCT03403530|Placebo Comparator|control group|antibiotics only
16483821|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
16483822|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
16483823|NCT03403504|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
16483824|NCT03403504|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
16483825|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
16483826|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
16483827|NCT03403478|No Intervention|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
16483828|NCT03403478|Experimental|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
16483829|NCT03403478|Experimental|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
16483830|NCT03403478|Experimental|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
16484027|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
16483831|NCT03403478|Experimental|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
16483832|NCT03403465|Other|Single arm interventional study|Research FDG-PET scan obtained before radiation therapy; a second research FDG-PET scan is obtained at about 3-5 weeks after treatment has started.
16483833|NCT03403452|Experimental|arm for Apatinib|500 mg,p.o.,qd
16483834|NCT03403439|Experimental|All Subjects|Reference Treatment - BI 1015550 alone followed by Test Treatment (itraconazole + BI 1015550)
16483835|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
16483836|NCT03403413|Experimental|Muscle Vibration|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
16483837|NCT03403400|Experimental|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
16483838|NCT03403400|Active Comparator|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
16483839|NCT03403400|No Intervention|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
16483840|NCT03403387|Experimental|GlutenShield|3 capsules of GlutenShield supplement/day for 28 days
16483841|NCT03403387|Placebo Comparator|Placebo|3 capsules of the placebo (Avicel and bentonite powder (for color))/ day for 28 days
16483842|NCT03403374|Experimental|Evolocumab|Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).
16483843|NCT03403361|Active Comparator|Arm A: Conventional SECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine single-energy computed tomography (SECT) or DECT scans
~In Arm A, patients are treated with treatment plans optimized and calculated on the SECT data. Plan dose is re-calculated for every patient with the clinical plan in a Monte Carlo dose calculation engine for better accuracy. The investigators will use TOPAS, an extension of Geant4 simulation toolkit, as the dose calculation engine.
~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.
~Scans can be performed on the Phillips or Siemens scanners"
16483844|NCT03403361|Experimental|Arm B1: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans
~In Arm B1, DECT data is used to estimate the actual dose delivered using the clinical plan based on SECT data.
~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.
~Scans can be performed on the Phillips or Siemens scanners"
16483845|NCT03403361|Experimental|Arm B2: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans
~In Arm B2, the plan is re-optimized on DECT data with the conventional uncertainty margin of 3.5% of proton range.
~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.
~Scans can be performed on the Phillips or Siemens scanners"
16483846|NCT03403361|Experimental|Arm B3: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans
~In Arm B3, the plan is re-optimized on DECT data with the SPR uncertainties derived from the patient-specific uncertainty model developed.
~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.
~Scans can be performed on the Phillips or Siemens scanners"
16483847|NCT03403348|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 7 cohorts and receive one of the 7 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
16483848|NCT03403348|Experimental|Part 2A: Food Effect|Participants enrolled in cohort 4 of part 1 will roll-over in Part 2A and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
16483849|NCT03403348|Experimental|Part 2B: Relative Bioavailability (Optional)|Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
16483850|NCT03403348|Experimental|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. There will be 3 optional cohorts and participants in these cohorts will follow 7- to 14-day dosing schedule. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
16483851|NCT03403348|Experimental|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging PK and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
16483852|NCT03403348|Experimental|Part 5: SAD/Japanese|Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
16483883|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
16483884|NCT03403218|Experimental|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
16483853|NCT03403348|Experimental|Part 6: MAD/Japanese (Optional)|Participants of Japanese descent may be enrolled in 3 cohorts and will receive one of the corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 to 14 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (Parts 1, 2, 3, and 5) cohorts.
16483854|NCT03403335|Experimental|Mindfulness Based Practices for Health Care Professionals|
16483855|NCT03403335|No Intervention|Control Group|
16483856|NCT03403322|Other|First test|All measures were evaluated
16483857|NCT03403322|Other|Second test|All measures were evaluated
16483858|NCT03403309|Experimental|Inosine 5'-monophosphate arm|Subjects are treated with inosine 5'-monophosphate to increase serum uric acid level.
16483859|NCT03403309|Placebo Comparator|Placebo arm|Subjects are treated with placebo not to increase serum uric acid level.
16483860|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
16483861|NCT03403283||Group 1|Diabetic
16483862|NCT03403283||Group 2|Healthy Controls
16483863|NCT03403270|Experimental|ENCOURAGE App Intervention|Users will download the ENCOURAGE mobile app. The App uses a time management technique (i.e. Pomodoro technique) as a strategy to provide prompts for users to engage in an activity. The App can be customized by the users to set prompts at intervals that fit into their schedule. For example, these activities can range from a stretching activity (e.g., a neck stretch), a standing activity (e.g., stand and read), or a physical activity (e.g., fill up the printer with paper, do a squat). Additionally, the App will use Behaviour Change Techniques as a strategy to support participants as they reduce their sedentary behaviour and improve their physical activity levels. The App uses a series of Behavior Change Techniques shown to be effective in promoting a more active lifestyle.
16483864|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
16483865|NCT03403257||Caregivers|Primary caregivers of subjects
16483866|NCT03403244|Experimental|US-MR image fusion-guided PTED|US-MR image fusion-guided PTED: the puncture procedure during PTED was performed under the guidance of ultrasound-MR fusion technique.
16483867|NCT03403244|Active Comparator|fluoroscopy-guided PTED|fluoroscopy-guided PTED: the puncture procedure during PTED was performed under the guidance of fluoroscopy.
16483868|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
16483869|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
16483870|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
16483871|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
16483872|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
16483873|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
16483874|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
16483875|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
16483876|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
16483877|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
16483878|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
16483879|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
16483880|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
16483881|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
16483882|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
16483885|NCT03403205|Experimental|ALXN1840|"ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.
~Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period."
16483886|NCT03403205|Active Comparator|Standard of Care (SoC) Medication|SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.
16483887|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
16483888|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
16483889|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
16483890|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
16483891|NCT03403179|Experimental|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
16483892|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
16483893|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
16483894|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
16483895|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
16483896|NCT03403140|Experimental|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes
~Source: GEMABIOTECH S. A. Formulation per unit:
~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
16483897|NCT03403101|Experimental|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
16483898|NCT03403088|Experimental|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
16483899|NCT03403088|Placebo Comparator|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
16483900|NCT03403088|Experimental|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
16483901|NCT03403088|Placebo Comparator|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
16483902|NCT03403088|Experimental|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
16483903|NCT03403088|Experimental|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
16483904|NCT03403075|Active Comparator|Usual Care|"Control Group will be offered usual care (UC), plus two sessions of therapeutic education delivered in small groups. In these educational sessions, patients are provided with useful information on communication strategies, problem solving strategies, recognition and management of symptoms and the management of any aids/orthoses provided in everyday life, etc. In the meetings, it will be emphasized the importance of maintaining an active lifestyle as much as possible by encouraging involvement in physical activity even during the cancer treatment period.
~Written information material that summarizes the concepts addressed during group meetings will be provided."
16483905|NCT03403075|Experimental|ETAF: Therapeutic Education Physical Activity|"Intervention group will perform UC, and the two sessions of therapeutic education delivered in small group, as for the Control Group. The Intervention group will also provided for 6 individual sessions of therapeutic education and physical activity held by physiotherapists dedicated to the study, according to the patients' needs and objectives.
~In these sessions, the topics discussed in group will be deepened, personalizing them according to the patient's characteristics. Furthermore, personalized physical activity is planned, taking into account the context of execution, the clinical condition and the patient's preferences. The patient will be trained to build an action plan aimed at self-plan physical activities and a diary will be provided to monitor the physical activity carried out autonomously.
~Written information material that summarizes the concepts addressed during group and individual sessions will be provided."
16483906|NCT03403049|Experimental|Arm 1|Dose-escalation phase I clinical study. In the initial dose levels, 'dose-escalation' refers to an increase in the radiotherapy dose delivered using carbon ion radiotherapy along with a corresponding decrease in the dose delivered using photons.
16483907|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
16483908|NCT03403023|Experimental|DES treated patients|This single group of patients is imaged by the Tear Film Imager (TFI) device before and after treatment with Restasis, the treatment indicated for their condition.
16483909|NCT03403010|No Intervention|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
16483910|NCT03403010|Active Comparator|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
16483911|NCT03403010|No Intervention|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
16483912|NCT03402997||Resistivity measurements|The resistivity measurements will be done by introducing the needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues
16483913|NCT03402984|Experimental|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
16483914|NCT03402984|Placebo Comparator|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
16483915|NCT03402971||healthy pregnant+healthy fetus|healthy pregnant women with suspected healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
16483916|NCT03402971||non healthy pregnant|non healthy women with suspected healthy or unhealthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
16483917|NCT03402971||non healthy fetus|healthy or non healthy pregnant women with suspected non healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
16483918|NCT03402945|Active Comparator|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.
~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
16483919|NCT03402945|Active Comparator|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.
~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
16483920|NCT03402945|Active Comparator|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.
~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
16483921|NCT03402945|Active Comparator|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.
~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
16483922|NCT03402932|Experimental|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
16483923|NCT03402932|Experimental|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
16483924|NCT03402932|Experimental|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
16483925|NCT03402932|Other|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
16483926|NCT03402919||Normal healthy elderly|participants with no subjective or objective cognitive deficits or decline.
16483927|NCT03402919||Subjective Cognitive Decline|Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
16483928|NCT03402919||Mild Cognitive Impairment (MCI)|Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
16483929|NCT03402919||Vascular MCI|Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
16483930|NCT03402919||Alzheimer's Disease|Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
16483931|NCT03402919||Dementia of Mixed Etiology|Participants with dementia and evidence of more than one etiology.
16483932|NCT03402919||Lewy Body/Parkinson's spectrum|Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
16483933|NCT03402919||Frontotemporal dementia (FTD) spectrum|Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
16483934|NCT03402906|Experimental|Family-Clinician Collaboration|"Experimental group which will be performing the Family-Clinician Collaboration Program. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the patient.
~Intervention: Behavioral - Family-Clinician Collaboration Program; Behavioral - Standard Care at KIR"
16483935|NCT03402906|Sham Comparator|Control|"Control group in which patient will receive the standard treatment provided at Kessler Institute for Rehabilitation (KIR).
~Intervention: Behavioral - Standard Care at KIR"
16483936|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
16483937|NCT03402880|Experimental|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
16483938|NCT03402867|Experimental|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
16483939|NCT03402854|Experimental|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
16483940|NCT03402854|Experimental|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
16483941|NCT03402841|Experimental|Olaparib|"Olaparib will be supplied as film-coated tablets containing 150 mg or 100 mg of olaparib.
~Patients will be administered olaparib orally twice daily (bid) at 300 mg."
16483942|NCT03402815|Experimental|A|Patients received Maraviroc 300 mg/day in addition to current ART for 24 weeks. At the end of the first 24-week period patients were switched to ART with no additional treatment.
16483943|NCT03402815|Experimental|B|Patients received ART with no additional treatment for 24 weeks. At the end of the first 24-week period patients were switched to Maraviroc 300 mg/day in addition to current ART.
16483944|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
16483945|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
16483946|NCT03402776|No Intervention|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
16483947|NCT03402776|Experimental|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
16483948|NCT03402776|No Intervention|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
16483949|NCT03402763|No Intervention|Control Arm|Participants receive a short informational handout on the process and choices involved in advance care planning.
16483950|NCT03402763|Experimental|Intervention|Participants are shown a 6-minute video that describe CPR, breathing tube placement, and mechanical breathing support in addition to the general process of advance care planning.
16483951|NCT03402750|Experimental|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
16483952|NCT03402750|Active Comparator|Standard Care|Electronic prescription with patient pickup at the pharmacy
16483953|NCT03402737|Experimental|Stereotactic body radiotherapy + IM|Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.
16483954|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
16483955|NCT03402698|Experimental|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
16483956|NCT03402685|No Intervention|NIBP-Group|NIBP will be shown, ClearSight will be covered.
16483957|NCT03402685|Experimental|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
16483958|NCT03402672|Experimental|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
16483961|NCT03402646|Experimental|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
16483962|NCT03402646|Experimental|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
16483963|NCT03402646|No Intervention|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
16483964|NCT03402620|Active Comparator|four ampoules group|gonadotropin starting dose is 4 ampoules daily
16483965|NCT03402620|Active Comparator|six ampoules group|gonadotropin starting dose is 6 ampoules daily
16483966|NCT03402607|Active Comparator|Percutaneous Local Abalation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
16483967|NCT03402607|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
16483968|NCT03402594|No Intervention|No oxygen|No oxygen supplementation given
16483969|NCT03402594|Active Comparator|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
16483970|NCT03402594|Experimental|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
16483971|NCT03402581||c-mac used for intubation|obese patients intubated with c-mac videolaryngoscope
16483972|NCT03402581||mc-grath used for intubation|obese patients intubated with mc-grath videolaryngoscope
16483973|NCT03402542||Cholecystectomy|Patients with a symptomatic vesicular lithiasis, having undergone cholecystectomy during a scheduled hospitalization in the CHU Brugmann Hospital between May 2016 and November 2017.
16483974|NCT03402529|Other|CESM|
16483975|NCT03402516|Experimental|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
16483976|NCT03402516|Active Comparator|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
16483977|NCT03402503|Experimental|Group A|Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.
16483978|NCT03402503|Placebo Comparator|Group B|Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.
16483979|NCT03402490|Experimental|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
16483980|NCT03402490|No Intervention|Usual care|Participants who served as controls received usual care.
16483981|NCT03402464|Experimental|Icotinib combined dihydroaremisinin|
16483982|NCT03402438|Experimental|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
16483983|NCT03402438|Experimental|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m*2
16483984|NCT03402438|Experimental|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m*2
16483985|NCT03402438|Experimental|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m*2
16483986|NCT03402425|Experimental|All included patients|A 18F-FET PET scan is performed
16483987|NCT03402412|Experimental|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
16483988|NCT03402399|Other|Primary Myelofibrosis|Blood test
16483989|NCT03402399|Other|Secondary Myelofibrosis|Blood test
16483990|NCT03402386|Experimental|MT-6548|
16483991|NCT03402373|Experimental|Lycoderm|soft gel contains nutritional supplement
16483992|NCT03402373|Placebo Comparator|Placebo|Soft gel without active ingredients
16483993|NCT03402360|Experimental|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
16483994|NCT03402360|Active Comparator|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
16483995|NCT03402347|Experimental|Laser irradiation regimes|Non-ionising radiation intervention will be applied to skin explants
16483996|NCT03402334|Experimental|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.
~Cardiovascular risk factor counseling will include:
~Increased risk for atherosclerosis with chronic HCV infection
~Increased risk of heart attack and stroke
~Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
16483997|NCT03402334|No Intervention|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:
~HCV infection poses an increased risk for hepatocellular carcinoma
~Hepatitis C is a curable disease
~Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles
~HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)
~HCV+ individuals should reduce alcohol intake and shellfish consumption"
16483998|NCT03402321|Active Comparator|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
16483999|NCT03402321|Experimental|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
16484000|NCT03402308|Experimental|Schisandra chinensis extract group|This group takes Schisandra chinensis extract for 12 weeks
16484001|NCT03402308|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
16484002|NCT03402295|Active Comparator|Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)|"Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.
~Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles"
16484003|NCT03402295|Active Comparator|Ctd- Cyclophosphamide, thalidomide and dexamethasone|"Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)
~28 days each cycles- total of four cycles"
16484063|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
16484007|NCT03402256|Experimental|Text Message (TM)|"Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. 1). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. high, med, low), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval."
16484008|NCT03402256|No Intervention|Standard Care (SC)|"Participants will receive only standard care provided by the liver transplantation team. No additional behavioral or psychosocial interventions will be provided. All aspects of care received by SC participants will also provided to the TM condition participants. Medical care will be managed by medical specialty providers. SC condition participants will receive behavioral treatment within the liver transplantation clinic by psychology fellows and/or psychologists/psychiatrists. Treatment schedules and session topics will be determined by individual providers, per usual practice.
~These participants will receive only study-specific assessments. Participants in this condition will complete assessments at baseline, 4-weeks and 8-weeks that measure self- reported substance use, stress, and coping skills. At each in-person assessment, participants will provide urine for EtG analysis and will be compensated."
16484009|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
16484010|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
16484011|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
16484012|NCT03402230|Experimental|Arm I (Avmacol lower dose, Avmacol higher dose)|Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
16484013|NCT03402230|Experimental|Arm II (Avmacol higher dose, Avmacol lower dose)|Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
16484014|NCT03402204|Experimental|Simvastatin 10 mg|Simvastatin 10 mg
16484015|NCT03402204|Experimental|Simvastatin 40 mg|Simvastatin 40 mg
16484016|NCT03402191|Active Comparator|L-arginine|l-arginine for pulmonary hypertension in patients with thalassemia.
16484017|NCT03402191|Active Comparator|Sildenafil|Sildenafil for pulmonary hypertension in patients with thalassemia.
16484018|NCT03402191|No Intervention|Control|No pulmonary hypertension
16484019|NCT03402178|Experimental|E2082|E2082 will be administered as a solution (0.2 milligram [mg]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
16484020|NCT03402178|Placebo Comparator|E2082-matched placebo|Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
16484021|NCT03402165|Experimental|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
16484022|NCT03402165|Experimental|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
16484023|NCT03402165|Experimental|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
16484024|NCT03402152|Experimental|NRX-101 vs. Placebo|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral placebo and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
16484025|NCT03402152|Experimental|NRX-101 vs. lurasidone HCl|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral lurasidone and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
16484028|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
16484029|NCT03402113|Experimental|Dexmedetomidine group|Dexmedetomidine consistent infusion as sedative.
16484030|NCT03402113|Active Comparator|Midazolam group|Midazolam consistent infusion as sedative.
16484031|NCT03402100|Experimental|0.01% atropine|children who received 0.01% atropine for myopia
16484032|NCT03402100|Experimental|0.005% atropine|children who received 0.005% atropine for myopia
16484033|NCT03402100|Experimental|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
16484034|NCT03402100|Experimental|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
16484035|NCT03402100|Experimental|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
16484036|NCT03402087|Experimental|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
16484037|NCT03402074|Experimental|Group Hypnosis|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home
16484038|NCT03402061||Community living seniors|Approximately 50 seniors will taste test each nutrient enhanced recipe and determine acceptability and palatability.
16484039|NCT03402061||LTC cognitively well|Approximately 15 seniors living in long term care who do not have cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
16484040|NCT03402061||LTC persons living with dementia|Approximately 15 seniors living in long term care with cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
16484041|NCT03402048|Active Comparator|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:
~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.
~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.
~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
16484042|NCT03402048|Experimental|experimental arm|"Treatment prescriptions will be based on gene analysis:
~Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.
~Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.
~Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.
~Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.
~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
16484045|NCT03402009|Experimental|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
16484046|NCT03402009|Active Comparator|Active Control|independent meditation using web-based tools and apps
16484047|NCT03401996|Experimental|Real tDCS|
16484048|NCT03401996|Sham Comparator|Sham tDCS|
16484049|NCT03401983|Experimental|PFMT + AT|Pelvic Floor Muscle Training and Abdominal Training
16484050|NCT03401983|Active Comparator|PFMT|Pelvic Floor Muscle Training
16484051|NCT03401970|Active Comparator|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
16484052|NCT03401970|Experimental|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
16484053|NCT03401970|Experimental|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
16484054|NCT03401957||RAS wild-type colorectal cancer|RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
16484055|NCT03401944|Active Comparator|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
16484056|NCT03401944|Placebo Comparator|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
16484057|NCT03401918|Experimental|Comparing the microbiome and ERA in RPL and infertility|"In this arm we will assess the uterine environment at the time of implantation in recurrent pregnancy loss patients and unexplained infertility patients and compare the environment in these patient populations to healthy parous controls.
~We will test the uterine endometrial gene expression using the ERA test and the uterine micro biome."
16484058|NCT03401918|Experimental|The impact of progesterone and antibiotics/probiotics|In this arm, recurrent pregnancy loss and unexplained infertility patients who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome.
16484059|NCT03401905|Experimental|Low frequency|Percutaneous electrical nerve stimulation with frequency of 2 Hz and 120 microseconds of pulse width will be applied.
16484060|NCT03401905|Active Comparator|High frequency|Percutaneous electrical nerve stimulation with frequency of 120 Hz and 200 microseconds of pulse width will be applied.
16484061|NCT03401892|Experimental|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
16484062|NCT03401892|Experimental|Healthy control subjects|healthy age-and sex- matched control subjects
16484065|NCT03401866|Other|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
16484066|NCT03401853|Experimental|Treatment (pembrolizumab, rituximab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive rituximab or obinutuzumab IV on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab Iv on day 1 of cycles 5, 9, 13, 17, 21, and 25 only."
16484067|NCT03401840|Experimental|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
16484068|NCT03401827|Experimental|Gemcitabine + nab-paclitaxel|Case with chemotherapy (Gemcitabine + nab-paclitaxel)
16484069|NCT03401801|Active Comparator|4 ml of 1% lidocaine|Procedure: 4 ml of 1% lidocaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
16484070|NCT03401801|Active Comparator|6 ml of 1% lidocaine|Procedure: 6 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
16484071|NCT03401801|Active Comparator|8 ml of 1% lidocaine|Procedure: 8 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
16484072|NCT03401788|Experimental|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
16484073|NCT03401775|Experimental|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
16484074|NCT03401775|No Intervention|Group2|No intervention will be administered
16484075|NCT03401762|Experimental|Chronic stroke MCI Electromyogram (EMG) pairs|Decoupling 2 muscles at a time with MCI
16484076|NCT03401762|Experimental|Chronic stroke MCI EMG triplets|Decoupling 3 muscles at a time with MCI
16484077|NCT03401762|Experimental|Chronic stroke MCI while reaching|Decoupling muscles with MCI while reaching to targets
16484078|NCT03401762|Sham Comparator|Chronic stroke Sham MCI|Sham control group
16484079|NCT03401762|Experimental|Acute stroke MCI|Decoupling muscles with MCI in acute stroke subjects
16484080|NCT03401762|Sham Comparator|Acute stroke Sham MCI|Acute stroke subjects sham comparator
16484081|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
16484082|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
16484083|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
16484084|NCT03401736|Experimental|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
16484085|NCT03401736|Active Comparator|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65~85 and the Ramsay score was 3 to 4.
16484086|NCT03401723|Other|Novices|"Any physician who has no experience of endoscopies or has done no more than 50 colonoscopies.
~Each subject included are to perform on the Endoscopy Training System (ETS) during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
16484087|NCT03401723|Other|Experienced|"Includes any physician who have succeeded more than 140 colonoscopies. Professional backgrounds include surgeons and gastroenterologists.
~Each subject included are to perform on the ETS during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
16484088|NCT03401710|Experimental|Group 1|Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
16484089|NCT03401710|No Intervention|Group 2|No recombinant human erythropoietin will be administered to this group
16484090|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
16484091|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
16484092|NCT03401684|Experimental|Resilient Minds|Four comprehensive, skill-building learning modules in the areas of psychological trauma, mental health problems, resiliency and workplace stress.
16484093|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
16484094|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
16484095|NCT03401645|Experimental|Treatment (Alarm Active)|"Participants will be wearing the wrist device with an alarm timer that sends out signals every 5 minutes. The alarm is a buzzing noise and a vibration. Participants must turn off the alarm then perform a series of visuomotor tasks. This will be done for one hour, twice a day for two weeks.
~Intervention: Device - Wrist Alarm; Behavioral - Home-based Arm and Hand Exercise"
16484096|NCT03401645|Sham Comparator|Control (Sham Control)|"Participants will perform the same tasks as the Alarm/Treatment group, but without the alarm timer. This is a series of visuomotor tasks for one hour, twice per day for two weeks.
~Intervention: Behavioral - Home-based Arm and Hand Exercise"
16484097|NCT03401619||Osteoporosis With Cognitive impairment|
16484098|NCT03401619||Osteoporosis With Arterial stiffness|
16484099|NCT03401619||Osteoporosis|
16484100|NCT03401619||Normal|
16484101|NCT03401606|Active Comparator|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
16484102|NCT03401606|Active Comparator|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
16484325|NCT03400150|Experimental|ProSpace group|Marking + ProSpace implantation + IMRT
16484103|NCT03401593|Active Comparator|ablation|Patients in this group are treated with radio-frequency catheter ablation.
16484104|NCT03401593|No Intervention|non-ablation|Patients in this group are treated with rate control medications (e.g., beta blocker, calcium channel blocker, and digitalis) and anti-arrhythmic drugs. They also can be treated with DC cardio-version.
16484105|NCT03401580|Experimental|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
16484106|NCT03401580|Experimental|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
16484107|NCT03401580|Experimental|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
16484108|NCT03401580|Experimental|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
16484109|NCT03401567|Experimental|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
16484110|NCT03401567|No Intervention|Control group|Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.
16484111|NCT03401554|Active Comparator|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
16484112|NCT03401554|Experimental|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
16484113|NCT03401541|Experimental|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
16484114|NCT03401541|Experimental|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
16484115|NCT03401541|Experimental|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
16484116|NCT03401541|Experimental|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
16484117|NCT03401528|Experimental|Single Ascending Dose - AVB-S6-500|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
16484118|NCT03401528|Placebo Comparator|Single Ascending Dose - placebo|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
16484119|NCT03401528|Experimental|Repeat Dose - AVB-S6-500|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
16484120|NCT03401528|Placebo Comparator|Repeat Dose - placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
16484121|NCT03401515|Active Comparator|Intervention|Adminstration of propranolol hydrochloride ( 1 MG /ml) 1 mg every 6 hrs .
16484122|NCT03401515|Placebo Comparator|Control|Adminstration of normal saline 1 mg every 6 hrs
16484123|NCT03401502|Experimental|Treatment groups|Ranolazine 1000 mg
16484124|NCT03401502|Placebo Comparator|Control group|Placebos
16484125|NCT03401489|Experimental|PACESETTER|
16484126|NCT03401489|No Intervention|Healthy Lifestyle Intervention Group|
16484127|NCT03401476|Active Comparator|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
16484128|NCT03401476|Active Comparator|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
16484129|NCT03401463|Active Comparator|once a day|Cuff pressure checks once a day.
16484130|NCT03401463|Active Comparator|three times a day|Cuff pressure checks three times a day
16484131|NCT03401450|Active Comparator|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
16484132|NCT03401450|Active Comparator|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
16484133|NCT03401437||Retrospective cohorte|Patients seen in consultation between January 2017 and August 2017, who have already completed the SF-36 questionnaire (pre-operative, M1 and M3), the HAD and ANSM questionnaires (pre-operative and M3)
16484134|NCT03401437||Prospective cohorte|Patients seen in consultation between August 2017
16484135|NCT03401424|Experimental|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
16484136|NCT03401424|Active Comparator|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
16484137|NCT03401411|Experimental|Standard SCCMP|Health care provider completes triage survey of 15 fictional patient case scenarios using the standard SCCMP to prioritize each for admission.
16484138|NCT03401411|Experimental|SCCMP + Algorithm-based Triage Tool|Health care provider completes triage survey of 15 fictional patient case scenarios using SCCMP in addition to a newly designed flowchart-based triage guide to prioritize each for admission.
16484139|NCT03401398|Active Comparator|Treatment|Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
16484140|NCT03401398|Placebo Comparator|Placebo|Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
16484141|NCT03401385|Experimental|Dose Escalation - All Participants|All participants enrolled in the dose escalation part
16484142|NCT03401385|Experimental|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
16484143|NCT03401372|Experimental|Doxycycline/BCD chemotherapy|Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy
16484144|NCT03401372|Active Comparator|BCD chemotherapy|Bortezomib-cyclophosphamide-dexamethasone chemotherapy
16484326|NCT03400150|Sham Comparator|Control group|Marking + IMRT
16484145|NCT03401346|Experimental|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
16484146|NCT03401346|Active Comparator|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
16484147|NCT03401346|Active Comparator|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
16484148|NCT03401333|Experimental|Text messaging and brief intervention|Brief motivational interview and 4-weeks of text messaging.
16484149|NCT03401320|Experimental|Cohort 1: Letrozole ISM 50 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 50 mg Letrozole ISM
16484150|NCT03401320|Experimental|Cohort 2: Letrozole ISM 100 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 100 mg Letrozole ISM
16484151|NCT03401320|Experimental|Cohort 3: Letrozole ISM 200 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 200 mg Letrozole ISM
16484152|NCT03401320|Experimental|Cohort 4: Letrozole ISM 400 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 400 mg Letrozole ISM
16484153|NCT03401307||Responders to Fampridine Treatment|Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
16484154|NCT03401307||Non-Responders to Fampridine Treatment|Participants, who are classified as non-responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify non-responders to Fampridine. Participants who do not improve with ≥20% on the T25FW are categorized as non-responders.
16484155|NCT03401294|Other|Single arm|FOLFOXIRI and Bevacizumab
16484156|NCT03401281|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
16484157|NCT03401281|Active Comparator|Butter|50g Butter to be consumed daily for four weeks
16484158|NCT03401281|Active Comparator|Olive oil|50g extra virgin olive oil to be consumed daily for four weeks
16484159|NCT03401268|Experimental|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
16484160|NCT03401229|Experimental|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
16484161|NCT03401229|Placebo Comparator|Placebo SC + MF|
16484162|NCT03401216|Experimental|SYNERGY 48 PCI + 3 month OCT follow-up|Synergy 48 mm stent implantation followed by 3 month OCT imaging
16484163|NCT03401216|Experimental|SYNERGY 48 PCI + 6 month OCT follow-up|Synergy 48 mm stent implantation followed by 6 month OCT imaging
16484164|NCT03401203|Experimental|rotational atherectomy followed by balloon angioplasty|
16484165|NCT03401203|Active Comparator|balloon angioplasty|
16484166|NCT03401190|Experimental|Low Dose Female|Cohort 1 will consist of 4 female patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
16484167|NCT03401190|Experimental|Low Dose Male|Cohort 2 will consist of 4 male patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
16484168|NCT03401190|Experimental|High Dose Female|Cohort 3 will consist of 8 female patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
16484169|NCT03401190|Experimental|High Dose Male|Cohort 4 will consist of 8 male patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
16484170|NCT03401177|Experimental|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
16484171|NCT03401177|Placebo Comparator|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
16484172|NCT03401125||Sickle cell disease patients (SS genotype)|Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
16484173|NCT03401112|Placebo Comparator|Placebo|
16484174|NCT03401112|Experimental|Dose 1|IMR-687
16484175|NCT03401112|Experimental|Dose 2|IMR-687
16484176|NCT03401099|Active Comparator|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
16484177|NCT03401099|Active Comparator|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
16484178|NCT03401086|Active Comparator|Study group|Kinesio Taping
16484179|NCT03401086|No Intervention|Control group|No intervention
16484180|NCT03401073|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
16484181|NCT03401073|Experimental|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
16484182|NCT03401060|Experimental|Experimental medication 1|Denosumab 60 mg subcutaneously injection with prefilled syringe
16484183|NCT03401060|Placebo Comparator|Experimental medication 2|NaCl 0.9%, 20ml phial, solution for injection
16484524|NCT03398824|Experimental|Treatment arm|Receive metformin HCl
16484184|NCT03401047|Experimental|Transdermal Estradiol|Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
16484185|NCT03401021||Crrent Male smokers|"Male smokers met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).
~be aged 18 or above,
~have a history of smoking at least one cigarette per day before their partners became pregnant,
~be involved with partners whose pregnancies could be confirmed,
~able to read Chinese and communicate in the Mandarin dialect."
16484186|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
16484187|NCT03400995|Experimental|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
16484188|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
16484189|NCT03400969|Active Comparator|Glycerol 17 %|Oral moisturizer
16484190|NCT03400969|Active Comparator|Aequasyal (OGT)|Oral moisturizer
16484191|NCT03400969|Active Comparator|Salient (new product)|Oral moisturizer
16484192|NCT03400956|Experimental|Vilaprisan (A1)|Vilaprisan in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
16484193|NCT03400956|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
16484194|NCT03400956|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan in treatment period 1 for 12 weeks, and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
16484199|NCT03400930||OptiDiag-Cohort, Liberia|A respresentative population of 275 Liberian children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
16484200|NCT03400930||OptiDiag/MANGO-Cohort, Burkina Faso|A respresentative population of 275 Burkinabé children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
16484201|NCT03400930||OptiDiag-cohort, Bangladesh|A respresentative population of 275 Bangladeshi children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
16484202|NCT03400917|Experimental|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
16484203|NCT03400891|Experimental|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
16484204|NCT03400891|No Intervention|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
16484205|NCT03400878|Active Comparator|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
16484206|NCT03400878|Active Comparator|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
16484207|NCT03400865|Experimental|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.
16484208|NCT03400852|Experimental|Period 1: MNK-1411|Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
16484209|NCT03400852|Experimental|Period 1: Placebo|Participants receive placebo at a volume appropriate to body weight during Period 1
16484210|NCT03400852|Experimental|Period 2: MNK-1411|All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2
16484211|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.
~Patients will be submitted to the assessment of:
~Daily physical activity levels;
~6-minute walk test;
~Cardiopulmonary exercise testing;
~Muscle Function;
~Lung Function;
~Body composition;
~HRQoL - SGRQ-I;
~HRQoL - SF36;
~Anxiety and depression;
~Symptoms - mMRC
~Symptoms - UCSD/SOBQ;
~Sleep quality;
~Sleepiness;
~Inflammatory markers and oxidative stress.
~Functional performance tests"
16484212|NCT03400839||Control Group|"Age-matched peers without lung diseases.
~Participants will be submitted to the assessment of:
~Daily physical activity levels;
~6-minute walk test;
~Cardiopulmonary exercise testing;
~Muscle Function;
~Lung Function;
~Body composition;
~HRQoL - SF36;
~Anxiety and depression;
~Sleep quality;
~Sleepiness;
~Inflammatory markers and oxidative stress.
~Functional performance tests"
16484213|NCT03400826|Experimental|Treatment Group|The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
16484214|NCT03400826|Placebo Comparator|Placebo Group|The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
16484215|NCT03400813|No Intervention|Control|Patients in this group continue their usual care without intervention.
16484216|NCT03400813|Experimental|R-TEP EMDR|Patients in R-TEP EMDR group will receive the intervention.
16484217|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
16484218|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
16484219|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.
~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
16484220|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
16484221|NCT03400774|Other|Control|Oral glucose tolerance test with no stair-climbing
16484222|NCT03400774|Experimental|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
16484223|NCT03400774|Experimental|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
16484224|NCT03400774|Active Comparator|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
16484225|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
16484226|NCT03400735|Experimental|Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets|
16484227|NCT03400735|Active Comparator|Cefdinir 300 mg Capsules|
16484228|NCT03400722|Experimental|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
16484229|NCT03400722|Experimental|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
16484230|NCT03400709|Experimental|N-acetylcisteine group|
16484231|NCT03400709|Placebo Comparator|Control group|
16484232|NCT03400696|Experimental|Randomized- Lower carbohydrate diet|
16484233|NCT03400696|Experimental|Randomized- Higher fiber diet|
16484234|NCT03400696|Experimental|Randomized- Exercise focused|
16484235|NCT03400696|Experimental|Participant chooses- Lower carbohydrate diet|
16484236|NCT03400696|Experimental|Participant chooses- Higher fiber diet|
16484237|NCT03400696|Experimental|Participant chooses- Exercise focused|
16484238|NCT03400683|Active Comparator|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
16484239|NCT03400683|Active Comparator|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
16484240|NCT03400683|Active Comparator|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
16484241|NCT03400670|Active Comparator|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
16484242|NCT03400670|Active Comparator|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
16484243|NCT03400657||fully implemented to the MDT decision|group of patients fully implemented to the MDT decision
16484244|NCT03400657||not completly implemented to the MDT-decision|group of patients not completly implemented to the MDT decision
16484245|NCT03400657||not implemented to the MDT decision|group of patients not implemented to the MDT decision
16484246|NCT03400644|Active Comparator|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
16484247|NCT03400644|No Intervention|Without Collar|Subjects do not need to wear any cervical collar postoperatively
16484248|NCT03400631|Experimental|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
16484249|NCT03400631|Experimental|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
16484250|NCT03400618|Experimental|Moderate carbohydrate diet|A healthy diet containing 30 E % carbohydrates
16484251|NCT03400618|Experimental|Higher carbohydrate diet|A healthy diet containing 50 E % carbohydrates
16484252|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
16484253|NCT03400592|Experimental|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
16484254|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
16484255|NCT03400566|Experimental|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
16484256|NCT03400566|Experimental|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
16484257|NCT03400566|Active Comparator|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
16484258|NCT03400566|Active Comparator|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
16484259|NCT03400553|Experimental|non-traumatic thoracic pain|Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.
16484260|NCT03400540|Experimental|Group A|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~squeeze the pelvic floor muscles
~squeeze and lift the pelvic floor muscles as if stopping the flow of urine
~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.
~contract all of the above together"
16484261|NCT03400540|Experimental|Group B|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~squeeze the pelvic floor muscles
~squeeze the anus
~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.
~contract all of the above together"
16484262|NCT03400527|Experimental|Exercise|Participant will be pedaling a stationary exercise bicycle
16484263|NCT03400501|Experimental|subjects receiving insulin degludec|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin degludec injections.
16484264|NCT03400501|Active Comparator|Subjects receiving insulin glargine|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin glargine injections.
16484265|NCT03400488|Experimental|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
16484266|NCT03400488|Placebo Comparator|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
16484267|NCT03400475|Experimental|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
16484268|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
16484269|NCT03400462|Experimental|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
16484270|NCT03400462|Experimental|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:
~Nimesulide 2*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
16484271|NCT03400462|Active Comparator|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.
~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
16484272|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
16484273|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
16484274|NCT03400423|Experimental|Non-caffeine exercise|Exercise cognition score
16484275|NCT03400423|Active Comparator|Non-caffeine cognition|Caffeine cognition score
16484276|NCT03400423|Experimental|Caffeine consumption exercise|Exercise cognition score
16484277|NCT03400423|Active Comparator|Caffeine consumption cognition|Caffeine cognition score
16484278|NCT03400423|Experimental|Deprived Caffeine consumers exercise|Exercise cognition score
16484279|NCT03400423|Active Comparator|Deprived caffeine consumers cognition|Caffeine administration cognition score
16484280|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.
~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
16484281|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.
~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
16484282|NCT03400397||Intervention|Treatment with the Cool Kids programme. The Cool Kids programme is a manualised cognitive behavioural treatment programme for children with anxiety disorders.
16484322|NCT03400176|Experimental|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
16484283|NCT03400384|Experimental|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
16484284|NCT03400384|No Intervention|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
16484285|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
16484286|NCT03400371||Controls|People without a lifetime history of seizures.
16484287|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
16484288|NCT03400332|Experimental|Part 1A: BMS-986253 + nivolumab|
16484289|NCT03400332|Experimental|Part 1B: BMS-986253 + nivolumab|
16484290|NCT03400332|Experimental|Part 1C: BMS-986253 + nivolumab + ipilimumab|
16484291|NCT03400332|Experimental|Part 2A: BMS-986253 + nivolumab + ipilimumab|
16484292|NCT03400332|Placebo Comparator|Part 2B: Placebo + nivolumab + ipilimumab|
16484293|NCT03400319||Thoracic Aortic Aneurysm|Patients with Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm.
16484294|NCT03400319||No Thoracic Aortic Aneurysm|Patients without Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva <39mm, or ascending aorta <42mm. Men: at the level of the sinus of valsalva <44mm, or ascending aorta <46mm.
16484295|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
16484296|NCT03400306|Experimental|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
16484297|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
16484298|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
16484299|NCT03400280|Experimental|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
16484300|NCT03400280|No Intervention|Current practice|Postoperative care according to current usual practice.
16484301|NCT03400267|Active Comparator|paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
16484302|NCT03400267|Active Comparator|fentanyl|
16484303|NCT03400254|Experimental|Phase II: Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
16484304|NCT03400254|Experimental|Phase II: Arm B|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
16484305|NCT03400254|Experimental|Phase II: Arm C|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
16484306|NCT03400254|Experimental|Phase II: Arm D|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
16484307|NCT03400254|Experimental|Phase Ib Arm|Patients will receive HCQ, 600 mg BID, and GED, administered weekly as an intravenous dose of 150 mg, for 6 weeks.
16484308|NCT03400241|Experimental|Tiotropium Easyhaler Product A|tiotropium bromide monohydrate 2 inhalations as a single dose
16484309|NCT03400241|Experimental|Tiotropium Easyhaler Product B|tiotropium bromide monohydrate 2 inhalations as a single dose
16484310|NCT03400241|Experimental|Tiotropium Easyhaler Product C|tiotropium bromide monohydrate 2 inhalations as a single dose
16484311|NCT03400241|Active Comparator|Spiriva HandiHaler|tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler
16484312|NCT03400228|Experimental|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
16484313|NCT03400228|Placebo Comparator|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
16484314|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
16484315|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
16484316|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
16484317|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
16484318|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
16484319|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
16484320|NCT03400189|Other|Single arm|"Single oral dose of sulthiame (Ospolot® tablets)
~Period I: 50 mg
~Period II: 100 mg
~Period III: 200 mg given 3 weeks apart"
16484321|NCT03400176|Experimental|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
16484323|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
16484327|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
16484328|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
16484329|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
16484330|NCT03400124|Active Comparator|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
16484331|NCT03400124|Active Comparator|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
16484332|NCT03400111|Experimental|Low-level laser therapy|Patients upper and lower jaws will be irradiated with low-level laser therapy at specific points on the alveolus around the teeth from the vestibular and lingual sides. This group of patients will be followed up till the end of treatment.
16484333|NCT03400111|Experimental|Panadol-extra|Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
16484334|NCT03400111|No Intervention|Traditional Treatment|Patients will not undergo any actual irradiation therapy or take any active tablets during orthodontic treatment.
16484335|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
16484336|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
16484337|NCT03400072|Experimental|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
16484338|NCT03400072|Experimental|Supervised APA program|usual care plus a 6-month supervised APA program
16484339|NCT03400072|No Intervention|Usual care|Usual care
16484340|NCT03400059|Experimental|Active Treatment|
16484341|NCT03400059|Sham Comparator|Sham Treatment|
16484342|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
16484343|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
16484344|NCT03400020|Experimental|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
16484345|NCT03400020|Placebo Comparator|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
16484346|NCT03400007||Prolapse surgery|
16484347|NCT03399994|Experimental|ABLUMINUS DES+|device implantation during coronary angioplasty
16484348|NCT03399994|Active Comparator|Everolimus-eluting DES|device implantation during coronary angioplasty
16484349|NCT03399981||Tysabri (TOUCH Cohort)|Patients from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
16484350|NCT03399981||Tysabri (EU MS Cohort)|Patients from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
16484351|NCT03399968|Experimental|ESWT|Application of shockwaves non-invasively at the level of injury
16484352|NCT03399968|Placebo Comparator|Placebo ESWT|Positioning of the therapy head at the injury level without application of shockwaves
16484353|NCT03399955|Experimental|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
16484354|NCT03399955|Experimental|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
16484355|NCT03399942|Experimental|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
16484356|NCT03399942|Experimental|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
16484357|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
16484358|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
16484359|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
16484360|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
16484361|NCT03399916|Experimental|Prompt|"An email based prompt was sent- containing either a stand or move message. Exploratory variations of the prompt were designed to include the addition of a goal e.g., stand for the next 5-minutes, and/or employer support e.g., PTS says stand for the next 5 minutes."
16484362|NCT03399916|No Intervention|No Prompt|Prompt delivery was sequentially randomized to be sent (ST) or not sent (NST) to all participants (probability of 0.5), at eight decision points per day (between 9am and 5pm), to achieve a total of 3200 randomizations across participants (160 per participant). Therefore 50% of the time, no prompt was sent.
16484363|NCT03399903|Experimental|Pentasa|40 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks
16484364|NCT03399903|Active Comparator|Align|40 participants will be randomized to take Align tablets, once daily for 8 weeks
16484365|NCT03399890||Group S|Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent. Neurological physical exam time was recorded.
16484366|NCT03399890||Group N|"Group N: Group Neostigmine
~Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded."
16484367|NCT03399877|Active Comparator|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
16484368|NCT03399877|Active Comparator|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
16484369|NCT03399877|Experimental|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
16484370|NCT03399864|Experimental|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
16484371|NCT03399864|Other|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
16484372|NCT03399851|Active Comparator|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
16484373|NCT03399851|Active Comparator|Watchman/FLX|Left atrial appendage closure (LAAC) with Watchman/FLX implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
16484374|NCT03399838|Experimental|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
16484375|NCT03399838|Active Comparator|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
16484376|NCT03399825||Healthy controls|Children without eye disease
16484377|NCT03399825||Retinopathy of prematurity (ROP)|Previously preterm children with a history of ROP
16484378|NCT03399825||Diabetic retinopathy|Children with diabetes
16484379|NCT03399812|Experimental|Whey protein isolate|
16484380|NCT03399812|Active Comparator|Pea protein isolate|
16484381|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Intravenous (IV)|Participants will receive IV infusion of Talquetamab at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
16484382|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Subcutaneous (SC)|Participants will receive Talquetamab SC. The dose levels will be selected to identify safe and tolerable putative RP2D(s).
16484383|NCT03399799|Experimental|Part 2: Dose Expansion (Talquetamab)|Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D[s]) as determined in Part 1.
16484384|NCT03399786|Experimental|evinacumab|
16484385|NCT03399786|Experimental|Placebo|
16484386|NCT03399773|Experimental|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A or regimen B.
~REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.
~REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0."
16484387|NCT03399760|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
16484388|NCT03399760|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
16484389|NCT03399747|Experimental|Abb-R-CHOP|
16484390|NCT03399734|Experimental|Treatment A|4 milligrams (mg) perampanel tablet
16484391|NCT03399734|Experimental|Treatment B|4 mg perampanel fine granules
16484392|NCT03399721|Active Comparator|Chordate S101 Active|Active treatment With Device Chordate S101
16484393|NCT03399721|Placebo Comparator|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
16484394|NCT03399695|Active Comparator|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
16484395|NCT03399695|Experimental|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
16484396|NCT03399682||Incidence of Post Cystography Urinary Tract Infections|all children less than 16 years having cystography
16484397|NCT03399669|Experimental|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
16484398|NCT03399656|Placebo Comparator|Placebo|4 placebo tablets
16484399|NCT03399656|Active Comparator|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
16484400|NCT03399656|Active Comparator|High Dose Avmacol|4 Avmacol tablets
16484401|NCT03399630|Active Comparator|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
16484402|NCT03399630|Placebo Comparator|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
16484403|NCT03399617|Active Comparator|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
16484404|NCT03399617|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
16484405|NCT03399617|Experimental|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
16484406|NCT03399604|Experimental|LIQ861 Inhaled Treprostinil|"LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.
~LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients."
16484412|NCT03399552|Experimental|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
16484413|NCT03399539|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16484414|NCT03399526|Experimental|Mapracorat|10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
16484415|NCT03399526|Active Comparator|Prednicarbate|10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
16484416|NCT03399526|Active Comparator|Clobetasol|10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
16484417|NCT03399526|Active Comparator|Calcipotriene|10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
16484418|NCT03399526|Active Comparator|Calcipotriene/Betamethasone dipropionate|10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
16484420|NCT03399500|Active Comparator|Usual Case Management (UCM)|Group receives standard case management at the shelter
16484421|NCT03399500|Experimental|UCM + Smartphone|Group receives standard case management and an unlimited smartphone
16484422|NCT03399500|Experimental|Smartphone Based Case Management (SPCM)|Group receives standard case management and an unlimited smartphone with the SPCM app
16484423|NCT03399487|Experimental|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.
~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.
~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
16484424|NCT03399474|Active Comparator|Lidocaine only|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.
16485157|NCT03394508|Placebo Comparator|Placebo|ALK diluent 0,3% human albumin'
16484425|NCT03399474|Experimental|0.5 ug/kg dexmedetomidine|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
16484426|NCT03399474|Experimental|0.25 ug/kg dexmedetomidine|1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.25 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min. for intravenous regional anesthesia.
16484427|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
16484428|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
16484429|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
16484430|NCT03399448|Experimental|Multiple Myeloma (MM)|
16484431|NCT03399448|Experimental|Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL)|
16484432|NCT03399448|Experimental|Melanoma|Not Recruiting at the UPenn Site
16484433|NCT03399435|Experimental|Part A|8 cohorts are planned to be treated.
16484434|NCT03399435|Experimental|Part B|Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.
16484435|NCT03399435|Experimental|Part C|Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
16484436|NCT03399422|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
16484437|NCT03399422|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
16484438|NCT03399409|Experimental|Motivational Interviewing|
16484439|NCT03399409|Active Comparator|Anti-inflammatory information program|
16484440|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
16484441|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
16484442|NCT03399383|Other|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
16484443|NCT03399370|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
16484444|NCT03399370|Placebo Comparator|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
16484445|NCT03399357||≥ 65 Years old|Healthy community-dwelling elderly (men and women) age 65 and above who are eligible for influenza vaccine and fulfil inclusion and exclusion criteria
16484446|NCT03399344|Other|DW-MRI|Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
16484447|NCT03399331|Experimental|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
16484448|NCT03399331|Experimental|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
16484449|NCT03399331|Placebo Comparator|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
16484450|NCT03399318|Experimental|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30mg/kg load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
16484451|NCT03399318|Placebo Comparator|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
16484452|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
16484453|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
16484454|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
16484455|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
16484456|NCT03399279|Experimental|Open flap debridement & perforated&Nano|Perforated collagen membrane and nano-hydroxyapatite and open flap debridement
16484457|NCT03399279|Active Comparator|Open flap debridment &Occlusive&Nano|Occlusive membrane and nano-hydroxyapatite and open flap debridement
16484458|NCT03399266|Experimental|Double balloon catheter for induction of labor|in this group a trans-cervical double balloon catheter will be inserted. Following device insertion, 20 minutes of external monitoring is performed. The patient will be transferred to the Ob/Gyn ward for hospitalization. 12 hours after insertion of the device the balloons are deflated and the device removed. At this stage the patient is assessed for a second Bishop score and expectant management is resuming.
16484459|NCT03399266|No Intervention|Expectant management|Women in the expectant management group will be transferred to the Ob/Gyn ward for hospitalization and conservative management until spontaneous labor ensues.
16484460|NCT03399253|Active Comparator|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
16484461|NCT03399253|Experimental|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
16485417|NCT03392623|Other|Control group|Macules of melasma without any treatment
16484462|NCT03399240|Experimental|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
16484463|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
16484464|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
16484465|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 1|IV injection, 0.27 mg/kg
16484466|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 2|IV injection, 0.54 mg/kg
16484467|NCT03399201|Active Comparator|General Anesthesia|Standard General Anesthesia will be applied.The change of the pulmonary functions will be evaluated via spirometer.
16484468|NCT03399201|Active Comparator|Neuraxial Anesthesia|Neuraxial anesthesia will be applied. The change of the pulmonary functions will be evaluated via spirometer.
16484469|NCT03399188|Experimental|FMT group|Group who received fecal microbiome transplantation
16484470|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
16484471|NCT03399162|Experimental|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
16484472|NCT03399162|Active Comparator|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
16484473|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
16484474|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.
~Time period: From March 2017 to end of study"
16484475|NCT03399136|Experimental|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
16484476|NCT03399136|Experimental|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
16484477|NCT03399123|Experimental|Low tidal volume group|Use a low tidal volume(6'8ml/kg) ventilation mode during liver segmentation。
16484478|NCT03399123|Active Comparator|Standard tidal volume group|Use a standard tidal volume(10'12ml/kg) ventilation mode during operation.
16484479|NCT03399110|Experimental|XELOX for 4 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease
16484480|NCT03399110|Active Comparator|XELOX for 6 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
16484481|NCT03399097||non-obese|non-obese
16484482|NCT03399097||obese|obese
16484483|NCT03399097||previously obese|previously obese
16484484|NCT03399084|Experimental|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
16484485|NCT03399084|Active Comparator|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
16484486|NCT03399071|Experimental|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.
~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
16484487|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
16484488|NCT03399058|Other|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2). The Hearth messages are contextualized messages on child feeding practices that women in the community have found helpful to successfully prevent child malnutrition. This program will be delivered through in person community meetings.
16484489|NCT03399058|Other|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a similar program as group 2 with contextualized child feeding messages (PDH lite program) and receive follow-up through mobile support phone calls (Group 3).
16484490|NCT03399045|Experimental|9-minute withdrawal group|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.
16484491|NCT03399045|Active Comparator|6-minute withdrawal group|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.
16484492|NCT03399032||Caspofungin|Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
16484493|NCT03399019|Experimental|Dexmedetomidine|"Dexmedetomidine
~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr
~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
16484494|NCT03399019|Active Comparator|Propofol|"Propofol
~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
16484495|NCT03399019|Active Comparator|Midazolam|"Midazolam
~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr
~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
16484496|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
16484497|NCT03399006||Normal pregnancy|women with normal blood presure
16484498|NCT03398993|Active Comparator|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.
~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
16484499|NCT03398993|Active Comparator|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
16484500|NCT03398980||survivors treated with CRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with convention radiotherapy (CRT).
16484501|NCT03398980||survivors treated with IMRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with intensity-modulated radiotherapy (IMRT).
16484502|NCT03398941|Experimental|Combined group|
16484503|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
16484504|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
16484505|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
16484506|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
16484507|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
16484508|NCT03398902|Experimental|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
16484509|NCT03398902|Active Comparator|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
16484510|NCT03398889||Unexplained Atherosclerosis phenotype|Residual score in linear regression >2
16484511|NCT03398889||Explained Atherosclerosis phenotype|Residual score in linear regression <-2, <2
16484512|NCT03398889||Protected Atherosclerosis phenotype|Residual score <-2
16484513|NCT03398876|Experimental|Part 1; Treatment Sequence ABDC|Participants will receive Treatment A (one spray of oromucosal nicotine spray [ONS]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette [10 puffs]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
16484514|NCT03398876|Experimental|Part 1; Treatment Sequence BCAD|Participants will receive Treatment B at Visit 1, then Treatment C at Visit 2, then Treatment A at Visit 3 followed by Treatment D at Visit 4. The visits will be separated by a period of at least 7 calendar days.
16484515|NCT03398876|Experimental|Part 1; Treatment Sequence CDBA|Participants will receive Treatment C at Visit 1, then Treatment D at Visit 2, then Treatment B at Visit 3 followed by Treatment A at Visit 4. The visits will be separated by a period of at least 7 calendar days. The visits will be separated by a period of at least 7 calendar days.
16484516|NCT03398876|Experimental|Part 1; Treatment Sequence DACB|Participants will receive Treatment D at Visit 1, then Treatment A at Visit 2, then Treatment C at Visit 3 followed by Treatment B at Visit 4. The visits will be separated by a period of at least 7 calendar days.
16484517|NCT03398876|Experimental|Part 2; Treatment Sequence EF|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment E (two consecutive sprays of ONS once every 30 minutes until 11.5 hours) at Visit 5, followed by Treatment F (two consecutive sprays of ONS once every 1 hour until 11 hours) at Visit 6. The visits will be separated by a period of at least 7 calendar days.
16484518|NCT03398876|Experimental|Part 2; Treatment Sequence FE|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment F at Visit 5 followed by Treatment E at Visit 6. The visits will be separated by a period of at least 7 calendar days.
16484519|NCT03398863|Active Comparator|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
16484520|NCT03398863|No Intervention|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
16484521|NCT03398837|Experimental|Cohort 1|Lenabasum 5 mg BID
16484522|NCT03398837|Experimental|Cohort 2|Lenabasum 20 mg BID
16484523|NCT03398837|Placebo Comparator|Cohort 3|Placebo BID
16484525|NCT03398811||"Group I the depot medroxy-progesterone acetate group"|where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
16484526|NCT03398811||"Group II Implanon group"|where they will have Implanon (etonogestrel implant) 68 mg implant
16484527|NCT03398811||group III (cerazette group)|where they are using Cerazette pills (desogestrel 75 µg l) one pill every day for 28 days without pill-free interval.
16484528|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
16484529|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
16484530|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
16484531|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
16484532|NCT03398785|Experimental|Intevention|Adrenal Artery Ablation
16484533|NCT03398785|No Intervention|Control|No intervention, but treated with standard anti-hypertensive drigs
16484534|NCT03398772|Experimental|Experiment|Comprehensive Health Coaching Program
16484535|NCT03398772|No Intervention|Control|Guideline-based usual care
16484536|NCT03398759|Experimental|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
16484537|NCT03398759|Placebo Comparator|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
16484538|NCT03398746|Experimental|LOOP Technique|Placement of subcutaneous loop drain
16484539|NCT03398746|Active Comparator|Incision and Drainage|Standard Incision and Drainage Technique
16484540|NCT03398733|Other|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively.
16484541|NCT03398720|Experimental|Cohort 1|One participant will receive HTI-1066 at the starting dose.
16484542|NCT03398720|Experimental|Cohort 2|Participants will receive HTI-1066 at dose level 2.
16484543|NCT03398720|Experimental|Cohort 3|Participants will receive HTI-1066 at dose level 3.
16484544|NCT03398720|Experimental|Cohort 4|Participants will receive HTI-1066 at dose level 4.
16484545|NCT03398694|Experimental|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-4 days prior to surgical resection.
16484546|NCT03398681|Active Comparator|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
16484547|NCT03398681|Placebo Comparator|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
16484548|NCT03398668|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
16484549|NCT03398668|Sham Comparator|Sham Comparator: Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
16484550|NCT03398655|Experimental|Arm 1|VB-111 + Paclitaxel
16484551|NCT03398655|Active Comparator|Arm 2|Placebo + Paclitaxel
16484552|NCT03398642|Experimental|French Lifestyle Redesign|16 older adults, 10 without and 6 with disabilities, participated to weekly 2-hour group sessions, including outings, and monthly 1-hour individual sessions led by a occupational therapist over 6-month period and promoting healthy lifestyle and involvement in meaningful activities.
16484553|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)>95th percentile).
16484554|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
16484555|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
16484556|NCT03398603||Group 1|25 women with age of 18-25 years
16484557|NCT03398603||Group 2|25 women with age of 26-40 years
16484558|NCT03398590|Experimental|mHealth Intervention for Older Adults|"Pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.
~This is a one Group Pretest-Posttest Designed study. Ten participants will be recruited from Joslin Diabetes Center, Boston, MA. They will receive a 2-month, self-regulation theory-based weight loss intervention (five 60-minute, biweekly group sessions) and will be provided with a technology toolkit for self-monitoring including an (1) iPhone Plus, (2) the Lose It! app for self-monitoring of dietary intake, (3) Fitbit for self-monitoring of physical activity, (4) Bluetooth-enabled scale for daily weight, and (5) Bluetooth-enabled blood glucose monitor for testing blood glucose levels."
16484559|NCT03398577|Experimental|Intervention group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Intervention group will receive Dapagliflozin 10 mg in addition to oral anti-diabetic medication administered prior to study enrollment.
16484560|NCT03398577|Placebo Comparator|Control group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Control group will receive placebo in addition to oral anti-diabetic medication administered prior to study enrollment.
16484561|NCT03398564|Placebo Comparator|Group I (Control)|ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline
16484562|NCT03398564|Active Comparator|Group II (ESP)|ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%
16484563|NCT03398564|Active Comparator|Group III(OSTAP)|Ultrasound-guided bilateral oblique subcostal TAP block
16484564|NCT03398538|Experimental|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
16484565|NCT03398538|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
16484566|NCT03398525|Active Comparator|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
16484567|NCT03398525|Experimental|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
16484568|NCT03398512|Experimental|Experimental|HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
16484569|NCT03398499|Experimental|Magnetoledotherapy|Active ELF EMF Participants will receive active transcranial low frequency elec-tromagnetic field and magnetic induction (ELF EMF) and high energy LED light were used stimulation,Using the Viofor JPS device (Med & Live)
16484570|NCT03398486|Experimental|Kinesiotaping|Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.
16484571|NCT03398486|Experimental|inactivation of trigger points (TrP)|Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break
16484572|NCT03398473|Experimental|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
16484573|NCT03398473|Experimental|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
16484574|NCT03398460|Other|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
16484575|NCT03398434|Experimental|MAA868 low dose regimen|patients receive dose monthly.
16484576|NCT03398434|Experimental|MAA868 middle dose regimen|patients receive dose monthly.
16484577|NCT03398434|Experimental|MAA868 high dose regimen|patients receive dose monthly.
16484578|NCT03398434|Active Comparator|Apixaban|Apixaban 5 mg b.i.d
16484579|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
16484580|NCT03398408|Experimental|Intervention|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.
~Participants in the intervention group will then be provided with the Lumosity cognitive flexibility training module and complete daily training for a total of five weeks. 1-3 days after completion of their training, all patients will be invited to complete the computerized versions of the TMT A and B, Color Match, and NCPT tests again on their personal computers."
16484581|NCT03398408|No Intervention|Control|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.
~Patients in the control group will complete all tests upon enrollment and approximately five weeks after their initial testing, but will not participate in training."
16484582|NCT03398395|Active Comparator|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
16484583|NCT03398395|Active Comparator|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
16484584|NCT03398382|Placebo Comparator|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
16484585|NCT03398382|Placebo Comparator|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
16484586|NCT03398382|Placebo Comparator|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
16484587|NCT03398382|Placebo Comparator|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.
~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
16484588|NCT03398369|Experimental|Intervention|CMR-Guided CRT
16484589|NCT03398369|No Intervention|Control|Standard CRT
16484590|NCT03398356|Other|group A|metformin dose 3 x 500 mg
16484591|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
16484592|NCT03398356|No Intervention|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
16484593|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
16484594|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
16484595|NCT03398317|Experimental|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
16484596|NCT03398317|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
16484597|NCT03398304|Experimental|Graded Exercise|Volunteers will participate in 3 study visits. The study visits will consist either of 20 minutes of walking, 20 minutes of running or 20 minutes of sitting. At the beginning of each study visit, prior to any exercise, a 4.5mL blood sample will be collected. The participant will then complete either 20 minutes of walking, running or sitting and will then have a 4.5mL blood draw taken from a new site.
16484598|NCT03398304|Experimental|Marathon Participation|On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
16484599|NCT03398291|Active Comparator|Standard treatment|Patients continue to receive standard chemotherapy.
16484600|NCT03398291|Experimental|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
16484601|NCT03398278|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
16484602|NCT03398278|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
16484603|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
16484604|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
16484605|NCT03398252|Experimental|Doxazosin XL|Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
16484606|NCT03398252|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
16484607|NCT03398239|Active Comparator|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
16484608|NCT03398239|Experimental|AVAPS|Non-invasive Ventilation with AVAPS mode
16484609|NCT03398226||Control group|
16484610|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
16484611|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
16484612|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
16484613|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
16484614|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
16484615|NCT03398200|Experimental|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
16484616|NCT03398200|Active Comparator|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
16484617|NCT03398174|Experimental|Motor Control Exercise Plus Patient Education|"Participants will receive a total of 12 sessions (2 sessions per week) of exercise program consisting of motor control training and group patient education session once a week (6 sessions) all over 6-weeks.
~The motor control training will be aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.
~The patient education program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.
~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
16484618|NCT03398174|Experimental|Motor Control Exercise|"Participants will receive the same motor control exercise program described in the patient education and motor control exercise group.
~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
16484619|NCT03398174|Experimental|Patient Education|"Participants will receive the same patient education program described in the motor control exercise plus patient education group.
~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
16484620|NCT03398161|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
16484636|NCT03398135|Placebo Comparator|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
16484637|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
16484638|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
16484639|NCT03398135|Experimental|Substudy 2: Open-label (OL) Clinical Assessment Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
16484640|NCT03398135|Experimental|Substudy 2: OL Therapeutic Drug Monitoring Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
16484641|NCT03398135|Experimental|Substudy 3: OL Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
16484642|NCT03398122|Experimental|Apatinib combined with TACE|patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
16484643|NCT03398122|Placebo Comparator|chemoemtranscatherer arterial bolization|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
16484644|NCT03398109|Experimental|Customized toric IOL|Customized toric IOL for post-Dalk atigmatism in cataract patients
16484645|NCT03398096|Experimental|Cardiac shock wave therapy (CSWT) group|The CWST group were performed with a CSWT equipment (Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan with respect to the shockwave output and the number of shots implemented to each spot and the protocol developed by the University of Essen, Germany.
16484646|NCT03398096|No Intervention|Control group|No CWST treatment.
16484647|NCT03398083|Active Comparator|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
16484648|NCT03398083|Active Comparator|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
16484649|NCT03398083|Active Comparator|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
16484650|NCT03398083|Active Comparator|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
16484651|NCT03398083|Active Comparator|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
16484652|NCT03398083|Placebo Comparator|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
16484653|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.
~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.
~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:
~Delivery of a positive rule-in diagnosis of functional neurological disorder
~Individuals are provided with educational materials on functional neurological disorders
~Referred to physical therapy and/or occupational therapy as clinically indicated
~FND related cognitive behavioral therapy (CBT) referral when appropriate
~Psychotropic medication management based on standard psychiatric care"
16484654|NCT03398057|Experimental|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
16484655|NCT03398057|Placebo Comparator|Control group|Placebo health education.
16484656|NCT03398044|Experimental|Dexamethasone|Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
16484657|NCT03398044|Placebo Comparator|Placebo|Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
16484658|NCT03398031|Active Comparator|Magnesium supplement|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
16484659|NCT03398031|Placebo Comparator|placebo|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
16484660|NCT03398018|Experimental|Treatment|Treated with repository corticotropin injection
16484661|NCT03398005|Experimental|CaPre|
16484662|NCT03398005|Placebo Comparator|Placebo|
16484663|NCT03397992|Active Comparator|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
16484664|NCT03397992|Active Comparator|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
16484665|NCT03397979|Active Comparator|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
16484839|NCT03396692|Active Comparator|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
16484666|NCT03397979|Active Comparator|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
16484667|NCT03397966|Experimental|BNP infusion|Subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32)) for 240 minutes.
16484668|NCT03397966|Placebo Comparator|saline infusion (control)|Subjects will receive an IV infusion of normal saline for 240 minutes. The volume of saline delivered will be equivalent to the volume of saline that the subject receives during the BNP infusion visit.
16484669|NCT03397953|Experimental|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
16484670|NCT03397940||Year Round School|Children attending year round school
16484671|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
16484672|NCT03397927|Experimental|orthosis|
16484673|NCT03397914|Experimental|Group A Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 2.5 mg/kg of colistimethate sodium intravenous as loading dose followed by 1.25 mg/kg every 12 hours as maintenance dose
16484674|NCT03397914|Experimental|Group B Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 5 mg/kg of colistimethate sodium intravenous as loading dose followed by 2.5 mg/kg every 12 hours as maintenance dose
16484675|NCT03397901|Experimental|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
16484676|NCT03397888|Experimental|Cohort 1|Mild Impairment, Child-Pugh Category A
16484677|NCT03397888|Experimental|Cohort 2|Moderate Impairment, Child-Pugh Category B
16484678|NCT03397888|Experimental|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 & 2 for age, sex and weight.
16484679|NCT03397875|Active Comparator|Zinc oxide based sealer|After root canal treatment obturation with gutta percha will be done using zinc oxide based sealer.
16484680|NCT03397875|Experimental|Epoxy resin based sealer|After root canal treatment obturation with gutta percha will be done using epoxy resin based sealer.
16484681|NCT03397875|Experimental|Bioactive silicone based sealer|After root canal treatment obturation with gutta percha will be done using bioactive silicone based sealer.
16484682|NCT03397862|Experimental|Corplex Donepezil TDS 5 mg/day|Subjects will receive Corplex Donepezil TDS 5 mg/day during Induction, Challenge, and Re-Challenge phase.
16484683|NCT03397862|Placebo Comparator|Vehicle TDS|Subjects will receive Vehicle TDS during Induction, Challenge, and Re-Challenge phase.
16484684|NCT03397849|Active Comparator|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
16484685|NCT03397849|No Intervention|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
16484686|NCT03397836|Experimental|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
16484687|NCT03397836|Active Comparator|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
16484688|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
16484689|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
16484690|NCT03397823||control group|age gender matched subjects
16484691|NCT03397810|Experimental|Singe arm|Subjects will receive a low dose radiotherapy focused to the heart
16484692|NCT03397797||Group with muscle relaxant|Rocuronium is used during the operation to maintain moderate relaxation.
16484693|NCT03397797||Group without muscle relaxant|Rocuronium is not used during the operation for the eletrophysiological monitoring.
16484694|NCT03397784||fluid responders|Patients whose stroke volume index increase by ≥15% in response to a 500-ml fluid bolus was defined as fluid responders.
16484695|NCT03397784||fluid non-responders|Patients whose stroke volume index increase by <15% in response to a 500-ml fluid bolus was defined as fluid non-responders.
16484696|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
16484697|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
16484698|NCT03397758|Experimental|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
16484699|NCT03397745|Other|BIS group|Patients who received the esophageal surgery
16484700|NCT03397732||Aorto-bifemoral bypass|Patients scheduled for elective aorto-bifemoral bypass surgery by vascular surgeons and consented to participate in the study.
16484701|NCT03397732||Aorta stentgraft|Patients scheduled for elective aorta stentgraft implantation by vascular surgeons and consented to participate in the study.
16484840|NCT03396692|Experimental|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
16484704|NCT03397706|Experimental|Phase 1b Dose Escalation|"VRx-3996 (cohort 1) and valganciclovir
~VRx-3996 (cohort 2) and valganciclovir
~VRx-3996 (cohort 3) and valganciclovir
~VRx-3996 (cohort 4) and valganciclovir
~VRx-3996 (cohort 5) and valganciclovir"
16484705|NCT03397706|Experimental|Phase 2 Dose Expansion|VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
16484706|NCT03397706|Experimental|PK Cohort|Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D
16484707|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
16484708|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
16484709|NCT03397693||3|Control fertile women with no treatment given.
16484710|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
16484711|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
16484712|NCT03397667|Other|Control|Primary Care
16484713|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
16484714|NCT03397654|Experimental|TACE followed by pembrolizumab|Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year
16484715|NCT03397641|Active Comparator|Active|x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion. Doses of HBI-3000 (Cohorts A to G) may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 µg.h/mL and Cmax of 20 µg/mL (based on the NOAEL) in both 14-day repeat-dose toxicology species rat and minipig) and the expected therapeutic dose.
16484716|NCT03397641|Placebo Comparator|Placebo|Matching placebo for x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion.
16484717|NCT03397628|No Intervention|Control|
16484718|NCT03397628|Experimental|Intervention|
16484719|NCT03397615|Active Comparator|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
16484720|NCT03397615|No Intervention|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
16484721|NCT03397602|No Intervention|standard care|Participants do not participate in a on site structured exercise training program.
16484722|NCT03397602|Experimental|standard care + MICE|standard care + moderate-intensity continuous exercise training (MICE)
16484723|NCT03397602|Experimental|standard care + HIIT|standard care + high-intensity interval training (HIIT)
16484724|NCT03397589|Experimental|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
16484725|NCT03397589|No Intervention|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
16484726|NCT03397576|Experimental|ATHENA|Subjects in the experimental arm will participate in monthly group medication adherence counseling sessions within prison led by a nurse and peer educator. After prison release, subjects in the experimental group will participate in four home visits during which intervention staff (nurses and peer educators working in teams) will deliver individualized medication adherence counseling based on the Freirian educational model.
16484727|NCT03397576|No Intervention|Control|Subjects in the control group will receive standard care, which includes a referral for HIV care and ART if prescribed ART within prison.
16484728|NCT03397563|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)
16484729|NCT03397563|Sham Comparator|Sham-CPAP treatment|sham Continuous Positive Airway Pressure (sham-CPAP)
16484730|NCT03397537|Other|the postmenopausal|2.5 mg letrozole every day for six months
16484731|NCT03397537|Experimental|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
16484732|NCT03397524|Experimental|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
16484733|NCT03397524|No Intervention|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
16484734|NCT03397511|Experimental|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
16484735|NCT03397498|Experimental|Computerized cognitive training|Received the Computerized cognitive training program, CogniFit™
16484736|NCT03397498|Active Comparator|Control-games|Received the Computerized games program
16484737|NCT03397485|Experimental|Growing Milk|"Experimental Fortified milk has energy from fatty acids, protein and carbohydrates. This milk has probiotics and essential micronutrients such as Zn, Fe, vitamins ( A, D, E, K, C and B complex), selenium and Copper among others.
~Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend."
16484906|NCT03396237||Group A|Case group contain cases of unexplained infertility women
16484738|NCT03397485|Active Comparator|Fortified Milk|Fortified milk has no energy from fatty acids nor micronutrients such as vitamin B12, Selenium and Copper. This milk was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend.
16484739|NCT03397472|Experimental|treatment group|use the sleep pillow with the magnetic field modulation treatment
16484740|NCT03397472|Placebo Comparator|placebo group|use the sleep pillow without magnetic field modulation treatment
16484741|NCT03397446|Experimental|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
16484742|NCT03397433|Experimental|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.
~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
16484743|NCT03397433|No Intervention|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
16484744|NCT03397420|Experimental|FAM-CARE|"Two facility clusters (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring"
16484745|NCT03397420|Active Comparator|Control Standard of Care|"Two clusters (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family."
16484746|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
16484747|NCT03397342|No Intervention|standard breath hold|"Breath-hold CT and 4D-CT without CPAP
~Breath-hold MRI and 4D-MRI without CPAP a) T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
16484748|NCT03397342|Experimental|CPAP intervention|"Breath-hold CT without CPAP
~4D-CT with and without CPAP
~4D-MRI with CPAP
~T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
16484749|NCT03397329|Active Comparator|Sequence A|
16484750|NCT03397329|Active Comparator|Sequence B|
16484751|NCT03397316|No Intervention|Marginal bone loss without grafting.|immediate implant placement in upper esthetic zone.
16484752|NCT03397316|Active Comparator|marginal bone loss with xenograft.|xenograft placement (Geistlich Bio-Oss) in immediate implant placement in upper esthetic zone between the residual labial bone and implant surface.
16484753|NCT03397303|Experimental|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
16484754|NCT03397303|Other|controls|
16484755|NCT03397290|Experimental|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
16484756|NCT03397277|Experimental|Screened positive intervention video|Safety behaviour promoting video
16484757|NCT03397277|Sham Comparator|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
16484758|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)
16484759|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)
16484760|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
16484761|NCT03397264|Experimental|Ph 2a: 2.0 mg aflibercept with highest tested or maximum tolerated dose OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed highest tested or maximum tolerated dose from Phase 1b OPT-302 intravitreal injection (0.05 mL)
16484762|NCT03397264|Sham Comparator|Ph 2a: 2.0 mg aflibercept with sham|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection
16484763|NCT03397251|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
16484764|NCT03397238||Non-metastatic TC|
16484765|NCT03397238||Metastatic TC|
16484766|NCT03397238||MNG surgery|
16484767|NCT03397238||MNG RAI treatment|
16484768|NCT03397238||Healthy volunteers|
16484769|NCT03397225|Experimental|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
16484770|NCT03397225|Active Comparator|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
16484771|NCT03397225|No Intervention|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
16484772|NCT03397212|Experimental|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
16484773|NCT03397212|Sham Comparator|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
16484774|NCT03397199|Experimental|Apatinib + S-1|Apatinib + S-1
16484907|NCT03396237||Group B|Control group contain fertile pregnant women
16484775|NCT03397186|Other|Basic science (trabectedin, biopsy)|Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 cycles. Beginning 1 week after completion of cycle 2 and prior to cycle 3, patients undergo a second biopsy. Patients who achieve clinical benefit (CR, PR, SD) after the first post-treatment scan and who continue trabectedin for 4 cycles undergo a third biopsy after cycle 4.
16484776|NCT03397173|Experimental|Azacitidine + Ascorbic acid|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, (allowing for weekends, and holidays) of each 28-day cycle. Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle.
16484777|NCT03397160|No Intervention|Usual care|Participants assigned to the control arm will receive usual care, including whatever information materials are provided to them by their urologist.
16484778|NCT03397160|Active Comparator|Decision Support Intervention (DSI)|"Participants assigned to the intervention will receive Decision Support Intervention in the form of a decision aid plus health coaching. The decision aid (delivered by internet and as a Portable Document Format (PDF) document) provides participants with a report on options and outcomes as described in the literature; along with more tailored risk information. The tailored risk information will include their estimated risk of harboring more aggressive prostate cancer based on their clinical/pathologic features (i.e., My Clinical Risk). The DSI was developed and piloted at UCSF according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332), and incorporates tailored risk models developed and validated."
16484779|NCT03397147|No Intervention|Usual Care|Usual Care
16484780|NCT03397147|Experimental|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
16484781|NCT03397134|Experimental|Roluperidone 64 mg|Roluperidone 64 mg for entire study
16484782|NCT03397134|Experimental|Roluperidone 32 mg|Roluperidone mg for entire study
16484783|NCT03397134|Placebo Comparator|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
16484784|NCT03397134|Placebo Comparator|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
16484785|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
16484786|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
16484789|NCT03397095|Experimental|CSWT+BMMSCs|Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.
16484790|NCT03397095|Sham Comparator|CSWT+Sham operation|Placebo group will receive a 3-month CSWT and a sham procedure.
16484791|NCT03397082|Experimental|Lidocaine + Paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
16484792|NCT03397082|Placebo Comparator|Placebo + paracervical blockade|5 minutes previous to endouterine manual aspiration, standard paracervical blockade was applied plus placebo gel (KY).
16484793|NCT03397069|Placebo Comparator|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
16484794|NCT03397069|Experimental|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
16484795|NCT03397069|Experimental|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
16484796|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.
~Intervention: Questionnaire"
16484797|NCT03397043|Experimental|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
16484798|NCT03397030|Experimental|Home-Based Exercise Program|Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.
16484799|NCT03397030|No Intervention|Waitlist-Control Group|Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.
16484800|NCT03397004|Active Comparator|doxycycline Hyclate|subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily
16484801|NCT03397004|Placebo Comparator|Placebo|subjects will be given a placebo oral capsule twice daily for 6-months
16484802|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
16484803|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
16485203|NCT03394144|Experimental|C1:AZD9150, C2:AZD9150+Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open
16484804|NCT03396978|Experimental|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
16484805|NCT03396965|Experimental|Mini-c-arm|Fluoroscopically aided reductions
16484806|NCT03396965|No Intervention|Standard|
16484807|NCT03396952|Experimental|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16484808|NCT03396939|Experimental|Orthosis|The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
16484809|NCT03396939|No Intervention|Control|The group will receive the same amount of a study-specific training program without the orthotic device.
16484810|NCT03396926|Experimental|Treatment (pembrolizumab, bevacizumab, capecitabine)|Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
16484811|NCT03396913|Experimental|IPL followed by Meibomian Gland Expression (MGX)|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
16484812|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
16484813|NCT03396900|Active Comparator|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
16484814|NCT03396900|Experimental|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
16484815|NCT03396887|Experimental|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
16484816|NCT03396887|Active Comparator|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
16484817|NCT03396874|Experimental|68Ga-PSMA|PET/CT imaging
16484818|NCT03396861|Experimental|Subconjunctival aflibercept|Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.
16484819|NCT03396848|Experimental|SHAReClinic|All participants will have access to the online clinic
16484820|NCT03396835|Experimental|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
16484821|NCT03396809|Experimental|Punctal Plugs|This arm of the study receives punctal plug intervention.
16484822|NCT03396796|Experimental|Vagus nerve-preserving group|Every patient of vagus nerve-preserving group will receive the modified vagus nerve-preserving laparoscopic azygoportal disconnection procedure.
16484823|NCT03396796|No Intervention|Conventional group|Every patient of conventional group will receive the conventional laparoscopic azygoportal disconnection procedure.
16484824|NCT03396783|Experimental|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
16484825|NCT03396783|Other|Control|during the visit, nurse will make a blood test for biological and immunological analysis
16484826|NCT03396770|Active Comparator|Control group|Standard clinical routine
16484827|NCT03396770|Experimental|Nephrocheck group|Nephrocheck test
16484828|NCT03396757|Active Comparator|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
16484829|NCT03396757|Experimental|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
16484830|NCT03396744|Active Comparator|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
16484831|NCT03396744|Active Comparator|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
16484832|NCT03396731|No Intervention|Standard care alone (control)|Multilayer/multi component compression bandaging treatment
16484833|NCT03396731|Active Comparator|6 hours geko™ (no longer recruiting)|geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
16484834|NCT03396731|Active Comparator|12 hours geko™|geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
16484835|NCT03396718|Experimental|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
16484836|NCT03396718|Experimental|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
16484837|NCT03396718|Active Comparator|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
16484838|NCT03396718|Active Comparator|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
16484841|NCT03396692|Experimental|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
16484842|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
16484843|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
16484844|NCT03396666|Experimental|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
16484845|NCT03396666|No Intervention|No intervention|Regular follow-up with advice on physical activity and nutrition
16484846|NCT03396653|Active Comparator|Peer-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
16484847|NCT03396653|Active Comparator|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
16484848|NCT03396640|Experimental|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
16484849|NCT03396640|Active Comparator|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
16484850|NCT03396627||muller muscle|muller muscle and conjunctiva excised during muller muscle conjunctival resection
16484851|NCT03396614||EEG, ECG, CT, MRI|
16484852|NCT03396601|Experimental|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
16484853|NCT03396601|Experimental|Saline (placebo) infusion|Infusion of IV Saline
16484854|NCT03396588|Active Comparator|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
16484855|NCT03396588|Active Comparator|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
16484858|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.
~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
16484859|NCT03396549|Experimental|real tDCS|20 min of 2 mA tDCS over the right and left dorsolateral prefrontal cortex
16484860|NCT03396549|Sham Comparator|new sham tDCS|20 min 2 mA tDCS over the left and right sensorimotor cortex
16484861|NCT03396536||Group 1|Group 1 will be implants with keratinized mucosa (KM).
16484862|NCT03396536||Group 2|Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
16484863|NCT03396523|Experimental|Losartan group|
16484864|NCT03396523|Placebo Comparator|Placebo group|
16484865|NCT03396510|Experimental|IMPROVED intervention|Patients randomized to the IMPROVED intervention will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the study team will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the study team will not provide guidance about what actions to take in response to patients' symptoms.
16484866|NCT03396510|No Intervention|Usual Care|Usual Care per hospital standard will be administered. Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports.
16484867|NCT03396497|Experimental|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
16484868|NCT03396484|Experimental|Methyldopa|"Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day
~Children: methyldopa dose based on weight twice daily for one week then increased to three times a day"
16484869|NCT03396484|Placebo Comparator|Placebo|Inactive agent to match active drug in appearance and dose frequency.
16484870|NCT03396471|Experimental|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
16484871|NCT03396458||Hepatitis B group|Hepatitis B serology and questionnaire
16484908|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
16484909|NCT03396211|Experimental|Apatinib (also known as rivoceranib) with Nivolumab|Oral daily doses of apatinib (as its mesylate salt) with a fixed dose of nivolumab given intravenously every 2 weeks
16484876|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:
~Storz C-MAC Video Laryngoscope"
16484877|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:
~Miller Laryngoscope"
16484878|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.
~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.
~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.
~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
16484879|NCT03396406|Experimental|PCRF group|received Pulsed radiofrequency (PRF) at 42°C for 8 minutes followed by CRF at 60°C for 270s
16484880|NCT03396406|Experimental|CRF group|received sole thermocoagulation at 70°C for 270 s
16484881|NCT03396393|Experimental|Dihydroartemisinin 40mg|Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
16484882|NCT03396393|Experimental|Dihydroartemisinin 80mg|Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
16484883|NCT03396393|Experimental|Dihydroartemisinin 120mg|Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
16484884|NCT03396393|Placebo Comparator|placebo|Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
16484885|NCT03396380|Active Comparator|vitamin D|93 women who will receive clomiphene citrate for induction of ovulation with vitamin D and calcium supplement
16484886|NCT03396380|Placebo Comparator|placebo|93 women who will receive clomiphene citrate for induction of ovulation with placebo and calcium supplement
16484887|NCT03396367|Experimental|PARTNER Intervention|This intervention is a four-session intervention designed to increase PrEP uptake, increase PrEP adherence, and reduce drug use and HIV transmission risk behaviors of individuals in relationships.
16484888|NCT03396367|Active Comparator|Education Intervention|This intervention is a four-session intervention that discussed drug use and its effect on physiological social functioning.
16484889|NCT03396354|Experimental|Integrated robotic surgery|
16484890|NCT03396354|Active Comparator|Conventional laparoscopic surgery|
16484891|NCT03396341||patients receiving a positive BRCA1/2 mutation result|All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
16484892|NCT03396328|Active Comparator|Conventional education|
16484893|NCT03396328|Experimental|Low salt dietary education by smartphone application|
16484894|NCT03396315|Active Comparator|alendronate|Subjects will receive oral alendronate
16484895|NCT03396315|Active Comparator|zoledronic acid|Subjects will receive zoledronic acid
16484896|NCT03396302|Experimental|Experimental|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education).
16484897|NCT03396302|No Intervention|Control|The control group will receive Hospital treatment as usual.
16484898|NCT03396289|Active Comparator|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
16484899|NCT03396289|Experimental|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
16484900|NCT03396276|Experimental|Suboxone induction into MAT in the ED|Suboxone induction into medication-assisted treatment (MAT) in the emergency department (ED)
16484901|NCT03396263|Experimental|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
16484902|NCT03396263|Experimental|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
16484903|NCT03396263|Placebo Comparator|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
16484904|NCT03396250|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
16484905|NCT03396250|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
16484910|NCT03396185|Experimental|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
16484911|NCT03396172|Other|Control|The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
16484912|NCT03396172|Active Comparator|FreeDom|"FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation):
~-initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met.
~After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,"
16484913|NCT03396159|Experimental|mini fluid challenge|mini fluid will be given and stroke volume will be assessed before and after
16484914|NCT03396146|Experimental|Type1diabetes with exocrine pancreatic function insufficiency|12 ml total blood tubes volume Fecal sample
16484915|NCT03396146|Experimental|Type1diabetes without exocrine pancreatic function insuficienc|12 ml total blood tubes volume Fecal sample
16484916|NCT03396146|Active Comparator|Type 3c diabetes|12 ml total blood tubes volume Fecal sample
16484917|NCT03396133|Experimental|Snap group|individuals in this arm used Snap according to the instruction on time and screened at the symptomatic
16484918|NCT03396133|No Intervention|RC group|patients in the RC arm accepted normal methods
16484919|NCT03396107|Active Comparator|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
16484920|NCT03396107|Placebo Comparator|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
16484921|NCT03396094|Experimental|Intervention|High-flow nasal cannula oxygenation at 60L/min for pre-oxygenation and apnoeic oxygenation
16484922|NCT03396094|Active Comparator|Control|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
16484923|NCT03396081|Experimental|PRADO-IC|
16484924|NCT03396081|Other|Usual care|
16484925|NCT03396068|Experimental|NRX-101|Subjects will be treated with oral NRX-101 (fixed dose combination of D-Cycloserine/lurasidone) that will be titrated to a combined dose of 950mg/66mg per day.
16484926|NCT03396068|Active Comparator|Lurasidone comparator|Subjects will be treated with oral lurasidone in a matched placebo capsule that will be titrated to a dose of 66 mg per day
16484927|NCT03396055|Experimental|Treatment group|Specific rehabilitation exercise
16484928|NCT03396055|No Intervention|Control|No intervention
16484929|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to <=20/200
16484930|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity >20/200 to <=20/50
16484931|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to <=20/200
16484932|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity >20/200 to <=20/50
16484933|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to <=20/200
16484934|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity >20/200 to <=20/50
16484935|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to <=20/200
16484936|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity >20/200 to <=20/50
16484937|NCT03396029|Experimental|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
16484938|NCT03396029|Experimental|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
16484939|NCT03396029|No Intervention|Control|No contact with the participant.
16484940|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
16484941|NCT03396003|Experimental|GALILEI G6 Lens Professional|The GALILEI G6 Lens Professional will measure anterior segment geometry and axial intra-ocular distances of the eye.
16484942|NCT03396003|Active Comparator|Oculus Pentacam AXL|The Oculus Pentacam AXL will measure anterior segment geometry and axial intra-ocular distances of the eye.
16484943|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
16484944|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
16484945|NCT03395977|Placebo Comparator|Placebos PO and IV|PO : per os IV : intraveinously
16484946|NCT03395977|Experimental|Febuxostat PO and Placebo IV|240 mg a day for 3 days
16484947|NCT03395977|Experimental|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
16484948|NCT03395977|Experimental|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
16484949|NCT03395964|Active Comparator|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
16484950|NCT03395964|Experimental|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
16484951|NCT03395938|Placebo Comparator|Current practice|"Intervention A depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation."
16484952|NCT03395938|Active Comparator|Proactive engagement|"Intervention B involves a series of proactive engagements in hope to spur patients into contacting their siblings and improve their receptiveness towards colorectal cancer screening."
16484953|NCT03395925|Experimental|Celon Pro Surge|Ablation of thyroid tissue
16484954|NCT03395912|Experimental|Intervention|Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
16484955|NCT03395912|No Intervention|control|Abdominal layers will be closed without Infiltration .
16484956|NCT03395899|Active Comparator|Atezolizumab alone|1200mg of Atezolizumab D1 C1
16484957|NCT03395899|Experimental|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
16484958|NCT03395899|Experimental|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
16484959|NCT03395899|Experimental|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
16484960|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
16484961|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
16484962|NCT03395873|Experimental|Single arm|"Decitabine 20mg/m2 IV day 1-5, every 28 days
~Avelumab 10mg/kg IV, day 1, every 14 days"
16484963|NCT03395860|Experimental|group A|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
16484964|NCT03395860|Experimental|group B|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
16484965|NCT03395847|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16484966|NCT03395834|Experimental|O3 monitor|tissue oxygenation comparison of O3 & INVOS
16484967|NCT03395821|Active Comparator|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
16484968|NCT03395821|Experimental|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
16484969|NCT03395808|Other|AVE-901 50mg|IV Tramadol
16484970|NCT03395795|Other|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
16484971|NCT03395782||Age group 40-49|30 patients will be stratified to this age group.
16484972|NCT03395782||Age group 50-59|30 patients will be stratified to this age group.
16484973|NCT03395782||Age group 60-69|30 patients will be stratified to this age group.
16484974|NCT03395782||Age group 70-79|30 patients will be stratified to this age group.
16484975|NCT03395756|Active Comparator|12-14 mm follicle size group|Once the participant's leading follicle reaches 12-14mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
16484976|NCT03395756|Active Comparator|15-17 mm follicle size group|Once the participant's leading follicle reaches 15-17mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
16484977|NCT03395756|Active Comparator|18 mm or greater follicle size group|Once the participant's leading follicle reaches 18mm or greater, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
16484978|NCT03395730|Experimental|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):
~Clamping and cutting the placental cord after delivery of the baby.
~Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
16484979|NCT03395730|Experimental|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):
~Clamping and cutting the placental cord after delivery of the baby.
~Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
16484980|NCT03395730|Active Comparator|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):
~Clamping and cutting the placental cord after 2 minutes of delivery of the baby.
~Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
16484981|NCT03395717|Experimental|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
16484982|NCT03395717|No Intervention|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.
~Traditional Over ground Gait Trainings include:
~Sit-to-Stand tasks
~Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.
~CG patients will not use any other robots or treadmill for gait training."
16484983|NCT03395704|Active Comparator|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
16484984|NCT03395704|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
16484985|NCT03395691|Active Comparator|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach.
16484986|NCT03395691|Active Comparator|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
16484987|NCT03395678|Experimental|Microneedling|Participants in this arm will receive 5 treatments of microneedling.
16484988|NCT03395678|Active Comparator|Fractional non-ablative 1,540nm laser|Participants in this arm will receive 5 treatments of fractional non-ablative1,540nm laser.
16484989|NCT03395639|Experimental|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
16484990|NCT03395639|Active Comparator|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
16484991|NCT03395626|Experimental|ID-JPL934|probiotics 20%, corn starch 80%
16484992|NCT03395626|Placebo Comparator|placebo|corn starch 100%
16484993|NCT03395613|No Intervention|Standard management|Standard sterile gauze dressing on surgical groin wound.
16484994|NCT03395613|Experimental|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
16484995|NCT03395600|Active Comparator|0.1%bupivacaine+10µg sufentanyl|Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
16484996|NCT03395600|Active Comparator|0.125%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
16484997|NCT03395600|Active Comparator|0.1%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
16484998|NCT03395587|Experimental|Experimental intervention|Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
16484999|NCT03395587|Other|Control intervention|"Standard therapy:
~Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)"
16485000|NCT03395574|Experimental|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
16485001|NCT03395574|Placebo Comparator|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
16485002|NCT03395561|Active Comparator|green coffe|2 capsuls of green coffe
16485003|NCT03395561|Placebo Comparator|control|2 capsuls
16485004|NCT03395548|Active Comparator|Inflammatory bowel disease|"The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.
~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
16485005|NCT03395548|Active Comparator|Irritable bowel syndrome|"The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.
~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
16485006|NCT03395548|Active Comparator|Healthy|"The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.
~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
16485007|NCT03395535|Experimental|'Laser-1st'|"Initial Selective Laser Trabeculoplasty (SLT) [PROCEDURE] followed by conventional medical therapy (eye-drops) as required.
~All participants in this arm start their treatment pathway with SLT. If this does not reach the predefined, patient-specific target IOP then repeat laser (once only) is given. If the IOP target is then not reached additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed."
16485047|NCT03395249|Placebo Comparator|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.
~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
16485158|NCT03394508|Experimental|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension
16485008|NCT03395535|Active Comparator|Medicine-1st|"Conventional medical therapy [DRUG] without laser. All participants in this arm start their treatment pathway medical treatment. If the IOP target is then not reached, additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed.
~During this pathway of treatment all commercially available medical treatments (eye-drops) are permitted according to a pre-specified step-wise intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
16485009|NCT03395522|Experimental|Device|ITind device implant
16485010|NCT03395496|Experimental|Biodentine|Dental materials
16485011|NCT03395496|Experimental|ProRoot MTA|Dental Materials
16485012|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
16485013|NCT03395470|Experimental|Group A1|Dose 1 or placebo
16485014|NCT03395470|Experimental|Group A2|Dose 2 or placebo
16485015|NCT03395470|Experimental|Group A3|Dose 3 or placebo
16485016|NCT03395470|Experimental|Group A4|Dose 4 or placebo
16485017|NCT03395470|Experimental|Group A5|Dose 5 or placebo
16485018|NCT03395470|Experimental|Group B|Dose + Rosuvastatin
16485019|NCT03395457|Active Comparator|Care as usual|This is the care provided by the neurologist for chronic migraine.
16485020|NCT03395457|Experimental|Care as usual plus manual therapy|Other
16485021|NCT03395444|Active Comparator|Study Group|Pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
16485022|NCT03395444|Sham Comparator|Control Group|Sham pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
16485023|NCT03395431|Active Comparator|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
16485024|NCT03395431|No Intervention|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
16485025|NCT03395405|Experimental|Nitazoxanide Arm|500 mg (one tablet) nitazoxanide by mouth twice daily with food for 56 consecutive doses. N=80
16485026|NCT03395405|Placebo Comparator|Placebo Arm|Placebo (one tablet) by mouth twice daily with food for 56 consecutive doses. N=80
16485027|NCT03395392|Experimental|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
16485028|NCT03395392|Active Comparator|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
16485029|NCT03395379||Group 1|RFA without air dissection protection
16485030|NCT03395379||Group 2|RFA with air dissection protection
16485031|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
16485032|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
16485033|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
16485034|NCT03395340|Experimental|Euxolitinib cream|Investigational cream to 1 location; vehicle cream to 2nd location
16485035|NCT03395340|Placebo Comparator|Vehicle cream|Investigational cream to 1 location; vehicle cream to 2nd location
16485036|NCT03395314|Placebo Comparator|midazolam|Midazolam IV; 0.04mg/kg over 40 minutes
16485037|NCT03395314|Active Comparator|low dose ketamine|ketamine IV; 0.5 mg/kg over 40 minutes
16485038|NCT03395301|Experimental|tubal occlusion|Fiber coils were inserted into the interstitial part of fallopian tubes, and IVF-ET was taken out in the following.
16485039|NCT03395288|Experimental|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
16485040|NCT03395288|No Intervention|RCT control arm|Participants in this arm will not use any additional intervention.
16485041|NCT03395288|Experimental|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
16485042|NCT03395275|Experimental|Intrathecal Pump Therapy Participants|Patients eligible for intrathecal pump therapy will undergo quantitative sensory tests and surveys during various stages of the treatment process.
16485043|NCT03395262|Experimental|Active with caffeine|Novel formula with caffeine
16485044|NCT03395262|Active Comparator|Active without caffeine|Novel formula without caffeine
16485045|NCT03395262|Placebo Comparator|Placebo|Dextrose
16485046|NCT03395249|Experimental|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.
~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
16485156|NCT03394534|No Intervention|Treatment as Usual|
16485048|NCT03395249|Other|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.
~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
16485050|NCT03395223|Experimental|ProvayBlue (Methylene Blue) arm|"Methylene Blue 0.5% will be administered.
~1 mg/kg will be administered intravenously over 5-30 minutes. If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose."
16485051|NCT03395210|Experimental|PRN1008 Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.
~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
16485054|NCT03395184|Experimental|PF-06700841 or placebo|
16485055|NCT03395184|Experimental|PF-06651600 or placebo|
16485056|NCT03395171|Experimental|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
16485057|NCT03395171|No Intervention|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
16485058|NCT03395158||Prior alert criteria|Patients who activated full, limited or no alert criteria according to the prior alert criteria
16485059|NCT03395158||Present alert criteria|Patients who activated full, limited or no alert criteria according to the present alert criteria
16485060|NCT03395145|Experimental|Bio-Oss Collagen and Mucograft Seal|Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
16485061|NCT03395145|No Intervention|Natural healing|Evaluation of Bone volume Changes after tooth extraction (natural healing)
16485062|NCT03395132|Experimental|Fucicort® Lipid cream|Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
16485063|NCT03395132|Active Comparator|Fucidin cream +betamethasone cream|The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.
16485064|NCT03395132|Placebo Comparator|Vehicle cream|The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.
16485065|NCT03395119|Sham Comparator|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
16485066|NCT03395119|Experimental|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
16485067|NCT03395119|Experimental|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
16485068|NCT03395106|Experimental|Parent source + intuitive story content|
16485069|NCT03395106|Experimental|Doctor source + intuitive story content|
16485070|NCT03395106|Experimental|Parent source + deliberative content|
16485071|NCT03395106|Experimental|Doctor source + deliberative content|
16485072|NCT03395093|Experimental|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
16485073|NCT03395093|Active Comparator|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
16485074|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EEC|300mg DKN-01 monotherapy in recurrent EEC
16485075|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EEC|300mg DKN-01+paclitaxel in recurrent EEC
16485076|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EOC|300mg DKN-01 monotherapy in recurrent EOC
16485077|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EOC|300mg DKN-01+paclitaxel in recurrent EOC
16485078|NCT03395080|Experimental|DKN-01 monotherapy in carcinosarcoma|600mg DKN-01 monotherapy in carcinosarcoma
16485079|NCT03395080|Experimental|DKN-01 +paclitaxel in carcinosarcoma|600mg DKN-01 +paclitaxel in carcinosarcoma
16485080|NCT03395067|Active Comparator|Lifestyle counseling|
16485081|NCT03395067|No Intervention|Control group|
16485082|NCT03395054|Other|the stabilization group|the stabilization group performed cervical stabilization exercises in lying, sitting, standing and on a swisball 3times a week during 8 weeks.
16485083|NCT03395054|Other|the control group|the control group performed conventional exercises including neck isometric, isotonic and posture exercises 3 times a week during 8 weeks.
16485084|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.
~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
16485085|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.
~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
16485086|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
16485087|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
16485088|NCT03395002|Experimental|Tiotropium/Salmeterol/Fluticasone|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Discair®
16485089|NCT03395002|Active Comparator|Tiotropium + Salmeterol/Fluticasone|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® + Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus®
16485090|NCT03394989|Experimental|Test|Fluticasone propionate/salmeterol 100/50 µg
16485091|NCT03394989|Active Comparator|Comparator|Fluticasone propionate/salmeterol 100/50 µg
16485092|NCT03394989|Other|Placebo|Test Placebo
16485093|NCT03394976||Study population|Participants will be enrolled passively at health centres. Passive enrolment will include patients referred to or presenting directly at the health facilities.
16485094|NCT03394950|Experimental|rtPA combined with Butyphthalide|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
16485095|NCT03394950|Active Comparator|rtPA compared with placebo|Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
16485096|NCT03394937|Experimental|Cohort 1 600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
16485097|NCT03394937|Experimental|Cohort 1 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
16485098|NCT03394937|Experimental|Cohort 2 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
16485099|NCT03394937|Experimental|Cohort 2 3600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
16485100|NCT03394924|Experimental|EDP-305 1 mg|Subjects will take 2 tablets once a day orally for 12 weeks
16485101|NCT03394924|Experimental|EDP-305 2.5 mg|Subjects will take 2 tablets once a day orally for 12 weeks
16485102|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
16485103|NCT03394911|Experimental|Experimental Group|250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
16485104|NCT03394911|Placebo Comparator|Placebo Group|Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
16485105|NCT03394885|Experimental|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by
~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by
~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).
~(Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
16485106|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
16485107|NCT03394846|Experimental|Pilot Test of MI Prototype|We will pilot test a Movement Integration product prototype with 60 elementary classroom teachers.
16485108|NCT03394833|Experimental|Preoperative fluids|40 individuals receiving preoperative colloid fluid bolus at 6 ml/kg LBW, (Gelofusine™, Fresenius Kabi AB, Sweden) before anesthesia induction by TCI (n = 20) or RSI (n =20).
16485109|NCT03394833|No Intervention|No preoperative fluids|40 individuals anesthetized by TCI (n = 20) or RSI (n =20) without preoperative fluids.
16485110|NCT03394820|Active Comparator|dexamethasone 1 hour prior to block|The patient will receive dexamethasone through IV one hour prior to receiving their block. During the patient's block, 1 hour after and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
16485111|NCT03394820|Experimental|dexamethasone during the block|The patient will receive dexamethasone through IV at the same time the patient has the SCB done. One hour prior to the block, one hour after the block and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
16485112|NCT03394820|Active Comparator|dexamethasone 1 hour after block|The patient will receive dexamethasone through IV one hour after the block has been administered. One hour prior to block, during the block and two hours after the block the patient will receive normal saline to maintain the blind.
16485113|NCT03394820|Active Comparator|dexamethasone 2 hours after block|The patient will receive dexamethasone 2 hours after the block has been administered. One hour prior to the block, during the block and one hour after the block the patient will receive normal saline to maintain the blind.
16485114|NCT03394807|Experimental|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
16485115|NCT03394807|Placebo Comparator|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
16485116|NCT03394794|Active Comparator|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
16485117|NCT03394794|Experimental|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
16485118|NCT03394794|Experimental|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
16485119|NCT03394794|Experimental|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
16485120|NCT03394781|Experimental|DUR-928 10 mg|10 mg oral suspension
16485121|NCT03394781|Experimental|DUR-928 50 mg|50 mg oral suspension
16485122|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
16485123|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
16485124|NCT03394755|Experimental|Thrombosomes|
16485125|NCT03394742|Experimental|Intervention group|Peer support group received, in addition to usual care, peer support via telephone 1-5 times according to their own preference. Peer support was started at the time between diagnosis and the beginning of treatments.
16485126|NCT03394742|No Intervention|Control group|The control group received usual care only. For ethical reasons, participants in the control group were not discouraged from seeking peer support by themselves if they felt a need for it.
16485127|NCT03394729|Experimental|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
16485128|NCT03394729|Active Comparator|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
16485129|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
16485130|NCT03394690|Active Comparator|green coffe|green coffe 2 capsuls of green coffe
16485131|NCT03394690|Placebo Comparator|control|2 capsuls of placebo
16485132|NCT03394677|Experimental|RVT-501 0.5% ointment|Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
16485133|NCT03394677|Placebo Comparator|RVT-501 vehicle ointment|Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
16485134|NCT03394664|Experimental|Very-Low Carbohydrate Diet|Feeding study. Dietary composition (approximately): 75% fat
16485135|NCT03394664|Experimental|High-Carbohydrate Low-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
16485136|NCT03394664|Experimental|High-Carbohydrate High-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
16485137|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
16485138|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
16485139|NCT03394638|Active Comparator|Conventional group|"Treatment includes:
~10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.
~Additional visits if necessary
~No further access to the BePATIENT website"
16485140|NCT03394638|Experimental|Online group|"Treatment includes:
~Added to conventional group: Continuation of access to the BePATIENT website with:
~eLearning programs
~Informative videos
~Patient network
~Video consulting"
16485141|NCT03394638|Experimental|Device group|"Added to Online group:Four wireless devices, which are
~Weight Scale
~Blood Pressure
~Oximeter
~Activity Tracker"
16485142|NCT03394625|Experimental|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
16485143|NCT03394625|Active Comparator|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
16485144|NCT03394612|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
16485145|NCT03394599|Active Comparator|TheraTrainer Only|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer only for the duration of their participation at the Geriatric program. Their carers will also be recruited.
16485146|NCT03394599|Experimental|TheraTrainer + Motiview|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer with the addition of Motiview (engaging videos to watching while cycling). Their carers will also be recruited.
16485147|NCT03394586||UC patients with golimumab|We will retrospectively analyze all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
16485148|NCT03394573||OCT guided treatment arm|OCT guided aflibercept injection
16485149|NCT03394573||VA guided treatment arm|VA guided aflibercept injection
16485150|NCT03394560|Experimental|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
16485151|NCT03394560|Sham Comparator|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
16485152|NCT03394547|Active Comparator|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
16485153|NCT03394547|Placebo Comparator|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
16485154|NCT03394547|No Intervention|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
16485155|NCT03394534|Experimental|CGA group|
16485159|NCT03394495|Experimental|BCE Combination group|"16-week BCE programme with exercise training.
~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
16485160|NCT03394495|No Intervention|Exercise group|"16-week programme with health talks and exercise training.
~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
16485161|NCT03394495|No Intervention|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
16485162|NCT03394482|Experimental|Lu AF35700 5 mg clinical formulation|
16485163|NCT03394482|Experimental|Lu AF35700 5 mg commercial formulation|
16485164|NCT03394482|Experimental|Lu AF35700 10 mg clinical formulation|
16485165|NCT03394482|Experimental|Lu AF35700 10 mg commercial formulation|
16485166|NCT03394482|Experimental|Lu AF35700 20 mg clinical formulation|
16485167|NCT03394482|Experimental|Lu AF35700 20 mg commercial formulation|
16485168|NCT03394469|Other|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
16485169|NCT03394456|Experimental|Intervention|Receive diabetes group visits
16485170|NCT03394456|No Intervention|Control|Receive usual care in the clinic, followed by group visits (wait list control)
16485171|NCT03394430|Placebo Comparator|Group A|
16485172|NCT03394430|Experimental|Group B|
16485173|NCT03394430|Experimental|Group C|
16485174|NCT03394417|No Intervention|standard clinical practice (control)|aqueous cream
16485175|NCT03394417|Active Comparator|StrataXRT (intervention)|silicon-based gel
16485176|NCT03394404|Experimental|ECG-I mapping and PVI|ECG-I mapping and PVI
16485177|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
16485178|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
16485182|NCT03394352|Experimental|Activity on Board|Blinded CGM data will be collected prior to the Experimental Admission to determine the insulin bolus that will be determined by the activity on board calculator. Subjects will wear a continuous glucose monitor during the study admission.
16485183|NCT03394352|Placebo Comparator|Usual Diabetes Care|Subjects will use their usual diabetes care, including basal rate, correction factor and carbohydrate-insulin ratio. Subjects will determine their own insulin usage during the Control Admission. Subjects will wear a continuous glucose monitor during the study admission.
16485184|NCT03394326|Experimental|LOW-ED|In the LOW-ED condition each participant will consume at least 10 low-ED foods/day (ED ≤1.0 kcal/g) and no more than 2 high ED foods/day (ED ≥3.0 kcal/g). Foods with an ED >1.0 kcal/g and <3.0 kcal/g will be unlimited; however, lowering the overall ED of the diet will be encouraged.
16485185|NCT03394326|Active Comparator|STANDARD|In the STANDARD condition participants will consume the recommendations for calories, fruits, vegetables and whole grains based on age and sex corresponding with MyPlate. The daily caloric recommendations from MyPlate are for weight maintenance.
16485186|NCT03394287|Experimental|SHR-1210 +Apatinib daily dosing|SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
16485187|NCT03394287|Experimental|SHR-1210+Apatinib intermittent dosing|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)
16485188|NCT03394274||Transfusion|Patients (n:892) were enrolled who underwent elective major surgery between the 01/01/2016-31/12/2016, and over the age of 18 years. They separated subgroups as restrictive and liberal blood transfusion groups
16485189|NCT03394261|Experimental|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
16485190|NCT03394261|No Intervention|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
16485191|NCT03394235|Experimental|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
16485192|NCT03394222|Experimental|Budesonide inhalation group|This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
16485193|NCT03394222|Placebo Comparator|Normal saline inhalation group|This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
16485194|NCT03394209|Experimental|Favipiravir+oseltamivir|Favipiravir+oseltamivir will be given twice daily for a 10-day period.
16485195|NCT03394196|Experimental|No HIV-2 resistance|
16485196|NCT03394196|Experimental|HIV-2 NRTI resistance only|
16485197|NCT03394196|Experimental|HIV-2 NRTI and PI resistance|
16485198|NCT03394183|Experimental|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
16485199|NCT03394183|Active Comparator|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
16485200|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
16485201|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
16485202|NCT03394157|Other|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
16485204|NCT03394131|Experimental|Hyalase|injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided
16485205|NCT03394131|Placebo Comparator|Placebo|injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided
16485206|NCT03394131|Active Comparator|Insilin|injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided
16485207|NCT03394118|Experimental|Group_TAGRISSO|Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period.
16485208|NCT03394105|Experimental|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
16485209|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
16485210|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
16485211|NCT03394079|Experimental|OCT-guided|
16485212|NCT03394079|Active Comparator|IVUS-guided|
16485213|NCT03394066|Experimental|TMS|All participants will receive TMS to investigate acute modulations of brain activity by TMS
16485214|NCT03394053||Affected Patient|Person with a clinical diagnosis of a PID; either known or unknown as defined by lab and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity
16485215|NCT03394053||Normal Volunteer|Persons (age 18-75 years) who are not related to another study subject, who do not have a PID, weight >110lbs, no history of viral hepatitis B or C, have a negative HIV screening test
16485216|NCT03394053||Relative of Patient|Biological relatives (age 0-75 years) of a subject who meets affected patient criteria, but who do not have a PID themselves
16485217|NCT03394040||1|The study seeks individuals of all ages experiencing diarrhea from the Washington Metropolitan area
16485218|NCT03394027|Experimental|Arm 1|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: ER + breast cancer, triple negative breast cancer, and endometrial cancer
16485219|NCT03394014|Active Comparator|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
16485220|NCT03394014|Active Comparator|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
16485221|NCT03394001|Active Comparator|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
16485222|NCT03394001|Active Comparator|Ketorolac tromethamine|Wound infiltration with Ketorolac
16485223|NCT03393988|Active Comparator|Group F|Fentanyl infusion (0.5 µg/kg/hr)
16485224|NCT03393988|Active Comparator|Group (TAP-Dex)|"Ultrasound guided TAP block and Dexmedetomidine
~Ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine
~Dexmedetomidine infusion(200 µg in 2 ml diluted in 48 ml of saline)
~Fentanyl infusion (0.5 µg/kg/hr)."
16485225|NCT03393975|Experimental|Prophylaxis Cohort I|Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
16485226|NCT03393975|Experimental|Prophylaxis Cohort II|Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
16485227|NCT03393975|Experimental|On Demand Cohort I|Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
16485283|NCT03393520|Experimental|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
16485284|NCT03393520|Experimental|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
16485285|NCT03393507|Experimental|apatinib combine with chemotherapy|
16485286|NCT03393507|Active Comparator|chemotherapy|
16485287|NCT03393494|Experimental|Perrigo active|Test product
16485228|NCT03393975|Experimental|On Demand Cohort II|Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
16485229|NCT03393962|Experimental|OC-EIEs|Autologous ovarian cancer antigen-specific cytotoxic lymphocytes
16485230|NCT03393949|Experimental|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
16485231|NCT03393949|Experimental|Group C|Patients in Group C received isotonic saline 1mg•kg-1
16485234|NCT03393923|No Intervention|Control Group|Patient will undergo gait analysis
16485235|NCT03393923|Experimental|Experimental group|Patient will undergo gait analysis with use of anterior wedge
16485236|NCT03393910|No Intervention|Observational|Normal pelvic exam exposures: External exam followed by speculum exam, followed by bimanual exam
16485237|NCT03393910|Active Comparator|Experimental Pelvic Exam|Changing the order of the pelvic exam Intervention: External exam, bimanual exam,speculum exam
16485238|NCT03393897||Hemodynamic instability with hypotension|
16485239|NCT03393884|Experimental|NACT + GEN-1|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
16485240|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
16485241|NCT03393858|Experimental|Immunotherapy plus Hyperthermia|
16485243|NCT03393832||Oral Care with Mother's Milk|All infants admitted to the Texas Children's Hospital NICUs who have mother's milk available will receive oral care with mother's milk.
16485244|NCT03393832||Oral Care with Sterile Water|Infants will receive oral care with sterile water when mother's milk is not available.
16485245|NCT03393819|Experimental|Duraprep Surgical Solution|Surgical site (hip) is prepared with Duraprep (iodine-alcohol) prior to surgery according to package instructions.
16485246|NCT03393819|Experimental|Chloraprep Surgical Solution|Surgical site (hip) is prepared with Chloraprep (chlorhexidine-alcohol) prior to surgery according to package instructions.
16485247|NCT03393806|Experimental|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
16485248|NCT03393806|Placebo Comparator|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
16485249|NCT03393767|Other|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
16485250|NCT03393754|Experimental|Sci-B-Vac® Hepatitis B Vaccination|Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
16485251|NCT03393754|Active Comparator|Engerix-B® Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
16485252|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
16485253|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
16485288|NCT03393494|Active Comparator|Reference active|RLD product
16485289|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
16485290|NCT03393481|Experimental|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
16485291|NCT03393481|Experimental|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
16485292|NCT03393481|Active Comparator|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
16485377|NCT03392818|Experimental|Fiberoptic bronchoscope|intubation of Uniblocker under the Under the guidance of Fiberoptic bronchoscope
16485418|NCT03392623|Experimental|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
16485254|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
16485255|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
16485256|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
16485257|NCT03393728|Experimental|Intervention|72-hour propanolol before specific treatment of hyperthyroidism
16485258|NCT03393715|Experimental|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
16485259|NCT03393715|Active Comparator|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
16485260|NCT03393702|Experimental|Gabapentin|"Single dose preoperative gabapentin.
~After surgery gabapentin 2 times per day for 3 days."
16485261|NCT03393702|Placebo Comparator|Placebo Control|"Single dose preoperative placebo control.
~After surgery placebo 2 times per day for 3 days."
16485262|NCT03393689|Experimental|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR
16485263|NCT03393650|Active Comparator|Exercise + Placebo group|50 subjects will receive a placebo supplementation with an exercise intervention (EX group)
16485264|NCT03393650|Active Comparator|Exercise + Protein group|50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)
16485265|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
16485266|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
16485267|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
16485268|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
16485269|NCT03393611|Experimental|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
16485270|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
16485271|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
16485272|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
16485273|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
16485274|NCT03393572|Active Comparator|Group BM|bupivacaine 0.25% plus magnesium sulphate.
16485275|NCT03393572|Active Comparator|Group BN|bupivacaine 0.25% plus nalbuphine
16485276|NCT03393559|Experimental|Group L|leg elevation during the beach chair position
16485277|NCT03393559|No Intervention|Group C|Patients' leg will be straightened without any intervention.
16485278|NCT03393546|Experimental|Auricular Point Acupressure - Interventionist|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day). The treatment will be administered by the research team's trained acupressure interventionist.
~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
16485279|NCT03393546|Experimental|Auricular Point Acupressure - Caregiver Training|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).
~If participants live more than 15 miles away from the research team's office, the caregiver will receive in-person training by the interventionist on how to administer the treatment to their patient for the 4 weeks of treatment.
~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
16485280|NCT03393533|Other|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
16485281|NCT03393533|Active Comparator|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
16485282|NCT03393520|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
16485295|NCT03393442|Experimental|1. Gd-exposed subjects|Diagnostic Test: Brain MRI scan Female subjects at high risk for breast cancer that previously underwent more than 6 Gd-based contrast enhanced MRI exams of the breast.
16485296|NCT03393442|Active Comparator|2. Healthy subjects|Diagnostic Test: Brain MRI scan Age-matched female control subjects that never received Gd-based contrast agents.
16485297|NCT03393429|Active Comparator|DAVID assisted training|Group I: Training assisted by DAVID devices
16485298|NCT03393429|Placebo Comparator|training recommendation|"Group II: Training based on stay active recommendations"
16485299|NCT03393416|Experimental|MASCT-I or MASCT-I +PD1 antibody|"This study is divided into three stages:
~The first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The first stage is MASCT-I, using 3+3 design. The second stage is divided into two groups: MASCT-I+PD1 antibody in low dose group and MASCT-I+PD1 antibody in high dose group, using 3+3 design. The third stage is the dose expansion stage , 10 patients in the low or high dose group were treated with the corresponding dose group."
16485300|NCT03393403|Experimental|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
16485301|NCT03393403|Experimental|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
16485302|NCT03393403|Active Comparator|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
16485303|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
16485304|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
16485305|NCT03393377|Experimental|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
16485306|NCT03393377|Placebo Comparator|control group|received placebo for 30 days
16485307|NCT03393364|Experimental|Opioid arm|Patients receive opioid medication, oxycodone, after outpatient urologic surgery.
16485308|NCT03393364|Experimental|Non-opioid arm|Patients receive a non-opioid medication, ketorolac, after outpatient urologic surgery.
16485309|NCT03393351|Experimental|Shared decision-making program|
16485310|NCT03393351|Active Comparator|Usual care|
16485311|NCT03393338|Experimental|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
16485312|NCT03393338|No Intervention|Usual Medical Care|Usual medical care
16485313|NCT03393312|Experimental|Bifrontal tDCS|"20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).
~The stimulation will be applied before or during task performance, depending on the condition assignment."
16485314|NCT03393312|Sham Comparator|Sham tDCS|"Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.
~The stimulation will be applied before or during task performance, depending on the condition assignment."
16485315|NCT03393299|Experimental|STOPP/START|Use of STOPP/START criteria during medication reconciliation
16485316|NCT03393299|No Intervention|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
16485317|NCT03393273|Experimental|Elotuzumab|This is a single arm phase II trial to assess the Very Good Partial Response rate of a strategy involving autologous hematopoietic stem cell transplantation, after intensive treatment and followed by consolidation phase, with elotuzumab, dexamethasone, velcade, and thalidomide in elderly patients.
16485318|NCT03393247|Active Comparator|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
16485319|NCT03393247|Active Comparator|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
16485320|NCT03393234|Experimental|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
16485321|NCT03393234|No Intervention|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
16485322|NCT03393221|Experimental|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
16485375|NCT03392831|Active Comparator|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
16485376|NCT03392818|Experimental|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
16485323|NCT03393221|Active Comparator|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
16485324|NCT03393208|Experimental|First Test GIR (Fasting), Then Reference GIR (Fasting)|Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
16485325|NCT03393208|Experimental|First Reference GIR (Fasting), Then Test GIR (Fasting)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
16485326|NCT03393208|Experimental|First Test GIR (Fed), Then Reference GIR (Fed)|Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
16485327|NCT03393208|Experimental|First Reference GIR (Fed), Then Test GIR (Fed)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
16485328|NCT03393195|Experimental|Time-restricted eating plan|Participants in this group will be instructed to fast every day from 8pm until 12pm the following day. From 12pm until 8pm, participants can eat and drink whatever they want. During fasting hours, participants can drink water and black coffee.
16485329|NCT03393195|Active Comparator|Consistent Meal Timing Plan|Participants in this group will be instructed to eat three daily meals during specified eating times. Their first meal will be between 7am-11am. Second meal between 11am and 3pm, and third meal between 4pm-10pm. Participants will be encouraged to eat small snacks if needed so that they can eat their next meal during the specified window.
16485330|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)
~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
16485331|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)
~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
16485332|NCT03393156|Experimental|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
16485333|NCT03393156|No Intervention|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
16485334|NCT03393143||Oregon patients|Adult Medicaid patients with back pain who get their care in community health clinics in Oregon
16485335|NCT03393143||California patients|Adult Medicaid patients with back pain who get their care in community health clinics in California
16485336|NCT03393130||Participants possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who possess at least one copy of the APOE-ε4 allele.
16485337|NCT03393130||Participants not possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who do not possess a copy of the APOE-ε4 allele.
16485338|NCT03393117|Experimental|Liposomal Bupivacaine + Bupivacaine|This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
16485339|NCT03393117|Active Comparator|Bupivacaine|This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
16485340|NCT03393104|Experimental|Motor Control Exercise and Patient Education|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise and 4 sessions (1 session per week) of patient education program as described in respective protocol.
~In addition, they will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
16485341|NCT03393104|Experimental|Motor Control Exercise|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.
~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
16485342|NCT03393104|Experimental|Patient Education|"Participants will receive patient education session once a week at interval of 1-week over 8-weeks (4 sessions). The program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
16485343|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
16485344|NCT03393078|Active Comparator|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
16485345|NCT03393078|Sham Comparator|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
16485346|NCT03393065|Experimental|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
16485347|NCT03393065|No Intervention|Control group|control group the fluid management will not be LUS guided
16485348|NCT03393052|Active Comparator|Left Radial access|Left Radial approach for coronary angiography in patients with prior history of CABG surgery
16485349|NCT03393052|Active Comparator|Femoral access|Femoral approach for coronary angiography in patients with prior history of CABG surgery
16485350|NCT03393039|Experimental|Behavioral|Negative Affect Task
16485351|NCT03393026|Experimental|Lurasidone 40-160 mg|Lurasidone 40-160 mg
16485352|NCT03393013|Experimental|KZR-616 60 mg + standard therapy (Phase 2)|60 mg dose level of KZR-616 selected based on data from the Phase 1 dose escalation and administered to patients with active Lupus Nephritis in combination with standard therapy.
16485353|NCT03393013|Experimental|KZR-616 45 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
16485354|NCT03393013|Experimental|KZR-616 60 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
16485355|NCT03393013|Experimental|KZR-616 75 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
16485356|NCT03393000|Experimental|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
16485357|NCT03393000|Active Comparator|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
16485358|NCT03392987|Experimental|OTL-200 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.
16485359|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
16485360|NCT03392961|Experimental|IN-105 (Insulin Tregopil)|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.
~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.
~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
16485361|NCT03392961|Placebo Comparator|Placebo tablet|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.
~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.
~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
16485362|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
16485363|NCT03392922|Experimental|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
16485364|NCT03392922|Experimental|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
16485365|NCT03392909|Experimental|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
16485366|NCT03392896|Experimental|Group A Active (DCR-PHXC)|HVs, single ascending doses of DCR-PHXC.
16485367|NCT03392896|Placebo Comparator|Group A Placebo|HVs, normal saline 0.9% injection to match active doses.
16485368|NCT03392896|Experimental|Group B Active (DCR-PHXC)|PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.
16485369|NCT03392883|Experimental|Digital Health Assisted Mental Healthcare|This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).
16485370|NCT03392870|Experimental|TAVA-ACTIVE|Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient>70, verbal communication and no behavioural alterations.
16485371|NCT03392870|Active Comparator|CONTROL|As usual
16485372|NCT03392844|Experimental|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
16485373|NCT03392844|Experimental|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
16485374|NCT03392831|Experimental|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
16485378|NCT03392818|Experimental|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of FOB.
16485379|NCT03392805|Experimental|sedentary life style|
16485380|NCT03392805|No Intervention|physically active life style|
16485381|NCT03392792|Active Comparator|tissue plasmnogen activator|
16485382|NCT03392792|Active Comparator|thrombectoy|
16485383|NCT03392779|Experimental|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
16485384|NCT03392779|Experimental|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo
~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
16485385|NCT03392779|Experimental|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo
~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
16485386|NCT03392779|Experimental|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo
~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
16485387|NCT03392779|Experimental|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo
~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
16485388|NCT03392779|Experimental|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo
~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
16485389|NCT03392779|Experimental|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.
~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
16485390|NCT03392779|Experimental|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE
~ZSP1601 50 mg/Placebo for 14 Days."
16485391|NCT03392779|Experimental|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.
~ZSP1601 100 mg/Placebo for 14 Days."
16485392|NCT03392766|Experimental|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
16485393|NCT03392766|Experimental|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
16485394|NCT03392753|Active Comparator|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
16485395|NCT03392753|Active Comparator|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
16485396|NCT03392740|Experimental|Lisinopril treatment|These patients will be initiated at 5mg lisinopril daily by the research nurse at the time of enrollment. The drug will then be titrated up by the research nurse in a stepwise fashion from 5mg, to 10mg, and then to 20mg once a day every 1 to 3 weeks according to their regular/scheduled next office visits. Blood pressure will be monitored at every visit by the research nurse if it is less than or equal to 90 mmHg
16485397|NCT03392740|Placebo Comparator|Placebo Oral Tablet|These patients will be started on the placebo medication at the time of enrollment. According to their regular scheduled visits every 1 to 3 weeks, they will meet with the research nurse and be given a new placebo medication to take once a day.
16485398|NCT03392727|Experimental|Study Box & Education Session|Parents are provided a baby box and infant health and safety products and participate in a face to face educational session
16485399|NCT03392727|Active Comparator|Community Box & Online Education|Parents are informed how to receive a free box from a community site and are provided a guide to online resources for prenatal and infant health promotion
16485400|NCT03392714|Experimental|R-B(O)AD|Intravenous R-B(O)AD every 4 weeks for up to 4 cycles
16485401|NCT03392701|Experimental|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
16485402|NCT03392701|Placebo Comparator|Placebo|NaCl
16485403|NCT03392688|Experimental|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.
~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
16485404|NCT03392688|Active Comparator|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.
~Surface EMG, Q angle measurement were administered to the control group."
16485405|NCT03392675|Experimental|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
16485406|NCT03392675|No Intervention|Control|Usual care and asked to complete measures at follow-up time points.
16485407|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
16485408|NCT03392662||Hemopatch Sealant Use with General Surgery|
16485409|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
16485410|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
16485411|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
16485412|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
16485413|NCT03392649|No Intervention|Sham Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, but the Parasym will not be turned on and the subject will not receive any stimulation. The clip will be switched to the other ear every 4 hours for a total of 48 hours.
16485414|NCT03392649|Experimental|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, and the subject will receive continuous stimulation for 48 hours. The clip will be switched to the other ear every 4 hours.
16485419|NCT03392623|Experimental|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
16485420|NCT03392623|Placebo Comparator|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
16485421|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
16485422|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
16485423|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
16485424|NCT03392597|Experimental|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
16485425|NCT03392597|Active Comparator|Programming-as-Usual|Usual programming implemented in afterschool programs.
16485426|NCT03392584||APR|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR)
16485427|NCT03392584||APR with VRAM|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) and subsequent reconstruction of the perineum with a vertical rectus abdominis myocutaneous flap (VRAM)
16485428|NCT03392571|Experimental|Resectable and borderline restable|"Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.
~Patients receive 3 cycles of preoperative chemotherapy (NGC-triple regimen). The regimen consists of gemcitabine 800 mg/m2, Nab-paclitaxel 100 mg/m2and Cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).
~Patients will be evaluated for adjuvant therapy within 12 weeks of surgery which will consist of Nab-paclitaxel, gemcitabine, and Cisplatin IV weekly x 2, every 3 weeks (one cycle) x 3 cycles."
16485429|NCT03392558|Experimental|Nature-Based Sensitive Skin Regimen|"Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):
~Burt's Bees Sensitive Facial Cleanser (to be used day and night)
~Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)
~Burt's Bees Sensitive Night Cream (to be used at night)"
16485430|NCT03392558|Active Comparator|Control Regimen|"Control Skin Care Regimen (Control Regimen, CR):
~Cetaphil Gentle Skin Cleanser (to be used day and night)
~Cetaphil Moisturizing Lotion (to be used day and night)"
16485431|NCT03392545|Experimental|Combined immune adjuvants and radiation|Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
16485432|NCT03392532|Other|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
16485433|NCT03392532|Other|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
16485434|NCT03392519||Chronic stroke|More than 3 months post-stroke Ischemic or hemorrhagic stroke
16485435|NCT03392506|Experimental|EBUS-TBNA-RTE|Patients do CT、 PETCT examination and EBUS-TBNA-RTE
16485436|NCT03392493|Experimental|Group A|In the phase 1 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week); In the phase 2 :12 training sessions of Standard treatment only. (60 minutes a time, 2 times a week)
16485437|NCT03392493|Active Comparator|Group B|In the phase 1 :12 training sessions of Standard treatment only(60 minutes a time, 2 times a week) ; In the phase 2 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
16485438|NCT03392480||Adult non-haptoglobin 2-2 group|Patients are 45 to 65 years old.
16485439|NCT03392480||Adult haptoglobin 2-2 group|Patients are 45 to 65 years old.
16485440|NCT03392480||Elder non-haptoglobin 2-2 group|Patients are elder than 65 years.
16485441|NCT03392480||Elder haptoglobin 2-2 group|Patients are elder than 65 years.
16485442|NCT03392467|Experimental|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
16485443|NCT03392467|Placebo Comparator|Placebo|normal saline
16485444|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
16485445|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
16485446|NCT03392441|Experimental|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
16485447|NCT03392428|Experimental|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.
~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
16485448|NCT03392428|Active Comparator|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.
~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
16485449|NCT03392415|Active Comparator|Initial conservative treatment|Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
16485450|NCT03392415|Experimental|initial interventional treatment|CTO PCI attempt as initial strategy with medical optimization simultaneously
16485451|NCT03392389|Experimental|mRNA-1653|
16485452|NCT03392389|Placebo Comparator|Placebo|
16486419|NCT03385512|Experimental|ASK Poster|Participants in this arm will experience the ASK intervention.
16485453|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.
~Other name: Serenase"
16485454|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
16485455|NCT03392350|Active Comparator|Behavioral Intervention arm|"A behavioral intervention consisting of a physician body scan consultation with a radiologist which included viewing self imagery followed by an 18 month behavioral intervention which included educational modules covering:
~Responding to Stress More Effectively Enhancing the effects of Relaxation Nourishing your immune system Energizing your Body Welcoming Others and Strengthening Relationships"
16485456|NCT03392350|Active Comparator|Control Group|No Intervention
16485457|NCT03392337|Experimental|Open Label Narrowband UVB phototherapy|Open Label Narrowband UVB phototherapy for 12 weeks.
16485458|NCT03392324|Experimental|PRIMA|Implantation of PRIMA device
16485459|NCT03392311|Experimental|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
16485460|NCT03392298|Experimental|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
16485461|NCT03392298|No Intervention|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
16485462|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
16485463|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
16485464|NCT03392272|Experimental|Tisseel|Müller's Muscle-Conjunctival Resection (MMCR) using glue instead of sutures
16485465|NCT03392272|Active Comparator|Sutures|Müller's Muscle-Conjunctival Resection (MMCR) using the usual procedure
16485466|NCT03392259|No Intervention|Control group|conventional treatment
16485467|NCT03392259|Experimental|App group|conventional treatment + use of smartphone app.
16485468|NCT03392246|Experimental|Osimertinib + Selumetinib|"Selumetinib are to be administered orally intermittently (4 days on, 3 days off)
~Osimertinib are to be administered orally on a daily basis"
16485469|NCT03392233|Experimental|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
16485470|NCT03392220|Experimental|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
16485471|NCT03392220|Experimental|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
16485472|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
16485473|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
16485474|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
16485475|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
16485476|NCT03392181|Experimental|18F-DCFPyL|
16485477|NCT03392168|Experimental|Cohort 1 - ARQ-151 cream 0.5%|Single-dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s)
16485478|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.5%|ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
16485479|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
16485480|NCT03392168|Placebo Comparator|Cohort 2 - ARQ-151 vehicle cream|Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
16485481|NCT03392155|Experimental|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
16485482|NCT03392142|Experimental|tabelecleucel|Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2 x 10^6 cells/kg on Days 1, 8 and 15, followed by observation through Day 35. Treatment will continue until maximal response, unacceptable toxicity, initiation of non-protocol therapy, or failure of multiple tabelecleucel cell products.
16485483|NCT03392129|Experimental|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
16485484|NCT03392129|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
16485485|NCT03392116|Experimental|Part A: NGM120|Single Dose
16485486|NCT03392116|Placebo Comparator|Part A: Placebo|Single Dose
16485487|NCT03392116|Experimental|Part B: NGM120|Multiple Dose
16485488|NCT03392116|Placebo Comparator|Part B: Placebo|Multiple Dose
16485489|NCT03392103|Experimental|postoperative CRT|postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
16485515|NCT03391882|Experimental|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
16485516|NCT03391882|Active Comparator|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
16485490|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care
~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.
~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences
~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
16485491|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
16485492|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
16485493|NCT03392064|Experimental|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
16485494|NCT03392051|Experimental|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
16485495|NCT03392051|Experimental|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
16485496|NCT03392038|Experimental|Thin ADM|Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR)
16485497|NCT03392038|Active Comparator|Thick ADM|Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM)
16485498|NCT03392025|Active Comparator|Flaxseed|Daily consumption of 30 grams flaxseed for 3 months
16485499|NCT03392025|Active Comparator|Flaxseed and the Mediterranean-like diet|Daily consumption of 30 grams flaxseed in adjunct to the Mediterranean-like diet for 3 months
16485500|NCT03392025|Placebo Comparator|Placebo|Daily consumption of Placebo for 3 months
16485501|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
16485502|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
16485503|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
16485504|NCT03391973|Experimental|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
16485505|NCT03391947|Experimental|semilunar coronally positioned flap|A semilunar incision will be done following the curvature of the gingival margin and ending about 2 to 3 mm short of the tip of the papillae. The most apical distance of this incision to the gingival margin will be obtained by adding the bone sounding measurement to the recession height. Perform a split-thickness dissection coronally from the incision, and connect it to an intrasulcular incision. The tissue will be collapsed coronally, covering the denuded root. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite. Finally, the area will be covered with a periodontal dressing. This is called semilunar coronally positioned flap.
16485506|NCT03391947|Active Comparator|coronally advanced flap|Coronally positioned flap will be initiated with two vertical incisions, extending from a mesial and distal linear angle at the cementoenamel junction (CEJ) and go beyond the mucogingival junction. A split thickness flap will be prepared by sharp dissection mesial and distal to the recession and connected with an intra crevicular incision. On the facial aspect of the tooth, a full thickness flap, approximately 3-4 mm apical to crest of alveolar bone. Then, the flap will be returned and sutured it at 1 mm coronal to the CEJ after de-epithelize the papillae. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite and sutured in the papilla region and releasing incision. Finally, the area will be covered with a periodontal dressing.
16485507|NCT03391934|Experimental|Cetuximab+ FOLFIRI|Cetuximab (Produced by CinnaGen Co.): 400 mg/m2 weekly in the first dose and 250 mg/m2 in the next doses Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
16485508|NCT03391934|Active Comparator|Cetuximab + FOLFIRI|Erbitux® (Produced by Merk Co.): 400 mg/m2 weekly Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
16485509|NCT03391921|Active Comparator|ARM B: 3 doses (0, 2 and 6 months)|ARM B: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
16485510|NCT03391921|Experimental|ARM A: 2 doses (0 and 6 months )|ARM A: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 2 doses at 0 and 6 months intramuscularly. A third facultative dose will be given if antibodies measured at month 7 are insufficent.
16485511|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
16485512|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
16485513|NCT03391895|Active Comparator|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
16485514|NCT03391895|Experimental|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
16485519|NCT03391856|Experimental|intervention arm|NAC 400mg p.o tid from day 60 to day 90 post transplant
16485520|NCT03391856|Other|controlled arm|Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count <20000/ul
16485521|NCT03391843|Experimental|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
16485522|NCT03391830|Active Comparator|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
16485523|NCT03391830|Placebo Comparator|Placebo|Placebo
16485524|NCT03391817|Active Comparator|Intervention arm|Fecal transplant from a thin donor
16485525|NCT03391817|Placebo Comparator|Placebo arm|Fecal transplant made from patients own feces
16485526|NCT03391804|Experimental|ALLN-177|ALLN-177 7,500 units (2 capsules)
16485527|NCT03391791||Genetically engineered T Cell Receptor- treated|Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial
16485528|NCT03391778|Experimental|Participants receiving GSK adoptive cell therapy|
16485529|NCT03391765|Experimental|M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
16485530|NCT03391765|Experimental|M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
16485531|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
16485532|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
16485533|NCT03391752||Royal Alexandria|Administrative records
16485534|NCT03391752||Pasqua Regional hospital|Administrative records
16485535|NCT03391752||Concordia Hospital|Administrative records
16485536|NCT03391752||Niagara General Hospital|Administrative records
16485537|NCT03391752||Hospital 6|Administrative Records
16485538|NCT03391752||Hospital 7|Administrative Records
16485539|NCT03391752||Hospital 8|Administrative Records
16485540|NCT03391752||Hospital 9|Administrative Records
16485541|NCT03391752||Hospital 10|Administrative records
16485542|NCT03391739|Experimental|Arm 1|CART-19 cells treat
16485543|NCT03391726|Experimental|Arm 1|CART-19 cells treat
16485544|NCT03391713|No Intervention|Control|No exposure to waiting room posters
16485545|NCT03391713|Active Comparator|Intervention|During the second half of the study (two weeks), there will be an education poster in the waiting room of the clinic, fashioned after the Face, Arms, Speech, Time (FAST) poster developed by the American Heart Association (AHA), but in Malay.
16485546|NCT03391700|Active Comparator|Moderate muscle relaxation|Rocuronium is administered to maintain moderate relaxation during operation. This is conventional muscle relaxation level of this institute.
16485547|NCT03391700|Experimental|Deep muscle relaxation|Rocuronium is administered to maintain deep relaxation during operation.
16485548|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
16485549|NCT03391674|Experimental|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
16485550|NCT03391674|No Intervention|Observational|Observational
16485551|NCT03391661|Experimental|Chronic Pain and the Brain|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
16485552|NCT03391661|Placebo Comparator|Health Behavior Control|This 15 to 20-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
16485553|NCT03391648||Cesarean|
16485554|NCT03391635|Experimental|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.
~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
16485659|NCT03390738|Experimental|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
16485555|NCT03391635|Active Comparator|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.
~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
16485556|NCT03391609|Placebo Comparator|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
16485557|NCT03391609|Active Comparator|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
16485558|NCT03391596|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
16485559|NCT03391596|Active Comparator|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
16485560|NCT03391596|Other|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
16485561|NCT03391583|Experimental|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
16485562|NCT03391583|No Intervention|Standard of Care|Current standard of care provided in tertiary health care setting
16485563|NCT03391570|Active Comparator|COX-2 inhibitor (Celecoxib)|Celebrex; COX-2 inhibitor
16485564|NCT03391570|Placebo Comparator|Placebo drug (Ramnos)|Ramnos; Lactobacillus casei variety rhamnosus
16485565|NCT03391557|Experimental|Patients with the UE examination|Patients with enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max > 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction were finally selected.
16485566|NCT03391544|Experimental|V4c toric ICL implantation Group|V4c toric ICL implantation Group
16485567|NCT03391531|Active Comparator|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine [Chirocaine®] 0.375% Epi 1/200000.
16485568|NCT03391531|Placebo Comparator|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
16485569|NCT03391505|Experimental|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
16485570|NCT03391505|Experimental|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
16485571|NCT03391505|Placebo Comparator|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
16485572|NCT03391492||influenza group|All consecutive patients older than 18 years ,admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
16485573|NCT03391492||control group|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza,
16485575|NCT03391466|Experimental|Axicabtagene Ciloleucel Treatment|
16485576|NCT03391466|Active Comparator|Standard of Care Therapy|
16485577|NCT03391440|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
16485578|NCT03391427|Experimental|Lidocaine|This group will receive lidocaine infusion perioperatively
16485579|NCT03391427|Experimental|Ketamine|This group will receive ketamine infusion perioperatively
16485580|NCT03391427|Experimental|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
16485581|NCT03391427|Placebo Comparator|placebo|This group will receive saline infusion as placebo perioperatively
16485582|NCT03391414|Experimental|hypertonic bicarbonate|subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer
16485583|NCT03391414|Active Comparator|hypertonic saline|subjects will be administered a solution of 7% sodium chloride by nebulizer
16485584|NCT03391401||Adip1|Patients with morbid obesity (i.e. BMI >35 kg/sqm) and age >18 scheduled for bariatric surgery (all standard procedures included)
16485585|NCT03391388|Experimental|Cohort I (3D-CRT APBI)|Patients undergo 3D-CRT APBI for 3-5 days.
16485586|NCT03391388|Experimental|Cohort II (proton APBI)|Patients undergo proton beam radiation therapy APBI for 3-5 days.
16485587|NCT03391388|Experimental|Cohort III (brachytherapy APBI)|Patients undergo brachytherapy ABPI for 3-5 days.
16485588|NCT03391375|Experimental|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
16485589|NCT03391362|Experimental|Stereotactic Radiation|"Stereotactic radiation will begin within 14 days of the MRI used for radiation planning
~Lesions <2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction
~Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction
~Lesions >3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
16485590|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
16485591|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
16485592|NCT03391323|Other|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
16485593|NCT03391323|Other|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
16485754|NCT03390140|Experimental|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
16486420|NCT03385499|Other|negative control group|blood additional samples on negative control group
16485594|NCT03391310|Experimental|Honey dressing group|In this group, the wound will be cleaned with normal saline and then honey (medicated ) will be applied to cover the wound surface. The dressing will be changed once soiled (alternate day in most cases). The dressing will be applied for a maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
16485595|NCT03391310|No Intervention|Standard treatment group|In this group, the wound will be first cleaned with 'povidone iodine' and then covered with hydrocolloid dressing changed alternate day for maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
16485596|NCT03391297|Experimental|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
16485597|NCT03391297|Active Comparator|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
16485598|NCT03391284|Experimental|Oral|1000 mg acetominophen oral
16485599|NCT03391284|Active Comparator|Intravenous|1000 mg acetominophen intravenous
16485600|NCT03391271|Experimental|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
16485601|NCT03391271|Placebo Comparator|Placebo group|No PBMT
16485602|NCT03391258|Experimental|Bone Regeneration with GLAM technique|At the beginning of each surgery, a venipuncture will be performed, to obtain the L-PRF membranes. Also, two white topped tubes will be centrifuged for 3 minutes to obtain PRP. After implant placement, achieving a primary stability of at least 45 Ncm, the stiff bone-block (L-PRF membranes and PRP combined with bovine xenograft) will be used in the buccal plate of the pre-maxilla, to enhance bone volume in the esthetic area.
16485603|NCT03391245||Cirrhotic patients with or without infection|"We will include admitted patients with liver cirrhosis irrespective of the underlying etiology during 6 months in Al Rajhi Tertiary Liver Hospital, Assiut, Egypt. They will be divided into 2 Groups. Group I: Cirrhotic patients with evidence of infections at any site and Group II: Cirrhotic patients without evidence of infections.
~Diagnosis of infection will based on related clinical symptoms and signs with laboratory and radiological findings."
16485604|NCT03391232|Experimental|PolyPEPI1018 CRC Vaccine|The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses.
16485605|NCT03391219|Active Comparator|intravitreal Bevacizumab|
16485606|NCT03391219|Active Comparator|intravitreal Bavacizumab and Fasudil|
16485607|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
16485608|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
16485609|NCT03391193|Experimental|Multi-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal containing) in multi-dose presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
16485610|NCT03391193|Active Comparator|Single-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free) in single-dose syringe presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
16485611|NCT03391180|Experimental|ICON Remineralization|Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.
16485612|NCT03391180|Active Comparator|CPP-ACPF|Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.
16485613|NCT03391167|Sham Comparator|Control|Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
16485614|NCT03391167|Experimental|ESP Block|In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
16485615|NCT03391154|Active Comparator|levothyroxine|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy
16485616|NCT03391154|No Intervention|control|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will not receive any drug throughout the pregnancy
16485617|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:
~Heart Failure
~COPD
~Cancer"
16485618|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:
~Heart Failure
~COPD
~Cancer"
16485619|NCT03391089|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
16485620|NCT03391076|Experimental|FilmArray group|Patients in this group will use FilmArray Respiratory Panel to test potential viral pathogens.
16485621|NCT03391076|No Intervention|Routine test group|Patients in this group will use clinical routine methods to test potential viral pathogens.
16485622|NCT03391063|Experimental|reinforced polyamide denture base|metal reinforced polyamide denture base
16485623|NCT03391063|Active Comparator|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
16485624|NCT03391050|Experimental|APR-246 + Dabrafenib|
16485816|NCT03389685|Experimental|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
16485625|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
16485626|NCT03391024|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
16485627|NCT03391011|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
16485628|NCT03390998||Peripartum SCAD|Female patients who experienced any SCAD event that occurred during pregnancy or up to 1 year post-delivery
16485629|NCT03390998||Non-peripartum SCAD|Female patients who experienced any SCAD with event onset outside of the pregnancy period
16485630|NCT03390972|Experimental|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
16485631|NCT03390972|Placebo Comparator|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
16485632|NCT03390959|Experimental|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
16485633|NCT03390959|Other|Control Group|The group continues in their daily lives with phone monitoring.
16485634|NCT03390946|Experimental|four-drug interval-compressed regimen|"Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.
~Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.
~Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.
~After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.
~Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'."
16485635|NCT03390933|Experimental|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
16485636|NCT03390920|Experimental|Umbilical Allograft|The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the product utilized will be either 1.0cc's or 2cc's.
16485637|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
16485638|NCT03390881|Experimental|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
16485639|NCT03390881|Active Comparator|Sugar condition|Effects of sugar consumption on breath acetone changes
16485640|NCT03390881|Active Comparator|Fat condition|Effects of fat consumption on breath acetone changes
16485641|NCT03390868|Experimental|Intervention arm|Phase 1, participants in the intervention group will take part in an web-based training for staff working with people with intellectual disabilities and challenging behaviour aiming to in a more effective way communicate to prevent challenging behaviour. The participants (staff) will by their own, go through the web-based training program during working hours. Measurement are conducted before intervention, at intervention completion an average of 12 weeks, and for a 3 month follow up after completed intervention
16485642|NCT03390868|Other|control arm|Control arm: participants in the control-group will maintain regular care and have the opportunity to receive the web-based training for staff working with people with intellectual disabilities and challenging behaviour in phase 2.
16485643|NCT03390855|Experimental|Broccoli sprout and follow up|Daily consumption of 30 g of raw, fresh, broccoli sprouts, not cooked, during 10 weeks (70 days), followed by other 90 days of no ingestion of broccoli sprouts
16485646|NCT03390829||Patients|
16485647|NCT03390829||Doctors|
16485648|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
16485649|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
16485650|NCT03390803||patients with hemifacial spasm|
16485651|NCT03390803||healthy control subjects|
16485652|NCT03390790|Experimental|Lidocaine gel|If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.
16485653|NCT03390790|Placebo Comparator|Lubricant gel|If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.
16485654|NCT03390777|Active Comparator|surgery only|Surgery consisting in debridement/removal of affected tissue/s will be performed.
16485655|NCT03390777|Active Comparator|surgery and PRGF|Surgery consisting in debridement/removal of affected tissue/s will be performed. Platelet Rich Growth Factor (device) will be produced by a venous blood sampling of the patient and applied to the treated area
16485656|NCT03390764|Active Comparator|4:1 closure group|Patients randomized to and receiving the intervention small stitch 4:1 technique for closure of the abdominal wall.
16485657|NCT03390764|Active Comparator|RTL plus 4:1 closure group|Patients randomized to and receiving the intervention reinforced tension-line suture plus small stitch 4:1 technique for closure of the abdominal wall.
16485658|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
16485817|NCT03389685|Placebo Comparator|Saline Placebo|Unmarked syringe with 5 ml of saline
16485660|NCT03390725|Experimental|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
16485661|NCT03390725|Active Comparator|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
16485662|NCT03390712||Paliperidone Palmitate|Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
16485663|NCT03390712||Risperidone Long-acting injection.|Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.
16485664|NCT03390699|Experimental|before and after partial maxillectomy|Microbial profile among patients before and after partial maxillectomy
16485665|NCT03390686|Experimental|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
16485666|NCT03390686|Active Comparator|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
16485667|NCT03390673|Experimental|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
16485668|NCT03390673|Active Comparator|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
16485669|NCT03390673|Active Comparator|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
16485670|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
16485671|NCT03390647|Experimental|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
16485672|NCT03390647|Experimental|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
16485673|NCT03390647|Experimental|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
16485674|NCT03390608||Women with T1ab breast cancer.|
16485675|NCT03390595|Experimental|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
16485676|NCT03390595|Active Comparator|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
16485677|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
16485678|NCT03390582||healthy controls|healthy controls are all from normal volunteers
16485679|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
16485680|NCT03390582||treated GD|GD patients treated by Methimazole Pill
16485681|NCT03390569|Experimental|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
16485682|NCT03390556|Experimental|Asthma education|
16485683|NCT03390543|Experimental|Device group (Group D)|Arm Description: Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound and simple needle guide device.
16485684|NCT03390543|Placebo Comparator|sono only group (Group S)|Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound without simple needle guide device.
16485685|NCT03390530|Active Comparator|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
16485686|NCT03390530|Placebo Comparator|Placebo treatment|Intravenous placebo treatment every 12 hours.
16485687|NCT03390517|Experimental|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
16485688|NCT03390517|No Intervention|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
16485689|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]).
16485690|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
16485691|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs).
16485692|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
16485693|NCT03390491|Experimental|OnTrack>TheGame (OTG)|Participants randomized to the OTG group (n=100) will have the option to play the online role-playing game for a period of 2 months. They will receive weekly email reminders that the game remains available to them.
16485694|NCT03390491|Other|Recovery Videos (RV)|Participants randomized to the RV group (n=100) will have the option to visit a website that will contain the recovery videos and the static information that is contained in the game. The RV group will also have 2 months to view the materials on the website and will receive weekly email reminders that the website/videos remain available to them. At the end of the study (after the follow-up assessment), the RV participants will be provided access to the game.
16485695|NCT03390478|No Intervention|Control Group|The participants that will be assign to the control group will receive institutional usual care.
16485696|NCT03390478|Experimental|Combined Intervention Group|The participants that will be assigned to the experimental group will receive the Combined Intervention Program
16485697|NCT03390465|Other|Arm1(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
16485698|NCT03390465|Other|Arm2(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
16485699|NCT03390465|Other|Arm3(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
16485700|NCT03390465|Other|Arm4(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
16485701|NCT03390465|Other|Arm5(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
16485702|NCT03390465|Other|Arm6(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
16485703|NCT03390452|Experimental|Intervention|"The parents will receive Mobile phone messages about oral hygiene and healthy dieting of their children through teachers.
~The message format will be text and images, depending upon the education/ literacy level of the parents. Parents will be reminded and information reinforced, at frequent intervals for a period of six months.
~Oral hygiene of School children will be assessed before intervention, after 6 months interval"
16485704|NCT03390452|No Intervention|Control|The primary school children in the control group will not receive any intervention via their parents or teachers (in-active controls) but will be observed on selected outcome measures for baseline data, then at six month interval to compare for differences (if any) with intervention group.
16485705|NCT03390439|Active Comparator|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
16485706|NCT03390439|Experimental|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
16485707|NCT03390426|Experimental|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
16485708|NCT03390426|Placebo Comparator|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
16485709|NCT03390413|Active Comparator|Robot|
16485710|NCT03390413|Experimental|Cryo|
16485711|NCT03390400|Active Comparator|Anterior Capsulotomy before Lens Fragmentation|Anterior capsulotomy will be performed by femtosecond laser before lens fragmentation
16485712|NCT03390400|Active Comparator|Lens Fragmentation before Anterior Capsulotomy|Lens fragmentation will be performed by femtosecond laser before anterior capsulotomy
16485713|NCT03390387|Experimental|Dexa intermittent|Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).
16485714|NCT03390387|Active Comparator|Dexa constant|Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).
16485715|NCT03390387|Active Comparator|Dexa|Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.
16485716|NCT03390387|Experimental|Medrol|Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.
16485717|NCT03390387|Experimental|IDA|Induction and consolidation therapy with Idarubicin
16485718|NCT03390387|Active Comparator|DNR|Induction and consolidation therapy with Daunorubicin
16485719|NCT03390387|Experimental|Protocol Ib+|Two-phase induction therapy (additional second phase of induction - protocol Ib)
16485720|NCT03390387|Active Comparator|Protocol Ib-|Standard induction therapy (without second phase)
16485721|NCT03390387|Active Comparator|Bortezomib-|Consolidation therapy without Bortezomib
16485722|NCT03390387|Experimental|Bortezomib+|Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)
16485723|NCT03390374|Experimental|Nystatin group|Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day
16485724|NCT03390374|No Intervention|Control group|Sterile water 1 mL three times a day for oral hygiene
16485725|NCT03390361|Active Comparator|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
16485726|NCT03390361|Placebo Comparator|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
16485727|NCT03390335|Experimental|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
16485728|NCT03390322|Experimental|Duodenal Glycemic Control™|
16485729|NCT03390309|Other|Partially Hydrolyzed Formula|Infant was identified and got 1 or more scores by using infant feeding & stool pattern questionnaire at Visit 1 will be assigned into experimental group randomly
16485730|NCT03390309|Placebo Comparator|Normal Formula|Normal Formula
16485731|NCT03390296|Experimental|Arm A (anti-OX40 antibody PF-04518600)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16485755|NCT03390140|Active Comparator|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
16485756|NCT03390140|No Intervention|Control|No group sessions, no YouTube videos, no workbook
16485732|NCT03390296|Experimental|Arm B (azacitidine, venetoclax, GO)|Patients receive azacitidine IV over 10-40 minutes or via injection SC on days 1-7 or 1-5 and 8-9. Patients also receive venetoclax PO on days 1-28 and GO IV over 2 hours on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16485733|NCT03390296|Experimental|Arm C (azacitidine, GO, avelumab)|Patients receive azacitidine and GO as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16485734|NCT03390296|Experimental|Arm D (azacitidine, venetoclax, avelumab)|Patients receive azacitidine and venetoclax as in Arm A and avelumab as in Arm C. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16485735|NCT03390296|Experimental|Arm E (azacitidine, avelumab, anti-OX40 antibody PF-04518600)|Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16485736|NCT03390296|Experimental|Arm F (GO, glasdegib)|Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16485737|NCT03390283||Observational (Online survey)|Participants complete online survey on an iPad over 20 minutes.
16485738|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
16485739|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
16485740|NCT03390244|Experimental|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
16485741|NCT03390231|Experimental|Stem Cell Educator|"The Stem Cell Educator (SCE) technology involves a closed-loop system that circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns only the educated immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have been conducted to demonstrate the proof of concept and clinical safety of SCE therapy. They suggest that SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages that are encountered through the action of the autoimmune regulator (AIRE) and other molecular mechanisms. Following induction of immune tolerance in the immune cells, the immune balance and homeostasis may be restored when treated cells are returned in vivo."
16485742|NCT03390218|Experimental|TAO (Therapy Assisted Online)|TAO participants will attend a once weekly group in a computer lab. Each participant will complete an interactive educational module using an evidence based protocoled treatment for anxiety and/or depression, and have a brief session with the group leader to discuss application of the content. Participants will have access to a companion app they may use between sessions to practice skills and reinforce learning.
16485743|NCT03390218|Active Comparator|Treatment as usual|After the completion of a psychosocial assessment, and development of a treatment plan, clients are offered individual and group therapy sessions, case management services, and medication management services depending on the diagnoses. Individual and group therapy is often generic in nature as well, although some structured, evidence-based treatments are offered such as Psycho-Education Multi-Family Group and Illness Management Recovery.
16485744|NCT03390205||Patients|
16485745|NCT03390205||Controls|
16485746|NCT03390192|Experimental|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
16485747|NCT03390192|Active Comparator|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
16485748|NCT03390179||diabetes|Patient with non insulin diabetes
16485749|NCT03390179||control|Patient without diabete
16485750|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
16485751|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
16485752|NCT03390153|Experimental|semi flexible socket group|A new form of residuum containment is the semi-flexible carbon fiber prosthetic socket. A semi-flexible carbon fiber socket is constructed with the same security for the subject in mind, and is even more lightweight than a rigid socket. The carbon fiber and resin used in a semi-flexible socket may provide the same durability and stability as previous designs, but will deform, intentionally, without failing (breaking). This distinct feature of semi-flexible sockets makes them a potential option for people living with limb loss. By moving slightly with the residual limb, the socket-user-interface should experience fewer forces/stresses, and yield greater comfort for the prosthetic user.
16485753|NCT03390153|Active Comparator|rigid fiber socket group|A rigid carbon fiber socket is constructed for security and is mechanically lightweight to ensure stability and efficient build height. Carbon is used for its durability and stability. It proves to be a detriment in comfort and flexibility. The standard for carbon fiber weaves come in two forms: Unidirectional (UD) and Bidirectional (BD). UD carbon fiber has a zero-degree alignment, which is highly durable when compressed, but has low torsional durability. The BD carbon fibers are aligned in a 90 degree angle allowing for moderate compression and torsional strength. When oriented at 45 degrees to the line of progression, fibers become more flexible and exhibit greater torsional strength. Resins and glass composites are added to ensure security and sturdiness.
16485757|NCT03390127|Experimental|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
16485758|NCT03390127|No Intervention|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
16485759|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
16485760|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
16485761|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.
~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
16485762|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.
~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
16485763|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.
~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
16485764|NCT03390075||ResearchNow NuVal shoppers|a convenience sample of 665 shoppers at two NuVal chains.
16485765|NCT03390062|Experimental|apatinib|apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death
16485766|NCT03390049|Active Comparator|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
16485767|NCT03390049|Sham Comparator|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
16485768|NCT03390036|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
16485769|NCT03390036|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
16485770|NCT03390036|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
16485771|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
16485772|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
16485773|NCT03390010|Active Comparator|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon and methergibe drugs during CS
~this group in which prevention of uterine atony is made by intrauterine misotac plus the usual syntocinon and methergine during cesarean section"
16485774|NCT03390010|Active Comparator|Active management of labour group|"Procedure: Giving syntocinon and methergine drugs during cesarean section
~this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and methergine during cesarean section"
16485775|NCT03389984|Experimental|Adalimumab|
16485776|NCT03389971|Active Comparator|multi-sidehole catheter|
16485777|NCT03389971|Experimental|USAT catheter|
16485778|NCT03389945|Active Comparator|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
16485779|NCT03389945|Experimental|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
16485780|NCT03389932|No Intervention|Standard of Care (Control)|For patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
16485781|NCT03389932|Experimental|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
16485782|NCT03389906|Experimental|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
16485814|NCT03389698|Active Comparator|Heatlthy Control Group|cognitively normal (CN) subjects in two age groups: young(20-40) and old (65-85)
16485815|NCT03389698|Active Comparator|Amnestic mild cognitive impairment (aMCI)|32 participants who have aMCI.
16486421|NCT03385499|Other|positive control group|blood additional samples on positive control group
16485783|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).
~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.
~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
16485784|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).
~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.
~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
16485785|NCT03389880|Active Comparator|Patellar denervation|
16485786|NCT03389880|Experimental|Non-patellar denervation|
16485787|NCT03389867|Experimental|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
16485788|NCT03389854|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
16485789|NCT03389854|Experimental|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
16485790|NCT03389854|Experimental|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
16485791|NCT03389854|Experimental|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
16485792|NCT03389841|Active Comparator|Intervention|Education of the caregiver
16485793|NCT03389841|No Intervention|No intervention|Usual care
16485794|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
16485795|NCT03389815|Experimental|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
16485796|NCT03389802|Experimental|Stratum 1|The recurrent, progressive, or refractory primary malignant non-brainstem CNS tumor patients will be treated with APX005M.
16485797|NCT03389802|Experimental|Stratum 2|The newly diagnosed diffuse intrinsic pontine gliomas (DIPGs) patients will be treated with APX005M.
16485798|NCT03389789|Experimental|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
16485799|NCT03389789|Experimental|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
16485800|NCT03389789|Active Comparator|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
16485801|NCT03389789|Active Comparator|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
16485802|NCT03389763|Experimental|SPI-guided remifentanyl|remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50%
16485803|NCT03389763|Experimental|PRD-guided remifentanyl|solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50%
16485804|NCT03389763|Experimental|BBS-guided remifentanyl|BBS assessment every 5 minutes, solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute; when BBS>2, infusion speed of remifentanyl will be increased by 50%
16485805|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxymorphone|Intravenous (IV) Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
16485806|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxycodone|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
16485807|NCT03389750|Active Comparator|Intravenous Challege Drug: Morphine|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
16485808|NCT03389750|Active Comparator|Intravenous Challege Drug: Hydromorphone|IV Dose Range: 0, 5.6, 10, 18 mg/70kg of the participant's body weight
16485809|NCT03389750|Placebo Comparator|Intravenous Challege Drug: Placebo|IV saline
16485810|NCT03389737|Experimental|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
16485811|NCT03389737|Active Comparator|Control|Control group will not have monthly contact with the physicians.
16485812|NCT03389724|Experimental|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
16485813|NCT03389724|No Intervention|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
16485818|NCT03389672||spinal anesthesia|The anesthesia technique were applied with modified approach and conventional approach
16485819|NCT03389672||epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
16485820|NCT03389672||combined spinal-epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
16485821|NCT03389659|Experimental|Vitamin D3 group|vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
16485822|NCT03389659|Placebo Comparator|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
16485823|NCT03389646|Active Comparator|Treated with Device: Including sham|"Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
16485824|NCT03389646|No Intervention|Control|Control without CERAMENT device
16485825|NCT03389633|Experimental|Rehabilitation group|this group follows a 3 months rehab program
16485826|NCT03389633|No Intervention|No rehabilitation|This group does not follow a rehab program
16485827|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
16485828|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
16485829|NCT03389607||diabetic|the patients must have diabetic disease
16485830|NCT03389607||control|the patients must not have diabetic
16485831|NCT03389594|No Intervention|Surgical guide designed from voxel size 0.2mm|Surgical guide will be designed based on CBCT voxel size 0.2mm
16485832|NCT03389594|Active Comparator|Surgical guide designed from voxel size 0.4m|Surgical guide will be designed based on CBCT voxel size 0.4 mm
16485833|NCT03389568|Experimental|Intervention for caregivers of ICU patients|
16485834|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :
~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days
~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days
~Hydrocortisone 50mg every 6 hours x 4-days"
16485835|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
16485836|NCT03389542|Experimental|Early mitral valve repair|Surgery will be performed within 3 months after randomization. Clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. Echocardiography will be performed at discharge, at 6 months and at the end of follow-up.
16485837|NCT03389542|Active Comparator|Conservative management|Patients will be followed up by clinical interview and echocardiography every 6 months.
16485838|NCT03389516|Active Comparator|Polymem breast pads|
16485839|NCT03389516|Active Comparator|Lanolin|
16485840|NCT03389503|Active Comparator|Right radial approach|Right radial approach for coronary angiography and coronary intervention
16485841|NCT03389503|Active Comparator|Left radial approach|Left radial approach for coronary angiography and coronary intervention
16485842|NCT03389490|Experimental|Active|Insulin glargine 300U/ml
16485843|NCT03389490|Active Comparator|Control|Neutral Protamine Hagedorn insulin
16485844|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cisplatin & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)
~Step 2: Cisplatin 100 mg/m^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks
~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin & IMRT"
16485845|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cetuximab & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)
~Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks
~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab & IMRT"
16485846|NCT03389464|Experimental|confrontation group|computer-based confrontation with dysfunctional beliefs
16485847|NCT03389464|No Intervention|control group|no computer-based confrontation with dysfunctional beliefs
16485848|NCT03389451|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
16485849|NCT03389438|Experimental|Experimental arm|Participants who were treated with autologous Tcm cells immunotherapy.
16485850|NCT03389438|No Intervention|No intervention arm|Participants who were treated with no autologous Tcm cells immunotherapy.
16485851|NCT03389425|Experimental|SIMPLE weightloss group|
16485852|NCT03389412|Experimental|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
16485853|NCT03389412|Experimental|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
16485854|NCT03389412|Active Comparator|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
16485855|NCT03389412|Active Comparator|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
16485856|NCT03389412|Active Comparator|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
16485857|NCT03389412|Active Comparator|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
16485903|NCT03388996||Malignant ovarian disease|The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.
16485904|NCT03388983|Experimental|6-week prehabilitation group|6-week prehabilitation
16486037|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
16485858|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
16485859|NCT03389386||Congestive Heart Failure (NYHA II-IV)|"N=90
~Patients with a clinically documented diagnosis of congestive heart failure (CHF), as assessed per New York Heart Association (NYHA) functional classification will be prospectively and consecutively enrolled in this group. Patients will be of both sexes, enrolled in 1:1 ratio.
~All subjects in this group will undergo blood withdrawal for laboratory analysis, transthoracic echocardiography (TTE) examination and will be treated with the Standard-of-care treatment according to their current clinical condition at admission."
16485860|NCT03389386||Healthy Control Group|"N=30
~Healthy volunteers (both sexes, enrolled in 1:1 ratio) with a negative history of cardiovascular diseases will be enrolled in this group that will serve as a study control.
~All subjects in this group will undergo blood withdrawal for laboratory analysis and transthoracic echocardiography (TTE) examination."
16485861|NCT03389373|Other|Child with full primary dentition|All children who match inclusion criteria are eligible to have a saliva sample obtained which will act as a proxy for bacterial levels. High bacteria levels are correlated with a higher risk of developing cavities.
16485863|NCT03389334|Experimental|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
16485864|NCT03389321|Experimental|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
16485865|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.
~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.
~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
16485866|NCT03389295|Experimental|Reduced Target Delineation and Radiation Doses|All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation. The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
16485867|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI > 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
16485868|NCT03389269||Matched controls|Healthy, obese with BMI > 27, the postprandial glucose metabolism will be tested with a meal test
16485869|NCT03389256|Experimental|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
16485870|NCT03389256|Active Comparator|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
16485871|NCT03389243|Experimental|metamizol|analgesic drug
16485872|NCT03389243|Experimental|paracetamol|analgesic drug
16485873|NCT03389243|Experimental|metamizole & paracetamol|analgesic drugs
16485874|NCT03389230|Experimental|Arm I (intratumoral/intracavitary delivery)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
16485875|NCT03389230|Experimental|Arm II (dual delivery Tcm enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
16486110|NCT03387605|Placebo Comparator|Placebo|Matching placebo given PO twice per day
16485876|NCT03389230|Experimental|ARM III (dual delivery Tn/mem enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tn/mem cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
16485877|NCT03389217|Experimental|Real-tDCS + rehabilitation programme|The real transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 minutes over the the left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
16485878|NCT03389217|Active Comparator|Sham-tDCS + rehabilitation programme|The sham transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
16485879|NCT03389204|Active Comparator|Breast surgery and exercise|Patient that underwent breast surgery only without other intervention with exercise of the upper limb and instruction to continue after discharge.
16485880|NCT03389204|Active Comparator|Breast surgery and no exercise|Patient after breast surgery alone are discharged without exercise and instructions.
16485881|NCT03389204|Active Comparator|Breast, axilar surgery with exercise|Patients that underwent surgery of the breast and axilar lymph node surgery with exercise of the upper limb and instruction to continue after discharge.
16485882|NCT03389204|Active Comparator|Breast, axillar surgery without exercise|The patients that underwent surgery of the breast and axilar nodes samples or dissection are discharged without exercise and instructions.
16485883|NCT03389191|Experimental|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
16485884|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.
~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
16485885|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control.
~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
16485886|NCT03389165|Experimental|Elderly adults|Stair climbing with and without a wearable hip assist robot
16485887|NCT03389139|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia. (Near infrared spectroscopy (spinal anesthesia))
16485888|NCT03389139|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia. (Near infrared spectroscopy (general anesthesia)).
16485889|NCT03389126|Experimental|Avelumab|Avelumab 10 mg/kg every 2 wks until disease progression or unacceptable toxicity
16485890|NCT03389113|Experimental|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
16485891|NCT03389113|Active Comparator|Exercise only group|The control group performed the same session without vibration.
16485892|NCT03389100|Experimental|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
16485893|NCT03389087|Experimental|Apatinib and Etoposide Capsule|Apatinib and Etoposide Capsule
16485894|NCT03389061|Active Comparator|sofosbuvir/velpatasvir tablet|Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
16485895|NCT03389061|Experimental|sofosbuvir/velpatasvir crushed|Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
16485896|NCT03389048|Experimental|degenerative lumbar spine disease|patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200
16485897|NCT03389035|Experimental|CARCIK-CD19|
16485898|NCT03389022|Active Comparator|Treatment|0,15mg/kg (LBM) of intravenous single pre-incisional injection of ketamine given for bariatric patients in the operating room.
16485899|NCT03389022|Placebo Comparator|Control|The same amount of intravenous single pre-incisional injection of saline for bariatric patients in the operating room.
16485900|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.
~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
16485901|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.
~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
16485902|NCT03388996||Benign ovarian disease|The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.
16486422|NCT03385499|Other|seroconversion group|blood additional samples on seroconversion group
16485905|NCT03388983|No Intervention|Control group|Patients will receive standard preoperative care (including information about the surgery from an orthopedic surgeon, and a pamphlet summarizing tips of maintaining proper posture and staying active). The usual postoperative care does not include routine rehabilitation program though a short course of rehabilitation may be given based on orthopedic surgeons' discretion.
16485906|NCT03388970|Experimental|research group|normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。
16485907|NCT03388970|Placebo Comparator|placebo group|normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1
16485908|NCT03388957|Experimental|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
16485909|NCT03388957|Experimental|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
16485910|NCT03388957|Experimental|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
16485911|NCT03388944|Experimental|PCT group|PCT group
16485912|NCT03388944|No Intervention|Standard practice group|No intervention
16485913|NCT03388931|Experimental|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
16485914|NCT03388918|Experimental|Intervention group|"The intervention group has three steps:
~Step I: Titration of medicine ( 0-3 months)
~Step II: Telerehabilitation program at healthcare center or by call center ( 3 months)
~Step III: Rehabilitation in everyday life ( 6 months)
~The patients is monitoring vital signs such as blood pressure, pulse, weight, steps, respiration, and sleep. Have access to a Heart Portal that is an information cite on heart failure. Via the portal patients can see measured values & communicate with staff. Every other week the patients fill in an online questionnaires on symptoms, sleep and well being."
16485915|NCT03388918|No Intervention|Traditional rehabilitation group|"This group follows the International Cardiac Guidelines. There are three steps in this arm:
~Step I: Titration of medicine (3 months).
~Step II: Traditional rehabilitation at the healthcare center ( 3 months).
~Step III: Everyday life with HF ( 6 months)
~The participants do not have access to the Heart Portal and is not monitoring any vital signs."
16485916|NCT03388905|Experimental|Wearable Cardioverter Defibrillator group|
16485917|NCT03388892|Experimental|Drug-Eluting Balloon|PTA with DEB at venous anastomotic stenosis of AVG
16485918|NCT03388892|Active Comparator|Plain Balloon|PTA with PCB at venous anastomotic stenosis of AVG
16485919|NCT03388879|Experimental|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
16485920|NCT03388879|Active Comparator|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
16485921|NCT03388866|Active Comparator|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mite Dermatophagoides pteronyssinus, as represented below:
~Weekly dose schedule Monday Wednesday Friday
~st week 1 drop 2 drops 4 drops
~nd week 6 drops 8 drops 8 drops
~Monthly Dilution Schedule Dilution of mite extract
~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v
~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v
~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
16485922|NCT03388866|Placebo Comparator|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:
~Weekly dose schedule Monday Wednesday Friday
~st week 1 drop 2 drops 4 drops
~nd week 6 drops 8 drops 8 drops
~Intervention: Placebo - Immunotherapy allergen diluent"
16485923|NCT03388853|Experimental|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
16485924|NCT03388853|Placebo Comparator|Placebo|Placebo once daily for four weeks
16485925|NCT03388840|Experimental|Adipose derived stem cells suspention|suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
16485926|NCT03388840|Active Comparator|Platelet rich plasma|platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
16485927|NCT03388827|Experimental|Laminaria|Laminaria tent was introduced in the cervical canal
16485928|NCT03388827|Active Comparator|Laminaria plus Misoprostol|Laminaria and Misoprostol were introduced
16485929|NCT03388814|Active Comparator|Bupivacaine Group|Those patients randomized to surgeon infiltration will have a skin wheal performed with lidocaine at the site where an actual pectoralis nerve block would be performed as visualized using ultrasound. Surgeons performing infiltration techniques will be blinded to the contents of the injectate and those patients randomized to surgeon infiltration will receive pharmacy study drug labeled bupivacaine injected in the same fashion and volume as the saline group for oncologic and plastic surgery.
16485930|NCT03388814|Experimental|Pectoralis Nerve block Group|Those patients who are randomized to pectoralis nerve block will have randomization immediately preoperatively and will undergo the nerve block procedure using local anesthetic in the standard fashion. Those patients randomized to pectoralis block will have a standard volume of normal saline injected for oncologic and plastic surgery.
16485931|NCT03388801|Experimental|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
16485932|NCT03388788|Experimental|Normal Weight|Healthy lean controls [18.5<BMI<25 kg/m2 and WC <94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
16485964|NCT03388541|Placebo Comparator|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
16485933|NCT03388788|Experimental|Overweight|Healthy obese [30≤BMI<40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
16485934|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.
~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
16485935|NCT03388762|Active Comparator|GlucoSupreme™ Herbal|Each daily serving of four GlucoSupreme™ Herbal tablets includes extracts from: cinnamon bark (Cinnamomum cassia) 500 mg, banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid) 200 mg, kudzu root (Pueraria lobata standardized to 40% isoflavones) 200 mg, fenugreek seed (Trigonella foenum-graceum standardized to contain 60% saponins) 200 mg, and gymnema leaf (Gymnema sylvestre standardized to contain 25% gymnemic acid). Additionally, American ginseng root (Panax quinquefolius standardized to contain 5% ginsenosides) 200 mg, and berberine HCl derived from bark (Berberis aristata) 500 mg. Other ingredients include Cellulose (capsule), microcrystalline cellulose, silicon dioxide, and vegetable stearate.
16485936|NCT03388762|Placebo Comparator|Control|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
16485937|NCT03388749|Experimental|Liposomal annamycin|
16485938|NCT03388736|No Intervention|No lavender|No mist will be diffused into the environment.
16485939|NCT03388736|Active Comparator|0,1 lavender|0,1 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
16485940|NCT03388736|Active Comparator|0,3 lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
16485941|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:
~Identification of epigenetic signatures
~Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood
~Glucose, insulin and lipids in mothers during pregnancy
~Anthropometry and blood pressure"
16485942|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
16485943|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:
~Stability of epigenetic signatures in offspring through childhood and adolescence
~Relation of these signatures with phenotype"
16485944|NCT03388671|Active Comparator|TAB Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Transversus abdominis plane block.
16485945|NCT03388671|Active Comparator|Psoas Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided psoas block.
16485946|NCT03388645|Experimental|Low Dose 10^6.3 PFU of RSV A2|Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
16485947|NCT03388645|Experimental|High Dose 10^7 PFU of RSV A2|Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
16485953|NCT03388606||Adolescents with Major Depression|Adolescents with a current or past history of meeting full critieria for major depressive disorder
16485954|NCT03388606||Adolescents with sub-threshold Major Depression|Adolescents with no past or current history of major depression who meet criteria at initialenrollment of sub-threshold major depression as defined in the protocol
16485955|NCT03388606||Health volunteer adolescents|Adolescents with no history of significant psychiatric or medical disorders (as defined in the protocol) currently or in the past.
16485956|NCT03388593|Placebo Comparator|Placebo|Placebo in addition to standard therapy
16485957|NCT03388593|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
16485958|NCT03388580||BAL|patients undergoing elective bronchoalveolar lavage
16485959|NCT03388567|Experimental|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
16485960|NCT03388567|No Intervention|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
16485961|NCT03388554|Active Comparator|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
16485962|NCT03388554|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
16485963|NCT03388541|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
16485965|NCT03388528|Experimental|Treatment Group|This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
16485966|NCT03388515|Experimental|SSS11, 1.5mg|SSS11, 1.5mg, iv, single dose at Day 1;
16485967|NCT03388515|Experimental|SSS11, 3.0mg|SSS11, 3.0mg, iv, single dose at Day 1;
16485968|NCT03388515|Experimental|SSS11, 6.0mg|SSS11, 6.0mg, iv, single dose at Day 1;
16485969|NCT03388515|Experimental|SSS11, 12.0mg|SSS11, 12.0mg, iv, single dose at Day 1;
16485970|NCT03388515|Experimental|SSS11, 24.0mg|SSS11, 24.0mg, iv, single dose at Day 1;
16485971|NCT03388502|Experimental|Text Messaging (SMS) Bot|Patients undergoing total joint (hip & knee) arthroplasty will be enrolled in their physician's automated 'Text Messaging (SMS) Bot' in addition to receiving the routine perioperative education and instructions.
16485972|NCT03388502|Active Comparator|Routine Perioperative Instructions|Patients undergoing total joint (hip & knee) arthroplasty will receive only their 'Routine Perioperative Instructions'.
16485973|NCT03388489|Experimental|Mind-Body Walking|breathing, walking and meditation
16485974|NCT03388489|No Intervention|Usual care|maintain their daily activity
16485975|NCT03388476||Suspicion of pulmonary hypertension|At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
16485976|NCT03388463|Active Comparator|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
16485977|NCT03388463|Placebo Comparator|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
16485978|NCT03388450|Active Comparator|Omega 3|Patients received enteral nutrition supplemented with 1000 mg omega-3.
16485979|NCT03388450|Placebo Comparator|Placebo|Patients received enteral nutrition supplemented without 1000 mg omega-3.
16485980|NCT03388437|Experimental|NI-NAVA|Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation
16485981|NCT03388437|Active Comparator|NIPPV|Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
16485982|NCT03388424||Control|Healthy people of both sex
16485983|NCT03388424||quantification of microbiota in Brain|Patients of both sex with neural disorders and diseases
16485984|NCT03388424||quantification of microbiota in GI|Patients of both sex with gastrointestinal diseases
16485985|NCT03388424||quantification of microbiota in Lung|Patients of both sex with Respiratory diseases
16485986|NCT03388424||quantification of microbiota Metabolic|Patients of both sex with Metabolic Diseases
16485987|NCT03388424||quantification of microbiota in UG|Patients of both sex with Uro-genital Diseases
16485988|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
16485989|NCT03388411||Non-obese children|5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
16485990|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
16485991|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
16485992|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
16485993|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
16485994|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
16485995|NCT03388385|Placebo Comparator|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
16485996|NCT03388385|Active Comparator|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
16485997|NCT03388372|Experimental|Nimotuzumab plus RT and temozolomide.|Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
16485998|NCT03388359|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment.
16485999|NCT03388359|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).
~Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment."
16486000|NCT03388346|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
16486001|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
16486002|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
16486003|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
16486004|NCT03388320|Experimental|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
16486005|NCT03388307|Experimental|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
16486006|NCT03388307|Experimental|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
16486179|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
16486009|NCT03388281||Patients with implanted pacemaker|Patients with implanted cardiac pacemaker registered in pacemaker database of the Department of Cardiology at the Medical University Vienna were included.
16486010|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
16486011|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
16486012|NCT03388255|Experimental|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.
~The study period consists of the following phases:
~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).
~Follow up period: 3 months after end of active treatment, without study medication."
16486013|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
16486014|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
16486015|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
16486016|NCT03388216|Experimental|Stage I - Drug: INM004 Dose 1|
16486017|NCT03388216|Placebo Comparator|Stage I - Placebo Dose 1|
16486018|NCT03388216|Experimental|Stage I- Drug: INM004 Dose 2|
16486019|NCT03388216|Placebo Comparator|Stage I- Placebo Dose 2|
16486020|NCT03388216|Experimental|Stage II- Drug: INM004 Repeated Dose|
16486021|NCT03388216|Placebo Comparator|Stage II- Placebo Repeated Dose|
16486022|NCT03388190|Active Comparator|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
16486023|NCT03388190|Experimental|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
16486024|NCT03388177|Experimental|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
16486025|NCT03388177|Other|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy [CBT], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
16486026|NCT03388164|Active Comparator|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
16486027|NCT03388164|Placebo Comparator|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
16486028|NCT03388151|Active Comparator|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
16486029|NCT03388151|Active Comparator|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
16486030|NCT03388138|Active Comparator|K-Lens|etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
16486031|NCT03388138|Placebo Comparator|Placebo Contact Lens|1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
16486032|NCT03388125|Active Comparator|Injection Sclerotherapy|5% ethano lamine oleate
16486033|NCT03388125|Active Comparator|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
16486034|NCT03388112|No Intervention|antibiotics|the patients in this arm will not receive probiotics.
16486035|NCT03388112|Experimental|probiotics concurrent with antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks concurrent with antibiotic.
16486036|NCT03388112|Experimental|probiotics after antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks after antibiotic.
16486180|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
16486038|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
16486039|NCT03388086||Onabotulinum 300 units|
16486040|NCT03388086||Onabotulinum 200 units|
16486041|NCT03388073|Experimental|Berry extract I|Plant-based antioxidant-rich berry-based extract.
16486042|NCT03388073|Experimental|Berry extract II|Plant-based antioxidant-rich berry-based extract.
16486043|NCT03388073|Experimental|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
16486044|NCT03388073|Placebo Comparator|Placebo|
16486045|NCT03388060|Active Comparator|Ultrasound guided SWL|ultrasound guided SWL for Radiolucent stone
16486046|NCT03388060|Active Comparator|Dissolution therapy|Dissolution therapy for Radiolucent stone
16486047|NCT03388060|Active Comparator|Combined ultrasound guided SWL and dissolution therapy|Combined treatment for Radiolucent stone.
16486048|NCT03388047|Experimental|Barrett's Esophagus patients|Multi-Spectral Endoscopic Imaging
16486049|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by swabbing"
16486050|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by swabbing
~Blood sampling:
~A blood sample collected by fingerprick"
16486051|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis
~Blood sampling:
~A blood sample collected by fingerprick"
16486052|NCT03388021|Experimental|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:
~Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire
~Balloon angioplasty and/or stenting
~Intraarterial thrombolysis
~Aiming to correct any residual angiographic lesion as:
~Residual thrombus
~Retained embolus
~Atheromatous plaque"
16486053|NCT03388021|Active Comparator|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
16486054|NCT03388008|Active Comparator|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
16486055|NCT03388008|Experimental|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
16486056|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
16486057|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
16486058|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
16486059|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
16486060|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
16486061|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
16486062|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
16486063|NCT03387969||meningitic group|Children suffering from fever , disturbed consciousnessand convulsion admitted in emergency department attending to assiut University Children Hospital aged between 2-18 years old
16486064|NCT03387956|Active Comparator|Atropine group|Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.
16486065|NCT03387956|Active Comparator|Dexamethasone group|Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).
16486066|NCT03387956|Active Comparator|Dexamethasone and Atropine group|Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.
16486067|NCT03387943|Experimental|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
16486068|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
16486069|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
16486070|NCT03387917|Experimental|TLD-1|"Duration of treatment
~1 cycle: 21 days
~1 cycle: 28 days (only comparative PK part, in cycle 1 or 2)
~until progression or occurrence of unacceptable toxicity or withdrawal, but
~maximum 9 cycles for patients previously not treated with anthracyclines
~maximum 6 cycles for patients previously treated with anthracyclines.
~Dose: i.v., according to DL on day 1 of each cycle or tentative MTD"
16486071|NCT03387917|Experimental|Caelyx (only for comparative PK part)|"Duration of treatment
~1 cycle: 28 days
~Caelyx is given only in one cycle (cycle 1 or 2)
~Dose: i.v., 40mg/m2"
16486072|NCT03387904|Experimental|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16486423|NCT03385486|Experimental|TBX-3400|TBX-3400 by intravenous infusion
16486073|NCT03387904|Active Comparator|Irinotecan|Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16486074|NCT03387891||Cancer patients|Cancer patients admitted to hospital for treatment or monitoring of health condition
16486075|NCT03387878|Other|Single Arm Study|This is a single arm study with no comparator
16486076|NCT03387852|Experimental|SAR440340/REGN3500 Monotherapy|SAR440340/REGN3500 administered by subcutaneous (SC) injections every 2 weeks for 12 weeks and coadministration of dupilumab placebo by SC injection every 2 weeks for 12 weeks
16486077|NCT03387852|Active Comparator|Dupilumab Monotherapy|Dupilumab administered by SC injection every 2 weeks for 12 weeks and coadministration of SAR440340/REGN3500 placebo by SC injections every 2 weeks for 12 weeks
16486078|NCT03387852|Experimental|SAR440340/REGN3500 and Dupilumab Coadministration|SAR440340/REGN3500 administered by SC injections every 2 weeks for 12 weeks and coadministration of dupilumab administered by SC injection every 2 weeks for 12 weeks
16486079|NCT03387852|Placebo Comparator|Placebo|Coadministration of matching placebos for SAR440340/REGN3500 and dupilumab administered by SC injections, respectively, every 2 weeks for 12 weeks
16486080|NCT03387839||Medial-Pivot Knee Prosthesis|
16486081|NCT03387839||Posterior-Stabilized Knee Prosthesis|
16486082|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
16486083|NCT03387826|Experimental|Ticagrelor|Ticagrelor 60mg twice daily followed by Prasugrel 5mg once daily
16486084|NCT03387826|Active Comparator|Prasugrel|Prasugrel 5m once daily followed by Ticagrelor 60mg twice daily
16486085|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.
~All subjects will receive a CardioMEMS™ HF System."
16486086|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.
~All subjects will receive a CardioMEMS™ HF System."
16486087|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.
~All subjects will receive a CardioMEMS™ HF System."
16486088|NCT03387800|Experimental|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
16486089|NCT03387800|Active Comparator|Basic health education messages|Members of the control group will receive health education messages that will also be sent to the intervention group through WeChat. The messages include topics on physical and psychological aspects of perceived severity of smoking and perceived benefits of smoking cessation, and tips/skills on resisting situational temptations that may lead to relapse.
16486090|NCT03387787|Experimental|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
16486091|NCT03387774|Experimental|Concurrent chemoradiotherapy and ulinastatin|"Concurrent chemoradiotherapy (CCRT) and intravenous drip of ulinastatin, the details are as follows:
~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT;
~Ulinastatin through intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline, 3 times every radiation day, until the end of radiotherapy."
16486092|NCT03387774|Active Comparator|Concurrent chemoradiotherapy|"Concurrent chemoradiotherapy (CCRT) alone:
~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT."
16486093|NCT03387761|Experimental|Cohort 1: Ipi + Nivo|"Day 1: Ipilimumab 3 mg/kg i.v.
~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.
~Day 43: Nivolumab 3 mg/kg i.v."
16486094|NCT03387761|Experimental|Cohort 2a: high-Ipi + low-Nivo|"Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.
~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.
~Day 43: Nivolumab 3 mg/kg i.v.
~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
16486095|NCT03387761|Experimental|Cohort 2b: low-Ipi + high-Nivo|"Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.
~Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.
~Day 43: Nivolumab 3 mg/kg i.v.
~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
16486096|NCT03387748|Experimental|Gesture elicitation|Observation: hand gesture elicitation task
16486097|NCT03387735|Placebo Comparator|Treatment as usual (TAU) + Internet|Patients will be given access to helpful websites such as National Institute on Aging.
16486098|NCT03387735|Experimental|Treatment as usual (TAU) + ElderTree|Patients will be given access to the ElderTree website for 12 months which provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.
16486099|NCT03387709|Experimental|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
16486100|NCT03387709|Active Comparator|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
16486101|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
16486102|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
16486103|NCT03387670|Active Comparator|Simvastatin|
16486104|NCT03387670|Placebo Comparator|Placebo|
16486105|NCT03387657|Experimental|Sotagliflozin + Hydrochlorothiazide (HCTZ)|Sotagliflozin to be administered alone in Period 1. HCTZ to be given in Period 2 for 4 days followed immediately by HCTZ and sotagliflozin for 5 days.
16486106|NCT03387644|Active Comparator|Pregabalin (PG)|Patients received 150 mg pregabalin one hour before the procedure.
16486107|NCT03387644|Placebo Comparator|Control placebo (C)|Patients received placebo tablet one hour before surgery.
16486108|NCT03387618|Experimental|Investigational Scan|new-generation digital PET/CT imaging technology
16486109|NCT03387605|Active Comparator|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
16486111|NCT03387592|Active Comparator|FOLFIRI regimen|CPT-11 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks followed by 5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a 48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of 12 cycles
16486112|NCT03387592|Experimental|CAPTEM regimen|Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with Temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum of 6 cycles
16486113|NCT03387579|Active Comparator|Composite fish oil lipid (Smoflipid)|Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
16486114|NCT03387579|Active Comparator|Soy-based lipid reduction|Patients randomized to this arm will receive soy-based lipid (Intralipid) at a dose of 1 g/kg/day throughout their enrollment in the study.
16486115|NCT03387566|Experimental|HB002.1M 0.3mg|Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.
16486116|NCT03387566|Experimental|HB002.1M 0.5mg|Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.
16486117|NCT03387566|Experimental|HB002.1M 1.0mg|Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.
16486118|NCT03387566|Experimental|HB002.1M 2.0mg|Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.
16486119|NCT03387566|Experimental|HB002.1M 3.0mg|Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.
16486120|NCT03387553|Active Comparator|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
16486121|NCT03387553|Active Comparator|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
16486122|NCT03387553|Experimental|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
16486123|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
16486124|NCT03387527|Experimental|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
16486125|NCT03387514|Experimental|18F-DCFPyL whole body PET/CT scan|18F-DCFPyL whole body PET/CT scan at three time-points
16486126|NCT03387501|Experimental|PRGF|Plasma rich in growth factors (PRGF) administration
16486127|NCT03387488|Experimental|Treatment|StingrayTM, Medtronic®
16486128|NCT03387475|Experimental|Deferasirox|efficacy of 3.5mg/kg/day
16486130|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
16486131|NCT03387436|No Intervention|1.) Treatment as usual (TAU)|Patients assigned to this arm will receive palliative treatment as usual.
16486132|NCT03387436|Sham Comparator|2.) Sham-Intervention|Patients assigned to this arm will receive an sham intervention with unspecific supportive therapy (i.e. listening, empathy etc., but no specific intervention rationale) and palliative treatment as usual.
16486133|NCT03387436|Experimental|3.) Study-Intervention|Patients assigned to this arm will receive the study-intervention and palliative treatment as usual.
16486134|NCT03387410|Experimental|Intravenous IRDye 800BK|Patients undergoing laparoscopic bowel resection & laparoscopic donor nephrectomy
16486135|NCT03387397||Lower Medications (LM) cohort|Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period.
16486136|NCT03387397||Higher Medications (HM) cohort|Patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
16486137|NCT03387371|Active Comparator|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
16486138|NCT03387371|Experimental|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
16486139|NCT03387358||Historical Comparison Group|This group includes patients who were admitted to St. Paul's Hospital ICU (Vancouver BC, Canada) from September 2014 to September 2015, and had a small bore feeding tube in place at some point during their ICU admission, and were matched to key variables to the prospective observational treated group.
16486140|NCT03387358||Prospective Observational Treated Group|This group includes all patients who were admitted to St. Paul's Hospital ICU from Nov. 2017 to Dec. 2018, and nasal bridle securement device for small bore feeding tubes at some point during their ICU admission. The clinical indicators for a nasal bridle securement device outlined in our nursing practice standards include one or more of the following: recurrent nasoenteric tube dislodgement; confused and/or agitated patients; fluoroscopically or endoscopically placed nasoenteric tube; history of difficult tube placement; facial burn victims with nasoenteric tube; and/or oily skin causing decreased adhesion of traditional securement.
16486141|NCT03387345|Experimental|bread-50/50-steelcut-80/20-flake-rice|25 g of available carbohydrate was delivered to participants via (1) white bread, followed by (2) 50/50 rice-barley mix, followed by (3) 100% steel cut barley, followed by (4) 80/20 rice-barley mix, followed by (5) 100% barley flakes, followed by (6) 100% rice
16486181|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
16486727|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
16486142|NCT03387345|Experimental|50/50-steelcut-80/20-flake-rice-bread|25 g of available carbohydrate was delivered to participants via (1) 50/50 rice-barley mix, followed by (2) 100% steel cut barley, followed by (3) 80/20 rice-barley mix, followed by (4) 100% barley flakes, followed by (5) 100% rice, followed by (6) white bread
16486143|NCT03387345|Experimental|steelcut-80/20-flake-rice-bread-50/50|25 g of available carbohydrate was delivered to participants via (1) 100% steel cut barley, followed by (2) 80/20 rice-barley mix, followed by (3) 100% barley flakes, followed by (4) 100% rice, followed by (5) white bread, followed by (6) 50/50 rice-barley mix
16486144|NCT03387345|Experimental|80/20-flake-rice-bread-50/50-steelcut|25 g of available carbohydrate was delivered to participants via (1) 80/20 rice-barley mix, followed by (2) 100% barley flakes, followed by (3) 100% rice, followed by (4) white bread, followed by (5) 50/50 rice-barley mix, followed by (6) 100% steel cut barley
16486145|NCT03387345|Experimental|flake-rice-bread-50/50-steelcut-80/20|25 g of available carbohydrate was delivered to participants via (1) 100% barley flakes, followed by (2) 100% rice, followed by (3) white bread, followed by (4) 50/50 rice-barley mix, followed by (5) 100% steel cut barley, followed by (6) 80/20 rice-barley mix
16486146|NCT03387345|Experimental|rice-bread-50/50-steelcut-80/20-flake|25 g of available carbohydrate was delivered to participants via (1) 100% rice, followed by (2) white bread, followed by (3) 50/50 rice-barley mix, followed by (4) 100% steel cut barley, followed by (5) 80/20 rice-barley mix, followed by (6) 100% barley flakes
16486147|NCT03387332|Experimental|APG-1252|The starting dose for this study was 40 mg and 1 patient would be enrolled at this dose level. The dose escalation will convert to a standard 3+3 design following the occurrence of DLT or two ≥ Grade 2 adverse event or at doses 80 mg.
16486148|NCT03387319|Experimental|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
16486149|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
16486150|NCT03387306||Patient group|This grup included 38 patients with NTG.
16486151|NCT03387306||Control group|This group included 38 healthy controls.
16486152|NCT03387293|Experimental|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
16486153|NCT03387293|Experimental|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
16486154|NCT03387280||proximal RCA stenosis|The stenosis site is before the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
16486155|NCT03387280||distal RCA stenosis|The stenosis site is after the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
16486156|NCT03387280||left circumflex coronary artery stenosis|The stenosis site is located at the left circumflex coronary artery according to the coronary angiograms.
16486157|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
16486158|NCT03387254|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
16486159|NCT03387254|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
16486160|NCT03387241|Experimental|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs
~Unit Strength:
~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
16486161|NCT03387241|Active Comparator|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs
~Unit Strength:
~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
16486162|NCT03387228|Experimental|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
16486163|NCT03387228|Active Comparator|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
16486164|NCT03387215|Experimental|10 mg ITI-214|Single oral dose
16486165|NCT03387215|Experimental|30 mg ITI-214|Single oral dose
16486166|NCT03387215|Experimental|75 mg - 150 mg ITI-214|Single oral dose
16486167|NCT03387215|Placebo Comparator|Placebo|Single oral dose
16486168|NCT03387202||pelvic organ prolapse|"Participants received Laparoscopic lateral suspension with mesh as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success."
16486169|NCT03387189||Quality Improvement Project|Quality Improvement Project: Regions Hospital
16486170|NCT03387189||No Quality Improvement Project|No Quality Improvement Project: The comparison group is Methodist Hospital, where the Quality Improvement project is not occurring.
16486171|NCT03387176||zonulin ≤17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
16486172|NCT03387176||zonulin >17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
16486173|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
16486174|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
16486175|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
16486176|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
16486177|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
16486178|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
16486182|NCT03387137|Experimental|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
16486183|NCT03387137|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
16486184|NCT03387137|Experimental|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
16486185|NCT03387137|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
16486186|NCT03387111|Experimental|NANT Squamous Cell Carcinoma (SCC) Vaccine|Combination of agents will be administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
16486187|NCT03387098|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ehtyl esters, oxaliplatin, SBRT.
16486188|NCT03387085|Experimental|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, SBRT.
16486189|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
16486190|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
16486191|NCT03387059|Experimental|Forielle Endometrial Washing|
16486192|NCT03387059|No Intervention|No Endometrial Washing|
16486193|NCT03387046|Experimental|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
16486194|NCT03387046|Placebo Comparator|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
16486195|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
16486196|NCT03387020|Experimental|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
16486197|NCT03387007|Experimental|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
16486198|NCT03387007|No Intervention|Control|The teachers from the schools in this arm did not receive training on psycho-social support
16486199|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
16486200|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
16486201|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
16486202|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
16486203|NCT03386955|Experimental|BPI-7711 treatment|"Phase I: Patients in dose escalation group will receive single dose of BPI-7711 on day -7 and start receive the 21 days/cycle continuous treatment once a day after 7 day washout period. Patients in the extension group will receive BPI-7711 once a day with the selected doses.
~Phase IIa: Patients will receive BPI-7711 capsule(recommend phase 2 dose) as the first line treatment."
16486204|NCT03386942|Experimental|MORAb-202|"Part 1 (Dose-escalation): The initial dose level of MORAb-202 will be 0.3 milligrams per kilogram (mg/kg) every 3 weeks in the first cohort with 1 participant for dose-limiting toxicity (DLT) evaluation. DLTs will be evaluated in successive dose level cohorts with a single participant until a drug-related Grade 2 or higher toxicity is observed. If such a toxicity is observed, the cohort will be expanded to enroll a total of 3 participants.
~Part 2 (Treatment Phase): MORAb-202 will be administered every 3 weeks during the treatment phase at the dose determined in Part 1 until participants meet any of the criteria for discontinuation. Criteria for discontinuation include: withdrawal of consent, major protocol violations, unable to continue due to adverse events, pregnancy, progressive disease, Investigator decision, or infusion reactions."
16486205|NCT03386929|Experimental|Avelumab, Axitinib, Palbociclib|"For the Phase 1:
~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).
~For the Phase 2:
~Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study."
16486206|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
16486207|NCT03386903|Experimental|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
16486731|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
16486208|NCT03386903|Placebo Comparator|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
16486209|NCT03386903|No Intervention|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
16486210|NCT03386877|Experimental|Dental pulp stem cells|Test sites (n=15) Periodontal regeneration using micro-grafts of Dental pulp stem cells seeded onto collagen sponge
16486211|NCT03386877|Active Comparator|coagulum|control sites (n=14) Periodontal regeneration using coagulum and collagen sponge alone
16486212|NCT03386864||Control|
16486213|NCT03386864||Insulin Resistant|
16486214|NCT03386864||Type 2 Diabetes|
16486215|NCT03386838|Experimental|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
16486216|NCT03386838|Active Comparator|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
16486217|NCT03386825||Regorafenib_DoT<4 months|DoT < 4 months
16486218|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT < 12 months
16486219|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
16486220|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
16486221|NCT03386786|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of a mobile application (app) and a web-based portal.
16486222|NCT03386786|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
16486223|NCT03386773|Experimental|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
16486224|NCT03386773|Active Comparator|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
16486225|NCT03386760|Experimental|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
16486226|NCT03386760|Active Comparator|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
16486227|NCT03386747|Experimental|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
16486228|NCT03386747|Experimental|Center based parenting group|Intervention: Center based parenting groups
16486229|NCT03386747|No Intervention|control group|The rest of pregnant women and their children who will not receive the intervention
16486230|NCT03386734|Experimental|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
16486231|NCT03386734|Active Comparator|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
16486232|NCT03386721|Experimental|Cohort A (Part I)|Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
16486233|NCT03386721|Experimental|Cohort B (Part I)|CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
16486234|NCT03386721|Experimental|Cohort C (Part I)|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
16486235|NCT03386721|Experimental|Cohort D Arm I (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.
~Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
16486236|NCT03386721|Experimental|Cohort D Arm 2 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.
~Participants will receive simlukafusp alfa intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
16486253|NCT03386695|Other|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
16486237|NCT03386721|Experimental|Cohort D Arm 3 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
16486238|NCT03386721|Experimental|Cohort E Arm I (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
16486239|NCT03386721|Experimental|Cohort E Arm 2 (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa IV infusion in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
16486240|NCT03386721|Experimental|Cohort F (Part I)|"CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of simlukafusp alfa and atezolizumab in a Q3W schedule. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional."
16486241|NCT03386721|Experimental|Cohort G (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
16486242|NCT03386721|Experimental|Cohort H (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort H Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
16486243|NCT03386721|Experimental|Cohort I (Part III)|Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
16486244|NCT03386721|Experimental|Cohort J (Part III)|Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
16486245|NCT03386721|Experimental|Cohort K (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
16486246|NCT03386721|Experimental|Cohort L (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort L Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
16486247|NCT03386721|Experimental|Cohort M (Part III)|Esophageal SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
16486248|NCT03386721|Experimental|Cohort N (Part III)|Cervical SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
16486249|NCT03386708|Experimental|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
16486250|NCT03386708|Placebo Comparator|NS intrauterine injection group|Normal saline (NS) (2ml)
16486251|NCT03386708|Experimental|hUC-MSC intravenous injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
16486252|NCT03386708|Placebo Comparator|NS intravenous injection group|Normal saline (NS) (30ml)
16486283|NCT03386500|Other|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
16486254|NCT03386695|Other|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
16486255|NCT03386682|Experimental|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
16486256|NCT03386669|Experimental|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
16486257|NCT03386656|Experimental|Amchafibrin|Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
16486258|NCT03386656|Placebo Comparator|Saline Solution 0,9%.|Comparator of tranexamic acid
16486259|NCT03386643|Experimental|Bifidobacterium animalis subsp. lactis|"Intervention:
~Bifidobacterium animalis subsp. lactis HN019"
16486260|NCT03386643|Active Comparator|Clobetasol propionate 0.05%|"Intervention:
~Clobetasol propionate 0.05%"
16486261|NCT03386630|Experimental|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
16486262|NCT03386630|Experimental|Hyperbaric bupivacaine+morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
16486263|NCT03386617|Experimental|NEPA|"Day 1 of each chemotherapy cycle:
~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
16486264|NCT03386604|Experimental|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
16486265|NCT03386604|Placebo Comparator|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
16486266|NCT03386591|Experimental|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
16486267|NCT03386591|Experimental|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
16486268|NCT03386591|Experimental|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
16486269|NCT03386591|Experimental|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
16486270|NCT03386591|Experimental|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
16486271|NCT03386578|Experimental|Pharmacokinetics Component: Group 1|Participants will be enrolled during singleton pregnancy at 14-24 weeks' gestation. Participants will receive a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) once daily under direct observation from Day 0 through Week 12.
16486272|NCT03386578|Experimental|Pharmacokinetics Component: Group 2|Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
16486273|NCT03386578|Experimental|PrEP Comparison Component: Cohort 1|Participants will receive daily oral PrEP (FTC/TDF) from Day 0 through Week 26. Participants will also receive behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
16486274|NCT03386578|Active Comparator|PrEP Comparison Component: Cohort 2|Participants will receive a behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
16486275|NCT03386565|Active Comparator|control group|"Sodium chloride solution 10 mL IV just before induction of anesthesia
~IV infusion during the surgery"
16486276|NCT03386565|Active Comparator|lidocaine group|"lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia
~IV infusion during the surgery"
16486277|NCT03386552|Experimental|Isifera+|Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml
16486278|NCT03386552|Placebo Comparator|Buffer|Subjects are pertubated with a buffer solution without lidocaine
16486279|NCT03386539|Experimental|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.
~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
16486280|NCT03386539|Active Comparator|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)
~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
16486281|NCT03386526|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
16486282|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 was administered by IV on 2 different schedules for patients with relapsed/refractory AML or BPDCN.
~Expansion: the study is currently enrolling in 2 BPDCN expansion cohorts at the RP2D:
~Cohort 1: Relapsed or refractory BPDCN patients who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)
~Cohort 6: Pivotal cohort for frontline BPDCN patients who have not received prior systemic therapy. Patients may have received local therapy (radiotherapy, surgical excision, photodynamic therapy). Eligible patients must have a recurrence or progression in the field of local therapy OR disease outside the field of local therapy.
~Other expansion cohorts (not currently enrolling):
~• Cohort 2: Relapsed AML; Cohort 3: Relapsed or refractory ALL; Cohort 4: Other relapsed or refractory hematologic malignancies; Cohort 5: Relapsed or refractory AML at alternate dose or schedule"
16486284|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
16486285|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
16486286|NCT03386474|Experimental|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
16486287|NCT03386474|Other|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16 to maintain the masking of the extension trial only.
16486288|NCT03386461|Experimental|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
16486289|NCT03386461|Placebo Comparator|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
16486290|NCT03386448|Placebo Comparator|control|Participants will receive placebo medication
16486291|NCT03386448|Experimental|Active|participants will receive active medications scopolamine and naltrexone
16486292|NCT03386435|Experimental|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
16486293|NCT03386435|No Intervention|Control|In the control group, the same maneuver was applied but without cuff inflation.
16486294|NCT03386422|Experimental|Mindfulness Self-Compassion Intervention MSC|"Mindfulness Self-Compassion (MSC) is a standardized program to increase self-compassion. It has been developed by Neff and Germer. The structure of the program is similar to de Mindfulness-Based Stress Reduction program (MBSR), with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with practical and experiential exercices in sessions and between sessions.
~The MSC program focuses primary on helping patients to develop self-compassion, and it includes Mindfulness just as a secondary component.
~The MSC program will be conducted by a clinician trained in this specific program."
16486295|NCT03386422|Active Comparator|Cognitive-Behavioural Intervention CBT|"It has been adapted a Cognitive-Behavioural Intervention for Chronic Pain by Moix and Kovacs. Our program will have 8 sessions, with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with homework between sessions.
~During these 8 sessions we will train the following techniques: psychoeducation about pain, relaxation training, cognitive restructuring training, solving problem training, psychoeducation about emotions, interpersonal skills and time organization."
16486296|NCT03386409|No Intervention|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
16486297|NCT03386409|Experimental|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
16486298|NCT03386409|Experimental|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
16486299|NCT03386396|Experimental|High protein/low carbohydrate|A breakfast shake will be made with high protein/low carbohydrate mixture.
16486300|NCT03386396|Experimental|High carbohydrate/low protein|A breakfast shake will be made with high carbohydrate/low protein mixture.
16486301|NCT03386383|Experimental|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
16486302|NCT03386383|No Intervention|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
16486303|NCT03386370|Other|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo
16486304|NCT03386357|Experimental|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases.
16486305|NCT03386357|Active Comparator|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w) without radiotherapy
16486306|NCT03386344|Placebo Comparator|Placebo|Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
16486307|NCT03386344|Experimental|Sotagliflozin 200 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
16486308|NCT03386344|Experimental|Sotagliflozin 400 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
16486309|NCT03386331|Other|Diet and Exercise|
16486310|NCT03386318||day surgery patients|20 patients female 30-60 years of age
16486311|NCT03386305|Experimental|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
16486369|NCT03385889|No Intervention|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
16486312|NCT03386305|Active Comparator|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
16486313|NCT03386279|Other|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
16486314|NCT03386279|Other|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
16486315|NCT03386279|Other|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
16486316|NCT03386279|Other|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
16486317|NCT03386279|Other|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
16486318|NCT03386279|Other|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
16486319|NCT03386253|Experimental|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
16486320|NCT03386253|Sham Comparator|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
16486321|NCT03386240|Experimental|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
16486322|NCT03386240|Placebo Comparator|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
16486323|NCT03386227|No Intervention|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
16486324|NCT03386227|Experimental|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
16486328|NCT03386201|Experimental|Intravenous methylene blue|
16486329|NCT03386188|Experimental|Healthy arm|posterior parietal cortex (PPC) transitory inactivation
16486330|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
16486331|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
16486332|NCT03386149|Experimental|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
16486333|NCT03386149|Active Comparator|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
16486334|NCT03386136|Experimental|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction [clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm] provided with 100% oxygen via non-rebreather face mask, for 6 hours
16486335|NCT03386123|Experimental|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.
~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
16486366|NCT03385902|Active Comparator|late start group|the DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE less than 30, which defined as late start time.
16486367|NCT03385889|Experimental|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
16486368|NCT03385889|Experimental|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
16486336|NCT03386123|Active Comparator|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.
~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
16486337|NCT03386123|Placebo Comparator|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.
~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
16486338|NCT03386110|Experimental|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
16486339|NCT03386110|Active Comparator|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
16486340|NCT03386097||Type 2 diabetes patients|
16486341|NCT03386097||Healthy controls|
16486342|NCT03386084|Experimental|direct application of microwave diathermy and motor control|
16486343|NCT03386084|Placebo Comparator|application of microwave diathermy without therapeutic effects|
16486344|NCT03386058|Experimental|Intervention|Temporary device deactivation
16486345|NCT03386045|Active Comparator|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
16486346|NCT03386045|Active Comparator|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
16486347|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
16486348|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
16486349|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.
~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
16486350|NCT03386019|Experimental|Sprinters|Sprinters will be recruited from the track and field team of National Taiwan Normal University (NTNU) in this study. After individuals' enrollments and baseline data collections, all subjects will receive all three different treatments (massage, cold water immersion and static stretching) in randomized orders a week apart, respectively. Outcome measures are: visual analogue scale (VAS) score, lower leg volume, pressure pain threshold and horizontal jump distance. All measurements will be recorded at baseline, immediately after exercise, immediately after treatment, and 10 minutes after treatment as the follow up.
16486351|NCT03386006|Experimental|Noom Coach for Bariatric Health|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app.
16486352|NCT03386006|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period."
16486353|NCT03385993|Experimental|Mediation and Relaxation Intervention|Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.
16486354|NCT03385980||Post-mortem patients|Post-mortem oncological patients (within 2-6 hrs from death, maximum time for tissue preservation).
16486355|NCT03385967|Active Comparator|ropivacaine only|0.5% ropivacaine
16486356|NCT03385967|Active Comparator|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
16486357|NCT03385954|Experimental|Intervention|distance education curse with 8 hours to be accomplished in 2 weeks,
16486358|NCT03385954|Experimental|Control|Wiil receive a lecture of 30 minutes
16486359|NCT03385941||Osteoporotic|Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
16486360|NCT03385941||Non-osteoporotic|Female, 27-40 years of age, no established history of osteoporosis
16486361|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
16486362|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
16486363|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
16486364|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
16486365|NCT03385902|Experimental|optimal start group|The DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE reaching to 30-35, which defined as the optimal start time.
16486370|NCT03385876|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
16486371|NCT03385863||early preterm infants with RDS|gestational age<34 weeks
16486372|NCT03385863||near term infants with RDS|34 weeks≤gestational age< 37 weeks
16486373|NCT03385863||term infants with RDS|Gestational age ≥ 37 weeks
16486374|NCT03385850|Experimental|early enteral nutrition|
16486375|NCT03385850|Active Comparator|delayed enteral nutrition|
16486376|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
16486377|NCT03385824|Experimental|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
16486378|NCT03385824|No Intervention|Control|SAIL workbook provided at the conclusion of the study.
16486379|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
16486380|NCT03385798|Active Comparator|Endo-GIA|
16486381|NCT03385798|Experimental|Endo-wrist|
16486382|NCT03385759|Active Comparator|UKA|Medial unicompartmental knee arthroplasty
16486383|NCT03385759|Active Comparator|TKA|Total knee arthroplasty
16486384|NCT03385746|Experimental|polyamide|metal reinforced polyamide denture base material
16486385|NCT03385746|Active Comparator|heat cured acrylic resin|conventional heat cured acrylic resin denture base
16486386|NCT03385733|Experimental|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
16486387|NCT03385733|No Intervention|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
16486388|NCT03385720|Experimental|Experimental group|
16486389|NCT03385720|Active Comparator|Control group|
16486390|NCT03385707|Experimental|CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
16486391|NCT03385694||Assessment|All the patients operated on Van Nes Rotationplasty for bone tumors at IOR and long term surviving
16486392|NCT03385681|Experimental|Intervention Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
16486393|NCT03385681|No Intervention|Control Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate in the study.
16486394|NCT03385668|Experimental|Pirfenidone|All patients will receive Pirfenidone
16486395|NCT03385655|Experimental|WEE-1 inhibitor|
16486396|NCT03385655|Experimental|cMET inhibitor|
16486397|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
16486398|NCT03385655|Experimental|CFI400945 PLK4 inhibitor|
16486399|NCT03385655|Experimental|Ipatasertib AKT inhibitor|
16486400|NCT03385655|Experimental|Durvalumab and Tremelimumab immunotherapy|
16486401|NCT03385655|Experimental|Carboplatin platinum based chemotherapy|
16486402|NCT03385642||Chondromimetic|Treatment of osteochondral defect in the knee with Chondromimetic device(s) in previous study 0MCM0107
16486403|NCT03385629|Experimental|CSM theory-based Arm|CSM theory-based didactic education and skills training Practice EMR changes
16486404|NCT03385629|Active Comparator|AAP-based Arm|AAP-based didactic education
16486405|NCT03385616|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS)
16486406|NCT03385603|Experimental|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
16486407|NCT03385603|Active Comparator|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
16486408|NCT03385590|Experimental|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
16486409|NCT03385590|Active Comparator|Maize|Complementary food composed of maize flour.
16486410|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
16486411|NCT03385564|Experimental|BI 655064|
16486412|NCT03385564|Placebo Comparator|Placebo|
16486413|NCT03385551||ARM 1|Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments
16486414|NCT03385551||ARM 2|Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments
16486415|NCT03385538|Experimental|Clopidogrel non-responders|Increasing doses og Clopidogrel depending on PRU values measured on VerifyNow
16486416|NCT03385525|Experimental|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
16486417|NCT03385512|Experimental|OPEN High Touch|Participants in this arm will experience the OPEN High Touch intervention.
16486418|NCT03385512|Experimental|OPEN High Tech|Participants in this arm will experience the OPEN High Tech intervention.
16486424|NCT03385473|Active Comparator|Pharmacological Adequation (PA)|Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug monitoring results.
16486425|NCT03385473|No Intervention|Standard of Care (SOC)|Without pharmacological adequation
16486426|NCT03385460|Experimental|ESWL BOTOX|Each patient will be subjected to Low Energy Shock Waves.The target dose of low energy shock waves will be 3000 shock delivered into SP region in 3 horizontal points at SP transverse crease . all patients will be catheterized using nylaton catheter 16 ch, the study group will be injected with 100 IU botulinium toxin A. vial will be dissolved in saline half of the estimated bladder capacity. All patients will be kept for 2 hours without micturation giving a chance of BOTOX absorption .
16486427|NCT03385447|Experimental|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
16486428|NCT03385434|Experimental|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
16486429|NCT03385434|No Intervention|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
16486430|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
16486431|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
16486432|NCT03385395|Experimental|OctaAlpha1|
16486433|NCT03385395|Active Comparator|Glassia®|
16486434|NCT03385382||Dexamethasone group|Patients with diabetic macular edema receiving dexamethasone
16486435|NCT03385382||ranibizumab|Patients with diabetic macular edema receiving ranibizumab
16486436|NCT03385369|Placebo Comparator|Placebo Japanese Descent|Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
16486437|NCT03385369|Experimental|MEDI0382 50 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.
16486438|NCT03385369|Experimental|MEDI0382 100 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
16486439|NCT03385369|Experimental|MEDI0382 150 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.
16486440|NCT03385369|Experimental|Placebo Chinese Descent|Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
16486441|NCT03385369|Experimental|MEDI0382 100 mcg Chinese Descent|Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
16486442|NCT03385356|Active Comparator|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
16486443|NCT03385356|Active Comparator|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
16486444|NCT03385343|Experimental|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
16486445|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
16486446|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
16486447|NCT03385317|Experimental|Mindfulness|
16486448|NCT03385304|Experimental|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
16486449|NCT03385304|Experimental|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
16486450|NCT03385291|Experimental|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
16486451|NCT03385291|Experimental|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
16486452|NCT03385278|Experimental|real-sham|the group first received real rTMS,then sham one.
16486453|NCT03385278|Experimental|sham-real|the group first received sham rTMS,then real one.
16486454|NCT03385265|Experimental|DIPPer Academy|Families randomized to this group will participate in the DIPPer Academy curriculum.
16486455|NCT03385265|Active Comparator|Standard of Care Control|
16486456|NCT03385252|Experimental|Egg Group|Egg Intervention: Provision of eggs to caregivers of enrolled infants, with instructions to prepare and feed one egg to the infant each day for 6 months time. Households will be visited twice weekly to provide eggs and monitor intake.
16486457|NCT03385252|Active Comparator|Control Group|Control Group: Caregivers will receive a food basket at the end of the study. Throughout the trial, households will be visited twice weekly and asked about food intake.
16486458|NCT03385239|Placebo Comparator|Pooled Placebo|Participants in each cohort (A,B,C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
16486728|NCT03383549|Experimental|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
16486459|NCT03385239|Experimental|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
16486460|NCT03385239|Experimental|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
16486461|NCT03385239|Experimental|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
16486462|NCT03385239|Placebo Comparator|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
16486463|NCT03385226|Experimental|Pembrolizumab with radiotherapy|"All patients will receive
~single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity
~radiotherapy, 12Gy in 3 fractions"
16486464|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
16486465|NCT03385213||Remission|Patients who get remission after curative surgery
16486466|NCT03385200|Active Comparator|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
16486467|NCT03385200|No Intervention|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
16486468|NCT03385187|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
16486469|NCT03385174|Other|Carbon monoxide|Each participant receives CO inhalation
16486470|NCT03385161|Active Comparator|botulinum toxin A|"Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.
~One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.
~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate."
16486471|NCT03385161|Active Comparator|Ethanol|"Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.
~An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.
~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate."
16486472|NCT03385148|Experimental|colorectal patients|the colorectal patients undergo 68Ga-Sgc8 PET/CT
16486473|NCT03385135|Active Comparator|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
16486474|NCT03385135|No Intervention|No Allopurinol group|Optimal medical therapy alone
16486475|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
16486476|NCT03385096|Experimental|BUCY+VP-16|For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
16486477|NCT03385096|Active Comparator|Melphalan|For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
16486478|NCT03385083|Experimental|ACTIVITY TRACKER|Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
16486479|NCT03385083|Placebo Comparator|Control|Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.
16486480|NCT03385070||Salt-sensitive group|"Patients (n:163)with HT who presented at the emergency service at least once with a minimum increase in their systolic and diastolic blood pressure of 10% after consuming salty foods were included in the SSH group.
~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
16486481|NCT03385070||Salt resistance group|"Patients(n:142) who did not exhibit this increase were included in the SRH group
~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
16486482|NCT03385070||Control group|"Sex- and age-matched patients(n:124) without a HT diagnosis were included in the control group.
~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
16486483|NCT03385057|Active Comparator|Ibuprofen Arm|
16486484|NCT03385057|Active Comparator|Acetaminophen|
16486485|NCT03385044|Active Comparator|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
16486486|NCT03385044|Active Comparator|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
16486487|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
16486488|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
16486489|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
16486490|NCT03385018|Experimental|Laparoscopic group|Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
16486491|NCT03385018|Active Comparator|Open group|Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
16486494|NCT03384992|Experimental|Group 1|Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
16486495|NCT03384992|Experimental|Group 2|Participants were exposed to the one of the following usual care conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3.
16486496|NCT03384992|Experimental|Group 3|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
16486497|NCT03384992|Experimental|Group 4|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
16486498|NCT03384992|Experimental|Group 5|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
16486499|NCT03384992|Experimental|Group 6|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
16486500|NCT03384992|Experimental|Group 7|Participants were exposed to the following conditions: cognitive restructuring for week 1, worry practice for week 2, and General Health and Diet (General and BCSS) for week 3. Telephone coaching was given.
16486501|NCT03384992|Experimental|Group 8|Participants were exposed to the following conditions: cognitive restructuring for week 1, scheduled worry practice for week 2, and General Health and Diet (General and BCSS) for week 3.
16486502|NCT03384992|Experimental|Group 9|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
16486503|NCT03384992|Experimental|Group 10|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3.
16486504|NCT03384992|Experimental|Group 11|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
16486505|NCT03384992|Experimental|Group 12|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3.
16486506|NCT03384992|Experimental|Group 13|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
16486507|NCT03384992|Experimental|Group 14|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and General health and Diet (General and BCSS) for week 3.
16486508|NCT03384992|Experimental|Group 15|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and cognitive restructuring for week 3. Telephone coaching was given.
16486509|NCT03384992|Experimental|Group 16|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and cognitive restructuring for week 3.
16486510|NCT03384979|Placebo Comparator|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
16486511|NCT03384979|Experimental|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
16486512|NCT03384966|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
16486513|NCT03384966|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
16486514|NCT03384966|Placebo Comparator|Placebo|Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
16486515|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
16486516|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
16486520|NCT03384914|Active Comparator|Dendritic Cell (DC1) Vaccine|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.
~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
16486521|NCT03384914|Active Comparator|pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.
~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
16486522|NCT03384888|Experimental|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
16486523|NCT03384888|Experimental|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
16486524|NCT03384888|Sham Comparator|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
16486525|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
16486526|NCT03384875|Placebo Comparator|Control|Standard of care
16486527|NCT03384862|Experimental|Nutritional Intervention Arm|5 μg vitamin B12 plus 400 μg folic acid
16486528|NCT03384862|Placebo Comparator|Control Arm|Placebo
16486529|NCT03384849||MRI patients|Up to 200 patients of different age, weight and sex, which undergo MRI examinations.
16486531|NCT03384823|Experimental|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
16486532|NCT03384823|Experimental|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
16486533|NCT03384823|Placebo Comparator|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
16486534|NCT03384823|Placebo Comparator|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
16486535|NCT03384797||Healthy Volunteers|
16486536|NCT03384797||Parkinson's Disease|
16486537|NCT03384784|Experimental|Galantamine|"This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day).
~The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures."
16486538|NCT03384784|Placebo Comparator|Placebo|"12-week placebo-controlled medication period
~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical.
~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period."
16486539|NCT03384771||MBSR Students|community-dwelling adults who register for relevant MBSR courses at UMass CFM, UCSF, or participating community sites
16486540|NCT03384771||MBSR Teachers|those teaching MBSR courses at UMass CFM, UCSF, or participating community sites
16486541|NCT03384771||Raters|experience mindfulness teachers, recruited by invitation, who will participate in MBI-TAC training
16486542|NCT03384758|Active Comparator|mild to moderate PAD|
16486543|NCT03384758|Active Comparator|Diabetes mellitus|
16486544|NCT03384758|Placebo Comparator|Healthy volunteers|
16486545|NCT03384745|Experimental|M1095 (Sonelokimab) 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
16486546|NCT03384745|Experimental|M1095 (Sonelokimab) 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
16486547|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
16486548|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
16486549|NCT03384745|Placebo Comparator|Placebo / M1095 (Sonelokimab) 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
16486550|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
16486551|NCT03384719|Experimental|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
16486552|NCT03384719|Experimental|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
16486553|NCT03384719|Active Comparator|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
16486554|NCT03384706|Active Comparator|Cognitive Processing Therapy (CPT)|PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
16486555|NCT03384706|Experimental|Accelerated Resolution Therapy (ART)|PTSD Psychotherapy
16486556|NCT03384706|No Intervention|Wait List Control|Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
16486557|NCT03384693|Experimental|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
16486558|NCT03384667|Experimental|MMDT group|
16486559|NCT03384667|Placebo Comparator|Placebo group|
16486732|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
16486563|NCT03384628|Active Comparator|First Pair Senofilcon A contact lens|The first pair of Senofilcon A contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the first pair Senofilcon A contact lens and subsequent removal.
16486564|NCT03384628|Active Comparator|Second pair Senofilcon A contact lens|The second pair of contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the second pair Senofilcon A contact lens and subsequent removal.
16486565|NCT03384628|Active Comparator|Third pair Senofilcon A contact lens|The third pair of Senofilcon A contact lens is applied (according to the fitting schedule), allowed to settle before assessment of the third pair Senofilcon A contact lens and subsequent removal.
16486566|NCT03384615|Experimental|Compassion-focused therapy|
16486567|NCT03384615|No Intervention|Waitlist control group|
16486568|NCT03384602|Active Comparator|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
16486569|NCT03384602|Active Comparator|home exercise strength program|simple strength training program to perform individually at home
16486570|NCT03384602|No Intervention|Control group|no change in the daily activities, no exercise intervention
16486571|NCT03384589|Active Comparator|Group 1: 3 doses of PCV13|PCV13, 0.5ml intramuscular at 2, 4 and 12 months of age
16486572|NCT03384589|Experimental|Group 2: 2 doses of PCV13|PCV13, 0.5ml intramuscular at 2 and 12 months of age
16486573|NCT03384576|Experimental|Music intervention|Participants listen to music in the waiting room
16486574|NCT03384576|Active Comparator|No music|Participants will not have music in the waiting room
16486575|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-6 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
16486576|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-6 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
16486577|NCT03384563|Placebo Comparator|Placebo 1-6 months|
16486578|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 6-12 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
16486579|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 6-12 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
16486580|NCT03384563|Placebo Comparator|Placebo 6-12 months|
16486581|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-3 years|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
16486582|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-3 years|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
16486583|NCT03384563|Placebo Comparator|Placebo 1-3 years|
16486584|NCT03384550|Active Comparator|Control|"Participants in this arm receive no incentives.
~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.
~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
16486585|NCT03384550|Experimental|Financial Incentives|"Participants in this arm receive financial incentives.
~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.
~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
16486586|NCT03384550|Experimental|Charity Incentives|"Participants in this receive charity incentives.
~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.
~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
16486587|NCT03384537|Experimental|Listerine total care zero|Listerine total care zero
16486588|NCT03384537|Active Comparator|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
16486589|NCT03384524|Active Comparator|Combination regiment|A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)
16486590|NCT03384524|Placebo Comparator|Placebo|Three placebo pills, matching the external appearance of active drugs
16486591|NCT03384511|Experimental|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
16486592|NCT03384485|Other|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
16486593|NCT03384459|Experimental|Experimental group|"For a total period of 12 months, perform the 308-nm excimer laser treatment once a month.
~At this time, the dose of the 308-nm excimer laser is based on the 50% of the maximum dose that the patient received for the treatment.
~Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
16486733|NCT03383536||Phase 2: HC|healthy controls
16486734|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
16486594|NCT03384459|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
16486595|NCT03384446|Active Comparator|Tooth-borne treatment|A cleaning aid that resembles tooth cleaning instruments and is empirically used for implant surface cleaning.
16486596|NCT03384446|Experimental|Implant-specific treatment|A cleaning aid that has been specifically designed for implant surface cleaning.
16486597|NCT03384433|Experimental|exosome or vesicle|CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
16486598|NCT03384420|Experimental|Intervention CD34+ cells enriched with MNV-BLD|Intervention CD34+ cells enriched with MNV-BLD
16486599|NCT03384407|Experimental|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
16486600|NCT03384394|Placebo Comparator|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
16486601|NCT03384394|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
16486602|NCT03384368|Placebo Comparator|Screw-Distraction (SD) group|six pedicle screws were implanted firstly, then distraction was achieved.
16486603|NCT03384368|Experimental|Distraction-Screw (DS) group|four pedicle screws were implanted firstly, then distraction was achieved, two additional screws were introduced at the fracture level at last.
16486604|NCT03384355||Class 0|no visible or palpable varicose veins
16486605|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
16486606|NCT03384355||Class 2|varicose veins
16486607|NCT03384355||Class 3|edema
16486608|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
16486609|NCT03384355||Class 5|healed venous ulcer
16486610|NCT03384355||Class 6|active venous ulcer
16486611|NCT03384342|Experimental|Experimental group|"For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.
~At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
16486612|NCT03384342|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
16486613|NCT03384329|Experimental|Resveratrol Pill|
16486614|NCT03384329|Placebo Comparator|Placebo|
16486615|NCT03384316|Experimental|1/Arm 1-Dose De-Escalation|Dose De-Escalation
16486616|NCT03384316|Experimental|2/Arm 2 - Dose Expansion|Dose Expansion
16486617|NCT03384303|Other|LBPL-RYGB|
16486618|NCT03384303|Other|S-RYGB|
16486619|NCT03384290|Placebo Comparator|Placebo|
16486620|NCT03384290|Experimental|PRS-060|
16486621|NCT03384277|Experimental|Steroid+Rituximab|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
16486622|NCT03384277|Active Comparator|Steroid +Cyclophosphamide|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
16486623|NCT03384264|Experimental|TG|
16486624|NCT03384264|No Intervention|CG|the CG maintained their normal physical activity habits over the study
16486625|NCT03384251|Experimental|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
16486626|NCT03384251|No Intervention|Control group|This group will not be given any form of education.
16486627|NCT03384238|Experimental|Cohort 1a|A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
16486628|NCT03384238|Experimental|Cohort 1b|Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
16486629|NCT03384238|Experimental|Cohort 1c|Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
16486630|NCT03384238|Experimental|Cohort 1d|Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
16486631|NCT03384238|Experimental|Cohort 2- Dose Expansion|Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1
16486632|NCT03384225|Experimental|CBA group|"CBA as HSCT conditioning:
~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
16486633|NCT03384225|Active Comparator|FBA group|"FBA as HSCT conditioning:
~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
16486634|NCT03384212|Experimental|CBA group|"CBA as HSCT conditioning:
~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
16486635|NCT03384212|Active Comparator|FBA group|"FBA as HSCT conditioning:
~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
16486636|NCT03384199|Experimental|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
16486637|NCT03384186|Experimental|Danicopan Modified Release Prototype Tablets|"Participants received danicopan once each period as a single oral dose as follows:
~Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions.
~There was a washout period of at least 14 days between each danicopan dosing."
16486638|NCT03384173|Experimental|NIRS monitoring|These infants will be monitored with NIRS
16486639|NCT03384160|Active Comparator|Group 1-Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction
16486640|NCT03384160|Active Comparator|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction
16486641|NCT03384147|Experimental|Drinking|"Occasional drinkers assigned to start with a 3week drinking period (women 1 u/day - men 2 u/day)
~Followed by crossover without washout to 3 week abstaining period"
16486642|NCT03384147|Experimental|Abstaining|"Habitual drinkers assigned to start 2 weeks of abstaining from alcohol
~Followed by crossover without washout to 3 weeks drinking (women 1 u/day - men 2 u/day)"
16486643|NCT03384134|Experimental|Pain Buddy|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
16486644|NCT03384134|No Intervention|Control|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
16486645|NCT03384121|Experimental|Rifampin|All subjects
16486646|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
16486647|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
16486648|NCT03384095|Experimental|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
16486649|NCT03384095|Placebo Comparator|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
16486650|NCT03384082|Experimental|Hysteroscopic treatment|Hysteroscopic surgery
16486651|NCT03384082|No Intervention|Control group|No treatment
16486652|NCT03384069|Experimental|Group-based Cognitive Behavioral Therapy (CBT)|The Group-based CBT will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
16486653|NCT03384069|Experimental|Phone-based Cognitive Behavioral Therapy (CBT)|This intervention will follow the same protocol as the group-based CBT, but without the opportunity for group-interaction. It will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
16486654|NCT03384069|No Intervention|Standard of care|Participants will continue to receive care and follow up from their primary care providers, that incorporates general education regarding lifestyle activities and AD prevention.
16486655|NCT03384056||Self Pressurized Airway Device with Blocker|
16486656|NCT03384056||Proseal Laryngeal Mask Airway|
16486657|NCT03384043|Experimental|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time--based tasks (...take my medicine at 7pm) and event--based tasks (pick-up milk at the grocery store)."
16486658|NCT03384043|Active Comparator|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When…then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
16486659|NCT03384030|Experimental|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
16486660|NCT03384017|Experimental|TSCS and gait training|
16486661|NCT03384004|Experimental|Irrigation Technique 1|Patients randomized into this group will be treated using EndoVac Pure followed by Ultrasonic Irrigation.
16486662|NCT03384004|Experimental|Irrigation Technique 2|Patients randomized into this group will be treated using EndoVac Pure only.
16486663|NCT03383991|Experimental|Reverse Total Shoulder Arthroplasty|
16486664|NCT03383991|Active Comparator|Hemiarthroplasty|
16486665|NCT03383978|Experimental|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
16486666|NCT03383965|Experimental|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
16486729|NCT03383549|No Intervention|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
16486730|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
16486667|NCT03383952|Experimental|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
16486668|NCT03383939|Experimental|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.
~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
16486669|NCT03383939|Placebo Comparator|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.
~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
16486670|NCT03383939|No Intervention|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
16486671|NCT03383926|Experimental|Group 1|Suture confection of theTobacco-pouch of 4.5cm from the anal margin.
16486672|NCT03383926|Experimental|Group 2|Suture confection of theTobacco-pouch of 6cm from the anal margin.
16486673|NCT03383913|Experimental|Intervention|The intervention arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure baseline and outcome assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firsbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. Participants placed in the intervention arm will receive 4-6 weeks of Heart Rate Variability Biofeedback training. All measures will be repeated at the end of the six week period.
16486674|NCT03383913|No Intervention|Control|The control arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firstbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. The control group will receive their usual care for SCD and complete baseline and post-baseline outcome assessments without any HRV-B training. All measures will be repeated at the end of the six week period.
16486675|NCT03383900|Experimental|G-IMT|The experimental group will first carry out a diaphragmatic reeducation program, followed a posteriori by an inspiratory muscle training program use progressive resistance loads up to 80% of the PImax during the 12 weeks
16486676|NCT03383900|Placebo Comparator|Gn-IMT|The Gn-IMT will use by an inspiratory muscle training program use resistance loads up to 10% PImax during the 12 weeks.
16486677|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
16486678|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
16486679|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
16486680|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
16486681|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
16486682|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
16486683|NCT03383848|Experimental|Experimental Software Group|Subjects in the experimental group will be provided with free access to the medication management software online, which will be able to be accessed on the SmartPhone/SmartDevice and home tablet(s) or computer(s) of their choice, through any browser. They will also be provided with links to the surveys to be filled out in the REDCap secure web application throughout the study.
16486684|NCT03383848|No Intervention|Control Group|Subjects in the control group will receive standard of care, and will receive emails with links to the surveys to be filled out in the REDCap secure web application throughout the study.
16486685|NCT03383835|Experimental|Omega-3 Supplementation|Participants will take the dose of omega-3 supplementation (600mg DHA and 300mg EPA) daily for 6 months.
16486686|NCT03383822|Experimental|Intranasal insulin|40 IU of intranasal insulin
16486687|NCT03383822|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
16486688|NCT03383809|Experimental|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
16486689|NCT03383809|Experimental|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
16486690|NCT03383809|Experimental|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
16486691|NCT03383796|Experimental|3D approach|Three dimensional laparoscopic resection for pCCA
16486692|NCT03383796|Experimental|open approach|Open resection for pCCA
16486693|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
16486694|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
16486695|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
16486696|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
16486697|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).
~A tuohy needle is used."
16486698|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).
~A facet needle is used."
16486699|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
16486700|NCT03383744|Experimental|Vitamin A supplementation 1|Vitamin A status assessed at Baseline and one month after the administration of 200,000 IU of vitamin A
16486701|NCT03383744|Experimental|Vitamin A supplementation 3|Vitamin A status assessed at Baseline and three months after the administration of 200,000 IU of vitamin A
16486702|NCT03383731|Active Comparator|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
16486703|NCT03383731|Experimental|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
16486704|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
16486705|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve
~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve
~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve
~Optimal Medical Treatment/OMT"
16486706|NCT03383705|Experimental|Treatment arm|
16486707|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
16486708|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3
16486709|NCT03383679|Experimental|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
16486710|NCT03383679|Other|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).
~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
16486711|NCT03383666|Experimental|Treatment Group|PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.
16486712|NCT03383640|No Intervention|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
16486713|NCT03383640|Other|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
16486714|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.
~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.
~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.
~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
16486715|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
16486716|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
16486717|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
16486718|NCT03383601||Users of IQOS with HeatStick|Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (>70%) use Heated Tobacco product IQOS/heatstick
16486719|NCT03383601||Smokers of combustible cigarettes|Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
16486720|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
16486721|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
16486722|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
16486723|NCT03383575|Experimental|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16486724|NCT03383575|Experimental|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16486725|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
16486726|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
16486735|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
16486736|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
16486737|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
16486738|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
16486739|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
16486740|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
16486741|NCT03383510|Experimental|Climate friendly group|The climate friendly group will receive instructions to eat according to a climate friendly diet, i.e., to replace the majority of their intake of animal based products with plant based food.
16486742|NCT03383510|Experimental|Organic group|The organic group will receive instructions to eat an organic diet, i.e., to replace at least 50% of their normally consumed food with organic equivalents.
16486743|NCT03383510|Experimental|Climate friendly and organic group|The climate friendly and organic group will receive instructions to consume a climate friendly and organic diet, i.e, to replace the majority of their intake of animal based products with plant based food AND to consume at least 50% organic food products.
16486744|NCT03383510|Placebo Comparator|Control group|The control group will receive instructions to eat according to the Nordic Nutrition Recommendations.
16486745|NCT03383497||Idiopathic Parkinson Disease|
16486746|NCT03383497||Other Parkinsonian syndromes|
16486747|NCT03383484|No Intervention|No intervention|No OMT, yoga, acupuncture, or other interventions.
16486748|NCT03383484|Experimental|OMT intervention|Weekly OMT for 3 months
16486749|NCT03383484|Experimental|Yoga intervention|Yoga 3 times per week for 3 months
16486750|NCT03383471|Experimental|Invossa K Inj.|Invossa K Inj.
16486751|NCT03383471|Placebo Comparator|Placebo|Placebo control
16486754|NCT03383445|Other|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
16486755|NCT03383445|Other|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
16486756|NCT03383432|Other|Trans-abdominal ultrasound intrauterine device group.|Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.
16486757|NCT03383432|Other|Uterine Sounding Sparing intrauterine device group|The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.
16486758|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
16486759|NCT03383406|Experimental|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
16486760|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
16486761|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
16486762|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
16486763|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
16486764|NCT03383367|Experimental|Tempo Colo|
16486765|NCT03383341|Experimental|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
16486766|NCT03383341|Placebo Comparator|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
16486767|NCT03383328|Active Comparator|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
16486768|NCT03383328|Active Comparator|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
16486769|NCT03383328|Experimental|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
16486770|NCT03383328|Experimental|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
16486771|NCT03383328|Experimental|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.
~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
16486772|NCT03383315|Experimental|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
16486773|NCT03383315|Active Comparator|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
16486774|NCT03383302|Experimental|Arm 1 Tolerabilty|This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status < 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
16486775|NCT03383289|Experimental|R-REM training|3 module training for frontline staff in assisted living facilities related to recognizing and management of resident-to-resident elder mistreatment
16486776|NCT03383289|No Intervention|Control condition|Usual care
16486777|NCT03383276|Experimental|IL-1Ra|
16486778|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
16486779|NCT03383250|Experimental|Meal ingestion|
16486780|NCT03383237|Experimental|Apatinib|Apatinib 500mg/d,q.d.,p.o.
16486781|NCT03383224|Experimental|Genotype-guided (A allele carriers)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (A allele carriers will be given pharmacologic therapy (nicotine replacement therapy --NRT; nicotine patch used according to FDA labelling).)
16486782|NCT03383224|Experimental|Genotype-guided (GG homozygotes)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (GG homozygotes will be given smoking cessation counseling)
16486783|NCT03383224|Active Comparator|Standard (non-genotype guided) - NRT|1/2 of patients in this arm will be given nicotine replacement therapy (NRT; nicotine patch used according to FDA labeling) but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
16486784|NCT03383224|Active Comparator|Standard (non-genotype guided)- counseling|1/2 of patients in this arm will be given smoking cessation counseling but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
16486789|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
16486790|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
16486791|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
16486792|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
16486793|NCT03383172|Experimental|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
16486794|NCT03383172|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
16486795|NCT03383172|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
16486796|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
16486797|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
16486798|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
16486799|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
16486800|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 52 weeks.
16486801|NCT03383146|Placebo Comparator|Placebo|Placebo injected twice daily for 52 weeks.
16486802|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
16486845|NCT03382938|Active Comparator|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
16487541|NCT03377842|Experimental|Apatinib and FOLFOX regimen|Apatinib combine with FOLFOX regimen.
16486803|NCT03383120|Experimental|Laser|Mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette. Adjunctive sub-mucosal diode laser application according to the instructions of the manufacturer (settings: 810 nm, 2.5 W, 50 Hz, 10 ms), 3x for 30 seconds, using a 400-µm thick fiber (Doctor Smile Wiser diode laser, Orcos Medical AG, Küsnacht, Switzerland), will be performed three times at one week intervals (days 0, 7, and 14).
16486804|NCT03383120|Active Comparator|Surgery|Active control includes mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette at day 1. An open flap debridement procedure is performed at day 14 using normal saline for implant decontamination. Adjunctive systemic antimicrobials will be prescribed; Amoxi-mepha 500mg 3x/day and Metronidazole 500mg 3x/day, for 1 week. A chlorhexidine 0.2% mouth rinse will also be prescribed 2x/day for one week. Suture removal and prophylaxis are performed 7-10 days post-operatively.
16486805|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
16486806|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
16486807|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
16486808|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
16486809|NCT03383094|Active Comparator|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)
16486810|NCT03383094|Experimental|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
16486811|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
16486812|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
16486813|NCT03383081|No Intervention|Control groups|No intervention
16486814|NCT03383068|Other|control|metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance
16486815|NCT03383068|Experimental|acarbose|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months
16486816|NCT03383068|Experimental|Exenatide|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months
16486817|NCT03383068|Experimental|Orlistat|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months
16486818|NCT03383055|Experimental|CMV positive cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
16486819|NCT03383055|Experimental|CMV negative cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
16486820|NCT03383042|Experimental|Cohort 1|Single-ascending cohort 1
16486821|NCT03383042|Experimental|Cohort 2|Single-ascending cohort 2
16486822|NCT03383042|Experimental|Cohort 3|Single-ascending cohort 3
16486823|NCT03383042|Experimental|Cohort 4|Single-ascending cohort 4
16486824|NCT03383042|Experimental|Cohort 5|Single-ascending cohort 5
16486825|NCT03383042|Experimental|Cohort 6|Multiple-ascending cohort 1
16486826|NCT03383042|Experimental|Cohort 7|Multiple-ascending cohort 2
16486827|NCT03383042|Experimental|Cohort 8|Multiple-ascending cohort 3
16486828|NCT03383042|Experimental|Cohort 9|Multiple-ascending cohort 4
16486829|NCT03383029|Experimental|iEAT|Children with food refusal will participate in the iEAT program.
16486831|NCT03383003|Experimental|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
16486832|NCT03383003|Active Comparator|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
16486833|NCT03382990||STEMI|Patients with STEMI treated with PCI and stent placement (DES or BMS)
16486834|NCT03382990||NSTEMI|Patients with NSTEMI treated with PCI and stent placement (DES or BMS)
16486835|NCT03382977|Experimental|Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
16486836|NCT03382977|Experimental|Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
16486837|NCT03382977|Experimental|Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
16486838|NCT03382977|Experimental|Dose Level 4|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
16486839|NCT03382977|Experimental|Dose Level 5|VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
16486840|NCT03382964|Active Comparator|VLA1553 low dose|VLA1553 with 3.2x10^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL (milliliter)
16486841|NCT03382964|Active Comparator|VLA1553 medium dose|VLA1553 with 3.2x10^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
16486842|NCT03382964|Active Comparator|VLA1553 high dose|VLA1553 with 3.2x10^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
16486843|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
16486844|NCT03382938|Active Comparator|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
16487625|NCT03377270|Other|Home Practice Arm|RST + Home Practice Arm
16486846|NCT03382938|Active Comparator|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
16486847|NCT03382938|Placebo Comparator|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
16486848|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
16486849|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
16486850|NCT03382912|Experimental|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.
~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
16486851|NCT03382912|Active Comparator|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
16486852|NCT03382899|Experimental|Pegilodecakin + Pembrolizumab|"Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.
~Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle."
16486853|NCT03382899|Active Comparator|Pembrolizumab|Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.
16486854|NCT03382886|Experimental|Nivolumab and bevacizumab, all patients|
16486855|NCT03382873|Active Comparator|Group Lifestyle Balance (GLB)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who achieve >2.5% weight loss at week 5 will remain in the GLB arm.
16486856|NCT03382873|Experimental|Group Lifestyle Balance Plus (GLB+)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who fail to achieve >2.5% weight loss at week 5 will transfer to the GLB+ arm.
16486857|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
16486858|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
16486859|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
16486860|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
16486861|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
16486862|NCT03382821|Active Comparator|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
16486863|NCT03382821|Active Comparator|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
16486864|NCT03382808|Experimental|SEE Training|The training sequence comprises four weekly sessions using a modified dote-probe paradigm (fearful vs. neutral expression).
16486865|NCT03382808|Active Comparator|GAZE Training|The GAZE training sequence comprises four weekly sessions using a modified dote-probe paradigm (averted vs. directed gaze).
16486866|NCT03382795|Experimental|EGFR retreat group|
16486867|NCT03382782|Active Comparator|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 12 months. BWLI consists of a 8-month initial intervention phase followed by 4-month maintenance phase. The initial intervention phase comprises four types of contact:
~1-hour to 1-hour, 30 minute group weight-management class led by facilitator (once per week; 26 classes followed by a one week break and an additional 8 weight management review classes)
~45 minute, physical activity led by facilitator (one-two times per week);
~20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and
~weigh-in during weight management group and individual visits (once each week)."
16486868|NCT03382782|Experimental|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:
~partnering with participant on BWLI homework;
~meeting with participant and BWLI facilitator individually;
~attending all other health care appointments; and
~partnering on tasks that arise out of those appointments."
16486869|NCT03382782|Active Comparator|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
16488206|NCT03373526|Active Comparator|Aerobic Physical Training|Aerobic Training
16486872|NCT03382756|Experimental|Group A|"Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition
~Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition"
16486873|NCT03382756|Experimental|Group B|"Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition
~Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition"
16486874|NCT03382743|Active Comparator|Group A (Lidocaine group)|5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy
16486875|NCT03382743|No Intervention|Group B (control group)|office hysteroscopy is done without analgesia
16486876|NCT03382730|Other|Oral Chlorhexidine Mouth Rinse|Application of chlorhexidine gluconate mouth rinse per unit protocol.
16486877|NCT03382730|Experimental|De-Adoption of Oral Chlorhexidine Mouth Rinse|No application of chlorhexidine gluconate mouth rinse. Oral care bundle.
16486878|NCT03382717|Experimental|Excilor Forte|
16486879|NCT03382717|Active Comparator|Loceryl 5%|
16486880|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
16486881|NCT03382691|Experimental|EXPERIMENTAL|Blood pressure check using mobile device and control device
16486882|NCT03382652||Patients who received the Continuum Metal on Metal System|Patients requiring total hip arthroplasty, who meet the inclusion/exclusion criteria and received the Continuum Metal on Metal System
16486883|NCT03382639|Experimental|Double-blind: TAK-831 50 mg|TAK-831 50 milligram (mg), tablets, orally, once daily up to 14 weeks.
16486884|NCT03382639|Experimental|Double-blind: TAK-831 125 mg|TAK-831 125 mg, tablets, orally, once daily up to 14 weeks.
16486885|NCT03382639|Experimental|Double-blind: TAK-831 500 mg|TAK-831 500 mg, tablets, orally, once daily up to 14 weeks.
16486886|NCT03382639|Placebo Comparator|Double-blind: Placebo|TAK-831 placebo-matching tablets, orally, once daily up to 14 weeks.
16486887|NCT03382626|Active Comparator|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve working memory, attention, and executive function).
16486888|NCT03382626|Sham Comparator|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve working memory, attention and executive function).
16486889|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
16486890|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
16486891|NCT03382600|Experimental|Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)|Participants receive Pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
16486892|NCT03382600|Experimental|Pembrolizumab + Cisplatin +TS-1 (Cohort 2)|Participants receive Pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
16486893|NCT03382587||Aflibercept|Treatment-naive wet age-related macular degeneration patients under routine intravitreal aflibercept treatment in a treat-and-extend scheme
16486894|NCT03382574|Experimental|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
16486895|NCT03382574|Active Comparator|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.
16486896|NCT03382561|Experimental|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
16486897|NCT03382561|Active Comparator|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16486898|NCT03382548|Active Comparator|Short antibiotic treatment duration for VAP (7 days or less)|
16486899|NCT03382548|Active Comparator|Long antibiotic treatment duration for VAP ( 8 days or more)|
16486900|NCT03382535|Active Comparator|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
16486901|NCT03382535|Experimental|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
16486948|NCT03382171|No Intervention|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
16486902|NCT03382535|Other|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
16486903|NCT03382509|Experimental|Single Dose Group|
16486904|NCT03382509|Experimental|Multiple Dose Group|
16486905|NCT03382496||Lung Cancer patients in France|Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
16486906|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
16486907|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
16486908|NCT03382457|Experimental|Treatment|Treatment with the Edwards Cardioband Tricuspid Valve Reconstruction System
16486909|NCT03382431|Experimental|PC786|Repeat dose
16486910|NCT03382431|Placebo Comparator|Placebo/vehicle|Repeat dose
16486911|NCT03382418|Experimental|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
16486912|NCT03382418|Experimental|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
16486913|NCT03382418|Placebo Comparator|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
16486914|NCT03382405|Experimental|mRNA-1647|
16486915|NCT03382405|Experimental|mRNA-1443|
16486916|NCT03382405|Placebo Comparator|Placebo|
16486917|NCT03382392||ALS|
16486918|NCT03382392||control 1|
16486919|NCT03382392||control 2|
16486920|NCT03382379|Experimental|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
16486921|NCT03382379|Placebo Comparator|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
16486922|NCT03382366|Other|Sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as sarcopenic by the DXA.
~This group will undergo the same evaluations/intervention of the second group."
16486923|NCT03382366|Other|Non-sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as non-sarcopenic by the DXA.
~This group will undergo the same evaluations/intervention of the first group."
16486924|NCT03382353|Active Comparator|No Treatment (NT)|Educational training
16486925|NCT03382353|Experimental|Partial Treatment (PT)|Nutritional supplementation & Counselling on a brain-healthy diet
16486926|NCT03382353|Experimental|Full Treatment (FT)|Nutritional supplementation & Counselling on a brain-healthy diet & Physical exercise training & Computerized cognitive training
16486927|NCT03382340|Experimental|Imx-110|
16486928|NCT03382327|Experimental|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
16486929|NCT03382314|Experimental|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
16486930|NCT03382314|Active Comparator|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
16486931|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
16486932|NCT03382301|Placebo Comparator|NaCl preconditioning|
16486933|NCT03382288|Experimental|Examination of participants|Examination of participants by means of the investigational device, Eyestar 900 as well as the comparative devices.
16486934|NCT03382262|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
16486935|NCT03382262|Active Comparator|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
16486936|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
16486937|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
16486938|NCT03382236|Experimental|Real osteopathy|
16486939|NCT03382236|Placebo Comparator|Sham osteopathy|
16486940|NCT03382210||ERP group|A prospective series of patients (N=100) undergoing elective colorectal resection and completing a standardized enhanced recovery protocol in 2013-2015 (ERP group) at the S. Anna University Hospital in Ferrara (Italy).
16486941|NCT03382210||Pre-ERP group|A retrospective series of patients (N=100) operated on at the the S. Anna University Hospital in Ferrara (Italy) in 2009-2011 (Pre-ERP group), before the introduction of ERP methodology.
16486942|NCT03382197|Experimental|Nebulization|control intervention, will only perform nebulization;
16486943|NCT03382197|Experimental|Positive expiratory pressure valve|Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP)
16486944|NCT03382197|Experimental|Nonivasive ventilation|intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;
16486945|NCT03382184|Experimental|Fraxel DUAL 1550 nm|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group.
16486946|NCT03382184|Experimental|Halo Hybrid Laser 1550 nm|The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group.
16486947|NCT03382171|Experimental|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
16486949|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
16486950|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
16486951|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
16486952|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
16486953|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
16486954|NCT03382132|Experimental|momHealth|Participants will receive support and information via the momHealth program.
16486955|NCT03382132|Active Comparator|Control|Participants will receive the normal support they would normally receive if they were not in a study.
16486956|NCT03382119||Patients having Fontan cardiac surgery|"This group includes pediatric patients, aged 2-5 years, who have had a Fontan operation. This surgery corrects a heart defect found at birth in which the heart has only one ventricle.
~Patients will have an Ultrasound with ARFI imaging."
16486957|NCT03382119||Patients with Liver disease|"This group includes pediatric patients, aged 2-5 years, who have chronic liver disease caused by biliary atresia.
~Patients will have an Ultrasound with ARFI imaging."
16486958|NCT03382106|Experimental|Smoking Cessation Group 1|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
16486959|NCT03382106|Placebo Comparator|Smoking Cessation Group 2|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day placebo oral tablet for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
16486960|NCT03382106|Experimental|Non-Smokers Group 1|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. We will provide 10 females and 10 males three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months.
16486961|NCT03382106|No Intervention|Non-Smokers Group 2|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. 10 females and 10 males will not receive any medication for the full 3 months.
16486962|NCT03382093|Active Comparator|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
16486963|NCT03382093|Active Comparator|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
16486964|NCT03382080|Experimental|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
16486965|NCT03382080|Experimental|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through
~Co-location of services and staff working in services
~One open door to increase accessibility to the services and staff for students
~Focus on the transition from lower to upper secondary school
~Close follow-up of students at risk to ensure tailored help to each student
~Early intervention and follow up when students starts being absent from school"
16486966|NCT03382080|No Intervention|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
16486967|NCT03382067|Active Comparator|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
16486968|NCT03382067|Placebo Comparator|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing < 0,0009 mg (-)-Epicatechin/100g
16486969|NCT03382054||Older surgical patients|Male and female patients with age 65 years and above scheduled for surgery
16486970|NCT03382041|Experimental|Carbon Fiber Implant|There is an alternative to the standard treatment, which is carbon fiber implants (tibial nails), especially in the prophylactic reinforcement of bones susceptible to pathological fractures following metastatic tumors. The new carbon fiber has also been used in the treatment of tibial non-union (non- healing bone); which has shown satisfactory outcomes.
16486971|NCT03382041|Active Comparator|Titanium Implant|The standard of practice in the treatment of fractures of the tibial shaft and other long bones has been the intramedullary nailing using titanium or stainless steel implants.
16486972|NCT03382015|Active Comparator|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
16486973|NCT03382015|Placebo Comparator|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
16486974|NCT03381989|Experimental|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
16486975|NCT03381976|Active Comparator|Intervention 2X/week (G2X)|This group performed resistance training twice a week (Tuesdays and Thursdays)
16486976|NCT03381976|Active Comparator|Intervention 3X/week (G3X)|This group performed resistance training three sessions a week (Mondays, Wednesdays, and Fridays).
16486977|NCT03381976|No Intervention|Control group (GC)|This group did not perform any type of organized physical exercise during the study period.
16486978|NCT03381963||Aromatase inhibitors|
16486979|NCT03381963||Tamoxifen|
16486980|NCT03381937|No Intervention|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
16486981|NCT03381937|Experimental|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
16486982|NCT03381937|Experimental|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
16486983|NCT03381924|Experimental|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
16486984|NCT03381924|Placebo Comparator|Control group|Routine clinical practice
16486985|NCT03381911|No Intervention|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
16486986|NCT03381911|Experimental|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
16486987|NCT03381898|Experimental|Telehealth Coordinated Allied Health|rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
16486988|NCT03381885|Experimental|Intervention Group|"A nudge grounded in behavioral economic theory (nudge=gentle incentive, preserving freedom of choice)"
16486989|NCT03381885|Placebo Comparator|Control|"No nudge"
16486990|NCT03381872|Active Comparator|Intravascular imaging arm|The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.
16486991|NCT03381872|Active Comparator|Angiography arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
16486992|NCT03381859|Experimental|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
16486993|NCT03381846|Experimental|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
16486994|NCT03381833|Active Comparator|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
16486995|NCT03381833|Active Comparator|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
16486996|NCT03381820|Experimental|music listening|Participants who were randomized into intervention group were assigned to listen to the music everyday (day 1st to day 30th), at anytime of day that was suitable with their lifestyles but not at the time of BP measurement. During day 31st -120th, participants did not listen to the music. Other treatment was the same as the control arm.
16486997|NCT03381820|No Intervention|control|control arm received conventional hypertension treatment.
16486998|NCT03381807|Experimental|TCRA and intrauterine infusion of hAESCs|hAESCs is infused into uterine cavity after TCRA.
16486999|NCT03381794||Patients with corneal transplantation|Aim is to include all patients in Germany treated with the different types of corneal transplantation with an interim-assessment of the period between 2001 and 2016.
16487000|NCT03381781|Experimental|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
16487001|NCT03381768|Experimental|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
16487002|NCT03381755|Experimental|half-dose ticagrelor|
16487003|NCT03381755|Active Comparator|standard-dose ticagrelor|
16487004|NCT03381742|Experimental|ticagrelor 45mg bidpo.|To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
16487005|NCT03381742|Experimental|ticagrelor 90mg qdpo.|To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
16487006|NCT03381742|Active Comparator|ticagrelor 90mg bidpo.|To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
16487007|NCT03381742|Active Comparator|clopidogrel 75mg qdpo.|To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
16487008|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of onasemnogene abeparvovec-xioi
16487009|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of onasemnogene abeparvovec-xioi
16487010|NCT03381729|Experimental|Dose C|Intrathecal administration 2.4 X 10^14 vg of onasemnogene abeparvovec-xioi
16487011|NCT03381716||male|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
16487012|NCT03381716||female|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
16487013|NCT03381703|Experimental|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
16487014|NCT03381703|Experimental|Part 2|Investigate the absolute bioavailability of YH12852
16487015|NCT03381690||Epidural (ED) emergent C-sec|
16487016|NCT03381690||Non-ED emergent C-sec|
16487017|NCT03381690||Non-ED elective C-sec|
16487018|NCT03381677|Experimental|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
16487019|NCT03381677|Active Comparator|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):
~DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and
~DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
16487020|NCT03381664|Experimental|AVP-923-20/10 capsule|Participants will receive a single AVP-923-20/10 (dextromethorphan hydrobromide [DM] 20 milligram [mg]/quinidine sulfate [Q] 10 mg) capsule administered orally.
16487021|NCT03381664|Experimental|AVP-923-20/10 via applesauce|Participants will receive the contents from a single AVP-923-20/10 capsule mixed and consumed in 1 tablespoon of applesauce.
16487022|NCT03381664|Experimental|AVP-923-20/10 via nasogastric feeding tube|Participants will receive the contents from a single AVP-923-20/10 capsule solubilized in feeding solution and administered through a nasogastric feeding tube.
16487023|NCT03381651|Active Comparator|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
16487024|NCT03381651|Active Comparator|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
16487025|NCT03381638||Normal Volunteer|Volunteers who report to have never had a concussion and are not at high risk of getting a concussion are scanned to obtain a baseline of all ages, sex, race, etc. All patients will be scanned with the Blink Reflexometer.
16487026|NCT03381638||Concussion Protocol|Athletes who had a potential concussion and will go through any stage of the approved protocol, are scanned by the Blink Reflexometer device. Results are then analyzed prior to unblinding the clinical diagnosis from an Athletic Trainer and/or Neurologist.
16487027|NCT03381625|Experimental|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
16487028|NCT03381625|Placebo Comparator|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
16487029|NCT03381599|Experimental|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
16487030|NCT03381586|Experimental|Group A|1.0 mg/ml ALT-803
16487031|NCT03381586|Experimental|Group B|2.0 mg/ml ALT-803
16487032|NCT03381573||Roflumilast exposed|Patients with COPD ever exposed to Roflumilast
16487033|NCT03381573||Roflumilast unexposed|Patients with COPD never exposed to Roflumilast
16487034|NCT03381547|Active Comparator|A|Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
16487035|NCT03381547|Active Comparator|B|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
16487036|NCT03381547|Active Comparator|C|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
16487037|NCT03381534|Placebo Comparator|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
16487038|NCT03381534|Experimental|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
16487039|NCT03381521|Experimental|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
16487040|NCT03381521|Active Comparator|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
16487041|NCT03381508||The study population|"The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.
~Intervention: Brizzy continuous positive pressure device"
16487042|NCT03381495|Experimental|Epidural analgesia during labor|The epidural analgesia technique was used to maintain analgesia for parturients who request labor analgesia.First, we injected a test dose of 5ml 1% lidocaine . If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the epidural catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h until the delivery of neonates.
16487043|NCT03381495|No Intervention|Non-epidural analgesia during labor|Women who refused epidural labor analgesia were included in the non-epidural analgesia group, and they don't receive epidural analgesia during labor
16487044|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
16487045|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
16487046|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
16487047|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
16487048|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
16487049|NCT03381469|Experimental|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
16487050|NCT03381469|Active Comparator|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
16487051|NCT03381469|Active Comparator|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
16487052|NCT03381456|Experimental|Healthy subject|LICI
16487053|NCT03381456|Experimental|Dystonic subject|LICI
16487054|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
16487055|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
16487056|NCT03381430|Experimental|Gefitinib + Radiotherapy|Experimental: Gefitinib Gefitinib 250 mg/day oral daily Radiotherapy Total dose 50-54Gy, divided dose 1.8-2Gy
16487057|NCT03381417|Experimental|Pegcyte (Nanogen pegfilgrastim)|6 mg in each cycle
16487058|NCT03381417|Active Comparator|Neulastim (Roche pegfilgrastim)|6 mg in each cycle
16487059|NCT03381404|Experimental|[14C] MT-8554|
16487060|NCT03381391|Experimental|Feedback intervention condition|
16487061|NCT03381391|No Intervention|Assessment-only control condition|
16487062|NCT03381365|Experimental|investigational arm|
16487063|NCT03381352|Experimental|Chemo-radiotherapy with IMRT technique|Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
16487064|NCT03381339|Experimental|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
16487065|NCT03381339|No Intervention|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
16487066|NCT03381313|Experimental|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
16487067|NCT03381300|Other|Single cohort|
16487068|NCT03381287|Experimental|500mg HTD1801|
16487069|NCT03381287|Experimental|1000mg HTD1801|
16487070|NCT03381287|Experimental|2000mg HTD1801|
16487073|NCT03381261|Experimental|Botulinum toxin type A injection arm|All patients will be injected with Botulinum toxin on one side of the back of the head.
16487074|NCT03381248|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
16487075|NCT03381248|Active Comparator|Hyaluronic Acid Injection|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain
16487076|NCT03381235|Experimental|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
16487077|NCT03381235|No Intervention|Mild exercise|Sessions will be focused on balance and stretching.
16487078|NCT03381209|Experimental|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
16487079|NCT03381209|Experimental|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
16487080|NCT03381209|Experimental|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
16487081|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
16487082|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
16487626|NCT03377257|Active Comparator|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
16487083|NCT03381183|Experimental|Phase 1 - Dose Escalation|Six patients will be enrolled at Dose Level 1 with IRX-2 230 units/day in combination with cyclophosphamide and durvalumab and treated sequentially at least 1 week apart. If less than 2 out of 6 patients have DLTs in Dose Level 1, the dose will be escalated to administration of IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab as Dose Level 2. If 2 of 6 patients have DLTs, stop accrual and re-evaluate. In the next safety phase, six patients at IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab will be enrolled and treated sequentially (at least 1 week apart). If DLT occurs in less than 2 of 6 patients during the first 6 weeks of treatment, enrollment can continue in the dose expansion phase at Dose Level 2. If DLT is observed in 2 of 6 patients, accrual will be stopped and Dose Level 1 will resume in the dose expansion phase.
16487084|NCT03381183|Experimental|Phase 2 - Dose Expansion|14 patients will be enrolled at the recommended dose level from the dose finding phase for a total enrollment of 20 patients; however, investigators will replace patients with any missing tumor sample collection and continue enrollment until there are at least 20 pre- and post-treatment paired tumors (i.e. minimum 2 of 3 tumors per patient). The 6 patients treated at the recommended dose in the dose finding phase of the study will be counted as a part of the dose expansion patient population,
16487085|NCT03381170|Experimental|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
16487086|NCT03381157||Cystic Fibrosis Group|
16487087|NCT03381157||Control Group|
16487088|NCT03381144|Experimental|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
16487089|NCT03381144|Placebo Comparator|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
16487090|NCT03381144|Experimental|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
16487091|NCT03381144|Placebo Comparator|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
16487092|NCT03381144|Experimental|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
16487093|NCT03381144|Placebo Comparator|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
16487094|NCT03381118|Experimental|Ara-C+HaploLymphocyte+Nivo|"Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:
~[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0
~+ Nivolumab 40 mg D+5] х 2-3 cycles"
16487095|NCT03381118|Experimental|Ara-C+ Nivo|"Patients treated with nivolumab and intermediate dose cytarabine:
~[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1] х 2-3 cycles"
16487096|NCT03381092||invasive breast cancer|Patients with invasive breast cancer who have clinically negative axilla and receive neoadjuvant treatment followed by sentinel lymph node biopsy are eligible for this study.
16487097|NCT03381079|Experimental|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
16487098|NCT03381079|No Intervention|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
16487099|NCT03381066|Experimental|Intercalating arm|gefitinib, pemetrexed,cisplatin
16487100|NCT03381066|Active Comparator|chemotherapy alone arm|Vinorelbine, cisplatin
16487101|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
16487102|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
16487103|NCT03381040|Active Comparator|Group A|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
16487104|NCT03381040|Active Comparator|Group B|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
16487105|NCT03381027|Experimental|Interventional Arm- Baby Massage|Interventional Arm= Baby Massage
16487106|NCT03381027|No Intervention|Control Arm- no Baby Massage|Control Arm= no Baby Massage
16487107|NCT03381001|Active Comparator|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
16487108|NCT03381001|Experimental|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
16487109|NCT03380988|Experimental|Fiber-enriched buckwheat pasta|Acute test meal
16487110|NCT03380988|Active Comparator|Corn pasta|Acute test meal
16487111|NCT03380975|Experimental|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
16487112|NCT03380962|Experimental|Clazakizumab|All twenty patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
16487165|NCT03380650|Other|directional atherectomy and LDD|The directional atherectomy and local drug delivery will be used to treat the femoropopliteal occlusion.
16487166|NCT03380637||Pregnant and non-pregnant females|The pregnant females posted for elective lower segment cesarean section and non-pregnant females posted for elective surgeries are scanned by ultrasound in the pre recovery room. The visibility of the gastric antrum is assessed. The qualitative and quantitative assessment is made and is compared.
16487113|NCT03380949|Experimental|PPI (Pain Pupillary Index)|Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
16487114|NCT03380949|Experimental|SPI (Surgical Pleth Index)|Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
16487115|NCT03380949|Experimental|NOL (Nociception Level)|Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
16487116|NCT03380949|Active Comparator|Control|Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
16487117|NCT03380936|Active Comparator|Arm 1 - conversion to Envarsus XR|Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet [Envarsus]) with goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
16487118|NCT03380936|Active Comparator|Arm 2 - plasma exchange and IVIG|Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
16487119|NCT03380923|Experimental|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.
~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with ~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.
~HR is monitored throughout each session and stored for analysis."
16487120|NCT03380923|Experimental|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.
~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.
~HR is monitored throughout each session and stored for analysis."
16487121|NCT03380910|Experimental|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
16487122|NCT03380910|Other|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
16487123|NCT03380897|Active Comparator|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with visual analogy scale at home. The intervention is to go home.
~Intervention for outpatient group was to go home."
16487124|NCT03380897|Placebo Comparator|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with visual analogy scale in the ward. The intervention is to stay at ward.
~Intervention for inpatient group was to stay at ward."
16487125|NCT03380884|No Intervention|Control|Control group will remain in their habitual life style and no vibration used
16487126|NCT03380884|Experimental|Vibration Group|The intervention group will undergo Low-magnitude high-frequency vibration (LMHFV) at 35Hz, 0.3g (peak to peak magnitude), displacement of <0.1mm, 20 min/day, at least 3 times per week, for 6 months in community centres
16487127|NCT03380871|Experimental|NEO-PV-01/Adjuvant + pembrolizumab + chemotherapy|Pembrolizumab at a dose of 200 mg administered by intravenous infusion (IV) plus chemotherapy with carboplatin (AUC 5) + pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with pembrolizumab.
16487167|NCT03380624|Experimental|Refresh Optive, then Refresh Optive MEGA-3|"Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.
~."
16487128|NCT03380845|Active Comparator|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face
~Fraxel Restore: acne scar correction
~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
16487129|NCT03380845|Active Comparator|Fractora on the other side of the face|"Fractora on the other side of the face
~Fractora: acne scar correction
~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
16487130|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
16487131|NCT03380819|Experimental|Genome sequencing|Patients undergo exome or whole-genome sequencing, and their patients receive an interpreted clinical report.
16487132|NCT03380806|Active Comparator|Arm 1|Conventional Radiotherapy (CRT) Prostate Boost Pelvic Radiation LHRH agonist
16487133|NCT03380806|Experimental|Arm 2|Stereotactic Body Radiotherapy (SBRT) Prostate Boost Pelvic Radiation LHRH agonist
16487134|NCT03380793|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
16487135|NCT03380780|Experimental|Emicizumab|
16487136|NCT03380767|Experimental|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
16487137|NCT03380767|Experimental|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
16487138|NCT03380754|Experimental|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
16487139|NCT03380754|Placebo Comparator|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
16487140|NCT03380754|No Intervention|No Drink|Group C will not receive any drink. This group will follow normal protocol.
16487141|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
16487142|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
16487143|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
16487144|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
16487145|NCT03380741||Group 5|Normal cervix at colposcopy
16487146|NCT03380728|Experimental|Group 1|Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
16487147|NCT03380728|Experimental|Group 2|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, placebo on day 7
16487148|NCT03380728|Experimental|Group 3|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, Ibogaine Hydrochloride 400 mg on day 7
16487149|NCT03380715|Active Comparator|right nostril in patients with rhinitis|Intervention : Administration of either 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity or
16487150|NCT03380715|No Intervention|Left nostril in patients with rhinitis|No nasal decongestion administration into the left nostril
16487151|NCT03380715|Active Comparator|Right nostril in patients with rhinitis|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
16487152|NCT03380702|Active Comparator|whitening photoactivation gel|exposure to hydrogen gel and photoactivation for teeth whitening
16487153|NCT03380702|Placebo Comparator|placebo|exposure to gel without active whitening substance and the same photoactivation source as active comparator
16487154|NCT03380689|Experimental|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
16487155|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
16487156|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
16487157|NCT03380663|Active Comparator|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
16487158|NCT03380663|Active Comparator|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
16487159|NCT03380663|Active Comparator|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
16487160|NCT03380663|Active Comparator|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
16487161|NCT03380663|Active Comparator|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
16487162|NCT03380663|No Intervention|Control - Healthy|No intervention.
16487163|NCT03380663|No Intervention|Control - HF|No intervention.
16487164|NCT03380650|Other|durg-coated balloon dilation|The drug-coated balloon will be used to treat the femoropopliteal occlusion.
16487168|NCT03380624|Experimental|Refresh Optive MEGA-3, then Refresh Optive|Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.
16487169|NCT03380611|Experimental|Wakame|Subjects will receive capsules containing wakame
16487170|NCT03380611|Experimental|Spirulina|Subjects will receive capsules containing spirulina
16487171|NCT03380611|Placebo Comparator|Control|Subjects will receive capsules containing microcrystalline cellulose
16487172|NCT03380598|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
16487173|NCT03380598|Active Comparator|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
16487174|NCT03380585|Experimental|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
16487175|NCT03380585|Active Comparator|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
16487176|NCT03380572|Experimental|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
16487177|NCT03380572|Active Comparator|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
16487178|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
16487179|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
16487180|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
16487181|NCT03380546|Experimental|acarbose|The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
16487182|NCT03380546|Active Comparator|prandial insulin|The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.
16487183|NCT03380533|Active Comparator|Buprenorphine Patch|"Buprenorphine 10mg Patch + Placebo Tablet + Multimodal Oral Scheme
~Multimodal Oral Scheme:
~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
16487184|NCT03380533|Active Comparator|Tramadol Tablet|"Placebo Patch + Tramadol 50mg Tablet + Multimodal Oral Scheme
~Multimodal Oral Scheme:
~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
16487185|NCT03380520|Experimental|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
16487186|NCT03380520|Placebo Comparator|Placebo|Normal saline (0.9%)
16487187|NCT03380507|Experimental|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.
~Triple therapy regimen:
~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
16487188|NCT03380507|No Intervention|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
16487189|NCT03380494|Experimental|Overhead perturbation training technique|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
16487190|NCT03380494|Active Comparator|Non-perturbed exercise|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied via a weight held in the hand- such that the glenohumeral joint is exposed to a load but without a perturbation of joint position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
16487191|NCT03380481||SECRETS-TCM|Stroke patients who treated by western medicine and/or traditional Chinese medicine in southern China
16487192|NCT03380468|Experimental|Cisplatin plus pemetrexed|Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
16487193|NCT03380468|No Intervention|Observation|Observation and follow up only
16487194|NCT03380455|Experimental|Treatment period A & B|"Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.
~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10)."
16487195|NCT03380442|Experimental|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
16487196|NCT03380442|Active Comparator|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
16487197|NCT03380442|No Intervention|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
16487198|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
16487199|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
16487200|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
16487201|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
16487202|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
16487203|NCT03380416|Experimental|Portfolio Diet|The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
16487204|NCT03380416|Active Comparator|MUFA Diet|The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
16487205|NCT03380403|Active Comparator|PDT|Methylene blue and Photon Irradiation , every each week, until total ulcer healing.
16487206|NCT03380403|Active Comparator|Ciprofloxacin|Diabetic foot patients were treated on conventional way, using antibiotics and surgery.
16487207|NCT03380390|Experimental|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
16487208|NCT03380377|Experimental|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
16487209|NCT03380364|Experimental|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
16487210|NCT03380351||SCDIC interventions|Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
16487211|NCT03380351||SCDIC control groups|Careful detail the control conditions of each of the SCDIC sites for each of the interventions being developed.
16487212|NCT03380338|Experimental|Exercise program|Twice weekly exercise program, combined aerobic and strenght training
16487213|NCT03380325|Experimental|Iloprost first|Cross-over starts with iloprost intervention, then second clamp without iloprost.
16487214|NCT03380325|Experimental|Iloprost second|Cross-over starts without iloprost intervention, then second clamp with iloprost.
16487215|NCT03380286||Coronary Stenosis|
16487216|NCT03380273|No Intervention|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
16487217|NCT03380273|Other|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
16487218|NCT03380260|Experimental|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
16487219|NCT03380260|No Intervention|Control Condition|No manipulation of paranoid ideation
16487220|NCT03380234|Experimental|Intervention|8 worksheets and around 15 online quizzes and 30 WhatsApp messages.
16487221|NCT03380234|Other|Control|Control students will receive the following minimal intervention to reduce their intention to smoke and SHS - a leaflet on smoking and SHS published by the Department of Health.
16487222|NCT03380221|Experimental|Watermelon|
16487223|NCT03380221|Active Comparator|Low fat cookies|
16487224|NCT03380195|Experimental|Watermelon juice|
16487225|NCT03380195|Active Comparator|Sport drink|
16487226|NCT03380195|Active Comparator|Sugar water|
16487227|NCT03380195|Placebo Comparator|Water|
16487228|NCT03380182|Experimental|Acupuncture/Acupressure Group|Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
16487229|NCT03380182|Sham Comparator|Control Group|Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
16487230|NCT03380169|Experimental|Advance dressing|Prophylactic advance wound dressing
16487231|NCT03380169|Active Comparator|Conventional gauze dressing|Prophylactic conventional wound dressing
16487232|NCT03380156|Experimental|Interventional|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
16487233|NCT03380156|Placebo Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
16487234|NCT03380143|Experimental|Wellscapes Intervention|The wellness landscape intervention (Wellscapes) will establish a multi-level system infrastructure (Community Hub, Organization Wellness Teams, Activity Setting/Leaders) and provide training and support for population health quality improvement cycle processes targeting two evidence-based practices (EBPs): (1) stacking time segments of PA episodes within an organization's daily routine, and (2) improving the quality of PA episodes (% time in PA).
16487235|NCT03380143|Active Comparator|Standard Practice|The standard collective impact public health practice intervention will establish a multi-level system infrastructure and provide training on community development.
16487236|NCT03380130|Experimental|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
16487237|NCT03380117|Experimental|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
16487238|NCT03380117|No Intervention|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
16487239|NCT03380104|Experimental|Single Arm|Intradural Spinal Cord Stimulation; Administration of Questionnaires
16487240|NCT03380091|Experimental|Metformin|Metformin 1000 mg PO bid
16487241|NCT03380091|Experimental|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
16487242|NCT03380078|Active Comparator|Standard|Programs assigned to the Standard condition will receive standard EBI training only
16487243|NCT03380078|Experimental|TEAMS Leadership Institute (TLI) ONLY|Programs assigned to the TLI ONLY condition will receive standard EBI training for providers and leaders will participate in TLI.
16487244|NCT03380078|Experimental|Motivational Enhancement (TIPS for Training) ONLY|Programs assigned to the TIPS ONLY condition will receive enhanced TIPS EBI training for providers.
16487245|NCT03380078|Experimental|TIPS + TLI|Programs assigned to the TIPS + TLI condition will receive TIPS EBI training for providers and leaders will participate in TLI
16487246|NCT03380065|Active Comparator|Late deflation of TR band|"first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.
~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
16487247|NCT03380065|Active Comparator|Early deflation of TR band|"First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.
~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
16487248|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
16487249|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
16487250|NCT03380039|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16487251|NCT03380026|Experimental|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
16487252|NCT03380026|Active Comparator|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
16487253|NCT03380013|Experimental|OMT group|Osteopathic Manipulative Therapy (OMT); two treatments between day 4 and 7 of life
16487254|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
16487255|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
16487256|NCT03379987|Experimental|PVB morphine|
16487257|NCT03379987|Active Comparator|PVB bupivacaine|
16487258|NCT03379974|Experimental|ARM A: DDAVP followed by exercise|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: Exercise intervention"
16487259|NCT03379974|Active Comparator|ARM B: DDAVP alone|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: no further intervention (rest)"
16487260|NCT03379974|Experimental|ARM C: Exercise intervention|"Intervention #1: Exercise intervention
~Intervention #2: no further intervention (rest)"
16487261|NCT03379974|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise intervention
~Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
16487262|NCT03379948||Group 1 with central venous line|lab investigation Complete blood count blood culture
16487263|NCT03379948||Group 2 with only peripheral line|lab investigation Complete blood count blood culture
16487264|NCT03379935||Bipolar radial head arthroplasty|Patients treated with bipolar head arthroplasty due to radial head fracture
16487265|NCT03379935||Unipolar radial head arthroplasty|Patients treated with unipolar head arthroplasty due to radial head fracture
16488207|NCT03373526|Experimental|Combined Physical Training|Inspiratory Muscle Training Aerobic Training
16487266|NCT03379922|Experimental|Stress balls|The first arm will be given stress balls to squeeze during their treatment and will also receive standard care (the offer of oral analgesia)
16487267|NCT03379922|Experimental|Headphones|The second arm will be given headphones to listen to music during their treatment and will also receive standard care.
16487268|NCT03379922|No Intervention|Control|The control group will receive standard care (the offer of oral analgesia)
16487269|NCT03379909|Experimental|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
16487270|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
16487271|NCT03379896||Control|Age-matched healthy control
16487272|NCT03379883|Placebo Comparator|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
16487273|NCT03379883|Experimental|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
16487274|NCT03379870|Experimental|Arm 1|"Subjects who receive a CI and present with a post-operative LFPTA of ≤ 75 dB HL.
~Electric Acoustic Speech Processor: EAS fitting. They will be evaluated in the EAS condition and the hearing aid (HA) alone condition."
16487275|NCT03379870|Experimental|Arm 2|"Subjects with pre-operative low frequency hearing who receive a CI and present with a post-operative LFPTA of > 75 dB HL.
~Electric Acoustic Speech Processor: Electric only fitting They will be evaluated in the traditional fully electric condition only."
16487276|NCT03379857|Other|Cannabis User|
16487277|NCT03379844|Experimental|Holmium-166 radioembolization|
16487278|NCT03379818|Experimental|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
16487279|NCT03379818|Experimental|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
16487280|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
16487281|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
16487282|NCT03379792|Active Comparator|Lean T1D|
16487283|NCT03379792|Active Comparator|Obese T1D|
16487284|NCT03379792|Active Comparator|Non-diabetic|
16487285|NCT03379779||Pneumonia patient with respiratory failure|Sputum and stool sampling day 1, 3 and 7 after enrolling into study
16487286|NCT03379766|Experimental|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
16487287|NCT03379766|Active Comparator|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
16487288|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
16487289|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
16487290|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :
~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
16487291|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :
~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
16487293|NCT03379714||Patients with ruptured or unruptured intracranial aneurysms|
16487294|NCT03379701||CRSwPolyps with no Eosonophilia|CRS patients with nasal polyposis, and no eosonophilia.
16487295|NCT03379701||CRSwPolyps with Eosonopholia|CRS patients with nasal polyposis and eosonophilia.
16487296|NCT03379701||CRS without Polyps|Patients with chronic rhinosinusitis and no nasalpolyposis.
16487297|NCT03379701||PCD|Patients with Primrary ciliary dyskinesia .
16487298|NCT03379701||AFRS|Patients with allergic fungal rhinosinusitis.
16487299|NCT03379701||allergic rhinitis|Patients with allergic rhinitis
16487300|NCT03379701||Control|Healthy subjects.
16487301|NCT03379688||Cardiac surgery patients|Patients undergoing cardiac surgery at Charité Campus Mitte
16487302|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
16487303|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
16487304|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
16487305|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
16487306|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
16487307|NCT03379649|Experimental|PRP|Patient with recurrent implantation failure who receives intrauterine infusion of platelet rich plasma
16487308|NCT03379649|Placebo Comparator|Placebo|Patient with recurrent implantation failure who receives intrauterine infusion of embryo culture media
16487309|NCT03379636|No Intervention|no tape|tests are realised without any shoulder tape
16487310|NCT03379636|Experimental|kinesiotape|tests are realised with a kinesiotape applied according to Dr Kase model, over the deltoid muscle and over the acromioclavicular joint
16487311|NCT03379636|Sham Comparator|sham tape|tests are realised with a sham tape, applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area
16487312|NCT03379623|Experimental|Intervention group|
16487313|NCT03379623|No Intervention|Usual care group|
16487314|NCT03379597|Experimental|Probiotics Group|"Probiotics add-on treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0*10^7 CFU.
~Bifico: 840mg Bid."
16487315|NCT03379597|No Intervention|Control Group|No probiotics or dietary fiber group.
16487316|NCT03379597|Experimental|Dietary fiber Group|Prebiotics add-on treatment: dietary fibers compound powder, 30g bid
16487317|NCT03379597|Experimental|Dietary fiber Probiotics group|Dietary fiber and probiotics group: receiving both Bifico 840mg Bid and dietary fiber 30g bid.
16487318|NCT03379584|Experimental|SGN-CD48A|SGN-CD48A
16487319|NCT03379558||Cohort 1 : alirocumab exposed|Pregnant women diagnosed with primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and exposed to alirocumab during the current pregnancy.
16487320|NCT03379558||Cohort 2 : disease matched comparison|Pregnant women diagnosed of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and unexposed to alirocumab during the current pregnancy.
16487321|NCT03379558||Cohort 3 : non disease comparison|Healthy pregnant women who do not have a known diagnosis of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and have no known exposure to a known human teratogen.
16487322|NCT03379545|Other|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
16487323|NCT03379532|Active Comparator|BCI-NMES|Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.
16487324|NCT03379532|Sham Comparator|Sham-NMES|Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.
16487325|NCT03379519|Experimental|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
16487326|NCT03379519|Active Comparator|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
16487327|NCT03379506|Experimental|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
16487328|NCT03379493|Experimental|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
16487329|NCT03379480|Active Comparator|Yoga arm|Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.
16487330|NCT03379480|No Intervention|Control arm|Healthy volunteers who will not receive yoga.
16487331|NCT03379467|Experimental|SMS Reminder|"Single SMS at each of the following times:
~3 days before immunization
~1 day before immunization
~Day of immunization"
16487332|NCT03379467|Experimental|Interactive Reminder|"Single SMS at each of the following times:
~3 days before immunization
~1 day before immunization
~Day of immunization On the day of immunization, study participants are required to respond back through SMS notifying us that child got vaccinated or if not, the reason for delay in immunization. In case of no response, 2 additional reminders will be sent at:
~1 day after scheduled immunization date
~1 week after scheduled immunization date"
16487333|NCT03379467|No Intervention|Control|Subjects in this arm will not receive any intervention
16487334|NCT03379441|Experimental|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:
~PD,
~unacceptable toxicity,
~investigator choice,
~patients IC withdrawal,
~up to a maximum of 24 months (35 administrations) Experimental"
16487335|NCT03379441|No Intervention|Observation|
16487336|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
16487337|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
16487338|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
16487339|NCT03379428|Experimental|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
16487340|NCT03379415|Experimental|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
16487341|NCT03379415|Experimental|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
16487342|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
16487343|NCT03379389|Experimental|Methenamine + Methylthioninium|Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
16487371|NCT03379142|Other|Behavioral: Faith-Based messages|We will send faith-based messages one week prior to Ramadan and twice a day during Ramadan.
16488320|NCT03372772|No Intervention|Control group|Control group - patients with only levothyroxine therapy
16487344|NCT03379389|Active Comparator|Methenamine+Methylthioninium+Acriflavine+Atropa belladona|Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
16487345|NCT03379376|Experimental|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
16487346|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
16487347|NCT03379350|Experimental|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
16487348|NCT03379350|No Intervention|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
16487349|NCT03379337|Experimental|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
16487350|NCT03379324|Active Comparator|Superiority of augmented repairs|Assess pain, function, and structural integrity of the rotator cuff at 3 months, 6 months, 1 year, and 2 years post-operation
16487351|NCT03379324|Active Comparator|Fat degeneration of supraspinatus muscle|MRI assessment the quantity and disposition of fat within the supraspinatus muscle body compared to pre-operation MRI, at 1 year and 2 years post-operation
16487352|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
16487353|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
16487354|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
16487355|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
16487356|NCT03379233|Active Comparator|Usual Care|Concept2 inhaler
16487357|NCT03379233|Experimental|Telehealth|Concept2 inhaler with patient application
16487358|NCT03379220||Subdural ECoG (Group 1)|For patients who require craniotomy to treat TBI, a subdural electrode strip will be placed intraoperatively following evacuation of a hematoma or contusion, as required. Electrode strips will be used for subsequent electrocorticography (ECoG) during intensive care. Patients will also undergo continuous scalp EEG monitoring.
16487359|NCT03379220||Burr Hole ECoG (Group 2)|For patients who do not require surgery but do require invasive monitoring, an intraparenchymal ECoG electrode array will be placed through a cranial burr hole. Depending on other monitoring needs, the location of injuries, and other clinical considerations, the burr hole may be the same as used for placement of other probes or may be separate. In cases of focal injury, the burr hole will be placed to allow electrode targeting to a lobe with significant primary lesion(s). Patients will also undergo continuous scalp EEG monitoring.
16487360|NCT03379220||EEG (Groups 1-3)|Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
16487361|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.
~Interventions:
~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 1, 7, and every week during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 1, 7, and and every week during ICU stay
~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
16487362|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.
~Interventions:
~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,
~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
16487363|NCT03379194|Experimental|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
16487364|NCT03379194|No Intervention|Control|No intervention
16487365|NCT03379181|Experimental|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
16487366|NCT03379168|Placebo Comparator|Placebo Injection|Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.
16487367|NCT03379168|Active Comparator|Corticosteroid Injection|Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.
16487368|NCT03379168|Experimental|Lipogems Injection|Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste.
16487369|NCT03379155|Experimental|Active Group|Internet-based self-help
16487370|NCT03379155|No Intervention|Waiting List Group|
16487372|NCT03379103|Active Comparator|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
16487373|NCT03379103|Placebo Comparator|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
16487374|NCT03379077|Experimental|LTP Plus Supported Implementation|LTP Plus Supported Implementation group participants will receive intervention by trained LHWs of HANDS, co-facilitated and supervised by senior trained PILL researchers, expert in delivering LTP plus intervention
16487375|NCT03379077|Active Comparator|LTP Plus|Participants in LTP Plus arm will receive LTP plus intervention by trained LHWs of Health and Nutrition Development Society (HANDS).
16487376|NCT03379064|Experimental|culturally adapted Cognitive Behavior Therapy|We will use The STreSS CBT manual developed by Schroder and his colleagues
16487377|NCT03379064|No Intervention|Treatment As Usual|The Treatment As Usual (TAU) group will receive regular treatment they have been receiving already as prescribed by the physician.
16487378|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
16487379|NCT03379051|Experimental|Ublituximab + Umbralisib + Lenalidomide|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days
16487380|NCT03379038|Experimental|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.
~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
16487381|NCT03379038|Placebo Comparator|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).
~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
16487382|NCT03379025|Experimental|Early Intervention Group|JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
16487383|NCT03379025|Other|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
16487384|NCT03379012|Experimental|Testosterone and Targeted therapy|Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)
16487385|NCT03379012|Active Comparator|Control|Targeted therapy (sunitinib or pazopanib) only
16487386|NCT03378999|Placebo Comparator|Control|Placebo capsules containing microcrystalline cellulose
16487387|NCT03378999|Experimental|Rhodospirillum rubrum 0.25 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day
16487388|NCT03378999|Experimental|Rhodospirillum rubrum 0.5 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day
16487389|NCT03378999|Experimental|Rhodospirillum rubrum 1.0 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day
16487390|NCT03378986||Unilateral THA|Patients who underwent to unilateral total hip arthroplasty
16487391|NCT03378986||Bilateral THA|Patients who underwent to simultaneous bilateral total hip arthroplasty
16487392|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
16487393|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
16487394|NCT03378960|Other|omeprazole|omeprazole 20 mg
16487395|NCT03378934|Experimental|Berberine Arm|In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
16487396|NCT03378934|Active Comparator|Control Arm|In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
16487397|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
16487398|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
16487399|NCT03378908|No Intervention|Conventional Treatment 6 meals|Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
16487400|NCT03378908|Experimental|Intervention Treatment 3 meals|Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
16487401|NCT03378895|Experimental|adults aged 35 to 55 years|
16487402|NCT03378817|Active Comparator|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
16487403|NCT03378817|Experimental|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
16487404|NCT03378804|Experimental|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:
~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
16487405|NCT03378804|Active Comparator|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:
~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
16487406|NCT03378791|Experimental|Group A|Iron bisglycinate (27mg of elemental iron)
16487407|NCT03378791|Active Comparator|Group B|Ferrous fumarate (115mg of elemental iron)
16487408|NCT03378778||Less than 33% Tooth Structure remaining|Root canal treatment followed by CAD CAM restoration
16487409|NCT03378778||33%-50% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
16487410|NCT03378778||50% -66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
16487411|NCT03378778||More than 66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
16487412|NCT03378765||African origin adults|African origin adults from Ghana, Jamaica, Seychelles, South Africa and USA between the ages of 30- 50.
16487413|NCT03378752||Atelectasis formation using HFJV|Computed tomography scans are performed every 15 minute during the first 45 minutes during general anaesthesia using high frequency jet ventilation.
16487414|NCT03378726|Experimental|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
16487415|NCT03378726|Experimental|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
16487416|NCT03378726|Experimental|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
16487417|NCT03378713|Experimental|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
16487418|NCT03378713|Active Comparator|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
16487419|NCT03378713|Active Comparator|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
16487420|NCT03378700|Experimental|Brief Hope Intervention Group|In addition to the pre-dialysis educational programme on self-care and treatment options for ESRF patients as per the control group, brief hope intervention will be offered: a four-weeks individual intervention. Two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between. A booklet modified from the goal worksheet in Lopez et al. (2000) will be prepared for the participants for reviewing their planned goals, recording achieved targets and successful experiences.
16487421|NCT03378700|Active Comparator|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
16487422|NCT03378687||status epileptius|Cases were patients 29 days to 18 years who were diagnosed with status epileptius in 35 hospitals in China between January 1， 2013 and December 31，2015.
16487423|NCT03378674|Experimental|Group A|remifentanil infusion of 0,15 mcg/Kg/min
16487424|NCT03378674|Active Comparator|Group B|remifentanil infusion of 0,3 mcg/Kg/min
16487425|NCT03378661|Experimental|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
16487426|NCT03378661|Experimental|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
16487427|NCT03378661|Experimental|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
16487428|NCT03378661|Experimental|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
16487429|NCT03378661|Experimental|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.
~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
16487537|NCT03377868|Other|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
16487430|NCT03378661|Experimental|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks
~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
16487431|NCT03378661|Placebo Comparator|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
16487432|NCT03378648|Experimental|CHF6366 active|
16487433|NCT03378648|Placebo Comparator|CHF6366|
16487434|NCT03378648|Active Comparator|Comparator|
16487435|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
16487436|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
16487437|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
16487438|NCT03378622|Experimental|Anchor|Anchor used for mesh attachment
16487439|NCT03378622|Active Comparator|Suture|Suture used for mesh attachment
16487440|NCT03378609|Other|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
16487441|NCT03378596|Experimental|L-citrulline & L-arginine|L-citrulline (6 grams) L-arginine (8 grams)
16487442|NCT03378596|Active Comparator|L-citrulline & Placebo|L-citrulline (6 grams) Placebo (6 grams)
16487443|NCT03378596|Active Comparator|L-arginine & Placebo|L-arginine (8 grams) Placebo (6 grams)
16487444|NCT03378596|Active Comparator|Placebo|Placebo (6 grams)
16487445|NCT03378583||control,|control normal ventilation
16487446|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
16487447|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
16487448|NCT03378570|Active Comparator|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
16487449|NCT03378570|Active Comparator|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
16487450|NCT03378544|Experimental|Experimental arm|Patients with suicidal ideation and depression will receive psychosocial interventions adapted from the WHO mental health Global Action Programme Intervention Guide (mhGAP-IG). The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity.
16487451|NCT03378544|No Intervention|Control group|Patients with suicidal ideation and depression will be trained on how to refer patients suffering from depression, using a referral note to the nearest health centre for further treatment
16487452|NCT03378531|Experimental|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 4 years.
16487453|NCT03378505|Experimental|Mobile App|Half of the students randomly assigned
16487454|NCT03378505|Experimental|Reflection|Half of the students randomly assigned
16487455|NCT03378492|Active Comparator|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
16487456|NCT03378492|Experimental|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
16487457|NCT03378479|Other|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
16487458|NCT03378479|Other|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
16487459|NCT03378466|Experimental|Unfractionated Heparin (UFH)|UFH initiated at 18 IU/kg/hr
16487460|NCT03378466|Other|Venous thromboprophylaxis (VTE)|as per local standard
16487461|NCT03378453|Other|NarCo|Narcolepsy type 1 over 65 years old
16487462|NCT03378453|Other|CoS|Cognitevement healthy controls
16487463|NCT03378427|Experimental|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (>= 6 weeks) tedizolid treatment given orally.
16487464|NCT03378414|Experimental|Intravenous infusion group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
16487465|NCT03378414|Experimental|Intrathecal injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
16487466|NCT03378414|No Intervention|Control groups|No intervention
16487467|NCT03378401|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
16487468|NCT03378401|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
16487469|NCT03378388||Vedolizumab|Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments without exclusion except participant refusal, and were potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.
16487470|NCT03378362|Experimental|Partial denervation of the wrist joint|Patients will be operated with a partial denervation of the wrist through a single dorsal approach.
16487471|NCT03378349|Experimental|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
16487538|NCT03377868|Other|Control|Parallel cohort of healthy age and sex matched subjects
16487539|NCT03377855|Experimental|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
16487472|NCT03378349|Placebo Comparator|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
16487473|NCT03378336||Observational Group|This is an observational study with only one group/cohort with no intervention
16487474|NCT03378323|Active Comparator|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
16487475|NCT03378323|Experimental|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
16487476|NCT03378310|Experimental|Reference tablet followed by BMS-986205 tablet with free base|BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2).
16487477|NCT03378310|Experimental|BMS-986205 tablet with free base followed by reference tablet|BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2).
16487478|NCT03378297|No Intervention|Feasibility study cohort|
16487479|NCT03378297|Experimental|Metformin|850 mg
16487480|NCT03378297|Experimental|Acetylsalicylic acid|160 mg
16487481|NCT03378297|Experimental|Olaparib|300 mg x 2
16487482|NCT03378297|Experimental|Letrozol|2.5 mg
16487483|NCT03378284|Experimental|Tegoprazan(Test drug)|Tegoprazan drug QD for 7 days
16487484|NCT03378284|Active Comparator|Active comparator drug|Active comparator drug QD for 7 days
16487485|NCT03378271|Experimental|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.
~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
16487486|NCT03378245|Experimental|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
16487487|NCT03378232|Placebo Comparator|Placebo Olive Oil|Placebo supplement with olive oil
16487488|NCT03378232|Experimental|High EPA Supplement|Supplements providing up to 3g per day of Omega-3, with increased EPA
16487489|NCT03378232|Experimental|High DHA Supplement|Supplements providing up to 3g per day of Omega-3, with increased DHA
16487490|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
16487491|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
16487492|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
16487493|NCT03378206|Experimental|Hinged 8-figure plate|Hinged 8-figure plate is a novel devise that has modifications in order to improve the treatment effect of conventional 8-figure plate. This arm will be used to verify the effectiveness and feasibility of the modification.
16487494|NCT03378206|Active Comparator|conventional 8-figure plate|Conventional 8-figure plate is widespread method to treat genu varum and valgus. This arm, as a comparator, will be the control group to verify the feasibility of the novel hinged 8-figure plate.
16487495|NCT03378167|Experimental|MICROBIOTA|Patients randomized to the INTERVENTION arm will receive a baseline fecal microbiota transplant (FMT) colonoscopic infusion at Week 0, followed by twice-weekly oral microbiota capsule (OMC) therapy for 6 weeks (including Week 0). (n = 30)
16487496|NCT03378167|Placebo Comparator|PLACEBO|Patients randomized to the CONTROL arm will receive a baseline normal saline (NS) colonoscopic infusion at Week 0, followed by twice-weekly dextrose-containing oral placebo capsule (OPC) therapy for 6 weeks (including Week 0). (n = 15)
16487497|NCT03378154|Experimental|Tracheal Intubation in infants using Macintosh laryngoscopes|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the Macintosh laryngoscope
16487498|NCT03378154|Experimental|Tracheal Intubation in infants using King vision|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the King vision videolaryngoscope
16487499|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
16487500|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive arm only receives standard MNCH services
16487501|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
16487502|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.
~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10^3- 2 x 10^5 per kg of recipient weight."
16487503|NCT03378089|Experimental|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
16487504|NCT03378089|Active Comparator|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
16487505|NCT03378076|Experimental|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
16487506|NCT03378076|Active Comparator|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
16487507|NCT03378063|Experimental|transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be given to the infants with BPD.
16487508|NCT03378063|Active Comparator|no transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be not given to the infants with BPD.
16487509|NCT03378050|Experimental|Intervention group|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages."
16487510|NCT03378050|Active Comparator|Control group|"Participants is the control group will be placed on a waiting list for 12 weeks. They will receive the intervention, after they complete the 12-week follow-up assessment. Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
16487511|NCT03378037|Experimental|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
16487512|NCT03378037|Sham Comparator|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
16487513|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).
~And follow up for 3 years to identify of the correlation with PAD outcome."
16487514|NCT03378011|Active Comparator|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
16487515|NCT03378011|Active Comparator|Topical PUVA|Topical PUVA in acral vitiligo
16487516|NCT03377998|Experimental|vitiligo patients|lesional skin biopsy to measure ERDR1 level
16487517|NCT03377998|Experimental|controls|normal skin biopsy to measure ERDR1 level
16487518|NCT03377985|Active Comparator|axillary brachial plexus block group|Patients placed in the supine position with arm to be blocked abducted and externally rotated. After sterilization of the axilla ultrasound device with high frequency of 8-12 MHZ, linear transducer was put parallel to the anterior axillary fold at axilla to identify the axillary artery, lateral, medial and posterior cords of the brachial plexus in relation to the axillary artery. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, 7-10 ml of bupivacaine 0.5% was injected around each cord of the brachial plexus
16487519|NCT03377985|Active Comparator|supraclavicular brachial plexus block group|patients placed in the supine position with the head of the bed elevated 30 degrees and patient's head turned away from the side to be blocked after skin disinfection, ultrasound device was put transversely parallel to and above the middle third of the clavicle, the probe was tilted till identification of the subclavian artery, 1st rib, pleura and brachial plexus lateral to the subclavian artery and above the 1st rib. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the lateral side of the probe. A needle was inserted in plane 1 cm lateral to the probe when adjacent to brachial plexus 25 ml of bubivacaine 0.5% was injected around the brachial plexus
16487520|NCT03377972||WHO diagnostic standard|
16487521|NCT03377972||Japan diagnostic standard|
16487522|NCT03377959|Experimental|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
16487523|NCT03377959|Other|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
16487524|NCT03377946|Experimental|probiotics on type 2 diabetes|take probiotics
16487525|NCT03377946|Experimental|probiotics on pre-diabetes|take probiotics
16487526|NCT03377946|Placebo Comparator|placebo on type 2 diabetes|take placebo
16487527|NCT03377946|Placebo Comparator|placebo on pre-diabetes|take placebo
16487528|NCT03377933|Experimental|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
16487529|NCT03377920|Experimental|Severe asthma patients; COPD patients|Cross sectional study Lung function measurement
16487530|NCT03377907|Active Comparator|Ketamine in hematoma block|Ketamine used in hematoma block
16487531|NCT03377907|Active Comparator|ketamine intravenous anesthesia|ketamine used in local intravenous anesthesia
16487532|NCT03377907|Active Comparator|lidocaine intravenous anesthesia|2.5 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
16487533|NCT03377894|Active Comparator|• Group (A) blunt incision|"100 primigravidas at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy.
~undergoing blunt uterine incision expansion"
16487534|NCT03377894|Active Comparator|• Group (B) sharp incision|100 primigravidas, at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy undergoing sharp uterine incision expansion
16487535|NCT03377881|Other|Traditional|The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed.
16487536|NCT03377881|Experimental|STHLM3+MRI/Fusion|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.
16487540|NCT03377842|Active Comparator|FOLFOX regimen|FOLFOX regime alone.
16487542|NCT03377829|Experimental|Percutaneous laser ablation(PLA)|Eligible participants with PTMC will be randomly assigned to this group and undergo percutaneous laser ablation(PLA). All the process is under the detection of real-time ultrasound.After surgery, all the patients will accept contrast-enhanced ultrasound(CEUS), regular ultrasound follow-up, thyroid functional detection, fine-needle aspiration biopsy(FNAB), neck CT.Per and post-operative complications, need of drug treatment, length of hospital admission and customer satisfaction will be registered.
16487543|NCT03377829|Active Comparator|Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/subtotal thyroid surgery.
16487544|NCT03377816|Experimental|Art Therapy|The AT intervention is an 8-week group intervention comprised of 8 1.5 hour weekly sessions conducted by an experienced Art Therapist who received special training in conducting the treatment protocol as designed.
16487545|NCT03377816|Sham Comparator|Mandala group|The comparison group will color prefabricated shapes. The same art materials as in the intervention group will be on the table as will the same instrumental music.
16487546|NCT03377803|Active Comparator|VP-102|VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
16487547|NCT03377803|Placebo Comparator|Placebo|Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
16487548|NCT03377790|Active Comparator|VP-102|VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
16487549|NCT03377790|Placebo Comparator|Placebo|Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
16487550|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
16487551|NCT03377764||Landmark Technique|Control group
16487552|NCT03377764||Ultrasound guided technique|Neuroaxial block using Ultrasound guidance
16487553|NCT03377751|Experimental|Additional posterior wall isolation|Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
16487554|NCT03377751|Experimental|Voltage-guided substrate homogenization|Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
16487555|NCT03377751|Active Comparator|PVI only group|Operator will perform PVI only
16487556|NCT03377738|No Intervention|anti-smoking therapy|All patients will be given only an intervention for tobacco cessation which will depend on the individual's cessation phase
16487557|NCT03377738|Experimental|anti-smoking therapy + spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase. In addition, in this group will be given a spirometry test as a motivational element for dishabituation.
16487558|NCT03377725|Experimental|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
16487559|NCT03377725|Active Comparator|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
16487560|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
16487561|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
16487562|NCT03377699|Experimental|Insulin Degludec|Insulin Degludec once daily and Insulin Aspart 2-4 times daily
16487563|NCT03377699|Active Comparator|Insulin Determir|Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily
16487564|NCT03377686||Asthma|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with doctor's diagnosed asthma
16487565|NCT03377686||Cystic fibrosis|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with CF
16487566|NCT03377686||Healthy|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years old without respiratory diseases
16487567|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
16487568|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
16487569|NCT03377647|Active Comparator|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
16487570|NCT03377647|Active Comparator|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
16487571|NCT03377647|Active Comparator|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
16487572|NCT03377634|Experimental|Intervention|Participants receive the MORPH intervention.
16487573|NCT03377634|No Intervention|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
16487574|NCT03377621|Experimental|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
16487575|NCT03377608||Depo-Provera|
16487576|NCT03377608||Non-hormonal contraception|
16487577|NCT03377595|Experimental|TAP (Transversus Abdominis Plane) block|20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.
16487578|NCT03377595|Experimental|Wound infiltration|20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.
16487579|NCT03377582|Active Comparator|Conventional therapy|Exercise-based cardiac rehabilitation
16487580|NCT03377582|Experimental|Virtual reality based therapy|Exercise-based virtual reality
16487581|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
16487582|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
16487583|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
16487584|NCT03377556|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16487585|NCT03377543|Experimental|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
16487586|NCT03377543|Experimental|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
16487587|NCT03377543|Experimental|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
16487588|NCT03377530||Premature neonates infected with bacillus Species|The investigators studied retrospectively eleven cases of these infections in our NICU and reviewed series and report cases in literature.
16487589|NCT03377517|Experimental|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
16487590|NCT03377504|Experimental|mirror group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. Mirror therapy will be applied to the mirror group for 30 minutes per day in addition to this routine treatment.
16487591|NCT03377504|Active Comparator|control group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. A total of 20 sessions of treatment will be given to each patient.
16487592|NCT03377491|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with gemcitabine and nab-Paclitaxel
16487593|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
16487594|NCT03377478|Experimental|Lung Transplant|Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
16487595|NCT03377465|Experimental|Experimental Group|Patients with stroke of undetermined cause age 18-65
16487596|NCT03377465|Active Comparator|Comparative group|Healthy patients age 18-65
16487597|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
16487598|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
16487599|NCT03377439||Group A|Participants with platelet counts <32×10^9/L.
16487600|NCT03377439||Group B|Participants with platelet counts between 32×10^9/L and 132×10^9/L.
16487601|NCT03377439||Group C|Participants with platelet counts >132×10^9/L.
16487602|NCT03377426|Experimental|LYS228|IV infusion
16487603|NCT03377426|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
16487604|NCT03377400|Experimental|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
16487605|NCT03377387|Experimental|capecitabine 7/7 with neratinib|"In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).
~The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine."
16487606|NCT03377374|Experimental|Probiotic|L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10^8 Colony Forming Units (CFU)
16487607|NCT03377374|Placebo Comparator|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
16487608|NCT03377361|Experimental|Part 1 Cohort 1 3rd Line (3L): nivolumab + trametinib|
16487609|NCT03377361|Experimental|Part 1A Cohort 2 2nd Line (2L): nivolumab + ipilimumab + trametinib|
16487610|NCT03377361|Experimental|Part 1A Cohort 3 (2L): nivolumab + ipilimumab + trametinib|
16487611|NCT03377361|Experimental|Part 2 Cohort 4 (3L): nivolumab + ipilimumab + trametinib|
16487612|NCT03377361|Experimental|Part 2 Cohort 5 (3L): Regorafenib|
16487613|NCT03377361|Experimental|Part 1B Cohort 6 (2L): nivolumab + ipilimumab + trametinib|
16487614|NCT03377348|Other|subconjunctival injection of triamcinolone acetonide|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
16487615|NCT03377335|Experimental|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).
~The total duration of treatment is 6 months."
16487616|NCT03377335|Placebo Comparator|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).
~The total duration of treatment is 6 months."
16487617|NCT03377322|Active Comparator|Treatment|Probiotics capsules
16487618|NCT03377322|Placebo Comparator|Placebo|Placebo capsules containing maltodextrin
16487619|NCT03377309|Experimental|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
16487620|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
16487621|NCT03377283|Active Comparator|AP-KTx/LTx|Transplant recipients receiving an rATG-perfused kidney or liver
16487622|NCT03377283|Placebo Comparator|CP-KTx/LTx|Transplant recipients receiving a control-perfused kidney or liver.
16487623|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
16487624|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
16487627|NCT03377257|Experimental|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
16487628|NCT03377244|Experimental|HBHS|Participants in the Healthy Bodies Healthy Souls (HBHS) arm received the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) with the addition of church-level policy changes to support the individual behavioral intervention of the WORD DPP. The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
16487629|NCT03377244|Active Comparator|HBHS Policy|Participants in the HBHS Policy arm included members of churches enrolled in the HBHS study who did not receive the WORD DPP intervention (ie, these participants were exposed to only the church-level policy changes). Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
16487630|NCT03377244|Other|WORD DPP|Participants in the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) arm included participants enrolled in a separate DPP study without the church-level policy changes (ie, these participants received only the WORD DPP intervention). The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length.
16487631|NCT03377231|Experimental|Prevention|
16487632|NCT03377231|Experimental|Treatment|
16487633|NCT03377218|No Intervention|Control|Without additional iodine supplementation.
16487634|NCT03377218|Experimental|Iodine|Receiving iodine.
16487635|NCT03377218|Experimental|Iodine + Selenium|Receiving iodine and selenium.
16487636|NCT03377205|Active Comparator|Plate|Compression screws and neutralization plate.
16487637|NCT03377205|Experimental|Intramedullary nail|Acumed Fibular Rod System
16487638|NCT03377179|Experimental|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
16487639|NCT03377166|Active Comparator|Vertigo|Participants with vestibular disorder
16487640|NCT03377166|Active Comparator|Control|Participants without vestibular disorder
16487641|NCT03377153|Active Comparator|Hesperidin and Flaxseed|
16487642|NCT03377153|Placebo Comparator|control|
16487643|NCT03377140|Active Comparator|Hesperidin|2 capsuls of Hesperidin
16487644|NCT03377140|Placebo Comparator|control|2 capsuls of placebo
16487645|NCT03377127|Active Comparator|Standard of Care (SOC)|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
16487646|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
16487647|NCT03377114|Active Comparator|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
16487648|NCT03377114|Experimental|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
16487649|NCT03377101|Active Comparator|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
16487650|NCT03377101|Experimental|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
16487651|NCT03377088|Placebo Comparator|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
16487652|NCT03377088|Experimental|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
16487653|NCT03377075||Healthy subjects|
16487654|NCT03377062||EEG monitoring|Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness
16487674|NCT03376932|Active Comparator|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
16487675|NCT03376919|Experimental|CLs++|CLs ++ gait training
16487655|NCT03377049|Experimental|Acetazolamide Challenge|Participants entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
16487656|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
16487657|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
16487658|NCT03377023|Experimental|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.
~Nivolumab: 3 mg/kg IV Q2 weeks.
~Ipilimumab: 1 mg/kg Q6 weeks.
~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg).
~Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg)
~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).
~Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg).
~Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg)."
16487659|NCT03377023|Active Comparator|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.
~Nivolumab + Ipilimumab + Nintedanib at RP2D."
16487660|NCT03377023|Active Comparator|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.
~Nivolumab + Ipilimumab + Nintedanib at RP2D."
16487661|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
16487662|NCT03376997|Experimental|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
16487663|NCT03376997|Experimental|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
16487664|NCT03376997|Experimental|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
16487665|NCT03376984|Active Comparator|Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. For all the patients into the control arm of the study, the root canals will be filled with gutta percha (current standard of care), using the vertical condensation obturation technique (standard of care RCT technique).
16487666|NCT03376984|Experimental|ND and Amox modified Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, gutta percha modified with nanodiamonds and amoxicillin (NDGX) will be used for the middle and coronal thirds.
16487667|NCT03376971|Experimental|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
16487668|NCT03376958|Experimental|Apatinib|Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
16487669|NCT03376945||trail cohort|n-3 FAs
16487670|NCT03376945||control cohort|Structolipid
16487671|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
16487672|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
16487673|NCT03376932|Active Comparator|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
16487708|NCT03376815||lung cancer,traditional sample method|Samples from 100 patients with lung cancer were obtained by traditional sampling method.
16487989|NCT03375008|Experimental|Imaging diagnostic and biopsy|47 subjects who are suspected NASH from June 2016 to December 2017.
16487676|NCT03376906|Experimental|Obese Subjetcs|The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions (HIIE 1, HIIE 3 and Control) in a random order, which were performed with a 96 h interval between them.
16487677|NCT03376893||SCA with overt stroke|Participants have sickle cell disease and a history of overt stroke.
16487678|NCT03376893||SCA with silent stroke|Participants have sickle cell disease and a history of silent stroke.
16487679|NCT03376893||SCA with no stroke|Participants have sickle cell disease and no history of stroke.
16487680|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
16487681|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
16487682|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
16487683|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
16487684|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
16487685|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
16487686|NCT03376867||Healthy volunteers|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
16487687|NCT03376867||Volunteers with chronic pain|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
16487688|NCT03376854|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
16487689|NCT03376854|Active Comparator|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
16487690|NCT03376841|Experimental|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
16487691|NCT03376841|Experimental|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
16487692|NCT03376828|Active Comparator|Hypertensive T group|Hypertensive T group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) Macintosh laryngoscopy using intubated
16487693|NCT03376828|Active Comparator|Hypertensive VL group|Hypertensive VL group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) C-Mac Videolaryngoscope using intubated
16487694|NCT03376828|Sham Comparator|Non-hypertensive T group|Non-hypertensive T group: (Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg) Macintosh laryngoscopy using intubated
16487695|NCT03376828|Sham Comparator|Non-hypertensive VL group|Non-hypertensive VL group: Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg C-Mac Videolaryngoscope using intubated
16487696|NCT03376815||prostate ,traditional sample method|Samples from 100 patients with prostate carcinoma were obtained by traditional sampling method
16487697|NCT03376815||prostate ,landscape sample method|Samples from 100 patients with prostate carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487698|NCT03376815||liver, traditional sample method|Samples from 100 patients with liver cancer were obtained by traditional sampling method.
16487699|NCT03376815||liver,landscape sample method|Samples from 100 patients with liver cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487700|NCT03376815||esophageal ,traditional sample method|Samples from 100 patients with esophageal carcinoma were obtained by traditional sampling method.
16487701|NCT03376815||esophageal ,landscape sample method|Samples from 100 patients with esophageal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487702|NCT03376815||GIST,traditional sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by traditional sampling method.
16487703|NCT03376815||GIST,landscape sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487704|NCT03376815||colorectal ,traditional sample method|Samples from 100 patients with colorectal carcinoma were obtained by traditional sampling method.
16487705|NCT03376815||colorectal ,landscape sample method|Samples from 100 patients with colorectal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487706|NCT03376815||pancreatic ,traditional sample method|Samples from 100 patients with pancreatic carcinoma were obtained by traditional sampling method.
16487707|NCT03376815||pancreatic,landscape sample method|Samples from 100 patients with pancreatic carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487709|NCT03376815||lung cancer,landscape sample method|Samples from 100 patients with lung cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487710|NCT03376815||Renal ,traditional sample method|Samples from 100 patients with renal carcinoma were obtained by traditional sampling method.
16487711|NCT03376815||Renal carcinoma,landscape sample method|Samples from 100 patients with renal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487712|NCT03376815||Breast cancer,traditional sample method|Samples from 100 patients with breast cancer were obtained by traditional sampling method.
16487713|NCT03376815||Breast cancer,landscape sample method|Samples from 100 patients with breast cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487714|NCT03376815||cervical ,traditional sample method|Samples from 100 patients with cervical carcinoma were obtained by traditional sampling method.
16487715|NCT03376815||cervical ,landscape sample method|Samples from 100 patients with cervical carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
16487716|NCT03376802|Experimental|SAR425899|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 19 days
16487717|NCT03376802|Placebo Comparator|Placebo|Repeated once daily SC doses of placebo administered over 19 days
16487718|NCT03376789|Active Comparator|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
16487719|NCT03376789|Active Comparator|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
16487720|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
16487721|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
16487722|NCT03376763|Experimental|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
16487723|NCT03376763|Experimental|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
16487724|NCT03376750|Experimental|CO - OP via telerehabilitation + standard care|10 CO-OP videoconferencing sessions from an occupational therapist . Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
16487725|NCT03376750|Experimental|CO - OP via face to face + standard care|10 CO - OP face to face sessions from an occupational therapist. Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
16487726|NCT03376750|No Intervention|control group - standard care|standard care as given from public health service
16487727|NCT03376737|Experimental|Apatinib + Pemetrexed|Apatinib + Pemetrexed
16487728|NCT03376724|Experimental|Functional exercise|
16487729|NCT03376724|Active Comparator|Control Group|
16487730|NCT03376711|No Intervention|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
16487731|NCT03376711|Experimental|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
16487732|NCT03376698|Active Comparator|Colchicine 0.5 mg|
16487733|NCT03376698|Active Comparator|Colchicine 0.25 mg|
16487734|NCT03376698|Placebo Comparator|Placebo|
16487735|NCT03376685|Experimental|Endurance Exercise Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
16487736|NCT03376685|Experimental|Sprint Exercise Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
16487737|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
16487738|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
16487739|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
16487740|NCT03376659|Experimental|Phase I - Safety|"MVA-BN-CV301 (prime) - Day 1 and Day 29.
~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.
~Durvalumab - q2 weeks
~Capecitabine - twice a day, Monday - Friday Weekly
~Bevacizumab - q2weeks (colorectal cancer patients only)"
16487741|NCT03376659|Experimental|Phase II - Colorectal Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.
~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.
~Durvalumab - q2 weeks
~Capecitabine - twice a day, Monday - Friday Weekly
~Bevacizumab - q2weeks"
16487742|NCT03376659|Experimental|Phase II - Pancreatic Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.
~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.
~Durvalumab - q2 weeks
~Capecitabine - twice a day, Monday - Friday Weekly"
16487743|NCT03376646|Experimental|Cohort A: Dissolve™|
16487744|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
16487745|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
16487746|NCT03376633|No Intervention|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
16487747|NCT03376633|Experimental|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
16487748|NCT03376620|Sham Comparator|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
16487749|NCT03376620|Active Comparator|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
16487750|NCT03376607|Experimental|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
16487751|NCT03376607|Experimental|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
16487752|NCT03376607|No Intervention|Control group|The control group will receive routine practice.
16487753|NCT03376594|Active Comparator|Benjakul Extract|Benjakul Extract 100 mg capsule by mouth 3 times a day for 42 days
16487754|NCT03376594|Placebo Comparator|Loratadine|Loratadine 10 mg capsule by mouth 3 times a day for 42 days
16487755|NCT03376581|Experimental|Prospective treatment|
16487756|NCT03376568||Narcolepsy with RBD & Control|Narcolepsy with REM sleep disorder lable(20) and Control subjects lable(20)
16487757|NCT03376568||Narcolepsy with /without RBD|Narcolepsy with REM sleep disorder lable(20) and Narcolepsy without REM sleep disorderlable (20)
16487758|NCT03376555|Active Comparator|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
16487759|NCT03376555|Experimental|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
16487760|NCT03376555|Experimental|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
16487761|NCT03376555|Experimental|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
16487762|NCT03376555|Experimental|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
16487763|NCT03376542|Experimental|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
16487764|NCT03376529|Experimental|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
16487765|NCT03376529|Experimental|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
16487766|NCT03376529|Experimental|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
16487767|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
16487768|NCT03376503|Experimental|Pegcyte (Nanogen pegfilgrastim)|pegcyte 6 mg in the first cycle
16487769|NCT03376503|Active Comparator|Neulastim (Roche pegfilgrastim)|Neulastim 6 mg in the first cycle
16487770|NCT03376477|Experimental|Lenalidomide plus GM-CSF Vaccine plus Prevnar13|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.
~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration."
16487771|NCT03376477|Placebo Comparator|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
16487772|NCT03376477|Placebo Comparator|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.
~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline."
16487773|NCT03376464|Experimental|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
16487774|NCT03376464|Experimental|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
16487775|NCT03376451|Other|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
16487776|NCT03376438||Prospective observational cohorts|1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
16487777|NCT03376412|Experimental|Single Arm Treatment.|All patients will be unilaterally implanted in the non-dominant eye with the Raindrop Near Vision Inlay for the compensation of presbyopia.
16487778|NCT03376386|Other|HNSCC receiving (chemo)radiotherapy|Imaging
16487779|NCT03376373|Experimental|active|Neurofeedback for FER
16487780|NCT03376373|No Intervention|control|waiting list
16488208|NCT03373513|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
16487781|NCT03376347|No Intervention|Conventional arm|Institutional Standard of Care with intention to keep MAP> 65 mmHg. The FlotracIQ will be connected, but fully covered.
16487782|NCT03376347|Active Comparator|Treatment arm|FlotracIQ with HPI algorithm.
16487783|NCT03376334|Experimental|Motor Imagery (MI)|Those meeting the inclusion criteria were selected (n=22). Each participant was necessary to complete the Movement Imagery Questionnaire in a quiet room. Finally, each participant assigned a score by using a 7-point scale regarding the ease/difficulty associated with representing each movement mentally. Next their baseline balance measurement was performed using the SEBT. Later this group had 9 motor imagery sessions, each session for 15 minutes, 3 sessions (alternate days) per week for a total of 3 weeks. Reassessment of balance was done after every 3 sessions.
16487784|NCT03376334|No Intervention|Control (C)|Those meeting the inclusion criteria were selected (n=10). Baseline measurement of SEBT was done on day 1, end of week 1, end of week 2 and end of week 3.
16487785|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
16487786|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
16487787|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.
~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
16487788|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter >2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.
~Pain score, withdrawal movement score and hemodynamic response was recorded."
16487789|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
16487790|NCT03376282|Other|HBOT treatment|HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
16487791|NCT03376282|No Intervention|Standard treatment|follow up with the standard recommended treatment
16487792|NCT03376269|Active Comparator|Combined HBOT/psychotherapy|combined concurrent intervention of HBOT and creative art psychotherapy.
16487793|NCT03376269|Other|psychotherapy|single intervention with creative art psychotherapy
16487794|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
16487795|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
16487796|NCT03376243|Experimental|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
16487797|NCT03376243|No Intervention|Control|Only structured parent education
16487798|NCT03376230||Control patients|
16487799|NCT03376230||Crohn's disease patients|
16487800|NCT03376230||Ulcerative colitis patients|
16487801|NCT03376217|No Intervention|Control|IPTp delivered at antenatal clinic
16487802|NCT03376217|Experimental|Intervention|IPTp delivered by HSAs
16487803|NCT03376204||Adult subjets|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
16487804|NCT03376178|Experimental|six-hole group|lidocaine and ropivacaine injection through catheters
16487805|NCT03376178|Active Comparator|end-hole group|lidocaine and ropivacaine injection through catheters
16487806|NCT03376152|Active Comparator|Treatment Arm|"Poverty households invited to attend cluster-level electric kettle promotion events and offered free kettles, information, and promotional materials 450 households in 15 clusters (30 households per cluster)"
16487807|NCT03376152|No Intervention|Control Arm|450 households in 15 clusters (30 households per cluster)
16487808|NCT03376139|Experimental|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
16487809|NCT03376139|Placebo Comparator|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
16487810|NCT03376126||MI-ILP|
16487811|NCT03376113|Experimental|VHS group|Patients will be asked to make links between critical situations and appropriate solutions in the volitional help sheet (VHS).
16487812|NCT03376113|No Intervention|Control group|Patients will be asked to read the VHS. This is an active control group. That means all patients in this study will be exposed to situations and solutions in the VHS.
16487813|NCT03376100|Active Comparator|Control Group|Patients with distal forearm fractures randomized to Hematoma Block.
16487814|NCT03376100|Active Comparator|Intervention Group|Patients with distal forearm fractures randomized to Ultrasound guided nerve block
16487815|NCT03376074|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
16487816|NCT03376074|Active Comparator|Conventional cold storage|
16487817|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
16487818|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
16487819|NCT03376048|Experimental|Wound infiltration plus TAP|Wound infiltration placed by surgeon + TAP-LAP placed laparoscopically guided by surgeon
16487820|NCT03376048|Active Comparator|Wound infiltration|Wound infiltration placed by surgeon
16487821|NCT03376035|Active Comparator|Unilateral breast reconstruction|Temperature measurements are obtained from the reconstructed breast and compared to the non-reconstructed breast.
16487822|NCT03376035|Experimental|Bilateral breast reconstruction|Temperature measurements are obtained from both reconstructed breasts and the core temperature is measured as well for comparison.
16487823|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.
~Interventions:
~Blood sample for serum and plasma biomarkers:
~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
16487824|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
16487825|NCT03375983|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
16487826|NCT03375970|Experimental|Collaborative Care of TCM and Western Medicine|
16487827|NCT03375970|Active Comparator|Western Medicine|
16487828|NCT03375957|Experimental|ATx201 2% Gel|
16487829|NCT03375957|Experimental|ATx201 4% Gel|
16487830|NCT03375957|Placebo Comparator|ATx201 Gel Placebo|
16487831|NCT03375944|No Intervention|control group|Cardiac supervision
16487832|NCT03375944|Other|study group|Cardiac supervision and rehabilitation
16487833|NCT03375931|Experimental|prayer group|
16487834|NCT03375931|Active Comparator|non-prayer group|
16487835|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
16487836|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
16487837|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
16487838|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
16487839|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
16487840|NCT03375905|Experimental|cNEP|cNEP treatment
16487841|NCT03375892|Active Comparator|Prone Position with DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
16487842|NCT03375892|Active Comparator|Supine Position with DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
16487843|NCT03375892|Active Comparator|Prone Position with no DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
16487844|NCT03375892|Active Comparator|Supine Position with no DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
16487845|NCT03375879|Active Comparator|Bandage contact lens|Placing a bandage contact lens in one eye.
16487846|NCT03375879|No Intervention|Sham contact lens (immediate removal)|Sham contact lens will be placed on other eye, placing it and immediately removing it so patient does not know which eye will have a bandage contact lens.
16487847|NCT03375866|Active Comparator|Pretzels|
16487848|NCT03375866|Experimental|Mixed nuts|
16487849|NCT03375853|Active Comparator|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
16487912|NCT03375424||1st subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced Vedolizumab (VDZ) therapy (n=1.800). A former therapy with other biologics is allowed. More than 30% of these Vedolizumab patients will be biologics-naiv.
16487850|NCT03375853|Experimental|Experimental Condition|"Participants will complete computer-based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer-based training, participants will be instructed to respond or inhibit responses to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention. To optimize the intervention, we narrowed the low-calorie food stimulus set to make a better distinction between high-calorie and low-calorie foods and we changed the filler images (water and furry mammals) in the go/no-go task from 100% go to 50% go and 50% no-go to measure learning of stimulus-specific respond associations."
16487851|NCT03375840|Experimental|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
16487852|NCT03375840|Experimental|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
16487853|NCT03375840|Experimental|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
16487854|NCT03375840|Experimental|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
16487855|NCT03375840|Experimental|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
16487856|NCT03375840|Experimental|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
16487857|NCT03375827|Experimental|Survey QOL|"Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.
~Participants will be asked to complete the IGCDG questionnaire prior to their next visit.
~Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
16487858|NCT03375814|Experimental|Experimental group|The group that takes the main drug. They received the conventional treatment group and crocin.
16487859|NCT03375814|Placebo Comparator|Placebo group|The group that takes the Placebo.
16487860|NCT03375801|No Intervention|control group/pre intervention|the first 164 patients will receive care as usual and will make the decision together with their clinician without support of the decision aid. They will be asked to fill out the questionnaires.
16487861|NCT03375801|Experimental|intervention arm|another 164 patients will receive the decision aid as support for the decision making process with their clinician.
16487862|NCT03375788|Experimental|Tesamorelin|tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
16487863|NCT03375788|Placebo Comparator|Placebo|identical placebo given subcutaneously daily
16487864|NCT03375775|Experimental|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
16487865|NCT03375775|Active Comparator|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
16487866|NCT03375762|Experimental|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
16487867|NCT03375762|Sham Comparator|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
16487868|NCT03375749|Experimental|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
16487869|NCT03375749|Other|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
16487870|NCT03375736|Experimental|Intervention arm|Whole body vibration will be provided by an equipment, GalileoTM Med L Plus (Novotech Medical GmbH). The study participant will stand still on the vibration platform with both knees slightly flexed.
16487871|NCT03375723|Experimental|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique
~Information about anatomy
~Information about physiology
~Breathing technique"
16487872|NCT03375723|Active Comparator|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
16487873|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
16487874|NCT03375697|Experimental|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
16487913|NCT03375424||2nd subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti-TNF-alpha therapy other than VDZ (n=350) in biologics-naiv patients.
16488209|NCT03373513|Active Comparator|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
16487875|NCT03375697|Experimental|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
16487876|NCT03375684|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
16487877|NCT03375684|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
16487878|NCT03375671|Experimental|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
16487879|NCT03375671|Active Comparator|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
16487880|NCT03375658|Experimental|Intervention arm|All vital signs registered as part of usual care are used for modelling patients state and trajectories and made available to clinicans via the Patient Deterioration Warning System in nursing and physician offices.
16487881|NCT03375658|No Intervention|Control arm|Usual care
16487882|NCT03375632|Experimental|Uric acid-overproduction Type|
16487883|NCT03375632|Experimental|Uric acid-underexcretion Type|
16487884|NCT03375619||Participants who received CAR-20/19-T cells.|Participants who received CAR-20/19-T cells in study NCT03019055.
16487885|NCT03375606|Experimental|CSL730|
16487886|NCT03375606|Placebo Comparator|Placebo|
16487887|NCT03375593|Experimental|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
16487888|NCT03375593|Experimental|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
16487889|NCT03375580|Placebo Comparator|TLC group|transform life custom (TLC) group
16487890|NCT03375580|Active Comparator|TLC + metformin group|transform life custom (TLC) combined with 0.5g metformin, PO tid
16487891|NCT03375580|Experimental|TLC + CZT capsules group|transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid
16487892|NCT03375580|Active Comparator|TLC + simvastatin group|transform life custom (TLC) combined with 20mg simvastatin, PO qn
16487893|NCT03375567|Experimental|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
16487894|NCT03375567|Active Comparator|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
16487895|NCT03375541|No Intervention|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
16487896|NCT03375541|Experimental|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
16487897|NCT03375528|Experimental|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
16487898|NCT03375515|Experimental|PCA IV Hydromorphone titration|PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.
16487899|NCT03375515|Active Comparator|non-PCA IV Hydromorphone titration|Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
16487900|NCT03375502|Experimental|MG1111(Varicella vaccine)|A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1
16487901|NCT03375502|Active Comparator|Comparator(Varicella vaccine)|A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1
16487902|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment
~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks
~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
16487903|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic
~PC visits will be scheduled on the same day as an oncology visit if possible"
16487904|NCT03375476||Vascular surgical patients|Patients undergoing elective vascular non-cardiac surgery in general anesthesia
16487905|NCT03375463|Experimental|Tirzepatide Test Part A|SC dose of tirzepatide solution formulation
16487906|NCT03375463|Experimental|Tirzepatide Reference Part A|SC dose of tirzepatide lyophilized formulation
16487907|NCT03375463|Experimental|Tirzepatide Formulation Part B|IV dose of tirzepatide formulation
16487908|NCT03375463|Experimental|Tirzepatide Part C|Titrated SC doses of tirzepatide solution formulation
16487909|NCT03375463|Placebo Comparator|Placebo Part C|SC dose of placebo matching tirzepatide dose
16487910|NCT03375450||Observation|Cohort of patients with COPD
16487911|NCT03375437|Experimental|NTRK, ROS and ALK molecular screening|
16487988|NCT03375021|Experimental|Sequence 4 HP|Eligible subjects were randomized to Sequence 2 PH in which they received CX717 800 mg High dose (H) of active treatment followed by crossover to placebo (P)
16487914|NCT03375424||3rd subpopulation|IBD patients (age at enrollment: 18-80 years) with an early disease (n=350), who were first diagnosed <2 years before the start of documentation in the Investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future.
16487915|NCT03375411|Experimental|INC1-Bare metal stent|Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
16487916|NCT03375398|Experimental|3 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™
16487917|NCT03375398|Placebo Comparator|Rice only|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice
16487918|NCT03375398|Experimental|6 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™
16487919|NCT03375385|Other|Hemodynamic parameters|
16487920|NCT03375385|Other|Ramsay sedation score|
16487921|NCT03375385|Other|Intraoperative side effects|
16487922|NCT03375385|Other|recovery of sedation|
16487923|NCT03375372|Active Comparator|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
16487924|NCT03375372|No Intervention|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
16487925|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
16487926|NCT03375346|Experimental|Whole body vibration group|Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
16487927|NCT03375346|Active Comparator|Exercise only group|The control group performed the same session without vibration.
16487928|NCT03375333||20GPs|20 general practitioners, who use ultrasound in the examination of patients.
16487933|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
16487934|NCT03375281|Experimental|No touch group|RFA for small HCC would be done by using no touch technique
16487935|NCT03375255|Experimental|SRP-5051|"Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051 on Day 1.
~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
16487936|NCT03375242||crizotinib|
16487937|NCT03375229|Active Comparator|Group On|This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
16487938|NCT03375229|Active Comparator|Group Off|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
16487939|NCT03375229|Placebo Comparator|Placebo group|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
16487940|NCT03375216|Active Comparator|taper|participants undergoing a taper as directed by their pain physician. Interventions include sensory testing ( heat, cold, and pressure) and PROMIS surveys.
16487941|NCT03375216|Placebo Comparator|non taper systemic <90|participants on systemic opioids < 90 MEDD (morphine equivalent daily dose) and no taper
16487942|NCT03375216|Placebo Comparator|non taper systemic >90|participants on systemic opioids > 90 MEDD and no taper
16487943|NCT03375216|Placebo Comparator|non taper intrathecal|Participants on intrathecal therapy and no taper
16487944|NCT03375216|Sham Comparator|non opioids|Participants on non-opioid therapy will undergo behavioral tests and PROMIS surveys
16487945|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
16487946|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
16487947|NCT03375203|Experimental|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
16487948|NCT03375203|Experimental|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
16487949|NCT03375203|Experimental|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
16487950|NCT03375190|Experimental|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
16487951|NCT03375190|Experimental|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM, Devon, UK) at insertion site
16487952|NCT03375190|Experimental|Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
16487953|NCT03375190|Experimental|Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
16487954|NCT03375190|Experimental|Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
16487955|NCT03375190|Experimental|Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
16487956|NCT03375164|Experimental|Cohort A|Patients between 3 months to 3 years of age, will receive intravenous SRP-9001.
16487957|NCT03375164|Experimental|Cohort B|Patients between 4 to 7 years of age, will receive intravenous SRP-9001.
16487958|NCT03375151|Experimental|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
16487959|NCT03375151|Other|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
16487960|NCT03375151|Other|No feedback|The participants will perform the exercise without feedback during practice.
16487961|NCT03375138|Experimental|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
16487962|NCT03375138|Experimental|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
16487963|NCT03375125|Experimental|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
16487964|NCT03375125|Placebo Comparator|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
16487965|NCT03375112|Experimental|Fascia Iliaca Compartment Block|A Fascia Iliaca Compartment Block will be administered in the block room.
16487966|NCT03375112|Placebo Comparator|Control|The patients will be brought back to the block room, prepped, and a blunt needle will be touched to the skin. A band aid will be applied over the site.
16487967|NCT03375099|Experimental|Lethal Means Counseling|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners.
16487968|NCT03375099|Active Comparator|Lethal Means Counseling plus Gun Locks|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners. Individuals in this condition will also receive a free gun (cable) lock for each of their personal firearms.
16487969|NCT03375099|Active Comparator|Health and Stress Reduction|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework.
16487970|NCT03375099|Active Comparator|Health + Stress Reduction plus Gun Locks|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
16487971|NCT03375086|Experimental|Single arm|Patients will receive APX3330 orally, twice per day until disease progression
16487972|NCT03375073|Experimental|Positive communication|Positive communication during medical transmission
16487973|NCT03375073|No Intervention|Non-optimized communication|Medical transmission with non-optimized communication.
16487974|NCT03375047|Experimental|Low Dose|8 mg MRT5005
16487975|NCT03375047|Experimental|Low/Mid Dose|12 mg MRT5005
16487976|NCT03375047|Experimental|Mid Dose|16 mg MRT5005
16487977|NCT03375047|Experimental|Mid/High Dose|20 mg MRT5005
16487978|NCT03375047|Experimental|High Dose|24 mg MRT5005
16487979|NCT03375047|Placebo Comparator|Placebo Comparator|Normal Saline 0.9% USP
16487980|NCT03375047|Experimental|Daily Dose|20 mg MRT5005 delivered in 5 consecutive daily doses of 4mg
16487981|NCT03375034|Experimental|NDMC 20mg|oral single dose
16487982|NCT03375034|Experimental|NDMC 60mg|oral single dose
16487983|NCT03375034|Active Comparator|Clonazepam 1.5mg|oral single dose
16487984|NCT03375034|Placebo Comparator|Placebo|oral single dose
16487985|NCT03375021|Experimental|Sequence 1 PL|Eligible subjects were randomized to Sequence 1 PL in which they received placebo (P) followed by crossover to CX717 200 mg low dose (L) of active treatment
16487986|NCT03375021|Experimental|Sequence 2 PH|Eligible subjects were randomized to Sequence 2 PH in which they received placebo (P) followed by crossover to CX717 800 mg High dose (H) of active treatment
16487987|NCT03375021|Experimental|Sequence 3 LP|Eligible subjects were randomized to Sequence 3 LP in which they received CX717 200 mg Low dose (L) of active treatment followed by crossover to placebo (P)
16487990|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
16487991|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
16487992|NCT03374982|Experimental|DentalVibe On|DentalVibe will be turned on during local anesthetic injection at one appointment.
16487993|NCT03374982|No Intervention|DentalVibe Off|DentalVibe will be be turned off during local anesthetic injection at one appointment.
16487994|NCT03374969|Experimental|Attachment and Biobehavioral Catch-Up|
16487995|NCT03374969|Active Comparator|Developmental Education for Families|
16487996|NCT03374956|Experimental|Intervention group|Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
16487997|NCT03374956|Active Comparator|Control Group|Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
16487998|NCT03374943|Experimental|KB004 dose escalation|Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
16487999|NCT03374930|Other|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
16488000|NCT03374917|Experimental|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
16488001|NCT03374904|Active Comparator|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
16488002|NCT03374904|Experimental|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
16488003|NCT03374891|No Intervention|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
16488004|NCT03374891|Active Comparator|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
16488005|NCT03374878|Experimental|oral contraceptive and training|Users of oral contraceptive training for 10 weeks
16488006|NCT03374878|Placebo Comparator|no oral contraceptive and training|Non-users of oral contraceptive training for 10 weeks
16488007|NCT03374865||Video-mediated consultation|Consultations using Facetalk videocommunication software
16488008|NCT03374865||Face-to-face consultation|Traditional face-to-face consultations
16488009|NCT03374852|Experimental|CPI-613 + mFOLFIRNOX|"CPI-613: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port mFOLFIRNOX (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port
~Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).
~Irniotecan at 140 mg/m2 given as a 90-min IV infusion via a central venous port via a Yconnector.
~Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan"
16488010|NCT03374839|Experimental|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.
~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
16488011|NCT03374826|Experimental|Dedicated axillary hybrid PET-MRI axilla|
16488012|NCT03374813|Experimental|MimetikOss|Ridge preservation bone grafting after tooth extraction
16488013|NCT03374813|Active Comparator|Bio-Oss|Ridge preservation bone grafting after tooth extraction
16488014|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
16488015|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
16488016|NCT03374787|Experimental|Fusion sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
16488017|NCT03374774||Participants with Type 2 Diabetes Mellitus|Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.
16488018|NCT03374761|Experimental|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
16488019|NCT03374761|No Intervention|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
16488020|NCT03374735|Experimental|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
16488021|NCT03374722||Mechanically ventilated critically ill patients|Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours
16488022|NCT03374709|Experimental|Treatment Group|This arm includes subjects who have been prescribed Oxtellar XR 150Mg Extended Release Tablets.
16488060|NCT03374475|Placebo Comparator|Lead-in period: Placebo|Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
16488210|NCT03373500|Experimental|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
16488023|NCT03374696|Experimental|Intervention group|The intervention SAFETY was performed in school facilities by professional actors and staff from the municipality's youth guidance center within the county. The actors first enacted a play portraying youths and problems with condom use. Next, a value exercise was held by the youth guidance center staff. The class continued with chlamydia games held by the youth guidance center staff, providing information on symptoms, protection, how to get tested, treatment and consequences. The youth guidance center staff and the actors, playing students, then held a condom school. Lastly, the students came up with new endings to the play. All replays were enacted and the students gave feedback on the new endings. The class ended with condoms being handed out.
16488024|NCT03374696|Active Comparator|Control group|The intervention in the control group contained standard education from school staff, based on the sex education guidelines of the Swedish National Agency for Education. Students got education on human sexuality, reproduction, menstruation, love, sex, pregnancy and how STIs and unwanted pregnancy are prevented.
16488025|NCT03374683|Experimental|RR Digital Tool|Participants in the RR digital tool were provided with a link to the web-based intervention (https://outsideplay.ca) to complete within one week.
16488026|NCT03374683|Active Comparator|RR In-Person Workshop|Participants in the in-person workshop attended the 45-90 minute in-person workshop.
16488027|NCT03374683|Sham Comparator|Position Statement on Active Outdoor Play|Participants in the control condition were provided with a web link to the Position Statement on Active Outdoor Play, which includes information on research and recommendations for action.
16488028|NCT03374670|Experimental|Cohort 1|Zimura dosage 1 + Eylea 2 mg
16488029|NCT03374670|Experimental|Cohort 2|Zimura dosage 2 + Eylea 2 mg
16488030|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
16488031|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
16488032|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
16488033|NCT03374657|Experimental|CPK Dose 4 (next to highest dose)|CPK850, one subretinal injection to the study eye
16488034|NCT03374657|Experimental|CPK Dose 5 (highest dose)|CPK850, one subretinal injection to the study eye
16488035|NCT03374644|Experimental|ETCO2 monitoring with nasal cannula|SentriTM ETCO2 adult nasal cannula (Intersurgical ® code 1144002) will be placed into patient's nostril following radial artery catheter insertion. A baseline (without oxygen flow) ETCO2, PaO2, SPO2, RR and PaCO2 will be recorded. Oxygen will then be administered at 2,4, and 6 liters per minute for a period of five minutes.ETCO2, PaCO2 and PaO2 will be recorded for each level of oxygen administration.Sedation will be given during intra-operative period with the target of Observer Assessment of alertness/sedation scale (OAA/S) score of 3. During intraoperative period, oxygen will be administered at 2 and 4 liters per minute for a period of five minutes. ETCO2, PaCO2 and PaO2 level will be recorded during each level of oxygen administration.
16488036|NCT03374631|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing
16488037|NCT03374631|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing
16488038|NCT03374618|Experimental|systemic lupus erythematosus|adult with systemic lupus erythematosus
16488039|NCT03374618|Experimental|systemic sclerosis|adult with systemic sclerosis
16488040|NCT03374618|Other|healthy volunteers|healthy volunteer (adult)
16488041|NCT03374605|Experimental|Active tDCS|
16488042|NCT03374605|Sham Comparator|Sham tDCS|
16488043|NCT03374592|Active Comparator|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
16488044|NCT03374592|Experimental|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
16488045|NCT03374579|Experimental|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
16488046|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
16488047|NCT03374553|Experimental|MINIject 636 implant|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.
~The intervention is to be performed as stand-alone surgery."
16488048|NCT03374540||Rivaroxaban|Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
16488049|NCT03374540||Vitamin K antagonist (VKA)|Patients who initiated OAC treatment with VKA
16488050|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
16488051|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
16488052|NCT03374527||Control group|Healthy subjects
16488053|NCT03374514|Experimental|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
16488054|NCT03374514|Placebo Comparator|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
16488055|NCT03374501|Experimental|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
16488056|NCT03374501|Experimental|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
16488057|NCT03374501|Placebo Comparator|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
16488058|NCT03374488|Experimental|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
16488059|NCT03374488|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
16488161|NCT03373877|Experimental|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
16488162|NCT03373877|Experimental|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
16488163|NCT03373877|Experimental|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
16488061|NCT03374475|Experimental|Treatment period: JNJ-42847922 or Placebo|Placebo lead-in period responders and non-responders will be randomized to receive either placebo or 20 milligram (mg) JNJ-42847922 or 40 mg JNJ-42847922 for 5 Weeks. Participants will swallow JNJ-42847922 20 mg (2*10-mg capsules) or JNJ-42847922 40 mg (2*20-mg capsules) or 2 matching placebo capsules once daily for 5 Weeks.
16488062|NCT03374475|Placebo Comparator|Withdrawal period: Placebo|Participants who will complete the treatment period prior to the end of Week 8 will enter the withdrawal period where they will be treated with placebo (2 capsules taken orally) for the remaining time of the double-blind phase of the study. Investigators and participants will be blinded to exact duration of each participant-specific withdrawal period.
16488063|NCT03374462|Experimental|Telemedicine Intervention|All participants will receive the study intervention, which consists of home-based telemedicine visits with a diabetes specialist, at a frequency determined by the patient's degree of glycemic control (every 4, 6, or 8 weeks).
16488064|NCT03374449|Experimental|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
16488065|NCT03374449|Active Comparator|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
16488066|NCT03374436|Experimental|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
16488067|NCT03374436|Experimental|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each)."
16488068|NCT03374436|Active Comparator|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
16488069|NCT03374423|Active Comparator|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
16488070|NCT03374423|Active Comparator|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
16488071|NCT03374397|Active Comparator|SurgiGuard|Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
16488072|NCT03374397|No Intervention|Bipolar electrocauterization|Bipolar electrocauterization during surgery Drug(-)
16488073|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
16488074|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
16488075|NCT03374358|No Intervention|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
16488076|NCT03374358|Experimental|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
16488077|NCT03374345|Experimental|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
16488078|NCT03374345|Placebo Comparator|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
16488079|NCT03374332|Experimental|Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)
~Patients < 70 years old: GO 9mg/m2 (3mg/m2 each dose)
~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^7 CD3+ cells and maximum of 2x10^7 CD3+ cells/kg irrespective of the number of CD34+ cells.
~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
16488080|NCT03374332|Experimental|Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)
~Patients: < 70 years old: GO 9mg/m2 (3mg/m2 each dose)
~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^8 CD3+ cells and maximum of 2x10^8 CD3+ cells/kg irrespective of the number of CD34+ cells.
~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
16488081|NCT03374319|Experimental|Intervention group|Modified amputation procedure
16488082|NCT03374319|Active Comparator|Control group|Amputation procedure with TMR and/or RPNI construction
16488083|NCT03374306|Experimental|Atropine 0.01%|Group receiving atropine treatment for 18 months
16488084|NCT03374306|Placebo Comparator|Artifical tear|Group receiving placebo for 18 months
16488085|NCT03374293|Experimental|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
16488086|NCT03374280|Experimental|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.
~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
16488087|NCT03374280|Active Comparator|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
16488088|NCT03374254|Experimental|Pembrolizumab + Binimetinib (Cohort A)|During Part 1, participants in Cohort A will receive a standard dose (DL1) of pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at a starting dose of 30 mg twice a day (BID). Based on dose-limiting toxicities (DLT) assessed during the initial 21 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (Dose Level 2 [DL2]). Once a preliminary RP2D for binimetinib is identified in Part 1 for Cohort A, participants will receive pembrolizumab 200 mg IV Q3W plus binimetinib orally at the preliminary RP2D during Part 2.
16488164|NCT03373877|Experimental|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
16488165|NCT03373864|Experimental|Unilateral spinal anesthesia|In this arm, the patients will have a hypobaric lateral spinal anesthesia. Sedation can be added for the patients comfort.
16488166|NCT03373864|Active Comparator|General anesthesia|In this arm, the patients will have a general anesthesia.
16488089|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 (Cohort B)|During Part 1, participants in Cohort B will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2 over 46-48 hours) IV every 2 weeks (Q2W). Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of mFOLFOX7 may be de-escalated to oxaliplatin 70 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours] IV Q2W. Once a preliminary RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D during Part 2.
16488090|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 + Binimetinib (Cohort C)|After an RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants may enroll in Cohort C and receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the RP2D determined for Cohort B Q2W plus binimetinib orally at the RP2D determined for Cohort C in Part 1.
16488091|NCT03374254|Experimental|Pembrolizumab + FOLFIRI (Cohort D)|During Part 1, participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) IV Q2W. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of FOLFIRI may be de-escalated to irinotecan 150 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours) IV Q2W. Once a preliminary RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D during Part 2.
16488092|NCT03374254|Experimental|Pembrolizumab + FOLFIRI + Binimetinib (Cohort E)|After an RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants may enroll in Cohort E and receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the RP2D determined for Cohort D Q2W plus binimetinib orally at the RP2D determined for Cohort E in Part 1.
16488093|NCT03374241|Experimental|Cohort 1|HM15211 or Placebo (single dose, subcutaneous injection)
16488094|NCT03374241|Experimental|Cohort 2|HM15211 or Placebo (single dose, subcutaneous injection)
16488095|NCT03374241|Experimental|Cohort 3|HM15211 or Placebo (single dose, subcutaneous injection)
16488096|NCT03374241|Experimental|Cohort 4|HM15211 or Placebo (single dose, subcutaneous injection)
16488097|NCT03374241|Experimental|Cohort 5|HM15211 or Placebo (single dose, subcutaneous injection)
16488098|NCT03374228|Experimental|BMS-986205|Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of [13C]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration
16488101|NCT03374202|Experimental|Group 1|5x10(10)vg/kg dose of AAV8-VRC07
16488102|NCT03374202|Experimental|Group 2|5x10(11)vg/kg dose of AAV8-VRC07
16488103|NCT03374202|Experimental|Group3|2.5x10(12) vg/kg dose of AAV8-VRC07
16488104|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
16488105|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
16488106|NCT03374176|Active Comparator|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.
~1 capsule tid during 7 days."
16488107|NCT03374176|Experimental|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.
~1 capsule tid during 7 days."
16488108|NCT03374163|Experimental|treatment group who recived intralipid|71 patients who recived intralipid on day of embryo transfer day, pregnancy day.
16488109|NCT03374163|No Intervention|control group|71 patient not recived intralipid
16488110|NCT03374150|Experimental|high protein|High protein (HP) group were given counseling about weight loss program by applying low calorie-high protein diet with diet menu composition of 22-30% protein, along with instructions for allowed cooking method.
16488111|NCT03374150|Active Comparator|standard protein|Active comparator receiving standard protein (SP) proportion were counseled about weight loss program by means of low calorie-balanced composition diet with menu comprised of 12-20% protein.
16488113|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
16488114|NCT03374111|Experimental|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
16488115|NCT03374111|Placebo Comparator|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
16488116|NCT03374098|Experimental|Education|Attend an hour-long classes once per week for three weeks
16488117|NCT03374098|Experimental|Home Visitation|Receive home visits that focus on the social determinants of health and attend hour-long classes once per week for three weeks
16488118|NCT03374085|Experimental|Administration of CC-92480 in combination with dexamethasone|Escalating doses of CC-92480 and in combination with a fixed dose of dexamethasone administered according to different dosing schedules
16488119|NCT03374085|Experimental|Administration of CC-92480 monotherapy|Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules
16488167|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
16488168|NCT03373838||Census|Epidemiological study. Sociodemographic and medical survey.
16488169|NCT03373838||Qualitative interview|Individual qualitative interview.
16488120|NCT03374072|Experimental|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in videoteleconference sessions with an Arc community provider. The content and format of the program is still being finalized. In the initial conception of the program, we proposed 6 sessions: Session 1 will focus on assessment and motivation (Sibling and adult with ASD). In Session 2, the sibling will learn family communication strategies. Session 3 will provide the sibling with information about adult services and how to navigate the service system. Session 5 will be a joint session with the family members with ASD. In the final session, the sibling will develop a plan of action outlining their involvement in family future planning.
16488121|NCT03374072|Active Comparator|Information Only Condition|We will create an information packet for siblings in the control condition. Siblings in the control condition will receive the same tip sheets and packet of information about resources for adults with ASD as those distributed in Session 3 of the Siblings FORWARD program.
16488122|NCT03374059|Experimental|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
16488123|NCT03374059|Experimental|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
16488124|NCT03374059|No Intervention|Control Group|Control group did not receive any treatments
16488125|NCT03374046|No Intervention|Control Group|Standard care
16488126|NCT03374046|Experimental|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula
~If 0-2 years: 3L/min NC of 100% FiO2
~If > or = to 2 through17 years: 5L/min NC of 100% FiO2"
16488127|NCT03374033|No Intervention|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
16488128|NCT03374033|Experimental|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
16488129|NCT03374033|Experimental|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
16488130|NCT03374033|Experimental|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
16488131|NCT03374020||Intermediate AMD|
16488132|NCT03374020||Advanced AMD|
16488133|NCT03374020||DR without macular edema|
16488134|NCT03374020||DR with macular edema|
16488135|NCT03374007|Experimental|GB226 1mg/kg single-dose|Geptanolimab, 1mg/kg, i.v., single-dose
16488136|NCT03374007|Experimental|GB226 3 mg/kg single-dose|Geptanolimab, 3mg/kg, i.v., single-dose
16488137|NCT03374007|Experimental|GB226 10mg/kg single-dose|Geptanolimab 10mg/kg, i.v., single-dose
16488138|NCT03374007|Experimental|GB226 1mg/kg multiple dosing, every 2 weeks|Geptanolimab, 1mg/kg, i.v., q2w*6
16488139|NCT03374007|Experimental|GB226 3mg/kg multiple dosing,every 2 weeks|Geptanolimab, 3mg/kg, i.v., q2w*6
16488140|NCT03374007|Experimental|GB226 10mg/kg multiple dosing, every 2 weeks|Geptanolimab,10mg/kg, i.v., q2w*6
16488141|NCT03374007|Experimental|GB226 280mg multiple dosing|Geptanolimab, 280mg, i.v., q3w
16488142|NCT03374007|Experimental|GB226 3mg/kg multiple dosing|Geptanolimab, 3mg/kg, i.v., q2w
16488143|NCT03373994||18F-FDG PET/CT initial-time imaging|PET/CT imaging was underwent 5min after 18F-FDG injection.
16488144|NCT03373994||18F-FDG PET/CT balanced-time imaging|PET/CT imaging was underwent 60min after 18F-FDG injection.
16488145|NCT03373981|Experimental|intervention|rTMS
16488146|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
16488147|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
16488148|NCT03373942||Primary Open Angle Glaucoma (POAG)|The study included 30 eyes of 30 patients diagnosed with POAG who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
16488149|NCT03373942||Pseudoexfoliation Syndrome (PEX)|The study included 30 eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
16488150|NCT03373942||Control|The control group included 30 eyes of 30 healthy individuals with similar age distribution with POAG and PEX group
16488151|NCT03373929|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO
16488152|NCT03373929|Other|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.
16488153|NCT03373916|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
16488154|NCT03373916|Active Comparator|Enhanced Usual Care (EUC)|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
16488155|NCT03373903|Placebo Comparator|Placebo once daily for 16 weeks|
16488156|NCT03373903|Experimental|BEZ235 once daily for 16 weeks|
16488157|NCT03373903|Experimental|BEZ235 twice daily for 16 weeks|
16488158|NCT03373903|Experimental|BEZ235 plus RAD001 once daily for 16 weeks|
16488159|NCT03373890|Experimental|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
16488160|NCT03373890|Active Comparator|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
16488170|NCT03373825|Experimental|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
16488171|NCT03373825|Experimental|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
16488172|NCT03373812|Active Comparator|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
16488173|NCT03373812|Active Comparator|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
16488174|NCT03373799|Experimental|Group 1|Video-Based Rehabilitation Group
16488175|NCT03373799|Active Comparator|Group 2|Physiotherapist-Supervised Rehabilitation Group
16488176|NCT03373786|Experimental|RG-012 Single Dose|1.5 mg/kg RG012 subcutaneous injection
16488177|NCT03373786|Experimental|RG012 Every Other Week|1.5 mg/kg RG012 subcutaneous injections every other week
16488178|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.
~Subjects in this arm will remove the Foley catheter at home."
16488179|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.
~Subjects in this arm will remove the Foley catheter in a medical office."
16488180|NCT03373760|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16488181|NCT03373747|Experimental|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
16488182|NCT03373747|Experimental|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
16488183|NCT03373708|Experimental|EC follow T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
16488184|NCT03373708|Experimental|TC follow endocrine|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for four cycles followed by goserelin acetate+tamoxifen for young patients/ letrozole for postmenopausal patients
16488185|NCT03373695|Experimental|Dissolve™|
16488186|NCT03373695|Active Comparator|SeQuent®Please|
16488187|NCT03373669|Active Comparator|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
16488188|NCT03373669|Experimental|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
16488189|NCT03373656|Experimental|low antibody titers|Antibody titers lower than protection level
16488190|NCT03373656|Other|high antibody titers|Antibody titers higher than protection level
16488191|NCT03373643|Experimental|Patient suspected for NAFLD|
16488192|NCT03373630|Experimental|Midline catheter|
16488193|NCT03373617||General anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under general anesthesia.
16488194|NCT03373617||Spinal anesthesia group|Patients in spinal anesthesia group are scheduled to undergo RIRS under spinal anesthesia
16488195|NCT03373604|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
16488196|NCT03373604|Active Comparator|No cognitive impairment|Healthy controls
16488197|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
16488198|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
16488199|NCT03373591|No Intervention|No TAP block|Patients will be randomized to receive no TAP block as a control group.
16488200|NCT03373578|Active Comparator|earmuffs|Preterm newborns with earmuffs during the Quiet time
16488201|NCT03373578|No Intervention|control|Preterm newborns without earmuffs during de Quiet time
16488202|NCT03373565|Active Comparator|Radial|Coronary angiography using radial approach
16488203|NCT03373565|Experimental|palmar|Coronary angiography using palmar approach
16488204|NCT03373552||non responder Group|"Platelet function assay:
~High platelet reactivity: PRU>208"
16488205|NCT03373552||responder Group|"Platelet function assay:
~PRU<208"
16488211|NCT03373500|No Intervention|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
16488212|NCT03373487|Experimental|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
16488213|NCT03373487|Other|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
16488214|NCT03373474|Experimental|local distribution points association|Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
16488215|NCT03373474|Experimental|local-distal points association|Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
16488216|NCT03373474|No Intervention|waiting-list|Patients in the waiting-list group will not receive any acupuncture treatment during the study. However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
16488217|NCT03373461|Placebo Comparator|Placebo|Placebo to LNP023
16488218|NCT03373461|Experimental|LNP023 dose 1|Dose 1 of LNP023
16488219|NCT03373461|Experimental|LNP023 dose 2|Dose 2 of LNP023
16488220|NCT03373461|Experimental|LNP023 dose 3|Dose 3 of LNP023
16488221|NCT03373448|Active Comparator|Labrida BioClean|Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
16488222|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided with titanium curettes.
16488223|NCT03373435|Experimental|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
16488224|NCT03373435|Experimental|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
16488225|NCT03373422|Experimental|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
16488226|NCT03373422|Experimental|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
16488227|NCT03373422|Experimental|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
16488228|NCT03373422|Experimental|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
16488229|NCT03373422|Experimental|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
16488230|NCT03373422|Placebo Comparator|Placebo|One placebo tablet in the morning and one in the evening
16488231|NCT03373409|Experimental|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
16488232|NCT03373409|Experimental|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
16488233|NCT03373409|Active Comparator|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
16488234|NCT03373396|Other|Case group with Metavir score between F1 and F4|Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
16488235|NCT03373396|Other|Control group with Metavir score of between F0|Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed.
16488236|NCT03373383|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
16488237|NCT03373383|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
16488238|NCT03373383|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
16488239|NCT03373383|Experimental|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
16488240|NCT03373383|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
16488241|NCT03373357|Other|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
16488242|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
16488243|NCT03373344|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
16488244|NCT03373344|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.
~They will receive placebo control exercises administered on a laptop computer."
16488556|NCT03371225|Active Comparator|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
16488245|NCT03373331|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
16488246|NCT03373331|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.
~They will receive placebo control exercises administered on a laptop computer.
~."
16488247|NCT03373318|Experimental|Experimental|Human Albumin
16488248|NCT03373318|Active Comparator|Control|Plasmalyte
16488249|NCT03373305|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
16488250|NCT03373292|Experimental|Venous stenting (Group-1)|Patients in this group will undergo venous stenting treatment at once after enrollment.
16488251|NCT03373292|Experimental|Stenting one-month after routine medical treatment (Group-2)|Patients in this group will undergo routine medical treatment for one month, followed by venous stenting intervention.
16488252|NCT03373266|Active Comparator|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
16488253|NCT03373266|Active Comparator|isoflurane|anesthesia was maintained with isoflurane 1-2%.
16488254|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
16488255|NCT03373240|Experimental|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
16488256|NCT03373240|Placebo Comparator|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
16488257|NCT03373227|Experimental|Prospective|25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care.
16488258|NCT03373227|No Intervention|Retrospective|25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.
16488259|NCT03373214|Experimental|30 µg Na-GST-1 + CPG 10104|
16488260|NCT03373214|Experimental|100 µg Na-GST-1 + CPG 10104|
16488261|NCT03373214|Experimental|100 µg Na-GST-1|
16488262|NCT03373201|Experimental|Tasimelteon|
16488263|NCT03373201|Placebo Comparator|Placebo|
16488264|NCT03373188|Active Comparator|Arm I (surgery)|Patients undergo surgery.
16488265|NCT03373188|Experimental|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
16488266|NCT03373188|Experimental|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
16488267|NCT03373188|Experimental|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
16488268|NCT03373175|Experimental|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record Pressure Support 10 (PS 10)record Pressure Support 15 (PS 15) record Pressure Support 20 (PS 20) record
16488269|NCT03373175|Experimental|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
16488270|NCT03373175|Experimental|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
16488271|NCT03373175|Experimental|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
16488272|NCT03373162|Experimental|MRI Scans Pre and Post-Botox Injection|Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.
16488273|NCT03373149|Experimental|Growth hormone/HPuFSH/GnRH antagonist|The patients receive growth hormone
16488274|NCT03373149|Active Comparator|HPuFSH/GnRH antagonist|Growth hormone is not used
16488275|NCT03373136|Experimental|Cold snaring|Polypectomy will be done without electrocautery
16488276|NCT03373136|Active Comparator|Hot snaring|Polypectomy will be performed with electrocautery
16488277|NCT03373123|Experimental|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
16488278|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
16488314|NCT03372837|Experimental|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.
~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
16488315|NCT03372824||Pregnant women|Primiparas above 25 years of age, singleton pregnancy
16488316|NCT03372811|Active Comparator|TC cream (10%)|
16488279|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
16488280|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
16488281|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
16488282|NCT03373084||hamstring muscle lesions|Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire
16488283|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
16488284|NCT03373058|Experimental|Experimental group|"Cytoreductive surgery
~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available.)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
16488285|NCT03373058|Active Comparator|Control group|"Cytoreductive surgery
~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
16488286|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
16488287|NCT03373032|Active Comparator|Stiper - A|Stiper, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
16488288|NCT03373032|Active Comparator|Acupuncture - B|Acupuncture with needles, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
16488289|NCT03373032|Active Comparator|Exercise - C|Exercise, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
16488290|NCT03373032|Experimental|Follow Up - D|Selected patients from the 3 groups Stiper / Acupuncture / Exercise. One session with a Peridell Massager
16488291|NCT03373032|No Intervention|Observation - S|Group patients who were unable to participate in the intervention group A / B and C. In this group, only the evaluation will be performed.
16488292|NCT03373019|Experimental|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
16488293|NCT03373006|Experimental|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
16488294|NCT03372980||Case|
16488295|NCT03372980||Control|
16488296|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
16488297|NCT03372954|Experimental|Bone marrow autologous cells concentrate (BMAC)|retrograde administration on non-selected BMAC via coronary sinus
16488298|NCT03372954|Placebo Comparator|Control|standard treatment o heart failure
16488301|NCT03372928|Experimental|Standard EAA Dose|EAA dose provided at 0.10 g/kg body mass
16488302|NCT03372928|Experimental|High EAA Dose|EAA dose provided at 0.30 g/kg body mass
16488303|NCT03372915|Active Comparator|Standard Exposure|This arm will receive exposure therapy conducted according to standard care practices.
16488304|NCT03372915|Experimental|Exposure + Inhibitory Learning|This arm will receive exposure therapy conducted according to principles of inhibitory learning.
16488305|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
16488306|NCT03372902||suspicious lesion group (BI-RADS 4)|
16488307|NCT03372889|Active Comparator|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
16488308|NCT03372889|Active Comparator|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
16488309|NCT03372876|Experimental|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
16488310|NCT03372876|Placebo Comparator|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
16488311|NCT03372863||Cardiac surgery patients|
16488312|NCT03372850|Experimental|Sequence Group 1|Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)
16488313|NCT03372850|Experimental|Sequence Group 2|Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)
16488317|NCT03372811|Placebo Comparator|Vehicle|
16488318|NCT03372785||Complete revascularization group|Complete Revascularization of CTO and non-CTO lesions
16488319|NCT03372785||Non-CTO revascularization group|Non-CTO vessel revascularization
16488321|NCT03372772|Experimental|Intervention group|Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
16488322|NCT03372759|Active Comparator|study group air|airtamponade
16488323|NCT03372759|Sham Comparator|study group saline|saline
16488324|NCT03372746||1|Participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2
16488325|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil
16488326|NCT03372733|Experimental|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
16488327|NCT03372720|Experimental|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
16488328|NCT03372720|Sham Comparator|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
16488329|NCT03372707|Experimental|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
16488330|NCT03372707|No Intervention|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
16488331|NCT03372694|Experimental|Chemotherapy+Training+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Rehabilitation training is mainly composed of gymnastic qigong, which will be started in one month after operation.
~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
16488332|NCT03372694|Experimental|Chemotherapy+Education+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.
~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
16488333|NCT03372694|Placebo Comparator|Chemotherapy+Education+Placebo|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.
~Patients who received rehabilitation education will not accept rehabilitation training.
~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages. The patient will take placebo granules for 3 months."
16488334|NCT03372681|Experimental|Antiperistaltic|In this group patients undergo the distal gestrectomy with antiperistaltic Billroth II + Braun anastomosis
16488335|NCT03372681|Active Comparator|Isoperistaltic|In this group patients undergo the distal gestrectomy with isoperistaltic Billroth II + Braun anastomosis
16488336|NCT03372668|Other|All Participants|Each study participant will progress through the three, 4-week study periods in the ABA withdrawal design in the same, designated order. The first and third 4-week study periods (or the A periods) have no intervention and only consist of twice weekly data collection. The second 4-week study period (or the B period) will include the twice weekly delivered massage therapy combined with components of mirror therapy intervention.
16488337|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
16488338|NCT03372629|Experimental|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
16488339|NCT03372629|Placebo Comparator|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
16488340|NCT03372629|Experimental|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
16488341|NCT03372629|Placebo Comparator|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
16488342|NCT03372616||All participants|Aortic blood pressure, LV filling pressrue, and LV volume will be measured in all participants. Meanwhile, echocardiography and non-invasive aortic blood presure measurement will be performed. Three devices will be used in non-invasive aortic blood presure measurement, including Sphygmocor (AtCor Medical, Australia), PulsePen (DiaTecne SRL, Italy), and Mobil-O-Graph (IEM, Germany). In conclusion, all participants will receive invasive and non-invasive left ventricular diastolic function assessment, together with invasive and non-invasive aortic blood pressure assessment.
16488343|NCT03372603|Experimental|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
16488507|NCT03371485|Active Comparator|Arm C:|Patients with previously treated NSCLC, currently disease free, to receive AST-VAC2 in the adjuvant setting.
16488344|NCT03372603|Experimental|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
16488345|NCT03372590|Experimental|NICU-based rehabilitation bundle|Patients identified to be at high risk for cerebral palsy will be enrolled after parental consent is obtained to the NICU rehabilitation program. This program consists of maternal-driven evidence based intervention that include: vocal soothing, scent exchange, comforting touch, kangaroo care, and infant massage. These intervention will be provided at GA-appropriate intervals.
16488346|NCT03372590|Other|Standard of care|Infants not participating in the intervention study will be provided with standard or care. Interventions include kangaroo care, physical therapy and infant massage provided by NICU staff.
16488347|NCT03372577|Experimental|patient and partner|
16488348|NCT03372577|Experimental|patient ,partner and cardiac rehabilitation team|
16488349|NCT03372577|Active Comparator|Treatment as usual|
16488350|NCT03372564|Experimental|Hip Capsule Repair|Patients in the intervention group (Hip capsule repair) will undergo initial diagnostic arthroscopy of the hip. Two to three standard portals (anterolateral, mid anterior, distal antero-lateral, posterolateral) will be used during the entire procedure to assess and treat the patient. After establishing standard portals, an interportal capsulotomy is completed to allow for complete evaluation of the central compartment of the hip. In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl). Three to four simples sutures will be placed and tied using arthroscopic technique.
16488351|NCT03372564|No Intervention|No Hip Capsule Repair (Control)|Patients in the control group (no hip capsule repair) have the same portals utilized and will have the same interportal capsulotomy performed. They will have all central and peripheral compartment pathologies addressed in the same way that the study group does. At the conclusion of the case, the hip capsule will be left open and not repaired.
16488352|NCT03372551|Experimental|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
16488353|NCT03372551|Active Comparator|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
16488354|NCT03372538||multidisciplinary team group|500 patients of placenta accreta managed by obstetricans and urologists
16488355|NCT03372538||obstetricians only group|500 patients of placenta accreta managed by obstetricans only
16488356|NCT03372525|Experimental|HFOV|Ventilated infants were randomized to HFOV.
16488357|NCT03372525|Active Comparator|CMV|Ventilated infants were randomized to CMV.
16488358|NCT03372512||Fluid overload (Liters) ≥ median|
16488359|NCT03372512||Fluid overload (Liters) < median|
16488360|NCT03372499|Experimental|nutritional management group|diet management strategy for encephalopathy
16488361|NCT03372499|No Intervention|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
16488362|NCT03372486|Active Comparator|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
16488363|NCT03372486|Placebo Comparator|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
16488364|NCT03372473|Experimental|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
16488365|NCT03372473|Active Comparator|Montelukast|Montelukast 5mg one dose per day
16488366|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
16488367|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS will include a 30-second ramp up to 1mA, 30 seconds of stimulation at 1mA, followed by a 30-second ramp down to off. The device will remain off for the remainder of the session. This process will be used for each of the 6 sessions during a 2 week period.
16488368|NCT03372447|Experimental|Megadose multivitamin complex|Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
16488369|NCT03372434|Experimental|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Model ZFR00
16488370|NCT03372434|Experimental|Investigational Lens Device #2|Investigational Intraocular Lens Device #1: Model ZYR00
16488371|NCT03372434|Active Comparator|Control Device|Control TECNIS Multifocal Intraocular Lens Model ZLB00
16488372|NCT03372421|Experimental|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
16488373|NCT03372421|Active Comparator|Standard Information|Participants will read standard information about what to expect from the assessment.
16488374|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
16488375|NCT03372395|Other|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
16488376|NCT03372395|Experimental|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
16488377|NCT03372382|Active Comparator|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
16488378|NCT03372382|Experimental|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
16488379|NCT03372369|Active Comparator|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
16488380|NCT03372369|Experimental|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
16488554|NCT03371225|Experimental|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
16488381|NCT03372356||Neuroendocrine tumors|Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.
16488382|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index < 0.9 or vascular Duplex confirmed peripheral artery disease.
~* Standard care for sepsis and PAD"
16488383|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index >= 0.9 or vascular Duplex found no evidence of peripheral artery disease.
~* Standard care for sepsis"
16488384|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
16488385|NCT03372304|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 10 mL, every 8th hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
16488386|NCT03372304|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
16488387|NCT03372304|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
16488388|NCT03372291|Experimental|Psychological app|"Psychological intervention consist of four components
~Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;
~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;
~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;
~Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.
~The psychological intervention will consist of five sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly for five weeks after diagnosis"
16488389|NCT03372291|Active Comparator|Usual Care|"Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.
~Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
16488390|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
16488391|NCT03372265|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
16488392|NCT03372265|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
16488393|NCT03372265|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
16488394|NCT03372252|Experimental|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
16488395|NCT03372252|Experimental|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
16488396|NCT03372239|Experimental|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:
~Single dose of Indoximod base formulation under fasting conditions
~Single dose of Indoximod HCL (salt) formulation under fed conditions
~Single dose of Indoximod HCL (salt) formulation under fasting conditions"
16488397|NCT03372239|Experimental|Part 2: Single Ascending Dose|
16488398|NCT03372226|Experimental|Online self-help program|"The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 10 modules with many interactional exercises and homework-sheets.
~Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse."
16488399|NCT03372226|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
16488400|NCT03372213||2003-2004|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
16488401|NCT03372213||2005-2006|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
16488402|NCT03372213||2011-2012|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
16488403|NCT03372213||2013-2014|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
16488404|NCT03372200|Experimental|FYU-981|
16488405|NCT03372200|Active Comparator|Febuxostat|
16488406|NCT03372187|Experimental|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
16488407|NCT03372174|Experimental|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
16488408|NCT03372174|Active Comparator|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
16488409|NCT03372161|Experimental|SP-102|SP-102
16488410|NCT03372161|Placebo Comparator|Placebo|Placebo
16488411|NCT03372148|Experimental|pHRMi in evaluation of swallowing function|Pharyngeal High Resolution Manometry and Impedance (pHRMi) evaluation of swallowing function at baseline, 3 months post radiation, then at 9 months
16488555|NCT03371225|Active Comparator|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
16488412|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
16488413|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
16488414|NCT03372122|Active Comparator|SAGE Chlorhexidine Gluconate Cloth|Ready to use disinfectant cloth
16488415|NCT03372122|Active Comparator|HUBS with Hibiclens|Dry cloths to be used with water and disinfectant
16488416|NCT03372109|Active Comparator|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
16488417|NCT03372109|Placebo Comparator|Placebo|Multivitamin tablet administered daily for 52 days
16488418|NCT03372096|Experimental|All patients|Patients will receive the Prostatic Artery Embolization procedure.
16488419|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
16488420|NCT03372070|Experimental|cNEP|silicone collar applied to anterior neck
16488421|NCT03372057|Experimental|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
16488422|NCT03372057|Experimental|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
16488423|NCT03372057|Experimental|Expansion Phase|Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)
16488424|NCT03372044|Experimental|PF-06865571|Treatment
16488425|NCT03372031|Experimental|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
16488426|NCT03372031|Experimental|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
16488427|NCT03372018|Experimental|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
16488428|NCT03372018|Active Comparator|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
16488429|NCT03372005|Experimental|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
16488430|NCT03372005|No Intervention|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
16488431|NCT03371992|Other|Lung Cancer Patients|Lung cancer patients receiving one of three standard of care immunotherapy drugs including nivolumab, pembrolizumab or atezolizumab. 3D-EX will be performed on biopsies from patients enrolled in the study to correlate with the patient's evaluation of response by RECIST.
16488432|NCT03371979|Experimental|Pegzilarginase plus Pembrolizumab|Phase 1 & 2
16488433|NCT03371966|Active Comparator|High Nitrate Beetroot Juice|Beetroot juice high in nitrate will contain approximately 10.0 mmole nitrate per 120 ml.
16488434|NCT03371966|Placebo Comparator|Low Nitrate Beetroot Juice|Beetroot juice low in nitrate will contain approximately 0.5 mmole nitrate per 120 ml.
16488435|NCT03371953|Active Comparator|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
16488436|NCT03371953|Active Comparator|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
16488437|NCT03371953|Active Comparator|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
16488438|NCT03371940|Experimental|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.
~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:
~Education about depression and the cognitive-behavioral therapy model;
~A safe relationship for participants to explore their symptom patterns and try to new tools to address them;
~Coaching as participants fully engage emotional and behavioral strategies."
16488439|NCT03371940|Experimental|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
16488440|NCT03371940|Experimental|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise as detailed above.
16488441|NCT03371940|Placebo Comparator|Usual care (UC)|Participants randomized to usual care received no study intervention.
16488442|NCT03371927|No Intervention|Standard Feeding Method|The control group consisted of prescribed volumes of oral and/or gavage feedings at two or three hour intervals per feeding.
16488443|NCT03371927|Experimental|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
16488473|NCT03371719|Experimental|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
16488444|NCT03371914|Experimental|Treatment: Management + data training|"The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.
~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis."
16488445|NCT03371914|No Intervention|Control: data training only|The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
16488446|NCT03371901|Experimental|Physical therapy with BFR-LLST|
16488447|NCT03371888|Experimental|PRP injections|Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle
16488448|NCT03371888|Placebo Comparator|0,9% NaCl injections|Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle
16488449|NCT03371875|Experimental|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
16488450|NCT03371875|No Intervention|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
16488451|NCT03371862|Experimental|Test group|
16488452|NCT03371849|Experimental|Group 1|Reference Drug → Test Drug
16488453|NCT03371849|Experimental|Group 2|Test Drug → Reference Drug
16488454|NCT03371836|Other|Clobazam|open label (single treatment arm)
16488455|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
16488456|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
16488457|NCT03371810|Experimental|Bright light therapy|"Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total.
~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
16488458|NCT03371810|Experimental|Physical exercise|"Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total.
~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
16488459|NCT03371810|No Intervention|Treatment as usual|Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
16488460|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
16488461|NCT03371784|Active Comparator|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
16488462|NCT03371784|Placebo Comparator|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
16488463|NCT03371771|Experimental|Volunteer-delivered Behavioral Activation|
16488464|NCT03371771|Active Comparator|MSW-delivered Behavioral Activation|
16488465|NCT03371758|Experimental|vitiligo patients|
16488466|NCT03371758|Experimental|healthy controls|
16488467|NCT03371745|Active Comparator|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
16488468|NCT03371745|Active Comparator|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
16488469|NCT03371745|Active Comparator|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
16488470|NCT03371732|Other|Groupe 1|G1 : Motivational Intervention group
16488471|NCT03371732|Other|Groupe 2|G2 : Educational advises group
16488472|NCT03371719|Placebo Comparator|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
16488506|NCT03371485|No Intervention|Arm B|Patients with advanced NSCLC, receiving no AST-VAC2 treatment and serving as a control for Arm A.
16488474|NCT03371706|Experimental|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
16488475|NCT03371706|Active Comparator|Evidence-Based Impairment Focused|The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
16488476|NCT03371693|Experimental|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.
~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
16488477|NCT03371693|Other|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
16488478|NCT03371680|Experimental|Injection of stable isotopes|Injection of 1-13 Carbon Leucine and deuterated water: all patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
16488481|NCT03371641|Other|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
16488482|NCT03371641|Other|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
16488483|NCT03371628|Experimental|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
16488484|NCT03371628|No Intervention|Group O2|Oxygen therapy
16488485|NCT03371615|Active Comparator|Fermented IF + LBG + Gos Fos|Fermented infant formula with Locust bean gum and Gos Fos
16488486|NCT03371615|Placebo Comparator|Fermented IF +LBG|Fermented infant formula with Locust bean gum
16488487|NCT03371602|Experimental|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
16488488|NCT03371602|Experimental|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
16488489|NCT03371602|Experimental|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
16488490|NCT03371602|Experimental|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
16488491|NCT03371589|Experimental|no P.O corticosteroids|Steroids injection
16488492|NCT03371576||2 different torical intraocular lenses|
16488493|NCT03371563||elderly patients|
16488494|NCT03371563||middle-aged patients|
16488495|NCT03371563||controls|
16488496|NCT03371563||young patients|
16488497|NCT03371550|Experimental|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
16488498|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
16488499|NCT03371524||Native valves_30 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.
16488500|NCT03371524||Native valves_30 and 60 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.
16488501|NCT03371524||Bioprosthesis_30 seconds loops|Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.
16488502|NCT03371511||MiLC Cohort|"Participants donated HM from two consecutive pumping sessions at home. Women pumped once with their own pump and milk collection kit, and once with a sterile and sterile collection kit. Both pumping sessions occurred at participants' homes between 0700 and 1100 hours. The second pumping session occurred within 3 hr (+/- 30 min) after the beginning of the first. Randomization was used to determine which pump was used first. Women elected from which breast they donated their HM and were asked not to nurse on that side 2 hr before the first pumping session and not until after the second. Before women pumped with their own pump, swabs were taken of the breast from which HM was donated, the women's dominant hand, their own bottle/flange, their own pumps (port of pump and tubing), and their babies' mouths.
~There was only one group but stratified enrollment was used to ensure equal numbers of women whose infants consumed HM only and women whose infants consumed HM and complementary foods."
16488503|NCT03371498|Experimental|Methylprednisolone Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
16488504|NCT03371498|Placebo Comparator|Control Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo
16488505|NCT03371485|Active Comparator|Arm A|Patients with advanced NSCLC, to receive AST-VAC2.
16488867|NCT03369015|Experimental|10 mg d-amphetamine, then 20mg d-amphetamine, then placebo|
16488508|NCT03371485|No Intervention|Arm D:|Patients with previously treated NSCLC, currently disease free, receiving no AST-VAC2 treatment and serving as a control for Arm C.
16488509|NCT03371472|Other|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
16488510|NCT03371472|Other|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
16488511|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
16488512|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
16488513|NCT03371446||Smokers/Non-smokers|It was an experimental study with parallel controls, comparing two groups, a group with patients who smoked for more than 10 years, consuming 10 more cigarettes per day and diagnosing chronic periodontitis (case) and another group (control) were non-smokers with chronic periodontitis, according to the standard of World Health Organization (WHO) definition of the smoking population
16488514|NCT03371420|Experimental|124I-PU-AD|A single dose of 124I-PU-AD will be administered by intravenous (IV) injection
16488515|NCT03371407||Parkinsonian patient under dopaminergic medication|
16488516|NCT03371407||Parkinsonian patient without dopaminergic medication|
16488517|NCT03371407||Control participants|
16488518|NCT03371394||median 1|
16488519|NCT03371394||median 2|
16488520|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
16488521|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
16488522|NCT03371368|Other|Gastric Bypass Diabetic and Non-diabetic|Roux-en-Y gastric bypass surgery
16488523|NCT03371368|Other|Sleeve Gastrectomy Diabetic and Non-diabetic|sleeve gastrectomy surgery
16488524|NCT03371368|Active Comparator|Very Low Calorie Diet Diabetic and Non-diabetic|very low calorie diet
16488525|NCT03371368|No Intervention|Obese Control Group|Non-diabetic obese subjects
16488526|NCT03371368|No Intervention|Lean Control Group|Non-diabetic lean subjects
16488527|NCT03371355|Placebo Comparator|Pooled Placebo|Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
16488528|NCT03371355|Experimental|Cohort B: ISIS 703802, 40 mg Q4W|Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
16488529|NCT03371355|Experimental|Cohort C: ISIS 703802, 80 mg Q4W|Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
16488530|NCT03371355|Experimental|Cohort A: ISIS 703802, 20 mg QW|Participants received ISIS 703802, 20 mg once every week for 26 doses.
16488531|NCT03371342|Experimental|MEDITOXIN|
16488532|NCT03371342|Active Comparator|BOTOX|
16488533|NCT03371329|Experimental|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.
16488534|NCT03371329|Experimental|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.
16488535|NCT03371329|Experimental|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.
16488536|NCT03371329|Experimental|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.
16488537|NCT03371316|Experimental|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
16488538|NCT03371303||diabetology|
16488539|NCT03371303||cardiology|
16488540|NCT03371303||rheumatology|
16488541|NCT03371303||geriatrics|
16488542|NCT03371290|Experimental|Mirror Therapy Intervention|
16488543|NCT03371290|Active Comparator|Control Intervention|
16488544|NCT03371277|Experimental|Arm1|patients with Parkinson's disease treated with deep brain stimulation.
16488545|NCT03371277|Experimental|Arm2|patients with Parkinson's disease treated without deep brain stimulation.
16488546|NCT03371264||Cohort R1 and Cohort T1|Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
16488547|NCT03371264||Cohort R2 and Cohort T2|Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)
16488548|NCT03371251|Experimental|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
16488549|NCT03371251|Placebo Comparator|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
16488550|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
16488551|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
16488552|NCT03371238|Experimental|Floorball|
16488553|NCT03371238|No Intervention|Control|
16488868|NCT03369015|Experimental|20 mg d-amphetamine, then 10mg d-amphetamine, then placebo|
16488557|NCT03371225|Sham Comparator|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
16488558|NCT03371212|Active Comparator|Conventional Cohort|Patients in this group will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
16488559|NCT03371212|Experimental|Modular Dual Mobility Cohort|Patients in this group will receive a Taperloc femoral stem, inner ceramic femoral head (28mm), mobile polyethylene bearing, cobalt alloy liner, and G7 acetabular shell.
16488560|NCT03371199|Active Comparator|Sodium arm|Sodium tablets
16488561|NCT03371199|Placebo Comparator|Placebo arm|Placebo tablets
16488562|NCT03371186|Experimental|Bundled RMNCH Intervention|Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
16488563|NCT03371173|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
16488564|NCT03371147|Experimental|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
16488565|NCT03371147|No Intervention|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
16488566|NCT03371134||Sarcopenic group|Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
16488567|NCT03371134||Control group|Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
16488568|NCT03371121|Other|Chondro-gide - Geistlich|Arthroscopic use of chondro-gide to treat symptomatic osteochondral talar lesion
16488569|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
16488570|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
16488571|NCT03371095|Experimental|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
16488572|NCT03371095|Active Comparator|Cyclophosphamide|Cyclophosphamide 0.7g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
16488573|NCT03371082|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
16488574|NCT03371082|Active Comparator|Lantus®|Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
16488575|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
16488576|NCT03371056|Experimental|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
16488577|NCT03371056|Experimental|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (> 12 hours before labor) but > 37 SA will be included.
16488578|NCT03371056|Experimental|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection <37SA
16488579|NCT03371056|Experimental|Women with premature delivery or premature delivery threat|Woman with high risk of infection <37SA and Women with premature delivery or premature delivery threat
16488580|NCT03371043||users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
16488583|NCT03371017|Experimental|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
16488584|NCT03371017|Placebo Comparator|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
16488585|NCT03371004|Experimental|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
16488586|NCT03370991|Experimental|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
16488587|NCT03370991|Placebo Comparator|Control|22 g/day placebo powder for 12 weeks
16488588|NCT03370978|Experimental|Text Messaging|Receives text messages to remind of upcoming follow-up appointment with primary care doctor. Also provides opportunity for subjects to text ED staff for follow-up care concerns or to reschedule primary care appointment.
16488589|NCT03370978|No Intervention|Usual Care|Received usual care including follow-up phone calls if clinically indicated.
16488590|NCT03370965|Experimental|Patients with optic neuritis|
16488714|NCT03370042|Active Comparator|Semilunar Coronally Positiones Flap + Free Gingival Graft|semilunar coronally positioned flap with free gingival graft for root coverage
16488715|NCT03370042|Sham Comparator|Semilunar Coronally Positioned Flap|semilunar coronally positioned flap alone without free gingival graft for root coverage
16488591|NCT03370952|Active Comparator|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).
~Aspiration of the cyst:
~Delivery of affected ovary outside the abdominal cavity:
~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.
~Ovarian cystectomy:
~Re-introduction of the ovary to inside the abdominal cavity:"
16488592|NCT03370952|Active Comparator|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
16488593|NCT03370913|Experimental|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
16488594|NCT03370900|No Intervention|Learning and Assessment at 12 months|Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
16488595|NCT03370900|Experimental|Testing Every Two Months|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests without any feedback at 2, 4, 6, 8, 10, 12 months.
16488596|NCT03370900|Experimental|Low Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 6 months, the 20-case post-test will be delivered with feedback.
16488597|NCT03370900|Experimental|High Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 4, 8, and 12 months, the 20-case post-test will be delivered with feedback.
16488598|NCT03370887|Experimental|Low dose AZD8601 (3 mg)|8 patients will be randomised to receive 3 mg AZD8601
16488599|NCT03370887|Experimental|High dose AZD8601 (30 mg)|8 patients will be randomised to receive 30 mg AZD8601
16488600|NCT03370887|Placebo Comparator|Placebo|8 patients will be randomised to receive placebo injections
16488601|NCT03370874|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
16488602|NCT03370874|Placebo Comparator|Vehicle Sheet|Hydrogel sheet without Allogenic mesenchymal stem cell
16488603|NCT03370848|Experimental|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.
~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER
~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
16488604|NCT03370848|Active Comparator|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.
~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
16488605|NCT03370835|Experimental|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10
~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
16488606|NCT03370835|Active Comparator|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10
~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
16488607|NCT03370822||Study Participants|Women who have continuous fetal monitoring using the MONICA AN24 device. The MONICA AN24 is a wearable monitor with five adhesive electrodes placed on the mother's abdomen. This records the fetal heart rate, maternal heart rate and uterine contractions.
16488608|NCT03370809|Experimental|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
16488609|NCT03370796|Experimental|Reminiscence Therapy|The Reminiscence program will consist of a set of sessions thematically sequenced topics that address the life course of the participant. Each session will integrate a group of activities that will be developed in group and will have a didactic character, privileging subjective interests and interpersonal communication.
16488610|NCT03370796|No Intervention|Control Group|The control group shall participate in the institutional care provided by the professionals of each RSE.
16488611|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
16488612|NCT03370757|Active Comparator|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
16488613|NCT03370757|Active Comparator|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
16488614|NCT03370744||Subjective cognitive decline, SCD|The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) failure to meet the following criteria for MCI.
16488615|NCT03370744||Normal control, NC|NC are individuals who have no self-report persistent decline in cognitive capacity, and with neither worry nor concern about their cognition. Without measurable cognitive impairment according to results of standard assessments.
16488616|NCT03370744||Mild cognitive impairment, MCI|MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9.
16488617|NCT03370744||Alzheimer's disease, AD|The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) with a total CDR score of 1.
16488869|NCT03369015|Experimental|20 mg d-amphetamine, then placebo, then 10mg d-amphetamine|
16488618|NCT03370744||Subjective Cognitive Decline plus, SCD-plus|The inclusion criteria for SCD-plus are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI.
16488619|NCT03370731|Experimental|Adenotonsillectomy|Surgical management, i.e. adenotonsillectomy, including adenoidectomy, tonsillectomy or adenoidectomy combined tonsillectomy
16488620|NCT03370731|Other|Nonsurgical management|Nonsurgical management, including nasal irrigation, inhaled corticosteroids etc.
16488621|NCT03370718|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
16488622|NCT03370705|Active Comparator|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l
16488623|NCT03370705|Experimental|Sulodexide + CT group|"78 patients will be treated by :
~Sulodexide (250ULS, twice daily , oral administration)
~Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l"
16488624|NCT03370666|Experimental|HFNT|HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.
16488625|NCT03370666|Active Comparator|NIV|NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.
16488626|NCT03370653|Experimental|Double-blind - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
16488627|NCT03370653|Experimental|Double-blind - odiparcil 500 mg per day|1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
16488628|NCT03370653|Placebo Comparator|Double-blind - placebo|2 tablets of placebo per os, twice daily (BID)
16488629|NCT03370653|Experimental|Open Label - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
16488630|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 1|An oral 25 mg dose of SEP 363856 once daily for 3 days, then 50 mg dose of SEP-363856 once daily for 7 days.
16488631|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 2|An oral 50 mg dose of SEP 363856 once daily for 3 days, then 75 mg dose of SEP-363856 once daily for 7 days.
16488632|NCT03370640|Experimental|SEP-363856 Part 2 Cohort 3|An oral 25 mg dose of SEP 363856 once daily for 3 days, 50 mg dose of SEP 363856 once daily for 4 days, and then 75 mg dose of SEP-363856 once daily for 7 days.
16488633|NCT03370627|Experimental|Patient|
16488634|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
16488635|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
16488636|NCT03370601|Other|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
16488637|NCT03370601|Other|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
16488638|NCT03370588|Experimental|dexmedetomidine infusion group|
16488639|NCT03370588|Active Comparator|normal saline infusion group|
16488640|NCT03370575|Experimental|ethiodized poppyseed oil|
16488641|NCT03370575|Active Comparator|the second-generation non-ionic monomer contrast|
16488642|NCT03370562|Active Comparator|Dexmedetomidine|Patient will receive 10 mcg of dexmedetomidine in 5 ml of normal saline, administered by slow intravenous injection
16488643|NCT03370562|Placebo Comparator|Placebo|Patient will receive 5 ml of normal saline, administered by slow intravenous injection
16488644|NCT03370549|Experimental|AWARE intervention|Group psychotherapy intervention for Asian-American women
16488645|NCT03370549|Other|Waitlist control|Delayed AWARE intervention for Asian-American women
16488646|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
16488647|NCT03370510|Experimental|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
16488648|NCT03370510|Placebo Comparator|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
16488649|NCT03370497|Active Comparator|Whey protein hydrolysate|Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
16488650|NCT03370497|Experimental|Whey protein hydrolysate plus milk mineral supplement|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
16488651|NCT03370484|Placebo Comparator|Control|Water with artificial sweetener
16488652|NCT03370484|Experimental|Milk mineral supplement|Milk Minerals containing 1000 mg calcium with artificial sweetener and water
16488653|NCT03370471|Experimental|Healthy Older Adults|"Participants complete all four interventions
~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
16489292|NCT03365856||RA patients|As routinary clinical practice and observational study
16488654|NCT03370471|Experimental|Individuals with Aphasia|"Participants complete all four interventions
~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
16488655|NCT03370458|Experimental|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.
~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
16488656|NCT03370458|Placebo Comparator|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
~Intervention: Dietary Supplement: Placebo"
16488657|NCT03370432||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
16488658|NCT03370432||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
16488659|NCT03370419|Experimental|The Pick Two to Stick To|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
16488660|NCT03370419|Other|Usual Care|Participants receive usual care only.
16488661|NCT03370406|No Intervention|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
16488662|NCT03370406|Experimental|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
16488663|NCT03370406|Experimental|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
16488664|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
16488665|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
16488666|NCT03370367|Experimental|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
16488667|NCT03370367|Placebo Comparator|Arm B|Take 2 placebo pills once a day for up to 2 years.
16488668|NCT03370354||Control group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is > 18, the patient will be in the control group.
16488669|NCT03370354||troubled sleeping patterns group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is < 18, the patient will be in the troubled patterns group.
16488670|NCT03370341|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
16488671|NCT03370341|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
16488672|NCT03370328|Experimental|Peppermint oil|post-op surgical patients
16488673|NCT03370328|Experimental|Ginger oil|post-op surgical patients
16488674|NCT03370328|Experimental|Peppermint and ginger oil|post-op surgical patients
16488675|NCT03370315|Experimental|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.
~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
16488676|NCT03370315|Experimental|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.
~Intervention administered: Walking program with 3 different moments."
16488677|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
16488678|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
16488679|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
16488716|NCT03370029||Primary ciliary dyskinesia patients|Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
16488717|NCT03370029||Healthy individuals|Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.
16488680|NCT03370276|Experimental|Phase I - Affiliate Sites Only|"Nivolumab and dose escalation of Cetuximab.
~Dose Level 1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.
~Dose Level -1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
16488681|NCT03370276|Experimental|Phase I - Moffitt Site Only|"Nivolumab and dose escalation of Cetuximab.
~Dose Level 1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.
~Dose Level -1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
16488682|NCT03370276|Experimental|Phase II - Affiliate Sites Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
16488683|NCT03370276|Experimental|Phase II - Moffitt Site Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
16488684|NCT03370263||Benlysta intravenous (IV)|This arm will include subjects who will receive Benlysta IV. Observation period per subject will be for 52 weeks from start of Benlysta administration.
16488685|NCT03370263||Benlysta subcutaneous (SC)|This arm will include subjects who will receive BENLYSTA SC. Observation period per subject will be for 52 weeks from start of Benlysta administration.
16488686|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16488687|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16488688|NCT03370211|Experimental|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
16488689|NCT03370211|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
16488690|NCT03370198|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
16488691|NCT03370198|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
16488692|NCT03370198|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
16488693|NCT03370185|Experimental|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
16488694|NCT03370172|Experimental|Cohort 1|Cohort 1 participants will receive a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10^12 capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).
16488695|NCT03370172|Experimental|Cohort 2|Cohort 2 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 6.0*10^12 cp/kg on the day of dosing (Day 0).
16488696|NCT03370172|Experimental|Cohort 3|Cohort 3 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 1.2*10^13 cp/kg on the day of dosing (Day 0).
16488697|NCT03370159|Experimental|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16488698|NCT03370146||TKA patients - Experimental Group|
16488699|NCT03370146||TKA patients - Control Group 1|
16488700|NCT03370146||Healthy subjects - Control Group 2|
16488701|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
16488702|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
16488703|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
16488704|NCT03370120|Experimental|Padsevonil|"Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study.
~Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available."
16488705|NCT03370107|Active Comparator|Active rTMS and H coil|
16488706|NCT03370107|Placebo Comparator|sham rTMS and Hcoil|
16488707|NCT03370094||patients with suspected stroke|patients with suspected stroke due to paramedic's initial evaluation of face, arm, and speech function will be diagnosed with audio-video-streaming of suspected stroke symptoms and signs
16488708|NCT03370081|Experimental|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
16488709|NCT03370081|No Intervention|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
16488710|NCT03370068|Experimental|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
16488711|NCT03370068|Active Comparator|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
16488712|NCT03370055|Active Comparator|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
16488713|NCT03370055|Placebo Comparator|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
16488718|NCT03370016|Experimental|Reduction in pressure|This group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
16488719|NCT03370016|Active Comparator|Stand Amount of Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
16488720|NCT03369990|Experimental|Botulinum toxin type A|DWP450
16488721|NCT03369990|Placebo Comparator|Placebo|Normal Saline
16488722|NCT03369977|Experimental|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
16488723|NCT03369977|Other|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
16488724|NCT03369964|Experimental|Atezolizumab + Emactuzumab|Participants will receive Atezolizumab and Emactuzumab on Day 1 of each 21- day cycle
16488725|NCT03369964|Active Comparator|Atezolizumab + Emactuzumab + Obinutuzumab|"Participants will receive Atezolizumab, Emactuzumab, and Obinutuzumab on Day 1 of each- 21 day cycle (starting in cycle 2)
~(Atezolizumab starting in cycle 2); and Obinutuzumab on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2-8."
16488726|NCT03369951|Experimental|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
16488727|NCT03369938|Experimental|exercise training intervention|
16488728|NCT03369938|No Intervention|usual care|
16488729|NCT03369925|Placebo Comparator|Placebo|
16488730|NCT03369925|Experimental|Cognizin|
16488731|NCT03369912|Experimental|Active|CSJ148
16488732|NCT03369912|Placebo Comparator|Placebo|5% dextrose
16488733|NCT03369886|Other|Early glaucoma group|Patients whose visual field mean deviation is > -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
16488734|NCT03369886|Other|Advanced glaucoma group|Patients whose visual field mean deviation is < -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
16488735|NCT03369873|Experimental|Nursing Orientation with guidance manual|The patients received the nursing orientation with validated guidance manual of cardiac catheterization.
16488736|NCT03369873|No Intervention|Routine Nursing Orientation|The patients received the routine nursing orientation about cardiac catheterization.
16488737|NCT03369860|Experimental|Healthy Subjects|Healthy Subjects take part in the experimental manipulation
16488738|NCT03369847|Experimental|Inhaled Corticosteroids|"Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.
~Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
16488739|NCT03369847|No Intervention|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
16488740|NCT03369834|No Intervention|Control Group|the volunteers of this group will not be submitted to the intervention.
16488741|NCT03369834|Experimental|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
16488742|NCT03369834|Active Comparator|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
16488743|NCT03369834|Active Comparator|LED group mixed|in the volunteers of this group will be applied Infrared and Red Light-emitting diode device with the wavelength of 940nm and 620nm throughout the tibialis anterior muscle and bilateral sural triceps.
16488744|NCT03369834|Placebo Comparator|Sham Group|LED device off.
16488745|NCT03369821||Study 1: Existing EET1D (Case)|"Aged 0 to 70 years
~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)
~Negative genetic test for mutations causing non-autoimmune neonatal diabetes if diagnosed <12 months
~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)."
16488746|NCT03369821||Study 1: T1D (Control)|"Age 0-70 years (matched to above)
~Clinical diagnosis of T1D (diagnosed age 1-20 years)
~Insulin treated from diagnosis."
16488747|NCT03369821||Study 2: Newly diagnosed EET1D (Case)|"Aged 0 to 24 months at recruitment
~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)
~Negative genetic test for mutations causing non-autoimmune neonatal diabetes
~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)"
16488748|NCT03369821||Study 2: NDM (Control)|"Diagnosis of diabetes <24 months
~Age 0 to 24 months at recruitment
~Diagnosis of NDM (confirmed by Exeter Molecular Genetics Laboratory)."
16488749|NCT03369808|Experimental|7.5μg H7N9 Vaccine|Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
16488750|NCT03369808|Experimental|15μg H7N9 Vaccine|Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
16488751|NCT03369808|Experimental|30μg H7N9 vaccine|Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
16488752|NCT03369808|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
16488753|NCT03369808|Placebo Comparator|Phosphate buffer solution|Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
16488754|NCT03369795|Experimental|Study Drug|Methotrexate 10mg
16488755|NCT03369795|Placebo Comparator|Placebo|Pills equivalent to other study arm (10 mg)
16488756|NCT03369782|Placebo Comparator|Placebo|Placebo alternative for rocuronium and for sugammadex
16488757|NCT03369782|Active Comparator|Rocuronium|Rocuronium as bolus and in syringe pump Sugammadex just before reduction of the joint
16488758|NCT03369769|Experimental|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine & handler
16488759|NCT03369769|Active Comparator|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy & handler
16488795|NCT03369470|Experimental|App Dexterity|
16488796|NCT03369470|Active Comparator|Theraband|
16488760|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
16488761|NCT03369717|Experimental|Antibiotics|To receive postoperative antibiotics
16488762|NCT03369717|No Intervention|No antibiotics|Will not receive any postoperative antibiotics
16488763|NCT03369704|Experimental|Omalizumab|Eligible patients randomized to this arm received omalizumab subcutaneously for 12 weeks
16488764|NCT03369704|Placebo Comparator|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 12 weeks
16488765|NCT03369665|Experimental|Mavenclad®|
16488766|NCT03369652|Experimental|Intervention|Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
16488767|NCT03369652|No Intervention|Control|Medication history by pharmaconomist. Usual care by physicians.
16488768|NCT03369626|Other|FareWell Program|All participants receive the FareWell Program intervention in this evaluation study
16488769|NCT03369613|Active Comparator|MRI - HC tDCS|Healthy controls in Phase 1 transcranial electrical stimulation set to direct current
16488770|NCT03369613|Active Comparator|MRI - HC tACS|Healthy controls in Phase 1- transcranial electrical stimulation set to alternating current
16488771|NCT03369613|Active Comparator|MRI - CD tCDS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to direct current
16488772|NCT03369613|Active Comparator|MRI - CD tACS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to alternating current
16488773|NCT03369613|Active Comparator|Phase II - Stim|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is active
16488774|NCT03369613|Sham Comparator|Phase II - Sham|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is sham
16488775|NCT03369600|Experimental|Healthy Controls|Women Supersonic Imagine Aixplorer SWE Ultrasound Imaging on two separate occasions.
16488776|NCT03369600|Experimental|FIB-Sx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to elective hysterectomy for treatment of symptomatic uterine fibroids.
16488777|NCT03369600|Experimental|FIB-Mx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to and at two points during elective medical therapy for treatment of symptomatic uterine fibroids.
16488778|NCT03369587|Experimental|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
16488779|NCT03369587|Active Comparator|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
16488780|NCT03369574||chronic rhinosinusitis and eosinophilic asthma|Adults over the age of 18, diagnosed with poorly controlled moderate to severe asthma with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment) who are initiating/undergoing reslizumab therapy and also carry a physician diagnosis of chronic rhinosinusitis with nasal polyposis
16488781|NCT03369561||normal cardiac patient|"Full history and clinical examination ECG on the left and right side Echocardiography and measurement of both left and right ventricular functions Laboratory investigation including cardiac enzymes, CK, CK MB, and cardiac troponin I.
~Serum urea and creatinine and the calculated e GFR"
16488782|NCT03369548|Experimental|Apple/ Polyphenol|Participants will be asked to consume 2 Renetta Canada apples (with skin) and 2 placebo capsules every day for 8 weeks.
16488783|NCT03369548|Experimental|Oats / Prebiotic|Participants will be asked to consume 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
16488784|NCT03369548|Experimental|Lactobacillus reuteri NCIMB 30242 / Probiotic|Participants will be asked to consume 2 probiotic capsules and 40g cornflakes with semi-skimmed milk every day for 8 weeks.
16488785|NCT03369548|Placebo Comparator|Placebo / cornflakes|Participants will be asked to consume 40g cornflakes with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
16488786|NCT03369535|Placebo Comparator|Baseline|Baseline corresponds to typical American diet
16488787|NCT03369535|Active Comparator|PROT rich diet|Protein rich diet for 6 weeks
16488788|NCT03369535|Active Comparator|MUFA rich diet|MUFA rich diet for 6 weeks
16488789|NCT03369535|Active Comparator|CARB rich diet|CARB rich diet for 6 weeks
16488790|NCT03369522||Construction|100 recordings that will be used for the algorithm development
16488791|NCT03369522||Validation|100 recordings for the validation of the algorithm
16488792|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
16488793|NCT03369496||MoNNET-HA Panel|Adults 25 years and older residing in the Montreal Metropolitan Area
16488794|NCT03369483||CPAP|At the end of the abdominal surgical procedure, mechanical ventilation withdrawal and extubation, patients will receive Continuous Positive Airway Pressure CPAP). CPAP will be be delivered using any commercially available CPAP equipment. CPAP will be started as soon as possible after the end of surgery. The starting airway pressure (PEEP) will be 5 cmH2O. PEEP may be changed at the discretion of the responsible physician. The maximum permissible PEEP during the trial intervention period will be 10 cmH2O. CPAP may be continued after the four-hour trial intervention period has finished, at the discretion of the responsible physician.
16488798|NCT03369431|Other|Group A|Group A starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
16488799|NCT03369431|Other|Group B|Group B starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
16488800|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
16488801|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
16488802|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
16488803|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
16488804|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
16488805|NCT03369392|Experimental|Feasibility Cycle 1|Participants use the initial PANDA application.
16488806|NCT03369392|Experimental|Feasibility Cycle 2|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1.
16488807|NCT03369392|Experimental|Feasibility Cycle 3|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1 and 2.
16488808|NCT03369379|Active Comparator|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
16488809|NCT03369379|Placebo Comparator|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
16488810|NCT03369366|Experimental|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
16488811|NCT03369340|Active Comparator|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
16488812|NCT03369340|Active Comparator|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
16488813|NCT03369340|Active Comparator|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
16488814|NCT03369340|Active Comparator|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
16488815|NCT03369340|Active Comparator|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
16488816|NCT03369340|Active Comparator|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
16488817|NCT03369327|Experimental|sofosbuvir/daclatasvir|Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic
16488818|NCT03369314||Patients Receiving octaplasLG®|The data will be collected in all patients who have received at least one infusion of octaplasLG®
16488819|NCT03369301||Gammanorm|Patients on Gammanorm per standard of care
16488820|NCT03369301||Other Subcutaneous Immunoglobulin|Patients on subcutaneous immunoglobulin treatments other than Gammanorm
16488821|NCT03369275|Experimental|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
16488822|NCT03369275|Placebo Comparator|Placebo|Intravenous infusion of Placebo, with excipients
16488823|NCT03369262|Experimental|Active|"OBE022 plus atosiban:
~OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start.
~Loading dose: 1 000 mg on Day 1.
~Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2.
~Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7)
~Atosiban will be administered over 48h as per label."
16488824|NCT03369262|Active Comparator|Placebo|"OBE022 matching placebo plus atosiban:
~OBE022 matching placebo administration will follow the same regimen as the active group.
~Atosiban will be administered over 48h as per label."
16488825|NCT03369249|Experimental|Link2CARE|This arm is comprised of participants randomized to the 4-session Link2CARE intervention.
16488826|NCT03369249|No Intervention|Standard of Care|This arm is comprised of participants who will not receive the 4-session Link2CARE intervention.
16488827|NCT03369236|Placebo Comparator|Placebo|Placebo tablets 3 times daily (TID) for the first 2 weeks (Dose Adjustment Period) with the opportunity for dose adjustment, then continued for an additional 6 months (Treatment Period). At the time of treatment completion, drug will be tapered as appropriate.
16488828|NCT03369236|Experimental|ACH-0144471|ACH-0144471 tablets at a starting dose of 100 mg TID for the first 2 weeks (Dose Adjustment Period) with the opportunity for dose adjustment, then continued for an additional 6 months (Treatment Period). At the time of treatment completion, drug will be tapered as appropriate.
16488829|NCT03369223|Experimental|Part 1A: BMS-986249|
16488830|NCT03369223|Experimental|Part 1B: BMS-986249 + nivolumab (nivo)|
16488831|NCT03369223|Experimental|Part 2A Arm C: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
16488832|NCT03369223|Experimental|Part 2A Arm D: ipilimumab + nivo then nivo|Previously untreated unresectable stage III-IV melanoma
16488833|NCT03369223|Experimental|Part 2A Arm F: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
16488834|NCT03369223|Experimental|Part 2B Cohort 1: BMS-986249 + nivo|Advanced hepatocellular carcinoma (HCC)
16488835|NCT03369223|Experimental|Part 2B Cohort 2: BMS-986249 + nivo|Metastatic castration-resistant prostate cancer (CRPC)
16488836|NCT03369223|Experimental|Part 2B Cohort 3: BMS-986249 + nivo|Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
16488837|NCT03369223|Experimental|Part 2A Arm A: BMS-986249 + nivo then nivo|"Previously untreated unresectable stage III-IV melanoma
~Enrollment is closed for this Arm"
16488838|NCT03369223|Experimental|Part 2A Arm B: BMS-986249 + nivo|"Previously untreated unresectable stage III-IV melanoma
~Enrollment is closed for this Arm"
16488839|NCT03369223|Experimental|Part 2A Arm E: Nivo|"Previously untreated unresectable stage III-IV melanoma
~Enrollment is closed for this Arm"
16488840|NCT03369210|Experimental|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
16488841|NCT03369210|Active Comparator|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
16488842|NCT03369197|Experimental|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
16488843|NCT03369197|Active Comparator|Control: Nasal cannula|Nasal Cannula with standard care
16488844|NCT03369184|Experimental|Supplemental oxygen|Inhalation of oxygen 6 L/min through an open face mask
16488845|NCT03369184|Sham Comparator|Ambient air|Breathing ambient air through an open face mask
16488846|NCT03369171|Experimental|patients with MYO armband|
16488847|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
16488848|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
16488849|NCT03369145|Experimental|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
16488850|NCT03369145|No Intervention|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
16488851|NCT03369132|Experimental|Angiflash|
16488852|NCT03369132|Placebo Comparator|Placebo|
16488853|NCT03369119|Active Comparator|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
16488854|NCT03369119|Placebo Comparator|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
16488855|NCT03369106||Multiple Sclerosis siblings|Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects
16488856|NCT03369093|Active Comparator|Ampicillin arm|Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days
16488857|NCT03369093|Experimental|Amoxicillin arm|Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days
16488858|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
16488859|NCT03369067|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
16488860|NCT03369067|Placebo Comparator|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
16488861|NCT03369054|Experimental|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
16488862|NCT03369054|Active Comparator|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
16488863|NCT03369028||2d and 3D image|A 2D and 3D image of the participants' face will be taken. It will at least last 2-3 sec.
16488864|NCT03369015|Experimental|Placebo, then 10 mg d-amphetamine, then 20mg d-amphetamine|
16488865|NCT03369015|Experimental|Placebo, then 20 mg d-amphetamine, then 10mg d-amphetamine|
16488866|NCT03369015|Experimental|10 mg d-amphetamine, then placebo, then 20mg d-amphetamine|
16488870|NCT03369002|Experimental|Normal|"Child-Pugh Score: N/A
~Subjects will receive a single 10 mg oral dose of seladelpar"
16488871|NCT03369002|Experimental|Mild Impairment|"Child-Pugh Score: A (5 to 6 points)
~Subjects will receive a single 10 mg oral dose of seladelpar"
16488872|NCT03369002|Experimental|Moderate Impairment|"Child-Pugh Score: B (7 to 9 points)
~Subjects will receive a single 10 mg oral dose of seladelpar"
16488873|NCT03369002|Experimental|Severe Impairment|"Child-Pugh Score: C (10 to 15 points)
~Subjects will receive a single 10 mg oral dose of seladelpar"
16488874|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
16488875|NCT03368976||Interscalene|
16488876|NCT03368976||Supraclavicular|
16488877|NCT03368976||Infraclavicular|
16488878|NCT03368976||Transversus Abdominus Plane|
16488879|NCT03368976||Paravertebral Space|
16488880|NCT03368976||Fascia Iliaca|
16488881|NCT03368976||Femoral Nerve|
16488882|NCT03368976||Saphenous Nerve via Adductor Canal|
16488883|NCT03368976||Popliteal Sciatic Nerve|
16488884|NCT03368963|Experimental|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Cycles repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
16488885|NCT03368950|Experimental|Intervention|Participants in this arm are invited to undertake an 8-week online mindfulness course
16488886|NCT03368950|Active Comparator|Wait list|Participants in this arm are informed they are on a wait list and are required to wait 8 weeks, before being invited to take part in the intervention itself (an 8-week online mindfulness course).
16488887|NCT03368937|Experimental|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
16488888|NCT03368924|Other|SCA patients (SS genotype)|"To compare the level of anti band 3 antibodies in steady state and during vaso-occlusive crises in SCA patients.
~To assess the relationship between level of biomarkers of oxidation of SS RBCs, altered hemorheological parameters, biomarkers of cellular activation (microparticles) and anti band 3 antibodies rate, taking into account the alpha-globin genes status.
~To study the relationship between level of anti band 3 antibodies and severity of these VOC using an index of clinical severity (IS2) calculated at the end of SCA patients hospitalization for VOC.
~To study early clinical (including the activity of the autonomic nervous system activity) and biological items to evaluate the relationship between these items and severity of VOC."
16488889|NCT03368911|Experimental|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
16488890|NCT03368911|Active Comparator|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
16488891|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
16488892|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
16488893|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
16488894|NCT03368885|Experimental|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:
~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
16488895|NCT03368885|No Intervention|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
16488896|NCT03368872|Experimental|Astaxanthin and exercise|Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
16488897|NCT03368872|Placebo Comparator|Placebo and exercise|Placebo intake for one month followed by 3-month exercise training with placebo intake.
16488898|NCT03368859|Experimental|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
16488899|NCT03368859|Active Comparator|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
16488900|NCT03368846|Experimental|[14C]-Varlitinib|
16488901|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
16488902|NCT03368833||Control|Patients who do not receive a caudal block.
16488903|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
16488904|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
16488905|NCT03368794|Experimental|Intervention|Telephone alert signal from ambulance staff to out-patient substance use disorder treatment facility, for active outreach aiming to locate and include the patient in long-term evidence-based treatment for the substance use disorder.
16488906|NCT03368794|Active Comparator|Control|Information-only. Ambulance staff hand over written information to the individual about how to seek treatment for the substance use disorder.
16488907|NCT03368781|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
16488908|NCT03368768||Contact group email of Mahidol-Oxford Research Unit (MORU)|The investigator aims to have at least 100 adult people who could provide information for the total of one year. This expects that at least 20 of those 100 people would have common cold or diarrhea at least one time over one year period. This should provide more than 80% power to detect whether the proportion of having antibiotics when they have common cold or diarrhea was lower than 50% or not. The hypothesized proportion was 20% as stated by the national strategy against AMR in Thailand
16488909|NCT03368755|Experimental|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
16488942|NCT03368495|Active Comparator|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
16488910|NCT03368755|Active Comparator|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with cases.
~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
16488911|NCT03368742|Experimental|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
16488912|NCT03368742|Experimental|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
16488913|NCT03368742|No Intervention|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
16488914|NCT03368729|Experimental|Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
16488915|NCT03368729|Experimental|Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
16488916|NCT03368729|Experimental|Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
16488917|NCT03368716|Experimental|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
16488918|NCT03368703|Experimental|COPD patients|COPD patients group
16488919|NCT03368703|Active Comparator|Healthy subjects|Healthy subject group, matched with COPD patients group on age, weight and BMI
16488920|NCT03368690|Experimental|Oligopin®|"Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.
~Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; > 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; > 60 kg body weight: 150 mg Oligopin®/day"
16488921|NCT03368690|Placebo Comparator|Placebo|Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )
16488922|NCT03368677||Teriflunomide group|20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.
16488923|NCT03368677||No disease modifying treatment|10 MS-patients who do not use any regular disease modifying MS treatment of their own volition
16488924|NCT03368664|Experimental|alemtuzumab|- alemtuzumab - Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, prednisolone, H1 antagonist [antihistamine], H2 antagonist, paracetamol, acyclovir) will be administered prior alemtuzumab administration. - Type: Experimental
16488925|NCT03368651|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
16488926|NCT03368651|No Intervention|control group|no neo-adjuvant treatment before operation
16488927|NCT03368638|Experimental|Intervention|
16488929|NCT03368599|Experimental|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
16488930|NCT03368599|Active Comparator|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
16488931|NCT03368573|No Intervention|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
16488932|NCT03368573|Experimental|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
16488933|NCT03368560|Active Comparator|Sudarshan Kriya Yoga|Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
16488934|NCT03368560|No Intervention|Control|The seven recruited age-matched controls will complete a screening appointment and an MRI only for comparison. Demographic information will also be collected from the control participants. These individuals will not undergo the study intervention.
16488935|NCT03368547|Experimental|Diagnostic (68Ga-PSMA-11, PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on day 1.
16488936|NCT03368534|Experimental|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
16488937|NCT03368521|Other|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
16488938|NCT03368521|No Intervention|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
16488939|NCT03368508|Experimental|Experimental group|the real-object rotatable 3D images were used in demonstrating these three techniques. The photogrammetry technique was used to produce the 3D images.
16488940|NCT03368508|Active Comparator|Control group|The control group received similar materials, but the only difference was that all the images were two-dimensional.
16488941|NCT03368495|Experimental|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
16488969|NCT03368339|Placebo Comparator|Vehicle|Placebo
16488943|NCT03368495|Active Comparator|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
16488944|NCT03368482|Experimental|Brain Gym Exercises|Brain Gym® (BG) is a movement-based program originally designed to improve learning capabilities through the performance of mind-body exercises. BG can be considered as an interesting field of research due to the need of identifying novel therapies which might be more pleasant for older adults who tend not to be prone to participating in conventional exercise programs and might have a positive effect on their cognitive function. In spite of this, scientific evidence regarding the effects of BG on people with cognitive impairment is scarce.
16488945|NCT03368482|Active Comparator|Standard Exercises|A traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
16488946|NCT03368469|Experimental|transcranial direct current stimulation|Transcranial direct current stimulation (35 sq cm anode over left dorsolateral prefrontal cortex, 35 sq cm cathode over right supraorbital area, 1 mA current, 20 min per treatment session, 1 session per day, 10 treatment sessions over two weeks)
16488947|NCT03368456|Experimental|S4E App Intervention|Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles
16488948|NCT03368456|Placebo Comparator|Usual Care Condition|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
16488949|NCT03368443|Active Comparator|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
16488950|NCT03368443|Experimental|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
16488951|NCT03368430|Experimental|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
16488952|NCT03368430|Placebo Comparator|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
16488953|NCT03368417|Active Comparator|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
16488954|NCT03368417|Experimental|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
16488955|NCT03368417|Experimental|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
16488956|NCT03368404|Experimental|CBL-102 eye drops|CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides
16488957|NCT03368404|Active Comparator|Vismed Multi eye drops|CE marked medical device, tear substitute containing 0.18% sodium hyaluronate
16488958|NCT03368391|Other|Sequence 1|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.
~Sequence 1 participants will receive the drugs in the following sequence: 1) tetracaine HCl and oxymetazoline HCl 2) 3% mepivacaine 3) 2% lidocaine with 1:100,000 epi"
16488959|NCT03368391|Other|Sequence 2|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.
~Sequence 2 participant will receive the drugs in the following sequence: 1) 2% lidocaine with 1:100,000 epi 2) tetracaine HCl and oxymetazoline HCl 3) 3% mepivacaine"
16488960|NCT03368391|Other|Sequence 3|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.
~Sequence 3 participants will receive the drugs in the following sequence: 1) 3% mepivacaine 2) 2% lidocaine with 1:100,000 epi 3) tetracaine HCl and oxymetazoline HCl"
16488961|NCT03368378|Experimental|Group 1|During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
16488962|NCT03368378|Active Comparator|Group 2|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
16488963|NCT03368365|Other|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
16488964|NCT03368352|No Intervention|Normoxia|Sleep in normal room air with no drug
16488965|NCT03368352|Placebo Comparator|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
16488966|NCT03368352|Experimental|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
16488967|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.045%)|topical Ophthalmic Drops (0.045%)
16488968|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.06%)|topical Ophthalmic Drops (0.06%)
16488970|NCT03368313|Experimental|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
16488971|NCT03368313|No Intervention|Control arm|No compression
16488972|NCT03368300|Other|Patients|Parkinson's patient
16488973|NCT03368300|Other|witnesses: without parkinson's disease|Subjects without parkinson's disease
16488974|NCT03368287|Experimental|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
16488975|NCT03368274|Experimental|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
16488976|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
16488977|NCT03368248||All neonatal resuscitation services.|All professionals in contact with children were interviewed: doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical.
16488978|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
16488979|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
16488980|NCT03368209|Experimental|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:
~Optical Coherence Tomography (OCT)
~Optical screening on measuring site with WM3.4.
~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
16488981|NCT03368209|Experimental|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.
~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
16488982|NCT03368209|Experimental|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.
~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
16488983|NCT03368196|Experimental|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
16488984|NCT03368183|Experimental|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
16488985|NCT03368183|Active Comparator|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
16488986|NCT03368170|Experimental|Mesdopetam (IRL790)|Capsule 2.5 mg, oral administration
16488987|NCT03368170|Placebo Comparator|Placebo|Identical capsule, oral administration
16488988|NCT03368144|Experimental|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
16488989|NCT03368131|Experimental|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
16488990|NCT03368131|Active Comparator|XELOX and radiotherapy|Capecitabine：825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
16488991|NCT03368118|Experimental|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.
16488992|NCT03368105|Experimental|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
16488993|NCT03368105|Placebo Comparator|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
16488994|NCT03368092|Experimental|Dornase alfa|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
16488995|NCT03368092|Placebo Comparator|Placebo|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
16488996|NCT03368079|Experimental|Negative Pressure Suction Device|
16488997|NCT03368066|Experimental|Hospitalized cirrhosis patients|Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency
16488998|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
16488999|NCT03368027|Experimental|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
16489000|NCT03368027|Active Comparator|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
16489003|NCT03368001|Experimental|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
16489004|NCT03368001|Active Comparator|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
16489005|NCT03367988|Experimental|Opioid-free Anesthesia|Patients will receive no intraoperative narcotics as part of their anesthesia regimen
16489006|NCT03367988|Active Comparator|Opioid Anesthesia|Patients will receive intraoperative narcotics as part of their anesthesia regimen
16489007|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
16489008|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
16489009|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
16489010|NCT03367949|No Intervention|Accuracy of surgical guide from Model optical scan|
16489011|NCT03367949|Active Comparator|Accuracy of surgical guide from Impression inversion Technique|
16489012|NCT03367936|Active Comparator|Self-monitoring group|All subjects will use a smartphone to self-monitor diet and monitor physical activity (Fitbit Charge 2), and a Withings or Fitibit digital scale for weight. Following randomization, participants will be oriented to Self-monitoring and provided a tutorial with images shown on the laptop and devices as well as printed materials showing the screen shots. At baseline, each participant will have a one-on-one session with the project interventionist, which covers the core principles of behavioral weight loss. The participant also will be given personalized fat, calorie, and PA goals for weight loss and information about how to access the intervention materials from the Diabetes Prevention Program (DPP) online which is publicly available (https://www.diabetesprevention.pitt.edu/).
16489013|NCT03367936|Experimental|Self-monitoring+Feedback group|All subjects will be asked to do everything the self-monitoring group is asked to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. Messages will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
16489014|NCT03367923|Experimental|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
16489015|NCT03367923|Experimental|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
16489016|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
16489017|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
16489018|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
16489019|NCT03367884|Experimental|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
16489020|NCT03367884|Active Comparator|Radiotherapy group|Definitive radiotherapy (70Gy)
16489021|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).
16489022|NCT03367858|Experimental|Motivational Interviewing (MI)|
16489023|NCT03367858|Active Comparator|Brief Adolescent Mindfulness (BAM)|
16489024|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
16489025|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
16489026|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
16489027|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
16489028|NCT03367832||Paediatric surgical patients|All patients < 16 years, admitted to participating centres during the study period who undergo elective and non-elective surgery
16489041|NCT03367780||RT with curative intent for HNSCC|several schemes for radical (chemo)radiotherapy, administered in 30-35 fractions over 6-7 weeks
16489042|NCT03367767||1|Former AREDS2 and AREDS2 Follow-On participants
16489043|NCT03367754|Experimental|1|Single dose of 200 mg (IV infusion)
16489044|NCT03367754|Placebo Comparator|2|Single dose (IV infusion)
16489047|NCT03367728|Placebo Comparator|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
16489048|NCT03367728|Experimental|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
16489049|NCT03367715|Experimental|Nivolumab + Ipilimumab + Short-course radiation therapy|within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1
16489050|NCT03367702|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
16489051|NCT03367702|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
16489052|NCT03367689|Experimental|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
16489053|NCT03367676|Experimental|Experimental Arm|12 weeks adjuvant docetaxel plus trastuzumab
16489054|NCT03367663|Experimental|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
16489055|NCT03367663|Experimental|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
16489076|NCT03367481|Active Comparator|Control toothbrush|The participants will use a toothbrush with soft bristles.
16489077|NCT03367481|Experimental|Test toothbrush|The participants will use a toothbrush with medium bristles.
16489056|NCT03367650|Other|ALS's patients in Guadeloupe and Martinique|"We shall determine:
~Impact of ALS in Guadeloupe and Martinique
~Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study
~The distribution of ALS various phenotypes in our population of patients.
~We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.
~Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease
~Search for possible environmental factors"
16489057|NCT03367637|Active Comparator|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).
~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
16489058|NCT03367637|Experimental|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
16489059|NCT03367611|Experimental|Immunochemical faecal occult blood test|All participants will collect a single faecal sample for haemoglobin measurement (immunochemical faecal occult blood test, iFOBT), and be examined by colonoscopy.
16489060|NCT03367598||Normal weight|nondiabetic and nonobese individuals (18.5 kg/m2 ≤ BMI < 25 kg/m2, n=349)
16489061|NCT03367598||Overweight|nondiabetic and nonobese individuals (25 kg/m2 ≤ BMI < 30 kg/m2, n=154)
16489062|NCT03367585|Experimental|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
16489063|NCT03367585|Placebo Comparator|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
16489064|NCT03367572|Experimental|Group I (netupitant/palonosetron hydrochloride, dexamethasone|Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
16489065|NCT03367572|Experimental|Group II (net/pal hydro, dexa, prochlorperazine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.
16489066|NCT03367572|Experimental|Group III (net/pal hydro, dexa, olanzapine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.
16489067|NCT03367559|Experimental|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
16489068|NCT03367546|Experimental|rATG, FLU/CY/TBI, & Thiotepa|Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), & Thiotepa
16489069|NCT03367533|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
16489070|NCT03367533|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
16489071|NCT03367520|Experimental|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
16489072|NCT03367507|Experimental|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
16489073|NCT03367507|Active Comparator|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
16489074|NCT03367494|Other|Subjects with Cystic Fibrosis|Diagnostic
16489075|NCT03367494|Other|Healthy Volunteers|Diagnostic
16489078|NCT03367468|Active Comparator|Physiotherapy group|Strengthening and stretching exercises,cross friction massage (supervised by physiotherapist) Mobilization techniques Daily usage of prescribed orthotic insole
16489079|NCT03367468|Active Comparator|Home exercise group|Strenthening and stretching exercises Daily usage of prescribed orthotic insole
16489080|NCT03367468|No Intervention|Control group|Follow ups Daily usage of prescribed orthotic insole
16489081|NCT03367455||ARIC and JHS participants|A combined cohort of Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) participants
16489082|NCT03367429|Experimental|Exp 2 & 3 - Arm 1|"If within-subject design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM and one standard BT injection of of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic MGM.
~If between-subjects design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM."
16489083|NCT03367429|Experimental|Exp 2 & 3 - Arm 2|"If within-subject study design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM and one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic MGM.
~If between-subjects design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM."
16489084|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
16489085|NCT03367403|Experimental|LY3002813|LY3002813 administered intravenously (IV).
16489086|NCT03367403|Placebo Comparator|Placebo|Placebo administered IV.
16489087|NCT03367390|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
16489088|NCT03367377|Experimental|LY3209590|Escalating doses of LY3209590 administered by subcutaneous (SC) injection
16489089|NCT03367377|Active Comparator|Insulin glargine|Insulin glargine administered by SC injection
16489090|NCT03367364|Active Comparator|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
16489091|NCT03367364|Placebo Comparator|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
16489092|NCT03367351|Experimental|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
16489093|NCT03367351|Placebo Comparator|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
16489094|NCT03367338|Active Comparator|Group A|Participants in group A consumed a 2-day very low-phosphate diet with PPR of 8 mg/g, followed by a 5-day washout period in which they adhered to usual diets, and then consumed a 2-day low-phosphate diet with PPR of 10 mg/g.
16489095|NCT03367338|Active Comparator|Group B|Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.
16489096|NCT03367325|Experimental|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
16489097|NCT03367325|No Intervention|CDS-NVAF not-benefiting group|
16489098|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
16489099|NCT03367299|Experimental|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
16489100|NCT03367286||Computed Tomography Perfusion (CTP)|
16489101|NCT03367286||Magnetic Resonance Perfusion (MRP)|
16489102|NCT03367273|Experimental|vitiligo patients|
16489103|NCT03367273|Experimental|controls|
16489104|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,
~A smartphone-based symptom management app,
~A print and web-based symptom management toolkit,
~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences
~BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks
~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
16489105|NCT03367247|Other|Enhanced Discharge Planning (EDP)|"Medication education,
~Self-management strategies for symptoms,
~Skills training,
~A list of red flag symptoms and numbers for who to call"
16489106|NCT03367234|Experimental|Personalized Addiction-to-Health (PATH)|Cognitive Behavioral Therapy (CBT) sessions with a behavioral health consultant twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed weeks 27-52; Contingency management rewards for specified recovery behaviors which could include medication adherence, attendance at CB/RP sessions and/or CB/RP exercise participation; Medication-assisted treatment, either extended-release naltrexone once monthly or buprenorphine once daily; Peer recovery specialist support twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed for weeks 27-52; Psychiatric consultation as needed.
16489143|NCT03366922|Experimental|Intervention Arm 1|Participants will be given HAART and Artemisia annua leaf powder 4 g per day. They will only receive Artemisia Annua, Moringa oleifera will not be given.
16489107|NCT03367234|Active Comparator|Standard Care|Treatment may differ slightly by treatment program, but addiction specialty Intensive Outpatient Treatment (ASAM Level 2.1) will generally include individual therapy sessions with a counselor 1 hour per week for week; Medication-assisted treatment, either extended-release naltrexone once monthly or suboxone once daily; Group therapy sessions 9 hours per week then decreasing to 3 hours per week; Psychiatric consultation as needed.
16489108|NCT03367221|Experimental|NAVA group|NAVA ventilation
16489109|NCT03367195|Active Comparator|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
16489110|NCT03367195|Experimental|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
16489111|NCT03367182||Weekly paclitaxel + bevacizumab|
16489112|NCT03367182||Topotecan + bevacizumab|
16489113|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
16489114|NCT03367169|Active Comparator|minimally invasive method|The patients are treated with minimally invasive method
16489115|NCT03367169|Active Comparator|open reduction method|The patients are treated with open reduction method
16489116|NCT03367156|Experimental|Group I (dexamethasone)|Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
16489117|NCT03367156|Active Comparator|Group II (placebo, dexamethasone)|Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
16489118|NCT03367143|Experimental|L-ICE|Lenalidomide 25mg/d po d1-10, Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3, Frequency every 21 days, Total cycles 4
16489119|NCT03367130|Experimental|Intervention|HIV-positive individuals will receive the standard HIV care following the national ART guidelines. In addition, the intervention group will receive mobile phone calls. A mobile phone reminder will be made two days prior to their scheduled appointment for pills pick up. Trained research assistants will remind them of their scheduled clinic appointment of pills pick up. If the first call is missed, the second call will be made within the same day, if the second call is also missed, the final call will be made next day. The intervention will be delivered over the period of six months. Outcome assessors will not be involved in the phone calls.
16489120|NCT03367130|Placebo Comparator|Control|Control group will also receive the standard HIV care following the national ART guidelines and phone calls educating them on healthy living. Phone calls will be made once a month.
16489121|NCT03367104||Normal healthy controls|
16489122|NCT03367104||Heart failure patients|
16489123|NCT03367091|Experimental|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:
~20-minute Ekso GT gait training with high swing assistance
~20-minute Ekso GT gait training with neutral swing assistance
~20-minute Ekso GT gait training with high swing resistance.
~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
16489124|NCT03367078||tDCS cohort|DOC patients treated according to usual care, plus anodal tDCS (prospective cohort)
16489125|NCT03367078||Historical control cohort|DOC patients treated according to usual care only (retrospective cohort of patients matched for demographic and clinical characteristics, admitted at the Montecatone Rehabilitation Institute no more than 3 years before the introduction of tDCS)
16489126|NCT03367065|Experimental|Dynamic contrast enhanced computerised tomography|
16489127|NCT03367052|Experimental|Two level Prodisc-C vivo|Two level Prodisc-C vivo cervical artificial disc replacement.
16489128|NCT03367052|Active Comparator|Hybrid|This group of patients will be treated with hybrid construct, i.e., one level of Prodisc-C vivo and one level of anterior cervical discectomy fusion (ACDF).
16489129|NCT03367039|Experimental|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
16489130|NCT03367039|Active Comparator|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
16489131|NCT03367026|Active Comparator|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
16489132|NCT03367026|No Intervention|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
16489133|NCT03367013|Experimental|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
16489134|NCT03367013|Sham Comparator|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
16489135|NCT03367000|Experimental|Ceprolac|Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months
16489136|NCT03367000|Placebo Comparator|Dietary counseling (DC)|Received standard diet counselling only for 6 months.
16489137|NCT03366974|Experimental|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2
~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9
~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
16489138|NCT03366961|Other|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
16489139|NCT03366935|Experimental|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
16489140|NCT03366935|Active Comparator|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
16489141|NCT03366935|Active Comparator|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
16489142|NCT03366922|Active Comparator|Control Arm|Participants will be on routine HAART only. No Artemisia Annua, Moringa oleifera will be given.
16489214|NCT03366402||Influenza A|
16489144|NCT03366922|Experimental|Intervention Arm 2|Participants will be given HAART with Artemisia annua leaf powder of 4 grams per day and Moringa oleifera leaf powder of 10 grams per day. Both Artemisia Annua, Moringa oleifera will be given.
16489145|NCT03366909|Experimental|MBRP group|20 patients 2 groups of 10 patients
16489146|NCT03366909|Active Comparator|classic care in addictology center|20 patients
16489147|NCT03366896|Experimental|Delirium|Diagnosis of delirium according to 5th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by Psychiatrist.
16489148|NCT03366883|Experimental|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
16489149|NCT03366883|Experimental|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
16489150|NCT03366870|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
16489151|NCT03366870|Experimental|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
16489152|NCT03366857|Active Comparator|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
16489153|NCT03366857|Active Comparator|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
16489155|NCT03366831|Active Comparator|15 minute version without questions|15 minute version of the TMW-Newborn intervention video without questions interspersed
16489156|NCT03366831|Active Comparator|15 minute version with questions|15 minute version of the TMW-Newborn intervention video with questions interspersed
16489157|NCT03366831|Active Comparator|7 minute version without questions|7 minute version of the TMW-Newborn intervention video without questions interspersed
16489158|NCT03366831|Active Comparator|7 minute version with questions|7 minute version of the TMW-Newborn intervention video with questions interspersed.
16489159|NCT03366818|Experimental|thrombectomy|thrombectomy by Versi system
16489160|NCT03366805|Active Comparator|Wound Care Video|Wound Care Patient Education Video
16489161|NCT03366805|Experimental|Pain Management Video Group|Pain Management Patient Education Video
16489162|NCT03366792|Experimental|MRI Targeted Biopsy|
16489163|NCT03366779|Other|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
16489164|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
16489165|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
16489166|NCT03366753|Experimental|Acute normovolemic hemodilution|acute normovolemic hemodilution by using hydroxyethyl starch
16489167|NCT03366753|Experimental|In-vitro hemodilution|adding additional hydroxyethyl starch for achieving further 30% dilution of whole blood sample which already underwent ANH of 4-6 ml/kg.
16489168|NCT03366740|Experimental|GB mixed full strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the GB mixed full strength rice suji.
~The allocated diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
16489169|NCT03366740|Experimental|Full strength rice suji alone|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.
16489170|NCT03366740|Active Comparator|3/4th strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.
16489171|NCT03366727|Experimental|DCB group|this group treated with drug coated balloon catheter, Orchid
16489172|NCT03366727|Experimental|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
16489173|NCT03366714|Experimental|RAM cannula|nasal CPAP support with RAM cannula
16489174|NCT03366714|Active Comparator|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
16489175|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
16489176|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
16489177|NCT03366688|Active Comparator|IBI306|Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
16489178|NCT03366688|Placebo Comparator|placebo|Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design
16489179|NCT03366675|Experimental|AZD2811|AZD2811 200mg IV QD CnD1 & D4 every 4weeks
16489180|NCT03366649|Other|UMA (Group 1)|Participants in the UMA group will receive an undersizing mitral annuloplasty (UMA).
16489181|NCT03366649|Other|UMA + PMA (Group 2)|Participants in the UMA + PMA group will receive an undersizing mitral annuloplasty (UMA) with papillary muscle approximation (PMA).
16489182|NCT03366649|No Intervention|Retrospectively identified patients|Retrospectively identified patients, who already underwent the standard of care surgery for the lesion of interest at Emory, within 6 months (± 1 month) after the date of their surgery, and are suitable for recruitment to the study for their post-operative research.
16489215|NCT03366402||Influenza B|
16489183|NCT03366636|No Intervention|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
16489184|NCT03366636|Experimental|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
16489185|NCT03366623|Other|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.
~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
16489186|NCT03366623|Other|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
16489187|NCT03366610||Patients Previously Treated with Daclatasvir-Based Regimens|Patients in China Previously Treated with Daclatasvir-Based Regimens
16489188|NCT03366597|Experimental|Sevoflurane|Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
16489189|NCT03366584|Experimental|Intervention|"beta carotene 25,000 IU
~vitamin D3 50,000 IU
~zinc 50 mg
~dexamethasone 6 mg"
16489190|NCT03366584|Active Comparator|Control|dexamethasone 6 mg
16489191|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
16489192|NCT03366571||Non anti-viral therapy group|History study from literature
16489193|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
16489194|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
16489195|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
16489196|NCT03366532||Nurses' Health Study|The NHS began in 1976 when 121,700 female nurses aged 33-55 years and residing in the United States responded to a baseline questionnaire.
16489197|NCT03366532||Nurses' Health Study II|The NHSII was initiated in 1989 with the recruitment of 116,671 younger female registered nurses, 24 to 44 years of age, from 14 states
16489198|NCT03366532||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was established in 1986 and was comprised of 51,529 US male health professionals ranging in age from 40 to 75 years at enrollment from 50 states
16489199|NCT03366519||patients with pulmonary embolism|patients with pulmonary embolism confirmed by tomography scan in emergency department
16489200|NCT03366506||ALS patients|"ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).
~Observation"
16489201|NCT03366493|Experimental|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
16489202|NCT03366493|Experimental|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
16489203|NCT03366493|Experimental|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
16489204|NCT03366480|Experimental|Endometrial cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
16489205|NCT03366480|Experimental|Squamous non-small cell lung cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
16489206|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
16489207|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
16489208|NCT03366441|Experimental|Telephone group|The telephone group received telephone calls. All non-response and refusing donors were included for further follow-up. Donors who answered the phone call and agreed to be interviewed were asked the reasons why they had stopped donating according to a pre-designed questionnaire. All of the responsed donors were re-recruited by altruistic appeal.
16489209|NCT03366441|Experimental|SMS group|"The SMS intervention group received the following text message:Dear donors, Thank you for your donation through which your love brought hope to those helpless patients and your donated blood reignited the fire in their lives. If you can, please consider donating blood again to save a life. Thank you again for your support! . All donors either receiving or not receiving the message were included for further follow-up."
16489210|NCT03366441|No Intervention|Control group|No intervention will be giving to this group.
16489211|NCT03366428|Experimental|All Participants|All participants will receive DS-8201a by intravenous infusion
16489212|NCT03366415|Experimental|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
16489213|NCT03366415|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
16489217|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
16489218|NCT03366376|Experimental|Experimental|WBRT with hippocampus-sparing and SIB
16489219|NCT03366363|Experimental|Electro-acupuncture|"5 compulsory acupoints (ST35、EX-LE5、LR8、GB33 and Ashi) and 3 optional matching acupoints (stomach meridian syndrome：ST34、ST36、ST32、ST40、EX-LE2；gallbladder meridian syndrome：GB31、GB36、GB34、GB39、GB41；bladder meridian syndrome：BL39、BL40、BL57、BL60；San Yin meridian syndrome：LR7、SP9、SP10、KI10、SP4、SP6、LR3、KI3) will be chosen. Needles will be stimulated manually to achieve De Qi sensation and an electrical apparatus (Nanjing Jisheng Medical Co., Ltd., wave of 2/100Hz) will be then connected to the needles with alligator clips in pairs LR8-GB33 and two other matching acupoints. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity. Patients will receive 30-minute, 24 sessions intervention over eight weeks."
16489220|NCT03366363|Experimental|manual acupuncture|Participants in the manual acupuncture group have the same schedule as the Electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
16489221|NCT03366363|Sham Comparator|sham acupuncture|Those in the sham acupuncture group receive shallow acupuncture at non-acupoints without manipulation，Deqi or actual current output.
16489222|NCT03366350|Experimental|Consolidative allo-HSCT following CAR-T therapy|Patients who had achieved MRD-negative complete remissions through CAR-T therapy (NCT02965092) will, on their own accord, receive allo-HSCT if there are no previous HSCT, contraindications, and other restrictions.
16489223|NCT03366337|Experimental|Patients with baseline ACR > 300 mg/g but ≤ 2,500 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, 20 mg at week 4, and then to 30 mg at Week 6.
16489224|NCT03366337|Experimental|Patients with baseline ACR ≤ 300 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2 and 20 mg at week 4.
16489225|NCT03366324|Experimental|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
16489226|NCT03366311|Active Comparator|holding position|different holding position of endotracheal tube
16489227|NCT03366311|Active Comparator|stylet shapes|banana shape versus straight-to-cuff shape
16489228|NCT03366311|Active Comparator|epiglottis lift|with epiglottis lift or without
16489229|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
16489230|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
16489231|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
16489232|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
16489233|NCT03366285||Fullterm infants|Quality of bonding is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from the local elementary school.
16489234|NCT03366285||Moderate to late preterm infants|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the trauma and depression in late preterm parents study (TraDelPP) conducted 2010 to 2011."
16489235|NCT03366285||Preterm infants with skin to skin contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the skin to skin contact group. The study was conducted from 2012 to 2015."
16489236|NCT03366285||Preterm infants with visual contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the visual contact group. The study was conducted from 2012 to 2015."
16489237|NCT03366272|Active Comparator|(R)-GemOx|eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
16489238|NCT03366272|Experimental|Nivo-(R)-GemOx|eight cycles of nivolumab (3 mg/kg) plus (R)-GemOx in 2-wk intervals followed by additional 18 infusions of Nivolumab (3 mg/kg) in 2-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
16489239|NCT03366259|Active Comparator|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
16489240|NCT03366259|Placebo Comparator|Group B (control group)|No prostaglandins administration before cesarean section
16489241|NCT03366246|Active Comparator|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
16489242|NCT03366246|Placebo Comparator|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
16489243|NCT03366233|Experimental|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
16489244|NCT03366233|Placebo Comparator|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
16489245|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
16489293|NCT03365843|Experimental|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
16489294|NCT03365843|Active Comparator|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
16489246|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
16489247|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
16489248|NCT03366181||heart failure patients|
16489249|NCT03366168||Group 1|Ages 18-39 years
16489250|NCT03366168||Group 2|Ages 40-59 years
16489251|NCT03366168||Group 3|Ages 60 years and older
16489252|NCT03366155|Experimental|1/Arm 1|HAIP chemotherapy + Systemic chemotherapy
16489253|NCT03366142|Experimental|Single Arm|treatment with ustekinumab based on weight
16489255|NCT03366116|Experimental|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
16489256|NCT03366103|Experimental|Treatment (navitoclax, vistusertib)|Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16489257|NCT03366090||IBD patients|Biopsies for immunological analyses
16489258|NCT03366090||healthy controls|Biopsies for immunological analyses
16489259|NCT03366077|Active Comparator|Active|L reuteri
16489260|NCT03366077|Placebo Comparator|Placebo|Placebo
16489261|NCT03366064|Experimental|Pemetrexed and donor NK cell infusion|Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion
16489262|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
16489263|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
16489264|NCT03366038||Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy is performed following pancreaticoduodenectomy.
16489265|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
16489266|NCT03366012|Other|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
16489267|NCT03365999|Active Comparator|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.
~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
16489268|NCT03365999|Experimental|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.
~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
16489269|NCT03365973||Spinal metastases of breast cancer|Patients with potentially unstable spinal metastases of breast cancer
16489270|NCT03365960|Active Comparator|Active1|watermelon rind
16489271|NCT03365960|Active Comparator|Active2|watermelon flesh
16489272|NCT03365960|Active Comparator|Active3|watermelon seeds
16489273|NCT03365960|Placebo Comparator|Control Comparator|placebo
16489274|NCT03365947|Active Comparator|ARO-HBV Injection|
16489275|NCT03365947|Placebo Comparator|Placebo|
16489276|NCT03365934|Experimental|ADHESIVE BANDAGE #1|bandage applied to wounded site.
16489277|NCT03365934|Experimental|ADHESIVE BANDAGE #2|bandage applied to wounded site.
16489278|NCT03365934|Experimental|ADHESIVE BANDAGE #3|bandage applied to wounded site
16489279|NCT03365934|Experimental|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
16489280|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
16489281|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
16489282|NCT03365921|Experimental|Hepatitis E vaccine lot 1|
16489283|NCT03365921|Experimental|Hepatitis E vaccine lot 2|
16489284|NCT03365921|Experimental|Hepatitis E vaccine lot 3|
16489285|NCT03365908|Experimental|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
16489286|NCT03365908|No Intervention|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
16489287|NCT03365895|Experimental|Diagnostic (non-enhanced MRI using MRN and DTI)|Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.
16489288|NCT03365882|Experimental|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16489289|NCT03365882|Experimental|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
16489290|NCT03365869|Active Comparator|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
16489291|NCT03365869|Placebo Comparator|placebo|sirolimus placebo: 2mg po. QD
16489295|NCT03365817|Experimental|Taper off|Decrease of opioid daily dose until discontinuation for up to six months.
16489296|NCT03365817|Active Comparator|Control Group|No changes on opioids and adjuvant medication for up to six months.
16489297|NCT03365804|Experimental|3D Printed Brace|This group will receive 3D printed brace
16489298|NCT03365804|No Intervention|Traditional Brace|This group will receive the traditional brace
16489299|NCT03365791|Experimental|PDR001+LAG525|PDR001 and LAG525 administered via i.v. infusion over 30 minutes once every 3 weeks (Q3W). LAG525 was given first followed by PDR001.
16489300|NCT03365778|Active Comparator|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
16489301|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
16489302|NCT03365778|Other|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
16489303|NCT03365765|Experimental|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
16489304|NCT03365765|Active Comparator|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
16489305|NCT03365752|Experimental|Chloroprocaine|
16489306|NCT03365752|Active Comparator|Mepivacaine|
16489307|NCT03365752|Active Comparator|General Anesthesia|
16489308|NCT03365739|Active Comparator|Active Comparator 1|Treatment - Mango (pulp/flesh-500 g)
16489309|NCT03365739|Active Comparator|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
16489310|NCT03365739|Placebo Comparator|Control Comparator|Vitamin C (100 mg)
16489311|NCT03365726|Experimental|DST (dobutamine-stress-test)|dobutamine stress echocardiography performed to patients undergoing major surgery
16489312|NCT03365726|No Intervention|NDST (no-dobutamine-stress-test)|patients refused the dobutamine stress test and transesophageal echocardiography measured the troponin level in first 24 hours after surgery
16489313|NCT03365700|Active Comparator|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
16489314|NCT03365700|Active Comparator|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
16489315|NCT03365687|Active Comparator|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
16489316|NCT03365687|Placebo Comparator|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
16489317|NCT03365674|Experimental|Vibration group|Vibrator head was applied (100Hz) on the popliteal fossa, during the trigger point injection
16489318|NCT03365674|Placebo Comparator|Placebo group|In placebo group, vibrator head was applied with switch-off sate, during the trigger point injection
16489319|NCT03365661|Experimental|ALT-803|
16489320|NCT03365648|Experimental|Lertal® + standard therapy|Lertal® double-layer tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
16489321|NCT03365648|Placebo Comparator|Placebo + standard therapy|Placebo tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
16489322|NCT03365635|Experimental|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
16489323|NCT03365635|Experimental|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
16489324|NCT03365635|Experimental|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
16489325|NCT03365635|Experimental|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
16489326|NCT03365635|Experimental|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
16489327|NCT03365635|Experimental|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
16489328|NCT03365622|Active Comparator|IV acetaminophen and placebo pills|
16489329|NCT03365622|Placebo Comparator|placebo IV (normal saline) + oral acetaminophen|
16489330|NCT03365609|Experimental|T-group|T-group(triple therapy)
16489331|NCT03365609|Experimental|S-group|S-group( sequential therapy)
16489332|NCT03365609|Experimental|B-group|B-group( bismuth quadruple therapy )
16489333|NCT03365609|Experimental|C-group|C-group( concomitant therapy)
16489334|NCT03365596||Subacute stroke|
16489335|NCT03365583||Vitamin B12 deficiency|"No intervention will be administered for this study. Serum vitamin B12 <203 pg/mL is considered as vitamin B12 deficiency.
~Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual"
16489336|NCT03365583||Vitamin B12 sufficient|Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
16489337|NCT03365557|Experimental|Intracuff pressure set by airway peak pressure|
16489338|NCT03365557|Other|Intracuff pressure set at 60 mmHg|
16489339|NCT03365544|Experimental|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
16489340|NCT03365544|Experimental|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
16489341|NCT03365531|Experimental|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
16489342|NCT03365531|Active Comparator|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
16489343|NCT03365518|Experimental|Cognitive Behavioural Therapy (CBT)|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
16489344|NCT03365518|Experimental|Mindfulness-Based Therapy|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
16489345|NCT03365518|No Intervention|Control - Usual Care|"Participants who are randomized to the control group will not receive mindfulness or CBT treatment. They will proceed with the course of treatment they were receiving prior to enrollment in the study. As resources for couples dealing with changes to their sexual lives after prostate cancer are limited, it is anticipated that the majority of these patients will have no treatment targeting sexual intimacy during the 6-week period between completing the first and second questionnaire.
~Those randomized to the control group will have the opportunity to be randomized to one of the treatment groups following their third and final questionnaire if they wish. In this case, they will be issued an additional participant ID within one of the treatment groups."
16489346|NCT03365492|Experimental|Treatment Arm|Patients with CAD who receive the BioFreedom™ Biolimus A9™ stent.
16489347|NCT03365479|Experimental|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
16489348|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
16489349|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
16489350|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
16489351|NCT03365466||Group D|Patients who did not receive any treatment.
16489352|NCT03365453|Experimental|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
16489353|NCT03365440||EP study with transseptal passage|"15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
~Focal pacing maneuvers"
16489354|NCT03365440||EP study without transseptal passage|- 15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
16489355|NCT03365440||Healthy participants|- 60 minute esophageal ECG (using esoECG-3D catheter) & respiration recording
16489356|NCT03365427|Experimental|Application Group|People in this arm will be introduced to an APP on smart phone, and receive lessons on how to use it on their own phones. The APP will be installed and prepare to use before surgery. People will be asked and monitored on-line to regularly use the APP.
16489357|NCT03365427|No Intervention|Convention Group|People in this arm receive exactly the same treatment and lessons on post-operative rehabilitation except the reach of the APP.
16489358|NCT03365414|Other|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
16489359|NCT03365414|Other|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
16489360|NCT03365401|Experimental|grade 1|Decompression surgery
16489361|NCT03365401|Active Comparator|grade 2|nonsurgical treatment
16489362|NCT03365388|Experimental|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
16489363|NCT03365388|Active Comparator|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
16489364|NCT03365375|Active Comparator|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
16489365|NCT03365375|Experimental|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
16489366|NCT03365362|Experimental|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
16489367|NCT03365362|Active Comparator|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
16489368|NCT03365362|Experimental|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
16489369|NCT03365362|Active Comparator|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
16489370|NCT03365349|Experimental|living theatre|One session consisting for the patient of telling a story about his/her own life with diabetes , which is first written and then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a little play.
16489371|NCT03365349|Active Comparator|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
16489372|NCT03365336|Experimental|Intervention Group|Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
16489373|NCT03365336|Active Comparator|Standard Care Group|Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
16489374|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
16489375|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
16489376|NCT03365310|Experimental|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
16489377|NCT03365310|Active Comparator|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
16489378|NCT03365297|Experimental|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
16489379|NCT03365284|Experimental|Smart Kneebrace|Smart Kneebrace with a smart phone app will be used during the rehabilitation after surgery for three months
16489380|NCT03365284|Placebo Comparator|without Smart Kneebrace|regular rehabilitation procedure will be applied after surgery
16489381|NCT03365271|Experimental|drainage|A drainage will be applied in this group.
16489382|NCT03365271|Active Comparator|without drainage|Non-drainage will be applied in this group.
16489383|NCT03365258|Other|High Nutritional Risk|modified NUTRIC score ≥ 5
16489384|NCT03365258|Other|Low Nutritional Risk|modified NUTRIC score < 5
16489385|NCT03365245|Other|study arm|Microperimetry and automated visual field are performed at three different days
16489386|NCT03365232|Experimental|non custom base attachment|
16489387|NCT03365232|Active Comparator|custom base attachment|
16489388|NCT03365219|Experimental|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
16489389|NCT03365219|Active Comparator|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
16489390|NCT03365180|Experimental|The Starter Kit Algorithm|Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
16489391|NCT03365167|Active Comparator|LANAP|LANAP (Laser Assisted New Attachment Procedure)
16489392|NCT03365167|Placebo Comparator|LANAP off|laser therapy in off mode
16489393|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
16489394|NCT03365141|Experimental|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
16489395|NCT03365141|Active Comparator|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
16489396|NCT03365115|Active Comparator|intrathecal fentanyl|
16489397|NCT03365115|Active Comparator|intrathecal morphine|
16489398|NCT03365115|Experimental|intrathecal morphine and fentantyl|
16489399|NCT03365102|Experimental|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
16489400|NCT03365102|Experimental|anodal tDCS over the lOFC|anodal tDCS over the lOFC
16489401|NCT03365102|Placebo Comparator|sham tDCS stimulation|sham tDCS stimulation
16489402|NCT03365089|Experimental|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
16489403|NCT03365089|No Intervention|Control|No collateral vein ligation.
16489404|NCT03365076|Experimental|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
16489405|NCT03365076|No Intervention|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
16489406|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
16489407|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
16489408|NCT03365037|Experimental|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
16489409|NCT03365037|Active Comparator|Fracture healing film|Patients with acute soft tissue injury treated with fracture healing film
16489410|NCT03365024|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
16489411|NCT03365024|Active Comparator|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
16489412|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.
~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
16489413|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.
~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
16489414|NCT03364998|Experimental|BAY94-9027 and Elocta|Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
16489415|NCT03364998|Experimental|Elocta and BAY94-9027|Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment
16489416|NCT03364985|Experimental|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
16489417|NCT03364985|Experimental|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
16489418|NCT03364985|Experimental|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
16489419|NCT03364985|Experimental|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
16489420|NCT03364985|Experimental|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
16489421|NCT03364985|Experimental|Cohort 6: DWP16001 Fmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
16489422|NCT03364985|Experimental|Cohort 7: DWP16001 Gmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
16489423|NCT03364985|Experimental|Cohort 8: DWP16001 Hmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
16489424|NCT03364985|Experimental|Cohort 9: DWP16001 Img|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
16489425|NCT03364985|Experimental|Cohort 10: DWP16001 Jmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
16489426|NCT03364972|Experimental|Experimental intraocular lens implant|'Alcon Clareon' : New monofocal, hydrophobic acrylic intraocular lens implant
16489427|NCT03364972|Active Comparator|Standard intraocular lens implant|Abbott Tecnis PCB00- Standard monofocal,hydrophobic acrylic intraocular lens implant
16489428|NCT03364959|Experimental|Flixotide|Patients inhale first Flixotide and then Qvar
16489429|NCT03364959|Experimental|Qvar|Patients inhale first Qvar and then Flixotide
16489430|NCT03364946||High Nasal Flow Therapy|Every patient in the ICU that requires High Nasal Flow Therapy
16489431|NCT03364933|Experimental|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
16489432|NCT03364933|No Intervention|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
16489433|NCT03364920||normal level of serum maresin-1|
16489434|NCT03364920||abnormal level of serum maresin-1|
16489435|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
16489436|NCT03364868|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
16489437|NCT03364868|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
16489438|NCT03364855|Active Comparator|SEBT exercise group|Star Excursion Balance Test will be used
16489439|NCT03364855|Active Comparator|KAT 2000 exercise group|Kinesthetic ability trainer will be used
16489440|NCT03364855|Active Comparator|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
16489441|NCT03364842|Experimental|F group|Furosemide group
16489442|NCT03364842|No Intervention|C group|Control group
16489443|NCT03364829|Experimental|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
16489444|NCT03364816||TDR with Prodisc-C|participant underwent total disc replacement with Prodisc-C artificial disc
16489445|NCT03364816||TDR with Mobi-C|participant underwent total disc replacement with Mobi-C artificial disc
16489446|NCT03364816||TDR with Prestige-LP|participant underwent total disc replacement with Prestige-LP artificial disc
16489447|NCT03364803||Participants with Cushing's Syndrome|
16489448|NCT03364790|Experimental|group1|participant with posterior lumbar interbody fusion(PLIF or PLF)
16489449|NCT03364790|Experimental|group2|participant with total knee arthroplasty (TKA)
16489450|NCT03364790|Experimental|group3|participant with PLIF and TKA on one stage
16489451|NCT03364790|No Intervention|group4|participant without operation
16489452|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
16489453|NCT03364764|Experimental|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
16489454|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
16489455|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
16489456|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
16489457|NCT03364725|Experimental|Open Label Treatment Arm|Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients
16489458|NCT03364712||pregnant|Pregnant women receiving routine medical care, including venipuncture.
16489459|NCT03364712||non-pregnant|Women not pregnant receiving routine medical care, including venipuncture.
16489460|NCT03364699|Active Comparator|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
16489461|NCT03364699|Experimental|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
16489462|NCT03364686|Experimental|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
16489463|NCT03364673|Experimental|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
16489464|NCT03364660|Experimental|Voluntary Movement Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for voluntary movement.
16489465|NCT03364660|Experimental|Cardiovascular Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function.
16489466|NCT03364660|Experimental|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
16489467|NCT03364660|Experimental|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
16489468|NCT03364647|Experimental|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
16489469|NCT03364647|Sham Comparator|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
16489470|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
16489471|NCT03364608|Experimental|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
16489472|NCT03364608|Experimental|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
16489473|NCT03364608|Placebo Comparator|• Placebo MDI|(2 actuations)
16489474|NCT03364608|Active Comparator|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
16489475|NCT03364608|Active Comparator|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
16489476|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
16489477|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
16489478|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
16489479|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
16489480|NCT03364569||Participant with tranexamic acid.|The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
16489481|NCT03364569||Participant without tranexamic acid.|This group concerns participants followed without acid tranexamic treatment. Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
16489482|NCT03364543||Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
16489483|NCT03364543||Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
16489484|NCT03364530|Other|Gemcitabine-Oxaliplatin Regimen|
16489485|NCT03364517|Experimental|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
16489486|NCT03364517|No Intervention|Control group|The classic care will be made according to the usual practices of the doctor and the center.
16489487|NCT03364504|Experimental|PXE patients|urine collection and culture of renal cells
16489488|NCT03364491|Experimental|Tranexamic Acid|Tranexamic Acid for intravenous administration
16489489|NCT03364491|Placebo Comparator|Placebo|Normal saline for intravenous administration
16489490|NCT03364478|Experimental|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach. In DML group, the dissecting based on CME is performed with dorsal approach and medial approach hybridized.
16489491|NCT03364478|Active Comparator|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach. In MLA group,the dissecting based on CME is performed with meidial-to-lateral approach.
16489492|NCT03364465|No Intervention|GruopFix|one-lung ventilation with constant tidal volume
16489493|NCT03364465|Active Comparator|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
16489494|NCT03364439|Experimental|One arm for all patients|Patients eligible for the study will receive 6 courses of R-CHOP14 or R-CHOP21.
16489495|NCT03364413||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
16489496|NCT03364400|Experimental|VT1021|Escalating doses of VT1021 to determine RP2D
16489497|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
16489498|NCT03364374||Controls|Healthy controls with no history of stroke
16489499|NCT03364361|Other|Acupuncture|Feasibility Study
16489500|NCT03364348|Experimental|Cohort 1 (Ado-trastuzumab emtansine + utomilumab)|Utomilumab at escalating doses of 20 mg and 100 mg will be given intravenously in combination with the FDA-approved dose and schedule of ado-trastuzumab emtansine (3.6 mg/kg IV) every 3 weeks.
16489501|NCT03364348|Experimental|Cohort 2 (trastuzumab + utomilumab)|Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 2).
16489502|NCT03364335|Placebo Comparator|Placebo|Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
16489503|NCT03364335|Experimental|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
16489504|NCT03364335|Experimental|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
16489505|NCT03364335|Experimental|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
16489506|NCT03364335|Experimental|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
16489507|NCT03364322||Dry eye syndrome|
16489508|NCT03364309|Experimental|Ixekizumab 80mg Q4W|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
16489509|NCT03364309|Experimental|Ixekizumab 80mg Q2W|Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
16489510|NCT03364309|Placebo Comparator|Placebo|Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
16489511|NCT03364296|Other|Patients hospitalized for stroke|
16489514|NCT03364270|Experimental|[F-18] RDG-K5|PET/CT Imaging with administration of [F-18] RGD-K5
16489515|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
16489516|NCT03364231|Experimental|Umbralisib|Umbralisib oral daily dose
16489517|NCT03364218|Experimental|Treatment Group|Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.
16489518|NCT03364218|No Intervention|Control Group|Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.
16489519|NCT03364205|Experimental|intervention|solution-focused interview techniques
16489520|NCT03364205|No Intervention|control|This group did not apply solution-focused interview techniques.
16489521|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
16489522|NCT03364179||young onset dementia|
16489523|NCT03364179||late onset dementia|
16489524|NCT03364166|Active Comparator|buccinator muscle excision with skin|surgical excision of the buccinator muscle with the skin in buccal squamous cell carcinoma and neck dissection also done
16489525|NCT03364166|Active Comparator|buccinator muscle excision without skin|surgical excision the buccinator muscle without the skin in buccal squamous cell carcinoma and neck dissection also done.
16489526|NCT03364153|Experimental|Cohort 1|Zimura dose group
16489527|NCT03364153|Sham Comparator|Cohort 2|Sham dose group
16489528|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
16489529|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
16489530|NCT03364114|Experimental|EndoRotor Resection|For the purpose of this study the EndoRotor System is investigationally indicated for use during endoscopic procedures to resect and remove refractory Barrett's esophagus tissue in conjunction with a submucosal saline injection mix using adrenaline and dye. Subjects randomized to the EndoRotor arm will be treated up to 3 times through the 9 month follow-up period to remove gross visible Barrett's.
16489531|NCT03364114|Active Comparator|Continued Ablation (Control)|The investigator shall exercise standard of care for subjects undergoing continued ablative therapies (RFA and/or Cryotherapy). These will constitute the control devices. The investigator will choose the system in this arm. Operation of each system will be done according to the manufacturer's IFU. Subjects randomized to the control arm may be treated up to 3 time through the 9 month follow-up period to remove gross visible Barrett's.
16489532|NCT03364101|Experimental|PowerOff|PowerOff is a nutraceutical and a blend of nine ingredients for sleep, including: melatonin; California Poppy; L-Cystine; Glycine; and Magnolia Officinalis
16489533|NCT03364101|Placebo Comparator|Placebo|The placebo pill will be manufactured at the same facility and appear identical in all aspects. However, the control agent will feature non-active ingredients with regards to sleep.Capsules will be instructed to commence on day 7 of the study after baseline appointment
16489534|NCT03364088|Active Comparator|Spinal anesthesia with tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.
~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
16489535|NCT03364088|Active Comparator|Spinal anesthesia without tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation.
~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
16489693|NCT03363022|Experimental|Standard Medical Treatment+Fecal Microbiota Transplant|
16489694|NCT03363022|Active Comparator|Standard Medical Treatment+Placebo|
16489809|NCT03362216|Active Comparator|Control group|Treated with Diclofenac Sodium Liniment group
16489536|NCT03364088|Active Comparator|General anesthesia with tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.
~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
16489537|NCT03364088|Active Comparator|General anesthesia without tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet.
~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
16489538|NCT03364075|Active Comparator|Duloxetine Treatment|patients treated with Duloxetine
16489539|NCT03364075|Active Comparator|Propranolol Treatment|patients treated with Propranolol
16489540|NCT03364075|Placebo Comparator|Placebo Treatment|patients treated with placebo
16489541|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
16489542|NCT03364049|Experimental|MK-7162+Pembrolizumab|Cycle 1: Participants receive MK-7162 (at a daily dose of between 25 mg and 400 mg) via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 (at a daily dose of between 25 mg and 400 mg) via oral tablets QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
16489543|NCT03364036|Experimental|Mavenclad®|
16489544|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
16489545|NCT03364010|Experimental|Dyslexic and non dyslexic Children|Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language
16489546|NCT03363997|Experimental|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
16489547|NCT03363997|Experimental|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
16489548|NCT03363997|Experimental|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
16489549|NCT03363984|Experimental|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
16489550|NCT03363971|Experimental|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
16489551|NCT03363971|Placebo Comparator|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
16489552|NCT03363958|Experimental|RIC Group|Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
16489553|NCT03363958|Sham Comparator|Control Group|Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
16489554|NCT03363945|Active Comparator|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
16489555|NCT03363945|No Intervention|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
16489556|NCT03363932||Perimembranous VSD with high pulmonary flow rate|"It is an observational study, no intervention or examination will be realized for the sole purpose of the study. Patient management will be at the discretion of referral cardiologists according to the practices of the centers.
~As part of the usual follow-up of these patients, the participating centers collect the clinical and echocardiography data from inclusion and the following year, as well as data from a functional assessment at baseline and at one year. and the collection of cardiovascular events at 5 years and 10 years of follow-up.
~Data from a possible percutaneous or surgical closure procedure will be collected. The indication of VSD closure will be left to the discretion of participating centers. There will be no recommendation for percutaneous or surgical closure of VSD for the sole purpose of this observatory."
16489559|NCT03363906|Experimental|Dulaglutide (Reference)|Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
16489560|NCT03363906|Experimental|Dulaglutide (Test)|Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
16489561|NCT03363893|Experimental|Module 1 Part A|Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). This module includes a cohort expansion of participants with breast cancer who provide paired biopsy samples.
16489562|NCT03363893|Experimental|Module 1 Part B|"Participants with advanced solid tumours that may include, but is not limited to, triple negative breast cancer (TNBC), castrate-resistant prostate cancer (CRPC), small cell lung cancer (SCLC) or ovarian cancer, will receive CT7001 (samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
~To date Module 1 Part B Arm has recruited a cohort of CRPC participants."
16489563|NCT03363893|Experimental|Module 1 Part B-1 TNBC Expansion|Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
16489564|NCT03363893|Experimental|Module 2 Part A|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.
16489565|NCT03363893|Experimental|Module 2 Part B|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will be randomized to receive CT7001 (samuraciclib) or matching placebo as oral monotherapy at the dose determined in Module 2 Part A, in combination with fulvestrant.
16489566|NCT03363893|Experimental|Module 2 Part C|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer who were enrolled to the placebo arm in Module 2 Part B will, on progression of disease, receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.
16489567|NCT03363893|Experimental|Module 4|Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
16489568|NCT03363893|Experimental|Module 6|Participants with advanced solid malignancies will receive CT7001 (samuraciclib) and a new enteric capsule CT7001 (EC) (samuraciclib) oral monotherapy in a randomized, single blind, balanced, two treatment two period, two sequence crossover with one wash out period in between, followed by once daily continuous dosing.
16489569|NCT03363880|Experimental|experimental group|The trauma treatment team will be established in the experimental group
16489570|NCT03363880|Active Comparator|control group|The trauma treatment team will not be established in this group，just establish the basic experimental settings
16489571|NCT03363867|Experimental|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
16489572|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):
~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen A."
16489573|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):
~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen B."
16489574|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):
~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen A."
16489575|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):
~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen A."
16489576|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):
~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.
~Week 16 to 32 (continuation period):
~Placebo continuation SC injection regimen A."
16489577|NCT03363841|Experimental|SCY-078|SCY-078
16489578|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
16489579|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
16489580|NCT03363815|Experimental|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
16489581|NCT03363815|Experimental|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
16489582|NCT03363815|Experimental|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
16489583|NCT03363815|Experimental|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
16489584|NCT03363789|Active Comparator|Brisement|Patients will receive a series of brisement injections for treatment of non insertional Achilles tendinosis.
16489585|NCT03363789|Active Comparator|Physical Therapy|Patients will undergo physical therapy for treatment of non insertional Achilles tendinosis.
16489586|NCT03363776|Experimental|Monotherapy|BMS-986277 administered alone
16489587|NCT03363776|Experimental|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
16489588|NCT03363776|Experimental|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
16489589|NCT03363763|Active Comparator|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
16489590|NCT03363763|Active Comparator|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
16489591|NCT03363763|Placebo Comparator|Arm 3|Placebo ointment applied topically hs x 12 weeks
16489592|NCT03363750|Experimental|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
16489593|NCT03363737|Active Comparator|Static|
16489594|NCT03363737|Experimental|Dynamic|
16489595|NCT03363724||HaGuide version 1.0 software module|Patients diagnosed with Parkinson's Disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinson's Disease, using the Neuro-Omega device for navigation and procedure's MER digital recorded data is available.
16489596|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
16489597|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
16489598|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
16489599|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
16489756|NCT03362567|Experimental|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
16489600|NCT03363659|Experimental|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
16489601|NCT03363633|No Intervention|Observation|
16489602|NCT03363633|Experimental|Injection + Compression|
16489603|NCT03363633|Active Comparator|Compression|
16489604|NCT03363620|Experimental|self ligation brackets damon ormco®|the self ligation bracket (damon system) in the orthodontic treatment, was used in the experimental group with the recommended protocol damon arches sequence.
16489605|NCT03363620|Active Comparator|conventional brackets orthos ormco®|the conventional bracket (orthos system) in the orthodontic treatment, was used in the active comparator group with the recommended protocol damon arches sequence as used in the experimental group.
16489606|NCT03363607|Experimental|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
16489607|NCT03363607|Active Comparator|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
16489608|NCT03363594||1|Diabetes Mellitus
16489609|NCT03363581||Control|Normal Weight Healthy Controls
16489610|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
16489611|NCT03363568|Experimental|Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
16489612|NCT03363568|Active Comparator|Non-Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
16489613|NCT03363555|Experimental|SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
16489614|NCT03363542|Active Comparator|Fruits and vegetables rich diet|dietary education to increase fruits and vegetable consumption
16489615|NCT03363542|Active Comparator|Whole grain fiber rich diet|dietary education to increase whole grain fiber consumption
16489616|NCT03363542|Active Comparator|Fruits and vegetables and whole grain fiber rich diet|dietary education to increase fruits and vegetable and whole grain fiber consumption
16489617|NCT03363542|No Intervention|Control group|Routine care
16489618|NCT03363529|Placebo Comparator|Standard|This study arm utilizes a standard lighting condition in the patient room
16489619|NCT03363529|Experimental|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
16489620|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
16489621|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
16489622|NCT03363503|Experimental|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
16489623|NCT03363503|Active Comparator|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
16489624|NCT03363490|Other|Control|The patients in this group will only receive health education intervention.
16489625|NCT03363490|Other|Neuromuscular exercise therapy|The patients in this group will receive exercise therapy intervention.Besides, health education will be performed for every group.
16489626|NCT03363490|Other|Self-management program|The patients in this group will receive self-management intervention.Besides, health education will be performed for every group.
16489627|NCT03363490|Other|Exercise therapy+self-management|The patients in this group will receive exercise therapy and self-management intervention.Besides, health education will be performed for every group.
16489628|NCT03363477|Experimental|AB treatment sequence|Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
16489629|NCT03363477|Active Comparator|BA treatment sequence|Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
16489630|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
16489631|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
16489632|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
16489633|NCT03363451||Infection Group|Patients with end stage liver disease with infection
16489634|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
16489635|NCT03363438||martinique|
16489636|NCT03363438||guadeloupe|
16489637|NCT03363425|Active Comparator|Lidocaine|
16489638|NCT03363425|Active Comparator|Dexmedetomidine|
16489639|NCT03363425|Placebo Comparator|Normal Saline 0,9%|
16489640|NCT03363412|Experimental|Underdilated TIPS|Patients will be treated with PTFE-covered stent grafts balloon-dilated to less than 8 mm.
16489641|NCT03363386|Experimental|Proprioceptive Exercise Group (PG)|Aerobic Exercise Proprioceptive Exercises
16489642|NCT03363386|Active Comparator|Resistive Exercise Group (RG)|Aerobic Exercise Resistive Exercises
16489695|NCT03363009|Experimental|Connected device with close following|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be analyzed every day and used for coaching
16489696|NCT03363009|Other|Connected device with standard coaching|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be saved but not used for coaching
16489757|NCT03362567|Experimental|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
16489644|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
16489645|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
16489646|NCT03363321|Experimental|PF-06741086 (Cohort 1)|
16489647|NCT03363321|Experimental|PF-06741086 (Cohort 2)|
16489648|NCT03363321|Experimental|PF-06741086 (Cohort 3)|
16489649|NCT03363321|Experimental|PF-06741086 (Cohort 4)|
16489650|NCT03363321|Experimental|PF-06741086 (Cohort 5)|
16489651|NCT03363321|Experimental|PF-06741086 (Cohort 6)|
16489652|NCT03363308|Experimental|Phase 1|training for health care workers supplemented by QI teams
16489653|NCT03363308|No Intervention|Phase 2|
16489654|NCT03363295|Experimental|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
16489655|NCT03363295|No Intervention|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
16489656|NCT03363282|Experimental|Mini-SLET|Simple Limbal Epithelial Transplantation
16489657|NCT03363282|Experimental|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
16489658|NCT03363269|Experimental|ID1201 100mg|
16489659|NCT03363269|Experimental|ID1201 200mg|
16489660|NCT03363269|Experimental|ID1201 400mg|
16489661|NCT03363269|Placebo Comparator|Placebo|
16489662|NCT03363256|Experimental|TAU+TES-NAV|Standard outpatient addiction treatment plus Therapeutic Education System adapted for AI/AN
16489663|NCT03363256|Active Comparator|TAU|Standard outpatient addiction treatment
16489664|NCT03363243|Experimental|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
16489665|NCT03363243|Active Comparator|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
16489666|NCT03363230|Experimental|Mindfulness skills|
16489667|NCT03363230|Active Comparator|Interpersonal effectiveness skills|
16489668|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
16489669|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
16489670|NCT03363217|Experimental|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
16489671|NCT03363217|Experimental|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
16489672|NCT03363204|Experimental|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
16489673|NCT03363191|Experimental|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
16489674|NCT03363191|Active Comparator|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
16489675|NCT03363178|Experimental|GC3107|BCG Vaccine, 0.1mL
16489676|NCT03363165|Active Comparator|VM202|Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
16489677|NCT03363165|Placebo Comparator|Placebo|Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.
16489678|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
16489679|NCT03363100|Experimental|Intervention|
16489680|NCT03363100|No Intervention|Control|
16489681|NCT03363087|Experimental|Mapping (Rhythmia) and ablation (IntellaNav MiFi)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation
16489682|NCT03363087|Experimental|Mapping (Rhythmia) and ablation (StablePoint)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation Contact force measurements
16489683|NCT03363087|Experimental|Mapping (Precision)|Automated high density left atrial mapping in AF and SR in different bipole orientations
16489684|NCT03363074|Experimental|Orthotic Insole|Device: Orthotic Insole 8-week follow-up with Orthotic Insole
16489685|NCT03363074|Experimental|Low-level Laser Therapy|Low-Level Laser 5-week follow-up
16489686|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
16489687|NCT03363048|Experimental|Restricted|
16489688|NCT03363048|Experimental|Restriction plus Incentive|
16489689|NCT03363048|No Intervention|Control|
16489697|NCT03362996|Experimental|Experimental Group|"50 patients Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.
~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
16489698|NCT03362996|Placebo Comparator|Control group 1|50 patients Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
16489699|NCT03362996|Other|Control Group 2|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
16489700|NCT03362983|Experimental|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
16489701|NCT03362983|No Intervention|Standard care|Standard care at separate specialty clinics and primary care as needed.
16489702|NCT03362970|Active Comparator|Standard of Care|For children randomized to the standard of care arm, the treating physician will be informed to proceed as per their usual practice and treatment patterns. If stool is unavailable a rectal swab will be collected and sent to Calgary Laboratory Services (CLS) for routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care. Home stool collection will be performed for those unable to provide a sample at enrolment and will be achieved by providing families with collection kits.
16489703|NCT03362970|Experimental|BioFire Gastrointestinal Panel FilmArray|For children randomized to the BioFire FilmArray arm, stool, if available, will be sent STAT to Calgary Laboratory Services (CLS) for the performance of the BioFire FilmArray test and routine culture. If stool is unavailable, a rectal swab will be performed and sent to CLS for the performance of the BioFire FilmArray test and routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care once it is available. Treatment decisions will be at the sole discretion of the ED treating physician who receives the result.
16489704|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
16489705|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
16489706|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
16489707|NCT03362944|Experimental|Active Music Therapy|
16489708|NCT03362944|Experimental|Passive Music Therapy|
16489709|NCT03362931|Experimental|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
16489710|NCT03362918|No Intervention|Control Group|"Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.
~Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study."
16489711|NCT03362918|Experimental|High-Intensity Interval Training|Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
16489712|NCT03362918|Experimental|Continuous Aerobic Exercise Training|Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
16489713|NCT03362905|Experimental|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
16489714|NCT03362905|Active Comparator|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
16489715|NCT03362905|Active Comparator|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
16489716|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
16489717|NCT03362853|Experimental|Nemonoxacin 500Mg Capsule|
16489718|NCT03362853|Experimental|Nemonoxacin 750Mg Capsule|
16489719|NCT03362853|Placebo Comparator|Placebo oral capsule|
16489720|NCT03362853|Active Comparator|Moxifloxacin 400Mg Tablet|
16489721|NCT03362840|Experimental|Early Start Denver Model (ESDM) group|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition.
16489722|NCT03362840|Active Comparator|Eclectic preschool intervention group|The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.
16489723|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
16489724|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
16489725|NCT03362814|Experimental|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
16489726|NCT03362814|Placebo Comparator|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
16489727|NCT03362801|Other|Sarcopenic|sarcopenic status the day before cystectomy.
16489728|NCT03362801|Other|not sarcopenic|sarcopenic status the day before cystectomy.
16489758|NCT03362554|Experimental|Intervention|
16489729|NCT03362788||VKA|"Patients receiving VKA as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
16489730|NCT03362788||NOAC|"Patients receiving a NOAC as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
16489731|NCT03362775|Other|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
16489732|NCT03362723|Experimental|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
16489733|NCT03362723|Experimental|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
16489734|NCT03362723|Experimental|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
16489735|NCT03362723|Experimental|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
16489736|NCT03362723|Experimental|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade </=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
16489737|NCT03362710|Experimental|PAD patients|"Patients referred for an arterial doppler assessment of lower limbs will be included.
~Intervention is a series of examination, followed by the measurement of the ABI and an arterial echo-doppler of the lower limbs +/- transcutaneous oxygen pressure measurements in case of suspected critical limb ischemia.
~A technician will perform the evaluation with simplified tools blinded to the results of vascular specialised investigations"
16489738|NCT03362697|Experimental|Probiotic|5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, PAC-A and Zinc
16489739|NCT03362697|Active Comparator|Antibiotic|Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick
16489740|NCT03362684|Experimental|FOLFOX-4 plus Cetuximab|
16489741|NCT03362684|Active Comparator|FOLFOX-4|
16489742|NCT03362671|Experimental|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
16489743|NCT03362658||Patients|ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
16489744|NCT03362658||Controls|Healthy controls who are age and gender matched to patients.
16489745|NCT03362645||Fabry cardiomyopathy|
16489746|NCT03362645||Hypertrophic cardiomyopathy|
16489747|NCT03362632||Infection Group|Patients with end stage liver disease with SBP
16489748|NCT03362632||Non-infection Group|Patients with end stage liver disease without SBP
16489749|NCT03362619|Experimental|CC-EIEs|Autologous cervical cancer specific engineered immune effectors (EIEs)
16489750|NCT03362606|Experimental|OC-CTLs|Autologous ovarian cancer specific cytotoxic lymphocytes
16489751|NCT03362593|Experimental|MEDI7219|Experimental Drug
16489752|NCT03362593|Placebo Comparator|Placebo|Placebo
16489753|NCT03362593|Placebo Comparator|Formulation without Active Drug|Formulation without Active Drug
16489754|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
16489755|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
16489759|NCT03362554|No Intervention|Control|
16489760|NCT03362541|Experimental|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
16489761|NCT03362541|Active Comparator|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
16489762|NCT03362528|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
16489763|NCT03362528|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for the initial 30 days, distributed over a time period of 60 days. Subjects will for the remaining 60 days of measurements, distributed over 120 days collect spectral data twice a day. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
16489764|NCT03362515|Experimental|Furosemide|
16489765|NCT03362515|Placebo Comparator|Placebo|
16489766|NCT03362502|Experimental|PF-06939926|
16489767|NCT03362489|Other|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
16489768|NCT03362489|Other|IUI|Intrauterine insemination
16489769|NCT03362476|Experimental|Computer-based alcohol reduction intervention.|Brief, computer-based, alcohol reduction intervention based on cognitive behavioral therapy (CBT) tailored for HIV/HCV co-infected women in conjunction with standard clinical care for current substance users.
16489770|NCT03362476|Other|Standard-of-care.|Routine counseling to avoid alcohol and drugs.
16489771|NCT03362463||Acute Coronary Syndrom|acute coronary syndrome in a real-life setting for patients hospitalized with an ACS (i.e. STEMI, NSTEMI, unstable angina)
16489772|NCT03362450||Pregnant patients seen for second or third trimester|Foetus with diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings
16489773|NCT03362437|Experimental|Treatment A|Receive 200 mg BMS-986177 Form A without food
16489774|NCT03362437|Experimental|Treatment B|Receive 200 mg BMS-986177 Form B without food
16489775|NCT03362437|Experimental|Treatment C|Receive 200 mg BMS-986177 Form B with food
16489776|NCT03362424|Experimental|Mesenchymal stem cell group|rotator cuff repair stem cells
16489777|NCT03362424|Active Comparator|Control group|rotator cuff repair
16489778|NCT03362411|Experimental|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
16489779|NCT03362411|Experimental|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
16489780|NCT03362411|Experimental|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
16489781|NCT03362411|Experimental|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
16489782|NCT03362398|Active Comparator|Omarigliptin|Drug: Omarigliptin 25 mg
16489783|NCT03362398|Active Comparator|Trelagliptin|Drug: Trelagliptin 100 mg
16489784|NCT03362385||OSA|
16489785|NCT03362385||Non-OSA|
16489786|NCT03362372|Experimental|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
16489787|NCT03362372|No Intervention|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
16489788|NCT03362359|Experimental|Ga-68-PSMA-11|
16489789|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
16489790|NCT03362333|Experimental|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
16489791|NCT03362333|Active Comparator|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
16489792|NCT03362320|Experimental|double layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with double layer fixation
16489793|NCT03362320|Experimental|single layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with single layer fixation
16489794|NCT03362307|Active Comparator|Laser Emitting group|subjects received Low-Level Laser and Light-Emitting Diodes after implant placement
16489795|NCT03362307|Placebo Comparator|Non Emitting group|In laser emitiiing group, subjects received Low-Level Laser and Light-Emitting Diodes after implant placement and in Non-emitting group,the same device was used while device was off.
16489796|NCT03362294|Experimental|GA Depot 40mg once monthly|Monthly IM injection
16489797|NCT03362294|Experimental|GA Depot 25mg once monthly|Monthly IM injection
16489798|NCT03362281|Experimental|Ilaprazole|
16489799|NCT03362281|Active Comparator|omeprazole|
16489800|NCT03362268|Experimental|Ilaprazole|
16489801|NCT03362268|Active Comparator|omeprazole|
16489802|NCT03362255|Active Comparator|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
16489803|NCT03362255|Active Comparator|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
16489804|NCT03362242|Active Comparator|ARO-AAT|
16489805|NCT03362242|Placebo Comparator|Placebo|
16489806|NCT03362229|Active Comparator|FIXATION|Medial malleolus fixation, with the method of fixation left to the surgeons discretion.
16489807|NCT03362229|Active Comparator|NON-FIXATION|A well reduced medial malleolus fracture is then left without fixation ie, non-operative management.
16489808|NCT03362216|Experimental|experimental group|Treated with Compound Methyl Salicylate Liniment group
16489810|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
16489811|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
16489812|NCT03362190|Experimental|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
16489813|NCT03362190|Experimental|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
16489814|NCT03362190|Experimental|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
16489815|NCT03362190|Experimental|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
16489818|NCT03362151|Experimental|Regular pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
16489819|NCT03362151|Experimental|High protein pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
16489820|NCT03362151|Experimental|White rice|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
16489821|NCT03362138||Dermoscopy|Dermoscopic imaging of a lesion decided to be biopsied
16489822|NCT03362099|No Intervention|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
16489823|NCT03362099|Active Comparator|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.
~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
16489824|NCT03362073|Experimental|Ketamine|continuous intravenous infusion of ketamine
16489825|NCT03362060|Experimental|PVX-410|"PVX-410 vaccine at W0, 1, 2, 3, 4, and 5 followed by booster PVX-410 vaccine doses at W10 and 28
~Pembrolizumab will be administered every 3 weeks intravenously starting with week 1"
16489826|NCT03362047|Experimental|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
16489827|NCT03362047|Experimental|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
16489828|NCT03362034|Active Comparator|single transfer tray|
16489829|NCT03362034|Experimental|double transfer trays|
16489830|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
16489831|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
16489832|NCT03362008|Experimental|Group I|Period I: administration of Zeropix Period II: administration of Champix®
16489833|NCT03362008|Experimental|Group II|Period I: administration of Champix® Period II: administration of Zeropix
16489834|NCT03361995|Experimental|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after PCI.
16489835|NCT03361995|Active Comparator|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
16489836|NCT03361982|No Intervention|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
16489837|NCT03361982|Experimental|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
16489838|NCT03361969|Active Comparator|estetrol|
16489839|NCT03361969|Placebo Comparator|placebo|
16489840|NCT03361956|Experimental|Part A: Arm 1 (JNJ-56136379 or NA) (open label)|Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]), and enter the 24 week post treatment follow-up phase.
16489841|NCT03361956|Placebo Comparator|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489842|NCT03361956|Experimental|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489843|NCT03361956|Placebo Comparator|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16490103|NCT03360110|Active Comparator|Test lens|Subjects randomized to wear pair of test lens either first or second
16489844|NCT03361956|Experimental|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489845|NCT03361956|Experimental|Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
16489846|NCT03361956|Placebo Comparator|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489847|NCT03361956|Experimental|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489848|NCT03361956|Placebo Comparator|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489849|NCT03361956|Experimental|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
16489850|NCT03361930|Experimental|CP participants|Single-day data collection for walking conditions; barefoot, with plain ankle-foot orthosis (flat foot plate) on involved side, with tone-reducing ankle-foot orthosis on involved side.
16489851|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
16489852|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
16489853|NCT03361891|No Intervention|Control|Patients receive no intervention
16489854|NCT03361891|Experimental|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
16489855|NCT03361878|Active Comparator|Metformin Tolerant|
16489856|NCT03361878|Active Comparator|Metformin Intolerant|
16489857|NCT03361865|Experimental|Pembrolizumab 200 mg + epacadostat 100 mg BID|Pembrolizumab + epacadostat
16489858|NCT03361865|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
16489861|NCT03361839|Active Comparator|1|patients with RIF
16489862|NCT03361839|Placebo Comparator|2|fertile arm as r reference for result
16489863|NCT03361826|Other|DBT Only|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder.
16489864|NCT03361826|Experimental|MagPro MST with Cool TwinCoil + DBT|MST treatments will be administered using the MagPro MST with Cool TwinCoil. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
16489865|NCT03361813|Active Comparator|trans-cutaneous ultrasound guided peritonsillar infiltration|
16489866|NCT03361813|Placebo Comparator|trans-oral ultrasound guided peritonsillar infiltration|
16489867|NCT03361800|Experimental|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
16489868|NCT03361787|Experimental|Parentship coaching intervention|
16489869|NCT03361774|Experimental|Test dentifrice|Participants in this arm will receive experimental dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 parts per million [ppm] fluoride).
16489870|NCT03361774|Active Comparator|Control dentifrice|Participants in this arm will receive comparator dentifrice containing 0.454% SnF2 (1100ppm fluoride).
16489871|NCT03361761||experimental|therapeutic coordination apartments with formalized/official Health education program
16489872|NCT03361761||active comparator|therapeutic coordination apartments without formalized/official Health education program
16489873|NCT03361748|Experimental|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.
16489874|NCT03361735|Experimental|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
16489875|NCT03361709|Active Comparator|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
16489876|NCT03361709|Placebo Comparator|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
16489877|NCT03361683|Experimental|High-flow nasal oxygen|Randomized patients will receive oxygen through a high flow nasal device capable of delivering humidified, heated air at an output rate of 40 L/min
16489878|NCT03361683|Active Comparator|Conventional oxygen|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
16489879|NCT03361670||Specimens that meet inclusion criteria|
16489880|NCT03361657||One sample|Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10-12mmHg
16489881|NCT03361644|Experimental|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
16489882|NCT03361644|Active Comparator|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
16489883|NCT03361631|Experimental|arm treated with MSC|"Type 1 diabetic man
~Aged from 18 to 50 years
~Having a diabetes evolving for at least 10 years
~Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot
~Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)
~IIEF-5 score less than or equal to 10"
16489884|NCT03361618|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
16489885|NCT03361618|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
16489886|NCT03361605|Experimental|Propofol Administration|
16489887|NCT03361592|Experimental|Spinal Manipulative Therapy|The participants assigned to the intervention group received the procedure Lumbar (SMT) was performed after baseline measurements, using Diversified techniques, aiming to correct vertebral dysfunctional segments after clinical assessment. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was performed in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
16489888|NCT03361592|Sham Comparator|Sham pre-load positioning SMT|"The participants assigned to the control group received the procedure Sham (pre-load positioning MVT). The Sham (SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained for approximately 1 minute in total, 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
16489889|NCT03361579|Other|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
16489890|NCT03361579|Other|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
16489891|NCT03361566|Experimental|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
16489892|NCT03361566|Experimental|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
16489893|NCT03361566|Experimental|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
16489894|NCT03361566|Experimental|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
16489895|NCT03361566|Experimental|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
16489896|NCT03361566|Experimental|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
16489897|NCT03361566|Experimental|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
16489898|NCT03361566|Experimental|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
16489899|NCT03361566|Experimental|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
16489900|NCT03361566|Experimental|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
16489901|NCT03361566|Experimental|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
16489902|NCT03361566|Experimental|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
16489903|NCT03361540|Experimental|Single dose of ASP8302 dose-1|Subjects will receive a single dose of ASP8302.
16489904|NCT03361540|Experimental|Single dose of ASP8302 dose-2|Subjects will receive a single dose of ASP8302.
16489905|NCT03361540|Experimental|Single dose of ASP8302 dose-3|Subjects will receive a single dose of ASP8302.
16489906|NCT03361540|Experimental|Single dose of ASP8302 dose-4|Subjects will receive a single dose of ASP8302.
16489907|NCT03361540|Placebo Comparator|Single dose of Placebo|Subjects will receive a single dose of Placebo.
16489908|NCT03361540|Experimental|Multiple dose of ASP8302 dose-5|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
16489909|NCT03361540|Experimental|Multiple dose of ASP8302 dose-6|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
16489910|NCT03361540|Placebo Comparator|Multiple dose of Placebo|Subjects will receive once daily dosing of Placebo for 14 consecutive days.
16489911|NCT03361514|Active Comparator|Supported Protocolized Discontinuation|Supported Protocolized Discontinuation (SPD) Patients will receive guidance of their GP and can have supportive meetings with the mental health assistant.
16489912|NCT03361514|Experimental|SPD + Mindfulness (MBCT)|In addition to the SPD (as mentioned above) patients are offered Mindfulness Based Cognitive Therapy (MBCT)
16489913|NCT03361501|Experimental|CaPre|
16489914|NCT03361501|Placebo Comparator|Placebo|
16489915|NCT03361488|Experimental|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
16489916|NCT03361488|No Intervention|Control anesthesiologist|Patient interview by control anesthesiologists
16489917|NCT03361475|Experimental|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
16489918|NCT03361475|No Intervention|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
16489921|NCT03361449|Active Comparator|Group 1|training with kinesthetic ability trainer.
16489922|NCT03361449|Active Comparator|Group 2|Flamingo exercise
16489923|NCT03361449|Active Comparator|Group 3|training with kinesthetic ability trainer and Flamingo exercise
16489924|NCT03361436|Experimental|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of cycle 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
16489925|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
16489926|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
16489927|NCT03361410|Experimental|Grape Powder|
16489928|NCT03361410|Placebo Comparator|Placebo Powder|
16489929|NCT03361397|Active Comparator|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
16489930|NCT03361397|Placebo Comparator|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
16489931|NCT03361384|Experimental|Alcohol condition|The amount of alcohol received in the alcohol condition will be determined by an algorithm developed by Curtin (Curtin, 2000). Participants in the alcohol condition will receive a dose of alcohol (target BAC = .08%), administered in a chilled beverage of 80-proof vodka mixed with tonic water and lime juice in a 1:4 ratio.
16489932|NCT03361384|Placebo Comparator|Placebo condition|Placebo participants will receive tonic water and lime juice served to enhance alcohol cues in an amount comparable to the amount that they would have received if assigned to the alcohol condition.
16489933|NCT03361384|No Intervention|Control (water)|Participants in the water control condition will receive a glass of chilled water in volume of liquid comparable to the amount that they would have received if assigned to the alcohol or placebo condition.
16489934|NCT03361371|Experimental|Interventional group|"Intervention Group: in addition to receiving the aforementioned bronchiolitis discharge instructions, this group will undergo nasal suctioning prior to each feeding as needed for 72 hours post discharge home, using exclusively the Zo-Li study device (see above under study device), with saline nose drops. Families in this group will be given the Zo-Li device at no cost and instructed in the appropriate technique and importance of using this tool.
~We shall not reveal the identity of the study devices to the ED physicians in order to minimize contamination of the control group. The ED treating physicians will also be blinded to which device the infant had been randomized to. We shall also ask the ED treating physicians not to recommend specific suctioning devices to the study patients."
16489935|NCT03361371|Placebo Comparator|Control group|Control Group: this group will receive standardized routine discharge instructions describing information about bronchiolitis, expected course of illness, recommended management strategies such as fever control, augmented air humidification, need for frequent feeding and warning signs prompting return for care. This group will be suctioned prior to feeds via bulb suction (with saline drops) which is expected to provide minimal effect, due to non-sustained negative pressures generated during bulb release. Since the benefit of nasal suction in bronchiolitis is unknown, this design is ethically reasonable. However, the use of no suction would likely meet with parental resistance and enrollment would be difficult. Families in the control group will be given the bulb device at no cost and instructed in the appropriate technique of using this tool prior to feeds.
16489936|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
16489937|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
16489938|NCT03361332||Healthy subjects|
16489939|NCT03361332||Patients with Gilles de la Tourette Syndrome|
16489940|NCT03361319|Experimental|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:
~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
16489941|NCT03361319|Experimental|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
16489942|NCT03361319|Placebo Comparator|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.
~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
16489943|NCT03361306|Experimental|KRd-Elotuzumab|Carfilzomib, Revlimid, Dexamethasone, Elotuzumab
16489944|NCT03361293|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
16489945|NCT03361293|Sham Comparator|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
16489946|NCT03361280|Experimental|Atenolol|Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
16489947|NCT03361280|Experimental|Bisoprolol|Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
16489948|NCT03361280|Experimental|Metoprolol|Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
16489949|NCT03361280|Experimental|Carvedilol|Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
16489950|NCT03361267|Active Comparator|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
16489951|NCT03361267|Experimental|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
16489952|NCT03361241|Experimental|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
16489953|NCT03361241|Active Comparator|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
16489954|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
16489955|NCT03361228|Experimental|INCB001158 + Epacadostat|
16489956|NCT03361202||Atrial fibrillation group|blood sampling
16489957|NCT03361202||control group|blood sampling
16489958|NCT03361189|Experimental|CLS-On|Subjects in this arm will programmed to CLS-on to received closed loop stimulation-based pacing.
16489959|NCT03361189|No Intervention|CLS-Off|Subjects in this arm, will be placed in a standard pacing mode (i.e. AAIR or DDDR).
16489960|NCT03361176|Active Comparator|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
16489961|NCT03361176|Experimental|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
16489962|NCT03361163|Experimental|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)
~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10^4 to 1-3x10^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
16489963|NCT03361150|Experimental|HIT|Preoperative nutrition, relaxation strategies + high intensity interval training (HIT). HIT alternates a series of high-intensity bouts with relief period. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
16489964|NCT03361150|Active Comparator|MCT|Preoperative nutrition, relaxation strategies + high intensity interval training (MCT). MCT is continuous exercise with a constant intensity below anaerobic threshold. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
16489965|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Surgery Not Performed Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled but did not have surgery. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
16489966|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
16489967|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
16489968|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
16490000|NCT03360903|Experimental|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
16490001|NCT03360903|Experimental|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
16489969|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
16489970|NCT03361124|Placebo Comparator|Control|Patient will receive standard post-partum Oxytocin (20 mU in 1 L LR) and 1 L LR over 8 hours following delivery.
16489971|NCT03361124|Experimental|Treatment|Patient will receive standard post-partum Oxytocin(20 mU in 1 L LR) an additional 20 mU Oxytocin in 1 L LR over 8 hours following delivery.
16489972|NCT03361098|Experimental|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
16489973|NCT03361098|Active Comparator|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
16489974|NCT03361098|Active Comparator|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
16489975|NCT03361098|Placebo Comparator|double placebo|placebo dapagliflozin and placebo exenatide twice daily
16489976|NCT03361085|Experimental|Intervention|nvHAP-Prevention Bundle
16489977|NCT03361072|Experimental|Milk allergy|Milk oral immunotherapy intervention for milk allergy
16489978|NCT03361072|Experimental|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
16489979|NCT03361072|Experimental|Egg allergy|Egg oral immunotherapy intervention for egg allergy
16489980|NCT03361046||Transcatheter Aortic Valve-in-Valve Implantation Cohort|
16489981|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
16489982|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
16489983|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
16489984|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
16489985|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
16489986|NCT03360994|Experimental|WATChmAN|Patients randomized to the WATChmAN Active Surveillance arm will receive their active surveillance testicular cancer care via an online virtual clinic. Importantly, patients will follow the same surveillance schedule as patients in the standard of care arm. However, patients in the WATChmAN arm will be able to see their upcoming tests and virtual appointments online, request requisitions to perform their required testing at outside institutions, and indicate any concerns for physicians to review during the virtual visit.
16489987|NCT03360994|Active Comparator|Standard of Care|Patients randomized to the standard of care arm (in-person active surveillance) will follow the current active surveillance protocol in place at Princess Margaret Cancer Centre's Multidisciplinary Testicular Cancer Clinic. This protocol involves the same schedule of testing as the WATChmAN arm, but will require patients to come into the clinic to receive their test results (as in current practice).
16489988|NCT03360981|Active Comparator|diabetics incretin-users (arm 1)|epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy.
16489989|NCT03360981|Placebo Comparator|diabetics never-incretin-users (arm 2)|epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.
16489990|NCT03360981|No Intervention|non diabetics (arm 3)|non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy.
16489991|NCT03360968|Experimental|Treatment A-B|Patient is treated with 1 hour SPN-CPAP/PS followed by 1 hour of Variable-PS ventilation mode
16489992|NCT03360968|Experimental|Treatment B-A|Patient is treated with 1 hour Variable-PS followed by 1 hour of SPN-CPAP/PS ventilation mode
16489993|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
16489994|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
16489995|NCT03360942||DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
16489996|NCT03360929|Experimental|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. two dose cohorts are planned for dose escalation, including: 150 and 250 mg twice daily.
~RP2D in dose expansion."
16489997|NCT03360916|Placebo Comparator|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
16489998|NCT03360916|Experimental|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
16489999|NCT03360916|Experimental|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
16490002|NCT03360890|Experimental|Cohort 1: salivary gland tumors without SOC treatment option|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
16490003|NCT03360890|Experimental|Cohort 2: 'aggressive' thyroid cancer without SOC treatment op|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
16490004|NCT03360877|Other|Health-care associated infection|
16490005|NCT03360864|Experimental|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.
~This program will take place within 6 months after biologic treatment initiation."
16490006|NCT03360864|No Intervention|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
16490007|NCT03360851|Experimental|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose <0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
16490008|NCT03360851|Experimental|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
16490009|NCT03360851|No Intervention|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
16490010|NCT03360838||CogCheck application|Performance in the application
16490011|NCT03360812|Experimental|Intervention group|The intervention is an online training resource to improve the recognition of imminent death in palliative care patients. The intervention should take approximately 15 minutes to complete. During this time, the participants who are in the intervention arm will be shown the results of a previous study which identified how expert palliative care doctors recognise imminently dying palliative care patients. The intervention will be implemented via the website, immediately after participants have completed the first set of vignettes.
16490012|NCT03360812|No Intervention|Control group|The participants assigned to the control group will not receive this additional information and will simply be informed that they are approximately half way through the task and will be asked to continue on to the next set of vignettes.
16490013|NCT03360799||Observational (questionnaire)|Participants complete 5 questionnaires.
16490014|NCT03360786|Experimental|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
16490015|NCT03360786|Active Comparator|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
16490016|NCT03360760|Experimental|Pre surgical Chemotherapy|Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).
16490017|NCT03360760|Other|Immediate Surgery|Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.
16490018|NCT03360747|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received a subcutaneous (SC) injection of AKCEA-ANGPTL3-LRx, 20 milligrams (mg), weekly (QW) for 13-weeks of treatment period. Participants were followed up to Week 26.
16490019|NCT03360734|Experimental|Combination|"First part: Combination of Gatipotuzumab (GAT) and Tomuzotuximab (TOM) Treatment: 5 weeks monotherapy with TOM (Day 1: 60mg, Day 2: 660mg, Week 2: 1200mg, Week 4: 1200mg). Then combination of 1200mg TOM with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity.
~Second part: Combination of GAT and TOM or an approved anti-EGFR antibody, i.e. Cetuximab, Panitumumab, or Necitumumab Treatment: One week monotherapy with TOM (Week 1, Day 1: 60mg, Day 2: 660mg). Then 1200mg TOM in combination with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity or commercial anti-EGFR antibody (dosage according to local practices) in combination with 1400mg of GAT every two weeks until disease progression or until unacceptable toxicity"
16490020|NCT03360721|Experimental|Treatment (abiraterone acetate, apalutamide, prednisone)|Participants receive abiraterone acetate PO once daily QD, apalutamide PO QD, and prednisone PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16490104|NCT03360110|Active Comparator|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
16490021|NCT03360708|Experimental|Treatment (vaccine therapy)|Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
16490022|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - PILOT|"Proactive Psychiatry Consultation and Case Management is:
~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.
~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.
~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.
~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
16490023|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - Randomized Trial|"Proactive Psychiatry Consultation and Case Management is:
~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.
~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.
~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.
~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
16490024|NCT03360695|Active Comparator|Enhanced Usual Care (EUC) - Randomized Trial|Study staff will send a templated email to the treating oncologist at enrollment informing the oncologists of the psychiatric diagnosis and available psychosocial services. Study staff will also inform the patient and caregiver of available psychosocial services.
16490025|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 1|"The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.
~treatment 48 weeks"
16490026|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 2|"The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.
~treatment 48 weeks"
16490027|NCT03360669|Experimental|Sequence: Clinical/Research|Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
16490028|NCT03360669|Active Comparator|Sequence: Research/Clinical|Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
16490029|NCT03360656|Experimental|Transnasal Thermal Regulating Device|Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours
16490030|NCT03360643|Active Comparator|Point-of-care ultrasound prior to radiology ultrasound|
16490031|NCT03360643|Active Comparator|Radiology-performed ultrasound|
16490032|NCT03360630|Experimental|Anti-PD-1 plus DC-CIK|
16490033|NCT03360630|Active Comparator|Anti-PD-1 alone|
16490034|NCT03360617|Experimental|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
16490035|NCT03360617|Sham Comparator|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
16490036|NCT03360604|Experimental|Low GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a low glycaemic index. This is the Low Glycaemic Diet intervention.
16490037|NCT03360604|Experimental|High GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a high glycaemic index. This is the High Glycaemic Diet intervention.
16490038|NCT03360591|Experimental|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.
~Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.
~Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.
~Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.
~In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
16490039|NCT03360591|Other|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
16490040|NCT03360552|Experimental|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
16490041|NCT03360552|Placebo Comparator|Usual care|support for patients without multidimensional evaluation (RAI-CA)
16490101|NCT03360123|Active Comparator|Midazolam Hydrochloride 2Mg/mL Syrup|"The participants in this arm will receive midazolam+nitrous oxide at the 1st dental appointment.
~Dosage: Midazolam: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment."
16490042|NCT03360539|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
16490043|NCT03360539|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
16490044|NCT03360526|Active Comparator|PICSI|Physiological ICSI
16490045|NCT03360526|Experimental|TESA|Testicular sperm aspiration
16490046|NCT03360513||general group|Comprised 70 caucasian Brazilian individuals with normal occlusion and at least four of Andrew's six keys.
16490047|NCT03360500|Experimental|EXERCISE PROTOCOL + CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
16490048|NCT03360500|Experimental|EXERCISE PROTOCOL|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
16490049|NCT03360500|Placebo Comparator|EXERCISE PROTOCOL + PLACEBO|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
16490050|NCT03360487|Sham Comparator|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
16490051|NCT03360487|Active Comparator|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
16490052|NCT03360487|Sham Comparator|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
16490053|NCT03360487|Active Comparator|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
16490054|NCT03360487|Sham Comparator|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
16490055|NCT03360487|Active Comparator|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
16490056|NCT03360474|Experimental|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
16490057|NCT03360461|Experimental|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
16490058|NCT03360448|Experimental|Experimental|Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
16490059|NCT03360448|Placebo Comparator|Placebo Comparator|Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
16490060|NCT03360435||Participants with transdermal patches|All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch
16490061|NCT03360422|Active Comparator|Survey group|Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
16490062|NCT03360422|Active Comparator|Focus Group|30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
16490063|NCT03360422|Active Comparator|Usability Study|10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
16490064|NCT03360409|Experimental|grade 1|ACD
16490065|NCT03360409|Active Comparator|grade 2|ACDF
16490066|NCT03360409|Active Comparator|grade 3|ACDA
16490067|NCT03360396|Experimental|Endobronchial Coils|Treatment with PneumRx Endobronchial Coil System
16490068|NCT03360396|No Intervention|Control|Medically-managed control group
16490069|NCT03360383|Experimental|grade 1|percutaneous vertebroplasty
16490070|NCT03360383|Active Comparator|grade 2|conservative treatment
16490071|NCT03360370||6 to 66 months children with significant CHD|"Children with significant congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages & Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays."
16490072|NCT03360357|Experimental|guided drills|These people will be going through all the guided drills before being evaluated.
16490073|NCT03360357|No Intervention|Self-trained|These people will watch a video and be able to practice by themselves without having any direction regarding how and what to practice.
16490074|NCT03360344|Experimental|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.
~A tape removal form will be provided should the participants want to remove it prior to the next visit."
16490075|NCT03360344|Sham Comparator|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
16491113|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
16490076|NCT03360344|Active Comparator|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
16490077|NCT03360318|Active Comparator|Elbow cast|Device: Elbow cast
16490078|NCT03360318|Experimental|Removable elbow brace|Device: Removable elbow brace
16490079|NCT03360305|No Intervention|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
16490080|NCT03360305|Experimental|Intervention|"ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.
~PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.
~Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.
~Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
16490081|NCT03360292|Experimental|Higher target range|Infants will be targeted to 92-97% oxygen saturation
16490082|NCT03360292|No Intervention|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
16490083|NCT03360279|Active Comparator|Regular balloon|Use the regular balloon to perform standard balloon angioplasty.
16490084|NCT03360279|Active Comparator|DCB (paclitaxel-coated balloon)|Use DCB (paclitaxel-coated balloon) to perform additional balloon angioplasty.
16490085|NCT03360266|Active Comparator|Profluorid group|5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
16490086|NCT03360266|Experimental|Enamel Pro|Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
16490087|NCT03360266|Experimental|MI varnish|Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth
16490088|NCT03360253|Experimental|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
16490089|NCT03360253|Placebo Comparator|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
16490090|NCT03360253|Experimental|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
16490091|NCT03360253|Placebo Comparator|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
16490092|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
16490093|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
16490094|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
16490095|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
16490096|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
16490097|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
16490098|NCT03360201|Experimental|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted in both content and implementation model based on formative research in this context. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection.
16490099|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.
~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
16490100|NCT03360136|Other|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
16490102|NCT03360123|Active Comparator|Triazolam 0.125 MG|The participants in this arm will receive triazolam+nitrous oxide at the 1st dental appointment. Dosage: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
16490105|NCT03360097|No Intervention|Fresh ET|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
16490106|NCT03360097|Experimental|Frozen Embryo Transfer|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
16490107|NCT03360071|Experimental|Allergen Immunotherapy Group|
16490108|NCT03360071|Placebo Comparator|Control Group|
16490109|NCT03360058|Experimental|Immediate access to STBD training|Immediate access to training materials and print pieces to support implementation
16490110|NCT03360058|Placebo Comparator|Delayed access to STBD training|Delayed access to training materials and print pieces
16490111|NCT03360045|Active Comparator|Tranexamic acid group|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
16490112|NCT03360045|Placebo Comparator|Placebo group|5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
16490113|NCT03360045|Active Comparator|Merocel Group|Merocel packing is applied.
16490114|NCT03360032||All participants|All patients will be asked to undertake an incremental shuttle walk test and a cardiopulmonary exercise test and the results will be compared.
16490115|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
16490116|NCT03360019|Active Comparator|Resident in independent living setting|
16490117|NCT03360019|Other|Care Partners|
16490118|NCT03360006|Experimental|ABBV-744 Dose Escalation|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
16490119|NCT03360006|Experimental|ABBV-744 Dose Expansion|ABBV-744 will be administered at the recommended Phase 2 dose determined during the Dose Escalation phase.
16490120|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
16490121|NCT03359980|Experimental|treated patients|Treated with Fecal Microbiota Transfer (FMT)
16490122|NCT03359954|Experimental|Treatment (radiation therapy, surgery)|Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
16490123|NCT03359941|Experimental|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
16490124|NCT03359928|Experimental|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
16490125|NCT03359928|Experimental|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
16490126|NCT03359928|Experimental|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).
~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
16490127|NCT03359915|Experimental|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
16490128|NCT03359915|No Intervention|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
16490129|NCT03359902|Experimental|Initial tVNS|This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
16490130|NCT03359902|Experimental|Initial Sham|This group will receive sham stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
16490131|NCT03359889||patients administered with PraxbindTM|
16490132|NCT03359876||Rivaroxaban|NVAF patients with renal dysfunction newly initiated on rivaroxaban 15 mg for stroke prevention
16490133|NCT03359876||Warfarin|NVAF patients with renal dysfunction newly initiated on vitamin K antagonist (warfarin) for stroke prevention
16490134|NCT03359863|Experimental|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
16490135|NCT03359850|Experimental|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
16490136|NCT03359850|Experimental|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
16490137|NCT03359837|Experimental|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
16490138|NCT03359837|Active Comparator|Premixed insulin|Twice daily premixed insulin
16490139|NCT03359824|Other|Exercise|Arm: Exercise: Combination of moderate intensity continuous training, high intensity interval training and endurance training 5 times per week for a total of 6 weeks. Out of 5 sessions three were supervised by trainer and two sessions were performed by subjects on their own.The duration of the exercise was increased progressively. The first two weeks was 30 minutes that increased to 45 minutes in the third and fourth week. It was 60 minutes for the last two weeks.
16490140|NCT03359811|Experimental|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
16490141|NCT03359811|Active Comparator|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
16490142|NCT03359798|Experimental|Narcotic counseling script|Study participants will be read a script regarding post-cesarean section narcotic use.
16490143|NCT03359798|Sham Comparator|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
16490144|NCT03359785|Experimental|TAK-831 500 mg + TAK-831 50 mg|TAK-831 500 milligrams (mg) or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by TAK-831 50 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
16490145|NCT03359785|Experimental|TAK-831 50 mg + TAK-831 500 mg|TAK-831 50 mg or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by TAK-831 500 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
16490146|NCT03359772|No Intervention|Group 1|Exercise Only Group
16490147|NCT03359772|Active Comparator|Group 2|Kinesthetic Ability Trainer Group
16490148|NCT03359746|Experimental|Treatment Group|This is a prospective, interventional, case-control study at King Faisal Specialist Hospital & Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir combination. Data will be compared with matched historical controls, which will be selected according to the following matching criteria: age, time from transplant to initiation of therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any patient who received at least one dose of Grazoprevir/Elbasvir combination will be included in the safety analysis.
16490149|NCT03359733|Experimental|TAK-659 100 mg Fasted + TAK-659 100 mg Fed|TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.
16490150|NCT03359733|Experimental|TAK-659 100 mg Fed + TAK-659 100 mg Fasted|TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.
16490151|NCT03359720||guyane|
16490152|NCT03359720||martinique|
16490153|NCT03359720||guadeloupe|
16490154|NCT03359694|Experimental|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
16490155|NCT03359694|Active Comparator|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
16490156|NCT03359694|Experimental|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
16490157|NCT03359694|No Intervention|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.
~No drugs treatment in this group."
16490158|NCT03359681|Active Comparator|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
16490159|NCT03359681|Placebo Comparator|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
16490160|NCT03359668|Experimental|Non-contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
16490161|NCT03359668|Active Comparator|Contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
16490162|NCT03359655|Active Comparator|Rectal misoprostol|200 mcg of misoprostol will be administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
16490163|NCT03359655|Active Comparator|Rectal hyoscine butyl bromide|10 mg hyoscine butyl bromide administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
16490164|NCT03359655|No Intervention|Sham administration|A rectal examination will be performed by a third party health professional who will be blinded to the procedure. No drug will be administered
16490165|NCT03359642|Experimental|Patients with anti-TNF alpha|12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which a first anti-TNF alpha treatment is indicated.
16490166|NCT03359642|Active Comparator|mirror group|"A mirror group of 12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which an all but anti-TNF alpha or biotherapy treatment is indicated will be included to distinguish the specific effects on microbiota of anti-TNF alpha."
16490167|NCT03359616|Experimental|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
16490168|NCT03359616|Active Comparator|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
16490353|NCT03358264|Experimental|Type 2 diabetic patients|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c>6
16490169|NCT03359603|Experimental|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
16490170|NCT03359603|Experimental|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
16490171|NCT03359590|Experimental|Sitagliptin arm|Sitagliptin 100 mg
16490172|NCT03359590|Placebo Comparator|Placebo arm|Placebo comparator
16490173|NCT03359577|Experimental|Psorax35|Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
16490174|NCT03359577|Placebo Comparator|MCT oil|Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil). Dose: 10 capsules of 590 mg: Route of administration: oral.
16490175|NCT03359564||micro endoscopic discectomy|the patients with lumbar disc herniation
16490176|NCT03359538|Placebo Comparator|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
16490177|NCT03359538|Active Comparator|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
16490178|NCT03359538|Active Comparator|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
16490179|NCT03359525|Experimental|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
16490180|NCT03359525|Experimental|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
16490181|NCT03359525|Experimental|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
16490182|NCT03359512|Experimental|qCON monitor|Simultaneous measurement of BIS and qCON
16490183|NCT03359499|Experimental|Bacillus clausii|Bacillus clausii administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
16490184|NCT03359499|Other|Antispasmodic|Trimebutine administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
16490185|NCT03359486|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
16490186|NCT03359486|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
16490187|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
16490188|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
16490189|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
16490190|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
16490192|NCT03359447|Experimental|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
16490193|NCT03359447|Active Comparator|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
16490194|NCT03359434|Experimental|Two measuring methods of blood pressure|
16490195|NCT03359421||Aeromedical transport|Patients transported to trauma center by helicopter
16490196|NCT03359421||Ground transport|Patients transported to trauma center by ground ambulance
16490197|NCT03359408|No Intervention|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
16490198|NCT03359408|Experimental|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
16490199|NCT03359395|Active Comparator|Alfentanil|
16490200|NCT03359395|Placebo Comparator|placebo|
16490201|NCT03359382|No Intervention|control|
16490202|NCT03359382|Experimental|exercise|
16490203|NCT03359369||Septic Patients|
16490204|NCT03359369||Non Septic Patients|
16490205|NCT03359356|Experimental|Dupilumab|An initial dose of 600 mg (two 300 mg subcutaneous injections), followed by 300 mg given every other week
16490206|NCT03359356|Placebo Comparator|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
16490207|NCT03359343||experts|In this group, two experts distinguish a set of polyps on LCI images as adenoma or non-adenoma.
16490208|NCT03359343||non-experts|In this group, two non-experts distinguish the set of polyps(the same to experts group) on LCI images as adenoma or non-adenoma.
16490209|NCT03359343||Computer-aided diagnosis system|In this group, a newly developed computer-aided diagnosis system will be used to distinguish a set of polyps as adenoma or non-adenoma.
16490210|NCT03359330||Degradable conduit small gap tublization|patients with fresh peripheral nerve injury in the upper extremities,repaired with degradable conduit small gap tublization
16490211|NCT03359317|Experimental|jogging|At least 5 times/week
16490354|NCT03358264|Experimental|Healthy volunteers|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers
16490212|NCT03359291|Experimental|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
16490213|NCT03359278||open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
16490214|NCT03359265|Active Comparator|Test|The test group used underpants made of precious metal fibers (germanium, titanium and phosphorus), developed by Green Energy Nano Technology Co., Ltd.
16490215|NCT03359265|Placebo Comparator|Control|The control group used commercially available underpants.
16490216|NCT03359252|Active Comparator|non-stent assisted coiling|patients treated with non-stent assisted coiling of unruptured intracranial aneurysms
16490217|NCT03359252|Experimental|stent assisted coiling|patients treated with stent assisted coiling of unruptured intracranial aneurysm
16490218|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
16490219|NCT03359226|Experimental|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
16490220|NCT03359213|Experimental|JR-141 1.0 mg/kg/week|
16490221|NCT03359213|Experimental|JR-141 2.0 mg/kg/week|
16490222|NCT03359213|Experimental|JR-141 4.0 mg/kg/week|
16490223|NCT03359187|Active Comparator|Normal saline with salt/Soda|Normal saline with salt/soda rinse 4 times a day/everyday and for each time 15 ml.
16490224|NCT03359187|Experimental|Clinacanthus nutans|Clinacanthus nutans in form of mouth wash rinse 4 times a day/everyday and for each time 15 ml.
16490225|NCT03359187|Experimental|Boesenbergia rotunda|Boesenbergia rotunda in form of mouth wash 4 times a day/everyday and for each time 15 ml.
16490226|NCT03359174|Experimental|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
16490227|NCT03359161|Experimental|In-Home Subcutaneous Furosemide Treatment ARm|Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
16490228|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
16490229|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
16490230|NCT03359135||group1|hEDS treated with rehabilitation only
16490231|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
16490232|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
16490233|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
16490234|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
16490235|NCT03359096|Experimental|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
16490236|NCT03359096|Sham Comparator|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
16490237|NCT03359070|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
16490238|NCT03359070|Active Comparator|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
16490239|NCT03359057|Experimental|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
16490240|NCT03359057|Placebo Comparator|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
16490241|NCT03359044||Sedation + topical anesthesia|midazolam 0.1～0.2 mg/kg for sedation, 2%lidocaine for topical anesthesia
16490242|NCT03359044||General anesthesia+ topical anesthesia|propofol 4～5mg/kg、Remifentanil2～3μg/kg for induction ,insert Laryngeal Mask Airway(LMA) , 2%lidocaine for topical anesthesia
16490243|NCT03359031|No Intervention|No patient education|This group of patients will not receive any additional information beyond standard of care educational pamphlets provided by the hospital.
16490244|NCT03359031|Other|Patient education|This group of patients will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
16490245|NCT03359018|Experimental|apatinib plus anti-PD1 therapy arm|Every patients will received apatinib 250mg or 500mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
16490246|NCT03359005|Experimental|5d VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 50mg/m2/d IV over 60 minutes on days 1-5.
~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
16490247|NCT03359005|Active Comparator|5d x 2 VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 20mg/m2/d IV over 60 minutes on days 1-5 and 8-12.
~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
16490248|NCT03358979||Severe eye dryness|
16490249|NCT03358979||absence of eye dryness|
16491114|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
16490250|NCT03358966||Early to moderate CKD (stage 1-3)|40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
16490251|NCT03358966||Advanced CKD (stage 4-5)|40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
16490252|NCT03358953|Other|Electronic Cigarettes|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the electronic cigarette arm. They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
16490253|NCT03358953|Other|Nicotine replacement patches|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the nicotine replacement patch arm (standard care). They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
16490254|NCT03358940|Other|patient with miscarriage complications or not|The day of inclusion, for patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
16490255|NCT03358927|Active Comparator|Standard Group|Deferred fast-track care
16490256|NCT03358927|Experimental|Immediate Fast-Track Group|Immediate fast-track care
16490257|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
16490258|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
16490259|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
16490260|NCT03358901|Experimental|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
16490261|NCT03358901|Placebo Comparator|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
16490262|NCT03358888|Active Comparator|Standard of Care|
16490263|NCT03358888|Active Comparator|Multi-modal with as needed opioids|
16490264|NCT03358888|Active Comparator|Multi-modal with one week of opioids offered|
16490265|NCT03358875|Experimental|BGB-A317|100 mg per vial, 200mg intravenous (IV), Q3W
16490266|NCT03358875|Experimental|Docetaxel|75 mg/m2 IV Q3W
16490267|NCT03358862||Myopes|Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
16490268|NCT03358849|Experimental|experimental group|
16490269|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
16490270|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
16490271|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of >10%
16490272|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
16490273|NCT03358810|Active Comparator|Active group|patients randomized to receive active PES
16490274|NCT03358810|Sham Comparator|Sham treatmment|Patients randomized to sham will not receive any PES.
16490275|NCT03358797|Experimental|intervention-HPP|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
16490276|NCT03358797|Experimental|CBLI+RT|based on randomization, group that will be assigned to CBLI+RT will receive the CBLI curriculum (as described in the intervention-HPP arm) in addition to the resiliency training
16490277|NCT03358797|Experimental|Attention control (CBLI-)|The attention control group will receive the core curriculum of the CBLI (as described in the intervention-HPP arm) only without the resiliency training. The sessions of the resiliency training will be replaced with sessions on health topics that do not contribute to our outcome (increased resiliency) (i.e. breast cancer, osteoporosis)
16490278|NCT03358797|Experimental|Pilot|This group will not be randomized. The group will receive the CBLI content (as described in the intervention-HPP arm) in addition to the resiliency training. The aim of this pilot is to create a resiliency training manual to be implemented in the following groups that will be assigned to receive the CBLI+RT
16490279|NCT03358784||PHILOS Plate|three or four-part fractures of proximal humerus treated with internal fixation
16490280|NCT03358784||Hemi-shoulder arthroplasty|three or four-part fractures of proximal humerus treated with hemi-shoulder arthroplasty
16490281|NCT03358771|No Intervention|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
16490433|NCT03357666|Experimental|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
16490282|NCT03358771|Active Comparator|COPD discharge care bundle|"COPD discharge care bundle:
~Ensure patient has demonstrated adequate inhaler technique
~Send discharge summary to family physician office and arrange follow-up
~Optimize and reconcile prescription of respiratory medications
~Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions
~Refer to pulmonary rehabilitation
~Screen for frailty and comorbid condition(s)
~Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
16490283|NCT03358771|Experimental|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
16490284|NCT03358745|Experimental|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
16490285|NCT03358745|Experimental|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
16490286|NCT03358745|Experimental|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
16490287|NCT03358745|Experimental|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
16490288|NCT03358732|Experimental|Mock embryo transfer|The patients underwent a mock embryo transfer one day before the scheduled actual transfer
16490289|NCT03358732|No Intervention|No mock embryo transfer|The patients did not undergo mock embryo transfer one day before the scheduled actual transfer
16490290|NCT03358719|Experimental|Treatment (CDX-1401, poly ICLC, decitabine, nivolumab)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.
16490293|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
16490294|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
16490295|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
16490296|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
16490297|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
16490298|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
16490299|NCT03358693||Atopic dermatitis patients receiving tralokinumab|Tralokinumab
16490300|NCT03358693||Atopic dermatitis patients receiving baricitinib|Baricitinib
16490301|NCT03358693||Atopic dermatitis patients receiving abrocitinib|Abrocitinib
16490302|NCT03358693||Atopic dermatitis patients receiving upadacitinib|Upadacitinib
16490303|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
16490304|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
16490305|NCT03358654|Experimental|mesenchymal stem cells|Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection
16490306|NCT03358641||Wuchuan residents|All residents that meet the criteria can be enrolled in this group, receiving a home interview (including IPA-Q to assess the level of physical activity) and a weight-bearing posteroanterior semiflexed view of radiographs at tibiofemoral (TF) joints at baseline and 3 years later.
16490307|NCT03358628||Osteosarcoma|Osteosarcoma patients with metastatic relapsed or unresectable progressive disease (total n= up to 20) following resection of the primary lesion and adjuvant chemotherapy.
16490308|NCT03358602|Experimental|Radiotherapy|Radiotherapy & open partial supraglottic laryngectomy(primary tumor)
16490309|NCT03358602|Active Comparator|Elective neck dissection|Elective neck dissection & open partial supraglottic laryngectomy(primary tumor)
16490310|NCT03358589|Other|MESTAR|All patients will have the same scans performed
16490311|NCT03358576|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
16490312|NCT03358576|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
16490313|NCT03358563|Experimental|Degarelix SC + bicalutamide + docetaxel|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3
16490434|NCT03357666|Experimental|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
16490314|NCT03358563|Experimental|DegarelixSC+bicalutamide+docetaxel+Ferumoxytol enhanced MRI|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3 + Ferumoxytol enhanced MRI within 21 days prior to start of hormonal therapy and second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
16490315|NCT03358550|Experimental|Accommodation in scotopic luminance|
16490316|NCT03358537|Active Comparator|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
16490317|NCT03358537|Active Comparator|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
16490318|NCT03358524|Experimental|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
16490319|NCT03358524|Placebo Comparator|Placebo|Placebo capsule once per day orally for 8 weeks
16490320|NCT03358511|Experimental|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
16490321|NCT03358498||β-thalassemia group|"SICT It is a questionnaire to assess patient satisfaction with ICT regimens. It comprises 19 items assessing four domains: perceived effectiveness of ICT (PE), burden of ICT (BD), acceptance of ICT (AC), and side effects of ICT (SE). Patients rate all items on scale from 1 very dissatisfied to 5 very satisfied.
~Lab methods :
~full history and thorough clinical evaluation.
~. Complete blood count. .3- Serum ferritin .
~4-Renal function tests. 5-liver function tests."
16490322|NCT03358485|Experimental|Aolanti Weikang tablets|3，6 or 8 Aolanti Weikang tablets each time,tid
16490323|NCT03358485|Placebo Comparator|Placebo|3,6 or 8 tablets each time,tid
16490324|NCT03358472|Experimental|Pembrolizumab + Epacadostat|
16490325|NCT03358472|Experimental|Pembrolizumab|
16490326|NCT03358472|Active Comparator|EXTREME|EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.
16490327|NCT03358459||EP|For diagnosis non-acquired epilepsy;
16490328|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.
~A group is the patients with non-overlapping range"
16490329|NCT03358446||S group|S group is the patients without non-overlapping range
16490330|NCT03358433|Experimental|Exercise|
16490331|NCT03358433|Active Comparator|Antidepressants|
16490332|NCT03358407|Experimental|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
16490333|NCT03358407|Experimental|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
16490334|NCT03358407|Experimental|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
16490335|NCT03358407|Experimental|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
16490336|NCT03358394|Experimental|Intervention group|The intervention group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention time period(i.e., after five weeks).
16490337|NCT03358394|Experimental|Control group|"The control group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention after six weeks.
~At the end of the pilot trial, control group will receive the full intervention. They would be sent the materials week by week as same as the intervention group."
16490338|NCT03358381|Experimental|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
16490339|NCT03358381|Active Comparator|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
16490340|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
16490341|NCT03358342||ED Patients treated using ePneumonia CDS|ED patients with community-acquired pneumonia treated in ED's after roll out of ePneumonia
16490342|NCT03358342||Usual care|ED patients with pneumonia receiving usual care without electronic CDS
16490343|NCT03358329|Experimental|S8 Sinus Implant|corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
16490344|NCT03358316||cuff tear patients|Patients with cuff tear
16490345|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
16490346|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
16490347|NCT03358290|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
16490348|NCT03358290|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
16490349|NCT03358290|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
16490350|NCT03358290|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
16490351|NCT03358290|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
16490352|NCT03358277|Experimental|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
16490624|NCT03356223|Experimental|Abemaciclib|
16490355|NCT03358251|Other|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
16490356|NCT03358238|Placebo Comparator|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
16490357|NCT03358238|Experimental|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
16490358|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
16490359|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
16490360|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
16490361|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
16490362|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
16490363|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
16490364|NCT03358186||revision of periprosthetic fracture|patients with surgically treated periprosthetic femur fracture
16490365|NCT03358173||Conservative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
16490366|NCT03358173||Operative Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the humeral shaft fracture will be carried out
16490367|NCT03358160||TKA|Orthopaedic patients who underwent surgical operation for total knee arthroprothesis.
16490368|NCT03358160||Rizoarthrosis|Orthopaedic patients who underwent surgical operation to treat chronic arthrosis of the thumb.
16490369|NCT03358160||Healthy Controls|Healthy age-matched controls.
16490370|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
16490371|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
16490372|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
16490373|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
16490374|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
16490375|NCT03358134|Experimental|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
16490376|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
16490377|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
16490378|NCT03358108||Group A: interferon group|formerly interferon group (including interferon alone or interferon combined with other drugs)
16490379|NCT03358108||Group B:nucleoside analogue group|formerly nucleoside analogue treatment group. Each group was followed for five years
16490380|NCT03358095|No Intervention|Early surgery|Patients in this group proceed to pancreatic resection within 2 week of recruitment.
16490381|NCT03358095|Active Comparator|Preoperative biliary drainage|Endoscopic retrograde cholangiopancreatography (ERCP) is used to place an endoprosthesis to the biliary ducts to drain biliary stasis, and the patients proceed to pancreatic resection within 6 weeks of recruitment.
16490382|NCT03358082|Active Comparator|Tacrolimus group|Tacrolimus 0.03% ointment twice daily for 6 months
16490383|NCT03358082|Active Comparator|Hydrocortisone group|hydrocortisone acetate 1% ointment twice daily for 6 months
16490384|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
16490385|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
16490386|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
16490387|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
16490388|NCT03358056|Experimental|Mindfulness-based Cognitive Therapy|
16490389|NCT03358030|Placebo Comparator|Placebo|Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
16490390|NCT03358030|Experimental|Cohort A: ISIS 416858, 200 mg|Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
16490391|NCT03358030|Experimental|Cohort B: ISIS 416858, 250 mg|Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
16490392|NCT03358030|Experimental|Cohort C: ISIS 416858, 300 mg|Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
16490393|NCT03358017|Active Comparator|ARM A - standard NACT|Standard anthracyclines/taxanes based neoadjuvant chemotherapy chosen by the investigator and administered according to clinical practice, for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
16490394|NCT03358017|Experimental|ARM B - standard NACT + Zol + atorvastatin|Standard anthracyclines/taxanes based neoadjuvant CT chosen by the investigator and administered according to clinical practice + Zoledronate 4 mg i.v. every 3-4 weeks and Atorvastatin 80 mg/die administered for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
16490395|NCT03358004|Experimental|ARM A|Vinorelbine 50 mg, thrice a week
16490396|NCT03358004|Experimental|ARM B|Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day
16491273|NCT03351894|Placebo Comparator|Conventional|Conventional phacoemulsification surgery
16490397|NCT03357978|Other|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution
~bioelectrical impedance Analysis
~blood draw
~transient elastography (FibroScan)
~ataxia score
~Five-Times-Sit-to-Stand Test"
16490398|NCT03357952|Experimental|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
16490399|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
16490400|NCT03357939|Experimental|HLX03|There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
16490401|NCT03357939|Active Comparator|Humira|There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
16490402|NCT03357926||Observation Group|
16490403|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
16490404|NCT03357900|Experimental|Orthotopic liver transplantation|
16490405|NCT03357874|Experimental|Clopidogrel group|
16490406|NCT03357874|Experimental|Ticagrelor group|
16490407|NCT03357848||Study group|Surgical patients receiving nutritional support (enteral and/or parenteral nutrition) pre and/or after surgery
16490408|NCT03357848||Control group|Surgical patients without nutritional support during the perioperative period
16490409|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
16490410|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
16490411|NCT03357822|Experimental|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
16490412|NCT03357822|Active Comparator|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
16490413|NCT03357809|Experimental|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
16490414|NCT03357796|Experimental|Group A: LY03005 cross-over to Pristiq®|Subjects in Group A will receive an 80 mg oral dose of LY03005 and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator followed by a 4-day stay in the CRU (Period 2).
16490415|NCT03357796|Experimental|Group B: Pristiq® cross-over to LY03005|Subjects in Group B will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005 followed by a 4-day stay in the CRU (Period 2).
16490416|NCT03357770|Experimental|low dose of mesenchymal stem cells|Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 × 10^7cells / 3mL
16490417|NCT03357770|Experimental|medium dose of mesenchymal stem cells|the medium-dose is 5 × 10^7cells / 3mL
16490418|NCT03357770|Experimental|high dose of mesenchymal stem cells|the high dose is 1 × 10^8cells / 3mL
16490419|NCT03357757|Experimental|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
16490420|NCT03357731|Experimental|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
16490421|NCT03357731|Experimental|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
16490422|NCT03357731|Experimental|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
16490423|NCT03357731|Experimental|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
16490424|NCT03357731|Experimental|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
16490425|NCT03357731|Experimental|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
16490426|NCT03357718|Experimental|Dexmedetomidine|2 µg/kg Precedex
16490427|NCT03357718|Active Comparator|Midazolam|0.5 mg/kg dormicum
16490428|NCT03357705|Experimental|synthetic|alveolar ridge preservation with synthetic bone
16490429|NCT03357705|Active Comparator|collagen|alveolar ridge preservation with bovine collagen
16490430|NCT03357692|Experimental|maxillary total edentulism|all on four implant rehabilitation with trans-sinusal implants
16490431|NCT03357679|Active Comparator|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
16490432|NCT03357679|Active Comparator|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
16490435|NCT03357666|Experimental|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
16490436|NCT03357666|Experimental|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
16490437|NCT03357666|Placebo Comparator|Placebo|Placebo, once a day, two tablets at a time for 7 days
16490438|NCT03357653|Experimental|Losartan group|Losartan 50 mg daily
16490439|NCT03357653|Placebo Comparator|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
16490440|NCT03357640|Placebo Comparator|no intervention|The women will receive one package of placebo. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
16490441|NCT03357640|Active Comparator|combined oral contraception pills|The women will receive intervention of one package of combined oral contraception pills and will be counseled about how to take oral contraception and informed of possible side effects. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
16490442|NCT03357627|Experimental|Dose Escalation: TAK-659 + Venetoclax|TAK-659 40, 60, 80, or 100 milligram (mg) (tablet, orally, once daily, up to 35 days in Cycle 1 or in different intermittent schedules [7 days dosing followed by 7 days off or 14 days dosing followed by 7 days off or other intermittent dosing schedules]) along with venetoclax 200, 400, 800 or 1200 mg (tablet, orally, once daily, up to 35 days in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.
16490443|NCT03357627|Experimental|Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
16490444|NCT03357627|Experimental|Safety Expansion: Follicular Lymphoma (FL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
16490445|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
16490446|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
16490447|NCT03357601|Experimental|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
16490448|NCT03357601|Experimental|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
16490449|NCT03357588|Active Comparator|Control|Standard of Care monitoring
16490450|NCT03357588|Experimental|Intervention|Intensified monitoring
16490451|NCT03357575|Experimental|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
16490452|NCT03357575|Active Comparator|hyaluronic acid|Hyaluronic acid will be injectied.
16490453|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
16490454|NCT03357549|Experimental|Brief Motivational Intervention|The women of this group will receive a Brief Motivational Intervention during 20 or 30 minutes.
16490455|NCT03357549|Active Comparator|Breastfeeding education|The women of this group will receive a standard education about breastfeeding during 20-30 minutes
16490456|NCT03357536|Experimental|Patients with Listeriosis|"Patients with Listeriosis.
~Human biological samples :
~Blood sample
~Skin biopsy
~Saliva"
16490457|NCT03357536|Experimental|Volunteers related with patients with Listeriosis|"Volunteers related with patients with Listeriosis.
~Human biological samples :
~Blood sample
~Skin biopsy
~Saliva"
16490458|NCT03357523|Experimental|Red LED|Light emitting diodes, 633 nm, 70 mW/cm2, Omnilux new-U (Red LED) (Photomedex, Horsham, PA, USA); RESPeRATE; Heating bag
16490459|NCT03357523|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/ cm2, Omnilux new-U (Near infrared LED) (Photomedex, Horsham, PA, USA); RESPeRATE metronome; Heating bag
16490460|NCT03357497|Experimental|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
16490461|NCT03357497|No Intervention|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
16490462|NCT03357484|Experimental|L-PRF|Third molar extraction sockets were filled with two leukocyte- and platelet rich fibrin (L-PRF) clots
16490463|NCT03357484|Active Comparator|Blood clot|Third molar extraction sockets allowed to form a natural blood clot and undergo natural healing
16490464|NCT03357471|Experimental|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
16490465|NCT03357471|Experimental|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
16490466|NCT03357458|Experimental|Family Integrated Care|Study participants receive FICare, a dynamic psycho-educational intervention, while their infant(s) was/were admitted to a Level II NICU.
16490467|NCT03357458|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
16490468|NCT03357445|Other|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
16490469|NCT03357445|Other|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
16490470|NCT03357432|Experimental|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
16490471|NCT03357419|Active Comparator|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.
~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
16490472|NCT03357419|Placebo Comparator|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
16490473|NCT03357406|Experimental|edentulism side 1|ultrasound implant site preparation
16490474|NCT03357406|Active Comparator|edentulism side 2|conventional implant site preparation
16490475|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
16490476|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
16490477|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
16490478|NCT03357380|Experimental|Semaglutide|Semaglutide will be initiated with a starting dose of 0.05 mg/day for the first 4 weeks. The dose will be increased every 4 weeks until the target dose of 0.4 mg/day has been reached.
16490479|NCT03357380|Placebo Comparator|Placebo|Placebo will be initiated with a starting volume corresponding to 0.05 mg/day of semaglutide for the first 4 weeks. The volume will then be increased every 4 weeks until the target volume corresponding to 0.4 mg/day of semaglutide has been reached.
16490480|NCT03357367|Experimental|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).
~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
16490481|NCT03357354|Experimental|Obese Children in precarious situations|
16490482|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
16490483|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
16490484|NCT03357328|Active Comparator|Therapy light room|This group (4 NH units, about 35 patients) will receive light therapy administered via LED technology. The light will vary in intensity and colour temperature throughout the day. Ceiling-mounted LED-lights are installed in the living rooms of participating nursing home units. Between 07:00 and 10:00 light of 400 lux at eye level, with 4000 K, will be provided. Between 10:00 and 15:00 the light will comprise 1000 lux at eye level, with 6000 K. From 15:00 to 18:00 the light will comprise 400 lux at eye level and 4000 K. When light is on from 18:00 to 07:00, standard light (about 100 lux at eye level, 3000K) will be administered.
16490485|NCT03357328|Placebo Comparator|Standard light|"This group (4 NH units, about 35 patients) will receive standard light (100 lux at eye level, 3000K). The light will be administered between 07:00 and 18:00; and the same when light is on between 18:00 to 07:00. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."
16490486|NCT03357315|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16490487|NCT03357315|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16490488|NCT03357289|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16490489|NCT03357289|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16490490|NCT03357276|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16490491|NCT03357276|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16490492|NCT03357263|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
16490493|NCT03357263|Active Comparator|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
16490494|NCT03357237|Experimental|XYLOGLUCAN|treatment regimen with oral rehydration solution and xyloglucan
16490495|NCT03357237|Placebo Comparator|PLACEBO|rehydration solution and placebo.
16490496|NCT03357224|Experimental|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
16490497|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
16490498|NCT03357172|Experimental|Recipient|
16490499|NCT03357172|Experimental|Donor|
16490500|NCT03357159|Experimental|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
16490501|NCT03357146||CRA|Patients with chronic retinal artery occlusion
16490502|NCT03357146||Control|Healthy
16490503|NCT03357133|Experimental|Tirofiban and alteplase|
16490504|NCT03357133|Placebo Comparator|Alteplase|
16490505|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
16490506|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
16490507|NCT03357068|Active Comparator|Control|Autogenous bone block surgery without treatment of bone surfaces.
16490508|NCT03357068|Experimental|Acid|Autogenous bone block surgery with citric acid treatment of bone block and recipient site
16490509|NCT03357055|Experimental|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
16490510|NCT03357055|Placebo Comparator|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
16490511|NCT03357042|Experimental|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
16490512|NCT03357042|Active Comparator|Healthy control|Persons without post-concussive symptoms. No intervention.
16490513|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
16490514|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
16490515|NCT03357016|Experimental|High Intensity Interval Training program (HIIT)|Subjects perform three sessions of training during 12 weeks: 35 min at 50% maximal aerobic power on bicycle.
16490516|NCT03357016|Experimental|Moderate Intensity Continuous Training program (MICT)|Subjects perform three sessions of training during 12 weeks: repeated cycles of sprinting for 8s and pedaling slowly for 12s (between 20 and 30 rpm) for a maximum of 60 repeats per session.
16490517|NCT03357016|Experimental|HIIT + Resistance Training program (RT)|Subjects perform three sessions of training during 12 weeks: Each subject performed HIIT protocol and then a single set of 8 exercises with 1 ou 2min resting period between exercises. Each set consisted of 8-12 repetitions at about 80% maximum repetition.
16490518|NCT03356990|Experimental|Resistant Starch|"Intervention:
~Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose in the evening
~Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).
~Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).
~Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks)."
16490519|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
16490520|NCT03356964|Active Comparator|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
16490521|NCT03356964|Experimental|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
16490522|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
16490523|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
16490524|NCT03356938|No Intervention|Baseline recording|
16490525|NCT03356938|Experimental|Sleep restriction|
16490526|NCT03356938|Experimental|Sleep deprivation|
16490527|NCT03356925|No Intervention|Centralised Xpert®Ultra testing|Patients are selected to receive the standard of care for TB diagnosis at a centralised laboratory facility
16490528|NCT03356925|Active Comparator|Xpert Ultra Point of Care testing|Patients are selected to receive the point of care for TB diagnosis at the clinic facility they are visiting
16490529|NCT03356912|Active Comparator|Cabazitaxel plus prednisone|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks, plus prednisone 10 mg orally given daily. Premedication must be administered according to Cabazitaxel Package Insert.
16490530|NCT03356912|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks. Premedication must be administered according to Cabazitaxel Package Insert.
16490531|NCT03356899|Active Comparator|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
16490532|NCT03356899|Active Comparator|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
16490533|NCT03356886|Experimental|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
16490534|NCT03356886|Active Comparator|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
16490535|NCT03356873|Experimental|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
16490536|NCT03356873|Placebo Comparator|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
16490537|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
16490538|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
16490539|NCT03356847|Experimental|SISA implant|
16490540|NCT03356834|Experimental|TDF switch to TAF|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
16490541|NCT03356834|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
16490542|NCT03356821|Experimental|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
16490543|NCT03356808|Experimental|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
16490544|NCT03356795|Experimental|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
16490545|NCT03356782|Experimental|Sarcoma-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.
16490546|NCT03356769|Experimental|experimental：asprin & AEDS|Aspirin 5mg/kg，maximum 300mg; once a day plus AEDS
16490547|NCT03356769|Placebo Comparator|control: placebo & AEDS|placebo 5mg/kg，maximum 300mg; once a day plus AEDS
16490548|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
16490549|NCT03356743|Experimental|Ex-Vivo|
16490550|NCT03356730|Experimental|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
16490551|NCT03356730|Placebo Comparator|Arm placebo|Placebo for 2 months (10 drops after lunch)
16490552|NCT03356717|Experimental|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.
~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
16490553|NCT03356717|Active Comparator|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
16490554|NCT03356704||General anaesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had general anesthesia
16490555|NCT03356704||continued spinal anesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had continued spinal anesthesia
16490556|NCT03356704||peripheral nerve blocks|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had peripheral nerve blocks
16490557|NCT03356691|No Intervention|Control group|No intervention.
16490558|NCT03356691|Experimental|Complementary Spiritist Therapy|"Prayer, Spirit education, Spiritist passe and magnetized water"
16490559|NCT03356691|Other|Prayer|Prayer during 1-2 minutes
16490560|NCT03356691|Other|"Spiritist passe"|"Spiritist passe during 5-10 minutes."
16490561|NCT03356691|Placebo Comparator|Laying on of hands with intent to heal|laying on of hands with intent to heal during 5-10 minutes.
16490562|NCT03356691|Other|Fluid water or magnetized water|Spiritist healers laying on of hands hands on the glass of water and desire health, restoration of balance and health for the patient.
16490563|NCT03356691|Other|Non-fluidic water|individuals receive water without fluidification (no laying on of hands hands on the glass of water).
16490564|NCT03356665|Experimental|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
16490625|NCT03356210|No Intervention|Treatment as usual (TAU)|This control group will receive treatment as usual; conventional counseling
16490566|NCT03356639|Experimental|ASP6981 50 mg, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
16490567|NCT03356639|Experimental|Matching Placebo, then ASP6981 50 mg|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
16490568|NCT03356639|Experimental|ASP6981 135 mg, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
16490569|NCT03356639|Experimental|Matching Placebo, then ASP6981 135 mg|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
16490570|NCT03356626|Experimental|ULTRACISION Harmonic Scalpel|Patients group randomized to use ULTRACISION Harmonic Scalpel when receives laparoscopic gastrectomy
16490571|NCT03356626|Experimental|Ligasure Maryland|Patients group randomized to use Ligasure Maryland when receives laparoscopic gastrectomy
16490572|NCT03356626|Experimental|Thunderbeat|Patients group randomized to use Thunderbeat when receives laparoscopic gastrectomy
16490573|NCT03356613||focus group of paramedical staff from Nancy|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
16490574|NCT03356613||focus group of paramedical staff from Metz|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
16490575|NCT03356613||focus group of paramedical staff from Dijon|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
16490576|NCT03356613||focus group of paramedical staff from Bar-le-Duc|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
16490577|NCT03356613||Test of the tool by paramedical staff center 1|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
16490578|NCT03356613||Test of the tool by paramedical staff center 2|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
16490579|NCT03356600|Experimental|Apatinib plus radiotherapy|"Apatinib:
~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.
~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.
~Radiotherapy:
~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy."
16490580|NCT03356587|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
16490581|NCT03356561|Experimental|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5*10^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
16490582|NCT03356561|Experimental|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5*10^10 vp on Day 1 and placebo on Day 57 via IM route.
16490583|NCT03356561|Experimental|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1*10^11 vp via IM route on Days 1 and 57.
16490584|NCT03356561|Experimental|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1*10^11 vp on Day 1 and placebo on Day 57 via IM route.
16490585|NCT03356561|Placebo Comparator|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
16490586|NCT03356509|Experimental|Exercise|They will do a 26-min bout of high intensity interval exercise.
16490587|NCT03356509|No Intervention|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
16490588|NCT03356496|Experimental|Intervention|Patient provided with instructions and video for the use of an incentive spirometry device. Patient instructed to use incentive spirometry device as frequently as every hour while awake but at least 4 times daily for at least 10 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
16490589|NCT03356496|No Intervention|Control|Patient receives only usual care as provided by perioperative healthcare providers.
16490590|NCT03356483|Experimental|Psilocybin|Psilocybin (0.25mg/kg)
16490591|NCT03356483|Placebo Comparator|Niacin|Niacin (250mg)
16490592|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
16490626|NCT03356210|Experimental|Neurofeedback + TAU|20 sessions of symptom-based NF training in conjunction with traditional therapy
16490627|NCT03356184|Experimental|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16490593|NCT03356457|Active Comparator|DCA in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
16490594|NCT03356457|Placebo Comparator|Placebo in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a placebo oral capsule.
16490595|NCT03356457|Active Comparator|DCA in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study. Each subject will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
16490596|NCT03356457|Placebo Comparator|Placebo in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study will receive a placebo oral capsule.
16490597|NCT03356444|Experimental|Abiraterone group|Abiraterone acetate is administered in this arm.
16490598|NCT03356444|Active Comparator|Docetaxel group|Docetaxel is administered in this arm.
16490599|NCT03356431|Experimental|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
16490600|NCT03356431|Experimental|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.
~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).
~The exercise program are the same as the supervised group exercise."
16490601|NCT03356418|Experimental|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
16490602|NCT03356418|Sham Comparator|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
16490603|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention: telephone call on day 90 to assess the primary outcome (mRs d90)
16490604|NCT03356379|Experimental|Patients|Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing
16490605|NCT03356379|Sham Comparator|Controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing
16490606|NCT03356366|Experimental|Principal study|Patients pathological process will be assessed using MRI 3T
16490607|NCT03356366|Experimental|Ancillary study 1|Patients pathological process will be assessed using MRI 1,5T
16490608|NCT03356366|Experimental|Ancillary study 2|Patients pathological process will be assessed using MRI 7T
16490609|NCT03356353|Experimental|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
16490610|NCT03356327|Experimental|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
16490611|NCT03356327|Active Comparator|Group 2|Group 2 consisting of 30 children who received only SOR.
16490612|NCT03356301|Experimental|Triathletes|Every triathlete will realize three cardiac MRI exams.The second of those will be done at the fitness peak, 2-3 weeks before the main objective of the sports season. Training will be increased between the study beginning and the first MRI, and the second exam. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
16490613|NCT03356301|Experimental|Controls|Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
16490614|NCT03356288||Asthma|20 Participants with moderate to severe asthma, as defined by British Thoracic Society (BTS) guidelines
16490615|NCT03356288||Chronic heart failure|10 Participants with a diagnosis of chronic heart failure
16490616|NCT03356288||Breathing Pattern Disorder|10 Participants with a diagnosis of Breathing Pattern Disorder
16490617|NCT03356288||Pneumonia|10 participants with a radiologically confirmed diagnosis of pneumonia
16490618|NCT03356288||Motor Neurone Disease|10 participants with a diagnosis of motor neurone disease with known hypercapnic failure.
16490619|NCT03356288||Healthy|10 Participants who have no known lung, cardiac or neuromuscular condition.
16490620|NCT03356275|Experimental|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
16490621|NCT03356249||Sepsis Group|Patients (n=500) with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions).
16490622|NCT03356236||Observation group 1|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1
16490623|NCT03356236||Observation group 2|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2
16490628|NCT03356184|Active Comparator|The Earlysense System Device Group|The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16490629|NCT03356171|Experimental|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
16490630|NCT03356171|Active Comparator|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
16490631|NCT03356158|Experimental|CPGJ 602 low dose|Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
16490632|NCT03356158|Experimental|CPGJ 602 normal dose|Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
16490633|NCT03356158|Active Comparator|Cetuximab normal dose|Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.
16490636|NCT03356132||Textured Group|Women undergoing primary and secondary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
16490637|NCT03356132||Polyurethane Group|Women undergoing primary and secondary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
16490638|NCT03356119|Experimental|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
16490639|NCT03356106|Experimental|CPAP|Nocturnal administration of continuous positive airway pressure treatment (CPAP) until delivery
16490640|NCT03356106|No Intervention|Control|Usual antenatal care for high risk pregnancy
16490641|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
16490642|NCT03356080|Experimental|DLAAG|"All patients receive 1-2 cycles of induction chemotherapy,that is DLAAG,which is expected to be 6 weeks/cycle,including decitabine,cytarabine, all-transretinoic acid,and Granulocyte Colony-Stimulating Factor(G-CSF).
~patients with CR after the first course of induction therapy (DLAAG) will continue to receive 1 cycle of consolidation therapy, while those with therapy failure will continue the second course of induction therapy. If CR is not achieved, quit the study.
~Patients who achieve CR after induction therapy will be in accordance with the guidelines, such as the proposed active treatment of allogeneic hematopoietic stem cell transplantation"
16490643|NCT03356067|Sham Comparator|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope.
16490644|NCT03356067|Experimental|Gastric endoscopic peroral pyloromyotomy|Experimental per-oral endoscopic myotomy of the pyloric sphincter
16490645|NCT03356054|Experimental|Brentuximab vedotin-R-DHAP|Brentuximab vedotin added to R-DHAP
16490646|NCT03356041|Active Comparator|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
16490647|NCT03356041|No Intervention|Usual care Group|The usual care group will be provided the standard medical services
16490648|NCT03356028|Other|impacted by the attack of 14 July 2016|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire following the mass trauma of 14 July 2016 in Nice on a sample of exposed pediatric population
16490649|NCT03356028|Other|control group|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire of children controls
16490650|NCT03356015|Experimental|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
16490651|NCT03356015|Active Comparator|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
16490652|NCT03356002|Active Comparator|High risk subjects|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.
~Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:
~c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms:"
16490653|NCT03356002|Experimental|Average risk|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.
~Average risk based on their age and demographics referred for screening for polyps."
16490654|NCT03355989|Experimental|Low Flat Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.80 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490655|NCT03355989|Experimental|Low Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490656|NCT03355989|Experimental|Low Sharp Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.75 on the BCG/Penta-1/Penta-2 vaccine and $1.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490657|NCT03355989|Experimental|Low Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $3.75 on the BCG/Penta-1/Penta-2 vaccine and $5.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490658|NCT03355989|Experimental|High Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490659|NCT03355989|Experimental|High Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490660|NCT03355989|Experimental|High Sharp Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.25 on the BCG/Penta-1/Penta-2 vaccine and $3.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490661|NCT03355989|Experimental|High Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $11.25 on the BCG/Penta-1/Penta-2 vaccine and $15.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
16490662|NCT03355989|Experimental|Easypaisa Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
16490663|NCT03355989|Experimental|Easypaisa Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
16490664|NCT03355989|Experimental|SMS Reminder Only|The intervention consists of only sending 3 SMS reminders before, at and after the due date.
16490665|NCT03355989|No Intervention|Control|No intervention will be provided either in the form of cash incentive or reminder SMS. Vaccination facilities will be provided as per usual.
16490666|NCT03355976|Experimental|Arm 1 Nivolumab Ovarian|Nivolumab 240 mg Day 1 Cycle = 2 weeks
16490667|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Ovarian|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
16490668|NCT03355976|Experimental|Arm 1 Nivolumab Extra-renal|Nivolumab 240 mg Day 1 Cycle = 2 weeks
16490669|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Extra-renal|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
16490670|NCT03355963|Placebo Comparator|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
16490671|NCT03355963|Active Comparator|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
16490672|NCT03355963|Active Comparator|Group C|"The treatment group C:
~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
16490673|NCT03355950|Active Comparator|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
16490674|NCT03355950|Active Comparator|Lichtenstein group|Patients who undergo Lichtenstein repair.
16490675|NCT03355937|Active Comparator|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
16490676|NCT03355937|Experimental|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
16490677|NCT03355937|Active Comparator|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
16490678|NCT03355937|Experimental|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
16490679|NCT03355872|Experimental|HLX01|
16490680|NCT03355872|Active Comparator|Rituximab|
16490681|NCT03355859|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
16490682|NCT03355846|Experimental|AAF treated with Centella® Complex|Centella® Complex 1 cps 60 mg per os
16490683|NCT03355846|Experimental|AAF treated with Proctocella® cream|Proctocella® Complex cream to be applied in anal area and anal canal
16490684|NCT03355846|Experimental|AAF treated with Flavonil® cps|Flavonil® 1 cps 300 mg per os
16490685|NCT03355846|Experimental|AAF treated with Flavonil® Cream|Flavonil® Cream Cream to be applied in anal region and anal canal
16490686|NCT03355846|Experimental|AAF treated with Rectalgan Mousse|Rectalgan Mousse cleansing cleanser for anal and perineal region
16490687|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
16490688|NCT03355807|Experimental|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
16490689|NCT03355807|No Intervention|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
16490690|NCT03355794|Experimental|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 300mg daily (DIPG only); </=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (>21yrs 2.5mg/day (DIPG only); </=21yr 1.2 mg/m2/day) BSA >/=0.75m2
16490691|NCT03355794|Experimental|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA >/=0.45m2
16490692|NCT03355794|Experimental|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA >/=0.45m2
16490725|NCT03355534|Experimental|nasal dexmedetomidine|dexmedetomidine is given nasally, saline is given intravenously
16490693|NCT03355794|Experimental|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
16490694|NCT03355781||Schizophrenic patients|Patients will have clinical psychiatric evaluation, brain imaging and blood sample
16490695|NCT03355781||Related volunteers (first degree relative of patient)|Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
16490696|NCT03355781||Healthy volunteers|Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
16490697|NCT03355768|Experimental|Romidepsin Arm|Control Arm: Subjects will receive Romidepsin 14 mg/m2 on Days 1, 8, 15.
16490698|NCT03355768|Experimental|Romidepsin + Pralatrexate Combination Arm|Combination Arm: Subjects will receive Romidepsin 12 mg/m2 and Pralatrexate 25 mg/m2.
16490699|NCT03355755|Experimental|Interventional Group|All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
16490700|NCT03355742|Experimental|XIENCE|XIENCE + Short duration (1 month) of DAPT
16490701|NCT03355716|Placebo Comparator|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
16490702|NCT03355716|Active Comparator|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
16490703|NCT03355716|Active Comparator|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
16490704|NCT03355716|Active Comparator|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
16490705|NCT03355690||Stroke patients|Stroke patients are treated according to the clinical practice which can be divided into: anti-aggregation, thrombectomy and/or thrombolysis
16490706|NCT03355677|Active Comparator|Case finding clinics|The visit will be a minimum 90 minutes long at the participants own GP surgery. This will include a respiratory assessment including spirometry will performed by a RT Respiratory Nurse Specialist (RNS) and where possible a Practice Nurse or Nurse Practitioner will attend. The visit will consist of objective measurements, investigations and questionnaires
16490707|NCT03355677|Placebo Comparator|Case finding Usual care|In the control arm of the study, practices will continue with usual care according to national guidance for case finding for COPD (NICE, 2010). Matched practices will have their eligible population identified through electronic searches based on data routinely recorded in primary care run in the HHRa. Case finding yield will be measured as the percentage of patients from the eligible population identified with a respiratory diagnosis in the 12 months from study beginning to study end.
16490708|NCT03355677|Active Comparator|At Risk Case clinics|The complex case clinic will be a minimum 120 minute appointment at the participants own GP surgery. The intervention will include an initial assessment by a RT Respiratory Nurse Specialist (RNS) and followed by a joint assessment by a respiratory physician (RP) working alongside a practice clinician (GP and/or Practice Nurse/Nurse Practitioner). The visit will consist of objective measurements, investigations and questionnaires as outlined in section 3 below. A personalised disease management and action plan will be agreed jointly between the RT, practice clinician and participant. The practice clinician will undertake the necessary tasks required for the agreed management plan. The clinical responsibility for the participant will remain with the GP practice.
16490709|NCT03355677|Placebo Comparator|At Risk Usual Care|In the control arm of the study, practices will continue with usual care according to national guidance for the management of COPD and asthma . A cohort of patients matched for practice and for age, sex, disease condition and, where possible, disease control will be identified. This cohort will be monitored against markers of sub-optimal disease (medication usage, exacerbations, unscheduled visits to the practice, attendance or admission to hospital).
16490710|NCT03355664|Active Comparator|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
16490711|NCT03355664|Experimental|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
16490712|NCT03355651|Active Comparator|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
16490713|NCT03355651|No Intervention|Control Group|Standard Rehabilitation + ACL reconstruction
16490714|NCT03355638|Active Comparator|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
16490715|NCT03355638|Experimental|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
16490716|NCT03355638|Experimental|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
16490717|NCT03355612|Experimental|experimental group|Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
16490718|NCT03355612|Active Comparator|active comparator|Drug:XELOX(Capecitabine and Oxaliplatin)
16490719|NCT03355599|Other|3d camera|3d camera
16490720|NCT03355586||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.
~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.
~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.
~These will be subjected to a combined approach of modalities with the main intervention being electromagnetic navigation."
16490722|NCT03355560|Experimental|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 6 doses.
16490723|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
16490724|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
16491415|NCT03351010|Experimental|Mindfulness|Receiving education program and mindfulness training
16490726|NCT03355534|Experimental|intravenous dexmedetomidine|saline is given nasally, dexmedetomidine is given intravenously
16490727|NCT03355534|Placebo Comparator|normal saline|saline is given nasally and intravenously
16490728|NCT03355521|Experimental|Nordic walking Experimental|Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.
16490729|NCT03355521|Active Comparator|Free walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
16490730|NCT03355508|Other|puncture bevel up|
16490731|NCT03355508|Other|puncture bevel domn|
16490732|NCT03355495|No Intervention|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
16490733|NCT03355495|Active Comparator|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
16490734|NCT03355482|Active Comparator|Depomedrol arm|Patients are treated with new or ascending doses of subcutaneous methotrexate, and receive a single intramuscular dose of Depomedrol (160mg) at baseline.
16490735|NCT03355482|Sham Comparator|Placebo arm|Patients are treated with new or ascending doses methotrexate, and receive a single intramuscular placebo injection at baseline.
16490736|NCT03355469|Placebo Comparator|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
16490737|NCT03355469|Placebo Comparator|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
16490738|NCT03355469|Active Comparator|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
16490739|NCT03355469|Active Comparator|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
16490740|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
16490741|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
16490742|NCT03355456|Active Comparator|PVI + Posterior wall ablation|PVI radiofrequency ablation along with ablation of the posterior wall.
16490743|NCT03355443|Active Comparator|Re-examination Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined in the same fashion. After that, the rest of the colon is examined in routine method.
16490744|NCT03355443|Experimental|Retroflexion Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined with the colonoscope tip in reverse direction (retroflexion fashion). After that, the rest of the colon is examined in routine method.
16490745|NCT03355430||moderate keratoconus group|moderate keratoconus group underwent combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
16490746|NCT03355417|Experimental|OT-SI|Occupational therapy using a sensory integration approach
16490747|NCT03355404|Experimental|"Standing Patient"|
16490748|NCT03355404|No Intervention|"Standardized management in stretcher"|
16490749|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
16490750|NCT03355378|Experimental|study group|gum chewing during spinal anesthesia and early ambulation
16490751|NCT03355378|No Intervention|Control group|no gum chewing
16490752|NCT03355365|Experimental|Intrathecal MSC-NP injection|Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.
16490753|NCT03355365|Placebo Comparator|Intrathecal saline injection|Patients will receive six placebo injections through spinal taps every 2 months over a year.
16490754|NCT03355352||Patients treated with conventional i.v. PCA|
16490755|NCT03355352||Patients treated with Zalviso|
16490756|NCT03355339|Experimental|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
16490757|NCT03355339|Active Comparator|No binasal occlusion|Participants will be fitted with non-occluded glasses.
16490758|NCT03355326|Experimental|Glycerin Suppository Group|
16490759|NCT03355326|No Intervention|Non-suppository Group|
16490760|NCT03355313|Experimental|Low level light therapy 1|
16490761|NCT03355313|Experimental|Low level light therapy 2|
16490762|NCT03355313|Experimental|Low level light therapy 3|
16490763|NCT03355300|Experimental|Cannabidiol Oral Solution|Cannabidiol Oral solution, dose as assigned in INS-17-103.
16490764|NCT03355287|Placebo Comparator|Traditionally Threshed Teff (TTT)|The control group will consume injera based on teff threshed under the hooves of cattle. We plan to have a certain number of teff flour suppliers, where the teff is traditionally threshed and contains at least 50 mg Fe per 100 g flour.
16491416|NCT03351010|Active Comparator|Control|Receiving education program
16490765|NCT03355287|Experimental|Lab Threshed Teff (LTT)|The intervention group will consume injera based on teff flour that has been lab threshed using a modern teff threshing machine.
16490766|NCT03355287|Active Comparator|Fortified Lab Threshed Teff (FTT)|This arm will be the positive control group consuming Ferrous Sulphate drops ( with injera that consist of lab-threshed teff. The Fe drops have to be consumed with the meal and will provide an additional 6 mg of Ferrous sulfate to the diet of the children.
16490767|NCT03355274|Experimental|Patients|Patients suspected of thoracic outlet syndrome Transcutaneous oximetry during upper arm manoeuvers
16490768|NCT03355274|Sham Comparator|controls|healthy asymptomatic subjects Transcutaneous oximetry during upper arm manoeuvers
16490769|NCT03355261|Experimental|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
16490770|NCT03355261|Experimental|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
16490771|NCT03355261|Experimental|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
16490772|NCT03355261|Experimental|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
16490773|NCT03355248|Active Comparator|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
16490774|NCT03355248|Experimental|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
16490775|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
16490776|NCT03355222|No Intervention|No Intervention|No intervention: The community receives no chickens and no special education is provided.
16490777|NCT03355222|Experimental|Experimental: providing chickens and egg shell|"Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers.
~The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens."
16490778|NCT03355209|Experimental|ZX008 0.2 or 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 0.2 mg/kg/day or 0.8 mg/kg/day.
16490779|NCT03355209|Placebo Comparator|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
16490780|NCT03355209|Experimental|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
16490781|NCT03355196|Experimental|LRX712|LRX712 given intra-articularly
16490782|NCT03355196|Placebo Comparator|Placebo|Placebo given intra-articularly
16490783|NCT03355183|Experimental|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
16490784|NCT03355170|Experimental|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
16490785|NCT03355170|Active Comparator|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
16490786|NCT03355157|Experimental|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
16490787|NCT03355157|Active Comparator|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
16490788|NCT03355144|Experimental|Internal Medicine residents at NYU|effect of supplying Internal Medicine residents at NYU with free coffee on self reported features of psychological health, energy and burnout
16490789|NCT03355131|Experimental|Adapted NASA's Mission X program|Adapted NASA's Mission X program for the intervention group
16490790|NCT03355131|No Intervention|Mission X Control|no intervention
16490791|NCT03355105|Experimental|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
16490792|NCT03355105|Active Comparator|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
16490793|NCT03355092|Experimental|vBloc Therapy + Usual Care for Type 2 Diabetes|
16490794|NCT03355092|No Intervention|Usual Care for Type 2 Diabetes|
16490795|NCT03355079|Experimental|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
16490796|NCT03355079|No Intervention|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake. Standard of care tube feeding or parenteral nutrition is allowed to start earliest 3 weeks after baseline visit, if required.
16490859|NCT03354624|Experimental|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
16490860|NCT03354624|Experimental|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
16491972|NCT03346837|Experimental|Inhibition (Cohort 1)|Single oral dose BMS-986205
16490797|NCT03355066|Experimental|Part 1A: Dose Escalation|Cohorts of subjects with advanced solid tumors will receive increasing doses (10, 20, 40, 60, 80, 120, 160, or 200 mg) of SM08502, administered orally, once daily, following 28-day treatment cycles. If the maximum tolerated dose (MTD) is not determined at the 200 mg dose, dosing will continue at 50 mg/dose increments until an MTD is determined. Cohorts will include approximately 1 to 6 subjects according to an accelerated escalation design and safety requirements for expansion of subject numbers. For the purpose of dose escalation and de-escalation, the dose of SM08502 and regimen may be modified based on the type of dose limiting toxicities (DLTs) observed and following data review and discussions between the Sponsor and Investigators.
16490798|NCT03355066|Experimental|Part 1B: Dose Finding|Indications eligible for Part 1B include castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Initially, two cohorts of 6-24 subjects will be evaluated comparing 2 different doses and schedules of SM08502 (30 mg daily and 40 mg 5 days on and 2 days off), administered orally following 28-day treatment cycles. If appropriate, alternative doses and schedules may be evaluated depending on the results.
16490799|NCT03355066|Experimental|Part 2: Expansion|Part 2 will evaluate the recommended Part 2 dose and schedule of SM08502, as determined in Part 1B, in 6 cohorts of subjects. The indications to be evaluated include subjects with advanced and/or metastatic CRPC, NSCLC, TNBC, CRC, endometrial cancer, and ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Each cohort will enroll approximately 20 subjects.
16490800|NCT03355053|Active Comparator|Dexmedetomidine (Dex) very-low dose group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:
~1) Group 1: Dex at 0.1 mcg/kg/h from 8PM until 7AM"
16490801|NCT03355053|Active Comparator|Dexmedetomidine (Dex) low dose group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:
~2) Group 2: NS at 0.3 mcg/kg/h from 8PM until 7AM"
16490802|NCT03355053|Placebo Comparator|Usual care + placebo group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:
~3) Group 3: NS at 0.075 ml/kg/h from 8PM until 7AM."
16490803|NCT03355027|Experimental|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
16490804|NCT03355027|Active Comparator|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
16490805|NCT03355014|Experimental|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day
~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
16490806|NCT03355014|Experimental|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg
~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
16490807|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
16490808|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
16490809|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
16490810|NCT03354988|Active Comparator|physical exercise group|For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
16490811|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
16490812|NCT03354975|Experimental|Experiential Training|
16490813|NCT03354975|Active Comparator|Training-as-usual|
16490814|NCT03354962|Active Comparator|ARM A|
16490815|NCT03354962|Experimental|ARM B|
16490816|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.
~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).
~Propulsion speed of a wheelchair."
16490817|NCT03354923|Experimental|immediate intervention group|Immediate PEERS intervention
16490818|NCT03354923|Other|delayed intervention|delayed PEERS intervention to begin after experimental group
16490819|NCT03354910|No Intervention|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
16490820|NCT03354910|Active Comparator|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
16490821|NCT03354910|Experimental|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
16490822|NCT03354897|Other|Treatment|16 weeks treatment 5mg/day
16490823|NCT03354884|Experimental|Cabozantinib|All subjects will receive open label Cabozantinib 60 mg orally once daily
16490824|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
16490825|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
16490826|NCT03354845|No Intervention|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
16490827|NCT03354845|Other|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
16490828|NCT03354832||Foetal death|In-utero dead foetus weighting at least 500 g or 22-amenorrhea weeks old. In utero death means that death occurs during delivery or per partum
16490829|NCT03354832||New-born death|New-born dead during post-birth hospital stay and at least 23-amenorrhea weeks old.
16490830|NCT03354832||Birth control for foetal death|Same gender child born, and alive, in the same hospital, and born on time (37-41 amenorrhea weeks old).
16490831|NCT03354832||Birth control for new-born death|"Same gender infant born, and alive, in the same hospital, and:
~for 23-amenorrhea weeks old new-born death: control new-born are born on time (37-41 amenorrhea weeks old).
~for 24 to 31-amenorrhea weeks old new-born death: control new-born are premature infant (24-31 amenorrhea weeks old), and are included when their hospital stay ends.
~for 32 and more-amenorrhea weeks old new-born death: control new-born are 32 and more-amenorrhea weeks old infant"
16490832|NCT03354819|Experimental|Modified MBCT|A group-based, 10-week, 7-session modified Mindfulness Based Cognitive Therapy (MBCT) will be adopted in the MBCT intervention group with a group size of 15-20. The program includes different mindfulness activities (such as mindful eating and mindful walking) and peer sharing.
16490833|NCT03354819|Active Comparator|SIRE on dementia|The frequency of the Social Interactions and Routine Education (SIRE) program is the same as that of modified MBCT which consists of seven sessions (weekly for the first four sessions and bi-weekly for the last three sessions) and each session will last about two hours for 10 weeks with group size 15-20.
16490834|NCT03354806|Experimental|Continuous peripheral nerve blocks|Ropivacaine-continous treatment using catheters for continous sciatic nerve blocks
16490835|NCT03354806|Active Comparator|Analgesic treatment|Pharmacological pain management in accordance with WHO's pain relief ladder
16490836|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
16490837|NCT03354793||non endometriosis|Survey on first pregnancy
16490838|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
16490839|NCT03354780||non endometriosis|Survey on first pregnancy
16490840|NCT03354767||Wasting patients|Patients with >10% loss of skeletal muscle one week after major aortic surgery
16490841|NCT03354767||Non-wasting patients|Patients with <10% loss of skeletal muscle one week after major aortic surgery
16490842|NCT03354754|Experimental|LYS228|IV infusion every 6 hours for at least 5 days
16490843|NCT03354754|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
16490844|NCT03354741|Other|Laser then Sham therapy|2nd cycle of chemotherapy : administration of laser therapy 3th cycle of chemotherapy : administration of a sham laser according to the same modalities
16490845|NCT03354741|Other|Sham therapy then laser|2nd cycle of chemotherapy : administration of a sham laser 3th cycle of chemotherapy : administration of laser therapy according to the same modalities
16490846|NCT03354728|Experimental|Supportive Care (multi-antigen CMV-modified vaccinia ankara)|Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
16490847|NCT03354715|Sham Comparator|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
16490848|NCT03354715|Sham Comparator|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
16490849|NCT03354702|Experimental|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
16490850|NCT03354702|Active Comparator|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
16490851|NCT03354676||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
16490852|NCT03354676||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
16490853|NCT03354663|Experimental|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
16490854|NCT03354650||complete blood count|blood sample is collected from infant to detect presence of sepsis
16490855|NCT03354650||c reactive protein|measuring c reactive protein in blood sample to determine neonatal sepsis
16490856|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
16490857|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
16490858|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
16490861|NCT03354611|Experimental|Diagnostic Workup|The subjects will first have a pre-contrast CBBCT scan. Iodinated contrast will be injected intravenously, and then another CBBCT scans will be performed to capture the tumor vasculature enhancement.
16490862|NCT03354598|Experimental|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
16490863|NCT03354598|Active Comparator|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
16490864|NCT03354585|Experimental|Meditation Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
16490865|NCT03354585|Active Comparator|Meditatin Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
16490866|NCT03354585|Active Comparator|Book Listening Control Group|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 12 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
16490867|NCT03354572|Active Comparator|NAC|receive 150 mg/kg acetylcysteïne in 200 ml saline (NaCl0,9%) prior to surgery
16490868|NCT03354572|Placebo Comparator|placebo|receive only NaCl 0.9% prior to surgery (volume identical to active comparator)
16490869|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count > 100.000 x 10 9/L
16490870|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
16490871|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
16490872|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
16490873|NCT03354533|Other|Treatment with ORL-1F - L-fucose|
16490874|NCT03354520|Active Comparator|Tailored Videos|
16490875|NCT03354520|Active Comparator|Standard Videos|
16490876|NCT03354520|Active Comparator|OSA Treatment|
16490877|NCT03354507|Experimental|Sodium Bicarbonate|"Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.
~< 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. > 42kg : 3/4 teaspoon bid."
16490878|NCT03354507|No Intervention|Control|Patients will not receive treatment if they do not have metabolic acidosis at baseline.
16490879|NCT03354494||DSG-CTP|
16490880|NCT03354481|Experimental|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
16490881|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
16490882|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
16490883|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
16490884|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
16490885|NCT03354455|Experimental|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
16490886|NCT03354455|Sham Comparator|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
16490887|NCT03354442|Experimental|Modified Fixed Mandibular Retractor|All patients in this group will be treated using Modified Fixed Mandibular Retractor Appliance. This appliance will be used full-time.
16490888|NCT03354442|No Intervention|Untreated control group|All patients in this group will be observed during the period of treating the patients in the other group to assess the growth changes.
16490889|NCT03354429|Experimental|TICAGRELOR|
16490890|NCT03354429|Placebo Comparator|TICAGRELOR PLACEBO|
16490891|NCT03354416||1/ Cohort 1|Subjects with an increased risk of prostate cancer or a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
16490892|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
16490893|NCT03354390|Experimental|1|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six hasexperienced a dose limiting toxicity (DLT).
16490894|NCT03354377|Experimental|Vegan Diet|"Participants in this group will follow a plant-based vegan diet. The vegan group diet will be based on investigators' pilot work, which instructs participants to favor a diet built around whole grains, fruits, vegetables, and legumes. This group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course.
~Interventions include intervention meetings, physical activity, and podcasts/mailings."
16490947|NCT03354078|Active Comparator|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
16490948|NCT03354065|Active Comparator|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
16490895|NCT03354377|Experimental|Omnivorous (Omni) Diet|"Participants in this group will follow a low-fat omni diet. The diet intervention for the omni group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide, A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course).
~Interventions include intervention meetings, physical activity, and podcasts/mailings."
16490896|NCT03354364|Active Comparator|Group 1|Receives pea hull fiber snack for the first 4 weeks and then control snack for the last 4 weeks of the study with 4-week washout between them.
16490897|NCT03354364|Active Comparator|Group 2|Receives control snack for the first 4 weeks and then pea hull fiber snack for the last 4 weeks of the study with 4-week washout between them
16490898|NCT03354351||NB-Group|Stepped-care model comprising a hierarchy of interventions, from the least to the most intensive, matched to the cardiac man's needs. The model involves three steps: Step 1 (therapist-guided and self-guided 3-session psychoeducational program), Step 2 (Group sessions involving care partners), and Step 3 (individual or dyadic (patient and care Partner) sessions. As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
16490899|NCT03354351||ON-Group|Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
16490900|NCT03354351||QC-Group|Standard Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
16490901|NCT03354338|Experimental|Experimental Group|Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
16490902|NCT03354338|Placebo Comparator|PLACEBO|Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
16490903|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
16490904|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
16490905|NCT03354312|Experimental|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
16490906|NCT03354312|Experimental|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
16490907|NCT03354299|Experimental|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
16490908|NCT03354299|Active Comparator|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
16490909|NCT03354286|Experimental|Developmental & Technological Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.
16490910|NCT03354286|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
16490911|NCT03354286|Experimental|Nutrition, Set Point, & C:I Ratio|Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.
16490912|NCT03354286|Experimental|Hypoglycemia management|Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia
16490913|NCT03354286|Placebo Comparator|Minimal Intervention|A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.
16490914|NCT03354273|Experimental|1|Flurpiridaz PET MPI (following off-study SPECT MPI)
16490915|NCT03354260|Experimental|intervention|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
16490916|NCT03354260|No Intervention|Control|
16490917|NCT03354247|No Intervention|Healthy Control|Participants in this group will attend small group sessions providing basic education about NAFLD/NASH, and about principles of healthy eating, physical activity and weight control. These sessions occur every 12 weeks and are conducted by a Master's level nutritionist or health educator. Providing basic education about diet and exercise has produced minimal weight loss in other clinical trials. The educational sessions will be included in this study in order to provide standard care to these patients and to maximize subject retention.
16490918|NCT03354247|Experimental|NAFLD Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants who are able to lose more than 10% of their body weight will be encouraged to do so. Participants will be seen weekly for the first 6 months and then biweekly for months 7-12. The lifestyle intervention focused on diet, exercise, and behavior modification.
16492478|NCT03343288|Experimental|Silver HA coated implants|Silver doped hydroxyapatite coated implants
16490919|NCT03354234|Experimental|Stimuli of slowly increasing intensities|"300-s check before the stimuli
~LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s
~180-second phase of rest between stimuli
~75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)
~180-second phase of rest between stimuli
~75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT
~120-s check after the stimuli"
16490920|NCT03354234|Experimental|Stimuli of rapidly increasing intensities|"120-s check before the stimuli
~75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)
~180-second phase of rest between stimuli
~LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.
~180 second phase of rest between stimuli
~push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT
~120-s check after the stimuli"
16490921|NCT03354221|Experimental|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
16490922|NCT03354208||Group 1|patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
16490923|NCT03354208||Group 2|patients with suspected HIE, non-confirmed
16490924|NCT03354208||Group 3|healthy, retrospectively classified as such
16490925|NCT03354195|Active Comparator|Group 1|"Group 1 - intact ACL ligament will be accepted as functionally intact
~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
16490926|NCT03354195|Active Comparator|Group 2|"Group 2 - intact but fibrillated (frayed) ligament) will be accepted as functionally intact
~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
16490927|NCT03354195|Active Comparator|Group 3|"Group 3 - nearly completely torn ligament (>50% and disrupted) will be deemed as having functionally absent ACLs
~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
16490928|NCT03354182|Active Comparator|Control group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen + Bio-gide
16490929|NCT03354182|Active Comparator|Test group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen alone
16490930|NCT03354169|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
16490931|NCT03354169|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
16490932|NCT03354156||High-LDL|patients with LDL cholesterol levels of >4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
16490933|NCT03354156||Control|control subjects with an LDL cholesterol level of <3.5 mmol/l
16490934|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
16490935|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
16490936|NCT03354130|Active Comparator|Tofu control|Volunteers will consume a vegetarian diet containing tofu during 3 days for 5 meals in total
16490937|NCT03354130|Experimental|Non-processed pork diet|Volunteers will consume a diet containing non-processed pork during 3 days for 5 meals in total
16490938|NCT03354130|Experimental|Bacon diet|Volunteers will consume a diet containing bacon during 3 days for 5 meals in total
16490939|NCT03354130|Experimental|Sausage diet|Volunteers will consume a diet containing sausage during 3 days for 5 meals in total
16490940|NCT03354130|Experimental|Dry-cured sausage diet|Volunteers will consume a diet containing dry-cured sausage during 3 days for 5 meals in total
16490941|NCT03354117|Experimental|Ulipristal 30mg plus Meloxicam 15mg|Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.
16490942|NCT03354104|Experimental|Recession coverage with connective tissue graft + Emdogain®|A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with 24% EDTA (PrefGel®, Straumann, Basel, Switzerland) for 2 minutes and then washed with saline. Subsequently, EMD (Emdogain®, Straumann, Basel, Switzerland) is applied on root surfaces. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
16490943|NCT03354104|Active Comparator|Recession coverage with connective tissue graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
16490944|NCT03354091|Experimental|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
16490945|NCT03354091|No Intervention|Control|Patient education program only.
16490946|NCT03354078|Active Comparator|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
16490949|NCT03354065|Experimental|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
16490950|NCT03354052|Experimental|Real-rTMS + Gloreha device|
16490951|NCT03354052|Active Comparator|Sham-rTMS + Gloreha device|
16490952|NCT03354039|Experimental|Tamoxifen 20 mg once daily|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.
16490953|NCT03354039|Placebo Comparator|Matching placebo once daily|Patients randomised to placebo will be administered matching placebo.
16490954|NCT03354026|Experimental|Experimental: AICH-PXZY|Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
16490955|NCT03354026|Experimental|Experimental: AICH-without PXZY|Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
16490956|NCT03354026|Placebo Comparator|Placebo: AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
16490957|NCT03354013|Experimental|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo 100% ICSI-AOA if less than 6 mature oocytes are collected upon oocyte retrieval. If 6 or more mature oocytes are retrieved, 50%ICSI and 50%ICSI-AOA will be applied.
~Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.
~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
16490958|NCT03354000|Placebo Comparator|Take-home online training|Participants received a link to access the online tutorial videos on their own.
16490959|NCT03354000|Active Comparator|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
16490960|NCT03353987|No Intervention|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
16490961|NCT03353987|Experimental|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
16490962|NCT03353974|Experimental|Video game therapy|Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 12 sessions of treatment within 4 weeks (3 sessions per week); each session will last 1 hour. To manage possible absence lasting one or more treatment sessions, a potential window of 5 weeks will be set to ensure the achievement of all 12 sessions. Will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
16490963|NCT03353974|Active Comparator|Balance platform therapy|"Subjects belonging to the control group will receive the same amount of therapy (12 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an entry level, and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback."
16490964|NCT03353961|Experimental|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
16490965|NCT03353961|Active Comparator|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
16490966|NCT03353948|Active Comparator|Metfrormin group (MET)|Drug: Metformin
16490967|NCT03353948|Active Comparator|COMBI group (COMBI)|Drug: liraglutide
16490968|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
16490969|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
16490970|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
16490971|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
16490972|NCT03353909|Experimental|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
16490973|NCT03353909|No Intervention|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
16490974|NCT03353896|Experimental|Treatment (medical device)|Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
16490975|NCT03353883|Active Comparator|(Group A) Midluteal Triptorelin depot|infertile women with impaired ovulation who will be subjected to Triptorelin sustained release(Decapeptyl depot 375 mg one injection )at D-21 of previous menstrual cycle Hormon Replacement Therapy (HRT)Cyclo-Progynova (estradiol, norgestrel)(Group A). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-HCG level and was confirmed 2-weeks later by TVU.
16490976|NCT03353883|Active Comparator|(Group B)first day Triptorelin depot|infertile women with impaired ovulation who will be subjected toTriptorelin sustained release(Decapeptyl depot 375 mg one injection) at D-1 of menses then Cyclo-Progynova (estradiol, norgestrel) (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-Human Chorionic Gonadotropin level and was confirmed 2-weeks later by TVU.
16490977|NCT03353870||qualitative interview|This study has only one arm
16490978|NCT03353857|Experimental|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
16490979|NCT03353857|Experimental|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
16490980|NCT03353857|Experimental|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
16490981|NCT03353857|Experimental|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
16490982|NCT03353857|Experimental|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.
~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
16490983|NCT03353844|Experimental|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
16490984|NCT03353844|No Intervention|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
16490985|NCT03353831|Placebo Comparator|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
16490986|NCT03353831|Experimental|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
16490987|NCT03353818|Active Comparator|Golf|In three different golf clubs patients will be introduced how to play golf. They will be taught techniques and recieve basic golf equipment. A total of 1 year membership free membership in the golf clubs will be given.
16490988|NCT03353818|Placebo Comparator|Placebo|No intervention given. No restrictions on physical activity.
16490989|NCT03353792|Active Comparator|CL/AP system|To improved glycemic control and strict avoidance of hypoglycemia via 8-week use of a CL/AP system (closed-loop/artificial pancreas) reverses brain metabolic adaptations in older adult T1DM patients.
16490990|NCT03353792|Placebo Comparator|usual care|Subjects in this control group will continue their usual diabetic care (insulin pump therapy) along with CGM recording.
16490991|NCT03353766|Experimental|Early crossbite correction|Early crossbite correction with Q-H Device
16490992|NCT03353766|No Intervention|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
16490993|NCT03353753|Active Comparator|Arm 1|150 mg QD DCC-2618
16490994|NCT03353753|Placebo Comparator|Arm 2|Placebo
16490996|NCT03353727|Experimental|Orthoptic rehabilitation|
16490997|NCT03353714|Placebo Comparator|Pudendal block with saline|Pudendal block with normal saline
16490998|NCT03353714|Active Comparator|Pudendal block with bupivacaine|Pudendal block with bupivacaine
16490999|NCT03353701|Other|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
16491000|NCT03353688|Active Comparator|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
16491001|NCT03353688|Placebo Comparator|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
16491002|NCT03353688|Active Comparator|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
16491003|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
16491004|NCT03353662||Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years
16491005|NCT03353662||Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6 - 59 months
16491006|NCT03353662||Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years
16491007|NCT03353662||Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between 6 - 59 months
16491008|NCT03353662||Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years
16491009|NCT03353662||Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6 - 59 months
16491041|NCT03353454|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
16491042|NCT03353441|Active Comparator|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
16491043|NCT03353441|Placebo Comparator|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
16491044|NCT03353441|No Intervention|No treatment|
16491045|NCT03353428|Experimental|LC-CTLs|Autologous lung cancer specific cytotoxic lymphocytes
16491010|NCT03353649|Experimental|Binge Eating Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (images of highly palatable foods for obese individuals), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets. Specifically, participants in this sample will be exposed to images of food and control non-food images. In different trials, subjects will be given a now cue instructing them to engage with the immediate hedonic properties of the stimulus or a later cue instructing them to imagine the long-term consequences of using the stimulus.
~This arm includes fMRI and the now vs. later cue intervention"
16491011|NCT03353649|Experimental|Smoking Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (tobacco-related images or smokers), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets.
~A similar approach to the Binge Eating sample will be used for the smoking sample using two stimulus sets. Instead of foods and non-food control images, smokers will see smoking-related images and the same control non-food non-smoking images as the Binge Eating sample.
~This Arm includes fMRI and the now vs. later cue intervention"
16491012|NCT03353636|Experimental|Natural Calm Magnesium|150mg elemental magnesium in a single oral dose
16491013|NCT03353636|Active Comparator|Magnesium Bis-glycinate|150mg elemental magnesium in a single oral dose
16491014|NCT03353636|Active Comparator|MAGSmart|150mg elemental magnesium in a single oral dose
16491015|NCT03353636|Active Comparator|Magnesium citrate|150mg elemental magnesium in a single oral dose
16491016|NCT03353636|Placebo Comparator|Placebo|
16491017|NCT03353623|Experimental|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
16491018|NCT03353623|Experimental|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
16491019|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
16491020|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
16491021|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
16491022|NCT03353597|Experimental|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
16491023|NCT03353584|No Intervention|Standard Care|Participants receive standard care treatment for their vaso-occlusive crisis. Participants will be randomized by age.
16491024|NCT03353584|Active Comparator|Virtual Reality|Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
16491025|NCT03353571|Other|C3 PATIENT PARTICIPANTS|This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the C3 in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days in patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.
16491026|NCT03353558||Study Group (CML group)|"This group will be CML patients. In this group each participant will be asked to wear a watch Actigraph for one week.
~He will be asked to fill the appropriate questionnaires, and a daily sleep diary."
16491027|NCT03353558||Control Group|"The control group will be non-CML patients, also without any known malignancy or known sleep disturbances.
~They will be asked to wear the watch Actigraph for one week, and to fill the appropriate questionnaires and a daily sleep diary."
16491028|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
16491029|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria
~Type of procedure
~Age
~ASA score
~BMI
~Duration of procedure (as percentile for this procedure)
~Diabetes
~Sex"
16491030|NCT03353519|Experimental|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
16491031|NCT03353519|No Intervention|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
16491032|NCT03353506|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
16491033|NCT03353506|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
16491034|NCT03353493|Experimental|MBCT + TAU|Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.
16491035|NCT03353493|Other|TAU|Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.
16491036|NCT03353480|Other|Reference|250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US
16491037|NCT03353480|Experimental|Experimental|250mg Azithromycin tablet manufactured at Pfizer Dalian, China
16491038|NCT03353467|Experimental|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
16491039|NCT03353467|Active Comparator|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
16491040|NCT03353454|Experimental|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
16491046|NCT03353415|Experimental|CGM Use|Each participant will wear the DexCom continuous glucose monitor for four weeks. During the first two weeks, participants will not be able to read the sensor glucose levels. In the second two weeks, participants will be able to read the sensor glucose levels. Frequency of hypoglycemia will be compared between the two phases of the study.
16491047|NCT03353402|Experimental|Fecal Microbiota Transplant (FMT)|FMT includes a colonoscopy conducted by a gastroenterologist followed by stool capsules which will be swallowed by the patient.
16491048|NCT03353389||No AKI|Adult admissions without Acute Kidney Injury during their stay
16491049|NCT03353389||CA-AKI|Adult admissions with Acute Kidney Injury diagnosed within 48 hours during their stay (Community-acquired Acute Kidney Injury)
16491050|NCT03353389||HA-AKI|Adult admissions with Acute Kidney Injury diagnosed after 48 hours during their stay (Hospital-acquired Acute Kidney Injury)
16491051|NCT03353376|Experimental|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
16491052|NCT03353376|Active Comparator|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
16491053|NCT03353363|Placebo Comparator|Normal Saline|Subject will receive 20ml of normal saline infiltration
16491054|NCT03353363|Experimental|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
16491055|NCT03353363|Experimental|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
16491056|NCT03353350|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
16491057|NCT03353350|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
16491058|NCT03353350|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
16491059|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
16491060|NCT03353337|Experimental|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 month.
16491061|NCT03353337|Placebo Comparator|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
16491062|NCT03353324|Active Comparator|intravitreal injection of bevacizumab|
16491063|NCT03353324|Active Comparator|intravitreal injection of bevacizumab+ targeted laser|Intervention intravitreal bevacizumab injection + targeted laser photocoagulation of retinal non perfused areas
16491064|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.
~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
16491065|NCT03353298|Active Comparator|Arm A|Allopurinol 300 mg
16491066|NCT03353298|Placebo Comparator|Arm B|Placebo Oral tablets
16491067|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
16491068|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
16491069|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
16491070|NCT03353272|No Intervention|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
16491071|NCT03353272|Experimental|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
16491072|NCT03353259|No Intervention|SS-TG|Standard surgery using burr-hole procedure, irrigation and drainage.
16491073|NCT03353259|Active Comparator|SS-TXA-TG|Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
16491074|NCT03353259|Active Comparator|SS-TXA-RoA|Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.
16491075|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
16491076|NCT03353233|Experimental|iPACK Block Group|A nerve block technique using a numbing medication called ropivacaine.
16491077|NCT03353233|Placebo Comparator|Sham Group|The same nerve block technique as above, however using an inactive solution of salt water.
16491078|NCT03353220|Experimental|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
16491079|NCT03353220|Experimental|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
16491080|NCT03353207||health Control|"No family history of RBD;
~Age- and sex- matched with isolated RSWA subjects
~Absence of dream enactment behaviors;
~A score of RBDQ-HK less than 19;
~Absence of RSWA as measured by v-PSG;
~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
16491081|NCT03353207||Case with isolated RSWA|"First degree relatives of patients with iRBD;
~Age 45 years or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;
~Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.
~for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
16491082|NCT03353207||Case without isolated RSWA|"First degree relatives of patients with iRBD;
~Age- and sex- matched with isolated RSWA subjects;
~Absence of dream enactment behaviors;
~A score of RBDQ-HK less than 19;
~Absence of RSWA as measured by v-PSG;
~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
16491083|NCT03353181|Experimental|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
16491084|NCT03353181|Active Comparator|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
16491085|NCT03353155|Active Comparator|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
16491086|NCT03353155|Active Comparator|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
16491087|NCT03353142|Experimental|Equal Breathing|
16491088|NCT03353116|Active Comparator|maxilla first group|the maxillary osteotomy is going to be done and fixed first
16491089|NCT03353116|Experimental|mandible first group|the mandibular osteotomy is going to be done and fixed first
16491090|NCT03353103|Active Comparator|symptomatic|
16491091|NCT03353103|Active Comparator|asymptomatic|
16491092|NCT03353077|Experimental|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
16491093|NCT03353064|Active Comparator|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
16491094|NCT03353064|Active Comparator|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.
~No EMS home visits will be set up"
16491095|NCT03353051||Group A: other - observational study|neonates ≥2000-<2500g and born with a gestation age <37 weeks.
16491096|NCT03353051||Group B: other- observational study|Group B will contain neonates >2500g and born with a gestation age <37 weeks.
16491097|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-<2500g but with a gestation age >37 weeks.
16491098|NCT03353051||Group D1:other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
16491099|NCT03353051||Group D2: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
16491100|NCT03353051||Group D3: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
16491101|NCT03353038|Active Comparator|Off-The-Shelf Pillbox vs 3D Printed Pillbox|Participants in the study were pillbox users at baseline. Participants described their experiences and preferences with their own pillbox. Then participants will be given a 3D printed pillbox. Researchers will compare participants' experiences and preferences between their off-the-shelf pillbox used at baseline and the customized 3D printed pillbox delivered to participants as part of the study.
16491102|NCT03353025|Experimental|transsphenoidal surgery treatment|Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
16491103|NCT03353025|Experimental|dopamine agonist treatment|Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
16491104|NCT03353012|Experimental|Levonorgestrel immediate post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 48-72 hr after child delivery
16491105|NCT03353012|Experimental|Etonogestrel immediate post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 48-72 hr after child delivery
16491106|NCT03353012|Active Comparator|Levonorgestrel delayed post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 5-7 weeks after child delivery
16491107|NCT03353012|Active Comparator|Etonogestrel delayed post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 5-7 weeks after child delivery
16491108|NCT03352999|Other|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
16491109|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
16491110|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
16491111|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
16491112|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
16491115|NCT03352973|Experimental|active tDCS on the dlPFC|tDCS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an active transcranial direct current stimulation (tDCS) intervention on this DLPFC region (1.5 mA for 20 minutes).
16491116|NCT03352973|Sham Comparator|sham tDCS on the dlPFC|Each participant will also receive a sham tDCS intervention as a controlled condition. The sham tDCS only include a 30-s ramp up and a 30-s ramp down.
16491117|NCT03352947|Active Comparator|Continuous (Standard)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle
16491118|NCT03352947|Experimental|Intermittent (experimental)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle
16491119|NCT03352934|Experimental|Avelumab|10 mg/kg Avelumab every 2 weeks
16491120|NCT03352921|Experimental|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
16491121|NCT03352921|Active Comparator|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
16491122|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
16491123|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
16491124|NCT03352895|Placebo Comparator|control|Control group will receive placebo medication therapy
16491125|NCT03352895|Experimental|test group|resveratrol group will receive oral resveratrol (100 mg per day)
16491126|NCT03352882|Other|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
16491127|NCT03352869|Experimental|Exenatide|Drug: Byetta Generic name: Exenatide Dosage form: 5ug and 10ug Dosage: 10-20ug/day Frequency: twice a day Duration: 3 months
16491128|NCT03352869|Active Comparator|Metformin|Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
16491129|NCT03352869|Experimental|Combination|Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
16491130|NCT03352856|Active Comparator|Active|Highly purified barley starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
16491131|NCT03352856|Placebo Comparator|Placebo|Maize starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
16491132|NCT03352843|Experimental|Single arm|
16491133|NCT03352830|No Intervention|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. Participants in the control arm will, however, receive no other intervention.
16491134|NCT03352830|Experimental|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
16491135|NCT03352830|Experimental|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
16491136|NCT03352830|Experimental|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. Participants in this arm also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
16491137|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
16491138|NCT03352804||Patients hospitalized in internal medicine ward|Patients included are patients hospitalized in internal medicine ward.
16491139|NCT03352791|Active Comparator|DSM-H Hospice Edition|training, assigning of champions to serve as mentors and performance improvement leads, and workflow changes including caregiver education pamphlets, interdisciplinary care plans, treatment algorithms, and assessment instruments.
16491140|NCT03352791|Active Comparator|Control Arm|Usual Care
16491143|NCT03352765|Experimental|rituximab, bendamustine & melphalan and ASCT|This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts.
16491144|NCT03352752|Experimental|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
16491145|NCT03352752|Experimental|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
16491146|NCT03352739|Experimental|DBS of the fornix, power on|
16491147|NCT03352739|Experimental|DBS of the NbM, power on|
16491148|NCT03352739|Sham Comparator|DBS of the fornix, power off|
16491149|NCT03352739|Sham Comparator|DBS of the NbM, power off|
16491150|NCT03352739|No Intervention|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
16491151|NCT03352726|Experimental|DBV712 Solution for Skin Prick Test|DBV712 In-House Reference Skin Prick Test preparation
16491152|NCT03352713|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
16491153|NCT03352700|Placebo Comparator|3L PEG|only used 3L PEG
16491154|NCT03352700|Experimental|3L PEG+Dyclonine Hydrochloride Mucilage|used 3L PEG+Dyclonine Hydrochloride Mucilage
16491155|NCT03352687|Experimental|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
16491156|NCT03352687|Experimental|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
16491157|NCT03352674|Experimental|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
16491158|NCT03352674|Active Comparator|Insulin Glargine Lantus|Insulin Glargine Pen Injector [Lantus]
16491159|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
16491160|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
16491161|NCT03352635||Native Hawaiians|One parent of Hawaiian descent.
16491162|NCT03352635||Japanese Americans|Two parents of Japanese descent.
16491163|NCT03352635||Non-Hispanic Whites|Two parents of non-Hispanic white descent.
16491164|NCT03352622|Active Comparator|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness
16491165|NCT03352622|Active Comparator|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
16491166|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
16491167|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
16491168|NCT03352596|Experimental|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
16491169|NCT03352596|No Intervention|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
16491170|NCT03352583|Active Comparator|Day|Group receives casein protein during the day (greater than 6 hours before bed).
16491171|NCT03352583|Experimental|Night|Group receives casein protein immediately before going to bed.
16491172|NCT03352570|Experimental|COLOVAC device|colorectal surgery performed per standard of care with deployment of the Colovac device to protect the anastomosis site
16491173|NCT03352557|Experimental|Low-dose BIIB092|Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.
16491174|NCT03352557|Experimental|Medium-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
16491175|NCT03352557|Experimental|High-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
16491176|NCT03352557|Placebo Comparator|Placebo|Intravenous (IV) infusion once every 4 weeks.
16491177|NCT03352544|Experimental|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week).
16491178|NCT03352544|No Intervention|Usual treatment|Usual treatment during 12 weeks, coinciding with exercise intervention time frame.
16491179|NCT03352531|Experimental|AK-105|Single-arm
16491180|NCT03352518|Experimental|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
16491181|NCT03352505||control|healthy walking control participants
16491182|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
16491183|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
16491184|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
16491185|NCT03352492|Experimental|Bilateral iridotomy: Superior|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
16491186|NCT03352492|Experimental|Bilateral iridotomy: Temporal|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
16491187|NCT03352479|Other|Opioids Prescribed|Each participant in the study will be given an envelope for return of unused opioids. The percentage of returned number of opioids will be calculated based on the number prescribed
16491188|NCT03352466|Experimental|NasoShield very low dose|Single intranasal spray (Part A)
16491189|NCT03352466|Experimental|NasoShield low dose|Single intranasal spray (Part A)
16491190|NCT03352466|Experimental|NasoShield medium dose|Single intranasal spray (Part A)
16491191|NCT03352466|Experimental|NasoShield high dose|Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
16491192|NCT03352466|Placebo Comparator|Placebo|Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
16491193|NCT03352466|Active Comparator|BioThrax|Three intramuscular injections 15 days apart (Part A)
16491194|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
16491195|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
16491196|NCT03352440|Experimental|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
16491197|NCT03352440|Experimental|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
16491198|NCT03352440|Active Comparator|Control Group - Kinect|Group with typical development that will perform the task on Kinect
16491199|NCT03352440|Active Comparator|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
16491200|NCT03352427|Experimental|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily
~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml
~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
16491201|NCT03352414|Experimental|Alvimopan|alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
16491202|NCT03352414|Placebo Comparator|Placebo|Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
16491203|NCT03352388|Experimental|Snack|Dairy- and berry-based snacks
16491204|NCT03352388|No Intervention|Reference|No snacks
16491205|NCT03352375|Active Comparator|Orotracheally Intubation|Intervention:orotracheally intubation
16491206|NCT03352375|Active Comparator|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
16491207|NCT03352362|Experimental|caldolor|intravenous caldolor injection during intraoperative period
16491208|NCT03352362|Active Comparator|denogan|intravenous denogan injection during intraoperative period
16491209|NCT03352362|Experimental|combination|intravenous denogan and caldolor injection during intraoperative period
16491210|NCT03352349|Experimental|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
16491211|NCT03352323|Experimental|oxymetazoline cream|
16491212|NCT03352310|Experimental|Study Group|autologous UCB transfusion
16491213|NCT03352310|Other|Control Group|standard care
16491214|NCT03352284|Experimental|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
16491215|NCT03352271|Experimental|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
16491216|NCT03352271|Active Comparator|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
16491217|NCT03352258|No Intervention|Observation|Subjects in this arm will only be followed and not treated (observational arm)
16491218|NCT03352258|Experimental|Treatment arm|Subjects will receive a low dose brain radiotherapy
16491219|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
16491220|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
16491221|NCT03352232|Experimental|Subacute Ischemic Stroke|Subacute stroke patients post stroke within 3 months of enrollment, have persistent neurological deficits despite conventional rehabilitation
16491222|NCT03352232|Experimental|Chronic Ischemic Stroke|Chronic stroke patients more than 6 months from stroke with persistent neurological deficits despite conventional rehabilitation
16491223|NCT03352219|Experimental|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
16491224|NCT03352219|Placebo Comparator|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
16491225|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
16491226|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
16491227|NCT03352193||SOTI group|Wheat spaghetti
16491228|NCT03352193||Historical control group|No intervention
16491229|NCT03352180|Active Comparator|subscapularis tendon repair|arthroscopic reapir of subscapularis tendon
16491230|NCT03352180|Active Comparator|subscapularis tendon debridement|arthroscopic debredement of subscapularis tendon
16491231|NCT03352167||ED Hjoerring|
16491232|NCT03352167||ED Aalborg|
16491233|NCT03352167||ED Aarhus|
16491234|NCT03352167||ED Herning|
16491235|NCT03352167||ED Aabenraa|
16491236|NCT03352167||ED Odense|
16491237|NCT03352167||ED Slagelse|
16491238|NCT03352167||ED Koege|
16491274|NCT03351894|Active Comparator|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
16491275|NCT03351881|Active Comparator|Opt Out|
16491239|NCT03352154|Experimental|patients with unilateral cochlear implants submitted to P300|Patients with unilateral cochlear implants, using the speech processor at least 6 months, submitted to P300 exam before CI surgery, on speech processor activation and after 06 months.
16491240|NCT03352141|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
16491241|NCT03352128|Experimental|Creatine supplementation|7-day creatine supplementation
16491242|NCT03352128|Placebo Comparator|Placebo supplementation|7-day calcium lactate supplementation
16491243|NCT03352115|Experimental|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
16491244|NCT03352115|Placebo Comparator|Control|Will receive placebo syrup for 5 days post-operatively
16491245|NCT03352102|Experimental|Diaphragm Group (DG)|"subjects who received conventional physical therapy once a day, plus a daily session of electrical stimulation in the diaphragm.
~Intervention: Electrical stimulation of the diaphragm."
16491246|NCT03352102|Active Comparator|Quadriceps Group (QG)|"subjects who also received conventional physical therapy once a day, plus a daily session of electrical stimulation in the quadriceps.
~Intervention: Electrical stimulation of the quadriceps."
16491247|NCT03352102|No Intervention|Control Group (CG)|subjects who received regular treatment, i.e., conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day, including weekend, during their stay in the ICU.
16491248|NCT03352089||Aortic stenosis group|Patients with severe aortic stenosis >70 years of age referred for aortic valve intervention
16491249|NCT03352089||Healthy volunteer group|Patients with no history of symptoms to suggest current cardiovascular disease >70 years of age
16491250|NCT03352076|Active Comparator|Oral Danatrol|200 mg orally TDS (600 mg daily) for 5-7 days
16491251|NCT03352076|Experimental|Vaginal Danazol|100 mg of Danazol Cream to be applied vaginally for 5-7 days on a single daily dose
16491252|NCT03352063|Active Comparator|Sitting with Exercise|Subjects will complete a short term training protocol while sitting >11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
16491253|NCT03352063|Active Comparator|Walking with exercise|Subjects will complete a short term training protocol while sitting <5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
16491254|NCT03352050|Active Comparator|ground beef|ground beef instead of mushrooms
16491255|NCT03352050|Active Comparator|Mushroom|2 servings of mushrooms
16491256|NCT03352037|Other|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
16491257|NCT03352024|Other|Standard Care|Relational care used to help the patient by reducing the fear and anxiety
16491258|NCT03352024|Other|Hypnosis|Hypno-analgesia is used to help the patient by reducing the fear and anxiety
16491259|NCT03352011|Experimental|Primary Care Brief Mindfulness Training|
16491260|NCT03352011|Active Comparator|PTSD Psychoeducational Class|
16491261|NCT03351998|Placebo Comparator|Placebo|Participants receiving matching placebo oral tablet.
16491262|NCT03351998|Active Comparator|Low dose statin|Participants will receive Lipitor 20Mg Tablet to take daily.
16491263|NCT03351998|Active Comparator|High dose statin|Participants will receive Lipitor 80Mg Tablet to take daily.
16491264|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
16491265|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
16491266|NCT03351972|Active Comparator|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
16491267|NCT03351972|Active Comparator|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
16491268|NCT03351972|Experimental|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
16491269|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
16491270|NCT03351946|Active Comparator|ZEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) until start of emergence preoxygenation.
~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
~First CT scan after completion of surgery, before emergence. After the first CT scan and immediately before start of emergence preoxygenation, this group will have the PEEP exchanged for zero PEEP (ZEEP). ZEEP will remain until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
16491271|NCT03351946|Active Comparator|PEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) even after start of emergence preoxygenation.
~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
~First CT scan after completion of surgery, before emergence. After the first CT scan, this group will have PEEP remained until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
16491272|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
16491278|NCT03351868|Experimental|Gene-modified autologous stem cells|Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo
16491279|NCT03351855|Experimental|HPV-CTLs|Autologous or allogenic HPV specific cytotoxic lymphocytes
16491280|NCT03351842|Active Comparator|Arm I|Undergo surgery, followed by observation. Patients receive no further therapy
16491281|NCT03351842|Experimental|Arm II|Undergo surgery, followed by chemotherapy (cis Platinum/Carboplatin, Pemetrexed Disodium). Patients receive chemotherapy comprising cisplatin 75mg/m2 or Carboplatin AUC=5mg/ml/min, and pemetrexed 500mg/m2 in day 1. Treatment continues every 3 weeks for 4 courses.
16491282|NCT03351829|Experimental|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
16491283|NCT03351816|Experimental|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
16491284|NCT03351816|Experimental|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
16491285|NCT03351803||Participants with Ashkenazi ancestry|
16491286|NCT03351790||All included participants|Patients that complete study questionnaire and have endoscopy recorded.
16491287|NCT03351777|Experimental|PR022 topical gel, 0.05%|Applied twice daily for 28 days
16491288|NCT03351777|Experimental|PR022 topical gel, 0.1%|Applied twice daily for 28 days
16491289|NCT03351777|Placebo Comparator|PR022 topical gel vehicle|Applied twice daily for 28 days
16491290|NCT03351764|Other|arm 1|these are within subject repeated measures studies across a number of conditions
16491291|NCT03351764|Placebo Comparator|arm 2|Placebo Comparator
16491292|NCT03351751|Placebo Comparator|Placebo|Subjects receiving placebo
16491293|NCT03351751|Experimental|PF-06372865|Subjects receiving PF-06372865
16491294|NCT03351738|Placebo Comparator|Placebo|Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
16491295|NCT03351738|Experimental|MEDI5884 50 mg|Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
16491296|NCT03351738|Experimental|MEDI5884 100 mg|Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
16491297|NCT03351738|Experimental|MEDI5884 200 mg|Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
16491298|NCT03351738|Experimental|MEDI5884 350 mg|Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
16491299|NCT03351738|Experimental|MEDI5884 500 mg|Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
16491300|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
16491301|NCT03351712|Active Comparator|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Gold Standard Intervention + Activity Tracker WITHOUT Feedback (Medical Rehabilitation, Motivational Support and Psycho-Education) During the in-patient phase, participants will participate in the intensive four-week hospital-based and medically-managed rehabilitation program for weight reduction. All patients will be placed on a hypocaloric nutritionally balanced diet tailored to the individual after consultation with a dietitian. Furthermore, they will receive nutritional counseling provided by dietitians, have physical activity training provided by physiotherapists and motivational support with elements of psycho-education provided by physicians trained and informed by psychologists-psychotherapists.
16491302|NCT03351712|Experimental|Gold Standard Intervention and Activity Tracker WITH Feedback|In this experimental condition, will be provided the same rehabilitation program for the 4-weeks in-patient phase. In addition, for these subjects will be implemented a Stepped Protocol using wearable devices / activity trackers to collect information about daily physical activity and providing meaningful and informative feedbacks. The additional procedure starts during the in-patients phase, delivering and explaining the use of the wearable devices. In this meeting, longer than the one previously described for the control condition, experimenters provide information, set individualized goals and explain feedbacks which will be delivered after ending in-patients phase by the electronic wearable devices.
16491303|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|In this experimental condition, the subjects followed the normal medical rehabilitation program described above for the first experimental condition. For the out-patient phase the ACT intervention includes monthly 30 minutes skype-telephone sessions. The ACT-based interventions includes different processes: 1) Acceptance, that involves the active awareness of difficult private experiences without attempts to control or avoid unpleasant emotions. 2) Mindfulness, refers to engaging in present moment experience and adopting an open and curious attitude. 3) Defusion: Participants will be encouraged to defuse from thoughts and feelings by turning attention toward the 'noticing-self', instead of becoming attached to thoughts and 'run' through life on 'auto-pilot'. 4) Values and Commitment: encouraging participants to live in accordance with their values, participants can engage in meaningful activities despite experiencing unwanted emotions/ sensations.
16491304|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITH Feedback|ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
16491305|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
16491306|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
16491307|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
16493190|NCT03338179|Experimental|Aged Patients|Schizophrenia patients aged 59.5 years and above
16491308|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
16491309|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
16491310|NCT03351686|Experimental|tranexamic acid group|
16491311|NCT03351686|No Intervention|non tranexamic (control) group|
16491312|NCT03351673|Experimental|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
16491313|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
16491314|NCT03351634|Experimental|Children with neurogenic incontinence with spinal dysraphism|
16491315|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
16491316|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
16491317|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
16491318|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
16491319|NCT03351608|Active Comparator|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
16491320|NCT03351582|Experimental|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
16491321|NCT03351582|Experimental|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
16491322|NCT03351582|No Intervention|Control|Group three will be the control group and will not receive the grief and communication family intervention.
16491323|NCT03351569|Experimental|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
16491324|NCT03351569|Placebo Comparator|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
16491325|NCT03351556|No Intervention|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
16491326|NCT03351556|Experimental|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.
16491327|NCT03351556|Experimental|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.
16491328|NCT03351543|Experimental|Exposed group|these volunteers receive microbial inoculate
16491329|NCT03351543|No Intervention|control|these volunteers do not receive microbial inoculate
16491330|NCT03351530||Pre-diabetes|
16491331|NCT03351530||Diabetes|
16491332|NCT03351530||Diabetes with periodontal disease|
16491333|NCT03351530||Periodontal patient|
16491334|NCT03351530||Healthy person|
16491335|NCT03351517|Experimental|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
16491336|NCT03351517|Placebo Comparator|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
16491337|NCT03351504|No Intervention|Control (usual lighting)|Participants will continue to use their usual lighting sources.
16491338|NCT03351504|Experimental|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
16491339|NCT03351478|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
16491340|NCT03351478|Active Comparator|Empagliflozin 25 mg|Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
16491341|NCT03351478|Placebo Comparator|Placebo|Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
16491342|NCT03351465|Experimental|CALM|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive-behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living that directly incorporates our previously optional modules for depression into the main program. The computerized/internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed. Participants in the intervention group will be visited by the calm specialist weekly between 6 and 8 times prenatally;postpartum visits will vary based on continuing assessment of symptoms.
16491343|NCT03351465|No Intervention|Treatment as Usual|Participants will receive pre-natal care as usual, and will be visited at 4 time points by the graduate student researchers: baseline, 12 weeks post baseline, and 10 weeks postpartum.
16491448|NCT03350789|Experimental|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
16491451|NCT03350763|Experimental|Self-expandable metallic biliary stent|A self-expandable metallic biliary stent is used to achieve biliary decompression
16491344|NCT03351452|Experimental|Real tDCS|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the VLPFC (current density: 0.057 mA/cm2) and cathodal 10x10 rubber electrode over supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16491345|NCT03351452|Experimental|Real tACS|20 min of 2 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
16491346|NCT03351452|Sham Comparator|Sham tES|30 s of 2 mA sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase of the memory task.
16491347|NCT03351439|Active Comparator|Group 1|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily x 3 weeks
16491348|NCT03351439|Experimental|Group 2|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Zopiclone 7.5 mg nightly for 7 days
16491349|NCT03351439|Experimental|Group 3|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Gabapentin 600 mg pre-operatively for one dose and 600 mg post-operatively for one dose
16491350|NCT03351439|Experimental|Group 4|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Celebrex 400 mg pre-operatively for one dose
16491351|NCT03351426|Active Comparator|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
16491352|NCT03351426|Sham Comparator|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
16491353|NCT03351413|Experimental|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:
~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls
~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk
~Medication review and feedback concerning medications with increased fall risk"
16491354|NCT03351413|No Intervention|Control|- An individualized fall risk assessment provided to participant and their primary care provider
16491355|NCT03351400|Experimental|Treatment group|Stem cells administered to participants
16491356|NCT03351387||SPY Intra-operative Angiography|The SPY Fluorescent Imaging System
16491357|NCT03351374||Temple Physicians Incorporated|A community-based provider, operating 32 primary care sites
16491358|NCT03351374||WhiteBark|For profit entity created by the Indiana Rural Health Association
16491359|NCT03351374||Drexel Family Intervention Science|Academic center that developed and deployed Attachment Based Family Therapy (ABFT) assessment, treatment, and prevention models with an interest in adolescents struggling with substance abuse, depression, trauma, and suicidality.
16491360|NCT03351374||Bon Secours Health System|A primary care clinic in Baltimore that provides care services to a population in a lower socioeconomic status in downtown Baltimore.
16491361|NCT03351374||Howard University Hospital CARES|A project provides free outpatient medical, dental, mental health, nutrition and social services for HIV positive uninsured and underinsured residents of the District of Columbia.
16491362|NCT03351361|Experimental|Nivolumab + Ipilimumab|
16491363|NCT03351361|Active Comparator|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
16491366|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
16491367|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
16491368|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
16491369|NCT03351322|Experimental|ENERGI-F701|ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
16491370|NCT03351322|Active Comparator|Regaine|Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
16491371|NCT03351309|Experimental|Telephone-based cognitive behavioral therapy|Telephone-based cognitive behavioral therapy (CBT) intervention - Four session protocol plus routine perioperative management.
16491372|NCT03351309|No Intervention|Treatment as Usual|Treatment as Usual (TAU) - Routine perioperative management.
16491373|NCT03351296|Experimental|LV5FU2 + streptozotocin +/- Bevacizumab|
16491374|NCT03351296|Experimental|Capecitabine + temozolomide +/- Bevacizumab|
16491449|NCT03350789|Sham Comparator|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
16491450|NCT03350763|Experimental|Plastic biliary stent|A plastic (ie Tannenbaum 10 Fr) biliary stent is used to achieve biliary decompression
16491375|NCT03351283|Experimental|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.
~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
16491376|NCT03351283|Active Comparator|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
16491377|NCT03351244|Experimental|BI 409306 high dose|
16491378|NCT03351244|Experimental|BI 409306 low dose|
16491379|NCT03351244|Placebo Comparator|Placebo|
16491380|NCT03351231|Experimental|Dose Escalation|BMS-986242 administered in combination with Nivolumab
16491381|NCT03351231|Experimental|Dose Expansion|BMS-986242 administered in combination with Nivolumab
16491382|NCT03351218|Other|Patients|25 patients with cervical and 25 patients with myoclonus dystonia
16491383|NCT03351218|Other|Controls|50 healthy volunteers matched to patents ( age, sex)
16491384|NCT03351205|Experimental|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
16491385|NCT03351205|Experimental|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
16491386|NCT03351179||AMI patients with HFpEF|
16491387|NCT03351179||AMI patients without HF|
16491388|NCT03351166|Experimental|Molidustat (BAY85-3934)|Molidustat group
16491389|NCT03351153|Other|X-ray group|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week.
16491390|NCT03351153|Other|CT group|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week.
16491391|NCT03351153|Other|Specimen group|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
16491392|NCT03351140||Subjects with breast cancer|Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
16491393|NCT03351140||Subjects with prostate cancer|Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
16491394|NCT03351140||Subjects with NSCLC|Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
16491395|NCT03351140||Subjects with multiple myeloma|Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
16491396|NCT03351140||Subjects with DLBCL or follicular lymphoma|Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
16491397|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
16491398|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
16491399|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
16491400|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
16491401|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
16491402|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
16491403|NCT03351114|Experimental|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
16491404|NCT03351101|Experimental|Senofilcon C|Senofilcon C Contact Lens
16491405|NCT03351101|Experimental|Samfilcon A|Samfilcon A Contact Lens
16491406|NCT03351088|Other|Preventive ligation|Preventive ligation of DVC is done after the opening of endopelvic fascia and before bladder neck dissection. DVC is ligated at the level of the apex with a 8-fashion single stich (1-0 Monocryl® CT-1 stich) trying to preserve puboprostatic ligaments and the muscle fibres of the rabdosphincter. DVC is then dissected at the end of prostatectomy before the section of the urethra.
16491407|NCT03351088|Other|Delayed ligation|Delayed ligation is done after the section of the urethra and once the prostatectomy is completed with a single stich (3-0 Monocryl® UR-6).
16491408|NCT03351075|Experimental|Intervention group|Standard physical therapy program + Modern educational program
16491409|NCT03351075|Active Comparator|Control group|Standard physical therapy program + Traditional biomedical educational program
16491410|NCT03351062|Active Comparator|Tamoxifen treatment group|Patients in this group will receive tamoxifen treatment.
16491411|NCT03351062|Active Comparator|Toremifene treatment group|Patients in this group will receive Toremifene treatment.
16491412|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
16491413|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
16491414|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
16491417|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
16491418|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
16491419|NCT03350984|Experimental|NPH insulin group|Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
16491420|NCT03350984|Active Comparator|Glargine and Lispro insulin group|"Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro.
~Intervention drug: Glargine and Lispro"
16491421|NCT03350971|Experimental|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
16491422|NCT03350971|Active Comparator|Control|chest physical therapy
16491423|NCT03350958|Experimental|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
16491424|NCT03350958|Placebo Comparator|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
16491425|NCT03350945|Active Comparator|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
16491426|NCT03350945|Active Comparator|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
16491427|NCT03350945|Experimental|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
16491428|NCT03350932|No Intervention|Control|This group of children, will have to perform a sensory imagination task about neutral facts before choosing the portion size of a food.
16491429|NCT03350932|Experimental|Food sensory imagination|"This group, the food sensory imagination group, will have to perform a sensory imagination task foods (being the intervention) before choosing the portion size of a food."
16491430|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
16491431|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
16491432|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The DHA/EPA soft gels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. The duration of the intervention will be 6 months.
16491433|NCT03350906|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
16491434|NCT03350893|Placebo Comparator|Control Group|Emulsion base without probiotics
16491435|NCT03350893|Experimental|Active Group|Emulsion base with probiotics
16491436|NCT03350880|Experimental|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
16491437|NCT03350880|Active Comparator|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
16491438|NCT03350867|Experimental|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
16491439|NCT03350867|Placebo Comparator|Placebo Group|The participants will use plane insoles.
16491440|NCT03350854|No Intervention|The non-intervention control group|In the non-intervention control group, providers are blind to the patient's preferred decision making role.
16491441|NCT03350854|Experimental|The intervention group|The provider will be informed of the patient preference in treatment decision making (preferred role) and have a discussion about this with the patient in the intervention group.
16491442|NCT03350841|Experimental|Revascularization|platelet rich plasma injected in the canals
16491443|NCT03350841|Active Comparator|root canal treatment|endodontic treatment obturated with gutta percha
16491447|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
16493229|NCT03337867|Active Comparator|Real-iTBS|
16491452|NCT03350750|Active Comparator|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
16491453|NCT03350750|Sham Comparator|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) four months after the procedure.
16491454|NCT03350737|Experimental|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
16491455|NCT03350737|Placebo Comparator|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
16491456|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
16491457|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
16491458|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
16491459|NCT03350698|Experimental|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
16491460|NCT03350685||Classic Whipple's disease (CWD)|"Classic Whipple's disease (CWD), defined as
~duodenal biopsy positive by PAS/immunohistochemistry
~or blood positive by PCR"
16491461|NCT03350685||Focal Whipple's disease (FWD)|"Focal Whipple's disease (FWD), defined as
~joint fluid positive by PCR
~but duodenal biopsy negative by PAS/immunohistochemistry"
16491462|NCT03350685||Chronic T. whipplei-associated arthritis (CTWA)|"Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and
~duodenal biopsy, stool, or saliva positive by PCR
~duodenal biopsy negative by PAS/immunohistochemistry
~joint fluid negative by PCR"
16491463|NCT03350672|Experimental|Cohort 1a|"Age 18 or older at the time of signed informed consent
~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP
~Willing and able to independently provide written informed consent
~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
16491464|NCT03350672|Experimental|Cohort 1b|"Age 18 or older at the time of signed informed consent
~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP
~Willing and able to independently provide written informed consent
~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
16491465|NCT03350672|Active Comparator|Cohort 2|"Age 18 or older at the time of signed informed consent
~Willing and able to independently provide written informed consent
~Last viral load < 20 copies/mL within the last four weeks of screening
~Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months
~Undetectable viral load, as defined by < 50 copies/ml, for at least 6 months"
16491466|NCT03350659|Experimental|Atomoxetine|Atomoxetine 18mg once a day.
16491467|NCT03350659|Active Comparator|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
16491468|NCT03350646|Other|Low volume (20-25 μl)|Low volume (20-25 μl)
16491469|NCT03350646|Other|High volume (40-45 μl)|High volume (40-45 μl)
16491470|NCT03350633|Experimental|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
16491471|NCT03350633|Active Comparator|Azathioprine|Imuran
16491472|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1
~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
16491473|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2
~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
16491474|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)
~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
16491475|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.
~There will be free exchanges along the lines between therapist and family, within the family and between therapists.
~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
16491476|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
16491477|NCT03350581|Active Comparator|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
16491478|NCT03350581|Experimental|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
16491479|NCT03350555|Experimental|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
16491480|NCT03350555|No Intervention|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
16491481|NCT03350542|Experimental|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
16493230|NCT03337867|Sham Comparator|Sham-iTBS|
16491482|NCT03350529|Experimental|Localised PC prior to RP|MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, index lesion(s) within prostate and if possible with 5mm angular extension (imaging based healthy tissue marginal) to both sides from the tumour boundary in transverse plane and 5 mm in coronal plane. The ablative effect is aimed to reach prostate capsule by heating the control boundary (3 mm from capsule) to temperature 57 °C. The focal approach is intended to be radical as for index lesion.
16491483|NCT03350529|Experimental|Symptomatic locally advanced PC|MRI guided transurethral HIFU ablation is targeted to main prostatic malignant tumour squeezing and/or invading the prostatic urethra and/or bladder neck. The approach is intended to be palliative.
16491484|NCT03350529|Experimental|Locally recurrent PC after EBRT|"MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, local recurrent index lesion(s) within and/or surrounding prostate and if possible with 5 mm angular extension to either side from the tumour boundary in transverse plane and 5 mm in coronal plane. The approach is intended to be focal and salvage.
~The whole-gland HIFU ablation approach will be considered in case of extensive organ confined recurrent prostate cancer (positive biopsies for malignancy from extensive/multiple area in prostate and/or extensive/multiple lesion(s) at baseline MRI) to cover whole prostate."
16491485|NCT03350529|Experimental|Symptomatic BPH|MRI guided transurethral HIFU ablation is targeted to adenomas of the prostate. The HIFU sector encompasses bilateral (anterolateral) transitional zones between bladder neck and verumontanum (colliculus seminalis).
16491486|NCT03350516|Experimental|Daily 500 mg Calcium|
16491487|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
16491488|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
16491489|NCT03350490|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16491490|NCT03350490|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16491491|NCT03350490|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16491492|NCT03350490|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16491493|NCT03350477|Active Comparator|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16491494|NCT03350477|Active Comparator|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16491495|NCT03350477|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16491496|NCT03350477|No Intervention|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16491497|NCT03350464|Experimental|Pain in PD Arm|This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.
16491498|NCT03350451|Experimental|Lumasiran (ALN-GO1)|
16491499|NCT03350438||PTSD Patients|patients ranging 18-60, diagnosed with PTSD following a trauma that occured over one year before the current study and do not have other health problems that may affect their everyday participation.
16491500|NCT03350438||healthy adults|healthy adults, ranging 18-60, without any health problems that may affect their everyday participation.
16491501|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
16491502|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
16491503|NCT03350399||level of placenta growth factor in IUGR|
16491504|NCT03350386|Experimental|Single dose|Single administration of FYU-981
16491505|NCT03350386|Experimental|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
16491506|NCT03350373|Experimental|Fasted dosing followed by fed dosing|Dosing of FYU-981 in the fasted state followed by fed dosing
16491507|NCT03350373|Experimental|Fed dosing followed by fasted dosing|Dosing of FYU-981 in the fed state followed by fasted dosing
16491508|NCT03350360|Experimental|Attention Control Training Clinic|"Attention Control Training Clinic will consist of:
~6 sessions in the clinic lasting approximately 10 minutes each.
~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
16491509|NCT03350360|Experimental|Attention Control Training Web-delivery|"Attention Control Training Web-delivery will consist of:
~6 sessions lasting approximately 10 minutes each logged into via the internet from the participants' home.
~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).
~Ideally participants will complete 2 sessions per week, allowing them to complete the trial in less than one month's time"
16491547|NCT03350087|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
16491967|NCT03346902|Active Comparator|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
16491510|NCT03350360|Placebo Comparator|Comparison Task Clinic|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.
~Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).
~(Note that those receiving this arm, are invited to repeat the attention control training web-delivery arm at the end of their participation)."
16491511|NCT03350347|Experimental|Molidustat (BAY85-3934)|Molidustat group
16491512|NCT03350347|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
16491513|NCT03350334|Active Comparator|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
16491514|NCT03350334|Placebo Comparator|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
16491515|NCT03350321|Experimental|Molidustat (BAY85-3934)|Molidustat group
16491516|NCT03350321|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
16491517|NCT03350308||Patients with chronic end-stage renal failure|
16491518|NCT03350295|Experimental|GRP1 - Assess relative bioavailability(3-way cross-over)|"GROUP 1 (Treatments A, B, C) All 3 treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets). Participants received the 3 treatments in one of six treatment sequences under fed condition.
~Treatment A, dose administration with fast in vitro dissolution characteristics Treatment B, dose administration with medium in vitro dissolution characteristics Treatment C, dose administration with slow in vitro dissolution characteristics"
16491519|NCT03350295|Experimental|GRP2 - Assess relative bioavailability (2-way cross-over)|"GROUP 2 (Treatments D and E) Participants received the 2 treatments in one of two treatment sequences under fed condition.
~Treatment D, a single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics Treatment E, a single dose of 120 mg nifurtimox"
16491520|NCT03350282|Experimental|Mixture GAA-creatine|Mixture of guanidinoacetic acid and creatine monohydrate
16491521|NCT03350282|Active Comparator|Creatine|Creatine monohydrate
16491522|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
16491523|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
16491524|NCT03350256|Experimental|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
16491525|NCT03350243|Experimental|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves a primary care provider and/or neonatal follow-up at routine times.
16491526|NCT03350243|No Intervention|Control group|Participants will receive the standard medical care at their institution, which involves a primary care provider and/or neonatal follow-up at routine times.
16491527|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
16491528|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
16491529|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
16491530|NCT03350204|Experimental|Meniscus Injured|These participants will come in pre and post operation
16491531|NCT03350204|Experimental|Healthy|These participants will be used as a standardised comparison for the patient group
16491532|NCT03350191|Experimental|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
16491533|NCT03350191|Experimental|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
16491534|NCT03350178|Experimental|treated patients|Treated wit FMT
16491535|NCT03350165|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
16491536|NCT03350165|Placebo Comparator|Control Group|placebo tablet twice daily.
16491537|NCT03350152||LAM group|Have a diagnosis of AML according to World Health Organization (WHO) classification Are at least 70 years of age
16491538|NCT03350139||Patients treated with gamma knife radiosurgery|Collection of non-genetic, chronobiological, therapeutic and co-morbidities
16491539|NCT03350126|Experimental|Experimental arm|Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months
16491540|NCT03350113|Experimental|HemoSpec|Blood Sampling for analysis in the HemoSpec device
16491541|NCT03350100|Experimental|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
16491542|NCT03350100|Experimental|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
16491543|NCT03350100|Placebo Comparator|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
16491544|NCT03350087|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
16491545|NCT03350087|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
16491546|NCT03350087|Experimental|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
16491578|NCT03349801||no AMD|No interventions
16491548|NCT03350087|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
16491549|NCT03350087|Experimental|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
16491550|NCT03350061|Experimental|SENSY benefit|Sensory feedback elicited by intraneural stimulation will be provided by SENSY with and without the leg prosthesis to improve walking ability, increase embodiment, and reduce metabolic cost, cognitive load and phantom pain.
16491551|NCT03350048||Training Set|"First 500 participants recruited for the Training Set:
~Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory
~Blood, sputum, saliva and urine collection for secondary objectives and repository"
16491552|NCT03350048||Test Set|"Subsequent 300 participants to be used for the Test Set:
~Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR
~Blood, sputum, saliva and urine collection for secondary objectives and repository"
16491553|NCT03350035|Experimental|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
16491554|NCT03350035|Placebo Comparator|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
16491555|NCT03350022|Experimental|Sham Feeding|
16491556|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
16491557|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
16491558|NCT03349996|Experimental|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
16491559|NCT03349983|Experimental|MVA-BN-Brachyury/ FPV-Brachyury|
16491560|NCT03349970||TEE vs PAC|we will compare the SV measurements obtained by PAC thermodilution technique to those obtained by different TEE methods in 60 patients undergoing coronary artery bypass grafting (CABG) and/or aortic valve (AV) or aortic surgery with cardiopulmonary bypass (CPB) in 2 different cardiac centres. The LV cardiac deformation, expressed as global longitudinal strain (GLS) will be calculated off-line from the acquired images. We will also determine the intra and inter-observer reproducibility of each TEE method.
16491561|NCT03349944|Active Comparator|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
16491562|NCT03349944|Experimental|High intensity training|High intensity interval training three times pr. week for 15 min.
16491563|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
16491564|NCT03349918|Experimental|Mobile Health Monitoring|Participants will monitor their blood pressure using a wireless-enabled blood pressure cuff or mood using a mobile health application once per week at baseline. The investigators will monitor their medical records to determine if a medication change has occurred. After this, the investigators will increase the frequency of notifications to monitor the participant's specific health condition to once daily for 1 month. This monitoring will continue for a study duration of 6 months.
16491565|NCT03349905|Active Comparator|Fresh transfer|"Women randomized in the non experimental group will have:
~Antagonist stimulation protocol
~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)
~All of their embryo kept in prolonged culture
~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)
~Supernumerary blastocysts cryopreserved"
16491566|NCT03349905|Experimental|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:
~Antagonist stimulation protocol
~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)
~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.
~A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
16491567|NCT03349892|Experimental|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
16491568|NCT03349879||Vitamin D deficiency|serum 25(OH)D < 30 nmol/L
16491569|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
16491570|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
16491571|NCT03349866|Experimental|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
16491572|NCT03349866|Active Comparator|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
16491573|NCT03349840|Active Comparator|Insulin glargine U100|Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
16491574|NCT03349840|Active Comparator|insulin degludec U100|Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening
16491575|NCT03349827|Experimental|Experimental|HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
16491576|NCT03349814||Appendicitis group|"Patients, who undergo a diagnostic laparoscopy, which because of the operative findings leads to an appendectomy, and the appendix is found to be inflamed in the pathology report.
~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed."
16491577|NCT03349814||Normal appendix group|"Patients, who undergo a diagnostic laparoscopy, that either because of the operative findings (mesenteric lymphadenitis or normal diagnostic laparoscopy) does not lead to appendectomy, or leads to appendectomy, but the appendix is not found to be inflamed in the pathology report.
~A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
~OR
~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed, but is not found to be inflamed in the pathology report."
16491582|NCT03349788|Experimental|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
16491583|NCT03349788|Active Comparator|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
16491584|NCT03349775|Active Comparator|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
16491585|NCT03349775|Placebo Comparator|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
16491586|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
16491587|NCT03349762||Observational 2|Huaier Granule & Radiotherapy or chemotherapy
16491588|NCT03349762||Observational 3|Huaier Granules
16491589|NCT03349749||Patients undergoing fluid resuscitation|Adult patients in the intensive care unit (ICU) undergoing fluid resuscitation guided by the LiDCOplus haemodynamic monitor.
16491590|NCT03349736|Other|Pelvic Floor Muscle Training|"Women visiting antenatal (up to16 weeks of gestation) will be enrolled for the study. The women will be follow up 4 times during the antenatal visit until 37 weeks of gestation. Questionnaire data and clinical measurements(strength of PFM by Electromyograph biofeedback) will be registered at baseline and and follow-up at week 37 of pregnancy.
~The treatment program will include
~1) Information, educational material (leaflets, posters, and video) and individual/group exercise on PFM exercise on the 1st day of the visit. Counseling about the importance of performing PFM exercise will be provided. Women are advised to perform home PFM exercise and record in the exercise diary."
16491591|NCT03349723|Experimental|BI 1265162|BI 1265162
16491592|NCT03349723|Placebo Comparator|Placebo|Placebo
16491593|NCT03349710|Experimental|Arm A|Cohort 1
16491594|NCT03349710|Experimental|Arm B|Cohort 1
16491595|NCT03349710|Experimental|Arm C|Cohort 2
16491596|NCT03349710|Experimental|Arm D|Cohort 2
16491597|NCT03349697|Experimental|Active Product then Placebo|
16491598|NCT03349697|Experimental|Placebo then Active Product|
16491599|NCT03349684|Experimental|Acarbose plus metformin arm|Participants received loose combination of acarbose and metformin 3 times daily.
16491600|NCT03349684|Active Comparator|Metformin plus placebo arm|Participants received loose combination of placebo and metformin 3 times daily.
16491601|NCT03349658|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia.
16491602|NCT03349658|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia.
16491603|NCT03349645|Experimental|Ampion|4 mL Ampion (<5 kilodatlon (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution
16491604|NCT03349632|Other|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
16491605|NCT03349632|Other|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
16491606|NCT03349632|Other|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
16491607|NCT03349619|Experimental|Resveratrol plus Carboxymethyl-β-Glucan|
16491608|NCT03349619|Placebo Comparator|Placebo|
16491609|NCT03349606|Experimental|Cocaine dependence|[C-11]FLB 457 PET at baseline and post d-amphetamine
16491610|NCT03349606|Experimental|Controls|[C-11]FLB 457 PET at baseline and post d-amphetamine
16491611|NCT03349580|Experimental|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
16491612|NCT03349580|No Intervention|The control group|The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
16491613|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
16491614|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
16491615|NCT03349554|Experimental|"standardized meditation technique body-scan"|
16491616|NCT03349541|Experimental|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
16491617|NCT03349541|No Intervention|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
16491618|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
16491619|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
16491620|NCT03349515|Active Comparator|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
16491676|NCT03349008|Placebo Comparator|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
16491621|NCT03349515|Active Comparator|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
16491622|NCT03349502|Experimental|MG4101|"MG4101 administration (Not yet commercialized)
~Dosage Bwt<50 : 2.0 x109 cells (2 bags) 50≤Bwt<70 : 3.0 x109 cells (3 bags) 70≤Bwt<100 : 4.0 x109 cells (4 bags) Bwt≥100 : 5.0 x109 cells (5 bags)
~Duration and frequency
~Intravenous over 1 hour
~Day 4, Day 11, Day 18 of each cycle"
16491623|NCT03349489|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
16491624|NCT03349489|Active Comparator|Reduction of insulin basal rate 90 minutes prior to exercise|
16491625|NCT03349476|Experimental|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.
~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
16491626|NCT03349463|Experimental|18F-Fluciclovine|
16491627|NCT03349450|Experimental|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.
~Pembrolizumab 200mg Intravenously.
~Cyclophosphamide 50mg Twice daily orally."
16491628|NCT03349437|Experimental|Vitabreath Device|The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
16491629|NCT03349437|Active Comparator|Pursed Lip Breathing|Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.
16491630|NCT03349424|Experimental|Stilamin group|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
16491631|NCT03349424|No Intervention|Control group|Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.
16491632|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
16491633|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
16491634|NCT03349398|Active Comparator|the group of Roux-en-Y|
16491635|NCT03349398|Experimental|the group of Uncut Roux-en-Y|
16491636|NCT03349346|Experimental|Cohort 1- Participants 12 to less than 18 years of age|"Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m^2 twice daily (BID), Dose level 2 = 85 mg/m^2 BID, Dose level 3 = 125 mg/m^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.
~Day 1: single dose of idelalisib
~Day 2 up to Day 21: initiate and continue idelalisib BID dosing
~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
16491637|NCT03349346|Experimental|Cohort 2- Participants 1 to less than 12 years of age|"Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.
~Day 1: single dose of idelalisib
~Day 2 up to Day 21: initiate and continue idelalisib BID
~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
16491638|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
16491639|NCT03349307|Experimental|No Intervention|
16491640|NCT03349281|Experimental|Dose Level 1: Pevonedistat 15 + VXLD|"Pevonedistat: 15 mg/m2 intravenously (IV)
~Vincristine: 1.5 mg/m2/dose IV push
~Dexamethasone: 10 mg/m2/day divided twice daily
~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.
~Doxorubicin: 60 mg/m2/day IV
~Intrathecal (IT) chemotherapy via injection per protocol:
~All subjects: Cytarabine 70 mg ;
~For central nervous system (CNS) negative subjects: Methotrexate 15 mg;
~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
16491641|NCT03349281|Active Comparator|Dose Level -1: Pevonedistat 10 + VXLD|"Pevonedistat: 10 mg/m2 IV
~Vincristine: 1.5 mg/m2/dose IV push
~Dexamethasone: 10 mg/m2/day divided twice daily
~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.
~Doxorubicin: 60 mg/m2/day IV
~Intrathecal (IT) chemotherapy via injection per protocol:
~All subjects: Cytarabine 70 mg ;
~For CNS negative subjects: Methotrexate 15 mg;
~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
16491677|NCT03349008|Experimental|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
16491968|NCT03346876||Study group|patients with pectus excavatum
16491642|NCT03349281|Active Comparator|Dose Level 2: Pevonedistat 20 + VXLD|"Pevonedistat: 20 mg/m2 IV
~Vincristine: 1.5 mg/m2/dose IV push
~Dexamethasone: 10 mg/m2/day divided twice daily
~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.
~Doxorubicin: 60 mg/m2/day IV
~Intrathecal (IT) chemotherapy via injection per protocol:
~All subjects: Cytarabine 70 mg ;
~For CNS negative subjects: Methotrexate 15 mg;
~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
16491643|NCT03349268|Active Comparator|Pulsed xenon ultraviolet light (PX-UV) Device Emitting Germicidal UV|Pulsed xenon ultraviolet light (PX-UV) Device to be used to disinfect rooms following post-discharge terminal cleaning
16491644|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
16491645|NCT03349255|Experimental|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
16491646|NCT03349255|Experimental|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
16491647|NCT03349216|Experimental|Intravenous regional Analgesia|in this arm patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes will be deflated (hence named Rapid MiniBier's block).
16491648|NCT03349216|Experimental|Systemic Analgesia|In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
16491649|NCT03349203|Experimental|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks before surgery and 2 years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity.
16491650|NCT03349177|Experimental|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
16491651|NCT03349177|Experimental|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
16491652|NCT03349177|Experimental|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
16491653|NCT03349151|Active Comparator|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
16491654|NCT03349151|Placebo Comparator|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
16491655|NCT03349138|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different standard motor training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16491656|NCT03349138|Experimental|Robotic Glove|Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16491657|NCT03349138|Experimental|Electrical Stimulation|Electrical Stimulation & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16491658|NCT03349138|Experimental|Electrical Stimulation and Robotic Glove|Electrical Stimulation & Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy or 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. Half of the sessions are allocated to the electrical stimulation system, and half are allocated to the robotic glove system. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16491659|NCT03349125||Collar On|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) on.
16491660|NCT03349125||Collar Off|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) off.
16491661|NCT03349112|Active Comparator|Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter, Participants in this group will additionally receive .8 mL of a 4% Lidocaine spray to both nares prior to HRPM.
16491662|NCT03349112|Placebo Comparator|Non-Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. Randomized participants in this group will not receive .8 mL of a 4% Lidocaine spray prior to HRPM .
16491663|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
16491664|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
16491665|NCT03349086|Active Comparator|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
16491666|NCT03349086|No Intervention|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
16491667|NCT03349073|Experimental|T-1101 (Tosylate)|
16491668|NCT03349060|Experimental|PF-04965842 100 mg|
16491669|NCT03349060|Experimental|PF-04965842 200 mg|
16491670|NCT03349060|Placebo Comparator|Placebo|
16491671|NCT03349047|Active Comparator|Behavioral Intervention|Behavioral Intervention Group - Education regarding nut allergy and will also have contact with nut.
16491672|NCT03349047|Placebo Comparator|Control|Education regarding nut allergy
16491673|NCT03349034|Experimental|Test Group|Local Ropivicaine Infusion
16491674|NCT03349034|Placebo Comparator|Control Group|Local Saline Infusion
16491675|NCT03349021|Experimental|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
16491969|NCT03346876||Control group|healthy subjects without pectus excavatum
16491679|NCT03348982|Experimental|Intervention group|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.
16491680|NCT03348982|No Intervention|Control group|Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).
16491681|NCT03348969|Experimental|Intervention|Neoadjuvant Mitomycin C
16491682|NCT03348969|Active Comparator|Control|Adjuvant Mitomycin C
16491683|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
16491684|NCT03348943|Active Comparator|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
16491685|NCT03348943|Experimental|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
16491686|NCT03348943|Active Comparator|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
16491687|NCT03348943|Experimental|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
16491688|NCT03348930|Experimental|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
16491689|NCT03348930|Placebo Comparator|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
16491690|NCT03348917|Active Comparator|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C
~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)
~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)
~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
16491691|NCT03348917|Active Comparator|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A
~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)
~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)
~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
16491692|NCT03348917|Active Comparator|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -> A ->B
~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)
~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)
~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
16491693|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
16491694|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
16491695|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
16491696|NCT03348891|Other|Subgroup 1|Patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
16491697|NCT03348891|Other|Subgroup 2|Patients treated with the combined treatment anti-PD-1+anti-CTLA-4 (nivolumab + ipilimumab)
16491698|NCT03348878|Other|cohort of uncontrolled hypertensive patients|
16491699|NCT03348865|Experimental|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.
~Each session is expected lasts 30 mins to 1 hour."
16491700|NCT03348865|No Intervention|Control|Patients are to undergo treatment as usual.
16491701|NCT03348852|Active Comparator|Active tDCS|Active transcranial direct current stimulation
16491702|NCT03348852|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
16491703|NCT03348839|Experimental|Cluster 1|NeLLY service is implemented after 8 months.
16491704|NCT03348839|Experimental|Cluster 2|NeLLY service is implemented after 12 months.
16491705|NCT03348839|Experimental|Cluster 3|NeLLY service is implemented after 16 months.
16491706|NCT03348839|Experimental|Cluster 4|NeLLY service is implemented after 20 months.
16491707|NCT03348839|Experimental|Cluster 5|NeLLY service is implemented after 24 months.
16491708|NCT03348839|Experimental|Cluster 6|NeLLY service is implemented after 28 months.
16491709|NCT03348839|Experimental|Cluster 7|NeLLY service is implemented after 32 months.
16491710|NCT03348826|Experimental|Alteplase then Sodium Bicarbonate|Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.
16491711|NCT03348826|Experimental|Sodium Bicarbonate then Alteplase|Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.
16491712|NCT03348813|Experimental|HIV/STI Prevention Intervention|Two-session, small group HIV/STI prevention intervention.
16491713|NCT03348813|Active Comparator|General Health Control Intervention|Two-session, small group general health promotion intervention.
16491714|NCT03348800|Experimental|Test Side|The side in which computer controlled anesthetic delivery system will be used as dental anesthesia before dental surgery
16491715|NCT03348800|Active Comparator|Control Side|The side in which conventional syringe will be used as dental anesthesia before dental surgery
16491716|NCT03348787|Experimental|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
16491747|NCT03348579||The third and final period|The third and final period will consist of all consecutive patients admitted to the participating ICUs after the formal training.
16491748|NCT03348553|Sham Comparator|control group|20 subjects do not receive any supplementation
16491749|NCT03348553|Active Comparator|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
16491750|NCT03348553|Active Comparator|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
16491717|NCT03348761|Experimental|rTMS Group|"Twenty sessions of neurostimulation at the left DLPFC.
~Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses).
~Phase II: A Neuro-MS/D Advanced Therapeutic Transcranial Magnetic Stimulator (Neurosoft, Russia) with a 100-mm cooled figure-of-eight coil and Neural Navigator navigation (Brain Science Tools, the Netherlands) are used. Stimulation parameters: triplet 50 hertz, repeated at 5 hertz, 120% resting motor threshold, 20 trains of 2 seconds with 8 seconds between trains, 600 pulses per day delivered 5 days per week (total: 12000 pulses)."
16491718|NCT03348748|Experimental|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
16491719|NCT03348748|Experimental|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
16491720|NCT03348748|Experimental|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
16491721|NCT03348735|Experimental|Lidocaine patch 5%|Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.
16491722|NCT03348735|Experimental|Capsaicin 8% patch|Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).
16491723|NCT03348735|Active Comparator|Pregabaline|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.
16491724|NCT03348722||Active surveillance|Newly diagnosed low risk prostate cancer patients managed according to an active surveillance program
16491725|NCT03348722||Radical prostatectomy|Newly diagnosed low risk prostate cancer patients undergoing radical prostatectomy
16491726|NCT03348722||Radiotherapy|Newly diagnosed low risk prostate cancer patients undergoing radiotherapy (external or brachitherapy)
16491727|NCT03348722||Other radical treatment|Newly diagnosed low risk prostate cancer patients undergoing other radical treatments (HIFU, cryotherapy, others)
16491728|NCT03348709|Experimental|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
16491729|NCT03348709|Active Comparator|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
16491730|NCT03348696|Active Comparator|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
16491731|NCT03348696|Active Comparator|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
16491732|NCT03348683|Experimental|Propranolol|2mg of IV push
16491733|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
16491734|NCT03348670|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein
~0.5 ml Lactated Ringer's Injection, USP"
16491735|NCT03348657|Other|Music intervention Group|Patients who participated to at least one music session provided by volunteers while being admitted to the geriatric assessment unit. Participation to the music sessions was voluntary.
16491736|NCT03348657|No Intervention|Control Group|Patients who did not want to participate to the music sessions provided by volunteers while being admitted to the geriatric assessment unit
16491737|NCT03348644|Experimental|Phosphate tablets.|800 mg oral phosphor supplement distributed over five times a day independently of any prior treatment dose.
16491738|NCT03348644|Active Comparator|High cheese intake.|Cheese with an estimated phosphate content of 800 mg distributed over 5 meals.
16491739|NCT03348644|Active Comparator|High milk intake.|800 ml of milk daily corresponding to approximately 800 mg phosphor per day.
16491741|NCT03348618|Experimental|IVIG|IVIG dose at 1 g/Kg/body weight
16491742|NCT03348605|Other|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
16491743|NCT03348605|Other|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
16491744|NCT03348592|Experimental|Oligofructose-enriched inulin (p-inulin)|Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
16491745|NCT03348579||The before period|The before period (control phase) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning hospital-acquired pneumonia.
16491746|NCT03348579||The second period|"Intensive care units are randomized in two groups:
~Standard training: The centers will receive the text of the recommendation electronically. The principal investigator of each center will then train doctors, interns, nurses and physiotherapists to the use of these recommendations (team leader). A computer presentation common to all the centers will be used and a communication strategy vis-à-vis the other caregivers of the investigative services will be put in place. All doctors, interns and nurses must have attended this theoretical training during the awareness phase."
16491751|NCT03348553|Active Comparator|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
16491752|NCT03348540|Experimental|Attention Control Training|"6 sessions in the clinic lasting approximately 10 minutes each.
~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
16491753|NCT03348540|Placebo Comparator|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.
~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
16491754|NCT03348527|Experimental|Stage I: Dose = 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
16491755|NCT03348527|Experimental|Stage I: Dose = 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
16491756|NCT03348527|Experimental|Stage II: Dose = 16mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 16mL
16491757|NCT03348527|Experimental|Stage II: Dose = 20mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 20mL
16491758|NCT03348514|Experimental|Accelerated Escalation Design|
16491759|NCT03348514|Experimental|"3+3 Dose Escalation Design"|
16491760|NCT03348488|No Intervention|Standard ultrafiltration|standard ultrafiltration (fluid removal from the body by dialysis at the prescribed volume and rate) during a conventional treatment
16491761|NCT03348488|Active Comparator|High dose ultrafiltration|Intervention= Fixed rate high dose ultrafiltration (fluid removed from the body by dialysis) of 1 litre per hour over 1 hr instaed of standard ultrafiltration rate and volume.
16491762|NCT03348475|Experimental|Experimental Group|Binge Focused Therapy (BFT) Intervention
16491763|NCT03348462|Experimental|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
16491764|NCT03348462|Active Comparator|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
16491765|NCT03348436|Experimental|patients with atrioventricular nodal reentrant tachycardia|radiofrequency catheter ablation therapy
16491766|NCT03348436|Experimental|patients with atrioventricular tachycardia|radiofrequency catheter ablation therapy
16491767|NCT03348423|Experimental|DEX-IN 50 µg|Dexmedetomidine Intranasal Spray
16491768|NCT03348423|Active Comparator|Fentanyl 50 µg|Intravenous Fentanyl
16491769|NCT03348423|Placebo Comparator|Placebo|Placebo
16491770|NCT03348410|Experimental|Intervention|Motivational interviewing
16491771|NCT03348410|No Intervention|Control|Control group
16491772|NCT03348397||Contegra patients|
16491773|NCT03348397||Pulmonary homograft patients|
16491774|NCT03348384|Experimental|Cocaine use disorders|PET scan
16491775|NCT03348384|Experimental|Controls|PET scan
16491776|NCT03348371|Experimental|Oral day|Participant receive ethanol orally
16491777|NCT03348371|Experimental|i.v. infusion day|Participant receive ethanol in an i.v. infusion
16491778|NCT03348358|Placebo Comparator|control|No music during labor
16491779|NCT03348358|Experimental|Quiet music|Women hearing quiet music during labor
16491780|NCT03348358|Experimental|Rhythmic music|Women hearing rhythmic music during labor
16491781|NCT03348345|Experimental|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
16491782|NCT03348345|No Intervention|Wait-List|Participants are placed on a wait-list receiving no intervention.
16491783|NCT03348332|No Intervention|Sedentary pregnant women|Pregnant women who do not exercise regularly during pregnancy
16491784|NCT03348332|Experimental|Exercise pregnant women|Pregnant women who participate in a supervised exercise program
16491785|NCT03348319||Cadaver organs|
16491786|NCT03348306|Experimental|All patients|
16491787|NCT03348293|Experimental|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
16491788|NCT03348280||Vitamin D Deficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of <20 ng/ml
16491789|NCT03348280||Vitamin D Sufficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of >30 ng/ml
16491790|NCT03348267|Experimental|Protein|On the match day, 25g of protein consumed immediately after the match and then 30g at 3h (+3h) and 25g at 6h (+6h). On each day of the remaining days, 20 g of protein consumed with breakfast.
16491791|NCT03348267|Active Comparator|Placebo|On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
16491792|NCT03348254||1|Group one will consist of patients receiving a single shot antibiotic prophylaxis preoperatively before primary arthroplasty of hip or knee
16491793|NCT03348254||2|Group two will consist of patients receiving multiple shot antibiotic prophylaxis perioperatively before and after primary arthroplasty of hip or knee
16491794|NCT03348241|Experimental|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
16491795|NCT03348241|Other|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
16491796|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
16491837|NCT03347916|Active Comparator|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
16491797|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
16491798|NCT03348215|Other|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
16491799|NCT03348202||Focus Group Participants|Approximately 24 groups (6 per country; Finland, Norway, Spain, Italy) consisting participants aged 80+ recruited from: senior community centres, adult day care centres, nursing homes. Each focus group will comprise from 4 to 8 people. Attempts would be made to create gender-balanced groups.
16491800|NCT03348189||Observational|Healthy males and females
16491801|NCT03348176|Experimental|Vegetable exposure|Repeated exposure to a variety of vegetables from the start of complementary feeding
16491802|NCT03348176|Experimental|VIPP-Feeding Infants|Promotion of responsive feeding practices from the start of complementary feeding
16491803|NCT03348176|Experimental|Exposure + VIPP-FI|Combination of repeated exposure to vegetables and promotion of responsive feeding practices
16491804|NCT03348176|Sham Comparator|Control|Phone calls on development child with no information on complementary feeding
16491805|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to B/FTC/TAF bfor 48 weeks
16491806|NCT03348163|Active Comparator|Continue Current ART|Continue current (ART) therapy (emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks
16491807|NCT03348150|Experimental|Gastrecomy + Cytoreductive surgery + HIPEC|
16491808|NCT03348150|No Intervention|palliative systemic chemotherapy|
16491809|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
16491810|NCT03348124|Experimental|Intervention|"Educational lessons based on the conversational material Toolkit Children - what does it involve?, will be delivered in the classroom at school and caring for the RCB simulator during three days and nights."
16491811|NCT03348124|No Intervention|Control|Education as usual.
16491812|NCT03348111|Experimental|Air-polishing device|Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®
16491813|NCT03348098|Experimental|single arm|Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC
16491814|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
16491815|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
16491816|NCT03348033|Experimental|Chronic Myeloid Leukemia + NK cell|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total.
~NK Cell infusion on Days 0 to 14 for 6 doses total."
16491817|NCT03348020|Experimental|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
16491818|NCT03348020|Experimental|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
16491819|NCT03348007|Experimental|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
16491820|NCT03348007|Active Comparator|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
16491821|NCT03347994|Experimental|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level
~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
16491822|NCT03347994|Experimental|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:
~0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
16491823|NCT03347994|Experimental|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1
~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
16491824|NCT03347994|Experimental|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2
~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
16491825|NCT03347981|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
16491826|NCT03347981|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
16491827|NCT03347968|Experimental|MEDI0382|All participants will receive MEDI0382.
16491828|NCT03347968|Active Comparator|Warfarin|All participants will receive Warfarin
16491829|NCT03347968|Active Comparator|Esmolol|All participants will receive Esmolol
16491830|NCT03347955|Experimental|Neural implantation group|Human embryonic dopamine neurons were implanted into brains of half the randomized participants (n = 20). Participants were evaluated at baseline, 4, 8, and 12 months after surgery.
16491831|NCT03347955|Sham Comparator|Sham Surgery group|This group (n = 20) received sham surgery with a steel frame affixed to their heads and four burr holes drilled into their foreheads without crossing the blood/brain barrier. Participants were assessed at baseline, 4, 8, and 12 months after surgery.
16491832|NCT03347942|Experimental|Intervention|During a period of 30 days the research participant in the intervention group will be instructed to wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before being served again if he or she feels the need.
16491833|NCT03347942|Other|Control|The control group will also serve the dish the same way, but you can serve additional portion without waiting.
16491834|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
16491835|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
16491836|NCT03347916|Placebo Comparator|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
16491838|NCT03347890|Experimental|Liraglutide 3.0 mg|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
16491839|NCT03347890|Placebo Comparator|Placebo|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
16491840|NCT03347877|Experimental|autologous bone-periosteal graft|The patients in experimental group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteo-periosteal cylinder graft transplantation.
16491841|NCT03347877|Active Comparator|autologous osteochondral graft|The patients in control group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteochondral graft transplantation.
16491842|NCT03347864|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 30-45 min later
16491843|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
16491844|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
16491845|NCT03347838|Experimental|Nivolumab Injection [Opdivo]|240 mg IV every 2 weeks for 4 doses
16491846|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
16491847|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
16491848|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
16491849|NCT03347812||Endovascular Aortic Repair|Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.
16491850|NCT03347812||Total Arch Replacement|Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.
16491851|NCT03347773|Experimental|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
16491852|NCT03347773|No Intervention|Control|The subjects will be assigned to receive standard care alone.
16491853|NCT03347760|Experimental|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
16491854|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
16491855|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
16491856|NCT03347734|Experimental|Eye Exercises Group (EEG)|For the individuals in the group of eye exercises (GEG), 10 repetitive eye exercises protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
16491857|NCT03347734|Experimental|Convergence Exercise Group (CEG)|For the individuals in the group of convergence exercise, 5 minutes convergence exercise protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
16491858|NCT03347734|Experimental|Oculomotor Exercise Group (OMEG)|For the individuals in the group of oculomotor exercise, 10 repetitive, four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
16491859|NCT03347721|Active Comparator|Lidocaine gel|
16491860|NCT03347721|Placebo Comparator|Lubricant Gel|
16491861|NCT03347708|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells).
16491862|NCT03347708|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
16491863|NCT03347708|Placebo Comparator|Saline|Single intradiscal injection with saline solution.
16491864|NCT03347708|Placebo Comparator|Sodium Hyaluronate Vehicle|Single intradiscal injection with Sodium Hyaluronate Vehicle.
16491966|NCT03346902|Placebo Comparator|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection
~Injection of Placebo into area of scarring (forehead)"
16491867|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
16491868|NCT03347669|Experimental|FM patients|50 fibromyalgia patients/50 healthy subjects
16491869|NCT03347669|Active Comparator|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
16491870|NCT03347643|Active Comparator|tDCS with real stimulation|A total of 25 patients will be allocated into active comparator with real stimulation with tDCS.
16491871|NCT03347643|Sham Comparator|tDCS with sham stimulation|A total of 25 patients will be allocated into sham comparator with sham stimulation with tDCS.
16491872|NCT03347630|Other|oesophagus cancer MRI|Diagnostic test
16491873|NCT03347617|Experimental|Diagnostic (Ferumoxytol MRI, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 years or 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI scans at baseline, 4 weeks after the last day of standard of care stereotactic radiosurgery or chemoradiotherapy, every 9 weeks thereafter until suspected radiographic progression, and then within 4 weeks from suspected radiographic progression.
16491874|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of > 0.85 in women, or > 0.9 in men.
16491875|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
16491876|NCT03347578||Lung cancer surgery|All patients undergoing thoracic surgery for lung cancer either with thoracoscopy or thoracotomy will receive diaphragmatic Ultrasonography 2 and 24 hours after surgery
16491877|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
16491878|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
16491879|NCT03347552|Experimental|Active Treatment|Participants in the active arm will be enrolled in the HOME Program.
16491880|NCT03347552|No Intervention|E-CARE|"Receiving enhanced care as usual. Participants at these sites are described as receiving enhanced care as usual or E-CARE because they will be recruited, enrolled and complete baseline and follow-up assessments in addition to care as usual."
16491881|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
16491882|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
16491883|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
16491884|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1 mg/mL|
16491885|NCT03347526|Active Comparator|Vigabatrin|
16491886|NCT03347513|Experimental|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).
~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.
~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
16491887|NCT03347513|Active Comparator|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
16491888|NCT03347500||obese OA patients|"Use of patient-derived biological samples
~Inclusion Criteria:
~Subscription of informed consent
~BMI ≥ 30
~age between 60-80 years included
~Kelgrenn-Lawrence equal or superior to grade III
~presence of synovitis
~patients undergoing knee replacement
~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice
~Exclusion criteria:
~- HCV, HIV, HBV, TPHA infection"
16491889|NCT03347500||Non-obese OA patients|"Use of patient-derived biological samples
~Inclusion criteria:
~Subscription of informed consent
~BMI ≤ 28
~age between 60-80 years included
~Kelgrenn-Lawrence equal or superior to grade III
~presence of synovitis
~patients undergoing knee replacement
~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice
~Exclusion criteria:
~- HCV, HIV, HBV, TPHA infection"
16491890|NCT03347487|Experimental|Deep Brain Stimulation of Bilateral Habenula|
16491891|NCT03347474|Experimental|Bilateral surgical implantation of DBS system to NAc|
16491892|NCT03347461|Experimental|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
16491893|NCT03347461|Active Comparator|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
16491894|NCT03347461|Active Comparator|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
16491895|NCT03347435|Experimental|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
16491896|NCT03347435|Active Comparator|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
16491897|NCT03347422|Experimental|Part A: sutimlimab or Placebo|In Part A, participants will be randomized 1:1 to receive an intravenous (IV) infusion of sutimlimab or placebo.
16491970|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
16491898|NCT03347422|Experimental|Part B: Response Extension Phase (sutimlimab)|In Part B, all participants will undergo blinded cross-over loading doses to allow all participants to receive sutimlimab while maintaining Part A blinding.
16491899|NCT03347409|No Intervention|Standard Perioperative (SP) care|
16491900|NCT03347409|Experimental|ERAS protocol|
16491901|NCT03347396|Experimental|Sutimlimab|Participants will receive an intravenous (IV) infusion of sutimlimab. Participants who complete Part A per protocol through the end of treatment visit (Day 182) will participate in Part B, and continue to receive sutimlimab up to 1 year after last patient out (LPO) in Part A.
16491902|NCT03347383|Experimental|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
16491903|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
16491904|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
16491905|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
16491906|NCT03347357|Experimental|tacrolimus|
16491907|NCT03347344|Experimental|RILUZOLE|Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.
16491908|NCT03347344|Placebo Comparator|PLACEBO|The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study
16491909|NCT03347331|Experimental|Input function group|Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling
16491910|NCT03347331|Experimental|Test-retest group|Each subject underwent 2 PET scans distant from 1 to 3 weeks
16491911|NCT03347305|Experimental|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
16491912|NCT03347305|Experimental|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
16491913|NCT03347292|Experimental|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
16491914|NCT03347292|Experimental|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
16491915|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
16491916|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
16491917|NCT03347266|Experimental|VVZ-149 injections|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.
16491918|NCT03347266|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
16491919|NCT03347240|Active Comparator|Brain lesioning group|Stereotactic lesioning of the thalamus or gloves pallidus
16491920|NCT03347240|Active Comparator|Combined rhizotomy group|Combined anterior and posterior lumbosacral rhizotomy
16491921|NCT03347240|Active Comparator|Deep brain stimulation group|Bilateral globus pallidus internus deep brain stimulation
16491922|NCT03347240|Active Comparator|Intra-thecal Baclofen infusion therapy|Intra-thecal infusion pump
16491923|NCT03347227|Active Comparator|Pulmonary Vein Isolation|Wide area circumferential catheter ablation for pulmonary vein isolation
16491924|NCT03347227|Experimental|Pulmonary Vein Isolation and scar ablation|Wide area circumferential catheter ablation for pulmonary vein isolation and scar ablation
16491925|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
16491926|NCT03347201|Experimental|Intervention Group|"Initial heparin bolus before CPB to be calculated using HMS Plus.
~Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.
~Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
16491927|NCT03347201|No Intervention|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of >480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
16491928|NCT03347188|Experimental|Fremanezumab|Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters [mL] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
16491929|NCT03347188|Placebo Comparator|Placebo|Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
16491930|NCT03347175|Experimental|Volume controlled ventilation|Intervention1: Ventilation with Volume controlled ventilation
16491931|NCT03347175|Active Comparator|Pressure controlled ventilation|Intervention2: Ventilation with Pressure controlled ventilation
16491932|NCT03347175|Active Comparator|CPAP mode|Intervention3: Ventilation with Continuous Positive Airway Pressure mode only
16491971|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
16491933|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
16491934|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
16491935|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
16491936|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
16491937|NCT03347136|Active Comparator|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
16491938|NCT03347136|Experimental|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
16491939|NCT03347123|Experimental|Treatment Group A|Epacadostat + nivolumab + ipilimumab
16491940|NCT03347123|Experimental|Treatment Group B|Epacadostat + nivolumab + lirilumab
16491942|NCT03347097|Experimental|TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
16491943|NCT03347097|Experimental|PD1-TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
16491944|NCT03347084|Active Comparator|Excitation|Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
16491945|NCT03347084|Active Comparator|Inhibition|Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
16491946|NCT03347071||Prevention Course Group|The Prevention Course Group is composed of female student-athletes enrolled in the 7-week prevention course. The course occurs once a week (1 hour, 40 minute sessions) for a total of 7-weeks during the academic semester. Approximately 1 hour of each class session is lecture based, leaving 40 minutes for yoga practice administered by a certified yoga instructor. The course instructor is certified in Eat Breathe Thrive Program delivery. The course teaching assistant is certified in yoga instruction.
16491947|NCT03347071||Control Group|The Control Group is composed of female student-athletes not enrolled in the 7-week prevention course. Female student-athletes in this group will not be enrolled in the course during the period of data collection, nor will they have previously completed the course.
16491948|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
16491949|NCT03347045|Experimental|Trimodal Prehab & ERP|"Trimodal prehab includes:
~Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.
~Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.
~Anxiety reduction workshop and take-home anxiety reduction program."
16491950|NCT03347045|Active Comparator|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
16491951|NCT03347032|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
16491952|NCT03347032|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
16491953|NCT03347019|Experimental|accelerated rehabilitation after surgery|patients were included progressive rehabilitation programme first week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
16491954|NCT03347019|Experimental|delayed rehabilitation after surgery|Patients were not allowed to start passive shoulder exercises first three weeks after surgery. Patients were included progressive rehabilitation programme third week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
16491955|NCT03347006|Placebo Comparator|Placebo|Placebo control
16491956|NCT03347006|Experimental|Dose 1|1.5 g of omega-3 supplement
16491957|NCT03347006|Experimental|Dose 2|3.0 g of omega-3 supplement
16491958|NCT03347006|Experimental|Dose 3|4.5 g of omega-3 supplement
16491959|NCT03346993|Experimental|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
16491960|NCT03346993|Experimental|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
16491961|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
16491962|NCT03346967|Experimental|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
16491963|NCT03346967|Experimental|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
16491964|NCT03346954|Experimental|Patients with Cushing's disease|Implementation of [11C]-Methionine PET/MRI
16491965|NCT03346915|Experimental|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
16491973|NCT03346837|Experimental|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
16491974|NCT03346837|Experimental|Induction (Cohort 3)|Single oral dose BMS-986205
16491975|NCT03346837|Experimental|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
16491976|NCT03346811|Experimental|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
16491977|NCT03346798|Experimental|Food Photography|On the first visit, participants will engage in food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
16491978|NCT03346798|Experimental|Non-Food Photography|On the first visit, participants will engage in non-food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
16491979|NCT03346785|Experimental|Food Photography|Participants will engage in food photography on their smart phones while eating
16491980|NCT03346785|Experimental|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
16491981|NCT03346785|Experimental|No Phone Use|Participants will not use their smart phones while eating
16491982|NCT03346772|Experimental|Influenza vaccination cohort|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
16491983|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
16491984|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
16491985|NCT03346746|Experimental|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
16491986|NCT03346746|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
16491987|NCT03346720||Participants recruited into biomedical research|Participants recruited into biomedical research where data collected may be shared with the wider research community.
16491988|NCT03346720||Frontline research staff|Frontline research staff directly involved in obtaining consent from participants in the above studies e.g. study nurses, investigators
16491989|NCT03346720||Research related staff and other stakeholders|Research related staff and other stakeholders involved in the implementation of the data sharing policy e.g. study managers, data access committee members, ethics committee members, study nurses, investigators, research collaborators, data managers and other clinical trials support staff.
16491990|NCT03346720||Community advisory board members|Community advisory board members and other community members
16491991|NCT03346707||10.5 Tesla|
16491992|NCT03346694|Active Comparator|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
16491993|NCT03346694|Active Comparator|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
16491994|NCT03346694|Active Comparator|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
16491995|NCT03346681|Experimental|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
16491996|NCT03346681|No Intervention|Albuterol|Albuterol will be administered via nebulization every six hours.
16491997|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
16491998|NCT03346642|Experimental|GVD and SHR-1210 with or without Decitabine|This is a two stage study. For the first stage, the participants will receive the combination of GVD chemotherapy and PD-1 antibody SHR-1210. The patients enrolled into the second stage will received the combination of GVD and SHR-1210 with low-dose decitabine primed.
16491999|NCT03346629|Experimental|Mifepristone + Misoprostol|Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
16492000|NCT03346616|Experimental|Texting Group|"The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2 pm and 3 pm."
16492001|NCT03346616|Active Comparator|Non Texting Group|The non-texting group received access to the journal articles from which the text message content was derived, but did not receive any text messages or any of the online material or question stems.
16492002|NCT03346590|Active Comparator|16 patients with active RA|"Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.
~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
16492032|NCT03346356|No Intervention|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
16492003|NCT03346590|Sham Comparator|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).
16492004|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
16492005|NCT03346564|Experimental|Ritual training program|ritual training program for 8 weeks, biweekly
16492006|NCT03346564|Placebo Comparator|Routine care|Routine care following hospital
16492007|NCT03346551|Experimental|women with postnatal depression|
16492008|NCT03346551|Other|women without postnatal depression|
16492009|NCT03346538|Experimental|Continuous infusion high-dose group (Group H)|High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
16492010|NCT03346538|Experimental|Continuous infusion low-dose group (Group L)|Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
16492011|NCT03346538|Experimental|Approved dosing regimen group (control group)|A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
16492012|NCT03346525|Experimental|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
16492013|NCT03346525|No Intervention|Control Arm|No prophylaxis
16492014|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
16492015|NCT03346499|Experimental|NK cells and IL-2|
16492016|NCT03346486|Placebo Comparator|Control diet|Regular diet
16492017|NCT03346486|Active Comparator|Intervention diet|Brainfood diet
16492018|NCT03346473||Adolescents aged 12-15 years in LMICs|No interventions administered
16492019|NCT03346460|Experimental|Tongue scraper group (Group 1)|Fifteen patients will be included in this group. Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
16492020|NCT03346460|Experimental|aPDT group (Group 2)|Fifteen patients will be included in this group. One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
16492021|NCT03346460|Experimental|Tongue scraper and aPDT (Group 3)|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
16492022|NCT03346434|Experimental|Part A (Open label Dupilumab): Age cohorts 1 & 2|"Age cohort 1: ≥2 years old to <6 years old
~Age cohort 2: ≥6 months to <2 years old"
16492023|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 1|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
16492024|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 2|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
16492025|NCT03346434|Experimental|Part B (Double-Blind): Placebo|
16492026|NCT03346421||diet and physical activity|
16492027|NCT03346408||Patients|data collection obtained from patient (self-questionnaire) and algologist physician (questionnaire).
16492028|NCT03346395|Experimental|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
16492029|NCT03346395|Active Comparator|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
16492030|NCT03346369|Experimental|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
16492031|NCT03346356|Experimental|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
16492033|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.
~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
16492034|NCT03346330|Experimental|TRK-750, single and multiple doses|
16492035|NCT03346330|Placebo Comparator|Placebo, single and multiple doses|
16492036|NCT03346317|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
16492037|NCT03346317|Experimental|estrogen|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
16492038|NCT03346304|Experimental|PDT treatment (Intervention Arm)|Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
16492039|NCT03346304|No Intervention|Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
16492040|NCT03346291|Experimental|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
16492041|NCT03346278|No Intervention|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
16492042|NCT03346278|Experimental|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
16492043|NCT03346265|Experimental|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.
~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
16492044|NCT03346265|Experimental|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
16492045|NCT03346252|Experimental|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
16492046|NCT03346239|Experimental|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
16492047|NCT03346239|Active Comparator|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
16492048|NCT03346239|Placebo Comparator|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
16492049|NCT03346226|Experimental|Dexmedetomidine Hydrochloride|Dex Group: 0.5 μg/kg of Dex is given 10 minutes before operation through injection pump during 15 minutes. After the operation starts, the initial pumping ratio of Dex is 0.5ug/kg/h and adjusted under BIS surveillance to keep BIS between 70-80 until 30 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
16492050|NCT03346226|Active Comparator|Propofol|Prop Group: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts. Under BIS surveillance, dripping rate is adjusted to keep BIS between 70-80 until 5 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
16492051|NCT03346213||Major surgery|"Adult patients undergoing elective surgery
~Having a CPET as part of routine care
~Patients with a Hb value of < 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.
~Able to provide written informed consent."
16492052|NCT03346200|Active Comparator|20 mg tamoxifen|
16492053|NCT03346200|Experimental|10 mg tamoxifen|
16492054|NCT03346200|Experimental|5 mg tamoxifen|
16492055|NCT03346200|Experimental|2.5 mg tamoxifen|
16492056|NCT03346200|Experimental|1 mg tamoxifen|
16492057|NCT03346200|Placebo Comparator|0 mg tamoxifen|
16492058|NCT03346187|Experimental|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.
~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
16492059|NCT03346187|Experimental|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.
~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
16492060|NCT03346174|Experimental|AAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage. By modulating manually the functional breathing level within the vital capacity, optimal airflow will be obtained at the targeted airway generations, where secretions have been identified. A gentle increase of manual pressure on the chest during each inspiration is performed to guide the breathing of the patient towards the desired lung volume level. During expiration the breathing movement of the patient is followed gently.
16492229|NCT03345082|Sham Comparator|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
16492061|NCT03346174|Experimental|BAAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage .AAD sometimes leads to crying or resistance against therapy.Bouncing (at low amplitude:6-8 cm) in a stable upright position is a gentle up-and-down movement on a physio ball. It is not an ACT, but used to maximize the relaxation of the infant, avoiding resistance against or crying during treatment. Due to the relaxing effect of bouncing, infants appear to tolerate better AAD, increasing the effectiveness of the treatment.
16492062|NCT03346161|Experimental|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
16492063|NCT03346161|Active Comparator|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
16492064|NCT03346135|Experimental|Treatment (ASCT, melphalan, daratumumab)|Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16492065|NCT03346122|Experimental|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
16492066|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
16492067|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
16492068|NCT03346122|Experimental|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
16492069|NCT03346122|Experimental|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
16492070|NCT03346122|Experimental|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
16492071|NCT03346122|Experimental|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
16492072|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
16492073|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
16492074|NCT03346122|Experimental|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
16492075|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
16492076|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
16492077|NCT03346096|Experimental|Thiotepa|Thiotepa for reduce toxicity and improve outcome following transplantation
16492078|NCT03346083|Experimental|Cohort 1 Bertrixaban/Andexanet|Single oral dose 40 mg
16492079|NCT03346083|Experimental|Cohort 2 Bertrixaban/Placebo|Single oral dose 80 mg
16492080|NCT03346070|Experimental|Sugammadex 2 mg/kg ABW|Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
16492081|NCT03346070|Experimental|Sugammadex 2 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
16492082|NCT03346070|Experimental|Sugammadex 4 mg/kg ABW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
16492230|NCT03345056|Other|included cases|vitrectomy done with planned foveal separation and followed for the result
16492231|NCT03345043|Experimental|VAL-339851|
16492083|NCT03346070|Experimental|Sugammadex 4 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
16492084|NCT03346070|Active Comparator|Neostigmine/Glycopyrrolate|Following administration of NMBA, participants received a single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW. Neostigmine/Glycopyrrolate was used for reversal of moderate NMB. Active comparator treatment for reversal for deep NMB was not available.
16492085|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
16492086|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
16492087|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
16492088|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
16492089|NCT03346044|Active Comparator|Carpentier-Edwards SAV bioprostheses|
16492090|NCT03346044|Active Comparator|Medtronic Mosaic bioprostheses|
16492091|NCT03346031|No Intervention|Group 1|Group 1 is control group that does not listen to music
16492092|NCT03346031|Active Comparator|Music Therapy Group 2|Group 2 is the group listening to preoperative music
16492093|NCT03346031|Active Comparator|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
16492094|NCT03346018||uveitis of tuberculous etiology|Analysis of aqueous humor and plasma samples: The patients with diagnosis of uveitis of tuberculous etiology, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
16492095|NCT03346018||uveitis of suspect sarcoidosis|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of suspect sarcoidosis, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
16492096|NCT03346018||uveitis of undifferentiated origin|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis), undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
16492097|NCT03346005|Experimental|Adult patients with positive FIT test|Adult patients with a positive FIT-test will breath into an e-nose device for 5 minutes.
16492098|NCT03345992|Placebo Comparator|Placebo|After enrollment, the placebo arm will receive water for injection at a volume of 20ml diluted to a final volume of 250 ml dextrose in water 5%, infused once daily through intravenous route, within 1 hour, for a duration of four consecutive days.
16492099|NCT03345992|Active Comparator|Clarithromycin|After enrollment, the active drug arm will receive 1g of clarithromycin (500 mg powder for concentrate for solution for infusion per vial), dissolved into 20 ml water for injection and then diluted to a final volume of 250 ml dextrose in water 5%. This will be infused through intravenous route, once daily within 1 hour, for a duration of four consecutive days.
16492100|NCT03345979|Experimental|Treatment Group 1|Regular injections
16492101|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
16492102|NCT03345966|Experimental|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.
~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
16492103|NCT03345966|Experimental|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):
~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:
~Finally, RQ was calculated according to the following equation:
~∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene
~∆∆ Ct = ∆ Ct sample - Ct control gene
~RQ = 2-(∆∆Ct)"
16492104|NCT03345953|Experimental|BP 1.4979|15 mg tablet BID
16492105|NCT03345953|Placebo Comparator|Placebo|Matching placebo tablet
16492106|NCT03345940|Active Comparator|Fingolimod 0.5 mg/day|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.
~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
16492107|NCT03345940|Active Comparator|Dimethyl Fumarate 240 mg twice daily|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.
~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
16492108|NCT03345927||high cardiovascular risk group|no intervention
16492109|NCT03345914|Experimental|Group 1|Participants will receive dupilumab, dosing regimen 1
16492110|NCT03345914|Experimental|Group 2|Participants will receive dupilumab, dosing regimen 2
16492111|NCT03345914|Experimental|Group 3|Participants will receive matching placebo
16492112|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
16492113|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
16492114|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
16492115|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
16492232|NCT03345043|Placebo Comparator|Placebo|
16492116|NCT03345875|Other|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
16492117|NCT03345862|Experimental|Intervention|Non-pharmacological multicomponent intervention
16492118|NCT03345862|No Intervention|Control|Not intervention, usual attention
16492119|NCT03345849|Experimental|Arm A: Upadacitinib|Participants will receive Upadacitinib dose A for 12 weeks. Non-responders will receive Upadacitinib dose B for 12 weeks
16492120|NCT03345849|Experimental|Arm B: Placebo and Upadacitinib|Participants will receive placebo for 12 weeks. Non-responders will receive Upadacitinib dose A for 12 weeks.
16492121|NCT03345836|Experimental|Arm A|Participants will receive upadacitinib dose A for 12 weeks.
16492122|NCT03345836|Experimental|Arm B|Participants will receive placebo for 12 weeks.
16492123|NCT03345836|Other|Arm C|Participants will receive open-label upadacitinib dose A for 12 weeks.
16492124|NCT03345823|Experimental|Group A - Arm A|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose B.
16492125|NCT03345823|Experimental|Group A - Arm B|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose C.
16492126|NCT03345823|Experimental|Group A- Arm C|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive placebo.
16492127|NCT03345823|Experimental|Group B - Arm A|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose B.
16492128|NCT03345823|Experimental|Group B - Arm B|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose C.
16492129|NCT03345823|Experimental|Group B - Arm C|This is a long-term extension group with 240 weeks which includes participants who complete group A.
16492130|NCT03345810|Active Comparator|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
16492131|NCT03345810|Experimental|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3
~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W"
16492132|NCT03345810|Experimental|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3
~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)"
16492133|NCT03345810|Active Comparator|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3
~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
16492134|NCT03345797|Experimental|Naive patients - ARM 1|TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
16492135|NCT03345797|Experimental|Non-naive patients - ARM 2|TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage >/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
16492137|NCT03345771|Active Comparator|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
16492138|NCT03345771|Active Comparator|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
16492139|NCT03345758||ECMO mode,outcome|ECMO mode includes VV-ECMO and VA-ECMO, outcome includes survive condition , physical and mental health, cognitive function and social adaptation
16492140|NCT03345745||Periodontally healthy subjects|Salivary samples
16492141|NCT03345745||Chronic periodontitis patients|Salivary samples
16492142|NCT03345745||Gingivitis patients|Salivary samples
16492143|NCT03345706|Experimental|Selective cerebral hypothermia|Selective cerebral hypothermia
16492144|NCT03345706|Active Comparator|Regular hypothermia|Regular hypothermia
16492145|NCT03345693|Experimental|Treated with MoTrack Therapy|Patients receive the MoTrack Therapy device to assist them in their at-home therapy exercises. The patient is instructed to use the MoTrack Therapy device when they want to do their at-home therapy exercises. The patients therapy in the clinic is not affected.
16492146|NCT03345680|No Intervention|Control Group|Children will be screened, both parents and children will be informed of any abnormalities in the mouth.
16492147|NCT03345680|Experimental|Interventional Group|Interventional (Dental Screening) Children will be screened for dental caries and referred to a specific hospital for treatment, namely King Saud University Dental College, treatment will be provided free of charge to the referred participants.
16492148|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
16492149|NCT03345654|Placebo Comparator|Standard-of-care hearing aid fit|
16492150|NCT03345654|Experimental|Toolset-directed hearing aid fit|
16492151|NCT03345641||dyads|dyads with babies and their mothers
16492152|NCT03345628||sedated|infants requiring intubation and ventilation who received sedatives for at least 3 days
16492153|NCT03345628||non-sedated|infants who received respiratory support by non-invasive ventilation and were not sedated
16492154|NCT03345615|Experimental|Intensive Monitoring|30-day ambulatory cardiac event monitoir
16492155|NCT03345615|No Intervention|Standard Care|Standard Care (no supplemental monitoring)
16492156|NCT03345589|Experimental|18-22mg/kg/d Ursodeoxycholic group|
16492157|NCT03345589|Placebo Comparator|13-15mg/kg/d Ursodeoxycholic group|
16492362|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
16492363|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
16492158|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
16492159|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
16492160|NCT03345563|Experimental|Body Mind Training (BMT)|Body mind training
16492161|NCT03345563|Active Comparator|Body Training (BT)|Body training only
16492162|NCT03345563|Other|Usual care (UC):|Control
16492163|NCT03345550|Experimental|Omega-3 Polyunsaturated Fatty Acid Treatment Arm|Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
16492164|NCT03345550|Placebo Comparator|Placebo Arm|Participants randomized to this study arm will receive placebo drug for 3 months.
16492165|NCT03345524|Experimental|Peer-buddy system|Will meet with peer-buddy who will help with them with CPAP usage. Also will receive standard of care CPAP educational training
16492166|NCT03345524|Active Comparator|Usual Care|Will receive educational material at the same frequency that those in the experimental arm. Will also receive standard of care CPAP educational training.
16492167|NCT03345511|Experimental|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
16492168|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
16492169|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
16492170|NCT03345485|Experimental|Tinostamustine (EDO-S101)|"Phase 1:
~Schedule A: Tinostamustine (EDO-S101), IV, 60mg/m2 up to 100mg/m2 Day 1 and 15 of each 28 day cycle
~Phase 2:
~The RP2D and selected schedule will be further investigated in patients with specific types of solid tumors: relapsed/refractory SCLC, soft tissue sarcoma, triple negative breast cancer, ovarian cancer and endometrial cancer."
16492171|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
16492172|NCT03345459|Experimental|Internet-Based Treatment (ICare)|ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
16492173|NCT03345459|No Intervention|Usual Care|Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
16492174|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF < 55% per the protocol).
16492175|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF > 55% per the protocol).
16492176|NCT03345433|Experimental|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
16492177|NCT03345420|Experimental|Treatment (hypofractionated radiation therapy)|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
16492178|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
16492179|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
16492180|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
16492181|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
16492182|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
16492183|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
16492184|NCT03345394|Active Comparator|Standard Treatment|12 weeks of standard treatment offered by Unidade Recomeço Helvétia treatment program
16492185|NCT03345394|Experimental|Contingency Management|12 weeks of standard treatment offered at Unidade Recomeço Helvétia treatment program associated with Contingency Management
16492186|NCT03345381|Experimental|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) plus usual care
16492187|NCT03345381|Active Comparator|Usual Care|Treatment as usual
16492188|NCT03345368|Experimental|rTMS treated group|A Magstim Rapid2 Stimulator equipped with a double 70mm alpha coil P/N 3191-00 (Magstim, Wales, UK) will be used to stimulate the motor cortex. Transcranial magnetic stimulation will be applied through a coil at 10 Hz, a field intensity of 90% of the motor threshold. Stimuli will be provided in 10 trains of 100 pulses, followed by a 28 s rest period.
16492189|NCT03345368|Sham Comparator|sham rTMS group|Sham rTMS will be administered with the coil held in contact with the head but a 180 degrees from scalp, and the power parameter will be reduced by half to avoid stimulation.b
16492190|NCT03345355||patient with axial spondyloarthritis|
16492191|NCT03345342|Experimental|PP1M: Transition Phase|Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
16492192|NCT03345342|Experimental|PP1M/PP3M: Maintenance Phase|All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
16492193|NCT03345342|Experimental|PP6M or Placebo: Double-Blind Phase|Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
16492194|NCT03345342|Experimental|PP3M: Double-Blind Phase|Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
16492195|NCT03345329||Periodontal patient|
16492196|NCT03345329||Healthy person|
16492197|NCT03345329||Peri-implantitis patient|
16492198|NCT03345316|Experimental|FFI-1010|
16492199|NCT03345303|Experimental|Bortezomib treatment|'Bortezomib Injectable Solution
16492200|NCT03345303|No Intervention|supportive care|supportive care
16492201|NCT03345290|Experimental|Subjects|Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
16492202|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
16492203|NCT03345264|Experimental|Cancer patients, survivors, and partners|
16492204|NCT03345251|Experimental|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
16492205|NCT03345251|Placebo Comparator|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
16492206|NCT03345238|Experimental|Active MTP|
16492207|NCT03345238|Experimental|Latent MTP|
16492208|NCT03345238|Experimental|Out of MTP|
16492209|NCT03345225|Active Comparator|Control Group|Participants will be randomized to receive DEB-TACE utilizing a standard endhole microcatheter
16492210|NCT03345225|Experimental|Surefire Group|Participants will be randomized to receive DEB-TACE utilizing the Surefire Infusion System
16492211|NCT03345212|No Intervention|Control group|Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
16492212|NCT03345212|Experimental|Training group|"Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.
~Patients will be informed about group allocation."
16492213|NCT03345199|Experimental|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
16492214|NCT03345186|Experimental|Nurse led plus standard of care|Nurse Led Patient Management Programme to Improve Outcomes in Gout and Standard of care for gout patients, including nurse delivered patient education and follow up
16492215|NCT03345186|No Intervention|Standard of care|Standard of care for gout patients
16492216|NCT03345173|Experimental|CI-581a|"CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.
~(0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)"
16492217|NCT03345173|Placebo Comparator|CI-581b|"CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.
~(2-min saline bolus followed by 0.0125 mg/kg over 90 min)"
16492219|NCT03345147||Normal Vitamin A intake|Normal Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to Normal Vit. A consumption if daily Vit. A is between 250 and 600 micrograms per day.
16492220|NCT03345147||High Vitamin A intake|High Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to High Vit. A consumption if daily Vit. A is above 900 micrograms per day.
16492221|NCT03345134|Experimental|MK-3475 and BCG|Single treatment group of high risk superficial upper urinary tract transitional cell carcinoma; combination treatment with MK-3475 and BCG
16492222|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
16492223|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
16492224|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
16492225|NCT03345095|Experimental|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
16492226|NCT03345095|Active Comparator|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
16492227|NCT03345082|Experimental|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
16492228|NCT03345082|Experimental|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
16492233|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
16492234|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
16492235|NCT03345004|Active Comparator|Active arm|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
16492236|NCT03345004|Placebo Comparator|Placebo arm|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)
16492241|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
16492242|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
16492243|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
16492244|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
16492245|NCT03344926|Experimental|ACTsmart|ACT treatment via a smart phone application
16492246|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
16492247|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
16492248|NCT03344900||Phase I|It is estimated that 100 participants with SCD will be enrolled for the Phase I portion which will identify barriers to hydroxyurea utilization.
16492249|NCT03344900||Phase II|It is estimated that 72 participants with SCD will be enrolled for the Phase II portion of the study which will evaluate the degree of feasibility and acceptance of mHealth intervention on hydroxyurea adherence.
16492250|NCT03344887|Active Comparator|RBC Transfusion from male donor|For the treatment of anemia
16492251|NCT03344887|Active Comparator|RBC Transfusion from female donor|For the treatment of anemia
16492252|NCT03344874|Experimental|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.
~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
16492253|NCT03344874|Active Comparator|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.
~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
16492254|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
16492255|NCT03344848|Experimental|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
16492256|NCT03344835||Prostate Cancer|Patients diagnosed with prostate cancer
16492257|NCT03344822|Experimental|68Ga-PSMA PET-CT|
16492258|NCT03344796||Focus Group|"32 subjects
~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days. The analysis will determine enablers and barriers to sun protected outdoor activities and determine strategies for achieving sun protected outdoor activities."
16492259|NCT03344796||Usability testing|"10 subjects
~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week."
16492260|NCT03344796||Cohort Study 1|"60 subjects
~First cohort study: It is expected that each of 60 melanoma survivors will wear the sensor and transmit data for 21 days in the warm weather months of June-Aug 2019. It will take about 2 months to enroll the subjects. Subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized to receive a survey item inviting selection of strategies to achieve sun-protected outdoor activities (structured goal attainment) or submit a free text description of their strategy (unstructured goal attainment)."
16492261|NCT03344796||Structured Interviews|50 young adults, ages 18-39 will participate in structured interviews to determine their barriers and enablers of sun exposure and sun protection. Eligible subjects will have at least one hour a day outdoors with 30 minutes of the hour being consecutive. It will take about 3 months to enroll the subjects. The audio files will be transcribed and analysis completed in 60 days.
16492262|NCT03344796||Cohort Study 2|Second cohort study: 40 young adults will wear the sensor and transmit data for 28 days in summer 2020.
16492263|NCT03344783||mother-children pairs|
16492264|NCT03344770|Experimental|Active rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
16492265|NCT03344770|Sham Comparator|Sham rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
16492266|NCT03344757|Experimental|C-CBSM|Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
16492267|NCT03344757|Active Comparator|CBSM|Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
16492268|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
16492269|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
16492270|NCT03344744||Control|Healthy volunteers
16492271|NCT03344731|Experimental|Experimental Group|Patient with any form ob brain damage
16492272|NCT03344731|Other|Control Group|Healthy volounteers
16492273|NCT03344705|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
16492274|NCT03344692|Experimental|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
16492275|NCT03344692|Placebo Comparator|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.
~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
16492276|NCT03344679|Other|Control group|Bupivacaine 0.25% for pectoral nerve block.
16492277|NCT03344679|Other|Adenosine|Bupivacaine 0.25% with added Adenosine 12mg for pectoral nerve block.
16492278|NCT03344679|Other|Magnesium sulphate|Bupivacaine 0.25% with Magnesium sulphate 500 mg for pectoral nerve block.
16492281|NCT03344653|Active Comparator|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
16492282|NCT03344653|Active Comparator|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
16492283|NCT03344640|Experimental|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
16492284|NCT03344640|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
16492285|NCT03344627|Active Comparator|Meropenem standard dose|Meropenem 1 g every 8 hours
16492286|NCT03344627|Active Comparator|Meropenem high dose|Meropenem 2 g every 8 hours
16492287|NCT03344614|Experimental|raltitrexed combined with apatinib|therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.
16492288|NCT03344601|No Intervention|Reference Cohort|A 12-month longitudinal evaluation of physical fitness and physical activity assessments in a cohort of individuals with HD (n=60) recruited from the Enroll-HD platform study.
16492289|NCT03344601|Experimental|Physcial Activity Intervention|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to a 12-month physical activity and coaching intervention.
16492290|NCT03344601|No Intervention|Activity as usual control|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to continue with physical activity as usual for 12 months
16492291|NCT03344588|Active Comparator|artery preserving varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group A (APV), testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
16492292|NCT03344588|Active Comparator|artery ligation varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group B (ALV), all vascular channels will be ligated without identifying or sparing the internal spermatic arteries
16492293|NCT03344575|Active Comparator|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
16492294|NCT03344575|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
16492295|NCT03344562|Experimental|CES Active|Active cranial electrical stimulation device
16492296|NCT03344562|Sham Comparator|CES Sham|Inactive device identical to the active device.
16492297|NCT03344549|Experimental|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
16492298|NCT03344549|Other|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
16492299|NCT03344536|Experimental|fulvestrant and Debio 1347|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter. Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated. The dosage in the phase 2 portion will be the MTD/RP2D determined in the phase 1b portion.
16492300|NCT03344523|Experimental|standard treatment + Iron succinylate|1 bottle orally, twice daily, take orally before meals
16492301|NCT03344523|Placebo Comparator|standard treatment + placebo|1 bottle orally, twice daily, take orally before meals
16492302|NCT03344510|Experimental|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
16492303|NCT03344510|Experimental|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
16492304|NCT03344497|Other|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
16492305|NCT03344497|No Intervention|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
16492306|NCT03344484|Experimental|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
16492307|NCT03344484|Experimental|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
16492308|NCT03344471|Other|women with PTSD after preterm deliver|
16492309|NCT03344471|Other|women without PTSD after preterm deliver|
16492310|NCT03344458|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
16492311|NCT03344445|No Intervention|traditional vist|Patients receive traditional anesthesiologist visit
16492312|NCT03344445|Experimental|video-assisted|Patients watch the video, then an anesthesiologist visit
16492313|NCT03344432||With intraocular pressure high|Intracranial pressure equal or more than 20 mmHg
16492314|NCT03344432||Without intraocular pressure high|Intracranial pressure smaller than 20 mmHg
16492315|NCT03344419|Experimental|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
16492316|NCT03344419|Active Comparator|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
16492317|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
16492318|NCT03344393|Active Comparator|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
16492319|NCT03344393|Active Comparator|normal saline|intravenous normal saline infusion in the intraoperative period
16492320|NCT03344380||Prospective cohort|Adult patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. The GWAS will be performed with the blood obtained from enrolled patients.
16492321|NCT03344380||Retrospective cohort|In previous study performed in adult patients undergoing liver transplantation (NCT02489474, 4-2015-0411), we enrolled patients and collected data regarding the development of acute kidney injury during the first 72 hours post-liver transplantation. Among these patients enrolled in this previous study, only patients who agreed to additional use of the blood sample for research purposes will be included in the present study. The GWAS will be performed with the blood obtained from enrolled patients.
16492364|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
16492365|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
16492322|NCT03344367|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.
16492323|NCT03344354|Active Comparator|Biogel 1|Biogel 1 (overglove) sterile surgical glove
16492324|NCT03344354|Active Comparator|Ansell|Ansell sterile surgical glove
16492325|NCT03344354|Active Comparator|Cardinal|Cardinal sterile surgical glove
16492326|NCT03344354|Active Comparator|Biogel 2|Biogel 2 (underglove) sterile surgical glove
16492327|NCT03344354|Active Comparator|Medline|Medline sterile sergical glove
16492328|NCT03344341|Experimental|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
16492329|NCT03344341|Active Comparator|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
16492330|NCT03344315|Active Comparator|autologous connective tissue graft|Soft tissue harvesting from patient palate
16492331|NCT03344315|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
16492332|NCT03344302|Experimental|study group|100 women were assigned to receive an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour minutes diluted into 500 mL of normal 0.9% sodium chloride) immediately after opening the visceral peritoneum just before incising the uterine wall during Cesarean section
16492333|NCT03344302|Active Comparator|Control group|100 women were assigned to an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour diluted into 500 mL of normal 0.9% sodium chloride) immediately after clamping the umbilical cord during cesarean section
16492334|NCT03344289|Experimental|Linked color imaging|When the patient is randomized for LCI, the imaging mode is switched to LCI and colonoscopic inspection will take place during withdrawal of the endoscope
16492335|NCT03344289|Active Comparator|High definition white light|When the patient is randomized for HD-WLE, the imaging mode is switched to HD-WLE and colonoscopic inspection will take place during withdrawal of the endoscope.
16492336|NCT03344276|Active Comparator|Control Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months). The two preoperative time points will serve as the control group.
16492337|NCT03344276|Experimental|Intervention Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points after invention (1 month and 2 months). The two postoperative time points will serve as the intervention group.
16492338|NCT03344263|Experimental|tests of attentional performance|
16492339|NCT03344250|Experimental|Main Study|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
16492340|NCT03344250|Experimental|Subcohort for MGMT unmethylated patients|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. About 4 weeks after completion of RT/TMZ, participants will receive 8 weekly doses of EGFR BATs.
16492341|NCT03344224||normal blood lipid/protein group|
16492342|NCT03344224||abnormal blood lipid/protein group|
16492343|NCT03344211|Experimental|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16492344|NCT03344211|Experimental|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16492345|NCT03344198|Experimental|Firefighter (Veteran) Group|Firefighters with >10yrs experience. Circuit Training exercise & Modified Mediterranean diet
16492346|NCT03344198|Experimental|Firefighter (Novice) Group|Firefighters with <10yrs experience. Circuit Training exercise & Modified Mediterranean diet
16492347|NCT03344198|Experimental|Control Non-Firefighter Group|Non-Firefighter adults. Circuit Training exercise & Modified Mediterranean diet
16492348|NCT03344185|Experimental|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
16492349|NCT03344185|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
16492350|NCT03344172|Experimental|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
16492351|NCT03344172|Experimental|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
16492352|NCT03344159|Experimental|Spironolactone|Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.
16492353|NCT03344159|Placebo Comparator|Placebo|Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.
16492354|NCT03344146|Other|Group 1|Intake reminders followed by crossover to no intake reminders
16492355|NCT03344146|Other|Group 2|No intake reminders followed by crossover to intake reminders
16492356|NCT03344133|Experimental|Exercise|4-week moderate intensity exercise programme
16492357|NCT03344133|No Intervention|Control|4 weeks of habitual life style
16492358|NCT03344120|Active Comparator|suture stent|suture stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
16492359|NCT03344120|Active Comparator|conventional double-J stent|conventional double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
16492360|NCT03344107|Active Comparator|Vortek double-J stent|Vortek double-J stent after RIRS.
16492361|NCT03344107|Active Comparator|Polaris Loop stent|Polaris Loop ureteral stent after RIRS.
16492366|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
16492367|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
16492368|NCT03344068|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radical radiotherapy with or without chemotherapy plus Nutren® Optimum of 7 scoops tid at begin of radiotherapy.
16492369|NCT03344068|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radical radiotherapy with or without chemotherapy plus routine diet guidance at begin of radiotherapy.
16492370|NCT03344055|Active Comparator|Colonoscopy with Endocuff Vision (ECV)|ECV-assisted colonoscopy ( with the use of Endocuff Vision (ECV) Second generation)
16492371|NCT03344055|No Intervention|Standard colonoscopy|Standard colonoscopy (without the use of Endocuff Vision (ECV) Second generation)
16492372|NCT03344042|Active Comparator|Fentanyl|100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation
16492373|NCT03344042|Active Comparator|Sufentanyl|10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation
16492374|NCT03344042|No Intervention|Control|No epidural analgesia
16492375|NCT03344029|Experimental|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
16492376|NCT03344029|Active Comparator|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
16492377|NCT03344016|No Intervention|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
16492378|NCT03344016|Active Comparator|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
16492379|NCT03344003||Wilate or Nuwiq prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
16492380|NCT03344003||Wilate or Nuwiq retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
16492381|NCT03343990||group A|Interlocking multi-twisted wires techniqe in sternal closure
16492382|NCT03343990||group B|Eight Figure techniqe in sternal closure
16492383|NCT03343977|Experimental|Every two weeks docetaxel|50 mg/m2 of docetaxel will be given on day 1 every 14 days over one hour IV infusion for up to 9 cycles (1 cycle = 14 days)
16492384|NCT03343977|Active Comparator|Every three weeks docetaxel|75 mg/m2 of docetaxel will be given on day 1 every 21 days over one hour IV infusion for up to 6 cycles (1 cycle = 21 days)
16492385|NCT03343964||Children with moderate to severe TBI|
16492386|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
16492387|NCT03343938|Experimental|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
16492388|NCT03343938|No Intervention|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
16492389|NCT03343912|Experimental|Test 1 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
16492390|NCT03343912|Experimental|Test 2 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
16492391|NCT03343912|Experimental|Test 3 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days
16492392|NCT03343873|Experimental|Midarolam|midarolam sensation group
16492393|NCT03343873|Experimental|Propofol|propofol sensation group
16492394|NCT03343873|Experimental|dexmedetomidine|dexmedetomidine sensation group
16492395|NCT03343860|Active Comparator|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
16492396|NCT03343860|Active Comparator|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
16492397|NCT03343847|Experimental|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
16492398|NCT03343847|Placebo Comparator|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
16492400|NCT03343821||Frail elderly patient|
16492401|NCT03343795|Experimental|study group 1|oral progesterone
16492402|NCT03343795|Active Comparator|study group 2|intramuscular progesterone
16492403|NCT03343782|Experimental|Stem cell transplantation|Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
16492404|NCT03343769||Patient|
16492405|NCT03343769||Control|
16492406|NCT03343743|Other|Hydration|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
16492407|NCT03343730|Experimental|Non-mydriatic color fundus photography|All participants will receive Non-mydriatic color fundus photography with the RetinaVue camera at an already scheduled annual physical exam or follow up clinic visit with their primary care provider (PCP).
16492408|NCT03343730|Active Comparator|Standard of Care (Control)|All patients will also receive a referral for a dilated eye exam with an eye care professional. A yearly dilated exam as referred by the PCP.
16492409|NCT03343717|Experimental|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.
~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.
~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
16492410|NCT03343717|Active Comparator|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
16492411|NCT03343704|Experimental|Group A - patients with uncontrolled or life-threatening bleeding|
16492412|NCT03343704|Experimental|Group B - patients not bleeding but requiring emergency surgery or invasive procedure|
16492413|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.
~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
16492414|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
16492415|NCT03343678|Experimental|Venetoclax + BI 836826|
16492416|NCT03343665|Experimental|Nivolumab 40 mg|Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16492417|NCT03343652|Experimental|NB|Nivolumab 3 mg/kg IV infusion on day 1,14 + Bendamustine hydrochloride 90 mg/kg IV infusion on day 1,2 up to 3 cycles. Duration of cycle 28 days
16492418|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
16492419|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
16492420|NCT03343626|Placebo Comparator|Placebo|TAK-426 placebo-matching injection, intramuscular, once on Days 1 and 29.
16492421|NCT03343626|Experimental|Low Dose: PIZV 2 microgram (mcg)|PIZV 0.5 milliliter (mL), 2 mcg antigen, injection, intramuscular, once on Days 1 and 29.
16492422|NCT03343626|Experimental|Medium Dose: PIZV 5 mcg|PIZV 0.5 mL, 5 mcg antigen, injection, intramuscular, once on Days 1 and 29.
16492423|NCT03343626|Experimental|High Dose: PIZV 10 mcg|PIZV 0.5 mL, 10 mcg antigen, injection, intramuscular, once on Days 1 and 29.
16492424|NCT03343613|Experimental|LY3381916 Escalation|LY3381916 administered orally.
16492425|NCT03343613|Experimental|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
16492426|NCT03343613|Experimental|LY3381916 Expansion|LY3381916 administered orally.
16492427|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B1|"Metastatic triple negative breast cancer (TNBC)
~LY3381916 administered orally and LY3300054 administered IV."
16492428|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B2|"Metastatic non-small cell lung cancer (NSCLC)
~LY3381916 administered orally and LY3300054 administered IV."
16492429|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B3|"Metastatic clear cell carcinoma renal cell carcinoma (RCC)
~LY3381916 administered orally and LY3300054 administered IV."
16492430|NCT03343600|Experimental|Imatinib|Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
16492431|NCT03343600|Placebo Comparator|Placebo|Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.
16492432|NCT03343587|Experimental|LY3375880 Single Dose|Single dose of LY3375880 administered IV or SC
16492433|NCT03343587|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered IV or SC
16492434|NCT03343587|Experimental|LY3375880 Multiple Dose|Multiple doses of LY3375880 administered IV or SC
16492435|NCT03343587|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered IV or SC
16492436|NCT03343574|Experimental|Abdominal Strengthening Exercise|All participants in this arm shall perform exercises for the strengthening of abdominal muscles for a period of three months in addition to the routine care provided to them for the management of Parkinson's Disease. The exercises are structured and need to be performed on a routine basis.
16492437|NCT03343574|No Intervention|Routine Care|All participants in this group shall continue to obtain routine care for the management of Parkinson's Disease.
16492438|NCT03343561|No Intervention|Control|Subjects would have subjects' own diet as usual
16492439|NCT03343561|Experimental|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
16492440|NCT03343561|Experimental|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
16492441|NCT03343561|Experimental|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
16492442|NCT03343548|Active Comparator|Group I|magnesium group (Mg)
16492443|NCT03343548|Placebo Comparator|Group II|control group (C)
16492444|NCT03343535|Experimental|OCS|OCS Lung Preservation
16492445|NCT03343522|No Intervention|Sedentarism|Patients assigned to this arm shall not perform regular exercise training.
16492446|NCT03343522|Experimental|Exercise Training|Patients assigned to this arm will be enrolled in exercise training program.
16492447|NCT03343509|Experimental|Group A - Oral|Oral metronidazole 400mg 3 times a day for 7 days Placebo ointment applied 3 time times a day for 7 days to affected region
16492448|NCT03343509|Experimental|Group B - Topical|Topical metronidazole ointment 10% 3 times a day for 7 days Oral placebo tablets 3 times a day for 7 days
16492449|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
16492450|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
16492451|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
16492452|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
16492453|NCT03343457|Experimental|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
16492454|NCT03343457|Experimental|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
16492455|NCT03343457|No Intervention|Control|Control group
16492456|NCT03343444|Active Comparator|Arm 1|Treatment-naïve is defined as having never received treatment for HCV with any interferon (IFN), ribavirin , or other approved or experimental HCV specific direct acting antivirals.
16492457|NCT03343444|Active Comparator|Arm 2|"Treatment-experienced is defined as:
~IFN Intolerant
~Non-response
~Relapse/Breakthrough"
16492458|NCT03343444|Experimental|Short Track|Treatment-naïve or Treatment-experienced who achived very rapid virological responce - Negative HCV PCR after treatment with (Sofosbuvir 400mg/Ledipasvir 90mg) for 1 week
16492459|NCT03343418|Active Comparator|desmopressin|Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.
16492460|NCT03343418|Placebo Comparator|Placebo|Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).
16492461|NCT03343405|Experimental|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
16492462|NCT03343405|No Intervention|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
16492463|NCT03343392|Experimental|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
16492464|NCT03343392|Placebo Comparator|Placebo group|One hour before in-office bleaching patients received either placebo.
16492465|NCT03343379|Other|Healthy cohort|Core stability test
16492466|NCT03343366|Experimental|Test Group 1|The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
16492467|NCT03343366|Active Comparator|Test Group 2|The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1
16492468|NCT03343366|Other|Control Group 3|The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.
16492469|NCT03343353|Experimental|LED red group (630nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
16492470|NCT03343353|Experimental|LED infrared group (940nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
16492471|NCT03343353|Sham Comparator|Group Sham|This group will not receive irradiation by led light. You will only receive the routine care of the hospital unit to which you are hospitalized. These patients will be evaluated in the same way as the other two intervention groups, and also by a blind evaluator.
16492472|NCT03343340|Experimental|Early CRRT|Early Continous Renal Replacement Therapy within 6 hours + Standard Medical Therapy
16492473|NCT03343340|Active Comparator|Late CRRT|Late Continous Renal Replacement Therapy + Standard Medical Therapy
16492474|NCT03343327|Experimental|Chronocort®, then Cortef®|Single dose of 20mg Chronocort® (oral administration), followed by a single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration).
16492475|NCT03343327|Active Comparator|Cortef®, then Chronocort®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration), followed by a single dose of 20mg Chronocort® (oral administration).
16492476|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
16492477|NCT03343301|Other|Phase 1 Study of FPA144 + mFOLFOX6|"Phase 1 dose escalation of FPA144 administered intravenously over approximately 30 minutes in cohorts of 3-6 patients to evaluate for the recommended dose (RD) of FPA144 for phase 3. mFOLFOX6 administered 30 minutes after the end of the FPA144 infusion as follows:
~Oxaliplatin 85 mg/m2 intravenously over 2 hours on day 1
~Leucovorin 400 mg/m2 intravenously over 2 hours. Can be administered concurrently with oxaliplatin using a Y-connector on day 1
~Immediately after completion of oxaliplatin and leucovorin, administer 5-fluorouracil (5-FU) 400 mg/m2 intravenously over 5 minutes
~Immediately after the 5-FU bolus, 5-FU 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
~Treatment is repeated every 2 weeks."
16492479|NCT03343275|Experimental|Experimental|"Dietary supplement : Lit-Control® pH Down
~Pharmaceutical form: capsules
~Administration : oral
~Dose: 3 capsules/day.
~• Sanitary product : Lit-Control® pH Meter
~In vitro diagnosis sanitary product
~Use:Urinary pH evaluation"
16492480|NCT03343275|Placebo Comparator|Placebo|"Placebo:
~Pharmaceutical form: capsules
~Administration : oral
~Dose: 3 capsules/day.
~• Sanitary product : Lit-Control® pH Meter
~In vitro diagnosis sanitary product
~Use:Urinary pH evaluation"
16492481|NCT03343262|Experimental|"ta-VNS yidan-pi"|"Device:ta-VNS & Electro-acupuncture(yidan-pi auricular acupoints):2 times per day,2 days per week for 12 weeks"
16492482|NCT03343262|Placebo Comparator|"ta-VNS jian"|"Device:ta-VNS & Electro-acupuncture(jian auricular acupoints):2 times per day,2 days per week for 12 weeks"
16492483|NCT03343249|Experimental|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.
~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
16492485|NCT03343223|Experimental|Intervention Group|"Public health personnel identify PrEP-eligible clients.
~PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.
~Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.
~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.
~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).
~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).
~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
16492486|NCT03343223|No Intervention|Control Group|"Public health personnel identify PrEP-eligible.
~Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.
~The client initiates contact with a PrEP provider in Iowa and schedules an appointment.
~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.
~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).
~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).
~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
16492487|NCT03343210|Experimental|cancer patient|cancer patient
16492488|NCT03343210|Active Comparator|no cancer patient|no cancer patient
16492489|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
16492490|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
16492491|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
16492492|NCT03343184|Active Comparator|SEE and incremental restoration|50 teeth will receive restorations using SEE Strategy and Incremental Restoration
16492493|NCT03343184|Experimental|SEE and bulk restoration|50 teeth will receive restorations using SEE Strategy and Bulk Fill Restoration
16492494|NCT03343184|Experimental|SET and incremental restoration|50 teeth will receive restorations using SET Strategy and Incremental Restoration
16492495|NCT03343184|Experimental|SET and bulk restoration|50 teeth will receive restorations using SET Strategy and Bulk Fill Restoration
16492496|NCT03343145|Experimental|Test Drug Group|Leucostim 5µg/kg/day
16492497|NCT03343145|Active Comparator|Reference Drug Group|Neupogen 5µg/kg/day
16492498|NCT03343132||Subacute SCI|
16492499|NCT03343132||Chronic SCI|
16492500|NCT03343132||Controls|
16492501|NCT03343119||Hospitalised patients|No intervention
16492502|NCT03343119||Healthy volunteers|No intervention
16492503|NCT03343119||Dog owners (healthy volunteers)|No intervention
16492504|NCT03343119||Veterinarians (healthy volunteers)|No intervention
16492505|NCT03343119||Pig farmers (healthy volunteers)|No intervention
16492506|NCT03343106|Experimental|ACT plus ERP|Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
16492557|NCT03342781|Active Comparator|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) > 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
16492560|NCT03342768|Other|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
16492507|NCT03343106|Experimental|ERP alone|ERP followed Kozak and Foa's treatment manual. Sessions 1 and 2 included information-gathering, psychoeducation about the cognitive-behavioral model of OCD and rationale for ERP, and introduction to self-monitoring of rituals. Session 3 was dedicated to developing the treatment plan (exposure hierarchy, response prevention plan). Sessions 4-16 included in-session prolonged and repeated gradual exposure therapy (in vivo and imaginal as needed), the assignment of daily exposure practices for between-sessions, and instructions to refrain from rituals (response prevention in session and between sessions), along with self monitoring of any rituals that were performed. Session 16 also addressed discontinuation and relapse prevention.
16492508|NCT03343093|Experimental|Intervention Evaluation Control Group|Surveys at 3 month intervals
16492509|NCT03343093|Experimental|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
16492510|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.
~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.
~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
16492511|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.
~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.
~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
16492512|NCT03343067|Experimental|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
16492513|NCT03343067|Experimental|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
16492514|NCT03343067|Experimental|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group
~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
16492515|NCT03343067|Experimental|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group
~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
16492516|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
16492517|NCT03343041|Active Comparator|low carbohydrate nutrition|"We will use a low-carbohydrate nutrition (LCN) formulated by the MICU registered dietitian and pharmacy staff, who routinely prepare enteral and parenteral nutrition which will provide:
~5% carb, 41% protein, 54% lipid."
16492518|NCT03343041|Active Comparator|standard enteral nutrition|"The standard enteral nutrition (SEN) and per cent contribution of carbohydrates used in the Yale MICU is as follows:
~Jevity 1.2 56% carb, 29.5% lipid, 18.5% protein Diabetisource 33% carb, 44% lipid, 20% protein Promote 55% carb, 25% lipid, 25% protein Vital AF 37% carb, 40% lipid, 25% protein Peptamin Intense 29% carb, 34% lipid, 37% protein Osmolite 1.5 54% carb, 29.5% lipid, 16.5% protein"
16492519|NCT03343028||Psychotherapy|The investigators will assess and acquire data on these Veterans across the course of the project prior to and after receiving Prolonged Exposure (PE) or Cognitive Processing Theory (CPT) treatment at VA Palo Alto (VAPAHCS) and the Albuquerque VA. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva at baseline on these Veterans and again 3 months after treatment to assess prediction and durability of the clinical and brain/behavioral metrics. All study assessments will take place at Stanford University/VAPAHCS. Subjects will be recruited through VAPAHCS and Albuquerque VA. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
16492520|NCT03343028||Healthy Controls|The investigators will assess and acquire data on these Veterans who do not have history of PTSD and have no history of any Axis I psychiatric disorder, are taking psychotropic medication, or use illicit drugs. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva once. All study assessments will take place at Stanford University. Subjects will be recruited through public flying, online ads and VAPAHCS. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
16492521|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
16492522|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
16492523|NCT03343002|Experimental|fentanyl at 10-15 min before end of surgery|
16492524|NCT03343002|Active Comparator|fentanyl at end of surgery|
16492558|NCT03342781|Active Comparator|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
16492525|NCT03342989|Experimental|Speed of Processing Training|Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
16492526|NCT03342989|Active Comparator|Internet-Based Contact Control|Training involves mentally stimulating activity and consists of three levels: (1) using a computer (e.g., mouse training, pull-down menus, selecting options), (2) internet search engine training, and (3) search engine proficiency tasks. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
16492527|NCT03342976|Active Comparator|Cases|"Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities.
~Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
16492528|NCT03342976|Placebo Comparator|Controls|"Pre-frail subjects will be followed according to best standard of care protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
16492529|NCT03342963|Experimental|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.
~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
16492530|NCT03342963|Experimental|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.
~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
16492531|NCT03342963|Experimental|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.
~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
16492532|NCT03342963|Experimental|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.
~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
16492536|NCT03342924|Experimental|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
16492537|NCT03342911|Experimental|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16492538|NCT03342898|Experimental|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
16492539|NCT03342898|Experimental|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
16492540|NCT03342898|Experimental|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
16492541|NCT03342885|Experimental|Intervention group|Participants enrolled into the intervention group receive specific sleep ergonomics guidance
16492542|NCT03342885|Active Comparator|Control group|Participants enrolled into the control group will receive general sleep ergonomics guidance
16492543|NCT03342872|Experimental|Core Training|
16492544|NCT03342872|Experimental|Core Training & Facilitation|
16492545|NCT03342872|No Intervention|Control|
16492546|NCT03342859|Experimental|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
16492547|NCT03342859|Active Comparator|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
16492548|NCT03342859|No Intervention|Control group|Patients undergoing surgery without any prior treatment, as control group
16492549|NCT03342846|Active Comparator|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
16492550|NCT03342846|Active Comparator|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
16492551|NCT03342833|Active Comparator|Blood flow restriction|
16492552|NCT03342833|Sham Comparator|Usual training|
16492553|NCT03342820|Experimental|Quadriceps muscle fatigue|Quadriceps muscle fatigue
16492554|NCT03342807|Experimental|Group Insulin|
16492555|NCT03342807|Experimental|Group Aphesis|
16492556|NCT03342794|Other|preexisting posterior capsule defects|congenital cataracts with a preexisting posterior capsule defect
16492559|NCT03342768|Experimental|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
16492561|NCT03342742|Experimental|Daily Caloric Restriction|The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.
16492562|NCT03342742|Experimental|Intermittent Fasting|Participants in the intermittent fasting group will be instructed to reduce energy intake to ~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~34% (similar to the daily caloric restriction group).
16492563|NCT03342729|Experimental|Intervention Group|Immediate exposure to the 10-week Aging Mastery Program (AMP)
16492564|NCT03342729|Placebo Comparator|Wait-list Group|Class to start 3 months after the Intervention Group
16492565|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
16492566|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
16492567|NCT03342703||Patients with Liver Fibrosis Measurement|Group1: Patients will undergo an Ultrasound to correlate fibrosis measurements obtained using standard-of-care MRI.
16492568|NCT03342703||Patients with Liver Steatosis Measurement|Group 2: Patients will undergo an Ultrasound to correlate steatosis measurements obtained using standard-of-care MRI.
16492569|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
16492570|NCT03342677|Other|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
16492571|NCT03342664|Experimental|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
16492572|NCT03342664|Active Comparator|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
16492573|NCT03342651|Other|Observational research|Vitamin D levels and respiratory complications; observational research.
16492574|NCT03342638|Experimental|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
16492575|NCT03342638|Experimental|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
16492576|NCT03342625|Experimental|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
16492577|NCT03342612|Experimental|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
16492578|NCT03342599|Experimental|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
16492579|NCT03342599|Placebo Comparator|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
16492581|NCT03342573|Experimental|Single Arm|Patients with a biopsy proven diagnosis of PRP
16492582|NCT03342560|Experimental|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
16492583|NCT03342547|Experimental|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
16492584|NCT03342534|Active Comparator|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
16492585|NCT03342534|Active Comparator|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
16492586|NCT03342534|Active Comparator|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
16492587|NCT03342534|Sham Comparator|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
16492588|NCT03342508|Experimental|Fetal Pillow Inflated (FPI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow. The obstetrician will not be aware to inflation of Fetal Pillow
~Cesarean delivery will then be performed
~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
16492589|NCT03342508|No Intervention|Fetal Pillow Not Inflated (FPNI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The Fetal Pillow will not be inflated.
~Cesarean delivery will then be performed. The obstetrician will continue to be able to use conventional methods for delivery of a second stage arrest including hand from below and reverse breech extraction.
~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
16492590|NCT03342495|Experimental|Patient Navigator Arm|"Patient Navigator (Social Worker) will assist youth adapt and attach to adult delivered healthcare for up to 24 months.
~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.
~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.
~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.
~Participants will be provided the opportunity to journal online about their experiences.
~Up to 100 participants will be provided the opportunity to be interviewed at baseline and end of study about their transition experience."
16492777|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
16492591|NCT03342495|Other|Usual Care Arm|"Youth will receive usual care from their pediatric clinics in preparation and transfer to adult care.
~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.
~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.
~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.
~Participants will be provided the opportunity to journal online about their experiences."
16492592|NCT03342482|Placebo Comparator|Placebo|5 g of placebo (sugar and salt) will be administered in veggie capsules
16492593|NCT03342482|Experimental|MSG|5 grams of MSG will be administered in veggie capsules
16492594|NCT03342469|Experimental|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
16492595|NCT03342469|Experimental|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
16492596|NCT03342469|Experimental|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
16492597|NCT03342469|Experimental|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
16492598|NCT03342456|Experimental|group 1|week1 to week2：Doxycycline Hyclate Enteric-Coated Capsules 0.1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily
16492599|NCT03342456|Active Comparator|group 2|"Amoxicillin Capsules 1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily.
~week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily"
16492600|NCT03342443|Experimental|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
16492601|NCT03342443|Placebo Comparator|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
16492602|NCT03342430||Early Dieting in Girls cohort|A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years
16492603|NCT03342417|Experimental|Neoadjuvant Breast Cancer|"Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy.
~Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab."
16492604|NCT03342417|Experimental|Platinum-resistant ovarian cancer|Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.
16492605|NCT03342417|Experimental|Advanced gastric cancer patients|"Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin.
~Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab."
16492606|NCT03342404|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
16492607|NCT03342404|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
16492608|NCT03342391|Other|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
16492609|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
16492610|NCT03342352|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
16492611|NCT03342352|Active Comparator|Arm B|EXTREME regimen.
16492612|NCT03342352|Experimental|Arm C|Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
16492709|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
16492811|NCT03340974|Experimental|Arm A: SBRT + Avasopasem (GC4419)|
16492613|NCT03342339|Other|patients with Parkinson's disease|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
~viewing of video : scale of differential emotions and Positive and Negative Affect Scale
~Test of Iowa Gambling Task"
16492614|NCT03342339|Other|witnesses|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
~viewing of video : scale of differential emotions and Positive and Negative Affect Scale
~Test of Iowa Gambling Task"
16492615|NCT03342326|Other|patient with Alzheimer's Disease|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
~Music Experience Questionnaire : questions about the past music training
~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
16492616|NCT03342326|Other|healthy volunteer|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
~Music Experience Questionnaire : questions about the past music training
~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.
~For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test"
16492617|NCT03342313|Experimental|healthy weight|BMI (kg/m2) ≥ 18.5 and < 23
16492618|NCT03342313|Experimental|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
16492619|NCT03342300|Experimental|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
16492620|NCT03342300|Placebo Comparator|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
16492621|NCT03342274|Experimental|Lifestyle Program Intervention|Participants receive usual care and group weight loss sessions adapted from the Diabetes Prevention Program delivered by Community Health Workers.
16492622|NCT03342274|Other|Wait list|Participants receive usual care and after 1 year receive the Lifestyle Program intervention
16492623|NCT03342261||HCV patients with mixed cryoglobulinemia|HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
16492624|NCT03342248|Experimental|access to the social network|This group is made up of carers who have access to the social network via a digital platform developed during step 1. This network will offer features from step 1 (sharing experiences on a forum, monitoring health status )
16492625|NCT03342248|No Intervention|no access to the network|"This group consists of caregivers who do not have access to the social network via a digital platform developed during step 1.
~Access to the social network will be offered to all carers at the end of the study, especially those assigned in the control group to limit their refusal to participate."
16492626|NCT03342235|Experimental|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
16492627|NCT03342235|Active Comparator|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
16492628|NCT03342222|Experimental|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
16492629|NCT03342222|Active Comparator|Biosure PK interference screw|Biosure PK interference screw from Smith & Nephew plc.
16492630|NCT03342209|Experimental|HFNC therapy|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
16492631|NCT03342196|Experimental|Thiotepa + Fludarabine + Melphalan + KGF|Melphalan 100 mg/m2 on day -8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days -6, -5, -4 and -3. Keratinocyte Growth Factor (KGF) 60mcg/kg IV on day -11, -10, and -9 and 0, +1, and +2.
16492632|NCT03342183|Experimental|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation). To be administered on a monthly basis from the baseline visit to the year 1 visit.
16492633|NCT03342183|Sham Comparator|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
16492634|NCT03342170||CIRRAL|alcoholic cirrhosis
16492635|NCT03342170||CIRVIR|Viral cirrhosis
16492636|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
16492637|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
16492640|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
16492710|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
16492641|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
16492642|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
16492643|NCT03342118|Experimental|Phloroglucin group|patients taken Phloroglucin(Flospan®)
16492644|NCT03342118|Placebo Comparator|Normal saline placebo group|patients taken normal saline placebo
16492645|NCT03342105|Experimental|Cettum (Electrical moxibustion)|The patients in this group will receive Cettum (Electrical moxibustion) treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
16492646|NCT03342105|Active Comparator|Acupuncture|The patients in this group will receive acupuncture treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
16492647|NCT03342092||Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation
16492648|NCT03342079|Experimental|Group 1|local anesthetic + placebo
16492649|NCT03342079|Experimental|Group 2|local anesthetic + nitrous oxide
16492650|NCT03342079|Placebo Comparator|Group 3|Placebo + nitrous oxide
16492651|NCT03342066||A|Cariogram
16492652|NCT03342066||B|CAMBRA
16492653|NCT03342053|Experimental|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
16492654|NCT03342053|Experimental|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
16492655|NCT03342040|Experimental|TAP block|Patients undergoing laparoscopic ventral hernia repair with TAP block with 0.2% ropivacaine under ultrasound guidance
16492656|NCT03342040|Active Comparator|No TAP block|Patients undergoing laparoscopic ventral hernia repair without TAP block
16492657|NCT03342027|Experimental|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
16492658|NCT03342027|Experimental|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
16492659|NCT03342027|Experimental|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
16492660|NCT03342027|Placebo Comparator|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
16492661|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
16492662|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
16492663|NCT03341988|Other|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
16492664|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
16492665|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
16492674|NCT03341949|Experimental|Patient with chronic kidney disease|Determination of the Cluster of Differentiation 146 (CD146)
16492812|NCT03340974|Placebo Comparator|Arm B: SBRT + Placebo|
16492675|NCT03341936|Experimental|Nivolumab+Lirilumab|"The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection.
~In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle
~In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle."
16492676|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
16492677|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
16492678|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
16492679|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
16492680|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
16492681|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
16492682|NCT03341897|Experimental|Surgical varicocelectomy|
16492683|NCT03341884|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
16492684|NCT03341884|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
16492685|NCT03341884|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
16492686|NCT03341884|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
16492687|NCT03341871||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.
16492688|NCT03341845|Experimental|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
16492689|NCT03341832|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
16492690|NCT03341832|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
16492691|NCT03341832|Placebo Comparator|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
16492692|NCT03341819|Active Comparator|Retained Urinary Catheter|
16492693|NCT03341819|Experimental|Non-retained Urinary Catheter|
16492694|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
16492695|NCT03341793|Experimental|Muscle secretion|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
16492696|NCT03341767|Experimental|Clofazimine|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
16492697|NCT03341767|Placebo Comparator|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
16492698|NCT03341767|Experimental|Clofazimine, no diarrhea|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
16492699|NCT03341754|Experimental|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.
~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
16492700|NCT03341754|Experimental|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.
~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
16492701|NCT03341754|Active Comparator|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
~Week 28 = Controlled Human Malaria Infection (CHMI)"
16492702|NCT03341741|Experimental|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
16492703|NCT03341741|Active Comparator|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
16492704|NCT03341728|Experimental|Intervention, then Control|Older adults will walk during exposure to optical flow perturbations
16492705|NCT03341728|Experimental|Control, then Intervention|Older adults will walk normally (without optical flow perturbations)
16492706|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
16492707|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
16492708|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
16492922|NCT03340194||Systemic sclerosis patients|
16492711|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
16492712|NCT03341676|Experimental|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
16492713|NCT03341676|Placebo Comparator|Placebo|8ml IV 0.9% w/v saline
16492714|NCT03341650|Experimental|High Pasta|Habitual pasta consumption equal or higher than 5 times/week.
16492715|NCT03341650|Experimental|Low Pasta|Habitual pasta consumption equal or lower than 3 times/week.
16492716|NCT03341637|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
16492717|NCT03341637|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
16492718|NCT03341624|Experimental|cataract surgery cataract extraction and intraocular implanta|
16492719|NCT03341611||Adults 55 and younger|
16492720|NCT03341611||Adults 55 and older|
16492721|NCT03341598|Active Comparator|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
16492722|NCT03341598|Experimental|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
16492723|NCT03341585|Experimental|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
16492724|NCT03341572|Experimental|high response group|patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
16492725|NCT03341572|Placebo Comparator|low response group|the change of CVP is less than 2.5cmH2O
16492726|NCT03341559||With Existing Diabetic Ulcers|Current DFU
16492727|NCT03341559||Diabetic Ulcers in remission|DFU in remission
16492728|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
16492729|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
16492730|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
16492731|NCT03341520|Experimental|interventional arm|Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
16492732|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a McIntosh laryngoscope will be performed.
16492733|NCT03341494|Experimental|Gefitinib 250mg qd thalidomide 200mg qn|
16492734|NCT03341494|Active Comparator|Gefitinib 250mg qd|
16492735|NCT03341481|Experimental|Femaltiker|7.7 g of Femaltiker twice a day for 14 days of the trial.
16492736|NCT03341481|Placebo Comparator|placebo|7.7 g placebo 14 days of the trial.
16492737|NCT03341468|Experimental|Urethral catheter immobilization|Subjects randomized to the intervention group will undergo radical prostatectomy with placement of the urethral catheter per the standard of care. The urethral catheter immobilization device will be applied in the operating room prior to the patient being transported to the recovery room. Subjects will be informed on safe use of the device and must demonstrate competency in removing and replacing the device prior to discharge. Subjects will also be given an elastic leg strap, which they may use concurrently with the device. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care, at which the device will no longer be needed.
16492738|NCT03341468|No Intervention|No urethral catheter immobilization|Subjects randomized to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care.
16492739|NCT03341455|Other|Intervention preschools|"Capacity building to support families affected by IPV & substance misuse will be provided to the intervention preschools.
~Specifically, capacity building, training and support will be provided to
~selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.
~selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.
~intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
16492776|NCT03341234|Active Comparator|Group Control|Ultrasound guided sham block with 2 ml saline subcutaneously
16492740|NCT03341455|No Intervention|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
16492741|NCT03341442|Experimental|No hip precautions|No hip precautions practiced after THA surgery
16492742|NCT03341442|No Intervention|Hip precautions|Hip precautions practiced per standard of care after THA surgery
16492743|NCT03341429|Experimental|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg
~Study dosing of liraglutide:
~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily
~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
16492744|NCT03341429|Placebo Comparator|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.
~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
16492745|NCT03341416|Experimental|Device - deep brain stimulation ON|"Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.
~The stimulation will remained turned ON during 3 months - phase 1 - blinded and continuous during the open-label phase"
16492746|NCT03341416|Sham Comparator|Device - deep brain stimulation Sham|"Sham stimulation: device (deep brain stimulation of the dentate nucleus in cerebellum). Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.
~During the sham stimulation the intervention will remained turned OFF during 3 months"
16492747|NCT03341403|Active Comparator|Synbiotic group|"severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive Probiotical ® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
16492748|NCT03341403|Placebo Comparator|Placebo group|severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
16492749|NCT03341390|Active Comparator|Aspirin|325 mg tablet, once daily for 5 days (Day -5 to -1)
16492750|NCT03341390|Experimental|BMS-986177 plus aspirin|200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
16492751|NCT03341390|Placebo Comparator|Placebo plus aspirin|200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)
16492752|NCT03341377||Lung cancer surgical patients|Patient-reported symptom assessments in patients undergoing lung cancer surgery.
16492753|NCT03341364|Experimental|ACT group treatment|Participants receiving the ACT-based group therapy.
16492754|NCT03341364|Active Comparator|ACT individual|Participants receiving individual ACT-based therapy.
16492755|NCT03341351|Active Comparator|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
16492756|NCT03341351|Active Comparator|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
16492757|NCT03341325|Experimental|animal-assisted intervention|the intervention is a real animal is presented in different forms to the participants
16492758|NCT03341325|Active Comparator|control intervention|the control intervention is a stuffed toy animal is presented in different forms to the participants
16492759|NCT03341312|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
16492760|NCT03341312|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
16492761|NCT03341312|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
16492762|NCT03341312|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
16492763|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
16492764|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
16492765|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
16492766|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
16492767|NCT03341286|Experimental|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
16492768|NCT03341286|Placebo Comparator|Placebo|Placebo orally, to be taken three times a day
16492769|NCT03341273|Experimental|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
16492770|NCT03341273|Placebo Comparator|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
16492771|NCT03341260|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg tablet to be administered one hour before treatment.
16492772|NCT03341260|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
16492773|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
16492774|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
16492775|NCT03341234|Active Comparator|Group SPB|Ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
16492778|NCT03341195|Active Comparator|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
16492779|NCT03341195|Active Comparator|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
16492780|NCT03341195|Active Comparator|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
16492781|NCT03341195|Active Comparator|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
16492782|NCT03341195|No Intervention|5. Control Arm|One time counseling at the baseline survey.
16492783|NCT03341182|Active Comparator|normal method group (group A)|A mirror is not used in tunnel view technique (conventional manner)
16492784|NCT03341182|Experimental|mirror use group (group B)|A mirror is used in tunnel view technique
16492785|NCT03341169|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
16492786|NCT03341169|Placebo Comparator|Placebo|
16492787|NCT03341156|Experimental|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
16492788|NCT03341156|Active Comparator|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
16492789|NCT03341143|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy. FMT will be performed on Cycle 1 Day 1 and will take 15 to 30 minutes.
~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT), and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
16492790|NCT03341130|Experimental|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
16492791|NCT03341130|Experimental|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
16492792|NCT03341130|No Intervention|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
16492793|NCT03341117|Active Comparator|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
16492794|NCT03341117|Placebo Comparator|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),
~1 capsule 300 mg before each meal for a period of 90 days."
16492795|NCT03341091|Experimental|Tai-chi group|"16-week 10-step simplified Tai-chi programme.
~Two 1-hour sessions of centre-based Tai-chi training and a minimum of three 30-minute Tai-chi sessions at home on a weekly basis."
16492796|NCT03341091|No Intervention|Control group|"Group recreational activities and continue their usual lifestyles and levels of physical activity as usual for 16 weeks.
~Two 1-hour sessions of group recreational activities on a weekly basis."
16492797|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
16492798|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
16492799|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
16492800|NCT03341065|Experimental|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
16492801|NCT03341065|Experimental|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
16492802|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
16492803|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
16492804|NCT03341026|Other|Induction day 1, 4, 7, 14|Patient will come to the hospital on day 1, 4, 7 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
16492805|NCT03341026|Other|Induction day 1, 7, 10, 14|Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
16492806|NCT03341013|Experimental|Sequence 1|formulation 2 on Day 1 and formulation 3 on Day 10
16492807|NCT03341013|Experimental|Sequence 2|formulation 3 on Day 1 and formulation 2 on Day 10
16492808|NCT03341000|Experimental|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
16492809|NCT03340987|Experimental|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
16492810|NCT03340987|Active Comparator|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
16492813|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
16492814|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
16492815|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
16492816|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
16492817|NCT03340948|Experimental|MBSR participation|Participation in the 8 week Mindfulness Based Stress Reduction (MBSR) course.
16492818|NCT03340935|Experimental|Fasting mimicking diet|Fasting mimicking diet (FMD)
16492819|NCT03340922|Experimental|Automatic annotation of LAT (WF-method)|The annotation of LAT in each acquired point will be automatically performed using the LAT annotation tool integrated into CARTO navigation system, called Wavefront (WF). Automatic annotation of LAT performed by the CARTO system uses the maximum negative slope of the distal U-EGM to set the timing of the mapping annotation, displayed on the corresponding B-EGM. Additionally, the automatic annotation of LAT will be aided by an ECG recognition pattern algorithm (included in the last version of CARTO), which is intended to avoid wrong annotation of ventricular complexes other than the clinical PVC.
16492820|NCT03340922|Active Comparator|Manual annotation of LAT (M-method)|A detailed electrocardiogram (ECG)-gated activation map of the chamber of interest will be acquired using the CARTO navigation system. An experienced electrophysiologist will perform the annotation of LAT in each acquired point. The LAT will be measured from the onset of B-EGM (earliest positive or negative deflection) of the distal dipole of the mapping catheter to the defined reference. The use of the U-EGM as a guidance to identify the real onset of B-EGM will be decided under electrophysiologist criteria.
16492821|NCT03340909|Experimental|Prednisolone|Prednisolone tablets 5 mg
16492822|NCT03340909|Placebo Comparator|Placebo|Placebo tablets with identical appearance to the experimental drug.
16492823|NCT03340896|Active Comparator|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy
~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
16492824|NCT03340896|Experimental|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy
~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
16492825|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
16492826|NCT03340870|Experimental|Sonazoid™ 0.12 microliter (µl)|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.
16492827|NCT03340870|Experimental|Sonazoid™ 0.60 µl|Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.
16492828|NCT03340857|Experimental|Intelligent electric bicycle (VELIS) sessions|Intelligent electric bicycle (VELIS) sessions with an instructor, twice a week for 6 weeks
16492831|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
16492832|NCT03340818|Experimental|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
16492833|NCT03340818|Sham Comparator|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
16492834|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
16492835|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
16492836|NCT03340792|Experimental|Exoskeleton robot ambulation training|Ambulation training utilizing an exoskeleton robot
16492837|NCT03340779|Experimental|Norepinephrine alone|Administration of norepinephrine with increasing dose
16492838|NCT03340779|Active Comparator|Norepinephrine plus Dobutamine|Administration of norepinephrine and dobutamine
16492839|NCT03340766|Experimental|COHORT Ia|Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 15).
16492840|NCT03340766|Experimental|COHORT IIa|Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 19).
16492841|NCT03340766|Experimental|COHORT IIIa|Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 19).
16492842|NCT03340766|Experimental|Expansion Cohort|This cohort will test the Maximum Tolerated Dose of Blinatumomab in combination with Pembrolizumab identified using cohort design from cohorts Ia, IIa, and IIIa tested in Part 1 of the study.
16492843|NCT03340753|Active Comparator|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) in capsule formulation in a 2-period crossover design with a 2-week washout/follow-up period
16492844|NCT03340753|Experimental|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) in tablet formulation in a 2-period crossover design with a 2-week washout/follow-up period
16492845|NCT03340740|Experimental|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
16492846|NCT03340740|Placebo Comparator|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
16492847|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
16492848|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
16492849|NCT03340714|Experimental|Device Feasibility (ADAMM)|Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
16492850|NCT03340701|Other|Vaginal Progesterone|micronized progesterone vaginal suppository 200mg
16492851|NCT03340688|Active Comparator|Cervical cerclage + vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤15mm and Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
16492852|NCT03340688|No Intervention|Vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
16492853|NCT03340675|Experimental|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
16492854|NCT03340675|Experimental|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
16492855|NCT03340675|Placebo Comparator|Placebos|Matching Placebo
16492856|NCT03340662|Experimental|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
16492857|NCT03340662|Experimental|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
16492858|NCT03340662|Experimental|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
16492859|NCT03340662|Experimental|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
16492860|NCT03340623||Mammary reconstruction by DIEP with venous coupler|
16492861|NCT03340623||Mammary reconstruction by DIEP without venous coupler|
16492862|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
16492863|NCT03340597|Experimental|A1; F901318 (10 days)|F901318 : 10 days dosing orally
16492864|NCT03340597|Experimental|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
16492865|NCT03340597|Experimental|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
16492866|NCT03340597|Experimental|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
16492867|NCT03340584|Experimental|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
16492868|NCT03340584|Other|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
16492869|NCT03340571||Alzheimer's Patients|
16492870|NCT03340571||Healthy Volunteers|
16492871|NCT03340558|Experimental|Monotherapy Cohort|The first 10 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No study treatment is administered while subjects are healing after surgery.
16492872|NCT03340558|Experimental|Combination Cohort|The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
16492873|NCT03340545|Other|Healthy Individuals|Healthy individuals will be imaged for comparison purposes
16492874|NCT03340545|Other|Disc Herniation|Subjects diagnosed with Intervertebral Disc Herniation will be imaged to evaluate sensitivity of the proposed method.
16492875|NCT03340532|Placebo Comparator|Sleep hygiene video|Participants will watch a sleep hygiene video
16492876|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
16492877|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
16492878|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
16492879|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
16492883|NCT03340493|Active Comparator|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
16492884|NCT03340493|Experimental|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over ~10 seconds).
16492885|NCT03340480|Experimental|NVP-1402-1|NVP-1402 was administered once a day for 24 hours
16492886|NCT03340480|Experimental|NVP-1402-2|NVP-1402 was administered once a day for 24 hours
16492887|NCT03340467|Experimental|CGM patch|Patient receives four models of CGM patches. Adhesion sites are randomly allocated (1 on each upper arm, 2 on the abdomen).
16492888|NCT03340454|Active Comparator|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
16492889|NCT03340454|Active Comparator|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
16492890|NCT03340428|Experimental|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
16492891|NCT03340428|No Intervention|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
16492892|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
16492893|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
16492894|NCT03340402|Experimental|Accelerated Partial Breast Irradiation|"Accelerated partial breast irradiation using proton beam scanning will consist of;
~5 daily treatments using custom prone patient immobilization, contrast-enhanced CT planning, and daily image guidance
~Radiation therapy may be delivered with photons if proton treatments cannot be delivered
~Dose will be prescribed such that the gross tumor (GTV) receives the prescription dose per institutional policy and standard of care
~Daily target localization will also be confirmed using AlignRTTM"
16492895|NCT03340389|Experimental|cataract surgery|cataract extraction and intraocular implantation
16492896|NCT03340376|Experimental|atezolizumab monotherapy|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease
16492897|NCT03340376|Experimental|atezolizumab combined with doxorubicin|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
16492898|NCT03340376|Active Comparator|doxorubicin monotherapy|Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
16492899|NCT03340363|Experimental|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
16492900|NCT03340363|Experimental|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
16492901|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
16492902|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.
~One week later, after a washout period, the fatigue will be measured with this type of current."
16492903|NCT03340337|Experimental|Aussie Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.
~One week later, after a washout period, the fatigue will be measured with this type of current."
16492904|NCT03340337|Experimental|RBS Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.
~One week later, after a washout period, the fatigue will be measured with this type of current."
16492905|NCT03340324|Experimental|One arm open label V-Endo recepients|This is single arm open label trial wherein active drug is V-Endo
16492906|NCT03340311|Other|Pre-Post|"(Phase one): Each participant will receive usual care (four weeks). Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.
~(Phase two): Each participant will receive a BG5 wireless glucose meter with supplies enough for four weeks. Each participant will download the iGluco application to their smartphone. Education will be given on the monitor and iGluco application use. Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.
~At the conclusion of phase 2, the participants will be asked to complete a satisfaction survey about the care received and their preference of monitors."
16492907|NCT03340298|Experimental|grain|25 gram fiber from whole grain products and 10 gram fiber from fruits and vegetables
16492908|NCT03340298|Experimental|fruits and vegetables|25 gram fiber from fruits and vegetables as main supplier and the remaining 10 grams from whole grain sources
16492909|NCT03340298|Experimental|grain-fruits and vegetables|17.5 gram fiber from whole grain and 17.5 gram fiber from fruits and vegetables
16492910|NCT03340285|Experimental|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
16492911|NCT03340285|Placebo Comparator|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
16492912|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
16492913|NCT03340246|Active Comparator|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
16492914|NCT03340246|Experimental|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
16492915|NCT03340233|Experimental|Group 1|Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
16492916|NCT03340233|Experimental|Group 2|Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
16492917|NCT03340233|Experimental|Group 3|Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
16492918|NCT03340220|Experimental|XPF-008|"Single ascending dose: Single oral dose for each cohort
~Multiple ascending dose: 7 days of single oral dose daily for each cohort"
16492919|NCT03340220|Placebo Comparator|Placebo - Microcrystalline cellulose|"Single Ascending Dose: Single oral dose for each cohort
~Multiple Ascending Dose: 7 days of single oral dose daily for each cohort"
16492920|NCT03340207|Experimental|Pneumaglide|After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
16492921|NCT03340207|No Intervention|non-pneumaglide|The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.
16492923|NCT03340181|Experimental|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
16492924|NCT03340181|Sham Comparator|control|patient in control group using a blood pressure cuff on an upper limb without inflating
16492925|NCT03340168|Experimental|Bisphenol-S kinetics - oral exposure|Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.
16492926|NCT03340168|Experimental|Bisphenol-S kinetics - dermal exposure|volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).
16492927|NCT03340142|Experimental|Single Arm|All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.
16492928|NCT03340129|Active Comparator|Nivolumab + ipilimumab|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.
~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
16492929|NCT03340129|Active Comparator|Nivolumab + ipilimumab,concurrent SRS|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.
~Stereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.
~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
16492930|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
16492931|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
16492932|NCT03340103|Experimental|Experimental group A|Group A (18 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
16492933|NCT03340103|Placebo Comparator|Control group B|Group B (18 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
16492934|NCT03340090|Experimental|Intervention|First group of patients will undergo standard CABG procedure in CPB. In addition, two pieces of Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of left internal mammary artery (LIMA) harvesting and second piece of Hemopatch will be placed beneath the sternum.
16492935|NCT03340090|No Intervention|Control|Second group of patients will undergo standard CABG procedure in CPB only.
16492936|NCT03340077|Experimental|MOR Toolkit|Medicines Optimisation Review consultation + My clinical companion (patient questionnaire about their medications)
16492937|NCT03340077|Active Comparator|Standard of Care|Current standard of care for patients with HIV receiving antiretroviral therapy, which consists of a phamacists review of ART prescriptions.
16492938|NCT03340064|Experimental|Levetiracetam|"Subjects aged 1 month to <6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.
~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months or by LEV 20 mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0 mg/kg/day."
16492939|NCT03340051|Active Comparator|EFT group|Episodic Future Thinking (EFT) is the intervention in this arm. EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
16492940|NCT03340051|Placebo Comparator|ERT group|Episodic Recent Thinking (ERT) is the intervention in this arm. ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
16492941|NCT03340038|Active Comparator|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
16492942|NCT03340038|No Intervention|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
16492943|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
16492944|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
16492983|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
16492945|NCT03340012|Experimental|GTR + radiation-sterilize allogenic bone graft (TEST)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of radiation-sterilized allogenic bone graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
16492946|NCT03340012|Active Comparator|GTR + xenogenic graft (CONTROL)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of xenogenic graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
16492947|NCT03339999|Placebo Comparator|Placebo|Placebo-matching AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
16492948|NCT03339999|Experimental|AGN-242428 Higher Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
16492949|NCT03339999|Experimental|AGN-242428 Medium Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
16492950|NCT03339999|Experimental|AGN-242428 Lower Dose|AGN-242428 capsule and placebo-matching AGN-242428 capsule, oral administration, once-daily for up to 12 weeks.
16492951|NCT03339986|Experimental|Reduction|Participants will be instructed to reduce all high energy dense snacks that they serve to thier children by 50%
16492952|NCT03339986|Experimental|Replacement|Participants will be instructed to replace all high energy dense snacks with fresh fruit and vegetables
16492953|NCT03339973|Experimental|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)
16492954|NCT03339973|Placebo Comparator|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
16492955|NCT03339960|Active Comparator|Robotic camera controlled|
16492956|NCT03339960|Active Comparator|Human camera controlled|
16492957|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
16492958|NCT03339921|Experimental|Botulinum toxin injections|Botulinum toxin injections for chronic compartment syndrome
16492959|NCT03339921|Active Comparator|surgical fasciotomy|surgical fasciotomy for chronic compartment syndrome
16492960|NCT03339908|Experimental|patients with Multiple Sclerosis|Patients will benefit from unilateral thalamotomy by Gamma Knife radiosurgery
16492961|NCT03339895|Experimental|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
16492962|NCT03339895|Experimental|traditional-guided|4-8 ml/kg/h infusion during surgery
16492963|NCT03339882|Experimental|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
16492964|NCT03339882|No Intervention|Control|No intervention during LHRH-a treatment in breast cancer
16492965|NCT03339869|Experimental|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
16492966|NCT03339856|Experimental|Treatment arm|Patients received selective retina therapy
16492967|NCT03339843|Experimental|Abemaciclib|"This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage.
~Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment.
~A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1."
16492968|NCT03339817|Other|Patients with severe MS|polysomnography and functional pulmonary testings.
16492969|NCT03339804|Experimental|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
16492970|NCT03339791|Active Comparator|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
16492971|NCT03339791|Active Comparator|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
16492972|NCT03339765|Experimental|Serious game intervention|Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
16492973|NCT03339765|No Intervention|Enhanced care as usual|If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
16492974|NCT03339752|Active Comparator|Treatment A|Rosuvastatin Day 1
16492975|NCT03339752|Experimental|Treatment B1|ACT-541468 Day 5 to Day 7
16492976|NCT03339752|Other|Treatment B2|Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
16492977|NCT03339739|Experimental|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
16492978|NCT03339739|Active Comparator|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
16492979|NCT03339739|Placebo Comparator|Counseling Group|Group of participants which receive education brochure and no further interventions.
16492980|NCT03339726|Experimental|New Formulation Phenylephrine HCl|
16492981|NCT03339726|Active Comparator|Marketed Phenylephrine HCl|
16492982|NCT03339726|Placebo Comparator|Placebo|
16492984|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
16492985|NCT03339700|Experimental|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY 2) conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then patients will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.
16492986|NCT03339687|Experimental|Induction of Open Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
16492987|NCT03339687|Experimental|Induction of a Closed Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
16492988|NCT03339674|Experimental|Intervention|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress: Psychological group intervention with 3 sessions of 60 min (Odenwald & Semrau, 2012). Contains psychoeducation on alcohol drinking related to stress and PTSD.
16492989|NCT03339674|Active Comparator|Control|Cognitive Training: Psychological group intervention with 3 sessions of 60 min. The content is paper-and-pencil based cognitive training of memory and attention functions.
16492990|NCT03339661|Experimental|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
16492991|NCT03339661|Experimental|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
16492992|NCT03339661|Experimental|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
16492993|NCT03339648|Experimental|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:
~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:
~E-Content Clinics- Content Clinics are offered online using digital video technology.
~Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.
~Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
16492994|NCT03339648|Active Comparator|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
16492995|NCT03339635|Experimental|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
16492996|NCT03339635|Placebo Comparator|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
16492997|NCT03339622|Experimental|smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
16492998|NCT03339622|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
16492999|NCT03339609||Immediate uroflow/EMG testing|Participants performed two direct repetitions of uroflowmetry in combination with EMG.
16493000|NCT03339609||uroflow measurement beforehand|Participants performed a preceding measurement of isolated uroflowmetry, followed by two randomized measurements of either isolated uroflowmetry or uroflowmetry with EMG.
16493001|NCT03339596|Experimental|Erythropoietin|4 intravenous infusions of recombinant human erythropoietin (EPO)
16493002|NCT03339596|Placebo Comparator|Saline|4 intravenous infusions of saline (1 ml NaCl)
16493003|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
16493004|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
16493005|NCT03339557|Active Comparator|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
16493006|NCT03339557|Active Comparator|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
16493007|NCT03339557|Active Comparator|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
16493008|NCT03339544|Experimental|Celebrex premedication|Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
16493009|NCT03339544|Placebo Comparator|Placebo tablets|placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
16493010|NCT03339531|Experimental|2D radiotherapy|Patients with prostate cancer were treated with 2D-radiotherapy
16493011|NCT03339518|Experimental|BRIM3 Educational intervention|Individuals will receive a booklet and counseling about risk.
16493012|NCT03339518|Other|Wait list Control|At the completion of the study, individuals in the wait list condition will receive a booklet.
16493013|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
16493014|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
16493015|NCT03339492|Active Comparator|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
16493016|NCT03339492|Sham Comparator|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
16493017|NCT03339479|Experimental|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
16493018|NCT03339479|Placebo Comparator|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
16493019|NCT03339479|Other|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
16493020|NCT03339453|Experimental|Nasal Glucagon|Single dose of Nasal Glucagon.
16493021|NCT03339453|Active Comparator|Intramuscular Glucagon|Single intramuscular (IM) dose of Glucagon.
16493022|NCT03339440|Experimental|Intervention Group|Patients in this group will be receiving the Hearts and Parks intervention.
16493023|NCT03339440|No Intervention|Control Group|Patients in this group will continue receiving standard of care.
16493024|NCT03339427|Active Comparator|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
16493025|NCT03339427|Other|control|A total of 150 subjects were recruited in the control group.
16493026|NCT03339401|Experimental|Brincidofovir|"Brincidofovir (BCV) for the treatment of adenovirs (AdV) infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
~Brincidofovir (BCV) treatment began no later than 100 days post-transplant and was to continue for a maximum of 16 weeks. Brincidofovir (BCV) was discontinued once AdV viremia was confirmed undetectable.
~Subjects who did NOT receive concurrent cyclosporine on Day 1:
~If ≥48kg body weight, one 100mg oral tablet BIW (or 10mL of 10mg/mL oral suspension if unable to take tablets).
~If <48kg body weight, 2mg/kg oral volume of 10mg/mL oral suspension BIW.
~Subjects who received cyclosporine on Day 1 (or initiated cyclosporine at any time):
~1.4mg/kg (maximum of 70mg) oral volume of 10mg/mL oral suspension BIW.
~2mg/kg (maximum of 100mg) oral volume of 10mg/mL oral suspension BIW if discontinued cyclosporine."
16493027|NCT03339401|Other|Standard of Care|"Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
~Management of these subjects was prescribed by the investigator as being in the best interests of the subject and may have included a watch-and-wait approach, with or without decreased immunosuppression (ergo, no treatment), or treatment administration with other available antivirals, most commonly cidofovir intravenously.
~Decisions regarding SoC, including administration of therapy, dose and regimen of therapy, modification of immunosuppression, and monitoring was the responsibility of the clinical team caring for the subject, according to institutional guidelines, local practices, and applicable guidelines for the management of AdV infection."
16493028|NCT03339375||control|Monitoring arterial pressure, central venous pressure and pulse pressure variation
16493029|NCT03339375||esophagela Doppler|Monitoring arterial pressure, central venous pressure Insertion of esophageal Doppler probe to patient Monitoring stroke volume, cardiac output, corrected flow time from esophageal Doppler Use stroke volume optimization goal directed therapy protocol
16493030|NCT03339362|Active Comparator|Active Procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.
~4 X-ray guided intra-articular facet-joint injections via a spinal needle at 2 bilateral lumbar levels, using 0.5ml 0.5% bupivacaine + 20mg methylprednisolone per joint"
16493031|NCT03339362|Sham Comparator|Sham procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.
~4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml normal saline per injection"
16493032|NCT03339349|Experimental|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
16493033|NCT03339336|Experimental|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
16493034|NCT03339336|Experimental|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
16493035|NCT03339336|Placebo Comparator|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
16493036|NCT03339323|No Intervention|Control|Standard rehabilitation procedure
16493037|NCT03339323|Experimental|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
16493038|NCT03339310|Experimental|Optimizer Smart System with 2-leads|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
16493039|NCT03339297|Experimental|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
16493040|NCT03339297|Active Comparator|Standard of Care|Standard of Care Immunoprophylaxis Alone
16493041|NCT03339284|Active Comparator|QLB with dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and dexamethasone 5 mg/ml 0,4 ml
16493042|NCT03339284|Active Comparator|QLB without dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and isotonic natriumchloride solution (NaCl 0,9%) 0,4 ml
16493043|NCT03339284|Placebo Comparator|Placebo|Single sided US-guided QLB using isotonic natriumchloride solution (NaCl 0,9%) 20,4 ml
16493044|NCT03339271|Active Comparator|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
16493045|NCT03339271|Active Comparator|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
16493046|NCT03339258|Experimental|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
16493047|NCT03339258|Placebo Comparator|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
16493048|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
16493049|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
16493050|NCT03339232|No Intervention|Usual Care|Participants will receive standardized information about a healthy diet, including the potential benefit of small, frequent meals and nighttime snacking . In addition, the treating hepatologist will counsel participants on the benefits of increased physical activity. These recommendations will be provided at the beginning of the study. The usual care arm reflects current clinical practice. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
16493051|NCT03339232|Other|BCAA Supplement|BCAA powder (Bulk Supplements®) will be provided as the powder was found to be easier to swallow. Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio. BCAA will be provided by the study investigators and half will be provided at baseline study visit and the second half at the week 6 visit. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
16493052|NCT03339232|Other|BCAA supplement plus supervised physical activity|BCAA supplement will be as described for group 2, above. Study coordinators will supervise the physical activity program for study participants at the Loyola Fitness Center. Participants will attend the fitness center one hour each week; the fitness session will consist of low-impact aerobic physical activity, beginning with walking on the indoor track and possibly building to a recumbent exercise bicycle and light resistance training. Participants will be given a list of exercises to perform at home at least two times during the week with a goal of >90 minutes of physical activity per week. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity which they will return during the weekly fitness center sessions. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study.
16493053|NCT03339219|Experimental|Cabozantinib 60 mg|Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.
16493054|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
16493055|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
16493056|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
16493057|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
16493121|NCT03338673|Experimental|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
16493058|NCT03339167|Experimental|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.
~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
16493059|NCT03339154|Experimental|Methionine bioavailability in chickpeas|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).
~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or chickpeas with or without rice, which will be provided by the investigators"
16493066|NCT03339115|Experimental|Cardiovalve Transfemoral Mitral Valve|Mitral replacement valve delivered through a transfemoral access and transseptal approach
16493067|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
16493068|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
16493069|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
16493070|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
16493071|NCT03339076|Other|For a single-arm trial|"Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 Mini Catheter
~Males > 50 years of age
~Signed subject informed consent
~Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter
~Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.
~Exclusion Criteria
~Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)
~Gross hematuria
~Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction)."
16493072|NCT03339050|Experimental|Health for Hearts United|Health for Hearts United (HHU) is a 18-month church-based intervention to reduce CVD risk in mid-life and older African Americans.
16493073|NCT03339037|Active Comparator|Hyperbaric oxygen therapy|"60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour.
~1 meter per minute compression and decompression."
16493074|NCT03339037|Sham Comparator|Normobaric air SHAM|"60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour.
~1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment"
16493075|NCT03339024|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.
~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
16493076|NCT03339024|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.
~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
16493077|NCT03339011|Experimental|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.
~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
16493078|NCT03339011|No Intervention|No intervention|No attention from the study
16493079|NCT03338998|Experimental|BAF312|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
16493080|NCT03338998|Placebo Comparator|Placebo|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
16493081|NCT03338985|Experimental|"Group cases patients"|patients with endometrial hyperplasia or endometrial cancers
16493082|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells)|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).
16493083|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
16493084|NCT03338946||CIED subjects|CIED interrogation
16493085|NCT03338933||Control Group|No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
16493086|NCT03338933||Nicotine Group|Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance
16493087|NCT03338933||Nicotine and Alcohol Group|DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling.
16493088|NCT03338933||Alcohol Group|DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
16493089|NCT03338920|Experimental|Sumatriptan nasal powder|Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
16493090|NCT03338920|Placebo Comparator|Placebo|Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.
16493091|NCT03338907|Experimental|Oxycarbon (5% CO2 + 95% O2)|Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.
16493092|NCT03338907|Placebo Comparator|Control (95% O2)|"Same procedure as arm active comparator"
16493093|NCT03338894|Other|Yoga group|Each subject will serve as their own control
16493094|NCT03338881|Experimental|[14C]-TAK-659 100 mg|[14C]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
16493095|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
16493096|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
16493097|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.
~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
16493098|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.
~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
16493099|NCT03338842|Experimental|Distractor and Lower limb VR|The training sessions consist of Phase 1 (Distractor VR) in which patients will explore VR environments and Phase 2 (Lower limb VR) in which they will play games using their VR lower-limbs.
16493100|NCT03338829|No Intervention|Control|The control arm will received compensation at time of enrollment for agreeing to participate.
16493101|NCT03338829|Experimental|Positive Incentive|The positive incentive arm will receive compensation per prescribed test, payable every month based on testing adherence.
16493102|NCT03338829|Experimental|Loss Aversion|"The loss aversion arm will have compensation deposited into a University of Iowa Women's Health account. The participant will then lose compensation depending on actual adherence to recommended testing"
16493103|NCT03338816|Experimental|Givosiran/Givosiran|Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
16493104|NCT03338816|Placebo Comparator|Placebo/Givosiran|Matching placebo (normal saline [0.9% NaCl]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.
16493105|NCT03338803||Patients with a written prescription for linagliptin|
16493106|NCT03338790|Experimental|nivolumab + rucaparib|Specified dose on specified days
16493107|NCT03338790|Experimental|nivolumab + docetaxel + prednisone|Specified dose on specified days
16493108|NCT03338790|Experimental|nivolumab + enzalutamide|Specified dose on specified days
16493109|NCT03338777|Experimental|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
16493110|NCT03338764|Experimental|Experimental (SM-1)|Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
16493111|NCT03338764|Placebo Comparator|Placebo|Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
16493112|NCT03338751|Active Comparator|Hearing Assistance Device (HAD) First|Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.
16493113|NCT03338751|Active Comparator|No Hearing Assistance Device (HAD) First|Sham hearing aid device
16493114|NCT03338738|Experimental|Patients with ESBL, antibiotic pressure|Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.
16493115|NCT03338725|Active Comparator|Patients without intervention|Patients without follow-up by clinical pharmacy model
16493116|NCT03338725|Experimental|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
16493117|NCT03338699|Experimental|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
16493118|NCT03338699|Active Comparator|Mogen clamp|Mogen clamp circumcision.
16493119|NCT03338686|Active Comparator|Free Gingival Graft|Free Gingival Graft (FGG)
16493120|NCT03338686|Experimental|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
16493189|NCT03338179|Experimental|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
16493122|NCT03338673|Experimental|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
16493123|NCT03338660|Placebo Comparator|Control (Placebo)|Subjects will receive infusion of placebo (saline).
16493124|NCT03338660|Active Comparator|Platelet storage routine|Subjects will receive infusion of platelets stored by routine method.
16493125|NCT03338660|Experimental|Platelet storage experimental|Subjects will receive infusion of platelets stored by a novel methodology.
16493126|NCT03338647|Active Comparator|TACE|Transarterial chemoembolization with drug eluted beads or doxorubicin/lipoidol
16493127|NCT03338647|Experimental|SBRT|Stereotactic radiation therapy with risk adapted dose prescription
16493128|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
16493129|NCT03338621|Experimental|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
16493130|NCT03338621|Active Comparator|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
16493131|NCT03338621|Experimental|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
16493132|NCT03338608|Experimental|Vertical Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the vertical platysma incision.
16493133|NCT03338608|Experimental|Transverse Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the transverse platysma incision.
16493134|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
16493135|NCT03338569|Active Comparator|Intervention|6000 mg per day Vitamin C supplement
16493136|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
16493137|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
16493138|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
16493139|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
16493140|NCT03338543|Experimental|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
16493141|NCT03338543|Experimental|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
16493142|NCT03338543|No Intervention|Control|Conventional analgesic medication is offered.
16493143|NCT03338530|Experimental|Comprehensive School-Based Intervention|Children with HFASD assigned to the CSBI received social skills groups, computer instruction in emotion recognition, therapeutic activities, and a behavioral reinforcement system (individual daily note) during the school year and their parents participated in monthly parent training. School staff received training prior to the school year and demonstrated fidelity with the protocol. Fidelity was also monitored during the school year by research assistants.
16493144|NCT03338530|No Intervention|Business-As-Usual (BAU) Control|Children with HFASD in the BAU schools received their typical special education programming as legally-mandated. The programming received by each was carefully monitored per the following: 1) Each student's IEP was reviewed to document the legally mandated services received; 2) For those receiving counseling or speech-language services, the related-service provider completed a survey indicating specific treatment targets and the protocol for service provision; 3) Parents completed a monthly survey of any external therapeutic programming their child may have received; and 4) Fidelity measures designed for the intervention group (with sequencing requirements removed) were completed for the control condition during two 60-minute classroom observations per week by research assistants.
16493145|NCT03338517|Active Comparator|Study group|Helium Neon Laser
16493146|NCT03338517|No Intervention|Control group|No intervention
16493147|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value >99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
16493148|NCT03338491|Experimental|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
16493149|NCT03338491|Experimental|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
16493150|NCT03338491|No Intervention|Control|Participants will revive no induction of any mindset.
16493151|NCT03338478|Experimental|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
16493152|NCT03338478|Experimental|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
16493153|NCT03338465|Active Comparator|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
16493154|NCT03338465|Active Comparator|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
16493155|NCT03338452|Experimental|participants|The participants will be subjected to low energy ketogenic diet.
16493156|NCT03338439||CSII|CSII: patients with continuous subcutaneous insulin infusion
16493157|NCT03338439||MDI|MDI: patients with multi-daily injections
16493158|NCT03338426|Experimental|Experimental|Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
16493159|NCT03338426|Active Comparator|Active Comparator 1|Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
16493160|NCT03338426|Active Comparator|Active Comparator 2|Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
16493161|NCT03338413|Experimental|Goal Management Training|
16493162|NCT03338413|Experimental|Computerized Cognitive Training|
16493163|NCT03338400|Active Comparator|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
16493164|NCT03338400|Placebo Comparator|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
16493165|NCT03338387|Experimental|Acipimox|Other Names: Olbetam
16493166|NCT03338387|Placebo Comparator|Placebo|"Other Names:
~Placebo (for Olbetam)"
16493167|NCT03338374|Experimental|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
16493168|NCT03338361|Experimental|AAT active - VPT sham|Approach avoidance training active intervention and visual probe training sham intervention
16493169|NCT03338361|Experimental|VPT active - AAT sham|Visual probe training active condition and approach avoidance training sham condition
16493170|NCT03338361|Experimental|AAT active - VPT active|Approach avoidance training active condition and visual probe training active condition
16493171|NCT03338361|Sham Comparator|AAT sham - VPT sham|Approach avoidance training sham condition and visual probe training sham condition
16493172|NCT03338348|Other|Azacitidine + Vosaroxin|"Cycle 1-8:
~Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
~Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
16493173|NCT03338322|Experimental|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
16493174|NCT03338322|Active Comparator|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
16493175|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
16493176|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
16493177|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
16493178|NCT03338283|Experimental|Electromassage|"Electromassage and conservatory treatment. All subjects will be received a conservatory treatment (1h and 40 min) and electro-massage (10min).
~The protocol will consist of six sessions, twice a week for three weeks. The duration will be 1 hour and 40 min for the conservatory treatment and 10 min for the electro-massage."
16493179|NCT03338283|Active Comparator|Conservatory Treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
16493180|NCT03338257|Experimental|Husky Reads Intervention|The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
16493181|NCT03338257|No Intervention|Wait list Control|Programs on the wait list for Husky Reads, participate in the pre and post intervention testing but do not receive the program.
16493182|NCT03338244|Active Comparator|Azithro|Communities will receive four rounds of biannual mass azithromycin.
16493183|NCT03338244|Placebo Comparator|Placebo|Communities will receive four rounds of biannual mass placebo.
16493184|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
16493185|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
16493186|NCT03338205|Experimental|Ketamine Treatment|"Everyone enrolled in study presenting in status asthmaticus to pediatric emergency department at Augusta University will receive a ketamine treatment, who include:
~Patients with a Clinical Asthma SCore (CAS) of greater than or equal to 10 on presentation and have received at least two (appropriately dosed based on weight) albuterol treatments prior to arrival
~OR
~Patients with a CAS of ≥ greater than or equal to 10 that have not received treatment prior to arrival and after receiving 1 hour of treatment per the severe asthma pathway do not have a decrease in CAS of greater than 2
~OR
~Patients with a CAS above > 6 but less than < 10 when as measured 1 hour after initiation of standard treatment per Augusta University's moderate asthma pathway"
16493187|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
16493188|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
16493191|NCT03338179|Active Comparator|Adult Controls|Controls aged between 18 and 45 years old
16493192|NCT03338179|Active Comparator|Aged Controls|Controls aged 59.5 years and above
16493193|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
16493194|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
16493195|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
16493196|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
16493197|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
16493198|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
16493199|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
16493200|NCT03338127||Participants|all patients recruited in the trial will be investigated for renal function test
16493201|NCT03338114|Experimental|FLX-787-ODT (orally disintigrating tablet)|FLX-787-ODT (orally disintigrating tablet)
16493202|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
16493203|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
16493204|NCT03338062|Experimental|Theragnostic SBRT Planning|The theragnostic SBRT plan using the HIDA scan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
16493205|NCT03338062|No Intervention|Standard SBRT Planning|The standard SBRT plan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
16493206|NCT03338049|Other|Veran System|Staged biopsy sampling methodology. If lymph node staging is negative, EMN-bronchoscopy will be performed. If EMN-bronchoscopy is negative, EMN-TTNA will be performed
16493207|NCT03338036|Experimental|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
16493208|NCT03338036|No Intervention|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
16493209|NCT03338036|No Intervention|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
16493210|NCT03338023|Experimental|LY2963016 + Insulin Lispro|Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
16493211|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
16493212|NCT03338010|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
16493213|NCT03338010|Active Comparator|Lantus®|Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
16493214|NCT03337997|Experimental|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
16493215|NCT03337971|Placebo Comparator|PLACEBO|"Intervention: Dietary Supplement: PLACEBO A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.
~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
16493216|NCT03337971|Active Comparator|Milk-based protein matrix|"Intervention: Dietary Supplement: MBPM A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.
~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
16493217|NCT03337958|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
16493218|NCT03337958|Experimental|INTERVENTION GROUP|The group received the standard medical and pharmacological care provided by the hospital. In addition, an educational program on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program, furthermore, the technique of inhaler use was trained.
16493219|NCT03337945|Experimental|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
16493220|NCT03337932|Active Comparator|MEM-7 days doxycycline|
16493221|NCT03337932|Active Comparator|MEM-14 days doxycycline|
16493222|NCT03337932|Placebo Comparator|Controls|
16493223|NCT03337919|Experimental|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
16493224|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
16493225|NCT03337893||Breastfed|The kids who breastfed
16493226|NCT03337893||non-breastfed|The kids who did not breastfed
16493227|NCT03337880||Cases|newborns who were delivered with an extractor
16493228|NCT03337880||Controls|newborns who were not delivered with an extractor
16493231|NCT03337841|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
16493232|NCT03337828|Active Comparator|Alcohol-free beer with regular composition|Two cans (33 cl.) per day of an alcohol-free beer with regular carbohydrates composition.
16493233|NCT03337828|Experimental|Alcohol-free beer with modified composition|Two cans (33 cl.) per day of alcohol-free beer with modified carbohydrates composition. This include the substitution of regular maltose by isomaltulose and the addition of maltodextrin (fiber).
16493234|NCT03337815|Active Comparator|Treatment of MTX and TwHF placebo|Patients were treated with Methotrexate (MTX) and Tripterygium wilfordii Hook F（TwHF）placebo.
16493235|NCT03337815|Experimental|Treatment of TwHF and MTX placebo|Patients were treated with Tripterygium wilfordii Hook F（TwHF）and Methotrexate (MTX) placebo.
16493236|NCT03337802|No Intervention|Pregnant women at standard diet|obstetrical and gynecological follow-up
16493237|NCT03337802|Experimental|Pregnant women at mediterranean diet|obstetrical and gynecological follow-up + nutritional counseling
16493238|NCT03337789|Experimental|Polygonatum sibiricum|
16493239|NCT03337789|Placebo Comparator|Placebo|
16493240|NCT03337776|Active Comparator|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
16493241|NCT03337776|Active Comparator|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
16493242|NCT03337750|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
16493243|NCT03337737|Placebo Comparator|Placebo|Placebo will be composed of microcrystalline cellulose in a gel capsule
16493244|NCT03337737|Active Comparator|Extreme Endurance|Dietary Supplement manufactured by LifeSpan International LLC
16493245|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
16493246|NCT03337724|Experimental|Placebo + Paclitaxel|
16493247|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
16493248|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493249|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493250|NCT03337698|Active Comparator|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493251|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493252|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493253|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493254|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493255|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493256|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
16493257|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
16493258|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
16493259|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
16493260|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
16493261|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
16493262|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
16493263|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
16493264|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Evolocumab|Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
16493265|NCT03337672|Experimental|Dexmedetomidine group|Subjects who receive dexmedetomidine for prevention of emergence delirium
16493266|NCT03337672|Active Comparator|Midazolam group|Subjects who receive midazolam for prevention of emergence delirium
16493267|NCT03337659|Experimental|FICare Intervention Group|Study participants received Family Integrated Care (intervention) while their infant(s) was/were admitted to a Level II NICU.
16493268|NCT03337659|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
16493269|NCT03337646|Other|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
16493270|NCT03337633|Active Comparator|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
16493271|NCT03337633|Active Comparator|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
16493272|NCT03337633|Active Comparator|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
16493273|NCT03337633|Active Comparator|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
16493274|NCT03337620|Active Comparator|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
16493275|NCT03337620|Placebo Comparator|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
16493276|NCT03337607|Active Comparator|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
16493277|NCT03337607|Active Comparator|rESWT alone|Patients will receive rESWT
16493278|NCT03337607|Active Comparator|C-E drugs alone|Patients will receive Celecoxib and Eperisone
16493279|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
16493280|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
16493281|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
16493282|NCT03337581|Sham Comparator|group 1.1|Normal saline group
16493283|NCT03337581|Experimental|group 1.2|0.25μg/kg dexmedetomidine group
16493284|NCT03337581|Experimental|group 1.3|0.5μg/kg dexmedetomidine group
16493285|NCT03337581|Experimental|group 1.4|0.75μg/kg dexmedetomidine group
16493286|NCT03337581|Experimental|group 1.5|1.0μg/kg dexmedetomidine group
16493287|NCT03337555|Active Comparator|Macintosh|intubation using Macintosh direct laryngoscope
16493288|NCT03337555|Experimental|McGrath|intubation using McGrath MAC®
16493289|NCT03337555|Experimental|Pentax|intubation using Pentax-airway scope®
16493290|NCT03337542|Other|Treatment arm description|Subjects will receive maintenance dosing with AR101.
16493291|NCT03337529|Experimental|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
16493292|NCT03337529|Placebo Comparator|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
16493293|NCT03337516|Experimental|Patients treated with Cytarabine|
16493294|NCT03337503|Experimental|THC and CDB in a 1 to 1 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.
~2.5 mg THC with 2.5 mg CBD capsule"
16493295|NCT03337503|Experimental|THC and CBD in a 1 to 2 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.
~2.5 mg THC with 5 mg CBD capsule"
16493296|NCT03337503|Experimental|high CBD with trace THC|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.
~20 mg CBD with traces of THC"
16493297|NCT03337503|Placebo Comparator|placebo|"Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.
~carrier oil capsule"
16493298|NCT03337490|Experimental|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
16493299|NCT03337490|Active Comparator|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
16493300|NCT03337490|Placebo Comparator|Placebo 0% Lotion|0% lotion, 117g, single dose
16493301|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
16493302|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
16493303|NCT03337464|Experimental|Parkinson's disease|Subjects with Parkinson's disease
16493304|NCT03337464|Active Comparator|Control|Subjects without Parkinson's disease
16493305|NCT03337451|Experimental|OPN-305|
16493306|NCT03337438|Other|Values-PFI|
16493307|NCT03337438|Other|Traditional-PFI with values assessment|
16493308|NCT03337438|Other|Traditional PFI no values assessment|
16493309|NCT03337425|Experimental|psychoeducational groups|Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
16493310|NCT03337425|Active Comparator|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
16493311|NCT03337412|Experimental|Patients|initial assessment of physical capacities, determination of personalized objectives on the occasion of 1 to 2 workshops during the hospital checkup. Telephone Contact by the APA educator at 6 months. One-year medical visit.
16493312|NCT03337412|Experimental|Employees|"initial assessment of physical capacities, participation in 10 to 20 physical activity workshops over 6 months on working time, then employees oriented towards autonomous activities over the following 6 months.
~Evaluation by computer-filled questionnaires."
16493313|NCT03337399|Experimental|Stepped PC|"Patients will receive Stepped PC
~During step 1, patients will be scheduled to meet with the outpatient PC clinician within four weeks of study enrollment and after they are admitted to the hospital or have a change in their cancer treatment
~Patients will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) to monitor their quality of life every six weeks and if their quality of life deteriorates substantially, they will step up to step 2 of the protocol
~Patients who transition to step 2 will then meet with the PC clinician at least every four weeks for the remainder of their illness"
16493314|NCT03337399|Experimental|Early Integrated PC|"Patients will receive Early Integrated PC
~Patients will meet with the PC clinician within four weeks of enrollment and at least every four weeks throughout their course of illness"
16493315|NCT03337386|Experimental|Inferior Vena Cava Collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
16493316|NCT03337386|Experimental|Subclavian Vein Collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
16493317|NCT03337386|Active Comparator|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
16493318|NCT03337373|Experimental|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
16493319|NCT03337360|Active Comparator|Impryl|One tablet daily for 6 months
16493320|NCT03337360|Placebo Comparator|Placebo|One tablet daily for 6 months
16493321|NCT03337334|Other|Non-Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable). One 5*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10*10 cm2 over the ankle. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation. By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
16493322|NCT03337334|Other|Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation. By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
16493323|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
16493324|NCT03337308|Experimental|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
16493325|NCT03337308|Experimental|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
16493326|NCT03337308|Active Comparator|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
16493327|NCT03337308|Placebo Comparator|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
16493328|NCT03337295||Low-MGD|
16493329|NCT03337295||High-MGD|
16493330|NCT03337282||Observational cohort|Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia
16493331|NCT03337269|Other|Control|Subject does not receive an educational intervention
16493332|NCT03337269|Other|Educational video|Subject watches an educational video
16493333|NCT03337269|Other|Educational handout|Subject reads an educational handout
16493334|NCT03337256|Experimental|GI bleeding score|Early endoscopy in emergency department + other clinical parameters
16493335|NCT03337243|Experimental|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
16493336|NCT03337243|No Intervention|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
16493337|NCT03337230|Experimental|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
16493338|NCT03337217|Experimental|Prone Position|Position during colonoscopy
16493339|NCT03337217|Active Comparator|Left lateral decubitus position|Position during colonoscopy
16493340|NCT03337204|Experimental|Engaged4Life|"Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later); and 2) a one-time, 3hr workshop and peer mentoring (via phone 2X/week for 3 weeks). The workshop includes psychoeducation on the relationship between active engagement and health and well-being and a goal setting activity focused on carefully assessing and then make improvements upon existing activity portfolios. Peer mentors provide support as participants implement their goals."
16493341|NCT03337204|Active Comparator|Technology-assisted self-monitoring only|Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
16493342|NCT03337191|Active Comparator|ultrasound guided caudal block|Caudal block was performed by ultrasound guided with %0,125 levobupivacaine + 10 mq/kg morphine
16493343|NCT03337191|Active Comparator|conventional caudal block|Caudal block was performed by conventional method with %0,125 levobupivacaine + 10 mq/kg morphine
16493344|NCT03337178|No Intervention|Control|Standard of care
16493345|NCT03337178|Experimental|Blinded Fitbit|Blinded Fitbit, no step goal, and no activity feedback
16493346|NCT03337178|Experimental|Fitbit|Fitbit plus step goal and activity feedback
16493347|NCT03337165|Experimental|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
16493348|NCT03337152|Other|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
16493349|NCT03337152|Other|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
16493350|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
16493351|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
16493352|NCT03337126|Active Comparator|Fasting Condition|Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
16493353|NCT03337126|Active Comparator|Fed Condition|Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
16493354|NCT03337113|Experimental|WMT + rTMS|WMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
16493355|NCT03337113|Active Comparator|Sham WMT + rTMS|Sham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
16493356|NCT03337113|Active Comparator|WMT + sham rTMS|WMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
16493357|NCT03337113|Sham Comparator|Sham WMT + sham rTMS|sham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
16493358|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
16493359|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:
~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
16493360|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16493361|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
16493362|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
16493363|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
16493364|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
16493365|NCT03337061|Experimental|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
16493366|NCT03337061|No Intervention|Control (Sleep Advice)|This is the control arm that will receive usual care
16493367|NCT03337048|Experimental|Measurement of endpoints|"In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter (SpeediCath).
~In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter."
16493368|NCT03337035|Active Comparator|oral probiotics and oxytocin spray|Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
16493369|NCT03337035|Placebo Comparator|oral placebo and oxytocin spray|Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
16493370|NCT03337022|Experimental|CC-90006; Dose level 1|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
16493371|NCT03337022|Experimental|CC-90006; Dose level 2|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
16493372|NCT03337022|Experimental|CC-90006; Dose level 3|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
16493373|NCT03337022|Experimental|CC-90006; Dose level 4|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
16493374|NCT03337022|Placebo Comparator|Placebo|Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29.
16493375|NCT03337009|Experimental|Naloxone Navigator|"Targeted, web-based animated video (Naloxone Navigator [NN]):
~This arm is a web-based intervention targeted to patients receiving chronic opioid therapy identified in the electronic health record. Participants in this arm have access to naloxone under standing orders from the pharmacy or with a prescription from their providers."
16493376|NCT03337009|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and clinicians. As part of usual care, participants can access naloxone through physician prescription or standing orders.
16493377|NCT03336996|Experimental|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
16493378|NCT03336996|Experimental|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
16493379|NCT03336996|Experimental|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
16493380|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
16493381|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
16493382|NCT03336970|Active Comparator|Single visit root canal treatment|The teeth were treated in single-visit (SV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
16493383|NCT03336970|Active Comparator|Multiple visit root canal treatment|The teeth were treated in multiple visit (MV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
16493384|NCT03336957|Experimental|Pregnant group|Test group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
16493385|NCT03336957|Active Comparator|Non-Pregnant|Control group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
16493386|NCT03336931||High-risk childhood cancers|Expected survival < 30%
16493387|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
16493388|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
16493389|NCT03336905|Experimental|Physical Activity and Prevention|"co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer
~balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation
~meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
16493390|NCT03336892|Experimental|Intervention|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
16493391|NCT03336892|No Intervention|Control|Enhanced usual care with written mental health resources and system navigation information.
16493435|NCT03336580|Experimental|PRX004|"Dose escalation in up to 6 dose levels
~Expansion of previously studied cohort(s) from Dose Escalation
~Extended dosing at RP2D"
16493468|NCT03336359|Active Comparator|LCI|Tandem colonoscopy with Linked Color Imaging system
16493469|NCT03336359|Active Comparator|NBI|Tandem colonoscopy with Narrow band imaging system
16493544|NCT03335943|Experimental|CDA-2 (Cell Differentiation Agent 2)|Patients will be given CDA-2 therapy.
16493392|NCT03336879|Experimental|Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
16493393|NCT03336866|Placebo Comparator|Placebo|Normal saline
16493394|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
16493395|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
16493396|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
16493397|NCT03336840|Experimental|Metformin|
16493398|NCT03336840|Experimental|Probiotics|
16493399|NCT03336840|Experimental|Metformin and Probiotics|
16493400|NCT03336827|Other|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
16493401|NCT03336827|Other|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
16493402|NCT03336814|Experimental|terlipressin associated with norepinephrine|
16493403|NCT03336814|Placebo Comparator|placebo (physiologic serum) associated with norepinephrine|
16493404|NCT03336801|Active Comparator|Sevoflurane|Intervention Back surgery and sevoflurane.
16493405|NCT03336801|Active Comparator|Propofol|Intervention Back surgery and propofol.
16493406|NCT03336788|Placebo Comparator|TMS|
16493407|NCT03336788|Active Comparator|TMS with virtual reali|
16493408|NCT03336775|Experimental|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
16493409|NCT03336775|No Intervention|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
16493410|NCT03336749|Experimental|Sensory group|Sensory re-learning in combination with task-specific training
16493411|NCT03336749|Active Comparator|Control group|Traditional task-specific training
16493412|NCT03336736||Pulmonary Sarcoidosis|"Self-reported and self-referred self-reported medically diagnosed pulmonary sarcoidosis.
~Exercise capacity and function will be assessed."
16493413|NCT03336736||Control|Healthy age-matched control group with no known lung disease. Exercise capacity and function will be assessed.
16493414|NCT03336723|Experimental|Experimental Group|Two piece zirconia dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
16493415|NCT03336723|Active Comparator|Control Group|Two piece titanium dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
16493416|NCT03336710||Primary sample|Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.
16493417|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
16493418|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
16493419|NCT03336684|Experimental|Patient Education Group|Patients will be provided with disease education literature
16493420|NCT03336684|No Intervention|Normal Group|Patients will not be provided with disease education literature
16493421|NCT03336671|Active Comparator|Adenoidectomy|Current standard of care for pediatric chronic rhino sinusitis.
16493422|NCT03336671|Experimental|Adenoidectomy plus Endoscopic Sinus Surgery|endoscopic sinus surgery in addition to adenoidectomy
16493423|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
16493424|NCT03336632|Experimental|Chidamide|Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5~D+100
16493425|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
16493426|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
16493427|NCT03336606|Active Comparator|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
16493428|NCT03336606|Active Comparator|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
16493429|NCT03336593|Experimental|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
16493430|NCT03336593|Experimental|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
16493431|NCT03336593|Experimental|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
16493432|NCT03336593|Active Comparator|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
16493433|NCT03336593|Experimental|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
16493434|NCT03336593|Experimental|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
16493436|NCT03336567||Subjects with hematological malignancies|It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
16493437|NCT03336567||Subjects with NSCLC or soft-tissue sarcoma|It will Include subjects with NSCLC on second or later-line therapy or soft-tissue sarcoma on second or later line therapy. Subjects will undergo a telephonic interview for up to 90 minutes.
16493438|NCT03336567||Oncologists from academic centers with CGT experience|It will include oncologists using TCR therapies, CAR-T or participating in CAR-T or TCR therapy clinical trials. Oncologists will undergo a telephonic interview for up to 60 minutes.
16493439|NCT03336567||Oncologists from community clinics|It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.
16493440|NCT03336554||observation group|One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
16493441|NCT03336541|Experimental|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
16493442|NCT03336541|Placebo Comparator|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
16493443|NCT03336528|Experimental|Degludec inpatient|Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals. Degludec insulin 100 Units/mL, average dose: 30-45 U/day. aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day.
16493444|NCT03336528|Active Comparator|Glargine U100 inpatient|"Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals. Glargine (U-100) insulin 100 Units/mL, average dose: 30-45 U/day.
~Aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day."
16493445|NCT03336528|Experimental|Degludec post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in the degludec inpatient arm will be invited to participate in the prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus degludec once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with degludec and aspart insulin before meals.
16493446|NCT03336528|Active Comparator|Glargine U100 post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in glargine inpatient arm will be invited to participate in this open label prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus glargine once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with glargine and aspart insulin before meals.
16493447|NCT03336515|Other|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
16493448|NCT03336515|Placebo Comparator|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
16493449|NCT03336515|Experimental|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
16493450|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
16493451|NCT03336476|Experimental|Videolaryngoscopy|Videolaryngoscopy the trachea will be intubated using a videolaringoscope
16493452|NCT03336476|Active Comparator|Direct laryngoscopy|Direct laringoscopy the trachea will be intubated using a laringoscope
16493453|NCT03336463||Controls|No intervention
16493454|NCT03336463||Cases|No intervention
16493455|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
16493456|NCT03336437|Active Comparator|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
16493457|NCT03336437|Placebo Comparator|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
16493458|NCT03336424|Experimental|Non-invasive investigations group|Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
16493459|NCT03336424|Experimental|Invasive investigations group|urodynamic study including: cystomanometry, pressure flow study, EMG
16493460|NCT03336411|Active Comparator|mHealth|
16493461|NCT03336411|Experimental|Personalized mHealth|
16493462|NCT03336398|Experimental|Tinnitus Distressed Patients|Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
16493463|NCT03336398|Experimental|Tinnitus Patients|Tinnitus patients are patients who do not experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
16493464|NCT03336385|Placebo Comparator|Placebo|Maltodextrin 12 gram used as placebo
16493465|NCT03336385|Active Comparator|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
16493466|NCT03336385|Active Comparator|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
16493467|NCT03336372|Experimental|Picato topical gel|
16493470|NCT03336346||DTG group|Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
16493471|NCT03336346||No ART group|Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
16493472|NCT03336346||EFV group|Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
16493473|NCT03336333|Experimental|Cohort 1, Arm A: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression
16493474|NCT03336333|Experimental|Cohort 1, Arm B: B+R|Participants will receive bendamustine plus rituximab for up to six 28-day cycles
16493475|NCT03336333|Experimental|Cohort 1a, Arm A (China only): Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression
16493476|NCT03336333|Experimental|Cohort 1a, Arm B (China only): B + R|Participants will receive bendamustine plus rituximab for up to six 28-day cycles
16493477|NCT03336333|Experimental|Cohort 2, Arm C: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression
16493478|NCT03336333|Experimental|Cohort 3, Arm D: Venetoclax + zanubrutinib|Participants with del[17p] or TP53 mutation will receive venetoclax until unacceptable toxicity, disease progression, or for maximum of 24 cycles; Participants will also receive zanubrutinib for a minimum of 27 cycles, or until unacceptable toxicity or disease progression, whichever occurs first.
16493479|NCT03336320|Experimental|Multidomain Intervention Group|Home-based multidomain intervention composed of nutritional counselling, exercise (balance, gait, , and cognitive training provided using ICT solutions. A web platform, containing information, questionnaires, videos, games, and tests related to each one of the three components of the multidomain intervention will be made available to participants in this group.
16493480|NCT03336320|Active Comparator|Control Group|"Participants from CG will also be equipped with wrist worn accelerometers (that will record daily activity data continuously) but contrary to MIG, participants won't have access to the password encrypted application, and therefore, to the multidomain intervention. However, they will be able to access the study website with overall information on the eMIND study and links to the website of health authorities (such as http://www.mangerbouger.fr/PNNS or the World Health Organization http://www.who.int/topics/ageing/fr/) regarding healthy ageing topics. Plus, in order to control for the social aspect of MIG, participants in CG will receive monthly phone calls from the research team."
16493481|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.
~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.
~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
16493482|NCT03336294|Other|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
16493483|NCT03336294|Other|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
16493484|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug [bDMARD] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
16493485|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
16493486|NCT03336268|Experimental|POINT|This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
16493487|NCT03336268|No Intervention|Standard Care|This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
16493488|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
16493489|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
16493490|NCT03336242|Experimental|Cohort 1: Cannabidiol Oral Solution 20 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.
16493491|NCT03336242|Experimental|Cohort 2: Cannabidiol Oral Solution 30 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.
~Treatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks."
16493492|NCT03336242|Experimental|Cohort 3: Cannabidiol Oral Solution 40 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days, followed by 30 mg/kg/day divided BID for 5 days.
~Treatment Period: Cannabidiol Oral Solution 40 mg/kg/day divided BID for 4 weeks."
16493495|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy:
~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
16493496|NCT03336216|Experimental|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
16493497|NCT03336216|Experimental|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
16493498|NCT03336216|Experimental|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
16493499|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
16493500|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
16493501|NCT03336190|Experimental|Intervention|Receives the full program, including the toolkit training and avatar interaction
16493502|NCT03336164|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage sold in the same campus university restaurant after the control period without food labelling.
~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
16493503|NCT03336151|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.
~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
16493504|NCT03336138|Active Comparator|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
16493505|NCT03336138|No Intervention|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
16493506|NCT03336125|Experimental|Vitamin D group|Intervention is vitamin D supplement
16493507|NCT03336125|Placebo Comparator|Control group|Placebo capsule contains olive oil
16493508|NCT03336112|Experimental|Intervention group|5 weeks guided internet-delivered cognitive behavioral therapy program The program consists of psychoeducation, exposure to physical activity, and awareness (mindfulness) training.
16493509|NCT03336112|Active Comparator|Control group|Information program delivered by the Internet during 5 weeks.
16493510|NCT03336099|Experimental|Spa Treatment|Bicarbonate and sulfurated water cares in Vals-les-Bains thermal cure center, massage, cataplasm.
16493511|NCT03336086|Other|experimental|This group underwent a weight loss program
16493512|NCT03336086|No Intervention|control|This group underwent adlibitum diet + physical activity
16493513|NCT03336073|Experimental|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
16493514|NCT03336073|Active Comparator|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
16493515|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
16493516|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
16493517|NCT03336047|Active Comparator|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
16493518|NCT03336047|Experimental|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
16493519|NCT03336034||IBS-C|Constipation-predominant irritable bowel syndrome
16493520|NCT03336021|Experimental|Intervention|FAS program
16493521|NCT03336021|No Intervention|Comparison|Comparison group
16493522|NCT03335982|Other|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
16493523|NCT03335969|Experimental|pre colon irrigation diaries followed by post diaries|4 week bowel movement and rescue medication diaries will be compared to same diaries used 4 weeks after the colon irrigation procedure
16493524|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 1|
16493525|NCT03335956|Experimental|SAD Part 1 Active Cohort Period 1|
16493526|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 2|
16493527|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 2|
16493528|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 3|
16493529|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 3|
16493530|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 4|
16493531|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 4|
16493532|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 5|
16493533|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 5|
16493534|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 6|
16493535|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 6|
16493536|NCT03335956|Placebo Comparator|MAD Placebo Cohort 1|
16493537|NCT03335956|Experimental|MAD Active Cohort 1|
16493538|NCT03335956|Placebo Comparator|MAD Placebo Cohort 2|
16493539|NCT03335956|Experimental|MAD Active Cohort 2|
16493545|NCT03335930|Experimental|Morning exercise|To exercise at morning (08:00-10:00)
16493546|NCT03335930|Active Comparator|Afternoon exercise|To exercise at afternoon (14:00-16:00)
16493547|NCT03335930|Active Comparator|Evening exercise|To exercise at evening (18:00-20:00)
16493548|NCT03335917|Placebo Comparator|Normobaric Normoxia|This will serve as the exercise only control trial
16493549|NCT03335917|Experimental|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
16493550|NCT03335917|Experimental|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
16493551|NCT03335904|Placebo Comparator|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
16493552|NCT03335904|Experimental|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
16493553|NCT03335891|Experimental|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
16493554|NCT03335891|Active Comparator|Control Group|Asthma Education Program Breathing Exercises
16493555|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
16493556|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
16493557|NCT03335852|Experimental|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
16493558|NCT03335839|Experimental|Intracoronary tPA 10 mg|
16493559|NCT03335839|Experimental|Intracoronary tPA 20 mg|
16493560|NCT03335839|Placebo Comparator|Placebo|saline
16493561|NCT03335826|Experimental|Combined epidural-general anesthesia|Patients assigned to this group receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
16493562|NCT03335826|Active Comparator|General anesthesia|Patients assigned to this group receive general anesthesia and postoperative patient-controlled intravenous analgesia.
16493563|NCT03335813|Experimental|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
16493564|NCT03335800|Experimental|Apple Heart Study App|
16493565|NCT03335787|Experimental|Intervention|Taping will be applied three times and will be reapplied one and two weeks later prior to first application for two weeks.
16493566|NCT03335787|Other|Control|Control group would not receive any taping in order to prevent sham taping sensory stimulation effect.
16493567|NCT03335774|Active Comparator|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
16493568|NCT03335774|Placebo Comparator|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
16493569|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
16493570|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
16493571|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
16493572|NCT03335748|Active Comparator|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
16493573|NCT03335748|Experimental|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
16493574|NCT03335735|Experimental|Loss-Framed Text Messages|Loss-framed text message
16493575|NCT03335735|No Intervention|Control|Participants in this arm will not receive any intervention.
16493576|NCT03335735|Experimental|Gain-Framed Messaging Group|Gain-framed text message
16493577|NCT03335722|Active Comparator|Active TDCS and Fluency Intervention|Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
16493578|NCT03335722|Sham Comparator|Sham TDCS and Fluency Intervention|Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
16493606|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
16493579|NCT03335709|Experimental|ADL intervention|The participants are assigned to an eight-week intervention program aiming at enhancing ADL ability. The program consists of a minimum of five and a maximum of eight sessions; Session one - First meeting and occupational therapy evaluation (mandatory), Session two - Goal setting and clarifying reasons for problems related to ADL (mandatory), Session three- seven - Interventions aiming at enhancing ADL ability (Number of sessions can vary. However, a minimum of two sessions are mandatory), Session eight - Re-evaluation (Mandatory)
16493580|NCT03335683|Experimental|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
16493581|NCT03335683|Placebo Comparator|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
16493582|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
16493583|NCT03335657|Experimental|CBPT Treatment|The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
16493584|NCT03335657|Placebo Comparator|Education Treatment|The education program provides a postoperative recovery and is based on education that would typically be provided by a treating physician or a physical therapist in an outpatient setting. The education program is matched to the CBPT treatment in terms of session frequency and contact with the study therapist. The therapist will call weekly to check in with the patient and encourage him/her to read the manual. Manuals contain educational information on injury patterns and symptoms, stress and recovery, benefits of physical therapy, and importance of daily exercise, and ways to promote healing. Education on sleep hygiene, energy management, healthy eating, and preventing future injury are also provided.
16493585|NCT03335631|Experimental|Group-supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
16493586|NCT03335631|Experimental|Home-based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
16493587|NCT03335618|Experimental|Active Coaching and Monitoring|
16493588|NCT03335618|Sham Comparator|Passive Monitoring|
16493589|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
16493590|NCT03335605||Healthy controls|Age and gender-matched control subjects
16493591|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
16493592|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
16493593|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
16493594|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
16493595|NCT03335553|Experimental|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
16493596|NCT03335553|Experimental|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
16493597|NCT03335540|Experimental|Arm B|Combination therapy determined by biomarker assessment
16493598|NCT03335540|Experimental|Arm C|Combination therapy determined by biomarker assessment
16493599|NCT03335540|Experimental|Arm D|Combination therapy determined by biomarker assessment
16493600|NCT03335540|Experimental|Arm F|Combination therapy determined by biomarker assessment
16493601|NCT03335540|Experimental|Arm G|Combination therapy determined by biomarker assessment
16493602|NCT03335527|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
16493603|NCT03335527|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
16493604|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
16493605|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
16493607|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
16493608|NCT03335501|Active Comparator|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
16493609|NCT03335501|Active Comparator|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
16493610|NCT03335488|Experimental|Arm 1, RAVICTI|Used for Baseline, Treatment, Transition, Maintenance, and Safety. Dosing will be based on participants disease and treatment status at entry to the study. RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose.
16493611|NCT03335488|Active Comparator|Arm 2, NaPBA (sodium phenylbutyrate)|"Used for Baseline and Treatment. Sodium Phenylbutyrate (NaPBA). Dosing will be based on participants disease and treatment status at entry to the study.
~NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose
~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
16493612|NCT03335475|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
16493613|NCT03335475|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
16493614|NCT03335462|Experimental|Paravertebral injections|Lumbar paravertebral injections containing contrast will be performed. The needles are kept in their position and afterwards followed by CT scan.
16493615|NCT03335449|Experimental|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
16493616|NCT03335449|No Intervention|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
16493617|NCT03335436|Experimental|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
16493618|NCT03335436|Placebo Comparator|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
16493619|NCT03335423|Experimental|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
16493620|NCT03335423|Experimental|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
16493621|NCT03335423|Experimental|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
16493622|NCT03335423|Experimental|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
16493623|NCT03335410||shoulder surgery|18-85 years, undergoing day case shoulder surgery during 15th Sept- 15th Oct 2017, possibility to e-mail and an internet connection, understands Finnish,
16493624|NCT03335397|Experimental|M-learning group|Participants receive mobile app (m-learning application) with interactive content (quiz).
16493625|NCT03335397|Other|Control group|Participants receive traditional learning process (books, journals available in the University library).
16493626|NCT03335384|Experimental|Measurement of Pdi|Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
16493627|NCT03335384|Experimental|Measurement of SNIPs|While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
16493628|NCT03335371|Experimental|TTP399 400 mg|
16493629|NCT03335371|Placebo Comparator|Placebo|
16493630|NCT03335358|Experimental|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
16493631|NCT03335358|Other|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
16493632|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
16493633|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
16493634|NCT03335332|Experimental|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
16493635|NCT03335332|Active Comparator|Moderate intensity exercise|
16493686|NCT03335085|Placebo Comparator|Placebo|All ingredients except for oxytocin.
16493687|NCT03335072|Active Comparator|WHO-recommended|Annual mass azithromycin distribution of all residents
16493688|NCT03335072|Experimental|Age-based core group|Annual mass azithromycin treatment of everyone plus quarterly treatment of children
16493636|NCT03335319|Experimental|Periodized Exercise Training Regime|The ET program will be carried out 3 times a week (60 minutes per session) on non-consecutive days for 48 weeks and supervised for both groups. Exercise prescription will be gradually progressed through various combinations of duration, frequency and/or intensity of training. Over the 1st-15th exercise sessions: MCT and anatomical resistance training; from the 16th-30th session: combined ET with HIIT and hypertrophy; from the 31st-45th exercise session, after the adjustments of the respectively time point assessments: MCT and maximal strength; from the 46th-60th exercise sessions: HIIT with hypertrophy; at the end of the 60th session until the end (6 months has passed): the same exercise prescription will repeat all over again at the same order.
16493637|NCT03335319|Active Comparator|Non Periodized Exercise Training Regime|participants will do a combined ET regime (aerobic and RT). Aerobic component: combine moderate to vigorous exercises 3 d.wk-1 on nonconsecutive days, for 20 min per session, involving major muscle groups using the available ergometers to perform continuous and rhythmic activities in nature. Resistance component: RT should be performed after the aerobic component of the exercise session to allow for adequate warm-up. Initial load should be trained initially with one set of 10-15 repetitions that can be lifted without straining (~30%-40% 1RM for the upper body; ~50%-60% 1 RM for the lower body). Each major muscle group should be trained initially with one set; multiple set regimens may be introduced later as tolerated. It will be performed 8-10 exercises of the major muscle groups.
16493638|NCT03335306||Healthy subjects in Hong Kong|
16493639|NCT03335293|Placebo Comparator|Placebo|normal saline vehicle added to subarachnoid block
16493640|NCT03335293|Experimental|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
16493641|NCT03335293|Experimental|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
16493642|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
16493643|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
16493644|NCT03335267|Experimental|CPX-351 (Cytarabine:Daunorubicin) Injection|"Dosing for first induction: CPX-351
~• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5
~Dosing for second induction:
~• CPX-351 at 100 u/m2 will be administered on days 1 and 3
~Dosing for consolidation:
~• CPX-351 at 65 u/m2 will be administered on days 1 and 3"
16493645|NCT03335254|Experimental|Dose-Escalating Arm 1|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493646|NCT03335254|Experimental|Dose-Escalating Arm 2|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 633 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493647|NCT03335254|Experimental|Dose-Escalating Arm 3|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493648|NCT03335254|Experimental|Dose-Escalating Arm 4|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease to 507 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493649|NCT03335254|Experimental|Dose-Escalating Arm 5|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493650|NCT03335254|Experimental|Dose-Escalating Arm 6|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 507 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493651|NCT03335254|Experimental|Dose-Escalating Arm 7|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493652|NCT03335254|Experimental|Dose-Escalating Arm 8|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493653|NCT03335254|Experimental|Dose-Escalating Arm 9|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493654|NCT03335254|Experimental|Dose-Escalating Arm 10|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 443 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493655|NCT03335254|Experimental|Dose-Escalating Arm 11|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493656|NCT03335254|Experimental|Dose-Escalating Arm 12|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493657|NCT03335254|Experimental|Dose-Escalating Arm 13|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493658|NCT03335254|Experimental|Dose-Escalating Arm 14|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 380 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493659|NCT03335254|Experimental|Dose-Escalating Arm 15|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493660|NCT03335254|Experimental|Dose-Escalating Arm 16|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 253 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493661|NCT03335254|Experimental|Dose-Escalating Arm 17|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493683|NCT03335111|Sham Comparator|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
16493662|NCT03335254|Experimental|Dose-Escalating Arm 18|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493663|NCT03335254|Experimental|Dose-Escalating Arm 19|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493664|NCT03335254|Experimental|Dose-Escalating Arm 20|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
16493665|NCT03335241|Experimental|Arm 1: Fludarabine and Pegylated liposomal doxorubicin|
16493666|NCT03335241|Active Comparator|Arm 2: Pegylated liposomal doxorubicin|
16493668|NCT03335215|Experimental|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
16493669|NCT03335215|No Intervention|usual care|
16493670|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
16493671|NCT03335189|Experimental|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
16493672|NCT03335189|No Intervention|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
16493673|NCT03335176|Experimental|Endurance and Resistance Training Exercise|
16493674|NCT03335176|No Intervention|Control group|Usual care
16493675|NCT03335163|Experimental|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
16493676|NCT03335150|Active Comparator|Supportive Care|Support Group for PD-MCI
16493677|NCT03335150|Experimental|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
16493678|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
16493679|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
16493680|NCT03335124|Experimental|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.
~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.
~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
16493681|NCT03335124|Placebo Comparator|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
16493682|NCT03335111|Experimental|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
16493684|NCT03335098|Experimental|Study arm|Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)
16493685|NCT03335085|Active Comparator|Oxytocin|Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)
16493689|NCT03335072|Experimental|PCR infection-based core group|Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
16493690|NCT03335072|Experimental|TI-based core group|Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
16493691|NCT03335059|Experimental|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
16493692|NCT03335046|Experimental|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
16493693|NCT03335046|Other|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
16493694|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
16493695|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
16493696|NCT03335020|Placebo Comparator|Normal|Healthy volunteers. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
16493697|NCT03335020|Active Comparator|Fibromuscular Dysplasia (FMD)|Subjects with diagnosis of FMD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
16493698|NCT03335020|Active Comparator|Atherosclerosis|Subjects with diagnosis of atherosclerosis. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
16493699|NCT03335020|Active Comparator|Spontaneous Coronary Artery Dissection (SCAD)|Subjects with diagnosis of SCAD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
16493700|NCT03335020|Active Comparator|Segmental Arterial Mediolysis (SAM)|Subjects with diagnosis of SAM. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
16493701|NCT03335007|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
16493702|NCT03335007|Placebo Comparator|Placebo|Placebo
16493703|NCT03334994|Active Comparator|Control group: immediate implant alone|Patient will be treated with immediate implant alone.
16493704|NCT03334994|Active Comparator|(Group A) immediate implant alone|Patient will be treated with immediate implant alone.
16493705|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
16493706|NCT03334968||Patient group|Acute ischemic stroke patients
16493707|NCT03334968||Control group|Those served as control group
16493708|NCT03334955|Experimental|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
16493709|NCT03334942|Experimental|CFTSI|Youth and caregivers randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 5 to 8 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
16493710|NCT03334942|No Intervention|Violence Intervention Program|Youth and caregivers randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
16493711|NCT03334929|Experimental|Virtual Reality intervention|Participants will be wearing Virtual Reality headset called Oculus gear equipped with Samsung galaxy S7 during the trigger point injections. The VR app chosen is called Relax VR - Rest, Relaxation & Meditation, which will provide a calm beach scene with waves and soothing musics.
16493712|NCT03334929|No Intervention|control|Participants in this group will receive trigger point injections without any intervention. The trigger point injections will be performed in daily manner.
16493713|NCT03334916|Experimental|YMC026|108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
16493714|NCT03334916|Placebo Comparator|Placebo|108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
16493715|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
16493716|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
16493717|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
16493718|NCT03334864||I Retrospective cohort|Diagnosis of advanced non-small cell lung cancer from 2012-2016
16493719|NCT03334864||II Prospective cohort|Advanced non-small cell lung cancer with driver gene mutations
16493720|NCT03334864||III Prospective cohort|Non-small cell lung cancer in immuno-therapy;
16493721|NCT03334864||IV Prospective cohort|Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
16493722|NCT03334864||V Prospective cohort|Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
16493723|NCT03334851|Experimental|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
16493724|NCT03334851|Experimental|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493725|NCT03334851|Experimental|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493726|NCT03334851|Experimental|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493727|NCT03334851|Experimental|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493728|NCT03334851|Experimental|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493729|NCT03334851|Experimental|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493730|NCT03334851|Experimental|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
16493731|NCT03334851|Experimental|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous administration.
16493732|NCT03334851|Experimental|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
16493733|NCT03334851|Experimental|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
16493734|NCT03334851|Experimental|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
16493735|NCT03334851|Experimental|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
16493736|NCT03334851|Experimental|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
16493737|NCT03334838|Experimental|GRP 1 - Assess relative bioavailability (4-way crossover)|"GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consisted of a dose of 120 mg nifurtimox (4 x 30 mg tablets).
~In Treatment A, dose administration was in a fasted state.
~For the other treatments, dose administration was in a fed state:
~Treatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast."
16493738|NCT03334838|Experimental|GRP 2 - Assess relative bioavailability (2-way crossover)|"All subjects in Group 2 received a single dose of nifurtimox in each of the Treatments D and E.
~In Treatment D, subjects received 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects received 240 mg nifurtimox (8 x 30 mg tablets). Both treatments were administered in a fed state, after a high-calorie and high-fat breakfast."
16493739|NCT03334825|Experimental|Enhanced housing placement assistance|
16493740|NCT03334825|Active Comparator|Standard housing placement assistance|
16493741|NCT03334812|Experimental|LNA043 20mg/ml|LNA043 20mg/ml single dose
16493742|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
16493743|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/ml single dose
16493744|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
16493745|NCT03334799|Other|Sacroiliac belt on and off|Belt on and belt off
16493746|NCT03334786|Experimental|FLX-787-ODT (orally disintegrating tablet)|Single dose
16493747|NCT03334773|Experimental|Intervention group|Nutrition education (group inclusive of education materials)
16493748|NCT03334773|No Intervention|Control group|Only receives education materials
16493749|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
16493750|NCT03334747|Experimental|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
16493751|NCT03334747|Experimental|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
16493752|NCT03334747|Experimental|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
16493753|NCT03334747|Experimental|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
16493754|NCT03334747|Experimental|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
16493755|NCT03334747|Experimental|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
16493756|NCT03334747|Experimental|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
16493757|NCT03334747|Active Comparator|Treatment arm 9: Coartem Control|Coartem® control
16493758|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
16493759|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
16493760|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
16493761|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
16493762|NCT03334721|Experimental|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
16493763|NCT03334721|Experimental|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
16493764|NCT03334708||Locally Advanced or Metastatic Pancreatic Cancer Cohort|For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
16493765|NCT03334708||Acute Benign Pancreatic Pathology Control Cohort|For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
16493766|NCT03334708||Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl|For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
16493767|NCT03334708||Healthy Control|For normal controls, blood specimens will be drawn once at study baseline.
16493768|NCT03334695|Experimental|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1*10^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
16493769|NCT03334695|Placebo Comparator|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
16493770|NCT03334682|Experimental|spironolactone|Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial (12 months: 6 months on double-blinded spironolactone then 6 months on open-label spironolactone), + topical therapy during all the trial (benzoyl peroxide 5%)
16493771|NCT03334682|Active Comparator|doxycycline|(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months, on double-blinded + topical therapy during all the trial (benzoyl peroxide 5%
16493772|NCT03334669|Experimental|Intervention|"Sites randomized to the intervention group will receive the following:
~Parents Connect for Healthy Living (PConnect)
~Enhanced Nutrition Support
~Media Resources"
16493773|NCT03334669|No Intervention|Control|Control sites will not receive any intervention components (i.e., standard practice).
16493774|NCT03334656|Experimental|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:
~Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.
~The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
16493775|NCT03334656|Active Comparator|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.
~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.
~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
16493776|NCT03334643|Experimental|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
16493777|NCT03334643|Experimental|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
16493778|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter
16493779|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter
16493780|NCT03334617|Experimental|Durvalumab + olaparib|Durvalumab given in combination with olaparib .
16493781|NCT03334617|Experimental|Durvalumab + AZD9150|Durvalumab given in combination with AZD9150.
16493782|NCT03334617|Experimental|Durvalumab + AZD6738|Durvalumab given in combination with AZD6738.
16493783|NCT03334617|Experimental|Durvalumab + vistusertib|Durvalumab given in combination with Vistusertib (AZD2014).
16493784|NCT03334617|Experimental|Durvalumab + Oleclumab|Durvalumab given in combination with Oleclumab
16493785|NCT03334617|Experimental|durvalumab + trastuzumab deruxtecan|durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)
16493786|NCT03334617|Experimental|durvalumab + cediranib|durvalumab given in combination with cediranib (AZD2171)
16493787|NCT03334617|Experimental|AZD6738 (ceralasertib) monotherapy|AZD6738 (ceralasertib) given as monotherapy
16493788|NCT03334617|Experimental|durvalumab & AZD6738 (ceralasertib)|durvalumab given in combination with AZD6738 (D15-D28)
16493789|NCT03334604|Experimental|Multispecies probiotic group|175 participants.
16493790|NCT03334604|Placebo Comparator|Control group|175 participants.
16493791|NCT03334591|Experimental|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
16493792|NCT03334591|Active Comparator|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
16493793|NCT03334578|Experimental|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.
~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
16493794|NCT03334578|No Intervention|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
16493795|NCT03334565|Sham Comparator|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
16493796|NCT03334565|Active Comparator|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
16493797|NCT03334565|Active Comparator|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
16493798|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|0.10% HL036 Ophthalmic Solution, BID for 8weeks
16493799|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|0.25% HL036 Ophthalmic Solution, BID for 8weeks
16493800|NCT03334539|Placebo Comparator|Placebo|Placebo vehicle Solution, BID for 8weeks
16493801|NCT03334526|Experimental|healthy volunteers|
16493802|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
16493803|NCT03334500|Experimental|Cohort 1|Gleason 6 (n=10)
16493804|NCT03334500|Experimental|Cohort 2|Gleason 7-8 (n=10)
16493805|NCT03334500|Experimental|Cohort 3|Gleason 9 or oligometastic disease (n=10)
16493806|NCT03334487|Experimental|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
16493807|NCT03334474||young|18-35 years old
16493808|NCT03334474||middle|35-65 years old
16493809|NCT03334474||aged|65-85 years old
16493810|NCT03334461|Experimental|high concentration enamel remineralisation agent|first month brushing teeth three times per day: twice per day with high-fluorides gel (Mirafluor K gel cola 6150 ppm F pH 5.1) and once per day without toothpaste and fluoride gel next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
16493811|NCT03334461|Experimental|oral antiseptic|first month brushing teeth without toothpaste three times per day and using oral antiseptic chlorhexidine mouthwash (Curasept ADS 212 a 200ml 0,12%) twice per day next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
16493812|NCT03334461|No Intervention|Control|regular oral hygiene without exposure to oral antiseptic or high concentration enamel remineralisation agent three months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
16493813|NCT03334448|Experimental|LY900014-U200|Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
16493814|NCT03334448|Experimental|LY900014-U100|Single SC dose of 15 U LY900014 U-100 in two of four study periods
16493815|NCT03334435|Experimental|Baricitinib High Dose Nonresponders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16493816|NCT03334435|Experimental|Baricitinib High Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16493817|NCT03334435|Experimental|Baricitinib Mid Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16493818|NCT03334435|Experimental|Baricitinib High Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16493819|NCT03334435|Experimental|Baricitinib Mid Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16493820|NCT03334435|Experimental|Baricitinib Low Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
16493821|NCT03334435|Placebo Comparator|Placebo Responders|Placebo administered orally.
16493822|NCT03334435|Experimental|Baricitinib Open Label Extension|Baricitinib administered orally.
16493823|NCT03334422|Experimental|4 Milligram (mg) Baricitinib|4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
16493824|NCT03334422|Experimental|2mg Baricitinib|2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
16493825|NCT03334422|Experimental|1mg Baricitinib|1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
16493826|NCT03334422|Placebo Comparator|Placebo|Placebo administered orally once daily.
16493827|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
16493828|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
16493829|NCT03334396|Experimental|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
16493830|NCT03334396|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
16493831|NCT03334396|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
16493832|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally once daily.
16493833|NCT03334396|Experimental|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
16493834|NCT03334396|Experimental|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
16493835|NCT03334396|Experimental|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
16493836|NCT03334396|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
16493837|NCT03334383|Experimental|Sponge group|Patients offered surgery with the retractor sponge
16493838|NCT03334383|No Intervention|Control group|Patients receiving standard care: surgery in Trendelenburg position
16493839|NCT03334370||DM subjects in Hong Kong|
16493840|NCT03334357|No Intervention|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
16493841|NCT03334357|Experimental|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).
~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.
~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.
~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).
~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
16493842|NCT03334357|Experimental|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be >95% VO2max and HIIT with short intervals (Type B session), >120% VO2max.
~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.
~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
16493843|NCT03334357|Experimental|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.
~Electrical parameters:
~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.
~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).
~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.
~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
16493844|NCT03334344|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
16493845|NCT03334344|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
16493846|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
16493847|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
16493848|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
16493849|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
16493850|NCT03334279||non smokers|
16493851|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
16493852|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
16493853|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
16493854|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
16493857|NCT03334240|Experimental|CLS003|Digoxin and Furosemide topical formulation
16493858|NCT03334240|Placebo Comparator|Vehicle|Inactive vehicle
16493859|NCT03334227|Experimental|High-Flow nasal cannula (HFNC)|"Treatment with HFNC will be adjusted for SpO2 >92%, even with FiO2 of 0.21, if needed.
~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow >50 L/min is uncomfortable for many patients.
~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat."
16493889|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed
~at baseline: on admission to inpatient treatment
~at follow-up: 6 months after admission on outpatient basis"
16493890|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
16493860|NCT03334227|No Intervention|Conventional therapy|"Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 < 92% by pulse oximetry.
~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 >95% without oxygen supply is acceptable. On the contrary, SpO2 <92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients."
16493861|NCT03334214|Experimental|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
16493862|NCT03334214|Placebo Comparator|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
16493865|NCT03334188|Other|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
16493866|NCT03334188|Active Comparator|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
16493867|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
16493868|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
16493869|NCT03334162|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for 12 weeks in addition to usual care.
16493870|NCT03334162|No Intervention|Control group|Children in the control group will receive treatment as usual. The control group will be given the opportunity to participate in the intervention after study completion
16493871|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
16493872|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
16493873|NCT03334136|Active Comparator|Vitamin D|25-hydroxyvitamin D 20.000 IU capsule given orally. Five capsules the first day and thereafter one capsule every week for 4 months.
16493874|NCT03334136|Placebo Comparator|Placebo|Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
16493875|NCT03334123|Experimental|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
16493876|NCT03334123|Active Comparator|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
16493877|NCT03334110|Experimental|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
16493878|NCT03334110|Other|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
16493879|NCT03334097|Experimental|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
16493880|NCT03334084|Experimental|1|Scheme 1
16493881|NCT03334084|Experimental|2|Scheme 2
16493882|NCT03334084|Experimental|3|Scheme 3
16493883|NCT03334071|Active Comparator|Exercise Intervention|Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
16493884|NCT03334071|No Intervention|Negative Control|Patients in the control arm will not undergo an exercise training program.
16493885|NCT03334071|No Intervention|Observational|Patients who do not enrol in RCT will be enrolled in the observational arm
16493886|NCT03334058|Experimental|ARGX-113|
16493887|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
16493888|NCT03334045||Controls|Healthy controls
16493974|NCT03333395|Active Comparator|S Group (control group)|
16493891|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
16493892|NCT03334006|No Intervention|A: Control group|Standard of Care
16493893|NCT03334006|Active Comparator|B: Pentaglobin®|Standard of Care + Pentaglobin®
16493894|NCT03333993|Experimental|Intervention Group|Patients in this group will be submitted to 10 sessions of Mat Pilates exercises, performed twice a week, lasting 60 minutes, for a period of 5 weeks (from the beginning to the end of radiotherapy). The program will consist of group sessions of up to 4 patients, supervised by a specialized physiotherapist. In addition, they will be guided to follow with the home exercises, according to the institutional routine.
16493895|NCT03333993|Active Comparator|Control Group|Patients assigned to this group will not participate in the Mat Pilates exercises and will be instructed to maintain the home exercises for upper limbs, guided by physiotherapists in the postoperative period, according to the institutional routine.
16493896|NCT03333941||RES (Regenerative Epithelial Suspension)|
16493897|NCT03333928|Active Comparator|500mg HTD1801, bid|
16493898|NCT03333928|Active Comparator|1000mg HTD1801, bid|
16493899|NCT03333928|Placebo Comparator|placebo, bid|
16493900|NCT03333915|Experimental|High-grade ovarian cancer and triple negative breast cancer|
16493901|NCT03333902|Experimental|QLB type 2|"Ultrasound-guided, Inject at the point posterior to quadratus lumborum muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
16493902|NCT03333902|Experimental|QLB type 3|"Ultrasound-guided, Inject at the point between the quadratus lumborum and the psoas major muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
16493903|NCT03333902|Experimental|QLB type 2+3|"Ultrasound-guided, conduct both QLB type 2 and 3, 0.2% ropivacaine 15mL in each point of injection, for a total of 60mL.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
16493904|NCT03333902|Active Comparator|epidural anesthesia group (EA)|"Epidural catheter placement was conducted when finishing spinal anesthesia. After surgery, 30 mL saline (placebo) was Injected at the point posterior to the quadratus lumborum in each side for a total of 60mL. We used a single bolus of 0.15% ropivacaine + 2 mg morphine (diluted in 6 ml saline) via epidural cathether.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
16493905|NCT03333889|Active Comparator|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
16493906|NCT03333889|Experimental|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
16493907|NCT03333876|Active Comparator|Nasal Dilator|Nasal dilators have been used to treat snoring and sleep apnea. Many studies focus on external nasal dilators like Breathe Right Strips. These interventions largely were not effective in treating OSA. However, there is some evidence to suggest internal to the nose dilators (like Mute) may work to reduce snoring
16493908|NCT03333876|Active Comparator|Mandibular Advancement|Mandibular advancement devices have shown to be effective, but not necessarily acceptable to primary snorers.
16493909|NCT03333876|Active Comparator|Positional Therapy|Studies have shown mixed results for positional therapy as a whole. Braver and Block reported that foam wedges used to keep patients in a lateral position were not effective in reducing snoring in 20 individuals.
16493910|NCT03333850|Experimental|Visual feedback of physical activity|Participants in the exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing and walking. This information will be visible to the health personnel, the patients and their relatives.
16493911|NCT03333850|Active Comparator|No feedback of physical activity|The participants in the non-exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation. No visual feedback is provided.
16493912|NCT03333837|Active Comparator|Dance Group|The Dance Group will participate in 1-hour group improvisational dance lessons 2x/week for 12 weeks. Improvisational dance classes are grounded in 4 principles that shape the tone of the class and result in a sense of social belonging: non-judgment, non-competitiveness, curiosity, and playfulness. The following training strategies are used to maintain: active imagination, variability, and pacing.
16493913|NCT03333837|Active Comparator|Non-group Dance|The Non-group dance intervention is designed to capture the same dance movement and auditory stimuli as the group class without social interaction. Recordings of the dance instructor teaching a dance class will be played. This will ensure participants hear comparable music and receive comparable verbal auditory cues to prompt dance movements that students in the group class will hear, without interacting with other people. Improvisational dance is particularly suited for this means of delivery because the primary method of instruction is verbal auditory cueing. Participants will be asked to follow the same schedule as participants in the Dance Group arm and complete 2 one-hour dance sessions each week.
16493914|NCT03333837|Active Comparator|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
16493915|NCT03333837|Sham Comparator|No Contact|A No Contact condition captures the condition of no added social contact and no added dance movement. Participants randomized to the No Contact condition will be asked to continue their current disease management and lifestyle for 12 weeks
16493916|NCT03333824|Experimental|Wee-1 kinase inhibitor AZD1775|To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval
16493917|NCT03333798|Experimental|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
16493918|NCT03333798|Active Comparator|Standard psychosocial care|Standard psychosocial care delivered by health services.
16493919|NCT03333785|Experimental|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
16493920|NCT03333785|No Intervention|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
16493921|NCT03333772|Experimental|REAL-T Intervention|The current feasibility study will evaluate the feasibility of implementing the REAL-T RCT by enrolling 10 participants who are 18-30 years of age, conducting the REAL-T intervention with all participants over a 3-month period, evaluating pre-to-post changes in their health and quality of life, and assessing the process of implementing the study (feasibility and participant satisfaction).
16493922|NCT03333759|Experimental|Laser Treatment|"Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.
~Laser parameters are as follows:
~iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap"
16493923|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16493924|NCT03333733|Experimental|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
16493925|NCT03333733|No Intervention|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
16493926|NCT03333720|Experimental|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
16493927|NCT03333707|Experimental|Active|Participants will be provided will full access to the Pacifica app.
16493928|NCT03333707|No Intervention|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
16493929|NCT03333694|Experimental|CLL442|Cutaneous Cream application twice daily
16493930|NCT03333694|Placebo Comparator|Placebo|Placebo Cutaneous Cream application twice daily
16493931|NCT03333681|Experimental|Refractory rheumatoid arthritis patients|Autologous mesenchymal stem cells
16493932|NCT03333668|Active Comparator|Lisdexamfetamine - Placebo|
16493933|NCT03333668|Active Comparator|Guanfacine - Placebo|
16493934|NCT03333668|Experimental|Lisdexamfetamine - Guanfacine|
16493936|NCT03333642|Experimental|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
16493937|NCT03333629|Experimental|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
16493938|NCT03333629|No Intervention|Usual care|Providers will not change their early detection strategies, but will be monitored.
16493939|NCT03333616|Experimental|Nivolumab+Ipilimumab|"Nivolumab and Ipilimumab are administered intravenously every 3 weeks for a total of 4 maximum doses. After combination therapy, nivolumab will be administered as monotherapy every 4 weeks.
~Doses are determined per protocol."
16493940|NCT03333603|Experimental|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
16493941|NCT03333590|Experimental|Cohort 1 (Minimal Efficacious Dose) rAAVrh74.MCK.GALGT2|N = 3 [2.5 x E13 vg/kg per leg, delivered bilaterally (total 5.0 x E13 vg/kg)]
16493942|NCT03333590|Experimental|Cohort 2 (Dose Escalation) rAAVrh74.MCK.GALGT2|N=3 [5 x E13 vg/kg per leg, delivered bilaterally (total 1.0 x E14 vg/kg)]
16493943|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
16493944|NCT03333564|Experimental|VD3 group|treated with 50,000 IU VD3 / week
16493945|NCT03333564|Experimental|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
16493946|NCT03333564|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
16493947|NCT03333564|Other|Control group|No intervention was given
16493948|NCT03333551|Experimental|Patients with AL cardiac amyloid|Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
16494045|NCT03333005|Experimental|APX001 with Standard of Care Anti-fungal agent|
16493949|NCT03333538|Experimental|Stage 1 (component A)|a single administration of component A (VSV) of vaccine
16493950|NCT03333538|Experimental|Stage 1 (component B)|a single administration of component B (Ad5) of vaccine
16493951|NCT03333538|Experimental|Stage 2 (Primary Group)|150 people who will receive the vaccine in the therapeutic scheme: the sequential introduction of components A and B with an interval of 21 days
16493952|NCT03333538|Placebo Comparator|Stage 2 (Controll Group)|50 people who will receive placebo in the therapeutic scheme: the sequential introduction of components A (placebo) and B (placebo) with an interval of 21 days
16493953|NCT03333525|Experimental|Insulin dose-CARB counting HPM group|HPM (high protein meal), contained 36 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
16493954|NCT03333525|Experimental|Insulin dose-CARB counting HPFM group|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
16493955|NCT03333525|Experimental|Insulin dose-CARB+FPU counting-HPFM|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting plus fat-protein counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
16493956|NCT03333525|Active Comparator|Insulin dose-CARB counting SM group|SM (standart meal), contained 24 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
16493957|NCT03333512|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
16493958|NCT03333512|No Intervention|No nap|After each night with a 6.5-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead watch documentaries.
16493959|NCT03333499|Placebo Comparator|the control group|YanXinShi placebo pills
16493960|NCT03333499|Experimental|YanXinShi group|YanXinShi pills
16493961|NCT03333499|Active Comparator|Trimetazidine group|Trimetazidine pills
16493962|NCT03333499|Other|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
16493963|NCT03333486|Experimental|Treatment (fludarabine, cyclophosphamide, TBI, PBSCT)|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
16493964|NCT03333473|Experimental|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
16493965|NCT03333473|No Intervention|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
16493966|NCT03333460|Experimental|Active Comparator: Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
16493967|NCT03333460|Placebo Comparator|Sham Comparator: Sham rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with the software necessary for the operator to remain blind to the stimulation condition. Also, the software will be pre-programmed by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the individual resting motor threshold so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
16493968|NCT03333447||Study Population|Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, treated with VPRIV® at the beginning of the study. Patients should have one MRI data in the 5 previous years before starting VPRIV® treatment (up to 3 months after initiation of VPRIV®.
16493969|NCT03333434|Other|AFO - Ankle_7 group|AFO is active comparator, ANKLE7 is the experimental treatment
16493970|NCT03333434|Other|Ankle-7 - AFO group|AFO is active comparator, ANKLE7 is the experimental treatment
16493971|NCT03333408|Active Comparator|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
16493972|NCT03333408|No Intervention|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
16493973|NCT03333395|Active Comparator|HS Group (study group)|
16493975|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
16493976|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
16493977|NCT03333369|Active Comparator|Madopar Arm|A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide
16493978|NCT03333369|Placebo Comparator|Placebo Arm|A single dose of a cachet filled with Dextrose
16493979|NCT03333356|Experimental|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
16493980|NCT03333356|No Intervention|Standard Arm|Surveillance
16493981|NCT03333343|Experimental|Arm 1|EGF816+ trametinib in escalation phase
16493982|NCT03333343|Experimental|Arm 2|EGF816 + ribociclib in escalation phase
16493983|NCT03333343|Experimental|Arm 3|EGF816 + LXH254 in escalation phase
16493984|NCT03333343|Experimental|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
16493985|NCT03333343|Experimental|Arm B|EGF816 + trametinib in expansion phase
16493986|NCT03333343|Experimental|Arm C|EGF816 + ribociclib in expansion phase
16493987|NCT03333343|Experimental|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
16493988|NCT03333343|Experimental|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
16493989|NCT03333343|Experimental|Arm F|EGF816 + gefitinib in expansion phase
16493990|NCT03333343|Experimental|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
16493991|NCT03333330|Experimental|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.
~Intervention is related to the administration of contrast agents:
~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
16493992|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
16493993|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
16493994|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
16493995|NCT03333304|Experimental|PCT group|Procalcitonin measurement and Discontinuation of antimicrobials according to Procalcitonin kinetics
16493996|NCT03333304|No Intervention|Standard of care|Standard practice
16493997|NCT03333291|Experimental|Fecal transplantation|Duodenal transfer of healthy donor fecal suspension
16493998|NCT03333278|Active Comparator|Vitamins|intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)
16493999|NCT03333278|Other|Control|Hydrocortisone (50mg every 6 hours)
16494000|NCT03333265|Experimental|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
16494001|NCT03333265|Experimental|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
16494002|NCT03333265|Placebo Comparator|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
16494003|NCT03333252|Experimental|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
16494004|NCT03333252|Placebo Comparator|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
16494005|NCT03333239|Experimental|psychodynamic psychotherapy|
16494006|NCT03333239|Experimental|cognitive behavioral psychotherapy|
16494007|NCT03333239|Active Comparator|psychodynamic family intervention|
16494008|NCT03333226|Experimental|ARM lymph node preservation|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.
16494009|NCT03333226|Active Comparator|ARM lymph node removal|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed.
16494010|NCT03333213|Experimental|Gua Sha therapy|Patients' backs were first covered with Tumarol N Balsam. The study physician then applied a round-edged instrument (the inside smooth edged lip of a metal cap) to patients' skin in downward strokes. Patients were treated twice with a 7-day interval.
16494011|NCT03333213|No Intervention|Waitlist control group|Treatments in the control group were not regulated but patients were asked to continue their self-directed medical care. They were offered the Gua Sha therapy once the trial was concluded.
16494012|NCT03333187|Experimental|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
16494013|NCT03333187|Active Comparator|Arm B|Treatment with Ruxolitinib continuous therapy
16494014|NCT03333174|Experimental|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
16494015|NCT03333174|Active Comparator|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
16494104|NCT03332758||RD treated with vitrectomy|Vitreous fluid from retinal detachment treated with pars plana vitrectomy
16494016|NCT03333161|Experimental|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is >7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
16494017|NCT03333161|Active Comparator|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is <7.45."
16494018|NCT03333148|Experimental|Arm A - Nestle IMPACT Immunonutrition|Treatment Arm A (n=146) - Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
16494019|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
16494020|NCT03333135|Experimental|HK100 Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
16494021|NCT03333135|Sham Comparator|HK100 Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
16494022|NCT03333135|Experimental|UTMB Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
16494023|NCT03333135|Sham Comparator|UTMB Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
16494024|NCT03333122||Breast Conserving Therapy|Patient who undergo breast conserving therapy or breast conserving therapy with oncoplastic therapies will complete the BREAST-Q Lumpectomy survey module.
16494025|NCT03333122||Mastectomy|Patients who undergo mastectomy will complete the BREAST-Q Mastectomy survey module.
16494026|NCT03333122||Mastectomy with Reconstruction|Patient who undergo breast reconstruction will complete the BREAST-Q Reconstruction survey module. This group will be further subdivided based on implant or autologous tissue reconstruction.
16494027|NCT03333109|Experimental|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
16494028|NCT03333109|Experimental|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
16494029|NCT03333109|Placebo Comparator|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
16494030|NCT03333096|Other|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery
~Ocusweep system compared to neuropsychological testing"
16494031|NCT03333083|Experimental|Raltegravir + Lamivudine|
16494032|NCT03333070|Active Comparator|Treatment Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.
~After 12 weeks of treatment they will be randomized: treated arm will receive probiotic containing Lactobacillus reuteri for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
16494033|NCT03333070|Placebo Comparator|Placebo Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.
~After 12 weeks of treatment they will be randomized: control arm will receive placebo for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
16494034|NCT03333057|Experimental|NOV03 4 times daily (QID)|Perfluorohexyloctance solution 4 times daily (QID)
16494035|NCT03333057|Experimental|NOV03 2 times daily (BID)|Perfluorohexyloctance solution 2 times daily (BID)
16494036|NCT03333057|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
16494037|NCT03333057|Placebo Comparator|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
16494038|NCT03333044|Experimental|CHW-led health coaching|Group sessions
16494039|NCT03333044|Experimental|HIT-enabled & CHW led|Supportive care enabled by mobile devices.
16494040|NCT03333044|Experimental|CHW & Physician Feedback|Patient setting progress communicated to physician via PHI
16494041|NCT03333031|Experimental|HS-196|HS-196 will be administered intravenously as a single dose
16494042|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
16494043|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
16494044|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
16494046|NCT03332992|Experimental|Viral changes + General intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
16494047|NCT03332992|Experimental|Viral changes + Behavioral intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
16494048|NCT03332992|Experimental|Viral changes + Accountability|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
16494049|NCT03332992|Experimental|Protect others + General intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
16494050|NCT03332992|Experimental|Protect others + Behavioral intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
16494051|NCT03332992|Experimental|Protect others + Accountability|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
16494052|NCT03332966||Participants|"The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.
~The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission."
16494053|NCT03332953|Other|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
16494054|NCT03332940|Experimental|Tc99m-sulfur colloid + Tc99m-tilmanocept|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
16494055|NCT03332927|Experimental|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
16494056|NCT03332927|Active Comparator|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
16494057|NCT03332914|Active Comparator|First group|control group fisrt and after washing out Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
16494058|NCT03332914|Active Comparator|Second group|"Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
~after washing out control group"
16494059|NCT03332888|Experimental|Interventional Group|For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.
16494060|NCT03332875|Experimental|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
16494061|NCT03332875|Experimental|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
16494062|NCT03332862|Experimental|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
16494063|NCT03332862|Active Comparator|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
16494064|NCT03332849|Experimental|Cohort 1|T1DM: Multiple dose subcutaneous administration
16494065|NCT03332849|Experimental|Cohort 2|T1DM: Multiple dose subcutaneous administration
16494066|NCT03332849|Experimental|Cohort 3|T2DM: Multiple dose subcutaneous administration
16494067|NCT03332849|Experimental|Cohort 4|T2DM: Multiple dose subcutaneous administration
16494068|NCT03332836|Experimental|Cohort 1|Single dose subcutaneous administration (Dose A)
16494069|NCT03332836|Experimental|Cohort 2|Single dose subcutaneous administration (Dose B)
16494070|NCT03332836|Experimental|Cohort 3|Single dose subcutaneous administration (Dose C)
16494071|NCT03332823|Experimental|SME Ambassadors training & program|- SME Ambassadors will participate in train-the-ambassador workshops and provide voluntary services and promote mental well-being activities to vulnerable groups.
16494072|NCT03332810|Experimental|SME family based physical activity|Adults and family members will participate into one core session and one booster session
16494073|NCT03332810|Active Comparator|Gathering activity|Adults and family members will participate into two gathering activities
16494074|NCT03332797|Experimental|Dose Escalation: GDC-9545|During dose escalation, postmenopausal participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
16494075|NCT03332797|Experimental|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose lower than the MTD or MAD determined in single-agent dose escalation, in combination with the label-recommended dose of palbociclib.
16494076|NCT03332797|Experimental|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 1).
16494077|NCT03332797|Experimental|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 1) in combination with an approved LHRH agonist.
16494482|NCT03330405|Experimental|B1. TNBC Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494078|NCT03332797|Experimental|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 2).
16494079|NCT03332797|Experimental|Dose Expansion: Cohort A4: GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 2) in combination with an LHRH agonist.
16494080|NCT03332797|Experimental|Dose Expansion: Cohort A5: GDC-9545 Dose 3|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 3).
16494081|NCT03332797|Experimental|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib.
16494082|NCT03332797|Experimental|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib and an approved LHRH agonist.
16494083|NCT03332797|Experimental|Dose Expansion: Cohort C1: GDC-9545 Dose 2 +/- Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2) as a single agent for 14 days, followed by treatment with either GDC-9545 (Dose 2) plus palbociclib or GDC-9545 (Dose 2) alone for the duration of the study, as determined by the investigator.
16494084|NCT03332797|Experimental|Dose Expansion: Cohort C2: GDC-9545 Dose 2 + Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2), in combination with the label-recommended dose of palbociclib.
16494085|NCT03332797|Experimental|Dose Expansion: Cohort X: GDC-9545 Dose 3|GDC-9545 will be administered at a pre-defined dose level (Dose 3) to postmenopausal participants currently receiving clinical benefit with GDC-0927 or GDC-0810 on Studies GO29656 (NCT02316509) or GO29642 (NCT01823835), respectively, upon completion of their studies.
16494086|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
16494087|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
16494088|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
16494089|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
16494090|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
16494091|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
16494092|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
16494093|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
16494094|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
16494095|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
16494096|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
16494097|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
16494098|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
16494099|NCT03332784|Placebo Comparator|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
16494100|NCT03332771|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
16494101|NCT03332771|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
16494102|NCT03332771|Active Comparator|Glimepiride|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
16494103|NCT03332771|Placebo Comparator|Placebo|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
16494105|NCT03332758||RD treated with external drainage|Subretinal fluid from retinal detachment treated with external drainage.
16494106|NCT03332758||Macular holes treated with vitrectomy|Vitreous fluid from patients treated for macular hole
16494107|NCT03332758||ERM treated with vitrectomy|Vitreous fluid from patients treated for epiretinal membrane
16494108|NCT03332745||Severe aortic stenosis|Patients with severe aortic stenosis who are scheduled to undergo aortic valve replacement surgery
16494109|NCT03332745||Control group|Patients scheduled to undergo non-aortic valve cardiac or elective ascending aortic surgery
16494110|NCT03332732|Experimental|Part 1A|In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..
16494111|NCT03332732|Experimental|Part 1B|In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.
16494112|NCT03332732|Experimental|Part 2 - 2A|Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022
16494113|NCT03332732|Experimental|Part 2 - 2B|Multiple dose administration of High Dose VNRX-5133 + VNRX-5022
16494114|NCT03332732|Placebo Comparator|Part 2 - 2C|Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)
16494115|NCT03332719|Active Comparator|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
16494116|NCT03332719|Experimental|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
16494117|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
16494118|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
16494119|NCT03332693|Active Comparator|No exercise|Volunteers will not participate in exercise
16494120|NCT03332693|Active Comparator|Light exercise|Volunteers will participate in one short exercise
16494121|NCT03332693|Active Comparator|Heavy exercise|Volunteers will participate in heavy exercise
16494122|NCT03332680|Experimental|EmbryoGlue® (laboratory culture medium)|"laboratory culture medium
~laboratory embryo culture medium, embryos are placed in this media prior to transfer into uterus via embryo transfer procedure to facilitate IVF. EmbryoGlue contains Hyaluronic acid."
16494123|NCT03332680|Active Comparator|Standard control medium|"laboratory culture medium
~In standard procedure embryos are placed in a media prior to transfer into uterus via embryo transfer procedure to facilitate IVF."
16494124|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
16494125|NCT03332667|Experimental|131I-MIBG with Dinutuximab and Vorinostat|Patients will receive vorinostat on days 0-13. 131I-MIBG will be received on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
16494126|NCT03332654||Multiple sclerosis|Prevalence and risk factor of stress urinary incontinence in women with multiple sclerosis and included in the database over 15 years from December 1999 to June 2014, who had undergone a urodynamic test
16494127|NCT03332641|Experimental|Citron peel Extract|Citron peel extract for 12 weeks
16494128|NCT03332641|Placebo Comparator|Placebo|Placebo for 12 weeks
16494129|NCT03332628|Other|Microneedle application|This is the only study arm, which all participants complete. Nine sites on the upper arm will be identified. Baseline measurements of transepidermal water loss, electrical resistance, hydration, and color will be made at each site. The 9 sites will be divided into clusters of 3 sites each. The first cluster will have small microneedle patches applied to at each site. This will only occur on the first study day. Transepidermal water loss and electrical resistance are re-measured immediately after microneedle application. The sites will be covered with a small patch secured with medical tape. The second cluster of sites will not receive microneedle application but will just be covered with patches. The last cluster of sites will not have microneedle application or patches. Electrical resistance will be re-measured at all sites for 4 days after microneedle application. Measurements from the 2nd and 3rd cluster of sites allow each subject to serve as their own control in data analysis.
16494130|NCT03332615|Active Comparator|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
16494131|NCT03332615|Placebo Comparator|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
16494132|NCT03332602|Experimental|free FeSO4|wheat bread fortified with free FeSO4
16494133|NCT03332602|Experimental|free FeSO4 and empty microspheres|wheat bread fortified with free FeSO4, and empty microspheres
16494134|NCT03332602|Experimental|free FeSO4 with eudragit polymer|wheat bread fortified with free FeSO4, and eudragit polymer
16494135|NCT03332602|Experimental|free FeSO4 with Hyaluronic Acid|wheat bread fortified with free FeSO4, and hyaluronic acid
16494136|NCT03332602|Experimental|encapsulated FeSO4 3.2%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading
16494137|NCT03332602|Experimental|encapsulated FeSO4 20%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 20% Fe loading
16494138|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading, and encapsulated Vitamin A as microspheres
16494139|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A, free folicacid|wheat bread fortified with encapsulated FeSO4 as microsphere with 3.2% Fe loading, encapsulated Vitamin A as microspheres and free folic acid
16494483|NCT03330405|Experimental|B2. HR+BC DDR Defect +Assay Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494140|NCT03332602|Experimental|FeSO4 embedded in Hyaluronic Acid|wheat bread fortified with FeSO4 that is embedded in hyaluronic acid.
16494141|NCT03332589|Experimental|Monotherapy Safety Run-in: E6201|"E6201 320 mg/m^2 administered IV over 2 hours twice weekly on Days 1, 4, 8, 11, 15 and 18, repeated every 28 days (=1 cycle).
~Dose reductions for toxicity are 240 mg/m^2 (Dose Level -1) and 160 mg/m^2 (Dose Level -2) twice weekly."
16494142|NCT03332589|Experimental|Combination Safety Run-in: E6201 Plus Dabrafenib|Dose Level 1: E6201 320 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -1: E6201 240 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -2: E6201 240 mg/m^2 twice weekly plus dabrafenib 100 mg BID. Dose Level -3: E6201 160 mg/m^2 twice weekly plus dabrafenib 100 mg BID Dose Level -4: E6201 160 mg/m^2 twice weekly plus dabrafenib 75 mg BID. Dose Level -5: E6201 160 mg/m^2 twice weekly plus dabrafenib 50 mg BID.
16494143|NCT03332589|Experimental|Expansion: E6201 Plus Dabrafenib|A total of up to N=18 will be treated at the E6201 plus dabrafenib combined MTD.
16494144|NCT03332576|Experimental|Cohort 1|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)
~Low dose cyclophosphamide"
16494145|NCT03332576|Experimental|Cohort 2|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)
~Low dose cyclophosphamide"
16494146|NCT03332576|Experimental|Cohort 3|"3 Doses DPX-Survivac (1 prime, 2 boost q8w)
~Low dose cyclophosphamide"
16494147|NCT03332576|Experimental|Cohort 4|"5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)
~Low dose cyclophosphamide"
16494148|NCT03332576|Experimental|Cohort 5|"5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)
~Low dose cyclophosphamide"
16494149|NCT03332563|Experimental|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
16494150|NCT03332563|No Intervention|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
16494151|NCT03332550||purulent peritonitis|Hinchey 3
16494152|NCT03332550||faecal peritonitis|Hinchey 4
16494153|NCT03332537|No Intervention|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
16494154|NCT03332537|Experimental|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
16494155|NCT03332524|Experimental|Arm 1 Product SP160412|oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.
16494156|NCT03332524|Placebo Comparator|capsules Ibuprofen&placebo|2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,
16494157|NCT03332524|Placebo Comparator|Capsule Chlorpheniramin&placebo|capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route
16494158|NCT03332511|Experimental|Investigational arm|Oral nilotinib 300mg twice daily with a 12-hour interval
16494159|NCT03332498|Experimental|Pembrolizumab and Ibrutinib|"Pembrolizumab intravenously (IV): 200 mg every 3 weeks (Q3W).
~Ibrutinib by mouth (PO): Phase I Dose Escalation at doses of 420 mg daily (cohort 0) and 560 mg daily (cohort 1);. Phase II treatment at Recommended Phase II dose."
16494160|NCT03332485|Experimental|ECP Colon Prep Kit|
16494161|NCT03332485|Active Comparator|MoviPrep®|
16494162|NCT03332472|Experimental|Telemedicine group|Telematics visit in front of the conventional visit face to face
16494163|NCT03332472|Placebo Comparator|Conventional group|Group with conventional medical visit
16494164|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
16494165|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
16494166|NCT03332446|Experimental|cooling|strength training and cold water immersion
16494167|NCT03332446|No Intervention|control|strength training and no cold water immersion
16494168|NCT03332433|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
16494169|NCT03332433|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
16494170|NCT03332420||Observational 1|Huaiqihuang Granule
16494171|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
16494172|NCT03332420||Observational 3|Standard treatment
16494173|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
16494174|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
16494175|NCT03332381|Active Comparator|Attention training technique|
16494176|NCT03332381|Active Comparator|Mindful self-compassion|
16494177|NCT03332368||TCM exposure group|TCM exposure group were treated with traditional Chinese medicine while the other do not treated with that
16494178|NCT03332355|Experimental|PAC-1 in combination with temozolomide|Temozolomide (PO) will be dosed at 150 mg (adjusted for body size area [m2]) daily for 5 days starting on day 8 at cycle 1, and then for each successive cycle. In Component 2, the first PAC-1 dose will be 1 dose level lower than the PAC-1 MTD established in Component 1, and the maximum dose will not exceed 450 mg. PAC-1 will be taken in the morning on days 1-21 in each 28-day cycle.
16494179|NCT03332342|Experimental|Daily rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.
16494180|NCT03332342|Active Comparator|Weekly rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.
16494181|NCT03332342|Experimental|Occasional rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions
16494182|NCT03332329|Experimental|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
16494183|NCT03332316|Placebo Comparator|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
16494184|NCT03332316|Experimental|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
16494185|NCT03332316|Experimental|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
16494186|NCT03332316|Experimental|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
16494187|NCT03332303|Experimental|Experimental: Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC)|"Estradiol Vaginal Cream, USP, 0.01%, administered once daily for 7 days.
~Intervention: Drug: Estradiol Vaginal Cream, USP, 0.01%"
16494188|NCT03332303|Active Comparator|Active Comparator: Estrace® Cream|"Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%), administered once daily for 7 days.
~Intervention: Drug: Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%)"
16494189|NCT03332303|Placebo Comparator|Placebo Comparator: Placebo (Test vehicle cream) Vaginal Cream|"Placebo (Test vehicle cream) Vaginal Cream, administered once daily for 7 days.
~Intervention: Drug: Placebo (Test vehicle cream) Vaginal Cream"
16494190|NCT03332290|Active Comparator|sport training|training course lasting 10 days. It included 10 days of multisports practice once (2h) per day.
16494191|NCT03332290|Experimental|diving|diving course lasting 10 days. It included 10 days of diving once (2h) per day. Diving will be carried out using air at a maximum depth of 30-meters
16494192|NCT03332264|Experimental|Drug coated balloon catheter|"PTA with paclitaxel coated SeQuent Please OTW"
16494193|NCT03332264|Active Comparator|Drug coated stent|"PTA with paclitaxel coated Eluvia Vascular Stent System"
16494194|NCT03332264|Active Comparator|Uncoated stent|PTA with bare nitinol stent (as commonly used in site)
16494195|NCT03332251|Experimental|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
16494196|NCT03332251|No Intervention|Control|No treatment will be provided for control participants.
16494197|NCT03332238|Placebo Comparator|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
16494198|NCT03332238|Active Comparator|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
16494199|NCT03332225|Experimental|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
16494200|NCT03332225|Placebo Comparator|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
16494201|NCT03332225|Experimental|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
16494202|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
16494203|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
16494204|NCT03332199|No Intervention|Control|Participants in the control group received standard treatment from oncologists and nurses at Hanoi Medical University Hospital.
16494205|NCT03332199|Experimental|Intervention|In addition to standard care provided by oncologists and nurses at Hanoi Medical University Hospital as described above, participants assigned to the intervention group received the psychoeducational intervention delivered by the nurse researcher.
16494206|NCT03332186|Experimental|Mild Renal Impairment|Mild renal impairment defined as eGFR 60 to <90 mL/min/1.73 m^2
16494207|NCT03332186|Experimental|Moderate renal impairment|Moderate renal impairment defined as eGFR 30 to <60 mL/min/1.73 m^2
16494208|NCT03332186|Experimental|Severe renal impairment|Severe renal impairment defined as eGFR <30 mL/min/1.73 m^2, not requiring dialysis
16494209|NCT03332186|Experimental|Normal renal function|Normal renal function defined as eGFR ≥90 mL/min/1.73 m^2
16494210|NCT03332173|Experimental|BGB-3111|
16494211|NCT03332160|Active Comparator|Standard of Care|Standard home lymphedema care
16494212|NCT03332160|Experimental|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
16494213|NCT03332147|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16494484|NCT03330405|Experimental|C1. Ovarian CA Recurrent Plat-Sensitive Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494214|NCT03332147|Active Comparator|reference group-Earlysense system|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16494215|NCT03332134|Experimental|Married Couple Dyad|Husband-wife dyads will receive the intimate partner violence (IPV) intervention program over the course of six weeks.
16494216|NCT03332134|No Intervention|Control Group|Husband-wife dyads in the control group will not receive an intervention.
16494217|NCT03332121|Experimental|B001,B001 dose escalation|5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
16494218|NCT03332108|Experimental|Intervention|Those allocated to the intervention arm will be enrolled in the mHealth intervention (EpxBreastfeeding) for six months, and will also be asked about breastfeeding status at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
16494219|NCT03332108|Other|Control|Those in the control arm will be asked about breastfeeding status (exclusive, supplementing, or formula only) at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
16494220|NCT03332095|Experimental|Cohort 1: DOR|Participants will receive a single dose of DOR at study entry (Day 0).
16494221|NCT03332095|Experimental|Cohort 2: DOR/3TC/TDF|Participants will receive DOR/3TC/TDF from Day 0 through Week 96.
16494222|NCT03332082|Experimental|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
16494223|NCT03332069|Experimental|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
16494224|NCT03332069|Active Comparator|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
16494225|NCT03332056|Active Comparator|Belladonna and Opium (B&O) suppository|A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation. The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine. Opium is compound drug that is composed of 20 alkaloids. The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
16494226|NCT03332056|Placebo Comparator|Placebo Suppository|placebo suppository
16494227|NCT03332043|Experimental|HIRREM|Subjects in the experimental arm will receive an in-office, open-label course of acoustic stimulation linked to brain activity (High-resolution, relational, resonance-based, electroencephalic mirroring, HIRREM).
16494228|NCT03332043|Active Comparator|Ambient Nature Sounds|Subjects in the active comparator arm will receive an in-office, open-label course of acoustic stimulation not linked to brain activity (ambient natures sounds).
16494229|NCT03332017|Experimental|Arm A|Approximately 140 subjects to receive BGB-3111 and obinutuzumab
16494230|NCT03332017|Experimental|Arm B|Approximately 70 subjects to receive obinutuzumab
16494231|NCT03332004|Experimental|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
16494232|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
16494233|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
16494234|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
16494235|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
16494236|NCT03331952||Invasive pneumococcal disease study (PCV-D)|"Prospective study of children with invasive pneumococcal disease / probable bacterial meningitis (PCV-D)
~Clinical procedures
~At study enrolment:
~Admission clinical findings / laboratory results will be recorded.
~A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status, household structure, environmental exposures, and recent antimicrobial use.
~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) may be performed as part of a child's diagnostic work up. CXRs will be read and interpreted primarily by the AHC radiologists. All CXR will subsequently be re-read by two study clinicians and interpreted according to the WHO paediatric radiologic pneumonia criteria.
~Laboratory procedures
~• Residual routine clinical specimens further analysed as part of the study protocol:
~Blood and cerebrospinal fluid culture specimens.
~EDTA / serum specimens.
~Urine."
16494485|NCT03330405|Experimental|C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494237|NCT03331952||Pneumonia study (PCV-P)|"Prospective study of children hospitalised with clinical and/or radiologic pneumonia (PCV-P)
~Clinical procedures As described for PCV-D.
~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) is performed on all children with an admission diagnosis of pneumonia. CXRs will be handled as described for PCV-D.
~Laboratory procedures
~Study specific specimens:
~o Nasopharyngeal swab at enrolment.
~Residual routine clinical specimens further analysed as part of the study protocol:
~As described for PCV-D."
16494238|NCT03331952||Pneumococcal colonisation study (PCV-C)|"Cross-sectional pneumococcal colonisation surveys in children attending the AHC out-patient department (PCV-C)
~Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees.
~Clinical procedures
~• Subjects will be recruited from the OPD waiting area after nurse triage. A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status (by review of the handheld immunisation card where possible), household structure, environmental exposures, and recent antimicrobial use.
~Laboratory procedures • Study specific specimens:
~o Nasopharyngeal swab at enrolment. A nasopharyngeal swab will be collected from each participant and these will be processed as described for PCV-P."
16494239|NCT03331939|Experimental|No stimulation|All patients will receive three different stimulations
16494240|NCT03331939|Other|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
16494241|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
16494242|NCT03331913|Active Comparator|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
16494243|NCT03331913|Experimental|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
16494244|NCT03331900|Placebo Comparator|Placebo|
16494245|NCT03331900|Active Comparator|COR388 TBD mg|
16494246|NCT03331887|Active Comparator|E-max CAD crowns retained with Fiber Reinforced Composite Post|"The modulus of elasticity of FRC post is (18-22 GPa) resembling that of dentin. Ideally the remaining tooth, the fiber post and the composite cement create a monoblock in which the loads are uniformly dissipated, ensuring a behavior similar to healthy teeth with a lower risk of root fracture. Using lithium disilicate e.max restorations is documented in literature as a successful restoration."
16494247|NCT03331887|Experimental|E-max CAD Endocrowns|Endocrowns have several advantages over conventional crowns like adequate function and esthetic with less chair time reduced number of interfaces in the restorative system. Stress concentration is less because of the reduction in the nonhomogenous material present. The preparation design is conservative compared to the traditional crown. Supragingival margin prevents interferences with periodontal tissues so involvement of the biological width is minimal. The application and polymerization of resins is also better controlled. Emax ceramic material have a high mechanical strength and are capable of being acid etched, with the adhesive capacity of adhesive systems and resinous cements, made it possible to restore endodontically treated teeth, without cores and intraradicular posts.
16494248|NCT03331874||Basal Cell Carcinoma|Diagnosis of Basal Cell Carcinoma by Reflectance confocal microscopy
16494249|NCT03331861|Experimental|Metformin|Metformin for 6 months
16494250|NCT03331861|Placebo Comparator|Placebo|Matched placebo for 6 months
16494251|NCT03331848|Placebo Comparator|PLACEBO|
16494252|NCT03331848|Experimental|PXT002331 - 20mg|
16494253|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
16494254|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>
~> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
16494255|NCT03331822|Experimental|Light|High illuminance ,white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux.
16494256|NCT03331822|No Intervention|No Light|Ambient, standard white fluorescent environmental light will serve as control.
16494257|NCT03331809|Active Comparator|Control|
16494258|NCT03331809|Experimental|Two-hand|
16494259|NCT03331796|Experimental|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
16494260|NCT03331796|Experimental|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
16494261|NCT03331796|Placebo Comparator|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
16494262|NCT03331783|Experimental|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.
~The difference between the four patches is that they are made of four different adhesives.
~The primary endpoint is measured after 8 hours and 24 hours."
16494263|NCT03331770|Experimental|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
16494264|NCT03331757|Experimental|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494265|NCT03331757|Experimental|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494486|NCT03330405|Experimental|D.Urothelial CA Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494266|NCT03331757|Experimental|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494267|NCT03331757|Experimental|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494268|NCT03331757|Experimental|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494269|NCT03331757|Experimental|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494270|NCT03331757|Experimental|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
16494271|NCT03331731|Experimental|Single arm|Single Arm
16494272|NCT03331718|No Intervention|Control|Pancreaticojejunostomy with duct-to-mucosa anastomosis is performed as usual.
16494273|NCT03331718|Active Comparator|PGA felt reinforcement|In addition to usual pancreaticojejunostomy, PGA felt is used in duplicate.
16494274|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
16494275|NCT03331692|Other|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.
~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
16494276|NCT03331692|Other|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
16494277|NCT03331679|Experimental|2 Wk HIIT|2 weeks of High Intensity Interval Training
16494278|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
16494279|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
16494280|NCT03331653|Experimental|Dry Needling and Ischemic Compression at the Trigger Point|Dry Needling and Ischemic Compression at the Trigger Point
16494281|NCT03331653|Active Comparator|Intervention at 1.5 cm from the Trigger Point|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
16494282|NCT03331640|Experimental|OFF|
16494283|NCT03331640|Experimental|FOLFIRI|
16494284|NCT03331627|Active Comparator|STR001-IT/STR001-ER|
16494285|NCT03331627|Active Comparator|STR001-IT/STR001-ER Placebo|
16494286|NCT03331627|Placebo Comparator|STR001-IT placebo/STR001- ER placebo|
16494287|NCT03331614|No Intervention|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
16494288|NCT03331614|Active Comparator|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
16494289|NCT03331588|Active Comparator|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted thoracic surgery, no use of rib-spreader.
16494290|NCT03331588|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted thoracic surgery, no use of rib-spreader.
16494291|NCT03331575|Experimental|Arm1(Hypofractionated Radiotherapy)|Hypofractionated Radiotherap（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
16494292|NCT03331575|Placebo Comparator|Arms2（Conventional Radiotherapy）|Conventional Radiotherapy（PTV-G60Gy/30Fx,2Gy/Fx; PTV-C 50.4Gy/30Fx, 1.8Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
16494293|NCT03331562|Active Comparator|pembrolizumab & paricalcitol|pembrolizumab 200 mg IV q 3 weeks and paricalcitol 25 mcg IV 3 xs per week
16494294|NCT03331562|Placebo Comparator|pembrolizumab & placebo|pembrolizumab 200 mg IV q 3 weeks & placebo- normal saline IV 3 xs per week
16494295|NCT03331549||Myocardial infarction|
16494296|NCT03331549||Control group|
16494297|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
16494298|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
16494299|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
16494300|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
16494301|NCT03331523|Experimental|Calcipotriene/betamethasone dipropionate|
16494302|NCT03331523|Active Comparator|Taclonex®|
16494303|NCT03331523|Placebo Comparator|Placebo|
16494304|NCT03331497|Experimental|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
16494305|NCT03331497|No Intervention|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
16494306|NCT03331484|Other|Ticagrelor and Rivaroxaban|All participants will be prescribed ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily for a year.
16494307|NCT03331471|Active Comparator|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
16494308|NCT03331471|Experimental|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
16494309|NCT03331458|Experimental|subjects with prostate cancer|
16494310|NCT03331445|Experimental|160 ppm Nitric Oxide|
16494311|NCT03331432|Placebo Comparator|Placebo|Taking daily placebo capsules for 4 weeks
16494312|NCT03331432|Experimental|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
16494313|NCT03331419||Males with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
16494314|NCT03331419||Females with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
16494315|NCT03331406|Experimental|12-week physical activity program|"The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.
~At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.
~Exercise Trainer --A exercise trainer will be assigned to design a physical activity program."
16494316|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
16494317|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
16494321|NCT03331367|Active Comparator|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
16494322|NCT03331367|Active Comparator|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
16494323|NCT03331367|Active Comparator|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
16494324|NCT03331367|Active Comparator|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
16494325|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
16494326|NCT03331354|Experimental|Compass|a distant learning vocational program
16494328|NCT03331328|Sham Comparator|Control/sham|The CO2 laser will not be activated but the same procedure of moving the probe inside the vagina in a systematic manner including depressing the foot pedal at similar frequency will be performed. The smoke evacuator will also be activated, laser eye glasses and masks worn by the laser team and the subject. However, the laser will remain in the standby mode.
16494329|NCT03331328|Active Comparator|Treated|Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
16494330|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
16494331|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
16494332|NCT03331302|Active Comparator|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
16494333|NCT03331302|Experimental|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
16494334|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
16494335|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
16494336|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
16494337|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
16494338|NCT03331276|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with high Sn-2 Palmitate, Alpha Lactalbumin and Osteopontin to better mimic human milk.
16494339|NCT03331276|Active Comparator|Brand|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
16494340|NCT03331263|Experimental|Abdominal application of 2% CHG|
16494341|NCT03331263|Experimental|Groin application of 2% CHG|
16494342|NCT03331263|No Intervention|Control treatment with no application|
16494343|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously
~Each cycle contains 21 days
~Dosing is per the FDA label for other cancers"
16494344|NCT03331237|Active Comparator|LVS group|interscalene injection
16494345|NCT03331237|Active Comparator|ISO group|in this group all patients will receive ISO block.
16494346|NCT03331224|Experimental|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
16494347|NCT03331224|Active Comparator|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
16494348|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
16494349|NCT03331198|Experimental|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
16494350|NCT03331198|Experimental|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose + ibrutinib
16494351|NCT03331198|Experimental|Phase 2 JCAR017 monotherapy|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
16494352|NCT03331198|Experimental|Phase 1 JCAR017 + venetoclax|Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
16494353|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
16494354|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
16494355|NCT03331172|Experimental|High Intensity Focused Ultrasound|
16494356|NCT03331159|Experimental|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
16494357|NCT03331159|Active Comparator|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
16494358|NCT03331146|Placebo Comparator|Control group|saline infusion will be administered after induction of general anesthesia
16494359|NCT03331146|Active Comparator|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
16494360|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
16494361|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
16494362|NCT03331120|Active Comparator|Control Group|"1--Control group
~. Conventional treatment:
~moist hot pack.
~manual therapy.
~Therapeutic Exercise.
~Home program routine."
16494363|NCT03331120|Experimental|Study or Experimental Group|"2--Experimental or study group:
~moist hot pack.
~manual therapy.
~Therapeutic Exercise.
~Home program routine.
~ambulatory mirror image functional re-training through wearing 3D adjustable cervical thoracic Posture Corrective orthosis (CTPCO) For 10 weeks(3Times/week for 20 minutes)."
16494364|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
16494365|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
16494366|NCT03331081|Experimental|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
16494367|NCT03331081|Active Comparator|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
16494368|NCT03331081|Active Comparator|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
16494369|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
16494370|NCT03331055|Experimental|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
16494371|NCT03331055|Experimental|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
16494372|NCT03331055|No Intervention|Control|Conventional analgesic medication is offered.
16494373|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
16494374|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
16494375|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
16494376|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
16494377|NCT03331029|Other|transesophageal echocardiography|Comparison of 3D Ultrasound with transesophageal echokardiography
16494440|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
16494378|NCT03331016|Other|Waitlist Control Group|Waitlist Control Group will serve as control group for 6 months, receiving no intervention during that time but completing periodic surveys to assess outcomes among controls (knowledge, attitudes, behaviors). They will also later receive the intervention (training program) and be followed for 6 more months.
16494379|NCT03331016|Experimental|Intervention Group|Intervention Group will receive the intervention (training program) right away, then will be followed for 6 months.
16494380|NCT03331003|Experimental|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
16494381|NCT03331003|Placebo Comparator|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
16494382|NCT03330990|Other|Entrectinib / Midazolam|
16494383|NCT03330977|Other|Before and after use of compression garments|"At inclusion, patients will only have medication prescription as usual but without compression garments, and thus, for 4 months.
~4 months after inclusion, patients will continue medication but will also be prescribed compression garments Then every 6 months, until 26 months, patients will come back to have new compression garments (as usual practice)"
16494384|NCT03330964|Experimental|electroacupuncture group|The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
16494385|NCT03330964|No Intervention|control group|The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
16494386|NCT03330938|Experimental|CBI and Resilience|8 sessions total, once a week, 2 hours long each, consistent of 6 sessions of Cognitive-behavioral Intervention (CBI) plus 2 sessions to improve resilience strengths.
16494387|NCT03330938|Active Comparator|Cognitive-behavioral Intervention|8 sessions total, once a week, 2 hours long each. Cognitive-behavioral Intervention (CBI) without resilience strengthening.
16494388|NCT03330925|Experimental|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
16494389|NCT03330912|Experimental|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
16494390|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
16494391|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
16494392|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
16494393|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
16494394|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
16494395|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
16494396|NCT03330899|Active Comparator|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.
~Each dose = 0,5 ml"
16494397|NCT03330899|Placebo Comparator|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.
~Each dose = 0,5 ml"
16494398|NCT03330873|Experimental|Foley catheter|After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.
16494399|NCT03330873|Experimental|Disposable balloon uterine stent|After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.
16494400|NCT03330860|Experimental|Neuromarketing strategy|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
16494401|NCT03330860|Active Comparator|No-capsule group|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
16494402|NCT03330847|Active Comparator|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
16494403|NCT03330847|Active Comparator|Olaparib+Ceralasertib|All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
16494404|NCT03330847|Active Comparator|Olaparib+adavosertib|All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
16494405|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
16494441|NCT03330561|Experimental|PRS-343|
16494442|NCT03330548|Active Comparator|TeleMOVE!|Veterans randomized to the control arm will participate in TeleMOVE!, an arm of the Management of Overweight Veterans (MOVE!) program. TeleMOVE! is telehealth treatment program within the VA designed to improve the lives of Veterans by assisting with weight management and health promotion. This program includes daily interaction with in-home messaging technologies and clinician contact as needed
16494407|NCT03330808|Experimental|Epidural with general anesthesia|Epidural anesthesia with 0.2% ropivacaine 10 ml
16494408|NCT03330808|No Intervention|General anesthesia alone|Sevoflurane and nitrous oxide.
16494409|NCT03330795|Experimental|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
16494410|NCT03330782|Experimental|Elderly|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.
16494411|NCT03330782|Active Comparator|Adult|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.
16494412|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
16494413|NCT03330756|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
16494414|NCT03330756|Experimental|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
16494415|NCT03330743|No Intervention|Usual care|
16494416|NCT03330743|Placebo Comparator|Parent Mentor|
16494417|NCT03330743|Active Comparator|Parent Mentor with Positive Deviance|
16494418|NCT03330730|Experimental|Experimental|"Patients with oncological follow up and home-care service package IsereADOM:
~Objects connected to patients' home (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer) with graduated protocol for medical platform support.
~Digital linkbook (different from the medical file) accessible to the patient and the standard care actors.
~Referent sentinel: a field actor to coordinate the care. Preferred contact of the patient outside the center Motivational coaching: 1 to 2 axes to be defined by the investigator among the following axes (physical activity, nutrition and hydration, drug compliance, medical follow-up, chronic and moral pain, acceptance of the disease and treatments)."
16494419|NCT03330730|No Intervention|Control|Patients with oncological follow up only
16494420|NCT03330717|Placebo Comparator|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
16494421|NCT03330717|Experimental|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
16494422|NCT03330717|Experimental|General anesthesia with preoperative session of hypnosis|Patients interested in hypnosis but too anxious to have surgery while on hypnosis sedation will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation using technology of virtual reality
16494423|NCT03330704|Active Comparator|Standard Therapy|This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.
16494424|NCT03330704|Experimental|Balanced Therapy|This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach
16494425|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v1|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
16494426|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v2|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
16494427|NCT03330678|Experimental|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
16494428|NCT03330665|No Intervention|Control|No meditation
16494429|NCT03330665|Experimental|Intervention|Meditate using headspace app 3 times a week
16494430|NCT03330639|Experimental|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
16494431|NCT03330639|Placebo Comparator|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
16494432|NCT03330626|Active Comparator|IO group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the intake-output balance.
16494433|NCT03330626|Experimental|InBody group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the bioimpedance analysis (InBody S10).
16494434|NCT03330613|Other|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
16494435|NCT03330613|Active Comparator|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
16494436|NCT03330600|Experimental|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
16494437|NCT03330600|Placebo Comparator|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
16494438|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
16494439|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
16494480|NCT03330405|Experimental|A1. NSCLC Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494481|NCT03330405|Experimental|A2. NSCLC PD-L1 Resistant DDR+ Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494443|NCT03330548|Experimental|Culinary Rx|Veterans randomized to the experimental arm will participate in Culinary Rx. Culinary Rx is an online instructional cooking and nutrition course that healthcare professionals can prescribe to patients who need to transition away from a Standard American Diet to a more health-supportive, whole foods, plant-based lifestyle. In partnership with The Plantrician Project, this course will focus on teaching the foundational cooking skills needed for long-term behavioral change, coupled with lifestyle education around nutrition and resources that will help users successfully face the many challenges inherent to dietary change.
16494444|NCT03330535|Active Comparator|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
16494445|NCT03330535|Experimental|Reminders once a week|Participants will receive active reminders once a week.
16494446|NCT03330535|Experimental|Reminders three times a week|Participants will receive active reminders three times a week.
16494447|NCT03330535|Experimental|Daily reminders|Participants will receive active reminders daily.
16494448|NCT03330522|Experimental|Intervention|"The active intervention is Love, Sex, & Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
16494449|NCT03330522|Active Comparator|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
16494450|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
16494451|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
16494452|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
16494453|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
16494454|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=15)
16494455|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=15)
16494456|NCT03330496||Small infants|1-3 month-old infants (n=15)
16494457|NCT03330496||Older infants|3-6 month-old infants (n=15)
16494458|NCT03330483||Female Speedicath nelathon|Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
16494459|NCT03330483||Female nelathon|Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
16494460|NCT03330483||Male Speedicath tiemann|Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
16494461|NCT03330483||Male tiemann|Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion
16494462|NCT03330470|Experimental|exercise and carnosine supplementation|exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
16494463|NCT03330470|Experimental|exercise and supplementation with placebo|exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
16494464|NCT03330470|Experimental|stretching controls and carnosine supplementation|stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
16494465|NCT03330470|Experimental|stretching controls and supplementation with placebo|stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
16494466|NCT03330457|Experimental|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
16494467|NCT03330457|Experimental|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
16494468|NCT03330457|Experimental|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
16494469|NCT03330457|Experimental|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
16494470|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
16494471|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
16494472|NCT03330431|Experimental|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
16494473|NCT03330431|Experimental|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
16494474|NCT03330431|Active Comparator|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
16494475|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
16494476|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
16494477|NCT03330405|Experimental|Dose Level 0 Phase 1b|"Drug: Avelumab
~Drug: Talazoparib"
16494478|NCT03330405|Experimental|Dose Level -1 Phase 1b|"Drug: Avelumab
~Drug: Talazoparib"
16494479|NCT03330405|Experimental|Dose Level -2 Phase 1b|"Drug: Avelumab
~Drug: Talazoparib"
16494487|NCT03330405|Experimental|E1. CRPC Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494488|NCT03330405|Experimental|E2. CRPC DDR Defect +Assay Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494489|NCT03330405|Experimental|F: Advanced Solid Tumors with BRCA or ATM defect Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
16494490|NCT03330392|Experimental|AGP|take two tablets per day (500 mg/day) for 8 weeks.
16494491|NCT03330392|Placebo Comparator|Placebo|take two tablets per day for 8 weeks.
16494492|NCT03330379|Experimental|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
16494493|NCT03330379|No Intervention|usual care|patients with usual care
16494494|NCT03330366|Experimental|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
16494495|NCT03330366|Placebo Comparator|Placebo|take two capsules per day for 8 weeks
16494496|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
16494497|NCT03330340||Percutaneous vertebroplasty|All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
16494498|NCT03330340||Conservative treatment|In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.
16494499|NCT03330327|Experimental|Part 1|Intravenous (IV) infusion of HM12470
16494500|NCT03330327|Experimental|Part 2: Sequence 1|Intravenous (IV) infusion of HM12470
16494501|NCT03330327|Experimental|Part 2: Sequence 2|Intravenous (IV) infusion of HM12470
16494502|NCT03330314|Experimental|Part 1|Intravenous (IV) infusion
16494503|NCT03330314|Experimental|Part 2: Cohort A|Intravenous (IV) infusion (Dose A)
16494504|NCT03330314|Experimental|Part 2: Cohort B|Intravenous (IV) infusion (Dose B)
16494505|NCT03330314|Experimental|Part 2: Cohort C|Intravenous (IV) infusion (Dose C)
16494506|NCT03330301||Exposed|"Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.
~Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
16494507|NCT03330301||Non-exposed|"Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.
~Controls: cohort of matched disease-free individuals"
16494508|NCT03330288||Participants with Stage I-III Knee osteoarthritis (KOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
16494509|NCT03330288||Participants with Stage I-III Hip osteoarthritis (HOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
16494510|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
16494511|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
16494512|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
16494513|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
16494514|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
16494515|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
16494516|NCT03330262|Experimental|BALCAP prosthesis, then Control|Participants performed exercises daily at home wearing the BALCAP prosthesis for 6 weeks. After 6 weeks, participants performed the control condition (the same exercises without the BALCAP). Tests were performed before and after each 6-week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
16494606|NCT03329703|Experimental|Immediate-Treatment|This group will receive Project UPLIFT immediately after completing surveys.
16494607|NCT03329703|Active Comparator|Waitlist Control|This group will receive Project UPLIFT after waiting approximately 3 months to begin the intervention.
16494517|NCT03330262|Experimental|Control, then BALCAP prosthesis|Participants performed exercises daily at home for 6 weeks without wearing the BALCAP prosthesis (control), followed by another 6 weeks of the same exercises with the BALCAP prosthesis (intervention). Tests were performed before and after each 6 week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
16494518|NCT03330249|Experimental|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
16494519|NCT03330249|Active Comparator|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
16494520|NCT03330236|Experimental|Study arm|"All patients in the study arm will receive the anesthetic care guided by the SedLine EEG Brain Function Monitor in addition to the conventional monitors. In addition to the conventional/standard interventions of anesthetic care, an additional intervention related to this trial is the anesthetic depth management via the titration of the propofol and remifentanil infusion rates to maintain SEF and PSI in the targeted ranges based on the SedLine EEG monitoring."
16494521|NCT03330236|No Intervention|Control arm|All patients in the control arm will receive the anesthetic care guided by the conventional monitors only. Patients in the control arm will be monitored using the SedLine EEG Brain Function Monitor; however, the screen of this monitor will be covered by an opaque cloth and blinded to the anesthesia team.
16494522|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
16494523|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
16494524|NCT03330197|Experimental|Arm 1 - Closed|Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
16494525|NCT03330197|Experimental|Arm 2 - Open|Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
16494526|NCT03330184|Experimental|Berberine Hydrochloride group|2/day, 16 weeks
16494527|NCT03330184|Experimental|Bifidobacterium group|2/day, 16 weeks
16494528|NCT03330184|Experimental|Berberine Hydrochloride and Bifidobacterium group|2/day, 16 weeks
16494529|NCT03330184|Placebo Comparator|placebo|bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks
16494530|NCT03330171|Other|HIV-unexposed children|HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
16494531|NCT03330171|Other|HIV-exposed children|A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
16494532|NCT03330158|Experimental|ASTS device|Implantation of device ASTS (for ACTIVE TREATMENT SCOLIOSIS SYSTEM ) in children between 4 and 10
16494533|NCT03330145|Experimental|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
16494534|NCT03330145|Active Comparator|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
16494535|NCT03330132|Active Comparator|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494536|NCT03330132|Experimental|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494537|NCT03330132|Experimental|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494538|NCT03330132|Experimental|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494539|NCT03330132|Experimental|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494540|NCT03330132|Experimental|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494608|NCT03329690|Experimental|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
16494541|NCT03330132|Experimental|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494542|NCT03330132|Experimental|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494543|NCT03330132|Experimental|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494544|NCT03330132|Experimental|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494545|NCT03330132|Experimental|Alternating recombinant vaccine and adjuvanted vaccine|Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
16494546|NCT03330119|Experimental|Alternate Management|
16494547|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
16494548|NCT03330106|Experimental|Part A: Pevonedistat 25 mg/m^2 + Pevonedistat 50 mg/m^2|Pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
16494549|NCT03330106|Experimental|Part A: Pevonedistat 50 mg/m^2 + Pevonedistat 25 mg/m^2|Pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
16494550|NCT03330106|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or pevonedistat 20 mg/m^2 in combination with carboplatin plus paclitaxel 175 mg/m^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m^2 or 20 mg/m^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.
16494551|NCT03330093|Experimental|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
16494552|NCT03330093|Active Comparator|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
16494553|NCT03330080||Ecological momentary assessment (EMA)|The ecological momentary assessment (EMA) will be used for participants to complete surveys from home on two occasions each day over seven days.
16494554|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
16494555|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
16494556|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
16494557|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
16494558|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
16494559|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
16494560|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
16494561|NCT03330028|Experimental|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
16494562|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
16494563|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
16494564|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
16494565|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
16494566|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
16494567|NCT03329950|Experimental|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
16494568|NCT03329950|Experimental|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
16494569|NCT03329950|Experimental|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
16494570|NCT03329950|Experimental|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
16494571|NCT03329937|Experimental|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor >=1 cm) will receive niraparib (200 mg PO).
16494572|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
16494573|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
16494574|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.
~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles
~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
16494575|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.
~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles
~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
16494576|NCT03329898|Experimental|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
16494577|NCT03329898|Sham Comparator|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
16494578|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
16494579|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
16494580|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
16494581|NCT03329872||Patients group|Patients follow-up in hospital will have data collection
16494582|NCT03329859|Experimental|Interventional arm|"High resolution standardized laparoscopic cholecystectomy Patients in which laparoscopic cholecystectomy was performed after high Resolution standardization and Training of the OR Team according to the Standard."
16494583|NCT03329859|Active Comparator|Control arm|No 'High resolution standardized laparoscopic cholecystectomy' Patients in which laparoscopic cholecystectomy was performed in the conventional way without prior standardization
16494584|NCT03329846|Active Comparator|Nivolumab + Placebo|"Specified dose on specified day
~Participants will no longer receive BMS-986205 Placebo"
16494585|NCT03329846|Experimental|Nivolumab + BMS-986205|"Specified dose on specified day.
~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
16494586|NCT03329833|Experimental|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
16494587|NCT03329833|Experimental|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
16494588|NCT03329833|Experimental|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
16494589|NCT03329833|No Intervention|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
16494590|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
16494591|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
16494592|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
16494593|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
16494594|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
16494595|NCT03329807|Experimental|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
16494596|NCT03329807|Sham Comparator|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.
~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
16494597|NCT03329781|Experimental|Trial|350 mg of BCM-95, 1 capsule per day, for 21 days.
16494598|NCT03329781|Placebo Comparator|Control|350 mg of starch, 1 capsule per day, for 21 days
16494599|NCT03329755|Experimental|Experimental|
16494600|NCT03329755|Other|Standard|
16494601|NCT03329742|Placebo Comparator|Control protein diet arm|20% protein content
16494602|NCT03329742|Experimental|Low protein diet arm|10% protein content
16494603|NCT03329729||Hyperlipidemic patients|
16494604|NCT03329716|Other|Immediate Brace Weaning|Immediate weaning of brace
16494605|NCT03329716|Other|Gradual Brace Weaning|Nocturnal brace wearing for 6 months prior to stopping brace
16494609|NCT03329690|Active Comparator|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
16494610|NCT03329690|Other|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
16494611|NCT03329690|Other|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
16494612|NCT03329677|Experimental|Transference-focused Psychotherapy (TFP)|Transference-focused psychotherapy is a psychodynamic talk therapy utilized in treating borderline personality disorder in men and women.
16494613|NCT03329664|Experimental|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
16494614|NCT03329664|Active Comparator|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
16494615|NCT03329651|Experimental|Metformin treatment|
16494616|NCT03329651|Placebo Comparator|Placebo treatment|
16494617|NCT03329638|Experimental|DE-127 Ophthalmic Solution low dose|
16494618|NCT03329638|Experimental|DE-127 Ophthalmic Solution medium dose|
16494619|NCT03329638|Experimental|DE-127 Ophthalmic Solution high dose|
16494620|NCT03329638|Placebo Comparator|Placebo Ophthalmic Solution|
16494621|NCT03329625|Experimental|Pathways Triple P|Families randomized to the Pathways Triple P received a 14 week home based intervention.
16494622|NCT03329625|Active Comparator|Services as Usual|Families randomized to the services as usual condition received services as usual through the Missouri Children's Division
16494623|NCT03329612|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
16494624|NCT03329612|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
16494625|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
16494626|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
16494627|NCT03329586|Experimental|Training|
16494628|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
16494629|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
16494630|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
16494631|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
16494632|NCT03329560|Experimental|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
16494633|NCT03329547|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= SKF101804 cefixime 400 mg test capsules and B= cefixime 400 mg reference capsules. Subjects will receive single oral dose of treatment A in treatment period 1 on Day 1 and treatment B in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
16494634|NCT03329547|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B= cefixime 400 mg reference capsules and A= SKF101804 cefixime 400 mg test capsules. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days. Subjects will receive single oral dose of treatment B in treatment period 1 on Day 1 and A in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
16494635|NCT03329534|Experimental|Subjects with GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.
16494636|NCT03329534|Active Comparator|Subjects without GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.
16494637|NCT03329521|Experimental|Multi-component quality improvement intervention|A multi-component quality improvement intervention will be provided at chronic kidney disease (CKD) programs.
16494638|NCT03329521|No Intervention|Usual Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
16494639|NCT03329508|Experimental|P2B001|Fixed dose combination once daily capsule of pramipexole and rasagiline
16494640|NCT03329508|Experimental|rasagiline capsule|rasagiline Once daily capsule
16494641|NCT03329508|Experimental|Pramipexole capsule|Pramipexole once daily capsule
16494642|NCT03329508|Active Comparator|Pramipexole Extended Release|pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg
16494643|NCT03329495|Active Comparator|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
16494644|NCT03329495|Experimental|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
16494645|NCT03329482|Experimental|Pulse Ultrasound Group A|This is the Pulse Ultrasound group. Twenty five patients will be in this group.
16494646|NCT03329482|Experimental|Kneading Massage Group B|This is kneading massage group . Also 25 patients will be in this group.
16494647|NCT03329469||Experimental: 1: Toshiba CT-FFR Arm|All patients who consent will receive Toshiba CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
16494648|NCT03329456|Other|Ropivacaine|Single arm intervention
16494652|NCT03329417|Active Comparator|Traditional occupational therapy|The program includes 30 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
16494653|NCT03329417|Active Comparator|Mirror therapy using a mirror box|The program includes 30 minutes of mirror therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
16494654|NCT03329417|Experimental|Virtual reality based mirror therapy|The program includes 30 minutes treatment session of virtual reality mirror therapy, followed by 20 minutes of motor task specific training in each treatment session.
16494655|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1-6°C
16494656|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
16494657|NCT03329391|Experimental|Intervention Group|The intervention group will receive a 8-week nurse-led psychosocial care group,which involve 90 minutes session every week.
16494658|NCT03329391|No Intervention|Control Group|The control group will receive usual care, which refers to the pharmacological therapy provided by psychiatrists in the Psychiatric Department.
16494661|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
16494662|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
16494663|NCT03329352|Experimental|F&P Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
16494664|NCT03329339|No Intervention|2 L PEG with ascorbic acid group|
16494665|NCT03329339|Experimental|1 L PEG with ascorbic acid with PLD|
16494666|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
16494667|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
16494668|NCT03329300|Other|All participants|Family-based Behavioral Treatment (FBT)
16494669|NCT03329287|Experimental|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
16494670|NCT03329287|Active Comparator|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
16494671|NCT03329287|Active Comparator|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
16494672|NCT03329274||Patients with Erdheim-Chester Disease|
16494673|NCT03329261|Active Comparator|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
16494674|NCT03329261|Active Comparator|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
16494675|NCT03329248|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, oxaliplatin, SBRT
16494676|NCT03329235|Experimental|Intraosseous and intra-articular|injection of PRP 2 ml
16494677|NCT03329235|Active Comparator|intra-articular PRP|injection PRP 2 ml
16494678|NCT03329235|Active Comparator|Intra-articular injection of HA|injection of HA 2 ml
16494679|NCT03329222|Experimental|Intervention group|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
16494680|NCT03329222|Active Comparator|Control group|Standard cow's milk with prebiotics mixture
16494681|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
16494682|NCT03329196|Experimental|MT-6548|
16494683|NCT03329196|Active Comparator|Darbepoetin alfa|
16494684|NCT03329183|Experimental|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
16494685|NCT03329183|No Intervention|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
16494686|NCT03329183|No Intervention|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
16494687|NCT03329170|Experimental|CHD intervention|educational intervention using motivational interviewing
16494688|NCT03329170|No Intervention|CHD control|At 24 and 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
16494689|NCT03329170|No Intervention|Healthy control|At 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
16494690|NCT03329157|Other|Rebuilding Bridges|This is a one-group study and the group will receive the Rebuilding Bridges intervention
16494691|NCT03329144|Experimental|Cognitive Behavioural Therapy|The women in this arm will receive a 9-week CBT-based curriculum delivered by Public Health Nurses to help build resilience and optimize mood, anxiety, and emotion regulation while attending a supported school program in Niagara Region.
16494692|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
16494693|NCT03329118|Experimental|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
16494694|NCT03329105|Experimental|Sea Salt Mouth Rinse|
16494695|NCT03329105|Active Comparator|Standardized Oral Health Practices|
16494698|NCT03329079|Experimental|Mobile Technology Plus (MT+)|Experimental arm will receive a 3-month MT+ intervention using the premium mobile phone app version with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
16494699|NCT03329079|Active Comparator|Mobile Technology (MT)|Comparison group will receive the basic version of the mobile phone app only.
16494700|NCT03329066|Experimental|MAST - Managing Asthma & Sleep in Teens|This is an eight week intervention consisting of 4 group and 4 individual tailored coaching sessions that focuses on both asthma and sleep. In this behavioral medicine intervention, teenagers learn ways to better care for their asthma and sleep hygiene. Teen sessions are delivered in school. Their caregivers will receive four educational booklets that correspond to each group session; topics mirror the objectives of each group and the booklets are sent at the time of each group.
16494701|NCT03329066|Active Comparator|ASMA - Asthma Self-Management for Adol|ASMA is an evidence-based intervention for students, caregiver education, and education for students' medical providers. The student intervention consists of 3 group sessions & 5 individual tailored coaching sessions. All sessions are held at school. The caregiver intervention includes 3 educational booklets that correspond to the timing of the student group and 4 brief telephone-counseling sessions to review the booklets, answer questions, and provide strategies to support adolescents' steps to care for their asthma. With caregiver permission, we mail students' healthcare providers a toolkit consisting of (1) a letter informing them their patient is participating in ASMA and is being directed to them for clinical evaluation and (2) summaries of key NHLBI guidelines for treating asthma.
16494702|NCT03329066|Placebo Comparator|Information & Referral Control Group|The information-and-referral control intervention is a student-only intervention that consists of 3 group sessions and 5 individual sessions. Sessions are held once a week at school, where students will receive guideline-based information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
16494703|NCT03329053|Experimental|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
16494704|NCT03329053|Active Comparator|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
16494705|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
16494706|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
16494707|NCT03329027|Experimental|Vibrating Mode 1|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
16494708|NCT03329027|Experimental|Vibrating Mode 2|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
16494709|NCT03329027|Sham Comparator|Sham|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week)
16494710|NCT03329014|Experimental|Intravenous Remimazolam|4 mg intravenous remimazolam as an intravenous control
16494711|NCT03329014|Experimental|10 mg Powder Remimazolam|Powder containing 10 mg remimazolam for intranasal administration
16494712|NCT03329014|Experimental|10 mg Solution Remimazolam|Solution containing 10 mg remimazolam for intranasal administration
16494713|NCT03329014|Experimental|20 mg Powder Remimazolam|Powder containing 20 mg remimazolam for intranasal administration
16494714|NCT03329014|Experimental|20 mg solution Remimazolam|Solution containing 20 mg remimazolam for intranasal administration
16494715|NCT03329014|Experimental|40 mg Powder Remimazolam|Powder containing 40 mg remimazolam for intranasal administration
16494716|NCT03329014|Experimental|40 mg Solution Remimazolam|Solution containing 40 mg remimazolam for intranasal administration
16494717|NCT03329014|Placebo Comparator|Placebo Powder|Powder containing 20 mg placebo for intranasal administration
16494718|NCT03329014|Placebo Comparator|Placebo solution|Solution containing 20 mg placebo for intranasal administration
16494719|NCT03329001|Experimental|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase
16494720|NCT03329001|Experimental|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
16494721|NCT03329001|Experimental|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.
16494722|NCT03329001|Experimental|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
16494723|NCT03329001|Experimental|Stage 3: High fat meal-fasted sequence|Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.
16494724|NCT03329001|Experimental|Stage 3: Fasted-high fat meal sequence|Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.
16494725|NCT03328988|Experimental|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
16494726|NCT03328988|No Intervention|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.
~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
16494727|NCT03328975|Active Comparator|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
16494728|NCT03328975|Placebo Comparator|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
16494729|NCT03328962|No Intervention|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
16494730|NCT03328962|Experimental|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
16494731|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
16494732|NCT03328936|Experimental|Arm I (melphalan hydrochloride for 3-day severe neutropenia)|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for for predicted 3-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
16494733|NCT03328936|Experimental|Arm II (melphalan hydrochloride or 5-day severe neutropenia))|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for predicted 5-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
16494734|NCT03328923|Experimental|500mg brown seaweed powder|2 x 250mg capsules InSea2® (brown seaweed powder)
16494735|NCT03328923|Placebo Comparator|Placebo|2 x capsules microcrystalline cellulose (bulking agent) (0mg InSea2®)
16494736|NCT03328910||Analgesia monitoring|After anesthesia induction, all participants received standard anesthesia monitoring, SPI monitor (GE Healthcare, Helsinki, Finland) and bispectral index (BIS). BIS was kept between 40-60, whereas no specific target was determined for SPI. At the end of surgery, anesthesia was terminated and the patients were stimulated to wake up. After the participants were able to breathe spontaneously and obey verbal commands, extubation was carefully performed, and the monitoring of SPI was stopped.
16494737|NCT03328897|Experimental|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
16494738|NCT03328897|Experimental|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
16494739|NCT03328897|Placebo Comparator|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
16494740|NCT03328884|Other|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
16494741|NCT03328871|Experimental|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
16494742|NCT03328871|Experimental|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
16494743|NCT03328858|Other|Ketogenic Diet|Participants will be provided a consultation with a ketogenic dietitian, and test the tolerance to the diet in an inpatient mode
16494744|NCT03328845|Other|Tresiba & NovoRapid|Patients treated with Tresiba insulin and NovoRapid insulin
16494745|NCT03328845|Other|Toujeo SoloStar & NovoRapid|Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
16494746|NCT03328845|Other|Tresiba & Humalog Kwikpen|Patients treated with Tresiba insulin and Humalog kwikpen insulin
16494747|NCT03328845|Other|Toujeo SoloStar & Humalog Kwikpen|Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
16494748|NCT03328845|Other|Tresiba & Apidra|Patients treated with Tresiba insulin and Apidra insulin
16494749|NCT03328845|Other|Toujeo SoloStar & Apidra|Patients treated with Toujeo SoloStar insulin and Apidra insulin
16494750|NCT03328832|Active Comparator|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
16494751|NCT03328832|Active Comparator|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
16494752|NCT03328819|Experimental|Acupuncture for Depression/Acupuncture for pain|
16494753|NCT03328819|Experimental|Acupuncture for pain/Acupuncture for Depression|
16494785|NCT03328572|Experimental|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
16494754|NCT03328793|Experimental|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:
~mood assessment
~emotion assessment
~mobility assessment
~communication assessment"
16494755|NCT03328793|Active Comparator|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:
~mood assessment
~emotion assessment
~mobility assessment
~communication assessment"
16494756|NCT03328780||Hemoglobin determination|In this study classical laboratory determination, determination with HemoCue® and Rad-67™ will be performed to compare precision of those three methods as well as their correlation.
16494757|NCT03328767|Experimental|Early activity and Mobilisation intervention|Patients will be randomised within 48 hrs of commencing ECMO. Patients unable to initially receive active physical training will receive passive physical training for a minimum of 20 minutes and a maximum of one hour per day to maintain joint and muscle activity until active physical training is commenced. The intervention involves a progression of exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 minutes) at each session, based on our published ICU mobility scale now used internationally in ICU trials. This is performed with or without IMV (including both endotracheal tubes or tracheostomies).
16494758|NCT03328767|No Intervention|Standard Care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
16494759|NCT03328754|Experimental|Group 1 Powerscope|Powerscope placed bilaterally for class II correction
16494760|NCT03328754|Experimental|Group 2 Forsus|Forsus placed bilaterally for class II correction
16494761|NCT03328741|Experimental|Joint Academy|Online osteoarthritis treatment
16494762|NCT03328741|Active Comparator|The BOA program|Face-to-face osteoarthritis treatment
16494763|NCT03328728|Experimental|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
16494764|NCT03328728|Active Comparator|Synvisc-One|One intra-articular injection of a crosslinked HA
16494765|NCT03328715|Active Comparator|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
16494766|NCT03328715|Sham Comparator|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
16494767|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
16494768|NCT03328689|Experimental|Physical activity in the community|The physical activity program will include an individualized exercise program delivered in community exercise facility plus education..
16494769|NCT03328689|Active Comparator|Control group standard care|Participants from the control group will receive no additional intervention other than being encouraged to continue with their physiotherapists or chiropractor recommendation which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
16494770|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
16494771|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
16494772|NCT03328663|Experimental|CARE intervention|"Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist
~The CARE intervention contain 3 component
~a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills
~a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty
~a self-care component to promote caregiver health and well-being"
16494773|NCT03328663|Active Comparator|Standard transplant care|"Standard Transplant Care
~Social work consults to help caregivers only upon request"
16494774|NCT03328650||Proximal Humerus Fracture Patients|As part of their routine care, patients who have experienced a proximal humerus fracture that requires operative fixation will receive the A.L.P.S® Proximal Humerus Plating System. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
16494775|NCT03328637|Experimental|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman & Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
16494776|NCT03328637|No Intervention|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
16494777|NCT03328624|Experimental|DVT Cuff users|Current or previous DVT cuff users
16494778|NCT03328598|Experimental|Positive psychology therapy group|This arm will be given a positive psychological group intervention developed from an foreign psychotherapy.
16494779|NCT03328598|Experimental|Resilience promotion therapy group|This arm will be given a resilience group intervention developed from our pervious research results.
16494780|NCT03328598|Active Comparator|Controlled routine activity group|This arm will continue to participate in conventional community activities.
16494781|NCT03328585|Active Comparator|CBT-I in person|
16494782|NCT03328585|Experimental|CBT-I via telemedicine|
16494783|NCT03328585|Other|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
16494784|NCT03328572|Active Comparator|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
16494882|NCT03327870||4|Healthy Volunteers
16494786|NCT03328559|Other|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
16494787|NCT03328559|Other|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
16494788|NCT03328533|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
16494789|NCT03328533|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine bitartrate infusion by a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min). The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
16494790|NCT03328520|Experimental|First Year Students in Wellness FYIs|
16494791|NCT03328507|Experimental|BLI4900|BLI4900 Bowel Preparation
16494792|NCT03328507|Active Comparator|PEG Control|Polyethylene glycol-based bowel preparation
16494793|NCT03328494|Experimental|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
16494794|NCT03328494|Experimental|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. During dose escalation, further exploration of the treatment schedule for the BOS172722-paclitaxel combination will be initiated. In such combination cohorts, BOS172722 will be administered with paclitaxel on Days 1, 8, and 15 only of each treatment cycle (except for Cycle 2 Day1), and will not be administered on Day 2, 9, and 16. These alternative schedules will be explored to further characterize the pharmacokinetics and tolerability of such a dosing regimen.
16494795|NCT03328494|Experimental|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
16494796|NCT03328481|Experimental|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
16494797|NCT03328481|Active Comparator|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
16494798|NCT03328468|Experimental|Breathing Exercise|
16494799|NCT03328455|Experimental|Active training|Adaptive training tailored to each individual's thresholds will be used. Specifically, a two-alternative forced-choice TOJ task will be used, where participants will be asked to judge the temporal order of the stimulus pair (an auditory beep and a visual flash) with varying SOAs. On each training day, the range of SOAs will be established for individuals based on their thresholds determined from the pre-training TOJ assessment given on the same day. The maximum SOA will be 0.2 log units greater than their estimated threshold and will be used for both visual leading (positive SOA) and auditory leading (negative SOA) stimuli. Feedback will be provided after each response.
16494800|NCT03328455|Sham Comparator|Passive training|To control for pure practice or exposure effects, a second group of elderly participants will undergo passive training. Participants will be exposed to the stimulus pair with varying SOAs, similarly as in the active training group. The maximum SOA for each individual will be likewise determined by his or her threshold from the TOJ assessment. However participants will not be asked to perform the TOJ task and no feedback will be provided. Instead, participants will perform an oddball task in which they are asked to detect a stimulus that occurs less frequently than the standard one. Having an oddball task in both auditory and visual modalities will ensure that participant's attention is divided between the two modalities as required in the active training task.
16494801|NCT03328442|Experimental|Vista technique|The vista technique with PRF membrane uses a Vestibular incision subperiosteal tunnel access in combination with Platelet rich fibrin membrane to treat gingival recession defects.
16494802|NCT03328442|Active Comparator|modified coronally advanced flap|A modified coronally advanced flap utilising Platelet rich fibrin membrane to treat gingival recession defects.
16494803|NCT03328429|Other|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
16494804|NCT03328429|Other|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
16494805|NCT03328416|Experimental|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
16494806|NCT03328403|Experimental|Aspiration First|Aspiration thrombectomy with large bore catheters
16494807|NCT03328403|Experimental|Stent retriever first|Thrombectomy with a licensed stent retriever device
16494808|NCT03328390|Experimental|Quadratus lumborum block Group|ultrasound guided
16494809|NCT03328390|Active Comparator|Transversus abdominis plane block Group|ultrasound guided
16494810|NCT03328364||enzalutamide (mCRPC pre-chemo)|Patients treated with enzalutamide prior to chemotherapy
16494811|NCT03328364||enzalutamide and chemotherapy (mCRPC post chemo)|Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
16494812|NCT03328351|Experimental|manual group|"The Manual therapy (Mobilization):
~Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set
~Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.
~Strengthening Exercises for deep neck flexor muscle"
16494813|NCT03328351|Sham Comparator|sham group|"Superficial soft tissue massage
~Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
16494814|NCT03328325|Experimental|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
16494883|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
16494815|NCT03328312|Active Comparator|Sugammadex|For reversal of rocuronium neuromuscular- block we will use Sugammadex
16494816|NCT03328312|Placebo Comparator|neostigmine+atropine|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
16494817|NCT03328312|Experimental|neostigmine+atropine+sugammadex|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.
16494818|NCT03328299|Active Comparator|Dexmedetomidine group|patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
16494819|NCT03328299|Placebo Comparator|bupivacaine group|patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
16494820|NCT03328286|Experimental|Weekly group meeting w/psychotherapist|All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or Problems the Group members have
16494821|NCT03328273|Other|Arm A Part 1 and 2|DISCONTINUED (ceralasertib monotherapy)
16494822|NCT03328273|Experimental|Arm B Part 1 and 2|ceralasertib + acalabrutinib in combination
16494823|NCT03328260|Experimental|Treatment|
16494824|NCT03328247|No Intervention|Control|Control group will attend their routine melanoma follow-ups
16494825|NCT03328247|Experimental|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
16494826|NCT03328234|Experimental|SIB-IMRT combined chemotherapy with IFI|
16494827|NCT03328234|Experimental|SIB-IMRT with IFI|
16494828|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
16494829|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
16494830|NCT03328195|Active Comparator|Neuro RX Gamma synchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
16494831|NCT03328195|Sham Comparator|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
16494832|NCT03328195|Active Comparator|Neuro RX Gamma asynchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril. The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
16494833|NCT03328182|Experimental|New oral endotracheal tube holder|Single Study Product Arm
16494834|NCT03328169|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia
16494835|NCT03328169|Experimental|Mindfulness|Mindfulness-Based Therapy
16494836|NCT03328156||patient with STEMI will treated by PPCI|Primary angioplasty procedure The procedure will be performed using a standard angioplasty technique. A bolus of100 IU kg of heparin will be administered intra-arterially after insertion of the vascular catheter. The target lesions will initially treated with appropriate balloon predilatation as necessary, followed by intracoronary stenting. After stent implantation, heparin will be routinely administered. The sheaths will be removed the same day.
16494837|NCT03328156||patient with STEMI will treated by Thrombolytic therapy|oral clopidogrel (300 mg), Low-flow nasal oxygen, oral acetylsalicylic acid (325 mg), Will be given to each patient. Streptokinase will be given intravenously at 1.5 million units over approximately 60 min. Reperfusion afterTT will be assessed according to clinical criteria .
16494838|NCT03328143|Experimental|Treatment with Lavender|Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.
16494839|NCT03328130|Experimental|Cohort 1 - Low Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.
16494840|NCT03328130|Experimental|Cohort 2a - Medium Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the medium dose. Confirmatory dose will be determined after DSMC assessment.
16494841|NCT03328130|Experimental|Cohort 2b - High Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.
16494842|NCT03328130|Experimental|Cohort 3 - High Dose (confirmatory cohort)|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
16494843|NCT03328117|Active Comparator|Intervention|
16494844|NCT03328117|Placebo Comparator|Placebo|
16494845|NCT03328104|Experimental|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
16494846|NCT03328091|Active Comparator|Traditional pre-test genetic counseling|"In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing
~Participant is given a pamphlet introducing prostate cancer genes, genetic testing
~Participant is sent electronic family history tool
~Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
16494847|NCT03328091|Experimental|Pre-test video education|"Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing
~Participant is sent electronic family history tool
~Participant is approached in clinic by research staff at a pre-planned time
~The patient is given the Genetic Testing Information for Decision Making packet
~The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
16494848|NCT03328078|Experimental|CA-4948 dose escalation|Part A1: Dose-level cohorts with up to 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for CA-4948.
16494884|NCT03327857|Experimental|Neihulizumab (AbGn-168H)|Intravenous doses of Neihulizumab (AbGn-168H)
16494849|NCT03328078|Experimental|CA-4948 and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral CA-4948 in combination with 560 mg daily (QD) of oral ibrutinib (or 420 mg QD for WM/LPL and CLL/SLL). Separate escalation will be performed for each of these ibrutinib doses. The starting dose of CA-4948 to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 18 patients will be required to establish optimal combination dosing.
16494850|NCT03328078|Experimental|CA-4948 and ibrutinib dose expansion|"In expansion phase, the CA-4948 recommended Phase 2 dose (RP2D) in combination with ibrutinib will be administered in Non-Hodgkin Lymphoma (NHL) disease-specific cohorts. Up to 46 NHL patients will be enrolled in each of the following 4 NHL disease-specific cohorts:
~Cohort 1 - Marginal zone lymphoma (MZL)
~Cohort 2 - ABC diffuse large B-cell lymphoma (DLBCL) or extranodal subtypes: Leg-, testicular-, or NOS-type
~Cohort 3 - Primary central nervous system lymphoma (PCNSL)
~Cohort 4 - Patients receiving ibrutinib monotherapy who have developed adaptive, secondary resistance. Indications include:
~Mantle Cell Lymphoma (MCL), MZL, CLL/SLL, or WM/LPL
~Indications for which ibrutinib is National Comprehensive Cancer Network (NCCN)-listed (e.g., PCNSL)
~Patients with NHL and known myddosome mutations
~Patients may be candidates for maintaining ibrutinib while CA-4948 will be added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks is acceptable."
16494851|NCT03328065||Stable patients, early responders to treatment and caregivers|
16494852|NCT03328065||Stable patients and intermediate responders and c|Stable patients and intermediate responders to treatments and caregivers
16494853|NCT03328065||Doctors|
16494854|NCT03328065||Patients in therapeutic escape and their caregivers|
16494855|NCT03328052|Experimental|MYnd Analytics PEER Online directed therapy|Patients in this arm will receive anti-depressants as recommended by the PEER Online algorithm as described below.
16494856|NCT03328052|Sham Comparator|Conventional therapy|Patients in this arm will receive anti-depressants as chosen by the physician without guidance by the PEER Online algorithm.
16494857|NCT03328026|Experimental|INCMGA00012, SV-BR-1-GM combination|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 with cycles every 3 weeks
16494858|NCT03328026|Experimental|INCMGA00012, Epacadostat 600 mg BID, SV-BR-1-GM combination|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 and epacadostat 600 mg BID with cycles every 3 weeks
16494859|NCT03328026|Experimental|INCMGA00012, Epacadostat, SV-BR-1-GM combination expansion|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 and epacadostat (dose to be determined) with cycles every 3 weeks
16494861|NCT03327987||31-90 days|Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
16494862|NCT03327987||91-180 days|91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
16494863|NCT03327987||181-365 days|181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
16494864|NCT03327974|Other|depressed patients|"All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.
~All patients are depressed patients."
16494865|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
16494866|NCT03327948|Experimental|Treatment group|Urinary Urgency Incontinence
16494867|NCT03327935|Experimental|Nutrition|Oral nutritional supplements and dietetic advice
16494868|NCT03327935|Experimental|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
16494869|NCT03327935|No Intervention|Control|Standard Hospital Procedure
16494870|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
16494871|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
16494872|NCT03327909|Experimental|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
16494873|NCT03327909|Experimental|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
16494874|NCT03327896||OCHIN EHR|"Patients who were established patients at OCHIN Primary Care Clinics in 2015 and had a face to face visit at the clinic in 2015.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
16494875|NCT03327896||OneFlorida EHR|"Patients who were established patients at OneFlorida Primary Care clinics in 2015 and had a face to fact visit at the clinic in 2015.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
16494876|NCT03327896||Oregon Medicaid|"Clients who were continuously insured through Oregon Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
16494877|NCT03327896||Florida Medicaid|"Clients who were continuously insured through Florida Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider. Florida Medicaid data is limited to clients who were 22 years or younger.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
16494878|NCT03327883||1/Patients medical records|Medical records of patients with metastatic bladder cancer
16494879|NCT03327870||1|Sjogren's Syndrome
16494880|NCT03327870||2|Sicca
16494881|NCT03327870||3|Incomplete Sjogren's Syndrome
16494887|NCT03327831|Experimental|Open Label Treatment Arm|This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
16494888|NCT03327818||conservative surgery group|
16494889|NCT03327818||hysterectomy group|
16494890|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 2 weeks prior to and during the testing period.
16494891|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 2 weeks prior to and during the testing period.
16494892|NCT03327792|Experimental|200 mg Mavoglurant|200 mg mavoglurant once daily for 7-10 days
16494893|NCT03327792|Placebo Comparator|Placebo|Placebo once daily for 7-10 days
16494894|NCT03327766||RPL group|history of unexplained recurrent pregnancy loss (defined as two or more consecutive missed miscarriage before 14 weeks of gestation).
16494895|NCT03327766||Control group|womens coming for contraception after normal pregnancy outcome.
16494896|NCT03327753|Experimental|Motor control exercises|A primary goal of the motor control exercise program is to regain control and coordination of the spine and pelvis using principles of motor learning such as segmentation and simplification. The whole intervention is based on assessment of the individual patient's motor control impairments and the patient's individual treatment goals (set collaboratively with the therapist).
16494897|NCT03327753|Experimental|Graded activity|A primary goal of the graded activity program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. The intervention uses cognitive behavioral approaches to deal with fear of movement and self efficacy.
16494898|NCT03327740||Subjects on DTG based ARV with ABC|These are subjects who begin a DTG based ARV regimen that includes ABC
16494899|NCT03327740||Subjects that start DTG based ARV regimen but without ABC|These are subjects who begin a DTG-based ARV regimen that does not contain ABC
16494900|NCT03327740||Subjects on other integrase inhibitor based regimen with ABC|These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
16494901|NCT03327740||Subjects on other integrase inhibitor based regimen but no ABC|These are subjects that start non-ABC containing RAL or EGV based regimens
16494902|NCT03327740||Subjects that start any other DTG based ARV regimen|These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
16494903|NCT03327727|Experimental|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
16494904|NCT03327727|Active Comparator|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
16494905|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
16494906|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
16494907|NCT03327701|Active Comparator|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
16494908|NCT03327701|Placebo Comparator|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
16494909|NCT03327688|Active Comparator|POCUS group|Point-of-care ultrasound
16494910|NCT03327688|No Intervention|Radiologist group|Traditional diagnostic way
16494911|NCT03327688|Active Comparator|DVT POCUS group|DVT group after POCUS education
16494912|NCT03327688|No Intervention|DVT traditional group|DVT group traditional diagnostic way before educational intervention
16494913|NCT03327675|Experimental|68Ga-PSMA PET/MR|Hybrid 68Ga-PSMA PET/MR scan
16494914|NCT03327662|Experimental|Interventional|Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
16494915|NCT03327662|No Intervention|Control|Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.
16494916|NCT03327649|Sham Comparator|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
16494917|NCT03327649|Experimental|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
16494918|NCT03327636|Experimental|High Intensity Focused Ultrasound|Apply the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the papillary thyroid microcarcinoma.
16494919|NCT03327636|No Intervention|Active surveillance|The participants will be monitored by the doctors actively, like more frequent in follow-up to observe their current situation.
16494920|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
16494921|NCT03327623||Control|Subjects who are healthy volunteers
16494922|NCT03327610|No Intervention|BASELINE|The subjects were kept in their current ventilatory mode.
16494923|NCT03327610|Experimental|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
16494924|NCT03327610|Experimental|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
16494925|NCT03327610|Experimental|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
16494926|NCT03327610|Experimental|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
16494927|NCT03327610|Experimental|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
16494928|NCT03327610|Experimental|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
16494929|NCT03327597|Active Comparator|Abnormal Non-MGUS|Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
16494930|NCT03327597|Experimental|MGUS group arm 1|Participants diagnosed with MGUS, randomized to group 1.
16494931|NCT03327597|Experimental|MGUS group arm 2|Participants diagnosed with MGUS, randomized to group 2.
16494932|NCT03327597|Experimental|MGUS group arm 3|Participants diagnosed with MGUS, randomized to group 3.
16494933|NCT03327597|Active Comparator|Normal group|Participants without MGUS.
16494934|NCT03327597|Active Comparator|Controls|Participants without MGUS, matched to MGUS participants by age and gender.
16494935|NCT03327584|Active Comparator|Ultrasound Guided Arthrocentesis|The patients in this group will have ultrasound guided arthrocentesis.
16494936|NCT03327584|Active Comparator|Landmark Guided Arthrocentesis|The patients in this group will have landmark guided arthrocentesis.
16494937|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
16494938|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
16494939|NCT03327558|Experimental|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
16494940|NCT03327558|Active Comparator|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
16494941|NCT03327545|Experimental|Experimental Group 1|Neural mobilization for a total of 12 minutes
16494942|NCT03327545|Experimental|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
16494943|NCT03327545|Placebo Comparator|Control group|Control group
16494944|NCT03327532|Experimental|Patients hospitalized for acute heart failure|"One arm study.
~Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination centered on congestion
~Cardiopulmonary and peritoneal ultrasound
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
16494945|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
16494946|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
16494947|NCT03327506|Experimental|hypnosis group|Intervention: hypnosis session the eve of the surgery
16494948|NCT03327506|Active Comparator|premedication|alprazolam 0,5 mg the eve and the morning of the surgery
16494949|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
16494950|NCT03327480|Experimental|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
16494951|NCT03327480|Experimental|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
16494952|NCT03327454||Benepali|Treatment of participants with the Benepali pre-filled pen takes place in accordance with the prescribing information and standard medical practice.
16494953|NCT03327441|Experimental|Almonds|
16494954|NCT03327441|Active Comparator|Omelette|
16494955|NCT03327428||Patients with Sickle Cell Disease|Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.
16494956|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
16494957|NCT03327402|Experimental|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
16494958|NCT03327389|Experimental|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
16494959|NCT03327389|Placebo Comparator|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
16494960|NCT03327376||Characteristic and regularity of CRT|The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT).
16494961|NCT03327363|Experimental|ICT base monitoring group|In the ICT-based centralized monitoring group, both subjects and medical staff receive feedback regarding decreased lung function and exacerbation in asthma symptoms in the form of text messages
16494962|NCT03327363|Placebo Comparator|control group|Use standard asthma treatment
16494993|NCT03327155|Experimental|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
16494994|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
16494963|NCT03327350||WATCHMAN transplantation|This group will receive WATCHMAN device implantation.Device implantation included concomitant antithrombotic medication to facilitate device endothelialization: warfarin and aspirin for 45 days. To assess for device stability, peridevice leaks, and device-related thrombus, transesophageal echo (TEE) imaging was performed at 45 days, 6 months, and 12 months. When the 45-day TEE revealed minimal residual peridevice flow (jet width ≤5 mm) and no device-related thrombus, warfarin will be stopped and replaced by clopidogrel, 75 mg daily, until the 6-month visit, after which only aspirin was continued. If an adequate seal is not obtained or a thrombus is detected, patients continue taking warfarin until an adequate seal is attained or thrombus is resolved before transitioning to aspirin.
16494964|NCT03327350||Oral anticoagulant therapy|"This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).
~For patients taking warfarin, international normalized ratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Follow-up visits occurred twice annually after the first year, with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected."
16494965|NCT03327337|Experimental|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
16494966|NCT03327337|Other|control group|operate with open reduction and internal fixation on this group patients
16494967|NCT03327324|Other|Resident of the Skilled Nursing Facility|
16494968|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
16494969|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
16494970|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
16494971|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
16494972|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
16494973|NCT03327298|Other|accuracy of pedicle screw insertion|postoperative CT lumbar spine axial and sagittal views.
16494974|NCT03327285|Experimental|C-CAR011|The amount of cells received：1.0-5.0×10^6 CAR+T cells/kg
16494975|NCT03327272|Active Comparator|Local injection of methylprednisolone|Drug: methylprednisolone Injection of 80mg methylprednisolone injectable suspension at surgical site prior to incision closure
16494976|NCT03327272|Placebo Comparator|Local injection of saline|Administration of saline at surgical site prior to incision closure.
16494977|NCT03327259|Active Comparator|Activity Planning Only|
16494978|NCT03327259|Experimental|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
16494979|NCT03327246|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
16494980|NCT03327246|No Intervention|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
16494981|NCT03327233|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
16494982|NCT03327233|No Intervention|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
16494983|NCT03327220|Experimental|iovera° Device Treatment Group|Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
16494984|NCT03327220|No Intervention|Standard of Care Treatment Group|All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
16494985|NCT03327207||Study group|Children who receive Growth hormone treatment. Non Interventional
16494986|NCT03327207||Control group|Healthy children . Non Interventional
16494987|NCT03327194|Experimental|ADHEAR Audio processor|
16494988|NCT03327181|Experimental|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
16494989|NCT03327181|Active Comparator|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
16494990|NCT03327168|Active Comparator|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
16494991|NCT03327168|No Intervention|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
16494992|NCT03327168|Experimental|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
16494995|NCT03327129||Patients with SI|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >=2).
16494997|NCT03327103|No Intervention|Enhanced Usual Care|Receive standard care
16494998|NCT03327103|Experimental|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
16494999|NCT03327090|Experimental|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):
~Gluteal maximus muscle.
~Quadriceps muscle.
~Gastrocnemius muscle and soleus muscle (triceps surae).
~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
16495000|NCT03327090|Sham Comparator|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.
~Gluteal maximus muscle.
~Quadriceps muscle.
~Gastrocnemius muscle and soleus muscle (triceps surae).
~There were no tension on the tape and no muscle stretching during the application."
16495001|NCT03327077|No Intervention|Control Group|
16495002|NCT03327077|Experimental|Intervention Group|Music group
16495003|NCT03327064|Active Comparator|Renal Transplant subjects receiving UAB30|Generally healthy renal transplant subjects receive UAB30 for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
16495004|NCT03327064|Placebo Comparator|Renal Transplant subjects receiving placebo|Generally healthy renal transplant subjects receive placebo for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
16495005|NCT03327051|Active Comparator|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
16495006|NCT03327051|Placebo Comparator|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
16495007|NCT03327038|Experimental|Psychological Intervention|Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
16495008|NCT03327038|Active Comparator|Control|Patients will be randomized to the control group after they have completed the study screening form. Patients randomized to the control group will receive the usual standard of care that is available to patients with moderate anxiety or depression. Additionally, control patients will completed detailed questionnaires for assessment of primary and secondary outcomes.
16495009|NCT03327025|Experimental|Intervention|
16495010|NCT03327012|Experimental|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
16495011|NCT03327012|Placebo Comparator|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
16495012|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
16495013|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
16495014|NCT03326986|Experimental|Panel A|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
16495015|NCT03326986|Experimental|Panel B|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
16495016|NCT03326986|Experimental|Panel C|Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
16495017|NCT03326973||online or telephone survey|This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.
16495018|NCT03326960||Sevoflurane|Patients in Sevoflurane group are maintained with sevoflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
16495019|NCT03326960||Propofol|Patients in Propofol group are maintained with propofol through intravenous administration guided by Narcrotrend index monitoring.
16495020|NCT03326960||Desflurane|Patients in Desflurane group are maintained with desflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
16495021|NCT03326947|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.
~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
16495022|NCT03326947|No Intervention|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
16495023|NCT03326934|Sham Comparator|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
16495024|NCT03326934|Experimental|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
16495025|NCT03326921|Experimental|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine for 1-3 doses 3-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
16495026|NCT03326908|Other|Normal conditions of light exposure|"Spectral Domain Optical Coherence Tomography (SD-OCT):
~Five SD-OCTs will be produced under the same lighting conditions (photopic).
~At baseline
~20 minutes after baseline
~25 minutes after baseline
~45 minutes after baseline
~60 minutes after baseline"
16495027|NCT03326908|Other|Light variations|"Spectral Domain Optical Coherence Tomography (SD-OCT):
~Five SD-OCT will be performed:
~at baseline, in a room with photopic artificial lighting (400 lux)
~after a period of adaptation to the dark (20 minutes in the dark: 0 lux)
~after 5 min of retinal glare, obtained by means of a projection of light of 1000 lux on the fundus of eye
~15 minutes after this period of retinal glare, in photopic artificial lighting
~30 minutes after the period of retinal glare, in photopic artificial lighting"
16495028|NCT03326895|Experimental|Group 1|Powered circular stapler used to complete anastomosis of colon
16495029|NCT03326882|Active Comparator|Glidescope|A device for endotracheal intubation
16495030|NCT03326882|Active Comparator|Macintosh laringoscope|A device for endotracheal intubation
16495031|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay
~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
16495032|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay
~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
16495033|NCT03326856|Placebo Comparator|Vehicle|Vehicle
16495034|NCT03326856|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
16495035|NCT03326856|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
16495036|NCT03326856|Experimental|Dose 3|botulinum toxin, Type A, Dose 3
16495037|NCT03326856|Experimental|Dose 4|botulinum toxin, Type A, Dose 4
16495038|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
16495039|NCT03326830|Active Comparator|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
16495040|NCT03326830|Experimental|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
16495041|NCT03326817|Active Comparator|Control Group|This group will receive standard care.
16495042|NCT03326817|Experimental|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
16495045|NCT03326791|Experimental|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
16495046|NCT03326791|Placebo Comparator|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
16495047|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
16495048|NCT03326765|Other|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
16495049|NCT03326765|Other|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
16495050|NCT03326752|Experimental|Dose Escalation Cohort 1-5|"Cohort 1-4
~DV281 - Dose Level 1-5
~DV281 in combination with nivolumab
~DV281 is administered via a breath actuated nebulizer"
16495051|NCT03326752|Experimental|Dose Expansion (RP2D)|"4 Cohorts
~Preliminary Recommended Phase 2 dosing of DV281 in combination with nivolumab
~Cohort 1: Non-squamous and non-EGFR/ ALK mutation and progressed on anti-PD-1/L1 therapy
~Cohort 2: Non-squamous and EGFR/ ALK mutation and progressed on targeted therapy
~Cohort 3: Squamous and anti-PD-1/ L1 therapy experienced
~Cohort 4: Squamous and anti-PD-1/L1 therapy naive
~DV281 is administered via a breath actuated nebulizer."
16495052|NCT03326739|Active Comparator|Ultrasound Guided A-Line Placement|Patients in this group will have ultrasound guided arterial line placement.
16495053|NCT03326739|Active Comparator|Landmark Guided A-line Placement|Patients in this group will have landmark guided arterial line placement.
16495054|NCT03326726|Experimental|Chlorhexidine Gluconate|2% CHG
16495055|NCT03326713|Experimental|Telephone Counseling & Navigation (TCN)|Telephone Counseling
16495056|NCT03326713|Active Comparator|Mailed Targeted Print (TP)|Mailed Targeted Print
16495057|NCT03326713|Other|Usual Care (UC)|Control
16495058|NCT03326700|Active Comparator|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
16495059|NCT03326700|Active Comparator|Open hernia repair.|Intervention: inguinal hernia repair.
16495060|NCT03326687|Experimental|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
16495061|NCT03326687|Experimental|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
16495184|NCT03325868|Experimental|Ulipristal|Ulipristal acetate 5mg daily for 12 weeks
16495062|NCT03326674|Experimental|Arm A: Tesetaxel (oral) and capecitabine (oral)|Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
16495063|NCT03326674|Active Comparator|Arm B: Capecitabine (oral)|Capecitabine (1,250 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
16495064|NCT03326661|Active Comparator|Needle aspiration|Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
16495065|NCT03326661|Active Comparator|Tonsillectomy a chaud|Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
16495066|NCT03326648|Experimental|Strength training + protein supplement|Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
16495067|NCT03326648|Experimental|Protein supplement|Daily protein supplementation for 10 weeks.
16495068|NCT03326635||frailty group|frailty score ≤ 3
16495069|NCT03326635||non-frailty group|frailty score >3
16495070|NCT03326622|Experimental|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
16495071|NCT03326622|Active Comparator|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
16495072|NCT03326609|Experimental|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
16495073|NCT03326609|Experimental|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
16495074|NCT03326609|Experimental|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
16495075|NCT03326609|Experimental|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
16495076|NCT03326609|Experimental|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
16495077|NCT03326596|Experimental|ProphylacticTranexamic Acid|Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.
16495078|NCT03326583|No Intervention|No Intervention: Pre-Treatment|This arm is the 2 week observation period before the start of the Patiromer treatment phase.
16495079|NCT03326583|Experimental|Intervention: Treatment|This arm is the 12 week treatment phase. Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks.
16495080|NCT03326583|No Intervention|No Intervention: Post-Treatment|This arm is the 2 week observation period after the Patiromer treatment phase.
16495081|NCT03326570||Bronchoscopy Data Collection|Medical information collected after bronchoscopy for up to 2 years.
16495082|NCT03326557|Active Comparator|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
16495083|NCT03326557|Active Comparator|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
16495084|NCT03326544|Experimental|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
16495085|NCT03326544|Experimental|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
16495086|NCT03326518|Experimental|Lumentin® 44|Contrast agent
16495087|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
16495088|NCT03326518|Active Comparator|Movprep®|Contrast agent
16495089|NCT03326505|Active Comparator|Injection of Umbilical cord derived UC- MSCs|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients
16495090|NCT03326505|Active Comparator|injection of UC- MSCs and SPT|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program
16495091|NCT03326505|Active Comparator|Supervised Physical Therapy (SPT)|Supervised physical therapy program without stem cells
16495092|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.
~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
16495093|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
16495094|NCT03326466||Patients with SAP|
16495095|NCT03326466||Healthy Controls|
16495096|NCT03326453|Experimental|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
16495097|NCT03326453|No Intervention|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
16495098|NCT03326440|Other|Study Arm|Patients with a histological diagnosis of prostate cancer are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system prior to the start of Radiotherapy.
16495099|NCT03326440|Other|Control Arm|Patients with a histological diagnosis of prostate cancer who are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system following completion of Radiotherapy.
16495100|NCT03326427|Experimental|Skill Training Group|A twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
16495101|NCT03326427|Active Comparator|Treatment as Usual|Patients will have one psychiatric session to control their medication adherence.
16495102|NCT03326414|Other|Constant PEEP - low tidal volume|PEEP is 10mbar, tidal volume is set to 4-5ml/kg IBW
16495103|NCT03326414|Other|Constant PEEP - high tidal volume|PEEP is 10mbar, tidal volume is set to 8-10ml/kg IBW
16495104|NCT03326414|Other|constant tidal volume - low PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 3mbar
16495105|NCT03326414|Other|constant tidal volume - high PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 12mbar
16495106|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
16495107|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
16495108|NCT03326388|Experimental|Selumetinib Intermittent Dosing|Phase 1 of the study to evaluate Intermittent Dosing (Selumetinib given twice daily on 5 out of 7 days) in children with NF1 and inoperable plexiform neurofibromas. The Maximum tolerated dose will define the Recommended phase 2 dose of selumetinib.
16495109|NCT03326375|Experimental|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
16495110|NCT03326375|No Intervention|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
16495111|NCT03326362|Experimental|High intensity resistance training (HIRT)|"12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions. The HIRT performed the squat, deadlift and lunge exercises, as these exercises induce high core muscles activity. HIRT started with two weeks of low intensity exercises emphasizing the activation of core muscles (pelvic elevation with feet on the floor, superman, static supine bridge on bosu), and the technique of the selected resistance exercises (e.g. squat, deadlift, and lunges). Participants performed 3 sets of 10 repetitions per exercise. In the third and forth weeks, participants performed the exercises from the previous weeks and also static unipedal forward flexion on bosu and dynamic unipedal forward flexion and the main exercises with a load corresponding to (50% of the 1 RM load (Brzycki, 1993).
~From the 5th to the 12th week, participants performed only the selected resistance exercises with progressive higher intensities (from 12RM to 8RM)."
16495112|NCT03326362|Active Comparator|Low intensity resistance training (LIRT)|12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions.The LIRT group performed very low intensity and volume exercises (i.e. 1 set per exercise). Exercises started with participants lying on a firm surface, with the back supported, knees bent and feet flat on the floor. Then, participants performed the following exercises: 1) inhaling and exhaling and then isometrically contract in gluteal and abdominal muscles for 20 seconds and relax; 2) raising the head, lifting the chin and shoulders toward the chest for 20 seconds and relax; 3) raising one knee towards the chest and raising the head and shoulders likewise in the second exercise for 20s, relaxing, and changing the leg.; 4) raising both knees towards the chest in the same time that raise the head and shoulder off the floor during 20 seconds and relax.
16495113|NCT03326349|Experimental|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) 5 days per week over 6 weeks.
16495114|NCT03326349|Sham Comparator|Ictus.online|Itus.online 5 days per week over 6 weeks
16495115|NCT03326336|Other|Cohort|3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
16495116|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
16495117|NCT03326310|Experimental|Azacitidine and selumetinib|Subjects will receive azacitidine subcutaneously on days 1-7. Selumetinib will be administered on days 8-21. Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
16495118|NCT03326297|Experimental|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
16495119|NCT03326297|Active Comparator|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
16495120|NCT03326297|No Intervention|No specific intervention|No specific intervention, prescriptions by pediatrician
16495121|NCT03326284|Experimental|15g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 15g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
16495122|NCT03326284|Experimental|35g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
16495123|NCT03326284|Experimental|60g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 60g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
16495124|NCT03326284|Experimental|35g protein energy balanced diet|Following a 5-day energy balanced diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
16495125|NCT03326271||Lubinus SP2 stem|Patients treated with a cemented Lubinus SP2 stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
16495126|NCT03326271||Exeter stem|Patients treated with a cemented Exeter stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
16495127|NCT03326258|Experimental|Treatment (glembatumumab vedotin, nivolumab, ipilimumab)|Patients receive glembatumumab vedotin IV over 90 minutes and nivolumab IV over 60 minutes on day 8 of course 1 and on day 1 of subsequent courses. Patients in melanoma expanded cohort also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 21 days for 4 courses in the absence of disease progression or unaccepted toxicity and courses with glembatumumab vedotin and nivolumab repeat every 21 days in the absence of disease progression or unaccepted toxicity.
16495128|NCT03326245|Active Comparator|1:Oral MP- IV PL|Oral Methylphenidate /IV Placebo
16495129|NCT03326245|Active Comparator|2 Oral PL/IV MP|Oral Placebo/IV Methylphenidate
16495130|NCT03326245|Placebo Comparator|3: Oral PL/IV PL|Oral Placebo/IV Placebo
16495131|NCT03326232|Experimental|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
16495132|NCT03326232|Experimental|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
16495133|NCT03326219|Other|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
16495134|NCT03326206||COPE participants|Individuals living with diabetes seen at a study site who were enrolled in the COPE programmatic intervention during the study period. Participation in COPE consists of receiving home visits by a Navajo Community Health Representative (CHR) once or twice a month for a period of at least 12 months. CHRs use structured patient coaching materials to support behavior change. CHRs also check vital signs, monitor blood glucose levels through finger sticks, and facilitate access to appointments and medical refills. CHRs communicate regularly with providers through electronic health record documentation and case management rounds. In-person or telephone communication is be used to address acute issues that may arise.
16495135|NCT03326206||Non-COPE participants|Individuals living with diabetes seen at a study site, did not participate in the COPE programmatic intervention, and had comparable baseline characteristics.
16495136|NCT03326193|Experimental|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle. On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
16495137|NCT03326180|Experimental|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
16495138|NCT03326180|Active Comparator|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.
~Administered as a single dose intra-operatively by periarticular infiltration."
16495139|NCT03326167||Patients with or suspected coronary heart disease|
16495140|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:
~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
16495141|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:
~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
16495142|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:
~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
16495143|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:
~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
16495144|NCT03326128|Active Comparator|BUP-300|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
16495145|NCT03326128|Experimental|BUP-450|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
16495146|NCT03326115|Experimental|Peer Visitation Program (PVP)|Participants in this group will begin participation in the Peer Visitation Program (PVP) beginning at amputation date with the initiation window ranging from immediately pre-operative to 7 days post operative.
16495147|NCT03326115|No Intervention|Delayed Peer Visitation (NoPVP)|Not participating in a Peer Visitation Program for 60 days post-operatively, followed by participation and completion in a PVP 60 days later than the PVP group for a total of 120 days.
16495187|NCT03325829||Patients with colonic diverticula|No interventional study
16495148|NCT03326102|Experimental|DHP107|"The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.
~Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days."
16495149|NCT03326102|Experimental|IV paclitaxel|Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)
16495150|NCT03326089|Active Comparator|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
16495151|NCT03326089|Placebo Comparator|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
16495152|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
16495153|NCT03326076||Control|A matched control cohort of 1000 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) or KidneyCare will be retrospectively selected
16495154|NCT03326076||Secondary donor-derived cell-free DNA|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
16495155|NCT03326076||Primary KidneyCare®|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
16495156|NCT03326076||Secondary KidneyCare®|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
16495157|NCT03326063|Active Comparator|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
16495158|NCT03326063|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
16495159|NCT03326050|Placebo Comparator|gemifloxacin and Rifampicin|first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..
16495160|NCT03326050|Placebo Comparator|gemifloxacin and ciprofloxacin|. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily
16495161|NCT03326050|Placebo Comparator|gemifloxacin and placipo|.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily
16495162|NCT03326024||A|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years.
16495163|NCT03326024||B|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling
16495164|NCT03326011|Experimental|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
16495165|NCT03325998|Experimental|Gait training group|"Gait training with Samsung Hip Assist v1
~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
16495166|NCT03325985|Experimental|Nurse-led telephonic case management|"Telephonic nurses will contact patients within 72 hours of enrollment
~Patients will speak with the telephonic nurse over the phone once a week (or as often as needed) for a duration of 6 months."
16495167|NCT03325985|Active Comparator|Facilitated, outpatient specialty palliative care|"Patients will be scheduled for their first in-person palliative care visit within two weeks of enrollment and then once a month for 6 months.
~Clinic visits will be scheduled the same day as other specialty appointments if possible"
16495168|NCT03325972|Experimental|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
16495169|NCT03325972|Placebo Comparator|Placebo|saline placebo
16495170|NCT03325959|Active Comparator|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
16495171|NCT03325959|Active Comparator|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.
~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
16495172|NCT03325946||Children and Adults with Cerebral Palsy|
16495173|NCT03325946||Children and Adults with Microcephaly|
16495174|NCT03325946||Children and Adults with other Neuromotor Impairments|
16495175|NCT03325933|Experimental|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
16495176|NCT03325933|Experimental|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
16495177|NCT03325933|No Intervention|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
16495178|NCT03325920|Experimental|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
16495179|NCT03325920|Experimental|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
16495180|NCT03325907|Experimental|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
16495181|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
16495182|NCT03325881|Experimental|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
16495183|NCT03325881|Placebo Comparator|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
16495188|NCT03325816|Experimental|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.
~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
16495189|NCT03325816|Experimental|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.
~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
16495190|NCT03325816|Experimental|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.
~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
16495191|NCT03325816|No Intervention|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
16495192|NCT03325803|Experimental|150μm-AFL-PDT|
16495193|NCT03325803|Experimental|350μm-AFL-PDT|
16495194|NCT03325803|Experimental|500μm-AFL-PDT|
16495195|NCT03325790|Placebo Comparator|Placebo|Placebo
16495196|NCT03325790|Experimental|200mg SPI-1005 twice daily (BID)|200mg SPI-1005 BID
16495197|NCT03325790|Experimental|400mg SPI-1005 BID|400mg SPI-1005 BID
16495198|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
16495199|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
16495200|NCT03325764|Other|sleeve gastrectomy|Assessment before and after sleeve gastrectomy
16495201|NCT03325751||Healthy subjects|
16495202|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
16495203|NCT03325725|Experimental|NewBreez LD Intra-laryngeal implant|
16495204|NCT03325712|Experimental|Dose Group 1|
16495205|NCT03325712|Experimental|Dose Group 2|
16495206|NCT03325712|Experimental|Dose Group 3|
16495207|NCT03325712|Experimental|Dose Group 4|
16495208|NCT03325712|Experimental|Dose Group 5|
16495209|NCT03325712|Placebo Comparator|Placebo|
16495210|NCT03325712|Experimental|Dose Group 8|
16495211|NCT03325699|Experimental|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
16495212|NCT03325699|No Intervention|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
16495213|NCT03325686|Experimental|vitamin D supplement|D
16495214|NCT03325686|Placebo Comparator|control|P
16495215|NCT03325673|Experimental|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
16495216|NCT03325673|Sham Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
16495217|NCT03325660|Active Comparator|study group|whole body vibration
16495218|NCT03325660|No Intervention|control group|No intervention
16495219|NCT03325647|Experimental|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
16495220|NCT03325647|Experimental|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
16495221|NCT03325634|Experimental|Treatment (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) every other day for 3 fractions.
16495222|NCT03325621|Active Comparator|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
16495223|NCT03325621|Placebo Comparator|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
16495224|NCT03325608|Experimental|Intervention|The POISED care management team consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) will conduct a biopsychosocial/environmental needs assessment by phone within 48 hours of emergency room discharge if not possible during the ED stay.
16495225|NCT03325608|Placebo Comparator|Usual Care|will receive referrals to services at the time of enrollment.
16495226|NCT03325595|Active Comparator|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
16495227|NCT03325595|Placebo Comparator|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
16495228|NCT03325569|Active Comparator|NGT|NGT - normal glucose tolerance. Women with PCOS and normal glucose tolerance
16495229|NCT03325569|Active Comparator|IGH|IGH - impaired glucose homeostasis Women with PCOS and impaired glucose homeostasis - that means impaired fasting glucose or impaired glucose tolerance.
16495230|NCT03325556|Placebo Comparator|Placebo|
16495231|NCT03325556|Experimental|Drug - Pimavanserin|
16495365|NCT03324438|Active Comparator|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
16495232|NCT03325543|Experimental|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
16495233|NCT03325543|Active Comparator|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
16495234|NCT03325530||Focus Group|
16495235|NCT03325504|Experimental|hBM-MSCs-Low Dose|Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells
16495236|NCT03325504|Experimental|hBM-MSCs-High Dose|Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells
16495237|NCT03325504|Active Comparator|Autologous Illiac crest graft|Autologous Iliac Crest Grafting
16495238|NCT03325491|Experimental|Acipimox plus exercise training|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
16495239|NCT03325491|Placebo Comparator|Placebo plus exercise training|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
16495240|NCT03325465|Experimental|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.
~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
16495241|NCT03325452|Experimental|cardio-respiratory arrest|
16495242|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
16495243|NCT03325426|No Intervention|Usual care|
16495244|NCT03325426|Experimental|Physical activity tracker|
16495245|NCT03325413|No Intervention|Control|Usual care with assessment only (no study-related intervention)
16495246|NCT03325413|Other|Implementation|Implementation of intervention measures
16495247|NCT03325413|Other|Full-scale intervention|
16495248|NCT03325400|Other|Non-fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
16495249|NCT03325400|Active Comparator|Fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
16495250|NCT03325387|Experimental|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
16495251|NCT03325387|Placebo Comparator|Placebo|Saline solution administered by SC injection
16495252|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
16495253|NCT03325361|Experimental|TD|
16495254|NCT03325361|No Intervention|NTD|
16495255|NCT03325348|Experimental|Oral Nifedipine|Nifedipine 10mg oral tablet & 1ml 0.9%N/Saline will be given every 15 minutes up till one hour
16495256|NCT03325348|Active Comparator|IV Labetalol|IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour
16495257|NCT03325335|Active Comparator|Midazolam premedication group (Group P)|Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery.
16495258|NCT03325335|Other|Control group (Group N)|Patients of group N were not premedicated with midazolam (Do not use placebo). [Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-> removed from interventions)]
16495259|NCT03325322|Experimental|Treatment|Fisetin 20 mg/kg/day, orally for 2 consecutive days
16495260|NCT03325322|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
16495261|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
16495262|NCT03325296|Experimental|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
16495263|NCT03325296|Placebo Comparator|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
16495264|NCT03325283|Experimental|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
16495265|NCT03325270|Experimental|ferrous fumarate|labeled iron as Ferrous Fumarate
16495266|NCT03325270|Experimental|ferrous fumarate and GOS|labeled ferrous fumarate + prebiotics
16495267|NCT03325270|Experimental|ferrous sulfate and GOS|labeled ferrous sulfate + prebiotics
16495268|NCT03325244||All participants|All participants will use a portable EEG monitor and FITBIT to monitor sleep and activity before and after night call
16495269|NCT03325231||Bladder Cancer Patients|Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
16495270|NCT03325218||Questionnaire Set A|
16495271|NCT03325218||Questionnaire Set B|
16495366|NCT03324438|Experimental|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
16495272|NCT03325205|Experimental|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
16495273|NCT03325205|Sham Comparator|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
16495274|NCT03325192|Placebo Comparator|Standard of care|Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
16495275|NCT03325192|Experimental|Rapid pleurodesis protocol|Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter
16495276|NCT03325179|Experimental|participants received treatment|100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial. Each will receive Thread-embedding therapy.
16495277|NCT03325166|Experimental|Treatment (pembrolizumab, ferumoxytol MRI)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (or up to 32 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI at baseline, 12 weeks after radiation, at suspected radiographic progression, and 6 weeks after suspected radiographic progression.
16495278|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
16495279|NCT03325114|Other|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
16495280|NCT03325101|Experimental|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
16495281|NCT03325088|Other|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
16495282|NCT03325088|Other|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
16495283|NCT03325088|Other|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
16495284|NCT03325075|Experimental|VAL-181388|
16495285|NCT03325075|Placebo Comparator|Placebo|
16495286|NCT03325062|Experimental|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
16495287|NCT03325062|Active Comparator|CONTROL|Contemporary progressive rehabilitation
16495288|NCT03325049|Experimental|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
16495289|NCT03325049|Active Comparator|Control Arm|Usual Care
16495290|NCT03325023|Active Comparator|Active Comparator:|Dietary modification + Probiotic supplementation (Sanprobi Super Formula)
16495291|NCT03325023|Placebo Comparator|Placebo Comparator|Dietary modification + placebo.
16495292|NCT03325010|Placebo Comparator|Placebo|Participants received placebo (matching valbenazine) once daily for 12 weeks.
16495293|NCT03325010|Experimental|Valbenazine|Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants <50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects <50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.
16495294|NCT03324997|Experimental|Restylane|half the chest to be treated with Restylane Silk
16495295|NCT03324997|Placebo Comparator|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
16495296|NCT03324984|Experimental|1% Chloroprocaine (PF)|1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
16495297|NCT03324984|Active Comparator|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
16495298|NCT03324971|Experimental|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
16495299|NCT03324958|Experimental|Virtual Reality Helmet|Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
16495300|NCT03324958|Active Comparator|No Virtual Reality Helmet|Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.
16495301|NCT03324945|Experimental|Neurocognitive Assessment +/- FMRI|All participants receive pre- and post-chemotherapy neurocognitive assessments. A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
16495302|NCT03324932|Other|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
16495303|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
16495304|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
16495305|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
16495367|NCT03324438|Experimental|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
16495368|NCT03324438|Experimental|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
16497103|NCT03311932|Experimental|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
16495306|NCT03324906|Active Comparator|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
16495307|NCT03324906|Active Comparator|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
16495308|NCT03324893|Experimental|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
16495309|NCT03324880|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) 50 microgram (mcg) subcutaneous (SC) injection once daily (QD), titrated within the dose range of 25-100 mcg QD as an adjunctive treatment with active vitamin D and calcium supplements based on metabolic response.
16495310|NCT03324880|Placebo Comparator|Placebo|Participants will receive placebo matched to rhPTH(1-84) as SC injection QD with active vitamin D and calcium supplements.
16495311|NCT03324867|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7
16495312|NCT03324867|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to POD 7
16495313|NCT03324854|Experimental|mosquito net mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the mosquito net mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
16495314|NCT03324854|Active Comparator|prolene mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the prolene mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
16495315|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
16495316|NCT03324828|Active Comparator|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
16495317|NCT03324828|Experimental|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
16495318|NCT03324828|Active Comparator|Placebo+clowns|Patients will receive placebo solution and clowns intervention
16495319|NCT03324828|No Intervention|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
16495320|NCT03324815|Active Comparator|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
16495321|NCT03324815|Active Comparator|Morphine|Morphine: 5mg/6h
16495322|NCT03324802|Experimental|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
16495323|NCT03324802|Experimental|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
16495324|NCT03324789|Experimental|Single Implant Partial Over-denture|The design will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
16495325|NCT03324789|Active Comparator|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
16495326|NCT03324776|Other|Afrezza Inhalant Product|Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
16495327|NCT03324763||stool sampling|
16495328|NCT03324737|No Intervention|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
16495329|NCT03324737|Active Comparator|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.
~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
16495330|NCT03324724|Experimental|Adolescents with Eating Disorder|Adolescents with bulimia nervosa or binge eating disorder, with one or more of their parents, will receive integrative cognitive-affective therapy for adolescents (ICAT-A).
16495331|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
16495332|NCT03324685|Experimental|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
16495333|NCT03324672|Active Comparator|TRIGGER|
16495334|NCT03324672|Experimental|TRIGGER+CURETAPE|
16495335|NCT03324659|Experimental|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
16495336|NCT03324659|Sham Comparator|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
16495337|NCT03324646||controls|healthy subjects
16495338|NCT03324620|Experimental|pre active HSCT|"Candidates for transplantation of hematopoietic progenitors since May 12, 2012, regardless of sex and age, who agree to participate in the study and sign informed consent.
~In the pre-transplantation visit with the physiotherapist: Measures of muscle mass and strength, quality of life questionnaires, program presentation, fitness assessment and lifestyle determination. The exercises will be personalized, stimulating your practice before admission and involving the family. During admission, the team will encourage the patient to remain active by adapting to the symptoms. At discharge, measures of resistance, exercise tolerance and quality of life at discharge, in the month after discharge, 3 months after discharge, 6 months after discharge and 12 months after discharge."
16495339|NCT03324620|No Intervention|control group|"Patients' candidates for transplantation of hematopoietic progenitors prior to May 12, 2012, regardless of gender and age, who meet the inclusion criteria and are collected correlatively until completing 104 subjects.
~Clinical history review to calculate the days of hospitalization in the different hospitalization units during the transplant. As well as the number and type of complications and the use of health resources. Status vitae. Baseline review of functional tests and exercise tolerance."
16495340|NCT03324607|Experimental|single arm|glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
16495341|NCT03324594|Active Comparator|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
16495342|NCT03324594|Active Comparator|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
16495343|NCT03324594|Active Comparator|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
16495344|NCT03324594|Active Comparator|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
16495345|NCT03324594|Active Comparator|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
16495346|NCT03324594|Active Comparator|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
16495350|NCT03324568|Other|Educational handout|
16495351|NCT03324568|Experimental|Video plus educational handout|
16495352|NCT03324555|Experimental|ORIC-101|
16495353|NCT03324529|Experimental|Participants in the NYU takotsubo registry|"10 patients with a confirmed history of takotsubo syndrome
~10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness"
16495354|NCT03324516|Experimental|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
16495355|NCT03324516|Active Comparator|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
16495356|NCT03324503|Experimental|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
16495357|NCT03324490|Active Comparator|TSA group|Thoracic Spinal Anesthesia; Bupivacaine 0.5% (hyperbaric) 7.5mg, Fentanyl 25 µg & Dexmedetomidine 5 µg by intrathecal injection
16495358|NCT03324490|Active Comparator|TEA group|Thoracic Epidural Anesthesia; Bupivacaine 0.5% (isobaric) 25-50 mg & Fentanyl 10-20 µg by epidural injection
16495359|NCT03324477|Experimental|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
16495360|NCT03324477|Experimental|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
16495361|NCT03324464|Experimental|CET-Working Memory (WM)|Central Executive Training: Working Memory
16495362|NCT03324464|Active Comparator|CET-Behavioral Inhibition (BI)|Central Executive Training: Inhibitory Control
16495363|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
16495364|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
16495369|NCT03324425|Experimental|Simvastatin|Simvastatin 80 mg in combination with anti-HER2 therapy regimen
16495370|NCT03324412|Active Comparator|Treatment of MTX|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.
16495371|NCT03324412|Experimental|Treatment of MTX and TwHF|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF).
16495372|NCT03324399|Experimental|High Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.
~Patients taking proprietary probiotic"
16495373|NCT03324399|Experimental|Low Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.
~Patients taking proprietary probiotic"
16495374|NCT03324386|Experimental|Individual Orientation|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients: Experimental: individual orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);The ntervention is composed by relational strategies characterized by interpersonal relationships
16495375|NCT03324386|Experimental|VLE for Distance Learning|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients:Experimental: a technological education strategy for distance learning (DL), using a technological education strategy (E-Care of Hypertension) for Distance Learning (DL) characterized by 7 nursing visits at 20-day intervals, for 4 months). The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in educational environments remotely accessed for health education specifically for hypertensive patients
16495376|NCT03324386|Experimental|E-blended Learning|This was a prospective randomized clinical study with the patient received experimental intervention: a technological education strategy with E-blended Learning modality with E-Care of Hypertension, associated with face-to-face consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months. The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in presential educational environments intended for health education specifically for hypertensive patients
16495377|NCT03324386|No Intervention|No intervention|No type of intervention was performed making 2 nursing visits at baseline and 1 after 120 days (No intervention)
16495378|NCT03324373|Experimental|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
16495379|NCT03324360|Experimental|Control Participants Part I|A MRI with injection of hyperpolarized 13C pyruvate.
16495380|NCT03324360|Experimental|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
16495381|NCT03324360|Experimental|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
16495382|NCT03324347|Experimental|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
16495383|NCT03324347|No Intervention|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
16495384|NCT03324334||Study group|Patients with ulcerative colitis Interventions to be administered: Thyroid antibodies and Thyroid sonography
16495385|NCT03324334||Control group|normal control subjects selected from general population at random Interventions to be administered: Thyroid antibodies and Thyroid sonography
16495386|NCT03324321|Experimental|Hyperventilation Protocol|This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
16495387|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.
~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
16495388|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
16495389|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
16495390|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
16495391|NCT03324282|Experimental|Arm A: GC + avelumab group|
16495392|NCT03324282|Active Comparator|Arm B: GC group|
16495393|NCT03324269|Other|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).
~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 or decrement of 1 ng/ml if NOL gradient < 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision. NOL and hemodynamic responses will be recorded during the entire duration of surgery."
16495394|NCT03324256|Active Comparator|Energy drink and placebo gum|Commercially-available energy drink (16oz) + 2 pieces of placebo gum
16495395|NCT03324256|Active Comparator|Caffeinated drink and placebo gum|Commercially-available caffeinated drink (16oz) + 2 pieces of placebo gum
16495396|NCT03324256|Active Comparator|Control drink and energy gum|Control drink (16oz) + 2 pieces of energy gum
16495397|NCT03324256|Placebo Comparator|Control drink and placebo gum|Control drink (16oz) + 2 pieces of placebo gum
16495398|NCT03324256|Active Comparator|Energy drink and total sleep deprivation|Commercially-available energy drink (16oz) + 2 pieces of placebo gum following total sleep deprivation
16495399|NCT03324243|Experimental|Crenolanib|
16495450|NCT03323853|Experimental|CARS-SA Report|Emergency care providers for subjects in this group will receive a copy of the subject's CARS-SA summary results.
16495400|NCT03324217|Experimental|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
16495401|NCT03324217|Experimental|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
16495402|NCT03324217|Active Comparator|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
16495403|NCT03324204|Experimental|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
16495404|NCT03324204|Active Comparator|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
16495405|NCT03324191|Placebo Comparator|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
16495406|NCT03324191|Experimental|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
16495407|NCT03324191|Experimental|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
16495408|NCT03324191|Experimental|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
16495409|NCT03324178|Experimental|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training performed once a day over the course of four weeks (four sessions each week)
16495410|NCT03324178|Active Comparator|Video game control group|Sixteen 30-minute sessions of playing video games once a day over the course of four weeks (four sessions each week)
16495411|NCT03324165|No Intervention|Usual Care Arm|Patients randomized to Usual Care Arm will be managed as per current best practice that is based on the individual doctor's discretion.
16495412|NCT03324165|Experimental|Intervention Arm|Patients randomized to Intervention Arm will be managed as per the proposed algorithm, which is based on the computation of Alvarado Score.
16495413|NCT03324152|Experimental|High-intensity interval training (HIIT) - myositis|12-week, 3d/w, HIIT
16495414|NCT03324152|Active Comparator|Standard low-intensity home exercise control (CG)|12-week, 5 d/w, home exercise.
16495415|NCT03324152|Active Comparator|High-intensity interval training (HIIT) - healthy|12-week, 3d/w, HIIT.
16495416|NCT03324139|Experimental|Study Group|Treatment with low molecular weight Heparin.
16495417|NCT03324139|Placebo Comparator|Control Group|Treatment with Placebo.
16495418|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
16495665|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (> 50%) in the coronary arteries
16495419|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
16495420|NCT03324113|Experimental|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
16495421|NCT03324100||Allergic Rhinitis Patients|
16495422|NCT03324100||Healthy Controls|
16495423|NCT03324087||Adult patients with ITP|The investigators are undertaking a multi-center, prospective trail of 1000 adult ITP patients and use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
16495424|NCT03324061|Experimental|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
16495425|NCT03324061|Active Comparator|Faslodex (R)|Faslodex (250 mg/mL)
16495426|NCT03324048|Other|Patients anxious|Patients anxious will be perform relaxation session.
16495427|NCT03324035|Experimental|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
16495428|NCT03324035|Placebo Comparator|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
16495429|NCT03324009|Experimental|2-stage screen|All patients will be enrolled in the two-stage cervical cancer screening protocol
16495430|NCT03323996||Health Professionals|Health Professionals attending a training in therapeutic education
16495431|NCT03323996||Patients|Patients of the health Professionals recruited for the study
16495432|NCT03323983||Normal lung clearance index|
16495433|NCT03323983||Elevated lung clearance index|
16495434|NCT03323970||Physicians|
16495435|NCT03323957||Patients|all infants admitted for care
16495436|NCT03323944|Experimental|Cohort 1: huCART-meso cells via intravenous infusion (IV).|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells on day 0 via intravenous infusion.
16495437|NCT03323944|Experimental|Cohort -1: low dose huCART-meso cells via intravenous infusion|In the event that 2 DLTs occur among subjects enrolled in Cohort 1, then enrollment in Cohort 1 will be stopped and the dose will be de-escalated by 10-fold to 1-3x10^6 cells/m2. Subjects will receive a single dose of 1-3x10^6 cells/m^2 lentiviral transduced huCART-meso cells on day 0.
16495438|NCT03323944|Experimental|Cohort 2 - huCART meso cells via intraperitoneal infusion (IP)|Eligible subjects will receive a single dose of 1-3x107/m2 lentiviral transduced huCART-meso cells on day 0 via intraperitoneal (i.p.) administration. The initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
16495439|NCT03323944|Experimental|Cohort 3 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Eligible subjects will receive a single dose of 1-3x107/m2 lentiviral transduced huCART-meso cells on day 0 via intrahepatic delivery (Hepatic Arterial Infusion). The initial intrahepatic infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
16495440|NCT03323931|Active Comparator|(1) standard therapy|Standard therapy based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the therapist reinforces the adaptive behavior of the child.
16495441|NCT03323931|Experimental|(2) robot--enhanced intervention|A treatment developed on the same principles as standard therapy, based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the robotic agent reinforces the adaptive behaviors of the child, under the supervision of the therapist.
16495442|NCT03323918|Experimental|ImPACT|Project ImPACT will be provided in 18 weekly intervention sessions, during which parents will learn how to stimulate their children's social imitation, social engagement, language and play skills. First, parents are taught techniques that promote interaction with the child (one technique per session, through demonstration and coaching). In the second half of the intervention, parents are taught direct teaching techniques, e.g., to promote language or play, again by means of demonstration and coaching. After completion of the program, families will receive guidance every 2-3 weeks for an additional 12 weeks, during which the support will generally not focus on social-communicative abilities, although ImPACT follow-up sessions might be given if necessary.
16495443|NCT03323918|Active Comparator|TAU|Treatment as usual (TAU) will be provided at the typical frequency, which is every 2-3 weeks. TAU can include targeting eating and sleeping problems, adaptive skills, or other goals. TAU will not include forms of intervention explicitly targeting social communicative skills. However, limited guidance on social communication development can be given if explicitly asked by parents.
16495444|NCT03323905|Experimental|MR Guided High Intensity Focused Ultrasound|
16495445|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
16495446|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.
~Intervention = second sperm sample"
16495447|NCT03323879|Experimental|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
16495448|NCT03323866|Active Comparator|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
16495449|NCT03323866|Experimental|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
16495706|NCT03321994|Experimental|Stereotaxic unit, navigation|
16495451|NCT03323853|Other|No CARS-SA Report|Emergency care providers for subjects in this group will not receive a copy of the subject's CARS-SA summary results.
16495452|NCT03323840|Experimental|Incentivized Care|Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement.
16495453|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.
~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) nondiabetics 20 subjects will be enrolled"
16495454|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.
~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 32 subjects will be enrolled"
16495455|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.
~Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 20 subjects will be enrolled."
16495456|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
16495457|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
16495458|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
16495460|NCT03323788||Aim 1|Aim 1. To determine whether the transcription factor expression response to exercise is dysregulated in muscle from type 2 diabetic patients. We will test the hypothesis that MZF1, NFKB1, RELA, SP1/KLF and EGR1 responses to an acute exercise bout are reduced in insulin resistant patients with type 2 diabetes.
16495461|NCT03323788||Aim 2|"Aim 2. To determine how insulin resistance changes the response of post-translational modifications of SP1/KLF family and MZF1 transcription factors to acute exercise in muscle from type 2 diabetic patients. We will test the hypothesis that:
~SP1/KLF2, 4, and 6 and phosphorylation/acetylation and MZF1 phosphorylation is altered in response to acute exercise.
~The response of SP1/KLF2, 4, and 6 phosphorylation and acetylation and MZF1 phosphorylation to acute exercise is abnormal in patients with type 2 diabetes."
16495462|NCT03323788||Aim 3|"Aim 3. To define the response of miRNAs to acute exercise in healthy and insulin resistant muscle from obese and type 2 diabetic patients. We will test the hypotheses that:
~The exercise-induced increases in expression of miR-378 members and miR-128 are lower in obese and type 2 diabetic muscle than in lean healthy controls.
~FOXO1 expression, a target of miR-378 and miR-128, is higher in obese and type 2 diabetic muscle and this is accompanied by decreased FOXO1 phosphorylation.
~The exercise-induced increases in expression of miR-30 family members, miR-10a, miR-422a, and miR-532 are lower in obese and type 2 diabetic muscle.
~There are novel miRNAs that regulate the transcriptional program induced by acute exercise and are dysregulated in insulin resistance."
16495463|NCT03323788||Aim 4|Aim 4. To determine whether treatment with PPAR-Alpha agonist fibrate derivatives suppresses the normal gene expression response to acute exercise. We will test the hypothesis that Gemfibrozil treatment inhibits the normal transcriptional response to exercise.
16495464|NCT03323762|Experimental|RIC|"RIC treatment arm The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes.
~The treatment will be carried out on the morning of day 2 to day 7 by the participants themselves at their home."
16495465|NCT03323749|Experimental|Part 1: Elamipretide|40 mg (0.5mL) elamipretide subcutaneous (SC) daily
16495466|NCT03323749|Placebo Comparator|Part 1: Placebo|Placebo SC daily
16495467|NCT03323749|Experimental|Part 2: Elamipretide open label|Elamepretide 40 mg (0.5 mL) SC daily
16495468|NCT03323736|Other|Pivotal Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office.
16495469|NCT03323736|Other|Office Lead-In Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office. Physician initial in-office iontophoresis and tube insertion procedures (minimum of 2 subjects per investigator).
16495470|NCT03323736|Other|OR Lead-In Cohort|Tubes insertion using the Tube Delivery System in the operating room (OR). Physician initial tube insertion procedures in the OR (minimum of 2 subjects per investigator).
16495471|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
16495472|NCT03323710|Experimental|Propranolol plus Sunitinib|
16495473|NCT03323697|Experimental|Herbal|SZ-05 (2.5 gr; 3 capsules twice a day)
16495474|NCT03323697|Active Comparator|Selective serotonin reuptake inhibitor|Escitalopram (10 mg capsule plus 5 placebo capsules)
16495475|NCT03323684|Experimental|Quadratus lumborum block Group (QL)|Quadratus lumborum block will be performed
16495476|NCT03323684|Experimental|Transversus abdominis plane Group (TAP)|Subcostal transversus abdominis plane will be performed
16495477|NCT03323684|Experimental|Control group (C)|Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac
16495478|NCT03323671|Experimental|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
16495479|NCT03323671|Experimental|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
16495480|NCT03323658|Experimental|Prevention (bexarotene)|Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.
16495481|NCT03323645||Patients with penile prostheses|
16495707|NCT03321994|Active Comparator|Conventional biopsy technique|
16495482|NCT03323632|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
16495483|NCT03323619||GA|No intervention. General anesthesia is decided by the physicien according to his usual practice
16495484|NCT03323619||LASed|No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice
16495485|NCT03323606|Active Comparator|Gambling Internet Intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
16495486|NCT03323606|Experimental|Gambling Internet Intervention + CYD|The G+A intervention condition will consist of the G-only intervention and an online intervention for drinking. The online drinking intervention chosen is Check Your Drinking, a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
16495487|NCT03323593|Active Comparator|iv|
16495488|NCT03323593|Active Comparator|drip|
16495489|NCT03323593|Active Comparator|atomizer|
16495490|NCT03323580|Experimental|SVV-based GDFT group|The patients will receive fluid therapy under SVV-directed goal.
16495491|NCT03323580|Sham Comparator|non-SVV-based GDFT group|The patients will receive fluid therapy without SVV-directed goal.
16495492|NCT03323567|Experimental|MD Muscle Collagen group|Group with collagen intramuscular injections
16495493|NCT03323567|Experimental|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
16495494|NCT03323567|Placebo Comparator|Saline|Group with 0,9% NaCl intramuscular injections
16495495|NCT03323554|Experimental|Ustrap®|Ustrap is a new adjustable-pressure 4-arm device
16495496|NCT03323554|Active Comparator|AMS 800®|Artificial sphincter currently considered the gold standard device in this field
16495497|NCT03323541||Group of patients treated with Zarxio|All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
16495498|NCT03323528|Active Comparator|Dorithricin|"Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.
~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
16495499|NCT03323528|Placebo Comparator|Placebo|"Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.
~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
16495500|NCT03323502|Experimental|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
16495501|NCT03323502|No Intervention|Usual Care|Facility will followed usual ACP procedures.
16495502|NCT03323489|Experimental|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
16495503|NCT03323476|Experimental|Discontinuation of maintenance treatment|
16495504|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
16495507|NCT03323450|Experimental|High grade gliomas(WHO grade III or IV; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
16495508|NCT03323450|Experimental|Low grade gliomas(WHO grade II; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
16495509|NCT03323437|Experimental|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
16495510|NCT03323437|No Intervention|Control|Healthy, psychosis-free controls who will not receive risperidone
16495511|NCT03323424|Experimental|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
16495512|NCT03323424|Active Comparator|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
16495708|NCT03321981|Experimental|Cohort 1 doublet|
16495709|NCT03321981|Experimental|Cohort 1 triplet|
16495513|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
16495514|NCT03323398|Experimental|Arm A: mRNA-2416 Alone|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 for six 28-day cycles.
16495515|NCT03323398|Experimental|Arm B: mRNA-2416 in Combination with Durvalumab|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 6 in combination with durvalumab through an intravenous infusion at a fixed dose on Day 1 of Cycles 1 through 6. The duration for each cycle is 28 days.
16495516|NCT03323385|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
16495517|NCT03323385|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
16495518|NCT03323372|Active Comparator|control group|In group 1 (G1-control), the operator applied a desensitizing gel based on 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2% ®, FGM , Joinville, Santa Catarina, Brazil) with the aid of a custom silicone tray, which was made from a model obtained from the patient, with a vacuum plasticizer. A small layer of the gel was placed on the surface of the tray that was in contact with the vestibular face of the upper anterior teeth of the participants. The tray remained in position in the mouth for 10 minutes, according to the manufacturer's specifications.
16495519|NCT03323372|Experimental|experimental group|In group 2 (G2-intervention group), the operator applied a desensitizing gel containing 3% potassium nitrate and 0.25% sodium fluoride (Ultra EZ®, Ultradent Products Inc, South Jordan, UT, Estados Unidos) with the help of a tray in which the material is stored on the vestibular surfaces of the upper anterior teeth of the participants. The tray remained in position in the mouth for 15 minutes, according to the manufacturer's specifications.
16495520|NCT03323359|Experimental|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
16495521|NCT03323359|Other|Standard Surgery Technique|Common surgical techniques
16495522|NCT03323346|Experimental|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.
~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.
~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
16495523|NCT03323333|Experimental|Intervention|
16495524|NCT03323307|Experimental|OCT imaging|OCT device images retina
16495525|NCT03323294||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
16495526|NCT03323294||Healthy Obese|Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
16495527|NCT03323294||Obese Insulin Resistant|Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
16495528|NCT03323294||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance (n=20)
16495529|NCT03323281||Diabetic Type 1 or Type 2 with foot wound|Type 1 or type 2 diabetic patients with hospitalization for foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
16495530|NCT03323281||Diabetic Type 1 or Type 2 without a foot wound or antecedent|Type 1 or Type 2 diabetic patients with no foot wounds or history of foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
16495531|NCT03323255|Active Comparator|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
16495532|NCT03323255|Sham Comparator|SHAM stimulation (placebo)|SHAM stimulation
16495533|NCT03323242|No Intervention|Control group|Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
16495534|NCT03323242|Experimental|LS group|Recipient hepatectomy applying LigaSure.
16495535|NCT03323242|Experimental|USD group|Recipient hepatectomy applying Harmonic Ultrasonic dissector.
16495536|NCT03323229|No Intervention|Usual care (control group)|Patient receives care as usual.
16495537|NCT03323229|Experimental|Enhanced communications & ultrasound|The paramedic will record a brief video summary of the patient's condition, then remotely supported point of care ultrasound scans will be performed, and both file types sent to the hospital for review and feedback from the consultant.
16495538|NCT03323216||No diabetes|Patients without diabetes
16495539|NCT03323216||Type 2 diabetes|Patients with diagnosis of type 2 diabetes (new/established)
16495540|NCT03323216||Prediabetes|Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.
16495541|NCT03323190|Experimental|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
16495542|NCT03323177|Experimental|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
16495543|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
16495544|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
16495545|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
16495710|NCT03321981|Experimental|Cohort 2|
16495546|NCT03323151|Experimental|Phase I: Ixazomib & Ibrutinib|Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
16495547|NCT03323151|Experimental|Phase II: Ixazomib & BTK-Naive|Patients who are BTK-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
16495548|NCT03323151|Experimental|Phase II: Ixazomib & BTK Pre-Treated (Closed 8/7/2020)|Patients previously treated with a BTK will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
16495549|NCT03323138|Experimental|Ex-PRESS and phacoemulsification|A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).
16495550|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
16495551|NCT03323099|Experimental|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
16495552|NCT03323099|Placebo Comparator|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
16495553|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
16495554|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
16495555|NCT03323073|Active Comparator|Bipolar disorder type I or II|a single resting state fMR for patients with bipolar disorder type I or II with acute depressive state
16495556|NCT03323073|Active Comparator|Unipolar disorder|a single resting state fMR for patients with monopolar disorder with acute depressive state
16495557|NCT03323073|Other|Healthy volunteers|a single resting state fMRI for subjects without psychiatric disorders assessed by the SCID
16495558|NCT03323060||Male and/or females ≥ 22 yrs old|≥ 22 years of age requiring transanal procedures in the areas of the anus, rectum, and distal colon Transanal endoscopic surgical procedure
16495559|NCT03323047|Experimental|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
16495560|NCT03323047|Active Comparator|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
16495561|NCT03323047|Placebo Comparator|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
16495562|NCT03323034|Experimental|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1. Beginning cycle 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan IV over 90 minutes on days 1-5. Treatment repeats every 28 days for cycle 1 and 21 days for subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
16495563|NCT03323021|Experimental|Treatment with DHACM|Partial nephrectomy patched with DHACM
16495564|NCT03323021|Active Comparator|Control without DHACM|Partial nephrectomy without DHACM.
16495565|NCT03323008|Experimental|Training Prototype|Testing of 3 modules
16495566|NCT03322995|Experimental|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
16495567|NCT03322995|Experimental|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
16495568|NCT03322995|Experimental|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
16495569|NCT03322982|Experimental|MS Diet|34 people with MS following low-fat diet
16495570|NCT03322982|No Intervention|MS Wait-List|34 people with MS following usual diet
16495571|NCT03322982|No Intervention|Diet Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Diet group
16495572|NCT03322982|No Intervention|Wait-List Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Wait-List group
16495573|NCT03322969|Experimental|receiving modified chemotherapy|Paclitaxel/DDP
16495574|NCT03322969|Active Comparator|receiving the original chemotherapy|XELOX/SOX
16495575|NCT03322956|Experimental|experimental group (EGR)|"Physical therapy intervention.
~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
16495576|NCT03322956|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.
~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
16495577|NCT03322930||Retinitis Pigmentosa|patients with a diagnosis of retinitis pigmentosa and reduced rod function on baseline testing
16495578|NCT03322930||Age-related Macular Degeneration|patients with a diagnosis of intermediate AMD and reduced rod function on baseline testing
16495711|NCT03321968|Experimental|Lot 1|Quadrivalent VLP Influenza Vaccine
16495579|NCT03322891|Experimental|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
16495580|NCT03322878|Experimental|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
16495581|NCT03322878|Active Comparator|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
16495582|NCT03322878|Placebo Comparator|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
16495583|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
16495584|NCT03322839|Experimental|Multifaceted implementation strategies|The school-management will participate in a one-day training. In addition each intervention school will form an implementation team that is responsible for the implementation of the guideline within their school. The implementation teams will participate in 4-5 workshops in order to support the implementation process.
16495585|NCT03322839|Active Comparator|Single implementation strategy|The control-schools will only receive training to the school-management.
16495586|NCT03322826|Active Comparator|Lymphadenectomy|systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
16495587|NCT03322826|Experimental|systematic sampling of the lymph nodes|systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
16495588|NCT03322813|Experimental|ExAblate 4000 - Type 2|ExAblate BBBD
16495589|NCT03322800|Experimental|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
16495590|NCT03322800|Experimental|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
16495591|NCT03322800|Experimental|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
16495592|NCT03322800|Experimental|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
16495593|NCT03322800|Experimental|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
16495594|NCT03322800|Other|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
16495595|NCT03322787|No Intervention|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
16495596|NCT03322787|Experimental|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
16495597|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
16495598|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
16495599|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
16495600|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
16495601|NCT03322761|Experimental|Systematic exercise training|Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
16495602|NCT03322761|Active Comparator|Educational program|Educational program on physical activity and health, consisting of four educational sessions in the intervention period.
16495603|NCT03322761|No Intervention|Standard treatment alone|Data from The Danish MS Registry will serve as control-data for standard treatment alone.
16495604|NCT03322748|Experimental|Experimental group|Usual physical therapy+ strengthening of lower limbs muscles
16495605|NCT03322748|Other|Control group|Usual physical therapy
16495606|NCT03322735|Experimental|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.
~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
16495607|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
16495608|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
16495609|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
16495610|NCT03322696||Cirr-PVT|Cirrhotic patients developing over 1 yr period thrombosis of portal vein or collaterals
16495611|NCT03322683|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 5 massage sessions with the PHYSIUM device for a month.
16495612|NCT03322683|Experimental|CONTROL GROUP|"The multimodal physical therapy program includes 10 sessions of:
~ultrasound pulsatil therapy (US) for 10 minutes.
~transcutaneous electric nerve stimulation (TENS) for 20 minutes.
~massage for 20 minutes."
16495613|NCT03322670||Signs of CAP and a positive chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
16495614|NCT03322670||Patients directly hospitalized|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and who are directly hospitalized before complementary examinations
16495615|NCT03322670||Control patients|Healthy Patients (age-matched with a radiologically confirmed CAP patient)
16495616|NCT03322670||Patients with partial participation|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and who can not or do not want to perform all the complementary examinations of the study
16495617|NCT03322670||Signs of CAP and a negative Chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
16495618|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
16495619|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
16495620|NCT03322644|Experimental|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
16495621|NCT03322644|No Intervention|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
16495622|NCT03322631|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
16495623|NCT03322631|Placebo Comparator|Placebo|Placebo administered SC.
16495624|NCT03322618|Experimental|SpA HLA-B27 +,|
16495625|NCT03322618|Experimental|SpA HLA-B27-|
16495626|NCT03322618|Active Comparator|healthy subject|
16495627|NCT03322592|Active Comparator|EUS-FNB with ROSE|Intervention: Rapid on-site evaluation (ROSE) In the EUS-FNB with ROSE arm, the material obtained with the first pass will be processed for ROSE using the touch imprint technique. The biopsy specimen is carefully pressed onto the slide, allowing the superficial cells to adhere, and then gently lifted with forceps thereby creating a touch imprint of the specimen on the slide. In case of inadequate sample, a second pass will be done and the touch imprint technique will be repeated up to a maximum of 3 passes. In case of adequate ROSE at the first or the second pass, the additional passes will be performed as EUS-FNB and the material obtained placed directly into formalin or other fixative for subsequent histopathological evaluation.
16495628|NCT03322592|Active Comparator|EUS-FNB without ROSE|Intervention: histologic evaluation In the FNB alone arm, 3 needle passes will be performed and the samples obtained will be placed directly in a vial containing formalin (or other fixative according to the local individual protocol). Macroscopic on-site evaluation (MOSE) of acquired sample will be then performed by the endoscopist.
16495629|NCT03322579|Experimental|Patients with Eustachian tube dysfunction|
16495630|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
16495631|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
16495632|NCT03322566|Experimental|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
16495633|NCT03322553|Experimental|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
16495634|NCT03322553|Sham Comparator|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
16495635|NCT03322540|Experimental|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
16495636|NCT03322540|Active Comparator|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
16495637|NCT03322514|Experimental|experimental group|10 g of Inulin-Propionate Esters will be administered per day
16495638|NCT03322514|Active Comparator|Inulin|10 g of Inulin will be administered per day
16495712|NCT03321968|Experimental|Lot 2|Quadrivalent VLP Influenza Vaccine
16495639|NCT03322501|Experimental|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
16495640|NCT03322488|Experimental|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
16495641|NCT03322488|Experimental|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
16495642|NCT03322475|Experimental|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
16495643|NCT03322462|Experimental|Flortaucipir PET Scan|
16495644|NCT03322449|Experimental|Animal Diet|during this Arm, the participants will receive a diet enriched in animal products
16495645|NCT03322449|Experimental|Plant Diet|during this Arm, the participants will receive a diet enriched in plant products
16495646|NCT03322436||AMI patients treated by PCI|AMI patient treated by PCI at risk to develop Heart Failure
16495647|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
16495648|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
16495649|NCT03322410|Experimental|Patients|
16495650|NCT03322397|Experimental|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
16495651|NCT03322397|Active Comparator|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
16495652|NCT03322397|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
16495653|NCT03322384|Experimental|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
16495654|NCT03322371|Other|Health Subjects in Sleep Lab|Adult patients (> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device. 2-lead limited electroencephalography recording
16495655|NCT03322371|Other|ICU patients, not sedated or ventilated|Adult ICU patients (> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited electroencephalography recording
16495656|NCT03322371|Other|ICU patients, sedated and ventilated|Adult ICU patients (> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited electroencephalography recording
16495657|NCT03322358|No Intervention|Control|No changes to normal sleep habits.
16495658|NCT03322358|Experimental|Naps only|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
16495659|NCT03322358|Experimental|Home sleep aids only|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
16495660|NCT03322358|Experimental|Home sleep aids + Sleep incentives|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful. In addition, they will be given a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
16495661|NCT03322358|Experimental|Naps + Home sleep aids|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
16495662|NCT03322358|Experimental|Naps + Home sleep aids + Sleep incentives|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish, and 3) a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period. The sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
16495663|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
16495664|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
16495666|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
16495667|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
16495668|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
16495669|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
16495670|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
16495671|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
16495672|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
16495673|NCT03322319|Experimental|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
16495674|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.
~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
16495675|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.
~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
16495676|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.
~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
16495679|NCT03322267|Experimental|Pembrolizumab|Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab
16495680|NCT03322228|Experimental|Music Therapy|1 music therapy session, lasting approximately 45 min-1 hr
16495681|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant
~Palbociclib:
~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.
~Fulvestrant:
~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
16495682|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
16495683|NCT03322202|Experimental|Motivational Interviewing|Physical and Occupational Therapists will have 16 hours of training in Motivational Interviewing and use these techniques during sessions with patients.
16495684|NCT03322202|No Intervention|Control|Therapists will not participate in additional training.
16495685|NCT03322150|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
16495686|NCT03322150|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
16495687|NCT03322137|Active Comparator|SNA-120 (0.05% )|Pegcantratinib Ointment
16495688|NCT03322137|Active Comparator|SNA-120 (0.5%)|Pegcantratinib Ointment
16495689|NCT03322137|Placebo Comparator|Vehicle|
16495690|NCT03322124|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
16495691|NCT03322124|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
16495692|NCT03322111|Experimental|Cyclofusion|
16495693|NCT03322098|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
16495694|NCT03322098|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
16495695|NCT03322085|Experimental|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
16495696|NCT03322085|Experimental|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
16495697|NCT03322085|Experimental|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
16495698|NCT03322072|Experimental|Real-Time Position Transponder Beacons|Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)
16495699|NCT03322059|Active Comparator|Control|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
~Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values."
16495700|NCT03322059|Experimental|Intervention|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit. Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values.
~Participants will be in the form of a charitable donation in their name to a cancer charity."
16495701|NCT03322046||Therapeutic Lifestyle Change (TLC) Intervention Group|TLC group received CVD risk lecture, enrolled in lifestyle program, received follow-up visits from team practitioner after each blood draw, access to food journaling portal for 12 month period, telephonic coaching
16495702|NCT03322046||Control Group|Control group received CVD risk lecture, then baseline, 3, 6, 12 month blood draws and 3 day food journals prior to each blood draw.
16495703|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
16495704|NCT03322020|Experimental|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
16495705|NCT03322020|Experimental|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
16495714|NCT03321955|Experimental|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
16495715|NCT03321942|Active Comparator|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
16495716|NCT03321942|Placebo Comparator|Control group|Treatment of chronic renal failure patients with conventional methods.
16495717|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects undergo lumpectomy as standard of care and will have the study intervention, guidance by intraoperative imaging using the LUM Imaging Device
16495718|NCT03321916|Experimental|Subthreshold Photothermal Therapy|
16495719|NCT03321916|Sham Comparator|Sham|
16495720|NCT03321903||1: Intraoral Squamous Cell Carcinomas|Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
16495721|NCT03321903||2: Cutaneous Malignant Tumors|Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
16495722|NCT03321903||3: Breast Cancers|Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
16495723|NCT03321903||4: Other tumors|Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
16495724|NCT03321890|Experimental|Combination therapy regimen|Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate
16495725|NCT03321877|Experimental|Study group|All included patients underwent dose reduction.
16495726|NCT03321864|Experimental|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
16495727|NCT03321851|Other|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
16495728|NCT03321838|Experimental|Accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
16495729|NCT03321825|Experimental|Belotero® Volume Lidocaine|Subdermal injection
16495730|NCT03321825|No Intervention|No treatment|
16495731|NCT03321812|Experimental|decalcification bone scaffold|Decalcification bone scaffold is a novel tissue engineered acellular matrix scaffold with the closest biomechanics and structure to normal cartilage.
16495732|NCT03321812|Active Comparator|Microfracture|Microfracture is a conventional treatment for cartilage lesions of the knee.
16495733|NCT03321799|Active Comparator|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
16495734|NCT03321799|Experimental|NPWT|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.
~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
16495735|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
16495736|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
16495737|NCT03321773|Experimental|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
16495738|NCT03321773|Active Comparator|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
16495739|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
16495740|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
16495741|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
16495742|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
16495748|NCT03321734|Experimental|Extended Caffeine Treatment|Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
16495749|NCT03321734|Placebo Comparator|Placebo|Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.
16495750|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
16495751|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
16495752|NCT03321682|Experimental|Functional Training|Patients in the functional training group, in addition to maintaining their usual care, will perform functional training including exercises for core strength, power training, knee dominance, hip dominance, horizontal pressure, vertical pressure, horizontal pull and vertical pull, using unstable surfaces.
16495753|NCT03321682|Active Comparator|Strength Training|These group, in addition to maintaining their usual care, will perform the exercise protocol as recommended by the American Heart Association.
16495754|NCT03321669|Active Comparator|Increased Fat Diet|
16495755|NCT03321669|Sham Comparator|Low Fat Diet|
16495756|NCT03321656|Active Comparator|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
16495757|NCT03321656|Experimental|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
16495758|NCT03321643|Experimental|Treatment (rituximab, gemcitabine, oxaliplatin, atezolizumab)|"INDUCTION PHASE: Patients receive rituximab IV, gemcitabine IV, and oxaliplatin IV every 2 weeks. Starting cycle 2, patients also receive atezolizumab IV over 30-60 minutes every 2 weeks. Treatment repeats every 14 days of cycle 1 and every 28 days for up to 4 cycles in the absence of disease progression or unaccepted toxicity.
~MAINTENANCE PHASE: Patients receive rituximab IV and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unaccepted toxicity."
16495759|NCT03321630|Other|Lenvatinib & Pembrolizumab|
16495760|NCT03321617|Experimental|POMA 40mg BID (80mg)|Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.
16495761|NCT03321617|Experimental|POMA 80mg BID (160 mg)|Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days
16495762|NCT03321617|Experimental|POMA 120mg BID (240mg)|Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days
16495763|NCT03321617|Experimental|POMA 160 mg BID (320 mg)|Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days
16495764|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
16495765|NCT03321539|Experimental|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
16495766|NCT03321539|Active Comparator|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
16495767|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
16495768|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
16495769|NCT03321513|Active Comparator|Aflibercept Group|2.0 mg intravitreous aflibercept
16495770|NCT03321513|Experimental|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
16495771|NCT03321500|Experimental|Versacyl soft liner|Versacryl soft liner are flexible biocompatible materials with a reported predictable long term performance, durable bonding to acrylic denture bases, high fatigue endurance, excellent wear characteristics and solvent resistance with almost no free monomer in the processed material
16495795|NCT03321266||Patients treated for a anorectal fistula|Patients who were treated for a anorectal fistula with a Biodesign Fistula plug
16495835|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
16495772|NCT03321500|Active Comparator|Silicone-based soft liner|Resilient liners were introduced in the1950s and have been used since then as a gold standard material to increase the tolerance, retention and comfort of complete dentures. Resilient liners also known as 'soft liners' can be classified as temporary or permanent, cold-cured or heat-cured.Resilient liners can be divided into two main types: plasticized acrylic resins and silicone elastomers.
16495773|NCT03321487|Experimental|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
16495774|NCT03321487|Experimental|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
16495775|NCT03321474|Experimental|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
16495776|NCT03321474|Active Comparator|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts
~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.
~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
16495777|NCT03321461|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
16495778|NCT03321461|Active Comparator|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
16495779|NCT03321448|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
16495780|NCT03321448|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
16495781|NCT03321435||placenta previa group|
16495782|NCT03321435||Normal control group|
16495783|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
16495784|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
16495785|NCT03321396|Experimental|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
16495786|NCT03321344|Experimental|Test Arm|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
16495787|NCT03321331|Experimental|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
16495788|NCT03321331|Active Comparator|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
16495789|NCT03321318|Experimental|A group|AK-R215, test drug
16495790|NCT03321318|Active Comparator|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
16495791|NCT03321292|Experimental|L-arginine and Acetylesalicylic acid|L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
16495792|NCT03321292|Active Comparator|Acetylesalicylic acid75mg|acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
16495793|NCT03321279|No Intervention|Control|Participants' daily step counts will be for weeks 2-13 after hospital discharge. Participants will be asked to complete surveys at 5, 9 and 13 weeks post-discharge.
16495794|NCT03321279|Experimental|Intervention|Participants' daily step counts will be monitored for weeks 2-13 after hospital discharge. Participants will have a weekly step goal that increases from baseline by 10% each week of the intervention (12 weeks). Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
16495930|NCT03320434|Active Comparator|Pred-forte|
16495931|NCT03320434|Placebo Comparator|PRT-2761 0%|
16495796|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
16495797|NCT03321240||The SEEG group|Group with the SEEG analysis
16495798|NCT03321240||The direct surgery group|Group with a direct surgery
16495799|NCT03321227|Experimental|Snack skipping|No snack provided
16495800|NCT03321227|Experimental|Whole eggs|2 whole large eggs as a snack
16495801|NCT03321227|Experimental|Egg whites|2 egg whites as a snack
16495802|NCT03321227|Experimental|Egg yolks|2 egg yolks as a snack
16495803|NCT03321227|Active Comparator|Yogurt|Full fat yogurt as a snack
16495804|NCT03321214|Experimental|Light use of Nima|Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).
16495805|NCT03321214|Experimental|Moderate use of Nima|Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).
16495806|NCT03321214|Experimental|Heavy use of Nima|Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).
16495807|NCT03321201|Experimental|Cauterization|
16495808|NCT03321201|Active Comparator|Fibrin glue|
16495809|NCT03321188|Experimental|HIPEC + adjuvant IV chemotherapy|"HIPEC
~HIPEC will be administered intraoperatively one time only.
~*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)
~Administration of HIPEC will have a duration of 90 minutes.
~Adjuvant IV chemotherapy
~IV Paclitaxel
~Dose: 80mg/m2 IV over 1 hour
~Schedule: Days 1, 8 and 15
~Cycle Length: 3 weeks (21 days)
~IV Carboplatin
~Dose: Area under the curve (AUC) 6 IV
~Schedule: Day 1
~Cycle Length: 3 weeks (21 days)"
16495810|NCT03321175|Experimental|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
16495811|NCT03321175|No Intervention|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
16495812|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
16495813|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
16495814|NCT03321149|Experimental|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
16495815|NCT03321136|Placebo Comparator|Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16495816|NCT03321136|Placebo Comparator|LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16495817|NCT03321136|Placebo Comparator|LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16495818|NCT03321136|Placebo Comparator|LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16495819|NCT03321136|Placebo Comparator|LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16495820|NCT03321136|Placebo Comparator|LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
16495821|NCT03321123|Experimental|CRA treatment|"The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 ~2x10e7 MB-CART19.1/kg.
~A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells."
16495822|NCT03321110|Experimental|Placebo|Placebo
16495823|NCT03321110|Experimental|Q10-150|coenzyme Q10 150 mg/d.
16495824|NCT03321110|Experimental|Q10-300|coenzyme Q10 300 mg/d.
16495825|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
16495826|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
16495827|NCT03321084|Experimental|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
16495828|NCT03321084|Other|Control|It continues in your daily life with phone monitoring.
16495829|NCT03321071|Experimental|Healthy Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (~45min-1hr time blocks).
16495830|NCT03321071|Active Comparator|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
16495831|NCT03321071|No Intervention|Passive control|Children in this condition will not attend a summer program.
16495832|NCT03321045|Experimental|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab [89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
16495833|NCT03321032|Experimental|Amphilimus-eluting stents|Polymer-free Amphilimus-eluting stents
16495834|NCT03321032|Active Comparator|Zotarolimus-eluting stents|Biolinx Polymer-based zotarolimus-eluting stents
16495836|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
16495837|NCT03321006|Active Comparator|Antidepressant (AD) + full amplification hearing aids|Participant will be randomized to active comparator and will receive escitalopram or duloxetine + active hearing aid for 12 weeks.
16495838|NCT03321006|Sham Comparator|Antidepressant (AD) + Low amplification (sham) hearing aids|Participant will be randomized to sham comparator and will receive escitalopram or duloxetine + sham hearing aid for 12 weeks.
16495839|NCT03320993|Active Comparator|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
16495840|NCT03320993|Experimental|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
16495841|NCT03320993|Experimental|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
16495842|NCT03320980||RALPPS|Patients with initial volume of FLR < 40% which underwent RALPPS and major liver resection (as the second stage of RALPPS) for hilar and intrahepatic cholangiocarcinoma
16495843|NCT03320980||Portal vein embolization (PVE)|Patients with initial volume of FLR < 40% undergoing PVE and major liver resection for hilar and intrahepatic cholangiocarcinoma
16495844|NCT03320954|Experimental|Anomia treatment|Phase 2 portion of the research during which participants with acquired brain injury will perform intervention activities.
16495845|NCT03320941|Experimental|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
16495846|NCT03320941|Experimental|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
16495847|NCT03320941|Experimental|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
16495848|NCT03320941|Experimental|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
16495849|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
16495850|NCT03320915|Experimental|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
16495851|NCT03320915|No Intervention|Usual care|Usual care
16495852|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
16495853|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
16495854|NCT03320889|Other|Pamphlets plus Review with Expert Educator|Educational Intervention includes Pamphlets plus Review with Expert Educator
16495855|NCT03320889|Other|Pamphlets only|Educational Intervention includes Pamphlets only
16495856|NCT03320876|Experimental|filgotinib|
16495857|NCT03320863|Active Comparator|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
16495858|NCT03320863|No Intervention|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
16495859|NCT03320850|Experimental|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495860|NCT03320850|Placebo Comparator|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495861|NCT03320850|Experimental|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495862|NCT03320850|Placebo Comparator|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495863|NCT03320850|Experimental|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495864|NCT03320850|Placebo Comparator|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495865|NCT03320850|Experimental|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495866|NCT03320850|Placebo Comparator|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
16495867|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
16495868|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
16495869|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
16495870|NCT03320824|Experimental|New Dermal Filler|hyaluronic acid
16495871|NCT03320824|Active Comparator|Dermal Filler|hyaluronic acid
16495872|NCT03320811||"group celiac disease"|
16495873|NCT03320811||"group no celiac disease"|
16495874|NCT03320798||"group Bullous pemphigoid"|Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
16495875|NCT03320772|Experimental|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
16495876|NCT03320772|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
16495877|NCT03320759|No Intervention|No rehabilitation|
16495878|NCT03320759|Experimental|Rehabilitation|
16495879|NCT03320746|Experimental|Activity trackers|The participants were requested to wear a commercial wrist-worn activity tracker (Polar Loop 2, Polar, Kempele, Finland) every day and night for 12 months.
16495880|NCT03320746|No Intervention|No activity trackers|Control group members were requested to abstain from the use of any type of activity trackers and they were informed that they will receive the activity trackers and guidance for using them after the follow-up.
16495881|NCT03320733|Experimental|Surgical|"Includes patients who will undergo surgery for their pancreatic cysts.
~In addition to the routine pre-operative CT abdomen performed for surgical planning purposes, these patients will receive Dual Energy CT scan with subtraction imaging before surgery."
16495882|NCT03320733|Experimental|Surveillance|"Includes patients who are undergoing surveillance for their pancreatic cysts.
~Dual Energy CT scan with subtraction imaging will be performed in addition to the standard-of-care surveillance method of MRI scans."
16495883|NCT03320720|Experimental|Home Treatment|Patients with acute mental illness are treated at their houses by a mobile and multiprofessional care team instead of being treated as inpatients if their medical condition permits.
16495884|NCT03320720|Active Comparator|Treatment-as-usual|Patients with acute mental illness are treated as inpatients in a psychiatric clinic.
16495885|NCT03320707|Experimental|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort. Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
16495886|NCT03320707|Placebo Comparator|Placebo|Participants will receive placebo as a single SC dose in each of first 7 cohorts.
16495887|NCT03320694|Experimental|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
16495888|NCT03320694|Active Comparator|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
16495889|NCT03320681|Active Comparator|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
16495890|NCT03320681|Other|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
16495891|NCT03320668|No Intervention|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
16495892|NCT03320668|Experimental|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
16495893|NCT03320655|Active Comparator|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
16495894|NCT03320655|Experimental|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
16495895|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
16495896|NCT03320629|Experimental|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
16495897|NCT03320629|Active Comparator|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
16495898|NCT03320616|Experimental|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
16495899|NCT03320616|Experimental|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
16495900|NCT03320616|Experimental|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
16495901|NCT03320616|Experimental|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
16495902|NCT03320603|Other|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
16495903|NCT03320603|Other|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
16495904|NCT03320590||Couple|Couple with female aged under 37 years
16495932|NCT03320421|Experimental|SIB group|"Radiation therapy:
~daily 5 days per week for 3 weeks. 43.5 Gy in 15 fractions to the whole breast 49.5 Gy in 15 fractions to the tumor bed boost"
16495933|NCT03320408||Asymptomatic AAA|These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.
16495905|NCT03320577|Active Comparator|Class instruction of breathing exercises|Class participation/instruction weekly for 6 weeks and requested to practice Pranayama breathing exercises of 15 minute duration for an additional 4x during the week; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
16495906|NCT03320577|Active Comparator|DVD instruction of breathing exercises|Received DVD with instructions and 15 minute Pranayama breathing exercises of 15 minute duration. Participants requested to practice breathing exercises 5x during the week for 6 week intervention; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
16495907|NCT03320577|Placebo Comparator|Control|Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
16495908|NCT03320564|Experimental|Infiltration|Repeat F-18 FDG PET
16495909|NCT03320551|Experimental|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
16495910|NCT03320538|Experimental|Hou Gu Mi Xi|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
16495911|NCT03320538|Experimental|Hou Gu Mi Xi + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
16495912|NCT03320538|Placebo Comparator|Placebo + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
16495913|NCT03320538|Placebo Comparator|Placebo|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Hou Gu Mi Xi (once 10 g, twice a day).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
16495914|NCT03320525|Experimental|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
16495915|NCT03320512|Experimental|P3|Participants will use P3
16495916|NCT03320512|Experimental|P3+|Participants will use P3+
16495917|NCT03320512|Placebo Comparator|Control|Participants will receive the standard of care
16495918|NCT03320499||echo doppler at the bed|
16495919|NCT03320499||echo doppler in the vascular exploration platform|
16495920|NCT03320486|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, once daily, during 42 days.
16495921|NCT03320486|Active Comparator|Group 2 - ketoconazole cream 2%|Topical application of ketoconazole cream 2%, once daily, during 42 days.
16495922|NCT03320473|Experimental|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
16495923|NCT03320460|Experimental|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
16495924|NCT03320460|Active Comparator|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
16495925|NCT03320447|Experimental|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
16495926|NCT03320447|Experimental|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
16495927|NCT03320434|Experimental|PRT-2761 0.5%|
16495928|NCT03320434|Experimental|PRT-2761 1%|
16495929|NCT03320434|Active Comparator|Patanol|
16495934|NCT03320408||Acute AAA|These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.
16495935|NCT03320408||Repaired AAA|These patients are included while they already had had AAA repair (both elective and emergency repair).
16495936|NCT03320395|Experimental|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
16495937|NCT03320369|Other|Treatment|Elemental formula Intervention: Elemental Diet Therapy
16495938|NCT03320356||shoulder pain|Patients presenting inflammatory, degenerative, or post-traumatic shoulder pain and consulting at Orthopaedic Department, Reims Teaching Hospital.
16495939|NCT03320343||Patients recruited for pelvic imaging examination|
16495940|NCT03320330|Experimental|Treatment (pepinemab)|Patients receive pepinemab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
16495941|NCT03320317||Colorectal cancer|
16495942|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
16495943|NCT03320291|Experimental|Regjoint|
16495944|NCT03320278||SPIDS,TMH|There will be two tests in this study for evaluation. Both of them will be measured in same group.
16495945|NCT03320265|Experimental|PC-mAb|Phosphorylcholine human monoclonal antibody, i.v. infusions
16495946|NCT03320265|Placebo Comparator|Placebo|Placebo to PC-mAb, i.v. infusions
16495947|NCT03320239|Experimental|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
16495948|NCT03320239|Experimental|intervention group 2|HIV risk behavior investigation and routine education
16495949|NCT03320239|Placebo Comparator|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
16495950|NCT03320226|Other|Probiotic 10 (Nature's Bounty)|The suggested dose will be two (2) pills of Probiotic 10 (Nature's Bounty) after dinner daily. Subjects will be asked to take probiotics for six (6) days after providing baseline fecal specimen. Subjects will self-report their daily GI function including the frequency of nausea, vomiting, and bowel movement(s). Then, the subjects will stop taking probiotics for two (2) days and resume taking probiotics for another six (6) days. This six (6)-day on and two (2)- day off cycle is repeated two (2) times.
16495951|NCT03320200|Experimental|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
16495952|NCT03320200|Experimental|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
16495953|NCT03320187|Experimental|Group A|Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
16495954|NCT03320187|Placebo Comparator|Group B|Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
16495955|NCT03320174|Active Comparator|Tafenoquine 200 mg (2 x 100 mg tablets)|Tafenoquine 200 mg (2 x 100 mg tablets) daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
16495956|NCT03320174|Placebo Comparator|Placebo|Placebo daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
16495957|NCT03320148|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
16495958|NCT03320148|Active Comparator|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
16495959|NCT03320135|Active Comparator|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
16495960|NCT03320135|Active Comparator|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
16495961|NCT03320122|Experimental|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
16495962|NCT03320122|Active Comparator|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
16495963|NCT03320122|Active Comparator|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
16495964|NCT03320096|Experimental|Microfocused ultrasound with visualization|
16495965|NCT03320083|Active Comparator|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
16495966|NCT03320083|No Intervention|Usual Care|General anticipatory guidance given
16495969|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
16495970|NCT03320057|Other|Pharmacists|Pharmacists providing services at one of the study pharmacies during the study
16495971|NCT03320031|Experimental|combined group|Drug: linagliptin&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.
16495972|NCT03320031|Active Comparator|linsulin group|Drug: premixed insulin Treated with premixed insulin for 12 weeks.
16495973|NCT03320018|Experimental|Hydrogen/Minocycliine|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, q 8 hours for 3 days.
~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
16495974|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
16495975|NCT03320005|Active Comparator|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
16495976|NCT03320005|No Intervention|Non training group|sedentary elderly
16495977|NCT03319992|No Intervention|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
16495978|NCT03319992|Experimental|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
16495979|NCT03319966||Oculomotor Dysfunction|This group consists of subjects with mTBI who have been diagnosed with OMD by objective OD measurements. These subjects will undergo neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury per usual clinical standard of care at the HCMC TBI Clinic.
16495980|NCT03319953|Experimental|Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics|TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
16495981|NCT03319953|Experimental|Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
16495982|NCT03319953|Experimental|Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics|TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
16495983|NCT03319953|Experimental|Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
16495984|NCT03319940|Experimental|Part A or Part B|AMG 757 Monotherapy
16495985|NCT03319940|Experimental|Part C|AMG 757 with Pembrolizumab
16495986|NCT03319940|Experimental|Part D|AMG 757 with additional cytokine release syndrome (CRS) mitigation strategies
16495987|NCT03319940|Experimental|Part E|AMG 757 administration with 24-hour monitoring
16495988|NCT03319940|Experimental|Part F|AMG 757 administered in outpatient infusion centers with 8-hour monitoring.
16495989|NCT03319927|Experimental|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
16495990|NCT03319927|Active Comparator|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
16495991|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
16495992|NCT03319901|Experimental|Venetoclax + Chemotherapy|"Venetoclax is administered orally once daily for 21 days in each cycle
~Standard Chemotherapy will be administered every 28 days"
16495993|NCT03319888|Experimental|cpap group|CPAP treatment plus conservative treatment with lifestyle modifications.
16495994|NCT03319888|Active Comparator|control group|Conservative treatment with lifestyle modifications.
16495995|NCT03319849|Experimental|NT-501|
16495996|NCT03319849|Sham Comparator|Sham|
16495997|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula [2015].
16495998|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula [2016].
16495999|NCT03319823|Experimental|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg
16496000|NCT03319823|Experimental|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
16496001|NCT03319810|Experimental|infusion of IVIG|
16496002|NCT03319797|Other|Treatment with NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte transplantation)
16496003|NCT03319784|Active Comparator|Ketorolac (Toradol) Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
16496004|NCT03319784|Active Comparator|Steroid Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Steroid group will receive a single dose of 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
16496005|NCT03319771|Experimental|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
16496006|NCT03319771|Active Comparator|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
16496007|NCT03319758|Experimental|thin or dehiscences buccal plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with thin or dehiscences buccal plate.
16496008|NCT03319745|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
16496009|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
16496010|NCT03319719|Experimental|Belotero® Balance with integral lidocaine|Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
16496011|NCT03319719|Active Comparator|Belotero Balance without lidocaine|Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
16496012|NCT03319706|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
16496013|NCT03319706|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
16496014|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
16496015|NCT03319680|Active Comparator|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
16496016|NCT03319680|No Intervention|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
16496017|NCT03319667|Experimental|Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm|"Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone
~Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone"
16496018|NCT03319667|Active Comparator|Bortezomib/Lenalidomide/Dexamethasone = VRd arm|"Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone
~Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone"
16496019|NCT03319667|Other|Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm|4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone
16496020|NCT03319654|Experimental|Spontaneous cycle IUI|"DNA fragmentation by TUNEL assay
~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination."
16496021|NCT03319641|Experimental|PSMA-PET/CT scan|PSMA-PET/CT imaging in advanced ACC/SDC
16496022|NCT03319628|Experimental|Dose Escalation|"XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.
~This cohort is closed to enrollment."
16496023|NCT03319628|Experimental|Dose Expansion - Ovarian Cancer|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.
~Patients with ovarian cancer will enroll until sites approve UPLIFT."
16496024|NCT03319628|Experimental|Dose Expansion - NSCLC adenocarcinoma|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.
~This cohort is closed to enrollment."
16496025|NCT03319628|Experimental|Pivotal Cohort (UPLIFT)|Patients with platinum-resistant ovarian cancer will receive XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy
16496026|NCT03319628|Experimental|QTc Sub-Study|For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536.
16496027|NCT03319615|No Intervention|Habitual dietary intake|Habitual dietary intake
16496028|NCT03319615|Experimental|Energy Restriction|Match period (to comparator) of dietary energy restriction
16496029|NCT03319602|Active Comparator|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
16496030|NCT03319602|Experimental|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
16496062|NCT03319368|Experimental|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
16496063|NCT03319342|Experimental|Group I (acts of kindness to others)|Participants perform small acts of kindness or generosity for others 3 times per week for 4 weeks and complete weekly online questionnaires.
16496031|NCT03319589|Experimental|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
16496032|NCT03319589|No Intervention|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
16496033|NCT03319576|Experimental|Early feeding|Patients randomized to early feeding will be fed 4 hours following gastrostomy tube placement
16496034|NCT03319576|No Intervention|Standard feeding|Patients randomized to standard feeding will be fed 24 hours following gastrostomy tube placement
16496035|NCT03319563|Experimental|local anesthetic-epinephrine group|"after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels:
~Subcutaneous: before incision at a volume 20 ml/10 cm/side.
~Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume.
~Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration."
16496036|NCT03319563|Placebo Comparator|saline group|after general anesthesia, the same infiltration volume and technique using normal saline.
16496037|NCT03319550|Experimental|Casein|"LPS + 36 hour fast and bedrest + Casein (9% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping."
16496038|NCT03319550|Experimental|Whey|"LPS + 36 hour fast and bedrest + Whey (11% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
16496039|NCT03319550|Experimental|Leucine-enriched whey|"LPS + 36 hour fast and bedrest + Leucine-enriched whey (16% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
16496040|NCT03319537|Experimental|Pevonedistat|
16496041|NCT03319537|Experimental|pevonedistat in combination with pemetrexed and cisplatin|
16496042|NCT03319511|Active Comparator|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
16496043|NCT03319511|Experimental|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
16496044|NCT03319498|Active Comparator|Peppermint Oil Vapor|Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.
16496045|NCT03319498|Placebo Comparator|Mineral Oil Vapor|Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.
16496046|NCT03319485|Experimental|ExAblate Pallidotomy|ExAblate treatment for Advanced Idiopathic Parkinson's Disease
16496047|NCT03319485|Sham Comparator|Sham ExAblate Pallidotomy|Sham (fake) treatment
16496048|NCT03319472||Benign Pleural Effusion|Patients that will be diagnosed within a month from admission with any non-malignant cause of pleural effusion, including but not limited to effusions caused by common or tuberculous or fungal infection, heart failure, etc. Documentation of the etiology will be required for inclusion in this group, including but not limited to bacteriology, virology, PCR, radiology, heart echocardiogram or catheterization, as appropriate.
16496049|NCT03319472||Malignant Pleural Effusion|Patients that will be diagnosed within a month from admission with any malignant cause of pleural effusion, including but not limited to effusions caused by lung, breast, colon, ovary, mesothelial, hematopoietic, prostate, or any other cancer. Diagnosis will be based on verification of the presence of malignant cells in the pleural fluid or tissues. Patients with cancer and an effusion without such documentation will be assigned to the benign group if an alternative diagnosis is made. In any other case, they will be excluded.
16496050|NCT03319459|Experimental|Regimen A|FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.
16496051|NCT03319459|Experimental|Regimen B|FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
16496052|NCT03319459|Experimental|Regimen C|Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
16496053|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index <3.5 when baseline monitors are attached while the patient is being prepared for surgery.
16496054|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index >3.5 when baseline monitors are attached while the patient is being prepared for surgery.
16496055|NCT03319420|Experimental|LO2A|1 drop of sodium hyaluronate instilled into each eye 4 times daily
16496056|NCT03319420|Active Comparator|Systane Ultra UD|1 drop of Systane Ultra UD instilled into each eye 4 times daily
16496057|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
16496058|NCT03319394|Experimental|The First Twenty|TF20 group completed a structured exercise program. Once a week a trained firefighter with current CPR and First Aid certifications met with the group to assess progress and answer questions about the workouts or the program. The rest of the time, the participants completed the workouts on their own time. Workouts contained a combination of aerobic (e.g., running, rowing, jumping), body weight (e.g., air squats, pushups, situps), and weight lifting (e.g., presses, back squats, lunges) exercises with workouts designed to use equipment available in an exercise/gym facility (e.g., weight racks, benches). Sixty-minute TF20 sessions included a warm-up, workout and cool down. All sessions were able to be logged online in TF20 program.
16496059|NCT03319394|Active Comparator|Comparison|The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
16496060|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
16496061|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
16496064|NCT03319342|Experimental|Group II (acts of kindness to self)|Participants perform small acts of kindness for themselves 3 times per week for 4 weeks and complete weekly online questionnaires.
16496065|NCT03319342|Experimental|Group III (self-kindness meditation)|Participants direct kind, loving thoughts to themselves, via guided meditation, 3 times per week for 4 weeks and complete weekly online questionnaires.
16496066|NCT03319342|Active Comparator|Group IV (track daily activities)|Participants keep track of their daily activities, focusing on factual information rather than thoughts and feelings, on 3 separate days each week. At the end of the week, participants report on their activities and complete several online questionnaires.
16496067|NCT03319329||critically ill adult patients|"Part I: A cross-sectional study to compare validity of several predictive equations used to predict REE in critically ill adult patients for staying ≤ 5 days, 6 - 10 days and > 10 days by using indirect calorimetry (IC) as the reference standard.
~Part II: To develop predictive equation for the estimation of energy requirement by identifying variables that might influence REE of mechanically ventilated critically ill patients.
~Part III: To validate the newly developed predictive equation for the estimation of energy requirement by using Ten fold cross-validation approach"
16496068|NCT03319316|Experimental|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
16496069|NCT03319316|No Intervention|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
16496070|NCT03319316|Experimental|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
16496071|NCT03319316|No Intervention|Cohort 2 - Squamous - Arm B|Patients will have observation
16496072|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
16496073|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
16496074|NCT03319264|Experimental|Patients with SpA|"Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :
~dynamometry exam
~walking test
~Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia & Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire."
16496075|NCT03319238||Patient cohort|Neuropathic pain patient taking ketamine
16496076|NCT03319225||Tetraplegia|Persons with Tetraplegia
16496077|NCT03319225||Paraplegia|Persons with Paraplegia
16496078|NCT03319225||Neurologically-intact|Neurologically-intact controls
16496079|NCT03319212|Other|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
16496080|NCT03319199|Active Comparator|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
16496081|NCT03319199|Placebo Comparator|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
16496082|NCT03319186|Experimental|EDIT Management|
16496083|NCT03319186|Active Comparator|Standard Care|
16496084|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.
~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
16496085|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.
~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
16496086|NCT03319160||Retrospective|Patients who have already completed use of LifeVest before start of the study
16496087|NCT03319160||Prospective|Patients receiving a LifeVest prescription in clinical routine
16496088|NCT03319147|Placebo Comparator|Placebo|4g of maltodextrin
16496089|NCT03319147|Active Comparator|Active|4g of essential amino acids
16496090|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
16496091|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
16496092|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
16496093|NCT03319121|Experimental|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
16496094|NCT03319121|Experimental|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
16496095|NCT03319108|Other|Low Comorbidity Index Score|CCI; 1-3 as Group 1
16496096|NCT03319108|Other|High Comorbidity Index Score|CCI; 4 and above as Group 2
16496097|NCT03319095|No Intervention|Control|Control group: participants will receive only verbal instructions on PFM anatomy and function during the first assessment when women will be required to contract their pelvic floor muscle. The participants will have no contact with the service until the second assessment
16496098|NCT03319095|Active Comparator|Intervention|Intravaginal Electrical Nerve Stimulation: participants will be submitted to Intravaginal Electrical Nerve Stimulation
16496099|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
16496100|NCT03319069|Experimental|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
16496101|NCT03319069|Active Comparator|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
16496102|NCT03319056|Active Comparator|Real purification|Air purifier turned on
16496103|NCT03319056|Sham Comparator|Sham purification|Air purifier turned off
16496104|NCT03319043|Experimental|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
16496105|NCT03319043|Placebo Comparator|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
16496106|NCT03319030||Duchenne Muscular Dystrophy (DMD)|Enrolls boys with a genetically confirmed diagnosis of DMD.
16496107|NCT03319017||Multiple-trauma patients|The patients who are diagnosed with multiple-trauma and have blood test in an emergency room. The patients with multiple-trauma are defined as the patients who have trauma in more than two regions.
16496108|NCT03319004|Experimental|Compare bispectral index and phase lag entropy|
16496109|NCT03318991|Active Comparator|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
16496110|NCT03318991|Active Comparator|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
16496111|NCT03318978|Experimental|25 ng dose|Capsule containing 25 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
16496112|NCT03318978|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
16496113|NCT03318978|Experimental|100 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
16496114|NCT03318978|Experimental|250 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
16496115|NCT03318952|Experimental|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
16496116|NCT03318952|Experimental|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
16496117|NCT03318939|Experimental|Poziotinib|"Cohort 1: Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)
~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)
~Cohort 3: Treatment naïve patients with EGFR exon 20 insertion-mutant positive NSCLC (fully enrolled)
~Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutant positive NSCLC
~Cohort 5: Patients who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed
~Cohort 6: Patients with acquired EGFR mutation who progressed while on treatment with first-line osimertinib
~Cohort 7: Patients with EGFR or HER2 activating mutations"
16496118|NCT03318913|No Intervention|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
16496119|NCT03318913|Placebo Comparator|DM Placebo|Sucralose
16496120|NCT03318913|Active Comparator|DM FHP|Fish protein hydrolysates
16496122|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
16496123|NCT03318874|Experimental|Blephasteam|Heat delivery device, to be used according to guidelines from manufacturer.
16496124|NCT03318874|Active Comparator|THERA°PEARL Eye Mask|Heat delivery device, to be used according to guidelines from manufacturer.
16497104|NCT03311932|Active Comparator|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
16496130|NCT03318848|Experimental|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
16496131|NCT03318848|No Intervention|Simulation without video|The students of the control group performed the simulation of the bed bath procedure, with the aid of a tutor.
16496132|NCT03318835|Experimental|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
16496133|NCT03318835|Active Comparator|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
16496134|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
16496135|NCT03318809|Experimental|Group 1: Severely Renal Impaired Participants|Participants with severely impaired renal function (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m^2) receive a single oral dose of 200 mg AMG 986.
16496136|NCT03318809|Active Comparator|Group 2: Healthy Participants|Participants with normal renal function (eGFR >= 90 mL/min/1.73 m^2 or above) receive a single oral dose of 200 mg AMG 986.
16496137|NCT03318796|Other|Interventional|Coronary artery stenting of De novo bifurcation lesions MB & SB
16496138|NCT03318783|Active Comparator|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
16496139|NCT03318783|Placebo Comparator|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
16496140|NCT03318770||All patients|All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
16496141|NCT03318757|Experimental|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
16496142|NCT03318757|Active Comparator|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
16496143|NCT03318744|Experimental|aspirin 100mg|Participants will be given aspirin 100mg once per day.
16496144|NCT03318744|Placebo Comparator|placebo|Participants will be given placebo oral tablets once per day.
16496145|NCT03318731|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
16496146|NCT03318731|Experimental|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
16496147|NCT03318731|Experimental|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
16496148|NCT03318718|Experimental|TOF measurement|TOF and MEP measurement after Anesthesia with non-depolarizing NMBA Rocuronium
16496149|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
16496150|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
16496153|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
16496154|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
16496155|NCT03318640|Experimental|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
16496156|NCT03318640|No Intervention|Control|Patient will have usual medical care.
16496157|NCT03318627|Other|Tension Measuring|Measuring intraoperative tension of rotator cuff tendon with sterile spring Balance.
16496158|NCT03318614|Experimental|Probiotics M-63 group|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (Morinaga Milk Industry Co., Ltd., Japan) to consume daily in addition to advice of good hygiene and sanitation practices.
16496159|NCT03318614|Placebo Comparator|Control group|No probiotic intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.
16496160|NCT03318601|Experimental|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
16496161|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
16496162|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
16496163|NCT03318575|Experimental|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
16496164|NCT03318575|Sham Comparator|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
16496165|NCT03318562|Experimental|TNBC Cohort|female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received >=1 prior cancer therapy regimen for metastatic disease
16496166|NCT03318562|Experimental|HCC Cohort|male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed >=1 systemic therapy, which must include sorafenib, or are intolerant to multikinase inhibitor therapies
16496167|NCT03318549||Glaucoma|Patients with diagnosed glaucoma
16496168|NCT03318549||Suspicious of having glaucoma|Patients with suspicious of having glaucoma based on intra-ocular pressure or optic nerve photographs with glaucoma appearance
16496169|NCT03318549||Non-glaucomatous optic neuropathies;|Patients with optic neuropathies that do not look glaucomatous-like
16496170|NCT03318549||Age-related macular degeneration (AMD)|Patients with diagnosed age-related macular degeneration
16496171|NCT03318549||Retinal degenerations|Patients with other retinal degenerations excluding AMD
16496172|NCT03318549||Other diseases of visual pathways|Other diseases of the visual pathway not included in the previous groups
16496173|NCT03318549||Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups
16496174|NCT03318536||No Granisetron|120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
16496175|NCT03318536||With Granisetron|120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
16496176|NCT03318523|Placebo Comparator|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.
~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
16496177|NCT03318523|Experimental|BIIB054 250 mg|Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
16496178|NCT03318523|Experimental|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
16496179|NCT03318523|Experimental|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
16496180|NCT03318497|Experimental|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
~Procedure: Computed Tomography
~Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
~Other: Laboratory Biomarker Analysis
~Procedure: Positron Emission Tomography"
16496181|NCT03318484|Active Comparator|Optimal Medical Care|Optimal medical care (OMC) only is administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
16496182|NCT03318484|Experimental|Optimal Medical Care and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
16496183|NCT03318471|Active Comparator|Group M|received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes
16496184|NCT03318471|Placebo Comparator|Group S|received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.
16496185|NCT03318458|Experimental|Pilates group|
16496186|NCT03318458|No Intervention|No intervention group|
16496187|NCT03318445|Experimental|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.
~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.
~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
16496188|NCT03318445|Experimental|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
16496189|NCT03318419|Experimental|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
16496190|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
16496191|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
16496192|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
16496194|NCT03318367|Experimental|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
16496195|NCT03318354|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
16496196|NCT03318354|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
16496197|NCT03318341|Other|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
16496198|NCT03318341|Other|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
16496199|NCT03318315|Experimental|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
16496200|NCT03318315|Experimental|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
16496201|NCT03318315|Active Comparator|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
16496202|NCT03318289|Experimental|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
16496203|NCT03318289|No Intervention|Control group|No intervention but can continue daily activities.
16496204|NCT03318276|Experimental|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
16496205|NCT03318276|Active Comparator|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
16496206|NCT03318263|Other|experimental|
16496207|NCT03318250|Active Comparator|Burst3D|"This is a device progamme setting which is being compared against DR6-LF.
~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant. Once device is implanted participants are assigned progammes in a randomized manner."
16496208|NCT03318250|Active Comparator|DRG-LF|"This is a device progamme setting which is being compared against Burst3D.
~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant.Once device is implanted participants are assigned progammes in a randomized manner."
16496209|NCT03318237||Patients with focal epilepsy|Patients undergoing ultra high field MRI of the brain
16496210|NCT03318211|Active Comparator|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
16496211|NCT03318211|Active Comparator|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
16496212|NCT03318198|Active Comparator|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
16496213|NCT03318198|Placebo Comparator|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
16496214|NCT03318185|Experimental|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
16496215|NCT03318185|Sham Comparator|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
16496216|NCT03318172|Experimental|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
16496217|NCT03318172|Active Comparator|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
16496218|NCT03318159|Other|posaconazole prophylaxis group|aplastic anemia / hypoplastic myelodysplastic syndrome patients undergoing antithymocyte globulin treatment and receiving posaconazole as prophylaxis antifungal agent
16496219|NCT03318146|Experimental|EXP-LP punctum plug|EXP-LP is a novel and innovative drug delivery system aiming to improve patient compliance and outcomes. EXP-LP punctum plug, is a non-invasive insert that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other major eye diseases. EXP-LP is a combination of an ophthalmic prostaglandin drug (Latanoprost). The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye
16496220|NCT03318146|Active Comparator|XALATAN®|XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension. XALATAN is administrated once a day
16496221|NCT03318133|Experimental|GA group|"general anesthesia(GA) group:
~Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring
~Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2
~Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed
~Transfer to ICU after surgery"
16496222|NCT03318133|Experimental|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:
~Open peripheral vein fluid infusion
~In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)
~Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block
~After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed
~Transfer to ICU after surgery"
16496223|NCT03318120|Experimental|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months. They will be monitored with an activity monitor.
16496224|NCT03318120|No Intervention|Control Arm|The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
16496255|NCT03317886|Active Comparator|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
16496225|NCT03318107|Experimental|Transvaginal probe (Photoacoustic + ultrasound imaging)|"A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images
~This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
16496226|NCT03318094|Placebo Comparator|Intact Day|Saline
16496227|NCT03318094|Experimental|Blocked Day|Phentolamine
16496228|NCT03318094|Active Comparator|Vasodilator Comparison|Sodium Nitroprusside
16496229|NCT03318081|Active Comparator|cognitive function rehabilitation group|The main content of cognitive function rehabilitation esecutive function,including working memory,sustained attention, response inhibition function and cognitive flexibility, 45 minutes a day over 6 weeks period.
16496230|NCT03318081|Active Comparator|cognitive bias modification group|The main content of cognitive bias modification groups were changing ATS related attention bias, 45 minutes a day over 6 weeks period.
16496231|NCT03318081|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center
16496232|NCT03318068|Experimental|Yoga intervention arm|The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
16496233|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.
~Inclusion Criteria:
~> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
16496234|NCT03318042|Experimental|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
16496235|NCT03318029|Placebo Comparator|Placebo UK trial|Placebo and living in the UK
16496236|NCT03318029|Active Comparator|Vitamin D UK trial|Vitamin D supplementation and living in the UK
16496237|NCT03318029|Placebo Comparator|Placebo Brazil Trial|Placebo and living in the Brazil
16496238|NCT03318029|Active Comparator|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
16496239|NCT03318016|Experimental|Cyclophosphamide|"Cohort -1: Cyclophosphamide 500 mg/m2
~Cohort 1: Cyclophosphamide 1000 mg/m2
~Cohort 2: Cyclophosphamide 2000 mg/m2
~Cohort 3: Cyclophosphamide 3000 mg/m2
~Cohort 4: Cyclophosphamide 4000 mg/m2"
16496240|NCT03318003|Experimental|Auto-PAP Therapy|
16496241|NCT03318003|No Intervention|No Therapy|
16496242|NCT03317990|Experimental|NeuroSAFE procedure|These patients will undergo robotic radical prostatectomy with bilateral nerve spare.The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade.The tissue sample will be snap frozen and embedded in OCT.Using a cryostat, 10 micron thick slices will be placed on slides.The entire length of the area of interest will be sampled in this way generating ≈10 frozen sections per side.The slides will be stained with H&E and will be examined by a consultant pathologist.As soon as examination is complete the pathologist will telephone the operating surgeon to give the result.Presence of cancer cells at the margin of resection constitutes a positive margin and the neurovascular bundle on that side will be resected
16496243|NCT03317990|Active Comparator|Control|These patients will undergo robotic radical prostatectomy with a nerve sparing procedure based on surgical planning performed by a consultant radiologist. The mp-MRI will be reviewed by a consultant radiologist along with the details of the prostate biopsy and DRE a decision to perform unilateral, bilateral or non-nerve sparing will be established and recorded in the clinical record form (CRF) for each patient.
16496244|NCT03317977|Experimental|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
16496245|NCT03317977|Active Comparator|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
16496246|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
16496247|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
16496248|NCT03317951|Experimental|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
16496249|NCT03317951|Active Comparator|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
16496250|NCT03317938|Experimental|Fecobionics studies|
16496251|NCT03317912|Active Comparator|Lidocaïne 2%|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
16496252|NCT03317912|Placebo Comparator|Placebo (for Lidocaïne)|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
16496253|NCT03317899|Experimental|Group I (auto HSCT tbo-filgrastim)|Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.
16496254|NCT03317899|Experimental|Group II (auto HSCT)|Patients undergo auto Hematopoietic Cell Transplantation (HSCT).
16496256|NCT03317886|Active Comparator|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
16496257|NCT03317873|Experimental|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
16496258|NCT03317873|Experimental|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
16496259|NCT03317860|Sham Comparator|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
16496260|NCT03317860|Active Comparator|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
16496261|NCT03317847|Experimental|Bromfenac|Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
16496262|NCT03317847|Active Comparator|Dexamethasone|Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
16496263|NCT03317834||Study Population|Total Knee Replacement with Navio Surgical Systems
16496264|NCT03317808|Active Comparator|Heavy slow resistance exercise|
16496265|NCT03317808|Placebo Comparator|Traditional supervised exercise|
16496266|NCT03317795|Active Comparator|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
16496267|NCT03317795|Active Comparator|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
16496268|NCT03317769|Experimental|Experimental Treatment|Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
16496269|NCT03317769|Active Comparator|Active Comparator|Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
16496270|NCT03317756|Experimental|Patient Variation 1|Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
16496271|NCT03317756|Experimental|Patient Variation 2|Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
16496272|NCT03317743|Experimental|NOV140101 (IDX-1197)|
16496273|NCT03317730|Experimental|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
16496274|NCT03317717|Experimental|botulinum toxin 2U|
16496275|NCT03317717|Experimental|botulinum toxin 5U|
16496276|NCT03317717|Experimental|botulinum toxin 10U|
16496277|NCT03317717|Experimental|botulinum toxin 20U|
16496278|NCT03317717|Experimental|botulinum toxin 30U|
16496279|NCT03317704|Active Comparator|speed endurance training (SET)|Training 6 weeks 3 times pr. week
16496280|NCT03317704|No Intervention|Controls|Asked to continue their usual life style
16496281|NCT03317704|Active Comparator|speed endurance training (SET) II|Training 6 weeks 3 times pr. week
16496282|NCT03317691||ST segment Elevation Myocardial Infarction|ST segment Elevation Myocardial Infarction patients' diagnosis was confirmed by coronary artery angiography. The prior surgery electrocardiogram need to be collected.
16496283|NCT03317678|Experimental|BioKefir (BKP)|BioKefir™ (Lifeway Foods) is a lactose-free fermented milk drink containing 12 different species of bacteria within the lactobacillus, bifidobacterium, and streptococcus generas totaling approximately 20 CFU per 3.5 ounce serving. The product also contains 2 g of fiber, including pectin and inulin. These fibers, especially inulin, are prebiotics that may function along with the probiotic species to support gastrointestinal health. The product is available commercially. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The probiotic will be provided in individual 3.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
16496284|NCT03317678|Placebo Comparator|Non-fermented Milk (NFM)|The NFM is dairy-based product ultra-filtered to remove lactose. In addition to being matched to lactose, the NFM contains similar energy, fat, and protein content as the probiotic. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The NFM control will be provided in 11.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
16496285|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
16496286|NCT03317652|Experimental|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.
~Interventions are:
~Hyperventilation
~6% CO2 breathing
~Infusion of sodium nitroprusside"
16496287|NCT03317639|Experimental|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
16496288|NCT03317639|No Intervention|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
16496405|NCT03316781|Experimental|HLX03 group|
16496406|NCT03316781|Active Comparator|adalimumab group|
16496289|NCT03317626|Experimental|Cold Stimulus|The study procedure will beto use a coldstimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted
16496290|NCT03317613|Experimental|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
16496291|NCT03317600|Active Comparator|Lidocaine block|
16496292|NCT03317600|Placebo Comparator|Isotonic saline block|
16496293|NCT03317587|Experimental|INSPIRE|
16496294|NCT03317574|Experimental|MEDITOXIN|
16496295|NCT03317574|Active Comparator|BOTOX|
16496296|NCT03317561||Myocardial injury|Subjects who have had an increase in troponin T level (> 99 percentile) in the perioperative period shall form the cases.
16496297|NCT03317561||Control|Subjects who do not have an increase in troponin T level (< 99 percentile) in the perioperative period shall form the controls.
16496298|NCT03317548||fresh embryo transfer|patients with fresh day 3 embryo transfer after oocyte pick up, the hormone including FSH, LH, E2 and progesterone was test before embryo transfer for analysis. The clinical outcomes including implantation and pregnancy were checked and recorded.
16496299|NCT03317548||frozen embryo transfer|"freeze-all embryo was performed after oocyte fertilization, the hormone including FSH, LH, E2 and progesterone was test before oocyte pick up and embryo transfer for analysis.
~vitrification of pronuclear stage embryo (zygote) and frozen embryo transfer"
16496300|NCT03317535|Other|Local anesthesia/conscious sedation|Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
16496301|NCT03317535|Other|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol (1-2mg/kg) and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60 with propofol and remifentanil. After tracheal intubation, patients will be kept with controlled ventilation.
16496302|NCT03317522||Belfast HAPO|"All pregnant women who attended the Royal Victoria Maternity Hospital, Belfast were eligible to participate unless they met one or more exclusion criteria.
~All eligible women from the Belfast centre were invited to take part in a prospective observational study involving an additional fasting serum sample for lipids at 28 weeks gestation and long term follow up of their HAPO offspring. Only those women who had remained blinded to oral glucose tolerance test (OGTT) results during pregnancy were included (fasting plasma glucose ≤5·8 mmol/L and 2-hour glucose ≤11·1 mmol/L). Offspring from these pregnancies had anthropometric measurements performed within 72 hours of birth and at age 5-7 years."
16496303|NCT03317509|Active Comparator|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
16496304|NCT03317509|Sham Comparator|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
16496305|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
16496306|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
16496307|NCT03317496|Experimental|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
16496308|NCT03317496|Experimental|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
16496309|NCT03317470|Active Comparator|Phase I:|"In Phase 1 of the study (first five months), the investigators will enroll new patients when they call them to remind them of their first colposcopy appointment. If patients consent, the investigators also will assess their basic needs during the call. Those who screen positive for at least one unmet basic need, will be referred to the 2-1-1 helpline at their clinic visit (or this information will be sent to them if they miss their clinic visit).
~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.
~For patients in phase 1, the follow-up survey will only assess acceptability of the basic needs survey (five questions)"
16496310|NCT03317470|Experimental|Phase 2:|"-In Phase 2 of the study (second five months), new colposcopy patients will be approached and consented in a similar fashion as in Phase 1 and asked to complete the basic needs survey. However, this time, patients who screen positive with at least one unmet basic need will be offered assistance by a life navigator (a trained case manager) who will contact the patients by phone within 2 business days of completing the survey.
~The life navigator will connect patients with community resources in each area to help with their unmet basic needs.
~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.
~Patients enrolled in phase 2 will be asked the same five questions in addition to seven more assessing perceived effectiveness of the life navigator"
16496311|NCT03317457|Experimental|Durvalumab and Tremelimumab|"Cycles/courses 1-3:
~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks
~Cycles/courses ≥4:
~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
16496312|NCT03317457|Active Comparator|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
16496313|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
16496314|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
16496315|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
16496316|NCT03317405|Experimental|Cohort I (Z-endoxifen hydrochloride)|Participants apply Z-endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
16496317|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
16496407|NCT03316755|No Intervention|without pamphlet|a group not exposed to pamphlet
16496320|NCT03317379|Experimental|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
16496321|NCT03317379|Active Comparator|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
16496322|NCT03317379|No Intervention|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
16496323|NCT03317353|Experimental|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
16496324|NCT03317353|Experimental|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
16496325|NCT03317353|Experimental|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
16496326|NCT03317353|No Intervention|Control group|Group D. No vestibular rehabilitation is developed.
16496327|NCT03317340||Patient Undergoing Urodynamics|
16496328|NCT03317327|Experimental|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
16496329|NCT03317301|Experimental|Experimental|Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
16496330|NCT03317301|Active Comparator|Active comparator|Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
16496331|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
16496332|NCT03317275|Experimental|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
16496333|NCT03317275|Active Comparator|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
16496334|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
16496335|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
16496336|NCT03317236|Experimental|Reference - Test|A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).
16496337|NCT03317236|Experimental|Test - Reference|A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).
16496340|NCT03317210|Other|iron therapy with good response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. The maximum total iron dose was 1,600 mg, therefore therapy was stopped if the maximal iron sucrose dose was administered, or target Hb > 10.5 g/dL was achieved.
16496341|NCT03317210|Other|iron therapy with poor response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. If response to therapy with iron sucrose was poor (i.e. Hb increase <0.7 g/dl after 2 weeks), patients additionally received recombinant human erythropoietin (10,000 U EPREX®, Janssen-Cilag, Baar, Switzerland).
16496342|NCT03317210|Other|iron therapy and erythropoietin|Patients with an Hb between 8.0 and 8.9 g/dl received 200mg iron sucrose and recombinant human erythropoietin intravenously twice weekly.
16496343|NCT03317197|Placebo Comparator|Control Group|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
~Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Saline solution
~Syringe No. 2 : Saline solution"
16496408|NCT03316755|Experimental|With pamphlets|a group exposed to pamphlet
16496344|NCT03317197|Active Comparator|Experimental Group 1|"Using Vasopressin [20 IU/CPR cycle] injection until the 5th cycle
~Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Vasopressin
~Syringe No. 2 : Saline solution"
16496345|NCT03317197|Active Comparator|Experimental Group 2|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
~Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Saline solution
~Syringe No. 2 : Steroid"
16496346|NCT03317197|Experimental|Experimental Group 3|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
~Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Vasopressin
~Syringe No. 2 : Steroid"
16496347|NCT03317184|Experimental|Periumbilical incisions|
16496348|NCT03317184|Experimental|Pfannenstiel incision|
16496349|NCT03317171|Experimental|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
16496350|NCT03317171|Placebo Comparator|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
16496351|NCT03317158|Experimental|Phase 1: (cohort 1):|Durvalumab monotherapy (cohort 1)
16496352|NCT03317158|Experimental|Phase 1: (cohort 2a) & (cohort 2b):|"(cohort 2a) - Durvalumab plus BCG
~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)"
16496353|NCT03317158|Experimental|Phase 2: (cohort 2a), (cohort 2b), & (BCG re-treatment)|"(cohort 2a) - Durvalumab plus BCG
~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)
~(BCG re-treatment) - Cross-over to Durvalumab Monotherapy"
16496354|NCT03317145|Active Comparator|Arm A (NMES followed by IPC)|Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
16496355|NCT03317145|Active Comparator|Arm B (IPC followed by NMES)|Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
16496356|NCT03317132|Experimental|Individual Placement and Support|One year of IPS Support
16496357|NCT03317132|No Intervention|Treatment as usual|Treatment as usual
16496358|NCT03317119|Experimental|Treatment (TAS-102, trametinib)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16496359|NCT03317080||patients with lung cancer|patients with stages I-IV lung cancer eligible for surgery
16496360|NCT03317067|Experimental|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
16496361|NCT03317067|Placebo Comparator|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
16496362|NCT03317041|Experimental|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
16496363|NCT03317041|No Intervention|Control group|Participants will test passively in a sitting position for 30-min period
16496364|NCT03317028|Experimental|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
16496365|NCT03317028|Experimental|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
16496366|NCT03317028|Experimental|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
16496367|NCT03317028|Placebo Comparator|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
16496368|NCT03317015|Experimental|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
16496369|NCT03317015|Active Comparator|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
16496370|NCT03317002|Experimental|AZD5718 Dose A|AZD5718 Dose A once daily
16496371|NCT03317002|Experimental|AZD5718 Dose B|AZD5718 Dose B once daily
16496372|NCT03317002|Placebo Comparator|Placebo|Matching placebo once daily
16496373|NCT03316989||obese children|Children and adolescents with BMI according to the CDC greater that 95%ile
16496374|NCT03316989||normal weight|Children and adolescents with BMI according to the CDC less than the 85%ile
16496375|NCT03316989||obese with the MetS|obese children with metabolic syndrome compared to obese children with out the MetS and normal weight children
16496376|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
16496377|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
16496378|NCT03316963|Experimental|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
16496554|NCT03315585|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
16496379|NCT03316950|Experimental|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
16496380|NCT03316950|Sham Comparator|IntraGen Sham|Patients will undergo all acts of receiving radiofrequency treatment, but no direct energy will be applied. Patients will have 3 sham treatments space one month apart. Each treatment session will be a total of 20 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
16496381|NCT03316950|Experimental|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
16496382|NCT03316950|Sham Comparator|DiVA Sham|Patients randomized into the DiVA sham group will undergo all acts of receiving DiVA treatment, but not direct energy will be applied. Patients will have a total of 3 treatments, spaced 1 month apart. Each treatment will last approximately 10 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
16496383|NCT03316950|Experimental|Dual Treatment|Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
16496384|NCT03316937|Experimental|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
16496385|NCT03316937|Experimental|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
16496386|NCT03316911|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
16496387|NCT03316911|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
16496388|NCT03316898|Placebo Comparator|Placebo|Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
16496389|NCT03316898|Experimental|AGN-242071 5 mg|One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
16496390|NCT03316898|Experimental|AGN-242071 15 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
16496391|NCT03316898|Experimental|AGN-242071 25 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
16496392|NCT03316885|Experimental|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted as a replacement of the human crystalline lens during cataract surgery
16496393|NCT03316872|Experimental|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks
~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
16496394|NCT03316859|Experimental|Naloxegol|naloxegol 25 mg pill
16496395|NCT03316859|Placebo Comparator|Placebo|placebo pill
16496396|NCT03316846|Experimental|Internet-delivered therapy|10 week, guided and individually tailored internet-delivered cognitive behavioral therapy.
16496397|NCT03316846|No Intervention|Wait list control group|Wait list control group, receives treatment at later point.
16496398|NCT03316820|Experimental|Treatment A|K0706 tablet
16496399|NCT03316820|Experimental|Treatment B|K0706 tablet
16496400|NCT03316820|Experimental|Treatment C|K0706 tablet
16496401|NCT03316820|Experimental|Treatment D|K0706 capsule
16496402|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16496403|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16496404|NCT03316794|Experimental|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
16496409|NCT03316742|Experimental|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
16496410|NCT03316742|Experimental|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
16496411|NCT03316729|Experimental|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
16496412|NCT03316729|Placebo Comparator|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
16496413|NCT03316716|No Intervention|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
16496414|NCT03316716|Experimental|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
16496415|NCT03316703|Active Comparator|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
16496416|NCT03316703|Experimental|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
16496417|NCT03316690|Experimental|Metformin treatment|
16496418|NCT03316690|Placebo Comparator|Placebo treatment|
16496419|NCT03316677|Other|colorectal resection and anastamosis|"Intraoperative testing of colorectal anastomoses
~Insert a Foley catheter through the anus into the rectum.
~Insufflate the Foley balloon with 5 cc of air.
~fill the pelvic space with 500 CC of warm saline
~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer
~Remove the saline from the pelvic space.
~Inject methylene blue in to the rectum up to a pressure of 35 mmH2o measured by external manometer
~Remove the methylene blue from rectum.
~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.
~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
16496420|NCT03316664|Experimental|INT|Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min.
16496421|NCT03316664|Active Comparator|IPT|Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min.
16496422|NCT03316664|Other|CoC|COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.
16496423|NCT03316651|Experimental|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:
~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.
~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
16496424|NCT03316638|Experimental|W0101 - Cohort A1|This is a 14 days treatment cycle cohort in a 2 weeks schedule
16496425|NCT03316638|Experimental|W0101 - Cohort A2|This is a 21 days treatment cycle cohort in a 3 weeks schedule
16496426|NCT03316638|Experimental|W0101 - Expansion Phase|Will be initiated after completion of cohorts A1 and A2
16496427|NCT03316625|Experimental|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
16496428|NCT03316612|Experimental|Intervention group|"Ingredients: Vaccinium Myrtillus L. extracts, and excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)
~Brown oval tablet, 650mg per tablet with 150mg Vaccinium Myrtillus L. extracts, twice a day, 2 tablets each time.
~The intervention period is about 3 months."
16496429|NCT03316612|Placebo Comparator|Placebo group|"Ingredients: excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)
~Brown oval tablet without Vaccinium Myrtillus L. extracts, 650mg per tablet, twice a day, 2 tablets each time.
~The intervention period is about 3 months."
16496430|NCT03316599|Experimental|Ficlatuzumab + Gemcitabine and Nab-Paclitaxel|"Ficlatuzumab will be administered intravenously days 1 and 15 of a 28 day cycle
~Gemcitabine 1000 mg/m2 and Nab-Paclitaxel 125mg/m2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
~Dosage of Ficlatuzumab is determined by dose level to which the patient is assigned at time of enrollment."
16496431|NCT03316586|Experimental|Nivolumab + Cabozantinib|"Nivolumab given every 4 weeks intravenously
~Cabozantinib given orally once daily"
16496432|NCT03316573|Experimental|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks for 35 cycles
16496433|NCT03316560|Experimental|Group 1: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 1 of rAAV2tYF-GRK1-RPGR study drug.
16496434|NCT03316560|Experimental|Group 2: Phase 1/2 Dose Escalation and Low Dose Group Phase 2 Dose Expansion|"Phase 1/2 Dose Escalation: male subjects at least 18 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug.
~Phase 2 Dose Expansion: male subjects at least 8 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug. This will be the low dose group for the phase 2 expansion."
16496435|NCT03316560|Experimental|Group 3 and Group 4 Phase 1/2 Dose Escalation|Group 3 male subjects at least 18 y/o and Group 4 male subjects at least 6 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
16496436|NCT03316560|Experimental|Group 5 Phase 1/2 Dose Escalation and High Dose Group Phase 2 Dose Expansion|"Phase 1/2 Dose Escalation: male subjects at least 18 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug.
~Phase 2 Dose Expansion: male subjects at least 8 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug. This will be the high dose group for the phase 2 expansion."
16496437|NCT03316560|Experimental|Group 6 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 6 of rAAV2tYF-GRK1-RPGR study drug.
16496438|NCT03316547|No Intervention|Control|The control group received standard hospital care.
16496439|NCT03316547|Experimental|Intervention|Parents in the sensory-based intervention group were educated to provide daily sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program). A sensory support team completed the doses of sensory exposures when parents were unable.
16496440|NCT03316534|Placebo Comparator|Placebo|Placebo
16496441|NCT03316534|Active Comparator|Aspirin|Aspirin (100 mg/daily)
16496442|NCT03316521|Experimental|Single Ascending Dose (SAD)|"In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). All cohorts will include at least four subjects each. Additional subjects may be added in any cohort if necessary.
~AMY-101 will be administered as a SQ or IV injection. Subjects in each cohort will be dosed sequentially, to allow for close safety monitoring. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee. Subsequent dose levels will be administered until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) is reached based on specified dose escalation criteria."
16496443|NCT03316521|Experimental|Multiple Dose (MD)|Depending on the results of the SAD, multiple doses of AMY-101 will be administered at the dose which has been identified as the dose which saturates target C3, for a duration that results to an exposure level equivalent to the maximum exposure achieved in the SAD. The dose and dosing interval will be determined based on the PK data obtained in the SAD part of the study. Each MD cohort will include at least four subjects and may be expanded with additional subjects if necessary. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee.
16496444|NCT03316495|No Intervention|without pamphlet|NOT EXPOSED TO PAMPHLETS
16496445|NCT03316495|Experimental|with pamphlet|EXPOSED TO PAMPHLETS
16496446|NCT03316482|Experimental|Leuplin DPS 11.25mg s.c. every 12 weeks|Open
16496447|NCT03316469|Experimental|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
16496448|NCT03316469|Experimental|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
16496449|NCT03316456||AL Patients Undergoing Induction Chemotherapy|Adults undergoing inpatient induction chemotherapy for newly diagnosed/relapsed acute leukemia.
16496450|NCT03316443|Active Comparator|(Group G)|Glidescope group: 45 patients will be intubated by Glidescope (Group G). For endotracheal intubation with glidoscope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
16496451|NCT03316443|Experimental|(Group M)|Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first, the laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced
16496452|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
16496453|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
16496454|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
16496455|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
16496456|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
16496457|NCT03316378|Experimental|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
16496458|NCT03316378|No Intervention|Group without Achilles Tendinopathy|The control group did not receive an injection between test repetitions
16496459|NCT03316365|Experimental|Continuous RAS|The experimental group (continuous treatment) trained daily with RAS for 24 weeks.
16496460|NCT03316365|Active Comparator|Intermittent RAS|The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks.
16496461|NCT03316352|Experimental|Ultrasound-assisted|Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
16496462|NCT03316352|Active Comparator|Landmark-guided|In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.
16496463|NCT03316339|Experimental|Dexmedetomidine|
16496464|NCT03316339|Active Comparator|Control|
16496465|NCT03316326|Experimental|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
16496466|NCT03316313||Date of birth|Those people born within the years 1945-1965
16496467|NCT03316300|Experimental|NT-501|
16496468|NCT03316300|Sham Comparator|Sham|
16496469|NCT03316287|Experimental|Hearing aid + mobile phone|
16496470|NCT03316287|Experimental|Hearing aid + mobile phone + biosensor|
16496471|NCT03316274|Experimental|Nivolumab (Cohort A-Safety)|All participants will receive 10mg in 1 mL injection into a single KS lesion in the skin, every 2 weeks for 4 doses.
16496472|NCT03316274|Experimental|Nivolumab (Cohort B-Expansion)|All participants will receive injection into up to two KS lesion in the skin, every 2 weeks for 4 doses. For participants in the expansion cohort whose injected lesion is improving as of week 26 and they also did not experience any serious adverse events (SAE), they can receive additional intra-lesional injections of nivolumab into up to 4 lesions every 2 weeks for up to 4 doses (for total up to 8 doses). The injected volume will not exceed 10 mg (or 1 mL) each time
16496473|NCT03316248|Experimental|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
16496474|NCT03316248|Active Comparator|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
16496475|NCT03316222|Experimental|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
16496476|NCT03316222|Experimental|Dose Expansion|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
16496477|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
16496478|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
16496479|NCT03316183|Experimental|Intervention Group|"Maintain rSO2 values at or above 75% of the baseline
~Midline position
~Target CO2 of ≥40 mmHg, target MAP >60 mm Hg
~Maintain cerebral perfusion pressure >50 mm Hg
~Target pump flow 2.5 L/m2/min
~If rSO2 persistently below treatment threshold:
~FiO2 is increased
~or propofol 50-100 mg bolus is administered
~If Hct below 20% packed red blood cells will be transfused
~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
16496480|NCT03316183|No Intervention|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
16496481|NCT03316170|Experimental|Social Support + NRT Sampling|"The treatment group will receive:
~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,
~a written directory of a range of social support resources delivered via mail,
~a brief phone consult (10-15 minutes via phone) germane to smoking cessation,
~a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and
~a free, 2-week supply of nicotine patches and lozenges delivered via mail."
16496482|NCT03316170|Active Comparator|Social Support|"The control group will receive:
~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,
~a written directory of a range of social support resources delivered via mail,"
16496483|NCT03316157|Experimental|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
16496484|NCT03316157|No Intervention|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
16496485|NCT03316144|Experimental|1 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs
16496486|NCT03316144|Experimental|3 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
16496487|NCT03316144|Experimental|10 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs
16496488|NCT03316131|Experimental|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:
~verinurad + febuxostat + dapagliflozin;"
16496489|NCT03316131|Experimental|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:
~verinurad + febuxostat + dapagliflozin matched placebo"
16496490|NCT03316118|Active Comparator|Group 1|Patient will receive genicular nerve block with bupivacaine
16496491|NCT03316118|Placebo Comparator|Group 2|Patient will receive normal saline as the nerve block
16496666|NCT03315000|Experimental|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
16496492|NCT03316105|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
16496493|NCT03316105|Sham Comparator|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
16496494|NCT03316079|Active Comparator|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
16496495|NCT03316079|Experimental|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
16496496|NCT03316066|Experimental|Group 5|stellate ganglion block with ropivacaine 0.2% 5 mL
16496497|NCT03316066|Active Comparator|Group 2|stellate ganglion block wit ropivacaine 0.2% 2 mL
16496498|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
16496499|NCT03316040|No Intervention|Control 1|This arm represent control schools. No JIC will be implemented.
16496500|NCT03316040|Experimental|Treatment 1|This arm implements the JIC among a random subset of students within the pre-defined grade.
16496501|NCT03316040|Experimental|Treatment 2|This arm implements the JIC among indegree central students within the pre-defined grade.
16496502|NCT03316040|Experimental|Treatment 3|This arm implements the JIC among edge betweeness central students within the pre-defined grade.
16496503|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
16496504|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
16496505|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
16496506|NCT03315988|Experimental|Vegan diet|"Intervention Description and Definition The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.
~The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly."
16496507|NCT03315975|Experimental|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
16496508|NCT03315962|Experimental|Aim 1: DHO Intervention Arm|A selection of DHO or TB district supervisors that are randomized to the multicomponent SPIRIT intervention.
16496509|NCT03315962|No Intervention|Aim 1: DHO Control Arm|A selection of DHO or TB district supervisors that are randomized to the country standard of care, but not to receive the study intervention.
16496510|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
16496511|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
16496512|NCT03315936|Experimental|Single rising dose part|
16496513|NCT03315936|Experimental|Relative bioavailability (rel BA) part|
16496514|NCT03315923|Experimental|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
16496515|NCT03315923|Experimental|Glatiramer acetate|Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
16496552|NCT03315611|Experimental|AD, sensitized, not treated|Allergen challenge chamber
16496553|NCT03315598|Experimental|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
16496520|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
16496521|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
16496522|NCT03315884|Experimental|Iliac segment recanalization and stenting Iliac segment CFA|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
16496523|NCT03315884|Active Comparator|Iliac segment recanalization, stenting and plastic CFA patch|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
16496524|NCT03315871|Experimental|1/combination therapy [close December 2018]|Combination immunotherapy
16496525|NCT03315871|Experimental|2/combination therapy + surveillance [closed]|Surveillance followed by Prostvac + CV301 then Prostvac + CV301 + MSB0011359C
16496526|NCT03315871|Experimental|3/combination vaccine therapy + surveillance|Surveillance followed by Prostvac + CV301 then Prostvac + CV301
16496527|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
16496528|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
16496529|NCT03315819|Experimental|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique. The procedure must be performed within 15 days of dislocation.
16496530|NCT03315819|Active Comparator|Immobilization interne rotation|Immobilization of the shoulder during 3 weeks
16496531|NCT03315806|Active Comparator|Beetroot Juice|Beetroot juice containing 9 mmol of nitrate per dose
16496532|NCT03315806|Placebo Comparator|Placebo juice (nitrate depleted)|Beetroot juice nitrate-depleted
16496533|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
16496534|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
16496535|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
16496536|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
16496537|NCT03315767|Other|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.
~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.
~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
16496538|NCT03315754|Experimental|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
16496539|NCT03315741|Experimental|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
16496540|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
16496541|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
16496542|NCT03315689|Placebo Comparator|Vehicle|Vehicle
16496543|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
16496544|NCT03315676|Active Comparator|Oral Bonoprazan|Daily intake of Bonoprazan
16496545|NCT03315676|Active Comparator|Oral Esomeprazol|Daily intake of Esomeprazol
16496546|NCT03315663|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
16496547|NCT03315663|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
16496548|NCT03315637|Experimental|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
16496549|NCT03315624|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
16496550|NCT03315611|Active Comparator|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
16496551|NCT03315611|Experimental|AD, not sensitized, not treated|Allergen challenge chamber
16496555|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
16496556|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
16496557|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
16496558|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
16496559|NCT03315533|Experimental|Duloxetine 30 milligrams (mg)|
16496560|NCT03315533|Placebo Comparator|Placebo|
16496561|NCT03315533|Experimental|Duloxetine 60 milligrams (mg)|
16496562|NCT03315520|Experimental|Relapsed/refractory malignant lymphomas|Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen
16496563|NCT03315507|Experimental|PB1046 Injection|PB1046 Subcutaneous Injection
16496564|NCT03315494|Experimental|SKI-O-703 200 mg (once daily)|SKI-O-703 capsule (1 x 200 mg)
16496565|NCT03315494|Experimental|SKI-O-703 400 mg (once daily)|SKI-O-703 capsule (2 x 200 mg, once daily)
16496566|NCT03315494|Experimental|SKI-O-703 200 mg (twice daily)|SKI-O-703 capsule (1 x 200 mg twice daily)
16496567|NCT03315494|Placebo Comparator|Placebo|Placebo capsule
16496568|NCT03315481|Active Comparator|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
16496569|NCT03315481|Active Comparator|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
16496570|NCT03315455|Experimental|Arm A: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm A will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
16496571|NCT03315455|Experimental|Arm B: Emicizumab Prophylaxis at 6 mg/kg Q4W|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm B will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 6 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
16496572|NCT03315455|Other|Arm C: No Prophylaxis (Control Arm)|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm C will not receive any prophylactic treatment for at least 24 weeks. After 24 weeks, participants will have the opportunity to switch to receive emicizumab prophylaxis at 3 mg/kg QW via SC injection for 4 weeks, followed by 6 mg/kg Q4W until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
16496573|NCT03315455|Experimental|Arm D: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants <12 years old with hemophilia A and FVIII inhibitors who are enrolled to Arm D will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
16496574|NCT03315442|Sham Comparator|Caffeine Group|Caffeine group consumed 200mg of caffeine one time.
16496575|NCT03315442|Experimental|Energy Drink Group|The energy drink group consumed 1 16 ounces energy drink one time.
16496576|NCT03315429|Other|Stress testing arm|Stress testing of patients with functional mitral regurgitation.
16496577|NCT03315416||NHS Sample|Children diagnosed with speech sound disorder aged 2-5 years
16496578|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
16496579|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
16496580|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.
~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
16496581|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
16496667|NCT03315000|Experimental|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
16496582|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
16496583|NCT03315390|Experimental|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
16496584|NCT03315390|Active Comparator|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
16496585|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
16496586|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
16496587|NCT03315364|Experimental|Liporaxel® (oral paclitaxel)|"28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.
~Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration."
16496588|NCT03315364|Active Comparator|Taxol® (IV paclitaxel)|"28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.
~Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL."
16496589|NCT03315351|Experimental|Study Procedure|Brachytherapy. PET-scan.
16496590|NCT03315338|Experimental|SAD Part 1 Active Cohort A|CORT118335, 25 mg
16496591|NCT03315338|Placebo Comparator|SAD Part 1 Placebo oral capsule Cohort A|
16496592|NCT03315338|Experimental|SAD Part 1 Active Cohort B|CORT118335, 75mg
16496593|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort B|
16496594|NCT03315338|Experimental|SAD Part 1 Active Cohort C|CORT118335, 225mg
16496595|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort C|
16496596|NCT03315338|Experimental|SAD Part 1 Active Cohort D|CORT118335, 675mg
16496597|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort D|
16496598|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fasting|CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast
16496599|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fed|CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast
16496600|NCT03315338|Placebo Comparator|SAD Part 2 Placebo PD Effect Cohort B|
16496601|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335|
16496602|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335|
16496603|NCT03315338|Experimental|MAD Part 3 Active Cohort A|CORT118335, 375mg qd for 14 days
16496604|NCT03315338|Placebo Comparator|MAD Part 3 Placebo Cohort A|Placebo qd for 14 days
16496605|NCT03315338|Experimental|SAD Part 4 Active Cohort A|CORT118335, 100mg
16496606|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort A|
16496607|NCT03315338|Experimental|SAD Part 4 Active Cohort B|CORT118335, 300mg
16496608|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort B|
16496609|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fasting|CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast
16496610|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fed|CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast
16496611|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fasting|Supplied as suspension for oral dosing given after an overnight fast
16496612|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fed|Supplied as suspension for oral dosing given after a high-fat breakfast
16496613|NCT03315338|Experimental|SAD Part 4 Active Cohort Part D|CORT118335, 1500mg
16496614|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort D|
16496615|NCT03315338|Experimental|MAD Part 5 Active Cohort A|CORT118335, 150mg
16496616|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort A|
16496617|NCT03315338|Experimental|MAD Part 5 Active Cohort B|CORT118335, dose to be determined
16496618|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort B|
16496619|NCT03315338|Experimental|MAD Part 5 Active Cohort C|CORT118335, dose to be determined
16496620|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort C|
16496621|NCT03315325|Experimental|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
16496622|NCT03315325|Experimental|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
16496623|NCT03315325|Experimental|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
16496624|NCT03315312|Active Comparator|Fissure sealant|
16496625|NCT03315312|Experimental|Fluoride varnish|
16496626|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
16496627|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
16496628|NCT03315273|Experimental|Traumatic brain injury|"Patients who have suffered a traumatic brain injury will be assessed with a test battery including
~a motor imagery ability questionnaire (MIQ-rs)
~a mental rotation test
~a chronometry test (TDMI)"
16496668|NCT03315000|Placebo Comparator|Placebo|Lactose powder inhaled through Ellipta® inhaler
16496629|NCT03315273|Active Comparator|Control|"Healthy volunteers matched for age, sex and educational level will be assessed with the same test battery including
~a motor imagery ability questionnaire (MIQ-RS)
~a mental rotation test
~a chronometry test (TDMI)"
16496630|NCT03315260||Bone metastatic CRPC patients|Japanese patients who are designated to undertake Ra-223/Xofigo therapy based on physician judgement
16496631|NCT03315247|No Intervention|Treatment as Usual|Participants assigned to the Treatment as Usual group will attend routine clinic visits at the Toronto Western Hospital Bariatrics Surgery Program (TWH-BSP). These visits generally include education on bariatric surgery and nutrition. Patients meet with select members of the multidisciplinary team at 1, 2, and 3 years post-surgery, and may attend an optional monthly support group. Participants' service utilization (i.e., attendance at optional sessions) will be documented and compared across groups.
16496632|NCT03315247|Experimental|Telephone-Based CBT|"The Tele-CBT intervention will be delivered 1 year following bariatric surgery. Participants will receive 6 weekly Telephone-based Cognitive Behavioural Therapy sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration and scheduled at a time convenient for the participants."
16496633|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
16496634|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
16496635|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
16496636|NCT03315221|Experimental|Test product|Human Milk Fortifier (HMF) with added lipids.
16496637|NCT03315221|Active Comparator|Control product|Commercially available HMF (without lipids).
16496638|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
16496639|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
16496640|NCT03315195|Experimental|Preoperative oral nutritional supplement|Oral nutritional supplement 500 kcal/day for 14 days and dietary advice
16496641|NCT03315195|No Intervention|Conventional treatment|Dietary advice
16496642|NCT03315182|Experimental|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:
~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)"
16496643|NCT03315182|Experimental|Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:
~• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)"
16496644|NCT03315182|Experimental|Cohort 3 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:
~• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)"
16496645|NCT03315169|Active Comparator|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
16496646|NCT03315169|Experimental|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
16496647|NCT03315156||Patients|patients with AOM
16496648|NCT03315143|Experimental|Sotagliflozin|Sotagliflozin dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
16496649|NCT03315143|Placebo Comparator|Placebo|Placebo dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
16496650|NCT03315130|Experimental|0.1 mg/kg zilucoplan (RA101495)|
16496651|NCT03315130|Experimental|0.3 mg/kg zilucoplan (RA101495)|
16496652|NCT03315130|Placebo Comparator|Placebo|
16496653|NCT03315104|Experimental|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.
~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
16496654|NCT03315104|Experimental|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.
~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
16496655|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.
~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
16496656|NCT03315091|Experimental|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
16496657|NCT03315091|Experimental|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
16496658|NCT03315078|Experimental|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
16496659|NCT03315065|Other|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
16496660|NCT03315052|Experimental|Budesonide treatment arm|Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen
16496661|NCT03315052|Active Comparator|Standard immunosuppression arm|Patients treated with standard immunosuppression after liver transplant
16496662|NCT03315039|Experimental|Liposomal annamycin|
16496663|NCT03315026|Experimental|Siltuximab|Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
16496664|NCT03315013|Experimental|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
16496665|NCT03315013|No Intervention|Standard|The standard arm will be referred to standard care after study enrollment.
16496669|NCT03314987|Active Comparator|intervention group|Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks
16496670|NCT03314987|Placebo Comparator|placebo group|Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks
16496671|NCT03314974|Experimental|TBI Regimen|
16496672|NCT03314974|Experimental|Non-TBI Regimen|
16496673|NCT03314935|Experimental|Treatment Group A|INCB001158 + FOLFOX
16496674|NCT03314935|Experimental|Treatment Group B|INCB001158 + gemcitabine/cisplatin
16496675|NCT03314935|Experimental|Treatment Group C|INCB001158 + paclitaxel
16496676|NCT03314922|Experimental|Parsaclisib|
16496677|NCT03314909|Experimental|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
16496678|NCT03314909|Experimental|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
16496679|NCT03314909|Experimental|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
16496680|NCT03314909|No Intervention|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
16496681|NCT03314896|Experimental|Laparoscopic surgery for T4 colon tumor|Laparoscopic surgery for T4 colon cancers
16496682|NCT03314896|No Intervention|Open surgery for T4 colon tumor|Conventional open surgery for T4 colon cancers
16496683|NCT03314883|Experimental|D-US ARF|Diaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
16496684|NCT03314870|Other|Retrospective study|Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
16496685|NCT03314870|Other|Prospective study|Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
16496686|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
16496687|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
16496688|NCT03314831||Systemic Inflammatory Response Syndrome|Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
16496689|NCT03314831||No inflammation|Patients without systemic inflammation.
16496690|NCT03314818||Ultrasound 3D Imaging|To investigate natural history of subclinical atherosclerosis as determined by 3D carotid ultrasound.
16496691|NCT03314805|Placebo Comparator|Control|Placebo
16496692|NCT03314805|Experimental|Treatment|Astragalus polysaccharides 500 mg
16496693|NCT03314792|Active Comparator|Oxycodone|Active comparator drug administrated.
16496694|NCT03314792|Experimental|Tapentadol|Experimental drug administrated.
16496695|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
16496696|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.
~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).
~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.
~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
16496697|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.
~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).
~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).
~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
16496698|NCT03314740|Active Comparator|Arm A|Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.
16496699|NCT03314740|Experimental|Arm B|"Oral administration of two experimental drugs:
~Cediranib 20 mg/day given 7 days per week
~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
16496700|NCT03314740|Experimental|Arm C|"Oral administration of two experimental drugs:
~Cediranib 20 mg/day given 5 days per week
~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
16496701|NCT03314727|No Intervention|Control group|Drink 200 ml soup with no added salt
16496702|NCT03314727|Experimental|High salt (NaCl) intake|Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water
16496703|NCT03314714|Experimental|Acute bout of endurance exercise|Intramyocellular lipid metabolism will be assessed in insulin resistant and healthy, sedentary individuals after an acute bout of endurance exercise.
16496704|NCT03314701|Active Comparator|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:
~Following endotracheal intubation BIPAP mode will be started with:
~Inspiratory positive airway pressure [IPAP] at 20 cmH2O
~Expiratory positive airway pressure [EPAP] at 5 cmH2O
~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]
~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
16496705|NCT03314701|Active Comparator|Group 2|"Airway Pressure Release Ventilation (APRV) group:
~high airway pressure (Phigh) will be set at 20 cmH2O
~low airway pressure ( Plow) will be set at 5 cmH2O
~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min
~T high at 4.5-6 seconds
~T low at 0.5 to 0.8 second"
16496706|NCT03314688|Active Comparator|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).
~Lifestyle intervention books for breast cancer survivors at the end of the 2-year study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
16496707|NCT03314688|Experimental|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
16496708|NCT03314675|Other|CRT-D Measurements|Pre-specified measurements and additional follow-ups
16496709|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
16496710|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
16496711|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
16496712|NCT03314649||Observational study|Patients with gastric cancer and non-cancerous disease planned to have laparotomy
16496713|NCT03314636|Experimental|PET-CT-positive patients|Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles
16496714|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
16496715|NCT03314597|Active Comparator|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
16496716|NCT03314597|Experimental|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
16496717|NCT03314584|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
16496718|NCT03314584|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex.
16496719|NCT03314571||non applicable|
16496720|NCT03314558||COPD patients following a pulmonary rehabilitation program|COPD patients following a pulmonary rehabilitation program
16496721|NCT03314545|Other|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
16496722|NCT03314545|Other|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
16496723|NCT03314532|No Intervention|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
16496724|NCT03314532|Experimental|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
16496725|NCT03314519|Experimental|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
16496726|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
16496727|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
16496728|NCT03314493|Experimental|Spironolactone group|Spironolactone oral tablet 25mg/day, for 12 months
16496729|NCT03314493|No Intervention|Control group|No spironolactone use
16496730|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
16496731|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
16496732|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
16496733|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
16496734|NCT03314467||Control|diabetic patients without ocular abnormalities
16496735|NCT03314454|Active Comparator|Elevated Mental Status|Elevated score on Patient Health Questionnaire
16496736|NCT03314454|Active Comparator|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
16496737|NCT03314454|Active Comparator|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
16496738|NCT03314454|Active Comparator|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
16496739|NCT03314441|Experimental|Yoga|Patients receiving Yoga lessons for 3 months
16496740|NCT03314428|Experimental|Gait retraining|Runners will be taught how to modify their running gait through multiple laboratory sessions and in-field training.
16496741|NCT03314415|Experimental|Early robotic intervention|Participants randomized to the early robotic intervention will attend robotic assistance sessions for a two-week period earlier in the study (during the first half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
16496742|NCT03314415|Experimental|Late robotic intervention|Participants randomized to the late robotic intervention will attend robotic assistance sessions for a two-week period later in the study (during the latter half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
16496743|NCT03314402|Experimental|group 1|Jaktinib Dihydrochloride Monohydrate
16496744|NCT03314402|Placebo Comparator|group 2|Placebo
16496745|NCT03314389|Experimental|Cochet bonnet esthesiometer|To examine sensation
16496746|NCT03314376|Experimental|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
16496747|NCT03314376|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
16496748|NCT03314363|Other|all patients|Classic CRRT with citrate predilution
16496749|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
16496750|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
16496751|NCT03314324|Experimental|ODM-201|
16496752|NCT03314324|Active Comparator|Enzalutamide|
16496753|NCT03314311|Experimental|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
16496754|NCT03314311|No Intervention|Control|Usual care control arm
16496755|NCT03314298|Experimental|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
16496756|NCT03314285|Other|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
16496757|NCT03314285|Other|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
16496758|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:
~<150 mg/dl: 0 units of insulin
~150-220 mg/dl: 2 units of insulin
~201-250 mg/dl: 4 units
~251-300 mg/dl: 6 units
~301-350 mg/dl: 8 units
~351-400 mg/dl: 10 units
~> 400 mg/dl: inform the MD on call"
16496759|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.
~Intervention:
~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.
~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
16496760|NCT03314259|Experimental|Tamsulosin|Patients will then consume oral tamsulosin 0.4mg every morning daily for 5 days prior to elective surgery
16496761|NCT03314259|Placebo Comparator|Placebo|Patients will then consume placebo every morning daily for 5 days prior to elective surgery
16496762|NCT03314246|Other|Intervention|FAST user
16496763|NCT03314246|Other|Control|Standard of care
16496764|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
16496765|NCT03314220|Experimental|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
16496766|NCT03314220|No Intervention|standard care|
16496767|NCT03314194|Experimental|Plant Based Diet Group|Study aims for two cohorts of 20 females each, being tested over 6 days in two conditions: habitual diet versus plant based diet.
16496768|NCT03314181|Experimental|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
16496769|NCT03314181|Experimental|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
16496770|NCT03314181|Experimental|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
16496771|NCT03314181|Experimental|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
16496794|NCT03314077||Controls|COPD patients didn't accepted standard COPD management or quality control, who are from hospital subjects with a retrospective cohort study.
16496772|NCT03314181|Experimental|Arm F: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
16496773|NCT03314181|Experimental|Arm G: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
16496774|NCT03314181|Active Comparator|Arm H: DVd Dose|Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1
16496775|NCT03314168|Active Comparator|Control group|Patients who are randomized in control group will receive the usual care in their respective hospital.
16496776|NCT03314168|Experimental|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
16496777|NCT03314168|Experimental|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
16496779|NCT03314142|Experimental|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16496780|NCT03314142|Experimental|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16496781|NCT03314142|Experimental|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16496782|NCT03314142|Experimental|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16496783|NCT03314142|Experimental|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16496784|NCT03314129|Experimental|Contrast sensitivity|UltimEyes
16496785|NCT03314129|Experimental|Perceptual organization|Contour Integration Training
16496786|NCT03314129|Experimental|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
16496787|NCT03314129|Active Comparator|Cognitive remediation|MyBrainSolutions
16496788|NCT03314116|Experimental|video group|guided by a 7-minute video that explains the importance of using ear plugs and correct installation.
16496789|NCT03314116|No Intervention|control group|instructed to use earplugs properly, including practical exercises by a medic
16496790|NCT03314103|Experimental|Vaccine|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
16496791|NCT03314103|Placebo Comparator|Placebo|Placebo with no live virus
16496792|NCT03314090|Experimental|Silicone Gel Group|Intervention: Silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day (BID). The amount being similar in size to a grain of rice.
16496793|NCT03314077||Standard managed subjects|COPD patients accepted standard COPD management.
16496795|NCT03314064|Experimental|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
16496796|NCT03314025|Experimental|Tamsulosin|The patients in the Experimental group will receive Tamsulosin Hydrochloride 0.4 MG (milligrams) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
16496797|NCT03314025|Placebo Comparator|Placebo|The patients in the Placebo group will receive a placebo oral capsule (sugar) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
16496798|NCT03314012|Experimental|Catheter-Based Carotid Body Ablation|All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
16496799|NCT03313999|Other|Durometer Measurement|All patients participating in the study will receive standard of care treatment for their lymphedema. As part of the study they will be measured by the durometer in addition to other, standard diagnostics to further characterize their lymphedema progression.
16496800|NCT03313973|Experimental|with self stretching same muscle|
16496801|NCT03313973|Sham Comparator|with self stretching forearm muscle|
16496802|NCT03313960|Active Comparator|"One Drop | Premium with Afrezza"|
16496803|NCT03313960|Other|"One Drop | Premium without Afrezza"|
16496804|NCT03313947|Other|Difficult Airway|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
16496805|NCT03313947|Other|Obstructive Sleep Apnea|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
16496806|NCT03313947|Other|Predictive Obstructive Sleep Apnea|"The following 6 questions will be asked during the preoperative visit:
~While sleeping, does your child snore more than half the time?
~While sleeping, does your child always snore?
~Have you ever seen your child stop breathing during the night?
~Does your child occasionally wet the bed?
~Did your child stop growing at a normal rate at any time since birth?
~Is your child overweight"
16496807|NCT03313934|Placebo Comparator|Hyaluronic Acid Filler with Saline|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.
16496808|NCT03313934|Experimental|Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.
16496809|NCT03313921|Experimental|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
16496810|NCT03313908|Experimental|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
16496811|NCT03313895|Active Comparator|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
16496812|NCT03313895|Active Comparator|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
16496813|NCT03313895|Experimental|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
16496814|NCT03313895|Sham Comparator|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
16496815|NCT03313882||donor|donor: normal heart samples from donor
16496816|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
16496817|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
16496818|NCT03313869|Experimental|Control|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol No cocktail during the protocol
~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
16496819|NCT03313869|Experimental|Cocktail intervention|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol + Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
16496820|NCT03313856|Placebo Comparator|Placebo|The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
16496821|NCT03313856|Experimental|Guazuma ulmifolia plus Tecoma stans|The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.
16496822|NCT03313830|Experimental|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
16496823|NCT03313830|Experimental|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
16496824|NCT03313804|Experimental|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
16496825|NCT03313791|Experimental|Whey protein concentrate|portion size that contains 25 g of protein, oral, single administration
16496826|NCT03313791|Experimental|Yoghurt|portion size that contains 25 g of protein, oral, single administration
16496827|NCT03313791|Experimental|50%whey-50% casein (Standard)|portion size that contains 25 g of protein, oral, single administration
16496828|NCT03313791|Experimental|50%whey-50% casein (Alternative)|portion size that contains 25 g of protein, oral, single administration
16496829|NCT03313791|Experimental|Micellar Casein Isolate- WPH|portion size that contains 25 g of protein, oral, single administration
16496830|NCT03313791|Experimental|Micellar Casein Isolate - Na-caseinate|portion size that contains 25 g of protein, oral, single administration
16496831|NCT03313791|Experimental|Micellar Casein Isolate|portion size that contains 25 g of protein, oral, single administration
16496832|NCT03313791|Experimental|UHT milk|portion size that contains 25 g of protein, oral, single administration
16496833|NCT03313791|Experimental|Recombined milk|portion size that contains 25 g of protein, oral, single administration
16496834|NCT03313791|Experimental|Recombined 50% whey milk|portion size that contains 25 g of protein, oral, single administration
16496835|NCT03313791|Experimental|Ca-caseinate|portion size that contains 25 g of protein, oral, single administration
16496836|NCT03313791|Experimental|Milk protein isolate|portion size that contains 25 g of protein, oral, single administration
16496837|NCT03313778|Experimental|Part A: Dose Escalation|Participants will receive a fixed applicable dose of mRNA-4157 administered via an intramuscular (IM) injection on Day 1 of each 21-day cycle for up to 9 cycles.
16496838|NCT03313778|Experimental|Part B: Dose Escalation|Participants will receive a fixed applicable dose of mRNA-4157 administered via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and fixed-dose of pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
16496839|NCT03313778|Experimental|Part A: Dose Expansion|Participants will receive mRNA-4157 via IM injection at an applicable dose, identified during the dose escalation phase of the study, on Day 1 of each 21-day cycle for up to 9 cycles.
16496840|NCT03313778|Experimental|Part B, C, and D: Dose Expansion|Participants will receive mRNA-4157 via IM injection at an applicable dose, identified during the dose escalation phase of the study, on Day 1 of each 21-day cycle for up to 9 cycles. Participants will also receive a fixed-dose of pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
16496841|NCT03313765|Experimental|Intervention|
16496842|NCT03313765|Active Comparator|Standard-of-care|
16496843|NCT03313752|Placebo Comparator|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
16496844|NCT03313752|Experimental|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
16496845|NCT03313739|Experimental|Intervention group|An Educational Program
16496846|NCT03313739|No Intervention|Control group|This group(n=30) received no intervention.
16496847|NCT03313726|Experimental|GnRh-antagonist A|
16496848|NCT03313726|Experimental|GnRh-antagonist B|
16496849|NCT03313713|Active Comparator|Beta-glucans|Beta-glucans, 3 g per day, per 8 weeks, at breakfast
16496850|NCT03313713|Placebo Comparator|Placebo|Placebo, 3 g per day, per 8 weeks, at breakfast
16496851|NCT03313700|Experimental|Robotic Distal Gastrectomy|Robotic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
16496852|NCT03313700|Active Comparator|Laparoscopic Distal Gastrectomy|Laparoscopic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
16496853|NCT03313674|Experimental|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
16496854|NCT03313674|No Intervention|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
16496855|NCT03313674|No Intervention|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
16496856|NCT03313661|Experimental|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
16496857|NCT03313661|Active Comparator|Gliclazide|gliclazide (60-120 mg) once daily
16496858|NCT03313661|No Intervention|Placebo|Placebo
16496859|NCT03313648|Experimental|Laparoscopic Hepatectomy|Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
16496860|NCT03313648|Active Comparator|Radiofrequency Ablation|With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
16496861|NCT03313635||Men presenting with low-T|Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.
16496862|NCT03313622||OCD group|"Day 1: Questionnaires/Assessments
~Day 2: Tasks"
16496863|NCT03313596|Active Comparator|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
16496864|NCT03313596|Experimental|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
16496865|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
16496866|NCT03313557|Experimental|Wee-1 kinase inhibitor AZD1775|To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.
16496867|NCT03313544|Experimental|NIVOLUMAB PATIENTS|
16496868|NCT03313531||Study group 1|Patients with severe hemophilia A
16496869|NCT03313531||Study group 2|Healthy volunteers
16496870|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population.
16496871|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
16496872|NCT03313518|Active Comparator|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
16496873|NCT03313518|Sham Comparator|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
16496874|NCT03313505||Patients who had been tested for S100B protein|
16496875|NCT03313505||Patients who have benefited from another strategy|
16496876|NCT03313492|Active Comparator|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
16496877|NCT03313492|Active Comparator|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
16496878|NCT03313492|Experimental|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
16496879|NCT03313479||Group 1|GA and Dexmedetomidine
16496880|NCT03313479||group 2|GA and peribulbar
16496881|NCT03313479||group3|GA and xylocaine gel
16496882|NCT03313466|Experimental|iCBTI|Intervention: An internet-based cognitive behavioral therapy program for insomnia (iCBTI) that is tailored to the individual's needs based on responses to questions.
16496883|NCT03313466|Active Comparator|Usual care|Intervention: A group class on insomnia provided at each Kaiser Permanente Southern California medical center.
16496884|NCT03313453|Experimental|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
16496885|NCT03313453|Placebo Comparator|Control comparator|Mock device of PuriCare in active mode
16496886|NCT03313440|Experimental|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
16496887|NCT03313440|Experimental|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
16496888|NCT03313427|Experimental|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
16496889|NCT03313427|Other|Control|Usual care
16496890|NCT03313414|Experimental|Treatment with Sofosbuvir/Velpatasvir|14 days of treatment with Sofosbuvir/Velpatasvir tablet
16496891|NCT03313388|Experimental|Tart Cherry Juice|290 mL per day of Tart Cherry juice for 7 days
16496892|NCT03313388|Active Comparator|Gatorade|290 mL per day of Gatorade for 7 days
16496893|NCT03313375|No Intervention|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
16496894|NCT03313375|Active Comparator|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
16496895|NCT03313375|Experimental|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
16496896|NCT03313362|Experimental|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
16496897|NCT03313349|Other|Usual Provision (UP)|"Usual Provision
~Psychotherapy: 1. cognitive therapy 2.family intervention"
16496898|NCT03313349|Other|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision
~Psychotherapy: 1.cognitive therapy 2.family intervention"
16496899|NCT03313336|Active Comparator|Cohort 1|EMLA Test Patch.
16496900|NCT03313336|Active Comparator|Cohort 2|EMLA Reference Patch.
16496901|NCT03313336|Placebo Comparator|Cohort 3|Placebo patch.
16496902|NCT03313323|Experimental|Zirconium-ipilimumab|Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
16496903|NCT03313310|Experimental|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
16496904|NCT03313297|Active Comparator|AZD4017|400mg oral AZD4017 twice daily for 35 days
16496905|NCT03313297|Placebo Comparator|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
16496906|NCT03313284|Experimental|Study Group|
16496907|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
16496908|NCT03313258|Active Comparator|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
16496909|NCT03313258|Experimental|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
16496910|NCT03313232|Experimental|Fragrance allergic patients|Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
16496911|NCT03313232|Experimental|Possible fragrance allergic patients|Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
16496912|NCT03313232|Experimental|Healty controls|Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.
16496913|NCT03313219|Experimental|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
16496914|NCT03313206|Experimental|Patients with Resectable head and neck mucosal melanomas|
16496915|NCT03313193|Experimental|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
16496916|NCT03313193|No Intervention|Arm B|Usual care alone
16496918|NCT03313167||Atrial Fibrillation-potential Patients|individuals 65 years of age or older with moderate-to-high risk of stroke
16496919|NCT03313154||Neuropsychiatric screening (treatment+)|Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
16496920|NCT03313154||Neuropsychiatric screening (treatment-)|Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
16496921|NCT03313141|Experimental|Subjects|Only one arm is considered
16496922|NCT03313128||Historic intervention|Infants born into the historic intervention arm of sanitation trial (NCT02362932)
16496923|NCT03313128||Historic control|Infants born into the historic control arm of sanitation trial (NCT02362932)
16496924|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
16496925|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
16496926|NCT03313102|Experimental|Horton disease|
16496927|NCT03313102|Experimental|control|
16496928|NCT03313089||PSAN + MNP|"PSAN (Papas más nutritivas project) + MNP (micronutrients powders):
~Children of the families beneficiaries of Community Schools of Family Agriculture of the municipalities of Cumbal, Carlosama Guachucal and Túquerres, who are part of the project Papas más nutritivas and exposed to project activities in which they work on topics related to food and nutritional security, equity and gender, production and entrepreneurship, Additionally, the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses (specified in the MNP only group). After the delivery of MNP, advising, measurements of weight and height, clarification of doubts regarding fortification with MNP, nutrition education, and accompaniment by the project staff will take place."
16496929|NCT03313089||MNP only|"Cohort of exposed to MNP (micronutrients powders):
~Children who will receive MNP delivered through the hospital or institutional health service providers of the municipalities of Guachucal and Carlosama, following the protocol for the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses: the first period consists of the taking of MNP for 2 months, followed by a rest period of 4 months and continues again by another MNP intake for 2 months and rest for 4 months, and exposed to dissemination of basic information with regard to MNP and monitoring by growth and development that is routinely performed by health staff."
16496930|NCT03313076|Experimental|n-3 PUFA (O3FA) + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule
16496931|NCT03313076|Experimental|n-3 PUFA (O3FA) Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
16496932|NCT03313076|Experimental|n-3 PUFAs (O3FA) + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
16496933|NCT03313076|Placebo Comparator|n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo|4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
16496934|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
16496935|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
16496936|NCT03313050|Experimental|Stage 1 multivalent (ages 50-64 years)|multivalent
16496937|NCT03313050|Active Comparator|Stage 1 Tdap (ages 50-64 years)|Tdap
16496938|NCT03313050|Experimental|Stage 2 multivalent (ages 65-85 years)|multivalent
16496939|NCT03313050|Active Comparator|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
16496940|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
16496941|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
16496942|NCT03313011||Progressive Apraxia of Speech|
16496943|NCT03312998|Experimental|Xrays|
16496944|NCT03312985|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
16496945|NCT03312985|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
16496946|NCT03312972|Experimental|HDR Brachytherapy|HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion in one to two fractions.
16496947|NCT03312959|Experimental|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
16496948|NCT03312959|Active Comparator|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
16496949|NCT03312946|Experimental|Treatment oscillating vibro|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks. Being performed twice a week, with a total duration of 50 minutes to the session, being 10 sessions total to end the treatment.
16496950|NCT03312933||Duration of boot >2 weeks|All patients who were placed into a CAM walker boot for >2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
16496951|NCT03312920|Experimental|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
16496952|NCT03312920|Sham Comparator|Sham tDCS|sham tDCS with Face Name associate Memory task
16496953|NCT03312920|Experimental|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
16496954|NCT03312907|Placebo Comparator|Arm A (Control) 0-52 Weeks|Eligible subjects will receive belimumab plus rituximab-placebo. No immunosuppressant medications are allowed after week 4. Subjects may receive standard of care therapy which may include anti-malarials, Non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day through Week 52. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study. Subjects will stop receiving Belimumab injections after week 52.
16496955|NCT03312907|Placebo Comparator|Arm A (Control) 53-104 Weeks|Eligible subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day in Week 53 through 104. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
16496956|NCT03312907|Experimental|Arm B (Combination) 0-52 Weeks|Eligible subjects will receive belimumab plus rituximab. No immunosuppressant medications are allowed after week 4 (Other than Rituximab at Week 6). Subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day through Week 52. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study. Subjects will stop receiving Belimumab injections after week 52.
16496957|NCT03312907|Experimental|Arm B (Combination) 53-104 Weeks|Eligible subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day in Week 53 through 104. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
16496958|NCT03312907|Experimental|Arm C (Reference) 0-52 Weeks|Eligible subjects will receive belimumab plus standard therapy including immunosuppressant which may be continued throughout the study. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
16496959|NCT03312907|Experimental|Arm C (Reference) 53-104 Weeks|Eligible subjects will receive belimumab plus standard therapy which may be continued throughout the study. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
16496960|NCT03312894|Experimental|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
16496961|NCT03312894|Placebo Comparator|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
16496962|NCT03312894|Experimental|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
16496963|NCT03312894|Placebo Comparator|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
16496964|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
16496965|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
16496966|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
16496967|NCT03312855|Experimental|Revacept 80 mg|single dose, intravenous
16496968|NCT03312855|Experimental|Revacept 160 mg|single dose, intravenous
16496969|NCT03312855|Placebo Comparator|Placebo|single dose, intravenous
16496970|NCT03312842|Experimental|CS1001|
16496971|NCT03312816|Placebo Comparator|Placebo|0 mg/d added POP
16496972|NCT03312816|Active Comparator|low dosage|low added POP
16496973|NCT03312816|Active Comparator|Medium dose|medium added POP
16496974|NCT03312816|Active Comparator|Hige dose|high added POP
16496975|NCT03312803|Active Comparator|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
16497060|NCT03312244|Experimental|Pyridostigmine|Pyridostigmine 180mg/d slow-release formulation
16496976|NCT03312803|Active Comparator|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
16496977|NCT03312790|Experimental|augmented reality device|Tasks realized using augmented reality device
16496978|NCT03312790|Other|Real condition|Same tasks than augmented reality realized in normal/real condition
16496979|NCT03312777|Experimental|Omnitram|Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
16496980|NCT03312777|Active Comparator|Tramadol|Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
16496981|NCT03312777|Placebo Comparator|Placebo|Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
16496982|NCT03312764|Experimental|Online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants in the online program receive paced curriculum, access to a live health coach, interactive group message forums, and connected weight scale and activity monitoring devices.
16496983|NCT03312764|Active Comparator|Enhanced Standard Care|All participants randomized to the standard-care/control group (SC) will be offered the opportunity to attend a single 90-minute diabetes prevention class with a trained health professional (MPH, RD, or related advanced degree). The class will focus on healthful eating based on the current MyPlate recommendations, guidance on gradual increases in moderate intensity physical activity, and action planning to be shared with friends and/or family. Control participants will also be given the opportunity to participate in the online digital intervention upon completion of the 12-month follow-up assessment.
16496984|NCT03312751|Experimental|Emapalumab|
16496985|NCT03312738|Experimental|Everolimus + Exemestane|Everolimus 10mg/Day + Exemestane 25mg/Day
16496986|NCT03312738|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
16496987|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
16496988|NCT03312712||Participants with sarcoidosis|"Bronchoscopy, BAL collection, and PFTs* [SoC] *if required
~Screening, research and safety bloods
~Dynamic 18F-FDG PET/CT scan"
16496989|NCT03312712||Healthy volunteers|"Part A:
~PFTs
~Screening, research and safety bloods
~Dynamic 18F-FDG PET/CT scan
~Part B:
~PFTs
~Screening, research and safety bloods
~Baseline and post challenge Dynamic 18F-FDG PET/CT scans
~LPS/saline challenge"
16496990|NCT03312699|Experimental|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496991|NCT03312699|Experimental|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496992|NCT03312699|Experimental|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496993|NCT03312699|Experimental|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496994|NCT03312699|Experimental|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496995|NCT03312699|Experimental|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496996|NCT03312699|Experimental|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496997|NCT03312699|Experimental|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16496998|NCT03312686||Eosinophilic Esophagitis patients|PPI treatment
16496999|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
16497000|NCT03312660|Experimental|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
16497001|NCT03312660|Placebo Comparator|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
16497002|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
16497003|NCT03312634|Experimental|Palovarotene Chronic/Flare-Up Regimen|Subjects will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing will be adjusted for weight in skeletally immature subjects.)
16497004|NCT03312621|Experimental|Intervention|The intervention group received all aspects of enhanced usual care but was also assigned a healthcare transition nurse who coordinated the delivery of specific intervention services. These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
16497005|NCT03312621|No Intervention|Control|The control group received enhanced usual care which provides standardized healthcare transition-specific written information including a written transition policy, as well as insurance and guardianship information. Participants were also provided with a transition readiness assessment and entered into a healthcare transition registry to facilitate tracking and communication.
16497006|NCT03312608||mild myelopathy (JOA>12)|40 patients (JOA>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
16497007|NCT03312608||moderate myelopathy|40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
16497008|NCT03312608||healthy control|As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
16497009|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
16497010|NCT03312582|Experimental|Manual debridement and 1% metformin gel|
16497011|NCT03312582|Placebo Comparator|Manual debridement and placebo|
16497012|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
16497013|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
16497014|NCT03312556|Placebo Comparator|Placebo pill or patch or sham CPAP|Placebo pill or patch or sham CPAP
16497015|NCT03312556|Active Comparator|CPAP (continuous positive airway pressure)|Continuous positive airway pressure during the night
16497016|NCT03312543|Experimental|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
16497017|NCT03312543|Sham Comparator|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
16497018|NCT03312530|Experimental|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
16497019|NCT03312530|Experimental|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
16497020|NCT03312530|Experimental|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
16497021|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
16497022|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
16497023|NCT03312517|Active Comparator|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
16497024|NCT03312517|Active Comparator|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
16497025|NCT03312517|Sham Comparator|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
16497026|NCT03312504|Experimental|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
16497027|NCT03312504|Placebo Comparator|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
16497028|NCT03312478|Other|Case|Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
16497029|NCT03312478|Other|Control|Age-matched non-diabetic controls as described in the inclusion criteria for controls
16497030|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
16497031|NCT03312452|Experimental|Infusion pump group|Study subjects assigned to this group will receive intravenous fluid via an infusion pump (Hospira plum pump) during their surgery.
16497032|NCT03312452|Active Comparator|Gravity drip group|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
16497033|NCT03312439|Active Comparator|Intervention group|Will be given advice as described above
16497034|NCT03312439|No Intervention|Control group|Consisting of subjects from the general Swedish population.
16497035|NCT03312426|Experimental|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
16497036|NCT03312426|Experimental|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
16497037|NCT03312426|Experimental|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
16497038|NCT03312426|Experimental|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
16497039|NCT03312413|Experimental|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
16497040|NCT03312413|Experimental|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
16497041|NCT03312413|Experimental|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
16497042|NCT03312413|Placebo Comparator|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
16497043|NCT03312400|Active Comparator|200 mg Arm|100 mg twice a day
16497044|NCT03312400|Active Comparator|400 mg Arm|200 mg twice a day
16497045|NCT03312387|Experimental|Essential Amino Acid and Exercise|Participants will be provided with essential amino acids during exercise training.
16497046|NCT03312387|Placebo Comparator|Placebo and Exercise|Participants will be provided with placebo supplement during exercise training.
16497047|NCT03312374||stage II CRC|Patients with stage II colorectal cancer
16497048|NCT03312374||stage III CRC|Patients with stage III colorectal cancer
16497049|NCT03312361|Experimental|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
16497050|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
16497051|NCT03312335|Experimental|Low-dose Aldesleukin (Proleukin®)|
16497052|NCT03312322|Experimental|CWT with high-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
16497053|NCT03312322|Experimental|CWT with low-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
16497054|NCT03312322|Experimental|CWT with sham electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
16497055|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .
~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .
~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
16497056|NCT03312283|Experimental|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
16497057|NCT03312283|Active Comparator|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
16497058|NCT03312270|Experimental|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
16497059|NCT03312257|Experimental|Multifocal D +2.50 add & 0.01% atropine|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine."
16497062|NCT03312231|Experimental|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
16497063|NCT03312231|Experimental|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
16497064|NCT03312231|Experimental|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
16497065|NCT03312231|Experimental|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
16497066|NCT03312231|Experimental|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
16497067|NCT03312218|Experimental|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
16497068|NCT03312218|No Intervention|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
16497069|NCT03312205|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
16497070|NCT03312192|Active Comparator|Plate and Cage|ACDF with interbody cage and anterior plating.
16497071|NCT03312192|Active Comparator|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
16497072|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
16497073|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
16497074|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
16497075|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
16497076|NCT03312166|Experimental|Compression device|
16497077|NCT03312153|Experimental|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
16497078|NCT03312153|Active Comparator|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
16497079|NCT03312140|Other|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
16497080|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
16497081|NCT03312114|Experimental|Single arm|Avelumab and SABR
16497082|NCT03312101|Experimental|Experimental|exercise program
16497083|NCT03312101|No Intervention|Control|observation
16497084|NCT03312075||cystic fibrosis patients|Sputum and blood samples
16497085|NCT03312062|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
16497086|NCT03312062|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
16497087|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
16497088|NCT03312023|Experimental|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
16497089|NCT03312023|Experimental|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
16497090|NCT03312023|Experimental|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.
~Randomized 1:1 with Group D."
16497091|NCT03312023|Experimental|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.
~Randomized 1:1 with Group C."
16497092|NCT03312010|Experimental|High Frequency|Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
16497093|NCT03312010|Sham Comparator|Sham|Subjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
16497094|NCT03311997|No Intervention|Non-operative treatment|Active rehabilitation program
16497095|NCT03311997|Active Comparator|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
16497096|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
16497097|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
16497098|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
16497099|NCT03311971|Experimental|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
16497100|NCT03311958|Experimental|Nivolumab|
16497101|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
16497102|NCT03311932|Active Comparator|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
16497105|NCT03311932|Experimental|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
16497106|NCT03311906|Experimental|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
16497107|NCT03311906|Active Comparator|Control Side|Scaling and Root Planing
16497108|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
16497109|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
16497110|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
16497111|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
16497112|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
16497113|NCT03311854|Experimental|Emapalumab|
16497114|NCT03311841|Experimental|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
16497115|NCT03311841|Experimental|Severe Impairment|Participants with <30 mL/min/1.73m^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
16497116|NCT03311841|Experimental|Moderate Impairment|Participants with 30 to <60 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
16497117|NCT03311841|Experimental|Mild Impairment|Participants with 60 to <90 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
16497118|NCT03311841|Active Comparator|Healthy Control|Participants with ≥90 mL/min creatinine clearance. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
16497119|NCT03311828|Experimental|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
16497120|NCT03311802||1|
16497121|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
16497122|NCT03311763|Active Comparator|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
16497123|NCT03311763|Experimental|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
16497124|NCT03311750|Experimental|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
16497125|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
16497126|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
16497127|NCT03311724|Experimental|4,8,12mg Tirzepatide|Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.
16497128|NCT03311724|Experimental|2.5,5,10,15mg Tirzepatide|Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.
16497129|NCT03311724|Experimental|2.5,7.5,15mg Tirzepatide|Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
16497130|NCT03311724|Placebo Comparator|Placebo|Placebo administered by SC injection.
16497131|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
16497132|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
16497468|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
16497133|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
16497134|NCT03311698|Experimental|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
16497135|NCT03311698|No Intervention|Control|Households receive the standard of care in the area for agricultural and health services.
16497136|NCT03311685|Experimental|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.
~vaginal tactile imager"
16497137|NCT03311685|Experimental|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
16497138|NCT03311672|Experimental|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
16497139|NCT03311672|Experimental|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
16497140|NCT03311659|Experimental|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
16497141|NCT03311646|Experimental|Nicotine Content Manipulation|All participants receive normal nicotine content (NNC) cigarettes during Baseline and all participants receive very low nicotine content (VLNC) cigarettes during the very low nicotine content condition.
16497142|NCT03311633|Experimental|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
16497143|NCT03311633|Active Comparator|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
16497144|NCT03311620|Other|Endobronchial ultrasound transbronchial needle aspirate|
16497145|NCT03311607|Other|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
16497146|NCT03311594|Experimental|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
16497147|NCT03311594|Experimental|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
16497148|NCT03311594|Experimental|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
16497149|NCT03311594|Experimental|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
16497150|NCT03311594|Placebo Comparator|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
16497151|NCT03311594|Experimental|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
16497152|NCT03311594|Placebo Comparator|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
16497153|NCT03311594|Experimental|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
16497154|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
16497155|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
16497156|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
16497157|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
16497158|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
16497159|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
16497161|NCT03311529|Experimental|Applied Relaxation|
16497162|NCT03311529|No Intervention|usual care|
16497163|NCT03311516|Experimental|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
16497164|NCT03311516|Other|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
16497165|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
16497166|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
16497167|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
16497168|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
16497169|NCT03311464|Experimental|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
16497170|NCT03311451|Other|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
16497171|NCT03311438|Other|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
16497172|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
16497173|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
16497174|NCT03311412|Experimental|Sym021 Dose Level 1|Part 1, Sym021 monotherapy dose level 1
16497175|NCT03311412|Experimental|Sym021 Dose Level 2|Part 1, Sym021 monotherapy dose level 2
16497176|NCT03311412|Experimental|Sym021 Dose Level 3|Part 1, Sym021 monotherapy dose level 3
16497177|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 1|Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022
16497178|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 2|Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022
16497179|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 3|Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022
16497180|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 4|Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022
16497181|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 1|Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023
16497182|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 2|Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023
16497183|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 3|Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023
16497184|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 4|Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023
16497185|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 5|Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023
16497186|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 6|Part 2, Arm B: Sym021 RP2D in combination with dose level 6 of Sym023
16497187|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 7|Part 2, Arm B: Sym021 RP2D in combination with dose level 7 of Sym023
16497188|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 1|Part 3, Sym021 in combination with Sym022 and Sym023
16497189|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 2|Part 3, Sym021 in combination with Sym022 and Sym023
16497190|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 3|Part 3, Sym021 in combination with Sym022 and Sym023
16497191|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 4|Part 3, Sym021 in combination with Sym022 and Sym023
16497192|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 5|Part 3, Sym021 in combination with Sym022 and Sym023
16497193|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 6|Part 3, Sym021 in combination with Sym022 and Sym023
16497194|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
16497195|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
16497196|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
16497197|NCT03311386||Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
16497198|NCT03311373|Experimental|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
16497199|NCT03311373|Experimental|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
16497200|NCT03311373|Experimental|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
16497201|NCT03311373|Experimental|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
16497202|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
16497203|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
16497204|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
16497205|NCT03311347|Experimental|Air breathing|Primary aim, item 1
16497206|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Nivolumab|
16497207|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Pembrolizumab|
16497208|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
16497209|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
16497210|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
16497211|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
16497212|NCT03311295|Experimental|ARTO System|
16497283|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis
~Dosage will be determine by the PI"
16497213|NCT03311282|Experimental|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
16497214|NCT03311282|Experimental|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
16497215|NCT03311282|Experimental|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
16497216|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
16497217|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
16497218|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
16497219|NCT03311269|Active Comparator|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
16497220|NCT03311269|Active Comparator|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
16497221|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
16497222|NCT03311243|Active Comparator|Systemically healthy controls|
16497223|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
16497224|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
16497225|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
16497226|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
16497227|NCT03311217|Experimental|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
16497228|NCT03311217|No Intervention|Control group|No intervention will be implemented in the stores in the control communities.
16497229|NCT03311204|Experimental|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
16497230|NCT03311204|Experimental|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
16497231|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
16497232|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
16497233|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
16497234|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
16497235|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
16497236|NCT03311152|Experimental|HCC-free cirrhotic patients|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
16497237|NCT03311152|Experimental|HCC-positive cirrhotic patients|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
16497238|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
16497239|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
16497240|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
16497241|NCT03311126|Experimental|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):
~Bendamustine 90 mg/m2 IV days 1 & 2 every 28 days X 4-6 cycles
~Obinutuzumab:
~Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 & 15
~Cycles 2-6: 1000 mg IV day 1
~Consolidation phase:
~Obinutuzumab 1000 mg IV weekly X 4 doses
~Maintenance phase (8 week cycles):
~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
16497242|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
16497243|NCT03311100||Lung cancer|
16497244|NCT03311100||Central Nervous System Cancers|
16497245|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
16497246|NCT03311100||Skin cancers|
16497247|NCT03311100||Sarcomas|
16497248|NCT03311100||Urothelial cancer|
16497249|NCT03311100||Hepatocarcinoma|
16497250|NCT03311074|Experimental|Strimvelis treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received Strimvelis will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
16497280|NCT03310892|Experimental|Generic Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a generic message encouraging colonoscopy scheduling."
16497281|NCT03310892|Experimental|Tailored Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a tailored message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions."
16497251|NCT03311061|Experimental|DREAMS|"The experimental group will be exposed to the DREAMS curriculum including the supplemental technology based application.It is composed of 10 modules: Introduction; Self Exploration; Healthy Relationships; Adolescent Sexuality; Attitudes and Adolescent Sexual Activity; Consequences of Sex - HIV/STI; Consequences of Sex - Pregnancy; Managing Pressure to Engage in Sexual Activity through the Lens of Social Media; Financial Literacy; Careers; Post secondary Education; Wrap up and Close Out.
~The technology app will include curriculum support and additional resources.
~Students will have access to the mobile app after the in school programming ends. The intent is for students to have access to portions of the app that deal with self developed goals and progress monitoring for goals, and resource material. This is similar to a student having continued access to a textbook/other class materials."
16497252|NCT03311061|Active Comparator|Non DREAMS|The control group experience will include health curriculum already adopted by the school district. Continued services as usual. The control group schools, for the most part, lack any formal pregnancy prevention services. All schools claim that lessons developed by the teachers meet the Texas Essential Knowledge Standards (TEKS). No outside services are provided to students and school based services are limited. The services offered at the schools is predominately abstinence based. Students attending the schools would need to initiate any services that are available within the community. The control group will not have access to the DREAMS curriculum or the technology-based application to enhance the DREAMS curriculum. The technology-based application will be a closed, password protected, system during the research trial.
16497253|NCT03311048|Experimental|Hospital|Hospital cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
16497254|NCT03311048|Experimental|University|Campus (university) cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
16497255|NCT03311048|Experimental|Housekeeper|Housemaid (cleaning workers) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
16497256|NCT03311048|Experimental|Control|Office workers (no relationship to cleaning) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
16497257|NCT03311035|Experimental|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
16497258|NCT03311035|Experimental|Group B|patients undergoing Seton method
16497259|NCT03311022|Experimental|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
16497260|NCT03311022|Active Comparator|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
16497261|NCT03311009|Experimental|GLPG1972|
16497262|NCT03311009|Placebo Comparator|Placebo|
16497263|NCT03310996|Experimental|tDCS Active arm|The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
16497264|NCT03310996|Placebo Comparator|tDCS Sham arm|The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
16497265|NCT03310983||ADORE Participants|Participants enrolled in the ADORE study are invited to participate in this study.
16497266|NCT03310970|Active Comparator|Lidocaine Patch|Each subject will wear three generic lidocaine patches for 12 hours.
16497267|NCT03310970|Active Comparator|Lidoderm® Topical Patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
16497268|NCT03310970|Active Comparator|Intravenous lidocaine|A single intravenous dose of 0.5 mg/kg lidocaine hydrochloride will be administered to each subject.
16497269|NCT03310957|Experimental|LV plus pembrolizumab|LV + pembrolizumab
16497270|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
16497271|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
16497272|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
16497273|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
16497274|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
16497275|NCT03310918|Experimental|Collaborative palliative and oncology care|"1st palliative care visit within 96 hours of randomization in the outpatient or hospital
~In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone
~During hospital admissions to MGH: At least twice weekly palliative care visits"
16497276|NCT03310918|Active Comparator|Standard leukemia care|"Palliative care consults only upon request
~Standard Leukemia care"
16497277|NCT03310905|Experimental|Isolated Abdominal Wall Transplant|
16497278|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
16497279|NCT03310892|No Intervention|Usual Care|Participants in this arm will Usual scheduling process without any intervention
16497282|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis
~Dosage will be determine by the PI"
16497465|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
16497284|NCT03310866|Active Comparator|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
16497285|NCT03310866|Experimental|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
16497286|NCT03310853|Experimental|Probiotic|Combination of two probiotic strains in one capsule
16497287|NCT03310853|Placebo Comparator|Placebo|Non active ingredients in a capsule
16497288|NCT03310827|Experimental|Personalized Nutrition|Participant receives gene test results with diet plan (personalized nutrition)
16497289|NCT03310827|Placebo Comparator|Gene Test Report Only|Participant receives standard diet plan
16497290|NCT03310814|Experimental|Personalized nutrition intervention|Participant receives gene-test results plus personalized nutrition information from a registered dietician
16497291|NCT03310814|Placebo Comparator|Usual nutrigenomics intervention|Participant receives usual nutrigenomics intervention (direct-to-consumer)
16497292|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
16497293|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
16497294|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
16497295|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.
~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
16497296|NCT03310762|Experimental|Alma Sana Bracelet Arm|Subjects in this arm will receive a vaccine reminder and tracker bracelet developed by Alma Sana Inc. This bracelet uses a combination of symbols and numbers to denote the entire vaccine schedule a child is supposed to receive before the age of 2 years. Shapes indicate vaccines, and numbers signify the child's age.
16497297|NCT03310762|Experimental|Simple Silicon Bracelet Arm|Subjects in this arm will receive a simple silicon bracelet. This bracelet has six symbols to remind parents that their child needs to get at least six vaccination visits before he reaches 2 years of age. The first five symbols are represented by a crescent shape and the sixth symbol is represented by a star shape to denote that the child is fully immunized.
16497298|NCT03310762|No Intervention|Control Arm|Subjects in this arm will not receive any bracelet/intervention.
16497299|NCT03310749|Other|Treatment sequence A|Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
16497300|NCT03310749|Other|Treatment sequence B|Gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days
16497301|NCT03310749|Other|Treatment sequence C|Metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days
16497302|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
16497303|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
16497304|NCT03310710|Experimental|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
16497306|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
16497307|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.
~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
16497308|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
16497309|NCT03310671||CASES|"Cases:
~Age ≥ 65 years at the time of cardiac ultrasound
~Genetically diagnosed HFH or in a first-degree relative
~History of hypercholesterolemia with LDLc levels> 220 mg / dL without lipid-lowering treatment"
16497310|NCT03310671||Controls|"Genetically Similar
~Siblings of the normocholesterolemic case, defined by LDLc <190 mg / dl without lipid-lowering treatment.
~In the absence of available siblings, first cousins may be included.
~In the presence of several siblings available, the same sex will be included,
~Environmentally similar
~Stable partner of the case with cohabitation> 25 years"
16497311|NCT03310658|Experimental|Single Study Site: UANL|As the only study arm, 10 enrolled subjects received vaginal cuff closure with the Zip-Stitch Soft Tissue Closure System as part of Total Laparoscopic Hysterectomy.
16497312|NCT03310645|Experimental|Dose 1 of BAY1817080|"Study Part 1:
~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
16497313|NCT03310645|Experimental|Dose 2 of BAY1817080|"Study Part 1:
~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
16497466|NCT03309722||early stage|
16497314|NCT03310645|Experimental|Dose 3 of BAY1817080|"Study Part 1:
~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
16497315|NCT03310645|Experimental|Dose 4 of BAY1817080|"Study Part 1:
~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
16497316|NCT03310645|Placebo Comparator|Placebo|"Study Part 1:
~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
16497317|NCT03310645|Experimental|Placebo+BAY1817080|"Study Part 2:
~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
16497318|NCT03310645|Experimental|BAY1817080+Placebo|"Study Part 2:
~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
16497319|NCT03310632|Experimental|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.
~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
16497320|NCT03310619|Experimental|Arm A: JCAR017 in combination with Durvalumab|JCAR017 will be administered at a single flat dose of 50 x 10^6 CAR+T cells or 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules
16497321|NCT03310619|Experimental|Arm B: JCAR017 in combination with CC-122|This arm will test JCAR017 in combination with the CC-122. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
16497322|NCT03310619|Experimental|Arm C: JCAR017 in combination with CC-220|This arm will test JCAR017 in combination with CC-220. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
16497323|NCT03310619|Experimental|Arm D: JCAR017 in combination with Ibrutinib|This arm will test JCAR017 in combination with ibrutinib. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at a fixed dose of 420 mg daily
16497324|NCT03310619|Experimental|Arm E: JCAR017 in combination with relatlimab and/or nivolumab|This arm will test JCAR017 in combination with relatlimab and/or nivolumab in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/or schedules
16497325|NCT03310619|Experimental|Arm F: JCAR017 in combination with CC-99282|This arm will test JCAR017 in combination with CC-99282 in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/or schedules.
16497326|NCT03310606|Other|Peritonitis|"Patient received for antibiotic treatment a B lactam according to French recommendation :
~type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem
~dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g"
16497327|NCT03310593|Experimental|Cannabidiol|Cannabidiol 150-300mg per day for 12 weeks.
16497328|NCT03310593|Placebo Comparator|Placebo|Cannabidiol comparator for 12 weeks.
16497329|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
16497330|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
16497331|NCT03310580|Placebo Comparator|Placebo Comparator|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
16497332|NCT03310567|Experimental|Epacadostat + pembrolizumab|
16497333|NCT03310554|Experimental|26cm suspended overlength biliary stents group|
16497334|NCT03310554|Experimental|30cm suspended overlength biliary stents group|
16497335|NCT03310554|Other|ordinary plastic biliary stents group|
16497336|NCT03310541|Experimental|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
16497337|NCT03310541|Experimental|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
16497338|NCT03310541|Experimental|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
16497339|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
16497340|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
16497341|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
16497342|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
16497343|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
16497344|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
16497345|NCT03310489|Active Comparator|Psychoeducation about anxiety|
16497346|NCT03310476|Experimental|Baked, consumed chilled potatoes|
16497347|NCT03310476|Experimental|Boiled, consumed hot potatoes|
16497348|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
16497467|NCT03309722||advanced|
16497349|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
16497350|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
16497351|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
16497352|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
16497353|NCT03310450||Group 140kms cycling|"Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.
~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
16497354|NCT03310450||Group 100kms cycling|"Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.
~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
16497355|NCT03310450||Group 240kms cycling|"Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.
~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
16497356|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
16497357|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
16497358|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
16497359|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
16497360|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
16497361|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
16497362|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
16497363|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
16497364|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
16497365|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
16497366|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
16497367|NCT03310372|Experimental|ultrafractionated brain irradiation - temozolomide|
16497368|NCT03310359|Active Comparator|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
16497369|NCT03310359|Placebo Comparator|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
16497370|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
16497371|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
16497372|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
16497373|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
16497374|NCT03310307|Active Comparator|vitamin D3|50,000 IU
16497375|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
16497376|NCT03310294|Placebo Comparator|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
16497377|NCT03310294|Active Comparator|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
16497378|NCT03310281|Active Comparator|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
16497379|NCT03310281|Active Comparator|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
16497380|NCT03310268|Experimental|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total).
16497381|NCT03310268|Active Comparator|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
16497382|NCT03310268|Active Comparator|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
16497383|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
16497384|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
16497385|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
16497386|NCT03310216|Experimental|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
16497387|NCT03310216|Active Comparator|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
16497388|NCT03310203|Experimental|Obese women: central obesity|OGTT with iron
16497389|NCT03310203|Experimental|Obese women: peripheral obesity|OGTT with iron
16497390|NCT03310203|Experimental|Lean women|OGTT with iron
16497391|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
16497392|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
16497393|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
16497394|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
16497395|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
16497396|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
16497397|NCT03310151|No Intervention|control|Follows usual care
16497398|NCT03310138|Active Comparator|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation
~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
16497399|NCT03310138|Active Comparator|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation
~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
16497400|NCT03310138|Placebo Comparator|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation
~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
16497401|NCT03310125|Experimental|Colchicine|Oral colchicine 0.5mg
16497402|NCT03310125|Placebo Comparator|Placebo|Placebo oral tablet
16497403|NCT03310112|Experimental|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
16497404|NCT03310112|Active Comparator|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
16497405|NCT03310112|No Intervention|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
16497406|NCT03310099|Experimental|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated [MUFA] and polyunsaturated fatty acids [PUFA]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
16497407|NCT03310086|Experimental|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
16497408|NCT03310086|Experimental|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
16497409|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.
~The subject received bOPV, Pentabio and IPV according to the study schedule."
16497410|NCT03310060|Active Comparator|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.
~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
16497411|NCT03310060|Placebo Comparator|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
16497412|NCT03310047|Experimental|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.
~This will be repeated after 24 hours."
16497413|NCT03310047|Experimental|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.
~This will be repeated after 24 hours."
16497414|NCT03310034|Active Comparator|Intervention|
16497415|NCT03310034|Placebo Comparator|Control|
16497416|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
16497417|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
16497418|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
16497419|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
16497420|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
16497421|NCT03310021|Experimental|Cohort 6|Apixaban + high dose andexanet
16497422|NCT03310021|Experimental|Cohort 7|Edoxaban + low dose andexanet
16497423|NCT03310021|Experimental|Cohort 8|Apixaban + low dose andexanet
16497424|NCT03310021|Experimental|Cohort 9|Rivaroxaban + low dose andexanet
16497425|NCT03310021|Experimental|Cohort 10|Edoxaban + low dose andexanet
16497426|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
16497427|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
16497428|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
16497429|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
16497430|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
16497431|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
16497432|NCT03309982|Experimental|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
16497433|NCT03309982|Placebo Comparator|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
16497434|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
16497435|NCT03309956|Other|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
16497436|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
16497437|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
16497438|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
16497439|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:
~MAP set at 80-85 mmHg for 5 min.
~MAP set at 70-75 mmHg for 5 min.
~MAP set at 60-65 mmHg for 5 min.
~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
16497440|NCT03309904|Experimental|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
16497441|NCT03309904|No Intervention|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
16497442|NCT03309891|Experimental|Cohort 1|GX-H9 subcutaneous injections (weekly)
16497443|NCT03309891|Experimental|Cohort 2|GX-H9 subcutaneous injections (weekly)
16497444|NCT03309891|Experimental|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
16497445|NCT03309891|Active Comparator|Cohort 4|Genotropin subcutaneous injections (daily)
16497446|NCT03309878|Experimental|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16497447|NCT03309878|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16497448|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
16497449|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
16497450|NCT03309826|Experimental|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
16497451|NCT03309826|Active Comparator|Nasal Dilator Strip|Nightly use of nasal dilator strip
16497452|NCT03309813|Experimental|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
16497453|NCT03309813|Sham Comparator|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
16497454|NCT03309800|Experimental|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
16497455|NCT03309800|Placebo Comparator|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
16497456|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
16497457|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
16497458|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
16497459|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.
~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
16497460|NCT03309761||Patients aged 55-60|
16497461|NCT03309748|Active Comparator|Dental Prophylaxis|Standard dental prophylaxis
16497462|NCT03309748|Active Comparator|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
16497463|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
16497464|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
16497469|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
16497470|NCT03309696|Experimental|tDCS and 1 Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC. .
16497471|NCT03309696|Experimental|tDCS and 10Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
16497472|NCT03309696|Experimental|tDCS over DLFC and 1 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
16497473|NCT03309696|Experimental|tDCS over DLFC and 10 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
16497474|NCT03309683|Experimental|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
16497475|NCT03309683|No Intervention|Control group|Standard treatment after EMR (as described in the detailed study description above)
16497476|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
16497477|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
16497478|NCT03309644||Peripheral nerve block|Peripheral nerve block
16497479|NCT03309644||No peripheral nerve block|No peripheral nerve block
16497480|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
16497481|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
16497482|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
16497483|NCT03309605|Experimental|ELX-02|ELX-02
16497484|NCT03309592|Other|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
16497485|NCT03309579|Experimental|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
16497486|NCT03309579|Active Comparator|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
16497487|NCT03309566|Experimental|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
16497488|NCT03309566|Experimental|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
16497489|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
16497490|NCT03309553|Experimental|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
16497491|NCT03309540|Experimental|experimental group (EGR)|"Physical therapy intervention.
~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
16497492|NCT03309540|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.
~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
16497493|NCT03309527|Experimental|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
16497494|NCT03309527|Active Comparator|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
16497495|NCT03309514|Experimental|Treatment|
16497496|NCT03309501|Experimental|Tong-Luo-Qu-Tong Plaster group|Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
16497497|NCT03309501|Active Comparator|Qi-Zheng-Xiao-Tong Plaster group|Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
16497498|NCT03309488||Food allergic|Patients with a positive oral challenge to the food being studied.
16497499|NCT03309488||Non food allergic|Patients with a negative oral challenge to the food being studied.
16497557|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
16497500|NCT03309475|Experimental|SocialMIND|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
16497501|NCT03309475|Active Comparator|Psychoeducational Multicomponent Intervention|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
16497502|NCT03309462|Experimental|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
16497503|NCT03309462|Experimental|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
16497504|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
16497505|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
16497506|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
16497507|NCT03309436|Experimental|Use Clomiphene Citrate protocol|Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
16497508|NCT03309436|Active Comparator|Procedure|Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
16497509|NCT03309423||Respiratory disease|Patients with acute respiratory insufficiency admitted to the ICU and with pH <7,35 or >7,45
16497510|NCT03309423||Metabolic disease|Patients with acute metabolic disease admitted to the ICU and with pH <7,35 or >7,45
16497511|NCT03309423||Sepsis|Patients with acute sepsis admitted to the ICU and with pH <7,35 or >7,45
16497512|NCT03309410||Pre-study|In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
16497513|NCT03309410||Main study|In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission. The clinical indication for ABG analysis was decided by the responsible physician in the ED upon patient admission and based on national guidelines and criteria.
16497514|NCT03309358|Experimental|Inhaled SNSP113|
16497515|NCT03309358|Placebo Comparator|Inhaled Placebo|
16497516|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
16497517|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
16497518|NCT03309332|Experimental|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
16497519|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
16497520|NCT03309306|No Intervention|Phase 1: Lab Testing (Visit 1, Day 0)|Participants will test the FoodImage App and Pen-and-paper Records with in a Laboratory Kitchen. Participants will use the FoodImage app and food records to measure food waste during simulated shopping trip and kitchen clean-out. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
16497521|NCT03309306|Active Comparator|Phase 2: RCT Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
16497558|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
16497913|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
16497522|NCT03309306|Experimental|Phase 2: RCT Food Waste Reduction|"Phase 2 will occur in participants' natural environment (free-living conditions). Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:
~Feedback on the amount of food waste their household created during the first week,
~A goal to reduce the next week's food waste by 20% or more, and
~Tips on how to reduce household food waste adapted from current consumer campaigns"
16497523|NCT03309293|Other|controls|biological samples bank
16497524|NCT03309293|Experimental|cases|
16497525|NCT03309280||Patient at risk for OSA scheduled for Cardiac surgery|Patients with a positive STOP-Bang and DES-OSA score (that means patients at risk for OSA)
16497526|NCT03309280||Patient not at risk for OSA scheduled for Cardiac surgery|Patients with a negative STOP-Bang and DES-OSA score (that means patients not at risk for OSA)
16497527|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
16497528|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
16497529|NCT03309254|Experimental|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
16497530|NCT03309254|Experimental|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
16497531|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
16497532|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
16497533|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
16497534|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
16497535|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
16497536|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
16497537|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
16497538|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
16497539|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
16497540|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
16497541|NCT03309176|Active Comparator|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
16497542|NCT03309176|Experimental|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
16497543|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
16497544|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
16497545|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
16497546|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
16497547|NCT03309137|Experimental|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
16497548|NCT03309137|No Intervention|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
16497549|NCT03309124|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
16497550|NCT03309124|Experimental|Baked potato with skin|Baked russet potato
16497551|NCT03309124|Experimental|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
16497552|NCT03309124|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
16497553|NCT03309124|Experimental|Meal skipping|No food given
16497554|NCT03309111|Experimental|ISB 1342|Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met
16497555|NCT03309098||Ankle Injury|Person who injures their ankle
16497556|NCT03309085|Experimental|Single arm|Repeated CT scan
16497559|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
16497560|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
16497561|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
16497562|NCT03309046|Experimental|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
16497563|NCT03309046|Active Comparator|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
16497564|NCT03309033||Observational (questionnaire, biospecimen collection)|Patients complete a short questionnaire regarding risk factors for HPV infection and undergo collection of blood samples for testing HPV16 and HPV18 levels at years 13 and 15 after receiving initial vaccination.
16497565|NCT03309020|Active Comparator|Control|Control with clinical need for cataract surgery
16497566|NCT03309020|Experimental|EVD Survivors|EVD survivors with need for cataract surgery
16497567|NCT03309007|Experimental|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
16497568|NCT03309007|Placebo Comparator|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
16497569|NCT03308994||Oral first line disease modifying treatments|
16497570|NCT03308994||Injectable first line disease modifying treatments|
16497571|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
16497572|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
16497573|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
16497574|NCT03308968|Placebo Comparator|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
16497575|NCT03308968|Experimental|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
16497576|NCT03308968|Experimental|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
16497577|NCT03308955|Active Comparator|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
16497578|NCT03308955|Sham Comparator|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
16497687|NCT03308110|Other|Relative Bioavailability Cohort|Relative Bioavailability cohort
16498794|NCT03300440|Experimental|Intervention group|Probiotics and vitamin B7
16497584|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
16497585|NCT03308890|Active Comparator|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
16497586|NCT03308890|Active Comparator|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
16497587|NCT03308890|No Intervention|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
16497588|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
16497589|NCT03308877|Active Comparator|Standard Care (SC)|
16497590|NCT03308864|Experimental|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
16497591|NCT03308864|Active Comparator|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
16497592|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
16497593|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
16497594|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
16497595|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
16497596|NCT03308825|Experimental|Group 1: 6 to < 36 Months|Children aged 6 to < 36 months received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
16497597|NCT03308825|Experimental|Group 2: 3 to < 9 Years|Children aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
16497598|NCT03308825|Experimental|Group 3: 18 to < 65 Years|Adults aged 18 to < 65 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
16497599|NCT03308825|Experimental|Group 4: >= 65 Years|Adults aged >= 65 years received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
16497600|NCT03308812|Active Comparator|Health360x|Participants will use the Health360x application for 6 months.
16497601|NCT03308812|Experimental|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
16497602|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
16497603|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
16497604|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
16497605|NCT03308786|Experimental|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks, in addition to combination antiretroviral therapy.
16497606|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
16497607|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
16497608|NCT03308734|Experimental|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
16497609|NCT03308734|No Intervention|Control Group|Following baseline testing, participants will receive usual care only.
16497610|NCT03308721|Experimental|NNC9204-1177|Dose trial with a sequential trial design
16497611|NCT03308721|Placebo Comparator|Placebo|
16497612|NCT03308708|No Intervention|Control group|
16497613|NCT03308708|Experimental|NE group|
16497614|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
16497615|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
16497616|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
16497617|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
16497618|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
16498795|NCT03300440|Placebo Comparator|Control group|Placebo and vitamin B7
16497619|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
16497620|NCT03308643|Experimental|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
16497621|NCT03308643|Placebo Comparator|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
16497622|NCT03308630|Experimental|Energy Alignment and Mantra|
16497623|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
16497624|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
16497625|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
16497626|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
16497627|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
16497628|NCT03308565|Experimental|Phase I|Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
16497629|NCT03308552|Active Comparator|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
16497630|NCT03308552|Placebo Comparator|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
16497631|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
16497632|NCT03308500|Experimental|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
16497633|NCT03308500|Active Comparator|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
16497634|NCT03308487|Active Comparator|vitamin D3 (1000 IU)|group 1
16497635|NCT03308487|Active Comparator|vitamin D3 (2000 IU)|group 2
16497636|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
16497637|NCT03308448|Active Comparator|Group 1|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
16497638|NCT03308448|Active Comparator|Group 2|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
16497639|NCT03308448|Active Comparator|Group 3|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
16497640|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
16497641|NCT03308409|Active Comparator|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
16497642|NCT03308409|Experimental|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
16497643|NCT03308409|Experimental|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
16497644|NCT03308396|Experimental|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.
~Phase Ib:
~Days 1-5
~Guadecitabine:
~Dose 0: 60 mg/m^2
~Dose -1: 45 mg/m^2
~Phase II:
~Days 1-5 Guadecitabine (at Ph II dose)
~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
16497645|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
16497646|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
16497870|NCT03306927|Experimental|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
16497871|NCT03306927|Placebo Comparator|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
16497647|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
16497648|NCT03308344|Experimental|Spouse Trainers (MT-ST)|Participants will engage in a short-form mindfulness training delivered by their peers who underwent an extensive training practicum.
16497649|NCT03308344|No Intervention|Wait-list control|Participants will be tested before and after a no-training interval and may receive training at a later time.
16497650|NCT03308344|Experimental|Mindfulness Expert (MT-ME)|Participants will engage in a short-form mindfulness training delivered by an expert mindfulness trainer.
16497651|NCT03308331|Experimental|HIV-1 smokers|
16497652|NCT03308331|No Intervention|HIV-1 nonsmokers|
16497653|NCT03308331|Active Comparator|Healthy control smokers|
16497654|NCT03308331|No Intervention|Healthy control nonsmokers|
16497655|NCT03308331|Active Comparator|HIV-1 nonsmokers using nicotine patch|
16497656|NCT03308331|No Intervention|HIV-1 nonsmokers using placebo patch|
16497657|NCT03308331|Active Comparator|Healthy control nonsmokers using nicotine patch|
16497658|NCT03308331|No Intervention|Healthy control nonsmokers using placebo patch|
16497659|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
16497660|NCT03308292|No Intervention|Control Group|
16497661|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
16497662|NCT03308279||Asinthomatic|The only group evaluated
16497663|NCT03308266||CLP children with pain-related TMD|
16497664|NCT03308266||CLP children with no TMD|
16497665|NCT03308266||CLP children with painfree TMD|
16497666|NCT03308253|Other|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
16497667|NCT03308253|Experimental|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
16497668|NCT03308240|Experimental|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.
~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
16497669|NCT03308240|No Intervention|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
16497670|NCT03308227||Experimental Group|septic shock patients;
16497671|NCT03308227||Conrol Group|non-septic shock patients;
16497672|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
16497673|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
16497674|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.
~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
16497675|NCT03308201|Experimental|Hemay022 and Letrozole|Part two: Hemay022 in combination with letrozole will be taken in OTR dose until disease progression, intolerable toxicity or death.
16497676|NCT03308201|Experimental|Hemay022 and Fulvestrant|Part two: Hemay022 in combination with fulvestrant will be taken in OTR dose until disease progression, intolerable toxicity or death.
16497677|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
16497678|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
16497679|NCT03308175|Experimental|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.
~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .
~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.
~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
16497680|NCT03308175|Experimental|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.
~Functional bite will be taken to position the mandible in the proper position forward.
~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
16497681|NCT03308162|Experimental|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
16497682|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
16497683|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
16497684|NCT03308123||Health Care Professionals|Health care professionals
16497685|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
16497686|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
16497688|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
16497689|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
16497690|NCT03308084|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
16497691|NCT03308084|Placebo Comparator|IV dexamethasone|Standard systemic (IV) dexamethasone only
16497692|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
16497693|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
16497694|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
16497695|NCT03308058|No Intervention|Printed Educational material|Printed educational material
16497696|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
16497697|NCT03308032|Experimental|Intervention|Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course. Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons. For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both
16497698|NCT03308032|Active Comparator|Control|"Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course.
~Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons (see below). For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both"
16497699|NCT03308019|Experimental|Adjunctive photodynamic therapy|This arm will be given scaling and root planing (SRP) with adjunctive photodynamic therapy (aPDT)
16497700|NCT03308019|Active Comparator|Dental scaling|This arm will be given scaling and root planing (SRP) only
16497701|NCT03308006|Experimental|Stem cells therapy|
16497702|NCT03307993|Experimental|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)
~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
16497703|NCT03307980|Experimental|PF-06838435 Dose-Escalation|Single intravaneous infusion of PF-06838435. After 2 participants receive initial dose, data will be evaluated and a decision will be made to escalate or reduce the dose being evaluated, increase the number of participants receiving the dose, or stop dosing. Multiple iterations may be undertaken.
16497704|NCT03307967|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
16497705|NCT03307954|Experimental|Ekso Therapy|Up to 12 weeks of Ekso Therapy. Three sessions per week. One hour per session
16497706|NCT03307954|Active Comparator|Control|Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.
16497707|NCT03307941|Other|Single arm (classic 3+3 design)|
16497708|NCT03307928|Experimental|Cardiopulmonary Exercise Test Protocol|All subjects performed an incremental cardiopulmonary exercise test (CPET) to maximum exercise tolerance. All the procedures were performed in agreement with the American Thoracic Society/American College of Chest Physicians guidelines for cycle ergometer tests.
16497709|NCT03307928|Experimental|Polysomnography Assessment|All hypertensive subjects were submitted to a polysomnography exam to diagnose OSA. The OSA diagnose was confirmed by the apnea/hypopnea index (AHI) and classified as follows: AHI < 5 events/h, absence of OSA; 5 ≤ AHI ≤ 15 events/h, low OSA; 15 ≤ AHI ≤ 30 events/h, moderate OSA; AHI > 30 events/h, severe OSA.
16497872|NCT03306927|Placebo Comparator|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
16497873|NCT03306914|Active Comparator|Albumin group|Albumin resuscitation Albumin 5%
16497874|NCT03306914|Experimental|Hydroxyethylstarch group|Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
16497713|NCT03307902|Experimental|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
16497714|NCT03307902|Active Comparator|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
16497715|NCT03307902|Active Comparator|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
16497716|NCT03307876||groups that are fac + and -|autologous PPP injection is given to all patients. Prior to injection, a lavage of the disc space is taken to test for FAC.
16497717|NCT03307863|Experimental|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
16497718|NCT03307863|Experimental|Topiramate-Implant|Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted
16497719|NCT03307863|Active Comparator|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
16497720|NCT03307850|Experimental|Observation of Exercise|Observation During Exercise and Stress
16497721|NCT03307837|Active Comparator|CA-008 Cohort 1 0.5 mg|Intra-operative, local administration
16497722|NCT03307837|Active Comparator|CA-008 Cohort 2 1 mg|Intra-operative, local administration
16497723|NCT03307837|Active Comparator|CA-008 Cohort 3 2 mg|Intra-operative, local administration
16497724|NCT03307837|Active Comparator|CA-008 Cohort 4 3 mg|Intra-operative, local administration
16497725|NCT03307837|Active Comparator|CA-008 Cohort 5 4.2 mg|Intra-operative, local administration
16497726|NCT03307837|Placebo Comparator|Placebo|Intra-operative, local administration of saline (equivalent volume in active comparator arm)
16497727|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
16497728|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
16497729|NCT03307811|Experimental|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
16497730|NCT03307785|Experimental|Part A: TSR-042 and niraparib 200 mg QD|Patients will receive TSR-042 500 milligram (mg), intravenous (IV) infusion on Day 1 of every cycle (every 3 weeks [Q3W]) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (every 6 weeks [Q6W]) beginning on Day 1 of Cycle 5 along with niraparib 200 mg, once daily (QD), orally on Days 1 to 21 repeated Q3W.
16497731|NCT03307785|Experimental|Part A: TSR-042 and niraparib 300 mg QD|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg, QD, orally on Days 1 to 21 repeated Q3W.
16497732|NCT03307785|Experimental|Part B: TSR-042 and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 milligram per square meter (mg/m^2), IV infusion on Day 1 Q3W administered for 4 to 6 cycles.
16497733|NCT03307785|Experimental|Part C: TSR-042, niraparib 200 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 200 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kilogram (kg), IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
16497734|NCT03307785|Experimental|Part C: TSR-042, niraparib 300 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
16497735|NCT03307785|Experimental|Part D: TSR-042, carboplatin-paclitaxel and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W administered for 4 to 6 cycles; and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
16497736|NCT03307785|Experimental|Part E: TSR-042 and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation) administered for 6 cycles (each cycle is 21 days).
16497737|NCT03307785|Experimental|Part F: TSR-042, TSR-022, and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); and TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W administered for 5 cycles (each cycle is 21 days); and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation).
16497951|NCT03306472|Experimental|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
16497738|NCT03307785|Experimental|Part G: TSR-042 and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (every week [Q1W]) of every 3 week cycle for 4 to 6 cycles.
16497739|NCT03307785|Experimental|Part H: TSR-042, TSR-022, and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (Q1W) of every 3 week cycle for 4 to 6 cycles.
16497740|NCT03307785|Experimental|Part I: TSR-042, TSR-022, and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days).
16497741|NCT03307772|Placebo Comparator|placebo drink|The placebo drink consists of fermented low-fat milk with no added Lactobacillus GG.(placebo)
16497742|NCT03307772|Active Comparator|LGG Drink (|The probiotic drink consists of fermented low-fat milk with added Lactobacillus GG. (probiotics)
16497743|NCT03307772|Active Comparator|FOS Drink|The prebiotics drink consists of fermented low-fat milk with fructooligosaccharides. (prebiotics)
16497744|NCT03307772|Active Comparator|LGG e FOS Drink|The probiotics and prebiotics drink consists of acidified low-fat milk with added Lactobacillus GG and fructooligosaccharides (prebiotics and probiotics)
16497745|NCT03307759|Active Comparator|SABR plus pembrolizumab|SABR followed by pembrolizumab
16497746|NCT03307759|Active Comparator|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
16497747|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
16497748|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
16497749|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
16497750|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
16497751|NCT03307720|Active Comparator|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
16497752|NCT03307720|Experimental|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
16497753|NCT03307720|Active Comparator|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
16497754|NCT03307720|Experimental|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
16497755|NCT03307720|Active Comparator|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
16497756|NCT03307720|Experimental|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
16497757|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) <50% or LVEF >50% and E/e'>10.
16497758|NCT03307707||No Heart Failure (NHF)|subjects with LVEF>50%
16497759|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
16497760|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
16497761|NCT03307681|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
16497762|NCT03307681|Experimental|Baked potato with skin|Baked russet potato
16497763|NCT03307681|Experimental|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
16497764|NCT03307681|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
16497765|NCT03307681|Experimental|Meal skipping|No food given
16497766|NCT03307668|Experimental|CaReS-1S|
16497767|NCT03307668|Active Comparator|Microfracture|
16497768|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
16497769|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
16497770|NCT03307642|No Intervention|SLIV + usual communication|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV
16497771|NCT03307642|Active Comparator|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
16497952|NCT03306472|Experimental|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
16498853|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
16497772|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.
~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.
~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
16497773|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.
~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The Safety Steering Committee will inform on dose for cohort expansion.
~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
16497774|NCT03307616|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
16497775|NCT03307616|Experimental|Arm B (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
16497776|NCT03307616|Experimental|Arm C (nivolumab, RT)|Patients receive nivolumab IV over 1 hour on days 1, 15, 29, and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
16497777|NCT03307616|Experimental|Arm D (nivolumab, ipilimumab, RT)|Patients receive nivolumab as in Arm C, ipilimumab as in Arm B, and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
16497778|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
16497779|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
16497780|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
16497781|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
16497782|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
16497783|NCT03307564|Experimental|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
16497784|NCT03307551|Active Comparator|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
16497785|NCT03307551|Active Comparator|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
16497786|NCT03307538|Experimental|Stereotactic body radiation therapy|
16497787|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
16497788|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
16497789|NCT03307499|Experimental|Treatment|NeoPatch
16497790|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
16497791|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
16497792|NCT03307460|Experimental|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
16497793|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
16497794|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
16497795|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
16497796|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
16497797|NCT03307421|Other|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .
~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
16497798|NCT03307395|Experimental|Middle Meningeal Artery Embolization|
16497875|NCT03306901|Experimental|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 ~ 4,000mg/m2) intravenously for 4 to 5 days.
~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
16497876|NCT03306901|Active Comparator|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
16497799|NCT03307382|Experimental|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
16497800|NCT03307356|Experimental|Uterine Transplantation|Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 6 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
16497801|NCT03307343|Experimental|Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
16497802|NCT03307343|No Intervention|Control|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
16497803|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
16497804|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
16497805|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
16497806|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
16497807|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
16497808|NCT03307304||Family members|Unaffected family members of individuals diagnosed with CLN3-Batten
16497809|NCT03307304||Proband/Affected Individuals|Individuals diagnosed with CLN3-Batten
16497810|NCT03307278|Experimental|Steroid resistance in HDM allergic patients|
16497811|NCT03307278|Experimental|Steroid resistance in non HDM allergic subjects|
16497812|NCT03307265|Experimental|Imbalance correction|
16497813|NCT03307265|Active Comparator|Control|
16497814|NCT03307252|Experimental|Treatment Reference 1|
16497815|NCT03307252|Experimental|Treatment Reference 2|
16497816|NCT03307252|Experimental|Treatment Reference 3|
16497817|NCT03307252|Experimental|Treatment 1|
16497818|NCT03307252|Experimental|Treatment 2|
16497819|NCT03307252|Experimental|Treatment 3|
16497820|NCT03307252|Experimental|Treatment 4|
16497821|NCT03307252|Experimental|Treatment 5|
16497822|NCT03307252|Experimental|Treatment 6|
16497823|NCT03307239|Experimental|cold application (experimental group)|subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before CTR
16497824|NCT03307239|Sham Comparator|tap water packs application (sham group)|subjects in the sham group (n = 30) received tap water packs.
16497825|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)
~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development
~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
16497826|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)
~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development
~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)
~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
16497827|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
16497828|NCT03307213|Experimental|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
16497829|NCT03307213|Active Comparator|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
16497830|NCT03307187|Experimental|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
16497831|NCT03307187|No Intervention|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
16497832|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:
~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.
~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
16498854|NCT03300063|No Intervention|control|Standard Medical care
16497833|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:
~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.
~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
16497834|NCT03307161|Active Comparator|Parkinsons fwd posture manual treatment|Subject will receive the intervention, osteopathic manual treatment protocol.
16497835|NCT03307161|No Intervention|Parkinsons forward posture|Subjects will receive counseling.
16497836|NCT03307161|No Intervention|Parkinsons without forward posture|Subjects will receive counseling.
16497837|NCT03307148|Experimental|ATRA in combination with Gemcitabine and Nab-Paclitaxel|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
16497838|NCT03307135|Experimental|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
16497839|NCT03307135|Experimental|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
16497840|NCT03307135|Experimental|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
16497841|NCT03307122|Active Comparator|Routine Infant Formula 1|Routine infant formula with probiotic
16497842|NCT03307122|Active Comparator|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
16497843|NCT03307109||Patients having prosthetic joint infection|The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
16497844|NCT03307096|Experimental|Microperc surgery|Patient is turned into prone position and the desired calyx is punctured by 4.8F microperc under fluoroscopic or sonographic guidance. No tract dilation is needed. A 200um holmium laser fiber will be used to break stone into less than 2mm. Pull out microperc without drainage tube left.
16497845|NCT03307096|Active Comparator|FURS|Patient is placed in the lithotomy position, pull out the pre-inserted double J, and place guidewire into the renal pelvis. A 12/14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and flexible ureteroscope is passed through the UAS. The stones are fragmented smeller than 2mm using a 200um holmium laser fiber. Fragments are removed using a stone basket for stone analysis if necessary, a double J stent is placed at the conclusion of the procedure and removed post-operative 4 weeks.
16497846|NCT03307070|Active Comparator|Active Group|Participants who are randomized to begin the Cognitive Behavioral Therapy for individuals with TBI immediately after screening. This treatment is a version of Cognitive Behavioral Therapy (CBT) adapted specifically for patients who have experienced a moderate to severe Traumatic Brain Injury (TBI).
16497847|NCT03307070|Other|Waitlist Control|Participants who are randomized to be put on a waitlist after screening. After 12 weeks of being on the waitlist, participants will be offered the Cognitive Behavioral Therapy for individuals with TBI
16497848|NCT03307057|Experimental|Social Communication Growth Charts (SCGC)|Infants with a sibling who is diagnosed with ASD, who are randomized to receive the Social Communication Growth Charts (SCGC) intervention.
16497849|NCT03307057|No Intervention|Usual care|Infants with a sibling who is diagnosed with ASD, who are randomized to receive usual care.
16497850|NCT03307057|Experimental|Parent-Implemented (P-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) based on the Early Social Interaction model.
16497851|NCT03307057|Experimental|Clinician-Implemented (C-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model.
16497852|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
16497853|NCT03307031|Experimental|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
16497854|NCT03307031|Experimental|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
16497855|NCT03307031|Placebo Comparator|Control Group|Did not exercise, during 10 weeks.
16497856|NCT03307018|Experimental|Bronch|Postoperative systematic bronchial aspiration.
16497857|NCT03307018|No Intervention|Control|In this arm bronchial aspiration with bronchoscope will not be done.
16497858|NCT03307005|Experimental|Intervention|
16497859|NCT03307005|Placebo Comparator|Control|
16497860|NCT03306992|Experimental|Personalized Exercise Program|
16497861|NCT03306992|No Intervention|Standard of Care - No Exercise|
16497862|NCT03306979|Active Comparator|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
16497863|NCT03306979|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
16497864|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
16497865|NCT03306953|Active Comparator|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
16497866|NCT03306953|No Intervention|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
16497867|NCT03306940|Placebo Comparator|unilateral injection group|Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.
16497868|NCT03306940|Experimental|bilateral injection group|Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.
16497869|NCT03306927|Experimental|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
16499277|NCT03296930|Active Comparator|first drug group|Sofosbuvir 400 MG Oral Tablet
16497877|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
16497878|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
16497879|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
16497880|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
16497881|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
16497882|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
16497883|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
16497884|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
16497885|NCT03306836|Experimental|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
16497886|NCT03306836|Active Comparator|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
16497887|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
16497888|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
16497889|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
16497890|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
16497891|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
16497892|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
16497893|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
16497894|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
16497895|NCT03306758|Experimental|Experimental: sodium bicarbonate|
16497896|NCT03306758|No Intervention|No Intervention|
16497897|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids
~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
16497898|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
16497899|NCT03306732|Active Comparator|Thiamine group|
16497900|NCT03306732|Placebo Comparator|Placebo group|
16497901|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
16497902|NCT03306719||Control Group|Pregnant women without IAI
16497907|NCT03306693|Experimental|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
16497908|NCT03306693|Sham Comparator|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
16497909|NCT03306680|Experimental|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy
~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy
~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy"
16497910|NCT03306667|Experimental|Normal group|Healthy control subjects
16497911|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
16497912|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
16497914|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
16497915|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16497916|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16497917|NCT03306641|Active Comparator|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
16497918|NCT03306641|Active Comparator|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
16497919|NCT03306628|Experimental|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
16497920|NCT03306628|Experimental|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
16497923|NCT03306602|Experimental|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
16497924|NCT03306602|Active Comparator|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
16497925|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
16497926|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
16497927|NCT03306576|Experimental|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
16497928|NCT03306576|Active Comparator|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
16497929|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
16497930|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
16497931|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
16497932|NCT03306550|Active Comparator|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
16497933|NCT03306550|Active Comparator|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
16497934|NCT03306550|Experimental|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
16497935|NCT03306524|Experimental|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
16497936|NCT03306524|Experimental|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
16497937|NCT03306524|Experimental|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
16497938|NCT03306524|Experimental|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
16497939|NCT03306524|Experimental|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
16497940|NCT03306524|Experimental|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
16497941|NCT03306524|Experimental|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
16497942|NCT03306524|Experimental|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
16497943|NCT03306524|Experimental|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
16497944|NCT03306524|Experimental|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
16497945|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
16497946|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
16497947|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
16497948|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
16497949|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure > 5% on pH monitoring performed off PPI).
~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
16497950|NCT03306472|Active Comparator|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
16497953|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting >35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
16497954|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
16497955|NCT03306446|Experimental|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
16497956|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
16497957|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
16497958|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
16497959|NCT03306420|Experimental|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
16497960|NCT03306420|Experimental|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
16497961|NCT03306420|Experimental|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
16497962|NCT03306420|Experimental|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
16497963|NCT03306420|Experimental|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
16497964|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
16497965|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
16497966|NCT03306394|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
16497967|NCT03306381|Experimental|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
16497968|NCT03306381|No Intervention|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
16497969|NCT03306368|No Intervention|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
16497970|NCT03306368|Experimental|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:
~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
16497971|NCT03306355|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
16497972|NCT03306355|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
16497973|NCT03306342|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
16497974|NCT03306329|Experimental|DNS-7801 (low-dose)|
16497975|NCT03306329|Experimental|DNS-7801 (high-dose)|
16497976|NCT03306329|Placebo Comparator|Placebo|
16497977|NCT03306316|Experimental|Experimental|Experimental Arm
16497978|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
16497979|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
16497980|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
16497981|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
16497982|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
16497983|NCT03306290|Other|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
16497984|NCT03306277|Experimental|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
16497985|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
16497986|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
16497987|NCT03306238|Active Comparator|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
16497988|NCT03306238|Active Comparator|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
16497989|NCT03306212|Experimental|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
16497990|NCT03306212|Active Comparator|Control Group|Patients treated by botulinum toxin A and occupational therapy
16497991|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
16497992|NCT03306173|Experimental|Ventilated cigarettes|Participants in this ARM will be assigned to ~25% filter ventilation commercially available cigarettes.
16497993|NCT03306173|Experimental|Unventilated cigarettes|Participants in this ARM will be assigned to ~0% filter ventilation commercially available cigarettes.
16497994|NCT03306147|Experimental|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
16497995|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
16497996|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
16497997|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
16497998|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
16497999|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
16498000|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
16498001|NCT03306082|Experimental|Image-guided Cochlear Implant Programming (IGCIP)|Cochlear implant programming using IGCIP.
16498002|NCT03306069|Experimental|Control|Nutritional therapy / no exercise
16498003|NCT03306069|Experimental|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
16498004|NCT03306069|Experimental|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
16498005|NCT03306069|Experimental|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding ~70-75% HRmax) combined with Nutritional therapy
16498006|NCT03306056|Experimental|Control|Nutritional therapy / no exercise
16498007|NCT03306056|Experimental|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
16498008|NCT03306056|Experimental|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
16498009|NCT03306056|Experimental|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
16498010|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
16498011|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
16498012|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
16498013|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
16498014|NCT03306004||Health Care Providers|Providers answer questionaires
16498015|NCT03306004||Mothers|Mothers answer questionaires
16498016|NCT03305978|Experimental|Ultra low dose chest CT|
16498017|NCT03305978|Active Comparator|Low dose chest CT|
16498018|NCT03305965|Experimental|Patient navigation|
16498019|NCT03305965|No Intervention|Care as usual|
16498020|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
16498021|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
16498022|NCT03305939|Experimental|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
16498023|NCT03305939|No Intervention|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
16498024|NCT03305926|Active Comparator|Conventional CVR|
16498025|NCT03305926|Experimental|eCVR|
16498026|NCT03305913|Experimental|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
16498027|NCT03305913|Experimental|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
16498028|NCT03305913|Experimental|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
16498029|NCT03305913|Experimental|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
16498030|NCT03305913|Experimental|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
16498031|NCT03305913|Experimental|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
16498032|NCT03305887|Experimental|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
16498033|NCT03305887|Active Comparator|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
16498034|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
16498035|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
16498036|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
16498037|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
16498038|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
16498039|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
16498040|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
16498041|NCT03305809|Placebo Comparator|Placebo|Participants received placebo administered orally once a day (QD).
16498042|NCT03305809|Experimental|10 milligram (mg) LY3154207|Participants received 10 mg LY3154207 administered orally QD.
16498043|NCT03305809|Experimental|30 mg LY3154207|Participants received 30 mg LY3154207 administered orally QD.
16498044|NCT03305809|Experimental|75 mg LY3154207|Participants received 75 mg LY3154207 administered orally QD.
16498045|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
16498046|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
16498047|NCT03305770|Experimental|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
16498048|NCT03305770|Active Comparator|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
16498049|NCT03305757|Active Comparator|conventional wound closure|The skin flaps will not undergo further treatment in this group.
16498050|NCT03305757|Experimental|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
16498051|NCT03305757|Experimental|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
16498052|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
16498053|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
16498054|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
16498055|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
16498056|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
16498068|NCT03305705|Experimental|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
16498069|NCT03305692|Experimental|ECG Belt|Use ECG Belt body surface mapping system to optimize CRT programming.
16498070|NCT03305692|Experimental|Echocardiography|Use mitral inflow echocardiography to optimize CRT programming.
16499278|NCT03296930|Active Comparator|second drug group|Ombitasvir/paritaprevir/ritonavir
16498057|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
16498058|NCT03305718|Experimental|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
16498059|NCT03305718|Experimental|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
16498060|NCT03305718|Experimental|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
16498061|NCT03305718|Experimental|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
16498062|NCT03305718|Experimental|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
16498063|NCT03305718|Experimental|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
16498064|NCT03305718|Experimental|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
16498065|NCT03305718|Experimental|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
16498066|NCT03305718|Experimental|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
16498067|NCT03305705|Experimental|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
16498071|NCT03305679|Experimental|Direct provisional technique|Patients here will be subjected to the direct provisional technique
16498072|NCT03305679|Active Comparator|Indirect Provisional technique|Patients here will be subjected to the indirect provisional technique
16498073|NCT03305666|Active Comparator|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
16498074|NCT03305666|Active Comparator|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
16498075|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
16498076|NCT03305627|Experimental|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
16498077|NCT03305627|Active Comparator|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
16498078|NCT03305614|Active Comparator|Aphasia therapy and tDCS|
16498079|NCT03305614|Sham Comparator|Aphasia therapy and sham-tDCS|
16498080|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
16498081|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
16498082|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
16498083|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
16498084|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
16498085|NCT03305549|Active Comparator|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
16498086|NCT03305549|Experimental|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
16498087|NCT03305536|Active Comparator|Interventional|1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve
16498088|NCT03305536|Active Comparator|interventional|5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study
16498089|NCT03305523|Experimental|Thermocautery|Circumcision with thermocautery technique was applied all participants
16498090|NCT03305510||Vitamin D deficiency|The level of vitamin D is below 20ng/ml.
16498091|NCT03305510||Vitamin D insufficient|The level of vitamin D is between 20ng/ml and 30ng/ml.
16498092|NCT03305510||Vitamin D sufficient|The level of vitamin D is above 30ng/ml.
16498093|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
16498094|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
16498095|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
16498096|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
16498097|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
16498098|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
16498099|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
16498100|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
16498101|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
16498102|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
16498103|NCT03305445|Experimental|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
16498104|NCT03305432|Experimental|PPI group|take preoperative PPI for 10 days
16498105|NCT03305432|Active Comparator|Control group|take placebo for for 10 days preoperative
16498106|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
16498107|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
16498108|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
16498109|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
16498110|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
16498111|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
16498112|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
16498113|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
16498114|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
16498115|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
16498116|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
16498117|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
16498118|NCT03305406||Focus Group Participants|Semi-structured focus groups
16498119|NCT03305406||Interview Participants|One-on-one interviews
16498120|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
16498121|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
16498122|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
16498123|NCT03305367|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
16498124|NCT03305367|Experimental|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
16498125|NCT03305367|Experimental|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
16498126|NCT03305354|Experimental|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
16498127|NCT03305354|Active Comparator|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
16498128|NCT03305341|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein
~0.5 ml Lactated Ringer's Injection, USP"
16498129|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
16498130|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
16498131|NCT03305315||Cases|Diseases of the temporomandibular joint
16498132|NCT03305315||Controls|Asymptomatic subjects
16498133|NCT03305289|Active Comparator|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
16498134|NCT03305289|Active Comparator|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
16498135|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
16498136|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
16498137|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
16498138|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
16498139|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
16498140|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
16499313|NCT03296709|Experimental|PPC z|
16498141|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
16498142|NCT03305224|Other|Ra-223 + Enzalutamide|
16498143|NCT03305211|Other|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
16498144|NCT03305198|Experimental|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
16498145|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
16498146|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
16498147|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
16498148|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
16498149|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
16498150|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
16498151|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
16498152|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
16498153|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
16498154|NCT03305146|Experimental|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.
~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
16498155|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.
~Children will then drink 240mL of chocolate milk"
16498156|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.
~Children will then drink 240mL of water"
16498157|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
16498158|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
16498159|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
16498160|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
16498161|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
16498162|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
16498163|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
16498164|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
16498207|NCT03304756|Experimental|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
16498208|NCT03304743||Post-menopausal women|A cohort of 124 consecutive post-menopausal women that performed a DXA scan within the previous 12 months
16498209|NCT03304730||facet inflammatory signs|patients with facet inflammatory signs identified on MRI
16498210|NCT03304730||no facet inflammatory signs|patients without facet inflammatory signs identified on MRI
16498165|NCT03305055|Experimental|Fentanyl Plus Ketamine|"Study drug group
~Ketamine Loading Dose (Low Dose, Slow Infusion) =
~• 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, … Then,
~Fentanyl Loading Dose (UC, injection) =
~• 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated < 1 minute prior to wound care.
~Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.
~Fentanyl PRN dose* = 1 mcg / kg. Provided when participant requires additional pain medication."
16498166|NCT03305055|Active Comparator|Fentanyl Plus Saline|"Usual care group
~Saline Loading Dose (Low Dose, Slow Infusion) =
~• An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), … Then, ...
~Fentanyl Loading Dose (UC, injection) =
~• 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated <1 minute prior to wound care.
~Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.
~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
16498167|NCT03305042||21-54 y|Ages 21-54 y
16498168|NCT03305042||55-74 y|Ages 55-74 y
16498169|NCT03305042||>75 y|Age >75 y
16498170|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
16498171|NCT03305016|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
16498172|NCT03305003|Active Comparator|Communication modality: spiral notebook|
16498173|NCT03305003|Experimental|Communication modality: mobile application|
16498174|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
16498175|NCT03304990||Risk Factors for CA|No dx of CA
16498176|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
16498177|NCT03304964|Experimental|100 mg FP-025 (b.i.d)|
16498178|NCT03304964|Experimental|200 mg FP-025 (b.i.d.)|
16498179|NCT03304964|Experimental|400 mg FP-025 (b.i.d)|
16498180|NCT03304964|Experimental|200 mg FP-025 (single dose; fasted)|
16498181|NCT03304964|Experimental|200 mg FP-025 (single dose; fed condition)|
16498182|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
16498183|NCT03304938|Active Comparator|Lavender oil|
16498184|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
16498185|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
16498186|NCT03304912||Cohort|The cohort will be comprised of women who inject drugs who are eligible for PrEP.
16498187|NCT03304899|Experimental|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:
~Airway control & breathing.
~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).
~Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.
~Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
16498188|NCT03304899|Active Comparator|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:
~Airway control & breathing.
~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
16498189|NCT03304886||Migraineurs|with a migraine
16498190|NCT03304886||Control|Participants without migraine
16498191|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
16498192|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
16498193|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
16498194|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
16498195|NCT03304834|Experimental|ECHOPULSE|Arm of patient treated by HIFU
16498198|NCT03304808|Experimental|device|
16498199|NCT03304808|Active Comparator|behavioral|
16498200|NCT03304808|No Intervention|waiting list|
16498201|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
16498202|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
16498203|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
16498204|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
16498205|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
16498206|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
16498439|NCT03303014|Experimental|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
16498211|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
16498212|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
16498219|NCT03304665||Healthy Volunteers|Healthy Volunteers
16498220|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16498221|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
16498222|NCT03304626|Experimental|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows
~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
16498223|NCT03304626|Active Comparator|Control Group|"Standard of Care
~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS"
16498224|NCT03304613|Active Comparator|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
16498225|NCT03304613|Experimental|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
16498226|NCT03304613|No Intervention|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
16498227|NCT03304600|Experimental|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
16498228|NCT03304600|Sham Comparator|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
16498229|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.
~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.
~Light therapy will be self-administered using a light visor cap
~Each participant will make (3) overnight visits to the sleep laboratory
~On 2 randomly selected days, the participants will wear a light meter during wake time"
16498230|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.
~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.
~Light therapy will be self-administered using a light visor cap
~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
16498231|NCT03304574|No Intervention|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
16498232|NCT03304574|Experimental|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
16498233|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
16498264|NCT03304340|Active Comparator|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
16498234|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
16498235|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
16498236|NCT03304522|Experimental|VX-150|
16498237|NCT03304522|Active Comparator|Placebo|
16498238|NCT03304509|No Intervention|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
16498239|NCT03304509|Experimental|Telematic follow-up|Telematic follow-up after hospital discharge
16498240|NCT03304496|Experimental|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
16498241|NCT03304496|Placebo Comparator|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
16498242|NCT03304483|Experimental|Athletes|246-km running
16498243|NCT03304470|Experimental|ATx201 2% CREAM|
16498244|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
16498245|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
16498246|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
16498247|NCT03304444|Active Comparator|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).
~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
16498248|NCT03304444|Experimental|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
16498249|NCT03304431|No Intervention|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
16498250|NCT03304431|Other|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
16498251|NCT03304418|Experimental|Radium Ra 223 dichloride and radiation, all patients|
16498252|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
16498253|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
16498254|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
16498255|NCT03304379|Experimental|Dosing regimen 1|
16498256|NCT03304379|Experimental|Dosing regimen 2|
16498257|NCT03304379|Experimental|Dosing regimen 3|
16498258|NCT03304379|Experimental|Dosing regimen 4|
16498259|NCT03304366||Patients with primary pterygium|"All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.
~All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
16498260|NCT03304353|Experimental|Self-managed protocol|
16498261|NCT03304353|Active Comparator|Predetermined protocol|
16498262|NCT03304340|Experimental|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device & Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
16498263|NCT03304340|Experimental|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
16498433|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
16498265|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
16498266|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
16498267|NCT03304314|Experimental|Control|
16498268|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
16498269|NCT03304301|No Intervention|control group|Participants will receive routine care.
16498270|NCT03304288|Experimental|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m^2 qd for 12 weeks.
16498271|NCT03304288|Active Comparator|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
16498272|NCT03304275|Experimental|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
16498273|NCT03304275|Experimental|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
16498274|NCT03304262|Active Comparator|Cathodal tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
16498275|NCT03304262|Active Comparator|Anodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
16498276|NCT03304262|Sham Comparator|Sham tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
16498277|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
16498278|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
16498279|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
16498280|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
16498281|NCT03304210|Experimental|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
16498282|NCT03304210|Experimental|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
16498283|NCT03304210|Experimental|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
16498284|NCT03304210|Experimental|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
16498285|NCT03304210|Experimental|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
16498286|NCT03304197|Experimental|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
16498287|NCT03304197|Experimental|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
16498288|NCT03304197|Experimental|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
16498289|NCT03304197|Experimental|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
16498290|NCT03304184|Placebo Comparator|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
16498291|NCT03304184|Experimental|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
16498292|NCT03304158|Experimental|FCHV visit-diabetes|
16498293|NCT03304158|No Intervention|FCHV no visit-diabetes|
16498294|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
16498295|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
16498296|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
16498297|NCT03304119||Control group control|Group that has not been checked for patellar instability.
16498298|NCT03304106|Experimental|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
16498299|NCT03304106|Experimental|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
16498300|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
16498301|NCT03304080|Experimental|HR-positive, Her2-positive Metastatic Breast Cancer|Women and men with HR-positive, HER2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
16498302|NCT03304067|Experimental|Intervention|
16498303|NCT03304067|No Intervention|Control|
16498304|NCT03304054|Experimental|amifamapridine phosphate tablets|
16498305|NCT03304054|Placebo Comparator|placebo tablets|
16498306|NCT03304041|Experimental|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.
~low-FODMAPs diet therapy for 3 weeks"
16498307|NCT03304041|Placebo Comparator|Traditional dietary advice|"Traditional dietary advice (TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period
~Traditional dietary advice for 3 weeks"
16498308|NCT03304028|Other|Refusal Group|"Refusal Questionnaires Intervention:
~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
16498309|NCT03304028|Other|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
16498310|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
16498311|NCT03304015|No Intervention|Control: No intervention|
16498312|NCT03303989|Experimental|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
16498313|NCT03303989|Placebo Comparator|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
16498314|NCT03303976|Experimental|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
16498315|NCT03303976|Experimental|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
16498316|NCT03303976|Experimental|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
16498317|NCT03303976|Active Comparator|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
16498318|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
16498319|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
16498321|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
16498322|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:
~Days 1-3 (6 times daily)
~Days 4-12 (5 times daily)
~Days 13-16 (4 times daily)
~Days 17-20 (3 times daily)
~Days 21-24 (2 times daily)
~Day 25 (Once daily)"
16498323|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:
~Days 1-3 (6 times daily)
~Days 4-12 (5 times daily)
~Days 13-16 (4 times daily)
~Days 17-20 (3 times daily)
~Days 21-24 (2 times daily)
~Day 25 (Once daily)"
16498324|NCT03303898|Other|asymptomatic carriers|
16498325|NCT03303898|Other|uninfected patient|
16498326|NCT03303872||AF-pacemaker registry|
16498327|NCT03303846|Experimental|Treatment (breast MRI, biopsy)|Participants undergo standard of care high risk breast cancer screening MRIs at baseline and follow-up and blood sample collection at baseline. Participants also undergo collection of breast tissue samples at any breast biopsy or breast surgery.
16498328|NCT03303833||Persons with Lynch syndrome|
16498329|NCT03303807|Other|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
16498330|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
16498331|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
16498332|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
16498333|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
16498334|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
16498335|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
16498336|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
16498337|NCT03303742|Experimental|feather edge finish line marginal design|intervention
16498338|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
16498339|NCT03303729|Experimental|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
16498340|NCT03303729|Active Comparator|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
16498341|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
16498342|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
16498343|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
16498344|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
16498345|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
16498346|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
16498434|NCT03303040|Experimental|Stimulation|Electrical stimulation of hemidiaphragm
16498435|NCT03303040|No Intervention|Control|No stimulation of hemidiaphragm
16498347|NCT03303664|Experimental|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
16498348|NCT03303664|No Intervention|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
16498349|NCT03303651|Experimental|PPI (Pain Pupillary Index)|Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
16498350|NCT03303651|Experimental|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electrics) Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide analgesics (15 - 17). 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
16498351|NCT03303651|Experimental|NOL (Nociception Level)|Opioid administration (sufentanil) guided by Nociception Level (NOL) derived from finger photoplethysmography performed with the analgesia monitoring device PMD200 manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature and finger motion. The composite algorithm of the device analyses the data and the numerical index NOL is presented on a scale from 0 (no pain) to 100 (extreme pain) (18). A NOL score between 10 and 25 has been proposed as the target range to guide analgesics. 5 µg Sufentanil will be administered every 5 minutes if NOL score is calculated more than 25.
16498352|NCT03303651|Active Comparator|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
16498353|NCT03303638|Other|Multi-sensory Environment during bathing|The MSE intervention will be provided by an interactive waterproof fiber optic kit that includes: a light-emitting diode (LED) wall-washer light, a waterproof fiber optic cable that can be controlled by a waterproof switch held by the participant while bathing, showering, and or tub bathing, and a mobile MSE cart. The wall-washer LED light creates the illusion that the room is painted a variety of bright colors that can be changed by the veteran being bathed. The mobile MSE cart includes an LED solar projector providing visual sensory stimulation by projecting scenes on the wall, an aroma therapy diffuser and a portable bubble tube to create positive distraction during the bathing process.
16498354|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
16498355|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
16498356|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
16498357|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
16498358|NCT03303612|Other|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.
~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
16498359|NCT03303612|Other|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
16498360|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
16498361|NCT03303586|Active Comparator|Asthma group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
16498362|NCT03303586|Active Comparator|Healthy group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
16498363|NCT03303573||recombinant human erythropoietin group|cerebral palsy patients who had received erythropoietin from January 2013 to November 2016
16498364|NCT03303547|Experimental|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
16498436|NCT03303027|Experimental|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
16498365|NCT03303534|Experimental|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
16498366|NCT03303534|No Intervention|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
16498367|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
16498368|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
16498369|NCT03303508|Other|anti-ds DNA|anti-ds DNA
16498370|NCT03303495|Experimental|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1; l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1; 5-FU - bolus 400 mg/m2 IV bolus Day 1; 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
16498371|NCT03303495|Experimental|CPT-11 +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1
16498372|NCT03303482|Experimental|Intervention Group|
16498373|NCT03303482|No Intervention|Waitlist Control Group|
16498374|NCT03303469|Experimental|FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT)|FMISO imaging at baseline, post-TACE and post-SBRT
16498375|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
16498376|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
16498377|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
16498378|NCT03303443||Younger|20-40 years old patients
16498379|NCT03303443||Elderly|over 60 years old patients
16498380|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
16498381|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
16498382|NCT03303417|Experimental|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
16498383|NCT03303417|Placebo Comparator|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
16498384|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
16498385|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
16498386|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
16498387|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
16498388|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
16498389|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
16498390|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
16498391|NCT03303352|Experimental|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.
~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.
~For each patient, the passes order with be either done as fast pass first, slow pass second."
16498392|NCT03303352|Experimental|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.
~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.
~For each patient, the passes order with be either done as slow pass first, fast pass second."
16498393|NCT03303339|Experimental|Phase 1b: Onvansertib + low-dose cytarabine|Onvansertib, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m^2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). Onvansertib administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days. Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
16498437|NCT03303027|Experimental|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
16498438|NCT03303014|Experimental|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
16498394|NCT03303339|Experimental|Phase 1b: Onvansertib + decitabine|Onvansertib will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). Onvansertib administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days (Day 1 through Day 5). Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
16498395|NCT03303339|Experimental|Phase 2: Onvansertib + decitabine|Onvansertib recommended phase 2 dose, orally Day 1 through Day 5 every 28 days (1 cycle) and decitabine, administered consistently as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
16498396|NCT03303326|Experimental|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
16498397|NCT03303326|No Intervention|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
16498398|NCT03303313|Experimental|Cemdisiran|
16498399|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
16498400|NCT03303287|No Intervention|control|usual
16498401|NCT03303274|Experimental|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
16498402|NCT03303274|No Intervention|Supine|Catheterization of right subclavian vein in supine position.
16498403|NCT03303248|Experimental|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
16498404|NCT03303248|No Intervention|Standard of Care|This group will be given only the standard of care during their clinic visit.
16498405|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group
~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
16498406|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group
~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
16498407|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
16498408|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
16498409|NCT03303196|Experimental|Bihormonal bionic pancreas admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
16498410|NCT03303196|No Intervention|Standard care admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
16498411|NCT03303183|Active Comparator|Direct Ear Scanner|Digitale impression via direct ear scanner
16498412|NCT03303183|Active Comparator|Silicone Ear impression|Impression via silicone
16498413|NCT03303170|Experimental|Sebacia Microparticles|
16498414|NCT03303170|Active Comparator|Nd:Yag Laser|
16498415|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
16498416|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
16498417|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
16498418|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
16498419|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
16498420|NCT03303118|Other|Left|No product administration will be done in this study.
16498421|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly [except for a loading dose of 675 mg in subjects with CM]).
16498422|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
16498423|NCT03303092|Experimental|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
16498424|NCT03303092|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
16498425|NCT03303092|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
16498426|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
16498427|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
16498428|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
16498429|NCT03303066|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
16498430|NCT03303066|Placebo Comparator|Placebo (Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
16498431|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
16498432|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
16498440|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
16498441|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
16498442|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
16498443|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
16498444|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
16498445|NCT03302962|Experimental|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
16498446|NCT03302962|No Intervention|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
16498447|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
16498448|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
16498449|NCT03302936|Experimental|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
16498450|NCT03302936|No Intervention|Control arm|No intervention in this group. Routine perioperative care.
16498451|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
16498452|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
16498453|NCT03302923|No Intervention|Control group|No brisk walking session
16498454|NCT03302910|Experimental|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
16498455|NCT03302910|Active Comparator|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
16498456|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
16498457|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
16498458|NCT03302884|Experimental|Biological sampling in ovarian carcinoma|Blood and tumor samples
16498459|NCT03302871|Experimental|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
16498460|NCT03302871|Active Comparator|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
16498461|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
16498462|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
16498463|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
16498464|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
16498465|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
16498466|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
16498467|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
16498468|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
16498469|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
16498470|NCT03302780|Experimental|Sham tDCS and BreEStim|This arm includes a 20-min sham tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
16498471|NCT03302780|Experimental|active tDCS (M1) and BreEStim|This arm includes a 20-min active tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
16498472|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
16498528|NCT03302299|Experimental|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
16498564|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
16498473|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).
~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).
~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
16498474|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
16498475|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
16498476|NCT03302728|Experimental|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
16498477|NCT03302715|Experimental|Mucosal biopsies|Only blood samples and mucosal biopsies
16498478|NCT03302702|Other|Exercise program|Treatment group
16498479|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
16498480|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
16498481|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.
~Daily registrations in a patient dairy."
16498482|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
16498483|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
16498484|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
16498485|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
16498486|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
16498487|NCT03302650|Experimental|Angiotensin group|Patients will receive Angiotensin II at a starting dose of 20 ng/Kg/min. During the first 30 minutes after randomization, the angiotensin II infusion will be titrated to achieve a mean arterial pressure of 65-75 mmHg while the norepinephrine infusion will be withdrawn and stopped. Following a stabilization of 60 minutes, the angiotensin II infusion is titrated to achieve a mean arterial pressure of 85-95 mmHg. Following a 30 minutes wash-in period and a 60 minutes stabilization period, a third set of measurements will be taken. Then, the angiotensin II infusion will be withdrawn in small steps and replaced by a norepinephrine infusion which will then be titrated to achieve a mean arterial pressure of 65-75 mmHg. Then, the final set of measurements will be taken.
16498488|NCT03302650|Placebo Comparator|Normal saline group|Patients will receive normal saline infusion in addition to norepinephrine infusion. The same mean arterial pressure levels (65-75 mmHg > 85-95 mmHg > 65-75 mmHg) will be achieved by titration of the norepinephrine infusion. Identical wash-in and stabilization periods will be kept as in the study group. Measurements will be taken at the same time points as in the study group. The maximum dose of norepinephrine applied will be 0.7 mcg/kg/min.
16498489|NCT03302637||Cases|subjects with histology-confirmed incident pancreatic cancer, with no prior history of cancer (except non-melanoma skin cancer), a valid consent, and pre-diagnostic oral wash samples.
16498490|NCT03302637||Control|selected by incidence density sampling63 among cohort members who had no cancer prior to selection, provided a valid consent and an oral wash. Controls were frequency matched to cases by cohort, age at cohort entry (5 year), sex, race, and calendar year of cohort entry.
16498491|NCT03302624||Patients who were included in ELVIS study|
16498492|NCT03302611|Experimental|Surf Therapy|Participants receive a physical activity-based intervention, which in this arm is surf therapy. Each service member is paired with a surf instructor who typically works with them each week for the length of the program.
16498493|NCT03302611|Active Comparator|Hike Therapy|Participants receive a physical activity-based intervention, which in this arm is hike therapy. During hike therapy, service members may hike together or at a self-selected pace.
16498494|NCT03302598|Other|patients with enterocutaneous fistula|
16498495|NCT03302585|Experimental|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:
~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
16498496|NCT03302585|Placebo Comparator|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:
~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
16498529|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
16498530|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
16498531|NCT03302273|Experimental|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
16498497|NCT03302572|Experimental|Brief information group|Patients will be given brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
16498498|NCT03302572|No Intervention|Control group|"Patients who fall into a control group will only be attended to their reason for visiting and will be asked for the necessary data to obtain the independent variables if they do not appear in their history. If the patient in this group wants the information, he will be excluded from the study because he refuses to participate."
16498499|NCT03302559|Experimental|Retinol Complex 0.5|During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
16498500|NCT03302546|Active Comparator|Incremental Hemodialysis|Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.
16498501|NCT03302546|Active Comparator|Conventional hemodialysis|Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.
16498502|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
16498503|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
16498504|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
16498505|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
16498506|NCT03302507|Experimental|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
16498507|NCT03302507|Active Comparator|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
16498508|NCT03302494|Experimental|WaveCrest|WaveCrest left atrial appendage occluder
16498509|NCT03302494|Active Comparator|Watchman (control)|Watchman left atrial appendage closure device
16498510|NCT03302481|Experimental|Experimental Group|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
16498511|NCT03302455|Experimental|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
16498512|NCT03302455|No Intervention|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
16498513|NCT03302429|Experimental|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
16498514|NCT03302429|Active Comparator|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
16498515|NCT03302416|Experimental|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
16498516|NCT03302403|Experimental|CAR T cell|"In this study, autologous T cells transduced with a chimeric antigen receptor are used to treat patients with malignant tumors:
~CAR-CD19 T cell is for the treatment of B-cell Leukaemia/Lymphoma; CAR-BCMA T cell is for the treatment of Myeloma; CAR-GPC3 T cell is for the treatment of Hepatocellular Carcinoma; CAR-CLD18 T cell is for the treatment of Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to CAR T cell infusion, which may improve in vivo cell count and survival of T cells.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
16498517|NCT03302390||Biopsy of Skin with Psoriasis|Shave biopsy of psoriasis lesion
16498518|NCT03302377|Experimental|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
16498519|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
16498520|NCT03302351|Experimental|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
16498521|NCT03302351|Experimental|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
16498522|NCT03302351|Experimental|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
16498523|NCT03302338|Experimental|SAFE group|SAFE group: simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
16498524|NCT03302338|Placebo Comparator|Placebo|Placebo group: distilled water 2.5 ml/kg every 3 hours enterally given.
16498525|NCT03302325||Stage IV solid tumors|adult patients with stage IV cancer that are starting a new line of treatment
16498526|NCT03302312||Participants|Service members who received at least one SGB study procedure as part of the clinical effectiveness trial during the three months prior to qualitative data collection or service members who received at least one SGB for PTSD symptoms at a study site in the three months prior to qualitative data collection.
16498527|NCT03302312||Providers|Behavioral Health or other (e.g., Family Medicine) clinicians who have referred or could potentially have referred service members for SGB for PTSD symptoms, as well as physicians who provide SGBs.
16498532|NCT03302260|No Intervention|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
16498533|NCT03302260|Experimental|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
16498534|NCT03302247|Experimental|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
16498535|NCT03302234|Experimental|Pembrolizumab + Ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
16498536|NCT03302234|Active Comparator|Pembrolizumab + Placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
16498537|NCT03302221|Other|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
16498538|NCT03302221|Experimental|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
16498539|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
16498540|NCT03302208|Active Comparator|pregabalin group|
16498541|NCT03302208|Placebo Comparator|placebo group|
16498542|NCT03302195|Active Comparator|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
16498543|NCT03302195|Experimental|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
16498544|NCT03302195|Experimental|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
16498545|NCT03302195|Experimental|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
16498546|NCT03302182|Experimental|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.
~For group1:
~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
~For group2:
~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
16498547|NCT03302182|Experimental|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.
~For group3:
~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
~For group4:
~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
16498548|NCT03302169|Experimental|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
16498549|NCT03302169|Active Comparator|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
16498550|NCT03302156|Other|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
16498551|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
16498552|NCT03302156|Other|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
16498553|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
16498554|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
16498555|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
16498556|NCT03302091|Experimental|BI 1467335 Normal (R)|Participants with normal renal function.
16498557|NCT03302091|Experimental|BI 1467335 Moderate (T)|Participants with moderate renal impairment.
16498558|NCT03302078|Experimental|Treatment T|Fed state
16498559|NCT03302078|Experimental|Treatment R|Fasted state
16498560|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
16498561|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
16498562|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
16498563|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
16498855|NCT03300063|Active Comparator|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
16498565|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
16498566|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
16498567|NCT03302026|Experimental|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
16498568|NCT03302026|No Intervention|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
16498569|NCT03302013|Experimental|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
16498570|NCT03302013|Active Comparator|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
16498571|NCT03302000|Experimental|Visual stimulation|"Early visual stimulation (EVS) will be implemented by caregivers.
~Three phases:
~the caregiver will establish eye-to-eye contact with the infant. The caregiver will communicate with the infant talking, singing, changing facial expressions, touching his/her face. Total duration of this part of stimulation is between 2 and 3 minutes
~the caregivers will present visual contrast cards at a distance of 15-20 centimetres
~the caregiver will present two toys to the infant
~Stimulation will last for 28 days (4 weeks) in total, one time a day for 10-15 minutes, all days week."
16498572|NCT03302000|Other|standard care|Caregivers will receive an Illustrated Handbook, according to the age range of birth to three months. Assessors will explain all information contained in the handbook after the first assessment and randomisation.
16498573|NCT03301987|Experimental|Therapeutic exercise|
16498574|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
16498575|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
16498576|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
16498577|NCT03301948|Experimental|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
16498578|NCT03301948|Experimental|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
16498579|NCT03301922|Experimental|Work-focused metacognitive therapy|Work-focused metacognitive therapy
16498580|NCT03301922|Other|Waiting list|Waiting list
16498582|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
16498583|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
16498585|NCT03301870|Experimental|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
16498586|NCT03301870|Experimental|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
16498587|NCT03301870|Experimental|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
16498588|NCT03301870|Experimental|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
16498589|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
16498590|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
16498591|NCT03301870|Active Comparator|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
16498592|NCT03301870|Active Comparator|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
16498593|NCT03301870|Active Comparator|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
16498594|NCT03301857|Experimental|Denosumab|"Cohort A (subjects who are still being treated with denosumab when 20062004 completes): 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
~For subjects undergoing retreatment with denosumab: 120 mg administered SC on Days 1, 8, 15 and 28 then every 4 weeks subsequently."
16498891|NCT03299803|No Intervention|Control group|Telephone contact only
16498595|NCT03301857|No Intervention|Safety Follow up|"Subjects still receiving treatment will have follow-up study visits in the clinic every 6 months while receiving denosumab (Cohort A).
~Subjects who completed denosumab treatment and were in safety follow-up at the conclusion of 20062004 will have follow-up visits performed every 6 months via telephone or in-person clinic visit (Cohort B)."
16498596|NCT03301844|Experimental|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
16498597|NCT03301844|Other|Standard treatment|Wet, warm gauze twice daily for one month.
16498600|NCT03301818|Experimental|Patients undergoing USI repair|
16498601|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
16498602|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
16498603|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
16498604|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
16498605|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
16498606|NCT03301766|Experimental|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
16498607|NCT03301766|Active Comparator|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
16498608|NCT03301740|Experimental|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.
~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
16498609|NCT03301740|Experimental|Conventional HD Phase First|"First treatment phase begins with conventional HD.
~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
16498610|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
16498611|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
16498612|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
16498613|NCT03301714|No Intervention|Control: Standard of Care|Regular dental care under the standard clinic operation
16498614|NCT03301714|Experimental|Intervention 1: Group-based oral health education|Group based oral health education
16498615|NCT03301714|Experimental|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
16498616|NCT03301701|Experimental|Arm 1|Radical prostatectomy
16498617|NCT03301701|Active Comparator|Arm 2|Radiotherapy
16498618|NCT03301688|Experimental|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
16498619|NCT03301688|Experimental|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
16498620|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
16498621|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
16498622|NCT03301649|Experimental|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
16498623|NCT03301649|Active Comparator|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
16498624|NCT03301649|Placebo Comparator|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
16498625|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
16498626|NCT03301636|Experimental|Nivolumab + Indoximiod|
16498627|NCT03301623|Experimental|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
16498628|NCT03301623|Experimental|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.
16498629|NCT03301610|Experimental|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
16498630|NCT03301610|Placebo Comparator|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
16498631|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
16498632|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
16498633|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
16498634|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
16498635|NCT03301584|Active Comparator|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.
~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.
~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.
~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.
~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
16498636|NCT03301584|Active Comparator|Usual Care Treatment|Standard rehabilitation
16498637|NCT03301571|Other|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:
~Change in preload and afterload
~Change in inspired oxygen
~Change in pacemaker modes"
16498638|NCT03301558|Active Comparator|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
16498639|NCT03301558|Active Comparator|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
16498673|NCT03301337|Experimental|Beef|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
16498674|NCT03301311|Experimental|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
16498640|NCT03301545|Active Comparator|Fast-Track to Bariatric Surgery|Patients will undergo standard of care for bariatric surgery patients in Manitoba and receive preoperative evaluation by the Centre for Metabolic and Bariatric Surgery (CMBS) team of nurses, dietitians, psychologist, and kinesiologist. Patients must attend the standard appointments and achieve the personalized program goals to be approved for laparoscopic Roux-En-Y gastric bypass surgery. Once approved, one of four surgeons performs surgery (within 12 months of randomization). Patients are followed post-operatively (by surgeon) at 6 weeks, and at 6 and 12 months. Pharmacologic glycemic control will be determined by an endocrinologist as per a standardized post-operative protocol. Post-procedural multidisciplinary follow-up occurs based on established CMBS guidelines (phone call 1 week post-operatively and an appointment at 3 and 12 months). Patients receive surgery within the current publically funded bariatric surgery program; no additional direct costs incurred by the patients.
16498641|NCT03301545|No Intervention|Best Diabetic Care Group|Patients will receive the best available medical practice for the treatment, education, and follow-up T2DM based on Manitoba Diabetes Care Recommendations and Diabetes Canada's clinical practice guidelines. Patients will have access to a general physician, endocrinologist, and a diabetes education nurse. An Endocrinologist will deliver the program to patients. Diabetes care, education and self-management support services will be provided by the Victoria General Hospital (VGH) Diabetes Education Centre; led by a registered nurse and dietitian. Patients will undergo individual diabetes management instruction which may include counseling on topics such as diet, exercise, smoking cessation, medications, diabetic complications, and blood sugar testing. Medical therapies, including pharmaceutical agents, will be determined on an individual basis as per standard protocol. There will be no direct patient-related medication costs (publicly funded).
16498642|NCT03301545|No Intervention|Retrospective Cohort|A retrospective cohort of non-Indigenous bariatric surgery patients from the Centre for Metabolic and Bariatric Surgery Program will allow comparison with the intervention group. The cohort will be age and gender matched.
16498643|NCT03301532|Experimental|Patients on a ketogenic diet|This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
16498646|NCT03301480||No contraception/18-19 years old|
16498647|NCT03301480||Use of ENG-I/18 - 19 years old|
16498648|NCT03301480||LNG-IUS/18-19 years old|
16498649|NCT03301480||No Contraception/ 25 - 45 years old|
16498650|NCT03301480||Use of ENG-I/25 - 45 years old|
16498651|NCT03301480||LNG-IUS/25-45 years old|
16498652|NCT03301467|Experimental|Avacopan|Avacopan (formerly CCX168) 10 mg capsules x 3 administered twice daily during the blinded 26 week blinded treatment period
16498653|NCT03301467|Placebo Comparator|Avacopan Matching Placebo|Matching placebo capsules x 3 administered twice daily during the 26 week blinded treatment period period
16498654|NCT03301454|Experimental|Arm A|Pursuit of chemotherapy.
16498655|NCT03301454|No Intervention|Arm B|Interruption of chemotherapy, best supportive care
16498656|NCT03301441||Migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine (Classification into migraine without or with aura)
16498657|NCT03301441||Non migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine A short questionnaire validating the absence of migraine
16498658|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
16498659|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
16498660|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
16498662|NCT03301402|Active Comparator|Filter|
16498663|NCT03301402|No Intervention|No filter|
16498664|NCT03301389||Control group|
16498665|NCT03301389||Pretreatment group|Patients in pretreatment state
16498666|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
16498667|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
16498668|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
16498669|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
16498670|NCT03301350|Experimental|Neoadjuvant Chemotherapy|"Regimen A (cycles 1-4):
~Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks)
~Regimen B (cycles 5-8):
~Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)
~There is a one week break between the end of cycle 4 and the beginning of cycle 5.
~Regimen C:
~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
16498671|NCT03301337|Experimental|Hydrolyzed meat protein|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
16498672|NCT03301337|Experimental|Minced Meat|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
16498765|NCT03300661|Experimental|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
16498675|NCT03301311|Experimental|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
16498676|NCT03301298|Experimental|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
16498677|NCT03301298|Experimental|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
16498678|NCT03301298|Experimental|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
16498679|NCT03301298|Experimental|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
16498680|NCT03301298|Experimental|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
16498681|NCT03301298|Experimental|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
16498682|NCT03301298|Placebo Comparator|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
16498683|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
16498684|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
16498685|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
16498686|NCT03301259|Experimental|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.
~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
16498687|NCT03301259|Experimental|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
16498688|NCT03301246|Experimental|Artimes Pro Low Profile Dilatation Catheter|Subjects who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional PTCA catheters and stents, according to standard of care will be enrolled in this study.
16498689|NCT03301233|Active Comparator|estradiol valerate|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma). One tablet every 12 hour from 2nd day of the cycle till the day of trigger of ovulation).
16498690|NCT03301233|Experimental|estradiol valerate and sildenafil|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25 mg, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
16498691|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
16498692|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
16498693|NCT03301207|Experimental|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
16498694|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
16498695|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
16498696|NCT03301181|Experimental|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
16498697|NCT03301181|Experimental|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
16498698|NCT03301168|Experimental|BPX-501 T cells and Rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.
~Rimiducid: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment."
16498699|NCT03301155|Experimental|Anaferon for children|"Tablet for oral use. One tablet per intake, once daily (approximately at the same time).
~The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature."
16498700|NCT03301155|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Anaferon for children scheme.
16498701|NCT03301142|Experimental|Device laser|treatment with application of Erbium Laser: YAG 2940nm, SMOOTH mode, one session per month for three months (n=20
16498702|NCT03301142|Active Comparator|kinesiotherapy|with supervision twice a week for three months (n=20)
16498703|NCT03301129|Experimental|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
16498704|NCT03301129|Experimental|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
16498705|NCT03301129|Experimental|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
16498706|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
16498707|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
16498708|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.
~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
16498709|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.
~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
16498710|NCT03301090|Experimental|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
16498711|NCT03301090|Experimental|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
16498712|NCT03301090|Experimental|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
16498713|NCT03301090|Experimental|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
16498714|NCT03301090|Experimental|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
16498715|NCT03301090|Experimental|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
16498716|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
16498717|NCT03301064|Experimental|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
16498718|NCT03301064|Active Comparator|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
16498719|NCT03301051|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
16498720|NCT03301051|Placebo Comparator|Placebo|Single dose - Placebo
16498721|NCT03301038|Experimental|All Subjects|
16498722|NCT03301025|Active Comparator|Pregabalin group|(n=53):
16498723|NCT03301025|Placebo Comparator|placebo group|(n=53):
16498724|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
16498725|NCT03301012|Experimental|Smartphone Addiction Recovery Coach (SARC) - Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-YA mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
16498726|NCT03300999|Experimental|Ginger Tea|"End of the second menstruation cycle - Start of the third menstruation cycle: Subjects will take ginger tea daily, avoid home remedies, refrain from taking pain medications and supplements, and keep track of ginger tea intake by placing a check mark each day in the daily log checklist.
~Start of the third menstruation cycle - End of the third menstruation cycle: Subjects will drink ginger tea daily. Subjects will rate discomfort using the visual analog pain scales and the symptom checklist at the end of each day during menstruation.
~After the third menstruation cycle ends: Subjects will meet with student investigators at a location convenient to the subject to turn in daily logs, visual analog pain scales, and symptom checklists."
16498766|NCT03300648|No Intervention|Unual care|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees
16498793|NCT03300453|Experimental|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
16498727|NCT03300999|No Intervention|No Ginger Tea|"End of the first menstruation cycle - Start of the second menstruation cycle: Subjects will not take ginger tea, avoid home remedies, and refrain from taking pain medications or supplements.
~Start of the second menstruation cycle - End of the second menstruation cycle: Subjects will rate discomfort using the visual analog pain scales and symptom checklist during menstruation. Subjects will meet with student investigators at a convenient location to the subject and will complete surveys and questionnaires. Subjects will be given daily logs, visual analog pain scales, symptom checklists, and supplies for the ginger tea."
16498728|NCT03300986||Functional Electrical Stimulation (FES) users|
16498729|NCT03300973|Active Comparator|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
16498730|NCT03300973|Active Comparator|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
16498731|NCT03300960|Experimental|Provera|
16498732|NCT03300960|Active Comparator|Orgalutrán Ganirelix (GnRH antagonist)|
16498733|NCT03300947|Experimental|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
16498734|NCT03300947|Experimental|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
16498735|NCT03300947|Placebo Comparator|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
16498736|NCT03300934|Experimental|closed loop glucose control system|Closed loop glucose control system
16498737|NCT03300934|No Intervention|CSII Pump treatment|CSII Pump treatment without the integrated algorithm and glucose sensor
16498738|NCT03300921|Experimental|Arm A|Arm A: 50mcg IV weekly
16498739|NCT03300921|Experimental|Arm B|Arm B: 12mcg PO daily
16498740|NCT03300908|Experimental|Project ADHERE|Participants will receive a 3-session antiretroviral medication adherence and risk reduction intervention called Project ADHERE.
16498741|NCT03300908|Active Comparator|Control MACE|Participants will receive a one-session antiretroviral medication adherence intervention called MACE.
16498742|NCT03300895|Experimental|High-intensity interval training|
16498743|NCT03300895|Active Comparator|Moderate-intensity continuous exercise|
16498744|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
16498745|NCT03300856||Chart Review|Existing records of patients within the NINDS database who have had TMS performed to measure central motor conduction time (CMCT).
16498746|NCT03300843|Experimental|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
16498747|NCT03300830||group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease
16498748|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
16498749|NCT03300804|Active Comparator|20-herb formulation|Active herb
16498750|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
16498751|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
16498752|NCT03300778|Experimental|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
16498753|NCT03300778|Placebo Comparator|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
16498754|NCT03300765|Experimental|Apatinib with IMRT|Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)
16498755|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
16498756|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
16498757|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
16498758|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
16498759|NCT03300713|Experimental|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
16498760|NCT03300713|Sham Comparator|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
16498761|NCT03300687|Active Comparator|Active|Subjects will receive FX-322 as an intratympanic injection
16498762|NCT03300687|Placebo Comparator|Placebo|Subjects will receive Placebo as an intratympanic injection
16498763|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
16498764|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
16498767|NCT03300648|Experimental|Mechanical ventilation|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days
16498768|NCT03300648|Experimental|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
16498769|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
16498770|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
16498771|NCT03300609|Experimental|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE:
~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
16498772|NCT03300609|Active Comparator|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE:
~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
16498773|NCT03300596|Experimental|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
16498774|NCT03300596|Other|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
16498775|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
16498776|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
16498777|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
16498778|NCT03300570|Experimental|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
16498779|NCT03300570|Placebo Comparator|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
16498780|NCT03300557|Experimental|Treatment (exemestane)|Patients receive exemestane PO QD over 21-42 days in the absence of disease progression or unaccepted toxicity. Patients undergo standard of care surgery between days 22-43.
16498781|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
16498782|NCT03300531|Experimental|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
16498783|NCT03300531|Experimental|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
16498784|NCT03300531|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
16498785|NCT03300518|Other|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
16498786|NCT03300518|Other|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
16498787|NCT03300505|Experimental|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.
~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
16498788|NCT03300492|Experimental|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days
~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
16498789|NCT03300479|Experimental|Clevidipine|The treatment starts at admission to the ICU for 24 hours with 2 mg to a maximum of 16 mg Clevidipine per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
16498790|NCT03300479|Active Comparator|Urapidil|The treatment starts at admission to the ICU for 24 hours with 5 mg to a maximum of 40 mg Urapidil per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
16498791|NCT03300466|Experimental|GP0045|Treatment with GP0045
16498792|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
16498976|NCT03299140|Other|Family Focused Therapy|Only 1 arm
16498796|NCT03300427|Experimental|sacubitril/valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. Two strengths of sacubitril/valsartan will be available for use after randomization, 49 mg sacubitril/51 mg valsartan and 97 mg sacubitril/103 mg valsartan. After randomization, subjects in this arm will receive sacubitril/valsartan 100 mg orally twice daily (BID). The dose will be then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration is not possible). Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate the 100 mg BID dose at the minimum. In total, participants will be on sacubitril/valsartan for a minimum of 8 weeks and a maximum of 10 weeks.
16498797|NCT03300427|Active Comparator|valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. In this arm, Valsartan 80 mg and 160 mg will be used as comparative drug, taken orally BID at home. Depending on the screening/run-in dose the subjects in this arm will get either valsartan 80 mg BID or valsartan 160 mg BID. During the treatment period the dose of valsartan will be up-titrated to the highest tolerated dose (160 mg BID) or maintained at 80 mg BID if up-titration is not possible. Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate at least 80 mg BID dose of valsartan. The treatment phase will be a minimum of 8 weeks, and a maximum of 10 weeks.
16498798|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
16498799|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
16498800|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
16498801|NCT03300388|Placebo Comparator|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
16498802|NCT03300388|Experimental|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
16498803|NCT03300388|Experimental|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
16498804|NCT03300388|Experimental|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
16498805|NCT03300375|Active Comparator|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
16498806|NCT03300375|Experimental|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
16498807|NCT03300362|Experimental|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1
16498808|NCT03300362|Placebo Comparator|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride
16498809|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
16498810|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
16498811|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
16498812|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
16498813|NCT03300336|Experimental|Intervention|Implementation of STRIDE program
16498814|NCT03300336|No Intervention|Usual Care|Pre-implementation before STRIDE program
16498815|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
16498816|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
16498817|NCT03300310|Experimental|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
16498818|NCT03300310|Experimental|without nursing visit|no nursing visit
16498819|NCT03300297|Active Comparator|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
16498820|NCT03300297|Sham Comparator|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
16498821|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
16498822|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
16498823|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
16498824|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
16498825|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
16498826|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
16498827|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
16498828|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
16498829|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
16498830|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
16498831|NCT03300232|No Intervention|Treatment as Usual|Participants randomized to the treatment as usual control condition will not undergo the CBT therapy.
16498832|NCT03300219|Experimental|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
16498833|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
16498834|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
16498835|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
16498836|NCT03300180|No Intervention|Control|The patients in this group will receive no AD screening
16498837|NCT03300180|Active Comparator|Screening Only|The patients in this group will receive screening for AD. Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic and some information about local clinical resources for them to peruse regarding follow-up care. The patient's PCP is also be notified of the screening results via EHR message.
16498838|NCT03300180|Experimental|Collaborative Dementia Care Program|The patients in this group will receive screening for AD, Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic. Also, the family member will receive two follow-up phone calls. One from the COADS Study Coordinator and one from a care coordinator at the Aging Brain Care Program (ABC). This phone call will include an opportunity for the family to ask questions and a conversation about the program and diagnostic evaluation and management. Dyads have the option to refuse the follow-up visit. The patient's PCP is also be notified of the screening results via EHR message,
16498839|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
16498840|NCT03300154|Experimental|Financial incentives|
16498841|NCT03300154|Experimental|Framing (SMS)|
16498842|NCT03300154|No Intervention|Usual care|
16498843|NCT03300141|Active Comparator|Healthy|Healthy participants will participate in reaching activity using the Looking Glass and Leap motion tracking system
16498844|NCT03300141|Experimental|Chronic Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
16498845|NCT03300141|Experimental|Chronic Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
16498846|NCT03300141|Experimental|Acute Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
16498847|NCT03300141|Experimental|Acute Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
16498848|NCT03300128|Experimental|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
16498849|NCT03300128|Active Comparator|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
16498850|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
16498851|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
16498852|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
16498856|NCT03300050|Experimental|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
16498857|NCT03300050|Experimental|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.
16498858|NCT03300050|Placebo Comparator|Group 3: Placebo|Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.
16498859|NCT03300050|Experimental|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
16498860|NCT03300050|Placebo Comparator|Group 5: Placebo|Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.
16498861|NCT03300024|Active Comparator|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
16498862|NCT03300024|Experimental|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
16498863|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
16498864|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
16498865|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
16498866|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
16498867|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
16498868|NCT03299985|Experimental|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
16498869|NCT03299985|Sham Comparator|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
16498870|NCT03299972|Placebo Comparator|Control|
16498871|NCT03299972|Experimental|Whey Protein|
16498872|NCT03299972|Experimental|Resistance Exercise + Control|
16498873|NCT03299972|Experimental|Resistance Exercise + Whey Protein|
16498874|NCT03299959|Experimental|Agili-C|
16498875|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
16498876|NCT03299946|Experimental|Arm 1|
16498877|NCT03299920|Active Comparator|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
16498878|NCT03299920|Other|Control|Patient will receive conventional instructions on postoperative pain management.
16498879|NCT03299907||COPD|Subject with FEV1/FVC post BD < 0.7 or LLN
16498880|NCT03299907||Non COPD|Subject with FEV1/FVC post BD >= 0.7 or LLN
16498881|NCT03299894|Experimental|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
16498882|NCT03299894|No Intervention|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
16498883|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
16498884|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
16498885|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
16498886|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
16498887|NCT03299842|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
16498888|NCT03299816|Active Comparator|Self-Shopping DASH group (S-DASH)|The Self-Shopping DASH group will receive printed patient-centered materials on the DASH diet and chronic kidney disease. Participants will also receive $30/week allowance for the purchase of food and drinks of their choosing from a local grocer (Klein's ShopRite stores of Maryland) during the first four months. During the remainder of the study (months 5-12), the participants in this group will be asked to continue to follow the dietary advice provided but will not receive the food allowance.
16498889|NCT03299816|Experimental|Coaching DASH group (C-DASH)|The C-DASH group intervention will be a patient-tailored program, delivered by a study coach that is trained by a dietitian, which emphasizes key self-management behaviors - diet and self-monitoring. This group will receive advice from the study coach and purchase $30 worth of fresh fruits, vegetables, nuts and beans that are high in potassium on a weekly basis for the first four months.
16498890|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
16498892|NCT03299790|Active Comparator|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
16498893|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
16498894|NCT03299790|No Intervention|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
16498895|NCT03299790|No Intervention|Healthy controls|
16498896|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
16498897|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
16498898|NCT03299764|Experimental|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
16498899|NCT03299764|Active Comparator|Control|Non-invasive ventilation with standard non-invasive ventilation device
16498900|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
16498901|NCT03299738|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
16498902|NCT03299725|Experimental|Treatment arm|
16498903|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
16498904|NCT03299686|Experimental|CJM112|Study treatment
16498905|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
16498906|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
16498907|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
16498908|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
16498909|NCT03299621|Experimental|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
16498910|NCT03299621|Experimental|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
16498911|NCT03299582|Experimental|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
16498912|NCT03299582|Experimental|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
16498913|NCT03299582|Experimental|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
16498914|NCT03299582|Experimental|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
16498915|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
16498916|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
16498917|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
16498918|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
16498919|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
16498920|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
16498921|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
16498922|NCT03299517|Experimental|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).
~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
16498923|NCT03299517|Experimental|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)
~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
16498924|NCT03299491|Experimental|MWA+IEC intervention|
16498925|NCT03299491|Experimental|IEC intervention|
16498926|NCT03299491|No Intervention|Control|
16498927|NCT03299478||NSCLC patients|
16498928|NCT03299465|Experimental|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
16498929|NCT03299452|Experimental|Alphacait-guided therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
16498930|NCT03299439|Experimental|acupuncture at highly sensitive points|
16498931|NCT03299439|Active Comparator|acupuncture at lowly/non-sensitive points|
16498932|NCT03299439|No Intervention|no acupuncture (waiting-list)|
16498933|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
16498934|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
16498935|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
16499138|NCT03297879|Active Comparator|metformin group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
16498936|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
16498937|NCT03299387|Active Comparator|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
16498938|NCT03299387|Active Comparator|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
16498939|NCT03299374|Active Comparator|Falls Group|Falls prevention intervention
16498940|NCT03299374|Experimental|Pilates Group|Pilates intervention
16498941|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
16498942|NCT03299348|Placebo Comparator|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
16498943|NCT03299335|Other|Early-stage sIMB patients|
16498944|NCT03299335|Other|Late-stage sIMB patients|
16498945|NCT03299335|Other|Control subjects|
16498946|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
16498947|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
16498948|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
16498949|NCT03299309|Experimental|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
16498950|NCT03299296|Experimental|Rivaroxaban arm|Rivaroxaban 10 Milligrams
16498951|NCT03299296|Active Comparator|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
16498952|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
16498953|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
16498954|NCT03299270||Group 1|Elderly patiences with solid malignancy
16498955|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
16498956|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
16498957|NCT03299244|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
16498958|NCT03299244|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
16498959|NCT03299231|Active Comparator|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
16498960|NCT03299231|Sham Comparator|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
16498961|NCT03299218|No Intervention|Control|Receiving current Government of Punjab health services
16498962|NCT03299218|Experimental|Cash-based transfers|Cash-based transfers only by BISP
16498963|NCT03299218|Experimental|Cash with SBCC|Cash-based transfers and Social & behaviour change communication (SBCC)
16498964|NCT03299218|Experimental|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
16498965|NCT03299218|Experimental|Cash,SNF (Wawamum) & SBCC|Cash-based transfers, SNF (Wawamum) and SBCC
16498966|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
16498967|NCT03299192|Experimental|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
16498968|NCT03299192|Active Comparator|Health Education|twice weekly classes for 12 weeks
16498969|NCT03299192|Active Comparator|Usual Medical Care|the usual care to which participants are entitled by their health insurance
16498970|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
16498971|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
16498972|NCT03299166|Experimental|BHV-4157|
16498973|NCT03299166|Placebo Comparator|Placebo|
16498974|NCT03299153|Experimental|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
16498975|NCT03299153|No Intervention|control group|patients in this group received no intervention
16498977|NCT03299127|Experimental|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
16498978|NCT03299127|No Intervention|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
16498979|NCT03299114|Active Comparator|Intervention Group|Treated with warm whirlpool
16498980|NCT03299114|Placebo Comparator|Placebo group|Treated with sham whirlpool
16498981|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
16498982|NCT03299088|Experimental|Arm A (trametinib, pembrolizumab)|Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16498983|NCT03299088|Experimental|Arm B (pembrolizumab, trametinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Beginning on day 1 of course 2, patients also receive trametinib PO daily. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16498984|NCT03299062|Active Comparator|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
16498985|NCT03299062|Active Comparator|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
16498986|NCT03299062|Placebo Comparator|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
16498987|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
16498988|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
16498989|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
16498990|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
16498991|NCT03299036|Experimental|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
16498992|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
16498993|NCT03298997|Experimental|Ligation and Hemorrhoidopexy|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Introduction of a proctoscope. Identification of the hemorrhoidal nodules (3rd, 7th, 11th hour). Confirmation of the hemorrhoidal artery location, through palpation. Ligation of the hemorrhoidal nodules using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).
~Placement of a fixative suture in the hemorrhoidal nodule and then performance of hemorrhoidopexy Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to pudendal nerve block. Using an atraumatic 25 Gauge (G) needle, a 20ml lidocaine solution (diluted with saline in a 1:1 rate) will be administered bilaterally, medially to the ischial tuberosity.
~10 minutes before the operation, the patient will receive 1-2.5mg midazolam and 0.1-0.2 mg fentanyl."
16498994|NCT03298997|Active Comparator|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Use of a proctoscope combined with a Doppler sensor. After the hemorrhoidal artery localization, Z ligations will be placed, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).
~The proper artery ligation will be confirmed by the absence of the Doppler signal.
~In the presence of residual hemorrhoidal tissue hemorrhoidopexy will be performed, by applying a continuous suture.
~Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to spinal anesthesia. Using an atraumatic 25 Gauge (G) needle, a levobupivacaine 5mg/ml and fentanyl 25mg solution, will be administered at the height of lumbar (L)2-L3 or L3-L4."
16498995|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
16498996|NCT03298971||Survivors of Childhood Osteosarcoma|Survivors of Childhood Osteosarcoma were invited to fill in a set of questionnaires.
16498997|NCT03298971||Healthy Subjects|Healthy Subjects were invited to fill in a set of questionnaires.
16498998|NCT03298958|Placebo Comparator|Placebo Oral Tablet|Subject will be randomized to take the Placebo once daily for 2 years or until disease recurrence
16498999|NCT03298958|Active Comparator|Sirolimus (Rapamycin) 0.5 mg/day for 2 years|Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence
16499002|NCT03298919|Experimental|Exercise Videogames|Exercise videogames 3 times weekly for 12 weeks followed by 6 months of home practice
16499003|NCT03298919|Active Comparator|Standard Exercise|Exercise using aerobic equipment such as stationary bikes and treadmills 3 times weekly for 12 weeks followed by home practice
16499004|NCT03298919|No Intervention|Wellness Control|Weekly mailings on general health and wellness topics for 12 weeks followed by monthly mailings for 6 months.
16499005|NCT03298906|Experimental|Esketamine + Ticlopidine|Participants will self-administer one 14 milligram (mg) spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg (Treatment A) in Treatment Period 1. After that participants will receive 250 mg of ticlopidine tablets orally twice daily on Day -9 through Day 1, and will self-administer one 14 mg spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later in the morning of Day 1, a total dose of 56 mg (Treatment B) in Treatment Period 2. A washout period of greater than or equal to (>=)10 days will separate the esketamine self-administrations between 2 treatment periods.
16499006|NCT03298893|Experimental|Nivolumab + radiochemotherapy|5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone
16499007|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
16499008|NCT03298867|Active Comparator|Teprotumumab 20 mg/kg|Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
16499009|NCT03298867|Placebo Comparator|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
16499010|NCT03298828|Experimental|CD19 CAR|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR T-cells.
16499011|NCT03298828|Experimental|CD19 CAR and PD-1 knock out|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR and PD-1 knock out engineered T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR and PD-1 knock out engineered T-cells.
16499012|NCT03298815|Active Comparator|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
16499013|NCT03298815|Placebo Comparator|Saline Solution - All participants, One eye|
16499014|NCT03298802|Active Comparator|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
16499015|NCT03298802|Placebo Comparator|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
16499016|NCT03298789|Experimental|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
16499017|NCT03298789|Other|Control|7 series of static stretching will be conducted in the control condition.
16499018|NCT03298776|Active Comparator|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
16499019|NCT03298776|Experimental|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
16499020|NCT03298763|Experimental|Phase 1 - RP2D finding study|Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients
16499021|NCT03298763|Active Comparator|Phase 2 Intervention Arm|"Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.
~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
16499022|NCT03298763|Placebo Comparator|Phase 2 Control Arm|"cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.
~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
16499023|NCT03298750|Experimental|Mechanical stimulation|Mechanical stimulation of ovarian tissue
16499024|NCT03298737||Correct to normal vision population|
16499025|NCT03298724|Experimental|TAPP Intervention|The Teachers and Partners intervention will be provided
16499026|NCT03298698|Experimental|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
16499027|NCT03298698|Active Comparator|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
16499028|NCT03298685||CF patient and parents cohort in 3 CF center|All adolescents for whom the transition to the adult center is scheduled within six months and their parent will be interviewed before and after transition.
16499029|NCT03298672|Experimental|NDX-1017|NDX-1017 will be administered via subcutaneous injection
16499030|NCT03298672|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection
16499031|NCT03298659|Experimental|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
16499032|NCT03298659|Active Comparator|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
16499033|NCT03298646|Experimental|Lidacaine hydrochloride|"Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.
~22 women."
16499034|NCT03298646|Active Comparator|Diclofenac|"100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.
~22 women."
16499035|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
16499139|NCT03297866||Incentive schemes 1|No incentive will be given after completing the follow-up survey
16499140|NCT03297866||Incentive schemes 2|Receiving $100 supermarket coupon after completing the follow-up survey
16499036|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
16499037|NCT03298620|Experimental|Intervention|Electric toothbrush
16499038|NCT03298620|Active Comparator|Control|New standard manual toothbrush
16499039|NCT03298607|Placebo Comparator|Placebo|2 capsules daily for 2 months containing inactive substances
16499040|NCT03298607|Active Comparator|Serelys PMS|2 capsules daily for 2 months containing pollen extract
16499041|NCT03298594|Experimental|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
16499042|NCT03298594|No Intervention|Usual cervicograph|The usual cervicograph in our unit is not having lines
16499043|NCT03298581|Experimental|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
16499044|NCT03298568|Experimental|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
16499045|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
16499046|NCT03298555|No Intervention|Control|This group will only receive standard care.
16499047|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
16499048|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
16499049|NCT03298529|Experimental|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
16499050|NCT03298529|Experimental|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
16499051|NCT03298529|Experimental|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
16499052|NCT03298529|Experimental|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
16499053|NCT03298529|Experimental|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
16499054|NCT03298516|Experimental|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
16499055|NCT03298516|Experimental|Arm B: DCLL9718S and Azacitidine|Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
16499056|NCT03298503|Active Comparator|early stage or non-freezers PD|"early stage defined as modified Hoehn and Yahr scale 1, 1.5 and 2, means that symptoms involved unilateral or bilateral without impairment of balance.
~non-freezers defined as without freezing of gait, means that patients without transient inability to generate effective stepping."
16499057|NCT03298503|Experimental|moderate stage or freezers PD|"moderate stage defined as modified Hoehn and Yahr scale 2.5 and 3, means that symptoms involved unilateral or bilateral without impairment of balance.
~freezers defined as with freezing of gait, means that patients have transient inability to generate effective stepping."
16499058|NCT03298477|Other|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
16499059|NCT03298464|Experimental|NGM313|
16499060|NCT03298464|Active Comparator|Pioglitazone|
16499065|NCT03298425|Active Comparator|Treatment NMES|Patients allocated to the NMES group will be given an information booklet on NMES machines. The Cefar Compex three electrical stimulator will be used. Participants are expected to use the NMES machine for half an hour and complete bed exercises twice daily. Patients should relax during the NMES as completing both does not demonstrate better results, due to unsynchronised activation of the NMES (Gregory & Bickel, 2005). Using the machine once daily will allow for the recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
16499141|NCT03297866||Incentive schemes 3|Receiving $200 supermarket coupon after completing the follow-up survey
16499421|NCT03295942|Experimental|OMP-336B11|Intravenous (in the vein) infusions of OMP-336B11
16499066|NCT03298425|Placebo Comparator|Placebo NMES|The placebo group will act as the control group. They will be expected to complete the same regime as previously described above, however these machines will be on TENS setting (80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is designed as a sensory stimulus therefore will have no effects on muscle strength however the patient will feel a small twitch sensation. This setting is not painful and will have no effect on muscle fatigue. The patient will not be expected to complete the bed exercises and the TENS session together.
16499067|NCT03298412|Experimental|Blinatumomab|"After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1).
~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval."
16499068|NCT03298399|Experimental|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
16499069|NCT03298399|Experimental|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
16499070|NCT03298399|Experimental|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
16499071|NCT03298386|Experimental|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
16499072|NCT03298386|No Intervention|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
16499073|NCT03298373|Placebo Comparator|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
16499074|NCT03298373|Experimental|11β-MNTDC|11β-MNTDC capsules administered orally (200 mg or 400 mg).
16499075|NCT03298347|Experimental|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP.
16499076|NCT03298347|Active Comparator|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP.
16499077|NCT03298334|Active Comparator|Receives Vaginal Seeding|
16499078|NCT03298334|Sham Comparator|No Vaginal Seeding|
16499079|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
16499080|NCT03298308|Experimental|Brainwave|Brainwave analysis after cranial electric stimulation
16499081|NCT03298295|Experimental|Insertion of Insulin Infusion Catheters|Non-diabetic patients scheduled for abdominoplasty will be inserted continuous subcutaneous insulin infusion (CSII) catheters of two different materials into the part of the abdomen which will be removed during surgery.
16499082|NCT03298282||Imaging Registry|Imaging cohort: Patients with intermediate lesions
16499083|NCT03298269|Experimental|Mindfulness-Oriented Recovery Enhancement|
16499084|NCT03298269|Active Comparator|Supportive Counseling|
16499085|NCT03298256||Lenke type 1 AIS|Patients will be given a new prescription for a custom made Boston type thoracic-lumbo- sacral-orthosis (TLSO) braces. All patients will undergo low dose biplanar X-rays using the EOS ® machine system.
16499086|NCT03298243|Experimental|Stroke Cohort - Optimize Delivery|Aim 1 intervention: Vibrotactile stimulation. An optimal location and style of vibrotactile feedback for reach and stabilization behaviors will be determined.
16499087|NCT03298243|Experimental|Stroke Cohort - Extended Training|Aim2 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching and stabilizing tasks using vibrotactile feedback to guide performance
16499088|NCT03298230|Experimental|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
16499089|NCT03298230|Active Comparator|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
16499090|NCT03298217|Other|Bronchiolitis patients sverity|In patients with bronchiolitis mWCAS / 3-5 : Measurement of the peak tidal inspiratory flow (PTIF)
16499091|NCT03298204||Chemoradiotherapy|
16499092|NCT03298204||Chemoradiotherapy following chemotherapy|
16499093|NCT03298204||Chemoradiotherapy followed by chemotherapy|
16499094|NCT03298191|Experimental|Magnesium sulphate|
16499095|NCT03298191|Experimental|Ritodrine|
16499096|NCT03298191|Experimental|Calcium channel blocker|
16499097|NCT03298178||all aortic stenosis|
16499098|NCT03298165|Experimental|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
16499099|NCT03298165|Placebo Comparator|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
16499100|NCT03298152|Active Comparator|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
16499101|NCT03298152|Experimental|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
16499102|NCT03298139|Experimental|parabolic flights|parabolic flights in normogravity (1g), hypergravity (1.8g) and microgravity (0g).
16499142|NCT03297866||Incentive schemes 4|Receiving $100 supermarket coupon before completing the follow-up survey and another $100 supermarket coupon after completing the follow-up survey
16499314|NCT03296696|Experimental|Dose exploration|Dose exploration of the intervention, AMG 596 alone or in combination with AMG 404
16499103|NCT03298126|Active Comparator|TR BAND Protocol A|In this group, air removal from TR band was initiated after 2 hours of TR band application. 3 ml of air was removed periodically at an interval of 15 minutes until all the air is eliminated from the band. In case of bleeding or hematoma while deflating air, 4 ml of air was re-injected and observed for 30 minutes until next attempt was made to deflate the band. The data including the attempts made at deflating TR band, time and amount of air injected along with the response to each deflation i.e. occurrence of bleeding or hematoma was noted down in the proforma
16499104|NCT03298126|Active Comparator|TR BAND PROTOCOL B|In this group deflation was initiated after 2 hours of TR band application as described by Cohen and Alfonso. [6] 5 ml of air was deflated at first attempt. Next attempt was carried out after 15 minutes in which further 5 ml was removed. After 15 minutes, the remaining 2 ml of air was released from the band. In case of bleeding or hematoma at any attempt, 6 ml air was re-injected and interval for 15 minutes taken to attempt further air deflation. All the attempts and its response were recorded in the proforma filled out by the assessor.
16499105|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
16499106|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
16499107|NCT03298100||Postmenopausal women|
16499108|NCT03298087|Experimental|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
16499109|NCT03298074|Experimental|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
16499110|NCT03298074|Active Comparator|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
16499111|NCT03298061|Experimental|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
16499112|NCT03298048|Active Comparator|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
16499113|NCT03298048|Active Comparator|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
16499114|NCT03298048|Active Comparator|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
16499115|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
16499116|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
16499117|NCT03298022|Experimental|AbGn-168H|intravenous doses of AbGn-168H
16499118|NCT03298009|Placebo Comparator|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
16499119|NCT03298009|Experimental|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
16499120|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
16499121|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
16499122|NCT03297983|Experimental|First M7583 Tablet:Fasted, Then PiC:Fasted, Then Tablet:Fed|
16499123|NCT03297983|Experimental|First M7583 PiC:Fasted, Then Tablet:Fasted, Then Tablet:Fed|
16499124|NCT03297970||Bogota School Children Cohort|"Children are classified according to exposure levels of:
~Micronutrient biomarker indicators:
~Ferritin
~Hemoglobin
~Mean corpuscular volume
~Zinc
~Vitamin A
~Vitamin B12
~Folate
~Vitamin D
~Serum fatty acids
~Inflammatory biomarkers:
~C-reactive protein
~Diet
~Socioeconomic status indicators
~Anthropometric indicators
~Incidence of infectious morbidity symptoms
~DNA biomarkers"
16499125|NCT03297957|Experimental|Arm 1: Goggle Imaging|-Patient will then be taken to the operating room for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room. Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce. Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this). The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization. After this is performed, the goggle system will be removed and the procedure will be completed per normal.
16499126|NCT03297944|Experimental|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
16499127|NCT03297931|Active Comparator|Commercial corn chips + Onion dip|Corn chips + onion dip
16499128|NCT03297931|Experimental|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
16499129|NCT03297931|Experimental|Novel pulse chip + pulse spread|Yellow pea chip + hummus
16499130|NCT03297931|Experimental|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
16499131|NCT03297931|Experimental|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
16499132|NCT03297931|Experimental|Non-pulse chip + pulse spread|Corn chips + hummus
16499133|NCT03297918|Active Comparator|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
16499134|NCT03297918|No Intervention|Control group|no intervention
16499135|NCT03297905|Experimental|Complementary and Integrative Therapies|Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
16499136|NCT03297905|Active Comparator|Standard Rehabilitative Care|Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
16499137|NCT03297879|Experimental|exenatide group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
16500432|NCT03288623|Experimental|Dark Chocolate|Dark chocolate (85% cocoa) 40 mg per day for 30 days
16499143|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
16499144|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
16499145|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
16499146|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
16499147|NCT03297814|Active Comparator|Platelet lysate|A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval
16499148|NCT03297814|Placebo Comparator|placebo|A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval
16499149|NCT03297801||Fish oil group|Women who chose to supplement with fish oil, rich in omega-3 polyunsaturated fatty acids, during gestation or lactation.
16499150|NCT03297801||No fish oil group|Women who chose not to supplement with fish oil during gestation or lactation.
16499151|NCT03297788|Experimental|Arm A: SRS|Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases
16499152|NCT03297788|Active Comparator|Arm B: WBRT|Patients receive whole brain radiotherapy (WBRT)
16499153|NCT03297775||Evidence of interstitial lung disease|"Subjects who screen positive for ILD will be followed annually until study closure.
~Assessments are as follows:
~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic - Assessment for airways disease, interstitial lung abnormalities
~Genetic - DNA, RNA
~Biologic - Serum, Plasma, Sputum"
16499154|NCT03297775||No evidence of interstitial lung disease|"Subjects who screen negative for ILD will be followed five years after the initial screen and re-screened with a chest CT scan to check for evidence of new lung disease.
~Assessments are as follows:
~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic - Assessment for airways disease, interstitial lung abnormalities
~Genetic - DNA, RNA
~Biologic - Serum, Plasma, Sputum"
16499155|NCT03297762|Experimental|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
16499156|NCT03297762|Active Comparator|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
16499157|NCT03297736|Active Comparator|Control|Subjects receive the control device.
16499158|NCT03297736|Experimental|Investigational device|Subject receives the 3D CAD/CAM autograft prosthesis implant.
16499159|NCT03297723||Experimental arm|The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.
16499160|NCT03297723||Controle arm|The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.
16499161|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
16499162|NCT03297697||Arm 1: Lymphotrack|-Patients will be treated with frontline chemotherapy per the treating physician's discretion. Collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay. The results of these studies will be performed in batches and therefore will not be available to patients and clinicians to make clinical decisions.
16499163|NCT03297671||Pregnant Women|2000 pregnant women from the communities in the catchment area of THQ Johi and DHQ Dadu. Rh negative women will receive two RhIg prophylaxis injections.
16499164|NCT03297671||Lady Health Visitors (LHVs)|3-5 LHVs who are full time employees at THQ Johi and DHQ Dadu. LHVs will perform ELDONCARD test and provide RhIg prophylaxis injections.
16499165|NCT03297658|Active Comparator|electro-acupuncture (EA) intervention|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects will receive electro-acupuncture (EA) (treatment) mixed frequency( continuous plus dense disperse) will be at 2Hz and 100 Hz the amplitude will be 1000 microA.
16499166|NCT03297658|Sham Comparator|sham electro acupuncture|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
16499167|NCT03297645|Experimental|Arm 1|school + asthma education + home environment remediation
16499168|NCT03297645|Experimental|Arm 2|asthma education + home environment remediation
16499169|NCT03297645|Active Comparator|Arm 3|enhanced standard of care
16499170|NCT03297632|Experimental|Intervention Group|Receives instructor-based functional resistance exercise. 45 minutes per session. 3 times per week, during 10 weeks in total.
16499171|NCT03297632|No Intervention|Control group|Asked to normally active according to their current lifestyle
16499172|NCT03297632|Active Comparator|Home-based group|Receives home-based exercises with written instructions and digital video support. 45 minutes per session. 3 times per week, during 10 weeks in total.
16499315|NCT03296696|Experimental|Dose expansion|Dose expansion of the intervention, AMG 596 alone or in combination with AMG 404
16499173|NCT03297619|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
16499174|NCT03297619|Active Comparator|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
16499175|NCT03297606|Experimental|Group 1|VEGFR1, VEGFR2, VEGFR3
16499176|NCT03297606|Experimental|Group 2|BCR-ABL, SRC
16499177|NCT03297606|Experimental|Group 3|ALK, ROS1, MET
16499178|NCT03297606|Experimental|Group 4|KIT, PDGFRA, PDGFRB, ABL1
16499179|NCT03297606|Experimental|Group 5|EGFR
16499180|NCT03297606|Experimental|Group 6|high mutation burden, POLE, POLD1
16499181|NCT03297606|Experimental|Group 7|BRCA1, BRCA2, mutations in HRD
16499182|NCT03297606|Experimental|Group 8|CDKN2A, CDK4, CCND1, SMARCA4
16499183|NCT03297606|Experimental|Group 9|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
16499184|NCT03297606|Experimental|Group 10|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
16499185|NCT03297606|Experimental|Group 11|ERBB2
16499186|NCT03297606|Experimental|Group 12|BRAFV600
16499187|NCT03297606|Experimental|Group 13|PTCH1, SMO
16499188|NCT03297593|Experimental|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).
~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
16499189|NCT03297567|Experimental|verbal guidance and booklet|verbal guidance and a booklet on the importance and benefits of movement during hospital stay, as well as what the patients should do to increase the level of physical activity.
16499190|NCT03297567|No Intervention|No Intervention|The control group will not receive any type of intervention
16499191|NCT03297554|Experimental|m-health approach|See intervention description
16499192|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
16499193|NCT03297528|Experimental|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
16499194|NCT03297528|No Intervention|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
16499195|NCT03297515|Experimental|Omega 3 fatty acids|Omega 3 fatty acids
16499196|NCT03297515|Placebo Comparator|Placebo|Placebo (sunflower oil)
16499197|NCT03297502|Experimental|Pimecrolimus cream, 1%|
16499198|NCT03297502|Active Comparator|Elidel (pimecrolimus) cream 1%|
16499199|NCT03297502|Placebo Comparator|placebo|
16499200|NCT03297489|Experimental|Diagnostic (intravital microscopy)|Patients receive fluorescein sodium injection IV. Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery.
16499201|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
16499202|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
16499203|NCT03297463|Experimental|Phase Ib (Dose Escalation)|
16499204|NCT03297463|Experimental|Phase II (Dose Expansion)|
16499205|NCT03297450|Active Comparator|Aphasia therapy and tDCS|
16499206|NCT03297450|Sham Comparator|Aphasia therapy and sham-tDCS|
16499207|NCT03297450|Sham Comparator|Standard of care and sham-tDCS|
16499208|NCT03297424|Experimental|PLX2853|"Phase 1b (Dose Escalation): Approximately 45 subjects with advanced malignancies to establish the MTD/RP2D. Up to 6 additional subjects may be enrolled at the MTD/RP2D as a dose confirmation.
~Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL."
16499209|NCT03297411|Active Comparator|Brief Temporoparietal ECT|Brief Pulse Temporoparietal ECT
16499210|NCT03297411|Active Comparator|Ultrabrief Temporoparietal ECT|Ultrabrief Pulse Temporoparietal ECT
16499211|NCT03297411|Active Comparator|Brief Frontoparietal ECT|Brief Pulse Frontoparietal ECT
16499212|NCT03297411|Active Comparator|Ultrabrief Frontoparietal ECT|Ultrabrief Pulse Frontoparietal ECT
16499213|NCT03297398|Placebo Comparator|Other|Placebo Group
16499214|NCT03297398|Experimental|Drug Group 1|15mg, OPK-88004
16499215|NCT03297398|Experimental|Drug Group 2|25,mg OPK-88004
16499216|NCT03297385|Experimental|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.
~After 3 months they will have a prostatectomy."
16499217|NCT03297372|Experimental|IOL Implantation experimental|Implantation of Micropure 1.2.3. in one of the eyes of the study subject
16499218|NCT03297359|Experimental|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.
~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)
~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
16499246|NCT03297177|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation & concentration in Centricyte 1000 closed system to create AD-cSVF
16500792|NCT03286205|Active Comparator|Weekly Dosage|weekly dose of 100mg
16499219|NCT03297346|Other|Breast cancer patients treated with RT|"Cardiac imaging and circulating biomarkers measurements to evaluate:
~myocardial dysfunction and deformation (ECHO-ST)
~coronary artery lesions and coronary artery calcium score (CT)
~myocardium including tissue abnormalities, cardiac morphology and function (MRI)
~blood-based biomarkers of cardiovascular changes (BLOOD)"
16499220|NCT03297333|Experimental|Resistance training group|Resistance training will consist of a supervised circuit training 3 sessions/week for approximately 45-50 min/session. The circuit will include 7 strength exercises engaging the major muscle groups (leg press, rows, back squats, weighted crunches, deadlifts, bench press, and squat jumps with weights). The participants will perform 3 sets of 10 repetitions with resting periods of 30 seconds between exercises, and 2 minutes between sets. The overall OMNI-Resistance Exercise Scale per set will range between 8-10. Heart rate and exercise energy expenditure during the workout will be monitored. The load will be changed depending on the participants' perception when needed. In addition, the intensity will be monitored assessing Lactate concentrations at baseline and at the end of each session. Circuit will be repeated until meeting the targeted exercise energy expenditure of 450-500 kcal/session.
16499221|NCT03297333|Experimental|Aerobic interval training group|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure. Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity, and the second period the intensity will be reduced for 2 minutes. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion as needed. Heart rate and exercise energy expenditure during the workout will be monitored. Intensity will be monitored assessing Lactate concentrations at the end of each session. Intervals will be repeated until meeting the targeted exercise energy expenditure (450-500 kcal/session).
16499222|NCT03297333|No Intervention|Control group|Participants in the control group will not participate in the training programs.
16499223|NCT03297320|Active Comparator|Team Referrals|In-depth conversations about Goals of Care and ACP (the intervention) will be held for the patients referred to the research team by the three healthcare teams in Internal Medicine at London Health Sciences Centre (University Campus)
16499224|NCT03297320|Active Comparator|Random selection|A random selection of patients (not referred to the research team by the healthcare team) in Internal Medicine at London Health Sciences Centre (University Campus) will be selected to have in-depth conversations about Goals of Care and ACP (the intervention)
16499225|NCT03297307|Experimental|Mother-Child with Intervention|Children will attend presurgical visits with their mother
16499226|NCT03297307|No Intervention|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
16499227|NCT03297294|Experimental|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
16499228|NCT03297294|Placebo Comparator|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
16499229|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
16499230|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
16499231|NCT03297268||Phase 1-Controlled Validation & Study Planning|Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.
16499232|NCT03297268||Phase 2 - In-situ Validation and Ethnographic Analysis|Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.
16499233|NCT03297268||Phase 3 - Intervention with Home-Based Caregivers|Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.
16499234|NCT03297229|Experimental|Peer mentoring|Peers will be patients with hypertension that have already been adequately controlled within the last six months. They will be selected within each center by the staff of the center and invited to participate in the study.
16499235|NCT03297229|Experimental|Self-monitoring|Each participant will receive a blood pressure monitor. The study nurse will teach the participant on how to use the device.
16499236|NCT03297229|No Intervention|Control|Usual care
16499237|NCT03297216|Active Comparator|250 mg 17P|weekly intramuscular injection of 250mg 17P
16499238|NCT03297216|Placebo Comparator|Placebo|weekly intramuscular injection of indistinguishable placebo
16499239|NCT03297203|Experimental|groupe1|patients in septic shock (group 1) in the medical intensive care unit of the Timone Hospital.
16499240|NCT03297203|Active Comparator|groupe 2|patients with a bacterial sepsis alone, during a 6 months period.
16499241|NCT03297190|Active Comparator|SMS|Participants will receive SMS messages on nutrition and health related topics
16499242|NCT03297190|Active Comparator|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
16499243|NCT03297190|Active Comparator|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
16499244|NCT03297190|No Intervention|Usual Care|
16499245|NCT03297177|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF Via Closed Syringe Microcannula
16499247|NCT03297177|Experimental|Sterile Normal Saline Infusion|Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
16499248|NCT03297164||optimized group|the patients in this group have been given the suggestive treatment from guideline.
16499249|NCT03297164||un-optimized group|the patients in this group have not been given the suggestive treatment from guideline.
16499250|NCT03297151|Sham Comparator|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.
~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.
~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
16499251|NCT03297151|Active Comparator|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.
~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
16499252|NCT03297151|Active Comparator|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.
~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
16499253|NCT03297125||Eligible Subjects|All enrolled subjects undergoing Optune therapy.
16499254|NCT03297112|Experimental|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
16499255|NCT03297099|Experimental|Robot-assisted Laparoscopic operation|Da Vinci surgical robot can overcome limitations of conventional laparoscopic surgery in terms of vision and instrumentation flexibility, making the minimally invasive treatment of complex hepatolithiasis possible.
16499256|NCT03297099|Active Comparator|Open surgery|The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
16499257|NCT03297086|Active Comparator|Bi-Flex|Medicontur Bi-Flex 677MY IOL was implanted into 24 eyes of 12 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
16499258|NCT03297086|Active Comparator|ReStor|and Alcon Acrysof Restor SN6AD1 IOL was implanted into 36 eyes of 18 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
16499259|NCT03297073|Experimental|major hepatic surgery|resection greater than or equal to three hepatic segments
16499260|NCT03297073|Experimental|hepatic surgery|resection less than three hepatic segments
16499261|NCT03297073|Experimental|hepatic surgery recovery|
16499262|NCT03297060|Experimental|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
16499263|NCT03297060|No Intervention|Standard Care|Standard Care SBIRT services
16499264|NCT03297047|Active Comparator|upper arm combi cast|standardized treatment
16499265|NCT03297047|Experimental|forearm combi cast|Treatment with a forearm combi cast should be a sufficient immobilization
16499266|NCT03297021|Placebo Comparator|Ondansetron 4mg Pre-emergence|
16499267|NCT03297021|Experimental|Ondansetron 8mg Pre-emergence|
16499268|NCT03297021|Experimental|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
16499269|NCT03296995|Experimental|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
16499270|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
16499271|NCT03296969|Active Comparator|rectus muscle approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
16499272|NCT03296969|Active Comparator|rectus muscle non approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
16499273|NCT03296956|Active Comparator|Day-5 postpartum - Active dietary supplement|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.
~Intervention: Full dose dietary supplement Motherwell"
16499274|NCT03296956|Placebo Comparator|Day-5 postpartum - Placebo|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.
~Intervention: Placebo"
16499275|NCT03296943|Experimental|Essential oil|Essential oil is prepared from the product of Thailada with manufacture standard ID 1087/2548 by Thailand Ministry of Industry. Essential oil is extracted by a cold compressed method from the lavandula angustifolia (lavender) grown in Australia.
16499276|NCT03296943|Sham Comparator|Perfume|Perfume is the synthetic perfume of lavender flavor without essential oil.
16499279|NCT03296917|Experimental|IMP - PrEP-001|"In Viral Challenge arm cohort:
~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).
~In the Safety arm's first dose cohort:
~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).
~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:
~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
16499280|NCT03296917|Placebo Comparator|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:
~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
16499281|NCT03296904|Experimental|CLs++|Baseline assessment, intervention, final assessment
16499282|NCT03296891|Active Comparator|PoCUS Guided Resuscitation of Shock|Participants randomized to this arm of the study will undergo PoCUS guided resuscitation of shock.
16499283|NCT03296891|No Intervention|Usual Care|Participants randomized to the 'usual care' arm of the study will be suggested to have the following guide resuscitation: 1) Pulse pressure variation (PPV), stroke volume variation (SVV) and/or systolic pressure variation (SPV) on their arterial line, 2) central venous pressure (CVP) and oxygen saturation(ScvO2) measurement, 3) Passive leg raise (PLR) maneuver, and/or 4) pulmonary artery catheter
16499284|NCT03296878|Other|Own-Price Elasticity|"The price of eggs will vary (own-price elasticity) while the price of other foods in the mock grocery store will remain constant."
16499285|NCT03296878|Other|Cross-Price Elasticity|"The eggs will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
16499286|NCT03296865|No Intervention|Without taping|Evaluations without taping
16499287|NCT03296865|Experimental|Kinesio taping|Kinesio taping was apllied only one time. It was removed after intervention.
16499288|NCT03296865|Placebo Comparator|Placebo|Placebo was apllied only one time. It was removed after intervention.
16499289|NCT03296852|Experimental|Healthy Volunteers|
16499290|NCT03296826||BRCA1/2 variant carriers|Japanese women who carry BRCA 1/2 variants.
16499291|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
16499292|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:
~1 mg oral torsemide = 2-4 mg oral furosemide
~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
16499293|NCT03296800|Experimental|Bexagliflozin/probenecid|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
16499294|NCT03296800|Experimental|Bexagliflozin/rifampin|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
16499295|NCT03296800|Experimental|Bexagliflozin/verapamil|Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
16499296|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
16499297|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
16499298|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
16499299|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
16499300|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
16499301|NCT03296774|Placebo Comparator|Usual Care|Usual postpartum care
16499302|NCT03296774|Experimental|Healthy Beyond Pregnancy|Web-based program for postpartum care and education and scheduling. Incentive for committing and returning for postpartum care.
16499303|NCT03296761||ESM-1<5ng/ml|
16499304|NCT03296761||ESM-1≥5ng/ml|
16499305|NCT03296748|Active Comparator|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
16499306|NCT03296748|Active Comparator|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
16499307|NCT03296735|Experimental|Ipsilateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
16499308|NCT03296735|No Intervention|Supine|Measuring the cross-sectional area of right subclavian vein in supine position.
16499309|NCT03296735|Active Comparator|Contralateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
16499310|NCT03296722|No Intervention|Control group|The control group comprised 41 patients, which was to go once a month to receive nutritional intervention with the prescription of a hypocaloric diet on the part of the nutritionist. The control group had a monthly monitoring for 3 months.
16499311|NCT03296722|Experimental|Intervention group|The intervention group made up of 42 patients using the transtheoretical model and MI through sessions group and sessions individual with topics of healthy eating habits taught by a nutritionist, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy and confrontation of barriers given by a psychologist. The intervention group had a monthly monitoring for 3 months. The diet that was prescribed to the intervention group was with the characteristics of the DASH diet.
16499312|NCT03296709|Active Comparator|PPC m|
16499316|NCT03296683|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
16499317|NCT03296670|Experimental|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
16499318|NCT03296670|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
16499319|NCT03296657|Experimental|stannous fluoride toothpaste|0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
16499320|NCT03296644|Active Comparator|PowerScope2 group (G1)|Class II correction using PowerScope2
16499321|NCT03296644|Active Comparator|Forsus group (G2)|Class II correction using Forsus
16499322|NCT03296631||children|"Enrollment of 15 to 20 children (< 9 months old) at the early beginning of their entry in nursery (crèche) between August and November 2017.
~This cohort will be followed during a maximum period of 36 months . Diapers with fresh stools will be collected once a week per child and then frozen.
~Spontaneous personal day care informations given by the parents to the nurses and recorded in each child's daily logbook will be collected for the research. No specific interviews will be conducted."
16499323|NCT03296618|Experimental|NSI-566 neural stem cell implantation|
16499324|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
16499325|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
16499326|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.
~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI
~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.
~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment
~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.
~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
16499327|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
16499328|NCT03296579|Active Comparator|Conventional asthma therapy.|Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
16499329|NCT03296579|Experimental|Non-invasive ventilation (CPAP).|Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
16499330|NCT03296579|Experimental|Non-invasive ventilation (BiPAP)|Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
16499331|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
16499332|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
16499333|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
16499334|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
16499335|NCT03296540|Active Comparator|Uncrushed|6 Integral tablets Prasugrel as loading dose
16499336|NCT03296540|Experimental|Crushed|6 Crushed tablets Prasugrel as loading dose
16499337|NCT03296527|Experimental|Follitropin delta|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
16499338|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
16499339|NCT03296514|No Intervention|Wait List Control|Will receive voucher for MBSR after study is concluded
16499340|NCT03296514|Other|Intervention|These people will receive the MBSR
16499341|NCT03296501|Experimental|Autologous ADRC injection|
16499342|NCT03296488|Experimental|Nalbuphine Sebacate|receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.
16499343|NCT03296488|Active Comparator|Fentanyl Citrate|receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
16499344|NCT03296475|Experimental|Midline Ventral Hernia|"Main inclusion criteria:
~Patients with midline hernia defects.
~Patients with either a maximal ventral hernia axial width of greater than 5cm or a loss of domain of greater then 20%.
~Patients aged ≥ 18 years old.
~Midline hernias closed in the midline with primary fascial closure with or without mesh augmentation.
~Midline ventral hernias of VHWG grade 2 or 3."
16499345|NCT03296462|Experimental|Hip external rotation exercise (alone)|Standardised hip external rotation exercise training - over 12 week period
16499346|NCT03296462|Experimental|Hip external rotation + PFM exercises|Standardised hip external rotation plus pelvic floor muscle exercises - over 12 week period
16499347|NCT03296462|Active Comparator|pelvic floor muscle exercises (alone)|Standardised pelvic floor muscle exercises - over 12 week period (usual care)
16499348|NCT03296449|No Intervention|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
16499420|NCT03295955|No Intervention|No postop antibiotics|Do not prescribe Amoxicillin Clavulanate
16499349|NCT03296449|Active Comparator|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
16499350|NCT03296449|Experimental|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
16499351|NCT03296436|Experimental|Treatment Group|Group that will be receiving the investigational product
16499352|NCT03296423|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
16499353|NCT03296423|Active Comparator|Vaccination|One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)
16499354|NCT03296410|Experimental|EV71 and two measles attenuated live vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and two measles attenuated live vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
16499355|NCT03296410|Experimental|EV71 and attenuated Japanese encephalitis vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and live attenuated Japanese encephalitis vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
16499356|NCT03296410|Active Comparator|two measles attenuated live vaccine|infants vaccinated with two measles attenuated live vaccine at 8 months old
16499357|NCT03296410|Active Comparator|live attenuated Japanese encephalitis vaccine|infants vaccinated with live attenuated Japanese encephalitis vaccine at 8 months old
16499358|NCT03296410|Active Comparator|EV71 vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
16499359|NCT03296397|Active Comparator|HPV Quadrivalent vaccine (QHV)|Gardasil
16499360|NCT03296397|Placebo Comparator|Placebo|Normal Saline
16499361|NCT03296384|Other|Patients with schizophrenia|
16499362|NCT03296384|Other|Relatives|
16499363|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
16499364|NCT03296358|No Intervention|Control group|Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
16499365|NCT03296358|Experimental|Experiment 1|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
16499366|NCT03296358|Experimental|Experiment 2|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
16499367|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment was to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores were collected using the FACES scale currently in place. In consenting patients, chart review was performed with the following data collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, and whether or not the patient was discharged.
~In addition, a survey, which is attached, was given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
16499368|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up three patient encounters within the prior year were compared to their visit in which they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients acted as their own controls in the above manner. Patients were allowed to re-enroll 4 weeks after presentation, which is typically considered a separate vaso-occlusive episode in the literature."
16499369|NCT03296319|Active Comparator|echocardiography guided fluid resuscitation|
16499370|NCT03296319|Experimental|clinically guided fluid resuscitation|
16499371|NCT03296306|Active Comparator|6 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional two to four cycles of chemotherapy (totally six cycles)
16499372|NCT03296306|Experimental|4 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional zero to two cycles of chemotherapy (totally four cycles)
16499373|NCT03296293|Other|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
16499374|NCT03296293|Other|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg
16499375|NCT03296293|Other|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD>6mmHg
16499376|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
16499377|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
16499378|NCT03296267|Other|gastroduodenoscopy|all participants undergo a gastroduodenoscopy to use the biopsies in an Ussing chamber experiment.
16499379|NCT03296254|Experimental|Course A|Body Mindfulness Exercised followed by Sitting Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
16499380|NCT03296254|Experimental|Course B|Sitting Mindfulness Exercises followed by Body Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
16499381|NCT03296241|Experimental|Laser|One session of non-ablative Er:YAG laser (2940 nm) treatment of the vaginal wall, introitus and vestibule.
16499382|NCT03296241|Sham Comparator|Sham control|The sham control group was treated with the same procedure but with zero intensity settings - without receiving therapeutic irradiation (placebo).
16499383|NCT03296228||Hong Kong|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)
~supine side-bending and fulcrum bending films"
16499384|NCT03296228||Turkey|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)
~Radiation: Flexibility Radiographs (awake traction)
~Radiation: Flexibility Radiographs (STUGA)
~supine side-bending, fulcrum bending films, awake traction and supine traction under GA"
16499385|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
16499386|NCT03296202||HIV patients|4500 patients infected with HIV-1
16499387|NCT03296189|Active Comparator|Local anaesthetic|Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
16499388|NCT03296189|Active Comparator|Local anaesthetic + steroid|Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
16499389|NCT03296189|Placebo Comparator|Placebo|Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
16499390|NCT03296176|Experimental|presymptomatic|
16499391|NCT03296176|Experimental|symptomatic|
16499392|NCT03296176|Other|controls|
16499393|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
16499394|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
16499395|NCT03296150|No Intervention|Control arm : Information|Patients will receive the usual standard information delivered to patients
16499396|NCT03296150|Experimental|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
16499397|NCT03296137|Experimental|All participants|
16499398|NCT03296098|Experimental|ulipristal acetate|Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
16499399|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
16499400|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
16499401|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
16499402|NCT03296059|Experimental|RBC transfusion with conventional treatment|Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
16499403|NCT03296059|Active Comparator|conventional treatment|neonates diagnosed with ARDS is treated with conventional treatment.
16499404|NCT03296046||PPBL patients|
16499405|NCT03296033|Active Comparator|24 Hours group|Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
16499406|NCT03296033|Experimental|36 Hours Group|Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.
16499407|NCT03296020|No Intervention|control group|"After the surgery, during the hospitalization ,the control group would get as is customary in our ENT department :acetaminophen syrup+ syrup oxycode( as necessary).
~After the discharge from the hospital - the patients would take( as is customary in our ENT department): acetaminophen syrup ( as necessary) and other painkillers ( as necessary).
~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
16499408|NCT03296020|Experimental|"case group-HONEY"|"After the surgery, during the hospitalization ,the case group would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup + syrup oxycode( as necessary).
~After the discharge from the hospital - the patients would take:acetaminophen syrup ( as necessary) and other painkillers+honey twice a day( 5 ml- one tea spoon each time) .
~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
16499409|NCT03296007|Experimental|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
16499410|NCT03296007|Active Comparator|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
16499411|NCT03295994|Active Comparator|Operative|surgery + post-operative physical therapy
16499412|NCT03295994|Active Comparator|Non-Operative|non-operative physical therapy
16499415|NCT03295968|No Intervention|Water and Rest|
16499416|NCT03295968|Experimental|Water and High Intensity Exercise|
16499417|NCT03295968|Experimental|Ibuprofen and Rest|
16499418|NCT03295968|Experimental|Ibuprofen and High Intensity Exercise|
16499419|NCT03295955|Active Comparator|Postop antibiotics group|Prescribe Amoxicillin Clavulanate
16499422|NCT03295916|Experimental|Systemic therapy plus SBRT to OM|Stereotactic Body Radiotherapy (SBRT) up to 5 OM sites
16499423|NCT03295903|Placebo Comparator|Placebo|Sugar pill that will have no effect.
16499424|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
16499425|NCT03295903|Active Comparator|Cannabidiol (1 dose)|Only cannabidiol supplement.
16499426|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
16499427|NCT03295903|Active Comparator|Cannabidiol only (2 dose)|Only cannabidiol supplement.
16499428|NCT03295890|Sham Comparator|Sham Needling|Intervention = Sham Needling
16499429|NCT03295890|Active Comparator|Active Needling|Intervention = Active Needling
16499430|NCT03295877|Experimental|RO7171009: SAD|Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
16499431|NCT03295877|Experimental|RO7171009: MD|Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
16499432|NCT03295864|Experimental|Patients with Chiari type 1 malformation|Tympanometry measurement at inclusion and 6 months after surgery
16499433|NCT03295864|Experimental|Healthy volunteers|Tympanometry measurement at inclusion. Every healthy volunteer will be match with a patient for his age and his BMI (body mass index).
16499434|NCT03295851|Experimental|IV Ferric Carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
16499435|NCT03295851|Active Comparator|Oral Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily
16499436|NCT03295838|Experimental|Mentalization-based Treatment|MBT was conducted according to the treatment manual developed by Bateman & Fonagy. Patients were offered individual sessions with a psychotherapist and group sessions with 6-8 participants and 1-2 group therapists for 18 months. An introductory psycho-educational component (9-12 sessions) was also offered focusing on explicit mentalising skills (i.e. understanding one's own or others' intentions). Group and individual MBT focused on implicit mentalising towards self and others.
16499437|NCT03295825|Other|Biomarker|Blood sampling
16499438|NCT03295799|Experimental|Patient Self-Management|Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
16499439|NCT03295799|No Intervention|Anticoagulation Clinic Care|Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
16499440|NCT03295786|Placebo Comparator|Placebo|Patients randomized to this group will receive 6 monthly infusions of placebo/vehicle
16499441|NCT03295786|Experimental|CDNF mid-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to mid-dose
16499442|NCT03295786|Experimental|CDNF high-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to high-dose
16499443|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
16499444|NCT03295760||Children with cyclic vomiting syndrome|Children followed at Children's Hospital of Nancy treated with Q10 coenzyme for cyclic vomiting syndrome
16499445|NCT03295747|Experimental|Peppermint oil soft gel|Children will be randomized to receive either 180 mg, 360 mg, or 540 mg of peppermint oil.
16499446|NCT03295734|Active Comparator|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
16499447|NCT03295734|Active Comparator|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
16499448|NCT03295734|Active Comparator|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
16499452|NCT03295708|Experimental|experimental group|the experimental group will be given 4 fish oil capsules (1g/one capsule)twice daily after two meals at roughly the same time each day,lasting for the first 6 months.fish oil capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.
16499453|NCT03295708|Placebo Comparator|control group|the control group will be given 4 soybean oil capsules ( placebo capsule,1g/one capsule) twice daily after two meals at roughly the same time each day,lasting for the first 6 months.placebo capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.The placebo capsule's appearance and flavor are made the exactly the same as the fish oil capsules .
16499454|NCT03295695|Experimental|Cardiac Imaging - All Participants|Study agent: 2-deoxy-2-[18F]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
16499455|NCT03295656|Experimental|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
16499456|NCT03295643|Other|Mobile smoking cessation program|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
16499457|NCT03295630|Other|Actigraph GT3X accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
16499458|NCT03295617||spinal thoracic herniation|
16500793|NCT03286205|Active Comparator|3 week dosage|every 3 week dosage.
16499459|NCT03295604|Experimental|test group|Miller class I-II gingival recession defects operated with sub epithelial connective tissue graft (SCTG) in addition with enamel matrix derivatives (EMD) (Emdogain ®, Switzerland ) in SCTG+EMD group.
16499460|NCT03295604|Experimental|control group|Miller class I-II gingival recession defects operated with only sub epithelial connective tissue graft (SCTG). No drug or something else were used
16499461|NCT03295578|Experimental|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
16499462|NCT03295578|Placebo Comparator|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
16499463|NCT03295565|Active Comparator|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
16499464|NCT03295565|Active Comparator|B: Abiraterone OR Enzalutamide|"At physician's discretion:
~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
16499465|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
16499466|NCT03295539|Other|Acute or Chronic clot|If chronic clot, no intervention given via Indigo
16499467|NCT03295526|No Intervention|Control group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and systematic pelvic lymphadenectomy
16499468|NCT03295526|Experimental|Experimental group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and selective enlarged lymph node dissection.
16499469|NCT03295513|Active Comparator|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
16499470|NCT03295513|Experimental|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
16499474|NCT03295487|Active Comparator|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
16499475|NCT03295487|Active Comparator|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
16499476|NCT03295474||Rehabilitation using telehealth technology|
16499477|NCT03295461|Active Comparator|test group|SRP+ 10% Emblica officinalis irrigation
16499478|NCT03295461|Active Comparator|positive control group|SRP + 0.2% Chlorhexidine irrigation
16499479|NCT03295461|Active Comparator|negative control group|SRP + 0.9% Saline irrigation
16499480|NCT03295461|Active Comparator|test gropup|SRP +10% E. officinalis gel application
16499481|NCT03295461|Placebo Comparator|control group|received SRP+ placebo gel application.
16499482|NCT03295448|Active Comparator|Fat - Sugar - Fiber|Intervention: consuming diets rich in fat, rich in sugar, and rich in fibers during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
16499483|NCT03295448|Active Comparator|Fat - Fiber - Sugar|Intervention: consuming diets rich in fat, rich in fiber, and rich sugar during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
16499484|NCT03295448|Active Comparator|Sugar - Fiber - Fat|Intervention: Consuming diets rich in sugar, rich in fiber, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
16499485|NCT03295448|Active Comparator|Sugar - Fat - Fiber|Intervention: Consuming diets rich in sugar, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
16499486|NCT03295448|Active Comparator|Fiber - Sugar - Fat|Intervention: Consuming diets rich in fiber, rich in sugar, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
16499487|NCT03295448|Active Comparator|Fiber - Fat - Sugar|Intervention: consuming diets rich in fiber, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
16499488|NCT03295422|Active Comparator|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
16499489|NCT03295422|Experimental|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
16499490|NCT03295409|Experimental|Experimental: Standard self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:
~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.
~If I feel threatened or anxious, then I will…
~think about the things I value about myself
~remember things that I have succeeded in
~think about what I stand for
~think about things that are important to me
~If…___________________________________________________________________"
16499491|NCT03295409|Experimental|Experimental: Familial self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:
~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.
~If I feel threatened or anxious, then I will…
~think about the things my family and I value about ourselves
~remember things that my family and I have succeeded in
~think about what my family and I stand for
~think about things that are important to my family and me
~If…__________________________________________________________________"
16499492|NCT03295409|No Intervention|Control|Participants are asked to complete a questionnaire.
16499493|NCT03295396|Experimental|Arm A|ONC201 in relapsed H3 K27M glioma
16499531|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
16499494|NCT03295396|Experimental|Arm B|"ONC201 in relapsed H3 K27M glioma, excluding:
~Primary malignant lesion located in the pons or spinal cord.
~Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).
~Prior bevacizumab treatment of >4 doses of >7.5 mg/Kg
~Tumors with known 1p/19q co-deletion."
16499495|NCT03295383|Experimental|Rituximab treatment|"Rituximab at a dose of 1000 mg (or matching placebo) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
~cyclophosphamide placebo will be administered orally once daily"
16499496|NCT03295383|Active Comparator|Cyclophosphamide treatment|"cyclophosphamide will be administered orally once daily at the following initial doses:
~patients younger than 75 years: 1.5 mg/kg/day, orally. patients older than 75 years: 1 mg/kg/day, orally.
~Rituximab placebo (NaCl 0.9 %) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197"
16499497|NCT03295370|Experimental|Active Group|Needle electrical stimulation of accessory spinal nerve
16499498|NCT03295370|Sham Comparator|Sham Group|Needle of accessory spinal nerve without electrical stimulation
16499499|NCT03295357||Patients with extubation while on ECLS|
16499500|NCT03295357||Patients without extubation|
16499501|NCT03295344||Patients|
16499502|NCT03295344||Healthy volunteers|
16499503|NCT03295331||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above
16499504|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.
~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
16499505|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.
~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
16499506|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.
~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
16499507|NCT03295305|Experimental|Action Based Cognitive Remediation|
16499508|NCT03295305|Active Comparator|Unstructured support group|
16499509|NCT03295292|Sham Comparator|Standard Surgery with Vehicle|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL Fibrin Sealant (sham) without cells.
16499510|NCT03295292|Experimental|Standard Surgery with Stem Cells|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL of a mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in the thrombin component of Fibrin Sealant (TISEEL, Baxter).
16499511|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate [eGFR] of ≤60mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
16499512|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
16499513|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
16499514|NCT03295253|Experimental|Female patients with Stress Incontinence|Female patients who will undergo autologous adipose tissue harvesting/grafting using Lipogems and grafting in urethra/bladder neck
16499515|NCT03295240|Experimental|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
16499516|NCT03295227|Experimental|Pembrolizumab|"Part 1: Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of every 21 day Cycle.
~Part 2: Participants received Pembrolizumab at the maximum tolerated dose from Part 1."
16499517|NCT03295214|Active Comparator|Acetaminophen 975mg Per Os|975mg of Acetaminophen given by mouth
16499518|NCT03295214|Active Comparator|Acetaminophen 1000mg Intravenous|1000mg of Acetaminophen given intravenously
16499519|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
16499520|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
16499521|NCT03295188|Experimental|Intervention Group|Two 0.5 mg plasmalogen capsules per day
16499522|NCT03295188|Placebo Comparator|Placebo Group|Two placebo capsules containing no plasmalogen per day
16499523|NCT03295175||Congenital Megaprepuce|Congenital Megaprepuce Hematoxylin-eosin and smooth muscle actin markers
16499524|NCT03295175||Hypospadias|Hypospadias Hematoxylin-eosin and smooth muscle actin markers
16499525|NCT03295175||Control|Circumcision for non-medical reasons. Hematoxylin-eosin and smooth muscle actin markers
16499526|NCT03295162|Experimental|Sepsis A Group|neonates diagnosed with Sepsis and will receive melatonin. 10 mg product as a total dose of 20 mg .together with conventional treatment of Neonatal sepsis
16499527|NCT03295162|Sham Comparator|Sepsis B Group|neonates diagnosed with Sepsis and willnot receive melatonin., they will recieve only the conventional treatment of Neonatal Sepsis
16499528|NCT03295162|No Intervention|Control|healthy neonates, in whom sepsis will be ruled-out on the basis of absence of any clinical or laboratory evidence suggestive of infection.
16499529|NCT03295136|Experimental|Health Promotion Training for Women Employees|Groups of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
16499530|NCT03295110|Experimental|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
16499532|NCT03295097|Other|Clinical Decision Support System|The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
16499533|NCT03295084|Experimental|Irinotecan|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily for 14 days within 3 week treatment cycle
16499534|NCT03295084|Experimental|Irinotecan with Capecitabine|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily in combination with Capecitabine tablet taken twice daily for 14 days within 3 week treatment cycle
16499535|NCT03295071||Single-group study|This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
16499536|NCT03295058|Experimental|Non ATG regimen|the first 50% of patients will receive Fludarabine + cyclophosphamide prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
16499537|NCT03295058|Experimental|ATG regimen|the other 50% will receive Cyclophosphamide + ATG prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
16499538|NCT03295032|Experimental|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
16499539|NCT03295032|No Intervention|Waiting list control|Waiting list control - received treatment as usual.
16499540|NCT03295019|Experimental|Test Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
16499541|NCT03295019|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their placebo mouth spray, 2 times daily (morning and evening), for the 4 week duration of the study.
16499542|NCT03295006||Previous Therasphere treatment|Patients who had received TheraSphere yttrium-90 microspheres
16499543|NCT03294993|Experimental|Ultrasound assess group|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
16499544|NCT03294967|Active Comparator|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
16499545|NCT03294967|Placebo Comparator|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
16499546|NCT03294954|Experimental|GINAKIT cells + cytoxan + fludara|"Cyclophosphamide and fludarabine will be administered prior to the GINAKIT cells.
~Day -4: Cyclophosphamide and Fludarabine
~Day -3: Cyclophosphamide and Fludarabine
~Day -2: Fludarabine
~Day -1: Rest
~Day 0: GINAKIT cells"
16499547|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
16499548|NCT03294928|Experimental|progressive increasing of PEEP level|four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level.
16499549|NCT03294915|Active Comparator|Resistant Starch|Green banana flour
16499550|NCT03294915|Placebo Comparator|Placebo|Maltodextrin, cellulose and guar gum
16499551|NCT03294902||Critical Limb Ischaemia (CLI) Group with tibial arterial dis|Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
16499552|NCT03294902||Peripheral Artery Disease (PAD) Group with SFA disease|Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
16499553|NCT03294902||PAD-free group (Healthy Volunteer Group)|Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
16499554|NCT03294863|Experimental|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound
16499555|NCT03294863|Placebo Comparator|Standard of Care|Another 1/2 of cutaneous wound will be treated per standard of care
16499556|NCT03294850|Experimental|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
16499557|NCT03294850|Active Comparator|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
16499558|NCT03294824||patients who reactivate CMV or AdV after allogeneic HSCT|allotransplanted patients who reactivated respectively CMV (n=30) and AdV (n=10)
16499559|NCT03294824||Control group: allogeneic HSC transplanted patients|allotransplanted patients who didn't reactivate CMV
16499560|NCT03294824||Healthy donors group|healthy donors serologically + for CMV
16499561|NCT03294811|Experimental|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
16499562|NCT03294811|No Intervention|Control group|Control group (usual care, without telemonitoring)
16499563|NCT03294798|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
16499564|NCT03294798|Active Comparator|Pegasys|Pegasys 180 mcg, once per week
16499619|NCT03294421|Experimental|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
16499620|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
16500982|NCT03284892|Active Comparator|Control group|Received usual care only
16499565|NCT03294785|Experimental|Chuna manual therapy|The Chuna manual therapy group will receive Chuna manual therapy alone. Chuna manual therapy will employ a semi-standardized treatment plan of Chuna manual therapy through Chuna technique selection based on physician judgement of techniques from Chuna Medicine (Korean Society of Chuna Manual Medicine for Spine & Nerves: Chuna Medicine: Seoul: Korean Society of Chuna Manual Medicine for Spine & Nerves; 2017) and osteopathic manipulative medicine. The Chuna techniques employed in this study are divided into cervical, thoracic and rib cage, lumbar, pelvic, sacral, pubic, and hip joint area techniques. Chuna manual therapy sessions will be administered 2 sessions/week over a period of 5 weeks (total 10 sessions). The time duration of 1 Chuna manual therapy session will consist of approximately 10-20 minutes of diagnosis and approximately 10 minutes of treatment.
16499566|NCT03294785|Active Comparator|Usual care|The usual care group will receive usual care alone. Usual care will be limited to physical therapy and conventional medication in this study. Usual care will be provided with reference to a list of most frequently used treatments in neck pain-related patients from Korean Health Insurance Review and Assessment (HIRA) 2014 statistics. Frequency and types of physical therapy used will be recorded in a separate electronic case report form for outcome assessor blinding purposes.
16499567|NCT03294772|Experimental|Hand sanitizer group|DCCs received alcohol-based hand sanitizer and a program educational. Characteristics of the hydroalcoholic gel (Alco aloe gel): chlorhexidine digluconate at 0.2% solution, phenoxyethanol 1%, benzalkonium chloride 0.1%. aloe barbadensis 5%, ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 70%, ph = 7-7,5.
16499568|NCT03294772|Experimental|Liquid soap group|DCCs received soap and program educational. The liquid soaps used for handwashing in this study did not contain specific antibacterial component, ph= 5.5.
16499569|NCT03294772|No Intervention|Control group|No hand sanitizer or educational program were used.
16499570|NCT03294759|Experimental|Bio-ACL (Amion)|Intervention: ACL Autograft Reconstruction with Amion Collagen Scaffold. Stem Cells isolated from bone marrow aspirate from distal femur will be injected inside the Amion Collagen Scaffold.
16499571|NCT03294759|Active Comparator|Control|Intervention: Normal ACL Autograft Reconstruction with either patella or hamstring autograft will be performed in the control group.
16499572|NCT03294746|Other|Clinical evaluations and Thoracic CT scan scoring of DIILD|
16499573|NCT03294733|Other|Ultrasound|Ultrasound wrists to determine carpal tunnel size
16499574|NCT03294720|Experimental|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
16499575|NCT03294707|Experimental|AG10 single oral dose|AG10 oral tablet, administered by mouth, once
16499576|NCT03294707|Placebo Comparator|Placebo single oral dose|Placebo Oral Tablet, administered by mouth, once
16499577|NCT03294694|Experimental|Ribociclib and PDR001 (Cohort A)|"The treatment regimen is defined as ribociclib + PDR001.
~Treatment will be administered on an outpatient basis.
~The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.
~Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.
~Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.
~Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer."
16499578|NCT03294694|Experimental|Ribociclib, PDR001 and Fulvestrant (Cohort B)|"The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .
~Treatment will be administered on an outpatient basis.
~There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.
~Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.
~Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC)."
16499579|NCT03294681||Cochlear Implant Recipients|
16499580|NCT03294668|Experimental|KONTAKT Australia|A social skills group training
16499581|NCT03294668|Active Comparator|Super Chef|A social cooking group
16499582|NCT03294655|No Intervention|No contact control|the no contact control group will do nothing
16499583|NCT03294655|Experimental|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
16499584|NCT03294642|Experimental|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
16499585|NCT03294642|Experimental|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
16499586|NCT03294642|Experimental|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
16499587|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
16499588|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.
~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
16499621|NCT03294395|Active Comparator|Ceftriaxone im|Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
16499622|NCT03294395|Experimental|Ertapenem im|Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
16501137|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
16499589|NCT03294616|Experimental|scleroderma patients-0|for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
16499590|NCT03294616|Experimental|scleroderma patient-1|for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
16499591|NCT03294616|Experimental|scleroderma patients-2|for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
16499592|NCT03294603|Experimental|[14C]-CC-220 solution|A single oral dose of 1 mg [14C]-CC-220 solution, containing approximately 1.4 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
16499593|NCT03294590|Experimental|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
16499594|NCT03294590|Active Comparator|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
16499595|NCT03294577|Active Comparator|TAC + Pegfilgrastim|"Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo
~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
16499596|NCT03294577|Experimental|TAC + Pegfilgrastim + Plinabulin|Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)
16499597|NCT03294564|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
16499598|NCT03294564|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
16499599|NCT03294551|No Intervention|Standard of Care Control|Usual source of care
16499600|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Autodialer|HPV Vaccine Reminder Recall - Autodialer: Receive up to 4 reminders via telephone (live call or voicemail) - includes brief educational message + providers name + providers telephone number
16499601|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Texting|HPV Vaccine Reminder Recall - Texting: Receive up to 4 reminders via text message - includes brief educational message + providers name + providers telephone number
16499602|NCT03294538|Experimental|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
16499603|NCT03294538|Active Comparator|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
16499604|NCT03294538|Placebo Comparator|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
16499605|NCT03294525||Escitalopram-for MDD|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
16499606|NCT03294525||Duloxetine-for MDD|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
16499607|NCT03294525||Mirtazepine-for MDD|Eligible patients were assigned to mirtazepine treatment based on investigators' clinical practice.
16499608|NCT03294525||other antidepressant-for MDD|Eligible patients were assigned to other antidepressant treatment (including sertraline, paroxetine, fluoxetine, venlafaxine, etc) based on investigators' clinical practice.
16499609|NCT03294512|Experimental|Heart Failure Patients|Patients who are seen at Intermountain Medical Center with heart failure, based on the Intermountain-specific Heart Failure Identification and Risk Stratification, will be screened for this study. The Principal Investigator and/or his delegate will confirm the presence of heart failure, based on established standard of care criteria for diagnosis.
16499610|NCT03294486|Experimental|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
16499611|NCT03294473|Experimental|Autodial R/R|R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
16499612|NCT03294473|Experimental|Text Message R/R|R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
16499613|NCT03294473|Experimental|Postcard R/R|R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
16499614|NCT03294473|No Intervention|Standard of Care Control|Participants in this group will not receive any influenza vaccination reminders
16499615|NCT03294460|Experimental|1|Alcohol self-administration (IV ethanol for sessions 1 and 3, oral for session 2)
16499616|NCT03294447|Experimental|Fall Prevention Intervention by OT|Fall prevention interventions implemented by an OT in a geriatric primary care setting for a client immediately following the provider visit within the office.
16499617|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
16499618|NCT03294421|Active Comparator|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
16501138|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
16499623|NCT03294395|Experimental|Fosfomycin po|Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
16499624|NCT03294395|Experimental|Gentamicin im|Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
16499625|NCT03294382|Experimental|Botulinum toxin|5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus
16499626|NCT03294382|Placebo Comparator|Normal Saline|0.1 mL normal saline, administered in the other intercanthus
16499627|NCT03294369||Cohort of the study|A sample from the general population aged 18 years or older, randomly selected from a database of sanitary cards stratified by age and gender.
16499628|NCT03294356|Experimental|FT210771 Group|7 day at-home use of electronic cigarette FT210771 followed by a 2 day in-clinic period.
16499629|NCT03294356|Experimental|FT210751 Group|7 day at-home use of electronic cigarette FT210751 followed by a 2 day in-clinic period.
16499630|NCT03294356|Experimental|6T30134157764 Group|7 day at-home use of electronic cigarette 6T30134157764 followed by a 2 day in-clinic period.
16499631|NCT03294356|Experimental|G41A7C071 Group|7 day at-home use of electronic cigarette G41A7C071 followed by a 2 day in-clinic period.
16499632|NCT03294356|Experimental|M011161212 Group|7 day at-home use of electronic cigarette M011161212 followed by a 2 day in-clinic period.
16499633|NCT03294356|Experimental|FT21002 Group|7 day at-home use of combustible cigarette FT21002 followed by a 2 day in-clinic period.
16499634|NCT03294343|Experimental|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
16499635|NCT03294343|Experimental|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
16499636|NCT03294343|Other|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
16499637|NCT03294330|Experimental|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
16499638|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
16499639|NCT03294304|Experimental|Nivolumab, Cisplatin, & Gemcitabine|
16499640|NCT03294291|Active Comparator|Quadratus Lumborum block group|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.7 ml/kg bupivacaine 0.25 % injected unilaterally at the posterior border of the quadratus lumborum muscle.
16499641|NCT03294291|Active Comparator|Caudal block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory caudal block wil performe with bupivacaine 0.7 ml/kg as 0.25%.
16499642|NCT03294278|Active Comparator|Ablation plus ICD|Epicardial ablation by radio-frequency
16499643|NCT03294278|Active Comparator|ICD alone|Implantation of ICD
16499644|NCT03294265|Experimental|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.
~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
16499645|NCT03294265|Active Comparator|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.
~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
16499646|NCT03294252|Experimental|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the CIPPA procedure (injection and nebulisation in intraperitoneal).
16499647|NCT03294239|Experimental|Group A (Transurethal group)|Patients will have trans urethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone disintegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
16499648|NCT03294239|Experimental|Group B (Percutaneous group)|Patients will have per cutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the mid line 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
16499649|NCT03294226|Experimental|AuraGain|After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
16501139|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
16499650|NCT03294226|Active Comparator|I-gel|After anesthetic induction, I-gel is inserted for airway management. Size of the device is selected according to the patient's weight; size 1.5 for 5-10kg, size 2 for 10-20kg.
16499651|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
16499652|NCT03294200|Experimental|Tricinch Coil System treatment|
16499653|NCT03294187|Experimental|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
16499654|NCT03294187|Placebo Comparator|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will *not* receive multimodal feedback.
16499655|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
16499656|NCT03294174||Opioid exposure|Patients who have been exposed to(> 6months), but not currently taking opioids, but will receive ropicacaine injection
16499657|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
16499658|NCT03294161|Experimental|Immucillin DI4G|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .
16499659|NCT03294161|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.
16499660|NCT03294148|Experimental|Placebo|The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
16499661|NCT03294148|Experimental|Psychotherapy|Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.
16499662|NCT03294148|No Intervention|Waitlist|Wait-listed patients will be asked not to change their treatment regime for the 4 weeks in between their two fMRI sessions. Wait-listed patients in the placebo injection arm will be offered the opportunity to receive the placebo treatment (optional). Waitlisted participants in the psychotherapy arm will be given a copy of Dr. Schubiner's book and free access to his online self-help program (optional to accept these).
16499663|NCT03294135|Experimental|Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 28 (+10) and 300 (+21), booster vaccination of 55 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
16499664|NCT03294135|Experimental|Accelerated/Rapid Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 7 (+3) and 21 (+7), booster vaccination of 9 subjects in study V48P7E1 (NCT00387634) 40 subjects received their booster vaccination before enrolment in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
16499665|NCT03294135|Experimental|Accelerated Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 133 subjects in study V48P7 on Days 0, 14 (+3) and 300 (+21), booster vaccination of 109 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
16499666|NCT03294122||PCa patients - Discovery cohort|External beam radiotherapy for prostate cancer
16499667|NCT03294122||HNCa patients - Discovery cohort|External beam radiotherapy for head and neck cancer
16499668|NCT03294122||PCa patients - Validation cohort|External beam radiotherapy for prostate cancer
16499669|NCT03294122||HNCa patients - Validation cohort|External beam radiotherapy for head and neck cancer
16499670|NCT03294109|Experimental|study|liposomal bupivacain
16499671|NCT03294109|No Intervention|control|no intervention
16499672|NCT03294096|Experimental|experimental group|
16499673|NCT03294096|Active Comparator|control group|
16499674|NCT03294083|Experimental|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.
~Cemiplimab will be administered via IV infusion every 3 weeks."
16499675|NCT03294083|Experimental|Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.
~Cemiplimab will be administered via IV infusion every 3 weeks."
16499676|NCT03294083|Experimental|Part 2-Arm B, Cemiplimab|"Cemiplimab will be administered via IV infusion every 3 weeks.
~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks."
16499677|NCT03294083|Experimental|Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.
~Cemiplimab will be administered via IV infusion every 3 weeks."
16499678|NCT03294083|Experimental|Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.
~Cemiplimab will be administered via IV infusion every 3 weeks."
16499679|NCT03294070|Experimental|Fimasartan 60 mg + amlodipine besylate 5 mg|Fimasartan 60 mg + amlodipine besylate 5 mg. In subjects with a DBP equal to or greater than 90 mmHg and / or SBP equal to or greater than 140 mmHg at week 8, the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD (in these cases, the subject will receive one 60 mg Fimasartan tablet plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate tablet.
16499680|NCT03294057|Experimental|ICT programs + Tele-coaching programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. And a trained nurse provides tele-coaching programs to subjects. After that, subjects will conduct self-management health care and tele-coaching programs for 12 weeks. After 3 months, they finish self-management ICT + coaching programs, and then they fill out the questionnaire.
16499681|NCT03294057|Experimental|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
16499682|NCT03294057|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
16499683|NCT03294044|Experimental|ICT programs|ICT programs that include health information learning by disease, and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
16499684|NCT03294044|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
16499685|NCT03294031|Experimental|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
16499686|NCT03294031|Active Comparator|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
16499687|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
16499688|NCT03294005||Subjects with nodular goiter|Enrolled subjects with nodular goiter had thyroid sonography and thyroidectomy from 2002 January to 2016 December in CMUH. Total enrolled subject about 2000. These subjects were confirmed by pathology. Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients. Gray scale ultrasonography was routinely performed in every subject. Color Doppler ultrasonography for blood flow and thyroid fine needle aspiration was not absolute done in routine procedure. All data at least was interpreted by 3 endocrinologists under the blind method. Each subject was analyzed under thyroid echogenicity, margin, calcification, inclusion, grooving change and size & ratio size of tall and transverse.
16499689|NCT03293992|Experimental|0.01% RO7058584 or Matching Placebo|
16499690|NCT03293992|Experimental|0.1% RO7058584 or Matching Placebo|
16499691|NCT03293992|Experimental|1% RO7058584 or Matching Placebo|
16499692|NCT03293992|Experimental|RO7058584 and Latanoprost 0.005%|
16499693|NCT03293940|Experimental|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.
~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
16499694|NCT03293940|Active Comparator|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.
~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
16499695|NCT03293927|Experimental|Fentanyl + Dexmedetomidine|
16499696|NCT03293927|Experimental|Dexmedetomidine + Fentanyl|
16499697|NCT03293927|Experimental|Fentanyl only|
16499698|NCT03293927|Experimental|Dexmedetomidine only|
16499699|NCT03293914|Experimental|Intervention|Participants will be invited to enroll in an occupational therapy (OT) lifestyle redesign intervention focused on diabetes management. The intervention includes approximately 8 one-hour OT sessions over 4 months.
16499700|NCT03293914|No Intervention|Usual Care Control|Participants will not be contacted; outcome data will be extracted from medical records.
16499701|NCT03293901|No Intervention|Rest|
16499702|NCT03293901|Active Comparator|Exercise|Militarily relevant exercise
16499703|NCT03293875|Other|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
16499704|NCT03293875|Other|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
16499705|NCT03293862|Active Comparator|Suture group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
16501871|NCT03278691|Experimental|Intervention|Ketorolac 15 mg (15mg/ml) IV Q6H
16499706|NCT03293862|Experimental|Prophylactic mesh group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
16499707|NCT03293849|Experimental|Patient Navigation Arm|After an assessment of supportive care needs, a patient navigator will present assessment results and develop and implement a personalized supportive care intervention plan based on the findings in collaboration with a multidisciplinary supportive care team, formed by oncologists and pain and palliative care specialists. The developed plan will be sent to the treating oncologist and oncology team.
16499708|NCT03293849|No Intervention|Control Arm|Assessment results will be provided in printed and electronic form to the treating oncologist for their review. Referrals or interventions for patients allocated to the control arm will be coordinated by the treating oncologist without involvement from the patient navigator or the study team.
16499709|NCT03293836|Experimental|Radiofrequency treatment|Radiofrequency ablation of insufficient saphenous and perforating veins plus multilayer compressive bandage treatment
16499710|NCT03293836|Active Comparator|Multilayer Compressive Bandage only|Receive only compressive treatment
16499711|NCT03293823|Experimental|vision-based speed of processing (VSOP) cognitive training|use the INSIGHT online program (Posit Science), which includes five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
16499712|NCT03293823|Active Comparator|active control|The standardized computerized leisure activities program - MLA, including crossword puzzle, Sudoku, etc. will be used
16499713|NCT03293797|Experimental|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
16499714|NCT03293784|Other|COHORT 1|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
16499715|NCT03293784|Other|COHORT 2|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
16499716|NCT03293771||Stage 1 Focus Groups|The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.
16499717|NCT03293771||Stage 2 Questionnaire Groups|Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.
16499718|NCT03293745|Active Comparator|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
16499719|NCT03293745|Experimental|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
16499720|NCT03293732|Active Comparator|HA antigen only|All subjects in this group received 2 doses of 22.2 μg HA antigens
16499721|NCT03293732|Experimental|7.5 μg of DCB07010|All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.
16499722|NCT03293732|Experimental|15 μg of DCB07010|All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.
16499723|NCT03293732|Experimental|30 μg of DCB07010|All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.
16499724|NCT03293732|Experimental|45 μg of DCB07010|All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.
16499725|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
16499726|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
16499727|NCT03293706|Active Comparator|CHO Control 1 Glucose|25 g glucose
16499728|NCT03293706|Active Comparator|CHO Control 2 Glucose|25 g glucose
16499729|NCT03293706|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
16499730|NCT03293706|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
16499731|NCT03293706|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
16499732|NCT03293706|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
16499733|NCT03293693|Experimental|Test meal 1|Test meal with 0.5 g beta-glucan
16499734|NCT03293693|Experimental|Test meal 2|Test meal with 3.5 g beta-glucan
16499735|NCT03293693|Experimental|Test meal 3|Test meal with 8 g beta-glucan
16499736|NCT03293680|Experimental|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
16499737|NCT03293667|Other|Exploratory arm|
16499738|NCT03293654|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16499739|NCT03293654|Active Comparator|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16499740|NCT03293654|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
16499741|NCT03293641|Experimental|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
16499742|NCT03293641|Placebo Comparator|Control Arm|Standard of Care for 6 months
16499743|NCT03293628|Experimental|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
16499744|NCT03293628|Active Comparator|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
16499745|NCT03293615|Experimental|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
16499746|NCT03293615|Active Comparator|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
16499747|NCT03293615|No Intervention|No myopathy|Patients without myopathy on muscle biopsy
16499748|NCT03293602|Experimental|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
16499749|NCT03293589||OR|patients treated with open revascularization
16499750|NCT03293589||EVT|patients treated with endovascular revascularization
16499751|NCT03293576|Experimental|Intervention|Volitional help sheet
16499752|NCT03293576|No Intervention|Control|Short Zimbardo's time perspective inventory (Orosz et al. 2017)
16499754|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
16499755|NCT03293537|Experimental|Patients with dementia|The subject will be informed of the procedure and their task before the sensors are attached. Electrodermal activity (EDA) and heart rate (HR) will be continuously monitored while the subject views the image sequence on a PC monitor. EDA will be measured using electrodes attached to the middle (D3) and ring finger (D4). Heart rate will be measured using an infrared pulseoximeter attached to one of the free digits of the hand. A pulseoximeter is a non-invasive sensor, using tissue absorption of infrared light to determine blood-oxygen saturation (SaO2). EDA and HR will be recorded concurrently using commercial software. Data analysis will involve both commercial and in-house software.
16499756|NCT03293524|Experimental|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
16499757|NCT03293524|Placebo Comparator|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
16499758|NCT03293511|Experimental|Order of administration: oxytocin - placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
16499759|NCT03293511|Experimental|Order of administration: placebo - oxytocin|Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
16499760|NCT03293498|Experimental|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
16499761|NCT03293498|Experimental|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
16499762|NCT03293498|Active Comparator|Group C|Fluzone HD - Day 0; Saline - Day 21
16499763|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
16499764|NCT03293472|Experimental|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm.
~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
16499765|NCT03293472|Active Comparator|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients < 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml > 180 cm.
~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
16499766|NCT03293459|Experimental|Shunt Occlusion +SMT|Shunt Occlusion +SMT
16499767|NCT03293459|Active Comparator|Standard Medical Treatment (SMT)|
16499768|NCT03293446|Experimental|Patients with chronic kidney disease|
16499769|NCT03293446|Active Comparator|Healthy controls|
16499770|NCT03293433||Patient with lung cancer|Patient with pulmonary nodule showed in scanner (defined as a rounded picture higher than 5 mm and less than 30 mm in the lung parenchyma) presenting at one of the 3 participant services and meeting the inclusion criteria and exclusion. A blood punction will be performed in order to extract micro RNA.
16499771|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
16499772|NCT03293394|Experimental|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
16499773|NCT03293394|Placebo Comparator|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
16499774|NCT03293368|Experimental|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
16499775|NCT03293368|Active Comparator|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
16499776|NCT03293355|No Intervention|Control|Standard of care
16499777|NCT03293355|Experimental|Intervention|"The VPN intervention has 2 in-person sessions:
~1) Providing training on service integration and team building for CHW and tools for them to network more effectively with OPC and MMT treatment providers as well as reach out to their patients; and 2) Learning to use effective communication tools such as motivational ruler and decision balance sheet to work more effectively with their patients and use Facebook group to facilitate collaboration among providers and e-chat for patient engagements. Sessions will occur once a week for two weeks, with each session featuring a different set of themes and relevant activities."
16499778|NCT03293342|Experimental|D CBT|Dentist administered cognitive behaviioral treatment
16499779|NCT03293342|Active Comparator|Control|Treatment as usual
16499780|NCT03293329|Experimental|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
16501910|NCT03278470|Experimental|HL237 400mg|take oral tablet once
16499781|NCT03293329|Experimental|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
16499782|NCT03293329|Active Comparator|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
16499783|NCT03293316|Sham Comparator|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
16499784|NCT03293316|Experimental|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
16499785|NCT03293316|Experimental|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
16499786|NCT03293303|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
16499787|NCT03293303|No Intervention|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
16499788|NCT03293290|Experimental|PrEP|For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
16499789|NCT03293277|Experimental|A1|20µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
16499790|NCT03293277|Experimental|A2|20µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intranasally on Day 8
16499791|NCT03293277|Experimental|B1|40µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
16499792|NCT03293277|Experimental|B2|40µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intranasally on Day 8
16499793|NCT03293277|Experimental|C|80µg Dexmedetomidine or Placebo is administered intranasally on Day 1
16499794|NCT03293264|Experimental|Exercise training group|The intervention group will be encouraged to perform 150 min of exercise training per week for 6 months. Subjects will be provided with individual feedback and exercise Training prescriptions. After month 6 subjects will be randomized to three different groups for follow-up observation.
16499795|NCT03293264|No Intervention|Waiting-control group|The control group will be provided with general informations on a healthy lifestyle. After 6 months wait-list-control months subjects will receive the guided exercise training intervention for 6 months.
16499796|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
16499797|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
16499798|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
16499799|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
16499800|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
16499801|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
16499802|NCT03293225||add H2RA|Add antihistamines to standard drug therapy
16499803|NCT03293225||change ns-H1RA|Change to ns-H1RA in standard medication
16499804|NCT03293225||ns-H1RA(3-4 tabs)|Standard treatment with ns-H1RA 4X dose
16499805|NCT03293225||ns-H1RA(3-4kinds)|Use of NS 4 kinds for standard treatment
16499806|NCT03293199|Active Comparator|Chest tube drainage|This group will undergo chest tube drainage as an intervention for spontaneous pneumothorax treatment.
16499807|NCT03293199|Active Comparator|Needle aspiration|This group will undergo repetitive needle aspiration as an intervention for spontaneous pneumothorax treatment.
16499808|NCT03293186|Experimental|Use MEDICLORE|use mediclore at the end of surgery
16499809|NCT03293186|No Intervention|No antiadhesive product|use no antiadhesive product at the end of surgery
16499810|NCT03293173|Experimental|Group A|Biologically low risk group, R-CHOEP-14
16499811|NCT03293173|Experimental|Group B|Biologically high risk group, DA-EPOCH-R
16499812|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
16499813|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
16499814|NCT03293147|Experimental|Arm A|Intervention group: Non-adherent hypertensive patients randomised in Arm A will receive standard clinical care plus HPLC-MS/MS-guided intervention.
16499815|NCT03293147|Active Comparator|Arm B|Control group: Non-adherent hypertensive patients randomised in Arm B will receive clinical standard care.
16499816|NCT03293147|Active Comparator|Arm C|Control group: Adherent hypertensive patients randomised in Arm C will receive clinical standard care.
16499817|NCT03293121|Experimental|Strength and Coordination Training|The strength and coordination group will perform a progression of exercises utilizing body weight and resistance bands as resistance. Exercises include squats, lunges, jumps etc. typical of a normal strength training program.
16499818|NCT03293121|Active Comparator|Walking|The walking group will be instructed to walk 3x/week, progressing from 30 to 45 min over 8 weeks.
16499819|NCT03293108|Experimental|AryoGen Pharmed Denosumab|"Arylia (Denosumab Prefilled Syringe produced by AryoGen Pharmed) 60 mg/1 ml in a prefilled syringe.
~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
16499820|NCT03293108|Active Comparator|Amgen Denosumab|"Prolia® (Denosumab Prefilled Syringe produced by Amgen) 60 mg/1 ml in a prefilled syringe.
~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
16499821|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
16499822|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
16499823|NCT03293069|Experimental|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
16499824|NCT03293069|Placebo Comparator|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
16499825|NCT03293056|Experimental|High-intensity Interval Hydrogynmastics|High-intensity Interval training Hydrogynmastics, 2x/week, for 3 months.
16499826|NCT03293056|Active Comparator|Hydrogynmastics Continuous Moderate|Hydrogynmastics Continuous Moderate training (HCM), 2x/week, for 3 months.
16499827|NCT03293043|Experimental|Experimental Group|After initial screening, appropriately obtained informed consent and confirmation of eligibility at time of transplant, those recipients (a total of 12 subjects) who agree to continue as participants will receive reconditioned marginal lungs should the lungs on the device meet acceptable criteria to proceed with clinical transplantation.
16499828|NCT03293030|Experimental|Dupilumab treatment|15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.
16499829|NCT03293017|Experimental|Baclofen 30 mg/day|baclofen 30 mg/day
16499830|NCT03293017|Experimental|Baclofen 60 mg/day|
16499831|NCT03293017|Placebo Comparator|Placebo|
16499832|NCT03293004|Experimental|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
16499833|NCT03293004|Experimental|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
16499834|NCT03293004|Experimental|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
16499835|NCT03293004|Placebo Comparator|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
16499836|NCT03292978|Experimental|probiotics intervention|"The probiotic is provided in sachets as a 2g powder dried with corn starch.
~The powder is orally taken once daily for 4 weeks.
~The powder contains totally 11 log 10 colony forming units(CFU) of probiotics.
~The types of probiotics are Lactobacillus.rhamnosus, Lactobacillus.acidophilus, Bifidobacteria.animalis and Bifidobacteria.longum."
16499837|NCT03292978|Placebo Comparator|non-probiotic control|The placebo is corn starch alone provided and the shape, color, weight,flavor and taste are same with the powder of probiotics intervention.
16499838|NCT03292965|Active Comparator|Neostigmine|"At the end of surgery, administrating neostigmine to participants according to the protocol below:
~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
16499839|NCT03292965|Active Comparator|Sugammadex|"At the end of surgery, administrating sugammadex to participants according to the protocol below:
~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
16499947|NCT03292185|Experimental|IDeg-Liraglutide-IDeglira|Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide
16501911|NCT03278470|Experimental|HL237 800mg|take oral tablet once
16499840|NCT03292952|Experimental|Double-blind KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:
~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
16499841|NCT03292952|Placebo Comparator|Double-blind Placebo|Placebo oral capsule
16499842|NCT03292952|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:
~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
16499843|NCT03292939|Other|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
16499844|NCT03292926|Active Comparator|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
16499845|NCT03292926|Active Comparator|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
16499846|NCT03292913|Experimental|Intervention Group|Receives the Positive Health Check intervention plus standard of care
16499847|NCT03292913|Other|Control Group|Receives standard of care
16499848|NCT03292887||Elaprase Treated|Participants with Hunters Syndrome received or receiving treatment with Elaprase as prescribed by their physician following locally approved prescribing information.
16499849|NCT03292887||Elaprase Non-Treated|Participants received no treatment for Hunters Syndrome.
16499850|NCT03292874|Other|Paired imaging|Single arm, paired imaging of high resolution MRI (hrMRI) and stand MRI (sMRI)
16499853|NCT03292848|Experimental|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
16499854|NCT03292848|Experimental|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
16499855|NCT03292822|Experimental|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.
16499856|NCT03292822|Active Comparator|Paclitaxel|chemotherapeutic drug
16499857|NCT03292809|Experimental|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
16499858|NCT03292809|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle only
16499859|NCT03292796|Other|Stop prostaglandin eye drops post op|Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
16499860|NCT03292796|Other|Continue prostaglandin eye drops post op|Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
16499861|NCT03292783|Experimental|NOV150101 (ABL001)|
16499862|NCT03292770|No Intervention|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
16499863|NCT03292770|Experimental|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.
~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
16499864|NCT03292757|Experimental|Mesenteric ICG|Indocyanine green injected into the small bowel mesentery during oesophagectomy.
16499865|NCT03292757|Experimental|Feeding jejunostomy ICG (cream)|Indocyanine green mixed with cream infiltrated into the feeding jejunostomy.
16499866|NCT03292744|Experimental|Alfacalcidol|Alfacalcidol 0,5 mcg once daily for 90 days
16499867|NCT03292744|Placebo Comparator|Placebo|Amylum same capsule form, weight and colour with treatment arm
16499868|NCT03292731|Active Comparator|hydroxyprogesterone caproate 250 mg|Pregnant subject will receive 250mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
16499869|NCT03292731|Experimental|hydroxyprogesterone caproate 500 mg|Pregnant subject will receive 500mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
16499870|NCT03292718|Experimental|use of MyCyFAPP|use of MyCyFAPP during 6 months
16501912|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
16499871|NCT03292705|Experimental|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.
~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.
~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
16499872|NCT03292705|Active Comparator|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
16499873|NCT03292692|Experimental|OurRelationship|Online Intervention
16499874|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
16499875|NCT03292679|No Intervention|Control|Subjects that are randomized into Arm A will have their fractures repaired in the usual fashion i.e. using plates that are bent by free hand.
16499876|NCT03292679|Experimental|3D template|Subjects that are randomized into Arm B will have custom models of relevant portions of their facial skeleton printed and used as templates for bending and shaping plates for stabilizing the fracture(s).
16499877|NCT03292666||Extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for > 3 months
16499878|NCT03292666||No extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for no longer than 3 months
16499879|NCT03292653|Placebo Comparator|Placebo|Participants were randomized to matching placebo to sotagliflozin administered as two tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
16499880|NCT03292653|Experimental|Sotagliflozin 200 mg|Participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
16499881|NCT03292653|Experimental|Sotagliflozin 400 mg|Participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
16499882|NCT03292640|Experimental|DFD-03 Lotion (0.1% tazarotene)|DFD-03 Lotion (0.1% tazarotene)
16499883|NCT03292640|Placebo Comparator|DFD-03 Vehicle (0% tazarotene)|DFD-03 Vehicle Lotion (0% tazarotene)
16499884|NCT03292627||mid age|mid age: 50-70 years old
16499885|NCT03292627||old age|old age: age older than 70 years old
16499886|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
16499887|NCT03292601|Experimental|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
16499888|NCT03292588|Experimental|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
16499889|NCT03292588|Placebo Comparator|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
16499890|NCT03292575||Stroke related to CAAF|
16499891|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
16499892|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
16499893|NCT03292549||Patients|Robotic partial surgery
16499894|NCT03292536|Experimental|Merestinib, all patients|
16499895|NCT03292523||Hyperventilation syndrome|
16499896|NCT03292510|Experimental|GO-OUT Group|Participants attend 1-day walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. The same activities are completed during both sessions within the same week. Each session includes a 10-minute warm-up, a distance walk, practice of a specific outdoor walking skill, a distance walk, and a 10-minute cool down. The warm up and cool down include stretching, functional strengthening exercises and balance exercises taught during the workshop. The program incorporates the principles of task-specific training by emphasizing repetitive practice of progressively more difficult outdoor walking tasks. The outdoor walking program is conducted in one or more large park settings given the mental health benefits of exercising in a natural environment.
16499897|NCT03292510|Active Comparator|Workshop Group|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
16499898|NCT03292497|Experimental|Treatment algorithm|"Mitral valve will be replaced if posterior leaflet tethering angle >=25 degrees.
~Mitral valve will be repaired if posterior leaflet tethering angle <25 degrees"
16499899|NCT03292497|Active Comparator|No treatment algorithm|Mitral valve will be repaired or replaced at surgeon's discretion.
16499948|NCT03292185|Experimental|IDeg-IDeglira-Liraglutide|Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide
16501913|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
16499900|NCT03292484|Experimental|Treatment Pathway 1, 2, 3, 4, 5|Subjects will be assigned to one of five treatment pathways when first enrolled into ARC008, which is dependent on the treatment received (AR101 or placebo) during the parent study and their tolerance of this treatment regimen (e.g., daily or non-daily schedule).
16499901|NCT03292471|Experimental|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
16499902|NCT03292471|Experimental|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
16499903|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
16499904|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
16499905|NCT03292445|Experimental|Immune tolerance after kidney transplant|Immune tolerance after kidney transplant will be induced by transfusion of enriched donor blood stem cells and T cells to initiate blood cell mixed chimerism in patients conditioned with total lymphoid irradiation and rabbit anti-thymocyte globulin after kidney transplant. Patients will receive corticosteroids for 14 weeks with gradual dose reduction. They will also receive 12 months of mycophenolate mofetil and 18 months of tacrolimus with dose tapering beginning 9 months post-transplant and continuing as long as mixed chimerism is maintained and there is no evidence of graft versus host disease and no kidney rejection evident. Patients losing chimerism will continue on low dose immunosuppressive drug doses unless additional kidney rejection therapy is needed.
16499906|NCT03292432|Active Comparator|Standard of Care (SOC)|Standard of Care for adherence support at Site
16499907|NCT03292432|Experimental|TERA Intervention (TERA)|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
16499908|NCT03292419|Other|Topography guided LASI|
16499909|NCT03292406|Experimental|CD11301 Gel 0.06%|Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
16499910|NCT03292406|Experimental|CD11301 Gel 0.03%|Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
16499911|NCT03292406|Experimental|Placebo|Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.
16499912|NCT03292393|Active Comparator|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
16499913|NCT03292393|Active Comparator|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
16499914|NCT03292393|Placebo Comparator|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
16499915|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
16499916|NCT03292367||ldTRA|Patients who are planned to perform coronary angiography will be enrolled via left distal radial artery
16499917|NCT03292354|Active Comparator|Body Weight (BW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on body weight.
16499918|NCT03292354|Active Comparator|Cardiac output (CO)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on cardiac output.
16499919|NCT03292354|Active Comparator|Lean Body weight (LBW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on Lean Body Weight.
16499920|NCT03292354|No Intervention|Control group|Patients in this group will be included retrospectively and have received the standard CM injection protocol previously used in our department.
16499921|NCT03292341|Experimental|Patients|"Patients diagnosed with larynx cancer and ex-larynx cancer patients:
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
16499922|NCT03292341|Experimental|Clinicians|"2.Clinicians Radiotherapy-oncologists, ENT(Ear-Nose-Throat)-specialists, General practitioners, Nurses
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
16499923|NCT03292341|Experimental|Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
16499949|NCT03292185|Experimental|Liraglutide-IDeg-IDeglira|Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide
16499950|NCT03292185|Experimental|Liraglutide-IDeglira-IDeg|Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec
16499924|NCT03292328|Experimental|Yoga Arm|After randomization, participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
16499925|NCT03292328|Active Comparator|Wait List Control Arm (WLC)|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
16499926|NCT03292315|Experimental|Exenatide 2 MG Injection [Bydureon]|20 subjects will be randomized to receive once weekly injection of Exenatide (Bydureon 2mg) for 26 weeks.
16499927|NCT03292315|Other|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
16499928|NCT03292302|Placebo Comparator|Placebo Comparator Arm|
16499929|NCT03292302|Active Comparator|Active treatment|ELX-02
16499930|NCT03292289|Experimental|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
16499931|NCT03292276|Experimental|Amadeo training|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The robotic exercises will be carried in passive modality (15 minutes), passive/plus (15 minutes), assisted modality (15 minutes).
16499932|NCT03292276|Active Comparator|occupational therapy|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The control group will receive the same amount of training by physiotherapist skilled in occupational tharapy.
16499933|NCT03292263|Experimental|Mel+Nivo|Autologous Stem Cell Transplant Drug: Melphalan 140-200 mg/m^2, Nivolumab100 mg iv days -3, +17
16499934|NCT03292250|Experimental|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
16499935|NCT03292250|Experimental|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
16499936|NCT03292250|Experimental|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
16499937|NCT03292250|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
16499938|NCT03292250|Experimental|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)
~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
16499939|NCT03292237|No Intervention|Standard Nutrition Arm|"In ICU:
~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.
~PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.
~Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.
~After ICU:
~Nutrition management will be as per usual site management at that hospital.
~Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
16499940|NCT03292237|Experimental|Intensive Arm|"Intervention
~In ICU:
~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation
~The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge
~If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.
~After ICU:
~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
16499941|NCT03292211|Experimental|early mobilization|early mobilization group will commence rehabilitation consisting of out-of-bed mobilization (including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.)
16499942|NCT03292211|Other|early standard intervention|early standard intervention included bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and the facilitation techniques during the period in a stroke center.
16499943|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.
~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
16499944|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.
~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
16499945|NCT03292185|Experimental|IDeglira-IDeg-Liraglutide|Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide
16499946|NCT03292185|Experimental|IDeglira-Liraglutide-IDeg|Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec
16499951|NCT03292172|Experimental|Group 1 - Escalation Dose: RO6870810 + Atezolizumab|Participants will be administered escalating doses of RO6870810 (0.3 milligram per kilogram [mg/kg], 0.45 mg/kg, and 0.65 mg/kg) subcutaneously (SC) once daily (QD) along with fixed dose of atezolizumab 1200 mg intravenously (IV) on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
16499952|NCT03292172|Experimental|Group 2 - Sequential Dose: RO6870810 + Atezolizumab|Participants will be administered RO6870810 monotherapy (starting dose 0.30 mg/kg) during the first 14 days of 21-day Run-in period. Following the Run-in period, participants will continue to receive RO6870810 at the same dose in combination with fixed dose of atezolizumab 1200 mg IV every 3 weeks in 21-day cycles.
16499953|NCT03292172|Experimental|Group 3 - Expansion in TNBC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
16499954|NCT03292172|Experimental|Group 4 - Expansion in OC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
16499955|NCT03292159|Experimental|RAVANS|
16499956|NCT03292159|Sham Comparator|Sham stimulation|
16499957|NCT03292146|Experimental|Active Denosumab 60mg Injection|Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
16499958|NCT03292146|Placebo Comparator|Placebo|Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
16499959|NCT03292133|Experimental|EGF816 + Gefitinib|"All patients will receive gefitinib orally once daily
~EGF816 will be administered orally once daily
~Participant will be requested to maintain a medication diary of each dose of medication"
16499960|NCT03292120|Experimental|patients with septic shock|
16499961|NCT03292094||Black men|294 young healthy men were included (clinic normotensive, non-HIV)
16499962|NCT03292094||White men|284 young healthy men were included (clinic normotensive, non-HIV)
16499963|NCT03292094||Black women|312 young healthy women were included (clinic normotensive, non-HIV)
16499964|NCT03292094||White women|312 young healthy women were included (clinic normotensive, non-HIV)
16499965|NCT03292081|Experimental|OFDI-guided PCI|
16499966|NCT03292081|Active Comparator|IVUS-guided PCI|
16499967|NCT03292068|Experimental|Acupuncture, acupressure|"Intervention with Pyonex-needles & Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.
~Intervention Acupressure & Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
16499968|NCT03292068|Experimental|Timbal diet|"Timbal diet including ice cream & Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
16499969|NCT03292068|Other|Extended telephone counseling|Extended telephone counseling & Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
16499970|NCT03292042|Experimental|Experimental Group|"This group will carry out the lifestyle intervention (Physical health promotion program) during 6 months.
~The group will attend a session per week."
16499971|NCT03292042|No Intervention|Control group|usual care
16499972|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
16499973|NCT03292016|Experimental|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
16499974|NCT03292016|Active Comparator|Subcutaneous APO-go|Subcutaneous APO-go, once daily
16499975|NCT03292016|Active Comparator|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
16499976|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
16499977|NCT03291990|Experimental|5 fraction radiotherapy with standard temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
16499978|NCT03291977|Experimental|Fluorescein sodique FAURE|Fluorescein (Fluorescéine sodique FAURE) will be given intravenously during the induction of the anesthesia
16499979|NCT03291977|Active Comparator|White-light surgery|"In the control arm, the surgery will be performed under classical conditions (so-called  white-light  surgery)."
16499980|NCT03291951|Experimental|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
16500004|NCT03291743|Experimental|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
16499981|NCT03291951|No Intervention|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
16499982|NCT03291938|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7 of cycle 1 in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of cycle 1 and then on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
16499983|NCT03291925|Experimental|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
16499984|NCT03291925|Active Comparator|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
16499985|NCT03291912|Experimental|Chuna Manual Therapy (CMT)|"Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)
~Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)
~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.
~CMT and UC group will receive the same UC regimen."
16499986|NCT03291912|Active Comparator|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)
~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.
~CMT and UC group will receive the same UC regimen."
16499987|NCT03291899|Experimental|Experimental single arm|"Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:
~Oxaliplatin-85 mg/m2 IV Day 1
~Leucovorin-400 mg/m2 IV Day 1
~Irinotecan-180 mg/m2 IV Day 1
~Fluorouracil (FU)-400 mg/m2 IV bolus Day 1
~Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1"
16499988|NCT03291886|Experimental|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.
~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
16499989|NCT03291886|Placebo Comparator|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.
~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
16499990|NCT03291873|Active Comparator|topography guided PRK in one eye|Topography-guided (placido disk- based) using T-CAT Contoura treatment.
16499991|NCT03291873|Active Comparator|Q-value adjusted ( custom Q) PRK in the other eye|The target Q will be estimated according to a nomogram considering the patient's age
16499992|NCT03291847|Experimental|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
16499993|NCT03291847|Active Comparator|Methadone treated|Participants receiving methadone treatment for opioid use disorder during pregnancy
16499994|NCT03291821|Experimental|DuoStim|Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
16499995|NCT03291821|Active Comparator|Conventional Stimulation|Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
16499996|NCT03291808|Experimental|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
16499997|NCT03291795|Experimental|Exercise Intervention|
16499998|NCT03291782|Experimental|D-0120 Dose 1|D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation
16499999|NCT03291782|Experimental|D-0120 Dose 2|D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation
16500000|NCT03291782|Experimental|D-0120 Dose 3|D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation
16500001|NCT03291782|Experimental|D-0120 Dose 4|D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation
16500002|NCT03291782|Experimental|D-0120 Dose 5|D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.
16500003|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
16500099|NCT03291002|Experimental|Cohort B|Optional expansion cohorts of CV8102
16500100|NCT03291002|Experimental|Cohort C|Dose escalation of CV8102 + anti-PD-1 therapy
16500005|NCT03291743|Active Comparator|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
16500006|NCT03291730|Experimental|Hand Lettering|"The participant will engage in art-therapy by tracing and coloring a detailed letter or word
~Participants will also be guided through a relaxation breathing and journaling exercise that can be incorporated into the art activity."
16500007|NCT03291717|Experimental|Bridging Community Gaps Photovoice (BCGP)|The BCGP program is a 6-month photovoice-based intervention to help individuals with psychiatric disabilities enhance their community participation.
16500008|NCT03291717|No Intervention|Services as Usual|Individuals in this group continue with their regular mental health services with no additional intervention.
16500009|NCT03291704|Experimental|Thermal Therapy|Heat application using at home thermal therapy device
16500010|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
16500011|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
16500012|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
16500013|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
16500014|NCT03291678|Experimental|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
16500015|NCT03291678|Active Comparator|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
16500016|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.
~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.
~Diagnosis procedure: DSA/3DRA"
16500017|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.
~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.
~Diagnosis procedure: DSA/3DRA"
16500018|NCT03291613|Experimental|Pinpoint App|Tablet application.
16500019|NCT03291600|Experimental|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
16500020|NCT03291600|No Intervention|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
16500021|NCT03291587|Experimental|Intervention - Key Informant|NCORP site coordinator will call each participant to administer a 5 minute telephone survey within 14 days of the lung cancer screening clinic visit. A participant contact log is appended. This assessment focuses on exposure to the intervention and subsequent quit attempts.
16500022|NCT03291587|No Intervention|Usual Care|Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)
16500023|NCT03291574|Experimental|Electroacupuncture group|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
16500024|NCT03291574|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
16500025|NCT03291561|Experimental|Electroacupuncture group|Electroacupuncture Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
16500026|NCT03291561|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu, sanli and bilateral Tian shu.
16500027|NCT03291548|Experimental|Quinoa Biscuit|The quinoa-enriched biscuits containing 7.11g quinoa flour.
16500028|NCT03291548|Placebo Comparator|Control biscuit|The placebo control biscuit: an iso-energetic, matched product in terms of appearance, taste, texture and smell.
16500029|NCT03291535|Placebo Comparator|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
16500030|NCT03291535|Active Comparator|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
16500031|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
16500032|NCT03291509|Active Comparator|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
16500033|NCT03291509|Experimental|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
16500101|NCT03291002|Experimental|Cohort D|Optional expansion of CV8102 + anti-PD-1 therapy
16500034|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
16500035|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
16500036|NCT03291496||Healthy Adult|One-time whole blood draw of 1ml collection
16500037|NCT03291483|Experimental|whole body vibration group|basketball players had done exercises on whole body vibration platform.
16500038|NCT03291483|Sham Comparator|plyometric training|Basketball players had done same plyometric exercises
16500039|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
16500040|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
16500041|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
16500042|NCT03291444|Experimental|CAR-T cells combined with peptide specific dendritic cell|CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell
16500043|NCT03291444|Active Comparator|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
16500044|NCT03291431|Active Comparator|Active iTBS|
16500045|NCT03291431|Sham Comparator|Sham iTBS|
16500046|NCT03291418|Experimental|ATB-346 OR Placebo|Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
16500047|NCT03291418|Active Comparator|Naproxen sodium|Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
16500048|NCT03291405||Body Mass Index less than 30|
16500049|NCT03291405||Body Mass Index more than 30|
16500050|NCT03291392||Atherosclerosis|"Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking.
~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
16500051|NCT03291392||Family members|"The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection.
~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
16500052|NCT03291392||Normal subjects|"Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking.
~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
16500053|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
16500054|NCT03291366|Experimental|MSC|infusion of aUCMSC and conventional therapy
16500055|NCT03291366|Active Comparator|conventional|conventional therapy
16500056|NCT03291353|Experimental|AML Patients|pembrolizumab 200 mg given IV once every three weeks
16500057|NCT03291340||Cognitively normal elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
16500058|NCT03291340||Cognitive impaired elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
16500059|NCT03291327|Active Comparator|Investigational product (Lactobacillus A)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.
~Lactobacillus (A) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
16500060|NCT03291327|Active Comparator|Investigational product (Lactobacillus B)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.
~Lactobacillus (B) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
16500061|NCT03291327|Placebo Comparator|Placebo Product (P)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.
~Placebo (P) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The placebo will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
16500062|NCT03291314|Experimental|Axitinib + Avelumab|On day 1 of the treatment phase, patients recruited to this arm will initiate concomitant continuous daily treatment with axitinib (InlytaTM, 5 mg comp BID) in combination with avelumab (10 mg/kg IV Q2 weeks)
16500102|NCT03290976|No Intervention|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
16500063|NCT03291314|Experimental|Axitinib (+Avelumab)|"On day 1 of the treatment phase, patients recruited to this arm will initiate treatment with continuous daily axitinib (InlytaTM, 5 mg comp BID).
~Patients who tolerate treatment with axitinib and are able to taper the dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone (or an equivalent dose of another oral corticosteroid) will initiate combination therapy with avelumab (10 mg/kg IV Q2 weeks) on day 43, following the the first MRI-based tumor response evaluation in week 6.
~Patients who do not tolerate monotherapy with axitinib, or cannot decrease their daily dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone will not be allowed to initiate avelumab treatment."
16500064|NCT03291301|Experimental|CBT Group|Cognitive Behavioral Therapy for Insomnia
16500065|NCT03291301|Experimental|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
16500066|NCT03291301|No Intervention|Wait-list Control Group|
16500067|NCT03291288|Experimental|Pexidartinib|"Part 1 (Drug-drug Interaction Phase):
~On Day 1, all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg). On Day 3, pexidartinib (800 mg/d) in twice daily (400 mg BID) dosing will be initiated and continue throughout the remainder of Part 1 and into Part 2. On the first day of pexidartinib treatment (Day 3), a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning pexidartinib dose (400 mg). On Day 13, a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning dose of pexidartinib (400 mg).
~Part 2 (Efficacy and Safety Phase):
~All participants will continue to receive pexidartinib 400 mg BID."
16500068|NCT03291249|Placebo Comparator|Group A|Group A will receive placebo solution for 30 consecutive days
16500069|NCT03291249|Experimental|Group B|Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
16500070|NCT03291249|Experimental|Group C|Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
16500071|NCT03291249|Experimental|Group D|Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
16500072|NCT03291223||GOS Participants|GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment
16500073|NCT03291210|Experimental|Normoxemia|Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.
16500074|NCT03291210|Active Comparator|Hyperoxemia|Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.
16500075|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
16500076|NCT03291171|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
16500077|NCT03291171|No Intervention|Waiting-list control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
16500078|NCT03291158|Experimental|Minocycline IV|Open label Minocin IV
16500079|NCT03291145|Experimental|Beta Blockers|With and without Beta Blockers
16500080|NCT03291145|Experimental|Spironolactone|With and without Spironolactone
16500081|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.
~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
16500082|NCT03291093|Experimental|18F-Flutemetamol PET/MRI dynamic|"All included patients will be patients with a recent stroke and a significant carotid plaque.
~The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging."
16500083|NCT03291093|Experimental|18F-Flutemetamol PET/MRI CEA|10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
16500084|NCT03291093|Experimental|18F-Flutemetamol PET/MRI|The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.
16500087|NCT03291067|Experimental|MT-8554 Low dose|
16500088|NCT03291067|Experimental|MT-8554 Medium dose|
16500089|NCT03291067|Experimental|MT-8554 High dose|
16500090|NCT03291067|Placebo Comparator|Placebo|
16500091|NCT03291054|Experimental|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
16500092|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
16500093|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
16500094|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
16500095|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
16500096|NCT03291015|Other|radiographic guided treatment|radiographic guided treatment of kienbock disease using plain x ray for determine treatment plan
16500097|NCT03291015|Other|arthroscopic guided treatment|arthroscopic guided treatment of kienbock disease using wrist arthroscopy for determine treatment plan (Wrist arthroscopy)
16500098|NCT03291002|Experimental|Cohort A|Dose escalation of CV8102
16500103|NCT03290976|Active Comparator|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
16500104|NCT03290976|Active Comparator|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
16500105|NCT03290963|Active Comparator|Ketamine plus Lithium|Lithium will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of lithium treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and lithium treatment .
16500106|NCT03290963|Placebo Comparator|Ketamine plus Placebo|Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
16500107|NCT03290950|Experimental|Cohort 1|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
16500108|NCT03290950|Experimental|Cohort 2|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
16500109|NCT03290937|Experimental|Treatment (irinotecan hydrochloride, cetuximab, utomilumab)|Patients receive irinotecan hydrochloride IV over 90 minutes and cetuximab IV over 1-2 hours on days 1 and 15, and utomilumab IV over 1 hour on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16500110|NCT03290924|Experimental|Intervention|Low-dose high-frequency health worker training approach to update skilled birth attendants in key evidence-based intrapartum and immediate newborn care practices
16500111|NCT03290924|Active Comparator|Comparison|Training on data collection and reporting
16500112|NCT03290898|Active Comparator|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.
~Training session:
~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
16500113|NCT03290898|No Intervention|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
16500114|NCT03290885|Experimental|Combined use of contact aspiration and stent retriever|Combined use of contact aspiration and stent retriever mechanical thrombectomy for recanalization
16500115|NCT03290885|Active Comparator|Stent retriever mechanical thrombectomy alone|Stent retriever mechanical thrombectomy alone for recanalisation
16500116|NCT03290872|Active Comparator|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral Valve Annuloplasty Ring Repair using Carpentier Edwards Physio 2 Complete flexible mitral ring
16500117|NCT03290872|Active Comparator|Simplici T Partial flexible mitral annuloplasty ring|Mitral Valve Annuloplasty Ring Repair using Simplici T Partial flexible mitral annuloplasty ring
16500118|NCT03290859||Training intervention|Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol.
16500119|NCT03290859||Effectiveness of training intervention|Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times.
16500120|NCT03290846|Experimental|Secretin study|PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo cold exposure PET scanning once.
16500121|NCT03290833|Experimental|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
16500122|NCT03290833|Active Comparator|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
16500123|NCT03290820|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
16500124|NCT03290820|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
16500125|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
16500126|NCT03290781|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
16500127|NCT03290781|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
16500162|NCT03290508||No Prolaris Testing|Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing
16500128|NCT03290781|Placebo Comparator|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
16500129|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
16500130|NCT03290755||MSM co-infected HIV-HCV|
16500131|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
16500132|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
16500133|NCT03290729|Experimental|narrow ridge|edentulous site with crestal bone width comprised between 3,5 and 5 millimeters wedge shape implants insertion
16500134|NCT03290716|Experimental|SS+SSSC|Salt substitute plus stepwise salt supply control
16500135|NCT03290716|Experimental|SS only|Salt substitute only
16500136|NCT03290716|Experimental|SSSC only|Stepwise salt supply control only
16500137|NCT03290716|No Intervention|control|No salt substitute and no stepwise salt supply control
16500138|NCT03290703|Experimental|Part 1: GDC-0853 (Effect of Formulation)|Participants will receive five single oral doses of test formulations of GDC-0853 co-administered with rabeprazole in the fasted state.
16500139|NCT03290703|Experimental|Part 2: GDC-0853 (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of one GDC-0853 formulations selected from Part 1 of this study. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
16500140|NCT03290703|Experimental|Part 3: GDC-0853 Optimized (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of an optimized tablet formulations of GDC-0853. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
16500141|NCT03290690||All Subjects|"All subjects in this study will have their wounds imaged and assessed in the following manner:
~Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form"
16500142|NCT03290677|Experimental|CT-guided Percutaneous Cryoablation of Lung Tumor|"Image-guided core needle biopsy to confirm cancer will be perform
~Patients will undergo cryoablation as a standard procedure
~cryoablation will be performed with a three-cycle freeze-thaw phase protocol
~Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
16500143|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
16500144|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
16500145|NCT03290638|Experimental|Dehydrated Human Amnion Chorion Membrane|This membrane was investigated to evaluate its use as an open barrier for guided bone regeneration (GBR) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.
16500146|NCT03290638|Active Comparator|Type I Bovine Collagen Membrane|This membrane has been tested as an open barrier for GBR after tooth extraction. The intentional use of this membrane to the oral environment did not compromise ridge dimensions and bone vitality for implant placement.
16500147|NCT03290625|Experimental|DexKet|Intranasal DEXMEDETOMIDINE (2.0 mcg/kg, maximum 100 mcg) + KETAMINE (1.0 mg/kg, maximum 100 mg)
16500148|NCT03290625|Active Comparator|Dex|DEXMEDETOMIDINE (2.5 mcg/kg, maximum 100 mcg)
16500149|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
16500150|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
16500151|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
16500152|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
16500153|NCT03290573|Active Comparator|Dorsum of hand group|short peripheral venous catheter place in the dorsum of the hand
16500154|NCT03290573|Experimental|Forearm group|short peripheral venous catheter place in the forearm
16500155|NCT03290560|Experimental|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
16500156|NCT03290560|Placebo Comparator|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
16500157|NCT03290547|Other|arm-1|Cutera enLighten laser treatments that allows the user to choose a wavelength between 640nm to 800nm.
16500158|NCT03290534|Experimental|CivaSheet Directional LDR Brachytherapy|FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
16500159|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
16500160|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
16500161|NCT03290508||Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
16500352|NCT03289156|Active Comparator|Exercise|Three 5-minute bouts of aerobic exercise at increasing intensities
16500163|NCT03290495|Active Comparator|isonly|This arm will receive spinal anesthesia. then this arm will receive saline during isoflurane anesthesia. this arm will serve as a control group.
16500164|NCT03290495|Active Comparator|isoket|this arm will receive spinal anesthesia. then will receive isoflurane inhalation. during isoflurane inhalation, this arm will receive single injection of ketamine. at end of anesthesia, effect of ketamine on recovery will be monitored.
16500165|NCT03290482||EE Study Patients 2000-2008|"All patients with the diagnosis of EE from the study period 2000 to 2008. Sixty patients participated in the 10 year follow up phone interview and questionnaire. These are the subjects we will contact to see if they are interested in participating in this study.
~If interested in participating, subjects will complete:
~Evaluation by the PI physical examination
~Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) questionnaires
~Barium Esophagram with maximal and minimal esophageal diameter measurement
~EsophaCap cytology"
16500166|NCT03290469|Experimental|15 day cWGS and Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 15 days of the sample receipt while still undergoing standard of care (SOC).
16500167|NCT03290469|No Intervention|Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 60 days of the sample receipt while still undergoing standard of care (SOC).
16500168|NCT03290456|Experimental|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day will be administered from Day 1 to Month 12
16500169|NCT03290456|Placebo Comparator|Placebo 5mg/day extended of 12 additional months|Placebo 5mg/day will be administered from Day 1 to Month 12
16500170|NCT03290443|Experimental|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
16500171|NCT03290430|Experimental|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
16500172|NCT03290430|Experimental|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
16500173|NCT03290430|Experimental|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
16500174|NCT03290430|Experimental|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
16500175|NCT03290417|No Intervention|Unmodified Diet|Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
16500176|NCT03290417|Experimental|Diet modification|Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
16500177|NCT03290391|Experimental|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
16500178|NCT03290391|No Intervention|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
16500179|NCT03290378|Active Comparator|AVE-901 50 mg|
16500180|NCT03290378|Active Comparator|AVE-901 25 mg|
16500181|NCT03290378|Placebo Comparator|Placebo|
16500182|NCT03290365|Active Comparator|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
16500183|NCT03290365|Placebo Comparator|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
16500353|NCT03289156|Experimental|Arousal Reappraisal + Exercise|Brief educational intervention about the stress response and arousal reappraisal followed by three 5-minute bouts of aerobic exercise at increasing intensities with practice applying the arousal reappraisal learned earlier.
16500354|NCT03289156|No Intervention|Control|Time-matched rest
16500184|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
16500185|NCT03290326|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
16500186|NCT03290313|Experimental|shu gan yi yang capsule|4 capsules / time, 3 times / day, taking 8 weeks
16500187|NCT03290313|Placebo Comparator|shu gan yi yang capsule capsule simulation agent|4 capsules / time, 3 times / day, taking 8 weeks
16500188|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
16500191|NCT03290274|Experimental|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
16500192|NCT03290274|Experimental|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
16500193|NCT03290261|Experimental|Patients with reccurent cystitis|Patient perform 3 hypnosis sessions
16500194|NCT03290248|Placebo Comparator|Vehicle|"Intranasal application:
~1 pump (140ul) per nostril BID for 14 days"
16500195|NCT03290248|Active Comparator|B 244 1x (low dose)|"Intranasal application:
~1 pump (140ul) per nostril BID for 14 days"
16500196|NCT03290248|Active Comparator|B244 4x (mid dose)|"Intranasal application:
~1 pump (140ul) per nostril BID for 14 days"
16500197|NCT03290235|Experimental|PEG-somatropin-1|Dosage 0.2mg/kg/w
16500198|NCT03290235|Experimental|PEG-somatropin-2|Dosage 0.1-0.2mg/kg/w
16500199|NCT03290222||TRACK|Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
16500200|NCT03290209|Experimental|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
16500201|NCT03290209|Active Comparator|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
16500202|NCT03290196|Other|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:
~size of surgical site
~volume required to cover the area
~individual patient factors that may impact the safety of an amide local anesthetic
~maximum doe of 266 mg (20 mL)"
16500203|NCT03290183||Intrathoracic malignancy|Patients with (strong suspicion of) intrathoracic malignancy and an indication for tissue collection by CT-guided, transthoracic or thoracoscopic approach undergo additional imaging with confocal laser endomicroscopy (CLE).
16500204|NCT03290170|Experimental|Measured resection technique|Measured resection surgical technique
16500205|NCT03290170|Experimental|Gap Balancing Technique|Gap Balancing surgical technique
16500206|NCT03290157|No Intervention|Control group|Regular colonoscopy preparation paper based information provided
16500207|NCT03290157|Other|ColoprAPP group|Regular colonoscopy preparation paper based information provided plus usage of a downloaded SPA (ColoprAPP) as a reminder system for colonoscopy preparation
16500208|NCT03290144||with diabetes|
16500209|NCT03290144||without diabetes|
16500210|NCT03290131|Active Comparator|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
16500211|NCT03290131|Active Comparator|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
16500212|NCT03290131|Placebo Comparator|Placebo|Placebo
16500213|NCT03290118|Experimental|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.
~Intervention is the Nutrition Rating System - Traffic Light"
16500214|NCT03290118|Experimental|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.
~Intervention is the Nutrition Rating System - Health Star Rating"
16500215|NCT03290118|Experimental|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.
~Intervention is the Nutrition Rating System - Warning Labels"
16500216|NCT03290118|No Intervention|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
16500217|NCT03290105||study population|Consecutive critically-ill patients admitted to the ICU and receiving invasive mechanical ventilation for more than 48 hours
16500218|NCT03290092|Experimental|Treatment|
16500219|NCT03290079|Experimental|Pembrolizumab & Lenvatinib treatment|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks, in addition to 20 mg Lenvatinib by mouth every day of each 3 week cycle. Estimated average length of treatment per participant: 4 months.
16500355|NCT03289143|Experimental|Dose 1 Semorinemab|
16500356|NCT03289143|Experimental|Dose 2 Semorinemab|
16500357|NCT03289143|Experimental|Dose 3 Semorinemab|
16500358|NCT03289143|Placebo Comparator|Placebo|
16500220|NCT03290066|Active Comparator|Kinesiotape|"Kinesiotape will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).
~Patients will be taped for four days , ıt will start at the beginning of the menstruation."
16500221|NCT03290066|Active Comparator|Usual care|"Participants will use the usual self-care for primary dysmenorrhea. It will start at the beginning of the menstruation.
~They will note the treatment indicating the dosage in a calendar."
16500222|NCT03290053|Experimental|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
16500223|NCT03290053|Sham Comparator|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
16500224|NCT03290053|Experimental|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
16500225|NCT03290053|Sham Comparator|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
16500226|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
16500227|NCT03290027|Placebo Comparator|Vehicle|Vehicle (0% tazarotene) Lotion
16500228|NCT03290014||Good sleepers|COPD patients with good sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
16500229|NCT03290014||Bad sleepers|COPD patients with poor sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
16500230|NCT03289988||Normal group|Normal group(control group): patients with negative colonoscopy findings (n= 238).
16500231|NCT03289988||Low risk adenoma group|Low risk adenoma group: patients having at least one low risk adenoma (n=250).
16500232|NCT03289988||High-risk adenoma group|High-risk adenoma group: patients having at least one of following criteria (more than 1 cm in size, villous or tubulovillous histologic type, high-grade dysplasia findings) (n=316).
16500233|NCT03289988||Colon cancer|Colon cancer: histologically confirmed colon cancer patients (n=160).
16500234|NCT03289962|Experimental|Phase 1a Flat Dose Escalation: Autogene Cevumeran|Participants will receive autogene cevumeran at escalated dosages.
16500235|NCT03289962|Experimental|Phase 1b Flat Dose Escalation: Autogene Cevumeran + Atezolizumab|Participants will receive autogene cevumeran at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg)
16500236|NCT03289962|Experimental|Phase Ib: Dose Exploration: Autogene Cevumeran + Atezolizumab|Non-small cell lung cancer (NSCLC) or melanoma cancer immunotherapy (CIT)-treated participants will receive autogene cevumeran (at dosage lower than maximum tolerated dose [MTD] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
16500237|NCT03289962|Experimental|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab|Participants with different indications as per inclusion criteria will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
16500238|NCT03289962|Experimental|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab (Serial Biopsy)|CIT-naive patients with selected tumor types who consent to optional serial biopsies will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a dixed dose of 1200 mg.
16500239|NCT03289949|Other|Project 1: Occupancy of psilocybin/ketanserin|After baseline MRI & 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
16500240|NCT03289949|Other|Project 2: Long term effects of psilocybin|After baseline MRI & CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.
16500241|NCT03289949|Other|Project 3: Functional connectivity and synaptic plasticity|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.
16500242|NCT03289936|Experimental|Start ventilation with NIPPV|Alternatively vented with NIPPV and SNIPPV
16500243|NCT03289936|Experimental|Start ventilation with SNIPPV|Alternatively vented with SNIPPV and NIPPV
16500246|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16500247|NCT03289910|Active Comparator|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16500248|NCT03289897|Experimental|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
16500249|NCT03289897|No Intervention|Control Arm|Standard of care as per guidelines of the local centre
16500250|NCT03289884||Control Group (CE1)|"All patients must have cystic lesions which must exceed 30mm in diameter.
~All patients must be aged 16 or over and able to provide informed consent.
~Patients will have an MRI scan (not involving ionising radiation)
~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'
~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
16500359|NCT03289117|Experimental|Novel gel installation device procedure|"Catheter change with novel device.
~Each subject will undergo catheter change with novel gel instillation device procedure"
16500360|NCT03289117|Active Comparator|Standard procedure|"Catheter change with standard procedure.
~Each subject will undergo catheter change with standard procedure"
16500361|NCT03289104|Active Comparator|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
16500429|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
16500251|NCT03289884||CE group (CE2-4)|"All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.
~All patients must be aged 16 or over and able to provide informed consent.
~All patients will have an MRI scan (not involving ionising radiation)
~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'
~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.
~Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
16500252|NCT03289871|Experimental|Excilor|2 applications per day for 6 months
16500253|NCT03289871|Active Comparator|Loceryl 5%|1 application per week for 6 months
16500254|NCT03289858|Experimental|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
16500255|NCT03289858|Placebo Comparator|Saline Control|Saline Solution (Sodium Chloride)
16500256|NCT03289845|Other|BHX implant|All patients implanted with BHX implant
16500257|NCT03289832|Active Comparator|Crucera-SGS®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) per day.
~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third days of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
16500258|NCT03289832|Active Comparator|Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.
~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks, for a total of 8 skin-punch biopsies per individual."
16500259|NCT03289832|Active Comparator|Crucera-SGS® and Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a cruciferous vegetable-free diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) and Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.
~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
16500260|NCT03289819|Experimental|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.
~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
~After the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.
~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
16500261|NCT03289806||Cases|Glaucoma surgery
16500262|NCT03289806||Controls|Strabismus surgery
16500263|NCT03289793|Experimental|Group A|"Children will be assigned to this group in a random fashion according to a ratio 2:1 with respect to group B (see below).
~20 subjects will be included in this group."
16500264|NCT03289793|Active Comparator|Group B|Children will be assigned in this group in a random fashion. 10 subjects will be included in this group.
16500265|NCT03289793|Active Comparator|Group C|"Will be included in this group children who meet the inclusion criteria and who, with their families, are motivated to participate in the study but cannot claim to be part of groups A or B (because of logistical constraints: living too far away to comply with the frequency of the visits required by the training).
~Group C allows to follow the natural evolution of children with ADHD with no intervention."
16500266|NCT03289767|Experimental|Curved-tube|Giving additional curve to the endotracheal tube by simple preparation.
16500267|NCT03289767|No Intervention|Control|No other manipulation of the endotracheal tube is done.
16500268|NCT03289754|Experimental|ConforMIS iTotal Knee with iPoly Insert|The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.
16500269|NCT03289741|Experimental|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
16500270|NCT03289741|Experimental|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
16500271|NCT03289728|Experimental|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.
~- Low or intermediate risk patients will receive optimal medical treatment."
16500272|NCT03289728|Active Comparator|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
16500273|NCT03289715|Experimental|arm 1|on demand humidification
16500274|NCT03289702|Experimental|CORETOX®|
16500275|NCT03289702|Active Comparator|BOTOX®|
16500276|NCT03289689|Experimental|Whole body vibration|"The subjects in the WBV group performed one series of five consecutive repetitions of 60 sec unsynchronised multidimensional WBV (Zeptoring, Scisen GmbH, Germany; 4 Hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. The construction of this device is designed to perform a nonharmonious generation of oscillating movements in vertical and horizontal planes in order to prevent occurrences of resonance and habituation of receptors.
~During the intervention, subjects wore thin-soled gymnastic-type shoes, carrying out in a squatting standing position, with slight flexion at the hips, knees and ankle joint, on the vibration platform."
16500277|NCT03289689|No Intervention|Control|The controls did not receive any training.
16500278|NCT03289676|Experimental|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
16500279|NCT03289676|Active Comparator|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
16500280|NCT03289663|Active Comparator|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
16500281|NCT03289663|Experimental|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
16500282|NCT03289650|Active Comparator|Standard of care tacrolimus twice-daily|
16500283|NCT03289650|Active Comparator|Extended-release tacrolimus once-daily|
16500284|NCT03289637|Experimental|Active intervention|"In the group randomised to active treatment and with a screening level of 25-OH-vitamin D 25-50nmol/L an intervention with 1600IE daily of vitamin D will be given.
~In those randomised to active treatment and with a screening level of 25-OH-vitamin D of <25nmol/L, an intervention of 2400IE of vitamin D will be given."
16500285|NCT03289637|Placebo Comparator|Placebo|In the group randomised to placebo and with a screening level of 25-OH-vitamin D <50 mol/L, the participants will be given placebo.
16500286|NCT03289624|Experimental|SHARE for Chronic Conditions|"Six weekly SHARE for Chronic Conditions (SHARE-CC) sessions will be conducted in the dyad's home or another location preferred by the participants. A care plan (the SHARE plan) is created that reflects the mutual decisions made by the dyad as a result of their participation in the SHARE-CC program. The SHARE plan is intended to help the caregiver (CG) ensure the PWCC's values and preferences are supported when decisions have to be made in an emergency or in the end stages of the disease. SHARE plans will be documented in a notebook that also contains information on key topics and provides links to local and online resources and services."
16500287|NCT03289624|No Intervention|Health Coaching|Six 30-minute weekly telephone calls to provide information and education related to the PWCC's conditions and information about services and care options will be conducted.
16500288|NCT03289611|No Intervention|Control|Usual management
16500289|NCT03289611|Experimental|Experimental|Ambulatory management if sFlt-1 / PlGF ratio is below 38 Usual management if sFlt-1/PlGF is between 38 and 85. If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued
16500290|NCT03289598|Experimental|Interventionsgroup|
16500291|NCT03289598|No Intervention|Controlgroup|
16500292|NCT03289585||Hidradenitis Suppurativa Cohort|Patients with Hidradenitis Suppurativa (ages 18-99 years old) will be asked to complete a series of questionnaires on how Hidradenitis Suppurativa impacts quality of life.
16500293|NCT03289559|No Intervention|Control|
16500294|NCT03289559|Placebo Comparator|GnRH antagonist + Placebo Gel|
16500295|NCT03289559|Active Comparator|GnRH antagonist + Testosterone Gel|
16500296|NCT03289546|Experimental|Mindfulness training only|1 mindfulness training class (1 hour) every week for 8 weeks.
16500297|NCT03289546|Experimental|Aerobic training only|3 aerobic training sessions (1 hour) per week for 12 weeks.
16500298|NCT03289546|Experimental|mindfulness + aerobic training|2 aerobic training sessions + 1 mindfulness training class every week for 8 weeks, then continue with 3 aerobic training sessions/ week for 4 additional weeks.
16500299|NCT03289546|No Intervention|Usual care|
16500300|NCT03289533|Experimental|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
16500301|NCT03289520|Experimental|Clopidogrel|
16500302|NCT03289520|Placebo Comparator|Placebo|
16500303|NCT03289507|Active Comparator|Treatment1|Longvida Capsule formulation A
16500304|NCT03289507|Active Comparator|Treatment 2|Longvida Capsule formulation B
16500305|NCT03289507|Experimental|Treatment3|Curcuma longa extract of Rhizomes
16500306|NCT03289494|Active Comparator|Diet A|Balanced diet high in Slowly Digestible Starch
16500307|NCT03289494|Placebo Comparator|Diet B|Balanced diet low in Slowly Digestible Starch
16500308|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
16500309|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
16500310|NCT03289468||Group1|Endometrial Benign Disease
16500311|NCT03289468||Group2|Endometrial Cancer and Precancerous Lesions
16500312|NCT03289455|Experimental|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
16500313|NCT03289442|Experimental|supine position group|
16500314|NCT03289442|No Intervention|left lateral position|
16500315|NCT03289429|Experimental|Atorvastatin|Atorvastatin and intravenous placebo
16500316|NCT03289429|Experimental|Magnesium sulfate|Magnesium sulfate and tablets placebo
16500317|NCT03289429|Placebo Comparator|Control|intravenous placebo and tablet placebo
16500362|NCT03289104|Experimental|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
16500394|NCT03288870|Experimental|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
16500430|NCT03288636|Experimental|Experimental|"PKGroup:
~Ravidasvir + Danoprevir/ Ritonavir"
16500431|NCT03288636|Placebo Comparator|Placebo|"Placebo Group:
~Placebo"
16500318|NCT03289416|Other|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
16500319|NCT03289416|Other|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
16500320|NCT03289403|Experimental|Study group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins)
16500321|NCT03289403|Active Comparator|Control group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
16500322|NCT03289390||Acetaminophen to close PDA|Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen
16500323|NCT03289377|Experimental|RDAD training to APNs|Half-day workshop to provide APNs with all skills necessary to conduct RDAD in their clinical settings. A subset of the trained APNs will implement RDAD as part of their ongoing care of persons with ADRD.
16500324|NCT03289364|Experimental|Penguin Cold Caps|Penguin Cold-cap therapy will commence at least 50 minutes prior to chemotherapy infusion, and will continue for 4 hours following completion of chemotherapy.
16500325|NCT03289351|No Intervention|2-drug Therapy|ceftriaxone/metronidazole
16500326|NCT03289351|Experimental|1-drug Therapy|piperacillin-tazobactam
16500327|NCT03289338|Experimental|Zoledronic acid|Bisphosphonate Zoledronic acid
16500328|NCT03289338|Active Comparator|Methylprednisolone|Glucocorticoid Methylprednisolone
16500329|NCT03289338|Placebo Comparator|Placebos|Placebo normal saline
16500330|NCT03289325|Experimental|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
16500331|NCT03289325|Placebo Comparator|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
16500332|NCT03289312||Sepsis|Diagnosis of new onset sepsis within 24h without history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.
16500333|NCT03289312||Health control|Health vonlunteers
16500334|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
16500335|NCT03289286|Other|Patients with breast cancer operated in ambulatory|
16500337|NCT03289260|Experimental|Interventional Arm|Imiquimod 5% cream therapy Fulguration
16500338|NCT03289260|Placebo Comparator|Placebo Arm|Placebo cream therapy Fulguration
16500339|NCT03289247|No Intervention|Regular|"Regular closure:
~The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure."
16500340|NCT03289247|Experimental|Additional tissue adhaesive|The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
16500341|NCT03289234|Experimental|mild hepatic impairment|
16500342|NCT03289234|Experimental|moderate hepatic impairment|
16500343|NCT03289234|Experimental|normal hepatic function|
16500344|NCT03289221|Experimental|Experimental Group|Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
16500345|NCT03289208|Experimental|mild renal impairment|
16500346|NCT03289208|Experimental|moderated renal impairment|
16500347|NCT03289208|Experimental|normal renal function|
16500348|NCT03289195|Experimental|MRI biopsy|All patients enrolled will have had complete MR imaging response post Neoadjuvant Chemotherapy (NAC) and will undergo percutaneous MR guided biopsy.
16500349|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
16500350|NCT03289169|Experimental|MEDITOXIN|Meditoxin(Botulinum toxin type A)
16500351|NCT03289156|Active Comparator|Arousal Reappraisal|Brief educational intervention about the stress response and arousal reappraisal
16500363|NCT03289091|Experimental|water-based continuous aerobic training|Participants who will be randomized for the intervention in the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
16500364|NCT03289091|Experimental|water-based interval aerobic training|Participants who will be randomized for the intervention in the interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
16500365|NCT03289078|Experimental|Thermal care|Spa Treatment realised daily 6 days a week during 18 days
16500366|NCT03289078|No Intervention|Standard Care|Usual care
16500367|NCT03289065||FOS Participant|FOS is a disease registry open to all Fabry participants irrespective of treatment status or type of treatment.
16500368|NCT03289052|Experimental|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
16500369|NCT03289052|No Intervention|No intervention arm|No treatment
16500372|NCT03289026|Experimental|aripiprazole group|Patients receive aripiprazole treatment
16500373|NCT03289013|Experimental|Testing of new adhesive strips|"Each subject will test six adhesive strips on pre-stripped skin.
~Standard adhesive 1
~Standard adhesive 2
~LT-2
~LT-21
~LT-25
~33-20
~The six strips are applied on the abdominal skin. The order of the adhesive strips on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of adhesive strips will be measured at 5 visits."
16500374|NCT03289000||ConforMIS PS Group|Patients who have undergone a total knee replacement with the ConforMIS iTotal PS Knee Replacement System
16500375|NCT03288987|Experimental|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
16500376|NCT03288987|Active Comparator|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
16500377|NCT03288974||Post Marketing Survey of MM patients treated with POMALYST®|As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline [standard for Re-examination of New Drugs, etc.] as a post approval commitment.
16500378|NCT03288948|Active Comparator|Standard Contrast Increment|
16500379|NCT03288948|Experimental|Reduced Contrast Increment|
16500380|NCT03288948|Experimental|No Contrast Increment|
16500381|NCT03288935|Active Comparator|Group 1 (TICM only)|Assigned to TICM group after reception & placement.
16500382|NCT03288935|Active Comparator|Group 2 (TICO only)|Assigned to TICO group after reception & placement.
16500383|NCT03288935|Active Comparator|Group 3 (TICM & TICO)|Assigned to both TICM and TICO group after reception & placement.
16500384|NCT03288935|No Intervention|Group 4 (None)|No additional intervention after reception & placement
16500385|NCT03288922|Experimental|Limited BF OL-HDF with SHF|Limited blood flow pre-dilution online hemodiafiltration using super high-flux dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of protein-bound toxin removals with the control period.
16500386|NCT03288922|Active Comparator|High-efficiency OL-HDF|High-efficiency post-dilution online hemodiafiltration using standard high-flux dialyzer was assigned as the control period.
16500387|NCT03288909||Early onset Parkinson's disease|Idiopathic Parkinson's disease within 1 year of symptom onset
16500388|NCT03288909||Idiopathic REM Sleep Behavior Disorder|Idiopathic REM Sleep Behavior Disorder
16500389|NCT03288909||Age-matched healthy controls|Age-matched healthy controls
16500390|NCT03288896|Experimental|Alerta Alcohol|Intervention Group: The Experimental Group receives the Alerta Alcohol intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. Evaluation takes place after four months.
16500391|NCT03288896|No Intervention|Control Group|Control Group: The Control Group just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition). Evaluation takes place after four months from baseline
16500392|NCT03288883|Active Comparator|Fractional Microablative CO2-laser|
16500393|NCT03288883|Active Comparator|Photothermal Non-ablative Erbium:YAG-laser|
16500428|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
16500395|NCT03288870|Active Comparator|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
16500396|NCT03288857|No Intervention|Bulb Aspirator|If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
16500397|NCT03288857|Experimental|Nasal Oral Aspirator (NeilMed Naspira)|If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
16500398|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
16500399|NCT03288831|Active Comparator|Normal Subjects, Gluten Drink|Normal subjects will drink a solution containing 6 grams of gluten one time.
16500400|NCT03288831|Placebo Comparator|Normal Subjects, Placebo Drink|Normal subjects will drink a solution without gluten one time.
16500401|NCT03288831|Active Comparator|Celiac Subjects, Gluten Drink|Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
16500402|NCT03288831|Placebo Comparator|Celiac Subjects, Placebo Drink|Subjects with celiac disease will drink a solution without gluten one time.
16500403|NCT03288831|Active Comparator|Gluten Sensitivity, Gluten Drink|Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
16500404|NCT03288831|Placebo Comparator|Gluten Sensitivity, Placebo Drink|Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
16500405|NCT03288818|Experimental|low dose TSEBT, mechlorethamine hydrochloride gel|Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
16500406|NCT03288792|Experimental|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
16500407|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
16500409|NCT03288753|Experimental|Adults and children above 14 years old|"Visit 1:
~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1
~Visit 2 (15 days after V1):
~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2
~Visit 3 (3 months after V2):
~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
16500410|NCT03288753|Experimental|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1
~Visit 2 (15 days after V1):
~Satisfaction questionnaire on Neuro 2
~Visit 3 (3 months after V2):
~Satisfaction questionnaire on Neuro 2
~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
16500411|NCT03288740|Experimental|Semaglutide 0.5 mg|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
16500412|NCT03288740|Placebo Comparator|Semaglutide 0.5 mg placebo|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
16500413|NCT03288740|Experimental|Semaglutide 1.0 mg|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
16500414|NCT03288740|Placebo Comparator|Semaglutide 1.0 mg placebo|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.
16500415|NCT03288727|Experimental|Negative IF result|
16500416|NCT03288727|Experimental|Positive IF result|
16500417|NCT03288714|Experimental|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
16500418|NCT03288714|Sham Comparator|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
16500419|NCT03288701|Experimental|Body Composition Analysis|Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
16500420|NCT03288688|Experimental|Exercise program and education|An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
16500421|NCT03288688|No Intervention|No intervention|Participants in this group will be asked to continue their usual activities.
16500422|NCT03288675|Active Comparator|Active aiTBS - active CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive active CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
16500423|NCT03288675|Experimental|Active aiTBS - sham CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive a control training for a period of 4 weeks in combination with an antidepressant (SSRI)
16500424|NCT03288675|Experimental|Sham aiTBS - aiTBS - active CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week receive CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
16500425|NCT03288675|Experimental|Sham aiTBS - aiTBS - sham CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week control training for a period of 4 weeks in combination with an antidepressant (SSRI)
16500426|NCT03288662|Experimental|CT and histopathological classification|With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .
16500427|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
16500433|NCT03288623|Placebo Comparator|White/Milk Chocolate|White chocolate or Milk chocolate administration in tablet (<35% cocoa) per day for 30 days
16500434|NCT03288610||With inflammatory response|"Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome.
~Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.
~Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2.
~Patients without postoperative severe SIRS and without postoperative vasodilation syndrome"
16500435|NCT03288597||A: advanced and metastatic neuroendocrine tumors|Advanced and metastatic neuroendocrine tumors receive syestematic treatment
16500436|NCT03288597||A: advanced and metastatic neuroendocrine carcinomas|Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment
16500437|NCT03288584||Tocilizumab|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
16500438|NCT03288584||Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
16500439|NCT03288584||Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
16500440|NCT03288571|Experimental|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.
~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
16500441|NCT03288558|Experimental|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
16500442|NCT03288558|No Intervention|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
16500443|NCT03288545|Experimental|EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L|Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
16500444|NCT03288545|Experimental|Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
16500445|NCT03288545|Experimental|Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
16500446|NCT03288545|Experimental|Cohort D: Enfortumab Vedotin + Cisplatin in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
16500447|NCT03288545|Experimental|Cohort E: Enfortumab Vedotin + Carboplatin in 1L|Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
16500448|NCT03288545|Experimental|Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L|Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
16500449|NCT03288545|Experimental|Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
16500450|NCT03288545|Experimental|Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 every 21 days
16500451|NCT03288545|Experimental|Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
16500452|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin Monotherapy|Enfortumab vedotin on days 1 and 8 every 21 days
16500453|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
16500454|NCT03288545|Experimental|Cohort L: Enfortumab vedotin in MIBC in perioperative setting|Enfortumab vedotin on days 1 and 8 and every 21 days
16500455|NCT03288532|No Intervention|Arm A (active monitoring)|Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse
16500456|NCT03288532|Experimental|Arm B (durvalumab monotherapy)|Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)
16500457|NCT03288532|Experimental|Arm C (durvalumab + tremelimumab)|Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)
16500458|NCT03288506|Experimental|Google Hangout (VC) group|This group receive peer led support for depression via Google Hangouts for 8-weeks
16500459|NCT03288506|No Intervention|Waiting list control group|Waiting list
16500460|NCT03288493|Experimental|Phase 1: P-BCMA-101 CAR-T cells|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
16500461|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort A)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
16500462|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort B)|Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
16500463|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort C)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
16500464|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
16500465|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
16500466|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
16500467|NCT03288493|Experimental|Phase 2: P-BCMA-101 CAR-T Cells|CAR-T cells administered via intravenous infusion as a total dose
16501914|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
16500468|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
16500469|NCT03288467|Active Comparator|Root canal treatment with 5% NaOCl|Root canal treatment with 5% NaOCl: 5 ml of 5% sodium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 5% sodium hypochlorite.
16500470|NCT03288467|Active Comparator|Root canal treatment with 1% NaOCl|5 ml of 1% soium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 1% sodium hypochlorite.
16500471|NCT03288454|Experimental|Cohort 1|ciraparantag (60 mg)
16500472|NCT03288454|Experimental|Cohort 2|ciraparantag (120 mg)
16500473|NCT03288454|Experimental|Cohort 3|ciraparantag (30 mg)
16500474|NCT03288454|Placebo Comparator|Placebo|placebo (saline for injection)
16500475|NCT03288441||antiplatelet only|"Patients receiving antiplatelet medication, but not anticoagulation. Antiplatelet drugs include any class, dose or duration of any platelet aggregation inhibitor.
~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
16500476|NCT03288441||anticoagulant-based|"Patients receiving only anticoagulants or both anticoagulant and antiplatelet medication combined. This includes any class, dose or duration of any antiplatelet or anticoagulant drug.
~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
16500477|NCT03288428|Experimental|nalbuphine|using nalbuphine for patient controlled analgesia
16500478|NCT03288428|Active Comparator|morphine|using morphine for patient controlled analgesia
16500479|NCT03288402|Experimental|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
16500480|NCT03288402|Experimental|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
16500481|NCT03288402|Experimental|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
16500482|NCT03288389|Placebo Comparator|Placebo|Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
16500483|NCT03288389|Active Comparator|NTFactor Lipids®|Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
16500486|NCT03288350|Experimental|mDCF + Avelumab|"Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.
~Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen."
16500487|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
16500488|NCT03288324|Experimental|Tofacitinib Arm|open-label study
16500489|NCT03288311|Active Comparator|Protocolized Post-extubation Respiratory Support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
16500490|NCT03288311|Active Comparator|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
16500491|NCT03288298|Experimental|luteolin|a natural extract derived flavinoids
16500492|NCT03288298|Active Comparator|nano-luteolin|nano-particles derived from a natural extract luteolin
16500493|NCT03288272|Active Comparator|Arm 1 - WBRT 10 x 2 Gy|Arm 1 - WBRT 10 x 2 Gy Whole brain radiotherapy with a total dose of 20 Gy in single fractions of 2 Gy
16500494|NCT03288272|Active Comparator|Arm 2 - WBRT 15 x 2 Gy|Arm 2 - WBRT 15 x 2 Gy Whole brain radiotherapy with a total dose of 30 Gy in single fractions of 2 Gy
16500495|NCT03288272|Active Comparator|Arm 3 - Best Supportive Care|Symptomatic treatment includes steroids, pain medication, nutritional support etc.
16500496|NCT03288259|Experimental|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
16500497|NCT03288246|No Intervention|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
16500498|NCT03288246|Experimental|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
16500499|NCT03288233||Primary Group|
16500500|NCT03288220||Healthy older adults|Healthy older adults-Age 50 and over
16500501|NCT03288220||Stroke patients|Age 18 and over; Mild to moderate unilateral or bilateral upper limb hemiparesis; Stroke onset > 6 months prior to participation
16500503|NCT03288194|Experimental|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
16500504|NCT03288194|Active Comparator|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
16500505|NCT03288181|Experimental|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
16500506|NCT03288181|No Intervention|Control Arm|This is the group who has undergone no splint for 4 weeks.
16500507|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
16500508|NCT03288155|Experimental|Flavonoid rich cocoa|Dark cocoa beverage rich in flavonoids
16500509|NCT03288155|Placebo Comparator|Low flavonoid cocoa|A control cocoa beverage low inn flavonoids
16500510|NCT03288142|Experimental|Intervention|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
16500511|NCT03288142|No Intervention|Control|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
16500512|NCT03288129|Experimental|Perampanel|Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
16500513|NCT03288116||patient|Scheimplug imaging and contrast and sensitivity test
16500514|NCT03288116||early disease|Scheimplug imaging and contrast and sensitivity test
16500515|NCT03288116||normal|Scheimplug imaging and contrast and sensitivity test
16500516|NCT03288103|Experimental|Growth Hormone Treatment for Participants with ACAN Deficiency|Pre-pubertal children with ACAN deficiency on daily growth hormone (Norditropin) regimen for 12 month period.
16500517|NCT03288090||Treated|
16500518|NCT03288090||Non-treated|
16500519|NCT03288077|Experimental|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
16500520|NCT03288064|Experimental|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
16500521|NCT03288064|Experimental|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
16500522|NCT03288064|Placebo Comparator|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
16500523|NCT03288051|Active Comparator|Crystalloid group|
16500524|NCT03288051|Active Comparator|Colloid group|
16500525|NCT03288038|Experimental|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
16500526|NCT03288038|Active Comparator|RSV5mg|Rosuvastatin 5mg
16500527|NCT03288038|Experimental|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
16500528|NCT03288038|Active Comparator|RSV10mg|Rosuvastatin 10mg
16500529|NCT03288038|Experimental|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
16500530|NCT03288038|Active Comparator|RSV20mg|Rosuvastatin 20mg
16500531|NCT03288025|Experimental|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
16500532|NCT03288025|No Intervention|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
16500533|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
16500534|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
16500535|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
16500536|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
16500537|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
16500538|NCT03287973|Active Comparator|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
16500539|NCT03287973|Other|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
16500540|NCT03287960|Experimental|setmelanotide|setmelanotide subcutaneous injection once daily
16500541|NCT03287960|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
16500542|NCT03287947|Experimental|A|Nintedanib
16500794|NCT03286192|Experimental|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
16500543|NCT03287934|Experimental|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
16500544|NCT03287934|Active Comparator|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
16500545|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
16500546|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
16500547|NCT03287908|Experimental|AMG 701|
16500548|NCT03287908|Experimental|AMG 701 + Pomalidomide|
16500549|NCT03287908|Experimental|AMG 701 + Pomalidomide + Dexamethasone|
16500550|NCT03287895|Experimental|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
16500551|NCT03287895|No Intervention|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
16500552|NCT03287882|No Intervention|Standard of care|"Preconception period: none
~Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy
~Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
16500553|NCT03287882|Experimental|MMN supplementation and life skills education|"Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials
~Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy
~Postpartum period: daily MMN supplementation to 6 months postpartum"
16500554|NCT03287869|Experimental|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
16500555|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
16500556|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
16500557|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
16500558|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
16500559|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message
~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
16500560|NCT03287817|Experimental|AUTO3|Patient with relapsed or refractory DLBCL
16500561|NCT03287804|Experimental|AUTO2|Relapsed or refractory Myeloma patients
16500562|NCT03287791|Experimental|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
16500563|NCT03287791|Active Comparator|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
16500564|NCT03287791|Placebo Comparator|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
16500565|NCT03287778|Active Comparator|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
16500566|NCT03287778|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
16500567|NCT03287765||Experimental 18F-AV-1451|
16500570|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
16500571|NCT03287726|Experimental|probiotics|
16500572|NCT03287726|Placebo Comparator|placebo|
16500573|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
16500574|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
16500575|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
16500576|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
16500577|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
16500578|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
16500579|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
16500580|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
16500581|NCT03287687|Active Comparator|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
16500582|NCT03287687|Experimental|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
16500583|NCT03287674|Experimental|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.
~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.
~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.
~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
16500584|NCT03287661|Experimental|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
16500585|NCT03287661|No Intervention|Wait-list Control Condition|Wait-list Control group (8-weeks)
16500586|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
16500587|NCT03287622|Experimental|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
16500588|NCT03287622|Experimental|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
16500589|NCT03287622|Experimental|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
16500590|NCT03287622|No Intervention|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
16500591|NCT03287609|Active Comparator|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
16500592|NCT03287609|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
16500593|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium"
16500594|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium
~3D Sequence ZTE2 DP with gadolinium
~3D sequence UTE with gadolinium"
16500595|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium
~3D Sequence ZTE2 DP with gadolinium
~3D sequence UTE with gadolinium"
16500596|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium
~3D Sequence ZTE2 DP with gadolinium
~3D sequence UTE with gadolinium"
16500597|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
16500598|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
16500599|NCT03287570|Experimental|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
16500600|NCT03287570|Active Comparator|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
16500601|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
16500602|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
16500603|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
16500604|NCT03287531|Experimental|conventional therapy (group I)|"Exercise therapy.
~For muscles around TMJ :
~Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric
~Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
16500605|NCT03287531|Experimental|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
16500606|NCT03287518|Active Comparator|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
16500834|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
16500607|NCT03287518|Placebo Comparator|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.
~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
16500608|NCT03287505|Experimental|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
16500609|NCT03287505|Experimental|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
16500610|NCT03287492|Experimental|Group I (QPS)|Participants receive QPS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
16500611|NCT03287492|Active Comparator|Group II (GIS)|Participants receive GIS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
16500612|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
16500613|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
16500614|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
16500615|NCT03287466|Active Comparator|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
16500616|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
16500617|NCT03287440|Active Comparator|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
16500618|NCT03287440|Active Comparator|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
16500619|NCT03287427|Experimental|TetMYB Vaccine & BGB-A317|
16500622|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
16500623|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
16500624|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
16500625|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
16500626|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 5 weeks interval.
16500627|NCT03287362|Experimental|ST-arm|one-third of the patients is randomized to schema therapy
16500628|NCT03287362|Active Comparator|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
16500629|NCT03287362|Placebo Comparator|IST-arm|one-third of the patients is randomized to individualized supportive therapy
16500630|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
16500631|NCT03287336|Experimental|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
16500632|NCT03287336|Experimental|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
16500633|NCT03287336|Experimental|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
16500634|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
16500635|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
16500636|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
16500637|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
16500638|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
16500639|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
16500640|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
16500641|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
16500642|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
16500643|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
16500644|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
16500645|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
16500646|NCT03287284|Active Comparator|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
16500647|NCT03287284|Placebo Comparator|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
16500648|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
16500649|NCT03287258|Active Comparator|three program|200 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
16500650|NCT03287258|Active Comparator|one program|200 patients are subjected to educational Pelvic floor dysfunction prevention program
16500652|NCT03287232|Placebo Comparator|Placebo|
16500653|NCT03287232|Experimental|Prasterone|
16500654|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
16500655|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
16500656|NCT03287180|Experimental|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
16500657|NCT03287180|Active Comparator|Control group|Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
16500658|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
16500659|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
16500660|NCT03287154|Experimental|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
16500661|NCT03287154|Sham Comparator|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).
~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
16500662|NCT03287141|Sham Comparator|First intervention|The subjects did a shuttle walk test without any previous intervention.
16500663|NCT03287141|Experimental|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
16500664|NCT03287141|Experimental|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
16500665|NCT03287115|Experimental|Broccoli|Subjects will consume a dose of broccoli on day 11
16500666|NCT03287102|Other|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
16500667|NCT03287102|Other|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
16500668|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
16500669|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
16500670|NCT03287076|Experimental|Active|Patients will receive exenatide injections
16500671|NCT03287076|No Intervention|Standard Care|Standard care for stroke as per hospital protocol
16500672|NCT03287050|Experimental|Pembrolizumab + SBRT|
16500673|NCT03287037|Experimental|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
16500674|NCT03287024|Experimental|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
16500675|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
16500676|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
16500677|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
16500678|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay >72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
16500679|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.
~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
16500680|NCT03286959|Active Comparator|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
16500681|NCT03286959|Active Comparator|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
16500682|NCT03286959|Active Comparator|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
16500683|NCT03286946|Experimental|Blunt-type block needle|block with Blunt-type block needle.
16500684|NCT03286946|Active Comparator|Sharp-type block needle|block with Sharp-type block needle.
16500685|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
16500686|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
16500687|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
16500688|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
16500689|NCT03286907|Experimental|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 & 8
16500690|NCT03286907|Experimental|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 & 8
16500691|NCT03286907|Active Comparator|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
16500692|NCT03286894||1264 healthy schoolchildren|There is only one study group consisting of 1264 children recruited at school.
16500693|NCT03286881|Experimental|Group 1|
16500694|NCT03286881|Experimental|Group 2|
16500695|NCT03286881|Experimental|Group 3|
16500696|NCT03286881|Experimental|Group 4|
16500697|NCT03286881|Active Comparator|Group 5|
16500698|NCT03286868|Placebo Comparator|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
16500699|NCT03286868|Experimental|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
16500700|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
16500701|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
16500702|NCT03286842|Experimental|Olaparib|Olaparib 150mg tablets administered orally twice daily continuously
16500703|NCT03286829|Experimental|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
16500704|NCT03286829|Experimental|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
16500705|NCT03286829|Active Comparator|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
16500706|NCT03286829|Experimental|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
16500707|NCT03286816|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
16500708|NCT03286816|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
16500709|NCT03286803|Experimental|Arm A|Inactivated Poliovirus vaccine
16500710|NCT03286803|Active Comparator|Arm B|fractional dose inactivated poliovirus vaccine
16500711|NCT03286803|Experimental|Arm C|inactivated poliovirus vaccine
16500712|NCT03286803|Active Comparator|Arm D|fractional dose inactivated poliovirus vaccine
16500713|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
16500714|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
16500715|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
16500716|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
16500717|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
16500718|NCT03286751|Experimental|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
16500719|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
16500720|NCT03286725|No Intervention|Control Group|The Control Group will be asked to continue with their normal PE lessons.
16500721|NCT03286725|Experimental|Intervention Group|'Physical Education (PE) Programme'
16500722|NCT03286712|Experimental|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
16501915|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
16500723|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
16500724|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
16500725|NCT03286686|Experimental|Experience 1|
16500726|NCT03286686|Experimental|Experience 2|
16500727|NCT03286686|Experimental|Experience 3|
16500728|NCT03286686|Experimental|Experience 4|
16500729|NCT03286686|Experimental|Experience 5|
16500730|NCT03286686|Experimental|Experience 6|
16500731|NCT03286673|Experimental|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
16500732|NCT03286673|Experimental|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
16500733|NCT03286673|Experimental|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
16500734|NCT03286673|Active Comparator|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
16500735|NCT03286660|Other|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.
~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
16500736|NCT03286647|Experimental|NORMALGRIEF|Oral hygiene instruction
16500737|NCT03286647|Experimental|COMPLICATEDGRIEF|Oral hygiene instruction
16500738|NCT03286647|Active Comparator|CONTROLS|Oral hygiene instruction
16500739|NCT03286634|Experimental|SR|"Standard Risk (SR) :
~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD <0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%
~SR strategy:
~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.
~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
16500740|NCT03286634|Experimental|LR|"Low Risk (LR):
~Time-point #1 (Day 15 induction) Flow MRD <1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) <0.01% AND CNS 1 only
~LR strategy:
~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.
~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
16500741|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
16500742|NCT03286621||Typically Developing Children|Typically developing children
16500743|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
16500744|NCT03286595|Experimental|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
16500745|NCT03286595|Experimental|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
16500746|NCT03286582|Experimental|AC-203|
16500747|NCT03286582|Active Comparator|Clobetasol|
16500748|NCT03286569|Active Comparator|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
16500749|NCT03286569|Placebo Comparator|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
16500750|NCT03286556|Experimental|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.
~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.
~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19
~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
16500751|NCT03286556|Active Comparator|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
16500752|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
16500753|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
16500754|NCT03286530|Experimental|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
16500755|NCT03286517|Experimental|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
16500756|NCT03286517|Experimental|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
16500757|NCT03286517|Experimental|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
16500758|NCT03286517|Experimental|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
16500759|NCT03286517|Experimental|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
16500760|NCT03286517|Experimental|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
16500761|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
16500762|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take ~ 2 hours.
16500763|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
16500764|NCT03286478|Experimental|Mindfulness|Mindfulness-based body image intervention
16500765|NCT03286478|Experimental|Dissonance|Cognitive dissonance-based body image intervention
16500766|NCT03286478|Experimental|Confident Me|Dove Confident Me body image intervention
16500767|NCT03286478|No Intervention|Control|Classes as usual, assessment-only control group.
16500768|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
16500769|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
16500770|NCT03286426|Experimental|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
16500771|NCT03286413|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
16500772|NCT03286413|Active Comparator|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
16500773|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
16500774|NCT03286387|Experimental|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
16500775|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
16500776|NCT03286361|Experimental|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
16500777|NCT03286335|Experimental|Proton Radiation|"Radiation therapy will be delivered typically five (5) days per week on weekdays
~Proton Radiation dose be determine by histology"
16500778|NCT03286322|Experimental|manual therapy cervical spine|
16500779|NCT03286322|Sham Comparator|control group|
16500780|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
16500781|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
16500782|NCT03286296|Experimental|LZM009|
16500783|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
16500784|NCT03286257|Experimental|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
16500785|NCT03286244|Experimental|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:
~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
16500786|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
16500787|NCT03286218|Placebo Comparator|Placebo|Placebo was administered orally in one of five treatment periods
16500788|NCT03286218|Active Comparator|Alprazolam 2 milligram (mg)|2 mg of alprazolam was administered orally in one of five treatment periods
16500789|NCT03286218|Experimental|Lasmiditan 100 mg|100 mg of lasmiditan was administered orally in one of five treatment periods
16500790|NCT03286218|Experimental|Lasmiditan 200 mg|200 mg of lasmiditan was administered orally in one of five treatment periods
16500791|NCT03286218|Experimental|Lasmiditan 400 mg|400 mg of lasmiditan was administered orally in one of five treatment periods
16500795|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.
~• Subjects will utilize autologous tears twice daily in the study eye."
16500796|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
16500797|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
16500798|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
16500799|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
16500800|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
16500801|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
16500802|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.
~(inpatient palliative care consultation team)"
16500803|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
16500804|NCT03286114|Experimental|Pembrolizumab|
16500805|NCT03286101|Experimental|0.5% Ivermectin Lotion|
16500806|NCT03286101|Placebo Comparator|Vehicle control|
16500810|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).
~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
16500811|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).
~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
16500812|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).
~Subjects will receive a 30-minutes SHAM session of tDCS."
16500813|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
16500814|NCT03286049||Healthy children (HC)|10 healthy children
16500815|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
16500816|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
16500817|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
16500818|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
16500819|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
16500820|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
16500821|NCT03286010|Experimental|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
16500822|NCT03286010|No Intervention|Control|Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.
16500823|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
16500824|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
16500825|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
16500826|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
16500827|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
16500828|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
16500829|NCT03285971|Experimental|CPP Alert Group|Device: Electronic CPP pager alert anesthesia providers will receive a pager alert when CPP decreases below 60 mmHg (median value over 5-minute epochs)
16500830|NCT03285971|No Intervention|Control|This arm will not receive the automated pager alerts.
16500831|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
16500832|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
16500833|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
16500835|NCT03285932|Experimental|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)
~Resection cavity:
~7 x 5 Gy @ 95%-isodose
~Potential additional brain metastases:
~20 Gy @ 70%-isodose (lesions < 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions > 3 cm max. diameter)"
16500836|NCT03285932|Other|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
16500837|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
16500838|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
16500839|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
16500840|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
16500841|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
16500842|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
16500843|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
16500844|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
16500845|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
16500846|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
16500847|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
16500848|NCT03285854||Healthy age and gender matched children|"All children <18 years
~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)
~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
16500849|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
16500850|NCT03285841||Vulvar sites|Imaging vulvar lesions
16500851|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
16500852|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
16500853|NCT03285815|Experimental|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
16500854|NCT03285815|Experimental|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
16500855|NCT03285802|Experimental|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
16500856|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
16500857|NCT03285789|Experimental|Dyslexics with normal visual attention span|
16500858|NCT03285789|Active Comparator|controls|
16500859|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
16500860|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
16500861|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
16500862|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
16500863|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
16500864|NCT03285737|Experimental|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
16500865|NCT03285737|Active Comparator|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
16500866|NCT03285724|Experimental|Harpoon Medical Transapical device TSD-5|This is a prospective, single arm, nonrandomized, early feasibility study to evaluate the safety and performance of the Harpoon Medical Device.
16500867|NCT03285711|Experimental|Lanraplenib 30 mg|"Participants receive lanraplenib 30 mg tablet + filgotinib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.
~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
16500888|NCT03285594|Placebo Comparator|Placebo|Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
16500983|NCT03284879||Patients with PsV and PsA treated with OTEZLA Tablets|Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
16500868|NCT03285711|Experimental|Filgotinib 200 mg|"Participants receive filgotinib 200 mg tablet + lanraplenib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.
~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
16500869|NCT03285711|Experimental|Lanraplenib 30 mg to Filgotinib 200 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive filgotinib 200 mg + lanraplenib placebo for additional 16 weeks.
~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
16500870|NCT03285711|Experimental|Filgotinib 200 mg to Lanraplenib 30 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive lanraplenib 30 mg + filgotinib placebo for additional 16 weeks.
~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
16500871|NCT03285698|Other|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
16500872|NCT03285698|Experimental|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
16500873|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
16500874|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
16500875|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
16500876|NCT03285672|Experimental|Arm 1|FP-101
16500877|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
16500878|NCT03285659|Experimental|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
16500879|NCT03285659|No Intervention|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
16500880|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
16500881|NCT03285646|Experimental|Placebo|SC every 4 weeks
16500882|NCT03285633|Other|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
16500883|NCT03285620|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram [mg]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
16500884|NCT03285620|Experimental|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
16500885|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.
~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:
~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)
~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)
~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)
~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
16500886|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.
~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:
~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)
~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)
~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)
~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
16500887|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.
~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:
~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)
~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)
~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)
~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
16500978|NCT03284918|Placebo Comparator|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
16500979|NCT03284905|Active Comparator|Probiotics|
16500889|NCT03285594|Experimental|Sotagliflozin 200 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
16500890|NCT03285594|Experimental|Sotagliflozin 400 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
16500891|NCT03285581|Other|Arm-1|Device:Treatment Subject(s) will receive 2 RF treatments
16500892|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
16500893|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
16500894|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
16500895|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
16500896|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
16500897|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
16500898|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
16500899|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
16500900|NCT03285503|Experimental|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
16500901|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment was applied once daily for 5 consecutive days on the face or scalp.
16500902|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment was applied once daily for 5 consecutive days on the face or scalp.
16500903|NCT03285477|Placebo Comparator|Placebo|Vehicle Ointment was applied topically once daily for 5 consecutive days on face or scalp
16500904|NCT03285477|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment 1% was applied topically once daily for 5 consecutive days on face or scalp
16500905|NCT03285464|Active Comparator|Hip|This group will perform a known hip strengthening program
16500906|NCT03285464|Experimental|Trunk|This group will use the trunk as a lever to strengthen the hip
16500907|NCT03285438|Experimental|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 24 months (12 to 48 months)
16500908|NCT03285438|Active Comparator|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 24 months (12 to 48 months).
16500911|NCT03285386|Experimental|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
16500912|NCT03285386|Active Comparator|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
16500913|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
16500914|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.
~Steps:
~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.
~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.
~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.
~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
16500980|NCT03284905|Placebo Comparator|Placebo|
16500981|NCT03284892|Experimental|PED Care group|Received PED care addition to usual care
16500915|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.
~Steps:
~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.
~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.
~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.
~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
16500916|NCT03285347|Experimental|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.
~Computer-based cognitive training."
16500917|NCT03285347|Experimental|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.
~Computer-based cognitive training."
16500918|NCT03285347|No Intervention|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
16500919|NCT03285334|Experimental|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
16500920|NCT03285334|Active Comparator|iRace|rotary files
16500921|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
16500922|NCT03285321|Experimental|Arm 2|Nivolumab 3mg/kg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
16500923|NCT03285308|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
16500924|NCT03285308|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 μg injected subcutaneously twice daily for up to 12 weeks.
16500925|NCT03285295|Experimental|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
16500926|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
16500927|NCT03285282|No Intervention|Control|
16500928|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
16500929|NCT03285256|Experimental|Experimental Memory Training|Experimental memory training program
16500930|NCT03285256|Active Comparator|Comparator Memory Training 1|Comparator memory training program
16500931|NCT03285256|Active Comparator|Comparator Memory Training 2|Alternative comparator memory training program
16500932|NCT03285243|Sham Comparator|Blue light - non monochromatic|
16500933|NCT03285243|Experimental|Monochromatic blue light|
16500934|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
16500935|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
16500936|NCT03285204||ALS patients|
16500937|NCT03285204||Friedreich Ataxia patients|
16500938|NCT03285204||Healthy control|
16500939|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
16500940|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
16500941|NCT03285178|Experimental|IW-1701 (Olinciguat) Low Dose|
16500942|NCT03285178|Experimental|IW-1701 (Olinciguat) Medium Dose|
16500943|NCT03285178|Experimental|IW-1701 (Olinciguat) High Dose|
16500944|NCT03285178|Experimental|IW-1701 (Olinciguat) Higher Dose|
16500945|NCT03285178|Placebo Comparator|Placebo|
16500946|NCT03285165|Active Comparator|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
16500947|NCT03285165|Active Comparator|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
16500948|NCT03285165|Active Comparator|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
16500949|NCT03285165|Active Comparator|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
16500950|NCT03285152|Experimental|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
16500951|NCT03285152|Active Comparator|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
16500952|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
16500953|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
16500954|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
16500955|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
16500956|NCT03285087|Experimental|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
16500957|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
16500958|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
16500959|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
16500960|NCT03285035||Non-operable esophageal cancer|Cryotherapy treatment
16500961|NCT03285022|Experimental|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
16500962|NCT03285022|Active Comparator|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
16500963|NCT03285009|Other|Training intervention|See information elsewhere
16500964|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
16500965|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
16500966|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
16500967|NCT03284957|Experimental|Amcenestrant Monotherapy: Arm #1 Part A Dose Escalation, Part B Dose Expansion|"Part A: Amcenestrant will be administered orally once daily (QD). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent participants is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in a 28-day cycle.
~Part B: When the dose escalation phase ends, the recommended dose will be administered for the expansion cohort. Drug will be administered in a 28-day cycle."
16500968|NCT03284957|Experimental|Amcenestrant/Palbociclib: Arm #2 Part C Dose Escalation, Part D Dose Expansion|"Part C: Amcenestrant will be administered in combination with palbociclib: amcenestrant starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of amcenestrant (with standard palbociclib dose) to subsequent participants will be based on occurrence of DLTs at initial and subsequent doses, until MAD of amcenestrant is reached. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle).
~Part D: Based on the results in Part C, participants will be administered either: 1) a determined amcenestrant dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of amcenestrant with standard dose of palbociclib in combination therapy. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle)."
16500969|NCT03284957|Experimental|Amcenestrant/Alpelisib: Arm #3 Part F Safety Run-In, Part G Dose Expansion|"Part F: Amcenestrant will be administered in combination with alpelisib at a fixed standard dose. Additional dose levels of amcenestrant with alpelisib could be explored if needed based on the safety and PK results. Lower dose of alpelisib could be explored based on the PK results and safety profile from the initial combination administration. Both amcenestrant and alpelisib will be administered in a 28-day cycle.
~Part G: Based on the conclusion in Part F, participants will be administered the determined RD of amcenestrant and alpelisib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
16500970|NCT03284957|Experimental|Amcenestrant/Everolimus: Arm #4 Part H Dose Escalation, Part I Dose Expansion|"Part H: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of everolimus. Additional dose levels of amcenestrant with everolimus could be explored if needed based on the safety and PK results. Both amcenestrant and everolimus will be administered in a 28-day cycle.
~Part I: Based on the conclusion in Part H, participants will be administered the determined RD of amcenestrant and RD of everolimus given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
16500971|NCT03284957|Experimental|Amcenestrant/Abemaciclib: Arm #5 Part J Dose Escalation, Part K Dose Expansion|"Part J: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of abemaciclib. Additional dose levels of amcenestrant with abemaciclib could be explored if needed based on the safety and PK results. Both amcenestrant and abemaciclib will be administered in a 28-day cycle.
~Part K: Based on the conclusion in Part J, participants will be administered the determined RD of amcenestrant and RD of abemaciclib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
16500972|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
16500973|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
16500974|NCT03284931|Experimental|SAGE-217 high dose|SAGE-217
16500975|NCT03284931|Experimental|SAGE-217 low dose|SAGE-217
16500976|NCT03284931|Placebo Comparator|Placebo|Placebo
16500977|NCT03284918|Experimental|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
16500984|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
16500985|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
16500986|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
16500987|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
16500988|NCT03284840||Adults (18-65 years)|
16500989|NCT03284840||Elderly (65-74 years)|
16500992|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
16500993|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
16500994|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
16500995|NCT03284788|Experimental|ABT Weight Loss Intervention|Adolescent girls will attend healthy lifestyle sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
16500996|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation
16500997|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
16500998|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
16500999|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
16501000|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
16501001|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.
~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
16501002|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
16501003|NCT03284723|Experimental|PF-06804103|Study Treatment
16501004|NCT03284723|Experimental|PF-06804103+Combination Regimen|Study Treatment
16501005|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
16501006|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
16501007|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
16501008|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
16501009|NCT03284697|Active Comparator|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
16501010|NCT03284697|Active Comparator|DPC with MTA|Direct pulp capping with MTA
16501011|NCT03284684||circulating DNA plasma level test|
16501012|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
16501013|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
16501014|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
16501015|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
16501016|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
16501017|NCT03284632||Smokers|
16501018|NCT03284632||E-cigarette users|
16501019|NCT03284632||Non-smokers|
16501020|NCT03284619|Experimental|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
16501021|NCT03284606|Experimental|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
16501022|NCT03284606|Placebo Comparator|NO TAPING|Common rehabilitation for hemiplegic patients without taping
16501023|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
16501024|NCT03284593||Azacitidine group|patients treated with azacitidine
16501025|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
16501026|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
16501027|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
16501028|NCT03284567|Active Comparator|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.
~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
16501029|NCT03284567|No Intervention|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
16501030|NCT03284554|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).
~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
16501031|NCT03284554|Sham Comparator|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.
~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
16501032|NCT03284554|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).
~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
16501033|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
16501034|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
16501035|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
16501036|NCT03284502|Experimental|Stage 1|Dose-escalation
16501037|NCT03284502|Experimental|Stage 1b|Dose-escalation
16501038|NCT03284502|Experimental|Stage 2 (Cohort I and II)|Dose-expansion
16501039|NCT03284502|Experimental|Stage 2 (Cohort III)|Dose-expansion
16501040|NCT03284489||ICU patients|Patients with pancreatitis
16501041|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
16501042|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
16501043|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
16501044|NCT03284450|Experimental|Dance performance fitness test (DPFT)|
16501045|NCT03284450|Active Comparator|Sport specific repeated sprints (SSRS)|
16501046|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
16501047|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
16501048|NCT03284424|Experimental|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
16501049|NCT03284424|Experimental|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
16501050|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
16501051|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
16501052|NCT03284385|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16501053|NCT03284372|Experimental|Intervention 1|Text Message Only
16501054|NCT03284372|Experimental|Intervention 2, Incentive|Text message + Incentive
16501055|NCT03284372|No Intervention|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
16501056|NCT03284372|No Intervention|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
16501057|NCT03284372|No Intervention|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
16501058|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
16503523|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
16501059|NCT03284359|No Intervention|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
16501060|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
16501061|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
16501062|NCT03284333|Experimental|other|no arm
16501063|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
16501064|NCT03284294|Placebo Comparator|Placebo|Oral placebo daily for 8 weeks
16501065|NCT03284294|Active Comparator|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
16501066|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
16501067|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
16501068|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
16501069|NCT03284255|Experimental|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
16501070|NCT03284255|Active Comparator|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
16501071|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
16501072|NCT03284229|Experimental|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
16501073|NCT03284216|Other|Normal glycemia + exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
16501074|NCT03284216|Experimental|Steady-state hyperglycemia + exercise|Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
16501075|NCT03284216|Experimental|Fluctuating hyperglycemia + exercise|Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
16501076|NCT03284216|No Intervention|Normal glycemia, no exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
16501077|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
16501078|NCT03284190||ASDH Copenhagen, Denmark|
16501079|NCT03284190||ASDH Odense, Denmark|
16501080|NCT03284190||ASDH Århus, Denmark|
16501081|NCT03284190||ASDH Ålborg, Denmark|
16501082|NCT03284190||ASDH Lund, Sweden|
16501083|NCT03284190||ASDH Linköping, Sweden|
16501084|NCT03284190||ASDH Gothenburg, Sweden|
16501085|NCT03284190||ASDH Stockholm, Sweden|
16501086|NCT03284190||ASDH Uppsala, Sweden|
16501087|NCT03284190||ASDH Umeå, Sweden|
16501088|NCT03284177|Experimental|C13-CAC|
16501089|NCT03284164|Experimental|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
16501090|NCT03284164|Experimental|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
16501091|NCT03284138|Active Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
16501092|NCT03284138|Sham Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
16501093|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
16501094|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
16501095|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
16501096|NCT03284099|Experimental|intervention|ACEIs or ARBs will be switch to be taken before bedtime
16501097|NCT03284099|Active Comparator|control|ACEIs or ARBs will be taken in the morning as usual
16501098|NCT03284086|Other|paraplegic|Well-trained participants with a spinal cord injury (<Th1) were included in this group.
16501099|NCT03284086|Other|able bodied|Upper-body trained, able-bodied participants were included in this group.
16501100|NCT03284073|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
16501101|NCT03284060|Experimental|Cognitive remediation program|
16501102|NCT03284047|Experimental|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
~2.5 U
~5 U
~7.5 U"
16501136|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
16501103|NCT03284047|Experimental|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
~2.5 U
~5 U
~7.5 U"
16501104|NCT03284047|Experimental|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
~2.5 U
~5 U
~7.5 U"
16501105|NCT03284034|Active Comparator|Cyrolipolysis|
16501106|NCT03284034|Experimental|Deoxycholic Acid|
16501107|NCT03284021|Other|Fraxel laser|
16501108|NCT03284008|Experimental|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
16501109|NCT03284008|Active Comparator|stretching exercise|Patients will receive education to perform stretching exercises at home.
16501110|NCT03283995||cardiogenic shock without SCA|
16501111|NCT03283995||cardiogenic shock with SCA|
16501112|NCT03283995||SCA,|
16501113|NCT03283995||acute left heart failure with severe alteration of LVEF|
16501114|NCT03283982|Active Comparator|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
16501115|NCT03283982|Active Comparator|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
16501116|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
16501117|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
16501118|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
16501119|NCT03283943|Experimental|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
16501120|NCT03283930|Experimental|Active ABMT|Active attention bias modification will be provided in addition to individual cognitive behavioral therapy
16501121|NCT03283930|Placebo Comparator|Placebo|Placebo attention bias modification will be provided in addition to individual cognitive behavioral therapy
16501122|NCT03283917|Experimental|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
16501123|NCT03283904|Experimental|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
16501124|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
16501125|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
16501126|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.
~< 120 kg - patients will receive 2 grams of cefazolin
~≥ 120 kg - patient will receive 3 grams of cefazolin
~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
16501127|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.
~< 120 kg - patients will receive 2 grams of cefazolin
~≥ 120 kg - patient will receive 3 grams of cefazolin
~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
16501128|NCT03283865|Experimental|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.
~All study participants will have ultrasound used for caudal block."
16501129|NCT03283839|Other|Temporomandibular disorder|
16501130|NCT03283839|Other|Without temporomandibular disorder|
16501131|NCT03283826|Experimental|ATA188|Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description.
16501132|NCT03283826|Placebo Comparator|Placebo|Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).
16501133|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
16501134|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
16501135|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
16501140|NCT03283761|Experimental|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m^2 and leucovorin IV 400 mg/m^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
16501141|NCT03283748|Experimental|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
16501142|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
16501143|NCT03283735|No Intervention|Control|This will be the control group.
16501144|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
16501145|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
16501146|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
16501147|NCT03283670|Experimental|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, in known N-methyl-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
16501148|NCT03283670|Experimental|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, in known N-methyl-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
16501149|NCT03283670|Placebo Comparator|Placebo Gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen
16501150|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
16501151|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
16501152|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
16501153|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
16501154|NCT03283631|Experimental|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
16501155|NCT03283618|No Intervention|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
16501156|NCT03283618|Experimental|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
16501157|NCT03283605|Experimental|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
16501158|NCT03283592|Experimental|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
16501159|NCT03283592|Active Comparator|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
16501160|NCT03283579||Pregnant women|
16501161|NCT03283566|Active Comparator|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
16501162|NCT03283566|Placebo Comparator|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
16501163|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
16501164|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
16501165|NCT03283540||TaTME|Trans-anal Total Mesorectal Excision (TaTME) is the visualization and dissection of the rectum located deep in the pelvis. In it, a trans-anal port is inserted for the duration of the surgery. Multiple surgical tools are then introduced through the port and the rectum is resected from down-to-up under direct visualization.
16503563|NCT03266822||RA patients on anti-TNF therapy|
16503564|NCT03266822||RA patients on anti-IL-6R therapy|
16501166|NCT03283540||abdominal TME|"Total Mesorectal Excision involves resecting the rectum along with its surrounding Mesorectal plane. If the anal sphincter is spared, this surgery is named Low Anterior resection (LAR) for rectal cancer. Traditionally, TME dissection in LAR is performed through open or laparoscopic incisions(s) made in the abdominal wall. Mobilization of the splenic flexure along with sigmoid dissection follows. Lastly, the rectum is dissected in accordance with TME principles from above. This up-to-down approach is known as abdominal TME."
16501167|NCT03283488|Experimental|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
16501168|NCT03283488|Active Comparator|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
16501169|NCT03283475|No Intervention|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.
~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
16501170|NCT03283475|Active Comparator|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.
~After assessment, one of the following techniques will be selected:-
~Liposuction only.
~thigh lift.
~Liposuction assisted thigh lift."
16501171|NCT03283462|Active Comparator|AMAZ-02|
16501172|NCT03283462|Placebo Comparator|Placebo|
16501173|NCT03283449|Experimental|AV-1451 Recipients|Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
16501174|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
16501175|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
16501176|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
16501177|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
16501178|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
16501179|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
16501180|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
16501181|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
16501182|NCT03283371|Experimental|Natalizumab 300 mg|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
16501183|NCT03283371|Placebo Comparator|Placebo|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
16501184|NCT03283358|Experimental|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
16501185|NCT03283358|No Intervention|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
16501186|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
16501187|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
16501188|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
16501189|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
16501190|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
16501191|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
16501192|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
16501193|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
16501194|NCT03283293|Experimental|Target volume delineation after NACT|
16501195|NCT03283280|Experimental|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
16501196|NCT03283280|Active Comparator|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
16501197|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
16501198|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
16501199|NCT03283254|Experimental|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
16501200|NCT03283254|Active Comparator|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
16501201|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
16501202|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
16501203|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
16501204|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
16501205|NCT03283202|Experimental|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
16501206|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
16501207|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
16501208|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
16501209|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
16501210|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
16501211|NCT03283189||Group 6|Liberal follow-up of pregnancy
16501212|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
16501213|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
16501214|NCT03283163|Experimental|Chronic Pain//PTSD group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
16501215|NCT03283163|Active Comparator|Trauma-exposed healthy control group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
16501216|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
16501217|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
16501218|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
16501219|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
16501220|NCT03283124|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
16501221|NCT03283124|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
16501222|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
16501223|NCT03283098|Placebo Comparator|Placebo|Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
16501224|NCT03283098|Experimental|Etelcalcetide|5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
16501300|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
16501301|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
16501225|NCT03283085|Experimental|25 mg Ontamalimab|Participants will be receiving 25 milligram (mg) of ontamalimab solution for injection subcutaneously (SC) every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
16501226|NCT03283085|Experimental|75 mg Ontamalimab|Participants will be receiving 75 mg of ontamalimab solution for injection SC every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
16501227|NCT03283072|Sham Comparator|Sham|normoxia for 2 minutes, normoxia 1 minute x 8 using hypoxicator
16501228|NCT03283072|Experimental|Trubower|15 bouts of hypoxia for 1 minute, normoxic 1 minute using hypoxicator
16501229|NCT03283072|Experimental|Hayes|15 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
16501230|NCT03283072|Experimental|Tester|8 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
16501231|NCT03283059|Experimental|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
16501232|NCT03283059|Active Comparator|Aricept|Aricept 5mg/day P.O.
16501233|NCT03283059|Placebo Comparator|Placebo|Placebo P.O. tid
16501234|NCT03283046|Experimental|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.
~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.
~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.
~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:
~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
16501239|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
16501240|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
16501241|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
16501242|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
16501243|NCT03282994|Experimental|Treatment with cryotherapy|Dermal Cooling System
16501244|NCT03282981|Experimental|Timolol|Timoptic-XE plus standard of care (SOC)
16501245|NCT03282981|Placebo Comparator|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
16501246|NCT03282968|Experimental|Experimental|Regular neurophysiotherapy plus REWIRE exercises
16501247|NCT03282968|Active Comparator|Control|Regular neurophysiotherapy plus standing balance exercises
16501250|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
16501251|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
16501252|NCT03282929|Experimental|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
16501253|NCT03282929|Experimental|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
16501254|NCT03282929|Experimental|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
16501255|NCT03282929|Experimental|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
16501256|NCT03282929|Experimental|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
16501257|NCT03282916|Active Comparator|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day.
16501258|NCT03282916|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day.
16501259|NCT03282903||Crohn's disease patients|1550 Crohn's disease patients who are symptomatically controlled.
16501260|NCT03282903||Ulcerative Colitis patients|1550 Ulcerative Colitis patients who are symptomatically controlled.
16501261|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
16501262|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
16501263|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
16501264|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
16501265|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
16501266|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
16501267|NCT03282851|Experimental|MSB11456|
16501268|NCT03282851|Active Comparator|US-licensed Actemra|
16501269|NCT03282851|Active Comparator|EU-approved RoActemra|
16501270|NCT03282838|Experimental|DFN-15 (fasted)|
16501271|NCT03282838|Experimental|DFN-15 (fed)|
16501272|NCT03282838|Experimental|Comparator (fed)|
16501273|NCT03282825|Experimental|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.
~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.
~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
16501274|NCT03282812||cases|
16501275|NCT03282812||controls|
16501276|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
16501277|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
16501278|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
16501279|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
16501280|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
16501281|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
16501282|NCT03282773|Experimental|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
16501283|NCT03282773|Active Comparator|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
16501284|NCT03282760|Experimental|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
16501285|NCT03282734|Experimental|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
16501286|NCT03282734|Active Comparator|The control group|Conventional home rehabilitation exercise education for 4 weeks
16501287|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
16501288|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
16501289|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).
~Data collection with self-administered questionnaire"
16501290|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
16501291|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.
~These patients will receive standard pain treatment until the planned surgery."
16501292|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.
~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.
~These patients will receive standard pain treatment until the planned surgery."
16501293|NCT03282682|Experimental|hypogonadal males without TRT|Strength training
16501294|NCT03282682|Experimental|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
16501295|NCT03282682|Active Comparator|healthy eugonadal males|Strength training
16501296|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
16501297|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
16501298|NCT03282656|Experimental|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
16501299|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
16501406|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
16501302|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
16501303|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
16501304|NCT03282617|Experimental|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
16501305|NCT03282617|Experimental|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
16501306|NCT03282604||male|
16501307|NCT03282604||female|
16501308|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
16501309|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
16501310|NCT03282578|Active Comparator|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
16501311|NCT03282578|Active Comparator|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
16501312|NCT03282565|Experimental|Functional Resistance Training|Participants will receive functional resistance training while walking on a treadmill 2-3 times a week for about 8 weeks.
16501313|NCT03282565|Sham Comparator|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
16501314|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.
~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
16501315|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.
~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
16501316|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.
~In this group all patients will receive the usual standard of care, with no other interventions included"
16501317|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
16501318|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
16501319|NCT03282526|Experimental|Whole body plethysmography|
16501320|NCT03282526|Active Comparator|spirometery|
16501321|NCT03282513|Experimental|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
16501322|NCT03282513|Active Comparator|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
16501323|NCT03282513|Experimental|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
16501324|NCT03282513|Active Comparator|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
16501325|NCT03282500|Experimental|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
16501326|NCT03282500|No Intervention|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
16501327|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
16501328|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
16501329|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
16501330|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
16501331|NCT03282461|Experimental|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
16501332|NCT03282448|Experimental|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
16501333|NCT03282448|No Intervention|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
16501334|NCT03282435|Experimental|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
16501335|NCT03282435|Active Comparator|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
16501407|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
16501336|NCT03282422|Experimental|Intervention group|Upper-limb splint and home-based protocol in specific tasks
16501337|NCT03282422|Active Comparator|Control group|Home-based protocol in specific tasks
16501338|NCT03282396|Experimental|Treatment (ibrutinib)|Participants receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for 5 years in the absence of disease progression or unacceptable toxicity.
16501339|NCT03282370|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
16501340|NCT03282370|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
16501341|NCT03282357|Experimental|Radiesse|Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.
16501342|NCT03282357|Active Comparator|Restylane|Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.
16501343|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
16501344|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
16501345|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
16501346|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
16501347|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
16501348|NCT03282318|Experimental|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
16501349|NCT03282318|Placebo Comparator|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
16501350|NCT03282292|Experimental|Jugular|CVC insertion in the left or right internal jugular vein
16501351|NCT03282292|Active Comparator|Femoral|CVC insertion in the right or left femoral vein
16501352|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
16501355|NCT03282240|Experimental|QIV-HD|Participants randomized to receive a single injection of 0.7 mL QIV-HD by intramuscular (IM) route at Day 0.
16501356|NCT03282240|Active Comparator|TIV-HD1 (Licensed TIV-HD1)|Participants randomized to receive a single injection of 0.5 mL licensed TIV-HD1 by IM route at Day 0.
16501357|NCT03282240|Active Comparator|TIV-HD2 (Investigational TIV-HD2)|Participants randomized to receive a single injection of 0.5 mL investigational TIV-HD2 by IM route at Day 0.
16501358|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
16501359|NCT03282214|Experimental|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
16501360|NCT03282214|No Intervention|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
16501361|NCT03282201||Transfused|Patients in whom blood transfusion is used
16501362|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
16501363|NCT03282188|Experimental|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
16501364|NCT03282188|Experimental|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
16501365|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
16501366|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
16501367|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
16501368|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
16501369|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
16501370|NCT03282149|Experimental|Dose 1|Lowest trial dose of XT-150
16501371|NCT03282149|Experimental|Dose 2|Second, escalating dose of XT-150
16501372|NCT03282149|Experimental|Dose 3|Third, escalating dose of XT-150
16501373|NCT03282149|Placebo Comparator|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
16501374|NCT03282136|Active Comparator|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
16501375|NCT03282136|Placebo Comparator|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
16501376|NCT03282123|Experimental|MDMA-assisted therapy|Three sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
16501377|NCT03282110|Experimental|ta-VNS & Electro-acupuncture|"Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months
~Other:Electro-acupuncture:3 times per week, once every other day for two months"
16501378|NCT03282110|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
16501379|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
16501380|NCT03282097|Active Comparator|Home safety guide|The home safety guide is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group away from talking about mammography with the patient's PCP.
16501381|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
16501382|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
16501383|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
16501384|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
16501385|NCT03282058|Experimental|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
16501386|NCT03282058|No Intervention|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
16501387|NCT03282045|Experimental|Lysobact Complete Sprey|"Lysobact Complete Sprey
~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open
~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
16501388|NCT03282045|Active Comparator|Tantum Verde® Spray|"Tantum Verde® Spray
~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.
~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
16501389|NCT03282045|Active Comparator|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray
~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.
~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
16501390|NCT03282045|Placebo Comparator|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.
~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
16501391|NCT03282032|Experimental|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
16501392|NCT03282032|No Intervention|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
16501393|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
16501394|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
16501395|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
16501396|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
16501397|NCT03281980|Experimental|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
16501398|NCT03281980|Sham Comparator|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
16501399|NCT03281980|No Intervention|Comparison|
16501400|NCT03281967|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
16501401|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
16501402|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
16501403|NCT03281941|Other|Patients without BT|
16501404|NCT03281941|Other|Post BT|
16501405|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
16501409|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
16501410|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
16501411|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.
16501412|NCT03281889|Experimental|Proton Radiotherapy|"Patients will be treated with Proton Beam once daily 5 days per week.
~Doses will be prescribed such that maximum possible coverage is achieved"
16501413|NCT03281876|Experimental|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
16501414|NCT03281876|Placebo Comparator|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
16501415|NCT03281837|Experimental|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
16501416|NCT03281837|Other|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
16501417|NCT03281837|Other|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
16501418|NCT03281824|Experimental|ALT-P7|"8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,
~Administration: Day 1 of each 3-week cycle"
16501419|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
16501420|NCT03281798|Experimental|Fetuses with LUTO|Performance of ultrasound-guided, percutaneous fetal cystoscopy with the Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set
16501421|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
16501422|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
16501423|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
16501424|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
16501425|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
16501426|NCT03281759|Active Comparator|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
16501427|NCT03281759|Placebo Comparator|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
16501428|NCT03281746|Active Comparator|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
16501429|NCT03281746|Experimental|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
16501430|NCT03281720|Experimental|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.
~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
16501431|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
16501432|NCT03281681|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
16501433|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
16501434|NCT03281655|Experimental|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
16501435|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
16501436|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
16501437|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
16501438|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
16501439|NCT03281603|Experimental|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.
~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
16501440|NCT03281603|Active Comparator|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
16501441|NCT03281590||Patients with stroke|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
16501442|NCT03281590||Patients without stroke|Control subject who have the risk factors but never had stroke.
16501443|NCT03281577|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
16501444|NCT03281577|Experimental|TAK-954 0.1 mg|TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
16501445|NCT03281577|Experimental|TAK-954 0.3 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
16501446|NCT03281577|Experimental|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
16501447|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
16501448|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
16501449|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
16501450|NCT03281499|Experimental|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
16501451|NCT03281486|Experimental|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
16501452|NCT03281486|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
16501453|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
16501454|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
16501455|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
16501456|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
16501457|NCT03281447|Experimental|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
16501458|NCT03281447|Active Comparator|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
16501459|NCT03281434|Active Comparator|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
16501460|NCT03281434|Experimental|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
16501461|NCT03281421|Experimental|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
16501462|NCT03281421|Active Comparator|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
16501463|NCT03281421|Active Comparator|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
16501464|NCT03281408||Suspected OSA Patients Undergoing Knee or Hip Arthroplasty|These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.
16501465|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
16501466|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
16501467|NCT03281382|Experimental|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
16501468|NCT03281369|Active Comparator|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
16501469|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
16501470|NCT03281369|Experimental|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
16501471|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
16501472|NCT03281369|Experimental|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
16501473|NCT03281369|Experimental|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
16501474|NCT03281369|Experimental|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
16501475|NCT03281369|Experimental|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
16501476|NCT03281369|Experimental|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
16501477|NCT03281369|Experimental|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
16501478|NCT03281369|Active Comparator|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
16501479|NCT03281369|Experimental|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
16501480|NCT03281356|Experimental|Intervention Group|
16501481|NCT03281343|Experimental|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
16501482|NCT03281343|Active Comparator|Standard of Care (SOC)|Approximates care currently provided at the prison.
16501483|NCT03281330||persons with Multiple Sclerosis|
16501484|NCT03281330||Healthy controls|
16501485|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
16501486|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
16501487|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
16501488|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
16501489|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
16501490|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
16501491|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
16501492|NCT03281239|Experimental|welder/airport agent|No drug and no placebo were used in this study.
16501493|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
16501528|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
16501529|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
16501494|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
16501495|NCT03281213||Female|
16501496|NCT03281213||Male|
16501497|NCT03281200||Anatomical main group:|
16501498|NCT03281200||Therapeutic subgroup|
16501499|NCT03281200||Pharmacological subgroup|
16501500|NCT03281200||Chemical subgroup|
16501501|NCT03281200||Chemical substance|
16501502|NCT03281187|Experimental|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
16501503|NCT03281187|Active Comparator|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
16501504|NCT03281187|Placebo Comparator|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
16501505|NCT03281187|Placebo Comparator|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
16501506|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
16501507|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
16501508|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
16501509|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
16501510|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
16501511|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
16501512|NCT03281135|Other|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
16501513|NCT03281135|No Intervention|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
16501514|NCT03281122|Experimental|Arm A|Specified dose on specified days
16501515|NCT03281122|Placebo Comparator|Arm B|Specified dose on specified days
16501516|NCT03281096|Experimental|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
16501517|NCT03281096|Placebo Comparator|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
16501518|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
16501519|NCT03281057|Experimental|Individual CRAFT|Individual CRAFT is offered to 135 participants and each participants are going to get 6 sessions.
16501520|NCT03281057|Experimental|Group CRAFT|Open group CRAFT is offered to 135 participants in 6 sessions.
16501521|NCT03281057|Experimental|Self-help materials|Self-help materials (control group) are going to be offered a self-help book, because it is unethically not to offer any intervention, as the CRAFT intervention in early studies have shown to be very effectful
16501522|NCT03281044|Experimental|FMT group|Patient group receiving active FMT capsules
16501523|NCT03281044|Placebo Comparator|Placebo group|Patient group receiving placebo capsules
16501524|NCT03281031|Other|Additional MRI Examination|Single arm, all patient will undergo CT followed by additional MRI examination
16501525|NCT03281018|Experimental|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
16501526|NCT03281018|No Intervention|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
16501527|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
16501531|NCT03280979|Experimental|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
16501532|NCT03280979|Experimental|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
16501533|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
16501534|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
16501535|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
16501536|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
16501537|NCT03280927|Experimental|Jublia®|
16501538|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
16501539|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
16501540|NCT03280901|Experimental|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
16501541|NCT03280901|Experimental|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
16501542|NCT03280875|Experimental|healthy volunteers|
16501543|NCT03280862|Active Comparator|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
16501544|NCT03280862|Experimental|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
16501545|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
16501546|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
16501547|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.
~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
16501548|NCT03280810|Experimental|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
16501549|NCT03280810|No Intervention|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
16501550|NCT03280797|Other|Control|
16501551|NCT03280797|Other|Rheumatoid arthritis patients|
16501552|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
16501553|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
16501554|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
16501555|NCT03280758|No Intervention|Control group|No exercise training.
16501556|NCT03280745|Active Comparator|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
16501557|NCT03280745|Active Comparator|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
16501558|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
16501559|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:
~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
16501560|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:
~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
16501561|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:
~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
16501562|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:
~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
16501563|NCT03280706|Experimental|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
16501564|NCT03280706|Active Comparator|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
16501565|NCT03280706|Active Comparator|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
16501569|NCT03280667|Experimental|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
16501570|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels <7,55
16501571|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels >=7,55
16501572|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
16501573|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
16501574|NCT03280628|Active Comparator|Absorbable Sutures|30 patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
16501575|NCT03280628|Experimental|Steri-Strips|"30 patients will have their laceration closed with a special medical tape called Steri-Strips."
16501576|NCT03280628|Experimental|Dermabond|"30 patients will have their laceration closed with a special skin glue called Steri-Strips."
16501577|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
16501578|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
16501579|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
16501580|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
16501581|NCT03280589|Active Comparator|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
16501582|NCT03280589|Experimental|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
16501583|NCT03280589|Experimental|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
16501584|NCT03280589|Experimental|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
16501585|NCT03280589|Experimental|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
16501586|NCT03280576||Sepsis|Patients with sepsis
16501587|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
16501588|NCT03280576||Healthy controls|Normal individuals
16501597|NCT03280550|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
16501598|NCT03280550|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
16501599|NCT03280537|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
16501600|NCT03280537|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
16501601|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
16501602|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
16501603|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
16501604|NCT03280498|Other|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
16501605|NCT03280472|Experimental|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
16501606|NCT03280472|Other|Symptom Tracking|Participants will track their symptoms.
16501607|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
16501608|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
16501609|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
16501610|NCT03280420|Active Comparator|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
16501611|NCT03280420|Active Comparator|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
16501612|NCT03280407|Active Comparator|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
16501613|NCT03280407|Experimental|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
16501614|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
16501615|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
16501616|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
16501617|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
16501618|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.
~Inclusion before initiation of anticoagulation."
16501619|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
16501620|NCT03280355|Experimental|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
16501621|NCT03280355|Active Comparator|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
16501622|NCT03280342|Active Comparator|IR-TPM (Topamax)|IR-TPM (Topamax)
16501623|NCT03280342|Active Comparator|XR-TPM (Trokendi XR)|
16501624|NCT03280329|No Intervention|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
16501625|NCT03280329|Active Comparator|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
16501626|NCT03280329|Active Comparator|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:
~Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;
~Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);
~Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, …);
~Mixing tracks so that there is continuity and fluidity of listening"
16501627|NCT03280316|Experimental|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
16501628|NCT03280316|Experimental|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
16501629|NCT03280316|Experimental|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
16501630|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
16501631|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)
~In a complete remission rate of leucocytes with ≥ 2G / L
~Affiliated to social security person or beneficiary of such a scheme."
16501632|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ
~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)
~Having a rate of circulating lymphocytes ≥ 1 G / L
~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population
~The statutes CMV and EBV are known (positive or negative).
~Affiliated to social security person or beneficiary"
16501633|NCT03280277|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
16501634|NCT03280264|Experimental|KHK7580|oral administration
16501635|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
16501636|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
16501637|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
16501638|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
16501639|NCT03280238|Experimental|Experiment|"Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode
~Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)
~Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
16501640|NCT03280225||VISNs requesting implementation support|VA has divided the country into regions of care and these are called Veteran Integrated Service Networks (VISNs). This group consists of VISNs with facilities that need additional implementation support to fully implement REACH VET and that agree to participate.
16501641|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)
~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
16501642|NCT03280212|No Intervention|Control Arm|"No intervention
~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
16501643|NCT03280199|Other|Type of simulator - 1|"VR simulator with physical mannequin and probe.
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
16501644|NCT03280199|Other|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
16501645|NCT03280199|Other|Type of image acquisition - 3|"US images are acquired through real US volumes from patients
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
16501646|NCT03280199|Other|Type of image acquisition - 4|"US images are acquired through computer-generated images.
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
16501647|NCT03280186|Experimental|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
16501648|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
16501649|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
16501650|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
16501651|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
16501713|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
16501652|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
16501653|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
16501654|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
16501655|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
16501656|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
16501657|NCT03280108|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
16501658|NCT03280108|Active Comparator|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
16501659|NCT03280095|Experimental|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
16501660|NCT03280095|Experimental|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
16501661|NCT03280095|Active Comparator|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
16501662|NCT03280082|Other|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.
~The criteria for admission include:
~MUAC <120 mm
~Bilateral edema of grade + or ++
~The criteria for release of care include:
~MUAC ≥ 125 mm at 2 consecutive visits
~Minimum stay 3 weeks in the program
~Absence of acute medical complications
~Absence of edema"
16501663|NCT03280082|Other|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC<125 mm will be referred to Nutrition Centers for admission.
~The criteria for admission include:
~MUAC<115 mm and/or
~Z score <-3 and /or
~Bilateral edema of grade + or ++
~The criteria for release of care include:
~MUAC ≥ 125 mm at 2 consecutive visits
~Minimum stay 3 weeks in the program
~Absence of acute medical complications
~Absence of edema"
16501664|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
16501665|NCT03280056|Active Comparator|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
16501666|NCT03280056|Placebo Comparator|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
16501667|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
16501668|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
16501669|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
16501670|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
16501671|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
16501672|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
16501673|NCT03280004||Moxifloxacin group|
16501674|NCT03280004||β-lactams group|
16501675|NCT03279978|Experimental|BI 730357|
16501676|NCT03279978|Placebo Comparator|Placebo|
16501677|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
16501678|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
16501679|NCT03279952|Other|medication arm|CNS Stimulant
16501680|NCT03279939|Experimental|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
16501681|NCT03279939|Experimental|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
16501682|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
16501683|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
16501684|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
16501685|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
16501714|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
16503598|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
16501686|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass
~ARF was defined as one of the following conditions:
~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,
~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
16501687|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
16501688|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
16501689|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
16501690|NCT03279835||Absence of cognitive disorder|
16501691|NCT03279835||Asymptomatic cognitive disorder|
16501692|NCT03279835||Symptomatic cognitive impairment|
16501693|NCT03279835||HIV associated dementia|
16501694|NCT03279822||Group|
16501695|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
16501696|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
16501697|NCT03279796|Experimental|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
16501698|NCT03279796|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
16501699|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
16501700|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
16501701|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
16501702|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
16501703|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
16501704|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
16501705|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
16501706|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
16501707|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
16501708|NCT03279744|Experimental|Single-Arm|Radion™-pdt
16501709|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
16501710|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
16501715|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks
~Pembrolizumab will be administered through IV infusion"
16501716|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
16501717|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
16501718|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
16501719|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
16501720|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
16501721|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
16501722|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
16501723|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1
~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
16501724|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1
~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
16501725|NCT03279627||Hypoglycemia|This group will be those who experience a BG < 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
16501726|NCT03279627||Hyperglycemia|This group will be those who experience a BG > 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
16501727|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
16501728|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
16501729|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
16501730|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
16501731|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
16501732|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
16501733|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
16501734|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
16501735|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
16501736|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
16501737|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
16501738|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
16501739|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
16501740|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
16501741|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
16501742|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
16501743|NCT03279510|Experimental|Hearing aids|All study participants will be fit with hearing aids.
16501744|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
16501745|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
16501746|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
16501747|NCT03279471|Experimental|CBT/BIACA|These participants will receive CBT treatment using Behavioral Interventions for Anxiety in Children with Autism (BIACA). BIACA is an anxiety treatment package designed for children with ASD that includes elements of CBT and social skills training.
16501748|NCT03279471|Active Comparator|Sertraline|These participants will receive sertraline
16501749|NCT03279471|Placebo Comparator|Pill Placebo|These individuals will receive a pill placebo.
16501750|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
16501751|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
16501752|NCT03279445||African American|Patient of African American race
16501753|NCT03279445||Caucasian|Patient of Caucasian race
16501754|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.
~Patient may or may not be receiving terlipressin therapy."
16501755|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.
~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
16501756|NCT03279393|Active Comparator|PTSD Subjects|
16501757|NCT03279393|Active Comparator|Trauma Control Subjects|
16501758|NCT03279393|Placebo Comparator|Healthy Control Subjects|
16501759|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
16501760|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).
~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
16501761|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).
~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
16501762|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
16501763|NCT03279354|Experimental|Intervention group|Family Move app intervention
16501764|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
16501765|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
16501766|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
16501767|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
16501768|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
16501769|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
16501770|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
16501771|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
16501772|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
16501773|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
16501774|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
16501775|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
16501776|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
16501777|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
16501778|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
16501779|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
16501780|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
16501781|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
16501782|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
16501783|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
16501784|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
16501785|NCT03279250|Experimental|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
16501786|NCT03279250|Experimental|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
16501787|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle
~Oxaliplatin is administered intravenously
~Leucovorin is administered intravenously
~Irinotecan is administered intravenously
~5-Fluorouracil is administered intravenously
~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
16501788|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
16501789|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
16501790|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
16501791|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
16501792|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
16501793|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
16501794|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
16501795|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
16501796|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
16501797|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
16501798|NCT03279172|Experimental|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
16501799|NCT03279172|Experimental|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
16501800|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
16501801|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
16501802|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
16501803|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
16501804|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
16501805|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
16501806|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
16501807|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
16501808|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
16501809|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
16501810|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
16501811|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
16501812|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
16501813|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
16501814|NCT03279094|Experimental|Haploidentical stem cell transplantation|
16501815|NCT03279081|Experimental|Cx601|Cx601 eASCs 120 million cells (5 million cells per milliliter [mL]) will be administered once by intralesional injection.
16501816|NCT03279081|Placebo Comparator|Placebo|CX601 placebo-matching eASCs cells will be administered once by intralesional administration.
16501817|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
16501818|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.
~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.
~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
16501819|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi
~SHUTi is delivered over 6 sessions, each taking 20-30 minutes
~SHUTi is delivered by a virtual therapist
~Participants will learn about the etiology and maintenance of their insomnia
~Participants will learn how to maintain their sleep log
~Participants will learn how to address lifestyle barriers that impact their sleep
~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom
~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior
~Participants will be taught how to gradually expand their restricted sleep"
16501820|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
16501821|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
16501822|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
16501823|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
16501824|NCT03279003|Experimental|Light-emitting diode therapy|Exposure to LED light
16501825|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
16501826|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
16501827|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
16501828|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
16501829|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
16501830|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
16501831|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
16501832|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
16501833|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
16501834|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
16501835|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
16501836|NCT03278925|Experimental|Prevention (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
16501840|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
16501841|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
16501842|NCT03278873|Experimental|Biological-Low dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single low dose of either AAV - CNGB3 or AAV - CNGA3
16501843|NCT03278873|Experimental|Biological-medium dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single medium dose of either AAV - CNGB3 or AAV - CNGA3
16501844|NCT03278873|Experimental|Biological-high dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single high dose of either AAV - CNGB3 or AAV - CNGA3
16501845|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
16501846|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
16501847|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
16501848|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
16501849|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.
~Twice per day for 45 minutes.
~Exercise - Home exercises programme once per day with 10 exercises."
16501850|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.
~Exercise - Home exercises programme once per day with 10 exercises."
16501853|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
16501854|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
16501855|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
16501856|NCT03278795|Active Comparator|PSV mode|PSV weaning group
16501857|NCT03278795|Experimental|VSV mode|VSV weaning group
16501858|NCT03278782|Experimental|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16501859|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
16501860|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
16501861|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
16501862|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
16501863|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
16501864|NCT03278730|Active Comparator|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.
~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.
~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
16501865|NCT03278730|Placebo Comparator|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.
~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.
~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
16501868|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
16501869|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
16501870|NCT03278691|Placebo Comparator|Placebo|Drug: Placebo Saline 1 ml IV Q6H
16501872|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
16501873|NCT03278652||Patient with renal colic|
16501874|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
16501875|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
16501876|NCT03278626|Other|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
16501877|NCT03278613|Experimental|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 36 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
16501878|NCT03278613|Sham Comparator|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation.
16501879|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
16501880|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
16501881|NCT03278587|Active Comparator|Community-based screening|
16501882|NCT03278587|Active Comparator|Cataract camp program|
16501883|NCT03278587|Active Comparator|Community health worker program|
16501884|NCT03278587|No Intervention|No intervention|
16501885|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
16501886|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
16501887|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
16501888|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
16501889|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
16501890|NCT03278548|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
16501891|NCT03278548|Active Comparator|Ionolyte|Ionolyte solution for infusion
16501892|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 20 men and 20 women aged between 18-29 years
16501893|NCT03278535||age group 30-39years|CAREN-based gait analysis: 20 men and 20 women aged between 30-39years
16501894|NCT03278535||age group 40-49years|CAREN-based gait analysis: 20 men and 20 women aged between 40-49years
16501895|NCT03278535||age group 50-59years|CAREN-based gait analysis: 20 men and 20 women aged between 50-59years
16501896|NCT03278535||age group 60-69years|CAREN-based gait analysis: 20 men and 20 women aged between 60-69years
16501897|NCT03278535||age group 70+|CAREN-based gait analysis: 20 men and 20 women aged between 70 years and older
16501898|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
16501899|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
16501900|NCT03278509|Experimental|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
16501901|NCT03278509|No Intervention|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
16501902|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
16501903|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
16501904|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
16501905|NCT03278483|Active Comparator|Isoniazid|Diabetic patients with a positive TST of >10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
16501906|NCT03278483|Active Comparator|Rifampin|Diabetic patients with a positive TST of >10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
16501907|NCT03278470|Experimental|HL237 50mg|take oral tablet once
16501908|NCT03278470|Experimental|HL237 100mg|take oral tablet once
16501909|NCT03278470|Experimental|HL237 200mg|take oral tablet once
16501916|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
16501917|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
16501918|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
16501919|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
16501920|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
16501921|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
16501922|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
16501923|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
16501924|NCT03278392|Experimental|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
16501925|NCT03278392|Sham Comparator|Placebo challenge task|Participants will be assigned to complete the placebo non-stress task immediately after consuming a standardized breakfast drink
16501926|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
16501927|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
16501928|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
16501929|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
16501930|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
16501931|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
16501932|NCT03278327|Other|Endoscopic resection|
16501933|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
16501934|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
16501935|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
16501936|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
16501937|NCT03278262||36-69 letters|Baseline VA 36-69 letters
16501938|NCT03278262||<=35 letters|Baseline VA <=35 letters
16501939|NCT03278249|Experimental|Modified Atkins Ketogenic Diet|Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
16501940|NCT03278236|Experimental|TRF|
16501941|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
16501942|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
16501943|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
16501944|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
16501945|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
16501946|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
16501947|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
16501948|NCT03278184|Sham Comparator|tDCS sham motor cortex|25 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
16501949|NCT03278184|Active Comparator|Active motor cortex stimulation|25 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
16501950|NCT03278184|Active Comparator|active prefrontal cortex stimulation|25 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
16501951|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
16501952|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
16501953|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
16501954|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
16501955|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
16501956|NCT03278158|Experimental|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
16501957|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
16501958|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
16501959|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
16501960|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
16501961|NCT03278119||Sleep Apnea|"Overall 56
~both male and female
~age group 55 to 75 years, having mild to severe obstructive sleep apnea
~in good general health with no significant comorbidities
~Located for the most part in boroughs of New York City"
16501962|NCT03278119||No Sleep Apnea|"Overall 56
~both male and female
~age group 55 to 75 years, without OSA
~in good general health with no significant comorbidities
~Located for the most part in boroughs of New York City"
16501964|NCT03278080|Other|driving test|
16501965|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
16501966|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
16501967|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
16501968|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
16501969|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
16501970|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
16501971|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
16501972|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
16501973|NCT03278028|Experimental|Active|A-101 Topical Solutions
16501974|NCT03278028|Placebo Comparator|Vehicle|Vehicle
16501975|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
16501976|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
16501977|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
16501979|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
16501980|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
16501981|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
16501982|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
16501983|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
16501984|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
16501985|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
16501986|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
16501987|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
16501988|NCT03277937|Experimental|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
16501989|NCT03277924|Experimental|Sunitinib+Nivolumab|"Adult patients will receive an initial induction phase from day 1 to day 14 of sunitinib 37.5 mg/day followed by a maintenance phase of sunitinib 25mg/day orally continuously + nivolumab 240mg intravenous every 2 weeks infused over 1 hour. Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
~Pediatric patients will receive an initial induction phase from day 1 to day 14 of sunitinib 25 mg/day, or 37.5 mg/day if BSA > 1.7, followed by a maintenance phase of sunitinib 25mg/day orally continuously + nivolumab 240mg intravenous every 2 weeks infused over 1 hour. Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
~Sunitinib (Sutent): Hard Capsule (12.5, 25 mg). Oral use.
~Nivolumab (Opdivo) 10 mg/mL concentrate for solution for infusion. Intravenous use"
16501990|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
16501991|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
16501992|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
16501993|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
16501994|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
16501995|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
16501996|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
16501997|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
16501998|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
16501999|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
16502000|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
16502001|NCT03277833|Placebo Comparator|Placebo|Placebo
16502002|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
16502003|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
16502004|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
16502005|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
16502006|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
16502007|NCT03277794|Active Comparator|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
16502008|NCT03277794|Experimental|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
16502009|NCT03277781||Current smokers|
16502010|NCT03277781||Ex-smokers|
16502011|NCT03277781||Coronary heart disease|
16502012|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
16502013|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
16502014|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
16502015|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
16502016|NCT03277742|Active Comparator|Control|This arm will receive the standard of care for patients with TB and DM2
16502017|NCT03277742|Experimental|Intervention|This arm will receive the community intervention
16502018|NCT03277729|Experimental|Treatment (CD20-specific CAR T cell, chemotherapy)|Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.
16502019|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
16502020|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
16502021|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
16502022|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
16502023|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
16502024|NCT03277677|Active Comparator|normal saline|
16502025|NCT03277677|Active Comparator|balanced solution|
16502026|NCT03277664|Experimental|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
16502027|NCT03277664|No Intervention|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
16502028|NCT03277651||liver fibrosis|liver biopsy proved
16502029|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
16502030|NCT03277638|Experimental|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
16502031|NCT03277638|Experimental|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
16502032|NCT03277638|Experimental|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
16502033|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
16502034|NCT03277612||C-Section|Infants delivered by C-section
16502035|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
16502036|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
16502037|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
16502038|NCT03277586|Experimental|Probio'Stick|
16502039|NCT03277586|Placebo Comparator|Placebo|
16502040|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
16502041|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
16502042|NCT03277534|Experimental|Electrical stimulation|
16502043|NCT03277534|Sham Comparator|Control|
16502044|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
16502045|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
16502046|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
16502047|NCT03277508|Experimental|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
16502048|NCT03277508|Active Comparator|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
16502049|NCT03277495|Active Comparator|nicotine SREC|The liquid in the e-cigarette refills contains nicotine
16502050|NCT03277495|Placebo Comparator|placebo SREC|The liquid in the e-cigarette refills does not contain nicotine
16502051|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy
~*q4 weeks durvalumab for 13 cycles or until progression"
16502052|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab
~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
16502053|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained
~MRI Tracker is used during catheter positioning with serial MR imaging during implant
~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice
~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
16502054|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained
~Standard process is used with serial MR imaging to evaluate catheter position during implant
~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice
~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
16502055|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
16502056|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.
~Modified model surgical tecnique:
~Obtain wax bite registration.
~Record face-bow transfer.
~Duplication of articulating model for surgical simulation.
~Measure all casts and bases in standard model surgery fashion.
~Fabricate intermediate splint & Final splint.
~Condylar repositional splint."
16502057|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.
~Computer-aided planning for study group:
~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.
~Pre-operative Fabrication of computer aided surgical splint:
~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.
~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
16502058|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
16502059|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
16502060|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
16502061|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
16502062|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
16502063|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
16502064|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
16502065|NCT03277391|Active Comparator|Serratus anterior plane block|Deep serratus anterior plane block
16502066|NCT03277391|Active Comparator|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
16502067|NCT03277378|Active Comparator|Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
16502068|NCT03277378|Active Comparator|Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
16502069|NCT03277352|Experimental|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
16502070|NCT03277339|Experimental|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
16502071|NCT03277339|Other|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
16502072|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
16502073|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
16502074|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
16502075|NCT03277313|Experimental|Epoch 1|Pediatric patients with primary immunodeficiency disease (PIDD) who are on intravenous (IV) or non-HYQVIA subcutaneous (SC) treatment with immunoglobulin (IV-pre-treated, SC-pre-treated) will be enrolled and treated with HYQVIA subcutaneously with a dose or interval ramp-up period of up to six weeks.
16502076|NCT03277313|Experimental|Epoch 2|"HYQVIA treatment at following intervals:
~For intravenous (IV)-pre-treated participants: every 3 or 4 weeks, depending on participant's previous IV schedule.
~For subcutaneous (SC)-pre-treated participants: every 3 or 4 weeks, at discretion of investigator and participant.
~After one year in Epoch 2, anti-rHuPH20 binding antibody assay results during year will decide next steps in study:
~Participants with anti-rHuPH20 antibody titer <160 at all time-points during study will complete the study completion visit at next possible occasion following 12-month visit.
~Participants with anti-rHuPH20 antibody titer ≥160 during study and/or at last measurement will continue in Epoch 2 for additional 2 years of HYQVIA treatment and observation, and complete study completion visits at next possible occasion following 36-month visit.
~Alternative treatment intervals, such as infusion every 2 weeks, may be considered for tolerability reasons, at discretion of investigator after informing sponsor"
16502077|NCT03277313|Active Comparator|Epoch 3|Approximately one year safety follow-up, if needed: for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a study drug related serious adverse event (SAE) or a related severe adverse event (AE) will be followed accordingly.
16502078|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
16502079|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
16502080|NCT03277287|No Intervention|Group C|No intervention
16502081|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
16502082|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
16502083|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
16502084|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
16502085|NCT03277261|Experimental|Ublituximab + Oral Placebo|IV Infusion
16502086|NCT03277261|Active Comparator|Teriflunomide + IV Placebo|Oral daily Administration
16502087|NCT03277248|Experimental|Ublituximab + Oral Placebo|IV infusion
16502088|NCT03277248|Active Comparator|Teriflunomide + IV Placebo|Oral daily administration
16502089|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
16502090|NCT03277235|No Intervention|Control|Usual care
16502091|NCT03277222|Active Comparator|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
16502092|NCT03277222|Placebo Comparator|IN Sterile Saline|Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
16502093|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
16502094|NCT03277196|Experimental|Ivacaftor Arm|
16502095|NCT03277196|No Intervention|Observational Arm|
16502096|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
16502097|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
16502098|NCT03277170|Experimental|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
16502099|NCT03277170|Placebo Comparator|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
16502100|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
16502101|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
16502102|NCT03277144|Experimental|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
16502103|NCT03277144|Active Comparator|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
16502104|NCT03277131|Experimental|1|Antimicrobial Dressing
16502105|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
16502106|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
16502107|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
16502108|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
16502109|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
16502110|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
16502111|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
16502112|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 1|Diclofenac sodium 1 topical patches will be compared against placebo patches.
16502113|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 2|Diclofenac sodium 2 topical patches will be compared against placebo patches.
16502114|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
16502115|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
16502116|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
16502117|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
16502118|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
16502119|NCT03277001|Active Comparator|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
16502120|NCT03277001|Experimental|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
16502121|NCT03276988|Other|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
16502122|NCT03276988|Other|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
16502123|NCT03276975|Active Comparator|Patching of CSF Leaks with Autologous Blood and Fibrin|CT fluoroscopy-guided blood and fibrin glue patching targeted to the site of CSF leak.
16502124|NCT03276975|Placebo Comparator|Simulated Patching Procedure|Instead of injection of blood and fibrin glue patching material through the needles, an equivalent volume of preservative free sterile Elliots B solution will be injected.
16502125|NCT03276962|Experimental|R012-20 Group|Subjects will receive full doses of RTS,S/AS01E at Month 0, Month 1, Month 2 and a full dose at Month 20.
16502126|NCT03276962|Experimental|R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26, Month 38.
16502127|NCT03276962|Experimental|Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38.
16502128|NCT03276962|Experimental|Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32.
16502129|NCT03276962|Experimental|Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2.
16502130|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
16502131|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
16502132|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
16502133|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
16502134|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
16502135|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
16502136|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
16502137|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
16502138|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
16502139|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
16502140|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
16502141|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
16502142|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
16502143|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
16502144|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
16502145|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
16502146|NCT03276845|Other|1|
16502147|NCT03276832|Experimental|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Courses repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity.
16502148|NCT03276819|Experimental|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:
~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
16502149|NCT03276819|Experimental|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.
~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.
~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
16502150|NCT03276819|Experimental|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
16502151|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
16502152|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
16502153|NCT03276793|Experimental|MRI and behavioral assessment|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
16502154|NCT03276780|Experimental|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
16502155|NCT03276780|Active Comparator|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
16502156|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
16502157|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
16502158|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
16502207|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
16502159|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
16502160|NCT03276728|Active Comparator|AMG 986 IV Dose Level A|or matching placebo
16502161|NCT03276728|Active Comparator|AMG 986 IV Dose Level B|or matching placebo
16502162|NCT03276728|Active Comparator|AMG 986 IV Dose Level C|or matching placebo
16502163|NCT03276728|Active Comparator|AMG 986 IV Dose Level D|or matching placebo
16502164|NCT03276728|Active Comparator|AMG 986 IV Dose Level E|or matching placebo
16502165|NCT03276728|Active Comparator|AMG 986 IV Dose Level F|or matching placebo
16502166|NCT03276728|Active Comparator|AMG 986 IV Dose Level G|or matching placebo
16502167|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A|or matching placebo - HV
16502168|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B|or matching placebo - HV
16502169|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C|or matching placebo - HV
16502170|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D|or matching placebo - HV
16502171|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E|or matching placebo - HV
16502172|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F|or matching placebo - HV
16502173|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A - MAD|or matching placebo - HV
16502174|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B MAD|or matching placebo - HV
16502175|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C MAD|or matching placebo - HV
16502176|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D MAD|or matching placebo - HV
16502177|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E MAD|or matching placebo - HV
16502178|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F MAD|or matching placebo - HV
16502179|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-HEF|Heart failure patients with reduced ejection fraction
16502180|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-REF|Heart failure patients with preserved ejection fraction
16502181|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
16502182|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
16502183|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
16502184|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
16502185|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
16502186|NCT03276663|Other|Formula fed group|Formula feeding regimen
16502187|NCT03276663|No Intervention|Human milk-fed group|
16502188|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
16502189|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
16502190|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
16502191|NCT03276598|Active Comparator|Amlodipine|One of the four monotherapy treatment periods.
16502192|NCT03276598|Active Comparator|Bisoprolol|One of the four monotherapy treatment periods.
16502193|NCT03276598|Active Comparator|Hydrochlorothiazide|One of the four monotherapy treatment periods.
16502194|NCT03276598|Active Comparator|Losartan|One of the four monotherapy treatment periods.
16502195|NCT03276598|Placebo Comparator|Placebo|Placebo treatment period.
16502196|NCT03276572|Experimental|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
16502197|NCT03276559|Experimental|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.
~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
16502198|NCT03276559|Placebo Comparator|Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.
~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
16502199|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
16502200|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
16502201|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
16502202|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
16502203|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
16502204|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
16502205|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
16502206|NCT03276494|Other|Intraosseous|Administration of intraosseous hypertonic saline
16502208|NCT03276468|Experimental|Experimental|Combination of venetoclax, atezolizumab and obinutuzumab
16502209|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
16502210|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
16502211|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
16502212|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
16502213|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
16502214|NCT03276390|Active Comparator|Intervention study site|"Exposure to the intervention, which is the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.
~The intervention study site will provide the intervention to its Hispanic patients.
~The intervention study will will also provide the routine care (control arm) to all other patients.
~For the purposes of this study, Hispanic potential recipients recruited into the study will be exposed to this intervention. Non-Hispanic Whites recruited into the study will not be exposed to this intervention."
16502215|NCT03276390|No Intervention|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
16502216|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
16502217|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
16502218|NCT03276364||Shock|
16502221|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
16502222|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
16502223|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
16502224|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
16502225|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
16502226|NCT03276312|No Intervention|Control|Routine clinical practice
16502227|NCT03276299|Active Comparator|test 1|six minute walking test
16502228|NCT03276299|Experimental|test 2|six minute walking test
16502229|NCT03276299|Experimental|test with encouragement|six minute walking test
16502230|NCT03276299|Active Comparator|test without encouragement|six minute walking test
16502231|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
16502232|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
16502233|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
16502234|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
16502235|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
16502236|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
16502237|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
16502238|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
16502239|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
16502240|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
16502241|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
16502242|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
16502243|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
16502244|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
16502245|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
16502246|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
16502247|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
16502248|NCT03276169|Experimental|Left atrial appendage closure group|
16502249|NCT03276169|Other|Radiofrequency ablation group|
16502250|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
16502251|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
16502326|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
16502252|NCT03276143|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
16502253|NCT03276143|Active Comparator|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
16502254|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
16502255|NCT03276143|Experimental|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
16502256|NCT03276143|Experimental|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
16502257|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
16502258|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
16502259|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
16502260|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
16502261|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
16502262|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
16502263|NCT03276104|Active Comparator|IOL repositioning group|
16502264|NCT03276104|Active Comparator|IOL exchange group|
16502265|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
16502266|NCT03276078|Experimental|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
16502267|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
16502268|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
16502269|NCT03276052|Experimental|Aclidinium Bromide 200 μg|One inhalation from the 200 μg Aclidinium Bromide inhaler.
16502270|NCT03276052|Experimental|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
16502271|NCT03276052|Experimental|Aclidinium Bromide 800 μg|Two inhalations from the 400 μg Aclidinium Bromide inhaler.
16502272|NCT03276039||25 patients with non-alcoholic fatty liver disease|
16502273|NCT03276039||25 patients with NAFLD and chronic HCV|
16502274|NCT03276039||20 healthy controls|
16502275|NCT03276026|Active Comparator|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
16502276|NCT03276026|Active Comparator|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
16502277|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
16502278|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
16502279|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
16502280|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
16502281|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
16502282|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
16502283|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
16502284|NCT03275974|Experimental|Treatment|Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
16502285|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
16502286|NCT03275948|Experimental|whole grain|
16502287|NCT03275948|Other|refrence|white wheat based product
16502288|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
16502289|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
16502290|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
16502291|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
16502292|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
16502293|NCT03275896|Experimental|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
16502294|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
16502295|NCT03275857|Other|Cisplatin|
16502296|NCT03275844||Group 1|Children with congenital heart disease
16502297|NCT03275844||Group 2|Control healthy subjects
16502300|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:
~Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days
~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing > 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
16502301|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will most likely begin the 12-week regiment at their first visit to our hip clinic.
16502302|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive treatment to normalization, but for no less than 6 weeks. Patients will begin their treatment around the time of their first visit to our designated hip clinic.
16502303|NCT03275792|Experimental|Admission/Intravascular Volume Expansion|"Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes
~0.9% NS with 5% dextrose at 150% of standard maintenance volume
~If urine output is <0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload
~Oral fluids ad lib along with strict input/output documentation
~Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload
~Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:
~A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child
~Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
16502304|NCT03275792|Active Comparator|Outpatient Observation|"Following standard emergency department (ED) care [volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).
~Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge
~Additional health assessments as required
~Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child"
16502305|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
16502306|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
16502307|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC
~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
16502308|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA
~should inhibit overactive premotor cortices"
16502309|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA
~should facilitate neural activity within premotor cortices"
16502310|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex
~should have no effect at all (no transcranial magnetic stimulation, only sound)"
16502311|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
16502312|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
16502313|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
16502314|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
16502315|NCT03275740|Experimental|PF-06755347 intravenous|intravenous administration
16502316|NCT03275740|Placebo Comparator|Placebo intravenous|intravenous administration
16502317|NCT03275740|Experimental|PF-06755347 subcutaneous|subcutaneous administration
16502318|NCT03275740|Placebo Comparator|Placebo subcutaneous|subcutaneous administration
16502319|NCT03275727|Experimental|A - iACT-BC experimental group|
16502320|NCT03275727|Other|B - Waiting list control group|
16502321|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
16502322|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
16502323|NCT03275701|Other|Triumeq|Single Arm, Open Label
16502324|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
16502325|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
16502327|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
16502328|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
16502329|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
16502330|NCT03275636|Experimental|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
16502331|NCT03275636|Active Comparator|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
16502332|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
16502333|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
16502334|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.
~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 300 mg via infusion (equivalent to 4 mg/kg) in one dose in patients >30 kg Weight-based dosing should be utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 4 mg/kg"
16502335|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
16502336|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
16502337|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
16502338|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
16502339|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
16502340|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
16502341|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
16502342|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
16502343|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
16502344|NCT03275506|Experimental|Pembrolizumab + Chemotherapy|"Arm B (n=60): 4 neo-adjuvant cycles of standard 3 weekly Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)
~Arm B: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).
~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).
~After chemotherapy:
~In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy.
~In the arm B, patient will receive Pembrolizumab 200 mg until a maximum of 15 months in total from the beginning of the adjuvant therapy."
16502345|NCT03275506|Active Comparator|Chemotherapy alone|"Arm A (n=30): 4 neo-adjuvant cycles of standard 3 weekly carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)
~Arm A: carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks +/- bevacizumab (15 mg/kg Q3W)
~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).
~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).
~After chemotherapy:
~- In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy."
16502346|NCT03275493|Experimental|Experimental: Cohort 1|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
16502347|NCT03275493|Experimental|Experimental: Cohort 2|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
16502348|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
16502349|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
16502350|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
16502351|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
16502352|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
16502353|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
16502354|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
16502420|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
16502421|NCT03275025|Experimental|YRA-1909 low dose|
16502422|NCT03275025|Experimental|YRA-1909 medium does|
16502423|NCT03275025|Experimental|YRA-1909 high dose|
16502355|NCT03275402|Experimental|131I-omburtamab|"One treatment cycle of 131I-omburtamab consists of 1 dose at 50mCi at week 1. For Japan only one treatment cycle of 131I-omburtamab consists of 2 doses: 2mCi at week 1 and 50mCi at week 2. First cycle is initiated right after confirmation of eligibility at week 1. At week 5 (week 6 for Japan) the participant will be evaluated for safety and if eligible, receive a second cycle of 131I-omburtamab.
~Secondary efficacy endpoints will be evaluated at week 26 and primary efficacy endpoint will be evaluated at week 156."
16502356|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502357|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502358|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502359|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502360|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502361|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502362|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502363|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502364|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502365|NCT03275389|Active Comparator|IIV4 Group|Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
16502366|NCT03275376|Experimental|Statin treated group|
16502367|NCT03275376|Placebo Comparator|Control group|
16502368|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
16502369|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
16502370|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
16502371|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
16502372|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
16502373|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
16502374|NCT03275350|Active Comparator|TAU|Treatment as usual
16502375|NCT03275337|Experimental|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
16502376|NCT03275337|Experimental|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
16502377|NCT03275337|Active Comparator|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
16502378|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
16502379|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
16502380|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
16502381|NCT03275272|Other|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
16502382|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
16502383|NCT03275246|Experimental|Total knee arthroplasty|Patients undergoing total knee arthroplasty
16502384|NCT03275207|Placebo Comparator|control group|an equal volume of saline
16502385|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
16502386|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
16502387|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
16502424|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
16502388|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
16502389|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
16502390|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
16502391|NCT03275168|Active Comparator|Control|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention
16502392|NCT03275168|Experimental|Intervention|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention plus dyadic counseling and negotiation practice with partner
16502393|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
16502394|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
16502395|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
16502396|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
16502397|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
16502398|NCT03275129|Experimental|Ultrasound assessment of heart and lungs|Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
16502399|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
16502400|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
16502408|NCT03275090|Active Comparator|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
16502409|NCT03275090|No Intervention|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
16502410|NCT03275077||Controls|Normal Healthy Volunteers
16502411|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
16502412|NCT03275064|Experimental|LNA043 40 mg Part B|LNA043 40 mg Part B
16502413|NCT03275064|Experimental|LNA043 20 mg Part B|LNA043 20 mg Part B
16502414|NCT03275064|Experimental|LNA043 20 mg Part A|LNA043 20 mg Part A
16502415|NCT03275064|Placebo Comparator|Placebo Part A|Placebo Part A
16502416|NCT03275064|Placebo Comparator|Placebo Part B|Placebo Part B
16502417|NCT03275051|Experimental|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
16502418|NCT03275038|No Intervention|Control group|Maintain the original life style
16502419|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
16502425|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
16502426|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
16502427|NCT03274999|Experimental|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
16502428|NCT03274999|Experimental|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
16502429|NCT03274986|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
16502430|NCT03274986|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
16502431|NCT03274973||Zomacton|
16502432|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
16502433|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
16502434|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
16502435|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
16502436|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
16502437|NCT03274947|Active Comparator|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
16502438|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
16502439|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
16502440|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
16502441|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
16502442|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
16502443|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
16502444|NCT03274908||Group|
16502445|NCT03274895|Experimental|PHMB 0.08% plus placebo|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
16502446|NCT03274895|Active Comparator|PPHMB 0.02% plus propamidine 0.1%|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
16502447|NCT03274882|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
16502448|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
16502449|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
16502450|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
16502451|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
16502452|NCT03274843|Experimental|Patient with stroke|
16502453|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
16502454|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
16502455|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
16502456|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
16502457|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
16502483|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
16504145|NCT03262545|Experimental|experimental group|apatinib 500 mg p.o. once daily
16502458|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.
~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
16502459|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.
~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
16502460|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.
~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.
~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
16502461|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
16502462|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
16502463|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
16502464|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
16502465|NCT03274739||Pregnant women|
16502466|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
16502467|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
16502468|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:
~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.
~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.
~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
16502469|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:
~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.
~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.
~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
16502470|NCT03274687|Experimental|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy for 37 fractions over 7 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
16502471|NCT03274687|Experimental|Arm II (hypofractionated radiation therapy|Patients undergo hypofractionated radiation therapy for 25 fractions over 5 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
16502472|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
16502473|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
16502474|NCT03274661|Experimental|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
16502475|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
16502476|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
16502477|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
16502478|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
16502479|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
16502480|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
16502481|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
16502482|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
16502873|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
16502484|NCT03274622|Experimental|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
16502485|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
16502486|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.
~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.
~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.
~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
16502487|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
16502488|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
16502489|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
16502490|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
16502491|NCT03274557|Active Comparator|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
16502492|NCT03274557|Active Comparator|Phusical therapy|Supervised eccentric training
16502493|NCT03274544|Experimental|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
16502494|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
16502495|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
16502496|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.
~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
16502497|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
16502498|NCT03274505||Stroke patients|Patients seen by a rehabilitation physician at a routine 3 months' post-stroke examination
16502499|NCT03274505||TIA patients|"Patients seen by a stroke specialist at the SOS TIA examination"
16502500|NCT03274492|Experimental|R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m^2) IV, cyclophosphamide 750 mg/m^2 IV, and doxorubicin 50 mg/m^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
16502501|NCT03274492|Placebo Comparator|R-CHOP plus Polatuzumab Vedotin Placebo|Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m^2 IV, cyclophosphamide 750 mg/m^2 IV, doxorubicin 50 mg/m^2 IV, and vincristine 1.4 mg/m^2 IV (maximum 2 milligrams per dose [mg/dose]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
16502502|NCT03274479|Experimental|PBF-1129_40mg|
16502503|NCT03274479|Experimental|PBF-1129_80mg|
16502504|NCT03274479|Experimental|PBF-1129_160mg|
16502505|NCT03274479|Experimental|PBF-1129_320mg|
16502506|NCT03274466|Experimental|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel & Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
16502507|NCT03274466|Active Comparator|Standard of Care Dressing|Silver impregnated dressing
16502508|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.
~Infusion will be maintained for 24 hours."
16502509|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
16502510|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
16502511|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.
~Infusion will be maintained for 24 hours."
16502512|NCT03274440|Experimental|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (<1%) content.
16502513|NCT03274440|Experimental|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (<1%) and high CBD (>10%) content.
16502514|NCT03274440|Placebo Comparator|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
16502515|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
16502516|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
16502517|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
16502518|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
16502874|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
16502519|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
16502520|NCT03274401|No Intervention|Control Arm|Standard of care
16502521|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
16502522|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
16502523|NCT03274375|Experimental|IA session|"4 Rituximab injections
~10 IA sessions"
16502524|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
16502525|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
16502526|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
16502527|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
16502528|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
16502529|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
16502530|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
16502531|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
16502532|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
16502533|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
16502534|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
16502535|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
16502536|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
16502537|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
16502538|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
16502539|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
16502540|NCT03274271|Experimental|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502541|NCT03274271|Experimental|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502542|NCT03274271|Experimental|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502543|NCT03274271|Experimental|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502544|NCT03274271|Experimental|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502545|NCT03274271|Experimental|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502546|NCT03274271|Experimental|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
16502547|NCT03274271|Active Comparator|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
16502587|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
16502548|NCT03274258|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16502549|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
16502550|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
16502551|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
16502552|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
16502553|NCT03274219|Experimental|bb21217 Experimental Arm|
16502554|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg
~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
16502555|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo
~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
16502556|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
16502557|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
16502558|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
16502559|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
16502560|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
16502561|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
16502562|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
16502563|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
16502564|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
16502565|NCT03274141||RC Patients|RA patients managed with routine care(RC)
16502566|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
16502567|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
16502568|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
16502569|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
16502570|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
16502571|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
16502572|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
16502573|NCT03274089|Experimental|Kiosk intervention group|
16502574|NCT03274089|No Intervention|Nurse clinician control group|
16502575|NCT03274076|Active Comparator|Tofacitinib|5mg Tofacitinib twice a day
16502576|NCT03274076|Placebo Comparator|Placebo|5mg Placebo twice a day
16502577|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
16502578|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
16502579|NCT03274050||patient group|Surgery with robot - all patients operated in pediatric surgery department with indication of robot in the routine care (all specialities).
16502580|NCT03274050||control group|Retroperitoneal coelioscopy - patient operated for pyeloplasty
16502581|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
16502582|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
16502583|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
16502584|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
16502585|NCT03273985|Experimental|Dry needling|
16502586|NCT03273985|Experimental|Ischemic compression|
16502588|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
16502589|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
16502590|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
16502591|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
16502592|NCT03273933|Active Comparator|10 children with DragONE only|
16502593|NCT03273933|Experimental|10 children with DragONE and SmartOne|
16502594|NCT03273920|Experimental|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
16502595|NCT03273920|Active Comparator|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
16502596|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
16502597|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
16502598|NCT03273881|Active Comparator|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
16502599|NCT03273881|Active Comparator|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
16502600|NCT03273868|Experimental|High velocity low amplitude manipulation|
16502601|NCT03273868|Sham Comparator|Sham manipulation|
16502604|NCT03273842|Experimental|PF-06881894|PF-06881894 6 mg SC
16502605|NCT03273842|Active Comparator|US-approved Neulasta|US-approved Neulasta 6 mg SC
16502606|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
16502607|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
16502608|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
16502609|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
16502610|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
16502611|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
16502614|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
16502615|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
16502616|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
16502617|NCT03273699|Experimental|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
16502618|NCT03273699|No Intervention|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
16502619|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
16502620|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
16502621|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
16502622|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
16502623|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
16502624|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
16502625|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
16502626|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
16502627|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
16502628|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
16502629|NCT03273595|Placebo Comparator|Control|
16502630|NCT03273595|Experimental|Experimental group|
16502631|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
16502632|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
16502633|NCT03273543|Experimental|Nasal Tip Projection|
16502634|NCT03273543|Experimental|Upper Lip Position|
16502635|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
16502636|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
16502637|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
16502638|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.
~The placebo product will be applied in the same way, on the controlateral leg."
16502639|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.
~Height and weight will be measured using standard procedures
~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.
~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
16502640|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.
~Height and weight will be measured using standard procedures
~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.
~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
16502641|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
16502642|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
16502643|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
16502644|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
16502645|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
16502646|NCT03273426|Experimental|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
16502647|NCT03273426|Experimental|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
16502648|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
16504146|NCT03262545|Placebo Comparator|control group|placebo p.o. once daily
16502649|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
16502650|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
16502651|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
16502652|NCT03273387|Placebo Comparator|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
16502653|NCT03273387|Experimental|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
16502654|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
16502655|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
16502656|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
16502657|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
16502658|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
16502659|NCT03273335||Surgical patients|Surgical patients will undergo CSF biomarker assays, cognitive testing and fMRI scans.
16502660|NCT03273322|Experimental|1: Rivaroxaban 10 mg qd|Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
16502661|NCT03273322|Experimental|2: Rivaroxaban 15 mg qd|"Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90
~should be taken between 8 and 10 AM"
16502662|NCT03273322|Active Comparator|3: DAPT|Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
16502663|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
16502664|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
16502665|NCT03273296|Active Comparator|Amoxicillin|
16502666|NCT03273296|Active Comparator|Azithromycin|
16502667|NCT03273296|Active Comparator|Vancomycin|
16502668|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
16502669|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
16502670|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
16502671|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
16502672|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
16502673|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
16502674|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
16502675|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
16502676|NCT03273231|Placebo Comparator|control group|0.9% saline solution
16502677|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
16502678|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
16502679|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:
~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
16502680|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:
~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
16502681|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
16502682|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
16502683|NCT03273166|Experimental|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
16502684|NCT03273153|Experimental|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
16502685|NCT03273153|Active Comparator|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
16502686|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).
~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
16502687|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
16502688|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
16502689|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
16502690|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
16502691|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
16502692|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
16502693|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
16502694|NCT03273088|Experimental|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
16502695|NCT03273088|Active Comparator|Pfizer etanercept|Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.
16502696|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
16502697|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
16502698|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.
~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
16502699|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.
~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
16502700|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID
~OR
~Placebo Comparator 15 days of Placebo pill TID"
16502701|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID
~OR
~Active Comparator 15 days of Tolcapone 200mg TID"
16502702|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
16502703|NCT03273036|Placebo Comparator|placebo injection|no injection agent
16502704|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
16502705|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
16502706|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
16502707|NCT03272984|Other|SC group|Patients will undergo the SC group.
16502708|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
16502709|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
16502710|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
16502711|NCT03272919|Experimental|Arm 1: Investigational INF|Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow.
16502712|NCT03272919|Other|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
16502713|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
16502714|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
16502715|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
16502716|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
16502717|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
16502718|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
16502719|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
16502720|NCT03272828|Active Comparator|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible. Outcomes between the groups will be compared
16502721|NCT03272828|Active Comparator|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible. Outcomes between the groups will be compared.
16502722|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
16502723|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
16502724|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:
~Tab. Rilutek 50 mg PO q12hr on empty stomach.
~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.
~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
16502725|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.
~Instructions:
~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
16502726|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
16502727|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
16502728|NCT03272763|Experimental|F&P Toffee mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
16502729|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
16502730|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
16502731|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
16502732|NCT03272737|Active Comparator|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.
~Interventions:
~Plethysmography;
~Protocols of isometric exercise;
~Pulse wave Velocity (PWV);
~Flow-mediated dilatation (FMD);
~Arterial pressure and blood pressure;
~Quality of life (Euro Qol);
~1RM test
~Speed gait test
~Anthropometric Assessment"
16502733|NCT03272737|Active Comparator|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.
~Interventions:
~Plethysmography;
~Protocols of isometric exercise;
~Pulse wave Velocity (PWV);
~Flow-mediated dilatation (FMD);
~Arterial pressure and blood pressure;
~Quality of life (Euro Qol);
~1RM test
~Speed gait test
~Anthropometric Assessment"
16502734|NCT03272711|Experimental|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
16502735|NCT03272711|Placebo Comparator|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
16502736|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
16502761|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
16502875|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
16502737|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
16502738|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.4 mg/g nicotine; 9 mg of tar)
16502739|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg/g nicotine; 9 mg of tar)
16502740|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
16502741|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
16502742|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.
~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
16502743|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
16502744|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
16502745|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
16502746|NCT03272633|Experimental|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
16502747|NCT03272633|Experimental|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
16502748|NCT03272607|No Intervention|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
16502749|NCT03272607|Experimental|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
16502750|NCT03272594|Experimental|Breastfeeding|
16502751|NCT03272594|Active Comparator|24% oral sucrose|
16502752|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
16502753|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
16502754|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.
~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
16502755|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.
~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
16502756|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
16502757|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
16502758|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
16502759|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
16502760|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
16502762|NCT03272516|Active Comparator|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
16502763|NCT03272516|Experimental|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
16502764|NCT03272503|Experimental|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
16502765|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
16502766|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
16502767|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
16502768|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.
~Adjuvant Therapy: Standard of care"
16502769|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.
~Adjuvant Therapy: Standard of care"
16502770|NCT03272464|Experimental|Trametinib + Dabrafenib + INCB039110|"Dabrafenib is administered orally every 12 hours
~Trametinib is administered orally once a day
~INCB039110 is administered orally once a day"
16502771|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
16502772|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
16502773|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
16502774|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
16502775|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
16502776|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
16502777|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
16502778|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
16502779|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
16502780|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
16502781|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
16502782|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
16502785|NCT03272360||Chronic Pelvic Pain|
16502786|NCT03272360||Elective Tubal Ligation|
16502787|NCT03272347|Experimental|Islatravir 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
16502788|NCT03272347|Experimental|Islatravir 0.75 mg|Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
16502789|NCT03272347|Experimental|Islatravir 2.25 mg|Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
16502790|NCT03272347|Active Comparator|Doravirine, Tenofovir, Lamivudine|Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and doravirine, tenofovir, lamivudine consisting of 100 mg DOR + 300 mg 3TC + 300 mg tenofovir disoproxil fumarate (TDF) for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only doravirine, tenofovir, lamivudine QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
16502872|NCT03271827|No Intervention|Standard care group|Standard airway management
16502791|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
16502792|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
16502793|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
16502794|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
16502795|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
16502796|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
16502797|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
16502798|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
16502799|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
16502800|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
16502801|NCT03272256|Experimental|IM156, Dose escalation|
16502802|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
16502803|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
16502804|NCT03272230|Experimental|bvFTD|"Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
16502805|NCT03272230|Experimental|Healthy control|"Healthy age, sex and education matched controls
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
16502806|NCT03272230|Experimental|Parkinson's disease without Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
16502807|NCT03272230|Experimental|Depression|"Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV).
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
16502808|NCT03272230|Experimental|Parkinson's disease with Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ICDs are closely related to use of dopaminergic medications.
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
16502809|NCT03272217|Experimental|Arm A - Atezolizumab + Bevacizumab|Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
16502810|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
16502811|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
16502812|NCT03272178||Triathlon knee total knee arthroplasty|50 Patients who are assigned to Triathlon knee, half cemented/half cementless
16502813|NCT03272178||Depuy knee total knee arthroplasty|50 Patients who are assigned to Depuy knee, half cemented/half cementless
16502814|NCT03272165|Experimental|MEDI1341|
16502815|NCT03272165|Placebo Comparator|Placebo|
16502816|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
16502817|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
16502818|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
16502819|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
16502820|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
16502821|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
16502822|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
16502823|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
16502824|NCT03272113|No Intervention|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.
~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
16502825|NCT03272113|Experimental|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
16502826|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
16502827|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
16502828|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
16502829|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
16502830|NCT03272074|Experimental|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
16502831|NCT03272074|Active Comparator|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
16502832|NCT03272061|Experimental|Aerobic-based exercise program|
16502833|NCT03272061|No Intervention|Control program|Maintenance of habitual physical activity levels
16502834|NCT03272048|Experimental|Low-Fear/Not-Temporary|
16502835|NCT03272048|Experimental|Low-Fear/Temporary|
16502836|NCT03272048|Experimental|High-Fear/Not-Temporary|
16502837|NCT03272048|Experimental|High-Fear/Temporary|
16502838|NCT03272022||women|never-pregnant women
16502839|NCT03272022||pregnant women|pregnant
16502840|NCT03272009|Experimental|Treatment A|oral EYP001a
16502841|NCT03272009|Experimental|Treatment B|oral EYP001a
16502842|NCT03272009|Experimental|Treatment C|oral EYP001a
16502843|NCT03272009|Experimental|Treatment D|oral EYP001a
16502844|NCT03272009|Placebo Comparator|Treatment E|oral placebo
16502845|NCT03272009|Active Comparator|Treatment F|oral Entecavir
16502846|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
16502847|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
16502848|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
16502849|NCT03271996|Experimental|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
16502850|NCT03271996|Experimental|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
16502851|NCT03271983|Other|metronidazole gel 1|RLD gel
16502852|NCT03271983|Other|metronidazole gel 2|generic gel
16502853|NCT03271983|Other|metronidazole cream|generic cream
16502854|NCT03271970||Patients with conductive hearing loss|
16502855|NCT03271944|Other|Single group 30 post menopause females.|
16502856|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
16502857|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
16502858|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
16502859|NCT03271918|Experimental|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
16502860|NCT03271918|No Intervention|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
16502861|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
16502862|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
16502863|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
16502864|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
16502865|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
16502866|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
16502867|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
16502868|NCT03271866|Other|metformin treatment|
16502869|NCT03271866|No Intervention|non-metformin treatment|
16502870|NCT03271853||SBS II|
16502871|NCT03271827|Experimental|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
16502876|NCT03271801|Active Comparator|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
16502877|NCT03271801|Experimental|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
16502878|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
16502879|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
16502880|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
16502881|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
16502882|NCT03271762|Experimental|MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
16502883|NCT03271762|Active Comparator|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
16502884|NCT03271749|No Intervention|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
16502885|NCT03271749|Experimental|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
16502886|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
16502887|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
16502888|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
16502889|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
16502890|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
16502891|NCT03271684|Experimental|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
16502892|NCT03271684|Other|control group|Will receive booklet consist of home exercises and education besides the usual care
16502893|NCT03271671|Active Comparator|PSV|Pressure support ventilation
16502894|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
16502895|NCT03271658|Experimental|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or usual care comparison.
16502896|NCT03271658|No Intervention|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
16502897|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
16502898|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
16502899|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
16502900|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
16502901|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
16502902|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
16502903|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
16502904|NCT03271606|Experimental|ERAS group|The patients in this group receive enhanced measures perioperatively
16502905|NCT03271606|Active Comparator|Traditional group|The patients in this group receive traditional measures perioperatively
16502906|NCT03271593||All children admitted|All children admitted to hospital
16502907|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:
~Finger prick test for HbA1c measurement
~Punch biopsy
~VAC sponge collection
~Ankle brachial index"
16502908|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:
~Finger prick test for HbA1c measurement
~Punch biopsy
~VAC sponge collection
~Ankle brachial index"
16502910|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:
~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.
~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:
~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.
~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
16502911|NCT03271528|Experimental|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
16502912|NCT03271528|Placebo Comparator|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
16502913|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
16502914|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
16502915|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
16502916|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
16502917|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
16502918|NCT03271489|Placebo Comparator|Placebo|Placebo
16502919|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
16502920|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
16502921|NCT03271450||Continuer at 90 Days: Dabigatran|
16502922|NCT03271450||Continuer at 180 Days: Dabigatran|
16502923|NCT03271450||Continuer at 270 Days: Dabigatran|
16502924|NCT03271450||Continuer at 90 Days: Apixaban|
16502925|NCT03271450||Continuer at 180 Days: Apixaban|
16502926|NCT03271450||Continuer at 270 Days: Apixaban|
16502927|NCT03271450||Continuer at 90 Days: Rivaroxaban|
16502928|NCT03271450||Continuer at 180 Days: Rivaroxaban|
16502929|NCT03271450||Continuer at 270 Days: Rivaroxaban|
16502930|NCT03271450||Continuer at 90 Days: Edoxaban|
16502931|NCT03271450||Continuer at 180 Days: Edoxaban|
16502932|NCT03271450||Continuer at 270 Days: Edoxaban|
16502933|NCT03271450||Continuer at 90 Days: Warfarin|
16502934|NCT03271450||Continuer at 180 Days: Warfarin|
16502935|NCT03271450||Continuer at 270 Days: Warfarin|
16502936|NCT03271450||Discontinuer at 90 Days: Dabigatran|
16502937|NCT03271450||Discontinuer at 180 Days: Dabigatran|
16502938|NCT03271450||Discontinuer at 270 Days: Dabigatran|
16502939|NCT03271450||Discontinuer at 90 Days: Apixaban|
16502940|NCT03271450||Discontinuer at 180 Days: Apixaban|
16502941|NCT03271450||Discontinuer at 270 Days: Apixaban|
16502942|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
16502943|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
16502944|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
16502945|NCT03271450||Discontinuer at 90 Days: Edoxaban|
16502946|NCT03271450||Discontinuer at 180 Days: Edoxaban|
16502947|NCT03271450||Discontinuer at 270 Days: Edoxaban|
16502948|NCT03271450||Discontinuer at 90 Days: Warfarin|
16502949|NCT03271450||Discontinuer at 180 Days: Warfarin|
16502950|NCT03271450||Discontinuer at 270 Days: Warfarin|
16502951|NCT03271437|Experimental|PC-trained therapists|
16502952|NCT03271437|Experimental|EMDR-trained therapists|
16502953|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
16502954|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
16502955|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
16502956|NCT03271411|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
16502957|NCT03271411|Experimental|Progressive counting (PC) arm|
16502958|NCT03271398||Adult victims of sexual assault|
16502959|NCT03271398||Children who have been exposed to domestic abuse|
16502960|NCT03271398||Women with perinatal emotional complications|
16502961|NCT03271398||Teens with behavior problems and histories of abuse|
16502962|NCT03271398||Veterans with military-related trauma|
16502963|NCT03271398||Survivors of intimate partner violence|
16502992|NCT03271177|Placebo Comparator|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
16502993|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
16502964|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
16502965|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
16502966|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
16502967|NCT03271372|Experimental|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
16502968|NCT03271372|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
16502969|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
16502970|NCT03271359|Experimental|Progressive counting (PC) arm|
16502971|NCT03271333||patients with systemic sclerosis|
16502972|NCT03271320||systemic sclerosis|patients with systemic sclerosis
16502973|NCT03271320||control|Healthy subjects
16502974|NCT03271307|No Intervention|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
16502975|NCT03271307|Experimental|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
16502976|NCT03271307|Experimental|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
16502977|NCT03271307|No Intervention|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
16502978|NCT03271307|Experimental|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
16502979|NCT03271294|Other|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
16502980|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
16502981|NCT03271255|Experimental|Arm Apatinib|"Apatinib-FOLFIRI:
~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
16502982|NCT03271255|Active Comparator|Arm Bevacizumab|"Bevacizumab-FOLFIRI:
~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
16502983|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
16502984|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
16502985|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
16502986|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
16502987|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
16502988|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
16502989|NCT03271190|Experimental|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
16502990|NCT03271190|Active Comparator|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
16502991|NCT03271177|Experimental|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
16504147|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
16502994|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
16502995|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
16502996|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
16502997|NCT03271138|Active Comparator|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
16502998|NCT03271138|Placebo Comparator|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
16502999|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
16503000|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
16503001|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
16503002|NCT03271099|No Intervention|Usual Care|Usual care
16503003|NCT03271099|Experimental|Navigator|Patient navigator services provided as part of survivorship care plan
16503004|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
16503005|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
16503006|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
16503007|NCT03271060|Active Comparator|Lumbar spondylolisthesis1|
16503008|NCT03271060|Active Comparator|Lumbar spondylolisthesis 2|
16503009|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
16503010|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
16503011|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
16503012|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
16503013|NCT03271034|Experimental|Baseline Lipedema characterization|Body composition and Fat distribution, adipose tissue biology, metabolic and immune function in women with Lipedema. Participants will receive a low-calorie diet therapy in the form of low calorie meals or shakes.
16503014|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
16503015|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
16503016|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
16503017|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
16503018|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
16503019|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
16503020|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
16503021|NCT03270982||Comprehensive SRS Replacement|
16503022|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
16503023|NCT03270956|Experimental|Renal Autologous Cell Therapy|Renal Autologous Cell Therapy (REACT) Treatment - Patients will receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
16503024|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
16503025|NCT03270943|Active Comparator|Healthy Lifestyles (HLG)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
16503026|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
16503027|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
16503028|NCT03270917|Other|Open|Open liver surgery
16503029|NCT03270917|Other|Laparoscopy|Laparoscopic liver surgery
16503030|NCT03270904|Experimental|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
16503031|NCT03270904|No Intervention|Group 2 - Usual care|This group receive routine care and no additional intervention.
16503034|NCT03270878|Experimental|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
16503035|NCT03270878|Experimental|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
16503036|NCT03270865|Experimental|Usability and Ergonomic Evaluation of Self-Positioning System|
16503037|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
16503038|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
16503039|NCT03270839|Active Comparator|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
16503040|NCT03270839|Placebo Comparator|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
16503041|NCT03270839|Active Comparator|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
16503042|NCT03270839|Placebo Comparator|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
16503043|NCT03270839|Active Comparator|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
16503044|NCT03270839|Placebo Comparator|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
16503045|NCT03270839|Active Comparator|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
16503046|NCT03270839|Placebo Comparator|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
16503047|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
16503048|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
16503049|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
16503050|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
16503051|NCT03270787|Placebo Comparator|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
16503052|NCT03270787|Experimental|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
16503053|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
16503054|NCT03270735|Experimental|Treatment|Snake venom thrombin
16503055|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
16503056|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
16503057|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
16503058|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
16503059|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 450,000 IU orally
16503060|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 450,000 IU orally
16503061|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 450,000 IU orally
16503062|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 450,000 IU orally
16503063|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.
~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
16503064|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.
~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
16503065|NCT03270657|Other|Intraoperative Recording During DBS Implant Surgery|Participants will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who already are scheduled to undergo the planned deep brain electrode placement for treatment of their movement disorder. Intraoperative recordings of participants' neural signals will be made through the implanted deep brain electrode(s).
16503066|NCT03270644|Experimental|Lasmiditan Reference|Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
16503067|NCT03270644|Active Comparator|Propranolol Reference|Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
16503068|NCT03270644|Experimental|Lasmiditan + Propranolol Test|Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
16503069|NCT03270631|No Intervention|Control|Multidisciplinary rehabilitation, no interventions
16503070|NCT03270631|Experimental|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
16503071|NCT03270631|Other|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
16503072|NCT03270631|Other|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
16503073|NCT03270631|Sham Comparator|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
16503074|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
16503075|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
16503076|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
16503077|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
16503078|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ-64511070 in the human brain with the appropriate arterial IF.
16503079|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
16503080|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
16503081|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
16503082|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
16503084|NCT03270514|Experimental|Exparel Injectable Product|Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (~30).
16503085|NCT03270514|Active Comparator|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~30).
16503086|NCT03270501|Experimental|Arm 1: Golimumab|
16503087|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
16503088|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
16503089|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
16503090|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
16503091|NCT03270449|Experimental|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
16503092|NCT03270449|No Intervention|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
16503122|NCT03270163|Experimental|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
16503123|NCT03270150|Experimental|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
16503150|NCT03269968|Experimental|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
16503151|NCT03269968|Placebo Comparator|Standard dressing|Standard dressing
16503093|NCT03270436|Experimental|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|The Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program (WORD DPP) is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. The first 8 modules are intended to be delivered weekly. The last 8 modules are intended to be delivered every other week. Participants in the WORD DPP will be encouraged to maintain a daily weight, nutrition, physical activity and prayer log.
16503094|NCT03270436|Experimental|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|The Partnership for Improving Lifestyle Intervention Diabetes Prevention Program (PILI DPP) is a family and community based diabetes prevention curriculum that teaches participants to engage their social support (family and community) to have a healthy weight, eat healthy, and be physically active. The PILI DPP includes 14 modules that are intended to be delivered over a 24 week period and each module approximately 90 minutes in length. The first 4 modules are intended to be delivered weekly. The last 10 modules are intended to be delivered every other week. Participants will be encouraged to track their weight, physical activity, and their nutrition in a log on a daily basis.
16503095|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
16503096|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
16503097|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
16503098|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
16503099|NCT03270410||Neonates|Babies born in Rennes University Hospital
16503100|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
16503101|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
16503102|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
16503103|NCT03270371|Experimental|MCO Dialysis|Theranova Dialyzer
16503104|NCT03270371|Active Comparator|Standard High Flux Dialysis|Standard High Flux Dialyzer
16503105|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
16503106|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
16503107|NCT03270332|Experimental|Albuterol followed by placebo|Participants in this group will receive albuterol first followed by Placebo on the next visit
16503108|NCT03270332|Experimental|Placebo followed by albuterol|Participants in this group will receive placebo first followed by albuterol on the next visit
16503109|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:
~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter
~intubated or tracheostomy in place
~echocardiography requested by the treating physician
~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
16503110|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:
~zygomatic protuberance
~nostril's angle
~inferior margin of tragus
~lip marionette lines
~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
16503111|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
16503112|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
16503113|NCT03270267||Patients with IBD|
16503114|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
16503115|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
16503116|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
16503117|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
16503118|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
16503119|NCT03270189|Experimental|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
16503120|NCT03270189|No Intervention|Controls|Patients without cervical dystonia.
16503124|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).
~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.
~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
16503125|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).
~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.
~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
16503126|NCT03270124|Active Comparator|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
16503127|NCT03270124|Experimental|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (steps per day) and resistance exercises
16503128|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
16503129|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
16503130|NCT03270098|Experimental|Aerobic Exercise|using traditional exercise equipment (i.e., treadmill, stationary bike) along with active-play video games (Xbox Kinect).
16503131|NCT03270098|Active Comparator|Stretching and Toning Exercise|
16503132|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.
~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.
~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.
~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
16503133|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.
~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
16503134|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
16503135|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
16503138|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.
~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
16503139|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.
~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
16503140|NCT03270033|Active Comparator|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16503141|NCT03270033|Active Comparator|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16503142|NCT03270033|Active Comparator|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16503143|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
16503144|NCT03270007|Experimental|Chemotherapy|
16503145|NCT03270007|No Intervention|Control|
16503146|NCT03269994|Active Comparator|Cefoxitin|
16503147|NCT03269994|Experimental|Piperacillin-tazobactam|
16503148|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
16503149|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
16503152|NCT03269955|Experimental|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
16503153|NCT03269955|No Intervention|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
16503154|NCT03269942|Active Comparator|Endovascular Flow-Diversion|Implantation of flow-diversion device
16503155|NCT03269942|Active Comparator|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
16503156|NCT03269929|Experimental|Music therapy|
16503157|NCT03269929|Active Comparator|Midazolam|
16503158|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
16503159|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
16503160|NCT03269903|Experimental|Patients|Patients with malignant dysphagia treated with the HILZO stent
16503161|NCT03269890|Experimental|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
16503162|NCT03269890|Active Comparator|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
16503163|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
16503164|NCT03269864|Active Comparator|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.
~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.
~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.
~Careful and meticulous dissection is done in a blunt way isolating the perforator.
~After deflation of the tourniquet, hemostasis is performed."
16503165|NCT03269864|Active Comparator|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.
~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
16503166|NCT03269812|Experimental|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
16503167|NCT03269812|Experimental|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
16503168|NCT03269799|Active Comparator|test group|vitamin C 500 mg oral capsule
16503169|NCT03269799|Placebo Comparator|control group|placebo
16503170|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
16503171|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
16503172|NCT03269773|Placebo Comparator|Placebo|
16503173|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
16503174|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
16503175|NCT03269747|Active Comparator|Prednisone|Prednisone 40 mg daily for 7 days
16503176|NCT03269747|Placebo Comparator|Placebo|Placebo daily for 7 days
16503177|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
16503178|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
16503179|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
16503180|NCT03269708|No Intervention|Control|Participants receive standard care in cardiac rehabilitation program
16503181|NCT03269708|Experimental|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
16503182|NCT03269695|Experimental|PF-06687234|PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
16503183|NCT03269695|Placebo Comparator|Placebo|PF-06687234 matched Placebo SC QW x 12 doses
16503184|NCT03269669|Experimental|Arm I (obinutuzumab, umbralisib)|Patients receive obinutuzumab IV on day 1 and umbralisib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16503185|NCT03269669|Experimental|Arm II (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16503186|NCT03269669|Active Comparator|Arm III (obinutuzumab, combination chemotherapy)|"PRIOR BENDAMUSTINE-BASED CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with combination chemotherapy repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~PRIOR CHOP CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, and bendamustine IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 or 12 cycles (bendamustine and obinutuzumab, respectively) in the absence of disease progression or unacceptable toxicity."
16503225|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
16503187|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
16503188|NCT03269643|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16503189|NCT03269643|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16503190|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"Pulmonary hypertension patients (WHO group 1-5)
~Systemic sclerosis patients without pulmonary hypertension
~Mixed connective tissue disease patients without pulmonary hypertension"
16503191|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
16503192|NCT03269630||Healthy controls|"Age>18
~Not actively smoking
~No chronic medical conditions"
16503193|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
16503194|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
16503195|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
16503196|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
16503197|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
16503198|NCT03269591|Active Comparator|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
16503199|NCT03269591|Experimental|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
16503200|NCT03269591|Other|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
16503201|NCT03269591|Other|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
16503202|NCT03269591|Other|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
16503203|NCT03269578||1|Patients with advanced, refractory cancers being treated on NCI/DTC studies
16503204|NCT03269565|Experimental|Arm 1|BCD-100 1 mg/kg Q2W;
16503205|NCT03269565|Experimental|Arm 2|BCD-100 3 mg/kg Q3W.
16503206|NCT03269552|Experimental|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
16503207|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
16503208|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
16503209|NCT03269526|Experimental|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.
16503210|NCT03269513|Experimental|Intervention group|"Adolescent Obesity
~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).
~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
16503211|NCT03269513|No Intervention|Control group|
16503212|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
16503213|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
16503214|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EB diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
16503215|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EB. Tissue specimen will be collected from an inconspicuous skin area.
16503216|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
16503217|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
16503218|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
16503219|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%
~+ Normal saline IV"
16503220|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV
~+ Bilateral greater occipital nerve block with normal saline"
16503221|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
16503222|NCT03269409|Sham Comparator|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
16503223|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
16503224|NCT03269396|Experimental|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
16503329|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
16503226|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
16503227|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
16503228|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
16503229|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
16503230|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
16503231|NCT03269357|Other|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
16503232|NCT03269357|No Intervention|Routine counselling|Clinics randomized to routine counselling
16503233|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
16503234|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
16503235|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
16503236|NCT03269331||Control Group|No CTEP EBP Immersion Course
16503237|NCT03269318|Experimental|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
16503238|NCT03269318|No Intervention|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
16503239|NCT03269292||warm autoimmune hemolytic anemia|corticosteroid either oral form or intravenous followed by oral
16503240|NCT03269279|Experimental|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
16503241|NCT03269240|Experimental|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
16503242|NCT03269240|Active Comparator|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
16503243|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.
~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.
~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
16503244|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
16503245|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
16503246|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
16503247|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
16503248|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
16503249|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
16503250|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia
~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
16503251|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
16503252|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
16503330|NCT03268707|Experimental|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
16504148|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
16503253|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
16503254|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
16503255|NCT03269175|Other|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
16503256|NCT03269175|Other|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
16503257|NCT03269162|Experimental|Jinfukang + Chemotherapy Group|
16503258|NCT03269162|Placebo Comparator|Chemotherapy Group|
16503259|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
16503260|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
16503265|NCT03269123|Other|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
16503266|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
16503267|NCT03269084||Children at HLA-conferred risk for T1D|
16503268|NCT03269071|Experimental|Treatment Cohort A|"See Study Description
~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
16503269|NCT03269071|Experimental|Treatment Cohort B|"See Study Description
~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
16503270|NCT03269071|Experimental|Treatment Cohort C|"See Study Description
~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
16503271|NCT03269071|Experimental|Treatment Cohort D|"See Study Description
~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
16503272|NCT03269058|Experimental|Patients not treated with statins|
16503273|NCT03269058|Experimental|Patients treated with statins|
16503274|NCT03269045|Other|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
16503277|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
16503278|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
16503279|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
16503280|NCT03269006|Experimental|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
16503281|NCT03269006|Experimental|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
16503282|NCT03269006|Experimental|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
16503283|NCT03269006|Experimental|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
16503284|NCT03269006|No Intervention|Control|without any study interventions
16503285|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
16503286|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
16503287|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
16503288|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
16503289|NCT03268967|Active Comparator|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
16503290|NCT03268967|No Intervention|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
16503382|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
16503291|NCT03268954|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 milligram per square meter (mg/m^2), intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+/-10) infusion, intravenous, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity.
16503292|NCT03268954|Experimental|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles until disease progression or unacceptable toxicity.
16503293|NCT03268941|Placebo Comparator|Part 1: Placebo|TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
16503294|NCT03268941|Experimental|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
16503295|NCT03268941|Experimental|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
16503296|NCT03268941|Experimental|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
16503297|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fed Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
16503298|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fasted Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
16503299|NCT03268941|Active Comparator|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
16503300|NCT03268928|Experimental|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.
~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
16503301|NCT03268928|Other|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.
~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
16503302|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
16503303|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
16503304|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
16503305|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
16503306|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
16503307|NCT03268889|Experimental|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
16503308|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (> stage IIa) at the participating institutions will be asked to participate.
16503309|NCT03268863|Experimental|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
16503310|NCT03268863|Sham Comparator|Control|Powered down Google Cardboard Virtual Reality headset
16503311|NCT03268850|Experimental|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
16503312|NCT03268850|Experimental|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
16503313|NCT03268837|Experimental|Programmed Intermittent Bolus|
16503314|NCT03268837|Active Comparator|Continuous Infusion|
16503315|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
16503316|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
16503317|NCT03268811|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.
16503318|NCT03268798|Experimental|Wrist extension training|
16503319|NCT03268785|No Intervention|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
16503320|NCT03268785|Experimental|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
16503321|NCT03268772|Experimental|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
16503322|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
16503323|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
16503324|NCT03268746|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
16503325|NCT03268733|Experimental|Treatment group|45 PCOS patients will receive 5 mg folic acid
16503326|NCT03268733|No Intervention|control group|45 PCOS patients will receive no folic acid
16503327|NCT03268720|Other|healthy controls|FODMAP low diet gluten-free diet
16503328|NCT03268720|Other|NCGS patients|FODMAP low diet gluten-free diet
16503331|NCT03268694|Experimental|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
16503332|NCT03268655|Experimental|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
16503333|NCT03268655|Experimental|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
16503334|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:
~intravenous immune globulin;
~large dose of glucocorticoids;
~mechanical ventilation;
~hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);
~continuous renal replacement therapy."
16503335|NCT03268642||conventional therapy group|"meet one of the following conditions:
~without/insufficient intravenous immune globulin;
~without/with various doses of glucocorticoid ;
~vasoactive drug;
~without/delayed mechanical ventilation;
~without/delayed hemodynamic support;
~without/delayed continuous renal replacement therapy."
16503336|NCT03268629|Experimental|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
16503337|NCT03268629|Active Comparator|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
16503338|NCT03268616|Experimental|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
16503339|NCT03268616|Experimental|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
16503340|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules.
16503341|NCT03268590|Experimental|All Study Participants|Breathing 21% oxygen via non-rebreather face mask followed by breathing 100% oxygen via non-rebreather face mask
16503342|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
16503343|NCT03268564|Experimental|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):
~Viewing a promotion video and a demonstration video
~Brief motivational interviewing through telephone
~Visiting the HIVST-online webpage
~Receiving a free self-testing kit and follow-up reminders
~Health promotion for re-testers:
~Viewing a promotion video and a demonstration video
~Visiting the HIVST-online webpage
~Receiving a free self-testing kit and follow-up reminders"
16503344|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
16503345|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
16503346|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
16503347|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
16503348|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
16503349|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
16503350|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
16503383|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
16503384|NCT03268187|Experimental|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
16503351|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
16503352|NCT03268473|Experimental|Experimental: Non-surgical periodontal therapy|"Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months
~Intervention: Procedure: Non-surgical periodontal therapy"
16503353|NCT03268473|Active Comparator|Delayed non-surgical periodontal therapy|No periodontal treatment for 3 months
16503354|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
16503355|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
16503356|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
16503357|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
16503358|NCT03268421|Experimental|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
16503359|NCT03268421|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
16503360|NCT03268421|Active Comparator|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
16503361|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
16503362|NCT03268408||Control|Usual care
16503363|NCT03268395|Other|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
16503364|NCT03268382|Experimental|APR-246 + PLD|
16503365|NCT03268369|Active Comparator|Control group|
16503366|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
16503367|NCT03268369|Experimental|Idiopathic generalized epilepsy|
16503368|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
16503369|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
16503370|NCT03268343|Experimental|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):
~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).
~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
16503371|NCT03268343|Experimental|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):
~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).
~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
16503372|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
16503373|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
16503374|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:
~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;
~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;
~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
16503375|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
16503376|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
16503377|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
16503378|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
16503379|NCT03268239|Other|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.
~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
16503380|NCT03268226|Experimental|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
16503381|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
16503385|NCT03268187|Active Comparator|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
16503386|NCT03268174|Active Comparator|AO+Mist|AO+Mist
16503387|NCT03268174|Placebo Comparator|Placebo|Placebo
16503388|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
16503389|NCT03268148|Experimental|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
16503390|NCT03268148|No Intervention|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
16503391|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
16503392|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
16503393|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
16503394|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
16503395|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
16503396|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
16503397|NCT03268109||people living with HIV|subjects infected with HIV and with cognitive complaints
16503398|NCT03268109||control subjects|subjects not infected with HIV and with cognitive complaints
16503405|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
16503406|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
16503407|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
16503408|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
16503409|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
16503410|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
16503411|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
16503412|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
16503413|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
16503414|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
16503415|NCT03268018|Other|Single arm|
16503416|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
16503417|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
16503418|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
16503419|NCT03267966|Experimental|Group A|Leeds Pathology Protocol (LEEPP)
16503420|NCT03267966|No Intervention|Group B|"Conventional method of pathological evaluation"
16503421|NCT03267953|Experimental|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
16503422|NCT03267953|Experimental|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
16503423|NCT03267953|Experimental|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
16503424|NCT03267940|Experimental|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m^2) of CIS plus 1000 mg/m^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
16503450|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
16503451|NCT03267732|Active Comparator|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
16503425|NCT03267940|Experimental|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
16503426|NCT03267940|Experimental|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
16503427|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
16503428|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
16503429|NCT03267940|Active Comparator|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
16503430|NCT03267927|Experimental|Patient with OSA|
16503431|NCT03267914|Experimental|Tray group|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
16503432|NCT03267914|Active Comparator|Brush group|Patients will brush with the fluoride for 2 minutes each day.
16503433|NCT03267901|Experimental|Walnut-Control|
16503434|NCT03267901|Experimental|Control-Walnut|
16503435|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
16503436|NCT03267875|Experimental|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
16503437|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
16503438|NCT03267836|Experimental|Avelumab + Proton Therapy|"Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months
~Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays
~After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care
~If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.
~After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
16503439|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
16503440|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
16503441|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
16503442|NCT03267797|Experimental|Treatment group|Peripheral blood mononuclear cells (PBMCs) were administered into the uterine cavity of RIF patients in this group.
16503443|NCT03267797|Placebo Comparator|Control group|Phosphate buffer saline (PBS) as placebo was injected into the uterine cavity of RIF patients in this group.
16503444|NCT03267784|Experimental|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
16503445|NCT03267771|Active Comparator|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
16503446|NCT03267771|Experimental|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
16503447|NCT03267758|Experimental|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
16503448|NCT03267758|Placebo Comparator|Placebo|Subjects in this arm will consume 1 serving of heat-killed placebo daily for first 6 weeks.
16503449|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
16503452|NCT03267732|Active Comparator|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
16503453|NCT03267719|Experimental|laser therapy|Erbium-laser therapy will be applied
16503454|NCT03267706|Active Comparator|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
16503455|NCT03267706|No Intervention|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
16503456|NCT03267680|Experimental|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
16503457|NCT03267680|Active Comparator|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
16503458|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
16503459|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
16503460|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
16503461|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
16503462|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
16503463|NCT03267628|Sham Comparator|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
16503464|NCT03267628|Active Comparator|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
16503465|NCT03267628|Active Comparator|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
16503466|NCT03267628|Active Comparator|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
16503467|NCT03267602|Experimental|Continuous Positive Airway Pressure (CPAP) Therapy|
16503468|NCT03267589|Experimental|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
16503469|NCT03267589|Experimental|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
16503470|NCT03267589|Experimental|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
16503471|NCT03267576|Experimental|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to [>=] 1500 milligram per day [mg/day]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin >=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
16503472|NCT03267576|Experimental|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
16503473|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
16503474|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
16503475|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
16503476|NCT03267550|Experimental|remote programming system|
16503477|NCT03267537|Active Comparator|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
16503478|NCT03267537|Experimental|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
16503479|NCT03267524|Experimental|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
16503480|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
16503481|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
16503482|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
16503483|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
16503484|NCT03267498|Experimental|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16503485|NCT03267446|Experimental|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
16503486|NCT03267433|Experimental|Group I (auto-HCT, rituximab)|Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 60-120 days after transplant, patients receive rituximab IV once every 8 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16503487|NCT03267433|Experimental|Group II (rituximab alone)|Patients receive standard of care induction chemotherapy. Beginning 40-120 days after completion of chemotherapy, patients receive rituximab as in Group I.
16503488|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
16503489|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
16503490|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
16503491|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
16503492|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
16503493|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
16503494|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
16503495|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
16503496|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
16503497|NCT03267368|Experimental|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
16503498|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
16503499|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
16503500|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
16503501|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
16503502|NCT03267316|Experimental|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. [Completed December 2018]
16503503|NCT03267316|Experimental|Monotherapy (Q1W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).
16503504|NCT03267316|Experimental|Monotherapy (Q1W/Q2W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).
16503505|NCT03267316|Experimental|Combination - NSCLC|Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).
16503506|NCT03267316|Experimental|Combination - PDAC|Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).
16503507|NCT03267316|Experimental|Combination - PDAC (1 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
16503508|NCT03267316|Experimental|Combination - PDAC (2,5 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
16503509|NCT03267303|Experimental|TS-091 5mg|
16503510|NCT03267303|Experimental|TS-091 10mg|
16503511|NCT03267303|Placebo Comparator|Placebo|
16503512|NCT03267290|Experimental|Sonazoid- CEUS+CEMRI or CECT+CEMRI|Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
16503514|NCT03267264|Experimental|Group 1|
16503515|NCT03267264|Experimental|Group 2|
16503516|NCT03267264|Experimental|Group 3|
16503517|NCT03267264|Experimental|Group 4|
16503518|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
16503519|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
16503520|NCT03267238|Experimental|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
16503521|NCT03267212|Active Comparator|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
16503522|NCT03267212|Sham Comparator|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
16503524|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
16503525|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
16503526|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
16503527|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
16503528|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
16503529|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis
~no intervention is given"
16503530|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
16503531|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
16503532|NCT03267108|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
16503533|NCT03267108|Placebo Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
16503534|NCT03267108|Other|Open Label Extension|Pulsed inhaled iNO 45 mcg/kg IBW/hr
16503535|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
16503536|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
16503537|NCT03267082|Experimental|Evaluation the role of Laparoscopic management of perforated a|
16503538|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
16503539|NCT03267056||DCB arm|drug eluting balloon catheter
16503540|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
16503541|NCT03267043|Experimental|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
16503542|NCT03267043|Active Comparator|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
16503543|NCT03267043|Experimental|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
16503544|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
16503545|NCT03267017||Patient scheduled for surgery under general anesthesia|
16503546|NCT03267004|Experimental|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
16503547|NCT03267004|Experimental|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
16503548|NCT03266991|Experimental|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
16503549|NCT03266991|Active Comparator|control|Participants treated with daily isoniazid for six months
16503550|NCT03266965|Experimental|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
16503551|NCT03266939|Placebo Comparator|Placebo|
16503552|NCT03266939|Active Comparator|Active Medication|
16503553|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
16503554|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
16503555|NCT03266913|Active Comparator|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
16503556|NCT03266913|No Intervention|No probiotic|Routine phototherapy
16503557|NCT03266900|Experimental|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
16503558|NCT03266900|Active Comparator|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
16503559|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
16503560|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
16503561|NCT03266835|Other|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
16503562|NCT03266822||Healthy control|
16503565|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:
~Early invasive breast cancer (stage I-III)
~Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)
~WHO performance status 0-2."
16503566|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
16503567|NCT03266783|Active Comparator|Apixaban group|10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment
16503568|NCT03266783|Active Comparator|Rivaroxaban group|15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment
16503569|NCT03266770|Other|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
16503570|NCT03266744|Other|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.
~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
16503571|NCT03266744|Other|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
16503572|NCT03266731|Experimental|use of aspirin and clopidogrel|
16503573|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
16503574|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
16503575|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
16503576|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
16503577|NCT03266692|Experimental|ACTR087 in combination with SEA-BCMA|
16503578|NCT03266679|Other|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker & Klion) - weekly for a period of 12 months. No control/comparison group.
16503579|NCT03266666|Other|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
16503580|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
16503581|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
16503582|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
16503583|NCT03266614|Experimental|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
16503584|NCT03266614|No Intervention|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
16503585|NCT03266601|Experimental|Recombinant Human Interferon α-2b Spray|
16503586|NCT03266601|Active Comparator|Ribavirin|
16503587|NCT03266588|Experimental|Rimegepant|
16503588|NCT03266575|Active Comparator|Pulmonary Rehabilitation|Participants will participate in formal Pulmonary Rehabilitation Exercise program
16503589|NCT03266575|Active Comparator|Home based program|Participants will participate in a Home based Exercise program
16503590|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
16503591|NCT03266549|Experimental|Botulinum toxin augmented surgery group|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
16503592|NCT03266549|Active Comparator|conventional surgery group|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia.The standard correction tables will be used as a guide for the amount of muscle recession and, or resection
16503593|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
16503594|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
16503595|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
16503596|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
16503597|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
16503599|NCT03266510|Experimental|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
16503600|NCT03266510|Sham Comparator|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
16503601|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.
~The probiotics sachets will be taken twice a day for 12 weeks."
16503602|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo
~The identical placebo sachets will be taken twice a day for 12 weeks."
16503603|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
16503604|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
16503605|NCT03266445|Active Comparator|FULL-BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
16503606|NCT03266445|No Intervention|LOW-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone reduced to 8mg on the day of surgery
16503607|NCT03266432|Other|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
16503608|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
16503609|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
16503610|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
16503611|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
16503612|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
16503613|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
16503614|NCT03266367||Healthy Group|control group
16503615|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
16503616|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
16503617|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
16503618|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
16503619|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
16503620|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
16503621|NCT03266276|No Intervention|Treatment as Usual Control Group|Treatment as usual.
16503622|NCT03266276|Experimental|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
16503623|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
16503624|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
16503625|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
16503626|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
16503627|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
16503628|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
16503629|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
16503630|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
16503631|NCT03266224||Wryneck|those with a condition
16503632|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
16503633|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
16503634|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
16503635|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
16503636|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
16503637|NCT03266172|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
16503638|NCT03266172|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
16503639|NCT03266172|Experimental|Subjects in Part C|Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
16503640|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
16503641|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
16503642|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
16503643|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
16503644|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
16503645|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
16503646|NCT03266146|Experimental|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
16503647|NCT03266146|Experimental|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
16503648|NCT03266133|Experimental|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
16503649|NCT03266133|No Intervention|Routine Care|Usual care
16503650|NCT03266120|Active Comparator|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
16503651|NCT03266120|Experimental|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
16503652|NCT03266107|Experimental|Treatment|BVN Ablation
16503653|NCT03266094|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs Radio frequency (RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
16503654|NCT03266081|Experimental|0.75% bupivacaine|
16503655|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
16503656|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
16503657|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
16503658|NCT03266055|Experimental|Blueberry powder|
16503659|NCT03266055|Placebo Comparator|Blueberry placebo powder|
16503660|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
16503661|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
16503758|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
16503759|NCT03265379||patients with an isolated recurrence in the chest wall|
16503662|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
16503663|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
16503664|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
16503665|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
16503666|NCT03265990|Experimental|Group A|Conventional haemrrhoidectomy,Ferguson technique
16503667|NCT03265990|Experimental|Group B|Ligasure haemorrhoidectomy
16503668|NCT03265977|Experimental|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
16503669|NCT03265977|Placebo Comparator|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
16503670|NCT03265964|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
16503671|NCT03265964|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
16503672|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
16503673|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
16503674|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
16503675|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
16503676|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
16503677|NCT03265925||Healthy|Healthy controls
16503678|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
16503679|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
16503680|NCT03265899|Experimental|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
16503681|NCT03265899|Placebo Comparator|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
16503682|NCT03265886|Experimental|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
16503683|NCT03265886|Active Comparator|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
16503684|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
16503685|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
16503686|NCT03265834|Experimental|Long course antibiotic therapy (28 days)|Antibiotic therapy for a duration of 28 days
16503687|NCT03265834|Active Comparator|Short course antibiotic therapy (≤10 days)|Antibiotic therapy for a duration of ≤10 days
16503688|NCT03265808|Experimental|allogeneic human mesenchymal stem cells (allo-hMSCs)|Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
16503689|NCT03265808|Placebo Comparator|Placebo|Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
16503690|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
16503691|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
16503692|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
16503693|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
16503694|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
16503695|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
16503696|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
16503697|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
16503760|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
16503761|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
16503698|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
16503699|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
16503700|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
16503701|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
16503702|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
16503703|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
16503704|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
16503705|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
16503706|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
16503707|NCT03265665|Experimental|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants during the adoptive phase (24-weeks) and 1 group session during the maintenance phase (12-weeks). Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
16503708|NCT03265665|Other|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
16503709|NCT03265652|Experimental|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
16503710|NCT03265652|Placebo Comparator|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
16503711|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
16503712|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
16503713|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
16503714|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
16503715|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
16503716|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.
~-No intervention package but standard service will be maintained"
16503717|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
16503718|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
16503762|NCT03265379||patients refusing to undergo surgery|
16503763|NCT03265366|Experimental|ABPA|15 patients with ABPA
16503764|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
16503719|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
16503720|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
16503721|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
16503722|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
16503723|NCT03265574|Experimental|Intervention|
16503724|NCT03265574|No Intervention|Standard care|
16503725|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
16503726|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
16503727|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
16503728|NCT03265548|Experimental|Intervention|Video laryngoscopy
16503729|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
16503730|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
16503731|NCT03265522|Experimental|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
16503732|NCT03265522|Experimental|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
16503733|NCT03265522|Placebo Comparator|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
16503734|NCT03265509|Active Comparator|Glutamine|30 g/day Glutamine supplementation for three months
16503735|NCT03265509|Placebo Comparator|Fantomalt|30 g/day Fantomalt supplementation for three months
16503737|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
16503738|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
16503739|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
16503740|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
16503741|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
16503742|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
16503743|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
16503744|NCT03265457||Normal people at same age|
16503745|NCT03265444|Experimental|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
16503746|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
16503747|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
16503748|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
16503749|NCT03265418|Experimental|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
16503750|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
16503751|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
16503752|NCT03265405|No Intervention|Observation|The subjects with sarcoidosis who do not have any indication for immunosuppressive treatment will be observed and monitored. If any treatment requiring indication arises during the observed period, the subjects will be randomized to one of the above study groups
16503753|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
16503754|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
16503755|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
16503756|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
16503757|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
16503843|NCT03264846||Group 4|systemically and periodontally healthy participants
16503765|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
16503766|NCT03265353|Other|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
16503767|NCT03265353|Other|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
16503768|NCT03265340|Active Comparator|A|dTMS standard protocol 10 min session
16503769|NCT03265340|Active Comparator|B|dTMS standard protocol 20 min session
16503770|NCT03265340|Active Comparator|C|dTMS standard protocol 40 min session
16503771|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
16503772|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
16503773|NCT03265314|Experimental|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
16503774|NCT03265314|Placebo Comparator|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
16503775|NCT03265301|Other|Office hysteroscopy|
16503776|NCT03265301|Other|Conventional hysteroscopy|
16503777|NCT03265288|Experimental|LAU-7b|Active drug fenretinide (as LAU-7b capsules)
16503778|NCT03265288|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
16503779|NCT03265262|Experimental|Children receiving OFC during a diagnost|paediatric patients attending food allergy
16503780|NCT03265249|Experimental|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
16503781|NCT03265249|No Intervention|Group 2|Subjects will receive the standard of care pain control analgesia
16503782|NCT03265236||Group1|Patients with early rheamatoid arthritis
16503783|NCT03265236||Group 2|patients with late rheamatoid arthritis
16503784|NCT03265236||Group 3|Healthy control
16503785|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
16503786|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
16503787|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
16503788|NCT03265210|Experimental|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
16503789|NCT03265210|No Intervention|Referral|Referral for mental health based on clinical indication.
16503790|NCT03265197|Experimental|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
16503791|NCT03265197|Active Comparator|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
16503792|NCT03265184|Experimental|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
16503793|NCT03265184|Placebo Comparator|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
16503794|NCT03265145|Experimental|Stiolto Respimat|
16503795|NCT03265145|Active Comparator|ICS plus LABA plus LAMA (triple therapy)|ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)
16503796|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
16503797|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
16503798|NCT03265119|Experimental|AEVI-001|
16503799|NCT03265119|Placebo Comparator|Placebo|
16503800|NCT03265106|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10^6/kg / 1x10^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
16503801|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
16503802|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
16503803|NCT03265080|Experimental|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.
~Two dose levels of ADXS-NEO will be explored: 1 x 10 to the 9th power and 1 x 10 to the 8th power colony forming unit (CFU)."
16503804|NCT03265080|Experimental|Part B|Two dose levels of ADXS-NEO will be explored [i.e., 1 x 10 to the 8th power and 5 x 10 to the 8th power colony forming unit (CFU)] in combination with 200mg of pembrolizumab.
16503805|NCT03265080|Experimental|Part C|ADXS-NEO will be explored at 1 x 10 to the 8th power colony forming unit (CFU) in combination with 200mg of pembrolizumab in an expansion cohort.
16503806|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
16503807|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
16503808|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
16503809|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
16503810|NCT03265028||Intervention|Invited to take the TRACE e-learning.
16503811|NCT03265028||Control|Not (yet) invited to take the TRACE e-learning.
16503812|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
16503813|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
16503814|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
16503815|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
16503816|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
16503817|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
16503818|NCT03264989|Experimental|crizanlizumab 5 mg/kg|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.
16503819|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
16503820|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
16503821|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
16503822|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
16503823|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
16503824|NCT03264963|Active Comparator|Control|
16503825|NCT03264963|Experimental|Intervention|
16503826|NCT03264950|Other|SIngle Arm|All patients undergo Elastography. This is a single arm study
16503827|NCT03264937|Experimental|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
16503828|NCT03264937|No Intervention|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
16503829|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
16503830|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
16503831|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
16503832|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
16503833|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
16503834|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
16503835|NCT03264898||FIT Group|Fecal immunochemical tests will be completed.
16503836|NCT03264885|No Intervention|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
16503837|NCT03264885|Other|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
16503838|NCT03264872|Experimental|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
16503839|NCT03264872|Other|Waitlist Control|Delayed Treatment.
16503840|NCT03264846||Group 1|PCOS participants with periodontitis
16503841|NCT03264846||Group 2|PCOS participants with periodontally healthy
16503842|NCT03264846||Group 3|systemically healthy participants with periodontitis
16503844|NCT03264820|Experimental|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.
~Then will be performed :
~Visit 1 :
~Biology report * (* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))
~Laser measurements at the forearm (with laser speckle)
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature
~Visit 2 :
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature"
16503845|NCT03264820|Experimental|Healthy volunteers|"The healthy volunteers (11) will undergo :
~Visit 1 :
~Biology report (+ urinary pregnancy test (if applicable))
~Laser measurements at the forearm (with laser speckle)
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature
~Visit 2 :
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature"
16503846|NCT03264807|Active Comparator|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
16503847|NCT03264807|Experimental|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
16503848|NCT03264794|Experimental|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
16503849|NCT03264794|Active Comparator|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
16503850|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
16503851|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
16503852|NCT03264768|Other|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
16503853|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
16503854|NCT03264755|Active Comparator|cortical excitability in smokers|
16503855|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
16503856|NCT03264729|Experimental|Isometric exercise|
16503857|NCT03264729|Active Comparator|Isotonic exercise|
16503858|NCT03264729|Active Comparator|Walking|
16503859|NCT03264716|Experimental|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
16503860|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
16503861|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
16503862|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
16503863|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
16503864|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
16503866|NCT03264651|Experimental|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
16503867|NCT03264638|Experimental|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
16503868|NCT03264638|Experimental|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
16503869|NCT03264638|Active Comparator|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
16503870|NCT03264625|Experimental|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
16503871|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
16503872|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.
~The exercise included three stages: warming up, swimming and cooling down."
16503873|NCT03264612|No Intervention|Non swimming group|no intervention
16503874|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
16503965|NCT03263884|Sham Comparator|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
16503875|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
16503876|NCT03264586|Active Comparator|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum
~EMLA cream was applied, 1 hour before the expected time of birth.
~With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.
~No additional anesthetic was applied if episiotomy was necessary.
~Before commancement of perineal repair any residual cream was wiped off."
16503877|NCT03264586|Active Comparator|mepivacaine infiltration group|"In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.
~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.
~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
16503878|NCT03264573|Active Comparator|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
16503879|NCT03264573|Active Comparator|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
16503880|NCT03264560|Active Comparator|Synchronous Telepsychiatry (STP) group|
16503881|NCT03264560|Experimental|Asynchronous Telepsychiatry (ATP) group|
16503882|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*
~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
16503883|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
16503884|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
16503885|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
16503886|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
16503889|NCT03264482|Active Comparator|THUVAP|thulium vaporization
16503890|NCT03264482|Active Comparator|M-TURP|monopolar transurethral resection
16503891|NCT03264456|Experimental|[18F] Fluciclovine PET/MRI|[18F] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
16503892|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
16503893|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
16503894|NCT03264430|Active Comparator|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
16503895|NCT03264430|Placebo Comparator|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
16503897|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
16503898|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
16503899|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
16503900|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
16503901|NCT03264352|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
16503902|NCT03264352|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
16503903|NCT03264339|Experimental|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
16503904|NCT03264326|Experimental|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
16503905|NCT03264326|Sham Comparator|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
16503906|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
16503907|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
16503908|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
16503966|NCT03263871|Experimental|Intervention|PTM202 and micro-nutrient sprinkles
16503909|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
16503910|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.
~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.
~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.
~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).
~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
16503911|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.
~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.
~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.
~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).
~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
16503912|NCT03264274|Other|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
16503913|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
16503914|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
16503915|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
16503916|NCT03264235|Experimental|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
16503917|NCT03264235|Active Comparator|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
16503918|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
16503919|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
16503920|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
16503921|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
16503922|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
16503923|NCT03264170|Active Comparator|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
16503924|NCT03264170|No Intervention|Control|Women will not receive the prediction score
16503925|NCT03264157|Experimental|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
16503926|NCT03264157|Active Comparator|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
16503927|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
16503928|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
16503929|NCT03264131|Experimental|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP [(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m^2 on D1; doxorubicin 50 mg/m^2 on D1, etoposide 100 mg/m^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)] for 2 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
16503930|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
16503931|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
16503932|NCT03264105|Experimental|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
16503933|NCT03264105|Active Comparator|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
16503934|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
16503935|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
16503936|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
16503937|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
16503938|NCT03264066|Experimental|Cohort 1 - SCCHN - Treatment Naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
16503967|NCT03263871|Other|Control|micro-nutrient sprinkles
16503968|NCT03263858|Experimental|Cohort 1 and 2|
16503939|NCT03264066|Experimental|Cohort 2 - UC - Treatment Naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
16503940|NCT03264066|Experimental|Cohort 3 - RCC - Treatment Naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
16503941|NCT03264066|Experimental|Cohort 4 - SCCHN - Previous Treatment Exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
16503942|NCT03264066|Experimental|Cohort 5 - UC - Previous Treatment Exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
16503943|NCT03264066|Experimental|Cohort 6 - RCC - Previous Treatment Exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
16503944|NCT03264066|Experimental|Cohort 7 - Biopsy Cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
16503945|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
16503946|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
16503947|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
16503948|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
16503949|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
16503950|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
16503951|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
16503952|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
16503953|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
16503954|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
16503955|NCT03263962||With canrenone|Patients with canrenone
16503956|NCT03263962||Without canrenone|Patients without canrenone
16503957|NCT03263936|Other|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
16503958|NCT03263923|Experimental|Intervention group|Online intervention is cognitive behavioral skills' training and 4 weeks of online journaling. Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they have learned/used.
16503959|NCT03263923|Active Comparator|Comparison group|Comparator intervention is Reflective journaling training and 4 weeks of online journaling. Participants watch a reflective journaling video with specific instructions, and then the participants complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations.
16503960|NCT03263910|Experimental|NPO-11|
16503961|NCT03263910|Placebo Comparator|Placebo|
16503962|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
16503963|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
16503964|NCT03263884|Experimental|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.
~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
16503969|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).
~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
16503970|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).
~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
16503971|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
16503972|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
16503973|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
16503974|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
16503975|NCT03263793|Experimental|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
16503976|NCT03263780|Experimental|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
16503977|NCT03263767|Experimental|LYMPHOID HEMOPATHY without ATG|patients with lymphoid hemopathy
16503978|NCT03263767|Experimental|MYELOID HEMOPATHY without ATG|patients with myeloid hemopathy
16503979|NCT03263767|Experimental|LYMPHOID HEMOPATHY witH ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
16503980|NCT03263767|Experimental|MYELOID HEMOPATHY with ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
16503981|NCT03263754|Experimental|Intervention|
16503982|NCT03263754|Active Comparator|Control|
16503983|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
16503984|NCT03263728|Experimental|Stress Cardiac MR|
16503985|NCT03263715|Experimental|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe [Actemra] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid [Glucocorticoids]
16503986|NCT03263715|Placebo Comparator|Placebo|Placebo [Placebos] and rapidly tapered Glucocorticoid [Glucocorticoids] treatment
16503987|NCT03263702|Experimental|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
16503988|NCT03263689|Experimental|Intervention|"ITM group were given
~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
~100 micrograms of preservative-free morphine."
16503989|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
16503990|NCT03263676|Experimental|Icon reusable underwear|
16503991|NCT03263676|Placebo Comparator|Disposable pad|
16503992|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
16503993|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
16503994|NCT03263650|Experimental|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
16503995|NCT03263650|Experimental|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
16503996|NCT03263650|No Intervention|Observation Only|Participants randomized to observation only beginning cycle 7.
16503999|NCT03263624|Experimental|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
16504000|NCT03263624|Active Comparator|Group (B)|Tazarotene Cream 0.1%
16504001|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
16504002|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
16504003|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
16504004|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
16504005|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
16504006|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
16504007|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
16504008|NCT03263572|Experimental|Treatment (blinatumomab, chemotherapy, ponatinib)|Patients receive blinatumomab IV nonstop on days 1-28 of cycles 1-5, and methotrexate and cytarabine intrathecally (by spinal tap) on days 1, 15, and 29 of cycles 1-4. Patients also receive ponatinib PO daily. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16504535|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg; Double-Blind|
16504010|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
16504011|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
16504012|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:
~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
16504013|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:
~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
16504014|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
16504015|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
16504016|NCT03263507|Experimental|IONIS-PKK-LRx|Ascending single and multiple doses of IONIS-PKK-LRx administered subcutaneously
16504017|NCT03263507|Placebo Comparator|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
16504018|NCT03263494|Active Comparator|CGM|
16504019|NCT03263494|No Intervention|BGM|
16504020|NCT03263481|Experimental|ERCP with intraductal secretin test|Subjects undergoing ERCP for biliary indication in which inadvertent pancreatic cannulation occurs will receive intraductal secretin testing using a one-time intravenous injection of 16 mcg of human secretin for injection administered over one minute.
16504021|NCT03263468|Experimental|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm).
16504022|NCT03263468|Active Comparator|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
16504023|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
16504024|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
16504027|NCT03263429|Experimental|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16504028|NCT03263416|Experimental|Arm A|
16504029|NCT03263416|Other|Arm B|Standard
16504030|NCT03263403|Experimental|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
16504031|NCT03263403|Active Comparator|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
16504032|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
16504033|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
16504034|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
16504035|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
16504036|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
16504037|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
16504038|NCT03263338|Active Comparator|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
16504039|NCT03263338|Experimental|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
16504075|NCT03263091|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
16504040|NCT03263338|Experimental|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
16504041|NCT03263325||AKI Group|Patients developing AKI after surgery
16504042|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
16504043|NCT03263312|Experimental|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
16504044|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
16504045|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
16504046|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
16504047|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
16504048|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
16504049|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
16504050|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
16504051|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
16504052|NCT03263247|Experimental|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.
~Intervention: Visual Imaging Training in individual sessions"
16504053|NCT03263247|Active Comparator|Psychoeducation|"Participants will receive information about memory functioning and aging.
~Intervention: behavioral: Psychoeducation in individual sessions"
16504054|NCT03263247|Experimental|Alphabet Search|"Participants will receive alphabet search training.
~Intervention: Alphabet Search in individual sessions"
16504055|NCT03263234|Active Comparator|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
16504056|NCT03263234|Active Comparator|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
16504057|NCT03263234|No Intervention|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.
~This group serves as a control for:
~Physiological or mental decline in participants during the study period
~Seasonal variation"
16504058|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
16504059|NCT03263195||HIV-infected women|Pregnant women infected with HIV only and their infants.
16504060|NCT03263195||ZIKV-infected women|Pregnant women infected with ZIKV only and their infants.
16504061|NCT03263195||HIV- and ZIKV-infected women|Pregnant women infected with HIV and ZIKV and their infants.
16504062|NCT03263195||Not HIV- or ZIKV- infected women|Pregnant women not infected with either HIV or ZIKV and their infants.
16504063|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
16504064|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
16504065|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
16504066|NCT03263156|Experimental|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
16504067|NCT03263156|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
16504068|NCT03263143|No Intervention|Standard of Care|
16504069|NCT03263143|Other|Early Palliative Care Consultation|
16504070|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
16504073|NCT03263104|Experimental|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
16504074|NCT03263104|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
16504076|NCT03263091|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
16504077|NCT03263091|Experimental|Open-Label High Erythropoietin|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
16504078|NCT03263078|Experimental|TIVA with Propofol in major surgery|Total intravenous anesthesia(TIVA) with Propofol
16504079|NCT03263078|Active Comparator|Sevoflurane in major surgery|Inhalation anesthesia with Sevoflurane
16504080|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
16504081|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
16504082|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
16504083|NCT03263052||Tacrolimus XR|
16504084|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
16504085|NCT03263026|Active Comparator|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
16504086|NCT03263026|Placebo Comparator|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
16504087|NCT03263013||FMD patients|patients with a diagnosis of clinically definite FMD who have been assessed at the HMCS clinic, and who have completed protocol 07-N-0190.
16504088|NCT03263000||Healthy|24 healthy volunteers (HVs)
16504089|NCT03263000||Patients|24 patients with blepharospasm
16504090|NCT03263000||Patients 2|24 patients with increased blinking alone.
16504091|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
16504092|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
16504093|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
16504094|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
16504095|NCT03262948|Experimental|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
16504096|NCT03262948|Active Comparator|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
16504097|NCT03262935|Experimental|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
16504098|NCT03262935|Active Comparator|Physician's choice|"Lap/Cap
~T/Cap
~T/Vino
~T/Eri"
16504099|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
16504100|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
16504101|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
16504102|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:
~Prolonged mechanical ventilation (longer than 96 hours)
~Tracheostomy
~Sepsis
~Serious injury (burn)
~Stroke (hemorhagic or ischemic)
~Traumatic brain injury"
16504103|NCT03262857|Experimental|time of start of anesthesia|
16504104|NCT03262857|Experimental|intensity of anesthesia|
16504105|NCT03262844|Placebo Comparator|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
16504106|NCT03262844|Experimental|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
16504107|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga
~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.
~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel
~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
16504108|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
16504109|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery
~Immediately after the transvaginal US, US/PAI imaging will be performed
~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
16504110|NCT03262805|Placebo Comparator|Placebo|Placebo
16504111|NCT03262805|Active Comparator|Active|Lanconone(R)
16504112|NCT03262792|Placebo Comparator|Placebo|Microcrystalline cellulose
16504113|NCT03262792|Active Comparator|Andrographis Paniculata 150|Andrographis Paniculata 150 mg
16504114|NCT03262792|Active Comparator|Andrographis Paniculata 300|Andrographis Paniculata 300 mg
16504115|NCT03262779|Experimental|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks.
16504116|NCT03262766|Active Comparator|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
16504117|NCT03262766|Experimental|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).
~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
16504118|NCT03262766|Active Comparator|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).
~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
16504119|NCT03262766|Sham Comparator|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
16504120|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
16504121|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
16504122|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
16504123|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
16504124|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
16504125|NCT03262714|Experimental|Dancing|Elderly women randomized to the dance intervention programme.
16504126|NCT03262714|Experimental|Walking|Elderly women randomized to the walking intervention programme.
16504127|NCT03262714|Active Comparator|Stretching|Elderly women randomized to the stretching intervention programme.
16504128|NCT03262701|Experimental|Hydrogen Peroxide gel for 13weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 13 weeks.
16504129|NCT03262701|Experimental|Hydrogen Peroxide gel for 26weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 26 weeks.
16504130|NCT03262701|Other|Scaling and Root Planing|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without any interventional hydrogen peroxide application in one or two visits.
16504131|NCT03262688|Experimental|INL-001|Bupivacaine HCl collagen-matrix implant
16504132|NCT03262688|Active Comparator|Infiltration|Bupivacaine HCl infiltration
16504133|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **
~+ 11 weeks of post-TQD varenicline
~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.
~Brief individual counseling at clinic visits"
16504134|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **
~+ 11 weeks of post-TQD varenicline
~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.
~Brief individual counseling at clinic visits"
16504135|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
16504136|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
16504137|NCT03262636|Other|Diagnostic value of Second Window ICG|"The primary study objective is to determine the diagnostic value of Second Window ICG (delayed, high dose IV administration of ICG) in the surgical resection of nervous system tumors.
~The first objective is to determine safety/efficacy of high dose, delayed indocyanine green (second window ICG) during surgery of nervous system tumors."
16504138|NCT03262636|Other|Optimal timing and dose of SWG|"The second study objective is to calculate diagnostic test characteristics (sensitivity/specificity) of delayed, high dose indocyanine green (second window ICG) as a diagnostic aid during surgery of nervous system tumors.
~The third study objective is to optimize timing and dose of second window Indocyanine Green during surgery of nervous system tumors, based on sensitivity/specificity."
16504139|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
16504140|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
16504141|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
16504142|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
16504143|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
16504144|NCT03262558||Patients with ECC|No intervention
16504149|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
16504150|NCT03262506|Experimental|Cognitive Training|
16504151|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
16504152|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
16504153|NCT03262480|Active Comparator|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
16504154|NCT03262480|Sham Comparator|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
16504155|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
16504156|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
16504157|NCT03262454|Experimental|Interventions|Atezolizumab
16504158|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
16504159|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
16504160|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
16504161|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
16504162|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
16504163|NCT03262402|Experimental|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
16504164|NCT03262402|Active Comparator|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
16504165|NCT03262389|Experimental|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
16504166|NCT03262376|Experimental|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
16504167|NCT03262376|Experimental|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
16504168|NCT03262376|Experimental|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
16504169|NCT03262376|Placebo Comparator|Placebo|Cellulose crystalline placebo
16504170|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
16504171|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
16504172|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
16504173|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
16504174|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
16504175|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
16504176|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
16504177|NCT03262311|Experimental|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
16504178|NCT03262298|Experimental|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
16504179|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
16504180|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
16504181|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
16504182|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
16504183|NCT03262259|Experimental|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
16504184|NCT03262259|No Intervention|Comparison|Comparison cities receiving no evidence-based interventions.
16504536|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo; Double Blind|
16504185|NCT03262233|Experimental|Active Deprived|"21 mg nicotine patches and 2 mg nicotine lozenges
~+ First NPU task takes place 24 hours after start of quit attempt"
16504186|NCT03262233|Experimental|Active Non-deprived|"21 mg nicotine patches and 2 mg nicotine lozenges
~+ First NPU task takes place during normal smoking prior to quit attempt"
16504187|NCT03262233|Active Comparator|Placebo Deprived|"Placebo patches and placebo lozenges
~+ First NPU task takes place 24 hours after start of quit attempt"
16504188|NCT03262233|Active Comparator|Placebo Non-deprived|"Placebo patches and placebo lozenges
~+ First NPU task takes place during normal smoking prior to quit attempt"
16504189|NCT03262207||testicular tumours|
16504190|NCT03262207||fertile|
16504191|NCT03262207||infertile|
16504192|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
16504193|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
16504194|NCT03262168|Other|Study Group One|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
16504195|NCT03262168|Other|Study Group Two|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
16504196|NCT03262168|Other|Study Group One - phase 2|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
16504197|NCT03262168|Other|Study Group Two - phase 2|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
16504198|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
16504199|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
16504200|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
16504201|NCT03262142|No Intervention|Antibiotic-free treatment|
16504202|NCT03262116|Experimental|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
16504203|NCT03262116|Experimental|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
16504204|NCT03262116|Experimental|Bionic Pancreas - BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
16504205|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
16504206|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
16504207|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
16504208|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
16504209|NCT03262090|No Intervention|control group|Subjects were randomly assigned to receive saline before skin incision
16504210|NCT03262090|Active Comparator|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
16504211|NCT03262090|Active Comparator|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
16504212|NCT03262090|Active Comparator|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
16504213|NCT03262090|Active Comparator|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
16504214|NCT03262090|Active Comparator|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
16504215|NCT03262077|Experimental|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
16504216|NCT03262077|Experimental|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
16504217|NCT03262077|Experimental|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
16504218|NCT03262077|Experimental|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
16504219|NCT03262077|Experimental|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
16504220|NCT03262077|Experimental|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
16504221|NCT03262051||Patient with acute inflammation (surgery)|patients undergoing hip surgery
16504222|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
16504223|NCT03262051||Patient with acute inflammation (SARS-CoV-2 infection)|patients with SARS-CoV-2 infection
16504224|NCT03262038|Experimental|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
16504225|NCT03262038|Placebo Comparator|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
16504226|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
16504227|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
16504228|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
16504229|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
16504230|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
16504231|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
16504232|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
16504233|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
16504234|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.
~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
16504235|NCT03261986|Other|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
16504236|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
16504237|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
16504238|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
16504239|NCT03261947|Experimental|Western Safety Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.
16504240|NCT03261947|Experimental|Pancreatic Cancer Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
16504241|NCT03261947|Experimental|Metastatic CRC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
16504242|NCT03261947|Experimental|sqEC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
16504243|NCT03261947|Experimental|sqNSCLC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.
16504244|NCT03261921|Active Comparator|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
16504245|NCT03261921|Active Comparator|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
16504246|NCT03261921|Active Comparator|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
16504247|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
16504248|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
16504249|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
16504250|NCT03261895|No Intervention|control group|usual diabetes care
16504251|NCT03261882||Foreign-born Mexican-Americans|
16504252|NCT03261882||US-born Mexican-Americans|
16504253|NCT03261882||non-Hispanic Whites|
16504254|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
16504255|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
16504256|NCT03261856||small intetsinal bacterial overgrowth|Glucose breath test, 75 g glucose in 250 ml water. Breath samples collected at baseline and every 15 min for 2 hours
16504537|NCT03259789|Experimental|Bexagliflozin Tablets, 20 mg; High Glycemic Group|
16504257|NCT03261856||Fructose breath Test|Fructose breath test, 25 g fructose in 250 ml water. Breath samples collected at baseline and every 30 min for 3 hours
16504258|NCT03261856||Lactose Breath test|Lactose breath test, 25 g lactose in 250 ml water. Breath samples collected at baseline and every 30 min for 5 hours
16504259|NCT03261843|Active Comparator|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
16504260|NCT03261843|Active Comparator|posterior lumbar interbody fusion|bone graft alone
16504261|NCT03261830|Active Comparator|Pre-operative Antibiotics|Patients randomized to preoperative antibiotics will receive 25mg/kg cefazolin IV up to 1g or clindamycin 10mg/kg up to 600mg IV in cases of documented allergy to cefazolin.
16504262|NCT03261830|Placebo Comparator|Saline Placebo|Patients randomized to the no-antibiotic group will receive a saline placebo. This placebo will consist of a 10 mL pre-filled syringe of normal saline.
16504263|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
16504264|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
16504265|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
16504266|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
16504267|NCT03261804||Group I:internal vaginal douching users|
16504268|NCT03261804||Group II: none internal vaginal douching users|
16504269|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
16504270|NCT03261778|Experimental|Acromion 2.0 Brace|
16504271|NCT03261778|Active Comparator|Mitella Sling|
16504272|NCT03261765||Multiple repeat cesarean (four or more)|
16504273|NCT03261765||Fewer repeat cesarean (two-three)|
16504274|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
16504275|NCT03261752||healthy people|blood sample will be collected for comparison
16504276|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
16504277|NCT03261739|Placebo Comparator|Placebo|vehicle control
16504278|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
16504279|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
16504280|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
16504281|NCT03261700|Experimental|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
16504282|NCT03261700|Active Comparator|Information and referral condition|This brochure-based intervention includes education about IPV, health effects of IPV, resources and referral options to address a wide-array of health and social issues associated with IPV, and safety planning. Participants randomized to this arm are offered resources and referrals to VA and community resources.
16504283|NCT03261687|Experimental|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
16504284|NCT03261687|Experimental|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
16504285|NCT03261674|Experimental|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBT-I)
16504286|NCT03261674|Experimental|ABTI|Arousal-Based Therapy for Insomnia (ABT-I)
16504287|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
16504288|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
16504289|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
16504290|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
16504291|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
16504292|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
16504293|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
16504294|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
16504295|NCT03261622|Active Comparator|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
16504334|NCT03261336|Experimental|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
16504296|NCT03261622|Sham Comparator|Intervention arm|"Alternation of stimulation amplitude
~Period - Stimulation amplitude 0.05 Volts (lowest possible)
~Period - Stimulation amplitude - 50% of sensory threshold.
~Period - Stimulation amplitude - 90% of sensory threshold."
16504297|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.
~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).
~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
16504298|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.
~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
16504299|NCT03261596|Experimental|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
16504300|NCT03261596|Experimental|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
16504301|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
16504302|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
16504303|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
16504304|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
16504305|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
16504306|NCT03261544||Proximal Femur Replacement|The proximal femur is a common site for primary bone sarcomas and metastatic disease. The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
16504307|NCT03261531|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
16504308|NCT03261505|Experimental|VGAIT|
16504309|NCT03261505|Sham Comparator|VGAIT Control|
16504310|NCT03261505|Active Comparator|Real Acupuncture|
16504311|NCT03261505|Placebo Comparator|Sham Acupuncture|
16504312|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
16504313|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
16504314|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
16504315|NCT03261466|Active Comparator|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
16504316|NCT03261466|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
16504317|NCT03261453|Experimental|Treatment|Patients randomized to treatment will receive the Elipse device.
16504318|NCT03261453|Sham Comparator|Control|Patients randomized to the control arm will receive the sham device.
16504319|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
16504320|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
16504321|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
16504322|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
16504323|NCT03261401|Experimental|Part A: M5717|
16504324|NCT03261401|Placebo Comparator|Part A: Placebo|
16504325|NCT03261401|Experimental|Part B: M5717|
16504326|NCT03261401|Placebo Comparator|Part B: Placebo|
16504327|NCT03261401|Experimental|Part C: M5717|
16504328|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
16504329|NCT03261375|Experimental|Renal denervation (RDN) Group|
16504330|NCT03261375|Sham Comparator|Control Group|
16504331|NCT03261362|Placebo Comparator|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
16504332|NCT03261362|Active Comparator|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
16504333|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
16504335|NCT03261323|Active Comparator|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
16504336|NCT03261323|Experimental|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
16504337|NCT03261310|Experimental|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
16504338|NCT03261310|Placebo Comparator|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
16504339|NCT03261310|Experimental|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
16504340|NCT03261310|Placebo Comparator|Placebo & Laminectomy|Placebo administered during laminectomy.
16504341|NCT03261284|Experimental|DOAC group|Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).
16504342|NCT03261284|Experimental|Higher-INR group|Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.
16504343|NCT03261284|No Intervention|Control group|Patients continue previous strategy without change.
16504344|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
16504345|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
16504346|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
16504347|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
16504348|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
16504349|NCT03261245||Controls|No hypertension disorder during pregnancy
16504350|NCT03261219|Experimental|Intrapulmonary Percussive ventilation|
16504351|NCT03261219|Active Comparator|Chest Physiotherapy vest|
16504352|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
16504353|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
16504354|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
16504355|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
16504356|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
16504357|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
16504358|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
16504359|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
16504360|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
16504361|NCT03261141||study group sixty three children|"severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.
~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).
~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
16504362|NCT03261141||control group sixty three children|"severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.
~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).
~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
16504363|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
16504364|NCT03261115|No Intervention|Control group|Topical Anesthesia
16504365|NCT03261115|Experimental|Study group|No topical anesthesia
16504366|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:
~Week 0: 160 mg SC
~Week 2: 80 mg SC
~Followed by 40 mg SC every 2 weeks' maintenance therapy"
16504367|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:
~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week
~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
16504501|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
16504538|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
16504368|NCT03261076|Experimental|SERIOUS Intervention|All youth will be juveniles in a residential facility for post-adjudicated youth. They will be recruited into the study as they are being placed in the facility post-adjudication, to ensure that they meet criteria and will be in the facility long enough to complete the program. All qualified youth will be invited to participate in the SERIOUS intervention; once a group of youth are recruited to complete the multiple baseline design and interventionists are free (from running interventions with other participants) to work with the youth, an intervention cycle will begin.
16504369|NCT03261063|Experimental|Evera Implanted Group|
16504370|NCT03261050||R61 (Phase 1)|In R61, participants are randomly assigned to either the treatment group or the wait-list condition. Participants assigned to the treatment group receive Counter Attitudinal Therapy (CAT). Participants in the treatment group are compared with participants in the wait-list condition. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. Additionally, at pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Electrocardiography (ECG) data will be collected at pre and post.
16504371|NCT03261050||R33 (Phase 2)|In R33, participants from wait-list condition are assigned to receive either Counter Attitudinal Therapy or Interpersonal Therapy. Participants will complete target and outcome measures at pretest and posttest, including a 6-month follow-up, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. At pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Additionally, thin-ideal valuation will be accessed outside the scanner at pre, post and follow-up. Similarly, binge food valuation will be accessed outside the scanner at pre, post, and follow-up and weeks 2, 4, and 6 during treatment for dose-response analysis. Electrocardiography (ECG) data will be collected at pre and post.
16504372|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
16504373|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.
~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.
~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.
~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.
~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
16504374|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.
~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.
~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.
~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
16504375|NCT03261011|Experimental|AK-104|Single-arm
16504376|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
16504377|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
16504378|NCT03260985|Experimental|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
16504379|NCT03260985|No Intervention|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
16504380|NCT03260972|Active Comparator|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
16504381|NCT03260972|Placebo Comparator|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
16504382|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
16504383|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
16504384|NCT03260920|Experimental|Low Dose|
16504385|NCT03260920|Experimental|Medium Dose|
16504386|NCT03260920|Experimental|High Dose|
16504387|NCT03260907|Experimental|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
16504388|NCT03260907|Experimental|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
16504389|NCT03260894|Experimental|Pembrolizumab + Epacadostat|
16504390|NCT03260894|Active Comparator|SoC (Sunitinib or Pazopanib)|Standard of care (SoC) (sunitinib or pazopanib monotherapy).
16504502|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
16504503|NCT03260023|Experimental|TG4001/Avelumab|
16504391|NCT03260881|Active Comparator|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for from a minimum of 4 weeks up to 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
16504392|NCT03260881|Placebo Comparator|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after from a minimum of 4 weeks up to 12 weeks.
16504393|NCT03260868|Experimental|Virtual|Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.
16504394|NCT03260868|Active Comparator|Traditional|Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.
16504395|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
16504396|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
16504397|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
16504398|NCT03260829|Active Comparator|vitamin C injection|orthodontic traction with vitamin C injection
16504399|NCT03260829|Placebo Comparator|orthodontic traction|orthodontic traction without vitamin C injection
16504400|NCT03260816|Experimental|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
16504401|NCT03260816|Active Comparator|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
16504402|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
16504403|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
16504404|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13
16504405|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
16504406|NCT03260777||children with Alopecia Areata|
16504407|NCT03260777||children with tinea capitis|
16504408|NCT03260777||children with trichotillomania|
16504409|NCT03260777||children with tractional alopecia|
16504410|NCT03260764|Experimental|group A|
16504411|NCT03260764|Placebo Comparator|group B|
16504412|NCT03260764|Experimental|group C|
16504413|NCT03260764|Placebo Comparator|group D|
16504414|NCT03260751|Experimental|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
16504415|NCT03260751|Placebo Comparator|Placebo|Placebo for 12 weeks
16504416|NCT03260738|Experimental|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 3 weeks included in a 3hours daily (5 days a week) rehabilitation program.
16504417|NCT03260738|Active Comparator|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 3 weeks
16504418|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
16504419|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
16504420|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
16504421|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
16504422|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
16504423|NCT03260686|Experimental|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
16504424|NCT03260686|No Intervention|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
16504425|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
16504426|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
16504427|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.
~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
16504428|NCT03260621|Other|echocardiographic increase in left atrial pressure|
16504429|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
16504430|NCT03260608|Experimental|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
16504431|NCT03260608|No Intervention|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
16504432|NCT03260595|Experimental|Crisaborole ointment 2%|
16504433|NCT03260595|Placebo Comparator|Vehicle|
16504434|NCT03260582|No Intervention|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
16504435|NCT03260582|Experimental|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
16504436|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
16504437|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
16504438|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
16504439|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
16504440|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
16504441|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
16504442|NCT03260517|Experimental|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
16504443|NCT03260504|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
16504452|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
16504453|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
16504454|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
16504455|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
16504456|NCT03260452|Experimental|Patients|'Abdominal subcutaneous biopsies and Blood test'
16504457|NCT03260439|Other|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
16504458|NCT03260439|Other|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
16504459|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
16504460|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
16504461|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
16504462|NCT03260400|Experimental|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
16504504|NCT03260023|Experimental|Avelumab|Applicable for Phase II part 2.
16504505|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
16504463|NCT03260400|Experimental|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
16504464|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
16504465|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-
~Electric compound action potential
~Electric stapedial reflex threshold
~Electric auditory brain stem response"
16504466|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
16504467|NCT03260361|Other|usual practice|physiopathology and treatments
16504468|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
16504469|NCT03260322|Experimental|ASP8374|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 (monotherapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 8 dose strengths).
16504470|NCT03260322|Experimental|ASP8374 and pembrolizumab|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 and pembrolizumab (combination therapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 5 dose strengths of ASP8374 and one fixed dose strength of pembrolizumab).
16504471|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
16504472|NCT03260309|Experimental|control group|Routine infusion therapy tactic
16504473|NCT03260296||University students|university students who use smartphones
16504474|NCT03260283|Experimental|Group I|0.4 mgkg-1 of pethidine hydrochloride
16504475|NCT03260283|Experimental|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
16504476|NCT03260257|Experimental|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
16504477|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
16504478|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
16504479|NCT03260205|Placebo Comparator|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
16504480|NCT03260205|Experimental|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
16504481|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
16504482|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
16504483|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
16504484|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
16504485|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
16504486|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
16504487|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
16504488|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
16504489|NCT03260127|Experimental|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
16504490|NCT03260127|Active Comparator|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
16504491|NCT03260114|No Intervention|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
16504492|NCT03260114|Active Comparator|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
16504493|NCT03260114|Active Comparator|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
16504494|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
16504495|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
16504496|NCT03260075||ward cat|Patients and staff at wards that have a cat present
16504497|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
16504498|NCT03260062|Experimental|PEARLS|Participants in this arm will receive 10 1-hour weekly sessions of the PEARLS intervention
16504499|NCT03260062|Active Comparator|Control|Participants in this arm will receive 10 1-hour weekly sessions of the standard of care LSL Speech Therapy
16504500|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
16504508|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
16504509|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
16504510|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
16504511|NCT03259971|Placebo Comparator|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
16504512|NCT03259971|Active Comparator|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
16504513|NCT03259971|Placebo Comparator|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
16504514|NCT03259971|Active Comparator|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
16504515|NCT03259958|Experimental|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
16504516|NCT03259958|Active Comparator|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
16504517|NCT03259932|Other|usual management|
16504518|NCT03259932|Experimental|physical training|
16504519|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
16504520|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
16504521|NCT03259906|Active Comparator|Osteosynthesis using a posterior plate|
16504522|NCT03259906|Active Comparator|Osteosynthesis using an anterior plate|
16504523|NCT03259893|Active Comparator|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
16504524|NCT03259893|Experimental|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
16504525|NCT03259867|Experimental|Hepatocellular carcinoma|"PD-1 inhibitor (either Opdivo 240 mg Q2W IV or Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
16504526|NCT03259867|Experimental|Colorectal cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
16504527|NCT03259867|Experimental|Gastric cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
16504528|NCT03259867|Experimental|NSCLC|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
16504529|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
16504530|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
16504531|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
16504532|NCT03259828|Experimental|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
16504533|NCT03259815|Experimental|PIOS Intervention Group|"Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is <0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).
~The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result."
16504534|NCT03259815|Active Comparator|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
16504541|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
16504546|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
16504547|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
16504548|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
16504549|NCT03259672|Active Comparator|Sevoflurane|
16504550|NCT03259672|Experimental|Desflurane|
16504551|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
16504552|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
16504553|NCT03259646|Experimental|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
16504554|NCT03259646|No Intervention|Standard Practice|Standard clinical practice
16504555|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
16504556|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
16504557|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
16504558|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
16504559|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
16504560|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
16504561|NCT03259594|Experimental|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
16504562|NCT03259594|Sham Comparator|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
16504563|NCT03259581|Experimental|Transarterial chemoembolization|Transarterial chemoembolization
16504564|NCT03259568|Active Comparator|Active rTMS|
16504565|NCT03259568|Sham Comparator|Sham rTMS|
16504566|NCT03259555|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
16504567|NCT03259555|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
16504568|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
16504569|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.
~Duration of cycle 28 days"
16504570|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.
~Duration of cycle 28 days"
16504571|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.
~Duration of cycle 28 days"
16504572|NCT03259516|Experimental|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
16504573|NCT03259516|Experimental|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
16504574|NCT03259516|Experimental|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
16504575|NCT03259516|Experimental|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
16504576|NCT03259516|Experimental|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
16504650|NCT03258905|Active Comparator|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
16504577|NCT03259503|Experimental|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
16504578|NCT03259490|Experimental|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
16504579|NCT03259490|Experimental|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
16504580|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
16504581|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
16504582|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
16504583|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
16504584|NCT03259438|Experimental|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
16504585|NCT03259438|Active Comparator|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
16504587|NCT03259412|Experimental|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
16504588|NCT03259412|Placebo Comparator|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
16504589|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
16504590|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
16504591|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
16504592|NCT03259373|Experimental|Early Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
16504593|NCT03259373|Experimental|Delayed Intervention|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
16504594|NCT03259360|Experimental|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
16504595|NCT03259360|Experimental|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
16504596|NCT03259347|Experimental|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
16504597|NCT03259347|Active Comparator|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
16504598|NCT03259334|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligrams (mg) of ontamalimab (SHP647) subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
16504599|NCT03259334|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
16504600|NCT03259334|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
16504601|NCT03259308|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
16504602|NCT03259308|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.
16504603|NCT03259308|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.
16504604|NCT03259295|Experimental|Skin tag removal initial|Removal of skin tags 1 cm or less using Digiclamp
16504605|NCT03259295|Experimental|Skin tag removal follow-up|Follow-up 2-3 months after skin tag removal.
16504606|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
16504607|NCT03259269||Delamanid and companion WHO Group 5 drugs|
16504608|NCT03259256|Experimental|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
16504609|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
16504950|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
16504610|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
16504611|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
16504612|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
16504613|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
16504614|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
16504615|NCT03259217|Experimental|stem cell product|stem cell transplant
16504616|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
16504617|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
16504618|NCT03259191|Other|completely circumferential ARMS|
16504619|NCT03259191|Other|semi-circumferential ARMS|
16504620|NCT03259165|Experimental|Nitrate Intense Strategy|Patients randomized to the Nitrate intense strategy will be treated according to protocol with nitrates in combination with IV loop diuretics. This protocol only involves therapies used in everyday AHF clinical practice.
16504621|NCT03259165|Experimental|Diuretic Intense Strategy|Patients randomized to the Diuretic intense strategy will be treated according to protocol with IV loop diuretics in combination with nitrates. This protocol only involves therapies used in everyday AHF clinical practice.
16504622|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
16504623|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
16504624|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
16504625|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
16504626|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
16504627|NCT03259126|Experimental|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
16504628|NCT03259126|No Intervention|Control|Control Group without the SCUT
16504629|NCT03259113|Other|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
16504630|NCT03259087|Experimental|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
16504631|NCT03259087|Experimental|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
16504632|NCT03259087|Experimental|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
16504633|NCT03259087|Experimental|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
16504634|NCT03259087|Experimental|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
16504635|NCT03259074|Experimental|Secukinumab 150 mg s.c.|Secukinumab 150 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
16504636|NCT03259074|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
16504637|NCT03259074|Experimental|GP2017 (adalimumab biosimilar) 40mg s.c.|GP2017 (adalimumab biosimilar) 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 102
16504638|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
16504639|NCT03259035|Experimental|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
16504640|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
16504641|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
16504642|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
16504643|NCT03258983||The Diet, Cancer and Health cohort|
16504644|NCT03258957|Experimental|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
16504645|NCT03258944|Experimental|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
16504646|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
16504647|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
16504648|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
16504649|NCT03258905|Experimental|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
16504951|NCT03256773||Notmal|No lung Disease
16504651|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
16504652|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
16504653|NCT03258879|Experimental|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
16504654|NCT03258879|Active Comparator|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
16504655|NCT03258866|Experimental|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
16504656|NCT03258866|Experimental|group B|In group B, Rituximab was given with a single dose of 375mg/m2
16504657|NCT03258853|Active Comparator|Usual Care|Usual Care diabetes management: Patients will manage their diabetes using standard of care for diabetes as per their typical regimen including use of an insulin pump or injectable insulin. Usual care arm for 14 days. Patients will wear a continuous glucose monitor (CGM) during this arm
16504658|NCT03258853|Experimental|Insulin only bionic pancreas|Insulin Only Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin using a continuous glucose monitoring (CGM) device, for 14 days.
16504659|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
16504660|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
16504661|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
16504662|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
16504663|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
16504664|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
16504665|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
16504666|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
16504667|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
16504668|NCT03258775|Active Comparator|250ml|
16504669|NCT03258775|Active Comparator|500ml|
16504670|NCT03258762|Experimental|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
16504671|NCT03258762|Experimental|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
16504672|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
16504673|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
16504674|NCT03258736|Other|Caudal block|Caudal block Marcaine
16504675|NCT03258736|Other|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
16504676|NCT03258723|Experimental|Intervention|Highest risk pre-diabetic patients
16504677|NCT03258723|No Intervention|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
16504678|NCT03258710|Experimental|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
16504679|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
16504680|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
16504681|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
16504682|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
16504683|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
16504684|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
16504685|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
16504686|NCT03258658|Experimental|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
16504687|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
16504688|NCT03258632|No Intervention|Usual Care|Under usual care, when a patient screens positive on the AUDIT-C administered at intake, a provider (social worker, nurse) provides Brief Intervention (BI), i.e., tells the patient that problems are associated with alcohol use, and about recommended drinking limits; notes the patient as ready to change drinking or not, and as agreeing to treatment or not. If the patient agrees to treatment, specialty addiction services are notified.
16504689|NCT03258632|Experimental|Intervention|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
16504690|NCT03258606||Individuals with affected capacity to consent|Individuals with who were unable to consent and were allowed by protocol to give surrogate consent.
16504693|NCT03258580|Experimental|Substudy 1: All participants|Measuring facial response to painful stimulation.
16504694|NCT03258580|No Intervention|Substudy 2: Healthy volunteers|Measuring pain assessment accuracy
16504695|NCT03258580|No Intervention|Substudy 3: Control|Subjects will judge stimuli with the same instructions as Sub-Study 2 (which provides a test of replication).
16504696|NCT03258580|Experimental|Substudy 3: Feedback Group|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
16504697|NCT03258567|Experimental|Nivolumab (A)|Nivolumab, 3mg/kg IV every 2 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment (closed effective with activation of Amendment C)
16504698|NCT03258567|Experimental|Nivolumab (B)|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
16504701|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
16504702|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.
~Infants were fed while in their positions via feeding tube."
16504703|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
16504704|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
16504705|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
16504706|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
16504707|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
16504708|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
16504709|NCT03258502|Experimental|RV521|RV521 drug substance in capsule for oral administration
16504710|NCT03258502|Placebo Comparator|Placebo|Micro-crystalline cellulose in capsule for oral administration
16504711|NCT03258489|Active Comparator|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
16504712|NCT03258489|Active Comparator|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
16504713|NCT03258489|Placebo Comparator|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
16504748|NCT03258268|Experimental|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.
~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
16504952|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
16504714|NCT03258476|Experimental|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
16504715|NCT03258476|Active Comparator|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
16504716|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
16504717|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
16504718|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
16504719|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
16504720|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
16504721|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
16504722|NCT03258424|Active Comparator|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
16504723|NCT03258424|Placebo Comparator|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
16504724|NCT03258411|Active Comparator|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
16504725|NCT03258411|Active Comparator|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
16504726|NCT03258411|Active Comparator|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
16504727|NCT03258398|Experimental|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
16504728|NCT03258398|Experimental|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
16504729|NCT03258398|Experimental|Part 2: eFT508 alone|subjects will receive eFT508 alone
16504730|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
16504731|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
16504732|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
16504733|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
16504734|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
16504735|NCT03258346|Experimental|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
16504736|NCT03258346|Placebo Comparator|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
16504737|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
16504738|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
16504739|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
~Procedure: radical prostatectomy surgery."
16504740|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
16504741|NCT03258307|Active Comparator|omentectomy|Preoperative
16504742|NCT03258307|Other|Omentectomy|Postoperative
16504743|NCT03258307|Other|No omentectomy|Preoperative post operative
16504744|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
16504745|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
16504746|NCT03258281|Active Comparator|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
16504747|NCT03258281|Placebo Comparator|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
16504953|NCT03256773||PCD|Primary Ciliary Dyskinesia
16504749|NCT03258268|Active Comparator|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.
~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
16504750|NCT03258255|Active Comparator|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
16504751|NCT03258255|Active Comparator|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
16504752|NCT03258242|Experimental|Experimental: Keluo Xin Capsule|
16504753|NCT03258242|Placebo Comparator|Placebo Comparator: Placebo|
16504754|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
16504755|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
16504756|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
16504757|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
16504758|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
16504759|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
16504760|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
16504761|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
16504762|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
16504763|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
16504764|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
16504765|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
16504766|NCT03258164|Experimental|ASC|
16504767|NCT03258164|Active Comparator|Control|
16504768|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
16504769|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
16504770|NCT03258138|Experimental|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
16504771|NCT03258138|Experimental|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
16504772|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
16504773|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
16504774|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
16504775|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
16504776|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
16504777|NCT03258086|Experimental|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
16504778|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
16504779|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
16504780|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
16504781|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
16504782|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
16504783|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
16504784|NCT03258008|Experimental|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.
~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
16504785|NCT03257995|Experimental|Sequence 1|A-B-C
16504786|NCT03257995|Experimental|Sequence 2|B-C-A
16504787|NCT03257995|Experimental|Sequence 3|C-A-B
16504788|NCT03257995|Experimental|Sequence 4|A-C-B
16504789|NCT03257995|Experimental|Sequence 5|B-A-C
16504790|NCT03257995|Experimental|Sequence 6|C-B-A
16504791|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
16504794|NCT03257956|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16504795|NCT03257956|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
16504796|NCT03257943|Experimental|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
16504797|NCT03257943|Active Comparator|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
16504798|NCT03257943|Placebo Comparator|Vehicle of the Test product|One 10 minute application, under at-home use conditions
16504799|NCT03257930|Experimental|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
16504800|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
16504801|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
16504802|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
16504803|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
16504804|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
16504805|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
16504806|NCT03257865|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
16504807|NCT03257865|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind
16504808|NCT03257852|Experimental|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
16504809|NCT03257852|Placebo Comparator|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
16504810|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
16504811|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
16504812|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
16504813|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
16504814|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.
~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
16504815|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.
~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
16504816|NCT03257787|Experimental|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
16504817|NCT03257774|Experimental|Test of three new adhesive strips|"The subjects test three new adhesive strips
~adhesive strip A
~adhesive strip B
~adhesive strip C"
16504818|NCT03257761|Experimental|Treatment (guadecitabine, durvalumab)|Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16504819|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
16504820|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
16504821|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
16504822|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
16504823|NCT03257709|Active Comparator|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
16504824|NCT03257709|Active Comparator|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
16504887|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
16504825|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
16504826|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
16504827|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
16504828|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
16504829|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.
~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
16504830|NCT03257644|Experimental|Cohort 1|Ruxolitinib phosphate cream 0.5%.
16504831|NCT03257644|Experimental|Cohort 2|Ruxolitinib phosphate cream 1.5%.
16504832|NCT03257644|Experimental|Cohort 3|Ruxolitinib phosphate cream 0.75%.
16504833|NCT03257644|Experimental|Cohort 4|Ruxolitinib phosphate cream 1.5%.
16504834|NCT03257644|Experimental|Cohort 5|Ruxolitinib phosphate cream 0.75%.
16504835|NCT03257644|Experimental|Cohort 6|Ruxolitinib phosphate cream 1.5%.
16504836|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
16504837|NCT03257618|Experimental|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.
~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
16504838|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
16504839|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
16504840|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
16504841|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
16504842|NCT03257579|Experimental|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
16504843|NCT03257579|Experimental|Education Alone|At St. Joseph's Hospital and Niagara Health System education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
16504844|NCT03257579|No Intervention|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
16504845|NCT03257553|Experimental|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
16504846|NCT03257540||Small Bone Intramedullary Nail|All study participants
16504847|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
16504848|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
16504849|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
16504850|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
16504851|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
16504852|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
16504853|NCT03257462|Experimental|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
16504854|NCT03257462|Experimental|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
16504888|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
16504954|NCT03256773||COPD|Chronic Obstructive Lung Disease
16504855|NCT03257462|Experimental|Cohort C|Cohort C will begin enrollment after Cohort B has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
16504856|NCT03257436|Other|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
16504857|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
16504858|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
16504859|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
16504860|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
16504861|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
16504862|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
16504863|NCT03257410|Experimental|Theranova 400|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
16504864|NCT03257410|Active Comparator|Elisio-17H|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
16504865|NCT03257397|Experimental|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
16504866|NCT03257397|Active Comparator|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
16504867|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
16504868|NCT03257358|Other|Cohort 1|RMS patients who were newly prescribed commercially available fingolimod 0.5mg per day
16504869|NCT03257358|Other|Cohort 2|RMS patients who had been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
16504870|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
16504871|NCT03257319|Experimental|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
16504872|NCT03257319|Placebo Comparator|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
16504873|NCT03257306|Active Comparator|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
16504874|NCT03257306|Active Comparator|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
16504875|NCT03257293|Active Comparator|Routine Cystoscopy|
16504876|NCT03257293|Experimental|Modified Cystoscopy|
16504877|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
16504878|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
16504879|NCT03257267|Experimental|Experimental Therapy|Cemiplimab
16504880|NCT03257267|Active Comparator|Control Therapy|Investigator choice (IC) chemotherapy
16504881|NCT03257241|Active Comparator|A arm (DA-90)|"Induction I:
~DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion
~Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
16504882|NCT03257241|Active Comparator|B arm (DAC)|"Induction I:
~DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion
~cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C
~Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
16504883|NCT03257241|Active Comparator|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
16504884|NCT03257241|Active Comparator|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
16504885|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
16504886|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
16504889|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
16504890|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
16504891|NCT03257202|No Intervention|Control|No topical treatment
16504892|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
16504893|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
16504894|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
16504895|NCT03257189|Other|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.
~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
16504896|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
16504897|NCT03257163|Experimental|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
16504898|NCT03257150|Experimental|Study Treatment|Single arm trial of irreversible electroporation using the NanoKnife system for locally advanced pancreatic ductal adenocarcinoma.
16504899|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
16504900|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
16504901|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)
~Leptomeningeal metastasis cohort (LM cohort)"
16504902|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
16504903|NCT03257085|Experimental|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
16504904|NCT03257085|Experimental|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
16504905|NCT03257072|Experimental|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
16504906|NCT03257072|Experimental|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
16504907|NCT03257072|Experimental|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
16504908|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
16504909|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
16504910|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
16504911|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
16504912|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
16504913|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
16504914|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
16504915|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
16504916|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
16504917|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
16504918|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
16504919|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
16504920|NCT03257007|No Intervention|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
16504921|NCT03257007|Active Comparator|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
16504922|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.
~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.
~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3."
16504923|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
16504924|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
16504925|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
16504926|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.
~Single injection session, injections into the lips."
16504927|NCT03256942|No Intervention|No Treatment|
16504928|NCT03256929|Experimental|depression participants - intervention|personalized diet intervention based on microbiota analysis and health status
16504929|NCT03256929|Experimental|depression participants - control|General information on nutrition and health
16504930|NCT03256929|Experimental|pre-depression participants - control|General information on nutrition and health for pre-depression participants
16504931|NCT03256929|Experimental|pre-depression participants - intervention|personalized diet intervention based on microbiota analysis and health status for pre-depression participants
16504932|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.
~Then Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
16504933|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).
~In this patient will receive Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
16504934|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
16504935|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
16504936|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
16504937|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
16504938|NCT03256877||All participants|Patients with haematuria.
16504939|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)
~Other Names:
~Prograf
~Advagraf
~Zortress
~Certican"
16504940|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)
~Other Names:
~Prograf
~Advagraf
~Zortress
~Certican"
16504941|NCT03256851|Active Comparator|In-Person Delivered Exercise|"Participants in the in-person training group will:
~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.
~complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
16504942|NCT03256851|Experimental|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:
~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.
~receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
16504943|NCT03256838|Experimental|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
16504944|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
16504945|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
16504946|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
16504947|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
16504948|NCT03256799|Experimental|Ivacaftor/Ataluren|
16504949|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
16504957|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
16504958|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
16504959|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
16504960|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
16504961|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
16504962|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
16504963|NCT03256695|Experimental|ABS eMDPI|Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.
16504964|NCT03256682|Experimental|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
16504965|NCT03256682|Active Comparator|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
16504966|NCT03256682|No Intervention|Selfcare|Use stress management materials to manage yourself.
16504967|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
16504968|NCT03256656|Experimental|Healthy subjects|
16504969|NCT03256656|Active Comparator|Patients with SCI|
16504970|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
16504971|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
16504972|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
16504973|NCT03256617|Experimental|Provider training|
16504974|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
16504975|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
16504976|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
16504977|NCT03256578|Experimental|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
16504978|NCT03256578|No Intervention|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
16504979|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
16504980|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
16504981|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
16504982|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
16504983|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
16504984|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
16504985|NCT03256526|Placebo Comparator|Placebo|
16504986|NCT03256526|Experimental|PF-06835919 Low Dose|75 mg once daily
16504987|NCT03256526|Experimental|PF-06835919 High Dose|300 mg once daily
16504988|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
16504989|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
16504990|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
16504991|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
16504992|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
16504993|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
16504994|NCT03256461|Experimental|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
16504995|NCT03256461|Experimental|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
16504996|NCT03256461|Placebo Comparator|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
16504997|NCT03256435|Experimental|Treatment Arm|RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
16504998|NCT03256435|No Intervention|Control Arm|Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
16504999|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
16505000|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
16505001|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
16505002|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
16505003|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
16505004|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
16505005|NCT03256383||Adult|Patients aged 18+ years
16505006|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
16505007|NCT03256383||Children <7|Patients aged under 7 years
16505008|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
16505009|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
16505010|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
16505011|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
16505012|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
16505013|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Triple Negative Breast Cancer (TNBC)|Participants with TNBC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 plaque-forming units/milliliter (PFU/mL) on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
16505014|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Colorectal Cancer (CRC)|Participants with CRC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 PFU/mL on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
16505015|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
16505016|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
16505017|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
16505018|NCT03256305|Experimental|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
16505019|NCT03256305|Active Comparator|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
16505020|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
16505021|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
16505022|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
16505023|NCT03256266||healthy controls|healthy controls
16505024|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
16505025|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
16505026|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
16505027|NCT03256240|Active Comparator|side-to-side functional end anastomosis|side-to-side functional end anastomosis creation
16505028|NCT03256240|Active Comparator|Kono-S|antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis
16505029|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
16505030|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
16505031|NCT03256214|Experimental|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
16505032|NCT03256214|Active Comparator|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
16505033|NCT03256201|Experimental|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
16505034|NCT03256201|Experimental|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
16505035|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
16505036|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
16505037|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
16505038|NCT03256162|Experimental|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
16505039|NCT03256162|Active Comparator|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
16505040|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
16505041|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
16505042|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
16505043|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
16505044|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
16505045|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
16505046|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
16505047|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
16505048|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
16505049|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
16505053|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).
~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
16505054|NCT03256071|Experimental|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
16505055|NCT03256071|Active Comparator|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
16505056|NCT03256058|Active Comparator|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
16505132|NCT03255512|Placebo Comparator|Placebo + isosorbite mononitrate|Administration of (vericiguat) matching placebo and isosorbite mononitrate.
16505057|NCT03256058|Placebo Comparator|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
16505058|NCT03256045|Experimental|Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
16505059|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
16505060|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
16505061|NCT03255993|Experimental|SPH3127 100mg|A single dose of SPH3127 50 mg*2 qd *7 days
16505062|NCT03255993|Placebo Comparator|Placebo to SPH3127 100mg|A single dose of placebo matching to SPH3127 50mg*2 qd *7 days
16505063|NCT03255993|Experimental|SPH3127 200mg|A single dose of SPH3127 100 mg*2 qd *7 days
16505064|NCT03255993|Placebo Comparator|Placebo to SPH3127 200mg|A single dose of placebo matching to SPH3127 100mg*2 qd *7 days
16505065|NCT03255993|Experimental|SPH3127 400mg|A single dose of SPH3127 100 mg*4 qd *7 days
16505066|NCT03255993|Placebo Comparator|Placebo to SPH3127 400mg|A single dose of placebo matching to SPH3127 100mg*4 qd *7 days
16505067|NCT03255980|Experimental|Xonrid®|Xonrid® is a medical device for radiation dermatitis
16505068|NCT03255980|Active Comparator|Standard of Care|Standard of care suggested by MASCC guidelines
16505069|NCT03255967|Experimental|QI program care|DSM-H performance improvement program Patients in the performance improvement group will receive care from a care team who has received the DSM-H performance improvement program
16505070|NCT03255967|Active Comparator|Control|provide usual carereceive usual care from a care team who has not received the performance improvement program
16505071|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
16505072|NCT03255941|Active Comparator|Clinic Provider - Urban|Urban Clinic Provider providing DMPA or Sayana Press
16505073|NCT03255941|Active Comparator|Lay Provider - Urban|Urban Lay Provider providing DMPA or Sayana Press
16505074|NCT03255941|Active Comparator|Clinic Provider- Rural|Rural Clinic Provider providing DMPA or Sayana Press
16505075|NCT03255941|Active Comparator|Lay Provider- Rural|Rural Lay Provider providing DMPA or Sayana Press
16505076|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
16505077|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
16505078|NCT03255915|Experimental|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
16505079|NCT03255915|Experimental|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
16505080|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
16505081|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
16505082|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
16505083|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
16505084|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
16505085|NCT03255863|Other|Questionnaire|Auto and hetero questionnaire
16505086|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
16505087|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
16505088|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
16505089|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
16505090|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
16505091|NCT03255837|Sham Comparator|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
16505092|NCT03255824|Active Comparator|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
16505093|NCT03255824|Experimental|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
16505094|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
16505095|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
16505096|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
16505097|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
16505818|NCT03251300|Active Comparator|group B|nighttime dosing of mirabegron
16505098|NCT03255759|Active Comparator|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
16505099|NCT03255759|No Intervention|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
16505100|NCT03255746|Experimental|Sleep Enhancement|
16505101|NCT03255746|Placebo Comparator|Health Education|
16505102|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
16505103|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.
~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
16505104|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
16505105|NCT03255707|Experimental|Group A|50 patients will receive the gold standard occlusion therapy
16505106|NCT03255707|Experimental|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
16505107|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
16505108|NCT03255681|Experimental|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
16505109|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
16505110|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
16505111|NCT03255642|Active Comparator|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
16505112|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
16505113|NCT03255629|Experimental|Treatment Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
16505114|NCT03255629|Placebo Comparator|Control Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
16505115|NCT03255616|Experimental|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
16505116|NCT03255616|Experimental|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
16505117|NCT03255603|Experimental|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
16505118|NCT03255603|Experimental|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
16505119|NCT03255603|Experimental|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
16505120|NCT03255603|Placebo Comparator|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
16505121|NCT03255590|Experimental|Real tDCS & Configuration task|Real-stimulation: Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved. Participants will receive REAL anodal tDCS stimulation during the training.
16505122|NCT03255590|Sham Comparator|Sham tDCS & Configuration task|Sham-stimulation: Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved. Participants will receive sham SHAM tDCS stimulation during the training.
16505123|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
16505124|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
16505125|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
16505126|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
16505127|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
16505128|NCT03255525|Active Comparator|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
16505129|NCT03255525|Experimental|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
16505130|NCT03255525|Experimental|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
16505131|NCT03255512|Experimental|Vericiguat + isosorbite mononitrate|Co-administration of vericiguat and isosorbite mononitrate.
16505133|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
16505134|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
16505135|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
16505136|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
16505137|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.
~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
16505138|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
16505139|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
16505140|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
16505141|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
16505142|NCT03255447|Experimental|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
16505143|NCT03255434|Active Comparator|Folfox 4|Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²
16505144|NCT03255434|Experimental|Folfox 4 LBM|Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)
16505145|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.
~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
16505146|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
16505147|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
16505148|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
16505149|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
16505150|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
16505151|NCT03255382|Experimental|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
16505152|NCT03255382|Active Comparator|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
16505153|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
16505154|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
16505155|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
16505156|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
16505157|NCT03255343|Experimental|IMDENDRIM|
16505158|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
16505159|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
16505160|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
16505161|NCT03255304|Experimental|health prime|
16505162|NCT03255304|Experimental|palatability prime|
16505163|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
16505184|NCT03255174|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
16505185|NCT03255161|Experimental|Immediate communication education and support group|
16505164|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
16505165|NCT03255291|Experimental|Risk Display Format:Table:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
16505166|NCT03255291|Experimental|Risk Display Format:Table: Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
16505167|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
16505168|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
16505169|NCT03255278|Experimental|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
16505170|NCT03255278|Placebo Comparator|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
16505171|NCT03255278|Experimental|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
16505172|NCT03255278|Experimental|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
16505173|NCT03255278|Experimental|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
16505174|NCT03255265||Acute rejection|
16505175|NCT03255265||No acute rejection|
16505176|NCT03255252|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
16505177|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
16505178|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
16505179|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
16505180|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
16505181|NCT03255213|Experimental|Late Onset Pompe Disease who have tongue weakness|
16505182|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
16505183|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
16505186|NCT03255161|No Intervention|Waitlist|
16505187|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
16505188|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
16505189|NCT03255135|Experimental|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
16505190|NCT03255122|Experimental|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
16505191|NCT03255122|Other|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
16505192|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
16505193|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
16505194|NCT03255083|Experimental|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 80 mg oral dose of osimertinib
16505195|NCT03255070|Experimental|ARX788 Phase 1a (Dose Escalation)|ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
16505196|NCT03255070|Experimental|ARX788 Phase 1b (Dose Expansion)|ARX788 will be administered every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
16505197|NCT03255057|Experimental|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
16505198|NCT03255057|Active Comparator|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
16505199|NCT03255044|Active Comparator|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
16505200|NCT03255044|Active Comparator|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
16505201|NCT03255031|Active Comparator|Diet Randomization-KD|Diet consists of a ketogenic diet (KD) snacks and shakes 3x p/day (high in fat). SA will receive the same KD solid snacks, in order to keep the diets blind to participants. KD will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
16505202|NCT03255031|Placebo Comparator|Diet Randomization-SA|Standard American (SA) diet consists of shakes 3x p/day in the proportions of carbohydrates, protein and fat of traditional western diet. SA will receive the same KD solid snacks, in order to keep the diets blind to participants. SA will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
16505203|NCT03255018|Experimental|1|Subjects with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
16505204|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
16505205|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
16505206|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
16505207|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
16505208|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
16505209|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
16505210|NCT03254979|Experimental|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
16505211|NCT03254979|Active Comparator|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
16505212|NCT03254966|Experimental|SHR0302 dose level 1|
16505213|NCT03254966|Experimental|SHR0302 dose level 2|
16505214|NCT03254966|Experimental|SHR0302 dose level 3|
16505215|NCT03254966|Experimental|SHR0302 dose level 4|
16505216|NCT03254966|Placebo Comparator|Placebo|
16505217|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet
~participants are asked to use the MyFitnessPal app for self-monitoring
~given goal to lose 5% weight by end of intervention (3 months)
~weekly personalized feedback via email
~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email
~weekly action plans via email"
16505218|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months
~participants are asked to use the MyFitnessPal app for self-monitoring
~given goal to lose 5% weight by end of intervention (3 months)
~weekly personalized feedback via email
~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email
~weekly action plans via email"
16505433|NCT03253796|Experimental|Open-label (OL) GLM SC QM ---> PBO SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with placebo (PBO) SC QM
16505219|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months
~participants are asked to use the MyFitnessPal app for self-monitoring
~given goal to lose 5% weight by end of intervention (3 months)"
16505220|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
16505221|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
16505222|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
16505223|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
16505224|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
16505225|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
16505226|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
16505227|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
16505228|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
16505229|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
16505230|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
16505231|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
16505232|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
16505233|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
16505234|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
16505235|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
16505236|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
16505237|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
16505238|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
16505239|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
16505240|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
16505241|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
16505242|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
16505243|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
16505244|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
16505245|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
16505246|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
16505247|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
16505248|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
16505249|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
16505250|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
16505251|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
16505252|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
16505253|NCT03254914||Control Site|Measure Clinic Blood Pressure
16505254|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
16505255|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
16505256|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
16505257|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
16505258|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
16505259|NCT03254888||Control group|"• 50 (age and sex matched )control
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
16505260|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
16505261|NCT03254875|No Intervention|Control|Usual care
16505262|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:
~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
16505263|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:
~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
16505264|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
16505265|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
16505266|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.
~Patients will recieve treatment as per standard of care."
16505267|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
16505268|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
16505269|NCT03254810|Experimental|SYN060|a single 0.57 mg/kg dose of SYN060
16505270|NCT03254810|Active Comparator|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
16505271|NCT03254810|Active Comparator|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
16505272|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.
~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
16505273|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.
~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
16505274|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
16505275|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
16505276|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
16505277|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
16505278|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
16505279|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
16505280|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
16505281|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
16505282|NCT03254758|Experimental|Mesenchymal stem cell|"Phase 1 Dose escalation : low Mid High Single administalation of ADR-001
~Phase 2 The recommended dose of ADR-001"
16505283|NCT03254745|Experimental|Pharmacist intervention|"Disease education (General education about rheumatoid arthritis in a verbal and written manner)
~Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)
~Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)
~Advice on medication use (General counseling on medication use as well as patient centered counseling)."
16505284|NCT03254745|No Intervention|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
16505285|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
16505286|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
16505287|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
16505288|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
16505289|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
16505290|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
16505291|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
16505292|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
16505293|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
16505294|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
16505295|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
16505296|NCT03254667||Brodalumad exposed|1500 subjects exposes to brodalumab
16505297|NCT03254667||Comparator Subjects|2000 comparator subjects
16505298|NCT03254654|Experimental|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20
~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
16505299|NCT03254654|Active Comparator|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
16505300|NCT03254641||hypogondal men|men referred for hCG stimulation test
16505301|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
16505302|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
16505303|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
16505304|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
16505305|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
16505306|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
16505307|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
16505308|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
16505309|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
16505310|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
16505311|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
16505312|NCT03254576||Children at high-risk for obesity|Healthy-weight children (30th-75thBMI%) with two overweight/obese parents (BMI>25)
16505313|NCT03254576||Children at low-risk for obesity|Healthy-weight children (30th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
16505314|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
16505315|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
16505316|NCT03254550|No Intervention|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
16505317|NCT03254550|Experimental|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
16505318|NCT03254537|Experimental|Mediterranean Organic|
16505319|NCT03254537|Experimental|Mediterranean conventional|
16505320|NCT03254524||Patients visiting an emergency department in New York State|
16505434|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with double-blinded (DB) GLM SC QM
16505321|NCT03254511|Experimental|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
16505322|NCT03254511|Active Comparator|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) alone.
16505323|NCT03254498|Active Comparator|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
16505324|NCT03254498|Placebo Comparator|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
16505325|NCT03254485|Experimental|IW-1973 High Dose|
16505326|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
16505327|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
16505328|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
16505329|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
16505330|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
16505331|NCT03254433|Experimental|BAS+|As part of the main study, participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
16505332|NCT03254433|Placebo Comparator|SC|As part of the main study, participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
16505333|NCT03254420|Active Comparator|Image-guided radiation therapy (IGRT) with standard margins|moderate hypofractionation during 4 weeks
16505334|NCT03254420|Experimental|Calypso tracking system with margin reduction|moderate hypofractionation during 4 weeks after calypso beacon implant 10 days before
16505335|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
16505336|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.
~FOLFOX:
~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
16505337|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.
~FOLFOX:
~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
16505338|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
16505339|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
16505340|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
16505341|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
16505342|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
16505343|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
16505344|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
16505345|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
16505346|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
16505347|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
16505348|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
16505349|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
16505350|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
16505351|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
16505352|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
16505353|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
16505354|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
16505355|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
16505626|NCT03252483|Active Comparator|HIV Only|Those randomized to the control group were offered only an HIV test.
16505356|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
16505357|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
16505358|NCT03254277|Experimental|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
16505359|NCT03254277|Experimental|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
16505360|NCT03254277|Experimental|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
16505361|NCT03254277|Experimental|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
16505362|NCT03254277|Experimental|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
16505363|NCT03254277|Experimental|Group 1D|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
16505364|NCT03254277|Experimental|Group 2D|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
16505365|NCT03254277|Experimental|Group 1E|HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
16505366|NCT03254277|Experimental|Group 1F|HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
16505367|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
16505368|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
16505369|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
16505370|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
16505371|NCT03254225|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
16505372|NCT03254225|No Intervention|Control|in this arm, the group will remain sedentary for the same period of the experimental group, and they will be invited to engage on the raining program after the sedentary period
16505373|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
16505374|NCT03254199|Experimental|Experimental|
16505375|NCT03254199|Placebo Comparator|Placebo Comparator|
16505376|NCT03254186|Experimental|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
16505377|NCT03254186|Placebo Comparator|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
16505378|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
16505379|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
16505380|NCT03254160|Experimental|DNS-3379 (0.5mg)|
16505381|NCT03254160|Experimental|DNS-3379 (2.5mg)|
16505382|NCT03254160|Placebo Comparator|Placebo|
16505383|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
16505384|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
16505385|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
16505386|NCT03254108|Experimental|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
16505387|NCT03254108|Experimental|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
16505388|NCT03254108|Experimental|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
16505389|NCT03254108|Experimental|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
16505390|NCT03254108|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
16505391|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
16505392|NCT03254082|Experimental|Sumac|Sumac sorghum flour
16505393|NCT03254082|Experimental|Wheat|Wheat flour
16505394|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
16505395|NCT03254082|Active Comparator|Sucrose|Table sugar
16505396|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
16505627|NCT03252483|Experimental|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
16505397|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
16505398|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
16505399|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
16505400|NCT03254043|Active Comparator|Treatment-as-Usual|Participants will routine methadone clinic care.
16505401|NCT03254043|Experimental|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
16505402|NCT03254043|Other|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
16505403|NCT03254030|Placebo Comparator|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
16505404|NCT03254030|Active Comparator|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
16505405|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
16505406|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
16505407|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
16505408|NCT03253978|Experimental|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
16505409|NCT03253978|Active Comparator|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
16505410|NCT03253965|Experimental|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
16505411|NCT03253965|Experimental|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
16505412|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
16505413|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
16505414|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
16505415|NCT03253939||Control group|Cytoreductive surgery alone
16505416|NCT03253926|Experimental|Lorcaserin + Marijuana|
16505417|NCT03253926|Placebo Comparator|Placebo + Marijuana|
16505418|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.
~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
16505419|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
16505420|NCT03253887|Experimental|Ethanol-lock therapy (ELT) Group|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
16505421|NCT03253887|No Intervention|Control Group|This group did not receive the ethanol-lock, being only followed daily and treated according to the standard protocol in operation at this healthcare unit.
16505422|NCT03253874|Experimental|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
16505423|NCT03253874|No Intervention|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
16505424|NCT03253861||control patients|patients without an infected pancreatic necrosis
16505425|NCT03253861||Case patients|patients with an infected pancreatic necrosis
16505426|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
16505427|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
16505428|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
16505429|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.
~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
16505430|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
16505431|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
16505432|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.
~ECG signals will be saved digitally for analysis"
16505435|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC Q2M|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with DB GLM SC Q2M
16505436|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
16505437|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
16505438|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.
~Intervention : paper cognitive aid in the hand of the leader during crises management."
16505439|NCT03253744|Experimental|1/Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy
16505440|NCT03253744|Experimental|2/Prostate and Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
16505441|NCT03253731||Healthy Volunteers|15 healthy volunteers
16505442|NCT03253718||Healthy Volunteers|Healthy Volunteers between 18 and 68 years of age
16505443|NCT03253705||Controls|Healthy Controls
16505444|NCT03253705||Research Subjects|Research Subjects already enrolled on other NIH protocols
16505445|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
16505446|NCT03253679|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16505447|NCT03253666||Nurses' Health Study|"See Detailed Description"
16505448|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
16505449|NCT03253653|Experimental|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
16505450|NCT03253653|No Intervention|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
16505451|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
16505452|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
16505453|NCT03253627|Experimental|MBSR|Mindfulness-Based Stress Reduction
16505454|NCT03253627|Active Comparator|HEP|Health Enhancement Program
16505455|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
16505456|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
16505457|NCT03253601|Experimental|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
16505458|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
16505459|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced
~2nd line metastatic/locally advanced"
16505460|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
16505461|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
16505462|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
16505463|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
16505464|NCT03253562|No Intervention|Healthy control|healthy volunteers not suffering from diabetes or hypertension
16505465|NCT03253562|No Intervention|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
16505466|NCT03253562|Other|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
16505467|NCT03253562|Other|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
16505468|NCT03253549|Experimental|SMArTVIEW|
16505469|NCT03253549|No Intervention|Standard Care|
16505470|NCT03253536||entire cohort|none (observational study)
16505471|NCT03253523|No Intervention|Continued maximal medical management|
16505472|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
16505473|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
16505474|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
16505475|NCT03253497|Active Comparator|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
16505476|NCT03253497|No Intervention|Control|before 15 minute normal salin will be administrated to oropharynx
16505477|NCT03253484|Experimental|NAFL-treated wounds|NAFL treated wounds
16505478|NCT03253484|No Intervention|Control|untreated control wound
16505479|NCT03253471|Experimental|AL-611|
16505480|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
16505481|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
16505628|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
16505482|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
16505483|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
16505484|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
16505485|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
16505486|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
16505487|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
16505488|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
16505489|NCT03253419|Other|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
16505490|NCT03253406|Experimental|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
16505491|NCT03253406|Active Comparator|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
16505492|NCT03253393|Experimental|Smart Touch Technology Contact Lens|
16505493|NCT03253393|Active Comparator|Contact Lens in Conventional Packaging|
16505494|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
16505495|NCT03253367||Current/former clozapine users|This group has only one visit.
16505496|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
16505497|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
16505498|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
16505499|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
16505500|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
16505501|NCT03253341|Experimental|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
16505502|NCT03253341|Active Comparator|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
16505503|NCT03253328|Active Comparator|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
16505504|NCT03253328|Placebo Comparator|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
16505505|NCT03253289|Experimental|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
16505506|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
16505507|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
16505508|NCT03253263|Experimental|SHP607 250 mcg/kg/24 hours|Participants will receive continuous intravenous (IV) infusion of SHP607 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) from birth up to postmenstrual age (PMA) 29 weeks +6 days.
16505509|NCT03253263|Experimental|SHP607 400 mcg/kg/24 hours|Participants will receive continuous IV infusion of SHP607 400 mcg/kg/24 hours through from birth up to PMA 29 weeks +6 days.
16505510|NCT03253263|No Intervention|Standard Neonatal Care|Standard neonatal care alone will be provided.
16505511|NCT03253250|Active Comparator|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
16505512|NCT03253250|Experimental|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\TDF\ADV) for 96 weeks.
16505513|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
16505514|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
16505515|NCT03253211||State|North Carolina
16505516|NCT03253211||SCD Patients|
16505517|NCT03253211||Providers|Primary care and emergency department clinicians
16505518|NCT03253211||Year|Baseline, year 2, year 3
16505519|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
16505520|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
16505521|NCT03253185|Experimental|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
16505522|NCT03253172|Placebo Comparator|Placebo|Placebo
16505523|NCT03253172|Experimental|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
16505524|NCT03253172|Experimental|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
16505629|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
16505525|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
16505526|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
16505527|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.
~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.
~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.
~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
16505528|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
16505529|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:
~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.
~Intravenous chemotherapy protocol:
~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
16505530|NCT03253120|Other|Patient|Patients will drink 5dl of water.
16505531|NCT03253120|Other|Healthy volunteer|Healthy volunteers will drink 5dl of water.
16505532|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
16505533|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
16505534|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
16505535|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
16505536|NCT03253094|Active Comparator|Fluconazole|150 mg/day for 1 day
16505537|NCT03253094|Experimental|Ibrexafungerp 750mg|750mg QD for 1 day only
16505538|NCT03253094|Experimental|Ibrexafungerp 300mg|300mg BID for 1 day only
16505539|NCT03253094|Experimental|Ibrexafungerp 450mg|450mg BID for 1 day only
16505540|NCT03253094|Experimental|Ibrexafungerp 150mg|150mg BID for 3 days
16505541|NCT03253094|Experimental|Ibrexafungerp 300mg D1-D3|300mg BID for 3 days
16505542|NCT03253081|Active Comparator|PARENT focused intervention|The PF condition will consist of a 90-minute parent group session twice per week. The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent.
16505543|NCT03253081|Active Comparator|CHILD focused intervention|In the CF condition both parent and child will attend the 90-minute session twice weekly. The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist.
16505544|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
16505545|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
16505546|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
16505547|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
16505548|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
16505549|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
16505550|NCT03253029|Experimental|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
16505551|NCT03253029|Placebo Comparator|Control|(arm 2): control group (no BCAAs provided)
16505552|NCT03253016|Experimental|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
16505553|NCT03253016|Experimental|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
16505554|NCT03253016|No Intervention|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
16505555|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
16505556|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
16505593|NCT03252756|Experimental|Phytocannabinoid cannabidiol (CBD)|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
16505668|NCT03252223|Active Comparator|Women with normal menses|
16505557|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
16505558|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
16505559|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
16505560|NCT03252964|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
16505561|NCT03252951|Experimental|Eccentric Training|
16505562|NCT03252951|Experimental|Concentric Training|
16505563|NCT03252951|Experimental|Isometric Training|
16505564|NCT03252951|Active Comparator|Biofeedback|
16505565|NCT03252938|Experimental|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
16505566|NCT03252938|Experimental|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
16505567|NCT03252938|Experimental|Solid tumors + chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
16505568|NCT03252938|Experimental|Solid tumors + Avelumab/IMP321 therapy|"Avelumab and IMP321 as follows:
~800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles [48 weeks])
~6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles [24 weeks])"
16505569|NCT03252925|Experimental|Experimental Group|N-Acetylcysteine
16505570|NCT03252925|Placebo Comparator|Control Group|Placebo Oral Tablet
16505571|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
16505572|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
16505573|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
16505574|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
16505575|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
16505576|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
16505580|NCT03252834||Patients with endometrial or ovarian cancer|
16505581|NCT03252834||Patients with colorectal cancer|
16505582|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
16505583|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
16505584|NCT03252821|No Intervention|Control group|Usual care
16505585|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
16505586|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
16505587|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
16505588|NCT03252795|Experimental|Uterus transplantation|
16505589|NCT03252782|Active Comparator|Functional Treatment|Acrylic Splint Herbst Appliance
16505590|NCT03252782|Active Comparator|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
16505591|NCT03252769|Other|Self-sampling|Invitation to self-sample
16505592|NCT03252756|Placebo Comparator|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
16505669|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
16505594|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
16505595|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
16505596|NCT03252717|Experimental|blood sample|Pre-treatment blood samples will be collected: 8 samples
16505597|NCT03252704|Experimental|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
16505598|NCT03252704|Experimental|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
16505599|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
16505600|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
16505601|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
16505602|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
16505603|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
16505604|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
16505605|NCT03252626|Active Comparator|Alprostadil|Based on the standard medical care, 2ml of Alprostadil
16505606|NCT03252626|Placebo Comparator|Normal saline|Based on the standard medical care, 2ml of 0.9% saline as the placebo
16505607|NCT03252600|Experimental|Arm I (lenalidomide, dexamethasone, elotuzumab)|"Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
16505608|NCT03252600|Experimental|Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)|"Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
16505609|NCT03252587|Experimental|BMS-986165 Dose 1 oral administration|
16505610|NCT03252587|Experimental|BMS-986165 Dose 2 oral administration|
16505611|NCT03252587|Experimental|BMS-986165 Dose 3 oral administration|
16505612|NCT03252587|Placebo Comparator|Placebo oral administration|
16505613|NCT03252574|Other|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
16505614|NCT03252574|Other|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
16505615|NCT03252561|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
16505616|NCT03252561|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
16505617|NCT03252535|Experimental|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
16505618|NCT03252535|Experimental|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
16505619|NCT03252535|Placebo Comparator|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
16505620|NCT03252522|Experimental|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
16505621|NCT03252522|Placebo Comparator|Placebo|Capsules of inactive placebo.
16505622|NCT03252522|Experimental|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
16505623|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
16505624|NCT03252496|Experimental|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
16505625|NCT03252496|Active Comparator|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
16505630|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
16505631|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
16505632|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
16505633|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
16505634|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
16505635|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
16505636|NCT03252418|Experimental|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
16505637|NCT03252418|Experimental|diode laser|photothermolysis by diode laser in one session
16505638|NCT03252405|Active Comparator|mask ventilation|induction is made with mask ventilation
16505639|NCT03252405|Experimental|intravenous induction|induction is made with intravenous cannulation
16505640|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
16505641|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
16505642|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
16505643|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
16505644|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
16505645|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.
~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
16505646|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
16505647|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
16505648|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
16505649|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
16505650|NCT03252327|No Intervention|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
16505651|NCT03252327|Experimental|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
16505652|NCT03252327|Experimental|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
16505653|NCT03252327|Experimental|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
16505654|NCT03252314||Subjects with ruptured aneurysms|
16505655|NCT03252288|No Intervention|No intervention|No intervention
16505656|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
16505657|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
16505658|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
16505659|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
16505660|NCT03252262|Active Comparator|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
16505661|NCT03252262|Active Comparator|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
16505662|NCT03252262|Active Comparator|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
16505663|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy is the intervention.
16505664|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy is the intervention.
16505665|NCT03252236|Experimental|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
16505666|NCT03252236|Active Comparator|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
16505667|NCT03252236|No Intervention|Control|No training was given to the subjects in this group
16505670|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.
~Post Hoc Multiple Comparisons"
16505671|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
16505672|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
16505673|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G1)|Low level laser therapy with energy dose of 18J will be applied on left brachial artery of the subject.
16505674|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G2)|Low level laser therapy with energy dose of 36J will be applied on left brachial artery of the subject.
16505675|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G3)|Low level laser therapy with energy dose of 54J will be applied on left brachial artery of the subject.
16505676|NCT03252184|Placebo Comparator|Phase 1 - Placebo low level laser therapy - 1 (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
16505677|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
16505678|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
16505679|NCT03252184|Placebo Comparator|Phase 2 - Placebo low level laser therapy - 2 (G3)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
16505680|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
16505681|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3(G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
16505682|NCT03252171|Experimental|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
16505683|NCT03252171|No Intervention|No Intervention|
16505684|NCT03252158|Experimental|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods
~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
16505685|NCT03252158|Experimental|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods
~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
16505686|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
16505687|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
16505688|NCT03252132|Active Comparator|12-week resistance training|
16505689|NCT03252132|No Intervention|No training|
16505690|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
16505691|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
16505692|NCT03252106|Experimental|Contour augmentation|
16505693|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
16505694|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
16505695|NCT03252080|Active Comparator|Education (Group A)|short-intensive education for one month
16505696|NCT03252080|Experimental|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
16505697|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
16505698|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
16505699|NCT03252015|Experimental|Probe Drug Cocktail (Cohort 1a)|Probe Drug Cocktail administered orally on Day -3.
16505700|NCT03252015|Experimental|200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)|200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
16505701|NCT03252015|Placebo Comparator|Placebo+Probe Drug Cocktail (Cohort 1b)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
16505702|NCT03252015|Experimental|400 mg Lasmiditan (Cohort 2a)|400 mg lasmiditan administered orally for 7 days.
16505703|NCT03252015|Experimental|Placebo (Cohort 2b)|Placebo administered orally for 7 days.
16505704|NCT03252002|Experimental|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
16505705|NCT03252002|Experimental|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
16505706|NCT03252002|Experimental|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
16505707|NCT03252002|Experimental|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
16505708|NCT03252002|Experimental|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
16505709|NCT03252002|Experimental|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
16505710|NCT03251989||1/Patient with a rare CNS diagnosis|A diagnosis of rare CNS Tumors
16505711|NCT03251976|Experimental|Intervention|video decision aid
16505713|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
16505714|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
16505715|NCT03251950|Experimental|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
16505716|NCT03251950|Other|Control group|Wait list control -- to receive intervention after serving as wait list group
16505717|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
16505718|NCT03251924|Experimental|BMS-986226|administered intravenously
16505719|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
16505720|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
16505721|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
16505722|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
16505723|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
16505724|NCT03251885||women with preterm labor|pregnant women < 37 weeks of gestations with regular uterine contractions and > 3 cm dilation, > 80% effacement
16505725|NCT03251885||women with term pregnancy|pregnant women > 37 weeks of gestation
16505726|NCT03251872|Experimental|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
16505727|NCT03251859|Active Comparator|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
16505728|NCT03251859|Experimental|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
16505729|NCT03251833||obese|Body mass index >30 Kilogram/m2
16505730|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
16505731|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
16505732|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
16505733|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
16505734|NCT03251781|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation
16505735|NCT03251768|Experimental|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
16505736|NCT03251768|Active Comparator|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
16505737|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
16505738|NCT03251755|No Intervention|Control|Usually clinical practice
16505739|NCT03251742|Active Comparator|Fontan patient population|
16505740|NCT03251742|Sham Comparator|Healthy volunteers|
16505741|NCT03251729|Experimental|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
16505742|NCT03251729|Other|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
16505743|NCT03251716|Experimental|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
16505744|NCT03251690|Experimental|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
16505745|NCT03251690|Active Comparator|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
16505746|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
16505747|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
16505748|NCT03251664||Anemic|Hemoglobin <11 g/l
16505749|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
16505750|NCT03251651|Experimental|PPF|Patient who received propofol during the operation
16505751|NCT03251651|Experimental|DEX|Patient who received dexmedetomidine during the operation
16505752|NCT03251625|Placebo Comparator|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
16505753|NCT03251625|Placebo Comparator|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
16505754|NCT03251612|Other|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
16505755|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
16505756|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
16505757|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505758|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505759|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505760|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505761|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505762|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505763|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505764|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
16505765|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
16505766|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
16505767|NCT03251560|Experimental|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
16505768|NCT03251560|Placebo Comparator|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
16505769|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
16505770|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
16505771|NCT03251508|Experimental|Peanut OIT/dietary peanut|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months. This is followed by daily ingestion of common dietary foods containing approximately 300 mg of peanut protein for an additional 6 months.
16505772|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
16505773|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
16505774|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
16505775|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
16505776|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
16505777|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
16505778|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
16505779|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
16505780|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
16505781|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
16505782|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
16505783|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
16505784|NCT03251469|Active Comparator|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
16505785|NCT03251469|Placebo Comparator|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
16505786|NCT03251456|Experimental|Tertiary care|
16505787|NCT03251456|Active Comparator|Usual care|
16505788|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
16505789|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
16505790|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
16505791|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
16505792|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
16505793|NCT03251404|Active Comparator|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
16505794|NCT03251404|Experimental|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
16505795|NCT03251391|Experimental|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
16505796|NCT03251391|Active Comparator|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
16505797|NCT03251378|Experimental|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
16505798|NCT03251378|Experimental|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
16505799|NCT03251378|Experimental|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
16505800|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort B|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
16505801|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort C|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
16505802|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort D|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
16505803|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort E|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
16505804|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
16505805|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
16505806|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
16505807|NCT03251339|Experimental|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
16505808|NCT03251339|Experimental|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
16505809|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
16505810|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
16505811|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
16505812|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
16505813|NCT03251313|Experimental|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
16505814|NCT03251313|Experimental|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
16505815|NCT03251313|Experimental|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
16505816|NCT03251313|Experimental|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
16505817|NCT03251300|Experimental|group A|daytime dosing of mirabegron
16505819|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
16505820|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
16505821|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
16505822|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
16505823|NCT03251261||Specimen collection|
16505824|NCT03251248|Experimental|First MSB11455 Then Neulasta|
16505825|NCT03251248|Experimental|First Neulasta Then MSB11455|
16505826|NCT03251235|Experimental|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
16505827|NCT03251235|No Intervention|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
16505828|NCT03251222|Experimental|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
16505829|NCT03251222|Placebo Comparator|Placebo Concentrate|Patients will recive 0.9% NaCl
16505830|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
16505831|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
16505832|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
16505833|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
16505834|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
16505835|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
16505836|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
16505837|NCT03251170|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
16505838|NCT03251170|Active Comparator|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
16505839|NCT03251144|Experimental|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be
~If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.
~If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
16505840|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
16505841|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
16505842|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
16505843|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
16505844|NCT03251092|Active Comparator|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
16505845|NCT03251092|Placebo Comparator|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
16505846|NCT03251092|Active Comparator|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
16505847|NCT03251092|Placebo Comparator|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
16505848|NCT03251092|Active Comparator|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
16505849|NCT03251092|Placebo Comparator|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
16505850|NCT03251092|Experimental|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
16505851|NCT03251092|Placebo Comparator|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
16505852|NCT03251092|Experimental|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
16505853|NCT03251092|Active Comparator|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
16505854|NCT03251092|Active Comparator|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
16505855|NCT03251092|Placebo Comparator|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
16505856|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428|In cohorts 3 & 4 subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
16505857|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
16505858|NCT03251092|Placebo Comparator|Part 4 CF PTI-808 placebo + PTI-801 placebo + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
16505859|NCT03251066|Other|Test group|Proponent Nasal Spray Medical device
16505860|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
16505861|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
16505862|NCT03251040|Other|Fibrin sealant|Single arm pilot study
16505863|NCT03251027|Experimental|Treatment (IM-SRT)|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
16505864|NCT03251014|Experimental|YSS/salmon group|YSS followed by salmon
16505865|NCT03251014|Experimental|Salmon/YSS group|Salmon followed by YSS
16505866|NCT03251001|Active Comparator|Control|Sites receiving a free gingival graft
16505867|NCT03251001|Experimental|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
16505870|NCT03250962|Experimental|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
16505871|NCT03250962|Experimental|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
16505872|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
16505873|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
16505874|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
16505875|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
16505876|NCT03250923|Experimental|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
16505877|NCT03250910|Experimental|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
16505878|NCT03250910|Experimental|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
16505879|NCT03250910|Active Comparator|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
16505880|NCT03250910|Active Comparator|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
16505881|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
16505882|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.
~It is divided into three phases:
~induction: attention of the patient fixed on an object or a part of the body,
~the dissociation where the patient cuts off auditory, visual and tactile perceptions,
~and finally the opening towards a hypnotic experience thanks to the imaginary."
16505883|NCT03250858|Placebo Comparator|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.
~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
16505884|NCT03250858|Experimental|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
16505885|NCT03250832|Experimental|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams [mg], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
16505980|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
16505981|NCT03250208|Placebo Comparator|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
16505886|NCT03250832|Experimental|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
16505887|NCT03250832|Experimental|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
16505888|NCT03250832|Experimental|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
16505889|NCT03250832|Experimental|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care [SOC]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
16505890|NCT03250832|Experimental|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
16505891|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
16505892|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
16505893|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
16505894|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
16505895|NCT03250780|Experimental|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
16505896|NCT03250767||Integra Titan Modular Shoulder System 2.5|
16505897|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
16505898|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
16505899|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
16505900|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
16505901|NCT03250728|Other|CDG with stroke-like history|
16505902|NCT03250728|Other|CDG without stroke-like history|
16505903|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
16505904|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
16505905|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
16505906|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
16505907|NCT03250676|Experimental|H3B-6545 Arm 1: Dose escalation|
16505908|NCT03250676|Experimental|H3B-6545 Arm 2: Phase 2|
16505909|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
16505910|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
16505911|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
16505912|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
16505913|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
16505914|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
16505915|NCT03250624|Experimental|CD5024 0.3% cream|Active drug
16505916|NCT03250624|Experimental|CD5024 cream placebo|Placebo of active drug
16505917|NCT03250611|Experimental|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
16505918|NCT03250598|Experimental|Cohort A|
16505919|NCT03250598|Experimental|Cohort B|
16505920|NCT03250598|Experimental|Cohort C|
16505982|NCT03250208|Experimental|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
16505921|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
16505922|NCT03250572||control group|
16505923|NCT03250572||NAFLD patients without hepatic fibrosis|
16505924|NCT03250572||NAFLD patients with hepatic fibrosis|
16505925|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.
~Intervention: percutaneous nephrolithotomy."
16505926|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.
~Intervention: percutaneous nephrolithotomy."
16505927|NCT03250546|Experimental|Haplo-identical group|
16505928|NCT03250546|Active Comparator|HLA-9/10 MMUD group|
16505929|NCT03250533|Experimental|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
16505930|NCT03250533|Experimental|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
16505931|NCT03250533|Experimental|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
16505932|NCT03250533|No Intervention|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
16505933|NCT03250520|Experimental|glioma brain stem|
16505934|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
16505935|NCT03250507|Active Comparator|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
16505936|NCT03250507|Active Comparator|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.
~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
16505937|NCT03250507|Experimental|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.
~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
16505938|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
16505939|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
16505940|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
16505941|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
16505942|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
16505943|NCT03250468|Experimental|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
16505944|NCT03250468|No Intervention|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
16505945|NCT03250455||CTA+CTP|
16505946|NCT03250455||CTA only|
16505947|NCT03250442|Other|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
16505948|NCT03250442|Active Comparator|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
16505949|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
16505950|NCT03250403|Experimental|PRP injection|
16505951|NCT03250403|Active Comparator|medical treatment|
16505952|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
16505953|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
16505954|NCT03250377|Experimental|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
16505955|NCT03250364|Experimental|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure (Emulsified Latex FoamTM 8mm, Thuasne, France); and the third layer of inelastic bandages (6, 8 and/or 10 cm Rosidal K Short Stretch Bandage, Germany). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
16505983|NCT03250195|Other|PET/MRI|All participants will have a PET/MRI performed
16505956|NCT03250364|Experimental|Simplified multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm Bande coton Short Stretch; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
16505957|NCT03250364|Experimental|Cohesive bandage group|Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject.
16505958|NCT03250364|Experimental|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
16505959|NCT03250364|Experimental|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
16505960|NCT03250351|Experimental|Neurodynamic group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
16505961|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program consisting of physical therapy aimed at reducing postoperative edema, treatment of the scar, the muscle pain and / or joint and recovery and integration of the upper limb functional motor patterns plus instructions with printed material about lymphatic system, lymphedema, pain, movement & pain; etc…. (educational strategy). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
16505962|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
16505963|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
16505964|NCT03250325|Experimental|Split dose of 5x10^9 TBI-1301|Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
16505965|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
16505966|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.
~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
16505967|NCT03250299|Experimental|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
16505968|NCT03250299|Experimental|Expansion Cohort|BAL101553 at the MTD / highest dose considered safe (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
16505969|NCT03250286|Experimental|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
16505970|NCT03250286|Active Comparator|ERCP group|ERCP without EUS is performed in all patients.
16505971|NCT03250273|Experimental|Arm A - Cholangiocarcinoma|
16505972|NCT03250273|Experimental|ARM B - Pancreatic Cancer|
16505973|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
16505974|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
16505975|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
16505976|NCT03250247|Experimental|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.
~Subjects randomized to EVT will receive the following:
~imaging-guided iliac vein stent placement, and
~endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.
~optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
16505977|NCT03250247|No Intervention|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
16505978|NCT03250234|Other|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
16505979|NCT03250234|Other|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
16505984|NCT03250182|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
16505985|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
16505986|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
16505987|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
16505988|NCT03250143|Active Comparator|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
16505989|NCT03250143|Active Comparator|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
16505990|NCT03250130|Experimental|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
16505991|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
16505992|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
16505993|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
16505994|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
16505995|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
16505996|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
16505997|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
16505998|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
16505999|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
16506000|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
16506001|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
16506002|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
16506003|NCT03250065|Experimental|ETT Study Group|The Sensing ET Tube study Group
16506004|NCT03250052|Experimental|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
16506005|NCT03250052|Experimental|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
16506006|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
16506007|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
16506008|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
16506009|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
16506010|NCT03250013|Experimental|Children and adolescents with ADHD|Children and adolescents medicating for ADHD of any subtype (presentation) with comorbidities
16506011|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
16506012|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
16506013|NCT03249987|Other|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
16506014|NCT03249987|Other|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
16506015|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
16506016|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
16506017|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
16506018|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
16506019|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
16506020|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
16506021|NCT03249935|Experimental|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
16506632|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
16506022|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
16506023|NCT03249909|Other|Exufiber Ag +|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
16506024|NCT03249909|Other|Exufiber|Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
16506025|NCT03249909|Other|Aquacel® Ag Extra|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
16506026|NCT03249896|Experimental|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
16506027|NCT03249896|No Intervention|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.
~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
16506028|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
16506029|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
16506030|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
16506031|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
16506032|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
16506033|NCT03249844|Experimental|experimental group|Children will be treated by methylprednisolone + prednisolone and standard of care
16506034|NCT03249844|No Intervention|control group|Children will be treated by standard of care alone
16506035|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.
~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.
~The minimally manipulated transplant product is manufactured using the CliniMACS device."
16506036|NCT03249818|Other|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
16506037|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
16506038|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
16506039|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
16506040|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
16506041|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
16506042|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
16506043|NCT03249779|Experimental|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
16506082|NCT03249519|Experimental|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m^2 (6 cycles) Hyperthermia: 10 times
16506044|NCT03249753|Experimental|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
16506045|NCT03249753|Experimental|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
16506046|NCT03249740|Experimental|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
16506047|NCT03249740|Experimental|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
16506048|NCT03249740|Active Comparator|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
16506049|NCT03249714|Experimental|OMB 20 mg|Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.
16506050|NCT03249714|Placebo Comparator|Placebo-OMB 20 mg|Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core
16506051|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
16506052|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
16506053|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
16506054|NCT03249688|Other|Control|Regular health advice
16506055|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
16506056|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
16506057|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
16506058|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:
~Acute: within 2 weeks of injury
~PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
16506059|NCT03249662|Experimental|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
16506060|NCT03249662|Active Comparator|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
16506061|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
16506062|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
16506063|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
16506064|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
16506065|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
16506066|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
16506067|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
16506068|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
16506069|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
16506070|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
16506071|NCT03249597||2. Control|Adult (>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
16506072|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
16506073|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
16506074|NCT03249571|Placebo Comparator|Placebo|Placebo
16506075|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
16506076|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
16506077|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
16506078|NCT03249532|Active Comparator|standard hemodialysis|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
16506079|NCT03249532|Active Comparator|cool hemodialysis|prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
16506080|NCT03249532|Active Comparator|low volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
16506081|NCT03249532|Active Comparator|high volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
16506083|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
16506084|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs >= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
16506085|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
16506086|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
16506087|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
16506088|NCT03249454|Experimental|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506089|NCT03249454|Experimental|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506090|NCT03249454|Experimental|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506091|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506092|NCT03249454|Experimental|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506093|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506094|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506095|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506096|NCT03249454|Experimental|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506097|NCT03249454|Experimental|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506098|NCT03249454|Experimental|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
16506099|NCT03249441|Experimental|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
16506100|NCT03249441|No Intervention|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
16506245|NCT03248505|Experimental|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
16506633|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
16506101|NCT03249428|Active Comparator|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
16506102|NCT03249428|Active Comparator|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
16506103|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
16506104|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
16506105|NCT03249376|Experimental|Lumateperone|Lumateperone (ITI-007 60 mg) administered once daily every evening for 6 weeks
16506106|NCT03249376|Placebo Comparator|Placebo|Placebo administered once daily every evening for 6 weeks
16506107|NCT03249363|Experimental|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
16506108|NCT03249363|Active Comparator|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
16506109|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
16506110|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
16506111|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
16506112|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
16506113|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
16506114|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
16506115|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
16506116|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
16506117|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
16506118|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids
~Bolus of 250 ml crystaloids will be infused regarding the measures"
16506119|NCT03249298|Active Comparator|Colloids|"Bolus of colloids
~Bolus of 250 ml colloids will be infused regarding the measures"
16506120|NCT03249285|Experimental|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
16506121|NCT03249285|Experimental|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
16506122|NCT03249285|Active Comparator|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
16506123|NCT03249285|Active Comparator|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
16506124|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
16506125|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
16506126|NCT03249272|Active Comparator|Control|
16506127|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
16506128|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
16506129|NCT03249246||Infection only|The patients have only infection
16506130|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
16506131|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
16506132|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
16506133|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
16506134|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
16506135|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
16506136|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
16506137|NCT03249220|Experimental|CBMS|
16506138|NCT03249207|Active Comparator|IL-1Ra twice daily|
16506139|NCT03249207|Placebo Comparator|Placebo twice daily|
16506140|NCT03249194|Experimental|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.
~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
16506141|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.
~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
16506142|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
16506143|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
16506144|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
16506145|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
16506146|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
16506147|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
16506148|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
16506149|NCT03249116|Active Comparator|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
16506150|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
16506151|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
16506152|NCT03249103|Placebo Comparator|Placebo|Up to 24 subjects will receive Placebo, NYX-2925 Low Dose, and NYX-2925 High Dose
16506153|NCT03249103|Experimental|NYX-2925 High Dose|Up to 24 subjects will receive High Dose of NYX-2925
16506154|NCT03249103|Experimental|NYX-2925 Low Dose|Up to 24 subjects will receive Low Dose of NYX-2925
16506155|NCT03249090|Experimental|Patient Self-Reporting of Symptoms|Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
16506156|NCT03249090|Active Comparator|Usual Care Delivery|Evidence-based symptom management pathways provided to patients and clinicians
16506157|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
16506158|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
16506159|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
16506160|NCT03249064||Vitiligo untreated patients|
16506161|NCT03249064||Control. Patients without vitiligo|
16506162|NCT03249051|Experimental|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
16506163|NCT03249051|No Intervention|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
16506164|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
16506165|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
16506166|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
16506167|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
16506168|NCT03248960|Experimental|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:
~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
16506169|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
16506170|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
16506171|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
16506172|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
16506173|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
16506174|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
16506175|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
16506634|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
16506176|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
16506177|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
16506178|NCT03248895|Active Comparator|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
16506179|NCT03248895|Active Comparator|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
16506180|NCT03248882|Placebo Comparator|Placebo|Double-Blind, PF-05221304-matching Placebo
16506181|NCT03248882|Active Comparator|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
16506182|NCT03248882|Active Comparator|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
16506183|NCT03248882|Active Comparator|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
16506184|NCT03248882|Active Comparator|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
16506185|NCT03248869|Active Comparator|Current Daily Survey|need description
16506186|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
16506187|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
16506188|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
16506189|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
16506190|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
16506191|NCT03248843|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
16506192|NCT03248817|Experimental|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
16506193|NCT03248817|Active Comparator|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
16506194|NCT03248817|Active Comparator|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
16506195|NCT03248804|Experimental|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
16506196|NCT03248804|Other|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
16506197|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
16506198|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
16506199|NCT03248778|Experimental|disclosure-support counseling|
16506200|NCT03248778|No Intervention|Treatment as Usual|
16506201|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
16506202|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
16506203|NCT03248752|Active Comparator|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
16506204|NCT03248752|Experimental|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
16506205|NCT03248739|Active Comparator|Clear Bactiseal 'large' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
16506250|NCT03248479|Experimental|R/R Safety Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; and 30 mg/kg weekly thereafter starting Cycle 3 up to end of the study.
16506282|NCT03248297|Placebo Comparator|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
16506206|NCT03248739|Active Comparator|Orange Bactiseal 'small' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
16506207|NCT03248726|Experimental|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
16506208|NCT03248726|Active Comparator|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
16506209|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
16506210|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
16506211|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
16506212|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
16506213|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
16506214|NCT03248661|Experimental|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
16506215|NCT03248661|No Intervention|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
16506216|NCT03248648|Active Comparator|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
16506217|NCT03248648|Active Comparator|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
16506218|NCT03248635||Focus group|Male and female adults age 40-75
16506219|NCT03248622||Anti-HBc positive|Anti-HBc positive
16506220|NCT03248622||HCV positive Cohort|HCV positive Cohort
16506221|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
16506222|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
16506223|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
16506224|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
16506225|NCT03248583|Experimental|Default|
16506226|NCT03248583|Active Comparator|Psychoeducation|
16506227|NCT03248583|Active Comparator|Incentive|
16506228|NCT03248570|Experimental|DNA damage repair proficient group|Twenty-five subjects with mismatch repair (MMR) intact
16506229|NCT03248570|Experimental|DNA damage repair defective group|Twenty-five subjects with defective DNA repair
16506230|NCT03248557||Study|Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.
16506231|NCT03248557||Control|Patients who are conscious (GCS=15) and whose neurological status is known and good at admission.
16506232|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
16506233|NCT03248544|Other|control|Control patients will not be received any intervention
16506234|NCT03248531|Experimental|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
16506235|NCT03248531|Active Comparator|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
16506236|NCT03248531|Placebo Comparator|Placebo|Subjects will receive several placebo applications to keep the blinding.
16506237|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
16506238|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
16506239|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
16506240|NCT03248505|Placebo Comparator|Placebo TENS|TENS unit turned on, but with zero amplitude.
16506241|NCT03248505|Experimental|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
16506242|NCT03248505|Experimental|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
16506243|NCT03248505|Experimental|Cryotherapy|1,5 Kg crushed ice pack
16506244|NCT03248505|Experimental|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
16506251|NCT03248479|Experimental|R/R Expansion Cohort:|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and Day 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
16506252|NCT03248479|Experimental|R/R MDS Magrolimab Monotherapy Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, weekly on Cycle 2, and then biweekly starting Cycle 3 up to end of the study.
16506253|NCT03248479|Experimental|Treatment-naive Unfit (TNU) Dose Evaluation Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, and then weekly starting Cycle 2 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
16506254|NCT03248479|Experimental|Treatment-naive Unfit (TNU) Dose Expansion Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1; 15 mg/kg weekly for Cycle 1 Day 8; 30 mg/kg weekly through end of cycle 2; and then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
16506255|NCT03248479|Experimental|RBC transfusion-dependent low-risk MDS, Safety Run-in Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 weeks starting on Cycle 2 Day 1 and thereafter up to end of the study. For participants who do not respond after Cycle 2, azacitidine 75 mg/m^2 may be added on subsequent cycles (ie starting at Cycle 3) on Days 1 to 5 of each cycle.
16506256|NCT03248479|Experimental|RBC transfusion-dependent low-risk MDS, Expansion Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; at 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 starting on Cycle 2 Day 1 and thereafter up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 5 of each cycle.
16506257|NCT03248479|Experimental|Rollover|Participants on a previous AML Phase 1 trial (SCI-CD47-002; NCT02678338) with clinical benefit on magrolimab treatment will receive the same dose level (0.1 mg/kg up to 30.0mg/kg based on the cohort to which the participant was assigned) twice weekly or may transition to once weekly dosing at the discretion of the Investigator and approval from Gilead.
16506258|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
16506259|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
16506260|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
16506261|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
16506262|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
16506263|NCT03248440|Experimental|SUN-131 1.5% TDS|
16506264|NCT03248440|Placebo Comparator|Placebo TDS|
16506265|NCT03248427|Experimental|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
16506266|NCT03248427|Other|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
16506267|NCT03248414|Experimental|Lactobacillus sakei|2 packs per day
16506268|NCT03248414|Placebo Comparator|Control|2 packs per day
16506269|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
16506270|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
16506271|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
16506272|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
16506273|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
16506274|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
16506275|NCT03248349||1|Pharmacokinetics
16506276|NCT03248336|Experimental|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
16506277|NCT03248323||pre-con|
16506278|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
16506279|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
16506280|NCT03248297|Experimental|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
16506281|NCT03248297|Experimental|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
16506283|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
16506284|NCT03248258||Metastatic Breast Interview Participants - Shared Decision Making|Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
16506285|NCT03248258||Early Stage Breast Interview Participants - Shared Decision Making|Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
16506286|NCT03248258||Provider Focus Group -Shared Decision Making|Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
16506287|NCT03248258||Non-UAB Provider Shared Decision Making|Non-UAB Provider Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
16506288|NCT03248258||Early Stage de-escalation Interview Participants|Early Stage Breast Patient Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
16506289|NCT03248258||Patient Advocate de-escalation Interview Participants|Patient Advocate Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
16506290|NCT03248258||Physician de-escalation Interview Participants|Physician Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
16506291|NCT03248258||Early Stage Feedback Interview Participants|Early Stage Breast Patient Participants will be interviewed to provide feedback on a decision making tool (video). This will be a one time, one-on-one interview with a trained interviewer.
16506292|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
16506293|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
16506294|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
16506295|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
16506296|NCT03248193|Experimental|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
16506297|NCT03248193|Experimental|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
16506298|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce < 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
16506299|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
16506300|NCT03248167|Experimental|Cannabidiol (CBD 600 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
16506301|NCT03248167|Placebo Comparator|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
16506302|NCT03248154|No Intervention|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
16506303|NCT03248154|Experimental|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn >=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
16506304|NCT03248154|No Intervention|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
16506305|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
16506306|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
16506307|NCT03248128|Experimental|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
16506308|NCT03248128|Active Comparator|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
16506309|NCT03248128|Experimental|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
16506310|NCT03248128|Active Comparator|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
16506311|NCT03248102|Experimental|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A&E
16506312|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
16506313|NCT03248063|Active Comparator|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion.
16506963|NCT03243591|Active Comparator|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
16506314|NCT03248063|Experimental|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
16506315|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
16506316|NCT03248050|No Intervention|Control pharmacy|
16506317|NCT03248037|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
16506318|NCT03248037|Placebo Comparator|Placebo|Placebo eye drop, dosed topically once a day for 9 months
16506319|NCT03248011|Experimental|Flexibility|Stretching exercise
16506320|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
16506321|NCT03248011|Experimental|Neuromuscular|Balance exercise
16506322|NCT03248011|No Intervention|Control|No exercise
16506323|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.
~See Detailed Description for additional details and description of follow-up procedures."
16506324|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.
~See Detailed Description for additional details and description of follow-up procedures."
16506325|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
16506326|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
16506327|NCT03247972||Patients with PAD|
16506328|NCT03247959|Experimental|Group A|Group A: Videogame distraction during extraction procedure
16506329|NCT03247959|Experimental|Group B|Group B: Video distraction during extraction procedure
16506330|NCT03247959|Active Comparator|Group C|group C: Verbatim during extraction procedure
16506331|NCT03247946|Active Comparator|Intervention group|intervention: upright head position
16506332|NCT03247946|No Intervention|Control group|no feeding position instructions
16506333|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).
~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.
~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
16506334|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.
~Clinical practice."
16506335|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.
~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
16506336|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
16506337|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
16506338|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
16506339|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
16506340|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
16506341|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
16506342|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
16506343|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
16506344|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
16506345|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
16506346|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
16506347|NCT03247881|Active Comparator|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
16506348|NCT03247868|Experimental|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
16506349|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
16506476|NCT03246945|No Intervention|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
16506350|NCT03247842|Active Comparator|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
16506351|NCT03247842|Active Comparator|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
16506352|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
16506353|NCT03247803|Experimental|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
16506354|NCT03247803|Experimental|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
16506355|NCT03247790|Experimental|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
16506356|NCT03247790|Experimental|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
16506357|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
16506358|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
16506359|NCT03247764||patients with epilepsy and depression|Patients with comorbidity of epilepsy and depression will be asked to use antidepressants such as selective serotonin reuptake inhibitor(SSRIs) or xylaria nigripes and followed up
16506360|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
16506361|NCT03247738|Experimental|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
16506362|NCT03247738|Placebo Comparator|Placebo|Normal saline bolus and infusion for 2 hours
16506363|NCT03247725|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
16506364|NCT03247725|Experimental|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
16506365|NCT03247725|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
16506366|NCT03247712|Experimental|Treatment Cohort 1|Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
16506367|NCT03247712|Experimental|Treatment Cohort 2|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
16506368|NCT03247712|Experimental|Treatment Cohort 3|Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
16506369|NCT03247712|Experimental|Treatment Cohort 4|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
16506370|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
16506371|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
16506372|NCT03247686|Placebo Comparator|Placebo|Placebo
16506373|NCT03247686|Active Comparator|RSLV-132|Experimental drug
16506374|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
16506375|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
16506376|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
16506377|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
16506378|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.
~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
16506379|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
16506380|NCT03247647|Experimental|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
16506381|NCT03247647|Placebo Comparator|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
16506382|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
16506383|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
16506384|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
16506385|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
16506386|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
16506387|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
16506388|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
16506389|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
16506390|NCT03247569||Edoxaban|Patients treated with Edoxaban
16506391|NCT03247556|Placebo Comparator|Placebo|Placebo, qd, oral capsule
16506392|NCT03247556|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
16506393|NCT03247556|Experimental|600mg SPN-812|600mg SPN-812, qd, oral capsule
16506394|NCT03247543|Placebo Comparator|Placebo|Placebo, qd, oral capsule
16506395|NCT03247543|Active Comparator|200mg SPN-812|200mg SPN-812, qd, oral capsule
16506396|NCT03247543|Active Comparator|400mg SPN-812|400mg SPN-812, qd, oral capsule
16506397|NCT03247530|Placebo Comparator|Placebo|Placebo, qd, oral capsule
16506398|NCT03247530|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
16506399|NCT03247530|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
16506400|NCT03247517|Placebo Comparator|Placebo|Placebo, qd, oral capsule
16506401|NCT03247517|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
16506402|NCT03247517|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
16506403|NCT03247491|Experimental|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
16506404|NCT03247491|No Intervention|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
16506405|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
16506406|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
16506407|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
16506408|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.
~2 liters of polyethylene glycol plus ascorbic acid will be administered"
16506409|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.
~2 liters of polyethylene glycol plus ascorbic acid will be administered"
16506410|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
16506411|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
16506412|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
16506413|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
16506414|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
16506415|NCT03247400|Active Comparator|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
16506416|NCT03247400|Active Comparator|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
16506417|NCT03247400|Placebo Comparator|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
16506418|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
16506419|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
16506635|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
16506420|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise
~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.
~Exercise: see group Combined aerobic/resistance exercise"
16506421|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise
~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.
~Exercise: see group Combined aerobic/resistance exercise"
16506422|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise
~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
16506423|NCT03247322|Experimental|mHealth Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
16506424|NCT03247322|No Intervention|Usual Care Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
16506425|NCT03247309|Experimental|IMA201 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~One dose of IMA201 product will be infused intravenously. Up to four dose levels will be evaluated. At least two patients per cohort will be treated.
~Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2"
16506426|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
16506427|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
16506428|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
16506429|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
16506430|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
16506431|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
16506432|NCT03247257|Active Comparator|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
16506433|NCT03247257|Active Comparator|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
16506434|NCT03247244|Other|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
16506435|NCT03247244|Other|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
16506436|NCT03247244|Other|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
16506437|NCT03247244|Other|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
16506438|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).
~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.
~The study drug will be taken once a day per os, during one year."
16506439|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
16506440|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.
~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
16506477|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
16506441|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.
~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
16506442|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.
~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
16506443|NCT03247179|Experimental|PTSD Coach Condition|PTSD Coach App
16506444|NCT03247179|No Intervention|Treatment as Usual Condition|Treatment as Usual
16506445|NCT03247166|Experimental|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
16506446|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
16506447|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
16506448|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
16506449|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
16506450|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
16506451|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
16506452|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
16506453|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
16506454|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
16506455|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
16506456|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
16506457|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
16506458|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
16506459|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
16506460|NCT03247101|Experimental|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
16506461|NCT03247101|Active Comparator|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
16506462|NCT03247101|Active Comparator|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
16506463|NCT03247088|Experimental|Treatment (sorafenib, busulfan, fludarabine, HSCT)|"PRE-STEM CELL INFUSION: Patients receive sorafenib orally PO QD or BID on days -24 to -5, busulfan IV over 3 hours on days -20 and -13 and -6 and -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.
~STEM CELL INFUSION: Patients receive allogeneic HSCT IV in the absence of disease progression or unacceptable toxicity.
~POST-STEM CELL INFUSION: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus PO BID beginning day 5 for about 50 days, filgrastim SC on day 7 and sorafenib PO BID beginning between days +30 and +120 for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with matched unrelated donor receive mycophenolate mofetil PO TID or IV over 2 hours TID beginning on day 5 for up to 90 days for longer."
16506464|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
16506465|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
16506466|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.
~The entire ICU population will be observed before and after intervention."
16506467|NCT03247023||Integra Cadence Total Ankle System|
16506468|NCT03246997|Other|Autumn Group|Intervention Group
16506469|NCT03246997|Other|Spring Group|Delayed Intervention
16506470|NCT03246984|Experimental|VasQ device implantation|
16506471|NCT03246971|Experimental|Wafermine™|
16506472|NCT03246971|Placebo Comparator|Placebo|
16506473|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
16506474|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
16506475|NCT03246945|Experimental|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
16506829|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
16506478|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
16506479|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
16506480|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
16506481|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
16506482|NCT03246906|Experimental|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
16506483|NCT03246906|Experimental|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
16506484|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
16506485|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
16506486|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
16506487|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
16506488|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
16506489|NCT03246867|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
16506490|NCT03246867|Experimental|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
16506491|NCT03246867|Active Comparator|Control group|The participants in this group will receive no stretching. They will only be evaluated.
16506492|NCT03246854|Experimental|DBPR112|
16506493|NCT03246841|Other|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
16506494|NCT03246828|Experimental|Omission of gliclazide|
16506495|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
16506496|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
16506497|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
16506498|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
16506499|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
16506500|NCT03246776|Experimental|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
16506501|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
16506524|NCT03246633|Other|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
16506525|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
16506526|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
16506527|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
16506528|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
16506636|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
16506502|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
16506503|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
16506504|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
16506505|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
16506506|NCT03246737||pregnant women|
16506507|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:
~• Cataracts
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
16506508|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:
~Pars plana vitrectomy
~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
16506509|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:
~Descemet Stripping Endothelial Keratoplasty (DSEK)
~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)
~Descemet Membrane Endothelial Keratoplasty (DMEK)
~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)
~Conjunctival and/or corneal lesion excisions
~Pterygium
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
16506510|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:
~Ahmed valve
~Ahmed valve with cataracts
~Trabeculectomy
~Trabeculectomy with cataracts
~Baerveldt
~Baerveldt with cataracts
~Endocyclophotocoagulation
~Endocyclophotocoagulation with cataracts
~Istent
~Cataracts with istent
~Kahook
~Cataracts with kahook
~Cypass
~Cypass with cataracts
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
16506511|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
16506512|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
16506513|NCT03246711||Non fasting|women who did not fast at all
16506514|NCT03246698|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
16506515|NCT03246698|Experimental|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.
~Additionally they will receive standard physiotherapy."
16506516|NCT03246698|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
16506517|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
16506518|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
16506519|NCT03246672|Experimental|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
16506520|NCT03246659|Experimental|arm 1|111In-CP04
16506521|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
16506522|NCT03246646|Experimental|Coaching + VA CRAFT|Telephone coaching along with web-based CRAFT course
16506523|NCT03246646|Other|Treatment as usual|Treatment as usual matched comparison
16506529|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.
~Placement of oesophageal probe for temperature measurement"
16506530|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.
~Intervention: Power limitation of RF generator"
16506531|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
16506532|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
16506535|NCT03246555|Experimental|Fimasartan or Fimasartan/Hydrochlorothiazide|
16506536|NCT03246555|Active Comparator|Perindopril or Perindopril/Indapamide|
16506537|NCT03246529|Experimental|BL-8040 1.25mg/kg + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
16506538|NCT03246529|Active Comparator|Placebo + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
16506539|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
16506540|NCT03246490|Other|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
16506541|NCT03246464|Placebo Comparator|Single-vision spectacles|
16506542|NCT03246464|Active Comparator|Orthokeratology lenses|
16506543|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
16506544|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
16506545|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
16506546|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
16506547|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
16506548|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
16506549|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
16506553|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
16506554|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
16506555|NCT03246399|Experimental|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
16506556|NCT03246399|Experimental|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
16506557|NCT03246399|Experimental|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
16506558|NCT03246386|Experimental|Obese subjects|Subjects with a BMI>35 kg/m2
16506559|NCT03246386|Active Comparator|Non-obese subjects|Subjects with a BMI>18.5 and <25 kg/m2
16506560|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
16506561|NCT03246360|Experimental|continuous administration of cloxacillin|
16506562|NCT03246347|Experimental|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
16506563|NCT03246334||Cohort|Case group: critically ill patients admitted >12 hours to the ICU. Control group: critically ill patients to the ICU <12 hrs, or to Post Anaesthesia Care Unit (PACU), or Medium Care or High Dependency Unit.
16506564|NCT03246321|Experimental|repetitive ePIPAC-OX|
16506565|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
16506566|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
16506567|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.
~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
16506568|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
16506569|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
16506570|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
16506571|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
16506572|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
16506573|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
16506627|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
16506628|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
16506629|NCT03245853|Other|Treatment|Treatment as per protocol, there is no placebo arm.
16506574|NCT03246243||Preterm infants|Group A will consist of preterm infants born < 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
16506575|NCT03246243||Term infants with HIE or at risk of brain injury|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia who are at risk of HIE; admitted with concern for neonatal stroke; seizures of unknown etiology; and those admitted who are at risk of abnormal neurodevelopment such as those with hypoglycemia or NAS. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
16506576|NCT03246243||Term infants healthy at birth|Group C will consist of healthy term infants from the community and term infants admitted to who had an initial uncomplicated postnatal course that will serve as the control group. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
16506577|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
16506578|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
16506579|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
16506580|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
16506581|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
16506582|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
16506583|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
16506584|NCT03246178|Other|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
16506585|NCT03246178|Experimental|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
16506586|NCT03246152|Experimental|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
16506587|NCT03246139|Experimental|Action observation, imagery & execution|
16506588|NCT03246139|Active Comparator|Action observation|
16506589|NCT03246139|Active Comparator|Control treatment|
16506590|NCT03246126|Experimental|Valiant™Thoracoabdominal Stent Graft System|The implantation of the Valiant™ Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance
16506591|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
16506592|NCT03246100|No Intervention|Control|These patients will receive no reminders from the health department and will receive usual care.
16506593|NCT03246100|Experimental|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
16506594|NCT03246100|Experimental|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
16506595|NCT03246087|Active Comparator|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
16506596|NCT03246087|Experimental|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
16506597|NCT03246087|Experimental|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
16506630|NCT03245840|Experimental|Budesonide Oral Suspension|Participants will be initiated on 10 milliliter (mL) of Budesonide oral suspension (0.2 milligram/mL) twice daily up to 72 months (Visit 12) or early termination (ET).
16506599|NCT03246061|Active Comparator|BVN Ablation|BVN ablation with continued standard care
16506600|NCT03246061|Active Comparator|Standard Care Control|Continue with non-surgical standard care
16506601|NCT03246035|Active Comparator|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
16506602|NCT03246035|Experimental|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
16506603|NCT03246022||Group l|SBP index was less than 30% of AHI
16506604|NCT03246022||Group 2|SBP index was less than 60% but more than 30%
16506605|NCT03246009|Experimental|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
16506606|NCT03246009|Experimental|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
16506607|NCT03246009|Experimental|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
16506608|NCT03246009|Experimental|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
16506609|NCT03246009|Experimental|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
16506610|NCT03246009|Experimental|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
16506611|NCT03245996|Experimental|Subjects|Subjects with a cardiac pacemaker
16506612|NCT03245983|Experimental|Patient willing to participate|
16506613|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.
~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
16506614|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
16506615|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
16506616|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
16506617|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
16506618|NCT03245944|Active Comparator|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
16506619|NCT03245944|Experimental|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
16506620|NCT03245918|Other|Aprepitant Capsule Study Period #1|
16506621|NCT03245918|Other|Aprepitant Oral Suspension Study Period#1|
16506622|NCT03245905|Experimental|Chidamide|Chidamide should be given at a fixed time with fixed dosage
16506623|NCT03245892|Experimental|Carboplatin and Paclitaxel Chemotherapy With Nivolumab (Closed)|Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
16506624|NCT03245892|Experimental|Nivolumab plus Ipilimumab plus Paclitaxel & Carboplatin|Patients will be treated with nivolumab plus ipilimumab plus standard of care dose dense paclitaxel & carboplatin chemotherapy for 3 cycles (up to a maximum of six), each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen. Paclitaxel 80mg/m2 IV will be administered over approx 1 hour on Days 1,8, & 15 of each 21 day cycle. Carboplatin AUC6 will be administered as an approx 30 minute IV infusion, following paclitaxel admin on Day 1 of each 21 day cycle. Nivolumab 360mg will be infused IV over approx 30 min on Day 1 of Cycles 1-6 (to 9) of each 21 day cycle. Ipilimumab 1mg/kg will be infused IV over approx 30 min on Day 1 of Cycles 1 & 3, as well as Cycle 4 & Cycle 6. Of note, if patients receive more than 3 cycles in the pre-operative setting, then ipilimumab will be administered with the first & third cycle in the post-operative setting. Nivolumab will then be infused Day 1 of each 28 day maintenance phase cycle.
16506625|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
16506626|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
16506631|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
16506639|NCT03245775|Experimental|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
16506640|NCT03245775|Experimental|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
16506641|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
16506642|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
16506643|NCT03245736|Experimental|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
16506644|NCT03245723|Active Comparator|Preterm|"Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).
~All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging."
16506645|NCT03245723|Placebo Comparator|Term - Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
16506646|NCT03245710|Experimental|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
16506647|NCT03245710|Placebo Comparator|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
16506648|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
16506649|NCT03245684|Experimental|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.
~assessment of inflammatory response during PSV"
16506650|NCT03245684|Active Comparator|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
16506651|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
16506652|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
16506653|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
16506654|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
16506658|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
16506659|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
16506660|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
16506661|NCT03245619|Experimental|Subjects receiving Placebo (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
16506662|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
16506663|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
16506664|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
16506665|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
16506666|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
16506667|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
16506668|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.
~Then will be performed:
~a liver biopsy
~an abdominal MRI
~a transient elastography"
16506669|NCT03245593||Shared Decision making for care|
16506670|NCT03245593||Standard decision making for care|
16506671|NCT03245580|Other|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
16506672|NCT03245580|Other|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
16506673|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
16506674|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
16506675|NCT03245554|Experimental|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
16506676|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
16506677|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
16506678|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
16506679|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
16506680|NCT03245489|Experimental|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
16506681|NCT03245489|Experimental|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
16506682|NCT03245476|Active Comparator|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
16506683|NCT03245476|Active Comparator|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
16506684|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
16506685|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
16506686|NCT03245450|Experimental|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m^2 or 40 mg/m^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m^2 or 125 mg/m^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
16506687|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
16506688|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
16506689|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
16506690|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
16506691|NCT03245411|No Intervention|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
16506692|NCT03245411|Experimental|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care
~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
16506693|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
16506694|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
16506695|NCT03245385|Experimental|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
16506698|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
16506699|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
16506700|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
16506701|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
16506702|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
16506703|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
16506704|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
16506705|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
16506706|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
16506707|NCT03245307|Experimental|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
16506708|NCT03245294|Active Comparator|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
16506709|NCT03245294|Active Comparator|Lumbar ESI with midline approach|Lumbar ESI with midline approach
16506710|NCT03245281|Experimental|Diuretic Suspension (DS)|
16506711|NCT03245281|Experimental|Diuretic Increase (DI)|
16506712|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
16506713|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
16506714|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
16506715|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
16506716|NCT03245229|Experimental|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
16506717|NCT03245229|Experimental|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
16506718|NCT03245229|Experimental|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.
~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
16506719|NCT03245216|Experimental|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
16506720|NCT03245216|Active Comparator|rest + motor skill practice|seated rest before motor learning
16506721|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
16506722|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
16506723|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
16506724|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
16506725|NCT03245164|Experimental|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
16506726|NCT03245164|Experimental|Basketball program|Basketball educaiton was presented for 12 weeks.
16506727|NCT03245164|No Intervention|Control group|This group did not continue any physical activity regularly.
16506728|NCT03245151|Experimental|Phase 1: Phase 1; Recurrent or refractory solid tumors|During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
16506729|NCT03245151|Experimental|Phase 2: Cohort 1, Ewing sarcoma/pPNET|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET) (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
16506730|NCT03245151|Experimental|Phase 2: Cohort 2, Rhabdomyosarcoma|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
16506731|NCT03245151|Experimental|Phase 2: Cohort 3, High Grade Glioma (HGG)|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
16506732|NCT03245138|Experimental|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
16506733|NCT03245138|Active Comparator|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
16506734|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
16506735|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
16506736|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
16506737|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
16506738|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
16506739|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
16506740|NCT03245073|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
16506741|NCT03245073|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
16506742|NCT03245060|Experimental|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
16506743|NCT03245060|Other|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
16506744|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
16506745|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
16506746|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
16506747|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
16506748|NCT03245008|Experimental|MT-5547 dosing regimen 1|MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.
16506749|NCT03245008|Experimental|MT-5547 dosing regimen 2|MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.
16506750|NCT03245008|Placebo Comparator|MT-5547-matching placebo|MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.
16506751|NCT03244995|Experimental|Group I (CBMB program)|Patients undergo CBMB program consisting of 4-5 deep-breathing and meditation exercise sessions over 60 minutes and 2 weekly telephone calls over 15 minutes for 6 weeks. Patients also complete questionnaires regarding health, mood, sleeping habits, relationship, health care, work productivity, and quality of life.
16506752|NCT03244995|Active Comparator|Group II (waitlist control)|Patients complete questionnaires as in Group I. Patients may undergo CBMB program after completion of study.
16506753|NCT03244982|Active Comparator|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
16506754|NCT03244982|Experimental|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
16506755|NCT03244956|Experimental|patients with RAS mutation|
16506756|NCT03244956|Experimental|patients with BRAFV600E mutation|
16506757|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
16506758|NCT03244930|Experimental|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
16506759|NCT03244917|Experimental|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
16506760|NCT03244917|No Intervention|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
16506761|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:
~before fluid challenge
~after fluid challenge
~During each phase, the subjects will be studied at:
~baseline - spontaneously breathing
~head down position - spontaneously breathing
~baseline - positive pressure ventilation
~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
16506762|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
16506763|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
16506764|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.
~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
16506765|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
16506766|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.
~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.
~Shared Care include the following
~Formal Care Coordination Plan
~Patient Engagement and Education
~Local Oncologist Engagement and Education
~Patient/Local Oncologist/Transplant Oncologist Web Portal"
16506767|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.
~Majority of routine visits in first 180 days will be at DFCI."
16506768|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
16506769|NCT03244813|Experimental|Adapted physical activity|
16506770|NCT03244813|No Intervention|Standard care|
16506892|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
16506771|NCT03244800|Placebo Comparator|Placebo Cohort 1|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
16506772|NCT03244800|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 7 days, followed by Dose 2 for 7 days, Dose 3 for 7 days, and Dose 4 for 28 days
16506773|NCT03244800|Placebo Comparator|PLacebo Cohort 2|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
16506774|NCT03244800|Experimental|MEDI0382 Cohort 2|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 14 days, followed by Dose 2 for 14 days, Dose 3 for 14 days, and Dose 4 for 7 days.
16506775|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
16506776|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
16506777|NCT03244774|Experimental|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.
~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:
~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)
~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
16506778|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
16506779|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
16506780|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
16506781|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
16506782|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
16506783|NCT03244722|Other|Obese - Very low energy diet (VLED)|Participants will adopt a very-low energy diet
16506784|NCT03244722|Other|Obese - Standard of care (SOC)|Participants will receive the standard of care for obese women looking to become pregnant.
16506785|NCT03244722|Other|Lean - Standard of care (SOC)|Participants will receive the standard of care for lean women looking to become pregnant.
16506786|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.
~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.
~Week 24. TCZ tapering every 8 weeks as follows:
~1 injection every 2 weeks
~1 injection every 3 weeks
~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
16506787|NCT03244696|Experimental|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
16506788|NCT03244696|Active Comparator|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
16506789|NCT03244683|Other|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
16506790|NCT03244683|Other|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
16506791|NCT03244657|Experimental|Q12W group|
16506792|NCT03244657|Experimental|TAE group|
16506793|NCT03244644|Placebo Comparator|Group A|Placebo is an enema of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
16506794|NCT03244644|Experimental|Group B|RBX2660 is an enema of a microbiota suspension in a 0.9% sodium chloride irrigation USP solution and cryoprotectant
16506795|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
16506796|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
16506797|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
16506798|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
16506799|NCT03244605|Experimental|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.
~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
16506828|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
16507089|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
16506800|NCT03244605|Placebo Comparator|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.
~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
~The patient will take placebo granules for 3 months."
16506801|NCT03244592|Active Comparator|Minocycline|200 mg/day
16506802|NCT03244592|Placebo Comparator|Sugar Pill|Matched placebo
16506803|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
16506804|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
16506805|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
16506806|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
16506807|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
16506808|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.
~PCA with morphine in the PACU"
16506809|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.
~PCA with morphine in the PACU"
16506810|NCT03244527|Experimental|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
16506811|NCT03244527|Placebo Comparator|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
16506812|NCT03244514|Experimental|Intervention group|"Implementation of the cardiovascular surgery AKI bundle
~discontinuation of all nephrotoxic agents when possible
~optimization of volume status and hemodynamic parameters
~close monitoring of serum creatinine, fluid balance and urinary output
~avoidance of hyperglycemia
~considerations of alternatives to radiocontrast agents
~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period
~avoidance of HES, gelatin, and chlorid-rich solutions"
16506813|NCT03244514|No Intervention|Control group|The patients will receive standard of care (according to each center)
16506814|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
16506815|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
16506816|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
16506817|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
16506818|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
16506819|NCT03244475|Experimental|Neurofeedback|mTBI Veterans blindly assigned to a 6 week IASIS neurofeedback treatment with two sessions per week.
16506820|NCT03244475|Placebo Comparator|Sham Treatment|mTBI Veterans blindly assigned to a sham treatment for 6 weeks with two sessions per week.
16506821|NCT03244475|No Intervention|Control|Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.
16506822|NCT03244475|Experimental|Nexalin|After IASIS treatment is complete and participants in the mTBI group may have remaining PCS, additional Nexalin treatment will be offered.
16506823|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:
~single oral dose of BAY1834845
~single oral dose of BAY1834845 + i.v. BAY1834845
~single oral dose of BAY1834845 under fed conditions"
16506824|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:
~single oral dose of BAY1834845+ i.v. BAY1834845
~single oral dose of BAY1834845
~single oral dose of BAY1834845 under fed conditions"
16506825|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:
~single oral dose of methotrexate (MTX)
~single oral dose of MTX + single oral dose of BAY1834845"
16506826|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:
~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845
~single oral dose of MTX"
16506827|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
16506830|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
16506831|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.
~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
16506832|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
16506833|NCT03244384|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
16506834|NCT03244384|Active Comparator|Arm B (observation)|Patients undergo observation.
16506835|NCT03244371|Experimental|Co infected HIV and HCV patients|
16506836|NCT03244358|Experimental|Epalrestat|Epalrestat added to standard treatment
16506837|NCT03244345|Experimental|Epileptic patient|
16506838|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
16506839|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
16506840|NCT03244319|Experimental|Edoxaban|
16506841|NCT03244319|Active Comparator|Warfarin|
16506842|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
16506843|NCT03244280|Other|MOB015B|
16506844|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
16506845|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
16506846|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
16506847|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
16506848|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
16506849|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
16506850|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
16506851|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
16506852|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
16506853|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
16506854|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
16506855|NCT03244215|Experimental|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.
~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.
~No drugs will be administered to the patients for the purpose of our study."
16506856|NCT03244215|Other|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
16506857|NCT03244202|Experimental|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
16506858|NCT03244202|Active Comparator|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
16506893|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
16506894|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
16506895|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
16506859|NCT03244189|Experimental|Intervention|"Participants in the intervention arm will receive an individualized fluid prescription, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake."
16506860|NCT03244189|No Intervention|Control|"Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a smart water bottle with capability to self-monitor their fluid intake."
16506861|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
16506862|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
16506863|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
16506864|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
16506865|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
16506866|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
16506867|NCT03244124|Active Comparator|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
16506868|NCT03244124|Experimental|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
16506869|NCT03244124|Experimental|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
16506870|NCT03244124|Experimental|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch&Rinse Wet Application Strategy, leaving dentin wet
16506871|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
16506872|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
16506873|NCT03244098|Experimental|Transition Assistance Program (TAP)|
16506874|NCT03244098|No Intervention|Standard of Care|
16506875|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
16506876|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
16506877|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
16506878|NCT03244072|Active Comparator|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
16506879|NCT03244072|Placebo Comparator|Placebo group|Intracameral injection of placebo after cataract surgery
16506880|NCT03244059|Experimental|Belimumab|"Subjects randomized to the experimental treatment arm will receive i.v. administrations of belimumab (10 mg/kg), consisting of three loading doses, two weeks apart, followed by five (5) more monthly infusions. The final assessment will be performed at month 8."
16506881|NCT03244059|Placebo Comparator|Placebo|"These subjects will be treated with identically appearing placebo i.v. on the same schedule as the experimental arm subjects (i.e., three loading doses, two weeks apart, followed by five more monthly infusions. Again, the final assessment will be performed at month 7 (210+10 days after treatment start)."
16506882|NCT03244046|Active Comparator|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
16506883|NCT03244046|Experimental|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
16506884|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
16506885|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
16506886|NCT03244020|Experimental|LMWH for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
16506887|NCT03244020|Experimental|ASA for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to aspirin 325 mg po daily for VTE prophylaxis
16506888|NCT03244020|Experimental|LMWH for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
16506889|NCT03244020|Experimental|ASA for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to aspirin 325 mg po daily for VTE prophylaxis
16506890|NCT03244020|Experimental|LMWH for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
16506891|NCT03244020|Experimental|ASA for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to aspirin 325 mg po daily for VTE prophylaxis
16506896|NCT03243981|Experimental|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
16506897|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
16506898|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
16506899|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
16506900|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
16506901|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
16506902|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
16506903|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
16506904|NCT03243916|Experimental|combination|TACE plus cyber knife
16506905|NCT03243903|Experimental|needle-free insulin injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
16506906|NCT03243903|Active Comparator|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
16506907|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
16506908|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
16506909|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.
~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
16506910|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.
~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
16506911|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
16506912|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :
~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks
~Metformin :
~1st cycle (4 weeks)
~1 week(1st~7th day) = 1,000mg/day
~1 week(8th~14th day) = 1,500mg/day
~2 weeks(15th ~28th day) = 2,000mg/day
~2nd to 6th cycle (20 weeks) = 2,000mg/day"
16506913|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :
~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks
~Placebo:
~1st cycle (4 weeks)
~1 week(1st~7th day) = 1,000mg/day
~1 week(8th~14th day) = 1,500mg/day
~2 weeks(15th~28th day) = 2,000mg/day
~2nd to 6th cycle (20 weeks) = 2,000mg/day"
16506914|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
16506915|NCT03243825|Experimental|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
16506916|NCT03243825|Active Comparator|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
16506917|NCT03243812|Active Comparator|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :
~Blood sample
~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test
~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
16506918|NCT03243812|Active Comparator|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :
~Blood sample
~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test
~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
16506919|NCT03243812|Active Comparator|control group|"Healthy subjects. Each subject will undergo the following :
~Blood sample
~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test
~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
16506920|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.
~Group psychoeducation."
16506921|NCT03243799|No Intervention|Control Group|Usual clinical care
16506922|NCT03243786|Active Comparator|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
16506923|NCT03243786|Active Comparator|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
16506924|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506925|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506926|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506927|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
16506928|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506929|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506930|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506931|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506932|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
16506933|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
16506934|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
16506935|NCT03243734|Experimental|trūFreeze® System spray cryotherapy|trūFreeze® System spray cryotherapy as clinically indicated for symptom relief
16506936|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
16506937|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
16506938|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
16506939|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
16506940|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
16506941|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
16506942|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
16506943|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
16506944|NCT03243669|Active Comparator|Fujinon standard|
16506945|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
16506946|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
16506947|NCT03243669|Active Comparator|Olympus standard|
16506948|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
16506949|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
16506950|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
16506951|NCT03243669|Active Comparator|Pentax standard|
16506952|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
16506953|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
16506954|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
16506955|NCT03243656|No Intervention|control arm|standard immunosuppressive therapy (antilymphocyte globulin and cyclosporine),
16506956|NCT03243656|Active Comparator|case arm|standard immunosuppressive therapy plus an oral dose of Eltrombopag
16506957|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.
~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
16506958|NCT03243630|Placebo Comparator|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
16506959|NCT03243630|Active Comparator|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
16506960|NCT03243630|Active Comparator|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
16506961|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
16506962|NCT03243617|Placebo Comparator|Placebo|Placebo
16506964|NCT03243591|Active Comparator|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
16506965|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
16506966|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
16506967|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
16506968|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
16506969|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
16506970|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
16506971|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
16506972|NCT03243500|Sham Comparator|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml
~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
16506973|NCT03243500|Active Comparator|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml
~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
16506974|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).
~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
16506975|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
16506976|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
16506977|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
16506978|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
16506979|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
16506980|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
16506981|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
16506982|NCT03243461|Experimental|Temozolomide + Valproic acid|E.g. Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
16506983|NCT03243448||The general public|people between 20-85 years old, without sympathetic hyperactivity disease
16506984|NCT03243448||Sympathetic hyperactivity diseases|Sympathetic hyperactivity diseases included: hypertension, heart failure atherosclerotic diseases, arrhythmias, cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, sleep apnea, pulmonary embolism, hepatitis, liver cirrhosis, hepatopulmonary syndrome, hepatorenal syndrome, renal failure, nephritis, irritable bowel syndrome.
16506985|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
16506986|NCT03243422|Active Comparator|Successful aging education intervention|Individual sessions on healthy aging topics
16506987|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
16506988|NCT03243396|Experimental|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
16506989|NCT03243396|Experimental|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
16506990|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
16506991|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
16506992|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
16506993|NCT03243357|Experimental|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha&epoxy resin sealer.
16506994|NCT03243357|Other|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
16506995|NCT03243344|Experimental|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
16506996|NCT03243344|Experimental|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
16506997|NCT03243344|Experimental|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
16506998|NCT03243344|No Intervention|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
16506999|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
16507000|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
16507001|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
16507002|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
16507003|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
16507004|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
16507005|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
16507006|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
16507007|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
16507008|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
16507009|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
16507010|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
16507011|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
16507012|NCT03243201|Experimental|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
16507013|NCT03243201|Placebo Comparator|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
16507014|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
16507015|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
16507016|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
16507017|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
16507018|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
16507019|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
16507020|NCT03243149|Sham Comparator|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
16507021|NCT03243149|Active Comparator|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
16507022|NCT03243149|Experimental|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
16507023|NCT03243123|Experimental|Passive mobilization|Upper limb passive mobilization assisted with robotic device
16507024|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.
~Participants must be 1 to 85 years old."
16507025|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
16507026|NCT03243084|Sham Comparator|Sham tACS|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
16507027|NCT03243084|Active Comparator|Active 10 Hz tACS|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
16507028|NCT03243071|Experimental|Intervention Group|The intervention group (n=50) will have access to culturally tailored website.
16507029|NCT03243071|Active Comparator|Control Group|Participants in the control group (n=50) will have access to NYU 's standard trial participation website.
16507030|NCT03243058|Active Comparator|Treatment Arm|ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
16507031|NCT03243058|Experimental|Treatment-Placebo Arm|Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
16507032|NCT03243058|Placebo Comparator|Placebo|Participants in this group will receive a placebo injection for two years.
16507033|NCT03243032|Experimental|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
16507034|NCT03243032|Placebo Comparator|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
16507035|NCT03243019|Experimental|SIROLIMUS|
16507036|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
16507037|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
16507038|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
16507039|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:
~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
16507040|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
16507041|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
16507042|NCT03242967|Experimental|Vadadustat|Oral tablet
16507043|NCT03242967|Active Comparator|Darbepoetin alfa|subcutaneous or intravenous
16507044|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Autonomous minor consent
16507045|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
16507046|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Parental permission required
16507047|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Autonomous minor consent, adult permission required, and parental permission required
16507048|NCT03242941|Experimental|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
16507049|NCT03242928|Placebo Comparator|Placebo|Matching tablet of placebo taken orally BID
16507050|NCT03242928|Experimental|AFQ056|Mavoglurant was up titrated on a bid regimen followed by fixed-dose bid regimen: 50 mg bid from Day 1 to Day 7, 100 mg bid from Day 8 to Day 14, and then fixed-dose 200 mg bid for 84 days
16507051|NCT03242915|Experimental|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
16507052|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
16507053|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
16507088|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)
~Pemetrexed (500 mg/m2, day 1)
~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)
~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose
~Dexa 4mg po bid on D0-2"
16507054|NCT03242889|Experimental|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram [mg] with Recombinant Human Hyaluronidase [rHuPH20] 30,000 units [U] that is 2000 U/milliliter [U/mL]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 [Day 1]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
16507055|NCT03242876|Placebo Comparator|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
16507056|NCT03242876|Experimental|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
16507057|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
16507058|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
16507059|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
16507060|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
16507061|NCT03242850|Experimental|Intervention group|
16507062|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
16507063|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
16507064|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
16507065|NCT03242811|Experimental|Examination by MRI|MRI scan of knee, ankle and wrist
16507066|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
16507067|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
16507068|NCT03242772|Active Comparator|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
16507069|NCT03242772|Placebo Comparator|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
16507070|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
16507071|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.
~a 3-years follow-up for pregnancy outcome
~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
16507072|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.
~a 3-years follow-up for pregnancy outcome
~Transvaginal ultrasound for pretreatment cervical dimensions/volume
~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit
~Estimation of cone dimensions/volume
~Calculation of the proportion of volume/length excised"
16507073|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
16507074|NCT03242720|Active Comparator|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
16507075|NCT03242720|Sham Comparator|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
16507076|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
16507077|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
16507078|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
16507079|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
16507080|NCT03242681|Active Comparator|Simple Probing|Simple Probing
16507081|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
16507082|NCT03242655|Experimental|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
16507083|NCT03242655|No Intervention|Control|Individual onsite HCV treatment at a primary care center
16507086|NCT03242629|Active Comparator|oral group|
16507087|NCT03242629|Experimental|enema group|
16507090|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
16507091|NCT03242590|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
16507092|NCT03242564|Experimental|Active Device|"Active Device: Vevazz LED red light therapy system
~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
16507093|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
16507094|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
16507095|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
16507096|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
16507097|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
16507098|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
16507099|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
16507100|NCT03242499|Experimental|Active|Lovastatin 80mg per day for 48 weeks.
16507101|NCT03242499|Placebo Comparator|Placebo|Placebo 80mg per day for 48 weeks.
16507102|NCT03242486|Experimental|toric intraocular lens|toric intraocular lens is implanted to all subjects
16507103|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
16507104|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
16507105|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
16507106|NCT03242447|Experimental|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
16507107|NCT03242447|Active Comparator|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
16507108|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
16507109|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
16507110|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
16507111|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
16507112|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
16507113|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
16507114|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
16507115|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
16507116|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
16507117|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
16507118|NCT03242343|Experimental|VasQ device implantation|"Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints.
~Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints."
16507119|NCT03242330|Experimental|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
16507120|NCT03242330|Active Comparator|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
16507162|NCT03242018|Placebo Comparator|Placebo|Following a 2-week run-in phase, participants received two placebo tablets (identical to sotagliflozin 200 milligrams [mg] in appearance) orally once daily for up to 56 weeks.
16507121|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
16507122|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
16507123|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
16507124|NCT03242291|Active Comparator|conventional resin-based flowable composite|
16507125|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
16507126|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
16507127|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
16507128|NCT03242252|Placebo Comparator|Placebo|Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.
16507129|NCT03242252|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 58 weeks.
16507130|NCT03242252|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.
16507131|NCT03242239|Experimental|ALT02|
16507132|NCT03242239|Active Comparator|EU-licensed Herceptin|
16507133|NCT03242239|Active Comparator|US-licensed Herceptin|
16507134|NCT03242226|Experimental|two spectacles|
16507135|NCT03242226|Active Comparator|single vision spectacles|
16507136|NCT03242213|No Intervention|Usual Care|Standard of Care
16507137|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
16507138|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
16507139|NCT03242187|Experimental|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
16507140|NCT03242187|Active Comparator|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
16507141|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
16507142|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
16507143|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
16507144|NCT03242148|Experimental|Toffee Nasal Pillows Mask|Participants will be placed on this arm for a total of 14 +- 5 days from visit 2. participants will be using the Toffee mask during this treatment arm
16507145|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
16507146|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
16507147|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
16507148|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
16507149|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
16507150|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
16507151|NCT03242096|Experimental|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
16507152|NCT03242096|Active Comparator|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
16507153|NCT03242083||Primary atrophic AMD|
16507154|NCT03242083||Secondary atrophic AMD|
16507155|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
16507156|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
16507157|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age
~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion
~Randomize to either NIPPV or NI-NAVA, 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.
~ABG or CBG to be obtained at 4 hrs. post extubation
~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
16507158|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age
~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion
~Randomize to either NIPPV or NI-NAVA, 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~ABG or CBG to be obtained at 4 hrs. post extubation
~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
16507159|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
16507160|NCT03242031|Experimental|1 session|
16507161|NCT03242031|Active Comparator|4 sessions|
16507163|NCT03242018|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in phase, participants received two tablets, one sotagliflozin 200 mg tablet and one placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily for up to 56 weeks.
16507164|NCT03242018|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received sotagliflozin 400 mg, administered as 2 sotagliflozin 200 mg tablets, orally once daily for up to 56 weeks.
16507165|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
16507166|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
16507167|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
16507168|NCT03241979||laryngeal microsurgery|
16507169|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
16507170|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
16507171|NCT03241953|Experimental|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
16507172|NCT03241953|Active Comparator|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
16507173|NCT03241940|Experimental|Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and cyclophosphamide IV over 60 minutes on day -2. Patients then receive CD19/CD22-CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22-CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
16507174|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
16507175|NCT03241927|No Intervention|Healthy Donors|
16507176|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16507177|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16507178|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):
~tablet for 5-14kg;
~tablets for 15-24 kg;
~tables for 25 - 34kg and
~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.
~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
16507179|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.
~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
16507180|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16507181|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16507182|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16507183|NCT03241875|Placebo Comparator|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
16507184|NCT03241875|Experimental|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
16507185|NCT03241875|Experimental|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
16507186|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
16507187|NCT03241849|Other|Modified surgical technique for placenta accreta|
16507188|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
16507189|NCT03241810|Experimental|Arm A|"Seribantumab
~Fulvestrant"
16507190|NCT03241810|Active Comparator|Arm B|"Placebo
~Fulvestrant"
16507191|NCT03241797|Experimental|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
16507192|NCT03241784|Experimental|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
16507193|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
16507194|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
16507195|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
16507196|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
16507197|NCT03241732|Active Comparator|Dietary (AID) Cohort|Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
16507198|NCT03241732|Active Comparator|Intravenous/Oral NAC Cohort|N-acetyl Cysteine: This arm provide patients with a natural supplement, n-acetyl cysteine (NAC) which is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, that supports antioxidants to reduce oxidative damage in the body. NAC is a common over-the-counter supplement. It is used as an injectable pharmaceutical to protect the liver in cases of acetaminophen overdose. Laboratory studies have suggested that NAC might have a beneficial effect in neurodegenerative disorders such as TBI. Patients in this arm will receive IV NAC once a week plus oral NAC supplement 500 mg twice per day for approximately 3 months until the follow up evaluation.
16507199|NCT03241732|No Intervention|Control Cohort|Control Group: Standard of Care Treatment for at least 3 months. After the first 3 month, participants in this arm may crossover to the NAC study arm.
16507200|NCT03241719|Experimental|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
16507201|NCT03241706|Placebo Comparator|Controls-saline|Each subject from Group 1 will undergo a metabolic study where saline is infused so as to not stimulate liver glucose uptake and glycogen deposition.
16507202|NCT03241706|Active Comparator|Controls-high fructose|A second group of control subjects will undergo a single metabolic study using a higher dose of fructose (6.5 mg/kg/min).
16507203|NCT03241706|Active Comparator|Controls-low fructose|Each subject from Group 1 will undergo another metabolic study where fructose (1.3 mg/kg/min) is infused so as to stimulate liver glucose uptake and glycogen deposition.
16507204|NCT03241693|Other|control group|Physiotherapy students
16507205|NCT03241693|Experimental|experimental group|Physiotherapy students
16507206|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
16507207|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
16507208|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
16507209|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
16507210|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
16507211|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
16507212|NCT03241641|Experimental|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
16507213|NCT03241641|Active Comparator|Switching from TDF to TAF|"Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks
~Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
16507214|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.
~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
16507215|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
16507216|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
16507217|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
16507218|NCT03241602|Active Comparator|Group of pulmonary recruitment|
16507219|NCT03241602|No Intervention|group receive passive exsufflation through port|
16507220|NCT03241589|Experimental|Direct to Patient Facing Apps Use|VA sites who have received the direct to patient facing apps from OCC
16507221|NCT03241589|Experimental|Control Direct to Patient Facing apps|VA sites to eventually receive the direct to patient facing apps but at present have not
16507222|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
16507223|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
16507224|NCT03241563|Active Comparator|without triamcinolone|sodium Deoxycholate without triamcinolone
16507225|NCT03241563|Active Comparator|with triamcinolone|sodium Deoxycholate with triamcinolone
16507290|NCT03241173|Experimental|INCAGN01949 + Ipilimumab|INCAGN01949 combined with ipilimumab.
16507226|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
16507227|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
16507228|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
16507229|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
16507230|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
16507231|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
16507232|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
16507233|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
16507234|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
16507235|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
16507236|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
16507237|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
16507238|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
16507239|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
16507240|NCT03241472|Experimental|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
16507241|NCT03241472|Active Comparator|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
16507242|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
16507243|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|
16507244|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
16507245|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
16507246|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
16507247|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
16507248|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
16507249|NCT03241433|Active Comparator|No exercise|No excercise training will be done
16507250|NCT03241420||Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
16507251|NCT03241420||Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
16507288|NCT03241186|Experimental|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days
~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
16507289|NCT03241173|Experimental|INCAGN01949 + Nivolumab|INCAGN01949 combined with nivolumab.
16507252|NCT03241407|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
16507253|NCT03241407|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
16507254|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
16507255|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
16507256|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
16507257|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
16507258|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
16507259|NCT03241368|Other|MRE, Patency Capsule (if needed), CE, and IC|Single-arm study, which includes MRE procedure, Patency Capsule Procedure (if needed), PillCam Crohn's Capsule Endoscopy Procedure and Ileocolonoscopy procedure.
16507260|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
16507261|NCT03241355|Placebo Comparator|placebo maltodextrin|
16507262|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
16507263|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
16507264|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
16507265|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
16507266|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
16507267|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
16507268|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
16507269|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
16507270|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
16507271|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
16507272|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
16507273|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
16507274|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
16507275|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
16507276|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
16507277|NCT03241264|Experimental|Module A|Lyophilized Formulation
16507278|NCT03241264|Experimental|Module B|Frozen Formulation
16507279|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
16507280|NCT03241238|Other|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
16507281|NCT03241238|Other|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
16507282|NCT03241238|Other|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
16507283|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
16507284|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
16507285|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.
~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
16507286|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.
~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
16507287|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
16507291|NCT03241173|Experimental|INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab and ipilimumab.
16507292|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
16507293|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
16507294|NCT03241147|Experimental|Healthy subjects (Group B)|
16507295|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
16507296|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
16507297|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
16507298|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
16507299|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
16507300|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
16507301|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
16507302|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
16507303|NCT03241095|No Intervention|Control|
16507304|NCT03241095|Sham Comparator|Sham OMT|
16507305|NCT03241095|Active Comparator|OMT|
16507306|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.
~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
16507307|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
16507308|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
16507309|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
16507310|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
16507311|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
16507312|NCT03241043|Experimental|Envarsus - Advagraf|
16507313|NCT03241043|Active Comparator|Advagraf - Envarsus|
16507316|NCT03241017|Experimental|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
16507317|NCT03241004|Experimental|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.
~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
16507318|NCT03241004|Experimental|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.
~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
16507319|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
16507320|NCT03240978|Experimental|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart rate maximum for 12 weeks.
16507321|NCT03240978|Experimental|Moderate intensity intervention|Exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
16507322|NCT03240978|No Intervention|non-exercise group|Participants will not receive any type of exercise training.
16507323|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
16507324|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
16507325|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
16507326|NCT03240939|Active Comparator|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
16507327|NCT03240939|Experimental|YY-201|YY-201 capsule, singe dose
16507328|NCT03240926|Experimental|Loop Band|Measure accuracy of vital sign measurements
16507329|NCT03240913|Experimental|Treatment Group|
16507330|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
16507430|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
16507331|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
16507332|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
16507333|NCT03240887|Experimental|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
16507334|NCT03240887|No Intervention|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
16507335|NCT03240874|Experimental|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups
~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
16507336|NCT03240874|Experimental|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing
~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
16507337|NCT03240874|Experimental|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm
~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
16507338|NCT03240874|No Intervention|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm
~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
16507339|NCT03240861|Experimental|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.
~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.
~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
16507340|NCT03240848|Experimental|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
16507341|NCT03240848|Active Comparator|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
16507342|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
16507343|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
16507344|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
16507345|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
16507346|NCT03240796|Experimental|minimal invasive surgery and secondary IOL implantation|
16507347|NCT03240796|Active Comparator|traditional cataract surgery and secondary IOL implantation|
16507348|NCT03240783|Experimental|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
16507349|NCT03240783|Experimental|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
16507350|NCT03240783|Experimental|Arm 3|"Dexamethasone Oral Tablet:
~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
16507351|NCT03240783|Other|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
16507352|NCT03240770|No Intervention|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
16507353|NCT03240770|Experimental|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ Sham"
16507354|NCT03240770|Experimental|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ Sham"
16507355|NCT03240770|Experimental|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ HFV with the VPro5 device at 5 min/day"
16507356|NCT03240770|Experimental|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ HFV with the VPro5 device at 5 min/day"
16507357|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
16507358|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
16507359|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
16507360|NCT03240731|Experimental|bone marrow transplant|"All the included patient will receive an haploidentical bone marrow transplant with the following protocol concerning the conditioning and GvHD prevention
~Conditioning
~THYMOGLOBULINE : 0.5mg/kg at D-9 and 2 mg/kg at D-8 and D-7
~THIOTEPA: 10mg/kg/j at D-7
~CYCLOPHOSPHAMIDE (Endoxan®):14.5mg/kg/j at D-6 and D-5
~FLUDARABINE (Fludara®): 30mg/m2 per Day from D-6 to D-2
~TBI : 2GY : D -1 Graft : Injection at D0 of G-CSF-stimulated bone marrow transplant.
~Prophylaxis of GvHD
~CYCLOPHOSPHAMIDE (Endoxan®): 50mg/Kg per Day from D+3 to D+4
~Sirolimus and MycophénolateMofétil (MMP) from D+5. In the absence of acute GvHD (aGvHD), stop of MMP to D35 and pursuit of sirolimus 1 year after the graft."
16507361|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
16507362|NCT03240718|No Intervention|Control scar|Standard care
16507363|NCT03240705|Experimental|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
16507364|NCT03240705|No Intervention|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
16507366|NCT03240679|Active Comparator|EMR with Extracelluar Matrix|Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive Extracellular Matrix to the defect site
16507367|NCT03240679|No Intervention|EMR|assess baseline dysphagia (Mellow-Pinkas scale and Mayo Dysphagia Questionnaire). Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive standard of care.
16507368|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
16507369|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
16507370|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
16507371|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
16507372|NCT03240627|Experimental|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
16507373|NCT03240627|Placebo Comparator|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
16507374|NCT03240614|Active Comparator|BMI <30 no lung disease|Patients with a BMI <30 with no lung disease
16507375|NCT03240614|Active Comparator|BMI <30 with lung disease|Patients with a BMI <30 with lung disease
16507376|NCT03240614|Active Comparator|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
16507377|NCT03240614|Active Comparator|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
16507378|NCT03240614|Active Comparator|BMI >35 with no lung disease|Patients with a BMI> 35 with no lung disease
16507379|NCT03240614|Active Comparator|BMI >35 with lung disease|Patients with a BMI> 35 with lung disease
16507380|NCT03240601|Sham Comparator|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
16507381|NCT03240601|Experimental|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
16507382|NCT03240588|Active Comparator|De Novo Cohort|Study subjects who have not previously attempted a Neurostimulator trial will be followed up to 36 months post-Neurostimulation trial procedure or IPG Activation on the use of their Neurostimulation system.
16507383|NCT03240588|Active Comparator|Existing Cohort|Study subjects who have completed permanent neurostimulator IPG implant and are in various stages of follow-up will be followed up to 36 months post-Neurostimulation trial or IPG Activation procedure on the use of their Neurostimulation system.
16507384|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
16507385|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
16507386|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
16507387|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
16507388|NCT03240549|No Intervention|conventional therapy group|Treatment with previous regimen of combined chemotherapy
16507389|NCT03240549|Experimental|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
16507390|NCT03240536|Experimental|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
16507391|NCT03240536|No Intervention|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
16507392|NCT03240523|Experimental|Group A1: Vilaprisan (3/1 regimen)|Orally, 2 mg, once daily, 3 months treatment followed by 1 menstrual bleeding episode
16507393|NCT03240523|Experimental|Group A2: Vilaprisan (6/2 regimen)|Orally, 2 mg, once daily, 6 months treatment followed by 2 menstrual bleeding episodes
16507394|NCT03240523|Experimental|Group A3/B (3/2 regimen)|"Orally, 2 mg, once daily, 3 months treatment followed by 2 menstrual bleeding episodes
~With protocol version 5.0 the blinded study arms A3 and B were converted to one open-label study arm called A3/B."
16507395|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
16507396|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
16507397|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
16507398|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
16507399|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
16507400|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
16507401|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
16507402|NCT03240471|Experimental|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
16507403|NCT03240471|Other|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
16507404|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
16507405|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
16507406|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
16507407|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
16507408|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
16507409|NCT03240419|Experimental|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
16507410|NCT03240419|Placebo Comparator|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
16507411|NCT03240406|Active Comparator|Anti-inflammatory dietary intervention|18 month intervention of dietary counseling to adhere to the Multicultural Healthy Diet or the anti-inflammatory diet,
16507412|NCT03240406|Placebo Comparator|Usual Diet plus Self-Care|18 month intervention of usual diet plus self-care modules
16507413|NCT03240393|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
16507414|NCT03240393|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
16507415|NCT03240393|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
16507416|NCT03240380|Experimental|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
16507417|NCT03240380|Active Comparator|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
16507418|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
16507419|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
16507420|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
16507421|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
16507422|NCT03240341|Experimental|Patient Activation Measure (PAM)|completion of the PAM questionnaire
16507423|NCT03240328|Experimental|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
16507424|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
16507425|NCT03240302|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
16507426|NCT03240302|Active Comparator|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
16507427|NCT03240289|Other|Texting|Texting group
16507428|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
16507429|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
16507431|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
16507432|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
16507433|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
16507434|NCT03240237|Experimental|CCM therapy|Optimizer SMART
16507435|NCT03240224|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507436|NCT03240224|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507437|NCT03240224|Experimental|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507438|NCT03240224|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507439|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate|Subjects will receive pembrolizumab 200 mg IV day 1 with pralatrexate 30 mg/m2 IV day 1, 8, and 15.
16507440|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate plus Decitabine|Subjects will receive pembrolizumab 200 mg IV day 8 with pralatrexate 20 mg/m2 IV day 1, 8, and 15 and decitabine 10 mg/m2 from day 1 to 5.
16507441|NCT03240211|Experimental|Pembrolizumab plus Decitabine|Subjects will receive pembrolizumab 200 mg IV and decitabine 20 mg/m2 from day 1 to 5.
16507442|NCT03240198||COPD|
16507443|NCT03240198||Controls|
16507444|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
16507445|NCT03240159|Active Comparator|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.
~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.
~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
16507446|NCT03240159|Active Comparator|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.
~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.
~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
16507447|NCT03240159|Active Comparator|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.
~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.
~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
16507448|NCT03240146|Active Comparator|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
16507449|NCT03240146|Placebo Comparator|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
16507450|NCT03240133|Experimental|Part1: BCX7353 750 mg|
16507451|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
16507452|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
16507453|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
16507454|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
16507455|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
16507456|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
16507457|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
16507458|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
16507459|NCT03240081|Active Comparator|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
16507460|NCT03240081|Active Comparator|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
16507461|NCT03240068|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
16507462|NCT03240068|Placebo Comparator|Saline|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
16507667|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
16507463|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
16507464|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
16507465|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
16507466|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
16507467|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
16507468|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
16507469|NCT03240016|Experimental|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
16507470|NCT03240003|Experimental|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
16507471|NCT03240003|Active Comparator|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
16507472|NCT03240003|Experimental|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
16507473|NCT03239990|Experimental|Incredible Years, Parent support|Incredible Years, Parent group supported by home visiting includes the Incredible Years Parent Training Program, Preschool Basic version, with 18-20 group meetings. Four home visits are added to the program to support parents in practicing new skills and to provide individual practical consultation.
16507474|NCT03239990|No Intervention|Treatment as usual|The control group will receive treatment as usual
16507475|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
16507476|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
16507477|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.
~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
16507478|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.
~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
16507479|NCT03239951|Experimental|Device|Temporary implant (iTind)
16507480|NCT03239938|Experimental|Modern pain neuroscience approach|Modern pain neuroscience approach
16507481|NCT03239938|Active Comparator|Usual care evidence-based physiotherapy|Usual care physiotherapy
16507482|NCT03239925|Experimental|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
16507483|NCT03239925|Placebo Comparator|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
16507484|NCT03239912|Experimental|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
16507485|NCT03239912|Experimental|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
16507486|NCT03239899|Experimental|Pembrolizumab arm|Pembrolizumab 200mg will be administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
16507487|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
16507488|NCT03239873|Experimental|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
16507489|NCT03239873|Active Comparator|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
16507490|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
16507491|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
16507492|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
16507493|NCT03239847|Experimental|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
16507494|NCT03239847|Experimental|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
16507495|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
16507496|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
16507497|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
16507498|NCT03239821|Sham Comparator|Placebo - deflated balloon|
16507499|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
16507500|NCT03239821|Active Comparator|Codeine - delfated balloon|
16507501|NCT03239821|Active Comparator|Codeine - inflated balloon|
16507502|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
16507503|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
16507504|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
16507505|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
16507506|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.
~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.
~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
16507507|NCT03239769|Active Comparator|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
16507508|NCT03239769|Experimental|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
16507509|NCT03239769|Experimental|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
16507510|NCT03239756|Experimental|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
16507511|NCT03239756|Experimental|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
16507512|NCT03239756|Experimental|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
16507513|NCT03239756|Experimental|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
16507514|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
16507515|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
16507516|NCT03239717|Placebo Comparator|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
16507517|NCT03239717|Experimental|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
16507518|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
16507519|NCT03239704|Active Comparator|Minimal Intervention|
16507520|NCT03239691|Experimental|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
16507521|NCT03239691|Placebo Comparator|Placebo|Placebo will be administered on two study days
16507522|NCT03239678|Active Comparator|group A|100% Oxygen
16507523|NCT03239678|Experimental|group B|30% Oxygen.
16507524|NCT03239678|Experimental|group C|21% Oxygen
16507525|NCT03239678|Experimental|group D|40% Oxygen
16507526|NCT03239678|Experimental|group E|60% Oxygen
16507527|NCT03239678|Experimental|group F|80% Oxygen
16507528|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
16507567|NCT03239366|Active Comparator|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
16507568|NCT03239366|Placebo Comparator|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
16507569|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
16507570|NCT03239353|Active Comparator|3 mg ETV XR tablet|
16507529|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
16507530|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
16507531|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
16507532|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
16507533|NCT03239626|Experimental|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
16507534|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
16507535|NCT03239600|Experimental|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
16507536|NCT03239600|Placebo Comparator|Part II: Placebo|Placebo will be administered IV with MTX
16507537|NCT03239587||No Musical Intervention - Control Group|"Participants wait for 30 minutes in a standard pre-surgery waiting area without music.
~Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.
~Participants complete 2 questionnaires about anxiety and stress levels."
16507538|NCT03239587||Musical Intervention Group|"Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
~Blood drawn before, and about 30 minutes after participant in the waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
~Participants complete 2 questionnaires about anxiety and stress levels."
16507539|NCT03239574|Experimental|MightySat Test group|The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter.
16507540|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
16507541|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
16507542|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
16507543|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
16507544|NCT03239535|Experimental|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
16507545|NCT03239535|Placebo Comparator|Normal saline|Normal saline, Intramuscular injection
16507546|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
16507547|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
16507548|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
16507549|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
16507550|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
16507551|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
16507552|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
16507555|NCT03239470|Experimental|Cohort 1: 1.0 x 10^8 PolyTregs|A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.
16507556|NCT03239470|Experimental|Cohort 2: 2.5x10^8 PolyTregs|A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.
16507557|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
16507558|NCT03239444|Other|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
16507559|NCT03239431||Asthma group|Patients with asthma
16507560|NCT03239418|Experimental|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
16507561|NCT03239418|Sham Comparator|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
16507562|NCT03239405||SCS|Treated via suction callibrated system
16507563|NCT03239405||Bougie|Treated with multiple tubes & bougie
16507564|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
16507565|NCT03239379|Placebo Comparator|Placebo|Normal saline
16507566|NCT03239379|Experimental|BNZ132-1-40|PEGylated BNZ-1 for Injection
16507571|NCT03239353|Active Comparator|6 mg ETV XR tablet|
16507572|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
16507575|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
16507576|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
16507577|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
16507578|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
16507579|NCT03239301|Active Comparator|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
16507580|NCT03239301|Active Comparator|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
16507581|NCT03239288|Placebo Comparator|Control digestible carbohydrate|Control baked breakfast bar
16507582|NCT03239288|Experimental|Test resistant starch type 4|Test baked breakfast bar
16507583|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.
~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
16507584|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
16507585|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
16507586|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
16507587|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
16507588|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
16507589|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
16507590|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
16507591|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
16507592|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.
~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
16507593|NCT03239223|Experimental|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
16507594|NCT03239223|Experimental|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
16507595|NCT03239210|Active Comparator|Ondansetron (OND)|24 mg/day for 4 weeks
16507596|NCT03239210|Placebo Comparator|Placebo (PL)|Placebo pill
16507597|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
16507598|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507599|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507668|NCT03238742|Experimental|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
16507600|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507601|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507602|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507603|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507604|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507605|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507606|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507607|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507608|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
16507609|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16507610|NCT03239145|Experimental|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
16507611|NCT03239145|Experimental|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
16507612|NCT03239145|Experimental|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
16507613|NCT03239145|Experimental|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
16507614|NCT03239145|Experimental|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
16507615|NCT03239132|Experimental|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
16507616|NCT03239132|Active Comparator|Control|The control will receive meditation educational materials.
16507617|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
16507618|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
16507619|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
16507620|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
16507621|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
16507622|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
16507623|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
16507624|NCT03239067||ticagrelor group|patients prescribed with ticagrelor
16507625|NCT03239067||clopidogrel group|patients prescribed with clopidogrel
16507626|NCT03239054|Experimental|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
16507627|NCT03239054|Other|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
16507628|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.
~The social navigation team will function as follows:
~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
16507629|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
16507630|NCT03239028||Danish National Birth Cohort|
16507669|NCT03238742|Placebo Comparator|Placebo group|normal saline 200 mL every 12 hours for 5 days
16507670|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
16507631|NCT03239015|Experimental|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib.
16507632|NCT03238976|Experimental|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.
~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.
~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
16507633|NCT03238976|No Intervention|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.
~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
16507634|NCT03238963|Experimental|BI 1467335|
16507635|NCT03238963|Placebo Comparator|Placebo|
16507636|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
16507637|NCT03238950|Other|Synthetic|Training conducted on synthetic model
16507638|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
16507639|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
16507640|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
16507641|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
16507642|NCT03238911|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
16507643|NCT03238911|Active Comparator|Ferric carboxymaltose|Administered IV
16507644|NCT03238898|Active Comparator|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
16507645|NCT03238898|Placebo Comparator|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
16507646|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
16507647|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
16507648|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
16507649|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
16507650|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
16507651|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
16507652|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
16507653|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
16507654|NCT03238833|Experimental|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
16507655|NCT03238833|Active Comparator|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
16507656|NCT03238820|Experimental|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
16507657|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
16507658|NCT03238807|No Intervention|Control Group|Control Group
16507659|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
16507660|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
16507661|NCT03238781|Placebo Comparator|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
16507662|NCT03238781|Experimental|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
16507663|NCT03238781|Experimental|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
16507664|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
16507665|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
16507666|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
16507671|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
16507672|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
16507673|NCT03238716|Active Comparator|NM Re-ed and Exercise|
16507674|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
16507675|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
16507676|NCT03238677|Experimental|Biofeedback, Massed->Distributed|Sequenced biofeedback Mass Practice--> Distributed Scheduling
16507677|NCT03238677|Active Comparator|No Biofeedback, Distributed|Speech Motor Chaining with no biofeedback. 2 sessions/wk for 10 weeks
16507678|NCT03238677|Experimental|Biofeedback, Distributed|Sequenced biofeedback, 2 sessions/wk for 10 weeks
16507679|NCT03238677|Experimental|No Biofeedback, Massed-> Distributed|Speech Motor Chaining with no biofeedback. Mass Practice--> Distributed Scheduling
16507680|NCT03238664|Experimental|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
16507681|NCT03238664|Active Comparator|Arm B (RARC)|Patients undergo standard of care RARC.
16507682|NCT03238651|Experimental|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
16507683|NCT03238651|Experimental|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
16507684|NCT03238651|Experimental|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
16507685|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.
~Cohort 1: Acquired Resistance Cohort
~Treat upon emergence of acquire resistance
~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease
~Progressive disease on recent scans
~Intercurrent therapy is allowed
~Cohort 2: Suboptimal Benefit Cohort
~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance
~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)
~Ongoing stable disease on recent scans
~Both cohorts will receive pembrolizumab and epacadostat."
16507686|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.
~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
16507687|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.
~Intervention: Every individual receives two injections:
~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
16507688|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
16507689|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
16507690|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
16507691|NCT03238586|Experimental|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
16507692|NCT03238586|No Intervention|Standard of Care|Five-week standard of care program.
16507693|NCT03238573||optical enhancment endoscopy|
16507694|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
16507723|NCT03238352|Experimental|Test Product|Participants will rinse twice daily (morning and evening) with 10 milliliters (mL) of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
16507724|NCT03238352|Other|Negative Control|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
16507796|NCT03237910|Experimental|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
16507695|NCT03238534|Active Comparator|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole [30' before meal] and Neobianacid® placebo [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.
~Treatment regimen:
~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo Lunch: Neobianacid® placebo Midafternoon: Neobianacid® placebo Dinner: Neobianacid® placebo Before going to bed: Neobianacid® placebo
~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo (both on demand) Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed
~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
16507696|NCT03238534|Experimental|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo [30' before meal] and Neobianacid® [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.
~Treatment regimen:
~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®
~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® (both on demand) Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed
~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
16507697|NCT03238521|Active Comparator|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
16507698|NCT03238521|Experimental|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
16507699|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
16507700|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
16507701|NCT03238495|Active Comparator|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
16507702|NCT03238495|Experimental|Chemotherapy plus Metformin|TCH+P plus metformin
16507703|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
16507704|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
16507705|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
16507706|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
16507707|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
16507708|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
16507709|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
16507710|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
16507711|NCT03238430|Experimental|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
16507712|NCT03238430|Experimental|intrathecal morphine|Rachianalgesia + PCA morphine
16507713|NCT03238430|Active Comparator|morphine PCA|PCA morphine alone
16507714|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
16507715|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
16507716|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
16507717|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
16507718|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
16507719|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
16507720|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
16507721|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
16507722|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
16507725|NCT03238352|Placebo Comparator|Placebo|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
16507726|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
16507727|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
16507729|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
16507730|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
16507731|NCT03238300|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg capsules by mouth, two pills twice daily for 10 days.
16507732|NCT03238300|Placebo Comparator|Placebo Oral Capsule|Placebo capsules by mouth, two pills twice daily for 10 days.
16507733|NCT03238287|Active Comparator|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
16507734|NCT03238287|Active Comparator|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
16507735|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
16507736|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
16507737|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
16507738|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
16507739|NCT03238261|Active Comparator|Radiotherapy|
16507740|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.
~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
16507741|NCT03238235|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
16507742|NCT03238235|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
16507743|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
16507744|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
16507745|NCT03238209|Experimental|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
16507746|NCT03238196|Experimental|Escalation|"Fulvestrant - injection into muscle 1 time per month
~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)
~Erdafitinib tablet taken by mouth 1 time per day"
16507747|NCT03238196|Experimental|Expansion|"Fulvestrant - injection into muscle 1 time per month
~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)
~Erdafitinib tablet taken by mouth 1 time per day"
16507748|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
16507749|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
16507750|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
16507751|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
16507752|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
16507753|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
16507754|NCT03238131|Active Comparator|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
16507755|NCT03238131|Experimental|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
16507756|NCT03238131|Active Comparator|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
16507757|NCT03238131|Active Comparator|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
16507758|NCT03238118|Experimental|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
16507759|NCT03238118|Placebo Comparator|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
16507760|NCT03238118|Placebo Comparator|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
16507761|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
16507762|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
16507763|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
16507764|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
16507765|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
16507766|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.
~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
16507767|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.
~If HDR BT is chosen:
~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT
~If PDR BT is chosen:
~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
16507768|NCT03238053|Active Comparator|Menopausal Laser|20 women with vaginal laser treatment
16507769|NCT03238053|Sham Comparator|Menopausal sham|20 women with probe, no active laser ray
16507770|NCT03238053|Active Comparator|breast cancer laser|20 women with breast cancer with vaginal laser treatment
16507771|NCT03238053|Sham Comparator|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
16507772|NCT03238053|Active Comparator|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
16507773|NCT03238053|Sham Comparator|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
16507774|NCT03238053|Active Comparator|overactive bladder laser|20 women with overactive bladder with vaginal laser treatment
16507775|NCT03238053|Sham Comparator|Overactive bladder sham|20 women with overactive bladder with vaginal probe, no active laser rays
16507776|NCT03238027|Experimental|Ph1a D1: 1 mg/kg SNDX-6352|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
16507777|NCT03238027|Experimental|Ph1a D2: 3 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
16507778|NCT03238027|Experimental|Ph1a D3: 6 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
16507779|NCT03238027|Experimental|Ph1a D4: 10 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 10 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
16507780|NCT03238027|Experimental|Ph1b D1: 1 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg SNDX-6352 dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
16507781|NCT03238027|Experimental|Ph1b D2: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
16507782|NCT03238027|Experimental|Ph1b D3: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
16507783|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
16507784|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
16507785|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
16507786|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
16507787|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
16507788|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
16507789|NCT03237975|Experimental|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
16507790|NCT03237975|Active Comparator|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
16507791|NCT03237962|Experimental|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
16507792|NCT03237962|Experimental|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
16507793|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
16507794|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
16507795|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
16507797|NCT03237910|Active Comparator|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
16507798|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
16507799|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
16507800|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
16507803|NCT03237845|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
16507804|NCT03237845|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
16507805|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
16507806|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
16507807|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
16507808|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
16507809|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
16507812|NCT03237806|No Intervention|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
16507813|NCT03237806|Experimental|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
16507814|NCT03237806|Experimental|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
16507815|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
16507816|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
16507819|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
16507820|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
16507821|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
16507822|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
16507823|NCT03237741|Experimental|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
16507824|NCT03237741|Experimental|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
16507857|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
16507858|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
16507859|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
16507825|NCT03237741|Experimental|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
16507826|NCT03237741|Experimental|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
16507827|NCT03237728|Experimental|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
16507828|NCT03237728|Experimental|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
16507829|NCT03237728|Experimental|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
16507830|NCT03237728|Experimental|Placebos|Group D:Placebos,Q8h,Day1-Day7
16507831|NCT03237715||Breast fed cohort|
16507832|NCT03237715||Formula fed cohort|
16507833|NCT03237702|Experimental|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
16507834|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
16507835|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
16507836|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
16507837|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
16507838|NCT03237663|Experimental|One enteric capsule|
16507839|NCT03237663|Experimental|Two enteric capsule|
16507840|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
16507841|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
16507842|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
16507843|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
16507844|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
16507845|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
16507846|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
16507847|NCT03237585|Experimental|i) Intervention arm- Receive Gender Centre's RRS package|
16507848|NCT03237585|No Intervention|No intervention|
16507849|NCT03237572|Experimental|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
16507850|NCT03237572|Experimental|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
16507851|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
16507852|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
16507853|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
16507854|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
16507855|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
16507856|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
16507860|NCT03237494||Participants at risk for hATTR and participants diagnosed with hATTR|Participants 18 years of age or older
16507864|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
16507865|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
16507866|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
16507867|NCT03237442|Experimental|group 1|
16507868|NCT03237442|Active Comparator|group 2|
16507869|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
16507870|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
16507871|NCT03237416|Experimental|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
16507872|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16507873|NCT03237377|Experimental|Durvalumab with Radiation|
16507874|NCT03237377|Experimental|Durvalumab and Trememlimumab with Radiation|
16507875|NCT03237351|Active Comparator|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
16507876|NCT03237351|Experimental|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV < 5%) .
16507877|NCT03237351|Experimental|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV < 8%) .
16507878|NCT03237338|Experimental|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
16507879|NCT03237338|Sham Comparator|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
16507880|NCT03237325|Experimental|SGX942|Patients are randomized 1:1 active/placebo.
16507881|NCT03237325|Placebo Comparator|Placebo|Patients are randomized 1:1 active/placebo.
16507882|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
16507883|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
16507884|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
16507885|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
16507886|NCT03237286|Experimental|Ketamine + Cognitive Training|
16507887|NCT03237286|Sham Comparator|Ketamine + Sham Training|
16507888|NCT03237286|Placebo Comparator|Saline + Cognitive Training|
16507889|NCT03237273|Experimental|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
16507890|NCT03237260|Experimental|Vedolizumab 300mg|vedolizumab open label
16507891|NCT03237247||Benign|cases with benign biliary stricture
16507892|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
16507893|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
16507894|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
16507895|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
16507896|NCT03237234|Sham Comparator|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
16507897|NCT03237234|Experimental|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
16507898|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
16507899|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
16507900|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
16507901|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
16507902|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
16507903|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
16507904|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
16507905|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
16507906|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
16507966|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
16507907|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
16507908|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
16507909|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
16507910|NCT03237117|Experimental|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
16507911|NCT03237117|Active Comparator|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
16507912|NCT03237117|No Intervention|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
16507913|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
16507914|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
16507915|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
16507916|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
16507917|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
16507918|NCT03237091|Active Comparator|sham-control|
16507919|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
16507920|NCT03237065|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
16507921|NCT03237065|Active Comparator|Ferric carboxymaltose|Administered IV
16507922|NCT03237052|Experimental|model|model aided decision
16507923|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
16507924|NCT03237039|Other|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
16507925|NCT03237026||Cohort A|Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.
16507926|NCT03237026||Cohort B|Validation cohort will be recruited in the next 24 months of the study period .
16507927|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
16507928|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
16507929|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
16507930|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.
~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
16507931|NCT03236987|Active Comparator|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :
~Rifampicin (10mg/kg once daily)
~Ethambutol (15 to 20 mg/kg once daily)
~Clarithromycin (500 mg twice daily)"
16507932|NCT03236987|Experimental|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :
~Rifampicin (10mg/kg once daily)
~Ethambutol (15 to 20 mg/kg once daily)
~Azithromycin (250 mg once daily)"
16507933|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
16507934|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
16507967|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
16507968|NCT03236675||EML4-ALK|ALK positive patients
16507935|NCT03236961|Active Comparator|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
16507936|NCT03236961|Active Comparator|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
16507937|NCT03236948|Experimental|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
16507938|NCT03236948|No Intervention|Control|
16507939|NCT03236935|Experimental|L-NMMA Plus Pembrolizumab|L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1-5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 20 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
16507940|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
16507941|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
16507942|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
16507943|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
16507944|NCT03236883|Experimental|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)*10^8/kg
16507945|NCT03236883|Other|Gemcitabine|
16507946|NCT03236883|Other|GPBSC|
16507947|NCT03236870||Participants with moderate to severe plaque psoriasis in China|Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.
16507948|NCT03236857|Experimental|Venetoclax with or without chemotherapy|Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
16507949|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
16507950|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
16507951|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
16507952|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
16507953|NCT03236805|Experimental|Ketamine IV|
16507954|NCT03236805|Active Comparator|Morphine IV|
16507955|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
16507956|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
16507957|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
16507958|NCT03236766|Other|No intervention|
16507959|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
16507960|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
16507961|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
16507962|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
16507963|NCT03236727|No Intervention|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
16507964|NCT03236727|Active Comparator|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
16507970|NCT03236662|Experimental|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
16507971|NCT03236649|Experimental|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
16507972|NCT03236649|Active Comparator|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
16507973|NCT03236636|Experimental|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
16507974|NCT03236636|Active Comparator|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
16507975|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
16507976|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
16507977|NCT03236610|Experimental|tenofovir|
16507978|NCT03236610|Active Comparator|tenofovir plus entecavir|
16507979|NCT03236597|No Intervention|Usual Desk|participants will work at their usual desk for four weeks.
16507980|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
16507981|NCT03236584|Active Comparator|lamivudine adefovir|
16507982|NCT03236584|Experimental|tenofovir|
16507983|NCT03236571|Experimental|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
16507984|NCT03236558|Experimental|Patients with diabetes|T1D patients with blood collection
16507985|NCT03236545|Experimental|No to Low Endogenous Estrogen|PMW and young women (YW) will receive medical study clearance after a detailed physical examination. YW will self-administer subcutaneous injections of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix acetate (Antagon, 0.25 mg/day in 0.5 ml of normal saline, Organon, Inc., West Orange, New Jersey,) daily to suppress endogenous ovarian hormone production (16, 17, 18). This will begin following a separate medical screening at Reproductive Associates of Delaware 48 hours prior to initiating the hormone intervention to rule out other contraindications prior to beginning the treatment. YW will begin using the antagonist on days 26-28 of their menstrual cycle, and continue daily for 10-12 days. The experimental protocol will be conducted in YW after 3-4 days of using the GnRH antagonist. PMW will complete the experimental protocol prior to use of the 17β-estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch).
16507986|NCT03236545|Experimental|Estrogen Add-Back|Estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch) will be administered for 7 days to both young and PMW. Young women will use the E2 over the last 7 days of Antagon administration.
16507987|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
16507988|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
16507989|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
16507990|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
16507991|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
16507992|NCT03236493|Experimental|PF-06700841|Multiple ascending doses of PF-06700841
16507993|NCT03236493|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
16507994|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
16507995|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
16507996|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
16507997|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
16507998|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
16507999|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
16508000|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
16508001|NCT03236428|Experimental|Daratumumab|Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20
16508002|NCT03236415|Active Comparator|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
16508003|NCT03236415|Active Comparator|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
16508004|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
16508005|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
16508006|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
16508007|NCT03236402||>65 years|Adults who were in the age group of >65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of >65 years.
16508008|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
16508009|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
16508010|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
16508011|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
16508012|NCT03236363|No Intervention|Control|No intervention
16508013|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
16508014|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
16508015|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
16508016|NCT03236337|No Intervention|Control|No intervention
16508017|NCT03236337|Experimental|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
16508018|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
16508019|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
16508020|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks.
16508021|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
16508022|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
16508023|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
16508024|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
16508025|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
16508026|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
16508027|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
16508028|NCT03236272||case group|patients with ARDS
16508029|NCT03236272||control group|patients Without ARDS
16508030|NCT03236259|Active Comparator|Brainport high dose|
16508031|NCT03236259|Active Comparator|Brainport low dose|
16508032|NCT03236259|Placebo Comparator|Placebo|Maltodextrin
16508033|NCT03236246|Experimental|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
16508034|NCT03236246|Experimental|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
16508035|NCT03236233|Experimental|Single dose - healthy subjects|
16508036|NCT03236233|Experimental|Repeat dose - healthy subjects|
16508037|NCT03236233|Experimental|Single dose - subjects with asthma|
16508038|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
16508039|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
16508040|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
16508041|NCT03236181|Other|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
16508042|NCT03236181|Other|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
16508043|NCT03236181|Other|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
16508044|NCT03236181|Other|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
16508045|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
16508046|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
16508047|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
16508048|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
16508049|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
16508050|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
16508051|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
16508052|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
16508053|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
16508054|NCT03236103|Other|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
16508055|NCT03236090|Active Comparator|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
16508056|NCT03236090|Active Comparator|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
16508059|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
16508060|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
16508061|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
16508062|NCT03236025|Experimental|Experimental group|Video+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group.
16508063|NCT03236025|Active Comparator|Conditional control group|Text-message+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. Text-message contains the same content with videos and will be sent in the same frequency with the videos through the smart phone to the participants in the Conditional control group.
16508064|NCT03236025|Placebo Comparator|Placebo control group|Participants in the control group will be given a one-sentence smoking cessation advice during the baseline assessment. A leaflet showed the information related to the smoking cessation will be allocated to them at the same time.
16508065|NCT03236012|Experimental|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.
~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
16508066|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
16508067|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
16508068|NCT03235986|Experimental|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
16508069|NCT03235986|Other|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
16508070|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
16508071|NCT03235947|Experimental|Fosfomycin disodium|"Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.
~Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
16508072|NCT03235947|Active Comparator|Trimethoprim / Sulfamethoxazole|"Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.
~Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
16508073|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
16508074|NCT03235921|Other|control group|no drug given to the patients in control group
16508075|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
16508076|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.
~Followed by one day face to face CME activity"
16508077|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
16508078|NCT03235895|No Intervention|Wait listed|No CME activity will be given
16508079|NCT03235882||observational group|"Infants born 24-32 weeks.
~Inclusion criteria:
~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:
~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or
~a nasogastric tube inserted as part of routine management of preterm infants.
~Written informed consent has been obtained"
16508080|NCT03235869|Experimental|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
16508081|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
16508082|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
16508083|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
16508084|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
16508085|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
16508086|NCT03235817|Experimental|Spontaneous ventilation|
16508087|NCT03235817|Experimental|Pressure support ventilation|
16508088|NCT03235817|Active Comparator|Pressure control ventilation|
16508089|NCT03235804|No Intervention|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat).
16508090|NCT03235804|Experimental|High-Protein Group|Those assigned to the High-Protein group will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
16508091|NCT03235778|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
16508092|NCT03235778|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
16508093|NCT03235778|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
16508094|NCT03235778|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
16508095|NCT03235778|Experimental|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
16508096|NCT03235778|Experimental|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
16508097|NCT03235778|Experimental|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
16508098|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
16508099|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
16508100|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
16508101|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
16508102|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
16508103|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
16508104|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
16508105|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
16508106|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
16508107|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
16508108|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
16508109|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
16508110|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
16508111|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
16508112|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
16508113|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
16508114|NCT03235700|Experimental|Adenosine followed by nicorandil|
16508115|NCT03235700|Experimental|Nicorandil followed by adenosine|
16508116|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
16508117|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
16508118|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
16508119|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
16508120|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
16508121|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
16508122|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
16508123|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
16508124|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
16508125|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
16508126|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
16508127|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
16508128|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
16508129|NCT03235583|Other|MotionPod Validation|Medical device validation
16508130|NCT03235570|Experimental|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
16508131|NCT03235544|Experimental|Cohort 1- Parsaclisib|Participants who have previously received ibrutinib.
16508132|NCT03235544|Experimental|Cohort 2 - Parsaclisib|Participants who have not previously received a BTK inhibitor.
16508133|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.
~CIWA Score 9-14: 1 mg IV push lorazepam
~CIWA Score >15: 2 mg IV push lorazepam
~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.
~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
16508134|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool
~CIWA Score 9-14: 1 mg IV push lorazepam
~CIWA Score >15: 2 mg IV push lorazepam
~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
16508548|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
16508135|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
16508136|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
16508137|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
16508138|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
16508139|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
16508140|NCT03235505|Experimental|Nicotine containing e-cigarettes|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
16508141|NCT03235505|Active Comparator|Nicotine-free e-cigarettes|Nicotine-free e-cigarettes + varenicline tartrate+ MI
16508142|NCT03235505|Placebo Comparator|Motivational Interview (MI)|Placebo-varenicline + nicotine -free e-cigarettes + MI
16508143|NCT03235492|Experimental|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
16508144|NCT03235479|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
16508145|NCT03235479|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
16508146|NCT03235466|Active Comparator|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
16508147|NCT03235466|Active Comparator|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
16508148|NCT03235466|Active Comparator|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
16508149|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
16508150|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
16508175|NCT03235284|Experimental|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
16508549|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
16508151|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
16508152|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
16508153|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
16508154|NCT03235414|Experimental|Normals|Will receive an MRI and a blood draw
16508155|NCT03235401||Pulmonary Arterial Hypertension patients|
16508156|NCT03235388|Experimental|Intervention|Audit filter implementation in hospital
16508157|NCT03235388|No Intervention|Control|Routine care
16508158|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
16508159|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
16508160|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
16508161|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
16508162|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
16508163|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
16508164|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
16508165|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.
~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
16508166|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
16508167|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
16508168|NCT03235349|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
16508169|NCT03235323|Experimental|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
16508170|NCT03235323|No Intervention|Control group|Patients of Control group received routine medicine treatment postoperatively
16508171|NCT03235297||Healthy subjects|Healthy subjects
16508172|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
16508173|NCT03235284|Active Comparator|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
16508174|NCT03235284|Active Comparator|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.
~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
16508230|NCT03234920|Experimental|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
16508176|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
16508177|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
16508178|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
16508179|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
16508180|NCT03235245|Active Comparator|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
16508181|NCT03235245|Experimental|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
16508182|NCT03235232|Experimental|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
16508183|NCT03235232|Active Comparator|Combigan®|1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
16508184|NCT03235219|Experimental|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
16508185|NCT03235219|Experimental|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
16508186|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
16508187|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
16508188|NCT03235180|Experimental|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.
~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
16508189|NCT03235167|Experimental|CpG DNA|CpG DNA concentrate
16508190|NCT03235167|Placebo Comparator|placebo|placebo concentrate
16508191|NCT03235154|Other|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
16508192|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
16508193|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
16508194|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
16508195|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
16508196|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
16508197|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
16508198|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
16508199|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
16508200|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
16508201|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
16508202|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
16508231|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase.
16508203|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
16508204|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
16508205|NCT03235089|Active Comparator|Test lens|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
16508206|NCT03235089|Active Comparator|nelfilcon A lens (control)|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
16508207|NCT03235076|Experimental|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
16508208|NCT03235076|Experimental|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
16508209|NCT03235076|Experimental|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
16508210|NCT03235076|Experimental|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
16508211|NCT03235050|Experimental|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
16508212|NCT03235050|Experimental|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
16508213|NCT03235050|Experimental|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
16508214|NCT03235050|Placebo Comparator|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
16508215|NCT03235050|Active Comparator|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
16508216|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
16508217|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle
~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
16508218|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle
~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
16508219|NCT03234998|Experimental|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
16508220|NCT03234998|Active Comparator|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
16508221|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
16508222|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
16508223|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death [each cycle is 28 days]), if recommended by the site investigator.
16508224|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
16508225|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
16508226|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
16508227|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
16508228|NCT03234933|Experimental|Mobility Tracker|"Each patient will be provided by the research team staff with a new mobility tracker
~The standard pre-operative assessment, surgical procedure and post-operative care will still be done
~Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
16508229|NCT03234920|Placebo Comparator|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
16508232|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV, infusion, at Weeks 0, 2, and 6 in the induction phase.
16508233|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q8W + Placebo Q8W|Vedolizumab 300 mg, IV, infusion, every 8 Weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching IV, infusion Q8W at Weeks 18, 26, 34, 42, 50 and 58 in the maintenance phase in participants who receive vedolizumab in the induction phase and achieve clinical response at Week 10.
16508234|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q4W|Vedolizumab 300 mg, IV, infusion, every 4 weeks (Q4W), from Week 14 to Week 58 in the maintenance phase in participants who receive vedolizumab or placebo in the induction phase and do not achieve clinical response at Week 10.
16508235|NCT03234907|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching IV, infusion, every 4 weeks, Week 14 to Week 58 in the maintenance phase in participants who receive placebo in the induction phase and achieve clinical response at Week 10.
16508236|NCT03234894|Other|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.
~There is a secondary metric as to patient reported pain on a 1-10scale."
16508237|NCT03234881|Active Comparator|MOVE! (virtual)|Weight management delivered as Treatment-as-Usual
16508238|NCT03234881|Experimental|MOVE!+gshCBT (virtual)|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
16508239|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
16508240|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
16508241|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
16508242|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.
~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:
~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
16508243|NCT03234855||LMD|Physician uses LMD during procedure.
16508244|NCT03234842|Experimental|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
16508245|NCT03234842|Active Comparator|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
16508246|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
16508247|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
16508248|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
16508249|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
16508250|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
16508251|NCT03234790|Active Comparator|Filtered Air Exposure|Exposure for 4 hours to filtered air
16508252|NCT03234790|Experimental|Diesel Exhaust Exposure|Volunteers exposed to different concentrations of diesel exhaust
16508253|NCT03234777|Experimental|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
16508254|NCT03234777|Sham Comparator|Regular video|3 minute video on hand washing for infection control
16508255|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
16508256|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
16508257|NCT03234738|Active Comparator|Cohort A|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16508258|NCT03234738|Active Comparator|Cohort B|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16508322|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
16508259|NCT03234738|Active Comparator|Cohort C|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16508260|NCT03234738|Active Comparator|Cohort D|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16508261|NCT03234738|Active Comparator|Cohort E|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16508262|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
16508263|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
16508264|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
16508265|NCT03234699|Experimental|Single Group|
16508266|NCT03234686|Experimental|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
16508267|NCT03234686|Placebo Comparator|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
16508268|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
16508269|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
16508270|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
16508271|NCT03234660|Experimental|Dexmedetomidine|dexmedetomidine infusion
16508272|NCT03234660|Placebo Comparator|control|placebo infusion
16508273|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
16508274|NCT03234634|No Intervention|Group 1: patients with good collateral|
16508275|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
16508276|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
16508277|NCT03234621|Experimental|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
16508278|NCT03234621|Experimental|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
16508279|NCT03234621|Experimental|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
16508282|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
16508283|NCT03234569|Experimental|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
16508284|NCT03234556|Active Comparator|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
16508285|NCT03234556|Experimental|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.
~If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.
~If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
16508286|NCT03234543|Experimental|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
16508287|NCT03234543|Sham Comparator|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
16508288|NCT03234530||WTC responders|WTC Health Program participants
16508289|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
16508290|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
16508291|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
16508292|NCT03234504||Normal healthy volunteers|
16508293|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
16508294|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
16508295|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
16508296|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
16508297|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
16508298|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
16508299|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
16508300|NCT03234465|Experimental|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
16508301|NCT03234465|Placebo Comparator|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
16508302|NCT03234452|Experimental|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
16508303|NCT03234452|Placebo Comparator|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
16508304|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
16508305|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
16508306|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
16508307|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
16508308|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
16508309|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
16508310|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
16508311|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes
~Inclusion criteria:
~Males and females ≥ 12 years of age
~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat) and, where possible, diagnostic genotyping
~Established CFRD in accordance with the most recent American Diabetes Association positional statement]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:
~2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)
~Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)
~Glycated hemoglobin ≥ 48 mmol/mol
~No contraindications to performing exhaustive exercise
~Can understand and cooperate with the study protocol
~No increase in symptoms or weight loss in the preceding 2 weeks"
16508312|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes
~Inclusion criteria:
~Males and females ≥ 12 years of age
~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired
~No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; [110]).
~No contraindications to performing exhaustive exercise
~Can understand and cooperate with the study protocol
~No increase in symptoms or weight loss in the preceding 2 weeks"
16508313|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
16508314|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
16508315|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
16508316|NCT03234361|Experimental|High Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.
16508317|NCT03234361|Placebo Comparator|Low Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.
16508318|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
16508319|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
16508320|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
16508321|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
16508323|NCT03234309|Experimental|Diagnostic (ferumoxytol, MRI)|Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
16508324|NCT03234296|Active Comparator|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
16508325|NCT03234296|Active Comparator|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
16508326|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
16508327|NCT03234270|Experimental|F35 pilots|
16508328|NCT03234270|Active Comparator|F15 pilots|
16508329|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
16508330|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
16508331|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
16508332|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
16508333|NCT03234231|No Intervention|Control Group|This group receive nothing during the study period.
16508334|NCT03234231|Experimental|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
16508335|NCT03234205|Experimental|MRI scan during free respiration|
16508336|NCT03234192|Active Comparator|Therapeutic ultra sound|
16508337|NCT03234192|Active Comparator|Astym Treatment Technique|
16508338|NCT03234192|Active Comparator|Graston Treatment Technique|
16508339|NCT03234153|Experimental|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
16508340|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :
~PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396
~RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441
~FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229
~MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178
~MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321
~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
16508341|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).
~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
16508342|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
16508343|NCT03234127|Other|Control|FH patient with atheroclerosis
16508344|NCT03234127|Other|the related population without familial hypercholesterolemia|No FH patient
16508345|NCT03234114|Experimental|1-month TT|Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 1 month (30 days) then quit aspirin till 12 months after PCI
16508346|NCT03234114|Experimental|6-month TT|Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 6 months (180 days）then quit aspirin till 12 months after PCI
16508347|NCT03234114|Experimental|12-month DT-1|Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg qd for 12 months after PCI
16508348|NCT03234114|Experimental|12-month DT-2|Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI
16508349|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
16508350|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
16508351|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
16508352|NCT03234062|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16508353|NCT03234062|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16508354|NCT03234062|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16508355|NCT03234062|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16508356|NCT03234062|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16508412|NCT03233711|Other|Arm B (clinical observation)|Patients undergo observation for up to 6 months.
16508357|NCT03234062|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
16508358|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
16508359|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
16508360|NCT03234036|Experimental|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.
~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.
~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.
~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
~There will be a wash out of 15 days between Part 1A and Part 1B."
16508361|NCT03234036|Experimental|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.
~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.
~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
~There will be a wash out of 15 days between Part 1A and Part 1B."
16508362|NCT03234036|Experimental|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
16508363|NCT03234036|Placebo Comparator|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
16508364|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
16508365|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
16508366|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
16508367|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
16508368|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
16508369|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
16508370|NCT03233997|Experimental|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
16508371|NCT03233997|Experimental|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
16508372|NCT03233997|Experimental|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
16508373|NCT03233997|Experimental|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
16508374|NCT03233984|No Intervention|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
16508375|NCT03233984|Active Comparator|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
16508376|NCT03233984|Experimental|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
16508377|NCT03233971||Older adults|
16508378|NCT03233971||Caregivers|
16508379|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
16508380|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
16508381|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
16508382|NCT03233919|Experimental|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:
~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.
~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.
~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
16508383|NCT03233919|No Intervention|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
16508384|NCT03233906|Active Comparator|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
16508385|NCT03233906|No Intervention|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
16508386|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
16508387|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
16508388|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
16508389|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
16508413|NCT03233685|Experimental|Experimental Group|Subjects will perform a visual training for 12 weeks
16508414|NCT03233685|Active Comparator|Control Group|Subjects will perform the normal training routine for 12 weeks
16508479|NCT03233217|Active Comparator|Cohort 2: QIV-SD by SC|Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
16508390|NCT03233854|Experimental|Treatment (CD19/CD22 CAR T cells, chemotherapy)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
16508391|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
16508392|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
16508393|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
16508394|NCT03233828|Experimental|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
16508395|NCT03233828|Placebo Comparator|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
16508396|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
16508397|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
16508398|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
16508399|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
16508400|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
16508401|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
16508402|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.
~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.
~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
16508403|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
16508404|NCT03233737|Experimental|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
16508405|NCT03233737|Active Comparator|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
16508406|NCT03233737|Experimental|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
16508407|NCT03233737|Active Comparator|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
16508408|NCT03233737|Placebo Comparator|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
16508411|NCT03233711|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16508415|NCT03233672|Other|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
16508416|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
16508417|NCT03233646|Experimental|Case|500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease
16508418|NCT03233646|Active Comparator|Controls|Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease.
16508419|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
16508420|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
16508421|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
16508422|NCT03233594||Chiropractic Group|Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
16508423|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
16508424|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
16508425|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
16508426|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
16508427|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
16508428|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
16508429|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
16508430|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
16508431|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
16508432|NCT03233542|Experimental|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
16508433|NCT03233542|No Intervention|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
16508434|NCT03233542|Other|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
16508435|NCT03233529|Experimental|Crisaborole ointment|
16508436|NCT03233529|Placebo Comparator|Placebo ointment (vehicle)|
16508437|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
16508438|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
16508439|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
16508440|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
16508441|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
16508442|NCT03233490|Experimental|CPR training intervention|CPR training without web course
16508443|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：
~Clinical diagnosis of Posner-Schlossman Syndrome
~Able to communicate with doctor and understand this study
~Exclusion criteria:
~Not be able to communicate with doctor and understand this study
~One or more authorized investigators think he or she will suffer from any severe risks from the study"
16508444|NCT03233477||cataract|"Inclusion criteria：
~Clinical diagnosis of age-related cataract
~Prepare for cataract operation
~Open angle and intraocular pressure is normally at anytime
~No family history of glaucoma
~Exclusion criteria:
~Patients above 65 years old
~With Secondary ocular hypertension
~Have the history of receiving any ophthalmologic operation or anti-viral therapy
~With diabetes mellitus
~With autoimmune disease
~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
16508478|NCT03233217|Experimental|Cohort 2: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
16508550|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
16508445|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：
~Both eyes involved
~Open angle
~Progressive glaucomatous optic neuropathy
~Specific visual field loss of glaucoma
~Intraocular pressure above the up limit of normal people
~Exclusion criteria:
~Patients above 65 years old
~With Secondary ocular hypertension
~Have the history of receiving any ophthalmologic operation or anti-viral therapy
~With diabetes mellitus
~With autoimmune disease
~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
16508446|NCT03233451|Experimental|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
16508447|NCT03233451|No Intervention|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
16508448|NCT03233438|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
16508449|NCT03233438|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
16508450|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
16508451|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
16508452|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
16508453|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
16508454|NCT03233386||Condition 1|Mexico City Cohort
16508455|NCT03233386||Condition 2|Monterrey Cohort
16508456|NCT03233386||Condition 3|Guadalajara Cohort
16508457|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
16508458|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
16508459|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
16508460|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
16508461|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
16508462|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
16508463|NCT03233308|Placebo Comparator|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
16508464|NCT03233295|Experimental|Vitamin D deficiency|
16508465|NCT03233282|Other|Cognitive Fatigability|
16508466|NCT03233282|Other|Physical Fatigability|
16508467|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
16508468|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
16508469|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
16508470|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
16508471|NCT03233230|Placebo Comparator|Placebo|
16508472|NCT03233230|Experimental|M2951 25 mg QD|
16508473|NCT03233230|Experimental|M2951 75 mg QD|
16508474|NCT03233230|Experimental|M2951 50 mg BID|
16508475|NCT03233217|Experimental|Cohort 1: QIV-HD by IM|Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
16508476|NCT03233217|Experimental|Cohort 1: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
16508477|NCT03233217|Experimental|Cohort 2: QIV-HD by IM|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
16508483|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
16508484|NCT03233178||Liraglutide|Patients initiation liraglutide
16508485|NCT03233178||Sitagliptin|Patients initiating sitagliptin
16508486|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
16508487|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.
~Intervention using Er:YAG laser"
16508488|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.
~Intervention using Er,Cr:YSGG laser"
16508489|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.
~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).
~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
16508490|NCT03233139|Experimental|REGN2810|Part 1
16508491|NCT03233139|Experimental|Cohort A|Part 2
16508492|NCT03233139|Experimental|Cohort B|Part 2
16508493|NCT03233126|Experimental|KRN23|
16508494|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
16508495|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
16508496|NCT03233100|Experimental|FMT group|
16508497|NCT03233087||Top third of subjects based levels of selected biomarker.|
16508498|NCT03233087||Middle third of subjects based levels of selected biomarker.|
16508499|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
16508500|NCT03233074||Acute Myeloid Leukemia patients|For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
16508501|NCT03233074||Healthy donors|Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
16508502|NCT03233061|Active Comparator|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
16508503|NCT03233061|Experimental|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
16508504|NCT03233048|Experimental|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
16508505|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
16508506|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
16508507|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
16508508|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
16508509|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16508546|NCT03232801|Active Comparator|educational group|A general midlife health and aging educational group, administered in 3 sessions over 6 weeks
16508547|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
16508510|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16508511|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
16508512|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
16508513|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
16508514|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
16508515|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
16508516|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
16508517|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
16508518|NCT03232983|Experimental|LY900014 (SC Abdomen)|Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
16508519|NCT03232983|Experimental|LY900014 (SC Thigh)|Single dose of 15-U of LY900014 administered SC into the thigh in one period
16508520|NCT03232983|Experimental|LY900014 (SC Arm)|Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
16508521|NCT03232983|Active Comparator|LY900014 (IV)|Single dose of 15-U of LY900014 administered intravenously (IV) in one period
16508522|NCT03232970|Experimental|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
16508523|NCT03232970|No Intervention|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
16508524|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
16508525|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
16508526|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
16508527|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
16508528|NCT03232931|Experimental|Multisensory Intervention|Preterm infants in the NICU who are randomized to receive a multisensory intervention, in addition to the standard of care. The multisensory intervention uses recordings of the parents' voices and nurturing touch administered in the NICU during 12 to 23 sessions of standardized, therapist-administered, auditory-tactile stimulation, dispersed over a 2 to 3 week period. The intervention includes 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
16508529|NCT03232931|Other|Standard of Care|Preterm infants in the NICU who are randomized to receive the standard of care. The standard care for preterm infants in the NICU currently follows medical protocols of skin-to-skin holding and exposure to recordings of parent's voice.
16508530|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
16508531|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
16508532|NCT03232905|Experimental|PF-06651600|Multiple ascending doses of PF-06651600
16508533|NCT03232905|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
16508534|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
16508535|NCT03232879|Experimental|Experimental 1|Motor Imagery
16508536|NCT03232879|Experimental|Experimental 2|Action Observation
16508537|NCT03232879|No Intervention|Control Group|No intervention
16508538|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
16508539|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
16508540|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
16508541|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
16508542|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
16508543|NCT03232827|Active Comparator|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
16508544|NCT03232814|Experimental|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
16508545|NCT03232801|Experimental|mindfulness group|A multicomponent group-based intervention rooted in mindfulness, administered in 3 sessions over 6 weeks
16508551|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
16508552|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
16508553|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
16508554|NCT03232736||Healthy Control|
16508555|NCT03232736||LVAD Group w/Pacemaker|
16508556|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
16508557|NCT03232710|Experimental|pilot study group|
16508558|NCT03232710|Experimental|group 1 (under fasting condition)|
16508559|NCT03232710|Experimental|group 2 (under fasting condition)|
16508560|NCT03232710|Experimental|group 3 (under fed condition)|
16508561|NCT03232710|Experimental|group 4 (under fed condition)|
16508562|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
16508563|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
16508564|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
16508565|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
16508566|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.
~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
16508567|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
16508568|NCT03232619|Experimental|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
16508569|NCT03232619|Experimental|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
16508570|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
16508571|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
16508572|NCT03232580|Experimental|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
16508573|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
16508574|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
16508575|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
16508576|NCT03232567|Placebo Comparator|Placebo|Normal saline administered by intranasal spray at a single dose
16508577|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
16508578|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
16508579|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
16508580|NCT03232541|Other|Standard care (A)|Standard care (A) with neutral communication (A1) or positive communication (A2)
16508581|NCT03232541|Placebo Comparator|Sham acupuncture (B)|Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
16508582|NCT03232541|Experimental|Genuine acupuncture (C)|Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
16508583|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
16508584|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
16508585|NCT03232515|Experimental|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
16508586|NCT03232502|No Intervention|Control|
16508587|NCT03232502|Experimental|Intervention|
16508629|NCT03232125|Placebo Comparator|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
16508588|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
16508589|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
16508590|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
16508591|NCT03232424|Experimental|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
16508592|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
16508593|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
16508594|NCT03232385|Experimental|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
16508595|NCT03232385|Active Comparator|EM Fusion or No Fusion Arm|
16508596|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
16508597|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
16508598|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
16508599|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
16508600|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
16508601|NCT03232359||Control group|This group included 20 pregnant women (gestational age of >20 weeks) having normal pregnancy with normal blood pressure and platelet count.
16508602|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
16508603|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
16508604|NCT03232333||MIRODERM|Biologic wound graft
16508605|NCT03232320|Experimental|MEDITOXIN|
16508606|NCT03232320|Placebo Comparator|Placebo|
16508607|NCT03232307|Experimental|Treatment (ibrutinib, rituximab, lenalidomide, dexamethasone)|Participants receive ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also receive rituximab IV on days 1, 8, 15 and 22 in course 1 and 2, on day 1 of course 3-8, and then on day 1 of every other 28-day course, lenalidomide PO on days 1-21, and dexamethasone PO weekly. Treatment with rituximab repeats every 28 days for 2 years, with lenalidomide for 1 year, and with dexamethasone for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16508608|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
16508609|NCT03232281|Experimental|Triptorelin pamoate PR 3-month|Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
16508610|NCT03232281|Active Comparator|Triptorelin acetate PR 1-month|Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).
16508611|NCT03232268|Experimental|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
16508612|NCT03232255|Experimental|Treatment Group|
16508613|NCT03232229||Tennis players|
16508614|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
16508615|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
16508616|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
16508617|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
16508618|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
16508619|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
16508620|NCT03232190|Experimental|INTNIC|NICU Intervention Group Web Application Infants < 32 weeks
16508621|NCT03232190|No Intervention|CNIC|NICU Control Group No Web Application Infants < 32 weeks
16508622|NCT03232190|No Intervention|CMAT|Maternity Unit Control Group No Web Application Infants > 37 weeks
16508623|NCT03232177|Experimental|Anagre Cap.|twice a day
16508624|NCT03232164|Experimental|18F-DCFPyL PET|We will have three separate sub-studies evaluating 18F-DCFPyL PET imaging of prostate cancer in three prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, and (3) androgen-resistant metastatic disease.
16508625|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
16508626|NCT03232138|Experimental|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
16508627|NCT03232138|Placebo Comparator|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
16508628|NCT03232125|Experimental|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
16508630|NCT03232112|Active Comparator|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
16508631|NCT03232112|Placebo Comparator|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
16508632|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
16508633|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
16508634|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16508635|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16508637|NCT03232047|Experimental|Combined cognitive training|The training is combined executive function and memory training. The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
16508638|NCT03232047|No Intervention|Waiting-list group|Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period. During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
16508639|NCT03232034|Placebo Comparator|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
16508640|NCT03232034|Active Comparator|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
16508641|NCT03232034|Experimental|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
16508642|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
16508643|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
16508644|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
16508645|NCT03232008|Experimental|Experiment A- experimental|3g Canderel in 250ml water
16508646|NCT03232008|No Intervention|Experiment A- control|3g of maltodextrin in 250 ml of water
16508647|NCT03232008|Experimental|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
16508648|NCT03232008|No Intervention|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
16508649|NCT03231995|Experimental|Respiratory microbiome biomarkers|
16508650|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
16508651|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
16508652|NCT03231969|Experimental|Bilastine 0.2%|
16508653|NCT03231969|Experimental|Bilastine 0.4%|
16508654|NCT03231969|Experimental|Bilastine 0.6%|
16508655|NCT03231969|Placebo Comparator|Bilastine 0%|
16508656|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
16508657|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
16508658|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
16508659|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
16508660|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
16508661|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
16508662|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
16508663|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
16508664|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
16508665|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
16508666|NCT03231878|Active Comparator|Active|
16508667|NCT03231878|Placebo Comparator|Placebo|
16508668|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
16508669|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
16508670|NCT03231839|Placebo Comparator|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
16508671|NCT03231839|Active Comparator|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
16508672|NCT03231839|Active Comparator|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
16508673|NCT03231813|Experimental|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
16508674|NCT03231813|Placebo Comparator|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
16508675|NCT03231813|Sham Comparator|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
16508676|NCT03231813|No Intervention|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
16508677|NCT03231800|Experimental|Dasotraline|Dasotraline capsule 2mg/day
16508678|NCT03231800|Placebo Comparator|Placebo|Placebo capsule
16508679|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.
~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.
~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
16508680|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
16508681|NCT03231761|Experimental|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
16508682|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
16508683|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
16508686|NCT03231722|Active Comparator|mFOLFOX6 + Panitumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by
~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by
~5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
16508687|NCT03231722|Experimental|mFOLFOXIRI + Panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by
~Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by
~Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
16508688|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
16508689|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
16508690|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
16508691|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
16508692|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
16508693|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
16508694|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:
~sFlt1/PlGF ratio >38: pre-eclampsia risk
~sFlt1/PlGF ratio >85: pre-eclampsia
~ISSHP pre-eclampsia definition + ratio >210: severe PE
~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
16508695|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
16508696|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
16508697|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.
~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
16508698|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.
~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
16508699|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
16508700|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
16508701|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
16508702|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
16508703|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
16508704|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
16508705|NCT03231566|Active Comparator|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
16508706|NCT03231566|Experimental|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
16508707|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
~Receive MiQuit text message cessation programme."
16508708|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
16508709|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
16508710|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
16508711|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
16508712|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
16508713|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
16508714|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
16508715|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
16508716|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
16508717|NCT03231501|Experimental|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
16508718|NCT03231488|Experimental|Mindfulness intervention|
16508719|NCT03231488|Active Comparator|Control intervention (unfocused attention)|
16508720|NCT03231475|Experimental|SPH1188-11|SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
16508721|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
16508722|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
16508723|NCT03231423|Experimental|DRAIN PLACEMENT|Effects of drainage
16508724|NCT03231423|No Intervention|DRAIN NOT PLACED|Effects of not using drain
16508725|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
16508726|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
16508727|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
16508728|NCT03231397|Other|AAA's undergoing treatment|"Six subjects (three males, AAA >5.5cm and three females, AAA >5.0cm) with AAAs that are indicated for treatment.
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
16508729|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
16508730|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
16508731|NCT03231371|Experimental|Study Arm|
16508732|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
16508733|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
16508734|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
16508735|NCT03231332|Experimental|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
16508736|NCT03231332|No Intervention|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
16508737|NCT03231332|Active Comparator|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
16508738|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
16508739|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
16508740|NCT03231319|Placebo Comparator|IV PCA only|
16508741|NCT03231306|Experimental|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.
~Recruitment of subjects 1 - 17 years of age (Stratum B) is currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) was established by a phase 1 study (NCT022)."
16508742|NCT03231280|Experimental|SB-061|SB-061
16508743|NCT03231280|Placebo Comparator|Placebo|Placebo
16508744|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
16508745|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
16508746|NCT03231254||Chinese patients with OSA|
16508747|NCT03231254||Canada patients with OSA|
16508748|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
16508749|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
16508750|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
16508751|NCT03231228|Active Comparator|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
16508752|NCT03231228|Active Comparator|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
16508753|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
16508754|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
16508755|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.
~Additional peripheral embolization is left to the discretion of the interventional radiologist.
~The study does not interfere with local diagnostic work-up and treatment protocols."
16508756|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
16508757|NCT03231176|Experimental|Varlitinib and Capecitabine|
16508758|NCT03231163|Placebo Comparator|No Music|
16508759|NCT03231163|Experimental|Relaxing Classical Music|
16508760|NCT03231163|Experimental|Self-Selected Relaxing Music|
16508761|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
16508869|NCT03230435||Healthy controls|No interventions.
16508762|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
16508763|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
16508764|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
16508765|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
16508766|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
16508767|NCT03231137|No Intervention|Control|Spontaneously healed socket
16508768|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.
~Days 1 - 3: 10 mg dose twice a day for three days
~Days 4 - 6: 20 mg dose twice a day for three days
~Days 7 - 11: 30 mg dose twice a day for five days
~Days 12: 30 mg dose once in the morning"
16508769|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.
~Days 1 - 3: 10 mg dose twice a day for three days
~Days 4 - 6: 20 mg dose twice a day for three days
~Days 7 - 11: 30 mg dose twice a day for five days
~Days 12: 30 mg dose once in the morning"
16508770|NCT03231111|No Intervention|traditional group|
16508771|NCT03231111|Experimental|Multimedia group|
16508772|NCT03231085|Active Comparator|Ferrous fumarate or ferrostrane|"The oral treatment should begin 21 days before surgery.
~Recommended Dosage ferrous fumarate according to the SPC in force:
~5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate
~8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate
~10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate
~Ferrostrane ® (syrup) Laboratory TEOFARMA SRL Either 34mg of iron per teaspoon
~Recommended dosage according to the SPC in force:
~Infant 5 to 8 kg (about 1 to 6 months): 2 teaspoons a day,
~Infant from 8 to 12 kg (about 6 to 30 months): 3 teaspoons a day."
16508773|NCT03231085|Experimental|Ferric carboxymaltose|The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.
16508774|NCT03231072|Experimental|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
16508775|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
16508776|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.
~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
16508777|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
16508778|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
16508779|NCT03231033|Experimental|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
16508780|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
16508781|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
16508782|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
16508783|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
16508784|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
16508785|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
16508786|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
16508787|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
16508788|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
16508789|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
16508825|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
16508826|NCT03230760|Experimental|treatment|
16509056|NCT03229252|Placebo Comparator|Placebo|Placebo Inhalation solution twice daily for 28 days.
16508790|NCT03230955|Experimental|Psychological and psycho-educational support|The intervention group (IG) [that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process]
16508791|NCT03230955|Active Comparator|Control Group|The control group (CG) [that will receive only a brief counselling session after discharge]
16508792|NCT03230942|Experimental|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
16508793|NCT03230942|Active Comparator|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
16508794|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
16508795|NCT03230916|Experimental|IMI/REL FDC|Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
16508796|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
16508797|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
16508798|NCT03230890|Experimental|HIRREM|This is the intervention, treatment arm that all participants receive in this open label, single arm trial. The intervention is High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
16508799|NCT03230864|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
16508800|NCT03230864|Experimental|Double-blind treatment (DBT) period, Lu AF35700 10 mg|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
16508801|NCT03230864|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period
16508802|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
16508803|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
16508804|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
16508805|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
16508806|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
16508807|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
16508808|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
16508809|NCT03230838|Experimental|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose) administered intravenously (IV) every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
16508810|NCT03230838|Active Comparator|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
16508811|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
16508812|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
16508813|NCT03230812|Experimental|Experimental: carnitine intervention (in all participants)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
16508814|NCT03230799|Active Comparator|traditional cataract surgery|
16508815|NCT03230799|Experimental|minimal invasive lens surgery|
16508816|NCT03230786|Placebo Comparator|Placebo|Placebo QD for 12 weeks as add-on to metformin
16508817|NCT03230786|Experimental|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
16508818|NCT03230786|Experimental|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
16508819|NCT03230786|Experimental|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
16508820|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
16508821|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
16508822|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
16508823|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
16508824|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
16530455|NCT03083275|No Intervention|Control|
16508827|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
16508828|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
16508829|NCT03230721|Active Comparator|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
16508830|NCT03230721|Active Comparator|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
16508831|NCT03230721|Active Comparator|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
16508832|NCT03230708|Experimental|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
16508833|NCT03230708|Active Comparator|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
16508834|NCT03230695|Active Comparator|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.
~Number of interventions sessions: 1"
16508835|NCT03230695|Sham Comparator|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.
~Number of interventions sessions: 1"
16508836|NCT03230682||major depressive disorder|
16508837|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
16508838|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
16508839|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:
~working memory strategies
~executive function program
~divided attention program
~environmental changes
~identification of problematic cognitive-communication situations"
16508840|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:
~- Same cognitive-communication therapy is administered"
16508841|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
16508842|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
16508843|NCT03230604|Active Comparator|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
16508844|NCT03230604|Active Comparator|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
16508845|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
16508846|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
16508847|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
16508848|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
16508849|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
16508850|NCT03230552|Experimental|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
16508851|NCT03230552|No Intervention|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
16508852|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
16508853|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
16508854|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
16508855|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
16508856|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
16508857|NCT03230500|Experimental|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
16508858|NCT03230500|Active Comparator|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
16508859|NCT03230487|Experimental|BI 1015550|
16508860|NCT03230487|Placebo Comparator|Placebo|
16508861|NCT03230474|Active Comparator|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
16508862|NCT03230474|Active Comparator|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
16508863|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
16508864|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
16508865|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
16508866|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
16508867|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
16508868|NCT03230435||Anorexia nervosa|Treatment settings as usual.
16547467|NCT02967081||Pulp necrosis|
16508870|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
16508871|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
16508872|NCT03230409|No Intervention|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
16508873|NCT03230409|Experimental|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:
~Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
~Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.
~Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.
~Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
16508874|NCT03230396|Placebo Comparator|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.
~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
16508875|NCT03230396|Experimental|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).
~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
16508876|NCT03230396|Experimental|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).
~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
16508877|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
16508878|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
16508879|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
16508880|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
16508881|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
16508882|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
16508883|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
16508884|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.
~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.
~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.
~Accordingly, one group can be used as the control group of the other one."
16508885|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.
~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.
~Accordingly,one group can be used as the control group of the other one."
16508886|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
16508887|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
16508888|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
16508889|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
16508890|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
16508891|NCT03230318|Experimental|derazantinib|Oral administration
16508892|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over
~With solid cancer irrespective of the stage
~Pre-screened or screened for at least one ongoing clinical trial in the center
~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)
~Social security affiliation"
16508893|NCT03230292|Experimental|Cohort 1|Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is >=50% to <75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
16573487|NCT02788474|Experimental|nintedanib|
16508894|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
16508895|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
16508896|NCT03230266|Other|collection|collection of biological and device samples
16508897|NCT03230253|Experimental|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
16508898|NCT03230253|Experimental|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
16508899|NCT03230253|Active Comparator|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
16508900|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
16508901|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
16508902|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
16508903|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
16508904|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
16508905|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
16508906|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
16508907|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
16508908|NCT03230175|Experimental|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
16508909|NCT03230162|Experimental|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
16508910|NCT03230162|Experimental|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow < 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily > 170 kg 75 u/kg/day
16508911|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
16508912|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
16508913|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
16508914|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
16508915|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
16508916|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
16508917|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
16508918|NCT03230097|Experimental|BI 409306|
16508919|NCT03230097|Placebo Comparator|Placebo|
16508920|NCT03230084|Experimental|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
16508921|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
16508922|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
16508923|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
16508924|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
16508925|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
~Patients will be followed up every week after being discharged until complete resolution is noted."
16508926|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
~Patients will be followed up every week after being discharged until complete resolution is noted."
16508927|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
16511736|NCT03210558|Placebo Comparator|Group B|Placebo cream
16508928|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
16508931|NCT03230019|Active Comparator|chest tube|VATS with chest tube placement
16508932|NCT03230019|Experimental|two-lumen catheter|VATS with two-lumen catheterization
16508933|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
16508934|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
16508935|NCT03229993|Experimental|OCT guided PCI|
16508936|NCT03229993|Experimental|OCT guided medicine|
16508937|NCT03229993|No Intervention|SPECT guided PCI|
16508938|NCT03229993|No Intervention|SPECT guided medicine|
16508939|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
16508940|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
16508941|NCT03229967||Exploration Cohort|Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
16508942|NCT03229967||Validation Cohort|Up to 10 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
16508943|NCT03229967||Well Baby Cohort|40 Well Baby Infants have been enrolled and may be used for secondary analysis of microbial community composition of the meconium.
16508944|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
16508945|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
16508946|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<7gm/dl
16508947|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<10gm/dl
16508948|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
16508949|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
16508950|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
16508951|NCT03229915|Active Comparator|PTSD|Will receive Cognitive Processing Therapy
16508952|NCT03229915|Active Comparator|Trauma-exponsed control|Will receive Cognitive Processing Therapy
16508953|NCT03229915|No Intervention|no trauma healthy control|Scanned twice (13 weeks apart) without any intervention
16508954|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
16509057|NCT03229252|Experimental|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
16508955|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
16508956|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
16508957|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
16508958|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
16508959|NCT03229876|Experimental|CD19-UCART|All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (5x10^6/kgBW, 7x10^6/kgBW, 10x10^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.
16508960|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
16508961|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
16508962|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
16508963|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
16508964|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
16508965|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
16508966|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
16508967|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
16508968|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
16508969|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
16508970|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
16508971|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
16508972|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
16508973|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
16508974|NCT03229785|Experimental|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
16508975|NCT03229772|Other|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
16508976|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
16508977|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
16508978|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
16508979|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
16508980|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
16508981|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
16508982|NCT03229733|Experimental|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
16508983|NCT03229733|Active Comparator|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
16508984|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
16508985|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
16508986|NCT03229707|Active Comparator|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :
~Modified (USPHS) criteria"
16508987|NCT03229707|Experimental|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)
~Software:
~0 to 1: no difference in perception
~1 to 2: only perceptible to a trained observer
~2 to 3.5: perceptible difference
~3.5 to 5: marked difference"
16508988|NCT03229694|Experimental|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
16508989|NCT03229694|Placebo Comparator|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
16508990|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
16508991|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
16508992|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
16508993|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
16508994|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
16508995|NCT03229655|Experimental|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
16508996|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
16508997|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
16508998|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
16508999|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
16509000|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC
~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
16509001|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)
~Within household, recipient of voucher (mother or father) will be randomly selected.
~Food voucher"
16509002|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC
~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)
~Within household, recipient of voucher (mother or father) will be randomly selected.
~BCC: Behavior Change Communication"
16509003|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC
~Husband/partner of the enrolled mother will receive BCC
~Enrolled participants will receive monthly voucher worth 200 birr(~$10)
~Within household, recipient of voucher (mother or father) will be randomly selected.
~BCC: Behavior Change Communication"
16509004|NCT03229629|No Intervention|Control|Control group
16509005|NCT03229616|Experimental|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
16509006|NCT03229616|Active Comparator|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
16509007|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
16509008|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
16509009|NCT03229577|Experimental|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
16509010|NCT03229577|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
16509011|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
16509012|NCT03229577|No Intervention|Control|The control group will receive no intervention.
16509013|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
16509014|NCT03229551|Experimental|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
16509015|NCT03229551|Active Comparator|Control|This arm is the standard of care saline irrigation solution.
16509016|NCT03229538|Experimental|Methylprednisolone Arm|IV Methylprednisolone
16509017|NCT03229538|Placebo Comparator|Placebo Arm|IV Isotonic Saline
16509018|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
16509058|NCT03229252|Experimental|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
16510594|NCT03218917|Experimental|INS1007 25 mg Oral Tablet|Once per day for 24 weeks.
16509019|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
16509020|NCT03229512|Experimental|Intervention|Topical 1% Sildenafil Cream
16509021|NCT03229499|Experimental|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
16509022|NCT03229499|Placebo Comparator|Placebo|1 tablet taken by mouth once a day for one year
16509023|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
16509024|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
16509025|NCT03229460|Active Comparator|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
16509026|NCT03229460|Experimental|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
16509027|NCT03229460|Placebo Comparator|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
16509028|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
16509029|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
16509030|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
16509031|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).
~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
16509032|NCT03229408|Experimental|Salsalate-Treated Lean PCOS without IR|n=15
16509033|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS without IR|n=15
16509034|NCT03229408|Experimental|Salsalate-Treated Lean PCOS with IR|n=15
16509035|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS with IR|n=15
16509036|NCT03229408|Experimental|Salsalate-Treated Obese PCOS|n=15
16509037|NCT03229408|Placebo Comparator|Placebo-Treated Obese PCOS|n=15
16509038|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
16509039|NCT03229395||control patients|Selected patients are matched for age and sex.
16509040|NCT03229382|Experimental|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|
16509041|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
16509042|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
16509043|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
16509044|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
16509045|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
16509046|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
16509047|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
16509048|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
16509049|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
16509050|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
16509051|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
16509052|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
16509053|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
16509054|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
16509055|NCT03229265|Experimental|Patiromer|
16512517|NCT03205137||Telmisartan and amlodipine group|
16509059|NCT03229239|Experimental|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
16509060|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
16509061|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
16509062|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
16509063|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
16509064|NCT03229187||neoadjuvant chemotherapy|
16509065|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
16509066|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
16509067|NCT03229161|Experimental|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
16509068|NCT03229161|No Intervention|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
16509069|NCT03229148|Active Comparator|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
16509070|NCT03229148|Active Comparator|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
16509071|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
16509072|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
16509073|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
16509074|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
16509075|NCT03229109|Experimental|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
16509076|NCT03229109|Experimental|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
16509077|NCT03229109|Experimental|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
16509078|NCT03229109|Experimental|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
16509079|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
16509080|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
16509081|NCT03229070|No Intervention|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
16509082|NCT03229070|Experimental|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
16509083|NCT03229070|Experimental|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
16509084|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
16509142|NCT03228693|Active Comparator|Group 3|Baseline lesional and non-lesional biopsy and re-biopsy 3-4 months later with intralesional triamcinolone injections at 18-20 and 24-32 weeks.
16575595|NCT02774356||Native Chinese speakers|
16509085|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
16509086|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
16509087|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
16509088|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
16509089|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
16509090|NCT03229031|Experimental|ES135|
16509091|NCT03229031|Placebo Comparator|Placebo|
16509092|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
16509093|NCT03229005|Active Comparator|A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
16509094|NCT03229005|Experimental|A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
16509095|NCT03229005|Active Comparator|B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
16509096|NCT03229005|Experimental|B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
16509097|NCT03228992|Active Comparator|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
16509098|NCT03228992|Placebo Comparator|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
16509099|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
16509100|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
16509101|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
16509102|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
16509103|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
16509104|NCT03228927||twin A|Sampling of the facial and fecal microbiome
16509105|NCT03228927||twin B|Sampling of the facial and fecal microbiome
16509106|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
16509107|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
16509108|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
16509109|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
16509110|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.
~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
16509111|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.
~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
16509112|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
16509113|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
16509114|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
16509115|NCT03228849|Active Comparator|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
16509116|NCT03228849|Active Comparator|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
16509117|NCT03228836|Experimental|Sintilimab (IBI308)|
16513025|NCT03201757|Experimental|ALKS 3831|Coated bilayer tablet
16509118|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
16509119|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
16509120|NCT03228810||Men >18 years old with metastatic prostate cancer|
16509121|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
16509122|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
16509123|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
16509124|NCT03228771|Active Comparator|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
16509125|NCT03228771|Active Comparator|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
16509126|NCT03228771|No Intervention|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
16509127|NCT03228758|Active Comparator|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.
~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
16509128|NCT03228758|Active Comparator|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.
~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
16509129|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
16509130|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
16509131|NCT03228732|Placebo Comparator|Placebo 1|"Visit 1:
~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo
~Visit 2:
~same as visit 1"
16509132|NCT03228732|Placebo Comparator|Placebo 2|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo
~Visit 2:
~same as visit 1"
16509133|NCT03228732|Active Comparator|Fluoxetine|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine
~Visit 2:
~same as visit 1"
16509134|NCT03228732|Active Comparator|DHEA|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA
~Visit 2:
~same as visit 1"
16509135|NCT03228732|Active Comparator|Fluoxetine and DHEA|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA
~Visit 2:
~same as visit 1"
16509136|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
16509137|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
16509138|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
16509139|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
16509140|NCT03228693|Active Comparator|Group 1|Baseline lesional and non-lesional biopsies and re-biopsy 6-8 weeks later with intralesional triamcinolone injections at 9-10, 12-16, and 24-32 weeks.
16509141|NCT03228693|Active Comparator|Group 2|Baseline lesional biopsy and re-biopsy at 6-8 weeks with intralesional triamcinolone injections at 3-4, 9-10, 12-16, and 24-32 weeks
16509143|NCT03228693|Active Comparator|Group 4|Baseline lesional biopsy and re-biopsy at 3-4 months with intralesional triamcinolone injections at 3-4, 6-8, 18-20 and 24-32 weeks.
16509144|NCT03228693|Active Comparator|Group 5|Normal patient skin (surgical or adjacent to other biopsy) from subjects with no self-reported history of keloids.
16509145|NCT03228693|Other|Earlobe Keloid|Complete excision of an earlobe keloid measuring > 10mm will be taken.
16509146|NCT03228680|Experimental|Follitropin delta|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
16509147|NCT03228680|Active Comparator|Follitropin beta|FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
16509148|NCT03228667|Other|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.
~1a - Non-small cell lung cancer
~1b - Small cell lung cancer
~1c - Urothelial carcinoma
~1d - Head and neck squamous cell carcinoma
~1e - Merkel cell carcinoma
~1f - Melanoma
~1g - Renal cell carcinoma
~1h - Gastric cancer
~1i - Cervical cancer
~1j - Hepatocellular carcinoma
~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
16509149|NCT03228667|Other|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
16509150|NCT03228667|Other|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
16509151|NCT03228667|Experimental|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
16509152|NCT03228667|Experimental|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
16509153|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
16509154|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
16509155|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
16509156|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
16509157|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
16509158|NCT03228615|Experimental|Shared Decision Making Intervention|
16509159|NCT03228615|No Intervention|Usual Care Group|
16509160|NCT03228602|Active Comparator|healthy subjects|
16509161|NCT03228602|Experimental|obese|
16509162|NCT03228602|Experimental|obese diabetic|
16509163|NCT03228602|Experimental|obese diabetic who are going to be operated on|25 of a sleeve gastrectomy and 25 of a Y gastric bypass
16509164|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
16509165|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
16509166|NCT03228576||TREVISE|
16509167|NCT03228563|Experimental|Probiotics|Taking two capsules of probiotics twice daily for 12 months.
16509168|NCT03228563|No Intervention|Healthy control|Healthy volunteers were: no hypertension (Blood pressure<140/90mmHg), no diabetes (Glucose AC 70~100mg/dl), no hyperlipidemia (Cholesterol Total 130~200mg/dL、Triglyceride<150mg/dL), no urinary protein (-) and normal renal function (eGFR>90), after signing the consent form, the stool samples will be collected.
16509169|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
16509170|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
16509171|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
16509172|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
16509173|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.
~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.
~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
16509174|NCT03228524|Experimental|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
16509175|NCT03228524|Placebo Comparator|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
16509176|NCT03228511|Experimental|Formerly Arm Label|
16509177|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day
~concomitant administration"
16509178|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only
~concomitant administration"
16509179|NCT03228485||MyBPH Care|All patients enrolled in this study.
16509180|NCT03228472|Experimental|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
16509181|NCT03228472|Placebo Comparator|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
16509182|NCT03228459|Experimental|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
16509183|NCT03228459|No Intervention|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
16509184|NCT03228446|Experimental|Young subjects|Working memory training & attentional filter training for participants (18-30 years)
16509185|NCT03228446|Experimental|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
16509186|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
16509187|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
16509188|NCT03228433|Experimental|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
16509189|NCT03228433|Experimental|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
16509190|NCT03228433|Experimental|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
16509191|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
16509192|NCT03228420|Active Comparator|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
16509193|NCT03228420|Other|CMM Alone|Conventional Medical Management
16509194|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
16509195|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
16509196|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
16509197|NCT03228394|Experimental|Ganaxolone|Intravenous
16509198|NCT03228394|Placebo Comparator|Placebo|Intravenous
16509199|NCT03228381|Experimental|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
16509200|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
16509201|NCT03228355|Active Comparator|Levcromakalim|
16509202|NCT03228355|Placebo Comparator|Saline|
16509203|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
16509204|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
16509205|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
16509206|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
16509207|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
16509208|NCT03228303|Active Comparator|Chronic phase CML treated by nilotinib|Newly diagnosed
16509209|NCT03228303|Active Comparator|Chronic phase CML treated by imatinib|Newly diagnosed
16509210|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
16509211|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
16509212|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
16509213|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
16509214|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
16509215|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
16509216|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
16509526|NCT03226119|Experimental|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
16509217|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
16509218|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
16509219|NCT03228225|Experimental|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
16509220|NCT03228212|Experimental|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
16509221|NCT03228212|Experimental|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
16509222|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
16509223|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
16509224|NCT03228186|Experimental|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
16509225|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
16509226|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
16509227|NCT03228147|Experimental|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
16509228|NCT03228134|Experimental|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
16509229|NCT03228134|Sham Comparator|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
16509230|NCT03228134|Experimental|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
16509231|NCT03228134|Sham Comparator|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
16509232|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
16509233|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
16509234|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:
~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or
~fosfomycin 3 g orally 2 hours before prostate biopsy, or
~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
16509235|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
16509236|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
16509237|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
16509238|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
16509239|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
16509240|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
16509241|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
16509242|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
16509243|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
16509244|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
16509245|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
16509246|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
16509247|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
16509248|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
16509249|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
16509250|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
16509251|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
16509252|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
16509253|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.
~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
16509254|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
16509255|NCT03228069|Experimental|single visit 4-site ID vaccination|Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.
16509256|NCT03228069|Active Comparator|Conventional IM vaccination|Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.
16509257|NCT03228056|Experimental|uniportal VATS lobectomy|"uniportal VATS lobectomy
~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)
~ketoprofene 100 mg i.v every 12 hours
~paracetamol 1000 mg i.v every 8 hours
~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)
~pain intensity measured in VAS scale"
16509258|NCT03228056|Active Comparator|two-ports VATS lobectomy|"two-ports VATS lobectomy
~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)
~ketoprofene 100 mg i.v every 12 hours
~paracetamol 1000 mg i.v every 8 hours
~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)
~pain intensity measured in VAS scale"
16509259|NCT03228056|Active Comparator|three-ports VATS lobectomy|"three-ports VATS lobectomy
~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)
~ketoprofene 100 mg i.v every 12 hours
~paracetamol 1000 mg i.v every 8 hours
~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)
~pain intensity measured in VAS scale"
16509304|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
16509260|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
16509261|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
16509262|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
16509263|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
16509264|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
16509265|NCT03228017|No Intervention|Healthy Control|
16509266|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
16509267|NCT03227991|Active Comparator|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
16509268|NCT03227991|Active Comparator|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
16509269|NCT03227978|Experimental|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
16509270|NCT03227965|Other|ELITE|
16509271|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
16509272|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
16509273|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
16509274|NCT03227939|Active Comparator|LSG Group|LSG only
16509275|NCT03227926|Experimental|Screening Phase|"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase."
16509276|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
16509277|NCT03227913|Active Comparator|Good chewing ability|
16509278|NCT03227913|Experimental|Impaired chewing ability|
16509279|NCT03227900|Active Comparator|Lidocaine|LIdocaine dissolved in water for injections
16509280|NCT03227900|Placebo Comparator|Placebo|Water for injections
16509281|NCT03227887|Active Comparator|Good chewing ability|
16509282|NCT03227887|Experimental|Impaired chewing ability|
16509283|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
16509284|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
16509285|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
16509286|NCT03227822|Experimental|Short spot stenting|Short spot stenting
16509287|NCT03227822|Experimental|Long lesion stenting|Long lesion stenting
16509288|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
16509289|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
16509290|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
16509291|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
16509292|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
16509293|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
16509294|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
16509295|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
16509296|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
16509297|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
16509298|NCT03227796|Experimental|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
16509299|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
16509300|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
16509301|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
16509302|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
16509303|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
16589327|NCT02683343||normals|no intervention
16509305|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
16509306|NCT03227796|Placebo Comparator|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
16509307|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.
~Current intensity: 2mA, 20min/day"
16509308|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects
~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
16509309|NCT03227770|Active Comparator|regular hemodialysis|Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.
16509310|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment once every two week
16509312|NCT03227744|Active Comparator|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
16509313|NCT03227744|Placebo Comparator|Not enrolled in group therapy|Patients in control arm will be issued surveys
16509314|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
16509315|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
16509316|NCT03227718||athletic background|ex-gymnasts
16509317|NCT03227718||control|age-matched non-gymnastics background
16509318|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
16509319|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
16509320|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
16509321|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
16509322|NCT03227679|Active Comparator|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
16509323|NCT03227679|Active Comparator|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
16509324|NCT03227666|Experimental|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
16509325|NCT03227666|No Intervention|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
16509326|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
16509327|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
16509328|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
16509329|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
16509330|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
16509331|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
16509332|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
16509333|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
16509334|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
16509404|NCT03227211||COPD exacerbated patients admitted|No specific intervention
16509643|NCT03225261|Experimental|Citrus extract|Citrus extract
16635446|NCT02378688|Experimental|MT-1303|
16509335|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
16509336|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
16509337|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
16509338|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
16509339|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
16509340|NCT03227549|Active Comparator|Posterior Approach|
16509341|NCT03227523||subjects with copd|
16509342|NCT03227523||subjects without pulmonary disease|
16509343|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
16509344|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
16509345|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.
~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
16509346|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
~Treatment arm includes 56 g of whole walnuts daily."
16509347|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
16509348|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
16509349|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
16509350|NCT03227471|Experimental|Part A: VX-445 in Healthy Subjects (HS)|Part A includes single dose escalation.
16509351|NCT03227471|Placebo Comparator|Part A: Placebo|
16509352|NCT03227471|Experimental|Part B: VX-445 in HS|Part B includes multiple-dose escalation.
16509353|NCT03227471|Placebo Comparator|Part B: Placebo|
16509354|NCT03227471|Experimental|Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-445 in TC with TEZ/IVA
16509355|NCT03227471|Placebo Comparator|Part C: Placebo|
16509356|NCT03227471|Experimental|Part D1: F/MF genotypes TC|Subjects will receive 100 mg VX-445 qd in TC with TEZ and IVA for 4 weeks.
16509357|NCT03227471|Placebo Comparator|Part D1: Placebo|Subjects will receive placebo for 4 weeks.
16509358|NCT03227471|Experimental|Part D2: F/MF genotypes TC-High|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
16509359|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Mid|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
16509360|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Low|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
16509361|NCT03227471|Placebo Comparator|Part D2: Placebo|
16509362|NCT03227471|Experimental|Part E: F/F genotype - TC|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks
16509363|NCT03227471|Active Comparator|Part E: TEZ/IVA|Subjects will receive TEZ and IVA for 4 weeks.
16509364|NCT03227471|Experimental|Part F: F/MF genotypes - TC|Subjects will receive VX-445 in TC with TEZ and VX-561 for 4 weeks.
16509365|NCT03227471|Experimental|Part F: Placebo|
16509366|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
16509367|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
16509368|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
16509369|NCT03227445|Experimental|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
16509370|NCT03227445|Experimental|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
16509371|NCT03227445|Experimental|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
16509372|NCT03227445|Experimental|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
16509405|NCT03227198|Experimental|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
16509406|NCT03227198|Placebo Comparator|Placebo|Placebo intramyocardial injection in patients with Heart Failure
16509644|NCT03225261|Placebo Comparator|Placebo|Maltodextrin
16509373|NCT03227432|Experimental|Nivolumab + Elotuzumab|"22 patients will be entered, If > 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.
~Nivolumab will be administered intravenously twice per cycle for cycle 1-4
~Nivolumab will be administered intravenously once per cycle for cycle 5
~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2
~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4
~Elotuzumab will be administered intravenously once per cycle for cycle 5"
16509374|NCT03227432|Experimental|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"Nivolumab will be administered intravenously twice per cycle for cycle 1-4
~Nivolumab will be administered intravenously once per cycle for cycle 5
~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2
~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4
~Elotuzumab will be administered intravenously once per cycle for cycle 5
~Pomalidomide will be administered for 21 days per cycle
~Dexamethasone will be administered weekly"
16509375|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.
~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
16509376|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.
~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
16509377|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
16509378|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
16509379|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
16509380|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
16509381|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
16509382|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
16509383|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
16509384|NCT03227367|Experimental|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
16509385|NCT03227367|Other|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
16509386|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
16509387|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
16509388|NCT03227328|Active Comparator|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
16509389|NCT03227328|Experimental|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
16509390|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
16509391|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
16509392|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
16509393|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
16509394|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
16509395|NCT03227276|Placebo Comparator|Placebo|
16509396|NCT03227276|Experimental|Litramine|
16509399|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
16509400|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper & pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
16509401|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper & pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
16509402|NCT03227224|Placebo Comparator|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
16509403|NCT03227224|Experimental|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
16514973|NCT03188744||Group 2|Patients with CC without PFMD.
16509407|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.
~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
16509408|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.
~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
16509409|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
16509410|NCT03227133|Experimental|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
16509411|NCT03227120|Experimental|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
16509412|NCT03227120|No Intervention|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
16509413|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
16509414|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
16509415|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
16509416|NCT03227081|No Intervention|Sleep|Sleep
16509417|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
16509418|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
16509419|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
16509420|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
16509421|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
16509422|NCT03227029|Experimental|RSV 276 vaccine|Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
16509423|NCT03227029|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
16509424|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
16509425|NCT03226977|Experimental|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
16509426|NCT03226977|Active Comparator|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
16509427|NCT03226964|Experimental|High flow nasal oxygen|(Optiflow; Fisher & Paykel, Auckland, New Zealand)
16509428|NCT03226964|Active Comparator|Nasal prongs|
16509429|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
16509430|NCT03226925|Experimental|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
16509431|NCT03226925|Experimental|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
16509432|NCT03226925|Experimental|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
16509433|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet once daily (QD) plus a stable, medically appropriate dose of an XOI
16509434|NCT03226899|Placebo Comparator|Placebo + XOI|lesinurad placebo matching tablet plus a stable, medically appropriate dose of an XOI
16509435|NCT03226886||All patients|"In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.
~CAPTURE Sub-study:
~We plan to enrol patients/participants into three groups:
~Group A: patients with confirmed or suspected COVID-19 and a history of cancer Group B: patients without a history of COVID-19 infection and a history of cancer Group C: Hospital staff with or without a history of COVID-19"
16509436|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
16509645|NCT03225248|Experimental|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
16509437|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
16509438|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
16509439|NCT03226847|Experimental|Pulmonary Vein Isolation|ablation
16509440|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
16509441|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
16509442|NCT03226821|Experimental|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
16509443|NCT03226808|Other|Vivacit-E Liner|All subjects enrolled receive the study implant.
16509444|NCT03226795|Experimental|interventional arm|
16509445|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
16509446|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.
~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
16509447|NCT03226769|Active Comparator|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
16509448|NCT03226769|Experimental|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
16509449|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
16509450|NCT03226743|Experimental|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
16509451|NCT03226743|No Intervention|Control Group|treatment as usual in German health care system
16509452|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
16509453|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
16509454|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
16509455|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
16509456|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
16509457|NCT03226704||1|Patients 3-39 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy.
16509458|NCT03226691|Experimental|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
16509459|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (CAD)|
16509460|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)|
16509461|NCT03226652||Patients with clinically suspected sleep disordered breathing (SDB)|Patients referred for Sleep disordered breathing assessment.
16509462|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
16509463|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
16509464|NCT03226613|Experimental|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
16509465|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
16509466|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
16509467|NCT03226587|Experimental|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
16509468|NCT03226587|Placebo Comparator|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
16509469|NCT03226574|Experimental|RTX epidural injection|Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.
16509470|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
16509471|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
16509472|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
16509473|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
16509474|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
16509475|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
16509476|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
16509477|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
16509478|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
16509479|NCT03226496|Experimental|Intervention Group|This group receives a brief motivational interviewing session about PrEP
16509480|NCT03226496|No Intervention|Control Group|This group receives standard of care clinic based counseling about PrEP
16509481|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.
~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
16509482|NCT03226470|Experimental|T27 group|Subjects will receive suppository with T27 at 2 intervals for one month.
16509483|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
16509484|NCT03226470|No Intervention|Control group|Observation
16509485|NCT03226457|Active Comparator|Empagliflozin/Placebo|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
16509486|NCT03226457|Active Comparator|Placebo/Empagliflozin|Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
16509487|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
16509488|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
16509489|NCT03226444|Placebo Comparator|placebo|placebo solution
16509490|NCT03226431|Experimental|ARINA-1|Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
16509491|NCT03226418|Experimental|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.
~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
16509492|NCT03226418|Experimental|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.
~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for >= 3 months orally. Glasdegib dose is 100 mg oral daily.
~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
16509493|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.
~The Patient Navigation Program include
~Education,
~Appointment reminders,
~Help with insurance,
~Transportation,
~Navigating the Cancer Center,
~Assisting in finding appropriate child care,
~Interpreting,
~Connecting the patient to psychosocial and/or palliative care teams,
~Physically escorting the patient to appointments"
16509494|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,
~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
16509495|NCT03226392|Active Comparator|QAW039|QAW039 once daily
16509496|NCT03226392|Placebo Comparator|Placebo|Placebo once daily
16509497|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:
~Health system strengthening
~Delivery of a co-designed education program tailored to frontline healthcare workers
~Implementation of an algorithm for HIV-related meningoencephalitis
~Infectious diseases/AHD mentorship and laboratory capacity building"
16509498|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
16509499|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
16509500|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
16509501|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
16509502|NCT03226353|Experimental|somofilcon A 1-day soft contact lenses|Habitual and refitted wearers of omafilcon A were refit into somofilcon A for a week
16509503|NCT03226340|Experimental|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
16509504|NCT03226340|Active Comparator|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
16509505|NCT03226327|Experimental|hypertension patients|
16509506|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
16509507|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.
~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
16509508|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.
~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
16509509|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.
~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.
~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:
~progression according to IWCLL criteria or
~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).
~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
16509510|NCT03226275|Experimental|Fasting: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
16509511|NCT03226275|Experimental|Fasting: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
16509512|NCT03226275|Experimental|Fed: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
16509513|NCT03226275|Experimental|Fed: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
16509514|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
16509515|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
16509516|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
16509517|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
16509518|NCT03226210|Experimental|NovoRapid group (group Asp)|
16509519|NCT03226210|Experimental|Prandilin group (group Lis)|
16509520|NCT03226197|Experimental|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
16509521|NCT03226171|Experimental|Dose-adjusted SK-1403|
16509522|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C
~Will have MRI Motility and High Resolution Manometry
~Then will have:
~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo
~Both agents will have their matched placebo dispensed alongside the active product of the other agent.
~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
16509523|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
16509524|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
16509525|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
16509527|NCT03226119|Experimental|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
16509528|NCT03226106|Experimental|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
16509529|NCT03226106|Active Comparator|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
16509530|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
16509531|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
16509532|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
16509533|NCT03226067|Experimental|GKT137831 400mg twice daily|"GKT137831 400mg twice daily
~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
16509534|NCT03226067|Experimental|GKT137831 400mg once daily|"GKT137831 400mg once daily
~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
16509535|NCT03226067|Placebo Comparator|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
16509536|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
16509537|NCT03226041|Experimental|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
16509538|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.
~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
16509539|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
16509540|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
16509541|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
16509542|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
16509543|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
16509544|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
16509545|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
16509546|NCT03225950||Chronic periodontitis donors|"Donors are medically healthy.
~Slow to moderate attachment loss and bone destruction.
~Good correlation between etiological factors and serverity of attachment loss."
16509547|NCT03225950||Aggressive periodontitis donors|"Donors are medically healthy.
~Rapid attachment loss and bone destruction.
~Familial aggregation.
~No correlation between etiological factors and serverity of attachment loss."
16509548|NCT03225950||Control donors|"Donors are medically healthy.
~No sign of inflammatory conditions."
16509549|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
16509550|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
16509551|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
16509552|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
16509553|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
16509646|NCT03225248|Active Comparator|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
16509731|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
16509732|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
16509554|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
16509555|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
16509556|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
16509557|NCT03225885|Active Comparator|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
16509558|NCT03225885|Experimental|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
16509559|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
16509560|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
16509561|NCT03225846|Experimental|WVE-120102 (2 mg) or placebo|
16509562|NCT03225846|Experimental|WVE-120102 (4 mg) or placebo|
16509563|NCT03225846|Experimental|WVE-120102 (8 mg) or placebo|
16509564|NCT03225846|Experimental|WVE-120102 (16 mg) or placebo|
16509565|NCT03225846|Experimental|WVE-120102 (32 mg ) or placebo|
16509566|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
16509567|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
16509568|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
16509569|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
16509570|NCT03225833|Experimental|WVE-120101 (Dose E) or placebo|
16509571|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.
~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
16509572|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.
~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
16509573|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
16509574|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
16509575|NCT03225768|Experimental|Guided Training|
16509576|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
16509577|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
16509578|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
16509579|NCT03225729|Experimental|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.
~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
16509580|NCT03225729|Active Comparator|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
16509581|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily
~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
16509582|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
16509583|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
16509584|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
16509585|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
16509586|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
16509587|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
16509588|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
16509685|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
16509686|NCT03224949||Alcoholic cirrhosis with HCC|
16509687|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
16509589|NCT03225664|Experimental|Treatment (trametinib, pembrolizumab)|Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16509590|NCT03225651|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
16509591|NCT03225651|Experimental|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
16509592|NCT03225638|Other|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
16509593|NCT03225638|Other|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
16509594|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
16509595|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
~Exoskeleton or equivalent stimulation following this treatment."
16509596|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
~Virtual Reality or equivalent visualization following this treatment."
16509597|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
16509598|NCT03225599|Experimental|Procedure|
16509599|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
16509600|NCT03225560|Experimental|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
16509601|NCT03225560|Active Comparator|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
16509602|NCT03225547|Experimental|Cohort 1|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with hormone receptor positive, hormone refractory advanced breast cancer will be enrolled in cohort 1. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
16509603|NCT03225547|Experimental|Cohort 2|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with triple-negative advanced breast cancer will be enrolled in cohort 2. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
16509604|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.
~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
16509605|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.
~The following interventions will be carried out:
~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
16509606|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.
~Interventions:
~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.
~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.
~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.
~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
16509607|NCT03225495|Active Comparator|Standard Implant|
16509608|NCT03225495|Experimental|Ultra-narrow Implant|
16509609|NCT03225482|Experimental|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
16509610|NCT03225482|Active Comparator|SC|8-week Goal-focused Supportive Contact group
16509611|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
16509612|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
16509613|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
16509614|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
16509615|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
16510595|NCT03218917|Placebo Comparator|Placebo Oral Tablet|Once per day for 24 weeks.
16509616|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
16509617|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.
~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
16509618|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
16509619|NCT03225417|Experimental|Experimental group|"Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.
~Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
~Starting Dose of Ixazomib according to phase I."
16509620|NCT03225417|Other|Control group|Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
16509621|NCT03225404|Experimental|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
16509622|NCT03225404|Experimental|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
16509623|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
16509624|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
16509626|NCT03225365|Other|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.
~30 patients will be included in the arm."
16509627|NCT03225365|Other|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.
~30 patients will be included in the arm."
16509628|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
16509629|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
16509630|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
16509631|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
16509632|NCT03225339|Experimental|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
16509633|NCT03225339|No Intervention|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
16509634|NCT03225326|Experimental|Computer controlled 4% articaine delivery by Anaeject|
16509635|NCT03225326|Active Comparator|Conventional 4% articaine delivery by carpule syringe|
16509636|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
16509637|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
16509638|NCT03225313|Experimental|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
16509639|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
16509640|NCT03225287|Experimental|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
16509641|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
16509642|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
16509647|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:
~tumor (RS) = 1.5
~Late rectal and bladder complications = 3.0
~early rectal and bladder complications = 10.0."
16509648|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
16509649|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
16509650|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
16509651|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
16509652|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:
~WK1-WK12 (5 MR/DAY)
~WK13-14 (4 MR/DAY)
~WK 15 (3 MR/DAY)
~WK 16 (2 MR/DAY)
~WK 17-18 (1 MR/DAY)
~WK 19-24 (No MR)"
16509653|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
16509654|NCT03225183||1|Framingham Heart Study participants
16509655|NCT03225170|Sham Comparator|Control|The control group will rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the 9th ranked item and why it might be important to someone else. The control condition is consistent with the control used in other SA intervention studies. The 9th ranked item is chosen to inhibit a reverse effect, where participants feel affirmed because they do not value something that is averse to them.
16509656|NCT03225170|Experimental|Intervention|Arm Description: Participants will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
16509657|NCT03225157||1|Adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tractwho will undergo cisplatin chemotherapy with concurrent radiation.
16509658|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
16509659|NCT03225131||0|participants without AMD meaning no large drusen (= 125 microns) or advanced AMD in either eye
16509660|NCT03225131||1|participants with large drusen (= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
16509661|NCT03225131||2|participants with bilateral large drusen (= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
16509662|NCT03225131||3|participants with large drusen (= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
16509663|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
16509664|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
16509665|NCT03225105|Experimental|M3541 + Palliative Radiotherapy (RT)|
16509666|NCT03225092|Experimental|PRP Injection|Ultrasound-guided platelet rich plasma injection
16509667|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
16509668|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
16509669|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
16509670|NCT03225027|Experimental|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
16509671|NCT03225027|Experimental|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
16509672|NCT03225027|Experimental|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
16509673|NCT03225014|Active Comparator|Physical Therapy|
16509674|NCT03225014|Active Comparator|ARP Wave Therapy|
16509675|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
16509676|NCT03224988||Normal Adults|
16509677|NCT03224988||MCI Adults|
16509678|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
16509679|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
16509680|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
16509681|NCT03224949||Healthy controls|
16509682|NCT03224949||Alcoholic hepatitis|
16509683|NCT03224949||Alcoholic steatosis|
16509684|NCT03224949||Alcoholic cirrhosis without HCC|
16509688|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:
~If score under 2, patients will receive only aspirin 81 mg once daily
~If DAPT score is ≥ 2
~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen
~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily
~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
16509689|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
16509690|NCT03224897|Active Comparator|Cathodal tDCS|
16509691|NCT03224897|Active Comparator|Anodal tDCS|
16509692|NCT03224897|Sham Comparator|Sham tDCS|
16509693|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
16509694|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
16509695|NCT03224871|Experimental|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
16509696|NCT03224871|Experimental|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
16509697|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
16509698|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
16509699|NCT03224845|Experimental|Cognitive behavioural skills training|
16509700|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
16509701|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
16509702|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
16509703|NCT03224819|Experimental|Exploration Phase|Dose finding phase of the study
16509704|NCT03224819|Experimental|Expansion Phase|Maximum Tolerated Dose identified by Exploration Phase administered to subjects
16509705|NCT03224806|Other|Wholegrain bread|
16509706|NCT03224806|Other|White bread|
16509707|NCT03224806|Other|15% fiber-rich bread|
16509708|NCT03224806|Other|30% fiber-rich bread|
16509709|NCT03224793|Experimental|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
16509710|NCT03224793|Experimental|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
16509711|NCT03224793|Experimental|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
16509712|NCT03224793|Experimental|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
16509713|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
16509714|NCT03224741|Placebo Comparator|Information|
16509715|NCT03224741|Active Comparator|Active Choice|
16509716|NCT03224741|Experimental|Monetary incentive|
16509717|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
16509718|NCT03224715|Experimental|Actinic Cheilitis patients|
16509719|NCT03224702|Experimental|M6495|
16509720|NCT03224702|Placebo Comparator|Placebo|
16509721|NCT03224689|Experimental|PEEK Femoral|Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis who require a uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator will be invited to take part in this clinical investigation.
16509722|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
16509723|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
16509724|NCT03224650||Surgical|Patients treated surgically for spinal metastases
16509725|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
16509726|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
16509727|NCT03224637|Active Comparator|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
16509728|NCT03224637|Active Comparator|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
16509729|NCT03224624|Experimental|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
16509730|NCT03224624|No Intervention|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
16509733|NCT03224598|Experimental|No medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
16509734|NCT03224598|Experimental|Medically abrading|A-101 40% with the identified DPN lesions medically abraded prior to treatment
16509735|NCT03224598|Experimental|Initial cohort - no medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
16509736|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
16509737|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
16509738|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
16509739|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
16509740|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
16509741|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
16509742|NCT03224546|No Intervention|Control Group|This group will receive payment for providing urine samples throughout the trial.
16509743|NCT03224546|Experimental|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
16509744|NCT03224546|Experimental|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
16509745|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
16509746|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
16509747|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
16509748|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
16509749|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
16509750|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
16509751|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
16509752|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
16509753|NCT03224507|Experimental|KRdD followed by auto-HCT|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22 (KRd-Dara). Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Days 8 and 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, auto-HCT is done (consolidation 1), then up to two 4-cycle blocks of KRd-Dara consolidation (consolidations 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
16509754|NCT03224507|Experimental|KRdD only|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then @ 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22. Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Day 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, Following induction therapy, patients will receive up to three 4-cycle blocks of KRd-Dara consolidation (consolidations 1, 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
16509755|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.
~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
16509756|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.
~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
16509757|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
16509758|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
16509759|NCT03224468|Active Comparator|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
16509760|NCT03224468|No Intervention|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
16509761|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
16509762|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
16509763|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
16509764|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
16509765|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
16509766|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
16509767|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
16509768|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
16509769|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
16509770|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
16509771|NCT03224403|Placebo Comparator|Placebo|Placebo
16509772|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
16509773|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
16509774|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
16509775|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
16509776|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
16509777|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
16509778|NCT03224351|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
16509779|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Low Dose|Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
16509780|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Medium Dose|Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
16509781|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - High Dose|Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
16509782|NCT03224351|Active Comparator|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
16509783|NCT03224351|Experimental|Part 2: VX-659/TEZ/IVA TC|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
16509784|NCT03224351|Placebo Comparator|Part 3: Placebo|Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
16509785|NCT03224351|Experimental|Part 3: VX-659/TEZ/VX-561 TC|Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
16509786|NCT03224338|Experimental|: Dolutegravir (DTG)|
16509787|NCT03224325|Other|Placebo (Pooled)|TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.
16509788|NCT03224325|Experimental|TAK-831 100 mg|TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.
16509789|NCT03224325|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.
16509790|NCT03224325|Experimental|TAK-831 600 mg|TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.
16509791|NCT03224325|Experimental|TAK-831 15 mg|TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.
16509792|NCT03224325|Experimental|TAK-831 800 mg|TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
16509793|NCT03224325|Experimental|TAK-831 1200 mg|TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
16509794|NCT03224312||Primary aldosteronism|screened, confirmed and subtyped according to the guidelines.
16509795|NCT03224312||Essential hypertension|screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion
16509796|NCT03224299|Experimental|Investigational Product #1 (IP1)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
16509797|NCT03224299|Experimental|Investigational Product #2 (IP2)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
16509798|NCT03224299|Active Comparator|Active Control|ChloraPrep® - Hi-Lite Orange® applicator
16509799|NCT03224299|Placebo Comparator|Negative Control|sterile 0.9% saline applied with single use applicator
16509800|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
16509801|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
16509802|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
16509803|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
16509804|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
16509805|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
16509806|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
16509807|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
16509808|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
16509809|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
16509810|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
16509811|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
16509812|NCT03224247|Active Comparator|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
16509813|NCT03224247|Active Comparator|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
16509814|NCT03224234|Experimental|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
16509815|NCT03224234|Active Comparator|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
16509816|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
16509817|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
16509818|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.
~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
16509819|NCT03224182|Experimental|Qapzola|Participants were randomized to receive a single dose of Qapzola 8 mg by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
16509820|NCT03224182|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of Qapzole-matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
16509821|NCT03224169|Experimental|Intervention|Directly observed hand hygiene
16509822|NCT03224169|No Intervention|Control|No directly observed hand hygiene
16509823|NCT03224156||Dilated Cardiomyopathy|
16509824|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:
~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.
~The nurse presents the object (doll or cube) to the patient.
~The nurse leaves the patient alone with the object.
~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.
~The nurse returns into the room and takes back the object."
16509825|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:
~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.
~The nurse presents the cube to the patient.
~The nurse leaves the patient alone with the cube.
~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.
~The nurse returns into the room and takes back the cube."
16509826|NCT03224130|Experimental|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
16509827|NCT03224130|Active Comparator|Standard of Care|This arm will receive standard of care.
16509828|NCT03224117|Placebo Comparator|Placebo|SQ injection
16509829|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
16509830|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
16509831|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
16509832|NCT03224104|Experimental|Group A - TG02 + RT|Elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and radiation therapy.
16509833|NCT03224104|Experimental|Group B - TG02 + TMZ|Elderly patients with IDH1R132H-non mutant and MGMT promoter-methylated anaplastic astrocytoma or glioblastoma who will receive TG02 and temozolomide.
16509834|NCT03224104|Experimental|Group C - TG02|Patients initially diagnosed with anaplastic astrocytoma or glioblastoma at first relapse post TMZ/RT --> TMZ therapy who will receive TG02.
16509835|NCT03224091||Patients at Psychiatric Center Ballerup|
16509836|NCT03224091||Healthy Controls|
16509837|NCT03224091||Healthy Controls recovered from an eating disorder|
16509838|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
16509839|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
16509840|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
16509877|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
16509878|NCT03223805|Other|Control Arm|Usual Care
16509879|NCT03223805|Experimental|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
16509880|NCT03223792|Active Comparator|Control|
16509881|NCT03223792|Experimental|Investigational|
16509841|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.
~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.
~The dosing of all antibiotics will be adjusted according to creatinine clearance."
16509842|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
16509843|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include
~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose
~Normal saline 1ml intravenous (IV) push x 1 dose"
16509844|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:
~Normal saline 0.3 mL IN x 1 dose
~Morphine 0.1 mg/kg IV push x 1 dose"
16509845|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
16509846|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
16509847|NCT03224013|Active Comparator|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
16509848|NCT03224013|Active Comparator|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
16509849|NCT03224000|Experimental|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
16509850|NCT03224000|Active Comparator|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
16509851|NCT03223974|Experimental|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
16509852|NCT03223974|Active Comparator|DES in MB|with regular techniques
16509853|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
16509854|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
16509855|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
16509856|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
16509857|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
16509858|NCT03223935|Active Comparator|Roasted snacks|Corn nuts
16509859|NCT03223935|Experimental|Roasted chickpeas|Chickpeas
16509860|NCT03223935|Experimental|Roasted yellow peas|Yellow peas
16509861|NCT03223935|Experimental|Roasted pinto beans|Pinto beans
16509862|NCT03223935|Experimental|Roasted soybeans|Soybeans
16509863|NCT03223935|Experimental|Roasted almonds|Almonds
16509864|NCT03223922|Experimental|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
16509865|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
16509866|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
~1 drop every 4 hours for 90 days."
16509867|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.
~1 drop every 4 hours for 90 days."
16509868|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
16509869|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
16509870|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
16509871|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
16509872|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
16509873|NCT03223844|Experimental|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
16509874|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
16509875|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
16509876|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
16509882|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator
~Photon SBRT will be given during TAS-102 dosing
~TAS-102 dosing occurs on days 1 through 5 and 8 through 12
~TAS-102 tablets should be taken twice a day orally"
16509883|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
16509886|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
16509887|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
16509888|NCT03223714|Experimental|Conbercept|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).
~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
16509889|NCT03223714|Sham Comparator|Conbercept or sham|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).
~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
16509890|NCT03223701|Other|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
16509891|NCT03223688|Experimental|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
16509892|NCT03223688|Experimental|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
16509893|NCT03223688|Active Comparator|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
16509894|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
16509895|NCT03223662|Other|Neoadjuvant Chemoradiotherapy and esophagectomy|Standard of care neoadjuvant chemoradiotherapy (nCRT) and esophagectomy
16509896|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
16509897|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
16509898|NCT03223636||Healthy Volunteers|Healthy Volunteers
16509899|NCT03223623|Active Comparator|FHD|adults with Focal Hand Dystonia
16509900|NCT03223623|Placebo Comparator|Healthy Volunteer|adult healthy volunteers
16509901|NCT03223610|Experimental|Arm 1 Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
16509902|NCT03223610|Experimental|Arm 2 Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
16509903|NCT03223610|Experimental|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
16509904|NCT03223610|Experimental|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab,lenalidomide) for cycles 2-6
16509905|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
16509906|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
16509907|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
16509908|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
16509909|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
16509910|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
16509911|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
16509912|NCT03223571||Controls|Healthy people with no history of neurological pathologies
16509913|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
16509914|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
16509915|NCT03223545|Experimental|Mindfulness-based cognitive therapy delivered by telephone|
16509916|NCT03223545|Placebo Comparator|Usual Care (UC)|
16509917|NCT03223532|Active Comparator|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.
~*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
16509918|NCT03223532|Experimental|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
16509919|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
16509920|NCT03223519|Placebo Comparator|Placebo|
16509921|NCT03223519|Active Comparator|Ibuprofen|
16509922|NCT03223519|Active Comparator|Magnesium|
16509923|NCT03223519|Active Comparator|Vitamin C|
16509924|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
16509925|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
16509926|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
16509927|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
16509928|NCT03223480|Experimental|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated. A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
16509929|NCT03223467|Active Comparator|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
16509930|NCT03223467|Active Comparator|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
16509931|NCT03223467|Active Comparator|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
16509932|NCT03223467|No Intervention|No intervention|Study participants that do not want to undergo surgical treatment.
16509933|NCT03223454|Experimental|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
16509934|NCT03223454|Placebo Comparator|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
16509935|NCT03223454|Experimental|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
16509936|NCT03223454|Experimental|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
16509937|NCT03223454|Experimental|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
16509938|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
16509939|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
16509940|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
16509941|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
16509942|NCT03223389|Experimental|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
16509943|NCT03223389|Experimental|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
16509944|NCT03223376|Active Comparator|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
16509945|NCT03223376|Placebo Comparator|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
16509946|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
16509947|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
16509948|NCT03223350|Experimental|Capsaicin|0.1% capsaicin cream, one application
16509949|NCT03223350|Placebo Comparator|Placebo|Topical cream with no active drug
16510041|NCT03222609|Experimental|Navitoclax + ruxolitinib|Participants will be administered navitoclax once daily (QD) at various doses and a dose greater than or equal to 10 mg of ruxolitinib twice daily (BID).
16514974|NCT03188744||Group 3|Patients without CC with PFMD.
16509950|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
16509951|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
16509952|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
16509953|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
16509954|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
16509957|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
16509958|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
16509959|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
16509960|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
16509961|NCT03223246|No Intervention|Usual care|
16509962|NCT03223246|Experimental|Additional teaching|
16509963|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
16509964|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
16509965|NCT03223220|Experimental|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
16509966|NCT03223220|Placebo Comparator|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
16509967|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
16509968|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
16509969|NCT03223194|Experimental|Cohort 1|1.5 x 10^12 vg/kg of AT342 delivered intravenously one time
16509970|NCT03223194|Experimental|Cohort 2|6.0 x 10^12 vg/kg of AT342 delivered intravenously one time
16509971|NCT03223194|Experimental|Cohort 3|1.5 x 10^13 vg/kg of AT342 delivered intravenously one time
16509972|NCT03223194|No Intervention|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
16509973|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
16509974|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
16509975|NCT03223155|Experimental|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
16509976|NCT03223155|Experimental|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
16509977|NCT03223142|Experimental|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
16510042|NCT03222609|Experimental|Navitoclax|Participants will be administered various doses of navitoclax once daily (QD)
16510043|NCT03222596|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
16509978|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.
~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
16509979|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.
~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
16509980|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.
~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
16509981|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
16509982|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
16509983|NCT03223090|Experimental|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
16509984|NCT03223090|Active Comparator|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
16509985|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
16509986|NCT03223064|Experimental|PSMA PET-CT and USPIO MRI|
16509987|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.
~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
16509988|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
16509989|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
16509990|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
16509991|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
16509992|NCT03222986||Sepsis with organ failure|Patients have organ failure
16509993|NCT03222986||Sepsis without organ failure|Patients have no organ failure
16509994|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
16509995|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
16509996|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
16509997|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
16509998|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
16509999|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
16510000|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
16510001|NCT03222908|No Intervention|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
16510002|NCT03222908|Experimental|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
16510003|NCT03222908|Experimental|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
16510004|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
16510005|NCT03222882|Experimental|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
16510006|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
16510007|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
16510008|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
16510009|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
16510010|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
16510011|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
16510012|NCT03222830|Experimental|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .
~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
16510013|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
16510014|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
16510015|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
16510016|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
16510017|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
16510018|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
16510019|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
16510020|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
16510021|NCT03222765|Placebo Comparator|Placebo|"Placebo
~Lifestyle modification (diet and physical activity recommendations)"
16510022|NCT03222765|Experimental|Metformin|"Metformin
~Lifestyle modification (diet and physical activity recommendations)"
16510023|NCT03222765|Experimental|Linagliptin|"Linagliptin
~Lifestyle modification (diet and physical activity recommendations)"
16510024|NCT03222765|Experimental|Linagliptin and Metformin|"Fixed dose combination of Linagliptin and metformin
~Lifestyle modification (diet and physical activity recommendations)"
16510025|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
16510026|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
16510027|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
16510028|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
16510029|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
16510030|NCT03222700||robotic thyroidectomy group|
16510031|NCT03222700||open thyroidectomy group|
16510032|NCT03222687|Experimental|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
16510033|NCT03222674|Experimental|Single arm|CAR T cells to treat AML
16510036|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
16510037|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
16510038|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
16510039|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
16510040|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
16511037|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
16510044|NCT03222596|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
16510045|NCT03222583|Experimental|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.
~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
16510046|NCT03222583|Experimental|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.
~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
16510050|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
16510051|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
16510052|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
16510053|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
16510054|NCT03222531|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"HCV seropositive non-viremic (HCV Ab+/NAT-) donor hearts to HCV seronegative recipients.
~Heart recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.
~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
~Intervention: Drug: sofosbuvir/velpatasvir"
16510055|NCT03222531|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|"HCV seropositive viremic (HCV Ab+/NAT+) donor hearts to HCV seronegative recipients.
~Starting post-operative day 1, heart recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
~Intervention: Drug: sofosbuvir/velpatasvir"
16510056|NCT03222518|Active Comparator|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
16510057|NCT03222518|Active Comparator|NSAID Group|The patient receives an envelope containing NSAID 20 mg piroxicam twice daily / day + follow-up sheet + appointment card.
16510058|NCT03222518|Active Comparator|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 20 mg piroxicam at a dose of 2 times/day + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
16510059|NCT03222505|Experimental|Treadmill|
16510060|NCT03222505|Experimental|Overground Walking|
16510061|NCT03222492|Experimental|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.
~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
16510062|NCT03222492|Placebo Comparator|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.
~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
16510063|NCT03222492|Experimental|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.
~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
16510197|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
16510246|NCT03221257|Experimental|Pirfenidone (PFD) + Mycophenolate (MMF)|Participants will receive Pirfenidone (PFD) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
16510064|NCT03222492|Placebo Comparator|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.
~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
16510065|NCT03222492|Experimental|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.
~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
16510066|NCT03222492|Placebo Comparator|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.
~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
16510067|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
16510068|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
16510069|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
16510070|NCT03222453|Experimental|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
16510071|NCT03222453|No Intervention|non-intervention Patient|No treatment
16510072|NCT03222440|Experimental|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
16510073|NCT03222427|Experimental|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
16510074|NCT03222427|Experimental|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion.
16510075|NCT03222414|Experimental|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
16510076|NCT03222414|Active Comparator|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
16510077|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
16510078|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
16510079|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
16510080|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
16510081|NCT03222388||IIEF5 paper-electronic|
16510082|NCT03222388||IIEF5 electronic-paper|
16510083|NCT03222388||IIEF15 paper-electronic|
16510084|NCT03222388||IIEF15 electronic-paper|
16510085|NCT03222388||IIEF5 electronic-electronic|
16510086|NCT03222388||IIEF15 electronic-electronic|
16510087|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
16510088|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
16510089|NCT03222349|Experimental|Interictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
16510090|NCT03222349|Experimental|Ictal/Peri-ictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
16510091|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
16510092|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
16510093|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
16510094|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
16510095|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
16510096|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
16510097|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
16510098|NCT03222284|Experimental|Group 1|"N=10 Device intervention
~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
16510099|NCT03222284|Experimental|Group 2|"N=20 Device intervention
~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
16510100|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:
~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).
~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.
~Respiratory rate (RR): 10-12 breath/minute."
16510307|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
16510101|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:
~Patient's height in cm..
~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).
~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O
~Minimum and maximum Pressure Support (PS) :8-16
~Respiratory rate :10-12 breath/min."
16510102|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
16510103|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
16510104|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
16510105|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
16510106|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
16510107|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
16510108|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
16510109|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
16510110|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
16510111|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
16510112|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
16510113|NCT03222206|Experimental|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
16510114|NCT03222206|Placebo Comparator|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
16510115|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
16510116|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
16510117|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
16510118|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
16510119|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
16510120|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
16510121|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
16510122|NCT03222141|Experimental|SAPIEN 3™ valve|
16510123|NCT03222128|Experimental|PIIS3i - SAPIEN 3|PIIS3i - SAPIEN 3 is Operable Group
16510124|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
16510125|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
16510126|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.
~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.
~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
16510127|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.
~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
16510128|NCT03222076|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16510129|NCT03222076|Experimental|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16510130|NCT03222076|Experimental|Arm C (ipilimumab, nivolumab)|Patients receive ipilimumab and nivolumab as in Arm B. Patients undergo post-treatment biopsy on day 1 of week 7, then receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks up to 2 years in the absence of disease progression or unacceptable toxicity.
16510165|NCT03221816|Placebo Comparator|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.
~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.
~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
16510558|NCT03219125||Group 2 (controls)|no history of fragility fracture
16510131|NCT03222063|Experimental|Experimental group|"Experimental Group:
~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
16510132|NCT03222063|No Intervention|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
16510133|NCT03222050|Experimental|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
16510134|NCT03222050|Experimental|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
16510135|NCT03222050|Experimental|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
16510136|NCT03222050|No Intervention|control group|Routine care was given during immunization and no intervention was given
16510137|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
16510138|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
16510139|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
16510140|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
16510141|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
16510142|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
16510143|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
16510144|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
16510145|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
16510146|NCT03221985|Other|Questionnaires|
16510147|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
16510148|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
16510149|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
16510150|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
16510151|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
16510152|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
16510153|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
16510154|NCT03221907|Experimental|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
16510155|NCT03221907|Active Comparator|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
16510156|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
16510157|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
16510158|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
16510159|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
16510160|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
16510161|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
16510162|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
16510163|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
16510164|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
16510195|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
16510196|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
16510166|NCT03221816|Experimental|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.
~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
16510167|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
16510168|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
16510169|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
16510170|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
16510171|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
16510172|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
16510173|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
16510174|NCT03221764|Experimental|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
16510175|NCT03221751|Experimental|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
16510176|NCT03221751|Placebo Comparator|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
16510177|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
16510178|NCT03221725|Experimental|sacrospinosus fixation group|The group which sacrospinous fixation was performed
16510179|NCT03221699|Placebo Comparator|control|Formula without ZnO
16510180|NCT03221699|Active Comparator|intervention|Formula with ZnO
16510181|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
16510182|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
16510183|NCT03221660|Experimental|F-Composite 2 system|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the F-Composite 2 system.
16510184|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
16510185|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
16510186|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
16510187|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
16510188|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
16510189|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
16510190|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
16510191|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
16510192|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
16510193|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
16510194|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
16511884|NCT03209427|Active Comparator|Group II|iIntrathecal injection of 200 μg morphine
16510198|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
16510199|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
16510200|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
16510201|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
16510202|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
16510203|NCT03221517|Experimental|Cohort 1|Shift workers receive a standardized meal with a glucose challenge test
16510204|NCT03221517|Experimental|Cohort 2|Matched healthy controls receive a standardized meal with a glucose challenge test
16510205|NCT03221504|Active Comparator|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
16510206|NCT03221504|Experimental|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
16510207|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
16510208|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
16510209|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
16510210|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
16510211|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
16510212|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
16510213|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
16510214|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
16510215|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
16510216|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
16510217|NCT03221439|Experimental|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
16510218|NCT03221439|Active Comparator|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
16510219|NCT03221426|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
16510244|NCT03221270|Sham Comparator|Sham tACS (alpha)|20 participants: Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation, then once weekly for 8 weeks of maintenance stimulation.
16510245|NCT03221257|Placebo Comparator|Placebo (Plac) + Mycophenolate (MMF)|Participants will receive Placebo (Plac) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
16510220|NCT03221426|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
16510221|NCT03221426|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).
~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion Day 1 Q3W PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
16510222|NCT03221426|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).
~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
16510223|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
16510224|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
16510225|NCT03221400|Experimental|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
16510226|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
16510227|NCT03221400|Experimental|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
16510228|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Niraparib|Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
16510229|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
16510230|NCT03221374|Experimental|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
16510231|NCT03221374|No Intervention|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
16510232|NCT03221361|Active Comparator|Thermoplastic resin group|Thermoplastic complete denture placement is done
16510233|NCT03221361|Placebo Comparator|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
16510234|NCT03221348|Experimental|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
16510235|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
16510236|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
16510237|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
16510238|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening
~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
16510239|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).
~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
16510240|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
16510241|NCT03221283|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
16510242|NCT03221283|Experimental|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
16510243|NCT03221270|Experimental|tACS (alpha)|20 participants: 10 Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily during 5 consecutive days of stimulation, then 40 minutes once weekly for 8 weeks of maintenance stimulation.
16514975|NCT03188744||Group 4|Patients without CC without PFMD.
16510247|NCT03221244|Experimental|VR Treatment|"The VR distractor condition is an adaptive training, experimental treatment. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context. Distractors will be presented intermittently throughout the test session. During training sessions, distractor saliency and frequency will increase or decrease based on performance on the tests.
~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.
~The investigators expect a decrease in distraction after adaptive distractor exposure in the VR classroom."
16510248|NCT03221244|Active Comparator|VR Active Control|"The VR classroom with no distractors presented is an active control group. This group will undergo the same training regimen, only their virtual classroom environment will not contain adaptive distractors. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context.
~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.
~The investigators expect no change in response to distraction in the ADHD group after control exposure to the VR classroom."
16510249|NCT03221231|Experimental|N-acetylcysteine|
16510250|NCT03221231|Placebo Comparator|Placebo|
16510251|NCT03221231|Active Comparator|Healthy controls|
16510252|NCT03221218|Experimental|Enhanced screening-informed letter|Family physicians will receive a letter that includes their patient's screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines for MTBI (2013).
16510253|NCT03221218|No Intervention|Standard letter|Family physicians will receive a letter that includes generic recommendations for managing MTBI based on the Ontario Neurotrauma Foundation clinical practice guidelines (2013). Screening test results will not be provided.
16510254|NCT03221205|Sham Comparator|Sham CPAP|Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
16510255|NCT03221205|Experimental|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
16510256|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
16510257|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
16510258|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
16510259|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
16510260|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
16510261|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
16510262|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
16510263|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
16510264|NCT03221114|Experimental|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
16510265|NCT03221114|No Intervention|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
16510266|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
16510267|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings
~PS mode
~IPAP according to clinical and hemodynamic tolerance
~EPAP according to air trapping
~RR around 12/ min.
~LOT for SaO2 > 90%
~Monitoring with capnometry for settings validation"
16510268|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
16510269|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
16510270|NCT03221088|No Intervention|Negative control group|Untreated Control Group
16510271|NCT03221075||Invasive Aspergillosis|
16510272|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
16510273|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
16510274|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
16510275|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
16510276|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
16510277|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
16510278|NCT03221036|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
16510279|NCT03221036|Placebo Comparator|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
16510280|NCT03221036|Experimental|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
16511126|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
16510281|NCT03221036|Placebo Comparator|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
16510282|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
16510283|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
16510284|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
16510285|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
16510286|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
16510287|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:
~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.
~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
16510288|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
16510289|NCT03220971||proposed cross-section study|"100 subjects with NAFLD/NASH and negative anti-HCV Ab
~50 subjects with HCC and negative anti-HCV Ab
~50 subjects with HCC and positive for genotype-1 HCV
~50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV
~50 controls with all negative for NAFL, NASH and HCV"
16510290|NCT03220971||proposed longitudinal study|"50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR
~10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR
~10 HCC patients and positive for genotype-1 HCV with SVR
~10 HCC patients and positive for genotype-1 HCV without SVR
~50 chronic hepatitis C but not NAFLD patients with SVR
~10 chronic hepatitis C but not NAFLD patients without SVR"
16510291|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
16510292|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
16510293|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
16510294|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
16510295|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
16510296|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
16510297|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
16510298|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
16510299|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
16510300|NCT03220893||Women with Dense Breast Tissue|"Subjects will have had heterogeneously dense or extremely dense breasts on most recent prior mammographic examination (Breast Imaging Reporting and Data System (BI-RADS) c or d) and be asymptomatic for breast disease.
~Subjects will receive Molecular Breast Imaging (MBI) and Digital Breast Tomosynthesis (DBT) at Year 0 screening within a 24-hour period. All patients who did not receive a diagnosis of breast cancer during the Year 0 screening will undergo DBT and MBI at approximately one year (Year 1 screening), again within a 24-hour period."
16510301|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
16510302|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
16510303|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
16510308|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
16510309|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
16510310|NCT03220828|Experimental|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
16510311|NCT03220815|Experimental|Biologic drilling drilling at low speed|
16510312|NCT03220815|Active Comparator|conventional drilling drilling at high speed|
16510313|NCT03220802|Experimental|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
16510314|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
16510315|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
16510316|NCT03220776|Experimental|N-Acetylcysteine|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
16510317|NCT03220776|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
16510318|NCT03220776|Placebo Comparator|Placebo Oral Tablet|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
16510319|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
16510320|NCT03220737|Experimental|Cohort 1 (active, 12-17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
16510321|NCT03220737|Placebo Comparator|Cohort 1 (placebo, 12 - 17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
16510322|NCT03220737|Experimental|Cohort 2 (active, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
16510323|NCT03220737|Placebo Comparator|Cohort 2 (placebo, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
16510324|NCT03220737|Experimental|Cohort 3 (active, 2 - 5 yrs)|Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
16510325|NCT03220737|Placebo Comparator|Cohort 3 (placebo, 2 - 5 yrs)|Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
16510326|NCT03220737|Other|Historical Control: Adult Bridging Population|This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
16510327|NCT03220724|Experimental|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
16510328|NCT03220724|Experimental|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
16510329|NCT03220724|Experimental|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
16510330|NCT03220724|Placebo Comparator|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
16510331|NCT03220724|Experimental|Part B: Group 5|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, 8, 12, and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
16510332|NCT03220724|Experimental|Part B: Group 6|Participants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8; CH505w78 at Months 12 and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
16510333|NCT03220724|Experimental|Part B: Group 7|Participants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, 8, 12, and 16.
16510334|NCT03220724|Placebo Comparator|Part B: Group 8|Participants will receive placebo at Months 0, 2, 4, 8, 12, and 16.
16510335|NCT03220711|Experimental|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
16510336|NCT03220685||1.normal persons|normal persons include 25 person
16510337|NCT03220685||2.CKD pt with anemia|includes 25 previously diagnosed CKD patients with or without treatment of anemia.
16510338|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
16510339|NCT03220659|Placebo Comparator|Standard settings|Usual pacing programming
16510340|NCT03220659|Experimental|Multi-point pacing|MPP programming
16510341|NCT03220646|Experimental|A:recurrent IDH wildtype RB1 intact grade II and III gliomas|The main study cohort will consist of patients with recurrent IDH wildtype, RB1 wildtype, WHO grade II and III gliomas that have failed previous therapy. This arm is currently on hold.
16510342|NCT03220646|Experimental|B:Recurrent glioma any grade|Ten patients who require standard of care cytoreductive surgery for recurrent astrocytoma, oligodendroglioma, or glioblastoma, will be offered pre-surgical abemaciclib and then resume the drug following recovery from surgery, continuing until disease progression or unacceptable toxicity analogous to the non-surgical patients in cohort A and C. This arm is closed to accrual.
16510343|NCT03220646|Experimental|C:All other recurrent brain tumors|This is an exploratory cohort including patients with recurrent IDH mutant glioma, meningioma, recurrent ependymoma, and recurrent PCNSL,and other primary brain tumors.
16512518|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
16510344|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
16510345|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
16510346|NCT03220620||GDT Group|receives goal-directed therapy
16510347|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
16510348|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
16510349|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
16510350|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
16510351|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
16510352|NCT03220581|Active Comparator|Referral for care|Referral for mental health issues and family support services
16510353|NCT03220581|Experimental|Behavioral therapy|8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors
16510354|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
16510355|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
16510356|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
16510357|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
16510358|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
16510359|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
16510360|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
16510361|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
16510362|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
16510363|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
16510364|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
16510365|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
16510366|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
16510367|NCT03220503|Experimental|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
16510368|NCT03220503|No Intervention|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
16510369|NCT03220490|Experimental|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.
~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.
~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
16510370|NCT03220490|Experimental|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.
~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.
~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
16510371|NCT03220490|Experimental|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.
~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
16514976|NCT03188731||Pregnant Women|
16510372|NCT03220490|Experimental|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.
~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
16510373|NCT03220477|Experimental|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
16510374|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
16510375|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
16510376|NCT03220438|Active Comparator|TMS|rTMS
16510377|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
16510378|NCT03220425|Experimental|Insulin detemir|
16510379|NCT03220425|Active Comparator|NPH insulin|
16510380|NCT03220412|Experimental|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
16510381|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
16510382|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1
~1capsule, oral dosing"
16510383|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2
~1Tablet, oral dosing"
16510384|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
16510385|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
16510386|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
16510387|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
16510388|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
16510389|NCT03220347|Experimental|CC-90010 in patients with solid tumors and NHL|Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
16510390|NCT03220334|Experimental|Apply platelet rich plasma to the artificial gastric ulcer|
16510391|NCT03220334|Placebo Comparator|Apply normal saline to the artificial gastric ulcer|
16510392|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
16510393|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
16510394|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
16510395|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
16510396|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
16510397|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
16510398|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
16510399|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
16510400|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
16510401|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
16510402|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
16510403|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
16510404|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
16510405|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
16510406|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
16510407|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
16510408|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
16510409|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
16510410|NCT03220282|Active Comparator|Donor milk|Pasteurized donor breast milk
16510411|NCT03220282|Placebo Comparator|Preterm infant formula|Preterm formula determined by clinical practice
16510412|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
16510413|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
16510414|NCT03220256|Experimental|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
16510415|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
16510416|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
16510417|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
16510418|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
16510419|NCT03220204|Experimental|PP-based health behavior intervention|Participants will undergo a 12-week, Positive Psychology (PP)-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
16510420|NCT03220204|Experimental|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. This Motivational Interviewing (MI)-based educational control condition will introduce these participants to motivational interviewing topics in concert with the health behavior education topics.
16510421|NCT03220204|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group will not receive any interventions between the baseline visit and follow-up visits.
16510422|NCT03220191|Experimental|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
16510423|NCT03220178|Experimental|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
16510424|NCT03220178|Other|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
16510425|NCT03220165|Experimental|Treatment|MGL-3196
16510426|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
16510427|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
16510428|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
16510429|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
16510430|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
16510431|NCT03220113|Experimental|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.
~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
16510432|NCT03220100|Experimental|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
16510433|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
16510434|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
16510435|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
16510436|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
16510437|NCT03220061|No Intervention|control|usual care was given to participant in control group
16510438|NCT03220048|Other|Cohort A: Sentinel Group|Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
16510439|NCT03220048|Experimental|Cohort B: PrEP-001|PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
16510440|NCT03220048|Experimental|Cohort B: Placebo|Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
16510442|NCT03220022|Experimental|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
16510443|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.
~PART II: Patients undergo active surveillance for 1 year."
16510444|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.
~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
16510445|NCT03219996||non-survivor group|
16510446|NCT03219996||survivor group|
16510447|NCT03219983|Active Comparator|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
16510448|NCT03219983|Active Comparator|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
16510449|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
16510450|NCT03219957|Experimental|AT-527|
16510451|NCT03219957|Placebo Comparator|Placebo|
16510452|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
16510453|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
16510454|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
16510455|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
16510456|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
16510457|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
16510458|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
16510459|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
16510460|NCT03219905|Experimental|Kinesio-taping Group|Therapeutic Kinesio-taping
16510461|NCT03219905|Sham Comparator|Control Group|Sham Kinesio-taping
16510462|NCT03219892|Experimental|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
16510463|NCT03219892|Sham Comparator|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
16510464|NCT03219879|Experimental|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
16510465|NCT03219879|Active Comparator|Usual care|Treatment as usual
16510466|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
16510467|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
16510468|NCT03219853|Experimental|Lower selenium-status|
16510469|NCT03219853|Experimental|higher selenium|
16510470|NCT03219840|Experimental|CPC + Xylitol chewing gum, then Xylitol only chewing gum|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
16510559|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
16510560|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
16510471|NCT03219840|Experimental|Xylitol only chewing gum, then CPC + Xylitol chewing gum|Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
16510472|NCT03219827|Experimental|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.
~Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)
~After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
16510473|NCT03219827|Experimental|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.
~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
16510474|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.
~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
16510475|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
16510476|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
16510477|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
16510478|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
16510479|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
16510480|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
16510481|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
16510482|NCT03219775|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy
~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
16510483|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
16510484|NCT03219749|Experimental|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
16510485|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
16510486|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
16510561|NCT03219086|Active Comparator|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
16512519|NCT03205137||telmisartan+amlodipine double-pill combination group|
16510487|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
16510488|NCT03219710|Active Comparator|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:
~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;
~The patient on control group with weight category of > 40 kg will receive:
~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg
~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
16510489|NCT03219710|Experimental|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)
~Weight category of > 40 kg in study group will receive:
~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant & Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
16510490|NCT03219697|Experimental|Parenting education program|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits
16510491|NCT03219697|No Intervention|Control|Receive regular health care
16510492|NCT03219671|Experimental|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
16510493|NCT03219658|Experimental|Parenting education sessions|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits.
16510494|NCT03219658|No Intervention|Control|Attend one-on-one check-ins with the interdisciplinary team at STOMP; wait-listed control group.
16510495|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
16510496|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
16510497|NCT03219619|Experimental|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
16510498|NCT03219619|Active Comparator|Duo group: Duo|Undergoing side-viewing duodenoscope
16510499|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
16510500|NCT03219593|Experimental|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
16510501|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
16510502|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
16510503|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
16510504|NCT03219541|Active Comparator|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
16510505|NCT03219541|Placebo Comparator|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
16510506|NCT03219528|Active Comparator|Rifaximin|Rifaximin 550 mg three times daily for 14 days
16510507|NCT03219528|Active Comparator|Low FODMAP Group|Low FODMAP diet for 4 weeks
16510508|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
16510509|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
16510510|NCT03219502|Experimental|Group I (rTMS)|Patients undergo rTMS over 30 minutes for 10 sessions over 10 business days.
16510511|NCT03219502|Sham Comparator|Group II (sham rTMS)|Patients undergo sham rTMS over 30 minutes for 10 sessions over 10 business days.
16510512|NCT03219502|Active Comparator|Group III (standard of care)|Patients receive standard of care.
16510513|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
16510514|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
16510562|NCT03219086|Active Comparator|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
16510515|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
16510516|NCT03219463|Experimental|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
16510517|NCT03219463|Active Comparator|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
16510518|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.
~The priming shots will comprise days 1, 4, 8, 15, and 22.
~Booster shots will be given on days 78 and 134."
16510519|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.
~The priming shots will comprise days 1, 4, 8, 15, and 22.
~Booster shots will be given on days 78 and 134.
~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
16510520|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide + Pembrolizumab|"NeoVax will be administered in a priming and booster phase.
~The priming shots will comprise days 1, 4, 8, 15, and 22.
~Booster shots will be given on days 78 and 134.
~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5
~Pembrolizumab will be administered starting on Week 12 Day 78 and for up to 2 years"
16510521|NCT03219437|Active Comparator|Methotrexate|Participants to receive double-blind methotrexate.
16510522|NCT03219437|Experimental|Risankizumab|Participants to receive double-blind risankizumab.
16510523|NCT03219411|Active Comparator|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
16510524|NCT03219411|Placebo Comparator|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
16510525|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
16510526|NCT03219398|Active Comparator|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
16510527|NCT03219385|Experimental|Treatment with the Mirabilis System|
16510528|NCT03219372|Experimental|Pravastatin Pill|Daily pravastatin (40mg)
16510529|NCT03219372|Placebo Comparator|Placebo Oral Tablet|Placebo
16510530|NCT03219359|Experimental|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
16510531|NCT03219346|Experimental|Oral hygiene|
16510533|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
16510534|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
16510535|NCT03219307|Experimental|NOVOCART 3D|Matrix associated autologous chondrocyte implant
16510536|NCT03219294|Active Comparator|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
16510537|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
16510540|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
16510541|NCT03219242|Experimental|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
16510542|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
16510543|NCT03219216|Experimental|Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
16510544|NCT03219216|Experimental|Arm B: GLE/PIB for 12 Weeks|Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.
16510545|NCT03219203|Experimental|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
16510546|NCT03219203|Active Comparator|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
16510547|NCT03219190|Experimental|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
16510548|NCT03219190|No Intervention|Treatment as Usual (Control)|Standard health education
16510549|NCT03219177|Experimental|Patient education group|
16510550|NCT03219177|Active Comparator|Control- Standard of care counseling|
16510553|NCT03219151|Experimental|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
16510554|NCT03219151|Active Comparator|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
16510555|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
16510556|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
16510557|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
16510563|NCT03219073|Sham Comparator|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
16510564|NCT03219073|Active Comparator|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
16510565|NCT03219060|Experimental|Intervention group|MI based four individual sessions
16510566|NCT03219060|Active Comparator|Control group|Brief advice following 5As
16510567|NCT03219047|Experimental|Cohort 2 (Co-trial cohort)|Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. Patients who experience relapse after treatment with ibrutinib are moved to Cohort I if the PDX models are not ready.
16510568|NCT03219047|Experimental|Cohort I (Traditional cohort)|Patients who have previously received ibrutinib, acalabrutinib, PI3K inhibitor ACP-319, or BTK inhibitor BGB-3111 receive treatment through ongoing clinical trials at MD Anderson or standard of care. At the same time, previously collected tissue is used to develop PDX models and suitable drugs/regimens are tested in the PDX models. Patients then receive treatment based on the results of the PDX models through another clinical trial or standard of care.
16510569|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
16510570|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
16510571|NCT03219008|Experimental|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
16510572|NCT03219008|Experimental|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
16510573|NCT03219008|Experimental|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
16510574|NCT03219008|Experimental|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
16510575|NCT03219008|Experimental|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
16510576|NCT03219008|Experimental|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
16510577|NCT03219008|Experimental|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
16510578|NCT03219008|Experimental|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
16510579|NCT03219008|Experimental|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
16510580|NCT03219008|Experimental|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
16510581|NCT03219008|Experimental|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
16510582|NCT03219008|Experimental|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
16510583|NCT03219008|Experimental|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
16510584|NCT03218995|Experimental|Experimental: Treated Group|
16510585|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
16510586|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
16510587|NCT03218969|Experimental|Study period 1|"Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by
~Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by
~Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
16510588|NCT03218969|Experimental|Study period 2|"Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by
~Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by
~Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
16510589|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
16510590|NCT03218943|Active Comparator|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
16510591|NCT03218943|Active Comparator|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
16510592|NCT03218930|Other|Social marketing intervention|Participants will receive a total combination of four interventions.
16510593|NCT03218917|Experimental|INS1007 10 mg Oral Tablet|Once per day for 24 weeks.
16510596|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
16510597|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
16510598|NCT03218891|Experimental|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.
~The intervention is the Cardiac Rehabilitation."
16510599|NCT03218891|No Intervention|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
16510600|NCT03218891|No Intervention|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
16510601|NCT03218891|No Intervention|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
16510602|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
16510603|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
16510604|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)
~cyclophosphamide(1g intravenous use,per 1 month*6months);
~supportive care,including ACE-I or ARBs and blood pressure control"
16510605|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);
~supportive care,including ACE-I or ARBs and blood pressure control"
16510606|NCT03218839|Experimental|HIV+ PrePex|PrePex male circumcision device
16510607|NCT03218826|Experimental|Treatment (docetaxel, PI3Kbeta inhibitor AZD8186)|Patients receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity.
16510608|NCT03218813|No Intervention|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
16510609|NCT03218813|Experimental|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
16510610|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
16510611|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
16510612|NCT03218787|Experimental|XIENCE + 3-month DAPT|
16510613|NCT03218774|Other|Home Group|
16510614|NCT03218774|Experimental|Center Group|
16510615|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.
~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
16510616|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.
~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
16510617|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.
~Fidelity to manual: rated by a research assistant who is present during the group session"
16510618|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
16510619|NCT03218735|Experimental|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
16510620|NCT03218735|Active Comparator|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
16510621|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
16510622|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
16510623|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
16510624|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
16510625|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
16510626|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
16510627|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
16510628|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
16510632|NCT03218657|Experimental|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
16510633|NCT03218657|Other|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
16510634|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
16510635|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
16510636|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
16510637|NCT03218605|Experimental|healthy active participants|
16510638|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
16510639|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
16510640|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
16510641|NCT03218579|No Intervention|No intervention|No intervention after antibiotic treatment.
16510642|NCT03218579|Active Comparator|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
16510643|NCT03218579|Active Comparator|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
16510644|NCT03218566|Other|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
16510645|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
16510646|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
16510647|NCT03218540|Experimental|SVV group|Fluid management protocol
16510648|NCT03218540|Active Comparator|CVP group|Fluid management protocol
16510649|NCT03218501|Active Comparator|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
16510650|NCT03218501|Active Comparator|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
16510651|NCT03218501|Placebo Comparator|Placebo|Placebo is to be administered orally once daily for 2 weeks
16510653|NCT03218475|Experimental|MR Guided Focused Ultrasound|
16510654|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
16510655|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
16510656|NCT03218449||1/NC|noninfective complication
16510657|NCT03218449||2/IC|infective complication
16510658|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
16510659|NCT03218436|No Intervention|Control cohort|no intervention
16510660|NCT03218410|Active Comparator|surgical pulmonary embolectomy|
16510661|NCT03218410|Active Comparator|catheter-directed thrombolysis|
16510662|NCT03218397|Active Comparator|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
16510663|NCT03218397|Active Comparator|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
16510664|NCT03218384|Experimental|ferric carboxymaltose|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
16510665|NCT03218384|Active Comparator|Placebo|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
16510666|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
16510667|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
16510668|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
16510669|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
16510670|NCT03218332||Healthy controls|Active Comparator
16510671|NCT03218319|Experimental|All patients|
16510672|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
16510673|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
16510674|NCT03218293|Experimental|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
16510675|NCT03218293|No Intervention|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
16510676|NCT03218280|Active Comparator|Antioxidant Therapy|
16510677|NCT03218280|No Intervention|Antioxidant Free|
16510775|NCT03217565|Experimental|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered intravenously (IV). For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
16510678|NCT03218267|Experimental|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
16510679|NCT03218267|Active Comparator|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
16510680|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
16510681|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
16510682|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
16510683|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
16510684|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
16510685|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
16510686|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
16510687|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
16510688|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
16510689|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
16510690|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
16510691|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
16510692|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
16510693|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
16510694|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
16510695|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
16510696|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
16510697|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
16510698|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
16510699|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
16510700|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
16510702|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
16510703|NCT03218111|Other|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
16510704|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
16510705|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
16510706|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
16510707|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
16510708|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
16510709|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
16510710|NCT03218033|No Intervention|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
16510711|NCT03218033|Active Comparator|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.
~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
16511125|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
16510712|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
16510713|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
16510714|NCT03218007|Experimental|acute coronary syndrome|
16510715|NCT03217994|Active Comparator|37.5% gel|37.5% gel to bleach teeth
16510716|NCT03217994|Experimental|6% gel|6% gel to bleach teeth
16510717|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
16510718|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
16510719|NCT03217968|Experimental|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
16510720|NCT03217955|Experimental|CBT-SA|"Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;
~Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
16510721|NCT03217955|Active Comparator|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
16510722|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
16510723|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
16510724|NCT03217929|Active Comparator|Active-taVNS|
16510725|NCT03217929|Sham Comparator|Sham-taVNS|
16510726|NCT03217916||normotensive groups|pregnant women with normal blood pressure
16510727|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
16510728|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
16510729|NCT03217877|Active Comparator|No Routine stress testing after PCI|
16510730|NCT03217877|Experimental|Routine stress testing at 9~15 months after PCI|
16510731|NCT03217851||Patients Presenting P. falciparum Malaria|
16510732|NCT03217838|Experimental|Part A - Group 1 Arm A: Monotherapy Dose Escalation|AZD2811 single agent on Days 1 and 4 of each 28 day cycle. Dose escalation
16510733|NCT03217838|Experimental|Part A - Group 1 Arm B: Monotherapy Dose Escalation|AZD2811 single agent on Days 1, 4, 15, and 18 of each 28 day cycle. Dose Escalation
16510734|NCT03217838|Experimental|Part A - Group 2 Arm A: AZD2811 plus Azacitidine Dose Escalation|AZD2811 on Days 1 and 4 plus Azacitidine combination therapy. Escalating doses of AZD2811
16510735|NCT03217838|Experimental|Part A - Group 3 Arm A: AZD2811 plus Venetoclax Dose Escalation|AZD2811on Days 1 and 4 plus Venetoclax combination therapy. Escalating doses of AZD2811
16510736|NCT03217838|Experimental|Part B - Group 1: AZD2811 Monotherapy Dose Expansion|Monotherapy dose expansion. Additional patients will be enrolled at the AZD2811 MTD in the dose/schedule that was found most tolerable and/or efficacious.
16510737|NCT03217838|Experimental|Part B - Group 2: AZD2811 plus Combination Drug Dose Expansion|Combination therapy (either azacitidine or venetoclax) dose expansion. Additional patients will be enrolled at the AZD2811 combination MTD based on the dose/schedule from Part A that was found to be most tolerable and/or efficacious.
16510738|NCT03217838|Experimental|Part A - Group 2 Arm B: AZD2811 plus Azacitidine Dose Escalation|AZD2811 on Days 1, 4, 15, and 18 plus azacitidine combination therapy. Escalating doses of AZD2811
16510739|NCT03217838|Experimental|Part A - Group 3 Arm B: AZD2811 plus Venetoclax Dose Escalation|AZD2811 on Days 1, 4, 15, and 18 plus Venetoclax combination therapy. Escalating doses of AZD2811
16510740|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
16510741|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
16510742|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
16510743|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
16510744|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is greater than [>]2 milligram per deciliter [mg/dL] at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
16510745|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
16510746|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
16510776|NCT03217565|Experimental|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension. For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
16510747|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
16510748|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
16510749|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
16510750|NCT03217747|Experimental|Arm A (utomilumab, avelumab)|Patients receive utomilumab IV over 60 minutes on day 1 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510751|NCT03217747|Experimental|Arm B (PF-04518600, avelumab)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510752|NCT03217747|Experimental|Arm C (PF-04518600, utomilumab, avelumab)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle, utomilumab over 60 minutes on day 1, and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510753|NCT03217747|Experimental|Arm D (avelumab, utomilumab, radiation therapy)|Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 of beginning day 15 of cycle 1 and utomilumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510754|NCT03217747|Experimental|Arm E (avelumab, PF-04518600, radiation therapy)|Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1 and anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 15, and. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510755|NCT03217747|Experimental|Arm F (avelumab, PF-04518600, radiation therapy)|Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1, utomilumab IV over 60 minutes on day 1, and anti-OX40 antibody PF-04518600 IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510756|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
16510757|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
16510758|NCT03217708||Children without OSA|Children for AT due to chronic tonsillitis without OSA.
16510759|NCT03217708||Children with OSA|Children with OSA for AT as determined by PSG
16510760|NCT03217695|Experimental|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
16510761|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
16510762|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
16510763|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.
~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.
~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
16510764|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).
~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
16510765|NCT03217656||Mother-child birth cohort|
16510766|NCT03217643|Experimental|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
16510767|NCT03217630||Diabetic patients|
16510768|NCT03217630||Non-diabetic patients|
16510769|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
16510770|NCT03217604|Placebo Comparator|Placebo|Placebo
16510771|NCT03217604|Experimental|PF-06852231|Single ascending doses of PF-06852231
16510772|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
16510773|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
16510774|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
16510777|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.
~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:
~The Mologic Biomarker Panel
~PCT
~CRP
~Other inflammatory markers or pathogen detection that may augment the panels accuracy
~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
16510778|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:
~Patients being managed for potential infection
~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.
~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
16510779|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
16510780|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
16510781|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
16510782|NCT03217526|Active Comparator|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.
~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
16510783|NCT03217526|Experimental|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
16510784|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
16510785|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
16510786|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
16510787|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
16510788|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
16510789|NCT03217487|Experimental|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
16510790|NCT03217487|Active Comparator|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
16510791|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
16510792|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
16510793|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
16510794|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
16510795|NCT03217448|Experimental|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
16510796|NCT03217448|Active Comparator|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
16510797|NCT03217435|Experimental|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
16510798|NCT03217435|Active Comparator|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
16510803|NCT03217409|Experimental|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
16510804|NCT03217409|Active Comparator|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
16510805|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
16510806|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
16510807|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
16513700|NCT03197766|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
16510808|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
16510809|NCT03217370|Other|all haematologists|"There will be only one arm: the haematologists will all be included in the interventional phase.
~Interventions are: 1) rewriting guidelines to order blood components; 2) to show the last hemoglobin value on the orders for erytrocytes and the last platelet count on the orders dor thrombocytes and 3)implementation of a clinical decision support system in the electronic rodering of blood components to stimulate restrictive blood transfusion."
16510810|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
16510811|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
16510812|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
16510813|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
16510814|NCT03217331|Experimental|CRD-102 Treatment|CRD102 Treatment
16510815|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
16510816|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
16510817|NCT03217305|Other|NAVA vs Pressure Support|Control (pressure support) - NAVA - Control (Pressure Support) Intervention is NAVA
16510818|NCT03217292|Experimental|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
16510819|NCT03217292|Active Comparator|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
16510820|NCT03217266|Experimental|Treatment (MDM2 inhibitor KRT-232, radiation therapy)|Patients receive MDM2 inhibitor KRT-232 PO on day 2, days 2 and 4, days 2-4, days 2-5, or days 1-5 of weeks -1 to 5. Patients also undergo radiation therapy daily on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity.
16510821|NCT03217253|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16510822|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
16510823|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
16510824|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:
~Cardiovascular Magnetic Resonance Imaging with Exercise Bike
~Blood Sampling
~Activity and Lifestyle Questionnaires
~Fat Mass Measurement"
16510825|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:
~Cardiovascular Magnetic Resonance Imaging with Exercise Bike
~Blood Sampling
~Cardiac Catheterization
~Activity, Lifestyle and Medication Compliance Questionnaires
~Fat Mass Measurement
~Retinal Photography (Optional)
~I123 MIBG scan (Optional)"
16510826|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)
~Passive Thermography (PT): 2 thermoscans of the following parts:
~Both carotid artery on left and right of the neck.
~Both superficial temporal artery on the left and right of forehead.
~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
16510827|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)
~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
16510828|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
16510829|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
16510830|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
16510831|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
16510832|NCT03217188|Experimental|fractionated full dose re-irradiation|
16510833|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
16510834|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
16511025|NCT03215875|Experimental|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
16510835|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
16510836|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
16510837|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
16510838|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
16510839|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
16510840|NCT03217136|Experimental|Ceftolozane/Tazobactam + Metronidazole|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose); plus Metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.
16510841|NCT03217136|Active Comparator|Meropenem + Placebo for Metronidazole|Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.
16510842|NCT03217123|Experimental|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 [Nacc],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
16510843|NCT03217110|Experimental|patient active rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
16510844|NCT03217110|Sham Comparator|patient sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
16510845|NCT03217110|Active Comparator|Control active rTMS|
16510846|NCT03217110|Sham Comparator|Control sham rTMS|
16510847|NCT03217097|Experimental|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
16510848|NCT03217097|Active Comparator|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
16510849|NCT03217097|Experimental|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
16510850|NCT03217097|Active Comparator|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
16510851|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
16510852|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.
~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
16510853|NCT03217071|Experimental|Pembrolizumab|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
16510854|NCT03217071|Experimental|Pembrolizumab + Radiation|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
16510855|NCT03217058||Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
16510856|NCT03217058||Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
16510857|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
16510858|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
16510859|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
16510860|NCT03217019|Experimental|Guidewire|"Radial artery puncture with direct radial pulse palpation.
~24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
16510861|NCT03217019|Active Comparator|Direct|"Radial artery puncture with direct radial pulse palpation.
~24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
16510862|NCT03217006|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
16510863|NCT03217006|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
16510864|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
16510865|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
16510866|NCT03216980|Experimental|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
16510867|NCT03216980|Placebo Comparator|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
16510868|NCT03216980|Experimental|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
16510869|NCT03216980|Placebo Comparator|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
16510870|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
16510871|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
16510872|NCT03216954|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules two times daily.
16510873|NCT03216954|Experimental|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
16510874|NCT03216954|Experimental|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
16510875|NCT03216941|Active Comparator|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
16510876|NCT03216941|Active Comparator|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
16510877|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
16510878|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
16510879|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
16510880|NCT03216902|Experimental|Ultra-low dose 0.0005% DE-126|
16510881|NCT03216902|Experimental|Low dose 0.001% DE-126|
16510882|NCT03216902|Experimental|Medium dose 0.002% DE-126|
16510883|NCT03216902|Experimental|High dose 0.003% DE-126|
16510884|NCT03216902|Active Comparator|0.005% Latanoprost|
16510885|NCT03216889|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
16510886|NCT03216889|Active Comparator|Control|6 weeks of stretching and thinking games.
16510887|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
16510888|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
16510889|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
16510890|NCT03216863|Experimental|8 weeks Respiratory rehabilitation|
16510891|NCT03216850||Patients in ICU requiring parenteral nutrition|
16510892|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
16510893|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
16510894|NCT03216824|Active Comparator|Dressing|A dressing is maintained on the CVAD exit site.
16510895|NCT03216824|Experimental|No-Dressing|The CVAD exit site is not covered with a dressing.
16510896|NCT03216811|Experimental|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
16510897|NCT03216772|Experimental|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
16511026|NCT03215875|Experimental|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
16510898|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
16510899|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.
~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.
~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
16510900|NCT03216746|Experimental|Oral orientation and App for smartphone|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
16510901|NCT03216746|Experimental|Oral orientation|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
16510902|NCT03216746|Experimental|Video orientation and App for smartphone|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
16510903|NCT03216746|Experimental|Video orientation|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.
16510904|NCT03216733|Experimental|COMBO|PCI with COMBO stent
16510905|NCT03216733|Active Comparator|ORSIRO|PCI with ORSIRO stent
16510906|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
16510907|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
16510908|NCT03216707|Sham Comparator|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
16510909|NCT03216707|Active Comparator|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
16510910|NCT03216707|Active Comparator|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
16510911|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
16510912|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
16510913|NCT03216668|Experimental|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
16510914|NCT03216668|Active Comparator|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
16510915|NCT03216655|Experimental|traditional group|phone call
16510916|NCT03216655|Experimental|new device group|wechat group
16510917|NCT03216629|Experimental|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
16510918|NCT03216629|No Intervention|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
16510919|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
16510920|NCT03216603|Experimental|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
16510921|NCT03216603|No Intervention|Usual care group|Usual care group will receive usual follow up
16510922|NCT03216590|No Intervention|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
16510923|NCT03216590|Experimental|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
16510924|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
16510925|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
16510926|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
16510927|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
16511027|NCT03215862|Active Comparator|Control|
16511028|NCT03215862|Experimental|Experimental|
16510928|NCT03216551||The assumed selective lymph node dissection group|Patients with consolidation tumor ratios ≤ 0.5 tumors will be considered to have negative mediastinal metastasis. Patients with intraoperative lepidic predominant adenocarcinoma diagnosis will be considered to have negative mediastinal metastasis. Patients with an apical tumor will be considered to have negative inferior mediastinal lymph node metastasis. If both N1 nodes and visceral pleural invasion are negative, patients with peripheral non-apical-segment upper lobe tumors will be considered to have negative inferior medistinal lymph node metastasis. If N1 nodes are negative, patients with left superior segment tumors will be considered to have negative 4L lymph node metasis, and patients with left basal segment tumors will be considered to have negative superior mediastinal lymph node metastasis.
16510929|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
16510930|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
16510931|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
16510932|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
16510933|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
16510934|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
16510935|NCT03216499|Experimental|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study
~Laboratory Biomarker Analysis
~Pharmacogenomic Study"
16510936|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
16510937|NCT03216473|Experimental|Neuronox|Botulinum Toxin Type A for injection
16510938|NCT03216473|Active Comparator|Botox|Botulinum Toxin Type A for injection
16510939|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
16510940|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
16510941|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
16510942|NCT03216434|Experimental|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
16510943|NCT03216434|Experimental|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
16510944|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
16510945|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
16510946|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
16510947|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
16510948|NCT03216395|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
16510949|NCT03216395|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
16510950|NCT03216382|Experimental|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
16510951|NCT03216382|Placebo Comparator|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
16510952|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
16510953|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
16510954|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
16510955|NCT03216356|Active Comparator|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
16510956|NCT03216343|Experimental|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
16510957|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.
~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.
~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)
~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.
~At least 18 years old"
16511029|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
16511030|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
16510958|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.
~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.
~At least 18 years old"
16510959|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
16510960|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
16510961|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
16510962|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
16510963|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
16510964|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
16510965|NCT03216278|Experimental|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
16510966|NCT03216278|Active Comparator|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
16510967|NCT03216278|Experimental|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
16510968|NCT03216278|Active Comparator|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
16510969|NCT03216278|Experimental|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
16510970|NCT03216278|Active Comparator|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
16510971|NCT03216278|Experimental|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
16510972|NCT03216278|Active Comparator|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
16510973|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
16510974|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
16510975|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
16510976|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
16510977|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
16510978|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
16510979|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
16510980|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
16510981|NCT03216213|No Intervention|Control|Vignette contains no extra information
16510982|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
16510983|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
16510984|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
16510985|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
16510988|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
16510989|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
16510990|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
16510991|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
16510992|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
16510993|NCT03216122|Active Comparator|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
16510994|NCT03216122|Active Comparator|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
16511031|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
16511032|NCT03215836|Other|Obese Asthmatics|BMI >/= 30 and without metabolic syndrome
16511033|NCT03215836|Other|Obese Astmatics|BMI >/= 30 and with metabolic syndrome
16511034|NCT03215836|Other|Obese non-asthmatics|BMI >/= 30
16511035|NCT03215836|Other|Non - obese asthmatics|BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
16510997|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
16510998|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
16510999|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
16511000|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
16511001|NCT03216057|Experimental|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
16511002|NCT03216057|Placebo Comparator|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
16511003|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
16511004|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
16511005|NCT03216005|Experimental|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
16511006|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
16511007|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
16511008|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
16511009|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
16511010|NCT03215966|Experimental|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
16511011|NCT03215966|Experimental|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
16511012|NCT03215953|Active Comparator|Group A|cast shoe plus standard wound care
16511013|NCT03215953|Active Comparator|Group B|removable walker plus standard wound care
16511014|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
16511015|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
16511016|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
16511017|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
16511018|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
16511019|NCT03215914|Experimental|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
16511020|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
16511021|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
16511022|NCT03215901|No Intervention|Pure Control|Participants view no video.
16511023|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
16511024|NCT03215888||controls|matched non-obese controls
16511036|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
16511038|NCT03215810|Experimental|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
16511039|NCT03215797|Active Comparator|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
16511040|NCT03215797|Other|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
16511041|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
16511042|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
16511043|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
16511044|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
16511045|NCT03215771|Experimental|MyoPro + Motor Learning-Based Therapy|Subjects received 9 weeks of motor learning-based therapy in combination with use of MyoPro myoelectric elbow wrist hand orthosis, followed by 9 weeks of home use with a customized exercise program.
16511046|NCT03215758|Active Comparator|QAW039|QAW039 once daily
16511047|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
16511048|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
16511049|NCT03215745|No Intervention|Control group|Usual care
16511050|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
16511051|NCT03215706|Experimental|Module A|Chemotherapy/Biologics combined
16511052|NCT03215706|Active Comparator|Module B|Chemotherapy Combination
16511053|NCT03215693|Experimental|X-396 capsule|225mg once daily
16511054|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
16511055|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
16511056|NCT03215667|Experimental|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
16511057|NCT03215654|Experimental|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
16511058|NCT03215654|Experimental|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
16511059|NCT03215654|Experimental|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
16511060|NCT03215654|No Intervention|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
16511061|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
16511062|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
16511063|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
16511064|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
16511065|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
16511066|NCT03215615|Active Comparator|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
16511067|NCT03215615|Active Comparator|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
16511068|NCT03215615|Active Comparator|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
16511069|NCT03215615|Active Comparator|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
16511123|NCT03215173|Experimental|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
16515810|NCT03183297|Placebo Comparator|Placebo|
16511070|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).
~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
16511071|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.
~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
16511072|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
16511073|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
16511074|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
16511075|NCT03215537|No Intervention|observation|No Intervention
16511076|NCT03215537|Active Comparator|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
16511077|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.
~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.
~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.
~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
16511078|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.
~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.
~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.
~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
16511079|NCT03215511|Experimental|Phase 1: Cancer patients <12 years|Dose escalation cohorts with pediatric patients aged <12 years. Dose escalation starts with 43 mg of selitrectinib per m2 body surface twice daily.
16511080|NCT03215511|Experimental|Phase 1: Cancer patients ≥12 years|Dose escalation cohorts with patients aged 12 years or older. Dose escalation starts with 100 mg of selitrectinib twice daily.
16511081|NCT03215511|Experimental|Phase 2: Cancer patients_Cohort 1|Expansion cohort consisting of patients with NTRK fusion cancers showing disease progression despite treatment with a TRK inhibitor. Patients receive selitrectinib at recommended dose twice daily.
16511082|NCT03215511|Experimental|Phase 2: Cancer patients_Cohort 2|Expansion cohort consisting of patients with NTRK fusion cancers showing intolerance or unresponsiveness to previous treatment with a TRK inhibitor. Patients receive selitrectinib at recommended dose twice daily.
16511083|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
16511084|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
16511085|NCT03215485|Experimental|Intervention Group|"All intervention youth participants will receive three components:
~Nutrition lessons
~Virtual World learning environment
~Newsletters"
16511086|NCT03215485|Active Comparator|Comparison|"All comparison youth participants will only receive one component:
~1) Newsletters"
16511087|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
16511088|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
16511089|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
16511090|NCT03215446|Active Comparator|propofol|
16511091|NCT03215446|Experimental|sevoflurane|
16511092|NCT03215420|Experimental|Certain or probable Meniere's disease|
16511093|NCT03215407|Experimental|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
16511094|NCT03215407|Active Comparator|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
16511095|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
16511124|NCT03215173|Active Comparator|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
16511096|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
16511097|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
16511098|NCT03215381|Other|[11C]AZD1390 Microdose|[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
16511099|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
16511100|NCT03215342|Experimental|pGMT|Pediatric Goal Management Training
16511101|NCT03215342|Experimental|pBHW|Pediatric Brain Health Workshop
16511102|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
16511103|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
16511104|NCT03215303|Experimental|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
16511105|NCT03215303|Placebo Comparator|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
16511106|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
16511107|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
16511108|NCT03215277|Experimental|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
16511109|NCT03215277|Experimental|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
16511110|NCT03215264|Experimental|Single Arm|
16511111|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
16511112|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
16511113|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
16511114|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
16511115|NCT03215225||Root canal treatment|
16511116|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
16511117|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
16511118|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
16511119|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
16511120|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
16511121|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
16511122|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
16517206|NCT03173755||People with normal weight|
16511127|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
16511128|NCT03215121|Active Comparator|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
16511129|NCT03215121|Active Comparator|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
16511130|NCT03215121|Active Comparator|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
16511131|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
16511132|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
16511133|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
16511134|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
16511135|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
16511136|NCT03215069|Experimental|Empagliflozin|Empagliflozin 10 mg PO daily
16511137|NCT03215069|Placebo Comparator|Placebo|Matched placebo PO daily
16511138|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.
~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.
~Dose of PENTHROX® should not exceed 6 mL in a single administration.
~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.
~The maximum dose administered will not exceed 6 mL of methoxyflurane."
16511139|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.
~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.
~Dose of normal saline should not exceed 10 mL in a single administration.
~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.
~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
16511140|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
16511141|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
16511142|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
16511143|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
16511149|NCT03215017|Experimental|Transanal irrigation|Manual transanal irrigation to control bowel function.
16511150|NCT03215017|Active Comparator|Medication|Medication to control bowel function.
16511151|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
16511152|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
16513701|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
16511153|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
16511154|NCT03214939|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
16511155|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
16511156|NCT03214913|Other|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
16511157|NCT03214913|Other|Ruijin Group|"Ruijin Strategy therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.
~target： fulfillment of two or more of four criteria:1. HR（heart rate） <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%~35%."
16511158|NCT03214887|Experimental|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
16511159|NCT03214887|Experimental|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
16511160|NCT03214887|Experimental|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
16511161|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
16511162|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
16511163|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
16511164|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
16511165|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
16511166|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
16511167|NCT03214835|Experimental|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
16511168|NCT03214835|Experimental|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
16511169|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
16511170|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
16511171|NCT03214809|Experimental|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
16511172|NCT03214809|No Intervention|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
16511173|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
16511174|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
16511175|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
16511176|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
16511177|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
16511178|NCT03214757||group with dilated cardiomyopathy without anemia|
16511179|NCT03214757||group with dilated cardiomyopathy with anemia|
16511180|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
16511181|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
16511182|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
16511183|NCT03214718|Experimental|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
16511184|NCT03214718|Active Comparator|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
16511185|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
16511186|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
16511187|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
16511188|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
16511189|NCT03214679|Active Comparator|Usual Care|Usual care represents the current procedure after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
16511190|NCT03214666|Experimental|GTB-3550 TriKE® (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE® at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE® followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
16511191|NCT03214666|Experimental|GTB-3550 TriKE® Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
16511192|NCT03214653|Active Comparator|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
16511193|NCT03214653|Active Comparator|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
16511194|NCT03214640|Active Comparator|Palpation with spinal block (Group C-P)|insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest) for placement of spinal block for cesarean delivery
16511195|NCT03214640|Active Comparator|Palpation with neuraxial block (Group L-P)|the needle insertion site for the neuraxial block will be identified with palpation for labor analgesia, using the spinous process and iliac crest for reference
16511196|NCT03214640|Experimental|Rivanna Accuro Ultrasound Device with spinal block (Group C-R)|insertion will be identified with Rivanna Accuro U/S device for placement of spinal block for cesarean delivery
16511197|NCT03214640|Experimental|Rivanna Ultrasound Device with neuraxial block (Group L-R)|insertion will be identified with Rivanna Accuro U/S device for placement of neuraxial block (combined spinal epidural) for labor analgesia
16511198|NCT03214627|Experimental|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period
~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period
~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
16511199|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
16511200|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
16511201|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
16511202|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
16511203|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
16511204|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
16511205|NCT03214588|Experimental|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
16511206|NCT03214588|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
16511207|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
16511208|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
16511209|NCT03214562|Experimental|Treatment (venetoclax, FLAG-IDA)|See detailed description.
16511210|NCT03214549|Active Comparator|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
16511211|NCT03214549|Active Comparator|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
16511212|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
16511213|NCT03214523|Experimental|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
16511214|NCT03214523|No Intervention|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
16511354|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
16511215|NCT03214510|Experimental|Arm I (TAE)|Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.
16511216|NCT03214510|Experimental|Arm II (TAP)|Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.
16511217|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
16511218|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
16511219|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.
~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
16511220|NCT03214484|Active Comparator|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.
~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
16511221|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
16511222|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
16511223|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
16511224|NCT03214445|Experimental|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
16511225|NCT03214445|Active Comparator|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
16511226|NCT03214445|No Intervention|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
16511227|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
16511228|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
16511229|NCT03214406|Experimental|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm & Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
16511230|NCT03214406|Active Comparator|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
16511231|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
16511232|NCT03214380|Experimental|LY900014|LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
16511233|NCT03214380|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
16511234|NCT03214380|Experimental|LY900014 Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
16511235|NCT03214380|Active Comparator|Insulin Lispro (Humalog) MEE|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
16511236|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
16511809|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
16511237|NCT03214367|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
16511238|NCT03214367|Experimental|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
16511239|NCT03214367|Experimental|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
16511240|NCT03214367|Active Comparator|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
16511241|NCT03214367|Experimental|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
16511242|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
16511243|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
16511244|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
16511245|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
16511246|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
16511247|NCT03214289|Experimental|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.
~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.
~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
16511248|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
16511249|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
16511250|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
16511251|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
16511252|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
16511253|NCT03214250|Experimental|Gem/NP/nivolumab|Gemcitabine+Nab-Paclitaxel+nivolumab
16511254|NCT03214250|Experimental|Gem/NP/APX005M|Gemcitabine+Nab-Paclitaxel+APX005M
16511255|NCT03214250|Experimental|Gem/NP/nivolumab/APX005M|Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M
16511256|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
16511257|NCT03214224|Experimental|remote PFT (rPFT) validation|Subjects in this arm perform both standard and remote PFT assessments in order to validate the procedure.
16511258|NCT03214198||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
16511259|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
16511260|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
16511261|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
16511262|NCT03214159|Experimental|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.
~Intervention:
~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
16511263|NCT03214159|Experimental|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.
~Intervention:
~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
16511264|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.
~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
16511265|NCT03214133|Experimental|Epicatechin Dose Response|This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
16511266|NCT03214133|Placebo Comparator|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
16511267|NCT03214107|Active Comparator|Full snack given before exercise|A snack containing ~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
16511268|NCT03214107|Active Comparator|Distributed snack over exercise period|A snack containing ~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
16511269|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
16511270|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
16511271|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
16511272|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
16511273|NCT03214016|Experimental|Pilates method group|The participants will do Mat Pilates.
16511274|NCT03214016|Active Comparator|Aerobic training group|The participants will do aerobic exercise on treadmill.
16511275|NCT03214003|Experimental|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
16511276|NCT03214003|Active Comparator|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
16511277|NCT03213990|Other|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
16511278|NCT03213990|Other|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
16511279|NCT03213977|Experimental|Arm I:R-DA-EPOCH|Protocol involves 8 cycles.
16511280|NCT03213977|Experimental|Arm II:R-DA-EPOCH + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
16511281|NCT03213977|Active Comparator|Arm III:R-CEOP90|Protocol involves 8 cycles.
16511282|NCT03213977|Active Comparator|Arm IV:R-CEOP90 + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
16511283|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.
~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).
~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.
~Lymphodepletion with Cyclophosphamide and Fludarabine."
16511284|NCT03213951||Prostate cancer|Gleason grade group 1-5 on prostate biopsy or prostate cancer recurrence.
16511285|NCT03213938|Experimental|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
16511286|NCT03213938|Sham Comparator|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
16511287|NCT03213925|Experimental|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.
~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
16511288|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
16511289|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
16511355|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
16511810|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
16511290|NCT03213873|Experimental|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
16511291|NCT03213873|Active Comparator|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
16511292|NCT03213860|Active Comparator|eye mask|
16511293|NCT03213860|No Intervention|Control|
16511294|NCT03213847|Other|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
16511295|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
16511296|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
16511297|NCT03213821|Experimental|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
16511298|NCT03213821|Active Comparator|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
16511299|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
16511300|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
16511301|NCT03213808||anaphylaxis|anaphylaxis
16511302|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
16511303|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
16511304|NCT03213782|Experimental|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
16511305|NCT03213782|No Intervention|Control group|Usual routine care was continued
16511306|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
16511307|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
16511308|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
16511309|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
16511310|NCT03213743|Other|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
16511311|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
16511312|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
16511313|NCT03213730|No Intervention|Control group|Standard care alone
16511314|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
16511315|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
16511316|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
16511318|NCT03213691|Experimental|Treatment (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16511320|NCT03213665|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16511322|NCT03213639|Experimental|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
16511323|NCT03213639|Placebo Comparator|control group|Patients will take an inert tablet similar in appearance, color and consistency
16511324|NCT03213626|Experimental|Cabozantinib + erlotinib|
16511356|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
16511357|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
16511325|NCT03213613|Experimental|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
16511326|NCT03213613|Placebo Comparator|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
16511327|NCT03213613|Placebo Comparator|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
16511328|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
16511329|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
16511330|NCT03213587|Experimental|apatinib|
16511331|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
16511332|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
16511333|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
16511334|NCT03213548|Experimental|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
16511335|NCT03213548|Active Comparator|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
16511336|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
16511337|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
16511338|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.
~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
16511339|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.
~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
16511340|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
16511341|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
16511342|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
16511343|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
16511344|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
16511345|NCT03213457|Placebo Comparator|Placebo|Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
16511346|NCT03213457|Experimental|Elagolix / Elagolix + E2/NETA|Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
16511347|NCT03213457|Experimental|Elagolix + E2/NETA|Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
16511348|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
16511349|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
16511350|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of <90 and ≥40 and 30 of their parents.
16511351|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
16511352|NCT03213418|Experimental|Contingency management|
16511353|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
16511594|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
16511358|NCT03213379|No Intervention|Referent group|"The patient of the referent group will have 2 measures of actimetry:
~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
16511359|NCT03213379|Experimental|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:
~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
16511360|NCT03213366|Experimental|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
16511361|NCT03213366|Active Comparator|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
16511362|NCT03213353|Experimental|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
16511363|NCT03213353|Experimental|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
16511364|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
16511365|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
16511366|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
16511367|NCT03213327|Other|Case management|Case management program Utilization of the StayOk web application
16511368|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
16511369|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
16511370|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
16511371|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
16511372|NCT03213301|Experimental|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
16511373|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
16511374|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
16511375|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
16511376|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
16511377|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
16511378|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision
~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists
~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling
~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
16511379|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision
~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists
~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling
~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
16511380|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
16511381|NCT03213210|Other|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
16511382|NCT03213197|Experimental|CPR video|Patient watches a short CPR video
16511383|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
16511384|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
16511385|NCT03213158|Experimental|Highly sensitized kidney transplant candidates|The study population will include all highly sensitized kidney transplant candidates on the waitlist for more than 24 months at University of Wisconsin.
16511386|NCT03213145|Experimental|Part 1|
16511387|NCT03213145|Experimental|Part 2|
16511388|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
16511389|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
16511390|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
16511391|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
16511392|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
16511393|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
16511394|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
16511395|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
16511396|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
16511397|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
16511398|NCT03213067||Mitochondrial Disease Patients|"Male and Females >18 years at the time of screening
~Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.
~Capacity to provide informed consent taken before any study related activities.
~Ability and willingness to adhere to the protocol, including all appointments.
~Ability to read and converse in English."
16511399|NCT03213067||Healthy Control Group|"Male and Females >18 years at the time of screening
~Capacity to provide informed consent taken before any study related activities.
~Ability and willingness to adhere to the protocol, including all appointments.
~Ability to read and converse in English."
16511400|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
16511401|NCT03213041|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
16511402|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
16511403|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
16511404|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
16511405|NCT03212989|Experimental|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:
~Step 2 - Single dose of Vorinostat (VOR) 400 mg PO
~Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions
~Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
16511406|NCT03212976|Other|Study Phase 1|Patients with an intracranial pressure monitor will undergo phase contrast magnetic resonance imaging to measure their ICP.
16511407|NCT03212976|Other|Study Phase 2|Patients with shunts or CSF access devices such as Ommaya reservoir, etc will undergo phase contrast magnetic resonance imaging
16511408|NCT03212963|Experimental|Halobetasol lotion treatment arm|All subjects will receive Halobetasol Topical Lotion, 0.05%.
16511409|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
16511410|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
16511411|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
16511412|NCT03212924|Experimental|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.
~Evaluation of speech comprehension in quiet
~Evaluation of speech comprehension in noise
~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)
~Auto evaluation of listening effort in quiet
~Auto evaluation of listening effort in noise"
16511413|NCT03212911|Active Comparator|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
16511414|NCT03212911|Active Comparator|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
16511415|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
16511416|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
16511417|NCT03212885|Experimental|1|STN Monopolar Stimulation
16511418|NCT03212885|Experimental|2|rZI + STN stimulation
16511419|NCT03212872|Other|Endoscopy|
16511420|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
16511421|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
16511422|NCT03212846|Experimental|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
16517207|NCT03173755||people with overweight and obesity|
16511423|NCT03212846|No Intervention|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
16511424|NCT03212820|Experimental|Biologic drilling|drilling at low speed
16511425|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
16511426|NCT03212807|Experimental|Investigational|Durvalumab + Lenalidomide
16511427|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
16511428|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
16511429|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
16511430|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
16511431|NCT03212755|Experimental|group 1|25 diabetic patients without diabetic nephropathy
16511432|NCT03212755|Experimental|group 2|25 type 2 diabetic patients with diabetic nephropathy
16511433|NCT03212755|Sham Comparator|group 3|25 healthy subjects
16511434|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:
~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.
~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.
~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
16511435|NCT03212729|Active Comparator|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
16511436|NCT03212729|Experimental|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
16511437|NCT03212716|Experimental|diltiazem|oseltamivir + diltiazem
16511438|NCT03212716|Placebo Comparator|oseltamivir + placebo|oseltamivir + placebo of diltiazem
16511439|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
16511440|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
16511441|NCT03212690|Experimental|Mechanically ventilated subjects|Subjects receiving invasive mechanical ventilation (Duration of ventilation <=48 hours) will be evaluated using standard care investigations.
16511442|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
16511443|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
16511444|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
16511445|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
16511446|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
16511447|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
16511448|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
16511449|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
16511450|NCT03212664|Other|Exercise|Schroth-based physical therapy exercises for patients who agree to participate in exercises. Will be compared to observation-only treatment
16511451|NCT03212651|Experimental|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
16511452|NCT03212638|Experimental|Baricitinib T1 (Part A)|4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
16511453|NCT03212638|Experimental|Baricitinib T2 (Part A)|4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
16511454|NCT03212638|Experimental|Baricitinib R (Part A)|4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
16511455|NCT03212638|Experimental|Baricitinib TF Fasted (Part B)|4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
16511456|NCT03212638|Experimental|Baricitinib TF Fed (Part B)|4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
16511457|NCT03212625|Experimental|Urea cream 20%|144 patients spread urea cream (urea 20%)
16511458|NCT03212625|Placebo Comparator|Placebo|144 patients spread placebo cream (urea 0%)
16511459|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.
~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
16511460|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
16511461|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
16511595|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
16511462|NCT03212573|Experimental|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
16511463|NCT03212573|Active Comparator|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
16511464|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
16511465|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
16511466|NCT03212547|Experimental|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
16511467|NCT03212547|No Intervention|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
16511468|NCT03212534|Experimental|Prediction Algorithm|
16511469|NCT03212534|No Intervention|Control|
16511470|NCT03212521|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
16511471|NCT03212495|Active Comparator|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
16511472|NCT03212495|Active Comparator|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
16511473|NCT03212469|Experimental|Patients with head and neck squamous cell carcinoma|
16511474|NCT03212469|Experimental|Patients lung cancer|
16511475|NCT03212469|Experimental|Patients with oesophagus cancer|
16511476|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
16511477|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
16511478|NCT03212443|Sham Comparator|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
16511479|NCT03212443|Active Comparator|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
16511480|NCT03212417|Other|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
16511481|NCT03212404|Experimental|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
16511482|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
16511483|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
16511484|NCT03212378||CHIP 1 - low risk patients|
16511485|NCT03212378||CHIP 2 - medium risk patients|
16511486|NCT03212378||CHIP 3 - high risk patients|
16511487|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
16511488|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
16511489|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
16511490|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
16511491|NCT03212339|Experimental|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
16511492|NCT03212339|Experimental|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
16511493|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
16511494|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
16511495|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
16511496|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
16511497|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
16511498|NCT03212300|Active Comparator|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
16511499|NCT03212300|No Intervention|treatment as usual|standard treatment
16511629|NCT03211351|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
16511501|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
16511502|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.
~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
16511503|NCT03212222|Experimental|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
16511504|NCT03212222|Active Comparator|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
16511505|NCT03212209|Experimental|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
16511506|NCT03212209|Experimental|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
16511507|NCT03212209|Active Comparator|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
16511508|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
16511509|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
16511510|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
16511511|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
16511512|NCT03212170|Experimental|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
16511513|NCT03212157|Experimental|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
16511514|NCT03212157|Experimental|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
16511515|NCT03212157|Experimental|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
16511516|NCT03212144|Experimental|High Intensity Interval Training then Peanut Consumption|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
16511517|NCT03212144|Experimental|Peanut Consumption then High Intensity Interval Training|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
16511518|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
16511519|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
16511520|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
16511521|NCT03212118|Other|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
16511522|NCT03212118|Active Comparator|Two talks|Two standard talks (not including elements from motivational interviewing)
16511523|NCT03212118|Experimental|Motivational interviewing|Two standard talks with a motivational interviewing content.
16511524|NCT03212105|Active Comparator|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
16511525|NCT03212105|Other|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
16511526|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
16511527|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
16511528|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
16511529|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
16511530|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
16511531|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
16511532|NCT03212066|No Intervention|Wait-List Control|Business as usual
16511533|NCT03212053|Other|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.
~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
16511534|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
16511535|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
16511536|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
16511537|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
16511538|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
16511539|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
16511540|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
16511541|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
16511542|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
16511543|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
16511544|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.
~Surveys conducted up to four times using validated survey tools."
16511545|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.
~Surveys conducted up to four times using validated survey tools."
16511546|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
16511547|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
16511548|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
16511549|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
16511550|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
16511551|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.
~PEEP 4 cmH2O
~Use ultrasound"
16511552|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.
~PEEP titrated
~Use ultrasound
~Impedance tomography
~Best PEEP for less collapse"
16511553|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
16511554|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
16511555|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
16511556|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
16511557|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
16511558|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
16511559|NCT03211910|Placebo Comparator|Standard Care of Treatment|Participants will be treated with standard of care treatment.
16511560|NCT03211910|Active Comparator|SacralSaver|SacralSaver
16511561|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
16511562|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
16511563|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
16511564|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
16511565|NCT03211884|Experimental|Problem-solving therapy|Couched within Bandura's social-cognitive theory, self-management refers to the process by which individuals accept responsibility for and take action to change their behaviors, obtain knowledge related to their situation (e.g., behavioral manifestations of a TBI) through increased awareness and use of effective personal resources (e.g., skill in every-day problem-solving). This ultimately enhances the caregivers' confidence that they can cope with caregiving and behavior-related stressors in the care recipient.
16511566|NCT03211884|No Intervention|Usual Care|Usual care was defined as various military caregiver organizations, support groups and services available to all family caregivers of combat Veterans (e.g., Military OneSource; Operation We Are Here; Veterans Administration Program of Comprehensive Assistance for Family Caregivers; American Red Cross Military and Veteran Caregiver Network; Project New Hope; Wounded Veteran Family Care; Women for Wounded Warriors).
16511567|NCT03211871|Active Comparator|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
16511568|NCT03211871|Placebo Comparator|Croup C|group C (control) received normal saline infusion
16511569|NCT03211858|Experimental|SAR341402|SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
16511570|NCT03211858|Active Comparator|NovoLog/NovoRapid|NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.
16511571|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
16511572|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
16511573|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
16511574|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.
~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
16511575|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
16511576|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
16511577|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
16511578|NCT03211793|Experimental|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
16511579|NCT03211793|Placebo Comparator|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
16511580|NCT03211780|Experimental|Ultrasound|
16511581|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
16511582|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
16511583|NCT03211754|Experimental|Obese patients|Treatment for 8 weeks
16511584|NCT03211741|Other|open label|
16511585|NCT03211728|Experimental|experimental group|
16511586|NCT03211728|Placebo Comparator|placebo group|
16511587|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
16511588|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
16511589|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
16511590|NCT03211676|Active Comparator|Theranova-500|
16511591|NCT03211676|Sham Comparator|Elisio-21H|
16511593|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
16511596|NCT03211637|Experimental|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
16511597|NCT03211637|Active Comparator|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
16511598|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
16511599|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
16511600|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
16511601|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
16511602|NCT03211598|Other|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
16511603|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
16511604|NCT03211559|Active Comparator|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
16511605|NCT03211559|Experimental|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
16511606|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
16511607|NCT03211507||Case|Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
16511608|NCT03211507||Controls|Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
16511609|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
16511610|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
16511611|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
16511612|NCT03211468|No Intervention|Control Group|No participation in intervention program.
16511613|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.
~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
16511614|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
16511615|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
16511616|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
16511617|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
16511619|NCT03211403|Experimental|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
16511620|NCT03211403|Experimental|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
16511621|NCT03211403|Experimental|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
16511622|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
16511623|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
16511624|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
16511625|NCT03211364|Active Comparator|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
16511626|NCT03211364|Active Comparator|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
16511627|NCT03211364|Placebo Comparator|Scapular mobilization|Scapular mobilization without glenohumeral movement.
16511628|NCT03211351|Experimental|Liposic|Liposic was applied to one eye of patients in this group
16511630|NCT03211338|Active Comparator|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511631|NCT03211338|Active Comparator|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511632|NCT03211338|Active Comparator|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511633|NCT03211338|Active Comparator|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511634|NCT03211338|Active Comparator|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
16511635|NCT03211338|Active Comparator|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
16511636|NCT03211338|Active Comparator|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
16511637|NCT03211338|Active Comparator|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
16511638|NCT03211338|Active Comparator|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511639|NCT03211338|Active Comparator|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511640|NCT03211338|Active Comparator|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511641|NCT03211338|Active Comparator|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
16511642|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :
~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.
~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
16511643|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :
~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.
~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
16511644|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :
~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.
~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
16511645|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
16511646|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
16511647|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
16511648|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
16511649|NCT03211286|Active Comparator|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
16511650|NCT03211286|Placebo Comparator|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
16511651|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
16511652|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
16511653|NCT03211247|Experimental|Viaskin Peanut 250 mcg|
16511654|NCT03211247|Experimental|Viaskin Peanut 100 mcg|
16511655|NCT03211247|Placebo Comparator|Placebo|
16511656|NCT03211234|Experimental|2.0 mg DE-122|2.0 mg DE-122 and Lucentis ® 0.5 mg
16511657|NCT03211234|Experimental|4.0 mg DE-122|4.0 mg DE-122 and Lucentis ® 0.5 mg
16511658|NCT03211234|Sham Comparator|Sham|Sham and Lucentis ® 0.5 mg
16511659|NCT03211221|Active Comparator|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
16511660|NCT03211221|Placebo Comparator|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
16519174|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
16511661|NCT03211195|Experimental|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
16511662|NCT03211195|Active Comparator|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
16511663|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
16511664|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
16511665|NCT03211169|Experimental|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
16511666|NCT03211169|Active Comparator|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
16511667|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
16511668|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
16511669|NCT03211143|Experimental|A|"TR group
~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days
~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
16511670|NCT03211143|Experimental|B|"RT group
~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days
~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
16511671|NCT03211130|Experimental|SystemCHANGE™|
16511672|NCT03211130|Active Comparator|Attention-Control|
16511673|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
16511674|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
16511675|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.
~formulation : curcumin powder 240mg/capsule
~general name : Diferuloylmethane
~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
16511676|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
16511677|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
16511678|NCT03211065|Experimental|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
16511679|NCT03211052|Experimental|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
16511680|NCT03211052|Other|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
16511681|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
16511682|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
16511683|NCT03211013|Experimental|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
16511684|NCT03211013|Placebo Comparator|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
16511685|NCT03210987|Active Comparator|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
16511686|NCT03210987|Active Comparator|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
16511687|NCT03210961|Experimental|PF-06826647 tablet|
16511688|NCT03210961|Placebo Comparator|Placebo tablet|
16511689|NCT03210961|Experimental|PF-06826647 oral suspension|
16511690|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
16511691|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
16511692|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
16511693|NCT03210935||Merkel cell carcinoma|
16511694|NCT03210935||Advanced basal cell carcinoma|
16511695|NCT03210935||Cutaneous adnexal carcinomas|
16511696|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
16511697|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
16511698|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
16511735|NCT03210558|Active Comparator|Group A|Testosterone cream 1% (Andro-Feme® )
16519175|NCT03160716|Other|Treatment|
16511699|NCT03210896|No Intervention|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
16511700|NCT03210896|Experimental|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 & 180 minutes.
16511701|NCT03210896|No Intervention|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
16511702|NCT03210870|Other|Intervention|In-person nutritional education classes
16511703|NCT03210870|No Intervention|Control|no in-person nutritional education classes
16511704|NCT03210857|Experimental|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.
~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
16511705|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
16511706|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
16511707|NCT03210805|Experimental|Supplementation|Omega-3 Polyunsaturated Fatty Acids
16511708|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
16511709|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
16511710|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
16511711|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
16511712|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
16511713|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
16511714|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
16511715|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
16511716|NCT03210727|Other|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
16511718|NCT03210701|Other|Patients requesting a HIV screening test|
16511719|NCT03210688|Active Comparator|High dose prednisolone|Prednisolone 1 mg/kg/day
16511720|NCT03210688|Experimental|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
16511721|NCT03210675|Other|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
16511722|NCT03210675|Other|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
16511723|NCT03210662|Experimental|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16511724|NCT03210649|Experimental|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
16511725|NCT03210649|Experimental|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
16511726|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
16511727|NCT03210623|Experimental|group A|subjects applying the stent retriever(TonbridgeMT)
16511728|NCT03210623|Active Comparator|group B|subjects applying Solitaire™
16511729|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
16511730|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
16511731|NCT03210597|Experimental|hydro-power|Resistance water exercise
16511732|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
16511733|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
16511737|NCT03210545|Active Comparator|betamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated physiological dose during one treatment period.
16511738|NCT03210545|Active Comparator|betamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated supra physiological dose during one treatment period.
16511739|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
16511740|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
16511741|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
16511742|NCT03210519|Experimental|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
16511743|NCT03210519|Placebo Comparator|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
16511744|NCT03210506|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
16511745|NCT03210506|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
16511746|NCT03210493|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
16511747|NCT03210493|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
16511748|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
16511749|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
16511750|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
16511751|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
16511752|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
16511753|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
16511754|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
16511755|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
16511756|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
16511757|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
16511758|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
16511759|NCT03210402|Active Comparator|Elevated night pacing on|
16511760|NCT03210402|Placebo Comparator|Elevated night pacing off|
16511761|NCT03210389|Experimental|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
16511762|NCT03210376|Experimental|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.
~Sugammadex intravenously as a single bolus injection after surgery.
~Pain assessment done at about 15, 45, and 90 minutes after surgery."
16511763|NCT03210376|Experimental|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.
~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.
~Pain assessment done at about 15, 45, and 90 minutes after surgery."
16511764|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :
~Two serum tubes of blood will be collected"
16511765|NCT03210337|Experimental|Active|A-101 Topical Solution
16511766|NCT03210337|Placebo Comparator|Vehicle|Vehicle
16511767|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
16511768|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
16511769|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
16511770|NCT03210311|No Intervention|control group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema
~Perform skin care
~Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
16511771|NCT03210311|Active Comparator|intervention group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema
~Perform skin care
~Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible
~Wear a compression sleeve"
16511772|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
16511773|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
16511774|NCT03210272|Experimental|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
16511775|NCT03210272|Experimental|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
16511776|NCT03210259|Experimental|BI 695501|
16511777|NCT03210259|Active Comparator|Humira®|
16511778|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
16511779|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
16511780|NCT03210233|Experimental|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
16511781|NCT03210233|Experimental|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
16511782|NCT03210233|Experimental|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
16511783|NCT03210220|Experimental|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
16511784|NCT03210220|No Intervention|control group|There is no block.
16511785|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.
~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.
~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
16511786|NCT03210194|Active Comparator|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
16511787|NCT03210194|Experimental|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
16511788|NCT03210181|Experimental|Block|Patients will receive superficial cervical plexus block
16511789|NCT03210181|Placebo Comparator|Placebo|Patients will receive normal saline
16511790|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
16511791|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
16511792|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
16511793|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
16511794|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
16511795|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
16511796|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
16511797|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
16511798|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
16511799|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
16511800|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
16511801|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
16511802|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
16511803|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
16511804|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
16511805|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
16511806|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
16511807|NCT03210025|Experimental|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
16511808|NCT03210025|Active Comparator|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
16511811|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
16511812|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
16511813|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
16511814|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
16511815|NCT03209973|Experimental|Tislelizumab|Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)
16511816|NCT03209947|Experimental|Ulnar nerve ultrasound|
16511817|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
16511818|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
16511819|NCT03209895|Experimental|Joint Health Product|
16511820|NCT03209895|Placebo Comparator|Placebo|
16511821|NCT03209895|Active Comparator|Glucosamine / Chondroitin|
16511822|NCT03209882|Experimental|One TILS, one sham, and then five TILS interventions|Participants first received a TILS intervention, followed by a sham session one week later. Then, participants received another five weekly TILS interventions.
16511823|NCT03209882|Experimental|One sham, then six TILS interventions|Participants first received a sham session, followed by six weekly TILS sessions.
16511824|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
16511825|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
16511826|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
16511827|NCT03209843|Other|Successfully CTO recanalization|
16511828|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
16511829|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
16511830|NCT03209817|Experimental|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
16511831|NCT03209817|Experimental|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
16511832|NCT03209817|No Intervention|Control No tomato|No tomato products consumption
16511833|NCT03209804|Other|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
16511834|NCT03209804|Experimental|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
16511835|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
16511836|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
16511837|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
16511838|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
16511839|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
16511840|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
16511841|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
16511842|NCT03209765|No Intervention|No reminder|
16511843|NCT03209739|Active Comparator|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
16511844|NCT03209739|No Intervention|No reminder|No additional reminder will be given
16511845|NCT03209713|Active Comparator|Parental Education|Participants will receive parental education on HPV vaccine and the vaccine's benefits.
16511846|NCT03209713|Experimental|Parental Education + Text Messaging|Participants will receive parental education on HPV vaccine and the vaccine's benefits plus text messaging reminder.
16511847|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
16511848|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
16511849|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
16511850|NCT03209661|Active Comparator|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
16511851|NCT03209661|Placebo Comparator|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
16511852|NCT03209661|Placebo Comparator|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
16511853|NCT03209648|Experimental|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
16511854|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
16511883|NCT03209427|Active Comparator|Group I|intrathecal injection of 100 μg morphine
16511855|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
16511856|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.
~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
16511857|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
16511858|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
16511859|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
16511860|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
16511861|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
16511862|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
16511863|NCT03209570|Experimental|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
16511864|NCT03209570|Active Comparator|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
16511865|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
16511866|NCT03209557|Experimental|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.
~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.
~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
16511867|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
16511868|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
16511869|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
16511870|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
16511871|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
16511872|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
16511873|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
16511874|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
16511875|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
16511876|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
16511877|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
16511878|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
16511879|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
16511880|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
16511881|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
16511882|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
16511885|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
16511886|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
16511887|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
16511888|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
16511889|NCT03209401|Experimental|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.
~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
16511890|NCT03209362|Experimental|SI-613|
16511891|NCT03209362|Placebo Comparator|Placebo|
16511892|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.
~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
16511893|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.
~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
16511894|NCT03209336|Experimental|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
16511895|NCT03209336|No Intervention|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
16511896|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
16511897|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
16511898|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
16511899|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
16511900|NCT03209310||Control Group|Children with typical development were included in this study
16511901|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
16511902|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
16511903|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
16511904|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
16511905|NCT03209271|Experimental|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
16511906|NCT03209271|Active Comparator|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
16511907|NCT03209258|Other|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
16511908|NCT03209258|Other|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
16511909|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.
~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
16513702|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
16511910|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
16511911|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
16511912|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
16511913|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
16511914|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
16511915|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
16511916|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
16511917|NCT03209193|Experimental|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
16511918|NCT03209193|Experimental|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
16511919|NCT03209180|Active Comparator|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
16511920|NCT03209180|Experimental|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
16511921|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
16511922|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
16511923|NCT03209154|Experimental|Study Group|Study Group intervention: Therapeutic drug monitoring.
16511924|NCT03209154|Active Comparator|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
16511925|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
16511926|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
16511927|NCT03209128||Irradiation prophyllactique cérébrale|
16511928|NCT03209115|Active Comparator|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
16511929|NCT03209115|Active Comparator|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
16511930|NCT03209102|Experimental|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
16511931|NCT03209102|Experimental|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
16511932|NCT03209076|Experimental|Robotic|Robotic low anterior resection
16511933|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
16511934|NCT03209063||Group 1|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy.
16511935|NCT03209063||Group 2|90 Patients having history of two or more miscarriages.
16511936|NCT03209050|Other|Central Venous Access Placement|Central venous access placement
16511937|NCT03209037|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
16511938|NCT03209037|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
16511939|NCT03209024|Other|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
16511940|NCT03209024|Experimental|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
16511941|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
16511942|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
16511943|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
16511944|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
16511945|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
16511946|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
16511947|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
16511948|NCT03208959|Experimental|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
16511949|NCT03208959|Experimental|Dose level 2|100% Increment from dose level 1
16511950|NCT03208959|Experimental|Dose level 3|100% Increment from dose level 2
16511951|NCT03208959|Experimental|Dose level 4|100% Increment from dose level 3
16511952|NCT03208959|Experimental|Dose level 5|50% Increment from dose level 4
16511953|NCT03208946|Experimental|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
16511954|NCT03208946|Sham Comparator|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
16511955|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
16511956|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
16511957|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
16511962|NCT03208894|Experimental|with salbutamol|
16511963|NCT03208894|Experimental|with furosemide|
16511964|NCT03208894|Experimental|both furosemide and salbutamol|
16511965|NCT03208894|No Intervention|no inervention|
16511966|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
16511967|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
16511968|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
16511969|NCT03208855|Experimental|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
16511970|NCT03208855|No Intervention|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
16511971|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits
~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of
~---the site of the intrauterine gestational sac in relation to the endometrial cavity .
~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.
~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
16511972|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits
~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of
~---the site of the intrauterine gestational sac in relation to the endometrial cavity .
~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.
~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
16511973|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
16511974|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
16511975|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
16511976|NCT03208790|Experimental|Group A|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.
16511977|NCT03208790|Experimental|Group B|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.
16511978|NCT03208790|Placebo Comparator|Group 3|patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.
16511979|NCT03208777||control group|taking blood samples from apparently healthy people
16511980|NCT03208777||benign colorectal|taking blood samples from patients
16511981|NCT03208777||malignant colorectal|taking blood samples from patients
16511982|NCT03208764|Experimental|Nitric Oxide treatment|
16511983|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
16511984|NCT03208738|No Intervention|Assessment only|
16511985|NCT03208738|Experimental|VetChange mobile app|
16511986|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
16511987|NCT03208725||Hospitalized children with severe wasting or kwashiorkor (SWK)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
16511988|NCT03208725||Community reference participants (CP)|Children recruited from the community who are seen a single appointment in the community.
16511989|NCT03208725||Hospitalized children with moderate wasting (MW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
16511990|NCT03208725||Hospitalized children without wasting (NW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
16511991|NCT03208712|Experimental|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
16511992|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
16512062|NCT03208088|Experimental|Sequence 3|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental)
16511993|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
16511994|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
16511995|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
16511996|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
16511997|NCT03208634|Experimental|Robotic intervention|Robotic intervention.
16511998|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
16511999|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
16512000|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
16512001|NCT03208556|Experimental|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
16512002|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
16512003|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
16512004|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
16512005|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
16512006|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).
~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
16512007|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
16512008|NCT03208491|Experimental|serious games|
16512009|NCT03208491|Active Comparator|usual care|
16512010|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
16512011|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
16512012|NCT03208465|Experimental|Patients with Empagliflozin|
16512013|NCT03208465|Active Comparator|Patients with Sitagliptin|
16512014|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
16512015|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
16512016|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
16512017|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
16512018|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
16512019|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
16512020|NCT03208413|Experimental|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
16512021|NCT03208400|Other|virtual reality exposure|one-session exposure conveyed via virtual reality technology
16512022|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
16512023|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
16512024|NCT03208387||Age-Matched Healthy Children Controls|
16512025|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
16512026|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
16512027|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
16512028|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
16513703|NCT03197740|Active Comparator|aricept Tab 5mg|
16512029|NCT03208335|Experimental|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
16512030|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
16512031|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
16512032|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
16512033|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
16512034|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
16512035|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
16512036|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
16512037|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
16512038|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
16512039|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
16512040|NCT03208257|Experimental|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
16512041|NCT03208244|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
16512042|NCT03208231|Experimental|Arm 1: VRC01|Participants will receive VRC01 at Weeks 0, 2, 6, and 10.
16512043|NCT03208231|Placebo Comparator|Arm 2: No study treatment|Participants will not receive the study treatment.
16512044|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
16512045|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
16512046|NCT03208192|Experimental|ErbeJet|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
16512047|NCT03208192|Experimental|Misonix|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
16512048|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
16512049|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
16512050|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
16512051|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
16512052|NCT03208166|Other|Usual Care|Standard medical care.
16512053|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
16512054|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
16512055|NCT03208127|Experimental|Treatment with Direct Acting Antiviral Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
16512056|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
16512057|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
16512058|NCT03208101|Experimental|Test group|DTP-HepB-IPV-Hib vaccine
16512059|NCT03208101|Active Comparator|Control group|DTP-HepB-Hib vaccine & IPV
16512060|NCT03208088|Experimental|Sequence 1|etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental)
16512061|NCT03208088|Experimental|Sequence 2|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator)
16513704|NCT03197740|Experimental|donepezil patch 25cm2|
16512063|NCT03208088|Experimental|Sequence 4|etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental)
16512064|NCT03208088|Experimental|Sequence 5|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental)
16512065|NCT03208088|Experimental|Sequence 6|etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental / etafilcon A Test Lens 1 (experimental)
16512066|NCT03208088|Experimental|Sequence 7|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental)
16512067|NCT03208088|Experimental|Sequence 8|etafilcon A Test Lens 1 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental / etafilcon A Test Lens 3 (experimental)
16512068|NCT03208088|Experimental|Sequence 9|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental / etafilcon A Control Lens (Active Comparator) /etafilcon A Test Lens 4 (experimental)
16512069|NCT03208088|Experimental|Sequence 10|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental / etafilcon A Control Lens (Active Comparator)
16512070|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
16512071|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
16512072|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
16512073|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:
~patients with osteoarthritis of the hip or knee and rehabilitated in the institute
~patients with primary and secondary tumors of the skeleton
~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
16512074|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs and adherence to treatment, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves having difficulty staying awake during the day, they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
16512075|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identify dysfunctional sleep cognitions, 2) challenge their validity, and 3) replace them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are provided with information about relevant elements of the science of sleep and healthy sleep practices.
16512076|NCT03208036|Experimental|TDCS|TDCS offered concurrent with working memory focused cognitive training
16512077|NCT03208036|Sham Comparator|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
16512078|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
16512079|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
16512080|NCT03208010|Experimental|Diabetes Prevention Intervention|The intervention is 12 weeks of education on diet and physical activity, followed by 15 bi-weekly support groups for problem solving. Then, 3 booster sessions are scheduled, each one at 6-month intervals. Further, motivational interviewing is integrated into all group sessions.
16512081|NCT03208010|Active Comparator|Enhanced Usual Care|"The comparator is an enhanced usual care control group that receives health care from personal physicians plus has access to: a) data collection sessions; b) individualized exit interviews with program staff after each data collection session to receive immediate feedback on lab results and trends in personal health indicators (e.g., BMI, A1C) and to ask questions; c) referral to a local physician or clinic, if needed; and d) Spanish-language materials on diabetes prevention."
16512082|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
16512083|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
16512084|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
16512085|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
16512086|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to treat multiple gingival recessions in aesthetic areas
16512087|NCT03207984|Experimental|Test MG|Root coverage surgery with Mucograft collagen matrix graft to treat multiple gingival recessions in aesthetic areas
16512088|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
16512089|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
16512091|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
16512340|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
16512092|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
16512093|NCT03207932||ultrasound|CVC insertion using ultrasound
16512094|NCT03207932||landmark technique|CVC insertion using landmark technique
16512095|NCT03207919|Experimental|Lullaby Project|
16512096|NCT03207919|No Intervention|Control Group|
16512097|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
16512098|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
16512099|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
16512100|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
16512101|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
16512102|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
16512103|NCT03207867|Experimental|NIR178 + PDR001|Part 1: all patients will receive NIR178 continuously in combination with PDR001 400mg every 4 weeks. The part 1 will enroll 9 different tumor types.
16512104|NCT03207867|Experimental|NIR178 BID Intermittent + PDR001|Three different dosing schedules of NIR178 will be explored.
16512105|NCT03207867|Experimental|Part 3|Initiation of part 3 will depend on results from parts 1 and 2 and will use a film-coated tablet of NIR178.
16512106|NCT03207867|Experimental|Japanese safety run-in part|Two different dosing schedules of NIR178 will be explored.
16512107|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
16512110|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
16512111|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.
~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
16512112|NCT03207815|Experimental|Filgotinib|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.
~All participants will receive filgotinib for up to 52 weeks."
16512113|NCT03207815|Placebo Comparator|Placebo|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.
~All participants will receive placebo to match filgotinib for up to 52 weeks."
16512114|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
16512115|NCT03207776|Other|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
16512116|NCT03207776|Other|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
16512117|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
16512118|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
16512150|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
16512151|NCT03207555|Experimental|Ibrutinib|Participants take Ibrutinib by mouth 1 time every day for up to 2 years (24 cycles).
16512119|NCT03207750|Experimental|HRV PCV-free Liq Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
16512120|NCT03207750|Active Comparator|HRV Lyo Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
16512121|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
16512122|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
16512123|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
16512124|NCT03207711|Active Comparator|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
16512125|NCT03207711|Experimental|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
16512126|NCT03207698|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
16512127|NCT03207698|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
16512128|NCT03207698|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
16512129|NCT03207685|Other|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
16512132|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
16512133|NCT03207659|Experimental|Basketing|stones will be actively extracted.
16512134|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
16512135|NCT03207646|No Intervention|Control|Standard-of-care alone.
16512136|NCT03207633|Active Comparator|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
16512137|NCT03207633|Active Comparator|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
16512138|NCT03207633|Sham Comparator|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
16512139|NCT03207620||smoker asthmatics|"Asthma control questionnaire (ACQ) score
~Spirometry
~Sputum cytology"
16512140|NCT03207620||non-smoker asthmatics|"Asthma control questionnaire (ACQ) score
~Spirometry
~Sputum cytology"
16512141|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
16512142|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
16512143|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
16512144|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
16512145|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
16512146|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
16512147|NCT03207594||Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
16512148|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
16512149|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
16512152|NCT03207542|Experimental|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.
~Each cycle is 28 days."
16512153|NCT03207542|Experimental|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.
~Each cycle is 28 days."
16512154|NCT03207529|Experimental|Treatment (alpelisib, enzalutamide)|Patients receive alpelisib PO and enzalutamide PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16512155|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast
~administration of two 100 g croissants prepared with sourdough after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.
~washout period: 7 days
~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
16512156|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough
~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.
~washout period: 7 days
~administration of two 100 g croissants prepared with sourdough after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
16512157|NCT03207503||MDD patients|Participants ages 35-75 determined to be clinically depressed via structured clinical interview. No interventions will be administered as part of this study.
16512158|NCT03207503||non-MDD patients|Participants ages 35-75 determined to be lifetime free of psychiatric conditions as assessed by structured clinical interview. No interventions will be administered as part of this study.
16512159|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
16512160|NCT03207477|Experimental|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
16512161|NCT03207477|Active Comparator|Term born infants|Visual acuity measurement in term born control infants
16512162|NCT03207464|Experimental|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 6.5.
16512163|NCT03207464|Experimental|Healthy Control|This group will serve as non disease population.
16512164|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
16512165|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
16512166|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
16512167|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
16512168|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
16512169|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
16512170|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
16512171|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
16512172|NCT03207425|Experimental|Mild hepatic impairment group|
16512173|NCT03207425|Experimental|Moderate hepatic impairment group|
16512174|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
16512175|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
16512176|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
16512177|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
16512178|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
16512179|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
16512180|NCT03207360|Experimental|Pain Coping Skills|
16512181|NCT03207347|Experimental|Cohort A|This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.
16512182|NCT03207347|Experimental|Cohort B (Closed to enrollment)|This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).
16512183|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
16513705|NCT03197740|Active Comparator|aricept Tab 10mg|
16512184|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
16512185|NCT03207321||Control|No supplement was provided in 14 control villages.
16512186|NCT03207308|Experimental|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
16512187|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
16512188|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
16512189|NCT03207282||Participants with Diagnosis of Depression|Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.
16512190|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
16512191|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
16512192|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
16512193|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
16512194|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
16512195|NCT03207243|Experimental|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
16512196|NCT03207243|Placebo Comparator|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
16512197|NCT03207230|Experimental|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
16512198|NCT03207217|Experimental|Phase I Knowledge Assessment|
16512199|NCT03207217|Experimental|Phase II Efficacy|
16512200|NCT03207217|Experimental|Phase II Acceptability|
16512201|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
16512202|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
16512203|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
16512204|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
16512205|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
16512206|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
16512207|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
16512208|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
16512209|NCT03207191|Experimental|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.
~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
16512210|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
16512211|NCT03207165|Active Comparator|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular [LV] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
16512212|NCT03207165|Active Comparator|Right ventricular [RV] dysfunction|Assessment of right ventricular [RV] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
16512213|NCT03207152|Experimental|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
16512214|NCT03207139|Experimental|Ga-68 PSMA ligand|Diagnostic performance of [Ga68] PSMA-11
16512215|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
16512216|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.
~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
16512217|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
16512218|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
16512219|NCT03207087|Experimental|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
16512220|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
16512221|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
16512222|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
16512223|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
16512226|NCT03207022|Active Comparator|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
16512227|NCT03207022|Experimental|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
16512228|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
16512229|NCT03206996|Experimental|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
16512230|NCT03206996|Experimental|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
16512231|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
16512232|NCT03206970|Experimental|zanubrutinib|160 mg administered orally twice daily (BID) for up to 3 years
16512233|NCT03206957|Other|Study group|Down Syndrome children
16512234|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
16512235|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
16512236|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
16512237|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
16512238|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
16512239|NCT03206918|Experimental|Zanubrutinib|
16512240|NCT03206905|Experimental|Endoscopic Sleeve Gastroplasty|
16512241|NCT03206905|Active Comparator|Diet and exercise only.|
16512242|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
16512243|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
16512244|NCT03206866||patients with HCC|
16512245|NCT03206866||patients with hepatitis C Ab positive|
16512246|NCT03206866||patients with hepatitis C Ab negative|
16512247|NCT03206853|Experimental|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
16512248|NCT03206853|Other|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
16512249|NCT03206840|Experimental|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
16512250|NCT03206840|Experimental|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
16512251|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
16512252|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
16512253|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
16512254|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
16512255|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
16512256|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
16512257|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
16512258|NCT03206788|Experimental|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
16512259|NCT03206788|Placebo Comparator|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
16512260|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
16512261|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
16512262|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
16512263|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
16512264|NCT03206775||Healthy Controls (Phase 3)|Participants will complete the full Posit Science cognitive assessment battery and self-report questionnaires for credit in the Research Experience Program at the University of Minnesota.
16512265|NCT03206775||Healthy Controls, Battery D (Phase 2)|Participants will complete the Cognitive Battery E (Phase 2) developed by Posit Science while at the Minnesota State Fair.
16512266|NCT03206775||Healthy Controls, Battery E (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
16512267|NCT03206775||Adolescents with anxiety diagnosis (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
16512268|NCT03206775||Adolescents, healthy controls (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
16512269|NCT03206762|Experimental|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
16512270|NCT03206762|Active Comparator|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
16512271|NCT03206749|Experimental|VX-150|
16512272|NCT03206749|Active Comparator|Hydrocodone Bitartrate/Acetaminophen (HB/APAP)|
16512273|NCT03206749|Placebo Comparator|Placebo|
16512274|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
16512275|NCT03206723|Active Comparator|Group 1|1. Standard care
16512276|NCT03206723|Active Comparator|Group 2|"Standard care
~Bandage contact lens"
16512277|NCT03206710||smokers who received Vitamin C|
16512278|NCT03206710||smokers who received placebo|
16512279|NCT03206710||control group non-smokers|
16512280|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
16512281|NCT03206684|Experimental|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
16512282|NCT03206684|Active Comparator|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
16512283|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
16512284|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
16512285|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
16512286|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
16512287|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
16512288|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
16512289|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
16512290|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; PTC596 PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
16512291|NCT03206632|Experimental|BI 690517 dose group 1|
16512292|NCT03206632|Experimental|BI 690517 dose group 2|
16512293|NCT03206632|Experimental|BI 690517 dose group 3|
16512294|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
16512295|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
16512296|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
16512297|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
16512298|NCT03206580|Experimental|Concentric training|Concentric training
16512299|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
16512300|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
16512301|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
16512302|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
16512303|NCT03206554|Sham Comparator|sham LIA|Saline injections
16512304|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
16512305|NCT03206541||Controls|"There are two age-matched control groups:
~Household controls that have lived with the case for at least three months before the onset of neurological symptoms.
~Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
16512306|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
16512307|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
16512308|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
16512309|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
16512310|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
16512311|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
16512312|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
16512313|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
16512314|NCT03206476|Active Comparator|Control group|Nutritional information
16512315|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
16512316|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
16512317|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
16512319|NCT03206437|Experimental|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
16512320|NCT03206437|Other|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
16512321|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
16512322|NCT03206385||CK Boost pelvis|
16512323|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
16512324|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
16512325|NCT03206359||Patients|Patients with SLE
16512326|NCT03206359||Healthy subjects|
16512327|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
16512328|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
16512329|NCT03206333||Breast cancer patients treated with radiotherapy|
16512330|NCT03206320|No Intervention|Control|
16512331|NCT03206320|Active Comparator|Reference|
16512332|NCT03206320|Experimental|New|
16512333|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
16512334|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
16512335|NCT03206294|Other|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
16512336|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
16512337|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
16512338|NCT03206268||healthy eyes|
16512339|NCT03206268||uveitis eyes|
16512341|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
16512342|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
16512343|NCT03206242||initial|0 month begin physiotherapy
16512344|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
16512345|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
16512346|NCT03206229|Experimental|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
16512347|NCT03206229|Active Comparator|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
16512348|NCT03206216|Experimental|Group A - Painful CIPN|Participants with painful chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
16512349|NCT03206216|Active Comparator|Group B - Painless CIPN|Participants with painless chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
16512350|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16512351|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
16512352|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
16512353|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
16512354|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
16512355|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
16512356|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
16512357|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
16512358|NCT03206151|Experimental|CMAB009 + FOLFIRI|"Drug: CMAB009(recombinant chimeric anti-EGFR monoclonal antibody injection), will be administered every 7 days at an initial dose of 400mg/m^2 and 250mg/m^2 for subsequent infusions until progression of disease , withdrawal of consent, or unacceptable toxicity.
~Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.
~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
16512359|NCT03206151|Active Comparator|FOLFIRI|"FOLFIRI Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.
~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
16512360|NCT03206138|Experimental|GX-188E, GX-I7|GX-188E + GX-I7
16512361|NCT03206138|Experimental|GX-188E, Imiquimod|GX-188E + Imiquimod
16512362|NCT03206125||Controls|Controls
16512363|NCT03206125||ESCC Cases|ESCC Cases
16512364|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
16512365|NCT03206112||Healthy Volunteers|Healthy Volunteers
16512366|NCT03206099||Biological relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
16512367|NCT03206099||Healthy volunteers|Select internal controls
16512368|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
16512369|NCT03206086|Experimental|Group|Eltrombopag
16512374|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
16512378|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
16512379|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
16512380|NCT03206021|Experimental|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
16512381|NCT03206021|Experimental|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
16512382|NCT03206021|Experimental|Recurrent Brain and Solid Tumour Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation up to 12 patients with recurrent/refractory brain and solid tumour.
16512383|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
16512384|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
16512385|NCT03205995|Experimental|OMS721|Administration of OMS721
16512386|NCT03205982|Sham Comparator|Control|WiseApp that delivers fitness reminders
16512387|NCT03205982|Experimental|Intervention|WiseApp that delivers medication adherence reminders
16512388|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
16512390|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
16512391|NCT03205917|Experimental|Group 1A HIV-Uninfected|PGDM1400 low dose
16512392|NCT03205917|Experimental|Group 1B HIV-Uninfected|PGDM1400 mid dose
16512393|NCT03205917|Experimental|Group 1C HIV-Uninfected|PGDM1400 high dose
16512394|NCT03205917|Experimental|Group 2A HIV-Uninfected|PGDM1400 + PGT121 low dose
16512395|NCT03205917|Experimental|Group 2B HIV-Uninfected|PGDM1400 + PGT121 mid dose
16512396|NCT03205917|Experimental|Group 2C HIV-Uninfected|PGDM1400 + PGT121 high dose
16512397|NCT03205917|Experimental|Group 3A HIV-infected off ART|PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
16512398|NCT03205917|Experimental|Group 3B HIV-infected off ART|PGDM1400 + PGT121 at high dose; HIV + without ART
16512399|NCT03205904|Active Comparator|Intervention group|Group that will be receive the diet
16512400|NCT03205904|No Intervention|control|Group that will not receive the diet
16512401|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.
~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.
~Each cycle is 21 days.
~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
16512402|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
16512403|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
16512404|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
16512405|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
16512406|NCT03205839|Experimental|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.
~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
16512407|NCT03205839|No Intervention|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
16512408|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
16512409|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
16512410|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
16512411|NCT03205787|Experimental|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
16512412|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
16512413|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
16512414|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
16512415|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
16512514|NCT03205150|Experimental|LIK066 150 mg|Film coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
16512416|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
16512417|NCT03205735||normal DPD result group|patients group with a normal DPD result
16512418|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
16512419|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
16512420|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
16512421|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
16512422|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
16512423|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
16512424|NCT03205683|Experimental|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
16512425|NCT03205683|Sham Comparator|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).
~Missing > 4 sessions will invalidate subject outcomes."
16512426|NCT03205670|Experimental|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
16512427|NCT03205631|Sham Comparator|Sham Natural Frequency Patch|
16512428|NCT03205631|Active Comparator|Active Natural Frequency Patch|
16512429|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
16512430|NCT03205605|Other|baseline patch|patch
16512431|NCT03205605|Other|baseline gel|gel
16512432|NCT03205605|Other|patch with heat|patch
16512433|NCT03205605|Other|gel with occlusion|gel
16512434|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
16512435|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
16512436|NCT03205566|Active Comparator|Arm A Raltegravir, then Raltegravir/Lamivudine|7 days Raltegravir 400mg bd followed by minimum 4 weeks wash out and then 7 days Raltegravir 400mg/lamivudine 150mg (oral tablets) bd.
16512437|NCT03205566|Active Comparator|Arm B Raltegravir/Lamivudine, then Raltegravir|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days followed by a minimum of 4 weeks wash out and then 7 days Raltegravir 400mg bd.
16512438|NCT03205553|Active Comparator|Standard of Care (SoC) Treatment Group|The SoC group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice and subsequently serially reduced in silo (staged silo reduction) until the bowel contents are at the level of fascia and deemed suitable for closure. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons.
16512439|NCT03205553|Experimental|Direct Peritoneal Resuscitation (DPR) Treatment Group|The DPR group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice. At the time of silo placement for staged procedure, the JP drain will be sterilely placed intra-abdominally through the top of the silo. Subjects will be treated with adjuvant direct peritoneal resuscitation (DPR) and subsequently serially reduced in silo until the abdomen is closed (during the entirety of silo placement), which is usually four to five days.
16512440|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
16512441|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
16512442|NCT03205527|Experimental|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
16512443|NCT03205527|No Intervention|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
16512444|NCT03205527|Experimental|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
16512445|NCT03205527|No Intervention|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
16512446|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (>0.80).
16512447|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.
~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
16512448|NCT03205488|Active Comparator|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
16512449|NCT03205488|Active Comparator|Cohort 2|Early/de novo Randomized 2:1
16512450|NCT03205475|Active Comparator|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
16512451|NCT03205475|Active Comparator|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
16512452|NCT03205475|Active Comparator|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
16512453|NCT03205475|Active Comparator|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
16512454|NCT03205475|Active Comparator|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
16512455|NCT03205475|Active Comparator|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
16512456|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
16512457|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
16512458|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
16512459|NCT03205449|Experimental|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
16512460|NCT03205449|Active Comparator|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
16512461|NCT03205436|Experimental|Graft|Affinity human amniotic membrane
16512462|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
16512463|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
16512464|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
16512465|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
16512466|NCT03205397|Experimental|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
16512467|NCT03205397|Other|Usual care|Consultation of anesthesia and the care of the child without parental presence
16512468|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
16512469|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
16512470|NCT03205371|Experimental|South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
16512471|NCT03205371|Experimental|South Korea (Group 2): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
16512472|NCT03205371|Active Comparator|South Korea (Group 3): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
16512473|NCT03205371|Experimental|Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
16512474|NCT03205371|Experimental|Thailand (Group 11):MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
16512475|NCT03205371|Active Comparator|Thailand (Group 12): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
16512515|NCT03205150|Experimental|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
16512516|NCT03205137||Telmisartan and hydrochlorothiazide group|
16512476|NCT03205371|Experimental|Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.
16512477|NCT03205371|Experimental|Mexico (Group 5): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
16512478|NCT03205371|Active Comparator|Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.
16512479|NCT03205371|Experimental|Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.
16512480|NCT03205371|Experimental|Russian Federation (Group 8): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
16512481|NCT03205371|Active Comparator|Russian Federation (Group 9): PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.
16512482|NCT03205358|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
16512483|NCT03205358|Active Comparator|Group 2: NIMENRIX®|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
16512484|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
16512485|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
16512486|NCT03205345|Placebo Comparator|Placebo|Matching placebo
16512487|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
16512488|NCT03205332|No Intervention|Control|Assessment only.
16512489|NCT03205319|Experimental|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
16512490|NCT03205319|No Intervention|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
16512491|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
16512492|NCT03205293|No Intervention|Control Group|Regular school curriculum
16512493|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
16512494|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
16512495|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
16512496|NCT03205241|Experimental|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
16512497|NCT03205241|Placebo Comparator|Placebo|Olive Oil - 6g/ day for 4 weeks
16512498|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
16512499|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
16512500|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
16512501|NCT03205215|Experimental|Immediate Treatment|This arm will receive hyperbaric oxygen therapy once consented.
16512502|NCT03205215|Experimental|Waitlist - to be treated|This arm will receive a hyperbaric oxygen therapy after waiting two months.
16512503|NCT03205202|Active Comparator|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)
~Dietary Supplement: Multivitamin"
16512504|NCT03205202|Active Comparator|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)
~Dietary Supplement: Multivitamin placebo"
16512505|NCT03205202|Active Comparator|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin
~Dietary Supplement: Cocoa extract placebo"
16512506|NCT03205202|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo
~Dietary Supplement: Multivitamin placebo"
16512507|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
16512508|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
16512509|NCT03205176|Experimental|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
16512510|NCT03205176|Experimental|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
16512511|NCT03205163|Experimental|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
16512512|NCT03205163|Experimental|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
16512513|NCT03205150|Experimental|LIK066 30 mg|Film coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
16512520|NCT03205124|Experimental|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
16512521|NCT03205124|Sham Comparator|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
16512522|NCT03205124|Experimental|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
16512523|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
16512524|NCT03205085|Experimental|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
16512525|NCT03205085|Experimental|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
16512526|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
16512527|NCT03205059|Experimental|LST MS curriculum+ Bullying/Cyberbullying serious game|
16512528|NCT03205059|Active Comparator|LST MS curriculum|
16512529|NCT03205046|Experimental|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
16512530|NCT03205046|Experimental|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
16512531|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
16512532|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
16512533|NCT03205020||women with preterm labor|
16512534|NCT03205020||women delivered at full term|
16512535|NCT03205007|Experimental|Health promotion nutrition program|Health promotion nutrition program
16512536|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
16512537|NCT03204981|Experimental|Intramural Needle Ablation|
16512538|NCT03204968|No Intervention|control|
16512539|NCT03204968|Active Comparator|Treated|
16512540|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
16512541|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
16512542|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
16512543|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
16512544|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
16512545|NCT03204929|Experimental|Cu(II)ATSM|Cu(II)ATSM dosed once daily
16512546|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.
~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.
~FOCUS GROUPS: Healthcare providers participate in focus groups over 2-3 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses which will be recorded on a flip-chart or white board, followed by discussion of the ideas for clarification"
16512547|NCT03204903|Experimental|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
16512548|NCT03204903|Sham Comparator|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
16512549|NCT03204890|Experimental|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
16512550|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
16513706|NCT03197740|Experimental|donepezil patch 50cm2|
16512551|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
16512552|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
16512553|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
16512554|NCT03204851|Active Comparator|Venous Stasis Ulcer|Venous Stasis Ulcer
16512555|NCT03204851|Active Comparator|Pressure Ulcers|Pressure Ulcers
16512556|NCT03204851|Active Comparator|Diabetic Foot Ulcers|Diabetic Foot Ulcers
16512557|NCT03204851|Active Comparator|Wounds from a variety of etiologies|Wounds from a variety of etiologies
16512558|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
16512559|NCT03204825|Experimental|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
16512560|NCT03204825|Placebo Comparator|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
16512561|NCT03204825|Experimental|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
16512562|NCT03204825|Experimental|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
16512563|NCT03204812|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
16512564|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
16512565|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
16512566|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
16512567|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
16512568|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
16512569|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
16512570|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
16512571|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
16512572|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
16512573|NCT03204773||HSP patients|Patients with hereditary spastic paraplegia regardless of their genetic mutation
16512574|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
16512575|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
16512576|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
16512577|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.
~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
16512578|NCT03204734|Experimental|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
16512579|NCT03204734|Experimental|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
16512580|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
16512581|NCT03204721|No Intervention|Controll|No procedure
16512582|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
16512583|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
16512584|NCT03204695|Experimental|LAA Occlusion|
16512585|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
16512586|NCT03204643|Experimental|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
16512587|NCT03204643|No Intervention|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
16512588|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
16512589|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
16512590|NCT03204630|Placebo Comparator|Control|Standard infant formula
16512591|NCT03204617|Experimental|DDDMM + CCM|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20. At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
16512592|NCT03204617|Placebo Comparator|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since fifth placebo administration, administration of 0.9% sterile normal saline solution at weeks 0, 12 and 24.
16512593|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
16512594|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
16512595|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
16512596|NCT03204578|Experimental|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
16512597|NCT03204578|Experimental|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
16512598|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
16512599|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
16512600|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
16512601|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
16512602|NCT03204526|Experimental|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
16512603|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
16512604|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
16512605|NCT03204500|Experimental|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
16512606|NCT03204500|Placebo Comparator|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
16512607|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
16512608|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
16512609|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
16512610|NCT03204461||PCOS-NIH|
16512611|NCT03204461||PCOS-Rotterdam|
16512612|NCT03204461||Controls|
16512613|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
16512614|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
16512615|NCT03204435|Other|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
16512616|NCT03204435|Experimental|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
16512617|NCT03204422||Children's group|no intervention. participants, whose age was 5 to 18 years, were enrolled in Children's group.
16512618|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
16512619|NCT03204409||Symptomatic adults|adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h)
16519965|NCT03155074|Experimental|High-Intensity Training|
16512620|NCT03204396|Active Comparator|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
16512621|NCT03204396|Placebo Comparator|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
16512622|NCT03204370||MPS4A patients|
16512623|NCT03204357|Experimental|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
16512624|NCT03204357|Active Comparator|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
16512625|NCT03204344|Experimental|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.
~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
16512626|NCT03204344|Sham Comparator|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.
~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
16512627|NCT03204331|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
16512628|NCT03204331|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
16512629|NCT03204331|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
16512630|NCT03204318|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
16512631|NCT03204318|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
16512632|NCT03204318|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
16512633|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
16512634|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
16512635|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
16512636|NCT03204279|Experimental|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients < 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
16512637|NCT03204279|Experimental|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients < 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
16512638|NCT03204266|Experimental|Immunonutrition: ARS + Omega-3 Fatty Acids|"Participants take 1 ounce (30mls) of Arginine recovery supplement (ARS) four times daily 5 days preoperatively and 14 days postoperatively.
~Participants also given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively."
16512639|NCT03204266|No Intervention|No Immunonutrition|Participants receive regular enhanced recovery after surgery (ERAS)/Optimized Surgical Journey (OSJ) education and follow up.
16512640|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
16512641|NCT03204253|Active Comparator|rFSH alone|control group
16512644|NCT03204227|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
16512645|NCT03204227|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
16512646|NCT03204201|Experimental|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
16512647|NCT03204188|Experimental|Treatment|Ibrutinib is given daily until disease progression or intolerable side effects
16512648|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
16512649|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
16512650|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
16519966|NCT03155074|No Intervention|Usual Care|
16512651|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
16512652|NCT03204149|Experimental|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.
~Intervention: MC-8XL low level laser device and Standard wound care"
16512653|NCT03204149|Sham Comparator|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.
~Intervention: Sham laser device and Standard wound care"
16512654|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
16512655|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
16512656|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with CT or MRI|Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.
16512657|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with MRI|Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted. This arm will be closed to accrual and these patients will be analyzed separately.
16512658|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
16512659|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
16512660|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
16512661|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
16512662|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
16512663|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
16512664|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
16512665|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
16512666|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
16512667|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
16512668|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
16512669|NCT03204045|Active Comparator|fentanyl|fentanyl 1 ㎍/kg
16512670|NCT03204045|Active Comparator|oxycodone|oxycodone 0.08 mg/kg
16512671|NCT03204045|Placebo Comparator|control|isotonic saline
16512672|NCT03204032|Experimental|Tegafur and Temozolomide|
16512673|NCT03204032|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|
16512674|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16512675|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16512676|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
16512677|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
16512678|NCT03203967|Experimental|Epidural morphine|"Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
16512679|NCT03203967|Placebo Comparator|Epidural placebo|"Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.
~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
16512680|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
16512681|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
16512682|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
16512683|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
16512684|NCT03203928|No Intervention|Control|No treatment provided.
16512685|NCT03203915|Experimental|Group 1|"Order of treatments:
~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
16512686|NCT03203915|Experimental|Group 2|"Order of treatments:
~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
16512687|NCT03203915|Experimental|Group 3|"Order of treatments:
~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
16512688|NCT03203915|Experimental|Group 4|"Order of treatments:
~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
16513132|NCT03201146|Experimental|Apatinib|Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
16512689|NCT03203915|Experimental|Group 5|"Order of treatments:
~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
16512690|NCT03203915|Experimental|Group 6|"Order of treatments:
~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
16512691|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:
~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)
~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
16512692|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:
~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)
~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
16512693|NCT03203902|No Intervention|Control|No intervention
16512694|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
16512695|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
16512696|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
16512697|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
16512698|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
16512699|NCT03203850|Experimental|Deferasirox FCT Arm|randomized in a 2:1 ratio: Deferasirox to surgery
16512700|NCT03203850|Experimental|phlebotomy|randomized in a 2:1 ratio: Deferasirox to surgery
16512701|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
16512702|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
16512703|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
16512704|NCT03203811|Experimental|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
16512705|NCT03203811|Experimental|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
16512706|NCT03203811|Experimental|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
16512707|NCT03203798|Active Comparator|Training of pelvic floor muscles|
16512708|NCT03203798|Experimental|Hipopressive abdominal gymnastics|
16512709|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
16512710|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
16512711|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
16512712|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
16512713|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
16512714|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
16512715|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
16512716|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
16512717|NCT03203733|Experimental|'Cooral™'|oral cooling with use of cooling device
16512718|NCT03203733|Active Comparator|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
16512719|NCT03203720|No Intervention|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
16512720|NCT03203720|Experimental|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
16512721|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
16512722|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
16513196|NCT03200717|Experimental|pazopanib 800 mg|administered after checkpoint inhibitor treatment
16512723|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
16512724|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
16512725|NCT03203694|Experimental|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
16512727|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
16512728|NCT03203655|Experimental|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
16512729|NCT03203655|Other|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
16512730|NCT03203642|Experimental|Treatment Group|50mg tesevatinib administered once daily for up to 24 months.
16512731|NCT03203642|Placebo Comparator|Control Group|Matching placebo administered once daily for up to 24 months.
16512732|NCT03203616|Experimental|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
16512733|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
16512734|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
16512735|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
16512736|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
16512737|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
16512738|NCT03203577|Active Comparator|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
16512739|NCT03203577|Experimental|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
16512740|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
16512741|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
16512742|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
16512743|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
16512744|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
16512745|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
16512746|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
16512747|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
16512748|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
16512749|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
16512750|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
16512751|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
16512752|NCT03203525|Experimental|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16512753|NCT03203525|Experimental|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16512754|NCT03203512|Active Comparator|Intervention|Fish oil capsules
16512755|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
16512756|NCT03203499|Experimental|ANS-6637|Single ascending doses of ANS-6637 administered orally
16512757|NCT03203499|Placebo Comparator|Placebo|Placebo administered orally
16512758|NCT03203486|Experimental|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
16512759|NCT03203473|Experimental|Initial Primary Treatment|"Therapy with nivolumab IV every 2 weeks
~Serial imaging assessments every 8 weeks
~After confirmatory scans, patients are assigned to Arm A or Arm B."
16512760|NCT03203473|Experimental|Arm A: Persistent (PR/CR)|"Serial imaging assessments every 8 weeks
~Therapy with nivolumab IV every 2 weeks
~If scans persistently show PR/CR, nivolumab is discontinued until progression.
~Nivolumab is re-initiated, and if there is subsequent progression, ipilimumab is added for x2 doses.
~Ipilimumab IV every 3 weeks (only in patients who progress after nivolumab re-initiation)
~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
16512761|NCT03203473|Experimental|Arm B: Persistent (PD/SD)|"Therapy with nivolumab IV every 2 weeks
~Ipilimumab IV every 3 weeks
~Serial imaging assessments every 8 week
~If scans show SD/PR/CR, nivolumab continued until progression. If progression, therapy discontinued."
16512762|NCT03203460|Experimental|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
16512763|NCT03203460|No Intervention|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
16512764|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
16512765|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
16512766|NCT03203434||Esophageal anastomotic leakage|
16512767|NCT03203434||Esophageal uncomplicated controls|
16512768|NCT03203434||Pancreatic anastomotic leakage|
16512769|NCT03203434||Pancreatic uncomplicated controls|
16512770|NCT03203421|Active Comparator|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10^9 vp) on day 0.
16512771|NCT03203421|Active Comparator|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10^10 vp) on day 0 and one dose of MVA LS2 (2 x 10^8 pfu) on day 56.
16512772|NCT03203421|No Intervention|Control Group A|No vaccinations will be administered.
16512773|NCT03203421|No Intervention|Control Group B|No vaccinations will be administered.
16512774|NCT03203408|Experimental|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
16512775|NCT03203408|Active Comparator|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
16512776|NCT03203395|Experimental|Heart patients|Screening and counselling
16512777|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
16512778|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
16512779|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
16512780|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
16512781|NCT03203343|Active Comparator|PIRS group|Patients operated laparoscopically - PIRS technique
16512782|NCT03203343|Active Comparator|Marcy group|Patients operated by open modified Marcy technique
16512783|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
16512784|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
16512785|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
16512786|NCT03203317|Experimental|Exercise|10 min of maximal exercise
16512787|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.
~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
16512788|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.
~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
16512789|NCT03203291|Experimental|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
16513262|NCT03200288|Placebo Comparator|Placebo|Single 2 ml intra-articular injection of Placebo (physiological solution)
16512790|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
16512791|NCT03203278|No Intervention|Control group|Usual care
16512792|NCT03203265|Other|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
16512793|NCT03203265|Other|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
16512794|NCT03203265|Other|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
16512795|NCT03203239|Experimental|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
16512796|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
16512797|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
16512798|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient
~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)
~A urine sample is taken if possible."
16512799|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
16512800|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
16512801|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
16512802|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
16512803|NCT03203174|Experimental|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
16512804|NCT03203174|Sham Comparator|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
16512805|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
16512806|NCT03203135|Experimental|Intervention Group|
16512807|NCT03203135|No Intervention|Control Group|
16512808|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
16512809|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
16512810|NCT03203096|Placebo Comparator|Placebo|identically tasting and looking Placebo
16512811|NCT03203096|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
16512812|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
16512813|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
16512814|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
16512815|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
16512816|NCT03203057||control group|10 individuals get randomised to control group.
16512817|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
16512818|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
16512819|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
16512820|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
16512821|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
16512822|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
16512823|NCT03203018|Experimental|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
16512824|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
16512825|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
16512826|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
16512827|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
16512828|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
16512829|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
16512830|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
16513707|NCT03197727|Other|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
16512831|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
16512832|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
16512833|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
16512834|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
16512835|NCT03202979|Experimental|Group 1|Trazodone 20 mg
16512836|NCT03202979|Experimental|Group 2|Trazodone 10 mg
16512837|NCT03202979|Placebo Comparator|Group 3|Placebo
16512838|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
16512839|NCT03202953|Experimental|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
16512840|NCT03202953|Active Comparator|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
16512841|NCT03202940|Experimental|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
16512842|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
16512843|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
16512844|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
16512845|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
16512846|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
16512847|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
16512848|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)
~Excipients:
~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
16512849|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
16512850|NCT03202875|Experimental|Test (T)|SAR341402: single dose injection
16512851|NCT03202875|Active Comparator|Reference 1 (R1)|NovoRapid®: single dose injection
16512852|NCT03202875|Active Comparator|Reference 2 (R2)|NovoLog®: single dose injection
16512853|NCT03202862|Experimental|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
16512854|NCT03202849|Experimental|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
16512855|NCT03202849|Active Comparator|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
16512856|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
16512857|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
16512858|NCT03202823||Diabetics|
16512859|NCT03202823||Non-diabetics|
16512860|NCT03202797||Patients|
16512861|NCT03202784|Experimental|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
16512862|NCT03202784|Experimental|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
16512863|NCT03202784|Experimental|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
16512864|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
16512865|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
16512866|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months
~Tremelimumab for up to 4 doses/cycles
~FOLFOX"
16512867|NCT03202745|No Intervention|Control|The control arm will not receive any communications as a result of this study.
16512868|NCT03202745|Experimental|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
16512869|NCT03202745|Experimental|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
16512870|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.
~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.
~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.
~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
16512871|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.
~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.
~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
16512872|NCT03202719|Active Comparator|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
16512873|NCT03202719|Active Comparator|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
16512874|NCT03202719|Active Comparator|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
16512875|NCT03202719|Active Comparator|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
16512876|NCT03202719|Active Comparator|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
16512877|NCT03202706||Patients|
16512878|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
16512879|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
16512880|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
16512881|NCT03202667|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
16512882|NCT03202667|Placebo Comparator|Placebo|Treatment with Placebo tablets once daily for 28 days
16512883|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
16512884|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
16512885|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).
~Interventions:
~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).
~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
16512886|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.
~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16512887|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
16512888|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
16512889|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
16512890|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
16512891|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
16512892|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
16512893|NCT03202563|Experimental|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.
~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
16512894|NCT03202563|Active Comparator|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.
~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
16512895|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
16513708|NCT03197714|Experimental|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
16512896|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
16512897|NCT03202537|Experimental|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
16512898|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
16512899|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
16512900|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
16512901|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
16512902|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
16512903|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
16512904|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
16512905|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
16512906|NCT03202485|Active Comparator|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
16512907|NCT03202485|Experimental|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
16512908|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
16512909|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
16512910|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
16512911|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
16512912|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
16512913|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
16512914|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
16512915|NCT03202433|Experimental|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
16512916|NCT03202433|No Intervention|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
16512917|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
16512918|NCT03202407|Placebo Comparator|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.
~all the following investigation will be done before and after consecutive 3 months of administration :
~Complete blood count
~Kidney function tests (serum urea and creatinine)
~Serum total calcium level.
~Serum phosphorus level.
~Calcium × phosphorus product.
~Serum parathormone level.
~Serum alkaline phosphatase level.
~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).
~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
16512919|NCT03202407|Experimental|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.
~all the following investigation will be done before and after consecutive 3 months of administration :
~Complete blood count
~Kidney function tests (serum urea and creatinine)
~Serum total calcium level.
~Serum phosphorus level.
~Calcium × phosphorus product.
~Serum parathormone level.
~Serum alkaline phosphatase level.
~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).
~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
16512920|NCT03202394|Active Comparator|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
16512921|NCT03202394|Placebo Comparator|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
16512922|NCT03202381|Experimental|Degarelix|
16512923|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
16512924|NCT03202355|Experimental|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
16512925|NCT03202355|Experimental|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
16512926|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
16512927|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
16512928|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
16512929|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
16512930|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
16512931|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
16512932|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
16512933|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
16512934|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
16512935|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
16512936|NCT03202329|Other|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
16512937|NCT03202329|Other|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
16512938|NCT03202316|Experimental|Cohort I (atezolizumab, cobimetinib, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-4. Cycles 1-4 repeat every 21 days and subsequent cycles with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16512939|NCT03202316|Experimental|Cohort II (atezolizumab, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 3 weeks for cycles 1-6 and every 4 weeks for subsequent cycles, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-6. Cycles 1-6 repeat every 21 days and subsequent cycles with atezolizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16512940|NCT03202303|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
16512941|NCT03202303|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
16512942|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
16512943|NCT03202290|Other|Controls|healthy controls
16512944|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
16512945|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
16512946|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
16512947|NCT03202238|Active Comparator|Conventional|Venepuncture without the use of any venepuncture assistive device
16512948|NCT03202238|Active Comparator|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
16512949|NCT03202238|Experimental|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
16512950|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
16512951|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
16512952|NCT03202199|Experimental|PET/MRI|PET/MRI examination
16512953|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
16512954|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
16512955|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
16512956|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
16512957|NCT03202173|Active Comparator|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
16512958|NCT03202173|Experimental|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
16512959|NCT03202173|Experimental|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
16512960|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
16513709|NCT03197688||Notapplicable|Not applicable as non-interventional study
16512961|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
16512962|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
16512963|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
16512964|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
16512965|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
16512966|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
16512967|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
16512968|NCT03202095|Experimental|Open Label Treatment with Creatine|5 grams daily of oral creatine monohydrate powde
16512969|NCT03202082|Experimental|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
16512970|NCT03202082|No Intervention|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
16512971|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
16512972|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
16512973|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
16512974|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
16512975|NCT03202056|No Intervention|Control|Control group. No intervention.
16512976|NCT03202043|Experimental|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
16512977|NCT03202043|Experimental|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
16512978|NCT03202043|Experimental|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
16512979|NCT03202043|Other|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
16512980|NCT03202030|Experimental|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
16512981|NCT03202030|Active Comparator|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
16512982|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
16512983|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
16512984|NCT03202004|Experimental|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram [mg/g]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
16512985|NCT03202004|Placebo Comparator|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
16512986|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
16512987|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
16512988|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
16512989|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
16512990|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
16513022|NCT03201783|Other|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
16513023|NCT03201783|Other|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
16512991|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
16512992|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
16512993|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
16512994|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
16512995|NCT03201926|Experimental|mealworms|mealworms
16512996|NCT03201926|Placebo Comparator|grain powder|grain powder
16512997|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).
~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
16512998|NCT03201900|Experimental|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
16512999|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
16513000|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
16513001|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
16513002|NCT03201887|No Intervention|Chronic pain|optimal effort
16513003|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
16513004|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
16513005|NCT03201861|Experimental|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
16513006|NCT03201861|Active Comparator|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel
~Investigators will declare one of the following regimens:
~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.
~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
16513007|NCT03201848|Experimental|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
16513008|NCT03201848|Placebo Comparator|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
16513009|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
16513010|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
16513011|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
16513012|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
16513013|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
16513014|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
16513015|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
16513016|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
16513017|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
16513018|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
16513019|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
16513020|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
16513021|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
16513024|NCT03201770|Experimental|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
16513026|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
16513027|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
16513028|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
16513029|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
16513030|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
16513031|NCT03201705|Experimental|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
16513032|NCT03201692|Active Comparator|Treadmill Training|40' treadmill training walking holding the handrail
16513033|NCT03201692|Experimental|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
16513034|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
16513035|NCT03201679||Patients without preoperative sepsis|
16513036|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
16513037|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
16513038|NCT03201640|Other|slideshow|Participant receives traditional slideshow presentation for preoperative preparation
16513039|NCT03201640|Other|virtual|Participant receives virtual reality presentation for preoperative preparation
16513040|NCT03201627|Experimental|treatment|
16513041|NCT03201614|Experimental|A-CP HA|Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.
16513042|NCT03201614|Active Comparator|ArthroVisc 40|Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.
16513043|NCT03201614|Placebo Comparator|Placebo|Patients randomized in this group will be treated with a saline solution.
16513044|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
16513045|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
16513046|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
16513047|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).
~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
16513048|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
16513049|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
16513050|NCT03201562|Experimental|Aceclidine+tropicamide combination|Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
16513051|NCT03201562|Active Comparator|Aceclidine|Aceclidine single dose
16513052|NCT03201562|Sham Comparator|Vehicle|Vehicle single dose
16513053|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
16513054|NCT03201536|Active Comparator|sutures|zipLine3 device verses conventional sutures
16513055|NCT03201536|Active Comparator|Zip3 Device|
16513056|NCT03201523|Experimental|Intervention|Community members will be exposed to multiple interventions designed through the participatory approach, integrating the socio-ecological model.
16513057|NCT03201510||Observational|Observational study
16513058|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
16513128|NCT03201159|Experimental|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
16513129|NCT03201146|Experimental|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
16521972|NCT03141073|Placebo Comparator|Placebo|BID
16513059|NCT03201471|Experimental|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
16513060|NCT03201458|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16513061|NCT03201458|Experimental|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16513062|NCT03201445|Experimental|Part A (Filgotinib or Placebo)|Participants will receive double-blind filgotinib or placebo for 13 weeks
16513063|NCT03201445|Experimental|Part B (Filgotinib or Placebo)|Based on inflammatory bowel disease response status and sperm parameters, participants will continue on the blinded treatment for up to an additional 13 weeks or discontinue blinded study drug and commence open-label filgotinib.
16513064|NCT03201445|Experimental|Open-Label Filgotinib Phase|Participants will receive open-label filgotinib for up to 13 weeks.
16513065|NCT03201445|Experimental|Monitoring Phase|Participants whose sperm parameters meet a pre- specified decrease threshold at any time during the study, regardless of inflammatory bowel disease response status, will discontinue study drug and receive standard of care therapy in the Monitoring Phase.
16513066|NCT03201445|Experimental|Long Term Extension Phase|Participants qualifying to enter the Long Term Extension Phase will receive either open-label filgotinib or blinded study drug for up to 195 weeks based on the individual's response criteria.
16513067|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
16513068|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
16513069|NCT03201419|Experimental|FE 201836 500 μg (Randomized Treatment Period)|FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
16513070|NCT03201419|Experimental|FE 201836 350 μg (Randomized Treatment Period)|FE 201836 350 μg oral solution and placebo ODT, administered once daily
16513071|NCT03201419|Experimental|FE 201836 250 μg (Randomized Treatment Period)|FE 201836 250 μg oral solution and placebo ODT, administered once daily
16513072|NCT03201419|Experimental|FE 201836 150 μg (Randomized Treatment Period)|FE 201836 150 μg oral solution and placebo ODT, administered once daily
16513073|NCT03201419|Experimental|FE 201836 100 μg (Randomized Treatment Period)|FE 201836 100 μg oral solution and placebo ODT, administered once daily
16513074|NCT03201419|Experimental|FE 201836 50 μg (Randomized Treatment Period)|FE 201836 50 μg oral solution and placebo ODT, administered once daily
16513075|NCT03201419|Experimental|Placebo (Randomized Treatment Period)|Placebo oral solution and placebo ODT, administered once daily
16513076|NCT03201419|Experimental|Desmopressin 25 μg (Randomized Treatment Period)|Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)
16513077|NCT03201419|Experimental|Desmopressin 50 μg (Randomized Treatment Period)|Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)
16513078|NCT03201393|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
16513079|NCT03201393|Placebo Comparator|Placebo|
16513080|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis
~- treated with rivaroxaban"
16513081|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
16513082|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
16513083|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
16513084|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
16513085|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
16513086|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
16513130|NCT03201146|Experimental|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
16513131|NCT03201146|Experimental|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
16514301|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
16513087|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
16513088|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
16513089|NCT03201328|Active Comparator|healthy subjects|
16513090|NCT03201328|Experimental|patients with unilateral cochlear implants|
16513091|NCT03201328|Experimental|patients with bilateral cochlear implants|
16513092|NCT03201302|Experimental|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
16513093|NCT03201302|Experimental|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
16513094|NCT03201302|Experimental|Martial arts|Children who participated in organized Martial arts training for the entire school year.
16513095|NCT03201302|Experimental|Climbing|Children who participated in organized climbing training for the entire school year.
16513096|NCT03201302|Experimental|Volleyball|Children who participated in organized volleyball training for the entire school year.
16513097|NCT03201302|Experimental|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
16513098|NCT03201302|Experimental|Swimming|Children who participated in organized swimming training for the entire school year.
16513099|NCT03201302|Experimental|Dance|Children who participated in organized dance training for the entire school year.
16513100|NCT03201302|Experimental|Basketball|Children who participated in organized basketball training for the entire school year.
16513101|NCT03201302|Experimental|Wrestling|Children who participated in organized wrestling training for the entire school year.
16513102|NCT03201302|Experimental|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
16513103|NCT03201302|Experimental|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
16513104|NCT03201302|Experimental|Track and field|Children who participated in organized track and field training for the entire school year.
16513105|NCT03201302|Experimental|Tennis|Children who participated in organized tennis training for the entire school year.
16513106|NCT03201302|Experimental|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
16513107|NCT03201302|Experimental|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
16513108|NCT03201289||Cardiac surgery|
16513109|NCT03201276||Drug group|patients taking glucosamine
16513110|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
16513111|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
16513112|NCT03201250|Experimental|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone
~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.
~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.
~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
16513113|NCT03201237|Experimental|30 min AOT|
16513114|NCT03201237|Placebo Comparator|60 min AOT|
16513115|NCT03201224||Group without image transmission|"Before Group"
16513116|NCT03201224||Group with image transmission|"After Group"
16513117|NCT03201211|Experimental|10-10-10-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, PE-PilA and UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
16513118|NCT03201211|Experimental|10-10-3-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
16513119|NCT03201211|Placebo Comparator|PLACEBO|Subjects who received two doses of placebo (saline solution), administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974) and were enrolled in the study.
16513120|NCT03201198|Experimental|Active Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
16513121|NCT03201198|Sham Comparator|Chair exercises|The Chair exercise intervention includes chair exercises, behavioral relaxation and health education.
16513122|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
16513123|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
16513124|NCT03201172||Univation® X|
16513125|NCT03201172||iUni®|
16513126|NCT03201159|Experimental|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
16513127|NCT03201159|Experimental|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
16514478|NCT03192202|Experimental|Cohort 2|1.5 mg/kg of AFM13 three times per week for weeks 1-8.
16513133|NCT03201146|Active Comparator|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.
16513134|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
16513135|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
16513136|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
16513137|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.
~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
16513138|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.
~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
16513139|NCT03201107|Experimental|Pilates group|This group receives physical training based on pilates exercises
16513140|NCT03201107|No Intervention|No intervention group|This group does not receive any treatment
16513141|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
16513142|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
16513143|NCT03201094|Experimental|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
16513144|NCT03201094|Experimental|HPRO only|Patients will receive HPRO three times daily during study period
16513145|NCT03201081|Experimental|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
16513146|NCT03201081|No Intervention|control group|The control group, did not participate in the motivational resistance-training program.
16513147|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
16513148|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
16513149|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
16513150|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
16513151|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
16513152|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
16513153|NCT03201003|Active Comparator|AR101|AR101 powder provided in capsules & sachets
16513154|NCT03201003|Placebo Comparator|Placebo|Placebo powder provided in capsules & sachets
16513155|NCT03200990|Experimental|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
16513156|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
16513157|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
16513158|NCT03200951|Experimental|Bolus group|
16513159|NCT03200951|Active Comparator|Infusion group|
16513160|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
16513161|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
16513162|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:
~their intention to practice skin to skin at the time of delivery
~if they participated in skin to skin in a previous pregnancy
~if they had any formal education about skin to skin
~if they did have formal education was it either
~a.) Provided at a prenatal appointment,
~b.) A formal class led by either a nurse or a lactation consultant.
~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
16513163|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.
~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.
~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
16513164|NCT03200912|Active Comparator|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
16513165|NCT03200912|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% [Test]
16513166|NCT03200912|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
16513167|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
16513168|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
16513169|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
16513170|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
16513171|NCT03200873|Active Comparator|high impulsivity|participants with high impulsivity (BIS >62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
16513172|NCT03200873|Active Comparator|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
16513173|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
16513174|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
16513175|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
16513176|NCT03200834|Active Comparator|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
16513177|NCT03200834|Experimental|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
16513178|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
16513179|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
16513180|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.
~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
16513181|NCT03200795|Experimental|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
16513182|NCT03200795|Experimental|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
16513183|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
16513184|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
16513185|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
16513186|NCT03200769|No Intervention|Group I|AHI/h < 15
16513187|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
16513188|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
16513189|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
16513190|NCT03200756|Experimental|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
16513191|NCT03200756|Active Comparator|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
16513192|NCT03200743||Hpertension|
16513193|NCT03200743||Health|
16513194|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
16513195|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
16513197|NCT03200704|Experimental|IC2000/SPY-PHI|Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.
16513198|NCT03200691|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.
~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.
~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
16513199|NCT03200678|Experimental|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
16513200|NCT03200678|Other|Control group|other Intervention: isokinetic assessment
16513201|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
16513202|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
16513203|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.
~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
16513204|NCT03200639|Active Comparator|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
16513205|NCT03200639|Active Comparator|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
16513206|NCT03200639|Experimental|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
16513207|NCT03200639|Experimental|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
16513208|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
16513209|NCT03200626||Routine plerixafor based mobilization|
16513210|NCT03200626||Chemomobilization|
16513211|NCT03200613|Experimental|Apixaban|Apixaban 2.5 mg orally twice daily
16513212|NCT03200613|Active Comparator|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
16513213|NCT03200600|Experimental|Dexamethasone and flurbiprofen axetil|"Dexamethasone 10 mg is administered before anesthesia induction.
~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
16513214|NCT03200600|Experimental|Dexamethasone and lipid microsphere|"Dexamethasone 10 mg is administered before anesthesia induction.
~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
16513215|NCT03200600|Experimental|Normal saline and flurbiprofen axetil|"Normal saline 2 ml is administered before anesthesia induction.
~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
16513216|NCT03200600|Experimental|Normal saline and lipid microsphere|"Normal saline 2 ml is administered before anesthesia induction.
~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
16513217|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
16513218|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
16513219|NCT03200561|Active Comparator|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
16513220|NCT03200561|Placebo Comparator|I group|IVIG (2g/Kg in 12 hours)
16513221|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
16513222|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
16513292|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
16513223|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
16513224|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
16513225|NCT03200535|No Intervention|Usual care|Usual care
16513226|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
16513227|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
16513228|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
16513229|NCT03200522|Active Comparator|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
16513230|NCT03200522|Active Comparator|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
16513231|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
16513232|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
16513233|NCT03200496|Experimental|TALION®|
16513234|NCT03200496|Experimental|DA-5206(Fasting)|
16513235|NCT03200496|Experimental|DA-5206(Fed)|
16513236|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
16513237|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
16513238|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
16513239|NCT03200470||Suspected PJI|
16513240|NCT03200457|Experimental|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla device and the other on a 3 Tesla device.
16513241|NCT03200444|Experimental|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.
~Standard adhesive 1
~standard adhesive 2
~Standard adhesive 3
~P-4
~P-15
~P-16
~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
16513242|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
16513243|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.
~The difference between the four patches is that they consist of different adhesives.
~One patch is made of a standard hydrocolloid adhesive
~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
16513244|NCT03200405|Experimental|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
16513245|NCT03200405|Active Comparator|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
16513246|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
16513247|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
16513248|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
16513249|NCT03200366|Active Comparator|Tailored DVD|Tailored digital video disc (DVD)
16513250|NCT03200366|Active Comparator|Tailored DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
16513251|NCT03200366|No Intervention|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
16513252|NCT03200353|Experimental|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
16513253|NCT03200340|Placebo Comparator|Placebo|Matching placebo
16513254|NCT03200340|Experimental|EC-18 500 mg|1 capsule of EC-18
16513255|NCT03200340|Experimental|EC-18 1000 mg|2 capsules of EC-18 500 mg
16513256|NCT03200340|Experimental|EC-18 2000 mg|4 capsules of EC-18 500 mg
16513257|NCT03200327|Active Comparator|laparoscopic promontofixation|
16513258|NCT03200327|Experimental|Anterior vaginal sacrospinofixation|
16513259|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
16513260|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
16513261|NCT03200288|Experimental|HL-01|Single 2 ml intra-articular injection of HL-01 (solution of high and low molecular weight hyaluronic acid (HA))
16513263|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.
~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
16513264|NCT03200249|Experimental|Treatment|"- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)
~Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy
~Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.
~- TME surgery (8 weeks after the end of treatment)"
16513265|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
16513266|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
16513267|NCT03200223|Experimental|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
16513268|NCT03200223|No Intervention|Conventional group|Patients with conventional care
16513269|NCT03200210|Experimental|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
16513270|NCT03200210|Placebo Comparator|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
16513271|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
16513272|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
16513273|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
16513274|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
16513275|NCT03200171||Group II|HCC patients who are naive to DAAs.
16513276|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
16513277|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
16513278|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
16513279|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
16513280|NCT03200093|Experimental|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.
~Taken by mouth once daily for:
~If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.
~If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
16513281|NCT03200093|Placebo Comparator|Placebo arm|"Ora-Sweet 5 mL
~Taken by mouth once daily for:
~If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.
~If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
16513282|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
16513283|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
16513284|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
16513285|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
16513286|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
16513287|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
16513288|NCT03200067|Experimental|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
16513289|NCT03200067|No Intervention|Conventional group|Breast cancer patients with conventional care
16513290|NCT03200054|No Intervention|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
16513291|NCT03200054|Experimental|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
16515424|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
16513293|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
16513294|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
16513295|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
16513296|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
16513297|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
16513298|NCT03199989|Active Comparator|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy[CapeOX（Capecitabine+Oxaliplatin）] by the current guidelines
16513299|NCT03199989|Experimental|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
16513300|NCT03199976|Experimental|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
16513301|NCT03199976|Active Comparator|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
16513302|NCT03199976|Active Comparator|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
16513303|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
16513304|NCT03199963|Placebo Comparator|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
16513305|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
16513306|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
16513307|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
16513308|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
16513309|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
16513310|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
16513311|NCT03199924|Active Comparator|diclofenac alone|diclofenac alone
16513312|NCT03199911|Experimental|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
16513313|NCT03199911|Placebo Comparator|Topical Non-Antibiotic Ointment|Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
16513314|NCT03199898||34-32 GA|premature infants born <34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
16513315|NCT03199898||32-28 GA|premature infants born <32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
16513316|NCT03199898||28-23 GA|premature infants born <28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
16513319|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
16513417|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
16514036|NCT03195309|Active Comparator|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
16513320|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
16513321|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
16513322|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
16513323|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
16513324|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
16513325|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
16513326|NCT03199833|Experimental|Arms|RETRAINER-S2 & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16513327|NCT03199833|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16513328|NCT03199820|Active Comparator|Cook Cervical balloon|Cook cervical double balloon catheter
16513329|NCT03199820|Active Comparator|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
16513330|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
16513331|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
16513332|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
16513333|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
16513334|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
16513335|NCT03199755|Active Comparator|ACT|"Standard Artemisinin Combination Therapy (ACT) being used as currently approved antimalarial therapy at WHO and manufacturer recommended dosage. The specific ACT used is artemether-lumefantrine (Coartem). Form is scored tablets that each contain 20 mg artemether and 120 mg lumefantrine.
~Tablets per dose, are given BID for 3 days as shown below:
~Coartem tablets/dose by bodyweight; tablets/day morning and evening for total of 6 doses over 3 days
~Body weight (kg) and Tablets: 5 to <15 kg, 1 tab; 15 to <25 kg, 2 tabs; 25 to <35 kg, 3 tabs; 35 kg and over, 4 tabs."
16513336|NCT03199755|Experimental|DLA1|"Dried leaf Artemisia annua (DLA) from 0.25-1 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.
~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.
~Body weight (kg) and tablets/dose:
~For DLA1x: 5 to < 15 kg, 1/4 tab; 15-30 kg, 1/2 tab; 1/2>30 kg, 1 tab."
16513337|NCT03199755|Experimental|DLA2|"Dried leaf Artemisia annua (DLA) from 0.5-2 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.
~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.
~Body weight (kg) and tablets/dose:
~For DLA2x: 5 to < 15 kg, 1/2 tab; 15-30 kg, 1 tab; >30 kg, 2 tabs."
16513338|NCT03199742|Active Comparator|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
16513339|NCT03199742|Experimental|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
16513340|NCT03199742|Experimental|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
16513341|NCT03199742|Experimental|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
16513342|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
16513343|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
16513344|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
16513345|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
16513346|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
16513347|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
16513348|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
16522095|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
16513349|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
16513350|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:
~Day 1 - 7
~- Dolutegravir 50 mg once daily with food
~Day 8 - 14 - Dolutegravir 100 mg once daily with food
~Day 15 - 28
~- Rifampicin 600 mg once daily
~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily
~Day 36 - 42
~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
16513351|NCT03199677|Experimental|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
16513352|NCT03199664|Active Comparator|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
16513353|NCT03199664|Active Comparator|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB & Tacrolimus 0.03 % ointment for 6 months
16513354|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
16513355|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
16513356|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
16513357|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
16513358|NCT03199638|No Intervention|control group|"in which we will use historic data from previous study (Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function) by choosing 12 children between 13-19 years with type 1 diabetes and meeting the very same inclusion/ exclusion criteria. We have readily available data for their HbA1C, CGM downloads, all labs and anthropometry for 3 months. We will select age, gender, and HbA1c-matched adolescents as these data were prospectively collected."
16513359|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
16513360|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
16513361|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
16513362|NCT03199612|Active Comparator|Sildenafil|Baseline blood samples and study measurements will be acquired. Then 20 mg of the study drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is < 5 mmHg after 2 hours and patient is asymptomatic), patient will proceed to take 20 mg of the study drug every 8 hours. The patient will return to clinic on day 8 and 20 mg of the study drug will be administered. After 2 hours blood samples and study measurements will be collected and the patient will resume 20 mg of the study for the next two doses. The patient will return for a third clinic visit on the next day and if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then the patient will continue taking 40 mg every 8 hours. The patient will return to clinic on day 15 for a final study visit and will be given the last 40 mg dose of the study drug and after 2 hours blood samples and study measurements will be taken.
16513363|NCT03199612|Placebo Comparator|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.
16513364|NCT03199586|Experimental|NP-G2-044|capsule
16513365|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
16513366|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
16513367|NCT03199547|Experimental|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
16513368|NCT03199547|Placebo Comparator|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
16513369|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
16513370|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
16513371|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
16513372|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
16513373|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
16513374|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
16513375|NCT03199508|Experimental|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
16513376|NCT03199508|Active Comparator|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
16513553|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
16513377|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
16513378|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
16513379|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
16513380|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
16513381|NCT03199469|Experimental|Lower Dose|"1.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.
~1.3 x10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time."
16513382|NCT03199469|Experimental|Higher Dose|"3.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.
~3.5 x 10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time"
16513383|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.
16513384|NCT03199456|Experimental|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
16513385|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
16513386|NCT03199443||Overactive bladder patients|
16513387|NCT03199443||Non Obstructive Urinary Retention patients|
16513388|NCT03199430|Placebo Comparator|Placebo|1450mg Corn flour
16513389|NCT03199430|Active Comparator|Epigallocatechin gallate|1450mg Epigallocatechin gallate
16513390|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
16513391|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
16513392|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
16513393|NCT03199378||Caucasian|English speaking Caucasian individuals
16513394|NCT03199378||African American|English speaking African American individuals
16513395|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
16513396|NCT03199365|Experimental|Prevention (TSSC intervention)|Participants undergo two TSSC intervention sessions delivered at participants' homes by trained CHWs over 1.5 hours.
16513397|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
16513398|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
16513399|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
16513400|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
16513401|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
16513402|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
16513403|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
16513404|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
16513405|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
16513406|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
16513407|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
16513408|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
16513409|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
16513410|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
16513411|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
16513412|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
16513413|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
16513414|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
16513415|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
16513416|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
16515425|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
16513418|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
16513419|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
16513420|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
16513421|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
16513422|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
16513423|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
16513424|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
16513425|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
16513426|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
16513427|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
16513428|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
16513429|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
16513430|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
16513431|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
16513432|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
16513433|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
16513434|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
16513435|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
16513436|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
16513437|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
16513438|NCT03199274|Experimental|Group I (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours and at approximately 7 and 14 days after yttrium Y-90 radioembolization.
16513439|NCT03199274|Active Comparator|Group II (standard of care)|Patients undergo standard of care yttrium Y-90 radioembolization.
16513440|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
16513441|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
16513442|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
16513443|NCT03199248||the participant accepted aspiration for DMC only|
16513444|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
16513445|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
16513446|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
16513447|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
16513448|NCT03199209|Experimental|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
16513449|NCT03199209|Experimental|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
16513487|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
16513488|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
16515462|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
16513450|NCT03199196|Experimental|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.
~Participant emailed electronic newsletters to read that may help participant be more physically active.
~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).
~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.
~Participants invited to take part in a final focus group sometime after the 16-week visit."
16513451|NCT03199196|Other|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.
~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).
~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.
~Participants invited to take part in a final focus group sometime after the 16-week visit."
16513452|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
16513453|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
16513454|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
16513455|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
16513456|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
16513457|NCT03199157|No Intervention|Control group|
16513458|NCT03199144|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
16513459|NCT03199131|Experimental|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
16513460|NCT03199131|Other|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
16513461|NCT03199118|Experimental|CAF+SCTG+PRF|The patients suffering from class I or II gingival recession in the intervention group will receive a subepithelial connective tissue graft (SCTG) covered by platelet rich fibrin membrane (PRF) followed by a coronally advanced flap (CAF)
16513462|NCT03199118|Active Comparator|CAF+SCTG|Control group patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG only
16513463|NCT03199105|Experimental|preoperative education and tetracaine|
16513464|NCT03199105|Experimental|tetracaine|
16513465|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
16513466|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
16513467|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
16513468|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
16513469|NCT03199066||All NHL subtypes|no interventions
16513470|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
16513471|NCT03199066||FL|only patients with follicular lymphoma
16513472|NCT03199066||MCL|only patients with mantle cell lymphoma
16513473|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
16513474|NCT03199066||MZL|only patients with marginal zone lymphoma
16513475|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
16513476|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
16513477|NCT03199053|Experimental|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
16513478|NCT03199053|Experimental|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12
16513479|NCT03199053|Experimental|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
16513480|NCT03199053|Experimental|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12
16513481|NCT03199053|Placebo Comparator|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
16513482|NCT03199040|Experimental|Neoantigen DNA vaccine + Durvalumab|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1
~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days
~For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
16513483|NCT03199040|Experimental|Neoantigen DNA vaccine|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1
~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
16513484|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
16513485|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
16513486|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
16513489|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
16513490|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
16513491|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
16513492|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
16513493|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
16513494|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
16513495|NCT03198936|Experimental|Cognizin® SynapsaTM|Dose - 2 capsules twice a day with meals
16513496|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
16513497|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
16513498|NCT03198910||Pulmonary arterial hypertension|
16513499|NCT03198910||Chronic thromboembolic pulmonary hypertension|
16513500|NCT03198897||Observation|Patients with a Homozygous familial Hypercholesterolemia or high-grade suspicion for Homozygous familial Hypercholesterolemia
16513501|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
16513502|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
16513503|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
16513504|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
16513505|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.
~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
16513506|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.
~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
16513507|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
16513508|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
16513509|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime
~For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days
~For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
16513510|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime
~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
16513511|NCT03198806|Active Comparator|Control group in supine position|"Intervention:
~- Only treadmill aerobic exercise with 60 min recovery in supine position"
16513512|NCT03198806|Experimental|Hydration group in supine position|"Interventions:
~Treadmill aerobic exercise with 60 min recovery in supine position
~Water intake"
16513513|NCT03198806|Active Comparator|Control group in orthostatic position|"Intervention:
~- Only treadmill aerobic exercise with 10 min recovery in orthostatic position"
16513514|NCT03198806|Experimental|Hydration group in orthostatic position|"Interventions:
~Treadmill aerobic exercise with 10 min recovery in orthostatic position
~Water intake"
16513515|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
16513516|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.
~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
16513517|NCT03198767|Experimental|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
16513518|NCT03198767|Experimental|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
16513519|NCT03198767|Experimental|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
16513520|NCT03198767|Experimental|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
16513521|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
16513522|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
16513523|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
16513524|NCT03198754|Experimental|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
16513525|NCT03198754|Active Comparator|Comparison Light|Ambient light fixture installed in the patient's hospital room
16513526|NCT03198741|Active Comparator|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.
~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
16513527|NCT03198741|Experimental|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
16513528|NCT03198741|Experimental|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
16513529|NCT03198728|Experimental|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
16513530|NCT03198728|Active Comparator|Andro-Gel treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 42.
16513531|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
16513532|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
16513533|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
16513534|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
16513535|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
16513536|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
16513537|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
16513538|NCT03198689|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
16513539|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
16513540|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
16513541|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
16513542|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
16513543|NCT03198663|Experimental|POSSE Intervention|
16513544|NCT03198663|Other|Control|Delayed intervention
16513545|NCT03198650|Experimental|Part 1 / Part 2|Acalabrutinib
16513546|NCT03198650|Experimental|Part 3|Acalabrutinib in combination with Obinutuzumab
16513547|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
16513548|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
16513549|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
16513550|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
16513551|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
16513552|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
16522096|NCT03140332|Other|Patient with CHC|
16513554|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
16513555|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
16513556|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
16513557|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:
~Mitral lateral annulus e' in tissue Doppler < 10 cm/s
~American society of echocardiography (ASE) criteria 2009
~ASE criteria 2016"
16513558|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
16513559|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
16513560|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
16513561|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
16513562|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
16513563|NCT03198598|No Intervention|Healthy subjects|
16513564|NCT03198585|Active Comparator|Empagliflozin 10 mg|
16513565|NCT03198585|Placebo Comparator|Placebo|
16513566|NCT03198572|Experimental|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
16513567|NCT03198572|Placebo Comparator|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
16513568|NCT03198559|Experimental|Experimental|"Participants current ART regimen:
~2 grams disulfiram by mouth per day for a total of 28 days
~400mg vorinostat by mouth per day on days 8, 9,10 and days 22, 23, 24"
16513569|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 and TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
16513570|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
16513571|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
16513572|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
16513573|NCT03198507|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
16513574|NCT03198507|Active Comparator|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
16513575|NCT03198494|Experimental|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
16513576|NCT03198494|Sham Comparator|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
16513577|NCT03198494|No Intervention|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
16513578|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
16513579|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
16513580|NCT03198468|Experimental|Vapor Ablation|
16513581|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
16513582|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
16513583|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
16513584|NCT03198429|Experimental|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:
~a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV
~access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV
~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,
~cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program
~clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
16513612|NCT03198273|Experimental|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
16513613|NCT03198260|Experimental|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
16513614|NCT03198260|Active Comparator|Running kinematics|the change in a range of joint angles during different phases of running
16514037|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
16513585|NCT03198429|Experimental|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:
~a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development
~access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues
~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,
~cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program
~clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
16513586|NCT03198429|Experimental|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
16513587|NCT03198429|No Intervention|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
16513589|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
16513590|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
16513591|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
16513592|NCT03198390||Healthy subjects|
16513593|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
16513594|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
16513595|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
16513596|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
16513597|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
16513598|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
16513599|NCT03198351||Cohort I|Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
16513600|NCT03198351||Cohort II|Pregnant women with MS not exposed to teriflunomide during the current pregnancy
16513601|NCT03198351||Cohort III|Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
16513602|NCT03198351||"Registry group (not eligible for cohorts)"|Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.
16513603|NCT03198338|Experimental|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
16513604|NCT03198338|Sham Comparator|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
16513605|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
16513606|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
16513607|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
16513608|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
16513609|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
16513610|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
16513611|NCT03198273|Experimental|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
16513696|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
16513615|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.
~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
16513616|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
16513617|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
16513618|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
16513619|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
16513620|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
16513621|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
16513622|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
16513623|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
16513624|NCT03198208||Reference group|No fentanyl dose administered during surgery
16513625|NCT03198208||Comparative group|Fentanyl dose administered during surgery
16513626|NCT03198182|Experimental|Module A|BMS-986036 Arm
16513627|NCT03198182|Placebo Comparator|Module B|Placebo Arm
16513628|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
16513629|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
16513630|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
16513631|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
16513634|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
16513635|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
16513636|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
16513637|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
16513638|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
16513639|NCT03198117|Experimental|Huaier Granule|Huaier Granule
16513640|NCT03198117|Placebo Comparator|placebo|placebo
16513641|NCT03198117|No Intervention|No-treatment Control|patients refused any treatment
16513697|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
16513698|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
16513642|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
16513643|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
16513644|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
16513645|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
16513649|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
16513650|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
16513651|NCT03198052|Experimental|CAR-T cell therapy group|Patients will receive 3 or more cycles of the CAR-T cells treatment via systemic or regional injection, from 1x10e6/kg-10x10e6/kg weight.
16513652|NCT03198039|Experimental|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
16513653|NCT03198039|Experimental|Group 2|Meditation twice daily for four weeks after surgery
16513654|NCT03198039|No Intervention|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
16513655|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|"Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.
~After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then annually for up to 2 years."
16513656|NCT03198013|Experimental|Module A|Single Ascending Dose
16513657|NCT03198013|Experimental|Module B|Multiple Ascending Dose
16513658|NCT03198000|Experimental|Formula # 13418-148|
16513659|NCT03198000|Experimental|Formula # 13418-158|
16513660|NCT03198000|Active Comparator|Control Formula # PF004390|
16513661|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
16513662|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
16513663|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
16513664|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
16513665|NCT03197961|Experimental|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
16513666|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
16513667|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
16513668|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
16513669|NCT03197922|Experimental|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
16513699|NCT03197766|Experimental|Active BMN 111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
16513670|NCT03197922|No Intervention|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
16513671|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
16513672|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
16513673|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
16513674|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
16513675|NCT03197883|Experimental|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
16513676|NCT03197883|Other|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
16513677|NCT03197870|Experimental|AKB-9778 15mg BID|
16513678|NCT03197870|Experimental|AKB-9778 15mg QD|
16513679|NCT03197870|Placebo Comparator|Placebo BID|
16513680|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
16513681|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
16513682|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
16513683|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
16513684|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
16513685|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
16513686|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
16513687|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
16513688|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
16513689|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
16513690|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
16513691|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
16513692|NCT03197805|Experimental|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
16513693|NCT03197792|Experimental|Pulmonary endarterectomy patients|All patients
16513694|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
16513695|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
16513710|NCT03197675|Sham Comparator|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
16513711|NCT03197675|Active Comparator|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
16513712|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
16513713|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
16513714|NCT03197649|No Intervention|Control|No laser phototherapy treatment
16513715|NCT03197649|Experimental|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
16513716|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
16513717|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
16513718|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
16513719|NCT03197623|Placebo Comparator|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
16513720|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
16513721|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
16513722|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
16513723|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
16513724|NCT03197571|Experimental|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
16513725|NCT03197558|Other|Tube insertion using Tube Delivery System (TDS)|Active Tymbion iontophoresis and tube insertion using the TDS
16513726|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
16513727|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
16513728|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
16513729|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
16513730|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
16513731|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
16513732|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
16513733|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
16513734|NCT03197506|Experimental|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.
~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.
~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.
~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
16514033|NCT03195322|Experimental|Pre-pectoral Tissue Expander|Pre-pectoral immediate tissue expander breast reconstruction with complete AlloDerm® coverage to reinforce breast tissues.
16513735|NCT03197506|Experimental|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.
~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
16513736|NCT03197493|Experimental|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
16513737|NCT03197493|Experimental|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
16513738|NCT03197480|Other|DME treatment group|"All patients will received 4 intravitreal injections of aflibercept.
~Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:
~Less than 20% reduction in CRT on OCT or <5 letter improvement of VA (if VA<6/6 and CRT>=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT"
16513739|NCT03197467|Experimental|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
16513740|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
16513741|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
16513742|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
16513743|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
16513744|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
16513745|NCT03197415|Experimental|PRP group|Intradisc injection of autologous platelet-rich plasma gel
16513746|NCT03197402|Active Comparator|Comparator group|Milk protein gel delivery system supplementation
16513747|NCT03197402|Experimental|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
16513748|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
16513749|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
16513750|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
16513751|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
16513752|NCT03197389|Other|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
16513753|NCT03197389|Other|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
16513754|NCT03197376|Experimental|Pneumosil Lot 1|Pneumosil Lot 1
16513755|NCT03197376|Experimental|Pneumosil Lot 2|Pneumosil Lot 2
16513756|NCT03197376|Experimental|Pneumosil Lot 3|Pneumosil Lot 3
16513757|NCT03197376|Active Comparator|Synflorix|Synflorix
16513758|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
16513759|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next 4 years. Eligible patients include those with age ≥50 years, LVEF ≥45%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) within the 60 days before inclusion.
~Intervention: cMR"
16513760|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.
~Intervention: cMR"
16513761|NCT03197337|Experimental|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
16513762|NCT03197337|Experimental|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
16513763|NCT03197324|Active Comparator|Digoxin Alone first, then Digoxin With Bexagliflozin|
16513764|NCT03197324|Active Comparator|Digoxin with Bexagliflozin, then Digoxin alone|
16513765|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
16515463|NCT03185663|Placebo Comparator|a pillow between the legs|
16513766|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
16513767|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
16513768|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
16513769|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
16513770|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.
~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
16513771|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
16513772|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
16513773|NCT03197246|Experimental|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
16513774|NCT03197246|Active Comparator|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
16513775|NCT03197220|Experimental|fish|
16513776|NCT03197220|Experimental|walnut|
16513777|NCT03197220|Experimental|fish-walnut|
16513778|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
16513779|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
16513780|NCT03197194|Experimental|A : Alteplase|Intravenous injection of Alteplase and one tablet of placebo
16513781|NCT03197194|Active Comparator|B : Acetylsalicylic Acid|one tablet of Acetylsalicylic Acid and one dose of IV placebo
16513782|NCT03197181|Experimental|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
16513783|NCT03197181|Sham Comparator|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
16513784|NCT03197168|Experimental|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
16513785|NCT03197168|Placebo Comparator|Control|Usual care
16513786|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
16513787|NCT03197129|Other|first sade|children that in the first appointment will wait in the SADE waiting room and in the traditional waiting room in the second visit
16513788|NCT03197129|Other|first traditional|children that in the first appointment will wait in the traditional waiting room and in the SADE waiting room in the second visit
16513789|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
16513790|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
16513791|NCT03197103|Experimental|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
16513792|NCT03197103|No Intervention|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
16513795|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
16513796|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
16513797|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
16513798|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
16513799|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
16513800|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
16513801|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
16513892|NCT03196401|Experimental|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
16515464|NCT03185663|Experimental|traction-stuck|
16513802|NCT03197038|Experimental|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
16513803|NCT03197038|Active Comparator|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
16513804|NCT03197025|Experimental|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
16513805|NCT03197025|Experimental|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
16513806|NCT03197012|Experimental|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
16513807|NCT03197012|Experimental|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
16513808|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
16513809|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
16513810|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
16513811|NCT03196986|Experimental|MIL60|MIL60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
16513812|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
16513813|NCT03196973|Experimental|DF289 plus DF277|Otic solution
16513814|NCT03196973|Active Comparator|DF289|Otic solution
16513815|NCT03196973|Active Comparator|DF277|Otic solution
16513816|NCT03196947|Experimental|Single arm, APO010 Dose escalation|
16513817|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
16513818|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
16513819|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
16513820|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
16513821|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
16513822|NCT03196895|Active Comparator|WR|Weight reduction training
16513823|NCT03196895|Active Comparator|GE|PPG training
16513824|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
16513825|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
16513826|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
16513827|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
16513828|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
16513829|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
16513830|NCT03196869|Experimental|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
16513831|NCT03196869|Other|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
16513832|NCT03196856|Experimental|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 12 weeks
16513833|NCT03196856|Placebo Comparator|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 12 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
16513834|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
16513835|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
16513836|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
16522097|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
16513837|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
16513838|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
16513839|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
16513840|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
16513841|NCT03196791|Experimental|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
16513842|NCT03196791|Experimental|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
16513843|NCT03196778|Experimental|Low Dose Radiation|
16513844|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
16513845|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
16513846|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
16513847|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
16513848|NCT03196713|Other|Tailored supervision|
16513849|NCT03196713|Other|Regular supervision|
16513850|NCT03196700|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
16513851|NCT03196674|Active Comparator|manipulated feedback|
16513852|NCT03196674|Active Comparator|non-manipulated feedback|
16513853|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
16513854|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
16513855|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
16513856|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
16513857|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
16513858|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
16513859|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
16513860|NCT03196635|Experimental|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal [CC] and mediolateral oblique [MLO]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
16513861|NCT03196622|Experimental|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
16513862|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:
~15 patients with non-small cell lung cancer (NSCLC)
~10 patients with hepatocellular cancer:
~10 patients with colorectal cancer
~10 patients with breast cancer
~10 patients with prostate cancer
~10 patients with glioblastoma"
16513863|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
16513864|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
16513865|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
16513924|NCT03196180|Experimental|Treatment (topical fluorouracil, imiquimod)|Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.
16523684|NCT03129399|Active Comparator|McGrath MAC video laryngoscope|
16513866|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
16513867|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
16513868|NCT03196557|Experimental|Arm A|Specified dose on specified days
16513869|NCT03196557|Placebo Comparator|Arm B|Specified dose on specified days
16513870|NCT03196544|Experimental|Social Approach Training (5 sessions)|
16513871|NCT03196544|Experimental|Social Approach Training (10 sessions)|
16513872|NCT03196544|No Intervention|Delayed Treatment (Waitlist)|
16513873|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
16513874|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
16513875|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
16513876|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
16513877|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
16513878|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
16513879|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
16513880|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
16513881|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
16513882|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
16513883|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
16513884|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
16513885|NCT03196466||antiepileptics titration and available blood samples|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
16513886|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
16513887|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
16513888|NCT03196453|Placebo Comparator|Placebo|Placebo
16513889|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous infusion, every 8 weeks for up to 5 years.
16513890|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive Vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive Vedolizumab 100 mg intravenous infusion, every 8 weeks for up to 5 years.
16513891|NCT03196414|Experimental|CART-138/BCMA/19/more|
16513893|NCT03196388|Experimental|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
16513894|NCT03196375|Experimental|Experimental|
16513895|NCT03196375|Placebo Comparator|Placebo Comparator|
16513896|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
16513897|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
16513898|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
16513899|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
16513900|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
16513901|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
16513902|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
16513903|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
16513904|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
16513905|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
16513906|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
16513907|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
16513908|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
16513911|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
16513912|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
16513913|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
16513914|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
16513915|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
16513916|NCT03196219|Other|Arm 1|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
16513917|NCT03196219|Placebo Comparator|Arm 2|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
16513918|NCT03196219|Other|Arm 3|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
16513919|NCT03196206|Experimental|Group A|Normal Renal Function
16513920|NCT03196206|Experimental|Group B|Moderate Renal Impairment
16513921|NCT03196206|Experimental|Group C|Severe Renal Impairment
16513922|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.
~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
16513923|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
16513925|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
16513926|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
16513927|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
16513928|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
16513929|NCT03196141|Active Comparator|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously & pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.
~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.
~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.
~This will determine inter-day variability. (total time is 53 min)."
16513930|NCT03196141|Active Comparator|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.
~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.
~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).
~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.
~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
16513931|NCT03196141|Active Comparator|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.
~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.
~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).
~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.
~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.
~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
16513932|NCT03196128|Active Comparator|Digital|
16513933|NCT03196128|Active Comparator|Non Digital|
16513934|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
16513935|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|BTI + Cigarette smoking military tailored pamphlet
16513936|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|Cigarette smoking military tailored pamphlet
16513937|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|Standard smoking cessation pamphlet
16513938|NCT03196089|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
16513939|NCT03196089|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
16513940|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
16513941|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
16513942|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
16513943|NCT03196063|Active Comparator|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.
~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
16513944|NCT03196063|Experimental|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.
~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
16513945|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
16513946|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
16513947|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
16514034|NCT03195309|Active Comparator|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
16513948|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
16513949|NCT03196011|Active Comparator|TKR with mechanical alignment|TKR implanted using traditional alignment methods
16513950|NCT03196011|Experimental|TKR using alternative alignment method|TKR implanted using alternative alignment methods
16513951|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
16513952|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
16513953|NCT03195985|Experimental|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
16513954|NCT03195985|Active Comparator|"Age Well psycho-education course"|4-week active control condition
16513955|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
16513956|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
16513957|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
16513958|NCT03195933|Experimental|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
16513959|NCT03195933|Experimental|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
16513960|NCT03195920|Experimental|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
16513961|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
16513962|NCT03195907||Control group|Those served as control group
16513963|NCT03195894|Experimental|Conventional treatment and TripleA|Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver
16513964|NCT03195894|No Intervention|Conventional treatment|Conventional treatment
16513965|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
16513966|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):
~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.
~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).
~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
16513967|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):
~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.
~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
16513968|NCT03195842|No Intervention|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
16513969|NCT03195842|Experimental|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
16513970|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
16513971|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
16513972|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
16513973|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
16513974|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
16513975|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
16513976|NCT03195790|Active Comparator|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
16513977|NCT03195790|Experimental|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
16513978|NCT03195777|Experimental|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
16513979|NCT03195764|Experimental|T-1101 (Tosylate)|
16513980|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
16513981|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
16514004|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
16514035|NCT03195309|Active Comparator|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
16513982|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
16513983|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
16513984|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
16513985|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
16513986|NCT03195699|Experimental|Dose escalation study|"In a 3 + 3 cohort design, three patients are initially enrolled into a given dose cohort. If there is no DLT observed in any of the first three subjects, the trial proceeds with enrolling additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in >1 of 6 subjects in a specific dose cohort will determine the MTD and no further dose escalation is done.
~Dose Level/TTI-101 (mg/kg/day) administered in divided doses every 12 hours 1/3.2 2/6.4 3/12.8 4/25.6
~At the end of the dose escalation phase of the study, the investigators will determine the characteristics of the patients who will be enrolled at the expansion phase of the study."
16513987|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.
~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
~Procedure: Carotid Artery Stenting"
16513988|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
16513989|NCT03195660|Experimental|ASV Therapy|ASV Therapy
16513990|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
16513991|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
16513992|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.
~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
16513993|NCT03195621|Experimental|Interventional therapy group|
16513994|NCT03195621|No Intervention|Conservative treatment group|
16513995|NCT03195608|Experimental|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
16513996|NCT03195608|Active Comparator|Control|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, participants will drive the scenario and receive feedback from a trained evaluator regarding their live performance. No lane change assistance system will be utilized. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world.
16513997|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
16513998|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
16513999|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.
~Parallel radiograph will be taken after the surgery"
16514000|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.
~Parallel radiograph will be taken after the surgery"
16514001|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
16514002|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
16514003|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
16514005|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
16514006|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
16514007|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
16514008|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.
~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.
~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
16514009|NCT03195517|No Intervention|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
16514010|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
16514011|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
16514012|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
16514013|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|Specified Dose of Nivolumab and Ipilimumab on specified days
16514014|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
16514015|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
16514016|NCT03195478|Experimental|Nivo/Ipi Combination Arm D|Specified dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
16514017|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
16514018|NCT03195452|Experimental|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
16514019|NCT03195439|Experimental|patients in ICU|
16514020|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.
~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.
~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
16514021|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
16514022|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
16514023|NCT03195400||CC Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 obese CC adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20.
16514024|NCT03195400||TT Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 TT subjects will be enrolled in this group. An anticipated 50 obese TT adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will be enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20
16514025|NCT03195387|Experimental|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
16514026|NCT03195387|Experimental|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
16514027|NCT03195387|Experimental|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
16514028|NCT03195387|Placebo Comparator|Placebo|MMV390048 placebo
16514029|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
16514030|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
16514031|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
16514032|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
16516222|NCT03180632|No Intervention|Group 3|Patient will receive no intervention.
16514038|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
16514039|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
16514040|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
16514041|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
16514042|NCT03195257|Experimental|Hypoglycemia-GIP|
16514043|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
16514044|NCT03195257|Experimental|Hyperglycemia-GIP|
16514045|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
16514046|NCT03195244|No Intervention|Observation|
16514047|NCT03195244|Active Comparator|One-on-one Aquatic Therapy|
16514048|NCT03195244|Experimental|Group Aquatic Therapy|
16514049|NCT03195231|Experimental|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
16514050|NCT03195231|Placebo Comparator|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
16514051|NCT03195218|Experimental|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
16514052|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
16514053|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
16514056|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
16514057|NCT03195153|Experimental|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
16514058|NCT03195153|Experimental|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
16514059|NCT03195153|Experimental|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
16514060|NCT03195140|Experimental|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
16514061|NCT03195140|No Intervention|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
16514062|NCT03195127|Experimental|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
16514063|NCT03195127|No Intervention|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
16514064|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
16514065|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
16514066|NCT03195088|Experimental|Active Treatment|Single rising doses of BI drug
16514067|NCT03195088|Placebo Comparator|Placebo|Matching volumes of drug-free solution
16514068|NCT03195075|Active Comparator|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
16514069|NCT03195075|Active Comparator|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
16514070|NCT03195062|Experimental|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
16514071|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
16514072|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
16514073|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
16514074|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
16514075|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
16514076|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
16514148|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
16514077|NCT03195010|Experimental|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
16514078|NCT03195010|Experimental|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
16514079|NCT03194997|Experimental|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
16514080|NCT03194997|Experimental|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
16514081|NCT03194997|No Intervention|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. Also, this group will be invited to three meeting during the 16 weeks of intervention, the first meeting will focus on stretching exercise to develop at home, a second meeting will be about self-esteem and the last meeting will be about prevented of lymphedema. The women in this group will not receive a dance or pilates intervention.
16514082|NCT03194984|Other|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
16514083|NCT03194984|Other|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
16514084|NCT03194971||TTField at Recurrence|
16514085|NCT03194971||TTField at New Diagnosis|
16514086|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
16514087|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
16514088|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
16514089|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
16514090|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
16514091|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
16514092|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
16514093|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
16514094|NCT03194932|Experimental|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.
~Note: Part 1 has been completed.
~Two expansion cohorts will be enrolled:
~Cohort A will be a group of 12 participants receiving the recommended phase 2 doses (RP2D) of venetoclax plus cytarabine.
~Cohort B will be a group of 12 participants receiving the RP2D of venetoclax plus cytarabine and idarubicin.
~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia.
~Cohort C: Participants will receive venetoclax PO on days 1-21, azacitidine IV on days 1-7, and cytarabine Q12H on days 8-11."
16514095|NCT03194919|Experimental|Negotiating quit date|Endre: a digital smoking cessation counsellor
16514096|NCT03194919|Active Comparator|Preset quit date|Endre: a digital smoking cessation counsellor
16514097|NCT03194906|Active Comparator|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
16514098|NCT03194906|Placebo Comparator|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
16514099|NCT03194893|Experimental|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
16514100|NCT03194893|Experimental|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
16514101|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
16514102|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.
~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
16514103|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.
~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
16514104|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
16514105|NCT03194854|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
16514106|NCT03194854|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
16514107|NCT03194841|Experimental|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
16514270|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
16514108|NCT03194828|Active Comparator|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
16514109|NCT03194828|Experimental|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
16514110|NCT03194815|Active Comparator|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
16514111|NCT03194815|Placebo Comparator|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
16514112|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
16514113|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
16514114|NCT03194789|Active Comparator|Traditional Pelvic Floor Therapy|up to six sessions, with one session every alternate week.
16514115|NCT03194789|Experimental|FGBMM plus Traditional pelvic floor therapy|Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
16514116|NCT03194776|Experimental|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
16514117|NCT03194776|Placebo Comparator|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
16514118|NCT03194750|Experimental|Share Data|
16514119|NCT03194750|Active Comparator|Do Not Share Data|
16514120|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
16514121|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
16514122|NCT03194724||High Vitamin A exposure|There was no intervention
16514123|NCT03194724||Low vitamin A exposure|No intervention
16514124|NCT03194711||Patients with stable CAD|
16514125|NCT03194698|Experimental|MGX and Intense Pulsed Light Treatment (IPL)|Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
16514126|NCT03194698|Active Comparator|Meibomian Gland Expression (MGX)|Treatment with 4 visits and 4 treatments of MGX only
16514127|NCT03194685|Experimental|Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514128|NCT03194685|Experimental|Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514129|NCT03194685|Experimental|Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514130|NCT03194685|Experimental|Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514131|NCT03194685|Experimental|Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514132|NCT03194685|Experimental|Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514133|NCT03194685|Experimental|Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514134|NCT03194685|Experimental|Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514135|NCT03194685|Experimental|Cohort 20: 50 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514136|NCT03194685|Experimental|Cohort 21: 75 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514137|NCT03194685|Experimental|Cohort 22: 100 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
16514138|NCT03194672|Experimental|Intervention Condition|"This experimental condition has three major components:
~Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.
~Transportation assistance for medical home appointments.
~Electronic Prompts/Reminders to Encourage Completion of Goals."
16514139|NCT03194672|No Intervention|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.
~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
16514140|NCT03194659|No Intervention|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
16514141|NCT03194659|Experimental|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the experimental arm of the trial, supplemental choline chloride will be added to the cocktail.
16514146|NCT03194633||Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.
16514147|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
16514149|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
16514150|NCT03194620|Experimental|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
16514151|NCT03194620|Experimental|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
16514152|NCT03194620|Active Comparator|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
16514153|NCT03194620|Experimental|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
16514154|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
16514155|NCT03194607||Patients|
16514156|NCT03194607||Controls|
16514157|NCT03194594|Active Comparator|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
16514158|NCT03194594|Active Comparator|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
16514159|NCT03194594|Experimental|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
16514160|NCT03194568|Experimental|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
16514161|NCT03194555|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
16514162|NCT03194555|Placebo Comparator|Placebo|
16514163|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
16514164|NCT03194529|Experimental|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
16514165|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
16514166|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
16514167|NCT03194490|Experimental|The combined intervention group|The combined intervention group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
16514168|NCT03194490|Active Comparator|The standard intervention|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
16514169|NCT03194477|Experimental|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
16514170|NCT03194477|No Intervention|Control - SOC Case Management|Standard of care (SOC) case management.
16514171|NCT03194464|Experimental|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
16514172|NCT03194438|Experimental|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
16514173|NCT03194425|Experimental|OAB|Patients with overactive bladder on sacral neuromodulation.
16514174|NCT03194425|Experimental|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
16514175|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
16514176|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
16514177|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
16514178|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
16514179|NCT03194412|No Intervention|Control group|Without intervention
16514180|NCT03194399|Experimental|Breast cancer patients|
16514181|NCT03194386|No Intervention|Control|usual care
16514182|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
16514183|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
16514184|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:
~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
16514185|NCT03194360||delirium group|
16514186|NCT03194360||nondelirium group|
16514187|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
16514188|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
16514189|NCT03194334|Experimental|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
16514190|NCT03194321|Experimental|Tacrolimus extended release arm|All patients will receive tacrolimus extended-release adjusted to target trough levels, mycophenolate mofetil or mycophenolate sodium, and prednisone per CSMC practice.
16524545|NCT03123094|Experimental|BI 655130 dose group 4 (Subcutaneous)|
16514191|NCT03194308|Other|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
16514192|NCT03194295|Experimental|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
16514193|NCT03194295|Active Comparator|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
16514194|NCT03194282|Experimental|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
16514195|NCT03194282|Sham Comparator|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
16514196|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
16514197|NCT03194256|Active Comparator|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
16514198|NCT03194256|Experimental|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
16514199|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
16514200|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
16514201|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
16514202|NCT03194217|Experimental|BEN-2001, 0.5mg|Experimental treatment
16514203|NCT03194217|Placebo Comparator|Placebo|Placebo comparator
16514204|NCT03194217|Experimental|BEN-2001, 1.0mg|Experimental treatment
16514205|NCT03194217|Experimental|BEN-2001, 3.0mg|Experimental treatment
16514206|NCT03194204|Active Comparator|RA patients treated with methotrexate|"Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .
~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
16514207|NCT03194204|Active Comparator|RA patients treated with methotrexate plus doxycycline|"Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.
~Cardiac assessment :
~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
16514208|NCT03194191|Experimental|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
16514209|NCT03194191|Sham Comparator|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
16514210|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
16514211|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
16514212|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
16514213|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
16514214|NCT03194139|Experimental|Sentinel Cohort|
16514215|NCT03194139|Experimental|Crossover Design|
16514216|NCT03194126|Experimental|Mifepristone + Misoprostol OR oxytocine + laminaria|
16514217|NCT03194126|Other|Mifepristone + Misoprostol OR oxytocine|
16514218|NCT03194113|Active Comparator|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
16514219|NCT03194113|Active Comparator|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
16514220|NCT03194113|Active Comparator|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
16514221|NCT03194100||Diabetes Mellitus|
16514222|NCT03194100||Prediabetes|
16514223|NCT03194100||Normal glucose tolerance|
16514224|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
16514225|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
16514226|NCT03194061|Experimental|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
16514227|NCT03194048|Experimental|Functional Chewing Training|Children with CP and have tongue thrust included this group.
16514228|NCT03194048|Active Comparator|Control|Children with CP and have tongue thrust included this group.
16514229|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
16514271|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
16514230|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
16514231|NCT03193996|Other|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
16514232|NCT03193983|Experimental|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
16514233|NCT03193983|Experimental|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
16514234|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
16514235|NCT03193957|Experimental|SB4|SB4 (etanercept) 50 mg/mL
16514236|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
16514237|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
16514238|NCT03193931|Experimental|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
16514239|NCT03193931|Active Comparator|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
16514240|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
16514241|NCT03193905|Other|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
16514242|NCT03193905|Other|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
16514243|NCT03193879||COPD group|COPD patients
16514244|NCT03193879||Asthma group|Asthma patients
16514245|NCT03193879||Health group|Healthy volunteers
16514246|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
16514247|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
16514248|NCT03193827|Experimental|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
16514249|NCT03193827|Active Comparator|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
16514250|NCT03193814|Experimental|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
16514251|NCT03193801|Experimental|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
16514252|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment
~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
16514253|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
16514254|NCT03193775|Active Comparator|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.
~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
16514255|NCT03193775|No Intervention|control group|A control group (n=100) did not receive HBV vaccine
16514256|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
16514257|NCT03193749|Experimental|Amiodarone Hydrochloride|Oral treatment for at least 6 months
16514258|NCT03193749|Placebo Comparator|Placebo|Oral treatment for at least 6 months
16514259|NCT03193736|Experimental|implant|
16514260|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
16514261|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
16514262|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
16514263|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
16514264|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
16514265|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
16514266|NCT03193684|Experimental|Treatment|dapagliflozin 10 mg per day
16514267|NCT03193684|Placebo Comparator|control|matching placebo 1 pill per day
16514268|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
16514269|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
16514272|NCT03193658|Active Comparator|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
16514273|NCT03193658|Active Comparator|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid & acetaminophen) only.
16514274|NCT03193645||Degarelix|
16514275|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
16514276|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
16514277|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
16514278|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
16514279|NCT03193593|Placebo Comparator|Placebo Injections|"Intervention: Drug: Placebo
~Single Saline Injection into the Pectoralis Muscle"
16514280|NCT03193593|Active Comparator|EB-001 Dose 1|"Intervention: Drug: EB-001
~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
16514281|NCT03193593|Active Comparator|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001
~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
16514282|NCT03193593|Active Comparator|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001
~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
16514283|NCT03193593|Active Comparator|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001
~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
16514284|NCT03193593|Active Comparator|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001
~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
16514285|NCT03193593|Active Comparator|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001
~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
16514286|NCT03193580|Experimental|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
16514287|NCT03193580|Experimental|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
16514288|NCT03193580|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
16514289|NCT03193567|Experimental|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
16514290|NCT03193502|Experimental|Portal Vein thrombosis|rivaroxaban
16514291|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
16514292|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
16514293|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
16514294|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
16514295|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
16514296|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
16514297|NCT03193437|Experimental|Selinexor|Open Label Selinexor 40 mg
16514298|NCT03193424|Experimental|Apatinib|
16514299|NCT03193424|Active Comparator|docetaxel|
16514300|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
16514302|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
16514303|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
16514304|NCT03193385||Closed reduction|
16514305|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
16514306|NCT03193359|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
16514307|NCT03193346|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
16514308|NCT03193346|Placebo Comparator|Placebo|Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.
16514309|NCT03193333|Experimental|PRO-122 group|"To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.
~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.
~Pharmaceutical form: Ophthalmic solution
~Made by: Laboratorios Sophia, S.A. de C.V.
~Posology: 1 drop every 12 hours for 90 days
~Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free
~Package description: 5 m multidose dropper bottle.
~Placebo (for
~Two pieces of approved placebo. Administered in 2 multidose dropper bottles.
~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
16514310|NCT03193333|Active Comparator|Concomitant triple therapy group|"Imot Ofteno
~Drug substance: Timolol 5 mg/mL
~Pharmaceutical form: Ophthalmic solution
~Made by Laboratorios Sophia S.A. de C.V.
~Alphagan
~Drug substance Brimonidine 2 mg/mL
~Pharmaceutical form: Ophthalmic solution
~Made by: Allergan, Inc.
~Trusopt
~Drug substance: Dorzolamide 20 mg/mL
~Pharmaceutical form: Ophthalmic solution
~Made by: Merck Sharp and Dohme Corp.
~Posology: 1 drop every 12 hours for 90 days"
16514311|NCT03193333|Active Comparator|Krytantek Ofteno Group|"To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.
~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.
~Pharmaceutical form: Ophthalmic solution
~Made by: Laboratorios Sophia, S.A. de C.V.
~Posology: 1 drop every 12 hours for 90 days
~Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.
~Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.
~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
16514312|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
16514313|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
16514314|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
16514315|NCT03193307|Experimental|All subjects|Microgynon alone (run in period) then Microgynon & BI 409306 treatment period
16514316|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
16514317|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
16514318|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).
~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.
~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
16514319|NCT03193268|Experimental|High intensity agility group|Exercise therapy
16514320|NCT03193268|Experimental|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
16514321|NCT03193268|No Intervention|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
16514322|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
16514323|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
16514324|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
16514325|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
16514472|NCT03192254|Experimental|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
16514473|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
16514326|NCT03193242|Experimental|Intervention|"Electronic Asthma Management System: eAMS Intervention
~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
16514327|NCT03193242|No Intervention|Control|"Electronic Asthma Management System: eAMS - Control
~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
16514328|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
16514329|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
16514330|NCT03193216|Experimental|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
16514331|NCT03193203|Experimental|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
16514332|NCT03193203|Experimental|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
16514333|NCT03193190|Active Comparator|Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)|"Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
~Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria."
16514334|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
16514335|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
16514336|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + AB928|Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
16514337|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
16514338|NCT03193190|Experimental|Cohort 2: Atezolizumab + Cobimetinib|"Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment."
16514339|NCT03193190|Experimental|Cohort 2: Atezolizumab + PEGPH20|"Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
16514340|NCT03193190|Experimental|Cohort 2: Atezolizumab + BL-8040|"Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
16514341|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 2 weeks|"Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
16514342|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 3 weeks|"Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
16514474|NCT03192241|Active Comparator|book|Mothers provided with a children's book
16514475|NCT03192215|Experimental|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
16526046|NCT03112616||Left-brain damaged chronic patients|
16514343|NCT03193190|Active Comparator|Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)|"Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
~Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
16514344|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab|Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
16514345|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
16514346|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
16514347|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
16514348|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
16514349|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
16514350|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
16514351|NCT03193099|Other|Premanifest HTT mutation carriers|
16514352|NCT03193099|Other|non HTT mutation carriers|
16514353|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
16514354|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.
~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.
~Iron study at time of diagnosis and 3 months after treatment .
~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.
~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
16514355|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.
~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.
~Pre-transplant full blood count serial measures every / 3 months for 2 years.
~Pre transplant serum Iron study and annually for 2 years.
~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.
~Post-transplant serum FGF-23 (as independent risk factor) at 6months.
~Different immunosuppressive protocols.
~Pre-transplant panel reactive antibody,donor-specific antibody"
16514356|NCT03193047|Experimental|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
16514357|NCT03193047|Placebo Comparator|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
16514358|NCT03193034|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
16514359|NCT03193021|Experimental|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
16514360|NCT03193021|Active Comparator|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
16514361|NCT03192995|Active Comparator|Experimental|lorcaserin, extended release
16514362|NCT03192995|Placebo Comparator|Control|Placebo
16514363|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
16514364|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.
~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
16514365|NCT03192969|Experimental|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
16514366|NCT03192969|Placebo Comparator|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
16514367|NCT03192969|Placebo Comparator|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
16514368|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
16514369|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
16514370|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
16514371|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
16514372|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
16514621|NCT03191318|Active Comparator|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
16514373|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
16514374|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
16514375|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
16514376|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
16514377|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.
~Diaphragmatic paralysis will be defined using ultrasounds."
16514378|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
16514379|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
16514380|NCT03192852|Experimental|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
16514381|NCT03192852|Experimental|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
16514382|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
16514383|NCT03192839|Experimental|Low dose PUFA|
16514384|NCT03192839|Experimental|High dose PUFA|
16514385|NCT03192839|Placebo Comparator|Placebo|
16514386|NCT03192826|Active Comparator|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
16514387|NCT03192826|Active Comparator|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
16514388|NCT03192826|Placebo Comparator|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
16514389|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
16514390|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
16514391|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
16514392|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
16514393|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
16514394|NCT03192735|Experimental|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
16514395|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
16514396|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
16514397|NCT03192722|Other|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
16514398|NCT03192722|Other|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
16514399|NCT03192709|Experimental|A|Sildenafil vaginal suppositories users
16514400|NCT03192709|Placebo Comparator|B|Daily vaginal placebo users with HMG administration
16514401|NCT03192709|Placebo Comparator|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
16514402|NCT03192696|Experimental|Treatment Cohort|Atherectomy of in-stent restenosis
16514403|NCT03192683|Active Comparator|Regular sling|
16514404|NCT03192683|Experimental|Cast-sling|
16514405|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
16514406|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.
~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.
~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
16514407|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.
~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.
~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
16514408|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.
~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.
~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
16514409|NCT03192657|Experimental|Basiliximab group|"Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.
~Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.
~Steroids: 1mg/kg/d, calculated with prednisone."
16514410|NCT03192657|Active Comparator|control group|"Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.
~Steroids: 1mg/kg/d, calculated with prednisone."
16514411|NCT03192644|Experimental|Group A (TAI)|
16514412|NCT03192644|Active Comparator|Group B (TACE)|
16514413|NCT03192631|Experimental|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
16514414|NCT03192631|No Intervention|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
16514415|NCT03192618|Experimental|treatment group|
16514416|NCT03192618|No Intervention|control group|
16514417|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
16514418|NCT03192605|Placebo Comparator|Placebo|Placebo control
16514419|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
16514420|NCT03192579|Experimental|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
16514421|NCT03192579|Active Comparator|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
16514422|NCT03192566|Experimental|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:
~children < 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children > or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
16514423|NCT03192553|Experimental|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
16514424|NCT03192553|Experimental|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
16514425|NCT03192553|Experimental|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
16514426|NCT03192553|Other|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
16514427|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
16514428|NCT03192527|Experimental|Arm A|KN015, Triptorelin
16514429|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
16514430|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
16514431|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
16514432|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
16514433|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
16514434|NCT03192488|Experimental|Cetirizine/Hypoxia|Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
16514435|NCT03192488|Placebo Comparator|Placebo/Normoxia|Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
16514436|NCT03192488|Placebo Comparator|Placebo/Hypoxia|Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
16514437|NCT03192475|Active Comparator|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
16514438|NCT03192475|Placebo Comparator|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
16514439|NCT03192462|Experimental|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
16514476|NCT03192215|Active Comparator|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
16514477|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
16514440|NCT03192462|Experimental|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
16514441|NCT03192462|Experimental|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
16514442|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
16514443|NCT03192436|Active Comparator|Real Ultrasound|The subjects will receive real ultrasound intervention.
16514444|NCT03192436|Sham Comparator|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
16514445|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
16514446|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
16514447|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
16514448|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.
~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.
~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
16514449|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
16514450|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
16514451|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
16514452|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
16514453|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
16514454|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
16514455|NCT03192345|Experimental|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
16514456|NCT03192345|Experimental|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses
16514457|NCT03192345|Experimental|Dose Escalation SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab
16514458|NCT03192345|Experimental|Dose Expansion SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab
16514459|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
16514460|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
16514461|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
16514462|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
16514463|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
16514464|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
16514465|NCT03192306|Active Comparator|Merlin|glycolic acid and ethanol mixture
16514466|NCT03192306|Placebo Comparator|Ethanol|
16514467|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:
~Metformin: 850mg (one tablet) twice a day
~Simvastatin: 20mg (one tablet) once every night
~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:
~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.
~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
16514468|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.
~Images of the treated area will be captured using multiple medical devices."
16514469|NCT03192267||No treatment|No treatment
16514470|NCT03192254|Active Comparator|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
16514471|NCT03192254|Experimental|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
16514479|NCT03192202|Experimental|Cohort 3|0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
16514480|NCT03192202|Experimental|Cohort 4|1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
16514481|NCT03192202|Experimental|Cohort 5|7.0 mg/kg of AFM13 once weekly for weeks 1-8.
16514482|NCT03192202|Experimental|Cohort 6|4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
16514483|NCT03192189||Patients with acute kidney injury|Requiring treatment with dialysis
16514484|NCT03192176|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
16514485|NCT03192176|Experimental|Fezolinetant 15 mg|Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.
16514486|NCT03192176|Experimental|Fezolinetant 30 mg|Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.
16514487|NCT03192176|Experimental|Fezolinetant 60 mg|Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.
16514488|NCT03192176|Experimental|Fezolinetant 90 mg|Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.
16514489|NCT03192176|Experimental|Fezolinetant 30 mg + Placebo|Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
16514490|NCT03192176|Experimental|Fezolinetant 60 mg + Placebo|Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
16514491|NCT03192176|Experimental|Fezolinetant 120 mg + Placebo|Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
16514492|NCT03192163||ResearchMatch Group|
16514493|NCT03192163||Northwestern Center for Ethnic Skin Group|
16514494|NCT03192150|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
16514495|NCT03192150|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
16514496|NCT03192137|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
16514497|NCT03192137|Placebo Comparator|Vehicle|DuraSite® 2 Vehicle
16514498|NCT03192111|Experimental|Mild Renal Impairment|Subjects with mild renal impairment
16514499|NCT03192111|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment
16514500|NCT03192111|Experimental|Severe Renal Impairment|Subjects with severe renal impairment
16514501|NCT03192111|Experimental|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
16514502|NCT03192098|Experimental|Progressive|Patients will be dilated > 3mm and can be dilated up to 6mm in diameter
16514503|NCT03192098|Active Comparator|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
16514504|NCT03192085|Other|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
16514505|NCT03192085|Active Comparator|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
16514506|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
16514507|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
16514508|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
16514509|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
16514510|NCT03192033|Other|Arterial closure device used is Proglide® (Abbott)|
16514511|NCT03192033|Other|Arterial closure device used is Femoseal® (Terumo)|
16514512|NCT03192020|Active Comparator|Percutaneous needle fasciotomy|
16514513|NCT03192020|Active Comparator|Collagenase clostridium histolyticum|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times.
16514514|NCT03192020|Active Comparator|Limited fasciectomy|
16514515|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
16514516|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
16514517|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
16514518|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
16514519|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
16514520|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
16514521|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
16514522|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
16514523|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
16514524|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
16514525|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
16514526|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
16514527|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
16516548|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
16514528|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
16514529|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
16514530|NCT03191916|Experimental|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
16514531|NCT03191916|Sham Comparator|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
16514532|NCT03191903|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
16514533|NCT03191903|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
16514534|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
16514535|NCT03191877|Experimental|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
16514536|NCT03191877|Active Comparator|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.
~Women in this group will not receive either coffee."
16514537|NCT03191877|No Intervention|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
16514538|NCT03191864|Experimental|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
16514539|NCT03191864|Experimental|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
16514540|NCT03191864|Experimental|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
16514541|NCT03191864|Experimental|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
16514542|NCT03191864|Placebo Comparator|Placebo BID|Placebo 30 minutes after breakfast and HS
16514543|NCT03191851|Active Comparator|Standard Device|Standard device
16514544|NCT03191851|Experimental|Melody Device|Melody device without Pump
16514545|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
16514546|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
16514547|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
16514548|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
16514549|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
16514550|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
16514551|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
16514552|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
16514553|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
16514554|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
16514555|NCT03191799|Experimental|1.5 mg/kg Emicizumab QW|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
16514556|NCT03191786|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
16514557|NCT03191786|Active Comparator|Single Agent Chemotherapy (Vinorelbine or Gemcitabine)|Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
16514558|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
16514589|NCT03191474|Experimental|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
16514700|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
16514559|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
16514560|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
16514561|NCT03191721|Experimental|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
16514562|NCT03191721|Placebo Comparator|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
16514563|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
16514564|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
16514565|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
16514566|NCT03191630|Experimental|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
16514567|NCT03191630|Experimental|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
16514568|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
16514569|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
16514570|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
16514571|NCT03191591|Experimental|First 1,000 Days Program|
16514572|NCT03191578|Experimental|RUTI® injection|
16514573|NCT03191578|Placebo Comparator|Sodium Chloride 0.9% injection|
16514574|NCT03191565|Experimental|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
16514575|NCT03191565|Active Comparator|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
16514576|NCT03191552|Experimental|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.
~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
16514577|NCT03191552|Experimental|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
16514578|NCT03191552|Active Comparator|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
16514579|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
16514580|NCT03191526|Experimental|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
16514581|NCT03191526|Placebo Comparator|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
16514582|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
16514583|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
16514584|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
16514585|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
16514586|NCT03191487|Experimental|ChimioPal|Systematic collection of clinical and laboratory toxicities.
16514587|NCT03191487|Active Comparator|Standard|The usual management and logistic pathways will be respected.
16514588|NCT03191474|No Intervention|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
16514590|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
16514591|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
16514592|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.
~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
16514593|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
16514594|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
16514595|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
16514596|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
16514597|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
16514598|NCT03191396|Experimental|Semaglutide|Half the study participants are randomised to receive semaglutide
16514599|NCT03191396|Active Comparator|Liraglutide|Half the study participants are randomised to receive liraglutide
16514600|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
16514601|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
16514602|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
16514603|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
16514604|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
16514605|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
16514606|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
16514607|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
16514608|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
16514609|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
16514610|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
16514611|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
16514612|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.
~no intervention/Observational"
16514613|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.
~no intervention/Observational"
16514614|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.
~no intervention/Observational"
16514615|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).
~no intervention/Observational"
16514616|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
16514617|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
16514618|NCT03191331|Experimental|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
16514619|NCT03191331|No Intervention|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
16514620|NCT03191318|Active Comparator|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
16516549|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
16514622|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
16514623|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
16514624|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
16514625|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
16514626|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
16514627|NCT03191266|Active Comparator|active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
16514628|NCT03191266|Sham Comparator|sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
16514629|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
16514630|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
16514631|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
16514632|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
16514633|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
16514634|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
16514635|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
16514636|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.
~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
16514637|NCT03191188|Experimental|Levothyroxine|
16514638|NCT03191188|Placebo Comparator|Placebo|
16514639|NCT03191175||HIV patients|
16514640|NCT03191175||Control patients|
16514641|NCT03191162|Active Comparator|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
16514642|NCT03191162|Experimental|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
16514643|NCT03191162|Experimental|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
16514645|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
16514646|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
16514647|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
16514648|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
16514649|NCT03191110||Colorectal cancer patients|
16514650|NCT03191097|Experimental|Ingavirin|
16514651|NCT03191097|Placebo Comparator|Placebo oral capsule|
16514652|NCT03191084|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
16514653|NCT03191084|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
16514654|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.
~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
16514655|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.
~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
16514656|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.
~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
16514657|NCT03191058|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
16514658|NCT03191058|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q.
16514659|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
16514660|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
16514661|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
16514662|NCT03191019|Experimental|Mobile-phone app for smoking cessation|"The intervention arm will receive a smoking cessation program based on a mobile-phone app. The program contains strategies to support smoking cessation, including motivational messages, tips on stress management, on how to ask support from friends and family, how to use distraction techniques and how to deal with cravings, lapses and early relapse. It also includes a saving calculator, a help button which provides extra messages in case of cravings and a lapse button, which provides advice about what to do if the participant presents lapses or relapse after being abstinent at least 24 hours."
16514663|NCT03191019|Placebo Comparator|Control mobile-phone app|The control arm will receive a mobile-phone app which will send 1 message every two weeks thanking participants for taking part in the study, and encouraging them to stay in the study for the 6 month follow-up period.
16514664|NCT03191006|Active Comparator|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
16514665|NCT03191006|No Intervention|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
16514666|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
16514667|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
16514668|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
16514669|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
16514670|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
16514674|NCT03190954|Placebo Comparator|[11C]NNC-112|[11C]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N /A
16514675|NCT03190954|Active Comparator|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
16514676|NCT03190954|Placebo Comparator|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to [11C] raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
16514677|NCT03190941|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
16514678|NCT03190941|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
16514679|NCT03190928||1|Patients with grades 1-2 or 3a follicular lymphoma (FL)
16514680|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16514681|NCT03190902|Experimental|specific computer training (ST) - POMS|
16514682|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
16514683|NCT03190902|Experimental|specific computer training (ST) - ADHD|
16514684|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
16514685|NCT03190889|No Intervention|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
16514686|NCT03190889|Other|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
16514687|NCT03190889|Experimental|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
16514688|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
16514689|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
16514690|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
16514691|NCT03190863|Experimental|Motor imagery combined with neurofeedback (MINF)|
16514692|NCT03190863|Active Comparator|Motor imagery (MI)|
16514693|NCT03190863|Sham Comparator|Control (C)|
16514694|NCT03190850|Experimental|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
16514695|NCT03190850|Placebo Comparator|Control|Control: Exercises without load
16514696|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
16514697|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
16514698|NCT03190811|Active Comparator|Anti-PD-1 alone|
16514699|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
16514701|NCT03190785|Experimental|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
16514702|NCT03190772|Experimental|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
16514703|NCT03190772|Placebo Comparator|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
16514704|NCT03190772|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
16514705|NCT03190746||No SNP|Subjects have two copies of the wild type gene
16514706|NCT03190746||SNP present|Subjects have one or two copies of the SNP
16514707|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
16514708|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
16514709|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
16514710|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
16514711|NCT03190707|Experimental|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
16514712|NCT03190707|No Intervention|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
16514713|NCT03190694|Experimental|Dapagliflozin 10mg Tablet|10 mg Green, plain, diamond shaped, film coated tablet (orally)
16514714|NCT03190694|Placebo Comparator|Placebo Matching Dapagliflozin Tablet|Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient
16514715|NCT03190681|Experimental|methylphenidate|
16514716|NCT03190681|Placebo Comparator|inactive pill|
16514717|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
16514718|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
16514719|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
16514720|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
16514721|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
16514722|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
16514723|NCT03190629|Active Comparator|High-flux hemodialysis|3 times per week
16514724|NCT03190629|Experimental|On line-hemodiafiltration|3 times per week
16514725|NCT03190616|Experimental|drug,apatinib|apatinib 500mg/qd, 28d/cycle
16514726|NCT03190603|Experimental|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
16514730|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
16514731|NCT03190551|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
16514732|NCT03190551|Active Comparator|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
16514733|NCT03190525||Multiple Myeloma patients|
16514734|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
16514735|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.
~Intervention: The Psychological questionnaires were filled."
16514736|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
16514737|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
16517887|NCT03169530|Active Comparator|Alcohol|One standard serving of alcohol (~15 gm) daily
16514738|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
16514739|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
16514740|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
16514741|NCT03190473|Experimental|Svelte|
16514742|NCT03190473|Active Comparator|Control|
16514743|NCT03190460|Experimental|Intervention|
16514744|NCT03190460|Other|Education|
16514745|NCT03190447|Active Comparator|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
16514746|NCT03190447|Experimental|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
16514747|NCT03190447|Experimental|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
16514748|NCT03190447|Experimental|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
16514749|NCT03190447|Experimental|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
16514750|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
16514751|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
16514752|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
16514753|NCT03190408||Shock|
16514754|NCT03190395|Experimental|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
16514755|NCT03190395|Active Comparator|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
16514756|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
16514757|NCT03190369|Placebo Comparator|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
16514758|NCT03190369|Experimental|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
16514759|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
16514760|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
16514761|NCT03190330|Experimental|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
16514762|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
16514763|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
16514764|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
16514765|NCT03190304|Active Comparator|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
16514766|NCT03190304|Experimental|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
16514767|NCT03190278|Experimental|Part 1: Dose Escalation|"Several tested doses of UCART123v1.2 with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)
~Dose Expansion: UCART123v1.2 administered at the selected dose determined from the dose escalation phase"
16514768|NCT03190265|Experimental|CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
16514769|NCT03190265|Experimental|Nivolumab, Ipilimumab, CRS-207|
16514770|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
16514771|NCT03190239|Experimental|Apatinib|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
16514772|NCT03190226|Experimental|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.
~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
16514773|NCT03190213|Experimental|Pembrolizumab, all patients|
16514774|NCT03190200||MRI|Subjects with healthy knees
16514775|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
16514776|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
16514777|NCT03190174|Experimental|Arm 1|"This is an open label, dose-seeking phase 1b study using a defined dose of nivolumab and escalating doses of Nab-Rapamycin (ABI-009) given intravenously.
~I. Dose Escalation Phase 1 Part of Study: The study will employ the standard cohort of three design. No intra-patient dose escalation will take place.
~II. Expansion Phase 1b Part of Study: Following dose escalation, an additional 22-28 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs."
16514778|NCT03190161|Experimental|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
16514779|NCT03190148|Other|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
16514780|NCT03190148|Other|Normal weight pregnant women|Normal weight pregnant women were investigated.
16514781|NCT03190148|Other|Obese Pregnant women|Obese pregnant women were investigated.
16514782|NCT03190135|Experimental|BOKS: 2 day per week|
16514783|NCT03190135|Experimental|BOKS: 3 day per week|
16514784|NCT03190135|No Intervention|Non-BOKS|
16514785|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
16514786|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
16514787|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
16514788|NCT03190070|Experimental|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
16514789|NCT03190057||Consecutive percutaneous coronary intervention|
16514790|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
16514791|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
16514792|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
16514793|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
16514794|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
16514795|NCT03190005||group 1|placebo control without medication.
16514796|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
16514797|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
16514798|NCT03190005||group 4|normo-reactive responser after clopidogrel.
16514799|NCT03190005||group 5|reaction after OPC-13013
16514800|NCT03190005||group 6|reaction after AR-C
16514801|NCT03190005||group 7|reaction after simastatin
16514802|NCT03189992|Experimental|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
16514803|NCT03189992|Placebo Comparator|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
16514804|NCT03189992|Experimental|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
16514805|NCT03189992|Placebo Comparator|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
16514806|NCT03189979|Experimental|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
16514807|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(0.8 ml/kg) after general anesthesia
16514808|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(0.8 ml/kg).after general anesthesia.
16514809|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
16514810|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
16514811|NCT03189940|Active Comparator|App user group|
16514812|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
16514813|NCT03189927|Experimental|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
16514814|NCT03189914|Experimental|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.
~Abraxane: 75 - 125 mg/m^2, infused once per week for 3 weeks. 1 washout week/ cycle."
16514815|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
16514816|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
16514817|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
16514818|NCT03189875||Observation|Cohort of patients with moderate-to-severe SLE
16514819|NCT03189862|Experimental|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement & physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction & practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) & 2-3 min motor skill closure activity that involves a review of the lesson & critical elements.
16514820|NCT03189862|No Intervention|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
16514821|NCT03189836|Experimental|ACTR707 in combination with rituximab|
16514822|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
16514823|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
16514824|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:
~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
16514825|NCT03189797|No Intervention|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
16514826|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
16514827|NCT03189784|No Intervention|Control group|The control group will receive no intervention
16514828|NCT03189771|Experimental|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
16514829|NCT03189771|Placebo Comparator|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
16514830|NCT03189758|Experimental|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
16514831|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
16514832|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
16514833|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
16514834|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
16514835|NCT03189719|Experimental|Pembrolizumab + SOC|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) plus standard of care (SOC) chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
16514836|NCT03189719|Placebo Comparator|Placebo + SOC|Participants receive placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
16514838|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
16514839|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
16514840|NCT03189680|Experimental|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
16514841|NCT03189680|No Intervention|Control|Parkinson's disease control group that will not receive exercise treatment.
16514842|NCT03189680|No Intervention|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
16514843|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation
~Vessel treatment with Drug-coated balloon"
16514844|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation
~Vessel treatment with additional Plain balloon angioplasty:"
16514845|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
16514846|NCT03189654||Control group|Oxygen Administration via nasal tube
16514847|NCT03189641|Experimental|Cilostazol eluting stent system (CES-1)|
16514848|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
16514849|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
16514850|NCT03189615|Experimental|Patients with mild hepatic impairment (Group1)|
16514851|NCT03189615|Experimental|Patients with moderate hepatic impairment (Group 2)|
16514852|NCT03189615|Experimental|Healthy subjects (Group 3)|
16514853|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
16514854|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
16514855|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
16514856|NCT03189563|Placebo Comparator|Placebo|placebo, tid
16514857|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
16514858|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
16514859|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
16514860|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
16517888|NCT03169530|No Intervention|Abstention|Abstention from alcohol
16514861|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
16514862|NCT03189537|Experimental|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
16514863|NCT03189537|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 7 days
16514865|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
16514866|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
16514867|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
16514868|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
16514869|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
16514870|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
16514871|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
16514872|NCT03189472|Experimental|active tDCS|
16514873|NCT03189472|Sham Comparator|sham tDCS|
16514874|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.
~Completion of Home Visit Program intervention."
16514875|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.
~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
16514876|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
16514877|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.
~Completion of Caregiver Mentorship Program intervention."
16514878|NCT03189446|Experimental|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
16514879|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
16514880|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
16514881|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
16514882|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
16514883|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
16514938|NCT03188991|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
16514884|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
16514885|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
16514886|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
16514887|NCT03189381|Experimental|Cohort A|Standard PCI dose
16514888|NCT03189381|Experimental|Cohort B|Low PCI dose
16514889|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.
~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
16514890|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
16514891|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
16514892|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
16514893|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
16514894|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
16514895|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
16514896|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
16514897|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
16514898|NCT03189290|Active Comparator|ropivacaine|"Active Comparator: ropivacaine group
~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
16514899|NCT03189290|Placebo Comparator|placebo|"Sham Comparator: saline group
~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
16514900|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
16514901|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
16514902|NCT03189238|Placebo Comparator|Placebo|
16514903|NCT03189238|Active Comparator|PRP|
16514904|NCT03189225|Other|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
16514905|NCT03189212|Active Comparator|Usual Care Visit|
16514906|NCT03189212|Experimental|Telemedicine Visit|
16514907|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
16514908|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.
~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:
~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
16514909|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
16514910|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
16514911|NCT03189160|No Intervention|Non-treatment control group|
16514912|NCT03189147|Experimental|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
16514913|NCT03189147|Active Comparator|Debridement|Patients in this group will received debridement intervention to address their labral lesion
16514914|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
16514915|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
16514916|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumors
16514917|NCT03189095|Experimental|Intervention|
16514918|NCT03189095|No Intervention|Wait-List Control|
16514919|NCT03189082|Experimental|Intervention group|
16514920|NCT03189069||Patients prescribed apixaban|
16514921|NCT03189069||Patients prescribed dabigatran|
16514922|NCT03189069||Patients prescribed rivaroxaban|
16514923|NCT03189069||Patients prescribed warfarin|
16514971|NCT03188757|Experimental|hyperglycaemic clamp|
16514924|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography
~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
16514925|NCT03189043|Experimental|Test|Use of antimicrobial surface
16514926|NCT03189043|No Intervention|Control|No antimicrobial surface
16514927|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
16514928|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.
~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
16514929|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.
~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
16514930|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
16514931|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
16514932|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
16514933|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
16514934|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
16514935|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
16514936|NCT03188991|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
16514937|NCT03188991|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
16514972|NCT03188744||Group 1|Patients with CC with PFMD.
16514939|NCT03188991|Experimental|Second Phase: NanoPac® at Best Dose|Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.
16514940|NCT03188978|Experimental|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
16514941|NCT03188978|Placebo Comparator|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
16514946|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
16514947|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
16514948|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
16514949|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
16514950|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
16514951|NCT03188900||preeclampsia|pregnancy with preeclampsia
16514952|NCT03188900||control|pregnancy without preeclampsia
16514953|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade.
16514954|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets
16514955|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
16514956|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
16514957|NCT03188835|Other|Isocaloric Diet|Two weeks of isocaloric diet
16514958|NCT03188835|Other|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
16514959|NCT03188835|Other|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
16514960|NCT03188822|Experimental|Bioabsorbable steroid releasing sinus implant|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
16514961|NCT03188822|Experimental|bioabsorbable nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
16514962|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
16514963|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
16514964|NCT03188796|Placebo Comparator|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
16514965|NCT03188796|Experimental|High Dose Vitamin D3|"oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000
~loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)
~followed by 4000 IU daily (10 drops) for the entire active study period (90 days)"
16514966|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
16514967|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
16514968|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
16514969|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
16514970|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
16514977|NCT03188718|Other|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
16514978|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
16514979|NCT03188692|Experimental|BK1310|
16514980|NCT03188679|Other|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
16514981|NCT03188666|Experimental|REGN2477|
16514982|NCT03188666|Experimental|Placebo|
16514983|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
16514984|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
16514985|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
16514986|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
16514987|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
16514988|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
16514989|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
16514990|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
16514991|NCT03188627|Experimental|Bronchial basal cells|Transplantation of autologous bronchial basal cells
16514992|NCT03188627|No Intervention|Control|Conventional treatment
16514993|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
16514994|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
16514995|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
16514996|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
16514997|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
16514998|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
16514999|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
16515000|NCT03188575|Active Comparator|Waiting List|Waiting list control
16515001|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT
~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
16515002|NCT03188562|Experimental|TEMLA|"PET/CT
~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
16515003|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
16515004|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
16515005|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
16515006|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
16515007|NCT03188523|Experimental|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
16515008|NCT03188523|Experimental|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
16515009|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
16515010|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
16515011|NCT03188510|Experimental|LY3074828 Reference|LY3074828 administered subcutaneously (SC) as 3 injections
16515012|NCT03188510|Experimental|LY3074828 Test 1|LY3074828 administered as SC injections in two prefilled syringes
16515013|NCT03188510|Experimental|LY3074828 Test 2|LY3074828 administered as SC injections in four prefilled syringes
16515014|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
16515015|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
16515016|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
16515017|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
16515018|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
16515019|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
16515020|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
16515021|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
16515022|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
16515023|NCT03188445|Experimental|IV administration|Iron isomaltoside (Monofer) Administered iv
16515024|NCT03188445|Active Comparator|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
16515324|NCT03186495|Experimental|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
16515025|NCT03188432|Experimental|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
16515026|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
16515027|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
16515028|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM >0
16515029|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
16515030|NCT03188393|Experimental|Diagnostic (biopsy of breast)|After completion of neoadjuvant therapy, patients undergo stereotactic biopsy of breast tumor any time prior to breast conserving surgery. Patients then undergo breast conserving surgery as per standard of care. Patients may also undergo postoperative radiation therapy per standard of care or adjuvant therapy at the investigator's discretion.
16515031|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
16515032|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
16515033|NCT03188367|Active Comparator|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515034|NCT03188367|Active Comparator|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515035|NCT03188367|Active Comparator|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515036|NCT03188367|Placebo Comparator|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515037|NCT03188367|Placebo Comparator|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515038|NCT03188367|Placebo Comparator|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515039|NCT03188367|Active Comparator|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515040|NCT03188367|Active Comparator|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515098|NCT03187964|No Intervention|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
16515041|NCT03188367|Active Comparator|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515042|NCT03188367|Placebo Comparator|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515043|NCT03188367|Placebo Comparator|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515044|NCT03188367|Placebo Comparator|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
16515045|NCT03188354|Experimental|CNS lymphoma patients|Patients included in the study will be examined with both 18F-FDG and 18F-Fluciclovine as well as standard MRI in the PET/MRI scanner on two consecutive days, both in primary staging and for therapy assessment
16515046|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure
~clinically disclosed cardiac complications during and after vascular surgery procedure"
16515047|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
16515048|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
16515049|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
16515050|NCT03188302|Other|Specimen collection|Collection of stool samples
16515051|NCT03188289|Placebo Comparator|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
16515052|NCT03188289|Active Comparator|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
16515053|NCT03188289|Active Comparator|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
16515054|NCT03188289|Active Comparator|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
16515055|NCT03188276|Active Comparator|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
16515056|NCT03188276|No Intervention|Healthy controls|20 Healthy controls without any treatment
16515057|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
16515058|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
16515059|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
16515060|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
16515061|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
16515062|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
16515063|NCT03188224|Experimental|Intervention|MyTransition app
16515064|NCT03188224|No Intervention|Control|Usual care
16515065|NCT03188211|Other|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
16515066|NCT03188211|Other|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
16515099|NCT03187964|Active Comparator|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
16515261|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
16526047|NCT03112616||Right-brain damaged chronic patients|
16515067|NCT03188198|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m^2 IV on Day 1.Doxorubicin 50 mg/m^2 IV on Day 1.Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.
~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
16515068|NCT03188198|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m^2/day CIVI on Days 1-4.Etoposide 50 mg/m^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.
~Interventions:
~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
16515069|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
16515070|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
16515071|NCT03188172|Experimental|Trial Treatment|"Induction:
~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11
~ASCT stem cell harvest:
~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly
~Consolidation part 1:
~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22
~Consolidation part 2:
~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1
~Maintenance:
~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
16515072|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
16515073|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
16515074|NCT03188133|Experimental|VH|schizophrenia patients with visual hallucinations
16515075|NCT03188133|Active Comparator|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
16515076|NCT03188133|Active Comparator|C|healthy controls
16515077|NCT03188120||Spiriva Respimat group|
16515078|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
16515079|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
16515080|NCT03188094||South Asians with Prediabetes|
16515081|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
16515082|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
16515083|NCT03188068|Active Comparator|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
16515084|NCT03188068|Active Comparator|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
16515085|NCT03188055|Experimental|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
16515086|NCT03188055|No Intervention|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.Usual care also consists of daily updates with patient and family, describing each new problem as it arises and what will be done to treat it, regardless of how this fits into the patient's overall prognosis or health trajectory.
16515087|NCT03188042|Experimental|rtACS Stimulation Group|
16515088|NCT03188042|Sham Comparator|Sham Intervention Group|Sham stimulation looks like rtACS, but is not active rtACS.
16515089|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
16515090|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
16515091|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
16515092|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.
~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
16515093|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.
~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
16515094|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
16515095|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
16515096|NCT03187977|Active Comparator|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
16515097|NCT03187977|No Intervention|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
16528136|NCT03098914||Beijing Tsinghua Chang gung Hospital|
16515100|NCT03187964|No Intervention|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
16515101|NCT03187964|Active Comparator|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
16515102|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.
~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
16515103|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.
~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.
~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
16515104|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
16515105|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
16515106|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
16515107|NCT03187899|Sham Comparator|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
16515108|NCT03187899|Active Comparator|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
16515109|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
16515110|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
16515111|NCT03187860|Experimental|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.
~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
16515112|NCT03187860|Experimental|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))
~Intervention: Bronchial Biopsy + ALI culture"
16515113|NCT03187860|Experimental|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD
~Intervention: Bronchial Biopsy + ALI culture"
16515114|NCT03187860|Experimental|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.
~Intervention: Bronchial Biopsy + ALI culture"
16515115|NCT03187834|Active Comparator|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.
~Children will receive treatment everyday, once a day as is:
~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
16515116|NCT03187834|Active Comparator|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.
~Children will receive treatment everyday, twice a day as is:
~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
16515117|NCT03187834|Active Comparator|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.
~Children will receive treatment everyday, once a day as is:
~Co-trimoxazole: 240 mg daily for Days 1-5"
16515118|NCT03187834|Placebo Comparator|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.
~Children will receive Placebo everyday, once a day."
16515119|NCT03187821|Active Comparator|Superior|Laser peripheral iridotomy done at superior part of iris.
16515120|NCT03187821|Active Comparator|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
16515121|NCT03187808|Experimental|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
16515122|NCT03187808|Experimental|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
16515123|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
16515158|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
16528137|NCT03098901|Other|no other arm|
16515124|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
16515125|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
16515126|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
16515127|NCT03187756|Experimental|Cyclophosphamide|
16515128|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
16515129|NCT03187730|Active Comparator|Intervention Arm|
16515130|NCT03187730|Placebo Comparator|Waitlist Control|
16515131|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
16515132|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
16515133|NCT03187704|Active Comparator|filtration|Air filtration in homes
16515134|NCT03187704|Sham Comparator|no filtration|Sham air filtration
16515135|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
16515136|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
16515137|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
16515138|NCT03187678|Experimental|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
16515139|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
16515140|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
16515141|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
16515142|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
16515143|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
16515144|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
16515145|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
16515146|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
16515147|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
16515148|NCT03187587|Experimental|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
16515149|NCT03187587|Active Comparator|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
16515150|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
16515151|NCT03187574||Group B|group received Perigee™ transvaginal mesh
16515152|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
16515153|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
16515154|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
16515155|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
16515156|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
16515157|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
16515159|NCT03187509|Experimental|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
16515160|NCT03187509|Active Comparator|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
16515161|NCT03187496|Experimental|Single Arm|
16515162|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
16515163|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
16515164|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
16515165|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
16515166|NCT03187444|Experimental|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
16515167|NCT03187431|Experimental|IPF patients|autologous bone marrow mesenchymal stem cells
16515168|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
16515169|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
16515170|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
16515171|NCT03187392|Active Comparator|lidocaine injection|
16515172|NCT03187392|Experimental|lidocaine-prilocaine cream|
16515173|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
16515174|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
16515175|NCT03187366|No Intervention|Status quo|Status quo pesticide use
16515176|NCT03187366|Active Comparator|Low risk|Villages shifted to low risk pesticides that don't kill prawns
16515177|NCT03187366|Experimental|No agrochemicals|Villages that eliminate agrochemicals
16515178|NCT03187353|Active Comparator|Lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
16515179|NCT03187353|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
16515180|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
16515181|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
16515182|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
16515183|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
16515184|NCT03187301|Placebo Comparator|Placebo|Placebo
16515185|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
16515186|NCT03187288|Experimental|CFI-400945|CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.
16515187|NCT03187275|Experimental|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
16515188|NCT03187275|Active Comparator|Light Touch Intervention|Participants in this arm will receive light touch only.
16515189|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance
~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day
~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle
~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
16515190|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
16515191|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
16515192|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
16515193|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
16515194|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
16515195|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
16515196|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
16515320|NCT03186495|Experimental|Normal renal function|Subjects with normal renal function
16515197|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:
~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
16515198|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin 1.8 mg/kg at day -8 together with standard BeEAM chemotherapy at days -7 to -1
~BeEAM Regimen:
~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
16515199|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
16515200|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
16515201|NCT03187184|Experimental|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
16515202|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
16515203|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
16515204|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
16515205|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
16515206|NCT03187145||diabetic patients|
16515207|NCT03187145||healthy control|
16515208|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
16515209|NCT03187132|Active Comparator|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
16515212|NCT03187106|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
16515213|NCT03187106|Placebo Comparator|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
16515214|NCT03187093|Active Comparator|Vortioxetine|
16515215|NCT03187093|Active Comparator|Escitalopram|
16515216|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
16515217|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
16515218|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
16515219|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
16515220|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
16515221|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
16515222|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
16515223|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
16515224|NCT03187067||Mozambique, cases|
16515225|NCT03187067||Mozambique, controls|
16515226|NCT03187067||Pakistan, cases|
16515227|NCT03187067||Pakistan, controls|
16515228|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
16515229|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
16515321|NCT03186495|Experimental|Mild renal impairment|Subjects with mild renal impairment
16515322|NCT03186495|Experimental|Moderate renal impairment|Subjects with moderate renal impairment
16515230|NCT03187041|Experimental|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.
~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
16515231|NCT03187028|Active Comparator|Diet only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
16515232|NCT03187028|Experimental|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling also receiving a fitness bracelet to facilitate counseling by the certified Cancer Exercise Trainer.
16515233|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
16515234|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
16515235|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
16515236|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
16515237|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
16515238|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
16515239|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
16515240|NCT03186963|Experimental|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
16515241|NCT03186963|Active Comparator|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
16515242|NCT03186950|Active Comparator|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
16515243|NCT03186950|Experimental|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
16515244|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.
~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.
~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
16515245|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
16515246|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
16515247|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
16515248|NCT03186898|Experimental|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
16515249|NCT03186898|Experimental|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
16515250|NCT03186885|Experimental|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
16515251|NCT03186885|Experimental|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
16515252|NCT03186885|Active Comparator|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
16515253|NCT03186872|No Intervention|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
16515254|NCT03186872|Experimental|Digital behavioral program app|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
16515255|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
16515256|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
16515257|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
16515258|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
16515259|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
16515260|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
16515262|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
16515263|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
16515264|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
16515265|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.
~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.
~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
16515266|NCT03186794|Experimental|SLE Exercise|We propose to enroll 20 sedentary, adult, women with negligible to mild SLE disease activity (SELENA-SLEDAI less than or equal to 4) in this pilot study. Subjects must also have a Fatigue Severity Scale (FSS) composite score less than or equal to 4.0. We will restrict our recruitment to women with SLE as this is a small pilot study and would like to eliminate possible gender-biased confounders of physical activity (approximately 90% of patients with SLE are women).
16515267|NCT03186781|Experimental|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
16515268|NCT03186781|Experimental|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
16515269|NCT03186781|Experimental|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
16515270|NCT03186781|Experimental|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
16515271|NCT03186781|Experimental|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
16515272|NCT03186781|Experimental|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
16515273|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
16515274|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
16515275|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
16515276|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
16515277|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
16515278|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
16515279|NCT03186729|Experimental|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
16515280|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
16515281|NCT03186716|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
16515282|NCT03186716|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
16515283|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
16515284|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
16515285|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
16515286|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
16515287|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
16515288|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
16515289|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
16515290|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
16515291|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
16515323|NCT03186495|Experimental|Severe renal impairment|Subjects with severe renal impairment
16515292|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
16515293|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
16515294|NCT03186651|Experimental|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
16515295|NCT03186651|No Intervention|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
16515296|NCT03186638|Experimental|Arm I (ibuprofen)|Patients receive ibuprofen PO BID for 6 weeks.
16515297|NCT03186638|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 weeks.
16515298|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
16515299|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
16515300|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
16515301|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
16515302|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
16515303|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
16515304|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.
~Patient with monthly feedback call
~Patients on continuous MEMS monitoring."
16515305|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
16515306|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
16515307|NCT03186573|No Intervention|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
16515308|NCT03186573|Active Comparator|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
16515309|NCT03186573|Placebo Comparator|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
16515310|NCT03186560|Active Comparator|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
16515311|NCT03186560|Active Comparator|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
16515312|NCT03186560|Active Comparator|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
16515313|NCT03186560|Active Comparator|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
16515314|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
16515315|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
16515316|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
16515317|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
16515318|NCT03186508|Active Comparator|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
16515319|NCT03186508|Active Comparator|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
16515325|NCT03186482|Active Comparator|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.
~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
16515326|NCT03186482|Active Comparator|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.
~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
16515327|NCT03186482|Active Comparator|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.
~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
16515328|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
16515329|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
16515330|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
16515331|NCT03186456|Experimental|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg
16515332|NCT03186456|Placebo Comparator|Group 2|Aspirin Tablet, 100mg/d; Placebo
16515333|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
16515334|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
16515335|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
16515336|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
16515337|NCT03186417|Experimental|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
16515338|NCT03186417|Experimental|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
16515339|NCT03186417|Experimental|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
16515340|NCT03186404|Placebo Comparator|Placebos|Placebos
16515341|NCT03186404|Experimental|Statin|Atorvastatin 40mg
16515342|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
16515343|NCT03186378|Experimental|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
16515344|NCT03186378|Experimental|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
16515345|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
16515346|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
16515347|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
16515348|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
16515349|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
16515350|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
16515351|NCT03186326|Active Comparator|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
16515352|NCT03186326|Experimental|Arm B - Immunotherapy (experimental arm)|Avelumab
16515353|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
16515354|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.
~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
16515355|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
16515356|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
16515357|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
16515358|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
16515359|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
16515360|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
16515361|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
16515362|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
16515363|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
16515364|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
16515365|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
16515366|NCT03186248|Experimental|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
16515367|NCT03186248|Active Comparator|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
16515368|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
16515369|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
16515370|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
16515371|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
16515372|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
16515373|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
16515374|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
16515377|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
16515378|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
16515379|NCT03186183|Experimental|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.
~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.
~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.
~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.
~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.
~1-2 supplemental sessions may be added as needed."
16515380|NCT03186170|Experimental|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.
~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
16515381|NCT03186170|Active Comparator|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.
~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
16515382|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
16515383|NCT03186144|Experimental|No arm : descriptive study|
16515384|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
16515385|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
16515386|NCT03186118|Experimental|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
16515387|NCT03186118|Experimental|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
16515421|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
16515388|NCT03186118|Experimental|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
16515389|NCT03186118|Experimental|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
16515390|NCT03186105|Experimental|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
16515391|NCT03186092|Active Comparator|Intervention Group|inspiratory muscle training with load
16515392|NCT03186092|Sham Comparator|Control Group|unloaded inspiratory muscle training
16515393|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
16515394|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
16515395|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
16515396|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
16515397|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
16515398|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
16515399|NCT03186040|Other|Lacosamide|
16515400|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.
~Active supplement based on Coenzyme Q10 plus NADH"
16515401|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.
~Placebo: phosphoserine plus vitamin C"
16515402|NCT03186014|Experimental|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
16515403|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
16515404|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
16515405|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
16515406|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA
16515407|NCT03185988|Experimental|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
16515408|NCT03185988|Experimental|Biliary tract cancer|HER2 positive Biliary tract cancer
16515409|NCT03185988|Experimental|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
16515410|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
16515411|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
16515412|NCT03185962||Successful extubation|extubated successfully
16515413|NCT03185962||Extubation failure|reintubated within 48 hours
16515414|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
16515415|NCT03185949|Sham Comparator|Sedation and subcutaneous lidocaine|Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
16515416|NCT03185949|Experimental|interventional: bariatric embolization|• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
16515417|NCT03185936|Experimental|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
16515418|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
16515419|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
16515420|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
16515426|NCT03185871|Experimental|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.
~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
16515427|NCT03185858|Experimental|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
16515428|NCT03185858|No Intervention|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
16515429|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
16515430|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
16515431|NCT03185832||CRT-D Cohort|Composite rate of first appropriately treated ventricular arrhythmia
16515432|NCT03185832||ICD Cohort|Composite rate of first appropriately treated ventricular arrhythmia
16515433|NCT03185832||PM / CRT-P Cohort|All cause mortality
16515434|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
16515439|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
16515440|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
16515441|NCT03185793|Placebo Comparator|Placebo|placebo for 5 weeks
16515442|NCT03185793|Experimental|2.5mg SHR4640|SHR4640 for 5 weeks
16515443|NCT03185793|Experimental|5mg SHR4640|SHR4640 for 5 weeks
16515444|NCT03185793|Experimental|10mg SHR4640|SHR4640 for 5 weeks
16515445|NCT03185793|Active Comparator|50mg benzbromarone|Benzbromarone for 5 weeks
16515446|NCT03185780|Experimental|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
16515447|NCT03185767|Other|SLE group|
16515448|NCT03185767|Other|control group|
16515449|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
16515450|NCT03185741|Experimental|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.
~Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.
~Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
16515451|NCT03185741|Experimental|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
16515452|NCT03185741|No Intervention|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
16515453|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
16515454|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
16515455|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
16515456|NCT03185715|Other|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
16515457|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
16515458|NCT03185702||Unaffected controls|Normal females and unaffected family members
16515459|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
16515460|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
16515461|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
16529135|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
16515465|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
16515466|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
16515467|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
16515468|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
16515469|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
16515470|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
16515471|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
16515472|NCT03185624|Experimental|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
16515473|NCT03185624|No Intervention|Blank control|No intervention after surgery
16515474|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
16515475|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
16515476|NCT03185598||non-MACE|no MACE occurred
16515477|NCT03185598||MACE|MACE occurred
16515478|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
16515479|NCT03185559|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
16515480|NCT03185559|Sham Comparator|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
16515481|NCT03185546|Experimental|Normal Nicotine Content (NNC) cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
16515482|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
16515483|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
16515484|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
16515485|NCT03185546|Experimental|Very Low Nicotine Content (VLNC) cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
16515486|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
16515487|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
16515488|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
16515489|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
16515490|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
16515491|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
16515492|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
16515493|NCT03185481|Experimental|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
16515494|NCT03185481|Experimental|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
16515495|NCT03185481|Experimental|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
16515496|NCT03185481|Experimental|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
16515497|NCT03185481|Experimental|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
16515498|NCT03185481|Experimental|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
16515499|NCT03185481|Experimental|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
16515500|NCT03185481|Experimental|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
16515553|NCT03185091|Other|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
16515501|NCT03185468|Experimental|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
16515502|NCT03185468|Experimental|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
16515503|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
16515504|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
16515505|NCT03185442|Experimental|PRF-fMRI|
16515506|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide
~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
16515507|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
16515508|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
16515509|NCT03185403|Active Comparator|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.
~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
16515510|NCT03185403|Active Comparator|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
16515511|NCT03185390|Other|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
16515512|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
16515513|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
16515514|NCT03185351|Active Comparator|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.
~."
16515515|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
16515516|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
16515517|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
16515518|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
16515519|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
16515554|NCT03185078|Experimental|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2.
16515555|NCT03185078|Experimental|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2.
16515811|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
16515520|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
16515521|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
16515522|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
16515523|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
16515524|NCT03185325||healthy voulnteers|venous blood samples
16515525|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
16515526|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
16515527|NCT03185312||control|"Skin biopsies will be taken from skin of controls.
~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
16515528|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
16515529|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
16515530|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
16515531|NCT03185247|Experimental|Group Intervention|10-week parent-child multi-family group
16515532|NCT03185234|Active Comparator|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
16515533|NCT03185234|Sham Comparator|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
16515534|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
16515535|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
16515536|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
16515537|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
16515538|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
16515539|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
16515540|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
16515541|NCT03185182|Experimental|experimental group|"185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.
~This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma."
16515542|NCT03185169|Other|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
16515543|NCT03185156|Experimental|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
16515544|NCT03185156|Placebo Comparator|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
16515545|NCT03185143|Experimental|Naltrexone and Acetaminophen Combination|
16515546|NCT03185143|Active Comparator|Sumatriptan 100 mg|
16515547|NCT03185143|Placebo Comparator|Placebo|
16515548|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
16515549|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
16515551|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
16515552|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
16515556|NCT03185078|Sham Comparator|Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
16515557|NCT03185065|Experimental|Arm A|amantadine, placebo, modafinil, methylphenidate
16515558|NCT03185065|Experimental|Arm B|placebo, methylphenidate, amantadine, modafinil
16515559|NCT03185065|Experimental|Arm C|modafinil, amantadine, methylphenidate, placebo
16515560|NCT03185065|Experimental|Arm D|methylphenidate, modafinil, placebo and amantadine
16515561|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
16515562|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
16515563|NCT03185026|Active Comparator|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
16515564|NCT03185026|Experimental|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
16515565|NCT03185013|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
16515566|NCT03185013|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
16515567|NCT03185000|Experimental|Immediate ATIMP (AP)|Patients randomised to AP will receive Treg immunotherapy (TR004) infusion at Week 0 and Placebo infusion at Week 8.
16515568|NCT03185000|Experimental|Delayed ATIMP (PA)|Patients randomised to PA will receive Placebo infusion at Week 0 and Treg immunotherapy (TR004) infusion at Week 8.
16515569|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
16515570|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
16515571|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.
~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
16515572|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.
~*No individual participants are recruited for this study."
16515573|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.
~*No individual participants are recruited for this study."
16515574|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.
~*No individual participants are recruited for this study."
16515575|NCT03184935|Experimental|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
16515576|NCT03184935|Placebo Comparator|Control group|Basic medication: Decitabine; placebo: saline.
16515577|NCT03184922|Active Comparator|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
16515578|NCT03184922|Experimental|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
16515579|NCT03184909|Experimental|Tulsi active|
16515580|NCT03184909|Placebo Comparator|Tulsi placebo|
16515581|NCT03184896||Hip Fracture|
16515582|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
16515583|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
16515584|NCT03184870|Experimental|Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI|FOLFIRI: FOL (folinic acid [leucovorin]) F (fluorouracil [5-fluorouracil]) IRI (irinotecan [CAMPTOSAR])
16515585|NCT03184870|Experimental|Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel|
16515586|NCT03184870|Experimental|Part 1 Arm C [2L Pancreatic & 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab|2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable
16515587|NCT03184870|Experimental|Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI|
16515588|NCT03184870|Experimental|Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI|
16515589|NCT03184870|Experimental|Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI|
16515590|NCT03184870|Experimental|Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel|
16515591|NCT03184870|Experimental|Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel|
16515592|NCT03184870|Experimental|Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel|
16515593|NCT03184870|Experimental|Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab|
16515594|NCT03184870|Experimental|Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab|
16515595|NCT03184870|Experimental|Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy|
16515596|NCT03184870|Experimental|Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy|
16515597|NCT03184857|Active Comparator|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
16515598|NCT03184857|Experimental|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
16515599|NCT03184844|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
16515600|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
16515601|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
16515602|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
16515603|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
16515604|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
16515605|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
16515606|NCT03184792|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous cervical electrical stimulation combined with physical therapy that targets rehabilitation of upper extremity functions
16515607|NCT03184792|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of upper extremity functions
16515608|NCT03184779|Experimental|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
16515609|NCT03184779|No Intervention|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
16515610|NCT03184766|Experimental|1|Treatment Order: Test, Comparator 1, Comparator 2
16515611|NCT03184766|Experimental|2|Treatment Order: Test, Comparator 2, Comparator 1
16515612|NCT03184766|Experimental|3|Treatment Order: Comparator 1, Test, Comparator 2
16515613|NCT03184766|Experimental|4|Treatment Order: Comparator 1, Comparator 2, Test
16515614|NCT03184766|Experimental|5|Treatment Order: Comparator 2, Test, Comparator 1
16515615|NCT03184766|Experimental|6|Treatment Order: Comparator 2, Comparator 1, Test
16515616|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
16515617|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
16515618|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
16515619|NCT03184714|No Intervention|Control|
16515620|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
16515621|NCT03184701|Experimental|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
16515622|NCT03184688|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
16515623|NCT03184688|Placebo Comparator|Normal saline|Normal saline for hydrodissection
16515624|NCT03184675|Experimental|Functional action observation training|
16515625|NCT03184675|Other|General action observation training group|
16515626|NCT03184662|Experimental|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.
~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
16515627|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
16515628|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
16515629|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
16515630|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
16515631|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
16515632|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
16515633|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
16515634|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
16515812|NCT03183258|Experimental|Sentinel Skin Flap|
16515635|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
16515636|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
16515637|NCT03184584|Experimental|PBI-4050|
16515638|NCT03184571|Experimental|Bemcentinib + pembrolizumab|"Cohort A enrols participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind to receive bemcentinib (BGB324) in combination with pembrolizumab.
~Cohort B enrolls participants who received a maximum of one prior line of an anti-PD-(L)1 therapy (monotherapy) to receive bemcentinib (BGB324) in combination with pembrolizumab.
~Cohort C enrolls participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.
~Bemcentinib capsules are administered at 400mg for days 1-3, and 200mg thereafter. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks."
16515639|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Bemcentinib (BGB324) in combination with pembrolizumab. Bemcentinib capsules are administered at 400mg on days 1-3, and 200mg there after. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks.
16515640|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
16515641|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
16515642|NCT03184532||D|diabetic patients
16515643|NCT03184532||ND|non-diabetic patients
16515644|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
16515645|NCT03184506|Sham Comparator|control group|
16515646|NCT03184506|Active Comparator|pre-warming group|
16515647|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
16515648|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
16515649|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
16515650|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
16515651|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
16515652|NCT03184467|Placebo Comparator|Control group|Normal saline 0.9%
16515653|NCT03184467|Experimental|Study group 1|GV1001 0.56 mg
16515654|NCT03184467|Experimental|Study group 2|GV1001 1.12 mg
16515655|NCT03184454|Experimental|Medtronic PC+S Deep Brain Stimulation|"Single open label arm.
~Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic PC+S deep brain stimulation (DBS) system."
16515656|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
16515657|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
16515658|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
16515659|NCT03184415|Active Comparator|DWC20155 Monotherapy|
16515660|NCT03184415|Active Comparator|DWC20156 Monotherapy|
16515661|NCT03184402|Experimental|DWJ1252|
16515662|NCT03184402|Active Comparator|Gasmotin|
16515663|NCT03184389|Other|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
16515664|NCT03184376|Experimental|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
16515665|NCT03184376|Placebo Comparator|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
16515666|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
16515667|NCT03184350|Other|Adjuvant pelvic proton radiation|
16515668|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
16515669|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
16515670|NCT03184324|Experimental|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
16515671|NCT03184324|Experimental|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
16515672|NCT03184324|Experimental|DWP14012 80mg|DWP14012 40mg*2, tablet, orally, once daily
16515673|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
16515674|NCT03184311|Experimental|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
16515872|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
16515675|NCT03184311|Placebo Comparator|Moderate-intensity continuous training (MCT)|A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
16515676|NCT03184298|Other|Group|Participants receive three interventions: Surveys, Interviews, and Group Workshops
16515677|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
16515678|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
16515679|NCT03184259|Experimental|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
16515680|NCT03184259|Experimental|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
16515681|NCT03184259|Placebo Comparator|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
16515682|NCT03184259|Placebo Comparator|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
16515683|NCT03184259|No Intervention|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
16515684|NCT03184246|Experimental|GlideScope|intubation with GlideScope
16515685|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
16515686|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
16515687|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.
~No rapid ventricular pacing is applied perioperatively."
16515688|NCT03184220|Experimental|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.
~Multimodal physical therapy program includes:
~Myofascial syndrome cervical therapy treatment."
16515689|NCT03184220|Experimental|CONTROL GROUP|"Multimodal physical therapy program includes:
~ultrasound therapy (US),
~transcutaneous electric nerve stimulation (TENS)
~massage."
16515690|NCT03184194|Experimental|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
16515691|NCT03184194|Experimental|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
16515692|NCT03184181|Experimental|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
16515693|NCT03184181|Active Comparator|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
16515694|NCT03184168|Experimental|treatment|[14C]lorlatinib
16515695|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
16515696|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
16515697|NCT03184142|Experimental|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
16515698|NCT03184142|Experimental|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
16515699|NCT03184142|Placebo Comparator|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
16518282|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
16515700|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
16515701|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
16515702|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
16515703|NCT03184116|No Intervention|Control|No additional intervention
16515704|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).
~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
16515705|NCT03184077|Active Comparator|Polyglactin 910|
16515706|NCT03184077|Active Comparator|poliglecaprone 25|
16515707|NCT03184064|Experimental|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
16515708|NCT03184064|Experimental|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
16515709|NCT03184064|Experimental|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
16515710|NCT03184064|Experimental|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
16515711|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
16515712|NCT03184038|Other|Assessment of neurocognitive function|Patients undergo assessment of neurocognitive function at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)
16515713|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
16515714|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
16515715|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
16515716|NCT03183999|Experimental|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
16515717|NCT03183999|Placebo Comparator|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
16515718|NCT03183986|Active Comparator|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
16515719|NCT03183986|Active Comparator|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
16515720|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
16515721|NCT03183973|Experimental|placebo group|
16515722|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
16515723|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
16515724|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
16515725|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
16515726|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
16515727|NCT03183908|Active Comparator|Adjuvanted influenza vaccine (FLUAD®)|In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.
16515728|NCT03183908|Active Comparator|High-dose influenza vaccine (Fluzone® HD)|In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.
16515729|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
16515730|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
16515731|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
16515806|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
16515732|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
16515733|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
16515734|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
16515735|NCT03183843|Active Comparator|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
16515736|NCT03183843|Active Comparator|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
16515737|NCT03183830|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
16515738|NCT03183830|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
16515739|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
16515740|NCT03183817|No Intervention|Usual Care|Evidence-based care
16515741|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
16515742|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
16515743|NCT03183791|Experimental|RELAX group|
16515744|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|
16515745|NCT03183778|Experimental|First Phase|During the first phase (week 1), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (1 serving/day), and eliminates high-potassium fruits and vegetables
16515746|NCT03183778|Active Comparator|Second Phase|During the second phase (weeks 2 and 3), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources
16515747|NCT03183765|Experimental|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
16515748|NCT03183765|Active Comparator|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
16515749|NCT03183752|Experimental|Metformin|patients randomized to Metformin group
16515750|NCT03183752|Placebo Comparator|Placebo|patients randomized to placebo group
16515751|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
16515752|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
16515753|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
16515754|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
16515755|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
16515756|NCT03183713|Active Comparator|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
16515757|NCT03183713|Active Comparator|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
16515758|NCT03183713|Active Comparator|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
16515759|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
16515760|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
16515761|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
16515762|NCT03183674|Experimental|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
16515763|NCT03183674|Placebo Comparator|placebo|saline nose spray, 0,9 %, once unique dose
16515764|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
16515765|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
16515766|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
16515767|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
16515807|NCT03183297|Experimental|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
16515770|NCT03183596|Active Comparator|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
16515771|NCT03183596|Active Comparator|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
16515772|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.
~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.
~IPF Patients will have a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
16515773|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.
~A repeat [18F]FP-R01-MG-F2 PET/CT scan will be performed within 3-8 weeks post initial scan if a signal is present in the first scan."
16515774|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
16515775|NCT03183557|Active Comparator|ZA alone|
16515776|NCT03183557|Active Comparator|ZA plus VD|
16515777|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
16515778|NCT03183518|Experimental|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
16515779|NCT03183518|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
16515780|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
16515781|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
16515782|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
16515783|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
16515784|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
16515785|NCT03183466|Experimental|Patients included in inclusion criteria|
16515786|NCT03183453|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
16515787|NCT03183453|No Intervention|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
16515788|NCT03183453|No Intervention|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
16515789|NCT03183440|Experimental|PREBIOTICS|188 pregnant women
16515790|NCT03183440|Placebo Comparator|PLACEBO|188 pregnant women
16515791|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
16515792|NCT03183427||Control group|Group of subjects without pineal cyst
16515793|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
16515794|NCT03183388|Experimental|BE-SMART|Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.
16515795|NCT03183375|Experimental|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
16515796|NCT03183375|No Intervention|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
16515797|NCT03183362|Experimental|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
16515798|NCT03183362|Active Comparator|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
16515799|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
16515800|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
16515801|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
16515802|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
16515803|NCT03183323|Experimental|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year periode. Electronic devices to trace activity.
16515804|NCT03183323|No Intervention|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
16515805|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
16515808|NCT03183297|Active Comparator|Naproxen|Naproxen 220mg or 440mg
16515809|NCT03183297|Active Comparator|Fexofenadine|fexofenadine 60mg or 120mg
16515813|NCT03183245|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
16515814|NCT03183245|Active Comparator|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
16515815|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
16515816|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
16515817|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
16515818|NCT03183219|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
16515819|NCT03183219|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16515820|NCT03183219|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
16515821|NCT03183206|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
16515822|NCT03183206|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
16515823|NCT03183206|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
16515824|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
16515825|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
16515826|NCT03183141|Experimental|SER-109|Received oral dose of SER-109
16515827|NCT03183128|Experimental|SER-109|Received oral dose of SER-109
16515828|NCT03183128|Placebo Comparator|Placebo|Received matching placebo
16515829|NCT03183115|Experimental|RFA group|Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD
16515830|NCT03183115|No Intervention|Control group|No intervention; surveillance endoscopy alone
16515831|NCT03183102|No Intervention|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
16515832|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
16515833|NCT03183089|Experimental|Active|
16515834|NCT03183089|Active Comparator|Active Comparator|
16515835|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
16515836|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
16515837|NCT03183063|Experimental|4DCT and SPECT/CT|Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
16515838|NCT03183063|Experimental|4DCT with BiPAP and SPECT/CT|Anticipated 5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP. Results in these patients will be analyzed for objective 6 only.
16515839|NCT03183063|Experimental|4DCT with CTA in suspected PE|Anticipated 124 participants with CTA ordered/performed for suspected PE will be enrolled to have 4DCT. Goal for analysis is 62 with positive CTA results for PE and 62 with negative CTA results for PE. Data will be analyzed for objectives 2 and 3.
16515840|NCT03183050|Experimental|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
16515841|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
16515842|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
16515843|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
16515844|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
16515845|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
16515846|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
16515847|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
16515848|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
16515849|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
16515850|NCT03182985|Experimental|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
16518515|NCT03165240|Experimental|Eplerenone|
16515851|NCT03182972|Experimental|Intervention arm|"Seminar presentation will be done using the followings:
~Power point presentation on the following topics as it relates to medication reconciliation:
~Communication skill (with patients and also with other members of the healthcare team)
~Documentation of pharmaceutical care activities
~Medication history taking
~Drug therapy problems
~Medication reconciliation practice
~Case studies on medication reconciliation
~Role plays on medication reconciliation"
16515852|NCT03182972|No Intervention|Control arm|Control group
16515853|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.
~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
16515854|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.
~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
16515855|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
16515856|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
16515857|NCT03182920|Experimental|200 mg Lasmiditan (Group 1 Elderly)|200 milligrams (mg) lasmiditan on Day 1 of 1 of 2 dosing periods.
16515858|NCT03182920|Placebo Comparator|Placebo (Group 1 Elderly)|Placebo on Day 1 of 1 of 2 dosing periods.
16515859|NCT03182920|Experimental|200 mg Lasmiditan (Group 2 Young)|200 mg lasmiditan on Day 1.
16515862|NCT03182894|Experimental|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
16515863|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
16515864|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
16515865|NCT03182868|Experimental|Repeatability Group|Healthy participants perform goggle testing on two consecutive days to determine if the testing results are repeatable. Testing will be between 10 am and 2 pm and testing on the two sessions will be within 30 minutes of the same time. Sessions can be on two consecutive days or separated by up to 4 days.
16515866|NCT03182868|Experimental|Time of Day Group|Healthy participants perform goggle testing at two different times of day to determine if time of day affects goggle testing performance. One quarter of the participants in this arm will undergo one test at 8 am on the first session and 10 am on the second session. A second quarter will undergo the tests at 10 am on first session and 8 am on the second session. A third quarter will undergo one test at 3 pm on the first session and 10 am on the second session. The fourth quarter will undergo the tests at 10 am on first session and 3 pm on the second session. In all these cases the sessions can be on consecutive days or separated by up to 4 days.
16515867|NCT03182868|Experimental|Learning Affect Group|Healthy participants perform goggle testing back to back on the same day to determine if performance on second test changes from first test suggesting a learning affect.
16515868|NCT03182868|Experimental|MSQ Group|Healthy participants perform goggle testing and upon completion of each goggle testing session will complete a Motion Sickness Questionnaire (MSQ) to determine if they show any signs of motion sickness.
16515869|NCT03182868|Experimental|OKN Only Group|OKN Only Group is for exploratory aims only. Healthy participants will undergo goggle testing limited to Optokinetic Nystagmus (OKN) recordings at two stimulus speeds (20 and 60 deg/s) in both the counterclockwise and clockwise directions.
16515870|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.
~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
16515871|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.
~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
16515873|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
16515874|NCT03182829||Factor Xa inhibitor|"Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.
~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
16515875|NCT03182829||Thrombin inhibitor|"Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.
~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
16515876|NCT03182816|Experimental|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
16515877|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
16515878|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
16515879|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
16515880|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
16515881|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
16515882|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
16515883|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
16515884|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
16515885|NCT03182751|Active Comparator|Tranexamic Acid Arm (TXA)|TXA will be administered intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours.
16515886|NCT03182751|Placebo Comparator|Control Arm|Patients in the control group will receive a placebo medication in the Emergency Department. Neither group will receive perioperative bolus dosing of TXA.
16515887|NCT03182738|Experimental|Intervention|VIP app that delivers HIV-related symptom strategies
16515888|NCT03182738|Sham Comparator|Control|VIP app without HIV-related symptom strategies
16515889|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
16515890|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
16515891|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
16515892|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
16515893|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
16515894|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
16515895|NCT03182686|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
16515896|NCT03182686|Other|Saline|Saline, solution, 4 mL, single intra-articular injection
16515897|NCT03182673|Experimental|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors
~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.
~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
16515898|NCT03182647||Non surgery|Patients were not treated with surgery initially
16515899|NCT03182647||Surgery|Patients had an initial surgical treatment
16515900|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
16515901|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
16515902|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
16515903|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
16515904|NCT03182634|Experimental|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
16518516|NCT03165240|Placebo Comparator|Placebo|
16515905|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
16515906|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
16515907|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
16515908|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
16515909|NCT03182595|Experimental|open---label|An open---label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period.
16515910|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.
~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.
~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
16515911|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.
~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.
~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
16515912|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
16515913|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
16515914|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
16515915|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
16515916|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
16515917|NCT03182543|Experimental|AM1|Mango pulp beverage
16515918|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
16515919|NCT03182543|Placebo Comparator|Control|Control beverage
16515920|NCT03182530|Active Comparator|ULTRA method group|
16515921|NCT03182530|Active Comparator|standard patent hemostasis group|
16515922|NCT03182530|Experimental|control group|
16515923|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
16515924|NCT03182504|Experimental|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
16515925|NCT03182491||Anaphylaxis|
16515926|NCT03182491||Febrile transfusion reactions|
16515927|NCT03182491||Mild allergic reactions|
16515928|NCT03182491||Healthy controls|
16515929|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
16515930|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
16515931|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
16515932|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
16515933|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
16515934|NCT03182439|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
16515935|NCT03182439|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
16515936|NCT03182439|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
16515937|NCT03182439|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
16516182|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
16515938|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.
~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).
~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.
~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
16515939|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.
~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).
~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
16515940|NCT03182413|Placebo Comparator|PBO|Placebo
16515941|NCT03182413|Active Comparator|MOD|Modafinil 100mg
16515942|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
16515943|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
16515944|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
16515945|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
16515946|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
16515947|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
16515948|NCT03182361|Experimental|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
16515949|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
16515950|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
16515951|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
16515952|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
16515953|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
16515954|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
16515955|NCT03182283|No Intervention|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
16515956|NCT03182283|Other|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
16515957|NCT03182270|Experimental|pancreatic cysts|
16515958|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
16515959|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
16515963|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
16515964|NCT03182205|Experimental|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
16515965|NCT03182205|Sham Comparator|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
16515966|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
16515967|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
16515968|NCT03182179|Experimental|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
16515969|NCT03182179|Experimental|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
16516073|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
16515970|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:
~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.
~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.
~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
16515971|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
16515972|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
16515973|NCT03182127|Other|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
16515974|NCT03182114|Placebo Comparator|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
16515975|NCT03182114|Experimental|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
16515976|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
16515977|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
16515978|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
16515979|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
16515980|NCT03182075|Experimental|Active Training|OCD participants will receive active emotional reactivity training (14 sessions) via computer.
16515981|NCT03182075|Sham Comparator|Passive Training|OCD participants will receive passive computerized training (14 sessions) via computer.
16515982|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
16515983|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.
~Postoperatively, standard oxygen therapy."
16515984|NCT03182049||GPA (Wegener's granulomatosis) patients|
16515985|NCT03182036|Experimental|Study group|Portable pulsed oxygen
16515986|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
16515987|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
16515988|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
16515989|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
16515990|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
16515991|NCT03181984|Experimental|Hemoporfin|
16515994|NCT03181958|Experimental|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:
~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
16515995|NCT03181958|Active Comparator|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
16515996|NCT03181958|Experimental|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
16515997|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
16515998|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
16516178|NCT03180788|Active Comparator|Traditional ESD|The patients in this Group will undergo traditional ESD.
16515999|NCT03181932|Experimental|Double-blind vancomycin inhalation powder|Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
16516000|NCT03181932|Placebo Comparator|Double-blind placebo inhalation powder|Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
16516001|NCT03181932|Experimental|Open-label vancomycin inhalation powder|In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
16516002|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
16516003|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
16516004|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
16516005|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
16516006|NCT03181893|Placebo Comparator|Placebo ARM|
16516007|NCT03181893|Experimental|PF-06823859 ARM high|
16516008|NCT03181893|Experimental|PF-06823859 ARM low|
16516009|NCT03181880|Active Comparator|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
16516010|NCT03181880|Active Comparator|Bronchodilators|The comparator arm consists of SOC.
16516011|NCT03181867|Experimental|Biochemical recurrence (BCR)|18F-DCFPyL PET/CT imaging
16516012|NCT03181867|Experimental|Localized High risk|18F-DCFPyL PET/CT imaging and possible prostatectomy
16516013|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
16516014|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
16516015|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
16516016|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
16516017|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
16516018|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
16516019|NCT03181828|No Intervention|Non- AHA|
16516020|NCT03181828|Active Comparator|AHA|All subjects (healthy adults and UCD patients) will receive a single oral dose of 60 mg/kg acetohydroxamic acid during one of the treatment periods, based on the randomization assignment determining whether treatment occurs in the first or the second treatment cycle; doses will be rounded to the nearest 250 mg to coincide with the available dosage form since the tablets cannot be scored. Patients will be instructed to fast for 4 hours prior to the study; subsequently, the 13C-Urea tracer will be administered 60 minutes after the ingestion of the acetohydroxamic acid dose.
16516021|NCT03181815|Experimental|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
16516022|NCT03181802|Experimental|botulinum toxin A|
16516023|NCT03181802|Placebo Comparator|Placebo|
16516024|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
16516025|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
16516026|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
16516027|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
16516028|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
16516029|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
16516030|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
16516031|NCT03181750|No Intervention|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
16516032|NCT03181750|Experimental|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
16516033|NCT03181737|Experimental|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms & complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.
~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
16516179|NCT03180788|Experimental|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
16516034|NCT03181737|Active Comparator|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
16516035|NCT03181737|No Intervention|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
16516036|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
16516037|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
16516038|NCT03181698||first group|patients with more than one episodes of mania
16516039|NCT03181698||second group|sex-matched and age- matched healthy controls
16516040|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
16516041|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
16516042|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
16516043|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
16516044|NCT03181659|Experimental|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
16516045|NCT03181659|Experimental|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
16516046|NCT03181659|Experimental|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
16516047|NCT03181659|Experimental|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
16516048|NCT03181646|No Intervention|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
16516049|NCT03181646|Experimental|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
16516050|NCT03181633|Experimental|ACH-0144471|All participants will receive ACH-0144471 during the treatment period.
16516051|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
16516052|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
16516053|NCT03181594|Experimental|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
16516054|NCT03181581|Experimental|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
16516055|NCT03181581|Experimental|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
16516056|NCT03181581|Active Comparator|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
16516057|NCT03181581|Active Comparator|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
16516058|NCT03181568|Other|Control|This arm group (control) will receive standard wound care of chronic wounds
16516059|NCT03181568|Other|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
16516060|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
16516061|NCT03181542|Experimental|Infrared vein illumination|Infrared illumination of veins, using the FDA approved AccuVein device, will be used to assist in vein location when inserting an intravenous access line
16516062|NCT03181542|No Intervention|Standard Technique|Standard vein location techniques will be used when inserting an intravenous access line
16516063|NCT03181529|Experimental|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
16516064|NCT03181529|Experimental|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
16516065|NCT03181516|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
16516066|NCT03181516|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
16516067|NCT03181503|Placebo Comparator|Placebo|Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
16516068|NCT03181503|Experimental|Nemolizumab 0.5 mg/kg|Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
16516069|NCT03181477|Other|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
16516070|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
16516071|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
16516072|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
16516180|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
16516074|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
16516075|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:
~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin
~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest
~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen
~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.
~In this group, will be administered 20 mL of 0.375% ropivacaine"
16516076|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:
~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin
~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest
~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen
~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.
~In this group, will be administered 20 mL of Saline"
16516077|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
16516078|NCT03181412||Patients with suspected ischemic stroke|The cohort will be constituted of patients treated for a stroke suspicion after calling emergency medical services of the Rhone and presenting a symptom-onset (the last time the patient was seen without deficit) less than 6 hours.
16516079|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
16516080|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
16516081|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
16516082|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
16516083|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
16516084|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
16516085|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
16516086|NCT03181347|Experimental|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Bypass surgery
16516087|NCT03181347|Experimental|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
16516088|NCT03181347|Active Comparator|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
16516089|NCT03181334|Active Comparator|Branch I|"Condition 1: (Standard Intervention)
~Mailed fecal immunochemical test (FIT) kit including the following:
~Invitation letter to complete free colorectal cancer (CRC) screening."
16516090|NCT03181334|Experimental|Branch II and Branch III|"Condition 2: (Time Guideline)
~Mailed fecal immunochemical test (FIT) kit including the following:
~Invitation to complete free colorectal cancer (CRC) screening within a specified time frame:
~Branch II - Brief Time (1-week)
~Branch III - Extended Time (3-weeks)"
16516091|NCT03181334|Experimental|Branch IV and Branch V|"Condition 3: (Time Guideline + Incentive)
~Mailed fecal immunochemical test (FIT) kit including the following:
~Invitation to complete free colorectal (CRC) screening within a specified time frame with a monetary incentive:
~Branch IV - High Incentive
~Branch V - Low Incentive"
16516092|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
16516093|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
16516094|NCT03181308|Experimental|TRC105 plus Nivolumab|
16516095|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
16516096|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
16516097|NCT03181282|Experimental|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
16516098|NCT03181282|No Intervention|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
16516099|NCT03181269|Experimental|Intervention education|Participants will receive the intervention education and data recording package.
16516100|NCT03181269|Placebo Comparator|Placebo education|Participants will receive the placebo educational and data recording package.
16518517|NCT03165227|Experimental|BI 685509 Dose 1|
16516101|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
16516102|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
16516103|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
16516104|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
16516105|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
16516106|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
16516107|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
16516108|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
16516109|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
16516112|NCT03181191|Active Comparator|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
16516113|NCT03181191|Active Comparator|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
16516114|NCT03181191|Active Comparator|Healthy control subjects|Oral glucose tolerance test and biopsies
16516115|NCT03181178|Active Comparator|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
16516116|NCT03181178|Active Comparator|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
16516117|NCT03181178|Active Comparator|Nutrition Education Only|Nutrition Education
16516118|NCT03181178|No Intervention|Growth Monitoring Only|Growth monitoring
16516119|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
16516120|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
16516121|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
16516122|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
16516123|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
16516124|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
16516125|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
16516126|NCT03181126|Experimental|Venetoclax + Navitoclax + Chemotherapy|Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase [or any other forms of asparaginase], vincristine, dexamethasone) and tyrosine kinase inhibitor [TKI, if applicable]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.
16516127|NCT03181113||peginterferon alfa 2b|
16516128|NCT03181113||peginterferon alfa 2a|
16516129|NCT03181100|Experimental|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
16516130|NCT03181100|Experimental|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
16516131|NCT03181100|Experimental|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
16516132|NCT03181100|Experimental|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
16516133|NCT03181087|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
16516134|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
16516135|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
16516136|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
16516181|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
16516138|NCT03181022|No Intervention|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
16516139|NCT03181022|No Intervention|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
16516140|NCT03181022|No Intervention|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
16516141|NCT03181022|Experimental|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
16516142|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
16516143|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
16516144|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
16516145|NCT03180983|No Intervention|CONTROL GROUP|No intervention
16516146|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
16516147|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
16516148|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
16516149|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
16516150|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
16516151|NCT03180957|Experimental|Anti-TNF|adalimumab
16516152|NCT03180957|Placebo Comparator|Placebo|saline
16516153|NCT03180944|Experimental|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
16516154|NCT03180944|Experimental|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
16516155|NCT03180944|Experimental|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
16516156|NCT03180944|Experimental|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
16516157|NCT03180944|Experimental|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
16516158|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
16516159|NCT03180918|Experimental|testicular tissue cryopreservation|
16516160|NCT03180905|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
16516161|NCT03180905|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points
16516162|NCT03180879|Experimental|1|Treatment Order: Test, Reference, Comparator
16516163|NCT03180879|Experimental|2|Treatment Order: Test, Comparator, Reference
16516164|NCT03180879|Experimental|3|Treatment Order: Reference, Test, Comparator
16516165|NCT03180879|Experimental|4|Treatment Order: Reference, Comparator, Test
16516166|NCT03180879|Experimental|5|Treatment Order: Comparator, Test, Reference
16516167|NCT03180879|Experimental|6|Treatment Order: Comparator, Reference, Test
16516168|NCT03180866|No Intervention|Non-treatment Control|Control arm will not have any intervention
16516169|NCT03180866|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
16516170|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
16516171|NCT03180840|Experimental|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
16516172|NCT03180827|Experimental|ovarian tissue cryopreservation|
16516173|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
16516174|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
16516175|NCT03180801|Placebo Comparator|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
16516176|NCT03180801|Experimental|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
16516177|NCT03180801|Experimental|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
16516183|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
16516184|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
16516185|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
16516186|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
16516187|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
16516188|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
16516189|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
16516190|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
16516191|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
16516192|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
16516193|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
16516194|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
16516195|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
16516196|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
16516197|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
16516198|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
16516199|NCT03180749||Patients implanted with vendor B anchor|
16516200|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
16516201|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
16516202|NCT03180723|Experimental|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
16516203|NCT03180723|Active Comparator|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
16516204|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
16516205|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
16516206|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
16516207|NCT03180710|Active Comparator|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
16516208|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
16516209|NCT03180684|Experimental|VGX-3100 + EP|Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.
16516210|NCT03180684|Experimental|VGX-3100 + EP + Imiquimod|IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
16516211|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
16516212|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
16516213|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
16516214|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
16516215|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
16516216|NCT03180658|Active Comparator|controlled|CGF+bone graft
16516217|NCT03180645|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
16516218|NCT03180645|Other|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
16516219|NCT03180645|Other|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
16516220|NCT03180632|Active Comparator|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
16516221|NCT03180632|Placebo Comparator|Group B|Patient will receive a placebo similar in color, form and size.
16516223|NCT03180619|Experimental|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
16516224|NCT03180619|Experimental|Part A (Renal Impairment): End Stage Renal Disease|Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
16516225|NCT03180619|Experimental|Part B: Hepatic Impairment|Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
16516226|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
16516227|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
16516228|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
16516229|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
16516230|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.
~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.
~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
16516231|NCT03180567|Experimental|Warfarin resistant patients|Genetic Mutations
16516232|NCT03180567|Placebo Comparator|Control|Genetic Mutations
16516233|NCT03180554|Other|tVNS version 1|Transcutaneous vagus nerve stimulation (tVNS) version 1 will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
16516234|NCT03180554|Other|tVNS version 2|Transcutaneous vagus nerve stimulation (tVNS) version 2 will be delivered non-invasively via a portable take-home stimulation device which attaches to the center of the left ear lobe. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
16516235|NCT03180554|Other|MNRB version 1|Motivational nondirective resonance breathing (MNRB) version 1 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a deep breathing session. Participants will practice MNRB version 1 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
16516236|NCT03180554|Other|MNRB version 2|Motivational nondirective resonance breathing (MNRB) version 2 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a paced breathing session. Participants will practice MNRB version 2 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
16516237|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
16516238|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:
~live in areas where no DBT intervention is currently available OR
~were offered a place on the DBT programme but decided not to partake at that time"
16516239|NCT03180528|Experimental|Treatment (remetinostat)|Patients receive topical remetinostat 1% gel applied TID directly to the lesion, for 6 weeks in the absence of disease progression or unacceptable toxicity.
16516240|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
16516241|NCT03180502|Active Comparator|Arm I (photon-based IMRT, temozolomide)|Patients undergo photon-based IMRT QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
16516242|NCT03180502|Experimental|Arm II (proton beam radiation therapy, temozolomide)|Patients undergo proton beam radiation therapy QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
16516243|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
16516244|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
16516245|NCT03180476|Experimental|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
16516246|NCT03180463|Experimental|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
16516247|NCT03180463|Placebo Comparator|Group 2|Core decompression surgery.
16516248|NCT03180450|Experimental|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
16516249|NCT03180450|Placebo Comparator|Control group|Conventional treatment
16516250|NCT03180437|Active Comparator|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
16516251|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
16516252|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
16516253|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
16516254|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
16516255|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
16516256|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.
~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
16516257|NCT03180398|Experimental|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
16516258|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
16516259|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
16516260|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
16516261|NCT03180359|Experimental|Patient already transplanted or waiting for a transplantation|
16516262|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
16516263|NCT03180346|Active Comparator|Standard of Care|
16516264|NCT03180333|Experimental|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
16516265|NCT03180333|Placebo Comparator|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
16516266|NCT03180333|Experimental|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
16516267|NCT03180333|Experimental|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
16516268|NCT03180333|Experimental|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
16516269|NCT03180320|Experimental|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
16516270|NCT03180320|Other|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
16516271|NCT03180307|Sham Comparator|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
16516272|NCT03180307|Experimental|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
16516273|NCT03180294|Experimental|Arm A (bupropion hydrochloride, placebo)|Patients receive bupropion hydrochloride PO QD on days 1-63 and placebo PO QD on days 8-71.
16516274|NCT03180294|Experimental|Arm B (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO QD on days 1-7 and 64-71, and BID on days 8-63.
16516275|NCT03180294|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD on days 1-7 and 64-71, and BID on days 8-63.
16516276|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
16516277|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
16516278|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
16516279|NCT03180268|Other|Arm I (Clinical Observation)|Patients undergo observation after gross total resection.
16516280|NCT03180268|Experimental|Arm II (Radiation Therapy)|Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions after gross total resection.
16516281|NCT03180255|Experimental|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
16516282|NCT03180255|Placebo Comparator|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
16516283|NCT03180242|Experimental|EG12014|EG12014
16516284|NCT03180242|Active Comparator|EU-sourced Herceptin|EU-sourced Herceptin
16516285|NCT03180242|Active Comparator|US-sourced Herceptin|US-sourced Herceptin
16516286|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
16516287|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
16516288|NCT03180216|Experimental|Prophylactic and treatment|"Virus Specific T cells (VSTs) for prophylactic and treatment of active viral infection(s) after HSCT.
~3 different dose levels starting with 1 x 10E7 /m2 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 2 x 10E7/m2 and a final dose 5 x 10E7 VSTs/m2"
16516289|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
16516290|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
16516359|NCT03179696|Experimental|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
16516417|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
16516291|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by
~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
16516292|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by
~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
16516293|NCT03180177|Experimental|Experimental group|"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
~2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks
~Interval debulking surgery
~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
~2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
16516294|NCT03180177|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks
~Interval debulking surgery
~3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
16516295|NCT03180164|Other|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
16516296|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
16516297|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
16516298|NCT03180138|No Intervention|Controls|
16516299|NCT03180138|Active Comparator|Reminders alone|
16516300|NCT03180138|Active Comparator|Reminders + compliance-linked incentives|
16516301|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
16516302|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
16516303|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
16516304|NCT03180112||control group|Healthy children of matching age and sex.
16516305|NCT03180099|Active Comparator|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
16516306|NCT03180099|Active Comparator|Epidural Block|Epidural Block
16516307|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
16516308|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
16516309|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
16516310|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
16516311|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
16516312|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
16516313|NCT03180034|Experimental|Arm I (Gardasil, DTaP)|Participants receive Gardasil IM at month 0 and DTaP IM at month 6.
16516314|NCT03180034|Experimental|Arm II (Cervarix, DTaP)|Participants receive Cervarix IM at month 0 and DTaP IM at month 6.
16516315|NCT03180034|Active Comparator|Arm III (Gardasil)|Participants receive Gardasil IM at month 0 and 6.
16516316|NCT03180034|Active Comparator|Arm IV (Cervarix)|Participants receive Cervarix IM at month 0 and 6.
16516317|NCT03180034|No Intervention|Arm V (epidemiologic survey)|A concurrent epidemiologic survey for HPV status among unvaccinated women. Survey participants are followed for two study visits six months apart to determine their HPV DNA status, with no further follow-up. These women will be offered HPV vaccination (Cervarix) at the two study visits.
16516318|NCT03180021||Patients with Lupus Nephritis|
16516319|NCT03180021||Patients with IgA Neuropathy|
16516320|NCT03180008|Active Comparator|Fit and Strong!|
16516321|NCT03180008|Experimental|Fit and Strong! Plus|
16516322|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
16516323|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
16516324|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.
~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
16516325|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
16516326|NCT03179956|Experimental|Ribociclib|
16516327|NCT03179943|Experimental|Atezolizumab + Guadecitabine|
16516328|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
16516329|NCT03179917|Experimental|Pembrolizumab and Involved Site Radiation Therapy|Following a PET/CT simulation to evaluate the extent of disease, pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Fourteen to 21 days after the completion of therapy, a PET/CT simulation will be repeated. Pts with complete response will proceed to 20 Gy of ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these ps will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these pts will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts with new sites of disease or progression on imaging will have a repeat biopsy, per treating physician's discretion & then be treated off study.
16516330|NCT03179904|Experimental|Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
16516331|NCT03179904|Experimental|Cohort B (TVB-2640, trastuzumab, endocrine therapy)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28 and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Patients also continue endocrine therapy of either anastrozole PO QD, exemestane PO QD, fulvestrant IM on days 1 and 14 of cycle 1 and day 1 of subsequent cycles, or letrozole PO QD. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
16516332|NCT03179891|Experimental|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
16516333|NCT03179891|Experimental|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
16516334|NCT03179878|Experimental|SYNB1020|SYNB1020
16516335|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
16516336|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
16516337|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
16516338|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
16516339|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
16516340|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
16516341|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
16516342|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
16516343|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
16516344|NCT03179774|Experimental|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
16516345|NCT03179774|No Intervention|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
16516346|NCT03179774|Experimental|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
16516347|NCT03179774|No Intervention|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
16516348|NCT03179761|Experimental|Group I (HD-TIV)|Patients receive HD-TIV intramuscularly once at baseline and once between 28-42 days.
16516349|NCT03179761|Active Comparator|Group 2(SD-QIV)|Patients receive SD-QIV intramuscularly once at baseline and once between 28-42 days.
16516350|NCT03179748||turoctocog alfa|Patients with haemophilia A
16516351|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
16516352|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
16516353|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
16516354|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
16516355|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
16516356|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
16516357|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
16516358|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
16516360|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
16516361|NCT03179683|No Intervention|No application|no treatment were aplied
16516362|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
16516365|NCT03179618|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
16516366|NCT03179618|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
16516367|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
16516368|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
16516369|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession
~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks
~Cytoreductive surgery
~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession
~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
16516370|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks
~Cytoreductive surgery
~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
16516371|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
16516372|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
16516373|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
16516374|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
16516375|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
16516376|NCT03179540|Experimental|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
16516377|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
16516378|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
16516379|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
16516380|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
16516381|NCT03179501|Experimental|NP001|NP001
16516382|NCT03179501|Placebo Comparator|Placebo|Normal saline
16516383|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
16516384|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
16516385|NCT03179475|Other|Oxycodone Naloxone Combination|Open-Label
16516386|NCT03179462|Experimental|Pork intake|Subjects will consume 2 ounces of cooked lean pork following diet normalization for 3 days.
16516387|NCT03179462|Experimental|Mixed nuts intake|Subjects will consume 1 ounce of mixed nuts following diet normalization for 3 days.
16516388|NCT03179462|Experimental|Tofu intake|Subjects will consume 2 ounces of tofu following diet normalization for 3 days.
16516389|NCT03179449|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
16516415|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
16516416|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
16516545|NCT03178409||MFCCC|Patients affected by classical MFCCC
16516403|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
16516404|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
16516405|NCT03179410|Experimental|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
16516406|NCT03179397|Experimental|Model SC9|Investigational IOL
16516407|NCT03179397|Active Comparator|Model LI61SE|FDA Approved IOL
16516408|NCT03179384|Experimental|ceftriaxone treatment|
16516409|NCT03179371||1|Mothers whose fetus has CDH
16516410|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
16516411|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
16516412|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
16516413|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
16516414|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
16518518|NCT03165227|Experimental|BI 685509 Dose 2|
16516418|NCT03179319|Experimental|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
16516419|NCT03179319|No Intervention|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
16516420|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
16516421|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
16516422|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
16516423|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
16516424|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
16516425|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
16516426|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
16516427|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
16516428|NCT03179228|Experimental|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
16516429|NCT03179202|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
16516430|NCT03179176|Experimental|HFUD utilisation|
16516431|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
16516432|NCT03179163|Experimental|Hypertensive - ACEi +SH|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
16516433|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
16516434|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
16516435|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
16516436|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
16516437|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
16516438|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
16516439|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
16516440|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
16516441|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
16516442|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
16516443|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
16516444|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
16516445|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
16516446|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
16516447|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
16516448|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
16516449|NCT03179007|Experimental|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
16518519|NCT03165227|Experimental|BI 685509 Dose 3|
16516450|NCT03178994|Experimental|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
16516451|NCT03178994|Placebo Comparator|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
16516452|NCT03178981|Active Comparator|Conventional cigarette|Commercially-available combustible cigarette
16516453|NCT03178981|Experimental|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
16516454|NCT03178981|Experimental|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
16516455|NCT03178981|Experimental|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
16516456|NCT03178981|Experimental|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
16516457|NCT03178981|Active Comparator|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
16516458|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
16516459|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
16516460|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
16516461|NCT03178942|Active Comparator|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
16516462|NCT03178942|Experimental|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
16516463|NCT03178929|Experimental|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.
~2000mg, po"
16516464|NCT03178929|No Intervention|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
16516465|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
16516466|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
16516467|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
16516468|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
16516469|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.
~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
16516470|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
16516471|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
16516472|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
16516473|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
16516474|NCT03178851|Experimental|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
16516475|NCT03178851|Experimental|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
16516476|NCT03178851|Experimental|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
16516477|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
16516478|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
16516479|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
16516480|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.)
16516481|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years. )
16516482|NCT03178786|Experimental|Parkinson's Disease|
16516483|NCT03178786|Sham Comparator|Healthy Control Subjects|
16516484|NCT03178773|Active Comparator|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
16516485|NCT03178773|Experimental|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
16516486|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
16516487|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
16516488|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
16516489|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
16516490|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
16516491|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
16516492|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
16516493|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
16516494|NCT03178695|Experimental|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
16516495|NCT03178695|No Intervention|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
16516496|NCT03178669|Experimental|Cobitolimod Dose 2x31 mg|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
16516497|NCT03178669|Experimental|Cobitolimod Dose 2x125 mg|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
16516498|NCT03178669|Experimental|Cobitolimod Dose 2x250 mg|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
16516499|NCT03178669|Experimental|Cobitolimod Dose 4x125 mg|Dose 125 mg of cobitolimod, at 4 occasions
16516500|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
16516501|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:
~sorafenib tablet, 400mg, bid."
16516502|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
16516503|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
16516504|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
16516505|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
16516506|NCT03178630||Patients with autoimmune liver disease|"Patients with autoimmune liver disease
~Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.
~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
16516507|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
16516508|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
16516509|NCT03178604|Active Comparator|Classic massage|Classic massage (CM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (20 minutes in total). This procedure was repeated for each muscle group.
16516510|NCT03178604|Active Comparator|Sham massage|Sham massage (SM). 20 minutes in total soft effleurage was performed. This procedure was repeated for each muscle group.
16516511|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
16516512|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
16516513|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
16516514|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
16516546|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
16516547|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
16516524|NCT03178539|Active Comparator|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
16516525|NCT03178539|Active Comparator|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
16516526|NCT03178526|Active Comparator|levostatin gel|levostatin gel 1.2% topical gel was put into teh periodontal pocket using an insulin syringe
16516527|NCT03178526|Placebo Comparator|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
16516528|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
16516529|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
16516530|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
16516531|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
16516532|NCT03178487|Experimental|Upadacitinib 15 mg|Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
16516533|NCT03178487|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
16516534|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
16516535|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
16516536|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
16516537|NCT03178461|No Intervention|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.
~The composition of the fluids given will be normal saline with 5% dextrose."
16516538|NCT03178461|Experimental|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.
~The composition of the fluids given will be normal saline with 5% dextrose."
16516539|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
16516540|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
16516541|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
16516542|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
16516543|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
16516544|NCT03178409||HCC|Patients affected by classical HCC
16516550|NCT03178383|Experimental|Integrated Approach|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
16516551|NCT03178383|Active Comparator|Standard Comparison|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
16516552|NCT03178370||Diabetic Gastroparesis|
16516553|NCT03178370||Idiopathic Gastroparesis|
16516554|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
16516555|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
16516556|NCT03178344|Experimental|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.
~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
16516557|NCT03178344|Experimental|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.
~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
16516558|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
16516559|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
16516560|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
16516561|NCT03178305|Experimental|Intervention|"Besides the behavior change programme (Do Something Different)
~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)
~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).
~Patients with hypertension will also be offered a bloodpressure monitor.
~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).
~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
16516562|NCT03178305|No Intervention|Care as usual|Patients in this arm will receive care as usual with no restrictions.
16516563|NCT03178292|Active Comparator|Levofloxacin|Levofloxacin 500 mg daily for 5 days
16516564|NCT03178292|Placebo Comparator|Placebo|Placebo tab daily for 5 days
16516565|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
16516566|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
16516567|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
16516568|NCT03178253||3|
16516569|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
16516570|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
16516571|NCT03178227|Experimental|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
16516572|NCT03178227|No Intervention|Control|No intervention.
16516573|NCT03178214|Experimental|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
16516574|NCT03178214|Experimental|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
16516575|NCT03178214|Active Comparator|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
16516576|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
16516577|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
16516578|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
16516579|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
16516580|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
16516607|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.
~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
16516608|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia
~Interventions: Psychoeducative advice to improve sleep"
16518520|NCT03165227|Placebo Comparator|Placebo|
16516581|NCT03178149|Experimental|ASP7317 Dose Escalation (Group 1)|Group 1 will consist of participants with Severe Vision Impairment. Successive cohorts of participants (3 participants/ cohort) will be treated in each escalating dose cohort (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Sentinel dosing will be required for each dose level. After the first participant in Group 1 dose cohort is dosed and followed for 3 weeks, the independent Data Safety Monitoring Board (DSMB) will review the 3-week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated. The DSMB recommendation to progress to the next dosing cohort will be based on 3-week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus twice daily starting at baseline through week 4.
16516582|NCT03178149|Experimental|ASP7317 Dose Escalation (Group 2)|Group 2 will consist of participants with Moderate Vision Impairment. Successive cohorts of participants (3 participants/ cohort) will be treated in each escalating dose cohort (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose). Dosing in cohort 4 (low cells/dose) may commence following the DSMB recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose). Dosing in Group 2 cohort 5 (medium cells/dose) may commence following DSMB review of the 3-week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Similarly, dosing in Group 2 cohort 6 (high cells/dose) may commence following DSMB review of 3-week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Participants will receive tacrolimus twice daily starting at baseline through week 4.
16516583|NCT03178136||case group|There is no intervention in case group.
16516584|NCT03178136||control group|The control group as the contrast for case group.
16516585|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
16516586|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
16516587|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
16516588|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).
~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
16516589|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
16516590|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
16516591|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.
~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
16516592|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
16516593|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
16516594|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
16516595|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
16516596|NCT03178019||Prediabetes group|Subjects with prediabetes
16516597|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
16516598|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
16516599|NCT03178006||obese|BMI 30-40kg/m2
16516600|NCT03178006||control|BMI 20-27,5kg/m2
16516601|NCT03177993|Experimental|IDA 1|"ivermectin, diethylcarbamazine and albendazole Day 0,
~permethrin Day 0 if excluded from ivermectin
~Details of dosing:
~ivermectin: 200 mcg/kg oral
~diethylcarbazine: 6mg/kg oral
~albendazole 400mg oral
~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
16516602|NCT03177993|Experimental|IDA 2|"ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8
~permethrin Day 0 and Day 8 if excluded from ivermectin
~Details of dosing:
~ivermectin: 200 mcg/kg oral
~diethylcarbazine: 6mg/kg oral
~albendazole 400mg oral
~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
16516603|NCT03177993|Active Comparator|DA|"diethylcarbamazine and albendazole Day 0
~permethrin Day 8 if scabies present in participant or household member
~Details of dosing:
~diethylcarbazine: 6mg/kg oral
~albendazole 400mg oral
~permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
16516604|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
16516605|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
16516606|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)
~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
16518521|NCT03165214|Active Comparator|coil group|micro coils
16516609|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
16516610|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.
~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
16516611|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.
~Assigned Interventions
~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
16516612|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
16516613|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
16516614|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
16516615|NCT03177915|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
16516616|NCT03177915|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
16516617|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
16516618|NCT03177902||Control group|Healthy Volunteers
16516619|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
16516620|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);
~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
16516621|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
16516622|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
16516623|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
16516624|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16516625|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16516626|NCT03177837|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16516627|NCT03177837|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16516628|NCT03177824|Experimental|S|Sildenafil citrate (25mg)
16516629|NCT03177824|Placebo Comparator|P|placebo oral tablet
16516630|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16516631|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16516632|NCT03177798|Experimental|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)
~1 week washout
~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
16516633|NCT03177798|Experimental|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)
~1 week washout
~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
16516634|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
16516635|NCT03177785|No Intervention|Control|Wait-list control
16516636|NCT03177772||LTC Facility 1|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
16517242|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 480mg."
16516637|NCT03177772||LTC Facility 2|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
16516638|NCT03177772||LTC Facility 3|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
16516639|NCT03177746|Experimental|Dapoxetine/Tadalafil 30/20 mg film coated tablet|
16516640|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
16516641|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
16516642|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
16516643|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
16516644|NCT03177681|Experimental|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.
~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.
~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.
~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
16516645|NCT03177681|Experimental|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.
~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.
~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.
~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
16516646|NCT03177668|Experimental|YS110|"Phase 1 part: Administration of 3 different dose cohort
~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
16516647|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
16516648|NCT03177655|Active Comparator|Journaling|Keeping a journal
16516649|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
16516650|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
16516651|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
16516652|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
16516653|NCT03177616|No Intervention|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
16516654|NCT03177616|Experimental|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
16516655|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
16516656|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
16516657|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
16516658|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
16516659|NCT03177590|Experimental|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
16516660|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
16516661|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
16516662|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
16516663|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
16516664|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
16516665|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
16516666|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
16516667|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
16516668|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
16516669|NCT03177525|Experimental|Social SUCCESS|
16516670|NCT03177525|Other|Wait List|
16516671|NCT03177512|Experimental|LYNX Mobile App|
16516672|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
16516673|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.
~Intervention: Procedure: Invasive PPG"
16516674|NCT03177473||CervicalStim PEMF group|all subjects will receive active CervicalStim bone growth stimulator
16516675|NCT03177460|Experimental|Arm A (daratumumab)|Patients receive daratumumab IV over 4-8 hours once weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy during week 6.
16516676|NCT03177460|Experimental|Arm B (FMS inhibitor JNJ-40346527)|Patients receive FMS inhibitor JNJ-40346527 PO BID for 4-5 weeks in the absence of disease progression or unacceptable toxicity. After a 3 day wash-out period, patients undergo radical prostatectomy.
16516677|NCT03177447|Other|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
16516678|NCT03177434|Active Comparator|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses
~Dosage:
~weight up to 8 kg - 1 sachet per day
~weight 8 - 12 kg - 2 sachets a day
~weight 12 - 20 kg - 3 sachets a day
~weight> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
16516679|NCT03177434|Active Comparator|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
16516680|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
16516681|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
16516682|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
16516683|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC
~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC
~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC
~PP100-01 treatment is administered intravenously over 5 minutes."
16516684|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
16516685|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
16516686|NCT03177356|Experimental|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
16516687|NCT03177356|Active Comparator|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
16516688|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
16516689|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
16516690|NCT03177291|Active Comparator|Squamous Cell Lung Cancer (SQCLC)|Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
16516691|NCT03177291|Active Comparator|Non-Squamous Cell Lung Cancer (SQCLC)|Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
16516692|NCT03177278|Experimental|Arm 1|
16516693|NCT03177265|Experimental|Text to Engage|This group will get 8 text messages that target common misperceptions around quitting and use of quit services prior to receiving the first counseling phone call.
16516694|NCT03177265|Other|Mail Notice|This group will only get a mailing indicating that they will receive a call from a quitline counseling in two weeks.
16516695|NCT03177265|Experimental|Text to Enhance|Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks.
16516696|NCT03177265|Active Comparator|Telephone Counseling|Telephone counseling condition will receive standard 8 weeks of telephone counseling only.
16516697|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine
~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
16517370|NCT03172780|Experimental|Diclofenac Sodium Gel|Diclofenac Sodium Gel, 1%
16516698|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline
~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
16516699|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.
~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
16516700|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
16516701|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
16516702|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
16516703|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
16516704|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
16516705|NCT03177187|Experimental|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
~RECRUITING"
16516706|NCT03177174|Active Comparator|Docetaxel|
16516707|NCT03177174|Active Comparator|Cisplatin|
16516708|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
16516709|NCT03177161|Experimental|Postal Questionnaire|
16516710|NCT03177161|Experimental|Online Questionnaire|
16516711|NCT03177161|Experimental|Face-to-face Questionnaire|
16516712|NCT03177161|Experimental|Telephone Questionnaire|
16516713|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar
~NO active enrollment of parents
~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses
~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
16516714|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention
~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.
~Enroll 35 eligible parents per practice
~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.
~Dietitians will provide up to 6 telephone counseling sessions.
~•Parents will complete surveys after enrollment and at the end of intervention"
16516715|NCT03177135|Experimental|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
16516716|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
16516717|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
16516718|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
16516719|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
16516720|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
16516721|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
16516722|NCT03177083|Active Comparator|peginterferon beta-1a|
16516723|NCT03177083|Active Comparator|Current Therapy|
16516724|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
16516725|NCT03177057|Experimental|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
16516726|NCT03177057|Experimental|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
16516727|NCT03177057|Experimental|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
16516728|NCT03177057|Sham Comparator|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
16516729|NCT03177044|Experimental|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
16516730|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
16516731|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
16516732|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
16516733|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
16516734|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
16516735|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
16516736|NCT03176979|Experimental|Diagnostic (CESM with DBT)|Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
16516737|NCT03176966|Active Comparator|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
16516738|NCT03176966|Active Comparator|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
16516739|NCT03176953|Experimental|prolonged exposure + topiramate|psychotherapy plus active medication
16516740|NCT03176953|Active Comparator|prolonged exposure + placebo|psychotherapy plus placebo medication
16516741|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
16516742|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
16516743|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
16516744|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
16516745|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
16516746|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
16516747|NCT03176927|Experimental|Gastroparesis|"magnetogastrogram
~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
16516748|NCT03176927|Experimental|Gastrectomy|"magnetogastrogram
~Total or partial gastrectomy group"
16516749|NCT03176927|Experimental|Functional dyspepsia|"magnetogastrogram
~Children with functional dyspepsia"
16516750|NCT03176927|Experimental|Chronic nausea|"magnetogastrogram
~Children with chronic nausea"
16516751|NCT03176927|Experimental|Control participants|"magnetogastrogram
~Group without any gastrointestinal diseases."
16516752|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
16516753|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
16516754|NCT03176901|Experimental|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
16516755|NCT03176901|Active Comparator|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
16516756|NCT03176888|Experimental|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
16516757|NCT03176888|No Intervention|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
16516758|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
16516759|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
16516760|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
16516761|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
16516762|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
16516763|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
16516764|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
16516765|NCT03176836|Experimental|MRI Imaging|"Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called diffusion weighted or DW MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results."
16516766|NCT03176823|Sham Comparator|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
16516767|NCT03176823|Experimental|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
16516768|NCT03176810|Active Comparator|OCT-guided PCI|PCI is performed by OCT guidance.
16516769|NCT03176810|Active Comparator|Angiography-guided PCI|PCI is performed by angiography guidance alone.
16516770|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
16516771|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID
~Standard Condition Nicotine Patches:
~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
16516772|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID
~Standard Condition Placebo Patches:
~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
16516773|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22
~Extended Condition Nicotine Patches:
~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
16516774|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22
~Extended Condition Placebo Patches:
~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
16516775|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
16516776|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
16516777|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
16516778|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
16516779|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
16516780|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline
~+ Total Knee Replacement ( which will not be the intervention of interest)"
16516781|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline
~+ Total Knee Replacement ( which will not be the intervention of interest)"
16516782|NCT03176745||healthy controls|"no history of pulmonary disease
~absence of symptoms, smoking history < 10 pack years
~normal lung function testing"
16516783|NCT03176745||chronic obstructive pulmonary disease|"clinical history and/or specialist diagnosis of COPD and risk factor(s)
~persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation
~dyspnea, cough and/or sputum production"
16516784|NCT03176745||bronchial asthma|"clinical history and/or specialist diagnosis of bronchial asthma
~respiratory symptoms compatible with asthma varying over time
~variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness
~exclusion of alternative explanation"
16516785|NCT03176745||sarcoidosis|"clinical history and/or specialist diagnosis of sarcoidosis
~lymphocytic alveolitis and CD4/CD8 > 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma
~exclusion of alternative explanation"
16516786|NCT03176732||Group 1: Normotensive|Categorized by 24-hr systolic BP (SBP): normotensive (< 125 mm Hg) on no BP medications
16516787|NCT03176732||Group 2: Controlled Hypertensive|Categorized by 24-hr systolic BP (SBP): controlled hypertensive (< 130 mm Hg) on BP medication(s) and/or lifestyle modification
16516788|NCT03176732||Group 3: Uncontrolled Hypertensive|Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications
16516789|NCT03176732||Group 4: Hypertensive|Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)
16516790|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
16516791|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
16516792|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
16516793|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
16516794|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
16516795|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
16516796|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
16516797|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
16516798|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
16516799|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
16516800|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
16516801|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
16516802|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
16516803|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
16516804|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
16516805|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
16516806|NCT03176667|Experimental|ESP for VATS|Erector Spinae plane (ESP) block
16516807|NCT03176667|Active Comparator|ICB for VATS|Intercostal block (ICB)
16516808|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
16516809|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
16516810|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
16516811|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
16516812|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
16516813|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
16516814|NCT03176615|Experimental|Group A (Cross-over Group 1)|Subjects randomly assigned to two experimental diets. This arm will receive high-fat meals first, followed by a washout period of two-seven days and then low-fat meals.
16516815|NCT03176615|Experimental|Group B (Cross-over Group 2)|Subjects randomly assigned to two experimental diets. This arm will receive low-fat meals first, followed by a washout period of two-seven days and then high-fat meals.
16516816|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
16516817|NCT03176589|Sham Comparator|sham PEP|3 cycles of 10 deep inspiration and expiration in a sham tube without expiratory resistance
16516818|NCT03176589|Active Comparator|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP) device or PEP bottle of 10-15 cm of water pressure
16516819|NCT03176589|Experimental|deep breathing maneuvers|3 cycled of 10 deep breathing maneuvers without PEP or sham PEP
16516820|NCT03176576|Experimental|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
16516821|NCT03176576|Other|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
16516822|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
16516823|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
16516824|NCT03176537|Placebo Comparator|Placebo|Gel, daily
16516825|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
16516826|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
16516827|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
16516828|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
16516829|NCT03176511|Experimental|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
16517371|NCT03172780|Active Comparator|Voltaren® Gel|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
16516830|NCT03176511|Active Comparator|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
16516831|NCT03176498|Experimental|Experimental group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
16516832|NCT03176498|Placebo Comparator|Control group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo：saline
16516833|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
16516834|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
16516835|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
16516836|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
16516837|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
16516838|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
16516839|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
16516840|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
16516841|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
16516842|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
16516843|NCT03176420|Experimental|Symptomayic chronically occluded cervical ICA|
16516844|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.
~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
16516845|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
16516846|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
16516847|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
16516848|NCT03176355|Other|Chronic dacryocystitis patients|
16516849|NCT03176342|Experimental|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
16516850|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
16516851|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
16516852|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
16516853|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
16516854|NCT03176277|Experimental|ONO-7475 (Part A)|Successive dose escalation cohorts to determine MTD/OBD
16516855|NCT03176277|Experimental|ONO-7475 + venetoclax (Part D)|Successive dose escalation of ONO-7475 cohorts + venetoclax
16516856|NCT03176264|Experimental|PDR001|
16516857|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
16516858|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
16516859|NCT03176238|Experimental|everolimus + exemestane|Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily
16516860|NCT03176225|Experimental|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
16516920|NCT03175809|Active Comparator|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
16516861|NCT03176225|Active Comparator|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
16516862|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
16516863|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
16516864|NCT03176199|Experimental|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
16516865|NCT03176199|Active Comparator|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
16516866|NCT03176186|No Intervention|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
16516867|NCT03176186|Active Comparator|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
16516868|NCT03176173|Experimental|Arm I (image guided radiation therapy)|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.
16516869|NCT03176173|Active Comparator|Arm II (standard of care immunotherapy)|Patients who decline to undergo radiation therapy receive standard of care immunotherapy.
16516870|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
16516871|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
16516872|NCT03176134|Experimental|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
16516873|NCT03176134|Active Comparator|Cohort 1 Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
16516874|NCT03176134|Experimental|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
16516875|NCT03176134|Active Comparator|Cohort 2 Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
16516876|NCT03176134|Experimental|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
16516877|NCT03176134|Active Comparator|Cohort 3: Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
16516878|NCT03176134|Experimental|Cohort 4: Tedizolid phosphate Birth to <28 Days Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
16516879|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days
16516880|NCT03176121|Experimental|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.
~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
16516881|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.
~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
16516882|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.
~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
16516883|NCT03176095|Active Comparator|Probiotic Group|"The participants in the Probiotic group were provided with dietary supplements in the form as sachets with freeze dried bacteria (active lactobacilli culture) mixed with maltodextrin for daily intake (1 per day). The powder was dissolved in water or other non-alcoholic cold drink mixed with fruit before ingestion.
~The probiotic product consisted of two different bacterial strains."
16516884|NCT03176095|Placebo Comparator|Placebo Group|The participants in the Placebo group were provided with dietary supplements in the form as sachets with maltodextrin for daily intake (1 per day).
16516885|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:
~A reminder letter indicating need for screening
~A FIT kit with completion instructions
~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)
~A pre-paid return mailer for FIT Kit"
16516886|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:
~A reminder letter indicating need for screening
~Instructions for obtaining a FIT kit
~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
16516917|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))
~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))
~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
16516918|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
16516919|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
16516887|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:
~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
16516888|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
16516889|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
16516890|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
16516891|NCT03176043|Experimental|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
16516892|NCT03176043|Active Comparator|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate >90 /min, systolic BP <100 mmHg, respiratory rate >20, peripheral capillary refill >2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
16516893|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
16516894|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
16516895|NCT03176017|Active Comparator|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
16516896|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
16516897|NCT03176004|Experimental|Attention Bias Modification|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a threatening word.
16516898|NCT03176004|Active Comparator|Active Control Condition|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a word with a specific color.
16516899|NCT03176004|No Intervention|Wait List|Participants simply return after 8 weeks.
16516900|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
16516901|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
16516902|NCT03175952||PCI|
16516903|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
16516904|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
16516905|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
16516906|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
16516907|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
16516908|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
16516909|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
16516910|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
16516911|NCT03175887|Experimental|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
16516912|NCT03175887|Other|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.
~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
16516913|NCT03175874|Other|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
16516914|NCT03175874|Other|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
16516915|NCT03175874|Other|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
16516916|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
16516921|NCT03175809|Experimental|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
16516922|NCT03175796|Experimental|IMH-HV Treatment Group|Infant Mental Health-Home Visiting. Weekly home visits for up to one year by a trained IMH-HV treatment provider. Treatment delivery consistent with the IMH-HV manual.
16516923|NCT03175796|No Intervention|Treatment as Usual Control Group|No intervention provided as part of participation in this study; families are free to access community resources including any available treatment(s) in the community.
16516924|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
16516925|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
16516926|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
16516927|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
16516928|NCT03175757|Placebo Comparator|Placebo|Placebo
16516929|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
16516930|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
16516931|NCT03175731|Experimental|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
16516932|NCT03175731|Placebo Comparator|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
16516933|NCT03175718|Experimental|VAC Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of Incisional Negative pressure wound therapy.
16516934|NCT03175718|Active Comparator|Control Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of standard gauze dressing with no negative pressure application.
16516935|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
16516936|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
16516937|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
16516938|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
16516939|NCT03175653|Experimental|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
16516940|NCT03175653|Active Comparator|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
16516941|NCT03175640|Experimental|Implementation intervention|
16516942|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
16516943|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
16516944|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
16516945|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
16516946|NCT03175588|Experimental|virtual rehabilitation|video based exercise
16516947|NCT03175588|No Intervention|physical Activity|different type of physical Activity
16516948|NCT03175562|Experimental|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
16516949|NCT03175562|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
16516950|NCT03175549|Active Comparator|Otezla (apremilast)|100 mg (50 mg/bid) taken orally for 5 days after a 9 day titration to recommended dose
16516951|NCT03175549|Placebo Comparator|Placebo|Placebo pill taken orally for 14 days
16516952|NCT03175536||HDHP with PDL|Enrollees switched from a high-deductible health plan (HDHP) to a HDHP with a preventive drug list (PDL)
16516953|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL). Enrollees who stayed in a HDHP without a PDL will also serve as controls for the study group who switch from HDHPs without PDLs to HDHPs with PDLs.
16516954|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
16516955|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
16516956|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
16516957|NCT03175510||patients group|Patients with low back pain (18-65 years)
16516958|NCT03175497|Experimental|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.
~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
16516959|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
16516988|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
16517023|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
16516960|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.
~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
16516961|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
16516962|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
16516963|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
16516964|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
16516965|NCT03175432|Experimental|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16516966|NCT03175432|Experimental|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16516967|NCT03175393||postprandial dyslipidemia|
16516968|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
16516969|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
16516970|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
16516971|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
16516972|NCT03175367|Experimental|Group A: matching placebo|Placebo SC QW for 16 weeks
16516973|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
16516974|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
16516975|NCT03175367|Experimental|Group B: matching placebo|Placebo IV Q4W for 24 weeks
16516976|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
16516977|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
16516978|NCT03175341|Experimental|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.
~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
16516979|NCT03175341|Active Comparator|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.
~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
16516980|NCT03175328|Experimental|early group|In the early group, continuous renal replacement therapies was started within 8 hours after randomization.
16516981|NCT03175328|Experimental|delayed group|In the delayed group, continuous renal replacement therapies was initiated if at least one of the following criteria was met: KDIGO 3, severe hyperkalemia, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter after randomization.
16516982|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).
~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
16516983|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
16516984|NCT03175302||Surgical group|Baseline preoperative digital cognitive testing performance in adults to predict frequency and severity of clinician reported outcomes within the first three months post-surgery.
16516985|NCT03175302||Control|Non-surgery matched peers with the same testing.
16516986|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
16516987|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
16516989|NCT03175250|Active Comparator|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
16516990|NCT03175250|Active Comparator|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
16516991|NCT03175250|Experimental|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
16516992|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
16516993|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
16516994|NCT03175224|Experimental|Single-Arm|APL-101 Oral Capsules
16516995|NCT03175211|Experimental|BI 456906|
16516996|NCT03175211|Placebo Comparator|Placebo|
16516997|NCT03175198||Prazaxa Capsules Group|
16516998|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
16516999|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
16517000|NCT03175172|Experimental|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
16517001|NCT03175159|Active Comparator|Standard of Care (SOC)|Sexual risk-reduction counseling sessions.
16517002|NCT03175159|Experimental|Behavioral Activation & Risk Reduction Counseling|Behavioral activation with risk reduction counseling.
16517003|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
16517004|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
16517005|NCT03175120|Experimental|Insulin degludec/liraglutide|
16517006|NCT03175120|Active Comparator|Insulin degludec|
16517007|NCT03175107|Experimental|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
16517008|NCT03175094|Experimental|Holistic Health Recovery Program for HIV+ Intervention|
16517009|NCT03175094|No Intervention|Control|
16517010|NCT03175081|Experimental|Test group|Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
16517011|NCT03175081|Experimental|Control group|Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure.
16517012|NCT03175068|Active Comparator|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
16517013|NCT03175068|Placebo Comparator|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
16517014|NCT03175055|Experimental|Phoenix|Phoenix
16517015|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
16517016|NCT03175029|Experimental|TAC-302|
16517017|NCT03175029|Placebo Comparator|Placebo|
16517018|NCT03175016|Experimental|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
16517019|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
16517020|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
16517021|NCT03175003|Experimental|Food Product 3|Experimental 1
16517022|NCT03175003|Experimental|Food Product 4|Experimental 2
16517372|NCT03172780|Placebo Comparator|Placebo gel|Placebo gel
16517024|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
16517025|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
16517026|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
16517027|NCT03174977|Experimental|18F-Raltegravir|
16517028|NCT03174964|Experimental|Treatment group|IVIg group
16517029|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
16517030|NCT03174951|Experimental|Treatment group|IVIg group
16517031|NCT03174951|No Intervention|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
16517032|NCT03174938|Other|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 300 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.
~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.
~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.
~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
16517033|NCT03174938|Other|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 300 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.
~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.
~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline."
16517034|NCT03174938|Other|COHORT C: SCD and MCI|"550 patients with either subjective cognitive decline or mild cognitive impairment will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, all cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio) will be included.
~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.
~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done every 2 years. Amyloid PET will be performed at baseline and after 4 years.
~A auxiliary cohort (Cohort C2) 150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y."
16517035|NCT03174938|Other|COHORT D: Dementia due to Alzheimer's disease|"300 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include 50 cases aged 40-65 years of age, 200 cases aged 66-79 years of age and 50 cases aged 80-100 years of age.
~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.
~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
16517036|NCT03174938|Other|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:
~160 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD), Progressive nonfluent aphasia (PNFA), semantic dementia (SD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD).
~50 cases with subcortical Vascular dementia (VaD).
~200 cases with either Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple system atrophy (MSA).
~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.
~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
16517037|NCT03174925|Experimental|Tissue Stiffness by Elastography|Potentially cancerous thyroid nodules were assessed by elastrography, then a fine needle biopsy specimen or the surgically-excised nodule was assessed pathologically to determine cancer status.
16517038|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
16517039|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
16517040|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
16517041|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
16517060|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
16517373|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
16517042|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
16517043|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
16517044|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
16517045|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
16517046|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
16517047|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
16517048|NCT03174873|Other|Laparoscopy for unexplained infertile couples|
16517049|NCT03174860|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
16517050|NCT03174860|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
16517051|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
16517052|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
16517053|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
16517054|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
16517055|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
16517056|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
16517057|NCT03174795|Experimental|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
16517058|NCT03174782|Active Comparator|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
16517059|NCT03174782|Placebo Comparator|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
16517152|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
16517061|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
16517062|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
16517063|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
16517064|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
16517065|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
16517066|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
16517067|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
16517068|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
16517069|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
16517070|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
16517071|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
16517072|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
16517073|NCT03174717|Experimental|Music intervention|LTC residents will participate in an individualized music performance with a musician
16517074|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
16517075|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
16517076|NCT03174678|Other|Control|Apple juice
16517077|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.
~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
16517078|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
16517079|NCT03174639|Experimental|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
16517080|NCT03174626|Experimental|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
16517081|NCT03174626|Other|Usual Care|No intervention is provided
16517082|NCT03174613|Experimental|LC51-0255|tablets, PO
16517083|NCT03174613|Placebo Comparator|Placebo|tablets, PO
16517084|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
16517085|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
16517086|NCT03174561|Other|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.
~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
16517087|NCT03174561|Other|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
16517088|NCT03174548|Experimental|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
16517089|NCT03174548|Experimental|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
16517090|NCT03174548|Experimental|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
16517091|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
16517092|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
16517093|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
16517094|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
16517095|NCT03174496||Children aged 4-7 years|
16517096|NCT03174496||Children and adolescents aged 8-16 years|
16517097|NCT03174483|Experimental|hypertonic saline|nasal spray will be used twice daily
16517098|NCT03174483|Active Comparator|fluticasone|nasal spray will be used once daily
16517099|NCT03174470|Experimental|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
16517100|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
16517101|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
16517102|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
16517203|NCT03173781|Placebo Comparator|placebo|sugar pill
16517374|NCT03172767||Term Preschoolers|Term children who haven't attend school.
16517103|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
16517104|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
16517105|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
16517106|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
16517107|NCT03174405|Experimental|AVELUMAB|
16517108|NCT03174392|Experimental|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
16517109|NCT03174392|Active Comparator|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
16517110|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
16517111|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
16517112|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
16517113|NCT03174353|Experimental|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
16517114|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:
~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.
~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.
~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.
~This is in addition to the diet (see below, control group)"
16517115|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
16517116|NCT03174327|Other|Hepatic Transplantation|
16517117|NCT03174314|Experimental|50 visually impaired|50 visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
16517118|NCT03174314|Active Comparator|50 healthy controls|50 healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
16517119|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
16517120|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
16517121|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
16517122|NCT03174275|Experimental|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).
~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.
~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
16517123|NCT03174275|Experimental|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).
~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.
~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
16517204|NCT03173768|No Intervention|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
16517375|NCT03172754|Experimental|Phase I patients|Phase I patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
16517124|NCT03174275|Experimental|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).
~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.
~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
16517125|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
16517126|NCT03174262|No Intervention|Control Group|
16517127|NCT03174249|Experimental|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
16517128|NCT03174236|Experimental|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day for a minimum of 48 hours and a usual maximum of seven days.
16517129|NCT03174236|Active Comparator|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours for a minimum of two days and a maximum of seven days.
16517130|NCT03174236|Experimental|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
16517131|NCT03174236|Placebo Comparator|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
16517132|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
16517133|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
16517134|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
16517135|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
16517136|NCT03174197|Experimental|Adjuvant phase (temozolomide, atezolizumab)|Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16517137|NCT03174197|Experimental|Concurrent phase (temozolomide, atezolizumab, RT)|Patients receive temozolomide PO daily on days 1-42 and atezolizumab IV over 30-60 minutes on day 1, 15, 29, and 42. Patients undergo RT 5 days per week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
16517138|NCT03174184|Experimental|Rifampin resistant A|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily (QD), MEROPENEM 2 grams (G) thrice daily (TID) intravenously, Amoxicillin/Clavulanate Potassium 500 milligrams (MG)-125 MG Oral Tablet once daily for 14 days
16517139|NCT03174184|Experimental|Rifampin resistant B|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID (thrice daily) intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
16517140|NCT03174184|Experimental|Rifampin susceptible C|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily, MEROPENEM 2 grams TID (thrice daily) intravenously, Amx/Clv orally at a dose of 500 mg/125 mg thrice daily for 14 days
16517141|NCT03174184|Experimental|Rifampin susceptible D|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
16517142|NCT03174184|Experimental|Rifampin susceptible E|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 1 gram TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
16517143|NCT03174184|Experimental|Rifampin susceptible F|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 3 grams QD intravenously, Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet once daily for 14 days
16517144|NCT03174171|Experimental|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
16517145|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
16517146|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
16517147|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
16517148|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
16517149|NCT03174145|Active Comparator|Active group|
16517150|NCT03174145|Sham Comparator|Control group|
16517151|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
16518522|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
16517153|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
16517154|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
16517155|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
16517156|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
16517157|NCT03174093|Experimental|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
16517158|NCT03174093|No Intervention|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
16517159|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
16517160|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
16517161|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
16517162|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
16517163|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
16517164|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
16517165|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
16517166|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
16517167|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
16517168|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
16517169|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
16517170|NCT03174015|Experimental|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
16517171|NCT03174015|No Intervention|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
16517174|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
16517175|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
16517176|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
16517177|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
16517178|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
16517179|NCT03173950|Experimental|1/Experimental Therapy|Participants will receive nivolumab at standard dose of240mg IV every 2 weeks for cycles 1 through 2, thendoses of 480mg every 4 weeks for a total of 14 additional doses
16517181|NCT03173924|Experimental|1/Experimental intervention|18F-DCFPyL is administered to cohorts
16517205|NCT03173768|Experimental|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
16517182|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
16517183|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
16517184|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
16517185|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
16517186|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
16517187|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
16517188|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
16517189|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
16517190|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
16517191|NCT03173859|Experimental|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
16517192|NCT03173859|Active Comparator|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
16517193|NCT03173846||Adult children of AD patients|
16517194|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
16517195|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.
~And they will be able to discuss their care needs with their health care practitioners."
16517196|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
16517197|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
16517198|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
16517199|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
16517200|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
16517201|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
16517202|NCT03173781|Experimental|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:
~Reaches the maximum permitted dosage of 600 mg TID;
~Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or
~Experiences intolerable adverse events (AEs)."
16517208|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
16517209|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
16517210|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
16517211|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
16517212|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
16517213|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
16517214|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
16517215|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
16517216|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
16517217|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
16517218|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
16517219|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
16517220|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
16517221|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
16517222|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
16517223|NCT03173703|Experimental|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
16517224|NCT03173703|Active Comparator|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
16517225|NCT03173690|Experimental|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
16517226|NCT03173690|Other|Control group|No intervention at the ICU, medication reconciliation at the ward
16517227|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
16517228|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
16517229|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
16517230|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
16517231|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
16517232|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
16517233|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
16517234|NCT03173625|Experimental|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
16517235|NCT03173625|Placebo Comparator|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
16517236|NCT03173612|Experimental|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
16517237|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal
~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
16517238|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
16517239|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
16517240|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
16517241|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
16517243|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal
~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
16517244|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.
~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.
~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
16517245|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
16517246|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
16517247|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
16517248|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
16517249|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
16517250|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
16517251|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
16517252|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
16517253|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
16517256|NCT03173547|Active Comparator|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
16517257|NCT03173547|Placebo Comparator|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
16517258|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=175 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
16517259|NCT03173534|Experimental|TAVR + WATCHMAN|n=175 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
16517260|NCT03173521|Experimental|open label|
16517261|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16517262|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16517263|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
16517264|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
16517265|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
16517266|NCT03173456|Active Comparator|oxycodone/APAP|5 mg oxycodone + 325 mg acetaminophen
16517267|NCT03173456|Active Comparator|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
16517268|NCT03173456|Active Comparator|codeine/APAP|30 mg codeine + 300 mg acetaminophen
16517269|NCT03173456|Active Comparator|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
16517270|NCT03173456|Active Comparator|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
16517271|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
16517272|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
16517273|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
16517274|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
16517275|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
16517276|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
16517277|NCT03173391|Experimental|HMS5552|75mg BID
16517278|NCT03173391|Placebo Comparator|Placebo|BID
16517279|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
16517280|NCT03173378||Control|Adult age-matched family members of the patients
16517376|NCT03172754|Experimental|Phase II patients: cohort 1|Phase II cohort 1 patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
16517281|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
16517282|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
16517283|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
16517284|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
16517285|NCT03173326|Experimental|Subarachnoid block|
16517286|NCT03173326|Active Comparator|General anesthesia|
16517287|NCT03173313|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
16517288|NCT03173313|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
16517289|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
16517290|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
16517291|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
16517292|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
16517293|NCT03173248|Experimental|AG-120 (ivosidenib) with Azacitidine|
16517294|NCT03173248|Placebo Comparator|Placebo with Azacitidine|
16517295|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
16517296|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
16517297|NCT03173222|Active Comparator|EA1|
16517298|NCT03173222|Active Comparator|EA2|
16517299|NCT03173222|No Intervention|Control|
16517300|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
16517301|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
16517302|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
16517303|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:
~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
16517304|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :
~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
16517305|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
16517306|NCT03173170|Experimental|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
16517307|NCT03173157|Experimental|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
16517308|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
16517309|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
16517310|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
16517311|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
16517312|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
16517313|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
16517314|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
16517315|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
16530456|NCT03083223||lung disease|Patients with lung disease
16517316|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs for up to 3 years.
16517317|NCT03173066|Experimental|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
16517318|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.
~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
16517319|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus
~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
16517320|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
16517321|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
16517322|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
16517323|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
16517324|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
16517325|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
16517326|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
16517327|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
16517328|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
16517329|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
16517330|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
16517331|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
16517332|NCT03172988|Experimental|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
16517333|NCT03172988|Experimental|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
16517334|NCT03172988|Experimental|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
16517335|NCT03172988|Placebo Comparator|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
16517336|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
16517337|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
16517377|NCT03172754|Experimental|Phase II patients: cohort 2|Phase II cohort 2 patients must not have received prior systemic therapy for advanced RCC.
16531440|NCT03076541||patients with restless legs syndrome|
16517338|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
16517339|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
16517340|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
16517341|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
16517342|NCT03172936|Experimental|Dosing Schedule A|Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
16517343|NCT03172936|Experimental|Dosing Schedule B|Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
16517344|NCT03172923|Active Comparator|sliding hip screw|fixation of fracture with a sliding hip screw
16517345|NCT03172923|Experimental|intramedullary nail|fixation of the fracture with an intramedullary nail
16517346|NCT03172910|Experimental|Cohort 1|ciraparantag (60 mg)
16517347|NCT03172910|Experimental|Cohort 2|ciraparantag (120 mg)
16517348|NCT03172910|Experimental|Cohort 3|ciraparantag (180 mg)
16517349|NCT03172910|Experimental|Cohort 4|ciraparantag (30 mg)
16517350|NCT03172910|Placebo Comparator|Placebo|placebo (saline for injection)
16517351|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
16517352|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
16517353|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
16517354|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with Child-Pugh B (score 7-9) at the screening visit
16517355|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
16517356|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with Child-Pugh C (score 10-15) at the screening visit
16517357|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):
~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
16517358|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):
~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
16517359|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.
~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
16517360|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
16517361|NCT03172845|Experimental|Vulnerable plaque|Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
16517362|NCT03172845|Active Comparator|Without any vulnerable plaqueStable plaque|patient with bifurcation lesion undergoing baseline coronary angiography and baseline OCT.
16517363|NCT03172832|Active Comparator|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
16517364|NCT03172832|Active Comparator|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
16517365|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
16517366|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
16517367|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
16517368|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
16517369|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
16517378|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
16517379|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
16517380|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
16517381|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
16517382|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.
~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
16517383|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.
~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
16517384|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.
~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
16517385|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
16517386|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
16517387|NCT03172689|Other|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
16517388|NCT03172676|No Intervention|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
16517389|NCT03172676|Active Comparator|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
16517390|NCT03172676|No Intervention|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
16517391|NCT03172663|Experimental|group 1|
16517392|NCT03172663|Active Comparator|group 2|
16517393|NCT03172650||study group|non alcoholic fatty liver disease patients
16517394|NCT03172650||Control group|fatty liver patients
16517395|NCT03172637||Group A|50 female end stage renal disease patients
16517396|NCT03172637||Group B|50 normal female patients
16517397|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
16517398|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
16517399|NCT03172611|Experimental|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
16517400|NCT03172598|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
16517401|NCT03172598|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
16517402|NCT03172598|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
16517403|NCT03172598|Experimental|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
16517404|NCT03172598|Experimental|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
16517520|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
16517405|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
16517406|NCT03172572||Indication for surgery|Solid neoplasms
16517407|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
16517408|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
16517409|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
16517410|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
16517411|NCT03172533|Active Comparator|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
16517412|NCT03172533|Placebo Comparator|placebo group|placebo
16517413|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
16517414|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
16517415|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
16517416|NCT03172494|Experimental|Insulin degludec/liraglutide|
16517417|NCT03172494|Active Comparator|Insulin degludec|
16517418|NCT03172494|Active Comparator|Liraglutide|
16517419|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
16517420|NCT03172481|Placebo Comparator|Placebo Treatment|
16517421|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
16517422|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
16517423|NCT03172442|Experimental|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
16517424|NCT03172442|No Intervention|Control group|without intervention
16517425|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
16517426|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
16517427|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
16517428|NCT03172416|Other|Oxaliplatin|"3+3 dose escalation of oxaliplatin
~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.
~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.
~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks
~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
16517429|NCT03172403|Experimental|Patients with digestive cancer requiring resection surgery|"Patients with cancer of digestive system requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.
~V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months"
16517430|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
16517431|NCT03172377|Experimental|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
16517432|NCT03172377|No Intervention|Control group|Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
16517433|NCT03172364|Experimental|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
16517434|NCT03172364|Experimental|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
16517435|NCT03172351|Experimental|EDoF1|
16517436|NCT03172351|Active Comparator|Monofocal|
16517437|NCT03172351|Active Comparator|EDoF2|
16517521|NCT03171753|Experimental|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
16517522|NCT03171753|Active Comparator|Control|patients wear headphones for 30 minuts without any sound
16517438|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
16517439|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
16517440|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
16517441|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
16517442|NCT03172299|Active Comparator|Injection of anti-VEGF|
16517443|NCT03172299|Placebo Comparator|false injection of anti-VEGF|
16517444|NCT03172286|Active Comparator|Patient treated with fake radiofrequencer|
16517445|NCT03172286|Experimental|Patient treated with radiofrequencer|
16517446|NCT03172273|Experimental|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
16517447|NCT03172273|Active Comparator|paracentesis|Paracentesis with albumine invision
16517448|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
16517449|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
16517450|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
16517451|NCT03172208|Experimental|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
16517452|NCT03172208|Placebo Comparator|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
16517453|NCT03172208|Experimental|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
16517454|NCT03172208|Experimental|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
16517455|NCT03172208|Experimental|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
16517456|NCT03172208|Placebo Comparator|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
16517457|NCT03172208|Experimental|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
16517458|NCT03172208|Placebo Comparator|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
16517459|NCT03172208|Experimental|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
16517460|NCT03172208|Placebo Comparator|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
16517461|NCT03172208|Experimental|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
16517462|NCT03172208|Placebo Comparator|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
16517463|NCT03172195|Experimental|Patients with ulcerative colitis|Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
16517464|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
16517465|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
16517466|NCT03172169||Healthy control group|no intervention
16517467|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
16517468|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
16517469|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
16517470|NCT03172143|Active Comparator|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
16517471|NCT03172143|Active Comparator|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
16517472|NCT03172130|Experimental|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
16517473|NCT03172130|Sham Comparator|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
16517474|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
16517475|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
16517476|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
16517477|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.
~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
16517601|NCT03171272|Experimental|Experimental Group|
16517602|NCT03171272|Sham Comparator|Control Group|
16517478|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
16517479|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
16517480|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
16517481|NCT03172078|Active Comparator|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
16517482|NCT03172078|Active Comparator|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
16517483|NCT03172065|Other|control group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline
16517484|NCT03172065|Other|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
16517485|NCT03172052|Experimental|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was <100 cc in 24 h provided that tube is patent and properly positioned.
16517486|NCT03172052|Experimental|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
16517487|NCT03172052|Experimental|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
16517488|NCT03172052|Experimental|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
16517489|NCT03172026|Experimental|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
16517490|NCT03172026|Placebo Comparator|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
16517491|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
16517492|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
16517493|NCT03172013||Healthy volunteers|Healthy individuals
16517494|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
16517495|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
16517496|NCT03171987|Experimental|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
16517497|NCT03171987|Active Comparator|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
16517498|NCT03171974|Experimental|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
16517499|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
16517500|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
16517501|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
16517502|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
16517503|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
16517504|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
16517505|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
16517506|NCT03171935|Active Comparator|Conventional Weaning|
16517507|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
16517508|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
16517509|NCT03171896|Experimental|Intervention|Medical clown
16517510|NCT03171896|Sham Comparator|No Intervention|No clown in the room
16517511|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
16517512|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
16517513|NCT03171831|Experimental|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).
~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）
~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
16517514|NCT03171818|Experimental|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
16517515|NCT03171818|Placebo Comparator|Placebo|Saline
16517516|NCT03171805|Experimental|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
16517517|NCT03171805|No Intervention|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
16517518|NCT03171779||Usual practice|
16517519|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
16518565|NCT03164876|Experimental|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
16517523|NCT03171740|Active Comparator|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
16517524|NCT03171740|Active Comparator|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
16517525|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
16517526|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
16517527|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
16517528|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
16517529|NCT03171701||maturation of arteriovenous fistula|
16517530|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
16517531|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
16517532|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
16517533|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
16517534|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
16517535|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
16517536|NCT03171662|Experimental|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
16517537|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16517538|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
16517539|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
16517540|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
16517541|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
16517542|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
16517543|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
16517544|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
16517545|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
16517546|NCT03171597|Other|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
16517547|NCT03171597|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
16517548|NCT03171597|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
16517549|NCT03171597|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
16517550|NCT03171584|Experimental|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
16517551|NCT03171584|Experimental|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
16517552|NCT03171584|Experimental|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
16517553|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
16517554|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
16517555|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
16517556|NCT03171545|Experimental|Patient Activation|This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
16517557|NCT03171545|Experimental|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
16517558|NCT03171545|No Intervention|No Intervention|Patients in clinic receive usual care.
16517559|NCT03171545|Experimental|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
16517560|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
16517603|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).
~Daily for up to 12 weeks."
16517732|NCT03170544|Experimental|Part 1, MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
16517561|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
16517562|NCT03171519|Active Comparator|Exercise|
16517563|NCT03171519|Experimental|Exercise + acupuncture|
16517564|NCT03171506|Experimental|Usual care plus ketogenic diet|
16517565|NCT03171506|Placebo Comparator|Usual care plus AND diet|
16517566|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
16517567|NCT03171480|Active Comparator|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
16517568|NCT03171480|Placebo Comparator|Placebo|The pharmacy has compounded an identical appearing placebo
16517569|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
16517570|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
16517571|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
16517572|NCT03171441||Controls|eutrophic children
16517573|NCT03171441||Overweight|Overweight children
16517574|NCT03171441||Obese|Obese children
16517575|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
16517576|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
16517577|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):
~40mg RZL-012 -administered at 8 sites
~80mg RZL-012 - administered at 16 sites
~120mg RZL-012 - administered at 24 sites
~180mg RZL-012 - administered at 36 sited"
16517578|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
16517579|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
16517580|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
16517581|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
16517582|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
16517583|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.
~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
16517584|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
16517585|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
16517586|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
16517587|NCT03171363|Experimental|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
16517588|NCT03171350|Experimental|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
16517589|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
16517590|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
16517591|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
16517592|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
16517593|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
16517594|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
16517595|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
16517596|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
16517597|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
16517598|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
16517599|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
16517600|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
16517604|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
16517605|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
16517606|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
16517607|NCT03171207|Experimental|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
16517608|NCT03171207|Experimental|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
16517609|NCT03171194|Experimental|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
16517610|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
16517611|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
16517612|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
16517613|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
16517614|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
16517615|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
16517616|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
16517617|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
16517618|NCT03171129|Experimental|High flow nasal cannula system w/ ADINA|The intervention is the insertion of the the ADINA device into the high flow nasal cannula system. ADINA will be placed according to weight class recommendations to increase the positive end expiratory pressure (PEEP). ADINA is actually a combination of the Neotech RAM Cannula and a clear Regulator/Pop off valve.
16517619|NCT03171129|Active Comparator|high flow nasal cannula system|High flow nasal cannula will deliver oxygen at 2-4 lpm of flow. High flow cannula are used to provide the control interface.
16517620|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
16517621|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
16517622|NCT03171116||RTx renal transplant|renal transplant recipients
16517623|NCT03171116||Controls|control subjects
16517624|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
16517625|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
16517626|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.
~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
16517627|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
16517628|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
16517629|NCT03171064|Experimental|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
16517630|NCT03171064|No Intervention|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
16517631|NCT03171051|Other|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.
~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
16517632|NCT03171038|Experimental|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
16517633|NCT03171038|No Intervention|Usual care group|Usual care from t0 up until the common stopping date (t2).
16517634|NCT03171025|Experimental|Nivolumab, all patients|
16517635|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
16517636|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
16517637|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
16517638|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
16517639|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
16517640|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
16517641|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
16517642|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
16517643|NCT03170986|No Intervention|Control Arm|
16517644|NCT03170973|Experimental|Comparison of fatty acids before and after exercise|
16517645|NCT03170973|No Intervention|Comparison of fatty acids at baseline and 24 hours after|
16517646|NCT03170960|Experimental|Dose Escalation|"Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard 3 plus 3 design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage."
16517647|NCT03170960|Experimental|Expansion Cohort 1|RCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
16517648|NCT03170960|Experimental|Expansion Cohort 2|UC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
16517649|NCT03170960|Experimental|Expansion Cohort 3|UC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
16517650|NCT03170960|Experimental|Expansion Cohort 4|UC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
16517651|NCT03170960|Experimental|Expansion Cohort 5|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
16517652|NCT03170960|Experimental|Expansion Cohort 6|CRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
16517653|NCT03170960|Experimental|Expansion Cohort 7|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
16517654|NCT03170960|Experimental|Expansion Cohort 8|Stage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
16517655|NCT03170960|Experimental|Expansion Cohort 9|Stage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
16517656|NCT03170960|Experimental|Expansion Cohort 10|RCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
16517657|NCT03170960|Experimental|Expansion Cohort 11|TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
16517658|NCT03170960|Experimental|Expansion Cohort 12|OC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
16517659|NCT03170960|Experimental|Expansion Cohort 13|EC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
16517660|NCT03170960|Experimental|Expansion Cohort 14|HCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
16517661|NCT03170960|Experimental|Expansion Cohort 15|GC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
16517662|NCT03170960|Experimental|Expansion Cohort 16|CRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
16517663|NCT03170960|Experimental|Expansion Cohort 17|H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
16517664|NCT03170960|Experimental|Expansion Cohort 18|DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
16517665|NCT03170960|Experimental|Expansion Cohort 19 (SAC)|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
16517666|NCT03170960|Experimental|Expansion Cohort 20 (SAC)|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
16517667|NCT03170960|Experimental|Expansion Cohort 21 (SAC)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
16517668|NCT03170960|Experimental|Expansion Cohort 22 (SAA)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
16517669|NCT03170960|Experimental|Expansion Cohort 23|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
16517670|NCT03170960|Experimental|Expansion Cohort 24|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
16517671|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
16517672|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
16517673|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
16517674|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
16517675|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
16517676|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
16517677|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
16517678|NCT03170895|Experimental|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.
~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.
~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
16517681|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.
~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.
~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.
~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
16517682|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
16517683|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
16517684|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
16517685|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
16517686|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
16517687|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
16517688|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
16517731|NCT03170557|Sham Comparator|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
16517690|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
16517691|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
16517692|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
16517693|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
16517694|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:
~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);
~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);
~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
16517695|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
16517696|NCT03170739|Experimental|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
16517697|NCT03170739|Experimental|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
16517698|NCT03170739|Experimental|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
16517699|NCT03170739|No Intervention|Control group|No intervention
16517700|NCT03170726|Active Comparator|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
16517701|NCT03170726|Active Comparator|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
16517702|NCT03170726|Placebo Comparator|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
16517703|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
16517704|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
16517705|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
16517706|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
16517707|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
16517708|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
16517709|NCT03170687|Experimental|foot cast|
16517710|NCT03170687|Active Comparator|short leg cast|
16517711|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
16517712|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
16517713|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
16517714|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
16517715|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
16517716|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
16517717|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
16517718|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
16517719|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
16517720|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
16517721|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
16517722|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
16517723|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
16517724|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
16517725|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
16517726|NCT03170609|Placebo Comparator|Placebo|Saline control
16517727|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
16517728|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
16517729|NCT03170570|Experimental|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
16517730|NCT03170557|Active Comparator|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
16518566|NCT03164876|Placebo Comparator|Placebo|Placebo to match AUT00206 twice daily for 28 days
16517733|NCT03170544|Experimental|Part 1, MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
16517734|NCT03170544|Experimental|Part 1, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
16517735|NCT03170544|Experimental|Part 1, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
16517736|NCT03170544|Experimental|Part 1, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
16517737|NCT03170544|Active Comparator|Part 1, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
16517738|NCT03170544|Experimental|Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg|MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
16517739|NCT03170544|Experimental|Part 3, MK-1092, 8.0 nmol/kg|MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
16517740|NCT03170544|Experimental|Part 3, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
16517741|NCT03170544|Active Comparator|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
16517742|NCT03170544|Experimental|Part 4, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
16517743|NCT03170544|Experimental|Part 4, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
16517744|NCT03170544|Experimental|Part 4, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
16517745|NCT03170544|Active Comparator|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
16517746|NCT03170531||Custom MR spine coil|
16517749|NCT03170505||Acellular Dermal Matrix|
16517750|NCT03170505||Conchal Cartilage|
16517751|NCT03170492|Experimental|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
16517752|NCT03170492|Active Comparator|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
16517753|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
16517754|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
16517755|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
16517756|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
16517757|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.
~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
16517758|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
16517759|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
16517760|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
16517761|NCT03170427|Sham Comparator|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
16517762|NCT03170427|Active Comparator|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
16517763|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
16517764|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
16517765|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
16517766|NCT03170388|Experimental|IDP-126 Gel|Gel
16517767|NCT03170388|Active Comparator|IDP-126 Component A|Component A
16517768|NCT03170388|Active Comparator|IDP-126 Component B|Component B
16517769|NCT03170388|Active Comparator|IDP-126 Component C|Component C
16517770|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
16517771|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
16517772|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
16517773|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
16517774|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
16517775|NCT03170362|Experimental|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
16517776|NCT03170362|No Intervention|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
16517777|NCT03170349|Experimental|Edwards PASCAL Transcatheter Mitral Valve Repair System|
16517778|NCT03170336|Experimental|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
16517779|NCT03170336|Active Comparator|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
16517780|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
16517781|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
16517782|NCT03170310|Experimental|Apatinib|
16517783|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
16517784|NCT03170271|Experimental|Benralizumab (Medi-563)|Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
16517785|NCT03170271|Placebo Comparator|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
16517786|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
16517787|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Both groups will be debriefed at the end of the study.
16517788|NCT03170245||B thalassemia group|"Laboratory investigations :
~complete blood count
~renal and liver function tests
~serum ferritin
~lipid profile
~Interleukin -6
~HsC-RP
~Adiponectin level
~Imaging :
~Abdominal ultrasound
~Echocardiography
~Carotid intima media thickness"
16517789|NCT03170245||Control group|"Laboratory investigations :
~complete blood count
~renal and liver function tests
~serum ferritin
~lipid profile
~Interleukin -6
~HsC-RP
~Adiponectin level
~Imaging :
~Abdominal ultrasound
~Echocardiography
~Carotid intima media thickness"
16517790|NCT03170232|Experimental|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
16517791|NCT03170232|Placebo Comparator|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
16517792|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
16517793|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
16517794|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 1|"Palbociclib will be administered orally once daily
~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
~Binimetinib will be administered orally twice daily
~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
16517795|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 2|"Palbociclib will be administered orally once daily
~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
~Binimetinib will be administered orally twice daily
~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
16517796|NCT03170206|Experimental|Binimetinib Phase 2|"Binimetinib will be administered orally twice daily
~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
16517797|NCT03170206|Experimental|Palbociclib Phase 2|"Palbociclib will be administered orally once daily
~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle"
16517798|NCT03170193|Experimental|AMG 529|Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
16517799|NCT03170193|Placebo Comparator|Placebo|Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
16517800|NCT03170180|Experimental|sunitinib|
16517801|NCT03170180|Experimental|gefitinib|
16517802|NCT03170180|Experimental|imatinib|
16517848|NCT03169868|Experimental|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
16517803|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
16517804|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
16517805|NCT03170154|Experimental|Clareon IOL|Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery
16517806|NCT03170141|Experimental|Antigen-specific IgT cells|Patients will receive non-myeloablative chemotherapy consisting of fludarabine and/or cyclophosphamide, followed by intravenous infusion of autologous IgT cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of IgT cells. The tested IgT cell dosage ranges from 0.5×10^5 /kg to 2.5×10^7 /kg
16517807|NCT03170128|Active Comparator|Outpatient Physical Therapy|
16517808|NCT03170128|Active Comparator|Home Exercises|
16517809|NCT03170115|Experimental|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
16517810|NCT03170115|Placebo Comparator|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
16517811|NCT03170102|Other|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
16517812|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
16517813|NCT03170089|No Intervention|Control|NO program or scaling done
16517814|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
16517815|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
16517816|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
16517817|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
16517818|NCT03170037|Active Comparator|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
16517819|NCT03170037|Experimental|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
16517820|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
16517821|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
16517822|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
16517823|NCT03169985|Active Comparator|Rosuvastatin plus ezetimibe arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.
16517824|NCT03169985|Active Comparator|High-dose rosuvastatin monotherapy arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.
16517825|NCT03169972||Previously treated patients (PTPs)|PTPs: patients who had 4 or more days to other Factor VIII (FVIII) products
16517826|NCT03169972||Previously untreated patients (PUPs)|PUPs: patients who had 3 or less previous exposure days to other products
16517827|NCT03169959|Experimental|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
16517828|NCT03169959|Experimental|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
16517829|NCT03169959|Experimental|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
16517830|NCT03169959|Experimental|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
16517831|NCT03169959|Experimental|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
16517832|NCT03169959|Experimental|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
16517833|NCT03169959|Experimental|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
16517834|NCT03169959|Experimental|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
16517835|NCT03169959|Experimental|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
16517836|NCT03169959|Experimental|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
16517837|NCT03169959|Experimental|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
16517838|NCT03169959|Experimental|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
16517839|NCT03169946|Active Comparator|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
16517840|NCT03169946|Active Comparator|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
16517841|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
16517842|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
16517843|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
16517844|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
16517845|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
16517846|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
16517847|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
16517886|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
16517849|NCT03169868|No Intervention|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
16517850|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
16517851|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
16517852|NCT03169842|Experimental|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
16517853|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
16517854|NCT03169816|Experimental|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
16517855|NCT03169816|Placebo Comparator|Placebo|a placebo comparator capsule taken twice daily
16517856|NCT03169803|Experimental|Single arm, NeuroTronik CANS Therapy System|
16517857|NCT03169790|Experimental|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
16517858|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
16517859|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
16517860|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
16517861|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
16517862|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
16517863|NCT03169725|Experimental|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
16517864|NCT03169725|Experimental|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
16517865|NCT03169725|Experimental|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
16517866|NCT03169725|Active Comparator|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
16517867|NCT03169712|Active Comparator|CBT for PTSD|15 sessions of trauma-focused CBT
16517868|NCT03169712|Experimental|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
16517869|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
16517870|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
16517871|NCT03169686|Experimental|Intervention Group|"Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team. One to six messages will be sent per day for the time leading up to the quit date and 12 weeks after quit data.
~One to three messages will be sent per week until the end of the 24 weeks follow up after quit data. They will also be encouraged to send self-help, peer support messages in their group. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points."
16517872|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points.
16517873|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
16517874|NCT03169647|Experimental|Intervention|listening-based protocol (type A)
16517875|NCT03169647|Placebo Comparator|Control|listening-based protocol (type B)
16517876|NCT03169634|Experimental|short or long stemmed rTKR cemented|
16517877|NCT03169634|Experimental|Cone with short stem|
16517878|NCT03169634|Experimental|Cone with long stem|
16517879|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
16517880|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
16517881|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
16517882|NCT03169569|Experimental|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
16517883|NCT03169569|Active Comparator|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
16517884|NCT03169556|Experimental|video-laryngoscope guided lightwand|
16517885|NCT03169556|Active Comparator|lightwand|
16517889|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
16517890|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
16517891|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
16517892|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
16517893|NCT03169491|Experimental|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
16517894|NCT03169491|Sham Comparator|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
16517895|NCT03169491|Other|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
16517896|NCT03169478|No Intervention|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
16517897|NCT03169478|Experimental|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
16517898|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
16517899|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
16517900|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
16517901|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.
~Intervention: taking beta-blocker"
16517902|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
16517903|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
16517904|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
16517905|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
16517906|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
16517907|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
16517908|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
16517909|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
16517910|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
16517911|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
16517912|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
16517913|NCT03169335|Experimental|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
16517914|NCT03169335|Active Comparator|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
16517915|NCT03169322|Active Comparator|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
16517916|NCT03169322|Active Comparator|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
16517917|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
16517918|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
16517919|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
16518019|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
16517920|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
16517921|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
16517922|NCT03169257|Experimental|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
16517923|NCT03169257|No Intervention|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
16517924|NCT03169244|Active Comparator|Bupropion|Bupropion extended release
16517925|NCT03169244|Placebo Comparator|Placebo|Placebo oral tablet
16517926|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
16517927|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
16517928|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
16517929|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
16517930|NCT03169231|Placebo Comparator|Study Group E|Single peripheral IV infusion of placebo.
16517931|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
16517932|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
16517933|NCT03169205||preexisting Diabetes mellitus type 1|
16517934|NCT03169205||preexisting Diabetes mellitus type 2|
16517935|NCT03169205||Gestational Diabetes mellitus|
16517936|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
16517937|NCT03169179|Experimental|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
16517938|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
16517939|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
16517940|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
16517941|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
16517942|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
16517943|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
16517944|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
16517945|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
16517946|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
16517947|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
16517948|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
16517949|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
16517950|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
16517951|NCT03169088|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
16517952|NCT03169075|Experimental|ARM A: A|Supervised physical exercise programs (SPEP)
16517953|NCT03169075|Active Comparator|ARM B: B|Adapted physical activity (APA)
16517954|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
16517955|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16517956|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
16517957|NCT03169023|Experimental|Arm 1: ScaleDown (only first 16 patients)|"Baseline quality of life and image surveys
~Weigh themselves every day on the provided Wi-Fi Scale
~Personalized feedback with text message comes as soon as participants step on the scale
~At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed
~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website
~Only 16 participants were in this arm because ScaleDown went out of business
~At 12 month follow-up weight will be abstracted from medical record"
16517958|NCT03169023|Active Comparator|Arm 2: Enhanced Usual Care|"Baseline quality of life and image surveys
~Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise
~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed
~At 12 month follow-up weight will be abstracted from medical record"
16517959|NCT03169023|Experimental|Arm 3: iOTA|"Baseline quality of life and image surveys
~Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale
~Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months
~Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals
~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed
~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website
~At 12 month follow-up weight will be abstracted from medical record"
16517960|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
16517961|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
16517962|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
16517963|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
16517964|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
16517965|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
16517966|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
16517967|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
16517968|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
16517969|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
16517970|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
16517971|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
16517972|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
16517973|NCT03168971|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
16517974|NCT03168971|No Intervention|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
16517975|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
16517976|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
16517977|NCT03168945|Active Comparator|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
16517978|NCT03168945|Placebo Comparator|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
16517979|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
16517980|NCT03168906|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
16517981|NCT03168906|Placebo Comparator|Placebo|Placebo
16517982|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
16533373|NCT03062774|Experimental|PB-119|intervention: PB-119 injection
16517983|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
16517984|NCT03168880|Active Comparator|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
16517985|NCT03168880|Experimental|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
16517986|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
16517987|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
16517988|NCT03168854|Experimental|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
16517989|NCT03168854|Experimental|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
16517990|NCT03168854|Active Comparator|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
16517991|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
16517992|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
16517993|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
16517994|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
16517995|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
16517996|NCT03168802|Active Comparator|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
16517997|NCT03168789|Experimental|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
16517998|NCT03168789|Active Comparator|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
16517999|NCT03168776|Experimental|BuMA Supreme Coronary Stent System|
16518000|NCT03168776|Active Comparator|Xience or Promus Everolimus Stent System|
16518001|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
16518002|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
16518003|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
16518004|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
16518006|NCT03168737|Experimental|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
16518007|NCT03168737|Experimental|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans >= 24 hours later up to 10 days.
16518008|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
16518009|NCT03168724|No Intervention|Control|Group not getting the intervention
16518010|NCT03168711|Experimental|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
16518011|NCT03168711|Placebo Comparator|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
16518012|NCT03168698|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16518013|NCT03168698|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16518014|NCT03168698|Active Comparator|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16518015|NCT03168698|Active Comparator|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16518016|NCT03168685|Experimental|Experimental|"Multiple device intervention
~SureSource Engage mobile application
~ActiGraph Link
~weight scale"
16518017|NCT03168672|Other|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
16518018|NCT03168659|Other|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
16518135|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
16518020|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
16518021|NCT03168633|Experimental|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.
~web-based DM2 information pages"
16518022|NCT03168620|Active Comparator|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
16518023|NCT03168620|Active Comparator|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
16518024|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
16518025|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
16518026|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
16518027|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
16518028|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
16518029|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
16518030|NCT03168555|Experimental|Intervention|chenodeoxycholic acid 1250mg po.
16518031|NCT03168542|Experimental|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
16518032|NCT03168542|Experimental|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
16518033|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
16518034|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
16518035|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
16518036|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
16518037|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
16518038|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
16518039|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
16518040|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
16518041|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
16518042|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
16518043|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
16518044|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
16518045|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
16518046|NCT03168477|Experimental|dry needling and spinal manipulation|
16518047|NCT03168477|Active Comparator|mobilization, exercise, modalities|
16518048|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
16518049|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
16518050|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
16518051|NCT03168438|Experimental|Arm 1: Letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
16518052|NCT03168438|Experimental|Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.
16518053|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
16518054|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
16518055|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
16518056|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
16518057|NCT03168399|Experimental|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
16518058|NCT03168386|Experimental|Intensive motor rehabilitation group|
16518059|NCT03168373|Experimental|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
16518060|NCT03168373|Active Comparator|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
16518061|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
16518062|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
16518067|NCT03168334|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
16518068|NCT03168334|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
16518069|NCT03168321|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
16518070|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
16518071|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
16518072|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
16518073|NCT03168295|Experimental|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
16518074|NCT03168295|Active Comparator|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
16518075|NCT03168295|Other|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
16518076|NCT03168256|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
16518077|NCT03168256|Experimental|CF101 3mg|CF101 3mg, orally q12 hours
16518078|NCT03168256|Active Comparator|Apremilast 30mg|Apremilast 30mg, orally q12 hours
16518079|NCT03168256|Placebo Comparator|Placebo|Placebo control , orally q12 hours
16518080|NCT03168243|Experimental|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
16518081|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
16518082|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
16518083|NCT03168204|Experimental|Risk of being frail experimental group|
16518084|NCT03168204|No Intervention|Risk of being frail control group|
16518085|NCT03168204|No Intervention|No/low risk of being frail|
16518086|NCT03168204|No Intervention|Risk of being frail care avoiders|
16518087|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
16518088|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
16518089|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
16518090|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
16518091|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
16518092|NCT03168165|No Intervention|Usual Care|Usual care, no intervention
16518093|NCT03168165|Experimental|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
16518094|NCT03168152|Experimental|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
16518095|NCT03168152|Experimental|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
16518096|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
16518097|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
16518098|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.
~*Peanut skin prick test wheal ≥ 8 mm."
16518099|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.
~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
16518100|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.
~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
16518707|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
16518101|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
16518102|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
16518103|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
16518104|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
16518105|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
16518106|NCT03168074|Experimental|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
16518107|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.
~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
16518108|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
16518109|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).
~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
16518110|NCT03168022|Experimental|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
16518111|NCT03168022|Experimental|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
16518112|NCT03168009|Experimental|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
16518113|NCT03167996|Experimental|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit
~Lab testing is the same for both Group A/ control and Group B patients"
16518114|NCT03167996|No Intervention|Group A/ Control|"Group B will not have access to HealthPals app
~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up
~Lab testing is the same for both Group A/ control and Group B patients"
16518115|NCT03167983||dementia|patients with dementia
16518116|NCT03167983||control|healthy control
16518117|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
16518118|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
16518119|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
16518120|NCT03167944|Experimental|Conventional electrocautery|
16518121|NCT03167944|Experimental|Low thermal electrosurgery system|
16518122|NCT03167931|Experimental|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
16518123|NCT03167931|Experimental|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
16518124|NCT03167918|Experimental|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
16518125|NCT03167918|Experimental|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
16518126|NCT03167918|Experimental|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)& Xuefuzhuyu Decoction（100 ml bid，po)
16518127|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
16518128|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
16518129|NCT03167892|Experimental|Intervention|Oral screen
16518130|NCT03167892|No Intervention|Control|No intervention
16518131|NCT03167879|Experimental|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
16518132|NCT03167879|Experimental|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
16518133|NCT03167879|No Intervention|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
16518134|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
16519342|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
16518136|NCT03167853|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
16518137|NCT03167840|Experimental|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
16518138|NCT03167840|Experimental|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
16518139|NCT03167840|Experimental|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
16518140|NCT03167840|No Intervention|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
16518141|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
16518142|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
16518143|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
16518144|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
16518145|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
16518146|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
16518147|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
16518148|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
16518149|NCT03167775|Experimental|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
16518150|NCT03167762|Experimental|Study group|
16518151|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
16518152|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
16518153|NCT03167736|Experimental|Electric dry needling, manipulation|
16518154|NCT03167736|Active Comparator|conventional physical therapy|
16518155|NCT03167723|Experimental|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
16518156|NCT03167723|Experimental|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
16518157|NCT03167710|Experimental|dry needling, manipulation stretching|
16518158|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
16518159|NCT03167697|Experimental|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
16518160|NCT03167697|Active Comparator|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
16518161|NCT03167684|Experimental|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
16518162|NCT03167684|No Intervention|Control|Sham oral appliance device
16518163|NCT03167671|Active Comparator|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy.
16518164|NCT03167671|Experimental|AposTherapy|Treatment with at home AposTherapy with daily use of the shoe.
16518165|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
16518166|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
16518167|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
16518168|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
16518169|NCT03167645|No Intervention|Control|Standard clinical care
16518170|NCT03167632||dental patients|
16518171|NCT03167619|Experimental|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
16518172|NCT03167619|Experimental|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
16518173|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile for the next three months.
16518174|NCT03167606|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile and will be asked to complete their surveys every 3 months and return to the study site in 9 months for a follow-up visit (at which time they will receive the MyPEEPS Mobile intervention).
16518175|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
16518176|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
16518177|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
16518178|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
16518179|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
16518180|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
16518181|NCT03167554|Sham Comparator|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
16518182|NCT03167554|Experimental|Experimental group 1|Electrolysis application with monopolar needle.
16518183|NCT03167554|Experimental|Experimental group 2|Electrolysis application with bipolar needle.
16518184|NCT03167541|Experimental|1|Treatment Order: Test, Reference
16518185|NCT03167541|Experimental|2|Treatment Order: Reference, Test
16518186|NCT03167528|Experimental|Lung transplant|"Patients who must undergo a lung transplant at the FOCH hospital.
~Before and after transplantation, patients benefits of learning and realization sessions of complementary techniques:
~Relaxation,
~Hypnosis,
~Holistic gymnastics,
~Transcutaneous electrical nerve stimulation (TENS),
~Sophrology."
16518187|NCT03167515|Experimental|074-6751 Lotion|
16518188|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
16518189|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
16518190|NCT03167489|Experimental|Lifestyle Plus Emotional Regulation|The core intervention will last 5 months. Nutrition content: Mediterranean diet education, social support, self-regulation techniques, and environmental support. Physical activity content: education, guidance in starting a routine, and a walking program with pedometers, weekly physical activity tips and step goals. Emotion regulation content: based on Dialectical Behavior Therapy adapted to binge eating disorders and other ER sources, emphasizing identifying emotions, recognizing the causes of emotions, accepting and tolerating negative emotions, effective self-support and self-compassion, and the ability to manage situations that elicit negative emotions, as well as re-appraisal skills, which are identified as particularly influential on eating behaviors.
16518191|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
16518192|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
16518193|NCT03167463|Experimental|choanoplasty with flap|flap surgery
16518194|NCT03167450||Adults|Adults have sickle cell disease
16518195|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
16518196|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
16518200|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
16518201|NCT03167411|Experimental|Bexagliflozin alone|
16518202|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
16518203|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
16518204|NCT03167385|Experimental|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
16518205|NCT03167372|Experimental|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.
~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
16518206|NCT03167372|Active Comparator|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.
~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
16518207|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
16518208|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
16518209|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
16518210|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
16518281|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
16518211|NCT03167307|Experimental|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to <13 year olds, and 1000mg EPA / 500mg DHA in the 13 to <18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
16518212|NCT03167307|Placebo Comparator|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
16518213|NCT03167294|Other|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
16518214|NCT03167281|No Intervention|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
16518215|NCT03167281|Experimental|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
16518216|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
16518217|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
16518218|NCT03167255|Experimental|NS-065/NCNP-01 40mg/kg|Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
16518219|NCT03167255|Experimental|NS-065/NCNP-01 80mg/kg|Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
16518220|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day|Cohort 1
16518221|NCT03167242|Experimental|KAF156 800 mg and LUM-SDF 960 mg QD for 1 day|Cohort 2
16518222|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 2 days|Cohort 3
16518223|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 480 mg QD for 3 days|Cohort 4
16518224|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 480 mg QD for 3 days|Cohort 5
16518225|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 3 days|Cohort 6
16518226|NCT03167242|Active Comparator|Coartem twice a day (BID) for 3 days|Cohort 7
16518227|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day|PK Run-in Cohort
16518228|NCT03167216|Experimental|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
16518229|NCT03167203|Experimental|hESC-RPE cells|Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells
16518230|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
16518231|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
16518232|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:
~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
16518233|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:
~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
16518234|NCT03167151|Experimental|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 & D64.
~Dose to be decided after safety run-in."
16518235|NCT03167151|Active Comparator|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
16518236|NCT03167138|Experimental|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
16518237|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
16518238|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
16518239|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
16518240|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
16518241|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
16518242|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
16518243|NCT03167086|Experimental|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
16518244|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
16518245|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
16518280|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
16518246|NCT03167073|Experimental|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
16518247|NCT03167073|Placebo Comparator|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
16518248|NCT03167060|Active Comparator|Active Rhinochill|Intranasal cooling device , using nasal cannula
16518249|NCT03167060|Sham Comparator|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
16518250|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).
~Patients will also receive standardised pain relief of paracetamol and fentanyl"
16518251|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.
~Patients will also receive standardised pain relief of paracetamol and fentanyl"
16518252|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16518253|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16518254|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
16518255|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).
~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
16518256|NCT03167008||fertile male group|"total of 30 fertile male (as control)
~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).
~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
16518257|NCT03166995|Experimental|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
16518258|NCT03166995|Experimental|Experimental group 2|Postural exercises group. 1hour, twice a week
16518259|NCT03166995|No Intervention|Control propriocepcion|No exercise, just proprioceptive control.
16518260|NCT03166982|Experimental|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
16518261|NCT03166982|Experimental|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
16518262|NCT03166969|Experimental|Patients taken care in neurovascular unit|
16518263|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.
~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
16518264|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:
~Subjects in the C group received isocaloric maltodextrin as placebo."
16518265|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
16518266|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
16518267|NCT03166930|Experimental|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
16518268|NCT03166930|Active Comparator|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management.
16518269|NCT03166917|Experimental|3D printing implant|3D printing implant in bone defect
16518270|NCT03166917|Placebo Comparator|Autogenous bone grafting|autogenous bone grafting in bone defect
16518271|NCT03166904|Experimental|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
16518272|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
16518273|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
16518274|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
16518275|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
16518276|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
16518277|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
16518278|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
16518279|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
16518283|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
16518284|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
16518285|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
16518286|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
16518287|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
16518288|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
16518289|NCT03166761|Experimental|Dexamethasone|dexamethasone injected into the sacroiliac joint
16518290|NCT03166761|Active Comparator|Triamcinolone|triamcinolone injected into the sacroiliac joint
16518291|NCT03166748|Active Comparator|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
16518292|NCT03166748|Experimental|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
16518293|NCT03166735|Experimental|BI 1467335 dose 1|
16518294|NCT03166735|Experimental|BI 1467335 dose 2|
16518295|NCT03166735|Experimental|BI 1467335 dose 3|
16518296|NCT03166735|Experimental|BI 1467335 dose 4|
16518297|NCT03166735|Placebo Comparator|Placebo|
16518298|NCT03166722|Experimental|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
16518299|NCT03166722|Active Comparator|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
16518300|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
16518301|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
16518302|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
16518303|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
16518304|NCT03166683|Experimental|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
16518305|NCT03166683|Active Comparator|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
16518306|NCT03166670||study group|children with acute secretory diarrhea
16518307|NCT03166670||Control group|normal healthy children
16518308|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
16518309|NCT03166644|Experimental|Intervention Group|Patients with standard practice
16518310|NCT03166631|Experimental|Part A|BI 891065 alone (Solid Tumours)
16518311|NCT03166631|Experimental|Part B|BI 891065 in combination with BI 754091 (Solid Tumours)
16518312|NCT03166631|Experimental|Part C|BI 891065 in combination with BI 754091 (Non Small Cell Lung Cancer)
16518313|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
16518314|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
16518315|NCT03166605|No Intervention|Control|"First group: Control
~Follow the current standard protocol used at Albany Medical Center that includes:
~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids
~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.
~Return to clinic (RTC) 8 hours after to remove equipment
~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
16518316|NCT03166605|Sham Comparator|Sham|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing
~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids
~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.
~Return to clinic (RTC) 8 hours after to remove equipment
~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
16518317|NCT03166605|Experimental|Experiment|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing.
~Receive 3 ml simethicone 1 hours after capsule swallowing
~Receive 1.5 ml simethicone 2 hours after capsule swallowing
~Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids
~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.
~Return to clinic (RTC) 8 hours after to remove equipment
~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
16518318|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
16518319|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
16518320|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
16518321|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
16518322|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
16518323|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
16518324|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
16518325|NCT03166527|Other|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
16518326|NCT03166514|Experimental|Commercially Available Food Bar|62 g. Fitjoy Bar
16518327|NCT03166514|Placebo Comparator|Placebo|25 g. Dextrose
16518328|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
16518329|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
16518330|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
16518331|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
16518332|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
16518333|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
16518334|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
16518335|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
16518336|NCT03166449|Experimental|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
16518337|NCT03166449|Active Comparator|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
16518338|NCT03166436|Experimental|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
16518339|NCT03166436|Active Comparator|Stenting alone|Biliary stenting alone
16518340|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.
~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
16518341|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
16518342|NCT03166410|Experimental|Cell Treatment|
16518343|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..
~Preparation and administration of TIL
~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
16518344|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.
~interventions: 'conventional suture and tie'"
16518345|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
~interventions: electrosurgical bipolar sealing devices"
16518346|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
16518347|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
16518348|NCT03166358|Experimental|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
16518349|NCT03166358|No Intervention|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
16518350|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
16518351|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
16518352|NCT03166345|No Intervention|No intervention|The control arm.
16518353|NCT03166332|Active Comparator|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
16518354|NCT03166332|Active Comparator|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
16518355|NCT03166332|No Intervention|No intervention|No intervention strategy
16518356|NCT03166319|Experimental|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
16518357|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
16518358|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
16518359|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
16518360|NCT03166293|Experimental|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
16518361|NCT03166293|Experimental|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
16518362|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
16518363|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
16518364|NCT03166254|Experimental|Cohort A: Stage IV squamous NSCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)
~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations
~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination
~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
16518365|NCT03166254|Experimental|Cohort B: Extensive stage SCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)
~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations
~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination
~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
16518366|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
16518367|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
16518368|NCT03166228|Active Comparator|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
16518369|NCT03166228|Placebo Comparator|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
16518370|NCT03166215|Placebo Comparator|Part 1: Placebo|TAK-935 matching-placebo tablets, orally or through gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) from Days 1 to 30 in dose titration period.
16518371|NCT03166215|Experimental|Part 1: TAK-935|TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
16518372|NCT03166215|Experimental|Part 2: TAK-935|TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 31 to 40 followed by TAK-935 100 mg tablets x1, x2 or x3, orally or through G-tube/PEG tube, BID from Days 31 to Day 85 as per investigator's discretion in the maintenance period. At the end of Part 2, the dose of TAK-935 was de-escalated until discontinuation.
16518373|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
16518374|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
16518375|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
16518376|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
16518377|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
16518378|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
16518379|NCT03166137|Experimental|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
16518380|NCT03166137|Active Comparator|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
16518381|NCT03166124|Experimental|Elderly Adults LY900014|Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
16518382|NCT03166124|Active Comparator|Elderly Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
16518383|NCT03166124|Experimental|Younger Adults LY900014|Single, SC 15-U dose of LY900014 in the younger adult group.
16518384|NCT03166124|Active Comparator|Younger Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.
16518385|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
16518386|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
16518387|NCT03166098||Diagnosis of Schizophrenia|
16518388|NCT03166098||Diagnosis of Bipolar Disorder|
16518389|NCT03166098||Unaffected siblings of the SZ groups|
16518390|NCT03166098||Unaffected siblings of the BP group|
16518391|NCT03166098||Healthy control (HC) comparison group|
16518392|NCT03166085|Experimental|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
16518393|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
16518394|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
16518395|NCT03166059|Experimental|Single arm|CaveoVasc® Thrombolysis Protection System
16518396|NCT03166046|Active Comparator|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
16518397|NCT03166046|Placebo Comparator|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
16518398|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
16518399|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
16518400|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
16518401|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
16518402|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
16518403|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
16518405|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
16518406|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
16518407|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
16518408|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
16518409|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
16518410|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
16518411|NCT03165929|Placebo Comparator|placebo-free gingival graft|
16518412|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
16518413|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
16518414|NCT03165916|Experimental|Reconstruction with stent placement|Subjects will undergo biliary reconstruction with stent placement at the anastomosis site.
16518415|NCT03165916|No Intervention|Reconstruction without stent placement|Subjects will undergo biliary reconstruction without stent placement.
16519411|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
16518416|NCT03165903|Experimental|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
16518417|NCT03165903|Other|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
16518418|NCT03165890|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16518419|NCT03165890|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16518420|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
16518421|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
16518422|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
16518423|NCT03165864|Placebo Comparator|Placebo|Saline .9%
16518424|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
16518425|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
16518426|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
16518427|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
16518428|NCT03165825|Experimental|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
16518429|NCT03165825|Active Comparator|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
16518430|NCT03165812|Experimental|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
16518431|NCT03165812|Experimental|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
16518432|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
16518433|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
16518434|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
16518435|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
16518436|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
16518437|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
16518438|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
16518439|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
16518440|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
16518441|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
16518442|NCT03165734|Experimental|Pacritinib 200 mg BID|To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food
16518443|NCT03165734|Active Comparator|Physician's Choice (P/C) therapy|The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.
16518444|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/Wild-Type GIST|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle
~Gastrointestinal stromal tumor (GIST)"
16518445|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle
~Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE"
16518446|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle
~Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca"
16518447|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
16518448|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
16534421|NCT03055936|Experimental|A2|levodopa 100 mg, carbidopa 25 mg
16518449|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
16518450|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
16518451|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
16518452|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
16518453|NCT03165669|Experimental|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.
~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
16518454|NCT03165669|Active Comparator|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
16518455|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
16518456|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
16518457|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
16518458|NCT03165643||NGT-normal birth weight|
16518459|NCT03165643||NGT-macrosomia|
16518460|NCT03165643||GDM-normal birth weight|
16518461|NCT03165643||GDM-macrosomia|
16518462|NCT03165630|No Intervention|Group 1|Education or Control group.
16518463|NCT03165630|Experimental|Group 2|Transportation incentives
16518464|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
16518465|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
16518466|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
16518467|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
16518468|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
16518469|NCT03165591|Experimental|Experimental|Daily tablet of V3-P given orally for 2 months
16518470|NCT03165578|Experimental|Neurofeedback|Neurofeedback training.
16518471|NCT03165578|Sham Comparator|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
16518472|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
16518473|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
16518474|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
16518475|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
16518476|NCT03165526||First Cohort|All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
16518477|NCT03165526||Second Cohort|"This cohort will consist of subjects over the age of 18 years who have previously been successfully implanted with the PIVSD Occluder and
~For living subjects, the subject or subject's legally authorized representative has provided consent to participate in this study.
~Subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.
~Therefore, this cohort will be composed of retrospectively enrolled subjects. This cohort will be utilized to determine acute and chronic closure and chronic survival."
16518478|NCT03165513|Experimental|Experimental arm|mhGAP-IG psychosocial intervention
16518479|NCT03165500|Active Comparator|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
16518480|NCT03165500|Active Comparator|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
16518481|NCT03165500|Active Comparator|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
16518482|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
16518483|NCT03165487||Triple Negative Breast Cancer|triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
16518484|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
16519412|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
16518485|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
16518486|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
16518487|NCT03165435|Experimental|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
16518488|NCT03165435|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
16518489|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
16518490|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
16518491|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
16518492|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
16518493|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
16518494|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
16518495|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
16518496|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
16518497|NCT03165357|Experimental|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
~Interventions:
~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
16518498|NCT03165357|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).
~Interventions:
~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
16518499|NCT03165344|Experimental|hydrocortisone group|
16518500|NCT03165344|Placebo Comparator|prednisone grope|
16518501|NCT03165331|Other|Intervention group|The intervention group will go through the intervention programme (Ung Face IT) after T1 and randomisation. Programme takes 7 weeks to complete + Treatment as usual (local health care services). Questionnaires after the 7 weeks (T2) and after three months (T3) and 6 months (T4).
16518502|NCT03165331|Other|Control group|Treatment as usual for three months after T1 and randomisation, with local health care support if needed. Questionnaires at T2 and T3 before participants are given access to the intervention (Ung Face IT) after three months. Questionnaire at T4 (post-intervention).
16518503|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
16518504|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
16518505|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
16518506|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
16518507|NCT03165292|Experimental|Arm A: High administered activity 131I-mIBG radiolabelled with iodine-131 and Topotecan|"The trial will evaluate two randomised arms. Each arm includes
~three cycles of Temozolomide-Irinotecan, similar in both arms,
~a specific consolidation course detailed hereinafter,
~a BuMel sequence, followed by an ASCT, similar in both arms,
~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
16518508|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes
~three cycles of Temozolomide-Irinotecan, similar in both arms,
~a specific consolidation course detailed hereinafter,
~a BuMel sequence, followed by an ASCT, similar in both arms,
~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
16518509|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
16518510|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
16518511|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
16518512|NCT03165240|Experimental|BI 690517 Dose 1|
16518513|NCT03165240|Experimental|BI 690517 Dose 2|
16518514|NCT03165240|Experimental|BI 690517 Dose 3|
16518523|NCT03165175|Experimental|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
16518524|NCT03165175|No Intervention|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
16518525|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
16518526|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
16518527|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
16518528|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
16518529|NCT03165136|Experimental|Hydroxychloroquine|The treatment will be orally administrated, at a daily dose of 400 mg of hydroxychloroquine . The treatment will be started before conception and will be stopped at the end of the tenth week of gestation or before in case of pregnancy loss.
16518530|NCT03165136|Placebo Comparator|Placebo|A similar placebo will be orally administrated every day.
16518531|NCT03165123|Placebo Comparator|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
16518532|NCT03165123|Active Comparator|Azithromycin group|The patients will receive 250 mg oral Azithromycin tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
16518533|NCT03165110|Experimental|Users of the Onyx Blood Glucose Meter/ app System at home|Participants have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin.
16518534|NCT03165097|Experimental|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.
~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
16518535|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
16518536|NCT03165097|Other|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
16518537|NCT03165097|Experimental|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
16518538|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
16518539|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
16518540|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
16518541|NCT03165071|Experimental|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
16518542|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
16518543|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
16518544|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
16518545|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
16518546|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
16518547|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
16518548|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
16518549|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
16518550|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
16518551|NCT03165006||Screened women with breast cancer|
16518552|NCT03164993|Placebo Comparator|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
16518553|NCT03164993|Active Comparator|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
16518554|NCT03164980|Experimental|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
16518555|NCT03164980|Experimental|Arm B|"Carboplatin/PLD
~Carboplatin/Gemcitabine
~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
16518556|NCT03164967|Other|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
16518557|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
16518558|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
16518559|NCT03164928|Other|Placebo|SC Q6M placebo
16518560|NCT03164928|Experimental|Denosumab|1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
16518561|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
16518562|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
16518563|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
16518564|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
16519413|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
16518567|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
16518568|NCT03164811|Experimental|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV >13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
16518569|NCT03164811|Other|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
16518570|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.
~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
16518571|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
16518572|NCT03164772|Experimental|Arm A|The run-in dose evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (including subjects from the run-in).
16518573|NCT03164772|Experimental|Arm B|The run-in dose evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (including subjects from the run-in).
16518574|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
16518575|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
16518576|NCT03164733||<40|patients younger than 40 years
16518577|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
16518578|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
16518579|NCT03164733||>80|patients older than 80 years
16518580|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
16518581|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
16518582|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
16518583|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
16518584|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
16518585|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
16518586|NCT03164655|Experimental|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"HAI oxaliplatin 100 mg/m² on D1
~I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT
~modified FOLFIRI regimen without fluorouracil bolus
~I.V. irinotecan 180 mg/m² D1
~I.V. bolus 5-Fluorouracil (5-FU): 0
~I.V. leucovorin 400 mg/m² in 2 hours D1
~I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours"
16518587|NCT03164655|Active Comparator|conventional systemic CT|"Response to systemic induction CT
~Toxicity and duration of the systemic induction CT
~RAS status
~Current guidelines/standard of care"
16518588|NCT03164642|Experimental|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
16518589|NCT03164642|Placebo Comparator|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
16518590|NCT03164629|Experimental|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
16518591|NCT03164629|Active Comparator|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
16518595|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
16518596|NCT03164590|Active Comparator|ketamine|
16518597|NCT03164590|Active Comparator|dexmedetomidine|
16518598|NCT03164590|Placebo Comparator|bupivacaine|
16518659|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
16519414|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
16518599|NCT03164577|Active Comparator|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
16518600|NCT03164577|Placebo Comparator|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
16518601|NCT03164564|Experimental|Arm A: CAB + Placebo TDF/FTC + CAB LA|During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
16518602|NCT03164564|Active Comparator|Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA|During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
16518603|NCT03164551|Active Comparator|GERI+ Incubator|
16518604|NCT03164551|Other|Conventional incubator|
16518605|NCT03164538|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
16518606|NCT03164538|Active Comparator|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
16518607|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
16518608|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
16518609|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
16518610|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
16518611|NCT03164499|Active Comparator|Control group|Individual counselling on lifestyles.
16518612|NCT03164499|Experimental|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
16518613|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
16518614|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
~plus orally placebo-azathioprine for 24 months"
16518615|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months
~plus 4 placebo-rituximab infusions given every 6 months for 18 months"
16518616|NCT03164460|Experimental|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
16518617|NCT03164460|Experimental|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
16518618|NCT03164447|Experimental|Multi-Drug Resistant|
16518619|NCT03164421|Experimental|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
16518620|NCT03164421|Active Comparator|L-carnitine|L-carnitine used by clomiphene resistant pcos women
16518621|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
16518622|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
16518623|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
16518624|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
16518625|NCT03164356|No Intervention|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
16518626|NCT03164356|Experimental|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
16518627|NCT03164356|No Intervention|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
16518628|NCT03164343|Experimental|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
16518629|NCT03164330|No Intervention|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
16518630|NCT03164330|Experimental|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
16518631|NCT03164330|Experimental|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
16518632|NCT03164330|Experimental|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
16518633|NCT03164330|Experimental|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
16518634|NCT03164330|Experimental|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
16518635|NCT03164330|Experimental|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
16518636|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
16518637|NCT03164317|Other|Control|No trained NCC and electronic decision support system
16518638|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
16518639|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
16518640|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
16518641|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
16518642|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
16518643|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
16518644|NCT03164252|Active Comparator|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
16518645|NCT03164252|Active Comparator|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
16518646|NCT03164252|Placebo Comparator|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
16518647|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
16518648|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
16518649|NCT03164226|Other|Patient consulting for chest Pain in ED|Any patient ≥ 30 years consulting for chest pain in the emergency department from 8:00 am to 8:00 pm (for the unavailability of the endopat device during the guard).
16518650|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
16518651|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
16518652|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
16518653|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
16518654|NCT03164187||Diabeton MR 60|
16518655|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
16518656|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
16518657|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
16518658|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
16519415|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
16518660|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
16518661|NCT03164122|Experimental|Intra-articular injection|
16518662|NCT03164109|Experimental|GC4419 IV|
16518663|NCT03164109|Placebo Comparator|Placebo|
16518664|NCT03164109|Active Comparator|Oral moxifloxacin|
16518665|NCT03164096|Experimental|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
16518666|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
16518667|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
16518668|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
16518669|NCT03164070||Control group|Control group of healthy persons
16518670|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA"|"Part 1 Tolerability with AZA - Low Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive low-risk intensifications I & II without azacitidine.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA."
16518671|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA"|"Part 1 Tolerability with DAC - Low Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive low-risk Intensifications I & II without decitabine.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
16518672|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | AZA+AE+Sor | AZA+MA+Sor"|"Part 2 Dose Expansion with AZA - Low Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and low- risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
16518673|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | DAC+AE+Sor|DAC+MA+Sor"|"Part 2 Dose Expansion with DAC - Low Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and low-risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
16518674|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with AZA - Intermediate Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive intermediate risk Intensifications I, II & III without azacitidine.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA,"
16518675|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with DAC - Intermediate Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive intermediate-risk Intensifications I, II & III without decitabine.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
16518676|NCT03164057|Experimental|"AZA| +ADE | +FLAG+Ida+Sor| +AE+Sor| +MA+Sor| +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - Intermediate-Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and intermediate-risk Intensification I, II, and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
16518677|NCT03164057|Experimental|"DAC|+ADE | +FLAG+Ida+Sor | +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - Intermediate-Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and intermediate-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
16518678|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I & II and high-risk intensifications I, II & III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
16518679|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I, II & III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
16518680|NCT03164057|Experimental|"AZA | + ADE | +FLAG+Ida+Sor| +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
16518704|NCT03163940|No Intervention|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
16518705|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
16518681|NCT03164057|Experimental|"DAC |+ADE |+FLAG+Ida+Sor |+AE+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
16518682|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA- High Risk (with donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
16518683|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (with donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
16518684|NCT03164057|Experimental|"DAC |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (with donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
16518685|NCT03164057|Experimental|"AZA |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (with donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensification I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
16518686|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
16518687|NCT03164031|Experimental|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
16518688|NCT03164031|Active Comparator|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
16518689|NCT03164005||Group 1|subjects without metabolic diseases
16518690|NCT03164005||Group 2|subjects with metabolic diseases
16518691|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
16518692|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
16518693|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:
~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
16518694|NCT03163979|Active Comparator|RapidArc|"RapidArc:
~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
16518695|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
16518696|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
16518697|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
16518698|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
16518699|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
16518700|NCT03163953|Experimental|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
16518701|NCT03163953|Experimental|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
16518702|NCT03163953|Other|Control|No intervention
16518703|NCT03163940|Experimental|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
16518706|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
16534422|NCT03055936|Experimental|B2|levodopa 100 mg, carbidopa 65 mg
16518708|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
16518709|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
16518710|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
16518711|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
16518712|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
16518713|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
16518714|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
16518715|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
16518716|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
16518717|NCT03163862|Placebo Comparator|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
16518718|NCT03163862|Experimental|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.
~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
16518719|NCT03163862|Sham Comparator|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
16518720|NCT03163849|Placebo Comparator|control group|oral tablets
16518721|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
16518722|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
16518723|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
16518724|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
16518725|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
16518726|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.
~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
16518727|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
16518728|NCT03163784|Placebo Comparator|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
16518729|NCT03163784|Experimental|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
16518730|NCT03163784|Experimental|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
16518731|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
16518732|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
16518733|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:
~Full medical History and physical examination
~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration
~Abdominal Ultrasound
~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
16518734|NCT03163732|Other|Large molecular profiling panel|This panel is FOne Panel with a 324 cancer-related gene.
16518735|NCT03163732|Other|Limited molecular profiling panel|This panel is CONTROL Panel with a 87 cancer-related gene.
16519416|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
16518736|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
16518737|NCT03163706|Experimental|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
16518738|NCT03163706|Other|Control group|Control, no schizophrenia
16518739|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
16518740|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
16518741|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
16518742|NCT03163667|Active Comparator|CB-839 plus everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
16518743|NCT03163667|Placebo Comparator|Placebo plus everolimus|Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
16518744|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
16518745|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
16518746|NCT03163641|Experimental|Treatment 1|Ocular Bandage Gel
16518747|NCT03163641|Experimental|Treatment 2|Ocular Bandage Gel
16518748|NCT03163641|Active Comparator|Control Group|Artificial tears with Acuvue Oasys
16518749|NCT03163628|Experimental|7 biomarkers combination|
16518750|NCT03163615|Experimental|Tibet Rhodiola Capsule|
16518751|NCT03163615|Placebo Comparator|Placebo oral capsule|
16518752|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
16518753|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
16518754|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
16518755|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
16518756|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
16518757|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
16518758|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
16518759|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
16518760|NCT03163550|Experimental|Cohort 1|Healthy volunteers
16518761|NCT03163550|Experimental|Cohort 2|Healthy volunteers
16518762|NCT03163550|Experimental|Cohort 3|Healthy volunteers
16518763|NCT03163550|Experimental|Cohort 4|Healthy volunteers
16518764|NCT03163550|Experimental|Cohort 5|Healthy volunteers
16518765|NCT03163537||Kidney transplantation, postmortal, day|
16518766|NCT03163537||Kidney transplantation, postmortal, night|
16518767|NCT03163537||Kidney transplantation, living donor|
16518768|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
16518769|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
16518770|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
16518771|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
16518772|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
16518773|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
16518774|NCT03163485|Experimental|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
16518775|NCT03163485|Other|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
16518776|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
16518777|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
16518778|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
16518812|NCT03163160|Experimental|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
16518813|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
16518814|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
16518779|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
16518780|NCT03163446|Experimental|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
16518781|NCT03163446|Placebo Comparator|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
16518782|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
16518783|NCT03163433|No Intervention|Control|Usual consultations
16518784|NCT03163420|Placebo Comparator|Placebo|placebo
16518785|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
16518786|NCT03163407|Active Comparator|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
16518787|NCT03163407|Active Comparator|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
16518788|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
16518789|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
16518790|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
16518791|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
16518792|NCT03163342|Other|Open label|Licensed seasonal influenza vaccine, intramuscular
16518793|NCT03163329|Experimental|TAVR group|
16518794|NCT03163329|Active Comparator|SAVR group|
16518795|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
16518796|NCT03163303|Experimental|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
16518797|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
16518798|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
16518799|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
16518800|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
16518801|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
16518802|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
16518803|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
16518804|NCT03163251|Experimental|READ-SG Cohort|Each post-graduate year (PGY) will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
16518805|NCT03163238|Active Comparator|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
16518806|NCT03163238|Placebo Comparator|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
16518807|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
16518808|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
16518809|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
16518810|NCT03163173|Experimental|Single Arm - Treatment Group|30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
16518811|NCT03163160|Experimental|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
16518832|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
16518815|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.
~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
16518816|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.
~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
16518817|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.
~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
16518818|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
16518819|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
16518820|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
16518821|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
16518822|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
16518823|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
16518824|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
16518825|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
16518826|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
16518827|NCT03163082|Active Comparator|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
16518828|NCT03163082|Active Comparator|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
16518829|NCT03163082|Active Comparator|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
16518830|NCT03163082|Active Comparator|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
16518831|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
16518833|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
16518834|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
16518835|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
16518836|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
16518837|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
16518838|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
16518839|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
16518840|NCT03163004|Experimental|Intervention group|Implementation of standing desks in the classroom
16518841|NCT03163004|No Intervention|Control group|
16518842|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
16518843|NCT03162991|No Intervention|12-Week Control Period|
16518844|NCT03162978|Experimental|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
16518845|NCT03162978|Experimental|HIIT only|High-intensity interval training (HIIT) only.
16518846|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
16518847|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
16518848|NCT03162926|Experimental|Single-group|Up to six (6) VC-02-20 implants
16518849|NCT03162913|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
16518850|NCT03162913|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
16518851|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
16518852|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
16518853|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
16518854|NCT03162874|Placebo Comparator|PLACEBO|
16518855|NCT03162874|Experimental|PXT002331 - 10mg|
16518856|NCT03162874|Experimental|PXT002331 - 30mg|
16518857|NCT03162861|Experimental|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
16518858|NCT03162861|Experimental|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
16518859|NCT03162848|Experimental|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
16518860|NCT03162848|No Intervention|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
16518861|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
16518862|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
16518863|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
16518864|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
16518924|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
16518865|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
16518866|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
16518867|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
16518868|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
16518869|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
16518870|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
16518871|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.1%)|
16518872|NCT03162783|Experimental|ADX-102 Ophthalmic Lipid Solution (0.5%)|
16518873|NCT03162770|Experimental|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
16518874|NCT03162770|No Intervention|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
16518875|NCT03162757|Experimental|Subclavian vein access|
16518876|NCT03162757|Experimental|Internal jugular vein access|
16518877|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
16518878|NCT03162731|Experimental|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over at least 30 minutes every 2 weeks and ipilimumab IV over at least 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
16518879|NCT03162718|Other|single arm|exercise
16518880|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
16518881|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
16518882|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
16518883|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
16518884|NCT03162640||P|for cannabis
16518885|NCT03162640||C|for the control group
16518886|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.
~When maximum tolerated dose reached, Dose Expansion Phase begins."
16518887|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
16518888|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
16518889|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
16518890|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
16518891|NCT03162614|Active Comparator|AduFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
16518892|NCT03162614|Experimental|2PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
16518893|NCT03162614|Experimental|PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
16518894|NCT03162614|Experimental|Adu2Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
16518895|NCT03162614|Active Comparator|Adu1Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
16518896|NCT03162614|Other|Control Group|Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
16518897|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
16535464|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
16518898|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
16518899|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
16518900|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
16518901|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
16518902|NCT03162549||Inflammatory Bowel Disease|Pts presenting to enrolling sites across the US are invited to enroll if eligible
16518903|NCT03162536|Experimental|Phase 1: Dose Escalation and Determination of RP2D|Phase I: Dose Escalation and determination of RP2D, multiple dose levels of nemtabrutinib to be evaluated (Up to approximately 22 months).
16518904|NCT03162536|Experimental|Phase 2: Expansion Cohort A|Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) participants with at least 2 prior systemic therapies and previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who must have a documented BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until progressive disease (PD), unacceptable adverse events (AEs), or discontinuation at investigator's discretion (up to approximately 40 months).
16518905|NCT03162536|Experimental|Phase 2: Expansion Cohort B|R/R CLL/SLL participants who have failed or were intolerant to a BTKi with documentation of the absence of BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518906|NCT03162536|Experimental|Phase 2: Expansion Cohort C|Richter's transformation (RT) participants who have failed at least one prior therapy receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518907|NCT03162536|Experimental|Phase 2: Expansion Cohort D|Follicular Lymphoma (FL) participants who have failed at least 2 prior systemic therapies and are histology grade 1, 2, or 3A receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518908|NCT03162536|Experimental|Phase 2: Expansion Cohort E|Mantle Cell Lymphoma (MCL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518909|NCT03162536|Experimental|Phase 2: Expansion Cohort F|Marginal Zone Lymphoma (MZL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518910|NCT03162536|Experimental|Phase 2: Expansion Cohort G|High-grade B-cell lymphoma (BCL) participants who have failed at least 2 prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations confirmed by flourescence in situ hybridization (FISH) or overexpression by immunohistochemistry (IHC) receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518911|NCT03162536|Experimental|Phase 2: Expansion Cohort H|Waldenström macroglobulinemia (WM) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518912|NCT03162536|Experimental|Phase 2: Expansion Food Effect Cohort I|B-cell Non-Hodgkin's lymphoma (NHL), CLL/SLL and WM participants receive up to 65 mg of nemtabrutinib fasted (1 hour prior to or 2 hours after meal) and non-fasted per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
16518913|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
16518914|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
16518915|NCT03162510|Experimental|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
16518916|NCT03162497|Experimental|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
16518917|NCT03162497|Active Comparator|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
16518918|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
16518919|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
16518920|NCT03162458|Experimental|Anaferon for children|
16518921|NCT03162458|Placebo Comparator|Placebo|
16518922|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
16518923|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
16535528|NCT03048396|Experimental|Uterus transplantation|
16518925|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
16518926|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
16518927|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
16518928|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
16518929|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
16518930|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
16518931|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
16518932|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
16518933|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
16518934|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
16518935|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
16518936|NCT03162367|Experimental|Autologous epidermal cell suspension group|
16518937|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
16518938|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
16518939|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
16518940|NCT03162341|Experimental|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.
~Those are interventions that are not part of the standard care of the patients."
16518941|NCT03162328|Placebo Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
16518942|NCT03162328|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
16518943|NCT03162315|No Intervention|Fresh embryo transfer|fresh embryo transfer (standard of care)
16518944|NCT03162315|Experimental|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
16518945|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
16518946|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
16518947|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
16518948|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
16518949|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
16518950|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
16518951|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
16518952|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
16518953|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
16519079|NCT03161314|Experimental|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
16518954|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
16518955|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
16518956|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
16518957|NCT03162237|Experimental|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg
16518958|NCT03162237|Active Comparator|AutologousTreg|Autologous Treg:2x10^6/Kg
16518959|NCT03162224|Experimental|HPV associated recurrent/metastatic HNSCC|Approximately 50 patients with HPV associated recurrent/metastatic HNSCC
16518960|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
16518961|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
16518962|NCT03162198||Cirrhosis with HCC|
16518963|NCT03162198||Cirrhosis without HCC|
16518964|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
16518965|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
16518966|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
16518967|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
16518968|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
16518969|NCT03162133|Experimental|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
16518970|NCT03162133|Experimental|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.
~After their post-assessment they were able to attend the Baduanjin classes."
16518971|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
16518972|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
16518973|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days
~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
16518974|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days
~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
16518975|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days
~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
16518976|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates
~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
16518977|NCT03162081||Non-users|"Age and gender matched controls not using the above
~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
16518978|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients
~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
16518979|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
16518980|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
16518981|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
16518982|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
16518983|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
16535836|NCT03046199|Experimental|Questionnaire + coordination|
16518984|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
16518985|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
16518986|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
16518987|NCT03162029||control group|CBCT imaging of medically-free participants
16518988|NCT03162016|Experimental|Transplants of acellular matrix|
16518989|NCT03162016|Active Comparator|Transplants of connective tissue|
16518990|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
16518991|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
16518992|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
16518993|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
16518994|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
16518995|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
16518996|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
16518997|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
16518998|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
16518999|NCT03161951||Control group|Control group of healthy persons
16519000|NCT03161938|Active Comparator|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
16519001|NCT03161938|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
16519002|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
16519003|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
16519004|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
16519005|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
16519006|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
16519007|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
16519008|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
16519009|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
16519010|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
16519011|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
16519012|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
16519013|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
16519014|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
16519015|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
16519016|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
16519017|NCT03161756|Experimental|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
16519018|NCT03161756|Experimental|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
16519019|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
16519020|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
16519021|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
16519022|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
16519023|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
16519024|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
16519025|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
16519026|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
16519027|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
16519028|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
16519029|NCT03161652|Placebo Comparator|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
16519030|NCT03161652|Experimental|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
16519031|NCT03161652|Placebo Comparator|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
16519032|NCT03161652|Experimental|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
16519033|NCT03161652|Placebo Comparator|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
16519034|NCT03161652|Experimental|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
16519035|NCT03161652|Placebo Comparator|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
16519036|NCT03161652|Experimental|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
16519037|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
16519038|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
16519039|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
16519040|NCT03161626||Moderate to Severe Factor X Deficiency|
16519041|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
16519042|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
16519043|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
16519044|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
16519045|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
16519046|NCT03161535|Experimental|exercise group|The rehabilitation program was composed of two parts: an exercise program and a diet-teaching program. The exercise program was a 12-week home-based program that comprised moderate-intensity brisk walking for 40 min per session, with 3 sessions per week; in addition, weekly exercise counseling was provided through telephone. The diet teaching program was provided to the patients by using a diet booklet at baseline (same timing as the exercise program), and its contents were used to instruct the patients regarding dietary principles to be followed.
16519047|NCT03161535|No Intervention|usual-care group|The control group (CG) received usual care, whereas a nurse, the manager for esophageal cancer treatment, provided routine care, conducted follow-ups, and offered information on esophageal cancer to the experimental group (EG).
16519048|NCT03161522|Experimental|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
16519049|NCT03161522|Experimental|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
16519050|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
16519051|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
16519052|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
16519053|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
16519054|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)
~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)
~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
16519167|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
16519055|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)
~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)
~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
16519056|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)
~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)
~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
16519057|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
16519058|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
16519059|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
16519060|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
16519061|NCT03161457|Experimental|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
16519062|NCT03161457|Active Comparator|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
16519063|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
16519064|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
16519065|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
16519066|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
16519067|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
16519068|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
16519069|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
16519070|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
16519071|NCT03161379|Experimental|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
16519072|NCT03161366|Experimental|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
16519073|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):
~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles
~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
16519074|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.
~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.
~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.
~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
16519075|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
16519076|NCT03161340|Experimental|Treatment group|Rapamycin group
16519077|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
16519078|NCT03161327|Other|ABI|ABI will be performed in patient
16539776|NCT03019263|Active Comparator|Control|Nutritional counseling
16519080|NCT03161314|Active Comparator|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
16519081|NCT03161301||Group 1|IL-37 genotype 1.1
16519082|NCT03161301||Group 2|IL-37 genotype 1.2
16519083|NCT03161301||Group 3|IL-37 genotype 2.2
16519084|NCT03161288|Experimental|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
16519085|NCT03161288|Experimental|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
16519086|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
16519087|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
16519088|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
16519089|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
16519090|NCT03161249|Experimental|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
16519091|NCT03161249|Other|Control group|"Control group: Treatment as usual
~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
16519092|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
16519093|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
16519094|NCT03161223|Other|A: Oral 5-azacitidine, durvalumab, romidepsin|Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
16519095|NCT03161223|Other|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
16519096|NCT03161223|Other|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
16519097|NCT03161223|Other|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
16519098|NCT03161210|Experimental|Dextrose Prolotherapy|
16519099|NCT03161210|Active Comparator|Local Anaesthetic|
16519100|NCT03161210|Placebo Comparator|Saline|
16519101|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
16519102|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
16519103|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:
~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling
~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
16519104|NCT03161158|Active Comparator|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
16519105|NCT03161158|Other|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
16519106|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
16519107|NCT03161132|Experimental|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
16519108|NCT03161132|Other|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
16541774|NCT03006276|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
16519109|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
16519110|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
16519111|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
16519112|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
16519113|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
16519114|NCT03161093|Experimental|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
16519115|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
16519116|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
16519117|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
16519118|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
16519119|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
16519120|NCT03161067|Experimental|Surgical implantation of BiCNS|
16519121|NCT03161054|Experimental|One arm for all patient|"Induction phase:
~Eligible Pts will receive 6 cycles (every 28 days) of the DEVEC combination: DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and R:Rituximab ; R will be administered only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of R will not repeat it during the metronomic therapy.
~Super-frail patients will not receive etoposide during cycles 1 and 2.
~Maintenance Phase:
~Pts in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.
~Post Maintenance Phase:
~Pts in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance"
16519122|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
16519123|NCT03161028|Experimental|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
16519124|NCT03161028|Placebo Comparator|Arm 2: Placebo|59 subjects receive placebo daily
16519125|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
16519126|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
16519127|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
16519128|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
16519129|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
16519130|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
16519131|NCT03160989|Experimental|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
16519132|NCT03160976|No Intervention|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
16519133|NCT03160976|Active Comparator|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
16519134|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
16519135|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
16519136|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
16519137|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
16519138|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
16519139|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
16519140|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
16519141|NCT03160950|Experimental|LuxaCrown|
16519142|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
16519143|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
16519168|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
16519169|NCT03160794|Experimental|[18F] DCFPyL PET/MRI|"[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.
~Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery."
16519170|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
16519171|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
16519172|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
16519173|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
16519144|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.
~Preoperative counselling by surgeon, dietician and physiotherapist
~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)
~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics
~Avoid use of drains
~Early resumption of diet
~Early mobilisation with physiotherapist
~Dietary counselling by dietician
~Early discharge if fulfil discharge criteria.
~Discharge criteria:
~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization
~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
16519145|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.
~No preoperative counselling
~No Preoperative carbohydrate-loaded drink
~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.
~Routine use of drains
~Diet will be resumed when there is flatus clinically
~Mobilisation as per patient's wish
~Dietary counselling by dietician
~Discharge if fulfil discharge criteria.
~Discharge criteria:
~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization
~Patients will be seen in clinic on post-operative D14."
16519146|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
16519147|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
16519148|NCT03160898|Experimental|Reldesemtiv 150 mg twice daily|Patients in this arm took 1 reldesemtiv 150 mg oral tablet and 2 matching placebo tablets every 12 hours for 12 weeks.
16519149|NCT03160898|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm took 2 reldesemtiv 150 mg oral tablets and 1 matching placebo tablet every 12 hours for 12 weeks.
16519150|NCT03160898|Experimental|Reldesemtiv 450 mg twice daily|Patients in this arm took 3 reldesemtiv 150 mg oral tablets every 12 hours for 12 weeks.
16519151|NCT03160898|Placebo Comparator|Placebo|Patients in this arm took 3 placebo oral tablets every 12 hours for 12 weeks.
16519152|NCT03160885|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16
~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
16519153|NCT03160885|Placebo Comparator|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):
~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
16519154|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
16519155|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.
~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
16519156|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52
~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
16519157|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52
~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
16519158|NCT03160885|Experimental|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52
~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W
~OR
~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W
~• TCS = topical corticosteroids"
16519159|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
16519160|NCT03160859|Other|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
16519161|NCT03160859|Other|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
16519162|NCT03160833|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
16519163|NCT03160820|Other|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
16519164|NCT03160820|Other|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
16519165|NCT03160820|Other|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
16519166|NCT03160820|Other|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
16519176|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
16519177|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
16519178|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
16519179|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
16519180|NCT03160677|Experimental|Intensive blood pressure management|
16519181|NCT03160677|Active Comparator|Standard blood pressure management|
16519182|NCT03160664|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
16519183|NCT03160664|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
16519184|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
16519185|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
16519186|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
16519187|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
16519188|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
16519189|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
16519190|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
16519191|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
16519192|NCT03160599|Experimental|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.
~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
16519193|NCT03160586|Active Comparator|Stutter|Children who stuttering
16519194|NCT03160586|Active Comparator|Control|Children who non stuttering
16519195|NCT03160573|Active Comparator|Test-Unflavored Rinse then Placebo Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
16519196|NCT03160573|Active Comparator|Test-Flavored Rinse then Placebo Flavored Rinse|Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
16519197|NCT03160573|Placebo Comparator|Flavored Oral Rinse-Placebo then Test-Flavored Rinse|Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
16519198|NCT03160573|Placebo Comparator|Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
16519199|NCT03160560|Active Comparator|Test-Unflavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.
16519200|NCT03160560|Active Comparator|Test-Flavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.
16519201|NCT03160560|Placebo Comparator|Placebo|CloSYS Oral Rinse product (no chlorine dioxide)
16519202|NCT03160547|Active Comparator|Usual Protein/Amino Acid Group|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
16519203|NCT03160547|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
16519204|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
16519205|NCT03160534|No Intervention|Control|Only measurements
16519206|NCT03160521|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
16519207|NCT03160521|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
16519208|NCT03160521|Placebo Comparator|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
16519209|NCT03160482||Papillary carcinoma, classical variant|
16519210|NCT03160482||Follicular carcinoma|
16519211|NCT03160482||Colloid nodule|
16519212|NCT03160482||Hyperplastic nodule|
16519213|NCT03160482||Adenomatoid nodule|
16519214|NCT03160482||Follicular adenoma|
16519215|NCT03160482||Papillary carcinoma, follicular variant|
16519216|NCT03160482||Medullary carcinoma|
16519217|NCT03160482||Lymphocytic thyroiditis|
16519218|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
16519374|NCT03159312|Experimental|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
16519219|NCT03160456|Experimental|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
16519220|NCT03160456|Active Comparator|Continuous positive airway pressure|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography and the initial assessment will be repeated.
16519221|NCT03160443|Other|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.
~All of them are patients with an eating disorder."
16519222|NCT03160430|Experimental|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
16519223|NCT03160430|Placebo Comparator|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
16519224|NCT03160430|Placebo Comparator|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
16519225|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
16519226|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
16519227|NCT03160391|Experimental|Music Training|Music Training
16519228|NCT03160391|Active Comparator|Dance Training|Dance Training
16519229|NCT03160391|No Intervention|Passive control group|Passive control group
16519230|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
16519231|NCT03160378|Other|Control|Control participants will receive treatment as usual.
16519232|NCT03160365|Other|ACQUISITION OF IMAGES|4 MRIs were performed at Day 0, day 1, day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
16519233|NCT03160352|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
16519234|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
16519235|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
16519236|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
16519237|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
16519238|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
16519239|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
16519240|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
16519241|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
16519242|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
16519243|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
16519247|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
16519248|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
16519249|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
16519250|NCT03160196|Experimental|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
16519272|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
16519251|NCT03160196|Active Comparator|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
16519252|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
16519253|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
16519254|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.
~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
16519255|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.
~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
16519256|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
16519257|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
16519258|NCT03160131|Active Comparator|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
16519259|NCT03160131|No Intervention|Control|All participants receive no NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
16519260|NCT03160118|Other|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
16519261|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
16519262|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
16519263|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
16519264|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
16519265|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).
~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).
~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.
~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
16519266|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|
16519267|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
16519268|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
16519269|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
16519270|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
16519271|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
16519341|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
16541922|NCT03005379|Active Comparator|1|Fecal Microbiota Therapy (FMT)
16519273|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
16519274|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
16519275|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
16519276|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
16519277|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
16519278|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
16519279|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
16519280|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
16519281|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
16519282|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
16519283|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
16519284|NCT03159962|Active Comparator|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
16519285|NCT03159962|Active Comparator|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
16519286|NCT03159962|No Intervention|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
16519287|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
16519288|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
16519289|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
16519290|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
16519291|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
16519292|NCT03159897|Experimental|Comparator arm|Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (<PR) or Progressive Disease. ISRT 30 Gy will be delivered to complete responders (5PS score 1-2-3) on the initial bulky site(s), to focal rests in case of CR scoring 3 on 5PS with a residual size ≥ 2.5 cm and to focal rests uptakes in the event of PR scoring 4 or 5, whichever is the size.
16519293|NCT03159897|Experimental|Experimental arm|Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. ISRT 30 Gy will be delivered to responder patients (DS=3), on focal PET-positive rests with a residual size ≥ 2.5 cm and on patients in PR with uptake scoring 4 or 5, whichever is the size.
16519294|NCT03159884|Experimental|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
16519295|NCT03159884|Experimental|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
16519296|NCT03159871|Experimental|Stratafix suture|
16519297|NCT03159871|Active Comparator|Vicryl suture|
16519298|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
16519299|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
16519300|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
16519301|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
16519302|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
16519303|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.
~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
16519304|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
16519305|NCT03159793|Active Comparator|Group A|Live Modelling
16519306|NCT03159793|Active Comparator|Group B|Filmed Modelling
16519307|NCT03159793|No Intervention|Group C|No Modelling
16519308|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
16519309|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
16519310|NCT03159754|Experimental|Early Appendectomy|
16519311|NCT03159754|Experimental|Interval Appendectomy|
16519312|NCT03159754|Experimental|No Appendectomy|
16519313|NCT03159741|Experimental|Inhibitor + GLP-2|
16519314|NCT03159741|Experimental|Placebo + GLP-2|
16519315|NCT03159741|Active Comparator|Placebo + GIP|
16519316|NCT03159741|Placebo Comparator|Placebo + Saline|
16519317|NCT03159728|Experimental|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
16519318|NCT03159728|No Intervention|Control group|"The control group will receive training about knowledge of chronic disease and care.
~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
16519319|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
16519320|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
16519321|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
16519322|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are < 60 years.
~Melphalan: 140 mg/m2/day IV on Day: -6
~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)
~TBI: 200 cGy Day: -1.
~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):
~Melphalan: 70 mg/m2/day IV on Day -6.
~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.
~TBI: 200 cGy; Days -1."
16519323|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
16519324|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
16519325|NCT03159650|Experimental|intravascular ultrasonography guided|
16519326|NCT03159650|Active Comparator|Angiography guided|
16519327|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
16519328|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
16519329|NCT03159611|Experimental|Tenoten for children|
16519330|NCT03159611|Placebo Comparator|Placebo|
16519331|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
16519332|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
16519333|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
16519334|NCT03159585|Experimental|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
16519335|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
16519336|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
16519337|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
16519338|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
16519339|NCT03159533|Placebo Comparator|Control Group|Wait-list
16519340|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
16519343|NCT03159494|Experimental|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
16519344|NCT03159494|Experimental|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
16519345|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
16519346|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
16519347|NCT03159468|Experimental|Cognitive Restructuring & Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
16519348|NCT03159468|Experimental|Mindfulness & Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
16519349|NCT03159468|Experimental|Nutrition Information & Alcohol Condition|Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
16519350|NCT03159468|Experimental|Cognitive Restructuring & No Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
16519351|NCT03159468|Experimental|Mindfulness & No Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
16519352|NCT03159468|No Intervention|Nutrition Information & No Alcohol Condition|Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.
16519353|NCT03159455|Experimental|BI 1467335|
16519354|NCT03159455|Placebo Comparator|Placebo|
16519355|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.
~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
16519356|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.
~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.
~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
16519357|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.
~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.
~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
16519358|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.
~Intervention: Nasal breathing rehabilitation"
16519359|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.
~Intervention: Standard rehabilitation"
16519360|NCT03159416|Experimental|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
16519361|NCT03159416|Experimental|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
16519362|NCT03159416|Experimental|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
16519363|NCT03159416|Experimental|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
16519364|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
16519365|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
16519366|NCT03159377||Patients scheduled for a chest CT|Inpatients or outpatients scheduled for a chest CT in our medical center
16519367|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
16519368|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
16519369|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
16519370|NCT03159338|Active Comparator|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
16519371|NCT03159338|Placebo Comparator|Control group|In control site , placebo gel will be placed before rigid fixation
16519372|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
16519373|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
16519375|NCT03159312|No Intervention|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
16519376|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
16519377|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
16519378|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
16519379|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
16519380|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
16519381|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
16519382|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
16519383|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
16519384|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
16519385|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
16519386|NCT03159234|Other|Diabetic pregnant women|
16519387|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
16519388|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
16519389|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
16519390|NCT03159182|Experimental|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
16519391|NCT03159182|Active Comparator|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
16519392|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
16519393|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
16519394|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
16519395|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
16519396|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
16519397|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
16519398|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
16519399|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
16519400|NCT03159117|Experimental|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
16519401|NCT03159104|Experimental|Tenoten for children|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
16519402|NCT03159104|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
16519403|NCT03159091|Experimental|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
16519404|NCT03159091|Placebo Comparator|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
16519405|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
16519406|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
16519407|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
16519408|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
16519409|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
16519410|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
16519417|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
16519418|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
16519419|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
16519420|NCT03159000|Experimental|GONB of lidocaine/bupivacaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
16519421|NCT03159000|Placebo Comparator|Placebo injection of 1/3 saline|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
16519422|NCT03158974|Experimental|VIR007|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
16519423|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
16519424|NCT03158948|Experimental|MOTREM 1|0.3 mg/kg/h
16519425|NCT03158948|Experimental|MOTREM 2|1.0 mg/kg/h
16519426|NCT03158948|Experimental|MOTREM 3|3.0 mg/kg/h
16519427|NCT03158948|Placebo Comparator|Placebo|
16519428|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
16519429|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
16519430|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
16519431|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
16519432|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
16519433|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
16519434|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.
~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
16519437|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
16519438|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day
~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
16519439|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)
~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
16519440|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
16519441|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
16519442|NCT03158831|Other|Placebo-Controlled Graded Drug Challenge|This is a single arm study. All patients will receive a placebo prior to a graded drug challenge. Each patient serves as his/her own control.
16519443|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
16519444|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
16519445|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
16519446|NCT03158792|Active Comparator|Enoxaparin 20 mg|
16519447|NCT03158792|Active Comparator|Enoxaparin 30 mg|
16519448|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.
~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.
~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
16519449|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
16519481|NCT03158480|Experimental|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
16519482|NCT03158480|Placebo Comparator|Placebo+interferon Group|saline as placebo plus interferon intervention
16519483|NCT03158467||Phase 1|
16519484|NCT03158467||Phase 2|
16519485|NCT03158454|Other|Capsula Closure|
16519486|NCT03158454|Other|Non-Capsula Closure|
16519450|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
16519451|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
16519452|NCT03158727|Experimental|Cx611|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each
16519453|NCT03158727|Placebo Comparator|Placebo|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate
16519454|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
16519455|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
16519456|NCT03158714|No Intervention|Control|No programming is offered.
16519459|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.
~Intervention:
~-Procedure: Fractional carbon dioxide laser.
~-Drug: Topical corticosteroid.
~-Radiation: Ultraviolet B narrow band."
16519460|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
16519461|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
16519462|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
16519463|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
16519464|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
16519465|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
16519466|NCT03158597||AMI|
16519467|NCT03158597||Control|
16519468|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
16519469|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
16519470|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
16519471|NCT03158558|Experimental|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
16519472|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
16519473|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
16519474|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
16519475|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
16519476|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
16519477|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
16519478|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
16519479|NCT03158519|Experimental|iMETX intervention|Individualized exercise recommendation
16519480|NCT03158506|Experimental|[C14]-labelled HMS5552|
16519536|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
16519487|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
16519488|NCT03158441||control|same patients , dynamic scan
16519489|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
16519490|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
16519491|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
16519492|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
16519493|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
16519494|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 800 mg i.v. for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
16519495|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
16519496|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
16519497|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
16519498|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
16519499|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks
~followed by a 4 weeks break (after last dose of 2nd cycle)
~and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
16519500|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
16519501|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally
~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution
~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
16519502|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally
~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine
~postoperative day 1 to 10: 1 placebo capsule x 3"
16519503|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:
~Test subjects undergo 48 hour exercise restriction and overnight fast.
~Study day 1:
~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.
~Study day 2:
~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.
~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.
~Study day 3:
~- Blood sample."
16519504|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.
~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.
~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
16519505|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
16519506|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
16519507|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
16519508|NCT03158324|Experimental|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
16519509|NCT03158311|Experimental|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
16519510|NCT03158311|Experimental|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
16519511|NCT03158311|Active Comparator|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
16519512|NCT03158285|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
16519513|NCT03158285|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
16519514|NCT03158285|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
16519515|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
16519516|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
16519517|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
16519518|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
16519519|NCT03158246|Experimental|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)
~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
16519520|NCT03158246|Active Comparator|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)
~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
16519521|NCT03158220|Experimental|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
16519522|NCT03158220|Active Comparator|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
16519523|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
16519524|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
16519525|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
16519526|NCT03158168|Experimental|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.
~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
16519527|NCT03158168|Active Comparator|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis [19]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.
~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
16519528|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
16519529|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
16519530|NCT03158129|Experimental|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
16519531|NCT03158129|Experimental|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
16519532|NCT03158129|Experimental|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
16519533|NCT03158129|Experimental|Arm D (ipilimumab, nivolumab, chemotherapy)|Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
16519534|NCT03158116|Experimental|Treatment|All participants will be receiving the study drug
16519535|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
16519537|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
16519538|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
16519539|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
16519540|NCT03158064|Experimental|Duravalumab + Tremelimumab|"Duravalumab/Tremelimumab: Durvalumab and Tremelimumab will be administered by IV every 4 weeks for up to 4 doses/cycles, then Durvalumab by IV every 4 weeks starting at Week 16 for 9 doses (total treatment duration of 12 months).
~Participants enrolled now will receive tremelimumab *300mg with durvalumab 1500mg for 1 cycle followed by 12 cycles of durvalumab 1500mg every 4 weeks or until lack of clinical benefit or unacceptable toxicity."
16519541|NCT03158051|Experimental|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
16519542|NCT03158051|No Intervention|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
16519543|NCT03158038|Experimental|Monovalent Influenza Vaccine|Participants will receive a single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain] by intranasal spray on Day 1.
16519544|NCT03158038|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.
16519545|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
16519546|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
16519547|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
16519548|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
16519549|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
16519550|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
16519551|NCT03158012|Active Comparator|Active treatment|
16519552|NCT03158012|Placebo Comparator|Placebo treatment|
16519553|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
16519554|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
16519555|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
16519556|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
16519557|NCT03157973|Experimental|Education intervention|
16519558|NCT03157973|No Intervention|Standard of Care|
16519559|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
16519560|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
16519561|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
16519562|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
16519563|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
16519564|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
16519565|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
16519566|NCT03157934||Primary CSC admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
16519567|NCT03157934||Primary non-CSC SU admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
16519568|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
16519569|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
16519570|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
16519571|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
16519572|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
16519573|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral
~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
16519574|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral
~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
16519575|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
16519576|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
16519577|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
16519578|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
16519579|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
16519580|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
16519581|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
16519582|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
16519583|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
16519584|NCT03157778|Experimental|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
16519585|NCT03157778|Active Comparator|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
16519586|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
16519587|NCT03157765|No Intervention|Routine care|These patient receive routine care
16519588|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
16520154|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
16519589|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.
~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
16519590|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.
~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
16519591|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
16519592|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
16519593|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
16519594|NCT03157700|Experimental|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
16519595|NCT03157700|No Intervention|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
16519596|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status
~Stool sampling before preventive gastroscopy and colonoscopy
~Questionnaires about general health, gastrointestinal symptoms and 3-day food record
~Collection of biopsies in duodenum during gastroscopy
~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
16519597|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status
~Stool sampling before indicated gastroscopy and colonoscopy
~Questionnaires about general health, gastrointestinal symptoms and 3-day food record
~Collection of biopsies in duodenum during gastroscopy
~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
16519598|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status
~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)
~Questionnaires about general health, gastrointestinal symptoms and 3-day food record
~Collection of biopsies in duodenum during gastroscopy
~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
16519599|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between
~01-Jan-2013 and 30-Sep-2016."
16519600|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.
~Inclusion Criteria:
~Patients included in the study will be:
~> 18 years of age
~Non-cardiac patients
~Non-obstetric patients
~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
16519601|NCT03157635|Experimental|Part 1 (Healthy Volunteers): Crovalimab|Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg). Doses are planned to be escalated up to Cohort 5.
16519602|NCT03157635|Placebo Comparator|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
16519603|NCT03157635|Experimental|Part 2 (PNH Participants): Crovalimab|PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
16519604|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab QW|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg QW on Day 8 for a maximum treatment duration of 5 months.
16519605|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q2W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg Q2W for a maximum treatment duration of 5 months.
16519606|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q4W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg Q4W starting on Day 8 for a maximum treatment duration of 5 months.
16519607|NCT03157635|Experimental|Part 4 (eculizumab pretreated PNH Participants): Crovalimab|"PNH Participants pretreated with eculizumab will receive crovalimab:
~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
16519608|NCT03157635|Experimental|Part 4 (treatment naïve PNH Participants): Crovalimab|"Treatment naïve PNH Participants will receive:
~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
16519609|NCT03157635|Experimental|OLE (PNH Participants): Crovalimab|PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight >/= 40 kg to < 100 kg) or 1020 mg SC Q4W (body weight >/= 100 kg) for up to a maximum treatment duration of five years from entry into OLE.
16519672|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
16519673|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
16519610|NCT03157622|Active Comparator|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
16519611|NCT03157622|Active Comparator|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
16519612|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
16519613|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
16519614|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.
~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.
~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.
~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.
~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .
~the same evaluation was carried out again 3 months after the intervention."
16519615|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
16519616|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
16519617|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
16519618|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
16519619|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
16519620|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
16519621|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
16519622|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
16519623|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
16519624|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
16519625|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
16519626|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
16519627|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
16519628|NCT03157544|Experimental|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
16519629|NCT03157531|Experimental|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
16519630|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
16519631|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
16519632|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
16519633|NCT03157492|Experimental|Aural Rehabilitation Group|The AR Group will receive six 90-minute sessions including auditory training, informational counseling, and communication strategies.
16519634|NCT03157492|Sham Comparator|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy.
16519635|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
16519636|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
16519637|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
16519638|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
16519639|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
16519640|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
16519641|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
16519642|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
16519643|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
16519644|NCT03157388|Experimental|Intervention|Combined Vancomycin and Gentamycin and Meropenem
16519645|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
16519646|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
16519647|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
16519648|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
16519649|NCT03157362|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
16519650|NCT03157362|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
16519651|NCT03157362|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
16519652|NCT03157362|Active Comparator|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
16519653|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
16519654|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
16519655|NCT03157336|Experimental|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
16519656|NCT03157336|Experimental|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
16519657|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
16519658|NCT03157310|Experimental|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
16519659|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
16519660|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
16519661|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
16519662|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
16519663|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
16519664|NCT03157258|Experimental|Social Network Endorsement|All participants will receive a brief single care-related counseling session and referral to HIV medical care upon enrollment. After randomization to this arm, all members of HIV+ social networks will attend a multi-session group intervention during which they will be trained to deliver messages endorsing compliance with medical guidelines and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained how to deliver effective messages.
16519665|NCT03157258|Active Comparator|HIV Counseling and Referral to Care|All study participants will receive a brief single care-related counseling session and referral to HIV medical care at baseline.
16519666|NCT03157245||participant|
16519667|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
16519668|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
16519669|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
16519670|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
16519671|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
16519674|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
16519675|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
16519676|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
16519677|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
16519678|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
16519679|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
16519680|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
16519681|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
16519683|NCT03157115|Experimental|HFrEF: Heart failure - reduced ejection fraction|Patients with heart failure and reduced ejection fraction (around 35%).
16519684|NCT03157115|Active Comparator|Control|Patients with a cardiac condition but a normal ejection fraction (>45%), without heart failure. The patients from the HFrEF group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
16519685|NCT03157102|Experimental|HFNC group|
16519686|NCT03157102|Other|Standard Oxygen Therapy group (STO group)|
16519687|NCT03157089|Experimental|All patients|
16519688|NCT03157076|Active Comparator|Pacing mode with CLS|
16519689|NCT03157076|Active Comparator|Intrinsic mode|
16519690|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
16519691|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
16519692|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
16519693|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
16519694|NCT03157037|Experimental|Treatment HMed-IdeS|IdeS intravenous infusion 0.25 mg/kg BW intravenous infusion
16519695|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
16519696|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
16519697|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
16519698|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
16519699|NCT03156972|Active Comparator|Group a|
16519700|NCT03156972|Active Comparator|Group b|
16519701|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.
~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
16519702|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.
~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
16519703|NCT03156946|Experimental|Breastfeeding support program|
16519704|NCT03156946|Other|Usual or routine care|
16519705|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
16519706|NCT03156920|Active Comparator|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
16519707|NCT03156920|Placebo Comparator|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
16519708|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
16519709|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.
~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
16519710|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
16519711|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
16519712|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
16519713|NCT03156842|Experimental|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
16519714|NCT03156842|Active Comparator|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
16519715|NCT03156842|Active Comparator|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
16519716|NCT03156829|Experimental|Splint alone|
16519717|NCT03156829|Experimental|Cortico-steroid alone|
16519718|NCT03156829|Experimental|Splint and cortico-steroid combined|
16519719|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
16519720|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
16519721|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
16519722|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
16519723|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
16519724|NCT03156764||Qp/Qs ratio monitoring|Qp/Qs ratio monitoring
16519725|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
16519726|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
16519727|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
16519728|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
16519729|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
16519730|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
16519731|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
16519732|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
16519733|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
16519734|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
16519735|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
16519736|NCT03156686|No Intervention|Control|Patients will be randomly assigned to conventional hospital care
16519737|NCT03156686|Experimental|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
16519738|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
16519739|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
16519740|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
16519741|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
16519742|NCT03156647||idiopathic Parkinson disease|
16519743|NCT03156647||iatrogenic parkinsonian syndrome|
16519744|NCT03156647||healthy volunteers|
16519745|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
16519746|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
16519747|NCT03156621|Experimental|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period
~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
16519748|NCT03156621|Experimental|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period
~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
16519749|NCT03156608|Experimental|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
16519750|NCT03156608|Active Comparator|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
16519753|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).
~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
16519754|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.
~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.
~Lesson 2 presents different strategies to generate helpful cognitions.
~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.
~Lesson 4 describes avoidance and safety behaviors and graded exposure.
~Lesson 5 is about problem solving and relapse prevention.
~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
16519755|NCT03156543|Experimental|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
16519756|NCT03156543|Experimental|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
16519757|NCT03156530|Experimental|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
16519758|NCT03156530|Placebo Comparator|Control|Not receive stimulation.
16519759|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
16519760|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
16519761|NCT03156504|Experimental|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
16519762|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
16519763|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
16519764|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
16519765|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
16519766|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
16519767|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
16519768|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
16519769|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
16519770|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
16519771|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
16519772|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
16519802|NCT03156179||Girls with type 1 diabetes|
16519773|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:
~Have received clearance from a primary physician to perform a exercise stress test.
~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
16519774|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:
~Have received clearance from a primary physician to perform a exercise stress test.
~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
16519775|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
16519776|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
16519777|NCT03156374|Experimental|Ovulation test use|Use of both ovulation tests and standardised care
16519778|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
16519779|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
16519780|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
16519781|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.
~Information will be collected that allows the characterization:
~Sociodemographic
~Morbid
~Pharmaco-therapeutic
~Functionality before (baseline), during and after hospitalization
~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
16519782|NCT03156335|Experimental|Focused Ultrasound|
16519783|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
16519784|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
16519785|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
16519786|NCT03156296|Active Comparator|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
16519787|NCT03156296|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
16519788|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
16519789|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
16519790|NCT03156270|Experimental|Vivaer Stylus Treatment|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
16519791|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
16519792|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
16519793|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
16519794|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
16519795|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
16519796|NCT03156218|Experimental|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 300.
~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
16519797|NCT03156218|Experimental|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 100 and < 300.
~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
16519798|NCT03156205|Experimental|Interactive Music Therapy|
16519799|NCT03156205|Other|passive music listening|
16519800|NCT03156205|Other|passive earphone-use|
16519801|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
16519803|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
16519804|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
16519805|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
16519806|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
16519807|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
16519808|NCT03156140|Experimental|motion|Right hand performs three different motion types
16519809|NCT03156127|Experimental|BR-UPS 5 mg tablet|
16519810|NCT03156127|Active Comparator|Inisia 5 mg tablet|
16519813|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
16519814|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
16519815|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.
~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.
~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
16519816|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
16519817|NCT03156062|Experimental|study group|
16519818|NCT03156062|Active Comparator|control group|
16519819|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
16519820|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
16519821|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
16519822|NCT03156036|Active Comparator|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
16519823|NCT03156036|Active Comparator|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
16519824|NCT03156036|Active Comparator|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.
~(n=37)"
16519825|NCT03156023|Active Comparator|Active|Receive active investigational product (AMG 570).
16519826|NCT03156023|Placebo Comparator|Placebo|Receive placebo investigational product
16519827|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
16519828|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
16519829|NCT03155997|Experimental|150 mg Abemaciclib + Endocrine Therapy|Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
16519830|NCT03155997|Other|Endocrine Therapy|Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
16519831|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
16519832|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
16519833|NCT03155945|Experimental|APD371 low dose treatment|
16519834|NCT03155945|Experimental|APD371 high dose treatment|
16519835|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
16519836|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
16519837|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
16519838|NCT03155906|Experimental|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
16519839|NCT03155906|Active Comparator|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
16519840|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
16519841|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
16519842|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
16519843|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
16519844|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
16519845|NCT03155867|Active Comparator|Meal replacement A|
16519846|NCT03155867|Active Comparator|Meal replacement B|
16519847|NCT03155867|Active Comparator|Meal replacement C|
16519848|NCT03155867|Active Comparator|Meal replacement D|
16519849|NCT03155867|Active Comparator|Meal replacement E|
16519850|NCT03155867|Active Comparator|Meal replacement F|
16519851|NCT03155854|Active Comparator|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
16519852|NCT03155854|Active Comparator|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
16519853|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
16519854|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
16519855|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
16519856|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
16519857|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)
~MI TLIF at L4-5 (n=10)
~XLIF at L4-5 (n=10)"
16519858|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)
~MI TLIF at L5-S1 (n=10)
~XLIF at L5-S1 (n=10)"
16519859|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)
~MI TLIF at L4-5 and L5-S1 (n=10)
~XLIF at L4-5 and L5-S1 (n=10)"
16519860|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
16519861|NCT03155750|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
16519862|NCT03155750|Active Comparator|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
16519863|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
16519864|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
16519865|NCT03155724|Experimental|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
16519866|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
16519867|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
16519868|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side
~Intervention:
~Combination Product: microneedling and Platelet rich plasma.
~radiation : NB-UVB phototherapy"
16519869|NCT03155659||CHNS|
16519870|NCT03155659||NHANES|
16519871|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
16519872|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
16520155|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
16519873|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
16519874|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
16519875|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
16519876|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
16519889|NCT03155607|No Intervention|Standard Care|
16519890|NCT03155607|Experimental|Virtual Reality Distraction|
16519891|NCT03155594|Experimental|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
16519892|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
16519893|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
16519894|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
16519895|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
16519896|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
16519897|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
16519898|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
16519899|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
16519929|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
16519930|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
16519931|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
16520156|NCT03153644||Patients|Women with chronic medical conditions
16519900|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).
~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.
~Exclusion Criteria：
~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI>30 ④With serious postoperative complications."
16519901|NCT03155516|Experimental|GPM Ward|Good Pain management ward
16519902|NCT03155516|Active Comparator|Control Ward|Current practice controlled ward
16519903|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
16519904|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
16519905|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
16519906|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
16519907|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
16519908|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
16519909|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.
~Indocyanine Green (ICG) will be used in both groups."
16519910|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.
~Indocyanine Green (ICG) will be used in both groups."
16519911|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
16519912|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation
~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
16519913|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation
~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
16519914|NCT03155425|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
16519915|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
16519916|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
16519917|NCT03155399|Experimental|Proprioceptive based training (PBT)|The treatment will last one hour and will be divided as follows: 2 proprioceptive based stimulation sessions per 3 minutes for each movement, with a rest of 2 minutes between each session. Every patient will receive 15 treatments, 5 days a week, for 3 weeks.
16519918|NCT03155399|Other|Conventional neuromotor treatment (CNT)|The CNT group will be treated for one hour daily by means of a CNT programme. The treatment will last 3 weeks.
16519919|NCT03155386||Standard Angiomammography (SenoBright®)|
16519920|NCT03155386||Optimized angiomammography|
16519921|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction >60%)
16519922|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
16519923|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction <60%)
16519924|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :
~Recurrent episodes of irritability, fussing or crying from birth to 4 months of age
~Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks
~Episodes can not be attributed to another disorder"
16519925|NCT03155360||Infant without colics|
16519932|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
16519933|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
16519934|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
16519935|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
16519936|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
16519937|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
16519938|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
16519939|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
16519940|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
16519941|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
16519942|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
16519943|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
16519944|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
16519945|NCT03155204|Experimental|Test Product 1|tiotropium pMDI 2 inhalations
16519946|NCT03155204|Experimental|Test Product 2|tiotropium pMDI 2 inhalations
16519947|NCT03155204|Experimental|Test Product 3|tiotropium pMDI 2 inhalations
16519948|NCT03155204|Experimental|Test Product 4|tiotropium pMDI 2 inhalations
16519949|NCT03155204|Active Comparator|Commercial Product|tiotropium Respimat 2 inhalations
16519950|NCT03155191|Experimental|Dose Level -1 to 2|"0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.
~cohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg."
16519951|NCT03155178|Experimental|3M CHG/IPA Prep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
16519952|NCT03155178|Active Comparator|ChloraPrep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
16519953|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
16519954|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
16519955|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
16519956|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
16519957|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
16519958|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
16519959|NCT03155126||Saline group|Patients resuscitated with saline
16519960|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
16519961|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.
~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
16519962|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
16519963|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
16519964|NCT03155087||healthy subjects|the healthy subjects was not intervened
16519967|NCT03155061|Experimental|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
16519968|NCT03155061|Experimental|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
16519969|NCT03155061|Experimental|Part C (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
16519970|NCT03155061|Experimental|Part D (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer
16519971|NCT03155048|Active Comparator|oral estradiol group|patients with the usage of 6 milligrams/day oral estradiol
16519972|NCT03155048|Active Comparator|estradiol transdermal patch group|patients with the usage of 3.9 milligrams estradiol transdermal patch
16519973|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
16519974|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
16519975|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
16519976|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
16519977|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
16519978|NCT03154996|Experimental|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
16519979|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
16519980|NCT03154970|Experimental|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
16519981|NCT03154970|No Intervention|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
16519982|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
16519983|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
16519984|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
16519985|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
16519986|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
16519987|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
16519988|NCT03154905||Control|Healthy controls
16519989|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
16519990|NCT03154892|Experimental|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
16519991|NCT03154892|Active Comparator|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
16519992|NCT03154879||Comatose cardiac arrest survivors|
16519993|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
16519994|NCT03154866|Placebo Comparator|Placebo|
16519995|NCT03154853|No Intervention|normal foot|no intervention
16519996|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
16519997|NCT03154840|Experimental|Eutropin 4IU|
16519998|NCT03154840|Experimental|Eutropin AQ 12IU|
16519999|NCT03154840|Experimental|Eutropin Pen 36IU|
16520000|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
16520001|NCT03154814|Experimental|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
16520002|NCT03154814|Placebo Comparator|control|conventional CPB was applied without ulinastatin treatment
16520003|NCT03154801|Experimental|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
16520004|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
16520005|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
16521116|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
16520006|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
16520009|NCT03154736|Experimental|Interview|Individual interview an in a group interview. Socio-economic questionnaire
16520010|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
16520011|NCT03154710|Experimental|Web-application follow up|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
16520012|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
16520013|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
16520014|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
16520015|NCT03154671|Experimental|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
16520016|NCT03154671|No Intervention|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
16520017|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
16520018|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
16520019|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
16520020|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
16520021|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
16520022|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
16520023|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
16520024|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
16520025|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
16520026|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
16520027|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
16520028|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
16520029|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (neutral)|
16520030|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
16520031|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
16520032|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
16520033|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
16520034|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
16520035|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
16520036|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
16520037|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
16520038|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
16520039|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.
~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
16520897|NCT03148496|Experimental|Biologic Mesh and Small Bytes|Biologic mesh placement and small bytes used for suturing.
16520040|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
16520041|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
16520042|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
16520043|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
16520044|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
16520045|NCT03154489|Other|Acenocoumarol|
16520046|NCT03154489|Other|control group|
16520047|NCT03154476|Experimental|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
16520048|NCT03154476|Placebo Comparator|Placebo|Subjects will receive placebo times per day for 12 months.
16520049|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
16520050|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
16520051|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
16520052|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
16520053|NCT03154424|Placebo Comparator|Bridging (control group)|External fixation in treatment the distal radius fracture
16520054|NCT03154424|Active Comparator|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
16520055|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
16520056|NCT03154398||1|case control
16520057|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.
~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
16520058|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
16520059|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
16520060|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
16520061|NCT03154333|Experimental|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
16520062|NCT03154333|Placebo Comparator|vehicle ointment|vehicle ointment will be used for 8 weeks
16520063|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 9, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
16520064|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
16520065|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
16520066|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
16520067|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
16520068|NCT03154307|Experimental|Short-term protocol|LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only
16520069|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
16520070|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
16520071|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
16520072|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
16520073|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
16520074|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
16520075|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
16520076|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
16520077|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
16520078|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
16520079|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
16520080|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
16520081|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
16520082|NCT03154216|Experimental|Exercise only|90 minutes of exercise
16520083|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
16520084|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
16520085|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
16520086|NCT03154190|Active Comparator|Arm A (usual care)|Patients receive usual care.
16520087|NCT03154190|Experimental|Arm B (health care coach support)|Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms.
16520088|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
16520089|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
16520090|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
16520091|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
16520092|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
16520093|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
16520094|NCT03154138|Experimental|Prismatic adaptation (PA) group|Patients in the experimental group will benefit from 10 sessions of adaptation prismatic (PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
16520095|NCT03154138|Placebo Comparator|Sham group|Patients in the sham group will benefit from 10 sessions of sham adaptation prismatic (S-PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
16520096|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
16520097|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
16520098|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
16520099|NCT03154086|Experimental|Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg|Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520157|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.
~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
16520100|NCT03154086|Experimental|Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520101|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520102|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520103|NCT03154086|Experimental|Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed|Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520104|NCT03154086|Experimental|Part A: Cohort 2: Placebo Fasted/Placebo Fed|Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520105|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150 mg/Placebo|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520106|NCT03154086|Experimental|Part A:Cohort 3: Placebo/GSK3352589 400 mg|Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520107|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
16520108|NCT03154086|Experimental|Part B: GSK3352589|Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.
16520109|NCT03154086|Placebo Comparator|Part B: Placebo|Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.
16520110|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
16520111|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
16520112|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
16520113|NCT03154047|Experimental|Open label|Open Label Study Drug NEOD001
16520114|NCT03154034||Severe mitral regurgitation|
16520115|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
16520116|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
16520117|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
16520118|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
16520119|NCT03153995|Active Comparator|periosteal releasing incision|periosteal releasing incision will be performed for Eight patients during ridge augmentation surgery .
16520120|NCT03153982|Experimental|Head and neck squamous cell carcinoma|"Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery.
~Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg)."
16520121|NCT03153969|Experimental|SHOFU Beautifil II LS|Composite: SHOFU Beautifil II LS, Bonding Agent: SHOFU BeautiBond
16520122|NCT03153969|Active Comparator|3M/ESPE Filtek Supreme|Composite: 3M/ESPE Filtek Supreme, Bonding Agent: 3M/ESPE Scotchbond Universal
16520123|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
16520124|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
16520125|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
16520126|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
16520127|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
16520266|NCT03152812||free muscle flaps|
16520128|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
16520129|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
16520130|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
16520131|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
16520132|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
16520133|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
16520134|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
16520135|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
16520136|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
16520137|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
16520138|NCT03153826|Other|Patients|
16520139|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
16520140|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
16520141|NCT03153800|Experimental|Bronchial basal cells|
16520142|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
16520143|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
16520144|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
16520145|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
16520146|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
16520147|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
16520148|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
16520149|NCT03153722|Experimental|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
16520150|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
16520151|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
16520152|NCT03153683||Acute Ischemic Stroke Patients|This is a registry. No above standard of care interventions will take place. Participants must have an acute thromboembolus within an intracranial artery in the anterior circulation (internal carotid, anterior cerebral, middle cerebral), which undergoes mechanical thrombectomy per standard of care.
16520153|NCT03153670||Deep brain stimulation (DBS) patients|We will observe brain activation changes in patient's who have received DBS as part of their standard of care
16520158|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
16520159|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
16520160|NCT03153618|No Intervention|Control|Current standard of care will be followed
16520161|NCT03153605|Experimental|SATISI_7|
16520162|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
16520163|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
16520164|NCT03153579|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
16520165|NCT03153579|Other|LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
16520166|NCT03153566|Experimental|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
16520167|NCT03153566|Active Comparator|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
16520168|NCT03153566|Experimental|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
16520169|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
16520170|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
16520171|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).
~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
16520172|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.
~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
16520173|NCT03153527|Placebo Comparator|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
16520174|NCT03153527|Active Comparator|Verum group (control/standard arm)|If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
16520175|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.
~Cycle 1: in the peri-transplant and transplantation phase
~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
16520176|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
16520177|NCT03153488|Experimental|Methylphenidate|Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
16520178|NCT03153488|Experimental|Amphetamine|Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
16520179|NCT03153475|Other|ATTUNE Revision Knee System|The ATTUNE Revision system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in revision knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
16520180|NCT03153449|Other|ATTUNE Revision knee system|The ATTUNE Revision knees system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in complex primary knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
16520181|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
16520182|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
16520183|NCT03153423|Other|Basic intermittent exotropia patients|
16520184|NCT03153410|Experimental|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
16520185|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
16520186|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
16520187|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
16520301|NCT03152526|Other|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
16520188|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
16520189|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
16520190|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
16520191|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
16520192|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
16520193|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
16520194|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
16520195|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
16520196|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
16520197|NCT03153319|Experimental|Adalimumab|20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
16520198|NCT03153319|Placebo Comparator|Placebo|Saline placebo comparator
16520199|NCT03153319|Experimental|Open-label adalimumab|Open-label extension of adalimumab dose
16520200|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
16520201|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
16520202|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
16520203|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
16520204|NCT03153267|Active Comparator|EM-7 days doxycycline|
16520205|NCT03153267|Active Comparator|EM-14 days doxycycline|
16520206|NCT03153267|Placebo Comparator|Controls|
16520207|NCT03153254|Experimental|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
16520208|NCT03153254|Experimental|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
16520209|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
16520210|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
16520211|NCT03153228||Control|29 healthy volunteers.
16520212|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
16520213|NCT03153215|Active Comparator|Control group|women with severe IUGR
16520214|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
16520215|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
16520216|NCT03153176|Experimental|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
16520217|NCT03153176|No Intervention|no intervention|Physical Education and school curriculum as usual
16520218|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
16520219|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:
~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or
~Direct thrombin inhibitor: Dabigatran or
~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
16520220|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:
~antiplatelet drug(s) or
~no antithrombotic drugs."
16520221|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
16520222|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
16520223|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
16520224|NCT03153124|No Intervention|Control|No intervention
16520225|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
16520226|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
16520227|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
16520228|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
16521185|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
16520229|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
16520230|NCT03153072|Other|A child with supraventricular tachycardia|
16520231|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
16520232|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
16520233|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
16520234|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
16520235|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
16520236|NCT03153020||Cohort of patients with stroke or transient ischemic attack|The cohort will be constituted of all consecutive patients admitted for a stroke or transient ischemic attack by the Rhône's emergency medical help service (SAMU), or in one of the emergency unit or stroke unit of the Rhône area, and presenting a symptom-onset (the last time the patient was seen without deficit) less than 24 hours.
16520237|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
16520238|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
16520239|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
16520240|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
16520241|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
16520242|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
16520243|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
16520244|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
16520245|NCT03152942|Experimental|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
16520246|NCT03152942|Active Comparator|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
16520247|NCT03152929|Active Comparator|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
16520248|NCT03152929|Active Comparator|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
16520249|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
16520250|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
16520251|NCT03152903|Placebo Comparator|Placebo|
16520252|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
16520253|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
16520254|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
16520255|NCT03152864|Experimental|Full Package|
16520256|NCT03152864|No Intervention|Sensing Only|
16520257|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
16520258|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
16520259|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.
~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.
~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
16520260|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.
~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.
~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
16520261|NCT03152825||Viable myocardium Group|"At least ONE of the following:
~Late gadolinium enhancement <75%.
~Improvement in segmental function ≥1 grade during low dose dobutamine"
16520262|NCT03152825||Non-viable myocardium group|"At least ONE of the following:
~Late gadolinium enhancement ≥75%.
~No improvement in segmental function during low dose dobutamine"
16520263|NCT03152825||Inducible ischaemia group|"At least ONE of the following:
~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine
~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
16520264|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
16520265|NCT03152812||free skin flaps|
16520267|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
16520268|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
16520269|NCT03152786|Experimental|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
16520270|NCT03152786|Active Comparator|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
16520272|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
16520273|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
16520274|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
16520275|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.
~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
16520276|NCT03152747||B|"Group B with no/partial PVD
~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.
~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
16520277|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
16520278|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
16520279|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
16520280|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
16520281|NCT03152682|Experimental|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
16520282|NCT03152682|Experimental|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
16520283|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
16520284|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
16520285|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
16520286|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
16520287|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
16520288|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
16520289|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
16520290|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
16520291|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
16520292|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
16520293|NCT03152552|Experimental|LIK066 2.5mg|Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
16520294|NCT03152552|Experimental|LIK066 10mg|Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
16520295|NCT03152552|Experimental|LIK066 50mg|Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
16520296|NCT03152552|Active Comparator|Empagliflozin|Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
16520297|NCT03152552|Placebo Comparator|Placebo|Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.
16520302|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
16520303|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
16520304|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
16520305|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
16520306|NCT03152474|Active Comparator|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
16520307|NCT03152474|Active Comparator|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
16520308|NCT03152474|Placebo Comparator|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
16520309|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
16520310|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
16520311|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
16520312|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
16520313|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
16520314|NCT03152396|Other|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
16520315|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
16520316|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
16520317|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
16520318|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
16520319|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
16520320|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
16520321|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.
~The patients will be proposed to perform the following tests and to fill in questionnaires"
16520322|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.
~The patients will be proposed to perform the following tests and to fill in questionnaires"
16520323|NCT03152331|Experimental|Receptive Awareness Training|
16520324|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.
~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.
~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
16520325|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.
~Cyclophosphamide one intravenous injection 2 days prior to procedure.
~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.
~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
16520326|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
16520327|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
16520328|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
16520329|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
16520330|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
16520331|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
16520332|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
16520333|NCT03152253|Experimental|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
16520334|NCT03152253|Placebo Comparator|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
16520335|NCT03152240||Women patients|Women patients
16520336|NCT03152240||Men patients|Men patients
16520337|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
16520338|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
16520339|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
16520340|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:
~1 session of exercise counseling
~3 weekly 25-minute sessions of vigorous intensity aerobic exercise
~1 weekly Team RWB event
~4 biweekly assessments
~Participants will also complete an online assessment at week 9 to provide follow-up data."
16520341|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:
~1 weekly Team RWB event
~4 biweekly assessments
~Participants will also complete an online assessment at week 9 to provide follow-up data."
16520342|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:
~• 4 biweekly assessments
~Participants will also complete an online assessment at week 9 to provide follow-up data."
16520343|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
16520344|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
16520345|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
16520346|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
16520347|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
16520348|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
16520349|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
16520350|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
16520351|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
16520352|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
16520353|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
16520354|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
16520355|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
16520356|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
16520357|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
16520358|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
16520359|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
16520360|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
16520361|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
16520362|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
16520363|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
16520364|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.
~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.
~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
16520365|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
16520366|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
16520367|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
16520368|NCT03152019|Active Comparator|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
16520369|NCT03152019|Placebo Comparator|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
16520370|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
16520371|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
16520372|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
16520373|NCT03151993|Active Comparator|Actilyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
16520374|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
16520375|NCT03151980|Other|Untreated skin and sun exposure|
16520376|NCT03151967|Active Comparator|applicator containing active drug|Vaginal applicator containing Lactobacillus crispatus CTV-05
16520377|NCT03151967|Placebo Comparator|placebo vaginal applicator|Inactive vaginal applicator without any drug
16520378|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.
~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;
~Explore the regulation of hippo-YAP pathway in NESCs."
16520379|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
16520380|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam
~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System
~Vaginal smear for evaluation with Gram's stain and Nuget's criteria
~Vaginal swab for yeast culture
~Vaginal swab for Trichomonas vaginalis NAAT
~Vaginal swab for discrepant analysis testing"
16520381|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
16520382|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
16520383|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
16520384|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB
~Chidamide administered orally on D-7, -4, 0,+3
~Cladribine administered at 10mg on D-6 to D-2
~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.
~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.
~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.
~Interventions:
~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
16520385|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
16520386|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
16520387|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
16520388|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
16520389|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
16520390|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
16521186|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
16520396|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
16520397|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
16520398|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
16520399|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
16520400|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
16520401|NCT03151759||No radiotherapy|Surgery only
16520402|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
16520403|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
16520404|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
16520405|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
16520406|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
16520407|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
16520408|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
16520409|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
16520410|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
16520411|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
16520412|NCT03151707|Experimental|Nicotinamide riboside 2g/day|
16520413|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
16520414|NCT03151681|Experimental|Propranolol pill + mismatch memory reactivation|Prediction-error will be incorporated into each treatment sessions.
16520415|NCT03151681|Experimental|Propranolol pill + standard memory reactivation|
16520416|NCT03151681|No Intervention|Waitlist|
16520417|NCT03151668|Experimental|Dexmedetomidin|
16520418|NCT03151668|No Intervention|Midazolam|
16520419|NCT03151655|Experimental|MATTeRS Video|
16520420|NCT03151655|Active Comparator|Didactic Video|
16520421|NCT03151629||Castrate Resistant Prostate Cancer|
16520422|NCT03151629||Hormone Sensitive Prostate Cancer|
16520423|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
16520424|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
16520425|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
16520426|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)
~and
~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
16520427|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),
~and
~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days
~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
16520428|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
16520429|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
16520430|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
16520574|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.
~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
16520431|NCT03151551|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.
~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.
~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps."
16520432|NCT03151551|Active Comparator|Adalimumab|"80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.
~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps."
16520433|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
16520434|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
16520435|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
16520436|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
16520437|NCT03151499|Experimental|All Subjects|Reference Treatment (BI 409306) given alone followed by Test Treatment (BI 409306 + Rifampicin)
16520438|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
16520439|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
16520440|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
16520441|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
16520442|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
16520443|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
16520444|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
16520445|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
16520446|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
16520447|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
16520448|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
16520449|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
16520450|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
16520451|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
16520452|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
16520453|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
16520454|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
16520455|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
16520456|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
16520457|NCT03151395|Other|Total Group|Moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) patients with at least 1 documented moderate or severe Acute exacerbation of COPD (AECOPD) in the year before enrolment and for whom sputum and blood samples are collected during specified visits
16520458|NCT03151382|Experimental|Experimental group|
16520459|NCT03151382|Other|Control group|
16520460|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
16520461|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
16520462|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
16520463|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
16520465|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
16520466|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
16520575|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
16520467|NCT03151304|Experimental|Stage 1a and 1b open-label pracinostat plus azacitidine|"open-label single arm pracinostat plus azacitidine. Pracinostat: 45 mg administered orally 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.
~In later cycles (i.e., after Cycle 4), pracinostat dose reduction to 45 mg orally 3 days each week × 2 weeks (instead of 3 weeks) or dose interruption is allowed to manage toxicity such as fatigue, gastrointestinal toxicity, or myelosuppression.
~Azacitine: 75 mg/m2 for 7 days of each 28-day cycle. Administration will occur by subcutaneous (SC) injection, or IV infusion if SC injections are not tolerated, on one of two schedules:
~Schedule 1 - daily therapy on Days 1 through 7
~Schedule 2 - 5-2-2 schedule in which subjects receive azacitidine for 5 consecutive days (Days 1 through 5) with rest on Days 6 and 7, and resume azacitidine dosing the first two days of the next week (Days 8 and 9) of each 28-day cycle"
16520468|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
16520469|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
16520470|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
16520471|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
16520472|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
16520473|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
16520474|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
16520475|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
16520476|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of Ensite NavX without fluoroscopy.
16520477|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of X-ray plus any tree dimensional mapping system.
16520478|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.
~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
16520479|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.
~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
16520480|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
16520481|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
16520482|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
16520483|NCT03151239|Placebo Comparator|Placebo|
16520484|NCT03151239|Experimental|NMN supplementation|
16520485|NCT03151226|Other|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
16520486|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
16520487|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
16520488|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
16520489|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
16520490|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
16520491|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
16520492|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
16520493|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
16520494|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
16520495|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;
~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
16520496|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
16520614|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
16520898|NCT03148496|Experimental|Small Bytes and No Biologic Mesh|Small bytes used for suturing with no placement of biologic mesh
16520497|NCT03151148|Experimental|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
16520498|NCT03151148|Placebo Comparator|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
16520499|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
16520500|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
16520501|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
16520502|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
16520503|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
16520504|NCT03151083|Active Comparator|Phase 1: Implementation As Usual (Implementation Through Research Team)|SHUTi digital CBTi Program was implemented in VACT primary care using implementation activities executed by the research team between June 2017 and January 2018 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), Single Referral Pathway Not Integrated Primary Care Workflow (Primary care provider contact research team for patient referral over email).
16520505|NCT03151083|Experimental|Phase 2: Primary Care Coached Digital CBTi Implementation (Implementation through primary Care)|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams June 2018 and January 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a primary care nurse trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Single Referral Pathway Not Integrated Primary Care Workflow.
16520506|NCT03151083|Experimental|Phase 3: Primary Care Mental Health Collaborative Care Implementation|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams April 2019 and November 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders, Patient Advertising/Information, patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a peer support specialist working on the primary care mental health collaborative care team, the digital CBTi coach was trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Additional members primary care mental health collaborative care team were educated to provide education about digital CBTi. Multiple referral pathways to digital CBTi: consults to the digital CBTi Coach, warm handoffs to primary care mental health collaborative care team. Digital CBTi coach consults integrated Primary Care Workflow.
16520507|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:
~San Rafael Petzal
~San Sebastian Huehuetenango
~San Gaspar Ixchil
~Santa Bárbara
~Colotenango
~Aguacatán"
16520508|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:
~Tamahú
~San Miguel Tucurú
~Panzós
~Senahú
~Telemán"
16520509|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:
~San Idelfonso Ixtahuacán
~La Democracia
~San Juan Atitán
~Tectitán
~Santiago Chimaltenango"
16520510|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:
~Lanquín
~Santa María Cahabón
~Chisec
~Chahal
~Raxruhá
~Campur"
16520511|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:
~Nenton
~Jacaltenango
~Todos Santos Cuchumatán
~Santa Eulalia
~San Mateo Ixtatán
~San Juan Ixcoy"
16520512|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:
~Santa Cruz Verapaz
~Tactic
~San Pedro Carchá
~San Juan Chamelco"
16520513|NCT03151057|Experimental|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.
~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
16520514|NCT03151057|Placebo Comparator|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
16520515|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:
~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;
~Plus/not plus:
~Rituximab 375mg/m2, i.v., Day 0"
16520516|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:
~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;
~Plus/not plus:
~Rituximab 375mg/m2, i.v., Day 0"
16520517|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
16520518|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
16520519|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
16541923|NCT03005379|Placebo Comparator|2|Placebo
16520520|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
16520521|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
16520522|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
16520523|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
16520524|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
16520525|NCT03150966|Experimental|Patients who received nanocurcumin|Patients who received nanocurcumin
16520526|NCT03150966|Placebo Comparator|Patients who received placebo|Patients who received placebo
16520527|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
16520528|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
16520529|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
16520530|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.
~ECG: 12 lead electrocardiogram that visualizes cardiac activity
~history and physical: background information about athlete's and their family history
~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
16520531|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
16520532|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
16520533|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
16520534|NCT03150914|Active Comparator|Treatment|Over-encapsulated 1 mg sirolimus tablet
16520535|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:
~Expression of insulin-like growth factor 1 receptor (IGF-1R)
~Adiponectin
~Leptin
~Resistin
~Osteocalcin
~Osteoprotegerin
~Insulin, c-peptid
~HOMA-IR"
16520536|NCT03150888||Hospital based hypertension cohort|
16520537|NCT03150888||Community based hypertension cohort|
16520538|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
16520539|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
16520540|NCT03150862|Experimental|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
16520541|NCT03150862|Experimental|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
16520542|NCT03150862|Experimental|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
16520543|NCT03150862|Experimental|Arm B (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
16520544|NCT03150862|Experimental|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
16520545|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
16520546|NCT03150849||patient group|patient with chronic lymphocytic leukemia
16520547|NCT03150849||control group|healthy control group
16520615|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
16520899|NCT03148496|Experimental|Biologic mesh and Large Bytes|Biologic mesh placement and large bytes used for suturing
16520548|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
16520549|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
16520550|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
16520551|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
16520552|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
16520553|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
16520554|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
16520555|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
16520556|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
16520557|NCT03150810|Experimental|Arm A (Dose Escalation) TMZ Pulse Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
16520558|NCT03150810|Experimental|Arm B (Dose Escalation) TMZ Continuous Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
16520559|NCT03150810|Experimental|Dose Expansion, 6 cohorts|Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
16520560|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
16520561|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
16520562|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
16520563|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main
~EPIC club: 60min session / 2 times weekly / 7 weeks"
16520564|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator
~EPIC club: 60min session / 2 times weekly / 7 weeks"
16520565|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
16520566|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
16520567|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
16520568|NCT03150745|Other|Colposcopic group|
16520569|NCT03150745|Other|office hysteroscopic group|
16520570|NCT03150732|Active Comparator|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
16520571|NCT03150732|Active Comparator|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
16520572|NCT03150719|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
16520573|NCT03150719|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
16520616|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
16520900|NCT03148496|Active Comparator|Large Bytes and no biologic mesh|Large bytes used for suturing and no placement of biologic mesh.
16520576|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
16520577|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
16520578|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
16520579|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
16520580|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
16520581|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
16520582|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
16520583|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
16520584|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
16520585|NCT03150628|Experimental|Study population|
16520586|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
16520587|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
16520588|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
16520589|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
16520590|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
16520591|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
16520592|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
16520593|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
16520594|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
16520595|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
16520596|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
16520597|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
16520598|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
16520599|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
16520600|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
16520601|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
16520602|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
16520603|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
16520604|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
16520605|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
16520606|NCT03150511|Experimental|Tesamorelin treatment|
16520607|NCT03150511|Placebo Comparator|Placebo|
16520608|NCT03150498|Experimental|BTD-001 (fed)|
16520609|NCT03150498|Experimental|BTD-001 (fasted)|
16520610|NCT03150485|Experimental|etafilcon A Toric Multifocal|
16520611|NCT03150485|Active Comparator|etafilcon A Multifocal|
16520612|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.
~This type of Graft Matrix will be administered as the intervention."
16520613|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.
~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.
~This type of Graft Matrix will be administered as the intervention."
16521113|NCT03146975|Experimental|Periodontitis compensated diabetes|
16520617|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
16520618|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
16520619|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
16520620|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
16520621|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
16520622|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
16520623|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
16520624|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
16520625|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
16520626|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
16520628|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
16520629|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
16520630|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
16520631|NCT03150329|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO BID on days 1-5 and 8-12 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
16520632|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
16520633|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
16520634|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
16520635|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
16520636|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
16520637|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
16520638|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
16520639|NCT03150264|Experimental|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
16520640|NCT03150264|Active Comparator|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
16520641|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
16520642|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
16520643|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
16520644|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
16520645|NCT03150225|Experimental|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.
~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
16520646|NCT03150225|Active Comparator|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
16520647|NCT03150225|Experimental|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.
~In addition participants will receive starch capsules to be taken daily."
16520748|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
16520648|NCT03150225|No Intervention|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
16520649|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
16520650|NCT03150212|Placebo Comparator|Placebo|
16520651|NCT03150199|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
16520652|NCT03150199|Active Comparator|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
16520653|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
16520654|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
16520655|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
16520656|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
16520657|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
16520658|NCT03150160|Experimental|Simbrinza + Travatan|Brinzolamide 1%/brimonidine 0.2% fixed combination + travoprost 0.004% ophthalmic solution
16520659|NCT03150160|Placebo Comparator|Placebo + Travatan|Placebo + travoprost 0.004% ophthalmic solution
16520660|NCT03150147|Experimental|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
16520661|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
16520662|NCT03150134|Experimental|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
16520663|NCT03150134|Placebo Comparator|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
16520664|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
16520665|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
16520666|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
16520667|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
16520668|NCT03150108|Experimental|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
16520669|NCT03150095|Experimental|Health coaching|Patients will work with a health coach to improve self-management skills
16520670|NCT03150095|No Intervention|Control|Patients will receive usual pre-transplant education to improve self-management skills
16520671|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
16520672|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
16520673|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
16520674|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
16520675|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
16520676|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
16520679|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
16520680|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
16520681|NCT03150030||Healthy controls|Healthy control subjects
16520682|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
16520683|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
16520684|NCT03150004|Experimental|CLAG-M regimen|Patients' treatment cycle is 30 days.
16520685|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
16520686|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
16520687|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
16520688|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
16520689|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
16520690|NCT03149926||Patients with Borderline Personality Disorder|
16520691|NCT03149926||Healthy controls|
16520692|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
16520693|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
16520694|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.
~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
16520695|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
16520696|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
16520697|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
16520698|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
16520699|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
16520700|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
16520701|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
16520702|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
16520703|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.
~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
16520704|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.
~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
16520749|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
16520750|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
16520705|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
16520706|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
16520707|NCT03149822|Experimental|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily for up to 35 cycles, until disease progression, unacceptable toxicity, or consent withdrawal. All participants who stop pembrolizumab after 35 cycles with SD or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping pembrolizumab from the initial treatment phase.
16520708|NCT03149809|Active Comparator|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
16520709|NCT03149809|Active Comparator|Drug Therapy|Daily solifenacin drug therapy
16520710|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.
~Laboratory blood tests will be collected and analyzed"
16520711|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
16520712|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
16520713|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
16520714|NCT03149770|Experimental|1|Naloxone, intranasal 4mg
16520715|NCT03149770|Placebo Comparator|2|Placebo
16520716|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
16520717|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
16520718|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
16520719|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
16520720|NCT03149692|Experimental|Penile allograft|Penile human allografts transplanted
16520721|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
16520722|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
16520723|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
16520724|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
16520725|NCT03149653|No Intervention|Comparator3|Healthy Control
16520726|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
16520727|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
16520728|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
16520729|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
16520730|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
16520731|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
16520732|NCT03149601||Obese|Participants with BMI > or = 95th percentile
16520733|NCT03149588|Experimental|propofol|
16520734|NCT03149588|Experimental|sevoflurane|
16520735|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
16520736|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
16520737|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
16520738|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
16520739|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
16520740|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
16520741|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
16520742|NCT03149549|Experimental|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
16520743|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
16520744|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
16520745|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
16520746|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
16520747|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
16520895|NCT03148509|Experimental|risperidone|receive risperidone
16520751|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
16520752|NCT03149510|Experimental|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
16520753|NCT03149510|No Intervention|Control Group|Participants will receive standard of care.
16520754|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
16520755|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
16520756|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
16520757|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
16520758|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
16520759|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
16520760|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
16520761|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
16520762|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
16520763|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
16520764|NCT03149432|Active Comparator|Reference analgesic|Gabapentin Rehabilitation Local care
16520765|NCT03149432|Experimental|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
16520766|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
16520767|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
16520768|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
16520769|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
16520770|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
16520771|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
16520772|NCT03149380|Experimental|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
16520773|NCT03149380|Sham Comparator|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
16520774|NCT03149367|Experimental|Fixed suture|
16520775|NCT03149367|Experimental|Adjustable suture|
16520776|NCT03149354|Other|Patients with HIV|Patients with HIV
16520777|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
16520778|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
16520779|NCT03149328|Experimental|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
16520780|NCT03149328|No Intervention|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
16520781|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
16520782|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
16520783|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
16520784|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
16520785|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
16520786|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
16520787|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
16520788|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
16520789|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.
~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
16520790|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
16520791|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa
~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
16520792|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
16520896|NCT03148509|Experimental|aripiprazole|receive aripiprazole
16520793|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group
~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
16520794|NCT03149237|No Intervention|Standard of Care|The 12 clinics randomized to the control arm will continue to provide standard of care (SOC) EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.
16520795|NCT03149237|Experimental|Couples-based Services|The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical EMTCT services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period at the EID clinic; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT.
16520796|NCT03149211|Active Comparator|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
16520797|NCT03149211|Experimental|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
16520798|NCT03149198|Experimental|Interventional group|Mat pilates exercises
16520799|NCT03149198|Active Comparator|Control group|Aquatic aerobic exercises
16520800|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
16520801|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
16520802|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
16520803|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
16520804|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
16520805|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
16520806|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
16520807|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
16520808|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
16520809|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
16520810|NCT03149120|Experimental|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
16520811|NCT03149120|Experimental|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
16520812|NCT03149107|Experimental|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).
~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
16520813|NCT03149107|Experimental|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
16520814|NCT03149107|Experimental|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).
~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
16520815|NCT03149107|Active Comparator|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
16520816|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
16520817|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
16520818|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
16520819|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
16520820|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
16520821|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
16520822|NCT03149042||CCTA|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
16520825|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
16521114|NCT03146975|Experimental|Periodontitis decompensated diabetes|
16520826|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
16520827|NCT03149003|Experimental|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
16520828|NCT03149003|Active Comparator|Arm 2: Bevacizumab|
16520829|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
16520830|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
16520831|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
16520832|NCT03148964||Follow-up Arm|Blood sampling only
16520833|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
16520834|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
16520835|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
16520836|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
16520837|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
16520838|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
16520839|NCT03148925|Experimental|SELA-070|
16520840|NCT03148925|Placebo Comparator|Saline|
16520841|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
16520842|NCT03148899|Experimental|Visit 1 Randomization|At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
16520843|NCT03148899|Experimental|Visit 2: Crossover Randomization|At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
16520844|NCT03148886|Experimental|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
16520845|NCT03148860|Active Comparator|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
16520846|NCT03148860|Placebo Comparator|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
16520847|NCT03148860|Active Comparator|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
16520848|NCT03148860|Placebo Comparator|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
16520849|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
16520850|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
16520851|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
16520852|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
16520853|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
16520854|NCT03148808|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
16520855|NCT03148795|Experimental|Talazoparib|Talazoparib 1 mg daily
16520856|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
16520857|NCT03148756|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
16520858|NCT03148756|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
16521115|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
16520859|NCT03148730|No Intervention|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
16520860|NCT03148730|Experimental|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
16520861|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
16520862|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
16520863|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
16520864|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
16520865|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
16520866|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
16520867|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
16520868|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
16520869|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
16520870|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
16520871|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
16520872|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
16520873|NCT03148652|Experimental|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
16520874|NCT03148652|Placebo Comparator|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
16520875|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
16520876|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
16520877|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
16520878|NCT03148626|Placebo Comparator|Control|Usual education.
16520879|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
16520880|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
16520881|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
16520882|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
16520883|NCT03148574|Experimental|misoprostol|intrauterine 400 microgram
16520884|NCT03148574|Active Comparator|oxytocin|intravenous infusion 10 units
16520885|NCT03148561|Other|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
16520886|NCT03148561|No Intervention|Expectant group|Women did not receive any medication.
16520887|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
16520888|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
16520889|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
16520890|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
16520891|NCT03148522|Experimental|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
16520892|NCT03148522|Experimental|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
16520893|NCT03148522|Experimental|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
16520894|NCT03148509|Experimental|bupropion|receive bupropion
16520901|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
16520902|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
16520903|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
16520904|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
16520905|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
16520906|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
16520907|NCT03148457|Experimental|Early treatment|Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).
16520908|NCT03148457|Other|Late treatment|Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).
16520909|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
16520910|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
16520911|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
16520912|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
16520913|NCT03148418|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
16520914|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
16520915|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
16520918|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy
~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
16520919|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
16520920|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon
~Device for guidance: high-resolution ultrasound
~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)
~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon
~Device for guidance: high-resolution ultrasound
~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
16520921|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only
~Device for guidance: high-resolution ultrasound
~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)
~Intervention procedure: lidocaine injection into the subacromial bursa only
~Device for guidance: high-resolution ultrasound
~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
16520922|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
16520926|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
16520927|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
16520928|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
16520929|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
16520930|NCT03148288|Placebo Comparator|placebo|
16520932|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
16520933|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
16520934|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
16520935|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
16520936|NCT03148236|Active Comparator|Vitamin C|
16520937|NCT03148236|Placebo Comparator|Placebo|
16520938|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
16543972|NCT02991222|Active Comparator|Reference001 type I|Treatment type I
16520939|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
16520940|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
16520941|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
16520942|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
16520943|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
16520944|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
16520945|NCT03148171|Active Comparator|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
16520946|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
16520947|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
16520948|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
16520949|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
16520950|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
16520951|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
16520952|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
16520953|NCT03148080||Observational|Participants complete a Current Medical Conditions Form, the CogState web-based cognitive assessment, and a Self-Report Questionnaire administration over 45-60 minutes containing measures of work ability and other work-related measures, cognitive, physical, and psychosocial symptoms, and characteristics of workplace environment. Self-report measures of individual and family characteristics, resources, and demands are also included.
16520954|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
16520955|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
16520956|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
16520957|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
16520958|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
16520959|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
16520960|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
16520961|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
16520962|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
16520963|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
16520964|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
16520965|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
16520966|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
16520967|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
16520968|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
16520969|NCT03147950|Active Comparator|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
16520970|NCT03147950|Active Comparator|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
16520971|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
16520972|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
16520973|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
16520974|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
16520975|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
16520976|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
16520977|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
16520978|NCT03147885|Experimental|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16520979|NCT03147872|No Intervention|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
16543973|NCT02991222|Active Comparator|Reference type II|Treatment type II
16520980|NCT03147872|Experimental|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
16520981|NCT03147859|Experimental|Group A-150mg dose of vedolizumab per infusion followed by ATI - Low Dose|* Please note that the previous low dose arm was 75mg of vedolizumab per infusion, but no participant was ever given this dose. The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 150 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
16520982|NCT03147859|Experimental|Group B-300mg dose of vedolizumab per infusion followed by ATI - Mid Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 300 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
16520983|NCT03147859|Experimental|Group C-600mg dose of vedolizumab per infusion followed by ATI - High Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 600 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
16520984|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.
~Keep the room temperature at 23-25˚C and wrap the baby if possible"
16520985|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
16520986|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
16520987|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
16520988|NCT03147807|Experimental|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
16520989|NCT03147807|No Intervention|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
16520990|NCT03147794|Experimental|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
16520991|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
16520992|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
16520993|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
16520994|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
16520995|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
16520996|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
16520997|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
16520998|NCT03147716|Active Comparator|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
16520999|NCT03147716|Experimental|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
16521000|NCT03147716|Experimental|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
16521001|NCT03147716|Experimental|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
16521002|NCT03147716|Experimental|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
16521003|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
16521004|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
16521005|NCT03147690|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
16521006|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
16521007|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
16521008|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
16521009|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.
~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
16521010|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
16521011|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
16521012|NCT03147638|Experimental|1 month|patient treated with Anti coagulation for one month
16521013|NCT03147638|Active Comparator|3 months|standard of care , treatment for 3 months
16521014|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
16521015|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
16521016|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
16521017|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
16521018|NCT03147599|Placebo Comparator|Placebo|Placebo
16521019|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
16521020|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
16521021|NCT03147573|Experimental|Blood pressure monitoring|
16521022|NCT03147560|Experimental|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
16521023|NCT03147560|Experimental|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
16521024|NCT03147560|Experimental|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
16521025|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
16521026|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
16521027|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
16521028|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
16521029|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
16521030|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
16521031|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
16521032|NCT03147508||Neck pain patients|
16521033|NCT03147495||the study group|The participants with medial compartment knee osteoarthritis and without lateral compartment knee osteoarthritis according to the Ahlbäck classification.
16521034|NCT03147495||the control group|The healthy volunteers without knee osteoarthritis according to the American College of Rheumatology criteria for the classification and reporting of OA of the knee joint. Radiographic evidence of the knee with Ahlbäck classification grade 0.
16521035|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
16521036|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
16521037|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
16521038|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
16521039|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
16521040|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
16521041|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
16521042|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.
~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
16521043|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
16521044|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
16521045|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
16521046|NCT03147404|Experimental|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
16521047|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
16521050|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
16521051|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
16521052|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
16521053|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
16521054|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
16521055|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
16521056|NCT03147339|No Intervention|control|Low calorie diet
16521057|NCT03147326|Other|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:
~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
16521058|NCT03147313|Sham Comparator|Sham|
16521059|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
16521060|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
16521061|NCT03147300|Active Comparator|Östergötland region - Control group|
16521062|NCT03147300|Experimental|Östergötland region - Intervention group|
16521063|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
16521064|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye
~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
16521065|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye
~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
~Avelumab will be administered intravebously once every 2 weeks"
16521066|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
16521067|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
16521068|NCT03147261|Experimental|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
16521069|NCT03147261|No Intervention|No intervention|Healthy diet recommendations following the usual pediatric advice
16521070|NCT03147248|Active Comparator|Cohort 1: CT-P13 IV 3 mg/kg|CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
16521071|NCT03147248|Experimental|Cohort 2: CT-P13 SC 90 mg|CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
16521072|NCT03147248|Experimental|Cohort 3: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
16521073|NCT03147248|Experimental|Cohort 4: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
16521074|NCT03147248|Experimental|Arm 1: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
16521075|NCT03147248|Active Comparator|Arm 2: CT-P13 IV 3 mg/kg|CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
16521076|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
16521077|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
16521078|NCT03147222|Experimental|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
16521079|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
16521080|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16521081|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16521082|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16521083|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16521084|NCT03147183||candidates for renal transplant|
16521085|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
16521086|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
16521087|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
16521088|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
16521089|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
16521090|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
16521091|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).
~Device: Fitmore Short Stem"
16521092|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).
~Device: CLS Straight Stem"
16521093|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
16521094|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
16521095|NCT03147092|Experimental|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
16521096|NCT03147079|Experimental|Intervention|Lifestyle intervention
16521097|NCT03147079|Experimental|Internal controls|
16521098|NCT03147079|Experimental|External controls|
16521099|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
16521100|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
16521101|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
16521102|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
16521104|NCT03147027||VT ablation group|
16521105|NCT03147027||medication group|
16521106|NCT03147014|Other|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
16521107|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
16521108|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
16521109|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
16521110|NCT03146988|Active Comparator|Neulasta®|
16521111|NCT03146975|No Intervention|Healthy|
16521112|NCT03146975|Experimental|Periodontitis without diabetes|
16521117|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
16521118|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
16521119|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
16521120|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
16521121|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
16521122|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
16521123|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
16521124|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
16521125|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
16521126|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16521127|NCT03146858|Experimental|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
16521128|NCT03146845|Experimental|Allevyn Life Non-Bordered|Foam Dressing
16521129|NCT03146845|Other|Standard care|Standard care dressing
16521130|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
16521131|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
16521132|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
16521133|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
16521134|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
16521135|NCT03146806|Experimental|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
16521136|NCT03146780|Placebo Comparator|Conventional|
16521137|NCT03146780|Active Comparator|Digital 1|
16521138|NCT03146780|Active Comparator|Digital 2|
16521139|NCT03146780|Active Comparator|Digital 3|
16521140|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
16521141|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
16521142|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
16521143|NCT03146754|Active Comparator|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
16521144|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
16521145|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
16521146|NCT03146728||able-bodied|age height and weight matched able bodied
16521147|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
16521148|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
16521187|NCT03146403|Experimental|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
16521188|NCT03146403|Placebo Comparator|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
16521189|NCT03146390|Active Comparator|Essential oils (Listerine Mentol)|"a single mouthwash with 20 ml of essential oils for 30 seconds
~20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
16521149|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:
~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).
~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
16521150|NCT03146663|Experimental|Arm A|NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
16521151|NCT03146663|Experimental|Arm B|NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
16521152|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
16521153|NCT03146637|Experimental|Activated CIK armed with bispecific antibody treatment group|CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
16521154|NCT03146637|Active Comparator|Traditional CIK treatment group|CIK cells were not activated
16521155|NCT03146624|Experimental|attachment|attachment retained obturator
16521156|NCT03146624|Active Comparator|clasp|clasp retained obturator
16521157|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
16521158|NCT03146611||control|healthy sex and age matched group
16521159|NCT03146585||Patients on artificial ventilation|
16521160|NCT03146585||Patients on renal replacement therapy|
16521161|NCT03146585||Patients with targeted temperature management|
16521162|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
16521163|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
16521164|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.
~5 days per week, for 3 weeks, 15 minutes per day."
16521165|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.
~5 days per week, for 3 weeks, 15 minutes per day."
16521166|NCT03146546||Septic Shock|Patients with septic shock as defined by the Sepsis-3 criteria(9)
16521167|NCT03146546||Septic Shock with AKI|Patients with septic shock as defined by the Sepsis-3 criteria(9) with concomitant AKI
16521168|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
16521169|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
16521170|NCT03146520||Polyps|subjects with adenoma or polyps
16521171|NCT03146520||Other cancers|subjects with other cancers
16521172|NCT03146520||Healthy|subjects with no evidence of CRC
16521173|NCT03146494||STAAD|
16521174|NCT03146494||Normal|
16521175|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
16521176|NCT03146481|Placebo Comparator|placebo|Placebo
16521177|NCT03146468|Experimental|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
16521178|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
16521179|NCT03146442|Active Comparator|Normal Protein (NP) Breakfast|The participants in the NP Breakfast group will be provided with NP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The NP breakfasts will be 11% protein (10g protein), 63% CHO, and 26% fat. The types of protein incorporated within the NP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
16521180|NCT03146442|Experimental|High Protein (HP) Breakfast|The participants in the HP Breakfast group will be provided with HP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The HP breakfasts will be 34% protein (30g protein), 40% CHO, and 26% fat. The types of protein incorporated within the HP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
16521181|NCT03146442|Placebo Comparator|Breakfast Skipping (BS)|The participants in the BS group will continue to skip breakfast each day over the 6-month intervention. They will have nothing to eat or drink (besides water) until 11 am.
16521182|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
16521183|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
16521184|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
16521190|NCT03146390|Placebo Comparator|Water|"a single mouthwash with 20 ml of sterile water for 30 seconds
~20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
16521191|NCT03146390|Experimental|Alcohol free essential oils|"a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds
~20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
16521192|NCT03146377|Experimental|Xeloxiri|
16521193|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
16521194|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
16521195|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
16521196|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
16521197|NCT03146338|Experimental|Magnesium-rich mineral water (Rozana)|Patients in this arm must take 1.5 Liter by day of a mineral water rich in magnesium (Rozana) during the treatment by anti-EGFR. The mineral water is provided.
16521198|NCT03146338|No Intervention|Standard|Patients will have the usual care (oral advice only according to the habits of the investigator)
16521199|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
16521200|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
16521201|NCT03146312|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
16521202|NCT03146312|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
16521203|NCT03146299|Active Comparator|Group A: TLH|
16521204|NCT03146299|Active Comparator|Group B: LAVH|
16521205|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
16521206|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
16521207|NCT03146286|Experimental|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
16521208|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
16521209|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
16521210|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
16521211|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
16521212|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
16521213|NCT03146234|Experimental|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.
~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
16521214|NCT03146221|Other|Person to be surgically treated for arteritis|
16521215|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
16521216|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
16521217|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
16521218|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
16521219|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
16521220|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
16521221|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
16521222|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
16521223|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
16521224|NCT03146156|Experimental|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
16521225|NCT03146156|No Intervention|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
16521226|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
16521227|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
16521228|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
16521229|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
16521230|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
16521231|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
16521232|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
16521233|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
16521234|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
16521235|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
16521236|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
16521237|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
16521238|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
16521239|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
16521240|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
16521241|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
16521242|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
16521243|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
16521244|NCT03146000|Experimental|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
16521245|NCT03146000|Active Comparator|meloxicam|women will receive one 15 mg meloxicam rectal suppository
16521246|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
16521247|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
16521248|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
16521249|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
16521250|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
16521251|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
16521252|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
16521253|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
16521254|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
16521255|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
16521256|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
16521257|NCT03145922||Sarcoidosis|
16521258|NCT03145922||Healthy Controls|
16521259|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
16521260|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
16521261|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
16521262|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
16521263|NCT03145883|No Intervention|Control group|Control group
16521264|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
16521265|NCT03145870|Other|Patient with multiple symptomatic myeloma|
16521266|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven [68]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
16521267|NCT03145844||Direct Acting Agents|No Intervention
16521268|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
16521269|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
16521270|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
16521271|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
16521272|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
16521273|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
16521274|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
16521275|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
16521276|NCT03145766|Experimental|Group 1: VRVg-2 Formulation 1|VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.
16521277|NCT03145766|Experimental|Group 2: VRVg-2 Formulation 2|VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
16521278|NCT03145766|Experimental|Group 3: VRVg-2 Formulation 3|VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
16521279|NCT03145766|Experimental|Group 4: VRVg-1|VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
16521280|NCT03145766|Active Comparator|Group 5: Imovax Rabies|Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
16521281|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
16521282|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
16521283|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
16521284|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
16521285|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
16521286|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
16521287|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
16521288|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .
~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.
~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
16521289|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .
~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.
~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.
~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
16521290|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
16521291|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
16521292|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
16521293|NCT03145675|Experimental|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
16521294|NCT03145675|Active Comparator|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
16521295|NCT03145675|Experimental|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
16521296|NCT03145675|Active Comparator|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
16521297|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
16521298|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
16521299|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
16521300|NCT03145649||Healthy|Healthy mother-infant dyads
16521301|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
16521302|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
16521303|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
16521304|NCT03145610|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
16521305|NCT03145610|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
16521306|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
16521307|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
16521308|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
16521309|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
16521310|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
16521311|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
16521312|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
16521313|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
16521314|NCT03145532|Experimental|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
16521315|NCT03145532|Sham Comparator|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
16521316|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
16521317|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
16521318|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
16521319|NCT03145493|Experimental|Usage of suction drains|Usage of suction drains
16521320|NCT03145493|No Intervention|No usage of suction drains|No usage of suction drains
16521321|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
16521322|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
16521323|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
16521324|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
16521325|NCT03145454|Experimental|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
16521326|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
16521327|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
16521328|NCT03145415|Experimental|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
16521329|NCT03145415|Active Comparator|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
16544447|NCT02987933||Healthy Normals|Age and gender matched controls
16521330|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
16521331|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
16521332|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
16521333|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
16521334|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
16521335|NCT03145363|Experimental|Intervention|receive interactive text messages
16521336|NCT03145363|Active Comparator|Control|Receive informational text messages
16521337|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
16521338|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
16521339|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
16521340|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
16521341|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
16521342|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
16521343|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
16521344|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
16521345|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.
~Treatment with single agent Abiraterone Acetate (AA) until progression"
16521346|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.
~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
16521347|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.
~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
16521348|NCT03145259|Other|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]
16521349|NCT03145259|Other|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) [47 h study duration]
16521350|NCT03145259|Other|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]
16521351|NCT03145246||tooth loss|regeneration treated teeth loss
16521352|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
16521353|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
16521354|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
16521355|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
16521356|NCT03145220|Active Comparator|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
16521357|NCT03145220|Placebo Comparator|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
16521358|NCT03145207|Other|name brand patch|name brand lidocaine patch
16521359|NCT03145207|Other|generic patch|generic lidocaine patch
16521360|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
16521361|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
16521362|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
16521363|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
16521364|NCT03145207|Other|both patches|brand name and generic lidocaine patch
16521365|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
16521366|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
16521367|NCT03145181|Experimental|Part 1: Dose Escalation (IV)|Participants will receive Teclistamab intravenously (IV).
16521368|NCT03145181|Experimental|Part 2: Dose Expansion (IV)|Participants will receive Teclistamab IV.
16521369|NCT03145181|Experimental|Part 1: Dose Escalation (SC)|Participants will receive Teclistamab subcutaneously (SC).
16521370|NCT03145181|Experimental|Part 2: Dose Expansion (SC)|Participants will receive Teclistamab SC.
16521371|NCT03145168|Experimental|High Target Mean Arterial Pressure|
16521372|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
16521373|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
16521374|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
16521375|NCT03145142|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infant at a speed of 20cm over 2 seconds.
16521376|NCT03145142|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for at least 60 seconds.
16521377|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
16521378|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
16521379|NCT03145116|Experimental|509|
16521380|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
16521381|NCT03145077|Experimental|Cohort 1 (DCE-MRI)|Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
16521382|NCT03145077|Experimental|Cohort 2 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
16521383|NCT03145077|Experimental|Cohort 3 (DCE-MRI)|Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
16521384|NCT03145077|Experimental|Cohort 4 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
16521385|NCT03145064|Experimental|Zanubrutinib|Participants receive zanubrutinib twice daily (BID)
16521386|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
16521387|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
16521388|NCT03145038|Experimental|Treatment A|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fed, American breakfast
16521389|NCT03145038|Experimental|Treatment B|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fasted
16521390|NCT03145038|Experimental|Treatment C|Single oral dose of 25 x 0.1 mg vericiguat high-dose pediatric formulation, fed, American breakfast
16521391|NCT03145038|Active Comparator|Treatment D|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, American breakfast
16521392|NCT03145038|Experimental|Treatment E|Single oral dose of 10 mg vericiguat crushed IR tablet, adult formulation, fed, American breakfast
16521393|NCT03145038|Experimental|Treatment F|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, continental breakfast
16521394|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.
~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
16521395|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
16521396|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
16521397|NCT03144999|Experimental|High Dose|AAVCAGsCD59
16521398|NCT03144986|Experimental|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.
~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
16521399|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
16521400|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
~After surgery, study patients will receive trastuzumab IV x 14 cycles"
16521401|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
16521402|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7
~6 subjects per each cohort
~twice administration with 4-week intervals"
16521403|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)
~2 subjects per each cohort
~twice administration with 4-week intervals"
16521404|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
16521493|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
16521405|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention) about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
16521406|NCT03144895|Other|Arterial catheter|by anatomical placement alone
16521407|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
16521408|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
16521409|NCT03144882|Placebo Comparator|placebo|control group
16521410|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.
~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
16521411|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
16521412|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
16521413|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
16521414|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
16521415|NCT03144830|Experimental|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
16521416|NCT03144817|No Intervention|Control Group|
16521417|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
16521418|NCT03144804|Experimental|Lamivudine|"Lamivudine administered orally every 4 weeks
~Treatment cycles will last 28 consecutive days
~The dosage will be determine by the PI"
16521419|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
16521420|NCT03144778|Experimental|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
16521421|NCT03144778|Experimental|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
16521422|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
16521423|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
16521424|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
16521425|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
16521426|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
16521427|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
16521428|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
16521429|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
16521430|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
16521431|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
16521433|NCT03144687|Experimental|Cohort A|Participants with MF who were tolerating a ruxolitinib dose of less than 20 milligrams (mg) daily with no dose increase or no dose modification in the 8 weeks before screening visit received a combination of the itacitinib at the dose of 200 mg, orally, once daily (QD) and ruxolitinib, orally, twice daily (BID) at their previous stable dose (must had been < 20 mg daily). Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
16521494|NCT03144180|No Intervention|Control|The Q-cup will not be used to collect umbilical cord blood.
16521495|NCT03144180|Active Comparator|Study Group|The Q-cup will be used to collect umbilical cord blood.
16521496|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
16521434|NCT03144687|Experimental|Cohort B|Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
16521435|NCT03144674|Experimental|Cohort 1- Closed to Further enrollment|Participants who have received prior ibrutinib.
16521436|NCT03144674|Experimental|Cohort 2|Participants who have not received a prior BTK inhibitor.
16521437|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
16521438|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
16521439|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
16521440|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
16521441|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
16521442|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
16521443|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
16521444|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
16521445|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
16521446|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
16521447|NCT03144596|Experimental|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
16521448|NCT03144596|Active Comparator|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
16521449|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
16521450|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
16521451|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
16521452|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
16521453|NCT03144531|Experimental|SKIP Intervention|
16521454|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
16521455|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
16521456|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
16521457|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).
~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
16521497|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
16521498|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
16521458|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.
~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
16521459|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
16521460|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
16521461|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
16521462|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
16521463|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
16521464|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
16521465|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
16521466|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
16521467|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
16521468|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
16521469|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
16521470|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
16521471|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
16521472|NCT03144388|Experimental|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
16521473|NCT03144388|Active Comparator|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
16521474|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
16521475|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
16521476|NCT03144362|Active Comparator|Bilateral Sliding Technique|
16521477|NCT03144362|Active Comparator|Unilateral Sliding Techniques|
16521478|NCT03144362|No Intervention|Standard care|
16521479|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.
~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
16521480|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
16521481|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
16521482|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
16521483|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
16521484|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
16521485|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
16521486|NCT03144245|Experimental|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
16521487|NCT03144245|Experimental|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
16521488|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
16521489|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
16521490|NCT03144206|Experimental|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
16521491|NCT03144206|No Intervention|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
16521492|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
16521499|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
16521500|NCT03144128|Placebo Comparator|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
16521501|NCT03144128|Experimental|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
16521502|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
16521503|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
16521504|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
16521505|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
16521506|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
16521507|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
16521508|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
16521509|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
16521510|NCT03144089|Active Comparator|Guedel oral airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
16521511|NCT03144089|Experimental|Articulated Oral Airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Articulated oral airway first and measurements were taken during breaths 6 through 10. After its removal the Guedel Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
16521512|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
16521513|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
16521514|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
16521515|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
16521516|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:
~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy
~Clinician's diagnosis based on his/her assessment
~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
16521517|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:
~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
16521518|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:
~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
16521519|NCT03144050||0|Control - no diabetes
16521520|NCT03144050||1|Diabetes
16521521|NCT03144050||2|Diabetes w/neuropathy
16521522|NCT03144050||3|Diabetes with vascular disease
16521523|NCT03144050||4|Diabetes w/healed ulcer
16521524|NCT03144050||5|Diabetes with current ulcer
16521525|NCT03144024|Experimental|band|
16521526|NCT03144024|Active Comparator|Rigid ring|
16521527|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
16521528|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
16521529|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
16521530|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
16521531|NCT03143985|Experimental|Vactosertib + Pomalidomide|"Vactosertib tablets, taken once daily for the first and second dose levels and twice a day for third and fourth dose level levels for 5 days followed by 2 days without treatment, repeated for 28-day cycles until evidence of progressive disease, intolerable toxicity, or participant discontinuation.
~For dose escalation - dosing initiated at 60 mg once daily by oral administration and will be increased to determine MTD. Provisional subsequent doses are 60, 120, once daily and 100 mg and 200 mg twice daily on days 1-5, 8-12, 15-19 and 22-26. Extension cohorts will enter at 200 mg twice daily (i.e. if MTD not defined) for 12 months until progression or intolerable toxicity.
~POM is administered orally (4 mg/day daily on Days 1 - 21 days). Treatment will occur in a suitable outpatient ambulatory care setting that is equipped for monitoring of patients with hematopoietic malignancies undergoing early clinical trial research."
16521532|NCT03143972|Experimental|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.
~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
16521533|NCT03143972|Experimental|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
16521534|NCT03143972|Experimental|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).
~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
16521535|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
16521536|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
16521537|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
16521538|NCT03143920|Experimental|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
16521539|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
16521540|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
16521541|NCT03143894|Active Comparator|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
16521542|NCT03143894|Sham Comparator|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
16521543|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
16521544|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
16521545|NCT03143868|Experimental|Aerobic Exercise|
16521546|NCT03143868|Experimental|Resistance Exercise|
16521547|NCT03143868|Placebo Comparator|No Exercise|
16521548|NCT03143855|Experimental|Lorcaserin|
16521549|NCT03143855|Placebo Comparator|Control Group|
16521550|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
16521551|NCT03143829|Experimental|Intervention group|electronic Symptom Self-Management Training- CINV (eSSET-CINV) is an educational intervention administered once at the start of treatment
16521552|NCT03143829|Active Comparator|Wait Control group|The Wait control group receives the electronic Symptom Self-Management Training- CINV (eSSET-CINV) at the last study visit. Outcomes will be compared to the Intervention group at the end of the study.
16521553|NCT03143816|Active Comparator|Technosphere insulin (TI, Afrezza) -Treatment arm|
16521554|NCT03143816|No Intervention|Insulin Aspart ( Novolog) -Control arm|
16521555|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
16521556|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
16521557|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
16521558|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
16521559|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
16521560|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
16521561|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
16521562|NCT03143751|No Intervention|Control|Standard cares alone.
16521563|NCT03143738|Experimental|continuous anesthesia of adductor canal|
16521564|NCT03143738|Experimental|continuous anesthesia of femoral nerve|
16521565|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
16521566|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
16521567|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
16521568|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
16521569|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
16521570|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
16521571|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
16521572|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
16521573|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
16521574|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
16521575|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
16521576|NCT03143660|Active Comparator|Coaching|A parent support component consisting of eight weekly telephone counseling calls by centrally located nutritionists to provide parents coaching tailored to their family's unique needs to help them set goals and make targeted lifestyle changes recommended by the American Academy of Pediatrics (AAP) for Stage 1, Prevention Plus, accompanied by a parent booklet
16521577|NCT03143660|Active Comparator|Materials|Parents will receive the same educational materials provided in the Fitline family workbook mailed over 8 weeks to control for weekly contact and educational curriculum, but no Fitline counseling.
16544690|NCT02986321|Placebo Comparator|Matched placebo|placebo control
16521578|NCT03143647||Control|"Female
~Over 18 years of age
~American Society of Anesthesiologists physical fitness scale 1
~Not pregnant"
16521579|NCT03143647||Case|"Female
~Pregnant with possible pre-eclampsia
~Over 18 years of age
~American Society of Anesthesiologists physical fitness scale 1"
16521580|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:
~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
16521581|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
16521582|NCT03143621|Experimental|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
16521583|NCT03143621|Placebo Comparator|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
16521584|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
16521585|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
16521586|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
16521587|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
16521588|NCT03143582|Experimental|Running group|13 week, bi-weekly running group
16521589|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
16521590|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
16521591|NCT03143556|Experimental|Magnetic Stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for magnetic stent group will receive magnetic stent and the removal of stent would be done by help of magnetic device.
16521592|NCT03143556|No Intervention|Routine stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for routine stent would receive routine stent and the removal of stent would be done by cystoscopy
16521593|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
16521594|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
16521595|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
16521596|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
16521597|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
16521598|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
16521599|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
16521600|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
16521601|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
16521602|NCT03143504|Other|Single arm.|All participants in the same arm.
16521603|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
16521604|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
16521605|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
16521606|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
16521607|NCT03143465|Experimental|CGRP|
16521608|NCT03143465|Experimental|Sildenafil|
16521609|NCT03143465|Placebo Comparator|Placebo|
16521610|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
16521611|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
16521612|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
16521613|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
16521614|NCT03143426|Experimental|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
16521615|NCT03143426|No Intervention|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
16521616|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
16521617|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
16521618|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
16521619|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
16521620|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
16521621|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
16521622|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
16521623|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
16521624|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
16521625|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
16521626|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
16521627|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
16521628|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
16521629|NCT03143322|Experimental|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
16521630|NCT03143322|No Intervention|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)
16521631|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
16521632|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
16521633|NCT03143296|Experimental|Current recipient of a Med-El cochlear implant|Participants who have received a MED-EL cochlear implant as a standard of care for treatment of hearing loss. Participants are tested at one time point with a simulated reverberant environment.
16521634|NCT03143296|Active Comparator|Future Med-El Recipient|Cochlear implant candidates not yet implanted and chose Med-El device as standard of care for treatment of hearing loss. Participants are tested at 3 time points over 6 months in a simulated reverberant environment.
16521635|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
16521636|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
16521637|NCT03143270|Experimental|Cohort 1, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Two weeks after deb-TACE, participants will begin nivolumab every two weeks for up to one year. If no participants experience a dose limiting toxicity (DLT), or 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 2.
16521638|NCT03143270|Experimental|Cohort 2, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Participants will receive nivolumab every two weeks for up to one year, starting 4 weeks prior to deb-TACE (week -4). Participants in this cohort will not receive nivolumab on the day of deb-TACE. If no participants experience a DLT in the initial group of 3 participants or if 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 3.
16521639|NCT03143270|Experimental|Cohort 3, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Nivolumab will be dosed every two weeks starting 4 weeks prior to deb-TACE (Week 4) and continue every 2 weeks for up to one year. If no participants experience a DLT in the initial group of 3 participants, an additional 3 participants will be added to confirm safety. If less than or equal to 1 of 6 participants experiences a DLT, this will be considered the optimal schedule.
16521640|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
16521641|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
16521642|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
16521643|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
16521644|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
16521645|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
16521646|NCT03143218|Active Comparator|SMC with SP+AQ|Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
16521647|NCT03143218|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
16521709|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
16521648|NCT03143218|Active Comparator|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
16521649|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
16521650|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
16521651|NCT03143192|Experimental|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
16521652|NCT03143192|Sham Comparator|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
16521653|NCT03143166|Experimental|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
16521654|NCT03143153|Experimental|Nivolumab + Ipilimumab|
16521655|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
16521656|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
16521657|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
16521658|NCT03143140|Other|tumor ablation|ablation of tumor directly
16521659|NCT03143114|Experimental|Myomectomy|Women will be subjected to laparotomy to remove the myomas
16521660|NCT03143114|No Intervention|Conservative management|Women will not be subjected to surgery (conservative management)
16521661|NCT03143101|Experimental|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
16521662|NCT03143101|Experimental|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
16521663|NCT03143101|Experimental|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
16521664|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
16521665|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
16521666|NCT03143075|Active Comparator|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
16521667|NCT03143075|Active Comparator|Non-inflammation group|Subjects with CRP<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
16521668|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
16521669|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
16521670|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
16521671|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
16521672|NCT03143036|Experimental|Daratumumab, thalidomide and dexamethasone|
16521673|NCT03143023|Experimental|arginine toothpaste|
16521674|NCT03143023|Active Comparator|fluoride toothpaste|
16521675|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
16521676|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
16521677|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
16521678|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
16521679|NCT03142997||group S|anesthetized children on spontaneous ventilation.
16521680|NCT03142997||group C|anesthetized children on controlled ventilation.
16521681|NCT03142984|Experimental|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash & Shampoo product and Baby Lotion.
~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
16521682|NCT03142984|Experimental|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.
~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Alternative Baby Wash & Shampoo (GTIN/UPC # 5011451106260)"
16521683|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
16521684|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
16521685|NCT03142958|Other|Integra® Cadence™ Total Ankle System|
16521851|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
16521686|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
16521687|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
16521688|NCT03142932|Active Comparator|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
16521689|NCT03142932|Experimental|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.
~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
16521690|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
16521691|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
16521692|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
16521693|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
16521694|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
16521695|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
16521696|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule
~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
16521697|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule
~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
16521698|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill
~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
16521699|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes
~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
16521700|NCT03142880|Active Comparator|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
16521701|NCT03142880|Experimental|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
16521702|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
16521703|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
16521704|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
16521705|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
16521706|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).
~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
16521707|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
16521708|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
16521852|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
16521710|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
16521711|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
16521712|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.
~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.
~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
16521713|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.
~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.
~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
16521714|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).
~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
16521715|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
16521716|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
16521717|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
16521718|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
16521719|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
16521720|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
16521721|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
16521722|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
16521723|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
16521724|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
16521725|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
16521726|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
16521727|NCT03142724|Experimental|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-968.
16521728|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
16521729|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
16521730|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
16521731|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
16521732|NCT03142672|Active Comparator|Control group|Tooth filling
16521733|NCT03142646|Experimental|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
16521734|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study
~Inclusion criteria:
~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
16521735|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
16521736|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
~+ vitamin D3 IU for 10 days"
16521737|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
~+ vitamin D3 IU for 28 days"
16521738|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
16521739|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
16521910|NCT03141424|Active Comparator|Group A|Usual care. Unchanged asthma medication during the entire study period.
16521740|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
16521741|NCT03142568|Experimental|Sildenafil cohort 1|Within cohort 1 infants will be randomized using a 3:1 scheme to receive sildenafil or placebo. Infants randomized to sildenafil will receive 0.125 mg/kg daily every 8 hours intravenously (IV), or 0.25 mg/kg daily every 8 hours enterally for 28 days.
16521742|NCT03142568|Placebo Comparator|Placebo cohort 1|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
16521743|NCT03142568|Experimental|Sildenafil cohort 2|Cohort 2 infants will receive sildenafil 0.5 mg/kg daily every 8 hours intravenously (IV) or 1 mg/kg daily every 8 hours enterally for 28 days.
16521744|NCT03142568|Placebo Comparator|Placebo cohort 2|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
16521745|NCT03142568|Experimental|Sildenafil cohort 3|Cohort 3 infants will receive sildenafil 1 mg/kg daily every 8 hours intravenously (IV) or 2 mg/kg daily every 8 hours enterally for 28 days.
16521746|NCT03142568|Placebo Comparator|Placebo cohort 3|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
16521747|NCT03142555|Experimental|Health talk plus intensive social media intervention|"Subjects in this group will receive:
~General health talk;
~Phone follow-up/counselling service (15 - 30 minutes);
~Social media (intensive reminders);
~Regular personalized what's app interaction ( up to 2 months duration)"
16521748|NCT03142555|Placebo Comparator|Health talk plus less intensive social media intervention|"Subjects in this group will receive:
~General health talk;
~Phone follow-up/counselling service (15 - 30 mintues);
~Social media ( less intensive reminders)"
16521749|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
16521750|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
16521751|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
16521752|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
16521753|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
~FOLFIRI
~Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.
~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
16521754|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
16521755|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
16521756|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
16521757|NCT03142490|Experimental|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
16521758|NCT03142490|Active Comparator|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
16521759|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
16521760|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
16521761|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
16521762|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
16521763|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
16521764|NCT03142451|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
16521765|NCT03142451|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
16521766|NCT03142438|Experimental|F&P Seal Improvement Project|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
16521767|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
16521768|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
16521769|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
16521770|NCT03142386|Active Comparator|Control Group|Physiotherapy
16521771|NCT03142373|Experimental|CV4 group|CV4 technique
16521772|NCT03142373|Experimental|RR group|Rib Raising technique
16521773|NCT03142373|Placebo Comparator|Placebo group|Light touch
16521774|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
16521775|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
16521776|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
16521777|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
16521778|NCT03142334|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles.
16521779|NCT03142334|Placebo Comparator|Placebo|Participants receive placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles.
16521780|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
16521781|NCT03142308||Surgeons|Young surgeons in all surgical specialities
16521782|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
16521783|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
16521784|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
16521785|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
16521786|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
16521787|NCT03142256|Active Comparator|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
16521788|NCT03142256|No Intervention|No incentive|Truvada 200Mg-300Mg Tablet
16521789|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
16521790|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
16521791|NCT03142217|Other|Patient with Huntington's Disease|
16521792|NCT03142191|Experimental|CC-90001 400 mg PO QD|55 subjects will be randomized to CC-90001 400mg
16521793|NCT03142191|Experimental|CC-90001 200 mg PO QD|55 subjects will be randomized to CC-90001 200mg
16521794|NCT03142191|Placebo Comparator|Placebo PO QD|55 subjects will be randomized to placebo
16521795|NCT03142191|Experimental|CC-90001 400 mg PO QD- Sub-Study|30 subjects will be randomized to CC-90001 400mg
16521796|NCT03142191|Placebo Comparator|Placebo PO QD- Sub-Study|15 subjects will be randomized to placebo
16521797|NCT03142178|Experimental|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
16521798|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
16521799|NCT03142178|Experimental|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
16521800|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
16521801|NCT03142178|Experimental|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
16521802|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
16521803|NCT03142165|Experimental|BMS-986263|
16521804|NCT03142165|Placebo Comparator|Placebo|
16521807|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib
~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
16521808|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
16521809|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
16521810|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
16521811|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
16521812|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
16521813|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA
~ECG-gated CT"
16521814|NCT03142061|Experimental|ECT|
16521969|NCT03141086|Experimental|Group 1|LML134, then placebo
16521815|NCT03142048|Experimental|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
16521816|NCT03142048|No Intervention|Comparison Group|Participants in the study that do not receive the intervention
16521817|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
16521818|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
16521819|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
16521820|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
16521821|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
16521822|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
16521823|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
16521824|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
16521825|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).
~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
16521826|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
16521827|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
16521828|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
16521829|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
16521830|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
16521831|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.
~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
16521832|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.
~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
16521833|NCT03141931|Experimental|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
16521834|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
16521835|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
16521836|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
16521837|NCT03141905|Active Comparator|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring
16521838|NCT03141905|Placebo Comparator|Usual Care|Standard clinical care
16521839|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
16521840|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
16521841|NCT03141879|No Intervention|Regular care|(Wait-list control)
16521842|NCT03141866|Experimental|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
16521843|NCT03141866|Experimental|Exercise Intervention 2: Machine-based resistance training|Specialised, chair-based resistance training equipment for older adults.
16521844|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
16521845|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
16521846|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
16521847|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
16521848|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
16521849|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
16521850|NCT03141814||asthma|20 patients with ongoing ashma
16521853|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
16521854|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
16521855|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
16521856|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
16521857|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
16521858|NCT03141788|Other|3M Clear Aligner|Clear Aligner for Orthodontic Treatment
16521859|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
16521864|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
16521865|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
16521866|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
16521867|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
16521868|NCT03141710|Experimental|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
16521869|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
16521870|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
16521871|NCT03141684|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16521872|NCT03141684|Experimental|Arm II (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16521873|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months
~Bicalutamide by mouth once/day for 6 months
~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
16521874|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months
~Abiraterone acetate by mouth once/day for 6 months
~Prednisone by mouth once/day for 6 months
~Apalutamide by mouth once/day for 6 months
~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
16521875|NCT03141658|Experimental|TS-134 20 mg|
16521876|NCT03141658|Experimental|TS-134 60 mg|
16521877|NCT03141658|Experimental|Placebo|
16521878|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
16521879|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
16521880|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
16521881|NCT03141632|Active Comparator|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
16521882|NCT03141632|Placebo Comparator|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
16521883|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
16521884|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
16521885|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
16521886|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
16521887|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
16521888|NCT03141580|Experimental|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
16521889|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
16521890|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
16521891|NCT03141554|Active Comparator|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C
~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
~Treatment C = Normal saline gargle (lukewarm)."
16521892|NCT03141554|Active Comparator|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A
~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
~Treatment C = Normal saline gargle (lukewarm).
~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
16521893|NCT03141554|Active Comparator|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -> A -> B
~Treatment C = Normal saline gargle (lukewarm).
~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
16521894|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
16521895|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
16521896|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
16521897|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
16521898|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
16521899|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
16521900|NCT03141502|Experimental|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
16521901|NCT03141502|Active Comparator|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
16521902|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
16521903|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
16521904|NCT03141476|Other|Cefuroxime 1,5g|BMI <30kg/m*m
16521905|NCT03141476|Other|Cefuroxime 3g|BMI 30-50kg/m*m
16521906|NCT03141476|Other|Cefuroxime 4,5g|BMI >50kg/m*m
16521907|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
16521908|NCT03141437|Active Comparator|Arm I (standard of care)|Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
16521909|NCT03141437|Experimental|Arm II (standard of care, decision-making website)|Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
16521911|NCT03141424|Experimental|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
16521912|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
16521913|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
16521914|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
16521915|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
16521916|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
16521917|NCT03141359|Experimental|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
16521918|NCT03141346|Active Comparator|Control|A control health education program to promote general health and safety
16521919|NCT03141346|Experimental|Sugar Reduction Program Only|A health education program that focuses on sugar reduction
16521920|NCT03141346|Experimental|Sugar Reduction Program & Water Delivery|A health education program that focuses on sugar reduction and provides home bottled water delivery
16521921|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
16521922|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
16521923|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
16521924|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
16521925|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
16521926|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
16521927|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
16521928|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
16521929|NCT03141281|Experimental|IADL training|Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
16521930|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
16521931|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
16521932|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
16521933|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
16521934|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
16521935|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
16521936|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
16521937|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
16521938|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
16521939|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
16521970|NCT03141086|Experimental|Group 2|Placebo, then LML134
16521971|NCT03141073|Experimental|HMS5552|75mg BID
16521940|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
16521941|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
16521942|NCT03141203|Experimental|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
16521943|NCT03141203|Experimental|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
16521944|NCT03141203|Experimental|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
16521945|NCT03141203|Experimental|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
16521946|NCT03141203|Experimental|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
16521947|NCT03141203|Experimental|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
16521948|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
16521949|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
16521953|NCT03141164|Experimental|Training|Computerized vision training
16521954|NCT03141164|Sham Comparator|Control|Sham
16521955|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
16521956|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
16521957|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
16521958|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
16521959|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
16521960|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
16521961|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.
~In addition, patients also received standard therapy for scleroderma."
16521962|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
16521963|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
16521964|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
16521965|NCT03141099|Active Comparator|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
16521966|NCT03141099|Active Comparator|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
16521967|NCT03141099|Active Comparator|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
16521968|NCT03141099|Active Comparator|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
16521973|NCT03141060|Experimental|Arm 1: Delamanid|Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
16521974|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
16521975|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
16521976|NCT03141034|Experimental|Irinotecan plus ramucirumab|-Patients will receive ramucirumab intravenously on an outpatient basis at a dose of 8 mg/kg over the course of 60 minutes on Day 1 of each 14-day cycle. They will then receive irinotecan intravenously at a dose of 180 mg/m2 over the course of 90 minutes on Day 1 of each 14-day cycle.
16521977|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:
~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
16521978|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:
~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
16521979|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
16521980|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
16521981|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
16521982|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
16521983|NCT03140969|Experimental|QR-110|Administered every 3 months
16521984|NCT03140956|Experimental|Levodopa formulation D|Levodopa formulation D
16521985|NCT03140956|Experimental|Levodopa formulation E|Levodopa formulation E
16521986|NCT03140956|Experimental|Levodopa formulation F|Levodopa formulation F
16521987|NCT03140956|Active Comparator|Sinemet IR 100/25mg|Sinemet IR 100/25MG
16521988|NCT03140956|Active Comparator|Sinemet CR 100/25mg|Sinemet IR 100/25MG
16521989|NCT03140956|Experimental|ODM-104 100mg|ODM-104 100MG
16521990|NCT03140956|Active Comparator|Carbidopa 20mg|Carbidopa 20MG
16521991|NCT03140956|Active Comparator|Carbidopa 65mg|Carbidopa 65MG
16521992|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
16521993|NCT03140930|Experimental|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
16521994|NCT03140930|Experimental|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
16521995|NCT03140930|Experimental|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
16521996|NCT03140930|Placebo Comparator|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
16521997|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
16521998|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
16521999|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
16522000|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
16522001|NCT03140878|Experimental|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
16522002|NCT03140878|Placebo Comparator|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
16522003|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
16522004|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
16522005|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
16522006|NCT03140852|Active Comparator|Treatment|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the spring 2017.
16522007|NCT03140852|Other|Control|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the fall 2017.
16522047|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
16522008|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
16522009|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
16522010|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
16522011|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
16522012|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
16522013|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
16522014|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
16522015|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
16522016|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
16522017|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
16522018|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
16522019|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
16522020|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
16522021|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
16522022|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
16522023|NCT03140774||Cohort 3: Phase 2 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo
16522024|NCT03140748|Other|Patients with fungal peritonitis|
16522025|NCT03140748|Other|Patients with peritonitis without yeast|
16522026|NCT03140735|Other|Control group of 150 heart disease-free individuals|
16522027|NCT03140735|Other|Patients with aortic sclerosis|
16522028|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
16522029|NCT03140735|Other|Patients with Serious Aortic Retention|
16522030|NCT03140722|Experimental|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
16522031|NCT03140722|Active Comparator|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
16522032|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
16522033|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
16522038|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
16522039|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
16522040|NCT03140644|Experimental|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
16522041|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
16522042|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
16522043|NCT03140618|Experimental|LEPPIC|The light and environment project in psychiatric inpatient care
16522044|NCT03140566|Experimental|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
16522045|NCT03140566|Sham Comparator|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
16522046|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
16522048|NCT03140540|Active Comparator|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
16522049|NCT03140540|Active Comparator|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
16522050|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
16522051|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
16522052|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
16522053|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
16522054|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
16522055|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
16522056|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
16522057|NCT03140527|Active Comparator|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
16522058|NCT03140527|Placebo Comparator|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
16522059|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
16522060|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
16522061|NCT03140527|Active Comparator|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
16522062|NCT03140527|Placebo Comparator|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
16522063|NCT03140527|Active Comparator|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
16522064|NCT03140527|Placebo Comparator|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
16522065|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
16522066|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
16522067|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
16522094|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
16522068|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
16522069|NCT03140488|No Intervention|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol
~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
16522070|NCT03140488|Experimental|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol
~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
16522071|NCT03140488|No Intervention|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol
~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
16522072|NCT03140488|Experimental|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol
~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
16522073|NCT03140475||Individuals with schizophrenia|"Behavioral variables:
~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)
~Physiological variables:
~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)
~Clinical variables:
~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents
~Neuropsychological variables:
~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
16522074|NCT03140475||Controls|"Behavioral variables:
~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /
~Physiological variables:
~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /
~Clinical variables:
~Calgary Depression Scale
~Neuropsychological variables:
~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
16522075|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
16522076|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
16522077|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
16522078|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
16522079|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
16522080|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
16522081|NCT03140423|Active Comparator|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
16522082|NCT03140423|Active Comparator|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
16522083|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
16522084|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
16522085|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
16522086|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
16522087|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
16522088|NCT03140384|Active Comparator|Administration of oral Misoprostol|
16522089|NCT03140384|Active Comparator|Administration of Misoprostol vaginally|
16522090|NCT03140384|Active Comparator|Administration of buccal Misoprostol|
16522091|NCT03140371|Experimental|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.
~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
16522092|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
16522093|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
16522098|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
16522099|NCT03140306|Experimental|Low dose CT abdomen and pelvis|Low dose computed tomography
16522100|NCT03140306|Experimental|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
16522101|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
16522102|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
16522103|NCT03140280|Experimental|Dietary Intervention|Freeze-dried black raspberry powder administration.
16522104|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
16522105|NCT03140254|Active Comparator|comparator|Chlorhexidine gluconate
16522106|NCT03140254|Experimental|experimental|BDIP-0001
16522107|NCT03140254|Placebo Comparator|placebo|Vehicle
16522108|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
16522109|NCT03140228|Experimental|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
16522110|NCT03140228|Active Comparator|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
16522111|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
16522112|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
16522113|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
16522114|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
16522115|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
16522116|NCT03140150|Experimental|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
16522117|NCT03140150|Other|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
16522118|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
16522119|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
16522120|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
16522121|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
16522122|NCT03140085|Active Comparator|Anbiotica|
16522123|NCT03140085|Active Comparator|Bacteriophages|
16522124|NCT03140085|Placebo Comparator|Placebo|
16522125|NCT03140072|Experimental|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
16522126|NCT03140072|Placebo Comparator|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
16522127|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
16522128|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
16522129|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
16522130|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
16522131|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
16522132|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
16544691|NCT02986321|Active Comparator|Budesonide|Budesonide DPI 800µg
16522133|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
16522134|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
16522135|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
16522136|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
16522137|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
16522138|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
16522139|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
16522140|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
16522141|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
16522142|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
16522143|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
16522144|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
16522145|NCT03139942|Experimental|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
16522147|NCT03139890|Experimental|High-fat milkshake|
16522148|NCT03139890|Experimental|High-carbohydrate milkshake|
16522149|NCT03139890|Experimental|High-protein milkshake|
16522150|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.
~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.
~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
16522151|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
16522152|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.
~This group will be asked to provide a fecal and blood sample at one time point."
16522153|NCT03139864|Experimental|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
16522154|NCT03139864|Active Comparator|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
16522155|NCT03139851|Other|Cyclophosphamide and Pembrolizumab|"The treatments received are:
~cyclophosphamide (50 mg/day, daily, per os)
~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
16522156|NCT03139838|Active Comparator|EHR-Based Intervention A|Intervention A (Prognostication) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
16522157|NCT03139838|Active Comparator|EHR-Based Intervention B|Intervention B (Accountable Justification) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
16522158|NCT03139838|Active Comparator|Combined EHR-Based Intervention (A+B)|Intervention A and B prompts will be combined and triggered for eligible patients simultaneously. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
16522208|NCT03139474|Active Comparator|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
16522415|NCT03137992|Active Comparator|Reference Product (Spiriva®)|Single dose of reference product (Spiriva®) 18 mcg
16522159|NCT03139838|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 5 months of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the hospital. The length of the control phase will differ at each hospital, dependent on the sequence in which hospitals are assigned to switch to the intervention phase.
16522160|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
16522161|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
16522162|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
16522163|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
16522164|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
16522165|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
16522166|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
16522167|NCT03139760|Experimental|POWERSforID|POWERSforID intervention group
16522168|NCT03139760|No Intervention|Control|Usual clinical care
16522169|NCT03139747|Experimental|Single Arm|
16522170|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
16522172|NCT03139708|Experimental|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
16522173|NCT03139708|Experimental|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
16522174|NCT03139708|Active Comparator|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
16522175|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
16522176|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
16522177|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
16522178|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
16522179|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
16522180|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
16522313|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 200 mg|Participants with CD having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522181|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
16522182|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
16522183|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
16522184|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
16522185|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
16522186|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
16522187|NCT03139604|Experimental|Itacitinib|Itacitinib plus corticosteroids
16522188|NCT03139604|Placebo Comparator|Placebo|Matching placebo plus corticosteroids
16522189|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
16522190|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
16522191|NCT03139578|Experimental|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
16522192|NCT03139578|Experimental|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
16522193|NCT03139578|Experimental|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
16522194|NCT03139578|Experimental|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
16522195|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
16522196|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
16522197|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
16522198|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
16522199|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
16522200|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
16522201|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
16522202|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
16522203|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
16522204|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
16522205|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
16522206|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
16522207|NCT03139487|Experimental|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks
~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
16522209|NCT03139474|Active Comparator|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
16522210|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
16522211|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
16522212|NCT03139448|Active Comparator|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
16522213|NCT03139448|Experimental|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
16522214|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
16522215|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
16522216|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
16522217|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
16522218|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
16522219|NCT03139396|Active Comparator|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
16522220|NCT03139396|Experimental|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
16522221|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
16522222|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
16522223|NCT03139370|Experimental|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.
~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
16522224|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
16522225|NCT03139344|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session low-frequency exercise or high-frequency exercise.
16522226|NCT03139344|Experimental|Training study|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with high-frequency exercise.
16522227|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
16522228|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
16522229|NCT03139305|Active Comparator|Glucagon Low Dose|
16522230|NCT03139305|Active Comparator|Glucagon High Dose|
16522231|NCT03139305|Placebo Comparator|Placebo|
16522232|NCT03139292|Experimental|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
16522233|NCT03139292|Experimental|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
16522234|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
16522235|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
16522236|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
16522237|NCT03139266|Other|Control Group|Treatment-as-usual
16522238|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.
~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
16522239|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
16522240|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
16522241|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
16522242|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
16522243|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
16522244|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
16522245|NCT03139227|Experimental|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
16522246|NCT03139214|Experimental|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
16522247|NCT03139214|No Intervention|Control|3 mailings about child development and stress management.
16522248|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
16522249|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
16522250|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
16522251|NCT03139175|Active Comparator|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
16522252|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
16522253|NCT03139149|Active Comparator|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
16522254|NCT03139149|Active Comparator|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
16522255|NCT03139136|Active Comparator|MBS2320|
16522256|NCT03139136|Placebo Comparator|Placebo|
16522257|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
16522258|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
16522259|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
16522260|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
16522261|NCT03139058|Other|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
16522262|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
16522263|NCT03139045|Active Comparator|Venous puncture without VVV|
16522264|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
16522265|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
16522266|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
16522267|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
16522268|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
16522269|NCT03138993|Active Comparator|Patient decision aid|
16522270|NCT03138993|Sham Comparator|General sleep education|
16522271|NCT03138980|Experimental|Mobile application|
16522272|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.
~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
16522351|NCT03138447|No Intervention|Retrospective Cohort|
16522416|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
16522273|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.
~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
16522274|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
16522275|NCT03138902|Experimental|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
16522281|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
16522282|NCT03138863|Experimental|Fetuses with Left CDH|Performance of fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
16522283|NCT03138850|Experimental|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
16522284|NCT03138850|Experimental|YX Mandibular advancement bite block|Mandibular advancement bite block group
16522285|NCT03138850|Experimental|Optiflow High flow nasal cannula|High flow nasal cannula group
16522286|NCT03138824|Experimental|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
16522287|NCT03138824|Experimental|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
16522288|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
16522289|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
16522290|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
16522291|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
16522292|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
16522293|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
16522294|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
16522295|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
16522296|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
16522297|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
16522298|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
16522299|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
16522300|NCT03138733|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg
16522301|NCT03138733|Active Comparator|Daptomycin|Daptomycin 6 mg/kg, with or without Aztreonam
16522302|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
16522303|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
16522304|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
16522305|NCT03138681|Placebo Comparator|Placebo|
16522306|NCT03138681|Experimental|ATP|
16522307|NCT03138681|Experimental|phosphocreatine|
16522308|NCT03138668|Experimental|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
16522309|NCT03138668|Experimental|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
16522310|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 100 mg|Participants with UC having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522311|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 200 mg|Participants with UC having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522312|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 100 mg|Participants with CD having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522314|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 150 mg|Participants with UC having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522315|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 300 mg|Participants with UC having baseline weight of >=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522316|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 150 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522317|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 300 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
16522318|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
16522319|NCT03138616|Experimental|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
16522320|NCT03138616|No Intervention|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~only receive lifestyle intervention."
16522321|NCT03138616|Experimental|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
16522322|NCT03138616|No Intervention|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~only receive lifestyle intervention."
16522323|NCT03138603|Experimental|Metoprolol|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg prior to extubation, and subsequently an oral doser 25mg metoprolol tartrate) in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
16522324|NCT03138603|Placebo Comparator|Placebo|Patients will receive up to 3 IV doses of placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
16522325|NCT03138590|Experimental|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
16522326|NCT03138590|Sham Comparator|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
16522327|NCT03138577|Other|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522328|NCT03138577|Other|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522329|NCT03138577|Other|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522330|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522331|NCT03138577|Other|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522332|NCT03138577|Other|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522333|NCT03138577|Other|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
16522334|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
16522335|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
16522336|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.
~A: Baseline - typical mealtimes in the home.
~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.
~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
16522337|NCT03138538|Experimental|Part 1: M8891|
16522338|NCT03138538|Experimental|Part 2A: Dose Escalation Cohort: M8891 and Cabozantinib|
16522339|NCT03138538|Experimental|Part 2B: Dose Expansion Cohort: M8891 and Cabozantinib|
16522340|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
16522341|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
16522347|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
16522348|NCT03138499|Experimental|Module B|Brentuximab alone
16522349|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
16522350|NCT03138447|Experimental|Prospective Cohort|
16522352|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
16522353|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.
~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.
~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
16522354|NCT03138421|Experimental|ABX-1431 HCl|
16522355|NCT03138421|Placebo Comparator|Placebo|
16522356|NCT03138408|Experimental|SC-004|
16522357|NCT03138408|Experimental|SC-004 and ABBV-181|
16522358|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
16522359|NCT03138382|Experimental|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
16522360|NCT03138382|Experimental|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
16522361|NCT03138356|Experimental|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
16522362|NCT03138356|Experimental|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
16522363|NCT03138356|Active Comparator|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
16522364|NCT03138356|Experimental|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state
~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
16522365|NCT03138356|Experimental|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
16522366|NCT03138356|Active Comparator|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
16522367|NCT03138356|Experimental|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
16522368|NCT03138356|Experimental|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
16522369|NCT03138356|Active Comparator|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
16522370|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
16522371|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
16522372|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
16522373|NCT03138304|Experimental|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
16522374|NCT03138304|Active Comparator|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
16522375|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
16522376|NCT03138278|No Intervention|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
16522377|NCT03138278|Active Comparator|Telephone support|ICU with day-time telephone support to care-givers
16522378|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
16522379|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
16522380|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
16522381|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)
~4 patients who have tested at staging, will be tested again after treatment.
~4 patients with treatment failure or recurrence."
16522382|NCT03138213|Experimental|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
16522383|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
16522384|NCT03138200|Other|Blood transfusion based on central venous oxygen saturation|
16522385|NCT03138187|No Intervention|control|without physical exercise sessions
16522386|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
16522387|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
16522388|NCT03138174||Diabetes|One group consisting of diabetic subjects
16522389|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.
~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
16522390|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
16522391|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
16522392|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
16522393|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
16522394|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
16522395|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
16522396|NCT03138096|Experimental|Group 1|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
16522397|NCT03138096|Experimental|Group 2|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
16522398|NCT03138096|Experimental|Group 3|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
16522399|NCT03138096|Other|Group 4|Infectivity control group
16522400|NCT03138096|Other|Group 5|Infectivity control group
16522401|NCT03138083|Experimental|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
16522402|NCT03138083|Experimental|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
16522403|NCT03138083|Experimental|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
16522404|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
16522405|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
16522406|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
16522407|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
16522408|NCT03138044|Experimental|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
16522409|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
16522410|NCT03138018|Active Comparator|Standard instruction|
16522411|NCT03138018|Experimental|Reduced threat instruction|
16522412|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
16522413|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
16522414|NCT03137992|Experimental|Test Product (tiotropium bromide inhalation powder)|Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
16522417|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
16522418|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
16522419|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
16522420|NCT03137966|Active Comparator|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
16522421|NCT03137966|Placebo Comparator|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
16522422|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
16522423|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
16522424|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
16522425|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
16522426|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
16522427|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
16522428|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
16522429|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
16522430|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
16522431|NCT03137914|Experimental|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis). Hyaluronic acid is used only as a soluble medium to dilute the chondrocytes, so it is not considered as another experimental group, or as part of interest in this investigation.
16522432|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
16522433|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
16522434|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
16522435|NCT03137875||patient smear negative|patient with a negative TB microscopy result
16522436|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
16522437|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
16522438|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
16522439|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
16522440|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
16522441|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
16522442|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
16522443|NCT03137836|Experimental|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
16522444|NCT03137836|No Intervention|Control|Control classroom will maintain their routine in sitting desks.
16522445|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
16522446|NCT03137810|Experimental|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
16522447|NCT03137810|Active Comparator|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
16522448|NCT03137784|Other|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
16522449|NCT03137784|Other|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
16522450|NCT03137784|Other|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
16522451|NCT03137784|Other|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
16522452|NCT03137784|Other|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
16522453|NCT03137784|Other|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
16545424|NCT02981173|Active Comparator|Psilocybin Low Dose|
16522454|NCT03137771|Active Comparator|Arm 1 (maintenance chemotherapy)|Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16522455|NCT03137771|Experimental|Arm 2 (SBRT + maintenance chemotherapy)|Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
16522456|NCT03137758|Experimental|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
16522457|NCT03137758|Experimental|Level 2 (100 mg) PCUR-101|
16522458|NCT03137758|Experimental|Level 3 (150 mg) PCUR-101|
16522459|NCT03137758|Experimental|Level 4 (200 mg) PCUR-101|
16522460|NCT03137758|Experimental|Level 5 (250 mg) PCUR-101|
16522461|NCT03137758|Experimental|Level 6 (300 mg) PCUR-101|
16522462|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
16522463|NCT03137732|Active Comparator|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
16522464|NCT03137732|Active Comparator|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
16522465|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
16522466|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
16522467|NCT03137680|No Intervention|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
16522468|NCT03137680|Experimental|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
16522469|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
16522470|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
16522471|NCT03137654|Active Comparator|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
16522472|NCT03137654|Active Comparator|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
16522473|NCT03137654|No Intervention|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
16522474|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:
~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
16522475|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
16522476|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
16522477|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery
~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.
~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
16522478|NCT03137602|Other|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
16522479|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
16522480|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
16522481|NCT03137576|Active Comparator|Paravertebral block (PVB)|"Intraoperative pain management
~Sedation
~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).
~Paravertebral Block
~Post operative pain management
~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
16522482|NCT03137576|Experimental|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management
~Sedation
~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).
~Erector Spinae Plane Block
~Post operative pain management
~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
16522688|NCT03136250|Experimental|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
16522483|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
16522484|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks
~Ivabradine is taken orally twice daily
~Dosage will be adjusted according to physician determination"
16522485|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks
~Placebo is taken orally twice daily
~Dosage will be adjusted according to physician determination"
16522486|NCT03137524|Experimental|Hand Held Fan Therapy|
16522487|NCT03137524|No Intervention|No Intervention|
16522488|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.
~The MG collects relevant clinical information
~The MG takes 2 photographs of the lesion with his smartphone.
~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information
~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.
~The dermatologist proposes an appointment to the patient."
16522489|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.
~General practitioners and dermatologists continue their practice in the usual way."
16522490|NCT03137498|Experimental|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
16522491|NCT03137498|Active Comparator|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
16522492|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
16522493|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
16522494|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
16522495|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
16522496|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
16522497|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
16522498|NCT03137446|No Intervention|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP>65, determined by the primary care team for the duration of the study.
16522499|NCT03137446|Experimental|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
16522500|NCT03137433|Experimental|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
16522501|NCT03137433|Experimental|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
16522502|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS > 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
16522503|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
16522504|NCT03137407|Experimental|DaxibotulinumtoxinA 240 units|Botulinum Toxins, Type A Intramuscular Injection
16522505|NCT03137407|Placebo Comparator|Placebo|Placebo Intramuscular Injection
16522506|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
16522507|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
16522508|NCT03137381|Experimental|CTP-543, 4 mg|Oral tablet, dosed twice-daily
16522509|NCT03137381|Experimental|CTP-543, 8 mg|Oral tablet, dosed twice-daily
16522510|NCT03137381|Experimental|CTP-543, 12 mg|Oral tablet, dosed twice-daily
16522511|NCT03137381|Placebo Comparator|Placebo|Oral tablet, dosed twice daily
16522512|NCT03137368|Experimental|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
16522513|NCT03137368|Active Comparator|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
16522514|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
16522572|NCT03137030|Active Comparator|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
16522515|NCT03137342|Experimental|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
16522516|NCT03137342|No Intervention|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
16522517|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
16522518|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
16522519|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.
~Subject demographic and contact information
~Co-morbid conditions
~Smoking history
~Medication history from patient and also from pharmacy used by subjects
~A respiratory exacerbation history in the past year
~Modified Medical Research Counsel (mMRC) dyspnea scale
~Quality of life measures
~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.
~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
16522520|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:
~Subject demographic and contact information
~Co-morbid conditions
~Smoking history
~Medication history from patient and also from pharmacy used by subjects
~A respiratory exacerbation history in the past year
~Modified Medical Research Counsel (mMRC) dyspnea scale
~Quality of life measures
~Pre and post-bronchodilator using Albuterol (BD) spirometry"
16522521|NCT03137290|Active Comparator|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
16522522|NCT03137290|Experimental|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
16522523|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
16522524|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
16522525|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
16522526|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
16522527|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.
~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
16522528|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.
~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
16522529|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
16522530|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
16522531|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
16522532|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
16522533|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
16522534|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.
~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
16522573|NCT03137030|Experimental|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.
~(GRT7014 - Abuse Deterrend Tablet)"
16522574|NCT03137030|Active Comparator|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
16522535|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.
~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
16522536|NCT03137212|Experimental|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
16522537|NCT03137212|Experimental|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
16522538|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
16522539|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
16522540|NCT03137186|Active Comparator|Investigational arm|Metformin will be added to standard of care
16522541|NCT03137186|No Intervention|Control arm|Patients will treated according to Standard of care only
16522542|NCT03137173|Experimental|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
16522543|NCT03137173|Active Comparator|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
16522544|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangranosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
16522545|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
16522546|NCT03137134|Active Comparator|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
16522547|NCT03137134|Experimental|Treatment B|(test) Crizotinib cMS 300 mg in fed state
16522548|NCT03137134|Experimental|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
16522549|NCT03137134|Experimental|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
16522550|NCT03137134|Experimental|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
16522551|NCT03137121|Experimental|Olanzapine|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
16522552|NCT03137121|Placebo Comparator|Placebo|Patients will receive a placebo orally for 1 to 7 days daily.
16522553|NCT03137108|Experimental|Incomplete Spinal cord injury|
16522554|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
16522555|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
16522556|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks
~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)
~Full dose: 3mgs/d (day 21- day 70)
~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
16522557|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks
~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)
~Full dose: 3mgs/d (day 21- day 70)
~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
16522558|NCT03137069|Placebo Comparator|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
16522559|NCT03137069|Experimental|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
16522560|NCT03137069|Placebo Comparator|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
16522561|NCT03137069|Experimental|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
16522562|NCT03137069|Experimental|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
16522563|NCT03137069|Experimental|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
16522564|NCT03137056|Active Comparator|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
16522565|NCT03137056|Active Comparator|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
16522566|NCT03137056|Active Comparator|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
16522567|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
16522568|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
16522569|NCT03137030|Experimental|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.
~(GRT7014 - Abuse Deterrend Tablet)"
16522570|NCT03137030|Experimental|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.
~(GRT7014 - Abuse Deterrend Tablet)"
16522571|NCT03137030|Active Comparator|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
16522686|NCT03136250|Active Comparator|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
16522575|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
16522576|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.
~The IMP must be administered as soon as the meal has been eaten."
16522577|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
16522578|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.
~The IMP must be administered as soon as the meal has been eaten."
16522579|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
16522580|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
16522581|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
16522582|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
16522583|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
16522584|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
16522585|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
16522586|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
16522587|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
16522588|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
16522589|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
16522590|NCT03136939||type 1 diabetes|
16522591|NCT03136939||type 2 diabetes|
16522592|NCT03136939||healthy people|
16522593|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
16522594|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
16522595|NCT03136900|Experimental|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
16522596|NCT03136900|Active Comparator|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
16522597|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
16522598|NCT03136874||Donors who procreated|
16522599|NCT03136874||Donors who don't procreated|
16522600|NCT03136861|Experimental|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
16522601|NCT03136861|Placebo Comparator|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
16522602|NCT03136861|Active Comparator|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
16522603|NCT03136861|Active Comparator|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
16522604|NCT03136861|Active Comparator|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
16522605|NCT03136861|Active Comparator|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
16522606|NCT03136861|Active Comparator|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
16522607|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
16522608|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
16522609|NCT03136822|Other|Control|Standard dressing
16522610|NCT03136822|Experimental|Treatment|Standard dressing + Wound dressing (DERMALIX)
16522611|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
16522612|NCT03136783|Other|Patient with stage IV melanoma|
16522613|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
16522614|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
16522615|NCT03136744|Experimental|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
16522618|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
16522619|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
16522620|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
16522621|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
16522622|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
16522623|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
16522624|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
16522625|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
16522626|NCT03136666|Experimental|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
16522627|NCT03136653|Experimental|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
16522629|NCT03136627|Experimental|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
16522630|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
16522631|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
16522632|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
16522633|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
16522634|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
16522635|NCT03136588|Experimental|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
16522636|NCT03136588|No Intervention|Control group|Use standard questionnaire to gather information for drug adherence
16522637|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
16522638|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
16522639|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
16522640|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
16522641|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
16522642|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
16522643|NCT03136510|Other|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
16522644|NCT03136510|Other|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
16522645|NCT03136497|Experimental|ABT-199 Plus Ibrutinib and Rituximab|Cycle length will be 28 days. Venetoclax will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
16522646|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
16522647|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
16522648|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.
~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.
~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
16522649|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.
~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.
~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
16522650|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.
~Inclusion criteria:
~Diabetes patients who consent to participate the study.
~Age 65+;
~Diagnosis code for diabetes in the last 2 years;
~Diagnosis code for at least one additional chronic condition in the last 2 years.
~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
16522687|NCT03136250|Experimental|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
16522651|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
16522652|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.
~Inclusion criteria:
~All patients age 18+ who registered at REACHnet.
~Able to provide informed consent
~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
16522653|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.
~Inclusion criteria:
~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.
~Able to provide informed consent
~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
16522654|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
16522655|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
16522656|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
16522657|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
16522658|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
16522659|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
16522660|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
16522661|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
16522662|NCT03136406|Experimental|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:
~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
16522663|NCT03136393|Active Comparator|Control|Community based antenatal counselling
16522664|NCT03136393|Experimental|Intervention|Community based dietary counselling
16522665|NCT03136380|Experimental|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
16522666|NCT03136380|Experimental|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
16522667|NCT03136380|Experimental|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
16522668|NCT03136380|Experimental|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
16522669|NCT03136380|Experimental|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
16522670|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
16522671|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
16522672|NCT03136367|No Intervention|Arm 3: Usual Care|In the usual care arm, surgeons provided their standard information about breast cancer
16522673|NCT03136354|Active Comparator|ESD Group|Endoscopic Submucosal Dissection
16522674|NCT03136354|Active Comparator|LAG Group|Laparoscopic Assisted Gastrectomy
16522675|NCT03136341|Active Comparator|Abobotulinum toxin A|
16522676|NCT03136341|Placebo Comparator|Placebo|
16522677|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
16522678|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
16522679|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
16522680|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
16522681|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
16522682|NCT03136276|Active Comparator|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
16522683|NCT03136276|Experimental|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
16522684|NCT03136263|Experimental|Drug order: Oxytocin - placebo|
16522685|NCT03136263|Experimental|Drug order: Placebo - oxytocin|
16522847|NCT03135158||Women in labor|All participants who have a vaginal delivery
16522689|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
16522690|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
16522691|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
16522692|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
16522693|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
16522694|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
16522695|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
16522696|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
16522697|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
16522698|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
16522699|NCT03136185|Experimental|IMG-7289|Single starting dose with individualized dose titrations throughout
16522700|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
16522701|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
16522702|NCT03136146|Experimental|Treatment (combination chemotherapy)|See detailed description
16522703|NCT03136133|Active Comparator|Active protein drink|Active protein drink
16522704|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
16522705|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
16522706|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
16522707|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
16522708|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
16522709|NCT03136094|Placebo Comparator|SBIRT+Usual Care|The control arm of the trial will receive the usual care prescribed in the Screening, Brief Intervention and Referral to Treatment (SBIRT) model.
16522710|NCT03136094|Experimental|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants will receive caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
16522711|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:
~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
16522712|NCT03136068|Experimental|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
16522713|NCT03136068|Placebo Comparator|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
16522714|NCT03136055|Experimental|Part A: Pembrolizumab only|Participants will receive 200 mg of pembrolizumab will be given every three weeks via IV infusion.
16522822|NCT03135327|Experimental|Interventional Phase - Ocufolin Group|Participants in this group will receive the Ocufolin medical food for 6 months.
16522715|NCT03136055|Experimental|Part B: Pembrolizumab + Chemotherapy|Participants will receive 200 mg of pembrolizumab will be given every three weeks via IV infusion and, either 125 mg/m2 of irinotecan given via IV infusion in a two week (on for one week, off for one week format in 3 week cycles) or 80 mg/m2 of paclitaxel given every week via IV infusion depending on physician assessment
16522716|NCT03136042|Experimental|physiotherapists maneuvers|physiotherapy techniques
16522717|NCT03136042|Active Comparator|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
16522718|NCT03136042|Active Comparator|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
16522719|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
16522720|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
16522721|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
16522722|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
16522723|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
16522724|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
16522725|NCT03136016|No Intervention|control|without any activity
16522726|NCT03136016|Experimental|educational activities|The students will receive educational activities in the classroom.
16522727|NCT03136016|Experimental|nudging|The students will receive changes in the school environment (nudge strategies);
16522728|NCT03136016|Experimental|nudging + educational activities|The students will receive educational activities and changes in the school environment.
16522729|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: Exercise"
16522730|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: no further intervention (rest)"
16522731|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise
~Intervention #2: no further intervention (rest)"
16522732|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise
~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
16522733|NCT03135990|Experimental|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
16522734|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
16522735|NCT03135964|Active Comparator|foam|PU foam dressing from KCI
16522736|NCT03135964|Active Comparator|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
16522737|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)
~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection
~Administered on Day 2 of each cycle after TC administration"
16522738|NCT03135938|Active Comparator|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
16522739|NCT03135938|Active Comparator|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
16522740|NCT03135925|Other|Intervention|Exercise program
16522741|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
16522742|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
16522743|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
16522744|NCT03135899|Experimental|BI 443651|
16522745|NCT03135899|Placebo Comparator|Placebo|
16522746|NCT03135886|Experimental|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
16522747|NCT03135886|Experimental|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
16522748|NCT03135886|Other|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
16522749|NCT03135873|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
16522750|NCT03135873|Placebo Comparator|Placebo|This arm of patients will receive placebo for a 6 month period.
16522751|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
16522752|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
16522757|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g
~- 2 packets of sachets once before breakfast and once before dinner."
16522758|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.
~TCM Drug A:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g
~TCM Drug B:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g
~TCM Drug C:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g
~TCM Drug D:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
16522759|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
16522760|NCT03135782|Experimental|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.
~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.
~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
16522761|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
16522762|NCT03135756||Depression and anxiety symptoms|
16522763|NCT03135756||Healthy controls|
16522764|NCT03135704|Active Comparator|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
16522765|NCT03135704|Active Comparator|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
16522766|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
16522767|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
16522768|NCT03135652|Experimental|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
16522769|NCT03135652|Active Comparator|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
16522770|NCT03135639|Experimental|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.
~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.
~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
16522771|NCT03135639|Experimental|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.
~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.
~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
16522772|NCT03135626|Experimental|Biodentine|Biodentine pulpotomy agent
16522773|NCT03135626|Experimental|ProRoot MTA|ProRoot MTA pulpotomy agent
16522774|NCT03135626|Experimental|MTA Plus|MTA Plus pulpotomy agent
16522775|NCT03135626|Active Comparator|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
16522776|NCT03135613|Experimental|Normal|Participants of this group are as controls.
16522777|NCT03135613|Experimental|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
16522778|NCT03135600|Experimental|Normal|The participants from this group are healthy people.
16522779|NCT03135600|Experimental|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
16522780|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
16522781|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
16522782|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
16522783|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
16522784|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
16522785|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
16522786|NCT03135561|Experimental|pedometer-plus-email|
16522787|NCT03135561|Active Comparator|pedometer-only|
16522788|NCT03135548|Experimental|Spesolimab (low dose)|
16522789|NCT03135548|Experimental|Spesolimab (high dose)|
16522790|NCT03135548|Placebo Comparator|Placebo|
16545425|NCT02981173|Placebo Comparator|Placebo|
16522792|NCT03135522|Active Comparator|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
16522793|NCT03135522|Placebo Comparator|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
16522794|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
16522795|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
16522796|NCT03135496||Surgery with CEC|
16522797|NCT03135496||Without CEC|
16522798|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
16522799|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
16522800|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
16522801|NCT03135457|Other|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
16522802|NCT03135457|Other|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
16522803|NCT03135444|Experimental|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
16522804|NCT03135444|Experimental|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
16522805|NCT03135431|Experimental|Salpingectomy|Bilateral salpingectomy following cesarean delivery
16522806|NCT03135431|Active Comparator|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
16522807|NCT03135418|Experimental|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
16522808|NCT03135418|Sham Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
16522809|NCT03135405|No Intervention|Usual care|
16522810|NCT03135405|Experimental|Intervention|
16522811|NCT03135392|Active Comparator|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
16522812|NCT03135392|Active Comparator|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
16522813|NCT03135392|Experimental|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
16522814|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
16522815|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
16522816|NCT03135366|Active Comparator|Standard of Care (Control)|
16522817|NCT03135366|Experimental|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
16522818|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
16522819|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
16522820|NCT03135340|Experimental|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
16522821|NCT03135340|Active Comparator|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
16546824|NCT02971592|Placebo Comparator|Placebo|
16522823|NCT03135327|No Intervention|Observational Phase Group|Participants in this group will be studied and followed up for 1-2 years.
16522824|NCT03135314|Active Comparator|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
16522825|NCT03135314|Placebo Comparator|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
16522826|NCT03135314|Active Comparator|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
16522827|NCT03135314|Placebo Comparator|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
16522828|NCT03135301|Experimental|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
16522829|NCT03135301|Active Comparator|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
16522830|NCT03135288|Experimental|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
16522831|NCT03135288|No Intervention|control group|will receive the same above adequate counseling with referral card but without any phone assistance
16522832|NCT03135275|Active Comparator|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
16522833|NCT03135275|Experimental|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
16522834|NCT03135262|Experimental|Dose-Escalation Cohort: FL|Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose [MTD] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
16522835|NCT03135262|Experimental|Dose-Escalation Cohort: DLBCL|Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
16522836|NCT03135262|Experimental|Expansion Cohort: FL|Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
16522837|NCT03135262|Experimental|Expansion Cohort: DLBCL|Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
16522838|NCT03135249|Other|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:
~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.
~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
16522839|NCT03135236|Experimental|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
16522840|NCT03135223|Experimental|Intervention group|Co-created, school-based intervention to promote physical activity
16522841|NCT03135223|No Intervention|Control group|
16522842|NCT03135210|Active Comparator|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
16522843|NCT03135210|Experimental|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
16522844|NCT03135197||Migalastat|Migalastat administered according to SmPC
16522845|NCT03135184|Experimental|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
16522846|NCT03135171|Experimental|Trastuzumab, Pertuzumab and Tocilizumab|
16522848|NCT03135145|Active Comparator|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
16522849|NCT03135145|Placebo Comparator|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
16522850|NCT03135132|Placebo Comparator|Control group|Usual dietary intake group
16522851|NCT03135132|Experimental|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
16522852|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
16522853|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
16522854|NCT03135106|Experimental|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
16522855|NCT03135106|Experimental|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
16522856|NCT03135106|Experimental|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
16522857|NCT03135093||Stroke subjects|
16522858|NCT03135093||Healthy subjects|
16522859|NCT03135080|Experimental|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
16522860|NCT03135080|Active Comparator|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
16522861|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
16522862|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
16522863|NCT03135054|Experimental|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.
~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
16522864|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
16522865|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
16522866|NCT03135028|Experimental|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
16522867|NCT03135028|Experimental|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.
~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.
~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission [CR] or morphologic complete remission with incomplete blood count recovery [CRi] and do not require or cannot proceed to allogeneic stem cell transplantation [SCT] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
16522868|NCT03135015|Other|Lean Participants|Participants with BMI >18.5 and <25.0kg/m²
16522869|NCT03135015|Other|Overweight/Obese Participants|Participants with BMI ≥25.0 and <35.0kg/m²
16522870|NCT03134989|Other|Cochlear implant recipients|Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.
16522871|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
16522872|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
16522961|NCT03134391|Active Comparator|EMLA|Subjects received EMLA before spinal anesthesia
16522873|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria
~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:
~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant
~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.
~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions
~Not demented"
16522874|NCT03134963||Alzheimer disease|"NIA/AA criteria
~Meets the criteria for dementia
~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains
~Insidious or gradual onset
~Clear history of worsening cognition by report or observation
~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:
~Amnestic: impaired learning and recall of recently learned information
~Non amnestic: language/visuospatial/executive dysfunction"
16522875|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:
~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.
~One or more of:
~Onset of dementia within 3 months of a diagnosed stroke
~Abrupt deterioration in cognitive function
~Fluctuating, stepwise progression of cognitive deficits"
16522876|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria
~No evidence of subjective or objective memory impairment on cognitive testing
~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
16522877|NCT03134950|Experimental|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
16522878|NCT03134950|No Intervention|Medical Treatment as Usual|Medical treatment as usual
16522879|NCT03134937|Other|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
16522880|NCT03134924|Experimental|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
16522881|NCT03134924|Other|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
16522882|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
16522883|NCT03134911||anticoagulation non controlled patients|Treated with VKA
16522884|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
16522885|NCT03134872|Experimental|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
16522886|NCT03134872|Active Comparator|Chemotherapy|Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
16522887|NCT03134859|Experimental|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
16522888|NCT03134859|Experimental|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
16522889|NCT03134859|Experimental|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
16522890|NCT03134846|Experimental|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
16522891|NCT03134846|Experimental|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
16522892|NCT03134846|Experimental|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
16522893|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 15 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 15 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
16522894|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 25 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 25 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
16522895|NCT03134846|Experimental|After having established the optimal cetuximab-IRDye800CW dose|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
16522922|NCT03134664|Experimental|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
16522962|NCT03134378|Experimental|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
16522896|NCT03134833|Experimental|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.
~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
16522897|NCT03134833|Experimental|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
16522898|NCT03134833|Experimental|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
16522899|NCT03134833|Experimental|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
16522900|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
16522901|NCT03134794|Experimental|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).
~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
16522902|NCT03134794|No Intervention|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
16522906|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
16522907|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
16522908|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
16522909|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
16522910|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
16522911|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours
~plus
~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
16522912|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
16522913|NCT03134716||Clinical follow-up|Clinical follow-up of MS-patients for 5 years. PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
16522914|NCT03134716||Healthy controls|comparison of healthy controls' and MS patients' PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
16522915|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
16522916|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
16522917|NCT03134690|Experimental|delayed start antagonist|30 women with f poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
16522918|NCT03134690|Experimental|conventional antagonist|30 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
16522919|NCT03134677|Experimental|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
16522920|NCT03134677|Experimental|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
16522921|NCT03134664|Experimental|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
16522923|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
16522924|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
16522925|NCT03134638|Experimental|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
16522926|NCT03134638|Experimental|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
16522927|NCT03134638|Experimental|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
16522928|NCT03134638|Experimental|Clear Cell Ovarian Cancer|Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
16522929|NCT03134638|Experimental|Advanced Solid Tumors|Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
16522930|NCT03134638|Experimental|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
16522931|NCT03134612|Active Comparator|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
16522932|NCT03134612|Active Comparator|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
16522933|NCT03134599|Active Comparator|etafilcon A|
16522934|NCT03134599|Active Comparator|methafilcon A - Interozzo|
16522935|NCT03134599|Active Comparator|methafilcon A - CVI|
16522936|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
16522937|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
16522938|NCT03134560|Active Comparator|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
16522939|NCT03134560|No Intervention|Without vein display instrument|vein cannulation was done without any vein display instrument
16522940|NCT03134547|Active Comparator|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
16522941|NCT03134547|Active Comparator|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
16522942|NCT03134534|Other|VATS group|Surgical procedure: VATS lobectomy
16522943|NCT03134534|Other|RATS group|Surgical procedure: RATS lobectomy
16522944|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
16522945|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
16522946|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
16522947|NCT03134495||non-exposed children|all children with no prescription of PPI
16522948|NCT03134482|Experimental|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.
~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.
~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.
~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
16522949|NCT03134482|Active Comparator|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.
~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.
~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.
~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.
~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
16522950|NCT03134469|Experimental|Probiotics|Intake of a probiotic capsule once daily
16522951|NCT03134469|Placebo Comparator|Placebo|Intake of a placebo capsule once daily
16522952|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
16522953|NCT03134443|Active Comparator|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
16522954|NCT03134443|Placebo Comparator|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
16522955|NCT03134430|Placebo Comparator|Normal saline|equal volume of normal saline as treatment group
16522956|NCT03134430|Active Comparator|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
16522957|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
16522958|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
16522959|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
16522960|NCT03134391|Active Comparator|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
16522963|NCT03134378|Placebo Comparator|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
16522964|NCT03134365|Experimental|Mixed meal|
16522965|NCT03134365|Active Comparator|Combined meal|
16522966|NCT03134352|Experimental|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
16522967|NCT03134352|Experimental|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
16522968|NCT03134352|Placebo Comparator|placebo group|Placebo AM + Placebo PM
16522969|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
16522970|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
16522971|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
16522972|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
16522973|NCT03134326|Experimental|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
16522974|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
16522975|NCT03134300|Active Comparator|Low SES|
16522976|NCT03134300|Placebo Comparator|Normal/high SES|
16522977|NCT03134287|Active Comparator|two-finger method|Those who received nasogastric tube placement by two-finger method
16522978|NCT03134287|Active Comparator|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
16522979|NCT03134274|Experimental|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
16522980|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
16522981|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
16522982|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
16522983|NCT03134248|Experimental|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
16522984|NCT03134248|Active Comparator|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
16522985|NCT03134248|Active Comparator|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
16522986|NCT03134235|Experimental|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
16522987|NCT03134222|Experimental|Lanraplenib 30 mg|Lanraplenib + filgotinib placebo for 48 weeks
16522988|NCT03134222|Experimental|Filgotinib 200 mg|Filgotinib + lanraplenib placebo for 48 weeks
16522989|NCT03134222|Placebo Comparator|Placebo|Filgotinib placebo + lanraplenib placebo for 12 weeks
16522990|NCT03134222|Experimental|Placebo to Lanraplenib 30 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
16522991|NCT03134222|Experimental|Placebo to Filgotinib 200 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
16522992|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
16522993|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
16522994|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
16522995|NCT03134196|Placebo Comparator|Placebo|Encapsulated masked placebo
16522996|NCT03134196|Active Comparator|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
16522997|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
16522998|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
16522999|NCT03134170|No Intervention|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
16523000|NCT03134170|Other|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
16523001|NCT03134157|Experimental|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
16523002|NCT03134157|Experimental|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
16523003|NCT03134157|Experimental|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
16523004|NCT03134144|Experimental|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
16523005|NCT03134144|Experimental|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
16523006|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
16523007|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
16523008|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
16547223|NCT02968823|Placebo Comparator|Sugar water|Sugar gargle
16523009|NCT03134092|No Intervention|Generalized Risk Communication (GRC)|Generalized Risk Communication (GRC): Participants in this arm will receive standard discharge instructions similar to instructions they would receive during usual care. This arm represents a standardized way of communicating post-discharge risk-benefit information about treatment options for patients with back pain and renal colic. The GRC, includes a standardized discharge information sheet about the clinical condition of interest and a written overview of population based evidence describing comparative benefits and side effects of alternative classes of medication acute pain.
16523010|NCT03134092|Active Comparator|Probabilistic Risk Communication (PRT)|Probabilistic Risk Communication (PRT): The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
16523011|NCT03134092|Active Comparator|Narrative Enhanced Risk Tool (NERT)|Narrative Enhanced Risk Tool (NERT): Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale related to prolonged opioid use. Narrative videos are developed from actual patient stories - put into a in a structured format of ~ 2-minute length and recorded.
16523012|NCT03134079|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
16523013|NCT03134079|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
16523014|NCT03134079|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
16523015|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
16523016|NCT03134053|Experimental|extracorporeal shock-wave|
16523017|NCT03134053|Sham Comparator|massage|
16523018|NCT03134040|Experimental|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
16523019|NCT03134040|Experimental|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
16523020|NCT03134040|Active Comparator|Control|Participants receive feedback on their exercise attendance on a weekly basis.
16523021|NCT03134027||Subjects from which PDXs have been generated.|Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
16523022|NCT03134027||Subjects without an existing PDX|Subjects with prostate cancer amenable to a tumor biopsy.
16523023|NCT03134014|No Intervention|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
16523024|NCT03134014|Active Comparator|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
16523025|NCT03134014|Active Comparator|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
16523026|NCT03134001|Experimental|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
16523027|NCT03134001|No Intervention|Control Group|Patients receiving oral analgesics by nurse, upon request
16523028|NCT03133975|Experimental|Treatment|Single high dose IM VIT D
16523029|NCT03133975|Active Comparator|Control|Usual diet mix of carbohydrates - lipid - protein - minerals & vitamins
16523030|NCT03133962|Other|Patients applying for CAP or long-term central catheter|
16523031|NCT03133949||Patients with idiopathic inflammatory aortitis|
16523032|NCT03133949||a group of witnesses|
16523033|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but <3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)[ ≥3.0logCCID50/ml but <3.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
16523034|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
16547830|NCT02964637||Non-fluent variant PPA|Observational Study
16523035|NCT03133923|Active Comparator|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
16523036|NCT03133897|Active Comparator|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
16523037|NCT03133897|Experimental|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
16523038|NCT03133884|Experimental|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
16523039|NCT03133884|Other|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
16523040|NCT03133845|Active Comparator|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
16523041|NCT03133845|Experimental|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS>60-70. Discretionary use of intrathecal morphine may be used.
16523042|NCT03133832|Experimental|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
16523043|NCT03133832|Experimental|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
16523044|NCT03133832|Experimental|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
16523045|NCT03133819|Other|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
16523046|NCT03133806|Experimental|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
16523047|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
16523048|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
16523049|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
16523050|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
16523051|NCT03133780|Active Comparator|Ketamine|Patients will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
16523052|NCT03133780|Active Comparator|Midazolam|Patients will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
16523053|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
16523054|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
16523055|NCT03133754|Experimental|DP-PEEP|recruitment maneuver + individualized PEEP
16523056|NCT03133754|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
16523057|NCT03133741|Placebo Comparator|Placebo|Saline
16523058|NCT03133741|Other|GIP-A|Infusion of GIP-A alone as study tool.
16523059|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
16523060|NCT03133741|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
16523061|NCT03133728||Pre-Intervention Group|The Investigators will visit each of the selected 3 clusters (i.e. 6 primary health clinics) to construct a retrospective cohort of high-risk HIV-infected women who entered the national PMTCT program and received the SOC between June 1, 2017 and May 31, 2018. Using existing data through the electronic health record information (SmartCare and LIMS), the investigators will gather individual-level retrospective data on high-risk Mother-Infant Pairs (MIPs) from PMTCT enrolment through the child's ART enrolment, initiation, and retention rate at 3 months.
16523092|NCT03133507|Experimental|Reassurance Condition|Children will receive empathic support from the experimenter.
16523093|NCT03133507|Experimental|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
16523094|NCT03133494|Active Comparator|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
16523095|NCT03133494|Placebo Comparator|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
16523096|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
16523062|NCT03133728||Post-Intervention Group|Study Research Assistants (RA) will review routine patient files and registers, augmented by existing electronic health record information, to identify a new cohort of high-risk Mother-Infant Pairs (MIPs) at each study site between the dates of June 1, 2019 and May 31, 2020. The outreach team will include, at a minimum, the study RA, a study peer, and an HIV counselor from the health facility, who will carry the Alere™ q HIV-1/2 Detect with them. When the outreach team contacts a high-risk MIP at community level, the team will approach the MIP for study screening, consent, and enrolment procedures. Study staff will ask the parent/guardian if the parent/guardian would like the IYC to be tested at their home, at a community health post, or other private space in the community. The IYC will be tested using both the Alere™ q HIV-1/2 Detect platform and a reflex DBS PCR test to evaluate performance of the POC platform in a mobile setting against the gold standard.
16523063|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
16523064|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
16523065|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
16523066|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
16523067|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
16523068|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
16523069|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
16523070|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
16523073|NCT03133663|Active Comparator|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
16523074|NCT03133663|Experimental|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
16523075|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
16523076|NCT03133637||Ceftriaxone Arm|
16523077|NCT03133611|Other|Parkinson's disease|Speech assessment. Routine clinical assessment.
16523078|NCT03133611|Other|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
16523079|NCT03133611|Other|Healthy controls|Speech assessment. Routine clinical assessment.
16523080|NCT03133572|Experimental|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
16523081|NCT03133572|Active Comparator|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
16523082|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
16523083|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
16523084|NCT03133559||Cohort 3|Matched healthy volunteers
16523085|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
16523086|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
16523087|NCT03133533|Active Comparator|laparoscopic|laparoscopic inguinal hernia repair
16523088|NCT03133533|Active Comparator|robot-assisted|robot-assisted inguinal hernia repair
16523089|NCT03133520|No Intervention|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
16523090|NCT03133520|Experimental|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
16523091|NCT03133507|Experimental|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
16547831|NCT02964637||FTD-motor neuron disease|Observational Study
16523097|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
16523098|NCT03133468|Experimental|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
16523099|NCT03133468|Placebo Comparator|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
16523100|NCT03133468|Experimental|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
16523101|NCT03133468|Experimental|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
16523102|NCT03133468|Experimental|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
16523103|NCT03133468|Placebo Comparator|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
16523104|NCT03133455|Other|Patient with Fibromyalgia|
16523105|NCT03133442|No Intervention|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
16523106|NCT03133442|Experimental|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
16523107|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
16523108|NCT03133416|Active Comparator|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
16523109|NCT03133416|Active Comparator|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
16523110|NCT03133416|Active Comparator|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
16523111|NCT03133377|Experimental|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
16523112|NCT03133377|No Intervention|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
16523113|NCT03133364|Active Comparator|Sensory optimized meals|"Intervention group is receiving:
~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
16523114|NCT03133364|Placebo Comparator|Control|"Control group is receiving:
~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
16523115|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
16523116|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
16523117|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
16523118|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
16523119|NCT03133299|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
16523415|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
16523120|NCT03133299|Experimental|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
16523121|NCT03133273|No Intervention|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
16523122|NCT03133273|Experimental|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
16523123|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
16523124|NCT03133247|Experimental|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
16523125|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
16523126|NCT03133221|Experimental|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
16523127|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
16523128|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
16523129|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
16523130|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
16523131|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
16523132|NCT03133182||Polypharmacy|People taking >=5 unique prescription drugs in the 3 months prior to surgery
16523133|NCT03133182||No polypharmacy|People taking <5 unique prescription drugs in the 3 months prior to surgery
16523134|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.
~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level
~Diagnostic Test: blood sample
~Diagnostic Test: Tricuspid regurge velocity"
16523135|NCT03133169||No chelation|"group 2: cases without chelation
~Diagnostic Test: blood sample
~Diagnostic Test: Tricuspid regurge velocity"
16523136|NCT03133169||splenectomy|"group 3: cases with splenectomy
~Diagnostic Test: blood sample
~Diagnostic Test: Tricuspid regurge velocity"
16523137|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
16523138|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
16523139|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
16523140|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
16523141|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
16523142|NCT03133143|Experimental|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
16523143|NCT03133143|Active Comparator|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
16523144|NCT03133143|No Intervention|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
16523145|NCT03133130|Experimental|BMT101|cp-lasiRNA
16523146|NCT03133130|Placebo Comparator|Placebo|Normal Saline
16523147|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
16523148|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
16523149|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
16523150|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.
~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
16523151|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.
~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
16523152|NCT03133078|Experimental|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
16523153|NCT03133078|Experimental|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
16523154|NCT03133065|Active Comparator|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
16523155|NCT03133065|Active Comparator|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
16523541|NCT03130504|Active Comparator|17α hydroxy progesterone caproate group|
16523156|NCT03133052|Active Comparator|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
16523157|NCT03133052|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
16523158|NCT03133039|Active Comparator|bioabsorbable screw|
16523159|NCT03133039|Active Comparator|titanium screw|
16523160|NCT03133026|Active Comparator|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
16523161|NCT03133026|Active Comparator|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
16523162|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
16523163|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
16523164|NCT03132987|Experimental|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
16523165|NCT03132974|Experimental|SGHH|Admission to Sogyeonghwalhyeol-tang granule
16523166|NCT03132974|Experimental|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
16523167|NCT03132974|Placebo Comparator|Placebo with manipulation therapy|
16523168|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
16523169|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
16523170|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
16523171|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
16523172|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
16523173|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
16523174|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
16523175|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
16523176|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
16523177|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
16523178|NCT03132922|Experimental|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
16523179|NCT03132896||Patients with moderate or severe ARDS|
16523180|NCT03132818||Patients undergoing AMP with oocyte donation|
16523181|NCT03132818||Couples supported in AMP with sperm donation|
16523182|NCT03132818||Couples supported in AMP intra torque|
16523183|NCT03132805|No Intervention|Control|Schools which receive no intervention
16523184|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
16523185|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
16523186|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
16523187|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
16523188|NCT03132766|Experimental|New Hope + Elders' Resilience + CM|Participants will receive case management plus the New Hope curriculum and subsequently the Elders' Resilience curriculum.
16523189|NCT03132766|Experimental|New Hope + CM|Participants will receive case management plus the New Hope curriculum.
16523190|NCT03132766|Experimental|Elders' Resilience + CM|Participants will receive case management plus the Elders' Resilience curriculum.
16523191|NCT03132766|Active Comparator|CM alone|Participants will receive case management only.
16523192|NCT03132753|Experimental|SUPPORT Group|Subjects enrolled in the intervention.
16523193|NCT03132753|No Intervention|Treatment as Usual|Subjects enrolled in standard services.
16523194|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
16523195|NCT03132714|Active Comparator|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
16523196|NCT03132714|Active Comparator|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
16523197|NCT03132714|Active Comparator|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
16523198|NCT03132714|Active Comparator|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
16523199|NCT03132714|Active Comparator|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
16523200|NCT03132714|Active Comparator|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
16523201|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
16523202|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
16523203|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
16523204|NCT03132675|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
16523205|NCT03132662|Active Comparator|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
16523206|NCT03132662|Experimental|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
16523207|NCT03132662|No Intervention|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
16523208|NCT03132636|Experimental|Group 1- metastatic BCC|Administration of cemiplimab in accordance with protocol dosing regimen
16523209|NCT03132636|Experimental|Group 2 - unresectable locally advanced BCC|Administration of cemiplimab in accordance with protocol dosing regimen
16523210|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
16523211|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
16523212|NCT03132610|Active Comparator|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
16523213|NCT03132610|Placebo Comparator|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
16523214|NCT03132597|Experimental|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
16523215|NCT03132597|Experimental|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
16523216|NCT03132597|No Intervention|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
16523217|NCT03132584|Experimental|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:
~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
~Cyclophosphamide
~Alemtuzumab"
16523218|NCT03132571|Experimental|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
16523219|NCT03132571|Placebo Comparator|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
16523220|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
16523221|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
16523222|NCT03132545||PCOS|
16523223|NCT03132545||controls|
16523224|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 60 gray (Gy)|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 60 Gy in 2 Gy daily fractions
16523225|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 66 Gy|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 66 Gy in 2 Gy daily fractions
16523226|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 72 Gy|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 72 Gy in 2 Gy daily fractions
16523227|NCT03132519|Experimental|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
16523228|NCT03132519|Experimental|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
16523229|NCT03132519|Experimental|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
16523230|NCT03132519|Experimental|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
16523231|NCT03132519|Active Comparator|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
16523232|NCT03132519|Active Comparator|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
16523233|NCT03132506||paper-based patient-reported-outcomes|
16523234|NCT03132506||on web-based patient-reported-outcomes|
16523235|NCT03132480|Experimental|hypovolemia|
16523236|NCT03132467|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
16523294|NCT03131999|Experimental|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
16523237|NCT03132454|Experimental|Arm I (palbociclib, sorafenib)|Patients receive palbociclib PO QD on days 1-28. Patients also receive sorafenib PO QD on days 1-28 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16523238|NCT03132454|Experimental|Arm II (palbociclib, decitabine)|Patients receive palbociclib as in Arm I. Beginning cycle 2, patients receive palbociclib PO QC on days 1-7 and decitabine IV QD over 1 hour on days 8-17 of cycle 2 and days 8-12 of cycles 3-8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16523239|NCT03132454|Experimental|Arm III (palbociclib, dexamethasone)|Patients receive palbociclib as in Arm I. Patients also receive dexamethasone PO QD or IV over 15-30 minutes on days 1-4 and 15-18 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16523240|NCT03132441|Experimental|Cardiac Rehabilitation|"Strength Training for Frailty:
~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
16523241|NCT03132428||P Neonates|Premature (P) neonates [at least 27 weeks but less than 34 weeks of gestational age]
16523242|NCT03132428||TNT Neonates|Term-Near-Term (TNT) neonates at least 34 weeks of gestational age
16523243|NCT03132415|Experimental|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
16523244|NCT03132415|Active Comparator|Non-tailored HIV Test Locator|Participants randomized to the control condition will be directed to a website that includes information on the AIDSVU.org testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
16523245|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
16523246|NCT03132376|Experimental|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.
~The drinks consisted of the following:
~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
16523247|NCT03132337||Stem Cell Transplant|Serial Blood Draws
16523248|NCT03132324|Experimental|INCB059872 0.5 mg|INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
16523249|NCT03132324|Experimental|INCB059872 1 mg|INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
16523250|NCT03132324|Experimental|INCB059872 2 mg|INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
16523251|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).
~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
16523252|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.
~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
16523253|NCT03132298|Experimental|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
16523254|NCT03132298|Active Comparator|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
16523255|NCT03132285|Other|PrePex Day 0 foreskin removal|Day 0 foreskin removal
16523256|NCT03132272|Experimental|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
16523257|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
16523258|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
16523259|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.
~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
16523295|NCT03131999|Placebo Comparator|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
16523296|NCT03131973|Experimental|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
16523260|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.
~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
16523261|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
16523262|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
16523263|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
16523264|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
16523265|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
16523266|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
16523267|NCT03132194|Experimental|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)
~Topical, twice daily on the face for 84 days."
16523268|NCT03132194|Placebo Comparator|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)
~Topical, twice daily on the face for 84 days."
16523269|NCT03132194|Active Comparator|Aczone|"dapsone 7.5
~Topical, twice daily on the face for 84 days."
16523270|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
16523271|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
16523272|NCT03132168|Other|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
16523273|NCT03132155|Experimental|AMG 337|AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
16523274|NCT03132142|Experimental|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
16523275|NCT03132142|Experimental|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
16523276|NCT03132142|Experimental|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
16523277|NCT03132142|Placebo Comparator|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
16523278|NCT03132129||Type 2 diabetics|
16523279|NCT03132129||Healthy controls|
16523280|NCT03132116|Experimental|Gentamicin|intra-nodal injection of gentamicin
16523281|NCT03132116|Placebo Comparator|Placebo|intra-nodal injection of placebo
16523282|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
16523283|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
16523284|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
16523285|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
16523286|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
16523287|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
16523288|NCT03132051|Experimental|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
16523289|NCT03132038|Experimental|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3 mg/kg to be administered as a 60 minute IV infusion
16523290|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
16523291|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
16523292|NCT03132012|Experimental|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
16523293|NCT03132012|Active Comparator|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
16523416|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
16523297|NCT03131973|Experimental|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
16523298|NCT03131960|Experimental|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
16523299|NCT03131960|Active Comparator|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
16523300|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
16523301|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
16523302|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:
~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12
~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.
~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
16523303|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
16523304|NCT03131908|Experimental|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.
~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
16523305|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
16523306|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
16523307|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
16523308|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
16523309|NCT03131882|Experimental|Hyaluronic acid|Hyaluronic acid
16523310|NCT03131882|Active Comparator|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
16523311|NCT03131856|Experimental|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
16523312|NCT03131856|No Intervention|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
16523313|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
16523314|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
16523315|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
16523316|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
16523317|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
16523318|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
16523319|NCT03131817|Experimental|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
16523320|NCT03131804|Experimental|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
16523321|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
16523322|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
16523323|NCT03131778|Active Comparator|Open Liver Resection|Conventional open liver resection trough subcostal incision
16523324|NCT03131778|Experimental|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
16523325|NCT03131765|Experimental|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.
~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
16523358|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
16523326|NCT03131752|Experimental|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.
~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
16523327|NCT03131752|No Intervention|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.
~Patients will be not receive intervention."
16523328|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
16523329|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
16523330|NCT03131726|Experimental|Simvastatin|simvastatin 40 mg daily for 6 months
16523331|NCT03131726|No Intervention|No treatment|No treatment
16523332|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
16523333|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
16523334|NCT03131700|Experimental|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
16523335|NCT03131700|Active Comparator|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
16523336|NCT03131687|Placebo Comparator|Placebo|Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
16523337|NCT03131687|Experimental|1 mg Tirzepatide|1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
16523338|NCT03131687|Experimental|5 mg Tirzepatide|5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
16523339|NCT03131687|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
16523340|NCT03131687|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
16523341|NCT03131687|Active Comparator|1.5 mg Dulaglutide|1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.
16523342|NCT03131674|Experimental|Direct treatment|
16523343|NCT03131674|Experimental|Delayed treatment|
16523344|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
16523345|NCT03131648|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:
~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
16523346|NCT03131648|Placebo Comparator|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:
~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
16523347|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
16523348|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.
~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
16523349|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:
~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
16523350|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52:
~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
16523351|NCT03131648|Experimental|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:
~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.
~OR
~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.
~*TCS = topical corticosteroids."
16523352|NCT03131648|Experimental|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 [Short term extension (Japan only)] :
~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
16523353|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
16523354|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
16523355|NCT03131622|Experimental|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
16523356|NCT03131622|No Intervention|Control|
16523357|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
16523359|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
16523360|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
16523361|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
16523362|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
16523363|NCT03131583|Experimental|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.
16523364|NCT03131570|Experimental|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
16523365|NCT03131570|Placebo Comparator|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
16523366|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
16523367|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
16523368|NCT03131544|Experimental|FLA for BPH Active Treatment|
16523369|NCT03131531||Hodgkin lymphoma|
16523370|NCT03131531||Non-Hodgkin lymphoma|
16523371|NCT03131531||Myeloma|
16523372|NCT03131518|Other|E-bicycle|Access to an e-bicycle will be provided.
16523373|NCT03131518|Other|Longtail bicycle|Access to a longtail bicycle will be provided.
16523374|NCT03131518|Other|Traditional bicycle|Access to a traditional bicycle will be provided.
16523375|NCT03131479|Experimental|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
16523376|NCT03131479|Experimental|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
16523377|NCT03131479|Experimental|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
16523378|NCT03131479|Experimental|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
16523379|NCT03131479|Experimental|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
16523382|NCT03131453|Experimental|CNP520 50 mg|50 mg capsule taken orally once daily
16523383|NCT03131453|Experimental|CNP520 15 mg|15 mg capsule taken orally once daily
16523384|NCT03131453|Placebo Comparator|Placebo|Matching placebo to 15 and 50 mg CNP520 taken orally once daily
16523385|NCT03131440|Experimental|Experimental Condition #1|core, support calls
16523386|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
16523387|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
16523388|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
16523389|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
16523390|NCT03131440|Experimental|Experimental Condition #6|core, app+
16523391|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
16523392|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
16523393|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
16523394|NCT03131440|Experimental|Experimental Condition #10|core, buddy
16523395|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
16523396|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
16523397|NCT03131440|Experimental|Experimental Condition #13|core, online gym
16523398|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
16523399|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
16523400|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
16523401|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
16523402|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
16523403|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
16523404|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
16523405|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
16523406|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
16523407|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
16523408|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
16523409|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
16523410|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
16523411|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
16523412|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
16523413|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
16523414|NCT03131440|Experimental|Experimental Condition #30|core
16523417|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
16523418|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
16523419|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
16523420|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
16523421|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
16523422|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.
~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
16523423|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.
~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
16523424|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.
~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
16523425|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.
~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
16523426|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
16523427|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
16523428|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
16523429|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
16523430|NCT03131336|Experimental|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
16523431|NCT03131336|Placebo Comparator|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
16523432|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
16523433|NCT03131284|No Intervention|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
16523434|NCT03131284|Experimental|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
16523435|NCT03131271|Experimental|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
16523436|NCT03131271|No Intervention|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
16523437|NCT03131258|Other|Donor Nephrectomy|Donor Nephrectomy
16523438|NCT03131219|Experimental|Ravulizumab|
16523542|NCT03130504|No Intervention|No intervention group|
16523439|NCT03131206|Experimental|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.
~Alectinib
~Oral, BID
~A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
16523440|NCT03131206|Experimental|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.
~Alectinib
~Oral, BID, participants will receive the RP2D identified during Phase 1.
~Each treatment cycle will be defined as 28 consecutive days."
16523441|NCT03131206|Experimental|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.
~Alectinib
~Oral, BID, participants will receive the RP2D identified during Phase 1.
~Each treatment cycle will be defined as 28 consecutive days."
16523442|NCT03131206|Experimental|Cohort C|"Participants with RET-rearranged thyroid cancer
~Alectinib
~Oral, BID, participants will receive the RP2D identified during Phase 1.
~Each treatment cycle will be defined as 28 consecutive days."
16523443|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
16523444|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
16523445|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
16523446|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
16523447|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
16523448|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
16523449|NCT03131180|Experimental|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
16523450|NCT03131180|No Intervention|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
16523451|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
16523452|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
16523453|NCT03131154|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
16523454|NCT03131154|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Solution|
16523455|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
16523456|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
16523457|NCT03131128|Experimental|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
16523458|NCT03131128|Active Comparator|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
16523459|NCT03131115|Active Comparator|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
16523460|NCT03131115|Active Comparator|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
16523461|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
16523462|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
16523463|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites >500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
16523501|NCT03130803|No Intervention|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
16523464|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
16523465|NCT03131050|Experimental|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
16523466|NCT03131050|Experimental|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
16523467|NCT03131050|Placebo Comparator|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
16523468|NCT03131037|Experimental|Study Arm|AdV-tk (aglatimagene besadenovec) + valacyclovir
16523469|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
16523470|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
16523471|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
16523472|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
16523473|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
16523474|NCT03130998|Active Comparator|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
16523475|NCT03130998|Experimental|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a remote knowledge broker (rKB) communicating via interactive technology. The rKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The rKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
16523476|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
16523477|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
16523478|NCT03130959|Experimental|Module A|nivolumab
16523479|NCT03130959|Experimental|Module B|nivolumab plus ipilimumab
16523480|NCT03130946|Experimental|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
16523481|NCT03130946|Active Comparator|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
16523482|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
16523483|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
16523484|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
16523485|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
16523486|NCT03130920|No Intervention|Control|
16523487|NCT03130920|Active Comparator|Remote ischemic preconditioning|
16523488|NCT03130920|Active Comparator|Local ischemic preconditioning|
16523489|NCT03130907|Active Comparator|Stent|
16523490|NCT03130907|Experimental|No stent|
16523491|NCT03130894||Healthy control|A FPG concentration < 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration < 7.8 mmol/l was considered normal glucose tolerance.
16523492|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
16523493|NCT03130881|Experimental|PLB1003|ALK-positive (ALK+) advanced NSCLC
16523494|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
16523495|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
16523496|NCT03130842|Active Comparator|Sublingual alprazolam|
16523497|NCT03130842|Active Comparator|Oral midazolam|
16523498|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
16523499|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
16523500|NCT03130816|Experimental|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.
~C. Oxygen saturation will be monitored during therapy."
16523502|NCT03130803|Experimental|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
16523503|NCT03130790|Experimental|Varlititib+mFOLFOX6|
16523504|NCT03130790|Placebo Comparator|Placebo+mFOLFOX6|
16523505|NCT03130777|Experimental|TPVR - Main Cohort|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.
16523506|NCT03130777|Experimental|TPVR - PDS Registry|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).
16523507|NCT03130764|Experimental|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
16523508|NCT03130751|Experimental|Mobile application|
16523509|NCT03130738|Active Comparator|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
16523510|NCT03130738|Active Comparator|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
16523511|NCT03130738|Placebo Comparator|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
16523512|NCT03130725|Experimental|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
16523513|NCT03130725|Active Comparator|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
16523514|NCT03130712|Experimental|GPC3-CART cells|
16523515|NCT03130699|Experimental|Dulce Digital|The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
16523516|NCT03130699|Experimental|Dulce Digital-Me (Automated Delivery)|The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
16523517|NCT03130699|Experimental|Dulce Digital-Me (Medical Assistant)|The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
16523518|NCT03130673||hip fracture|fracture of proximal femur
16523519|NCT03130660|Experimental|Short Axis Ultrasonography|one person does both ultrasound and line insertion
16523520|NCT03130660|Experimental|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
16523521|NCT03130647|Experimental|Focused ultrasound|Repeated measures sham control
16523522|NCT03130634|Experimental|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
16523523|NCT03130634|No Intervention|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
16523524|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
16523525|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
16523526|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.
~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
16523527|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
16523528|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
16523529|NCT03130582||Disease status at mobilization PR|
16523530|NCT03130582||Disease status at mobilization PD|
16523531|NCT03130569|No Intervention|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
16523532|NCT03130569|Experimental|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
16523533|NCT03130556|Experimental|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
16523534|NCT03130556|Experimental|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
16523535|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
16523536|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
16523537|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
16523538|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
16523539|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
16523540|NCT03130517|Other|Control group|Control group will recieve phototherapy only
16523543|NCT03130491|Other|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
16523544|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
16523545|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
16523546|NCT03130452|Active Comparator|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
16523547|NCT03130452|Experimental|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
16523548|NCT03130452|Experimental|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
16523549|NCT03130439|Experimental|Abemaciclib|-Abemaciclib will be administered orally, twice daily on days 1 to 28
16523550|NCT03130426|Experimental|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
16523551|NCT03130426|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
16523552|NCT03130413|Experimental|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
16523553|NCT03130413|Active Comparator|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
16523554|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
16523555|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
16523556|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
16523557|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
16523558|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
16523559|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
16523560|NCT03130374|Experimental|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
16523561|NCT03130374|No Intervention|Control group|Patients treated according to current clinical protocols
16523562|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
16523563|NCT03130348|Experimental|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
16523564|NCT03130335|Experimental|Bone Marrow Aspirate (BMA) Injection|
16523565|NCT03130322|Experimental|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
16523566|NCT03130322|Experimental|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
16523567|NCT03130322|Experimental|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
16523568|NCT03130322|Experimental|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
16523569|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
16523570|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
16523571|NCT03130270|Experimental|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
16523572|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
16523573|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
16523574|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
16523575|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
16523576|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
16523577|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
16523578|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
16523579|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
16523580|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
16523581|NCT03130179|Experimental|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
16523582|NCT03130179|Active Comparator|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
16523583|NCT03130166|Experimental|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
16523584|NCT03130166|Active Comparator|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
16523585|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
16523586|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
16523587|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
16523588|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
16523589|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
16523590|NCT03130127|Experimental|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
16523591|NCT03130127|Active Comparator|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
16523592|NCT03130114|Placebo Comparator|Control|Placebo mixture, 0.25 ml / kg / day
16523593|NCT03130114|Experimental|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
16523594|NCT03130101|Other|80% basal insulin reduction|
16523595|NCT03130101|Other|50% basal insulin reduction|
16523596|NCT03130101|Other|100% basal insulin reduction|
16523597|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
16523598|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
16523599|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
16523600|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
16523601|NCT03130036|Experimental|No risk of disease|Subjects with no identifiable risk of Alzheimer's Disease
16523602|NCT03130036|Experimental|Asymptomatic|Asymptomatic subjects with increased risk of Alzheimer's disease
16523603|NCT03130036|Experimental|Early Alzheimer's or Mild Cognitive Impairment|Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)
16523604|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
16523605|NCT03130010|Placebo Comparator|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
16523606|NCT03130010|Active Comparator|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
16523607|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
16523608|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
16523609|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
16523610|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
16523611|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
16523612|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
16523613|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
16523614|NCT03129932|Active Comparator|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
16523615|NCT03129932|Placebo Comparator|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
16523616|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
16523617|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
16523618|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
16523619|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
16523683|NCT03129399|Experimental|King Vision video laryngoscope|
16523620|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
16523621|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
16523622|NCT03129880|Placebo Comparator|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
16523623|NCT03129880|Active Comparator|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
16523624|NCT03129854|Experimental|experimental group|Prostate cryotherapy plus ADT
16523625|NCT03129854|No Intervention|control group|standard of care ADT continually
16523626|NCT03129841|Experimental|early dinner+Diet|
16523627|NCT03129841|Experimental|late dinner+Diet|
16523628|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
16523629|NCT03129776|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
16523630|NCT03129776|Active Comparator|18F-FDG|Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.
16523631|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
16523632|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
16523633|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
16523634|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
16523635|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
16523636|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
16523637|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
16523638|NCT03129711|Experimental|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
16523639|NCT03129711|Active Comparator|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
16523640|NCT03129698|Other|Formerly Arm Label|Apatinib 250mg daily
16523641|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
16523642|NCT03129659|Experimental|CT-group|Coronary CT angiography
16523643|NCT03129646|Experimental|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
16523644|NCT03129646|Experimental|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
16523645|NCT03129646|Active Comparator|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
16523646|NCT03129633|Experimental|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
16523647|NCT03129633|No Intervention|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
16523648|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
16523649|NCT03129607||Observation group|Patients without POPF will be included into observation group.
16523650|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
16523651|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
16523652|NCT03129568|Experimental|CDC infusion|CDCs infusion by coronary intervention.
16523653|NCT03129568|No Intervention|Observation (Control group)|Coronary angiogram without placebo infusion.
16523654|NCT03129555|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523655|NCT03129555|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523656|NCT03129555|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523657|NCT03129555|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523658|NCT03129542|Active Comparator|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
16523659|NCT03129542|Placebo Comparator|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
16523660|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
16523661|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
16523662|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
16523663|NCT03129490|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523664|NCT03129490|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523665|NCT03129490|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523666|NCT03129490|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
16523667|NCT03129477|Experimental|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.
~• Education and adaptation of the patient to NIV."
16523668|NCT03129477|No Intervention|2- conventional monitoring group|"Conventional monitoring group
~• Education and adaptation of the patient to NIV."
16523669|NCT03129464|Experimental|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
16523670|NCT03129464|No Intervention|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
16523671|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
16523672|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
16523673|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
16523674|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
16523675|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
16523676|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
16523677|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
16523678|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
16523679|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
16523680|NCT03129425|Experimental|Intervention group|Sessions in groups
16523681|NCT03129425|Sham Comparator|Control group|Sessions in groups
16523682|NCT03129412|Experimental|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
16523685|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)
~Maximum 3 application by the technician in charge of the study.
~Apply between 15 to 20 sec on hand and 40 sec on feet."
16523686|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):
~Maximum 3 application by the technician in charge of the study.
~Apply between 15 to 20 sec on hand and 40 sec on feet."
16523687|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):
~Maximum 3 application by the technician in charge of the study.
~Apply between 15 to 20 sec on hand and 40 sec on feet."
16523688|NCT03129360|Experimental|Levetiracetam 185 mg|A single dose of 185mg of levetiracetam be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
16523689|NCT03129360|Experimental|Levetiracetam 500mg|A single dose of 500mg of levetiracetam will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
16523690|NCT03129360|Placebo Comparator|Placebo|A single dose of placebo will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
16523691|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
16523692|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
16523693|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
16523694|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
16523695|NCT03129334|Experimental|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
16523696|NCT03129334|No Intervention|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
16523697|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
16523698|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
16523699|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
16523700|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
16523701|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
16523702|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
16523703|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
16523704|NCT03129282|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
16523705|NCT03129282|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
16523706|NCT03129269|Experimental|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.
~Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.
~In addition, at 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check.
~PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance
~A blood sample for biobank will be taken at visit 2 and at the end of the study (visit 5)."
16523707|NCT03129256|Experimental|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
16523708|NCT03129230|Experimental|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
16523709|NCT03129217||Patients weaning from mechanical ventilation|
16523710|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
16523711|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
16523712|NCT03129191|Active Comparator|AB arm|"Sequence:
~Aided with non-invasive bone conduction hearing aid A
~Aided with non-invasive bone conduction hearing aid B"
16523713|NCT03129191|Active Comparator|BA arm|"Sequence:
~Aided with non-invasive bone conduction hearing aid B
~Aided with non-invasive bone conduction hearing aid A"
16523714|NCT03129178|Experimental|Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
16523715|NCT03129178|Experimental|Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
16523716|NCT03129165|Experimental|Screening and prevention of CVD|
16523717|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
16523718|NCT03129139|Experimental|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
16523719|NCT03129139|Experimental|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
16523723|NCT03129113|Experimental|maraviroc (Arm A)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).
16523724|NCT03129113|Experimental|metformin (Arm B)|metformin 500mg BID p/o.
16523725|NCT03129113|Experimental|maraviroc + metformin (Arm C)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.
16523726|NCT03129113|No Intervention|no adjunctive therapy (Arm D)|no adjunctive therapy
16523727|NCT03129100|Experimental|Ixekizumab (IXE) 80Q4W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
16523728|NCT03129100|Experimental|Ixekizumab (IXE) 80Q2W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
16523729|NCT03129100|Placebo Comparator|Placebo|Participants received subcutaneous dose of placebo.
16523730|NCT03129087|Experimental|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
16523731|NCT03129087|Experimental|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
16523732|NCT03129074|Experimental|Varlitinib given in combination with capecitabine|"PO varlitinib 300 mg BID
~PO capecitabine 1000 mg/m2 BID"
16523733|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
16523734|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
16523735|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
16523736|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
16523737|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
16523738|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
16523739|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
16523740|NCT03129022|Active Comparator|Successful epidural anaesthesia|It is defined as VAS score <5, 30 min after a loading dose, given after the last attempt.
16523741|NCT03129022|Active Comparator|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
16523742|NCT03129009|Active Comparator|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
16523743|NCT03129009|Experimental|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
16523744|NCT03128996|Experimental|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
16523745|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
16523746|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
16523748|NCT03128931|Experimental|Test Group|The subjects will be enrolled in the test group and will receive the Pediatric SedLine forehead EEG sensor.
16523749|NCT03128905|Active Comparator|Colchicine|Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
16523750|NCT03128905|Experimental|Prednisone (corticoids)|Patients assigned to this group will receive Prednisone : Cortancyl 20mg.
16523751|NCT03128892|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Noninvasive Oxygen Reserve Index - RD Lite Sensors
16523949|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
16523752|NCT03128879|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO QD and ibrutinib PO QD. Courses repeat every 4 weeks for up to 24 courses in the absence of disease progression or unaccepted toxicity.
16523753|NCT03128866|Experimental|Arm I (tranexamic acid)|Patients receive tranexamic acid IV over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity.
16523754|NCT03128866|Experimental|Arm II (no tranexamic acid)|Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity.
16523755|NCT03128853|Experimental|Test subjects|Each subject receives the Rad-67 and DCI Mini sensor that will measure hemoglobin repeatedly in order to compare those measurements against a blood sample reference.
16523756|NCT03128827|Experimental|Test Subjects|All test subjects were pediatric patients following general anesthesia who received the RAM sensor which measures respiration rate.
16523757|NCT03128814||Elite (pre)adolescent tennis players|
16523758|NCT03128814||Age- and gender-matched controls|
16523759|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
16523760|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
16523761|NCT03128788|Active Comparator|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
16523762|NCT03128788|Active Comparator|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
16523763|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
16523764|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
16523765|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
16523766|NCT03128775|No Intervention|Control|without any activity
16523767|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.
~Intervention: ILC2 levels in blood"
16523768|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.
~Intervention: ILC2 levels in blood"
16523769|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.
~These patients will be also attending to their regular psychiatric visits for medication control."
16523770|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
16523771|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
16523772|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
16523773|NCT03128723|Experimental|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
16523774|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
16523775|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
16523776|NCT03128697|Experimental|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
16523777|NCT03128697|Experimental|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
16523778|NCT03128697|Active Comparator|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
16523779|NCT03128697|Active Comparator|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
16523780|NCT03128684|Experimental|Small Green Lentil Muffin|
16523781|NCT03128684|Experimental|Split Red Lentil Muffin|
16523782|NCT03128684|Placebo Comparator|Wheat Muffin|
16523783|NCT03128684|Experimental|Small Green Lentil Chili|
16523784|NCT03128684|Experimental|Split Red Lentil Chili|
16523785|NCT03128684|Placebo Comparator|Rice Chili|
16523786|NCT03128671|Experimental|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
16523787|NCT03128671|No Intervention|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
16523950|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
16523788|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
16523789|NCT03128645||Group 1|Standard method group
16523790|NCT03128645||Group 2|Abdominal corset group
16523791|NCT03128619|Experimental|Arm A (copanlisib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression, or unacceptable toxicity.
16523792|NCT03128619|Experimental|Arm B (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16523793|NCT03128619|Experimental|Arm C (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive palbociclib PO QD for days 1-14 of course 1 and letrozole PO continuously on days 1-14. Patients then undergo biopsy. Patients then receive copanlisib IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment with copanlisib (MTD) and letrozole repeats every 28 days for up to 3.5 courses in the absence of disease progression or unacceptable toxicity.
16523794|NCT03128619|Experimental|Phase Ib (copanlisib, palbociclib, letrozole)|PHASE Ib: Patients with metastatic breast cancer receive copanlisib IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16523795|NCT03128606|Experimental|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
16523796|NCT03128606|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension.
16523797|NCT03128606|Experimental|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
16523798|NCT03128606|Experimental|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
16523799|NCT03128606|Experimental|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
16523800|NCT03128606|Experimental|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
16523801|NCT03128606|Experimental|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
16523802|NCT03128606|Experimental|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
16523803|NCT03128606|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension.
16523804|NCT03128606|Experimental|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
16523805|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
16523806|NCT03128606|Experimental|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
16523807|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
16523808|NCT03128593|Experimental|Experimental: JR-141|
16523809|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
16523810|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
16523811|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
16523812|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
16523813|NCT03128554|Experimental|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
16523814|NCT03128554|No Intervention|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
16523815|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
16523816|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
16523817|NCT03128528|Placebo Comparator|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
16523818|NCT03128528|Active Comparator|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
16523819|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
16523820|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
16523821|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
16523822|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
16523823|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
16523879|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
16523824|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
16523825|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
16523826|NCT03128476|Active Comparator|1 bottle|
16523827|NCT03128476|Active Comparator|2 bottles|
16523828|NCT03128476|Placebo Comparator|Placebo|
16523829|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
16523830|NCT03128463||effective group|visual improvement ≥5 letters and <15 letters in EDTRS table after intravitreal injection of conbercept
16523831|NCT03128463||invalid group|visual improvement <5 letters and visual reduction<5 letters in EDTRS table after intravitreal injection of Combercept
16523832|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
16523833|NCT03128450|Experimental|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.
~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
16523834|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
16523835|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.
~Assessments will take place at baseline, week 2, week 4, and week 8."
16523836|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
16523837|NCT03128411|Experimental|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
16523838|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
16523839|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
16523840|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
16523841|NCT03128359|Experimental|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.
~Patients undergo PBSC HCT on day 0.
~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
16523842|NCT03128359|Experimental|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.
~Patients undergo PBSC HCT on day 0.
~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
16523843|NCT03128359|Experimental|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.
~Patients undergo PBSC HCT on day 0.
~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
16523844|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
16523845|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
16523846|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
16523847|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
16523951|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
16523848|NCT03128320|Experimental|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
16523849|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
16523850|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
16523851|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
16523852|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
16523853|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
16523854|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
16523855|NCT03128268|Experimental|All Enrollees|"Intervention: Diagnostic test
~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
16523856|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
16523857|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
16523858|NCT03128242|Experimental|oxytocin group|oxytocin treatment
16523859|NCT03128242|Placebo Comparator|placebo group|placebo treatment
16523860|NCT03128216|Active Comparator|Blind Local Anesthetic Infiltration|
16523861|NCT03128216|Active Comparator|Transversals Fascia Block|
16523862|NCT03128216|Active Comparator|Spinal Anesthesia|
16523863|NCT03128203|Experimental|Oxytocin|
16523864|NCT03128203|Placebo Comparator|Placebo|
16523865|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
16523866|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
16523867|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
16523868|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
16523869|NCT03128164|Experimental|HMPL-689|HMPL-689, oral, BID, doses should be taken at ~12-hour intervals (eg, at ~8 AM and at ~8 PM)
16523870|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
16523871|NCT03128151||Control group|Treated according to usual clinical practice
16523872|NCT03128138|Experimental|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.
~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
16523873|NCT03128138|Experimental|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.
~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
16523874|NCT03128138|Experimental|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
16523875|NCT03128138|Experimental|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
16523876|NCT03128138|Experimental|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
16523877|NCT03128138|Experimental|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
16523878|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
16523952|NCT03127553|No Intervention|A - control|Free diet with standard bread
16523880|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
16523881|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
16523882|NCT03128099|Experimental|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
16523883|NCT03128099|Experimental|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
16523884|NCT03128099|No Intervention|Healthy Control Participants|23 healthy control participants were recruited and consented to yield baseline comparison data. These participants did not undergo VR training. Only baseline comparison data were collected.
16523885|NCT03128086|Experimental|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
16523886|NCT03128086|No Intervention|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
16523887|NCT03128073|Experimental|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
16523888|NCT03128060|Experimental|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
16523889|NCT03128060|Active Comparator|Enhanced Usual Care|Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.
16523890|NCT03128047|Experimental|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.
~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
16523891|NCT03128034|Experimental|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27, or every 8 hours on day 0 and then reduced to every 12 hours on days 30-40. Patients with HLA-matched unrelated donors receive sirolimus PO QD on days -3 to 150 and then tapered to day 180.
16523892|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
16523893|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.
~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
16523894|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.
~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
16523895|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
16523896|NCT03128008|Experimental|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
16523897|NCT03127995|Experimental|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.
~If the patient is candidate for a boost it will be provided as follows:
~sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions
~or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
16523898|NCT03127995|Other|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.
~If the patient is candidate for a boost it will be provided as follows:
~sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions
~or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
16523899|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
16523900|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
16523901|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
16523902|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
16523903|NCT03127956|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
16523904|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.
~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
16523905|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.
~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
16523906|NCT03127930|Experimental|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
16523907|NCT03127930|No Intervention|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
16523908|NCT03127917|Experimental|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
16523909|NCT03127917|Experimental|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
16523912|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
16523913|NCT03127891|Placebo Comparator|control group|no intervention
16523914|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
16523915|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
16523916|NCT03127852|Experimental|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
16523917|NCT03127852|No Intervention|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
16523918|NCT03127839|Active Comparator|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
16523946|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
16523919|NCT03127839|Active Comparator|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
16523920|NCT03127839|Active Comparator|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.
~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
16523921|NCT03127839|Active Comparator|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.
~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
16523922|NCT03127826|Active Comparator|Usual Care|"Managing Low Back Pain pamphlet from DoD/VA
~No specific guidance regarding physical therapy (PT) or other referrals, thus decision to refer or not will be made by the primary care manager (PCM) according to their preference"
16523923|NCT03127826|Experimental|Risk Stratified Care|"Managing Low Back Pain pamphlet from DoD/VA
~Self-management education and tools
~2-item spinal manipulation screening/delivery if indicated
~Low Risk:
~Home Exercise Program as indicated
~No referral for ongoing physical therapy
~Medium Risk and High Risk
~Referral to physical therapy for ongoing care at physical therapists discretion
~Managed by a psychologically informed physical therapy trained physical therapist"
16523924|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
16523925|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
16523926|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
16523927|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
16523928|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
16523929|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
16523930|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
16523931|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
16523932|NCT03127735|Experimental|BAY1436032|"Dose escalation:
~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.
~Dose expansion:
~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
16523933|NCT03127722|Experimental|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
16523934|NCT03127722|Active Comparator|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
16523935|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
16523936|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
16523937|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
16523938|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
16523939|NCT03127683|Experimental|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.
~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
16523940|NCT03127670|Experimental|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
16523941|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
16523942|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
16523943|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
16523944|NCT03127644|Placebo Comparator|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
16523945|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label antiplatelet agents, statins, ACE-I, and other antihypertensive medications where appropriate.
16523947|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
16523948|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
16523953|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
16523954|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
16523955|NCT03127514|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
16523956|NCT03127514|Experimental|AMX0035|AMX0035 administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
16523957|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
16523958|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
16523959|NCT03127462|Experimental|Individualized Education|
16523960|NCT03127462|No Intervention|Control group|
16523961|NCT03127449|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
16523962|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.
~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
~Data on tolerability are documented by the physicians."
16523963|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
16523964|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
16523965|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
16523966|NCT03127397|No Intervention|Standard of Care|
16523967|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
16523968|NCT03127384|Experimental|No-treatment control|
16523969|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
16523970|NCT03127371|Experimental|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
16523971|NCT03127371|Experimental|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
16523972|NCT03127358|Experimental|AiCure App|Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.
16523973|NCT03127358|No Intervention|Treatment As Usual|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.
16523974|NCT03127358|Active Comparator|AiCure with gamification|Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.
16523975|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
16523976|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
16523977|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
16523978|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
16523979|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment
~Polish version of BPS tool validation.
~Other Names:
~Pain assessment in non-verbal patients"
16523980|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment
~Polish version of BPS tool validation.
~Other Names:
~Pain assessment in non-verbal patients"
16523981|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
16523982|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
16523983|NCT03127280|No Intervention|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
16523984|NCT03127280|Experimental|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
16524012|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
16524013|NCT03127072|Experimental|Arm A|RFA plus chemotherapy ± target therapy
16523985|NCT03127267|Experimental|Masitinib (4.5) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d
16523986|NCT03127267|Experimental|Masitinib (6.0) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.
16523987|NCT03127267|Placebo Comparator|Placebo & Riluzole|Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.
16523988|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
16523989|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
16523990|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
16523991|NCT03127228|Other|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
16523992|NCT03127228|Experimental|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
16523993|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
16523994|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
16523995|NCT03127202|Experimental|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
16523996|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
16523997|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
16523998|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
16523999|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
16524000|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
16524001|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.
~Intervention: Genome sequencing of fecal samples"
16524002|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.
~Intervention: Genome sequencing of fecal samples"
16524003|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
16524004|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.
~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
16524005|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
16524006|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
16524007|NCT03127137|Other|Control cohort Group|Control cohort group will receive medications not predetermined by the set protocol.
16524008|NCT03127137|Active Comparator|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
16524009|NCT03127137|Placebo Comparator|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
16524010|NCT03127124|Experimental|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
16524011|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
16524014|NCT03127072|Active Comparator|Arm B|chemotherapy ± target therapy
16524015|NCT03127059|Experimental|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.
~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
16524016|NCT03127059|Other|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.
~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
16524017|NCT03127046|Experimental|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
16524018|NCT03127046|Experimental|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
16524019|NCT03127046|Experimental|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
16524020|NCT03127046|Experimental|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
16524021|NCT03127046|Experimental|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
16524022|NCT03127046|Experimental|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
16524023|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
16524024|NCT03127007|Experimental|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.
~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
16524025|NCT03127007|Active Comparator|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.
~Rectal surgery is planned during week 15"
16524026|NCT03126994|Experimental|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
16524027|NCT03126981|Experimental|Whole, natural almonds|1.5 oz of whole, natural almonds
16524028|NCT03126981|Placebo Comparator|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
16524029|NCT03126968|Experimental|Prophylactic topical epinephrine|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
16524030|NCT03126968|Placebo Comparator|Placebo|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.
16524031|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
16524032|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
16524033|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
16524034|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
16524035|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
16524036|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
16524037|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
16524038|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
16524039|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description. Closed to accrual as of 12/17/20.
16524040|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
16524041|NCT03126916|Experimental|Arm E (crizotinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
16524042|NCT03126903|Experimental|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
16524043|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
16524044|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
16524045|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
16524046|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
16547832|NCT02964637||Healthy controls|Observational Study
16524047|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.
~Fludarabine administered by vein on Days -5 to -3.
~Cyclophosphamide administered by vein on Day -3.
~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
16524048|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.
~Fludarabine administered by vein on Days -5 to -3.
~Cyclophosphamide administered by vein on Day -3.
~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
16524053|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement < 10 ml, and / OR diaphragmatic thickening fraction < 36 %.
16524054|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement > 10 ml, and / OR diaphragmatic thickening fraction > 36 %.
16524055|NCT03126825|Other|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
16524056|NCT03126825|Other|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
16524057|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
16524058|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:
~Erlotinib 150mg. po, qd, daily, q 3weeks"
16524059|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
16524060|NCT03126786|Active Comparator|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
16524061|NCT03126786|Sham Comparator|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
16524062|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
16524063|NCT03126760|Experimental|Acthar Gel|Participants receive Acthar Gel under the skin once a day for 14 consecutive days
16524064|NCT03126760|Placebo Comparator|Placebo|Participants receive Placebo under the skin once a day for 14 consecutive days
16524065|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
16524066|NCT03126734|Experimental|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
16524067|NCT03126734|No Intervention|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
16524068|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
16524069|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
16524070|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
16524071|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
16524072|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:
~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
16524073|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:
~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
16524074|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:
~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
16524075|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:
~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
16524076|NCT03126682|Active Comparator|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
16524077|NCT03126682|Active Comparator|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
16524078|NCT03126669|Active Comparator|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
16547938|NCT02963935|Experimental|Liraglutide|
16524079|NCT03126669|Placebo Comparator|Placebo|normal air, in the hyperbaric chamber
16524080|NCT03126656|Experimental|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels <11.4 nmol / L);
16524081|NCT03126656|Experimental|Hypogonadic|patients just with hypogonadism (testosterone <11.4 nmol / L) in the absence of documented cardiovascular disease
16524082|NCT03126656|No Intervention|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels > 11.4 nmol / L), in optimized standard therapy for heart failure
16524085|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
16524086|NCT03126604||Cesarean section|Women underwent elective Cesarean section
16524087|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
16524088|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
16524089|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
16524090|NCT03126578|Experimental|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.
~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
16524091|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
16524092|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
16524093|NCT03126552|Experimental|Intervention|Four healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae.
16524094|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
16524095|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
16524096|NCT03126526|Experimental|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
16524097|NCT03126526|Active Comparator|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
16524098|NCT03126526|No Intervention|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
16524099|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
16524100|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
16524101|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
16524102|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
16524103|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
16524104|NCT03126448|Other|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
16524105|NCT03126448|Other|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
16524106|NCT03126448|Other|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or < 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
16524107|NCT03126435|Experimental|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly plus gemcitabine 1000mg/m² once weekly for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
16524209|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
16524546|NCT03123094|Placebo Comparator|Matching placebo for each dose group (Intravenous)|
16524108|NCT03126435|Other|Gemcitabine|Gemcitabine 1000mg/m² once weekly, for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
16524109|NCT03126422|Experimental|Dexmedetomidine 0 μg/kg/min|
16524110|NCT03126422|Experimental|Dexmedetomidine 0.03 μg/kg/min|
16524111|NCT03126422|Experimental|Dexmedetomidine 0.06 μg/kg/min|
16524112|NCT03126422|Experimental|Dexmedetomidine 0.09 μg/kg/min|
16524113|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
16524114|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
16524115|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
16524116|NCT03126370|Experimental|TAF with a boosted PI and LDV/SOF|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.
~Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.
~After taking TAF/FTC for 12 weeks, participants will then start taking ledipasvir 90mg/sofosbuvir 400mg (LDV/SOV, Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.
~Participants will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
16524117|NCT03126357|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524118|NCT03126357|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524119|NCT03126357|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524120|NCT03126357|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524121|NCT03126357|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524122|NCT03126357|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524123|NCT03126357|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524124|NCT03126357|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524125|NCT03126357|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524126|NCT03126357|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
16524127|NCT03126344|Experimental|King Vision video laryngoscope|
16524128|NCT03126344|Experimental|McGrath MAC video laryngoscope|
16524129|NCT03126344|Active Comparator|Macintosh|
16524130|NCT03126331|Experimental|Cohort I: Intermittent Nivolumab|Nivolumab monotherapy. Participants who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
16524131|NCT03126331|Experimental|Cohort II: combination ipilimumab/nivolumab|"Combination of ipilimumab/nivolumab for previously untreated intermediate and poor risk mRCC
~Includes participants treated front-line ipilimumab/nivolumab. Participants with treatment-naïve mRCC who receive up to four doses of induction ipilimumab/nivolumab and 24 weeks (+/- 8 weeks; minimum 3 infusions) of maintenance nivolumab and achieve stable disease (SD), complete response (CR), or partial response (PR) will be eligible for inclusion. Participants who achieve SD will continue with nivolumab maintenance per standard of care while those who achieve a PR or CR will enter an observation period off therapy. Upon disease progression, participants will be re-challenged with combination ipilimumab/nivolumab."
16524132|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
16524133|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
16524134|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
16524135|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
16524136|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
16524137|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
16524138|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
16524139|NCT03126266|Experimental|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
16524210|NCT03125824|Other|Tattoos previously treated in Soliton 2016-001 trial|Identical tattoos treated by Laser + AWD in Soliton's previous trial
16524211|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
16524212|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
16524140|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
16524141|NCT03126227|Active Comparator|Peanut allergen formulation|Subjects will be randomized to active arm of ARC007 and will be administered IP (AR101) in escalating doses for approximately 6 months.
16524142|NCT03126227|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC007 and will be administered escalating doses of IP (placebo) for approximately 6 months.
16524143|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
16524144|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
16524145|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
16524146|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
16524147|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
16524148|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
16524149|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
16524150|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
16524151|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
16524152|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
16524153|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
16524154|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
16524155|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
16524156|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
16524157|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
16524158|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
16524159|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
16524160|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
16524161|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
16524162|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
16524163|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
16524164|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
16524165|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
16524166|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
16524167|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
16524168|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
16524169|NCT03126136|Experimental|Pregnant women|
16524170|NCT03126123|Other|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
16524171|NCT03126110|Experimental|INCAGN01876 + Nivolumab|INCAGN01876 combined with nivolumab.
16524172|NCT03126110|Experimental|INCAGN01876 + Ipilimumab|INCAGN01876 combined with ipilimumab.
16524173|NCT03126110|Experimental|INCAGN01876 + Nivolumab + Ipilimumab|INCAGN01876 combined with nivolumab and ipilimumab.
16524174|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
16524175|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.
~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.
~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
16524176|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.
~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.
~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
16524177|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.
~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.
~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
16524178|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
16524179|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
16524180|NCT03126058|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:
~Multimodal analgesia
~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet
~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.
~Early activity
~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
16524181|NCT03126045|Active Comparator|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
16524182|NCT03126045|Experimental|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
16524183|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.
~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
16524184|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.
~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
16524185|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
16524186|NCT03126019|Experimental|Group A|Parsaclisib once daily (QD) for 8 weeks followed by Parsaclisib once weekly
16524187|NCT03126019|Experimental|Group B|Parsaclisib QD
16524188|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
16524189|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
16524190|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
16524191|NCT03125980|Experimental|Perioperative chemotherapy with CapOX regimen|
16524192|NCT03125980|Active Comparator|Postoperative chemotherapy with CapOX regimen|
16524193|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
16524194|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
16524195|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
16524196|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
16524197|NCT03125928|Experimental|Investigational Arm|
16524198|NCT03125915|Active Comparator|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
16524199|NCT03125915|Experimental|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
16524200|NCT03125915|Experimental|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
16524201|NCT03125915|Experimental|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
16524204|NCT03125889|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
16524205|NCT03125876|Experimental|CT053PTSA|60mg-100mg
16524206|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
16524207|NCT03125850|Experimental|day-ward group|
16524208|NCT03125850|Active Comparator|inpatient group|
16524213|NCT03125798|Experimental|LigaSure|In this arm, LigaSure™ will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
16524214|NCT03125798|Active Comparator|Monopolar electrocautery|In this arm, conventional monopolar electrocautery will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
16524215|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
16524216|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
16524217|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
16524218|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
16524219|NCT03125759||Control|patients without any history of stroke
16524220|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
16524221|NCT03125746|Experimental|LXI-15029|
16524222|NCT03125746|Experimental|LXI-15029+Exemestane|
16524223|NCT03125733|Experimental|STESD|Submucosal tunneling endoscopic septum division
16524224|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
16524225|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
16524226|NCT03125694|Active Comparator|Sitagliptin|
16524227|NCT03125694|Active Comparator|Pioglitazone|
16524228|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
16524229|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
16524230|NCT03125668|Experimental|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
16524231|NCT03125668|Active Comparator|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
16524232|NCT03125642|Experimental|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
16524233|NCT03125642|Experimental|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
16524234|NCT03125642|Experimental|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
16524235|NCT03125629|Experimental|18F-FDG PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 18F-FDG.
16524236|NCT03125629|Experimental|18F-FDG PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 18F-FDG.
16524237|NCT03125629|Experimental|68Ga-DOTA-TATE PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 68Ga-DOTA-TATE.
16524238|NCT03125629|Experimental|68Ga-DOTA-TATE PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 68Ga-DOTA-TATE.
16524239|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
16524240|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
16524241|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.
~Consultation of the patient's medical files at the hospital."
16524242|NCT03125577|Experimental|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
16524243|NCT03125564|Experimental|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
16524244|NCT03125564|Sham Comparator|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
16524245|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
16524246|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
16524247|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
16524248|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
16524249|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
16524250|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
16524251|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
16524252|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
16524253|NCT03125512|Experimental|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
16524254|NCT03125512|Active Comparator|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
16524255|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
16524256|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
16524257|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
16524258|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
16524259|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
16524260|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
16524261|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
16524262|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
16524263|NCT03125434|Experimental|healthy volunteers|EOS full-spine, MRI, gait analysis
16524264|NCT03125421|Other|control period|standard preventive methods of pressure sores in each center
16524265|NCT03125421|Experimental|experimental period|experimental multifaceted preventive methods of pressure sores
16524266|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
16524267|NCT03125395|Experimental|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
16524268|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
16524269|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
16524270|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
16524271|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
16524272|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
16524273|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
16524274|NCT03125356|Experimental|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
16524275|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
16524276|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
16524277|NCT03125330|Experimental|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.
~Additional requirements for One-to-One Coaching:
~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.
~Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.
~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.
~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
16524310|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
16524278|NCT03125330|Active Comparator|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.
~Additional requirements:
~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.
~Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.
~Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.
~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.
~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
16524279|NCT03125330|No Intervention|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.
~Additional requirements:
~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
16524280|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
16524281|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
16524282|NCT03125317||The control group|no intervention
16524285|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
16524286|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
16524287|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
16524288|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
16524289|NCT03125252|Experimental|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
16524290|NCT03125252|Other|Control|Standard paramedical and medical practices
16524291|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.
~After the screening procedures confirm participation in the research study:
~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
~Merestinib
~LY2874455"
16524292|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
16524293|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
16524294|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
16524295|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.
~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
16524296|NCT03125187|Experimental|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
16524297|NCT03125187|Experimental|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
16524298|NCT03125174||control|healthy individuals with no history of lung disease
16524299|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
16524300|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
16524301|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
16524302|NCT03125148|Other|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
16524303|NCT03125148|Other|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
16524304|NCT03125135|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.
16524305|NCT03125083|Experimental|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
16524306|NCT03125070|Experimental|Group I (INSPIRE, survivorship care plan)|Patients receive immediate access to the INSPIRE online program and personalized survivorship care plan.
16524307|NCT03125070|Active Comparator|Group II (usual care)|Patients receive an online program linking to existing online survivor resources and a personalized survivorship care plan. Patients may receive access to the INSPIRE online program after 12 months.
16524308|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
16524309|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
16524311|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
16524312|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
16524313|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
16524314|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
16524315|NCT03124966|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
16524316|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
16524317|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
16524318|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
16524319|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
16524321|NCT03124862|Experimental|Test group|The subjects will be enrolled into the test group and will receive ARM sensor.
16524322|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
16524323|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
16524324|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
16524325|NCT03124784|Experimental|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
16524326|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
16524327|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
16524328|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
16524329|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
16524330|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
16524331|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
16524332|NCT03124667|Active Comparator|Video Condition|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
16524333|NCT03124654||Education|
16524334|NCT03124641|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
16524335|NCT03124641|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
16524336|NCT03124628|Experimental|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
16524337|NCT03124628|Active Comparator|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
16524338|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
16524339|NCT03124602|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
16524340|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
16524341|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
16524342|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
16524343|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
16524344|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
16524345|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
16524467|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
16524346|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
16524347|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
16524348|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
16524349|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
16524350|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
16524351|NCT03124524|No Intervention|Control group|33 healthy controls
16524352|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
16524353|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
16524354|NCT03124498|Experimental|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule
~Phase II - The recommended dose level according to the results from Phase I"
16524355|NCT03124485|Experimental|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
16524356|NCT03124485|Active Comparator|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
16524357|NCT03124472|Active Comparator|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.
~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.
~Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.
~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
16524358|NCT03124472|Active Comparator|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.
~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.
~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
16524359|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
16524360|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
16524361|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
16524362|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
16524363|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
16524364|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
16524365|NCT03124446|Active Comparator|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
16524366|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
16524367|NCT03124420|Active Comparator|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
16524547|NCT03123094|Placebo Comparator|Matching placebo (Subcutaneous)|
16524368|NCT03124420|Sham Comparator|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
16524369|NCT03124407|Active Comparator|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
16524370|NCT03124407|Placebo Comparator|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
16524371|NCT03124407|Active Comparator|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
16524372|NCT03124407|Placebo Comparator|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
16524373|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
16524374|NCT03124381|Active Comparator|Acne Mask|Cleanser, Acne Mask
16524375|NCT03124381|Experimental|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
16524376|NCT03124368|Experimental|Group 1: Danicopan 100 mg TID (Sentinel)|All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
16524377|NCT03124368|Experimental|Group 2: Danicopan up to 200 mg TID|All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
16524378|NCT03124355|Experimental|Placebo pill with vagal/sham stimulation|Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
16524379|NCT03124355|Experimental|Pyridostigmine with vagal/sham stimulation|Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
16524380|NCT03124355|Experimental|Galantamine with vagal/sham stimulation|Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation
16524381|NCT03124342|Experimental|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
16524382|NCT03124342|No Intervention|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
16524383|NCT03124329|Experimental|Coronally Advanced Flap|
16524384|NCT03124329|Experimental|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
16524385|NCT03124329|Experimental|Intrasulcular tunneling|
16524386|NCT03124329|Experimental|VISTA + Leukocyte-Platelet Rich Fibrin|
16524387|NCT03124316|No Intervention|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
16524388|NCT03124316|Experimental|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
16524389|NCT03124316|Experimental|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
16524390|NCT03124316|Experimental|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
16524391|NCT03124316|Experimental|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
16524392|NCT03124316|Experimental|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
16524393|NCT03124316|Experimental|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
16524394|NCT03124316|Experimental|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
16524395|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
16524396|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
16524397|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
16524398|NCT03124277|Other|Control group|Best local diet
16524399|NCT03124238|Experimental|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
16524400|NCT03124238|No Intervention|Control|Rest during 5 minutes in a prone position
16524401|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
16524402|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
16524403|NCT03124199|Experimental|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
16524404|NCT03124186|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
16524548|NCT03123081|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
16524405|NCT03124186|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
16524406|NCT03124173|Other|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
16524407|NCT03124160|Experimental|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
16524408|NCT03124160|Active Comparator|ParaGard® CuT380A|ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
16524409|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
16524410|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
16524411|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
16524412|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
16524413|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
16524414|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
16524415|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
16524416|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
16524417|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
16524418|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
16524419|NCT03124121|Other|Induction cohort|Golimumab induction therapy
16524420|NCT03124121|Other|Maintenance cohort|Golimumab maintenance therapy
16524421|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
16524422|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
16524423|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
16524424|NCT03124095|Experimental|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
16524425|NCT03124095|No Intervention|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
16524426|NCT03124082|Active Comparator|opioid|remifentanil 0,15-0,25 mcg/kg/h
16524427|NCT03124082|Experimental|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
16524428|NCT03124069|Experimental|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
16524429|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
16524430|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
16524431|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
16524432|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
16524433|NCT03124017|Experimental|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
16524434|NCT03124017|No Intervention|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
16524435|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
16524436|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
16524437|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
16524438|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
16524439|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16524440|NCT03123939|Experimental|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
16524441|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
16524442|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
16524443|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
16524444|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
16524445|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
16524446|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
16524447|NCT03123874|Experimental|Sterile pump set-up first|Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
16524448|NCT03123874|Experimental|Mother's Own pump set-up first|Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.
16524449|NCT03123861|Active Comparator|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
16524450|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
16524451|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
16524452|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
16524453|NCT03123822|Experimental|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
16524454|NCT03123822|Experimental|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
16524455|NCT03123822|Experimental|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
16524456|NCT03123809|Active Comparator|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.
~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
16524457|NCT03123809|Placebo Comparator|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.
~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
16524458|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
16524459|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
16524460|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
16524461|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
16524462|NCT03123783|Experimental|APX005M in combination with nivolumab|Subjects will receive intravenously APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death.
16524463|NCT03123770|Experimental|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
16524464|NCT03123770|Active Comparator|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
16524465|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
16524466|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
16524468|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
16524469|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
16524470|NCT03123718|Other|Intrathecal Methotrexate|
16524471|NCT03123718|Active Comparator|High-dose Intravenous Methotrexate|
16524472|NCT03123692|Experimental|Treatment|14 days treatment with NBMI 300 mg/day
16524473|NCT03123692|Placebo Comparator|Placebo|14 days treatment with Placebo
16524474|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
16524475|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
16524476|NCT03123653|Experimental|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
16524477|NCT03123640|Experimental|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
16524478|NCT03123640|No Intervention|Control group|Standard treatment without pharmacist intervention in the emergency department
16524479|NCT03123627|Experimental|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
16524480|NCT03123627|Active Comparator|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
16524481|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
16524482|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
16524483|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
16524484|NCT03123588|Experimental|Ruxolitinib|
16524485|NCT03123588|Active Comparator|Anagrelide|
16524486|NCT03123562|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
16524487|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
16524488|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=188) of a previously completed two level cervical disc trial.
16524489|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
16524490|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
16524491|NCT03123523||Patients group|35 patients
16524492|NCT03123523||Healthy volunteers|20 healthy volunteers
16524493|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
16524494|NCT03123510|Placebo Comparator|placebo|sugar pills
16524495|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
16524496|NCT03123484|Experimental|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
16524497|NCT03123484|Active Comparator|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
16524498|NCT03123471|Experimental|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
16524499|NCT03123471|Placebo Comparator|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
16524500|NCT03123458|Experimental|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
16524501|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
16524502|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
16524503|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
16524541|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
16524542|NCT03123094|Experimental|BI 655130 dose group 1 (Intravenous)|
16524543|NCT03123094|Experimental|BI 655130 dose group 2 (Intravenous)|
16524504|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
16524505|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
16524506|NCT03123406|Experimental|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH>900 pg/ml from 1st to 32nd week.
16524507|NCT03123406|Experimental|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH<900 pg/ml from 1st to 32nd week.
16524508|NCT03123406|Experimental|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH<600 pg/ml from 1st to 32nd week.
16524509|NCT03123393|Experimental|Cohort A: TAK-659 100 mg|TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
16524510|NCT03123393|Experimental|Cohort B: TAK-659 Ramp-up Dosing|TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).
16524511|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
16524512|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
16524513|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
16524514|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
16524515|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
16524516|NCT03123328|Experimental|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
16524517|NCT03123315|Experimental|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
16524518|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
16524519|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
16524520|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
16524521|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
16524522|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
16524523|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.
~Note that same patients scanned with different radiotracers serve in both arms."
16524524|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
16524525|NCT03123250|Experimental|Aquablation procedure|
16524526|NCT03123237|Placebo Comparator|Control|"control will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
16524527|NCT03123237|Active Comparator|Diabetic|"diabetic cases will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
16524528|NCT03123237|Active Comparator|Hypertensive|"hypertesive cases will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
16524529|NCT03123237|Active Comparator|Diabetic & Hypertensive|"Diabetic & Hypertensive cases will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
16524530|NCT03123224|Experimental|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
16524531|NCT03123224|Active Comparator|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
16524532|NCT03123198|Experimental|Dialectical Behavior Therapy|All participants receive six months of standard DBT which includes individual therapy, skills training, and as-needed phone consultation.
16524533|NCT03123185|Experimental|Single rising dose part|Groups of healthy volunteers receive rising single doses of BI 705564
16524534|NCT03123185|Experimental|Food effect part|Groups of healthy volunteers receive single doses of BI 705564 with and without food
16524535|NCT03123172|Other|co2 gap|arterial and central venous blood gases to measure Co2 gap
16524536|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
16524537|NCT03123146|Experimental|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
16524538|NCT03123146|No Intervention|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
16524539|NCT03123120|Experimental|Spesolimab|
16524540|NCT03123120|Placebo Comparator|Placebo|
16524544|NCT03123094|Experimental|BI 655130 dose group 3 (Intravenous)|
16524549|NCT03123081|No Intervention|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
16524550|NCT03123068|Active Comparator|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
16524551|NCT03123068|Placebo Comparator|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
16524552|NCT03123055|Experimental|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
16524553|NCT03123055|Experimental|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
16524554|NCT03123042|Experimental|Sentinel basin dissection|Intervention: Sentinel basin dissection
16524555|NCT03123016|Experimental|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
16524556|NCT03123003|Experimental|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
16524557|NCT03122990|Experimental|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
16524558|NCT03122990|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
16524559|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
16524560|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
16524561|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
16524562|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
16524563|NCT03122938|Experimental|Lactoferrin Group|lactoferrin-supplemented formula
16524564|NCT03122938|Placebo Comparator|Control Group|formula without lactoferrin supplementation
16524565|NCT03122925||Control|Healthy subjects
16524566|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
16524567|NCT03122912|Experimental|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
16524568|NCT03122912|Active Comparator|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
16524569|NCT03122899|Other|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
16524570|NCT03122899|Other|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
16524571|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
16524572|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
16524573|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
16524574|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
16524575|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
16524576|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
16524577|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
16524578|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
16524579|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
16524580|NCT03122860|Placebo Comparator|Placebo|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
16524581|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
16524582|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
16524583|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
16524584|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
16524585|NCT03122821|Experimental|Group 1|Trans-cranial direct stimulation + Mental Imagery
16524586|NCT03122821|Active Comparator|Group 2|Trans-cranial direct stimulation only
16524587|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:
~Moderate or severe neonatal encephalopathy
~Gestational age of 35+0 weeks or greater
~Singleton pregnancy
~Inborn
~The exclusion criteria will be:
~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia
~Major congenital abnormalities
~Less than 15 minutes of digital CTG recording from labour available"
16524720|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
16524588|NCT03122808||Control|"The inclusion criteria will be:
~Gestational age of 35+0 weeks or greater
~Singleton pregnancy
~Inborn
~The exclusion criteria will be:
~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes
~Admission to the neonatal unit
~Major congenital abnormalities
~Less than 15 minutes of digital CTG recording from labour available"
16524589|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
16524590|NCT03122782|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
16524591|NCT03122782|Placebo Comparator|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
16524592|NCT03122769|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
16524593|NCT03122756|Experimental|Group (D)|will include 50 women who will receive intravenous dexamethasone.
16524594|NCT03122756|Placebo Comparator|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
16524595|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
16524596|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
16524597|NCT03122717|Experimental|Gefitinib + Osimertinib|"Gerfitinib will administered orally at a pre determine dose daily
~Osimertinib will administered orally at a pre determine dose daily"
16524598|NCT03122704|Experimental|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
16524599|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
16524600|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
16524601|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
16524602|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
16524603|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
16524604|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
16524605|NCT03122678|Experimental|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
16524606|NCT03122678|Placebo Comparator|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
16524607|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
16524608|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
16524609|NCT03122652|Experimental|Terifunomide|
16524610|NCT03122652|Placebo Comparator|Placebo|
16524611|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
16524612|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
16524613|NCT03122626|Experimental|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
16524614|NCT03122626|No Intervention|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
16524615|NCT03122613|Active Comparator|Curcumin|Dietary supplements of Curcumin capsules
16524616|NCT03122613|Placebo Comparator|Curcumin Placebo|Identical looking placebo of the active arm
16524617|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
16524618|NCT03122587|Sham Comparator|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
16524619|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
16524620|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
16524621|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
16524622|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
16524623|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
16524624|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
16547939|NCT02963935|Placebo Comparator|Placebo|
16524625|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
16524626|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
16524627|NCT03122548|Experimental|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
16524628|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
16524629|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
16524630|NCT03122522|Experimental|ipilimumab and nivolumab|Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 & week 10) & repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks & then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy & subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
16524631|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
16524632|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
16524633|NCT03122496|Experimental|durvalumab (MEDI4736) & tremelimumab with SBRT|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks. SBRT delivered to one metastatic site per standard of care using a standard 9Gy x 3 fractions will be given within 2 weeks after the completion of the first cycle of durvalumab (MEDI4736) and tremelimumab. After 4 cycles of durvalumab (MEDI4736) and tremelimumab, patients will then continue with single agent durvalumab (MEDI4736) every 4 weeks until disease progression or unacceptable toxicity or a total of 12 months from date of initial treatment.
16524634|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
16524635|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
16524636|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
16524637|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
16524638|NCT03122444|Experimental|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
16524639|NCT03122431|Other|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
16524640|NCT03122431|No Intervention|Inactive SLE with standard dose of HCQ|This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) and in the other, the dose will be reduced to 400mg 3 times a week for two years.
16524641|NCT03122431|Active Comparator|Inactive SLE with reduced dose of HCQ|This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced) for two years.
16524642|NCT03122431|Experimental|Active SLE with initial high dose of HCQ|This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.
16524643|NCT03122431|No Intervention|Active SLE with standard dose of HCQ|This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for three months and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.
16524644|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
16547940|NCT02963922|Experimental|liraglutide 3.0 mg|
16524645|NCT03122405|Experimental|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
16524646|NCT03122392|Experimental|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.
~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.
~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
16524647|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
16524648|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
16524649|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
16524650|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
16524651|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
16524652|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
16524653|NCT03122314|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
16524654|NCT03122314|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
16524655|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
16524656|NCT03122301|Sham Comparator|Saline|Saline injection
16524659|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:
~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.
~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
16524660|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
16524661|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
16524662|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
16524663|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
16524664|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
16524665|NCT03122236|Active Comparator|Standard walking with tDCS dosage A|Neurorehabilitation of Standard Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
16524666|NCT03122236|Active Comparator|Complex walking with tDCS dosage A|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
16524667|NCT03122236|Active Comparator|Complex walking with tDCS dosage B|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage B
16524668|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
16524669|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
16524670|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
16524671|NCT03122223|Placebo Comparator|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
16524672|NCT03122210|Other|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
16524673|NCT03122210|Other|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
16524674|NCT03122210|Other|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
16524721|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
16524722|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
16524723|NCT03121846|Experimental|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
16547941|NCT02963922|Placebo Comparator|Placebo|
16524675|NCT03122197|Experimental|Letrozole|"The treatment starting dose will be 2.5mg administered orally once daily. Daily doses up to 10mg and single doses of 30mg have been shown to be safe in prior studies and therefore we expect that letrozole doses up to 20mg in this study will be safe.
~The recommended phase II dose (RP2D) will be considered the dose that results in ≥ 2uM letrozole concentration in the tumor or the highest dose achieved (20mg daily for cohort level 7) with < 2/6 patients with DLTs. This dose will be planned for future phase II studies to determine potential efficacy."
16524676|NCT03122184|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
16524677|NCT03122184|Active Comparator|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
16524678|NCT03122171|Experimental|Prosthesis|
16524679|NCT03122158|Active Comparator|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
16524680|NCT03122158|Active Comparator|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
16524681|NCT03122145|Experimental|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
16524682|NCT03122145|Experimental|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
16524683|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
16524684|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
16524685|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.
~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.
~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
16524686|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
16524687|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
16524688|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
16524689|NCT03122080|Active Comparator|Electroacupuncture group|electroacupuncture+standard care
16524690|NCT03122080|Placebo Comparator|Control A group|placebo acupuncture+standard care
16524691|NCT03122080|Other|Control B group|standard care
16524692|NCT03122067|Experimental|oxytocin group|male participants with oxytocin treatment
16524693|NCT03122067|Placebo Comparator|placebo group|male participants with placebo treatment
16524694|NCT03122054|Other|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
16524695|NCT03122054|Other|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
16524696|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
16524697|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
16524698|NCT03122028|Experimental|LAmbre closure system|
16524719|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.
~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
16524699|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
16524700|NCT03122015|No Intervention|Standard care|
16524701|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
16524702|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
16524703|NCT03121989|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
~After the injection research, MRI will be done and images evaluated."
16524704|NCT03121989|Placebo Comparator|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
16524705|NCT03121976|Experimental|Ultrasound|Femoral catheters inserted using ultrasound only
16524706|NCT03121976|Active Comparator|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
16524707|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
16524708|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
16524709|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
16524710|NCT03121950|Active Comparator|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
16524711|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
16524712|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
16524713|NCT03121924|Experimental|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .
~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
16524714|NCT03121924|Experimental|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .
~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
16524715|NCT03121911|Experimental|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.
~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
16524716|NCT03121911|Experimental|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.
~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
16524717|NCT03121911|No Intervention|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
16524718|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.
~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
16548327|NCT02961413||cohort 6|N- acetylcysteine
16524724|NCT03121833|Experimental|Endostar & AIM regimen / GT regimen|Endostar & AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
16524725|NCT03121833|Placebo Comparator|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
16524726|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
16524727|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
16524728|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
16524729|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
16524730|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
16524731|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
16524732|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
16524733|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
16524734|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
16524735|NCT03121742|Placebo Comparator|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
16524736|NCT03121742|Experimental|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
16524737|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:
~Multimodal analgesia
~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet
~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early
~Early activity
~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
16524738|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
16524739|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
16524740|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
16524741|NCT03121690|Experimental|prednisone|prednisone 40 mg/day for 7 days
16524742|NCT03121690|Experimental|placebo|5ml saline /day for 7 days
16524743|NCT03121677|Experimental|Nivolumab/Poly-ICLC/Vaccine/+/- Rituximab|"All cycles are 4 weeks (wks), with nivolumab every 2 wks during Cycles 1-6 & every 4 wks during Cycles 7-12 & vaccine on Cycle 1 Days 1, 4, 8, 15; Cycle 2 Day 1; and then on Day 1 of Cycles 4, 6, 8, 10, 12
~After 2 cycles, restaging will be performed, & patients with CR, PR, or SD will continue on nivolumab + vaccine. Patients with evidence of PD may initiate anti-CD20 mAb therapy (drug to be determined by the treating physician) weekly for 4 wks during Cycle 3, followed by a dose on Day 1 of every other cycle (Cycles 6, 8, 10, and 12).
~After 6 cycles, restaging will be performed again, and patients with CR, PR, or SD will continue nivolumab + vaccine. Patients with PD at that time point (but not treated with anti-CD20 mAb therapy thus far on this protocol) will initiate anti-CD20 mAb (drug to be determined by the treating physician) therapy weekly for 4 wks during Cycle 7, followed by a dose Day 1 of Cycles 10 & 12 & 2 additional doses 8 wks apart."
16524744|NCT03121664|Experimental|Cohort 1|
16524745|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).
~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
16524746|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
16524747|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
16524748|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
16524749|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
16524750|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
16524751|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
16524847|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
16524932|NCT03120260|Experimental|Short Sleep|Diet+ have 5 hour sleep at night (SS)
16524752|NCT03121612|Experimental|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. [Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement]
16524753|NCT03121612|Active Comparator|Fisher-Paykel CPAP|Fisher-Paykel (F&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
16524754|NCT03121599|Experimental|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
16524755|NCT03121586|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, + background antipsychotic, taken once daily by mouth
16524756|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
16524757|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
16524758|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
16524759|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
16524760|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
16524761|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
16524762|NCT03121534|Experimental|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.
~Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab.
~Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment."
16524763|NCT03121521|Experimental|melatonin|Melatonin 10mg/d p.o.
16524764|NCT03121521|Placebo Comparator|placebo|placebo 10mg/d p.o.
16524765|NCT03121508|Other|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
16524766|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
16524767|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
16524768|NCT03121482|Active Comparator|HFNC alone|Control group
16524769|NCT03121482|Experimental|HFNC and NIV|
16524770|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
16524771|NCT03121456|Experimental|18F-FDG PET SCAN|"REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
~MRI DIFFUSION REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1."
16524772|NCT03121443||Patient position|Perfusion index
16524773|NCT03121430|Experimental|Group A|subjects using the drug eluting peripheral vascular stent system
16524774|NCT03121430|Active Comparator|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
16524775|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
16524776|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
16524777|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
16524778|NCT03121391|No Intervention|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
16524779|NCT03121391|Active Comparator|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
16524780|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
16524781|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
16524782|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
16524783|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
16524784|NCT03121352|Experimental|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
16524785|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
16524786|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
16524787|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.
~Dose of tegafur-uracil will be based on patient's body surface area (BSA):
~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)
~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
16524788|NCT03121300||High Risk Lung Cancer Patients|
16524789|NCT03121287||Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test & 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
16524790|NCT03121274|Active Comparator|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
16524791|NCT03121274|Active Comparator|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
16524792|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
16524793|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
16524794|NCT03121248|Experimental|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
16524795|NCT03121248|Active Comparator|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
16524796|NCT03121248|Experimental|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
16524797|NCT03121248|Active Comparator|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
16524798|NCT03121248|Experimental|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
16524799|NCT03121248|Active Comparator|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
16524800|NCT03121248|Experimental|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
16524801|NCT03121248|Active Comparator|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
16524802|NCT03121248|Experimental|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
16524803|NCT03121248|Active Comparator|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
16524804|NCT03121222|Placebo Comparator|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
16524805|NCT03121222|Experimental|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
16524806|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
16524807|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
16524808|NCT03121183||Patients who have undergone an extraction of implantable pace|
16524809|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
16524810|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
16524811|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
16524848|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
16548586|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6a)|
16524812|NCT03121157|Experimental|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
16524813|NCT03121157|No Intervention|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
16524814|NCT03121144|Experimental|Masimo Centroid System|Single-arm study. All subjects are enrolled into the test group wherein the noninvasive positional monitoring device will be administered.
16524815|NCT03121131|Other|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
16524816|NCT03121131|Other|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
16524817|NCT03121131|Other|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
16524818|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
16524819|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
16524820|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
16524821|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
16524822|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
16524823|NCT03121066|Active Comparator|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
16524824|NCT03121066|Sham Comparator|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
16524825|NCT03121066|No Intervention|Non TMS Control group|Conventional intervention alone
16524826|NCT03121053|Active Comparator|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
16524827|NCT03121053|Active Comparator|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
16524828|NCT03121040|Experimental|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
16524829|NCT03121040|Experimental|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
16524830|NCT03121040|No Intervention|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
16524831|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
16524833|NCT03120988|Experimental|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
16524834|NCT03120975|Experimental|Computerized decision support|
16524835|NCT03120975|Active Comparator|Standard antibiotic stewardship|
16524836|NCT03120962|Experimental|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
16524837|NCT03120962|Active Comparator|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
16524840|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
16524841|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
16524842|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
16524843|NCT03120910|Experimental|Test Subjects|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensor, including nasal sensors, with the same or similar technology and materials as the Masimo FDA cleared devices and sensors.
16524844|NCT03120897|Experimental|Test group|The subjects will be enrolled into the test group and will receive RAM sensor.
16524845|NCT03120884|Experimental|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
16524846|NCT03120884|Experimental|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
16524849|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
16524850|NCT03120832|Experimental|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
16524851|NCT03120819|Active Comparator|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
16524852|NCT03120819|Experimental|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
16524853|NCT03120806|Active Comparator|continous subcuticular|skin closed with continous subcuticular mattress suture using non-absorbable polypropylene
16524854|NCT03120806|Active Comparator|Interrupted subcuticular|skin closed with interrupted subcuticular mattress suture using non-absorbable polypropylene
16524855|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
16524856|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
16524857|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
16524858|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
16524859|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
16524860|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
16524861|NCT03120754|Experimental|Experimental Group|Placement of peritoneal drainage
16524862|NCT03120754|Active Comparator|Control group|No peritoneal drainage
16524863|NCT03120728|Experimental|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
16524864|NCT03120728|Experimental|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
16524865|NCT03120728|Experimental|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
16524866|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
16524867|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
16524868|NCT03120702|Experimental|Neonatal Test Subjects|All test subjects in this group are neonatal patients who will receive a investigational Rainbow SpHb sensor.
16524869|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
16524870|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
16524871|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
16524872|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
16524873|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
16524874|NCT03120650|Experimental|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
16524875|NCT03120650|Active Comparator|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
16524876|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
16524877|NCT03120637|No Intervention|Standard Treatment|
16524878|NCT03120624|Experimental|Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
16524879|NCT03120624|Experimental|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
16524880|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
16524881|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
16524882|NCT03120598|Active Comparator|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
16524883|NCT03120598|Experimental|ISF strategy|Behavioral: Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
16524884|NCT03120585|Experimental|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
16524885|NCT03120585|No Intervention|Control Group|Infants with respiratory distress will receive standard of care fluid management.
16524886|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.
~- Examination and diagnosis (15 min).
~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).
~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).
~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
16524887|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
16524888|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).
~New Floss Holder - Gum Chucks/SMS"
16524889|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
16524890|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
16524891|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
16524892|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
16524893|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
16524894|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
16524895|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
16524896|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
16524897|NCT03120494|Experimental|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
16524898|NCT03120481||Normal control|
16524899|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
16524900|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
16548587|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6b)|
16524901|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
16524902|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
16524903|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
16524904|NCT03120442|Experimental|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
16524905|NCT03120442|Experimental|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
16524906|NCT03120442|Experimental|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
16524907|NCT03120429|Experimental|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
16524908|NCT03120429|Experimental|Control group|subjects will have no seafood.
16524909|NCT03120416|Experimental|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
16524910|NCT03120416|No Intervention|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
16524911|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
16524912|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
16524913|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
16524914|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
16524915|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
16524916|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
16524917|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
16524918|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
16524919|NCT03120364|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
16524920|NCT03120364|Active Comparator|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
16524921|NCT03120351|Experimental|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
16524922|NCT03120351|Placebo Comparator|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
16524923|NCT03120338|Experimental|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
~The DAWBA will be administered in addition to care as usual."
16524924|NCT03120338|No Intervention|Care as Usual|Care as usual
16524925|NCT03120325|Experimental|Vagal Nerve Stimulation|All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
16524926|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
~Other Names:
~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
16524927|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
16524928|NCT03120286||Overweight and obesity|Women with BMI >25
16524929|NCT03120286||Normal weight group|Women with BMI =18-24
16524930|NCT03120273|Experimental|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
16524931|NCT03120273|Active Comparator|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
16524933|NCT03120260|Experimental|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
16524934|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
16524935|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
16524936|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
16524937|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
16524938|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
16524939|NCT03120221||First trimester pregnant women|
16524940|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
16524941|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
16524942|NCT03120208|Experimental|Partners|
16524943|NCT03120195|Experimental|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
16524944|NCT03120182|Active Comparator|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
16524945|NCT03120182|Placebo Comparator|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
16524946|NCT03120169|Active Comparator|treadmill endurance training|
16524947|NCT03120169|Active Comparator|cycling endurance training|
16524948|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
16524949|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
16524950|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
16524951|NCT03120143|Experimental|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
16524952|NCT03120143|Experimental|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
16524953|NCT03120143|No Intervention|Control group|This group continued their usual life style without intervention
16524954|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
16524955|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
16524956|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
16524957|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
16524958|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
16524959|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
16524960|NCT03120117|Experimental|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
16524961|NCT03120104|Active Comparator|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
16524962|NCT03120104|Active Comparator|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) two weeks after the stoma closure
16524963|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
16524964|NCT03120065|Other|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
16524965|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
16525027|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
16524966|NCT03120026|Experimental|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
16524967|NCT03120026|Placebo Comparator|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
16524968|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
16524969|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
16524970|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
16524971|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
16524972|NCT03119974|Other|Tpo-RA discontinuation|
16524973|NCT03119961|Experimental|SONOCLOUD®|BBB opening by ultrasound
16524974|NCT03119948|Placebo Comparator|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
16524975|NCT03119948|Active Comparator|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
16524976|NCT03119948|Active Comparator|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
16524977|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
16524978|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
16524979|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
16524980|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
16524981|NCT03119909|Other|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.
~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
16524982|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
16524983|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
16524984|NCT03119883|Other|MGUS group|MGUS patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
16524985|NCT03119883|Other|Multiple Myeloma group|Multiple Myeloma patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
16524986|NCT03119870|Experimental|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
16524987|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
16524988|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
16524989|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
16524990|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
16524991|NCT03119831|Experimental|C31G (Group A)|C31G
16524992|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
16524993|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
16524994|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
16524995|NCT03119792|Experimental|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
16524996|NCT03119792|Active Comparator|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
16524997|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
16524998|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
16524999|NCT03119766|Experimental|Kolofort|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
16525000|NCT03119766|Placebo Comparator|Placebo|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
16525001|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
16525002|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
16525003|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
16525004|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
16525005|NCT03119727|Other|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
16525006|NCT03119714|Active Comparator|Pemirolast|Pemirolast 200mg bid 14-16 days
16525007|NCT03119714|Placebo Comparator|Placebo Oral Tablet|Matching placebo bid 14-16 days
16525008|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
16525009|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
16525010|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
16525011|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
16525012|NCT03119688|Other|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
16525013|NCT03119688|Other|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
16525014|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
16525015|NCT03119662|Experimental|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
16525016|NCT03119662|Placebo Comparator|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
16525017|NCT03119649|Experimental|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
16525018|NCT03119649|Experimental|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
16525019|NCT03119649|Experimental|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
16525020|NCT03119649|Experimental|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
16525021|NCT03119649|Placebo Comparator|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
16525022|NCT03119649|Placebo Comparator|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
16525023|NCT03119636|Experimental|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
16525024|NCT03119636|Experimental|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
16525025|NCT03119636|Experimental|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
16525026|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
16525030|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
16525031|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
16525032|NCT03119584|Active Comparator|1)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
16525033|NCT03119584|Active Comparator|2)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
16525034|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
16525035|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
16525036|NCT03119558|Experimental|18F-Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F-Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45-60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
16525037|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
16525038|NCT03119545|No Intervention|Comparison group|This Group will have standard care
16525039|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
16525040|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
16525041|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
16525042|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
16525043|NCT03119506||Long Recess Duration/Before Lunch|
16525044|NCT03119506||Short Recess Duration/Before Lunch|
16525045|NCT03119506||Long Recess Duration/After Lunch|
16525046|NCT03119506||Short Recess Duration/After Lunch|
16525047|NCT03119493|Experimental|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming [5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)], followed by periodized aerobic interval training on treadmill, and cooling down [5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest]
16525048|NCT03119493|No Intervention|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
16525049|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
16525050|NCT03119467|Experimental|Single arm|RP4010 to be administered
16525051|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
16525052|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
16525053|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
16525054|NCT03119441|Active Comparator|Dental floss|Dental floss
16525055|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
16525056|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
16525057|NCT03119415|Experimental|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
16525058|NCT03119415|No Intervention|Business as Usual|Schools continue with business as usual.
16525059|NCT03119402|Experimental|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
16525060|NCT03119402|Sham Comparator|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
16525061|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
16525062|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
16525121|NCT03118986|Placebo Comparator|Placebo Oral Tablet|Standard antiemetics plus placebo
16525063|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
16525064|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
16525065|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
16525066|NCT03119363|Experimental|Experimental Light|The experimental systematic light exposure consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses (AYO) each morning for 4 weeks. The AYO light glasses is a lightweight pair of glasses that emits light from LEDs at a distance of 15 millimeters (15mm, 0.015m) from the eye.
16525067|NCT03119363|Active Comparator|Comparison Light|The active comparator condition consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses each morning for 4 weeks.
16525068|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.
~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.
~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
16525069|NCT03119337|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
16525070|NCT03119337|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
16525071|NCT03119324|Experimental|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.
~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.
~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.
~Patients were instructed to perform the applications always at the same time."
16525072|NCT03119324|Placebo Comparator|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.
~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.
~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.
~Patients were instructed to perform the applications always at the same time."
16525073|NCT03119324|Active Comparator|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non-consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).
~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.
~Patients were instructed to assume the therapy always at the same time"
16525074|NCT03119311|Experimental|VOG group|Video-oculography
16525075|NCT03119311|Active Comparator|APCT group|alternative prism cover test
16525076|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
16525077|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
16525078|NCT03119298||Control group|Healthy subjects matched for age and sex
16525079|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
16525080|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
16525081|NCT03119259|Active Comparator|ABC Clinical Program Only and Usual Care|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.
16525082|NCT03119259|Experimental|BCN Mobile App Plus ABC and BCN Mobile app only|Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
16525083|NCT03119246|Experimental|HD patients|
16525084|NCT03119246|Experimental|Controls|
16525085|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
16525743|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
16525086|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
16525087|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
16525088|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
16525089|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
16525090|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
16525091|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.
~Single dose administration on a single occasion."
16525092|NCT03119181|Experimental|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
16525093|NCT03119181|Sham Comparator|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
16525094|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
16525095|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
16525096|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
16525097|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
16525098|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
16525099|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
16525100|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
16525101|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
16525102|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
16525103|NCT03119103|Other|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
16525104|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
16525105|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
16525106|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.
~Nanoliposomal irinotecan :
~Dose Level 1 50mg/m2 IV every 2 weeks"
16525107|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.
~Nanoliposomal irinotecan :
~Dose Level 2 70 mg/m2 IV every 2 weeks"
16525108|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.
~Nanoliposomal irinotecan :
~Dose Level 3 80mg/m2 IV every 2 weeks"
16525109|NCT03119051|Experimental|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
16525110|NCT03119051|No Intervention|no training|Patients will not undergo preoperative cognitive training.
16525111|NCT03119051|Experimental|Cognitive training and physical exercise|Patients will receive 3-4 times of 20-30 minutes' training game every week and 2 times of 60 minutes' Tai Chi Training
16525112|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
16525113|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
16525114|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
16525115|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
16525116|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
16525117|NCT03118999|Experimental|OM3-FFA|Omega3 linked to free fatty acids
16525118|NCT03118999|Experimental|OM3 -MAG|Omega3 linked to Monoacylglycerol
16525119|NCT03118999|Experimental|OM3-EE|Omega3 linked to ethylester
16525120|NCT03118986|Active Comparator|Olanzapine|Standard antiemetics plus olanzapine
16525744|NCT03114826||Renal cell carcinoma in renal transplant patients|
16525122|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
16525123|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
16525124|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
16525125|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
16525126|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
16525127|NCT03118934|Experimental|AOA MF|Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 10 ± 3 days
16525128|NCT03118934|Experimental|DACP MF|Nelfilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
16525129|NCT03118934|Experimental|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
16525130|NCT03118921|Experimental|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software
16525131|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
16525132|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
16525133|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
16525134|NCT03118882|Active Comparator|Diet Group|
16525135|NCT03118882|Active Comparator|Physical activity group|
16525136|NCT03118882|Active Comparator|Physical activity and diet group|
16525137|NCT03118882|No Intervention|Control group|
16525138|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
16525139|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
16525140|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
16525141|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
16525142|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
16525143|NCT03118817|Experimental|HM95573|Single arm
16525144|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
16525145|NCT03118791|Placebo Comparator|Placebo|Capsules containing maltodextrin
16525146|NCT03118791|Active Comparator|80 mg ACN|Capsules containing 80 mg anthocyanins
16525147|NCT03118791|Active Comparator|160 mg ACN|Capsules containing 160 mg anthocyanins
16525148|NCT03118791|Active Comparator|240 mg ACN|Capsules containing 240 mg anthocyanins
16525149|NCT03118791|Active Comparator|320 mg ACN|Capsules containing 320 mg anthocyanins
16525150|NCT03118791|Active Comparator|480 mg ACN|Capsules containing 480 mg anthocyanins
16525151|NCT03118765|Experimental|Test Treatment T1: GSP304 Inhalation Solution|
16525152|NCT03118765|Experimental|Test Treatment T2: GSP304 Inhalation Solution|
16525153|NCT03118765|Experimental|Test Treatment T3: GSP304 Inhalation Solution|
16525154|NCT03118765|Placebo Comparator|Test Treatment T4: GSP304 Placebo Inhalation Solution|
16525155|NCT03118765|Active Comparator|Test Treatment T5: Spiriva® Respimat® inhalation spray|
16525156|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
16525157|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
16525158|NCT03118739|Experimental|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
16525159|NCT03118739|Placebo Comparator|Placebo|Capsule administered orally, once daily for 24 weeks
16525160|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
16525161|NCT03118713|Experimental|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
16525162|NCT03118713|Experimental|glimepiride and metformin|Subjects will receive daily dosage of glimepiride and metformin as single tablets
16525163|NCT03118700|No Intervention|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
16525164|NCT03118700|Experimental|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
16525165|NCT03118700|Experimental|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
16525166|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
16525167|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1
~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
16525168|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home
~First stroke deficit with non-regressive clinical expression in 24 hours
~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities
~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)
~No psychiatric history that led to hospitalization for more than six months
~Written informed consent after reading the briefing note
~Patient affiliated or beneficiary of a social security scheme."
16525169|NCT03118635|Experimental|Intervention|Daily, four-hour physical activity intervention
16525170|NCT03118635|No Intervention|Control|No treatment control
16525171|NCT03118622||Pentax group|Intubation using Pentax
16525172|NCT03118622||Macintosh group|Intubation using Macintosh
16525173|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.
~Up to 150 participants will complete the Understanding Needs survey"
16525174|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
16525175|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
16525176|NCT03118583|Experimental|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
16525177|NCT03118570|Experimental|BPS804 Dose 1|BPS804 IV Infusion
16525178|NCT03118570|Experimental|BPS804 Dose 2|BPS804 IV Infusion
16525179|NCT03118570|Experimental|BPS804 Dose 3|BPS804 IV Infusion
16525180|NCT03118570|Experimental|BPS804 Dose 4|BPS804 IV Infusion
16525181|NCT03118557|Experimental|Pilates pelvic floor strengthening exercise|
16525182|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
16525184|NCT03118518|Active Comparator|Anti-arrhythmic drug|
16525185|NCT03118518|Experimental|Cryoablation|
16525186|NCT03118505|Experimental|Group 1|Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
16525187|NCT03118505|Experimental|Group 2|Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
16525188|NCT03118505|Experimental|Group 3|Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
16525189|NCT03118505|Active Comparator|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
16525190|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
16525191|NCT03118479|Experimental|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
16525192|NCT03118479|Experimental|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
16525246|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
16525193|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
16525194|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
16525195|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
16525196|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
16525197|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
16525198|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
16525199|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
16525200|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
16525201|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
16525202|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.
~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
16525203|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
16525204|NCT03118401|Experimental|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
16525205|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.
~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
16525206|NCT03118388|Experimental|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
16525207|NCT03118388|Experimental|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
16525208|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
16525209|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
16525210|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
16525211|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation Initial to maximum tolerated dose
16525212|NCT03118349|Experimental|Expansion Cohort|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
16525213|NCT03118336|Placebo Comparator|placebo group|
16525214|NCT03118336|Experimental|empaglifozine group|
16525215|NCT03118323||Patients in need of endodontic treatment|n = 200
16525216|NCT03118310|Placebo Comparator|Placebo|Placebo diet
16525217|NCT03118310|Experimental|5:2|5:2 diet
16525218|NCT03118310|Experimental|LCHF|LCHF diet
16525219|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
16525220|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
16525221|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
16525222|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
16525223|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
16525245|NCT03118141|Active Comparator|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
16525224|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
16525225|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
16525226|NCT03118258|Experimental|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
16525227|NCT03118258|Experimental|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.
~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
16525228|NCT03118245|Experimental|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children <5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
16525229|NCT03118245|Experimental|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
16525230|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
16525231|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
16525232|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
16525233|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
16525234|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
16525235|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
16525236|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
16525237|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
16525238|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
16525239|NCT03118167|Experimental|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
16525240|NCT03118167|Experimental|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
16525241|NCT03118167|Active Comparator|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
16525242|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
16525243|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
16525244|NCT03118141|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
16525247|NCT03118128|No Intervention|No metformin|
16549109|NCT02956499|Experimental|Cohort 5|single intravenous dose
16525248|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
16525249|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
16525250|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
16525251|NCT03118089|Experimental|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
16525252|NCT03118089|No Intervention|Standard Care|Participants will remain on their current oral nutritional supplement
16525253|NCT03118076|Placebo Comparator|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
16525254|NCT03118076|Experimental|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
16525255|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
16525256|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
16525257|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
16525258|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
16525259|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
16525260|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
16525261|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
16525262|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
16525263|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
16525264|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
16525265|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
16525266|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
16525267|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
16525268|NCT03118011|Active Comparator|No smoking|The ward where the patients can not go out to smoke
16525269|NCT03118011|Placebo Comparator|Smoking|The ward where the patients can go out to smoke.
16525270|NCT03117998|Experimental|REMD-477 Treatment A|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
16525271|NCT03117998|Experimental|REMD-477 Treatment B|Administered as a repeated SC doses in subjects with Type 1 Diabetes
16525272|NCT03117998|Placebo Comparator|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
16525273|NCT03117985|Experimental|Antiretroviral therapy|Stopping antiretroviral therapy
16525274|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
16525275|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
16525276|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
16525277|NCT03117959|Experimental|Stryker shape match|no longer RCT
16525278|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.
~Tumor tissues will be collected if available."
16525279|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
16525280|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
16525281|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
16525282|NCT03117920|Experimental|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
16525283|NCT03117907||Infants with low infectious status|
16525284|NCT03117907||Infants with high infectious status|
16525285|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
16525286|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
16525287|NCT03117881|Experimental|DirectCAM|The DirectCAM arm receives the intervention content via therapists at participating clinics.
16525288|NCT03117881|Experimental|TeleCAM|The TeleCAM arm receives the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
16525289|NCT03117881|Experimental|rDirectCAM|The rDirectCAM arm is being implemented in response to Covid-19. The rDirectCAM arm receives the intervention content delivered remotely in real-time by therapists via videoconferencing technology.
16525290|NCT03117855|Experimental|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
16525291|NCT03117842|Experimental|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
16525292|NCT03117842|No Intervention|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
16525293|NCT03117829|Experimental|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
16525296|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
16525297|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
16525298|NCT03117764|Active Comparator|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.
~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
16525299|NCT03117764|Experimental|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.
~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
16525300|NCT03117751|Experimental|B-ALL and B-LLy, Low-risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL1-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.
~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
16525301|NCT03117751|Experimental|B-ALL and B-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD >5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and <1%), certain genetic subtypes and Down syndrome.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin."
16525302|NCT03117751|Experimental|B-ALL and B-LLy, High-risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor [CAR] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard-risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
16525303|NCT03117751|Experimental|T-ALL and T-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
16525304|NCT03117751|Experimental|T-ALL and T-LLy, High-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard-risk T-ALL but are discontinued in Reintensification therapy.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
16525336|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
16526048|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
16525305|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine beginning with Continuation Week 1.
~Intervention: vincristine."
16525306|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment.
~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
16525307|NCT03117738|Experimental|AstroStem|
16525308|NCT03117738|Placebo Comparator|Placebo-Control|
16525309|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.
~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
16525310|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.
~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
16525311|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
16525312|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
16525313|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.
~Phase 1 :
~3 seated-standing passages with a handle equipped with 6 force captors
~3 seated-standing passages with the device"
16525314|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .
~Phase 1 :
~3 seated-standing passages without help
~3 seated-standing passages with a handle equipped with 6 force captors
~3 seated-standing passages with the device"
16525315|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
16525316|NCT03117686||patients after lung transplantation|10 patients > 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
16525317|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
16525318|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
16525319|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
16525320|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
16525321|NCT03117660|No Intervention|Control|Subjects will receive no treatment
16525322|NCT03117634|Active Comparator|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
16525323|NCT03117634|Experimental|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and indocyanine green angiography (ICGA). Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
16525324|NCT03117621||Patients initiating Blinatumomab|Patients initiating Blinatumomab after Country-Specific Reimbursement approval in routine clinical practice.
16525325|NCT03117608|Experimental|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
16525326|NCT03117608|Active Comparator|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
16525327|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
16525328|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
16525329|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
16525330|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
16525331|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
16525332|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
16525333|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
16525334|NCT03117530|Experimental|Minocycline|
16525335|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
16525438|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
16525337|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
16525338|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
16525339|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
16525340|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
16525341|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
16525342|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
16525343|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
16525344|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
16525345|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
16525346|NCT03117465|Experimental|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
16525347|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
16525348|NCT03117452|Experimental|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
16525349|NCT03117452|No Intervention|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
16525350|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
16525351|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
16525352|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).
~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
16525353|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.
~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
16525354|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
16525355|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
16525356|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
16525357|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
16525358|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
16525359|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
16525360|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
16525361|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
16525362|NCT03117374|Experimental|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
16525363|NCT03117374|No Intervention|Control|Participants were invited to follow the regular school curricular for an 8-week period
16525364|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone
~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)
~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk
~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
16525365|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
16525366|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
16525367|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
16525368|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
16525369|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:
~agave inulin (4 g) in powder
~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
16525370|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
16525371|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
16525372|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
16525375|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
16525376|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
16525377|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
16525378|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
16525379|NCT03117270|Experimental|oral filgotinib tablets|
16525380|NCT03117270|Placebo Comparator|placebo tablets|
16525381|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
16525382|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
16525383|NCT03117244|Experimental|Exercise Group|
16525384|NCT03117244|Active Comparator|Exercise and NMES Group|
16525385|NCT03117244|No Intervention|Control Group|
16525386|NCT03117231|Experimental|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
16525387|NCT03117231|Sham Comparator|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
16525388|NCT03117205|Experimental|Kinesio Taping® group|
16525389|NCT03117205|Placebo Comparator|placebo group|
16525390|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
16525391|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
16525392|NCT03117179|Other|Patient with an interview|
16525393|NCT03117179|Other|Patient without an interview|
16525394|NCT03117166|Experimental|Lidocaine|treatment arm
16525395|NCT03117166|Placebo Comparator|Saline|placebo arm
16525396|NCT03117153|Experimental|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.
~everyday 3 times for 6 weeks"
16525397|NCT03117153|Placebo Comparator|placebo|"no active ingredients
~everyday 3 times for 6 weeks"
16525398|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
16525399|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
16525400|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
16525401|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
16525402|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
16525403|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
16525404|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
16525405|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
16525406|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.
~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
16525407|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
16525408|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
16525409|NCT03117075|Experimental|Experimental|"using device for scoring pain scale, named ANAPA®"
16525410|NCT03117062|Experimental|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
16525411|NCT03117062|No Intervention|non-occlusal reduction|occlusal surface left intact
16525567|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
16525568|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
16525412|NCT03117049|Experimental|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
16525413|NCT03117049|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
16525414|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
16525415|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
16525416|NCT03117023|No Intervention|control group|sufentanil + saline
16525417|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria
~Subjects should have at least one of the following problems
~Presence of hemophagocytosis in tissue or bone marrow
~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
~Age > 18 years
~Written informed consents
~Subjects receive steroids and etoposide"
16525418|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
16525419|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
16525420|NCT03116984|Active Comparator|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition for patients who are randomly assigned to group of TACE treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.It has a possibility of observeation alone if tumor achieves a complete response after two times TACE.
16525421|NCT03116984|Experimental|External-beam radiotherapy|EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
16525422|NCT03116971|Experimental|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
16525423|NCT03116971|Experimental|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
16525424|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.
~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
16525425|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.
~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
16525426|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
16525427|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.
~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
16525428|NCT03116919|Other|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
16525429|NCT03116919|Other|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
16525430|NCT03116906|Experimental|BI 685509|multiple rising doses of BI 685509
16525431|NCT03116906|Placebo Comparator|Placebo|matching placebo
16525432|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
16525433|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
16525434|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
16525435|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
16525436|NCT03116880||Image registration|
16525437|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
16525439|NCT03116828|Experimental|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
16525440|NCT03116828|Experimental|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
16525441|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
16525442|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
16525443|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.
~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
16525444|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
16525445|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
16525446|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
16525447|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
16525448|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
16525449|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
16525450|NCT03116737|Experimental|Benzocaine Otic Solution|
16525451|NCT03116737|Placebo Comparator|Placebo|
16525452|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.
~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
16525453|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
16525454|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
16525455|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
16525456|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
16525457|NCT03116698|Experimental|Low dose DFD07 once daily|
16525458|NCT03116698|Experimental|High dose DFD07 once daily|
16525459|NCT03116698|Experimental|High dose DFD07 twice daily|
16525460|NCT03116698|Placebo Comparator|Placebo twice daily|
16525461|NCT03116685|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes HC-1
16525462|NCT03116685|Placebo Comparator|Placebo capsules|Placebo
16525463|NCT03116672|Experimental|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
16525464|NCT03116672|Experimental|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
16525465|NCT03116672|Experimental|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
16525466|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
16525467|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
16525468|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
16525469|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
16525470|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
16525471|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
16525472|NCT03116607|No Intervention|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
16525473|NCT03116607|Experimental|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.
~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
~patient education/ recommendations to the health team"
16525474|NCT03116594|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
16525475|NCT03116594|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
16525476|NCT03116594|Active Comparator|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
16525477|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.
~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
16525478|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
16525479|NCT03116568||IBD Case|"Pregnant women with IBD
~Newborns of pregnant women with IBD
~Family member of pregnant women with IBD
~Siblings of newborns"
16525480|NCT03116568||Control|"Pregnant women without IBD
~Newborns of pregnant women without IBD
~Family member of pregnant women without IBD
~Siblings of newborns"
16525481|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).
~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
16525482|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
16525483|NCT03116529|Experimental|Treatment|Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
16525484|NCT03116516|Other|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
16525485|NCT03116516|Other|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
16525486|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
16525487|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
16525488|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
16525489|NCT03116464|Experimental|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
16525490|NCT03116451|Experimental|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
16525491|NCT03116451|No Intervention|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
16525492|NCT03116425|Experimental|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
16525493|NCT03116425|Experimental|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
16525494|NCT03116425|Active Comparator|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
16525495|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
16525496|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
16525497|NCT03116399|Experimental|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
16525498|NCT03116399|Placebo Comparator|Tablet Condition|Exposing participants to the regular computer/tablet
16525499|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of
~reporting all the falls occurring during the night
~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night
~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
16525569|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
16525500|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
16525501|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
16525502|NCT03116373|Active Comparator|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
16525503|NCT03116373|Active Comparator|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
16525504|NCT03116360|Experimental|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
16525505|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
16525506|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer ≥160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
16525507|NCT03116347|Active Comparator|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
16525508|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.
~Route of administration:Oral."
16525509|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.
~Route of administration:Oral."
16525510|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.
~Route of administration:Oral."
16525511|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
16525512|NCT03116295|Experimental|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC [AF] or a single 25 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
16525513|NCT03116295|Experimental|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC [AF], or a single 50 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
16525514|NCT03116282|Experimental|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
16525515|NCT03116282|No Intervention|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
16525516|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
16525517|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
16525518|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
16525519|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
16525520|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
16525521|NCT03116243||MSHS children and families|"Cohort includes:
~children (1272)
~parents (1272)
~teachers (159)
~teaching assistants (159)
~program and center directors (253)"
16525522|NCT03116230|Experimental|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
16525523|NCT03116230|Experimental|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
16525524|NCT03116204||Patients hospitalized in a FRC department|
16525525|NCT03116191|Experimental|SK-1404 high dose|
16525526|NCT03116191|Experimental|SK-1404 middle dose|
16525527|NCT03116191|Experimental|SK-1404 low dose|
16525528|NCT03116191|Placebo Comparator|Placebo|
16525570|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
16525529|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.
~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
16525530|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
16525531|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
16525532|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
16525533|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
16525534|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
16525535|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
16525536|NCT03116139|Active Comparator|Randomized to V/Q|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
16525537|NCT03116139|Active Comparator|Randomized to CT|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
16525538|NCT03116126|Active Comparator|Guanfacine|
16525539|NCT03116126|Placebo Comparator|Placebo|
16525540|NCT03116113|Experimental|Part 1: BIIB112 Dose 1|Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
16525541|NCT03116113|Experimental|Part 1: BIIB112 Dose 2|Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
16525542|NCT03116113|Experimental|Part 1: BIIB112 Dose 3|Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
16525543|NCT03116113|Experimental|Part 1: BIIB112 Dose 4|Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
16525544|NCT03116113|Experimental|Part 1: BIIB112 Dose 5|Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
16525545|NCT03116113|Experimental|Part 1: BIIB112 Dose 6|Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
16525546|NCT03116113|Experimental|Part 2: BIIB112 High Dose|Participants will receive a single high dose of BIIB112 by sub-retinal injection.
16525547|NCT03116113|Experimental|Part 2: BIIB112 Low Dose|Participants will receive a single low dose of BIIB112 by sub-retinal injection.
16525548|NCT03116113|No Intervention|Part 2: Untreated Group|Participants will receive no intervention to allow for a controlled comparison.
16525549|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
16525550|NCT03116087|Placebo Comparator|Placebo|Placebo patches
16525551|NCT03116074|No Intervention|Study 1: Pre-intervention 1|"Usual care.
~Patients/caregivers do not have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
16525552|NCT03116074|Experimental|Study 1: Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging
~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
16525553|NCT03116074|No Intervention|Study 1: Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.
~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
16525554|NCT03116074|No Intervention|Study 2: Pre-intervention|"Usual care on three general medicine units.
~Patients/caregivers do not have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
16525555|NCT03116074|Experimental|Study 2: Post-intervention|Patients/caregivers have access to the discharge preparation checklist. Providers have access to safety dashboard.
16525556|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
16525557|NCT03116048|Other|Pecs group (study group)|Chronic pain assessment with study questionnaire
16525558|NCT03116048|Other|Control group (placebo group)|Chronic pain assessment with study questionnaire
16525559|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
16525560|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
16525561|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
16525562|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
16525563|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
16525564|NCT03116009|Active Comparator|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
16525565|NCT03116009|Experimental|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
16525566|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
16525571|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
16525572|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
16525573|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
16525574|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
16525575|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
16525576|NCT03115918|Active Comparator|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
16525577|NCT03115918|Active Comparator|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
16525578|NCT03115892|Experimental|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
16525579|NCT03115892|Active Comparator|control arm|Chlorhexidine Mouthwash twice daily for one week
16525580|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
16525581|NCT03115879|Experimental|Manipulation Group|Hip manipulation
16525582|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
16525583|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
16525584|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
16525585|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.
~Then HCTZ 25 mg po plus Placebo"
16525586|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.
~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
16525587|NCT03115840||Adults (≥18 years old) with critical illness|
16525588|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
16525589|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.
~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
16525590|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
16525593|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
16525594|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
16525595|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
16525596|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
16525597|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
16525598|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
16525599|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
16525600|NCT03115749|Sham Comparator|Crohn's disease patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
16525601|NCT03115749|Sham Comparator|Ulcerative colitis patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
16525602|NCT03115749|Sham Comparator|Control group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
16525603|NCT03115736|Experimental|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
16525604|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
16525605|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
16525606|NCT03115697|Active Comparator|Lactulose with Rifaximin|
16525607|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
16525608|NCT03115671|Experimental|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
16525609|NCT03115671|No Intervention|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
16525610|NCT03115658|Experimental|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.
~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
16525611|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
16525612|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
16525613|NCT03115632||Obese asthmatic & lean asthmatic|men and women with asthma and either obese or lean BMI
16525614|NCT03115632||Obese non-asthmatic & lean non-asthmatic|men and women without asthma and either obese or lean BMI
16525615|NCT03115632||Asthmatic undergoing bariatric surgery|Obese asthmatic men and women undergoing bariatric surgery
16525616|NCT03115632||Non-asthmatic undergoing bariatric surgery|Obese men and women undergoing bariatric surgery
16525617|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
16525618|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
16525619|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
16525620|NCT03115593|Experimental|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).
~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
16525621|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
16525622|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
16525623|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
16525624|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
16525625|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
16525626|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
16525627|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
16525628|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
16525629|NCT03115515|Experimental|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:
~TSH>10mIU/L, increase by 3 doses/week
~TSH 5.0-9.9mIU/L, increase by 2 doses/week
~TSH 2.0-4.9mIU/L, increase by 1 dose/week
~TSH 0.4-1.9mIU/L, no change
~TSH<0.4mIU/L, decrease by 1 dose/week
~TSH<0.1mIU/L, decrease by 2 doses/week
~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
16525630|NCT03115515|Experimental|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:
~TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg
~TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg
~TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg
~TSH 0.4-1.9mIU/L, no change
~TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day
~TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day
~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
16525631|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
16525632|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
16525633|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
16525634|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
16525635|NCT03115476|Placebo Comparator|Vehicle gel|
16525636|NCT03115463|Experimental|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
16525637|NCT03115463|No Intervention|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
16525638|NCT03115463|Active Comparator|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
16525639|NCT03115437|Experimental|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
16525640|NCT03115437|Experimental|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
16525641|NCT03115424|Placebo Comparator|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
16525642|NCT03115424|Active Comparator|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
16525643|NCT03115424|Sham Comparator|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
16525644|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
16525645|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
16525646|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
16525647|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
16525648|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
16525649|NCT03115372|Experimental|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
16525650|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
16525651|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
16525652|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
16525653|NCT03115346|Experimental|decision aid|the experimental group will receive the decision aid
16525654|NCT03115346|No Intervention|control|the control group will only receive the survey
16525656|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
16525657|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
16525658|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
16525659|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
16525660|NCT03115294|Experimental|Study group|Patients undergo procedure with stepwise measurements and ventilator + volume adjustment + iv theophylline Myocardial movement recording using videoscanning
16525661|NCT03115268|Experimental|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
16525662|NCT03115268|Active Comparator|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
16525663|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
16525664|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.
~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
16525665|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
16525666|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
16526148|NCT03111992|Experimental|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
16525667|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
16525668|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
16525669|NCT03115203|Other|Facial paralysis|
16525670|NCT03115203|Other|Healthy subject|
16525671|NCT03115190|Other|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
16525672|NCT03115190|No Intervention|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
16525673|NCT03115190|No Intervention|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.
~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
16525674|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
16525675|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
16525676|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
16525677|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
16525678|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
16525679|NCT03115138|Other|Patients with glial tumor|
16525680|NCT03115125|Other|Adult patients with severe sepsis|
16525681|NCT03115112|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
16525682|NCT03115112|Active Comparator|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
16525683|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
16525684|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
16525685|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
16525686|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
16525687|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
16525688|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
16525689|NCT03115086||Existing User|Patients who have been using Cholbam for at least 30 days
16525690|NCT03115086||New User|First-time initiators of Cholbam
16525691|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
16525692|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
16525693|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
16525694|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
16525695|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
16525696|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
16525697|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
16525698|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:
~intravenous injection
~0.35 mcg/kg
~in two minutes
~if shivering 5 minutes after delivery"
16525699|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:
~intravenous injection
~0.35 mg/kg
~in two minutes
~if shivering 5 minutes after delivery"
16525700|NCT03115034|Active Comparator|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
16525701|NCT03115034|Placebo Comparator|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
16525702|NCT03115034|Sham Comparator|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
16525706|NCT03115008|Experimental|Video-based terminal feedback|
16525707|NCT03115008|No Intervention|Conventional concurrent feedback|
16525742|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
16525708|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
16525709|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
16525710|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
16525711|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
16525712|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
16525713|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
16525714|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
16525715|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
16525716|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
16525717|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
16525718|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
16525719|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
16525720|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
16525721|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
16525722|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
16525723|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
16525724|NCT03114956|Experimental|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
16525725|NCT03114956|Experimental|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
16525726|NCT03114956|Experimental|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
16525727|NCT03114956|Experimental|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
16525728|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
16525729|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
16525730|NCT03114930|Other|Standard output|
16525731|NCT03114930|Other|Non standard output|
16525732|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
16525733|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
16525734|NCT03114904|Other|"Usual weaning management"|
16525735|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
16525736|NCT03114891|Experimental|fMRI-guided target|This site of stimulation will be created from participants' individualized resting connectivity data to guide stimulation that we show is especially effective in influencing downstream brain areas of interest. We will focus on a target region of the lateral prefrontal cortex (LPFC) that our data suggest is particularly effective at influencing the sgACC. Theta-burst stimulation will be administered to this target.
16525737|NCT03114891|Active Comparator|Standard brain target|As an alternative brain target, we will also test the efficacy of the dorsolateral prefrontal cortex as a target given its precedence as an FDA-approved stimulation site for remediating depressive symptoms. Theta-burst stimulation will be administered to this target.
16525738|NCT03114878|Active Comparator|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
16525739|NCT03114878|Active Comparator|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
16525740|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
16525741|NCT03114852||CKD patients|"'blood collection'
~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
16525745|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.
~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.
~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.
~After 1 week, participants will return for dose optimisation
~After 4-12 weeks of treatment, participants will have:
~repeat one hour MRI scan
~repeat HVPG to evaluate treatment response"
16525746|NCT03114800|Experimental|E-Scale|Weight monitoring
16525747|NCT03114787|Other|Patient receiving respiratory physiotherapy|
16525748|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
16525749|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
16525750|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
16525751|NCT03114761|Experimental|CTA-IH|
16525752|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
16525753|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
16525754|NCT03114722|Active Comparator|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
16525755|NCT03114722|Experimental|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
16525756|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
16525757|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
16525758|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
16525759|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
16525760|NCT03114683|Experimental|IBI308|
16525761|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
16525762|NCT03114657|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
16525763|NCT03114657|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
16525764|NCT03114644|Other|Babies born prematurely between 27 and 37 SA|
16525765|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
16525766|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
16525767|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
16525768|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
16525769|NCT03114605|No Intervention|Control|Waiting List
16525770|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.
~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
16525771|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.
~Review a 15-20 minute educational tool on a tablet about kidney health
~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
16525772|NCT03114579|Other|Measure of the cardiac output obtained by a reference methode|
16525773|NCT03114579|Other|Measurement of cardiac output obtained by NEXFIN HD.|
16525774|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
16525775|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
16525776|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
16525777|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
16525778|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
16525779|NCT03114527|Experimental|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
16525780|NCT03114527|Experimental|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
16525781|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
16525782|NCT03114501|Experimental|Yoga Program Group|"Participants take part in the partner-based yoga program.
~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
16525783|NCT03114501|Experimental|Waitlist Control Group (WLC)|"Participants receive standard of care.
~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
16525784|NCT03114488|Experimental|Anodal Stimulation|
16525785|NCT03114488|Sham Comparator|Sham Stimulation|
16525786|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
16525787|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
16525788|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.
~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
16525789|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
16525790|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
16525791|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
16525792|NCT03114423|Experimental|Treatment As Usual + Treatment with EMDR|
16525793|NCT03114423|Sham Comparator|Treatment As Usual + Cognitive Training|
16525794|NCT03114410|Experimental|Re:MIX|In the experimental arm, the Re:MIX curriculum was implemented. The Re:MIX curriculum is a comprehensive teen pregnancy prevention consisting of ten hour-long sessions, delivered approximately once per week. The Re:MIX curriculum is taught by a professional health educator, partnered with a young parent educator who is a young parent (aged 18-25).
16525795|NCT03114410|No Intervention|Comparison|"In the comparison arm, teachers were given the option of implementing the Healthy Youth, Healthy You curriculum (focusing on nutrition, mental health, and fitness) or proceed with business as usual (no curriculum)."
16525796|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
16525797|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
16525798|NCT03114384|Experimental|Healthy volunteers|
16525799|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
16525800|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
16525801|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
16525802|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
16525803|NCT03114345|Other|Single arm|Measurement of interface pressure and Measurement of micro-vascularization related parameters
16525804|NCT03114332|Experimental|Study Group|Patients for whom a subcutaneous drain was used
16525805|NCT03114332|No Intervention|Control group|No drain group
16525806|NCT03114319|Experimental|TNO155|TNO155 for oral administration
16525807|NCT03114319|Experimental|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
16525808|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
16525809|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
16525810|NCT03114293|No Intervention|Waiting group|Waiting group
16525811|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
16525812|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
16525813|NCT03114267||Patient with chronic lymphocytic thyroiditis|
16525814|NCT03114267||Healthy subjects|
16525815|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:
~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
16525816|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
16525817|NCT03114241|No Intervention|Control|Usual care.
16525818|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
16525819|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
16525820|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
16525821|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
16525822|NCT03114189|Active Comparator|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.
~Information about wrong and correct behaviour."
16525823|NCT03114189|Active Comparator|Care of sleep|Information about wrong and correct behaviour.
16525824|NCT03114176|Experimental|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference [CTRL] and to measure physiological modifications due to immersion [NTRX]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive [KETO-NTRX]
16526186|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
16525825|NCT03114163||Cohort 1: Nivolumab|≥2nd line treatment for recurrent/ metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN), prior platinum-based therapy was administered for locally advanced, metastatic or recurrent disease
16525826|NCT03114163||Cohort 2: Nivolumab|1st line treatment for R/M SCCHN, prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting
16525827|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
16525828|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
16525829|NCT03114137||sickle cell patients|"age: five-year-old or more
~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0
~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
16525830|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients
~hospital staff or their children matched on country and age +/- 3 ans with the patients"
16525831|NCT03114124|Active Comparator|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
16525832|NCT03114124|Experimental|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
16525833|NCT03114111|Active Comparator|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
16525834|NCT03114111|Placebo Comparator|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
16525835|NCT03114098|Experimental|CYP2D6 gene abnormalities|"A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.
~Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.
~Electrocardiogram
~Clinical exam
~Clinical Global Impression Scale (CGI-S)
~Children's Global Assessment Scale (CGAS)
~Sheehan Disability Scale (SDS)
~Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )
~Wechsler Intelligence Scale for Children - 4 (WISC-4)
~Wechsler Adult Intelligence Scale 4 (WAIS 4)
~Diagnostic and Statistical Manual of Mental Disorders (DSM)
~Autism Diagnostic Interview (ADI)"
16525836|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
16525837|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
16525838|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
16525839|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
16525840|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
16525841|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
16525842|NCT03114033|Experimental|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
16525843|NCT03114033|Active Comparator|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
16525844|NCT03114020|Experimental|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
16525845|NCT03114020|Placebo Comparator|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
16526313|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
16525846|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
16525847|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
16525848|NCT03114007|No Intervention|Control|Treatment as usual
16525851|NCT03113981|Experimental|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
16525852|NCT03113981|Active Comparator|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
16525853|NCT03113968|Active Comparator|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
16525854|NCT03113968|Active Comparator|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
16525855|NCT03113955|Experimental|single -arm|A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
16525856|NCT03113942|Experimental|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
16525857|NCT03113929||Alcoholic Liver Disease Patients|
16525858|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
16525859|NCT03113916|No Intervention|Enhanced usual care|Printed materials
16525860|NCT03113903|Experimental|scheduled surgery|
16525861|NCT03113903|Other|healthy volunteers|
16525862|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
16525863|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
16525864|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
16525865|NCT03113864|Placebo Comparator|Placebo|Will be identical looking to treatment
16525866|NCT03113864|Experimental|Lutein|10 mg of FloraGLO Lutein
16525867|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
16525868|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
16525869|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
16525870|NCT03113812|Experimental|ABvac40|
16525871|NCT03113812|Placebo Comparator|Placebo|
16525872|NCT03113799|Other|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
16525873|NCT03113786|No Intervention|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
16525874|NCT03113786|Active Comparator|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
16525875|NCT03113786|Active Comparator|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
16525876|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
16525877|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
16525878|NCT03113760|Experimental|Tadekinig alfa|Patients that have completed the SAOL phase without a flare will receive Tadekinig alfa for addition 8 weeks.
16525879|NCT03113760|Placebo Comparator|0.9% sodium chloride|Patients that have completed the SAOL phase without a flare will receive placebo comparator for addition 8 weeks.
16525880|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
16525909|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
16526530|NCT03109587|Placebo Comparator|Placebo|identical in appearance, but without probiotics.
16525881|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:
~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;
~Systemic antibiotic therapy for preventing infectious complications;
~Adequate analgesia and sedation;
~Decompression necrotomy in the first 24 hours following the burn trauma;
~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;
~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
16525882|NCT03113708|Sham Comparator|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
16525883|NCT03113708|Experimental|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
16525884|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
16525885|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
16525886|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
16525887|NCT03113656|Experimental|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
16525888|NCT03113656|Experimental|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
16525889|NCT03113643|Experimental|SL-401+ Azacitidine|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously
16525890|NCT03113643|Experimental|SL-401+ Azacitidine + Venetoclax|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally
16525891|NCT03113630|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
16525892|NCT03113630|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
16525893|NCT03113630|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
16525894|NCT03113630|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
16525895|NCT03113630|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
16525896|NCT03113630|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
16525897|NCT03113617|Experimental|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
16525898|NCT03113604||Patients with untreated CHC not sorafenib|
16525899|NCT03113604||Patients with non-sorafenib CHC|
16525900|NCT03113604||Patients with CHCs responding to sorafenib|
16525901|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
16525902|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
16525903|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.
~Each subjects will have the two CT-scans on the same day."
16525904|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
16525905|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
16525906|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
16525907|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
16525908|NCT03113500|Experimental|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
16525975|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
16525910|NCT03113474|Experimental|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
16525911|NCT03113474|Experimental|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
16525912|NCT03113461|Experimental|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
16525913|NCT03113461|Active Comparator|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
16525914|NCT03113461|No Intervention|No OSA|Study participants who do not have OSA
16525915|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
16525916|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
16525917|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
16525918|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
16525919|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
16525920|NCT03113422|Experimental|Induction Venetoclax|Cycle 1-6: Obinutuzumab intravenously (IV) and bendamustine IV. Cycle 2-6: Venetoclax (oral)
16525921|NCT03113422|Experimental|Maintenance Venetoclax|Patients with stable or improved disease will receive venetoclax by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab IV every 2 months for 12 cycles.
16525922|NCT03113409|Experimental|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
16525923|NCT03113409|Experimental|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
16525924|NCT03113409|Experimental|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
16525925|NCT03113396|Experimental|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
16525926|NCT03113396|Placebo Comparator|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
16525927|NCT03113383|Experimental|Primary Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
16525928|NCT03113383|Experimental|Expanded Selection Arm|Patient that meets the criteria for inclusion in the primary study arm but has one or more of the inclusion criteria which would exclude them from the primary study arm.
16525929|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
16525930|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
16525931|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
16525932|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
16525933|NCT03113344||Children with the usage of anti-infective drugs|
16525934|NCT03113318|Experimental|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
16525935|NCT03113318|Active Comparator|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
16525936|NCT03113305||Gastric bypass patients|Patients planned to undergo Gastric bypass procedure. Patients will be assessed -1 month, 3 month, 24 month and 48 months post surgery.
16525937|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
16525976|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
16525977|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
16525938|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
16525939|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
16525940|NCT03113279||Obese older individuals|Obese older individuals
16525941|NCT03113279||Lean older individuals|Lean older individuals
16525942|NCT03113279||Young lean individuals|Young lean individuals
16525943|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
16525944|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:
~1g of tranexamic acid by slow intravenous injection
~1g of tranexamic acid by syringe pump during 8 hours"
16525945|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:
~10 mL of 0.9% sodium chloride by slow intravenous injection
~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
16525946|NCT03113240|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
16525947|NCT03113240|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
16525948|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
16525949|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
16525950|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
16525951|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
16525952|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
16525953|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
16525954|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
16525955|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
16525956|NCT03113201|Experimental|Collabri Flex|Collaborative care
16525957|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
16525958|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
16525959|NCT03113175|Experimental|Collabri Flex|Collaborative care
16525960|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
16525961|NCT03113162|Experimental|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
16525962|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
16525963|NCT03113136|Active Comparator|Low wattage E cigarette device|
16525964|NCT03113136|Active Comparator|High wattage E cigarette device|
16525965|NCT03113136|Active Comparator|Usual brand cigarette|
16525966|NCT03113123|Other|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later
~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
16525967|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
16525968|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
16525969|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
16525970|NCT03113084|Experimental|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
16525971|NCT03113084|Experimental|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
16525972|NCT03113071|Experimental|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
16525973|NCT03113071|Experimental|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
16525974|NCT03113058|Experimental|study group|
16525978|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
16525979|NCT03113019|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
16525980|NCT03113006|Active Comparator|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
16525981|NCT03113006|Experimental|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
16525982|NCT03112993|Experimental|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
16525983|NCT03112993|Active Comparator|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
~Dosing will be based on actual body weight not ideal body weight."
16525984|NCT03112980|Experimental|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
16525985|NCT03112980|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
16525986|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
16525987|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
16525988|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
16525989|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
16525990|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
16525991|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
16525992|NCT03112928|Experimental|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
16525993|NCT03112928|Active Comparator|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
16525994|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)
~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
16525995|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)
~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
16525996|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 1|This is a triple cross-over with a sham control condition; the standard tACS administered first, then Nested, then sham.
16525997|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active 1|This is a double cross-over with a sham control condition; the tACS administered first, then the sham
16525998|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active 1|This is a cross-over with a sham control condition; the standard tACS administered first, then sham.
16525999|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 2|This is a triple cross-over with a sham control condition; the standard tACS administered first, then sham, then nested tACS.
16526000|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 3|This is a triple cross-over with a sham control condition; the sham tACS administered first, then nested tACS, then standard tACS.
16526001|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active 2|This is a double cross-over with a sham control condition; the sham administered first, then the tACS.
16526002|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active 2|This is a cross-over with a sham control condition; the sham administered first, then standard tACS.
16526003|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 4|This is a triple cross-over with a sham control condition; the sham tACS administered first, then standard tACS, then nested tACS.
16526004|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 5|This is a triple cross-over with a sham control condition; the nested tACS administered first, then sham, then standard tACS.
16526005|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 6|This is a triple cross-over with a sham control condition; the nested tACS administered first, then standard tACS, then sham.
16526006|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
16526007|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
16526008|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
16526009|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
16526010|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
16526011|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
16526012|NCT03112863|Experimental|Bakuchiol|
16526013|NCT03112863|Active Comparator|Retinol|
16526014|NCT03112850|Active Comparator|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
16526015|NCT03112850|Active Comparator|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
16526016|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
16526017|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
16526018|NCT03112837|No Intervention|healthy control group|
16526019|NCT03112824|Experimental|Ashwagandaha Root Extract Capsule|Participants will take one 300 mg. Ashwaganda capsule twice a day for 12 weeks.
16526020|NCT03112824|Placebo Comparator|Placebo Capsule|Participants will take one placebo capsule twice a day for 12 weeks.
16526021|NCT03112811|Experimental|Intubated infant|
16526022|NCT03112811|Experimental|Extubated infant|
16526023|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
16526024|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
16526025|NCT03112772|Experimental|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
16526026|NCT03112772|Experimental|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
16526027|NCT03112772|No Intervention|Group III|No grafting materials will be inserted, so it serves as a negative control group.
16526028|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
16526029|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
16526030|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
16526031|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
16526032|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
16526033|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
16526034|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
16526035|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
16526036|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
16526037|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
16526038|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
16526039|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
16526040|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
16526041|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA, neopterin and 5-hydroxytryptophan detection
16526042|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
16526043|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.
~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
16526044|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
16526045|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
16526049|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
16526050|NCT03112590|Experimental|Combination Therapy|"Phase 1: Participants with HER-2 positive metastatic breast cancer enrolled in groups of 3-6 or more; each group participant to be given the same dose and schedule of Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. If group participants do not have bad side effects, the next group will be given a higher dose of Interferon-gamma. This will continue until the highest safe dose of Interferon-gamma is found. Once highest safe dose of Interferon-gamma is found, participants may be enrolled in Phase II.
~Phase 2: Approximately 31 participants with Stage 2-3 HER2 positive early stage breast cancer enrolled to receive therapy with Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. Interferon-gamma given at dose found in the Phase 1.
~Phase 2: Post therapy surgery."
16526051|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
16526052|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
16526053|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
16526054|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
16526055|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
16526056|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
16526057|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
16526058|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
16526059|NCT03112538|Active Comparator|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
16526060|NCT03112538|Active Comparator|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
16526061|NCT03112525||Patient under Rivaroxaban|
16526062|NCT03112525||Patient under Apixaban|
16526063|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
16526064|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
16526065|NCT03112499|Active Comparator|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
16526066|NCT03112499|Active Comparator|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
16526067|NCT03112499|Active Comparator|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
16526068|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
16526069|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
16526070|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
16526071|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side and sham electrical stimulation on the non-paretic side
16526072|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
16526073|NCT03112473|No Intervention|Control group|No Active intervention
16526074|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
16526075|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
16526076|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
16526077|NCT03112408|Experimental|FORWARD (Axe 1)|
16526078|NCT03112408|Experimental|BACKWARD (Axe 1)|
16526079|NCT03112408|Experimental|CONTROL (Axe 1)|
16526080|NCT03112408|Experimental|ADAPTATION (Axe 2)|
16526081|NCT03112408|Experimental|CONTROL (Axe 2)|
16526082|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
16526083|NCT03112382|Active Comparator|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
16526084|NCT03112382|Active Comparator|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
16526085|NCT03112382|No Intervention|no vitamins|patients will be observed for 3 months
16526086|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
16526087|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
16526088|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
16526089|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
16549110|NCT02956499|Experimental|Cohort 6|single intravenous dose
16526090|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
16526091|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
16526092|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
16526093|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
16526094|NCT03112304|Experimental|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
16526095|NCT03112304|Experimental|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
16526096|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
16526097|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
16526098|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
16526099|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
16526100|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
16526101|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
16526102|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
16526103|NCT03112226|Active Comparator|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
16526104|NCT03112226|Placebo Comparator|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
16526105|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
16526106|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
16526107|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:
~Partial meniscectomy
~Lavage
~Debridement
~Loose body removal
~Synovectomy
~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)
~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
16526108|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
16526109|NCT03112174|Experimental|Safety Run-in Period|"Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.
~Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018."
16526110|NCT03112174|Experimental|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
16526111|NCT03112174|Placebo Comparator|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
16526112|NCT03112174|Experimental|Treatment-naive|"This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.
~Approximately 75 subjects (of which ~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax."
16549111|NCT02956499|Experimental|Cohort 7|multiple intravenous doses
16526113|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
16526114|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
16526115|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
16526116|NCT03112148|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
16526117|NCT03112148|Experimental|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
16526118|NCT03112148|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
16526119|NCT03112148|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
16526120|NCT03112148|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
16526121|NCT03112148|Experimental|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
16526122|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
16526123|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
16526124|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
16526125|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
16526126|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
16526127|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
16526128|NCT03112109||Intervention Group|Patients receiving 'new care'
16526129|NCT03112109||Control group|Patients receiving 'old / usual care'
16526130|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
16526131|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
16526132|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
16526133|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
16526134|NCT03112070|Experimental|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
16526135|NCT03112070|No Intervention|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
16526136|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
16526137|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
16526138|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
16526139|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
16526140|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
16526141|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
16526142|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
16526143|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
16526144|NCT03112018|Active Comparator|Standard care|"Data strengthening
~modified Safe Childbirth Checklist (mSCC) implementation"
16526145|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening
~modified Safe Childbirth Checklist (mSCC) implementation
~Health provider training (PRONTO)
~Quality Improvement (QI) Cycles"
16526146|NCT03111992|Experimental|Arm A|Dose escalation of single agent CJM112
16526147|NCT03111992|Experimental|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
16549112|NCT02956499|Experimental|Cohort 8|multiple intravenous doses
16526149|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
16526150|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
16526151|NCT03111966||Spanish cohort with HCV treated with DAA|
16526152|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
16526153|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
16526154|NCT03111940|Experimental|PCI optimisation|Post PCI FFR below 0.9
16526155|NCT03111940|No Intervention|No PCI optimisation|Post PCI FFR 0.9 or higher
16526156|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
16526157|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
16526158|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
16526159|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
16526160|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
16526161|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
16526162|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
16526163|NCT03111875|Active Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An Multi-Position Upper Body Warming Blanket forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
16526164|NCT03111875|Experimental|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
16526165|NCT03111849||hospitalized chronic obstructive patients|
16526166|NCT03111836|Sham Comparator|Control group|The Control group received limited to general information on blood pressure management
16526167|NCT03111836|Active Comparator|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
16526168|NCT03111836|Active Comparator|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
16526169|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
16526170|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
16526171|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
16526172|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
16526173|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
16526174|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
16526175|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
16526176|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
16526177|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
16526178|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
16526180|NCT03111732|Experimental|1/Arm 1|Pembrolizumab plus Oxaliplatin plus Capecitabine
16526181|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
16526182|NCT03111706||Intact scar|women with intact scar detected during cesarean section
16526183|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
16526184|NCT03111680|Experimental|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
16526185|NCT03111680|No Intervention|control|the control participants received no interventions
16526613|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
16526187|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
16526188|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
16526189|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
16526190|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
16526191|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
16526192|NCT03111654|Other|Patients with pericardial closure of the auricle|
16526193|NCT03111654|Other|Patients without closure of the auricle|
16526194|NCT03111641|Experimental|Lung ultrasonography|
16526195|NCT03111628|Other|Omalizumab|Omalizumab 300mg every month for 3 doses
16526196|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
16526197|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
16526198|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
16526199|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
16526200|NCT03111602|Experimental|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
16526201|NCT03111602|No Intervention|control group|healthy group as comparator
16526202|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
16526203|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
16526204|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
16526205|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
16526206|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
16526207|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
16526208|NCT03111563|Other|warm saline|case group ,
16526209|NCT03111563|Other|room temperature|control group
16526210|NCT03111550|Other|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
16526211|NCT03111550|Other|Investigational Lens Device #2|Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
16526212|NCT03111550|Other|Control Device|Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
16526213|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
16526214|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
16526215|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
16526216|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
16526217|NCT03111524|Active Comparator|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
16526218|NCT03111524|Active Comparator|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
16526219|NCT03111524|Active Comparator|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
16526220|NCT03111524|Active Comparator|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
16526352|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
16526221|NCT03111524|Active Comparator|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
16526222|NCT03111524|Placebo Comparator|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
16526223|NCT03111524|Placebo Comparator|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
16526224|NCT03111524|Placebo Comparator|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
16526225|NCT03111524|Placebo Comparator|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
16526226|NCT03111524|Placebo Comparator|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
16526227|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
16526228|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
16526229|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
16526230|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
16526231|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
16526232|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
16526233|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
16526234|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
16526235|NCT03111446|Active Comparator|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
16526236|NCT03111446|Active Comparator|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
16526237|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
16526238|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
16526239|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
~Loading dose day 1. Maintenance dose over subsequent 7 days."
16526240|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
~Loading dose day 1. Maintenance dose over subsequent 7 days."
16526241|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
~Loading dose day 1. Maintenance dose over subsequent 7 days."
16526242|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
16526243|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
16526244|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
16526245|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
16526246|NCT03111368|Active Comparator|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
16526247|NCT03111368|Active Comparator|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
16526248|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
16526249|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
16526250|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
16526251|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
16526314|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
16526252|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
~Intervention = NO aspiration of gastric residuals"
16526253|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
16526254|NCT03111316|Other|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
16526255|NCT03111316|Other|Foley Catheter Alone|a Foley catheter alone
16526256|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
16526257|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
16526258|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
16526259|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
16526260|NCT03111277|Experimental|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
16526261|NCT03111264|Experimental|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
16526262|NCT03111264|Experimental|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
16526263|NCT03111264|No Intervention|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
16526264|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
16526265|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
16526266|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
16526267|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
16526268|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
16526269|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
16526270|NCT03111212|Active Comparator|Iloprost|
16526271|NCT03111212|Placebo Comparator|control|
16526272|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
16526273|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
16526274|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
16526275|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
16526276|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
16526277|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
16526278|NCT03111173|Other|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
16526279|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
16526280|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
16526281|NCT03111147|Experimental|0 degrees humeral component version|Reverse Total Shoulder Arthroplasty with humeral component positioned in 0 degrees of version
16526282|NCT03111147|Experimental|30 degrees humeral component retroversion|Reverse Total Shoulder Arthroplasty with humeral component positioned in 30 degrees of retroversion
16526283|NCT03111134|No Intervention|Routine Abdominal Closure|
16526284|NCT03111134|Experimental|New Abdominal Closure|modified component separation technique is used to abdomen closing.
16526315|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
16526316|NCT03110926|Experimental|Induction Chemotherapy /Chemoradiation|mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.
16526353|NCT03110731|No Intervention|Control Group|no intervention
16526285|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
16526286|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
16526287|NCT03111108|Experimental|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
16526288|NCT03111108|Experimental|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
16526289|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
16526290|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
16526291|NCT03111082||Lean|BMI less than or equal to 29.9
16526292|NCT03111082||Obese|BMI between 30.0 and 39.9
16526293|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
16526294|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
16526295|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.
~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
16526296|NCT03111056|Experimental|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
16526297|NCT03111056|No Intervention|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
16526298|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
16526299|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
16526300|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
16526301|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
16526302|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
16526303|NCT03111004||Comparator Group|The comparator group receives usual care
16526304|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
16526305|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
16526306|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
16526307|NCT03110978|Experimental|Arm I (stereotactic body radiation therapy)|Patients undergo stereotactic body radiation therapy over 1-2 weeks.
16526308|NCT03110978|Experimental|Arm II (stereotactic body radiation therapy, nivolumab)|Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
16526309|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
16526310|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
16526311|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
16526312|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
16549113|NCT02956499|Experimental|Cohort 9|multiple intravenous doses
16526317|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).
~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
16526318|NCT03110900|Active Comparator|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
16526319|NCT03110900|Experimental|loxapine|Inhaled loxapine 10mg + IM normal saline
16526320|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
16526321|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)
~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)
~video based education"
16526322|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)
~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)
~direct education"
16526323|NCT03110861|Experimental|Pulsta® Transcatheter Pulmonary Valve|Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
16526324|NCT03110848|Experimental|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
16526325|NCT03110848|Active Comparator|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
16526326|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
16526327|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
16526328|NCT03110822|Experimental|Rux Len and Steroid|Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
16526329|NCT03110822|Experimental|Rux and Steroid until progression, then add Len|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
16526330|NCT03110809|Placebo Comparator|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
16526331|NCT03110809|Placebo Comparator|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
16526332|NCT03110809|Experimental|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
16526333|NCT03110809|Experimental|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
16526334|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
16526335|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
16526336|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
16526337|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
16526338|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
16526339|NCT03110770|Experimental|Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 injections|Zika virus wildtype (ZIKVwt) DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered intramuscularly (IM) by a needle-free injection device
16526340|NCT03110770|Experimental|Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
16526341|NCT03110770|Experimental|Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 8 mg of vaccine administered IM by a needle-free injection device
16526342|NCT03110770|Experimental|Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
16526343|NCT03110770|Placebo Comparator|Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 injections|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 1 mL of placebo administered IM by a needle-free injection device
16526344|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
16526345|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
16526346|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
16526347|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
16526348|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
16526349|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
16526350|NCT03110757|Active Comparator|Pooled Active Comparator Group|Euvax B Hepatitis B vaccine (n=12)
16526351|NCT03110744|Experimental|Palbociclib|application on 21 consecutive days of a 28 days cycle
16526354|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
16526355|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.
~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
16526356|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
16526357|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
16526358|NCT03110692|No Intervention|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
16526359|NCT03110692|Experimental|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
16526360|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
16526361|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
16526362|NCT03110666|Experimental|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
16526363|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
16526364|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
16526365|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
16526366|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
16526367|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
16526368|NCT03110601|Active Comparator|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
16526369|NCT03110601|No Intervention|Washout Period|1 day where no stimulation is provided
16526370|NCT03110601|Experimental|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
16526371|NCT03110588|Experimental|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
16526372|NCT03110588|Experimental|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
16526373|NCT03110575|Experimental|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
16526374|NCT03110562|Active Comparator|selinexor+bortezomib+dexamethasone (SVd)|Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
16526375|NCT03110562|Active Comparator|bortezomib+dexamethasone (Vd)|Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
16526376|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
16526377|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
16526378|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
16526379|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
16526380|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
16526381|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
16526382|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
16526383|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
16526384|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
16526385|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
16526386|NCT03110523|Experimental|Group A|High Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
16526387|NCT03110523|Experimental|Group B|Low Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
16526388|NCT03110510|Experimental|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
16526491|NCT03109808|Active Comparator|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
16526389|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
16526390|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
16526391|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
16526392|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
16526393|NCT03110471||Neuadd Drymmau Care Home|As above
16526394|NCT03110471||Monkstone House,|As above
16526395|NCT03110471||Danygraig House|As above
16526396|NCT03110471||Ty Coch|As above
16526397|NCT03110471||Swn y mor|As above
16526398|NCT03110471||Hengoed court|As above
16526399|NCT03110471||Hengoed park|As above
16526400|NCT03110471||Cefn Lodge care home|As above
16526401|NCT03110458|Experimental|SENS-111 100mg|SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)
16526402|NCT03110458|Experimental|SENS-111 200mg|SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)
16526403|NCT03110458|Placebo Comparator|Placebo|Placebo: 2 placebo Oral Dispersible Tablets
16526404|NCT03110445|Experimental|rVV-740CTA vaccine|
16526405|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
16526406|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
16526407|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
16526408|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
16526409|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
16526410|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
16526411|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
16526412|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
16526413|NCT03110380|Experimental|B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for 48 Weeks
16526414|NCT03110380|Active Comparator|DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for 48 Weeks
16526415|NCT03110380|Experimental|Open-Label Extension Phase|After Week 48, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive open-label B/F/TAF for up to 96 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
16526416|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:
~- Memory reframe with parent facilitated by researcher:
~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
16526417|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.
~Participants will be randomized into this group:
~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
16526418|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.
~Participants will be randomized into this group:
~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
16526529|NCT03109587|Active Comparator|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
16526419|NCT03110354|Experimental|DS-3201b in AML or ALL|DS-3201b is administered orally to participants with AML or ALL at a starting dose of 100 mg once a day, and then possibly at higher doses depending on safety observations
16526420|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
16526421|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
16526422|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
16526423|NCT03110315|Experimental|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
16526424|NCT03110315|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
16526425|NCT03110302|Active Comparator|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
16526426|NCT03110302|Active Comparator|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
16526427|NCT03110302|Experimental|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
16526428|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
16526429|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
16526430|NCT03110276|Experimental|EYP001a|
16526431|NCT03110276|Placebo Comparator|Placebo|
16526432|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
16526433|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
16526434|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
16526435|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
16526436|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
16526437|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
16526438|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
16526439|NCT03110198|Experimental|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
16526440|NCT03110198|Active Comparator|Mesalazine|Mesalazine （4g）enema
16526441|NCT03110198|Active Comparator|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
16526442|NCT03110185|Other|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
16526443|NCT03110185|Other|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
16526444|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
16526445|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
16526446|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
16526447|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
16526448|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.
~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
16526449|NCT03110133|Experimental|CP101|Full Spectrum Microbiota Capsule
16526450|NCT03110133|Placebo Comparator|Placebo|Matching Placebo Capsule
16526451|NCT03110120|Active Comparator|serratus|Serratus plane block and local control
16526452|NCT03110120|Sham Comparator|local|serratus control and local anesthesia
16526453|NCT03110107|Experimental|Part 1A: Monotherapy (BMS-986218)|
16526454|NCT03110107|Experimental|Part 1B: Combination Therapy (BMS-986218 + Nivolumab)|
16526455|NCT03110107|Experimental|Part 2A: Monotherapy (BMS-986218 OR Ipilimumab)|
16526456|NCT03110107|Experimental|Part 2B: Monotherapy (BMS-986218)|
16526457|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
16526458|NCT03110094|Other|Healthy volunteer|
16526459|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
16526460|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
16526461|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
16526462|NCT03110055|Experimental|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.
~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
16526463|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
16526464|NCT03110029|Active Comparator|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
16526465|NCT03110029|Placebo Comparator|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
16526466|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
16526467|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
16526468|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
16526469|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
16526470|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
16526471|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
16526472|NCT03109964|Active Comparator|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
16526473|NCT03109964|Experimental|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
16526474|NCT03109951|Other|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
16526475|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
16526476|NCT03109912|No Intervention|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
16526477|NCT03109912|Experimental|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
16526478|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
16526479|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
16526480|NCT03109886|Experimental|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
16526481|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
16526482|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
16526483|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
16526484|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
16526485|NCT03109834|Active Comparator|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)
~During weight stabilization phase (phase 2) MR counted to food choice option."
16526486|NCT03109834|Other|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)
~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
16526487|NCT03109834|Active Comparator|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)
~Duration: 6-month weight maintenance phase (phase 3)"
16526488|NCT03109834|Placebo Comparator|Placebo group|"Placebo capsules
~Duration: 6-month weight maintenance phase (phase 3)"
16526489|NCT03109821||THA patients|
16526490|NCT03109808|Experimental|e-health strategy|Assigned intervention: e-health strategy
16526492|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
16526493|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
16526494|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
16526495|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
16526496|NCT03109756|Experimental|Single-dose 5 mg OV101|
16526497|NCT03109743|Experimental|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for ~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
16526498|NCT03109743|Active Comparator|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
16526499|NCT03109730|Experimental|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
16526500|NCT03109730|Experimental|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
16526501|NCT03109730|Experimental|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
16526502|NCT03109730|Experimental|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
16526503|NCT03109730|Experimental|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
16526504|NCT03109730|Experimental|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
16526505|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
16526506|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
16526507|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
16526508|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
16526509|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
16526510|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
16526511|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
16526512|NCT03109678|Experimental|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
16526513|NCT03109678|Experimental|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
16526514|NCT03109678|Experimental|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
16526515|NCT03109678|Experimental|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
16526516|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
16526517|NCT03109652|Active Comparator|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
16526518|NCT03109652|Experimental|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
16526519|NCT03109652|Experimental|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
16526520|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
16526521|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
16526522|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
16526523|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
16526524|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
16526525|NCT03109600|Experimental|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
16526526|NCT03109600|Active Comparator|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
16526527|NCT03109600|Experimental|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
16526528|NCT03109600|Active Comparator|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
16526531|NCT03109574|Other|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
16526532|NCT03109574|Other|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
16526533|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
16526534|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
16526535|NCT03109522|Experimental|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
16526536|NCT03109522|Active Comparator|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
16526537|NCT03109509|Active Comparator|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
16526538|NCT03109509|Experimental|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
16526539|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
16526540|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
16526541|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
16526542|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.
~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
16526543|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.
~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
16526544|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
16526545|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.
~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
16526546|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
16526547|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
16526548|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
16526549|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
16526550|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
16526551|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
16526552|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
16526553|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
16526614|NCT03108963|Experimental|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
16526554|NCT03109379|Experimental|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
16526555|NCT03109379|Experimental|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
16526556|NCT03109366|Other|Online self-management support|Access to online self-management support tool for six months
16526557|NCT03109353|Experimental|ALA-ECP|Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen
16526558|NCT03109340|Active Comparator|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
16526559|NCT03109340|Experimental|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
16526560|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
16526561|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
16526562|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
16526563|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
16526564|NCT03109301|Experimental|Arm 1|Patients > 18 years of age
16526565|NCT03109301|Experimental|Arm 2|Patients < 18 years of age
16526566|NCT03109288|Experimental|Combination Therapy|Any two-drug combination of study interventions
16526567|NCT03109288|Experimental|Monotherapy|Any of the study Interventions
16526568|NCT03109275|Active Comparator|Single MRI examination|40 subjects will benefit from a full MRI
16526569|NCT03109275|Sham Comparator|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
16526570|NCT03109262|Experimental|Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans|All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans
16526571|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
16526572|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
16526573|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state.
~5 dose GCSF will be administered 5 days consecutively before bone marrow harvesting.
~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system.
~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
16526574|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:
~Patients will receive 5 doses of GCSF"
16526575|NCT03109223|Active Comparator|Commercially availabel infant formula|
16526576|NCT03109223|Experimental|Test formula with 2-FL|
16526577|NCT03109223|Active Comparator|Breast Fed|
16526578|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
16526579|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
16526580|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
16526581|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
16526582|NCT03109184|No Intervention|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
16526583|NCT03109184|Experimental|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
16526789|NCT03107871|Experimental|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
16526584|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
16526585|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.
~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
16526586|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.
~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.
~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
16526587|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
16526588|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
16526589|NCT03109132|Active Comparator|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
16526590|NCT03109132|Active Comparator|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
16526591|NCT03109132|Active Comparator|Model 3|Device - Experimental sample line Model 3
16526592|NCT03109132|Active Comparator|Model 4|Device - Experimental sample line Model 4
16526593|NCT03109132|Active Comparator|Model 5|Device - Experimental sample line Model 5
16526594|NCT03109132|Active Comparator|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
16526595|NCT03109119|Active Comparator|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
16526596|NCT03109119|Sham Comparator|Group P|These patients will be induced and maintained with propofol during anaesthesia.
16526597|NCT03109106|Experimental|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.
~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
16526598|NCT03109106|No Intervention|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
16526599|NCT03109093|Experimental|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.
~Patients entered with MRD level <10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab.
~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
16526600|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
16526601|NCT03109067|Experimental|Standardized meal|"Standardized meal for :
~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
16526602|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
16526603|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
16526604|NCT03109041|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
16526605|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
16526606|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
16526607|NCT03109015|Active Comparator|Schedule 4/2|
16526608|NCT03109015|Experimental|Schedule 2/1|
16526609|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
16526610|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
16526611|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
16526612|NCT03108976|Sham Comparator|Control group|Children with a typical development.
16526615|NCT03108963|Active Comparator|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
16526616|NCT03108950|Experimental|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
16526617|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
16526618|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
16526619|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
16526620|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
16526621|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
16526622|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
16526623|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
16526624|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
16526625|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
16526626|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
16526627|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
16526628|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
16526629|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
16526630|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
16526631|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
16526632|NCT03108820|Experimental|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
16526633|NCT03108820|Active Comparator|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
16526634|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
16526635|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
16526636|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
16526637|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
16526638|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:
~by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.
~endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.
~at least 2 features of cirrhosis:
~irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness > 4.0cm or > 5 rib units) on ultrasound ,CT or MRI;
~PLT<100×109/L without other causes;
~Serum album in<35 g/L or INR>1.3 or PT prolongs>3s;
~LSM>13 kpa (ALT<5×ULN)."
16526639|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
16526640|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
16526641|NCT03108781|Active Comparator|Lavender Oil|
16526642|NCT03108781|Placebo Comparator|sunflower oil|
16526643|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
16549114|NCT02956499|Experimental|Cohort 10|multiple intravenous doses
16526644|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
16526645|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
16526646|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
16526647|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
16526648|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
16526649|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
16526650|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
16526651|NCT03108742|Experimental|dermal stapler|
16526652|NCT03108742|Active Comparator|classic intradermal suture|
16526653|NCT03108729|Experimental|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
16526654|NCT03108716|Experimental|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
16526655|NCT03108716|Experimental|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
16526656|NCT03108716|Experimental|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
16526657|NCT03108703|Experimental|SBRT|RCC patients
16526658|NCT03108690|Experimental|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
16526659|NCT03108690|No Intervention|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
16526660|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
16526661|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
16526662|NCT03108664|Experimental|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
16526663|NCT03108664|Experimental|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
16526664|NCT03108651|Active Comparator|Case|Motivational message will be administrated.
16526665|NCT03108651|No Intervention|Control|Motivational message will not be administrated.
16526666|NCT03108638||R3 Supervisor Strategy Region 1|First cohort to be trained and monitored with remote coaching in the R3 model
16526667|NCT03108638||R3 Supervisor Strategy Region 2|Second cohort to be trained and monitored with remote coaching in the R3 model
16526668|NCT03108638||R3 Supervisor Strategy Region 3|Third cohort to be trained and monitored with remote coaching in the R3 model
16526669|NCT03108638||R3 Supervisor Strategy Region 4|Fourth cohort to be trained and monitored with remote coaching in the R3 model
16526670|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
16526671|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
16526672|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
16526673|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
16526674|NCT03108586|Active Comparator|FDI|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
16526675|NCT03108586|Experimental|CARS|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
16526676|NCT03108560|Experimental|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
16526677|NCT03108560|Active Comparator|Lobectomy group|Patients receive lobectomy.
16526678|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
16526679|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
16526680|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
16526681|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
16526682|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
16526683|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
16526684|NCT03108521|Experimental|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
16526685|NCT03108521|No Intervention|non-T2DM group|Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.
16526686|NCT03108508|Experimental|Prod1|G5 Siliplant
16526687|NCT03108508|Experimental|Prod2|Orgono Powder®
16526688|NCT03108508|Experimental|Prod3|G7 ALOE
16526689|NCT03108495|Experimental|Cohort 1 LN-145 monotherapy|Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
16526690|NCT03108495|Experimental|Cohort 2 LN-145 monotherapy|Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
16526691|NCT03108495|Experimental|Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only|Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab every 3 or 6 weeks post IL-2 administration up to 24 months.
16526692|NCT03108495|Experimental|Cohort 4 - Non-enrolling Cohort|Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
16526693|NCT03108495|Experimental|Cohort 5 Retreatment Cohort|Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
16526694|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
16526695|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
16526696|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
16526697|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
16526698|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
16526699|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
16526700|NCT03108456|Active Comparator|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
16526701|NCT03108456|Active Comparator|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
16526702|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
16526703|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
16526704|NCT03108430||Inhalation pneumonia|
16526705|NCT03108430||Proven inhalations|
16526706|NCT03108430||Suspected inhalations (coma + anamnesis)|
16526707|NCT03108417|Experimental|cNEP|continuous negative external pressure will be used nightly by all participants
16526708|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
16526709|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
16526710|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
16526711|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
16526712|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
16526713|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
16526714|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
16526715|NCT03108365|Experimental|Axiostat|"Size: 1 x 1 cm
~Chitosan based haemostatic dressing"
16526716|NCT03108365|Active Comparator|Cotton Gauze|Size: 1 x 1 cm
16526717|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
16526718|NCT03108352|Sham Comparator|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
16526719|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
16526720|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
16526721|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
16526722|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
16526723|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
16526724|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
16526725|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
16526726|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
16526727|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
16526728|NCT03108287|Active Comparator|RAK therapy|rabeprazole+amoxicillin+clarithromycin
16526729|NCT03108287|Active Comparator|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
16526730|NCT03108274|Experimental|Part 1: Danicopan and Midazolam|"Period 1: Participants received a single dose of midazolam.
~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of midazolam.
~Scheduled pharmacokinetics (PK) blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
16526731|NCT03108274|Experimental|Part 2: Danicopan and Fexofenadine|"Period 1: Participants received a single dose of fexofenadine.
~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of fexofenadine.
~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
16526732|NCT03108274|Experimental|Part 3: Danicopan and MMF|"Period 1: Participants received a single dose of MMF.
~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of MMF.
~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
16526733|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
16526734|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
16526735|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
16526736|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
16526737|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
16526738|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
16526739|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
16526740|NCT03108209|Experimental|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
16526741|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
16526742|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
16526743|NCT03108170|Active Comparator|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
16526744|NCT03108170|Active Comparator|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
16526745|NCT03108157|Experimental|GROUP A: intervention group|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
16526746|NCT03108157|No Intervention|GROUP B: no intervention group|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
16526747|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
16526748|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
16526749|NCT03108131|Experimental|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16526750|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
16526751|NCT03108105|Experimental|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
16526752|NCT03108092|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
16526753|NCT03108092|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
16526790|NCT03107871|Placebo Comparator|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
16526791|NCT03107858|Active Comparator|Norepinephrine|
16526792|NCT03107858|Active Comparator|Dopamine|
16526754|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.
~Interventions are listed in the Interventions Section."
16526755|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
16526756|NCT03108053|Active Comparator|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
16526757|NCT03108053|Experimental|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
16526758|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
16526759|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
16526760|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
16526761|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
16526762|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
16526763|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
16526764|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
16526765|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
16526766|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
16526767|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
16526768|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
16526769|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
16526770|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
16526771|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
16526772|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
16526773|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
16526774|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
16526775|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
16526776|NCT03107975|Experimental|Cell Therapy|intrathecal injection of human amniotic epithelial cells
16526777|NCT03107962|Experimental|PD-1 Blocking Antibody|Pembrolizumab
16526778|NCT03107949|Experimental|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
16526779|NCT03107936|Experimental|smokeSCREEN game play|Participants are instructed to access the web-based videogame intervention, smokeSCREEN, through a secured website and play the game using their unique User ID and password.
16526780|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
16526781|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
16526782|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
16526785|NCT03107884|Experimental|Metformin (Bed Rest)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
16526786|NCT03107884|Placebo Comparator|Placebo (Bed Rest)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
16526787|NCT03107884|Experimental|Metformin (2 week run-in only)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). These participants will not participate in the bed rest portion of the protocol.
16526788|NCT03107884|Placebo Comparator|Placebo (2 week run-in only)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
16552067|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
16526793|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
16526794|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
16526795|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
16526796|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
16526797|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
16526798|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
16526799|NCT03107806|Other|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
16526800|NCT03107806|Other|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
16526801|NCT03107793|Experimental|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
16526802|NCT03107793|Experimental|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
16526803|NCT03107793|Experimental|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with <25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with >=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
16526804|NCT03107793|Experimental|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score <=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
16526805|NCT03107780|Experimental|Treatment (MDM2 inhibitor AMG 232 [KRT-232])|"PART I: Patients with recurrent glioblastoma receive MDM2 inhibitor AMG 232 (KRT-232) PO QD for 2 days. Within 3-6 hours of the last dose, patients undergo standard of care surgery. Upon recovery (within 45 days), patients with TP53 wild-type tumors continue to receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7. Cycles repeat every 21 days in absence of disease progression or unacceptable toxicity.
~PART II: Within 6 weeks of standard of care surgery, patients with newly diagnosed glioblastoma undergo radiation therapy daily during weeks 1-6. Patients also receive MDM2 inhibitor AMG 232 (KRT-232) PO 2 times weekly (days 2, 4), 3 times weekly (days 2, 3, 5), 4 times weekly (days 2, 3, 4, 5), or 5 times weekly (days 1-5) for 6 weeks during radiation therapy.
~PART II (EXPANSION COHORT): Patients receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7. Cycles repeat every 21 days in absence of disease progression or unacceptable toxicity."
16526806|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
16526807|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
16526808|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
16526809|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
16526810|NCT03107741|No Intervention|Passive Control|Subjects in this group will not receive any intervention.
16526811|NCT03107741|Placebo Comparator|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
16526812|NCT03107741|Active Comparator|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
16526813|NCT03107728|Experimental|Advanced orthotic brace|
16526814|NCT03107728|Active Comparator|Conventional orthotic brace|
16526815|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
16526816|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
16526817|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
16526818|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
16526819|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
16526820|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
16526821|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
16526822|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
16526823|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
16526824|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
16526825|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
16526826|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
16526827|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
16526828|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
16526829|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
16526830|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
16526831|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
16526832|NCT03107546|Other|Skin graft|full thickness skin graft
16526833|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
16526834|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
16526836|NCT03107507|Active Comparator|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.
~Duration: until seizure free"
16526837|NCT03107507|Active Comparator|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.
~Duration: until seizure free"
16526838|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
16526839|NCT03107481|Active Comparator|Acetaminophen|
16526840|NCT03107481|Active Comparator|Hydromorphone|
16526841|NCT03107468|Experimental|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
16526842|NCT03107468|Active Comparator|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
16526843|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
16526844|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
16526845|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.
~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
16526846|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.
~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
16526905|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
16526847|NCT03107416|Experimental|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
16526848|NCT03107403|Experimental|Healthy subjects|
16526849|NCT03107390|Other|Patients with CD or RCH|
16526850|NCT03107390|Other|The control population|
16526851|NCT03107377|Active Comparator|EVO100|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
16526852|NCT03107377|Placebo Comparator|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
16526853|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
16526854|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
16526855|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
16526856|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
16526857|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
16526858|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
16526859|NCT03107325|Other|F-18 FDG|Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
16526860|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
16526861|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
16526862|NCT03107299|Other|Control|
16526863|NCT03107299|Other|Send sms to patients|
16526864|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
16526865|NCT03107286|Other|Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
16526866|NCT03107273||Diagnostic patient|
16526867|NCT03107273||Control|
16526868|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
16526869|NCT03107247|Other|Tc-99m MDP|Patients ages 1-16 years old will be included. Routine SPECT imaging will be collected 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ for 10-15 s per view using a 1282 matrix. Half of the subjects will also be imaged between 30 and 90 min, PA. The 2nd half will be at 4-6 h, PA. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
16526870|NCT03107234||Patient with breast cancer requiring surgery to|
16526871|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
16526872|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
16526873|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
16526874|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
16526875|NCT03107195|Other|Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
16526876|NCT03107182|Experimental|Induction Chemotherapy|"All enrolled patients will receive three 21-day cycles of chemotherapy consisting of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total), carboplatin (AUC 5 on day 1; 3 doses total), and nivolumab (360 mg on days 1; 3 doses total). Growth factor support will be provided using G-CSF administered on days 16-18.
~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy."
16526877|NCT03107182|Experimental|Single Modality De-escalation Arm (SDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.
~Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. De-intensified adjuvant RT will be given for adverse pathologic features. Patients may refuse TORS treatment.
~Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 G."
16526878|NCT03107182|Experimental|Intermediate De-escalation Arm (IDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.
~Patients who have low risk disease with <50% but ≥30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 45 Gy (3 cycles).
~Patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles)."
16526879|NCT03107182|Experimental|Regular Dose Arm (RDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.
~Patients who have low risk disease and <30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 75 Gy (5 cycles).
~Patients who have high risk disease and <50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).
~Any patient who has progressive disease will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
16526880|NCT03107169|Active Comparator|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
16526881|NCT03107169|Experimental|FMT-FURM|Patients in this arm receive FMT-FURM
16526882|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
16526883|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
16526884|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
16526885|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
16526886|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
16526887|NCT03107104|Experimental|Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
16526888|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
16526889|NCT03107078|Experimental|Group Ia|"I:The increase of fat volume dominates .
~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
16526890|NCT03107078|Experimental|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
16526891|NCT03107078|Experimental|Group IIa|"II:The increase of extraocular muscles volume dominates .
~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
16526892|NCT03107078|Experimental|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
16526893|NCT03107065|Experimental|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
16526894|NCT03107052|Experimental|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 milliliter {mL}] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
16526895|NCT03107052|Experimental|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 12, 24, and 36) through Week 36.
16526896|NCT03107052|Experimental|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
16526897|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
16526898|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
16526899|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
16526900|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
16526901|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
16526902|NCT03107013|Experimental|[14C]-BTD-001|
16526903|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
16526904|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
16552068|NCT02937051|Active Comparator|Own Brand Cigarette Condition|
16526906|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
16526907|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
16526908|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
16526909|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
16526910|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
16526911|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
16526912|NCT03106935|Active Comparator|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
16526913|NCT03106935|No Intervention|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
16526914|NCT03106922|Experimental|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:
~2<=Age<6
~500 ml in 1-1.5 hours <= to 18 kg
~625 ml in 1-1.5 hours >18 kg 6<=Age<12:
~750 ml in 1-2 hours <=25 kg
~1000 ml in 1-2 hours 25-35 kg
~1250 ml in 1-2 hours >35 kg 12>=Age<18 :
~1500 ml in 2-3 hours <= 45 kg
~1750 ml in 2-3 hours>45 kg.
~Rescue dose (if no clear watery stools 3 hours after the entire solution):
~250 ml 2 Age <=6;
~500 ml 6 <=Age<12; up to a cumulative maximum volume of 2000 ml 12<=Age<18."
16526915|NCT03106922|Active Comparator|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:
~2<=Age<6:
~90 ml/kg in 1-1.5 hours 2<=Age<6
~80 ml/kg in 1-1.5 hours 5<=Age<6
~2<=Age<6:
~80 ml/kg in 1-2 hours 6<=Age<10
~70 ml/kg in 1-2 hours 10<=Age<12
~12<=Age<18:
~70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
16526916|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
16526917|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
16526918|NCT03106896||healthy control (CON group)|healthy population
16526919|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions
~Five five-minute blocks separate by 90-second rest periods"
16526920|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)
~Five five-minute blocks separate by 90-second rest periods"
16526921|NCT03106870|Active Comparator|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
16526922|NCT03106870|Active Comparator|insulin therapy only|Intervention 'Insulin Mixtard' had included
16526923|NCT03106857|Placebo Comparator|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
16526924|NCT03106857|No Intervention|Group B|No intervention
16526925|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
16526926|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
16526927|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
16526928|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
16526929|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
16526930|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
16526931|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
16526932|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
16526933|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
16526934|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
16526935|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
16526936|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
16526939|NCT03106766|Experimental|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
16526940|NCT03106766|Experimental|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
16526970|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
16526971|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
16526972|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
16526941|NCT03106753|Active Comparator|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
16526942|NCT03106753|Experimental|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
16526943|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
16526944|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
16526945|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
16526946|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
16526947|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
16526948|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
16526949|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
16526950|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
16526951|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
16526952|NCT03106701|Experimental|Ablation|Radiofrequency epicardial ablation
16526953|NCT03106688|Active Comparator|Low-risk group|Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
16526954|NCT03106688|Active Comparator|High-risk group|Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
16526955|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging
~Pre-treatment questionnaires and laboratory blood samples
~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)
~Follow-up (imaging, questionnaires, laboratory)
~Follow-up pain medication usage"
16526956|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging
~Pre-treatment questionnaires and laboratory blood samples
~Intervention (Varian Truebeam Radiotherapy System)
~Follow-up (imaging, questionnaires, laboratory)
~Follow-up pain medication usage"
16526957|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
16526958|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
16526959|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
16526960|NCT03106636|Active Comparator|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
16526961|NCT03106636|Experimental|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
16526962|NCT03106623|Experimental|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
16526963|NCT03106623|Active Comparator|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
16526964|NCT03106623|Placebo Comparator|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
16526965|NCT03106610|Experimental|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).
~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
16526966|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
16526967|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
16526968|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.
~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
16526969|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.
~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
16526973|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
16526974|NCT03106558|Active Comparator|Manual instrument total knee replacement|
16526975|NCT03106558|Active Comparator|Robitic arm total knee replacement|
16526976|NCT03106545|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
16526977|NCT03106545|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
16526978|NCT03106545|Sham Comparator|General anesthesia|General anesthesia
16526979|NCT03106532|Experimental|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
16526980|NCT03106532|Experimental|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
16526981|NCT03106532|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
16526982|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
16526983|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
16526984|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
16526985|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
16526986|NCT03106493||Primary|Singletons and 1 twin of each pair
16526987|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
16526988|NCT03106493||Tertiary|Higher order multiples and siblings
16526989|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
16526990|NCT03106467|Experimental|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
16526991|NCT03106467|Active Comparator|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
16526992|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
16526993|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
16526994|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
16526995|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
16526996|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
16526997|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
16526998|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
16526999|NCT03106415|Experimental|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of cycle 1 and on days 1-21 of cycle 2 and subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycle 1 equals 14 days. Cycles 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16527000|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
16527001|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
16527002|NCT03106389|Active Comparator|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
16527003|NCT03106389|Experimental|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
16527004|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
16527005|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
16527006|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
16527007|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
16527008|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
16527009|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
16527086|NCT03105700|Experimental|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
16527010|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
16527011|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
16527012|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
16527013|NCT03106311|Active Comparator|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
16527014|NCT03106311|Active Comparator|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
16527015|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
16527016|NCT03106285|Experimental|Lactobacillus reuteri DSM17938|Oil drops
16527017|NCT03106285|Placebo Comparator|Placebo|Oils drops
16527018|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
16527019|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
16527020|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
16527021|NCT03106246||T2DM|Patients with established type II diabetes.
16527022|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
16527023|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
16527024|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
16527025|NCT03106220|Active Comparator|home exercise|participate in home exercise program
16527026|NCT03106220|Placebo Comparator|standard care|encouraged to join physical therapy and walking goals
16527027|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
16527028|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.
~Case management"
16527029|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
16527030|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
16527031|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
16527032|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
16527033|NCT03106155|Experimental|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
16527034|NCT03106142|Other|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
16527035|NCT03106142|No Intervention|control group|The two case vignettes will also be presented to GP who did not received the intervention.
16527036|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
16527037|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
16527038|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
16527039|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
16527040|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
16527041|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
16527042|NCT03106077|Experimental|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
16527043|NCT03106077|Experimental|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
16527044|NCT03106064|Placebo Comparator|Usual Care Group|Intervention: Usual care
16527045|NCT03106064|Experimental|Intervention Group|Intervention:Promoting independence in self-care
16527046|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
16527047|NCT03106038|Experimental|Nerindocianine for Injection|One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.
16527116|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
16552069|NCT02937051|Experimental|Original-flavor Black&Mild cigar|
16527048|NCT03106025|Experimental|Patients Receiving Ultrasound|Enrolled participants will receive a bedside ocular ultrasound of the affected eye and the ultrasound will be compared with the ophthalmologist diagnosis. The participant's medical record will also be reviewed for information regarding demographics, complications, and outcomes.
16527049|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
16527050|NCT03105986|Experimental|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
16527051|NCT03105986|Experimental|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
16527052|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
16527053|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .
~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
16527054|NCT03105960|Active Comparator|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash
~."
16527055|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
16527056|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
16527057|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
16527058|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
16527059|NCT03105921|Experimental|Electrodes|Electrodes
16527060|NCT03105908|Other|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
16527061|NCT03105908|Other|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
16527062|NCT03105882|Experimental|Neuro-Spinal Scaffold|
16527063|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
16527064|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
16527065|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
16527066|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
16527067|NCT03105843|Experimental|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
16527068|NCT03105843|Experimental|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
16527069|NCT03105843|Experimental|Control|Individuals with no history of asthma or chronic cough
16527070|NCT03105830|Experimental|intervention and data collection|pain management by iv paracetamol
16527071|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
16527072|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
16527073|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
16527074|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
16527075|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
16527076|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
16527077|NCT03105765|Active Comparator|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.
~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
16527078|NCT03105765|Placebo Comparator|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.
~Placebo (normal Saline) for 24 hours."
16527079|NCT03105752|Experimental|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
16527080|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
16527081|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
16527082|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
16527083|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
16527084|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is three patient safety checklists for patients to be performed: a) before admission to hospital; b) under hospital stay (discharge); c) after discharge from hospital.
16527085|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
16527153|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
16527087|NCT03105687|No Intervention|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.
~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
16527088|NCT03105687|Experimental|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
16527089|NCT03105674|Active Comparator|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
16527090|NCT03105674|Experimental|Multi-drug local anaesthetics|"Patients will receive a combination [Multi-drug local anesthetics (Combination)] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)
~Ropivacaine 0.5% - 30 ml
~Ketorolac 30mg/ml - 1 ml
~Kenalog 10 mg/ml - 5 ml
~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
16527091|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.
~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
16527092|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
16527093|NCT03105648||thyroid cancer|
16527094|NCT03105648||benign thyroid nodules|
16527095|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
16527096|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.
~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.
~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
16527097|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
16527098|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
16527099|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
16527100|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
16527101|NCT03105596|Experimental|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
16527102|NCT03105583||Pregnant women visiting the obstetrics department|
16527103|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
16527104|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
16527105|NCT03105544|No Intervention|Control|No intervention.
16527106|NCT03105518|Experimental|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
16527107|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
16527108|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
16527109|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
16527110|NCT03105492||Pregnant women|Women who are pregnant
16527111|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
16527112|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
16527113|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
16527114|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
16527115|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
16527117|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
16527118|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
16527119|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
16527120|NCT03105440|Experimental|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
16527121|NCT03105440|Experimental|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.
~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
16527122|NCT03105440|Experimental|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.
~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
16527123|NCT03105440|Experimental|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
16527124|NCT03105440|Experimental|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
16527125|NCT03105440|Experimental|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
16527126|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
16527127|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
16527128|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
16527129|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
16527130|NCT03105362|Experimental|Amino Acid-ORS arm|Patients consumed an amino acid based oral rehydration solution (enterade®) as part of their oral rehydration care plan. Enterade® oral rehydration solution volumes varied from patient to patient depending on baseline clinical need.
16527131|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
16527132|NCT03105336|Experimental|axicabtagene ciloleucel|
16527133|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
16527134|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
16527135|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
16527136|NCT03105297|Experimental|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
16527137|NCT03105297|Experimental|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
16527138|NCT03105297|Experimental|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
16527139|NCT03105284|Active Comparator|Liposuction of fat|The intervention examined is the extraction method by liposuction.
16527140|NCT03105284|No Intervention|Excision of fat|Control group
16527141|NCT03105245|Active Comparator|Short time interval + Normal ventilation|
16527142|NCT03105245|Active Comparator|Short time interval + Hyperventilation|
16527143|NCT03105245|Active Comparator|Long time interval + Normal ventilation|
16527144|NCT03105245|Active Comparator|Long time interval + Hyperventilation|
16527145|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
16527146|NCT03105232||Group B|Buprenorfin
16527147|NCT03105232||Group C|Fentanyl
16527148|NCT03105232||Group D|Opioid rotation
16527149|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
16527150|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
16527151|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
16527152|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
16527154|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
16527155|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
16527156|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
16527157|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
16527158|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
16527159|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
16527160|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
16527161|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
16527162|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
16527163|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
16527164|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
16527165|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
16527166|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
16527167|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
16527168|NCT03105128|Placebo Comparator|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
16527169|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
16527170|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
16527171|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
16527172|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
16527173|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
16527174|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
16527175|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
16527176|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
16527177|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
16527178|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
16527179|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or other AbbVie risankizumab Crohn's disease study or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 or dose 2 depending on their preceding study beginning at Week 56.
16527180|NCT03105102|Experimental|Risankizumab On-Body Injector and Open Label (Sub-Study 4)|Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
16527181|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
16527182|NCT03105089|No Intervention|control|no intervention will be done
16527183|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
16527184|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
16527185|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
16527297|NCT03104374|Experimental|ABT-494 Dose A|It is administered once daily.
16527186|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
16527187|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
16527188|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
16527189|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
16527190|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
16527191|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
16527192|NCT03104998|Other|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
16527193|NCT03104985|Active Comparator|Conventional treatment|"Conventional treatment only.
~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2
~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.
~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
16527194|NCT03104985|Experimental|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:
~- 365-405nm, power 1-2mW, exposure 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min"
16527195|NCT03104972|Experimental|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
16527196|NCT03104972|Experimental|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
16527197|NCT03104972|Experimental|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
16527198|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
16527199|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
16527200|NCT03104946||Bronchopulmonary Dysplasia|
16527201|NCT03104946||Retinopathy|
16527202|NCT03104946||Severe Retinopathy|
16527203|NCT03104946||Neonatal Necrotizing Enterocolitis|
16527204|NCT03104946||Brain injury|
16527205|NCT03104946||sepsis|
16527206|NCT03104946||Patent Ductus Arteriosus|
16527207|NCT03104946||Respiratory Distress Syndrome|
16527208|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
16527209|NCT03104920|Experimental|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
16527210|NCT03104920|Active Comparator|Traditional treatment|We give routine clinic practices for the treatment of HCC.
16527211|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
16527212|NCT03104894|Experimental|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
16527213|NCT03104894|Sham Comparator|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
16527214|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
16527215|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
16527216|NCT03104868|No Intervention|Usual Care|Patients in this group will receive the usual standard of care.
16527217|NCT03104868|Experimental|Intervention|Patients in this group will receive the TAKE IT strategy components.
16527218|NCT03104855|Experimental|Single pharmacokinetics arm|
16527219|NCT03104842|Experimental|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Induction Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd), after intensification another 4 cycles of I-KRd as consolidation will be followed by IKR maintenance until PD or Toxicity
16527220|NCT03104842|Experimental|Arm B No-Transplantation|Patients > 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd) (6 Cycles Induction, 2 Cycles Intensification, 4 Cycles Consolidation),to be followed by I-KR maintenance util PD or Toxicity
16527221|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
16527222|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
16527223|NCT03104816|Experimental|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
16527224|NCT03104816|Experimental|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
16527225|NCT03104816|Active Comparator|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
16527226|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
16527227|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
16527228|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
16527229|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
16527230|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
16527231|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
16527232|NCT03104764|Active Comparator|Scalpel|Frenotomy performed with conventional scalpel
16527233|NCT03104764|Experimental|Er:YAG laser|Frenotomy performed with Er:YAG laser
16527234|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
16527235|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
16527236|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
16527237|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
16527238|NCT03104725|Experimental|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
16527239|NCT03104725|Experimental|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
16527240|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
16527241|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
16527242|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
16527243|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
16527244|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
16527245|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
16527246|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
16527247|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
16527248|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
16527249|NCT03104699|Experimental|Monotherapy|Dose of 3 mg/kg IV every 2 weeks for up to 24 months.
16527250|NCT03104686|Active Comparator|Bread|Bread (50g available carbohydrate, 109 g) eaten with 500 mL of water
16527251|NCT03104686|Experimental|Short pasta (dry)|Cooked penne (142 g; 71 g uncooked) eaten with 500 mL of water
16527252|NCT03104686|Experimental|Long pasta (dry)|Cooked spaghetti (142 g; 71 g uncooked) eaten with 500 mL of water
16527253|NCT03104686|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
16527254|NCT03104660|Experimental|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
16527255|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
16527256|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
16527257|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
16527258|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
16527259|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
16527260|NCT03104608|Active Comparator|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
16527298|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose B|It is administered once daily.
16527261|NCT03104608|Placebo Comparator|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
16527262|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
16527263|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
16527264|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
16527265|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
16527266|NCT03104582|Experimental|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
16527267|NCT03104582|Active Comparator|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
16527268|NCT03104569|Experimental|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent
16527269|NCT03104569|No Intervention|Injection of normal contrast agent|Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent
16527270|NCT03104543|Experimental|Education|Educational materials
16527271|NCT03104543|Active Comparator|Test results|Test results only; with delayed access to the experimental materials
16527272|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
16527273|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
16527274|NCT03104517|Experimental|AMDC-USR|AMDC-USR is the study product (autologous muscle derived cells for urinary sphincter repair).
16527275|NCT03104517|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
16527276|NCT03104504|No Intervention|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
16527277|NCT03104504|Other|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.
~suicide risk screening
~safety planning
~means restriction counseling
~Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
16527278|NCT03104491|Experimental|Inotuzumab Ozogamicin|"Phase I:
~A maximum of 12 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for ALL participants is 0.1-0.6mg/m^2 and for NHL participants 0.2-0.8mg/m^2
~Dosing in the NHL cohort will start at Dose Level 0 (0.3mg/m^2) or one dose level below the ALL cohort maximum tolerated dose (MTD), whichever is higher.
~Phase II:
~ALL and NHL participants: Will be enrolled until all Phase I ALL/NHL participants (respectively) have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. Repeat cycles every 28 days for up to 12 cycles"
16527279|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
16527280|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
16527281|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle
~Ipilimumab will be administered intravenously once per cycle
~Radiation Therapy will be administered per hospital standard"
16527282|NCT03104426|Active Comparator|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
16527283|NCT03104426|No Intervention|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
16527284|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 1)|Participants randomized to receive risankizumab dose 1 in Induction Period 1.
16527285|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 1)|Participants randomized to receive risankizumab dose 2 in Induction Period 1.
16527286|NCT03104413|Placebo Comparator|Placebo (Induction Period 1)|Participants randomized to receive placebo for risankizumab in Induction Period 1.
16527287|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
16527288|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
16527289|NCT03104413|Experimental|Risankizumab Dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
16527290|NCT03104400|Experimental|ABT-494 Dose A + Placebo Adalimumab|It is administered once daily.
16527291|NCT03104400|Experimental|ABT-494 Dose B + Placebo Adalimumab|It is administered once daily.
16527292|NCT03104400|Active Comparator|Adalimumab + Placebo ABT-494|It is administered subcutaneously once every two weeks.
16527293|NCT03104400|Experimental|Placebo ABT-494 + Placebo Adalimumab Then ABT-494 Dose A|It is administered once daily.
16527294|NCT03104400|Experimental|Placebo ABT-494 + Placebo Adalimumab Then ABT-494 Dose B|It is administered once daily.
16527295|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
16527296|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
16527299|NCT03104374|Experimental|ABT-494 Dose B|It is administered once daily.
16527300|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose A|It is administered once daily.
16527301|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
16527302|NCT03104348|Other|COPD screening|
16527303|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
16527304|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
16527305|NCT03104309|Other|Levonorgestrel intrauterine system|
16527306|NCT03104283|Experimental|Apatinib Group|take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
16527307|NCT03104270|Experimental|Elo Pom Car and Dex|"Drug dosing and administration:
~All drugs are administered on a 28-day cycle.
~Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2. 20 mg/kg on Day 1 of Cycles 3 and beyond.
~Pomalidomide: 3 mg PO on days 1-21
~Carfilzomib: 20 mg/m2 IV on days 1 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles.
~Dexamethasone: On days 1,8,15,22 of Cycle 1-2 and day 1 of Cycle 3 and every day 1 thereafter, pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO. On days 8,15,22 of Cycle 3 and beyond, 40mg of DEX PO or IV. On Day 8 and 15 of Cycle 3 and beyond, pre-treatment with DEX 40mg PO or IV at least 30 min and no more than 4 hours prior to the start of CFZ."
16527308|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
16527309|NCT03104257||Healthy Controls|Subjects with no current cannabis use
16527310|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
16527311|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
16527312|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
16527313|NCT03104218|Experimental|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
16527314|NCT03104218|Sham Comparator|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
16527315|NCT03104205|Experimental|Evaluate home-based MOWI|Conduct and assess the feasibility, acceptability, and potential effectiveness of home-based MOWI in improving physical function.
16527316|NCT03104192|Active Comparator|Develop & Refine MOWI w/o Amulet (2A)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
16527317|NCT03104192|Experimental|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
16527318|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit (2B)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
16527319|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit/Protein (2P)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
16527320|NCT03104179|Experimental|Treatment|CPB with Cytosorb
16527321|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
16527322|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
16527323|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
16527324|NCT03104153|No Intervention|Output-based|
16527325|NCT03104153|Active Comparator|Early-removal|
16527326|NCT03104140|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
16527327|NCT03104140|Active Comparator|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
16527328|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
16527329|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
16552070|NCT02937051|Experimental|Apple-flavor Black&Mild cigar|
16527330|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
16527331|NCT03104114|Placebo Comparator|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
16527332|NCT03104114|Experimental|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
16527333|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
16527334|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
16527335|NCT03104088||SPG4 patients|
16527336|NCT03104088||Healthy controls|
16527337|NCT03104075|Active Comparator|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
16527338|NCT03104075|Active Comparator|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
16527339|NCT03104062|Other|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
16527340|NCT03104062|Other|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
16527341|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
16527342|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
16527343|NCT03104036|Active Comparator|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
16527344|NCT03104036|Experimental|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
16527345|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
16527346|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
16527347|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
16527348|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
16527349|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
16527350|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
16527351|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
16527352|NCT03103984|Experimental|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
16527353|NCT03103984|Experimental|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
16527354|NCT03103971|Experimental|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
16527355|NCT03103958|Active Comparator|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
16527356|NCT03103958|Placebo Comparator|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
16527357|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
16527358|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
16527359|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
16527360|NCT03103919|Active Comparator|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
16527361|NCT03103919|Experimental|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
16527402|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
16527403|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
16527404|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
16527362|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
16527363|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
16527364|NCT03103893|Experimental|Rapamycin|Rapamycin
16527365|NCT03103880|Experimental|Medication Adherence and Pulmonary Function Tests|
16527366|NCT03103880|Experimental|Medication Adherence and Peak Flow Measurements|
16527367|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
16527368|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
16527369|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
16527370|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
16527371|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
16527372|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
16527373|NCT03103841||Children and young people with epilepsy|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
16527374|NCT03103841||Healthy controls|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
16527375|NCT03103828|Active Comparator|Computer-tailored intervention|
16527376|NCT03103828|Active Comparator|Motivational Interviewing|
16527377|NCT03103828|Active Comparator|Motivational Enhancement Therapy|
16527378|NCT03103828|No Intervention|Control Group|
16527379|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
16527380|NCT03103802|Experimental|Intra-oral scanning|
16527381|NCT03103802|Experimental|extra-oral scanning of the plaster model obtained via alginate|
16527382|NCT03103802|Experimental|extra-oral scanning of plaster model obtained via rubber base|
16527383|NCT03103802|Experimental|extra-oral scanning of the rubber base impression|
16527384|NCT03103802|Experimental|extra-oral scanning of the alginate impression|
16527385|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
16527386|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
16527387|NCT03103776|Other|Patients who have Graves disease|
16527388|NCT03103776|Other|Patients having a goiter|
16527389|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
16527390|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
16527391|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
16527392|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
16527393|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
16527394|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
16527395|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
16527396|NCT03103724|Experimental|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
16527397|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
16527398|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
16527399|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
16527400|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
16527401|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
16527405|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
16527406|NCT03103646|Experimental|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
16527407|NCT03103646|Experimental|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
16527408|NCT03103633|Experimental|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
16527409|NCT03103633|Sham Comparator|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
16527410|NCT03103594|Active Comparator|DMSO alone|Half of the patients will undergo DMSO instillation
16527411|NCT03103594|Experimental|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
16527412|NCT03103581|Experimental|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
16527413|NCT03103568|Experimental|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.
~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
16527414|NCT03103568|Experimental|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.
~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
16527415|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
16527416|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
16527417|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
16527418|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
16527419|NCT03103516|Experimental|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
16527420|NCT03103516|Experimental|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
16527421|NCT03103490|Other|18F-FSPG PET/MRI|Patients undergoing 18F-FSPG PET/MRI scan
16527422|NCT03103490|Other|18F-FSPG PET/CT|Patients undergoing 18F-FSPG PET/CT scan
16527423|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.
~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
16527424|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
16527425|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
16527426|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
16527427|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527428|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527429|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527430|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527431|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527432|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527433|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
16527434|NCT03103438|Experimental|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
16527435|NCT03103438|Experimental|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
16527436|NCT03103438|Experimental|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
16527437|NCT03103438|Experimental|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
16527438|NCT03103438|Experimental|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
16527439|NCT03103438|Experimental|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
16527440|NCT03103438|Experimental|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.9 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
16527441|NCT03103412|Experimental|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
16527442|NCT03103412|Experimental|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
16527443|NCT03103412|Experimental|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
16527444|NCT03103412|Placebo Comparator|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
16527445|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
16527446|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
16527447|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
16527448|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
16527449|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
16527450|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
16527725|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
16527451|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
16527452|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
16527453|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
16527454|NCT03103334|Experimental|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
16527455|NCT03103334|Experimental|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
16527456|NCT03103334|Experimental|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
16527457|NCT03103334|Experimental|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
16527458|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
16527459|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
16527460|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
16527461|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
16527462|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
16527463|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
16527464|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones
~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
16527465|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.
~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
16527466|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.
~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.
~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
16527467|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.
~This group does not receive the Challenge! Small Group Intervention.
~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
16527468|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
16527469|NCT03103256|Experimental|YHP1701|PO, Once daily (QD), 8 weeks
16527470|NCT03103256|Active Comparator|YHR1703|PO, Once daily (QD), 8 weeks
16527471|NCT03103256|Active Comparator|YHR1704|PO, Once daily (QD), 8 weeks
16527472|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
16527473|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
16527474|NCT03103217|Experimental|Brief CBT intervention|
16527475|NCT03103204|Experimental|Normal weight full-mouth disinfection|"Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
16527476|NCT03103204|Experimental|Overweight full-mouth disinfection|"Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
16527477|NCT03103204|Experimental|Obesity I full-mouth disinfection|"Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
16527478|NCT03103204|Experimental|Obesity II full-mouth disinfection|"Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
16527479|NCT03103204|Experimental|Obesity III full-mouth disinfection|"Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
16527480|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.
~50 subjects with pulmonary fibrosis secondary to collagen diseases."
16527481|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.
~75 subjects with collagen disease without pulmonary fibrosis."
16527482|NCT03103152|Experimental|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
16527483|NCT03103152|Experimental|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
16527484|NCT03103152|Experimental|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
16527485|NCT03103152|Placebo Comparator|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
16527486|NCT03103152|Experimental|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
16527487|NCT03103152|Experimental|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
16527488|NCT03103139|Active Comparator|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
16527489|NCT03103139|Experimental|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
16527490|NCT03103126|No Intervention|Control|Standard care.
16527491|NCT03103126|Experimental|Combined resistance exercise and walking|Combined resistance exercise and walking.
16527492|NCT03103100|Active Comparator|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
16527493|NCT03103100|Active Comparator|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
16527494|NCT03103100|Active Comparator|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
16527495|NCT03103087|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
16527496|NCT03103087|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
16527497|NCT03103087|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
16527498|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
16527499|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
16527500|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
16527501|NCT03103048|Active Comparator|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
16527502|NCT03103048|Placebo Comparator|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
16527503|NCT03103048|Active Comparator|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
16527504|NCT03103048|Active Comparator|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
16527505|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
16527506|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
16527507|NCT03103022|Experimental|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
16527508|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
16527509|NCT03102996|Experimental|Verum|Patients will receive Nephrotrans.
16527510|NCT03102996|Placebo Comparator|Placebo|Patients will receive Placebo.
16527511|NCT03102983|Experimental|Healthy Volonteers|
16527512|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
16527513|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
16527514|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
16527515|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
16527516|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
16527517|NCT03102918|Placebo Comparator|Placebo|Placebo
16527518|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
16527519|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
16527520|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
16527521|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
16527522|NCT03102866|Active Comparator|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
16527523|NCT03102866|Experimental|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
16527524|NCT03102853|Active Comparator|Nordic diet|
16527525|NCT03102853|Other|Control diet|
16527526|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
16527527|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
16527528|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
16527529|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
16527530|NCT03102814|Active Comparator|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
16527531|NCT03102814|Experimental|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
16527532|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
16527533|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
16527534|NCT03102788|Active Comparator|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
16527535|NCT03102788|Experimental|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
16527536|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
16527537|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
16527538|NCT03102762|Experimental|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
16527539|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:
~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
16527540|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
16527541|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
16527542|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
16527543|NCT03102736|Placebo Comparator|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
16527544|NCT03102736|Experimental|Nitroprusside and Ketamine|0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)
16527545|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
16527546|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
16527547|NCT03102710|Experimental|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
16527548|NCT03102710|Experimental|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
16527549|NCT03102710|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
16527726|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
16527550|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
16527551|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
16527552|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
16527553|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
16527554|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
16527555|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
16527556|NCT03102658|Experimental|Obese subjects 100mg|8 subjects with a BMI>40kg/m2 will receive 100mg Micafungin
16527557|NCT03102658|Active Comparator|Obese subjects 200mg|8 subjects with a BMI>40kg/m2 will receive 200mg Micafungin
16527558|NCT03102658|Active Comparator|non-obese subjects|8 non obese subjects with a BMI >18.5 and <25 kg/m2 will receive 100mg Micafungin
16527559|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
16527560|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
16527561|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
16527562|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
16527563|NCT03102606|Active Comparator|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|
16527564|NCT03102606|Experimental|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|
16527565|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
16527566|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
16527567|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
16527568|NCT03102580|Experimental|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
16527569|NCT03102580|No Intervention|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
16527570|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
16527571|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
16527572|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
16527573|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
16527574|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
16527575|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
16527576|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
16527577|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
16527578|NCT03102502|Experimental|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
16527579|NCT03102502|Active Comparator|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
16527580|NCT03102489|Experimental|BP101|Treatment with BP101
16527581|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
16527582|NCT03102476|Other|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
16527583|NCT03102463|Sham Comparator|Water Control|
16527584|NCT03102463|Active Comparator|Milk derived hydrolysate|
16527585|NCT03102463|Active Comparator|Parent Protein|
16527586|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
16527587|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
16527727|NCT03101410|Experimental|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
16527588|NCT03102424|Experimental|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
16527589|NCT03102424|Placebo Comparator|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
16527590|NCT03102398|Experimental|Single-arm and Open-label Study|
16527591|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
16527592|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
16527593|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
16527594|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
16527595|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
16527596|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
16527597|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
16527598|NCT03102359|No Intervention|Control|No intervention in this group
16527599|NCT03102346|Experimental|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
16527600|NCT03102346|No Intervention|routine group|no instructed exercise training
16527601|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
16527602|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
16527603|NCT03102320|Experimental|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.
~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
16527604|NCT03102320|Experimental|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
16527605|NCT03102320|Experimental|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
16527606|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
16527607|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
16527608|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
16527609|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
16527610|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
16527611|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
16527612|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
16527613|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
16527614|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
16527615|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
16527616|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
16527617|NCT03102242|Experimental|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.
~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions
~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.
~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
16527618|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks
~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
16527619|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
16527620|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
16527621|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
16527622|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
16527623|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
16527624|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
16527625|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
16527626|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
16527627|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
16527628|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
16527629|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
16527630|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
16527631|NCT03102190|Experimental|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
16527632|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
16527633|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
16527634|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
16527635|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
16527636|NCT03102125|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
16527637|NCT03102125|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
16527638|NCT03102125|Experimental|Cardiac allograft vasculopathy|Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
16527639|NCT03102125|Experimental|ACR/AMR|Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
16527640|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
16527641|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
16527642|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
16527643|NCT03102073||Radner test|reading speed evaluation
16527644|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
16527645|NCT03102047|Experimental|durvalumab|IV infusion once every 2 weeks for 4 total doses
16527646|NCT03102034|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
16527647|NCT03102034|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
16527648|NCT03102021|Active Comparator|1|erythropoeitin
16527649|NCT03102021|Placebo Comparator|2|saline placebo
16527728|NCT03101410|Experimental|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
16527650|NCT03102008|No Intervention|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
16527651|NCT03102008|No Intervention|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
16527652|NCT03102008|No Intervention|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
16527653|NCT03102008|Experimental|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
16527654|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
16527655|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
16527656|NCT03101982|No Intervention|control|ASIA score, blood taking
16527657|NCT03101956|Experimental|L/S Manipulation Study Group|
16527658|NCT03101956|Active Comparator|Control Group|
16527659|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
16527660|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
16527661|NCT03101930|Experimental|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
16527662|NCT03101930|Active Comparator|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
16527663|NCT03101930|Active Comparator|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
16527664|NCT03101917|Experimental|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
16527665|NCT03101917|Experimental|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
16527666|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).
~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
16527667|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).
~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
16527668|NCT03101891|Experimental|Serial amnioinfusions with isotonic fluid|Patients will undergo amnioinfusions with isotonic fluid every 2-12 days.. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at a RAFT center.
16527669|NCT03101891|No Intervention|Expectant|Patients will be observed serially by ultrasound, fetal echocardiogram and MRI. Standard postnatal care will occur at a RAFT center.
16527670|NCT03101878|Experimental|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
16527671|NCT03101878|Placebo Comparator|Placebo|Saline .9%
16527672|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
16527673|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
16527761|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
16527674|NCT03101852|Experimental|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: WHO recommends a Plumpy Nut® prescription of 75 to 100 kcal/kg/d in children aged 5 to 10 years and 60 to 90 kcal/kg/d above that age. The lowest value was used and maximum energy intake provided by RUF was limited to 2,000 kcal/d i.e. 4 sachets in order to preserve habitual diet and prevent appetite saturation
16527675|NCT03101852|Experimental|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 60kcal/kg/day, limited to 4 doses/day.
16527676|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
16527677|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
16527678|NCT03101800|Experimental|Azathioprine and Allopurinol|
16527679|NCT03101800|Active Comparator|Azathioprine|
16527680|NCT03101787|No Intervention|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).
~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.
~No special preparations for the trial are needed before the patient's arrival."
16527681|NCT03101787|Experimental|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).
~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).
~Time from arrest to start of cannulation is < 60 minutes."
16527682|NCT03101774|Experimental|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
16527683|NCT03101774|Experimental|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
16527684|NCT03101774|Sham Comparator|control group|not conduct inspiratory muscle training for 8 weeks
16527685|NCT03101748|Experimental|Group A (Cohort 1 Phase Ib)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
16527686|NCT03101748|Experimental|Group B (Cohort 1 Phase II)|Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
16527687|NCT03101748|Experimental|Group C (Cohort 2)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.
16527688|NCT03101722|Experimental|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day. BTHE：basic treatment and health education
16527689|NCT03101722|Sham Comparator|control|Participants in the BTHE group will receive advice regarding lifestyle modification, avoiding alcohol and cigarette consumption.
16527690|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
16527691|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
16527692|NCT03101670|Experimental|filgotinib|
16527693|NCT03101670|Placebo Comparator|placebo|
16527694|NCT03101644|Other|Darunavir|All patients treated with darunavir
16527695|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):
~Nutritional Assessment: Mini Nutritional Assessment (MNA)
~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.
~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)
~Psychological status: Geriatric Depression Scale (GDS)
~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)
~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)
~Age
~Haemoglobin
~Creatinine Clearance (CrCl)
~Presence of Geriatric Syndromes"
16527696|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
16527697|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
16527698|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
16527699|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
16527700|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
16527701|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
16527702|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
16527729|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
16528205|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
16527703|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
16527704|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
16527705|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
16527706|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
16527707|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
16527708|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
16527709|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks
~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks
~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks
~If there is continued benefit after 6 months, then:
~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
16527710|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab
~1 mg/kg IV on day 1 every 6 weeks
~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
16527711|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
16527712|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
16527713|NCT03101540|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
16527714|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
16527715|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
16527716|NCT03101488|Experimental|KN035|KN035 is to be injected subcutaneously 0.1mg/kg or 0.3mg/kg or 1mg/kg or 2.5mg/kg or 5mg/kg or 10mg/kg weekly until disease progresses or unacceptable tolerability occurs.
16527717|NCT03101475|Experimental|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
16527718|NCT03101462|Active Comparator|Group 1|One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0
16527719|NCT03101462|Active Comparator|Group 2|One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0
16527720|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
16527721|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
16527722|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
16527723|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)
~Washout 15 days
~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
16527724|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)
~Washout 15 days
~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
16527730|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
16527731|NCT03101397||stable group|not included in improved group or deteriorated group
16527732|NCT03101384||Patient with a diagnostic error|"Defined by one of :
~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician
~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.
~More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
16527733|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
16527734|NCT03101371|Active Comparator|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
16527735|NCT03101371|Experimental|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
16527736|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
16527737|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
16527738|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
16527739|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
16527740|NCT03101332|Experimental|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
16527741|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
16527742|NCT03101319|Placebo Comparator|Antipsychotic and B Complex|Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
16527743|NCT03101306|Experimental|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
16527744|NCT03101293|Experimental|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
16527745|NCT03101293|Experimental|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
16527746|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
16527747|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].
~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
16527748|NCT03101267|Experimental|ASP4070 4 mg|Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
16527749|NCT03101267|Experimental|ASP4070 1 mg|Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
16527750|NCT03101267|Placebo Comparator|Placebo|Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
16527751|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
16527754|NCT03101228|Experimental|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
16527755|NCT03101228|No Intervention|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
16527756|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
16527757|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
16527758|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
16527759|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
16527760|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
16527762|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
16527763|NCT03101176|Experimental|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
16527764|NCT03101163|Experimental|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
16527765|NCT03101163|Active Comparator|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
16527766|NCT03101150|Active Comparator|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
16527767|NCT03101150|Experimental|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
16527768|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
16527769|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
16527770|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
16527771|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
16527772|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
16527773|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
16527774|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.
~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.
~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
16527775|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.
~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.
~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
16527776|NCT03101098|Experimental|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
16527777|NCT03101098|Active Comparator|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
16527778|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
16527779|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
16527780|NCT03101072|Active Comparator|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
16527781|NCT03101072|Experimental|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
16527782|NCT03101072|Experimental|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
16527783|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
16527784|NCT03101046|Other|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.
~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
16527785|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having <5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
16527786|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
16527787|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
16527788|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
16527789|NCT03101020|Placebo Comparator|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
16527790|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
16527791|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
16527792|NCT03100994|No Intervention|Group A|without nerve block
16527793|NCT03100994|Active Comparator|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
16527794|NCT03100994|Active Comparator|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
16527795|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
16527796|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
16527797|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
16527836|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
16527798|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
16527799|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
16527800|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
16527801|NCT03100942|Experimental|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
16527802|NCT03100942|Experimental|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
16527803|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
16527804|NCT03100942|Placebo Comparator|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:
~filgotinib + lanraplenib placebo + tirabrutinib placebo
~lanraplenib + filgotinib placebo + tirabrutinib placebo
~tirabrutinib + filgotinib placebo + lanraplenib placebo"
16527805|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
16527806|NCT03100916|Experimental|Dose Ranging Arm|
16527807|NCT03100916|Experimental|Food Effect arm|
16527808|NCT03100903|Experimental|BI 655130|
16527809|NCT03100890|No Intervention|Control|Non-active comparator
16527810|NCT03100890|Active Comparator|Balance-Proprioception (Hospital)|Preoperative training (hospital)
16527811|NCT03100890|Experimental|Balance-Proprioception (Home)|Preoperative training (home)
16527812|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.
~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.
~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
16527813|NCT03100864|Experimental|Spesolimab|
16527814|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
16527815|NCT03100838|Experimental|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
16527816|NCT03100838|Active Comparator|Nifedipine (Brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
16527817|NCT03100838|Active Comparator|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
16527818|NCT03100838|Active Comparator|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
16527819|NCT03100825|Experimental|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
16527820|NCT03100812|Experimental|Group A|
16527821|NCT03100812|Experimental|Group B|
16527822|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
16527823|NCT03100786|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
16527824|NCT03100786|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
16527825|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
16527826|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
16527827|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
16527828|NCT03100747|Active Comparator|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
16527829|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
16527830|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
16527831|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
16527832|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
16527833|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
16527834|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
16527835|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
16552071|NCT02937051|Experimental|Cream-flavor Black&Mild cigar|
16527837|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
16527838|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
16527839|NCT03100656|Other|Anorexia nervosa I|Anorexia nervosa with BMI <=17.5 kg/m² or BMI >17.5 kg/m² with regular binge-purge episodes
16527840|NCT03100656|Other|Anorexia nervosa II|Anorexia nervosa with BMI > 18.5 kg/m² for at least 12 months.
16527841|NCT03100656|Other|Controls|Healthy control women
16527842|NCT03100630|Active Comparator|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
16527843|NCT03100630|Active Comparator|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
16527844|NCT03100630|Active Comparator|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
16527845|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
16527846|NCT03100604|Experimental|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
16527847|NCT03100604|Experimental|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
16527848|NCT03100591|Experimental|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
16527849|NCT03100578|Experimental|PLASTIC STENT|"Endoscopic double pigtail plastic stent, with formal indication on pancreatic collection, according to the instruction forms of the manufacturer.
~Interventions associated:
~EUS-guided transmural drainage of pancretic collection: PLASTIC STENT."
16527850|NCT03100578|Active Comparator|SELF EXPANDABLE METALLIC STENT|"Lumen apposing metal stent with formal indicaction on pancreatic collection, according to the manufacturer instruction forms.
~Interventions associated:
~EUS-guided transmural drainage of pancretic collection: METALLIC STENT."
16527851|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
16527852|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
16527853|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP >= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
16527854|NCT03100539|Experimental|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
16527855|NCT03100539|No Intervention|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
16527856|NCT03100526|Experimental|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
16527857|NCT03100526|No Intervention|Usual care|High-Risk patients receiving care in PACT.
16527858|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
16527859|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
16527860|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
16527861|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
16527862|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
16527863|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
16527864|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
16527865|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
16527866|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
16527867|NCT03100448|Other|On1 Concept|On1 Concept & NobelActive implants
16527868|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
16527869|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
16527870|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
16527871|NCT03100435|No Intervention|No Treatment|No treatment (control)
16527872|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
16527873|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
16527874|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
16527875|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
16527879|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
16527880|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
16527881|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
16527882|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
16527883|NCT03100331|Experimental|Single Arm; all receive neuropsychological testing & follow-up|
16527884|NCT03100318|Experimental|FYU-981|
16527885|NCT03100318|Active Comparator|Benzbromarone|
16527886|NCT03100305||Extremely preterm infants|
16527887|NCT03100305||Very preterm infants|
16527888|NCT03100305||Moderately preterm infants|
16527889|NCT03100305||Late preterm infants|
16527890|NCT03100292|Experimental|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).
~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
16527891|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
16527892|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
16527893|NCT03100266|Placebo Comparator|placebo|Inactive capsules
16527894|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
16527895|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR
~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
16527896|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
16527897|NCT03100240|No Intervention|control group|long protocol
16527898|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
16527899|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
16527900|NCT03100214|Active Comparator|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
16527901|NCT03100214|Experimental|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
16527902|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
16527903|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
16527904|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
16527905|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.
~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly
~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
16527906|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
16527907|NCT03100162|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 3 months.
16527908|NCT03100162|Active Comparator|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
16527909|NCT03100162|Active Comparator|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
16528068|NCT03099291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16527917|NCT03100136|Experimental|[11C]PF-06809247|A dose intravenous injection of [11C]PF-06809247 followed by PET scanning.
16527918|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
16527919|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
16527920|NCT03100110|Experimental|NeuroCognitive Communicator|
16527921|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
16527922|NCT03100097|No Intervention|Medical Management|Normal medical management
16527923|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.
~Blood sampling."
16527924|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).
~Blood sampling."
16527925|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.
~Blood sampling"
16527926|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
16527927|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.
~Blood sampling."
16527928|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.
~Blood sampling."
16527929|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
16527930|NCT03100058|Experimental|LIK066 2.5mg qd (Epoch 3)|LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
16527931|NCT03100058|Placebo Comparator|Placebo (Epoch 3)|Matching placebo tablets for 24 weeks
16527932|NCT03100058|Experimental|LIK066 10mg qd (Epoch 3)|LIK066 10mg qd (once daily) dosing frequency for 24 weeks
16527933|NCT03100058|Experimental|LIK066 50mg qd (Epoch 3)|LIK066 50mg qd (once daily) dosing frequency for 24 weeks
16527934|NCT03100058|Experimental|LIK066 150mg qd (Epoch 3)|LIK066 150mg qd (once daily) dosing frequency for 24 weeks
16527935|NCT03100058|Experimental|LIK066 2.5mg bid (Epoch 3)|LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
16527936|NCT03100058|Experimental|LIK066 5mg bid (Epoch 3)|LIK066 5mg bid (once daily) dosing frequency for 24 weeks
16527937|NCT03100058|Experimental|LIK066 25mg bid (Epoch 3)|LIK066 25mg bid (once daily) dosing frequency for 24 weeks
16527938|NCT03100058|Experimental|LIK066 50mg bid (Epoch 3)|LIK066 50mg bid dosing frequency for 24 weeks
16527939|NCT03100058|Experimental|LIK066 qd/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
16527940|NCT03100058|Experimental|LIK066 bid/LIK066 35mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
16527941|NCT03100058|Experimental|Placebo/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
16527942|NCT03100058|Placebo Comparator|Placebo/Placebo (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
16527943|NCT03100045|Experimental|ART 200 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 200 mg/day
16527944|NCT03100045|Experimental|ART 200 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 200 mg/day
16527945|NCT03100045|Experimental|ART 400 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 400 mg/day
16527946|NCT03100045|Experimental|ART 400 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 400 mg/day
16527947|NCT03100045|Experimental|ART 600 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 600 mg/day
16527948|NCT03100045|Experimental|ART 600 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 600 mg/day
16527949|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
16527950|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
16527951|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
16527952|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
16527953|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
16527954|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
16527955|NCT03100006|Experimental|Nivolumab and Oregovomab|
16527956|NCT03099993|Other|A: Healthy volunteers|
16527957|NCT03099993|Other|B: Patient with heamiplegia|
16527958|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
16527959|NCT03099980|Experimental|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
16528069|NCT03099278|Experimental|Ezetimibe|
16552072|NCT02937051|Experimental|Wine-flavor Black&Mild cigar|
16527960|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
16527961|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
16527962|NCT03099928||Qualitative Interviews|
16527963|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
16527964|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
16527965|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
16527966|NCT03099889|No Intervention|Control arm|Receive general health mailings
16527967|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
16527968|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
16527969|NCT03099863|Placebo Comparator|Standard Care|Standard cystoscopy with normal saline solution.
16527970|NCT03099863|Active Comparator|Neosporin G. U. Irrigant|Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
16527971|NCT03099850||Chronic Pancreatitis|
16527972|NCT03099837||Pregnant mothers|
16527973|NCT03099837||infants|
16527974|NCT03099837||children|
16527975|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (82mg)|
16527976|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (164mg)|
16527977|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (246mg)|
16527978|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-111 (175mg)|
16527979|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-112 (145mg)|
16527980|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-119 (233mg)|
16527981|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-125 (233mg)|
16527982|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
16527983|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
16527984|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
16527985|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
16527986|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
16527987|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
16527988|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
16527989|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
16527990|NCT03099772|Experimental|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
16527991|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
16527992|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
16527993|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
16527994|NCT03099746|Experimental|INVOLVE|"The first study condition, called Interactive Virtual Decision Support for End-of-Life and Palliative Care (INVOLVE) will consist of exposures to an avatar-based decision support technology that will be administered via tablet computer and allow SDMs opportunities to practice their communication and decision making skills through interactions with avatars that portray a decision coach and various healthcare providers."
16527995|NCT03099746|Experimental|Informational Support|The second condition, called Informational Support (IS), will also be administered via tablet computers and expose SDMs to educational resources of INVOLVE without the experiential components.
16527996|NCT03099746|Experimental|Usual Care|The third condition, usual care (UC), will expose SDMs to the routine communication and decisional support practices provided by the healthcare team.
16527997|NCT03099733|Experimental|concussion|patients who present to ED with concussion
16527998|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
16527999|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
16528000|NCT03099707|No Intervention|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
16528001|NCT03099707|Active Comparator|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
16529271|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
16528002|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
16528003|NCT03099694|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
16528004|NCT03099681||Epitheloid Sarcoma patients|Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
16528005|NCT03099668|Experimental|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
16528006|NCT03099668|No Intervention|Routine care|Routine care
16528007|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
16528008|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
16528009|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
16528010|NCT03099629|Experimental|IMT|inspiratory muscle training
16528011|NCT03099616|Active Comparator|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
16528012|NCT03099616|Active Comparator|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
16528013|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
16528014|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
16528015|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
16528016|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
16528017|NCT03099590|Experimental|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
16528018|NCT03099590|Placebo Comparator|Placebo Control|Matched dextran containing capsules will serve as placebo.
16528019|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
16528020|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
16528021|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
16528022|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
16528023|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
16528024|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
16528025|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
16528026|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
16528027|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
16528028|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
16528029|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
16528030|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
16528031|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
16528032|NCT03099512|Experimental|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
16528033|NCT03099512|Active Comparator|Ex Group|Individuals in this group who will perform exercises for knee only
16528034|NCT03099499|Experimental|ONC201 treatment Arm|
16528035|NCT03099486|Experimental|Regorafenib + 5FU/LV Treatment Arm|
16528036|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
16528037|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
16528038|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
16528039|NCT03099460|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
16528040|NCT03099460|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
16528070|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
16528041|NCT03099460|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
16528042|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
16528043|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
16528044|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
16528045|NCT03099434|Active Comparator|Live Donor Champion + Facebook App|The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
16528046|NCT03099434|Active Comparator|Facebook App|The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.
16528047|NCT03099434|No Intervention|Standard of Care|Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
16528048|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
16528049|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
16528050|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
16528051|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
16528052|NCT03099382|Experimental|SHR-1210|
16528053|NCT03099382|Active Comparator|Investigator's Choice Standard Therapy|Docetaxel or Irinotecan
16528054|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.
~Week 1: walk at least 3,000 steps every day.
~Week 2: walk at least 3,500 steps every day.
~Week 3: walk at least 4,000 steps every day.
~Week 4: walk at least 4,500 steps every day.
~Weeks 5-12: walk at least 5,000 steps every day."
16528055|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).
~Walk on a flat surface at a constant speed until there is mild to moderate pain
~Rest until the pain has completely ceased
~Resume walking at the same speed
~Increase the speed when you can walk 8 minutes without stopping for leg symptoms
~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
16528056|NCT03099356|Experimental|Cyclophosphamide and Sirolimus|Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
16528057|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
16528058|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
16528059|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
16528060|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
16528061|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
16528062|NCT03099304|Experimental|Ruxolitinib cream 1.5% twice daily (BID)|Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
16528063|NCT03099304|Experimental|Ruxolitinib cream 1.5% once daily (QD)|Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
16528064|NCT03099304|Experimental|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
16528065|NCT03099304|Experimental|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if < 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
16528066|NCT03099304|Placebo Comparator|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
16528067|NCT03099291|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the RSV D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
16528071|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.
~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:
~Parent-targeted BSweet2Babies video
~Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video
~BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units
~Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)
~Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
16528072|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
16528073|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
16528074|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
16528075|NCT03099226|Experimental|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.
~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.
~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.
~The patients were administered between 7:00 and 9:00 o'clock a.m"
16528076|NCT03099226|Experimental|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.
~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.
~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.
~The patients were administered between 7:00 and 9:00 o'clock a.m"
16528077|NCT03099226|Experimental|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.
~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.
~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.
~The patients were administered between 7:00 and 9:00 o'clock a.m"
16528078|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
16528079|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
16528080|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
16528081|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
16528082|NCT03099187|Experimental|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
16528083|NCT03099187|Experimental|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
16528092|NCT03099161|Experimental|Preladenant 25 mg Twice a Day (BID)|During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
16528093|NCT03099161|Experimental|Preladenant 50 mg BID|During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
16528134|NCT03098914||Beijing Haidian Hospital|
16528135|NCT03098914||Chinese PLA General Hospital|
16528094|NCT03099161|Experimental|Preladenant + Pembrolizumab|During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
16528095|NCT03099148|Experimental|LY3337641 (R-fasted)|A single dose of LY3337641 reference formulation (R) given orally with water after an overnight fast in one of four periods.
16528096|NCT03099148|Experimental|LY3337641 (T1-fasted)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
16528097|NCT03099148|Experimental|LY3337641 (T1-fed)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
16528098|NCT03099148|Experimental|LY3337641 (T2-fasted)|A single dose of LY3337641 test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
16528099|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
16528100|NCT03099122|Experimental|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.
~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
16528101|NCT03099109|Experimental|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
16528102|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
16528103|NCT03099109|Experimental|LY3321367 Dose Expansion|LY3321367 given IV.
16528104|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
16528105|NCT03099109|Experimental|Japanese Arm D LY3321367|LY3321367 given IV.
16528106|NCT03099109|Experimental|Japanese Arm E LY3300054|LY3300054 given IV.
16528107|NCT03099109|Experimental|Japanese Arm F LY3321367 + LY3300054|LY3321367 and LY3300054 given IV.
16528108|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
16528109|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
16528110|NCT03099070|No Intervention|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
16528111|NCT03099070|Experimental|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
16528112|NCT03099070|Experimental|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
16528113|NCT03099070|Experimental|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
16528114|NCT03099044|Active Comparator|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
16528115|NCT03099044|Active Comparator|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
16528116|NCT03099044|Placebo Comparator|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
16528117|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
16528118|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
16528119|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
16528120|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
16528121|NCT03098992|Active Comparator|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
16528122|NCT03098992|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
16528123|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
16528124|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
16528125|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
16528126|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
16528127|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
16528128|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
16528129|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
16528130|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
16528131|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
16528132|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
16528133|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
16528138|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.
~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
16528139|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.
~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
16528144|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
16528145|NCT03098849|No Intervention|Control Group|Standard care as usual
16528146|NCT03098836|Experimental|Caucasian|
16528147|NCT03098836|Experimental|African American|
16528148|NCT03098823|Experimental|RAYOS®|
16528149|NCT03098823|Active Comparator|IR prednisone|
16528150|NCT03098810|Placebo Comparator|Normal children|Placebo
16528151|NCT03098810|Experimental|Malnourished children|Oral zinc sulphate syrup
16528152|NCT03098797|Experimental|Experimental: Elamipretide|Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.
16528153|NCT03098797|Placebo Comparator|Placebo|Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.
16528154|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.
~Intervention: Exposure to aircraft exhaust"
16528155|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.
~Intervention: Non exposure to aircraft exhaust"
16528156|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
16528157|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
16528158|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
16528159|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
16528160|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
16528161|NCT03098732|Experimental|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
16528162|NCT03098732|Sham Comparator|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
16528163|NCT03098719|Experimental|Intervention|
16528164|NCT03098719|No Intervention|Control|
16528165|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
16528166|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
16528167|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
16528168|NCT03098680|Experimental|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.
~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
16528169|NCT03098680|Experimental|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.
~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
16528170|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
16528204|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
16528171|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
16528172|NCT03098654|Experimental|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:
~Community mobilization activities to inform community members of available services
~Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.
~HIV counseling and serial rapid HIV testing
~Blood glucose and blood pressure testing
~DM/HTN medications as needed
~Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
16528173|NCT03098654|No Intervention|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
16528174|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
16528175|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
16528176|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
16528177|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
16528178|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
16528179|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
16528180|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
16528181|NCT03098576||Matched|Matched targeted drug treatment
16528182|NCT03098576||Control|Unmatched standard of care
16528183|NCT03098563|Experimental|Arm 1|Blinded study medication. This is a within-subject study so all session procedures will be identical. The specific medications administered that study day will be the only change each session. Study days will last approximately 8 hours and will be conducted on an outpatient basis. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
16528184|NCT03098563|Experimental|Arm 2|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
16528185|NCT03098563|Experimental|Arm 3|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
16528186|NCT03098563|Experimental|Arm 4|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
16528187|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
16528188|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
16528189|NCT03098537|Active Comparator|Enteral nutrion only|
16528190|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
16528191|NCT03098524|Experimental|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
16528192|NCT03098524|Placebo Comparator|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
16528193|NCT03098511|Other|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
16528194|NCT03098498|Experimental|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
16528195|NCT03098498|Active Comparator|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
16528196|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
16528197|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
16528198|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
16528199|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
16528200|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
16528201|NCT03098446|Experimental|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
16528202|NCT03098446|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
16528203|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
16553963|NCT02924818|Experimental|Interstitial lung disease (ILD)|
16528206|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
16528207|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
16528208|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
16528209|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
16528210|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
16528211|NCT03098394|Experimental|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
16528212|NCT03098394|Active Comparator|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
16528213|NCT03098368|Active Comparator|Patient (active) group|"Rotigotine titration up to 16 mg/24 hr
~Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose
~Duration up to 12 weeks
~The treatment was titrated until optimal dosage
~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)
~(or patient can not tolerated the side effects such as dyskinesia)
~All previous dopaminergic medications were not allowed to adjusted during the study period."
16528214|NCT03098368|Placebo Comparator|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.
~Duration up to 12 weeks
~The treatment (placebo patch) was titrated until optimal dosage
~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)
~(or patient can not tolerated the side effects such as dyskinesia)
~All previous dopaminergic medications were not allowed to adjusted during the study period."
16528215|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
16528216|NCT03098342|Experimental|MB-PDT for Onychomycosis|
16528217|NCT03098342|Active Comparator|Amorolfine for Onychomycosis|
16528218|NCT03098329|Experimental|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
16528219|NCT03098316||POAG|Primary open angle glaucoma patients
16528220|NCT03098316||NTG|Normal/Low tension glaucoma patients
16528221|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
16528222|NCT03098290||Intermittent Claudication|Mild to severe claudication
16528223|NCT03098290||Ischaemic Rest Pain|
16528224|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
16528225|NCT03098277|Experimental|Observational (physical activity, accelerometer, PROs)|Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
16528226|NCT03098264|Experimental|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
16528227|NCT03098264|Active Comparator|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
16528228|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
16528229|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
16528230|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
16528231|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
16528232|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
16528233|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
16528234|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
16528235|NCT03098212|Experimental|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
16528236|NCT03098212|No Intervention|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
16528237|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
16528238|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
16528239|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
16528240|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
16528241|NCT03098186|Active Comparator|Intervention SMS|"SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.
~Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
16528242|NCT03098186|Placebo Comparator|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
16528243|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
16528244|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
16528245|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
16528246|NCT03098134|Experimental|VR-Video-Exposure|
16528247|NCT03098134|Active Comparator|Education-Video-|
16528248|NCT03098121|Experimental|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
16528249|NCT03098108|Experimental|CCPT|
16528250|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
16528251|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
16528252|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
16528253|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
16528254|NCT03098056|Experimental|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
16528255|NCT03098030|Experimental|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
16528256|NCT03098030|Active Comparator|Part 2: Irinotecan|Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
16528257|NCT03098030|Experimental|Part 2: Dinutuximab + Irinotecan|Dinutuximab (16 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
16528258|NCT03098030|Active Comparator|Part 2: Topotecan|Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.
16528259|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
16528260|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
16528261|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
16528262|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
16528263|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
16528264|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
16528265|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
16528266|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
16528267|NCT03097978|Experimental|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
16528268|NCT03097978|Experimental|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
16528269|NCT03097978|Experimental|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
16528270|NCT03097978|Experimental|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
16528271|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan
~Physical activity
~Cognitive behavioral program"
16528272|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan
~Physical activity
~Cognitive Behavioral Program
~Protein Shakes
~Phytosterols supplement
~Berberine supplement
~Anti-oxidant supplement
~Probiotic supplement
~Fish Oil supplement
~Multiple Vitamin/Multiple Mineral supplement"
16528273|NCT03097939|Experimental|Nivolumab and Ipilimumab|
16530269|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
16528274|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
16528275|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
16528276|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
16528277|NCT03097900|Active Comparator|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
16528278|NCT03097900|Placebo Comparator|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
16528279|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
16528280|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
16528281|NCT03097874|Experimental|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
16528282|NCT03097874|Experimental|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
16528283|NCT03097861|Active Comparator|Lubiprostone Capsule|Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
16528284|NCT03097861|Experimental|Lubiprostone Sprinkle|Lubiprostone 24 mcg sprinkle BID for 7 days.
16528285|NCT03097861|Placebo Comparator|Placebo|Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.
16528286|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
16528287|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
16528288|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
16528289|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
16528290|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
16528291|NCT03097796|Experimental|PUL-042|PUL-042 Inhalation Solution
16528292|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
16528293|NCT03097783|No Intervention|No intervention arm|No treatment
16528294|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
16528295|NCT03097757|No Intervention|(standard of care fracture reduction|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray.
16528296|NCT03097757|Experimental|ultrasound guided fracture reduction|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
16528297|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
16528298|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
16528299|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
16528300|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
16528301|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
16528302|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
16528303|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
16528304|NCT03097666|Other|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
16528305|NCT03097653|Experimental|Decision-aid|
16528306|NCT03097653|Active Comparator|Standard information|
16528307|NCT03097640|Experimental|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
16528308|NCT03097640|No Intervention|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
16528309|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
16528310|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
16553964|NCT02924818|Experimental|controls|
16528311|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
16528312|NCT03097588|Experimental|Supportive care (NEPA)|"Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.
~Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies"
16528313|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
16528314|NCT03097562|Experimental|CT1|"FLACS- Initial Wound parameters (CT1)
~Sample size calculation based on woundleak incidence estimated from preliminary results:
~For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.
~For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)
~A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
16528315|NCT03097562|Experimental|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.
~The traditional manual wound performed with a standard keratome wil be used as a reference."
16528316|NCT03097562|Active Comparator|MT control group|Standard manual technique (MT)
16528317|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
16528318|NCT03097549|Other|Tät®II Information app|"Information only.
~."
16528319|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
16528320|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
16528321|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:
~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed
~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)
~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
16528322|NCT03097510|Experimental|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
16528323|NCT03097510|No Intervention|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
16528324|NCT03097497|Experimental|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
16528325|NCT03097497|Active Comparator|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut
~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
16528326|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
16528327|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
16528328|NCT03097458|Experimental|Counselling|short-term counselling for families
16528329|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
16528330|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
16528331|NCT03097445|No Intervention|Control|No intervention control group
16528332|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.
16528333|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
16528334|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
16528335|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
16530270|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
16528336|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
16528337|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
16528338|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
16528339|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
16528340|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
16528341|NCT03097380|Experimental|AZD2115|
16528342|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
16528343|NCT03097380|Experimental|[11C]AZ13754366|
16528344|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
16528345|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
16528346|NCT03097341|Experimental|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
16528347|NCT03097341|Experimental|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
16528348|NCT03097341|Experimental|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
16528349|NCT03097341|Experimental|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
16528350|NCT03097341|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
16528351|NCT03097328|Experimental|TAK-228|"TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle
~Dosage will be determined by the study team"
16528352|NCT03097315|Experimental|4 mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
16528353|NCT03097289|Experimental|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
16528354|NCT03097276|Other|Patients who underwent open decompression surgery|
16528355|NCT03097263||Patients|Patients included for rehabilitation program
16528356|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
16528357|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
16528358|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
16528359|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
16528360|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
16528361|NCT03097224|No Intervention|Control group|Usual care
16528362|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
16528363|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
16528364|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
16528365|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
16528366|NCT03097198|Experimental|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
16528367|NCT03097198|Experimental|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
16528368|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx
~30 patients total"
16528369|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery
~10 x LAD 10 x RCA
~20 patients total"
16528370|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
16528371|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
16528372|NCT03097146|Other|comprehensive multidisciplinary stroke care|
16528373|NCT03097133|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
16528374|NCT03097133|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
16528375|NCT03097120|Active Comparator|unopposed estrogen|0.625 mg of conjugated equine estrogen
16530271|NCT03084276|Experimental|High-fat meal|
16528376|NCT03097120|Active Comparator|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
16528377|NCT03097120|Placebo Comparator|placebo|placebo
16528378|NCT03097107|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks
16528379|NCT03097107|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks
16528380|NCT03097107|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks
16528381|NCT03097107|Placebo Comparator|Placebo|Placebo tablet orally once a day for 12 weeks
16528382|NCT03097094|Active Comparator|Male dog|Male dog extract used for skin prick test and conjunctival provocation
16528383|NCT03097094|Active Comparator|Female dog|Female dog extract used for skin prick test and conjunctival provocation
16528384|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
16528385|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
16528386|NCT03097068|Experimental|0.3 mg Lucentis|Aqueous Humor sample post injection of 0.3 mg Lucentis
16528387|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
16528388|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
16528389|NCT03097042|Active Comparator|Study group|The catheter will be pulled back slowly and without rotation
16528390|NCT03097042|Active Comparator|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
16528391|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
16528392|NCT03097016|Experimental|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
16528393|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
16528394|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
16528395|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
16528396|NCT03096964|Experimental|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
16528397|NCT03096964|Experimental|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
16528398|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
16528399|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
16528400|NCT03096938|Placebo Comparator|Normal screening group|patients receive the routine screening examination
16528401|NCT03096938|Experimental|methylation markers screening group|patients receive the methylation markers screening
16528402|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
16528403|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
16528404|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
16528405|NCT03096886|Experimental|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy
~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
16528406|NCT03096886|Experimental|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy
~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.
~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
16528407|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison
~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
16528408|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
16528409|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
16528410|NCT03096860|Experimental|Alcohol consumption and hookah|
16528411|NCT03096860|Placebo Comparator|Placebo consumption and hookah|
16528412|NCT03096847|Experimental|ribociclib + letrozole cohort A|"ribociclib + letrozole cohort A - postmenopausal women, or men; naïve.
~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily."
16530272|NCT03084276|Active Comparator|Low-fat meal|
16528413|NCT03096847|Experimental|ribociclib + letrozole cohort B1|"ribociclib + letrozole cohort B1 - premenopausal women or perimenopausal women; naïve
~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.
~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
16528414|NCT03096847|Experimental|ribociclib + letrozole cohort B2|"ribociclib + letrozole cohort B2 - premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.
~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.
~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
16528415|NCT03096834|Placebo Comparator|Placebo|Matching placebo injection, subcutaneous
16528416|NCT03096834|Experimental|AMG 334|AMG 334 injection, subcutaneous
16528417|NCT03096821||ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
16528419|NCT03096795|Placebo Comparator|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
16528420|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
16528421|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
16528422|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
16528423|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
16528424|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
16528425|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
16528426|NCT03096795|Experimental|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
16528427|NCT03096795|Placebo Comparator|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
16528428|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
16528429|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
16528430|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
16528431|NCT03096795|Placebo Comparator|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
16528432|NCT03096795|Experimental|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
16528433|NCT03096782|Experimental|Group I (chemotherapy, TBI, cord blood)|"Patients receive rituximab IV on day -11, ATG IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1 hour, busulfan IV over 3 hours on days -7 through -4, and TBI on day -3. Patients then receive a cord blood transfusion IV on day 0.
~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
16528434|NCT03096782|Experimental|Group II (chemotherapy, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a cord blood transplant IV on day 0.
~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
16528435|NCT03096782|Experimental|Group III (chemotherapy, TBI, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.
~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
16528436|NCT03096769|Other|Study Arm|
16528437|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
16528438|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
16528439|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
16528440|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
16528441|NCT03096730|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
16528496|NCT03096314|Active Comparator|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
16528442|NCT03096730|Sham Comparator|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
16528443|NCT03096730|Active Comparator|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
16528444|NCT03096730|Active Comparator|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
16528445|NCT03096730|Active Comparator|Dexmedetomidine-Nalmefene|A dose of 0.1ug/kg nalmefene and a dose of 0.25ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
16528446|NCT03096704||slow transit time constipation|
16528447|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
16528448|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
16528449|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
16528450|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
16528451|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
16528452|NCT03096652|Active Comparator|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
16528453|NCT03096652|Active Comparator|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
16528454|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
16528455|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
16528456|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
16528457|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
16528458|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
16528459|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
16528460|NCT03096574||Pregnant women|"Over the age of 16
~Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust
~Able to read and write in English and give fully informed consent"
16528461|NCT03096574||Maternity healthcare professionals|"Over the age of 18
~Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust
~Able to read and write in English and give fully informed consent"
16528462|NCT03096574||UK General Practitioners|"Fully-qualified general practitioners practicing in the UK
~Able to read and write in English and give fully informed consent"
16528463|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
16528464|NCT03096548|Experimental|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
16528465|NCT03096548|Active Comparator|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
16528466|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
16528467|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
16528468|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
16528469|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
16528470|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
16528471|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
16528472|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
16528473|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
16528474|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
16528494|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
16528495|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
16528475|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.
~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
16528476|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
16528477|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
16528478|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
16528479|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
16528480|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
16528481|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
16528482|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
16528483|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
16528484|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
16528485|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.
~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
16528486|NCT03096392|Experimental|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
16528487|NCT03096392|Active Comparator|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
16528488|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
16528489|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
16528490|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
16528491|NCT03096353|Experimental|Naloxone, then Placebo|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again.
~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again."
16528492|NCT03096353|Experimental|Placebo, then Naloxone|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again.
~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again."
16528493|NCT03096340|Experimental|IT-141|
16530592|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
16528497|NCT03096314|Placebo Comparator|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
16528498|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
16528499|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).
~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.
~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
16528500|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
16528501|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
16528502|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
16528503|NCT03096275|Experimental|MMF+MTX+Glucocorticoids|Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
16528504|NCT03096275|Active Comparator|CYC/AZA+Glucocoticoids|Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
16528505|NCT03096262|Experimental|Stroke Patients|
16528506|NCT03096262|Active Comparator|Healthy Controls|
16528507|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
16528508|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
16528509|NCT03096223|Experimental|KHK4083|
16528510|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
16528511|NCT03096210|Other|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
16528512|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
16528513|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
16528514|NCT03096184|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
16528515|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
16528516|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
16528517|NCT03096158|Experimental|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
16528518|NCT03096158|Experimental|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
16528519|NCT03096158|Experimental|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
16528520|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
16528521|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
16528834|NCT03094078|Experimental|News without spin|News items reporting results of pre-clinical studies without spin
16528522|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
16528523|NCT03096093|Experimental|Immunotherapy - pancreatic cancer|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.
16528524|NCT03096093|Experimental|Immunotherapy - other late stage cancers|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.
16528525|NCT03096080|Experimental|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
16528526|NCT03096080|Experimental|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
16528527|NCT03096080|Experimental|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
16528528|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
16528529|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
16528530|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
16528531|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
16528532|NCT03096041|Experimental|Experimental arm|Auriculotherapy for analgesic use
16528533|NCT03096041|Placebo Comparator|Controle arm|Placebo auriculotherapy
16528534|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 & 28 weeks.
16528535|NCT03096015|Experimental|Intensive Treatment for Aphasia|
16528536|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
16528537|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
16528538|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
16528539|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
16528540|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
16528541|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
16528542|NCT03095950|Active Comparator|News with Spin|News items reporting results of RCTs with spin
16528543|NCT03095950|Experimental|News without spin|News items reporting results of RCTs without spin
16528544|NCT03095924|Active Comparator|News with Spin|News items reporting results of RCTs with spin
16528545|NCT03095924|Experimental|News without spin|News items reporting results of RCTs without spin
16528546|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
16528547|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
16528548|NCT03095898|Experimental|True Acupuncture|
16528549|NCT03095898|Sham Comparator|Sham Acupuncture|
16528550|NCT03095898|No Intervention|Control Group|
16528552|NCT03095872|Experimental|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
16528553|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
16528554|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
16528555|NCT03095846|Experimental|Winter Swimmers|Individualized cooling protocol
16528556|NCT03095846|Experimental|Not-winter Swimmers|Individualized cooling protocol
16528557|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
16528558|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
16528559|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
16528560|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.
~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
16528561|NCT03095807|Experimental|NNC9204-1706 A|
16528562|NCT03095807|Placebo Comparator|Placebo|
16528563|NCT03095794|Experimental|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
16528564|NCT03095781|Experimental|Treatment (pembrolizumab, XL888)|Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16528565|NCT03095768|Experimental|Intervention|Lifestyle Education and Cooking Demonstration
16528566|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
16528567|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
16528568|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
16528569|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
16528570|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
16528571|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
16528572|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
16528573|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
16528574|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
16528575|NCT03095690|Other|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
16528576|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
16528577|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
16528578|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
16528579|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
16528580|NCT03095651|Experimental|T1DM MK-5160 16 nmol/kg|Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528581|NCT03095651|Experimental|T1DM MK-5160 32 nmol/kg|Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528582|NCT03095651|Experimental|T1DM MK-5160 64 nmol/kg|Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528583|NCT03095651|Active Comparator|T1DM Glargine 0.4 U/kg|Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528584|NCT03095651|Experimental|T2DM MK-5160 16 nmol/kg|Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528585|NCT03095651|Experimental|T2DM MK-5160 32 nmol/kg|Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528586|NCT03095651|Experimental|T2DM MK-5160 64 nmol/kg|Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528587|NCT03095651|Active Comparator|T2DM Glargine 0.6 U/kg|Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
16528588|NCT03095638|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
16528589|NCT03095638|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
16528590|NCT03095638|Experimental|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
16528835|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
16528591|NCT03095638|Experimental|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
16528592|NCT03095638|Experimental|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
16528593|NCT03095638|Experimental|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
16528594|NCT03095638|Experimental|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
16528595|NCT03095638|Experimental|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
16528596|NCT03095612|Experimental|Selinexor in Combination with Docetaxel|Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 100, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks.
16528597|NCT03095599|Experimental|Vaccine|Received one dose of IVACFLU-S vaccine intramuscularly.
16528598|NCT03095599|Placebo Comparator|Placebo|Received one dose of placebo intramuscularly.
16528599|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
16528600|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
16528601|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
16528602|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
16528603|NCT03095560|Experimental|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
16528604|NCT03095560|Experimental|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
16528605|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
16528606|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
16528607|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
16528608|NCT03095547|Experimental|F901318|F901318 alone
16528609|NCT03095534|Experimental|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
16528610|NCT03095521|Experimental|Arm A|Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
16528611|NCT03095521|Active Comparator|Arm B|ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
16528612|NCT03095508|Experimental|Angal S (Arm A)|Patients received Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
16528613|NCT03095508|Active Comparator|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
16528614|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
16528615|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
16528616|NCT03095482|Active Comparator|Active tDCS + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 1.7 mA, followed by 30 minutes of in vivo exposure therapy.
16528673|NCT03095118|Experimental|Daratumumab|Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
16528836|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
16528617|NCT03095482|Sham Comparator|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
16528618|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
16528619|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
16528620|NCT03095456|Experimental|Revefenacin|Active Revefenacin and placebo (in place of Spiriva Handihaler®)
16528621|NCT03095456|Active Comparator|Spiriva Handihaler®|Active Spiriva Handihaler® and placebo (in place of Revefenacin)
16528622|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
16528623|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
16528624|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
16528625|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
16528626|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
16528627|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
16528628|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
16528629|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
16528630|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
16528631|NCT03095404|Experimental|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
16528632|NCT03095404|Experimental|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
16528633|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
16528634|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
16528635|NCT03095391||Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
16528636|NCT03095391||Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
16528637|NCT03095378|Active Comparator|Control|Root treatment with scaling and root planing.
16528638|NCT03095378|Experimental|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
16528639|NCT03095378|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
16528640|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
16528641|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
16528642|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
16528643|NCT03095352|Experimental|Arm A: Pembrolizumab + Carboplatin|Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
16528671|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
16528672|NCT03095131|Experimental|12-lead ECG|
16528709|NCT03094845|Placebo Comparator|Placebo|
16528644|NCT03095352|Experimental|Arm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only|Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16528645|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
16528646|NCT03095339|No Intervention|Control|The control group did not receive any intervention
16528647|NCT03095326|Experimental|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
16528648|NCT03095326|Placebo Comparator|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
16528649|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
16528650|NCT03095287|Experimental|Alphanate|Daily intravenous infusion of Alphanate 100 IU/kg/day
16528651|NCT03095274|Experimental|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.
~Weight-based dosing should be used for patients <30 kg: durvalumab 20 mg/kg."
16528652|NCT03095274|Experimental|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.
~Weight-based dosing should be used for patients <30 kg: tremelimumab 1 mg/kg Q4."
16528653|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
16528654|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
16528655|NCT03095248|Experimental|Stratum 1 - NF2 related vestibular schwannomas|Stratum 1 will include patients with NF2 with vestibular schwannomas who exhibit hearing loss. Participants will receive continuous twice daily dosing of selumetinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
16528656|NCT03095248|Experimental|Stratum 2: other NF2 related tumors (meningiomas and ependymom|Stratum 2 will include patients who have progressive lesions other than VS (including non-vestibular schwannomas, meningiomas, and spinal cord lesions). Participants will receive continuous twice daily dosing of selumentinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
16528657|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
16528658|NCT03095222|Active Comparator|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
16528659|NCT03095222|Active Comparator|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
16528660|NCT03095209||Standard of care concurrent chemo-radiation therapy|
16528661|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
16528662|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
16528663|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
16528664|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
16528665|NCT03095170|Experimental|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.
~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
16528666|NCT03095170|Experimental|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.
~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
16528667|NCT03095170|Active Comparator|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
16528668|NCT03095157|Placebo Comparator|Placebo|
16528669|NCT03095157|Experimental|Treatment|
16528670|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
16528710|NCT03094845|Experimental|hdmASIT+TM|
16528674|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.
~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
16528675|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.
~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
16528676|NCT03095092|Experimental|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
16528677|NCT03095092|Experimental|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
16528678|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
16528679|NCT03095066|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
16528680|NCT03095066|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
16528681|NCT03095053|Active Comparator|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
16528682|NCT03095053|No Intervention|Morphology group|morphological assessment of blastocyst by light microscope
16528683|NCT03095040|Experimental|CM082 combined with everolimus|
16528684|NCT03095040|Experimental|CM082|
16528685|NCT03095040|Active Comparator|Everolimus|
16528686|NCT03095027|Other|FID122819, then stenfilcon A|FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
16528687|NCT03095027|Other|Stenfilcon A, then FID122819|Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
16528688|NCT03095014|Experimental|Cesarean Myomectomy|Myomectomy plus Cesarean section
16528689|NCT03095014|Active Comparator|Cesarean section|Cesarean section only
16528690|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles
~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
16528691|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks
~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
16528692|NCT03094988|Other|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
16528693|NCT03094988|Experimental|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
16528694|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
16528695|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
16528696|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
16528697|NCT03094936|Other|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
16528698|NCT03094936|Active Comparator|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
16528699|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
16528700|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
16528701|NCT03094910|Other|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
16528702|NCT03094910|Other|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
16528703|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
16528704|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
16528705|NCT03094871|Experimental|Intervention group|FACE-PC comprises 3 weekly and 2 bi-weekly sessions (total 5 sessions), delivered by a bachelors' prepared nurse care manager (CM) over 8 weeks. Over the five sessions, the nurse care manager will (1) review the patient medical history and set health goals for depression and chronic condition with the dyad, (2) review all medication, the level of adherence, challenges and facilitating factors of adherence, (3) deliver brief behavioral activation therapy.
16528706|NCT03094871|No Intervention|Enhanced usual care group|Participants in this group will receive a typical primary care enhanced with reporting of their depression status and their goal for medical condition to their PCP for 8 weeks. Upon enrolment, a research nurse will review the patient medical history and identify goals for depression and a chronic condition with the dyad.
16528707|NCT03094858|Active Comparator|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
16528708|NCT03094858|Experimental|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
16528711|NCT03094832|Experimental|Part A: Miransertib PROS/PS|Participants with either PROS or PS receive miransertib orally at 15 mg/m^2 once daily (QD) for at least three 28-day cycles with an option to dose increase to 25 mg/m^2.
16528712|NCT03094832|Experimental|Part B: Miransertib PROS (Cohort 1)|Participants with PROS who have a measurable lesion by volumetric MRI receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
16528713|NCT03094832|Experimental|Part B: Miransertib PS (Cohort 2)|Participants with PS who have a measurable lesion by standardized digital photography receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
16528714|NCT03094832|Experimental|Part B: Miransertib PROS/PS (Cohort 3)|Participants with PROS or PS who do not meet all the eligibility criteria for Cohorts 1 or 2 receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
16528715|NCT03094832|Experimental|Part B: Miransertib Compassionate Use/Expanded Access (Cohort 4)|Participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access. Participants receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Participants receiving miransertib at the time of enrollment under Compassionate Use/Expanded Access will continue with their current dose (not to exceed 25 mg/m^2). Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
16528716|NCT03094819|No Intervention|Group 1|Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
16528717|NCT03094819|Experimental|Financial Incentive|Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
16528718|NCT03094819|Experimental|Retinal Care DR|Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
16528719|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
16528720|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
16528721|NCT03094793|Experimental|abnormal EEGs|
16528722|NCT03094780|Other|Quality of Life Counseling|
16528723|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
16528724|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
16528725|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
16528726|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
16528727|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
16528728|NCT03094715|Other|Best medical care|Best medical treatment
16528729|NCT03094689|No Intervention|Control group|
16528730|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
16528731|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
16528732|NCT03094676|No Intervention|Control|Only the HRV will be followed for two hours without intervention.
16528733|NCT03094676|Experimental|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
16528734|NCT03094676|Experimental|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
16528735|NCT03094676|Experimental|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
16528736|NCT03094676|Experimental|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
16528737|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)
~Injection prior to cementation
~bupivacaine 0.5% with epinephrine 30cc;
~methylprednisolone, 40 mg/ml, 1 ml
~cefazolin, 500 mg in 10 ml
~normal saline, 22cc
~Superficial injection prior to closure.
~20cc 0.25% bupivacaine
~2 mg IV dexamethasone."
16528738|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)
~Injection prior to cementation
~bupivacaine 0.25% with epinephrine 30cc;
~methylprednisolone, 40 mg/ml, 1 ml
~cefazolin, 500 mg in 10 ml
~normal saline, 22cc
~Superficial injection prior to closure.
~a. 20cc 0.25% bupivacaine
~Adductor canal block technique (supine position, post IV sedation)
~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
16528739|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
16555155|NCT02917252|Placebo Comparator|Placebo|Subjects drink saline
16528741|NCT03094624|Experimental|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
16528742|NCT03094624|Sham Comparator|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
16528743|NCT03094611|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
16528744|NCT03094598|No Intervention|Control|No intervention
16528745|NCT03094598|Experimental|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
16528746|NCT03094598|Experimental|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
16528747|NCT03094598|Experimental|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
16528748|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
16528749|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
16528750|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
16528751|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
16528752|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
16528753|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
16528754|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
16528755|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
16528756|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
16528757|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
16528758|NCT03094559|Experimental|FlowMet device|This is a feasibility study
16528759|NCT03094546|Experimental|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation): 750 mg wheat germ extract
16528760|NCT03094546|Placebo Comparator|Placebo|Intervention: Dietary Supplement Placebo: 750 mg cellulose
16528761|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
16528762|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
16528763|NCT03094520|Experimental|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
16528764|NCT03094520|Sham Comparator|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
16528765|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
16528766|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
16528767|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
16528768|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
16528769|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
16528770|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
16528771|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
16528772|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
16529022|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
16528773|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
16528774|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
16528775|NCT03094468|Experimental|P-3058|
16528776|NCT03094468|Placebo Comparator|Vehicle|
16528777|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
16528778|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
16528779|NCT03094442|Active Comparator|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.
~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
16528780|NCT03094442|Placebo Comparator|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
16528781|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
16528782|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
16528783|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
16528784|NCT03094416|Experimental|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
16528785|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
16528786|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
16528787|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
16528788|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
16528789|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
16528790|NCT03094364|Active Comparator|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.
~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
16528791|NCT03094364|Active Comparator|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.
~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
16528792|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
16528793|NCT03094351|Active Comparator|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
16528794|NCT03094325|Experimental|Septal myectomy|
16528795|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
16528796|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
16528797|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
16528798|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
16528799|NCT03094247|Active Comparator|Conventional RUTF (S-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
16528800|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
16528833|NCT03094078|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin
16528801|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
16528802|NCT03094234|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
16528803|NCT03094234|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
16528804|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
16528805|NCT03094208|Experimental|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
16528806|NCT03094208|Active Comparator|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
16528807|NCT03094195|Experimental|EMA401 25mg BID|Ema401 25 mg was administered orally twice a day
16528808|NCT03094195|Experimental|EMA401 100mg BID|Ema401 100 mg was administered orally twice a day
16528809|NCT03094195|Placebo Comparator|Placebo BID|Matching placebo capsules administered orally twice a day
16528810|NCT03094182|Experimental|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
16528811|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
16528812|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
16528813|NCT03094169|Experimental|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
16528814|NCT03094169|Experimental|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
16528815|NCT03094169|Experimental|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
16528816|NCT03094156|Experimental|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
16528817|NCT03094156|Experimental|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
16528818|NCT03094156|Experimental|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
16528819|NCT03094156|Experimental|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
16528820|NCT03094156|Experimental|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
16528821|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
16528822|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
16528823|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
16528824|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
16528825|NCT03094130|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
16528826|NCT03094130|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
16528827|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
16528828|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
16528829|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
16528830|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
16528831|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
16528832|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
16528837|NCT03094052|Experimental|Neratinib Monotherapy|Patients will receive up to 240mg neratinib once a day for up to 55 weeks on study. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity
16528838|NCT03094052|Experimental|Neratinib and Trastuzumab|Patients will receive up to 240mg orally while receiving standard of care maintenance adjuvant trastuzumab (duration of maintenance trastuzumab up to the treating physician) for up to 55 weeks . After the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib can continue as monotherapy to complete a maximum of 55 weeks. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity
16528839|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
16528840|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
16528841|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
16528842|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
16528843|NCT03094000|Experimental|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
16528844|NCT03094000|Active Comparator|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
16528845|NCT03093987|No Intervention|control group|usual care
16528846|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
16528847|NCT03093974|Experimental|treatment|Inhaled colistimethate sodium twice daily
16528848|NCT03093974|Placebo Comparator|Saline solution|inhaled placebo twice daily
16528849|NCT03093961|Experimental|Intervention|IASD Implantation
16528850|NCT03093948|Experimental|Remote Ischemic post-conditioning|
16528851|NCT03093948|No Intervention|standard of care|
16528852|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.
~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
16528853|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
16528854|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
16528855|NCT03093922|Experimental|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
16528856|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).
~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.
~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
16528857|NCT03093896|Placebo Comparator|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
16528858|NCT03093896|Active Comparator|almonds, 1.5 ounces|almonds, 1.5 ounces/day
16528859|NCT03093896|Active Comparator|almonds, 3 ounces|almonds, 3 ounces/day
16528860|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
16528861|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
16528862|NCT03093870|Experimental|Varlitinib and Capecitabine|
16528863|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
16528864|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.
~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
16528865|NCT03093831|Experimental|Ibrutinib|
16528866|NCT03093818|Experimental|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
16528867|NCT03093818|No Intervention|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
16528868|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
16528869|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
16528870|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
16528871|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
16528872|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
16528873|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
16528874|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
16528875|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
16528876|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
16528877|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
16528878|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
16528879|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
16528880|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
16528881|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
16528882|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
16528883|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
16528884|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
16528885|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
16528886|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
16528887|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
16528888|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
16528889|NCT03093740|Experimental|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
16528890|NCT03093740|Experimental|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
16528891|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
16528892|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
16528893|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
16528894|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
16528895|NCT03093701|Experimental|Group 1|TLC399 (ProDex) 0.36mg DSP with 100 mM PL
16528896|NCT03093701|Experimental|Group 2|TLC399 (ProDex) 0.6 mg DSP with 100 mM PL
16528897|NCT03093701|Experimental|Group 3|TLC399 (ProDex) 0.6 mg DSP with 50 mM PL
16528898|NCT03093701|Experimental|Group 4|TLC399 (ProDex) 0.84 mg DSP with 50 mM PL
16528899|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
16528900|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
16528901|NCT03093662|Experimental|Ventilation with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula.
16528902|NCT03093662|Active Comparator|Ventilation without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula.
16528903|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
16528904|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
16528905|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
16528906|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
16528907|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
16528908|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
16528909|NCT03093610|Active Comparator|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
16528910|NCT03093610|Active Comparator|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
16528911|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
16528912|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
16528913|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
16528914|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
16528915|NCT03093584|Active Comparator|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
16528916|NCT03093584|Experimental|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
16528917|NCT03093584|No Intervention|No intervention|No intervention, just observation and monitoring of outcome measures
16528918|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
16528919|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
16528920|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
16528921|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
16528922|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
16528923|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
16528924|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
16528925|NCT03093532|No Intervention|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
16528926|NCT03093532|Active Comparator|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:
~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
16528927|NCT03093532|Active Comparator|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
16528928|NCT03093519|Experimental|KHK6640|Intravenous administration
16528929|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
16528930|NCT03093506|Active Comparator|Low-dose rhEpo|RhEpo 60IU/kg/week
16528931|NCT03093506|Active Comparator|Micro-dose rhEpo|RhEpo 20IU/kg/week
16528932|NCT03093506|Placebo Comparator|Placebo Control|Saline
16528933|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
16528934|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
16528935|NCT03093480|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants were to receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who met the criteria for immune tolerance induction (ITI) success entered the tapering period and received rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up was for 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
16528936|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
16528937|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
16528938|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
16528939|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
16528940|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
16529100|NCT03092492||Unaffected Age-matched controls|Healthy age-matched controls
16528941|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
16528942|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
16528943|NCT03093428|Experimental|Radium-223|-Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
16528944|NCT03093428|Experimental|Pembrolizumab Plus Radium-223|"Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
~Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose"
16528945|NCT03093415|Active Comparator|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
16528946|NCT03093415|Active Comparator|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
16528947|NCT03093415|Other|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health & Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
16528948|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
16528949|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
16528950|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
16528951|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
16528952|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
16528953|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
16528954|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
16528955|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
16528956|NCT03093376|Experimental|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
16528957|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
16528958|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
16528959|NCT03093350|Experimental|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
16528960|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
16528961|NCT03093337|No Intervention|Control|No specific support.
16528962|NCT03093324|Experimental|ALKS 8700|Oral capsules, administered orally twice daily.
16528963|NCT03093324|Active Comparator|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
16528964|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
16528965|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
16528966|NCT03093298|Experimental|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
16528967|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
16528968|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily
~Docetaxel will be administered every 3 weeks intravenously
~Prednisone will be taken orally twice daily
~Leuprolide Acetate will be administered at the specification of the physician"
16528969|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
16528970|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
16528971|NCT03093246|Placebo Comparator|Control group|In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.
16528972|NCT03093246|Experimental|Test Group|In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
16528973|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)
~Association of hematoma evacuation surgery with clinical outcomes
~Associations of antithrombotic management with ischemic and hemorrhagic complications
~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
16528974|NCT03093220||community-acquired pneumonia|all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
16528975|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
16528976|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
16528977|NCT03093194|Active Comparator|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
16529134|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
16528978|NCT03093194|Placebo Comparator|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
16528979|NCT03093181|Placebo Comparator|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
16528980|NCT03093181|Experimental|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
16528981|NCT03093181|Active Comparator|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
16528982|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
16528983|NCT03093155|Active Comparator|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
16528984|NCT03093155|Experimental|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15
~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
16528985|NCT03093142|Experimental|tDCS & neurofeedback|30 minutes tDCS & 30 minutes neurofeedback
16528986|NCT03093142|Active Comparator|real neurofeedback|30 minutes real neurofeedback.
16528987|NCT03093142|Sham Comparator|sham neurofeedback|30 minutes sham neurofeedback.
16528988|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
16528989|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
16528990|NCT03093116|Experimental|Repotrectinib (TPX-0005)|"Phase 1
~Oral repotrectinib (TPX-0005):
~Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.
~Phase 2
~Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts
~EXP-1: ROS1 TKI-naïve ROS1+ NSCLC
~EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC
~EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)
~EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)
~EXP-5: TRK TKI-naïve NTRK+ solid tumors
~EXP-6: TRK TKI-pretreated NTRK+ solid tumors"
16528991|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
16528992|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
16528993|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
16528994|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
16528995|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
16528996|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
16528997|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
16528998|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
16528999|NCT03093064|Experimental|Patient Group: Natalizumab|Natalizumab 300mg, intravenous, once monthly, total of 3 doses
16529000|NCT03093064|Placebo Comparator|Patient Group: Placebo|Saline, intravenous, once monthly, total of 3 doses
16529001|NCT03093051|Experimental|UPT Treatment|Investigational therapy (UPT)
16529002|NCT03093038|Active Comparator|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem and the Delta-TT cup with polyethylene insert
16529003|NCT03093038|Experimental|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem and the Delta-TT cup with ceramic insert
16529004|NCT03093038|Experimental|C2 stem & Delta-TT cup + ceramic|C2 femoral stem and the Delta-TT cup with ceramic insert
16529005|NCT03093025|Experimental|TS-121 10mg|
16529006|NCT03093025|Experimental|TS-121 50mg|
16529007|NCT03093025|Placebo Comparator|Placebo|
16529008|NCT03092999|Experimental|Healthy subjects|healthy subjects
16529009|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
16529010|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
16529011|NCT03092986|Active Comparator|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
16529012|NCT03092986|Experimental|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
16529013|NCT03092973||Epistaxis Group|
16529014|NCT03092973||Control Group|
16529015|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
16529016|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
16529017|NCT03092934|Experimental|25 milligrams (mg) LY3295668 (Phase 1)|25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.
16529018|NCT03092934|Experimental|50 mg LY3295668 (Phase 1)|50 mg LY3295668 BID administered orally in 21-day cycles.
16529019|NCT03092934|Experimental|75 mg LY3295668 (Phase 1)|75 mg LY3295668 BID administered orally in 21-day cycles.
16529020|NCT03092934|Experimental|25 mg LY3295668 (Phase 2)|25 mg LY3295668 BID administered orally in 21-day cycles.
16529021|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
16529023|NCT03092908|Placebo Comparator|Control group|Administer 5 ml placebo (purified water) three times a day.
16529024|NCT03092908|Experimental|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
16529025|NCT03092895|Experimental|SHR-1210+Apatinib(Arm A）|
16529026|NCT03092895|Experimental|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
16529027|NCT03092882|Experimental|Intervention|Diabetes Self-Management Program
16529028|NCT03092882|No Intervention|Control|
16529029|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
16529030|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
16529031|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16529032|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16529033|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
16529034|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
16529035|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
16529036|NCT03092817|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
16529037|NCT03092817|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
16529038|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both
~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
16529039|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
16529040|NCT03092791|Experimental|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
16529041|NCT03092791|Placebo Comparator|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
16529042|NCT03092791|Experimental|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
16529043|NCT03092791|Active Comparator|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
16529044|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
16529045|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
16529046|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
16529047|NCT03092791|Active Comparator|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
16529048|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
16529049|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529050|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529051|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529052|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529053|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529054|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529055|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529056|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
16529057|NCT03092752||Patients with T2DM|
16529058|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
16529059|NCT03092726|Experimental|ASP8062|Participants received 30 mg of ASP8062 orally once daily for 8 weeks.
16529060|NCT03092726|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 8 weeks.
16529063|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
16529064|NCT03092687||substance disorders|decedents with and without substance use disorders
16529065|NCT03092674|Active Comparator|Arm A (azacitidine)|Patients receive azacitidine SC or IV daily on days 1-7 or on an interrupted schedule which ensures that all 7 days of therapy are received within a 12 day period. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16529066|NCT03092674|Experimental|Arm B (azacitidine, nivolumab)|Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16529067|NCT03092674|Experimental|Arm C (azacitidine, midostaurin)|Patients receive azacitidine as in Arm A and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16529068|NCT03092674|Experimental|Arm D (decitabine, cytarabine)|"INDUCTION: Patients receive decitabine IV over 2 hours on days 1-5 and cytarabine IV continuously on days 6-11. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients deemed stable at the discretion of the treating physician receive decitabine as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16529069|NCT03092648|Experimental|Bronchial basal cells|
16529070|NCT03092648|No Intervention|Control|
16529071|NCT03092635|Experimental|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
16529072|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
16529073|NCT03092609|Experimental|Attention Bias Modification|
16529074|NCT03092609|Active Comparator|Attention Control|
16529075|NCT03092596|Experimental|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
16529076|NCT03092596|Experimental|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
16529077|NCT03092596|Experimental|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
16529078|NCT03092596|No Intervention|Treatment as usual|Patients will receive standard care.
16529079|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
16529080|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
16529081|NCT03092570|Experimental|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
16529082|NCT03092570|Sham Comparator|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
16529083|NCT03092570|Experimental|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
16529084|NCT03092570|Sham Comparator|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
16529085|NCT03092570|Experimental|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
16529086|NCT03092570|Sham Comparator|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
16529087|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
16529088|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
16529089|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
16529090|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
16529091|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
16529092|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
16529093|NCT03092531|Experimental|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates >90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
16529094|NCT03092531|No Intervention|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
16529096|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
16529097|NCT03092492||Participants with bilateral early AMD|Participants with bilateral early AMD
16529098|NCT03092492||Participants with large RPD|Participants with large RPD
16529099|NCT03092492||Participants with small or medium-sized drusen|Participants with small or medium-sized reticular pseudodrusen (RPD)
16529101|NCT03092479|Experimental|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
16529102|NCT03092479|No Intervention|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
16529103|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
16529104|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
16529105|NCT03092453|Experimental|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
16529106|NCT03092440||"Nursing students group"|nursing students
16529107|NCT03092440||"New nurses group"|Nurses with < 2 years experience
16529108|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
16529109|NCT03092427|Experimental|Probiotic VSL#3|
16529110|NCT03092427|Placebo Comparator|Placebo|
16529111|NCT03092414|Experimental|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
16529112|NCT03092414|Experimental|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
16529113|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
16529114|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
16529115|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
16529116|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
~Additionally, during daytime a special test with random parts of the study group basic is performed:
~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
16529117|NCT03092375|Experimental|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
16529118|NCT03092375|Experimental|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
16529119|NCT03092375|Experimental|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
16529120|NCT03092375|Experimental|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
16529121|NCT03092336|Experimental|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:
~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
16529122|NCT03092336|Experimental|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
16529123|NCT03092323|Experimental|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
16529124|NCT03092323|No Intervention|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
16529125|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
16529127|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
16529128|NCT03092284|Placebo Comparator|Placebo|Saline
16529129|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
16529130|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
16529131|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
16529132|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
16529133|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
16529136|NCT03092219|Experimental|TEOSYAL RHA Redensity|Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
16529137|NCT03092219|No Intervention|No Treatment|No treatment control group (n=52).
16529138|NCT03092206|Experimental|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
16529139|NCT03092206|Experimental|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
16529140|NCT03092206|Experimental|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
16529141|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
16529142|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
16529143|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
16529144|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
16529145|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
16529146|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
16529147|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
16529148|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
16529149|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
16529150|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
16529151|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
16529152|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
16529153|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
16529154|NCT03092102|Experimental|A single dose HEC585（A1）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529155|NCT03092102|Experimental|A single dose HEC585（A2）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529156|NCT03092102|Experimental|A single dose HEC585/FE（A3）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule
~Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing"
16529157|NCT03092102|Experimental|A single dose HEC585（A4）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529158|NCT03092102|Experimental|A single dose HEC585（A5）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529159|NCT03092102|Experimental|A single dose HEC585（A6）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529160|NCT03092102|Experimental|A single dose HEC585（A7）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529161|NCT03092102|Experimental|A single dose HEC585（A8）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529162|NCT03092102|Experimental|Multiple doses HEC585（B1）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529163|NCT03092102|Experimental|Multiple doses HEC585（B2）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529164|NCT03092102|Experimental|Multiple doses HEC585（B3）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529165|NCT03092102|Experimental|Multiple doses HEC585（B4）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529166|NCT03092102|Experimental|Multiple doses HEC585（B5）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529167|NCT03092102|Experimental|Multiple doses HEC585（B6）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
16529168|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
16529169|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
16529170|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
16529171|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
16529172|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
16529173|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
16529174|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
16529175|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
16529176|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
16529177|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
16529178|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
16529179|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
16529180|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
16529181|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
16529182|NCT03092024|Experimental|SPIN-HAND program|
16529183|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
16529184|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
16529185|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
16529186|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
16529187|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
16529188|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:
~PersonalFit - Breast shield & Brownie - Breast shield
~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
16529189|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:
~Brownie - Breast shield & PersonalFit - Breast shield
~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
16529190|NCT03091972|Experimental|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
16529191|NCT03091972|Active Comparator|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
16529192|NCT03091946|Placebo Comparator|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
16529193|NCT03091946|Experimental|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
16529194|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
16529195|NCT03091920|Experimental|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
16529196|NCT03091920|Experimental|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
16529197|NCT03091920|Placebo Comparator|Placebo|On Days 1-14: Placebo taken in AM and in PM.
16529198|NCT03091907||Case|Children with a history of necrotizing enterocolitis
16529199|NCT03091907||control|Children with no history of necrotizing enterocolitis
16529200|NCT03091894|Active Comparator|propofol|patients will receive only propofol intravenous infusion for sedation
16529201|NCT03091894|Active Comparator|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
16529202|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
16529203|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
16529204|NCT03091868|Experimental|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
16529205|NCT03091868|Experimental|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
16529206|NCT03091868|Experimental|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
16529207|NCT03091868|Experimental|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
16529208|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
16529209|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
16529210|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
16529211|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
16529212|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
16529213|NCT03091816|Experimental|Diagnostic (DPCT)|Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.
16529214|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
16529215|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
16529216|NCT03091790|Active Comparator|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
16529217|NCT03091790|Active Comparator|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
16529218|NCT03091777|Experimental|Test Drug|GDC-229 gel applied vaginally as directed.
16529219|NCT03091777|Active Comparator|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
16529220|NCT03091777|Placebo Comparator|Vehicle Placebo Gel|GDC-229 Vehicle
16529221|NCT03091764||NMIBC Patient High Risk|"Any of the following:
~T1 tumours
~CIS (carcinoma in situ)
~Multiple and recurring and large (>3cm) Ta, G1, G2 tumours (all these conditions must be presented)
~(Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years)"
16529222|NCT03091764||NMIBC Patient Intermediate Risk|"All cases between High and Low Risk
~(Patients requiring intravesical therapy which lasts between 6 weeks to 3 years)"
16529223|NCT03091764||NMIBC Patient Low Risk|"Primary, solitary, Ta, LG/G1, <3cm, no CIS
~(Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy)"
16529224|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
16529225|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
16529226|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
16529227|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
16529228|NCT03091712|Experimental|Paper Titration Tool and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.
~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
16529229|NCT03091712|No Intervention|Paper Titration tool|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).
~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
16529230|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
16529231|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
16529232|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)
~HAPA SB Intervention Slideshow"
16529233|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)
~HAPA MVPA Intervention Slideshow"
16529234|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)
~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
16529235|NCT03091673|Experimental|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
16529236|NCT03091673|Experimental|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
16529272|NCT03091400|Experimental|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
16529237|NCT03091660|Active Comparator|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
16529238|NCT03091660|Experimental|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
16529239|NCT03091660|Experimental|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
16529240|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
16529241|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
16529242|NCT03091634|Experimental|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
16529243|NCT03091634|Placebo Comparator|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
16529244|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
16529245|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
16529246|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
16529247|NCT03091582|Experimental|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
16529248|NCT03091582|Experimental|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
16529249|NCT03091569|Active Comparator|Vitamin K|
16529250|NCT03091569|Placebo Comparator|Control|
16529251|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
16529252|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
16529253|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
16529254|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
16529255|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
16529256|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
16529257|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
16529258|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
16529259|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
16529260|NCT03091504|Experimental|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
16529261|NCT03091491|Experimental|Nivolumab|
16529262|NCT03091491|Experimental|Nivolumab and Ipilimumab|
16529263|NCT03091478|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
16529264|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
16529265|NCT03091439|Experimental|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
16529266|NCT03091439|Active Comparator|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
16529267|NCT03091426|Experimental|Omiganan 1%|
16529268|NCT03091426|Experimental|Omiganan 1.75%|
16529269|NCT03091426|Experimental|Omiganan 2.5%|
16529270|NCT03091426|Placebo Comparator|Vehicle|
16557496|NCT02900664|Experimental|PDR001+ EGF816 in CRC|
16529273|NCT03091400|Placebo Comparator|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
16529274|NCT03091374|Experimental|Growth Hormone|
16529275|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
16529276|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
16529277|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
16529278|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
16529279|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
16529280|NCT03091322||SR-T group|single chamber pacemaker
16529281|NCT03091322||DR-T group|dual chamber pacemaker
16529282|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
16529283|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
16529284|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
16529285|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
16529286|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
16529287|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
16529288|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
16529289|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
16529290|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS
~BRAF V600 mutated
~Treat cohort with Dabrafenib
~Analysis
~Treat cohort with Dabrafenib"
16529291|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS
~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated
~Treat cohort with Dabrafenib and Trametinib
~Analysis
~Treat cohort with Dabrafenib and Trametinib"
16529292|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS
~KRAS or NRAS mutated
~Treat cohort with Trametinib
~Analysis
~Treat cohort with Trametinib"
16529293|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
16529294|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
16529295|NCT03091192|Experimental|Savolitinib|See: intervention description
16529296|NCT03091192|Active Comparator|Sunitinib|See: intervention description
16529297|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
16529298|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
16529299|NCT03091166|Active Comparator|Dexmedetomidine|
16529300|NCT03091166|No Intervention|No Dexmedetomidine|
16529301|NCT03091153|No Intervention|Control|Standard care. Annual medication review
16529302|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
16529303|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
16529304|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
16529305|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
16529306|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
16529307|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
16529308|NCT03091088|Active Comparator|Control|walking at an intense pace
16529309|NCT03091088|Experimental|Experimental|osteoporosis specific-oriented training
16529310|NCT03091075|Experimental|Treatment Group|receiving oral Oxandrolone 24 mg (12mg tablets) per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
16529311|NCT03091075|Placebo Comparator|Placebo Group|receiving placebo medication (Placebo Oral Tablet), oral tablet, with dosing beginning at time of surgery and continuing for 12 weeks postoperative
16529312|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
16529313|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
16529314|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
16529315|NCT03091036|Other|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
16529316|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:
~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
16529317|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
16529318|NCT03091010|Experimental|Fecal Microbiota Transplantation|
16529319|NCT03091010|Active Comparator|Steroid|
16529320|NCT03090997|Placebo Comparator|Group 1|vitamin C (500 mg/day/orally) + placebo
16529321|NCT03090997|Placebo Comparator|Group 2|resveratrol (500 mg/day/orally) + placebo
16529322|NCT03090997|Active Comparator|Group 3|vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
16529323|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
16529324|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
16529325|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
16529326|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
16529327|NCT03090958|Experimental|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
16529328|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
16529329|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
16529330|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
16529331|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
16529332|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
16529333|NCT03090880|No Intervention|Control|usual care,
16529334|NCT03090880|Experimental|Experimental|tinzaparin sodium
16529335|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
16529336|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.
~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.
~All care are planned and perform under the supervision or/and in collaboration with a caregiver.
~Each care is written down on a collecting sheet."
16529337|NCT03090854||Alzheimer disease patients|
16529338|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
16529339|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
16529340|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
16529341|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
16529342|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
16529343|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
16529344|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
16529345|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
16529346|NCT03090802|Experimental|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
16529347|NCT03090802|No Intervention|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
16529349|NCT03090776|Other|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
16529350|NCT03090776|Other|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
16529351|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
16529352|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
16529353|NCT03090750|Experimental|Lavender|Lavender oil
16529354|NCT03090750|Experimental|Bergamot|Bergamot oil
16529355|NCT03090750|Placebo Comparator|Water|Water
16529356|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
16529357|NCT03090724|Experimental|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.
~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
16529358|NCT03090724|Experimental|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.
~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
16529359|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
16529360|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
16529361|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
16529362|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
16529363|NCT03090698|Active Comparator|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
16529364|NCT03090698|Active Comparator|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
16529365|NCT03090698|Active Comparator|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
16529366|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
16529367|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
16529368|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
16529369|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
16529370|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
16529371|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
16529372|NCT03090646|No Intervention|Standard of Care|Participants in the control arm will be instructed to attend required follow-up as is standard of care, but will not receive a financial incentive.
16529373|NCT03090646|Experimental|Financial Incentive|Up to three gift cards to a major online retailer will be mailed to participants assigned to the intervention arm after complete (i.e. all components addressed) and timely (i.e. within the policy-defined follow-up period) submission of follow-up data at each 6-month, 1-year, and 2-year follow-up visit.
16529374|NCT03090633|Experimental|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
16529375|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
16529376|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
16529377|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
16529378|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
16529379|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
16529380|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
16529381|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
16529382|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
16529383|NCT03090568|Experimental|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
16529384|NCT03090568|Experimental|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
16529418|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
16529419|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
16530634|NCT03082131|Experimental|Group 2|"Order of treatments:
~A. Regular Wheat B. Resistant Starch Wheat"
16529385|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.
~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
16529386|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
16529387|NCT03090542|No Intervention|Control|
16529388|NCT03090542|Active Comparator|Product|
16529389|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
16529390|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
16529391|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
16529392|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
16529393|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
16529394|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
16529395|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
16529396|NCT03090490|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
16529397|NCT03090490|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
16529398|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
16529399|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
16529400|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
16529401|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
16529402|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
16529403|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
16529404|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
16529405|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
16529406|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
16529407|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
16529408|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
16529409|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
16529410|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.
~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.
~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
16529411|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.
~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.
~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
16529412|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
16529413|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
16529414|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
16529415|NCT03090347|Experimental|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
16529416|NCT03090334|Experimental|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:
~antifungal therapy will be stopped immediately after the BG response in case of serum BG <80 pg/ml in presence of clinical stability (CS);
~antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG <80 pg/ml in patients without CS. In these cases, if the following BG value is <80 pg/ml antifungal therapy will be stopped independently from the CS achievement.
~antifungal therapy will be continued until day 10 for BG levels >200 pg/ml"
16529417|NCT03090334|No Intervention|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.
~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
16529420|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
16529421|NCT03090321|Placebo Comparator|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
16529422|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
16529423|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
16529424|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally
~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
16529425|NCT03090256|Experimental|PanOptix IOL|AcrySof® IQ PanOptix™ IOL, bilateral implantation
16529426|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
16529427|NCT03090230|Experimental|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
16529428|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
16529429|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
16529430|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
16529431|NCT03090191|Experimental|Clostridium difficile vaccine|
16529432|NCT03090191|Placebo Comparator|Placebo|
16529433|NCT03090178|Experimental|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:
~sleep diary
~Pruritus
~dermatology life quality index"
16529434|NCT03090178|Active Comparator|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:
~sleep diary
~Pruritus
~dermatology life quality index"
16529435|NCT03090165|Experimental|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.
~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.
~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.
~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients."
16529436|NCT03090152|Active Comparator|Periarticular Injection (PAI)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.
~Peri-articular injection in the operating room
~Combined Spinal Epidural with 1.5% Mepivacaine 4cc
~A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV
~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
16529437|NCT03090152|Active Comparator|Epidural Patient-Controlled Analg (EPCA)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.
~Combined Spinal Epidural with 1.5% Mepivacaine 4cc
~A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.
~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
16529438|NCT03090152|Experimental|PAI + EPCA|"Aspirin and nerve pain medications including duloxetine and clonidine
~Combined Spinal Epidural with 1.5% Mepivacaine 4cc
~Anesthetic, Antiemetic and peri-articular injection in the operating room
~A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.
~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
16529439|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
16529440|NCT03090126||Alveolar hypoventilation|
16529441|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
16529442|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
16529443|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
16529444|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
16529445|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
16529446|NCT03090074|Active Comparator|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
16529447|NCT03090074|Active Comparator|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
16529448|NCT03090074|Active Comparator|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
16529449|NCT03090074|Active Comparator|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
16529450|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
16529451|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
16529452|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
16529453|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
16529454|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
16529455|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
16529458|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
16529459|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
16529460|NCT03089996|Experimental|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
16529461|NCT03089996|Experimental|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
16529462|NCT03089996|Experimental|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
16529463|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
16529464|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
16529465|NCT03089983|Experimental|Buprenorphine/Naloxone|Participants who choose buprenorphine/naloxone will receive an induction phase for 10 days and then move on to receiving it in the community for 6 months. Buprenorphine/naloxone has been authorized and is available for use in Malaysia.
16529466|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
16529467|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
16529468|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
16529469|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
16529470|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
16529471|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
16529472|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
16529473|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
16529474|NCT03089918|Experimental|Part A (Healthy Adult Male Participants)|Participants will receive intravenous (IV) injection with 370 megabecquerel (MBq) 11C-JNJ-63779586 on Day 1 of Part A.
16529475|NCT03089918|Experimental|Part B (Mild AD and Healthy age- and Gender-Matched Controls)|Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
16529476|NCT03089905|Experimental|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.
~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.
~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
16529477|NCT03089905|Active Comparator|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
16529478|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
16529479|NCT03089879|Experimental|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
16529480|NCT03089879|Experimental|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
16529481|NCT03089879|Experimental|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
16529482|NCT03089866||ASA Patients I or II|Participants are healthy (BMI <35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
16529483|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
16529484|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
16529485|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
16529570|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
16529486|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
16529487|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
16529488|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
16529489|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
16529490|NCT03089788|Other|Home-based test and skin test|
16529491|NCT03089775|Experimental|BBI-2000|Cohort A
16529492|NCT03089775|Placebo Comparator|Vehicle|Cohort A
16529493|NCT03089775|Other|Multiple treatments|Cohort B
16529494|NCT03089762|Experimental|SVF and PRP|
16529495|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
16529496|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:
~At 24h from the time of CNS insult
~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult
~At 3, 6, and 12 months from the time of CNS insult
~Annually for the next four years Total of up to 16 blood draws.
~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:
~Age
~Sex
~History of prior CNS insult
~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients
~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.
~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
16529497|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:
~At 24h from the time of CNS insult
~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult
~At 3, 6, and 12 months from the time of CNS insult
~Annually for the next four years Total of up to 16 blood draws.
~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:
~Age
~Sex
~History of prior CNS insult
~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)
~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.
~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
16529498|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:
~At 24h from the time of CNS insult
~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult
~At 3, 6, and 12 months from the time of CNS insult
~Annually for the next four years Total of up to 16 blood draws.
~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:
~Age
~Sex
~History of prior CNS insult
~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.
~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.
~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
16529499|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
16529500|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
16529501|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.
~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
16529502|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.
~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
16529503|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.
~Applied colloid: hydroxyethyl starch"
16529504|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
16529505|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
16529506|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
16529673|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
16529507|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
16529508|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
16529509|NCT03089645|Experimental|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
16529510|NCT03089645|Experimental|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
16529511|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
16529512|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
16529513|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
16529514|NCT03089606|Other|C11-AMT PET|"Whole body FDG PET/CT scan with IV contrast will be performed at least 24 hours before C11-AMT PET scanning, as per standard of care.
~C11-AMT PET will be performed at least 24 hours before pembrolizumab treatment and at least 24 hours after FDG PET/CT scan.
~Pembrolizumab 200mg by IV flat dose will be administered over 30 minutes on Day 1; Pembrolizumab dosing will be repeated every 3 weeks until progression or subject withdrawal for other reasons.
~Whole body FDG PET/CT scan with IV contrast at end of treatment."
16529515|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
16529516|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
16529517|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
16529518|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
16529519|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
16529520|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
16529521|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
16529522|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
16529523|NCT03089541|Experimental|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
16529524|NCT03089528|Experimental|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
16529525|NCT03089528|Active Comparator|Direct laringoscopy|the trachea will be intubated using a laringoscope
16529526|NCT03089515|Active Comparator|Healthy Controls|
16529527|NCT03089515|Experimental|Survivors|
16529528|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
16529529|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
16529530|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
16529531|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
16529532|NCT03089476|Other|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
16529533|NCT03089476|Other|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
16529534|NCT03089463||Observation group|The entire participants in this study will be included in this group.
16529535|NCT03089450|Experimental|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
16529536|NCT03089450|Active Comparator|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
16529537|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
16529674|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
16529538|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
16529539|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
16529540|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
16529541|NCT03089398|Active Comparator|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
16529542|NCT03089398|Active Comparator|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
16529543|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
16529544|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
16529545|NCT03089372|Active Comparator|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
16529546|NCT03089372|Active Comparator|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
16529547|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
16529548|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
16529549|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
16529550|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
16529551|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy
~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
16529552|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
16529553|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
16529554|NCT03089294|Active Comparator|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
16529555|NCT03089294|Active Comparator|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
16529556|NCT03089294|Active Comparator|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
16529557|NCT03089294|Active Comparator|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
16529558|NCT03089281|Other|SmartDelay™ algorithm|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
16529559|NCT03089281|Other|Fixed AV Delay with BiV pacing|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
16529560|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.
~Polypectomy or biopsy will be performed if necessary (following current guidelines).
~Specific molecular analysis of serrated lesions and CRC will be carried out."
16529561|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
16529562|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
16529563|NCT03089216|Experimental|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
16529564|NCT03089216|Experimental|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
16529565|NCT03089216|Experimental|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
16529566|NCT03089216|Experimental|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
16529567|NCT03089203|Experimental|Cohort 1|CART T cells 1-3x10^7 Day 0
16529568|NCT03089203|Experimental|Cohort 2|Cart T cells 1-3x10^8 Day 0
16529569|NCT03089203|Experimental|Cohort -3|Cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day Day -3 CART T cells 1-3x10^7 Day 0
16529571|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
16529572|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
16529573|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
16529574|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
16529575|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
16529576|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
16529577|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
16529578|NCT03089138|Experimental|Regan Tangjiang，Simulation Shufengjiere Capsules|
16529579|NCT03089138|Active Comparator|Simulation Regan Tangjiang，Shufengjiere Capsules|
16529580|NCT03089138|Placebo Comparator|Simulation Regan Tangjiang and Shufengjiere Capsules|
16529581|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
16529582|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions
~Patients will receive:
~Psychoeducation
~Relaxation training for reducing physiological stress
~Behavioral techniques for managing acute breathlessness"
16529583|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
16529584|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
16529585|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
16529586|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
16529587|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
16529588|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
16529589|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
16529590|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
16529591|NCT03089060|Experimental|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
16529592|NCT03089060|Active Comparator|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
16529593|NCT03089047|Experimental|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
16529594|NCT03089047|Sham Comparator|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
16529595|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
16529596|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
16529597|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
16529598|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
16529599|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
16529600|NCT03088969||patient with a chronic back pain|
16529601|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
16529602|NCT03088956||Healthy|Healthy Participants (n=10)
16529603|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
16529604|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
16529605|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
16529606|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
16529607|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
16529608|NCT03088904|Experimental|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16529609|NCT03088904|Experimental|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
16529610|NCT03088904|Experimental|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
16529611|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
16529612|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
16529613|NCT03088878|Experimental|Part 1|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
16529614|NCT03088878|Experimental|Part 2|Cirmtuzumab plus ibrutinib
16529615|NCT03088878|Experimental|Part 3 - Arm A|Cirmtuzumab plus ibrutinib
16529616|NCT03088878|Active Comparator|Part 3 - Arm B|Ibrutinib only
16529617|NCT03088878|Active Comparator|Part 4|Cirmtuzumab plus ibrutinib
16529618|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
16529619|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
16529620|NCT03088852|Active Comparator|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
16529621|NCT03088852|No Intervention|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
16529622|NCT03088839||30 ALS patients|
16529623|NCT03088839||30 healthy controls|
16529624|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
16529625|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
16529626|NCT03088813|Experimental|Experimental Arm|Irinotecan liposome injection
16529627|NCT03088813|Active Comparator|Control Arm|Topotecan
16529628|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
16529629|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
16529630|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
16529631|NCT03088787||Patients for TAVR|Patients for TAVR
16529632|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
16529633|NCT03088774|Experimental|Patient Handbook|Public available information.
16529634|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.
~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
16529635|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
16529636|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
16529637|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
16529638|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
16529639|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
16529640|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
16529675|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
16529676|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
16529677|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
16529678|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
16557497|NCT02900664|Experimental|canakinumab in TNBC|
16529641|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.
~GVHD Prevention Treatment:
~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.
~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.
~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
16529642|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
16529643|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
16529644|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
16529645|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
16529646|NCT03088670|Experimental|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
16529647|NCT03088670|Active Comparator|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
16529648|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
16529649|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
16529650|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
16529651|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
16529652|NCT03088631|Active Comparator|Metformin group|
16529653|NCT03088631|Placebo Comparator|Placebo group|
16529654|NCT03088618|Experimental|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
16529655|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
16529656|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
16529657|NCT03088592|Other|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
16529658|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
16529659|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
16529660|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:
~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
16529661|NCT03088540|Experimental|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
16529662|NCT03088527|Experimental|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.
~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
16529663|NCT03088514|Experimental|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
16529664|NCT03088514|Placebo Comparator|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
16529665|NCT03088514|Experimental|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
16529666|NCT03088514|Placebo Comparator|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
16529667|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
16529668|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.
~Brief talk by health professionals.
~Role-plays"
16529669|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
16529670|NCT03088488||Periodontally healthy subjects|
16529671|NCT03088488||Chronic periodontitis patients|
16529672|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
16531115|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
16529679|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
16529680|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
16529681|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
16529682|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
16529683|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
16529684|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
16529685|NCT03088358|Experimental|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
16529686|NCT03088358|Experimental|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
16529687|NCT03088358|Experimental|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
16529688|NCT03088358|Active Comparator|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
16529689|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
16529690|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
16529691|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
16529692|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
16529693|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
16529694|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
16529695|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
16529696|NCT03088280|Experimental|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
16529697|NCT03088280|Active Comparator|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
16529698|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
16529699|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
16529700|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
16529701|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
16529702|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
16529703|NCT03088241|Experimental|Intervention|switch to second-line ART
16529704|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
16529705|NCT03088228||healthy pregnants|
16529706|NCT03088228||mild preeclampsia|
16529707|NCT03088228||severe preeclampsia|
16529708|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
16529709|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
16529710|NCT03088202|Experimental|Intervention arm|Educational program Standardized care pathways Early palliative care
16529711|NCT03088202|No Intervention|Control arm|Usual care
16529712|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
16529713|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
16529714|NCT03088189||Placebo|Mothers are receiving placebo
16529715|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.
~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
16529716|NCT03088163|Experimental|DWI-MRI|
16529717|NCT03088150|Active Comparator|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
16529718|NCT03088150|Experimental|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
16529719|NCT03088137|Experimental|Primapur (Follitropin alfa)|
16529720|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
16529721|NCT03088124|No Intervention|active surveillance|Active surveillance without androgen deprivation
16529722|NCT03088124|Experimental|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
16529791|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
16557498|NCT02900664|Experimental|canakinumab in NSCLC|
16529723|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.
~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
16529724|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
16529725|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
16529726|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
16529727|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
16529728|NCT03088072|Other|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
16529729|NCT03088059|Experimental|Patient Cohort B1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
16529730|NCT03088059|Experimental|Patient Cohort B2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
16529731|NCT03088059|Experimental|Patient Cohort B3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
16529732|NCT03088059|Experimental|Patient Cohort B4|Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
16529733|NCT03088059|Experimental|Patient Cohort B5|Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
16529734|NCT03088059|Experimental|Patient Cohort B6|Patients with FGFR1/2/3 mRNA overexpression will receive rogaratinib
16529735|NCT03088059|Experimental|Patient Cohort I1|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
16529736|NCT03088059|Experimental|Patient Cohort I2|Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
16529737|NCT03088046|Other|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
16529738|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
16529739|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
16529740|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
16529741|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
16529742|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
16529743|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance once during the study
16529744|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
16529745|NCT03087968|Experimental|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days
~HepQuant SHUNT Test"
16529746|NCT03087968|Placebo Comparator|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days
~HepQuant SHUNT Test"
16529747|NCT03087955|Experimental|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
16529748|NCT03087942|Experimental|Group 1|ESRD patients
16529749|NCT03087942|Experimental|Group 2|healthy volunteers
16529750|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
16529751|NCT03087942|Experimental|Group 4|mild renal impaired patients
16529752|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
16529753|NCT03087903|Experimental|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
16529754|NCT03087890|Active Comparator|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
16557499|NCT02900664|Experimental|canakinumab in CRC|
16529755|NCT03087890|Placebo Comparator|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
16529756|NCT03087877|Other|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
16529757|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
16529758|NCT03087851|Active Comparator|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.
16529759|NCT03087851|Active Comparator|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.
~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
16529760|NCT03087851|Active Comparator|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.
~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
16529761|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
16529762|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
16529763|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
16529764|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
16529765|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
16529766|NCT03087799|No Intervention|Wait List Control|
16529767|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
16529768|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
16529769|NCT03087773|Active Comparator|Empagliflozin|The subjects will receive Empagliflozin 10mg.
16529770|NCT03087773|Placebo Comparator|Placebo Oral Tablet|The subjects will receive placebo.
16529771|NCT03087760|Experimental|Single Arm|Single Arm, Open Label
16529772|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
16529773|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
16529774|NCT03087734|Active Comparator|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
16529775|NCT03087734|Experimental|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
16529776|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
16529777|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
16529778|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
16529779|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
16529780|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
16529781|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.
~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
16529782|NCT03087656|Active Comparator|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
16529783|NCT03087656|No Intervention|No Antibiotic arm|No prophylactic antibiotics will be administered.
16529784|NCT03087643|Experimental|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
16529785|NCT03087643|No Intervention|Control group - ctrl|Participants will receive ther standard therapies.
16529786|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
16529787|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
16529788|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
16529789|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
16529790|NCT03087617|Active Comparator|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
16529842|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
16557836|NCT02897882|Experimental|Lung transplant|Pain evaluation
16529792|NCT03087617|Active Comparator|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
16529793|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
16529794|NCT03087604|Active Comparator|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
16529795|NCT03087604|Experimental|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
16529796|NCT03087591|Experimental|Treatment (APN401)|Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity.
16529797|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
16529798|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
16529799|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.
~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
16529800|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
16529801|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
16529802|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
16529803|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
16529804|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
16529805|NCT03087513|Active Comparator|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
16529806|NCT03087513|Active Comparator|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
16529807|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
16529808|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
16529809|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
16529810|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
16529811|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
16529812|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
16529813|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
16529814|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
16529815|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.
~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.
~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
16529816|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
16529840|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
16531384|NCT03076970|Experimental|Combination of lasmiditan and sumatriptan|single oral tablet of each
16529817|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.
~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.
~PHASE II Cohort A (ALKi Naïve): those who have had no prior ALK inhibitor therapy (prior chemotherapy or immunotherapy is allowed). Aim 20 evaluable patients.
~Cohort B (Post-crizotinib PD): those who have received prior treatment with crizotinib and documented disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Aim 21 evaluable patients.
~Cohort C (PD on 2nd generation ALKi): those who have received prior treatment with 2nd generation ALKi (e.g. ceritinib, alectinib, loratinib, or brigatinib) and documented disease progression by RECIST 1.1 criteria. Aim 10 evaluable patients.
~The Phase II doses will be determined by Phase I dose escalation study"
16529818|NCT03087422|Experimental|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.
~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.
~Also, the patients allocated in this group will receive the standard care."
16529819|NCT03087422|No Intervention|control|The patients allocated in this group will receive the standard care.
16529820|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
16529821|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
16529822|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
16529823|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
16529824|NCT03087344|Experimental|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
16529825|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
16529826|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:
~3 sessions / week at least
~at least during 30 minutes each session
~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)
~during 3 months."
16529827|NCT03087318|Experimental|Private sport club|"Physical activity:
~3 sessions / week at least
~at least during 30 minutes each session
~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)
~during 3 months."
16529828|NCT03087318|Experimental|Sport association|"Physical activity:
~3 sessions / week at least
~at least during 30 minutes each session
~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)
~during 3 months."
16529829|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
16529830|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
16529831|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
16529832|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
16529833|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
16529834|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
16529835|NCT03087266|Experimental|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
16529836|NCT03087266|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
16529837|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
16529838|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
16529839|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
16529841|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
16560032|NCT02882230||patients non exposed to the drugs|
16529843|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
16529844|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
16529845|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
16529846|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
16529847|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
16529848|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
16529849|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
16529850|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
16529851|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
16529852|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
16529853|NCT03087110|Experimental|Cord blood infusion|Matched sibling donor cord blood cell infusion
16529854|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
16529855|NCT03087097|No Intervention|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
16529856|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
16529857|NCT03087071|Experimental|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
16529858|NCT03087071|Experimental|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16529859|NCT03087071|Experimental|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
16529860|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 - < 18 years
16529861|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 - < 12 years
16529862|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 - < 6 years
16529863|NCT03087032|Experimental|Liraglutide-bolus|'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
16529864|NCT03087032|Active Comparator|Basal-bolus|'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
16529865|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation
~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab
~Pembrolizumab will be administered on day 1 of each 21day cycle
~Pembrolizumab is delivered intravenously"
16529866|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle
~Pembrolizumab is delivered intravenously"
16529867|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
16529868|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
16529869|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
16529926|NCT03086551|Experimental|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
16561535|NCT02871583|No Intervention|control|healthy volunteers
16529870|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
16529871|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
16529872|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
16529873|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
16529874|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
16529875|NCT03086954|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
16529876|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
16529877|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
16529878|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
16529879|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
16529880|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
16529881|NCT03086902|Experimental|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
16529882|NCT03086902|Active Comparator|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
16529883|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
16529884|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
16529885|NCT03086876|Experimental|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
16529886|NCT03086876|No Intervention|Treatment as usual (TAU)|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:
~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.
~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
16529887|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally
~Needle insertion by 10-15 mm and de qi sensation
~Park sham guide tubes
~Low frequency electronic stimulation (30 Hz)
~Retention for 20 minutes."
16529888|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally
~Needle installation without penetration
~Park sham guide tubes
~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction
~Retention for 20 minutes."
16529889|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
16529890|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
16529891|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
16529892|NCT03086837|No Intervention|Control|No information
16529893|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
16529927|NCT03086551|Placebo Comparator|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
16529894|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
16529895|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
16529896|NCT03086798|Experimental|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
16529897|NCT03086798|Experimental|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
16529898|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
16529899|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
16529900|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
16529901|NCT03086759|Experimental|Platelet rich plasm group|
16529902|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
16529903|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
16529904|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
16529905|NCT03086720|Experimental|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
16529906|NCT03086720|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching
16529907|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.
~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
16529908|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.
~Subjects will not be allowed to smoke until discharge at Visit 3."
16529909|NCT03086694||group surgery|using medications to maintain low stable blood pressure
16529910|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
16529911|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
16529912|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
16529913|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
16529914|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
16529915|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
16529916|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
16529917|NCT03086629|Other|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
16529918|NCT03086629|Other|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
16529919|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
16529920|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
16529921|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
16529922|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
16529923|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
16529924|NCT03086564|Experimental|ADCC & TACE|"The first course :
~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2*10^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.
~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.
~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
16529925|NCT03086564|Active Comparator|TACE|"Every course:
~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.
~The 31th day is the same as the first day in the second course.
~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
16531385|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
16529928|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
16529929|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
16529930|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
16529931|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
16529932|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
16529933|NCT03086486|Experimental|1200mg L x 26 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
16529934|NCT03086486|Experimental|1200 mg L x 9 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
16529935|NCT03086486|Experimental|600 mg L x 26 weeks + Pa + B|"1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
16529936|NCT03086486|Experimental|600 mg L x 9 weeks + Pa + B|"1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
16529937|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
16529938|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
16529939|NCT03086460|Experimental|Treatment A|"Treatment A, CHF 1531 pMDI:
~CHF 1531 pMDI 6 μg total daily dose (TDD):
~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
16529940|NCT03086460|Experimental|Treatment B|"Treatment B, CHF 1531 pMDI:
~CHF 1531 pMDI 12 μg TDD:
~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
16529941|NCT03086460|Experimental|Treatment C|"Treatment C, CHF 1531 pMDI:
~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID."
16529942|NCT03086460|Experimental|Treatment D|"Treatment D, CHF 1531 pMDI
~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID."
16529943|NCT03086460|Experimental|Treatment E|"Treatment E, Matched placebo
~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID."
16529944|NCT03086460|Active Comparator|Treatment F|"Treatment F, Formoterol fumarate inhalation solution (IS)
~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID."
16529945|NCT03086447|Experimental|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
16529946|NCT03086447|Active Comparator|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
16529947|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
16529948|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
16529949|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
16529950|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
16529951|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
16531787|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
16529952|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
16529953|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
16529954|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
16529955|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
16529956|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given intravenously (IV).
16529957|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given IV.
16529958|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)|(Double Blind) Olaratumab, nab-paclitaxel and gemcitabine given IV.
16529959|NCT03086369|Placebo Comparator|Placebo + Nab-paclitaxel + Gemcitabine|(Double Blind) Placebo, nab-paclitaxel and gemcitabine given IV.
16529960|NCT03086356|Experimental|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
16529961|NCT03086343|Active Comparator|Abatacept|500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
16529962|NCT03086343|Experimental|Upadacitinib 15 mg|One 15 mg tablet taken once per day by mouth for 24 weeks
16529963|NCT03086330|Experimental|Semaglutide|
16529964|NCT03086330|Placebo Comparator|Placebo|
16529965|NCT03086317|Active Comparator|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
16529966|NCT03086317|Active Comparator|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
16529967|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
16529968|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
16529969|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
16529970|NCT03086278|Experimental|Single Ascending Dose|
16529971|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
16529972|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
16529973|NCT03086252|Experimental|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
16529974|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
16529975|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
16529976|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.
~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
16529977|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.
~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
16529978|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
16529979|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
16529980|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
16529981|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
16529982|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
16529983|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
16529984|NCT03086174|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
16531788|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
16529985|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
16529986|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
16529987|NCT03086148|Experimental|ketamine group|
16529988|NCT03086148|Placebo Comparator|normal saline group|
16529989|NCT03086135|Experimental|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
16529990|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
16529991|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
16529992|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
16529993|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
16529994|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
16529995|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
16529996|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
16529997|NCT03086057|Experimental|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
16529998|NCT03086057|Experimental|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
16529999|NCT03086057|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
16530000|NCT03086057|No Intervention|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
16530001|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 4 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily
~Participants who receive either heart or lung allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation."
16530002|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring
~Participants who receive either heart or lung allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
16530003|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
16530004|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
16530005|NCT03086018|Experimental|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
16530006|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
16530007|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
16530008|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
16530009|NCT03085979|Experimental|Burch|Burch Colposuspension
16530010|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
16530011|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
16530012|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
16530013|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
16530014|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
16530015|NCT03085940|Experimental|Hydroxychloroquine|
16530016|NCT03085940|Placebo Comparator|Placebo|
16530017|NCT03085927|Experimental|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
16530045|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
16530018|NCT03085927|Experimental|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
16530019|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
16530020|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
16530021|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
16530022|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
16530023|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
16530024|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
16530025|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
16530026|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
16530027|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
16530028|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
16530029|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio < 200.
16530030|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.
~Dose escalation phase: 6-12 patients
~MTD expansion cohort: 10 patients"
16530031|NCT03085836|Experimental|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
16530032|NCT03085836|Experimental|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
16530033|NCT03085836|Experimental|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
16530037|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
16530038|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
16530039|NCT03085784|Experimental|Loading Dose|"20 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.
~Treat & Extend Protocol entails patients being extended as long as:
~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND
~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.
~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
16530040|NCT03085784|Experimental|Treat and Extend|"20 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.
~Treat & Extend Protocol entails patients being extended as long as:
~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND
~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.
~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
16530041|NCT03085771|Active Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
16530042|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
16530043|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
16530044|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
16530046|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
16530047|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
16530048|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
16530049|NCT03085719|Experimental|High Dose Radiation + Pembrolizumab|"High dose radiation will be given in 3 fractions
~Pembrolizumab administered intravenously on day one of each cycle."
16530050|NCT03085719|Experimental|High Dose + Low Dose Radiation + Pembrolizumab|"High Dose radiation will be given in 3 fractions
~Low Dose Radiation will be given in 2 fractions
~Pembrolizumab administered intravenously on day one of each cycle."
16530051|NCT03085706|Experimental|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
16530052|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
16530053|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
16530054|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
16530055|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
16530056|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
16530057|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
16530058|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
16530059|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
16530060|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.
~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:
~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)
~High flow rate: 40-50 L/min without additional oxygen
~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)
~High flow rate: 40-50 L/min with FiO2 of 28%"
16530061|NCT03085628|Experimental|Oxytocin|Oxytoxin nasal spray
16530062|NCT03085628|Placebo Comparator|Placebo|Placebo nasal spray
16530063|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
16530064|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
16530065|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
16530066|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
16530067|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
16530068|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
16530069|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
16530070|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
16530071|NCT03085550|No Intervention|Control|Conventional dressings management
16530072|NCT03085550|Experimental|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
16530073|NCT03085550|Experimental|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
16530074|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
16530075|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
16530076|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:
~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
16530109|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
16561681|NCT02870543|Placebo Comparator|Placebo|Placebo
16530077|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:
~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
16530078|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
16530079|NCT03085485|Placebo Comparator|Placebo|matching placebo
16530080|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
16530081|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
16530082|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
16530083|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
16530084|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
16530085|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
16530086|NCT03085446|Experimental|PDM nutritional intervention|
16530087|NCT03085446|Experimental|control|General information on nutrition and health
16530088|NCT03085433|Experimental|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
16530089|NCT03085433|Active Comparator|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
16530090|NCT03085420|Experimental|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
16530091|NCT03085420|No Intervention|<30% TBSA burn injury|For patients in Group 2 with <30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
16530092|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
16530093|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
16530094|NCT03085394|Active Comparator|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
16530095|NCT03085394|Placebo Comparator|Control Arm|Preoperative intravenous administration of 10ml normal saline.
16530096|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
16530097|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
16530098|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
16530099|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
16530100|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
16530101|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
16530102|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
16530103|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
16530104|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
16530105|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
16530106|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
16530108|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
16530239|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
16530110|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
16530111|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
16530112|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
16530113|NCT03085277|Active Comparator|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
16530114|NCT03085277|Experimental|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
16530115|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
16530116|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
16530117|NCT03085251|Experimental|Blood glucose measurement|
16530118|NCT03085238|Experimental|M-Trap|
16530119|NCT03085225|Experimental|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.
~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
16530120|NCT03085212|Experimental|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
16530121|NCT03085212|Active Comparator|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
16530122|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
16530123|NCT03085173|Experimental|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
16530124|NCT03085160|Experimental|Learning to Breathe|Six-week mindfulness-based group program for adolescents
16530125|NCT03085160|Active Comparator|Health Education|Six-week health education group program for adolescents
16530126|NCT03085147|Experimental|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
16530127|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
16530128|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
16530129|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
16530130|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
16530131|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
16530132|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
16530133|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
16530134|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
16530135|NCT03085095|Experimental|Relugolix|Relugolix for 48 weeks
16530136|NCT03085095|Active Comparator|Leuprolide Acetate|Leuprolide acetate for 48 weeks
16530137|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
16530138|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
16530139|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
16530140|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
16530141|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
16530142|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
16530143|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
16530144|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
16530145|NCT03085043|Experimental|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
16530146|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
16530147|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
16530148|NCT03085017|Active Comparator|Ostene|Application of Ostene onto cut sternal site for hemostasis.
16530149|NCT03085017|Experimental|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
16530150|NCT03085004|Active Comparator|Control Group|Cyst will be lavaged for 3 to 5 minutes with 98% ethanol. Following lavage with 98% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
16530151|NCT03085004|Experimental|Study group|Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
16530152|NCT03084991||OCT group|1500 AMI patients with OCT imaging guidance during PCI
16530153|NCT03084991||CAG group|3000 AMI patients without OCT imaging guidance during PPCI
16530154|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
16530155|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
16530156|NCT03084952|Experimental|1 mg/day|
16530157|NCT03084952|Experimental|4 mg/day|
16530158|NCT03084952|Experimental|8 mg/day|
16530159|NCT03084952|Experimental|12 mg/day|
16530160|NCT03084952|Active Comparator|Glucantime|
16530161|NCT03084952|Experimental|Best dose 18-MC|
16530162|NCT03084952|Experimental|Minimum effective dose 18-MC|
16530163|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
16530164|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
16530165|NCT03084926|Experimental|MP0274|
16530166|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
16530167|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
16530168|NCT03084900|Experimental|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
16530169|NCT03084900|No Intervention|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
16530170|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
16530171|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
16530172|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
16530173|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
16530174|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
16530175|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:
~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic
~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
16530176|NCT03084848|Experimental|Active control|
16530177|NCT03084848|Experimental|Inhibitor control|
16530178|NCT03084835|Active Comparator|UC|Usual Care
16530179|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
16530180|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
16530267|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
16530181|NCT03084822|Experimental|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
16530182|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:
~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.
~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
16530183|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:
~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
16530184|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose [TDD] of CHF 5259 12.5 μg)
16530185|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
16530186|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
16530187|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
16530188|NCT03084796|Placebo Comparator|Treatment E|Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
16530189|NCT03084796|Active Comparator|Treatment F|Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
16530190|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
16530191|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
16530192|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
16530193|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
16530194|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
16530195|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
16530196|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
16530197|NCT03084731|Experimental|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
16530198|NCT03084731|Experimental|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
16530199|NCT03084731|Experimental|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
16530200|NCT03084731|No Intervention|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : >-1
16530201|NCT03084718|Experimental|Treatment A|CHF 718 pMDI Dose 1
16530202|NCT03084718|Experimental|Treatment B|CHF 718 pMDI Dose 2
16530203|NCT03084718|Experimental|Treatment C|CHF 718 pMDI Dose 3
16530204|NCT03084718|Placebo Comparator|Treatment D|Placebo Control, Placebos
16530205|NCT03084718|Active Comparator|Treatment E|Beclomethasone dipropionate HFA, 80µg (pMDI)
16530206|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
16530207|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
16530208|NCT03084692|Experimental|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
16530268|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
16562359|NCT02865967|Other|Block2_Control|Usual care
16530209|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
16530210|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
16530211|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
16530212|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
16530213|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
16530214|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
16530215|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
16530219|NCT03084627|No Intervention|Generic dietary advice for pregnancy|
16530220|NCT03084627|Experimental|Generic dietary advice for pregnancy + Tailored dietary advice|
16530221|NCT03084614||Controls|non exposed controls
16530222|NCT03084614||donors with naturally enriched antimicrobial blood samples and|Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.
16530223|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
16530224|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
16530225|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
16530226|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
16530227|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
16530228|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
16530229|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
16530230|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
16530231|NCT03084549|Experimental|Ropivacaïne|
16530232|NCT03084549|Placebo Comparator|Placebo|
16530233|NCT03084536|Active Comparator|Preoperative PECS blocks|"PECS I & II block will be administered preoperatively
~For unilateral surgeries, PECS I block will be performed bupivacaine. The PECS II block will be performed with the same solution. If there is a contralateral surgery (simple mastectomy) a PECS II block will also be performed on the other side.
~To ensure blind integrity, study drug syringes will be marked only study drug and subject number
~Perioperative analgesic will be encouraged.. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative area. All patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist"
16530234|NCT03084536|Placebo Comparator|Placebo PECS blocks|"A sham block (normal saline) will be placed preoperatively
~To ensure blind integrity, study drug syringes will be marked only study drug and subject number.
~Perioperative analgesic regimen will be encouraged. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative holding area. On the day of surgery all patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist."
16530237|NCT03084510|Experimental|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
16530238|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
16562360|NCT02865967|Experimental|Block3_Intervention|Usual care + a-GPS
16530240|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.
~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
16530241|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.
~Subjects in the control group didi not receive any dietary advice."
16530244|NCT03084458|No Intervention|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
16530245|NCT03084458|Experimental|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
16530246|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
16530247|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
16530248|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
16530249|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
16530250|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
16530251|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
16530252|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
16530253|NCT03084380|Experimental|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
16530254|NCT03084367||iFR post angiographically successful PCI|
16530255|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
16530256|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
16530257|NCT03084341|No Intervention|Control Group|No intervention
16530258|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
16530259|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
16530260|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
16530261|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
16530262|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
16530263|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
16530264|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
16530265|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
16530266|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
16530273|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
16530274|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
16530275|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
16530276|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
16530277|NCT03084237|Experimental|HLX02+docetaxel|
16530278|NCT03084237|Active Comparator|Herceptin®+docetaxel|
16530279|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
16530280|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
16530281|NCT03084198|Active Comparator|Control group|Standard care for ALF
16530282|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
16530283|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
16530284|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment). Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
16530285|NCT03084159|Experimental|Intervention Only|This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys. Some of these providers/staff were not involved in the initial design of the intervention.
16530286|NCT03084159|No Intervention|Usual Care|A second site included usual care, which did not include the intervention. Participants were given post visit surveys similar to those in the two other study / intervention arms. This site served as a usual care comparison.
16530287|NCT03084146|Experimental|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
16530288|NCT03084146|No Intervention|Healthy Control|Healthy Control patients will receive no intervention
16530289|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.
~Intervention 'Therapeutic Education Strategy'"
16530290|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
16530291|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
16530292|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
16530293|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
16530294|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
16530295|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
16530296|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
16530297|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
16530298|NCT03084094|Sham Comparator|Sham|sham stimulation
16530299|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
16530300|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
16530301|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
16530302|NCT03084068|Experimental|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
16530303|NCT03084068|Placebo Comparator|Placebo Control|Open Rotator Cuff Repair with standard suture repair
16530304|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
16530305|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
16530306|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
16530307|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
16530308|NCT03084042||Healthy controls|Demographically matched healthy controls.
16530309|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
16530310|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
16530311|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
16530312|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
16530313|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
16530314|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
16530315|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
16530316|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
16530317|NCT03083990|Experimental|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
16530318|NCT03083990|Active Comparator|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
16530319|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
16530320|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
16530321|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
16530322|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
16530323|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
16530324|NCT03083938|Experimental|Omental Roll-up|
16530325|NCT03083938|No Intervention|No Omental Roll-up|
16530326|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
16530327|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
16530328|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
16530329|NCT03083912||Fortimel Complete|All of the residents included receive ONS
16530330|NCT03083899|Experimental|Diatast|Free patient-initiated use of out-patient services
16530331|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
16530332|NCT03083886|Active Comparator|Usual PCP led care|
16530333|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
16530334|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
16530335|NCT03083873|Experimental|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
16530336|NCT03083873|Experimental|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
16530337|NCT03083873|Experimental|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
16530338|NCT03083873|Experimental|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
16530339|NCT03083873|Experimental|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
16530340|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
16530341|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
16530342|NCT03083847|Experimental|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 5x10^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
16530343|NCT03083847|Experimental|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
16530344|NCT03083847|Experimental|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
16530345|NCT03083847|Experimental|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
16530346|NCT03083847|Experimental|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
16530347|NCT03083847|Experimental|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
16530348|NCT03083847|Experimental|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
16530349|NCT03083847|Experimental|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
16562361|NCT02865967|Other|Block3_Control|Usual care
16530350|NCT03083847|Experimental|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
16530351|NCT03083847|Experimental|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
16530352|NCT03083834|Experimental|healthy subjects|low-dose cosyntropin stimulation test
16530353|NCT03083834|Experimental|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
16530354|NCT03083834|Experimental|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
16530355|NCT03083821|Experimental|Arm A|
16530356|NCT03083808|Experimental|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m^2 IV D1 and D8 every three weeks, docetaxel 75mg/m^2 IV D1 every three weeks, or pemetrexed 500mg/m^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
16530357|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.
~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.
~These participants will continue to receive BC Diabetes standard care."
16530358|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
16530359|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
16530360|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
16530361|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
16530362|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
16530363|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
16530364|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
16530365|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
16530366|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)
~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
16530367|NCT03083717||Patients with compensated heart failure|
16530368|NCT03083717||Patients with decompensated heart failure|
16530369|NCT03083717||Healthy subjects|
16530370|NCT03083704|Experimental|Cohort 1|
16530371|NCT03083704|Experimental|Cohort 2|
16530372|NCT03083704|Experimental|Cohort 3|
16530373|NCT03083704|Experimental|Cohort 4|
16530374|NCT03083704|Experimental|Cohort 5|
16530375|NCT03083704|Experimental|Cohort 6|
16530376|NCT03083704|Experimental|Cohort 7|
16530377|NCT03083704|Experimental|Cohort 8|
16530378|NCT03083704|Experimental|Cohort 9|
16530379|NCT03083704|Experimental|Cohort 10|
16530380|NCT03083704|Experimental|Cohort 11|
16530381|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
16530382|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
16530383|NCT03083678|Experimental|Afatinib|Afatinib active treatment.
16530416|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
16530417|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
16530387|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
16530388|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
16530389|NCT03083639|Experimental|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
16530390|NCT03083639|Experimental|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
16530391|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
16530392|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
16530393|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles
~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,
~Eery 3 weeks"
16530394|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
16530395|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
16530396|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
16530397|NCT03083600|Placebo Comparator|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
16530398|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
16530399|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
16530400|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
16530401|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
16530402|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
16530403|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
16530404|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of LY3337641 administered orally, with a two week follow-up period.
16530405|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally, with a two week follow-up period.
16530406|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of LY3337641 administered orally, with a two week follow-up period.
16530407|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
16530408|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
16530409|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
16530410|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
16530411|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
16530412|NCT03083522|Experimental|OJS group|admission to Ojeok-san granule
16530413|NCT03083522|Placebo Comparator|Placebo Group|admission to placebo
16530414|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
16530415|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
16530418|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
16530419|NCT03083483|Experimental|Bilateral M1, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the bilateral M1 areas of the brain by measurement of 20% length of periauricular distance left and right of the vertex. The anode was placed on the left side and the cathode was placed on the right side.
16530420|NCT03083483|Experimental|SMA, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the supplementary motor area. The cathode was placed 10% of nasion-inion distance above the nasion and 15% of nasion-inion distance anterior to the vertex.
16530421|NCT03083483|Sham Comparator|sham tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants in this group were either randomized into either Bilateral or SMA configurations using the same measurements, but did not receive active stimulation. Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
16530422|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
16530423|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
16530424|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
16530425|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
16530426|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
16530427|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
16530428|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
16530429|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
16530430|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
16530431|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
16530432|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
16530433|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg·d in 3-4 divided dosages) given for 4 10 weeks (depending on postmenstrual gestational age at birth)
16530434|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
16530435|NCT03083418|Experimental|Control group|No EDP treatment.
16530436|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
16530437|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
16530438|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
16530439|NCT03083405||Healthy controls|Patients without diagnosed SB.
16530440|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
16530441|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
16530442|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
16530443|NCT03083366|Experimental|Sacral neuromodulation|Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.
16530444|NCT03083366|No Intervention|Standard care|Patients will receive standard neurogenic bladder care.
16530445|NCT03083353|Experimental|isradipine|Participants will receive 15mg of immediate release isradipine.
16530446|NCT03083353|Placebo Comparator|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
16530447|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
16530448|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
16530449|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.
~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
16530450|NCT03083314|Experimental|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
16530451|NCT03083314|Active Comparator|COMPLETE AXILLARY DISSECTION (ALND)|
16530452|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
16530453|NCT03083288|Experimental|Single Arm|
16530454|NCT03083275|Experimental|Resistance Training|
16530457|NCT03083210|Experimental|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
16530458|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
16530459|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
16530460|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
16530461|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
16530462|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
16530463|NCT03083171|Placebo Comparator|Placebo|
16530464|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
16530465|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
16530466|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
16530467|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
16530468|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
16530469|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
16530470|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
16530473|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
16530474|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
16530475|NCT03083106|Other|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
16530476|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
16530477|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
16530478|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
16530479|NCT03083067|Experimental|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
16530480|NCT03083067|Active Comparator|Control(CT) group|CT group maintain the original treatment
16530481|NCT03083054|Experimental|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
16530482|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
16530483|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
16530484|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
16530485|NCT03083028|Active Comparator|Non Operative|"Non-Operative
~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
16530486|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
16530487|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
16530488|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
16530489|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
16530490|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
16530491|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
16530492|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
16530493|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
16530494|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
16530495|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
16530496|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
16530593|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
16530497|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
16530498|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
16530499|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).
~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.
~Each phone call will last approximately 5 minutes."
16530500|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
16530501|NCT03082898|Experimental|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
16530502|NCT03082898|Experimental|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
16530503|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
16530504|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
16530505|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
16530506|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
16530507|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
16530508|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
16530509|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
16530510|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
16530511|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
16530512|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
16530513|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
16530514|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
16530515|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
16530516|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
16530517|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
16530518|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
16530519|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
16530520|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
16530521|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
16530522|NCT03082755|Experimental|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
16530523|NCT03082755|Placebo Comparator|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
16530524|NCT03082742|Active Comparator|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
16530525|NCT03082742|Active Comparator|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
16530526|NCT03082729|Other|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
16530527|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
16530594|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
16533438|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
16530528|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
16530529|NCT03082703|Experimental|Text Messaging|
16530530|NCT03082703|No Intervention|Control|
16530531|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
16530532|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
16530533|NCT03082664|No Intervention|Standard dressing|Standard dressing will be applied after C-section.
16530534|NCT03082664|Experimental|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
16530535|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
16530536|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
16530537|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
16530538|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
16530539|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
16530540|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
16530541|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
16530542|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
16530543|NCT03082612|Experimental|Intervention plus usual care|Participants (patients and their family caregivers) in this study arm will receive the Overcoming Psychological Distress through Hymns Intervention.
16530544|NCT03082612|Active Comparator|Usual care|Immediately after randomization and completion of baseline measures, participants in this study arm will receive usual care. Patients and their family caregivers will receive the Overcoming Psychological Distress through Hymns Intervention after the 3 week period of usual care.
16530545|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
16530546|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
16530547|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
16530548|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
16530549|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
16530550|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
16530551|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
16530552|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
16530553|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.
~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.
~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
16530554|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.
~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.
~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
16530555|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
16530556|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
16530557|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
16530558|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
16530559|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
16562657|NCT02864069|Experimental|Cognitive Training Intervention|
16530560|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
16530561|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
16530562|NCT03082508|Experimental|Algisyl|Algisyl device (implants) administered during a surgical procedure.
16530563|NCT03082508|Active Comparator|Standard Medical Therapy|as per protocol
16530564|NCT03082495|Experimental|Exercise|Aerobic exercise
16530565|NCT03082495|No Intervention|Usual Care|Standard medical care
16530566|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
16530567|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
16530568|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
16530569|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
16530570|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
16530571|NCT03082443|Experimental|Therapeutic group|
16530572|NCT03082443|No Intervention|Control group|
16530573|NCT03082430|Other|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
16530574|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.
~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
16530575|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:
~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
16530576|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
16530577|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
16530578|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
16530579|NCT03082391|Active Comparator|Heavyweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavyweight mesh.
16530580|NCT03082391|Active Comparator|Mediumweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a mediumweight mesh.
16530581|NCT03082365||pre-dialysis|
16530582|NCT03082365||end stage renal disease|
16530583|NCT03082352|Experimental|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
16530584|NCT03082352|Active Comparator|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
16530585|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
16530586|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
16530587|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time with 1/3 single and 2/3 bilateral leg movements.
16530588|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
16530589|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
16530590|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
16530591|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
16530595|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
16530596|NCT03082261|Other|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite Implantable Pulse Generator (IPG).
16530597|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
16530598|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
16530599|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
16530600|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
16530601|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
16530602|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
16530603|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
16530604|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
16530605|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
16530606|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
16530607|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
16530608|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
16530609|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
16530610|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
16530611|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
16530612|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
16530613|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
16530614|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
16530615|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
16530624|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
16530625|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
16530626|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
16530627|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
16530628|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
16530629|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
16530630|NCT03082157|No Intervention|Comparison|Exercise-only small group sessions
16530631|NCT03082144|Active Comparator|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
16530632|NCT03082144|Experimental|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
16530633|NCT03082131|Experimental|Group 1|"Order of treatments:
~A. Resistant Starch Wheat B. Regular Wheat"
16530635|NCT03082118|Experimental|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
16530636|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
16530637|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
16530638|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
16530639|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
16530640|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
16530641|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
16530642|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
16530643|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
16530644|NCT03082066||Adults|Even or older 18 years
16530645|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
16530646|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
16530647|NCT03082040|Experimental|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
16530648|NCT03082040|Other|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
16530649|NCT03082027||ultrasonography|diagnostic tool
16530650|NCT03082027||operative release|
16530651|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
16530652|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
16530653|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
16530654|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.
~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
16530655|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.
~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.
~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
16530656|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer
~evaluation of disease status: endoscopy, CT, and/or PET-CT"
16530657|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer
~evaluation of disease status: endoscopy, CT, and/or PET-CT"
16530658|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
16530659|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
16530660|NCT03081962|Experimental|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
16530661|NCT03081962|Active Comparator|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
16530662|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
16530663|NCT03081949|No Intervention|Control|No treatment
16530664|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
16530665|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
16530666|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
16530667|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
16530668|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
16530692|NCT03081728|Experimental|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
16530693|NCT03081728|Experimental|control|IV analgesia only with diclofenac and paracetamol
16530730|NCT03081494|Experimental|spartalizumab (PDR001) + regorafenib|Subjects with metastatic MSS CRC received a combination of spartalizumab and regorafenib.
16530731|NCT03081481|Experimental|PRX302|intraprostatic administration
16531116|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
16530669|NCT03081910|Experimental|Autologous CD5.CAR/28zeta CAR T cells (Group A)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.
~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
16530670|NCT03081910|Experimental|Allogeneic CD5.CAR/28zeta CAR T cells (Group B)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.
~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
16530671|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
16530672|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
16530673|NCT03081884|Experimental|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
16530674|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
16530675|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
16530676|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
16530677|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
16530678|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.
~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
16530679|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
16530680|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
16530681|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
16530682|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
16530683|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
16530686|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
16530687|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
16530688|NCT03081780|Experimental|FATE NK-100|
16530689|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
16530690|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
16530691|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
16530694|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.
~A total of 1 to 10 x 10^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
16530695|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.
~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
16530696|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
16530697|NCT03081676|Active Comparator|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
16530698|NCT03081676|Active Comparator|Placebo + GIP|Placebo tablet + infusion of GIP
16530699|NCT03081676|Active Comparator|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
16530700|NCT03081676|Active Comparator|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
16530701|NCT03081676|Active Comparator|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
16530702|NCT03081676|Placebo Comparator|Placebo + Placebo|Placebo tablet + infusion of placebo (saline)
16530703|NCT03081663|Experimental|Quads-Sparing Approach with Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.
16530704|NCT03081663|Active Comparator|Medial Para-Patellar with Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
16530705|NCT03081663|Active Comparator|Quads-Sparing Approach w/o Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.
16530706|NCT03081663|Active Comparator|Medial Para-Patellar w/o Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
16530707|NCT03081650|Experimental|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.
~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
16530708|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
16530709|NCT03081624||Term Preschoolers|Term children who haven't attend school.
16530710|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
16530711|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
16530712|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
16530713|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
16530714|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
16530715|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
16530716|NCT03081585||Healthy Controls|Normal weight, healthy female participants
16530717|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
16530718|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
16530719|NCT03081559|Experimental|Intervention|Healthy Divas intervention
16530720|NCT03081559|No Intervention|Control|Treatment as usual
16530721|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.
~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
16530722|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
16530723|NCT03081533|Experimental|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
16530724|NCT03081533|No Intervention|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
16530725|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
16530726|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
16530727|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
16530728|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
16530729|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
16530820|NCT03080883|Experimental|Group II (higher dose apixaban)|Patients receive higher dose apixaban PO BID for 365 days.
16530732|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
16530733|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
16530734|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
16530735|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
16530736|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
16530737|NCT03081429||Perioperative covert stroke|
16530738|NCT03081429||Postoperative cognitive dysfunction|
16530739|NCT03081416|Experimental|Intranasal Ketamine arm|Intranasal ketamine administered to participant
16530740|NCT03081416|Active Comparator|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
16530741|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
16530742|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
16530743|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
16530744|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
16530745|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
16530746|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
16530747|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
16530748|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
16530749|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
16530750|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
16530751|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
16530752|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
16530753|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
16530754|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
16530755|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
16530756|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
16530757|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
16530758|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
16530759|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
16530760|NCT03081260|Other|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
16530761|NCT03081260|Other|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
16530762|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
16530763|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
16530764|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
16530765|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
16530766|NCT03081208|Experimental|Nolasiban 900 mg|
16530767|NCT03081208|Placebo Comparator|Placebo|
16530768|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:
~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
16530769|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:
~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
16530770|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)
~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
16530771|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
16530772|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
16530773|NCT03081156|Active Comparator|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
16530774|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
16530775|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
16530776|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
16530777|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
16530778|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
16530779|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
16530780|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
16530781|NCT03081104|Active Comparator|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
16530782|NCT03081104|Active Comparator|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
16530783|NCT03081104|Active Comparator|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
16530784|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
16530785|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.
~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
16530786|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
16530787|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
16531117|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
16530788|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
16530789|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
16530790|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
16530791|NCT03081065|No Intervention|Control|Usual care
16530792|NCT03081052|Active Comparator|Lung transplant with iNO|
16530793|NCT03081052|Active Comparator|Lung transplant with iEPO|
16530794|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
16530795|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
16530796|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
16530797|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
16530798|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.
16530799|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
16530800|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
16530801|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
16530802|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
16530803|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
16530804|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
16530805|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
16530806|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
16530807|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
16530808|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
16530809|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
16530810|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
16530811|NCT03080948||History of Melanoma (cases)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
16530812|NCT03080948||No Melanoma History (controls)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
16530813|NCT03080935|Experimental|Evolocumab|Single arm study administering Evolocumab.
16530814|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
16530815|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.
~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
16530816|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.
~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
16530817|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
16530818|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
16530819|NCT03080883|Experimental|Group I (lower dose apixaban)|Patients receive lower dose apixaban PO BID for 365 days.
16533439|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
16530821|NCT03080870|Experimental|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.
~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
16530822|NCT03080870|No Intervention|Control|Baseline and follow-up measurements.
16530823|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
16530824|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
16530825|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
16530826|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
16530827|NCT03080831|Active Comparator|Glucion 5%|
16530828|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
16530829|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
16530830|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
16530831|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
16530832|NCT03080792|Experimental|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
16530833|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
16530834|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
16530835|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.
~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.
~The drug will then be administrated intravenously.
~Dosage 20 mg/m2
~28-day course, for each course, receive decitabine for 10 days"
16530836|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
16530837|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
16530838|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
16530839|NCT03080714|Active Comparator|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
16530840|NCT03080714|Active Comparator|Subjects presenting with Retinal Disease|Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
16530841|NCT03080714|Active Comparator|Subjects presenting with Glaucoma|Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
16530842|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
16530843|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
16530844|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
16530845|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
16530846|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
16530847|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
16530848|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
16530849|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
16530850|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
16530851|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
16530852|NCT03080636|Experimental|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
16530853|NCT03080636|Experimental|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
16530892|NCT03080324|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
16530854|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
16530855|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
16530856|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
16530857|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
16530858|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
16530859|NCT03080558|Experimental|endometriosis recto vaginal node|
16530860|NCT03080545|Experimental|Open Label Enstilar|open label
16530861|NCT03080532||european population|
16530862|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
16530863|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
16530864|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
16530865|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
16530866|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo
~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
16530867|NCT03080480|Experimental|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
16530868|NCT03080467||Suture|Wound repair with suture
16530869|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
16530870|NCT03080454|Placebo Comparator|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
16530871|NCT03080454|Active Comparator|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
16530872|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
16530873|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
16530874|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
16530875|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
16530876|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
16530877|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
16530878|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
16530879|NCT03080415|Experimental|Combined Therapy SOF and DCV|
16530880|NCT03080402|Experimental|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
16530881|NCT03080402|No Intervention|Normal KAM|No intervention
16530882|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
16530883|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
16530884|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
16530885|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
16530886|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
16530887|NCT03080363|No Intervention|Group Control|No intervention
16530888|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
16530889|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
16530890|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
16530891|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
16530893|NCT03080324|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
16530894|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
16530895|NCT03080298|Experimental|Treatment with BP101|
16530896|NCT03080298|Placebo Comparator|Treatment with placebo|
16530897|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.
~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
16530898|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.
~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
16530899|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
16530900|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
16530901|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
16530902|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
16530903|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
16530904|NCT03080259|Active Comparator|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
16530905|NCT03080259|No Intervention|Treatment As Usual|Standard clinical care
16530906|NCT03080246|Active Comparator|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 2-3 days per week for about an hour each day. The investigators also have a site on High Point University's campus. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest and High Point University will go on for 9 months, followed by another 9 months of option to continue at facility, plus follow-up via email and 2 group meetings/runs at Fleet Feet (at around months 12 and 15).
16530907|NCT03080246|No Intervention|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings/runs at Fleet Feet (at around months 1, 3, 6, 12, and 15). After the 18 months, the participants will be offered a free 8-week strength training program at the Clinical Research Center or High Point University.
16530908|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital
~Consenting to participate in the study"
16530909|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
16530910|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
16530911|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
16530912|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
16530913|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
16530914|NCT03080207|Experimental|Low Level Laser|
16530915|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
16530916|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
16530917|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
16530918|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.
~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
16530919|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
16530920|NCT03080142|Experimental|Group 1|Single injection of Exparel
16530921|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
16530922|NCT03080129|Experimental|Cirrhosis + sarcopenia|Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
16530923|NCT03080129|No Intervention|Control|Patients with sarcopenia and no evidence of cirrhosis and healthy controls
16530924|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
16530925|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
16530926|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
16530927|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
16530928|NCT03080090|Experimental|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 60% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
16530929|NCT03080090|Active Comparator|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 20% to 40% of age-predicted HRmax.
16530930|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
16530931|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
16530932|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
16530933|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
16530934|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
16530935|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
16530936|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.
~It focuses on six essential key parts for the development of compassion:
~Developing attentional stability and clarity of the mind (Mindfulness)
~Cultivating insight into the nature of mental experience
~Cultivating self-compassion
~Developing impartiality
~Developing appreciation and affection for others
~Developing empathy and realizing engaged compassion"
16530937|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
16530940|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
16530941|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
16530942|NCT03079973|Experimental|P-3073|
16530943|NCT03079973|Placebo Comparator|Vehicle|
16531073|NCT03079024|No Intervention|Treatment as Usual (TAU)|Treatment as Usual
16530944|NCT03079960|Experimental|Original patient group (PG-O)|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.
~Cables and connectors of the macro electrodes will stay externalized for four days for cDBS adjustment procedures. During externalization, patients take part in test stimulation and recording sessions during which they perform short motor tasks.
~The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
16530945|NCT03079960|No Intervention|Chronic patient group (PG-chronic)|"Patients in this group will take part in one recording session at any desired point in time after they have been implanted with a DBS system as part of their clinical routine treatment. During this session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.
~Recordings are performed while applying different DBS strategies. The different DBS strategies are selected as a set of safe configurations as they are used in clinical routine. The behavioral tests performed for PG-chronic are the same as conducted for PG-O."
16530946|NCT03079960|No Intervention|Preoperative patient group (PG-pre)|"Patients in this group will take part in one recording session that will take place one week prior to implantation surgery at the earliest, i.e. between day -7 and day 0. Decision for DBS treatment has been made prior to inclusion into this study.
~During this recording session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.
~The behavioral tests performed for PG-pre are the same as conducted for PG-O."
16530947|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
16530948|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
16530949|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
16530950|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
16530951|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
16530952|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
16530953|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
16530954|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
16530955|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
16530956|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
16530957|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
16530958|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
16530959|NCT03079882||Living Donor Recipients|Recipients of renal transplants with the transplanted organ originating from living donors
16530960|NCT03079882||Deceased Donor Recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
16530961|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
16530962|NCT03079856|Experimental|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
16530963|NCT03079856|No Intervention|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
16530964|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
16530965|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
16530966|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
16530967|NCT03079830|Sham Comparator|Saline continous|Piritramid
16530968|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
16530969|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
16530970|NCT03079804|Experimental|Experimental MWM|"Other names:
~4 mobilizations - 10 seconds 20 seconds of rest"
16530971|NCT03079804|Active Comparator|Experimental Thrust|"Other names:
~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
16530972|NCT03079804|Placebo Comparator|Placebo|"Other names:
~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
16530973|NCT03079778|Active Comparator|TACE alone|Transarterial chemoembolization (TACE)
16530974|NCT03079778|Experimental|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
16530975|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
16530976|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
16530977|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
16530978|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
16530979|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
16530980|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
16530981|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
16530982|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
16530983|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
16530984|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
16530985|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
16530986|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
16530987|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
16530988|NCT03079648|Experimental|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
16530989|NCT03079648|Placebo Comparator|Placebo|Placebo for 12 weeks
16530990|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
16530991|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
16530992|NCT03079622|Active Comparator|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
16530993|NCT03079622|Active Comparator|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
16530994|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
16530995|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
16530996|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
16530997|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
16530998|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
16530999|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
16531000|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
16531001|NCT03079531|Experimental|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
16531002|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
16531003|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
16531004|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
16531005|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
16531006|NCT03079479||Two Years Group|
16531007|NCT03079479||Five Years Group|
16531008|NCT03079479||Ten Years Group|
16531009|NCT03079479||Control Group|
16531010|NCT03079466|Active Comparator|Treatment CPAP|A group treated with CPAP
16531011|NCT03079466|Sham Comparator|group without treatment|
16562658|NCT02864069|Experimental|Combined Intervention|
16531012|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
16531013|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
16531014|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
16531015|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
16531016|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
16531017|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
16531018|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.
~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
16531019|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
16531020|NCT03079388|Experimental|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
16531021|NCT03079388|Active Comparator|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
16531022|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
16531023|NCT03079375|Sham Comparator|basic intervention|Medication review
16531024|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
16531025|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
16531026|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
16531027|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
16531028|NCT03079336|Experimental|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
16531029|NCT03079336|Experimental|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
16531030|NCT03079323|Experimental|PART-trial|External beam radiotherapy
16531031|NCT03079310|Experimental|Spinal cord stimulation|Boston Scientific SCS system
16531032|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
16531033|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
16531034|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
16531035|NCT03079271|Other|open label|
16531036|NCT03079258|Experimental|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
16531037|NCT03079258|No Intervention|Control|Those randomized to the control group will continue with their standard care.
16531038|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
16531039|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
16531040|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
16531041|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
16531042|NCT03079232|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
16531043|NCT03079232|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
16531044|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
16531045|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
16531046|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
16531047|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
16531048|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
16531049|NCT03079180|Experimental|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years
~Training programs:
~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.
~Training exercises: A Warm-up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.
~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
16531050|NCT03079180|Experimental|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years
~The training program and training exercises in this group are the same as for the Aged & strength training at 80% 1RM arm except for the two following parameters.
~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).
~The subjects will perform 6 to 12 repetitions at 55% 1RM.
~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
16531051|NCT03079180|Experimental|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years
~The training program and training exercises in this group are the same as for the Aged & strength training at 55% 1RM arm"
16531052|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
16531053|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
16531054|NCT03079154|Experimental|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
16531055|NCT03079154|Active Comparator|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
16531056|NCT03079154|No Intervention|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
16531057|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.
~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
16531058|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.
~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
16531059|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
16531060|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
16531061|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
16531062|NCT03079102|Experimental|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
16531063|NCT03079102|Placebo Comparator|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
16531064|NCT03079089|Other|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
16531065|NCT03079076|Active Comparator|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
16531066|NCT03079076|Placebo Comparator|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
16531067|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
16531068|NCT03079063|Active Comparator|Novoseven|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
16531069|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
16531070|NCT03079037||Stimulation|Traditional deep brain stimulation
16531071|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
16531072|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
16531074|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
16531075|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
16531076|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
16531077|NCT03078998|Experimental|Juvenile idiopathic Arthritis|
16531078|NCT03078998|Experimental|Obstetric Brachial Plexus Palsy|
16531079|NCT03078998|Experimental|Cerebral Palsy|
16531080|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
16531084|NCT03078946|Active Comparator|Dexmedetomidine Group (N=30)|
16531085|NCT03078946|Active Comparator|Morphine with Midazolam (N=30)|
16531086|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
16531087|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
16531088|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
16531089|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
16531090|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
16531091|NCT03078920|Other|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
16531092|NCT03078907|Experimental|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
16531093|NCT03078907|Placebo Comparator|Placebo|Regimen and titration scheme similar to those in the selexipag group
16531094|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
16531095|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
16531096|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
16531097|NCT03078855|Experimental|Vitamin D plus rituximab|
16531098|NCT03078855|Placebo Comparator|Placebo plus rituximab|
16531099|NCT03078842|Active Comparator|Zinc-20|Zinc tablets, 20 mg per day
16531100|NCT03078842|Experimental|Zinc-10|Zinc tablets, 10 mg per day
16531101|NCT03078842|Experimental|Zinc-05|Zinc tablets, 5 mg per day
16531102|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
16531103|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:
~Activa PC Primary Cell Neurostimulator - (Model 37601)
~Activa RC Rechargeable Neurostimulator - (Model 37612)
~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)
~DBS Lead - (Model 3387)
~DBS Extension - (Models 37085/6)
~Patient Programmer - (Model 37642)
~Test Stimulator - (Model 3625)
~N'Vision Clinician Programmer - (Model 8840)
~N'Vision Software Application Card - (Model 8870)"
16531104|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
16531105|NCT03078803|Placebo Comparator|Placebo|Water
16531106|NCT03078790|Experimental|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
16531107|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
16531108|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
16531109|NCT03078764|Experimental|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
16531110|NCT03078764|Experimental|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
16531111|NCT03078751|Experimental|Ribociclib + adjuvant endocrine therapy (ET)|"Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy.
~ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)"
16531112|NCT03078751|Placebo Comparator|Placebo + adjuvant endocrine therapy (ET)|Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen
16531113|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
16531114|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
16531118|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
16531119|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
16531120|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
16531121|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
16531122|NCT03078712|Active Comparator|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
16531123|NCT03078712|Active Comparator|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
16531124|NCT03078699|Experimental|stereotactic body radiation therapy|
16531125|NCT03078686|Active Comparator|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
16531126|NCT03078686|Experimental|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
16531127|NCT03078686|Experimental|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
16531128|NCT03078686|Experimental|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
16531129|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
16531130|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
16531131|NCT03078673|Experimental|Control group|Only regular training
16531132|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
16531133|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
16531134|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
16531135|NCT03078634|Active Comparator|Multi-Disciplinary clinic|
16531136|NCT03078634|Placebo Comparator|Standard Gastrointestinal clinic|
16531137|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
16531138|NCT03078608|Experimental|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
16531139|NCT03078608|Active Comparator|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
16531140|NCT03078608|Other|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
16531141|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
16531142|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
16531143|NCT03078582|Experimental|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
16531144|NCT03078582|Experimental|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
16531145|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
16531146|NCT03078569|No Intervention|Control group|without testosterone treatment
16531147|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
16531148|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
16531149|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
16531150|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
16531151|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
16531152|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
16531153|NCT03078543|Other|ANTHEM™ PS Total Knee System implant|The ANTHEM™ PS Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
16531154|NCT03078530|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
16531155|NCT03078530|Experimental|Visbiome|Visbiome (probiotic mixture) is given to this group.
16531156|NCT03078530|Experimental|VSL #3|VSL #3 (probiotic mixture) is given to this group
16531157|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
16531158|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
16531159|NCT03078504|Experimental|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
16531160|NCT03078491|Experimental|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
16531161|NCT03078491|No Intervention|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
16531162|NCT03078478|Experimental|IDeg 200 U/mL|
16531163|NCT03078478|Active Comparator|IGlar 300 U/mL|
16531164|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
16531165|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
16531166|NCT03078452|Experimental|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
16531167|NCT03078452|Active Comparator|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
16531168|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
16531169|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
16531170|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
16531171|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
16531172|NCT03078400|Experimental|Safety Phase|"Six to 12 subjects
~Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles
~Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
16531173|NCT03078400|Experimental|Exploratory Expansion Phase|"Up to 12 subjects
~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
16531174|NCT03078374|Other|Reduced Anticoagulation|Reduced anticoagulation
16531175|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
16531176|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
16531177|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:
~Baseline
~6 month follow-up"
16531178|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:
~Baseline
~Post 6 month follow-up"
16531179|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
16531180|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
16531181|NCT03078322|Experimental|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
16531182|NCT03078322|Placebo Comparator|Placebo|Placebo
16531183|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
16531184|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
16531185|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
16531186|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
16531187|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
16531281|NCT03077659|Experimental|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
16531188|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
16531189|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
16531190|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
16531191|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
16531192|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
16531193|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
16531194|NCT03078218|No Intervention|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
16531195|NCT03078218|Experimental|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
16531196|NCT03078205|No Intervention|The control group|No Intervention
16531197|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
16531198|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
16531199|NCT03078192|Experimental|PVD, left heart disease, lung disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
16531200|NCT03078192|Experimental|Pulmonary Vascular Disease|92 subjects being evaluated for undergoing right heart catheterization for evaluation of PAH or other cardiac or pulmonary disease for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
16531201|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:
~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
16531202|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
16531203|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
16531204|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
16531205|NCT03078153|No Intervention|Control|No intervention
16531206|NCT03078140|Active Comparator|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
16531207|NCT03078140|Active Comparator|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
16531208|NCT03078127|Active Comparator|Sequence A|"In this arm, the interventions were performed in the following order:
~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
16531209|NCT03078127|Active Comparator|Sequence B|"In this arm, the interventions were performed in the following order:
~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
16531210|NCT03078127|Active Comparator|Sequence C|"In this arm, the interventions were performed in the following order:
~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
16531211|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
16531212|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
16531213|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
16531214|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
16531215|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
16531216|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
16531217|NCT03078088|Placebo Comparator|saline|normal saline
16531218|NCT03078088|Experimental|treatment|tham
16531219|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
16531220|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
16531221|NCT03078062|Active Comparator|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
16531222|NCT03078062|Placebo Comparator|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
16531223|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
16531224|NCT03078049||Sitagliptin|Patients take sitagliptin
16531342|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
16531225|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
16531226|NCT03078023|Experimental|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) > than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, >15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
16531227|NCT03078010|Active Comparator|Piperacillin-tazobactam|
16531228|NCT03078010|Experimental|cefepime|
16531229|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
16531230|NCT03077984|Experimental|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
16531231|NCT03077984|No Intervention|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
16531232|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
16531233|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
16531234|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
16531235|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
16531236|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
16531237|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.
~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
16531238|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
16531239|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
16531240|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.
~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
16531241|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.
~Patients who developped gastroœsophageal reflux de novo."
16531242|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
16531243|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
16531244|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
16531245|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
16531246|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
16531247|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
16531248|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
16531249|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
16531250|NCT03077854|Experimental|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy
~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
16531251|NCT03077854|Active Comparator|Standard-TRT|"Standard Thoracic Radiotherapy
~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
16531252|NCT03077841|Experimental|Arm I (hypofractionated partial breast irradiation)|Patients undergo hypofractionated partial breast irradiation daily for 10 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
16531253|NCT03077841|Active Comparator|Arm II (hypofractionated partial breast irradiation)|Patients undergo standard breast irradiation daily for 15 days. Patients may then receive 5 additional boost fractions at the discretion of the doctor.
16531254|NCT03077828|Experimental|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
16531255|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
16531256|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
16531257|NCT03077802|Experimental|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
16531258|NCT03077802|Active Comparator|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
16531259|NCT03077802|Experimental|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
16531260|NCT03077802|Active Comparator|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
16531261|NCT03077789|Experimental|TRABECULOTOMY|
16531262|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:
~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy
~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).
~Biopsy of a metastatic site in the event of disease recurrence.
~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
16531263|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
16531264|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
16531265|NCT03077750|Experimental|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
16531266|NCT03077750|Placebo Comparator|Vehicle|Vehicle Gel Applied to Affected Area BID
16531267|NCT03077737|Experimental|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
16531268|NCT03077737|Active Comparator|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
16531269|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
16531270|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
16531271|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
16531272|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
16531273|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
16531274|NCT03077685|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
16531275|NCT03077685|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
16531276|NCT03077685|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
16531277|NCT03077685|Experimental|Second Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
16531278|NCT03077685|Experimental|Third Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
16531279|NCT03077672||NYP-WCM|The NYP-WCM cohort will consist of patients presenting to the NewYork-Presbyterian/Weill Cornell Medicine Emergency Department with suspected sepsis.
16531280|NCT03077672||NYP-BMH|The NYP-BMH cohort will consist of patients presenting to the NewYork-Presbyterian Brooklyn Methodist Hospital Emergency Department with suspected sepsis.
16531282|NCT03077659|Experimental|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
16531283|NCT03077659|Experimental|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
16531284|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
16531285|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
16531286|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
16531287|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
16531288|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
16531289|NCT03077620|Experimental|Poor sleep group treatment 1|10mg Suvorexant tablet h.s. for two consecutive nights
16531290|NCT03077620|Placebo Comparator|Poor sleep group control|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
16531291|NCT03077620|Placebo Comparator|Good sleep group|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
16531292|NCT03077620|Experimental|Poor sleep group treatment 2|20mg Suvorexant tablet h.s. for two consecutive nights
16531293|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
16531294|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
16531295|NCT03077594|Other|Successfully ablated patients|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy.
16531296|NCT03077594|Other|Successfully ablated patients - VLE|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy. Volumetric laser endomicroscopy (VLE) will be done.
16531297|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
16531298|NCT03077581|Active Comparator|Rectus sheath block group|
16531299|NCT03077581|Active Comparator|local infiltration group|
16531300|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
16531301|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
16531302|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
16531303|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
16531304|NCT03077542|Experimental|recipient|recipient
16531305|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
16531306|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
16531307|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
16531308|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
16531309|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
16531310|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
16531311|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
16531312|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);
~SAD cohorts are defined as follows:
~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.
~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each
~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each
~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
16531313|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.
~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each
~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each
~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
16531314|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).
~FE Crossover:
~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
16531343|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
16531315|NCT03077464|Active Comparator|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
16531316|NCT03077464|Experimental|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
16531317|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.
~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
16531318|NCT03077438|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MenACYW Conjugate vaccine on Day 0.
16531319|NCT03077438|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MENVEO® Conjugate vaccine on Day 0.
16531320|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
16531321|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.
~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
16531322|NCT03077412|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
16531323|NCT03077412|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
16531324|NCT03077412|Experimental|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
16531325|NCT03077399|Experimental|stroke|stroke patients, application of SCALA
16531326|NCT03077399|Experimental|control|patients without stroke, application of SCALA
16531327|NCT03077386|Experimental|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
16531328|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
16531329|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
16531330|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
16531331|NCT03077360|Experimental|Weight loss only|
16531332|NCT03077360|Experimental|Exercise Only|
16531333|NCT03077360|No Intervention|Delayed Intervention Control|
16531334|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
16531335|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
16531336|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
16531337|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
16531338|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
16531339|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
16531340|NCT03077321|No Intervention|Control|Wait list control
16531341|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
16531344|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
16531345|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet
~Phase 2: consumption of HF meals for 4 weeks
~Phase 3: washout for 1 week, controlled maintenance diet
~Phase 4: consumption of HP meals for 4 weeks"
16531346|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet
~Phase 2: consumption of HP meals for 4 weeks
~Phase 3: washout for 1 week, controlled maintenance diet
~Phase 4: consumption of HF meals for 4 weeks"
16531347|NCT03077282|Experimental|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
16531348|NCT03077282|Experimental|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
16531349|NCT03077243|Experimental|≤ 10 pack years smoking history|
16531350|NCT03077243|Experimental|> 10 py smoking history, no p53 mutation|
16531351|NCT03077243|Active Comparator|> 10 py smoking history, p53 mutation|
16531352|NCT03077230|Experimental|Pre/Post Test of a Lung Cancer Screening Decision Aid|
16531353|NCT03077217|Active Comparator|the high-dose rifaximin|The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.
16531354|NCT03077217|Active Comparator|the low-dose rifaximinl group|The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.
16531355|NCT03077217|Placebo Comparator|the control group|The control group didn't receive rifaximin treatment
16531356|NCT03077204|Other|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
16531357|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR 23, before the start of the radiotherapy, at the end of the radiotherapy and then at every follow-up visit ( the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
16531358|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
16531359|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
16531360|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
16531361|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
16531362|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
16531363|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
16531364|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
16531365|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
16531366|NCT03077126|Other|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
16531367|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.
~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
16531368|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
16531369|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
16531370|NCT03077074|Experimental|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
16531371|NCT03077061|Active Comparator|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
16531372|NCT03077061|Experimental|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
16531373|NCT03077048|No Intervention|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
16531374|NCT03077048|Experimental|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
16531375|NCT03077035|Experimental|glass ionomer sealant|
16531376|NCT03077035|Active Comparator|resin-based sealant|
16531377|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
16531378|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
16531379|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
16531380|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
16531381|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
16531382|NCT03076970|Experimental|Lasmiditan 200 mg|single oral tablet
16531383|NCT03076970|Active Comparator|Sumatriptan 100 mg|single oral tablet
16531386|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
16531387|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
16531388|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
16531389|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
16531390|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
16531391|NCT03076918|Active Comparator|Conventional PDT|Aktilite® Galderma
16531392|NCT03076918|Experimental|FLEXITHERALIGHT PDT|Light Emitting Textile Device
16531393|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
16531394|NCT03076892|Active Comparator|Conventional PDT|Aktilite® Galderma
16531395|NCT03076892|Experimental|PHOS ISTOS PDT|Light Emitting textile device
16531396|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
16531397|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
16531398|NCT03076853||Patients with Pharmaceutical Record|
16531399|NCT03076840|Active Comparator|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
16531400|NCT03076840|Sham Comparator|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
16531401|NCT03076840|No Intervention|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
16531402|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
16531403|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
16531404|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
16531405|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
16531406|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.
~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
16531407|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.
~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
16531408|NCT03076775|Experimental|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
16531409|NCT03076775|No Intervention|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
16531410|NCT03076762|Experimental|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
16531411|NCT03076762|Active Comparator|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
16531412|NCT03076736|Active Comparator|Resource pack|Aphasia resource pack
16531413|NCT03076736|Experimental|Singing group + resource pack|Singing group + Aphasia resource pack
16531414|NCT03076723|Sham Comparator|Fixed opening pressure|The shunt opening pressure is changed to the same setting as at surgery.
16531415|NCT03076723|Experimental|Individual shunt opening pressure|The shunt opening pressure is adjusted (up one step, down one step or unchanged) according to an individual analysis of the pulsatility curve (as assessed after shunt surgery).
16531416|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
16531417|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
16531435|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
16531436|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
16531437|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
16531438|NCT03076567||control|Controls from two previously conducted studies in China
16562659|NCT02864056|No Intervention|Control|Usual care
16531418|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
16531419|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
16531420|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
16531421|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
16531422|NCT03076684|Experimental|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
16531423|NCT03076684|Experimental|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
16531424|NCT03076684|No Intervention|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
16531425|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
16531426|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
16531427|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
16531428|NCT03076658|Other|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
16531429|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
16531430|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.
~Interventions:
~Cervical plus transcranial stimulation
~Cervical stimulation plus hand/wrist exercise
~Electromyographic (EMG)-triggered (closed-loop) stimulation"
16531431|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.
~Interventions:
~Cervical plus transcranial stimulation
~Cervical stimulation plus hand/wrist exercise
~Electromyographic (EMG)-triggered (closed-loop) stimulation"
16531432|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.
~Interventions:
~Cervical plus transcranial stimulation
~Cervical stimulation plus hand/wrist exercise
~Electromyographic (EMG)-triggered (closed-loop) stimulation"
16531433|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
16531434|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
16531441|NCT03076528|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle & foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
16531442|NCT03076528|Active Comparator|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
16531443|NCT03076515|Active Comparator|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
16531444|NCT03076515|Sham Comparator|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
16531445|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
16531446|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
16531447|NCT03076476|Active Comparator|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
16531448|NCT03076476|Experimental|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.
~After the interim analysis DES-slow to be compared with BVS."
16531449|NCT03076476|Experimental|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
16531450|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
16531451|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
16531452|NCT03076450|Active Comparator|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
16531453|NCT03076450|Experimental|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
16531454|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
~Interventions:
~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
16531455|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
16531456|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
16531457|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
16531458|NCT03076385|Experimental|VAL-506440|
16531459|NCT03076385|Placebo Comparator|Placebo|
16531460|NCT03076372|Experimental|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
16531461|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
16531462|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.
~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
16531463|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
16531464|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency an duration: topically applied every 12 hours for 6 months."
16531465|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency and duration: topically applied every 12 hours for 6 month"
16531466|NCT03076307|Experimental|Parkinson's disease|
16531467|NCT03076307|Active Comparator|Control group|
16531468|NCT03076294|Experimental|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
16531469|NCT03076294|Experimental|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
16531497|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
16533549|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
16531470|NCT03076294|Sham Comparator|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
16531471|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
16531472|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
16531473|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
16531474|NCT03076268|Experimental|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
16531475|NCT03076268|No Intervention|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
16531476|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
16531477|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
16531478|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
16531479|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
16531480|NCT03076216|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
16531481|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16531482|NCT03076190|No Intervention|Active Control Group (Health Education)|"Prior to surgery:
~Demographics survey
~Baseline surveys
~Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.
~Follow-up questions about the handouts (detailed above)
~Post-surgery:
~Daily surveys (detailed above)
~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
16531483|NCT03076190|Experimental|My Surgical Success Treatment Group|"Prior to surgery:
~Demographics survey
~Baseline surveys
~Intervention:
~90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.
~audio file
~personalized plan that incorporates the information learned in the video.
~Follow-up questions about the video (detailed above)
~Post-surgery:
~Daily surveys (detailed above)
~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
16531484|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
16531485|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
16531486|NCT03076164|Experimental|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
16531487|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
16531488|NCT03076138|Experimental|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
16531489|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
16531490|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
16531491|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin
~** Metformin and sulfonylurea's dosages
~Metformin 500 mg - 2550 mg
~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
16531492|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin
~** Metformin and sulfonylurea's dosages
~Metformin 500 mg - 2550 mg
~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
16531493|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
16531494|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
16531495|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
16531496|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
16531558|NCT03075605||Controls|Controls
16531559|NCT03075592||ERCP candidates|ERCP candidates
16531498|NCT03076060|Experimental|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.
~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
16531499|NCT03076060|Sham Comparator|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.
~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
16531500|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
16531501|NCT03076034|Experimental|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
16531502|NCT03076034|Experimental|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
16531503|NCT03076021|Other|Adolescents|dextromethorphan pre- and post isotretinoin
16531504|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
16531505|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
16531506|NCT03075956|Experimental|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
16531507|NCT03075956|Experimental|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
16531508|NCT03075956|Experimental|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
16531509|NCT03075956|Experimental|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
16531510|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
16531511|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
16531512|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
16531513|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
16531514|NCT03075917|Experimental|Experimental|questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
16531515|NCT03075904|Experimental|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
16531516|NCT03075904|Experimental|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
16531517|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
16531518|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
16531519|NCT03075878|Experimental|Cohort 1: ALXN1830|SYNT001 Dose 1
16531520|NCT03075878|Experimental|Cohort 2: ALXN1830|SYNT001 Dose 2
16531521|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
16531522|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
16531523|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
16531524|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
16531525|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
16531526|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.
~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
16531527|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
16531528|NCT03075800|No Intervention|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
16531529|NCT03075800|Experimental|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
16531530|NCT03075787||patients with obstructive sleep apneas|
16531588|NCT03075397|Other|HIV-1 infected patients|Blood sample and sperm sample are collected
16562980|NCT02861599|Experimental|proprioceptive therapy|
16531531|NCT03075761|Experimental|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
16531532|NCT03075761|Active Comparator|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
16531533|NCT03075748|Experimental|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
16531534|NCT03075748|Experimental|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
16531535|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
16531536|NCT03075722|Experimental|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
16531537|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
16531538|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
16531539|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
16531540|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
16531541|NCT03075696|Experimental|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
16531542|NCT03075696|Experimental|Part II: Dose Escalation|"In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment); or 2000 mg either administered on Day -7, or split into two 1000 mg doses on Days -1 and -7. The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered.
~Monotherapy, glofitamab as a single agent: ascending doses of glofitamab administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.
~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined.
~Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles."
16531543|NCT03075696|Experimental|Part III: Dose Expansion|"Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered.
~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II."
16531544|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
16531545|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
16531546|NCT03075670|Experimental|N9-GP|
16531547|NCT03075670|Active Comparator|ALPROLIX®|
16531548|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
16531549|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
16531550|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
16531551|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
16531552|NCT03075644|Experimental|Somapacitan|
16531553|NCT03075644|Active Comparator|Norditropin|
16531554|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
16531555|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
16531556|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
16531557|NCT03075605||Subjects with previous attack|Subjects with previous attack
16531560|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16531561|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
16531562|NCT03075527|Experimental|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
16531563|NCT03075514|Active Comparator|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
16531564|NCT03075514|Active Comparator|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
16531565|NCT03075501|Active Comparator|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
16531566|NCT03075501|Other|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
16531567|NCT03075488|Active Comparator|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
16531568|NCT03075488|Experimental|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
16531569|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
16531570|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
16531571|NCT03075462|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
16531572|NCT03075436|Experimental|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
16531573|NCT03075436|Active Comparator|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
16531574|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a flat dose of 240 mg nivolumab biweekly until progression.
16531575|NCT03075423|Active Comparator|Sunitinib|Sunitinib will be administered at a starting dose of 50 mg/die p.o. for 4 weeks on and 2 weeks off per cycle until progression.
16531576|NCT03075410|Experimental|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
16531577|NCT03075410|Placebo Comparator|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
16531589|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
16531590|NCT03075371|Active Comparator|intragastric glucose administration|
16531591|NCT03075371|Placebo Comparator|intragastric water administration|
16531592|NCT03075358|Experimental|Lidocaine spray|
16531593|NCT03075358|Sham Comparator|Normal saline spray|
16531594|NCT03075358|No Intervention|No spray|
16562981|NCT02861599|Placebo Comparator|speech therapy|
16531578|NCT03075410|Experimental|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
16531579|NCT03075410|Placebo Comparator|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
16531580|NCT03075410|Experimental|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
16531581|NCT03075410|Placebo Comparator|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
16531582|NCT03075410|Experimental|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
16531583|NCT03075410|Placebo Comparator|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
16531584|NCT03075410|Experimental|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
16531585|NCT03075410|Placebo Comparator|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
16531586|NCT03075410|Experimental|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
16531587|NCT03075410|Placebo Comparator|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
16531595|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
16531596|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
16531597|NCT03075332|Experimental|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
16531598|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
16531599|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
16531600|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
16531601|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
16531602|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
16531603|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
16531604|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
16531605|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
16531606|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
16531607|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
16531608|NCT03075254|Active Comparator|Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
16531609|NCT03075254|Experimental|Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
16531610|NCT03075254|Experimental|Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
16531611|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
16531612|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
16531613|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
16531614|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
16531615|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
16531616|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.
~Diet registration and testing at baseline, discharge and follow-up."
16531617|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.
~Diet registration and testing at baseline, discharge and follow-up."
16531618|NCT03075176|Active Comparator|Wavefront optimized LASIK|
16531619|NCT03075176|Active Comparator|Wavefront optimized Photorefractive Keratectomy|
16531620|NCT03075176|Active Comparator|Topography-guided LASIK|
16531621|NCT03075176|Active Comparator|Topography-guided Photorefractive Keratectomy|
16531622|NCT03075163|Experimental|Acupressure|Manual pressure will be applied on the wrists bilaterally.
16531623|NCT03075163|Active Comparator|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
16531624|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
16531625|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
16531626|NCT03075124|Experimental|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
16531627|NCT03075124|No Intervention|Control group|Guideline-driven standard medical treatment
16531628|NCT03075098|Experimental|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
16531629|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
16531630|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
16531631|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered
~A hippocampal sparing approach will be used when possible
~Dose will be 30 Gy in 10 fractions"
16531632|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered
~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
16531633|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
16531634|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
16531635|NCT03075046|Experimental|blue LED 405 nm in vulvovaginal candidiasis|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session. This part of the study will see if there is fungicidal effect of the blue led 405 nm
16531636|NCT03075046|Experimental|blue LED 405 nm in healthy women|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.This part of the study will see the security and the effects of the blue led 405 nm in healthy vaginal microflora
16531637|NCT03075046|No Intervention|Sociodemographic data of women with vulvovaginal candidiasis|The women will answer some questions of the anamnesis as: Age, weight, height, form of intimate hygiene, and others to evaluate possible correlations of these data with the presence of vulvovaginal candidiasis
16531638|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
16531639|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
16531640|NCT03075020|Active Comparator|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
16531641|NCT03075020|Placebo Comparator|Air|
16531642|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
16531643|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
16531644|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
16531645|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
16531646|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.
~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.
~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
16531647|NCT03074968|Placebo Comparator|control|normal saline
16531648|NCT03074968|Active Comparator|benzydamine hydrochloride|Benzydamine Hydrochloride
16531649|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position
~Apply elastic bandages to both legs without tension.
~Maintain supine position after injecting propofol.
~After 3 minutes from propofol injection, remove elastic bandages
~induction using propofol 2mg/kg
~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg
~intubate patient between 3 and 4 minutes after propofol injection
~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection
~phenylephrine injection if hypotension develops"
16531650|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position
~Apply elastic bandages to both legs without tension.
~After injecting propofol, apply Trendelenburg position ( 10 degree )
~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.
~induction using propofol 2mg/kg
~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg
~intubate patient between 3 and 4 minutes after propofol injection
~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection
~phenylephrine injection if hypotension develops"
16531651|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position
~Apply elastic bandages to both legs with tension.
~After injecting propofol, apply Trendelenburg position ( 10 degree )
~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.
~induction using propofol 2mg/kg
~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg
~intubate patient between 3 and 4 minutes after propofol injection
~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection
~phenylephrine injection if hypotension develops"
16531652|NCT03074942|Experimental|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
16531653|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
16531654|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
16531655|NCT03074916||DIP arthroplasty|
16531656|NCT03074916||DIP arthrodesis|
16531657|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
16531658|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
16531659|NCT03074890|Experimental|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
16531660|NCT03074890|No Intervention|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
16531661|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
16531662|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
16531663|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
16531664|NCT03074864|Experimental|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
16531665|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
16531666|NCT03074851|Other|informational intervention|to give 1 month informational intervention
16531667|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
16531668|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
16531669|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
16531670|NCT03074812|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation where current will be reduced to zero after standardized ramp up to 2 mA
16531671|NCT03074812|Experimental|Active tDCS|Transcranial direct current stimulation according to protocol maintained for 30 minutes after ramping up to 2 mA
16531672|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
16531673|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
16531674|NCT03074786|Experimental|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
16531675|NCT03074786|Experimental|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
16531676|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
16531677|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
16531678|NCT03074760||Contaminated acequias|
16531679|NCT03074760||Non-contaminated acequias|
16531680|NCT03074734|Other|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
16531681|NCT03074721|Other|PCI with PCI Suite Software|
16531682|NCT03074721|Other|conventional PCI|
16531683|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
16531684|NCT03074695|Experimental|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
16531685|NCT03074695|Experimental|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
16531686|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
16531687|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
16531688|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
16531689|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
16531690|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
16531691|NCT03074656|Experimental|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
16531692|NCT03074656|Active Comparator|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
16531693|NCT03074643|Placebo Comparator|RecProt|Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
16531694|NCT03074643|Active Comparator|6-mon HiProt|Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
16531695|NCT03074643|Active Comparator|18-mon HiProt|"Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.
~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
16531696|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
16531697|NCT03074617|Experimental|LTE field|
16531698|NCT03074617|Sham Comparator|sham field|
16531699|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
16531700|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
16531701|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
16531702|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
16531703|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
16531704|NCT03074578|Experimental|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
16531705|NCT03074578|Sham Comparator|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
16531706|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
16531707|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
16531708|NCT03074552|Experimental|Probiotics|The probiotic preparation [ LactoLevure] will consist a combination of four probiotics.
16531709|NCT03074552|Placebo Comparator|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
16531710|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.
~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
16531711|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.
~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
16531712|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.
~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
16531713|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
16531714|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
16531715|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
16531747|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
16563123|NCT02860663|Active Comparator|25OHD|10 ug/ of 25OHD for 6 weeks
16531716|NCT03074513|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16531717|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
16531718|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
16531719|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
16531720|NCT03074474|Other|OviTex Permanent 1S|All subjects included in this post-market study will have a ventral hernia repaired with OviTex Permanent 1S reinforced bioscaffold.
16531721|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
16531722|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
16531723|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
16531724|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
16531725|NCT03074435|No Intervention|Control|No intervention
16531726|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
16531727|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
16531728|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
16531729|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
16531730|NCT03074422|Experimental|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
16531731|NCT03074422|No Intervention|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
16531732|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
16531733|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
16531734|NCT03074396|Other|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
16531735|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
16531736|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
16531737|NCT03074344|Experimental|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
16531738|NCT03074344|Active Comparator|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
16531739|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16531740|NCT03074318|Experimental|Treatment (avelumab, trabectedin)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
16531741|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.
~Residual stenosis after lesion preparation : %DS <20%
~Delivery time : < 30 seconds
~Total inflation time : > at least 1 minute
~Previous BVS : DEB diameter ratio : > 1.0:1
~Maximum inflation pressure : at least above nominal pressure of DEB"
16531742|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
16531743|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
16531744|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
16531745|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
16531746|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
16531748|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.
~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
16531749|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.
~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
16531750|NCT03074240|Active Comparator|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
16531751|NCT03074240|Active Comparator|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
16531752|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
16531753|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
16531754|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
16531755|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
16531756|NCT03074188||pre-dialysis patients|
16531757|NCT03074188||end stage renal disease|
16531758|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
16531759|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
16531760|NCT03074162|Experimental|Diclofenac Sodium (A)|
16531761|NCT03074162|Experimental|Diclofenac & Capsaicin (B)|
16531762|NCT03074162|Active Comparator|Diclofenac Sodium Topical Gel|
16531763|NCT03074149||Idiopathic Pulmonary Disease patients|IPF patients/ only one group
16531764|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
16531765|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
16531766|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
16531767|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
16531768|NCT03074110|Active Comparator|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
16531769|NCT03074110|No Intervention|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
16531770|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
16531771|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
16531772|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
16531773|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
16531774|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
16531775|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
16531778|NCT03074032|Experimental|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
16531779|NCT03074032|Experimental|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
16531780|NCT03074032|Experimental|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
16531781|NCT03074032|Experimental|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
16531782|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
16531783|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
16531784|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
16531785|NCT03074006|Experimental|low dose|
16531786|NCT03074006|Experimental|high dose|
16531789|NCT03073980|Experimental|Group 1: IV acetaminophen/PO placebo|In the pre-op suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
16531790|NCT03073980|Active Comparator|Group 2: IV placebo/PO acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
16531791|NCT03073980|Placebo Comparator|Group 3: Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
16531792|NCT03073967|Experimental|Part C, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
16531793|NCT03073967|Active Comparator|Part C, Foscarnet|iv solution, 40 mg/kg tid or 60mg/kg bid for up to 28 days and potential prolongation for up to additional 14 days.
16531794|NCT03073967|Experimental|Part D, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
16531795|NCT03073967|Experimental|Part E, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
16531796|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
16531797|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
16531798|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
16531799|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
16531800|NCT03073928|Active Comparator|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).
~We will administer injection of saline similar to experimental group to blind the patient"
16531801|NCT03073928|Experimental|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
16531802|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
16531803|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
16531804|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
16531805|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
16531806|NCT03073876|Experimental|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
16531807|NCT03073876|Placebo Comparator|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.
~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
16531808|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
16531809|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
16531810|NCT03073850|Experimental|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
16531811|NCT03073850|Experimental|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
16531812|NCT03073850|Active Comparator|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
16531813|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
16531814|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
16531815|NCT03073811|Experimental|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and four weeks after surgery.
16531816|NCT03073811|Active Comparator|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian and one oral nutrition supplement per day for two weeks before surgery.
16531817|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
16531818|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
16531819|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
16531877|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
16531820|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
16531821|NCT03073772|No Intervention|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
16531822|NCT03073772|Active Comparator|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
16531823|NCT03073772|Active Comparator|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
16531824|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
16531825|NCT03073759|Sham Comparator|Sham|Patients will receive a sham.
16531826|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
16531827|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
16531828|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
16531829|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
16531830|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
16531831|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
16531832|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
16531833|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
16531834|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
16531835|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
16531836|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
16531837|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
16531838|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
16531839|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
16531840|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
16531841|NCT03073642|Active Comparator|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.
~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
16531842|NCT03073642|Experimental|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.
~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.
~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
16531843|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
16531844|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
16531845|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
16531848|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
16531849|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
16531878|NCT03073369|Placebo Comparator|Placebo|
16533550|NCT03061552|Experimental|IVCD arm|IVCD-assisted determination of target post-dialysis weight
16531850|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
16531851|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
16531852|NCT03073577|Experimental|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
16531853|NCT03073564|No Intervention|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
16531854|NCT03073564|Experimental|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
16531855|NCT03073564|Experimental|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
16531856|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
16531857|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
16531862|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
16531863|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
16531864|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
16531865|NCT03073486|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
16531866|NCT03073486|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
16531867|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
16531868|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
16531869|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
16531870|NCT03073460|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
16531871|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
16531872|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
16531873|NCT03073408|Active Comparator|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
16531874|NCT03073408|Experimental|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
16531875|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
16531876|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
16531879|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
16531880|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
16531881|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
16531882|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
16531883|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
16531884|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
16531885|NCT03073330|Experimental|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
16531886|NCT03073330|Active Comparator|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
16531887|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
16531888|NCT03073317|No Intervention|CONTROL|Usual clinic control
16531889|NCT03073304|Active Comparator|Control|Erythrocyte based prime solution
16531890|NCT03073304|Experimental|Intervention|Crystalloid based prime solution
16531891|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
16531892|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
16531893|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
16531894|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
16531895|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
16531896|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
16531897|NCT03073252|Experimental|Normal Protein|Consumption of normal protein (NP) meal
16531898|NCT03073252|Experimental|High Protein|Consumption of high protein (HP) meal
16531899|NCT03073239||ALS epidemiological characterization|epidemiological characterization
16531900|NCT03073239||Genetic findings in ALS patients|genética characterization
16531901|NCT03073226|Experimental|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
16531902|NCT03073226|Experimental|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
16531903|NCT03073226|Experimental|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
16531904|NCT03073226|Experimental|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
16531905|NCT03073213|Experimental|Ixekizumab single dose|Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
16531906|NCT03073213|Experimental|Ixekizumab Multiple Regimen 1 (80mg Q2W)|Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
16531907|NCT03073213|Experimental|Ixekizumab Multiple Regimen 2 (80mg Q4W)|Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
16531908|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
16531909|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
16531910|NCT03073200|Experimental|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
16531911|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
16531912|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
16531913|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
16531914|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
16534254|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
16531915|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
16531916|NCT03073148|Experimental|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
16531917|NCT03073148|Placebo Comparator|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
16531918|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
16531919|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
16531920|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
16531921|NCT03073096|Other|Intervention arm|LVA at time of nodal dissection
16531922|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
16531923|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
16531924|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
16531925|NCT03073070|Experimental|Biotin labeled RBCs in 4-10 year old diabetes children|Biotin labeled autologous RBCs will be transfused to the subjects
16531926|NCT03073070|Experimental|Biotin labeled RBCs in 10-18 year old diabetes children|Biotin labeled autologous red blood cells will be transfused to the subjects
16531927|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
16531928|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
16531929|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
16531930|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
16531931|NCT03073031|Active Comparator|Intervention|Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
16531932|NCT03073031|No Intervention|Control|Patients have their side effects monitored by a physician every 3 weeks (control)
16531933|NCT03073018|Experimental|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
16531934|NCT03073018|Active Comparator|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
16531935|NCT03073018|Active Comparator|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
16531936|NCT03073018|Placebo Comparator|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
16531937|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
16531938|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
16531939|NCT03072992|Active Comparator|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
16531940|NCT03072992|Placebo Comparator|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
16531941|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
16531942|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
16531943|NCT03072940||Patients with idiopathic RBD|
16531944|NCT03072940||Healthy volunteers|
16531947|NCT03072914|No Intervention|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
16531948|NCT03072914|Active Comparator|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
16531949|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
16531950|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
16531951|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
16531952|NCT03072875|Experimental|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
16531953|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
16531954|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
16531955|NCT03072836|Experimental|CD alone|
16531956|NCT03072836|Experimental|SPA alone|
16531957|NCT03072836|Experimental|CD + SPA|
16531958|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
16531959|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
16531960|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
16531961|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
16531962|NCT03072784|Active Comparator|group S|short time <90 m aortic cross clamping
16531963|NCT03072784|Active Comparator|group L|> 90 minutes aortic cross clamping
16531964|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:
~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7
~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)
~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)
~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2
~Auto-SCT will take place on Day 0 as per institutional guidelines
~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
16531965|NCT03072758|Experimental|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
16531966|NCT03072758|No Intervention|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
16531967|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
16531968|NCT03072732|Other|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
16531969|NCT03072732|Other|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
16531970|NCT03072719|Experimental|Dentifrice containing stannous fluoride|Toothpaste
16531971|NCT03072719|Active Comparator|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
16531972|NCT03072706|Active Comparator|Standard group|2D X-ray templating technology
16531973|NCT03072706|Experimental|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
16531974|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
16531975|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
16531976|NCT03072680|Experimental|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
16531977|NCT03072680|Experimental|BPS FUT|Participants practice BPS FUT during the two weeks.
16531978|NCT03072680|Active Comparator|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
16531979|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
16531980|NCT03072641|No Intervention|Control|
16531981|NCT03072628|Experimental|Nicotine: use e-cig with nicotine|One time exposure to e-cig with nicotine
16531982|NCT03072628|Experimental|no nicotine: use e-cig without nicotine|One time exposure to e-cig without nicotine
16531983|NCT03072628|Experimental|Nicotine inhaler: use a nictoine inhaler|One time exposure to nicotine inhaler
16531984|NCT03072628|Sham Comparator|Sham control|Use an empty e-cigarette
16531985|NCT03072615||1|receiving TE before and 30 min after TIPS
16531986|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
16531987|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
16531988|NCT03072602|Active Comparator|White|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
16531989|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
16531990|NCT03072550|Experimental|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
16531991|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
16532024|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
16531992|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
16531993|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
16531994|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
16531995|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
16531996|NCT03072472|Experimental|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
16531997|NCT03072472|No Intervention|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
16531998|NCT03072446|Experimental|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
16531999|NCT03072433|Active Comparator|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
16532000|NCT03072433|Experimental|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
16532001|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
16532002|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
16532003|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
16532004|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
16532005|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
16532006|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
16532007|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
16532008|NCT03072394|Experimental|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
16532009|NCT03072394|Active Comparator|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
16532010|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
16532011|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
16532012|NCT03072368|Active Comparator|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
16532013|NCT03072368|Active Comparator|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
16532014|NCT03072368|Active Comparator|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
16532015|NCT03072368|Active Comparator|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
16532016|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
16532017|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
16532018|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
16532019|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
16532020|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
16532021|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
16532022|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
16532023|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
16532025|NCT03072290|Experimental|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
16532026|NCT03072290|Active Comparator|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
16532027|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
16532028|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
16532029|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
16532030|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
16532031|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
16532032|NCT03072251||Anyone|Any individual may complete this survey
16532033|NCT03072238|Active Comparator|Placebo + Abiraterone|Participants received Placebo plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
16532034|NCT03072238|Experimental|Ipatasertib + Abiraterone|Participants received Ipatasertib plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
16532035|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
16532036|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
16532037|NCT03072212||HIV infected with stroke|No intervention will be administered
16532038|NCT03072212||HIV uninfected with stroke|No intervention will be administered
16532039|NCT03072199|Experimental|Rituximab|
16532040|NCT03072186|Experimental|near-infrared light nasal endoscope used with ICG|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery and tumor dissection: before intradural dissection and during tumor dissection.
16532041|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG
~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
16532042|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG
~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
16532043|NCT03072160|Experimental|Cohort 1: Participants that had an immune stimulating cancer vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.
~Group 1: cancer vaccine"
16532044|NCT03072160|Experimental|Cohort 2: Participants that have had no vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.
~Group 2: had no previous vaccine"
16532045|NCT03072147|Active Comparator|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
16532046|NCT03072147|Placebo Comparator|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
16532047|NCT03072134|Experimental|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
16532048|NCT03072134|Experimental|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
16532049|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
16532050|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
16532051|NCT03072108|Experimental|Bonolive|
16532052|NCT03072108|Placebo Comparator|Placebo|
16532053|NCT03072095|Experimental|Text-only|Text-only outreach
16532054|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
16532055|NCT03072082|Experimental|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
16532056|NCT03072082|Placebo Comparator|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
16532057|NCT03072056|Experimental|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
16532058|NCT03072056|Experimental|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
16532059|NCT03072056|Experimental|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
16532060|NCT03072056|Experimental|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
16532061|NCT03072056|Experimental|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
16532062|NCT03072056|Experimental|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
16532063|NCT03072043|Experimental|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
16532064|NCT03072043|Experimental|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
16532065|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
16532066|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
16532067|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
16532068|NCT03072004|Sham Comparator|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
16532069|NCT03072004|Experimental|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
16532070|NCT03071991||Study group|Preincisional bupivacain will be used
16532071|NCT03071991||Control group|No preincisional anesthetic drug will be used
16532072|NCT03071978|Experimental|LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
16532073|NCT03071978|Active Comparator|BV pacing|Bi-Ventricular pacing
16532074|NCT03071965|Experimental|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
16532075|NCT03071965|Experimental|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
16532076|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
16532077|NCT03071926|Experimental|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
16532078|NCT03071913||Ancillary-correlative (biospecimen collection)|As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.
16532079|NCT03071900|Experimental|SCCHN|squamous cell carcinoma of the head and neck
16532080|NCT03071900|Experimental|Control|health volunteers
16532081|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
16532082|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose
~Twice daily for two consecutive days out of every seven days
~Cycles will last 28 days"
16532083|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
16532084|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
16532085|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
16532086|NCT03071822|Experimental|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
16532087|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
16532088|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
16532089|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
16532090|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
16532091|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
16532092|NCT03071783|No Intervention|conventional|conventional handle
16532093|NCT03071770|Experimental|ivosidenib (AG-120)|
16532094|NCT03071757|Experimental|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
16532095|NCT03071757|Experimental|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
16532096|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
16532097|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
16532098|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
16532099|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).
~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
16532100|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
16532101|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
16532102|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
16532103|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
16532104|NCT03071705|Experimental|Intervention|TKI plus Metformin
16532105|NCT03071705|Active Comparator|Control|TKI
16532106|NCT03071692|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
16532107|NCT03071692|Placebo Comparator|Control Group|Matching K-877 placebo tablet twice daily.
16532108|NCT03071679|Experimental|Omiganan|
16532109|NCT03071679|Experimental|Imiquimod|
16532110|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
16532111|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
16532112|NCT03071679|Placebo Comparator|Placebo|Vehicle
16532113|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
16532114|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
16532115|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
16532116|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
16532117|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
16532118|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
16532119|NCT03071614|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
16532120|NCT03071614|Experimental|News without spin|News items reporting results of animal studies without spin.
16532121|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
16532122|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
16532123|NCT03071588|Active Comparator|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
16532124|NCT03071588|Experimental|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
16532125|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
16532126|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
16532127|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
16532128|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
16532129|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
16532130|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
16532131|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.
~Urine output will be recorded hourly for 6 hours."
16532132|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
16532133|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
16532134|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
16532135|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
16534417|NCT03055936|Experimental|A1|levodopa 50 mg, carbidopa 12.5 mg
16532136|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
16532137|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
16532138|NCT03071432|Active Comparator|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
16532139|NCT03071432|Active Comparator|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
16532140|NCT03071432|Active Comparator|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
16532141|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
16532142|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
16532143|NCT03071406|Active Comparator|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
16532144|NCT03071406|Active Comparator|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
16532145|NCT03071393|Active Comparator|Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen.
16532146|NCT03071393|Sham Comparator|Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo a sham placebo protocol with normal oxygen air (21% inspired oxygen).
16532147|NCT03071380|Experimental|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
16532148|NCT03071380|Active Comparator|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
16532149|NCT03071367|Experimental|Clinical Simulation|
16532150|NCT03071367|No Intervention|Classical Learning|
16532151|NCT03071354|Experimental|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.
~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
16532152|NCT03071354|Active Comparator|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.
~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
16532153|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
16532154|NCT03071328|Experimental|Bone metastatic site|
16532155|NCT03071328|Experimental|Liver metastatic site|
16532156|NCT03071328|Experimental|Lymph node metastatic site|
16532157|NCT03071328|Experimental|Soft tissue metastatic site|
16532158|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
16532159|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
16532194|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
16532195|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
16532811|NCT03066739|Active Comparator|HI-high dose remifentanil with placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
16532160|NCT03071302|Active Comparator|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.
~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus
~Group C Keratoconus / Keratoconus"
16532161|NCT03071302|Placebo Comparator|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.
~Group B Sound Cornea / Sound Cornea"
16532162|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
16532163|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
16532164|NCT03071276|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
16532165|NCT03071263|Experimental|Group 1 - Patiromer|spironolactone + blinded patiromer
16532166|NCT03071263|Experimental|Group 2 - Placebo|spironolactone + blinded placebo
16532167|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
16532168|NCT03071224|Experimental|[18F]MNI-946|To evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
16532169|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
16532170|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
16532171|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
16532172|NCT03071198|Experimental|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
16532173|NCT03071198|Experimental|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
16532174|NCT03071198|Active Comparator|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
16532175|NCT03071185|Experimental|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
16532176|NCT03071185|No Intervention|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
16532177|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
16532178|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
16532179|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
16532180|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
16532181|NCT03071120|Experimental|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
16532182|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
16532183|NCT03071107|No Intervention|Control arm|Standard of care
16532184|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase I|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
16532185|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase IIa|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
16532186|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
16532187|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
16532188|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
16532189|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
16532190|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
16532191|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
16532192|NCT03071068|Experimental|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
16532193|NCT03071068|Experimental|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
16532196|NCT03071042|Experimental|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
16532197|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
16532198|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
16532199|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
16532200|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
16532201|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
16532202|NCT03070990|Experimental|Arm A: Enfortumab vedotin 1.0 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
16532203|NCT03070990|Experimental|Arm B: Enfortumab vedotin 1.25 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
16532204|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
16532205|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
16532206|NCT03070964|Experimental|Plitidepsin|
16532207|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
16532208|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Add-back|
16532209|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
16532210|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Add-back|
16532211|NCT03070951|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|
16532212|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
16532213|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Add-back|
16532214|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
16532215|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Add-back|
16532216|NCT03070899|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
16532217|NCT03070886|Active Comparator|Arm I (androgen deprivation therapy, EBRT)|Patients receive androgen deprivation therapy comprising leuprolide acetate, goserelin acetate, bicalutamide, flutamide, or nilutamide for 6 months. Beginning 8 weeks after the start of androgen deprivation therapy, patients receive EBRT for 7.5 weeks.
16532218|NCT03070886|Experimental|Arm II (androgen deprivation therapy, EBRT, docetaxel)|Patients receive androgen deprivation therapy and EBRT as in Arm I. Within 4-6 weeks after completion of radiation therapy, patients receive docetaxel IV on day 1 of every 21 days for 6 courses in the absence of disease progression or unexpected toxicity.
16532219|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
16532220|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
16532221|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
16532222|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
16532223|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
16532224|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
16532225|NCT03070834|Experimental|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
16532226|NCT03070834|No Intervention|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
16532227|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
16532228|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
16532229|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
16532230|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
16532231|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
16532232|NCT03070782|Experimental|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
16532233|NCT03070782|Experimental|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
16534418|NCT03055936|Experimental|B1|levodopa 50 mg, carbidopa 65 mg
16532234|NCT03070782|Experimental|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
16532235|NCT03070782|Experimental|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
16532236|NCT03070782|Experimental|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
16532237|NCT03070782|Placebo Comparator|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
16532238|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
16532239|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
16532240|NCT03070756|Other|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.
~Interventions:
~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
16532241|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
16532242|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
16532243|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.
~Placebo is used to control the administration effect."
16532244|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
16532245|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
16532246|NCT03070704||Insulin degludec /liraglutide|
16532247|NCT03070691|Active Comparator|LDE225 0.75% cream|
16532248|NCT03070691|Placebo Comparator|Vehicle|
16532249|NCT03070678|Experimental|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
16532250|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
16532251|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
16532252|NCT03070652|Experimental|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
16532253|NCT03070652|Experimental|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
16532254|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
16532255|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
16532256|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
16532257|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
16532258|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
16532259|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
16532260|NCT03070600|Active Comparator|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
16532261|NCT03070600|Experimental|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
16532262|NCT03070587|Experimental|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
16532263|NCT03070587|No Intervention|Wait list Control|These participants will not be given an intervention until after they have completed the study.
16532264|NCT03070574|Experimental|2400 MG mesalamine (5-ASA) total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
16532265|NCT03070574|Experimental|1200 MG mesalamine (5-ASA) total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
16532266|NCT03070574|Placebo Comparator|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
16532267|NCT03070561|Experimental|Sublingual film with peanut extract|
16532268|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
16532269|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
16532270|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
16532271|NCT03070522|Active Comparator|Placebo|Placebo
16532272|NCT03070522|Active Comparator|Treatment|Prednisone
16532273|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
16532274|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
16532275|NCT03070496|Experimental|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :
~an additional blood sampling at 6 months
~an additional electrocardiogram (ECG) at 6 months
~Magnetic Resonance Imaging (MRI)
~Quality of life questionnaire"
16532276|NCT03070483|Experimental|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
16532277|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
16532278|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
16532279|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
16532280|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
16532281|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
16532282|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
16532283|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
16532284|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
16532285|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.
~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
16532286|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.
~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
16532287|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
16532288|NCT03070418|Experimental|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
16532289|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
16532290|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
16532291|NCT03070392|Experimental|IMCgp100|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
16532292|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine
~1 of 3 Investigator's Choice options: Systemic Ipilimumab
~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
16532293|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
16532294|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
16532295|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:
~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)
~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).
~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.
~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
16532296|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
16532297|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
16532298|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
16532299|NCT03070327|Experimental|BCMA Targeted CAR T Cells with or without Lenalidomide|
16532300|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
16532301|NCT03070301|Experimental|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
16532302|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
16532303|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
16532304|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
16532305|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
16532306|NCT03070262|Experimental|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
16532307|NCT03070262|Placebo Comparator|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
16532308|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
16532309|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
16532310|NCT03070223||Experimental: Pitavastatin|Participants who receive pitavastatin in the main study REPRIEVE (A5332).
16532311|NCT03070223||Placebo Comparator: Placebo|Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
16532312|NCT03070210|Other|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
16532313|NCT03070210|Active Comparator|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia <1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
16532314|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
16532315|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
16532316|NCT03070184|Experimental|African-American|Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
16532317|NCT03070184|Active Comparator|Caucasians (White)|Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
16532318|NCT03070171|Experimental|Dabigatran Etexilate Capsule|
16532319|NCT03070171|Experimental|Dabigatran Etexilate Tablet|
16532320|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
16532321|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
16532322|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training
~150 minute moderate aerobic activities, such as brisk walking
~Strength training 3 days /week
~One on one sessions with exercise physiologist
~Optional group sessions"
16532323|NCT03070145|No Intervention|Usual Care|Usual Care provided
16532324|NCT03070132|Experimental|BIIB074|Optimized oral dose three times daily (TID)
16532325|NCT03070132|Experimental|Placebo|Administered orally TID
16532326|NCT03070119|Experimental|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
16532327|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
16532328|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
16532329|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
16532330|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
16532331|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
16532332|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
16532333|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
16532334|NCT03070054|No Intervention|Control|non-LIA group prior to surgery
16532335|NCT03070054|Experimental|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
16532336|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
16532337|NCT03070028|Experimental|Phenol|crystallised phenol application
16532338|NCT03070028|Experimental|platelet rich plasma|PRP application
16532339|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
16532340|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
16532341|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
16532342|NCT03069989|Experimental|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16532343|NCT03069989|Placebo Comparator|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16532344|NCT03069989|Experimental|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16532345|NCT03069989|Placebo Comparator|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16532346|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
16532347|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
16532348|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
16532349|NCT03069950|Experimental|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
16532350|NCT03069950|Experimental|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
16532351|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
16532352|NCT03069924|Active Comparator|No NRT - No Messaging|Brief counseling, but no NRT and no gain-framed messaging.
16532353|NCT03069924|Active Comparator|NRT - No Messaging|Brief counseling plus NRT but no gain-framed messaging.
16532354|NCT03069924|Active Comparator|No NRT - Messaging|Brief counseling plus gain-framed messaging but no NRT.
16532355|NCT03069924|Experimental|NRT plus Messaging|Brief counseling plus NRT and gain-framed messaging.
16532356|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
16532357|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
16532358|NCT03069898|Experimental|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
16532359|NCT03069898|No Intervention|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
16532360|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
16532361|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
16532362|NCT03069872|Experimental|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
16532363|NCT03069859|Experimental|TXA (1g)|For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
16532364|NCT03069859|Placebo Comparator|Placebo (0.9% saline)|For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
16532365|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
16532366|NCT03069833|Experimental|Computer-aided diagnosis|
16532367|NCT03069833|No Intervention|traditional diagnosis|
16532368|NCT03069820|Experimental|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
16532369|NCT03069807|Experimental|Intervention|Participants with LTBI will be treated in the Community/Primary Care.
16532370|NCT03069807|Active Comparator|Control|Participants with LTBI will be treated in the Hospital/TB Clinic
16532371|NCT03069794|Other|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
16532372|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
16532373|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
16533002|NCT03065335|Experimental|Phase III|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
16532374|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
16532375|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
16532376|NCT03069742|Experimental|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
16532377|NCT03069742|No Intervention|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
16532378|NCT03069729||Control group|non-diabetic; no intervention
16532379|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
16532380|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
16532381|NCT03069716|Experimental|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
16532382|NCT03069716|Other|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
16532383|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
16532384|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
16532385|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
16532386|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
16532387|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
16532388|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
16532389|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
16532390|NCT03069677|Active Comparator|Music group|research-selected music
16532391|NCT03069677|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
16532392|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
16532393|NCT03069664|No Intervention|Control group|control group
16532394|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.
~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
16532395|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
16532396|NCT03069638|Experimental|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
16532397|NCT03069638|Active Comparator|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
16532398|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
16532399|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
16532400|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
16532401|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
16532402|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
16532403|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
16532404|NCT03069599||10 resection only|patients undergoing surgical resection only
16532405|NCT03069586|Other|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
16532406|NCT03069586|Active Comparator|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
16532407|NCT03069573||Eosinophilic Esophagitis - EoE|Diagnosis of pediatric EoE under current guidelines.
16532408|NCT03069573||Gastroesophageal reflux disease - GERD|Diagnosis of pediatric GERD under current guidelines.
16532409|NCT03069573||Control|Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.
16532410|NCT03069560|Experimental|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
16532411|NCT03069547|Active Comparator|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
16532412|NCT03069547|Active Comparator|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
16532563|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.
~will be followed with PET MRI"
16532413|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
16532414|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
16532416|NCT03069508|Experimental|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
16532417|NCT03069508|Experimental|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
16532418|NCT03069508|Experimental|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
16532419|NCT03069508|Experimental|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
16532420|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
16532421|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
16532422|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
16532423|NCT03069482|Experimental|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
16532424|NCT03069482|Active Comparator|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
16532425|NCT03069469|Other|Experimental Treatment|"Dose Escalation Phase: Increasing doses of DCC-3014 beginning at 10 mg QD for 28 day cycles until disease progression or unacceptable toxicity.
~Expansion Phase: Dosing of different patient cohorts at the dose level determined from the Dose Escalation Phase of the study."
16532426|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
16532427|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
16532428|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
16532429|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
16532430|NCT03069417|Experimental|Intervention: INSPireD|"This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aims to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content is based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression."
16532431|NCT03069417|Other|Wait-list control|The Wait-list control group will be referred to standard of care counseling services, and will start the intervention upon completion of the first experimental group. They will receive the intervention with the next experimental group cycle.
16532432|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
16532433|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
16532434|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
16532435|NCT03069365|Experimental|GLE/PIB for 8 weeks|HCV genotype 1,2,4-6 non-cirrhotic, treatment-naive or treatment-experienced; genotype 3 non-cirrhotic, treatment-naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 8 weeks
16532436|NCT03069365|Experimental|GLE/PIB for 12 weeks|HCV genotype 1,2,4-6 compensated cirrhosis, treatment-naive or treatment-experienced; genotype 3 compensated cirrhosis, treatment- naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 12 weeks
16532437|NCT03069365|Experimental|GLE/PIB for 16 weeks|HCV genotype 3 non-cirrhotic or with compensated cirrhosis, treatment-experienced participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 16 weeks
16532438|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
16532439|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
16532440|NCT03069339|Experimental|Carvedilol+EVL|
16532441|NCT03069339|Experimental|Carvedilol|
16532442|NCT03069339|Active Comparator|EVL|
16532443|NCT03069326|Experimental|Cohort A: Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
16533003|NCT03065335|No Intervention|Phase IV|Follow-up evaluations
16532444|NCT03069326|Experimental|Cohort B: Ruxolitinib and Thalidomide|"A cohort expansion, for patients with baseline thrombocytopenia, will enroll 35 additional patients
~After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs."
16532445|NCT03069313|Experimental|Arm I|Oral Vitamin B12
16532446|NCT03069300|Experimental|prednisolone+NAC|40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
16532447|NCT03069300|No Intervention|prednisolone|40mg prednisolone for 28 days
16532448|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
16532449|NCT03069274|Other|Control|Only general nutritional recommendations were given.
16532450|NCT03069274|Experimental|Intervention|General nutritional recommendations, change their drinking habits.
16532451|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
16532452|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
16532453|NCT03069248|Experimental|treatment arm|"Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.
~."
16532454|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
16532455|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
16532456|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
16532457|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
16532458|NCT03069222||Control|age and gender matched with patient enrolled
16532459|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
16532460|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
16532461|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
16532462|NCT03069170|Experimental|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
16532463|NCT03069170|Experimental|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
16532464|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
16532465|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
16532466|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
16532467|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
16532468|NCT03069131|Experimental|Active rifaximin|
16532469|NCT03069131|Placebo Comparator|Rifaximin placebo|
16532470|NCT03069118|Experimental|Treatment|Three-month intervention on the online Workit Health platform
16532471|NCT03069118|Placebo Comparator|Control|A list of online resources/waitlist
16532472|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
16532473|NCT03069092|Experimental|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
16532474|NCT03069092|Experimental|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
16532475|NCT03069092|Experimental|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
16532476|NCT03069092|No Intervention|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
16532629|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
16532477|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.
~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
16532478|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
16532479|NCT03069040|Experimental|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
16532480|NCT03069040|Active Comparator|radical hysterectomy|The patient recived surgury of radical hysterectomy.
16532481|NCT03069027|Placebo Comparator|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
16532482|NCT03069027|Active Comparator|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
16532483|NCT03069014|Active Comparator|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
16532484|NCT03069014|Active Comparator|800mg LM11A-31-BHS|800mg LM11A-31-BHS
16532485|NCT03069014|Placebo Comparator|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
16532486|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.
~Simeprevir 150 mg orally once-daily.
~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
16532487|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.
~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).
~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
16532488|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
16532489|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
16532490|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
16532491|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
16532492|NCT03068962|Experimental|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
16532493|NCT03068962|Experimental|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
16532494|NCT03068962|Experimental|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
16532495|NCT03068949|Active Comparator|FluBlok|FluBlok 0.5 mL given IM X1
16532496|NCT03068949|Active Comparator|Fluzone|Fluzone 0.5 mL given IM X1
16532497|NCT03068949|Active Comparator|FluCelVax|FluCelVax 0.5 mL given IM X 1
16532498|NCT03068949|Active Comparator|Fluzone HD|Fluzone HD 0.5 mL given IM X1
16532499|NCT03068936|Experimental|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
16532500|NCT03068936|Other|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
16532501|NCT03068910|Experimental|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
16532502|NCT03068910|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
16532503|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
16532504|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
16532505|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
16532506|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
16532507|NCT03068884|Sham Comparator|Tdcs sham|
16532508|NCT03068884|Placebo Comparator|Placebo|
16532509|NCT03068884|Experimental|Tdcs cathodal|
16532510|NCT03068884|Experimental|Tyrosine|
16532511|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
16532512|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
16532513|NCT03068858|Experimental|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
16532514|NCT03068858|No Intervention|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
16532515|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
16532516|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
16532655|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
16532517|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.
~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.
~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
16532518|NCT03068819|Experimental|CIML NK cell after T cell DLT (Pilot Pediatric/Young Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, cytarabine, & G-CSF (FLAG) (or decitabine as an acceptable alternative) to be started 2-4 weeks prior to the CIML NK cell infusion, with Day -1 the day of T cell DLI, & Day 0 denoting the CIML NK cell infusion day. The donor will undergo non-mobilized large volume (20L) leukapheresis on Day -2 or -1, anticipating processing for T cell DLI & NK cell isolation on Day -1.
~A 2nd cycle of therapy may be administered if the patient shows evidence of AML > 30 days after the administration of the 1st course of protocol therapy, & if they continue to meet the eligibility criteria. Salvage chemotherapy may be omitted before a second infusion of DLI & CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, & ML NK cells administered. This optional second cycle will be considered a re-treatment, with date of 2nd NK cell infusion considered a 2nd Day 0."
16532519|NCT03068819|Experimental|CIML NK cell after T cell DLT (Phase 2 Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, cytarabine, & G-CSF (FLAG) (or decitabine as an acceptable alternative) to be started 2-4 weeks prior to the CIML NK cell infusion, with Day -1 the day of T cell DLI, & Day 0 denoting the CIML NK cell infusion day. The donor will undergo non-mobilized large volume (20L) leukapheresis on Day -2 or -1, anticipating processing for T cell DLI & NK cell isolation on Day -1.
~A 2nd cycle of therapy may be administered if the patient shows evidence of AML > 30 days after the administration of the 1st course of protocol therapy, & if they continue to meet the eligibility criteria. Salvage chemotherapy may be omitted before a second infusion of DLI & CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, & ML NK cells administered. This optional second cycle will be considered a re-treatment, with date of 2nd NK cell infusion considered a 2nd Day 0."
16532520|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
16532521|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
16532522|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
16532523|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
16532524|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
16532525|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
16532526|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
16532527|NCT03068780|Experimental|Oleogel-S10|
16532528|NCT03068780|Placebo Comparator|Placebo|
16532529|NCT03068767|Experimental|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
16532530|NCT03068767|No Intervention|Control group|Patients without receiving vitamin D supplement
16532531|NCT03068754|Experimental|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.
~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
16532532|NCT03068754|Placebo Comparator|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.
~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
16532533|NCT03068754|Experimental|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
16532534|NCT03068754|Experimental|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
16532535|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
16532536|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
16532537|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
16532538|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
16532539|NCT03068728|Other|All Study Participants|"Participants received hemostatic packing agent in one nasal cavity and no packing in the other.
~Participants were randomized to one of three hemostatic packing agents (Arista, Nexfoam, Nasopore) through sealed envelope, chosen by surgeon prior to placement, with packing agent allocation and sidedness."
16532540|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
16532541|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
16532542|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
16532543|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
16532544|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
16532545|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
16532546|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
16532547|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:
~blood and saliva: at consultations after inclusion in the study
~faeces: day before the surgery
~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
16532548|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:
~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery
~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery
~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
16532549|NCT03068637|Experimental|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
16532550|NCT03068624|Experimental|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.
~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.
~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
16532551|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
16532552|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
16532553|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
16532554|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
16532555|NCT03068585|No Intervention|Control|Control therapy
16532556|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
16532557|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
16532558|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.
~Patient has to be aged ≥ 18
~Patient has to be able to complete questionnaire in French
~Patient must benefit from health insurance
~Patient must sign an informed consent form
~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
16532559|NCT03068546||Participants providing samples|NCI employees agreeing to provide samples for microbiome sample study
16532560|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
16532561|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
16532562|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
16532564|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.
~will be followed with PET MRI"
16532565|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
16532566|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
16532567|NCT03068494||Coronary Bifurcation Lesion|
16532568|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
16532569|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
16532570|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
16532571|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
16532572|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
16532573|NCT03068468|Experimental|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
16532574|NCT03068468|Placebo Comparator|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
16532575|NCT03068455|Experimental|nivolumab + ipilimumab|Specified Dose on Specified Days
16532576|NCT03068455|Experimental|nivolumab|Specified Dose on Specified Days
16532577|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
16532578|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
16532580|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
16532581|NCT03068403|Other|Radiochemotherapy|
16532584|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
16532585|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
16532586|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
16532587|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
16532588|NCT03068338|Active Comparator|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
16532589|NCT03068338|Experimental|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
16532590|NCT03068325|Experimental|TF-EAT|
16532591|NCT03068312|Experimental|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
16532592|NCT03068312|Experimental|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
16532593|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
16532594|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
16532656|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
16563201|NCT02860104|Other|microwave ablation|microwave ablation
16532595|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
16532596|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
16532597|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
16532598|NCT03068273|Experimental|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
16532599|NCT03068273|Experimental|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
16532600|NCT03068260|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.
~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
16532601|NCT03068260|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.
~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
16532602|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
16532603|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
16532604|NCT03068234|Experimental|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
16532605|NCT03068234|Placebo Comparator|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
16532606|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
16532607|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
16532608|NCT03068208|Experimental|MB-PDT|
16532609|NCT03068208|No Intervention|Control|
16532610|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
16532611|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
16532612|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
16532613|NCT03068182|Experimental|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
16532614|NCT03068182|Experimental|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
16532615|NCT03068156|Experimental|excimer laser|
16532616|NCT03068156|No Intervention|Control|
16532617|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
16532618|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.
~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).
~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
16532619|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
16532620|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
16532621|NCT03068078|No Intervention|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
16532622|NCT03068078|Experimental|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
16532623|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
16532624|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
16532625|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
16532626|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
16532627|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
16532628|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
16533005|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
16532630|NCT03068026|Experimental|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
16532631|NCT03068026|Experimental|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
16532632|NCT03068013|Experimental|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
16532633|NCT03068013|Active Comparator|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
16532634|NCT03068000|Experimental|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
16532635|NCT03068000|Active Comparator|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
16532636|NCT03067987|Active Comparator|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
16532637|NCT03067987|Active Comparator|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)
~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
16532638|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
16532639|NCT03067961|Experimental|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
16532640|NCT03067961|Experimental|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
16532641|NCT03067948|Experimental|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
16532642|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
16532643|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
16532644|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
16532645|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
16532646|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.
~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.
~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).
~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
16532647|NCT03067870|Experimental|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
16532648|NCT03067857|Experimental|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
16532649|NCT03067844|Experimental|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
16532650|NCT03067844|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
16532651|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
16532652|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
16532653|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
16532654|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
16532657|NCT03067792|Active Comparator|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
16532658|NCT03067792|Active Comparator|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
16532659|NCT03067779|Other|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.
~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
16532660|NCT03067766|Experimental|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
16532661|NCT03067766|Experimental|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
16532662|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
16532663|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
16532664|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
16532665|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
16532666|NCT03067727|Experimental|Dinoprostone vaginal insert|
16532667|NCT03067727|Placebo Comparator|Placebo|
16532668|NCT03067714|Experimental|Active product: partially hydrolysed formula + synbiotics|
16532669|NCT03067714|Active Comparator|Control product: standard formula (intact protein)|
16532670|NCT03067701|Experimental|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
16532671|NCT03067688|Experimental|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
16532672|NCT03067688|Active Comparator|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
16532673|NCT03067688|Active Comparator|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
16532674|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
16532675|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
16532676|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
16532677|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
16532678|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
16532679|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
16532680|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
16532681|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.
~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
16532682|NCT03067623|Experimental|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
16532683|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
16532684|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
16532685|NCT03067571|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16532686|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to <2 months, children 2 to <12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
16532687|NCT03067558||Consistency evaluation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
16532688|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
16532689|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
16532690|NCT03067532|Experimental|A|
16532691|NCT03067532|Active Comparator|B|
16532692|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
16532693|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
16532694|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
16532695|NCT03067493|Experimental|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, >1) and type of surgery (RFA，hepatectomy).
16532696|NCT03067493|No Intervention|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first year and every 4 months in the second and third year.
16532697|NCT03067480|Experimental|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
16532698|NCT03067480|Experimental|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
16532699|NCT03067467||Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
16532700|NCT03067467||Controls|Healthy Control subjects will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI. This will be followed by a Brain MRI with gadolinium-based contrast.
16532701|NCT03067454|Other|conservative group|Treatment with early mobilisation
16532702|NCT03067454|Other|operative group|Treatment with operation
16532703|NCT03067441|Experimental|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
16532704|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
16532705|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
16532706|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
16532707|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
16532708|NCT03067402|Other|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
16532709|NCT03067402|Experimental|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
16532710|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
16532711|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
16532712|NCT03067376|Experimental|[14C]-CORT125134|Two capsules each containing 125 milligrams (mg) [14C]-CORT125134 administered to each participant on 1 occasion
16532713|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
16532714|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
16532715|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
16532716|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
16532717|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
16532718|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
16532719|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
16532720|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
16532721|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
16532722|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
16532723|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
16532724|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
16532725|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
16532726|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
16532727|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
16532728|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
16532729|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
16532730|NCT03067272|Experimental|FemBloc® Permanent Contraceptive System|Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
16532731|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
16532732|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
16532733|NCT03067246|Active Comparator|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
16532734|NCT03067246|Active Comparator|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
16532735|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
16532736|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
16532737|NCT03067220|Experimental|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
16532738|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
16532739|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
16532740|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
16532741|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
16532747|NCT03067168|Active Comparator|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
16532748|NCT03067168|Placebo Comparator|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
16532749|NCT03067155|Experimental|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
16532750|NCT03067155|Active Comparator|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
16532751|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
16532752|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
16532753|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
16532784|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
16532754|NCT03067129|Experimental|Cohort 1: Adult formulation GLE/PIB, participants 12 to < 18 yrs|Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to < 18 years of age
16532755|NCT03067129|Experimental|Cohort 2: Pediatric formulation GLE/PIB, participants 9 to < 12 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to < 12 years of age
16532756|NCT03067129|Experimental|Cohort 3: Pediatric formulation GLE/PIB, participants 6 to < 9 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to < 9 years of age
16532757|NCT03067129|Experimental|Cohort 4: Pediatric formulation GLE/PIB, participants 3 to < 6 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to < 6 years of age
16532758|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
16532759|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
16532760|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
16532761|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
16532762|NCT03067090|Experimental|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
16532763|NCT03067077|Active Comparator|SMILE|SMILE surgery
16532764|NCT03067077|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
16532765|NCT03067051|Experimental|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.
~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.
~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).
~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
16532766|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
16532767|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
16532768|NCT03067025||30 youth with MS|
16532769|NCT03067025||30 healthy control participants|
16532770|NCT03067012|Experimental|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
16532771|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
16532772|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
16532773|NCT03066986|Experimental|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
16532774|NCT03066986|Experimental|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
16532775|NCT03066986|Active Comparator|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
16532776|NCT03066986|Experimental|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
16532777|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
16532778|NCT03066973|No Intervention|Control group|control group that received standard care service.
16532779|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
16532780|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
16532781|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
16532782|NCT03066934||NIV Failure Group|NIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
16532783|NCT03066934||NIV success group|Children who successfully managed their noninvasive ventilation therapy
16563408|NCT02858765|Experimental|white polychromatic light D|
16532785|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
16532786|NCT03066908|Experimental|Single Arm|Sinopsys® Lacrimal Stent
16532787|NCT03066895|Experimental|Experimental|BabyGentleStick
16532788|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
16532789|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
16532790|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
16532791|NCT03066869|Experimental|H.P. ACTHAR GEL|
16532792|NCT03066856|Experimental|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
16532793|NCT03066856|No Intervention|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
16532794|NCT03066843|Experimental|Zero incubation with ALA (5-aminolevulinic acid)|Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
16532795|NCT03066843|Experimental|One hour incubation with ALA (5-aminolevulinic acid)|Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
16532796|NCT03066830|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
16532797|NCT03066830|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
16532798|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
16532799|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
16532800|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.
~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).
~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
16532801|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).
~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).
~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).
~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
16532802|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:
~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.
~Supplied by Sabinsa Corporation"
16532803|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:
~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.
~Supplied by Sabinsa corporation"
16532804|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets
~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.
~Dose: subjects in this group will take 6 placebo tablets per day"
16532807|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
16532808|NCT03066752||7 pediatric-onset multiple sclerosis|
16532809|NCT03066752||7 non-patient healthy volunteers|
16532810|NCT03066739|Active Comparator|LO-low dose remifentanil|low dose remifentanil (LO, 0.1 micrograms/kg/mL),
16532812|NCT03066739|Active Comparator|HN-high dose remifentanil with ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).
16532813|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
16532814|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
16532815|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
16532816|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
16532817|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
16532818|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
16532819|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
16532820|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
16532821|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
16532822|NCT03066674|Experimental|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
16532823|NCT03066674|Experimental|Control group|The Group will not receive Hand-on technique on the lumbar spine.
16532824|NCT03066648|Experimental|Decitabine and PDR001|Decitabine in combination with PDR001
16532825|NCT03066648|Experimental|Decitabine and MBG453|Decitabine in combination with MBG453
16532826|NCT03066648|Experimental|Decitabine, PDR001 and MBG453|Decitabine in combination with PDR001 and MBG453
16532827|NCT03066648|Experimental|MBG453|MBG453 alone
16532828|NCT03066648|Experimental|MBG453 and PDR001|MBG453 in combination with PDR001
16532829|NCT03066648|Experimental|Azacitidine and MBG453|Azacitidine in combination with MBG453
16532830|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
16532831|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
16532832|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
16532833|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
16532834|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
16532835|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
16532836|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
16532837|NCT03066596|Experimental|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
16532838|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
16532839|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
16532840|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
16532841|NCT03066557|Active Comparator|study group|TACE and Apatinib
16532842|NCT03066557|Experimental|control group|TACE alone
16532843|NCT03066544|Active Comparator|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
16532844|NCT03066544|Active Comparator|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
16532845|NCT03066544|Active Comparator|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
16532846|NCT03066544|Active Comparator|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
16532847|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
16532848|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.
~Assigned Interventions: Behavioral: usual care (CBT)"
16532849|NCT03066518|Placebo Comparator|Melatonin|Melatonin 5 mg, daily, eight weeks
16532850|NCT03066518|Placebo Comparator|placebo|Placebo, daily, eight weeks
16532851|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
16532852|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
16532853|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
16532854|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
16532855|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
16533084|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
16563444|NCT02858479|Other|patients with pain allodynic peripheral|
16532856|NCT03066466|Experimental|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant & continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
16532857|NCT03066466|Active Comparator|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
16532858|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
16532859|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
16532860|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
16532861|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
16532862|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
16532863|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.
~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
16532864|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.
~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
16532865|NCT03066388|Experimental|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
16532866|NCT03066375|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
16532867|NCT03066362|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
16532868|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
16532869|NCT03066349||Patients with PCOS undergoing IVM|
16532870|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
16532871|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
16532872|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
16532873|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
16532874|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
16532875|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
16532876|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
16532877|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
16532878|NCT03066271|Experimental|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.
~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
16532879|NCT03066271|Experimental|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
16532880|NCT03066258|Experimental|Dose 1|3E9 GC/eye of RGX-314
16532881|NCT03066258|Experimental|Dose 2|1E10 GC/eye of RGX-314
16532882|NCT03066258|Experimental|Dose 3|6E10 GC/eye of RGX-314
16532883|NCT03066258|Experimental|Dose 4|1.6E11 GC/eye of RGX-314
16532884|NCT03066258|Experimental|Dose 5|2.5E11 GC/eye of RGX-314
16532885|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
16532886|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
16532887|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
16532888|NCT03066206|Experimental|Treatment (poziotinib)|Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16532889|NCT03066193|Experimental|Dronabinol and Palmitoylethanolamide|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
16532890|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
16532891|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
16532892|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
16532893|NCT03066167||Controls|Healthy Controls with no known dysphagia
16532894|NCT03066154|Experimental|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
16532895|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
16532896|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
16532897|NCT03066128|Experimental|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
16532898|NCT03066128|Experimental|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
16532899|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
16532900|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.
~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
16532901|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
16532902|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
16532903|NCT03066076|Active Comparator|Thyroidectomy|Total thyroidectomy
16532904|NCT03066076|Active Comparator|Antithyroid drug|Thiamazol, Propylthiouracil
16532905|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
16532906|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
16532907|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
16532908|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
16532909|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
16532910|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
16532911|NCT03066011||Voriconazole Group|Oral and Intravenous
16532912|NCT03066011||Posaconazole Group|Oral and Intravenous
16532913|NCT03065998|Active Comparator|Drug-A|opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
16532914|NCT03065998|Active Comparator|Drug-B|baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
16532915|NCT03065972|Active Comparator|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
16532916|NCT03065972|Active Comparator|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
16532917|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
16532918|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
16532919|NCT03065946||Case series|Early wakening
16532920|NCT03065933|Experimental|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
16563445|NCT02858479|Other|patients with pain allodynic central|
16532921|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
16532922|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
16532923|NCT03065894|Experimental|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
16532924|NCT03065894|Active Comparator|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
16532925|NCT03065881|Active Comparator|Dilated versus Natural pupil|
16532926|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
16532927|NCT03065868|Experimental|eradictaion|H. pylori eradication group
16532928|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
16532929|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
16532930|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
16532931|NCT03065842|Experimental|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
16532932|NCT03065842|Active Comparator|Usual standards|Usual standards
16532933|NCT03065829|Experimental|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
16532934|NCT03065829|Experimental|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
16532935|NCT03065816|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
16532936|NCT03065816|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
16532937|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).
~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
16532938|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
16532939|NCT03065777|Experimental|ONE ENDO|Single file rotary system
16532940|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
16532941|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
16532942|NCT03065764|Other|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
16532943|NCT03065751|Active Comparator|TPE|
16532944|NCT03065751|No Intervention|Kontroll|
16532945|NCT03065738|Experimental|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
16532946|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.
~Procedure: Computed Tomography
~Drug: [F-18] fluoroestradiol: [F-18]FES
~Other: Laboratory Biomarker Analysis
~Procedure: Positron Emission Tomography"
16532947|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
16563446|NCT02858466|Experimental|peripheric nervous lesion|MRI scan
16532948|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
16532949|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
16532950|NCT03065673|Active Comparator|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
16532951|NCT03065673|Placebo Comparator|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
16532952|NCT03065660|Active Comparator|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
16532953|NCT03065660|Placebo Comparator|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
16532954|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
16532955|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.
~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
16532956|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
16532957|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
16532958|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
16532959|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
16532960|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
16532961|NCT03065595|Placebo Comparator|Intervention|Ophicephalus striatus extract
16532962|NCT03065595|Active Comparator|Control|Placebo drug
16532963|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
16532964|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
16532965|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
16532966|NCT03065556|Experimental|188-0551 Solution|188-0551 Solution applied topically twice daily
16532967|NCT03065556|Placebo Comparator|Vehicle Solution|Vehicle Solution applied topically twice daily
16532968|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
16532969|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
16532970|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
16532971|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
16532972|NCT03065517|Experimental|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
16532973|NCT03065517|Placebo Comparator|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial.
16532974|NCT03065504|Active Comparator|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )
~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
16533004|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
16563447|NCT02858466|Experimental|medullar or encephalic lesion|MRI scan
16532975|NCT03065504|Active Comparator|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:
~Turmeric (Curcuma longa) - 50 mg/tablet
~Hemidesmus Indicus root (Anantamul)
~Indian Madder root
~Neem leaf
~Gotu Kola leaf
~Indian TInospora stem
~Amla fruit
~Licorice root
~Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
16532976|NCT03065504|Placebo Comparator|Placebo tablets group|"Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals
~Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder
~Dose: subjects in this group will take 2 tablets twice per day"
16532977|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
16532978|NCT03065491|Placebo Comparator|Placebo|Placebo
16532979|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
16532980|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
16532981|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
16532982|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
16532983|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
16532984|NCT03065439|Experimental|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
16532985|NCT03065439|Experimental|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
16532986|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
16532987|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
16532988|NCT03065400|Experimental|Pembolizumab|
16532989|NCT03065387|Experimental|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16532990|NCT03065387|Experimental|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16532991|NCT03065387|Experimental|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16532992|NCT03065374|Experimental|Treatment arm A|IMM-529, 1000 mg three times daily, orally
16532993|NCT03065374|Placebo Comparator|Treatment arm B|Matching Placebo, three times daily, orally
16532994|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.
~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
16532995|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
16532996|NCT03065348|Experimental|Intervention|"Around 2 to 4 weeks before surgery:
~Fried frailty score
~CARE score assessment
~NRS Kondrup assessment
~Plasma albumin and CRP values
~Start with daily oral whey protein administration until evening before surgery45
~Around 5-7 days before surgery:
~- Start with immunonutrition
~Evening before surgery:
~CARE score assessment
~NRS Kondrup
~CERAD cognition test assessment
~Plasma albumin and CRP values, urine specific gravity
~Carbohydrate loading
~If urine specific gravity is >1.020 then additional tap water drinking will be encouraged
~Day of surgery:
~Carbohydrate loading
~Start anesthesia with spinal anesthesia (continuous)
~POD 7:
~CARE assessment
~CERAD assessment
~Plasma albumin and CRP values
~POD14:
~CARE assessment
~Plasma albumin and CRP value
~POD 30:
~CARE assessment
~NRS Kondrup
~CERAD assessment
~Plasma albumin and CRP values
~POD 90:
~CARE assessment
~NRS Kondrup
~CERAD assessment"
16532997|NCT03065335|Experimental|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
16532998|NCT03065335|No Intervention|Phase I|Medication taper, drug-free period, and baseline assessments
16532999|NCT03065335|Experimental|Phase II Arm 1|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG or MEG
16533000|NCT03065335|Placebo Comparator|Phase II, Arm 2|Double-blind, single dose of 0.5 mg/kg IV saline
16533001|NCT03065335|Placebo Comparator|Phase II, Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
16533006|NCT03065296|Experimental|Musculoskeletal (MSK) Exercise Prescription|"Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.
~In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
~Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1
~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
16533007|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
16533008|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
16533009|NCT03065270|Experimental|A group|
16533010|NCT03065270|Experimental|B group|
16533011|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
16533012|NCT03065244|Active Comparator|IVIG|Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
16533013|NCT03065244|Active Comparator|Infliximab|Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours
16533014|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
16533015|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
16533016|NCT03065218|Experimental|99mTc sestamilbi|25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite
16533017|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
16533018|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
16533019|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
16533020|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
16533021|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
16533022|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
16533023|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
16533024|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy Followed by a period of detraining.
~They will then undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy"
16533025|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.
~They will then undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy"
16533026|NCT03065127|Experimental|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
16533027|NCT03065127|Experimental|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
16533028|NCT03065127|Experimental|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
16533029|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
16533030|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape
~Resistance to femoral head rotation and cut-out
~Active compression through linear motion without rotation
~Single subtrochanteric lag screw option for stable fractures below lesser trochanter
~Preloaded cannulated set screw converts construct to fixed angle device
~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon
~Clothespin tip for stress modulation in femoral shaft
~Potential for improved patient mobility and recovery
~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.
~Interventions:
~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
16533031|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.
~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.
~Participating sites may use whichever brand of SHS is currently in use.
~Interventions:
~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
16533032|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
16533033|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
16533034|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
16533035|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
16533036|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
16533037|NCT03065062|Experimental|Combination Of Palbociclib and Gedatolisib|"Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.
~Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
16533038|NCT03065049|Experimental|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
16533039|NCT03065049|Active Comparator|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
16533040|NCT03065049|No Intervention|Usual Care|Participants do not receive any intervention but participate in the assessments only.
16533041|NCT03065036|Experimental|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
16533042|NCT03065036|Other|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
16533043|NCT03065023|Experimental|Group A: Cutaenous lesions|Participants with transdermally/transmucosally injectable tumors including cutaneous, subcutaneous or lymph node injectable tumors received escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection twice each week (Q2W) over a period of 4 weeks. Participants may have continued to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years).
16533044|NCT03065023|Experimental|Group B: Liver lesions|Participants with injectable liver tumors or liver metastases were to receive escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection once each week over a period of 4 weeks. Participants were to have been able to continue to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years). (Group B was not started. Development will continue with new protocol.)
16533045|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
16533046|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
16533047|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
16533048|NCT03064984|Active Comparator|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
16533049|NCT03064984|Active Comparator|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
16533050|NCT03064971|Experimental|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
16533051|NCT03064971|Active Comparator|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
16533052|NCT03064971|Active Comparator|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
16533053|NCT03064958|Active Comparator|Control|Consumption of a high fat meal (1000kcal, 45g fat)
16533054|NCT03064958|Experimental|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
16533085|NCT03064724|Experimental|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
16534419|NCT03055936|Experimental|C1|levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
16533055|NCT03064958|Experimental|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
16533056|NCT03064945|Sham Comparator|Shame device|
16533057|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
16533058|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).
~Post prandial test meal will be contain minimal amounts of spice."
16533059|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).
~Post prandial test meal will be contain a moderate amount of spice."
16533060|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).
~Post prandial test meal will be contain a culinary amount of spice."
16533061|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
16533062|NCT03064906|Other|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.
~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
16533063|NCT03064893|Active Comparator|Dermacell|Device for immediate implant based breast reconstruction
16533064|NCT03064893|Active Comparator|Alloderm|Device for immediate implant based breast reconstruction
16533065|NCT03064880|Active Comparator|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
16533066|NCT03064880|No Intervention|SV normalization|NO active fluid therapy.
16533067|NCT03064867|Experimental|V+RICE|"Venetoclax given in combination with R-ICE chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide)
~Phase I part of this study is a 3 + 3 design, with 3 dose levels, a minimum of 6 participants (maximum of 18) will be required to identify the recommended phase 2 dose (RP2D).
~Phase II involvs two stages: In stage I, a total of 16 participants will be accrued. If there are 7 or fewer complete responses (CR), the study will be stopped. Otherwise, an additional 30 participants will be accrued in stage II.
~The maximum number of treatment cycles with V+RICE is three. Participants who achieve complete remission at the interim response assessment after 2 cycles may omit cycle 3 in order to proceed to subsequent consolidation therapy with autologous stem cell transplant (AHSCT).
~Participants will proceeed to other treatment including RICE, other chemotherapy, peripheral blood stemm cell collection, and ASCT per institutional guidelines."
16533068|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
16533069|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
16533070|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
16533071|NCT03064854|Experimental|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
16533072|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
16533073|NCT03064828|Active Comparator|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
16533074|NCT03064828|Experimental|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
16533075|NCT03064815|Experimental|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
16533076|NCT03064815|Experimental|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
16533077|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
16533078|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
16533079|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to
~Continuously capture multidimensional behaviour as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.
~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision support system (CDSS) and Recommender operation.
~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient-initiated (i.e. on-demand) real-time assessments, to the participants and in their own environment."
16533080|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
16533081|NCT03064763|Experimental|Talimogene laherparepvec|"Participants will receive talimogene laherparepvec administered by intralesional injection only into injectable cutaneous, subcutaneous, and nodal tumors, with or without image ultrasound guidance.
~On Day 1 (Week 0), the initial dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 Plaque forming units per millilitre (PFU/mL). Subsequent doses of talimogene laherparepvec will be up to 4.0 mL of 10^8 or 10^7 PFU/mL. The second dose is to be administered 3 weeks (+ 5 days) after the initial dose, and subsequent doses were to be given every 2 weeks (+ 3 days)."
16533082|NCT03064750|Experimental|Pre-surgery exercise|pelvic floor exercises individually and in groups
16533083|NCT03064750|Other|Waiting list|wait as usual until surgery
16563448|NCT02858466|Other|control group|MRI scan
16533086|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
16533087|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
16533088|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
16533089|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
16533090|NCT03064672|Experimental|induction by transcervical Balloon Catheters insertion|
16533091|NCT03064672|No Intervention|induction without transcervical Balloon Catheters|
16533092|NCT03064646|Experimental|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
16533093|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
16533094|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
16533095|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
16533096|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
16533097|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
16533098|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
16533099|NCT03064594||cornuostomy|cornuostomy
16533100|NCT03064594||wedge resection|wedge resection
16533101|NCT03064581|Experimental|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
16533102|NCT03064581|No Intervention|Control|Usual care with delayed intervention at the end of study.
16533103|NCT03064568|Experimental|Misoprostol 100Mcg Tab|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
16533104|NCT03064568|Placebo Comparator|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
16533105|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test
~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.
~Constant load exercise test
~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
16533106|NCT03064555||Healthy participants|"Cardiopulmonary exercise test
~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.
~Constant load exercise test
~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
16533107|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
16533108|NCT03064516|Experimental|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
16533109|NCT03064516|Active Comparator|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
16533110|NCT03064503|Experimental|Healthy volunteers|Sedentary healthy subjects will be recruited in this study. MRI, skin auto-fluorescence measures and blood sampling will be performed
16533112|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.
~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
16533113|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
16533114|NCT03064464||CA-MRSA infection|None intervention
16533115|NCT03064464||HA-MRSA infection|None intervention
16533116|NCT03064464||CA-MSSA infection|None intervention
16533117|NCT03064451|Experimental|Intervention|cartofinder guided ablation followed by PVI
16533118|NCT03064438|Experimental|ACU-D1 Ointment|Twice-daily application of ACU-D1 ointment to the face for 12 weeks.
16564054|NCT02854293||Booklet-Question List (BQL) group|76 patients
16533119|NCT03064438|Placebo Comparator|ACU-D1 Ointment Vehicle|Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.
16533120|NCT03064399|Experimental|lateral ligament repairment|
16533121|NCT03064399|Experimental|without lateral ligament repairment|
16533122|NCT03064386|Experimental|plate group|internal fixation with the plate
16533123|NCT03064386|Experimental|screw group|internal fixation with the screw
16533124|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
16533125|NCT03064347|Active Comparator|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
16533126|NCT03064347|Placebo Comparator|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
16533127|NCT03064347|Active Comparator|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
16533128|NCT03064347|Placebo Comparator|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
16533129|NCT03064347|Active Comparator|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
16533130|NCT03064347|Placebo Comparator|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
16533131|NCT03064347|Active Comparator|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
16533132|NCT03064347|Placebo Comparator|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
16533133|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.
~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
16533134|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
16533135|NCT03064321|Other|Information Control|General health information website
16533136|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
16533137|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
16533138|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
16533139|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
16533140|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
16533141|NCT03064282|Placebo Comparator|Placebo|Drug free base as placebo
16533142|NCT03064282|Experimental|group two- papaverine arm|papaverine in a suitable base
16533143|NCT03064269|Experimental|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
16533144|NCT03064256|Experimental|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.
~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
16533145|NCT03064256|No Intervention|Control Group|Control participants receive routine outpatient care for a 12-week period.
16533146|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
16533147|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.
~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.
~QoL questionnaire SF-12 and and a screening questionnaire were requested"
16533148|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.
~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
16533149|NCT03064217|Active Comparator|CLP and 12 weeks waiting|After core build-up and initial tooth preparation, a clinical crown lengthening procedure (CLP) will be performed. Restorative treatments will be initiated 12 weeks after CLPs.
16533150|NCT03064217|Experimental|Digital impression taken at surgery|The final impression will be taken at surgery. The final crown will be delivered at suture removal.
16533151|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
16533152|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
16533153|NCT03064191|Active Comparator|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
16533154|NCT03064191|Active Comparator|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
16533155|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
16533156|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
16533157|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
16533158|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
16533159|NCT03064139|Experimental|MCG - Mindful Walking|Participants will be trained in mindful walking technique
16533160|NCT03064139|Active Comparator|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
16533163|NCT03064113|Experimental|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
16533164|NCT03064113|Experimental|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
16533165|NCT03064113|Experimental|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
16533166|NCT03064113|Experimental|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
16533167|NCT03064100||Specimens that meet inclusion criteria|
16533168|NCT03064074|Experimental|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).
~At each study visit, the participant may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug"
16533169|NCT03064074|Experimental|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).
~At each study visit, the participant may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug"
16533170|NCT03064074|Experimental|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.
~At each study visit, participants may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug
~Skeletal survey
~Peripheral quantitative CT (pQCT) of the forearm
~Quality of Life Surveys
~Pulmonary function test
~Walk test"
16533171|NCT03064074|Experimental|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.
~At each study visit, participants may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug
~Skeletal survey
~Peripheral quantitative CT (pQCT) of the forearm
~Quality of Life Surveys
~Pulmonary function test
~Walk test"
16533172|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
16533173|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
16533174|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
16533175|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
16533176|NCT03064035|Experimental|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.
~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
16533177|NCT03064035|Active Comparator|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:
~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR >6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
16533178|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
16533179|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
16533180|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
16533181|NCT03064022||Size for gestational age|Small size for gestational age
16533182|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
16533183|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
16533184|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
16533185|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
16533186|NCT03063983|No Intervention|Control|31 weeks of MAP
16533187|NCT03063970|Experimental|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
16533188|NCT03063970|Active Comparator|Comparison Group|Usual rehabilitation
16533189|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
16533190|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
16533191|NCT03063944|Experimental|Treatment (STAT inhibitor OPB-111077, venetoclax, decitabine)|"INDUCTION CYCLE 1: Patients receive STAT inhibitor OPB-111077 PO QD on days 1-28, and venetoclax PO QD on days 4-28 of cycle 1. Patients also receive decitabine IV over approximately 1 hour on days 4-8 of cycle 1. Patients who achieve complete remission (CR) after 1 cycle move on to Maintenance, and patients who do not achieve a CR move on to Cycle 2.
~INDUCTION CYCLE 2: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Patients who achieve CR, CRi, PR, or stable disease (or clinically significant hematologic improvement as determined by the investigator) move on to Maintenance.
~MAINTENANCE: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16533192|NCT03063931|Experimental|magnesium|
16533193|NCT03063931|Placebo Comparator|placebo|
16533194|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
16533195|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
16533196|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
16533197|NCT03063892|Placebo Comparator|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
16533198|NCT03063892|Experimental|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
16533199|NCT03063879|Experimental|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
16533200|NCT03063866|Active Comparator|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
16533201|NCT03063866|Active Comparator|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
16533202|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
16533203|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
16533204|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
16533205|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
16533206|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
16533207|NCT03063814|Experimental|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
16533208|NCT03063814|Active Comparator|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
16533209|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
16533210|NCT03063788|Experimental|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
16533211|NCT03063788|Experimental|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
16533212|NCT03063788|Experimental|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
16533213|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
16533214|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
16533215|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
16533216|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
16533217|NCT03063775|No Intervention|5. Spongostan®|
16533262|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
16567034|NCT02833064||Stable Cirrhotics|- biological sampling
16533218|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
16533219|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
16533220|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: no new participants are being enrolled in the arm at this time."
16533221|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: no new participants are being enrolled in the arm at this time."
16533222|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: no new participants are being enrolled in the arm at this time."
16533223|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: Arm D is closed for future enrollment"
16533224|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
16533225|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
16533226|NCT03063736|Experimental|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
16533227|NCT03063736|Placebo Comparator|Td vaccine only|Td vaccine (4 ug) (n=15)
16533228|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
16533229|NCT03063723||Healthy controls|10 Healthy controls without any treatment
16533230|NCT03063697||patients who check the safety data after taking Dilatrend SR|
16533231|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.
~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
16533232|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.
~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.
~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.
~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
16533233|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
16533234|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
16533235|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
16533263|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
16533236|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
16533237|NCT03063658|Active Comparator|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
16533238|NCT03063658|Active Comparator|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
16533239|NCT03063645|Experimental|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
16533240|NCT03063645|Experimental|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
16533241|NCT03063645|Experimental|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
16533242|NCT03063632|Experimental|Group I (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
16533243|NCT03063632|Experimental|Group II (pembrolizumab, interferon gamma-1b)|Patients pembrolizumab IV over 30 minutes on day 1 and interferon gamma-1b SC once a week. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity.
16533244|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
16533245|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
16533246|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
16533247|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
16533248|NCT03063580|Experimental|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
16533249|NCT03063567|Other|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
16533250|NCT03063567|Other|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
16533251|NCT03063567|Other|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
16533252|NCT03063554|Active Comparator|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
16533253|NCT03063554|Placebo Comparator|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
16533254|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
16533255|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
16533256|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.
~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips
~website and mobile app"
16533257|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.
~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips
~website and mobile app"
16533258|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
16533259|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
16533260|NCT03063489|Experimental|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
16533261|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.
~All subjects will undergo the same procedures and interventions."
16534423|NCT03055936|Experimental|C2|levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
16533264|NCT03063450|Experimental|Nivolumab|Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
16533265|NCT03063450|Placebo Comparator|Placebo|Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
16533266|NCT03063437|Experimental|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
16533267|NCT03063437|Placebo Comparator|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
16533268|NCT03063424|Other|Healthy subjects|
16533269|NCT03063424|Other|Asthmatics with EIB|
16533270|NCT03063411|Experimental|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
16533271|NCT03063411|Active Comparator|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
16533272|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
16533273|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
16533274|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
16533275|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
16533276|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
16533277|NCT03063359|Experimental|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
16533278|NCT03063359|Active Comparator|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
16533279|NCT03063346|Experimental|Protein hydrolysate high dose|
16533280|NCT03063346|Experimental|Protein hydrolysate low dose|
16533281|NCT03063346|Placebo Comparator|Placebo|
16533282|NCT03063333|Experimental|Coping-oriented hypnosis|
16533283|NCT03063333|Placebo Comparator|Neutral hypnosis|
16533284|NCT03063333|No Intervention|current treatment only|
16533285|NCT03063320|Active Comparator|Low Spice|The test meal (~1200kcal and 44g fat) will contain ~0.6g of spice blend
16533286|NCT03063320|Experimental|Moderate Spice|The test meal (~1200kcal and 44g fat) will contain ~3.7g of spice blend
16533287|NCT03063320|Experimental|Culinary Spice|The test meal (~1200kcal and 44g fat) will contain ~7.4g of spice blend
16533288|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
16533289|NCT03063307|Experimental|Silver Diamine Fluoride|
16533290|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
16533291|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
16533292|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
16533293|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
16533294|NCT03063268|Experimental|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
16533295|NCT03063268|Experimental|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
16533296|NCT03063268|Active Comparator|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
16533297|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
16533298|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
16533299|NCT03063242|Experimental|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
16533300|NCT03063242|Experimental|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels <1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
16533371|NCT03062787|Experimental|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
16533301|NCT03063242|Experimental|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count <1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
16533302|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
16533303|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
16533304|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
16533305|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
16533306|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
16533307|NCT03063203|Experimental|Decitabine|"Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle
~Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.
~Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
16533308|NCT03063190|Placebo Comparator|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
16533309|NCT03063190|Active Comparator|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
16533310|NCT03063190|Placebo Comparator|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
16533311|NCT03063190|Active Comparator|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
16533312|NCT03063177|Experimental|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
16533313|NCT03063177|Experimental|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
16533314|NCT03063177|Experimental|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
16533315|NCT03063177|No Intervention|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
16533316|NCT03063164|Active Comparator|Intralase IFS|Intralase IFS vs. Visumax
16533317|NCT03063164|Active Comparator|Visumax|Visumax vs. Intralase iFS
16533318|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
16533319|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
16533320|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
16533321|NCT03063112|Active Comparator|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
16533322|NCT03063112|Placebo Comparator|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
16533323|NCT03063099|Experimental|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
16533324|NCT03063086|Active Comparator|Sequence 1|A-B-C
16533325|NCT03063086|Active Comparator|Sequence 2|A-C-B
16533326|NCT03063086|Active Comparator|Sequence 3|B-C-A
16533327|NCT03063086|Active Comparator|Sequence 4|B-A-C
16533328|NCT03063086|Active Comparator|Sequence 5|C-A-B
16533329|NCT03063086|Active Comparator|Sequence 6|C-B-A
16533330|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
16533331|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
16533332|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
16533333|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
16533334|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
16533335|NCT03063034|Active Comparator|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
16533336|NCT03063034|Active Comparator|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
16533337|NCT03063021|Experimental|Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)|Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) in the aqueous.
16533372|NCT03062787|Active Comparator|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
16533338|NCT03063021|Experimental|Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)|Subjects with RP who don't have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.
16533339|NCT03063008|Other|Lumbar fusion with PEEK cage|Control arm
16533340|NCT03063008|Other|Lumbar fusion with TiPEEK cage|Study arm
16533341|NCT03062995|Experimental|Active product: partially hydrolysed formula + synbiotics|partially hydrolysed formula + synbiotics
16533342|NCT03062995|Active Comparator|Control product: standard formula (intact protein)|standard formula (intact protein)
16533343|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
16533344|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
16533345|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
16533346|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
16533347|NCT03062956|Experimental|Single oral dose of MYK-491|single-dose, oral suspension
16533348|NCT03062956|Placebo Comparator|Single oral dose of placebo|single-dose, oral suspension
16533349|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
16533350|NCT03062930|Active Comparator|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
16533351|NCT03062930|Sham Comparator|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
16533352|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
16533353|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
16533354|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
16533355|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
16533356|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
16533357|NCT03062904|Experimental|drug|
16533358|NCT03062891|Experimental|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.
~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
16533359|NCT03062891|No Intervention|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
16533360|NCT03062878||Breast Cancer/Lymphoma Patient|Breast cancer or lymphoma patients currently undergoing anthracycline-based chemotherapy treatment. Patients are eligible if they have completed at least 1 cycle of chemotherapy. Free of known clinical cardiovascular disease.
16533361|NCT03062878||Breast Cancer/Lymphoma Survivor|Individuals with history of breast cancer or lymphoma (1-5 years removed from last date of chemotherapy) who have a treatment history of anthracycline-based chemotherapy. Free of known clinical cardiovascular disease.
16533362|NCT03062878||Control|Individuals with no history of caner or chemotherapy. Free of known clinical cardiovascular disease
16533363|NCT03062852|Experimental|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
16533364|NCT03062852|No Intervention|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
16533365|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
16533366|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
16533367|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
16533368|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
16533369|NCT03062800|Experimental|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):
~Pemetrexed + Platinum + Thalidomide [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn ]
~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):
~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
16533370|NCT03062800|Experimental|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):
~Pemetrexed + Platinum [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt ]
~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):
~Pemetrexed (500mg/m^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
16533374|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
16533375|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
16533376|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
16533377|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
16533378|NCT03062722|Experimental|keyhole approach|open minimally invasive approach
16533379|NCT03062709|Experimental|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
16533380|NCT03062696|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
16533381|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
16533382|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
16533383|NCT03062670|Experimental|Retreat|A full day off-site training session
16533384|NCT03062670|No Intervention|Control|Care teams normal process
16533385|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
16533386|NCT03062644|Experimental|MR308 100 mg bid|Tramadol/Celecoxib)
16533387|NCT03062644|Experimental|MR308 150 mg bid|Tramadol/Celecoxib
16533388|NCT03062644|Experimental|MR308 200 mg bid|Tramadol/Celecoxib
16533389|NCT03062644|Active Comparator|Tramadol 100 mg qid|Tramadol
16533390|NCT03062644|Active Comparator|Celecoxib 100 mg bid|Celecoxib
16533391|NCT03062644|Placebo Comparator|Placebo|Placebo
16533392|NCT03062618|Experimental|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
16533393|NCT03062618|Placebo Comparator|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
16533394|NCT03062618|Experimental|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
16533395|NCT03062618|Placebo Comparator|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
16533396|NCT03062618|Experimental|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
16533397|NCT03062618|Placebo Comparator|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
16533398|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
16533399|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
16533400|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
16533401|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
16533402|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
16533403|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
16533404|NCT03062566||Severe TBI patients|GCS 3-8
16533405|NCT03062553|Experimental|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.
~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.
~The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
16533406|NCT03062553|Experimental|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.
~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
16533440|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
16533441|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
16533407|NCT03062553|Experimental|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.
~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.
~TAU is a four week waitlist control group."
16533408|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
16533409|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
16533410|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.
~Interventions:
~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
16533411|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)
~Interventions:
~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
16533412|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
16533413|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
16533414|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
16533415|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
16533416|NCT03062488|Active Comparator|opioid only|2 mcg/Kg of fentanyl
16533417|NCT03062488|Active Comparator|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
16533418|NCT03062488|Active Comparator|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
16533419|NCT03062475|Experimental|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
16533420|NCT03062475|No Intervention|control group|Pregnant women allocated to this group receive standard prenatal care.
16533421|NCT03062462|Active Comparator|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
16533422|NCT03062462|Experimental|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
16533423|NCT03062449|Active Comparator|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
16533424|NCT03062449|Placebo Comparator|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
16533425|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
16533426|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
16533427|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16533428|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16533429|NCT03062410|Other|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
16533430|NCT03062397|Experimental|Low-dose group|JPI-289 Low dose or placebo
16533431|NCT03062397|Experimental|High-dose group|JPI-289 High dose or placebo
16533432|NCT03062397|Placebo Comparator|Placebo group|Same dosage of JPI-289 low and high dose
16533433|NCT03062384|Experimental|AT-001|Yeast-selenium supplement
16533434|NCT03062384|Placebo Comparator|Placebo|Yeast supplement devoid of selenium
16533435|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
16533436|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
16533437|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
16533442|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
16533443|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
16533444|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
16533445|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
16533446|NCT03062319|Active Comparator|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
16533447|NCT03062319|Active Comparator|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
16533448|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
16533449|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
16533450|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
16533451|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
16533452|NCT03062254|Experimental|Radium-223|
16533453|NCT03062241|Experimental|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
16533454|NCT03062241|No Intervention|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
16533455|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.
~No interventions will be administered."
16533456|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
16533457|NCT03062215|No Intervention|Control Group|Waiting list
16533458|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
16533459|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
16533460|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
16533461|NCT03062176|Experimental|Active Treatment|Anakinra (Kineret)
16533462|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
16533463|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
16533464|NCT03062150|Placebo Comparator|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
16533465|NCT03062150|Active Comparator|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH
~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
16533466|NCT03062150|Active Comparator|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
16533467|NCT03062150|Active Comparator|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH
~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
16533468|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
16533469|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
16533470|NCT03062098|Experimental|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
16533471|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
16533472|NCT03062085||Age-related cataract group|Age-related cataract patients.
16533473|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
16533474|NCT03062059|Sham Comparator|Control arm|normal saline bladder irrigaiton
16533475|NCT03062059|Experimental|Intervention arm|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
16533476|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
16533477|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
16533478|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
16534424|NCT03055936|Experimental|D2|levodopa 100 mg, carbidopa 37,5 mg
16533479|NCT03062020|Experimental|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
16533480|NCT03062020|No Intervention|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
16533481|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
16533482|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
16533483|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
16533484|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
16533485|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
16533486|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
16533487|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
16533488|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
16533489|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
16533490|NCT03061942|Active Comparator|Conventional|Arthroscopic rotator cuff repair without synovectomy
16533491|NCT03061942|Experimental|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
16533492|NCT03061929||Undernourised|Mother's with BMI less than 18.5
16533493|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
16533494|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
16533495|NCT03061916|Experimental|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
16533496|NCT03061916|Experimental|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
16533497|NCT03061916|Active Comparator|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
16533498|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
16533499|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
16533500|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
16533501|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
16533502|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
16533503|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
16533504|NCT03061877||Anxiety or depression|
16533505|NCT03061877||Non-anxiety or depression|
16533506|NCT03061864|No Intervention|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
16533507|NCT03061864|Experimental|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
16533508|NCT03061851|Experimental|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
16533509|NCT03061851|Experimental|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
16533510|NCT03061838|Active Comparator|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
16533511|NCT03061838|Experimental|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
16533512|NCT03061812|Experimental|Rovalpituzumab tesirine|"Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.
~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered."
16533513|NCT03061812|Active Comparator|Topotecan|Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m^2 on Days 1 to 5 of each 21-day cycle.
16533514|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).
~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
16533515|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
16533516|NCT03061786||AKI|
16533517|NCT03061786||non-AKI|
16567035|NCT02833064||Non-cirrhotic liver disease|- biological sampling
16533518|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
16533519|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
16533520|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
16533521|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
16533522|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
16533523|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
16533524|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
16533525|NCT03061734|Experimental|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
16533526|NCT03061734|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
16533527|NCT03061734|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
16533528|NCT03061734|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
16533529|NCT03061734|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
16533530|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
16533531|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
16533532|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
16533533|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
16533534|NCT03061708|Experimental|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
16533535|NCT03061682|Experimental|Add on lens|
16533536|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)
~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)
~Tandem HDCT/autoSCT
~First HDCT (cyclophosphamide, etoposide, carboplatin)
~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)
~Local radiotherapy
~Retinoic acid, interleukin-2"
16533537|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
16533538|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
16533539|NCT03061617|Other|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
16533540|NCT03061617|Experimental|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
16533541|NCT03061604|Experimental|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.
~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
16533542|NCT03061604|Active Comparator|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.
~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
16533543|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.
~Pukka's Wholistic Turmeric"
16533544|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
16533545|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.
~Subjects in the non-dry eye criteria must meet all of the following criteria:
~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes
~OSDI questionnaire score <13.
~Fluorescein TBUT > 7 s in both eyes.
~CFS of 0 in all areas in both eyes.
~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
16533546|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.
~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:
~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye
~Mean CFS of ≥1 in either eye.
~Fluorescein TBUT ≤5 s in either eye.
~OSDI questionnaire score ≥20
~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
16533547|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.
~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:
~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye
~Mean CFS of ≥1 in either eye.
~Fluorescein TBUT ≤5 s in either eye.
~OSDI questionnaire score ≥20
~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
16533548|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
16533551|NCT03061552|No Intervention|conventional arm|conventional determination of target post-dialysis weight
16533552|NCT03061539|Experimental|Nivolumab & Ipilimumab|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
16533553|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
16533554|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
16533555|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).
~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).
~The investigation consist in:
~taking a preoperative blood sample to evaluate the MMPs circulating levels
~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
16533556|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.
~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).
~The investigation consist in:
~taking a preoperative blood sample to evaluate the MMPs circulating levels
~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
16533557|NCT03061474|Experimental|Nicotinamide|1500mg twice daily: 2, 750mg tablets taken orally twice daily
16533558|NCT03061474|Placebo Comparator|Placebo|1500mg twice daily: 2, 750mg tablets taken orally twice daily
16533559|NCT03061461|Active Comparator|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:
~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.
~Six treatment sessions, two treatment sessions per week.
~1000 radial shock waves per cm^2 wound and treatment session.
~Energy flux density 0.07 mJ/mm^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).
~Frequency of the radial shock waves set at 15 Hz."
16533560|NCT03061461|Sham Comparator|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:
~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.
~Six treatment sessions, two treatment sessions per week.
~1000 sham radial shock waves per cm^2 wound and treatment session.
~Energy flux density 0.00 mJ/mm^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).
~Frequency of the sham radial shock waves set at 15 Hz."
16533561|NCT03061448|Experimental|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
16533562|NCT03061448|Active Comparator|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
16533563|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
16533564|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
16533565|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
16533566|NCT03061422|Experimental|xylitol chewing gum|intervention
16533567|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
16533568|NCT03061422|Active Comparator|Paraffin pellet|comparator
16533569|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
16533570|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
16533571|NCT03061396|Experimental|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
16533572|NCT03061396|Experimental|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
16533573|NCT03061383|Active Comparator|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
16533574|NCT03061383|Active Comparator|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
16533575|NCT03061383|Placebo Comparator|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
16533576|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
16533577|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
16533578|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
16533579|NCT03061331|Experimental|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
16533580|NCT03061331|Experimental|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
16533581|NCT03061292|Experimental|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
16533582|NCT03061292|Sham Comparator|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
16533583|NCT03061279|Experimental|Fixation by Acutrak headless screw|
16533584|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
16533585|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
16533586|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
16533587|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
16533588|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
16533589|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
16533590|NCT03061240|Experimental|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
16533591|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
16533592|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
16533593|NCT03061214|Experimental|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
16533594|NCT03061214|Experimental|Semaglutide 1 mg OW + sitagliptin placebo OD|
16533595|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
16533596|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 1 mg OW|
16533597|NCT03061201|Experimental|Sequential dose escalation|SB-525 (PF-07055480) is administered as a single infusion
16533598|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16533599|NCT03061175|Experimental|Arm I (Web-Based Contralateral Prophylactic Mastectomy CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based Contralateral Prophylactic Mastectomy (CPM)- Decision Aid (DA).
16533600|NCT03061175|Experimental|Arm II (Usual Care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
16533601|NCT03061162|Experimental|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
16533602|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).
~Additionally, nerve and gliding exercises were administered."
16533603|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
16533604|NCT03061136|Placebo Comparator|Placebo|Placebo administered orally
16533605|NCT03061136|Experimental|Clonazepam 0.1mg|0.1mg clonazepam administered orally
16533606|NCT03061136|Experimental|Clonazepam 0.2mg|0.2mg clonazepam administered orally
16533607|NCT03061136|Experimental|Clonazepam 0.3mg|0.3mg clonazepam administered orally
16533608|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
16533609|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
16533610|NCT03061097|Experimental|Treatment (autologous fecal microbiota preparation)|"Participants randomized into the treatment arm will receive a single dose of autologous fecal microbiota preparation (auto-FMP) via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months.
~Route of Administration: Enema Dosing Regimen: 125mL x 1 dose"
16533643|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
16533611|NCT03061097|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive a single dose of placebo FMT via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months. The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
16533612|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
16533613|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
16533614|NCT03061058|Experimental|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.
~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).
~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).
~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).
~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w)."
16533615|NCT03061058|Active Comparator|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.
~Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w)."
16533616|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
16533617|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.
~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
16533618|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.
~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
16533619|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.
~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
16533620|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
16533621|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
16533622|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
16533623|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
16533624|NCT03061006|Experimental|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
16533625|NCT03061006|Active Comparator|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
16533626|NCT03060993|Placebo Comparator|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
16533627|NCT03060993|Active Comparator|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
16533628|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
16533629|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
16533630|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
16533631|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
16533632|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
16533633|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
16533634|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
16533635|NCT03060941|Experimental|Group 1|Physical activity education
16533636|NCT03060941|Experimental|Group 2|Physical activity education and facility access
16533637|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
16533638|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
16533639|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
16533640|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
16533641|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
16533642|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
16533644|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
16533645|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
16533646|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
16533647|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
16533648|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
16533649|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
16533650|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
16533651|NCT03060928|Active Comparator|Control|Arthroscopic Rotator Cuff Repair with standard treatment
16533652|NCT03060928|Experimental|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
16533653|NCT03060928|Experimental|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
16533654|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
16533655|NCT03060902|Experimental|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
16533656|NCT03060902|No Intervention|Family Services as Usual|Mothers will continue with services they are receiving in the community
16533657|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
16533658|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
16533659|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
16533660|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
16533661|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
16533662|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
16533663|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
16533664|NCT03060850|Experimental|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
16533665|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
16533666|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
16533667|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
16533668|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
16533669|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
16533670|NCT03060772|Experimental|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
16533671|NCT03060772|No Intervention|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
16533672|NCT03060772|No Intervention|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
16533673|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
16533674|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
16533675|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
16533676|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
16533677|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
16533678|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
16533824|NCT03059680|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
16533679|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
16533680|NCT03060681|No Intervention|C group|
16533681|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.
~Nutritional therapy will be initiated in the first 24 hours after admission.
~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
16533682|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.
~Nutritional formula in this group will be Novasource senior (Nestle Health Care).
~Nutritional therapy will be initiated in the first 24 hours after admission."
16533683|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
16533684|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
16533685|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
16533686|NCT03060642||Controls|Non-BE endoscopic controls
16533689|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
16533690|NCT03060577|Experimental|Inclisiran-only|Participants will receive subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
16533691|NCT03060577|Active Comparator|Switching|Participants will receive self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, the participants will receive subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
16533692|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
16533693|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
16533694|NCT03060551|Experimental|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
16533695|NCT03060538|Experimental|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
16533696|NCT03060538|Placebo Comparator|Placebo|Participants will receive BFKB8488A-matching placebo.
16533697|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
16533698|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
16533699|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
16533700|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
16533701|NCT03060512|Active Comparator|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350
~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
16533754|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
16533702|NCT03060512|Active Comparator|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik
~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
16533703|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
16533704|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
16533705|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
16533706|NCT03060460|Experimental|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
16533707|NCT03060460|No Intervention|Conventional arm - Randomized group|Conventional arm during randomized phase
16533708|NCT03060460|No Intervention|Historical control group|Conventional arm, non-randomization phase
16533709|NCT03060447|Experimental|Vesatolimod|Participants in Period 1 will receive 10 doses of vesatolimod (4 mg to 8 mg) once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and vesatolimod and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
16533710|NCT03060447|Experimental|Placebo|Participants in Period 1 will receive 10 doses of placebo matched to vesatolimod once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and placebo and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
16533711|NCT03060434|Active Comparator|Control|Ibuprofen
16533712|NCT03060434|Experimental|Pentoxifylline|Pentoxifylline oral tablets
16533713|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
16533714|NCT03060408||Open|Patients underwent open distal pancreatectomy
16533715|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
16533716|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:
~Days 1 and 2: 100 mL twice a day
~Days 3 and 4: 150 mL twice a day
~Days 5 and 6: 200 mL twice a day
~Days 7 to 14: 250 mL twice a day"
16533717|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.
~Progressive intake of intervention milk as follows:
~Days 1 and 2: 100 mL twice a day
~Days 3 and 4: 150 mL twice a day
~Days 5 and 6: 200 mL twice a day
~Days 7 to 14: 250 mL twice a day"
16533718|NCT03060382|Experimental|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
16533719|NCT03060382|Placebo Comparator|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
16533720|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:
~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
16533721|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:
~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
16533722|NCT03060356|Active Comparator|Melanoma|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
16533723|NCT03060356|Active Comparator|Breast|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
16533724|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
16533725|NCT03060330|Experimental|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
16533726|NCT03060330|Experimental|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
16533727|NCT03060317||Validation group DOC|Examination with neurological scales.
16533728|NCT03060304|Experimental|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
16533755|NCT03060122|No Intervention|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
16533956|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
16533729|NCT03060304|Active Comparator|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness <7mm and E2<100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
16533730|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
16533731|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
16533732|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
16533733|NCT03060278|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
16533734|NCT03060278|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
16533735|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
16533736|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
16533737|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
16533738|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
16533739|NCT03060226|Other|Control group|
16533740|NCT03060226|Other|radiosensibility group|
16533741|NCT03060213|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
16533742|NCT03060213|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
16533743|NCT03060200|Experimental|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
16533744|NCT03060200|No Intervention|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
16533745|NCT03060200|Placebo Comparator|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
16533746|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
16533749|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.
~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
16533750|NCT03060148|Active Comparator|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
16533751|NCT03060148|No Intervention|Control|No implantation of Medtronic neurostimulation system
16533752|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
16533753|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
16533823|NCT03059680|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
16533756|NCT03060122|Experimental|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.
~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.
~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
16533757|NCT03060122|Active Comparator|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.
~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.
~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
16533758|NCT03060109||Suspected traumatic brain injury|
16533759|NCT03060096|Experimental|Moderate Anxiety/depression: Low Intensity Stepped care|participants with moderate symptoms (PHQ-9-14; GAD-7: 10-14) will be randomized to either low-intensity stepped care or enhanced usual care. Stepped care consist of a self-guided cognitive behavioral therapy (CBT) workbook to reduce anxiety and depressive symptoms and biweekly (every two weeks) check-in calls from research staff to assess changes in symptom severity/immediate need for psychiatric treatment and provide minimal support.
16533760|NCT03060096|Experimental|Severe Anxiety/depression: High Intensity Stepped Care|Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
16533761|NCT03060096|Active Comparator|Enhanced Usual Care Control (EUC)|"Participants randomized to EUC will receive information about local referrals/resources (support groups, mental health providers, etc.). They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the NCI to assist with transition from active treatment to survivorship. Participants will receive information on self-help workbooks for anxiety & depressive symptoms. EUC control will receive a copy of the CBT workbook on completion of the study."
16533762|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
16533763|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
16533764|NCT03060070|Placebo Comparator|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
16533765|NCT03060070|Active Comparator|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
16533766|NCT03060070|Active Comparator|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
16533767|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
16533768|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
16533769|NCT03060044|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
16533770|NCT03060044|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
16533771|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
16533772|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
16533773|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
16533774|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
16533775|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
16533776|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
16533777|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
16533778|NCT03059992|Experimental|Ibrexafungerp (SCY-078)|Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.
16533779|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
16533780|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
16533781|NCT03059966|Experimental|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
16533782|NCT03059966|Placebo Comparator|Placebo|Microsurgery for root coverage associated with a Placebo comparator
16533821|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
16533783|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.
~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
16533784|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.
~LDCT provider and patient discuss options for pharmacotherapy.
~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
16533785|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.
~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
16533786|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
16533787|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
16533788|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
16533789|NCT03059914|Experimental|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
16533790|NCT03059914|Active Comparator|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
16533791|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
16533792|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
16533793|NCT03059888|Experimental|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
16533794|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
16533795|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
16533796|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
16533797|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
16533798|NCT03059849|Active Comparator|Temporary increase in adalimumab|
16533799|NCT03059849|No Intervention|Continued monitoring as per standard of care|
16533800|NCT03059836|Experimental|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
16533801|NCT03059836|Placebo Comparator|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
16533802|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
16533803|NCT03059823|Experimental|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
16533804|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
16533805|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
16533806|NCT03059810|Experimental|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
16533807|NCT03059797|Experimental|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
16533808|NCT03059797|Placebo Comparator|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
16533809|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
16533810|NCT03059784|No Intervention|control|usual care without APP
16533811|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
16533812|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
16533813|NCT03059758|Experimental|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
16533814|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
16533815|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
16533816|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
16533817|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
16533818|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
16533819|NCT03059706|Experimental|RegenoGel-OSP™|
16533820|NCT03059706|Placebo Comparator|Placebo|
16533822|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
16533825|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:
~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)
~or re-induction by carboplatin - etoposide chemotherapy."
16533826|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
16533827|NCT03059654|Active Comparator|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
16533828|NCT03059654|Active Comparator|Surgical tracheostomy|Surgical tracheostomy
16533829|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
16533830|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
16533831|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
16533832|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
16533833|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
16533834|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
16533835|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
16533836|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
16533837|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
16533838|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
16533839|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
16533840|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
16533841|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
16533842|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
16533843|NCT03059524||patients with multiple organ failure|
16533844|NCT03059524||patients without multiple organ failure|
16533845|NCT03059524||normal subjects|
16533846|NCT03059511|Active Comparator|intravenous|single iv application of nalbuphine 0.05mg/kg
16533847|NCT03059511|Active Comparator|intranasal|single intranasal application of nalbuphine 0.1mg/kg in infants.
16533848|NCT03059498|Active Comparator|unilateral PECS block patients|unilateral PECS I and II block using bupivacaine
16533849|NCT03059498|Active Comparator|bilateral PECS block patients|bilateral PECS I and II block using bupivacaine
16533850|NCT03059485|Experimental|DC/AML Vaccine|- Patients will be vaccinated with DC/AML Fusion Vaccine
16533851|NCT03059485|Experimental|Observation|- Patients will be monitored with routine labs and bone marrow biopsies
16533852|NCT03059472|Experimental|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
16533853|NCT03059472|Experimental|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
16533854|NCT03059446|Experimental|Cenicriviroc|Cenicriviroc (CVC) 150 mg tablet once daily in the morning with food until CVC is commercially available or the study is terminated.
16533855|NCT03059433||AVID Intervention|175 students will be randomized via lottery by the participating high school to be part of the AVID program. These students will receive 4 surveys (8th, 9th, 10th, and 11th grade).
16533856|NCT03059433||Non AVID|175 students will be randomized via lottery by the participating high school to be part of our control group. This group of students will be similar to the AVID group, except they will not be in the AVID program. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
16533857|NCT03059433||High Performing|175 students who are identified as high performing (middle school grade point average >3.5) by the participating high school. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
16533858|NCT03059407|Other|Dog therapy only|Canine assisted therapy only during echocardiogram
16533859|NCT03059407|Other|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
16533860|NCT03059407|Other|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
16533861|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
16533887|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533862|NCT03059368|Experimental|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
16533863|NCT03059355|Experimental|Pilot Phase: Group 1 (UCMSCs)|Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
16533864|NCT03059355|Experimental|Pilot Phase: Group 2 (UCMSCs - 100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
16533865|NCT03059355|Experimental|Pilot Phase: Group 3 (BMMSCs - 20 million)|Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
16533866|NCT03059355|Experimental|Pilot Phase: Group 4 (BMMSCs -100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
16533867|NCT03059355|Experimental|Group A (UCMSCs - 20 Million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
16533868|NCT03059355|Experimental|Group B (UCMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
16533869|NCT03059355|Experimental|Group C (BMMSCs - 20 million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
16533870|NCT03059355|Experimental|Group D (BMMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
16533871|NCT03059355|Placebo Comparator|Group E (Placebo)|Five (5) subjects will be treated with a single administration of placebo delivered via peripheral intravenous infusion.
16533872|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
16533873|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
16533874|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
16533875|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
16533876|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
16533877|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
16533878|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
16533879|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
16533880|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533881|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533882|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533883|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533884|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533885|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533886|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
16533888|NCT03059290|Active Comparator|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
16533889|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
16533890|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
16533891|NCT03059264||Control|Healthy Children
16533892|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
16533893|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
16533894|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
16533895|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
16533896|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention of contralesional 1Hz-rTMS for 10 daily sessions.
16533897|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program.
16533898|NCT03059225|Experimental|High frequency rTMS|High-frequency rTMS to ipsilesional region for 10 daily sessions.
16533899|NCT03059212|Experimental|High frequency rTMS|Real rTMS, one session per day, for 10 days
16533900|NCT03059212|Experimental|High frequency rTMS with cognitive training|Real rTMS and cognitive training, one session per day, for 10 days
16533901|NCT03059212|Sham Comparator|Sham rTMS|Sham rTMS, one session per day, for 10 days
16533902|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
16533903|NCT03059186|Experimental|Intervention|Online daily gratitude journal.
16533904|NCT03059186|No Intervention|Control|
16533907|NCT03059160|Experimental|open label|
16533908|NCT03059147|Experimental|SF1126 + Nivolumab|SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
16533909|NCT03059134|Experimental|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
16533910|NCT03059134|Active Comparator|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
16533911|NCT03059134|Active Comparator|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
16533912|NCT03059134|Active Comparator|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
16533913|NCT03059108|Experimental|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
16533914|NCT03059108|Active Comparator|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
16533915|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
16533916|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.
~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
16533917|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
16533918|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
16533919|NCT03059069|Experimental|Glitamin|800mg/day
16533920|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
16533921|NCT03059056|Experimental|pharmacokinetic evaluation|Empagliflozin 25 mg
16533922|NCT03059043|Experimental|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
16533923|NCT03059043|Active Comparator|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
16533924|NCT03059030|Experimental|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
16533925|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
16533926|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
16533955|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
16534425|NCT03055936|Experimental|A3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
16533927|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
16533928|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
16533929|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
16533930|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
16533931|NCT03058991|Experimental|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
16533932|NCT03058991|Experimental|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
16533933|NCT03058991|Active Comparator|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
16533934|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
16533935|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
16533936|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
16533937|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
16533938|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
16533939|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
16533940|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
16533941|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
16533942|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
16533943|NCT03058926||Chronic Pancreatitis|
16533944|NCT03058926||Diabetes|
16533945|NCT03058926||Pancreatic Cancer|
16533946|NCT03058900|Experimental|Fecal microbiota transplantation (FMT)|
16533947|NCT03058900|Sham Comparator|Placebo (saline)|
16533948|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
16533949|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
16533950|NCT03058887|No Intervention|Control group|No exercise intervention.
16533951|NCT03058874|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
16533952|NCT03058874|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
16533953|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
16533954|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
16533957|NCT03058822|Experimental|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
16533958|NCT03058822|Experimental|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
16533959|NCT03058822|Experimental|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
16533960|NCT03058822|Experimental|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
16533961|NCT03058822|Experimental|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
16533962|NCT03058822|Experimental|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
16533963|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
16533964|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
16533965|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
16533966|NCT03058783|Experimental|IDP-124 Lotion|Lotion
16533967|NCT03058783|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
16533968|NCT03058770|Experimental|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
16533969|NCT03058770|Active Comparator|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
16533970|NCT03058757|No Intervention|Control arm|No intervention applied.
16533971|NCT03058757|Experimental|Intervention arm|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
16533972|NCT03058744|Experimental|IDP-118 Lotion|8 Weeks
16533973|NCT03058744|Experimental|HP Monad Lotion|8 Weeks
16533974|NCT03058744|Active Comparator|Ultravate Cream|2 Weeks
16533975|NCT03058744|Active Comparator|Tazorac Cream|4 Weeks
16533976|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
16533977|NCT03058731||Control|Other biological mesh
16533978|NCT03058718|Experimental|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:
~No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.
~Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
16533979|NCT03058718|Active Comparator|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
16533980|NCT03058705|Experimental|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
16533981|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
16533982|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
16533983|NCT03058679|Experimental|Specific Carbohydrate Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
16533984|NCT03058679|Active Comparator|Mediterranean Style Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.
16533985|NCT03058666|Experimental|Aerosolized Calfactant|"NICU Patients with a clinical diagnosis of RDS
~Inspired oxygen ≥21% to maintain adequate oxygen saturation
~Not Intubated
~Requiring Nasal continuous positive airway pressure"
16533986|NCT03058666|No Intervention|Usual Care|There will be no protocol driven interventions in the usual care group.
16533987|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
16534120|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
16533988|NCT03058640|Experimental|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
16533989|NCT03058640|No Intervention|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
16533990|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
16533991|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR < 0.80 in vessels ≥ 2.5 mm in diameter .
16533992|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
16533993|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
16533994|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND
~a first- or second-degree relative with acute leukemia or other myeloid malignancies
~a first- or second-degree relative with lymphoproliferative neoplasms
~or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
16533995|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
16533996|NCT03058575|Other|Control|No Intervention
16533997|NCT03058562|Experimental|Crossover Sequence A|"Each in the fasting state:
~Period 1: Single-dose matching placebo
~Period 2: Single-dose ABX-1431"
16533998|NCT03058562|Experimental|Crossover Sequence B|"Each in the fasting state:
~Period 1: Single-dose ABX-1431
~Period 2: Single-dose matching placebo"
16533999|NCT03058562|Experimental|Crossover Sequence C|"Each with a standard high fat meal:
~Period 3: Single-dose matching placebo
~Period 4: Single-dose ABX-1431"
16534000|NCT03058562|Experimental|Crossover Sequence D|"Each with a standard high fat meal:
~Period 3: Single-dose ABX-1431
~Period 4: Single-dose matching placebo"
16534001|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
16534002|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
16534003|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
16534004|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone
~400 mg micronized vaginal progesterone daily from randomization to 36 weeks
~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
16534005|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
16534006|NCT03058536|No Intervention|No intervention|Expectant management
16534007|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
16534008|NCT03058523||Pregnant|30 pregnant women
16534009|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
16534010|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
16534011|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
16534012|NCT03058484|No Intervention|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
16534013|NCT03058484|Experimental|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
16534014|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
16534015|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
16534016|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
16534017|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
16534018|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
16534019|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
16534020|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
16534021|NCT03058432|Experimental|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
16534022|NCT03058432|Active Comparator|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
16534121|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
16534023|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
16534024|NCT03058406||Eribulin mesylate|
16534025|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
16534026|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
16534027|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
16534028|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
16534029|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
16534030|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
16534031|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
16534032|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
16534033|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
16534034|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
16534035|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
16534036|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
16534037|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
16534038|NCT03058289|Experimental|Cohort A|"INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.
~Closed to enrollment"
16534039|NCT03058289|Experimental|Cohort B1|"INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor
~Closed to enrollment"
16534040|NCT03058289|Experimental|Cohort EA|"INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor
~Closed to enrollment"
16534041|NCT03058289|Experimental|Cohort EC|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor
~Closed to enrollment"
16534042|NCT03058289|Experimental|Cohort EC2|INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC
16534043|NCT03058289|Experimental|Cohort DEC: Safety with INT230-6|"INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.
~Closed to enrollment"
16534044|NCT03058289|Experimental|EC3: INT230-6 monotherapy fixed maximal dose|INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.
16534045|NCT03058289|Experimental|DEC2: INT230-6 combined with pembrolizumab|INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.
16534046|NCT03058289|Experimental|FEC: INT230-6 combined with ipilimumab|INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.
16534047|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
16534048|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
16534049|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
16534050|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
16534051|NCT03058263|Experimental|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
16534052|NCT03058263|Experimental|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
16534053|NCT03058250|No Intervention|Control|Standard of care, no intervention
16534054|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
16534055|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
16534056|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
16534057|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
16534058|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
16534059|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
16534060|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
16534061|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
16534062|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
16534063|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
16534064|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
16534065|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
16534066|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
16534067|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
16534068|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
16534069|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
16534070|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
16534071|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
16534072|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
16534073|NCT03058198|Experimental|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
16534074|NCT03058172|Other|Odors (food and non-food)|Odorants diluted in mineral oil.
16534075|NCT03058172|Other|Pictures (food and non-food)|Pictures of objects or scenes.
16534076|NCT03058159|Other|Subjects with a high dream recall frequency|
16534077|NCT03058159|Other|Subjects with a law dream recall frequency|
16534078|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
16534079|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
16534080|NCT03058133|Other|fMRI study|
16534081|NCT03058120|No Intervention|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
16534082|NCT03058120|Active Comparator|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
16534083|NCT03058107|Experimental|Nutrition Therapy (NT) group|Nutrition Therapy is intensive dietary counseling based on practical measurements of energy expenditure, rather than calculating it using theoretic formulas or no method at all.
16534084|NCT03058107|Active Comparator|Control Therapy (CT) group|Control Therapy is standard dietary counseling bij state-wide recognized onco-dietitians. Energy expenditure is never measured in this standard protocol.
16534085|NCT03058094|Experimental|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
16534086|NCT03058094|Active Comparator|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
16534087|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
16534088|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
16534089|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
16534090|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
16534091|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
16534092|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
16534093|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
16534094|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
16534095|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
16534096|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
16534097|NCT03058042|Experimental|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
16534098|NCT03058042|Sham Comparator|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
16534099|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
16534100|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
16534101|NCT03058016|Experimental|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.
~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
16534102|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
16534103|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
16534104|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
16534105|NCT03057977|Experimental|Empagliflozin|
16534106|NCT03057977|Placebo Comparator|Placebo|
16534107|NCT03057964|Experimental|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
16534108|NCT03057964|No Intervention|Control|
16534109|NCT03057951|Experimental|Empagliflozin|
16534110|NCT03057951|Placebo Comparator|Placebo|
16534111|NCT03057938|Experimental|18F-Florbetaben (FBB)|18F-Florbetaben
16534112|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
16534113|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
16534114|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
16534115|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
16534116|NCT03057912|No Intervention|Control group|Observation
16534117|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
16534118|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
16534119|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
16534426|NCT03055936|Experimental|B3|levodopa 150 mg, carbidopa 65 mg
16534122|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
16534123|NCT03057834|Active Comparator|Functionally impaired|Women with urinary incontinence and short physical performance battery score of <9
16534124|NCT03057834|Placebo Comparator|Functionally normal|Women with urinary incontinence and short physical performance battery score of > 10
16534125|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
16534126|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
16534127|NCT03057808|Experimental|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
16534128|NCT03057808|Experimental|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
16534129|NCT03057808|Experimental|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
16534130|NCT03057795|Experimental|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16534131|NCT03057782||Group A|"Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);
~Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
16534132|NCT03057782||Group B|"Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);
~Patients who are not anticipated to receive acute post-surgical NMB
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
16534133|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
16534134|NCT03057782||Group D|"No plan for surgery
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
16534135|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
16534136|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
16534137|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
16534138|NCT03057730|Experimental|Group 1: Thin Biotype|"Gingival thickness < 0.8 mm
~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.
~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
16534139|NCT03057730|Experimental|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm
~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.
~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
16534140|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
16534141|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
16534142|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
16534143|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
16534144|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
16534145|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
16534146|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
16534147|NCT03057678|Experimental|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
16534148|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
16534149|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
16534150|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
16534252|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
16534151|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
16534152|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
16534153|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
16534154|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
16534155|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
16534157|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
16534158|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Pac-CB combination
~Patients must self-identify as African ancestry (AA; includes African American).
~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.
~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.
~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
16534159|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination
~Patients must self-identify as African ancestry (includes African American).
~No prior systemic therapy for advanced or metastatic disease.
~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
16534160|NCT03057600|Experimental|Cohort 3 - Non-AA, 3rd line+|"Intervention = Pac-CB combination
~Patients do not self-identify as African ancestry.
~Otherwise have the same criteria as Cohort 1."
16534161|NCT03057600|Experimental|Cohort 4 - Non-AA, 1st line|"Intervention = Pac-CB combination
~Patients do not self-identify as African ancestry.
~Otherwise have the same criteria as Cohort 2."
16534162|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
16534163|NCT03057574|Experimental|Treatment|Follitropin Alfa (Gonapure)
16534164|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
16534165|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
16534166|NCT03057548|Active Comparator|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins
~or
~Radiofrequency ablation only of Pulmonary Veins
~Pulmonary Vein Isolation (PVI) alone."
16534167|NCT03057548|Experimental|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall
~or
~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall
~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
16534168|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
16534169|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
16534170|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
16534171|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
16534172|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.
~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.
~Standard LAR Octreotide will be administered.
~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.
~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
16534173|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
16534174|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
16534175|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
16534176|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
16534177|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
16534178|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
16534179|NCT03057470|Active Comparator|0% Bolus Insulin Correction|0% Bolus Insulin Correction
16534180|NCT03057470|Active Comparator|50% Bolus Insulin Correction|50% Bolus Insulin Correction
16534181|NCT03057470|Active Comparator|100% Bolus Insulin Correction|100% Bolus Insulin Correction
16534182|NCT03057470|Active Comparator|150% Bolus Insulin Correction|150% Bolus Insulin Correction
16534183|NCT03057457||Kidney Injury|
16534184|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
16534253|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
16534189|NCT03057418|Experimental|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.
~Mode of administration: intravenous."
16534190|NCT03057405||intra-operative CBCT|
16534191|NCT03057405||3D virtual planning + intra-operative navigation|
16534192|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
16534193|NCT03057392|Experimental|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
16534194|NCT03057392|Sham Comparator|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
16534195|NCT03057379|No Intervention|Control arm|Usual source of care
16534196|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
16534197|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
16534198|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
16534199|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
16534200|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
16534201|NCT03057340|Experimental|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
16534202|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
16534203|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
16534204|NCT03057314|Experimental|Amorphous calcium carbonate|"The investigation product will include:
~ACC tablets, containing 200 mg elemental calcium
~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
16534205|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
16534206|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
16534207|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
16534208|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
16534209|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
16534210|NCT03057236|No Intervention|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
16534211|NCT03057236|Experimental|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
16534212|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
16534213|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
16534214|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
16534215|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
16534216|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
16534217|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
16534218|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
16534219|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
16534220|NCT03057184|Experimental|Intervention group|behavioral intervention program
16534221|NCT03057184|No Intervention|Usual care|Usual care
16534222|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
16534223|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
16534224|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
16534225|NCT03057171||health individuals|patients who will undergo screening EGD
16534226|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
16534227|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
16534228|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
16534229|NCT03057158||4|Healthy Volunteers
16534230|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.
~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
16534231|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
16534232|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
16534233|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
16534234|NCT03057106|Active Comparator|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
16534235|NCT03057106|Active Comparator|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)
~Followed by:
~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
16534236|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
16534237|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
16534238|NCT03057080|Other|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
16534239|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
16534240|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
16534241|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
16534242|NCT03057041|Experimental|Fentanyl|
16534243|NCT03057041|Placebo Comparator|Placebo|
16534244|NCT03057028|Experimental|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
16534245|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
16534246|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
16534247|NCT03057002||HCM Group|HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
16534248|NCT03057002||Control Group|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
16534249|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
16534250|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
16534251|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
16568315|NCT02823782|Other|Control|Structural and functional MRI markers
16534255|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
16534256|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
16534257|NCT03056950|No Intervention|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
16534258|NCT03056950|Active Comparator|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
16534259|NCT03056937||Obese with metabolic syndrome|bariatric surgery
16534260|NCT03056937||Obese without metabolic syndrome|bariatric surgery
16534261|NCT03056937||Healthy|Control
16534262|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
16534263|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
16534264|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
16534265|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
16534266|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
16534267|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
16534268|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
16534269|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
16534270|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
16534271|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
16534272|NCT03056872||Healthy Controls|Community sample
16534273|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
16534274|NCT03056846|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16534275|NCT03056846|Experimental|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16534276|NCT03056846|Experimental|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16534277|NCT03056846|Experimental|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16534278|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
16534279|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
16534280|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
16534281|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
16534282|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
16534284|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
16534285|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
16534286|NCT03056768|Active Comparator|active control|Health promotion provided by local health bureau.
16534287|NCT03056768|Experimental|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
16534291|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
16534292|NCT03056729|Experimental|Cohort HV1|
16534293|NCT03056729|Experimental|Cohort HV2|
16534294|NCT03056729|Experimental|Cohort HV3|
16534295|NCT03056729|Experimental|Cohort HV4|
16534296|NCT03056729|Experimental|Cohort HV5|
16534297|NCT03056729|Experimental|Cohort AD1|
16534298|NCT03056716|Experimental|Silastic drain|Placement of 19FR silastic drain as basal drain
16534299|NCT03056716|Active Comparator|Conventional drain|Placement of 32FR conventional drain as basal drain
16534300|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
16534301|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
16534302|NCT03056690|Experimental|ASP0819|Participants received ASP019 15 mg capsules, orally, once daily in the morning, with or without food for 8 weeks.
16534303|NCT03056690|Placebo Comparator|Placebo|Participants received ASP019 matching placebo capsules, orally, once daily in the morning, with or without food for 8 weeks.
16534304|NCT03056677|Experimental|Control|No Whey Protein
16534305|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
16534306|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
16534307|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
16534308|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
16534309|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
16534310|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
16534311|NCT03056638|Experimental|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
16534312|NCT03056638|Experimental|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
16534313|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
16534314|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
16534315|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
16534316|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
16534317|NCT03056612||ACLF|ACLF-patients were specified the patients who were admitted at hospital with ACLF,
16534318|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
16534319|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.
~Follow-up will be after 3, 6, and 12 month period."
16534320|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
16534321|NCT03056573|Experimental|Subclavian/axillary|Subclavian/axillary access route
16534322|NCT03056573|Experimental|Transaortic|Transaortic access route
16534323|NCT03056560|Experimental|Video Bystander Program|TakeCARE video
16534324|NCT03056560|No Intervention|Control Video|Study Skills Video
16534325|NCT03056547|Experimental|Induced dyspnea|
16534326|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.
~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
16534327|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
16534328|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
16534329|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
16534330|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
16534331|NCT03056482|Active Comparator|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
16534332|NCT03056482|Experimental|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
16534333|NCT03056482|Experimental|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
16534334|NCT03056469|Active Comparator|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
16534335|NCT03056469|Active Comparator|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
16534336|NCT03056469|No Intervention|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
16534337|NCT03056456|Experimental|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
16534338|NCT03056456|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
16570399|NCT02809495||Patients who will use the clinical application|
16534339|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
16534340|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
16534341|NCT03056430|Experimental|Training Group 1|Slackline training
16534342|NCT03056430|Experimental|Training Group 2|Slackline training
16534343|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
16534344|NCT03056417|No Intervention|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
16534345|NCT03056404|Experimental|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
16534346|NCT03056391|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.
~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
16534347|NCT03056391|No Intervention|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.
~If temperature >39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
16534348|NCT03056378|Experimental|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
16534349|NCT03056378|Active Comparator|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
16534350|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
16534351|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
16534352|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
16534353|NCT03056339|Experimental|Fludarabine + Cyclophosphamide + CAR-NK Cells|"On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.
~On Day 0, participants receive genetically modified NK cells as a cell infusion.
~If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein."
16534354|NCT03056326|Experimental|CHF6333 Active|
16534355|NCT03056326|Placebo Comparator|Placebo|
16534356|NCT03056313|Experimental|proactive support of labor|delayed labor; 1 cm opening and painful contractions
16534357|NCT03056313|Active Comparator|support of labor as usual|delayed labor; 3-4 cm opening of the cervix and regular contractions
16534358|NCT03056300|Experimental|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
16534359|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
16534360|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
16534361|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
16534362|NCT03056287|Sham Comparator|Sham|Sham rTMS
16534363|NCT03056274|Active Comparator|Metformin arm|Metformin
16534364|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
16534365|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
16534366|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
16534367|NCT03056248|Active Comparator|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
16534368|NCT03056248|Placebo Comparator|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
16534369|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
16534370|NCT03056235|Placebo Comparator|Saline control|Saline
16534371|NCT03056222|Active Comparator|HeartLight® EGLA|Participants will be treated with the endoscopically guided laser ablation catheter
16534372|NCT03056222|Active Comparator|Contact Force Sensing Irrigated RF ablation|Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter
16534373|NCT03056209|Experimental|KL1333 25mg|Group 1
16534374|NCT03056209|Experimental|KL1333 50mg|Group 2
16534375|NCT03056209|Experimental|KL1333 100mg|Group 3
16534376|NCT03056209|Experimental|KL1333 200mg|Group 4
16534377|NCT03056209|Experimental|KL1333 400mg|Group 5
16534378|NCT03056209|Experimental|KL1333 600mg|Group 6
16534379|NCT03056209|Experimental|KL1333 800mg|Group 7
16534380|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
16534381|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
16534420|NCT03055936|Experimental|D1|levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
16534382|NCT03056170|Active Comparator|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
16534383|NCT03056170|Sham Comparator|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
16534384|NCT03056157|Experimental|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
16534385|NCT03056157|Active Comparator|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role, but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
16534386|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
16534387|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
16534388|NCT03056131|No Intervention|Control Group|
16534389|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
16534390|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
16534391|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
16534392|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
16534393|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
16534394|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
16534395|NCT03056092|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
16534396|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
16534397|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
16534398|NCT03056040|Experimental|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.
~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
16534399|NCT03056040|Active Comparator|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.
~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
16534400|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
16534401|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
16534402|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
16534403|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
16534404|NCT03056014|Placebo Comparator|placebo|
16534405|NCT03056014|Active Comparator|PUFA 1000 mg|
16534406|NCT03056014|Active Comparator|PUFA 2000 mg|
16534407|NCT03056014|Placebo Comparator|Placebo|
16534408|NCT03056001|Experimental|Pembrolizumab + doxorubicin|Participants receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of each cycle.
16534409|NCT03055988|Experimental|Tiotropium/Olodaterol Fixed Dose Combination|
16534410|NCT03055988|Active Comparator|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
16534411|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
16534412|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
16534413|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
16534414|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
16534415|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
16534416|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
16534427|NCT03055936|Experimental|C3|levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
16534428|NCT03055936|Experimental|D3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
16534429|NCT03055936|Experimental|A4|levodopa IR 100 mg (Sinemet), carbidopa 25 mg
16534430|NCT03055936|Experimental|B4|levodopa 100 mg, carbidopa 65 mg
16534431|NCT03055936|Experimental|C4|levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
16534432|NCT03055936|Experimental|D4|levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
16534433|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
16534434|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
16534435|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
16534436|NCT03055897|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
16534437|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
16534438|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
16534439|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
16534440|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
16534444|NCT03055858|Experimental|PDA closure|
16534445|NCT03055845|Experimental|STA363 dose 1|
16534446|NCT03055845|Experimental|STA363 dose 2|
16534447|NCT03055845|Experimental|STA363 dose 3|
16534448|NCT03055845|Placebo Comparator|Placebo|
16534449|NCT03055832|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
16534450|NCT03055832|Active Comparator|LipiFlow Thermal Pulsation System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
16534451|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
16534452|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
16534453|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
16534454|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
16534455|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
16534456|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
16534457|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
16534458|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
16534459|NCT03055754|Experimental|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
16534460|NCT03055754|Active Comparator|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
16534461|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
16534462|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
16534463|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
16534507|NCT03055403|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
16570400|NCT02809495||Patients who do not make use of clinical application|
16534464|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
16534465|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
16534466|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
16534467|NCT03055702|Experimental|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
16534468|NCT03055702|No Intervention|Usual care group|Usual care, either telephone reminder or no reminder
16534469|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
16534470|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
16534471|NCT03055676|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
16534472|NCT03055676|Active Comparator|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
16534473|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
16534474|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
16534475|NCT03055650|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
16534476|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
16534477|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
16534478|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
16534479|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
16534480|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
16534481|NCT03055598|Experimental|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
16534482|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
16534483|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
16534484|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
16534485|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
16534486|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
16534487|NCT03055559||Globifer Forte|
16534488|NCT03055546|Experimental|Oxytocin|intranasal administration of oxytocin
16534489|NCT03055546|Placebo Comparator|Placebo|intranasal administration of placebo
16534490|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment. Participation may be in clinic or via telehealth.
16534491|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks). Participation may be in clinic or via telehealth.
16534492|NCT03055520|Experimental|arithmetic training (Kumon method)|
16534493|NCT03055520|Placebo Comparator|nonspecific recreation|
16534494|NCT03055507|Active Comparator|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN pain.
16534495|NCT03055507|Experimental|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
16534496|NCT03055494|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
16534497|NCT03055494|Placebo Comparator|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
16534498|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
16534499|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
16534500|NCT03055468|Experimental|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
16534501|NCT03055468|Active Comparator|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
16534502|NCT03055455||Sepsis|Children with severe sepsis or septic shock
16534503|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
16534504|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
16534506|NCT03055403|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
16534508|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
16534509|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
16534510|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
16534511|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
16534512|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
16534513|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
16534514|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
16534515|NCT03055338|Experimental|MK-8189|Participants receive MK-8189 (4 mg controlled release [CR] oral tablet[s]) in combination with placebo matching risperidone (oral capsule[s]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
16534516|NCT03055338|Active Comparator|Risperidone|Participants receive risperidone (2 mg oral capsule[s]) in combination with placebo matching MK-8189 (oral tablet[s]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
16534517|NCT03055338|Placebo Comparator|Placebo|Participants receive both placebo matching MK-8189 (oral tablet[s]) as well as placebo matching Risperidone (oral capsule[s]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
16534518|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
16534519|NCT03055312|Active Comparator|TPC chemotherapy|"Conventional chemotherapy(choose a):
~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
16534520|NCT03055312|Experimental|Bicalutamide|Bicalutamide 150mg/day every 28 days
16534521|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
16534522|NCT03055286|Experimental|CWP232291 in combination with cytarabine (ara-C)|
16534523|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
16534524|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
16534525|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
16534526|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
16534527|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
16534528|NCT03055234|Experimental|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
16534529|NCT03055234|Placebo Comparator|Placebo|Placebo (sugar pill) for TID administration
16534530|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
16534531|NCT03055208|Experimental|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):
~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
16534532|NCT03055195|Experimental|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
16534533|NCT03055195|Placebo Comparator|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
16534534|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
16534535|NCT03055182|No Intervention|Control subjects|No intervention administered
16534536|NCT03055169||intensive care patients|patients with a least one organ dysfunction
16534537|NCT03055156|Experimental|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
16534538|NCT03055156|Experimental|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
16534539|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
16534540|NCT03055143|Active Comparator|Ref-08-038|
16534541|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
16534542|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
16534543|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
16534544|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
16534545|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
16534607|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.
~All patients undergo spirometry before and on every second day after lung surgery."
16534546|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
16534547|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
16534548|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
16534549|NCT03055078|Experimental|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
16534550|NCT03055052|Active Comparator|Control Formula|Standard formula for preterm infants.
16534551|NCT03055052|Experimental|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
16534552|NCT03055026|Experimental|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
16534553|NCT03055026|Placebo Comparator|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
16534556|NCT03055000|Experimental|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
16534557|NCT03055000|Experimental|AGS-v with adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
16534558|NCT03055000|Placebo Comparator|Placebo|WFI (0.5mL) on Day 0 and Day 21
16534559|NCT03054987|Active Comparator|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
16534560|NCT03054987|Active Comparator|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
16534561|NCT03054974|Experimental|Modern rehabilitation treatment|Modern rehabilitation treatment
16534562|NCT03054974|Experimental|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
16534563|NCT03054974|Experimental|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
16534564|NCT03054974|Experimental|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
16534565|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
16534566|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
16534567|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
16534568|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
16534569|NCT03054922|Active Comparator|Normal Saline|0.9% Sodium Chloride
16534570|NCT03054922|Active Comparator|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:
~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
16534571|NCT03054922|Active Comparator|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
16534572|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
16534573|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
16534574|NCT03054896|Experimental|VR-EPOCH|"Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients
~Chemotherapy cycles will be administered approximately every 3 weeks
~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
16534575|NCT03054896|Experimental|VR-CHOP|"Standard chemotherapy regimen, R-CHOP, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients
~Chemotherapy cycles will be administered approximately every 3 weeks
~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
16534576|NCT03054870|Other|Xe-133 Followed by Technegas|Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
16534577|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
16534578|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
16534579|NCT03054844|Experimental|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
16534580|NCT03054844|Experimental|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
16534608|NCT03054662|Experimental|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
16537353|NCT03036046|Experimental|F901318 with fluconazole low dose|safety assessment
16534581|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
16534582|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
16534583|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
16534584|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
16534585|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.
~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
16534586|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
16534587|NCT03054805|No Intervention|Healthy Children|Healthy Children
16534588|NCT03054792|Experimental|FAZA - BOLD- DW- MRS|"18F-FAZA (F18-Fluoroazomycin Arabinoside) is a radioactive agent developed as a non-invasive probe for the assessment of cellular hypoxia. 18F-FAZA Injection is indicated in a single dose of (5.2 MBq/kg [0.14 mCi/kg]) Route/method of administration: intravenous injection.
~Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, MR Spectroscopy [MRS]"
16534589|NCT03054779|Experimental|Canola oil|regular canola oil
16534590|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
16534591|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
16534592|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization
~Interventions :Ranibizumab injection Interventions :Sham macular laser"
16534593|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization
~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
16534594|NCT03054753|Other|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
16534595|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
16534596|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
16534597|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call
16534598|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call
16534599|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
16534600|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
16534601|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.
~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
16534602|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.
~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
16534603|NCT03054688|Experimental|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
16534604|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:
~Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)
~A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)
~New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
16534605|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
16534606|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.
~All patients undergo spirometry before and on every second day after lung surgery."
16570401|NCT02809482|Other|Eucaloric Feeding|
16534609|NCT03054662|Experimental|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
16534610|NCT03054649|Experimental|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
16534611|NCT03054649|Experimental|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
16534612|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
16534613|NCT03054610|Active Comparator|Control|5 ml of local anesthetic (ropivacaine 7.5%)
16534614|NCT03054610|Active Comparator|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
16534615|NCT03054610|Experimental|BTX-A|200U Botulinum Toxins, Type A
16534616|NCT03054597|Experimental|Adults|"The arm consisted of adult participants who underwent:
~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
16534617|NCT03054597|Experimental|Children|"The arm consisted of child participants who underwent:
~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
16534618|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
16534619|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
16534620|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
16534621|NCT03054532|Experimental|Durvalumab and lenalidomide|"Open-label use of 2 drugs:
~Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.
~Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
16534622|NCT03054519|Active Comparator|Metformin|Metformin daily
16534623|NCT03054519|Placebo Comparator|Placebo|Placebo daily for six months.
16534624|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
16534625|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
16534626|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
16534627|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
16534628|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
16534629|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
16534630|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
16534631|NCT03054454|Active Comparator|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
16534632|NCT03054454|No Intervention|comparator|This group will receive usual care
16534633|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
16534634|NCT03054441||Control group|Children, Adolescents and Young with typical development
16534635|NCT03054428|Experimental|Placebo|Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling the amount of placebo on day 1 to match the loading dose). In order to maintain blinding for the study, participants in the <60 kilogram (kg) weight stratum received, in a 1:1 ratio, either placebo matching 200 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose) or placebo matching 300 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose). In the ≥60 kg weight stratum, the participants randomized to the placebo group received placebo matching 300 mg dupilumab (including doubling the amount of placebo on day 1 to match the loading dose).
16534636|NCT03054428|Experimental|Dupilumab 300 mg Q4W|Participants received once every 4 weeks (Q4W) subcutaneous (SC) injections of 300 milligrams (mg) dupilumab following a loading dose of 600 mg on day 1. In order to maintain blinding, all participants received an injection once every 2 weeks (Q2W) from day 1 to week 14. Participants received placebo 2 milliliter (mL) injection at the weeks dupilumab was not given.
16534637|NCT03054428|Experimental|Dupilumab 200 mg or 300 mg Q2W|Participants with baseline weight <60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
16534638|NCT03054415|Other|Healthy Subjects|
16534639|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
16534640|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
16534641|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
16534642|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
16570402|NCT02809482|Other|Overfeeding|
16534645|NCT03054363|Experimental|Tucatinib in Combination with Palbociclib and Letrozole|During phase 1b part of this trial (N=20 patients), treatment will be administered in cycles of 28 days and consist of tucatinib 300 mg PO BID, palbociclib 125 mg PO daily for 21 days followed by 7 days off, and letrozole 2.5 mg PO daily. Dose modifications of tucatinib, palbociclib and letrozole will be allowed per protocol. There will be an interim safety analysis performed after enrollment of 10 patients. Safety analysis will take into account proportion of patients requiring dose modifications or interruption for therapy because of toxicity. If excessive toxicity or significant changes in PKs are found, further patients will be enrolled at a lower starting dose level. There will be a second interim safety analysis after enrollment of 20 patients in the study. Once the recommended phase II dose (RP2D) has been determined, testing of this drug combination will be expanded in the phase II part of this trial (N=20 patients) to determine the progression-free survival (PFS) rate.
16534646|NCT03054350|Experimental|Vadadustat, Dose 1|Daily oral dose
16534647|NCT03054350|Experimental|Vadadustat, Dose 2|Daily oral dose
16534648|NCT03054350|Experimental|Vadadustat, Dose 3|Daily oral dose
16534649|NCT03054350|Placebo Comparator|Placebo|Daily oral dose
16534650|NCT03054337|Experimental|Vadadustat, Dose 1|Daily oral dose
16534651|NCT03054337|Experimental|Vadadustat, Dose 2|Daily oral dose
16534652|NCT03054337|Experimental|Vadadustat, Dose 3|Daily oral dose
16534653|NCT03054337|Placebo Comparator|Placebo|Daily oral dose
16534654|NCT03054311|Experimental|Lifestyle Matters intervention|
16534655|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
16534656|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
16534657|NCT03054298|Active Comparator|Cohort 3|PERMANENTLY CLOSED
16534658|NCT03054298|Active Comparator|Cohort 4|PERMANENTLY CLOSED
16534659|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x107 huCART-meso cells/m2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.
16534660|NCT03054298|Active Comparator|Cohort 6|Dose of 1-3x107 huCART-meso cells/m2 via IV infusion on Day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Cohort 6 was activated with Protocol V6. Enrollment into Cohort 6 will occur in parallel with Cohort 5.
16534661|NCT03054298|Active Comparator|Cohort 7|a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. Infusion #1 for the first three subjects in Cohort 7 will be staggered by at least 21 days to allow for the assessment of DLTs. Enrollment into Cohort 7 will occur in parallel with Cohort 5 and Cohort 6.
16534662|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
16534663|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
16534664|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
16534665|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
16534666|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
16534667|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
16534668|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
16534669|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
16534670|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
16534671|NCT03054220|Experimental|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
16534672|NCT03054220|Experimental|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
16534673|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
16534674|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
16534675|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
16534676|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
16534677|NCT03054194|Experimental|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
16534678|NCT03054194|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
16534679|NCT03054194|Experimental|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
16534680|NCT03054194|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
16534681|NCT03054194|Experimental|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
16534682|NCT03054194|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
16534683|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
16534684|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)
~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
16534685|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
16534686|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)
~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
16534687|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
16534688|NCT03054155|Experimental|Treatment Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
16534689|NCT03054155|No Intervention|Control Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
16534690|NCT03054142||AKI|
16534691|NCT03054142||non-AKI|
16534692|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.
~Patients will also implement home exercise program. Balance training will be non-supervised program."
16534693|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.
~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.
~Patients will also implement home exercise program."
16534694|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
16534695|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
16534696|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
16534697|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
16534698|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
16534699|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
16534700|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
16534701|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
16534702|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
16534703|NCT03054038|Experimental|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16534704|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
16534705|NCT03054012||CAS group|computer-assisted surgery group
16534706|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
16534707|NCT03053986|Active Comparator|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
16534708|NCT03053986|Placebo Comparator|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
16534709|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
16534710|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
16534711|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
16572991|NCT02791997|Experimental|Migraine patients|
16534712|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
16534713|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
16534714|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
16534715|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
16534716|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
16534717|NCT03053908|Experimental|Elderly Patients|
16534718|NCT03053895|Experimental|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
16534719|NCT03053895|Active Comparator|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
16534720|NCT03053882|Active Comparator|green tea and peppermint|
16534721|NCT03053882|Active Comparator|peppermint and green tea|
16534722|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.
~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.
~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
16534723|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.
~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
16534724|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
16534725|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
16534726|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
16534727|NCT03053830|Experimental|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
16534728|NCT03053817|Experimental|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
16534729|NCT03053817|No Intervention|Control|No treatment
16534730|NCT03053804|Experimental|MR/PET|hypothesize that MR/PET can have better information than current CT image study
16534731|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
16534732|NCT03053778|Experimental|Intervention|Early follow-up after discharge
16534733|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
16534734|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
16534735|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
16534736|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
16534737|NCT03053752|Experimental|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
16534738|NCT03053739|Active Comparator|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug
~Tab Sildenafil 20 mg - three times a day for 6 months,and
~Tab Bosentan 62.5mg - twice a day for 6 months"
16534739|NCT03053739|Placebo Comparator|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
16534740|NCT03053726|Experimental|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
16534741|NCT03053726|Sham Comparator|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
16534742|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
16534743|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
16534744|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
16534745|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
16534746|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
16534747|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
16534748|NCT03053674|Experimental|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
16534749|NCT03053674|Active Comparator|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
16534750|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
16534751|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
16534752|NCT03053648|Experimental|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
16534753|NCT03053648|Active Comparator|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
16534754|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):
~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
16534755|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|Mirikizumab test formulation given as a single injection under the skin in healthy participants
16534756|NCT03053622|Experimental|Mirikizumab Test SC 2|Mirikizumab test formulation given as two injections under the skin in healthy participants
16534757|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|Mirikizumab test formulation given as an infusion into the vein in healthy participants
16534758|NCT03053622|Active Comparator|Mirikizumab Reference|Mirikizumab reference formulation given as three injections under the skin in healthy participants
16534759|NCT03053583|Active Comparator|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
16534760|NCT03053583|Active Comparator|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
16534761|NCT03053583|Active Comparator|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
16534762|NCT03053570|Experimental|Cryoballoon|
16534763|NCT03053570|Experimental|Radiofrequency Energy(Contact Force)|
16534764|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
16534765|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
16534766|NCT03053544|Experimental|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
16534767|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
16534768|NCT03053518|Active Comparator|Life Style|
16534769|NCT03053518|Experimental|Life Style + Metformin|
16534770|NCT03053505|Experimental|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
16534771|NCT03053505|Active Comparator|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
16534772|NCT03053505|Experimental|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
16534773|NCT03053492|Experimental|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
16534774|NCT03053492|Active Comparator|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
16534775|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
16534776|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
16534810|NCT03053271|Placebo Comparator|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
16534811|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
16573922|NCT02785484|Other|Label with litter message|
16534777|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
16534778|NCT03053466|Experimental|Single-Arm|APL-501
16534779|NCT03053453|Active Comparator|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
16534780|NCT03053453|Experimental|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
16534781|NCT03053440|Experimental|Arm A (Experimental Arm-BGB-3111)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]
16534782|NCT03053440|Active Comparator|Arm B (Active Comparator-Ibrutinib)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]
16534783|NCT03053440|Experimental|Arm C (Experimental Arm-BGB-3111)|Approximately 22 participants found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]
16534784|NCT03053427|Placebo Comparator|Placebo|Placebo was administered orally once daily after the evening meal.
16534785|NCT03053427|Experimental|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
16534786|NCT03053414|Active Comparator|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
16534787|NCT03053414|Active Comparator|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
16534788|NCT03053414|Active Comparator|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
16534789|NCT03053414|Active Comparator|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
16534790|NCT03053401|Active Comparator|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
16534791|NCT03053401|Active Comparator|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
16534792|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
16534793|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
16534794|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
16534795|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
16534796|NCT03053375|Experimental|Chronic; active device|MDCure active device
16534797|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
16534798|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65
~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.
~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
16534799|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
16534800|NCT03053336|Experimental|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.
~Intervention: App-technology to increase physical activity"
16534801|NCT03053336|No Intervention|Control group|The control group will receive standard care
16534802|NCT03053323|Experimental|Lifestyle Intervention|
16534803|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis
~Patients treated with curative intent (stage I-IVb)"
16534804|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour
~Patients treated with curative intent (stage I-IVb)"
16534805|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
16534806|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
16534807|NCT03053284|Placebo Comparator|Placebo|Normal saline s.c. injection once
16534808|NCT03053284|Experimental|Pasireotide|Pasireotide 0.6mg s.c. once
16534809|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
16534812|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
16534813|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
16534814|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
16534815|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
16534816|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
16534817|NCT03053206|Experimental|ADE arm|"ADE arm
~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
16534819|NCT03053180||Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir|"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir/ritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.
~The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study."
16534820|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.
~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1
~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
16534821|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
16534822|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
16534823|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
16534824|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
16534825|NCT03053128|Experimental|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
16534826|NCT03053128|Sham Comparator|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
16534827|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
16534828|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
16534829|NCT03053102|Experimental|Danicopan|Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).
16534830|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
16534831|NCT03053089|Experimental|Stage 2 (children)|AGT-181
16534832|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
16534833|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
16534834|NCT03053063|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.
~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
16534835|NCT03053063|Experimental|SEL 18 mg|"Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.
~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
16534836|NCT03053063|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.
~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
16534837|NCT03053050|Experimental|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks
~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
16534838|NCT03053050|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks
~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
16534839|NCT03053050|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks
~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
16534840|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
16534841|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
16534906|NCT03052517|Placebo Comparator|Placebo|Placebo once daily
16534907|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
16534842|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
16534843|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
16534844|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
16534845|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
16534846|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
16534847|NCT03052972|Experimental|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
16534848|NCT03052972|Experimental|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
16534849|NCT03052959|Experimental|Immediate Intervention|
16534850|NCT03052959|Other|Wait List Intervention|
16534851|NCT03052946|Active Comparator|Bulking agent|Bulking agent in fecal incontinence
16534852|NCT03052946|Placebo Comparator|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
16534853|NCT03052933|Experimental|Copanlisib/gemcitabine|
16534855|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
16534856|NCT03052894|Experimental|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
16534857|NCT03052894|Active Comparator|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
16534858|NCT03052881|Experimental|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
16534859|NCT03052881|No Intervention|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
16534860|NCT03052868|Other|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
16534861|NCT03052855|Other|Participants|All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.
16534862|NCT03052842|Other|Arm 1|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
16534863|NCT03052842|Other|Arm 2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
16534864|NCT03052842|Other|Arm 3|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
16534865|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
16534866|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
16534867|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.
~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.
~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge
~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.
~Patients will be discharged home with PO Tylenol and PO toradol PRN."
16534868|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3
~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain
~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain
~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.
~Patients will be discharged home with Motrin and Percocet for pain PRN."
16534869|NCT03052790|Active Comparator|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
16534908|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
16534870|NCT03052790|Experimental|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
16534871|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
16534872|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
16534873|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
16534874|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
16534875|NCT03052751|Experimental|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
16534876|NCT03052751|Experimental|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
16534877|NCT03052725|Experimental|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
16534878|NCT03052712|Active Comparator|Patients|battery of tests of social cognition
16534879|NCT03052712|Active Comparator|Control|battery of tests of social cognition
16534880|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
16534881|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
16534882|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.
~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
16534883|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.
~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
16534884|NCT03052660|Experimental|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
16534885|NCT03052660|Placebo Comparator|Placebo|Placebo, oral, once, 30-45 minutes before surgery
16534886|NCT03052647|Active Comparator|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
16534887|NCT03052647|Active Comparator|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
16534888|NCT03052634|Experimental|RC48-ADC 1.5 mg/kg (HER2 Positive)|
16534889|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Positive)|
16534890|NCT03052634|Experimental|RC48-ADC 2.5 mg/kg (HER2 Positive)|
16534891|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|
16534892|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
16534893|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
16534894|NCT03052608|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
16534895|NCT03052608|Active Comparator|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
16534896|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
16534897|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
16534898|NCT03052582|Active Comparator|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
16534899|NCT03052582|Active Comparator|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
16534900|NCT03052556|Other|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
16534901|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
16534902|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
16534903|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
16534904|NCT03052517|Experimental|QAW039 150mg|QAW039 Dose 1 once daily
16534905|NCT03052517|Experimental|QAW039 450 mg|QAW039 Dose 2 once daily
16534909|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
16534910|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
16534911|NCT03052491|Experimental|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
16534912|NCT03052478|Experimental|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
16534913|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
16534914|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
16534915|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
16534916|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
16534917|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
16534918|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
16534919|NCT03052426|Active Comparator|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
16534920|NCT03052426|Active Comparator|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
16534921|NCT03052426|Active Comparator|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
16534922|NCT03052413|Active Comparator|Active|
16534923|NCT03052413|Placebo Comparator|Placebo|
16534924|NCT03052400|Experimental|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
16534925|NCT03052400|Placebo Comparator|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
16534926|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.
~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.
~Decortication of the bone bed to increase the blood supply to the onlay graft.
~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.
~Periosteal incisions are usually needed to allow tension free sutures.
~Vicryl 3/0 sutures for closer.
~augmentin 1g twice daily for 5 days.
~catflam 50g twice daily for 3 days"
16534927|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.
~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.
~Drilling of pilot drill and first drill only.
~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.
~splitting osteotomes are used and mallet to complete the splitting of the bony segment.
~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.
~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.
~Drilling through the bony segment and the block graft.
~Immediate implant placement
~chin graft block dental implants"
16534928|NCT03052374|No Intervention|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
16534929|NCT03052374|Experimental|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
16534930|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
16534931|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
16534932|NCT03052348|Active Comparator|Group R|Polyethylene glycol hexadecyl ether & betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
16534933|NCT03052348|Experimental|Group A|Fusidic acid & Polyethylene glycol hexadecyl ether,& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
16534934|NCT03052335|Experimental|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
16534935|NCT03052322|Experimental|MSB11022|
16534936|NCT03052322|Active Comparator|EU-Humira|
16534937|NCT03052283||Patients with CF|>1000 in Germany, France, Italy, Spain, Denmark, Belgium, Portugal, GB, Ireland, USA...
16534938|NCT03052283||Age-matched healthy controls|>100 in Germany
16534962|NCT03052127|Experimental|Single High Dose Light-activated AU-011|High dose Light-activated AU-011 followed by a single laser light application
16534939|NCT03052270|Experimental|Vaginal progesterone and Pessary|"Short cervical length equal or less than 20 mm
~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.
~18 years or older at the time of enrollment.
~Consent to participate in the study
~Vaginal progesterone as standard of care plus Arabin pessary"
16534940|NCT03052270|Active Comparator|Vaginal progesterone only|"Short cervical length equal or less than 20 mm
~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.
~18 years or older at the time of enrollment.
~Consent to participate in the study
~Vaginal progesterone as standard of care"
16534941|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
16534942|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
16534943|NCT03052244|Experimental|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
16534944|NCT03052244|Sham Comparator|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
16534945|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
16534946|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
16534947|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
16534948|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
16534949|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.
~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.
~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.
~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.
~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.
~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
16534950|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.
~Matched individually with patients in the FAM group by age, sex, and municipality.
~Examined at inclusion and 52 weeks after inclusion.
~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
16534951|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)
~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
16534952|NCT03052179|Active Comparator|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
16534953|NCT03052179|Placebo Comparator|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
16534954|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
16534955|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
16534956|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
16534957|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
16534958|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
16534959|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
16534960|NCT03052127|Experimental|Single Low Dose Light-activated AU-011|Low dose Light-activated AU-011 followed by a single laser light application
16534961|NCT03052127|Experimental|Single Medium Dose Light-activated AU-011|Medium dose Light-activated AU-011 followed by a single laser light application
16534963|NCT03052127|Experimental|2 Repeat Medium Dose Light-activated AU-011|2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application
16534964|NCT03052127|Experimental|3 Repeat Medium Dose Light-activated AU-011|3 repeat medium doses of Light-activated AU-011 followed by a single laser light application
16534965|NCT03052127|Experimental|Single High Dose Light-activated AU-011 x 2 lasers|High dose Light-activated AU-011 followed by two laser light applications
16534966|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011|3 repeat high doses of Light-activated AU-011 each followed by a single laser light application
16534967|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011 x 2 lasers|3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
16534968|NCT03052127|Experimental|Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers|Expansion of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications (up to 12 additional subjects)
16534969|NCT03052127|Experimental|Observation until Documented Growth of Tumor|Observation until documented growth of tumor and then treatment with 2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
16534970|NCT03052127|Experimental|2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
16534971|NCT03052127|Experimental|Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications in subjects with evidence of documented tumor growth prior to study entry
16534972|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
16534973|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
16534974|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
16534975|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
16534976|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
16534977|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
16534978|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
16534979|NCT03052023|Experimental|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
16534980|NCT03052023|Active Comparator|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
16534981|NCT03052023|Active Comparator|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
16534983|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
16534984|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
16534985|NCT03051984|Experimental|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
16534986|NCT03051984|No Intervention|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
16534989|NCT03051958|Experimental|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
16534990|NCT03051958|Active Comparator|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.
~After 12 weeks, patients in this arm are crossed over to treatment."
16534991|NCT03051945|Experimental|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
16534992|NCT03051945|Placebo Comparator|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
16534993|NCT03051932|Active Comparator|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
16534994|NCT03051932|Placebo Comparator|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
16534995|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
16534996|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
16534997|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
16534998|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
16534999|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
16535000|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
16535001|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
16535002|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
16535003|NCT03051880|Experimental|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
16535004|NCT03051880|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
16535005|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
16535006|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
16535007|NCT03051854|Experimental|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
16535008|NCT03051854|No Intervention|Control schools|The control school do not receive any intervention.
16535009|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
16535010|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
16535011|NCT03051789|Experimental|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
16535012|NCT03051789|Experimental|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
16535013|NCT03051789|Experimental|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
16535014|NCT03051789|No Intervention|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
16535015|NCT03051776|Experimental|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
16535016|NCT03051776|Active Comparator|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
16535017|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
16535018|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
16535019|NCT03051724|Experimental|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.
~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
16535020|NCT03051724|No Intervention|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
16535021|NCT03051711|Experimental|GBT440 Dose 1|Dose 1
16535022|NCT03051711|Experimental|GBT440 Dose 2|Dose 2
16535023|NCT03051698|Experimental|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
16535024|NCT03051698|Placebo Comparator|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
16535025|NCT03051698|Experimental|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
16535026|NCT03051685|Experimental|DFN-15 Dose 1|
16535027|NCT03051685|Experimental|DFN-15 Dose 2|
16535028|NCT03051685|Experimental|DFN-15 Dose 3|
16535029|NCT03051685|Active Comparator|Active Comparator|
16535030|NCT03051672|Experimental|Pembrolizumab With Radiation|"pembrolizumab : 200 mg intravenously 2 to 7 days prior to radiotherapy (RT) and on day 1 of repeating 21-day cycles. Treatment up to 35 cycles.
~Palliative radiation: a total dose of 20 Gy in 5 fractions"
16535031|NCT03051659|Experimental|Eribulin Mesylate|"Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle.
~Eribulin mesylate will be administered intravenously"
16535032|NCT03051659|Experimental|Eribulin Mesylate Combine with Pembrolizumab|"Pembrolizumab will be administered in clinic once per cycle
~Pembrolizumab will be given intravenously prior to Eribulin Mesylate
~Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle.
~Eribulin mesylate will be administered intravenously"
16535033|NCT03051646|Experimental|Acetylsalicylic acid first, placebo second|Participant is administered acetylsalicylic acid one hour prior to exercise.
16535185|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
16535034|NCT03051646|Placebo Comparator|Placebo oral capsule first, ASA second|Participant is administered placebo one hour prior to exercise.
16535035|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
16535036|NCT03051633|No Intervention|Control|Assessment only
16535037|NCT03051607|Experimental|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
16535038|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
16535039|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
16535040|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
16535041|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
16535042|NCT03051568|Experimental|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
16535043|NCT03051555|Experimental|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
16535044|NCT03051542|Experimental|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
16535045|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
16535046|NCT03051516|Experimental|Arm I (recombinant human papillomavirus nonavalent vaccine)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
16535047|NCT03051516|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM at baseline, 2 months, and 6 months.
16535048|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
16535049|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
16535050|NCT03051490|Experimental|Liprotamase|Individually-optimized dose to be administered orally
16535051|NCT03051490|Active Comparator|porcine PERT|Individually-optimized dose to be administered orally
16535052|NCT03051477|Experimental|Helixor® M|Advanced solid tumors
16535053|NCT03051464|Experimental|Chemoradiation + EBRT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
16535054|NCT03051464|Experimental|Chemoradiation + HDRBT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
16535055|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:
~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).
~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
16535056|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:
~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).
~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
16535057|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
16535058|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
16535059|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
16535060|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
16535061|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
16535062|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
16535063|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
16535064|NCT03051412||Control|This is a control group with no history of knee pain.
16535065|NCT03051399|Placebo Comparator|Placebo|Maltodextrin, 500 mg/day, single serving
16535066|NCT03051399|Active Comparator|EpiCor|EpiCor, 500 mg/day, single serving
16535067|NCT03051386|Experimental|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
16535068|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
16535069|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
16535070|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
16535071|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
16535072|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
16535073|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
16535074|NCT03051347|Other|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
16535075|NCT03051347|Other|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
16535076|NCT03051334||BiAV|Bicuspid aortic valve
16535077|NCT03051334||TAV|Tricuspid aortic valve
16535078|NCT03051321|Experimental|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
16535079|NCT03051308|Experimental|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
16535080|NCT03051308|Experimental|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
16535081|NCT03051308|Experimental|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
16535082|NCT03051308|Experimental|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
16535083|NCT03051308|Experimental|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
16535084|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
16535085|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
16535086|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
16535087|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
16535088|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
16535089|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
16535090|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
16535091|NCT03051256|Experimental|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
16535092|NCT03051256|Experimental|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
16535093|NCT03051256|Placebo Comparator|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
16535094|NCT03051243|Active Comparator|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
16535095|NCT03051243|Active Comparator|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
16535096|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
16535097|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
16535098|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
16535099|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
16535100|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
16535101|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
16535102|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
16535103|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
16535104|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
16535105|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
16535106|NCT03051178|Experimental|Subjects with Essential Tremor|This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
16535107|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
16535108|NCT03051152|Experimental|Elderly with CCS>5 - D1 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with limited lymphadenectomy
16575867|NCT02772458|Experimental|Crohn's Disease|Active Crohn's Disease
16535109|NCT03051152|Experimental|Elderly with CCS>5 - D2 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with extended lymphadenectomy
16535110|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
16535111|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
16535112|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
16535113|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
16535114|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
16535115|NCT03051087|Experimental|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
16535116|NCT03051087|Active Comparator|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
16535117|NCT03051074|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
16535118|NCT03051074|Active Comparator|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
16535119|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
16535120|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
16535121|NCT03051035|Experimental|KO-947|
16535122|NCT03051022|Active Comparator|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
16535123|NCT03051022|Active Comparator|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
16535124|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
16535125|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
16535126|NCT03051009|Experimental|Desmopressin ODT 25 μg (female)|New female subjects
16535127|NCT03051009|Experimental|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
16535128|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
16535129|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
16535130|NCT03051009|Experimental|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
16535131|NCT03051009|Experimental|Desmopressin ODT 50 μg (male)|New male subjects
16535132|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
16535133|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
16535134|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
16535135|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
16535136|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
16535137|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
16535138|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
16535139|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
16535140|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
16535141|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
16535142|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
16535143|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
16535144|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
16535145|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
16535146|NCT03050866|Other|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
16535147|NCT03050853|Experimental|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
16535148|NCT03050853|No Intervention|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
16535149|NCT03050840|Other|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
16575868|NCT02772458|Experimental|Healthy|Healthy volunteers
16535150|NCT03050840|Experimental|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
16535151|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
16535152|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
16535153|NCT03050814|Active Comparator|A /FOLFOX-A alone|Suubjects will receive FOLFOX + bevacizumab + for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine until disease progression.
16535154|NCT03050814|Experimental|B/Lead in, FOLFOX-A + Avelumab + Ad-CEA|Subjects will receive FOLFOX + bevacizumab + avelumab + Ad-CEA vaccine (given weeks 0,2,4,8,12,16 and then every 12 weeks) for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine + avelumab + Ad-CEA vaccine (following the every 12 week dosing schedule) until disease progression.
16535155|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 1 day|Experiment 1
16535156|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 3 days|Experiment 1
16535157|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 4 days|Experiment 1
16535158|NCT03050801|Experimental|Experiment 2 - Parietal Cortex rTMS stimulation - 3 days|Experiment 2
16535159|NCT03050801|Experimental|Experiment 2 - Vertex rTMS stimulation - 3 days|Experiment 2
16535160|NCT03050801|Experimental|Experiment 2 - Prefrontal Cortex rTMS stimulation - 3 days|Experiment 2
16535161|NCT03050788|Experimental|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
16535162|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
16535163|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
16535164|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.
~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
16535165|NCT03050749|Other|Princess® VOLUME|
16535166|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
16535167|NCT03050723|Other|Princess® FILLER|
16535168|NCT03050710|Other|Princess® VOLUME Lidocaine|
16535169|NCT03050697|Experimental|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
16535170|NCT03050684|Active Comparator|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
16535171|NCT03050684|Placebo Comparator|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
16535172|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
16535173|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
16535174|NCT03050645||previous GDM|Women with previous GDM
16535175|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
16535176|NCT03050632|Experimental|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
16535177|NCT03050632|Placebo Comparator|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
16535178|NCT03050619||New users of Empagliflozin|New users of empagliflozin
16535179|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
16535180|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
16535181|NCT03050606|Experimental|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.
~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
16535182|NCT03050606|Active Comparator|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.
~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
16535183|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
16535184|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
16535186|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
16535187|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
16535188|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
16535189|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
16535190|NCT03050554|Experimental|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
16535191|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
16535192|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
16535193|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
16535194|NCT03050528|Experimental|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
16535195|NCT03050528|Active Comparator|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
16535196|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.
~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
16535197|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
16535198|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
16535199|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
16535200|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
16535201|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
16535202|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion of 9000 IU over the next 24 hours.
16535203|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24 hours.
16535204|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
16535205|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
16535206|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
16535207|NCT03050450|Experimental|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
16535208|NCT03050450|Experimental|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
16535209|NCT03050450|Experimental|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
16535210|NCT03050450|Experimental|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
16535211|NCT03050450|Experimental|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
16535212|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
16535213|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
16535214|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
16535215|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
16535216|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
16535217|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole per the core study
16535218|NCT03050385|Active Comparator|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)
~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
16537354|NCT03036046|Experimental|F901318 with fluconazole high dose|safety assessment
16535219|NCT03050385|Sham Comparator|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA
~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
16535220|NCT03050372|Experimental|Active Low Field Magnetic Stimulation|LFMS - Active
16535221|NCT03050372|Sham Comparator|Sham Low Field Magnetic Stimulation|LFMS - Sham
16535222|NCT03050359|Experimental|TAK-438 20 mg|H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
16535223|NCT03050359|Experimental|Lansoprazole 30 mg|H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
16535224|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
16535225|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
16535226|NCT03050320|Experimental|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
16535227|NCT03050320|Other|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
16535228|NCT03050307|Experimental|TAK-438 20 mg|Helicobacter Pylori positive (HP+) participants: TAK-438 20 mg tablet, twice daily (BID) along with lansoprazole placebo-matching, capsule BID in addition to bismuth-containing quadruple antibiotic therapy for the first 2 weeks. Following 2 weeks of eradication therapy participants received TAK-438 20 mg QD along with lansoprazole matching placebo 30 mg, capsule QD for up to 6 weeks. HP negative (HP-) participants: TAK-438 20 mg tablet, (QD) along with lansoprazole matching placebo, 30 mg capsule QD for up to 8 weeks.
16535229|NCT03050307|Experimental|Lansoprazole 30 mg|HP+ participants: Lansoprazole 30 mg, capsule, orally, BID and TAK-438 placebo-matching tablet, orally, BID along with bismuth-containing quadruple antibiotic therapy for first 2 weeks. Following 2 weeks participants received Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 6 weeks. HP- participants: Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 8 weeks.
16535230|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
16535231|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
16535232|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
16535233|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
16535234|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
16535235|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
16535236|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~medical air (MA)
~Oxygen (2 Liter/min)
~Oxygen (4 Liter/min)"
16535237|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~medical air (MA)
~Oxygen (4 Liter/min)
~Oxygen (2 Liter/min)"
16535238|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (2 Liter/min)
~Medical air (MA)
~Oxygen (4 Liter/min)"
16535239|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (2 Liter/min)
~Oxygen (4 Liter/min)
~Medical air (MA)"
16535240|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (4 Liter/min)
~Medical air (MA)
~Oxygen (2 Liter/min)"
16535241|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (4 Liter/min)
~Oxygen (2 Liter/min)
~Medical air (MA)"
16535242|NCT03050242|Experimental|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
16535243|NCT03050242|No Intervention|Control|No injection is conducted in this group.
16535244|NCT03050229|Experimental|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
16535245|NCT03050229|Placebo Comparator|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
16535246|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide
~ALT-803 Activation of Donor NK Cells
~ALT-803 to Facilitate NK Cell Survival and Expansion"
16535247|NCT03050203|Experimental|custom pack|
16535248|NCT03050203|Active Comparator|standard care|
16535249|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
16535250|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
16535251|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
16535252|NCT03050164|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
16535253|NCT03050164|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
16535254|NCT03050151|Experimental|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
16535255|NCT03050151|Experimental|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
16535256|NCT03050151|Experimental|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
16535257|NCT03050151|Experimental|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
16535258|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
16535259|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
16535260|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
16535261|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
16535262|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
16535263|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
16535264|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
16535265|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
16535266|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
16535267|NCT03050086|Experimental|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
16535268|NCT03050086|Experimental|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
16535269|NCT03050086|Placebo Comparator|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
16535270|NCT03050060|Experimental|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.
16535271|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
16535272|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
16535273|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
16535274|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
16535275|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
16535276|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
16535277|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
16535278|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
16535279|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
16535280|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
16535292|NCT03049969|Experimental|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.
16535293|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
16535462|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
16535281|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
16535282|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
16535283|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
16535284|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
16535285|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
16535286|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
16535287|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age > 10 years, height > 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
16535288|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
16535289|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
16535290|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
16535291|NCT03049982|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
16535463|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
16535294|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
16535295|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
16535296|NCT03049930|Experimental|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
16535297|NCT03049930|Placebo Comparator|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
16535298|NCT03049917|No Intervention|No incentive|No incentive
16535299|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
16535300|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
16535301|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
16535302|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
16535303|NCT03049904|No Intervention|Wait List Control|Participants wait 3 weeks before receiving the intervention.
16535304|NCT03049904|Experimental|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
16535305|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
16535306|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
16535307|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
16535308|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
16535309|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
16535310|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
16535311|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
16535312|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
16535313|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
16535314|NCT03049839|Experimental|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
16535315|NCT03049839|Experimental|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).
~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
16535316|NCT03049839|Experimental|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.
~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
16535317|NCT03049826|Experimental|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
16535318|NCT03049826|No Intervention|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
16535319|NCT03049826|No Intervention|Healthy reference group|Healthy children
16535320|NCT03049813|Experimental|Virtual Reality Job Interview Training|Virtual Reality Job Interview Training
16535321|NCT03049813|Other|Supported Employment (Services as Usual)|Supported Employment (Services as Usual)
16535322|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
16535323|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
16535324|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
16535325|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
16535326|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
16535387|NCT03049384|Experimental|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
16535327|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
16535328|NCT03049761|Active Comparator|Water Flosser|Power interdental Cleaning Device
16535329|NCT03049761|Active Comparator|String floss|Manual interdental cleaning device
16535330|NCT03049761|Active Comparator|Manual Toothbrush|ADA standard manual toothbrush
16535331|NCT03049748|Active Comparator|Control Group|Participants in the control group (20 LVAD patients) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
16535332|NCT03049748|Experimental|Intervention Group|Participants in the experimental group (20 LVAD patients) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
16535333|NCT03049735|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
16535334|NCT03049735|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
16535335|NCT03049735|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
16535336|NCT03049722|Experimental|AVOPT Patient|
16535337|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
16535338|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
16535339|NCT03049696|No Intervention|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
16535340|NCT03049696|Experimental|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
16535341|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
16535342|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score > 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
16535343|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
16535344|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
16535345|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
16535346|NCT03049644|Active Comparator|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
16535347|NCT03049644|Active Comparator|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
16535348|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
16535349|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
16535350|NCT03049618|Experimental|Treatment (pembrolizumab, sEphB4-HSA)|Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
16535351|NCT03049605|Experimental|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
16535352|NCT03049605|Experimental|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
16535353|NCT03049605|Experimental|Medical therapy|Fifteen patients were received only medical treatment .
16535354|NCT03049592|Experimental|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
16535355|NCT03049592|No Intervention|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
16535356|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
16535357|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
16535358|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
16535359|NCT03049553|Other|HPV-test|Cobas HPV-DNA test is performed on the cervical sample in addition to the routine cytology
16535360|NCT03049553|No Intervention|Routine|Screening with cytology as usual in the cervical screening program
16535361|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
16535362|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
16535363|NCT03049527|Experimental|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
16535364|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
16535365|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
16535366|NCT03049488|Experimental|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
16535367|NCT03049488|Experimental|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
16535368|NCT03049488|Experimental|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)
~*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
16535369|NCT03049488|Experimental|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
16535370|NCT03049488|Experimental|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
16535371|NCT03049488|Experimental|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
16535372|NCT03049475||Control|Healthy, between age 18-80, African/African decent
16535373|NCT03049475||Subjects in steady State|Steady state is defined as the period from at any time 8 weeks prior to or after a crisis and samples obtained during this time would be considered steady state samples .
16535379|NCT03049449|Experimental|1|All patients will be receiving starting dose: 0.3x106 CAR+ T cells/kg (weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells /kg)infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamid on days -5, -4,and -3
16535380|NCT03049436||Patients with program of adapted physical activity|
16535381|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
16535382|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
16535383|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
16535384|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
16535385|NCT03049397|Experimental|Supportive Care (Enhancing Connections program)|Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
16535386|NCT03049384|Active Comparator|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
16535388|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
16535389|NCT03049358|Experimental|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
16535390|NCT03049358|Sham Comparator|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
16535391|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
16535392|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
16535393|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
16535394|NCT03049306|Placebo Comparator|Placebo Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.
16535395|NCT03049306|Active Comparator|Propranolol Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.
16535396|NCT03049306|Active Comparator|CPAP|Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.
16535397|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
16535398|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
16535399|NCT03049280|Experimental|Transoral robotic surgery|
16535400|NCT03049267|Experimental|Apremilast|N=15
16535401|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
16535402|NCT03049254||Proband|Proband - the person who is the first to present with a diagnosis of AVC
16535403|NCT03049254||Family members (consultands)|First-degree relatives of probands with AVC (who may be living or deceased) In some circumstances where multiple family members are or may be affected, they may be eligible.
16535404|NCT03049241||knee extensors|
16535405|NCT03049241||ankle plantar|
16535406|NCT03049228||Type 2 Diabetic Patients|"Obese (BMI > 27 kg/m2 < 35 kg/m2)
~Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months
~They should have a (moderately) well-controlled diabetes (defined by a HbA1c<8%)"
16535407|NCT03049228||Obese Subjects|"A similar BMI as T2DM patients (BMI > 27 kg/m2< 35)
~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
16535408|NCT03049228||Lean subjects|"BMI between 20-25 kg/m2
~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
16535409|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
16535410|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
16535411|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
16535412|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: > 10 pack years. Definition of ex-smoker: > 2 years since smoke cessation.
16535413|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
16535414|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
16535415|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
16535416|NCT03049189|Experimental|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)
~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.
~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
16535461|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
16535417|NCT03049189|Active Comparator|Everolimus|"Everolimus (Afinitor ®)
~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
16535418|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
16535419|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
16535420|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
16535421|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
16535422|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
16535423|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
16535424|NCT03049124|Experimental|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
16535425|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
16535426|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
16535427|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
16535428|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
16535429|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
16535430|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
16535431|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
16535432|NCT03049059|Active Comparator|4% hydroquinone cream alone|
16535433|NCT03049046|Active Comparator|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
16535434|NCT03049046|Active Comparator|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
16535435|NCT03049046|Active Comparator|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
16535436|NCT03049046|Placebo Comparator|Placebo|Placebo once daily by mouth for 7 days
16535437|NCT03049033|Experimental|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and auditory cues to specifically improve fine motor movements.
16535438|NCT03049033|Active Comparator|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
16535439|NCT03049033|No Intervention|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
16535440|NCT03049033|Active Comparator|Music Supported Therapy (MST)|Music Supported Therapy uses musical instruments to train fine motor movements.
16535441|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
16535442|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
16535443|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
16535444|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
16535445|NCT03048994|Placebo Comparator|Placebo|Placebo
16535446|NCT03048994|Active Comparator|Glutamine|Glutamine
16535447|NCT03048981|Experimental|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
16535448|NCT03048968|Experimental|study group1: elderly adults|Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS
16535449|NCT03048968|Experimental|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
16535450|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
16535451|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
16535452|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
16535453|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
16535454|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
16535455|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
16535456|NCT03048916|Other|general swallowing therapy|"including:
~oral exercises
~tactile stimulation
~compensatory techniques
~swallowing maneuvers"
16535457|NCT03048916|Experimental|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
16535458|NCT03048916|Active Comparator|: the combined NMES and general swallowing therapies|
16535459|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
16535460|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
16535465|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
16535466|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
16535467|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
16535468|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
16535469|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
16535470|NCT03048838|Experimental|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
16535471|NCT03048838|Active Comparator|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
16535472|NCT03048825|Experimental|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
16535473|NCT03048825|Experimental|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
16535474|NCT03048825|Experimental|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
16535475|NCT03048825|Placebo Comparator|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
16535476|NCT03048812|Experimental|O'Ring attachment (A)|One arm of our research will receive O'Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
16535477|NCT03048812|Experimental|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
16535478|NCT03048799|Active Comparator|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
16535479|NCT03048799|Placebo Comparator|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.
~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
16535480|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
16535481|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
16535482|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece
~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
16535483|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece
~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
16535484|NCT03048760|Experimental|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan & 1 after approx. 2 weeks of radiotherapy treatment.
16535485|NCT03048747|Experimental|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
16535486|NCT03048734||Group (1): Men with Nocturia ≥2.|
16535487|NCT03048734||Group (2): Men with no nocturia (0-1).|
16535488|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
16535489|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
16535490|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
16535526|NCT03048422|Active Comparator|Arm 3: Maternal EFV/FTC/TDF|Mothers will receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
16535527|NCT03048409||Enteral tube fed adults|Enteral formula
16535491|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
16535492|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
16535493|NCT03048695|No Intervention|Waiting list|
16535494|NCT03048682|Experimental|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.
~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
16535495|NCT03048682|Active Comparator|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.
~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
16535496|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
16535497|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
16535498|NCT03048656|Experimental|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
16535499|NCT03048656|Active Comparator|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
16535500|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
16535501|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
16535502|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
16535503|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
16535504|NCT03048604|Experimental|Genio(TM) system therapy|
16535505|NCT03048591|Experimental|Electroacupuncture group|
16535506|NCT03048591|No Intervention|control group|
16535507|NCT03048578|Experimental|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
16535508|NCT03048578|Placebo Comparator|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
16535509|NCT03048565|No Intervention|Usual care|No intervention
16535510|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
16535511|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
16535512|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
16535513|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
16535514|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
16535515|NCT03048526|Experimental|NovaTears®|
16535516|NCT03048526|Active Comparator|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
16535517|NCT03048500|Experimental|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
16535518|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
16535519|NCT03048461|Experimental|Platelet Rich Plasma|Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart
16535520|NCT03048461|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart
16535521|NCT03048448|Experimental|Fevipiprant 450mg|450mg Film Coated Tablet
16535522|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
16535523|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
16535524|NCT03048422|Experimental|Arm 1: Maternal DTG+FTC/TAF|Mothers will receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
16535525|NCT03048422|Experimental|Arm 2: Maternal DTG+FTC/TDF|Mothers will receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
16535529|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
16535530|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
16535531|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
16535532|NCT03048370|Experimental|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
16535533|NCT03048370|Experimental|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
16535534|NCT03048370|Experimental|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
16535535|NCT03048370|Experimental|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
16535536|NCT03048370|Experimental|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
16535537|NCT03048370|Experimental|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
16535538|NCT03048357|Active Comparator|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
16535539|NCT03048357|Other|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
16535540|NCT03048344|Experimental|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
16535541|NCT03048344|Experimental|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
16535542|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.
~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
16535543|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
16535544|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
16535545|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
16535546|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
16535547|NCT03048292||Mobilized Patient|
16535548|NCT03048292||Core Comprehensive Stroke Center Treatment|
16535549|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
16535550|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
16535551|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
16535552|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
16535553|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
16535554|NCT03048227|Experimental|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
16535555|NCT03048227|No Intervention|Control|Patients will manage their diabetes as usual as recommended by their care team.
16535556|NCT03048214|Sham Comparator|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
16535557|NCT03048214|Experimental|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
16535558|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
16535559|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
16535560|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
16535561|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
16535562|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
16535563|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
16535564|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
16535565|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
16535566|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
16535567|NCT03048136|Experimental|Flat-Dose|Nivolumab flat dose + Ipilimumab
16535568|NCT03048136|Experimental|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
16535569|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
16535837|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation >12 month prior to inclution.
16535570|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
16535571|NCT03048110|Experimental|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
16535572|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
16535573|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
16535574|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
16535575|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
16535576|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
16535577|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
16535578|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
16535579|NCT03048045||Supportive Periodontal Treatment (SPT)|"at least 18 years old.
~periodontal treatment (antiinfective therapy with subgingival debridement under local anesthesia and if required periodontal surgery) at the Dept. of Periodontology starting after April 2005 durchgeführt.
~complete periodontal charting (PPD and PAL-V at 6 sites per tooth, furcation involvement [Hamp et al. 1975] at all furcation sites of multi-rooted teeth) prior to treatment (baseline, T0) and after completion of active periodontal treatment (APT) (reevaluation 1 or 2/start of supportive periodontal therapy, T1)
~radiographs of all teeth (periapical radiographs or panoramic radiograph) from baseline
~written informed consent"
16535580|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
16535581|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
16535582|NCT03048019||Tirofiban Therapy|
16535583|NCT03048019||Cangrelor Therapy|
16535584|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
16535585|NCT03047993|Experimental|Treatment (glutaminase inhibitor CB-839, azacitidine)|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.
16535586|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
16535587|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
16535588|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
16535589|NCT03047954|Experimental|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
16535590|NCT03047954|Placebo Comparator|Placebo|Matching placebo capsule
16535591|NCT03047941||All patients|All patients included in the present study
16535592|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.
~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.
~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
16535593|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
16535726|NCT03047018|Experimental|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
16535594|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
16535595|NCT03047902|Active Comparator|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.
~Intervention: Parents will be present for the questionnaire but not for the CO test."
16535596|NCT03047902|Active Comparator|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.
~Intervention: Parents will not be present for the questionnaire or the CO test"
16535597|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
16535598|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
16535599|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
16535600|NCT03047850||Study Group|All patients included in this study.
16535601|NCT03047837|Placebo Comparator|Arm A|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID)
16535602|NCT03047837|Experimental|Arm B|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
16535603|NCT03047837|Experimental|Arm C|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID)
16535604|NCT03047837|Experimental|Arm D|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
16535605|NCT03047824|Other|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
16535606|NCT03047824|Other|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
16535607|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
16535608|NCT03047798|Experimental|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
16535609|NCT03047798|Experimental|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
16535610|NCT03047798|Placebo Comparator|Control|The control mouthrinse only contained sodium fluoride
16535611|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
16535612|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
16535613|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
16535614|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
16535615|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
16535616|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
16535617|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
16535618|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
16535619|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
16535620|NCT03047759|Active Comparator|Intervention A|water flosser
16535621|NCT03047759|Active Comparator|Intervention B|air floss
16535622|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia excluding Fanconi Anemia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
16535623|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
16535624|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/ Fanconi Anemia|Patients with acquired or inherited bone marrow failure (iBMF) with Fanconi Anemia and related DNA Repair Disorders will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
16535625|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).
~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
16535626|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).
~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.
~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
16535627|NCT03047720|Other|One: Study Phases (S1 and S2)|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
16535628|NCT03047720|Other|Two: Study Phases (S2 and S1)|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
16535629|NCT03047707|Experimental|S-Shearwave and TE|
16535630|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
16535631|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
16535632|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
16535633|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
16535634|NCT03047668|Active Comparator|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
16535635|NCT03047668|Active Comparator|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), without walnuts / walnut-sunflower muffins
16535636|NCT03047668|Active Comparator|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
16535637|NCT03047668|Active Comparator|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), without walnuts / walnut-sunflower muffins
16535638|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
16535639|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
16535640|NCT03047642||Malawi febrile patients|Children and adults with fever presenting at the outpatient department
16535641|NCT03047642||Brazil febrile patients|Children and adults with fever presenting at the outpatient department
16535642|NCT03047642||Gabon febrile patients|Children with fever or with a recent history of fever presenting at the outpatient department
16535643|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
16535644|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
16535645|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
16535646|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
16535647|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
16535648|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
16535649|NCT03047590|Experimental|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
16535650|NCT03047590|Experimental|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
16535651|NCT03047590|Experimental|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
16535652|NCT03047590|Active Comparator|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
16535653|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
16535654|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
16535655|NCT03047564|Experimental|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
16535656|NCT03047564|Active Comparator|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
16535657|NCT03047551|Active Comparator|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.
~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
16535658|NCT03047551|Active Comparator|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.
~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
16537355|NCT03036046|Experimental|F901318 with posaconazole|safety assessment
16535659|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
16535660|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
16535661|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
16535662|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
16535663|NCT03047512|Experimental|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
16535664|NCT03047512|No Intervention|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
16535665|NCT03047499||Scar Length|
16535666|NCT03047499||Vancouver scar scale|
16535667|NCT03047499||Scar width|
16535668|NCT03047473|Experimental|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
16535669|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses
~Intervention: multimodal evoked potentials"
16535670|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:
~Aged 18 to 58 years old, inclusive, at the time of informed consent.
~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.
~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb
~Have no comorbid condition (ie neuropathy) that could affect testing.
~Intervention: multimodal evoked potentials"
16535671|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
16535672|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
16535673|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
16535674|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
16535675|NCT03047408|Experimental|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
16535676|NCT03047395|Experimental|Risankizumab|Participants will receive risankizumab administered by subcutaneous injection.
16535677|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
16535678|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
16535679|NCT03047356|Experimental|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
16535680|NCT03047356|Experimental|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
16535681|NCT03047356|Placebo Comparator|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
16535682|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
16535683|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
16535684|NCT03047330|Experimental|Unfragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some unfragmented sleep periods.
16535685|NCT03047330|Experimental|Fragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some fragmented sleep periods.
16535686|NCT03047317|Experimental|MABp1|
16535687|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
16535688|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
16535689|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
16535723|NCT03047031||Group A|Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.
16535724|NCT03047031||Group B|Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.
16535725|NCT03047031||Group C|Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance
16535760|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
16535690|NCT03047278|Active Comparator|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) was administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, was administered. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling.
16535691|NCT03047278|Experimental|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
16535692|NCT03047278|Experimental|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
16535693|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
16535694|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
16535695|NCT03047252|Experimental|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.
~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
16535696|NCT03047252|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
16535697|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
16535698|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16535699|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
16535700|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:
~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
16535701|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.
~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
16535702|NCT03047161||High-risk pregnancy|abnormal fetal heart rate or rhythm or risk of abnormal fetal heart rate or rhythm
16535703|NCT03047161||Uncomplicated pregnancy|uncomplicated pregnancy
16535704|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
16535705|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
16535706|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
16535707|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
16535708|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
16535709|NCT03047096|Experimental|HA & CS group|hyaluronic acid and corticosteroids
16535710|NCT03047096|Experimental|HA group|hyaluronic acid
16535711|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
16535712|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
16535713|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
16535714|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
16535715|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
16535716|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
16535717|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
16535718|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
16535719|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
16535720|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
16535721|NCT03047044|Active Comparator|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
16535722|NCT03047044|Experimental|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
16535802|NCT03046394|Active Comparator|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
16535727|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
16535728|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
16535729|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts
~Dose Expansion Phase: Consists of 5 Cohorts
~Dose Extension Phase: Consists of 2 Cohorts"
16535730|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
16535731|NCT03046966|Other|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
16535732|NCT03046966|Other|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
16535733|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
16535734|NCT03046940|No Intervention|Control group|No communication with a doctor
16535735|NCT03046940|Experimental|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
16535736|NCT03046940|Experimental|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
16535737|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
16535738|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
16535739|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
16535740|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
16535741|NCT03046888|Experimental|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
16535742|NCT03046888|Experimental|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
16535743|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
16535744|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
16535746|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 IU intranasal Oxytocin
16535747|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
16535748|NCT03046810|Experimental|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
16535749|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
16535750|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
16535751|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.
~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
16535752|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
16535753|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
16535754|NCT03046758|Experimental|Participants|
16535755|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
16535756|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
16535757|NCT03046732|Experimental|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
16535758|NCT03046732|No Intervention|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
16535759|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
16578556|NCT02754921|Experimental|Ciaglia Blue Dolphin|
16535761|NCT03046706|Active Comparator|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
16535762|NCT03046706|Experimental|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
16535763|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
16535764|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
16535765|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
16535766|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
16535767|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
16535768|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
16535769|NCT03046654|Experimental|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
16535770|NCT03046641|Experimental|continuous training group|With the continuous training program
16535771|NCT03046641|Experimental|interval training group|With the interval training program
16535772|NCT03046628|Experimental|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
16535773|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
16535774|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
16535775|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
16535776|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
16535777|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
16535778|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
16535779|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
16535780|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
16535781|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
16535782|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
16535783|NCT03046550|Experimental|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
16535784|NCT03046550|Experimental|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
16535785|NCT03046550|Experimental|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
16535786|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
16535787|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
16535788|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
16535789|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
16535790|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
16535791|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
16535792|NCT03046498|Experimental|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
16535793|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
16535794|NCT03046485|No Intervention|Wait list control|Wait list control
16535795|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.
~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.
~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.
~Total duration 12 weeks/3 months"
16535796|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.
~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.
~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
16535797|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
16535798|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
16535799|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
16535800|NCT03046394|Active Comparator|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
16535801|NCT03046394|Active Comparator|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
16535803|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
16535804|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
16535805|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
16535806|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
16535807|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
16535808|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
16535809|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
16535810|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
16535811|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
16535812|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
16535813|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
16535814|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
16535815|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
16535816|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
16535817|NCT03046316|Other|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
16535818|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
16535819|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
16535820|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
16535821|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
16535822|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
16535823|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
16535824|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
16535825|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
16535826|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
16535827|NCT03046238|Active Comparator|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
16535828|NCT03046238|Placebo Comparator|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
16535829|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
16535830|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
16535831|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
16535832|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
16535833|NCT03046199|No Intervention|Control|
16535834|NCT03046199|Experimental|Questionnaire|
16535835|NCT03046199|Experimental|Coordination|
16535838|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
16535839|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass >12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
16535840|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
16535841|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
16535842|NCT03046160|Experimental|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)
~The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets
~tape (postural correction of scapular anterior tilt)
~A program of 12 neck and scapular exercises."
16535843|NCT03046160|Active Comparator|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)
~tape (postural correction of scapular anterior tilt)
~A program of 12 neck and scapular exercises."
16535844|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
16535845|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
16535846|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
16535847|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
16535848|NCT03046108|Active Comparator|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.
~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.
~Up to 4 injections are allow in the first three months of follow-up"
16535849|NCT03046108|Active Comparator|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.
~Up to 4 injections are allow in the first three months of follow-up"
16535850|NCT03046108|Active Comparator|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
16535851|NCT03046108|Experimental|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
16535852|NCT03046108|Experimental|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.
~Up to 4 injections are allow in the first three months of follow-up"
16535853|NCT03046108|Experimental|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
16535854|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
16535855|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
16535856|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
16535857|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
16535858|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
16535859|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
16535860|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
16535861|NCT03046056|Experimental|Filgotinib 200 mg|Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
16535862|NCT03046056|Experimental|Filgotinib 100 mg|Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
16535863|NCT03046056|Placebo Comparator|Placebo|PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
16535886|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
16535887|NCT03045887|Experimental|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
16535864|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed
~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation
~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™
~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.
~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
16535865|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.
~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
16535866|NCT03046030|Experimental|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
16535867|NCT03046017|Active Comparator|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
16535868|NCT03046017|Sham Comparator|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
16535869|NCT03046017|Other|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
16535870|NCT03046004|Experimental|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
16535871|NCT03046004|Active Comparator|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
16535872|NCT03045991|Experimental|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.
~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
16535873|NCT03045991|Active Comparator|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.
~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
16535874|NCT03045965|Experimental|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
16535875|NCT03045965|No Intervention|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
16535876|NCT03045952|Experimental|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
16535877|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
16535878|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
16535879|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
16535880|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
16535881|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
16535882|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
16535883|NCT03045887|Experimental|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
16535884|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
16535885|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
16535952|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
16535888|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
16535889|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
16535890|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
16535891|NCT03045887|Experimental|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
16535892|NCT03045887|Experimental|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
16535893|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
16535894|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
16535895|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
16535896|NCT03045874||22 parent-child dyads|The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
16535897|NCT03045874||5 childcare teachers|Teachers will be trained to deliver a brief sleep health intervention
16535898|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
16535899|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
16535900|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
16535901|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
16535902|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
16535903|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
16535904|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
16535905|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
16535906|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
16535907|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
16535908|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
16535909|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
16535910|NCT03045770|Experimental|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
16535911|NCT03045770|Experimental|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
16535912|NCT03045770|Experimental|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
16535913|NCT03045757||Healthy Newborn|Healthy Newborn
16535914|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
16535915|NCT03045744|Experimental|incomplete SCI patients|
16535916|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
16535917|NCT03045718|Experimental|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
16535953|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise
~regular rehabilitation programe
~alternative video-teaching materials"
16535918|NCT03045718|Other|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
16535919|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
16535920|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
16535921|NCT03045692|Active Comparator|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
16535922|NCT03045692|Experimental|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
16535923|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
16535924|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
16535925|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
16535926|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
16535927|NCT03045653|Experimental|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
16535928|NCT03045640|Experimental|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
16535929|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF
~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
16535930|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF
~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .
~One course includes 28 days."
16535931|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
16535932|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
16535933|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
16535934|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
16535935|NCT03045562|Placebo Comparator|Control group|Patients will be assigned to receive 100ml of normal saline
16535936|NCT03045562|Experimental|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
16535937|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
16535938|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
16535939|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
16535940|NCT03045523|Experimental|GLPG2222 Dose 1|
16535941|NCT03045523|Experimental|GLPG2222 Dose 2|
16535942|NCT03045523|Placebo Comparator|Placebo|
16535943|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
16535944|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
16535945|NCT03045484|Experimental|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
16535946|NCT03045484|Experimental|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
16535947|NCT03045471||R-EPOCH|
16535948|NCT03045471||R-CHOP|
16535949|NCT03045458|Active Comparator|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
16535950|NCT03045458|Active Comparator|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
16535951|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
16535954|NCT03045432|Other|control group|"regular passive ROM exercise
~regular rehabilitation programe
~regular oral-teaching materials"
16535955|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC
~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
16535956|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease
~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup
~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
16535957|NCT03045406|Experimental|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
16535958|NCT03045406|Active Comparator|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
16535959|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
16535960|NCT03045380|Experimental|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
16535961|NCT03045380|Active Comparator|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
16535962|NCT03045380|No Intervention|No intervention|Waitlist
16535963|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
16535964|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
16535965|NCT03045354|Experimental|French fries|Eggs with a side of French fries
16535966|NCT03045354|Experimental|Beans|Eggs with a side of beans
16535967|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
16535968|NCT03045354|Experimental|Breakfast skipping|No breakfast
16535969|NCT03045341|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
16535970|NCT03045341|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
16535971|NCT03045341|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
16535972|NCT03045341|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
16535973|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
16535974|NCT03045315|Experimental|women included in a IVF program|
16535975|NCT03045302|Experimental|BIM23B065|
16535976|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
16535977|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
16535978|NCT03045276|Active Comparator|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
16535979|NCT03045276|Active Comparator|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
16535980|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
16535981|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
16535982|NCT03045250|Active Comparator|Type 1 Diabetes|Subjects with known Type 1 diabetes
16535983|NCT03045250|Placebo Comparator|Healthy Controls|Healthy controls
16535984|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
16535985|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
16535986|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.
~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
16535987|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
16535988|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
16535989|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
16535990|NCT03045172|Active Comparator|Group 1|20 subjects with Platelet Rich Plasma injections
16535991|NCT03045172|Placebo Comparator|Group 2|10 subjects with placebo injections
16535992|NCT03045159|Experimental|Strong Families|parenting program
16535993|NCT03045159|Active Comparator|Strong Parents|self-care program
16535994|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
16535995|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
16535996|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
16535997|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
16535998|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
16535999|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
16536000|NCT03045120||bosutinib cohort|Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
16536001|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
16536002|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
16536003|NCT03045081|No Intervention|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
16536004|NCT03045081|Experimental|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
16536005|NCT03045068|Experimental|Study Group|"Platelet Transfusion Management
~Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35*C, (the Sano or BT shunt clip is still on in children with SV physiology)
~Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
16536006|NCT03045068|Active Comparator|Control Group|"Platelet Transfusion Management
~Pre-Termination of CPB- No intervention
~Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
16536007|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
16536008|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
16536009|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
16536010|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
16536011|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
16536012|NCT03045016|Experimental|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
16536013|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
16536014|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
16536015|NCT03044977|Experimental|Cohort 1|"This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)"
16536016|NCT03044977|Experimental|Cohort 2|"This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
16536017|NCT03044977|Experimental|Cohort 3|"This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
16536018|NCT03044977|Experimental|Cohort -1 (alternative cohort)|"This treatment arm is opened if Cohort 1 is not tolerated.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
16536080|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
16536019|NCT03044977|Experimental|Cohort 2.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
16536020|NCT03044977|Experimental|Cohort 2.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
16536021|NCT03044977|Experimental|Cohort 3.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
16536022|NCT03044977|Experimental|Cohort 3.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
16536023|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
16536024|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
16536025|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
16536026|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
16536027|NCT03044938|Experimental|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
16536028|NCT03044938|Placebo Comparator|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
16536029|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
16536030|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
16536031|NCT03044912|Experimental|treatment group|Mirabegron 50 mg for comparison
16536032|NCT03044912|Active Comparator|Comparative group|Patient take Mirabegron 25 mg
16536033|NCT03044899||Adult surgical patients|All surgeries in adult patients
16536034|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
16536035|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
16536036|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
16536037|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
16536038|NCT03044860|Experimental|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
16536039|NCT03044860|Experimental|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
16536040|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
16536041|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
16536042|NCT03044834||Pleuropulmonary Blastoma|"Patients born between 01/01/2000 and 01/01/2016 ;
~Followed up for PPB
~Treated in a French department of paediatric oncology or paediatric surgery
~Study agreement"
16536043|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
16536044|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
16536045|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
16536046|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
16536047|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
16536048|NCT03044769||Patient with CLA with surgery|
16536049|NCT03044769||Patient with CLA without surgery|
16536050|NCT03044756|Experimental|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
16536051|NCT03044756|No Intervention|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
16579240|NCT02750475|Experimental|Arm 1|All subjects are patched.
16536052|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).
~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.
~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
16536053|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16536054|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.
~This group will also complete a 3-hour nutrition module prior to study completion."
16536055|NCT03044691|No Intervention|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
16536056|NCT03044691|Experimental|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
16536057|NCT03044678|Experimental|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
16536058|NCT03044678|Active Comparator|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
16536059|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
16536060|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
16536061|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
16536062|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
16536063|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
16536064|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
16536065|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
16536066|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
16536067|NCT03044626|Experimental|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:
~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.
~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
16536068|NCT03044626|Other|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:
~Nivolumab 240 mg fixed dose (q2w)."
16536069|NCT03044613|Experimental|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
16536070|NCT03044613|Experimental|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
16536071|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
16536072|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
16536073|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
16536074|NCT03044574|Experimental|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
16536075|NCT03044574|Active Comparator|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
16536076|NCT03044561|Experimental|Sildenafil citrate|
16536077|NCT03044561|Placebo Comparator|placebo|
16536078|NCT03044548|Experimental|Experimental|Supportive supervision
16536079|NCT03044548|No Intervention|Control|No intervention
16536081|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 10 years post-implant). Participants in this group must already have an MCS device in place.
16536082|NCT03044522|No Intervention|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
16536083|NCT03044522|Other|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
16536084|NCT03044509||TB exposure|
16536085|NCT03044509||TB infection (latent TB)|
16536086|NCT03044509||TB disease (active TB)|
16536087|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
16536088|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
16536089|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
16536090|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
16536091|NCT03044470|Experimental|Cold saline|Saline stored at 4 degrees centigrade
16536092|NCT03044470|Experimental|Normal Saline|Saline stored at room temperature
16536093|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
16536094|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
16536095|NCT03044444|Experimental|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
16536096|NCT03044444|Experimental|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
16536097|NCT03044444|Placebo Comparator|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
16536098|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
16536099|NCT03044418||anesthesia with laser tube|The special endotracheal (ET) laser tube is tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
16536100|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
16536101|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
16536102|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
16536103|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
16536104|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
16536105|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
16536106|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
16536107|NCT03044366||Comorbidities|Evaluate the average value of these data.
16536108|NCT03044353|Experimental|Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants|Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR will be included. Participants will receive 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
16536109|NCT03044353|Experimental|Group 2: Post-chemotherapy AL Amyloidosis participants|Immunoglobin light chain amyloidosis (AL) participants who attain either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
16536110|NCT03044353|Experimental|Group 3: Newly diagnosed Mayo stage II/IIIa AL participants|Newly diagnosed Mayo stage II/IIIa AL participants who attain a free light chain CR during the first 3 cycles of first-line chemotherapy where the first cycle was cyclophosphamide, bortezomib, dexamethasone (CyBorD) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.
16536111|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
16536112|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
16536113|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
16536114|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
16536115|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
16536116|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
16536117|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
16536118|NCT03044288|Experimental|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.
~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
16536119|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.
~New adhesive strip Standard adhesive strip"
16536120|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
16536121|NCT03044249|Experimental|MP-101|"Week 0:
~Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps.
~Week 1:
~Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps.
~Week 2 through Week 9:
~Participants received 60 mg MP-101 orally QD (3 x 20-mg caps )."
16536122|NCT03044249|Placebo Comparator|Placebo|Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
16536123|NCT03044236|Experimental|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
16536124|NCT03044236|Active Comparator|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
16536125|NCT03044210|Other|Cockayne patients|"Interventions performed:
~blood sample
~urinary collection
~metabolic evaluation
~clinical evaluation"
16536126|NCT03044210|Other|Control subjects|"Interventions performed:
~urinary collection
~metabolic evaluation
~clinical evaluation"
16536127|NCT03044197|Experimental|MRI/ultrasound transperineal prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
16536128|NCT03044197|Active Comparator|transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
16536129|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage
~AND
~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
16536130|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage
~AND
~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
16536131|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
16536132|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
16536133|NCT03044158|No Intervention|Control group|Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols
16536134|NCT03044158|Experimental|Intervention|Onsite molecular testing for TB with GeneXpert I + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback
16536135|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
16536136|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
16536137|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
16536138|NCT03044132|Experimental|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
16536139|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
16536140|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
16536141|NCT03044106|Active Comparator|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
16536142|NCT03044106|Sham Comparator|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
16536143|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
16536144|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.
~Mifepristone"
16536145|NCT03044080|Active Comparator|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
16536146|NCT03044080|Active Comparator|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
16536147|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
16536148|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
16536149|NCT03044054|Experimental|ECHOPULSE|ECHOPULSE HIFU
16536150|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
16536151|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
16536152|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
16536153|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
16536154|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
16536155|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
16536156|NCT03044015|Active Comparator|Control|Intervention as usual
16536157|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
16536158|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
16536159|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.
~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
16536160|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.
~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
16536161|NCT03043976|Active Comparator|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
16536162|NCT03043976|Active Comparator|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
16536200|NCT03043729|Experimental|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
16537839|NCT03032666|Experimental|sofosbuvir/velpatasvir|Epclusa
16536163|NCT03043976|Placebo Comparator|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.
~If patients are not being started on drug therapy then they will be withdrawn from the study"
16536164|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
16536165|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
16536166|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
16536167|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
16536168|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
16536169|NCT03043937||cardiac patients WHO class 1,2|
16536170|NCT03043937||cardiac patients WHO class 3,4|
16536171|NCT03043924|Other|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
16536172|NCT03043924|Other|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
16536173|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
16536174|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
16536175|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.
~Intervention: Lung sound transmission measurement for part B(i) of the study."
16536176|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.
~Intervention: Lung sound transmission measurement for part B(ii) of the study."
16536177|NCT03043885|Experimental|PRF|
16536178|NCT03043885|Experimental|PRF+FDBA|
16536179|NCT03043885|Active Comparator|FDBA|
16536180|NCT03043885|Active Comparator|Blood Clot|
16536181|NCT03043872|Experimental|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
16536182|NCT03043872|Experimental|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
16536183|NCT03043872|Active Comparator|Arm 3|EP (carboplatin or cisplatin + etoposide)
16536184|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
16536185|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
16536186|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
16536187|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
16536188|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
16536189|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
16536190|NCT03043820|Active Comparator|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
16536191|NCT03043820|Placebo Comparator|Placebo|Placebo 2 tablets daily for 12 weeks.
16536192|NCT03043807|Experimental|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
16536193|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
16536194|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
16536195|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
16536196|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
16536197|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
16536198|NCT03043742|Experimental|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:
~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
16536199|NCT03043729|Active Comparator|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
16536467|NCT03041779|Active Comparator|Paracetamol|Paracetamol 500Mg Suppository
16536201|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
16536202|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
16536203|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
16536204|NCT03043677||Non-inflamed|
16536205|NCT03043677||Inflamed ulcerative colitis|
16536206|NCT03043677||inflamed Crohn´s disease|
16536207|NCT03043664|Experimental|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) every 3 weeks and Somatuline Depot (lanreotide depot) 90mg subcutaneous (SQ) every 3 weeks
16536208|NCT03043651|Experimental|Oral treprostinil|Sustained-release tablets for TID administration
16536209|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
16536210|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
16536211|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
16536212|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
16536213|NCT03043612|Experimental|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
16536214|NCT03043612|Active Comparator|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
16536215|NCT03043599|Experimental|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
16536216|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
16536217|NCT03043573|Experimental|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
16536218|NCT03043573|Active Comparator|Supportive Therapy|Supportive Therapy focuses on: 1. Facilitating expression of affect; 2. Conveying to the patient that he or she is understood; 3. Offering empathy; and 4. Highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
16536219|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
16536220|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
16536221|NCT03043547|Experimental|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
16536222|NCT03043547|Other|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
16536223|NCT03043534|Experimental|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
16536224|NCT03043534|No Intervention|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
16536225|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
16536226|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
16536227|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
16536228|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
16536229|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.
~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
16536230|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.
~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
16536231|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
16536232|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
16536233|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
16536234|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
16536235|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
16536236|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
16536237|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
16536468|NCT03041779|Active Comparator|Voltaren|Diclofenac Sodium 50Mg Suppository
16536238|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
16536239|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
16536240|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
16536241|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
16536242|NCT03043456|Active Comparator|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
16536243|NCT03043456|Placebo Comparator|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
16536244|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
16536245|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
16536246|NCT03043430|Experimental|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
16536247|NCT03043430|Active Comparator|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
16536248|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
16536249|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
16536250|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
16536251|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
16536252|NCT03043378||Chronic Non-Malignant Pain - Cancer Patients|Chronic non-malignant pain among cancer patients undergoing a consultation at the outpatient Supportive Care Clinic at MD Anderson Cancer Center.
16536253|NCT03043365|Experimental|Arm 1: Control Fish Oil first, then Saury Oil|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm
16536254|NCT03043365|Experimental|Arm 2: Saury Oil first, then Control Fish Oil|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm
16536255|NCT03043365|No Intervention|Washout Period|8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.
16536256|NCT03043352|Experimental|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC < 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
16536257|NCT03043352|Active Comparator|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
16536258|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.
~All participants will complete the following interventions:
~Stool Specimen Collection
~Anal Swab Sampling
~Short Diet Assessment (SDA)
~NHANES Dietary Screener Questionnaire (DSQ)"
16536259|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.
~All participants will complete the following interventions:
~Stool Specimen Collection
~Anal Swab Sampling
~Short Diet Assessment (SDA)
~NHANES Dietary Screener Questionnaire (DSQ)"
16580996|NCT02738723|Experimental|GROUP 1|SBRT plus EP
16536263|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:
~No greater than 4 weeks prior to travel departure: Screening Criteria Review
~One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection
~Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection
~14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
16536264|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
16536265|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
16536266|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
16536267|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
16536268|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
16536269|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
16536270|NCT03043235||African American Females|No intervention
16536271|NCT03043235||African American Males|No intervention
16536272|NCT03043235||Caucasian Females|No intervention
16536273|NCT03043235||Caucasian Males|No intervention
16536274|NCT03043222|Experimental|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
16536275|NCT03043222|Active Comparator|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
16536276|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
16536277|NCT03043196|Active Comparator|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
16536278|NCT03043196|Placebo Comparator|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
16536279|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
16536280|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，<9
16536281|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
16536282|NCT03043144||End stage renal disease|Observational study, no intervention
16536283|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
16536284|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
16536285|NCT03043118|Experimental|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
16536286|NCT03043118|No Intervention|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
16536287|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
16536288|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
16536289|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
16536290|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
16536291|NCT03043066|Placebo Comparator|Group A -control group|15 subjects underwent scaling and root planing
16536292|NCT03043066|Active Comparator|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
16536293|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
16536294|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
16536295|NCT03043040|Experimental|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.
~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
16536296|NCT03043040|Active Comparator|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
16536297|NCT03043027|Experimental|Liposomal bupivicaine|
16536298|NCT03043027|Active Comparator|bupivicaine|
16536299|NCT03043027|Placebo Comparator|saline|
16536300|NCT03043014|Experimental|Mifépristone group|
16536301|NCT03043014|Active Comparator|misoprostol group|
16536302|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
16536303|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
16536304|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
16536305|NCT03042975||Spasmodic dysphonia|Patients with spasmodic dysphonia will undergo MRI of the brain and blood draw.
16536306|NCT03042975||Unaffected relatives|Unaffected relatives of patients with spasmodic dysphonia will undergo MRI of the brain and blood draw.
16536307|NCT03042975||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
16536308|NCT03042962||Patients with dystonia|Patients with dystonia (spasmodic dysphonia, singer's dystonia, writer's cramp, musician's focal hand dystonia) will undergo MRI of the brain and blood draw.
16536309|NCT03042962||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
16536310|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
16536311|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
16536312|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
16536313|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
16536314|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
16536315|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
16536316|NCT03042884|Experimental|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.
~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
16536317|NCT03042884|Experimental|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.
~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
16536318|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
16536319|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
16536320|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
16536321|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
16536322|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
16536323|NCT03042845|Experimental|Tiger cardiac catheter|
16536324|NCT03042832|Experimental|LOCI|Leadership development with coaching and organizational change support
16536325|NCT03042832|Active Comparator|Internet Based Training|Internet based Webinar leadership training
16536326|NCT03042819|Experimental|Selinexor plus Doxorubicin|"Selinexor will be given by mouth (orally) once a week:
~Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg
~Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks."
16536327|NCT03042806|Other|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
16536328|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
16536329|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
16536330|NCT03042767|Experimental|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
16536331|NCT03042767|Placebo Comparator|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
16536332|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
16536333|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
16536334|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
16536335|NCT03042728|Active Comparator|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
16536336|NCT03042728|Active Comparator|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
16536337|NCT03042715||Psychological Intervention refinement|"Eight weekly sessions in-person or via telephone
~Qualitative interviews
~Feedback from 5-10 caregivers to refine the intervention."
16536338|NCT03042702|Experimental|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
16536339|NCT03042702|Experimental|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
16536340|NCT03042689|Experimental|Regorafenib|
16536341|NCT03042676||ATLG group|ATLG treatment for GVHD prophylaxis.
16536342|NCT03042676||no ATLG group|No ATLG treatment.
16537194|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
16536343|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
16536344|NCT03042650|Experimental|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
16536345|NCT03042650|Active Comparator|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
16536346|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
16536347|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
16536348|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
16536349|NCT03042611|Experimental|Apatinib|
16536350|NCT03042611|Experimental|Placebo|
16536351|NCT03042598|Experimental|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
16536352|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
16536353|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
16536354|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
16536355|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
16536356|NCT03042572|Experimental|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
16536357|NCT03042572|Placebo Comparator|Placebo|Intramuscular placebo injection
16536358|NCT03042559|Active Comparator|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
16536359|NCT03042559|Experimental|Sport cords|Resistive sports cord to resist knee flexion.
16536360|NCT03042546|Active Comparator|Calcium Sulphate|
16536361|NCT03042546|Active Comparator|PMMA|
16536362|NCT03042546|Active Comparator|Nothing|
16536363|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
16536364|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
16536365|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
16536366|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
16536367|NCT03042520||Sofosbuvir-based therapy observational group|"Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)
~Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.
~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:
~Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response
~Patients who have ever participated study will be collected as historical control."
16536368|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
16536369|NCT03042494|Placebo Comparator|Control|Isocaloric food without the test prebiotic.
16536370|NCT03042494|Experimental|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
16536371|NCT03042468|Experimental|All subjects|"177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
~68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging"
16536372|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
16536373|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
16536374|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
16536375|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
16536376|NCT03042442||health patients (controls)|Health patients
16536603|NCT03040830|Experimental|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
16536377|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
16536378|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
16536379|NCT03042416|Experimental|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
16536380|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
16536381|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
16536382|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
16536383|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
16536384|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
16536385|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
16536386|NCT03042364|No Intervention|No intervention|Standard treatment
16536387|NCT03042364|Experimental|Intervention|Endometrial scratching before standard treatment
16536388|NCT03042351|Other|Unique arm|Magic Kegel app
16536389|NCT03042338|Experimental|Central Executive Training1|Training tasks targeting working memory
16536390|NCT03042338|Active Comparator|Central Executive Training2|Training tasks targeting inhibitory control and response speed
16536391|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
16536392|NCT03042312|Experimental|177Lu-PSMA-617 (6.0 GBq)|Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
16536393|NCT03042312|Experimental|177Lu-PSMA-617 (7.4 GBq)|Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
16536394|NCT03042299|Experimental|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
16536395|NCT03042299|Experimental|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
16536396|NCT03042273|Experimental|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
16536397|NCT03042273|Placebo Comparator|Placebo|1 capsule of Matching Placebo orally daily for 6 months
16536398|NCT03042260|Experimental|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
16536399|NCT03042260|Placebo Comparator|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.
~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
16536400|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
16536401|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
16536402|NCT03042234|Experimental|Group Insulin-resistant|Insulin-resistant obese adolescents
16536403|NCT03042234|Experimental|Group Insulin-sensitive|Insulin-sensitive obese adolescents
16536404|NCT03042208|Experimental|Intervention|Access to Weight Watchers in-person meetings and online tools.
16536405|NCT03042208|Other|Self-Guided Control Group|Received handout with basic weight management advice.
16536406|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
16536407|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
16536408|NCT03042182|Experimental|Single pill of V3-X vaccine administered once daily|One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months and changes in CA19.9 tumor marker from baseline levels versus post-treatment levels will be assessed as correlates of changes in tumor burden
16536409|NCT03042169|Active Comparator|continuation of chemotherapy|"Patients assigned to arm A will continue to receive the same chemotherapy regimen they received before randomization. Chemotherapy should be restarted between D1 and D30 after randomization.
~In case of poor tolerance to the induction chemotherapy, alternative chemotherapy regimen might be discussed, according to local standards and national guidelines (www.tncd.org)."
16536410|NCT03042169|Experimental|surgical removal of the primary tumour and treatment of the metastatic site followed by chemotherapy|"Patients assigned to arm B will undergo gastrectomy (subtotal or total according to the location of the primary tumour) between D1 and D30 after randomization.
~Subtotal gastrectomy is recommended if it allows a complete resection of the primary tumour to limit postoperative morbidity in such metastatic situations, based on the results of REGATTA"
16536411|NCT03042143|Experimental|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
16536412|NCT03042143|Placebo Comparator|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
16536413|NCT03042130|Experimental|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject
~the medicine will be given twice within one week."
16536414|NCT03042130|Other|control|standard of care
16536415|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
16536416|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
16536417|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
16536418|NCT03042104|Experimental|TAVR|Transcatheter aortic valve replacement (TAVR)
16536419|NCT03042104|No Intervention|CS|Clinical surveillance (CS)
16536420|NCT03042091|Active Comparator|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
16536421|NCT03042091|Experimental|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
16536422|NCT03042078|Experimental|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
16536423|NCT03042078|Active Comparator|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
16536424|NCT03042065|Experimental|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
16536425|NCT03042065|Active Comparator|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
16536426|NCT03042052||Patients suffering from NDO managed with Botox|"Doses used were 300 units Botox® from January 2001 to January 2011 and 200 units after 2011
~Frequency depended on patient's symptoms
~Duration was an outcome of the study"
16536427|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
16536428|NCT03042026||Acromegaly patients|Acromegaly patients
16536429|NCT03042026||Healthy subjects|Healthy volunteers
16536430|NCT03042013|Experimental|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
16536431|NCT03042000|Experimental|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
16536432|NCT03042000|Active Comparator|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
16536433|NCT03042000|Experimental|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
16536434|NCT03042000|Active Comparator|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
16536435|NCT03042000|Experimental|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
16536436|NCT03042000|Active Comparator|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
16536437|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR <60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment."
16536438|NCT03041974||Transfused critical care patients|Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
16536439|NCT03041961|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
16536440|NCT03041961|Active Comparator|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
16536441|NCT03041961|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
16536442|NCT03041948|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL).
16537195|NCT03036943|Experimental|Fluciclovine (18F) PET/CT|
16536443|NCT03041948|Experimental|ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL).
16536444|NCT03041935|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
16536445|NCT03041935|Experimental|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
16536446|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
16536447|NCT03041909|Experimental|Single Arm|Single Arm / open label
16536448|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
16536449|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
16536450|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
16536451|NCT03041896||Hybrid|coflex and fusion at adjacent levels
16536452|NCT03041883|Experimental|Kpro with crosslinked graft-support|Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
16536453|NCT03041883|Active Comparator|KPro with normal graft-support|Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
16536454|NCT03041870|Experimental|Dominance|Healthy subjects
16536455|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
16536456|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
16536457|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
16536458|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
16536459|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
16536460|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
16536461|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
16536462|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
16536463|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
16536464|NCT03041818|Experimental|hippotherapy|16 sessions of horseback riding therapy
16536465|NCT03041792|Experimental|Active|Liraglutide
16536466|NCT03041792|Placebo Comparator|Placebo|Placebo comparator
16536469|NCT03041766|Experimental|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
16536470|NCT03041766|Experimental|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
16536471|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
16536472|NCT03041740|No Intervention|Usual Care (Control) Group|Control subjects will be treated as per standard of care for preterm infants with BPD.
16536473|NCT03041740|Active Comparator|Perfluorooctylbromide (PFOB) Group|Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
16536474|NCT03041727|Active Comparator|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.
~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
16536475|NCT03041727|Experimental|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
16536476|NCT03041714||Normal volunteers|people who are healthy and without tremor
16536477|NCT03041714||Essential tremor|Patients with essential tremor
16536478|NCT03041714||Dystonic tremor|patient with tremor who also have dystonia
16536479|NCT03041701|Experimental|1|Phase I: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
16536480|NCT03041701|Experimental|2|Phase II: Combination of ganitumab and dasatinib at the MTD (or highest safe dose)
16536481|NCT03041688|Experimental|Treatment (decitabine, MDM2 inhibitor KRT-232)|"Patients receive decitabine IV over 1 hour on days 1-10 and MDM2 inhibitor KRT-232 PO QD on days 4-10. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.
~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5 and KRT-232 PO QD on days 4-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16536482|NCT03041675|Experimental|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
16536483|NCT03041675|Sham Comparator|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
16536486|NCT03041636|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
16536487|NCT03041610|Experimental|Walking intervention|
16536488|NCT03041610|No Intervention|Control|
16536489|NCT03041597|Experimental|Immediate loading|
16536490|NCT03041597|Active Comparator|delayed loading|
16536491|NCT03041584|Experimental|Materialise Universal®/ mucosa (Mat Mu)|
16536492|NCT03041584|Experimental|Materialise Universal®/ bone (Mat Bo)|
16536493|NCT03041584|Experimental|FacilitateTM/ mucosa (Fac Mu)|
16536494|NCT03041584|Experimental|FacilitateTM/ bone (Fac Bo)|
16536495|NCT03041584|Active Comparator|mental navigation (Mental)|
16536496|NCT03041584|Active Comparator|pilot-drill template (Templ)|
16536497|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
16536498|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
16536499|NCT03041558|Experimental|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
16536500|NCT03041558|Active Comparator|SafeCare (SC)|SafeCare intervention as usual
16536501|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
16536502|NCT03041532|Experimental|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
16536503|NCT03041532|Active Comparator|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
16536504|NCT03041519|Experimental|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
16536505|NCT03041519|Active Comparator|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
16536506|NCT03041506|Active Comparator|Sedation|"Analgesia and sedation through IV medication for pain relief will be administered to the patient.
~Midazolam: up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 second).
~Ketamine: up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds)."
16536884|NCT03038893|Active Comparator|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
16536507|NCT03041506|Experimental|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.
~Lidocaine 2%: 15-20 ml."
16536508|NCT03041493|Experimental|Electronic cigarettes (EC) smokers|
16536509|NCT03041493|Experimental|traditional cigarette (TC) smokers|
16536510|NCT03041493|Active Comparator|nonsmokers|
16536511|NCT03041480||GROUP I|Estimation of serum lipid levels and Lp-PLA2 in generalized severe chronic periodontitis
16536512|NCT03041480||GROUP II|Estimation of serum lipid levels and Lp-PLA2 in generalized moderate chronic periodontitis
16536513|NCT03041480||GROUP III|Estimation of serum lipid levels and Lp-PLA2 in systemically and periodontally healthy controls
16536514|NCT03041467|Experimental|IN.PACT AV DCB|"PTA will be performed using the IN.PACT AV Access Drug Coated Balloon. IN.PACT AV Access DCB was the device name used during the clinical study. Medtronic has changed the name of the device to IN.PACT™ AV Paclitaxel-Coated Balloon Catheter (also referred as IN.PACT AV DCB). Hence, throughout posting, the study device will be referred to as the IN.PACT AV DCB."
16536515|NCT03041467|Active Comparator|Standard Balloon Angioplasty|PTA will be performed using a commercially available uncoated PTA balloon.
16536516|NCT03041454|Experimental|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
16536517|NCT03041454|No Intervention|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
16536518|NCT03041441|Experimental|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
16536519|NCT03041428|Experimental|Recruited patients|Ultraprotective ventilation
16536520|NCT03041415|Active Comparator|ALED Alone Physical Activity Program|"The Active Living Every Day (ALED) comprehensive 12-week PA training and support program is appropriate for delivery by trained instructors from diverse backgrounds.
~Participants are taught self-regulatory skills aimed at increasing and sustaining regular physical activities such as walking."
16536521|NCT03041415|Experimental|ALED + Our Voice PA Program|"The ALED physical activity program is combined with the Our Voice citizen science engagement program, which teaches participants how to assess the barriers and enablers of neighborhood physical activity using a simple mobile app.
~Residents then share their data and build consensus around major barriers and potential solutions, which they share with local decision makers."
16536522|NCT03041402|Active Comparator|PSP ventilation|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
16536523|NCT03041402|Active Comparator|NAVA ventilation|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
16536524|NCT03041402|Experimental|PSN ventilation|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
16536525|NCT03041389|Experimental|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
16536526|NCT03041389|Active Comparator|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
16536527|NCT03041376|Experimental|Walking intervention|
16536528|NCT03041376|No Intervention|Control|
16536529|NCT03041363|Experimental|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
16536530|NCT03041350|Experimental|Smartphone video-assisted ALS & Conventional CPR|"In study period, using this video medical control, high-quality CPR, cardiac arrest rhythm confirmation, defibrillation, proper drug administration instructions, advanced airway insertion, etc. are performed. The medical director then decides on patient transfer if the asystole and pulseless electrical activity findings are persistent even after more than 20-minutes of ALS.
~The conventional CPR is Basic life support only in the automatic external defibrillator (AED) mode 5-10 minutes at the scene, are not allowed to stop resuscitation at the scene unless there is a return of spontaneous circulation (ROSC) or pre-hospital cardiac arrest patient has already been transported to a hospital."
16536531|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
16536532|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
16536533|NCT03041324|Experimental|Experimental: Cohort 1: SB-913: Starting Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
16536534|NCT03041324|Experimental|Experimental: Cohort 2: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
16536535|NCT03041324|Experimental|Experimental: Cohort 3: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
16580997|NCT02738723|Active Comparator|GROUP 2|IMRT plus EP
16536536|NCT03041324|Experimental|Experimental: Cohort 4: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
16536537|NCT03041311|Experimental|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive trilaciclib 240 mg/m2 administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.
~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
16536538|NCT03041311|Experimental|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive placebo administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.
~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
16536539|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
16536540|NCT03041285|Experimental|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
16536541|NCT03041285|Experimental|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
16536542|NCT03041272||Nurses and nursing personnel|All registered nurses and assistive nursing personnel, including patient care associates (PCAs) , patient care technicians (PCTs), clinical technicians (CTs), primary employment on the study unit, minimum of 24 hours per week of employment on study unit.
16536543|NCT03041259|Experimental|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
16536544|NCT03041259|Experimental|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
16536545|NCT03041246|Experimental|Study group - Treatment with PFFM|Manual treatment for the pelvic floor will be provided in two sessions two weeks apart as long as guidance towards exercise for strengthening of the pelvic floor
16536546|NCT03041246|No Intervention|Control group -|Guidance towards exercise for strengthening of the pelvic floor with no other interventional treatment.
16536547|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
16536548|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
16536549|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
16536550|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
16536551|NCT03041181|Experimental|Arm A - Single Agent Chemotherapy + Nivolumab|"Single Agent Chemotherapy of choice plus nivolumab:
~Taxotere Pemetrexed Gemcitabine"
16536552|NCT03041181|Active Comparator|Arm B - Single Agent Chemotherapy|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
16536553|NCT03041155|Experimental|treatment|Muscle respiratory training
16536554|NCT03041155|No Intervention|control|No intervention
16536555|NCT03041142|Experimental|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;
~1 session/week 60 minutes nutrition education week;
~1 session/week 120 minutes behaviour therapy.
~Mothers
~1 sessions/week 50-60 minutes of physical activity;
~1 session/week 60 minutes nutrition education week;
~1 session/week 120 minutes behaviour therapy."
16536556|NCT03041142|Active Comparator|Routine|Mothers and children followed their routine activities
16536557|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
16536558|NCT03041129||Metformin PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
16536559|NCT03041129||Oral Contraceptive PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
16536560|NCT03041129||Obese Control group-(Study arm not funded)|Obese Regular menses at least 18 months post-menarche Females only
16536561|NCT03041116|Experimental|Fosmetpantotenate|Administered as powder for reconstitution.
16536562|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
16536563|NCT03041103|Experimental|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
16536564|NCT03041103|Experimental|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
16536565|NCT03041090|Experimental|Static Imaging participants|"This arm of the study assessed participants' static PET/CT images. These were the standard of care images acquired after their standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.
~Intervention was Lucerno sensors (Lucerno Device Identity Document (LD ID), Lucerno Device 1 (LD1), Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
16536601|NCT03040856|Experimental|Omega 3 enriched diet ( DHA+EPA)|Enriched diet with 2 capsules of DHA+EPA supplementation a day (Each capsule consist of 240 mg DHA and 360 mg EPA).
16536602|NCT03040856|Placebo Comparator|Placebo|Control group - Will receive 2 placebo capsule a day - containing olive oil
16536566|NCT03041090|Experimental|Dynamic image participants|"This arm of the study assessed participants' dynamic PET/CT images. These were the study related images of and around the injection site acquired during the participants' standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.
~Intervention was Lucerno sensors (LD ID, LD1, Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
16536567|NCT03041077|Experimental|Instaflex Advanced|Dietary supplement: Joint function
16536568|NCT03041077|Placebo Comparator|Placebo|Dietary supplement: Placebo
16536569|NCT03041064|Experimental|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
16536570|NCT03041064|Experimental|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
16536571|NCT03041051|Experimental|PCV13|
16536572|NCT03041051|Experimental|PPV23|
16536573|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
16536574|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
16536575|NCT03041025|Experimental|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
16536576|NCT03041025|Experimental|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
16536577|NCT03041025|Placebo Comparator|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
16536578|NCT03041025|Placebo Comparator|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
16536579|NCT03041012|Placebo Comparator|antiretrovirals|Standard of care
16536580|NCT03041012|Active Comparator|antiretrovirals + romidepsin|Standard of care + LRA
16536581|NCT03041012|Active Comparator|antiretrovirals + 3BNC117|Standard of care + bNAb
16536582|NCT03041012|Active Comparator|antiretrovirals + romidepsin + 3BNC117|Standard of care + LRA + bNAb
16536583|NCT03040999|Experimental|Pembrolizumab + Cisplatin + CRT|Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.
16536584|NCT03040999|Placebo Comparator|Placebo + Cisplatin + CRT|Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.
16536585|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate by mouth (PO) twice daily (BID). Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
16536586|NCT03040973|Experimental|INC280|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent INC280 protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
16536587|NCT03040973|Experimental|INC280/EGF816|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
16536588|NCT03040973|Active Comparator|INC280/Gefitinib|The starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated.
16536589|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
16536590|NCT03040947||Diseased (Suspected or Known Cardiac Conditions)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
16536591|NCT03040934|Active Comparator|Firehawk implantation|98 subjects will be enrolled to receive a test device (Firehawk™).
16536592|NCT03040934|Active Comparator|XIENCE implantation|98 subjects will be enrolled to receive a control device (XIENCE).
16536593|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
16536594|NCT03040895|Experimental|ICDP-intervention for caregivers|Group-based ICDP-intervention for caregivers through a sequence of eight meetings. The groups are led by facilitators trained in the ICDP.
16536595|NCT03040895|Other|Treatment as usual|Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
16536596|NCT03040882|Experimental|cotton sock|
16536597|NCT03040882|Active Comparator|Elastic Compression Wraps|
16536598|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
16536599|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
16536600|NCT03040856|Experimental|Alpha Linolenic Acid enriched diet|Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
16536604|NCT03040830|Active Comparator|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
16536605|NCT03040817|Experimental|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
16536606|NCT03040817|Active Comparator|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
16536608|NCT03040791|Experimental|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
16536609|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
16536610|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
16536611|NCT03040765|Active Comparator|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe
~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
16536612|NCT03040765|Active Comparator|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj
~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
16536613|NCT03040752|Active Comparator|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
16536614|NCT03040752|Active Comparator|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
16536615|NCT03040739||case|
16536616|NCT03040739||control|
16536617|NCT03040726|Experimental|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
16536618|NCT03040726|Placebo Comparator|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
16536619|NCT03040713|Experimental|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
16536620|NCT03040700|No Intervention|Clinical|Regular medical visits every 6 months.
16536621|NCT03040700|Experimental|Myocardial Perfusion Scan|Myocardial perfusion stress test using cardiac scintigraphy (Sestamibi) at rest and during pharmacological stress (dipyridamole)
16536622|NCT03040700|Experimental|Coronary CTA|Coronary computed tomography angiography
16536623|NCT03040687|Experimental|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
16536624|NCT03040687|Experimental|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
16536625|NCT03040687|Experimental|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
16536626|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
16536627|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
16536628|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
16536629|NCT03040648|Experimental|cervical TFEB under DSA|cervical TFEB was performed under DSA
16536630|NCT03040648|Active Comparator|TFEB under RTF|cervical TFEB was performed under RTF
16536631|NCT03040635|Experimental|Risdiplam '2' Milligrams (mg)|A single dose of 2 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
16536632|NCT03040635|Experimental|Risdiplam '6' mg|A single dose of 6 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
16536633|NCT03040635|Experimental|Risdiplam '12' mg|A single dose of 12 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
16536634|NCT03040635|Placebo Comparator|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
16536635|NCT03040622||Watchman Left Atrial Appendage Closure|
16536636|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
16536637|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
16536638|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
16536639|NCT03040596|Experimental|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
16536640|NCT03040596|Other|voice therapy only|standard voice therapy
16536641|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
16536642|NCT03040570|Experimental|Conservative oxygenation target|Children in the conservative oxygenation target group receive treatment targeting oxygen saturation values of 88-92%.
16536643|NCT03040570|Active Comparator|Liberal oxygenation target|Children in the liberal oxygenation target group receive treatment targeting oxygen saturation values of >94%.
16536644|NCT03040557|Active Comparator|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (MFG), acute n=12 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
16536645|NCT03040557|Active Comparator|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (COIG, acute n=14 and chronic=14) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
16536718|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
16536719|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
16536646|NCT03040544|Experimental|LTB-Curriculum|First group/arm undergo MIS training according to the LTB curriculum after the first own laparoscopic cholecystectomy in the OR as a baseline. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using the Global Operational Assessment of Laparoscopic Skill (GOALS) score.
16536647|NCT03040544|Active Comparator|no LTB-Curriculums|Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
16536648|NCT03040531|Experimental|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.
~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
16536649|NCT03040531|Active Comparator|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.
~Once a week subjects will take one tablet containing 70mg alendronate."
16536650|NCT03040518|Experimental|Narrative SMS|"Participants will receive narrative SMS for 12 months.
~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
16536651|NCT03040518|Experimental|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.
~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
16536652|NCT03040518|No Intervention|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.
~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
16536653|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
16536654|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
16536655|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
16536656|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
16536657|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
16536658|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
16536659|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
16536660|NCT03040453|Other|Microwave ablation|20 patients will be treated with microwave ablation
16536661|NCT03040453|Other|Irreversible electroporation|20 patients will be treated with irreversible electroporation
16536662|NCT03040440|Active Comparator|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
16536663|NCT03040440|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
16536664|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
16536665|NCT03040414|Active Comparator|PID Algorithm|Participants will receive insulin delivered by the Medtronic Minimed 670G 3.0 HCL system using a PID algorithm..
16536666|NCT03040414|Experimental|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system (Minimed 670G 4.0 AHCL) with Guardian Sensor (3) continuous glucose monitoring sensor.
16536667|NCT03040401|Experimental|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.
~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.
~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
16536668|NCT03040401|Experimental|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.
~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.
~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
16536669|NCT03040401|Experimental|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.
~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.
~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
16536670|NCT03040375|Experimental|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
16536671|NCT03040375|No Intervention|Non peer counselling|Usual health messages
16536672|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
16536782|NCT03039556|Experimental|Change in physical activity for older adults|Older adult participants undergo alterations in daily ambulation by completing Normal Daily Steps for one week, followed by a two-week Step-Reduction and a subsequent Return to Normal Daily Steps for two weeks
16536957|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
16536673|NCT03040349|Experimental|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
16536674|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
16536675|NCT03040336|No Intervention|Standard of Care|Standard of Care
16536676|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
16536677|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
16536678|NCT03040310|Experimental|Back Rx program|Study patients will use their smartphone apps to view their Back Rx program content, exercises, and videos.
16536679|NCT03040297|Active Comparator|TGI 6 L/min|Tracheal gas insufflation 6 L/min
16536680|NCT03040297|Active Comparator|TGI 11 L/min|Tracheal gas insufflation 11 L/min
16536681|NCT03040297|Active Comparator|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
16536682|NCT03040284|Experimental|aneurysmal subarachnoid hemorrhage|
16536683|NCT03040271|Experimental|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
16536684|NCT03040271|No Intervention|Control group|Group of students not receiving any intervention
16536685|NCT03040258|Experimental|Intervention group- Health-E-PALS-Pilot|Group of students receiving the school-based intervention: Health-E-PALS (pilot), it consists of in class activities and lessons.
16536686|NCT03040258|No Intervention|Control group|Group of students not receiving any intervention
16536687|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
16536688|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
16536689|NCT03040232|Experimental|MPFl Reconstruction|subjects that have had MPFL reconstruction surgery
16536690|NCT03040232|Active Comparator|Active Controls|subjects that have not had MPFL reconstruction surgery
16536691|NCT03040219|Active Comparator|Treatment group|
16536692|NCT03040219|Placebo Comparator|Control|
16536693|NCT03040206||Nodal PTCL|"newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative) between January 1, 2005 and Jun 30, 2016
~initially treated with curative intent
~Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
16536694|NCT03040193|Experimental|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
16536695|NCT03040193|Placebo Comparator|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
16536696|NCT03040180|Experimental|Electrochemotherapy with bleomycin|"Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.
~BSA by Du Bois formula."
16536697|NCT03040180|No Intervention|Standard care|Standard care
16536698|NCT03040167|Placebo Comparator|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
16536699|NCT03040167|Active Comparator|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
16536700|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
16536701|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
16536702|NCT03040141|Experimental|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
16536703|NCT03040141|Experimental|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
16536704|NCT03040141|Placebo Comparator|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
16536705|NCT03040128|Placebo Comparator|placebo|normal saline infusion
16536706|NCT03040128|Experimental|minocycline|intravenous minocycline
16536707|NCT03040102|Experimental|Hospice Video Educational Tool|"The hospice video educational tool is a 6 minute video
~Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
16536708|NCT03040102|Active Comparator|Hospice Verbal Narrative|"The RA will read a verbal narrative that is identical to the narrative of the video to participants
~Standard of Care practice is used"
16536709|NCT03040089|Experimental|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
16536710|NCT03040089|Sham Comparator|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
16536711|NCT03040076|Experimental|Cognitive Bias Treatment|Intervention condition
16536712|NCT03040076|Active Comparator|Relaxation Condition|Active control condition
16536713|NCT03040063|Experimental|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
16536714|NCT03040063|Experimental|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
16536715|NCT03040050|Other|Men scheduled for prostate biopsy randomized to Control|
16536716|NCT03040050|Experimental|Men scheduled for a prostate biopsy randomized to Intervention|
16536717|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
16536720|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
16536721|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
16536722|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
16536723|NCT03039998||HAP Patients|HAP, intubated and mechanically ventilated.
16536724|NCT03039985|Experimental|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
16536725|NCT03039985|Experimental|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
16536726|NCT03039985|Experimental|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
16536727|NCT03039985|Experimental|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
16536728|NCT03039972||Pulmonary Hypertension|Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
16536729|NCT03039959||Pulmonary hypertension cohort|Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.
16536730|NCT03039959||Heart failure cohort|Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.
16536731|NCT03039946|Experimental|Closed-loop GDFT|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid maintenance with Plasmalyte is carried out using a closed-loop system guided by the Clearsight non-invasive hemodynamic flow monitor.
16536732|NCT03039946|Active Comparator|Restrictive fluid therapy|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid management is based on a restrictive (4ml/kg/h) Plasmalyte infusion.
16536733|NCT03039933|Active Comparator|Fear of Hypoglycemia Intervention|Cognitive behavioral therapy based psychological intervention occurring every other week for 12 weeks.
16536734|NCT03039933|Other|Treatment As Usual|Control group completes questionnaires but does not receive any study intervention. Receives medical care as usual.
16536735|NCT03039920|Active Comparator|Electronic cigarette with or without nicotine|Electronic cigarette assisted cessation program
16536736|NCT03039920|Active Comparator|Smoker control|Conventional cigarette smoking continuation
16536737|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
16536738|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
16536739|NCT03039868||Normal Pap smears|This is the control group.
16536740|NCT03039868||Abnormal Pap smears|This is the case group.
16536741|NCT03039855|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
16536742|NCT03039842|Experimental|30 mg DM|30mg dextromethorphan+valproate
16536743|NCT03039842|Experimental|5 mg MM|5mg memantine+valproate
16536744|NCT03039842|Experimental|DM+MM|dextromethorphan+memantine+ valproate
16536745|NCT03039842|Placebo Comparator|placebo|Placebo+valproate
16536746|NCT03039829|Experimental|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
16536747|NCT03039829|Active Comparator|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
16536748|NCT03039829|Placebo Comparator|Placebo|Placebo at 6.0 grams dextrose
16536749|NCT03039816|Active Comparator|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
16537651|NCT03033953|Experimental|Native whey|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g native whey protein.
16536750|NCT03039816|Placebo Comparator|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
16536751|NCT03039803|Active Comparator|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
16536752|NCT03039803|Active Comparator|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
16536753|NCT03039790|Experimental|NoV Vaccine|Participants who previously received NoV vaccine adjuvanted with aluminum as aluminum hydroxide or with monophosphoryl lipid A (MPL), injection, intramuscularly as planned in studies NOR-107, NOR-210 and NOR-204 will be assessed over 5 years post-primary vaccination. Vaccine formulations according to the parent trials: NOR-107, 210 and 204.
16536754|NCT03039764|No Intervention|Standard occupational therapy|This group will receiving standard occupational therapy for the treatment of acute stroke.
16536755|NCT03039764|Experimental|SOT plus VR Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
16536756|NCT03039751|Experimental|AdvVEGF-D|Intramyocardial AdVEGF-D
16536757|NCT03039751|Placebo Comparator|Control|Intramyocardial placebo (buffer solution without gene)
16536758|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
16536759|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
16536760|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
16536761|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
16536762|NCT03039699|Experimental|Ergoferon|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
16536763|NCT03039699|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
16536764|NCT03039686|Experimental|RO7239361 Low Dose|Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
16536765|NCT03039686|Experimental|RO7239361 High Dose|Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
16536766|NCT03039686|Placebo Comparator|Placebo|Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
16536767|NCT03039673|Experimental|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.
~Intervention: Riluzole Intervention: IL-2"
16536768|NCT03039673|Placebo Comparator|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.
~Intervention: Riluzole Intervention: 5% glucose water solution"
16536769|NCT03039660|Experimental|RefreshMD|An online course for sleep improvement in medical students
16536770|NCT03039660|Placebo Comparator|Bond Between Us|An online course covering communication skills and the physician-patient relationship
16536771|NCT03039647||Entry Point IR (SSPG, HOMA-IR)|All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
16536772|NCT03039647||Change in IR (HOMA-IR)|The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
16536773|NCT03039621|Experimental|Ergoferon|Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
16536774|NCT03039621|Placebo Comparator|Placebo|Placebo using Ergoferon scheme.
16536775|NCT03039608|Experimental|combination group|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
16536776|NCT03039608|Active Comparator|control group|oral steroid administration（prednisone）
16536777|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
16536778|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
16536779|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
16536780|NCT03039569|Experimental|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
16536781|NCT03039569|No Intervention|Control|Participants will not receive text message intervention. This is the measurement-only group
16536880|NCT03038919|Experimental|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
16536783|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
16536784|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
16536785|NCT03039530|Experimental|Treatment Group|Group CBT for PPD. Women in the treatment group will attend a 9-week group CBT intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
16536786|NCT03039530|Active Comparator|Control Group|Standard Care. The usual care group will receive standard care from their family physician and midwife or obstetrician. They will also be made aware of the perinatal programming available to them through Niagara Region Public Health. Women and family physicians will also receive a copy of the Canadian Practice Guidelines for the Treatment of Perinatal Depression.
16536787|NCT03039517|Experimental|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
16536788|NCT03039517|Experimental|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
16536789|NCT03039504|Experimental|Potensa|succinate-based dietary supplement
16536790|NCT03039504|Placebo Comparator|Placebo|placebo
16536791|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
16536792|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
16536793|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count >200 to receive PPV23 only
~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
16536794|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PPV23 only
~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
16536795|NCT03039491|Active Comparator|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
16536796|NCT03039491|Active Comparator|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.
~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
16536797|NCT03039491|Active Comparator|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
16536798|NCT03039491|Active Comparator|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
16536799|NCT03039478|Active Comparator|Xylitol 7g in 300mL tap water|12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
16536800|NCT03039478|Active Comparator|Xylitol 17g in 300mL tap water|12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
16536801|NCT03039478|Active Comparator|Xylitol 35g in 300mL tap water|12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
16536802|NCT03039478|Active Comparator|Erythritol 10g in 300mL tap water|12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
16536803|NCT03039478|Active Comparator|Erythritol 25g in 300mL tap water|12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
16536804|NCT03039478|Active Comparator|Erythritol 50g in 300mL tap water|12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
16536805|NCT03039465|Experimental|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
16536806|NCT03039452|Experimental|High intensity interval training|
16536807|NCT03039439||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.
16536808|NCT03039426|Experimental|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
16536809|NCT03039426|Active Comparator|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
16536810|NCT03039413|Experimental|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
16536811|NCT03039400|Experimental|Web-based physio group|Those in the web-based physio group will have an individual exercise program set up by a treating physiotherapist on webbasedphysio.com after an initial face-to-face assessment. They will be encouraged to undertake their exercise program at least twice per week and diarize their work. Participants will receive a weekly phone call from their treating physiotherapist for the first two weeks. The treating physiotherapist will review the exercise diary of each participant every two weeks, and remotely alter the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
16537652|NCT03033940||ATTUNE TM subjects|
16536812|NCT03039400|Active Comparator|Standard care group|Those in the standard care group will have their exercise program explained to them at an initial face-to-face assessment with a treating physiotherapist as per usual care. They will receive a written, home-based exercise program. Participants in the usual care group will also be encouraged to undertake their exercise program at least twice per week, and will be asked to keep an exercise diary, in paper format. Participants in the usual care group will also receive a weekly phone call from the physiotherapist for the first two weeks to check on progress.
16536813|NCT03039387|Active Comparator|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
16536814|NCT03039387|Placebo Comparator|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
16536815|NCT03039374||OASI patients|All patients older than 18 and a 3rd or 4th degree perineal tear during birth meet the inclusion criteria. All women who have obtained such a injury during birth in the Vaasa or Seinäjoki Central hospitals will be evaluated for eligibility.
16536816|NCT03039361|Experimental|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
16536817|NCT03039361|No Intervention|Control|Standard of Care, Existing PTSD therapy
16536818|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
16536819|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
16536820|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
16536821|NCT03039322||HCC|
16536822|NCT03039322||liver cirrhosis No HCC|
16536823|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
16536824|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
16536825|NCT03039283||Nucleus CI532 cochlear implant|
16536826|NCT03039270|Active Comparator|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
16536827|NCT03039270|Experimental|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
16536828|NCT03039257|Other|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
16536829|NCT03039244|Experimental|Test Group|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
16536830|NCT03039244|Sham Comparator|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
16536831|NCT03039231|Experimental|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
16536832|NCT03039218|Active Comparator|Active|Subjects assigned to this group will receive Active treatments using the Dornier Aries 2.
16536833|NCT03039218|Placebo Comparator|Placebo / Sham|Subjects assigned to this group will receive placebo / sham (no active treatment).
16536834|NCT03039205|Active Comparator|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
16536835|NCT03039205|Active Comparator|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
16536836|NCT03039205|Active Comparator|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
16536837|NCT03039205|Active Comparator|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
16536838|NCT03039192|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
16536839|NCT03039192|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
16536840|NCT03039179|Experimental|Polyurethane foam|
16536841|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
16536842|NCT03039166|Experimental|parkinson|
16536843|NCT03039166|Experimental|partial epilepsy|
16536844|NCT03039166|Experimental|alzheimer disease|
16536845|NCT03039166|Experimental|multiple sclerosis|
16536846|NCT03039166|Experimental|amyotrophic lateral sclerosis|
16536847|NCT03039166|Active Comparator|healthy control patients|
16536881|NCT03038919|Other|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
16536882|NCT03038906||Cohort|Patients enrolling in NHLBI PETAL Network ROSE study of cisatracurium for moderate/severe ARDS at participating centers
16536883|NCT03038893|Experimental|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
16536848|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
16536849|NCT03039127|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
16536850|NCT03039114|Experimental|Parsaclisib + Hexal and Gazyvaro|
16536851|NCT03039101|Experimental|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
16536852|NCT03039101|Placebo Comparator|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
16536853|NCT03039088||Fibromyalgia patients|
16536854|NCT03039088||Not fibromyalgia patients|
16536855|NCT03039075|Active Comparator|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
16536856|NCT03039075|Active Comparator|Glucophage|The original drug of metformin
16536857|NCT03039062||Chemotherapy group|A total of 120 malignant tumor patients who need to receive chemotherapy are involved for miR-122 detection. They are from 3 centers, 40 for each center. For the first cycle of chemotherapy, the investigators will collect 0.5-1ml blood from the remained blood sample after routine blood test during chemotherapy for each patient.Each patient will have a routine blood test before(±3 days) each cycle of chemotherapy and 7(±3)days after chemotherapy. A routine blood test will include the test of ALT,AST,ALP and TBIL. Sample collection will stop after 4 cycles of chemotherapy. All blood samples collected by investigators are the remained sample after routine tests. Patients in routine care will also have blood tests before each cycle and on day 7(+/- 3) of each cycle of chemotherapy. These patients will also have blood test at these time points even if they are not in this trial.
16536858|NCT03039062||Healthy population|Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
16536859|NCT03039062||Patients of intensive care unit|Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
16536860|NCT03039049|Experimental|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.
~Other Names:
~• Decapeptyl 0.1 mg"
16536861|NCT03039049|No Intervention|Control|No intervention
16536862|NCT03039036|Experimental|Early Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy within 1 hour of Foley catheter removal.
16536863|NCT03039036|Active Comparator|Delayed Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy no sooner than 4 hours following removal of Foley catheter.
16536864|NCT03039023|Experimental|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
16536865|NCT03039023|Experimental|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
16536866|NCT03039023|Experimental|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
16536867|NCT03039023|Experimental|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
16536868|NCT03039023|Experimental|Phosphatidylcholine Capsules|Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.
16536869|NCT03038984|Experimental|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
16536870|NCT03038984|Active Comparator|On demand|screening On demand: (home monitoring: FC and DA)
16536871|NCT03038971|Other|Concentration 1: Short and Tall Ragweed Mix|
16536872|NCT03038971|Other|Concentration 2: Short and Tall Ragweed Mix|
16536873|NCT03038971|Other|Placebo: Saline with 0.4% Phenol|
16536874|NCT03038958|Active Comparator|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
16536875|NCT03038958|Active Comparator|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
16536876|NCT03038945|Experimental|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
16536877|NCT03038945|Active Comparator|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
16536878|NCT03038932||Discovery Cohort|"A minimum of 50 recurrent Atopic Dermatitis with a history of Eczema Herpeticum(ADEH+), 500 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-), and 237 Non-Atopic (NA) European American participants from the Atopic Dermatitis Research Network (ADRN) DNA Repository.
~The study will learn from this cohort:
~All Single Nucleotide Variants (SNVs) in ADEH+
~ADEH+ specific deleterious SNVs
~The study will determine the function of:
~4. ADEH+ risk variants"
16536879|NCT03038932||Independent populations of participants|"Two independent populations of participants:
~Children, aged 3-17 years and
~Adults 18-64 years of age.
~A minimum of 12 recurrent Atopic Dermatitis with a history of Eczema Herpeticum (ADEH+) with ≥3 Eczema Herpeticum (EH) episodes, 12 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-) and 12 Non-Atopic (NA) participants will be enrolled in each of the two populations."
16536885|NCT03038880|Experimental|6 mg Faricimab Q12W|6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
16536886|NCT03038880|Experimental|6 mg Faricimab Q16W|6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
16536887|NCT03038880|Active Comparator|0.5 mg Ranibizumab Q4W|0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
16536888|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
16536889|NCT03038867|Placebo Comparator|Placebo|Placebo
16536890|NCT03038854|Experimental|Test GUM|This group will drink a test toddler growing up milk (GUM) with higher amounts of key nutrients
16536891|NCT03038854|Active Comparator|Standard GUM|This group will drink a standard toddler growing up milk (GUM)
16536892|NCT03038854|Placebo Comparator|Comparator Group|This group will drink liquid full fat cows' milk
16536893|NCT03038854|No Intervention|Population Group|This group will eat and drink their usual foods with no interventions.
16536894|NCT03038828|Experimental|Arm A|Cohort A - 200IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off two weeks, then repeat 200IU 5 days/week x 2 weeks.
16536895|NCT03038828|Experimental|Arm B|Arm B - 400IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off 2 weeks, 400IU 5 days/week x 2 weeks.
16536896|NCT03038815|Experimental|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
16536897|NCT03038815|Experimental|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
16536898|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
16536899|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
16536900|NCT03038776|Experimental|1|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
16536901|NCT03038776|Experimental|2|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
16536902|NCT03038776|Experimental|3|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
16536903|NCT03038776|Experimental|4|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
16536904|NCT03038776|Experimental|5|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
16536905|NCT03038776|Experimental|6|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
16536906|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
16536907|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
16536908|NCT03038750||EDNRA Sub-study|"Study population will be split into two groups defined by the allele of EDNRA the participant possesses:
~Participants Homozygous for the A-allele of EDNRA, are assigned to the 'case' group.
~Participants that are Homozygous for the G-allele will be assigned to the 'control' group.
~20 participants will be recruited to each group, 40 in total."
16536909|NCT03038750||PNPLA3 Sub-study|"Study population will be split into two groups defined by the allele of PNPLA3 the participant possesses:
~Participants Homozygous for the G-allele of PNPLA3, are assigned to the 'case' group.
~Participants that are Homozygous for the C-allele of PNPLA3 will be assigned to the 'control' group.
~60 participants will be recruited to each group, 120 in total."
16536910|NCT03038750||PROCR Sub-study|"Study population will be split into two groups defined by the allele of PROCR the participant possesses:
~Participants Homozygous for the G-allele of PROCR, are assigned to the 'case' group.
~Participants that are Homozygous for the A-allele of PROCR will be assigned to the 'control' group.
~30 participants will be recruited to each group, 60 in total."
16536911|NCT03038737|Active Comparator|group 1|patients will receive partial denture constructed from breflex material
16536912|NCT03038737|Experimental|group 2|patients will receive partial denture constructed from PEEK material
16536913|NCT03038724|Other|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
16536914|NCT03038724|Other|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
16536915|NCT03038711|Experimental|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
16536916|NCT03038711|Experimental|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
16536917|NCT03038711|Experimental|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
16536994|NCT03038295|Placebo Comparator|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
16536918|NCT03038685|Experimental|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
16536919|NCT03038685|No Intervention|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
16536922|NCT03038659||Penile Duplex|Measuring intima media thickness
16536923|NCT03038646|Experimental|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
16536924|NCT03038646|Experimental|Regimen B|32 mg MIN-101 MR administered in the fasted state
16536925|NCT03038646|Experimental|Regimen C|32 mg MIN-101 MR administered in the fasted state
16536926|NCT03038646|Experimental|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
16536927|NCT03038633|Experimental|Cohort 1|"900 mg novel medical food containing 22.2mg iron
~receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
16536928|NCT03038633|Experimental|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron
~receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
16536929|NCT03038633|Experimental|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron
~receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
16536930|NCT03038633|Experimental|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron
~receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
16536931|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug
~Other Names:
~Saxenda
~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
16536932|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL
~Other Names:
~Placebo
~Saline injection
~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
16536933|NCT03038607|Active Comparator|Aspirin group|
16536934|NCT03038607|No Intervention|No intervention|
16536935|NCT03038594|Experimental|Growth Hormone|Daily subcutaneous injections of 0.05 mg/kg/day of Growth Hormone [somatropin, Genotropin, Pfizer, New York, NY] will be administered, from one week prior to discharge until 9 months post-burn.
16536936|NCT03038594|Placebo Comparator|0.09% saline solution|Daily subcutaneous injections of 0.09% of saline solution will be administered, from one week prior to discharge until 9 months post-burn.
16536937|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
16536938|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
16536939|NCT03038568||Cohort 1|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
16536940|NCT03038568||Cohort 2|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
16536941|NCT03038568||Cohort 3|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
16536942|NCT03038568||Cohort 4|-10 second time gap between routine abdominal CT and add on CT, Noise index 12
16536943|NCT03038568||Cohort 5|-10 second time gap between routine abdominal CT and add on CT, Noise index 14
16536944|NCT03038568||Cohort 6|-10 second time gap between routine abdominal CT and add on CT, Noise index 16
16536945|NCT03038568||Cohort 7|- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
16536946|NCT03038568||Cohort 8|- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
16536947|NCT03038568||Cohort 9|- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
16536948|NCT03038568||Cohort 10|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
16536949|NCT03038568||Cohort 11|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
16536950|NCT03038568||Cohort 12|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
16536951|NCT03038568||Cohort 13|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
16536952|NCT03038568||Cohort 14|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
16536953|NCT03038568||Cohort 15|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
16536954|NCT03038568||Cohort 16|+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
16536955|NCT03038568||Cohort 17|+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
16536956|NCT03038568||Cohort 18|+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
16536958|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
16536959|NCT03038542|Experimental|Treatment Text Arm|
16536960|NCT03038542|Active Comparator|Standard Text Arm|
16536961|NCT03038529|Other|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.
~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
16536962|NCT03038529|Active Comparator|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).
~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
16536963|NCT03038516|Active Comparator|Vitamin D|Cholecalciferol (Detremin) solved in MIGLYOL® 812
16536964|NCT03038516|Placebo Comparator|Placebo|MIGLYOL® 812
16536965|NCT03038503|No Intervention|A|standard care septic shock according sepsis bundles
16536966|NCT03038503|Experimental|B|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
16536967|NCT03038503|Experimental|C|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
16536968|NCT03038490|Experimental|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
16536969|NCT03038490|No Intervention|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
16536970|NCT03038477|Experimental|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
16536971|NCT03038477|No Intervention|No Durvalumab|Patients in Arm B will be observed.
16536972|NCT03038451|Experimental|s-amlodipine besylate 2,5 and 5 mg tablets|
16536973|NCT03038438|Experimental|Abre|Abre Venous Self-expanding Stent System
16536974|NCT03038425|Placebo Comparator|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
16536975|NCT03038425|Active Comparator|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
16536976|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
16536977|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
16536978|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
16536979|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
16536980|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
16536981|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
16536982|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
16536983|NCT03038373||Group III|Lean Diabetics, No surgery
16536984|NCT03038373||Group IV|Lean Non Diabetics, No surgery
16536985|NCT03038347|Experimental|Training|In the training group, participants work six weeks on the training program, one module per week. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises that participants perform independently. The main purpose of this intervention is the improvement of cross-cultural competencies in psychotherapists
16536986|NCT03038347|Active Comparator|Education only|In the education only group, participants work six weeks on a slimmed down version of the training program. The modules only contain text-based information without any exercises. After completion, participants receive access to the practical exercises, case studies and video files as well. Main purpose of the education only group is to determine whether the practical part of the training program can offer additional benefit.
16536987|NCT03038347|No Intervention|Waiting control|Initially, participants do not receive any training contents. After a six week waiting period, they can participate in the training program as well. Modules are equivalent to those of the training group. Purpose of this group is to determine whether the training program is effective.
16536988|NCT03038334|Experimental|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
16536989|NCT03038321|Active Comparator|solifenacin|(Sofenacin ''solifenacin 10 m'') [Marcyrl Pharmaceutical Industries - Egypt]
16536990|NCT03038321|Active Comparator|levofloxacin|(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]
16536991|NCT03038321|Active Comparator|lornoxicam|(Xefo ''lornoxicam 8 mg'') [Multi-Apex - Egypt, under license of: NYCOMED, Austria]
16536992|NCT03038308|Experimental|ROP Intervention|Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study
16536993|NCT03038295|Experimental|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).
~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
16536995|NCT03038295|Experimental|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .
~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
16536996|NCT03038295|Placebo Comparator|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
16536997|NCT03038282|Experimental|Chromium Chloride|Participants transdermal chromium chloride 50 to 600 mcg/day.
16536998|NCT03038282|Experimental|Individual Exercise|Exercise 150 minutes per week (over 3 to 5 days) for 12 weeks.
16536999|NCT03038282|No Intervention|Control Group|Participants or participant's caregiver will be provided educational materials on starting an exercise program and instructions for the application of transdermal chromium chloride, but will receive no formal support for their exercise program.
16537000|NCT03038269|Sham Comparator|Sham tDCS|Participant will receive a placebo-type stimulation followed by upper extremity robotic training.
16537001|NCT03038269|Active Comparator|Active tDCS|Participant will receive active transcranial direct current stimulation followed by upper extremity robotic training.
16537002|NCT03038256|Experimental|4 Cycles XELOX pre- TME|experimental group (arm B): concurrent capecitabine-based long-term radiotherapy, 4 cycles of XELOX as neoadjuvant chemotherapy and TME surgery
16537003|NCT03038256|Active Comparator|6 Cycles XELOX post- TME|control group (arm A): concurrent capecitabine-based long-term radiotherapy, TME surgery and 6 cycles of XELOX as adjuvant chemotherapy.
16537004|NCT03038243|Experimental|Cohort 1|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
16537005|NCT03038243|Experimental|Cohort 2|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
16537006|NCT03038243|Experimental|Cohort 3|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
16537007|NCT03038230|Experimental|MCLA-117 bispecific antibody|"Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.
~Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment."
16537008|NCT03038217|Experimental|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
16537009|NCT03038217|Experimental|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
16537010|NCT03038217|Experimental|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
16537011|NCT03038217|Experimental|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
16537012|NCT03038204||PMA+MVA+CABG|patients with ischemic cardiomyopathy and mitral regurgitation who underwent coronary artery bypass grafting, mitral annuloplasty, and papillary muscles approximation.
16537013|NCT03038204||MVA+CABG|patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting and mitral valve annuloplasty.
16537014|NCT03038178|Experimental|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
16537015|NCT03038152|Experimental|Diagnostic (Magseed marker)|Patients receive the Magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =< 3mm from the clipped node. Patients then undergo axillary lymph node localization and targeted dissection within 30 days.
16537016|NCT03038139|Experimental|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.
~Applying exercises 3 times per week."
16537017|NCT03038139|Experimental|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.
~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.
~Applying exercises 3 times per week."
16537018|NCT03038126|Active Comparator|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
16537019|NCT03038126|Placebo Comparator|Usual care|
16537020|NCT03038113|Experimental|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
16537021|NCT03038113|Experimental|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
16537022|NCT03038100|Experimental|Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
16537023|NCT03038100|Placebo Comparator|Placebo With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
16537024|NCT03038087|Experimental|SENSE Device Monitoring in ICH Patients|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:
~A molded plastic headpiece containing the antenna array, and
~A processing control unit that contains:
~The driving electronics for the array;
~A spectrum analyzer coupled with a computer; and,
~The operating software that controls the device function and data acquisition, processing and archiving.
~For this study, the research personnel will place the headset over the subject's head. The headset will be sized to fit snuggly. Each headset is marked with a unique headset identification number. The patient-contacting components of the molded plastic form are made from a medical grade (USP Class VI), biocompatible plastic and foam."
16537025|NCT03038074|Experimental|Test Group|The subjects will be enrolled in the test group and will receive Pulse Oximeter with respiration rate sensor to examine the respiration rate.
16537026|NCT03038061|Experimental|Experimental group|Patients undergoing Laparoscopic Surgery
16537027|NCT03038048|Experimental|33 g needle - right eye|33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye
16537028|NCT03038048|Experimental|33 g needle - left eye|33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye
16537029|NCT03038035|Active Comparator|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day
~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
16537030|NCT03038035|Placebo Comparator|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.
~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
16537031|NCT03038022|Experimental|MGL-3196|Study Drug
16537032|NCT03038022|Placebo Comparator|Placebo|Matching Placebo
16537033|NCT03038009|Active Comparator|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
16537034|NCT03038009|Experimental|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
16537035|NCT03037983|Active Comparator|Active rTMS|Subjects will receive actual rTMS treatment.
16537036|NCT03037983|Sham Comparator|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
16537037|NCT03037970|Experimental|ABSOLVE|Type I collagen sheet soaked in a solution containing rhPDGF-BB.
16537038|NCT03037970|Placebo Comparator|Placebo|Collagen sheet soaked with saline solution.
16537039|NCT03037957||Group A Strep Assay|
16537040|NCT03037944|Experimental|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
16537041|NCT03037944|Experimental|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
16537042|NCT03037931|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices.
16537043|NCT03037931|Placebo Comparator|Placebo|Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
16537044|NCT03037918|Experimental|Treatment Group|"Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.
~Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28."
16537045|NCT03037918|No Intervention|Control Group|Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.
16537046|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
16537047|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
16537048|NCT03037892|Active Comparator|Midazolam and Fentanyl|Midazolam and Fentanyl Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain
16537049|NCT03037892|Experimental|Midazolam and Remifentanil|Midazolam and Remifentanil Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
16537653|NCT03033940||PFC Sigma subjects|
16537050|NCT03037892|Experimental|Remifentanil|Remifentanil Group Patients will receive only Remifentanil in the same doses as given in group 2. During the procedure if the pain is excessive and persistent in spite of increasing the respective doses as prescribed in each group, or causing loss of cooperation of patient and interfering in the performance of procedure, the patients will be given sleep dose of Inj Propofol and further anaesthesia care as required will be provided for same.
16537051|NCT03037879|Experimental|SPT|Speed of Processing Training
16537052|NCT03037879|Active Comparator|Control Group SPT|Control group to SPT treatment group
16537053|NCT03037879|Experimental|mSMT|Story Memory Technique
16537054|NCT03037879|Active Comparator|Control mSMT|Control group to mSMT treatment group
16537055|NCT03037866|Experimental|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
16537056|NCT03037866|No Intervention|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
16537057|NCT03037853||Healthy volunteers|Healthy volunteers
16537058|NCT03037840||cancer patients|Low intensity amplitude-modulated RF EMFs
16537059|NCT03037840||healthy participators|Low intensity amplitude-modulated RF EMFs
16537060|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
16537061|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
16537062|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
16537063|NCT03037814|Other|Compomer|Adhesive agent+Compomer
16537064|NCT03037814|Other|RMGIC|Primer+RMGIC
16537065|NCT03037814|Other|Giomer|Adhesive Agent+ Giomer
16537066|NCT03037814|Other|Amalgam|Amalgam
16537067|NCT03037801|No Intervention|Control|
16537068|NCT03037801|Experimental|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
16537069|NCT03037788|Experimental|WO3979|Formulation containing WO3979 for topical application
16537070|NCT03037788|Experimental|WO3970|Formulation containing WO3970 for topical application
16537071|NCT03037788|Experimental|WO3992|Formulation containing WO3992 for topical application
16537072|NCT03037788|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
16537073|NCT03037775|Other|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
16537074|NCT03037749|Experimental|Distressed Violent Partners|Distressed violent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
16537075|NCT03037749|Experimental|Distressed Nonviolent Partners|Distressed nonviolent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
16537076|NCT03037736|Placebo Comparator|Placebo|Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
16537077|NCT03037736|Active Comparator|5-Fluorouracil|Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
16537078|NCT03037736|Active Comparator|Bevacizumab|Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
16537079|NCT03037723|Other|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
16537080|NCT03037697|Experimental|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
16537081|NCT03037697|Active Comparator|Traditional Treatment Arm|"Traditional Treatment Arm
~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board
~3 months"
16537082|NCT03037684||chronic pain|individuals suffering from chronic pain
16537083|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
16537084|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
16537085|NCT03037658|Experimental|Personal - self|Participants had the opportunity to earn money for themselves by increasing their average steps per day.
16537086|NCT03037658|Experimental|Prosocial - loved one|Participants had the opportunity to earn money for a loved one of their choice by increasing their average steps per day.
16537087|NCT03037658|Experimental|Prosocial - charity|Participants had the opportunity to earn money for a charity of their choice by increasing their average steps per day.
16537088|NCT03037658|Experimental|Choice|Participants were given the choice to earn money either for themselves, a loved one, or a charity by increasing their average steps per day.
16537089|NCT03037658|No Intervention|Control|Participants were not offered a financial incentive to increase their average steps per day. They simply wore the pedometer for three weeks.
16537090|NCT03037645|Experimental|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
16537091|NCT03037632|Experimental|Communication Tool|
16537092|NCT03037632|No Intervention|No Communication Tool|
16537093|NCT03037619|Experimental|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
16537094|NCT03037619|Experimental|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
16537095|NCT03037606|Experimental|Rabelis DDR 50 mg Capsules and 1 placebo tablet|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
16537096|NCT03037606|Active Comparator|Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
16537097|NCT03037593|Experimental|Intervention|4000 IU vitamin D3 +prenatal vitamin
16537098|NCT03037593|No Intervention|Control|standard prenatal vitamin
16537099|NCT03037580|Experimental|Oral treprostinil|Sustained-release oral tablets for TID administration
16537100|NCT03037580|Placebo Comparator|Placebo|Placebo (sugar pill) for TID oral administration
16537101|NCT03037567|Experimental|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
16537102|NCT03037554|Experimental|Lateralized Thermal Sleepwear|For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
16537103|NCT03037554|Sham Comparator|Sham-Lateralized Sleepwear|For two consecutive nights subjects will wear Sham-Lateralized Sleepwear
16537104|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
16537105|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
16537106|NCT03037528|Experimental|Positive Affect, Mindfulness, Tracking|Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
16537107|NCT03037528|Experimental|Mindfulness, Tracking|Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
16537108|NCT03037528|Experimental|Positive Affect, Tracking|Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
16537109|NCT03037528|Experimental|Tracking|Participants will be asked to actively track what they eat in addition to receiving the core program.
16537110|NCT03037528|Experimental|Positive Affect, Mindfulness|Participants will receive information about positive affect and mindfulness in addition to the core program.
16537111|NCT03037528|Experimental|Positive Affect|Participants will receive information about positive affect in addition to the core program.
16537112|NCT03037528|Experimental|Mindfulness|Participants will receive information about mindfulness in addition to the core program.
16537113|NCT03037528|Experimental|No Extras|Participants will receive the core program.
16537114|NCT03037515|Active Comparator|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
16537115|NCT03037515|Active Comparator|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
16537116|NCT03037502|Experimental|Intervention: Tailor Made|Intervention Arm: In the pilot intervention, participants will receive: tailored goals/ messages, self-monitoring, weekly small groups to receive health education and community-based information and resources. Participants will also complete two assessment with blood work and anthropometric measurements. These intervention components were selected based on investigator's formative research and experience using them in prior studies. These components will be implemented simultaneously as they complement one another. While all of these components have not been tested together in an intervention for this population, they are variations and enhancements of previous interventions by the investigators.
16537117|NCT03037502|No Intervention|Comparison|Comparison Condition: Participants in the attention control group will receive self-help materials on how to improve healthy eating, physical activity and weight loss, self-monitoring, and complete two assessments with blood work and anthropometric measurements. Participants in this condition will receive a copy of their assessment data and the nurses will provide this personalized information as well as answer any questions participants may have about their assessment results.
16537118|NCT03037489|Experimental|MIV-711|MIV-711 for a total of 26 weeks
16537119|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Studies 2 and 3 will receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
16537120|NCT03037476|Experimental|In-person PFI|Participants randomized to the in-person PFI condition in Study 3 will be scheduled to meet with a trained intervention provider in a Student Counseling and Health Center setting for a 1.5 hour session to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback. The intervention provider will utilize a motivational interviewing approach in reviewing the students personalized feedback with them. They will use the student's past experiences with PSM as a starting point and will help the student to develop discrepancies, elicit change talk, provide students with opportunities to more thoroughly explore and question their beliefs, and offer alternatives by reviewing their personalized responses.
16537121|NCT03037476|No Intervention|Control|The control group will only receive assessments in Studies 2 and 3.
16537122|NCT03037463||Parkinson's Disease|
16537123|NCT03037463||Control|
16537124|NCT03037450|Other|Miniinvasive corneal neurotization|
16537125|NCT03037437|Experimental|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
16537126|NCT03037437|Experimental|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
16537127|NCT03037424|Active Comparator|Fibrinogen concentrate Octafibrin|
16537128|NCT03037424|Active Comparator|Cryoprecipitate|
16537129|NCT03037411||ELUVIA stent implantation|Peripheral stenting
16537130|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
16537131|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
16537132|NCT03037385|Experimental|Phase 1 Dose Escalation|Multiple doses of pralsetinib (BLU-667) for oral administration.
16537133|NCT03037385|Experimental|Phase 2 Dose Expansion|Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
16537134|NCT03037372|Experimental|ART-Atorvastatin adjunct therapy|ART, atorvastatin
16537135|NCT03037372|Experimental|ART-Rosuvastatin adjunct therapy|ART, rosuvastatin
16537136|NCT03037372|Experimental|ART-without statin adjunct therapy|ART, no statin
16537137|NCT03037372|Experimental|Healthy-HIV-negative|Age-matched HIV-negative, healthy volunteers from the same community
16537138|NCT03037359||Bivigam|Patients with primary immunodeficiency disease treated with Bivigam™
16537139|NCT03037359||Other IGIV|Patients with primary immunodeficiency disease treated with other IGIVs
16537140|NCT03037346|Experimental|Supportive Care (questionnaires, educational video)|Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
16537141|NCT03037333|Other|fluoroscopy|
16537142|NCT03037333|Other|ECG/ECHO|
16537143|NCT03037320|Experimental|group A|root coverage to be performed by semilunar vestibular incision technique
16537144|NCT03037320|Other|group B|root coverage by coronally advanced flap
16537145|NCT03037307|Experimental|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
16537146|NCT03037307|Active Comparator|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
16537147|NCT03037307|Other|Negative Control|Participants of this group will not be assigned to any treatment.
16537148|NCT03037294|No Intervention|Control group|Subjects in the control group will receive no intervention.
16537149|NCT03037294|Experimental|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
16537150|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
16537151|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
16537152|NCT03037268||Patients undergoing dilated examination|"examined in the Retina Service of Wills Eye Hospital
~with and without visually significant posterior retinal or optic nerve pathology
~imaged with a Lytro Plenoptic Camera and 28D lens"
16537153|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
16537154|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.
~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG
~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG
~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU
~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
16537191|NCT03036995|Experimental|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
16537192|NCT03036995|Placebo Comparator|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
16537155|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.
~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG
~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG
~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU
~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
16537156|NCT03037216|Experimental|Experimental Exercise-Training Intervention|Subjects will undergo a 10-week aerobic exercise protocol.
16537157|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
16537158|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
16537159|NCT03037203|Placebo Comparator|Arm C|Placebo
16537160|NCT03037190|Experimental|Group A|Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes
16537161|NCT03037190|No Intervention|B normal diet|Group B will have normal not glutenfree diet, no planned intervention
16537162|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
16537163|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
16537164|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
16537165|NCT03037164|Experimental|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
16537166|NCT03037164|Active Comparator|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
16537167|NCT03037151|Experimental|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
16537168|NCT03037151|Experimental|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
16537169|NCT03037151|Experimental|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
16537170|NCT03037151|Experimental|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
16537171|NCT03037138|Other|Washed-out scale after using BFR profiling|Blood flow profiling will be used as intervention for washed-out dialysis patients
16537172|NCT03037125|Active Comparator|Control Arm|Split crest without PRF
16537173|NCT03037125|Experimental|Intervention Arm|Split crest with PRF
16537174|NCT03037112|Active Comparator|Education|All providers will receive identical training on the appropriate prescribing of antibiotics for ARTIs in a 20 minute presentation. Follow up refresher video clips will also be available for all providers to view at their convenience throughout the study. Parents in both arms will receive identical high quality education on the pros and cons of antibiotics and tips for communicating with their provider.
16537175|NCT03037112|Active Comparator|Communication Skills|Providers randomized to the communication intervention will receive additional training on communication skills in a 40 minute communication skills training session. This training session will include good and bad communication examples, training on positive and negative behavioral framing, and education regarding key drivers of patient satisfaction.
16537176|NCT03037099|Experimental|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
16537177|NCT03037099|No Intervention|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
16537178|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
16537179|NCT03037073|Active Comparator|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
16537180|NCT03037073|Active Comparator|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
16537181|NCT03037060|Experimental|Experimental|"5 experimental sessions per participant:
~(1) [11C]-(+)-PHNO PET scan, (2), Alcohol Self-Administration, (3) Craving Task, (4) MRI scan and (5) Neuropsychological Assessment."
16537182|NCT03037047|Placebo Comparator|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
16537183|NCT03037047|Experimental|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
16537184|NCT03037034|Experimental|Forcep Strip Method Treatment|patients who have Gastrointestinal Subepithelial Tumors Originating from the Muscularis Propria are enrolled
16537185|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
16537186|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
16537187|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
16537188|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
16537189|NCT03037008|Active Comparator|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
16537190|NCT03037008|Active Comparator|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
16537193|NCT03036982||Use of Mobile ACT|Will answer ACT (or cACT) and other asthma questions using mobile app
16537196|NCT03036930|Experimental|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Patients are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Patients may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series.
16537197|NCT03036904|Experimental|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
16537198|NCT03036891|Experimental|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
16537199|NCT03036891|Placebo Comparator|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
16537200|NCT03036878|Experimental|ReNu Injection|Injection of ReNu allograft into the joint capsule.
16537201|NCT03036865|Experimental|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
16537202|NCT03036865|Placebo Comparator|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
16537203|NCT03036865|Experimental|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
16537204|NCT03036865|Placebo Comparator|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
16537205|NCT03036865|Experimental|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
16537206|NCT03036865|Placebo Comparator|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
16537207|NCT03036865|Experimental|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
16537208|NCT03036865|Placebo Comparator|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
16537209|NCT03036865|Experimental|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
16537210|NCT03036865|Placebo Comparator|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
16537211|NCT03036865|Experimental|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
16537212|NCT03036865|Experimental|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
16537213|NCT03036865|Placebo Comparator|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
16537214|NCT03036865|Experimental|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
16537215|NCT03036865|Placebo Comparator|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
16537216|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16537217|NCT03036839|Experimental|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
16537218|NCT03036839|Experimental|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
16537219|NCT03036839|Experimental|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
16537220|NCT03036826||Piperacillin/Tazobactam|Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy
16537221|NCT03036826||Meropenem|Group of patients receiving Meropenem as antiinfective therapy
16537222|NCT03036813|Active Comparator|Dose 1|voxelotor
16537223|NCT03036813|Active Comparator|Dose 2|voxelotor
16537224|NCT03036813|Placebo Comparator|Placebo|Placebo
16537225|NCT03036800|Experimental|Targeted Prescribing Pathway (LIRA 3mg + Standard Care)|Standard care plus targeted use of the intervention Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply
16537226|NCT03036800|Active Comparator|Standard Care|standard Tier 3 obesity specialist service care
16537227|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
16537228|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
16537229|NCT03036774|Experimental|Diabetic patient|Diabetic patients (type 1 or type 2 diabetes) with scheduled surgery . Ultrasonic measurement of antral area
16537230|NCT03036774|Other|Non diabetic patient|"Patients with scheduled surgery without history of diabetes or a current, treated or untreated, diabetic disease.
~Ultrasonic measurement of antral area"
16537231|NCT03036761|Experimental|AUR+: Auriculotherapy|Patients benefit from 3 sessions of auriculotherapy at one month intervals.
16537232|NCT03036761|No Intervention|AUR-: No auriculotherapy|Patients do not benefit from auriculotherapy.
16537233|NCT03036748|Experimental|TX control|Kidney transplant recipients with ACR <30mg/g
16537234|NCT03036748|Experimental|TX Proteinuria|Kidney transplant recipients with ACR> 300mg/g
16537235|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.
~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
16537236|NCT03036722|Experimental|Flaxseed porridge group|22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.
16537237|NCT03036722|Placebo Comparator|Placebo control porridge group|22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).
16537654|NCT03033927||Participants with Stage IV Pancreatic Cancer|
16537238|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
16537239|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
16537240|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
16537241|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
16537242|NCT03036657|Experimental|Manual Acupuncture|"Device:
~Sterile single-use MAC acupuncture needles - 0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea
~Used for Intervention:
~Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
16537243|NCT03036657|Experimental|Low-Frequency Electroacupuncture|"Device:
~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
~Used for Intervention:
~Low-frequency Continuous Electroacupuncture (2Hz) to PC3, PC5 or HT3, HT4 for 20 min"
16537244|NCT03036657|Experimental|High-Frequency Electroacupuncture|"Device:
~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
~Used for Intervention:
~High-frequency Continuous Electroacupuncture (100 Hz) to PC3, PC5 or HT3, HT4 for 20 min"
16537245|NCT03036644|Experimental|e-cigarette nic_O LT|e-cigarette (without nicotine; low temperature)
16537246|NCT03036644|Experimental|e-cigarette Nic_1 LT|e-cigarette (with nicotine; low temperature)
16537247|NCT03036644|Experimental|e-cigarette Nic_0 HT|e-cigarette (without nicotine; high temperature)
16537248|NCT03036644|Experimental|e-cigarette NIC_1 HT|e-cigarette (with nicotine; high temperature)
16537249|NCT03036644|Active Comparator|Tobacco cigarette|Tobacco cigarette
16537250|NCT03036644|Placebo Comparator|Placebo|No E-cigarettes, Nor tobocco cigarettes
16537251|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
16537252|NCT03036631||General Anesthesia|
16537253|NCT03036618|Placebo Comparator|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
16537254|NCT03036618|Experimental|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
16537255|NCT03036605|Active Comparator|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
16537256|NCT03036605|Active Comparator|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
16537257|NCT03036592|Experimental|MTNR1B CC|Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
16537258|NCT03036592|Experimental|MTNR1B GG|Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
16537259|NCT03036592|Experimental|MTNR1B CG|Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
16537260|NCT03036579|Experimental|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
16537261|NCT03036579|Experimental|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
16537262|NCT03036566|Experimental|Bridge|Three unit high strength ceramic (lithium disilicate/emaxCAD by Ivoclar) bridges replacing a single tooth.
16537263|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.
~(iii) duration of symptoms: more than 3 months."
16537264|NCT03036527|Experimental|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
16537265|NCT03036527|Experimental|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
16537266|NCT03036527|Experimental|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
16537267|NCT03036514|Experimental|Case|Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
16537268|NCT03036514|Active Comparator|Control|Patient-controlled intravenous analgesia (PCIA) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. This classic patient-controlled IV-pump contains 1mg/ml morphine and 50mcg/ml dehydrobenzperidol. Pump characteristics include 1ml each asked bolus, lockout interval of 8 minutes.
16537269|NCT03036501|Experimental|[^14C]-Risdiplam|Participants will be administered with [^14C]-Risdiplam solution orally under fasted conditions on Day 1.
16537320|NCT03036228|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution or tablets to be taken BID. Each cycle is defined as 28 days.
16537270|NCT03036488|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
16537271|NCT03036488|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
16537272|NCT03036462|Experimental|Verum group (FCM)|I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is > 16.0 g/dL or ferritin is > 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
16537273|NCT03036462|Placebo Comparator|Placebo group (NaCL)|Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.
16537274|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
16537275|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
16537276|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
16537277|NCT03036436|Experimental|Intervention|Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
16537278|NCT03036423|Active Comparator|Online video education|Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.
16537279|NCT03036423|Active Comparator|Computerized mental exercises|Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.
16537280|NCT03036410|Other|bimodal user|wearing one hearing aid and one CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
16537281|NCT03036410|Other|unilateral hearing aid users|wearing one hearing aid Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
16537282|NCT03036410|Other|bilateral hearing aid users|wearing two hearing aids Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
16537283|NCT03036410|Other|CI users|wearing CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
16537284|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537285|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537286|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537287|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537288|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537289|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537290|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537291|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537292|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537293|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
16537294|NCT03036371|Experimental|High Intensity Interval Exercise|home exercise sessions
16537295|NCT03036358|Other|Teledermatology consult|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment will be entered into the patients chart.
16537296|NCT03036358|Other|Routine Care|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment WILL NOT be entered into the patients chart
16537297|NCT03036345|Experimental|Surgery patients|Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.
16537298|NCT03036332|Experimental|intervention|Aerobic interval training
16537299|NCT03036332|No Intervention|Control group|The participants performed only initial evaluation and at the end of the study
16537300|NCT03036319|Experimental|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
16537301|NCT03036319|Placebo Comparator|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
16537302|NCT03036319|Experimental|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
16537303|NCT03036319|Experimental|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
16537304|NCT03036319|Experimental|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
16537305|NCT03036319|Experimental|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
16537306|NCT03036319|Experimental|Active and Sham TES|Participants will receive active and sham TES
16537307|NCT03036306|Experimental|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
16537308|NCT03036306|Experimental|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
16537309|NCT03036306|Placebo Comparator|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
16537310|NCT03036293|Experimental|Tenoten, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
16537311|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
16537312|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
16537313|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
16537314|NCT03036267|Experimental|BREATHE|7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach
16537315|NCT03036267|Active Comparator|Attention Control Condition|7-minute diet and exercise discussion
16537316|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
16537317|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
16537318|NCT03036241|Experimental|Drug-eluting balloon|
16537319|NCT03036241|Active Comparator|Conventional angioplasty|
16537321|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
16537322|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
16537323|NCT03036202||one group|All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
16537324|NCT03036189|Experimental|Intervention arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
16537325|NCT03036189|Experimental|Wait-list control arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
16537326|NCT03036176|Other|SAM intervention group|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
16537327|NCT03036176|Other|SAM control Group|The control children received routine medical treatment and nutritional rehabilitation services in hospital. Though they had access to playground facilities neither the control children nor their caregivers had access to the playroom materials and the basic orientation on child care, feeding and stimulation.
16537328|NCT03036163|Experimental|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
16537329|NCT03036163|Experimental|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
16537330|NCT03036163|Experimental|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
16537331|NCT03036163|Experimental|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
16537332|NCT03036163|Experimental|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
16537333|NCT03036163|Experimental|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
16537334|NCT03036163|Experimental|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
16537335|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
16537336|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
16537337|NCT03036137|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
16537338|NCT03036137|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
16537339|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
16537340|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
16537341|NCT03036111|Sham Comparator|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
16537342|NCT03036111|Active Comparator|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
16537347|NCT03036085|Active Comparator|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
16537348|NCT03036085|Experimental|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
16537349|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
16537350|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
16537351|NCT03036059|Active Comparator|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
16537352|NCT03036059|Experimental|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
16537356|NCT03036033|Experimental|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
16537357|NCT03036020|Experimental|Contraindication anesthesiologists|Ability of anesthesiologists to detect contraindications to thrombolysis in acute stroke patients prehospital by interpretation of prehospital cerebral CT scans
16537358|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
16537359|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
16537360|NCT03035994|Experimental|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
16537361|NCT03035994|Experimental|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
16537362|NCT03035994|Experimental|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
16537363|NCT03035994|No Intervention|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
16537364|NCT03035981|Experimental|White rice, low amylose|Cooked white rice with low amylose content
16537365|NCT03035981|Experimental|White rice, high amylose|Cooked white rice with high amylose content
16537366|NCT03035981|Experimental|White rice, slow|Cooked white rice with slow digesting starch
16537367|NCT03035981|Experimental|White rice, resistant|Cooked white rice with resistant starch
16537368|NCT03035981|Experimental|Brown rice, low amylose|Cooked brown rice with low amylose content
16537369|NCT03035981|Experimental|Brown rice, high amylose|Cooked brown rice with high amylose content
16537370|NCT03035981|Experimental|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
16537371|NCT03035968|Experimental|Vojta arm|Patients in the interventional arm are treated with Vojta therapy from randomization until discharge.
16537372|NCT03035968|Active Comparator|conventional physiotherapy arm|Patients in this control arm are treated with conventional physiotherapy for motor improvement from randomization until discharge.
16537373|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
16537374|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
16537375|NCT03035942|Experimental|D Group|Dexamethasone 8 mg
16537376|NCT03035942|Experimental|O group|Ondansetron 4 mg
16537377|NCT03035942|Placebo Comparator|S group|Normal saline (5 mL total volume)
16537378|NCT03035929|Experimental|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.
~All subjects will undergo the same procedures and interventions."
16537379|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
16537380|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
16537381|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
16537382|NCT03035903|Experimental|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
16537383|NCT03035903|Active Comparator|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
16537384|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
16537385|NCT03035877|Experimental|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
16537386|NCT03035877|Active Comparator|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
16537387|NCT03035864|Experimental|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
16537388|NCT03035864|Placebo Comparator|Vehicle|Vehicle eye drops six times daily
16537389|NCT03035851|Experimental|Aerobic exercise|Participants will take part in a supervised 6-month-long aerobic (walk/jog) training program held 3 days/week. Each session will include a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions will follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cool-down, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise will increase from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity will be based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity will build from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
16537462|NCT03035318|Experimental|DePuy Instrumentation with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Instrumentation with SmartBone™, to position the glenoid component.
16538295|NCT03029533|Experimental|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
16537390|NCT03035851|Other|Stretch and Strength|A control group will meet on a similar schedule as the exercise group for sessions on stretching and toning but without aerobic exercise. Based on prior RCTs of similar interventions the investigators expect this control to be ineffective or minimally effective, but anticipate that it will increase participant enthusiasm and retention. All assessments will be conducted in this arm.
16537391|NCT03035838|Other|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
16537392|NCT03035825|Experimental|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
16537393|NCT03035825|Active Comparator|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
16537394|NCT03035812|Experimental|Alkali|Patients in whom an oral alkalinization whatever the formulation
16537395|NCT03035799|Experimental|Paleolithic Diet|Paleolithic Diet
16537396|NCT03035799|Active Comparator|General Healthful Diet|General Healthful Diet
16537397|NCT03035773|Experimental|ARM A|SCP document delivered to the patient & Primary Care Provider
16537398|NCT03035773|Experimental|ARM B|SCP document provided to the patient in an in-person survivorship visit and copy sent to PCP
16537399|NCT03035773|Experimental|ARM C|SCP document provided to the patient in an in-person survivorship visit with an additional follow-up visit and copy of the document sent to PCP
16537400|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
16537401|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
16537402|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
16537403|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
16537404|NCT03035734|Active Comparator|A|Single oral dose BMS-986141 Form A tablet under fasting conditions
16537405|NCT03035734|Experimental|B|Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions
16537406|NCT03035734|Experimental|C|Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions
16537407|NCT03035734|Experimental|D|Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions
16537408|NCT03035721|Experimental|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
16537409|NCT03035721|Active Comparator|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
16537410|NCT03035721|No Intervention|Breastfeeding group|Breastfed full term healthy infants
16537411|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
16537412|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
16537413|NCT03035695|Experimental|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.
~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
16537414|NCT03035695|Active Comparator|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
16537415|NCT03035682|Active Comparator|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
16537416|NCT03035682|Experimental|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
16537417|NCT03035669|Experimental|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
16537418|NCT03035669|Active Comparator|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
16537419|NCT03035656|Experimental|Experimental|Administration of epidural Ropivaciane
16537420|NCT03035656|Placebo Comparator|Control|Administration of saline
16537421|NCT03035643|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
16537422|NCT03035630|Experimental|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:
~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.
~Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.
~Second-Line Medication:
~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.
~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
16537423|NCT03035630|Experimental|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:
~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.
~Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.
~Second-Line Medication:
~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.
~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
16537424|NCT03035617|Placebo Comparator|Controlled Arm|Mesh will be soaked in normal saline solution as is routinely done.
16537425|NCT03035617|Experimental|Intervention Arm|Mesh will be soaked in .5% bupivacaine solution before application.
16537426|NCT03035604||Nutritional geriatric assessment|Participants undergo nutritional geriatric assessment over 15 minutes in person or on the phone every 3 months for 12 months.
16537427|NCT03035591|Experimental|ODM-207|Escalating doses of ODM-207
16537807|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
16537428|NCT03035578|Experimental|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:
~a)patients <1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to <5kg, morphine 1mg/25mL.
~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates < 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
16537429|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
16537430|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
16537431|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
16537432|NCT03035552|Experimental|Treatment prior to surgery|Infants randomized to receive the pacifier activated music player and mother's voice treatment prior to surgery for 5 sessions, and mother's voice playing freely post surgery.
16537433|NCT03035552|Experimental|Treatment post surgery|Infants randomized to receive the mother's voice playing freely prior to surgery,and pacifier activated music player and mother's voice treatment post surgery for 5 sessions.
16537434|NCT03035539|Active Comparator|Standard treatment|Standard treatment after randomization
16537435|NCT03035539|Experimental|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
16537436|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
16537437|NCT03035513||CSWS patients|The data of CSWS patients will be statistically compared to healthy volunteers
16537438|NCT03035513||healthy volunteers|The data of CSWS patients will be statistically compared to healthy volunteers
16537439|NCT03035500|Experimental|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
16537440|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:
~Low resolution transrectal ultrasound examination (LR-TRUS)
~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
16537441|NCT03035474|Other|Direct & Digital|Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence
16537442|NCT03035474|Other|Direct & Registry|Health system engagement to improve local QI programs and patient and control
16537443|NCT03035474|Other|Digital & Registry|Patient engagement to improve self-management/medication adherence and control
16537444|NCT03035474|No Intervention|Registry|Control
16537445|NCT03035448|Experimental|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.
~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
16537446|NCT03035448|Experimental|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.
~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
16537447|NCT03035435||study group|fast-track rehabilitation
16537448|NCT03035435||control group|standard care rehabilitation
16537449|NCT03035422|Other|Patients with primary refractory acute myeloid leukemia|Patients with primary refractory acute myeloid leukemia
16537450|NCT03035409|Experimental|Supportive Care (anamorelin, physical activity, counseling)|Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.
16537451|NCT03035396|Experimental|Diassess Influenza A and B Test|
16537452|NCT03035383|Experimental|Purse String Technique|Thyroidectomy closure is performed using purse string technique.
16537453|NCT03035383|Active Comparator|Conventional technique|Thyroidectomy closure is performed using conventional technique.
16537454|NCT03035370|Experimental|Viaskin PT 25 mcg|Viaskin PT 25 mcg
16537455|NCT03035370|Experimental|Viaskin PT 50 mcg|Viaskin PT 50 mcg
16537456|NCT03035370|Placebo Comparator|Viaskin PT Placebo|Viaskin PT Placebo
16537457|NCT03035357|Experimental|Daratumumab|Participants receive Daratumumab by vein over about 1 hour 1 time a week during Weeks 1-4.
16537458|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
16537459|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
16537460|NCT03035331|Experimental|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of cycles 2 and 3, and day 2 of cycles 4 and 5. Patients undergo cryosurgery on day 2 of cycle 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of cycles 2-5. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who are CR, PR, or SD after completion of therapy, may receive pembrolizumab for an additional 18 cycles in the absence of disease progression or unacceptable toxicity.
16537461|NCT03035318|Active Comparator|DePuy Global® Anchor Peg Glenoid|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Glenoid Instrumentation to position the glenoid component.
16537463|NCT03035318|Experimental|IRI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBone™, to position the glenoid component.
16537464|NCT03035318|Experimental|RTI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses Real Time Instrumentation (RTI), with a SmartBone™, to position the glenoid component.
16537465|NCT03035318|Experimental|IRI with SmartBase|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBase™, to position the glenoid component.
16537466|NCT03035305|Experimental|SMC and LNS (intervention group)|Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
16537467|NCT03035305|Other|SMC only (control group)|Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
16537468|NCT03035279|Experimental|Arm A|SC-006 Dose regimen finding
16537469|NCT03035279|Experimental|Arm B|SC-006 Dose expansion
16537470|NCT03035279|Experimental|Arm C|SC-006 and ABBV-181 Combination escalation and expansion
16537471|NCT03035266|Experimental|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
16537472|NCT03035266|Active Comparator|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
16537473|NCT03035253|Experimental|OMP-305B83 combined with FOLFIRI or FOLFOX|
16537474|NCT03035240|Experimental|Financial Education Intervention|
16537475|NCT03035240|No Intervention|No Financial Education Intervention|
16537476|NCT03035227|Active Comparator|Catheter Ablation|Catheter ablation procedure of atrial and/or ventricular arrhythmias.
16537477|NCT03035227|Active Comparator|Medical Therapy|Medical management using antiarrhythmic drugs per standard of care of treating physician.
16537478|NCT03035214|Other|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or <80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
16537479|NCT03035201||Cocoa extract + multivitamin|2 capsules containing 500 mg/d cocoa extract; daily MTV
16537480|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 500 mg/d cocoa extract; daily MTV placebo
16537481|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
16537482|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
16537483|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
16537484|NCT03035175|Experimental|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
16537485|NCT03035175|Active Comparator|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
16537486|NCT03035162|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20 minutes for the active conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
16537487|NCT03035162|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow only 2 minutes for the sham conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
16537488|NCT03035149|Experimental|Weight Management Program|Obese subjects participate in a year long medically supervised weight management program.
16537489|NCT03035149|No Intervention|Normal Weight Controls|Normal weight age and sex-matched controls. Unlike the obese subjects, the controls did not participate in the Weight Management Program. Pulmonary function, exercise performance and dyspnea results for normal weight controls were compared against the results for obese subjects.
16537490|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
16537491|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
16537492|NCT03035123|No Intervention|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
16537524|NCT03034928|Other|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
16537808|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
16537493|NCT03035123|Experimental|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.
~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.
~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
16537494|NCT03035110|Experimental|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
16537495|NCT03035084|Experimental|Group-2-D3|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
16537496|NCT03035084|Placebo Comparator|Group-2-Placebo|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
16537497|NCT03035084|Experimental|Group-1-D2|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
16537498|NCT03035084|Placebo Comparator|Group-1-Placebo|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.
16537499|NCT03035071|Experimental|minimally invasive esophagectomy|minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
16537500|NCT03035071|Active Comparator|open esophagectomy|open gastric mobilization and gastric tube formation
16537501|NCT03035058|Experimental|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
16537502|NCT03035058|Experimental|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
16537503|NCT03035058|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
16537504|NCT03035045|Experimental|Comparator1: Paracetamol 650 mg (325 mg/tablet) oral|Drug: Paracetamol Comparison pain score between paracetamol and placebo
16537505|NCT03035045|Placebo Comparator|Comparator 2: Placebo oral|Drug: placebo Comparison pain score between paracetamol and placebo
16537506|NCT03035032|Experimental|Leuprolide Acetate 22.5 milligrams (mg)|Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
16537507|NCT03035019|Experimental|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
16537508|NCT03035006|Experimental|Lipotecan based chemoradiotherapy|Patients will receive Lipotecan based CCRT. Lipotecan will be given as a 30-minute (±3 minutes) iv infusion qw for 6 weeks at the predefined dose level for each cohort. A total of 6 doses of Lipotecan will be administered to each patient in conjunction with RT at 3.5 Gy per fraction for 16 fractions. During CCRT period, Lipotecan should be given within 2 hours prior to the start of RT, and the Lipotecan and RT should be delivered on the same day, unless any conditions fulfils with the dose interruption standards. Radiotherapy treatment, at the allocated dose level, is only permitted if the normal tissue dose constrain criteria are maintained
16537509|NCT03034993|Experimental|Text Messaging|This group will receive text messages with appointment reminders, medication taking education and motivation, and for reporting of mood.
16537510|NCT03034993|Placebo Comparator|Control|This group will receive simple text messages about general health promotion, such as about the importance of drinking water on hot days, using sunscreen, etc.
16537511|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
16537512|NCT03034967|Experimental|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
16537513|NCT03034967|Experimental|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
16537514|NCT03034967|Experimental|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
16537515|NCT03034967|Experimental|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
16537516|NCT03034967|Experimental|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
16537517|NCT03034967|Placebo Comparator|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
16537518|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
16537519|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
16537520|NCT03034941|Active Comparator|metformin group|Drug: metformin
16537521|NCT03034941|Active Comparator|COMBI group|Drug: liraglutide + metformin
16537522|NCT03034941|No Intervention|CONTROL group|control group of obese PCOS patients without therapy
16537523|NCT03034928|Other|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
16537557|NCT03034720|No Intervention|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
16537558|NCT03034707|Experimental|Biotin arm|biotin 10 mg/day for 7 days
16537525|NCT03034928|Other|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
16537526|NCT03034928|Other|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
16537527|NCT03034915|Experimental|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
16537528|NCT03034915|Experimental|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
16537529|NCT03034915|Experimental|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
16537530|NCT03034889||Exposed|Children age 4-10 who required general anesthesia before the age of 36 months in the context of surgical and diagnostic procedures or sedation during intensive care, excluding neurosurgical interventions or cardiac surgery as well as preexisting hereditary or acquired neurocognitive deficits
16537531|NCT03034889||Control|Children age 4-10 who did not require any anesthesia before the age of 36 months. Excluding preexisting hereditary or acquired neurocognitive deficits.
16537532|NCT03034863|Experimental|Treatment|SAFER: A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
16537533|NCT03034863|Active Comparator|Control|The comparison condition will be an assessment-only enhanced treatment-as-usual (E-TAU), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran?s primary mental health provider.
16537534|NCT03034850||CRS/HIPEC|Patients with a confirmed histological diagnosis of peritoneal disease treated by cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC).
16537535|NCT03034837|Active Comparator|Resin sealant|"Sealing pit and fissures of the included permanent first molars using SDI conseal f resin sealant material once at the baseline of the study."
16537536|NCT03034837|Experimental|ART sealant|"Sealing pit and fissures of the included permanent first molars using 3M ESPE KetacTM Molar Easymix glass ionomer cement material once at the baseline of the study."
16537537|NCT03034824|Experimental|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
16537538|NCT03034824|Experimental|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
16537539|NCT03034824|Experimental|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
16537540|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
16537541|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
16537542|NCT03034785|No Intervention|Group 1|Term
16537543|NCT03034785|No Intervention|Group 2|Preterm
16537544|NCT03034785|Experimental|Group 3|Term
16537545|NCT03034785|Experimental|Group 4|Preterm
16537546|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
16537547|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
16537548|NCT03034759|Experimental|All participants|+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
16537549|NCT03034746|Experimental|Alzheimer's Disease (G1)|(G1) physical activity (PA)
16537550|NCT03034746|Experimental|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
16537551|NCT03034746|No Intervention|Healthy Old Subjects (G1)|Control group old
16537552|NCT03034746|No Intervention|Healthy young Subjects (G2)|Control group young
16537553|NCT03034733|Experimental|dexamethasone 0,15 mg/kg|single-dose intravenous dexamethasone 0,15 mg/kg, intraoperative
16537554|NCT03034733|Experimental|dexamethasone 0,25 mg/kg|single-dose intravenous dexamethasone 0,25 mg/kg, intraoperative
16537555|NCT03034733|Placebo Comparator|Sodium Chloride, (24)NaCl 0,9%|single-dose intravenous saline, intraoperative
16537556|NCT03034720|Experimental|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
16537559|NCT03034694|Placebo Comparator|Routine Care|The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
16537560|NCT03034694|Experimental|Teledermatology INtervention|The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
16537561|NCT03034681|Other|Vojta|Vojta therapy consists in activating certain overall and innate locomotion patterns or complexes: reflex creeping and reflex rolling, which provokes the contraction of striated muscle in the entire body in a determined coordination with the central nervous system (CNS). These patterns are triggered from different positions (prone, supine and side lying) and only with certain stimulation. They contain all the locomotion components: automatic postural control, uprighting and phase movements. This therapy allows for the changing from pathological patterns to painless and cheaper patterns. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
16537562|NCT03034681|Active Comparator|TENS|TENS procedure used at our unit consists in applying a high frequency current (80Hz), which is the most effective way to combat pain, for a phase duration of 60-200 microseconds at a comfortable range. Electrodes are placed on the skin over the sciatic nerve path, the (-) cathode on the most painful area as it is the most stimulating and the (+) another is placed distal. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
16537563|NCT03034668|Experimental|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
16537564|NCT03034668|Experimental|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
16537565|NCT03034668|Placebo Comparator|Placebo|Maltodextrin
16537566|NCT03034655|Experimental|CDP exercises (10 sessions)|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
16537567|NCT03034655|Experimental|CDP exercises (5 sessions)|Group B. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
16537568|NCT03034655|Experimental|Mobile posturography exercises (10 sess)|Group C. Up to six tasks with the most prominent deviations from normative control values were included in the training program. Training was performed by using the training function of Vertiguard1-RT device. This neurofeedback system contains one vibration stimulator on the front, back, left and right side, respectively. Training was performed daily under supervision of a physician over 2 weeks (10 sessions, weekend was excluded). A training session consisted of 5 repetitions of six selected training tasks. The patient received a vibrotactile feedback signal during training in those directions which showed a higher body sway than preset thresholds. Vibration was reinforced with increasing sway No vibrotactile feedback was applied if the patient's sway was below preset thresholds. The exercise difficulty was progressively increase throughout the rehabilitation sessions.
16537569|NCT03034655|Experimental|Mobile posturography exercises (5 sess)|Group D. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
16537570|NCT03034642|Experimental|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.
~Drugs: No test substances, only moderate conscious sedation using standard medications.
~Devices: No test devices."
16537571|NCT03034642|Experimental|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.
~Drugs: No test substances, only moderate conscious sedation using standard medications.
~Devices: No test devices."
16537572|NCT03034629|Experimental|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
16537573|NCT03034616|Experimental|ex vivo activation|"'OLIVA device' in patients that undergo oophorectomy on the cortex of the removed ovary we will perform 5 parallel slashes 3 cm long.
~this will be followed by investigation by the pathologist as to the depth of cuts."
16537574|NCT03034616|Active Comparator|in vivo activation|'OLIVA device' in patients undergoing oophorectomy before the resection from is pedicle on cortex of the ovary we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels.
16537575|NCT03034616|Active Comparator|POI OLIVA|'OLIVA device' in patients with premature ovarian failure and following safety data from arm 2 activation by ovarian slashing will be performed laparoscopically by closed cutting device (OLIVA). follow-up by sonography and hormonal markers of ovarian activity
16537576|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of Nutri-jelly with PEITC for 200 milligrams per day, five days per week for 3 months.
16537577|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of Nutri-jelly for 200 milligrams per day, five days per week for 3 months.
16537578|NCT03034577|Active Comparator|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more
~Neostigmine"
16537579|NCT03034577|Active Comparator|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
16537580|NCT03034564|Active Comparator|1|Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).
16537581|NCT03034564|Placebo Comparator|2|Dosing regimen identical to active group
16537809|NCT03032861|Experimental|Orange juice|Ten women will consume 100% orange juice (300 mL/day) during 60 days.
16537582|NCT03034551|Experimental|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
16537583|NCT03034551|No Intervention|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
16537584|NCT03034538|Active Comparator|100mg|Zonegran 100mg
16537585|NCT03034538|Active Comparator|200mg|Zonegran 200mg
16537586|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
16537587|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
16537588|NCT03034499|Active Comparator|Single-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by single-port sacrocolpopexy.
16537589|NCT03034499|Active Comparator|Multi-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by multi- port sacrocolpopexy.
16537590|NCT03034486|Experimental|A single sequence, 3-period|
16537591|NCT03034473|Other|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
16537592|NCT03034460|Experimental|CD5024 1% cream|Active drug;
16537593|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
16537594|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
16537595|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
16537596|NCT03034447|Other|Asthma|Children and teenagers with persistent asthma will perform questionnaires, lung function test, and home sleep study
16537597|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
16537598|NCT03034421|Active Comparator|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
16537599|NCT03034421|No Intervention|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
16537600|NCT03034408|Other|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
16537601|NCT03034408|Other|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
16537602|NCT03034395|Other|Wide Local Excision 1cm|
16537603|NCT03034395|Other|Wide Local Excision 2cm|
16537604|NCT03034382|Experimental|Morphine|5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
16537605|NCT03034382|Experimental|Nalbuphine|5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
16537606|NCT03034382|Experimental|Morphine and Nalbuphine|"5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
~combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block"
16537607|NCT03034382|Placebo Comparator|Bupivacaine 0.5%|10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.
16537608|NCT03034369||Safety Net Clinic Patients|A Cohort of patients in 12 different primary care clinics will be studied to measure how changes in different integration factors impacts the following patient reported outcomes at baseline and 12 months: Access to Care, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, and Social Support. Health care claims data will be accessed to analyze Depression Screening, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, and Post-Admission follow-up at baseline and 12 months.
16537609|NCT03034356|Experimental|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
16537610|NCT03034356|Experimental|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
16537611|NCT03034343|Experimental|TAU+mindfulness applied face to face|4 sessions of 90 minutes/session Mindfulness based intervention applied in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is one month.
16537612|NCT03034343|Experimental|TAU + Mindfulness ICTs intervention|4 sessions of 60 minutes/session Mindfulness based intervention applied by ICTs (Internet-based program). The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the online program is two months.
16537613|NCT03034343|No Intervention|Usual medical treatment (TAU)|In this group the general practitioner will apply the usual treatment (medication) but there will be no psychological treatment.
16537614|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
16537615|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
16537616|NCT03034317|Active Comparator|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
16537617|NCT03034317|No Intervention|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
16537810|NCT03032848|Active Comparator|Conjugated Estrogen Group|use of 1 gram per day
16537618|NCT03034304|Experimental|MASCT-I alone or in combination with chemical drugs or in comb|"Group 1: treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
~Group 2: treatment with MASCT-I in combination with ifosfamide. In the event of disease progression, treatment with a combination of PD1 antibodies is added. Patients with soft tissue sarcomas should be discontinued and treated with MASCT-I +PD1 antibody only until disease progression occurs again.
~Group 3: Advanced metastatic or recurrent urothelial carcinoma, soft tissue sarcoma/osteosarcoma, and cholangiocarcinoma that progressed after first-line chemotherapy were treated with MASCT-I combined with PD1 antibody until the disease progressed. If disease progression occurs during treatment, treatment is discontinued and follow-up is initiated.
~Group 4: Recurrent metastatic solid tumors that had failed previous treatment with PD1 antibody were treated with MASCT-I regimen 2 + PD1 antibody until the disease progressed."
16537619|NCT03034291|Experimental|Cacao 70%|Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.
16537620|NCT03034291|Placebo Comparator|White chocolate|Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.
16537621|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
16537622|NCT03034239|Experimental|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
16537623|NCT03034239|Placebo Comparator|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
16537624|NCT03034226|Active Comparator|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
16537625|NCT03034226|Active Comparator|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
16537626|NCT03034213|Active Comparator|Treatment|Gentrix(TM) Surgical Matrix
16537627|NCT03034213|Active Comparator|Control|Standard of care mesh
16537628|NCT03034200|Experimental|ONC201 phase 2 d1d2 weekly cohort|625 mg ONC201 by mouth daily for 2 consecutive days weekly
16537629|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.
~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
16537630|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
16537631|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
16537632|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
16537633|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
16537634|NCT03034148|Other|Coronary artery disease|blood sampling for biomarkers assessment in a population undergoing coronary angiogram
16537635|NCT03034135|Experimental|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
16537636|NCT03034109|Experimental|tDCS conventional stimulation|"Transcranial Direct Current Stimulation:
~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes."
16537637|NCT03034109|Experimental|High Definition (HD)-tDCS stimulation|"Transcranial Direct Current Stimulation:
~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes."
16537638|NCT03034109|Sham Comparator|tDCS sham stimulation|"Transcranial Direct Current Stimulation:
~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators."
16537639|NCT03034096|Experimental|Propofol infusion|Maintenance of general anesthesia with propofol infusion
16537640|NCT03034096|Experimental|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
16537641|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
16537642|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
16537643|NCT03034070|Other|Diagnostic performance 3D T1|A 3D T1-weighted GE mDixon MR imaging sequence will be added to the routine 3D T1-weighted FSE sequence. mDixon sub-sequences (Fat and In Phase) are compared to 3D T1-weighted FSE in terms of diagnostic accuracy for M and N staging in prostate cancer patients: Fat, In Phase, Fat+In Phase and the routine 3D T1 will be analyzed separately, blindly and randomly.
16537644|NCT03034057|Other|sayana press|single arm
16537647|NCT03034005|Experimental|Patients with asthma|6 weeks treatment with 1600 ug budesonide
16537648|NCT03034005|No Intervention|Healthy Controls|Healthy controls to establish baseline level of Na/K pumps.
16537649|NCT03033992|Experimental|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
16537650|NCT03033953|Placebo Comparator|Milk supplementation|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g milk protein.
16537657|NCT03033888|Other|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
16537658|NCT03033888|No Intervention|Control Group|
16537659|NCT03033875|Experimental|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program immediately.
16537660|NCT03033875|Other|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Healthy Living Education Program. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
16537661|NCT03033875|No Intervention|Usual Care Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to continue to receive care through whatever arrangement has been in place. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
16537662|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|Implant of Abbott Bioresorbable stent
16537663|NCT03033862||Intervention with Drug Eluting Stent|implant of drug eluting stent
16537664|NCT03033849|Experimental|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
16537665|NCT03033836|Experimental|single arm|ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
16537666|NCT03033823|Experimental|Intervention|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
16537667|NCT03033823|Placebo Comparator|Control|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
16537668|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
16537669|NCT03033797|Experimental|MoviLetrando-MoveHero|Half of the children will play first two different levels of the game MoviLetrando (2 minutes each) and, after the game MoveHero, more 2 minutes
16537670|NCT03033797|Experimental|MoveHero-MoviLetrando|The other half of the children will play first 2 minutes of the game MoveHero and after, two different levels of the Game MoviLetrando, two minutes each.
16537671|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
16537672|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
16537673|NCT03033771|Experimental|Treatment|Patients presenting with chronic type B aortic dissection will have the MFM implanted.
16537674|NCT03033745|Experimental|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
16537675|NCT03033745|Experimental|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
16537676|NCT03033745|Experimental|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
16537677|NCT03033732|Other|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
16537678|NCT03033732|Other|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
16537679|NCT03033719|Active Comparator|Laparotomy|Open surgery
16537680|NCT03033719|Experimental|Laparoscopy|Minimally invasive surgery
16537681|NCT03033706|Active Comparator|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.
16537811|NCT03032848|Active Comparator|Promestriene Group|use of 1 gram per day
16537812|NCT03032848|Active Comparator|Estriol Group|use of 1 gram per day
16538296|NCT03029533|Active Comparator|Leuplin DPS Inj|Leuplin DPS Inj
16537682|NCT03033706|Placebo Comparator|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
16537683|NCT03033693|Other|The deep anesthesia group|
16537684|NCT03033693|Other|The light anesthesia group|
16537685|NCT03033680|Experimental|Multiple System Atrophy (MSA)|Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a [F-18]PBR06 PET scan at baseline, and at 9 months follow-up.
16537686|NCT03033667|Experimental|Glucose group (G group)|patients received 500 cc of glucose 10% that containing 50 g of glucose and provides patients with 200 Kcal with 556 mosmoles/L.
16537687|NCT03033667|Experimental|Lipid Group (L group)|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid and provides patients with 200 Kcal with osmolarity of 380 mosmoles /L.
16537688|NCT03033667|Experimental|Control Group (C group)|patients was fasting overnight from 11 pm till 9 am except for clear fluids that was allowed till 5 am.
16537689|NCT03033654|Experimental|Intervention|Two Consecutive Sunscreen Applications
16537690|NCT03033641|Experimental|Ablation procedure|
16537691|NCT03033628|Experimental|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
16537692|NCT03033628|Active Comparator|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
16537693|NCT03033615|Active Comparator|Chest CT|Conventional processing vs. PixelShine processing
16537694|NCT03033615|Active Comparator|Abdominal CT|Conventional processing vs. PixelShine processing
16537695|NCT03033602|Experimental|Written exposure therapy|5 sessions of imaginal exposure therapy.
16537696|NCT03033602|Active Comparator|CPT, cognitive only|12 sessions of cognitive therapy.
16537697|NCT03033589|Active Comparator|Adductor Canal Nerve Block|
16537698|NCT03033589|Active Comparator|Femoral Nerve block|
16537699|NCT03033576|Active Comparator|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16537700|NCT03033576|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16537701|NCT03033563||Testicular tissue versus ejaculate|Evaluation of ICSI outcome.
16537702|NCT03033550|Experimental|single|single arm- behavioral educational intervention of a brief negotiated mobile application
16537703|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
16537704|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
16537705|NCT03033524|Experimental|Cohort 1|Patients will be treated with 8mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
16537706|NCT03033524|Experimental|Cohort 2|Patients will be treated with 12mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
16537707|NCT03033524|Experimental|Cohort 3|Patients will be treated with 12mg/kg of TTAC-0001 weekly in every 4 weeks of cycle.
16537708|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
16537709|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
16537710|NCT03033498|Experimental|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
16537711|NCT03033498|Experimental|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
16537712|NCT03033498|Experimental|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
16537713|NCT03033498|Experimental|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
16537714|NCT03033498|Experimental|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
16537715|NCT03033498|Experimental|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
16537716|NCT03033498|Experimental|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
16537717|NCT03033498|Experimental|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
16537718|NCT03033485|Experimental|Melanoma patients|Melanoma patients enrolled for the clinical diagnosis study are performed with both 18F-P3BZA PET/CT and18F-FDG PET/CT scans before surgery.
16537719|NCT03033472|Experimental|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
16537720|NCT03033472|Placebo Comparator|Placebo|placebo 30 minutes Orally before treatment
16537721|NCT03033459|Experimental|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
16537722|NCT03033459|Active Comparator|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
16537723|NCT03033446|Experimental|Y90-Radioembolization and Nivolumab|
16537724|NCT03033433|Experimental|DCB-DM101, 500 mg tablet, determination of optimal dose|Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
16537725|NCT03033420|Experimental|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
16537726|NCT03033420|No Intervention|Control group|Treatment-as-usual
16537727|NCT03033407|Experimental|Intervention-Maintenance group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. This study was divided into two phases. In six-month phase 1 study, the participants in I-M group received tailored mobile coaching. And during the second half six-month phase 2 study, they could receive only regular information messages without individualized coaching.
16537728|NCT03033407|Active Comparator|Control-Intervention group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
16537729|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
16537730|NCT03033381|Active Comparator|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
16537731|NCT03033381|Sham Comparator|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
16537732|NCT03033368|Experimental|opened label|Open-label, single-arm study, rilpivirine is the study drug
16537733|NCT03033355||Pre- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction prior to receiving intradetrusor injection of Botulinum Toxin-A.
16537734|NCT03033355||Post- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction who receive intradetrusor Botulinum Toxin-A.
16537735|NCT03033342|Experimental|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
16537736|NCT03033342|Experimental|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
16537737|NCT03033342|Experimental|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
16537738|NCT03033342|Placebo Comparator|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
16537739|NCT03033342|Placebo Comparator|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
16537740|NCT03033342|Placebo Comparator|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
16537741|NCT03033329|Experimental|Single intravenous doses of MRX-4|Single escalating intravenous doses of MRX-4 from 150 mg to 1800 mg
16537742|NCT03033329|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-4
16537743|NCT03033329|Active Comparator|Multiple intravenous doses of MRX-4|Twice daily escalating intravenous doses of MRX-4 for 10 days: 600 mg, 900 mg, 1200 mg, and 1500 mg
16537744|NCT03033329|Placebo Comparator|Multiple intravenous doses of placebo|Twice daily intravenous doses of placebo to match MRX-4 for 10 days
16537745|NCT03033329|Active Comparator|Single dose of intravenous and oral MRX-4|Crossover of single dose of intravenous and oral MRX-4
16537746|NCT03033316|Experimental|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
16537747|NCT03033303|Experimental|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
16537748|NCT03033290|Experimental|Bu-Zhong-Yi-Qi-Tang (BZYQT)|capsule of BZYQT, 4gm tid, 12gm a day for 2 months
16537749|NCT03033290|Placebo Comparator|placebo control|similar placebo capsule 4gm tid, 12gm a day for 2 months
16537750|NCT03033277|Placebo Comparator|Control group|Hormone replacement therapy, placebo transplantation.
16537751|NCT03033277|Experimental|Experimental group|Hormone replacement therapy,HUC-MSCs transplantation.
16537752|NCT03033264|Experimental|BMI>30+Dinoprostone|Women with a BMI>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
16537753|NCT03033264|Experimental|BMI<30+Dinoprostone|Women with a BMI<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
16537754|NCT03033264|Experimental|BMI>30+Cervical ripening balloon|Women with a BMI>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
16537755|NCT03033264|Experimental|BMI<30+Cervical ripening balloon|Women with a BMI<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
16537756|NCT03033251|Active Comparator|Non invasive ventilation|Patients will receive non invasive ventilation with setting decided by the attending physician.
16537757|NCT03033251|Active Comparator|High Flow 50 L/min|High Flow Oxygen Cannula with a flow set at 50 L/min.
16537758|NCT03033251|Active Comparator|High Flow 30 L/min|High Flow Oxygen Cannula with a flow set at 30 L/min.
16537759|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts [2,660 were enrolled].
~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018 [1,525 were enrolled]."
16537760|NCT03033225|Experimental|Treatment (verteporfin, EUS-guided PDT)|Patients receive verteporfin IV and after 60 minutes undergo EUS-guided PDT.
16537761|NCT03033212|Experimental|Early Structured Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 7 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
16537762|NCT03033212|Experimental|Delayed Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 13 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
16537763|NCT03033212|Active Comparator|Self Rehabilitation|Patients will begin Self-Guided Rehabilitation at 7 weeks postoperatively in a self-guided fashion. They will be provided with instructions for recommended exercises. They will undergo rehabilitation for a total of 10 weeks.
16537813|NCT03032848|Placebo Comparator|Vaginal Moisturizer Cream|use of 1 gram per day
16537814|NCT03032835||Study participants|No intervention
16537764|NCT03033199|Active Comparator|Probiotic Agent Combining HD-DXM|"probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
~Dexamethasone 40mg per day, 4 consecutive day"
16537765|NCT03033199|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days
16537766|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
16537767|NCT03033173||CTS group|
16537768|NCT03033173||Healthy subjects|
16537769|NCT03033160|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
16537770|NCT03033160|No Intervention|Observation|Observation
16537771|NCT03033147|Experimental|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
16537772|NCT03033147|Placebo Comparator|Placebo|placebo 30 minutes before root canal treatment
16537773|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
16537774|NCT03033121|Active Comparator|group A|Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
16537775|NCT03033121|Active Comparator|group B|Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
16537776|NCT03033108|Experimental|Emixustat Dose 1|lowest dose of once-daily oral emixustat
16537777|NCT03033108|Experimental|Emixustat Dose 2|middle dose of once-daily oral emixustat
16537778|NCT03033108|Experimental|Emixustat Dose 3|highest dose of once-daily oral emixustat
16537779|NCT03033095|Experimental|etanercept|"The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
~Modality of administration :
~Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit."
16537780|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
16537781|NCT03033082||Normal males|Questionnaire sheets.
16537782|NCT03033069|Experimental|Brexpiprazole Monotherapy|Flexible dose
16537783|NCT03033069|Active Comparator|Brexpiprazole & Zoloft (sertaline) Combination Therapy|Flexible dose
16537784|NCT03033069|Active Comparator|Zoloft (setraline) monotherapy|Flexible dose
16537785|NCT03033069|Placebo Comparator|Placebo|Placebo
16537786|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
16537787|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
16537788|NCT03033043|Experimental|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
16537789|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
16537790|NCT03033017||HIV-infected on antiretroviral therapy 2 years|HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
16537791|NCT03033004|Active Comparator|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
16537792|NCT03033004|Active Comparator|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
16537793|NCT03033004|Active Comparator|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
16537794|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
16537795|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
16537796|NCT03032978|Experimental|Calcium silicate|intervention
16537797|NCT03032978|Active Comparator|Calcium Hydroxide|Comparator
16537798|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
16537799|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
16537800|NCT03032952|Experimental|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
16537801|NCT03032952|No Intervention|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
16537802|NCT03032926||Open Trial|N/A - Open Trial
16537803|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
16537804|NCT03032913||Non-cancer patients|Patients with no Cancer
16537805|NCT03032887|Experimental|voice prompts|Agitation (education, reminders and optimising materials) plus voice prompts
16537806|NCT03032887|Other|no voice prompts|only Agitation (education, reminders and optimising materials); no voice prompts
16583435|NCT02722252||Embryo culture without incorporated camera group|
16537816|NCT03032809||Intracranial vasculopathy|Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.
16537817|NCT03032796|Experimental|BBT|Body-Brain Trainer
16537818|NCT03032796|Active Comparator|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
16537819|NCT03032796|Active Comparator|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
16537820|NCT03032796|Placebo Comparator|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
16537821|NCT03032783|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
16537822|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
16537823|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
16537824|NCT03032757|Experimental|Resting leg of young males|
16537825|NCT03032757|Experimental|Exercising leg of young males|
16537826|NCT03032757|Experimental|Resting leg of elderly males|
16537827|NCT03032757|Experimental|Exercising leg of elderly males|
16537828|NCT03032744|Experimental|Intervention|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the intervention group will be prescribed the appropriate asthma therapy based on their assessment (i.e. providing 'asthma assessment & management'), and receive the morning dose of their daily asthma controller medication at school on school days.
16537829|NCT03032744|Active Comparator|Usual Care|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
16537830|NCT03032731|Experimental|Website and pedometer Intervention|Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals. The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website. For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress. After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
16537831|NCT03032731|Other|Control|Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)). Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks. Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
16537832|NCT03032718|Experimental|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
16537833|NCT03032718|No Intervention|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
16537834|NCT03032705|Experimental|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
16537835|NCT03032705|Active Comparator|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
16537836|NCT03032692|Experimental|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
16537837|NCT03032692|Active Comparator|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
16537838|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
16537840|NCT03032653|Active Comparator|Late WB|Intervention: Patients receive a plaster splint in the operating room. They are not permitted to WB or ROM on the affected limb at this stage. At the first follow-up appointment (two weeks post-op), the splint is removed and a removable pre-fabricated walking boot applied. At this stage the patient is permitted to WB as tolerated while wearing the boot, and to perform ROM exercises with the boot removed. At six weeks post-op, the boot is discontinued and full unrestricted and unprotected weightbearing and ROM is permitted.
16537841|NCT03032653|Experimental|Immediate unprotected WB and ROM|Patient do NOT receive a brace or splint of any kind. They are permitted to weightbear and range of motion as tolerated within the limitations of their own comfort. Use of ambulatory aids of any kind is permitted as needed without restrictions.
16537842|NCT03032640|Active Comparator|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
16537843|NCT03032640|Active Comparator|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
16537844|NCT03032640|Active Comparator|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
16537845|NCT03032640|Active Comparator|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
16537846|NCT03032627|Other|Cardiac surgery|Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.
16537847|NCT03032614|Experimental|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
16537848|NCT03032601|Active Comparator|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 600mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
16537849|NCT03032601|No Intervention|Control Cohort|Standard of Care Treatment
16537850|NCT03032588|Experimental|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
16537851|NCT03032588|Active Comparator|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
16537852|NCT03032575|Other|sample size 100|Study Design: This is a prospective observational cohort of Thai MSM who initiated ART at the time of AHI, defined as the first 30 days after HIV acquisition (Fiebig stages 1 through 5). Volunteers will be examined at baseline to determine the prevalence of HPV infection and HSIL at HIV diagnosis. They will then be followed longitudinally for new incidence of HPV and HSIL, as well as progression or regression of existing lesions.
16537853|NCT03032562||1|Patients with neuromuscular disease
16537854|NCT03032562||2|Patients with chronic obstructive pulmonary disease
16537855|NCT03032549|Experimental|RTD|2.1 g. beta alanine, 1.3 g arginine nitrate, 200 mg caffeine, 65 mg niacin, 325 mcg folic acid, 45 mcg vitamin B12
16537856|NCT03032549|Placebo Comparator|Placebo|dextrose and non-caloric flavoring
16537857|NCT03032536|Experimental|Treatments A, B, C|"Part 1: Cross-Over
~Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.
~Treatment B: AL-3778 2 x 300-mg tablets (fasted) once
~Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
16537858|NCT03032536|Experimental|Treatments D, E, F|"Part 2 (optional): Cross-Over
~Treatment D: AL-3778 2×300-mg tablets (fasted) once.
~Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg
~Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
16537859|NCT03032536|Experimental|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.
~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:
~600mg: 2 x 300-mg OR
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
16537860|NCT03032536|Active Comparator|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
16537861|NCT03032536|Experimental|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.
~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:
~600mg: 2 x 300-mg OR
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
16537862|NCT03032536|Active Comparator|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
16537863|NCT03032536|Experimental|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.
~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:
~600mg: 2 x 300-mg OR
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
16537864|NCT03032523|Experimental|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
16537865|NCT03032523|No Intervention|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
16537866|NCT03032510|Experimental|Eravacycline (Intravenous)/Levofloxacin (Oral)|
16537867|NCT03032510|Active Comparator|Ertapenem (Intravenous)/Levofloxacin (Oral)|
16537940|NCT03031990|No Intervention|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
16537868|NCT03032497|Experimental|EEG-based BCI analysis of fear avoidance|"All participants complete two experiments one after another-EEG patterns, skin conductance and pulse rate are recorded. The EEG cap is mounted on the participant's head, the GSR sensor secured on the fingers and the PPG sensor secured on the wrist using a Velcro strap. Exp 1-participants watch a series of 15, 1 min videos of people doing daily activities. Exp 2-participants do 15 movements (15 reps each in 1 min) as guided by a physiotherapist. 2 identical buzzers (labelled lesser pain and more pain) are available to press accordingly should participants experience 'lesser' or 'more' pain any time during the experiment. If 'more' pain experienced, participants' condition will be assessed and they can choose to continue the experiment at a lower intensity or stop."
16537869|NCT03032484|Experimental|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
16537870|NCT03032484|Experimental|Bevacizumab|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle.
16537871|NCT03032471||DCI group|"Patients that experience DCI, defined as
~Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and
~Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
16537872|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
16537873|NCT03032458|Active Comparator|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
16537874|NCT03032458|Active Comparator|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
16537875|NCT03032458|Active Comparator|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
16537876|NCT03032445|Experimental|Alcoholic beer|At least 6% alcohol content
16537877|NCT03032445|Placebo Comparator|Non alcoholic beer|Less than 0.5% alcohol content
16537878|NCT03032432|Experimental|Dynamic elastic garment and injection|
16537879|NCT03032432|Active Comparator|Corticosteroid injection|
16537880|NCT03032419|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
16537881|NCT03032419|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
16537882|NCT03032406|Experimental|HCQ alone (Arm A)|
16537883|NCT03032406|Experimental|EVE alone (Arm B)|
16537884|NCT03032406|Experimental|combination HCQ and EVE (Arm C)|
16537885|NCT03032406|Experimental|observation (Arm D)|
16537886|NCT03032393|Experimental|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
16537887|NCT03032393|Active Comparator|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
16537888|NCT03032380|Experimental|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
16537889|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
16537890|NCT03032367|Other|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
16537891|NCT03032367|Other|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
16537892|NCT03032354|Experimental|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
16537893|NCT03032354|Placebo Comparator|Placebo arm: Placebo group|Placebo - maltodextrin
16537894|NCT03032341||Patient group|20 patient in poor mobility group (MAT-sf < 51.38 in men and <45.61 in women), mid-mobility group (51.38< MAT-sf≤65.5 in men and 45.61≤MAT-sf<54.02) and high mobility group (MAT-sf>65.5 in men and MAT-sf>54.02 in women) for a total of 60 patients.
16537895|NCT03032341||Surrogate group|A family member/caregiver that attends visits with the patient and will be asked to answer the Mobility Assessment Test questionnaire on behalf of the patient at the initial visit and the follow up visit 1-14 days later.
16537896|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
16537897|NCT03032315|Experimental|TAH(80/10/12.5) tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide(80/10/12.5) tablet
16537898|NCT03032315|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
16537899|NCT03032302|Experimental|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
16537900|NCT03032302|Experimental|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
16537901|NCT03032302|No Intervention|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
16537902|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
16537903|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
16537904|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
16537905|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
16537906|NCT03032250|Experimental|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
16537907|NCT03032250|Experimental|Group II Control Group|Caregivers received standard of care throughout course of intervention, with option to receive study intervention at end of study
16537908|NCT03032237|Experimental|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
16537909|NCT03032237|Placebo Comparator|Standard assortment|The control group receives standard meals and food products.
16537910|NCT03032211|Experimental|Treatment|Alfapump
16537911|NCT03032198|Experimental|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
16537912|NCT03032185|Active Comparator|Active TENS|Active TENS, 10 Hz/200 μs
16537913|NCT03032185|Sham Comparator|Not Active TENS|Sham TENS
16537915|NCT03032159|No Intervention|Control Group|Participants randomized to the control group will receive their usual asthma care from their provider. Additionally, participants in the control group will receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment.
16537916|NCT03032159|Experimental|Text2Breathe Study Group|"The study group spends about 10-20 minutes learning about ways to have better communication with their child's primary care provider about his/her asthma. Additionally this group is enrolled in the Text2Breathe messaging program which sends asthma related educational text messages 2 times a week for 3 months. Participants randomized to the study group will also receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment."
16537917|NCT03032146|Experimental|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
16537918|NCT03032146|No Intervention|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
16537919|NCT03032133|Active Comparator|Regional pain control|Regional pain catheter
16537920|NCT03032133|Experimental|Local pain control|Local intraarticular pain catheter
16537921|NCT03032120|Experimental|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
16537922|NCT03032120|Experimental|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
16537923|NCT03032120|Experimental|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
16537924|NCT03032107|Experimental|Pembrolizumab Combine With Trastuzumab Emtansine|"Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
~Pembrolizumab will be administered prior to T-DM1 administration
~Pembrolizumab will be given at a predetermine dose
~T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
~T-DM1 will be given at a predetermine dose"
16537925|NCT03032094|Active Comparator|1mm thick graft|connective tissue graft of 1mm thickness
16537926|NCT03032094|Active Comparator|2mm thick graft|connective tissue graft of 2mm thickness
16537927|NCT03032081|Experimental|High Intensity Group|3 set of 4 minutes of cycling intense exercise, 4 days per week, for 8 weeks at about 80% to 90% of heart rate reserve
16537928|NCT03032081|Active Comparator|Moderate Intensity Group|40 to 47 minutes of continuous cycling exercise at 50% to 60% of heart rate reserve, 4 days per week, for 8 weeks.
16537929|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
16537930|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.
~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .
~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
16537931|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.
~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .
~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
16537932|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 7|
16537933|NCT03032042|Experimental|azithromycin at day 0, albendazole at day 7|
16537934|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 0|
16537935|NCT03032042|Other|Delayed treatment|albendazole at day 7, azithromycin at day 7
16537936|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
16537937|NCT03032003|Active Comparator|Cysticlean arm|Cysticlean (2 BID for 15 days)
16537938|NCT03032003|Placebo Comparator|Placebo arm|Placebo (2 BID for 15 days)
16537939|NCT03031990|Experimental|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
16537941|NCT03031977|Experimental|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
16537942|NCT03031977|Sham Comparator|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
16537943|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
16537944|NCT03031951|Experimental|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 90-120 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
16537945|NCT03031951|No Intervention|Control Group - Waiting List|"Participants assigned to the control group will have access to the intervention after the 12-month period - waiting list. Meanwhile, participants will receive multimedia health information fortnightly by e-mail over the first 4-month period. The health information covers healthy lifestyle topics.
~During the 12 months of study participation, control group participants will be instructed to maintain their baseline level of physical activity. Individuals assigned to the control group will be asked to maintain their current nutritional practices and physical activity patterns."
16537946|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
16537947|NCT03031925|Experimental|SLE patients|Systemic Lupus Erythematosus
16537948|NCT03031925|Active Comparator|control subjects|age- and sex-matched control subjects
16537949|NCT03031912|Active Comparator|Group 1: 50 HIV-infected adults CD4 ≥ 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
16537950|NCT03031912|Active Comparator|Group 2: 50 HIV-infected adults CD4 > 350 and < 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
16537951|NCT03031912|Active Comparator|Group 3: 50 HIV-infected adults CD4 ≥ 200 and ≤ 350 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of theV920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
16537952|NCT03031912|Active Comparator|Group 4: HIV infected adolescents CD4 ≥ 200 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
16537953|NCT03031899||Rose Bengal positive lesion and biopsy|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
16537954|NCT03031899||Toluidine blue positive lesion and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
16537955|NCT03031886|Experimental|high GI|Cereal, milk, tea, cheese, steamed glutinous rice with chicken, carrots, bread, strawberry jam, margarine, high GI sweetener (sucrose).
16537956|NCT03031886|Experimental|Low GI|Cereal, milk, tea, steamed basmati rice with chicken, spinach, bread, strawberry jam, low GI sweetener (isomaltulose).
16537957|NCT03031873|Other|MRI perfusion imaging|"SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard out-of-the-box protocols.
~Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes."
16537958|NCT03031847|Other|Pacemaker|Cardiac resynchronization therapy Pacemaker
16537959|NCT03031847|Other|Defibrillator|Cardiac resynchronization therapy Defibrillator
16537960|NCT03031821|Experimental|Metformin|Metformin 850 mg PO OD X 30 days, then 850mg PO BID for a total of 18 months
16537961|NCT03031821|Placebo Comparator|Placebo|"Placebo Oral Tablet
~1 tablet (850mg) PO OD X 30 days, then 850mg PO BID for a total of 18 months"
16537962|NCT03031808|Other|Lidocaine spray|Endotracheal lidocaine spray prior to intubation
16537963|NCT03031808|Other|Muscle relaxant|Muscle relaxant prior to intubation
16537964|NCT03031808|Other|No Muscle relaxant, no Lidocaine|'No Muscle relaxant, no Lidocaine Control group
16537965|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
16537966|NCT03031795|Placebo Comparator|placebo|look alike placebo
16537967|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
16537968|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|Placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
16537969|NCT03031756|Experimental|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
16537970|NCT03031756|Active Comparator|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
16538003|NCT03031522|Experimental|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
16538004|NCT03031522|Experimental|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
16537971|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
16537972|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
16537973|NCT03031704||Endoscopic mucosectomy|
16537974|NCT03031691|Experimental|Brontictuzumab and trifluridine/tipiracil|Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label.
16537975|NCT03031678|Other|Study procedures|
16537976|NCT03031665||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
16537977|NCT03031665||Remitted MDD|Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
16537978|NCT03031665||Control Subjects|Subjects who have no history of clinical depression or other psychological disorder.
16537979|NCT03031652||Enrolled group|Patients who had senile cataract and underwent phacoemulsification with topical anesthesia.
16537980|NCT03031639||Endoscopic|This group is the patients who underwent endoscopic approaches thyroidectomy.
16537981|NCT03031639||Conventional|This group is the patients who underwent conventional approach thyroidectomy
16537982|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
16537983|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
16537984|NCT03031613|Experimental|PEEP group|Application of 5 cmH2O PEEP during mechanical ventilation
16537985|NCT03031613|Active Comparator|ZEEP group|No application of PEEP during mechanical ventilation
16537986|NCT03031600|Active Comparator|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
16537987|NCT03031600|Experimental|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
16537988|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
16537989|NCT03031574|Active Comparator|Food Effect|SUVN-D4010 tablets single dose
16537990|NCT03031574|Active Comparator|Gender Effect|SUVN-D4010 tablets single dose
16537991|NCT03031574|Active Comparator|Age Effect|SUVN-D4010 tablets single dose
16537992|NCT03031561|Experimental|Diagnostic (standard ultrasound, MicroPure, biopsy)|Patients undergo grayscale and MicroPure ultrasound imaging followed by sonographic or stereotactic guided core needle biopsy or surgical resection. Surgical specimens are then x-rayed.
16537993|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and CXR as standard of care - received point-of-care ultrasound exam as part of the study
16537994|NCT03031535|Experimental|Study Part 1 - Arm 1|Day 1 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 7 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms.
16537995|NCT03031535|Experimental|Study Part 1 - Arm 2|Day 1 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 5 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 2000 micrograms.
16537996|NCT03031535|Experimental|Study Part 1 - Arm 3|Day 1 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 3 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 1200 micrograms.
16537997|NCT03031535|Experimental|Study Part 1 - Arm 4|Day 1 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 400 micrograms.
16537998|NCT03031535|Experimental|Study Part 2 - Arm 1|Day 1 - 1 microgram/kilogram of growth hormone-releasing hormone (GHRH) + 30 grams arginine hydrochloride; Day 3 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
16537999|NCT03031535|Experimental|Study Part 2 - Arm 2|Day 1 - 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 3 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
16538000|NCT03031522|Experimental|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
16538001|NCT03031522|Experimental|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
16538002|NCT03031522|Experimental|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
16538400|NCT03028909|Active Comparator|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
16538005|NCT03031522|Experimental|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
16538006|NCT03031509|Experimental|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
16538007|NCT03031509|Sham Comparator|debridement surgery|debridement surgery
16538008|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
16538009|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
16538010|NCT03031483|Experimental|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
16538011|NCT03031470|Experimental|Reparixin|Reparixin 2.772 mg/kg/hour 168 hrs continuous intravenous infusion
16538012|NCT03031470|Other|Standard Care Procedures|No treatment; standard care procedure
16538013|NCT03031457||1|Patients undergo primary fascial closure of abdominal donor-site
16538014|NCT03031444|Active Comparator|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab [Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks] or FOLFOX plus Cetuximab [Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks]
16538015|NCT03031444|Active Comparator|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks] or FOLFOX[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks] or CapeOX[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks] was adopted in this control arm.
16538016|NCT03031431|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens [soft, semisoft, or hardened]).
16538017|NCT03031418||Cohort 1|Enroll up to 500 patients to confirm performance of ExoDx Prostate IntelliScore (EPI) for men scheduled for initial biopsy. The treating physician will collect a urine sample from from a consented subject to test before their scheduled prostate biopsy (during your established clinic visit).
16538018|NCT03031418||Cohort 2|Enroll up to 500 patients to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy. The treating physician will collect a urine sample for testing and 2 weeks later discuss whether to perform a prostate biopsy with the subject knowing the results of the urine test and comparing them to the overall consensus report from Cohort 1 as well as other clinical factors the treating physician would otherwise use to determine whether they should have a prostate biopsy.
16538019|NCT03031405|Experimental|Oxytocin and trauma film paradigm|
16538020|NCT03031405|Placebo Comparator|Placebo and trauma film paradigm|
16538021|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
16538022|NCT03031392||non-peri-implantitis patients|Individuals with implants <2mm of radiographic bone loss
16538023|NCT03031379|No Intervention|A - control|standard fast, at least 6 hours prior to tracheotomy
16538024|NCT03031379|Experimental|B - shortened fast|fast of only 45 minutes prior to incision
16538025|NCT03031366|Experimental|3D roadmap|TIPS was established using 3d roadmap guidance
16538026|NCT03031366|Active Comparator|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
16538027|NCT03031353|Experimental|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
16538028|NCT03031353|Active Comparator|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
16538029|NCT03031340|Placebo Comparator|Placebo|
16538030|NCT03031340|Experimental|Pregabalin|
16538031|NCT03031327|Experimental|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
16538032|NCT03031327|Experimental|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
16538033|NCT03031327|Active Comparator|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
16538034|NCT03031314|Active Comparator|Standard suture|standard suture used (monocryl)
16538035|NCT03031314|Active Comparator|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
16538036|NCT03031301|Active Comparator|Vibrant capsule|Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment
16538037|NCT03031301|Sham Comparator|Sham capsule|Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment
16538038|NCT03031288|Experimental|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
16538039|NCT03031288|Experimental|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
16538040|NCT03031262|Active Comparator|High Dose of Cytarabine|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
16538041|NCT03031262|Experimental|HDAC + Chidamide|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
16538042|NCT03031249|Active Comparator|High Dose of Cytarabine|Patients receive high dose of cytarabine.
16538043|NCT03031249|Experimental|HDAC + ATRA + ATO|Patients receive high dose of cytarabine plus ATRA and ATO treatment.
16538044|NCT03031236|Active Comparator|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
16538045|NCT03031236|No Intervention|Only regular health messages|Only regular health message from government health services
16538046|NCT03031223|Experimental|low-level laser therapy|"The treatment group will receive LLLT following the protocol outlined below:
~LLLT protocol - radiance will be administered to the injury site transcutaneously at a wavelength of 808 nm using a Twin Flex Evolution diode laser (MMO Equipamento Opto-Eletronicos, Brazil). Twelve sessions will be held (three per week over four weeks). The dose administered to the surface of the skin will be 983 J/cm2 per session, with a treatment area of 4.72 W/cm² and total radiant energy of 25 J. According to the literature, this dose is capable of enhancing functional recovery following an injury."
16538047|NCT03031223|Placebo Comparator|placebo|laser therapy is applied at low intensity without emitting radiation.
16538048|NCT03031210|Experimental|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
16538049|NCT03031210|Active Comparator|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
16538050|NCT03031197|Experimental|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
16538051|NCT03031197|No Intervention|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
16538052|NCT03031184|Experimental|Mirtazapine|15mg of Mirtazapine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
16538053|NCT03031184|Placebo Comparator|Placebo|Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
16538054|NCT03031171|Experimental|Navigated: Screening patient navigation|Clinic patients who received navigation
16538055|NCT03031171|Active Comparator|Non-Navigated|Randomly matched sample of non-navigated clinic patients
16538056|NCT03031158|Experimental|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
16538057|NCT03031158|Active Comparator|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
16538058|NCT03031145|Active Comparator|Felis Domesticus treated Non-smoker|
16538059|NCT03031145|Active Comparator|Felis Domesticus treated E-cigarette smoker|
16538060|NCT03031145|Active Comparator|Felis Domesticus treated Cigarette smoker|
16538061|NCT03031132|Experimental|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
16538062|NCT03031132|Experimental|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
16538063|NCT03031132|Experimental|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until ~5h post habitual breakfast time on testing day 7.
16538064|NCT03031119|Placebo Comparator|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
16538065|NCT03031119|Experimental|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
16538066|NCT03031119|Experimental|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
16538084|NCT03031041|Active Comparator|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
16538085|NCT03031028|Other|ketogenic diet|Ketogenic diet
16538067|NCT03031093|Experimental|Healthy, non obese + HFNC|Healthy, non obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538068|NCT03031093|Active Comparator|Healthy, non obese|Healthy, non obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538069|NCT03031093|Experimental|COPD, non obese + HFNC|non obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538070|NCT03031093|Active Comparator|COPD, non obese|non obese COPD participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538071|NCT03031093|Experimental|healthy, obese + HFNC|Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538072|NCT03031093|Active Comparator|healthy, obese|Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538073|NCT03031093|Experimental|COPD, obese + HFNC|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538074|NCT03031093|Active Comparator|COPD, obese|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
16538075|NCT03031080|Active Comparator|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
16538076|NCT03031080|No Intervention|Un-Splinted|Patients will not wear a night splint
16538077|NCT03031067|Experimental|Machine perfusion - Kidney|The marginal kidney will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
16538078|NCT03031067|No Intervention|Static cold storage - Kidney|The marginal kidney that was stored to cold (SCS), previously.
16538079|NCT03031067|Experimental|Machine perfusion - Liver|The marginal liver will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
16538080|NCT03031067|No Intervention|Static cold storage - Liver|The marginal liver that was stored to cold (SCS), previously.
16538081|NCT03031054|Experimental|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
16538082|NCT03031054|Active Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
16538083|NCT03031041|Experimental|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
16538816|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
16538086|NCT03031015|Experimental|Cemented K-wire Fixation|The mean age of group A was 41 years (range, 18-63 years). There were 56 male and 11 female patients. The mean time from injury to operation was 5±4.53 days. Injured digits included index (n=24), long (n=19), ring (n=9), and little (n=15) fingers. Types of fractures were transversal (n=31), oblique or spiral (n=14), and comminuted (n=22) fractures. The patients were treated with Cemented K-wire Fixation.
16538087|NCT03031015|Active Comparator|Plating|The mean age of group A was 39 years (range, 19-61 years). There were 51 male and 13 female patients. The mean time from injury to operation was 6±5.53 days. Injured digits included index (n=21), long (n=17), ring (n=10), and little (n=16) fingers. Types of fractures were transversal (n=34), oblique or spiral (n=11), and comminuted (n=19) fractures.The patients were treated with Plating.
16538088|NCT03031002|Experimental|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
16538089|NCT03031002|No Intervention|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
16538090|NCT03030989|Active Comparator|Chlorhexidine Gluconate 2% Wipe|
16538091|NCT03030989|Placebo Comparator|Placebo wipe|
16538092|NCT03030976|Experimental|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
16538093|NCT03030976|Experimental|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
16538094|NCT03030963|Experimental|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
16538095|NCT03030963|Active Comparator|Control group|ventilator inspiration to expiration ratio will be set 1:2.
16538096|NCT03030950|Experimental|Dexmedetomidine group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
16538097|NCT03030950|Placebo Comparator|Control group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
16538098|NCT03030937|Experimental|Irinotecan plus apatinib|"Irinotecan:160mg/m2, ivgtt,given on the eighth day; Apatinib:initial dose:250mg,oral,once a day, after meal ( try to take the medicine at the same time of the dauntoy ).
~Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities."
16538099|NCT03030937|Active Comparator|Irinotecan|Irinotecan:180mg/m2, ivgtt,given on the eighth day. Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities.
16538100|NCT03030911|Active Comparator|Dexmedetomidine group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.
~Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1)
~Intervention: indirect calorimetry"
16538101|NCT03030911|Placebo Comparator|midazolam group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.
~Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1.
~Intervention: indirect calorimetry"
16538102|NCT03030898|Other|respiratory variation of the right internal jugular vein|
16538103|NCT03030885|Experimental|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.
~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
16538104|NCT03030872||Predicate software|Olea Sphere PACS with Perfusion and DWI Modules
16538105|NCT03030872||Investigational software|Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging
16538106|NCT03030859|Experimental|Group I (Usual Care)|Patients receive monthly automated system telephone call for 12 months.
16538107|NCT03030859|Experimental|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
16538108|NCT03030859|Experimental|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
16538109|NCT03030846|Experimental|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
16538110|NCT03030846|Experimental|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
16538111|NCT03030820|Experimental|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
16538112|NCT03030794|Active Comparator|Repetitive TMS|Subjects will receive the repetitive transcranial magnetic stimulation study procedure.
16538113|NCT03030794|Placebo Comparator|No (blocked) repetitive TMS|Subjects will not receive the repetitive transcranial magnetic stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked.
16538114|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
16538115|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
16538116|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
16538117|NCT03030729||Intermediate AMD|
16538118|NCT03030729||Advanced AMD|
16538119|NCT03030729||DR without macular edema|
16538120|NCT03030729||DR with macular edema|
16538121|NCT03030716|Experimental|0.03 mg 95% condensed proanthocyanidin|0.03 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.03 g 95% condensed proanthocyanidins from grape seed extract at week 4
16538122|NCT03030716|Experimental|0.25 g 95% condensed proanthocyanidin|0.25 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.25 g 95% condensed proanthocyanidins from grape seed extract at week 4
16538123|NCT03030716|Experimental|1.5 g 95% condensed proanthocyanidin|1.5 g 95% condensed proanthocyanidins from grape seed extract at week 0 1.5 g 95% condensed proanthocyanidins from grape seed extract at week 4
16538124|NCT03030703|Experimental|350 mg phytic acid|350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
16538125|NCT03030690|Experimental|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
16538126|NCT03030690|Active Comparator|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
16538127|NCT03030690|Active Comparator|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
16538128|NCT03030677|Other|Interventional Without Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound without injecting 10 ml of lidocaine 1% as a dissecting solution
16538129|NCT03030677|Other|Interventional With Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound after injecting 10 ml of lidocaine 1% as a dissecting solution
16538130|NCT03030664|Active Comparator|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
16538131|NCT03030664|Placebo Comparator|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
16538132|NCT03030651|Experimental|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
16538133|NCT03030651|No Intervention|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
16538134|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
16538135|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
16538136|NCT03030625|Other|IGRT/VMAT focal therapy boost to DIL|Localized prostate cancer (PCa) of intermediate and high risk according to NCCN criteria
16538137|NCT03030612|Experimental|ARGX-110 with Azacytidine (AZA)|Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV). Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m^2 BSA, administered SC/IV as per local practice.
16538138|NCT03030599|Placebo Comparator|Placebo|Placebo
16538139|NCT03030599|Experimental|JZP-258|JZP-258
16538140|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
16538141|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:
~75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),
~50 patients with Parkinson's disease dementia (PDD),
~50 patients with Dementia with Lewy Bodies (DLB) and
~25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
16538142|NCT03030586||Healthy Controls|200 healthy subjects
16538143|NCT03030573|Other|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
16538144|NCT03030560|Active Comparator|Lidocaine group|Patients will receive lidocaine infusion.
16538145|NCT03030560|Placebo Comparator|Control group|Patients will receive 0.9% Sodium-chloride infusion infusion
16538146|NCT03030547|Experimental|Muscle Disease Group|Adult patients with muscle diseases diagnosed by neurologist, will wear SenseWear activity monitor for 5 days
16538147|NCT03030547|Active Comparator|Healthy Individuals Group|Healthy individuals with similar demographic characteristics as adult patients with muscle diseases, will wear SenseWear activity monitor for 5 days
16538150|NCT03030521||experimental group|In this group, the specimen of aortic wall is bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
16538151|NCT03030521||control group|In this group, the specimen of aortic wall is not bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
16538152|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
16538153|NCT03030495||Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve<2 & Index of microvascular resistance>25U
16538154|NCT03030495||No Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve>2 & Index of microvascular resistance<25U
16538155|NCT03030482|Experimental|Touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
16538156|NCT03030482|No Intervention|control|standard care ICU
16538157|NCT03030469|Experimental|10-pill default|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
16538158|NCT03030469|Experimental|5-pill default|New opioid analgesic prescriptions will automatically default to 5 pills.
16538159|NCT03030469|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
16538160|NCT03030456|No Intervention|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
16538161|NCT03030456|Experimental|Power Plate®|Power Plate®: training of elderly women
16538162|NCT03030443||Oral Sedation|"Patients in this group will receive a standard procedure first trimester abortion using oral sedation for pain management following the clinic's protocol.
~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
16538163|NCT03030443||Nitrous Oxide|"Patients in this group will receive a standard procedure first trimester abortion using titrated nitrous oxide for pain management following the clinic's protocol.
~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
16538164|NCT03030430|Experimental|BAT1706|BAT1706 injection
16538165|NCT03030430|Active Comparator|EU-sourced Avastin|EU-sourced Avastin
16538166|NCT03030430|Active Comparator|US-sourced Avastin|US-sourced Avastin
16538170|NCT03030365||Healthy Controls|"Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
16538171|NCT03030365||Amnestic Mild cognitive impaired|"Patients diagnosed with mild cognitive impairment, exhibiting impairment mostly in memory that is significant but does not interfere with everyday activities.
~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
16538172|NCT03030365||Alzheimer's disease patients|"Patients exhibiting significant loss of intellectual ability that interferes with everyday functioning that meet Alzheimer's pattern of decline, and following exclusion of alternative neurodegenerative, cerebrovascular, and metabolic etiologies.
~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
16538173|NCT03030352|Experimental|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
16538174|NCT03030352|No Intervention|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
16538175|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
16538176|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
16538177|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
16538178|NCT03030326|Experimental|Heart rate variability biofeedback|This group will receive treatment in the first three months of the study and will be observed during the second three months
16538179|NCT03030326|No Intervention|Observation first|This group will be observed during the first three months and given biofeedback during the second three months
16538180|NCT03030313|Experimental|Respiration rate monitoring|Reassure Non-Contact Respiration Monitor
16538181|NCT03030300|Experimental|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
16538182|NCT03030287|Experimental|OMP-305B83 plus paclitaxel|
16538183|NCT03030274|Experimental|Occlutech AFR Device|Prospective, non-randomized, pilot study to assess safety and efficacy of a novel Atrial Flow Regulator in Heart Failure Patients with with reduced Ejection Fraction (HFrEF) and Heart Failure Patients with preserved Ejection Fraction (HFpEF); the AFR-Prelieve Trial
16538185|NCT03030248|Active Comparator|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
16538186|NCT03030248|Placebo Comparator|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
16538187|NCT03030235|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks
16538188|NCT03030235|Placebo Comparator|Placebo|Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks
16538189|NCT03030222|Active Comparator|Empagliflozin|Empagliflozin 10 mg tab, once daily, for 12 weeks
16538190|NCT03030222|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 12 weeks
16538191|NCT03030209||Distal Pancreatectomy|Patients undergoing distal pancreatectomy
16538192|NCT03030196|Active Comparator|Denosumab|subcutaneous injection with 60 mg Denosumab once
16538193|NCT03030196|Placebo Comparator|Placebo|subcutaneous injection with NaCl once
16538194|NCT03030183|Experimental|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
16538195|NCT03030170|Experimental|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
16538196|NCT03030170|Active Comparator|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
16538197|NCT03030157|Experimental|Long-term Intravesical Instillation of pirarubicin(THP)|A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 72-168 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
16538198|NCT03030157|Active Comparator|Single Intravesical Instillation of pirarubicin|A single intravesical instillation of THP after nephroureterectomy was performed. This instillation was initiated within 72-168 hours after surgery . THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
16538199|NCT03030144|No Intervention|Control group|Routine nursing care
16538200|NCT03030144|Other|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
16538201|NCT03030131|Experimental|Durvalumab|durvalumab 750 mg IV J1, J15, J29
16538202|NCT03030118|Active Comparator|Hydroxychloroquine|Hydroxychloroquine will be administered as a once daily dose of 200 or 400 mg, based on the patient's weight. Treatment will be for 96 weeks.
16538203|NCT03030118|Placebo Comparator|Placebo oral capsule|Placebo will be administered as one or two capsules as a single daily dose, based on the patient's weight. Treatment will be for 96 weeks.
16538204|NCT03030105|Placebo Comparator|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
16538205|NCT03030105|Placebo Comparator|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
16538206|NCT03030105|Experimental|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
16538207|NCT03030105|Experimental|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
16538208|NCT03030105|Active Comparator|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
16538209|NCT03030105|Experimental|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
16538210|NCT03030092|No Intervention|Control group|Today's standard care
16538211|NCT03030092|Experimental|Intervention group|Maximal Strength Training
16538212|NCT03030079|Experimental|Experimental Electrical stimulation Regimen|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
16538213|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
16538214|NCT03030053|Experimental|Active|Cocoa-Flavanol Supplements: 3 capsules per day each containing 300mg (total dose of 900mg daily) for 24 weeks
16538215|NCT03030053|Placebo Comparator|Control|Control Supplements: 0mg cocoa-flavanols per day for 24 weeks
16538216|NCT03030040|Experimental|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
16538217|NCT03030040|No Intervention|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
16538218|NCT03030027|Experimental|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
16538219|NCT03030027|Other|Basic Skills Building|This arm focuses on skill building.
16538220|NCT03030014|Experimental|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.
~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
16538292|NCT03029559|Sham Comparator|Sham IH|Sham intermittent hypoxia subjects will be exposed to a single 45-minute session of sham IH alone.
16538817|NCT03026036||HC|Healthy control participants
16538221|NCT03030014|Placebo Comparator|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
16538222|NCT03030001|Experimental|PD-1 antibody expressing CAR-T cells|PD-1 antibody expressing mesothelin specific CAR-T cells
16538223|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
16538224|NCT03029988|Experimental|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.
~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
16538225|NCT03029975|Active Comparator|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
16538226|NCT03029975|Experimental|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
16538227|NCT03029962|Experimental|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
16538228|NCT03029962|No Intervention|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
16538229|NCT03029949|Experimental|ACT with VR|acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management
16538230|NCT03029949|Active Comparator|Self-treatment VR|self-treatment vestibular rehabilitation in addition to clinical management
16538231|NCT03029936||Obesity Group|
16538232|NCT03029936||Asthma Group|
16538233|NCT03029936||Obesity-Asthma Group|
16538234|NCT03029936||Control|
16538235|NCT03029923|Experimental|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
16538236|NCT03029923|Active Comparator|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
16538237|NCT03029910|Experimental|Cryotherapy and eccentric exercise|
16538238|NCT03029910|Experimental|Vibration and eccentric exercise|
16538239|NCT03029910|No Intervention|Control|
16538240|NCT03029897|Experimental|experimental|Patients are educated on the use of a mobile application to report adverse drug reactions
16538241|NCT03029897|No Intervention|control|Patients are not educated on the use of a mobile application to report adverse drug reactions
16538242|NCT03029884|Active Comparator|Active DBS|Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in active DBS, blinded to the participant.
16538243|NCT03029884|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. Brain recordings will remain active during this period. Both thalamic pain syndrome and phantom pain participants will participate in inactive DBS, blinded to the participant.
16538244|NCT03029871|Experimental|Arm 1|Nine subjects (3 cohorts, 3 subjects/cohort) with medically inoperable stage I/IIA (T1a - T2b) NSCLC with tumors measuring > 2 to ≤ 5 cm will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels (1 x 1011 vp, 3 x 1011 vp, 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors). Two days later, subjects will be administered (orally) a 10 day course of 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy along with 48 Gy (4 fractions of 12 Gy) of SBRT. Prior to and following the adenovirus injection, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify HSV-1 TK gene expression.
16538245|NCT03029845|Active Comparator|propranolol 1|20 mg propranolol twice a day
16538246|NCT03029845|Active Comparator|propranolol 2|10 mg propranolol twice a day
16538247|NCT03029845|Placebo Comparator|Placebo|Placebo twice a day
16538248|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
16538249|NCT03029832|Active Comparator|Atezolizumab|
16538250|NCT03029819|Active Comparator|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
16538251|NCT03029819|Experimental|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
16538252|NCT03029806|Active Comparator|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
16538253|NCT03029806|Placebo Comparator|Cauc risk allele|Caucasians carrying the LSD1 affected allele
16538254|NCT03029806|Placebo Comparator|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
16538255|NCT03029806|Placebo Comparator|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
16538293|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.
~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
16538294|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
16538256|NCT03029793||Biomarkers and Imaging analysis|This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
16538257|NCT03029780|Experimental|Co-Administration|Nivolumab and Ipilimumab Co-Administration
16538258|NCT03029780|Experimental|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
16538259|NCT03029767|Experimental|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
16538260|NCT03029767|Experimental|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
16538261|NCT03029767|Experimental|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
16538262|NCT03029767|No Intervention|Control group|standard or usual activity carried out.Additional intervention will not be given.
16538263|NCT03029754|Experimental|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
16538264|NCT03029754|No Intervention|No leg raise|Participants will lie flat prior to IV insertion.
16538265|NCT03029741|Experimental|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.
~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy subjects."
16538266|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
16538267|NCT03029715|Other|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
16538268|NCT03029715|Other|Inhalation anaesthesia|Desflurane Remifentanil
16538269|NCT03029702|Active Comparator|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
16538270|NCT03029702|Active Comparator|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
16538271|NCT03029689|Experimental|Current ART + Raltegravir|Current ART + Raltegravir
16538272|NCT03029689|Placebo Comparator|Current ART + placebo|Current ART + placebo
16538273|NCT03029676|Experimental|Group B|spinal anesthesia premedication with benzodiazepine and opioid
16538274|NCT03029676|Active Comparator|Group K|spinal anesthesia premedication with opioid
16538275|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
16538276|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
16538277|NCT03029637|Experimental|No preparation resin bonded bridges|RBBs with no or minimal preparation of their abutment teeth
16538278|NCT03029637|Active Comparator|Routine resin bonded bridges|RBBs with routine tooth preparation of their abutment teeth
16538279|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
16538280|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
16538281|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16538282|NCT03029585|Experimental|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
16538283|NCT03029585|Experimental|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
16538284|NCT03029585|Experimental|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
16538285|NCT03029585|Experimental|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
16538286|NCT03029585|Active Comparator|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
16538287|NCT03029572|Active Comparator|Standard diet|Standard healthy diet after RYGB surgery
16538288|NCT03029572|Experimental|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
16538289|NCT03029559|Experimental|IH + ITL|Subjects will be exposed to a session of Intermittent hypoxia (IH) (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of Inspiratory threshold loading (ITL) at 80%MIP (10 breaths per set).
16538290|NCT03029559|Experimental|Intermittent hypoxia (IH)|Subjects will only be exposed to a session of intermittent hypoxia.
16538291|NCT03029559|Experimental|Sham IH + ITL|Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
16538297|NCT03029520|Active Comparator|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
16538298|NCT03029520|Active Comparator|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
16538299|NCT03029520|Active Comparator|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
16538300|NCT03029520|Active Comparator|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
16538301|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT
~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
16538302|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
16538303|NCT03029494|Experimental|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
16538304|NCT03029494|Active Comparator|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
16538305|NCT03029494|No Intervention|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
16538306|NCT03029468|Experimental|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
16538307|NCT03029468|Active Comparator|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their personal or study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
16538308|NCT03029468|No Intervention|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
16538309|NCT03029455|Experimental|Part A: VX-659 or Matching Placebo|Part A includes single-dose escalation.
16538310|NCT03029455|Experimental|Part B: VX-659 or Matching Placebo|Part B includes multiple-dose escalation.
16538311|NCT03029455|Experimental|Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
16538312|NCT03029455|Experimental|Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part D includes subjects with CF. Participants will receive TC or matching placebos.
16538313|NCT03029442|Experimental|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
16538314|NCT03029442|Placebo Comparator|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
16538315|NCT03029442|Experimental|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
16538316|NCT03029442|Placebo Comparator|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
16538317|NCT03029429|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
16538318|NCT03029429|Placebo Comparator|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
16538319|NCT03029416|Experimental|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
16538320|NCT03029416|Experimental|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
16538321|NCT03029403|Experimental|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
16538322|NCT03029403|Experimental|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
16538323|NCT03029403|Experimental|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
16538324|NCT03029403|Experimental|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
16538325|NCT03029390|Experimental|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.
~The patients will have a forced titration period:
~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
16538369|NCT03029091|Experimental|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
16538370|NCT03029091|Experimental|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
16538326|NCT03029390|Experimental|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.
~The patients will have a forced titration period:
~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).
~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
16538327|NCT03029377|Experimental|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
16538328|NCT03029377|Active Comparator|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
16538329|NCT03029364||Male and Female Adults|Completion of Study Protocol
16538330|NCT03029351|Experimental|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
16538331|NCT03029351|Placebo Comparator|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
16538332|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
16538333|NCT03029312|Experimental|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
16538334|NCT03029312|No Intervention|Regular Care|Regular Care, including physiotherapy for 5 months
16538335|NCT03029299|No Intervention|Control|Subjects receive standard of care testing as determined by the clinician.
16538336|NCT03029299|Experimental|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
16538337|NCT03029286|Experimental|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
16538338|NCT03029286|Active Comparator|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
16538339|NCT03029273|Experimental|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with Cyclophosphamide (250-500mg/m2/day) and Fludarabine (25mg/m2/day) for 3 days.
~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject."
16538340|NCT03029260|Experimental|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
16538341|NCT03029260|Active Comparator|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
16538342|NCT03029247|Active Comparator|Participants receiving Epoetin alfa|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
16538343|NCT03029247|Experimental|Participants receiving Daprodustat|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
16538344|NCT03029234|Experimental|Carfilzomib with Dexamethasone|"Participants will receive carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).
~Participants will also receive 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.
~Participants will receive treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, non-compliance, or intercurrent illness or worsening of a chronic condition, whichever occurs first."
16538397|NCT03028922|Other|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
16538398|NCT03028909|Experimental|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
16538399|NCT03028909|Experimental|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
16538345|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
16538346|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
16538347|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
16538348|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
16538351|NCT03029195|Experimental|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
16538352|NCT03029195|No Intervention|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
16538353|NCT03029195|No Intervention|Age matched Norms|Normal (non-cleft) age matched infants
16538354|NCT03029182|Experimental|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
16538355|NCT03029182|Active Comparator|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
16538356|NCT03029169|Active Comparator|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.
~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
16538357|NCT03029169|Active Comparator|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.
~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
16538358|NCT03029156|Active Comparator|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
16538359|NCT03029156|Experimental|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
16538360|NCT03029143|Experimental|Vedolizumab IV Standard Treatment Arm|Vedolizumab 300 milligram (mg), IV infusion on Day 1 and Week 2 as induction therapy in Lead-in Period followed by vedolizumab 300 mg, IV infusion, once in every 8 weeks (Q8W) (Weeks 6, 14, and 22) as standard treatment.
16538361|NCT03029143|Experimental|Vedolizumab IV Dose Optimized Arm|Vedolizumab 300 mg, IV infusion on Day 1 and Week 2 as induction therapy in Lead-in Period followed by Regimen A: vedolizumab 600 mg, IV infusion at Week 6 and 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26), or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 6, 10, 14, 18, 22 and 26). At Week 14 and beyond, dosing in the dose optimized arm will continue as previously assigned unless the subjects most recent preceding serum vedolizumab concentration is >90 microg/mL. In the event that steady-state Ctrough levels exceed safety exposure limits of 90 microg/mL, the next dose will be withheld and another Pharmacokinetics (PK) sample will be taken 1 week prior to the next scheduled dose. If at the next scheduled visit the Ctrough is still >90 microg/mL, the next dose will be similarly held and the PK repeated 1 week prior to the next scheduled dose. Once Ctrough is <90 microg/mL, the subject will move to the next lowest dose.
16538362|NCT03029130|Experimental|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
16538363|NCT03029130|No Intervention|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
16538364|NCT03029117||corrected and uncorrected rheumatic valve lesions|
16538365|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
16538366|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
16538367|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
16538368|NCT03029091|Experimental|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
16538371|NCT03029078|Experimental|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.
~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.
~Patient will be monitored for 24h to rule out potential adverse events."
16538372|NCT03029065||lung adenocarcinoma with brain (meningeal) metastasis|
16538373|NCT03029052|No Intervention|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
16538374|NCT03029052|Experimental|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
16538375|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
16538376|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
16538377|NCT03029039||blood donor voluntary|Blood samples will be collected.
16538378|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
16538379|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
16538380|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
16538381|NCT03029013|Experimental|experimental group|Apatinib and chemotherapy
16538382|NCT03029000|Experimental|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.
~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.
~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
16538383|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
16538384|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
16538385|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
16538386|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
16538387|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
16538388|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
16538389|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
16538390|NCT03028974|Other|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
16538391|NCT03028974|Other|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
16538392|NCT03028961|Experimental|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
16538393|NCT03028961|Active Comparator|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
16538394|NCT03028948|Experimental|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
16538395|NCT03028948|Active Comparator|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
16538396|NCT03028935|Experimental|Prevention (exercise, nutrition education program)|Exercise Intervention & Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
16538401|NCT03028896|No Intervention|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
16538402|NCT03028896|Experimental|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
16538403|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
16538404|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
16538405|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
16538406|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
16538407|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
16538408|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
16538409|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
16538410|NCT03028844|No Intervention|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
16538411|NCT03028844|Experimental|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
16538412|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
16538413|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
16538414|NCT03028805|No Intervention|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
16538415|NCT03028805|Active Comparator|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
16538416|NCT03028805|Active Comparator|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
16538417|NCT03028805|Active Comparator|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
16538418|NCT03028792|Experimental|Attention Modification Training|Attention Modification Program Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral stimuli.
16538419|NCT03028792|Sham Comparator|Attention Control Training|Placebo Comparator: Attention Control Condition Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral stimuli or the threat stimuli.
16538420|NCT03028779|Experimental|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
16538421|NCT03028766|Experimental|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
16538422|NCT03028766|Experimental|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
16538423|NCT03028753|Experimental|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
16538424|NCT03028740|Experimental|Drug: Cenicriviroc|150 mg cenicriviroc
16538425|NCT03028740|Placebo Comparator|Drug: Placebo|Placebo
16538426|NCT03028727|Active Comparator|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
16538427|NCT03028727|Experimental|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
16538428|NCT03028714|Experimental|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
16538429|NCT03028714|No Intervention|Control group|Participants in the control group will receive no intervention.
16538430|NCT03028701|Experimental|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
16538431|NCT03028688|No Intervention|Current standard of care|Participants in the current standard of care will receive the usual anesthesia care for upper GI endoscopy. In addition participants will have transcutaneous PCO2 measurements performed.
16538432|NCT03028688|Experimental|High flow nasal cannula group|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen and will also have transcutaneous PCO2 measurements performed.
16538433|NCT03028675||Multiple Sclerosis|
16538434|NCT03028675||Healthy Volunteer|10 age-matched control volunteers
16538435|NCT03028662|Experimental|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
16538534|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
16538436|NCT03028662|Active Comparator|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
16538437|NCT03028662|Active Comparator|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
16538438|NCT03028649|Experimental|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.
~Interventions:
~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.
~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
16538439|NCT03028649|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.
~Interventions:
~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.
~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
16538440|NCT03028623|Other|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
16538441|NCT03028623|Experimental|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
16538442|NCT03028610|Experimental|Acessa™ System|radiofrequency generator
16538443|NCT03028597|Experimental|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
16538444|NCT03028597|Active Comparator|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
16538445|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:
~Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation
~Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor
~Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians
~Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
16538446|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.
~Survey of clinicians will be sent via e-mail."
16538447|NCT03028571|Placebo Comparator|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
16538448|NCT03028571|Experimental|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
16538449|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
~Between the ages of 21-35 years old."
16538450|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes >5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
16538451|NCT03028545|Other|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
16538452|NCT03028545|Other|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
16538453|NCT03028545|Other|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
16538454|NCT03028545|Other|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
16538455|NCT03028532|Experimental|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
16538456|NCT03028519|Experimental|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
16538457|NCT03028493|Experimental|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
16538458|NCT03028493|Active Comparator|Original SAFE Intervention|Original version of the SAFE intervention.
16538460|NCT03028467|Experimental|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
16538461|NCT03028467|Experimental|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
16539088|NCT03024060|Experimental|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
16538462|NCT03028467|Experimental|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
16538463|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
16538464|NCT03028454|Experimental|Ginger Root Capsule|
16538465|NCT03028454|Placebo Comparator|Placebo Capsule|
16538466|NCT03028441|Experimental|Group 1- low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
16538467|NCT03028441|Experimental|Group 2-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
16538468|NCT03028441|Experimental|Group 3-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
16538469|NCT03028441|Experimental|Group 4 -high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
16538470|NCT03028441|Experimental|Group 5-high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
16538471|NCT03028441|Experimental|Group 6-dose-High Dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
16538472|NCT03028428|Experimental|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
16538473|NCT03028428|Active Comparator|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
16538474|NCT03028415|Experimental|AMPLEX|
16538475|NCT03028415|Active Comparator|Autogenous Bone Graft (ABG)|
16538476|NCT03028402||Asymptomatic Controls|Individuals who have no history of neck pain, trauma or surgery, similar in age and sex to the surgical patients
16538477|NCT03028402||C5-C6 arthrodesis|Patients scheduled to undergo C5-C6 anterior cervical arthrodesis
16538478|NCT03028402||C6-C7 arthrodesis|Patients scheduled to undergo C6-C7 anterior cervical arthrodesis
16538479|NCT03028402||C4-C5-C6 arthrodesis|Patients scheduled to undergo C4-C5-C6 anterior cervical arthrodesis
16538480|NCT03028402||C5-C6-C7 arthrodesis|Patients scheduled to undergo C5-C6-C7 anterior cervical arthrodesis
16538481|NCT03028389|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
16538482|NCT03028389|No Intervention|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
16538483|NCT03028376||Moderate TBI patients|GCS 9-13
16538484|NCT03028363|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
16538485|NCT03028363|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
16538486|NCT03028350|Experimental|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
16538487|NCT03028350|Placebo Comparator|Placebo Oral Capsule|Oral placebo daily for 8 weeks
16538488|NCT03028337|Experimental|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
16538489|NCT03028337|Active Comparator|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
16538490|NCT03028324|Experimental|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
16538491|NCT03028311|Other|Treatment (angiography, yttrium Y-90 radioembolization)|"The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging.
~All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours."
16538492|NCT03028298|Experimental|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
16538493|NCT03028298|Experimental|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
16538494|NCT03028285|Experimental|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
16538495|NCT03028285|Experimental|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
16538496|NCT03028285|Experimental|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
16538497|NCT03028272|Active Comparator|Fascia|Autologous donor substrate
16538498|NCT03028272|Experimental|Skye Barrier|Amniotic membrane allograft
16538499|NCT03028259||lab results|monitoring of
16538500|NCT03028246|Experimental|ExAblate 4000 System|MR-Guided Focused Ultrasound
16538501|NCT03028233|Experimental|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
16539089|NCT03024060|Experimental|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
16538502|NCT03028233|Active Comparator|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
16538503|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
16538504|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
16538505|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
16538506|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
16538507|NCT03028194|Experimental|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
16538508|NCT03028194|Placebo Comparator|Placebo|No procedure performed after delivery of the placenta.
16538509|NCT03028181||1|Control group non-exposed to tobacco smoking
16538510|NCT03028181||2|Control group exposed to tobacco smoking
16538511|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
16538512|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
16538513|NCT03028168|Experimental|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
16538514|NCT03028168|Experimental|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
16538515|NCT03028168|Experimental|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
16538516|NCT03028155|Active Comparator|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
16538517|NCT03028155|Active Comparator|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
16538518|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
16538519|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
16538520|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
16538521|NCT03028129|Experimental|Treatment|Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
16538522|NCT03028129|Placebo Comparator|Control|Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).
16538523|NCT03028116|Active Comparator|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
16538524|NCT03028116|Placebo Comparator|Placebo|Water for Injection
16538525|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.
~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
16538526|NCT03028077|Experimental|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
16538527|NCT03028077|Experimental|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
16538528|NCT03028077|Placebo Comparator|Placebo|Placebo for 12 weeks
16538529|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
16538530|NCT03028038|Experimental|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
16538531|NCT03028038|Experimental|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
16538532|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
16538533|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
16538535|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
16538536|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
16538537|NCT03027999|Experimental|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
16538538|NCT03027999|No Intervention|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
16538539|NCT03027986|Experimental|postural rehabilitation program based on sensory-motor control|
16538540|NCT03027986|No Intervention|Standard physiotherapy|
16538541|NCT03027973|Experimental|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
16538542|NCT03027973|Active Comparator|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
16538543|NCT03027960|Experimental|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
16538544|NCT03027960|Experimental|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
16538545|NCT03027947|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
16538546|NCT03027934|Active Comparator|Group 1|
16538547|NCT03027934|Active Comparator|Group 2|
16538548|NCT03027921|Experimental|hepatic ultrasound|all patients will have hepatic ultrasound
16538549|NCT03027908|Experimental|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
16538550|NCT03027908|Active Comparator|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
16538551|NCT03027895|Experimental|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
16538552|NCT03027895|Active Comparator|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
16538553|NCT03027869|Active Comparator|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
16538554|NCT03027869|Sham Comparator|Sham tDCS|30sec ramp-up and 30sec ramp-down
16538555|NCT03027869|Active Comparator|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
16538556|NCT03027856|Experimental|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
16538557|NCT03027843|Active Comparator|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
16538558|NCT03027843|No Intervention|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
16538559|NCT03027830|Experimental|iFR pressure-wire|
16538560|NCT03027830|Active Comparator|Conventional|
16538561|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
16538562|NCT03027791|Experimental|Parishoners at HUMC|African-American adults aged 18-85 who attend services at Holman United Methodist Church will be exposed to Group Sessions for 12 weeks and Virtual Reality for 6 weeks.
16538563|NCT03027778|Experimental|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
16538564|NCT03027778|No Intervention|Usual care|Participants receive their usual dialysis for the duration of 4 months.
16538565|NCT03027765||Egyptian children|"Population1:
~Egyptian children with constructed space maintainers at Cairo University."
16538566|NCT03027765||Pediatric dentists|"Population2:
~Pediatric dentists at Cairo University."
16538567|NCT03027752|Active Comparator|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
16538568|NCT03027752|Experimental|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
16538569|NCT03027739|Experimental|Arm 1|CART-19 cells treated
16538570|NCT03027726|Active Comparator|Control group|Family-based lifestyle education and psycho-educational program
16538571|NCT03027726|Experimental|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
16538572|NCT03027713|Other|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
16538573|NCT03027713|Other|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
16538574|NCT03027700|Active Comparator|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
16538575|NCT03027700|Active Comparator|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
16538576|NCT03027700|Active Comparator|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
16538577|NCT03027700|Active Comparator|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
16538578|NCT03027687|Experimental|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
16538579|NCT03027687|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
16538580|NCT03027674|Experimental|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
16538581|NCT03027674|Active Comparator|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
16538582|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
16538583|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
16538584|NCT03027648|Other|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
16538585|NCT03027635|Experimental|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
16538586|NCT03027635|Active Comparator|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
16538587|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
16538588|NCT03027609|Experimental|AR-105|One intravenous infusion of AR-105 20mg/'kg
16538589|NCT03027609|Placebo Comparator|Control|Matching placebo
16538590|NCT03027596|Experimental|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
16538591|NCT03027596|No Intervention|Control group|no intervention
16538592|NCT03027583|Experimental|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
16538593|NCT03027583|Placebo Comparator|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
16538594|NCT03027570|Experimental|Control|Five-month program at two centers for the treatment of overweight children.
16538595|NCT03027570|Experimental|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
16538596|NCT03027557|Experimental|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
16538597|NCT03027557|Active Comparator|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
16538598|NCT03027557|Placebo Comparator|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
16538599|NCT03027544|Experimental|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.
~Intervention：tomotherapy"
16538600|NCT03027531|Experimental|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
16538601|NCT03027531|Experimental|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
16538602|NCT03027518|Other|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
16538603|NCT03027518|Other|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
16538604|NCT03027505|Experimental|MUAC<125mm|no medical complication
16538605|NCT03027492|Active Comparator|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
16538606|NCT03027492|Active Comparator|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
16538687|NCT03026946|Active Comparator|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
16538688|NCT03026933|Experimental|Treatment|KI1107
16538689|NCT03026933|Active Comparator|Control|Rosuvastatin calcium
16539180|NCT03023397|Other|Der f treated Non-smoker|
16538607|NCT03027492|Active Comparator|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
16538608|NCT03027492|Active Comparator|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
16538609|NCT03027492|Active Comparator|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
16538610|NCT03027492|Active Comparator|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
16538611|NCT03027479|Experimental|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
16538612|NCT03027479|Other|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
16538613|NCT03027466|Experimental|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will receive affirmation text messages throughout the study"
16538614|NCT03027466|Active Comparator|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not receive affirmation text messages throughout the study"
16538615|NCT03027466|Active Comparator|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
16538616|NCT03027466|Placebo Comparator|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free United Kingdom (UK) app without any affirmation content Smoke Free UK app (no baseline affirmation quiz and no affirmation text messages)
16538617|NCT03027440||CPP Cohort|offspring born to historic CPP cohort participant mothers between 1959 and 1966 who were known to be alive at age 7 (if still alive at the time of NDI search, ages 50 to 57 years old)
16538619|NCT03027414|Active Comparator|Substudy 1 and 2 Active|HVs that receive active TMS over the right dlPFC
16538620|NCT03027414|Sham Comparator|Substudy 1 and 2 Sham|HVs that receive sham TMS over the right dlFPC
16538621|NCT03027414|Experimental|Substudy 3 offline|HVs will receive offline TMS to the lest IPS (FPN)
16538622|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
16538624|NCT03027375|Experimental|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
16538625|NCT03027375|Placebo Comparator|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks).
16538626|NCT03027362|Experimental|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
16538627|NCT03027362|Active Comparator|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
16538628|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.
~The exclusion criteria will be:
~age younger than 18 years
~renal and liver failure and insufficiency
~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)
~any type of cancer
~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption
~transplantation
~sarcoidosis
~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism
~familial hypocalciuric hypercalcemia
~hypophosphoremia sustained by genetic causes or secondary to other causes."
16538690|NCT03026920|Experimental|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
16538691|NCT03026907|Active Comparator|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
16538629|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.
~The exclusion criteria will be:
~age younger than 18 years
~renal and liver failure and insufficiency
~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)
~any type of cancer
~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption
~transplantation
~sarcoidosis
~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism
~familial hypocalciuric hypercalcemia
~hypophosphoremia sustained by genetic causes or secondary to other causes."
16538630|NCT03027336|Experimental|coleosoma|coleosoma 500mg tablet daily
16538631|NCT03027336|Placebo Comparator|placebo|placebo tablets
16538632|NCT03027323|Other|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
16538633|NCT03027323|No Intervention|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
16538636|NCT03027284|Experimental|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
16538637|NCT03027284|Experimental|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
16538638|NCT03027284|Experimental|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
16538639|NCT03027258|Experimental|Intervention|mHealth intervention
16538640|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
16538641|NCT03027206|Experimental|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
16538642|NCT03027206|Experimental|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
16538643|NCT03027193|Experimental|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^9 vp through intramuscular route.
16538644|NCT03027193|Experimental|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10^10 vp through intramuscular route.
16538645|NCT03027193|Experimental|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^10 vp through intramuscular route.
16538646|NCT03027193|Experimental|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10^7 pfu through intramuscular route.
16538647|NCT03027193|Experimental|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10^8 pfu through intramuscular route.
16538648|NCT03027193|Experimental|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10^10 vp followed by MVA HAV, 2 x 10^8 pfu (8 weeks apart) through intramuscular route.
16538649|NCT03027180|Active Comparator|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
16538650|NCT03027180|Experimental|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
16538651|NCT03027180|Experimental|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
16538652|NCT03027167|Active Comparator|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
16538653|NCT03027167|Experimental|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
16538654|NCT03027154|Experimental|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
16538655|NCT03027154|Experimental|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
16538656|NCT03027154|Experimental|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
16538692|NCT03026907|Active Comparator|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
16538693|NCT03026894|Active Comparator|CD group|Panoramic Radiographs and T-Scan III occlusal system
16538694|NCT03026894|Active Comparator|IOD group|Panoramic Radiographs and T-Scan III occlusal system
16538695|NCT03026881|Experimental|Fluzoparib + Apatinib + Paclitaxel|
16538657|NCT03027154|Experimental|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
16538658|NCT03027141|Active Comparator|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
16538659|NCT03027141|Experimental|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
16538660|NCT03027128|Experimental|haNK™ for Infusion|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous Infusion
16538661|NCT03027115|Experimental|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
16538662|NCT03027115|No Intervention|Control|no treatment
16538663|NCT03027102|Experimental|Patient Arm|Patients will receive DNT cells from healthy donors.
16538664|NCT03027102|No Intervention|Donor Arm|Healthy volunteer donors will donate blood.
16538665|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
16538666|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
16538667|NCT03027076||Women with UCPPS|Collect midstream urine samples
16538668|NCT03027076||Asymptomatic Women|Collect midstream urine samples
16538669|NCT03027063|Experimental|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.
~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
16538670|NCT03027063|Active Comparator|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
16538671|NCT03027050|Experimental|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
16538672|NCT03027050|Active Comparator|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
16538673|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
16538674|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
16538675|NCT03027024|Experimental|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
16538676|NCT03027011|Active Comparator|Remote Ischemic Preconditioning(RIPC)|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
16538677|NCT03027011|Placebo Comparator|Control|Control group without remote ischemic preconditioning
16538678|NCT03026998|Other|MRI|
16538679|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.
~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
16538680|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
16538681|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
16538682|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
16538683|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
16538684|NCT03026959|Experimental|Mindfulness Group|Participants assigned to the mindfulness group will attend four weekly sessions that are each 1.5 hours in length. The sessions will follow the structure described by Short, Mazmanian, Ozen, & Bédard (2015). The structure is designed to first enhance learners' foundation skills in mindfulness and progresses into teaching learners more advanced mindfulness skills.
16538685|NCT03026959|No Intervention|Social (control) Group|Participants assigned to the social group will also attend four weekly sessions that are each 1.5 hours in length. Each session will have participants focus on a creative tasks while permitting task related discussion. In this way the format is designed to parallel the mindfulness group, where participants engage in a new activity each week and have an opportunity to discuss the activities with the group without engaging in any formal intervention.
16538686|NCT03026946|Active Comparator|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
16538696|NCT03026868|Experimental|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
16538697|NCT03026855|Experimental|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
16538698|NCT03026842|Experimental|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
16538699|NCT03026842|Active Comparator|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
16538700|NCT03026829|Experimental|CART sound therapy|
16538701|NCT03026816|Experimental|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
16538702|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
16538703|NCT03026790|Active Comparator|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
16538704|NCT03026790|Active Comparator|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
16538705|NCT03026790|Active Comparator|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
16538706|NCT03026790|Active Comparator|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
16538707|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
16538708|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
16538711|NCT03026738|Experimental|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
16538712|NCT03026738|Active Comparator|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
16538713|NCT03026725|Experimental|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
16538714|NCT03026725|Placebo Comparator|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
16538715|NCT03026712|Experimental|Real tDCS|
16538716|NCT03026712|Sham Comparator|Sham tDCS|
16538717|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
16538718|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
16538719|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
16538720|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
16538721|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
16538722|NCT03026686||Controls|women with similar risk factors but did not require readmission
16538723|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
16538724|NCT03026660|Experimental|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
16539181|NCT03023397|Other|Der f treated Cigarette smoker|
16538725|NCT03026660|Placebo Comparator|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
16538726|NCT03026621|Placebo Comparator|Placebo|This will be an herbal tea the looks similar to the control.
16538727|NCT03026621|Experimental|Lignite Extract|This will be the Restore gut supplement
16538728|NCT03026608|Experimental|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
16538729|NCT03026608|Active Comparator|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
16538730|NCT03026569|Experimental|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
16538731|NCT03026569|No Intervention|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
16538732|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
16538733|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
16538734|NCT03026543|Experimental|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
16538735|NCT03026543|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
16538736|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
16538737|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
16538738|NCT03026517|Experimental|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The maximally tolerated Phenformin dose was determined to be 100 mg BID. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor. In this cohort, patients may be treated with any of the 3 FDA-approved BRAFi/MEKi combinations: dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib.
16538739|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
16538740|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
16538741|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
16538742|NCT03026478|Experimental|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
16538743|NCT03026478|Active Comparator|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
16538744|NCT03026465|Experimental|Coroflex ISAR stent|PCI with a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR stent) with very thin struts (50 µm). During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
16538745|NCT03026465|Active Comparator|Biomatrix stent|PCI with a biodegradable-polymer biolimus-eluting stent (Biomatrix stent) with 120 µm struts. During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
16538746|NCT03026452|Experimental|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
16538747|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
16538748|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.
16538749|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.
16538750|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.
16538751|NCT03026426|Experimental|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.
~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
16538752|NCT03026426|No Intervention|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
16538753|NCT03026413|Experimental|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
16538754|NCT03026413|Active Comparator|Control arm|pulmonary vein isolation without contact force
16538755|NCT03026400|Other|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
16538756|NCT03026400|Other|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
16538757|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.
~All of them are suicide attempters without psychotic features"
16538758|NCT03026374|Experimental|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
16538759|NCT03026374|No Intervention|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
16538760|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.
~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
16538761|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.
~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
16538762|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.
~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
16538763|NCT03026348|Active Comparator|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
16538764|NCT03026348|Active Comparator|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
16538765|NCT03026348|Active Comparator|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
16538766|NCT03026348|Active Comparator|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
16538767|NCT03026348|Active Comparator|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
16538768|NCT03026348|Active Comparator|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
16538769|NCT03026348|Active Comparator|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
16538770|NCT03026348|Active Comparator|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
16538771|NCT03026348|Active Comparator|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
16538772|NCT03026348|Active Comparator|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
16538773|NCT03026348|Active Comparator|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
16538774|NCT03026348|Placebo Comparator|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
16538775|NCT03026335|Experimental|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
16538776|NCT03026335|Active Comparator|Control/Comparison Group|Business as usual with students in non-intervened schools
16538777|NCT03026322|Active Comparator|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
16538778|NCT03026322|Active Comparator|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
16538779|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
16538780|NCT03026309||healthy|healthy volunteers.
16538781|NCT03026296|Experimental|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
16538782|NCT03026283||1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
16538783|NCT03026270|Other|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
16538813|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
16538814|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
16538815|NCT03026036||MDD|Patients with current Major Depressive Disorder
16538784|NCT03026270|Other|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
16538785|NCT03026257|Experimental|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
16538786|NCT03026257|Active Comparator|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
16538787|NCT03026244|Active Comparator|Nutritional intervention product|Milk protein, prebiotics, vitamin D
16538788|NCT03026244|Placebo Comparator|Placebo product|placebo product
16538789|NCT03026231|Active Comparator|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
16538790|NCT03026231|Placebo Comparator|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
16538791|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
16538792|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
16538793|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
16538794|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
16538795|NCT03026205|Experimental|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
16538796|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
16538797|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
16538798|NCT03026179|Other|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
16538799|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).
~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
16538800|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).
~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
16538801|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).
~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
16538802|NCT03026153|Other|Control group - Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
16538803|NCT03026153|Other|Intervention Group - Oral Survey 2|Oral Survey 2 will be administered as the intervention : patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
16538804|NCT03026140|Active Comparator|group 1|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)
16538805|NCT03026140|Experimental|group 2|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)
16538806|NCT03026127|Experimental|CRISP|Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
16538807|NCT03026127|Active Comparator|Supportive Therapy (ST)|Supportive Therapy focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
16538808|NCT03026101|Experimental|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
16538809|NCT03026088|Experimental|Bisoprolol|
16538810|NCT03026075|Experimental|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
16538811|NCT03026062|Experimental|Arm I (sequential tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Upon progression, patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. This arm is closed to enrollment.
16538812|NCT03026062|Experimental|Arm II (combination tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
16538818|NCT03026023|Experimental|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
16538819|NCT03025997|Active Comparator|Active yoghurt|Yoghurt snack containing encapsulated lipid
16538820|NCT03025997|Placebo Comparator|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid
~+ empty encapsulation matrix"
16538821|NCT03025984|Active Comparator|Texting|"Patients in the Texting group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed."
16538822|NCT03025984|No Intervention|No texting|Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
16538823|NCT03025971|Other|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
16538824|NCT03025958|Experimental|Nimotuzumab|Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
16538825|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
16538826|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
16538827|NCT03025932||Patient cohort|Patients who underwent laparoscopic hernia repair of giant hiatal hernia with mesh and received anterior fundoplication
16538828|NCT03025906|Experimental|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
16538829|NCT03025906|Experimental|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
16538830|NCT03025893|Experimental|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
16538831|NCT03025893|Active Comparator|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
16538832|NCT03025880|Experimental|Single arm|"Eligible patients will be enrolled and treated with Pembrolizumab (P) at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle in combination with Gemcitabine (G) at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with P in the initial exploratory run-in-phase if necessary) as a IV infusion on day 1 and 8 of each 21-day cycle.
~Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of G in combination with fixed doses of P."
16538833|NCT03025841|Other|Ceftaroline|Patients receive Ceftaroline 600mg BID
16538834|NCT03025828|Experimental|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
16538835|NCT03025815|Experimental|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
16538836|NCT03025815|Sham Comparator|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
16538837|NCT03025789|Experimental|Open label arm|children and adults to receive fexinidazole either as inpatients or outpatients.
16538838|NCT03025776||stroke|individuals chronic (> 6 months) post-stroke
16538839|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
16538840|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
16538841|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
16538842|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
16538843|NCT03025750|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
16538844|NCT03025750|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
16538845|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
16538846|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
16538847|NCT03025724|No Intervention|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
16538879|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.
~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
16538848|NCT03025724|Experimental|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
16538849|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
16538850|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
16538851|NCT03025698|Experimental|Cohort A (Option 1)|
16538852|NCT03025698|Experimental|Cohort A (option 2)|
16538853|NCT03025698|Experimental|Cohort B|
16538854|NCT03025685|Experimental|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
16538855|NCT03025685|Active Comparator|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
16538856|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
16538857|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
16538858|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
16538859|NCT03025633|Other|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
16538860|NCT03025633|No Intervention|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
16538861|NCT03025620|Placebo Comparator|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
16538862|NCT03025620|Active Comparator|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
16538863|NCT03025607|No Intervention|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
16538864|NCT03025607|Experimental|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
16538865|NCT03025607|Experimental|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
16538866|NCT03025594|Experimental|Gonyautoxin|Gonyautoxin 40mcg
16538867|NCT03025594|Active Comparator|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
16538868|NCT03025581|Active Comparator|Intervention group|Nipple stimulation.
16538869|NCT03025581|No Intervention|Control group|No intervention (expectant management only).
16538870|NCT03025568|Active Comparator|group 1|Patient will receive partial denture constructed from Bre_flex
16538871|NCT03025568|Experimental|group 2|Patients will receive removable partial denture constructed from PEEK
16538872|NCT03025555|Active Comparator|group 1|patients will receive partial denture constructed from breflex material.
16538873|NCT03025555|Experimental|group 2|patients will receive partial denture constructed from PEEK material.
16538874|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
16538875|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
16538876|NCT03025529|Experimental|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
16538877|NCT03025529|Sham Comparator|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
16538878|NCT03025529|No Intervention|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
16538880|NCT03025503|Experimental|nipple stimulation|
16538881|NCT03025503|No Intervention|no intervention|
16538882|NCT03025490|No Intervention|standard of Care|Patient undergoing sedation, treatment team does not have capnography data available.
16538883|NCT03025490|Experimental|Capnography|Patient undergoing sedation, treatment team does have capnography data available.
16538884|NCT03025477|Active Comparator|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.
~The regimen of administration of the chemotherapy is as following:
~Carboplatin AUC 6 - IV - Day (D) 1
~Paclitaxel 80mg / m² - IV - D1, D8, D15
~one cycle every 3 weeks"
16538885|NCT03025477|Experimental|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.
~Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.
~Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.
~The regimen of administration of the chemotherapy is as following:
~Cisplatin 80mg / m² - IV or IP - D1
~Epirubicin 60mg / m² - IV - D3
~one Cycle every 3 weeks."
16538886|NCT03025451|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
16538888|NCT03025412|Experimental|Endoscopic surgery|Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
16538889|NCT03025412|Active Comparator|Conservative treatment|Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.
16538890|NCT03025399|Experimental|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
16538891|NCT03025399|Placebo Comparator|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
16538892|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
16538893|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
16538894|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
16538895|NCT03025347|Experimental|Control|Experimental day where participants rest.
16538896|NCT03025347|Experimental|Exercise|Experimental day where participants complete a run.
16538897|NCT03025334|Sham Comparator|Sham tDCS|sham tDCS (30sec ramp-up and 3sec ramp-down)
16538898|NCT03025334|Active Comparator|Real tDCS right|Real anodal tDCS (right DLPFC)
16538899|NCT03025321|Experimental|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
16538900|NCT03025321|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
16538905|NCT03025295|Experimental|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
16538906|NCT03025295|Placebo Comparator|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
16538907|NCT03025282|Experimental|CD10367 3% Solution - Non-desquamated zone|
16538908|NCT03025282|Experimental|CD10367 1% Solution - Non-desquamated zone|
16538909|NCT03025282|Placebo Comparator|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
16538910|NCT03025282|Active Comparator|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
16538911|NCT03025282|Experimental|CD10367 3% Solution - Desquamated zone|
16538912|NCT03025282|Placebo Comparator|CD10367 solution placebo - Desquamated zone|
16538913|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
16538914|NCT03025256|Experimental|Treatment (nivolumab)|Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16538915|NCT03025243|Experimental|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
16538916|NCT03025243|Active Comparator|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
16538917|NCT03025230|Experimental|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
16538918|NCT03025230|Active Comparator|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
16538919|NCT03025217|Experimental|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
16538920|NCT03025204|Active Comparator|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
16538921|NCT03025204|Experimental|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
16538922|NCT03025204|Active Comparator|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
16538923|NCT03025191|Experimental|Prison Connect|
16538924|NCT03025178|Experimental|Central venous catheterization|Central venous catheterization will be performed using 4Fr central venous catheter at left internal jugular vein in infant. The tip of central venous catheter will be confirmed by transthoracic echocardiography. The actual insertion depth of central venous catheter will be compared to the predicted insertion depth derived from two calculation methods using height and the distance between the anatomical landmarks.
16538925|NCT03025165|Experimental|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
16538926|NCT03025165|Experimental|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
16538927|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
16538928|NCT03025152|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
16538929|NCT03025152|Placebo Comparator|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
16538930|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
16538931|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
16538932|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
16538933|NCT03025126|Experimental|HEAD Rehabilitation|rehabilitation with IT multimedial devices
16538934|NCT03025126|Active Comparator|Usual care program|usual care program
16538935|NCT03025113|Experimental|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
16538936|NCT03025113|Active Comparator|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
16538937|NCT03025100||Prospective|A sample of 120 patients aged 60 years or older admitted to General Medicine at Duke University Hospital will be enrolled in the prospective cohort study. A convenience sample will be derived from a randomized daily list of general medicine admissions; weekend admissions will be excluded as these patients will not be captured within 24 hours of hospital admission.
16538938|NCT03025087|Experimental|Phase 1|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.
16538939|NCT03025087|Experimental|Phase 2|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 1-5
16538940|NCT03025087|Experimental|Phase 3|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 1-5.
16538941|NCT03025087|Experimental|Phase 4|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 1-5.
16538942|NCT03025087|Experimental|Phase 5|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ 1-2 hours after separation from CPB or at end of noncardiac surgery followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 1-5.
16538943|NCT03025061||15 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 15 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
16538944|NCT03025061||30 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 30 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
16538945|NCT03025035|Experimental|Pembrolizumab + Olaparib|This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.
16538946|NCT03025022|Experimental|14C-JNJ-42847922 40 miiligram (mg)|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.
16538947|NCT03025009|Experimental|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
16538948|NCT03025009|Placebo Comparator|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
16538949|NCT03025009|Experimental|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
16538950|NCT03025009|Active Comparator|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
16538951|NCT03025009|Active Comparator|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
16539083|NCT03024099|Experimental|Hippotherapy twice a week|hippotherapy twice a week
16538952|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
16538953|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
16538954|NCT03024983|Active Comparator|Control|Glucose monohydrate (isoglucidic portion -50 g of available carbohydrates-)
16538955|NCT03024983|Experimental|Semolina|Semolina soup (isoglucidic portion -50 g of available carbohydrates-)
16538956|NCT03024983|Experimental|Bread|Bread (isoglucidic portion -50 g of available carbohydrates-)
16538957|NCT03024983|Experimental|Short pasta (fresh)|Fresh penne (isoglucidic portion -50 g of available carbohydrates-)
16538958|NCT03024983|Experimental|Short pasta (dry)|Short pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
16538959|NCT03024983|Experimental|Long pasta (dry)|Long pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
16538960|NCT03024970|Experimental|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
16538961|NCT03024970|Active Comparator|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
16538962|NCT03024957|Active Comparator|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
16538963|NCT03024957|Active Comparator|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
16538964|NCT03024957|Active Comparator|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
16538965|NCT03024944|Experimental|Brain Imaging with 18F-THK-5351|This group consists of 30 adult subjects: 10 with Type 2 diabetes, 10 with pre-diabetes, and 10 with normal glucose tolerance. Each subject will receive a baseline scan and a follow-up PET scan with 18F-THK-5351.
16538966|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
16538967|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
16538968|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
16538969|NCT03024905|Experimental|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.
~Interventions are behavioural and device:
~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
16538970|NCT03024905|Experimental|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.
~Interventions are behavioural and device:
~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
16538971|NCT03024905|Experimental|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.
~Interventions are behavioural and device:
~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
16538972|NCT03024905|Experimental|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.
~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
16538973|NCT03024892|Experimental|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
16538974|NCT03024892|Experimental|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
16538975|NCT03024892|Sham Comparator|LC conventional|Patients received conventional laparoscopic cholecystectomy
16538976|NCT03024892|Sham Comparator|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
16538977|NCT03024879|Active Comparator|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
16538978|NCT03024879|Placebo Comparator|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
16538979|NCT03024866||Electronic Brachytherapy|Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System
16538980|NCT03024866||Mohs Surgery|Previously completed treatment for non-melanoma skin cancer using Mohs Surgery
16538981|NCT03024853|Experimental|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
16538982|NCT03024853|Experimental|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
16539084|NCT03024086|Experimental|DWJ1252|DWJ1252 + Placebo of Gasmotin
16539182|NCT03023397|Other|Der f treated E-cig user|
16538983|NCT03024853|Experimental|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
~This is the original BPS exercise (already validated in other studies)."
16538984|NCT03024853|Active Comparator|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
16538985|NCT03024840|Experimental|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
16538986|NCT03024840|Experimental|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
16538987|NCT03024827|Experimental|Medical Cannabis Oil|CanniMed® 1:20
16538988|NCT03024814|Experimental|acetaminophen group|Babies who took acetaminophen
16538989|NCT03024814|Experimental|Placebo group (Dextrose 5)|Babies who took placebo
16538990|NCT03024801|Experimental|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
16538991|NCT03024801|Experimental|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
16538992|NCT03024775|Active Comparator|Active Comparator 1|Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
16538993|NCT03024775|Active Comparator|Active Comparator 2|Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
16538994|NCT03024775|Placebo Comparator|Placebo 1|Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
16538995|NCT03024775|Placebo Comparator|Placebo 2|Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
16538996|NCT03024762|Experimental|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
16538997|NCT03024762|No Intervention|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
16538998|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
16538999|NCT03024710|Experimental|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.
~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
16539000|NCT03024710|No Intervention|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
16539001|NCT03024697|Active Comparator|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
16539002|NCT03024697|Active Comparator|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
16539003|NCT03024697|Active Comparator|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
16539004|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
16539005|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
16539006|NCT03024671|Experimental|patch test|Patients with patch test of cosmetics
16539007|NCT03024658|No Intervention|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
16539008|NCT03024658|Experimental|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
16539009|NCT03024645|Experimental|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
16539010|NCT03024645|Active Comparator|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
16539011|NCT03024632||trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a trial of labor
16539012|NCT03024632||No trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a a repeat cesarean section
16539013|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
16539014|NCT03024606|No Intervention|control group|No text messages
16539015|NCT03024593|Experimental|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
16539016|NCT03024593|No Intervention|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
16539085|NCT03024086|Active Comparator|Gasmotin|Gasmotin + Placebo of DWJ1252
16539296|NCT03022604|Experimental|C4/Generation 4|12 grams of C4/Generation 4 Extreme
16539017|NCT03024580|Experimental|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
16539018|NCT03024580|Active Comparator|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
16539019|NCT03024580|Active Comparator|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
16539020|NCT03024580|Active Comparator|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
16539021|NCT03024580|Active Comparator|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
16539022|NCT03024580|Active Comparator|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
16539023|NCT03024567|Active Comparator|Salt|6 grams sodium chloride per day for 14 days
16539024|NCT03024567|Placebo Comparator|Placebo|6 grams gelatine per day for 14 days
16539025|NCT03024554|Experimental|treatment|aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
16539026|NCT03024541||LASA study|
16539027|NCT03024541||InterRAI consortium|
16539028|NCT03024528||CAM-ICU (+)|Delirious patients.
16539029|NCT03024528||CAM-ICU (-)|Non-delirious patients
16539030|NCT03024515|Experimental|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
16539031|NCT03024515|Experimental|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
16539032|NCT03024502|Experimental|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
16539033|NCT03024502|Experimental|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
16539034|NCT03024502|Experimental|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
16539035|NCT03024489|Experimental|Palbociclib-Cetuximab-IMRT|"IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
~Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
~Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
16539036|NCT03024476|Experimental|Intensive management arm|"Description:
~Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan
~Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).
~Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.
~Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee."
16539037|NCT03024476|Active Comparator|Control arm|"Description:
~Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.
~Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups)."
16539038|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
16539039|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.
~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
16539040|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.
~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
16539041|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 or PDL1 inhibitor.
~Patients in Cohort B will be treated with the same combination therapy as in Cohort A."
16539042|NCT03024424|Experimental|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
16539043|NCT03024424|Active Comparator|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
16539044|NCT03024411|Experimental|Music/video games|iPod (Music/video games)
16539045|NCT03024411|No Intervention|No intervention|No intervention
16539046|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
16539047|NCT03024372|Active Comparator|Conventional sutures|AV fistula creation with sutures
16539048|NCT03024372|Active Comparator|Anastoclips|AV fistula creation with clips
16539086|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
16539087|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
16539049|NCT03024359|Active Comparator|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
16539050|NCT03024359|Active Comparator|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
16539051|NCT03024333||Healthy subjects|"Healthy subjects are:
~Between 19-60 years old
~Able to sign the informed consent after the whole study is explained to them
~Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery
~Able to sit upright with or without back support of chair
~No other diseases affect swallowing function"
16539052|NCT03024320|Experimental|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
16539053|NCT03024320|Experimental|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program, as well as group-based tele-coaching session.
16539054|NCT03024320|Active Comparator|Attention Control|Participants receive health-focused articles and infographics throughout 48 weeks and receive a Fitbit.
16539055|NCT03024307|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
16539056|NCT03024307|No Intervention|usual care only|Patients were provided with usual care.
16539057|NCT03024294|Other|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
16539058|NCT03024268|Experimental|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
16539059|NCT03024268|No Intervention|B: no intervention|Best medical supportive care (n=40)
16539060|NCT03024255|Experimental|BBI-4000 Concentration 1|Low Concentration
16539061|NCT03024255|Experimental|BBI-4000 Concentration 2|Medium Concentration
16539062|NCT03024255|Experimental|BBI-4000 Concentration 3|High Concentration
16539063|NCT03024255|Placebo Comparator|Vehicle|Vehicle (Placebo)
16539064|NCT03024242|Experimental|Tight vaginoscope|The vaginoscope was extracted and loaded inside a thick rubber ring before its reinsertion inside the vagina again. To avoid leakage from the center of the thick rubber ring, the vaginoscopy is inserted through a premade central cruciate incision.
16539065|NCT03024229|Other|LifePort® perfusion machine|Metabolomic analysis of the preservation fluid of the graft, donor and recipient urine by nuclear magnetic resonance spectroscopy, and if possible by liquid and gas chromatography coupled with mass spectrometry.
16539066|NCT03024216|Experimental|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
16539067|NCT03024216|Experimental|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
16539068|NCT03024203|Experimental|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
16539069|NCT03024203|Experimental|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
16539070|NCT03024190|Experimental|with Kinesiotaping|"stretching exercises combined with Kinesiotaping
~regular OT rehabilitation program for 3 weeks"
16539071|NCT03024190|Other|control group|"the patients will receive 15-min stretching exercises
~regular OT rehabilitation program for 3 weeks"
16539072|NCT03024177|Experimental|Vapendavir 528 mg|
16539073|NCT03024177|Placebo Comparator|Placebo|
16539074|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
16539075|NCT03024151|Active Comparator|T4/T3 combination replacement|Comthyroid
16539076|NCT03024151|Active Comparator|T4 mono replacement|Synthroid
16539077|NCT03024138||Repeat CT|
16539078|NCT03024125|Experimental|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
16539079|NCT03024125|Placebo Comparator|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
16539080|NCT03024112|Experimental|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
16539081|NCT03024112|Active Comparator|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
16539082|NCT03024099|Experimental|Hippotherapy once a week|Hippotherapy once a week;
16539090|NCT03024060|Placebo Comparator|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
16539091|NCT03024034|Active Comparator|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
16539092|NCT03024034|Active Comparator|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
16539093|NCT03024034|Active Comparator|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
16539094|NCT03024034|Active Comparator|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
16539095|NCT03024034|Active Comparator|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
16539096|NCT03024034|Active Comparator|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
16539097|NCT03024034|Active Comparator|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
16539098|NCT03024008|Experimental|Intervention Arm|"Clinical Interventions:
~Blood tests: complete blood count, full blood chemistry and biochemistry including phosphate, alkaline phosphatase, calcium, renal and liver function, and coagulation. Serology tests: HIV, Hepatitis B, Hepatitis C.
~Xray
~Urine Test
~CT
~Liposuction - harvest of 50-300ml autologous adipose tissue from the subject's abdomen
~Single transplantation of Investigational Medicinal Product BonoFill-II into long bone extra-articular comminuted fracture or large bone defect/critical gap"
16539099|NCT03023995|Experimental|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
16539100|NCT03023995|Active Comparator|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
16539101|NCT03023982|Experimental|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
16539102|NCT03023982|Active Comparator|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
16539103|NCT03023969|Active Comparator|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
16539104|NCT03023969|Active Comparator|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
16539105|NCT03023956||ANF|anatomic neck fractures of proximal humerus
16539106|NCT03023956||SNF|surgical neck fractures of proximal humerus
16539107|NCT03023943|Experimental|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
16539108|NCT03023930|Experimental|Evidenced-based Practice Dissemination|Evaluating standard dissemination practice compared with implementation facilitation
16539109|NCT03023917|Active Comparator|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
16539110|NCT03023917|Experimental|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
16539111|NCT03023904|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
16539112|NCT03023891|Experimental|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone
~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
16539113|NCT03023878|Experimental|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.
~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.
~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
16539114|NCT03023865|Experimental|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
16539115|NCT03023852|Experimental|Panel 1: Group 1|Participants will receive Treatment A (JNJ-63623872 600 milligram (mg) (2*300 mg) oral tablets [reference]) followed by Treatment B (JNJ- 63623872 600 mg (2*300 mg) concept oral tablet formulation 1 (test 1) and then Treatment C (JNJ-63623872 600 mg (2*300 mg) concept oral tablet formulation 2 (test 2). Each treatment period will be separated 7 days washout period.
16539116|NCT03023852|Experimental|Panel 1: Group 2|Participants in Group 2 will receive Treatment A followed by Treatment C and then Treatment B with a washout period of minimum 7 days.
16539117|NCT03023852|Experimental|Panel 1: Group 3|Participants in Group 3 will receive Treatment B followed by Treatment A and then Treatment C with a washout period of minimum 7 days.
16539118|NCT03023852|Experimental|Panel 1: Group 4|Participants in Group 4 will receive Treatment B followed by Treatment C and then Treatment A with a washout period of minimum 7 days.
16539119|NCT03023852|Experimental|Panel 1: Group 5|Participants in Group 5 will receive Treatment C followed by Treatment A and then Treatment B with a washout period of minimum 7 days.
16539120|NCT03023852|Experimental|Panel 1: Group 6|Participants in Group 6 will receive Treatment C followed by Treatment B and then Treatment A with a washout period of minimum 7 days.
16539121|NCT03023852|Experimental|Panel 2: Group 7|Participants in Group 7 will receive Treatment D [JNJ-63623872/37.5 mg Oseltamivir oral fixed dose combination (FDC) tablet concept formulation (test 3)] followed by Treatment E (JNJ-63623872 600 mg, administered as 2*300 mg and Oseltamivir 75 mg, administered as 1*75 mg). Both treatment periods will be separated with a minimum of 7 days washout period.
16539122|NCT03023852|Experimental|Panel 2: Group 8|Participants in Group 8 will receive Treatment E followed by Treatment D with a washout period of minimum 7 days.
16539123|NCT03023839||Severe trauma patients|Severe Trauma patients (ISS >15) admitted to Intensive Care Unit (ICU)
16539124|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) capsule under fasting conditions.
16539125|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) tablet under fasting conditions.
16539126|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
16539127|NCT03023813|Experimental|Intervention|Individualized preventive care recommendations will be distributed to subjects.
16539128|NCT03023813|No Intervention|Control|Usual care
16539129|NCT03023813|Experimental|Development Phase|Non-randomized receipt of individualized preventive care recommendations
16539130|NCT03023800|Experimental|Buckle|Macular buckling and intraocular gas (C3F8) injection.
16539131|NCT03023800|Active Comparator|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
16539132|NCT03023787|Experimental|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
16539133|NCT03023787|Placebo Comparator|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
16539134|NCT03023774|Other|neupogen|neupogen (granulocyte colony-stimulating factor) 30 IU once intrauterine at the time of ovum pickup
16539135|NCT03023761|Active Comparator|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
16539136|NCT03023761|Placebo Comparator|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
16539137|NCT03023748|Experimental|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.
~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
16539139|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
16539140|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
16539141|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
16539142|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
16539145|NCT03023670|Active Comparator|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
16539146|NCT03023670|Active Comparator|Group B|This group will receive low rate (4\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
16539147|NCT03023657|Experimental|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
16539148|NCT03023644|Experimental|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
16539149|NCT03023644|No Intervention|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
16539150|NCT03023631|Experimental|Prevention (Gardasil 9 vaccine)|Patients undergo standard of care allogeneic stem cell transplant. 6-12 months following transplant, patients receive recombinant human papillomavirus nonavalent vaccine IM on day 0 and at 2 and 6 months in the absence of disease progression or unacceptable toxicity.
16539151|NCT03023618|No Intervention|control group|patients before 2014, in which fluids were administered without FloTrac monitoring
16585360|NCT02709928|Placebo Comparator|Placebo|Capsule formulation
16539152|NCT03023618|Active Comparator|case group|patients after 2014, after management of fluid therapy has been guided by FloTrac parameters as a standard clinical practice (NICE protocol)
16539153|NCT03023605|No Intervention|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
16539154|NCT03023605|Experimental|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.
~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
16539155|NCT03023592|Experimental|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
16539156|NCT03023579|Experimental|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
16539157|NCT03023566||Dotarem Enhanced MRI|All pediatric patients (< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
16539158|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
16539159|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
16539160|NCT03023540|Active Comparator|PXT3003 dose 1|Period 1, PXT3003 : Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
16539161|NCT03023540|Active Comparator|PXT3003 dose 2|"Period 1, PXT3003: Liquid oral solution (1.2 mg/mL baclofen, 0.14 mg/mL naltrexone HCl and 420 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
~Period 2, PXT3003: Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 10 mL bid (taken morning and evening with food)"
16539162|NCT03023527|Experimental|nivo-pom-dex|Nivolumab in combination with Pomalidomide and low dose dexamethasone
16539163|NCT03023527|Experimental|nivo-pom-dex-elo|Pomalidomide in combination with Nivolumab , dexamethasone and elotuzumab
16539164|NCT03023514|Experimental|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
16539165|NCT03023514|Active Comparator|P|vaginal Progesterone
16539166|NCT03023501|Experimental|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
16539167|NCT03023501|Placebo Comparator|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
16539168|NCT03023488|Experimental|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
16539169|NCT03023475|Active Comparator|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
16539170|NCT03023475|Active Comparator|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
16539171|NCT03023462|Active Comparator|Transmuscular Quadratus lumborum Block|A single shot unilateral transmuscular Quadratus lumborum Block with Ropivacaine 7,5 mg/ml, 20 ml
16539172|NCT03023462|Active Comparator|TAP Block|A single shot unilateral TAP block with Ropivacaine 7,5 mg/ml, 20 ml
16539173|NCT03023449|Experimental|Healthy Controls|The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be called at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
16539174|NCT03023449|Experimental|Acute Ischemic Stroke|Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
16539175|NCT03023436|Experimental|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.
~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
16539176|NCT03023423|Experimental|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
16539177|NCT03023423|Experimental|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
16539178|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
16539179|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
16539183|NCT03023358|Experimental|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
16539184|NCT03023358|Active Comparator|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
16539185|NCT03023345|Experimental|Microwave|Microwave trans rectal focal treatment
16539186|NCT03023332|Experimental|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
16539187|NCT03023332|Experimental|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
16539188|NCT03023332|No Intervention|Control|No intervention or treatment
16539189|NCT03023332|Active Comparator|Usual care|Bipolar education
16539190|NCT03023319|Experimental|Bosutinib and Pemetrexed|Bosutinib and pemetrexed
16539191|NCT03023306|Active Comparator|preemptive group|"The preemptive group will receive the anti-emetic regimen i.v. (4 mg of ondansetron) 1h before the start of surgery. During surgery, 30 min before the end of operation, this group will receive i.v. 0.9% NaCl in equal volumes.The intervention consists of the different time points of antiemetic treatment, thus 1h before surgery vs intraopertively.
~Intervention: Antiemetic treatment 1h before surgery"
16539192|NCT03023306|Other|intraoperative group|"The preventive group will receive i.v. 0.9% NaCl 1h before surgery and ondansetron 4 mg 30 min before the end of surgery at equal volumes.
~Intervention: Antiemetic treatment intraoperatively"
16539193|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
16539194|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
16539195|NCT03023267|Experimental|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
16539196|NCT03023267|Active Comparator|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
16539197|NCT03023254|Other|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-week Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
16539198|NCT03023254|No Intervention|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
16539199|NCT03023241|Experimental|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
16539200|NCT03023228|Experimental|diabetes self-management education|Diabetes survival skills self-management education (DSME) program content was aligned with American Diabetes Association and Joint Commission suggested key areas for hospital diabetes education. Content areas were as follows: when and how to take diabetes medications; glycemic goals and self-blood glucose monitoring; definition, prevention, recognition, and treatment of hypoglycemia and hyperglycemia; what to do before you see the dietitian; sick day management; and when to call the doctor or go to the ED. Program content was created for delivery via either DVD or print format.
16539201|NCT03023215|Experimental|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
16539202|NCT03023215|Active Comparator|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
16539203|NCT03023215|Active Comparator|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).
~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
16539204|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.
~All standard of care functions will be performed by standard procedures."
16539205|NCT03023189|Active Comparator|Tranexamic acid|At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
16539206|NCT03023189|Placebo Comparator|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
16539207|NCT03023176|Other|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
16539208|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
16539209|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
16539210|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
16539297|NCT03022604|Active Comparator|C450X|12 grams of C4X (150% of regular dose)
16539211|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
16539212|NCT03023150|Experimental|Ischemic Preconditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
16539213|NCT03023150|Sham Comparator|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
16539214|NCT03023137|Active Comparator|Walking & dietary modification (W&D)|W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
16539215|NCT03023137|No Intervention|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
16539216|NCT03023124|Experimental|Trabectedin|trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
16539217|NCT03023124|Experimental|Adriamycin and Dacarbazine|Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
16539218|NCT03023111|Active Comparator|Sbv|"Meglumine antimoniate (Glucantime):
~Dosage: 20 mg / kg / day, intravenously, during 20 days."
16539219|NCT03023111|Experimental|Miltefosine plus placebo|Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)
16539220|NCT03023111|Experimental|Miltefosine plus GM-CSF|Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)
16539221|NCT03023098|Experimental|Drug-eluting balloon|
16539222|NCT03023098|Active Comparator|Conventional PTA|
16539223|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
16539224|NCT03023072||Phase 1|Subjects will use the incontinence pad with incontinence detection notifications turned on
16539225|NCT03023072||Phase 2|Subjects will use the incontinence pad with incontinence notification turned off
16539226|NCT03023059|Experimental|Escalating dose of carbidopa-levodopa|The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
16539227|NCT03023046|Experimental|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16539228|NCT03023033|Experimental|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
16539229|NCT03023033|Experimental|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
16539230|NCT03023033|No Intervention|Clinic group 3|Services provided under the Ministry of Health standard care
16539231|NCT03023020|Other|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).
~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
16539232|NCT03023020|Other|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).
~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
16539233|NCT03023007|Experimental|Loco-regional anaesthesia|Loco-regional anaesthesia Anesthesia technique used : loco-regional PECS for patients requiring Mastectomy; And/or Axillary node dissection ; And/or Reconstruction of breast by prosthesis
16539234|NCT03022994||NCWS patients|"Forty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2016 and February 2017 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
16539235|NCT03022994||IBS patients|"Forty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as control group. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
16539266|NCT03022812|Active Comparator|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
16539298|NCT03022604|Placebo Comparator|Placebo|12 grams of flavored dextrose
16539236|NCT03022981|Experimental|12 to < 18 Years Old|"PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) 400/100 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.
~Treatment Phase: SOF/VEL 400/100 mg once daily for 12 weeks."
16539237|NCT03022981|Experimental|6 to < 12 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.
~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks."
16539238|NCT03022981|Experimental|3 to < 6 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 7 days for participants who weigh < 17 kg. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.
~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 12 weeks for participants who weigh < 17 kg."
16539239|NCT03022968|Experimental|Alzheimer disease|[18F]T807 PET
16539240|NCT03022968|Experimental|Benson disease|[18F]T807 PET
16539241|NCT03022968|Experimental|Healthy volunteer|[18F]T807 PET
16539242|NCT03022955|Active Comparator|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
16539243|NCT03022955|Active Comparator|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
16539244|NCT03022955|Placebo Comparator|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
16539245|NCT03022955|Placebo Comparator|White chocolate: Physiological Measurement|150 g white chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
16539246|NCT03022942|Experimental|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
16539247|NCT03022942|Active Comparator|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
16539248|NCT03022929|No Intervention|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
16539249|NCT03022929|Experimental|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
16539250|NCT03022916|Active Comparator|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
16539251|NCT03022916|Placebo Comparator|Nail Polish Only|Both big toes will use nail polish only
16539252|NCT03022916|Active Comparator|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
16539253|NCT03022916|Active Comparator|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
16539254|NCT03022903|Other|Photodynamic Therapy (PDT)|PDT with ALA (photosensitizer) for 3 hours
16539255|NCT03022890|Experimental|Hatha yoga|12 weeks of hatha yoga classes, once per week
16539256|NCT03022890|Placebo Comparator|Health education|12 weeks of health education classes, once per week
16539257|NCT03022877|Placebo Comparator|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
16539258|NCT03022877|Active Comparator|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
16539259|NCT03022877|Active Comparator|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
16539260|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
16539261|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
16539262|NCT03022851|Experimental|Occlutech AFR Device|Patients who will get the AFR Device implantation
16539263|NCT03022838|Active Comparator|Caffeine|Caffeine tablets (Recip) 100 mg, 300-800 mg
16539264|NCT03022838|Placebo Comparator|Placebo|Placebo tablets
16539265|NCT03022825|Experimental|BCG+N-803|
16539267|NCT03022812|Experimental|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
16539268|NCT03022799|Experimental|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
16539269|NCT03022799|Placebo Comparator|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
16539270|NCT03022786|No Intervention|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
16539271|NCT03022786|No Intervention|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.
~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
16539272|NCT03022786|Other|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
16539273|NCT03022773|Other|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
16539274|NCT03022760|Active Comparator|Work-related measures|"One-day training for GP:s and rehabilitation coordinators
~A treatment protocol which includes contact with the patient's employer
~Clinical support from the Institute of Stress Medicine"
16539275|NCT03022760|No Intervention|Treatment as usual|
16539276|NCT03022747|Active Comparator|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
16539277|NCT03022747|Experimental|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
16539278|NCT03022734|Experimental|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
16539279|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.
~No interventions are planned."
16539280|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.
~No interventions are planned."
16539281|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.
~no interventions are planned."
16539282|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.
~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:
~Tetralogy of Fallot
~Truncus Arteriosus
~Pulmonary Atresia
~Transposition of Great Arteries with Ventricular Septal Defect
~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes
~In addition, the PV conduit can be used for the following indications:
~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).
~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
16539283|NCT03022695|Experimental|Treatment with high-intensity focused ultrasound|
16539285|NCT03022669|Experimental|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
16539286|NCT03022669|Experimental|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
16539287|NCT03022669|Experimental|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
16539288|NCT03022656|Active Comparator|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
16539289|NCT03022656|Active Comparator|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
16539290|NCT03022643|No Intervention|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
16539291|NCT03022643|No Intervention|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
16539292|NCT03022643|Experimental|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
16539293|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
16539294|NCT03022630|Other|Usual hepatic care|Usual hepatic care
16539295|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
16539299|NCT03022578|Experimental|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
16539300|NCT03022565|Experimental|Vorinostat|"Vorinostat:
~400 mg orally, once daily for 15 days."
16539301|NCT03022552||MINOCA|Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
16539302|NCT03022552||MI-CAD|Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
16539303|NCT03022552||CATH-NOCA|Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
16539304|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
16539305|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
16539306|NCT03022513|Active Comparator|NCWS patients|Fifty consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
16539307|NCT03022513|No Intervention|CD patients|Fifty sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as first control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
16539308|NCT03022513|No Intervention|IBS patients|Fifty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as second control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo.
16539309|NCT03022500|Experimental|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
16539310|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for at least 12 months for endpoints.
16539311|NCT03022474|Experimental|Intervention group|
16539312|NCT03022474|No Intervention|Control group|
16539313|NCT03022461||Ongoing HM3 CE Mark study patients|The study will include the ongoing HM3 CE Mark study patients that have consented to continue the long term follow-up data collection.
16539314|NCT03022448||Treatment Group|Trabectedin will be used according to the local SmPC. Modification of the treatment schedule should follow the standard medical practice at the discretion of the treating physician and is not part of this Observational Plan.
16539315|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
16539316|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
16539317|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
16539318|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
16539319|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
16539320|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
16539321|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
16539322|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
16539323|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
16539324|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
16539325|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
16539326|NCT03022409|Experimental|AZD6738|AZD6738 (160 mg) tablet twice daily continuous dosing for a minimum of 9 days and a maximum of 21 days.
16539327|NCT03022409|Experimental|Olaparib|Olaparib (300 mg) tablets administered orally twice daily continuously for a minimum of 9 days and a maximum of 21 days.
16539328|NCT03022396|Other|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
16539329|NCT03022396|Other|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
16539330|NCT03022396|Other|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
16539331|NCT03022396|Other|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
16539332|NCT03022396|Other|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
16539333|NCT03022396|Other|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
16539335|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
16539392|NCT03021980|No Intervention|Control|This is the control group. Participants will receive 'care as usual' in this arm.
16539336|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
16539337|NCT03022344|Sham Comparator|Healthy|Patients in this cohort consist of 100 healthy patients
16539338|NCT03022344|Sham Comparator|Diabetes mellitus|Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
16539339|NCT03022331||Observational|
16539340|NCT03022318|Experimental|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
16539341|NCT03022318|Experimental|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
16539342|NCT03022305|Experimental|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
16539343|NCT03022305|Experimental|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
16539344|NCT03022305|No Intervention|Group three - no treatment|No physical therapy treatment will be given to this group.
16539345|NCT03022292|Experimental|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
16539346|NCT03022279|Active Comparator|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
16539347|NCT03022279|Active Comparator|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
16539348|NCT03022266|Experimental|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
16539349|NCT03022266|No Intervention|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
16539350|NCT03022253|Experimental|Liberal Platelet transfusion group|"Platelet transfusion to maintain a platelet count above 1,00,000 per microliter until one of the endpoints is met.
~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:
~Ibuprofen:
~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
~Paracetamol:
~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
16539351|NCT03022253|Active Comparator|Restrictive platelet transfusion group|"Platelet transfusion for standard criteria.
~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:
~Ibuprofen:
~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
~Paracetamol:
~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
16539352|NCT03022240|Experimental|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
16539353|NCT03022240|Experimental|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
16539354|NCT03022227|Experimental|group A start with the remote session followed by on site|
16539355|NCT03022227|Active Comparator|group B start with on site followed by telemedecine|
16539356|NCT03022214|Experimental|Placebo|5 capsules of placebo (microcrystalline cellulose) taken once in the morning with breakfast and once in the evening with dinner for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal
16539357|NCT03022214|Experimental|Intervention|"For presentation to volunteers, the daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:
~EnduraCell broccoli sprout powder: 3 capsules
~Bulk Powders Green tea extract: 1 capsule
~Bulk Powders Cinnamon Bark Extract: 1 capsule to be taken for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal"
16539510|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg + 14 mg|
16539511|NCT03021187|Placebo Comparator|Placebo|
16539358|NCT03022201|Experimental|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
16539359|NCT03022201|Active Comparator|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
16539360|NCT03022188||Observational|Observational
16539361|NCT03022175|Experimental|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.
~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.
~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
16539362|NCT03022175|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).
~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.
~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
16539363|NCT03022149|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
16539364|NCT03022149|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
16539365|NCT03022136|Experimental|Epidural Block|Epidural block for patients undergoing urological surgery
16539366|NCT03022123|Experimental|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
16539367|NCT03022123|Active Comparator|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
16539368|NCT03022110|Active Comparator|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
16539369|NCT03022110|Experimental|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
16539370|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
16539371|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
16539372|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
16539373|NCT03022097|Placebo Comparator|Placebo|Placebo
16539374|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
16539375|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
16539376|NCT03022071|Experimental|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
16539377|NCT03022071|Active Comparator|Psychodynamic psychotherapy|The included patients will receive time-limited psychodynamic psychotherapy for 28 weeks.
16539378|NCT03022058|Experimental|Patients with type 1 diabetes mellitus|
16539379|NCT03022045|Experimental|Risankizumab 75 mg|Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
16539380|NCT03022045|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
16539381|NCT03022032|Experimental|Comparing Steps Collected by Accelerometer (HOPE)|"10 patients will be enrolled in stage 1 to refine the HOPE App intervention
~All participants will receive :
~HOPE App
~The Fitbit Zip
~The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
16539382|NCT03022032|Other|Usual care (HOPE)|"Stage 2 will consist of arm 2-5 and will enroll 100 randomized patients.
~Usual care
~The app will also collect passive data from the smartphone"
16539383|NCT03022032|Experimental|Wearable accelerometer (HOPE)|"Participants will be asked to wear the Fitbit
~The Hope App will measure daily steps
~The app will also collect passive data from the smartphone"
16539384|NCT03022032|Experimental|Refined smartphone app (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily
~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.
~The app will also collect passive data from the smartphone"
16539385|NCT03022032|Experimental|Refined smartphone app and accelerometer (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily
~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.
~Participants will be asked to wear the Fitbit
~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
16539386|NCT03022032|Experimental|SMART Study Arm|"Two smartphone apps and a wearable accelerometer (Fitbit) in 30 patients with gynecologic cancers receiving chemotherapy at two NCI Community Oncology sites.
~The SMART intervention refers to the combination of both smartphone apps (SMART app and Beiwe app) and the accelerometer (Fitbit).
~The SMART app is the technology that is actively collecting symptom reporting information from patients (e.g. patients are receiving surveys, recording their symptoms daily, and receiving tailored symptom management materials on their phone in response).
~The Beiwe app is the technology involved in the passive data collection of participants' symptoms (GPS and accelerometer data) without their involvement."
16539387|NCT03022019|No Intervention|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
16539388|NCT03022019|Experimental|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
16539389|NCT03022006|Other|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
16539390|NCT03021993|Experimental|Nivolumab|Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
16539391|NCT03021980|Experimental|SuperFIT|This is the intervention group. They will receive the intervention SuperFIT.
16539393|NCT03021954|Experimental|Platelet rich plasma|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
16539394|NCT03021954|No Intervention|Control|No intervention given, patient will only get local anesthesia injection before perineoraphy
16539395|NCT03021941|Other|Elelyso 60 units/kg|All patients receive 60 units/kg of Elelyso.
16539396|NCT03021928|Experimental|60 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
16539397|NCT03021928|Experimental|132 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
16539398|NCT03021928|Experimental|228 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
16539399|NCT03021928|Experimental|324 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
16539400|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
16539401|NCT03021902|Experimental|IV amino acid + in-bed cycle ergometry|Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise
16539402|NCT03021902|No Intervention|Usual care|Participants randomized to the usual care arm will receive usual care protein and exercise.
16539403|NCT03021889|Experimental|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
16539404|NCT03021889|Other|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
16539405|NCT03021876|Placebo Comparator|ordinary group|usual intake prior to liver surgery
16539406|NCT03021876|Active Comparator|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
16539407|NCT03021863|Active Comparator|Group A Reminder|Tone of reminder email (duty 14 days followed by duty for non-responders 28 days)
16539408|NCT03021863|Active Comparator|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement for non-responders 28 days)
16539409|NCT03021863|Active Comparator|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
16539410|NCT03021863|Active Comparator|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
16539411|NCT03021863|Active Comparator|Group E Reminder|Tone of reminder email (generic reminders at 14 days followed by generic for non-responders 28 days)
16539412|NCT03021863|Active Comparator|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
16539413|NCT03021863|Active Comparator|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
16539414|NCT03021863|Active Comparator|Group H Reminder|Tone of reminder email (duty 14 days followed by generic for non-responders 28 days)
16539415|NCT03021863|Active Comparator|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic for non-responders 28 days)
16539416|NCT03021850|Active Comparator|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
16539417|NCT03021850|Active Comparator|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
16539418|NCT03021850|Other|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
16539419|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
16539420|NCT03021824||Moderate-Severe ARDS|All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.
16539421|NCT03021811|Other|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
16539422|NCT03021785|Experimental|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
16539423|NCT03021785|Experimental|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
16539657|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
16539424|NCT03021785|Experimental|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
16539425|NCT03021772|Active Comparator|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
16539426|NCT03021772|Active Comparator|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
16539427|NCT03021759|No Intervention|Control|No intervention
16539428|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
16539429|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
16539430|NCT03021746|Experimental|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
16539431|NCT03021746|Experimental|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
16539432|NCT03021746|Experimental|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
16539433|NCT03021733||Non-operative|Patients whom elected non-operative treatment
16539434|NCT03021733||Operative|Patients whom elected operative treatment
16539435|NCT03021720|Active Comparator|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
16539436|NCT03021720|Experimental|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
16539437|NCT03021694|Experimental|Young Males Week 1|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
16539438|NCT03021694|Experimental|Young Males Week 3|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
16539439|NCT03021694|Experimental|Young Males Week 5|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
16539440|NCT03021681|Other|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
16539441|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
16539442|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
16539443|NCT03021655|Experimental|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
16539512|NCT03021174|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
16539444|NCT03021655|Experimental|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
16539445|NCT03021655|Other|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
16539446|NCT03021642|Experimental|First Tepotinib Test, Then Tepotinib Reference|
16539447|NCT03021642|Experimental|First Tepotinib Reference, Then Tepotinib Test|
16539448|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
16539449|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
16539450|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
16539451|NCT03021616|Experimental|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
16539452|NCT03021616|Active Comparator|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
16539453|NCT03021616|Placebo Comparator|placebo control|32oz placebo control drink
16539454|NCT03021603|Experimental|Intervention Group|"This is a 4-week Brief Hope Intervention
~Four sessions in total:
~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.
~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
16539455|NCT03021603|Experimental|Control Group|"Standard care:
~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
16539456|NCT03021590|Experimental|Clarithromycin :Concomitant Therapy|Amoxicillin 1000 mg Tablets, Clarithromycin 500 mg Tablets , Tinidazole 500 mg Tablets and Esomeprazole 20 mg Capsule each every 12 hours for 14 days all by mouth
16539457|NCT03021590|Active Comparator|Levofloxacin :Concomitant Therapy|Levofloxacin 500 mg Tablets Amoxicillin 1000 mg Tablets,Tinidazole 500 mg Tablets and Esomeprazole 20 mg each every 12 hours for 14 days all by mouth
16539458|NCT03021577|Active Comparator|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
16539459|NCT03021577|Active Comparator|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
16539460|NCT03021538||Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
16539461|NCT03021538||Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
16539462|NCT03021525|Experimental|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
16539463|NCT03021525|Active Comparator|Control|Patients in the control group will be treated according to established basic treatment goals.
16539464|NCT03021512||Group 1 (BFG)|(Bifocal group). Subjects that underwent bifocal intraocular lenses implantation. (ie. Phaco with Restor intervention).
16539465|NCT03021512||Group 2 (TFG)|(Trifocal group). Subjects that underwent trifocal intraocular lenses implantation. (ie. Phaco with Panoptix intervention).
16539466|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg twice daily (BID)
16539467|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
16539468|NCT03021486|Experimental|Group I (haloperidol)|Patients receive haloperidol IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
16539469|NCT03021486|Experimental|Group II (chlorpromazine)|Patients receive chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
16539470|NCT03021486|Experimental|Group III (haloperidol, chlorpromazine)|Patients receive haloperidol and chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
16539471|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16539472|NCT03021434|Experimental|Standard Testing|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
16539473|NCT03021434|Experimental|Test Kits|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. Data collectors will demonstrate the use of the low-cost microbiological water test kits and test household stored drinking water. A study team member will return to the household within 72 hours and review the household-specific water quality information from the initial test with household members. Households will be given 10 water test kits to use at their discretion over the 1-2 month follow up period. They will be appropriately trained in how to both perform the test and interpret the results. Households will also review information on safe water handling, storage, and use behaviours.
16539513|NCT03021174|Active Comparator|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
16539474|NCT03021434|Active Comparator|Comparison|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Results from this analysis will be returned to the household at project endline. A study team member will return to the household within 72 hours to review the information on safe water handling, storage, and use behaviours.
16539475|NCT03021421|Sham Comparator|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
16539476|NCT03021421|Active Comparator|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)
~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
16539477|NCT03021408|Experimental|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
16539478|NCT03021408|Experimental|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
16539479|NCT03021408|Experimental|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
16539480|NCT03021395|Experimental|MRD-positive|MRD-positive patients receive Decitabine regimen.
16539481|NCT03021395|No Intervention|MRD-negative|MRD-negative patients receive no intervention.
16539482|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
16539483|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and <1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
16539484|NCT03021369|Active Comparator|Pleural drainage system Medela|These patients receive the digital Medela system
16539485|NCT03021369|Active Comparator|Pleural drainage system Ocean|These patients receive the analogue Maquet system
16539486|NCT03021356|Active Comparator|Trifecta aortic xenograft|The Trifecta aortic xenograft is implanted in these patients.
16539487|NCT03021356|Active Comparator|Magna Ease aortic xenograft|The Magna Ease aortic xenograft is implanted in these patients.
16539488|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
16539489|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
16539490|NCT03021330|Active Comparator|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
16539491|NCT03021330|Experimental|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
16539492|NCT03021317|Experimental|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
16539493|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
16539494|NCT03021291|Experimental|Gelesis100|Gelesis100 (2.25 g) twice daily
16539495|NCT03021278|Experimental|Saline Injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
16539496|NCT03021278|Experimental|Sham Injection|In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
16539497|NCT03021278|No Intervention|Control Group|The control group will not receive any kind of pain or pinprick sensation.
16539498|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
16539499|NCT03021252|Experimental|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
16539500|NCT03021252|Sham Comparator|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
16539501|NCT03021239|Active Comparator|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
16539502|NCT03021239|Active Comparator|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
16539503|NCT03021226|Experimental|Group I: Adults|Participants in Group I will be adults ages 20 to 24 years of age, 50 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
16539504|NCT03021226|No Intervention|Group II: No Intervention: Adults|Participants in Group II will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
16539505|NCT03021200|Experimental|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
16539506|NCT03021200|Experimental|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
16539507|NCT03021200|Experimental|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
16539508|NCT03021187|Experimental|Semaglutide 3 mg|
16539509|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg|
16539514|NCT03021161|Experimental|intervention group|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).
16539515|NCT03021161|Placebo Comparator|Placebo Oral Capsule|The control group will receive once daily similar capsules containing placebo.
16539516|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
16539517|NCT03021135|Active Comparator|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
16539518|NCT03021135|Experimental|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
16539519|NCT03021122|Experimental|Arm A (PedAMINES™ / Conventional Method)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of PedAMINES™ first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of a Conventional Method.
16539520|NCT03021122|Active Comparator|Arm B (Conventional Method / PedAMINES™)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of a Conventional Method first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of PedAMINES™.
16539521|NCT03021109|Experimental|Inferior vena cava diameteres|Measurement of inferior vena cava diameters with ultrasound
16539522|NCT03021083|Experimental|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.
~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.
~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
16539523|NCT03021070|Experimental|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
16539524|NCT03021070|No Intervention|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
16539525|NCT03021057|Experimental|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
16539526|NCT03021044|Other|STANDARD OF CARE|The standard of care group will be recommended about medications and a correct life style (physical activity, low salt and low fat diet, no smoking) in order to prevent cardiovascular events. In this 15-minutes talk study doctor will explain to patients and relatives the importance of aerobic physical activity (30-60 minutes daily, moderate intensity, for example speedy walking, for at least 5 days/weekly) with the aim of reducing cardiovascular risk. Patients will also receive a brochure with clear explanations. Study doctor and study coordinator will be helpful for any question and they will ensure that patients and relatives understand the importance of physical activity for cardiovascular health.
16539527|NCT03021044|Experimental|PHYSICAL ACTIVITY INTERVENTION|Besides standard of care, the experimental group will participate to a program of physical activity intervention. Following hospital discharge, participants in stable clinical conditions will be referred by their cardiologist to the exercise-based secondary prevention program. All exercise testing and training sessions will be performed without discontinuing the prescribed medications. On admission to the program, and quarterly during follow-up, each patient will perform a 1-km treadmill walk test as previously described (1k-TWT).
16539528|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
16539529|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
16539530|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
16539531|NCT03021005|Experimental|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
16539532|NCT03021005|No Intervention|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
16539533|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
16539534|NCT03020979|Experimental|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
16539535|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
16539536|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
16539537|NCT03020953|Experimental|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
16539538|NCT03020953|Active Comparator|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
16539564|NCT03020745|Experimental|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
16539957|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
16539539|NCT03020927|Active Comparator|Therapist Delivered|Children in the therapist-delivered condition will receive two, 60-minute long sessions of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. Parents will be permitted to observe sessions via live video, but will not be directly involved in intervention.
16539540|NCT03020927|Experimental|Parent + Therapist Delivered|Children in the parent + therapist-delivered condition will receive one, 60-minute long session of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. During the same period of time, parents/guardians of children will receive one, 60-minute long parent education session per week with graduate and post-graduate research staff, aimed at teaching parents to implement Reciprocal Imitation Training at home with the child.
16539541|NCT03020914|Experimental|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
16539542|NCT03020914|No Intervention|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
16539543|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.
~Marker located during surgery using the Sentimag system, and removed with the lesion."
16539544|NCT03020875|Active Comparator|PO Acetaminophen|"Preop:
~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.
~Postop:
~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:
~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.
~Postop supplemental pain medications:
~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
16539545|NCT03020875|Active Comparator|Intravenous Acetaminophen|"Preop:
~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.
~Postop:
~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:
~• IV Acetaminophen 1,000 mg [100 ml] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.
~Postop supplemental pain medications:
~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
16539546|NCT03020862|Experimental|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.
~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
16539547|NCT03020862|Experimental|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
16539548|NCT03020836|Other|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
16539549|NCT03020836|Other|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
16539550|NCT03020823|Experimental|SCB01A alone|intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
16539551|NCT03020797|Experimental|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
16539552|NCT03020797|Placebo Comparator|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
16539553|NCT03020784|Placebo Comparator|Placebo|IV placebo
16539554|NCT03020784|Experimental|PF-06818883|Experimental drug
16539555|NCT03020771|Active Comparator|5 mcg IM|
16539556|NCT03020771|Active Comparator|5 mcg SC|
16539557|NCT03020771|Placebo Comparator|5 mcg IM control|0.9% NaCl Solution
16539558|NCT03020771|Placebo Comparator|5 mcg SC control|0.9% NaCl Solution
16539559|NCT03020771|Active Comparator|10 mcg IM|
16539560|NCT03020771|Active Comparator|10 mcg SC|
16539561|NCT03020758|Experimental|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
16539562|NCT03020758|Experimental|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
16539563|NCT03020745|Experimental|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
16539565|NCT03020745|Experimental|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
16539566|NCT03020745|Experimental|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
16539567|NCT03020745|Experimental|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 <= 240 mg or matching placebo
16539568|NCT03020745|Experimental|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
16539569|NCT03020732|Experimental|test groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups.In test groups, a special centrifuge machine(Medifuge) and subjects venous blood were used to obtain Concentrated growth factor. A special compress was used to transform Concentrated growth factor membrane.
16539570|NCT03020732|Active Comparator|control groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups. In control groups, subepithelial connective tissue graft was taken from the palatal canine teeth-first molar teeth area with a trap door technique according to the width of the exposed root surface and the adjacent bone margins. The graft's thickness was adjusted between 1.5 and 2 mm.
16539571|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
16539572|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
16539573|NCT03020706|Experimental|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
16539574|NCT03020706|No Intervention|Control|No intervention
16539575|NCT03020693|Experimental|Invasive electrostimulation combined with exercises.|Dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to therapeutic intensity) combined with exercises program.
16539576|NCT03020693|Active Comparator|Placebo electrostimulation and exercises.|Sham dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to non-therapeutic intensity) with surface electrodes combined with exercises program.
16539577|NCT03020680|Experimental|ubiquinol|It is the reduced form of coenzyme Q10
16539578|NCT03020680|Active Comparator|ubiquinone|It is the oxidized form of coenzyme Q10
16539579|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
16539580|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
16539581|NCT03020654|Experimental|Treatment group|Virtual environment with fast moving objects these are graded in intensity from 1-7. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
16539582|NCT03020654|Active Comparator|Control group|Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
16539583|NCT03020641|Experimental|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
16539584|NCT03020641|Active Comparator|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
16539585|NCT03020628|Experimental|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
16539586|NCT03020628|Active Comparator|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
16539587|NCT03020615|Active Comparator|Stable Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
16539588|NCT03020615|Experimental|Intensive Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
16539589|NCT03020602|Experimental|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16539590|NCT03020589|Experimental|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
16539591|NCT03020589|No Intervention|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
16539592|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
16539593|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
16539594|NCT03020563|Active Comparator|Liposomal Bupivacaine|Time release Bupivacaine
16539595|NCT03020563|Placebo Comparator|Bupivacaine|Immediate Acting Bupivacaine
16539596|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
16539597|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
16539958|NCT03018093|Experimental|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
16539598|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
16539599|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
16539600|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
16539601|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
16539602|NCT03020511|Other|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
16539603|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
16539604|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
16539605|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
16539606|NCT03020485|Experimental|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
16539607|NCT03020485|Experimental|Sucrose|50g of sucrose dissolved in 250ml of water
16539609|NCT03020459|Experimental|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
16539610|NCT03020459|Active Comparator|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
16539611|NCT03020446|Experimental|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
16539612|NCT03020433|Active Comparator|rTMS Contralesional M1 Inhibition|
16539613|NCT03020433|Active Comparator|rTMS Contralesional PMC facilitation|
16539614|NCT03020433|Active Comparator|rTMS Ipsilesional PMC facilitation|
16539615|NCT03020433|Sham Comparator|rTMS Sham at Ipsilesional M1|
16539616|NCT03020420|Experimental|treatment arm|receive cicatricell cream
16539617|NCT03020420|No Intervention|control arm|to treatment
16539618|NCT03020407|Experimental|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI > 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI > 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI < 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
16539619|NCT03020407|No Intervention|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
16539620|NCT03020394||Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
16539621|NCT03020394||Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
16539622|NCT03020394||High flow nasal cannula|High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
16539623|NCT03020381||Cognitively Normal (Control Group)|Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
16539624|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
16539655|NCT03020186|Experimental|Physical activity+ green-MED diet|"On top of the PA intervention described in Arm 1, the participants will guided for moderate weight loss with a MED diet, low in simple carbohydrates that will be rich in plants and polyphenols and low in processed meat. The diet will include 1oz/day of walnuts, 3-4 cups/day of green tea and ~500cc green shake/dinner based on specific strain of duckweed [Wolffia globose, Mankai], an aquatic plant, which might serve as a plant protein source. All the above will be provided free of charge."
16539625|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 60 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
16539626|NCT03020368|Experimental|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
16539627|NCT03020368|Active Comparator|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
16539628|NCT03020355|Experimental|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
16539629|NCT03020355|Active Comparator|not Placental Blood Drainage|In the control group, the clamped cord will not released.
16539630|NCT03020329|Experimental|Paclitaxel liposome, Cisplatin, 5-Fu,|Patients receive paclitaxel liposome(135mg/m2 on day 1), cisplatin (75mg/m2 on day 1,Separate injection on day 1 to 3) and fluorouracil (3750mg/m2 CIV 120h) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
16539631|NCT03020316|No Intervention|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.
~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
16539632|NCT03020316|Active Comparator|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.
~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
16539633|NCT03020316|Active Comparator|Peer Mentor|"We are no longer recruiting in this arm.
~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
16539634|NCT03020303|Placebo Comparator|Placebo Oral Tablet|A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance
16539635|NCT03020303|Active Comparator|Spironolactone 25 MG Tablet|25 mg of active spironolactone in tablet form
16539636|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
16539637|NCT03020277|Other|ASD children families|
16539638|NCT03020264|Experimental|Patients older than 75 years|Collection of hypoglycaemia épisodes with the glycemic sensor FREESTYLE Libre Pro
16539639|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
16539640|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
16539641|NCT03020238|Placebo Comparator|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
16539642|NCT03020238|Active Comparator|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
16539643|NCT03020225|Active Comparator|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
16539644|NCT03020225|Experimental|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
16539645|NCT03020225|Experimental|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
16539646|NCT03020212|Active Comparator|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
16539647|NCT03020212|No Intervention|Not oxygen|No intervention ( no therapy with oxygen)
16539648|NCT03020199|Experimental|A1|80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.
16539649|NCT03020199|Active Comparator|B1|80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.
16539650|NCT03020199|Experimental|A2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
16539651|NCT03020199|Experimental|C1|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)
16539652|NCT03020199|Experimental|C2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
16539653|NCT03020186|Placebo Comparator|Physical activity|Physical activity (PA) group will receive free gym memberships and the instruction necessary to engage in moderate-intensity physical activity, ~80% of which will have an aerobic component. The participants will get basic health promoting guideline for healthy diet .
16539654|NCT03020186|Experimental|Physical activity+ MED diet|On top of the PA intervention described in Arm 1, the participants will be guided for moderate weight loss with a traditional Mediterranean (MED) diet, low in simple carbohydrates. The diet will include 1oz/day of walnuts that will be provided free of charge.
16539656|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
16539658|NCT03020160|Experimental|Emicizumab: Expansion Part|Participants will received SC emicizumab at a loading dose of 3 mg/kg every week for initial 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
16539659|NCT03020160|Experimental|Emicizumab: PK Run-in Part|Participants will received SC emicizumab at a dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
16539660|NCT03020147||early BCG|Children received BCG soon after their birth between 2008 and 2013.
16539661|NCT03020147||delayed BCG|Children received BCG when they are 2,5kg between 2008 and 2013.
16539662|NCT03020134|Experimental|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
16539663|NCT03020134|Placebo Comparator|Placebo Group|Placebo
16539664|NCT03020121|Experimental|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
16539665|NCT03020108||Group 1|The group 1 will comprise of 30 patients with benign ovarian cysts such as mature teratoma or simple serous cysts on ultrasound examination.
16539666|NCT03020108||Group 2|The group 2 will comprise of 30 patients with diagnosis of stage 1-2 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
16539667|NCT03020108||Group 3|The group 3 will comprise of 30 patients with diagnosis of stage 3-4 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
16539668|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
16539669|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
16539670|NCT03020069|Experimental|Glucose Meter|Continuing Glucose Monitoring Device
16539671|NCT03020069|Active Comparator|No Glucose Meter|Average Blood glucose measure
16539672|NCT03020056|Placebo Comparator|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
16539673|NCT03020056|Experimental|expedited surgery|Cataract surgery will be performed within 4 weeks.
16539674|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.
~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
16539675|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1
~And: No VHR characteristics
~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
16539676|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)
~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
16539677|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~All treatment completed 24 months from date of complete remission."
16539678|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~All treatment completed 24 months from date of complete remission."
16539679|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~All treatment completed 24 months from date of complete remission."
16539706|NCT03019822|Other|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
16539707|NCT03019822|Other|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
16539777|NCT03019250|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
16539680|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
16539681|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
16539682|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL
16539683|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
16539684|NCT03020017|Experimental|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
16539685|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
16539686|NCT03019991|Experimental|PK Group (Danoprevir,Ritonavir)|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;
16539687|NCT03019991|Placebo Comparator|Placebo Group|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;
16539688|NCT03019965|Active Comparator|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
16539689|NCT03019965|Experimental|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
16539690|NCT03019965|Active Comparator|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
16539691|NCT03019965|Experimental|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
16539692|NCT03019965|Active Comparator|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
16539693|NCT03019965|Experimental|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
16539695|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
16539696|NCT03019861|Active Comparator|Ayurvedic nutritional counseling|Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.
16539697|NCT03019861|Active Comparator|Conventional nutritional counseling|Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.
16539698|NCT03019848|Experimental|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
16539699|NCT03019848|Placebo Comparator|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
16539700|NCT03019835|Active Comparator|GROUP 1|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
16539701|NCT03019835|Active Comparator|GROUP 2|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
16539702|NCT03019835|Active Comparator|GROUP 3|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
16539703|NCT03019835|Active Comparator|GROUP 4|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
16539704|NCT03019835|Active Comparator|CONTROL|A control group : not receiving an antagonist (spontaneous recovery)
16539705|NCT03019822|Other|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
16539774|NCT03019276|Experimental|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16539708|NCT03019822|Other|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
16539709|NCT03019809|Experimental|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
16539710|NCT03019796|Experimental|PLACEBO FIRST THEN MEDICATED|Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
16539711|NCT03019796|Experimental|MEDICATED FIRST THEN PLACEBO|Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
16539712|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
16539713|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
16539714|NCT03019770|Experimental|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
16539715|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
16539716|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
16539717|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
16539718|NCT03019744|Experimental|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
16539719|NCT03019744|Active Comparator|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
16539720|NCT03019731|Experimental|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
16539721|NCT03019718|Experimental|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
16539722|NCT03019705||Participants|Individuals with pathological health anxiety
16539723|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
16539724|NCT03019679||Study group|Patients with polycystic ovary syndrome
16539725|NCT03019679||Control group|Patients without polycyctic ovary syndrome
16539726|NCT03019666|Experimental|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
16539727|NCT03019666|Experimental|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
16539728|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
16539729|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
16539730|NCT03019640|Experimental|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
16539731|NCT03019627|Experimental|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
16539732|NCT03019627|Placebo Comparator|Vehicle|vehicle eye drops six times daily
16539733|NCT03019614|Experimental|Group 1|"Volunteers in group 1 received the following interventions:
~Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).
~Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).
~Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).
~Each administration of IMP was separated by a washout period of at least 7 days."
16539734|NCT03019614|Experimental|Group 2|"Volunteers in group 2 received the following interventions:
~Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).
~Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).
~Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).
~Each administration of IMP was separated by a washout period of at least 7 days."
16539735|NCT03019601|Experimental|Group education|Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions.
16539736|NCT03019588|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
16539737|NCT03019588|Active Comparator|Paclitaxel 80 mg/m^2|Participants receive paclitaxel 80 mg/m^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.
16539775|NCT03019263|Experimental|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
16539738|NCT03019575|Experimental|Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)|Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was >60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
16539739|NCT03019562|Experimental|Oxycodone|4mg of oxycodone iv bolus
16539740|NCT03019562|Active Comparator|Fentanyl|50ug of fentanyl iv bolus
16539741|NCT03019549|Experimental|Rosuvastatin|Period 1: 20 mg rosuvastatin administered once orally (PO)
16539742|NCT03019549|Experimental|Lanabecestat + Rosuvastatin|Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
16539743|NCT03019536|Experimental|LY3303560 IV|Multiple doses of LY3303560 administered intravenously (IV) for up to 48 weeks, followed by a 16 week follow-up period
16539744|NCT03019536|Experimental|Placebo IV|Multiple doses of placebo administered IV for up to 48 weeks, followed by a 16 week follow-up period
16539745|NCT03019523|Placebo Comparator|Sugar Pill|Maltodextrin (~2 grams to match weight of active treatment) placebo pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
16539746|NCT03019523|Active Comparator|Caffeine Blend|75 mg caffeine, 75 mg theanine, and 2g tyrosine pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
16539752|NCT03019484|Experimental|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
16539753|NCT03019484|No Intervention|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.
~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
16539754|NCT03019471||Lung cancer|Isolate Tumor DNA from the patients blood.
16539755|NCT03019471||Breast cancer|Isolate Tumor DNA from the patients blood.
16539756|NCT03019471||Colorectal cancer|Isolate Tumor DNA from the patients blood.
16539757|NCT03019471||Glioma|Isolate Tumor DNA from the patients blood.
16539758|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
16539759|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
16539760|NCT03019419|Experimental|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
16539761|NCT03019419|Experimental|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
16539762|NCT03019419|Placebo Comparator|Placebo|Once daily placebo for control for 48 weeks
16539763|NCT03019406|Experimental|avalglucosidase alfa|Administered intravenously every 2 weeks as an ascending dose cohort
16539764|NCT03019406|Active Comparator|alglucosidase alfa|administered intravenously at current stable dose (i.e. administered regularly for a minimum of 6 months immediately prior to study entry)
16539765|NCT03019393|Other|Beef|Beef topside fully cooked, 200g
16539766|NCT03019380|Experimental|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
16539767|NCT03019367|Active Comparator|Umbilical cord milking UCM|Milking the umbilical cord 4 times towards the infant at a speed of 20cm/2seconds.
16539768|NCT03019367|Active Comparator|Delayed cord clamping DCC|Delayed clamping of the umbilical cord for at least 60 seconds.
16539769|NCT03019354|Experimental|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
16539770|NCT03019354|Active Comparator|Oxygen mask|oxygen mask was used during intravenous general anesthesia
16539771|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
16539772|NCT03019302|Experimental|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
16539773|NCT03019289|Experimental|pridopidine|Pridopidine (TV-7820) capsules
16539778|NCT03019250|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
16539779|NCT03019237|Experimental|intranasal anti-IgE|Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
16539780|NCT03019237|Active Comparator|intranasal allergen|GMP produced rBet v 1 will be freshly diluted in sterile 0.9% sodium chloride solution (50 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
16539781|NCT03019237|Placebo Comparator|intranasal saline|Sterile 0.9% sodium chloride solution will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
16539782|NCT03019224|Placebo Comparator|Group 1|The use of desensitizing dentifrice [Sucralose (S) Control dentifrice)] in plastic tray.
16539783|NCT03019224|Experimental|Group 2|The use of desensitizing dentifrice [Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)] in plastic tray.
16539784|NCT03019224|Experimental|Group 3|The use of desensitizing dentifrice [Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)] in plastic tray.
16539785|NCT03019224|Experimental|Group 4|The use of desensitizing dentifrice [Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate] in plastic tray.
16539786|NCT03019211|Experimental|Hydrotherapy|Exercise performed in an aquatic environment. The participants will perform static/dynamic exercises (balance and resistance training) in an aquatic environment. Training volume and intensity we will increase systematically over 12 weeks.
16539787|NCT03019211|Active Comparator|Control|The participants will perform exercises (balance and resistance training) like hydrotherapy group but out of the aquatic environment, during a 12 weeks training period (3sessions/week). Training volume and intensity we will increase systematically over 12 weeks.
16539788|NCT03019198|Experimental|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
16539789|NCT03019198|Placebo Comparator|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
16539790|NCT03019185|Experimental|Phase 2 Cohort|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
16539791|NCT03019185|Active Comparator|Phase 3 Bardoxolone Cohort|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
16539792|NCT03019185|Placebo Comparator|Phase 3 Placebo Cohort|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
16539793|NCT03019172|Experimental|Lactobacillus reuteri|Women in experimental branch will receive two sachets. Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
16539794|NCT03019172|Placebo Comparator|Sachet with cranberry + placebo|Women in control branch will receive two sachets. Sachet one contains only Maltodextrin and sachet two contains instant cranberry drinkcomposed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica Both sachets should be emptied in a glass and mixed with 200 ml of cold water
16539795|NCT03019159||Tele-consulting|One visit out of two takes place with teleconsulting and the other is a face-to-face consultation
16539796|NCT03019159||No tele-consulting|
16539797|NCT03019146|Experimental|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
16539798|NCT03019146|Experimental|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
16539799|NCT03019146|Experimental|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
16539800|NCT03019146|No Intervention|Control|No intervention
16539801|NCT03019133|No Intervention|Usual Care|Usual care will be provided.
16539802|NCT03019133|Active Comparator|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
16539803|NCT03019133|Active Comparator|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
16539804|NCT03019120|Experimental|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
16539805|NCT03019094|Experimental|Treatment|Implantation of the RENOVA tibial nerve stimulation system
16539992|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
16539806|NCT03019081|Experimental|Anorexia nervosa-study drug|"Drug: Isoproterenol Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant. The isoproterenol dose will range from 0.1 micrograms to 4.0 micrograms and exposure during each visit will not exceed 25.0 micrograms. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
~Other Names: Isuprel"
16539807|NCT03019081|Placebo Comparator|Anorexia nervosa-placebo|"Drug: Normal Saline Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
~Other Names:
~Saline"
16539808|NCT03019055|Experimental|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
16539809|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
16539810|NCT03019055|Experimental|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
16539811|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
16539812|NCT03019042|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 30 g/day (contain 10.1 herb materials) during entire follow up period (2 years). HGMX is composed of 10 dietary Chinese herbs (including ginseng (Renshen), tuckahoe (Fuling), coixenolide (Yiyiren), Chinese yam (Shanyao), lotus seed (Lianzi), amomum (Sharen), platycodon (Jiegen), white hyacinth bean (Baibiandou), licorice (Gancao), and orange peel (Jupi)), early rice, and oats.
16539813|NCT03019042|Placebo Comparator|placebo|Patients in this arm receive placebo, with oral dose of 30 g/day during entire follow up period (2 years). The placebo is only consist of early rice and oats.
16539814|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
16539815|NCT03019016||Robotic RC (IA)|Benign or malignant disease under going a right colectomy.
16539816|NCT03019016||Robotic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
16539817|NCT03019016||Laparoscopic RC (IA)|Patients with benign or malignant disease under going a right colectomy.
16539818|NCT03019016||Laparoscopic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
16539820|NCT03018990|Active Comparator|Alcoholic liver fibrosis|
16539821|NCT03018990|Active Comparator|Non-alcoholic steatohepatitis|
16539822|NCT03018990|Active Comparator|Healthy control|
16539823|NCT03018977|Active Comparator|Sedative weaning protocol|We create the new sedative weaning protocol and then use the sedative weaning protocol.
16539824|NCT03018977|Placebo Comparator|Usual Care|no use sedative weaning protocol. Sedative or/and analgesic medications are adjusted base on physician
16539825|NCT03018964|Experimental|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
16539826|NCT03018964|Active Comparator|Ca-SILC|No solo surgery, operation with a camera operator in SILC
16539827|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
16539828|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
16539829|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
16539830|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
16539831|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
16540030|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
16539832|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.
~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.
~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
16539833|NCT03018912|Experimental|Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Investigators or research associates will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
16539834|NCT03018912|No Intervention|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
16539835|NCT03018899|Experimental|paravertebral block|patients received ultrasound guided two-segment paravertebral block for percutaneous nephrolithotomy
16539836|NCT03018899|Active Comparator|Epidural|patients received thoracic epidural anesthesia for percutaneous nephrolithotomy
16539837|NCT03018886|Other|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
16539838|NCT03018886|Experimental|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
16539839|NCT03018873|Experimental|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).
~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
16539840|NCT03018873|Active Comparator|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
16539841|NCT03018873|No Intervention|control group|routine treatment, no RIPC
16539842|NCT03018860|Experimental|"Moderate management"|Women are encouraged by physicians to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.
16539843|NCT03018860|Active Comparator|"Intensive management"|Usual obstetrical care in France
16539844|NCT03018834|Experimental|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
16539845|NCT03018834|Placebo Comparator|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
16539846|NCT03018821|Active Comparator|Standard CMF|"Standard Chinese medical formulas (CMF) for the corresponding TCM syndromes, plus an anti-virus treatment of western drugs (such as Entecavir or Tenofovir).
~Yinchengao Decoction plus Ganlu Detoxification Pill for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao
~Chaihu Shugan San for the TCM syndrome: Liver depression and qi stagnation
~Xiaoyao powder for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
~Yiguan Decoction for the TCM syndrome: Yin deficiency of liver and kidney
~Fuzilizhong Decoction plus Jinkui Shenqi Bolus for the TCM syndrome: Yang deficiency of spleen and kidney
~Ge Xia Zhu Yu Decoction for the TCM syndrome: Internal blood stasis"
16539847|NCT03018821|Experimental|Advanced CMF|"Advanced TCM formulas for corresponding TCM syndromes provided by famous TCM doctors who were national wide known in China, plus an anti-virus western drugs (such as Entecavir or Tenofovir).
~Taohong Huazhuo Decoction for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao
~Soothe the liver and regulate qi Decoction for the TCM syndrome: Liver depression and qi stagnation
~Supplemented Ganbi Decoction for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
~Supplemented Zimu Dan for the TCM syndrome: Yin deficiency of liver and kidney
~Guifu Erxian Decoction for the TCM syndrome: Yang deficiency of spleen and kidney
~Supplemented Ganji Decoction for the TCM syndrome: Internal blood stasis"
16539848|NCT03018821|Experimental|Pure Entecavir or Tenofovir|Use an anti-virus western drug alone (such as Entecavir or Tenofovir).
16539849|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
16539850|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
16539851|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
16539852|NCT03018795|Active Comparator|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
16539853|NCT03018795|Active Comparator|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
16539854|NCT03018782|Other|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
16539855|NCT03018769||chronic SCAD|
16539914|NCT03018379||Assessment of physical activity|The participants were instructed to wear the accelerometer triaxial (GT3X+) attached to an elasticized belt around the waist, once they woke up until bed time at night for 7 consecutive days and to remove the accelerometer any time they were to perform activities that involve the use of water and when going to bed.
16540114|NCT03017053|Experimental|Radiotherapy|Primary surgery & Radiotherapy
16539856|NCT03018756|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
16539857|NCT03018756|Placebo Comparator|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
16539858|NCT03018743||dapoxetine treatment group|Consecutive patients who seek medical treatment for PE will be enrolled in the study.
16539859|NCT03018730|Experimental|PRX-102|PRX-102 infusion every 2 weeks
16539860|NCT03018717|Other|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
16539861|NCT03018717|Other|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
16539862|NCT03018704|Placebo Comparator|Placebo|a placebo control arm
16539863|NCT03018704|Experimental|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients.
16539864|NCT03018691|Experimental|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
16539865|NCT03018691|Experimental|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
16539866|NCT03018691|Placebo Comparator|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
16539867|NCT03018678||Patients with HOFH|No intervention
16539868|NCT03018665|Experimental|Exenatide and Metformin|Exenatide in Combination With Metformin
16539869|NCT03018665|Active Comparator|BIAsp30 and Metformin|BIAsp30 in Combination With Metformin
16539870|NCT03018652|Experimental|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
16539871|NCT03018652|Placebo Comparator|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
16539872|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
16539873|NCT03018626|Active Comparator|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
16539874|NCT03018626|Experimental|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
16539875|NCT03018613|Active Comparator|treatment for part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.
16539876|NCT03018613|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.
16539877|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
16539878|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
16539879|NCT03018587|Experimental|TruSculpt|Subject(s) will receive 1 radio frequency treatment in desired area.
16539880|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
16539881|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
16539882|NCT03018561|Active Comparator|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
16539883|NCT03018561|Experimental|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
16539884|NCT03018561|Experimental|patients with coronary heart disease|CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
16539885|NCT03018561|Experimental|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:
~≥18 years
~Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)
~NYHA functional class I-III
~Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).
~Able to perform an symptom limited exercise test.
~Capacity and willingness to sign the informed consent form."
16539886|NCT03018548|Experimental|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
16539887|NCT03018535|Experimental|RITUXIMAB|1 g. IV of Rituximab on days 1 and 15
16539888|NCT03018535|Active Comparator|Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for 3 doses; oral methylprednisolone (0.4mg/kg/day) or prednisone (0.5/mg/kg/day); Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
16539889|NCT03018509|Experimental|JTE-451 Dose 1|JTE-451 dose 1 for 28 days
16539890|NCT03018509|Experimental|JTE-451 Dose 2|JTE-451 dose 2 for 28 days
16539891|NCT03018509|Experimental|JTE-451 Dose 3|JTE-451 dose 3 for 28 days
16539892|NCT03018509|Experimental|JTE-451 Dose 4|JTE-451 dose 4 for 28 days
16539893|NCT03018509|Experimental|Placebo|Placebo for 28 days
16539894|NCT03018496|Experimental|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
16539895|NCT03018496|Experimental|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
16539896|NCT03018483|Experimental|Variable PSV|
16539897|NCT03018483|Active Comparator|Conventional PSV|
16539898|NCT03018483|Active Comparator|Automated PSV|
16539899|NCT03018483|Active Comparator|NAVA|
16539900|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
16539901|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
16539902|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
16539903|NCT03018457||patients who need a dental implants|
16539904|NCT03018444|Experimental|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
16539905|NCT03018444|Placebo Comparator|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
16539906|NCT03018431||Physician routine evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon clinical and biological, associated with standard radiographs, performed by the physician in chrage of the patient.
16539907|NCT03018431||independent evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon early CT scan, and repeated lung ultrasonography, performed by an independent operator.
16539908|NCT03018418|Experimental|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
16539909|NCT03018405|Experimental|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
16539910|NCT03018405|Experimental|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort cohort 8-9 ( only in CRC) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
16539911|NCT03018392|Experimental|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
16539912|NCT03018379||Assessment of body composition|The collection of the samples and the analyses were undertaken according to the guidelines of the International Atomic Energy Agency. In brief, after having emptied the bladder, each participant provided a predose saliva sample using a cotton ball.A 99.8 % deuterium dose of 0.5 g per kg body weight was given orally to the participant. The postdose sample was collected from 3h to 4h after the administration of the dose. The saliva samples were stored at 20°C until analysis by Fourier transform infrared spectroscopy (FTIR).
16539913|NCT03018379||Assessment of energy expenditure|"Each participant provided a predose urine sample. A dose of doubly labelled water 2.625 ml per kg body weight was given orally to the participant.
~The post dose sample was collected at 3h to 4h , and on days 3, 7 and 14 after dosing. An aliquot of those samples were stored at 20°C in tightly sealed containers until analysis by isotope-ratio mass spectrometry (IRMS)."
16539915|NCT03018366|Active Comparator|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (200mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 200mg is a peanut based product
16539916|NCT03018366|Placebo Comparator|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
16539917|NCT03018353|Other|Navigation services with sof/vel therapy|This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
16539918|NCT03018340|Experimental|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
16539919|NCT03018340|Placebo Comparator|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
16539920|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
16539921|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
16539922|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
16539923|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
16539924|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility <%32 and Kruger morphology <4%.
16539925|NCT03018301|Active Comparator|Ketamine group|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
16539926|NCT03018301|Placebo Comparator|Control group|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
16539927|NCT03018288|Other|1/Radiation Therapy|Standard radiation therapy
16539928|NCT03018288|Experimental|2/RT+TMZ+Pembrolizumab|Standard treatment with experimental treatment (pembro) added
16539929|NCT03018288|Experimental|3/RT+TMZ+Pembrolizumab+HSPPC96 Vaccine|Standard treatment with experimental treatment (pembro+ vaccine) added
16539930|NCT03018288|Placebo Comparator|4/RT+TMZ+Pembrolizumab+ Placebo Vaccine|Standard treatment with experimental treatment and placebo added
16539931|NCT03018275|Experimental|1|"Vials of lyophilized R mucosa (103, 104, or 105 CFU)"
16539932|NCT03018262||Healthy Volunteers - Sub-study 1|Healthy Volunteers
16539933|NCT03018262||Healthy Volunteers - Sub-study 2|Healthy Volunteers
16539934|NCT03018262||Healthy Volunteers - Sub-study 3|Healthy Volunteers
16539935|NCT03018249|Active Comparator|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
16539936|NCT03018249|Experimental|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
16539937|NCT03018236|Experimental|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
16539938|NCT03018236|Placebo Comparator|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
16539939|NCT03018236|Experimental|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
16539940|NCT03018236|Placebo Comparator|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
16539941|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.
~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.
~Peripheral blood hematopoietic cell transplantation
~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.
~Growth factor support: G-CSF"
16539942|NCT03018197|Experimental|Medication Education|Patients will receive training on the use of the personal health record and health education via the personal health record.
16539943|NCT03018197|No Intervention|No Medication Education|Patients will receive the current standard of care for the personal health record. Patients will not receive training on the use of the personal health record or health education via the personal health record.
16539944|NCT03018171|Experimental|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
16539945|NCT03018171|Active Comparator|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
16539946|NCT03018158|No Intervention|dentulous|MR Imaging was collected with condition at the tongue at rest position.
16539947|NCT03018158|No Intervention|edentulous without denture wear.|MR Imaging was collected without denture wear.
16539948|NCT03018158|Experimental|edentulous with denture wear.|MR Imaging was collected with denture wear.
16539949|NCT03018145|Experimental|Standard stretcher group|Use a standard stretcher car as a transporting method in the operating room
16539950|NCT03018145|Active Comparator|Wagon group|Use a wagon as a transporting method in the operating room
16539951|NCT03018132|Other|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
16539952|NCT03018119|Active Comparator|Anesthesiologists|Total: 11 Intervention: Survey
16539953|NCT03018119|Active Comparator|Obstetricians|Total: 11 Intervention: Survey
16539954|NCT03018119|Active Comparator|Registered Nurses|Total: 10 Intervention: Survey
16539955|NCT03018119|Active Comparator|Surgical Technicians|Total: 6 Intervention: Survey
16539956|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
16539959|NCT03018080|Experimental|Cohort A|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
16539960|NCT03018080|Experimental|Cohort B|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
16539961|NCT03018067|Placebo Comparator|Placebo|Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.
16539962|NCT03018067|Experimental|10 g qd|RDX227675, 10 g qd
16539963|NCT03018067|Experimental|20 g qd|RDX227675, 20 g qd
16539964|NCT03018067|Experimental|30 g qd|RDX227675, 30 g qd
16539965|NCT03018054|Experimental|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
16539966|NCT03018054|Experimental|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
16539967|NCT03018054|Placebo Comparator|Placebo|Participants will receive matching placebo once daily after breakfast.
16539968|NCT03018041|Experimental|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
16539969|NCT03018041|Placebo Comparator|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
16539970|NCT03018028|Experimental|Oral semaglutide 3 mg|
16539971|NCT03018028|Experimental|Oral semaglutide 7 mg|
16539972|NCT03018028|Experimental|Oral semaglutide 14 mg|
16539973|NCT03018028|Placebo Comparator|Oral placebo|
16539974|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
16539975|NCT03018015|Experimental|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
16539976|NCT03018015|Active Comparator|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
16539977|NCT03018015|Active Comparator|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
16539978|NCT03018002|No Intervention|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
16539979|NCT03018002|Experimental|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
16539980|NCT03017989|Experimental|NIRF imaging|After the white light (WL) imaging, NIRF imaging will be performed. 2.5 mg of ICG will be administered i.v. up to 5 times if needed. The lesions identified in WL, are inspected in NIRF mode. The surgeon indicated whether the lesions are more easily identified in WL or the NIRF mode and scores the visibility on a 1-10 scale. Next, inspection will take place for lesions that are seen in NIRF mode but not in WL. Biopsies will be taken from the lesions and from normal tissue for reference and sent for histology. Evaluation will take place whether the lesions differ in histological characteristics
16539981|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
16539982|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
16539983|NCT03017963|Experimental|dose-escalation cohort|Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.
16539984|NCT03017950|Experimental|Part1 (A)|"Number of Subjects: 10
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: CKD-330
~IPs for Period 2: CKD-330 + D086"
16539985|NCT03017950|Experimental|Part1 (B)|"Number of Subjects: 10
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: CKD-330 + D086
~IPs for Period 2: CKD-330"
16539986|NCT03017950|Experimental|Part2 (A)|"Number of Subjects: 30
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: D086
~IPs for Period 2: CKD-330 + D086"
16539987|NCT03017950|Experimental|Part2 (B)|"Number of Subjects: 30
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: CKD-330 + D086
~IPs for Period 2: D086"
16539988|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
16539989|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
16539990|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
16539991|NCT03017911||Patients with PICC Lines|All patients included in this study have undergone PICC Line placement before enrollment.
16539996|NCT03017872|Active Comparator|Standard of Care (SoC) arm|2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
16539997|NCT03017872|Experimental|Dolutegravir arm|Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
16539998|NCT03017872|Experimental|Dolutegravir 2NRTI arm (D2N)|Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)
16539999|NCT03017859|Experimental|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
16540000|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
16540001|NCT03017833|Experimental|Treatment (metformin, sapanisertib)|Patients receive metformin PO 1-3 times daily on days 1-42 and sapanisertib PO daily on days 15-42 of cycle 1. Patients then receive metformin PO daily and sapanisertib PO daily on days 1-28 of cycle 2 and beyond. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16540002|NCT03017820|Experimental|Group A (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
16540003|NCT03017820|Experimental|Group B (VSV-IFNbeta-NIS, ruxolitinib)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days -1 to 9. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
16540004|NCT03017820|Experimental|Group C (VSV-IFNbeta-NIS, ruxolitinib, cyclophosphamide)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days -1 to 9. Patients also receive cyclophosphamide IV over 2 hours on day 2. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
16540005|NCT03017807|Experimental|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance.
16540006|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
16540007|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
16540008|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
16540009|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
16540010|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
16540011|NCT03017768|Active Comparator|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
16540012|NCT03017768|Placebo Comparator|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
16540013|NCT03017716|No Intervention|IBP patients on standard therapy|IBP patients on standard therapy.
16540014|NCT03017716|Active Comparator|IBP patients on standard therapy and GFD|IBP patients on standard therapy and GFD
16540015|NCT03017703|Experimental|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
16540016|NCT03017703|Experimental|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
16540017|NCT03017690||lanreotide group (Somatuline Depot®)|
16540018|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
16540019|NCT03017677||Group|
16540020|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
16540021|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
16540022|NCT03017651|Experimental|OM3-supplement 1|1 g capsule for OM3-supplement 1 given once
16540023|NCT03017651|Active Comparator|OM3-supplement 2|1 g capsule for OM3-supplement 2 given once
16540024|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
16540025|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:
~Maximal PACU VAS pain score (per nursing charts)
~Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)
~POD 24 and 48 hours and 4 weeks Respiratory complications"
16540026|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
16540027|NCT03017599|Experimental|Intervention group|EUS-FNB using 20-gauge procore needle
16540028|NCT03017586|Experimental|STN|DBS target with Subthalamic Nucleus (STN).
16540029|NCT03017586|Experimental|GPi|DBS target with Globus Pallidus Internus (GPi).
16585411|NCT02709681||SCD patients|Patients followed in 32 Italian Centers.
16540031|NCT03017560|Experimental|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
16540032|NCT03017560|No Intervention|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
16540033|NCT03017547|Experimental|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
16540034|NCT03017547|Placebo Comparator|Placebo|Placebo IV once daily on Study Day 1-4
16540035|NCT03017534|Experimental|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
16540036|NCT03017534|Experimental|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
16540037|NCT03017534|Experimental|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
16540038|NCT03017534|Experimental|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
16540039|NCT03017534|Experimental|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
16540040|NCT03017534|Experimental|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
16540041|NCT03017534|Experimental|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
16540042|NCT03017534|Experimental|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
16540043|NCT03017521|Experimental|TAS-117|TAS-117, 16mg, orally, daily
16540044|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
16540045|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
16540046|NCT03017495|Experimental|Food effect and Drug-Drug interaction|Treatments will be given to all subjects in the same fixed sequence: Treatment A (Day 1, single dose of midazolam, fasted), Treatment B (Day 2, single dose of ACT-541468 followed by single dose of midazolam, fasted), Treatment C (Day 4, single dose ACT-541468, fed), Treatment D (multiple doses of ACT-541468 from Day 5 to Day 8 + single dose of midazolam on Day 8, fasted).
16540047|NCT03017469|Experimental|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
16540048|NCT03017469|No Intervention|Control Group|Nurses who do not participate in the ARISE Intervention
16540049|NCT03017456|No Intervention|Usual Care (UC)|Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
16540050|NCT03017456|Active Comparator|SCP-Intervention vs usual care|behavioral intervention vs control Patients in the SCP-Int arm will be asked to attend a one-time appointment with a trained oncology nurse. The SCP-Int is comprised of a 30-minute nurse-led face-to-face intervention and the provision of a tailored PC-specific SCP (PC-SCP). Persistent effects and concerns that are identified will prompt the development of a tailored management plan captured within the PC-SCP. Relevant patient education materials will be linked electronically. Nurses will use motivational interviewing techniques to effective in increase healthy behaviors and empower the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support.
16540051|NCT03017443|Experimental|Nutrisystem My Way|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem My Way plan.
16540052|NCT03017443|Experimental|Nutrisystem Turbo 10|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem Turbo 10 plan.
16540053|NCT03017443|Experimental|Nutrisystem DASH|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem DASH plan.
16540054|NCT03017443|Active Comparator|Dieting on Your Own (DIY) - DASH|All subjects provided publically available information on the DASH diet and instructed to follow a reduced calorie DASH diet meal plan on their own.
16540055|NCT03017430|Experimental|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
16540115|NCT03017053|Active Comparator|Elective neck dissection|Primary surgery & Elective neck dissection
16540116|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
16540117|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
16540056|NCT03017430|Active Comparator|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
16540057|NCT03017417|Experimental|Exercise Intervention arm|"exercise training intervention to include:
~DEXA scan will collect data on via a full body scan to determine post-cranial appendicular whole body LM, whole body fat free mass (FFM) and whole body FM.
~Muscle Strength assessment
~Physical function assessment
~Questionnaires and diet diaries"
16540058|NCT03017417|Active Comparator|standard of care arm|"standard treatment
~exercise advice
~Questionnaires"
16540059|NCT03017404|Experimental|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
16540060|NCT03017404|Experimental|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
16540061|NCT03017404|Experimental|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
16540062|NCT03017404|Experimental|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
16540063|NCT03017391|Active Comparator|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
16540064|NCT03017391|Active Comparator|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.
~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
16540065|NCT03017378|Active Comparator|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
16540066|NCT03017378|Active Comparator|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
16540067|NCT03017365|Active Comparator|M-SRT|Machine-based stable resistance training. Exercising 'traditional' machine-based resistance training.
16540068|NCT03017365|Experimental|F-URT|Free weight unstable resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
16540069|NCT03017365|Experimental|M-ART|Machine-based adductor/abductor resistance training. Exercising with 'traditional' adductor/abductor machines.
16540070|NCT03017352|Experimental|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
16540071|NCT03017352|Placebo Comparator|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
16540072|NCT03017339|Experimental|Laser Group|The subjects participated in a functional exercise program associated with low level laser therapy applied in the quadriceps, hamstrings and triceps sural
16540073|NCT03017339|Placebo Comparator|Placebo Group|The subjects participated in a functional exercise program associated with placebo low level laser therapy applied in the quadriceps, hamstrings and triceps sural
16540074|NCT03017326|Other|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
16540075|NCT03017326|Active Comparator|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
16540076|NCT03017326|Active Comparator|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
16540077|NCT03017326|Active Comparator|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
16540078|NCT03017326|Other|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
16540079|NCT03017326|Active Comparator|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
16540080|NCT03017300|Experimental|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
16540081|NCT03017300|Experimental|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
16540082|NCT03017287|Experimental|GlucoMe App|Self monitoring of glucose blood measurements using the GlucoMe glucose monitoring glucose device and App
16540147|NCT03016858|Experimental|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
16540083|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
16540084|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
16540085|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
16540086|NCT03017248|Active Comparator|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
16540087|NCT03017248|Experimental|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
16540088|NCT03017248|Experimental|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
16540089|NCT03017235|Experimental|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
16540090|NCT03017235|Active Comparator|PREPOPIK®|
16540091|NCT03017222|Active Comparator|Ondansetron group|
16540092|NCT03017222|Experimental|Ramosetron group|
16540093|NCT03017209|Experimental|Locally-prepared bar|The bar is similar to one tested recently in a pilot study and is a locally prepared bar designed to facilitate growth and cognitive development. It will provide 300 kcal/day and will have ≈20-30% of energy from protein (of which 25-50% is from an animal protein source), 20-35% from total carbohydrate and ≈40-60% from fat. The bar will be fortified with vitamins and minerals to meet USAID recommendations for moderate malnutrition and Dietary Reference Intake recommendations for at-risk and healthy children of the ages studied, and at the same time will not exceed Upper Level nutrient recommendations for any micronutrient. Ingredients in the bar will be a combination of local products and imported shelf-stable ingredients.
16540094|NCT03017209|Active Comparator|USAID Corn Soy Blend Plus|The usual-intervention condition will be 300 kcal/day of USAID Corn Soy Blend Plus cooked in the usual manner with fortified vegetable oil (10:3 ratio) and sugar. The community health workers or other designated villagers will prepare the supplement freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
16540095|NCT03017209|Placebo Comparator|Locally-purchased rice|The placebo condition will be 300 kcal/day of locally-purchased rice cooked with a small amount of oil (10:2 ratio), which mimics the usual breakfast of children in this region. The community health workers or other designated villagers will prepare the rice freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
16540096|NCT03017196|Experimental|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
16540097|NCT03017196|No Intervention|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
16540098|NCT03017183|Other|EBUS-TBNA - Endobrochial Forceps Biopsy|In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
16540099|NCT03017183|Other|Forceps - EBUS-TBNA|In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
16540100|NCT03017170|Experimental|Cranberry|500mg Dried Cranberry
16540101|NCT03017170|Placebo Comparator|Placebo Oral Capsule|Color Matching Placebo
16540102|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
16540103|NCT03017144||Resuscitation team|Resuscitation pit crew model is educated to the resuscitation team.
16540104|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
16540105|NCT03017118|Experimental|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
16540106|NCT03017118|Placebo Comparator|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
16540107|NCT03017105|Active Comparator|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
16540108|NCT03017105|Experimental|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
16540109|NCT03017092|Experimental|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
16540110|NCT03017079|Experimental|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.
~Intervention: Other: bolus Intermittent enteral feeding"
16540111|NCT03017079|Placebo Comparator|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.
~Intervention: Other: Standard enteral feeding"
16540112|NCT03017066|Experimental|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
16540113|NCT03017066|Experimental|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
16540118|NCT03017027|Experimental|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
16540119|NCT03017027|Other|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
16540120|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
16540121|NCT03017001|Experimental|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
16540122|NCT03017001|Experimental|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
16540123|NCT03017001|Experimental|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
16540124|NCT03017001|No Intervention|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
16540125|NCT03016988|Other|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
16540126|NCT03016975|Experimental|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
16540127|NCT03016975|No Intervention|Control|Guideline directed medical therapy (GDMT)
16540128|NCT03016962|Experimental|Cap-assisted colonoscopy|cap-assisted colonoscopy
16540129|NCT03016962|Active Comparator|Standard colonoscopy|Standard colonoscopy
16540130|NCT03016949|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
16540131|NCT03016949|Experimental|Group B|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
16540132|NCT03016949|Experimental|Group C|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
16540133|NCT03016949|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
16540134|NCT03016949|Experimental|Group E|3 doses IPV IM at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
16540135|NCT03016949|Experimental|Group F|3 doses f-IPV ID at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
16540136|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI <2 and NSQIP- MICA <1%
16540137|NCT03016923|Experimental|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
16540138|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
16540139|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
16540140|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
16540141|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
16540142|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
16540143|NCT03016884|Experimental|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
16540144|NCT03016884|Experimental|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
16540145|NCT03016871|Experimental|Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
16540146|NCT03016871|Experimental|Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
16540467|NCT03014895|Placebo Comparator|Cohort 3: Placebo|Intravenous placebo infusion
16540148|NCT03016858|Active Comparator|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
16540149|NCT03016832|Experimental|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
16540150|NCT03016832|Active Comparator|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
16540151|NCT03016832|Other|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
16540152|NCT03016819|Experimental|Indication A: ASPS AL3818 Arm - OPEN|All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16540153|NCT03016819|Experimental|Indication B: LMS AL3818 Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16540154|NCT03016819|Active Comparator|Indication B: LMS Dacarbazine Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
16540155|NCT03016819|Experimental|Indication C: SS AL3818 Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
16540156|NCT03016819|Active Comparator|Indication C: SS Dacarbazine Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
16540157|NCT03016819|Placebo Comparator|Indication D: LMS AL3818 or Placebo Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or placebo in a double-blind manner. AL3818 or placebo will be administrated as one 12 mg capsule orally once daily in 21-day cycles for 14 days on treatment (Days 1-14) and 7 days off treatment (Days 15-21).
16540158|NCT03016806|Other|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
16540159|NCT03016806|Other|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
16540160|NCT03016806|Other|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
16540161|NCT03016806|Other|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
16540162|NCT03016793|Experimental|puerarin and β- tricalcium phosphate|"purabone (puerarin) is an osteoinductive bone grafts used to augment bone healing.
~β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing"
16540163|NCT03016793|Active Comparator|β- tricalcium phosphate alone|β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing
16540164|NCT03016780|Active Comparator|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
16540165|NCT03016780|Placebo Comparator|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
16540166|NCT03016767|Experimental|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.
~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
16540167|NCT03016767|No Intervention|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
16540168|NCT03016741|Other|Arm I (abiraterone acetate, prednisone)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive abiraterone acetate PO and prednisone PO BID in the absence of disease progression or unacceptable toxicity. Patients then undergo cognitive assessment comprising of neuro-cognitive tests and assessments of overall quality of life, fatigue, pain, and symptoms at baseline, 3, 6, and 12 months. Patients also undergo MRI program for 40 minutes comprising of DTI, fMRI, ASL MRI, MPRAGE MRI, FLAIR MRI, and BOLD MRI at baseline and 3 months.
16540169|NCT03016741|Other|Arm II (enzalutamide)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo cognitive assessment and MRI program as in Arm I.
16540170|NCT03016728|Experimental|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
16540257|NCT03016221|No Intervention|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
16540171|NCT03016728|No Intervention|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
16540172|NCT03016715|Experimental|Treatment|Sirolimus, 2% topical ointment will be used during randomization
16540173|NCT03016715|Placebo Comparator|Vehicle|A placebo topical ointment will be used during randomization.
16540174|NCT03016702|Experimental|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
16540175|NCT03016702|Experimental|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
16540176|NCT03016676|Experimental|Spinal manipulation|Spinal manipulation -High velocity low amplitude thrust (HVLA), Dosages : 2 repetition at the same time, Duration-10-20 minutes. total 2 weeks.
16540177|NCT03016676|Experimental|Exercise therapy|Exercise Therapy(ET): Exercise therapy (ET) 3 program: self education, supervised exercise visits, and home exercise. Duration-45 minutes,Total number of visits 12 for 2 weeks.
16540178|NCT03016663||Breast Lipofilling Technique|Preliminary MRI breast were performed for volumetric measurement. Fat harvesting performed by same surgeon using water-assisted liposuction (WAL) and subsequent washing with buffered lactate in a standardized technique. Fat transfer performed using Berlin autologous lipotransplantation technique according to the BEAULI protocol .Patient were followed up monthly and MRI breast were repeated at 1st and 6th months after lipofilling. Clinical assessment and MRI Volumetric measurement performed using OsiriX (v7.0.3, 64 bit, Pixmeo c) software by same radiologist based on predefined operational procedure
16540179|NCT03016650|Active Comparator|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
16540180|NCT03016650|Active Comparator|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
16540181|NCT03016637|Experimental|EUS biopsy|EUS guided SharkCore (TM) biopsy of pancreatic lesions suspected of malignancy
16540182|NCT03016624|Active Comparator|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
16540183|NCT03016624|Active Comparator|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
16540184|NCT03016611|Active Comparator|Chewing Ticagrelor|
16540185|NCT03016611|Experimental|Chewing Prasugrel|
16540186|NCT03016598|Experimental|Oxytocin|Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
16540187|NCT03016598|Placebo Comparator|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
16540188|NCT03016585|Experimental|Tai Chi Training|Tai Chi exercises 3 times per wk for 12 weeks
16540189|NCT03016585|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 weeks.
16540190|NCT03016572|Experimental|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
16540191|NCT03016572|Experimental|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
16540192|NCT03016572|Experimental|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
16540193|NCT03016559|Other|releasing muscle|The physical therapist placed thumbs on the quadratus lumborum to release muscle.
16540194|NCT03016546|Experimental|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
16540195|NCT03016546|Active Comparator|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
16540196|NCT03016533|Experimental|Dolutegravir (Tivicay)|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 10 milligram (mg), 25 mg and 50 mg; and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant is discontinued, or until development of dolutegravir is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
16540197|NCT03016533|Experimental|ABC/DTG/3TC|All participants will receive ABC/DTG/3TC immediate release tablets or film-coated dispersible tablets at appropriate doses selected as per their weight bands. For those participants who were previously receiving ABC/DTG/3TC in study P2019 (parent study), ABC/DTG/3TC will be supplied as immediate release tablets containing 600 mg, 50 mg and 300 mg of ABC, DTG, and 3TC respectively and film-coated dispersible tablets containing 60 mg, 5 mg and 30 mg of ABC, DTG, and 3TC respectively. Participants will receive ABC/DTG/3TC until age-appropriate formulations are available to them from some other source, until participant is no longer deriving benefit from treatment, or until participant is discontinued, or until development of ABC/DTG/3TC is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
16540198|NCT03016520|Experimental|Test drug|DWJ1392
16540199|NCT03016520|Experimental|Reference drug|DWC20164
16540200|NCT03016494|Experimental|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
16540201|NCT03016494|Experimental|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
16540202|NCT03016481|Active Comparator|the Community Health Worker -Personalized Support for Progress|Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
16540203|NCT03016481|Active Comparator|Care as Usual- Social Worker|Patients in the Care as Usual- Social Worker (CAU-SW) arm, will do intake with a social worker, who follows hospital procedures for intake and referrals, does a needs assessment, and offers safety planning in referral.
16540204|NCT03016468|Experimental|Parenteral Remodulin then Oral Treprostinil|
16540205|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
16540206|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
16540207|NCT03016455||Stable patients|No DSA No cAMR
16540208|NCT03016442|Experimental|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
16540209|NCT03016442|Active Comparator|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
16540210|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
16540211|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
16540212|NCT03016403|Experimental|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
16540213|NCT03016403|Active Comparator|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
16540214|NCT03016377|Experimental|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
16540215|NCT03016377|Experimental|Expansion Cohort Second Administration of iC9-CAR19 cells|After the recommended phase 2 dose (RP2D) of iC9-CAR19 T cells has been determined in adults, up to 18 additional adult subjects will be enrolled in an expansion cohort at the RP2D. In the expansion cohort, subjects will be offered a second infusion of iC9-CAR19 T cells based on B-cell recovery and minimal residual disease (MRD) status. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before second administration of iC9-CAR19 T cells.
16540216|NCT03016364|Experimental|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
16540256|NCT03016221|Experimental|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540468|NCT03014895|Experimental|Cohort 3: E3112|Intravenous E3112 infusion
16540217|NCT03016351|Experimental|Aerobic Training|Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
16540218|NCT03016351|Experimental|Resistance Training|Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
16540219|NCT03016338|Experimental|Niraparib +TSR-042|200/300 mg Niraparib by mouth once a day for 21 days cycle. 500 mg of TSR-042 intravenously on the first day of each cycle.
16540220|NCT03016325|Experimental|Part 1 Cohort 1 HNO Donor|
16540221|NCT03016325|Placebo Comparator|Placebo Part 1 Cohort 1|
16540222|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- low dose|
16540223|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- high dose|
16540224|NCT03016325|Placebo Comparator|Placebo Part 2 Cohort 2|
16540227|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
16540228|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
16540229|NCT03016286|Experimental|WBV group|whole-body vibration (WBV) group
16540230|NCT03016273|Experimental|Bladder flap|The bladder flap is made by superficially incising and dissecting the peritoneal lining to separate the urinary bladder from the lower uterine segment.
16540231|NCT03016273|No Intervention|Non bladder flap|
16540232|NCT03016260||Infliximab (Remicade®)|
16540233|NCT03016260||Adalimumab (Humira®)|
16540234|NCT03016260||Etanercept (Enbrel®)|
16540235|NCT03016260||Golimumab (Simponi®)|
16540236|NCT03016260||Certolizumab Pegol (Cimzia®)|
16540237|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
16540238|NCT03016260||Etanercept biosimilar (Benepali®)|
16540239|NCT03016260||Infliximab biosimilar (Flixabi®)|
16540240|NCT03016247|Active Comparator|Enhanced Usual Care|Group will receive a single visit with a Nutritionist for dietary and physical activity counseling
16540241|NCT03016247|Experimental|TRUST intervention|Group will receive parent-adolescent trust-building and weight self-management training.
16540242|NCT03016234|Active Comparator|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
16540243|NCT03016234|Active Comparator|Propofol|intravenous anesthesia administration for maintenance of anesthesia
16540244|NCT03016221|Experimental|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540245|NCT03016221|No Intervention|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
16540246|NCT03016221|Experimental|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540247|NCT03016221|No Intervention|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
16540248|NCT03016221|Experimental|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540249|NCT03016221|No Intervention|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
16540250|NCT03016221|Experimental|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540251|NCT03016221|No Intervention|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
16540252|NCT03016221|Experimental|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540253|NCT03016221|No Intervention|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
16540254|NCT03016221|Experimental|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540255|NCT03016221|No Intervention|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
16540258|NCT03016221|Experimental|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
16540259|NCT03016221|No Intervention|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
16540260|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
16540261|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
16540262|NCT03016182|Active Comparator|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
16540263|NCT03016182|Placebo Comparator|Control|Control group without remote ischemic preconditioning
16540264|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
16540265|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
16540266|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
16540267|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
16540268|NCT03016143|Active Comparator|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
16540269|NCT03016143|Active Comparator|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
16540270|NCT03016143|Experimental|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
16540271|NCT03016143|Experimental|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
16540272|NCT03016130|Active Comparator|Liberalized Hospital Diet (Diet A)|Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
16540273|NCT03016130|Active Comparator|Neutropenic Diet (Diet B)|Diet B is the hospital neutropenic diet.
16540274|NCT03016117|Experimental|Pecs II block and parasternal block|Pecs II block and parasternal block performed to provide anesthesia of breast, before of quadrantectomy with or without axillary dissection. Pecs II block performed at the 4th rib level and 20 ml of 0.5% Levobupivacaine injected, and parasternal block performed at the level of the 2nd and 4th intercostal space level, and 4 ml of 0.375% Levobupivacaine injected
16540275|NCT03016104|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
16540276|NCT03016104|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
16540277|NCT03016091|Experimental|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
16540278|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
16540279|NCT03016065|Experimental|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
16540280|NCT03016065|Placebo Comparator|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
16540281|NCT03016052|Experimental|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
16540282|NCT03016039|Experimental|Dietary supplementation|This group will receive Dietary supplementation
16540283|NCT03016039|No Intervention|conventional treatment|conventional Antibiotic treatment without curcumin supplementation
16540284|NCT03016026|Experimental|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
16540285|NCT03016013|Placebo Comparator|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
16540286|NCT03016013|Experimental|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
16540287|NCT03016000|Experimental|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
16540288|NCT03016000|Other|Observation|Observation
16540289|NCT03015987|Experimental|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
16540290|NCT03015987|Active Comparator|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.
~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
16540291|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
16540292|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
16540293|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
16540294|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|EXPAREL 266 mg + bupivacaine HCl
16540295|NCT03015961|Placebo Comparator|Bupivacaine HCl|Bupivacaine HCl
16540296|NCT03015948|Experimental|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
16540297|NCT03015948|Experimental|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
16540298|NCT03015948|Experimental|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
16540299|NCT03015948|Experimental|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
16540300|NCT03015948|Experimental|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
16540301|NCT03015935||Optical|visual-assisted entry
16540302|NCT03015935||Veress|Veress entry
16540303|NCT03015922|Experimental|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.
~Plus (all patients):
~REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
16540304|NCT03015909|Other|Eutropin pen inj.|
16540305|NCT03015896|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16540306|NCT03015883|Experimental|Diffusing Alpha Radiation Emitters Therapy (DaRT)|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices
16540307|NCT03015870|Experimental|Feedback|Behavioral: Vocal exercise with real-time feedback.
16540308|NCT03015870|Active Comparator|Recording|Behavioral: Vocal exercise with recording
16540309|NCT03015857|Active Comparator|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
16540310|NCT03015857|Active Comparator|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
16540311|NCT03015831|Active Comparator|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
16540312|NCT03015831|Placebo Comparator|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
16540313|NCT03015818|Experimental|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
16540314|NCT03015805|Experimental|Contingency Management|This group will receive regular probation services but will also receive the Contingency Management program for substance abuse from their juvenile probation officer during regular meetings.
16540315|NCT03015805|Active Comparator|Probation as Usual|This group will receive regular services that are usually provided by juvenile probation officers.
16540316|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
16540317|NCT03015779|Experimental|experimental group|cultured autologous oral mucosal epithelial cell sheet
16540318|NCT03015766|Experimental|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
16540319|NCT03015766|Sham Comparator|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
16540320|NCT03015753|Experimental|Tai Chi training|The participants in this arm will receive 12-week Tai Chi training (1 hour per day, 5 days per week).
16540321|NCT03015753|Other|Waiting list control group|Participants in this arm will be asked to maintain their usual lifestyles and exercises for 12 weeks. At the end of the trial , the participants will be offered Tai Chi training similar as Tai Chi group.
16540322|NCT03015740|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
16540323|NCT03015727|Experimental|IC+RT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.
16540324|NCT03015727|Active Comparator|IC+CCRT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.
16540325|NCT03015714|Active Comparator|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
16540326|NCT03015714|Active Comparator|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
16540327|NCT03015701|Experimental|Arm 1|Mifepristone 200 mg orally daily for two years
16540328|NCT03015701|Placebo Comparator|Arm 2|Placebo orally daily for two years
16540329|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
16540330|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
16540331|NCT03015675|Experimental|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks
~mFOLOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
16540332|NCT03015675|Active Comparator|mFOLFOX6 group|"mFOLOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
16540333|NCT03015662|Experimental|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
16540334|NCT03015662|Active Comparator|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
16540335|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.
~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
16540336|NCT03015636|Experimental|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
16540337|NCT03015636|Other|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
16540338|NCT03015623|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
16540339|NCT03015623|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
16540340|NCT03015623|Sham Comparator|Control|Sham device containing no MSCs
16540341|NCT03015610|Placebo Comparator|Placebo|participants will receive oral blinded matched placebo once daily
16540342|NCT03015610|Experimental|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
16540343|NCT03015597|Experimental|Contingency Management: smoking|"Contingency Management: smoking
~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
16540344|NCT03015597|Placebo Comparator|Contingency Management: attendance|"Contingency Management: attendance
~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
16540345|NCT03015584||Septic patients admitted to the ICU|
16540346|NCT03015571|Experimental|NBI|Use of Narrow Band Imaging with regular care of cervical inlet patches detection.
16540347|NCT03015571|Placebo Comparator|WL|Use of High Definition White Light (WL) with regular care of cervical inlet patches detection.
16540348|NCT03015571|Experimental|NBI increased care|Use of Narrow Band Imaging with increased care of cervical inlet patches detection.
16540349|NCT03015571|Placebo Comparator|WL increased care|Use of High Definition White Light (WL) with increased care of cervical inlet patches detection.
16540350|NCT03015558|Experimental|patients|
16540351|NCT03015558|Active Comparator|healthy subjects|
16540352|NCT03015545|Active Comparator|Control|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval, but no vibration will be given.
16540353|NCT03015545|Active Comparator|High intensity whole body vibration|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval. The whole body vibration platform will be set with frequency at 30Hz and amplitude at 1.5mm.
16585412|NCT02709668|Placebo Comparator|placebo|gel cap with placebo
16540361|NCT03015519|Experimental|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
16540362|NCT03015519|Placebo Comparator|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
16540363|NCT03015519|Experimental|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
16540364|NCT03015519|Placebo Comparator|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
16540365|NCT03015519|Experimental|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
16540366|NCT03015519|Placebo Comparator|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
16540367|NCT03015506|Active Comparator|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
16540368|NCT03015506|Experimental|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
16540369|NCT03015506|Experimental|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
16540370|NCT03015506|Experimental|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
16540371|NCT03015506|Experimental|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
16540372|NCT03015493|Experimental|Neural mobilization and traction|Patients in this group are treated with neural mobilization techniques combined with cervical traction
16540373|NCT03015493|Experimental|Traction group|Patients in this group are treated with cervical traction
16540374|NCT03015493|No Intervention|Control group|Patients in this group comprise the control group and are not treated with any intervention
16540375|NCT03015480|Experimental|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
16540376|NCT03015467|Active Comparator|treatment for part 1|Fecal Microbiota Transplantation (FMT) and traditional treatments according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 1.
16540377|NCT03015467|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline (NS) according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 2.
16540378|NCT03015454|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
16540379|NCT03015454|Active Comparator|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
16540380|NCT03015441|Other|Arm 1: Fermented milk product containing probiotics|
16540381|NCT03015441|Other|Arm 2: Milk-based non-fermented dairy product|
16540382|NCT03015428|Experimental|Psychoeducation|"Interventions:
~Give information Teach and train strategies"
16540383|NCT03015415|Experimental|surgical|Patients undergoing surgical elbow arthrolysis. Elbow Open Arthrolyses
16540384|NCT03015415|Experimental|non-surgical|Patients submitted to a non-surgical rehabilitation protocol using splints Non-surgical intervention
16540385|NCT03015402|Experimental|Sodium Nitrite|
16540386|NCT03015402|Placebo Comparator|Placebo|
16540387|NCT03015389||Barrett's associated esophageal dysplasia|
16540388|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
16540389|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
16540390|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
16540391|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
16540392|NCT03015337|Experimental|New Physical Education Instructions|
16540393|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
16540394|NCT03015311|Experimental|Intensive BP control|SBP within 110 - <130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - <130 mm Hg.
16540395|NCT03015311|Active Comparator|Standard BP control|SBP within 130 - <150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - <150 mm Hg.
16540396|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
16540397|NCT03015285|Experimental|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
16540398|NCT03015285|Active Comparator|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
16540469|NCT03014895|Placebo Comparator|Cohort 4: Placebo|Intravenous placebo infusion
16540470|NCT03014895|Experimental|Cohort 4: E3112|Intravenous E3112 infusion
16540471|NCT03014895|Placebo Comparator|Cohort 5: Placebo|Intravenous placebo infusion
16540399|NCT03015272|Experimental|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
16540400|NCT03015272|Active Comparator|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
16540401|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
16540402|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
16540403|NCT03015259|Placebo Comparator|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
16540404|NCT03015246|Placebo Comparator|Extended-Release Morphine + placebo stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. The placebo stressor will be administered on one day.
16540405|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day.
16540406|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. The placebo stressor will be administered on one day.
16540407|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + placebo stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. The placebo stressor will be administered on one day.
16540408|NCT03015246|Experimental|Extended-Release Morphine + active stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
16540409|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
16540410|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
16540411|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + active stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
16540412|NCT03015220|Experimental|Oral semaglutide 3 mg|
16540413|NCT03015220|Experimental|Oral semaglutide 7 mg|
16540414|NCT03015220|Experimental|Oral semaglutide 14 mg|
16540415|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
16540416|NCT03015207|Experimental|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
16540417|NCT03015207|Placebo Comparator|Placebo|Injected s.c. /subcutaneously (under the skin)
16540418|NCT03015194|Experimental|Laceration of Anterior Mitral Leaflet in Mitral Valve Failure Participants With no Surgical Option|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
16540419|NCT03015181|Experimental|Group 1: 1 mg/kg IV Single Dose|Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
16540420|NCT03015181|Experimental|Group 2: 5 mg/kg IV Single Dose|Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
16540421|NCT03015181|Experimental|Group 3: 5 mg/kg SC Single Dose|Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
16540422|NCT03015181|Experimental|Group 4: 20 mg/kg IV Single Dose|Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
16540423|NCT03015181|Experimental|Group 5: 40 mg/kg IV Single Dose|Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
16540424|NCT03015181|Experimental|Group 6: 5 mg/kg SC Multiple Doses|Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
16540425|NCT03015181|Experimental|Group 7: 20 mg/kg IV Multiple Doses|Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.
16540426|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
16540427|NCT03015155|Experimental|Hypothermia|Infusion of Cold Saline into Local Infarction Myocardium. A standard working guide-wire, Runthrough NS (Terumo, Japan), is advanced into the distal part of the target coronary artery by using angiography. Compared to the standard PPCI after the balloon expansion, the aspirated catheter (Diver C.E. MAX, Italy) is firstly placed at the location of the distal occlusion lesion to achieve local myocardial hypothermia by infusing the cold saline (4℃, 2.5ml/min, 5min). Then we retract the aspirated catheter, following the balloon expansion and the drug eluting stent implanting. Subsequently, the infusion catheter is tautologically placed at the location of the opened occlusion, within the stent, to persistently perfuse the infarct myocardium with cold saline (4℃, 2.5ml/min, 15min).
16540472|NCT03014895|Experimental|Cohort 5: E3112|Intravenous E3112 infusion
16540473|NCT03014882|Other|Antioxidant treatment|
16540782|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
16540428|NCT03015155|No Intervention|Standard treatment|We place a standard working guide-wire, Runthrough NS (Terumo Corporation, Japan), crossover the criminal lesion of to the distal of the target coronary artery after angiography. Then the pre-dilated balloon is placed at the occluded lesion site to expand the criminal vessel without hypothermia intervention. The operation will be completed when the flow of target coronary artery achieves TIMI class 3 after the drug eluting stent implanting.
16540429|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
16540430|NCT03015129|Experimental|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
16540431|NCT03015129|Experimental|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
16540432|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
16540433|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
16540434|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
16540435|NCT03015103|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
16540436|NCT03015090|Experimental|theophylline|
16540437|NCT03015077|Active Comparator|Glutamine|"intake of 5g glutamine and 10g maltodextrin. Oral glutamine is a food additive issued by food and drug government in Taiwan with number 009929.L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin.
~The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy."
16540438|NCT03015077|Placebo Comparator|placebo|intake of 15g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
16540439|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
16540440|NCT03015051|Experimental|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
16540441|NCT03015051|Active Comparator|Low flow|Low flow (max 3 L/min) oxygen therapy
16540442|NCT03015025||Stable treatment with acenocoumarol|Patients in stable anticoagulant treatment with acenocoumarol for auricular fibrillation, venous thromboembolic disease and/or cardiac valve replacement.
16540443|NCT03015012|Active Comparator|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
16540444|NCT03015012|Experimental|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
16540445|NCT03014999|Experimental|High frequency rTMS|Volunteers will be submitted to high frequency of repetitive transcranial magnetic stimulation (10Hz)
16540446|NCT03014999|Experimental|Low frequency rTMS|Volunteers will be submitted to low frequency of repetitive transcranial magnetic stimulation (1Hz)
16540447|NCT03014999|Sham Comparator|Sham rTMS|Volunteers will be submitted to sham session of repetitive transcranial magnetic stimulation
16540448|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
16540449|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
16540450|NCT03014973|Experimental|prostate cancer patients resistant to castration|
16540451|NCT03014973|Experimental|patients naif of hormonal treatment|
16540452|NCT03014960|Experimental|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
16540453|NCT03014960|No Intervention|Control Condition|No intervention
16540454|NCT03014947|Experimental|MSB11022|
16540455|NCT03014947|Active Comparator|US-licensed Humira|
16540456|NCT03014947|Active Comparator|EU-approved Humira|
16540457|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
16540458|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
16540459|NCT03014921|Placebo Comparator|placebo injection group|saline solution injection as placebo
16540460|NCT03014921|Active Comparator|iron injection group|iron injection
16540461|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
16540462|NCT03014908||NMR-C|non-diabetic children and adolescents
16540463|NCT03014895|Placebo Comparator|Cohort 1: Placebo|Intravenous placebo infusion
16540464|NCT03014895|Experimental|Cohort 1: E3112|Intravenous E3112 infusion
16540465|NCT03014895|Placebo Comparator|Cohort 2: Placebo|Intravenous placebo infusion
16540466|NCT03014895|Experimental|Cohort 2: E3112|Intravenous E3112 infusion
16585413|NCT02709668|Experimental|enlyte|gel cap of B vitamins brand Enlyte
16540474|NCT03014869|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.
16540475|NCT03014869|No Intervention|Noninvasive positive ventilation|Parameters are set according to NPPV protocols
16540476|NCT03014856||OB-NMR|overweight and obese children and adolescents
16540477|NCT03014856||NMR-C|normal-weight children and adolescents
16540478|NCT03014843|Active Comparator|Naloxone|Administration of a centrally acting µ-opioid receptor antagonist Naloxone (20µg/kg/h intravenous infusion after 0.4mg bolus) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
16540479|NCT03014843|Active Comparator|Methylnaltrexone bromide|Administration of a peripherally acting µ-opioid receptor antagonist Methylnaltrexone (12mg/0.6mL subcutaneous injection) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
16540480|NCT03014843|Placebo Comparator|Placebo|Administration of placebo injection (1mL 0.9% saline IV or 0.6 IM) as a control condition to compare to the administration of naloxone or methylnaltrexone bromide in the multimodal esophageal stimulation protocol.
16540481|NCT03014830|Active Comparator|Alirocumab|Subjects will receive alirocumab for 6 weeks.
16540482|NCT03014830|Placebo Comparator|Placebos|Subjects will receive placebo for 6 weeks.
16540483|NCT03014817|Experimental|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
16540484|NCT03014817|Active Comparator|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
16540485|NCT03014804|Experimental|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
16540486|NCT03014804|Experimental|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
16540487|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.
~Large artery endothelial function:
~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)
~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)
~Forearm blood flow
~Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)
~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)
~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
16540488|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.
~Large artery endothelial function:
~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)
~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)
~Forearm blood flow
~Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)
~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)
~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
16540489|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.
~Large artery endothelial function:
~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms
~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms
~Recruited from community-based cohort studies - CLEAREST and ACCT
~Equal recruitment across the following parameters:
~Age: 3 groups <30, 30-60, >60 years
~Gender
~BMI: 3 groups <25, 25-30, >30 Kg/m2"
16540490|NCT03014778|Experimental|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
16540491|NCT03014778|Active Comparator|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
16540492|NCT03014752|Active Comparator|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
16540493|NCT03014752|Active Comparator|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
16540494|NCT03014726|Experimental|DCB Treatment|Stricture patients treated by DCB
16540495|NCT03014713|Active Comparator|Control Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
16540496|NCT03014713|Experimental|Dexmedetomidine Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
16540497|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
16540498|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
16540523|NCT03014531|Experimental|almond|In this group, participants were provided with 56 g of almonds per day either as preload before meals or snack between meals. A snack was defined as an eating event that occurred between participants' regular meals, specifically two hours before and after meals. All the participants in almond group were provided daily portions of packaged almonds.
16540524|NCT03014531|Other|high-carbohydrate control food item|In this group, participants were provided with high-carbohydrate control food item that had a similar number of calories as 56 g of almonds.
16540525|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
16540499|NCT03014687|Placebo Comparator|Standard Nasal Care|One dose of preoperative intravenous (iv) antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Postoperative antibiotics: Study participants will receive one dose only of postoperative intravenous antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Placebo PO BID (twice daily) will commence on the morning of postoperative day 1 and continue for 7 days.
16540500|NCT03014687|Experimental|Standard Nasal Care + Oral Antibiotics|One dose of preoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg) will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Participants will receive 1 dose only of postoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Oral antibiotics will commence on the morning of postoperative day 1; this group will receive oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.
16540501|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
16540502|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
16540503|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
16540504|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
16540505|NCT03014648|Experimental|Atezolizumab|"Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV over 60 (plus or minus 15) minutes for first infusion; can be decreased to 30 (plus or minus 10) minutes for subsequent cycles.
~Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression.
~There will be no dose reduction for Atezolizumab. Patients may temporarily suspend study treatment for up to 84 days beyond the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If Atezolizumab is held because of adverse events for greater than 84 days beyond the scheduled date of infusion, the patient will be discontinued from Atezolizumab and will be followed for safety and efficacy."
16540506|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
16540507|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
16540508|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
16540509|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
16540510|NCT03014596|Experimental|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
16540511|NCT03014596|No Intervention|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
16540512|NCT03014583|Experimental|HF/TCS/BURST|HF/TCS/BURST
16540513|NCT03014583|Experimental|HF/BURST/TCS|HF/BURST/TCS
16540514|NCT03014583|Experimental|BURST/HF/TCS|BURST/HF/TCS
16540515|NCT03014583|Experimental|BURST/TCS/HF|BURST/TCS/HF
16540516|NCT03014583|Experimental|TCS/BURST/HF|TCS/BURST/HF
16540517|NCT03014583|Experimental|TCS/HF/BURST|TCS/HF/BURST
16540518|NCT03014570|Active Comparator|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
16540519|NCT03014570|Experimental|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
16540520|NCT03014557||WATCHMAN|subjects with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN left atrial appendage closure device
16540521|NCT03014544||Group 1: Sequence AABB|Participants of main study with Major Depressive Disorder (MDD) will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
16540522|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
16540526|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
16541604|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
16540527|NCT03014505|Experimental|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
16540528|NCT03014505|Active Comparator|The traditional treatments|
16540529|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
16540530|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
16540531|NCT03014479|Experimental|Trelagliptin|Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
16540532|NCT03014479|Active Comparator|Daily DPP-4 inhibitors|An inhibitor orally administered at the dosage and administration in the package inserts for each drug, for up to 12 weeks.
16540533|NCT03014466|Active Comparator|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
16540534|NCT03014466|Experimental|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
16540535|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
16540536|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
16540537|NCT03014401|Experimental|Stem Cells|Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.
16540538|NCT03014401|Active Comparator|Placebo|Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation
16540539|NCT03014388|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
16540540|NCT03014388|Experimental|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
16540541|NCT03014375|Experimental|Etamicastat|Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules
16540542|NCT03014362|Active Comparator|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;
~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.
~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
16540543|NCT03014362|Sham Comparator|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;
~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
16540544|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
16540545|NCT03014336|No Intervention|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
16540546|NCT03014336|Experimental|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
16540547|NCT03014323|Experimental|Galantamine then Placebo, WW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)
16540548|NCT03014323|Placebo Comparator|Placebo then Galantamine, WW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)
16540549|NCT03014323|Experimental|Galantamine then Placebo, AAW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)
16540550|NCT03014323|Placebo Comparator|Placebo then Galantamine, AAW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)
16540551|NCT03014310|Experimental|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
16540552|NCT03014310|Experimental|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
16540553|NCT03014310|Active Comparator|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
16540554|NCT03014310|Experimental|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
16540555|NCT03014310|Experimental|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
16540556|NCT03014310|Active Comparator|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
16540557|NCT03014297|Experimental|everolimus + fosbretabulin|everolimus + fosbretabulin
16540558|NCT03014271|Experimental|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide (SOS) Prevention Program
16540559|NCT03014271|Active Comparator|SOS Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program after 16 months.
16540560|NCT03014258|Active Comparator|Control Cohort 1|Immunologic malaria-naïve subjects will undergo CHMI #2 with 5 NF54 P. falciparum-infected mosquitoes at months 8-9. n=6.
16540561|NCT03014258|Active Comparator|Control Cohort 2|Immunologic malaria-naïve subjects will undergo a CHMI #3 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #2. n=6.
16540562|NCT03014258|Active Comparator|Control Cohort 3|Immunologic malaria-naïve subjects will undergo a CHMI #4 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #3. n=6.
16540563|NCT03014258|Active Comparator|Control Cohort 4|Immunologic malaria-naïve subjects will undergo a CHMI #5 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #4. n=6.
16585414|NCT02709655|Experimental|Vortioxetine 10 mg/day|
16540564|NCT03014258|Experimental|Repeat CHMI|Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
16540565|NCT03014245||Pregnant|Normal pregnant women (first baby) singleton
16540566|NCT03014245||Control|Non pregnant healthy women
16540567|NCT03014232|Experimental|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
16540568|NCT03014232|Active Comparator|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
16540569|NCT03014219|Experimental|Only 1 arm: treatment with MSC-AFP|Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells.
16540570|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
16540571|NCT03014167|Experimental|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
16540572|NCT03014167|Active Comparator|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
16540573|NCT03014154|Active Comparator|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
16540574|NCT03014154|Active Comparator|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
16540575|NCT03014141|Active Comparator|Oat bran (Oatwell 28)|A beverage containing 11 gram (3 gram of oat beta-glucan) of Oat bran (Oatwell 28) will be consumed before breakfast
16540576|NCT03014141|Placebo Comparator|Maltodextrin|A beverage containing 11 gram of maltodextrin will be consumed before breakfast.
16540577|NCT03014128||Inspection and Packaging|self-descriptive
16540578|NCT03014128||Grinding, Polishing and Matting|self-descriptive
16540579|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
16540580|NCT03014115|Active Comparator|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
16540581|NCT03014115|Experimental|DHA|0% ARA +0.4% DHA in infant formula per day
16540582|NCT03014102|Experimental|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
16540583|NCT03014102|Active Comparator|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
16540584|NCT03014089|Experimental|mRNA-1325|
16540585|NCT03014089|Placebo Comparator|Placebo|0.9% sodium chloride
16540586|NCT03014076|Experimental|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
16540587|NCT03014076|Active Comparator|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
16540588|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
16540589|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
16540590|NCT03014050|Experimental|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
16540591|NCT03014050|Active Comparator|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
16540592|NCT03014037|Other|Unilateral Procurement of Bone Marrow|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.
16540593|NCT03014037|Experimental|Bilateral Bone Marrow Procurement|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow.
16540594|NCT03014024|Experimental|Low-Level Laser therapy|After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
16542302|NCT03002714|Experimental|Exercise|Performance of two resistance exercise sessions
16540595|NCT03014024|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, patients will be treated with placebo LLLT. This placebo laser is identical in appearance to the other super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated on the same areas, and have the same procedure and time. Since the light from the laser is invisible neither the participant nor the therapist will know whether the laser is a placebo.
16540596|NCT03014011|Other|Hypoglycaemic clamp first, then euglyceamic clamp|First intervention with a hypoglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with an euglycaemic clamp (approximately 5 hours).
16540597|NCT03014011|Other|Euglycaemic clamp first, then hypoglycaemic clamp|First intervention with an euglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with a hypoglycaemic clamp (approximately 5 hours).
16540598|NCT03013998|Experimental|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
16540599|NCT03013998|Experimental|BAML-16-001-S2|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
16540600|NCT03013998|Experimental|BAML-16-001-S3|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
16540601|NCT03013998|Experimental|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
16540602|NCT03013998|Experimental|BAML-16-001-S5 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
16540603|NCT03013998|Experimental|BAML-16-001-S6|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
16540604|NCT03013998|Experimental|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
16540605|NCT03013998|Experimental|BAML-16-001-S16 (Closed)|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
16540606|NCT03013998|Experimental|BAML-16-001-S8|This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients, so the triple combination of gilteritinib in combination with decitabine and venetoclax (Group 2) is now being evaluated in this study.
16540651|NCT03013686|Active Comparator|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.
~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
16540652|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
16542769|NCT02999503|No Intervention|No intervention|Patients not subject to nutritional education
16540607|NCT03013998|Experimental|BAML-16-001-S10 (Closed)|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
16540608|NCT03013998|Experimental|BAML-16-001-S14|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
16540609|NCT03013998|Experimental|BAML-16-001-S18|This is an open-label Phase 1b clinical study of AZD5991 + azacitidine in patients aged ≥60 years with newly diagnosed, previously untreated, hypermethylated and marker-negative AML. The phase 1b1 study will adopt a standard 3+3 design with dose escalation based upon dose limiting toxicities. The recommended Phase 2 dose (RP2D) is defined in this study as the highest dose level where less than 2 dose limiting toxicities (DLT) are observed out of 6 patients. Once the RP2D is defined, patients will be enrolled into 2 separate cohorts (hypermethylation and marker negative group) for the phase 1b2 expansion. These 2 groups will both be treated at the RP2D determined from phase 1b1.
16540610|NCT03013985|Experimental|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
16540611|NCT03013985|Active Comparator|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
16540612|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
16540613|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
16540614|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
16540615|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
16540616|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
16540617|NCT03013946|Experimental|Arm A (Coaching)|Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
16540618|NCT03013946|No Intervention|Arm B (Control)|Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
16540619|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16540620|NCT03013907|Experimental|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
16540621|NCT03013907|Active Comparator|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
16540622|NCT03013881|Experimental|UB-921 2 mg/kg (Main-study)|Intravenous infusion
16540623|NCT03013881|Experimental|UB-921 6 mg/kg (Main-study)|Intravenous infusion
16540624|NCT03013881|Experimental|UB-921 8 mg/kg (Main-study)|Intravenous infusion
16540625|NCT03013881|Experimental|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
16540626|NCT03013881|Active Comparator|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
16540627|NCT03013855|Active Comparator|FIT-SOC|Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
16540628|NCT03013855|Experimental|FIT-DRE|Fecal immunochemical test completed with stool collected during digital rectal exam.
16540629|NCT03013842|Experimental|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
16540681|NCT03013452|Active Comparator|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
16540682|NCT03013439|Experimental|cohort 1 iron isomaltoside|treated with first dose level of iron isomaltoside
16540683|NCT03013439|Experimental|cohort 2 iron isomaltoside|treated with second dose level of iron isomaltoside
16540630|NCT03013829|No Intervention|Usual Care|"Potential LKDs and recipients will receive standard-of-care LD (Live Donor) and KPD education. As noted previously, during standard care, incompatible potential LKDs are informed of the KPD option and the potential LKD is provided with living donation information and a link to the UNOS KPD website, which includes a written description of KPD. This information is available in English and Spanish. For those who do not have internet access, the written educational materials are mailed. The potential LKD is advised to call the donor nurse coordinator with any questions about KPD and/or to initiate the full donation evaluation. This process occurs for the intended recipient only if their potential donor decides to initiate the full evaluation.
~For study purposes, potential LKDs and waitlisted recipients assigned to the UC group will be sent an email after randomization, which will include a link and a reminder to review their transplant center's standard of care educational materials."
16540631|NCT03013829|Experimental|Video-Based KPD education|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch the embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
16540632|NCT03013816|Experimental|Testimonial Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
16540633|NCT03013816|Experimental|Informational Messaging|This video mirrors common educational campaigns and included segments of HRSA's animated video, Organ Donation and Transplantation: How Does it Work? The IM video presents facts about donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, donation myths, and the importance of communicating with parents about donation. Information about how to register as a donor is also included. The video contains no personal testimonials.
16540634|NCT03013816|Experimental|Blended Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
16540635|NCT03013803|Experimental|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
16540636|NCT03013790|Active Comparator|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
16540637|NCT03013790|Active Comparator|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
16540638|NCT03013790|Placebo Comparator|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
16540639|NCT03013777|Experimental|Cognitive behavioral therapy (CBT)|The patient would participate in eight forty-five minute sessions of CBT with a mental health therapist. Cognitive behavioral therapy (CBT), defined as a program of interventions that utilize education to teach relaxation, healthy coping skills, stress management, assertiveness training in order to help the individual identify and correct maladaptive beliefs in combination with education to help practice symptom reduction and improve quality of life and function.
16540640|NCT03013764|Placebo Comparator|normal protein intake|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
16540641|NCT03013764|Experimental|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
16540642|NCT03013751|Experimental|Drug|Udenafil administered for 52 weeks
16540643|NCT03013738|Experimental|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.
~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.
~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
16540644|NCT03013738|Other|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
16540645|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
16540646|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
16540647|NCT03013712|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
16540648|NCT03013699|Active Comparator|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
16540649|NCT03013699|Experimental|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
16540650|NCT03013686|Active Comparator|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.
~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
16585415|NCT02709655|Experimental|Vortioxetine 20 mg/day|
16540653|NCT03013660|No Intervention|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
16540654|NCT03013660|Experimental|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
16540655|NCT03013647|Other|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
16540656|NCT03013634|Experimental|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
16540657|NCT03013634|Placebo Comparator|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
16540658|NCT03013608|Experimental|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
16540659|NCT03013595|Experimental|TRAM feedback|"The completion of the Transition Readiness and Appropriateness Measure (TRAM, a standardized structured assessment ) prior to the transition boundary by the child and adolescent mental health service (CAMHS) clinician, young person and parent/carer.
~Feedback of TRAM findings to the CAMHS clinician to support decisions made regarding transition, communication with stakeholders and the transition process. Clinicians will be expected to communicate the findings to the young person and parent/carer, and, if a referral is made, to send the TRAM feedback to the adult clinician along with the referral letter.
~The clinicians will also receive information prior to recruitment begin on the use of TRAM and the way in which it fits in with optimal transition."
16540660|NCT03013595|No Intervention|Usual care|Patients, parent/carers and clinicians in the control arm will complete the TRAM prior to the transition boundary, but the clinicians won't receive any feedback from it nor any information on the benefits of using the decision support tool.
16540661|NCT03013582|Experimental|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
16540662|NCT03013582|Placebo Comparator|Tenolysis control|Standard surgical tenolysis alone
16540663|NCT03013556|Active Comparator|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
16540664|NCT03013556|Experimental|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
16540665|NCT03013556|Experimental|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
16540666|NCT03013543|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
16540667|NCT03013530||Patients with chronic disease|
16540668|NCT03013517|Experimental|Viaskin Peanut 250µg|
16540669|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.
~Neoadjuvant chemotherapy:
~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
16540670|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.
~Neoadjuvant chemotherapy:
~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
16540671|NCT03013491|Experimental|CX-072|Monotherapy CX-072
16540672|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
16540673|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
16540674|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
16540675|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
16540676|NCT03013478|No Intervention|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
16540677|NCT03013478|Active Comparator|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
16540678|NCT03013465|Other|Control Diet|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of broccoli (control).
16540679|NCT03013465|Active Comparator|Brassica Diet|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily.
16540680|NCT03013452|Active Comparator|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
16586090|NCT02705209|Placebo Comparator|Control|
16540684|NCT03013439|Experimental|cohort 3 iron isomaltoside|treated with third dose level of iron isomaltoside
16540685|NCT03013439|Experimental|cohort 4 iron isomaltoside|treated with fourth dose level of iron isomaltoside
16540686|NCT03013426|Experimental|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
16540687|NCT03013413|Experimental|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
16540688|NCT03013400|Active Comparator|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
16540689|NCT03013400|Placebo Comparator|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
16540690|NCT03013387|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|"The 90Y--DOTA-tyr3-Octreotide initial, Cycle 1 dose will be 50 mCi/m2 in children; 120 mCi in adults. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed. Cycles 2 and 3 doses will be determined by dosimetry-based calculation of renal doses from previous cycles; total renal dose ≤ 23Gy. 90Y-DOTA-tyr3-Octreotide will be administered with an amino acid solution to prevent radiation damage to kidneys. Amino acid infusion will begin 30 min prior to infusion of 90Y-DOTATOC and continue 3.5 hrs after infusion of study drugs.
~68Ga-DOTATOC will be administered intravenously to perform the PET/CT scan. The dose will be 3-5 mCi (target 4mCi). The pediatric dose will be 0.043 mCi/kg with a minimum dose of 0.3 mCi and a maximum dose of 3 mCi in children <18 years old."
16540691|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment
~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
16540692|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.
~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
16540693|NCT03013361|Active Comparator|Group B (n=20)|Group B (n=20): The patients in this group were infiltrated with 3 mL of 0.5% bupivacaine.
16540694|NCT03013361|Active Comparator|Group R (n=20):|Group R (n=20): The patients in this group were infiltrated with 3 mL of 0.5% ropivacaine.
16540695|NCT03013361|Placebo Comparator|Group S (n=20, Control):|Group S (n=20, Control): The patients in this group were infiltrated with 3 mL of normal saline.
16540696|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
16540697|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
16540698|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
16540699|NCT03013335|Experimental|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).
~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
16540700|NCT03013322|Active Comparator|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
16540701|NCT03013322|Placebo Comparator|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
16540702|NCT03013309|Experimental|Intervention|Receives the Family Check-Up 4 Health
16540703|NCT03013309|Experimental|Control|Receives Treatment as Usual
16540704|NCT03013296|Placebo Comparator|Placebo|Saline
16540705|NCT03013296|Other|GIP-A|Infusion of GIP-A alone as study tool.
16540706|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
16540707|NCT03013296|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
16540708|NCT03013270|Experimental|ARIS group|Aerobic-Resistance-Inspiratory
16540709|NCT03013270|Active Comparator|AT/RT group|Aerobic-Resistance
16540710|NCT03013270|Active Comparator|AT/IMT group|Aerobic-Inspiratory
16540711|NCT03013270|Active Comparator|AT group|Aerobic Training
16540712|NCT03013257|Experimental|High Intensity Focused Ultrasound|Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
16540713|NCT03013257|No Intervention|Fixed-dose radioiodine-131|Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
16540714|NCT03013244|No Intervention|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
16540715|NCT03013244|Experimental|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
16540716|NCT03013231||s/p ACLR|Patients having undergone ACL Reconstruction Surgery with goal of returning to sport. 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
16540717|NCT03013218|Experimental|Evorpacept (ALX148)|The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
16540718|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
16540719|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
16540720|NCT03013218|Experimental|Evorpacept (ALX148) + Rituximab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
16540721|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
16540722|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
16540723|NCT03013205|Experimental|PT+IA+CHL|"Intraarticular triamcinolone injection
~Intraarticular Xylocaine injection
~Coracohumeral ligament triamcinolone injection
~Physiotherapy"
16540724|NCT03013205|Active Comparator|PT+IA|"Intraarticular triamcinolone injection
~Intraarticular Xylocaine injection
~Physiotherapy"
16540725|NCT03013192|No Intervention|Control|No text message reminders, usual patient protocol
16540726|NCT03013192|Experimental|Intervention (text messaging)|Text message reminders for PT
16540727|NCT03013179||Black/African American Women and their 3-5 year old children|
16540728|NCT03013166||Cohort 1|IR hydrocortisone
16540729|NCT03013166||Cohort 2|IR prednisolone
16540730|NCT03013166||Cohort 3|MR hydrocortisone
16540731|NCT03013166||Cohort 4|IR to MR hydrocortisone
16540732|NCT03013153|Experimental|Low ligation with apical lymph node dissection|Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
16540733|NCT03013153|Active Comparator|High ligation|Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
16540734|NCT03013140|Experimental|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) <5%"
16540735|NCT03013140|Active Comparator|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
16540736|NCT03013127|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg i.v. every 3 weeks for up to 35 cycles
16540737|NCT03013114|Experimental|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
16540738|NCT03013101|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
16540739|NCT03013088|Experimental|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
16540740|NCT03013075|Experimental|SPINAL PLUS GENERAL ANESTHESIA|Patient will receive the intervention SPINAL ANESTHESIA before the start of surgery using Bupivacaine heavy 40 mg and Morphine 250 micro grams comprising a total volume of 8 ml to achieve a spinal block up to T2 level followed by general anesthesia
16540741|NCT03013075|Active Comparator|ONLY GENERAL ANESTHESIA|Patient will receive only general anesthesia before the start of surgery
16540742|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP > 25 mm Hg at rest or >30 mm Hg during exercise with PVR > 3 wood units and PCWP < 15 mm Hg.
16540743|NCT03013049|Active Comparator|Non cultured epidermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.
16540744|NCT03013049|Experimental|Non cultured dermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done.
16540745|NCT03013036|Other|Group I|Patients between 1 and 2 years
16540746|NCT03013036|Other|Group II|patients between 3 and 5 years
16540747|NCT03013036|Other|Group III|patients between 6 and 8 years
16540748|NCT03013023|Placebo Comparator|Routine care|Control group
16540749|NCT03013023|Active Comparator|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
16540750|NCT03013023|Active Comparator|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
16540751|NCT03013023|Active Comparator|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
16540752|NCT03013010|Experimental|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.
~5 weeks preoperative chemoradiotherapy.
~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.
~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
16540753|NCT03013010|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.
~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
16540754|NCT03012997|Active Comparator|Active Comparator: 40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the induction, surgery and in Postoperative care unit.
16540755|NCT03012997|Active Comparator|Active Comparator: 100% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen during 100% induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.
16540756|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
16540757|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
16540758|NCT03012971|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
16540759|NCT03012971|Placebo Comparator|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
16540760|NCT03012958||Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.
~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
16540761|NCT03012958||Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.
~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
16540762|NCT03012945|Experimental|Combined epidural-general anesthesia|Patients assigned to this group (experimental group) receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
16540763|NCT03012945|Active Comparator|General anesthesia|Patients assigned to this group (control group) receive general anesthesia and postoperative patient-controlled intravenous analgesia.
16540764|NCT03012932|Other|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
16540765|NCT03012919|Other|active decision support system (GDT protocol)|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
16540766|NCT03012893|Experimental|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
16540767|NCT03012893|Experimental|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
16540768|NCT03012893|Active Comparator|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
16540769|NCT03012880|Experimental|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
16540770|NCT03012867|Active Comparator|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
16540771|NCT03012867|Active Comparator|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
16540772|NCT03012854|Experimental|short-myotomy|Short-POEM for patients with esophageal achalasia
16540773|NCT03012854|Active Comparator|long-myotomy|Long-POEM for patients with esophageal achalasia
16540774|NCT03012854|Experimental|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
16540775|NCT03012854|Active Comparator|circular myotomy|Circular-POEM for patients with esophageal achalasia
16540776|NCT03012841|Experimental|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
16540777|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
16540778|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
16540779|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
16540780|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
16540781|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
16540783|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
16540784|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
16540785|NCT03012789|Other|Post Surgery|
16540786|NCT03012776|Experimental|TOPS System|Investigational surgical treatment using TOPS System
16540787|NCT03012776|Active Comparator|Transforaminal Lumbar Interbody Fusion (TLIF)|Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
16540788|NCT03012763|Placebo Comparator|non-caloric water|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
16540789|NCT03012763|Active Comparator|caloric drink|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
16540790|NCT03012763|Active Comparator|grapefruit juice|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
16540791|NCT03012750|Experimental|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
16540792|NCT03012737|Other|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
16540793|NCT03012724|Active Comparator|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
16540794|NCT03012724|Experimental|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
16540795|NCT03012711|Experimental|Training|Neuromuscular exercise training group will complete a 5 week NME training program
16540796|NCT03012711|No Intervention|Control|Control group will have 5 weeks with no intervention prior to being re-tested
16540797|NCT03012698|Experimental|RMS treatment|
16540798|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
16540799|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16540800|NCT03012659|Experimental|Intervention Arm|Full-day contraceptive counseling training for health center staff
16540801|NCT03012659|No Intervention|Control Arm|Usual care
16540802|NCT03012646|Experimental|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
16540803|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
16540804|NCT03012607|Experimental|Perfect Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] once daily for 6 weeks
16540805|NCT03012607|Experimental|Moderate Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 4 times per week (Monday, Wednesday, Friday, and Saturday) for 6 weeks
16540806|NCT03012607|Experimental|Poor Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 2 times per week (Monday, Thursday) for 6 weeks
16540807|NCT03012594|Experimental|Lanreotide|Open label
16540808|NCT03012581|Experimental|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
16540809|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
16540810|NCT03012542|Experimental|Diet 1|Administered for 8 weeks.
16540811|NCT03012542|Experimental|Diet 2|Administered for 8 weeks.
16540812|NCT03012529|Active Comparator|Active drug|Patients receive oral adjunctive rifampin therapy
16540813|NCT03012529|Placebo Comparator|Placebo|Patients receive oral riboflavin
16540814|NCT03012516|Experimental|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
16540815|NCT03012516|Active Comparator|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
16540816|NCT03012503|Placebo Comparator|Control|Five minutes before cervical manipulation, controls received a placebo gel applied to their neck.
16540817|NCT03012503|Experimental|Treatment|Five minutes before cervical manipulation the treatment group received a menthol containing gel (Biofreeze®) applied to their neck.
16540818|NCT03012490|Active Comparator|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
16540873|NCT03012113|Placebo Comparator|Placebo|Subjects will receive one dosage of Placebo, which is packed and labeled to mach the active compound.
16540819|NCT03012490|Experimental|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
16540820|NCT03012477|Experimental|AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatinIV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days later.
~- AZD1775 will be administered as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.
~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
16540821|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
16540822|NCT03012451|Experimental|Advancing Adolescents|Received structured eight-week psychosocial sessions
16540823|NCT03012451|No Intervention|Control|Controls wait-listed for the intervention, matched for age and urban residence
16540824|NCT03012438|Experimental|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.
~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
16540825|NCT03012425|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation & compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction & Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control & sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control & sleep restriction procedures, introduce & practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control & sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control & sleep restriction procedures Session 7- Review of sleep diary & overall progress, discuss relapse prevention, further sleep restriction guidelines & prophylaxis.
16540826|NCT03012425|Experimental|Acupuncture|Session 1 - Detailed history and examination, introduction to acupuncture. Sessions 2 - 10 - Each session will begin with insertion and manipulation of needles, which will remain in place for 30 minutes.
16540827|NCT03012412|Experimental|Mindfulness Based Program for Infertility|"Behavioral: MBPI
~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
16540828|NCT03012412|No Intervention|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
16540829|NCT03012399|Experimental|Group I (hypnosedation)|Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.
16540830|NCT03012399|Active Comparator|Group II (verbal support)|Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.
16540831|NCT03012386|Experimental|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
16540832|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (A)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
16540833|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (B)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
16540834|NCT03012360|Placebo Comparator|no antibiotic treatment for VAT|3 days of placebo
16540835|NCT03012360|Experimental|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:
~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .
~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.
~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.
~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
16540836|NCT03012347|Experimental|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
16540837|NCT03012334|Experimental|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
16540838|NCT03012334|Experimental|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
16540839|NCT03012334|Experimental|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
16540906|NCT03011957||Group 2|HIV negative 50-65 years old CD4 > 350 cells/ml Male or Female
16586415|NCT02703064|Experimental|Furocyst|Furocyst 500mg capsule, BD
16540840|NCT03012334|Active Comparator|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
16540841|NCT03012334|Placebo Comparator|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
16540842|NCT03012321|Active Comparator|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
16540843|NCT03012321|Active Comparator|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
16540844|NCT03012321|Active Comparator|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
16540845|NCT03012321|Active Comparator|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
16540846|NCT03012282|Experimental|Diagnostic (CT perfusion sequence)|Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.
16540847|NCT03012269|Experimental|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
16540848|NCT03012269|No Intervention|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
16540849|NCT03012256|Experimental|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
16540850|NCT03012256|No Intervention|Control|Home care (standard of care)
16540851|NCT03012243|Active Comparator|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
16540852|NCT03012243|Experimental|Gallbladder aspiration|Gallblader aspiration without drain
16540853|NCT03012230|Experimental|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16540854|NCT03012217||Specimens that meet inclusion criteria|
16540855|NCT03012204|Experimental|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
16540856|NCT03012204|Experimental|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
16540857|NCT03012204|Active Comparator|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
16540858|NCT03012204|Sham Comparator|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
16540859|NCT03012191|Experimental|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
16540860|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
16540861|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
16540862|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
16540863|NCT03012165|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
16540864|NCT03012152|Active Comparator|Standard conservative group|"Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
~."
16540865|NCT03012152|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
16540866|NCT03012139||Cancer with cachexia|Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
16540867|NCT03012139||Cancer without cachexia|Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
16540868|NCT03012139||No cancer|Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
16540869|NCT03012126|Experimental|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
16540870|NCT03012126|Experimental|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
16540871|NCT03012113|Other|Short term mild cooling|Subjects will undergo a short term mild cooling protocol consisting of personalized water cooling method for approximately 2 hours.
16540872|NCT03012113|Active Comparator|Mirabegron|Subjects will receive one dosage of 200 mg Mirabegron (Astellas Pharma).
16540971|NCT03011567|Experimental|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
16540874|NCT03012100|Experimental|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of cycle 1 only. Starting cycle 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
16540875|NCT03012100|Placebo Comparator|Arm II (placebo, sargramostim)|Patients receive cyclophosphamide as in Arm I. Starting cycle 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
16540876|NCT03012087|Experimental|Intervention Group|MyHealthyChoices
16540877|NCT03012087|Placebo Comparator|Control Group|Health Risk Assessment
16540878|NCT03012074|Experimental|Patients with Type II Diabetes|Patients with Type II Diabetes
16540879|NCT03012061|Placebo Comparator|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
16540880|NCT03012061|Experimental|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
16540881|NCT03012061|Experimental|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
16540882|NCT03012048|Experimental|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.
~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
16540883|NCT03012048|Active Comparator|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.
~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
16540884|NCT03012048|Active Comparator|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
16540885|NCT03012048|No Intervention|No intervention|Households are encouraged to continue their usual water treatment practices.
16540886|NCT03012035|Experimental|experimental group|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
16540887|NCT03012035|Other|comparator group|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
16540888|NCT03012022||Healthy Volunteers|
16540889|NCT03012009|Active Comparator|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
16540890|NCT03012009|Active Comparator|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
16540891|NCT03011996|Experimental|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
16540892|NCT03011996|Experimental|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
16540893|NCT03011996|Active Comparator|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
16540894|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
16540895|NCT03011996|Experimental|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
16540896|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
16540897|NCT03011983||Adolescents With Concussion|Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
16540898|NCT03011983||Adolescents Without Concussion|Age- and gender-matched healthy controls (n=160) will be recruited to establish a normative database of whole-brain slow-wave maps from MEG resting-state data as well as white-matter diffusion measures from MRI.
16540899|NCT03011970|Active Comparator|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
16540900|NCT03011970|Active Comparator|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
16540901|NCT03011970|Active Comparator|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
16540902|NCT03011970|Active Comparator|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
16540903|NCT03011970|Active Comparator|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
16540904|NCT03011970|Placebo Comparator|Placebo|Placebo nasal spray.
16540905|NCT03011957||Group 1|HIV positive viral load < 200 copies/ml 50-65 years old CD4 > 350 cells/ml Male or Female
16540907|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
16540908|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
16540909|NCT03011931|Experimental|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
16540910|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
16540911|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
16540912|NCT03011905|Experimental|Dexamethasone|Single dose of dexamethasone (Dexagalen) 16 mg iv during operation.
16540913|NCT03011905|Placebo Comparator|Control|Single dose of NaCl, 4 ml, iv during operation.
16540914|NCT03011892|Placebo Comparator|Double Blind (DB): Vehicle BID|Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
16540915|NCT03011892|Active Comparator|DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID|Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
16540916|NCT03011892|Experimental|DB: Ruxolitinib 0.15% Once Daily (QD)|Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
16540917|NCT03011892|Experimental|DB: Ruxolitinib 0.5% QD|Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
16540918|NCT03011892|Experimental|DB: Ruxolitinib 1.5% QD|Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
16540919|NCT03011892|Experimental|DB: Ruxolitinib 1.5% BID|Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
16540920|NCT03011892|Placebo Comparator|Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
16540921|NCT03011892|Active Comparator|OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
16540922|NCT03011892|Experimental|OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
16540923|NCT03011892|Experimental|OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
16540924|NCT03011892|Experimental|OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
16540925|NCT03011892|Experimental|OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
16540926|NCT03011879||1.STEMI patients with symptom onset within 30 days|First round enrollment of STEMI patients with symptom onset within 30 days
16540927|NCT03011879||2.STEMI patients with symptom onset within 30 days|Second round enrollment of STEMI patients with symptom onset within 30 days
16540928|NCT03011879||3.STEMI patients with symptom onset within 30 days|Third round enrollment of STEMI patients with symptom onset within 30 days
16540929|NCT03011866|Experimental|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.
~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
16540930|NCT03011866|Other|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.
~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
16540931|NCT03011853||Non-invasive only|Non-invasive ventilation as first and only respiratory support
16540932|NCT03011853||Invasive|Invasive ventilation with intubation as first respiratory support
16540933|NCT03011853||NIV+Inv|Non-invasive ventilation as first respiratory support followed by invasive ventilation with intubation
16540934|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.
~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
16540935|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
16540936|NCT03011827|Experimental|Prospective cohort|Fibrinogen and/or platelet administration
16540937|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
16586416|NCT02703051|Experimental|GMI-1271|GMI-1271
16540938|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
16540939|NCT03011801|Experimental|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
16540940|NCT03011801|Placebo Comparator|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
16540941|NCT03011788|Active Comparator|Single day|Single day Golytely purge 4L purge
16540942|NCT03011788|Active Comparator|2 day colon purge|Two days of Golytely purge 8L purge
16540943|NCT03011775|Experimental|study|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
16540944|NCT03011775|Other|control|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
16540945|NCT03011762|Other|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
16540946|NCT03011749|Experimental|FLT PET/CT|FLT PET/CT
16540947|NCT03011736|Experimental|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
16540948|NCT03011723|Experimental|Music therapy|10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions. The treatment is administered individually.
16540949|NCT03011710|Experimental|E-cigarette with nicotine|Nicotine level: 6 mg/ml
16540950|NCT03011710|Experimental|E-cigarette without nicotine|Nicotine level: 0 mg/ml
16540951|NCT03011710|Experimental|Conventional cigarette|Nicotine content: 0,5mg
16540952|NCT03011710|Placebo Comparator|Cigarette tip|Placebo device
16540953|NCT03011684|Experimental|ER Positive - Letrozole|
16540954|NCT03011684|Experimental|ER Positive - Tamoxifen|
16540955|NCT03011684|No Intervention|ER Negative|
16540956|NCT03011671|Experimental|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
16540957|NCT03011658|Placebo Comparator|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
16540958|NCT03011658|Other|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
16540959|NCT03011645|Active Comparator|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
16540960|NCT03011645|Active Comparator|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
16540961|NCT03011645|Placebo Comparator|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
16540962|NCT03011632|Experimental|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
16540963|NCT03011632|Placebo Comparator|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
16540964|NCT03011619|Active Comparator|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
16540965|NCT03011619|Experimental|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
16540966|NCT03011606|Experimental|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
16540967|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
16540968|NCT03011580|Experimental|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.
~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
16540969|NCT03011580|Placebo Comparator|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
16540970|NCT03011567|Experimental|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
16543320|NCT02995785|Other|Active comparatorr: traditional training|Traditional
16540972|NCT03011567|Experimental|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
16540973|NCT03011567|Experimental|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
16540974|NCT03011554|Experimental|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
16540975|NCT03011541|Active Comparator|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
16540976|NCT03011541|Active Comparator|Arm 2|BMSC provided retrobulbar, subtenon, intravitreal and intravenous for one or both eyes
16540977|NCT03011541|Active Comparator|Arm 3|BMSC provided either intraoptic nerve or subretinal for eye with worse vision with fellow eye receiving either retrobulbar and subtenon or retrobulbar, subtenon and intravitreal; followed by intravenous.
16540978|NCT03011528|Other|VDC - IE x2 & Surgery|"Patients in Arm A receive
~VDC-IE x2: Intensified induction phase:
~4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association
~Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added
~Maintenance phase
~1st year : VC (Vincristine Cyclophosphamide) association
~2nd year : Cyclophosphamide po 25 mg/m²"
16540979|NCT03011528|Other|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive
~VDC-IE & TEMIRI: Intensified induction phase:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:
~4 cycles of TEMIRI (Temozolomide-Irinotecan) association
~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Maintenance phase
~1st year : VC (Vincristine Cyclophosphamide) association
~2nd year : Cyclophosphamide po 25 mg/m²"
16540980|NCT03011528|Other|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive
~VDC-IE x2: Intensified induction phase:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Maintenance phase
~1st year : VC (Vincristine Cyclophosphamide) association
~2nd year : Cyclophosphamide po 25 mg/m²"
16540981|NCT03011528|Other|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive
~VDC-IE & TEMIRI: Intensified induction phase:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:
~4 cycles of TEMIRI (Temozolomide-Irinotecan) association
~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Maintenance phase
~1st year : VC (Vincristine Cyclophosphamide) association
~2nd year : Cyclophosphamide po 25 mg/m²"
16540982|NCT03011515||LRTI patients|Patients with suspicion of LRTI, excluding episodes of COPD exacerbations
16540983|NCT03011515||Non-infectious patients|Afebrile patients with no apparent infectious disease
16540984|NCT03011515||LRTI patients with COPD|Patients with suspicion of LRTI in a sub-group of patients with COPD
16540985|NCT03011502|Experimental|Experimental arm|
16540986|NCT03011489|Experimental|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
16540987|NCT03011489|No Intervention|control group|This group will not receive any treatment
16540988|NCT03011476|Active Comparator|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
16540989|NCT03011476|Placebo Comparator|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
16540990|NCT03011463|Active Comparator|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
16540991|NCT03011463|Active Comparator|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
16540992|NCT03011463|Active Comparator|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
16540993|NCT03011463|Active Comparator|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
16540994|NCT03011463|Active Comparator|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
16540995|NCT03011463|Active Comparator|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
16540996|NCT03011450|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
16540997|NCT03011450|Active Comparator|40 week extension|K-877 or fenofibrate comparator for 40 weeks
16540998|NCT03011437||cases|Patients who undergo esophagogastroduodenoscopy during 01/12/2016 and 31/12/2016 in the First People's Hospital of Kashgar Region.
16540999|NCT03011424|Experimental|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
16541027|NCT03011242||Longitudinal Cohort: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis starting standard of care treatment with a TNFi or non-biologic DMARD.
16541343|NCT03009136|Placebo Comparator|placebo group|3g, three times a day, each taken before or between meals
16541000|NCT03011385|Experimental|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
16541001|NCT03011385|Experimental|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
16541002|NCT03011385|Experimental|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
16541003|NCT03011385|Active Comparator|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
16541004|NCT03011372|Experimental|Pemigatinib|
16541005|NCT03011359|Experimental|1) Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
16541006|NCT03011359|Active Comparator|2) Optimizing B.I PCA mode|Optimizing Basal Infusion (New) PCA mode(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
16541007|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
16541008|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
16541015|NCT03011320|Experimental|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 4 mg/m2 EC1456 at <8 hours prior to surgery"
16541016|NCT03011320|Experimental|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
16541017|NCT03011320|Experimental|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 8 mg/m2 EC1456 at <8 hours prior to surgery"
16541018|NCT03011320|Experimental|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
16541019|NCT03011307|Experimental|Oxytocin|Oxytocin 100 micrograms administered intrathecally
16541020|NCT03011307|Placebo Comparator|Placebos|Placebo injection administered intrathecally
16541021|NCT03011294|Active Comparator|CPAP (in the partner)|Positive airway pressure for treating OSA in the bed partner.
16541022|NCT03011294|Placebo Comparator|Nasal strips (in the partner)|Nasal dilator as a placebo for treating OSA in the bed partner.
16541023|NCT03011281||RA patients who start Tofacitinib|Korean RA patients who start Tofacitinib with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate or biologics.
16541024|NCT03011268|Experimental|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
16541025|NCT03011268|Active Comparator|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
16541026|NCT03011255|Experimental|peptide specific CTL arm|peptide specific CTL, radiation
16541344|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
16541028|NCT03011242||Assay Development: Healthy or Psoriatic Arthritis|Individuals that are healthy or with a diagnosis of Psoriatic Arthritis will be enrolled for blood draws for assay development and/or for an ultrasound for development of techniques and scoring system validation.
16541029|NCT03011242||Cross-Sectional: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis in good disease state on stable non-biologic DMARDS or on stable TNFi.
16541030|NCT03011229|Active Comparator|Pro Core|Subject is randomized to ProCore standard needle.
16541031|NCT03011229|Experimental|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
16541032|NCT03011216|Experimental|Adaptive emotional cognitive control training|"Adaptive emotional n-back task: On each trial of this task, participants are presented with an emotional facial expression. Participants have to indicate whether the emotion presented in the current trial is the same as n trials back. In order to train participants at their individual ability level, the n-level varies by trial block based on participants' performance on the previous block.
~The adaptive emotional n-back task is assumed to train the ability to continuously update emotional material in working memory."
16541033|NCT03011216|Active Comparator|Placebo training|"Adaptive non-emotional feature match task: On each trial of this task, participants are presented with two panels containing 8-12 shapes each. Participants are asked to compare the two panels and decide whether or not they are identical. The panels contain a minimum of 8 shapes and a maximum of 12 shapes, depending on participants' performance on the previous block.
~The adaptive non-emotional feature match task is assumed to train the speed of responding (involving processes like visual search and concentration). It does not trait working memory updating."
16541034|NCT03011203|Experimental|Ketone-ester drink|Oral intake - physical exercise
16541035|NCT03011203|Active Comparator|Carbohydrate drink|Oral intake - physical exercise
16541036|NCT03011190|Experimental|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
16541037|NCT03011190|Active Comparator|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
16541038|NCT03011177|Experimental|teneligliptin|teneligliptin 20mg qd
16541039|NCT03011177|Active Comparator|linagliptin|linagliptin 5mg qd
16541040|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
16541041|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
16541042|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
16541043|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
16541044|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
16541045|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
16541046|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
16541047|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
16541048|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
16541049|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
16541050|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
16541051|NCT03011125|Placebo Comparator|placebo|
16541052|NCT03011125|Experimental|Dexlansoprazole Injection|
16541053|NCT03011112||KL 1|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
16541054|NCT03011112||KL 2|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
16541055|NCT03011112||KL 3|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
16541056|NCT03011112||KL 4|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
16541057|NCT03011099|Experimental|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
16541058|NCT03011099|Active Comparator|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
16541059|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
16541060|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
16541299|NCT03009500|Active Comparator|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
16541061|NCT03011060|Experimental|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.
~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
16541062|NCT03011060|Experimental|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
16541063|NCT03011060|No Intervention|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
16541064|NCT03011047|Experimental|endoscopic trans-antral approach|The maxillary sinus and prolapsed orbital contents will be visualized employing a 30-degree endoscope for the repair of orbital blow out fracture (sinus scope 4 mm, 30 degrees short one 17 cm).
16541065|NCT03011047|Active Comparator|trans-orbital surgical approach|trans-orbital surgical approach through the lower eyelid Sub-ciliary incision ( through the lower eyelid) The skin incision is made just below the eyelashes.
16541066|NCT03011034|Experimental|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
16541067|NCT03011034|Experimental|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
16541068|NCT03011021|Experimental|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
16541069|NCT03011021|Active Comparator|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.
16541070|NCT03011021|Active Comparator|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
16541071|NCT03011021|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
16541072|NCT03011008|Experimental|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
16541073|NCT03011008|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
16541074|NCT03010995|Active Comparator|18 mg nicotine|E-cigarette with 18 mg nicotine
16541075|NCT03010995|Active Comparator|9 mg nicotine|E-cigarette with 9 mg nicotine
16541076|NCT03010995|Placebo Comparator|0 mg nicotine|E-cigarette with 0 mg nicotine
16541077|NCT03010982|Experimental|Tazemetostat and [14C] Tazemetostat|"Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;
~A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat on Day 15;
~A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of [14C] tazemetostat on Day 16."
16541078|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
16541079|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
16541080|NCT03010943|Experimental|Brain surgery with virtual reality headset|
16541081|NCT03010930|Experimental|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
16541082|NCT03010930|Sham Comparator|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
16541083|NCT03010917|Experimental|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
16541084|NCT03010917|Placebo Comparator|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
16541085|NCT03010904|Experimental|pasteurized milk|milk that has undergone pasteurization treatment
16541086|NCT03010904|Experimental|homogenized pasteurized milk|Milk that has undergone homogenization and pasteurization treatment
16541087|NCT03010904|Experimental|UHT milk|Milk that has undergone homogenization and ultra high temperature treatment
16541088|NCT03010891|Active Comparator|control condition|Preterm infants in the control condition will receive only usual NICU care, plus positioning and gentle touch during intrusive procedures.
16541089|NCT03010891|Experimental|experimental condition|The bundle of supportive interventions will be designed to alleviate preterm infants' stress/pain from birth to discharge from the hospital NICU.
16541090|NCT03010878|Experimental|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
16541091|NCT03010878|Experimental|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
16541092|NCT03010865|Experimental|Sodium Butyrate|Dietary Supplement: Sodium Butyrate 4.38 gms of sodium butyrate per day for 12 weeks
16541093|NCT03010865|Placebo Comparator|Placebo Oral Capsule|Placebo Oral Capsule placebo capsules containing approximately 9 mg of sodium butyrate per day
16541300|NCT03009500|Placebo Comparator|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
16543671|NCT02993185|Active Comparator|Eat Smart|Nutrition education intervention
16541094|NCT03010852|No Intervention|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
16541095|NCT03010852|Experimental|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
16541096|NCT03010839|Active Comparator|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
16541097|NCT03010839|Placebo Comparator|Control|Control group without remote ischemic preconditioning
16541098|NCT03010826||40 Demyelinating Disease patients|
16541099|NCT03010826||40 Non-patient participants|
16541100|NCT03010813|Experimental|Novel single port robotic system|A single port innovation designed to deliver an articulating 3D high definition camera and three fully articulating instruments through a single 25-mm cannula
16541101|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
16541102|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
16541103|NCT03010787|Experimental|Part 1|Single ascending dose of oral V565
16541104|NCT03010787|Experimental|Part 2 - V565|Single dose level of oral V565 TID for 14 days
16541105|NCT03010787|Placebo Comparator|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
16541106|NCT03010787|Experimental|Part 3|Single dose of V565 in patient volunteers
16541107|NCT03010787|Experimental|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
16541108|NCT03010774|Experimental|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
16541109|NCT03010774|Active Comparator|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
16541110|NCT03010761|Experimental|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
16541111|NCT03010761|Experimental|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
16541112|NCT03010761|Experimental|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
16541113|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
16541114|NCT03010735|Active Comparator|Probiotics|The patient take two chewing tablet per day, which contain 4.0E+10 CFU of probiotics.
16541115|NCT03010735|Placebo Comparator|Placebo|The patient take two placebo chewing tablet per day.
16541116|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle
~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
16541117|NCT03010696||Healthy subjects|Normal kidney function
16541118|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
16541119|NCT03010683|Active Comparator|liraglutide|
16541120|NCT03010683|Active Comparator|Metformin|
16541121|NCT03010670|Experimental|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
16541122|NCT03010670|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
16541123|NCT03010657|Experimental|Experimental intervention|Subjects will add certain foods to what they normally eat.
16541124|NCT03010657|No Intervention|Non-experimental intervention|Subjects will continue eating normally.
16541125|NCT03010657|No Intervention|Observational|Subjects will continue eating normally.
16541126|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
16541127|NCT03010631|Active Comparator|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
16541128|NCT03010631|Experimental|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
16541129|NCT03010631|Experimental|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
16541130|NCT03010631|Experimental|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
16541131|NCT03010618|Other|Study Group|
16541132|NCT03010605|Active Comparator|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
16541133|NCT03010605|Active Comparator|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
16541301|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
16541134|NCT03010579|Experimental|erythropoietin group|For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
16541135|NCT03010579|Active Comparator|iron supplementation|If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
16541136|NCT03010553|Experimental|Oropharynx|Tumors of the oropharynx T1T2N0 treated with radiotherapy
16541137|NCT03010553|Experimental|Larynx|Tumors of the T1T2N0 larynx treated by surgery, laser or robot
16541138|NCT03010540|Experimental|Morphine Plus Fentanyl|
16541139|NCT03010540|Active Comparator|Fentanyl only|
16541144|NCT03010514||case|
16541145|NCT03010514||control|
16541146|NCT03010501|Experimental|100% Food Energy Density|Baseline Food Energy Density
16541147|NCT03010501|Experimental|80% Food Energy Density|Lower Food Energy Density
16541148|NCT03010501|Experimental|120% Food Energy Density|Higher Food Energy Density
16541149|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
16541150|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
16541151|NCT03010475|Experimental|Furosemide/Rosuvastatin/SNAC/Semaglutide|
16541152|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
16541153|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
16541154|NCT03010449|Experimental|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
16541155|NCT03010436|Other|Open-Label|All subjects will receive the study medication- benralizumab
16541156|NCT03010423|Experimental|Nicorandil|
16541157|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
16541158|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
16541159|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
16541160|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
16541161|NCT03010384|Active Comparator|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
16541162|NCT03010384|No Intervention|Control|Standard treatment from the Department of Rheumatology
16541163|NCT03010371|Experimental|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the presential version of the positive psychotherapy
16541164|NCT03010371|Experimental|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
16541165|NCT03010371|Experimental|Cognitive Behavioral Therapy|A group of breast cancer survivors are randomly allocated to the presential cognitive behavioral therapy (Cognitive Behavioral Stress Management, CBSM)
16541166|NCT03010358|Experimental|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
16541167|NCT03010345|Experimental|Osmed self inflating tissue expanders|All patients will undergo a two-stage procedure ,second stage under General endotracheal anesthesia. The first stage will be placement of the expanders. The second stage will be 21 days later, with removal of the expanders, palatal revision, and closure of the oronasal fistula
16541168|NCT03010345|Experimental|Iliac bone graft|Placement of bone graft without the use of self inflating expanders
16541169|NCT03010319|Experimental|PriMatrix|Arm will receive PriMatrix Dermal Repair Scaffold plus secondary dressings to maintain a moist wound healing environment and an appropriate off-loading device.
16541170|NCT03010319|Active Comparator|Standard of Care|Arm will receive moist wound therapy consisting of 0.9% Sodium Chloride gel plus secondary dressings and an appropriate off-loading device.
16541171|NCT03010306|No Intervention|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
16541216|NCT03010059|Experimental|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541302|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
16541172|NCT03010306|Active Comparator|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation & knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
16541173|NCT03010280|Experimental|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
16541174|NCT03010280|Active Comparator|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
16541175|NCT03010267|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
16541176|NCT03010267|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
16541177|NCT03010254|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
16541178|NCT03010254|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
16541179|NCT03010241|Experimental|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
16541180|NCT03010241|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
16541181|NCT03010228|Active Comparator|VLA15 12 µg with Alum|VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).
16541182|NCT03010228|Active Comparator|VLA15 12 µg w/o Alum|VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).
16541183|NCT03010228|Active Comparator|VLA15 48 µg with Alum|VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).
16541184|NCT03010228|Active Comparator|VLA15 48 µg w/o Alum|VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).
16541185|NCT03010228|Active Comparator|VLA15 90 µg with Alum|VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).
16541186|NCT03010228|Active Comparator|VLA15 90 µg w/o Alum|VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).
16541187|NCT03010215|Other|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
16541188|NCT03010202|Experimental|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
16541189|NCT03010202|No Intervention|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
16541190|NCT03010202|Experimental|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
16541191|NCT03010202|No Intervention|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
16541192|NCT03010189|Experimental|Patient|Cluster headache patients are examined with light reflex pupillometry, two weeks actigraphy and heart-rate variability monitoring both in headache phase and remission phase.
16541193|NCT03010189|Active Comparator|Controls|Healthy controls undergo the same examinations once: light reflex pupillometry, actigraphy and heart-rate variability monitoring.
16541194|NCT03010176|Experimental|Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)|Participants with cutaneous (cut) or subcutaneous (subcut) lesions receive escalating doses of ulevostinag monotherapy via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond for up to 35 cycles (up to approximately 2 years).
16541195|NCT03010176|Experimental|Part 1 Arm 2: Ulevostinag +Pembro (Cut/Subcut Lesions)|Participants with cut or subcut lesions receive escalating doses of ulevostinag via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond PLUS pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
16541196|NCT03010176|Experimental|Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)|Participants with visceral lesions receive escalating dose frequencies of ulevostinag via IT injection at escalating dose frequencies (Day 1 of each 21-day cycle for up to 35 cycles, then Days 1 and 8 of each 21-day cycle for two cycles, then Day 1 of each 21 day cycle up to 35 cycles, then Days 1, 8 and 15 of each 21-day cycle for two cycles followed by Day 1 of each 21-day cycle up to 35 cycles, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
16541197|NCT03010176|Experimental|Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory|Participants with HNSCC who are anti-programmed cell death-1 or anti-programmed cell death-ligand 1 refractory receive ulevostinag at the preliminary Recommended Phase 2 Dose (RP2D) determined by dose escalation in Part 1 Arm 1 and 2 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
16541198|NCT03010176|Experimental|Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC|Participants with TNBC who are anti-PD-1/PD-L1 treatment-naïve or who have refractory unresectable locally advanced or metastatic TNBC receive ulevostinag at the preliminary RP2D determined by dose escalation in Part 1 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
16541303|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
16541199|NCT03010176|Experimental|Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver|Participants with solid tumors with liver metastases/lesions who are anti-PD-1/PD-L1 treatment-naïve receive ulevostinag at the preliminary RP2D based on Part 1: ulevostinag +pembro (visceral lesions) treatment arm via IT injection in a to-be-determined dose and frequency, based on data from Arm 3, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
16541200|NCT03010163|Active Comparator|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
16541201|NCT03010163|Experimental|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
16541202|NCT03010163|Experimental|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants . Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
16541203|NCT03010163|Experimental|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
16541204|NCT03010150||Observational (blood tests, questionnaires)|Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
16541205|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
16541206|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
16541207|NCT03010124|Other|Patients with ovarian cancer|
16541208|NCT03010111|Other|health care workers|health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital
16541209|NCT03010098|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
16541210|NCT03010098|Experimental|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
16541211|NCT03010085|Active Comparator|A (Open left-sided hepatectomy)|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
16541212|NCT03010085|Experimental|B (Laparoscopic left-sided hepatectomy)|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
16541213|NCT03010072|Active Comparator|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
16541214|NCT03010072|Active Comparator|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
16541215|NCT03010059|Experimental|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541304|NCT03009474|Experimental|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
16543709|NCT02992912|Experimental|Cohort 3: metastatic renal cell carcinoma|
16541217|NCT03010059|Experimental|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541218|NCT03010059|Experimental|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541219|NCT03010059|Experimental|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541220|NCT03010059|Experimental|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541221|NCT03010059|Experimental|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541222|NCT03010059|Experimental|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541223|NCT03010059|Experimental|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541224|NCT03010059|Experimental|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541225|NCT03010059|Experimental|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541226|NCT03010059|Experimental|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
16541227|NCT03010046|Experimental|ANX005 Monotherapy|ANX005 intravenous infusion
16541228|NCT03010046|Experimental|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
16541229|NCT03010046|Placebo Comparator|Placebo|Placebo intravenous infusion
16541230|NCT03010033|No Intervention|regular care|[Control group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary and regular rehabilitation-propaganda; postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time) and early ambulation unless serious patients.
16541231|NCT03010033|Experimental|pulmonary rehabilitation|[Study group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary, regular rehabilitation-propaganda and interventional pulmonary rehabilitation (preoperative part); postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time), early ambulation unless serious patients and interventional pulmonary rehabilitation (postoperative part).
16541232|NCT03010020|Experimental|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
16541233|NCT03010020|Placebo Comparator|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
16541234|NCT03010020|No Intervention|STI-Negative|MSM without rectal GC and/or CT infection
16541235|NCT03009994|Other|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
16541236|NCT03009994|Other|Non exteriorization group|Uterine incision will be repaired intra abdominally
16541237|NCT03009981|Active Comparator|Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide|Patients will receive degarelix OR leuprolide with bicalutamide.
16541238|NCT03009981|Experimental|Arm B: Degarelix/Apalutamide|Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
16541239|NCT03009981|Experimental|Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone|Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
16541240|NCT03009968|No Intervention|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
16541305|NCT03009474|Active Comparator|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
16541241|NCT03009968|Experimental|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
16541242|NCT03009955||Group P|patients who received primary caesarean section
16541243|NCT03009955||Group R|patients who received repeated caesarean section
16541244|NCT03009916|Other|Healthy controls|Healthy controls found according to the protocol
16541245|NCT03009916|Other|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
16541246|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
16541247|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
16541248|NCT03009890|Experimental|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
16541249|NCT03009890|Active Comparator|Plaster immobilization|Standard local hospital protocol for cast treatment
16541250|NCT03009877|Active Comparator|Preoxygenation with face mask|Standard preoxygenation with a mask will be performed for five minutes. Once preoxygenation is complete, patients will be induced with standard induction medications including lidocaine, midazolam, fentanyl and propofol. Once the patient is apneic, one breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. The 5.5mm flexible intubation scope will be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope. Once the flexible intubation scope is in the trachea, the endotracheal tube (7.0 mm unless otherwise specified) will be advanced. Ventilation will not begin until the primary or secondary endpoints are reached.
16541251|NCT03009877|Experimental|Preoxygenation via hi flow nasal cannula|The high flow nasal cannula (Optiflow) will be applied as soon as the patient is in the operating room. The patient will be preoxygenated with high flow nasal cannula at 50 L/min for 5 minutes. After induction, general anesthesia will be maintained with a propofol infusion. One breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. Upon apnea, the Optiflow™ flow will be increased to 70 L/min and jaw thrust will be performed until the patient is adequately relaxed. The video laryngoscope (C-MAC) will then be introduced into the oropharynx and the flexible intubation scope advanced into the trachea with the assistance of the C-MAC. Once the flexible intubation scope is in the trachea, the endotracheal tube will be advanced.
16541252|NCT03009864|Experimental|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
16541253|NCT03009864|Placebo Comparator|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription
~, every bag weighs 4.87g, take it one bag each time, two times a day."
16541254|NCT03009851|Experimental|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
16541255|NCT03009851|No Intervention|Control|The control group only received the typical activities conducted in LTC facilities.
16541256|NCT03009838|Active Comparator|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
16541257|NCT03009838|Active Comparator|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
16541258|NCT03009812|Active Comparator|Group 1|26 subjects who are planned for transverse uterine incision
16541259|NCT03009812|Active Comparator|Group 2|26 subjects who are planned for longitudinal uterine incision
16541260|NCT03009799|Active Comparator|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
16541261|NCT03009799|Placebo Comparator|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
16541262|NCT03009786||Elderly institutionalized subjects or outpatients|
16541263|NCT03009773|Experimental|multitasking walking|Multitasking Group: rehabilitation multitasking walking.
16541264|NCT03009773|Active Comparator|walking simple task|Simple task group : Traditional walking rehabilitation
16541265|NCT03009760|Experimental|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
16541266|NCT03009760|Experimental|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
16541267|NCT03009760|Experimental|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
16541268|NCT03009760|Experimental|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
16541269|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
16541270|NCT03009734|Other|ATx201 (2% dermal formulation A) and Placebo|
16541271|NCT03009734|Other|ATx201 (2% dermal formulation B) and Placebo|
16541272|NCT03009734|Other|ATx201 (2% dermal formulation C) and Placebo|
16541273|NCT03009708|Experimental|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
16541274|NCT03009695|Experimental|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
16541275|NCT03009695|Experimental|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
16541276|NCT03009695|Experimental|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
16541277|NCT03009695|Experimental|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
16541278|NCT03009695|Sham Comparator|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
16541279|NCT03009682|Other|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
16541280|NCT03009643|Experimental|iNO Group|Patients are treated with iNO at a concentration of 5-10 ppm for 3-5 days according to the clinical conditions
16541281|NCT03009643|Other|Control|Patients are treated without iNO.
16541282|NCT03009630|Experimental|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
16541283|NCT03009617|Experimental|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
16541284|NCT03009617|No Intervention|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
16541285|NCT03009604|Experimental|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
16541286|NCT03009604|Active Comparator|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation.
16541287|NCT03009591|Experimental|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
16541288|NCT03009591|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
16541289|NCT03009578|Experimental|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = [body weight (kilogram)× (15-actual Hemoglobin)] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
16541290|NCT03009578|Active Comparator|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
16541291|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
16541292|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
16541293|NCT03009539|Experimental|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
16541294|NCT03009539|No Intervention|Treatment as Usual|Participants in this condition will not receive an intervention.
16541295|NCT03009526|Active Comparator|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
16541296|NCT03009526|Experimental|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:
~24-35.9 kg: Two tablets
~36-59.9 kg: Three tablets
~60-79.9 kg: Four tablets
~≥80 kg: Five tablets"
16541297|NCT03009513|Experimental|single arm|
16541298|NCT03009500|Active Comparator|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
16541342|NCT03009136|Experimental|SCRT group|3g, three times a day, each taken before or between meals
16541306|NCT03009461|Experimental|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
16541307|NCT03009461|Active Comparator|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
16541308|NCT03009448||Late onset depression|
16541309|NCT03009435|Experimental|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :
~Tarnier and Chantreuil technique
~or SOGC technique"
16541310|NCT03009435|No Intervention|expectative management|Expectative management . No manual rotation
16541311|NCT03009422|Experimental|Treatment|CO2 fractional laser with local application of Pentostam
16541312|NCT03009422|Active Comparator|control|Intra-lesinal Pentostam injedction
16541313|NCT03009409|Active Comparator|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
16541314|NCT03009409|Placebo Comparator|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
16541315|NCT03009396|Experimental|RHB-104 - patients on ACTIVE therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
16541316|NCT03009396|Experimental|RHB-104 - patients on PLACEBO therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
16541317|NCT03009383|Experimental|A bedside portable endoscopy|
16541318|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at< 20 weeks of gestation.
16541319|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
16541320|NCT03009357||control|euthyroid, healthy adults
16541321|NCT03009344|Experimental|tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later).
16541322|NCT03009331|Experimental|Prone position|Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.
16541323|NCT03009331|Active Comparator|Supine position|Intervention: Lungrecruitment in supine position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s. Clinical routine.
16541324|NCT03009318|Other|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
16541325|NCT03009305|Experimental|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
16541326|NCT03009292|Experimental|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
16541327|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
16541328|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
16541329|NCT03009266|Experimental|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
16541330|NCT03009266|Experimental|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
16541331|NCT03009253|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
16541332|NCT03009253|Experimental|Chemotherapy Group|"Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
~Followed by Concurrent chemoradiotherapy:
~(Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)"
16541333|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
16541334|NCT03009227|Active Comparator|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
16541335|NCT03009227|Experimental|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
16541336|NCT03009214|Experimental|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion
~Planned doses are:
~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
16541337|NCT03009201|Experimental|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16541338|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
16541339|NCT03009162|Experimental|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
16541340|NCT03009162|Experimental|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
16541341|NCT03009149|Experimental|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
16541345|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
16541346|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
16541347|NCT03009110|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
16541348|NCT03009110|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
16541349|NCT03009097|Active Comparator|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
16541350|NCT03009097|Active Comparator|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
16541351|NCT03009084|Experimental|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
16541352|NCT03009084|No Intervention|Control group|Usual care.
16541353|NCT03009071|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
16541354|NCT03009071|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
16541355|NCT03009058|Experimental|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
16541356|NCT03009058|Experimental|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541357|NCT03009058|Experimental|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine +capecitabine combination therapy.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541358|NCT03009058|Experimental|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.
~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541359|NCT03009058|Experimental|IMM-101+FOLFOX colorectal cancer|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541360|NCT03009058|Experimental|IMM-101+FOLFIRI+CETUXIMAB CRC|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541361|NCT03009058|Experimental|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
16541362|NCT03009058|Experimental|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
16541363|NCT03009058|Experimental|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.
~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541364|NCT03009058|Experimental|IMM-101+anti-PD1 lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.
~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
16541365|NCT03009058|Experimental|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
16541400|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
16543710|NCT02992912|Experimental|Cohort 4: metastatic sarcoma|
16541366|NCT03009058|Experimental|IMM-101+anti-PD1 melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
16541367|NCT03009058|Experimental|IMM-101+ anti-CTLA-4 melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
16541368|NCT03009058|Experimental|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
16541369|NCT03009058|Experimental|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541370|NCT03009058|Experimental|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
16541371|NCT03009058|Experimental|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
16541372|NCT03009045|Experimental|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
16541373|NCT03009032|Experimental|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
16541374|NCT03009032|Placebo Comparator|PLACEBO|Lactose
16541375|NCT03009019|Experimental|DFN-15 Active|DFN-15 Active
16541376|NCT03009019|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
16541377|NCT03009006|Experimental|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
16541378|NCT03009006|Experimental|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
16541379|NCT03009006|Placebo Comparator|Placebo|Mechanical preparation without intracanal medications.
16541380|NCT03008993|Experimental|Post-Intervention|The HQIS comprises three phases: 1) clinician training - to improve communication-relational skills and to instruct on the project; 2) center support - 4 on site visits by experts of the project team, aimed to introduce the project and boost motivation, instruct staff on how to implement recommendations, help with context analysis and identification of solutions; assess actual implementation in the center; 3) implementation of EBM recommendations.
16541381|NCT03008993|No Intervention|Control|
16541382|NCT03008980||Community GI Group|Diagnostic Test
16541383|NCT03008980||Academic GI Group|Diagnostic Test
16541384|NCT03008980||Academic Esophageal Dysplasia and Cancer|Diagnostic Test
16541385|NCT03008980||Community Barrett's Esophagus Screening|Diagnostic Test
16541386|NCT03008980||Community Esophageal Dysplasia|Diagnostic Test
16541387|NCT03008980||Post-Ablation BE and Esophagus Dysplasia|Diagnostic Test
16541388|NCT03008980||GERD, BE, and Esophageal Dysplasia|Diagnostic Test
16541389|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
16541390|NCT03008954|Placebo Comparator|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
16541391|NCT03008954|Experimental|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
16541392|NCT03008954|Experimental|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
16541393|NCT03008941|Experimental|FMT|"Fecal microbiota capsules (provided by Openbiome).
~Dosage:
~Induction: 10 capsules (single dose)
~Maintenance: 5 capsules, weekly, during 7 weeks."
16541394|NCT03008941|Placebo Comparator|Placebo|"Placebo capsules (provided by Openbiome).
~Dosage:
~Induction: 10 capsules (single dose)
~Maintenance: 5 capsules, weekly, during 7 weeks."
16541395|NCT03008928|No Intervention|Control|No intervention
16541396|NCT03008928|Experimental|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
16541397|NCT03008915|Active Comparator|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
16541398|NCT03008915|Placebo Comparator|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
16541399|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
16541472|NCT03008447|Experimental|ZOL; PBO; LEM10; LEM5|Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
16541401|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
16541402|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
16541403|NCT03008876|Experimental|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
16541404|NCT03008876|Active Comparator|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
16541405|NCT03008863|Experimental|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.
~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
16541406|NCT03008863|No Intervention|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
16541407|NCT03008850|Active Comparator|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
16541408|NCT03008850|Active Comparator|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
16541409|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
16541410|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
16541411|NCT03008811|Active Comparator|Cryoballoon|Pulmonary vein isolation with cryoballoon catheter.
16541412|NCT03008811|Active Comparator|Radiofrequency|Pulmonary vein isolation with radiofrequency ablation catheter.
16541413|NCT03008798|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
16541414|NCT03008798|Placebo Comparator|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
16541415|NCT03008785|Experimental|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
16541416|NCT03008785|Experimental|group placebo and exercise|The placebo group received 100mg containing starch of corn.
16541417|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
16541418|NCT03008772||Stent Types|the stent types for angina classification at follow up
16541419|NCT03008759|Placebo Comparator|Placebo|Dentifrice without fluoride
16541420|NCT03008759|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
16541421|NCT03008759|Experimental|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
16541422|NCT03008759|Experimental|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
16541423|NCT03008746|Experimental|not Pseudomonas aeruginosa colonized|
16541424|NCT03008746|Experimental|Pseudomonas aeruginosa colonized|
16541425|NCT03008746|Experimental|Pseudomonas aeruginosa OprD mutant colonized|
16541426|NCT03008733|Active Comparator|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
16541427|NCT03008733|Active Comparator|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
16541428|NCT03008733|Active Comparator|anti MAG|patient with neuropathy antibody Anti-MAG
16541429|NCT03008733|Placebo Comparator|healthy|healthy patient
16541430|NCT03008720|Active Comparator|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
16541431|NCT03008720|Placebo Comparator|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
16541432|NCT03008720|Active Comparator|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
16541433|NCT03008720|Placebo Comparator|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
16541434|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
16541435|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
16541436|NCT03008694|Experimental|1|PET/CT
16541473|NCT03008447|Experimental|PBO; LEM5; ZOL; LEM10|Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
16541474|NCT03008434|Experimental|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
16541475|NCT03008421|Experimental|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
16541437|NCT03008681|Experimental|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.
~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.
~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
16541438|NCT03008668|Experimental|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
16541439|NCT03008668|Active Comparator|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
16541440|NCT03008655|Active Comparator|Nd-YAG|ND-YAG only
16541441|NCT03008655|Experimental|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
16541442|NCT03008642|Experimental|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
16541443|NCT03008629|Experimental|Podofix nail brace|for mild ingrown toenails
16541444|NCT03008629|Experimental|Combiped nail brace|for Severe dystrophic ingrown toenails
16541445|NCT03008629|Experimental|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
16541446|NCT03008616|Active Comparator|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
16541447|NCT03008616|Placebo Comparator|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
16541448|NCT03008603|Experimental|Procedures with XACT Robotic System|CT-guided minimally invasive percutaneous procedures using the XACT Robotics system
16541449|NCT03008590|Other|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
16541450|NCT03008590|Other|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
16541451|NCT03008577|No Intervention|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
16541452|NCT03008577|Active Comparator|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
16541453|NCT03008551|Experimental|Empagliflozin group|Each participant will receive empagliflozin 25mg daily for 3 months
16541454|NCT03008551|Active Comparator|Metformin group|Each participant will receive metformin 1500mg daily for 3 months
16541455|NCT03008538|Experimental|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
16541456|NCT03008538|Active Comparator|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
16541457|NCT03008525|Experimental|obese patients (group OB)|patients with body mass index ≥ 35 kg/m²
16541458|NCT03008525|Active Comparator|non-obese patients (group NO)|patients with body mass index < 30 kg/m²
16541459|NCT03008512|Experimental|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
16541460|NCT03008499|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541461|NCT03008499|No Intervention|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541462|NCT03008486|Active Comparator|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
16541463|NCT03008486|Placebo Comparator|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
16541464|NCT03008486|Active Comparator|Stroke - real|Spastic patients stroke receiving the real soft splint
16541465|NCT03008486|Placebo Comparator|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
16541466|NCT03008473|Experimental|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
16541467|NCT03008473|Experimental|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
16541468|NCT03008460|Experimental|Eziclen®/Izinova®|
16541469|NCT03008460|Active Comparator|Klean-Prep®|
16541470|NCT03008447|Experimental|LEM5; LEM10; PBO; ZOL|Participants will receive LEM5 (one lemborexant [LEM] 5 milligram [mg] tablet and one zolpidem [ZOL]-matched placebo [PBO] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
16541471|NCT03008447|Experimental|LEM10; ZOL; LEM5; PBO|Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
16543841|NCT02992041|Experimental|Lower dose VVZ-149 Injections|
16541476|NCT03008421|Placebo Comparator|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
16541477|NCT03008408|Experimental|Arm I (ribociclib, everolimus, letrozole)|Patients receive ribociclib PO QD, everolimus PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16541478|NCT03008408|Experimental|Arm II (everolimus, letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16541479|NCT03008395|Experimental|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
16541480|NCT03008395|Active Comparator|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
16541481|NCT03008382|Other|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.
~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
16541482|NCT03008382|Other|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.
~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
16541483|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
16541484|NCT03008356|Experimental|L-carnitine|Oral L-carnitine 1000mg twice daily
16541485|NCT03008356|Experimental|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
16541486|NCT03008356|Placebo Comparator|Placebo|Placebo capsules twice daily
16541487|NCT03008343|Experimental|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541488|NCT03008343|Active Comparator|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541489|NCT03008330|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541490|NCT03008330|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541491|NCT03008317|Active Comparator|non metallic|PEEK denture base,
16541492|NCT03008317|Placebo Comparator|metallic denture base|cobalt chromium alloy denture base
16541493|NCT03008304|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541494|NCT03008304|No Intervention|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541495|NCT03008291||Heart Failure Group|Patients who have left bundle branch block (LBBB), right bundle branch block (RBBB) or interventricular conduction delay (IVCD) with a QRS duration of greater than 120 ms and left ventricular ejection fraction (LVEF) ≤ 35% will be enrolled in this arm. The primary care physician will have recommended either CRT-D Implantation or CRT-P Implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
16541496|NCT03008291||Atrioventricular Block Group|Patients who have developed second or third degree atrioventricular block (AV block). The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
16541498|NCT03008265||Colonic cancer resection|
16541548|NCT03007836|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541499|NCT03008239|Experimental|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.
~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
16541500|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
16541501|NCT03008200||RDS +|postpartum RDS developed group
16541502|NCT03008200||RDS -|postpartum RDS undeveloped group
16541503|NCT03008187|Experimental|SEL24/MEN1703|"SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
~Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.
~Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1."
16541504|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.
~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.
~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
16541505|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.
~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
16541506|NCT03008161|Experimental|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
16541507|NCT03008161|Experimental|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
16541508|NCT03008161|Experimental|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
16541509|NCT03008161|Experimental|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
16541510|NCT03008148|Active Comparator|Radiation,Temozolomide|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
~Rest Phase: Rest for 4 weeks.
~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
~Maintenance Phase: No maintenance treatment until disease progression confirmed."
16541511|NCT03008148|Experimental|Radiation,Temozolomide,Siroquine(JP001)|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).
~Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.
~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).
~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
16541512|NCT03008122|Experimental|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
16541513|NCT03008122|Experimental|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
16541514|NCT03008109|Experimental|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
16541515|NCT03008083|Active Comparator|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
16541516|NCT03008083|Active Comparator|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
16541517|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
16541518|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
16541519|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
16541520|NCT03008057|Active Comparator|vitamin D supplementation|patients with type 2 diabetes receive 1 tablet (4000 IU ) vitamin D supplementation, one time a day, for 3 months.
16541521|NCT03008057|Placebo Comparator|vitamin D placebo|patients with type 2 diabetes receive one tablet of vitamin D placebo for 3 months
16541522|NCT03008044|Experimental|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
16541523|NCT03008044|Experimental|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
16541524|NCT03008031|Experimental|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
16541525|NCT03008031|Experimental|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
16541526|NCT03008031|Experimental|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
16541527|NCT03008018|Other|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
16541528|NCT03008005|Placebo Comparator|Placebo Oral Capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.
~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
16541549|NCT03007836|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541529|NCT03008005|Experimental|Dronabinol Cap 5 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.
~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
16541530|NCT03008005|Experimental|Dronabinol Cap 10 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.
~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
16541531|NCT03007992|Experimental|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
16541532|NCT03007979|Experimental|Palbociclib + letrozole or + fulvestrant|"Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
~Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
~Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
~Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
~Optional research biopsy at baseline and progression
~Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
16541533|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
16541534|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
16541535|NCT03007953|Experimental|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
16541536|NCT03007953|No Intervention|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
16541537|NCT03007940|Experimental|NIATx Strategy|"The implementation intervention, NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective."
16541538|NCT03007940|Placebo Comparator|Wait List Control|The wait-list control group will receive the NIATx strategy at the end of the twelve month implementation period for the initial cohort. During the first year of the study, they will follow a business as usual approach to the integration of co-occurring substance use and mental health services.
16541539|NCT03007927|Experimental|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
16541540|NCT03007927|Active Comparator|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
16541541|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
16541542|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
16541543|NCT03007901|Experimental|Pilot Cohort 1|This Pilot Study will be conducted to allow us to evaluate and test the various study processes, including: consent/enrollment, run-in-trial monitoring, measurement tools, outcome assessment, educational materials, and especially the mindfulness-based climate action trainings. The pilot study does not include a control group, and data will not be used for efficacy outcome analysis.
16541544|NCT03007888|Other|Sequence 1|Treatment Period 1: ER CD-LD Capsules - 15 days; Washout Period 7-days; Treatment Period 2- IR CD-LD Tablet - 15 days
16541545|NCT03007888|Other|Sequence 2|Treatment Period 1- IR CD-LD Tablet - 15 days; Washout Period 7-days; Treatment Period 2- ER CD-LD Capsules - 15 days
16541546|NCT03007875|Experimental|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541547|NCT03007875|No Intervention|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541569|NCT03007693|Placebo Comparator|Placebo (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 matching placebo for 7 days.
16541550|NCT03007823|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541551|NCT03007823|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16541552|NCT03007810|Experimental|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
16541553|NCT03007810|Placebo Comparator|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
16541554|NCT03007797||vaccination rate- pregnant- influenca|
16541555|NCT03007784|Experimental|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
16541556|NCT03007784|Active Comparator|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
16541557|NCT03007771|Experimental|MR-HIFU|"Philips 1.5T MRI scanner equipped with a Sonalleve V2 HIFU system will be used
~Will be scanned in the MRI in 1 or more positions to the extremities and/or pelvis while aligned to the HIFU system. The HIFU device will then be used to apply sub-clinical levels (≤ 41°C) of heat to one or more small volumes. Regions will be heated to the desired temperature for variable short durations of time not exceeding 30 minutes.
~After the session is complete, the patient will be removed from the MR-HIFU system and, following a 15-30-minute period of monitoring for any adverse events, allowed to leave.
~Before the scan, after the scan and 5-10 days following the scan, participants will be asked to rate any pain, discomfort, in the area to be heated, as well as any anxiety or claustrophobia on a scale of 1-10 with 1 being minimal/none and 10 being extreme. The skin area to be treated will also be reviewed for any redness/discoloration."
16541560|NCT03007745|Experimental|REVAMP|Veterans randomized to this arm will have access to the Remote Veteran Apnea Management Platform (REVAMP) a personalized, interactive website that allows Veterans to be evaluated for OSA without travelling to the sleep center.
16541561|NCT03007745|Active Comparator|In-person management|Veterans randomized to this arm will receive standard in-person management of their sleep apnea in the sleep center.
16541562|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
16541563|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
16541564|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
16541565|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
16541566|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
16541567|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
16541568|NCT03007693|Experimental|JNJ-61393215 (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 once daily for 7 days. 4 sequential cohorts will be enrolled to evaluate escalating doses which will be defined, based on safety, tolerability and pharmacokinetic (PK) data from the preceding cohorts. Dose adjustment/selection (increase/decrease) for the next cohort will be based on the JNJ- 61393215 PK profile up to and including the last day of dosing (24 hours postdose) and the safety and tolerability profile of the current cohort.
16541570|NCT03007680|Experimental|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
16541571|NCT03007680|No Intervention|No core muscle activation|
16541572|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
16541573|NCT03007654|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
16541574|NCT03007654|No Intervention|No treatment|standard treatment for surgery
16541575|NCT03007654|Active Comparator|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
16541576|NCT03007641|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.
~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.
~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
16541577|NCT03007628|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
16541578|NCT03007628|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
16541579|NCT03007615|Experimental|Experimental group|
16541580|NCT03007602|Experimental|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
16541581|NCT03007602|No Intervention|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
16541582|NCT03007589|Other|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
16541583|NCT03007589|Other|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
16541584|NCT03007576|Experimental|RegStem|Autologous MSC, 5×10^7 cells, one injection
16541585|NCT03007563|Experimental|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
16541586|NCT03007550|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
16541587|NCT03007550|Other|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
16541588|NCT03007537|Placebo Comparator|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
16541589|NCT03007537|Experimental|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
16541590|NCT03007524|Experimental|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
16541591|NCT03007524|Active Comparator|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
16541592|NCT03007511|Experimental|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
16541593|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
16541594|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
16541595|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
16541596|NCT03007459||Female Fitness Athletes|Psychological health and physiological health of fitness athletes
16541597|NCT03007459||Female, physically active Controls|Psychological health and physiological health of female controls
16541598|NCT03007446|Experimental|Apatinib plus Oxaliplatin/S-1|"Apatinib :
~A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.
~Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.
~S-1:40mg，bid，d1-14，po，in a 21 day cycle."
16541599|NCT03007433|Experimental|healthy volunteers|60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (<40, 41-60, >60) are recruited.
16541600|NCT03007433|Experimental|Functional dyspeptic patients|20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population
16541601|NCT03007420|Experimental|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.
~If patients exhibit < 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
16541602|NCT03007420|Experimental|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.
~If patients exhibit < 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
16541603|NCT03007407|Experimental|durvalumab and tremelimumab|
16541605|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
16541606|NCT03007381|Experimental|Ketorolac tromethamine|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
16541607|NCT03007381|Sham Comparator|Normal Saline|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
16541608|NCT03007368|Experimental|Rice|Cooked white rice and tomato-based sauce
16541609|NCT03007368|Experimental|Potato|Cooked white peeled potato and tomato-based sauce
16541610|NCT03007368|Experimental|Pasta|Cooked macaroni product and tomato-based sauce
16541611|NCT03007368|Experimental|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
16541612|NCT03007368|Experimental|Millet thick porridge|Millet thick porridge and tomato-based sauce
16541613|NCT03007368|Experimental|Millet couscous|Cooked millet couscous and tomato-based sauce
16541614|NCT03007368|Experimental|Millet thin porridge|Millet thin porridge
16541615|NCT03007368|Experimental|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
16541616|NCT03007342|Experimental|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
16541617|NCT03007342|Placebo Comparator|control group|Oral tablet placebo every 12 hours for five days.
16541618|NCT03007329|Active Comparator|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily & Exenatide 2mg subcutaneous once weekly
16541619|NCT03007329|Placebo Comparator|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily & Exenatide matching Placebo 2mg subcutaneous once weekly
16541620|NCT03007316|Experimental|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
16541621|NCT03007316|No Intervention|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
16541622|NCT03007303||schizophrenia|"15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT.
~The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated."
16541623|NCT03007303||health controls|15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
16541624|NCT03007290|Experimental|Treatment group|Group with therapeutic drug monitoring
16541625|NCT03007277|Experimental|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
16541626|NCT03007277|Active Comparator|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
16541627|NCT03007264|Experimental|CAP treated|volar arm will be treated with cold atmospheric plasma.
16541628|NCT03007264|Experimental|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
16541629|NCT03007264|No Intervention|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
16541630|NCT03007251|Experimental|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
16541631|NCT03007251|Experimental|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
16541632|NCT03007251|Experimental|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
16541633|NCT03007251|Active Comparator|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
16541634|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
16541734|NCT03006523|Active Comparator|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
16541635|NCT03007225|Active Comparator|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
16541636|NCT03007225|Active Comparator|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
16541637|NCT03007212|Experimental|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
16541638|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
16541639|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
16541640|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
16541641|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
16541642|NCT03007160|Experimental|Experimental group|Potassium Citrate Extended-release Tablets
16541643|NCT03007160|No Intervention|Blank control group|Subjects do not take the investigational product
16541644|NCT03007147|Experimental|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
16541645|NCT03007147|Experimental|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
16541646|NCT03007147|Experimental|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
16541647|NCT03007121|Experimental|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
16541648|NCT03007121|Active Comparator|Bupivacaine + Sufentanil epidural|An epidural catheter will be inserted before induction of anaesthesia in a sitting position between T9 and T10 - T12 and L1 vertebrae. A test dose of 4 ml 0.5 bupivacaine will be administered to rule out intravascular injection or subarachnoid or subdural block. Standard general anaesthesia will be performed. Thirty minutes before the end of the surgery, patients will be administered a bolus of a mixture of bupivacaine 0.5% (3 ml) + sufentanil 10 mcg (2 ml) + NS 5 ml followed by a continuous infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h. At the same time patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
16541649|NCT03007121|Active Comparator|Morphine intravenous|Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be < 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.
16541650|NCT03007108|Experimental|healthy infants|
16541651|NCT03007095|Experimental|preterm children|
16541652|NCT03007095|Active Comparator|term children|
16541653|NCT03007069|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
16541654|NCT03007069|Active Comparator|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
16541655|NCT03007056||Period 1|year 2011 nCPAP
16541656|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
16541657|NCT03007043||Normal responders|Normal response following IVF
16541658|NCT03007043||Suboptimal responders|Suboptimal response following IVF
16541659|NCT03007030|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16541660|NCT03007017|Experimental|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
16541661|NCT03007017|Active Comparator|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
16541662|NCT03007004|Experimental|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
16541663|NCT03007004|Sham Comparator|Physiological saline (control drug) group|"0.2mL in one injection site
~Total 1.0mL (For both hands total 2.0 mL)"
16541664|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
16541665|NCT03006991||poor efficacy|patients can not reach effective outcome.
16541666|NCT03006978|Experimental|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
16541667|NCT03006978|Active Comparator|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
16541668|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (octocog alfa) or Adynovi® (rurioctocog alfa pegol), or patients using already myPKFit®.
~Patients will be given a dose of octocog alfa or rurioctocog alfa pegol according to usual clinical practice, and two blood samples will be taken in case of octocog alfa: one sample will be extracted 3-4h postdose (+/- 30 minutes), and the second sample will be extracted 24-32h postdose (+/- 60 minutes). In case of rurioctocog alfa pegol, the first sample is taken in the same conditions than octocog alfa, and the second sample will be extracted 48h postdose (+/- 120 minutes), and other sample post 72h(+/- 120 minutes) optional."
16541669|NCT03006952|Active Comparator|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
16541670|NCT03006952|Active Comparator|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
16541773|NCT03006276|Experimental|DFN-15 Active|DFN-15 Active
16541672|NCT03006913|Active Comparator|Randomization to counseling: In-person|Behavioral: Comparing genetic counseling modes.
16541673|NCT03006913|Active Comparator|Randomization to counseling: By phone|Behavioral: Comparing genetic counseling modes.
16541674|NCT03006913|Active Comparator|Randomization to counseling: By video|Behavioral: Comparing genetic counseling modes.
16541675|NCT03006900|Experimental|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
16541676|NCT03006900|Active Comparator|Massage|Massage (once per week for one hour)
16541677|NCT03006887|Experimental|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants with selected tumors will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once daily in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
16541678|NCT03006874|Experimental|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
16541679|NCT03006874|Experimental|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
16541680|NCT03006874|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
16541681|NCT03006861|Experimental|Oral creatine supplementation|21 g/d oral creatine for 7 days
16541682|NCT03006861|Placebo Comparator|Oral placebo supplementation|21 g/d oral placebo for 7 days
16541683|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.
~Interventions: Avelumab and quality of life questionnaires."
16541684|NCT03006835|Experimental|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
16541685|NCT03006835|Experimental|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
16541686|NCT03006835|Experimental|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
16541687|NCT03006835|Active Comparator|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
16541688|NCT03006822|Experimental|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
16541689|NCT03006822|Experimental|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
16541690|NCT03006822|Experimental|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
16541691|NCT03006809|Experimental|1|pretreatment antibiotics + FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
16541692|NCT03006809|Experimental|2|no antibiotics, FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
16541693|NCT03006809|Experimental|3|pretreatment antibiotics + FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
16541694|NCT03006809|Experimental|4|no antibiotics, FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
16541695|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
16541696|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
16541697|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
16541698|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
16541699|NCT03006770|Experimental|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
16541700|NCT03006770|Placebo Comparator|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
16541701|NCT03006757|Experimental|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
16541702|NCT03006757|Experimental|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
16541703|NCT03006744|Experimental|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
16541704|NCT03006744|Placebo Comparator|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
16541705|NCT03006731|Experimental|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
16541706|NCT03006731|Active Comparator|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
16541707|NCT03006718|Experimental|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.
~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
16541708|NCT03006705|Experimental|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.
~S-1 therapy(maximum 1 year):
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
~CapeOX Therapy(maximum 6 months):
~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
16541709|NCT03006705|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).
~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.
~S-1 therapy(maximum 1 year):
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
~CapeOX Therapy(maximum 6 months):
~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
16541710|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
16541711|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
16541712|NCT03006679|Experimental|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
16541713|NCT03006679|Active Comparator|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
16541714|NCT03006679|Experimental|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
16541715|NCT03006679|Active Comparator|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
16541716|NCT03006666|Active Comparator|Control Group (Data Only)|The teams randomly allocated to the Control Group will not have access to CHWs.
16541717|NCT03006666|Experimental|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
16541718|NCT03006640|Placebo Comparator|Control group|
16541719|NCT03006640|Active Comparator|NTG group|
16541720|NCT03006627|Active Comparator|Male group|All male patients scheduled for upper abdominal surgeries
16541721|NCT03006627|Active Comparator|Female group|All female patients scheduled for upper abdominal surgeries
16541722|NCT03006614|Experimental|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
16541723|NCT03006614|Active Comparator|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
16541724|NCT03006601|Placebo Comparator|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
16541725|NCT03006601|Experimental|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
16541726|NCT03006588|Experimental|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
16541727|NCT03006575|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose at the initial course: 40-51Gy/10-17f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 15-24 Gy/5-8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
16541728|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
16541729|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
16541730|NCT03006549|Experimental|Emergency Manual|emergency manual present
16541731|NCT03006549|No Intervention|No Emergency|NO emergency manual present
16541732|NCT03006536|Experimental|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
16541733|NCT03006536|Sham Comparator|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
16541735|NCT03006523|Experimental|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
16541736|NCT03006510|Active Comparator|Alert|If glucose <90 mg/dl and hypoglycemia prediction score >35, then alert with suggestion for intervention sent to treating team
16541737|NCT03006510|No Intervention|No alert|Routine standard care. If glucose <90 mg/dl and hypoglycemia prediction score >35, then report for investigators will be collected, but no active alert will be sent to teams.
16541738|NCT03006497|No Intervention|Control|The control group will not participate in any exercise program. However, at the end, home based exercises and special advice will be given to the participants.
16541739|NCT03006497|Experimental|Intervention|The intervention group will participate in an exercise program based on motor learning principles for 4 weeks/3 sessions per week, for a total of 12 sessions of 30-45 minutes each.
16541740|NCT03006484||Before Period|Patients who developed in-hosptial cardiac arrest before the implementation of new legislation on life-sustaining treatments
16541741|NCT03006484||After Period|Patients who developed in-hosptial cardiac arrest after the implementation of new legislation on life-sustaining treatments
16541742|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
16541743|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
16541744|NCT03006458|Experimental|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.
~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
16541745|NCT03006458|Active Comparator|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
16541746|NCT03006445|Experimental|FYU-981|
16541747|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
16541748|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
16541749|NCT03006419|Active Comparator|Group A (Basiliximab group)|Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.
16541750|NCT03006419|Experimental|B (Low-dose Thymoglobulin group)|Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.
16541751|NCT03006406|Active Comparator|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
16541752|NCT03006406|Experimental|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
16541755|NCT03006380|Experimental|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
16541756|NCT03006380|Experimental|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
16541757|NCT03006367|Experimental|NFC-1 100 mg|Single Dose of NFC-1 100 mg
16541758|NCT03006367|Experimental|NFC-1 200 mg|Single Dose of NFC-1 200 mg
16541759|NCT03006367|Experimental|NFC-1 400 mg|Single Dose of NFC-1 400 mg
16541760|NCT03006367|Experimental|NFC-1 800 mg|Single Dose of NFC-1 800 mg
16541761|NCT03006354|Experimental|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.
~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.
~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
16541762|NCT03006354|Active Comparator|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.
~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.
~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
16541763|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
16541764|NCT03006341||Warfarin|NVAF patients initiating warfarin
16541765|NCT03006328|Experimental|Obese Subjects + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
16541766|NCT03006328|Active Comparator|Obese Subjects + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
16541767|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants <65 years old and will accrue a total of 20 patients.
16541768|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants >/= 65 years and will accrue a total of 20 patients.
16541769|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207|
16541770|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CRS-207|
16541771|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
16541772|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
16541775|NCT03006263|Experimental|Totally Laparoscopic Total Gastrectomy|Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.
16541776|NCT03006263|Experimental|Laparoscopy Assisted Total Gastrectomy|Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
16541777|NCT03006250|Experimental|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
16541778|NCT03006250|Active Comparator|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
16541779|NCT03006237|Experimental|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
16541780|NCT03006224|Active Comparator|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
16541781|NCT03006224|Active Comparator|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
16541782|NCT03006211|Active Comparator|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
16541783|NCT03006211|Active Comparator|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
16541784|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
16541785|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
16541786|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
16541787|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
16541788|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
16541789|NCT03006185|Active Comparator|Test Area A|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
16541790|NCT03006185|Active Comparator|Test Area B|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
16541791|NCT03006172|Experimental|Stage I Arm A: Inavolisib Single Agent|Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541792|NCT03006172|Experimental|Stage I Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541793|NCT03006172|Experimental|Stage I Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541794|NCT03006172|Experimental|Stage II Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541795|NCT03006172|Experimental|Stage II Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541796|NCT03006172|Experimental|Stage II Arm D: Inavolisib + Fulvestrant|Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541797|NCT03006172|Experimental|Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541798|NCT03006172|Experimental|Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541799|NCT03006172|Experimental|Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab|Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
16541800|NCT03006159|Experimental|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
16541801|NCT03006159|Experimental|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
16541802|NCT03006159|Experimental|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
16541803|NCT03006146|Experimental|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
16541804|NCT03006120||Group 1|Conservative management
16541805|NCT03006120||Group 2|Angiografic stenting
16541806|NCT03006120||Group 3|Surgery
16541807|NCT03006107|Experimental|intraligamentary injection of piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .
~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
16541808|NCT03006107|Active Comparator|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
16541809|NCT03006081|Experimental|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
16541810|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
16541811|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
16541812|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose C|The participants in this arm will receive Upadacitinib (ABT-494) dose C.
16541813|NCT03006068|Experimental|Participants receiving Placebo|The participants in this arm will receive placebo until study is unblinded.
16541814|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A or Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
16541815|NCT03006055|Experimental|MBC Group|metastatic breast cancer Age：18-75 ECOG:0-2
16541816|NCT03006055|Experimental|Control Group|benign breast tumour Age：18-75 ECOG:0-2
16541817|NCT03006029|Experimental|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
16541818|NCT03006016|Experimental|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
16541819|NCT03006016|Placebo Comparator|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
16541820|NCT03006003|Experimental|Raloxifene group|Raloxifene treatment
16541821|NCT03006003|Active Comparator|Comparator group|Alendronate treatment
16541822|NCT03006003|No Intervention|Control group|To refuse anti-osteoporosis treatment
16541823|NCT03005990|Experimental|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
16541824|NCT03005990|No Intervention|Control group|Control group only provide standard outpatient care program.
16541825|NCT03005977|Other|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)
~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
16541826|NCT03005964|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
16541827|NCT03005964|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles.
16541828|NCT03005951|Experimental|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
16541829|NCT03005951|Experimental|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
16541830|NCT03005938|Experimental|Spinal manipulation|Spinal manipulation
16543842|NCT02992041|Experimental|Higher dose VVZ-149 Injections|
16541831|NCT03005938|Sham Comparator|Imitation of the spinal manipulation|Imitation of the spinal manipulation
16541832|NCT03005925|Experimental|connected group|remote monitoring by smartphone in the care management of patients with rheumatoid arthritis
16541833|NCT03005925|Active Comparator|control group|standard outpatient follow-up by physical consultation
16541834|NCT03005912|Placebo Comparator|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
16541835|NCT03005912|Active Comparator|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
16541836|NCT03005912|Active Comparator|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
16541837|NCT03005912|Active Comparator|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
16541838|NCT03005899|Experimental|SyB P-1501 group|One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
16541839|NCT03005899|Placebo Comparator|SyB P-1501 placebo group|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
16541840|NCT03005886|Experimental|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:
~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
16541841|NCT03005886|Active Comparator|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:
~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
16541842|NCT03005886|Sham Comparator|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
16541843|NCT03005873|Experimental|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
16541844|NCT03005873|Experimental|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
16541845|NCT03005873|Placebo Comparator|Placebo group|1.5 mL normal saline
16541846|NCT03005860|Active Comparator|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
16541847|NCT03005860|Experimental|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI [target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
16541848|NCT03005847|Experimental|FPP arm|active treatment with fermented papaya preparation
16541849|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
16541850|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
16541851|NCT03005821|Experimental|pediatric massage|Patients will receive Montmorillonite Powder and racecadotril granules as usual care according to different age or weight. Intravenous infusion, Oral Rehydration Salts (ORS), Zn,and antibiotics will be used if the pediatrician in charge considers necessary. Patients will receive Chinese pediatric massage once per day and for three days continuously. A cloak which can cover the child's hands and upper body will be required to put on, all the manipulations will be done under the cloak. Six acupoints will be adopted,i.e. Neibagua, Dachang,Xiaochang, Banmen, Fu, Tuishang Qijiegu. Each visit, children who are under 2 years old will receive manipulations on Neibagua for 500 times, 300 times for the other 5 acupoints each; if they are from 2-3 years old, the manipulations on Neibagua will be 700 times and 500 times for the other 5 acupoints respectively; while the manipulations on Neibagua will be 1000 times, and 800 times for the other 5 acupoints if the children are from 4-6 years old.
16541852|NCT03005821|Sham Comparator|sham massage|Patients will receive the same usual care as the experimental group. For the sham massage, the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead childrens' hand or childrens' body. Patients will be required to put on the same kind of cloak as that for the the experimental group, all the manipulations will be done under the cloak. The manipulation times for each acupoints will be the same as those for experimental group in accordance with different age. The sham massage will be given once per day for 3 days continuously.
16541853|NCT03005808|No Intervention|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
16541854|NCT03005808|Experimental|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
16541855|NCT03005808|Experimental|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
16541856|NCT03005795|Experimental|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
16541857|NCT03005795|Active Comparator|Colposcopy without music|During the colposcopic examination women will not hear music
16541858|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
16541859|NCT03005782|Experimental|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
16541860|NCT03005756|Experimental|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
16541861|NCT03005743|Experimental|MR based BT|Magnetic Resonance Image based Brachytherapy
16541862|NCT03005743|Other|Conventional BT|Conventional Radiograph based Brachytherapy
16541863|NCT03005730|Experimental|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
16541864|NCT03005730|Placebo Comparator|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
16541865|NCT03005717|Experimental|Active High|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
16541866|NCT03005717|Experimental|Active Low|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
16541867|NCT03005717|Placebo Comparator|Placebo|Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
16541868|NCT03005704|Experimental|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
16541869|NCT03005704|No Intervention|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
16541870|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
16541871|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
16541872|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
16541873|NCT03005678|Active Comparator|Denosumab|denosumab subcutaneous 60mg every 6 months
16541874|NCT03005678|Placebo Comparator|Alendronate|alendronate 70mg orally every week
16541875|NCT03005665|Experimental|Group A - Acetazolamide|Acetazolamide 5 mg/kg diluted in 10 ml normal saline through orogastric Ryle's Tube soon after the induction of anaesthesia followed by 10 ml normal saline flush.
16541876|NCT03005665|Placebo Comparator|Group s - Normal saline|20 ml normal saline total volume.
16541877|NCT03005652|Experimental|Mindfulness intervention|consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.
16541878|NCT03005652|Active Comparator|Health education intervention|"follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration.
~The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention."
16541879|NCT03005639|Experimental|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
16541880|NCT03005626|Experimental|Therapeutic education|Structured therapeutic education programs
16541881|NCT03005626|Active Comparator|Control group|standard outpatient follow-up
16541882|NCT03005613|Active Comparator|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
16541883|NCT03005613|Experimental|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
16541884|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).
~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.
~3400 pregnant women in early pregnancy will be studied in this cohort."
16541885|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.
~4000 pregnant women in early pregnancy will be studied in this cohort."
16541886|NCT03005587||Cirrhotics with no previous decompensation|
16541887|NCT03005587||Cirrhotics with previous one or more than one decompensation|
16541924|NCT03005366|Active Comparator|Flecainide|Conventional cardioversion group using intravenous flecainide.
16541888|NCT03005574|Experimental|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
16541889|NCT03005574|Active Comparator|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
16541890|NCT03005561|Experimental|Intervention|100 participants that will be participating in the Play Back meetings.
16541891|NCT03005561|No Intervention|Control|100 participants that will not be participating in the Play Back meetings.
16541892|NCT03005548|Experimental|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
16541893|NCT03005548|Sham Comparator|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
16541894|NCT03005535|Active Comparator|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
16541895|NCT03005535|Placebo Comparator|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
16541896|NCT03005522|Placebo Comparator|placebo|dosed with placebo
16541897|NCT03005522|Active Comparator|intervention|10mg oral dexamethasone
16541898|NCT03005509|No Intervention|Pre-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.
~The Trauma Quality Improvement Meeting (TQIM) checklist will not be introduced during this phase."
16541899|NCT03005509|Other|Post-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.
~The Trauma Quality Improvement Meeting (TQIM) checklist will be used at all Trauma Quality Improvement Meetings (TQIMs)"
16541900|NCT03005496|Placebo Comparator|Intervention|"Nifedipin 4x10 mg oral
~Dexamethasone 2x6 mg iv for 2 days
~Zinc 50 mg/day
~Beta-carotene 25,000 IU
~Vitamin D3 50,000 IU/weekly"
16541901|NCT03005496|Active Comparator|Control|"Nifedipin 4x10 mg
~Dexamethasone 2x6 mg iv for 2 days"
16541902|NCT03005483|Experimental|Gabapentin|Gabapentin 10 mg/kg in children submitted unilateral limb surgery
16541903|NCT03005483|Placebo Comparator|Placebo|Placebo in children submitted unilateral limb surgery
16541904|NCT03005470|Experimental|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
16541905|NCT03005470|Experimental|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
16541906|NCT03005470|Experimental|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
16541907|NCT03005470|Active Comparator|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
16541908|NCT03005457|Experimental|Stroke|
16541909|NCT03005457|Experimental|Hemiparesis other|
16541910|NCT03005444|Experimental|Anticoagulation|Rivaroxaban：10mg/d for 2 years
16541911|NCT03005444|No Intervention|Non-anticoagulated|No anticoagulants will be used.
16541912|NCT03005431|Experimental|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
16541913|NCT03005431|No Intervention|Waitlist control group|These parents will receive regular or typical services
16541914|NCT03005418|Experimental|Limb Cohort|Patients with limb-threatening vascular trauma in an extremity will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
16541915|NCT03005418|Experimental|Torso Cohort|Patients with life-threatening vascular trauma in the torso will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
16541916|NCT03005405|Active Comparator|restoration - control|Restoration
16541917|NCT03005405|Experimental|sealant - test|Sealant
16541918|NCT03005392|Experimental|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
16541919|NCT03005392|Experimental|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
16541920|NCT03005392|Experimental|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
16541921|NCT03005392|No Intervention|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
16541925|NCT03005366|Active Comparator|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
16541926|NCT03005353|Experimental|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
16541927|NCT03005353|Active Comparator|clotrimazole|Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
16541928|NCT03005340|Active Comparator|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
16541929|NCT03005340|Active Comparator|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
16541930|NCT03005340|Active Comparator|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
16541931|NCT03005340|Active Comparator|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
16541932|NCT03005340|Active Comparator|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
16541933|NCT03005340|Active Comparator|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
16541934|NCT03005327|Experimental|X4P-001|"Initial Treatment Phase: Participants will initiate treatment with mavorixafor at 50 milligrams (mg) once daily (QD) orally or a higher dose, with potential escalation based on area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values to a maximum total daily dose of 400 mg. Participants are expected to receive treatment for 24 weeks in the initial Treatment Period or until development of a treatment-limiting toxicity (TLT).
~Extension Phase: All participants will receive mavorixafor; the dose will not exceed 400 mg. In the Extension Phase, treatment may continue until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the sponsor."
16541935|NCT03005314|Other|Surgery|Postoperative chemotherapy group
16541936|NCT03005314|Other|Chemotherapy|Preoperative chemotherapy group
16541937|NCT03005301|Experimental|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
16541938|NCT03005301|Active Comparator|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
16541939|NCT03005288|Experimental|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
16541940|NCT03005288|Placebo Comparator|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
16541941|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).
~Follicle and endometrium can be evaluated: on the day of final injection or one day later.
~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.
~OPU: 1,5 day after hCG injection (normally 36-42 hours later).
~Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.
~Embryo transfer: 3 days after OPU.
~Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
16541942|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.
~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.
~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
16541943|NCT03005249|Experimental|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
16541944|NCT03005249|Experimental|the control group|The patients will be assigned to the control group for cerebral palsy.
16541945|NCT03005236|Experimental|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
16541946|NCT03005236|Active Comparator|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
16541947|NCT03005223|Experimental|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
16541948|NCT03005223|Experimental|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
16541949|NCT03005210|Experimental|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
16541950|NCT03005210|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
16541951|NCT03005210|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
16541952|NCT03005184|Experimental|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541953|NCT03005184|Experimental|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541979|NCT03005067|Experimental|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
16541954|NCT03005184|Experimental|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541955|NCT03005184|Experimental|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541956|NCT03005184|Experimental|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541957|NCT03005184|Experimental|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541958|NCT03005184|Experimental|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541959|NCT03005184|Experimental|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541960|NCT03005184|Experimental|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541961|NCT03005184|Experimental|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541962|NCT03005184|Experimental|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541963|NCT03005184|Experimental|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
16541964|NCT03005171|Active Comparator|Epidural|"Epidural catheters will be placed in the 9th or 10th thoracic intervertebral space prior to induction of anesthesia.Through the thoracic epidural catheter 0.125% bupivacaine at a rate of 5 mL/h will be infused.
~The infusion continues for 24h"
16541965|NCT03005171|Active Comparator|Lidocaine|"Intravenous lidocaine infusion will typically start in the operating room prior to induction of anesthesia at a rate of 2 to 3 mg/min. Postoperatively, the rate will be decreased to 0.5 to 1 mg/min.
~The infusion continues for 24h"
16541966|NCT03005158|Other|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
16541967|NCT03005158|Other|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
16541968|NCT03005158|Active Comparator|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
16541969|NCT03005145|Active Comparator|Short duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
16541970|NCT03005145|Active Comparator|Long duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
16541971|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
16541972|NCT03005132||GBM tissues|GBM tissues from GBM patients
16541973|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
16541974|NCT03005119|Experimental|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
16541975|NCT03005119|Placebo Comparator|Placebo|PTL201 and placebo capsules will be identical in appearance
16541976|NCT03005106|Experimental|StrataGraft Skin Tissue|
16541977|NCT03005093||CAREGIVERS|Caregivers of pediatric patients with swallowing disorders will be recruited.
16541978|NCT03005093||CHILDREN OF CAREGIVERS|Pediatric patients with swallowing disorders will be recruited.
16542184|NCT03003624|Active Comparator|BP Blade group|No.15 surgical blade was used to give incisions.
16541980|NCT03005067|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
16541981|NCT03005054|Experimental|StrataGraft skin tissue|
16541982|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
16541983|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
16541984|NCT03005028||Control|
16541985|NCT03005015|Experimental|Lenvatinib|Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
16541986|NCT03005015|Active Comparator|Doxorubicin|Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
16541987|NCT03005002|Experimental|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
16541988|NCT03004989||Programme 1|RTW group in day clinics
16541989|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
16541990|NCT03004989||Programme 3|My work and I
16541991|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
16541992|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
16541993|NCT03004963|Active Comparator|clinical group|evaluate the volume status just according to clinical indexes in this group.
16541994|NCT03004963|Experimental|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
16541995|NCT03004937|Experimental|Single-Arm, Non-Randomized, Stepped Wedge|All patients who meet the inclusion criteria will receive the same intervention.
16541996|NCT03004924|Experimental|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
16541997|NCT03004924|Active Comparator|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
16541998|NCT03004924|Placebo Comparator|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
16541999|NCT03004911|Experimental|Mobile application|
16542000|NCT03004911|Active Comparator|Paper booklet|
16542001|NCT03004898|Experimental|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
16542002|NCT03004885|Experimental|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
16542003|NCT03004885|Experimental|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
16542004|NCT03004885|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
16542005|NCT03004859||Adults ≥ 65 with a positive test result|Adults ≥ 65 that are got a positive test result were asked to visit their general practitioner and are called for an interview two times, 8 weeks and 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacies as well as of the two telephone interviews are compared to the results of the adults ≥ 65 with a negative test result.
16542006|NCT03004859||Adults ≥ 65 with a negative test result|Adults ≥ 65 that are got a negative test result are called for an interview 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacy as well as of the telephone interview are compared to the results of the adults ≥ 65 with a positive test result.
16542007|NCT03004846|Experimental|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
16542008|NCT03004846|Experimental|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
16542009|NCT03004833|Experimental|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
16542010|NCT03004833|Experimental|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
16542011|NCT03004820|Experimental|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
16542012|NCT03004807|Experimental|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
16542013|NCT03004807|Placebo Comparator|Control|Matching tablet to active multivitamin arm: 1/day
16542014|NCT03004781|No Intervention|Waiting-list|8-week period without intervention, N=45
16542015|NCT03004781|Experimental|self-efficacy|8-week group-based parenting program on self-efficacy beliefs, N=19
16542016|NCT03004781|Experimental|self-efficacy/emotion coaching|8-week group-based parenting program on self-efficacy beliefs and emotion coaching practice, N=26
16542017|NCT03004768|Experimental|Single dose of radiolabeled BMS-986165|
16542018|NCT03004742|Experimental|Flavonoid|Flavonoid supplement
16542019|NCT03004742|Placebo Comparator|Placebo|Placebo
16542020|NCT03004729|Other|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
16542021|NCT03004703|Experimental|Active drug|Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
16542022|NCT03004703|Placebo Comparator|Placebo|Sodium chloride 0.9%; 100 ml i.v. once.
16542023|NCT03004690|Experimental|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
16542024|NCT03004690|Experimental|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
16542025|NCT03004677|Experimental|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
16542026|NCT03004677|Active Comparator|Standard Care|Infants and parents will receive standard care provided in the NICU
16542027|NCT03004664||Support Empowerment Model|"The Center for Diabetes Education at the University of New Mexico Hospital (CDE) uses the Diabetes Self-Management Support Empowerment Model (DSMS). The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions. Patients attend a six-week group instructional session with 9 hours of class plus an individual follow-up with a certified diabetes educator. The group sessions have discussion supported by didactic conversation maps where the facilitator guides but does not control the conversation based on session thematic goals."
16542028|NCT03004664||The Chronic Care Model|One Hope Centro de Vida Diabetes Program is based on the Chronic Care Model (CCM). The CCM involves 6 synergistic domains: 1.) Improved access to care, 2.) Patient self-management support, 3.) Patient decision support, 4.) Care coordination, 5.) Integrated health information systems, and 6.) Access to community resources. To create a holistic care regime, the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design.
16542029|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
16542030|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
16542031|NCT03004638|Experimental|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
16542032|NCT03004638|Placebo Comparator|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
16542033|NCT03004638|Experimental|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
16542034|NCT03004638|Experimental|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
16542035|NCT03004638|Experimental|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
16542036|NCT03004638|Placebo Comparator|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
16542037|NCT03004625|Experimental|Study Arm|HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)
16542038|NCT03004612|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 24 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
16542039|NCT03004612|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 24 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
16542040|NCT03004599|Other|Transcatheter Aortic Valve Implantation (TAVI)|
16542041|NCT03004586|Experimental|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
16542042|NCT03004586|Experimental|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
16542043|NCT03004573|Experimental|Deep brain stimulation|
16542044|NCT03004560|Active Comparator|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
16542045|NCT03004560|Active Comparator|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
16542046|NCT03004547||Chronic hemodialysis patients|Patients on standard in-centre 3 times a week hemodialysis
16542047|NCT03004547||Peritoneal dialysis patients|Patients on peritoneal dialysis
16542048|NCT03004547||Adult and paediatric patients with CKD stage 1-5|Patients with chronic kidney disease stage 1-5 (not dialysis dependent)
16542049|NCT03004547||Healthy adult and paediatric controls|Subjects without kidney disease
16542050|NCT03004547||Heart failure patients with and without renal dysfunction|Heart failure patients (atrial fibrillation etc ...) with and without renal dysfunction
16542051|NCT03004534|Experimental|Presurgical Molecular Assessment|Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
16542052|NCT03004521|Active Comparator|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
16542053|NCT03004521|Experimental|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
16542054|NCT03004508|Experimental|Gingko biloba Extract|
16542055|NCT03004508|Placebo Comparator|Placebo|
16542056|NCT03004495|Experimental|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
16542057|NCT03004495|Active Comparator|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
16542058|NCT03004495|Active Comparator|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
16542059|NCT03004469|Experimental|P-3074 + Finasteride Placebo|Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
16542185|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
16542060|NCT03004469|Placebo Comparator|P-3074 Vehicle + Finasteride Placebo|Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
16542061|NCT03004469|Active Comparator|Oral Finasteride + P-3074 Vehicle|Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.
16542062|NCT03004456|Experimental|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
16542063|NCT03004456|No Intervention|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
16542064|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
16542065|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
16542066|NCT03004430|Experimental|MAM|Mantra Meditation Group
16542067|NCT03004430|Active Comparator|PMR|Progressive Muscle Relaxation Group
16542068|NCT03004417|Experimental|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
16542069|NCT03004417|Experimental|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
16542070|NCT03004417|Placebo Comparator|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
16542071|NCT03004404|Experimental|BI 730357|
16542072|NCT03004404|Placebo Comparator|Placebo|
16542073|NCT03004378|No Intervention|Control|Participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
16542074|NCT03004378|Experimental|Intervention|Fitbit (activity tracker) + participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
16542075|NCT03004365|Active Comparator|Study Arm 1|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
16542076|NCT03004365|Active Comparator|Study Arm 2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
16542077|NCT03004365|Active Comparator|Study Arm 3|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
16542078|NCT03004352|Experimental|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
16542079|NCT03004352|No Intervention|control subjects-control|
16542080|NCT03004352|Experimental|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
16542081|NCT03004352|No Intervention|hypoxemic COPD-control|
16542082|NCT03004352|Experimental|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
16542083|NCT03004352|Experimental|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
16542084|NCT03004339|Experimental|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
16542085|NCT03004339|Experimental|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
16542086|NCT03004339|Experimental|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
16542087|NCT03004339|Experimental|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
16542088|NCT03004339|Placebo Comparator|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
16542089|NCT03004339|Active Comparator|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
16542090|NCT03004313|Experimental|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:
~Blood and urine samples will be collected
~Complete a series of questionnaires; some of which will be completed daily
~Quantitative Sensory Test (QST)will be performed
~Magnetic Resonance Imaging (MRI)
~PET imaging (during and outside of a migraine attack)"
16542091|NCT03004313|Active Comparator|Healthy|"20 healthy subjects will undergo the following:
~Blood and urine samples will be collected
~Complete a series of questionnaires; some of which will be completed daily
~Quantitative Sensory Test (QST)will be performed
~Magnetic Resonance Imaging (MRI)
~PET imaging"
16542092|NCT03004300|Active Comparator|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
16542093|NCT03004300|Experimental|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
16542094|NCT03004300|Experimental|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
16542095|NCT03004287|Experimental|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).
~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.
~Immunological Consolidation 1: Daratumumab.
~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).
~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.
~Immunological Consolidation 2: Daratumumab.
~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.
~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
16542096|NCT03004274|Active Comparator|Running sutures|Deep layers will be closed using running sutures
16542097|NCT03004274|Experimental|Interrupted sutures|Deep layers will be closed using interrupted sutures
16542098|NCT03004261|Experimental|CMV-CTL|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.
16542099|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
16542100|NCT03004222|Experimental|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
16542101|NCT03004222|Placebo Comparator|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
16542102|NCT03004209|Other|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
16542103|NCT03004196|Active Comparator|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
16542104|NCT03004196|Experimental|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
16542105|NCT03004196|Experimental|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
16542106|NCT03004183|Experimental|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.
~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.
~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.
~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
16542107|NCT03004170|Experimental|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher & Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
16542108|NCT03004170|Active Comparator|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus & Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
16542109|NCT03004157|Experimental|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
16542110|NCT03004157|Experimental|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
16542111|NCT03004157|Experimental|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
16542112|NCT03004144|Other|FLOAT-Support|
16542113|NCT03004131|Experimental|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
16542114|NCT03004131|Placebo Comparator|Placebo|Nasal spray with no active dose plus Placebo tablet
16542115|NCT03004131|Active Comparator|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
16542116|NCT03004118|Active Comparator|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
16542117|NCT03004118|Placebo Comparator|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
16542118|NCT03004105|Experimental|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
16542119|NCT03004105|Experimental|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.
~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
16542120|NCT03004105|Experimental|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
16542121|NCT03004092|Experimental|Total cohort|
16542122|NCT03004053||Volunteers will be identified by the Head and Neck Service|25 volunteers (Part I - 8 volunteers. Part II - 17 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
16542300|NCT03002740||NVAF patients newly prescribed dabigatran|
16542123|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
16542124|NCT03004040||Control|matched control subjects (non-LCII)
16542125|NCT03004027|Experimental|Enhanced|self help leaflet enhanced with implementation intentions
16542126|NCT03004027|Active Comparator|Standard|self help leaflet standard (without implementation intentions)
16542127|NCT03004027|No Intervention|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
16542128|NCT03004014|No Intervention|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
16542129|NCT03004014|Other|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep
~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
16542130|NCT03004001|Experimental|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
16542131|NCT03004001|Placebo Comparator|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
16542132|NCT03003988|Experimental|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
16542133|NCT03003988|Active Comparator|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
16542134|NCT03003988|Placebo Comparator|Placebo|6.5 g. dextrose
16542135|NCT03003975|Active Comparator|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).
~If the vein then is isolated after a single application, the operator can move on to the next vein."
16542136|NCT03003975|Active Comparator|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
16542139|NCT03003949|Placebo Comparator|Placebo Patch and Placebo Capsule|Placebo patches worn for 16 weeks. On the 9th week of patch, oral placebo capsule taken daily for 12 days. Following the 16 weeks of patch use oral placebo capsule taken daily for 12 days.
16542140|NCT03003949|Active Comparator|Estradiol patch and progesterone capsule|Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
16542141|NCT03003936|Experimental|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
16542142|NCT03003936|Experimental|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
16542143|NCT03003923|Experimental|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
16542144|NCT03003923|Experimental|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
16542145|NCT03003923|Experimental|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
16542146|NCT03003923|No Intervention|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
16542147|NCT03003910|Experimental|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.
~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
16542148|NCT03003910|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
16542149|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
16542150|NCT03003897||Placebo Treatment|Participants receiving placebo.
16542151|NCT03003884|Experimental|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
16542152|NCT03003884|Experimental|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
16542153|NCT03003884|Experimental|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
16542154|NCT03003884|Experimental|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
16542155|NCT03003884|Active Comparator|Propofol|IV of Propofol at 1.5mg/kg for initial dose
16542156|NCT03003871|Experimental|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
16542157|NCT03003871|Active Comparator|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
16542158|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
16542159|NCT03003832|Experimental|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
16542160|NCT03003832|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
16542161|NCT03003819|Active Comparator|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
16542162|NCT03003819|Active Comparator|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
16542163|NCT03003806|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
16542164|NCT03003806|Active Comparator|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
16542165|NCT03003793||Control group|Healthy control subjects
16542166|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
16542167|NCT03003780|Experimental|Mindful Steps|Web-based behavioral intervention
16542168|NCT03003780|No Intervention|Usual Care|
16542169|NCT03003754|Experimental|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.
~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
16542170|NCT03003754|Active Comparator|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
16542171|NCT03003728|Experimental|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
16542172|NCT03003715|Experimental|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
16542173|NCT03003715|Experimental|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
16542174|NCT03003702|Experimental|ETH|Overnight monitoring
16542175|NCT03003702|Other|CTH|Morning monitoring
16542176|NCT03003689|Active Comparator|Scaling and Root Planing|"Hand instruments + ultrasonic scaler
~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
16542177|NCT03003689|Experimental|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler
~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
16542178|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).
~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
16542179|NCT03003663|Experimental|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
16542180|NCT03003650|Experimental|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
16542181|NCT03003637|Experimental|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
16542182|NCT03003624|Experimental|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
16542183|NCT03003624|Experimental|Cautery group|Electrosurgery tip was used to give incisions.
16542186|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
16542187|NCT03003598|Active Comparator|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
16542188|NCT03003598|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
16542189|NCT03003585|Active Comparator|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
16542190|NCT03003585|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
16542191|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
16542192|NCT03003559|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
16542193|NCT03003559|No Intervention|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
16542194|NCT03003546|Experimental|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16542195|NCT03003533|Experimental|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
16542196|NCT03003520|Experimental|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.
~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
16542197|NCT03003520|Experimental|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.
~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.
~Enrollment into Arm B was discontinued."
16542198|NCT03003507|Active Comparator|Diet 1|Low-carbohydrate Enteral Formula With Fructose
16542199|NCT03003507|Active Comparator|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
16542200|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
16542201|NCT03003468|Experimental|Arm A - Phase Ib|"Dose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 of each 21 day cycle. Imprime PGG will be administered at 2mg/kg on Day 1,8, and 15 of cycles 1-4, and on Day 1 of cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab.
~Experimental: Arm A - Phase II Investigational Treatment The maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 for cycles 1-4, and on Day 1 of cycles 5-16.
~Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 for Cycles 1-4 and on Day 1 only for Cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab."
16542202|NCT03003455|Active Comparator|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
16542203|NCT03003455|Experimental|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
16542204|NCT03003442|Experimental|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
16542205|NCT03003442|Placebo Comparator|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
16542206|NCT03003429|Experimental|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
16542207|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
16542208|NCT03003403|Experimental|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
16542209|NCT03003403|No Intervention|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
16542210|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
16542211|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
16542212|NCT03003377|Experimental|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
16542213|NCT03003377|Active Comparator|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
16542214|NCT03003364|Experimental|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
16542215|NCT03003364|Placebo Comparator|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
16542216|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
16542217|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
16542218|NCT03003338|Experimental|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
16542219|NCT03003338|Experimental|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
16542220|NCT03003325|Active Comparator|Phlebotomies + ASA|Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
16542221|NCT03003325|Experimental|Phlebotomies + ASA + AOP2014|Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
16542222|NCT03003299|Experimental|TAVR - Failing surgical valve|Patients with a failing surgical bioprosthetic valve will undergo transcatheter aortic valve replacement (TAVR).
16542223|NCT03003299|Experimental|TAVR - Failing transcatheter valve|Patients with a failing transcatheter bioprosthetic valve will undergo TAVR.
16542224|NCT03003286|Experimental|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
16542225|NCT03003286|Experimental|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
16542226|NCT03003273|Experimental|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
16542227|NCT03003273|Active Comparator|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
16542228|NCT03003260|Experimental|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
16542229|NCT03003260|Experimental|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
16542230|NCT03003247|Experimental|IDP-120 Gel|IDP-120 Gel is a combination treatment
16542231|NCT03003247|Active Comparator|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
16542232|NCT03003247|Active Comparator|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
16542233|NCT03003247|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
16542234|NCT03003234|Other|Duodenal fluid aspiration|
16542235|NCT03003221|Active Comparator|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
16542236|NCT03003221|Experimental|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
16542237|NCT03003208|Other|Pulmonary rehabilitation|
16542238|NCT03003195|Experimental|Vaccination: P10s-PADRE/MONTANIDE ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
16542239|NCT03003182||in clinical trials|
16542240|NCT03003182||out of clinical trials|
16542241|NCT03003169||ambulatory surgery description|
16542242|NCT03003156|Experimental|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
16542243|NCT03003156|Experimental|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
16542244|NCT03003143|Experimental|Vigabatrin treatment group|
16542245|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
16542246|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
16542247|NCT03003117|Experimental|Intervention Program|Experimental: Intervention Program
16542248|NCT03003117|Active Comparator|Usual Care|Active comparator: Usual Care
16542249|NCT03003104|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
16542250|NCT03003104|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
16542251|NCT03003091|Experimental|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
16542252|NCT03003091|Active Comparator|Traditional patient education|The participants received all structured information
16542253|NCT03003078|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
16542254|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
16542255|NCT03003039|Experimental|GB241|GB241:375 mg/m2, iv, one infusion
16542256|NCT03003039|Active Comparator|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
16542257|NCT03003026|Experimental|Novel task-specific program|Intervention arm - see detailed intervention group description below
16542258|NCT03003026|Active Comparator|Parent-led home-based program|Comparison arm - see detailed comparison group description below
16542259|NCT03003013|Active Comparator|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
16542301|NCT03002740||NVAF patients newly prescribed VKA|
16542260|NCT03003013|Active Comparator|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
16542261|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
16542262|NCT03003000|Active Comparator|ibuprofen|
16542263|NCT03003000|Placebo Comparator|placebo|
16542264|NCT03002987|Active Comparator|Intervention, education|Education of leaders (3 hours) in how to implement Active Pregnancy policy at their departements/workplaces
16542265|NCT03002987|No Intervention|control|as usual
16542266|NCT03002974|Experimental|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
16542267|NCT03002974|Experimental|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
16542268|NCT03002974|Active Comparator|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
16542269|NCT03002961|Experimental|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
16542270|NCT03002961|Experimental|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
16542271|NCT03002961|Experimental|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
16542272|NCT03002961|Experimental|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
16542273|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
16542274|NCT03002935|Experimental|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
16542275|NCT03002922|Experimental|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
16542276|NCT03002909|Active Comparator|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
16542277|NCT03002909|Active Comparator|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
16542278|NCT03002896|Experimental|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
16542279|NCT03002896|Active Comparator|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
16542280|NCT03002883|Placebo Comparator|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
16542281|NCT03002883|Active Comparator|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
16542282|NCT03002883|Active Comparator|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
16542283|NCT03002870|Other|Endometriosis|Patients whom pathology results post surgery document endometriosis
16542284|NCT03002857|Experimental|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
16542285|NCT03002857|Experimental|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
16542286|NCT03002857|Experimental|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
16542287|NCT03002844|Experimental|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
16542288|NCT03002844|Experimental|EGFR-TK Inhibitor|Gefitinib
16542289|NCT03002831|Experimental|CIK combined chemotherapy|Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.
16542290|NCT03002831|Active Comparator|Chemotherapy|Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w
16542291|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
16542292|NCT03002792||general anesthesia|caries treatment under general anesthesia
16542293|NCT03002792||caries treatment only|caries treatment without general anesthesia
16542294|NCT03002779|Experimental|JNJ-53718678|
16542295|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
16542296|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
16542297|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
16542298|NCT03002740||NVAF patients newly prescribed apixaban|
16542299|NCT03002740||NVAF patients newly prescribed rivaroxaban|
16542303|NCT03002701|No Intervention|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
16542304|NCT03002701|Active Comparator|Intervention group|After implementation the intervention package will be implemented as standard care.
16542305|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
16542306|NCT03002675|Experimental|exenatide|Participants will receive exenatide (Bydureon, 2mg s.c. 1x/wk, AstraZeneca) during 12 weeks
16542307|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI <18.5 underweight (Group 1)
16542308|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
16542309|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
16542310|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ>30 obese (Group 4)
16542311|NCT03002649|Experimental|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
16542312|NCT03002636|Experimental|Morbid Obesity group|Morbid Obesity group(n=300)
16542313|NCT03002636|Experimental|severe Obesity group|severe Obesity group (n=300)
16542314|NCT03002636|Other|non-Obesity group|non-Obesity group(n=300)
16542315|NCT03002623|Experimental|Group|CUDC-907 for thyroid cancer
16542316|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
16542317|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
16542318|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
16542319|NCT03002597|Experimental|Blind Children|Children between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
16542320|NCT03002597|Experimental|Sighted Children|Children between the ages of 4 and 17 who are sighted in both eyes.
16542321|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.
~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).
~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
16542322|NCT03002571|Experimental|IDP-124 Lotion|Lotion
16542323|NCT03002571|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
16542324|NCT03002558||control (non-OSA)|Patients without sleep apnoea
16542325|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
16542326|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
16542327|NCT03002545|Placebo Comparator|Placebo|identically tasting and looking Placebo
16542328|NCT03002545|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
16542329|NCT03002532|Active Comparator|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
16542330|NCT03002532|Experimental|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
16542331|NCT03002519|Experimental|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
16542332|NCT03002506|Experimental|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
16542333|NCT03002493|Experimental|Eribulin mesylate + Rifampicin|
16542334|NCT03002480|Other|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
16542335|NCT03002467|Experimental|PESI score|treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care)
16542336|NCT03002467|No Intervention|Standard care|standard care (i.e. no formally calculation of PESI on top)
16542337|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
16542338|NCT03002441|Active Comparator|Same-day Dilators|Participants will have Dilapan-S cervical dilators placed 4-6 hours prior to D&E and will receive 400 mcg buccal misoprostol pills 3 hours prior to D&E.
16542339|NCT03002441|Active Comparator|Overnight dilators|Participants will have Dilapan-S cervical dilators placed the day prior to their D&E procedure and will receive buccal placebo pills (vitamin B12) 3 hours prior to D&E.
16542340|NCT03002428|Experimental|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
16542341|NCT03002428|Active Comparator|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
16543843|NCT02992041|Placebo Comparator|Placebo|
16542344|NCT03002402|Experimental|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
16542345|NCT03002389|Other|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.
~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
16542346|NCT03002376|Experimental|REGN2810|REGN2810 treatment
16542347|NCT03002363|Experimental|Video Modeling Intervention|The intervention group receives a video that is a behavior modeling video that walks through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment.
16542348|NCT03002363|Placebo Comparator|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
16542349|NCT03002337|Experimental|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
16542350|NCT03002337|Experimental|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
16542351|NCT03002337|No Intervention|Control|the control group received only routine prenatal care.
16542352|NCT03002324|Active Comparator|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
16542353|NCT03002324|Experimental|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
16542354|NCT03002324|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
16542355|NCT03002311|No Intervention|Control|Receiving current standard of care as designated by emergency department (ED) standard operating practice.
16542356|NCT03002311|Experimental|Epharmix/CareSignal eHealth Intervention|After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).
16542357|NCT03002298|Experimental|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
16542358|NCT03002298|Experimental|DMD button-press task|Experimental group that made the task pressing the button
16542359|NCT03002298|Active Comparator|Control group gesture task|Control group that made the task using a gesture in front of a webcam
16542360|NCT03002298|Active Comparator|Control group button-press task|Control group that made the task pressing the button
16542361|NCT03002285|Experimental|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
16542362|NCT03002285|Active Comparator|Control group|Group with typical development that performed the Fitts law in a computer task
16542363|NCT03002272||TAVR|This observational study will enroll subjects that underwent TAVR more than 3 years ago.
16542364|NCT03002272||SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
16542365|NCT03002259|No Intervention|Control|No placebo required
16542366|NCT03002259|Active Comparator|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
16542367|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
16542368|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
16542369|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
16542370|NCT03002233|Experimental|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
16542371|NCT03002220|Experimental|open-label|Patient will be treated with radium-223 at a dose of 55 kBq (after 2015 NIST implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
16542410|NCT03001999|Experimental|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
16542411|NCT03001986|Experimental|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
16542376|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
16542377|NCT03002181|Experimental|PNE group|Pain neurophysiology education group.
16542378|NCT03002181|Experimental|Red Flag group|Red Flags education group.
16542379|NCT03002168|Active Comparator|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
16542380|NCT03002168|Placebo Comparator|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
16542381|NCT03002155|Experimental|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
16542382|NCT03002155|No Intervention|Control|Usual care.
16542383|NCT03002142|Experimental|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
16542384|NCT03002142|Placebo Comparator|Patients treated with placebo device|Patients fitted with non-functional hearing aids
16542385|NCT03002129|Other|fluid challenge|
16542386|NCT03002116|Active Comparator|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
16542387|NCT03002116|Experimental|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
16542388|NCT03002116|Experimental|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
16542389|NCT03002116|Experimental|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
16542390|NCT03002103|Experimental|ET+P+G|
16542391|NCT03002103|Active Comparator|Control|
16542392|NCT03002090|Experimental|Iron trained|
16542393|NCT03002090|Experimental|Iron Untrained|
16542394|NCT03002090|Experimental|BZKL Trained|
16542395|NCT03002090|Experimental|BZKL Untrained|
16542396|NCT03002090|Experimental|Placebo Trained|
16542397|NCT03002090|Placebo Comparator|Placebo Untrained|
16542398|NCT03002077|Experimental|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
16542399|NCT03002064|Experimental|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
16542400|NCT03002064|Active Comparator|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
16542401|NCT03002051|Experimental|EUS guided drainage|Patients suffering from the conditions in focus would receive EUS guided drainage with the lumen apposing stent
16542402|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
16542403|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
16542404|NCT03002025|Experimental|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
16542405|NCT03002025|Experimental|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
16542406|NCT03002025|Experimental|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
16542407|NCT03002025|Experimental|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
16542408|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
16542409|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
16542412|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
16542413|NCT03001960|Experimental|Group 1- PREloading BEFORE TAVI|"Aspirin 100 mg loading orally 6-12 hours before TAVI and
~Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
16542414|NCT03001960|Experimental|Group 2 - POSTLoading AFTER TAVI|"Aspirin 100 mg loading orally 6-12 hours after TAVI and
~Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
16542415|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
16542416|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
16542417|NCT03001921||Hemodialysis patients|End stage renal disease patients receiving hemodialysis treatment
16542418|NCT03001908|Active Comparator|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
16542419|NCT03001908|Active Comparator|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
16542420|NCT03001908|Experimental|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
16542421|NCT03001908|Experimental|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
16542422|NCT03001895|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
16542423|NCT03001882|Experimental|Combination therapy|Nivolumab + Ipilimumab
16542424|NCT03001869|Experimental|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
16542425|NCT03001856|Experimental|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
16542426|NCT03001856|Experimental|Intradermal Suture|Conventional interrupted intradermal suture
16542427|NCT03001843|Active Comparator|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
16542428|NCT03001843|Active Comparator|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
16542429|NCT03001830|Experimental|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
16542430|NCT03001817|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
16542431|NCT03001817|Active Comparator|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
16542432|NCT03001804||Cohort A|Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
16542433|NCT03001804||Cohort B|Initial treatment (up to 8 cycles): Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsule by mouth (PO) on day 1 through 14 of a 21 day cycle, Bortezomib 1.3mg/m2 s.c. on day 1, 4, 8, and 11 of a 21 day cycle, and Dexamethasone 20mg PO on days 1,2,4,5,8,9,11,12 of a 21 day cycle; Successive Treatment: Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
16542434|NCT03001791|Experimental|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
16542435|NCT03001791|Experimental|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
16542436|NCT03001791|Experimental|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
16542437|NCT03001778|Experimental|Usability Testing|Prototype testing
16542438|NCT03001765|Other|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
16542439|NCT03001752|Active Comparator|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
16542440|NCT03001752|Active Comparator|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
16542441|NCT03001752|Active Comparator|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
16542442|NCT03001739|Experimental|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg
16542443|NCT03001739|Active Comparator|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
16542444|NCT03001726|Experimental|Gastrectomy plus chemotherapy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
16542445|NCT03001726|Other|chemotherapy alone|Patients received chemotherapy alone.All patients received oral S1 80 mg/m2 per day (80-120 mg/day total dose depending on the patient's body surface area as follows: <1.25 m2, 80 mg; 1.25-1.5 m2, 100 mg; and >1.5 m2, 120 mg) on days 1-21 of every 3-week cycle, oxaliplatin 100 mg/m2 on day 1 of every 3-week cycle and docetaxel 40mg/m2 on day 1 of every 3-weeks cycle.
16542446|NCT03001713|Active Comparator|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
16586417|NCT02703051|Active Comparator|Filgrastim|Filgrastim
16542447|NCT03001713|Active Comparator|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
16542448|NCT03001700|Experimental|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
16542449|NCT03001687|Experimental|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
16542450|NCT03001687|Placebo Comparator|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
16542451|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
16542452|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
16542453|NCT03001661|Active Comparator|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
16542454|NCT03001661|Experimental|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
16542455|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
16542456|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
16542457|NCT03001635|Experimental|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
16542458|NCT03001635|Placebo Comparator|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
16542459|NCT03001622|Other|IFX-1|
16542460|NCT03001609|Experimental|AC0010|each participant will be given a single dose of 14C-labeled AC0010
16542461|NCT03001596|Experimental|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
16542462|NCT03001596|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
16542463|NCT03001583|Experimental|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
16542464|NCT03001583|Active Comparator|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
16542465|NCT03001570|Experimental|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.
~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:
~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
16542466|NCT03001557|Experimental|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
16542467|NCT03001557|Experimental|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
16542468|NCT03001557|Experimental|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
16542469|NCT03001557|Experimental|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
16542470|NCT03001557|Placebo Comparator|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
16542471|NCT03001544|Experimental|Experimental Ascending Dose Cohort|TS23
16542472|NCT03001531|Active Comparator|HydroSun|application of ultraviolet light for 30 minutes
16542473|NCT03001531|Active Comparator|Hilotherm|application of heat (maximum of 43°C) for 30 minutes
16542474|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
16542475|NCT03001505||Patients with pancreatic cancer|Patients diagnosed with pancreatic cancer evaluated at this institution.
16542611|NCT03000582|Active Comparator|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
16542476|NCT03001479|No Intervention|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
16542477|NCT03001479|Experimental|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
16542478|NCT03001466|Experimental|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
16542479|NCT03001466|Placebo Comparator|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
16542480|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
16542481|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
16542482|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
16542483|NCT03001427|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
16542484|NCT03001427|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
16542485|NCT03001414|Experimental|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
16542486|NCT03001414|Experimental|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
16542487|NCT03001414|Experimental|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
16542488|NCT03001401|Active Comparator|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
16542489|NCT03001401|Active Comparator|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
16542490|NCT03001375|Active Comparator|Mobilization group|Laparoscopic splenic flexure mobilization will be done.
16542491|NCT03001375|Active Comparator|Non mobilization group|No mobilization of splenic flexure.
16542492|NCT03001362|Experimental|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
16542493|NCT03001349|Experimental|Diagnostic (gallium Ga 68-edotreotide, PET/CT)|Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.
16542494|NCT03001323|Experimental|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
16542495|NCT03001323|Active Comparator|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.
16542496|NCT03001310|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of range AAV - CNGB3
16542497|NCT03001310|Experimental|Biological-medium dose AAV - CNGB3|Subretinal administration of a single medium dose of range AAV - CNGB3
16542498|NCT03001310|Experimental|Biological-high dose AAV - CNGB3|Subretinal administration of a single high dose of range AAV - CNGB3
16542499|NCT03001297|Experimental|MEDI5884 Dose 1|Participants will receive single dose of MEDI5884 Dose 1 injection SC on Day 1.
16542500|NCT03001297|Placebo Comparator|Placebo|Placebo will be administered subcutaneously (SC).
16542501|NCT03001297|Experimental|MEDI5884 Dose 2|Participants will receive single dose of MEDI5884 Dose 2 injection SC on Day 1.
16542502|NCT03001297|Experimental|MEDI5884 Dose 3|Participants will receive single dose of MEDI5884 Dose 3 injection SC on Day 1.
16542503|NCT03001297|Experimental|MEDI5884 Dose 4|Participants will receive single dose of MEDI5884 Dose 4 injection SC on Day 1.
16542504|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
16542505|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
16542506|NCT03001271|Experimental|Healthy Subjects|Placebo and Angiotensin-(1-7) acute infusion
16542507|NCT03001271|Experimental|Hypertensive Subjects|Placebo and Angiotensin-(1-7) acute infusion
16542508|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.
~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
16542565|NCT03000894|No Intervention|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
16542509|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.
~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
16542510|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.
~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
16542511|NCT03001245|Experimental|IPC|Interpersonal Counseling
16542512|NCT03001245|Active Comparator|ST|Standard treatment
16542513|NCT03001232|Experimental|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
16542514|NCT03001232|No Intervention|Care as usual|The control group received care as usual
16542515|NCT03001219|Placebo Comparator|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
16542516|NCT03001219|Experimental|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
16542517|NCT03001219|Placebo Comparator|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
16542518|NCT03001219|Experimental|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
16542519|NCT03001219|Placebo Comparator|Part 3: Placebo|"Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
~NOTE: Part 3 was not conducted."
16542520|NCT03001219|Experimental|Part 3: RO7123520|"Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
~NOTE: Part 3 was not conducted."
16542521|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :
~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
16542522|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :
~For patients referred to stress imaging with suspected ischemia."
16542523|NCT03001193|Experimental|DF01 low dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in low dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
16542524|NCT03001193|Experimental|DF01 medium dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in medium dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
16542525|NCT03001193|Experimental|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
16542526|NCT03001193|Placebo Comparator|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
16542527|NCT03001154|Experimental|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
16542528|NCT03001154|Experimental|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
16542529|NCT03001141||Single group - observational|
16542530|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
16542531|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
16542532|NCT03001115||Participants with Hidradenitis suppurativa (HS)|Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.
16542533|NCT03001102|Sham Comparator|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
16542534|NCT03001102|Experimental|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
16542535|NCT03001102|Active Comparator|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
16542536|NCT03001089|Active Comparator|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
16542537|NCT03001089|Placebo Comparator|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
16542538|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
16542539|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
16542540|NCT03001063|Experimental|Intervention|This arm will receive the Supported Self- Management intervention, which consists of bibliotherapy that is provided with the regular support of health or social workers for a duration of two months.
16542541|NCT03001063|Other|Control|This arm will receive enhanced treatment as usual, which consists of a leaflet with information about depression and regular care as provided by primary care centres. The control arm will receive the intervention after the intervention arm has completed the intervention period.
16542612|NCT03000582|Placebo Comparator|Placebo|6.5 gm dextrose
16542542|NCT03001050|Other|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
16542543|NCT03001037||Group A - Low Back Pain|"Group A:
~Subject provides written authorization and/or consent per institution and geographical requirements
~Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100
~Subjects in Group A are intended to be assessed with ViMove based on standard of care
~Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment
~Observational study, no intervention"
16542544|NCT03001037||Group B - Without Low Back Pain|"Subject is without current low back pain
~Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months
~Subject is willing to follow up 3 months post initial assessment
~Observational study, no intervention"
16542545|NCT03001024|Experimental|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary [UC] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
16542546|NCT03001024|Active Comparator|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
16542547|NCT03001011|Placebo Comparator|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (<=) 4.6 mg/dL (<=1.49 mmol/L).
16542548|NCT03001011|Experimental|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus <=4.6 mg/dL (<=1.49 mmol/L).
16542549|NCT03000998|Experimental|Web App Intervention Group|The BoyVac mobile web app will be evaluated in a pair-matched group-randomized pretest-posttest controlled design. In Year 2, 30 clinics in New Mexico will be pair-matched and one member of each pair will be randomized to the intervention (mobile web app) or a usual and customary (UC) HPV vaccine adoption procedures comparison group. Clinics will be paired based on similarities in patient demographic (ethnicity and % Medicaid patients) and location (urban and rural).
16542550|NCT03000998|Active Comparator|Usual Customary Care Group|Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
16542551|NCT03000985|Experimental|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
16542552|NCT03000985|No Intervention|Control|Treatment as usual
16542553|NCT03000972|Active Comparator|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
16542554|NCT03000972|Experimental|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
16542555|NCT03000946|Experimental|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
16542556|NCT03000946|Active Comparator|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
16542557|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
16542558|NCT03000920|No Intervention|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
16542559|NCT03000920|Experimental|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
16542560|NCT03000920|Experimental|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
16542561|NCT03000920|Experimental|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
16542562|NCT03000907|Experimental|Intervention|"diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.
~physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
16542563|NCT03000907|No Intervention|Control|Clinical practise
16542564|NCT03000894|Experimental|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
16542566|NCT03000881|Experimental|Cohort 6|This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours.
16542567|NCT03000868|Experimental|Cold EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
16542568|NCT03000868|Active Comparator|Hot EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
16542569|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
16542570|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
16542571|NCT03000842|Experimental|Healthy Subjects|transcutaneous vagal nerve stimulation
16542572|NCT03000842|Experimental|Hypertensive Subjects|transcutaneous vagal nerve stimulation
16542575|NCT03000816|Experimental|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
16542576|NCT03000803|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
16542577|NCT03000803|Active Comparator|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
16542578|NCT03000790|Experimental|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.
~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
16542579|NCT03000777|Experimental|Melatonin plus Zinc|Melatonin plus Zinc
16542580|NCT03000777|Placebo Comparator|Placebo|Isomaltose
16542581|NCT03000764|Experimental|Biomarkers|
16542582|NCT03000751|Active Comparator|Track A|Simple Audit Report In-Person Meeting Multi-Component Intervention
16542583|NCT03000751|Active Comparator|Track B|In-Person Meeting Simple Audit Report Multi-Component Intervention
16542584|NCT03000751|Other|Track C|Simple Audit Report Multi-Component Intervention
16542585|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age >=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
16542586|NCT03000725|Active Comparator|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
16542587|NCT03000725|Active Comparator|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
16542588|NCT03000712|Experimental|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
16542589|NCT03000712|No Intervention|No treatment|No treatment (after high tibial osteotomy)
16542590|NCT03000699|Experimental|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
16542591|NCT03000699|No Intervention|Assessment-Only Control|No training will be provided.
16542592|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
16542593|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
16542594|NCT03000673|Active Comparator|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
16542595|NCT03000673|Active Comparator|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
16542596|NCT03000673|Active Comparator|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
16542597|NCT03000673|Active Comparator|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
16542598|NCT03000660|Experimental|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
16542599|NCT03000647|Active Comparator|Guided Pelvic floor exercises|Pelvic floor exercises guided by a physiotherapist
16542600|NCT03000647|Active Comparator|Non-guided pelvic floor exercises|Pelvic floor exercises not guided
16542601|NCT03000634|Experimental|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
16542602|NCT03000634|Other|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
16542603|NCT03000621||Patients with liver injury|
16542604|NCT03000621||Healthy subjects|
16542605|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
16542606|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
16542607|NCT03000595|Experimental|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
16542608|NCT03000595|Placebo Comparator|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
16542609|NCT03000582|Experimental|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
16542610|NCT03000582|Active Comparator|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
16542613|NCT03000569|Experimental|Part A: Antiparkinsonian Agent(s) Followed by SAGE-217|Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.
16542614|NCT03000569|Experimental|Part B: Antiparkinsonian Agent(s) + SAGE-217|Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.
16542615|NCT03000556|Experimental|experience|
16542616|NCT03000556|No Intervention|control|
16542617|NCT03000543|No Intervention|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
16542618|NCT03000543|Experimental|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
16542619|NCT03000530|Experimental|Part A: SAGE-217|Participants received SAGE-217, 30 milligrams (mg), oral solution, once daily for 14 days, as tolerated.
16542620|NCT03000530|Placebo Comparator|Part B: Placebo|Eligible participants received matching placebo capsules once daily for 14 days.
16542621|NCT03000530|Experimental|Part B: SAGE-217|Eligible participants received SAGE-217, 30 mg, oral capsules, once daily for 14 days.
16542622|NCT03000504|Experimental|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
16542623|NCT03000504|Active Comparator|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
16542624|NCT03000478|Active Comparator|Prolonged Exposure|12 sessions of PE as per protocol
16542625|NCT03000478|Experimental|VRET|12 sessions of Virtual Reality Exposure Therapy
16542626|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
16542627|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.
~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
16542630|NCT03000426|Sham Comparator|Free gingival graft + PBM Sham|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which do not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications.
16542631|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 60|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 60 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 60 Joules/cm2 and a time of 56 seconds per point (1,68 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
16542632|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 15|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 15 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 Joules/cm2 and a time of 14 seconds per point (0,42 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
16542633|NCT03000413|Experimental|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
16542634|NCT03000413|Active Comparator|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
16542635|NCT03000400|Experimental|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
16542636|NCT03000400|Active Comparator|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
16542637|NCT03000387|Experimental|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
16542638|NCT03000387|Placebo Comparator|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
16542639|NCT03000387|Active Comparator|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
16542676|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
16542640|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:
~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
16542641|NCT03000361|Experimental|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
16542642|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
16542643|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
16542644|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
16542645|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
16542646|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
16542647|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
16542648|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
16542649|NCT03000335||Remission|B-ALL patients who are in remission
16542650|NCT03000322|Experimental|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
16542651|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
16542652|NCT03000296|Experimental|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
16542653|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
16542654|NCT03000270|Active Comparator|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
16542655|NCT03000270|Active Comparator|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
16542656|NCT03000257|Experimental|ABBV-181 plus Venetoclax|Venetoclax will be taken once daily beginning 7 days prior to cycle 1 and continuing daily for a 28 day cycle and ABBV-181 will be administered every 4 weeks.
16542657|NCT03000257|Experimental|ABBV-181|ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine or venetoclax.
16542658|NCT03000257|Experimental|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
16542659|NCT03000244||1/Patients|Patients who underwent hematopoietic stem cell transplant for any indication (malignant ornon-malignant).
16542660|NCT03000244||2/Donors|Related stem cell donors of those in Patients cohort.
16542661|NCT03000244||3/Parents of patients|Parents/guardians of minors enrolled in cohort 1
16542662|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
16542663|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
16542664|NCT03000218|Experimental|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
16542665|NCT03000218|Experimental|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
16542666|NCT03000218|Placebo Comparator|Placebo|Day 1 to 56: Placebo bid
16542667|NCT03000205|Experimental|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
16542668|NCT03000205|Placebo Comparator|Normal Saline|normal saline and Lidocaine as placebo for sham group
16542669|NCT03000192||Breast cancer|Women aged <50 years
16542670|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
16542671|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
16542673|NCT03000166|Experimental|Step-Up Intervention Group|Participants assigned to the Step-up intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
16542674|NCT03000166|No Intervention|Attention Control Group|Participants assigned to the attention control group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
16542675|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
16542677|NCT03000140|Experimental|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
16542678|NCT03000140|Active Comparator|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
16542679|NCT03000127|Experimental|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
16542680|NCT03000114|Active Comparator|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
16542681|NCT03000114|Active Comparator|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
16542682|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
16542683|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
16542684|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
16542685|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
16542686|NCT03000075|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16542687|NCT03000075|Experimental|Risankizumab 75 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16542688|NCT03000075|Experimental|Risankizumab 150 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16542689|NCT03000062|Experimental|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.
~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.
~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.
~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
16542690|NCT03000062|No Intervention|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.
~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.
~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
16542691|NCT03000036|Other|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
16542692|NCT03000010|Active Comparator|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
16542693|NCT03000010|Active Comparator|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
16542694|NCT02999997|Experimental|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
16542695|NCT02999997|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
16542696|NCT02999984|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
16542697|NCT02999971|Experimental|circuit class therapy in water|CCT on water. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
16542698|NCT02999971|Experimental|circuit class therapy on land|CCT on land. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
16542699|NCT02999958|No Intervention|Control|Sequential culture media without addition of antioxidants
16542700|NCT02999958|Active Comparator|Treatment|Sequential culture media with the addition of antioxidants
16542701|NCT02999945|Active Comparator|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
16542736|NCT02999711|Experimental|Cohort 2|REGN3500 medium dose or placebo
16542702|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
16542703|NCT02999945|Active Comparator|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
16542704|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
16542705|NCT02999932|Experimental|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
16542706|NCT02999932|Active Comparator|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
16542707|NCT02999919|Active Comparator|BMI ≥ 30|BMI ≥ 30
16542708|NCT02999919|Active Comparator|BMI < 30|BMI <30
16542709|NCT02999906|Placebo Comparator|Placebo|Matching placebo (sugar pill)
16542710|NCT02999906|Active Comparator|Active|Oral treprostinil sustained release tablet
16542711|NCT02999893|Experimental|APR-246|"The trial regimen consists of the investigational agent APR-246, along with standard chemotherapy, Cisplatin and 5-FU. A maximum of 8 cycles of treatment will be given.
~APR-246 and 5-FU must both commence on Day 1 and given on days 1 to 4 via intravenous infusion over 6 hours, whilst 5-FU must be given as a continuous infusion over 96 hours.
~On Days 2-4, APR-246 must be given first via intravenous infusion over 6 hours, then commence cisplatin via intravenous infusion over one hour.
~This is a dose-escalation study to determine the maximum tolerated dose (MTD) of the combination therapy. The 3 dose levels are described as follows:
~Dose Level 1:
~APR-246 Dose: 75mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI
~Dose Level 2:
~APR-246 Dose: 100mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI
~Dose Level -1:
~APR-246 Dose: 50mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI"
16542712|NCT02999880|Experimental|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
16542713|NCT02999880|No Intervention|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
16542714|NCT02999867|Experimental|M1 triticale and mung bean|M1: triticale and mung bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
16542715|NCT02999867|Experimental|M2 adzuki bean|M2: adzuki bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
16542716|NCT02999854|Experimental|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
16542717|NCT02999854|Active Comparator|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
16542718|NCT02999841|Experimental|Group A|Acarbose
16542719|NCT02999841|Active Comparator|Group B|Vildagliptin
16542720|NCT02999828|Experimental|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
16542721|NCT02999815|Active Comparator|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
16542722|NCT02999815|Sham Comparator|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
16542723|NCT02999802|Experimental|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
16542724|NCT02999789|Active Comparator|Intervention group|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
16542725|NCT02999789|Placebo Comparator|Placebo|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
16542726|NCT02999776|Active Comparator|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
16542727|NCT02999776|Experimental|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
16542728|NCT02999776|Active Comparator|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
16542729|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
16542730|NCT02999750|Other|individual therapy|individual therapy
16542731|NCT02999737|Other|Platelet Rich Plasma for 4 sessions|Autologous Platelet Rich Plasma injected in the scalp monthly x 3 then every 3 months x 1
16542732|NCT02999737|Other|Platelet rich plasma for 2 sessions|Autologous Platelet Rich Plasma injected in the scalp every 3 months
16542733|NCT02999724|Experimental|gabapentin|gabapentin 300-600 mg 1 hour preop
16542734|NCT02999724|Placebo Comparator|placebo|placebo capsule(s) 1 hour preop
16542735|NCT02999711|Experimental|Cohort 1|REGN3500 low dose or placebo
16542737|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
16542738|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
16542739|NCT02999685|Active Comparator|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
16542740|NCT02999685|Active Comparator|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
16542741|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
16542742|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
16542743|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
16542744|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
16542745|NCT02999646|Experimental|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
16542746|NCT02999633|Experimental|Isatuximab|Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
16542747|NCT02999620|Active Comparator|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
16542748|NCT02999620|Placebo Comparator|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
16542749|NCT02999607|Experimental|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
16542750|NCT02999607|Sham Comparator|Sham tDCS|Comparator to active arm
16542751|NCT02999594|Experimental|tramadol|50mg tramadol hydrochloride will be used intramuscularly as an experimental drug for evaluating its safety and efficacy as labor analgesic
16542752|NCT02999594|Placebo Comparator|distilled water|2ml distilled water intramuscularly will be used as a placebo.
16542753|NCT02999581|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 10 mg Bitter Orange (Citrus Aurantium) fruit standardized for 30% synephrine (Advantra Z), 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
16542754|NCT02999581|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
16542755|NCT02999581|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
16542756|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
16542757|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
16542758|NCT02999555|Experimental|Aspirated follicular fluid|Follicular fluid aspirated by follicle size and tested for the novel markers after eggs were identified and separated for the purpose of fertilization
16542759|NCT02999542|Experimental|Music|Children will receive music via headphones
16542760|NCT02999542|Experimental|No music|Children will listen to silence via headphones
16542761|NCT02999529|Experimental|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
16542762|NCT02999516|Experimental|Motor imaginary|Intervention with Motor imaginary with video
16542763|NCT02999516|Experimental|Non Motor imaginary|Intervention with Rest without motor imaginary
16542764|NCT02999516|Experimental|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
16542765|NCT02999516|Sham Comparator|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
16542766|NCT02999516|Experimental|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
16542767|NCT02999516|Sham Comparator|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
16542768|NCT02999503|Experimental|Nutritional intervention|Patients subject to nutritional education by CINUSA group protocol
16542770|NCT02999490|No Intervention|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
16542771|NCT02999490|Experimental|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
16542772|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in
~Biopsy will be performed
~Post mono therapy Nab-Paclitaxel administered weekly
~Post mono therapy Pembrolizumab administered every 3 weeks
~Agents administered for a total of 15 weeks"
16542773|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in
~Biopsy will be performed
~Post mono therapy Nab-Paclitaxel administered weekly
~Post mono therapy Pembrolizumab administered every 3 weeks
~Agents administered for a total of 14 weeks"
16542774|NCT02999464|Experimental|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
16542775|NCT02999464|Active Comparator|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
16542776|NCT02999451|Experimental|snare group|snare-assisted POEM
16542777|NCT02999451|Active Comparator|conventional group|knife-assisted POEM
16542778|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:
~Single ventricle physiology s/p Fontan
~Heart failure diagnosed by a cardiologist
~Pulmonary hypertension diagnosed by cath"
16542779|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
16542780|NCT02999425|Experimental|Education|Educational intervention to study participants
16542781|NCT02999412|Active Comparator|Comprehensive medication review (I1)|
16542782|NCT02999412|Active Comparator|Comprehensive medication review with active follow-up (I2)|
16542783|NCT02999412|Other|Usual care (Control)|
16542784|NCT02999399|Experimental|[D10]phe and Brussels sprouts|All subjects are given 1 microgram [D10]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
16542785|NCT02999373|Experimental|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
16542786|NCT02999373|Placebo Comparator|Placebo|0.9% sodium chloride infusion 24 hours after birth
16542787|NCT02999360|Experimental|Treatment 1|
16542788|NCT02999360|Active Comparator|Treatment 2|
16542789|NCT02999347||Cases|Women having undergone at least one pregnancy/delivery after their MUS surgery
16542790|NCT02999347||Controls|Every case will be matched with two controls. The controls will be matched with the study cases' age and year of surgery (+- 2 years of age if a perfect match is not obtainable). These controls have not undergone a subsequent pregnancy/delivery.
16542791|NCT02999334|No Intervention|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
16542792|NCT02999334|Experimental|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
16542793|NCT02999321|Experimental|0% aspartame (water)|participants will not have any aspartame, this is a control.
16542794|NCT02999321|Experimental|5 mg aspartame|participants will receive 5 mg aspartame in a beverage.
16542795|NCT02999321|Experimental|15mg aspartame|participants will receive 5 mg aspartame in a beverage, and 10mg in capsules.
16542796|NCT02999308|Experimental|single arm|
16542797|NCT02999295|Experimental|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
16542798|NCT02999295|Experimental|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
16542799|NCT02999282|Experimental|Presymptomatic real tDCS|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
16542800|NCT02999282|Sham Comparator|Presymptomatic sham tDCS|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
16542801|NCT02999282|Experimental|Symptomatic real tDCS|Symptomatic patients - 10 days anodal transcranial direct current stimulation
16542802|NCT02999282|Sham Comparator|Symptomatic sham tDCS|Symptomatic patients - 10 days sham transcranial direct current stimulation
16542803|NCT02999269|Experimental|600 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
16542804|NCT02999269|Experimental|700 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
16542805|NCT02999269|Active Comparator|800 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
16542806|NCT02999256|Placebo Comparator|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.
~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
16542807|NCT02999256|Experimental|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.
~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
16542808|NCT02999243|Experimental|HIV self-testing|HIV self-testing kits plus harm reduction education materials will be offered to the intervention group.
16542809|NCT02999243|Placebo Comparator|Education|Harm reduction educational materials will be offered to the control group.
16542810|NCT02999230|Active Comparator|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
16542811|NCT02999230|Placebo Comparator|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
16542812|NCT02999230|Active Comparator|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
16587433|NCT02696070|Other|Sham of Provant|Sham of Provant
16542813|NCT02999230|Placebo Comparator|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
16542814|NCT02999217|Active Comparator|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
16542815|NCT02999217|Placebo Comparator|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
16542816|NCT02999204|Active Comparator|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
16542817|NCT02999204|Experimental|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
16542818|NCT02999191|Experimental|BI 1467335 (Treatment A)|Tablet under fasted conditions
16542819|NCT02999191|Experimental|BI 1467335 (Treatment B)|Oral solution under fasted conditions
16542820|NCT02999191|Experimental|BI 1467335 (Treatment C)|Tablet under fed conditions
16542821|NCT02999178|Experimental|Nintedanib|
16542822|NCT02999178|Placebo Comparator|Placebo|
16542823|NCT02999165||CPAP group|25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
16542824|NCT02999165||HHFNC group|25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.
16542825|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
16542826|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
16542827|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
16542828|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
16542829|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
16542830|NCT02999126|Experimental|Group 1|Patients < 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
16542831|NCT02999126|Experimental|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
16542832|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
16542833|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
16542834|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
16542835|NCT02999087|Active Comparator|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment
~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2
~Maintenance phase : no treatment until follow-up phase"
16542836|NCT02999087|Experimental|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg
~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg
~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
16542837|NCT02999087|Experimental|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg
~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg
~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
16542838|NCT02999087|Active Comparator|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2
~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2
~Maintenance phase : no treatment until follow-up phase"
16542839|NCT02999074|Active Comparator|Resistance exercise|
16542840|NCT02999074|Active Comparator|Aerobic exercise|
16542841|NCT02999074|Other|Waitlist control|
16542935|NCT02998450|Experimental|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
16542936|NCT02998450|Experimental|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
16542842|NCT02999048|No Intervention|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
16542843|NCT02999048|Other|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
16542844|NCT02999035||corneal sensitivity measurement|"Air jet aesthesiometry and liquid jet aesthesiometry:
~All patients will receive the same intervention of corneal sensitivity measurement with air jet aesthesiometry and liquid jet aesthesiometry.
~Thresholds represent the intensity of air / liquid jet that can just be perceived by the patients."
16542845|NCT02999022|Experimental|Lithium carbonate|Lithium carbonate 300mg capsule; once per day for 2 weeks.
16542846|NCT02999022|Placebo Comparator|Lactose placebo|Lactose placebo capsule; once per day for 2 weeks.
16542847|NCT02999009|Other|Trident II Tritanium Acetabular Shell|
16542848|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
16542849|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
16542850|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
16542851|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
16542852|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
16542853|NCT02998996|Active Comparator|i.n. comparator|
16542854|NCT02998983|Experimental|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
16542855|NCT02998970|Placebo Comparator|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
16542856|NCT02998970|Active Comparator|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
16542857|NCT02998957|Experimental|AcuTENS|"Stimulation using a portable TENS electrostimulation device at Dingchuan point using a biphasic rectangular wave with a frequency of 2Hz and a pulse width of 200 ms. The stimulation will be achieved using the highest intensity tolerated by the patient without pain during 40 minuts.
~Once a day during 5 consecutive days."
16542858|NCT02998957|Sham Comparator|Sham AcuTENS|"Stimulation using a modified portable TENS electrostimulation device at Dingchuan point with no electrical output, even though the screen will light up and display the same data as in the unmodified device during 40 minuts. Patients in this group will be informed that, due to the frequency of stimulation, it is unlikely that they will feel the electric stimulation.
~Once a day during 5 consecutive days."
16542859|NCT02998931|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
16542860|NCT02998931|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
16542861|NCT02998918|Experimental|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
16542862|NCT02998918|Experimental|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
16542863|NCT02998905|Experimental|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
16542864|NCT02998905|Active Comparator|Acetylsalicylic Acid|Acetylsalicylic acid
16542865|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
16542866|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
16542868|NCT02998866|Other|Multi-center, prospective outcomes registry|The study is a multi-center, prospective outcomes registry
16542869|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
16542870|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
16542871|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
16542872|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
16542873|NCT02998827|Experimental|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
16542874|NCT02998827|Active Comparator|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
16542970|NCT02998190|Experimental|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
16542875|NCT02998814|Active Comparator|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
16542876|NCT02998814|Active Comparator|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
16542877|NCT02998814|Active Comparator|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
16542878|NCT02998814|Active Comparator|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
16542879|NCT02998801|Placebo Comparator|Watch video using IPAD|Patient will watch the educational video using an IPAD
16542880|NCT02998801|Active Comparator|Watch video using VR goggles|Patient will watch the educational video using VR goggles
16542881|NCT02998775|Other|6 participants with mild renal impairment|Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
16542882|NCT02998775|Other|6 participants with moderate renal impairment|Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
16542883|NCT02998775|Other|6 participants with severe renal impairment|Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
16542884|NCT02998775|Other|8 participants normal renal status|Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
16542885|NCT02998775|Other|6 participants with mild hepatic impairment|Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
16542886|NCT02998775|Other|6 participants with moderate hepatic impairment|Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
16542887|NCT02998775|Other|6 participants with severe hepatic impairment|Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
16542888|NCT02998775|Other|8 participants normal hepatic status|Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
16542889|NCT02998736|Experimental|Intervention|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.
~Influenza vaccine 0.5mL day of surgery"
16542890|NCT02998723|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
16542891|NCT02998723|Active Comparator|Late booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
16542892|NCT02998723|No Intervention|Control group|The control group will receive no booster at all.
16542893|NCT02998697|Experimental|Treated Group|Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days
16542894|NCT02998697|Placebo Comparator|Control Group|Systolic heart failure patients received placebo oral capsule t.i.d for 90 days
16542895|NCT02998684|Active Comparator|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
16542896|NCT02998684|Sham Comparator|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
16542897|NCT02998671|Experimental|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
16542898|NCT02998671|Experimental|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
16542899|NCT02998671|Placebo Comparator|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
16542900|NCT02998658|Experimental|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
16542901|NCT02998658|Active Comparator|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
16542903|NCT02998632|Experimental|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.
~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.
~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
16542971|NCT02998190|Placebo Comparator|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
16542904|NCT02998632|Active Comparator|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.
~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.
~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.
~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
16542905|NCT02998619||Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
16542906|NCT02998606|Experimental|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
16542907|NCT02998606|Placebo Comparator|Control Group|Placebo Oral Capsule 25 mg, daily
16542908|NCT02998593|Experimental|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
16542909|NCT02998593|Placebo Comparator|Placebo|500 mg of placebo once time a day
16542910|NCT02998580|Active Comparator|Convential Sequential Bilateral rTMS|"LFR followed by HFL.
~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
16542911|NCT02998580|Experimental|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.
~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
16542912|NCT02998567|Experimental|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
16542913|NCT02998567|Experimental|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
16542914|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
16542915|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
16542916|NCT02998541|Experimental|SHP640|Participants will receive one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
16542917|NCT02998541|Active Comparator|PVP-I 0.6%|Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
16542918|NCT02998541|Placebo Comparator|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days.
16542919|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
16542920|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
16542921|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
16542922|NCT02998515|Experimental|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
16542923|NCT02998515|Experimental|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
16542924|NCT02998502|Experimental|Device Group|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
16542925|NCT02998502|No Intervention|Control Group|The device will be given to those in the control group after 8-week baseline period.
16542926|NCT02998489|Experimental|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
16542927|NCT02998489|Active Comparator|Traditional milk advancement|20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
16542928|NCT02998476|Experimental|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
16542929|NCT02998476|Experimental|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
16542930|NCT02998463|Experimental|Snuby® users|This group receives the Snuby® skin-to-skin facilitating garment to use in the first six weeks following birth with their baby. The use of the Snuby® garment is participant led, and used for as long and as often as they wish in the six week period.
16542931|NCT02998463|No Intervention|Conventional Care|This group does not receive any intervention, and collects data on the research outcomes when having conventionally facilitated skin-to-skin contact, using a towel, blanket, or clothing as preferred. Skin-to-skin contact frequency and duration is dictated by the participant.
16542932|NCT02998450|Experimental|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
16542933|NCT02998450|Experimental|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
16542934|NCT02998450|Experimental|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
16542937|NCT02998450|Experimental|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
16542938|NCT02998437|Experimental|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day
~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
16542939|NCT02998437|Active Comparator|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
16542940|NCT02998437|Active Comparator|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
16542941|NCT02998424|Experimental|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.
~Pupillary diameter measurement after 10 minutes."
16542942|NCT02998424|Experimental|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.
~Pupillary diameter measurement after 10 minutes."
16542943|NCT02998424|Experimental|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.
~Pupillary diameter measurement after 10 minutes."
16542944|NCT02998411||AI treatment and dosage|
16542945|NCT02998385|Active Comparator|Radiotherapy|"Arm A
~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.
~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
16542946|NCT02998385|Experimental|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy
~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).
~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.
~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
16542947|NCT02998359|Active Comparator|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
16542948|NCT02998359|Active Comparator|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
16542949|NCT02998333|Active Comparator|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
16542950|NCT02998333|Active Comparator|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
16542951|NCT02998320|Experimental|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
16542952|NCT02998307|Experimental|Monthly|Receive bedside CPR training monthly
16542953|NCT02998307|Experimental|3 months|Receive bedside CPR training every 3 months
16542954|NCT02998307|Experimental|6 months|Receive bedside CPR training every 6 months
16542955|NCT02998307|No Intervention|Control|No additional training and only performance evaluation after 1 year
16542956|NCT02998294|Experimental|Respiratory monitoring group|
16542957|NCT02998281|Active Comparator|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
16542958|NCT02998281|Sham Comparator|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
16542959|NCT02998268|Other|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.
~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
16542960|NCT02998268|Experimental|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.
~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
16542961|NCT02998255|Experimental|Single dose of 2L PEG|2 L of PEG solution was used on the day of colonoscopy.
16542962|NCT02998255|Active Comparator|Split-dose of 4L PEG|Split-dose of 4l PEG was used before and on the day of colonoscopy
16542963|NCT02998242|Active Comparator|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
16542964|NCT02998242|Experimental|RT with apatinib|selected dose administered PO during and after SBRT
16542965|NCT02998229|Experimental|Artisse™ Intrasaccular Device|
16542966|NCT02998203|No Intervention|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
16542967|NCT02998203|Experimental|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
16542968|NCT02998190|Experimental|Single oral dose of EB8018|Single ascending doses, sequential group design
16542969|NCT02998190|Placebo Comparator|Single oral dose of placebo|Single doses, matching placebo
16542972|NCT02998164|Experimental|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
16542973|NCT02998164|Active Comparator|usual care|This group will be usual care children are already receiving.
16542974|NCT02998151|Placebo Comparator|Placebo|Placebo pill
16542975|NCT02998151|Experimental|Acamprosate|
16542976|NCT02998151|Experimental|Lovastatin|
16542977|NCT02998151|Experimental|Minocycline|
16542978|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
16542979|NCT02998112|Placebo Comparator|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
16542980|NCT02998112|Experimental|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
16542981|NCT02998099|Experimental|Aged 18-45 years|A single dose of IV rivipansel over 20 minutes.
16542982|NCT02998099|Experimental|Aged 65 and older|A single dose of IV rivipansel over 20 minutes.
16542983|NCT02998086|Experimental|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
16542984|NCT02998086|Experimental|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
16542985|NCT02998086|No Intervention|Usual Care|Usual non-directed psychosocial supportive care
16542986|NCT02998073|Experimental|Conduct Disorder|Participants are justice-involved youth with conduct disorder. Participants will receive Stop, Now and Plan (SNAP) psychosocial intervention.
16542987|NCT02998073|No Intervention|Control|Participants are healthy males. Participants receive no intervention.
16542988|NCT02998060|Active Comparator|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
16542989|NCT02998060|Active Comparator|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
16542990|NCT02998060|Active Comparator|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
16542991|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.
~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
16542992|NCT02998034|Experimental|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
16542993|NCT02998034|Experimental|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
16542994|NCT02998021|Experimental|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
16542995|NCT02998021|Active Comparator|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
16542996|NCT02998008|Other|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
16542997|NCT02998008|Other|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
16542998|NCT02997995|Experimental|Immune-attractant/lymphocyte activation|After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
16542999|NCT02997982|Experimental|Valaciclovir treatment|Valaciclovir 500Mg Tablet
16543000|NCT02997969|Active Comparator|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
16543001|NCT02997969|Active Comparator|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
16543002|NCT02997969|Placebo Comparator|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
16543003|NCT02997969|Active Comparator|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
16543004|NCT02997969|Active Comparator|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
16543005|NCT02997969|Placebo Comparator|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
16543006|NCT02997956|Experimental|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.
~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
16543242|NCT02996370|Active Comparator|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
16543007|NCT02997943|Experimental|Step 1: Optimal First Line Treatment|"Participants will first be randomized to an optimal first line treatment in order to compare APP vs. APP + coaching. Participants assigned to Step 1 treatment APP will receive a study-specific smartphone application. Participants assigned to Step 1 treatment APP + coaching will receive a study-specific smartphone application plus 12 weekly telephone coaching sessions."
16543008|NCT02997943|Experimental|Step 2: Optimal Strategy to Address Nonresponse|Beginning at week 2, participants who are identified as treatment non-responders will be re-randomized in order to compare two strategies to address non-response: a modest step-up or vigorous step-up treatment augmentation tactic. Step 2 treatment strategy: modest step-up will include provision of an additional mHealth intervention component (push notifications). Step 2 treatment strategy vigorous step-up will include provision of an additional mHealth intervention component (push notifications), plus a traditional weight loss intervention component (coaching, meal replacements). Participants will continue to receive their first line treatment.
16543009|NCT02997930|Experimental|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
16543010|NCT02997917|Experimental|Education|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the real education group, solutions at suprathreshold concentration for detection will be given with a subsequent comment on the flavor and an explanation of the components and preparation of the soup (low temperature cooking to preserve flavors).
16543011|NCT02997917|Sham Comparator|Sham|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the sham education group solutions at subthreshold concentration for detection with no explanation will be provided.
16543012|NCT02997904|Experimental|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
16543013|NCT02997904|Placebo Comparator|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
16543014|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
16543015|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
16543016|NCT02997878|Experimental|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
16543017|NCT02997878|Experimental|AiH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
16543018|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
16543019|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
16543020|NCT02997852|Experimental|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
16543021|NCT02997852|No Intervention|Control|Usual care in the intensive care unit.
16543022|NCT02997839|No Intervention|group 2|no intervention
16543023|NCT02997839|Other|group 1|sleep disruption
16543024|NCT02997826|Other|1 to 21-days old child|
16543025|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
16543026|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
16543027|NCT02997800|Experimental|Esmolol|Esmolol infusion and 1 ml saline infusion
16543028|NCT02997800|Experimental|Labetalol|Labetalol Bolus and saline infusion
16543029|NCT02997800|Active Comparator|Fentanyl|Fentanyl Bolus and saline infusion
16543030|NCT02997787||adenomyosis|First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
16543031|NCT02997787||leiomyoma|Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
16543032|NCT02997787||control|Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
16543033|NCT02997774|Active Comparator|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
16543034|NCT02997774|Experimental|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
16543100|NCT02997306|Experimental|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
16543035|NCT02997761|Experimental|Treatment (ibrutinib, blinatumomab)|"INDUCTION THERAPY: Patients receive ibrutinib PO QD on days 1-49 of course 1 and days 1-42 of course 2, and blinatumomab IV on days 8-35 of course 1 and days 1-28 of course 2 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Patients with CR/CRi after Induction Therapy receive ibrutinib PO QD on days 1-42 and blinatumomab IV on days 1-28. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16543036|NCT02997748|No Intervention|Observational group|No intervention, standard care
16543037|NCT02997748|Sham Comparator|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
16543038|NCT02997748|Experimental|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
16543039|NCT02997748|Experimental|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
16543040|NCT02997748|Experimental|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
16543041|NCT02997748|Experimental|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
16543042|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
16543043|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
16543044|NCT02997722|Experimental|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
16543045|NCT02997722|Placebo Comparator|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
16543046|NCT02997709||Radiation Therapy Group|Participants with prostate cancer diagnosis who are scheduled to undergo standard of care radiotherapy with or without the addition of Androgen Deprivation Therapy (ADT) will be evaluated
16543047|NCT02997709||Prostatectomy Group|Participants with prostate cancer diagnosis who are scheduled to undergo prostatectomy will be evaluated
16543048|NCT02997696|Experimental|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
16543049|NCT02997696|Experimental|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
16543050|NCT02997696|Placebo Comparator|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
16543051|NCT02997683|Experimental|3-month home based training on whole body vibration platform|This Group will receive a training device to perform their given exercises on
16543052|NCT02997683|Placebo Comparator|3-month home based training on floor|This Group will perform their given exercises at home on the floor
16543053|NCT02997670|Experimental|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
16543054|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
16543055|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
16543056|NCT02997644|Experimental|Video Education|Video education delivered on a tablet computer
16543057|NCT02997644|Placebo Comparator|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
16543058|NCT02997631|Experimental|MEDi Distraction|The intervention will be the use of the MEDi robot. The robot will be at the child's eye level, and will be programmed to introduce itself, interact with the child, and make encouraging comments about how brave he/she was. The duration of its actions will coincide with the length of the procedure (approximately 5-8 minutes).
16543059|NCT02997631|No Intervention|Standard Care|The control group will receive standard care, which generally includes the use of topical anesthetic cream. This comparison is based on the pragmatic preferences of physicians at the Stollery Children's Hospital as well as precedent in the literature. Overall, it is felt that any new intervention (e.g., the MEDi robot) should be compared to what is currently in practice (i.e., standard care), as no single distraction therapy is consistently and routinely employed in EDs at this time.
16543060|NCT02997618|Active Comparator|Control|"1. Usual care (control)
~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:
~Smoking Exercise Weight Diet"
16543097|NCT02997332|Experimental|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
16543098|NCT02997319||Night Shift-Workers|
16543099|NCT02997319||Day Workers|
16543143|NCT02997033||Total study cohort|
16543061|NCT02997618|Experimental|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:
~Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.
~Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.
~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
16543062|NCT02997605|Active Comparator|Glucocorticoid (GC) tapering|"GC tapering group: patients will be asked to taper prednisone taken every morning at 8.00 AM by decreasing the daily dose by 1 mg every month as soon as they are in remission or Low Disease Activity (LDA). In addition they will receive a placebo of 20 mg/day of hydrocortisone (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg/day (at 8.00 AM) of hydrocortisone placebo for 3 months before discontinuing the hydrocortisone placebo."
16543063|NCT02997605|Active Comparator|Hydrocortisone replacer|"Hydrocortisone replacer group: patients will replace prednisone with 20 mg of hydrocortisone on a daily basis (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg daily (at 8.00 AM) for 3 months then stop as soon as they are in remission or LDA, as well as a prednisone placebo (at 8.00 AM) with a schedule to taper the prednisone placebo by 1mg/day every month until discontinuation."
16543064|NCT02997592|Experimental|SpinCare|Patients with partial thickness burns treated with the SpinCare dressing
16543065|NCT02997579|Experimental|patellar resurfacing|patellar resurfacing TKA
16543066|NCT02997579|No Intervention|patellar non-resurfacing|patellar non-resurfacing TKA
16543067|NCT02997566||Autistic Disorder|Age: 3 to 14 years-old Gender: male and female Autism Spectrum Disorder
16543068|NCT02997566||Typical|Age: 3 to 14 years-old Gender: male and female Typical
16543069|NCT02997553|Experimental|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.
~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
16543070|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
16543071|NCT02997527|Experimental|Intraluminal impedance testing|"During the participant's clinical endoscopy the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope.
~The catheter (tiny tube) will be placed through the endoscope in your esophagus 1 cm above where your stomach and esophagus meet for 5 seconds.
~At 2 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds
~And at 3 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.
~At 4 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.
~At 5 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds."
16543072|NCT02997514|Active Comparator|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
16543073|NCT02997514|Active Comparator|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
16543074|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
16543075|NCT02997488||McGrath|McGrath Videolaryngoscope
16543076|NCT02997488||Pentax|Pentax Airwayscope
16543077|NCT02997475||Women with Bulimia Nervosa|
16543078|NCT02997475||Women Healthy Controls|
16543081|NCT02997449||NSCLC, SABR, nodal staging|Patients with a clinical or pathological diagnosis of Non-Small Cell Lung Cancer (NSCLC), and who are medically inoperable or refuse surgery, are eligible if Stereotactic ablative radiotherapy (SABR) is recommended by a multi-disciplinary tumor board. All patients undergo complete mediastinal and hilar staging procedure (EBUS+EUS-B). Pre endoscopy imaging data will be compared with endosonography data.
16543082|NCT02997436|Experimental|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).
~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
16543083|NCT02997410|Experimental|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
16543084|NCT02997410|Placebo Comparator|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
16543085|NCT02997410|Experimental|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
16543086|NCT02997397||tourniquet (+)|The cases in which the tourniquet technique is used
16543087|NCT02997397||tourniquet(-)|The cases in which the tourniquet technique is not used
16543088|NCT02997384||General practitioner|
16543089|NCT02997384||gynecologist|
16543090|NCT02997384||radiologist|
16543091|NCT02997371|Placebo Comparator|Placebo|Isotonic saline administered as an injection and infusion
16543092|NCT02997371|Experimental|1.5 g Kineret|Kineret provided as a 500 mg injection followed by a 1g infusion.
16543093|NCT02997371|Experimental|3.0 g Kineret|Kineret provided as a 500 mg injection followed by a 2.5g infusion.
16543094|NCT02997358|Active Comparator|Doxorubicin|6 cycles - 1 cycle every 3 weeks (day 1 to day 21) On day 1: Doxorubicin 75 mg/m² IV
16543095|NCT02997358|Experimental|doxorubicin + trabectedin followed by maintenance trabectedin|"Doxorubicin + trabectedin 6 cycles - 1 cycle every 3 weeks (day 1 to day 21) Doxorubicin 60 mg/m² IV D1, then Trabectedin 1.1 mg/m² per CIV 3 hours D1. Surgery for residual disease is possible after 6 cycles (in case of non evolutive disease)
~In case of response or stable disease after 6 cycles 3-weeks cycle until disease progression or for a maximum of 12 months of treatment (maximum 17 cycles in maintenance therapy), whichever occurs first Trabectedin 1.1 mg/m² per CIV 3 hours"
16543096|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
16543243|NCT02996357||Cases|Patients with IAD Category 2 (red skin with skin breakdown)
16543244|NCT02996357||Controls|Patients with IAD Cat. 0 (at risk, no redness and skin intact)
16543101|NCT02997306|Experimental|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
16543102|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
16543103|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
16543104|NCT02997280|Experimental|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight > 40 kg, 0.15 mg/kg bid for children with body weight < 40 kg.
16543105|NCT02997267|Experimental|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
16543106|NCT02997267|Active Comparator|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
16543107|NCT02997241|Other|high genetic risk and high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
16543108|NCT02997241|Active Comparator|low genetic risk but high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
16543109|NCT02997241|Active Comparator|high genetic risk but low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
16543110|NCT02997241|Other|low genetic risk and low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
16543114|NCT02997215|Experimental|intravenous lidocaine|intravenous lidocaine 1.5mg/kg during induction then infused at 2mg/kg/h until the end of procedure.
16543115|NCT02997215|Placebo Comparator|saline placebo|same amount volume saline infusion
16543116|NCT02997202|Experimental|Gilteritinib|Participants will take gilteritinib once daily for continuous daily dosing.
16543117|NCT02997202|Placebo Comparator|Placebo|Participants will take placebo once daily for continuous daily dosing.
16543118|NCT02997189|Active Comparator|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
16543119|NCT02997189|No Intervention|Control|The ear not receiving OTO-104 will receive no treatment
16543120|NCT02997176|Experimental|Group A (control, normal hepatic function)|
16543121|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
16543122|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
16543123|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
16543124|NCT02997163|Experimental|Group A (control, normal renal function)|
16543125|NCT02997163|Experimental|Group B (mild renal impairment)|
16543126|NCT02997163|Experimental|Group C (moderate renal impairment)|
16543127|NCT02997163|Experimental|Group D (severe renal impairment)|
16543128|NCT02997150|Experimental|IL-2 low dose|
16543129|NCT02997137|Active Comparator|BOT-01|Dietary supplement: specific amino acid composition with micronutrients
16543130|NCT02997137|Placebo Comparator|Placebo|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
16543131|NCT02997124|Experimental|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
16543132|NCT02997124|Experimental|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
16543133|NCT02997111|Other|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
16543134|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
16543135|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
16543136|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
16543137|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
16543138|NCT02997059|Experimental|Fluconazole|200mg per day for 6 months
16543139|NCT02997059|Placebo Comparator|Placebo|One capsule per day for 6 months
16543140|NCT02997046||Pre-transplant assessment|"CTA abdominal and aortoiliac vasculature before transplantation
~FeMRA abdominal and aortoiliac vasculature & CMR before transplantation"
16543141|NCT02997046||Mapping & surveillance (for fistula)|"US vascular mapping before fistula creation
~6 week US fistula arm
~FeMRA fistula arm/central veins & CMR before fistula creation and at 6 weeks"
16543142|NCT02997046||Mapping & surveillance (for graft)|"US vascular mapping before graft creation
~6 week US graft arm
~FeMRA fistula arm/central veins & CMR before graft creation and at 6 weeks"
16543144|NCT02997020||CRS Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
16543145|NCT02997020||Control Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
16543146|NCT02997007|Experimental|MCI-active|Patients will receive verum tDCS over the angular gyrus on five consecutive days.
16543147|NCT02997007|Sham Comparator|MCI-sham|Patients will receive sham tDCS over the angular gyrus on five consecutive days.
16543148|NCT02997007|Experimental|Healthy Old-active|Participants will receive verum tDCS over the angular gyrus on five consecutive days.
16543149|NCT02997007|Sham Comparator|Healthy old-sham|Participants will receive sham tDCS over the angular gyrus on five consecutive days.
16543150|NCT02996981||Cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2016 and September 2016 and discharged home with an indwelling urinary catheter following the surgery. This group of people had cranberry juice capsules prescribed.
16543151|NCT02996981||No cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2015 and September 2015. This group of people did not have cranberry juice capsules prescribed.
16543152|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
16543153|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
16543154|NCT02996955|Experimental|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
16543155|NCT02996955|Active Comparator|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
16543156|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
16543157|NCT02996929|Experimental|Study group|Subjects who are scheduled for CIED lead extraction with the LC system
16543158|NCT02996916|Active Comparator|Olmesartan|Olmesartan 10-40mg daily
16543159|NCT02996916|Active Comparator|Amlodipine|Amlodipine 2.5-10mg daily
16543160|NCT02996890|Experimental|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
16543161|NCT02996890|Experimental|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
16543162|NCT02996890|Experimental|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
16543163|NCT02996890|Placebo Comparator|Placebo|Physiological saline, two treatments
16543164|NCT02996877||Guideline Directed Medical Therapy|Patients who have an initial treatment strategy of using guideline-directed medical therapy only.
16543165|NCT02996877||Percutaneous Coronary Intervention|Patients who will have a Percutaneous Coronary Intervention as the initial treatment strategy along with guideline directed medical therapy.
16543166|NCT02996864|Experimental|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
16543167|NCT02996864|Placebo Comparator|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
16543168|NCT02996838|Experimental|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16543169|NCT02996825|Experimental|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
16543170|NCT02996812|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
16543171|NCT02996812|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
16543172|NCT02996812|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
16543173|NCT02996812|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
16543174|NCT02996799|No Intervention|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
16543175|NCT02996799|Experimental|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
16543176|NCT02996786|Experimental|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
16543177|NCT02996786|Placebo Comparator|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
16543178|NCT02996773|Experimental|Cyclophosphamide and Bendamustine|"Experimental: Cyclophosphamide and Bendamustine Control: Cyclophosphamide
~Interventions:
~Drug: Bendamustine
~Drug: Cyclophosphamide"
16543179|NCT02996760|Experimental|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.
~Less than 5mm despite 10 days with standard doses of estrogen"
16543180|NCT02996760|No Intervention|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.
~More than 5mm despite 10 days with standard doses of estrogen"
16543245|NCT02996344|Active Comparator|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
16543181|NCT02996721|No Intervention|Standard of Care|Patients randomized to the standard of care arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25[OH] Vit D testing, use of vitamin D supplementation, and outcomes.
16543182|NCT02996721|Experimental|Treatment|Patients randomized to the treatment arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25[OH] Vit D >40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25[OH] Vit D levels are <40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25[OH] Vit D level. At 3 months, if 25[OH] Vit D >40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25[OH] Vit D <40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25[OH] Vit D reaches a level >40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25[OH] Vit D testing.
16543183|NCT02996708||Group with teleconsultation - before period|
16543184|NCT02996708||Group without teleconsultation - before period|
16543185|NCT02996708||Group with teleconsultation - after period|
16543186|NCT02996708||Group without teleconsultation - after period|
16543187|NCT02996695|Experimental|204,800 PfSPZ of PfSPZ Challenge|204,800 PfSPZ of PfSPZ Challenge every 4 weeks x 3 doses by DVI, n=31
16543188|NCT02996695|Placebo Comparator|NaCl placebo|NaCl placebo every 4 weeks x 3 doses by DVI, n=31
16543189|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16543190|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
16543191|NCT02996669||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
16543192|NCT02996669||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
16543193|NCT02996656|Active Comparator|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
16543194|NCT02996656|Experimental|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
16543195|NCT02996643|No Intervention|Traditional method|The traditional brace design method will be used to design a spinal brace.
16543196|NCT02996643|Active Comparator|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
16543197|NCT02996630|Other|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
16543198|NCT02996630|Other|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
16543199|NCT02996617|Active Comparator|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L for total 4 courses.
16543200|NCT02996617|Experimental|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.
16543201|NCT02996604|Experimental|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
16543202|NCT02996604|Experimental|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
16543203|NCT02996604|Active Comparator|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
16543204|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
16543239|NCT02996383|Active Comparator|Cemented hemiarthroplasty|Treatment of the fracture by a replacement arthroplasty with a cemented CPT hemiarthroplasty (manafactured by Zimmer company, Warsaw IN, USA) inserted via an anteriolateral approach to the hip
16543240|NCT02996383|Active Comparator|Internal fixation|Internal fixation of the fracture with a screw and plate device (Targon FN plate, Aesculap cooperation, Tuttingham, Germany)
16543205|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
16543206|NCT02996578|Active Comparator|Solid Matrix - Intervention|"Dietary Supplement: polyphenol rich chocolate bar
~17.5g of commercially available dark chocolate will be consumed daily for 8 weeks"
16543207|NCT02996578|Active Comparator|Powder Matrix - Intervention|"Dietary Supplement: polyphenol rich cocoa powder
~6g of commercially available cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
16543208|NCT02996578|Placebo Comparator|Solid Matrix Intervention - Placebo|"Dietary Supplement: low polyphenol chocolate
~17.5g of commercially available, nutritionally similar, dark chocolate will be consumed daily for 8 weeks"
16543209|NCT02996578|Placebo Comparator|Powder Matrix - Placebo|"Dietary Supplement: nutritionally similar low polyphenol cocoa powder
~6g of commercially available, nutritionally similar, cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
16543210|NCT02996565|Active Comparator|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
16543211|NCT02996565|Active Comparator|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
16543212|NCT02996552|Experimental|M & T Repair Group|Both mitral and tricuspid valves repair
16543213|NCT02996552|Active Comparator|Mitral-Only Group|Only mitral valve repair
16543214|NCT02996539||Type 2 diabetes|With Clinical examination and laboratory measurements
16543215|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
16543216|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
16543217|NCT02996513|Experimental|Retinol Isotope dilution (RID)|A once-off dose of 0.4 mg 13C4-retinyl acetate will be administered to subjects as a capsule
16543218|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
16543219|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
16543220|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
16543221|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
16543222|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
16543223|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
16543224|NCT02996487|Placebo Comparator|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
16543225|NCT02996487|Active Comparator|vancomycin|Vancomycin 125 mg by mouth every 6 hours
16543226|NCT02996474|Experimental|Pembrolizumab and Decitabine for treatment of AML|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
16543227|NCT02996461|Experimental|Group 1|ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
16543228|NCT02996461|Experimental|Group 2|ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
16543229|NCT02996461|Experimental|Group 3|ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
16543230|NCT02996448|Experimental|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
16543231|NCT02996435|Experimental|Mobile Adherence Platform|Participant adherence will be monitored using a mobile application and platform which provides a real-time reminder that alerts the participant to take his or her medication. The application will also send an alert to the participant when a refill is needed based on calculated medication or pill supply. The intervention will focus only on daily adherence to rivaroxaban.
16543232|NCT02996435|Other|Control: Standard of Care|Participants will receive physician- or nurse-guided standard of care for their rivaroxaban adherence. No drug will be administered as part of this study.
16543233|NCT02996422|Experimental|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
16543234|NCT02996422|No Intervention|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
16543235|NCT02996422|Experimental|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
16543236|NCT02996409|Experimental|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
16543237|NCT02996409|Placebo Comparator|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
16543238|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
16543241|NCT02996370|Active Comparator|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
16543246|NCT02996344|Experimental|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
16543247|NCT02996331|Active Comparator|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
16543248|NCT02996331|Experimental|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
16543249|NCT02996331|Experimental|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
16543250|NCT02996318|Experimental|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
16543251|NCT02996318|Active Comparator|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
16543252|NCT02996305|Experimental|OV101 regimen 1|OV101 once daily
16543253|NCT02996305|Experimental|OV101 regimen 2|OV101 twice daily
16543254|NCT02996305|Placebo Comparator|Placebo|Twice daily
16543255|NCT02996292|Experimental|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
16543256|NCT02996292|Experimental|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
16543257|NCT02996292|Experimental|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
16543258|NCT02996279||group 1|maternal chorioamnionitis
16543259|NCT02996279||group 2|no maternal chorioamnionitis
16543260|NCT02996266|Experimental|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
16543261|NCT02996266|Active Comparator|Standard Care|Standard care in which fever may spontaneously develop
16543262|NCT02996240|Experimental|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
16543263|NCT02996227|Experimental|TAP block with Exparel|Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
16543264|NCT02996227|Active Comparator|Epidural analgesia with Bupivacaine|Epidural catheters with an infusion of Bupivacaine standard solution without additives
16543265|NCT02996214|Experimental|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
16543266|NCT02996214|Active Comparator|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
16543267|NCT02996201|Experimental|Electronic reporting of PRO-CTCAE items|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
16543268|NCT02996201|No Intervention|Standard practice|
16543269|NCT02996188||Patients with refractory tense ascites|
16543270|NCT02996175|Experimental|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.
~Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems
~Information on healthy sleep hygiene, preventative techniques, and use of visual supports
~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking
~Information on procedures for delayed sleep onset and problematic sleep associations
~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
16543271|NCT02996175|Active Comparator|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
16543272|NCT02996136|Experimental|Nasal Swab|Nasal Swab
16543273|NCT02996136|Experimental|Nasopharyngeal Swab|Nasopharyngeal Swab
16543274|NCT02996123|Experimental|cad/cam maxillary dentures|single maxillary dentures fabricated by cad/cam method
16543275|NCT02996123|Active Comparator|conventional dentures|heat cured single maxillary dentures
16543276|NCT02996110|Active Comparator|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
16543277|NCT02996110|Experimental|Nivolumab + Relatlimab|Nivolumab + Relatlimab
16543278|NCT02996110|Experimental|Nivolumab + BMS-986205|Nivolumab + BMS-986205
16543279|NCT02996110|Experimental|Nivolumab + BMS-813160|Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
16543280|NCT02996097|Experimental|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
16543281|NCT02996097|Active Comparator|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
16543282|NCT02996071|Active Comparator|low waist to height ratio|laparoscopic sleeve gastrectomy
16543283|NCT02996071|Active Comparator|high waist to height ratio|laparoscopic sleeve gastrectomy
16543284|NCT02996058|Active Comparator|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
16543319|NCT02995785|Other|Experimental:simulation-based training|Experimental
16543285|NCT02996058|Active Comparator|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
16543286|NCT02996045|Experimental|Treatment|Clinical Decision Support (CDS)
16543287|NCT02996045|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
16543288|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
16543289|NCT02996019|Experimental|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
16543290|NCT02996019|Active Comparator|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
16543291|NCT02996019|Experimental|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
16543292|NCT02996019|Active Comparator|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
16543293|NCT02995993|Experimental|Moss-aGal|Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion
16543294|NCT02995980|Experimental|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
16543295|NCT02995967|Active Comparator|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
16543296|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
16543297|NCT02995954|Active Comparator|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
16543298|NCT02995954|Active Comparator|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
16543299|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
16543300|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
16543301|NCT02995928|Experimental|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
16543302|NCT02995928|Active Comparator|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure >25 mm Hg for 1-12 hours to keep the patients safe.
16543303|NCT02995915|Experimental|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
16543304|NCT02995915|Active Comparator|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
16543305|NCT02995902|Experimental|FLT-PET/MRI|
16543306|NCT02995889|Experimental|FLT-PET|
16543307|NCT02995876|No Intervention|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
16543308|NCT02995876|Experimental|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
16543309|NCT02995876|Experimental|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
16543310|NCT02995863|Experimental|Experimental Group|Rigid rocker sole footwear
16543311|NCT02995863|Active Comparator|Control Group|Therapeutic footwear
16543312|NCT02995850|Experimental|anti-cancer drug|
16543313|NCT02995837||Obstructive Sleep Apnea Syndrome (OSAS)|"The study duration is estimated at 12-14 months approximately. However, this will depend on the timing of treatment as they will undergo testing pre- and post-OSAS treatment. Participation will entail a total of 8 visits including:
~Pre-treatment - neurocognitive testing, and CBF during wakefulness testing duration is one full day. The CBF nighttime testing is one full night.
~Post-treatment - Six to twelve weeks after clinically indicated surgical treatment, OSAS participants will have a repeat baseline polysomnogram (one full night) to assess for residual OSA. Six and twelve months after the surgical treatment, the sleep study with the nighttime CBF testing, as well as the daytime neurocognitive testing and CBF testing will be repeated to assess for changes."
16543314|NCT02995837||Controls|The study will include 7 total visits for controls: a baseline sleep study to ensure normalcy, three full days of neurocognitive testing and CBF testing (baseline, 6 and 12 months), and three sleep studies with CBF testing (baseline, 6 and 12 months). A daytime visit and one night time visit may be scheduled during a 24-hour period if the participant and family wish so. Otherwise, they will be scheduled on separate days.
16543315|NCT02995811||Observational Cohort|"On Days 1, 3, 7 and 10 of ICU admission, patients will undergo ultrasound assessment of the diaphragm, transverse and rectus abdominis, quadriceps rectus femoris, and tibialis anterior muscles. Imaging all four muscles together requires approximately 1 hour.
~Physical activity monitoring: On Days 1-10 of ICU admission patients will wear an activity monitor. These devices use several inertial motion sensors to track the movement and acceleration of the limbs in horizontal and vertical directions.
~Patients will also undergo daily assessment of global peripheral skeletal muscle strength assessed by the Medical Research Council Sum-score and global function measured by the Chelsea Critical Care Physical Assessment Scale"
16543316|NCT02995798||Group A|T-score ≥-1
16543317|NCT02995798||Group B|-2.5<T-score<-1.0
16543318|NCT02995798||Group C|T-score≤-2.5
16587434|NCT02696070|Other|Active Treatment|Active Provant Treatment
16543321|NCT02995772|Active Comparator|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
16543322|NCT02995772|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
16543323|NCT02995759||SE before Seizure Action Plan|450 patients with status epilepticus prior to seizure action plan initiation
16543324|NCT02995759||SE after Seizure Action Plan|450 patients with status epilepticus after seizure action plan initiation
16543325|NCT02995746|Experimental|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
16543326|NCT02995733|Active Comparator|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
16543327|NCT02995733|No Intervention|Usual Care|Provider-enhanced usual care arm; no change in asthma management
16543328|NCT02995720|Experimental|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
16543329|NCT02995720|Active Comparator|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
16543330|NCT02995707|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
16543331|NCT02995694|Experimental|Test|Estradiol Vaginal Cream
16543332|NCT02995694|Active Comparator|Reference.|Estrace Vaginal Cream
16543333|NCT02995694|Placebo Comparator|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
16543334|NCT02995681|Experimental|Pulmonary rehab and balance training|The intervention group will receive standard pulmonary rehab plus additional balance training.
16543335|NCT02995681|Active Comparator|Pulmonary rehab|The control group will receive pulmonary rehab only and a pulmonary rehab home program (walking and lower extremity resistance exercises) upon discharge from pulmonary. They will also receive the same monthly phone calls and three home visits at three, six and nine months to ensure proper technique and progression.
16543336|NCT02995668|No Intervention|Control|Non-active comparator
16543337|NCT02995668|Active Comparator|Strength-Function|Active comparator
16543338|NCT02995668|Experimental|Balance-Proprioception|Experimental
16543339|NCT02995655|Experimental|CX-01 + Azacitidine|"CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
~Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
~Up to 6 cycles of treatment allowed"
16543340|NCT02995642|Experimental|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
16543341|NCT02995629|Experimental|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
16543342|NCT02995629|Experimental|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
16543343|NCT02995616|Experimental|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
16543344|NCT02995603|Experimental|Patient rotation|Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.
16543345|NCT02995590|Experimental|MRI of lung motion during breathing|"A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.
~A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.
~Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.
~During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.
~Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.
~Hyperpolarized helium 3 imaging will be performed at breath hold."
16543346|NCT02995577||Feeding tolerant|Patients that are able to reach 80-100% of full enteral feeds (whether fed by mouth or through a nasogastric tube) 7 days after the initiation of feeds. Patients will be excluded from this group if they are ever diagnosed with NEC at any time during this hospitalization.
16543347|NCT02995577||Feeding intolerant|Patients with GI symptoms (vomiting, abdominal distention, diarrhea, hematemesis, and/or hematochezia) that persist for 48 hours or longer while needing to be NPO, this patient is retrospectively categorized into the feeding intolerance group. Patients with feeding intolerance may also include infants that are made NPO, placed on bowel rest, and are started on antibiotics to rule out NEC, but are never diagnosed with NEC. Exclusion criteria include patients that are continued on antibiotics for greater than 48 hours due to diagnosed bacterial sepsis or diagnosed NEC, and those that have a positive blood, urine, or sputum culture.
16543348|NCT02995577||Necrotizing enterocolitis|Any infant that is diagnosed (radiographically, by Bell's criteria) with and treated for NEC.
16543349|NCT02995564|Experimental|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
16543350|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
16543351|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
16543352|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
16543353|NCT02995512|Experimental|Myocardial Infarction (MI) Patients|
16543354|NCT02995486|No Intervention|Control|Standard care with only an educational pamphlet.
16543355|NCT02995486|Experimental|Intervention|Post-discharge exercise group
16543356|NCT02995473|Experimental|NP000888|Pharmaceutical form: Ointment
16543357|NCT02995473|Placebo Comparator|Vehicle|Pharmaceutical form: Ointment
16543358|NCT02995460|Experimental|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
16543359|NCT02995460|No Intervention|controls|No change in diet and training habits
16543360|NCT02995447||epilepsy patients|The group consists of patients with therapy refractory epilepsy, in which intracerebral electrodes were implanted to locate the seizure origin and to determine whether the patients are eligible for epilepsy surgery. In an observational study, differences between surface and intracerebral EEG are recorded.
16543361|NCT02995434|Experimental|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
16543362|NCT02995434|Active Comparator|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the Virtual Reality headset use). These will be functionally similar to the VR experiences.
16543363|NCT02995408|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
16543364|NCT02995408|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
16543365|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
16543366|NCT02995382|Experimental|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
16543367|NCT02995369|Other|Dryshield Isolation (right)|Dryshield will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
16543368|NCT02995369|Other|Cotton Roll Isolation (right)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
16543369|NCT02995369|Other|Dryshield Isolation (left)|Dryshield will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
16543370|NCT02995369|Other|Cotton Roll Isolation (left)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
16543371|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
16543372|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
16543373|NCT02995343|Experimental|Hypogastric and/or uterine artery ligation|Patients who had been ligated hypogastric artery and or uterine artery for ceasing uterine bleeding during c-section
16543374|NCT02995343|No Intervention|Normal postpartum women|
16543375|NCT02995330|Experimental|Bone marrow transplantation|"Bone marrow transplantation followed by Cytoxan and testosterone
~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen
~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.
~Subjects will receive GVHD prophylaxis consisting of:
~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning [dose adjusted to maintain trough level of 5-15 ng/mL] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.
~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.
~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses
~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180."
16543376|NCT02995317||Fall accidents|
16543377|NCT02995304|Active Comparator|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
16543378|NCT02995304|Active Comparator|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
16543379|NCT02995291|Placebo Comparator|Control|1.7ml saline water
16543380|NCT02995291|Experimental|OraVerse|1.7ml OraVerse
16543381|NCT02995265|Experimental|Exoskeleton Program|Exoskeleton-based walking rehabilitation until discharge (or to a maximum of 8 weeks), 3 - 5 days a week for 30-60 minutes per session. Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke. The exoskeleton will allow standing and walking with full weight bearing from the first sessions in rehabilitation.
16543382|NCT02995265|Active Comparator|Usual Care Program|Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
16543383|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
16543384|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.
~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
16543385|NCT02995239|Active Comparator|CJ-12420 formulation 1|CJ-12420 formulation 1
16543386|NCT02995239|Active Comparator|CJ-12420 formulation 2|CJ-12420 formulation 2
16543387|NCT02995226|Other|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
16543388|NCT02995226|Other|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
16543389|NCT02995226|Other|Controls (with no eating disorder)|Other
16543390|NCT02995213|Experimental|Feedback Intervention|
16543391|NCT02995200|Experimental|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
16543392|NCT02995200|No Intervention|Healthy Control Group|
16543393|NCT02995187|Experimental|Apatinib Mesylate tablet|Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).
16543394|NCT02995174|Experimental|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
16543395|NCT02995174|Placebo Comparator|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
16543396|NCT02995161|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543397|NCT02995148|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543398|NCT02995135|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543399|NCT02995122|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543400|NCT02995109|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543401|NCT02995083|Active Comparator|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
16543402|NCT02995083|Placebo Comparator|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
16543403|NCT02995083|Sham Comparator|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
16543404|NCT02995070|Experimental|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
16543435|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
16543436|NCT02994810|Experimental|Intervention group|Guidelines and review of the breastfeeding techniques.
16543405|NCT02995070|Sham Comparator|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
16543406|NCT02995057||Nickel allergic|Participants have proven nickel allergy
16543407|NCT02995044|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543408|NCT02995031|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543409|NCT02995018|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543410|NCT02995005|Experimental|Tenofovir Disoproxil Fumarate|Women early in pregnancy (end of first or beginning second trimester) will be treated with TDF to determine the efficacy of this strategy to bring >=95% of women to undetectable HBV DNA levels at delivery.
16543411|NCT02994992|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16543412|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
16543413|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
16543414|NCT02994966|Experimental|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
16543415|NCT02994966|Active Comparator|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
16543416|NCT02994953|Experimental|Avelumab and M9241|
16543417|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (MTD)|
16543418|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (RP2D) (Expansion cohort)|
16543419|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
16543420|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
16543421|NCT02994927|Experimental|CCX168 (avacopan)|CCX168 in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
16543422|NCT02994927|Active Comparator|Prednisone|Prednisone in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
16543423|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
16543424|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
16543425|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
16543426|NCT02994901||Group 1|Geriatric patient with Sarcopenia
16543427|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
16543428|NCT02994901||Group 3|healthy control group
16543429|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
16543430|NCT02994875|Placebo Comparator|Placebo First|Placebo - Participants will receive placebo for one week. Following a two-week washout period, they will receive NAC for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
16543431|NCT02994875|Active Comparator|NAC First|N-acetylcysteine - Participants will receive NAC for one week. Following a two-week washout period, they will receive placebo for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
16543432|NCT02994862|Experimental|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
16543433|NCT02994862|Active Comparator|Conventional Bonding|Normal Bonding Method
16543434|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
16543437|NCT02994810|No Intervention|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
16543438|NCT02994784|Experimental|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
16543439|NCT02994771|Active Comparator|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
16543440|NCT02994771|Active Comparator|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
16543441|NCT02994758|Other|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
16543442|NCT02994745|Experimental|A fixed dose combination group|A fixed dose combination of Fimasartan/Atorvastatin
16543443|NCT02994745|Active Comparator|Co-administration group|Co-administration of Fimasartan and Atorvastatin
16543444|NCT02994732|Experimental|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
16543445|NCT02994719||Neurological Disease subjects|Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
16543446|NCT02994719||Healthy control subjects|The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
16543447|NCT02994719||Ataxia Subjects|The ataxia subjects will participate in an additional cohort that will test and validate the gait model.
16543448|NCT02994719||Huntington Disease Subjects|The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.
16543449|NCT02994706|Experimental|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
16543450|NCT02994706|Active Comparator|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
16543451|NCT02994693||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
16543452|NCT02994680|Experimental|Intervention arm|"Will receive:
~Three-burner LPG stove (at enrollment)
~Delivery of LPG tanks (beginning at enrollment for one year)
~The study will be conducted over three years, with staggered enrollment over one year, one year of observations during the intervention period, and one year of follow-up observations after the intervention period for each participant.
~Participants in the intervention arm will receive an LPG stove upon enrollment and the research team will deliver fuel twice monthly to their homes during the first year. Participants in the intervention arm will not receive fuel during the second year, but researchers will encourage these participants to continue using LPG fuel for cooking."
16543453|NCT02994680|Active Comparator|Control arm|"Will receive:
~Three-burner LPG stove (one year after enrollment)
~Vouchers for LPG tanks (one year after enrollment)
~Participants in the control arm but will not receive an LPG stove or fuel during the first year. Instead, participants will receive an LPG stove at the end of the first year and vouchers to obtain free fuel at distribution centers during the course of the second year."
16543454|NCT02994667||Pacemaker After TAVR|The study cohort will comprise all consecutive patients who undergo permanent pacemaker placement for new conduction disturbances after TAVR at THHBP between 1/1/2015 and 12/31/2016.
16543455|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
16543456|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
16543457|NCT02994641||Adverse discharge disposition|Patients who were discharged to a skilled nursing facility or died in the hospital
16543458|NCT02994641||No adverse discharge disposition|Patients who were not discharged to a skilled nursing facility or did not die in the hospital
16543459|NCT02994628|Active Comparator|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
16543460|NCT02994628|Experimental|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
16543461|NCT02994628|Experimental|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
16543462|NCT02994628|Experimental|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
16543463|NCT02994615||hypertrophic cardiomyopathy|
16543464|NCT02994615||Control|
16543593|NCT02993692|Other|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
16589367|NCT02683096||Failed Hearing Screen Infants|
16543465|NCT02994602|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
16543466|NCT02994589|Experimental|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
16543467|NCT02994589|Active Comparator|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
16543468|NCT02994589|Active Comparator|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
16543469|NCT02994576|Experimental|Stage IB(≥ 2 cm)-IIIA non N2, resectable and untreated NSCLC|
16543470|NCT02994563|Experimental|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
16543471|NCT02994550|Experimental|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
16543472|NCT02994550|Experimental|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
16543473|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
16543474|NCT02994524|Other|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
16543475|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
16543476|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
16543477|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
16543478|NCT02994485|Active Comparator|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
16543479|NCT02994485|No Intervention|no treatment|no treatment
16543480|NCT02994472|Experimental|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.
~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
16543481|NCT02994459||Metabolically Normal Obese (likely insulin sensitive)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
16543482|NCT02994459||Metabolically Abnormal Obese (likely insulin resistant)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
16543483|NCT02994459||Metabolically Normal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
16543484|NCT02994459||Metabolically Abnormal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
16543485|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
16543486|NCT02994433|Experimental|Nitrous Oxide|One hour inhalation of nitrous oxide
16543487|NCT02994433|Placebo Comparator|Placebo Gas|One hour inhalation of placebo gas
16543488|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
16543489|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
16543490|NCT02994407|Experimental|N8-GP s.c.|
16543491|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
16543492|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
16543493|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
16543494|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
16543495|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
16543496|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
16543497|NCT02994381|Experimental|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
16543498|NCT02994368||Primary Cohort|No intervention
16543499|NCT02994368||Expansion Cohort|No intervention
16543594|NCT02993692|Other|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
16543974|NCT02991209|Experimental|Tostran 2%|1 years treatment with transdermal Tostran 2%
16543500|NCT02994355|Experimental|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
16543501|NCT02994355|No Intervention|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
16543502|NCT02994342|Active Comparator|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
16543503|NCT02994342|No Intervention|Lifestyle counseling|Every subject has been observed for 56 consecutive days
16543504|NCT02994329|Active Comparator|Oral HIV self test|In this arm, community health workers conducting door-to-door HIV testing will offer oral HIV self testing (OraQuick® HIV Self-Test (Orasure Technologies, Thailand)) as an alternative to standard of care finger-prick HIV testing for individuals who are present at the time of the visit. In addition they will provide demonstration to an adult who is present at the time of the visit and leave up to 2 oral HIV self test kits to allow testing with the partner
16543505|NCT02994329|No Intervention|Standard of Care|In this arm community health workers will conduct door-to-door HIV testing using the current Zambian national HIV testing algorithm of finger-prick rapid HIV tests
16543506|NCT02994316|Experimental|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate < 15mmol/L)"
16543507|NCT02994316|Sham Comparator|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate> 15 mmol/L)"
16543508|NCT02994290|Experimental|receive inpatient HPV vaccine|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
16543509|NCT02994290|Experimental|decline the inpatient dose|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
16543510|NCT02994277|Experimental|UVa and ITBA/UNLP algorithm arm|To control glycaemia in T1DM patients through UVa and ITBA/UNLP algorithm
16543511|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
16543512|NCT02994238|Experimental|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
16543513|NCT02994238|No Intervention|Control|The control group will receive only standardized education.
16543514|NCT02994225|Experimental|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.
~Near Infra-red images acquisition is performed during surgery"
16543515|NCT02994212|Experimental|Intervention group|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF. Anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response.
16543516|NCT02994199|Experimental|Active video gaming|Participants will engage in active video game play.
16543517|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
16543518|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
16543519|NCT02994173|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
16543520|NCT02994173|Active Comparator|Ketamine 0.25|Oxycodone 1 mg / ml + S-ketamine 0.25 mg / ml (ratio 1:0.25)
16543521|NCT02994173|Active Comparator|Ketamine 0.5|Oxycodone 1 mg / ml + S-ketamine 0.5 mg / ml (ratio 1:0.5)
16543522|NCT02994173|Active Comparator|Ketamine 0.75|Oxycodone 1 mg / ml + S-ketamine 0.75 mg / ml (ratio 1:0.75)
16543523|NCT02994160|Experimental|FastLIFE electrodes|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
16543524|NCT02994147|Placebo Comparator|Placebo|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.
~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
16543525|NCT02994147|Experimental|AC-201CR 72mg|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.
~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
16543526|NCT02994134|Active Comparator|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
16543527|NCT02994134|Experimental|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
16543528|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
16543529|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
16543530|NCT02994108|Experimental|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.
~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
16543531|NCT02994108|Active Comparator|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.
~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
16543532|NCT02994095|Experimental|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
16543533|NCT02994082|Experimental|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
16543534|NCT02994082|Active Comparator|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
16543535|NCT02994069|Experimental|Every 3 Weeks Cisplatin + XRT|Every 3 Weeks Cisplatin + XRT
16543536|NCT02994069|Experimental|Weekly Cisplatin + XRT|Weekly Cisplatin + XRT
16543537|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
16543538|NCT02994043|Active Comparator|MBRP|
16543539|NCT02994043|Active Comparator|RP|
16543540|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
16543541|NCT02994017|Other|cystic fibrosis patients|
16543542|NCT02993991|Experimental|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.
~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
16543543|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
16543544|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
16543545|NCT02993965|No Intervention|Control 11-17|No additional intervention done aside from usual care for 11-17 year olds
16543546|NCT02993965|Experimental|1 R/R per Dose 11-17|Sending up to one recall notice per dose of HPV vaccine needed for 11-17 year olds
16543547|NCT02993965|Experimental|2 R/R per Dose 11-17|Sending up to two recall notices per dose of HPV vaccine needed for 11-17 year olds
16543548|NCT02993965|Experimental|3 R/R per Dose 11-17|Sending up to three recall notices per dose of HPV vaccine needed for 11-17 year olds
16543549|NCT02993965|No Intervention|Control 11-14|No additional intervention done aside from usual care for 11-14 year olds
16543550|NCT02993965|Experimental|Phone R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via autodialer for 11-14 year olds
16543551|NCT02993965|Experimental|Mail R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via mailed postcards for 11-14 year olds
16543552|NCT02993952|Active Comparator|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
16543553|NCT02993952|Sham Comparator|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
16543554|NCT02993939|Active Comparator|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
16543555|NCT02993939|Experimental|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
16543595|NCT02993679|Other|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
16589368|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
16543556|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
16543557|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
16543558|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 [i.e. 1 day] to 12 months).
16543559|NCT02993913|Experimental|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
16543560|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
16543561|NCT02993887|Placebo Comparator|Mindfulness|Mindfulness (Decentering) only using the Stop, Breathe, Think Smart Phone application
16543562|NCT02993887|Experimental|Resourcefulness and Mindfulness|Resourcefulness Training (a cognitive behavioral intervention that teaches self-help and help-seeking skills) and Mindfulness using the Stop, Think, Breathe app.
16543563|NCT02993874|Experimental|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
16543564|NCT02993874|Placebo Comparator|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
16543565|NCT02993861||Levetiracetam|Children with epilepsy who are treated with levetiracetam per local standard of care
16543566|NCT02993861||Valproic Acid|Children with epilepsy who are treated with valproic acid per local standard of care
16543567|NCT02993861||Topiramate|Children with epilepsy who are treated with topiramate per local standard of care
16543568|NCT02993861||Oxcarbazepine|Children with epilepsy who are treated with oxcarbazepine per local standard of care
16543569|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
16543570|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
16543571|NCT02993835|Active Comparator|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
16543572|NCT02993835|Active Comparator|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
16543573|NCT02993835|Experimental|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
16543574|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
16543575|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
16543576|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
16543577|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
16543578|NCT02993809|Experimental|BM-ECs and PRPE|Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
16543579|NCT02993809|Active Comparator|BM-ECs|Intramuscular injection of bone marrow derived endothelial cells only.
16543580|NCT02993783|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
16543581|NCT02993783|Experimental|Vedolizumab 600 mg|Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
16543582|NCT02993770|Experimental|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
16543583|NCT02993770|Active Comparator|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
16543584|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
16543585|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
16543586|NCT02993744||Case Group|75 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, threatening preterm delivery, application of Betamethasone
16543587|NCT02993744||Control Group|65 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, no threatening preterm delivery
16543588|NCT02993731|Experimental|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
16543589|NCT02993731|Active Comparator|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
16543590|NCT02993718|Experimental|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
16543591|NCT02993718|Experimental|Propofol|Intraoperative sedation is performed by using propofol
16543592|NCT02993705|Experimental|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
16543596|NCT02993679|Other|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
16543597|NCT02993666|Experimental|upper body|warming with upper body blankets
16543598|NCT02993666|Experimental|lower body|warming with lower body blankets
16543599|NCT02993653|Experimental|Intensity-modulated radiotheapy arm|Intensity-modulated radiotheapy with stereotactic boost or intracavitary radiotherapy
16543600|NCT02993640|Experimental|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
16543601|NCT02993627|Experimental|Spirulina|daily intake of spirulina tablets weight reduction diet therapy
16543602|NCT02993627|Placebo Comparator|placebo|daily intake of placebo tablets weight reduction diet therapy
16543603|NCT02993601||20 outpatients with peripheral oedema|20 outpatients with clinically detectable peripheral oedema for 1 set of measurements.
16543604|NCT02993601||20 cardiology controls|20 outpatients with heart failure without clinically detectable peripheral oedema (control group) for 1 set of measurements.
16543605|NCT02993601||10 in-patients peripheral oedema|10 in patients hospitalised as a result of heart failure and fluid congestion with peripheral oedema, those patients will have several sets of measurements taken over time to measure the reduction of peripheral oedema which is likely to show common features with the formation of peripheral oedema.
16543606|NCT02993601||30 control without cardiac conditions|less than 30 normal controls (healthy volunteers and patients without heart failure) in the age group 55 and above who agree to have images taken using the Heartfelt-1 device (not the whole set of measurements).
16543607|NCT02993588|Experimental|Melatonin|Melatonin 6 mg tablet once daily.
16543608|NCT02993588|Placebo Comparator|Placebo|Placebo tablet once daily
16543609|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
16543610|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
16543611|NCT02993523|Placebo Comparator|Placebo followed by Azacitidine|Matching Placebo for Venetoclax 400 mg orally QD on Days 1 - 28 plus Azacitidine 75 mg/m^2 SC or IV QD on Days 1 - 7 (28-day cycle)
16543612|NCT02993523|Active Comparator|Venetoclax followed by Azacitidine|Venetoclax 400 mg orally every day (QD) on Days 1 - 28 plus Azacitidine 75 mg/m^2 subcutaneously (SC) or intravenous (IV) QD on Cycle Days 1 - 7 (28-day cycle)
16543613|NCT02993510|Active Comparator|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
16543614|NCT02993510|Experimental|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
16543615|NCT02993510|Experimental|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
16543616|NCT02993497|Experimental|Respiratory monitoring group|
16543617|NCT02993484|Experimental|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
16543618|NCT02993484|Experimental|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
16543619|NCT02993484|Experimental|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
16543620|NCT02993484|Experimental|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
16543621|NCT02993484|Experimental|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
16543622|NCT02993484|Experimental|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
16543623|NCT02993484|Experimental|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
16543624|NCT02993484|Experimental|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
16543625|NCT02993471|Experimental|Drug Cocktail|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).
16543626|NCT02993471|Experimental|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
16543627|NCT02993458|Experimental|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
16543628|NCT02993458|Active Comparator|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
16543629|NCT02993458|Active Comparator|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
16543630|NCT02993458|Active Comparator|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
16543631|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
16543668|NCT02993198|Experimental|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
16543669|NCT02993198|No Intervention|No Therapy|Standard of care monitoring without prophylactic treatment.
16543670|NCT02993185|Experimental|Your Move|Sex education intervention
16543632|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
16543633|NCT02993432|Active Comparator|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
16543634|NCT02993432|Experimental|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
16543635|NCT02993419|Experimental|Bacillus licheniformis Intervention|The intervention is use Bacillus licheniformis particles，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
16543636|NCT02993419|Placebo Comparator|placebo Intervention|The intervention is use placebo，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
16543637|NCT02993406|Experimental|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
16543638|NCT02993406|Placebo Comparator|Placebo Comparator|Matching placebo tablet taken orally, once daily
16543639|NCT02993393||Teachers|Anesthesiologists who have involved in SBL and PBL with more than 3 years of experience in teaching
16543640|NCT02993393||Students|Students were nurse anesthetist students in the academic years of 2015
16543641|NCT02993380|Experimental|Stir-fried olive oil group|olive oil in heated under 150 degrees
16543642|NCT02993380|Experimental|Natural olive oil group|olive oil in without heated
16543643|NCT02993367|Experimental|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
16543644|NCT02993367|Placebo Comparator|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
16543645|NCT02993354||Pregnant women|Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.
16543646|NCT02993341|Experimental|Tranexamic Acid Wash|Participants in the experimental arm will receive a wash of tranexamic acid topically at the site of surgery.
16543647|NCT02993341|Placebo Comparator|Saline Wash|Participants in the control arm will receive a wash of saline topically at the site of surgery.
16543648|NCT02993328|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
16543649|NCT02993328|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
16543650|NCT02993315|Experimental|nDC vaccination arm|Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10^6 nDC).
16543651|NCT02993315|Placebo Comparator|placebo arm|Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
16543652|NCT02993302|Active Comparator|PTU-Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
16543653|NCT02993302|Placebo Comparator|PTU-Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
16543654|NCT02993289|Active Comparator|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
16543655|NCT02993289|Active Comparator|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
16543656|NCT02993289|Active Comparator|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
16543657|NCT02993289|No Intervention|Control group 1: Episodic migraine|
16543658|NCT02993289|No Intervention|Control group 2: Healthy volunteers|
16543659|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
16543660|NCT02993263|Other|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
16543661|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
16543662|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
16543663|NCT02993237|Experimental|Group 1: DRV/COBI Placebo followed by D/C/F/TAF Placebo|Participants will receive fixed dose combination (FDC) of darunavir/cobicistat (DRV/COBI) matching placebo tablets (Intake 1) and FDC of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
16543664|NCT02993237|Experimental|Group 2: D/C/F/TAF Placebo followed by DRV/COBI Placebo|Participants will receive FDC of D/C/F/TAF matching placebo tablets (Intake 1) and FDC of DRV/COBI matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
16543665|NCT02993224|Experimental|Deferasirox DT followed by deferasirox FCT|Participants were treated with deferasirox DT followed by deferasirox FCT (core phase). Those who entered the extension phase were treated with deferasirox FCT
16543666|NCT02993211|Active Comparator|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
16543667|NCT02993211|Experimental|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
16543672|NCT02993159|Experimental|Arm I (afimoxifene, placebo)|Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
16543673|NCT02993159|Active Comparator|Arm II (placebo, tamoxifen citrate)|Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
16543675|NCT02993133|Experimental|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
16543676|NCT02993120||Cohort 1|For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.
16543677|NCT02993120||Cohort 2|• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.
16543678|NCT02993120||Cohort 3|For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks
16543679|NCT02993107|Other|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
16543680|NCT02993107|Other|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
16543681|NCT02993094|Experimental|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.
~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
16543682|NCT02993068|Experimental|Arm A (online education)|Patients watch genetic testing online educational video and receive genetic testing online test results report.
16543683|NCT02993068|Experimental|Arm B (online education, post telephone counseling)|Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
16543684|NCT02993068|Active Comparator|Arm C (online education, pre- and post-telephone counselling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
16543685|NCT02993068|Experimental|Arm D (online education, pre-telephone counseling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
16543686|NCT02993055|Experimental|Ulimorelin|Active
16543687|NCT02993055|Placebo Comparator|Placebo|Placebo
16543688|NCT02993042|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
16543689|NCT02993029|Experimental|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
16543690|NCT02993029|Active Comparator|celecoxib|celecoxib capsule 200mg qd by mouth.
16543691|NCT02993016|Experimental|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
16543692|NCT02993016|Active Comparator|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
16543693|NCT02993003|Other|Children between 7 months and 12 months|nasopharyngeal probe will be marked with indelible ink from 2-10 cm in 1-cm increments and inserted 10 cm
16543694|NCT02993003|Other|children between 1 and 5 years|nasopharyngeal probe will be marked with indelible ink from 2-15 cm in 1.5-cm increments and inserted 10 cm
16543695|NCT02993003|Other|children between 6 and 12 years|a nasopharyngeal probe will be marked with indelible ink from 2 to 20 cm at 2 cm increments from its tip, and inserted 20 cm
16543696|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
16543697|NCT02992977|Experimental|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
16543698|NCT02992964|Experimental|Nivolumab|"Regimen: Nivolumab will be administered every 14 days until disease progression or treatment discontinuation due to unacceptable toxicities. Treatment may extend up to 2 years in patients who show clinical and radiological benefit.
~Dose: 3 mg/kg intravenously as a continuous infusion over 60 min (+/-10 min window)"
16543699|NCT02992951|Experimental|DACC-Coated Post-Operative Dressing|DACC-Coated Post-Operative Dressing
16543700|NCT02992951|No Intervention|Non-DACC coated Occlusive Post-operative Film Dressing|Non-DACC coated Occlusive Post-operative Film Dressing
16543701|NCT02992938|Experimental|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
16543702|NCT02992938|Placebo Comparator|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
16543703|NCT02992925|Experimental|Cohort 1: BK1310-High|
16543704|NCT02992925|Experimental|Cohort 1: BK1310-Low|
16543705|NCT02992925|Experimental|Cohort 2: BK1310-High or -Low|Either BK1310-High or -Low will be chosen based on the result of cohort 1
16543706|NCT02992925|Active Comparator|Cohort 2: ActHIB® and Tetrabik|
16543707|NCT02992912|Experimental|Cohort 1: metastatic colorectal cancer|
16543708|NCT02992912|Experimental|Cohort 2: metastatic non-small lung cancer|
16543711|NCT02992899|Experimental|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
16543712|NCT02992899|Sham Comparator|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
16543713|NCT02992886|Experimental|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
16543714|NCT02992873|Experimental|Layperson allocated to fetch an AED and start CPR|In the intervention group mobile lifesavers will be directed to fetch the nearest AED and then attach it to the victim of OHCA. At least 1 volunteer will be directed to start CPR only
16543715|NCT02992873|Active Comparator|Layperson allocated to start CPR|In the control group all mobile lifesavers will be directed to the patient to start CPR.
16543716|NCT02992860|Experimental|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
16543717|NCT02992847||Dotarem|At least 5 injection with Dotarem exclusively
16543718|NCT02992847||Multihance|At least 5 injection with Multihance exclusively
16543719|NCT02992834|Active Comparator|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
16543720|NCT02992834|Active Comparator|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
16543721|NCT02992821|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries by junior doctors. All participants will then be examined by reference imaging in specific ultrasound laboratories with conventional high end equipment and new doppler techniques and when appropriate computer tomography or magnetic resonance imaging.
16543722|NCT02992808|Active Comparator|Recombinant preparations|
16543723|NCT02992808|Active Comparator|HP-HMG|Highly purified human menopausal gonadotropin
16543724|NCT02992795||Cohort Ia|Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
16543725|NCT02992795||Cohort Ib|Athletes in this cohort are subjects currently subscribed to the Head Health Network. They will have a BrainPulse recording completed every week through the entire season. Similarly, if subjects in this cohort sustain an injury, they will crossover to Cohort II.
16543726|NCT02992795||Cohort IIa|Athletes from Cohort I will be assigned to cohort IIa once they sustain an injury other than concussion. They will have been pulled out of the game by the athletic trainer and removed from play until at least the end of the game. Once the subjects have been assigned to Cohort IIa, they will have a BrainPulse recording and a symptom evaluation within 3 days of their injury. After two weeks of recovery, subjects in this cohort will return to Cohort 1 and resume their participation in the study in their respective sub-cohort.
16543727|NCT02992795||Cohort IIb|Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
16543728|NCT02992782|Active Comparator|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
16543729|NCT02992782|Experimental|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
16543730|NCT02992782|Experimental|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
16543731|NCT02992756|Experimental|Instillation of growth factors|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-3 oocytes.
16543733|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
16543734|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
16543735|NCT02992704|Experimental|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
16543736|NCT02992704|Experimental|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
16543737|NCT02992704|No Intervention|Control|No treatment for 72 weeks
16543738|NCT02992691|Experimental|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
16543739|NCT02992691|Experimental|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
16543740|NCT02992691|Experimental|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
16543741|NCT02992691|Active Comparator|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
16543742|NCT02992691|Other|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
16543743|NCT02992678|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
16543744|NCT02992678|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
16543745|NCT02992665|Experimental|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
16543746|NCT02992665|Experimental|Placebo|Placebo was used to control the group of Calcium ionophore
16543747|NCT02992652|Active Comparator|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
16543748|NCT02992652|No Intervention|Control Group|Underwent ERCP without allopurinol prophylaxis
16543749|NCT02992639|Placebo Comparator|Control group|No calorie restriction group
16543750|NCT02992639|Experimental|Weight loss group|Mild calorie restriction group (300kcal/day intake reduction)
16543751|NCT02992626|Experimental|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
16543752|NCT02992626|Experimental|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
16543753|NCT02992613|Experimental|Ultra-Congruent(UC) group|Ultra-Congruent(UC) insert will be used in total knee arthroplasty.
16543754|NCT02992613|Active Comparator|posterior-stabilized(PS) group|Posterior-stabilized(PS) insert will be used in total knee arthroplasty.
16543755|NCT02992600||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
16543756|NCT02992600||control group|we enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
16543757|NCT02992574|Experimental|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
16543758|NCT02992574|No Intervention|Observation (No PMRT)|No adjuvant radiotherapy will be given.
16543759|NCT02992561|Active Comparator|Narrative Exposure Therapy (FORNET, adapted version)|Version of Narrative Exposure Therapy for Forensic Offender Rehabilitation including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
16543760|NCT02992561|No Intervention|Waitlist control or treatment as usual|No intervention or non-specific measures of support on request
16543761|NCT02992548|Experimental|pravastatin group|Use of pravastatin 20mg to 40mg
16543762|NCT02992535|Experimental|Single arm|Intense pulse light therapy (E-Schwin)
16543763|NCT02992522|Experimental|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16543764|NCT02992509|Other|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
16543765|NCT02992496|Active Comparator|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
16543766|NCT02992496|Active Comparator|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
16543767|NCT02992483|Experimental|MIK665|
16543768|NCT02992470|Experimental|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
16543769|NCT02992470|Placebo Comparator|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
16543770|NCT02992457|Active Comparator|Sof-Riba|Sofosbuvir ribavirin 6 months.
16543771|NCT02992457|Active Comparator|Sof- Riba- Pegylated interferon|Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
16543772|NCT02992457|Active Comparator|Sof- Olysio|Sofosbuvir and simeprevir for 3 months.
16543773|NCT02992457|Active Comparator|Sof- Dacla|Sofosbuvir and Daclatasvir for 3 months.
16543774|NCT02992457|Active Comparator|Harvony|Sofosbuvir and ledipasvir for 3 months
16543775|NCT02992457|Active Comparator|Ritaprevir, paritaprevir, ombetasvir|Querevo for 3 months
16543776|NCT02992457|Active Comparator|Salvage therapy|sofosbuvir, daclatasvir, simeprevir,ribavirin or sofosbuvir and querevo
16543777|NCT02992444|Experimental|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.
~There is one visit:
~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
16543778|NCT02992431|Active Comparator|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
16543779|NCT02992431|Experimental|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
16543780|NCT02992418|Experimental|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
16543781|NCT02992418|Experimental|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
16543782|NCT02992405|Experimental|FOCUS Resilience Enhancement Program|Those assigned to the immediate treatment group will participate in the 10-week treatment.
16543783|NCT02992405|Experimental|Waitlist Treatment|After the 10-week immediate treatment period, wait-list control participants will be administered the treatment.
16543784|NCT02992392|Experimental|Liposic|Liposic was applied to one eye of patients in this group
16543785|NCT02992392|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
16543786|NCT02992379|Active Comparator|stabilizing splint|Active Comparator: stabilizing splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
16543787|NCT02992379|Experimental|pivot splint|"Experimental: pivot splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks.
~Other Names: PS"
16543788|NCT02992366|Experimental|socket shield (A)|"Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.
~After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.
~The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.
~The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)
~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
16543789|NCT02992366|Active Comparator|conventional immediate implant (B)|"Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.
~The implant fixture will be inserted in the empty socket by conventional manner.
~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
16543790|NCT02992353|Active Comparator|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
16543791|NCT02992353|Active Comparator|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
16543792|NCT02992340|Experimental|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
16543793|NCT02992327||Cohort|Patients age ≥ 8 years of age with a GCS >13 presenting to the emergency department with a diagnosis of concussion.
16543794|NCT02992314|Experimental|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.
~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.
~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
16543795|NCT02992314|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
16543796|NCT02992301|Experimental|Open Label|All enrolled patients will receive open label Praluent (Alirocumab).
16543797|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
16543798|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
16543799|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
16543800|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
16543801|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
16543802|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
16543803|NCT02992275|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
16543804|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
16543805|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
16543975|NCT02991209|Placebo Comparator|Placebo|1 years treatment with placebo gel
16543806|NCT02992210|Experimental|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
16543807|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
16543808|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
16543809|NCT02992184||HCV patients|228 HCV patients
16543810|NCT02992184||control|189 controls
16543811|NCT02992171|Experimental|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
16543812|NCT02992158|Experimental|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
16543813|NCT02992158|Other|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
16543814|NCT02992145||Case group: This group will include forty (40) preeclampt|
16543815|NCT02992145||Control group: This group will include forty (40) normoten|
16543816|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
16543817|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
16543818|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
16543819|NCT02992119|Experimental|Group 1|RTS,S/AS01B Fractional dose
16543820|NCT02992119|Experimental|Group 2|Double RTS,S/AS01E Fractional dose
16543821|NCT02992119|Experimental|Group 3|RTS,S/AS01E Standard dose
16543822|NCT02992119|Experimental|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
16543823|NCT02992119|Experimental|Group 5|RTS,S/AS01E Fractional dose
16543824|NCT02992119|Experimental|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
16543825|NCT02992119|Experimental|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
16543826|NCT02992106|Other|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
16543827|NCT02992106|Other|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI > 29 kg/m² during their singleton pregnancy.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
16543828|NCT02992106|Other|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
16543829|NCT02992106|Other|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
16543830|NCT02992093||obese with PCOS|all the indicators
16543831|NCT02992093||nonobese with PCOS|all the indicators
16543832|NCT02992093||PCOS with IGT|all the indicators
16543833|NCT02992093||PCOS with T2DM|all the indicators
16543834|NCT02992093||Healthy volunteers|all the indicators
16543835|NCT02992080|Other|Cystic fibrosis Patients|
16543836|NCT02992080|Other|Patients without fibrosis cystic|
16543837|NCT02992080|Other|Cystic fibrosis Patients (secondary use of samples)|
16543838|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
16543839|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
16543840|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
16543844|NCT02992028|Experimental|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
16543845|NCT02992028|Placebo Comparator|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
16543846|NCT02992015|Experimental|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
16543847|NCT02991989|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening. They will also be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers.
16543848|NCT02991989|Other|Yogurt Only Group|For 28 days, this group will be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers. Apart from consuming the yogurt, this group will be asked to continue their normal lifestyle.
16543849|NCT02991976|Active Comparator|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
16543850|NCT02991976|Active Comparator|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
16543851|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
16543852|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
16543853|NCT02991950|Experimental|parnaparin sodium|"Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.
~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.
~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI"
16543854|NCT02991950|No Intervention|no treatment|Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.
16543855|NCT02991937|Active Comparator|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
16543856|NCT02991937|Active Comparator|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
16543857|NCT02991911|Experimental|Arm A|MEDI3726 Post-Chemo
16543858|NCT02991911|Experimental|Arm B|MEDI3726 Pre-Chemo
16543859|NCT02991911|Experimental|Arm C|MEDI3726 & Enzalutamide Combo
16543860|NCT02991898|Experimental|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
16543861|NCT02991885|Experimental|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
16543862|NCT02991885|Placebo Comparator|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
16543863|NCT02991872|Other|V49_24E1 Group|Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49_24 (NCT01680016), will be invited to participate to this extension study.
16543864|NCT02991859|Experimental|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
16543865|NCT02991859|Experimental|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
16543866|NCT02991859|Experimental|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
16544080|NCT02990533|Experimental|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
16543867|NCT02991859|Experimental|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
16543868|NCT02991859|Experimental|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
16543869|NCT02991859|Experimental|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
16543870|NCT02991859|Experimental|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
16543871|NCT02991859|Experimental|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
16543872|NCT02991859|Experimental|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
16543873|NCT02991859|Experimental|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
16543874|NCT02991859|Experimental|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
16543932|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
16544359|NCT02988635|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
16543875|NCT02991859|Experimental|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
16543876|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
16543877|NCT02991833|Experimental|Of A New Incontinence Care Product|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
16543878|NCT02991833|Active Comparator|Diaper|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
16543879|NCT02991820|Experimental|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
16543880|NCT02991820|Experimental|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
16543881|NCT02991807|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg or 2.5mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
16543882|NCT02991807|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
16543883|NCT02991781|Experimental|COPD Patients|"C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) < 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production
~Biofeedback and Neurofeedback Training
~Varenicline use for smoking cessation
~Passive Control"
16543884|NCT02991781|Experimental|Asthma Patients|"Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by >12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) <8 mg or mannitol provocation test (with FEV1 decrease of 15%)
~Biofeedback and Neurofeedback Training
~Varenicline use for smoking cessation
~Passive Control"
16543885|NCT02991781|Experimental|Smokers|"Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.
~Biofeedback and Neurofeedback Training
~Varenicline use for smoking cessation
~Sham Neurofeedback
~Passive Control"
16543886|NCT02991768|Experimental|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
16543887|NCT02991768|Placebo Comparator|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
16543888|NCT02991742||Iodixanol|Iodixanol contrast media
16543889|NCT02991742||Ioxaglate|Ioxaglate contrast media
16543890|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
16543891|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
16543892|NCT02991716||Recorded patients|Patients requiring Intracradiac Defibrillator (ICD) implantation, Electrophysiology (EP) study or a holter monitor recording, mainly due to suspected ventricular tachy - arrhythmias
16543893|NCT02991703|Active Comparator|SphygmoCor®|
16543894|NCT02991703|Experimental|pOpmètre®|
16543895|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
16543896|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
16543897|NCT02991677|Other|control|This is an attention control group with regular contact by study staff.
16543898|NCT02991677|Experimental|aerobic exercise|Aerobic exercise intervention is for 12 weeks 3 times weekly with training on site.
16543899|NCT02991677|Experimental|resistive training|Intervention is for 12 weeks 3 times weekly with training on site.
16543900|NCT02991664|Active Comparator|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
16543901|NCT02991664|Active Comparator|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
16543902|NCT02991651|Experimental|Dose Level 1|IRX4204 5 mg/day PO + erlotinib 100 mg/day PO
16543903|NCT02991651|Experimental|Dose Level 2|IRX4204 5 mg/day PO + erlotinib 150 mg/day PO
16543904|NCT02991651|Experimental|Dose Level 3|IRX4204 10 mg/day PO + erlotinib 150 mg/day PO
16543905|NCT02991638|Other|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
16543906|NCT02991625|Experimental|Placebos|Chronic Back Pain participants will enter an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
16543907|NCT02991625|Other|Waitlist|Chronic Back Pain participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar.
16543908|NCT02991625|Other|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
16543909|NCT02991612|Experimental|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
16543910|NCT02991612|No Intervention|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
16543911|NCT02991599|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16543912|NCT02991599|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16543913|NCT02991586|Experimental|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
16543914|NCT02991586|No Intervention|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
16543915|NCT02991573|Active Comparator|existing adhesive (control)|control adhesive
16543916|NCT02991573|Experimental|new adhesive: technique 1|Prime & Bond Universal: technique 1
16543917|NCT02991573|Experimental|new adhesive: technique 2|Prime & Bond Universal: technique 2
16543918|NCT02991560|Experimental|Kinesio tape (KT)|The KT group was taped 2 days a week for 4 weeks using the muscle and fascia correction techniques
16543919|NCT02991560|Experimental|Athletic taping (AT)|An athletic tape with adhesive backing was used (38 mm wide-Muller Protape-The Netherlands).
16543920|NCT02991534|Other|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
16543921|NCT02991521|Experimental|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
16543922|NCT02991508|Placebo Comparator|Placebo|Vehicle (20 mM His/HCl pH 6.0)
16543923|NCT02991508|Active Comparator|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
16543924|NCT02991508|Active Comparator|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
16543925|NCT02991508|Active Comparator|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
16543926|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
16543927|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
16543928|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
16543929|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
16543930|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
16543931|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
16543933|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
16543934|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
16543935|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
16543936|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
16543937|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
16543938|NCT02991482|Experimental|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
16543939|NCT02991482|Active Comparator|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.
~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
16543940|NCT02991469|Experimental|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
16543941|NCT02991456|Active Comparator|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
16543942|NCT02991456|Active Comparator|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
16543943|NCT02991443|Experimental|Mindfulness based stress reduction|Parents of children with IBD will undergo mindfulness based stress reduction (MBSR) intervention consisted of 8 group sessions. The effect on stress and anxiety will be assessed using 3 validated questionnaires which will be filled prior to intervention, at the end of intervention and 3 months following intervention.
16543944|NCT02991430|Active Comparator|active|active neuromodulation
16543945|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
16543946|NCT02991417|Experimental|CDVAX|
16543947|NCT02991404|Active Comparator|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
~Multimodal peripheral nerve block injection."
16543948|NCT02991404|Sham Comparator|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
16543949|NCT02991378|Experimental|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
16543950|NCT02991378|No Intervention|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
16543951|NCT02991365|Active Comparator|nasal insulin|daily administration of 160 U of human insulin as nasal spray
16543952|NCT02991365|Placebo Comparator|placebo spray|daily administration of placebo solution as nasal spray
16543953|NCT02991352|Experimental|Experimental|Image guided needle placement into vascular malformations based on MRI
16543954|NCT02991339|Experimental|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
16543955|NCT02991339|No Intervention|control|Patients are not treated with glucocorticoids.
16543956|NCT02991326|Experimental|Test Group (TG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to Osteopathic Manipulative Treatment - OMT.
16543957|NCT02991326|Sham Comparator|Control Group (CG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to sham intervention (Osteopathic Manipulative Treatment simulated).
16543958|NCT02991313|Experimental|Endocardial Ablation Procedure|ablation with Linear type catheter
16543959|NCT02991287||Chronic post-surgical pain patients|Patients scheduled for differents types of surgery (inguinal, hernia repair, abdominal hysterectomy, vaginal hysterectomy, and thoracotomy).
16543960|NCT02991274||T790M mutation test|genomic testing of T790M mutation
16543961|NCT02991261|Experimental|SPARC001 type I|Treatment type I
16543962|NCT02991261|Experimental|SPARC001 type II|Treatment type II
16543963|NCT02991261|Active Comparator|Reference001 type I|Hydrocodone-Acetaminophen
16543964|NCT02991261|Active Comparator|Reference type II|Hydrocodone-Acetaminophen
16543965|NCT02991248|Experimental|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
16543966|NCT02991248|Active Comparator|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
16543967|NCT02991248|Placebo Comparator|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
16543968|NCT02991235|Experimental|PRJ212|PRJ212 is a nutritional product with active food ingredients.
16543969|NCT02991235|Placebo Comparator|Placebo|Placebo is like PRJ212 without active food ingredients.
16543970|NCT02991222|Experimental|SPARC001 type I|Treatment type I
16543971|NCT02991222|Experimental|SPARC001 type II|Treatment type II
16543976|NCT02991196|Experimental|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
16543977|NCT02991183|Experimental|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
16543978|NCT02991170|Active Comparator|control group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
16543979|NCT02991170|Experimental|interventional group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
16543980|NCT02991144|Experimental|Dose 1: 2.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
16543981|NCT02991144|Experimental|Dose 2: 6.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
16543982|NCT02991144|Experimental|Dose 3: 1.0 × 10^13 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
16543983|NCT02991144|Experimental|Dosing Process Optimization at Optical Biological Dose (OBD)|Oral prednisone (or prednisolone), 60 mg tapered over 9 weeks, initiated before dosing with DTX301. DTX301 (scAAV8OTC; optimal biologic dose) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
16543984|NCT02991131||Tedizolid|Hospitalized ABSSSI patients treated with tedizolid
16543985|NCT02991131||Linezolid|Hospitalized ABSSSI patients treated with linezolid
16543986|NCT02991118|Experimental|bempedoic acid|bempedoic acid 180 mg/day
16543987|NCT02991118|Placebo Comparator|Placebo|Placebo control
16543988|NCT02991105||Solid organ transplant recipients|National cohort = 85,410 solid organ transplant recipients receiving their transplant between January 1st 1985 to December 31st 2015
16543989|NCT02991092|Experimental|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
16543990|NCT02991092|Other|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
16543991|NCT02991079|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
16543992|NCT02991079|Experimental|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
16543993|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
16543994|NCT02991066||Control|healthy volunteers.
16543995|NCT02991053|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
16543996|NCT02991053|Active Comparator|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
16543997|NCT02991053|Active Comparator|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
16543998|NCT02991053|Active Comparator|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
16543999|NCT02991053|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
16544000|NCT02991040|Experimental|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
16544002|NCT02991014|Active Comparator|researcher-selected frequency-modulated music|
16544003|NCT02991014|Placebo Comparator|researcher-selected non-modulated music|
16544004|NCT02991014|Experimental|participant-selected non-modulated music|
16544005|NCT02991001|Experimental|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
16544006|NCT02991001|Placebo Comparator|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
16544007|NCT02990988||Iron repletion|Subjects participating in the associated study under the Iron Repletion arm will also provide stool collection and answers to questionnaire and diet diary.
16544008|NCT02990988||Placebo|Subjects participating in the associated study under the Placebo arm will also provide stool collection and answers to questionnaire and diet diary.
16544009|NCT02990975|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
16544010|NCT02990975|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
16544011|NCT02990975|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
16544012|NCT02990962|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
16544013|NCT02990962|Active Comparator|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
16544014|NCT02990949|Experimental|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
16544015|NCT02990949|No Intervention|Control group|
16544016|NCT02990936||head and neck squamous cell carcinoma|Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
16544017|NCT02990923|No Intervention|Control|In this group, patients will use traditional standard hemodialysis connector and receive typical disinfection management
16544018|NCT02990923|Experimental|Only High-Flow Valve|In this group, patients will use High-Flow Needleless Valve instead of traditional standard hemodialysia connector, but still receiving typical disinfection management
16544019|NCT02990923|Experimental|Both Divices|In this group, patients will receive both High-Flow Needleless Valve and DualCap Disinfection Devices in hemodialysis
16544020|NCT02990910|Other|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
16544021|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
16544024|NCT02990884|Active Comparator|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
16544025|NCT02990884|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
16544026|NCT02990884|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
16544027|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
16544028|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
16544029|NCT02990858|Experimental|PRO 140|
16544030|NCT02990845|Experimental|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
16544031|NCT02990832|Experimental|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
16544032|NCT02990819|Other|Reduced intensity regimen|Conditioning regimen is dependent on patient diagnosis and age. Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care reduced intensity conditioning will include Busulfan, Fludarbine, Thiotepa followed by stem cell infusion.
16544033|NCT02990819|Other|Myeloablative regimen|"Conditioning regimen is dependent on patient diagnosis and age. Patients with chronic granulomatous disease or Wiskott-Aldrich syndrome will receive cyclophosphamide in lieu of thiotepa to ensure engraftment.
~Myeloablative regimen with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care myeloablative regimen will include Busulfan, Fludarbine, Thiotepa, or Cyclophosamide followed by stem cell infusion."
16544034|NCT02990819|Other|Immunotherapy|Conditioning regimen is dependent on patient diagnosis and age. Severe combined immunodeficiency (SCID) patients will be conditioned with immunotherapy only followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Immunotherapy regimen will include anti-thymocyte globulin followed by stem cell infusion.
16544035|NCT02990806|Experimental|NI-071|Proposed biosimilar
16544036|NCT02990806|Active Comparator|Infliximab|Reference product
16544037|NCT02990793|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
16544038|NCT02990793|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
16544039|NCT02990780|Active Comparator|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
16544040|NCT02990780|Experimental|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
16544041|NCT02990767||observational women|collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation.
16544042|NCT02990754|Experimental|Intervention Group|Individuals attending one or more fearless physical activity events
16544043|NCT02990741||Usual screening group|ECG recordings at baseline plus at 1 and 2 year of follow-up; three ECG recordings in total.
16544044|NCT02990741||Intensive screening subgroup|ECG recordings at baseline plus quarterly during follow-up, at months 3, 6, 9 ,12, 15, 18, 21 and 24; 9 ECG recordings in total.
16544045|NCT02990741||More intensive screening subgroup|ECG recordings at baseline plus weekly during the first month of follow-up and quarterly afterwards, at weeks 1, 2, 3 and 4 and months 3, 6, 9, 12, 15, 18, 21 and 24; 13 ECG recordings in total.
16544075|NCT02990546|Experimental|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
16544076|NCT02990546|Other|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal > 65 mmHg
16544077|NCT02990533|Placebo Comparator|Placebo|Placebo Supplement Placebo Injection
16544078|NCT02990533|Experimental|Testosterone|Placebo Supplement Testosterone Injection
16589533|NCT02682095||Focus-group interviews|Hypertensive patients
16544046|NCT02990728|Experimental|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
16544047|NCT02990728|Active Comparator|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
16544048|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
16544049|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
16544050|NCT02990702|Active Comparator|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
16544051|NCT02990702|Active Comparator|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
16544052|NCT02990689|Active Comparator|809M|bifocal intraocular lens (IOL)
16544053|NCT02990689|Active Comparator|839MP|trifocal intraocular lens (IOL)
16544054|NCT02990689|Active Comparator|SN6AD1|bifocal intraocular lens (IOL)
16544055|NCT02990676|Experimental|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
16544056|NCT02990676|No Intervention|Control group|Asked to continue as normal
16544057|NCT02990663|Experimental|Bedtime BP Meds|Use of blood pressure lowering medication at bedtime
16544058|NCT02990663|Active Comparator|Morning BP Meds|Use of blood pressure lowering medication in the morning
16544059|NCT02990650|Active Comparator|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
16544060|NCT02990650|Experimental|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
16544061|NCT02990650|Experimental|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
16544062|NCT02990637|Active Comparator|OLECOL|Olive leaf extract
16544063|NCT02990637|Placebo Comparator|Placebo|Maltodextrin
16544064|NCT02990624|Active Comparator|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
16544065|NCT02990624|Active Comparator|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
16544066|NCT02990624|No Intervention|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
16544067|NCT02990611||Cohort 1: Nivolumab/Ipilimumab combination therapy|Participants who start a new systemic therapy with nivolumab/ipilimumab combination therapy for the first time
16544068|NCT02990611||Cohort 2: Nivolumab monotherapy|Participants who start a new systemic therapy with nivolumab monotherapy for the first time
16544069|NCT02990611||Cohort 3: Nivolumab adjuvant therapy|Participants who start adjuvant treatment with nivolumab after complete surgical tumor resection and no evidence of disease
16544070|NCT02990585|Active Comparator|One individual back school session|The 1 individual session will consist of a 60 min 1-on-1 education/exercise session with an athletic trainer. Information will be an abbreviated version of the 8-session school and fill focus on the strengthening, stretching, pain control and movement re-education most needed for the individual.
16544071|NCT02990585|Active Comparator|8 group session of back school|All sessions last 45-60 minutes. There will be up to 8 participants in each session which will be led by an athletic trainer or rehabilitation trainer. Pain management, prevention strategies, and active treatment will be covered in the 8 sessions. Active treatment includes strengthening, stretching, pain control, movement re-education, and walking.
16544072|NCT02990572||Amish and Mennonite|"Agree to allow access to past, current, and future medical records
~Provide a detailed family health history
~Provide contact information that may be used for future approach regarding research studies"
16544073|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
16544074|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
16544079|NCT02990533|Experimental|Protein Supplement|Protein Supplement Placebo Injection
16544081|NCT02990507|Experimental|AVEED|AVEED is composed of arm and leg cranks that can be used independently or together with a virtual exercise environment (VEE). Participants rotate arm and/or leg cranks under 4 conditions for 5 min each with a 5 min rest between: 1) Arm rotation with VEE, while sitting or standing (AVEED: Arm rotation, video display); 2) Arm rotation without VEE, while sitting or standing (AVEED: Arm rotation, without video display); 3) Leg rotation with arm-energy input to assist the legs with VEE, while sitting (AVEED: Leg rotation, arm-energy input, video display); 4) Leg rotation with arm-energy input to assist the legs without VEE, while sitting (AVEED: Leg rotation, arm-energy input, without video display). VEE controlled with voice commands, leaning, or keyboard buttons.
16544082|NCT02990494|Active Comparator|STANDARD|12-week Internet-delivered behavioral weight loss program
16544083|NCT02990494|Experimental|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
16544084|NCT02990494|Experimental|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
16544088|NCT02990468|Experimental|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
16544089|NCT02990455|Experimental|Reduced Nicotine Cigarette - Moderate|Nicotine Research Cigarette Drug Supply Program Category Codes NRC600 and NRC601 (menthol); each cigarette contains 0.8mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
16544090|NCT02990455|Experimental|Reduced Nicotine Cigarette - Low|Nicotine Research Cigarette Drug Supply Program Category Codes NRC102 and NRC103 (menthol); each cigarette contains 0.03mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
16544091|NCT02990442|Experimental|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
16544092|NCT02990429|Experimental|Forced Air warmer (bair hugger)|".
~In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC"
16544093|NCT02990429|Experimental|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
16544094|NCT02990416|Experimental|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
16544095|NCT02990403|Experimental|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
16544096|NCT02990403|Experimental|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
16544097|NCT02990403|Experimental|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
16544098|NCT02990403|Experimental|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
16544099|NCT02990403|Other|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
16544100|NCT02990377|Experimental|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
16544101|NCT02990377|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
16544102|NCT02990364|Active Comparator|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.
~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
16544103|NCT02990364|Active Comparator|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.
~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
16544104|NCT02990364|Active Comparator|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.
~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
16544105|NCT02990364|Active Comparator|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.
~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
16544360|NCT02988635|No Intervention|Standard of Care|Subjects receive standard of care.
16544106|NCT02990351||HCC patients|29 HCC patients who had loco regional therapies for HCC were analyzed. Twenty patients met the Milan criteria (68.97%) & 4 (13.8%) were beyond Milan but met UCSF criteria and 5 were exceeding UCSF criteria (17.2%).All patients underwent preoperative LRTs, The protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before LT and their outcomes after LT were recorded.
16544109|NCT02990325|Experimental|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
16544110|NCT02990325|Experimental|ABX464 50mg|ABX464, 50mg per Capsule One Capsule per day for 28 or 84 days
16544111|NCT02990312|Experimental|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
16544112|NCT02990299|No Intervention|Usual Care|Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will crossover to the mDAS intervention arm for one year.
16544113|NCT02990299|Experimental|mHealth for Diabetes Adherence Support|Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
16544114|NCT02990286|Experimental|Rituximab with Mycophenolate Mofetil|
16544115|NCT02990286|Placebo Comparator|Placebo of rituximab with Mycophenolate Mofetil|
16544116|NCT02990273|Active Comparator|TEG|Blood transfusion
16544117|NCT02990273|Active Comparator|Prothrombin Time (PT)/International normalized ratio (INR)|Blood transfusion
16544118|NCT02990260|Active Comparator|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
16544119|NCT02990260|Active Comparator|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
16544120|NCT02990260|Placebo Comparator|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
16544121|NCT02990247|Experimental|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
16544122|NCT02990234|Active Comparator|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
16544123|NCT02990234|Placebo Comparator|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
16544124|NCT02990221|Active Comparator|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
16544125|NCT02990221|Active Comparator|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
16544126|NCT02990208|Experimental|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
16544127|NCT02990208|Active Comparator|VR exposure|Virtual Reality Exposure Therapy
16544128|NCT02990195|Other|Double enterostomy|
16544129|NCT02990169|Active Comparator|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
16544130|NCT02990169|Active Comparator|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
16544131|NCT02990156|Experimental|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
16544132|NCT02990156|Active Comparator|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
16544133|NCT02990143|No Intervention|Glaucoma Drainage implant no Ologen|The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
16544134|NCT02990143|Active Comparator|Glaucoma Drainage implant with Ologen|the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
16544135|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
16544161|NCT02989948|Experimental|Main Arm - Physician-modified fenestrated endovascular graft|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
16544136|NCT02990117||Asthmatic patient|Asthma patients aged >18 in out-patient clinic of the first affiliated hospital of Xi'an Jiaotong university from November 2016 to January 2018 were investigated. A two-stage study was applied which was non-assumptive deep dive qualitative scoping to investigate the determinants of poor compliance in stage 1 asthma patients, and developed new questionnaire for cross sectional survey in stage 2 to obtain more accurate information about the critical issues on asthma management.
16544137|NCT02990091|Experimental|1,000mg/day n-3 HUFA|Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
16544138|NCT02990091|Experimental|4,000 mg/day n-3 HUFA|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
16544139|NCT02990091|Placebo Comparator|1 capsule safflower seed oil|Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
16544140|NCT02990091|Placebo Comparator|4 capsules safflower seed oil|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
16544141|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
16544142|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
16544143|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
16544144|NCT02990065|Experimental|PROTEIN-FORTIFIED DIET|The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
16544145|NCT02990065|No Intervention|STANDARD DIET|The standard diet consists on an energy goal based on weight formula (20-25 kcal/kg/die). According to the ICU nutritional protocol, EN is started at an initial rate of 10ml/h, and increased by 20ml/h every 12 hours in the absence of significant gastric residuals (<250ml), with the aim of reaching the energy goal within 72 hours from admission. The EN formulae used are standard (1-1,5 kcal/ml, 40g/l protein). If enteral nutrition is not tolerated or is not indicated, supplemental PN is used to make up the energy shortfall. The PN formula used is standard (1000 kcal/l, 37 g/l protein).
16544146|NCT02990052|Active Comparator|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
16544147|NCT02990052|Active Comparator|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
16544148|NCT02990039|Experimental|Counseling letter (intervention group)|Participants of the intervention group received a brief counseling letter intervention aiming to reduce sedentary time and to increase physical activity. The intervention comprised up to three tailored letters based on separate questionnaires.
16544149|NCT02990039|No Intervention|No counseling letter (control group)|Participants of the control group did not received the brief counseling letter intervention.
16544150|NCT02990026|Experimental|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
16544151|NCT02990026|Active Comparator|Control|Standard probation - delivered by a standard probation officer - care as usual
16544152|NCT02990013|Experimental|Treatment arm|All patients will be in the treatment arm where they will be subject to skin testing with various cleansing agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
16544153|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
16544154|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
16544155|NCT02989987|Active Comparator|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
16544156|NCT02989987|Active Comparator|Treatment-as-usual|Social support (provided on demand)
16544157|NCT02989974|Experimental|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
16544158|NCT02989974|Experimental|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
16544159|NCT02989961|Experimental|A-Resticutis|Autologous, Activated-Platelets type of preparation.
16544160|NCT02989961|Placebo Comparator|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
16544228|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
16544162|NCT02989948|Experimental|Expanded Access Arm - Physician-modified fenestrated endovascular graft.|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
16544163|NCT02989935|Experimental|Fluticasone vilanterol bronchodilator|"Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler.
~Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation."
16544164|NCT02989922|Experimental|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
16544165|NCT02989922|Experimental|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
16544166|NCT02989909|Active Comparator|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
16544167|NCT02989909|Experimental|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
16544168|NCT02989883|Other|Peroral endoscopic myotomy (POEM)|Patients who received POEM
16544169|NCT02989870|Experimental|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
16544170|NCT02989857|Active Comparator|AG-120 experimental study drug|AG-120, 500mg daily continuous dosing
16544171|NCT02989857|Placebo Comparator|AG-120 matched placebo|AG-120 matched placebo, daily continuous dosing. Subjects who experience disease progression and were receiving placebo, will be allowed to cross-over and receive AG-120
16544172|NCT02989844|Experimental|N-803|
16544173|NCT02989831|Experimental|Vibrating insoles 'on'|Duration: 30-60 seconds
16544174|NCT02989831|No Intervention|Vibrating insoles 'off'|Duration: 30-60 seconds
16544175|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
16544176|NCT02989805|Active Comparator|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
16544177|NCT02989805|Experimental|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
16544178|NCT02989792|Other|Unique study arm|
16544179|NCT02989779|Experimental|Active/Placebo crossover|NK1 Antagonist 7 days followed by placebo 7 days.
16544180|NCT02989779|Active Comparator|Placebo/Active Crossover|Placebo for 7 days followed by NK1 Antagonist 7 days.
16544181|NCT02989766|Active Comparator|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
16544182|NCT02989766|No Intervention|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
16544183|NCT02989753|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
16544184|NCT02989753|Experimental|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
16544185|NCT02989753|Experimental|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
16544186|NCT02989740||Group A|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
16544187|NCT02989740||Group B|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
16544188|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
16544189|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
16544190|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
16544191|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
16544192|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
16544193|NCT02989714|Experimental|HD IL2 and Nivolumab|
16544194|NCT02989701|Experimental|Single arm|
16544195|NCT02989688|Active Comparator|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
16544196|NCT02989688|Active Comparator|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
16544197|NCT02989688|Active Comparator|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
16544229|NCT02989402|Experimental|Rivastigmine patch|15 cm2 patch sizes loaded with 27 mg of rivastigmine
16544446|NCT02987933||Chronic Pain|Adults, > 6 months duration, daily pain
16544198|NCT02989675|Experimental|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
16544199|NCT02989675|No Intervention|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
16544200|NCT02989662|Active Comparator|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
16544201|NCT02989662|Placebo Comparator|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
16544202|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
16544203|NCT02989636|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
16544204|NCT02989636|Experimental|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
16544205|NCT02989623|Experimental|Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)|Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.
16544206|NCT02989610|Experimental|Omnidirectional followed by directional DBS|Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
16544207|NCT02989597|Experimental|Intra-operative Methadone Hydrochloride|Patient who will be given a single dose of intra-operative methadone, and having standard care otherwise
16544208|NCT02989597|Active Comparator|Control|Patients administered standard of care
16544209|NCT02989584|Experimental|Atezolizumab, Gemcitabine, Cisplatin|"This is a two phase study with a single study arm for each phase.
~For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.
~Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously."
16544210|NCT02989571|Placebo Comparator|Group 1 - Placebo Arm|Intravenous normal saline administered at 125ml/hr
16544211|NCT02989571|Active Comparator|Group 2 - Intervention Arm|Intravenous normal saline administered at 250ml/hr
16544212|NCT02989558|Active Comparator|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
16544213|NCT02989558|Active Comparator|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
16544214|NCT02989545|No Intervention|Off treatment|2 week period without intervention
16544215|NCT02989545|Experimental|Treatment period|2 week period with intervention
16544216|NCT02989519|No Intervention|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
16544217|NCT02989519|Experimental|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
16544218|NCT02989519|Experimental|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
16544219|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
16544220|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
16544221|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
16544222|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
16544223|NCT02989467|Active Comparator|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
16544224|NCT02989467|Placebo Comparator|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
16544225|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
16544226|NCT02989428|Experimental|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
16544227|NCT02989428|No Intervention|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
16544230|NCT02989389|Experimental|LY3323795 (Part A)|Participants received escalating doses of 0.3 mg (milligrams), 1 mg, 3 mg, 10 mg, 30 mg and 100 mg of LY3323795 orally.
16544231|NCT02989389|Placebo Comparator|Placebo (Part A)|Participants received placebo identical to LY3323795 orally.
16544232|NCT02989389|Experimental|LY3323795 (Part B)|Participants received 6 mg, 20 mg and 80 mg of LY3323795 orally.
16544233|NCT02989389|Placebo Comparator|Placebo (Part B)|Participants received placebo identical to LY3323795 orally.
16544234|NCT02989389|Experimental|LY3323795 (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
16544235|NCT02989389|Experimental|LY3323795 + Itraconazole (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
16544236|NCT02989376|Experimental|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
16544237|NCT02989363|Experimental|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
16544238|NCT02989363|Experimental|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
16544239|NCT02989363|Experimental|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
16544240|NCT02989363|Experimental|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
16544241|NCT02989350|Active Comparator|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
16544242|NCT02989350|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
16544243|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
16544244|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
16544245|NCT02989324|Experimental|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
16544246|NCT02989324|Active Comparator|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
16544247|NCT02989311|Active Comparator|Study 1:Morning test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the morning test meal A:12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe.
~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
16544248|NCT02989311|Active Comparator|Study 1:Afternoon test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the afternoon test meal B:12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10mg of 56Fe.
~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
16544249|NCT02989311|Active Comparator|Study 2: Consecutive meals+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meals:Test meal A will contain 12mg of ferrous sulphate given as 2mg 54Fe and 10mg 56Fe. Test meal B will contain 12mg of ferrous sulphate given as 2mg 57Fe and 10mg 56Fe.
~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
16544250|NCT02989311|Active Comparator|Study 2:Alternate meal+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meal C: 12mg of ferrous sulphate given as 2mg 58Fe and 10mg.
~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
16544251|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
16544252|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
16544253|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
16544254|NCT02989272|Placebo Comparator|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
16544255|NCT02989272|Experimental|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
16544256|NCT02989259|Experimental|apatinib|apatinib 500mg p.o. qd
16544258|NCT02989233|Active Comparator|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544259|NCT02989233|Active Comparator|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544260|NCT02989233|Active Comparator|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544261|NCT02989233|Active Comparator|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544262|NCT02989233|Active Comparator|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544263|NCT02989233|Active Comparator|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544264|NCT02989233|Active Comparator|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544265|NCT02989233|Active Comparator|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544266|NCT02989233|Active Comparator|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544267|NCT02989233|Active Comparator|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544268|NCT02989233|Active Comparator|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544269|NCT02989233|Active Comparator|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
16544270|NCT02989220|Experimental|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
16544271|NCT02989220|No Intervention|Control Group|Will follow the current recommended care pathway
16544272|NCT02989207|Active Comparator|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
16544273|NCT02989207|Active Comparator|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
16544274|NCT02989207|Active Comparator|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
16544275|NCT02989194|Experimental|VIS410 low dose|Single intravenous fixed low dose of VIS410
16544276|NCT02989194|Experimental|VIS410 high dose|Single intravenous fixed high dose of VIS410
16544277|NCT02989194|Placebo Comparator|Placebo|Single intravenous placebo infusion
16544278|NCT02989181|Experimental|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
16544279|NCT02989181|No Intervention|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
16544280|NCT02989168|Experimental|GBT440 900 mg Dose|"Part A, 900 mg
~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
16544281|NCT02989168|Experimental|GBT440 1500 mg Dose|"Part B , 1500 mg
~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
16544282|NCT02989142|No Intervention|Control arm|No intervention
16544283|NCT02989142|Experimental|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.
~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
16544284|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.
~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
16544285|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.
~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
16544286|NCT02989116|Experimental|Preterm Inhibition|"In children born very preterm:
~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
16544287|NCT02989116|Experimental|Full-term Inhibition|"In children born full-term:
~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
16544288|NCT02989116|Experimental|Full-term Working memory|"In children born full-term:
~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
16544289|NCT02989116|Experimental|Full-term Mindfulness|"In children born full-term:
~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
16544290|NCT02989116|Active Comparator|Full-term Active control|"In children born full-term:
~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
16544291|NCT02989103||Hyperthyroidism Follow-up Cohort Study|Hyperthyroid patients enrolled and treated between 1946 and 1964 in 25 U.S. and 1 UK site
16544292|NCT02989090|Experimental|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
16544293|NCT02989090|Active Comparator|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
16544294|NCT02989090|No Intervention|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
16544295|NCT02989077||Group A|Having combined coronary and cerebral ischemia.
16544296|NCT02989077||Group B|Having only coronary ischemia
16544297|NCT02989077||group C|Having only cerebral ischemia
16544298|NCT02989064|Experimental|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
16544299|NCT02989051|Experimental|Restrictive fluid treatment|Restrictive fluid regimen
16544327|NCT02988921|Experimental|Esophageal or esophagogastric cancer|
16544300|NCT02989051|Active Comparator|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
16544301|NCT02989038|Experimental|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
16544302|NCT02989038|Experimental|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
16544303|NCT02989038|Experimental|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
16544304|NCT02989038|Experimental|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
16544305|NCT02989038|Experimental|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
16544306|NCT02989038|Experimental|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
16544307|NCT02989025|Experimental|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
16544308|NCT02989012|Experimental|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
16544309|NCT02989012|Sham Comparator|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
16544310|NCT02988999|Experimental|D-allulose|D-allulose 5 gm 3 times a day
16544311|NCT02988999|Active Comparator|erythritol|erythritol 5 gm 3 times a day
16544312|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.
~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
16544313|NCT02988973|Experimental|rHuEPO or DA to ASP1517|Participants will receive roxadustat according to the prior randomization treatment, with starting doses of 70mg thrice weekly (TIW) to participants on <4500 IU/week of rHuEPO or <20 microgram (μg)/week of darbepoetin alfa (DA) and 100mg TIW to participants on ≥4500 IU/week rHuEPO or ≥ 20 μg/week DA. Participants roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
16544314|NCT02988973|Experimental|rHuEPO or DA to DA|Participants will receive DA according to the prior randomization treatment, with starting doses of 15 μg/2weeks to participants on ≤ 1500 IU/week of rHuEPO or <11.25 microgram (μg)/week of DA, 30μg/2weeks to participants on >1500 to <6000 IU/week of rHuEPO or ≥ 11.25 to < 22.5 μg/week of DA, 60μg/2weeks to participants on ≥ 6000 IU/week of rHuEPO or ≥ 22.5 to < 37.5 μg/week of DA, 90μg/2weeks to participants on ≥ 37.5 to < 52.5 μg/week of DA, 120μg/2weeks to participants on ≥ 52.5 to < 75 μg/week of DA, 180μg/2weeks to participants on ≥ 75 μg/week of DA. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 15, 30, 60, 90, 120, and 180 μg.
16544315|NCT02988973|Experimental|Epoetin beta pegol to ASP1517|Participants will receive roxadustat according to the prior registration treatment, with starting doses of 70mg thrice weekly (TIW) to participants on ≤100 μg/week of Epoetin beta pegol and 100mg TIW to participants on >100 μg/week of Epoetin beta pegol. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
16544325|NCT02988947|Experimental|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
16544326|NCT02988947|No Intervention|Control Group|No intervention / Standard care
16544328|NCT02988908|Experimental|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.
~Participants also received 2 weeks of memory training at weeks 13-14"
16544329|NCT02988908|Placebo Comparator|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.
~Participants also received 2 weeks of memory training at weeks 13-14"
16544330|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
16544331|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
16544332|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
16544333|NCT02988869|Experimental|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
16544334|NCT02988869|Active Comparator|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
16544335|NCT02988869|Active Comparator|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
16544336|NCT02988856|Experimental|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
16544337|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.
~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
16544338|NCT02988830|Experimental|Chronic lumbar pain|
16544339|NCT02988817|Experimental|Enapotamab vedotin (HuMax-AXL-ADC)|All arms of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC)
16544340|NCT02988804|Active Comparator|endotracheal tube|"Procedure: Endotracheal tube
~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:
~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)
~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)
~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
16544341|NCT02988804|Active Comparator|Laryngeal mask|"Procedure: Laryngeal mask
~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:
~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)
~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)
~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
16544342|NCT02988791|Experimental|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
16544343|NCT02988791|Placebo Comparator|Placebo|Placebo
16544344|NCT02988778|Experimental|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
~Treatment of 28 days."
16544345|NCT02988778|Active Comparator|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
~Treatment of 28 days."
16544346|NCT02988765|Experimental|Invasive vulvar cancer (IVC)|"Vulvar carcinoma (stromal infiltration > 1 mm)
~Histotypes different from squamous cells carcinomas are included"
16544347|NCT02988752|Experimental|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
16544348|NCT02988752|Active Comparator|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
16544349|NCT02988739|Experimental|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.
~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
16544350|NCT02988739|Active Comparator|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
16544351|NCT02988726|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
16544352|NCT02988713|Experimental|Spinal cord stimulation|Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
16544353|NCT02988700|Active Comparator|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
~be given by ."
16544354|NCT02988700|Active Comparator|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
16544355|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
16544356|NCT02988661|Active Comparator|Chronic Disease Self-management Program (CDSMP)|A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
16544357|NCT02988661|No Intervention|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
16544358|NCT02988648|Experimental|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
16544361|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
16544362|NCT02988609|Experimental|Concussion Group|Players with a recent (<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
16544363|NCT02988609|Active Comparator|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
16544364|NCT02988596|Active Comparator|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich/Berlin protocol). This protocol will follow the Zurich/Berlin guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
16544365|NCT02988596|Experimental|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich/Berlin protocol).
16544366|NCT02988583|Experimental|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
16544367|NCT02988583|Active Comparator|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
16544368|NCT02988570|Experimental|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
16544369|NCT02988557|Experimental|Treadmill|
16544370|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
16544371|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
16544372|NCT02988531|Experimental|PET/MR|Participants to have PET/MR scan
16544373|NCT02988518|Experimental|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
16544374|NCT02988492|Other|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
16544375|NCT02988466|Experimental|Arm A: Haplo-HCT <55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients <55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2
16544376|NCT02988466|Experimental|CLOSED Arm B: Haplo-HCT ≥55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
16544377|NCT02988466|Experimental|Arm C: Haplo-HCT HCT-CI ≤2 aged ≥55 and < 65yo|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and < 65 years old.
16544378|NCT02988466|Experimental|Arm D: Haplo-HCT aged ≥65 and ≤75yo OR any age HCT-CI ≥3|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
16544379|NCT02988453|Experimental|MBT-CD|Mentalization-based treatment program
16544380|NCT02988440|Other|PDR001 + Sorafenib|PDR001 at 400 mg given intravenously every 4 weeks and sorafenib 400 mg taken orally once or twice per day (escalating doses)
16544381|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
16544382|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
16544383|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
16544384|NCT02988401|Experimental|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
16544385|NCT02988401|Experimental|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
16544386|NCT02988401|Placebo Comparator|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
16544387|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
16544388|NCT02988375|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
16544389|NCT02988375|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
16544390|NCT02988362|Experimental|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
16544391|NCT02988362|Experimental|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
16544392|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
16544393|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
16544394|NCT02988323|Experimental|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
16544395|NCT02988323|Experimental|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
16544396|NCT02988323|Other|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
16544397|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
16544398|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
16544399|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
16544400|NCT02988297|Experimental|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
16544401|NCT02988297|Placebo Comparator|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
16544402|NCT02988271|Experimental|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
16544403|NCT02988271|Active Comparator|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
16544404|NCT02988258|Experimental|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^4 T cells/kg recipient weight
16544405|NCT02988258|Experimental|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^5 T cells/kg recipient weight
16544406|NCT02988258|Experimental|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10^3 T cells/kg recipient weight
16544407|NCT02988245|Experimental|Genetically-Guided Treatment for HTN|Using a patient's genetic composition to guide BP prescribing for patients with hypertension, post diagnosis.
16544408|NCT02988245|Active Comparator|JNC-8-Guided Treatment|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension, post diagnosis.
16544409|NCT02988232|Experimental|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
16544410|NCT02988232|Placebo Comparator|Placebo|admission to placebo
16544411|NCT02988219|Active Comparator|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
16544412|NCT02988219|Experimental|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
16544413|NCT02988206|Other|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
16544414|NCT02988206|Other|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
16544415|NCT02988193|Experimental|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:
~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;
~medication treatment recommendation;
~active link to access additional treatment analysis tools."
16544416|NCT02988193|No Intervention|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
16544417|NCT02988180|Other|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
16544418|NCT02988180|Other|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
16544419|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
16544420|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
16544421|NCT02988115|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
16544422|NCT02988115|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
16544423|NCT02988089|Experimental|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.
~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.
~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
16544424|NCT02988089|Experimental|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
16544425|NCT02988089|Other|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
16544426|NCT02988089|Other|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
16544427|NCT02988076|No Intervention|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
16544428|NCT02988076|Active Comparator|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
16544429|NCT02988063|Experimental|Compression plus PEM|Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy. If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
16544430|NCT02988050|Other|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
16544431|NCT02988050|Other|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
16544432|NCT02988037|Experimental|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
16544433|NCT02988024|Experimental|LY03005|LY03005 80 mg
16544434|NCT02988024|Active Comparator|Pristiq|Pristiq 50 mg
16544435|NCT02988011|Active Comparator|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
16544436|NCT02988011|Active Comparator|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
16544437|NCT02987998|Experimental|Resectable Patients|Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy
16544438|NCT02987985|Experimental|Opioid-free anesthesia|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis
16544439|NCT02987985|Active Comparator|Opioid-sparing anesthesia|Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis
16544440|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
16544441|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
16544442|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
16544443|NCT02987959|Experimental|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
16544444|NCT02987946|Active Comparator|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
16544445|NCT02987946|Experimental|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
16544448|NCT02987920|Active Comparator|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.
~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
16544449|NCT02987920|Experimental|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet
~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
16544450|NCT02987907|Experimental|treatment group|use dexamethasone 10mg (2ml) I.A. during TACE
16544451|NCT02987907|Placebo Comparator|control group|use normal saline 2ml I.A. during TACE
16544452|NCT02987881|Experimental|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
16544453|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
16544454|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
16544455|NCT02987855|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
16544456|NCT02987855|Experimental|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
16544457|NCT02987855|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
16544458|NCT02987842|Experimental|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
16544459|NCT02987842|Sham Comparator|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
16544460|NCT02987829|Experimental|Dose Level 1: TRC253 40 mg daily|40 mg of single-agent TRC253 to be administered as oral capsules once daily
16544461|NCT02987829|Experimental|Dose Level 2: TRC253 80 mg|80 mg of single-agent TRC253 to be administered as oral capsules once daily
16544462|NCT02987829|Experimental|Dose Level 3: TRC253 160 mg|160 mg of single-agent TRC253 to be administered as oral capsules once daily
16544463|NCT02987829|Experimental|Dose Level 4: TRC253 240 mg|240 mg of single-agent TRC253 to be administered as oral capsules once daily
16544464|NCT02987829|Experimental|Dose Level 5: TRC253 280 mg|280 mg of single-agent TRC253 to be administered as oral capsules once daily
16544465|NCT02987829|Experimental|Dose Level 6: TRC253 320 mg|320 mg of single-agent TRC253 to be administered as oral capsules once daily
16544466|NCT02987816|Sham Comparator|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
16544467|NCT02987816|Experimental|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
16544470|NCT02987790|Experimental|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are <35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak > 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
16544471|NCT02987790|No Intervention|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:
~7 full days for most infections
~10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.
~14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
16544472|NCT02987764|Experimental|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
16544473|NCT02987764|No Intervention|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
16544474|NCT02987751|Experimental|Glargine + Glulisine|Insulin Glargine + Glulisine (12U/day + 4U/day) at pre-breakfast/dinner for 24 weeks
16544475|NCT02987751|Active Comparator|Premixed Analogue Insulin (70/30)|Premixed analogue Insulin (70/30) 16U/day at pre-breakfast/dinner for 24 weeks
16544476|NCT02987738|Experimental|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
16544477|NCT02987738|Placebo Comparator|Placebo Oral Tablets|two administrations identical to the experimental drug
16544478|NCT02987725|Active Comparator|Attention Control|Participants will listen to a 30-minute historical story.
16544479|NCT02987725|Experimental|Hypnosis|Participants will receive a 30-minute hypnosis session
16544480|NCT02987712|No Intervention|Survey 1|Common practice
16544481|NCT02987712|Experimental|Survey 2|Thromboelastography based protocol
16544482|NCT02987699|Experimental|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
16544483|NCT02987699|Experimental|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
16544484|NCT02987699|Experimental|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
16544485|NCT02987686|Experimental|Topical Infliximab|Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
16544486|NCT02987686|No Intervention|Observational group|Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
16544487|NCT02987673|Experimental|Mini/One anastomosis gastric bypass|Execution of a laparoscopic mini/one anastomosis gastric bypass (MGB/OAGB)
16544488|NCT02987673|Active Comparator|Laparoscopic sleeve gastrectomy|Execution of a laparoscopic sleeve gastrectomy (LSG)
16544489|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
16544490|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
16544491|NCT02987647|Experimental|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.
~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
16544492|NCT02987647|Active Comparator|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.
~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
16544493|NCT02987647|Active Comparator|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.
~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
16544494|NCT02987647|Active Comparator|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.
~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
16544495|NCT02987634|Experimental|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
16544496|NCT02987634|Active Comparator|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
16544497|NCT02987621|Experimental|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.
~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.
~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
16544498|NCT02987621|Experimental|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.
~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.
~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
16544499|NCT02987608|No Intervention|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
16544500|NCT02987608|Experimental|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
16544501|NCT02987595|Experimental|Whole-grain rye then wheat|Whole-grain rye, high lignan Whole-grain rye products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain wheat products for 8 weeks
16544502|NCT02987595|Experimental|Whole-grain wheat then rye|Whole-grain wheat, low lignan Whole-grain wheat products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain rye products for 8 weeks
16544504|NCT02987569|Experimental|Group One|Intervention
16544505|NCT02987569|Active Comparator|Group Two|Control
16544506|NCT02987556|Active Comparator|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
16544507|NCT02987556|Experimental|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
16544508|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
16544538|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
16544539|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
16544509|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:
~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.
~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
16544510|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
16544511|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
16544512|NCT02987517|Experimental|Cadence|Runners who use an increased running cadence of 7.5 percent over preferred running cadence.
16544513|NCT02987517|Experimental|Forefoot Strike|Runners who use a forefoot strike instead of a rear foot strike
16544514|NCT02987504|Experimental|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.
~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
16544515|NCT02987491|Experimental|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.
~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
16544516|NCT02987491|No Intervention|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.
~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
16544517|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
16544518|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
16544519|NCT02987452|Experimental|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
16544520|NCT02987452|Active Comparator|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
16544521|NCT02987452|Active Comparator|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
16544522|NCT02987439|No Intervention|Standard care group|"Standard medical treatment for the exacerbation of COPD
~Standard medical treatment of COPD according to GOLD
~A visit by a pulmonary nurse at the patients own home 3-5 days after discharge. Lung function and smoking history is recorded. Correct use of inhaler is instructed.
~Visit in the outpatient clinic within the next 2-6 months after discharge as follow-up
~In the outpatient clinic they will receive an offer of pulmonary rehabilitation"
16544523|NCT02987439|Experimental|Rehabilitation group|"The group will begin pulmonary rehabilitation during hospital admission. Afterwards a rehabilitation program twice weekly for 7 weeks.
~Beside rehabilitation they will receive same treatment as the standard care group"
16544524|NCT02987426|Experimental|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
16544525|NCT02987426|No Intervention|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
16544526|NCT02987413|Experimental|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
16544527|NCT02987400|Experimental|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
16544528|NCT02987387||TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
16544529|NCT02987374|Other|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
16544530|NCT02987361|Experimental|treatment group 1|anodal stimulation on the lesioned primary motor cortex DC-STIMULATOR PLUS
16544531|NCT02987361|Experimental|treatment group 2|cathodal stimulation on the non-lesioned primary motor cortex DC-STIMULATOR PLUS
16544532|NCT02987361|Experimental|treatment group 3|dual stimulation such as anodal stimulation on the lesioned side and cathodal stimulation on the non-lesioned side DC-STIMULATOR PLUS
16544533|NCT02987361|Sham Comparator|sham group|sham group
16544534|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
16544535|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
16544536|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
16544537|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
16544692|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
16544540|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
16544541|NCT02987335||Nondiabetic Subjects|N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
16544542|NCT02987322|Experimental|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
16544543|NCT02987296|Active Comparator|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
16544544|NCT02987296|Placebo Comparator|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
16544545|NCT02987270|Experimental|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
16544546|NCT02987270|No Intervention|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
16544547|NCT02987257|Placebo Comparator|Harmonized supportive care|Harmonized supportive care with placebo cyclosporine days 0-14 and etanercept placebo days 0 and 3
16544548|NCT02987257|Active Comparator|Cyclosporine 5mg/kg bid days 0-14|Harmonized supportive care with placebo etanercept days 0 and 3
16544549|NCT02987257|Active Comparator|Etanercept 50mg sc day 0 and day 3|Harmonized supportive care with placebo cyclosporine days 0-14
16544550|NCT02987244|Experimental|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
16544551|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
16544552|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
16544553|NCT02987218|Active Comparator|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
16544554|NCT02987218|Active Comparator|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
16544555|NCT02987205|Experimental|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
16544556|NCT02987205|Active Comparator|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
16544557|NCT02987192|Experimental|traditional group|Traditional group patients will receive cutting type 22 gauge needles
16544558|NCT02987192|Experimental|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
16544559|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.
~Age ≥18 years and able to give written informed consent to the study
~On chronic hemodialysis for ≥ 90 days at time of enrollment
~Ability to read
~Consent to have video recording taken during study visit"
16544560|NCT02987166|Experimental|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.
~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.
~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
16544561|NCT02987166|Experimental|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.
~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.
~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
16544594|NCT02986893|Experimental|Dietary Intervention Arm|Participants will be assigned to follow a specific dietary intervention for 6 months
16544595|NCT02986893|Experimental|Non-dietary Intervention Arm|Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
16544693|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
16544562|NCT02987166|Experimental|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.
~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.
~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
16544563|NCT02987153|Experimental|KYPHO-IORT - 10 Gy and Kyphoplasty|Intra-operative radiation therapy followed by standard kyphoplasty
16544564|NCT02987140|Experimental|PD+FoG|PD patients with FoG
16544565|NCT02987140|Active Comparator|PD-FoG|PD patients without FoG
16544566|NCT02987140|Active Comparator|Control|age-matched non-disabled adults
16544567|NCT02987114|Experimental|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
16544568|NCT02987101|Experimental|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.
~Standard wound care is given independent of this study."
16544569|NCT02987101|Other|Standard of care|Standard wound care is given independent of this study.
16544570|NCT02987075|Other|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
16544571|NCT02987075|Other|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
16544572|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
16544573|NCT02987062||Warfarin|Patients with AF treated with warfarin.
16544574|NCT02987062||Apixaban|Patients with AF treated with apixaban.
16544575|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
16544576|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
16544577|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
16544578|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
16544579|NCT02987036|Experimental|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
16544580|NCT02987036|Other|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
16544581|NCT02987010|Experimental|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
16544582|NCT02987010|Experimental|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
16544583|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
16544584|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
16544585|NCT02986971|Experimental|New IMD|Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
16544586|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
16544587|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
16544588|NCT02986945|Experimental|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT-an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.
~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
16544589|NCT02986945|Other|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
16544590|NCT02986932|Experimental|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
16544591|NCT02986919|Experimental|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
16544592|NCT02986906|Experimental|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
16544593|NCT02986906|Active Comparator|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
16544656|NCT02986529|Experimental|GV-971 450mg/capsule|900mg, oral
16544596|NCT02986880|Experimental|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
16544597|NCT02986880|Experimental|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
16544598|NCT02986880|Experimental|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
16544599|NCT02986880|Experimental|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
16544600|NCT02986880|Experimental|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
16544601|NCT02986880|Experimental|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
16544602|NCT02986880|Experimental|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
16544603|NCT02986880|Experimental|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
16544604|NCT02986880|Experimental|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
16544605|NCT02986880|Placebo Comparator|Group P|Patients receiving placebo in the third muscles groups
16544606|NCT02986867|Experimental|SAbR|SAbR treatment of lesions
16544607|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
16544608|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
16544609|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
16544610|NCT02986828|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
16544611|NCT02986828|Active Comparator|Normal saline|Normal saline for ultrasound-guided hydrodissection
16544612|NCT02986815|Experimental|[11C]Acetate Brain Imaging|[11C]Acetate will be administered The patient will have one intravenous line placed prior to [11C]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which [11C]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
16544613|NCT02986802||Genital herpes treated before third trimester|Women with genital herpes receiving treatment before the 3rd trimester
16544614|NCT02986802||Genital herpes treated only during third trimester|Women with genital herpes receiving treatment during the 3rd trimester
16544615|NCT02986802||Genital herpes untreated|Women with untreated genital herpes
16544616|NCT02986802||Control group|Women (controls) with neither genital herpes nor treatment
16544617|NCT02986776|Active Comparator|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
16544618|NCT02986776|Active Comparator|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
16544619|NCT02986776|Active Comparator|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
16544620|NCT02986776|Active Comparator|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
16544621|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
16544622|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
16544623|NCT02986750|Experimental|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
16544624|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
16544625|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
16544626|NCT02986737|Experimental|ACURATE neo™ and ACURATE TA™ LP|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System
16544627|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
16544628|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
16544629|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
16544657|NCT02986529|Placebo Comparator|Placebo|Oral
16544658|NCT02986516|Experimental|Randomized Cohort|Participants who will decided to undergo to randomization, will receive surgical treatment or definitive radiotherapy according with randomization assignment
16544659|NCT02986516|Active Comparator|Prospective Cohort|Participants who will not decide to be randomized, will received the surgical or definite radiotherapy treatment according to their choice
16544694|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
16544630|NCT02986698|Experimental|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).
~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
16544631|NCT02986685|Experimental|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
16544632|NCT02986685|Other|rabeprazole|rabeprazole 20mg once daily
16544633|NCT02986672|Active Comparator|Calanus oil|Children receiving omega-3 in form om calanus oil in capsule form
16544634|NCT02986672|Placebo Comparator|Placebo|Children receiving medical paraffin in capsule form (2 ml volume per day)
16544635|NCT02986659|Active Comparator|Metformin then Placebo|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months. Will then cross over to 3 months on placebo.
16544636|NCT02986659|Placebo Comparator|Placebo then Metormin|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months. After 3 months on placebo, participants will then cross over to 3 months of metformin as described in the other arm.
16544637|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
16544638|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
16544639|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
16544640|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
16544641|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
16544642|NCT02986607|Experimental|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.
~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
16544643|NCT02986594|Experimental|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
16544644|NCT02986594|Experimental|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
16544645|NCT02986594|Experimental|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
16544646|NCT02986568|Experimental|Cervical cancer|"Primary cervical cancer patients, FIGO stage IB1-IIB
~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy
~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
16544647|NCT02986568|Experimental|Uterine cancer|"Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA
~Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy
~Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy"
16544648|NCT02986568|Experimental|Cervical cancer, pelvic sidewall invasion|"Cervical cancer patients showing pelvic sidewall invasion
~Primary cervical cancer
~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy
~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
16544649|NCT02986568|Experimental|Non-cervical cancer, pelvic sidewall invasion|"Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis
~Patients showing uncontrolled pelvic pain due to the tumor invasion"
16544650|NCT02986555|Placebo Comparator|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
16544651|NCT02986555|Active Comparator|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
16544652|NCT02986542|Active Comparator|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
16544653|NCT02986542|Active Comparator|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
16544654|NCT02986529|Active Comparator|GV-971 150mg/capsule|900mg, oral
16544655|NCT02986529|Experimental|GV-971 300mg/capsule|900mg, oral
16544660|NCT02986503||Chemotherapy for Good responder|Doxorubicin + cisplatin + ifosfamide Pre-operative and post-operative chemotherapy for patients with good responder high grade osteosarcoma
16544661|NCT02986503||Chemotherapy for Poor responder|Doxorubicin+cisplatin+ifosfamide+methotrexate Pre-operative and post-operative chemotherapy for patients with poor responder high grade osteosarcoma
16544662|NCT02986490|Other|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
16544663|NCT02986477|Other|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
16544664|NCT02986464|Active Comparator|Standard pharmacological treatment|
16544665|NCT02986464|Experimental|Virtual Reality distraction|
16544666|NCT02986451|Experimental|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
16544667|NCT02986438|Active Comparator|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
16544668|NCT02986438|Sham Comparator|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
16544669|NCT02986425|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
16544670|NCT02986425|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
16544671|NCT02986412|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
16544672|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
16544673|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
16544674|NCT02986386|Experimental|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
16544675|NCT02986386|Other|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
16544676|NCT02986386|Experimental|Intervention 2|Orthodontic treatment of malocclusion.
16544677|NCT02986386|Other|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
16544678|NCT02986373|Experimental|Risankizumab|Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.
16544679|NCT02986360|Active Comparator|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
16544680|NCT02986360|No Intervention|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
16544681|NCT02986347|Active Comparator|Intravenous regional anesthesia (Bier)|The anesthetic technique described by Bier will be done by the anesthesiologist. The following steps were followed: 1)Placement double tourniquet on the proximal portion of the arm 2)Asepsis and antisepsis of the operative limb 3)Puncture and venous catheterization most distal in the limb 4)Elevation of limb for 1 to 2 minutes, next the limb will be spirally wrapped with Esmarch from the distal to proximal 5)The proximal cuff will be inflated 6)Withdrawal of Esmarch and injection of 40ml of lidocaine without epinephrine at 0.5% 7)Removal the canula until the distal cuff is inflated and the proximal cuff is emptied 8)Removal of the club must be done after the surgery, at least 40 minutes after the injection of the anesthetic.
16544682|NCT02986347|Active Comparator|Local anesthesia with adrenaline|Patients will be anesthetized by surgeons, who are familiar with the technique described by Lalonde. Around thirty minutes before surgery, will be infused with 20 ml of an anesthetic solution. The infiltrated solution is composed of 1% lidocaine with epinephrine in 1: 100,000. Initially 10 mL of the solution will be applied slowly in the flexion fold region of the wrist just below the skin and subfascial plane. The needle is moved slowly. The needle is then redirected to the radial side of the proximal palmar region for infiltration of another 2-3 mL of the subcutaneous solution. The remaining 7-8mL in the subdermal plane and anterior to the transverse carpal ligament.
16544683|NCT02986334|No Intervention|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
16544684|NCT02986334|Active Comparator|Active Treatment Intervention|Naproxen & Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
16544685|NCT02986334|Placebo Comparator|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
16544686|NCT02986321|Experimental|CHF6001 DOSE1|DOSE1
16544687|NCT02986321|Experimental|CHF6001 DOSE2|DOSE2
16544688|NCT02986321|Experimental|CHF6001 DOSE3|DOSE3
16544689|NCT02986321|Experimental|CHF6001 DOSE4|DOSE4
16544695|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
16544696|NCT02986282|Other|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
16544697|NCT02986269|Experimental|Group SB|"Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is spontaneous breathing(SB) without pressure support ventilation (PSV) under laryngeal mask airway (LMA).
~General anesthesia across LMA under SB without PSV"
16544698|NCT02986269|Active Comparator|Group PSV|General anesthesia across LMA under SB with PSV Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is SB with PSV under LMA.
16544699|NCT02986256|No Intervention|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
16544700|NCT02986256|Experimental|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
16544701|NCT02986243|Experimental|Treatment|Subjects receive a diet plan and exercise regimen.
16544702|NCT02986230|Experimental|PCP-focused group|The PCP-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
16544703|NCT02986230|Experimental|SDMT-focused group|The SDMT-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The SDMT-focused arm also provides shared decision making tools to patient and provider at the time of the visit.
16544704|NCT02986217|No Intervention|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
16544705|NCT02986217|Experimental|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
16544706|NCT02986204|Other|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
16544707|NCT02986204|Other|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
16544708|NCT02986191|Experimental|Mucograft|One side of the mouth will be subjected to Mucograft in this split-mouth study design.
16544709|NCT02986191|Active Comparator|Connective tissue graft|The opposite side of the mouth will be subjected to a connective tissue graft.
16544710|NCT02986178|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|Polio/Rhinovirus Recombinant (PVSRIPO)
16544711|NCT02986165|Placebo Comparator|Placebo control|100 g of flavoured water
16544712|NCT02986165|Experimental|Low dose pomace extract|1 g pomace extract powder
16544713|NCT02986165|Experimental|High dose pomace extract|2.5 g pomace extract powder
16544714|NCT02986152|Experimental|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
16544715|NCT02986152|Other|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
16544716|NCT02986139|Experimental|Sequence AB|Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
16544717|NCT02986139|Experimental|Sequence BA|Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).
16544718|NCT02986126|Active Comparator|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
16544758|NCT02985892|Experimental|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
16544759|NCT02985892|Experimental|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
16544912|NCT02984826|Active Comparator|Strength training|Intervention with specific strength training program runs for 10 weeks.
16544719|NCT02986126|Active Comparator|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
16544720|NCT02986113|Experimental|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
16544721|NCT02986113|Active Comparator|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
16544722|NCT02986100|Experimental|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.
~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
16544723|NCT02986087|Experimental|Fetal Tracheal Occlusion|Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.
16544724|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
16544725|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
16544726|NCT02986061|Active Comparator|Control Group|Patients with indwelling urinary catheter
16544727|NCT02986061|No Intervention|Study Group|Patients without indwelling urinary catheter
16544728|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
16544729|NCT02986035|Experimental|Intervention|
16544730|NCT02986022|Experimental|Resilience|Participants will receive four sessions covering Resilience intervention content
16544731|NCT02986022|Active Comparator|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
16544732|NCT02986009|Experimental|Parenting|To receive the parenting intervention
16544733|NCT02986009|Experimental|Information|To receive the information intervention
16544734|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
16544735|NCT02985996|Experimental|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
16544736|NCT02985996|Experimental|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
16544737|NCT02985996|Experimental|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
16544738|NCT02985996|Experimental|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
16544739|NCT02985983|Experimental|KHK4827|KHK4827 administered SC
16544740|NCT02985983|Placebo Comparator|Placebo|Placebo administered SC
16544741|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
16544749|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
16544750|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
16544751|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
16544752|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
16544753|NCT02985931||Suspected CAD subjects|
16544754|NCT02985918|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
16544755|NCT02985918|Active Comparator|Conventional-intensity NPPV|The patients will receive conventional-intensity noninvasive positive pressure ventilation.
16544756|NCT02985905|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
16544757|NCT02985905|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
16544760|NCT02985879|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection/Solution for Infusion; intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks
16544761|NCT02985879|Experimental|ABBV-8E12 2000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
16544762|NCT02985879|Experimental|ABBV-8E12 4000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
16544763|NCT02985866|Experimental|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
16544764|NCT02985866|Active Comparator|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
16544765|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
16544766|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
16544767|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
16544768|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
16544769|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.
16544770|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
16544771|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
16544772|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
16544773|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
16544774|NCT02985775|Experimental|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
16544775|NCT02985762|Other|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
16544776|NCT02985749|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
16544777|NCT02985736|Experimental|open label|
16544778|NCT02985723|Experimental|939MP|AT LISA tri toric 939MP intraocular lens
16544779|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
16544780|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
16544781|NCT02985697|Experimental|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
16544782|NCT02985697|Experimental|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
16544783|NCT02985697|Experimental|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
16544784|NCT02985697|Active Comparator|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
16544785|NCT02985684|Experimental|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
16544786|NCT02985671|Experimental|Experimental Drug & Voltaren Placebo|"Orphenadrine + acetaminophen + caffeine + diclofenac sodium & Placebo of Voltaren
~01 tablet of experimental drug (orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg) + 01 tablet of placebo of Voltaren, to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
16544851|NCT02985242|Experimental|Empagliflozin/glimepiride placebo|"Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily
~Duration of treatment: 12 months"
16544913|NCT02984826|Active Comparator|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
16544787|NCT02985671|Active Comparator|Voltaren® + Experimental Drug Placebo|"Voltaren & Placebo of Orphenadrine + acetaminophen + caffeine + diclofenac sodium
~01 tablet of Voltaren + 01 tablet of placebo of experimental drug (orphenadrine, acetaminophen, caffeine and diclofenac sodium), to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
16544788|NCT02985645|Experimental|Treatment|maxillary sinus augmentation with CGF
16544789|NCT02985632|Experimental|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
16544790|NCT02985632|Experimental|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
16544791|NCT02985632|Experimental|Healthy Subjects|Subjects given an oral dose of BMS-986141.
16544792|NCT02985619|Active Comparator|IVB randomised group II|"Randomised patients (IVB group II) with central foveal thickness >300µm on OCT were submitted to 6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata, or as needed), with monthly visits for central subfoveal thickness map more than 300µm by Optic Coherence Tomography."
16544793|NCT02985619|Active Comparator|IVT randomised group I|Randomised patients (IVT group I) with central foveal thickness >300µm on OCT were submitted to 6 months treatment with 0.03ml (1.20mg) intravitreous injection of triamcinolone each 3 months (prn, as needed) for central sufoveal thickness map more than 300µm by Optic Coherence Tomography.
16544794|NCT02985619|Other|IVB group III (not randomised)|Patients with central foveal thickness ≤300µm were allocated to group III (IVB)
16544795|NCT02985606|Active Comparator|Caffeine -60|Caffeine at 60 minutes prior to time trial
16544796|NCT02985606|Active Comparator|Caffeine -30|Caffeine at 30 minutes prior to time trial
16544797|NCT02985606|Active Comparator|Caffeine 0|Caffeine immediately prior to time trial
16544798|NCT02985606|Placebo Comparator|Placebo|Placebo drink at all time points
16544799|NCT02985593|Experimental|KHK4083|IV/SC administration
16544800|NCT02985593|Placebo Comparator|Placebo|IV/SC administration
16544801|NCT02985580|Active Comparator|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
16544802|NCT02985580|Placebo Comparator|Placebo|Placebo concentrate consumed daily for 12 weeks.
16544803|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
16544804|NCT02985567||Safety of sedation|"Documentation of:
~The need for repeat dosing of chloral hydrate.
~The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge
~Interventions required for the patient including administration of oxygen, and need for intubation."
16544805|NCT02985554|Experimental|Nivolumab|Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
16544806|NCT02985541|Experimental|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena, an Levonorgestrel intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg Levonorgestrel per day.
16544807|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
16544808|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
16544809|NCT02985515|Experimental|Smell Training|Participants will first undergo a 30-day trial of budesonide nasal saline irrigation. If there is no subsequent improvement in olfaction, participants will undergo a 12-week smell training intervention.
16544810|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
16544811|NCT02985489|Experimental|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
16544812|NCT02985489|No Intervention|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
16544813|NCT02985476|Active Comparator|Interventional|Care as usual plus 8 weekly ELIJAH health reports shared with the participant and General Practitioner for 6 months i.e.: My history, My plan, My Update delivered via post or by email (dependant on participant preference) in addition to care as usual.
16544814|NCT02985476|No Intervention|Observational|Care as usual dictated by disease pathway of diagnosed inflammatory bowel disease i.e.; access to out-patient and in-patient hospital based care and community health resources via General Practitioner.
16544815|NCT02985437|Experimental|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
16544816|NCT02985437|Active Comparator|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
16544817|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
16544818|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
16544819|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
16544820|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:
~Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen
~Those compatible with life are managed by full investigation and given standard care for each case"
16544821|NCT02985385||Normal Fetal Ultrasounds|Given normal care
16544822|NCT02985372|Experimental|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
16544823|NCT02985359||Comparison district|Existing routine community health services by government
16544852|NCT02985242|Active Comparator|Glimepiride/empagliflozin placebo|"Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily
~Duration of treatment: 12 months"
16544853|NCT02985229|Experimental|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
16544824|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
16544825|NCT02985346|Experimental|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
16544826|NCT02985346|Active Comparator|Control group|Patients received standard treatment
16544827|NCT02985333|Experimental|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
16544828|NCT02985320|Experimental|Phase I Adult Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of high dosage investigational sIPV"
16544829|NCT02985320|Experimental|Phase I Adult Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of medium dosage investigational sIPV"
16544830|NCT02985320|Experimental|Phase I Child Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of high dosage investigational sIPV"
16544831|NCT02985320|Experimental|Phase I Child Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of medium dosage investigational sIPV"
16544832|NCT02985320|Experimental|Phase I Infant Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of high dosage investigational sIPV"
16544833|NCT02985320|Experimental|Phase I Infant Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of medium dosage investigational sIPV"
16544834|NCT02985320|Experimental|Phase I Infant Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of low dosage investigational sIPV"
16544835|NCT02985320|Experimental|PhaseⅡExperimental Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of high dosage investigational sIPV"
16544836|NCT02985320|Experimental|PhaseⅡExperimental Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of medium dosage investigational sIPV"
16544837|NCT02985320|Experimental|PhaseⅡExperimental Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of low dosage investigational sIPV"
16544838|NCT02985320|Active Comparator|PhaseⅡControl Group -commercialized sIPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention:Three-dose regimen of commercialized sIPV"
16544839|NCT02985320|Active Comparator|PhaseⅡ Control Group -commercialized IPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of commercialized IPV"
16544840|NCT02985307|Experimental|Short Message Text Service|Participants receive short messages daily via their mobile phone
16544841|NCT02985307|Active Comparator|Standard Weight Management Group|Participants attend standard group weight management sessions
16544842|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
16544843|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
16544844|NCT02985281|Active Comparator|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).
~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
16544845|NCT02985281|Active Comparator|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.
~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).
~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
16544846|NCT02985268|Active Comparator|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
16544847|NCT02985268|Active Comparator|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
16544848|NCT02985268|Active Comparator|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.
~CRT-D will be programmed to ON"
16544849|NCT02985268|Active Comparator|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.
~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
16544850|NCT02985255|Experimental|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
16545120|NCT02983253||Patients with HHT|blood sample of patients with HHT
16544854|NCT02985216|Experimental|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
16544855|NCT02985216|Active Comparator|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
16544856|NCT02985203|Experimental|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
16544857|NCT02985203|No Intervention|Physician's choice|Observation or maintenance therapy other than orla navelbine.
16544858|NCT02985190|Experimental|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles
~in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles
~in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
16544859|NCT02985177|Active Comparator|INF + HM|The participant will receive a dose of intranasal fentanyl (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral hydromorphone (0.04mg/kg up to a maximum of 2 mg).
16544860|NCT02985177|Active Comparator|INF + IBU|The participant will receive a dose of intranasal (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral ibuprofen (10 mg/kg up to a maximum of 600 mg)
16544861|NCT02985164|Experimental|PDSa (Pocket radiation dosimeter a)|"A co-researcher reset and prepared 4 pocket dosimeters (PDS) and labelled as PDSa1, PDSa2, PDSb1 and PDSb2.
~The PDSa1 and PDSa2 were placed on the outside and inside of a lead shirt respectively. The shirt-covered box was close to an anesthetic machine. This box would represent anesthetic personnel on duty and marked as position A. Position A was 160 cm. above the floor"
16544862|NCT02985164|Experimental|PDSb (Pocket radiation dosimeter b)|"The PDSb1 and PDSb2 were placed on the outside and inside of the glass shield of control room respectively. This glass shield would represent all personnel working in the operating theatre and marked as position B.
~Position B was 160 cm. above the floor."
16544863|NCT02985151|Active Comparator|High Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at either the Mid mode or the Deep mode of the laser at visits three months apart. Thereafter, individuals in this group will be offered a third optional treatment at one of these settings.
16544864|NCT02985151|Placebo Comparator|Low Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at the Light mode of the laser at visits three months apart. Individuals in this group will be offered two optional high energy treatments subsequent to receiving the two light energy treatments.
16544865|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
16544866|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
16544867|NCT02985125|Experimental|Phase I - Dose Level 1|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 250mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
16544868|NCT02985125|Experimental|Phase I - Dose Level 2|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 300mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
16544869|NCT02985125|Experimental|Phase I - Dose Level -1|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 200mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
16544870|NCT02985125|Experimental|Phase I - Dose Level -2|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 150mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
16544871|NCT02985125|Experimental|Phase II - Dose|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
16544872|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
16544873|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
16544874|NCT02985099|Active Comparator|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
16544875|NCT02985099|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
16544876|NCT02985086|Active Comparator|Immediate induction with antibiotic prophylaxis|Immediate induction with antibiotic prophylaxis
16544877|NCT02985086|Active Comparator|Immediate induction without antibiotic prophylaxis|Immediate induction without antibiotic prophylaxis
16544878|NCT02985086|Active Comparator|Delayed induction with antibiotic prophylaxis|Delayed induction (>= 12 hours after PROM) with antibiotic prophylaxis
16544879|NCT02985073|Experimental|Veritas® mesh|Use of Veritas mesh in conjunction with immediate breast reconstruction on one side
16544880|NCT02985073|Experimental|TIGR® mesh|Use of TIGR® mesh in conjunction with immediate breast reconstruction on one side
16544881|NCT02985060|Experimental|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
16544882|NCT02985060|Other|Control group|Stroke care based on international guidelines
16544883|NCT02985047|Experimental|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
16544884|NCT02985047|No Intervention|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
16544885|NCT02985021|Experimental|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.
~Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity."
16544886|NCT02984995|Experimental|Initial dose 30 mg/day quizartinib|Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
16544887|NCT02984995|Experimental|Initial dose 20 mg/day quizartinib|Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
16544888|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 milligrams per deciliter (mg/dL).
16544889|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
16544890|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
16544891|NCT02984969||Healthy subjects|Healthy controls
16544892|NCT02984943|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen
16544893|NCT02984930|Experimental|PPI + mosapride group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
16544894|NCT02984930|Placebo Comparator|PPI + placebo group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus placebo drug of mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
16544895|NCT02984917|Experimental|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
16544896|NCT02984917|Experimental|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
16544897|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
16544898|NCT02984878|Experimental|Revanesse Ultra|Revanesse Ultra open label retreatment
16544899|NCT02984865|Active Comparator|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
16544900|NCT02984865|Experimental|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
16544901|NCT02984865|Experimental|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
16544902|NCT02984865|Experimental|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
16544903|NCT02984865|Other|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
16544904|NCT02984852|Experimental|Treatment sequence ABC|Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
16544905|NCT02984852|Experimental|Treatment sequence ACB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment A in treatment session 1, then Treatment C in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
16544906|NCT02984852|Experimental|Treatment sequence BCA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment C in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
16544907|NCT02984852|Experimental|Treatment sequence BAC|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment A in session 2 followed by Treatment C in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
16544908|NCT02984852|Experimental|Treatment sequence CAB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment A in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
16544909|NCT02984852|Experimental|Treatment sequence CBA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment B in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
16544910|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.
~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
16544911|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.
~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
16544914|NCT02984813|Experimental|GlaucoHealth|2 pills once daily in the morning for 3 months
16544915|NCT02984813|Experimental|GlaucoSelect|2 pills once daily in the morning for 3 months
16544916|NCT02984813|Placebo Comparator|Placebo|2 pills once daily in the morning for 3 months
16544917|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
16544918|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
16544919|NCT02984787|Experimental|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
16544920|NCT02984787|Active Comparator|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
16544921|NCT02984774|Experimental|Infertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
16544922|NCT02984774|Experimental|Fertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
16544923|NCT02984774|Other|Control|Ovarian tissue sampling, endometrial sampling from hysterectomy and oophorectomy pieces and peripheric blood sampling during intravenous catheterization during anesthesia.
16544924|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
16544925|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
16544926|NCT02984748||Cochlear Implant Recipients|
16544927|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
16544928|NCT02984722|Experimental|1|PCOS women treated with 1500 mg/die of extended-release metformin
16544929|NCT02984722|Experimental|2|PCOS women treated with 1500 mg/die of immediate-release metformin
16544930|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
16544931|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
16544932|NCT02984696|Experimental|Hormonal Replace Therapy|1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months
16544933|NCT02984683|Experimental|SAR566658 90 mg/m^2|Participants received SAR566658 90 milligram per square meter (mg/m^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
16544934|NCT02984683|Experimental|SAR566658 120 mg/m^2|Participants received SAR566658 120 mg/m^2 as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
16544935|NCT02984670|Experimental|Behavior Therapy|
16544936|NCT02984670|Experimental|Cognitive Therapy|
16544937|NCT02984670|Other|Waitlist|
16544938|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
16544939|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
16544940|NCT02984644|Active Comparator|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
16544941|NCT02984644|Placebo Comparator|Placebo|16 subjects will receive placebo
16544942|NCT02984631|Other|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
16544943|NCT02984631|Other|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
16544944|NCT02984618|Experimental|Treatment group|Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
16544945|NCT02984618|Active Comparator|Control group|Patients will receive classic epidural blood patch with 20ml of autologous blood
16544946|NCT02984605|Experimental|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement & exercise prescription
~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
16544947|NCT02984605|No Intervention|Control group|"Arm：Hypoglycemic agents
~without take nutrition meal replacement & exercise prescription"
16544948|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
16544949|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
16545121|NCT02983253||probands|blood sample of healthy controls
16544950|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.
~Investigators and Operators were blinded to all other results for a sample upon data entry."
16544951|NCT02984566|Experimental|SABR with or without KIM|All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.
16544952|NCT02984540|Experimental|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
16544953|NCT02984540|Experimental|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
16544954|NCT02984527|Active Comparator|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
16544955|NCT02984527|Active Comparator|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
16544956|NCT02984514|Experimental|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
16544957|NCT02984501|Experimental|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
16544958|NCT02984488|Experimental|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
16544959|NCT02984488|Active Comparator|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
16544960|NCT02984475|Active Comparator|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
16544961|NCT02984475|No Intervention|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
16544962|NCT02984462|Experimental|screw fixation|Surgical Percutaneous Akin osteotomy with fixation by a percutaneous cannulated screw and forefoot surgery dressing.
16544963|NCT02984462|No Intervention|No fixation|Surgical Percutaneous Akin osteotomy non-fixed, hold by forefoot surgery dressing.
16544964|NCT02984449|Experimental|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
16544965|NCT02984449|Active Comparator|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
16544966|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
16544967|NCT02984410|Other|Intensity-Modulated Radiation Therapy (IMRT)|PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
16544968|NCT02984410|Other|Trans Oral Surgery (TOS)|"The following surgical techniques are allowed:
~Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)"
16544969|NCT02984397|Experimental|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
16544970|NCT02984397|Placebo Comparator|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
16544971|NCT02984397|Active Comparator|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
16544972|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
16544973|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
16544974|NCT02984371|Experimental|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
16544975|NCT02984371|Active Comparator|Group 2|Coronary artery bypass grafting
16593865|NCT02653274|Active Comparator|RYE PORRIDGE|Rye breakfast porridge
16544976|NCT02984358|Placebo Comparator|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
16544977|NCT02984358|Active Comparator|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
16544978|NCT02984358|Active Comparator|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
16544979|NCT02984345|Active Comparator|Mycoprotein beverage|
16544980|NCT02984345|Placebo Comparator|Milk protein beverage|
16544981|NCT02984332|Experimental|Lower limb immobilisation|All participants will undergo 7 days of unilateral leg immobilization. Participants will wear a leg brace (Donjoy X-ACT, DJO Global, USA) on one of their legs which will fix the leg at 40 degrees of flexion for the 7 days. Participants will not be allowed to remove the brace at any stage and are prohibited from bearing weight on the immobilized leg, and will ambulate on crutches throughout the week of immobilization.
16544982|NCT02984319|Active Comparator|Cherry|Cherry concentrate
16544983|NCT02984319|Placebo Comparator|Placebo|Placebo concentrate
16544984|NCT02984306|Experimental|Dietary supplement|
16544985|NCT02984293|Active Comparator|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
16544986|NCT02984293|Placebo Comparator|Placebo|The participants will receive matched placebo orally once daily for 28 days.
16544987|NCT02984267|Experimental|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
16544988|NCT02984267|Other|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
16544989|NCT02984254|Experimental|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
16544990|NCT02984254|Experimental|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
16544991|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
16544992|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
16544993|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
16544994|NCT02984228|Active Comparator|Platelet-rich plasma (PRP)|Patients will receive an injection of PRP.
16544995|NCT02984228|Active Comparator|Hyaluronic Acid|Patients will receive an injection of hyaluronic acid.
16544996|NCT02984202|Experimental|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
16544997|NCT02984189|Experimental|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
16544998|NCT02984189|Active Comparator|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
16544999|NCT02984189|Sham Comparator|Sham Group|6 cmH20 will be used for training.
16545000|NCT02984176|Active Comparator|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
16545001|NCT02984176|Placebo Comparator|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
16545002|NCT02984163|Experimental|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
16545003|NCT02984150|Experimental|fatty acid|the nutrient that can be widely found in daily food.
16545004|NCT02984150|Sham Comparator|saline|saline
16545005|NCT02984137|Experimental|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
16545006|NCT02984137|Active Comparator|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
16545007|NCT02984137|Placebo Comparator|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
16545008|NCT02984124|Experimental|Intervention|Participants (n= approximately 100 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
16545152|NCT02983045|Experimental|Experimental: Combination of NKTR-214 + nivolumab + ipi|NKTR-214 will be combined with nivolumab and ipilimumab. The goal of this dose schedule finding part of the study is to define the RP2D and administration schedule.
16546108|NCT02976246|Placebo Comparator|RenaKvit-bone control|One tablet of non-active drug given once daily
16545009|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 100 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
16545010|NCT02984111|Active Comparator|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
16545011|NCT02984111|Active Comparator|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
16545012|NCT02984111|Placebo Comparator|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
16545013|NCT02984098|Experimental|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
16545014|NCT02984098|Active Comparator|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
16545015|NCT02984085|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.
~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
16545016|NCT02984072|Active Comparator|Menthol|5% menthol in aqueous cream (Dermacool Forte)
16545017|NCT02984072|Placebo Comparator|Placebo|Aqueous cream
16545018|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.
~Pain questionnaires:
~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
16545019|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
~Pain questionnaires:
~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
16545020|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
16545021|NCT02984046|Experimental|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
16545022|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
16545023|NCT02984007|Experimental|Motivational Interviewing|Educational session based on the motivational interviewing
16545024|NCT02984007|Other|Information flyer|Information flyer on childhood vaccines
16545025|NCT02983994||Patients with asthma with an inhaled steroid|Patients with a diagnosis of asthma with indication of Treatment with an inhaled steroid (CI)
16545026|NCT02983994||Patients with asthma with an inhaled Beta agonist|Patients with a diagnosis of asthma with indication of Treatment with an inhaled Beta agonist (LABA)
16545027|NCT02983981|Experimental|open label|Topicort topical spray
16545028|NCT02983955|Other|SCI with Tetraplegia|
16545029|NCT02983942|Experimental|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
16545030|NCT02983942|Active Comparator|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
16545031|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
16545032|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
16545033|NCT02983916||Group 1: adhesiolysis|Group 1 (the operative group) consisted of all patients who underwent laparoscopy and/or laparotomy. Typically patients had positive cine-MRI. A few patients with inconclusive cine-MRI who underwent diagnostic laparoscopy are also included in this group. Patients with no adhesions found during operation remain in group 1, because analysis is performed on intention-to-treat basis.
16545034|NCT02983916||Group 2: Adhesions, conservative|Patients with evidence of adhesions based on cine-MRI who did not undergo laparoscopy or laparotomy.
16545035|NCT02983916||Group 3: No adhesions|Patients in whom no evidence of adhesions was found on cine-MRI, and who did not undergo laparoscopy or laparotomy .
16545036|NCT02983903|Experimental|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
16545037|NCT02983890|Active Comparator|Arm of study1|Dicloxacillin tablets.
16545038|NCT02983890|Placebo Comparator|Arm of study 2|No treatment
16546109|NCT02976233||Acute Respiratory Failure in NIV|
16545039|NCT02983877|Experimental|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.
~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
16545040|NCT02983864|Active Comparator|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
16545041|NCT02983864|Active Comparator|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
16545042|NCT02983851|Experimental|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
16545043|NCT02983851|Active Comparator|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
16545044|NCT02983838||depression with cognitive impairment|depression onset after 60 years old with subjective cognitive impairment
16545045|NCT02983838||depression without cognitive impairment|depression onset after 60 years old without subjective cognitive impairment
16545046|NCT02983838||normal control|older than 65 years, free from other neurocognitive disorder
16545047|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
16545048|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
16545049|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
16545050|NCT02983799|Experimental|gBRCAm;|germline BRCA mutant
16545051|NCT02983799|Experimental|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
16545052|NCT02983799|Experimental|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
16545053|NCT02983799|Experimental|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
16545054|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.
~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
16545055|NCT02983773|Experimental|High THC dose|1 marijuana cigarette (7.2% THC)
16545056|NCT02983773|Experimental|Low THC dose|1 marijuana cigarette (3.0% THC)
16545057|NCT02983773|Placebo Comparator|Placebo|Placebo marijuana cigarette
16545058|NCT02983760|Active Comparator|Planar V/Q-based strategy|Control arm
16545059|NCT02983760|Active Comparator|CTPA-based strategy|Control arm
16545060|NCT02983760|Experimental|V/Q SPECT-based strategy|Experimental arm
16545061|NCT02983747|Experimental|PRP Treatment(P)|PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
16545062|NCT02983747|Active Comparator|Medication Treatment(M)|NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
16545063|NCT02983734|Active Comparator|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
~DCS = d-cycloserine
~Dosage: 100mg
~Dosage form: Pill, administered orally
~Frequency: Daily for four weeks"
16545064|NCT02983734|Placebo Comparator|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
16545065|NCT02983721|Active Comparator|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
16545066|NCT02983721|Active Comparator|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
16545067|NCT02983708|Experimental|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
16545068|NCT02983708|Placebo Comparator|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
16545069|NCT02983695|Experimental|treatment|all participants will be in this arm and will receive study drug 'Cannabidiol-Rich whole Plant Extract (TIL-TC150) to assess dosing and tolerability according to study protocol
16545070|NCT02983682|Experimental|Lidocaine Infusion|All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
16545071|NCT02983669|Experimental|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
16545072|NCT02983669|Placebo Comparator|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
16545073|NCT02983617|Experimental|Tirabrutinib + Entospletinib|Participants will receive tirabrutinib and entospletinib for up to 104 weeks.
16545074|NCT02983617|Experimental|Tirabrutinib + Entospletinib + Obinutuzumab|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and entospletinib for up to 104 weeks.
16545075|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
16545076|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
16545077|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
16545078|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
16545079|NCT02983591|Experimental|Misoprostol|Rectal misoprostol
16545080|NCT02983591|Experimental|Oxytocin|intravenous oxytocin
16545081|NCT02983578|Experimental|Treatment (danvatirsen, durvalumab)|Patients receive danvatirsen IV over 1 hour on days 7, 5 and 3 prior to cycle 1, then on days 1, 8, 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16545082|NCT02983565|No Intervention|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
16545083|NCT02983565|Experimental|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
16545084|NCT02983552|Experimental|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
16545085|NCT02983552|Active Comparator|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
16545086|NCT02983513|Experimental|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.
~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
16545087|NCT02983513|No Intervention|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
16545088|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
16545089|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by aspiration or swabbing
~Blood sampling:
~A blood sample collected by fingerprick"
16545090|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis
~Blood sampling:
~A blood sample collected by fingerprick"
16545091|NCT02983461|Placebo Comparator|Placebo|Double Blind Placebo 3 times a day for 10 weeks.
16545092|NCT02983461|Active Comparator|Sildenafil|Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.
16545093|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.
~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
16545094|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.
~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
16545095|NCT02983435|Experimental|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
16545153|NCT02983045|Experimental|Dose Expansion of the Part 3 RP2D|Experimental Combination of NKTR-214 + nivolumab + ipilimumab that may enroll between 12-26 patients per tumor type
16545223|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
16594826|NCT02646735|Active Comparator|Exemestane|Exemestane 25mg
16545096|NCT02983435|Active Comparator|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
16545097|NCT02983422|Active Comparator|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
16545098|NCT02983422|Placebo Comparator|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
16545099|NCT02983409||Pstone|Adult Patients (> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
16545100|NCT02983396|Experimental|no transmural ischemia (NTI) and transmural ischemia (TI)|"Case cross-over from no transmural ischemia (NTI) to transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)
~Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia."
16545101|NCT02983383|Active Comparator|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
16545102|NCT02983383|Active Comparator|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
16545103|NCT02983370|Experimental|Blind volunteer|Blind volunteers will be implanted with our existing vision neuroprosthetic system, which utilizes a FDA cleared microelectrode array, using a minicraniotomy. The array will be implanted near the occipital pole or in extra striate areas. The investigators will collect descriptive feedback regarding thresholds, evoked perceptions and stimulation parameters leading to recognizable patterns.
16545104|NCT02983357||Case Series Study|Subjects who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of Orthopaedic Surgery at University of Nebraska Medical Center / Nebraska Medicine and are now at least 9 years out from surgery.
16545105|NCT02983344|Active Comparator|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
16545106|NCT02983344|Active Comparator|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
16545107|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
16545108|NCT02983305|Experimental|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
16545109|NCT02983305|Experimental|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
16545110|NCT02983279|Experimental|Dietary counseling, caloric restriction diet|Patients then undergo 25% caloric intake for 3-12 weeks prior to definitive cancer surgery.
16545111|NCT02983266|Experimental|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
16545112|NCT02983266|Experimental|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
16545113|NCT02983266|Sham Comparator|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
16545114|NCT02983266|Experimental|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.
~Device: InTENsity MicroCombo"
16545115|NCT02983266|Experimental|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.
~Device: InTENsity MicroCombo"
16545116|NCT02983266|Placebo Comparator|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.
~Device: InTENsity MicroCombo"
16545117|NCT02983266|Experimental|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
16545118|NCT02983266|Experimental|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.
~Device: InTENsity MicroCombo"
16545119|NCT02983266|Experimental|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.
~Device: InTENsity MicroCombo"
16545122|NCT02983240|Experimental|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
16545123|NCT02983240|Experimental|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
16545124|NCT02983240|Experimental|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
16545125|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 1|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
16545126|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 2|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
16545127|NCT02983214|Active Comparator|Clopidogrel|Clopidogrel 75 mg/day
16545128|NCT02983214|Active Comparator|Clopidogrel plus cilostazol|Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day
16545129|NCT02983201|Active Comparator|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
16545130|NCT02983201|Experimental|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
16545131|NCT02983188|Active Comparator|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
16545132|NCT02983188|Placebo Comparator|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
16545133|NCT02983175|Experimental|ultrasound assessment of gastric content|
16545134|NCT02983149|Other|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
16545135|NCT02983149|Other|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
16545136|NCT02983149|Other|EZ blocker|One lung ventilation will be achieved using the EZ blocker
16545137|NCT02983136|Experimental|Study site|The study arm will consist of managers and staff at at the operating department of a University hospital in western Sweden' The intervention is based on partnership, dialogue and inter-professional learning
16545138|NCT02983136|No Intervention|Control site|The Control arm will consist of managers and staff at at the operating department of a University hospital in south Sweden
16545139|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
16545140|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
16545141|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
16545142|NCT02983110||Cohort E|Group E will be HIV infected men
16545143|NCT02983097|Experimental|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide
~Dosage:
~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.
~peripheral stem cell collection after cycle 1 or 2"
16545144|NCT02983084|Experimental|Multiforce|Variable modulus version of a current orthodontic archwire
16545145|NCT02983084|Active Comparator|CuNiTi A|".016 current orthodontic archwire"
16545146|NCT02983084|Active Comparator|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
16545147|NCT02983071|Experimental|Once-Daily G1T38 Dosing|G1T38 (lerociclib) orally (once daily) in combination with fulvestrant.
16545148|NCT02983071|Experimental|Twice-Daily G1T38 Dosing|G1T38 (lerociclib) orally (twice daily) in combination with fulvestrant.
16545149|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
16545150|NCT02983045|Experimental|Dose Escalation: Combination of NKTR-214 + nivolumab|NKTR-214 in escalating doses will be combined with one of the two proposed doses of nivolumab. The goal of this dose escalation Part 1 of the study is to find the RP2D.
16545151|NCT02983045|Experimental|Dose Expansion: Combination of NKTR-214 + nivolumab|"Combination of NKTR-214+nivolumab in combination with cytotoxic chemotherapies for the following 2 cohorts of the Part 2:
~NSCLC 1L nonsquamous plus platinum/pemetrexed NSCLC 1L squamous plus platinum/taxane"
16594827|NCT02646722||No pain|patients show no pain on rocuronium injection
16545154|NCT02983032|Experimental|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
16545155|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
16545156|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
16545158|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
16545159|NCT02982980|Experimental|Physiotherapy Guidance Mastectomy|Patients who underwent radical breast surgery, received pre and postoperative assessment and orientation.
16545160|NCT02982980|Experimental|Phys Muscle strengthening Mastectomy|Patients who underwent radical breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
16545161|NCT02982980|Experimental|Physiotherapy Guidance Quadrantectomy|Patients who underwent partial breast surgery, received pre and postoperative assessment and orientation.
16545162|NCT02982980|Experimental|Phys Muscle strengthening Quadrantectomy|Patients who underwent partial breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
16545163|NCT02982967|Other|Physical Activity|Single-arm study with recreational physical activity intervention by 10 weeks (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
16545164|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
16545165|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
16545166|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
16545167|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
16545168|NCT02982941|Experimental|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
16545169|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
16545170|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
16545171|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
16545172|NCT02982902|Experimental|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
16545173|NCT02982889|Experimental|LIQ865A bupivacaine formulation|Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg
16545174|NCT02982889|Experimental|LIQ865B bupivacaine formulation|Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg
16545175|NCT02982889|Placebo Comparator|Diluent for LIQ865|Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf
16545176|NCT02982889|Active Comparator|0.5% bupivacaine hydrochoride|Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).
16545177|NCT02982876|No Intervention|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
16545178|NCT02982876|Active Comparator|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
16545179|NCT02982863||All Patients|
16545180|NCT02982850|Experimental|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
16545181|NCT02982850|Active Comparator|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
16545182|NCT02982837|Experimental|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
16545183|NCT02982837|Active Comparator|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
16545184|NCT02982824|Experimental|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.
16545185|NCT02982824|Placebo Comparator|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
16545186|NCT02982824|No Intervention|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
16545187|NCT02982811|No Intervention|Control group|Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
16545188|NCT02982811|Experimental|Experimental group|Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
16545189|NCT02982798|Experimental|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
16545190|NCT02982798|Experimental|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
16545191|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.
~Doses will be tailored and adjust as need it"
16545192|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.
~Standard Flavored gums will be used as needed for 10 weeks."
16545193|NCT02982759|Other|Comparison Arm|The comparison group will receive 2 generic newsletters
16545194|NCT02982759|Experimental|Intervention Arm|The intervention arm will receive the multi-level intervention.
16545195|NCT02982746|Experimental|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
16545196|NCT02982746|No Intervention|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
16545197|NCT02982733|Active Comparator|ABS|Ankaferd blood stopper
16545198|NCT02982733|Placebo Comparator|CS|Conventional sterile gauze
16545199|NCT02982733|Active Comparator|TR BAND|Dedicated hemostatic device
16545200|NCT02982720|Experimental|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
16545201|NCT02982707|Experimental|Mild Hepatic Subjects|Subjects are given a single dose of BMS-986177
16545202|NCT02982707|Experimental|Moderate Hepatic Subjects|Subjects are given a single dose of BMS-986177
16545203|NCT02982707|Experimental|Healthy Match Subjects|Subjects are given a single dose of BMS-986177
16545204|NCT02982694|Experimental|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be < 10 days.
16545205|NCT02982681|Experimental|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
16545206|NCT02982681|Active Comparator|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
16545207|NCT02982668|Active Comparator|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
16545208|NCT02982668|Experimental|Modified full enteral feeding|Consistent with full enteral feeding plan, preventively add erythromycin or mosapride everyday to improve gastrointestinal (GI) motility.
16545209|NCT02982668|Experimental|Permissive underfeeding|The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
16545210|NCT02982655|Experimental|Individualized BP lowering|Management policy is to lower the systolic or diastolic BP by 10-15% within 2 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
16545211|NCT02982655|Active Comparator|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP > 200 mmHg or diastolic BP >110 mmHg in patients with ischemic stroke, and systolic BP > 180 mmHg or diastolic BP > 110 mmHg in patients with cerebral hemorrhage.
16545212|NCT02982642|Experimental|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
16545213|NCT02982642|Placebo Comparator|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
16545214|NCT02982629|Placebo Comparator|Usual Care|Patients in this group do not receive any letters or phone calls after missing follow-up appointment.
16545215|NCT02982629|Active Comparator|Reminder Letter Intervention|Patients in this group receive letters and phone calls after missing follow-up appointment to reschedule the appointment.
16545216|NCT02982616|Experimental|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
16545217|NCT02982616|Experimental|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
16545218|NCT02982616|Experimental|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
16545219|NCT02982616|Placebo Comparator|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
16545220|NCT02982603|Experimental|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
16545221|NCT02982603|Active Comparator|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
16545222|NCT02982603|Placebo Comparator|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
16594868|NCT02646501|Active Comparator|group A|Antiarrhythmic drug group
16545224|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
16545225|NCT02982577|Experimental|Pilocarpine|Spray with Pilocarpine
16545226|NCT02982577|Placebo Comparator|Placebo|Spray without Pilocarpine
16545227|NCT02982564|Experimental|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
16545228|NCT02982564|Experimental|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
16545229|NCT02982551|Experimental|Hyperinsulinemic Clamp|Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
16545230|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
16545231|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
16545232|NCT02982525|Experimental|No Mussels|The control group will continue to consume their normal habitual diet
16545233|NCT02982525|Experimental|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
16545234|NCT02982525|Experimental|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
16545235|NCT02982525|Experimental|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
16545236|NCT02982512|No Intervention|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
16545237|NCT02982512|Experimental|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
16545238|NCT02982499||control group|Healthy participants will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
16545239|NCT02982499||optic neuropathy group|Participants with optic neuropathy will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
16545240|NCT02982486|Experimental|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
16545241|NCT02982460|Experimental|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
16545242|NCT02982460|Active Comparator|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
16545243|NCT02982447|Active Comparator|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
16545244|NCT02982447|Experimental|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
16545245|NCT02982434|Experimental|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
16545246|NCT02982434|Active Comparator|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
16545247|NCT02982421|Experimental|Research|Group Art Therapy
16545248|NCT02982421|Sham Comparator|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
16545249|NCT02982408|Experimental|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW<10th percentile)
16545421|NCT02981186|Experimental|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
16545250|NCT02982408|Experimental|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
16545251|NCT02982395|Experimental|Nanoxel®M|75 mg in 100mL normal saline
16545252|NCT02982395|Active Comparator|Mitomycin|40 mg in 100mL normal saline
16545253|NCT02982382|Experimental|Manipulative Treatment|Subjects will receive Manipulative Therapy
16545254|NCT02982382|Sham Comparator|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
16545255|NCT02982369|Experimental|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.
~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
16545256|NCT02982369|Sham Comparator|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
16545257|NCT02982356|Other|Fetal Selective Reduction Technology|Potassium chloride fetal heart injection in the dichorial twins with abnormal chromosome and structure
16545258|NCT02982356|No Intervention|control group|normal dichorial twins without any intervention
16545259|NCT02982343|Experimental|Falls management plus exercise training|Falls management and education session. Home proximal lower limb strength training and multi-sensory balance training.
16545260|NCT02982343|Active Comparator|Falls management only|Falls management and education session only.
16545261|NCT02982330|Experimental|Low Carbohydrate Breakfast|Breakfast composition containing <10% carbohydrate, 75% fat, 15% protein Matched calories
16545262|NCT02982330|Active Comparator|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
16545263|NCT02982317||Study group|All patients recruited will undergo the same protocol. An anesthesiologist will perform manual palpation of the patients lumbar spine and identification of the intervertebral spaces from L1-S1. A member of the UBC Department of Engineering will perform the US scanning and level identification using the novel US technology. In addition, freehand US will be used by two practitioners to determine the participant's lumbar level locations as per gold standard.
16545264|NCT02982304|Active Comparator|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
16545265|NCT02982304|Experimental|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
16545266|NCT02982304|Experimental|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
16545267|NCT02982291|Active Comparator|Standard|
16545268|NCT02982291|Experimental|Individualized|
16545269|NCT02982278|Experimental|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. Registered Nurse (RN) developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
16545270|NCT02982278|Experimental|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
16545271|NCT02982252|Experimental|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
16545272|NCT02982252|No Intervention|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
16545273|NCT02982252|Experimental|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
16545274|NCT02982252|No Intervention|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
16545275|NCT02982239|Other|Sleep Intervention|N=20 Participants received fitness tracker, information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks
16545276|NCT02982239|Other|Sleep Intervention plus Tech|N=20 Participants received fitness tracker, LED light, Blue-blocking glasses along with information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks.
16545277|NCT02982226|Experimental|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
16545278|NCT02982226|Active Comparator|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
16545279|NCT02982213|No Intervention|No companion present|No companion is present during the placement of the epidural catheter.
16545280|NCT02982213|Active Comparator|Companion present|A companion will be present during the placement of the epidural catheter.
16545281|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
16545282|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
16595828|NCT02639975|Placebo Comparator|Placebo 400 mg|
16545283|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
16545284|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
16545285|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
16545286|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
16545287|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
16545288|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
16545290|NCT02982161|Active Comparator|MR308 100 mg bid|Tramadol/Celecoxib 100 mg
16545291|NCT02982161|Active Comparator|MR308 150 mg bid|Tramadol/Celecoxib 150 mg
16545292|NCT02982161|Active Comparator|MR308 200 mg bid|Tramadol/Celecoxib 200 mg
16545293|NCT02982161|Active Comparator|Tramadol 100 mg qid|Tramadol IR 100 mg
16545294|NCT02982161|Placebo Comparator|Placebo|Placebo to match MR308 and Tramadol IR
16545295|NCT02982148|Experimental|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
16545296|NCT02982148|Active Comparator|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
16545297|NCT02982135|Other|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
16545298|NCT02982135|Other|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
16545299|NCT02982122|Experimental|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
16545300|NCT02982122|Active Comparator|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.
~CPPopt information is recorded but hidden for the treating clinicians."
16545301|NCT02982109||Postop pain level 1|Minor postoperative pain anticipated
16545302|NCT02982109||Postop pain level 2|Might experience postoperative pain
16545303|NCT02982109||Postop pain level 3|Moderate pain/substantial surgery performed
16545304|NCT02982109||Postop pain level 4|Severe postoperative pain expected/major surgery
16545305|NCT02982096|Active Comparator|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
16545306|NCT02982096|Other|Standard of Care|Standard of Care: Acellular wound management
16545307|NCT02982083|Active Comparator|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
16545308|NCT02982083|Placebo Comparator|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
16545309|NCT02982070|Experimental|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
16545310|NCT02982070|No Intervention|College as Usual|no training provided
16545311|NCT02982057|Active Comparator|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.
~Intervention:Device"
16545312|NCT02982057|Active Comparator|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.
~Intervention: medical treatment"
16545313|NCT02982044|Experimental|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
16545314|NCT02982031|Sham Comparator|shamrock|shamrock: both left and right sided scan,both intertransverse and transverse process window
16545315|NCT02982031|Active Comparator|paramedian transverse scan|paramedian transverse scan (PMTS): both left and right, both intertransverse and transverse process window
16545316|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
16545317|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
16545318|NCT02982005|Experimental|KHK4827|KHK4827 administered SC
16545319|NCT02982005|Placebo Comparator|Placebo|Placebo administered SC
16595829|NCT02639975|Placebo Comparator|Placebo 600 mg|
16545320|NCT02981979|Active Comparator|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
16545321|NCT02981979|Placebo Comparator|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
16545322|NCT02981966|Active Comparator|Normal Glucose Tolerance (NGT)|Individuals with normal glucose tolerance - dapagliflozin vs placebo
16545323|NCT02981966|Active Comparator|T2DM individuals|Individuals with type 2 diabetes mellitus - dapagliflozin vs placebo
16545324|NCT02981953|Other|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
16545325|NCT02981940|Experimental|Abemaciclib with Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule
~Patients who require re-operation will receive a short preoperative course of Abemaciclib
~Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier.
~After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days.
~NOTE: enrollment to this arm is complete"
16545326|NCT02981940|Experimental|Abemaciclib without Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule. Each Cycle last 28 days.
~NOTE: enrollment to this arm is complete"
16545327|NCT02981940|Experimental|Cohort 1 Surgery Arm|Participants who require reoperation will be treated with abemaciclib for 10-14 days prior to surgery. Tissue will be used to further investigate the abilities of Abemaciclib. After surgery participants will come off study and pursue standard of care treatments at their treating physician's discretion.
16545328|NCT02981927|No Intervention|Control|24 h habitual physical activity fed in energy balance
16545329|NCT02981927|Experimental|Bed rest matched diet|24 hour period of whole body bed-rest with a matched diet
16545330|NCT02981927|Experimental|Bed rest balanced diet|24 hour period of whole body bed-rest fed in energy balance
16545331|NCT02981914|Experimental|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
16545332|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
16545333|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
16545334|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
16545335|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
16545336|NCT02981875|Experimental|experimental|oculomotor training
16545337|NCT02981875|Placebo Comparator|control|placebo vision training exercises
16545338|NCT02981862|Experimental|CaptHPV method|
16545339|NCT02981836|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated varicella vaccine;"
16545340|NCT02981836|Sham Comparator|Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;
~Intervention: diluent of lyophilized vaccine;"
16545341|NCT02981823|Experimental|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
16545342|NCT02981810|Active Comparator|control|tonsillectomy
16545343|NCT02981810|Experimental|coblation|coblation of the tonsills
16545344|NCT02981797||Radium 223 Standard of Care|Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
16545345|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
16545346|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
16545347|NCT02981771|Experimental|experiment|A physical activity program that is based on balance and coordination exercises
16545348|NCT02981771|Placebo Comparator|control|A physical activity program that is based on strength exercises
16545349|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
16545350|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
16545351|NCT02981745|Experimental|CT-1530|
16545352|NCT02981732|Experimental|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
16545353|NCT02981732|No Intervention|the control group|the control group,there is no intervention
16545354|NCT02981719|Experimental|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment.
16545355|NCT02981719|Other|IRE group|percutaneous irreversible electroporation for locally advanced pancreatic cancer.
16545356|NCT02981706|Active Comparator|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
16545422|NCT02981186|Active Comparator|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
16545357|NCT02981706|Active Comparator|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
16545358|NCT02981693|Experimental|iRoot SP sealer|iRoot SP sealer was used as root canal sealer in root canal obturation.
16545359|NCT02981693|Active Comparator|AH Plus sealer|AH Plus sealer was used as a gold standard to be compared with iRoot SP sealer in root canal obturation.
16545360|NCT02981680|Experimental|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
16545361|NCT02981680|Sham Comparator|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
16545362|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
16545363|NCT02981654|Experimental|Femilift treatment|"The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.
~Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length."
16545364|NCT02981641|Experimental|Intraoperative radiotherapy (IORT) Group|Radiotherapy (Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1) + Sequential chemotherapy
16545365|NCT02981641|Experimental|Concurrent Chemoradiotherapy (CCRT) Group|Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
16545368|NCT02981615|Experimental|treatment arm|Subjects allocated to the treatment arm of the study will be administrated Levofloxacin 500mg/d given p.o. once a day, starting on day 10 from beginning of each cycle until day 28 on an ambulatory basis. Levofloxacin will be continued in the first 4 Azacytidine cycles.
16545369|NCT02981615|Placebo Comparator|placebo|Subject allocated to the placebo arm will be treated with placebo once a day, starting on day 10 from beginning until day 28 of each of the first 4 cycles.
16545370|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
16545371|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
16545372|NCT02981576|Active Comparator|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
16545373|NCT02981576|Active Comparator|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
16545374|NCT02981563|Experimental|Time Together|"Time Together as described under Interventions"
16545375|NCT02981537|Experimental|two-staged|positioning endobronchial blockers to appropriate bronchus with two-staged methods
16545376|NCT02981537|Active Comparator|single-staged|positioning endobronchial blockers with traditional single-staged methods
16545377|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
16545378|NCT02981498|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
16545379|NCT02981485|Experimental|Experimental|Treatment of breast cancer related lymphedema by fat grafting
16545380|NCT02981472|Experimental|Apixaban|
16545381|NCT02981472|Active Comparator|LMWH/VKA|
16545382|NCT02981459|Experimental|Mirabegron 25 mg or 50 mg|
16545383|NCT02981446|Experimental|DE-117 ophthalmic solution|
16545384|NCT02981446|Active Comparator|Latanoprost ophthalmic solution 0.005%|
16545385|NCT02981420|No Intervention|Pre-intervention|Pre-intervention baseline comparison
16545386|NCT02981420|Experimental|Safety Planning|Intervention group
16545387|NCT02981420|No Intervention|Regression discontinuity|Subthreshold no intervention
16545388|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
16545423|NCT02981173|Active Comparator|Psilocybin High Dose|
16545389|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
16545390|NCT02981394||BMAC Group|Intervention Group
16545391|NCT02981381|Experimental|Active sTMS (NEST-1)|"Subjects randomized to this group will receive 20 active synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 active sTMS sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place on the last day of active sTMS.
~Participants that elect to participate in the open-label continuation phase, will receive an additional 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.
~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
16545392|NCT02981381|Sham Comparator|Sham sTMS (SHAM)|"Subjects randomized to this group will receive 20 sham synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 sham sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place immediately after the final sham session.
~Participants that elect to participate in the open-label continuation phase, will receive 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.
~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
16545393|NCT02981368|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
16545394|NCT02981355|Active Comparator|Microfracture treatment|Microfracture surgery of the femoral condyle
16545395|NCT02981355|Experimental|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
16545396|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
16545397|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
16545398|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
16545399|NCT02981329|Experimental|Group A: Hydroxyurea + Metformin|Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.
16545400|NCT02981329|Experimental|Group B: Metformin (Group B has closed to enrollment)|Subjects who are not taking Hydroxyurea as part of standard of care and have sickle cell anemia.
16545401|NCT02981316|Active Comparator|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
16545402|NCT02981316|Active Comparator|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
16545403|NCT02981316|Active Comparator|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
16545404|NCT02981316|Active Comparator|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
16545405|NCT02981303|Experimental|Melanoma|Imprime PGG + Pembrolizumab
16545406|NCT02981303|Experimental|Triple Negative Breast Cancer|Imprime PGG + Pembrolizumab
16545407|NCT02981290|Experimental|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
16545408|NCT02981290|Experimental|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
16545409|NCT02981290|Experimental|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
16545410|NCT02981290|Experimental|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
16545411|NCT02981277|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
16545412|NCT02981277|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
16545413|NCT02981264|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
16545414|NCT02981264|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
16545415|NCT02981251|Experimental|Intervention|Health education with support by trained female health volunteer
16545416|NCT02981251|No Intervention|Control|Extra intervention will not be provided except usual care by their physician of the participant.
16545417|NCT02981212|Experimental|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
16545418|NCT02981212|Active Comparator|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
16545419|NCT02981199|Active Comparator|Micro-SCT|"patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.
~microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles"
16545420|NCT02981199|Active Comparator|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.
16545426|NCT02981160|No Intervention|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
16545427|NCT02981160|Experimental|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
16545428|NCT02981147|Experimental|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
16545429|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
16545430|NCT02981121|No Intervention|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
16545431|NCT02981121|Experimental|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).
~Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)
~Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
16545432|NCT02981121|Active Comparator|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
16545433|NCT02981108|Experimental|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
16545434|NCT02981108|Experimental|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
16545435|NCT02981108|Experimental|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
16545436|NCT02981108|Experimental|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
16545437|NCT02981108|Experimental|Escalation Cohort 5|Oral Once-Daily Administration of HS-10296(MTD)
16545438|NCT02981108|Experimental|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 220mg
16545439|NCT02981108|Experimental|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 260mg
16545440|NCT02981108|Experimental|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
16545441|NCT02981108|Experimental|Phase 2 Expansion|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
16545442|NCT02981095|Active Comparator|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
16545443|NCT02981095|Placebo Comparator|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
16545444|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
16545445|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
16545446|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:
~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
16545447|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
16545448|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:
~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS
~Dapagliflozin:
~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
16545449|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
16545450|NCT02981056|Active Comparator|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).
~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
16545451|NCT02981056|Active Comparator|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).
~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
16545452|NCT02981056|Active Comparator|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
16545453|NCT02981030|Experimental|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
16545454|NCT02981017|No Intervention|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
16545455|NCT02981017|Experimental|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
16545456|NCT02980991|Experimental|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
16545457|NCT02980978|Experimental|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
16545458|NCT02980978|No Intervention|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
16545459|NCT02980965|Experimental|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
16545460|NCT02980965|Active Comparator|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
16545461|NCT02980952|Placebo Comparator|Energy-balanced diet|Forearm immobilization whilst consuming an energy-balanced diet
16545462|NCT02980952|Experimental|High-fat overfeeding|Forearm immobilization whilst consuming a high-fat diet, 50% energy excess
16545463|NCT02980939|Placebo Comparator|Euhydration - no thirst|
16545464|NCT02980939|Experimental|Dehydration - no Thirst|
16545465|NCT02980926|Experimental|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
16545466|NCT02980926|Active Comparator|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
16545467|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
16545468|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
16545469|NCT02980900|Placebo Comparator|Placebo supplement|Post exercise placebo supplement Pre bed placebo supplement
16545470|NCT02980900|Active Comparator|Post exercise supplement|Post exercise protein-polyphenol supplement Pre bed placebo supplement
16545471|NCT02980900|Active Comparator|Pre bed supplement|Post exercise placebo supplement Pre bed protein-polyphenol supplement
16545472|NCT02980900|Active Comparator|Post exercise + pre bed supplement|Post exercise protein-polyphenol supplement Pre bed protein-polyphenol supplement
16545476|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
16545477|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
16545478|NCT02980861|Experimental|Laparoscopic total gastrectomy|Participants including in the laparoscopic total gastrectomy (LTG) group will undergo LTG with spleen-preserving splenic hilum lymph nodes dissection.
16545479|NCT02980861|Active Comparator|Open total gastrectomy|Participants who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
16545480|NCT02980848||Screening group|Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
16545481|NCT02980848||Women with breast cancer|Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
16545482|NCT02980835|Experimental|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
16545483|NCT02980835|Active Comparator|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
16545484|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register
~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register
~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
16545485|NCT02980809|Experimental|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
16545486|NCT02980809|Placebo Comparator|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
16545487|NCT02980796|Experimental|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
16545488|NCT02980796|Active Comparator|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
16545547|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
16545489|NCT02980783|Experimental|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
16545490|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
16545491|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
16545492|NCT02980770||Normal Blood Gases|Normal Blood Gases
16545493|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
16545494|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
16545495|NCT02980757|Active Comparator|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
16545496|NCT02980744|Experimental|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
16545497|NCT02980731|Experimental|Venetoclax|Venetoclax will be administered orally 20 mg once daily (QD) beginning with a dose-titration phase, and then escalated up to 400 mg QD.
16545498|NCT02980718|Experimental|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
16545499|NCT02980718|Experimental|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
16545500|NCT02980718|No Intervention|controls|20 participants represent a control group with no olfactory training
16545501|NCT02980705|Experimental|SUNPG1622 I|SUNPG1622 I dose
16545502|NCT02980705|Placebo Comparator|Placebo|Placebo dose
16545503|NCT02980692|Experimental|SUNPG1623 dose I|low range dose
16545504|NCT02980692|Experimental|SUNPG1623 dose II|mid range dose
16545505|NCT02980692|Experimental|SUNPG1623 dose III|mid range dose
16545506|NCT02980692|Experimental|SUNPG1623 dose IV|mid range dose to high dose
16545507|NCT02980692|Placebo Comparator|Placebo|mid range dose to high dose
16545508|NCT02980679|Experimental|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
16545509|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
16545510|NCT02980653|Experimental|Megestrol|Single arm
16545511|NCT02980627|Experimental|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
16545512|NCT02980614|Experimental|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:
~4D MR sequence in cine mode 4D velocity mapping sequence"
16545513|NCT02980601|Experimental|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
16545514|NCT02980601|Active Comparator|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
16545515|NCT02980588|Other|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
16545516|NCT02980575|Experimental|Exercise with music|Participants will listen to music when they exercise
16545517|NCT02980575|Active Comparator|Exercise|Participants will not listen to music when they exercise
16545518|NCT02980562|Active Comparator|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
16545519|NCT02980562|Active Comparator|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
16545520|NCT02980523|Experimental|PRO-157 BID (2 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days
~instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
16545521|NCT02980523|Experimental|PRO-157 TID (3 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
16545548|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
16545522|NCT02980523|Experimental|PRO-157 QID (4 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
16545523|NCT02980523|Active Comparator|Moxifloxacin (Vigamox®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
16545524|NCT02980523|Active Comparator|Gatifloxacin (Zymar®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
16545525|NCT02980510|Experimental|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² given as a 2-hour intravenous (IV) infusion with the addition, after 30 minutes of irinotecan 150 mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400 mg/m² IV bolus then 5-fluoruracil (5-FU) 2400 mg/m² over 46 hours continuous infusion.
16545526|NCT02980510|Active Comparator|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² IV infusion over 2 hours followed by fluorouracil 400 mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
16545527|NCT02980497|Active Comparator|Listerine Zero Mouthwash (without alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Zero Mouthwash (without alcohol) for 30 seconds.
16545528|NCT02980497|Active Comparator|Listerine Antiseptic Mouthwash (with alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Antiseptic Mouthwash (with alcohol) for 30 seconds.
16545529|NCT02980497|No Intervention|Brush only|Brush only twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush.
16545530|NCT02980484|Experimental|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
16545531|NCT02980484|Sham Comparator|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
16545532|NCT02980458|Experimental|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
16545533|NCT02980458|Active Comparator|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
16545534|NCT02980445|No Intervention|Control|
16545535|NCT02980445|Experimental|Outdoor Activity 1|40min outdoor time in total.
16545536|NCT02980445|Experimental|Outdoor Activity 2|80min outdoor time in total
16545537|NCT02980432|Experimental|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
16545538|NCT02980419|Experimental|intervention arm|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
16545539|NCT02980406|Active Comparator|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
16545540|NCT02980406|Active Comparator|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
16545541|NCT02980406|Active Comparator|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
16545542|NCT02980406|Placebo Comparator|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
16545543|NCT02980393|Experimental|Lifestyle intervention|Participants are guided by a fitness specialist who will help the participants to incorporate physical activity into their daily life. Based on the cardiologist assessment, an individual home-based exercise program will be developed. Participants are also guided and advised on nutrition with emphasis on low fat content and increased fiber. The nutrition counseling will focus on sustainable changes and will help participants to make healthy food choices.
16545544|NCT02980380||Locked-in and complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state as well as in transition from locked-in to complete locked-in state who have no means of communication.
16545545|NCT02980367|Experimental|ACL Rehabilitation Group|Non-surgical management [Rehabilitation] with option for later Anterior Cruciate Ligament (ACL) reconstruction, only if required.
16545546|NCT02980367|Active Comparator|ACL Reconstruction Group|Surgical Management - Anterior Cruciate Ligament (ACL) reconstruction surgery
16545549|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
16545550|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
16545554|NCT02980328|Experimental|LLLT group|Low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each
16545555|NCT02980328|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
16545556|NCT02980315|Experimental|CAR-T cells|the group treat with CAR-T cells
16545557|NCT02980315|No Intervention|placebo|the group treat with CAR-T cells
16545558|NCT02980302|Other|Patient|
16545559|NCT02980302|Other|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
16545560|NCT02980302|Other|Two control patients|
16545561|NCT02980289||Patients|Patients over 18 years old with advanced cancer defined as metastatic disease, no curable treatment options. The patients may not have received chemotherapy or irradiation within 4 weeks, no operations within 2 weeks and no general anesthesia within 4 days.
16545562|NCT02980276|Active Comparator|Treatment|Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
16545563|NCT02980276|Placebo Comparator|Control|Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
16545564|NCT02980263|Experimental|Kawasaki patients|
16545565|NCT02980250|Experimental|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
16545566|NCT02980250|Experimental|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
16545567|NCT02980250|Experimental|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
16545568|NCT02980250|Placebo Comparator|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
16545569|NCT02980237|Experimental|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. The course could be access in the workplace but they will be additional support.
16545570|NCT02980237|Active Comparator|eHealth|This group will receive an e-learning education program same as the intervention group . However, the participants will not receive additional support by team.
16545571|NCT02980224|Experimental|OmegaD|OmegaD Softgels
16545572|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
16545573|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
16545574|NCT02980198|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
16545575|NCT02980198|Placebo Comparator|Placebo|Placebo + ISA 51
16545576|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
16545577|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
16545578|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
16545579|NCT02980159||Before triage liaison physician|All patients admitted before the introduction of the function of triage liaison physician.
16545580|NCT02980159||After triage liaison physician|All patients admitted after the introduction of the function of triage liaison physician.
16545581|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
16545582|NCT02980133|Placebo Comparator|Placebo MDPI|Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
16545583|NCT02980133|Experimental|Fp MDPI 25 mcg BID|Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
16545584|NCT02980133|Experimental|Fp MDPI 50 mcg BID|Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
16545585|NCT02980133|Experimental|FS MDPI 50/12.5 mcg BID|Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
16545586|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off <17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
16545643|NCT02979743|Active Comparator|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
16545587|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range <17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
16545588|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
16545589|NCT02980107|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
16545590|NCT02980107|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
16545591|NCT02980094|Placebo Comparator|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
16545592|NCT02980094|Experimental|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
16545593|NCT02980094|Experimental|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
16545594|NCT02980094|Experimental|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
16545595|NCT02980081||Plain abdominal x-ray|All patients admitted to 2 EDs and with a prescription of an abdominal plain x-ray.
16545596|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
16545597|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
16545598|NCT02980055|Experimental|Test: collagen matrix|Root coverage using collagen matrix
16545599|NCT02980055|Active Comparator|Control: connective tissue graft|Root coverage using connective tissue graft
16545600|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
16545601|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
16545602|NCT02980029|Experimental|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme.
16545603|NCT02980029|Placebo Comparator|Placebo|Placebo
16545604|NCT02980016|Active Comparator|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
16545605|NCT02980016|Active Comparator|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
16545606|NCT02980016|Active Comparator|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
16545607|NCT02980003|Active Comparator|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
16545608|NCT02980003|Active Comparator|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
16545609|NCT02980003|Experimental|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.
~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
16545610|NCT02979990|Placebo Comparator|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
16545611|NCT02979990|Experimental|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
16545612|NCT02979977|Experimental|All subjects|Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 30 mg per day and weekly/bi-weekly intravenous cetuximab.
16545613|NCT02979964|Experimental|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
16545614|NCT02979964|Experimental|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
16545615|NCT02979964|Experimental|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
16545616|NCT02979964|Experimental|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
16545617|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
16545618|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
16545619|NCT02979912|Experimental|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
16545620|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
16545621|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
16545622|NCT02979886|Experimental|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150~300 IU. An appropriate dose of HMG (75~150 IU) will be added when follicles are larger than 12~14mm in diameter. When one leading follicle is >18mm in diameter, or two follicles are >17mm in diameter, or three follicles are >16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
16545629|NCT02979847|Experimental|Treated|hybrid approach (epicardial and subsequent endocardial mappings and ablations)
16545630|NCT02979847|Active Comparator|Control|conventional endocardial approach
16545631|NCT02979834||Early perception group|The group with early perception of fetal movement (<25th percentile)
16545632|NCT02979834||Average perception group|The group with average perception of fetal movement (>25th and <75th percentile)
16545633|NCT02979834||Late perception group|The group which late perception of fetal movement (>75 percentile)
16545634|NCT02979821|Experimental|Poziotinib|The study drug(poziotinib) will be administered orally as one 12 mg tablet once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug 12 mg daily can be reduced to 8 mg once daily according to dose reduction criteria.
16545635|NCT02979808|Experimental|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
16545636|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
16545637|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
16545638|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
16545639|NCT02979769|Experimental|Palovarotene|"All participants will receive non-flare-up based treatment of 5 mg palovarotene once daily for 24 months.
~Participants who continued non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to an additional 48 months (therefore 72 months over the entire study).
~Participants who start non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to 48 months.
~Participants that are skeletally immature will receive weight-adjusted doses.
~In the event of an eligible flare-up all participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days. Participants under the age of 18 years will receive weight-adjusted doses."
16545640|NCT02979756|Experimental|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
16545641|NCT02979756|No Intervention|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
16545642|NCT02979743|Placebo Comparator|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
16545733|NCT02979067|Active Comparator|High-flow 100% oxygen|Nasal oxygen flow
16545644|NCT02979730|Active Comparator|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
16545645|NCT02979730|Experimental|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
16545646|NCT02979717|Experimental|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
16545647|NCT02979717|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
16545648|NCT02979704|Active Comparator|Rosuvastatin|Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.
16545649|NCT02979704|Active Comparator|Atorvastatin|Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
16545650|NCT02979691|Active Comparator|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
16545651|NCT02979691|Experimental|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
16545652|NCT02979678|Experimental|Questionnaire|Breast cancer
16545653|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
16545654|NCT02979665||Control|DME consults not requiring anti-VEGF
16545655|NCT02979639|Experimental|GSK1437173A Group|Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
16545656|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:
~Fever >39
~Lower respiratory tract infection
~Acute otitis media
~Serious extra-pulmonary manifestations (myositis, encephalitis)"
16545657|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
16545658|NCT02979613|Experimental|TAF 25 mg|Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
16545659|NCT02979613|Active Comparator|TDF 300 mg|DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
16545660|NCT02979587|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
16545661|NCT02979574|Active Comparator|Electro-Acupuncture (EA) Procedure|Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
16545662|NCT02979574|Active Comparator|Battle Field Acupuncture (BFA) Procedure|Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
16545663|NCT02979574|Active Comparator|Wait List Control (WLC) Usual Care Procedure|Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
16545664|NCT02979561|Experimental|group of dabigatran|
16545665|NCT02979561|Active Comparator|group of warfarin|
16545666|NCT02979548|Experimental|Group A : Aprepitant (Add on therapy)|Aprepitant group will receive aprepitant capsules 1 h prior to chemotherapy on days 1-3 in addition to 5HT3 RA (Ondansetron). The dose of aprepitant will be given based on weight groups Weight 15-40 kg : Aprepitant 80 mg on days 1-3 Weight > 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
16545667|NCT02979548|Active Comparator|Group B : 5HT3 RA (Ondansetron)|"On the day of chemotherapy, ondansetron will be administered to all patients as per our institutional practice in a dose of 0.15 mg/kg as an intravenous bolus 30 minutes before chemotherapy followed by every 8 hourly for 8 days.
~Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day."
16545668|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
16545669|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
16545734|NCT02979067|Active Comparator|Low-flow 100% oxygen|Nasal oxygen flow
16545735|NCT02979067|Active Comparator|High-flow 30% oxygen|Nasal oxygen flow
16545736|NCT02979054|Experimental|T4020|1 drop every other day during 5 days
16545671|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
16545672|NCT02979496|Other|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
16545673|NCT02979496|Experimental|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
16545674|NCT02979496|Experimental|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
16545675|NCT02979496|Other|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
16545676|NCT02979483|Other|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
16545677|NCT02979457|No Intervention|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
16545678|NCT02979457|Experimental|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
16545679|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
16545680|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
16545681|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
16545682|NCT02979431|Experimental|ALX-0171 3.0 mg/kg|Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
16545683|NCT02979431|Experimental|ALX-0171 6.0 mg/kg|Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
16545684|NCT02979431|Experimental|ALX-0171 Dose 9.0mg/kg|Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
16545685|NCT02979431|Placebo Comparator|Placebo|Inhalation of Placebo once daily for 3 consecutive days
16545686|NCT02979405|Experimental|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
16545687|NCT02979405|Placebo Comparator|group 2|Saline solution 21 cc, infusion during 5 minutes
16545688|NCT02979392|Experimental|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
16545689|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
16545690|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
16545691|NCT02979366|Experimental|S64315 (also referred as MIK665) administered once a week|
16545692|NCT02979366|Experimental|S64315 (also referred as MIK665) administered twice a week|
16545693|NCT02979353|Experimental|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
16545694|NCT02979353|No Intervention|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
16545695|NCT02979327|Experimental|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
16545696|NCT02979327|Experimental|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
16545697|NCT02979314|Experimental|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
16545698|NCT02979301|Experimental|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
16545699|NCT02979301|Experimental|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
16545700|NCT02979288|Experimental|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
16545701|NCT02979288|Active Comparator|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
16545702|NCT02979288|Experimental|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
16545703|NCT02979288|Active Comparator|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
16545704|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
16545737|NCT02979054|Placebo Comparator|Saline solution|1 drop every other day during 5 days
16545705|NCT02979262|Experimental|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
16545706|NCT02979262|Active Comparator|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
16545707|NCT02979249|Experimental|Oral Iron|standard dose of iron pills
16545708|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
16545709|NCT02979223|Experimental|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
16545710|NCT02979223|Active Comparator|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
16545711|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
16545712|NCT02979197|Experimental|Amlodipine+Celecoxib|OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
16545713|NCT02979197|Active Comparator|Amlodipine+Placebo|OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
16545714|NCT02979197|Sham Comparator|Placebo+Placebo|Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
16545715|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
16545716|NCT02979171|Active Comparator|LMA-Classic|airway management with LMA-Classic
16545717|NCT02979171|Active Comparator|LMA-Flexible|airway management with LMA-Flexible
16545718|NCT02979171|Active Comparator|LMA-Proseal|airway management with LMA-Proseal
16545719|NCT02979158|Experimental|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
16545720|NCT02979158|Experimental|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
16545721|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
16545722|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
16545723|NCT02979132|Active Comparator|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
16545724|NCT02979132|Active Comparator|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
16545725|NCT02979132|Active Comparator|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
16545726|NCT02979119||Cohort I|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2000 until January 1st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
16545727|NCT02979119||Cohort II|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2009 until January 1st 2020 who have been or are to be treated with coagulation proteins in one of the participating centres
16545728|NCT02979119||Cohort III|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2020 until January 1st 2030 who have been or are to be treated with coagulation proteins in one of the participating centres
16545729|NCT02979106|Experimental|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
16545730|NCT02979093|Other|Addicted|The addiction group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
16545731|NCT02979093|Other|Control|The control group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
16545732|NCT02979080|Experimental|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
16545738|NCT02979041|Active Comparator|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
16545739|NCT02979041|Experimental|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
16545740|NCT02979028|Experimental|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
16545741|NCT02979028|Sham Comparator|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
16545742|NCT02979028|Placebo Comparator|Control group|Control patients will receive the same treatment without electrical stimulation.
16545743|NCT02979015|Experimental|Alirocumab|Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
16545744|NCT02979015|Placebo Comparator|Placebo|Subcutaneous injection of a single dose of matching placebo
16545745|NCT02978989|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC.
16545746|NCT02978989|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
16545747|NCT02978976|Experimental|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
16545748|NCT02978976|Placebo Comparator|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
16545749|NCT02978963|Experimental|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
16545750|NCT02978950|Experimental|Surveillance arm|Bilateral duplex ultrasound surveillance
16545751|NCT02978950|Active Comparator|No surveillance arm|no duplex ultrasound surveillance
16545752|NCT02978937||Metabolically healthy and abnormal obese|Obese patients divided into two groups according to their metabolic profile (healthy vs unhealthy)
16545753|NCT02978924|Active Comparator|Cathodal tsDCS|20 min of active treatment
16545754|NCT02978924|Sham Comparator|Sham tsDCS|20 min of sham treatment
16545755|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
16545756|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :
~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
16545757|NCT02978898||PB peripheral blood|"Samples obtained from patients with :
~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
16545758|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
16545759|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
16545760|NCT02978859|Experimental|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
16545761|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
16545762|NCT02978833|Experimental|PRP|
16545763|NCT02978833|Active Comparator|Whole Blood|
16545764|NCT02978820|Experimental|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
16545765|NCT02978820|Experimental|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
16545766|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.
~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
16545767|NCT02978781|Experimental|Part A: SAGE-217 Oral Solution|Participants received SAGE-217 10 mg oral solution on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7 with food in the morning.
16545768|NCT02978781|Experimental|Part A: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7, orally, with food in the morning.
16545769|NCT02978781|Placebo Comparator|Part B: Placebo|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 matching placebo for 7 days beginning on Day 8 with food in the morning.
16545770|NCT02978781|Experimental|Part B: SAGE-217 Capsules|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 for 7 days beginning on Day 8 with food in the morning.
16546110|NCT02976220|Experimental|Digital Education|1 month digital education program
16545771|NCT02978781|Experimental|Part C: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2, 30 mg on Day 3, orally, with food in the evening. Beginning on Day 4 through Day 14, participants received a 40-mg total daily dose (administered as 10 mg with food in the morning and 30 mg with food in the evening).
16545772|NCT02978768|Experimental|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
16545773|NCT02978768|Experimental|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
16545774|NCT02978768|Experimental|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
16545775|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
16545776|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
16545777|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
16545778|NCT02978742|Experimental|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
16545779|NCT02978742|Active Comparator|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
16545780|NCT02978729|Active Comparator|Telephone|Telephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
16545781|NCT02978729|Experimental|Videoconference|Two-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
16545782|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin|GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
16545783|NCT02978716|Experimental|Group 2: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV prior to GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
16545784|NCT02978716|Experimental|Group 3: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV on Days 1, 2, 8 and 9. GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 2 and 9 in 21-day cycles.
16545785|NCT02978690|Experimental|BI655130|
16545786|NCT02978677|Experimental|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
16545787|NCT02978677|Experimental|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
16545788|NCT02978677|Active Comparator|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
16545789|NCT02978664|Active Comparator|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
16545790|NCT02978664|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
16545791|NCT02978664|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
16545792|NCT02978651|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
16545793|NCT02978651|Placebo Comparator|Placebo|Placebo
16545794|NCT02978638|Other|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence and voiding in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
16545795|NCT02978625|Experimental|Treatment (talimogene laherparepvec, nivolumab)|Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16545796|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
16545797|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
16545798|NCT02978599|Experimental|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
16545799|NCT02978599|Experimental|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
16545800|NCT02978599|Placebo Comparator|Placebo|Placebo daily for 5 days
16545801|NCT02978586||[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of [Ga-68]PSMA tumor uptake
16545802|NCT02978573|Experimental|Cartiva|Cartiva Synthetic Cartilage Implant
16545803|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
16545804|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
16545872|NCT02978040|Active Comparator|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
16545805|NCT02978547|Experimental|Metformin|All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.
16545806|NCT02978534||Quetiapine|Patients taking quetiapine during pregnancy are eligible to participate in the study. Their dose and plasma concentration levels of quetiapine will be monitored throughout pregnancy and up to three months postpartum.
16545807|NCT02978521|Experimental|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:
~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
16545808|NCT02978521|No Intervention|Control Group|CG will receive information and recommendations on physical activity
16545809|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
16545810|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
16545811|NCT02978495|Experimental|A- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
16545812|NCT02978495|Active Comparator|B- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
16545813|NCT02978495|Experimental|C- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
16545814|NCT02978495|Active Comparator|D- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
16545815|NCT02978482|Experimental|durvalumab|durvalumab alone
16545816|NCT02978482|Experimental|durvalumab+tremelimumab|durvalumab plus tremelimumab
16545817|NCT02978469|Experimental|Life style changing: reducing sedentary behavior|Meetings with social worker and physical therapist.
16545818|NCT02978469|Active Comparator|Physical exercise group|Physical therapy exercise training in group, strengthening and stretching muscles.
16545819|NCT02978456|Experimental|quantitative coronary angiography guided|
16545820|NCT02978456|Active Comparator|Intravascular ultrasound guided|
16545821|NCT02978443|Experimental|Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
16545822|NCT02978430|Active Comparator|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
16545823|NCT02978430|Active Comparator|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.
~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
16545824|NCT02978417|Active Comparator|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
16545825|NCT02978417|Active Comparator|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
16545826|NCT02978404|Experimental|Radiosurgery and Nivolumab|"Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)
~Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter."
16545827|NCT02978391|Experimental|EWD|Adhesive, synthetic biopolymer powder
16545828|NCT02978391|Active Comparator|epinephrine|Submucosal epinephrine injection
16545829|NCT02978365|Experimental|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
16545830|NCT02978352|Experimental|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
16545903|NCT02977793||Non-pathologic young adults|18-28 years old
16545904|NCT02977793||Non-pathologic adults|29-80 years old
16545905|NCT02977793||Pathologic adults|29-80 years old
16545831|NCT02978352|Experimental|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
16545832|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
16545833|NCT02978326|Experimental|SAGE-217 dosing|SAGE-217
16545834|NCT02978326|Placebo Comparator|Placebo|Placebo
16545835|NCT02978313|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
16545836|NCT02978313|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
16545837|NCT02978300|Active Comparator|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
16545838|NCT02978300|Experimental|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
16545839|NCT02978287|No Intervention|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
16545840|NCT02978287|Experimental|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
16545841|NCT02978287|Experimental|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
16545842|NCT02978287|Experimental|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
16545843|NCT02978287|Experimental|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
16545844|NCT02978274||experimental group|MMF withdrawal by engraftment post haplo-SCT
16545845|NCT02978274||control group|MMF withdrawal by 2 month post haplo-SCT
16545846|NCT02978261|Experimental|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
16545847|NCT02978235|Experimental|TAS4464|
16545848|NCT02978222|Experimental|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
16545849|NCT02978222|Placebo Comparator|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
16545850|NCT02978209|No Intervention|Only moisturizer, no carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. One body half
16545851|NCT02978209|Active Comparator|Moisturizer + 7,5 % carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. Other body half
16545852|NCT02978196|Experimental|Injection of 99m-Tc-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.
16545853|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
16545854|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
16545855|NCT02978170|Experimental|Diagnostic (CBCT)|Patients undergo CBCT during standard of care bronchoscopy.
16545856|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
16545857|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
16545858|NCT02978144|Other|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
16545859|NCT02978144|Other|Current smokers|Healthy controls who are currently smoking (> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
16545860|NCT02978144|Other|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
16545861|NCT02978144|Other|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
16545862|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
16545865|NCT02978105|Experimental|Experimental|self-conditioning techniques plus standard care
16545866|NCT02978105|Active Comparator|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
16545867|NCT02978079|Experimental|Pupillometry in stroke patients|All eligible patients will undergo pupillometry test for the finding of Horner's syndrome
16545868|NCT02978053|Experimental|Bright light|10 000 lux
16545869|NCT02978053|Placebo Comparator|Red light|400 lux
16545870|NCT02978040|Experimental|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
16545871|NCT02978040|Active Comparator|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min).
16545873|NCT02978027|Active Comparator|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
16545874|NCT02978027|Active Comparator|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
16545875|NCT02978027|Experimental|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
16545876|NCT02978014|Experimental|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
16545877|NCT02978014|No Intervention|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
16545878|NCT02978001||Patients with Psoriasis|Patients with moderate to severe psoriasis (PASI>8)
16545879|NCT02978001||Healthy Control Subjects|Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
16545880|NCT02977988|Experimental|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
16545881|NCT02977988|Active Comparator|Active Comparator|Brain and Recovery (B&R)
16545882|NCT02977975|Experimental|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
16545883|NCT02977975|Other|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
16545884|NCT02977962|Experimental|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
16545885|NCT02977962|Placebo Comparator|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
16545886|NCT02977923|Active Comparator|Standard pharmacological treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
16545887|NCT02977923|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
16545888|NCT02977910|Experimental|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
16545889|NCT02977910|No Intervention|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
16545890|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
16545891|NCT02977884|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
16545892|NCT02977871|No Intervention|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
16545893|NCT02977871|Active Comparator|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
16545894|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
16545895|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
16545896|NCT02977845|Experimental|Primary aim|The primary aim of this study is to assess the effect of Qigong on managing dyspnea, fatigue, and anxiety (as a cluster) in lung cancer patients.
16545897|NCT02977845|Experimental|Secondary aim|The secondary aim of this study is exploring the effect of Qigong on cough which is another common symptom linked with dyspnea, fatigue, and anxiety as a cluster, and QOL in lung cancer patients.
16545898|NCT02977832|Experimental|odyliresin|Odyliresin (Iresine celosia) 2 ml
16545899|NCT02977832|Experimental|alphalytic|alpha-antagonist (alfuzosin 10 mg)
16545900|NCT02977819|Experimental|Meditation program|Meditation courses and at-home practice
16545901|NCT02977819|Active Comparator|English learning courses|English learning courses and at-home practice
16545902|NCT02977819|No Intervention|No intervention|Follow-up without Meditation courses or English Learning courses
16545906|NCT02977780|Active Comparator|Temozolomide|"Daily Radiation for a maximum of 49 days.
~Temozolomide will be administered orally on a daily dosing schedule
~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
~Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
16545907|NCT02977780|Experimental|Neratinib with Temozolomide|"Daily Radiation for a maximum of 49 days.
~Temozolomide will be administered orally on a daily dosing schedule
~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
~Neratinib will be taken post radiation at a daily oral pre-determine dose"
16545908|NCT02977767|Experimental|Conversational hypnosis|Use of conversational hypnosis during the tracheal cannula replacement
16545909|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
16545910|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
16545911|NCT02977715|Experimental|Intervention|Up to 1600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation [n=1000 subjects] or lyophilized formulation [n=600 subjects]) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
16545912|NCT02977689|Experimental|IDH305|IDH305 550 mg, oral, two times per day
16545913|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
16545914|NCT02977637|Experimental|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
16545915|NCT02977624|Experimental|Hadassah Medical Organization, Jerusalem, Israel|
16545916|NCT02977611|Experimental|High Dose, Rapid Infusion Iron Sucrose|Patients will receive an infusion of 500 mg of iron sucrose over one hour and will be monitored for four hours.
16545917|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
16545918|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
16545919|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
16545920|NCT02977585|Active Comparator|group 1|high level support
16545921|NCT02977585|No Intervention|group 0|low level support
16545922|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
16545923|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
16545924|NCT02977559|Experimental|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
16545925|NCT02977559|Experimental|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
16545926|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA >= 2 based on a reduced left ventricular ejection fraction (LV-EF <= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
16545927|NCT02977533|Experimental|GZ402668|Dose 1 (up to a maximum optional Dose 2) will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
16545928|NCT02977533|Placebo Comparator|Placebo|A dose of matching placebo will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
16545929|NCT02977520|Experimental|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
16545930|NCT02977520|No Intervention|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
16545931|NCT02977507|Experimental|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
16546211|NCT02975544|No Intervention|Control group|Continued with their habitual school routine
16545932|NCT02977507|Active Comparator|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the other side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
16545933|NCT02977494|Experimental|Daratumumab Bortezomib|
16545934|NCT02977468|Experimental|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein one to two times before Intraoperative radiation therapy (IORT).
~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
16545935|NCT02977442|Experimental|exercise|12 week exercise program, 5 days/week, 60 min/day
16545936|NCT02977442|No Intervention|standard of care|12 week standard of care recommendations
16545937|NCT02977429|Active Comparator|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:
~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
16545938|NCT02977429|Sham Comparator|control group|"The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:
~ScvO2<70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
16545939|NCT02977416|Experimental|patients treated withTNF blockade|22 patients treated with TNF blockade
16545940|NCT02977416|Experimental|patients without TNF blockade|22 patients without TNF blockade
16545941|NCT02977416|Experimental|healthy subjects|22 matched healthy subjects by pubertal stage and sex
16545946|NCT02977390|Other|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.
~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.
~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
16545947|NCT02977377|Active Comparator|Whole body vibration/ Exercise|Exercise therapy and whole body vibration will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. Whole body vibration (20-30 Hz, minimum amplitude) will be applied to cases in the form of 4 sets (1 min application and 1min rest) before exercises. After 1 week washout period, exercise program will apply for 8 weeks.
16545948|NCT02977377|Active Comparator|Exercise/ Whole body vibration|Exercise therapy will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise therapy and whole body vibration will be applied together for 8 weeks.
16545949|NCT02977364|Experimental|HS-10241 100mg|HS-10241 100mg daily
16545950|NCT02977364|Experimental|HS-10241 200mg|HS-10241 200mg daily
16545951|NCT02977364|Experimental|HS-10241 400mg|HS-10241 400mg daily
16545952|NCT02977364|Experimental|HS-10241 600mg|HS-10241 600mg daily
16545953|NCT02977364|Experimental|HS-10241 800mg|HS-10241 800mg daily
16545954|NCT02977364|Experimental|HS-10241 1000mg|HS-10241 1000mg daily
16545955|NCT02977351|Experimental|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
16545956|NCT02977351|Active Comparator|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
16545957|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
16545958|NCT02977325||water cure exclusively|This group followed exclusively the water cure
16545959|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
16545960|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
16546010|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
16546011|NCT02977000|Experimental|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
16546012|NCT02976987|Experimental|Cidofovir|Women receiving an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (CIN 2 and 3).
16545961|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
16545962|NCT02977286|Experimental|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:
~Adverse event potentially attributable to the study drug.
~Use of Relistor.
~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.
~The participant has been administered 10 days of study medication.
~The participant is discharged from the ICU.
~The participant requires the initiation of a strong CYP3A4 inhibitor medication.
~Other Name: Movantik"
16545963|NCT02977286|Placebo Comparator|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:
~Adverse event potentially attributable to the study drug.
~Use of Relistor.
~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.
~The participant has been administered 10 days of study medication.
~The participant is discharged from the ICU.
~The participant requires the initiation of a strong CYP3A4 inhibitor medication.
~Other Name: AstraZeneca provided Movantik placebo"
16545964|NCT02977273|Experimental|Test Meal 1|Thin/100% portion
16545965|NCT02977273|Experimental|Test Meal 2|Thin/150% portion
16545966|NCT02977273|Experimental|Test Meal 3|Thick/100% Portion
16545967|NCT02977273|Experimental|Test Meal 4|Thick/150% Portion
16545968|NCT02977260|Experimental|Test Meal 1|Thin/Low Energy
16545969|NCT02977260|Experimental|Test Meal 2|Thin/High Energy
16545970|NCT02977260|Experimental|Test Meal 3|Thick/Low Energy
16545971|NCT02977260|Experimental|Test Meal 4|Thick/High Energy
16545972|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
16545973|NCT02977234|Experimental|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
16545974|NCT02977221|Experimental|Piezosurgery|Piezosurgery will be performed on the anterior lower segment of the dental arch in order to accelerate the correction of mandibular anterior crowding.
16545975|NCT02977221|No Intervention|Ordinary Alignment|Treatment will be provided to the patients without any surgical interventions.
16545976|NCT02977208|Active Comparator|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.
~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
16545977|NCT02977208|Active Comparator|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.
~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
16545978|NCT02977195|Experimental|NP137|Therapeutic Class Recombinant humanized IgG1 monoclonal antibody against Netrin 1, Administered. Route of Administration is intravenous infusion over 180 min, given every 2 week at 14 mg/kg.
16545979|NCT02977182|No Intervention|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
16545980|NCT02977182|Experimental|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
16545981|NCT02977169|Experimental|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
16545982|NCT02977169|Placebo Comparator|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
16546013|NCT02976974|Experimental|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
16546014|NCT02976974|Experimental|Therapeutic exercise (E)|"E: Therapeutic Exercise.
~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.
~Thoracic column movements: Flexion-extension"
16546105|NCT02976246|Active Comparator|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
16545983|NCT02977156|Experimental|Combination PexaVec + Ipilimumab|"PEXA-VEC (Pexastimogene devacirepvec): Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF of Classe 1, administered by Intra-tumoral injection with fixed-dosage regimen of 1x109 pfu (9.0 Log pfu)/ injection. Up to 5 IT injections, at Week 1 Day 1, Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed in case of disease progression following a documented objective response at W12. Provided by Transgene.
~IPILIMUMAB: Anti-CTLA-4 monoclonal antibody (IgG1k) produced in CHO cells by recombinant DNA technology, administered by Intra-tumoral injection. Up to 4 IT injections at Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed In case of disease progression following a documented objective response at W12. Four dose levels of ipilimumab will be tested in dose escalation step: 2.5mg, 5mg, 7.5mg, 10mg, 20mg or 40 mg."
16545984|NCT02977143|Experimental|Fluid responsiveness test|"First, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation).
~Second, measure the increase in cardiac index after administration of volulyte 300 ml.
~If cardiac index increase more than 10%, fluid responsiveness is confirmed."
16545985|NCT02977130|Experimental|Map group|patients receiving general shared care for diabetes and the conversation map intervention
16545986|NCT02977130|Active Comparator|Control group|patients receiving general shared care for diabetes
16545987|NCT02977117|Experimental|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
16545988|NCT02977117|Active Comparator|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
16545989|NCT02977104|Other|Patients in afib or flutter|Maestro ECG
16545990|NCT02977104|Other|Patients in sinus rhythm|Maestro ECG
16545991|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
16545992|NCT02977091||short stature|healthy short children
16545993|NCT02977078|Sham Comparator|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
16545994|NCT02977078|Experimental|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
16545995|NCT02977065|Active Comparator|Atorvastatin 20 mg|To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks
16545996|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 50 mg|To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks
16545997|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 100 mg|To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
16545998|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 200 mg|To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks
16545999|NCT02977065|Active Comparator|Rosuvastatin 10 mg|To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks
16546000|NCT02977065|Experimental|Rosuvastatin 10 mg + CKD-519 100 mg|To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
16546001|NCT02977052|Experimental|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
16546002|NCT02977052|Experimental|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
16546003|NCT02977052|Experimental|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
16546004|NCT02977052|Experimental|PRADO extension cohort|"Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B.
~Surgery and adjuvant therapy
~Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes.
~Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment.
~Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK"
16546005|NCT02977039|Experimental|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
16546006|NCT02977039|Experimental|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
16546007|NCT02977026|No Intervention|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
16546008|NCT02977026|Experimental|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
16546009|NCT02977026|Experimental|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
16546288|NCT02975089|Experimental|Nutritional Intervention 1|"Multi-nutrient supplement"
16546015|NCT02976961|Experimental|Intervention|Implantable cardioverter defibrillator implant + usual care + supportive care given via an e-health platform. The supportive care consists of information, dialogue with a nurse or psychologist, CBT-based psychological intervention online, quizzes to increase knowledge
16546016|NCT02976961|No Intervention|Usual care|Implantable cardioverter defibrillator implant + usual care
16546017|NCT02976935||Healthy Volunteers|Subjects will receive 1L non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath while the MRI scan is performed. Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2:Identical to Study Visit 1 but with the further series of inhalations being up to a maximum of 4 (maximum total exposure to hyperpolarised 129Xenon will be 5L).Optional Study Visit #3: Identical to Study Visit 2 (maximum total exposure to hyperpolarised 129Xenon will be 5L)
16546018|NCT02976935||Chronic Obstructive Pulmonary Disease|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
16546019|NCT02976935||Idiopathic Pulmonary Fibrosis|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
16546020|NCT02976922|Active Comparator|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
16546021|NCT02976922|Placebo Comparator|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
16546022|NCT02976909|Experimental|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
16546023|NCT02976896|Experimental|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
16546024|NCT02976883|Experimental|[18F]HX4 diagnostic PET/CT scan|[18F]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
16546025|NCT02976870|Experimental|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
16546026|NCT02976857|Experimental|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
16546027|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
16546028|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
16546029|NCT02976831|Experimental|AZD0284|"Part 1A:
~Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL.
~Part 1B (food cohort):
~Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL.
~Part 2:
~In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
16546030|NCT02976831|Active Comparator|Placebo|"Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing.
~Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
16546031|NCT02976805|Experimental|Regimen A|4L PegLyte + 15 mg bisacodyl
16546032|NCT02976805|Experimental|Regimen B|6L PegLyte + 15 mg bisacodyl
16546033|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
16546034|NCT02976779|Experimental|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
16546035|NCT02976779|Placebo Comparator|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
16546036|NCT02976766|Experimental|Gypenosides|
16546037|NCT02976766|Placebo Comparator|Placebo|
16546038|NCT02976753||Elocta|Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
16546039|NCT02976753||Conventional factor VIII product|Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
16546079|NCT02976467|Placebo Comparator|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
16546106|NCT02976246|Placebo Comparator|RenaKvit-vessel Control|One tablet of non-active drug given once daily
16546107|NCT02976246|Active Comparator|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
16546040|NCT02976740|Experimental|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
16546041|NCT02976727|Experimental|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
16546042|NCT02976727|Active Comparator|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
16546044|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
16546045|NCT02976701|Placebo Comparator|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
16546046|NCT02976688|Experimental|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
16546047|NCT02976675|Experimental|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
16546048|NCT02976675|Experimental|PEG-somatropin per two weeks|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
16546049|NCT02976675|Active Comparator|Jintropin AQ|Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks
16546050|NCT02976662|Experimental|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
16546051|NCT02976662|No Intervention|Without Artificial shrinkage|Vitrify expanded blastocysts.
16546052|NCT02976636|Active Comparator|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
16546053|NCT02976636|Experimental|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
16546054|NCT02976623|Other|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
16546055|NCT02976623|No Intervention|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
16546056|NCT02976610|No Intervention|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
16546057|NCT02976610|Experimental|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.
~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
16546058|NCT02976597|Active Comparator|Bupivacaine 0.25%|Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side on each side at end of the surgery.
16546059|NCT02976597|Active Comparator|Morphine 10mg|Morphine 10mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery.Patients will recieve 5mg morphine on each side
16546060|NCT02976597|Active Comparator|Morphine 15mg|Morphine 15mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery. Patients will recieve 7.5mg morphine on each side
16546061|NCT02976571|Experimental|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
16546062|NCT02976571|Active Comparator|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
16546063|NCT02976571|Active Comparator|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
16546064|NCT02976571|Placebo Comparator|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
16546065|NCT02976558|Experimental|Treatment Group|"Interventions:
~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.
~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
16546066|NCT02976558|No Intervention|Control Group|control group. No interventions
16546067|NCT02976545|Other|PNES|Psychogenic Non-epileptic Seizures subjects
16546068|NCT02976545|Other|PTSD|Post Traumatic Stress Disorder
16546069|NCT02976545|Other|Healthy controls|Healthy controls
16546070|NCT02976532|Other|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
16546071|NCT02976519|Experimental|BI 443651|
16546072|NCT02976519|Placebo Comparator|Placebo|
16546073|NCT02976506|Experimental|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
16546074|NCT02976506|Experimental|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
16546075|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
16546076|NCT02976480|Active Comparator|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
16546077|NCT02976480|Experimental|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
16546078|NCT02976467|Experimental|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
16546080|NCT02976454|Experimental|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
16546081|NCT02976454|Active Comparator|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
16546082|NCT02976441|Experimental|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide
~Focal radiation therapy: standard of care dose daily for approximately 6 weeks
~Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation
~2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient
~Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
16546083|NCT02976428|Active Comparator|Standard Soft Tissue Balancing|In the control group where the sensor device is not used in optimization of knee balance and alignment, definitive implants will be cemented in place and the sensor trial inserted using a thickness based on prior standard bearing insert trialing. Peak load data will be captured intraoperatively through full ROM. Custom shims will be affixed to the sensor to replicate thickness of the standard trial. The knee will then be cycled and loads recorded in the medial and lateral compartments at 10, 45 and 90 degrees of flexion. The surgeon will be blinded to the sensor output and the system will be located outside of their visual field.
16546084|NCT02976428|Experimental|Sensor Guided Soft Tissue Balancing|In the experimental group where the sensor device is used to optimize balance and alignment, the sensor trial will be inserted and tibial baseplate rotated until medial and lateral femoral contact points are parallel on the sensor output. Quantitative balance is defined as a mediolateral intercompartmental loading difference of ≤15 pounds. Flexion balance is achieved when femoral contact point position is within the midposterior third of the tibial insert and intercompartmental loads are balanced. Loads in the medial and lateral compartments are recorded at 10, 45 and 90 degrees. If compartment loads differ by >15 lbs between compartments, unbalanced, further soft tissue release/bone resection will be done to achieve a side to side compartment pressure difference of <15 lbs through ROM.
16546085|NCT02976402|Experimental|SBRT|"Postoperative RT consisting in:
~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week
~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
16546086|NCT02976389|Experimental|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
16546087|NCT02976389|Active Comparator|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
16546088|NCT02976389|Active Comparator|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
16546089|NCT02976376|Experimental|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
16546090|NCT02976376|No Intervention|Control|Patients who are randomized to the control group will receive regular care.
16546091|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
16546092|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
16546093|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
16546094|NCT02976337|Experimental|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
16546095|NCT02976337|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
16546096|NCT02976324|Experimental|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
16546097|NCT02976324|No Intervention|control group|No inervention, just receive conventional therapy
16546098|NCT02976311|Active Comparator|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
16546099|NCT02976311|Active Comparator|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
16546100|NCT02976298|Sham Comparator|transcranial magnetic stimulation|sham transcranial magnetic stimulation
16546101|NCT02976298|Experimental|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
16546102|NCT02976298|Experimental|cerebellar stimulation|cerebellar transcranial magnetic stimulation
16546103|NCT02976272||patients with myeloma multiple|
16546104|NCT02976259|Experimental|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
16546111|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
16546112|NCT02976194|Experimental|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
16546113|NCT02976168|No Intervention|Horizontal|Subjects will be in horizontal supine Position for 21 hours
16546114|NCT02976168|Experimental|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
16546115|NCT02976155|No Intervention|Pre-intervention|enteral nutrition according routine practice
16546116|NCT02976155|Experimental|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
16546117|NCT02976142|Experimental|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
16546118|NCT02976142|No Intervention|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
16546119|NCT02976129|Experimental|V565|V565 TID PO for 6 weeks
16546120|NCT02976129|Placebo Comparator|Placebo|Placebo TID PO for 6 weeks
16546121|NCT02976116|Experimental|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
16546122|NCT02976103|Other|Standard Care|-Standard Care pain medicine/management will be given
16546123|NCT02976103|Experimental|JACKI® RECOVERY JACKET + Standard Care|"Patient will be encouraged to use the Jacki Recovery Jacket at home
~Patient will be taught how to tuck the drainage tubes in the jacket pocket
~Patient will be taught how to un-tuck the drainage tubes from jacket pocket
~Standard care pain medicine/management will be given"
16546124|NCT02976077|Experimental|RC2S+|"RC2S+
~Preparation sessions (sessions 1 & 2):
~Functional Outcomes Scale - Social Cognition (ERF-CS)
~Psychoeducation about social cognitive impairments
~Concrete objectives
~Cognitive remediation (sessions 3 to 22):
~Paper-and-pencil session
~Simulation session
~Home-based task
~Transfer sessions (sessions 23 & 24):
~Transfer of skills in dayly life - generalization
~Assessment of the achievement of objectives"
16546125|NCT02976077|Active Comparator|Control therapy|"Control therapy
~Preparation sessions (sessions 1 & 2):
~Functional Outcomes Scale - Neurocognition
~Psychoeducation about cognitive impairments
~Concrete objectives
~Cognitive remediation (sessions 3 to 24):
~Paper-and-pencil session
~Simulation session
~Home-based task"
16546126|NCT02976064|Experimental|PreHab_Intervention|Experimental group of the prehabilitation trial
16546127|NCT02976064|No Intervention|PreHab_Control|Control group of the prehabilitation trial
16546128|NCT02976064|Experimental|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
16546129|NCT02976064|No Intervention|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
16546130|NCT02976064|Experimental|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
16546131|NCT02976064|No Intervention|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
16546132|NCT02976051|Experimental|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
16546133|NCT02976038|Experimental|elamipretide|Open-label once daily subcutaneous injection of 40mg elamipretide
16546134|NCT02976025|Experimental|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
16546135|NCT02976025|Active Comparator|Collaborative Care|This comparator arm will consist of 10 cluster randomized health centers who receive training in collaborative care.
16546136|NCT02976012|Active Comparator|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
16546137|NCT02976012|Active Comparator|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
16546138|NCT02975999|Experimental|Vasopressin|Vasopressin at 0.4mU/kg/min
16546139|NCT02975999|Placebo Comparator|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
16546140|NCT02975986|Other|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
16546141|NCT02975973|Experimental|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
16546142|NCT02975973|Experimental|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
16546143|NCT02975973|Experimental|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
16546144|NCT02975973|Sham Comparator|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
16546145|NCT02975960|Experimental|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
16546146|NCT02975947|Active Comparator|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
16546147|NCT02975947|Experimental|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
16546148|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
16546149|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
16546150|NCT02975921|No Intervention|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
16546151|NCT02975921|Experimental|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
16546152|NCT02975921|No Intervention|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
16546153|NCT02975921|Experimental|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
16546154|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
16546155|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
16546156|NCT02975882|Experimental|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on cycle 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on cycle 2. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16546157|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
16546158|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
16546159|NCT02975856|Experimental|Table Red Wine|250 ml Table Red Wine (12% ethanol)
16546160|NCT02975856|Experimental|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
16546161|NCT02975843|Experimental|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
16546162|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
16546163|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
16546164|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
16546165|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
16546166|NCT02975817|Experimental|Hibler's|Insert description from protocol
16546167|NCT02975817|Active Comparator|Warm Air|Insert description from protocol
16546168|NCT02975804|Experimental|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
16546169|NCT02975804|No Intervention|Standard Therapy|Children in the control group will continue their usual therapy.
16546170|NCT02975791|Active Comparator|palpation|"Marking the cricothyroid membrane after ultrasound
~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
16546171|NCT02975791|Active Comparator|ultrasound|"Marking of the cricothyroid membrane after Palpation
~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
16546172|NCT02975778|Experimental|Aged, 65 and over|
16546173|NCT02975765|Experimental|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
16546174|NCT02975765|No Intervention|Traditional method|No intervention is going to be applied to the patients in this group.
16546175|NCT02975739|Experimental|Holmium-166 microspheres|Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.
16546176|NCT02975726|Experimental|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
16546177|NCT02975726|Active Comparator|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
16546178|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated
~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
16546289|NCT02975089|Experimental|Nutritional Intervention 2|"Multi-nutrient & soy protein supplement"
16546179|NCT02975687|Experimental|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
16546180|NCT02975674|Experimental|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
16546181|NCT02975674|Active Comparator|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
16546182|NCT02975661||Observational 1|Huaier Granule
16546183|NCT02975661||Observational 2|Radiotherapy or chemotherapy
16546184|NCT02975661||Observational 3|treatment abandoned
16546185|NCT02975661||Observational 4|Huaier Granule & Radiotherapy or chemotherapy
16546186|NCT02975648|Active Comparator|Usual Care|At discharge, paticipants received guidance from health professionals. The paticipants had a medical return five to seven months after the percutaneous coronary intervention.
16546187|NCT02975648|Experimental|Educational model + follow up|The paticipants received the hospital's instructions at discharge and participated in the educational program (booklets with telephone follow-up). The paticipants had a medical return five to seven months after discharge
16546188|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
16546189|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
16546190|NCT02975622|Active Comparator|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
16546191|NCT02975622|Active Comparator|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
16546192|NCT02975609|Active Comparator|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
16546193|NCT02975609|Experimental|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
16546194|NCT02975596|Other|Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
16546195|NCT02975596|Other|College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
16546196|NCT02975596|Other|Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
16546197|NCT02975596|No Intervention|Parent focus group|Parents discussed barriers and reviewed MenB education materials.
16546198|NCT02975596|No Intervention|Provider focus groups|Providers discussed barriers and reviewed MenB education materials.
16546199|NCT02975583|Active Comparator|Experimental: Vorapaxar|Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity
16546200|NCT02975583|Placebo Comparator|Placebo Comparator: Placebos|Medication: Matching Placebo Daily tablet
16546201|NCT02975570|Experimental|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
16546202|NCT02975570|Experimental|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
16546203|NCT02975570|Experimental|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
16546204|NCT02975570|Experimental|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
16546205|NCT02975570|Experimental|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
16546206|NCT02975570|Active Comparator|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
16546207|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
16546208|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
16546209|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
16546210|NCT02975544|Experimental|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
16546212|NCT02975531|Experimental|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
16546213|NCT02975531|Experimental|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
16546214|NCT02975531|Experimental|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
16546215|NCT02975531|Experimental|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
16546216|NCT02975531|Experimental|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
16546217|NCT02975518|Active Comparator|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
16546218|NCT02975518|Active Comparator|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
16546219|NCT02975518|Experimental|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
16546220|NCT02975518|Experimental|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
16546221|NCT02975505|Experimental|Strict SBP Target|Target Systolic Blood Pressure <120 mm Hg
16546222|NCT02975505|No Intervention|Usual SBP Target|Target Systolic Blood Pressure 130-140 mm Hg
16546223|NCT02975492|Experimental|Cholecalciferol sequential dose|cholecalciferol : 100 000 Unit International (UI), sequential dose (2 mL)
16546224|NCT02975492|Experimental|Cholecalciferol daily dose|cholecalciferol : 1000 UI, daily dose during 28 days (0.1 ml by day)
16546225|NCT02975479|Placebo Comparator|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
16546226|NCT02975479|Active Comparator|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.
~***IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. ***"
16546227|NCT02975466|Experimental|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
16546228|NCT02975466|Experimental|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
16546229|NCT02975466|Experimental|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
16546230|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
16546231|NCT02975440|Experimental|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
16546232|NCT02975427||Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
16546233|NCT02975388|Experimental|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
16546234|NCT02975388|Experimental|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
16546235|NCT02975388|Experimental|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
16546236|NCT02975388|Active Comparator|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
16546237|NCT02975388|Experimental|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
16546238|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
16546239|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
16546240|NCT02975362|Experimental|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
16546241|NCT02975362|Experimental|Rehabilitation|Rehabilitation Treatment
16546242|NCT02975349|Experimental|Placebo then Evobrutinib 25 mg QD|Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 milligram (mg) orally, once daily (QD) in blinded extension (BE) period from week 25 to week 48.
16546243|NCT02975349|Experimental|Evobrutinib 25 mg QD|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
16546244|NCT02975349|Experimental|Evobrutinib 75 mg QD|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
16546245|NCT02975349|Experimental|Evobrutinib 75 mg BID|Participants received Evobrutinib 75 mg orally, twice daily (BID) up to Week 48 in active treatment period 1 and BE period.
16546290|NCT02975089|Experimental|Nutritional Intervention 3|Nutrition education on balanced diet & food supplement
16546246|NCT02975349|Active Comparator|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period.
16546247|NCT02975349|Placebo Comparator|Placebo|Participants received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1.
16546248|NCT02975336|Placebo Comparator|Double-Blind Placebo-Controlled (DBPC) Period: Placebo|
16546249|NCT02975336|Experimental|DBPC Period: M2951 25 mg QD|
16546250|NCT02975336|Experimental|DBPC Period: M2951 75 mg QD|
16546251|NCT02975336|Experimental|DBPC Period: M2951 50 mg BID|
16546252|NCT02975336|Experimental|Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID|
16546253|NCT02975336|Experimental|LTE Period: M2951 25 mg QD/ M2951 50 mg BID|
16546254|NCT02975336|Experimental|LTE Period: M2951 75 mg QD/ M2951 50 mg BID|
16546255|NCT02975336|Experimental|LTE Period: M2951 50 mg BID/ M2951 50 mg BID|
16546256|NCT02975323|Experimental|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
16546257|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
16546258|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
16546259|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
16546260|NCT02975297|Placebo Comparator|Placebo plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
16546261|NCT02975271|Experimental|Serlopitant|Dose of experimental drug Serlopitant
16546262|NCT02975271|Placebo Comparator|Placebo|Matching dose of Placebo
16546263|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
16546264|NCT02975232|Experimental|Treatment|F&V economic incentive with Cooking Matters store tour
16546265|NCT02975232|No Intervention|Control|no intervention
16546266|NCT02975219|Experimental|Treatment group|4.5mg Bevacizumab-800CW intravenously
16546267|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
16546268|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
16546269|NCT02975206|Placebo Comparator|Placebo Oral Tablet|matching placebo tablets
16546270|NCT02975193|Active Comparator|Control group|"Healthy adults ages 18-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.
~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
16546271|NCT02975193|Active Comparator|Parkinson's disease group with DBS|"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.
~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
16546272|NCT02975180|Experimental|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
16546273|NCT02975180|Experimental|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
16546274|NCT02975167|Experimental|Inpatient|"Subjects randomized to this group will receive the same intervention as the outpatient group -- cervical ripening with Foley catheter -- but remain within the hospital. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.
~The intervention: randomization to inpatient cervical ripening"
16546275|NCT02975167|Experimental|Outpatient|"Subjects randomized to this group will receive the same intervention as the inpatient group -- cervical ripening with Foley catheter -- but will be discharged home. Subjects will be asked to return to the hospital when the catheter falls out or if 24 hours has elapsed. They will be given detailed instructions and provided a 24 hour phone number to call should they have any concerns. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.
~The intervention: randomization to outpatient cervical ripening"
16546276|NCT02975154|Active Comparator|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.
~Previous treatments will be continued."
16546277|NCT02975154|Active Comparator|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
16546278|NCT02975154|Sham Comparator|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
16546279|NCT02975154|No Intervention|No Intervention|No Intervention. Previous treatments will be continued.
16546280|NCT02975141|Experimental|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
16546281|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
16546282|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
16546283|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
16546284|NCT02975128|Experimental|Patients|
16546285|NCT02975102|Experimental|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
16546286|NCT02975102|Active Comparator|Vismed® Multi|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
16546287|NCT02975089|No Intervention|Control|A leaflet of healthy diet for elderly
16546291|NCT02975076|Experimental|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
16546292|NCT02975076|Placebo Comparator|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
16546293|NCT02975063|Experimental|A&T IYCF intervention|A&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
16546294|NCT02975063|No Intervention|Control|No intervention.
16546295|NCT02975050||Side location|u-Cor device will be applied on side location
16546296|NCT02975050||Front location|u-Cor device will be applied on front location
16546297|NCT02975037|Experimental|sildenafil+erythromycin|Sildenafil 25 mg PO (single dose); Erythromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Erythromycin 250 mg PO (single dose)
16546298|NCT02975037|Experimental|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
16546299|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
16546300|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
16546301|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
16546302|NCT02974998|Experimental|Young Women's Health CoOp (YWHC)/ HTC|Participants received an enhanced gender-focused HTC intervention.
16546303|NCT02974998|Active Comparator|Standard HTC|Participants received the standard HTC available in South Africa for this population.
16546304|NCT02974985|Experimental|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
16546305|NCT02974985|Experimental|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
16546306|NCT02974972||Pith Moromo 2 Cohort|
16546307|NCT02974959|Experimental|gammaCore active device|Patients in this arm will be using an active device which delivers a treatment dose of current to the vagus nerve twice daily for 120 seconds
16546308|NCT02974959|Sham Comparator|gammaCore Sham device|Patients in this arm will be using a sham device which does not deliver a treatment dose of current, but will deliver enough current to cause tingling on the skin.
16546309|NCT02974946|Experimental|Study group|Patients will receive the RenalGuard system
16546310|NCT02974946|No Intervention|Control group|Standard practice will be performed with no RenalGuard system
16546311|NCT02974933|Experimental|apatinib|combined with pemetrexed
16546312|NCT02974920|Active Comparator|Aspirin 100 mg|100 mg of aspirin daily for 180 days
16546313|NCT02974920|Active Comparator|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
16546314|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
16546315|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
16546316|NCT02974894|Experimental|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
16546317|NCT02974894|Placebo Comparator|Placebo|Capsules containing potato starch
16546318|NCT02974881|Experimental|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
16546319|NCT02974868|Experimental|Cohort 1|PF-06651600
16546320|NCT02974868|Experimental|Cohort 2|PF-06700841
16546321|NCT02974868|Placebo Comparator|Cohort placebo|placebo
16546322|NCT02974855|Experimental|PF-06741086 (Cohort 1)|
16546323|NCT02974855|Experimental|PF-06741086 (Cohort 2)|
16546324|NCT02974855|Experimental|PF-06741086 (Cohort 3)|
16546325|NCT02974855|Experimental|PF-06741086 (Cohort 4)|
16546326|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
16546327|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
16546328|NCT02974816|No Intervention|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
16546329|NCT02974816|Experimental|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
16546330|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
16546331|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
16546332|NCT02974777|Active Comparator|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
16546333|NCT02974777|Active Comparator|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
16546334|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
16546335|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
16546336|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
16546337|NCT02974738|Experimental|Part 1A|"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors."
16546338|NCT02974738|Experimental|Part 1B|"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC."
16546339|NCT02974738|Experimental|Part 2|"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
16546340|NCT02974738|Experimental|Part 2A|"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
16546344|NCT02974712|Experimental|Fentanyl|After routine Induction, fentanyl was administrated.
16546345|NCT02974712|Placebo Comparator|Saline|After routine Induction, same volume saline was administrated.
16546346|NCT02974699|Experimental|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
16546347|NCT02974699|Placebo Comparator|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
16546348|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
16546349|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
16546350|NCT02974673|Experimental|Ejaculatory test|Measures of sphincter pressures during ejaculation
16546351|NCT02974660|Active Comparator|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
16546352|NCT02974660|Placebo Comparator|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
16546353|NCT02974647|Experimental|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
16546354|NCT02974647|Experimental|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
16546355|NCT02974647|Experimental|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
16546356|NCT02974647|Experimental|Rare sub-type expansion cohort: T-PLL and T-LGL and non-MF CTCL with JAK fusion mutations.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
16546357|NCT02974634|Active Comparator|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
16546358|NCT02974634|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
16546359|NCT02974621|Experimental|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16546360|NCT02974621|Experimental|Arm B (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16546361|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
16546362|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
16546363|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
16546367|NCT02974582|Experimental|1/Part 1|60 Participants of high and low SES
16546368|NCT02974582|Experimental|2/Part 2 - Discount Coupons|Randomized to view direct mail marketing
16546369|NCT02974582|Experimental|3/Part 2 - No Discount Coupons|Randomized to view direct mail marketing
16546370|NCT02974582|Experimental|4/Part 2 - Control|Randomized to view direct mail marketing
16546371|NCT02974569||C-SCAT|C-SCAT arm: Completes and uses Computerized Symptom Capture Tool (C-SCAT) during visit with provider for two clinic visits.
16546372|NCT02974556|Active Comparator|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.
~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
16546373|NCT02974556|Experimental|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.
~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
16546374|NCT02974543|Other|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.
~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
16546375|NCT02974543|Other|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.
~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
16546376|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
16546377|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
16546378|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
16546379|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
16546380|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
16546381|NCT02974504|Experimental|evogliptin|evogliptin 5mg qd
16546382|NCT02974504|Active Comparator|linagliptin|linagliptin 5mg qd
16546383|NCT02974491|Experimental|Apple Juice|
16546384|NCT02974478|Experimental|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
16546385|NCT02974478|Experimental|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
16546386|NCT02974478|Experimental|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
16546387|NCT02974465|Experimental|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
16546388|NCT02974465|Sham Comparator|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
16546389|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
16546390|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
16546391|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
16546392|NCT02974439|Experimental|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
16546393|NCT02974439|Active Comparator|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
16546394|NCT02974426|Experimental|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
16546395|NCT02974426|Active Comparator|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
16546396|NCT02974413|Experimental|Intervention|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.
16546397|NCT02974413|No Intervention|Control|The study will also include a Control Group (CG), and the participants of this group will participate in conversation circles at the beginning and the end of the six month follow-up.
16546398|NCT02974400|Experimental|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
16546399|NCT02974400|No Intervention|Wait-List|Wait-list control group (8 weeks)
16546400|NCT02974387|Active Comparator|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
16546401|NCT02974387|Active Comparator|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
16546402|NCT02974374|Experimental|PF-06835919|
16546403|NCT02974374|Placebo Comparator|Placebo|
16546404|NCT02974361|Active Comparator|Part A Ibuprofen control|
16546405|NCT02974361|Experimental|Part A Ibuprofen-LDH|
16546406|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 1|
16546407|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 2|
16546408|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 3|
16546409|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 4|
16546410|NCT02974361|Active Comparator|Part A Ibuprofen Lysine|
16546411|NCT02974361|Active Comparator|Part B Ibuprofen|
16546412|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 1|
16546413|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 2|
16546414|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 3|
16546415|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 4|
16546416|NCT02974361|Active Comparator|Part C Ibuprofen|
16546417|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 1|
16546418|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 2|
16546419|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 3|
16546420|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 5|
16546421|NCT02974348|Active Comparator|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
16546422|NCT02974348|Active Comparator|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
16546423|NCT02974348|Active Comparator|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
16546424|NCT02974348|Other|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
16546425|NCT02974348|Other|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
16546426|NCT02974348|Other|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
16546427|NCT02974335||Identify screening and intervention approaches|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
16546428|NCT02974322|Experimental|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
16546429|NCT02974322|Experimental|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
16546430|NCT02974322|Placebo Comparator|Placebo once daily|Placebo once daily (QD)
16546431|NCT02974309|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
16546432|NCT02974309|Sham Comparator|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
16546433|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
16546434|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
16546435|NCT02974283|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
16546436|NCT02974283|No Intervention|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
16546437|NCT02974270|Experimental|Leuprolide acetate|
16546438|NCT02974257|Experimental|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
16546439|NCT02974257|Placebo Comparator|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
16546440|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
16546441|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
16546442|NCT02974205|Active Comparator|Rehabilitation with orthosis (Jack brace)|
16546443|NCT02974205|Active Comparator|Rehabilitation without orthosis|
16546444|NCT02974205|Active Comparator|Rehabilitation with orthosis (össur brace)|
16546445|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
16597973|NCT02625818||acute psychiatric condition|
16546446|NCT02974166|Active Comparator|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
16546447|NCT02974166|Experimental|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
16546448|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
16546449|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
16546450|NCT02974153|Placebo Comparator|Placebo|Placebo (IV)
16546451|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
16546452|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
16546453|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
16546454|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
16546455|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
16546456|NCT02974101|Experimental|spinal cord stimulation(RestoreSensor)|
16546457|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
16546458|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
16546459|NCT02974075|Experimental|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
16546460|NCT02974062|Experimental|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
16546461|NCT02974062|No Intervention|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
16546462|NCT02974049|Active Comparator|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
16546463|NCT02974049|Experimental|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
16546464|NCT02974049|Experimental|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
16546465|NCT02974049|Experimental|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
16546466|NCT02974036|Experimental|Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
16546467|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
16546468|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101
16546469|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
16546470|NCT02973971||Healthy subjects|
16546471|NCT02973971||Alzheimer patients|
16546472|NCT02973958|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen post-operatively as needed.
16546473|NCT02973958|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
16546474|NCT02973945|Experimental|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
16546475|NCT02973945|Active Comparator|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
16546476|NCT02973932|Experimental|Internet-based psychotherapy|
16546477|NCT02973919|Experimental|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
16546478|NCT02973919|Active Comparator|Control|virtual reality exposure therapy
16546479|NCT02973906|Other|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
16546480|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
16546481|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
16546482|NCT02973893|Placebo Comparator|Placebo plus Standard Care|Placebo plus Standard Care
16546483|NCT02973893|Experimental|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose [LD])
16546484|NCT02973893|Experimental|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose [HD])
16546485|NCT02973880|Experimental|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.
~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
16546486|NCT02973880|Active Comparator|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.
~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
16546487|NCT02973867||Cohort called Elodie|Obese patients
16546488|NCT02973841|Experimental|Sono-ease group|insertion IJV catheter using sono-ease device
16546489|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
16546490|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
16546491|NCT02973828||C) Pathway development studies|Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
16546492|NCT02973828||D) On going imaging development & quality improvement|This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.
16546493|NCT02973815|Experimental|NU-HOME Intervention|Participants randomized to the intervention condition will receive the NU-HOME family intervention program that includes group sessions with other families focused on nutrition education, cooking skills, and physical activity. The intervention program also includes individual goal setting phone calls with parents and online, complementary materials.
16546494|NCT02973815|No Intervention|Delayed Intervention|Participants randomized to the delayed intervention condition will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a shortened version of the NU-HOME intervention program that was offered to the intervention families.
16546495|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
16546496|NCT02973789|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with immune checkpoint inhibitors or docetaxel
16546497|NCT02973789|Active Comparator|Best Standard of Care|Patients receive best standard of care with immune checkpoint inhibitors or docetaxel
16546498|NCT02973776|Experimental|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
16546499|NCT02973776|Active Comparator|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
16546500|NCT02973776|Active Comparator|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
16546501|NCT02973776|Active Comparator|Elocon®|"Elocon® mometasone furoate 0.1% cream
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
16546502|NCT02973776|Active Comparator|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
16546503|NCT02973776|Placebo Comparator|LEO 90100 foam vehicle|"LEO 90100 foam vehicle
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
16546504|NCT02973763|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
16546505|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
16546506|NCT02973737|Experimental|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
16546507|NCT02973737|Active Comparator|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
16546508|NCT02973724|Experimental|Remifentanil|Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
16546509|NCT02973711|Experimental|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.
~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
16546510|NCT02973698|Other|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
16546511|NCT02973698|Other|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
16546512|NCT02973698|Other|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
16546513|NCT02973685|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
16546514|NCT02973685|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, with or without MMC), and embolization with polyvinyl alcohol particles (PVA).
16546515|NCT02973672|Experimental|SGM-101|
16546516|NCT02973659|Experimental|patients with palmar hyperhidrosis|oxybutynin Vs placebo
16546517|NCT02973659|Experimental|patients with plantar hyperhidrosis|oxybutynin Vs placebo
16546518|NCT02973659|Experimental|patients with axillary hyperhidrosis|oxybutynin Vs placebo
16546519|NCT02973646|Experimental|Nucleos(t)ide analogues treatment|Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
16546520|NCT02973646|Active Comparator|Peginterferon treatment|Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
16546521|NCT02973633|Active Comparator|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
16546522|NCT02973633|Active Comparator|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
16546523|NCT02973633|Active Comparator|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
16546524|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
16546525|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
16546526|NCT02973594|Active Comparator|Ivabradine|Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
16546527|NCT02973594|Placebo Comparator|Placebo|Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
16546528|NCT02973581|Experimental|metamizol|analgesic drug
16546529|NCT02973581|Experimental|acetaminophen|analgesic drug
16546530|NCT02973581|Experimental|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
16546531|NCT02973581|Experimental|Proxymetacaine|topical analgesia
16546532|NCT02973581|Placebo Comparator|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
16546533|NCT02973555|Experimental|PRP injection|
16546534|NCT02973542|Experimental|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
16546535|NCT02973542|Placebo Comparator|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
16546536|NCT02973529|Experimental|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
16546537|NCT02973529|Experimental|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
16547618|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
16546539|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
16546540|NCT02973490|Experimental|Transanal Tube Drainage|patients with transanal tube drainage after ESD
16546541|NCT02973490|No Intervention|Without Transanal Tube Drainage|patients without transanal tube drainage after ESD
16546542|NCT02973477|Experimental|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
16546543|NCT02973477|Experimental|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
16546544|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
16546545|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
16546546|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
16546547|NCT02973451|Active Comparator|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
16546548|NCT02973451|Active Comparator|local|Trocar Site Infiltration of Bupivacaine
16546549|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
16546550|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
16546551|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
16546552|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
16546553|NCT02973425|Active Comparator|NRT and mHealth assessment tool without feedback|"For the comparison group, implementation will be balanced in all variables except the Take a Break Intervention. The investigators will balance the two groups further by having the comparison (NRT-Sampling group) complete mHealth assessments (without feedback or goal-setting) as an attention control.
~Participants randomized to the comparison group will only have access to a mHealth assessment tool similar to the Challenge Quizzes but without feedback."
16546554|NCT02973425|Experimental|Take a Break as an augmentation to NRT in Motivation|"The Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase. Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At weeks 1 and 3 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and collect data.Participants in the intervention will receive the full tool suite."
16546555|NCT02973399|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
16546556|NCT02973386|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
16546557|NCT02973386|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
16546558|NCT02973373|Experimental|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
16546559|NCT02973373|Active Comparator|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
16546560|NCT02973360|Experimental|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
16546561|NCT02973360|Experimental|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
16546562|NCT02973360|Experimental|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
16546563|NCT02973360|Placebo Comparator|Placebo|Soybean oil
16546564|NCT02973347|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
16546565|NCT02973347|Active Comparator|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
16546566|NCT02973334|Experimental|Sugar|Effects of ingestion of sugar-sweetened beverages on acute stress response
16546567|NCT02973334|Experimental|Artificial sweetener|Effects of ingestion of artificially-sweetened beverages on acute stress response
16546568|NCT02973334|Active Comparator|Water|Effects of ingestion of water on acute stress response
16546569|NCT02973321|Placebo Comparator|Placebo|Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
16546638|NCT02972879|Active Comparator|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
16546570|NCT02973321|Experimental|SAR425899 0.12 mg|SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
16546571|NCT02973321|Experimental|SAR425899 0.16 mg|SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
16546572|NCT02973321|Experimental|SAR425899 0.20 mg|SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
16546573|NCT02973321|Active Comparator|Liraglutide|Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).
16546574|NCT02973308|Other|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
16546575|NCT02973308|Other|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
16546576|NCT02973308|Other|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
16546577|NCT02973308|Other|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
16546578|NCT02973295|Experimental|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
16546579|NCT02973295|Placebo Comparator|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
16546580|NCT02973269|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
16546581|NCT02973269|Placebo Comparator|Placebo|Placebo Intramuscular injection
16546582|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
16546583|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
16546584|NCT02973217|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
16546585|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
16546586|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
16546587|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
16546588|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
16546589|NCT02973191|Experimental|JCAR015 administration|Single dose of 1.0-3.0 mg/m^2 IV cyclophosphamide, JCAR015 Dose 1 1x10^6 Tcells/kg, JCAR015 Dose 2 3x10^6 Tcells/kg
16546590|NCT02973178|Other|Usability|Evaluate and validate the user-interface of the Scanadu Urine Device by the intended users for human factors and user interface of the Scanadu Urine Device.
16546591|NCT02973178|Active Comparator|Method Comparison|"Evaluate and validate the clinical performance of the Scanadu Urine Device in the hands of intended users as compared to:
~The visual read of chemical test strips performed by lab technicians utilizing the Siemens Multistix® 10SG technology (K905396),
~Scanadu Urine Device tests performed by lab technicians."
16546592|NCT02973178|Other|Reproducibility|Evaluate the reproducibility in the hands of the lay-users after repeated testing of samples with known test levels.
16546593|NCT02973152|Active Comparator|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
16546594|NCT02973152|Active Comparator|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
16546595|NCT02973139|Active Comparator|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
16546596|NCT02973139|Active Comparator|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
16546597|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
16546598|NCT02973113|Experimental|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.
~EBVST- 1 x 10^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.
~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
16546599|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
16546600|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
16546601|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
16546602|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
16546603|NCT02973087|Experimental|All Study Participants|Participants will receive prophylaxis with rVWF in two cohorts: on-demand (OD) cohort (previously treated with OD) and pdVWF switch cohort (participants switching from prophylactic treatment with pdVWF).
16546604|NCT02973074|Other|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
16546605|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
16546606|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
16598322|NCT02623699|Experimental|Fixed Dose|Part C: Fixed Dose
16546607|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
16546608|NCT02973048|Active Comparator|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
16546609|NCT02973035|Experimental|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
16546610|NCT02973035|Experimental|Valsartan|Valsartan 40mg added to antihypertensive therapy
16546611|NCT02973022||Community CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group in the community will be exposed to the modified CC&S educational sessions in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational sessions. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
16546612|NCT02973022||Community Control Group|Once participants are randomized, they will be given survey 1. The control group in the community will be exposed to a nutrition education program in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational session. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
16546613|NCT02973022||ACEC CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group at ACEC (Adams-Columbia Electric Company) will be exposed to the modified CC&S educational sessions in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. The researchers anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
16546614|NCT02973022||ACEC Control Group|Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
16546615|NCT02972996|Experimental|Blueberry|
16546616|NCT02972996|Placebo Comparator|Placebo|
16546617|NCT02972983|Placebo Comparator|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
16546618|NCT02972983|Experimental|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
16546619|NCT02972970|Other|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
16546620|NCT02972957|Experimental|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
16546621|NCT02972957|Experimental|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
16546622|NCT02972957|No Intervention|Unvaccinated|control group C
16546623|NCT02972957|Experimental|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
16546626|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
16546627|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
16546628|NCT02972918||Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
16546629|NCT02972905|Placebo Comparator|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
16546630|NCT02972905|Experimental|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
16546631|NCT02972905|Experimental|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
16546632|NCT02972905|Experimental|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
16546633|NCT02972905|Placebo Comparator|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
16546634|NCT02972905|Experimental|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
16546635|NCT02972905|Experimental|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
16546636|NCT02972905|Experimental|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
16546637|NCT02972879|Active Comparator|Therapeutic Modalities|"Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing
~Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.
~Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
16546672|NCT02972619|No Intervention|Usual Care|Control group receive usual care in the polyclinics
16546639|NCT02972866|Experimental|Noex 32mcg|"Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.
~Tretament of 28 days."
16546640|NCT02972866|Experimental|Budecort Aqua 32 mcg|"Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.
~Tretament of 28 days."
16546642|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
16546643|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
16546644|NCT02972827|Experimental|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
16546645|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
16546646|NCT02972801|Experimental|Testicular tissue biopsy|Testicular biopsy
16546647|NCT02972788|Experimental|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
16546648|NCT02972788|Sham Comparator|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
16546649|NCT02972762|Active Comparator|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
16546650|NCT02972762|Active Comparator|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
16546651|NCT02972749|Experimental|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
16546652|NCT02972749|No Intervention|Control|No intervention. patients are instructed to continue prescribed medical therapy.
16546653|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
16546654|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
16546655|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
16546656|NCT02972723|Experimental|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
16546657|NCT02972710|Active Comparator|Supine thoracic spine manipulation|Supine thoracic spine thrust manipulation (lying face-up on the treatment table) will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
16546658|NCT02972710|Active Comparator|Seated thoracic spine manipulation|Seated thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
16546659|NCT02972697|Experimental|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
16546660|NCT02972684|No Intervention|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
16546661|NCT02972684|Experimental|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
16546662|NCT02972671|Experimental|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
16546663|NCT02972671|Active Comparator|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
16546664|NCT02972658|Experimental|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
16546665|NCT02972658|Experimental|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
16546666|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
16546667|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
16546668|NCT02972645|Experimental|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
16546669|NCT02972645|Placebo Comparator|Placebo|Placebo administered SC
16546670|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
16546671|NCT02972619|Experimental|Intervention|Structured multicomponent intervention (MCI)
16546673|NCT02972593|Other|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb >7 g/dL.
16546674|NCT02972593|Other|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb > 5.5 g/dL.
16546675|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
16546676|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
16546677|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
16546678|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
16546679|NCT02972567|Experimental|Probiotic|Lactobacillus strain
16546680|NCT02972567|Placebo Comparator|Control|Maltodextrin
16546681|NCT02972554|Experimental|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
16546682|NCT02972554|Placebo Comparator|Placebo|This is the control group given a placebo.
16546683|NCT02972541|Experimental|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
16546684|NCT02972541|Active Comparator|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
16546685|NCT02972528|Active Comparator|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
16546686|NCT02972528|Placebo Comparator|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
16546687|NCT02972515|Experimental|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
16546688|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
16546689|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
16546690|NCT02972489|Experimental|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
16546691|NCT02972489|Active Comparator|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
16546692|NCT02972476|Active Comparator|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
16546693|NCT02972476|Active Comparator|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
16546694|NCT02972476|Active Comparator|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
16546695|NCT02972476|Active Comparator|4: Duaklir Genuair|Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
16546696|NCT02972463|Placebo Comparator|Placebo|9 maltodextrin capsules, once daily for 12 weeks
16546697|NCT02972463|Experimental|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
16546698|NCT02972463|Experimental|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
16546699|NCT02972463|Experimental|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
16546700|NCT02972450|Experimental|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:
~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
16546701|NCT02972450|Experimental|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
16546702|NCT02972450|Experimental|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
16546703|NCT02972450|Placebo Comparator|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.
~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.
~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
16546704|NCT02972424|Experimental|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
16546705|NCT02972424|Placebo Comparator|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
16546706|NCT02972411|Experimental|Intervention|Voluntary increase in respiration
16546780|NCT02971891|Placebo Comparator|Vehicle|Vehicle Topical Gel
16599317|NCT02616991|Experimental|Cohort|computed tomography venography
16546707|NCT02972411|Active Comparator|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
16546710|NCT02972372|Active Comparator|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
16546711|NCT02972372|Active Comparator|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
16546712|NCT02972359|Experimental|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
16546713|NCT02972346|Experimental|ACTH(+)|routine treatment + ACTH
16546714|NCT02972346|No Intervention|ACTH(-)|routine treatment
16546715|NCT02972333|Experimental|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
16546716|NCT02972320|Experimental|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
16546717|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
16546718|NCT02972294|Experimental|TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
16546719|NCT02972294|Experimental|Placebo TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
16546720|NCT02972294|Experimental|TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
16546721|NCT02972294|Experimental|Placebo TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid
16546722|NCT02972281|Other|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
16546723|NCT02972268|Experimental|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
16546724|NCT02972268|Placebo Comparator|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
16546725|NCT02972255|Experimental|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
16546726|NCT02972255|Placebo Comparator|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
16546727|NCT02972255|Experimental|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than [>] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
16546728|NCT02972255|Placebo Comparator|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
16546729|NCT02972255|Experimental|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
16546730|NCT02972255|Placebo Comparator|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
16546731|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
16546781|NCT02971878|No Intervention|Control|Culture media without addition of antioxidants
16546782|NCT02971878|Active Comparator|Treatment|Culture media with the addition of antioxidants
16599449|NCT02616159|Placebo Comparator|Ready to eat cereal|32.2 g cereal
16546732|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
16546733|NCT02972229|Experimental|partial body group|10x(3-5) Gy IMRT on partial vertebral body
16546734|NCT02972229|Active Comparator|whole body group|10x3 Gy IMRT on whole vertebral body
16546735|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
16546736|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
16546737|NCT02972203|Experimental|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
16546738|NCT02972203|Active Comparator|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
16546739|NCT02972190|Experimental|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
16546740|NCT02972190|Active Comparator|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
16546741|NCT02972177|Experimental|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
16546742|NCT02972177|Experimental|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
16546743|NCT02972164|No Intervention|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
16546744|NCT02972164|Experimental|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
16546745|NCT02972151|Experimental|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
16546746|NCT02972151|Active Comparator|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.
~（3 months after the start of the trial and 1 months after the end of the trial.）"
16546747|NCT02972125|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
16546748|NCT02972125|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
16546749|NCT02972112|Active Comparator|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
16546750|NCT02972112|Sham Comparator|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
16546751|NCT02972099|Experimental|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.
~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
16546752|NCT02972099|Placebo Comparator|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
16546753|NCT02972086|Experimental|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
16546821|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
16546822|NCT02971605|Experimental|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
16546823|NCT02971592|Experimental|Experimental|
16546754|NCT02972073|Experimental|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:
~core stabilization exercise
~movement system impairment approach
~neuromuscular activation using suspension
~kinematic linkage imbalance"
16546755|NCT02972073|No Intervention|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
16546756|NCT02972060|Active Comparator|ADT|"The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.
~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
16546757|NCT02972060|Experimental|ODM 201|"ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.
~Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.
~Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment."
16546758|NCT02972047|Experimental|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.
~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.
~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker
~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
16546759|NCT02972047|Sham Comparator|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)
~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)
~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker
~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
16546760|NCT02972034|Experimental|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
16546761|NCT02972034|Experimental|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16546762|NCT02972034|Experimental|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
16546763|NCT02972034|Experimental|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
16546764|NCT02972021|Other|control|Pure oxygen by nasal cannula group
16546765|NCT02972021|Experimental|HFNC|oxygen by High-flow nasal cannula
16546766|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
16546767|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
16546768|NCT02971995|Experimental|Prostate cancer/TEP scan|
16546769|NCT02971995|Active Comparator|Prostate cancer/mpMRI|
16546770|NCT02971982|Experimental|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
16546771|NCT02971982|Experimental|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
16546773|NCT02971943|Other|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
16546774|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
16546775|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
16546776|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
16546777|NCT02971917|Experimental|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
16546778|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
16546779|NCT02971891|Experimental|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
16546783|NCT02971865|Experimental|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
16546784|NCT02971865|Active Comparator|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
16546785|NCT02971839|Experimental|VX-561 20 mg|
16546786|NCT02971839|Experimental|VX-561 100 mg|
16546787|NCT02971839|Experimental|VX-561 150 mg|
16546788|NCT02971839|Active Comparator|Ivacaftor|
16546789|NCT02971839|Placebo Comparator|Placebo|
16546790|NCT02971826|Experimental|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
16546791|NCT02971813|Experimental|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
16546792|NCT02971813|Active Comparator|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
16546793|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.
~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
16546794|NCT02971787|Experimental|Probiotics and salt|Lactobacillus enrichment and salt increase
16546795|NCT02971774||questionnary|self administered questionnary
16546796|NCT02971761|Experimental|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
16546797|NCT02971748|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16546798|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
16546799|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
16546800|NCT02971722|Experimental|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546801|NCT02971722|Experimental|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546802|NCT02971722|Experimental|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546803|NCT02971722|Placebo Comparator|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546804|NCT02971722|Experimental|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546805|NCT02971722|Experimental|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546806|NCT02971722|Experimental|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546807|NCT02971722|Placebo Comparator|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
16546808|NCT02971709|Experimental|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
16546809|NCT02971709|No Intervention|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
16546810|NCT02971696|Experimental|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
16546811|NCT02971696|Active Comparator|HCC patients (Group 2)|Patient will take best supportive care
16546812|NCT02971683|Active Comparator|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
16546813|NCT02971683|Placebo Comparator|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
16546814|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
16546815|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
16546816|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
16546817|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
16546818|NCT02971644|Experimental|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
16546819|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
16546820|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
16546825|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:
~necrotizing enterocolitis (stage ≥2)
~spontaneous intestinal perforation
~feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
16546826|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
16546827|NCT02971553|Experimental|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
16546828|NCT02971553|Active Comparator|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
16546829|NCT02971540|Experimental|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
16546830|NCT02971540|Experimental|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
16546831|NCT02971540|Experimental|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
16546832|NCT02971540|Experimental|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
16546833|NCT02971540|Experimental|control group|no pre-emptive analgesia will be used.
16546834|NCT02971527|Experimental|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
16546835|NCT02971527|Experimental|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
16546836|NCT02971514|Experimental|Floss-Brush group|The participants flossed first followed by brushing
16546837|NCT02971514|Active Comparator|Brush-Floss group|They used dental floss after brushing
16546838|NCT02971501|Experimental|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16546839|NCT02971501|Experimental|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16546840|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
16546841|NCT02971475|Experimental|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
16546842|NCT02971475|Active Comparator|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
16546843|NCT02971462|Experimental|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
16546844|NCT02971462|No Intervention|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
16546845|NCT02971449|Experimental|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
16546846|NCT02971449|Active Comparator|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
16546847|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
16546848|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
16546849|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
16546850|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
16546851|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
16546852|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
16546853|NCT02971423|Experimental|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
16546854|NCT02971423|Experimental|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
16546855|NCT02971423|Experimental|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
16546856|NCT02971423|Experimental|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
16546857|NCT02971423|Experimental|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
16546877|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
16546858|NCT02971423|Experimental|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
16546859|NCT02971423|Experimental|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
16546860|NCT02971423|Experimental|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
16546861|NCT02971423|Experimental|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
16546862|NCT02971423|Experimental|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
16546863|NCT02971423|Experimental|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
16546864|NCT02971423|Experimental|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
16546865|NCT02971423|Experimental|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
16546866|NCT02971423|Experimental|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
16546867|NCT02971423|Experimental|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
16546868|NCT02971410|Experimental|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
16546869|NCT02971397|Experimental|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity >= 10% and > 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
16546870|NCT02971384|Experimental|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
16546871|NCT02971384|Active Comparator|Vitamin C Tablets|synthetically produced ascorbic acid
16546872|NCT02971371|Experimental|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
16546873|NCT02971371|Active Comparator|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
16546874|NCT02971358|Experimental|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
16546875|NCT02971345|Experimental|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.
~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
16546876|NCT02971345|Active Comparator|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
16546878|NCT02971306|Active Comparator|Standard Medical therapy|standard medical therapy
16546879|NCT02971306|Experimental|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
16546880|NCT02971306|Experimental|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
16546881|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
16546882|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
16546883|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
16546884|NCT02971254|Active Comparator|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
16546885|NCT02971254|Active Comparator|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
16546886|NCT02971241|Experimental|Immediate intervention group|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.
~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers with a lead instructor."
16546887|NCT02971241|Other|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
16546888|NCT02971228|Experimental|Part 1, Lilly glucagon then ZP4207|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
16546889|NCT02971228|Experimental|Part 1, ZP4207 then Lilly Glucagon|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
16546890|NCT02971228|Experimental|Part 2, Lilly glucagon then ZP4207|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
16546891|NCT02971228|Experimental|Part 2, ZP4207 then Lilly Glucagon|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
16546892|NCT02971215|Experimental|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
16546893|NCT02971215|Sham Comparator|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
16546894|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
16546895|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
16546896|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
16546937|NCT02970890|Placebo Comparator|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
16547099|NCT02969720|Placebo Comparator|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
16546897|NCT02971189|Other|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
16546898|NCT02971176|Experimental|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
16546899|NCT02971176|Active Comparator|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
16546900|NCT02971163|Experimental|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
16546901|NCT02971163|No Intervention|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
16546902|NCT02971150|Experimental|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
16546903|NCT02971150|No Intervention|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
16546904|NCT02971137|Experimental|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
16546905|NCT02971137|Active Comparator|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
16546906|NCT02971124||Healthy Elderly|
16546907|NCT02971124||Mild Cognitive Impaired Elderly|
16546908|NCT02971098|Experimental|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
16546909|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men < 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density < 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
16546910|NCT02971072|Experimental|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
16546911|NCT02971059|Experimental|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
16546912|NCT02971059|Experimental|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
16546914|NCT02971033|Placebo Comparator|placebo|placebo
16546915|NCT02971033|Experimental|20mg/day ezetimibe|20mg/day ezetimibe
16546916|NCT02971033|Experimental|40mg/day exetimibe|40mg/day ezetimibe
16546917|NCT02971020|Other|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
16546918|NCT02971020|Other|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
16546919|NCT02971007|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
16546920|NCT02971007|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
16546921|NCT02971007|Active Comparator|Fluconazole 150 mg|Fluconazole Diflucan
16546922|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates <34 weeks with in 48 hours of admission
16546923|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)
~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
16546924|NCT02970968|Experimental|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
16546925|NCT02970968|Placebo Comparator|Placebo|Placebo oral capsule for 4 weeks.
16546926|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
16546927|NCT02970942|Experimental|Semaglutide 0,1 mg|
16546928|NCT02970942|Experimental|Semaglutide 0,2 mg|
16546929|NCT02970942|Experimental|Semaglutide 0,4 mg|
16546930|NCT02970942|Placebo Comparator|Placebo 1|
16546931|NCT02970942|Placebo Comparator|Placebo 2|
16546932|NCT02970942|Placebo Comparator|Placebo 3|
16546933|NCT02970929|Experimental|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
16546934|NCT02970916|Experimental|FOLFIRI+aflibercept|
16546935|NCT02970903|Experimental|VitalPAD|Using VitalPAD prototype device
16546936|NCT02970903|Active Comparator|Control|Using traditional tools (monitors, paper records)
16547100|NCT02969707|Experimental|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
16546938|NCT02970890|Active Comparator|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
16546939|NCT02970877|Experimental|Allogenic treatment group|Fecal filtrate from 150 g stool from healthy lean donors
16546940|NCT02970877|Placebo Comparator|Autologous control group|Fecal filtrate from 150 g of the recipient's own stool
16546941|NCT02970864|Experimental|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
16546942|NCT02970838|Experimental|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
16546943|NCT02970825|Experimental|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining structured aerobic exercise (at least 20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
16546944|NCT02970825|Active Comparator|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, social relaxation, flexibility training).
16546945|NCT02970812|Experimental|Electrical Muscle Stimulation|Electrical Muscle Stimulation (EMS) program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
16546946|NCT02970812|Placebo Comparator|Transcutaneous Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
16546947|NCT02970786|Experimental|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c[RGDyK])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
16546948|NCT02970773|Other|rivaroxaban|Rivaroxaban Oral Tablet
16546949|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
16546950|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
16546951|NCT02970747||Car/Dex/Dara (KdD)|Patients treated with carfilzomib, dexamethasone and daratumumab dosage form, dosage, frequency and duration of treatment according to current SmPC
16546952|NCT02970734|Experimental|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
16546953|NCT02970734|Active Comparator|Resource webpage|Webpage that provides general resources on anxiety
16546954|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
16546955|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
16546956|NCT02970708|Experimental|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
16546957|NCT02970708|Active Comparator|Patching group|amblyopia in patching group will receive patching treatment.
16546958|NCT02970695|Active Comparator|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
16546959|NCT02970695|Active Comparator|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
16546960|NCT02970695|Experimental|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
16546961|NCT02970682|Experimental|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
16546962|NCT02970682|Experimental|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
16546963|NCT02970682|Experimental|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
16546964|NCT02970669|Active Comparator|Enalapril|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.
~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
16547034|NCT02970097|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
16547101|NCT02969707|Sham Comparator|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
16546965|NCT02970669|Experimental|Sacubitril/Valsartan|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may have sequentially been up-titrated to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.
~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1. Patients may sequentially have been up-titrated to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
16546966|NCT02970656|Experimental|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
16546967|NCT02970656|No Intervention|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
16546968|NCT02970643|Experimental|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
16546969|NCT02970630|Experimental|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.
~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
16546970|NCT02970617|Active Comparator|Group A (no bell after final radiation)|Patients undergo standard of care radiation therapy with or without chemotherapy.
16546971|NCT02970617|Experimental|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
16546972|NCT02970604|Experimental|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
16546973|NCT02970604|No Intervention|No treatment|No treatment for 7 days
16546974|NCT02970591|Experimental|Diet B|Low carbohydrate diet
16546975|NCT02970591|Active Comparator|Medical treatment|Optimized Medical treatment
16546976|NCT02970591|Experimental|Diet A|Traditional dietary advice and low FODMAP content
16546977|NCT02970578|Experimental|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
16546978|NCT02970565|Experimental|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
16546979|NCT02970565|Experimental|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
16546980|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
16546981|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
16546982|NCT02970539|Experimental|Oraxol +Ramucirumab|"Oraxol (oral HM30181 + oral paclitaxel)
~HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets
~Paclitaxel - supplied as 30-mg capsules Ramucirumab - supplied as a solution at a concentration of 10 mg/mL"
16546983|NCT02970526||colorectal cancer survivors|
16546984|NCT02970513|Experimental|patients operated on for colorectal cancer|
16546985|NCT02970500|Experimental|Methylphenidate HCl 10Mg SR|Participants of the intervention group (n=20) will receive 1 capsule of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 1 and 2 capsules of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 2.
16546986|NCT02970500|Placebo Comparator|Placebo Group|Participants of the control group (n=20) will receive 1 capsule of placebo each morning during 14 days during phase 1 and 2 capsules of placebo each morning during 14 days during phase 2.
16546987|NCT02970487|Experimental|investigational device|Subjects implanted with the Precisight intraocular lens.
16546988|NCT02970474|Other|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
16546989|NCT02970461|Placebo Comparator|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
16546990|NCT02970461|Experimental|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
16546991|NCT02970448|Experimental|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
16547035|NCT02970097|Active Comparator|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
16546992|NCT02970435|Experimental|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
16546993|NCT02970435|Active Comparator|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
16546994|NCT02970422||Quartile 1 [Mild]|
16546995|NCT02970422||Quartile 2 [Moderate]|
16546996|NCT02970422||Quartile 3 [Severe]|
16546997|NCT02970422||Quartile 4 [Very Severe]|
16546998|NCT02970409|Active Comparator|heparin|Catheter Lock Therapy with Heparin
16546999|NCT02970409|Experimental|saline|Catheter Lock Therapy with saline
16547000|NCT02970396|Active Comparator|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
16547001|NCT02970396|Active Comparator|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
16547002|NCT02970383|Experimental|10 group|Initial prescription for 10 narcotic tabs
16547003|NCT02970383|Active Comparator|30 group|Initial prescription for 30 narcotic tabs
16547004|NCT02970357|Other|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
16547005|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
16547006|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
16547007|NCT02970331|Experimental|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
16547008|NCT02970318|Experimental|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
16547009|NCT02970318|Active Comparator|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
16547010|NCT02970305|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
16547011|NCT02970305|Placebo Comparator|Placebo|Placebo, taken as two tablets + background antipsychotic, once daily by mouth
16547012|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
16547013|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
16547014|NCT02970279|Experimental|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;
~Implementation intentions
~Dose-response psychoeducation"
16547015|NCT02970253|Active Comparator|Capsular resection|Capsular resection
16547016|NCT02970253|Active Comparator|Capsular retention|Capsular retention
16547017|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
16547018|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
16547019|NCT02970240||Control group|Healthy control persons
16547020|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
16547021|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
16547022|NCT02970201|Other|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
16547023|NCT02970201|Other|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
16547024|NCT02970188|No Intervention|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
16547025|NCT02970188|Experimental|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
16547026|NCT02970175|Experimental|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
16547027|NCT02970175|Placebo Comparator|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
16547028|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
16547029|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
16547030|NCT02970136|Experimental|Home Based Screening|The participant will be receiving home-based screening tests (OraQuick Swab, OraQuick Fingerstick, Human Papillomavirus (HPV) Self-Sampling Test, Fecal Immunochemical Test) delivered by the community health worker
16547031|NCT02970136|Active Comparator|Clinic Based Screening|The participant will meet the Community Health Worker and will be navigated to a clinic appointment for standard screening tests
16547032|NCT02970123|Experimental|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
16547033|NCT02970123|No Intervention|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
16547098|NCT02969720|Experimental|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
16547036|NCT02970084|Experimental|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.
~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
16547037|NCT02970084|No Intervention|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
16547038|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
16547039|NCT02970058|Active Comparator|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
16547040|NCT02970058|Placebo Comparator|Control|30 patients will receive sterile saline post-spinal anesthesia
16547041|NCT02970045||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
16547042|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
16547043|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
16547044|NCT02970019|Experimental|K0706|K0706 will be administered once a day
16547045|NCT02970019|Experimental|Placebo|Placebo will be administered once a day
16547046|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
16547047|NCT02969993|Experimental|Questionnaire|Questionnaire to previously operated patients
16547048|NCT02969980|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
16547049|NCT02969967|Experimental|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
16547050|NCT02969954|Experimental|Intervention arm|Study has one arm - who will all receive the intervention
16547051|NCT02969941|Active Comparator|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
16547052|NCT02969941|Placebo Comparator|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
16547053|NCT02969928|Active Comparator|Amoxicillin and Metronidazole|In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
16547054|NCT02969928|Experimental|Clarithromycin|In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
16547055|NCT02969915|Active Comparator|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
16547056|NCT02969915|Experimental|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
16547057|NCT02969902|Experimental|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
16547058|NCT02969902|Active Comparator|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
16547059|NCT02969889|Active Comparator|intubation time|handling the device till the endotracheal tube passing through the glottis
16547060|NCT02969889|Active Comparator|insertion time|handling of the device till the glottic visualization
16547061|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
16547062|NCT02969863|Active Comparator|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.
~Monitored for hypoglycemia"
16547063|NCT02969863|Active Comparator|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.
~Not monitored for hypoglycemia"
16547064|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.
~Monitored for hypoglycemia"
16548890|NCT02957929|Experimental|Cohort 1a, Period D|single oral dose, crossover
16547065|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.
~Not monitored for hypoglycemia"
16547066|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.
~Monitored for hypoglycemia"
16547067|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.
~Not monitored for hypoglycemia"
16547070|NCT02969837|Experimental|E-KRd regimen|Participants will receive elotuzumab, carfilzomib, lenalidomide, and dexamethasone.
16547071|NCT02969837|Experimental|E-Rd Regimen|Participants will receive elotuzumab, lenalidomide, and dexamethasone.
16547072|NCT02969824|No Intervention|Usual Care Group|"These individuals will undergo a period of physical rest and standard care until symptoms spontaneously resolve. For the purposes of this study, rest will be defined as the avoidance of any activities beyond those of daily living, including participation in sport and physical activity. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines."
16547073|NCT02969824|Experimental|Supervised Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
16547074|NCT02969798|No Intervention|Healthy normal glucose tolerance (NGT) subjects|Subjects (Fasting Plasma Glucose or FPG < 100 mg/dl and 2-h PG < 140 mg/dl) without FH (family history) of diabetes in a first degree relative
16547075|NCT02969798|Active Comparator|Isolated IGT with Dapagliflozin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive dapagliflozin, 10 mg/day
16547076|NCT02969798|Active Comparator|Isolated IGT with Saxagliptin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive saxagliptin, 5 mg/day
16547077|NCT02969798|Active Comparator|Isolated IGT with Pioglitazone|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
16547078|NCT02969798|Active Comparator|Isolated IGT with Metformin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
16547079|NCT02969798|Active Comparator|Isolated IFG with Dapagliflozin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive dapagloflozin, 10mg/day
16547080|NCT02969798|Active Comparator|Isolated IFG with Saxagliptin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive saxagliptin, 10mg/day
16547081|NCT02969798|Active Comparator|Isolated IFG with Pioglitazone|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
16547082|NCT02969798|Active Comparator|Isolated IFG with Metformin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
16547083|NCT02969798|Active Comparator|IGT plus IFG with Dapagliflozin|Healthy subjects with IGT plus IFG will receive dapagliflozin, 10mg/day
16547084|NCT02969798|Active Comparator|IGT plus IFG with Saxagliptin|Healthy subjects with IGT plus IFG will receive saxagliptin, 10mg/day
16547085|NCT02969798|Active Comparator|IGT plus IFG with Pioglitazone|Healthy subjects with IGT plus IFG will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
16547086|NCT02969798|Active Comparator|IGT plus IFG with Metformin|Healthy subjects with IGT plus IFG will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
16547087|NCT02969785|Experimental|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
16547088|NCT02969785|Active Comparator|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
16547089|NCT02969772|Experimental|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
16547090|NCT02969772|Experimental|Training protocol|Training with electrical stimulation of upper limb
16547091|NCT02969759|Other|Patients|ALS defined by El Escorial Criteria.
16547092|NCT02969759|Other|Controls|Asymptomatic subjects with normal examination.
16547093|NCT02969746|Experimental|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
16547094|NCT02969746|No Intervention|control|Standard practice
16547095|NCT02969733|Experimental|Xylocaine|intravenous administration
16547096|NCT02969733|Experimental|Ketamine|intravenous administration
16547097|NCT02969733|Placebo Comparator|isotonic saline serum|isotonic saline serum intravenous administration
16547102|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.
~The patients will answer to the G-STAT questionnaire."
16547103|NCT02969681|Experimental|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
~mFOLFOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
~with or without bevacizumab 5mg/kg, every 2 weeks"
16547104|NCT02969681|Active Comparator|Chemotherapy group|"mFOLFOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
~with or without bevacizumab 5mg/kg, every 2 weeks"
16547105|NCT02969655|Experimental|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
16547106|NCT02969655|Active Comparator|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
16547107|NCT02969642|Sham Comparator|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
16547108|NCT02969642|Active Comparator|Treatment|Treatment laser.
16547109|NCT02969629|Experimental|apomorphine|1.5 mg apomorphine, administered subcutaneously
16547110|NCT02969629|Placebo Comparator|Normal saline|saline, administered subcutaneously
16547111|NCT02969603|Other|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
16547112|NCT02969603|Other|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined [11C]acetate PET/MRI scan
16547113|NCT02969590|No Intervention|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
16547114|NCT02969590|Active Comparator|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).
~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.
~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.
~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
16547115|NCT02969590|Active Comparator|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).
~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.
~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.
~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
16547116|NCT02969577|Experimental|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
16547117|NCT02969577|Active Comparator|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
16547118|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
16547119|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
16547120|NCT02969538|Other|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
16547121|NCT02969538|Experimental|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
16547122|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
16547123|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
16547124|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
16547125|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
16547126|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
16547217|NCT02968875|Active Comparator|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
16547129|NCT02969473|Active Comparator|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
16547130|NCT02969473|Experimental|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
16547131|NCT02969460|Experimental|Neurotrack Virtual Cognitive Health Program|This program is a multi-domain lifestyle intervention designed to prevent or delay cognitive decline and impairment in older at-risk adults. The first 6 months of the program emphasizes lifestyle change, while the last 6 months of the program emphasizes habit reinforcement. The program focuses on nutrition, physical exercise, and cognitive training.
16547132|NCT02969447|Experimental|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
16547133|NCT02969447|No Intervention|No additional medication after fetal expulsion|
16547134|NCT02969434|Experimental|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
16547135|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
16547136|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
16547137|NCT02969408|Experimental|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
16547138|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
16547139|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
16547140|NCT02969369|Experimental|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
16547141|NCT02969369|Placebo Comparator|Placebo Capsule|Placebo once daily
16547142|NCT02969356|Experimental|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary treatment target (TT) limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
16547143|NCT02969343|Experimental|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
16547144|NCT02969343|No Intervention|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
16547145|NCT02969330|Experimental|Glucose|Glucose ingestion
16547146|NCT02969330|Active Comparator|PES|Single session of short PES treatment before glucose ingestion.
16547147|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
16547148|NCT02969304||Off-Label|Any DMF prescription for MS patients <18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
16547149|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
16547150|NCT02969291|Other|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
16547151|NCT02969278|Experimental|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:
~T > 4 cm;
~multicentric tumors (mono or bilateral);
~primary lesion completely excised during prior diagnostic surgery
~patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0
~previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
16547152|NCT02969265|Experimental|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.
~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.
~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
16547153|NCT02969265|Experimental|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.
~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.
~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
16547154|NCT02969252|Other|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
16547155|NCT02969239|Experimental|norepinephrine|norepinephrine 5mcg intravenously administered
16547156|NCT02969239|Active Comparator|phenylephrine|phenylephrine 100mcg intravenously administered
16547157|NCT02969226|Active Comparator|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS> 0 and =< 8 cm H2O with PEEP> 0 and =< 5 cm H2O.
16547218|NCT02968849|Active Comparator|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
16547158|NCT02969226|Experimental|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team [RTs and physicians]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS>0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O.
16547159|NCT02969226|Active Comparator|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
16547160|NCT02969226|Active Comparator|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
16547161|NCT02969213||Genetic|patients with Gene detection (+)
16547162|NCT02969213||Metabolism|patients with Metabolic disturbance
16547163|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
16547164|NCT02969213||infection|patients with the Infection of central nervous system
16547165|NCT02969213||structure|patients with abnormal image of brain
16547166|NCT02969213||unknown|patients not found any reason
16547167|NCT02969187|Experimental|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
16547168|NCT02969187|Active Comparator|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
16547169|NCT02969148|Experimental|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
16547170|NCT02969148|Active Comparator|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
16547171|NCT02969135|Experimental|Progressive early passive and active movement|Active exercise starts one week after surgery.
16547172|NCT02969135|Active Comparator|Limited early passive movement|Active exercise starts six weeks after surgery.
16547173|NCT02969122|Active Comparator|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
16547174|NCT02969122|Experimental|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
16547175|NCT02969096|Experimental|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
16547176|NCT02969083|Other|Radical nephro-ureterectomy (RNU)|Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) <55 ml/min or unfit for cisplatin-based chemotherapy)
16547177|NCT02969083|Other|Gemcitabine/Cisplatin plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery
16547178|NCT02969083|Other|RNU plus Gemcitabine/Cisplatin|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery
16547179|NCT02969083|Other|M-VAC protocol plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery
16547219|NCT02968849|Placebo Comparator|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
16547220|NCT02968836|Active Comparator|Active group|Blend of amino acids
16547180|NCT02969083|Other|RNU plus M-VAC protocol|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery
16547181|NCT02969070|Active Comparator|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
16547182|NCT02969070|Active Comparator|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
16547183|NCT02969057|No Intervention|Breakfast only|Control breakfast providing 50g carbohydrate
16547184|NCT02969057|Active Comparator|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
16547185|NCT02969057|Active Comparator|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
16547186|NCT02969057|Active Comparator|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
16547187|NCT02969057|Active Comparator|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
16547188|NCT02969044|Experimental|PF-06651600|Study Drug
16547189|NCT02969044|Placebo Comparator|Placebo|Placebo
16547190|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
16547191|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
16547192|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
16547193|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
16547194|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
16547195|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
16547196|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
16547197|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
16547198|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
16547199|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
16547200|NCT02969005|Experimental|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
16547201|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
16547202|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
16547203|NCT02968966|Experimental|Therapy regime|Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
16547204|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.
~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
16547205|NCT02968927|Active Comparator|2HRbEZ/4HRb|2HRbZE
16547206|NCT02968927|Experimental|Everolimus|Everolimus 0.5 MG
16547207|NCT02968927|Experimental|Auranofin|Auranofin 6 MG
16547208|NCT02968927|Experimental|Vitamin D|Vitamin D3
16547209|NCT02968927|Experimental|CC-11050|CC-11050
16547210|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
16547211|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
16547212|NCT02968901|Experimental|bitherapy|Macitentan and tadalafil
16547213|NCT02968888|Placebo Comparator|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
16547214|NCT02968888|Experimental|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
16547215|NCT02968888|Experimental|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
16547216|NCT02968875|Active Comparator|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
16547221|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
16547222|NCT02968823|Active Comparator|Licorice|Licorice gargle
16547224|NCT02968810|Experimental|Group I (simvastatin)|Patients receive simvastatin PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
16547225|NCT02968810|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
16547226|NCT02968784|Experimental|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.
~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.
~Additional foci in the same hemisphere that are confirmed by biopsy and are < Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
16547227|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
16547228|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
16547229|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
16547230|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
16547231|NCT02968732|Experimental|Surgical|
16547232|NCT02968719|Experimental|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.
~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
16547233|NCT02968719|Experimental|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.
~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
16547234|NCT02968719|Active Comparator|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
16547235|NCT02968719|Experimental|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
16547236|NCT02968719|Experimental|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
16547237|NCT02968706|Experimental|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
16547238|NCT02968706|Active Comparator|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
16547239|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
16547240|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
16547241|NCT02968680|Experimental|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
16547242|NCT02968667|Experimental|Intervention|Intervention group received 6 weeks of empowerment program
16547243|NCT02968667|No Intervention|Treatment as usual|Medications
16547244|NCT02968654|Other|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
16547245|NCT02968654|Other|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
16547246|NCT02968641|Active Comparator|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
16547247|NCT02968641|Active Comparator|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
16547248|NCT02968641|Active Comparator|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
16547249|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.
~Interventions:
~Video Electroencephalogram (EEG)
~Point-of Care Blood Sugar Testing
~Medical Record Data Extraction
~Maternal Questionnaire"
16547250|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.
~Interventions:
~Video Electroencephalogram (EEG)
~Point-of Care Blood Sugar Testing
~Medical Record Data Extraction
~Maternal Questionnaire"
16547251|NCT02968615|Experimental|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
16547254|NCT02968589|Experimental|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.
~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.
~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
16547281|NCT02968394|Experimental|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
16547255|NCT02968589|Active Comparator|Other training|"A training session for caregivers of patients with hip fracture on patient management.
~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
16547256|NCT02968576|Active Comparator|Truvada|Naked form Truvada (drug)
16547257|NCT02968576|Experimental|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
16547258|NCT02968563|Experimental|Tirabrutinib + Idelalisib|Participants will receive tirabrutinib and idelalisib for up to 104 weeks.
16547259|NCT02968563|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and idelalisib for up to 104 weeks.
16547260|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
16547261|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
16547262|NCT02968537|Experimental|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
16547263|NCT02968537|Experimental|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
16547264|NCT02968537|Placebo Comparator|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
16547265|NCT02968537|Experimental|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
16547266|NCT02968537|Experimental|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
16547267|NCT02968537|Placebo Comparator|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
16547268|NCT02968511|Experimental|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
16547269|NCT02968498|Active Comparator|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
16547270|NCT02968498|Active Comparator|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
16547271|NCT02968485|Experimental|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
16547272|NCT02968472|Experimental|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
16547273|NCT02968459|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord MSCs
16547274|NCT02968459|Placebo Comparator|Placebo-Controlled Group|1ml of 0.9% saline
16547275|NCT02968446|Placebo Comparator|Group 1: 4 placebo - 0 Vitamin D with Valchlor|Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
16547276|NCT02968446|Experimental|Group 2: 0 placebo - 4 Vitamin D with mechloroethamine|Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.
16547277|NCT02968433|Experimental|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.
~Participants will receive 1 unit of young plasma, twice a week over a four week duration.
~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
16547278|NCT02968420|Active Comparator|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
16547279|NCT02968420|Active Comparator|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
16547280|NCT02968420|Active Comparator|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
16547282|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
16547283|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
16547284|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
16547285|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
16547286|NCT02968355||Subjects/Specimens|Subjects/Specimens that meet the eligibility criteria
16547287|NCT02968342|Experimental|Vaginal progesterone 8%|Vaginal progesterone application 8%
16547288|NCT02968342|Placebo Comparator|Placebo|Oral multivitamin supplement
16547289|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
16547290|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
16547291|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
16547292|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
16547293|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
16547294|NCT02968303|Experimental|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
16547295|NCT02968303|No Intervention|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
16547296|NCT02968290|Active Comparator|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
16547297|NCT02968290|Active Comparator|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
16547298|NCT02968277|Experimental|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
16547299|NCT02968277|Experimental|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
16547300|NCT02968277|Experimental|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
16547301|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
16547302|NCT02968251|Experimental|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
16547303|NCT02968251|No Intervention|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
16547304|NCT02968238|Active Comparator|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
16547305|NCT02968238|Active Comparator|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
16547306|NCT02968238|Active Comparator|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
16547307|NCT02968238|Active Comparator|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
16547308|NCT02968225|Experimental|Computer Game|"All Computer Game participants will complete:
~online screening
~Diagnostic and eye-tracking pre-testing
~2 month intervention
~Eye-tracking post-testing"
16547309|NCT02968225|No Intervention|Waitlist control|"All Treatment as usual control participants will complete:
~online screening
~Diagnostic and eye-tracking pre-testing
~Eye-tracking post-testing"
16547310|NCT02968212|Experimental|clofazimine|Participants receive lamprene
16547311|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
16547312|NCT02968199|Experimental|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
16547313|NCT02968186|Experimental|Implementation program|Health professionals will receive a training and support implementation program
16547314|NCT02968186|No Intervention|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
16547315|NCT02968173|Experimental|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
16547316|NCT02968160|Experimental|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks
~* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
16547317|NCT02968160|Active Comparator|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks
~* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
16599450|NCT02616159|Placebo Comparator|Hot cereal|28.8 g cereal
16547318|NCT02968147|Experimental|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
16547319|NCT02968147|Experimental|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
16547320|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
16547321|NCT02968121|Experimental|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
16547322|NCT02968121|Experimental|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
16547323|NCT02968121|Experimental|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
16547324|NCT02968121|Experimental|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
16547325|NCT02968121|Experimental|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
16547328|NCT02968095|Experimental|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
16547329|NCT02968095|Active Comparator|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
16547330|NCT02968082|Placebo Comparator|Placebo group (P group)|"The group that not existed scopolamine ingredient.
~dosage form: apply
~dosage: 1.5 mg
~frequency: 1 times (at 9 p.m. of the day before the operation day)
~duration: Until the 24hr after operation.
~Patients will be applied patch that not existed scopolamine ingredient."
16547331|NCT02968082|Experimental|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'
~The group that existed scopolamine ingredient
~dosage form: apply
~dosage: 1.5 mg
~frequency: 1 times (at 9 p.m. of the day before the operation day)
~duration: Until the 24hr after operation.
~Patients will be applied patch that existed scopolamine ingredient."
16547332|NCT02968069|Experimental|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
16547333|NCT02968056|Experimental|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
16547334|NCT02968056|Active Comparator|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
16547335|NCT02968043|Active Comparator|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
16547336|NCT02968043|Experimental|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
16547337|NCT02968030|Experimental|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
16547338|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
16547339|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
16547340|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
16547341|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
16547342|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
16547343|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
16547344|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
16547345|NCT02967965||Cohort|Clinical Evaluation, Coronarography, Imagery by MRI, Echocardiography and Biologial samples will be collected for each patient.
16547346|NCT02967952|Active Comparator|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
16547347|NCT02967952|Active Comparator|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
16547348|NCT02967939|Experimental|DA-2802|DA-2802 319mg tablet qd
16547349|NCT02967939|Active Comparator|Viread®|Viread® 300mg tablet qd
16547350|NCT02967926|Experimental|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
16547351|NCT02967913|Experimental|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
16547352|NCT02967913|No Intervention|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
16547353|NCT02967887|Experimental|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
16547354|NCT02967874|Experimental|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.
~This group of subjects (n=16) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
16547355|NCT02967874|Active Comparator|Intra-articular Hyaluronic Acid|This group of subjects (n=11) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
16547356|NCT02967861|Active Comparator|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP & pranayama for 3 months
16547357|NCT02967861|Placebo Comparator|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
16547358|NCT02967848||Patients with Cancers in Liver|Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
16547359|NCT02967835|Experimental|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
16547360|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.
~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
16547361|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.
~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
16547362|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
16547363|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
16547364|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
16547365|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
16547366|NCT02967783|Active Comparator|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
16547367|NCT02967783|Experimental|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
16547368|NCT02967783|Experimental|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
16547369|NCT02967770|Experimental|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
16547370|NCT02967770|Active Comparator|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
16547371|NCT02967757||liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg|
16547372|NCT02967744|Experimental|NSAID treatment|8 weeks of NSAID treatment
16547373|NCT02967731|Experimental|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
16547374|NCT02967718||Control group|the healthy patients
16547375|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
16547376|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
16547377|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
16547378|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
16547379|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
16547380|NCT02967705|Experimental|Pain management group|6 + 1 meetings 2 hours each
16547381|NCT02967705|No Intervention|Treatment as usual|Waiting list - will receive treatment as usual
16547382|NCT02967692|Experimental|Investigational treatment arm|"Part 1: Safety run-in Up to 18 evaluable patients with previously untreated unresectable or metastatic BRAF V600 mutated melanoma will be enrolled and treated at different dose levels to determine the recommended Phase 3 regimen of PDR001 in combination with dabrafenib and trametinib.
~Part 2: Biomarker cohort Approximately 20 patients with previously unresectable or metastatic BRAF V600 mutated melanoma will be enrolled to describe changes in the immune microenvironment and biomarker modulations
~Part 3: Randomized double blind Approximately 500 patients with previously untreated unresectable and metastatic BRAF V600 mutated melanoma will be enrolled to compare the anti-tumor activity of PDR001 in combination with dabrafenib and trametinib versus placebo plus dabrafenib and trametinib."
16547383|NCT02967692|Placebo Comparator|Placebo comparator arm|Matching placebo in combination with dabrafenib and trametinib
16547384|NCT02967679|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 48 weeks
16547385|NCT02967666|Experimental|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
16547386|NCT02967653|Placebo Comparator|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
16547387|NCT02967653|Experimental|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
16547388|NCT02967640|Experimental|Ketalar|ketalar injection, subacromial
16547389|NCT02967640|Placebo Comparator|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
16547390|NCT02967627|Experimental|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
16547391|NCT02967627|Active Comparator|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
16547392|NCT02967614|Experimental|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days
~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
16547393|NCT02967614|Experimental|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days
~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
16547394|NCT02967601||Elective Cesarean Section|
16547395|NCT02967588|Experimental|Intervention|
16547396|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
16547397|NCT02967562|Active Comparator|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
16547398|NCT02967562|Experimental|Sustained inflation|One fifteen second 'sustained inflation'
16547399|NCT02967549|Experimental|NAVA then PAV|Infants randomised to NAVA then PAV
16547400|NCT02967549|Experimental|PAV then NAVA|Infants randomised to PAV then NAVA
16547401|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) >5 events/hour and <10 events/hour with Epworth Sleepiness Score (ESS)>9.
16547402|NCT02967536||Severe OSA|Untreated OSA patients. AHI >30 events/hour, with excessive sleepiness (ESS >9).
16547403|NCT02967536||Healthy control|Healthy control. AHI <5 events/hour.
16547404|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
16547405|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
16547406|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
16547407|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
16547408|NCT02967497|No Intervention|Blank|No intervention, just observation.
16547409|NCT02967497|Experimental|YQ1 group|Cisplatin-based chemotherapy + YQ1
16547410|NCT02967484|Experimental|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.
~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
16547411|NCT02967484|No Intervention|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.
~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
16547412|NCT02967471||ARDS group|
16547413|NCT02967471||control group|
16547414|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
16547415|NCT02967445|Experimental|Cervical pessary|Arabin Pessary
16547416|NCT02967445|Active Comparator|Cervical cerclage|McDonald Cerclage
16547417|NCT02967432|Experimental|Mupirocin|
16547418|NCT02967432|Placebo Comparator|Petroleum jelly|
16547419|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
16547420|NCT02967419||Control group|People who had normal pregnancy
16547421|NCT02967406|Experimental|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
16547422|NCT02967406|No Intervention|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
16547423|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
16547424|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
16547425|NCT02967380|Experimental|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
16547426|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
16547427|NCT02967354|Experimental|Healthy control|Healthy control
16547428|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
16547429|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
16547430|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
16547431|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
16547432|NCT02967341|Other|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
16547466|NCT02967094|Placebo Comparator|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
16547433|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
16547434|NCT02967315|Experimental|Study Group|"Procedures include:
~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
16547435|NCT02967302|Experimental|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
16547436|NCT02967302|Active Comparator|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
16547437|NCT02967302|Placebo Comparator|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
16547438|NCT02967289|Experimental|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
16547439|NCT02967289|Active Comparator|Arm B|mFOLFOX 6 Folfox Protocol
16547440|NCT02967276|Experimental|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.
~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
16547441|NCT02967263||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
16547442|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
16547443|NCT02967237|Experimental|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
16547444|NCT02967224|Experimental|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
16547445|NCT02967224|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
16547446|NCT02967211|Experimental|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
16547447|NCT02967211|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
16547448|NCT02967198|Experimental|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
16547449|NCT02967185|Experimental|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
16547450|NCT02967185|No Intervention|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
16547451|NCT02967172|Experimental|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:
~20 mL injected into the peri-incisional soft tissues in a circumferential fashion
~5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
~Interventions:
~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
16547452|NCT02967172|No Intervention|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
16547453|NCT02967159|Experimental|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
16547454|NCT02967159|Experimental|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
16547455|NCT02967159|Experimental|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
16547456|NCT02967159|Experimental|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
16547457|NCT02967146|Experimental|Mediclore|
16547458|NCT02967146|No Intervention|Not done|Standard treatment for surgery
16547459|NCT02967133|Active Comparator|Arm A|Nivolumab q 14 days until disease progression/toxicity
16547460|NCT02967133|Active Comparator|Arm B|"Nivolumab every 21 days until disease progression
~Nab-paclitaxel every 21 days"
16547461|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
16547462|NCT02967107|Active Comparator|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
16547463|NCT02967107|Active Comparator|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
16547464|NCT02967094|Experimental|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
16547465|NCT02967094|No Intervention|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
16547468|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
16547469|NCT02967081||Irreversible pulpitis|
16547470|NCT02967081||Normal pulp|
16547471|NCT02967042|Other|18F-PET-TT|
16547472|NCT02967029|Active Comparator|b group|b group controlled hypotension with esmolol hydrochloride
16547473|NCT02967029|Active Comparator|r group|r group controlled hypotension with remifentanil hydrochloride
16547474|NCT02967016|Experimental|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
16547475|NCT02967016|Experimental|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
16547476|NCT02966990|Other|hand orthosis patients|Patients using hand orthosis for better hand function
16547477|NCT02966977|Active Comparator|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
16547478|NCT02966977|Experimental|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
16547479|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
16547480|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
16547481|NCT02966964|Placebo Comparator|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
16547482|NCT02966951|Experimental|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
16547483|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
16547484|NCT02966925|Experimental|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
16547485|NCT02966912|Experimental|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
16547486|NCT02966912|Active Comparator|Comparator|20 participants will receive no treatment
16547487|NCT02966899|Experimental|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
16547488|NCT02966886|Active Comparator|Participants with 10-15 degrees of glenoid retroversion|
16547489|NCT02966886|Active Comparator|Participants with >15 degrees of glenoid retroversion|
16547490|NCT02966873|Experimental|N-Acetylcysteine (NAC) Treatment Group|"Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.
~Participant will receive one week of study medication at a time from the study physician or the study coordinator. The study medication provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
16547491|NCT02966873|Placebo Comparator|Placebo Group|"Participant will receive 12 weeks of inactive placebo comparator daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.
~Participant will receive one week of study medication (placebo) at a time from the study physician or the study coordinator. The study medication (placebo) provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
16547492|NCT02966860|Experimental|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
16547493|NCT02966847|Experimental|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
16547494|NCT02966834|Placebo Comparator|Placebo|Participants will receive matching placebo
16547495|NCT02966834|Experimental|GSK2330672 20 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
16547496|NCT02966834|Experimental|GSK2330672 90 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
16547497|NCT02966834|Experimental|GSK2330672 180 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
16547498|NCT02966834|Experimental|GSK2330672 40 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
16547499|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
16547500|NCT02966821|Experimental|Surufatinib|Surufatinib 300mg once-daily
16547501|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
16547502|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 8 Weeks|Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
16547503|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 12 Weeks|Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.
16547504|NCT02966782|Experimental|Venetoclax monotherapy (Cohort 1)|
16547505|NCT02966782|Experimental|Venetoclax + azacitidine (Cohort 2)|
16547506|NCT02966782|Experimental|Safety Expansion (Cohort 3)|
16547507|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (>/= 60 Gy) plus Platinum-based Chemotherapy
16547508|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus >/= 45Gy) followed by Surgery
16547509|NCT02966756|Experimental|Cohort 1: Venetoclax|Participants with 17p deletion status will receive various doses of venetoclax once daily (QD).
16548891|NCT02957929|Experimental|Cohort 1b, Period E|Single oral dose under fasted conditions, crossover
16547510|NCT02966756|Experimental|Cohort 2: Venetoclax|Participants who have failed a B-Cell Receptor Signaling Pathway Inhibitor (BCRI) therapy and who have also failed, were intolerant to, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status will receive various doses of venetoclax once daily (QD).
16547511|NCT02966743|Experimental|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
16547512|NCT02966743|Active Comparator|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
16547513|NCT02966730|Experimental|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
16547514|NCT02966717|Active Comparator|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
16547515|NCT02966717|Experimental|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
16547516|NCT02966704|Experimental|meal 1|mixed meal with high level of intrinsically labeled milk protein
16547517|NCT02966704|Experimental|meal 2|mixed meal with low level of intrinsically labeled milk protein
16547518|NCT02966691|Active Comparator|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :
~a positive result of bladder endoscopy
~or an negative endoscopy and a positive result of the conventional cytology
~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
16547519|NCT02966691|Active Comparator|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.
~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
16547520|NCT02966691|Active Comparator|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).
~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
16547521|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
16547522|NCT02966665|Experimental|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547523|NCT02966665|Experimental|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547524|NCT02966665|Experimental|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547525|NCT02966665|Experimental|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547526|NCT02966665|Experimental|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547527|NCT02966665|Experimental|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547528|NCT02966665|Experimental|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
16547529|NCT02966652|Active Comparator|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
16547530|NCT02966652|Experimental|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
16547531|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
16547532|NCT02966613|Active Comparator|CI|TKA using conventional instrumentation (CI)
16547533|NCT02966613|Experimental|PSCG|TKA performed using Patient specific cutting guides (PSCG)
16547534|NCT02966613|Experimental|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
16547535|NCT02966600|Experimental|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
16547536|NCT02966600|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine
16547537|NCT02966587|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
16547538|NCT02966574|Experimental|metastatic breast cancer|
16547539|NCT02966561|Experimental|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
16547540|NCT02966561|Active Comparator|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
16547541|NCT02966548|Experimental|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
16547542|NCT02966548|Experimental|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
16547543|NCT02966535|Experimental|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
16547544|NCT02966535|Active Comparator|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
16547545|NCT02966522|Experimental|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
16547546|NCT02966509|Experimental|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
16547547|NCT02966509|No Intervention|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
16547548|NCT02966496|Experimental|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
16547549|NCT02966496|Experimental|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
16547550|NCT02966483|Experimental|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
16547551|NCT02966483|Active Comparator|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
16547552|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
16547553|NCT02966457|Experimental|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
16547554|NCT02966457|No Intervention|"Wait and watch strategy"|Group without decolonization interventions
16547555|NCT02966444|Experimental|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
16547556|NCT02966444|Experimental|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
16547557|NCT02966444|Experimental|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
16547558|NCT02966431|Experimental|Counseling|Receive counseling for 8-wks
16547559|NCT02966431|Placebo Comparator|Control|Does not receive counseling for 8-wks
16547560|NCT02966418|Active Comparator|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
16547561|NCT02966418|Sham Comparator|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
16547562|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
16547563|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
16547564|NCT02966392|Experimental|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
16547565|NCT02966392|No Intervention|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
16547566|NCT02966379|Experimental|Cochlear implantation|Cochlear implantation with EVO electrode lead. This electrode lead has been specially designed for atraumatic surgery, in order to preserve the residual hearing of the patients included in the study. All patients are implanted with the same electrode lead.
16547567|NCT02966366|Experimental|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
16547568|NCT02966353|Experimental|All Subjects|10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.
16547569|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
16547570|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
16547571|NCT02966327|Experimental|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
16547572|NCT02966327|Other|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
16547573|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
16547574|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
16547575|NCT02966301|Experimental|interventional|Single arm : Arsenic trioxide Injectable Solution
16547576|NCT02966288|Experimental|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
16547577|NCT02966288|Active Comparator|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
16547578|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.
~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
16547579|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.
~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
16547580|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
16547581|NCT02966249|Other|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
16547582|NCT02966249|Active Comparator|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
16547583|NCT02966249|Active Comparator|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
16547584|NCT02966249|Placebo Comparator|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
16547585|NCT02966249|Other|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
16547586|NCT02966249|Other|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
16547587|NCT02966236|Experimental|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
16547588|NCT02966236|Placebo Comparator|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
16547589|NCT02966223|Experimental|MRI and HIDA scan|
16547590|NCT02966197|Experimental|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
16547591|NCT02966197|No Intervention|Control group|no intervention
16547592|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
16547593|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
16547594|NCT02966171|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
16547619|NCT02966015|Experimental|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
16547620|NCT02966002|Experimental|Intervention: aspirin|650 mg. Twice a day for 8 weeks
16547621|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
16547622|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
16600166|NCT02611687|Experimental|pitolisant|tablet, oral, once a day.
16547595|NCT02966158|Experimental|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.
~The AIT exercise protocol includes the following components:
~Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.
~Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.
~Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
16547596|NCT02966158|No Intervention|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.
~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.
~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
16547597|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
16547598|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
16547599|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
16547600|NCT02966132|Experimental|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
16547601|NCT02966132|Active Comparator|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
16547602|NCT02966119|Experimental|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
16547603|NCT02966119|No Intervention|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
16547604|NCT02966106|Active Comparator|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
16547605|NCT02966106|Placebo Comparator|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
16547606|NCT02966093|Experimental|Lenvatinib|In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
16547607|NCT02966093|Experimental|Placebo|In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
16547608|NCT02966080|Other|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
16547609|NCT02966080|Other|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
16547610|NCT02966067|Experimental|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
16547611|NCT02966067|Active Comparator|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
16547612|NCT02966054|Experimental|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
16547613|NCT02966054|No Intervention|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
16547614|NCT02966041|Experimental|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
16547615|NCT02966041|Placebo Comparator|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
16547616|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
16547617|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
16600167|NCT02611687|Placebo Comparator|placebo|tablet, oral, once a day.
16547623|NCT02965976|Experimental|Arm I (botulinum toxin type A, esophagectomy)|Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
16547624|NCT02965976|Active Comparator|Arm II (esophagectomy)|Patients undergo standard minimally invasive esophagectomy.
16547625|NCT02965963|Experimental|Dopamine|Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max
16547626|NCT02965963|Experimental|Metoclopramide|Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max
16547627|NCT02965963|Experimental|Placebos|Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max
16547628|NCT02965950|Experimental|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
16547629|NCT02965950|Experimental|TP53 mutated, MBC, first line|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide first line metastatic disease
16547630|NCT02965950|Experimental|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
16547631|NCT02965950|Experimental|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
16547632|NCT02965950|Experimental|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
16547633|NCT02965937|Experimental|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
16547634|NCT02965937|Active Comparator|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
16547635|NCT02965924|Experimental|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
16547636|NCT02965911|Active Comparator|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
16547637|NCT02965911|Experimental|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
16547640|NCT02965885|Experimental|TAS-116|
16547641|NCT02965872||Healthy individuals|
16547642|NCT02965859|Experimental|Metacavir Enteric-coated Capsule 80mg|"Metacavir Enteric-coated Capsules 80mg
~Metacavir Enteric-coated Capsules Placebo 240mg
~Adefovir Dipivoxil Capsule Placebo 10mg;"
16547643|NCT02965859|Active Comparator|Metacavir Enteric-coated Capsules 160mg|"Metacavir Enteric-coated Capsules 160mg
~Metacavir Enteric-coated Capsules Placebo 160mg
~Adefovir Dipivoxil Capsule Placebo 10mg;"
16547644|NCT02965859|Placebo Comparator|Metacavir Enteric-coated Capsules 320mg|"Metacavir Enteric-coated Capsules 320mg
~Adefovir Dipivoxil Capsule Placebo 10mg"
16547645|NCT02965859|Active Comparator|Adefovir Dipivoxil Capsule|"Metacavir Enteric-coated Capsules Placebo 320mg
~Adefovir Dipivoxil Capsule 10mg;"
16547646|NCT02965859|Placebo Comparator|Placebo|"Metacavir Enteric-coated Capsules Placebo 320mg
~Adefovir Dipivoxil Capsule Placebo 10mg;"
16547647|NCT02965846|Experimental|AGN-195263|
16547648|NCT02965846|Placebo Comparator|Vehicle|
16547649|NCT02965833|Other|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
16547650|NCT02965833|Other|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
16547651|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
16547652|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
16547653|NCT02965807|Experimental|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
16547654|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
16547655|NCT02965794||Care Pathway|Care pathways for colorectal cancer
16547656|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
16547657|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
16547658|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
16547659|NCT02965768|Active Comparator|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
16602482|NCT02596347||Beryllium Sensitization (BeS)|Blood draw
16547660|NCT02965768|Other|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo
~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
16547661|NCT02965755|Other|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
16547662|NCT02965742|Experimental|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
16547663|NCT02965742|Experimental|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
16547664|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
16547665|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
16547666|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
16547667|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
16547668|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity.
16547669|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity.
16547670|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity.
16547671|NCT02965690|Active Comparator|NexGen CR|Patients receive a NexGen Total Knee Replacement
16547672|NCT02965690|Active Comparator|GMK Sphere|Patients receive a GMK Total Knee Replacement
16547673|NCT02965677|Experimental|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
16547674|NCT02965677|Active Comparator|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
16547675|NCT02965664|Experimental|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
16547676|NCT02965664|Placebo Comparator|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
16547677|NCT02965651|Experimental|ECA System|Access to website and virtual patient advocate
16547678|NCT02965651|No Intervention|Standard of Care|Patient information sheets and meditation CD
16547679|NCT02965638|Active Comparator|Oxygen Group|The mothers will be asked to be on 4 liter of oxygen through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
16547680|NCT02965638|Placebo Comparator|Control Group|The mothers will be asked to be on air through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
16547681|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
16547682|NCT02965612|Experimental|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
16547683|NCT02965612|Active Comparator|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
16547684|NCT02965599|Experimental|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
16547685|NCT02965599|Placebo Comparator|Placebo|Subjects will receive placebo for 28 days.
16547686|NCT02965586|Active Comparator|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
16547687|NCT02965586|Active Comparator|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
16547688|NCT02965586|Placebo Comparator|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
16547689|NCT02965573|Active Comparator|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
16547690|NCT02965573|Placebo Comparator|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
16547691|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
16547692|NCT02965547|Experimental|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take RIPC intervention, blood collection and 7 dCA measurements.
16547693|NCT02965534|Experimental|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
16547694|NCT02965534|Active Comparator|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
16547695|NCT02965521|Experimental|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
16547696|NCT02965521|No Intervention|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
16547697|NCT02965508|Experimental|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
16547698|NCT02965508|Active Comparator|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
16547699|NCT02965495|Experimental|YYD302 2ml|YYD302 2ml
16547700|NCT02965495|Experimental|YYD302 3ml|YYD302 3ml
16547701|NCT02965495|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
16547702|NCT02965482|Active Comparator|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
16547703|NCT02965482|Active Comparator|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
16547704|NCT02965469|No Intervention|Usual care|Participants randomized to this arm will have no change to their usual care
16547705|NCT02965469|Experimental|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
16547706|NCT02965456|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
16547707|NCT02965456|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
16547708|NCT02965443|Active Comparator|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
16547709|NCT02965443|Placebo Comparator|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
16547710|NCT02965430|Experimental|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
16547711|NCT02965417|Experimental|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
16547712|NCT02965404|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated varicella vaccine."
16547713|NCT02965404|Active Comparator|Positive Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;
~Intervention: control live attenuated varicella vaccine."
16547714|NCT02965404|Sham Comparator|Negative Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;
~Intervention: diluent of lyophilized vaccine."
16547715|NCT02965378|Experimental|Arm I - AZD4547|Participants receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16547716|NCT02965378|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.
~-closed to accrual 12/18/2015"
16547717|NCT02965378|Experimental|Arm III - AZD4547 re-registration|Participants in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16547718|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
16547719|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
16547720|NCT02965352|Experimental|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
16547721|NCT02965326|Other|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
16547722|NCT02965326|Other|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
16547723|NCT02965326|Other|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
16547724|NCT02965313|Active Comparator|SSLS Procedure|
16547725|NCT02965313|Active Comparator|BSSVF-M Procedure|
16547726|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
16547727|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
16547728|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
16547729|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.
~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
16547730|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
16547731|NCT02965274|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
16547732|NCT02965274|Active Comparator|Reference|Warner Chilcott LLC, USA
16547733|NCT02965261|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
16547734|NCT02965261|Active Comparator|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
16547735|NCT02965248|Active Comparator|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
16547736|NCT02965248|Experimental|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
16547737|NCT02965248|Experimental|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
16547738|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
16547739|NCT02965235||POCD|Patients who develop POCD after surgery.
16547740|NCT02965222|Experimental|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
16547741|NCT02965222|Experimental|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
16547742|NCT02965209|Experimental|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
16547743|NCT02965196|Active Comparator|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
16547744|NCT02965196|Placebo Comparator|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
16547745|NCT02965183|Experimental|Temperature measurements|
16547746|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
16547747|NCT02965157|Experimental|CART20|
16547748|NCT02965144||HGG patients|single-group study- long term survivors
16547749|NCT02965131|No Intervention|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
16547750|NCT02965131|Experimental|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
16547751|NCT02965118|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
16547752|NCT02965118|Placebo Comparator|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
16547753|NCT02965105|Experimental|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
16547754|NCT02965105|Experimental|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
16547755|NCT02965092|Experimental|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
16547756|NCT02965066|Experimental|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
16547757|NCT02965066|Experimental|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
16547758|NCT02965053|Experimental|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
16547759|NCT02965053|Experimental|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
16547760|NCT02965053|Experimental|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
16547761|NCT02965053|Experimental|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
16547762|NCT02965040|Experimental|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m^2. Single dose of roxadustat
16547763|NCT02965040|Experimental|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m^2. Single dose of roxadustat
16547764|NCT02965040|Experimental|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
16547765|NCT02965040|Experimental|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
16547766|NCT02965027|Experimental|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
16547767|NCT02965027|Placebo Comparator|Placebo|Placebo capsules
16547768|NCT02965014|Experimental|Face-to-Face Young Women's CoOp (YWC)|Participants in this arm will be offered a two-session face-to-face Young Women's CoOp (YWC) intervention.
16547769|NCT02965014|Experimental|mHealth Young Women's CoOp (YWC)|Participants in this arm will be offered training on the mobile health application mHealth Young Women's CoOp (YWC) and offered tablets with the mHealth application to complete the two-session intervention.
16547770|NCT02965014|Active Comparator|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing services.
16547771|NCT02965001|Experimental|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
16547772|NCT02964988|Experimental|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
16547773|NCT02964975|Active Comparator|Optimal medical therapy|conservative treatment
16547774|NCT02964975|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
16547775|NCT02964962|Experimental|29 mm LOTUS Edge™|
16547776|NCT02964949|Experimental|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
16547777|NCT02964949|Active Comparator|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
16547778|NCT02964936|Experimental|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
16547779|NCT02964936|Experimental|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
16547780|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
16547781|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
16547782|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.
16547783|NCT02964910|Experimental|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
16547784|NCT02964910|Active Comparator|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
16547785|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
16547786|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
16547787|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.
~And one week of intensive, one-on-one reading tutoring intervention"
16547788|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
16547789|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
16547790|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.
~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
16547791|NCT02964871|Active Comparator|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
16547792|NCT02964871|Placebo Comparator|LTCF Control|"Usual care.
~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
16547793|NCT02964858|Active Comparator|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
16547794|NCT02964858|Experimental|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
16547823|NCT02964676|Active Comparator|Trab group|PACG in AIT group will receive trabeculectomy.
16547824|NCT02964650|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
16547825|NCT02964650|Experimental|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
16547826|NCT02964637||Progressive supranuclear palsy|Observational Study
16547827|NCT02964637||Corticobasal syndrome|Observational Study
16547828|NCT02964637||Behavoral variant FTD|Observational Study
16547829|NCT02964637||Semantic variant PPA|Observational Study
16547795|NCT02964845|Experimental|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
16547796|NCT02964845|Other|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
16547797|NCT02964832|Active Comparator|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
16547798|NCT02964832|Active Comparator|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
16547799|NCT02964832|Active Comparator|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
16547800|NCT02964819|Active Comparator|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
16547801|NCT02964819|Experimental|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
16547802|NCT02964819|Placebo Comparator|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
16547803|NCT02964806|Other|Ordinary Diet|Ordinary Diet
16547804|NCT02964806|Other|Modified Atkin's Diet|Modified Atkin's Diet
16547805|NCT02964806|Other|Ketogenic Diet|Ketogenic Diet
16547806|NCT02964793|Experimental|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
16547807|NCT02964793|No Intervention|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
16547808|NCT02964780||Gastric Bypass Surgery|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
16547809|NCT02964780||Conservative weight loss|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
16547810|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
16547811|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
16547812|NCT02964754|Experimental|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
16547813|NCT02964754|Experimental|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
16547814|NCT02964741|Active Comparator|Migraine Patients Active Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
~*Active Comparator"
16547815|NCT02964741|Sham Comparator|Migraine Patients Sham Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
~*Sham Comparator"
16547816|NCT02964741|No Intervention|Healthy Control Group|"Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).
~Healthy volunteer data (n </= 10) may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
16547817|NCT02964728|Experimental|Botulinum toxin type A|Botulinum neurotoxin injections
16547818|NCT02964728|Placebo Comparator|Placebo|Normal saline solution injections
16547819|NCT02964715|Experimental|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
16547820|NCT02964702|Experimental|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
16547821|NCT02964689|Experimental|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:
~Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib
~Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
16547822|NCT02964676|Experimental|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
16547833|NCT02964624|Other|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
16547834|NCT02964611||Alzheimer's disease|Observational Study
16547835|NCT02964611||Parkinson's disease|Observational Study
16547836|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
16547837|NCT02964611||Healthy Controls|Observational Study
16547838|NCT02964598|Experimental|Control|Minimal information on sleep timing
16547839|NCT02964598|Experimental|Psychoeducation|An extensive psychoeducational platform
16547840|NCT02964598|Experimental|Bright light|Bright light treatment with 10 000 lux at max
16547841|NCT02964598|Experimental|Gamified intervention|A new gamified intervention designed for mobile phones
16547842|NCT02964598|Experimental|Bright light and gamified intervention|A combination of the two
16547843|NCT02964598|Experimental|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
16547844|NCT02964598|Experimental|Sleep coaching + bright light|A combination of the two
16547845|NCT02964585|Active Comparator|Active Arm|100 mg of Canagliflozin for 16 weeks
16547846|NCT02964585|Placebo Comparator|Placebo Arm|Placebo for 16 weeks
16547847|NCT02964572|Active Comparator|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
16547848|NCT02964572|Experimental|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
16547849|NCT02964559|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16547851|NCT02964533|Experimental|TFM|thunder-fire moxibustion therapy
16547852|NCT02964533|Active Comparator|MSM|common moxa-stick moxibustion therapy
16547853|NCT02964520|Experimental|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
16547854|NCT02964520|Sham Comparator|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).
~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
16547855|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|
16547856|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|
16547857|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|
16547858|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
16547859|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
16547860|NCT02964468|Experimental|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
16547861|NCT02964468|Active Comparator|Treatment with 3DCRT|3DCRT treatment (sequential boost)
16547862|NCT02964455|Experimental|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation.
16547863|NCT02964442|Experimental|Capsinoids|8 gel capsules equivalent to 12mg
16547864|NCT02964442|Experimental|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
16547865|NCT02964429|Experimental|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
16547866|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
16547867|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
16547868|NCT02964403|Experimental|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
16547869|NCT02964403|Active Comparator|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
16547870|NCT02964390|Experimental|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
16547871|NCT02964377|Experimental|Open-label (+)- Epicatechin|8-weeks open-label (+)- Epicatechin at 25mg/day twice per day, 25mg/day three times per day, or 75mg/day at two times per day.
16547872|NCT02964351||High PSA (prostate-specific antigen) levels|
16547873|NCT02964338|Placebo Comparator|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
16547874|NCT02964338|Experimental|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
16547875|NCT02964338|Experimental|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
16547876|NCT02964325|Experimental|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
16547877|NCT02964325|Active Comparator|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
16547878|NCT02964312|Other|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
16547879|NCT02964299||Standard|Standard bite block
16547880|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
16548091|NCT02963077|Experimental|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
16602483|NCT02596347||Chronic Beryllium Disease(CBD)|blood draw BAL
16547881|NCT02964286|Experimental|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
16547882|NCT02964286|No Intervention|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
16547883|NCT02964273|Active Comparator|Phase A Tolvaptan|Participants will be randomized to receive active tolvaptan for 12 months. Study medication will be administered orally as a split dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. The starting dose is based on weight.
16547884|NCT02964273|Placebo Comparator|Phase A Placebo|Participants receive matching-placebo spray dried, immediate release tablets orally as a split-dose, with first dose taken upon awakening and second dose taken approximately 8 hours later.
16547885|NCT02964273|Active Comparator|Phase B Tolvaptan|Participants will receive open-label tolvaptan for 24 months. Study medication will be administered orally as a split dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. The starting dose is weight based.
16547886|NCT02964260|Experimental|TAE combined ablation simultaneously|TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
16547887|NCT02964260|Other|TACE combined ablation sequentially|TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
16547888|NCT02964247|Experimental|liraglutide + SGLT2i ± metformin|
16547889|NCT02964247|Placebo Comparator|liraglutide placebo + SGLT2i ± metformin|
16547890|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
16547891|NCT02964234|Experimental|Education|Behavior: Education
16547892|NCT02964195|Experimental|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
16547893|NCT02964195|No Intervention|Control|Routine endoscopic treatment without prophylactic use of antibiotics
16547894|NCT02964182|Experimental|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.
~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.
~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
16547895|NCT02964182|Experimental|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.
~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.
~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
16547896|NCT02964169|Experimental|Family Planning Support|Family planning voucher and phone reminders
16547897|NCT02964169|No Intervention|No Family Planning Support|Routine care
16547898|NCT02964156|Experimental|Walking test using insoles|Supersole
16547899|NCT02964156|Experimental|Walking test not using insoles|no intervention
16547900|NCT02964143|Experimental|Experimental group|Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device
16547901|NCT02964143|Active Comparator|Control group 1|Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil® Plus
16547902|NCT02964143|Active Comparator|Control group 2|Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1
16547903|NCT02964130|Other|Follow-up patient|Medical follow-up visit
16547904|NCT02964104|Experimental|Insulin 287 + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
16547905|NCT02964104|Active Comparator|Insulin degludec + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
16547906|NCT02964091|Other|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
16547907|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
16547908|NCT02964065|Experimental|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
16547909|NCT02964065|Placebo Comparator|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
16547910|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
16547911|NCT02964039|Experimental|Error reduction|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error reduction mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
16547912|NCT02964039|Experimental|Error augmentation|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error augmentation mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
16547942|NCT02963909|Experimental|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
16547913|NCT02964039|Sham Comparator|Activity matched control|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in transparent mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
16547914|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
16547915|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
16547916|NCT02964013|Experimental|vibostolimab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of vibostolimab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547917|NCT02964013|Experimental|vibostolimab + pembrolizumab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of vibostolimab has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of vibostolimab is established, participants will continue receiving the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547918|NCT02964013|Experimental|Advanced solid tumor cohort|Participants will receive the RPTD of vibostolimab monotherapy or the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547919|NCT02964013|Experimental|Randomized dose 1 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547920|NCT02964013|Experimental|Randomized dose 2 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547921|NCT02964013|Experimental|vibostolimab +pembrolizumab+pemetrexed+carboplatin|Participants will receive a fixed dose of vibostolimab in combination with 200 mg pembrolizumab, 500 mg/m^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of vibostolimab in combination with 200 mg pembrolizumab and 500 mg/m^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
16547922|NCT02964013|Experimental|vibostolimab Dose 1 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547923|NCT02964013|Experimental|vibostolimab Dose 2 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
16547924|NCT02964013|Experimental|pembrolizumab/vibostolimab coformulation|Participants will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
16547925|NCT02964013|Experimental|vibostolimab+pembrolizumab+carboplatin OR cisplatin+etoposide|Participants will receive 200 mg vibostolimab in combination with 200 mg pembrolizumab, plus the investigator's choice of Area Under Curve (AUC) 5 mg/mL/min carboplatin OR 75 mg/m^2 cisplatin on Day 1 of each 21-day cycle plus 100 mg/m^2/day etoposide on Days 1-3 of each 21-day cycle for up to 4 cycles. Maintenance therapy with 200 mg vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day cycle will continue for up to an additional 31 cycles. A participant will be allowed to switch from cisplatin to carboplatin in the event of an adverse event (AE), ineligibility for further cisplatin therapy, and/or the investigator considers switching to carboplatin to be in the best interest of the participant.
16547926|NCT02964013|Experimental|pembrolizumab/vibostolimab coformulation China cohort|Participants from mainland China will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
16547927|NCT02964000|Active Comparator|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.
~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.
~Each treatment session will last for 20-40 minutes."
16547928|NCT02964000|Experimental|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.
~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.
~Each treatment session will last for 20-40 minutes."
16547929|NCT02964000|Experimental|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.
~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.
~Each treatment session will last for 20-40 minutes."
16547930|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
16547931|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
16547932|NCT02963974|Experimental|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
16547933|NCT02963961|Experimental|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
16547934|NCT02963961|No Intervention|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
16547935|NCT02963948||Medical Staff|Approximately 40 medical staff will be enrolled for the focus groups
16547936|NCT02963948||Medical staff surveyed using SAAS|Approximately 100 medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS)
16547937|NCT02963948||Wave 1 Patients|Approximately 200 patients at a Wave 1 clinic
16547943|NCT02963909|Experimental|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
16547944|NCT02963909|Experimental|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
16547945|NCT02963896|Experimental|gentamicin|intratympanic application of gentamicin 0.5 ml
16547946|NCT02963883|Experimental|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
16547947|NCT02963883|Active Comparator|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of <9 g / dl for patients with cardiovascular antecedents.
16547948|NCT02963870|Experimental|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
16547949|NCT02963870|Active Comparator|standard treatment only.|group receiving standard treatment only.
16547950|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
16547951|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
16547952|NCT02963831|Experimental|Dose Escalation|"During Phase 1 of the study, subjects will be evaluated for DLTs before proceeding to a subsequent cohort. Dose escalation for the determination of RCD will be performed based on the available dose levels and the respective rules for a standard 3 + 3 dose escalation study design.
~For Cohort A, ONCOS-102 will be given as monotherapy the first six weeks, and then durvalumab (1500 mg) will be starting on day 71.
~For Cohorts B and C, ONCOS-102 will be administered for a total of 6 weeks while durvalumab will be given for a total of 12 four-week cycles."
16547953|NCT02963831|Experimental|Cohort 1: Platinum-resistant epithelial ovarian cancer|ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
16547954|NCT02963831|Experimental|Cohort 2: Colorectal cancer|ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
16547955|NCT02963818|Experimental|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
16547956|NCT02963818|Experimental|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
16547957|NCT02963818|Experimental|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
16547958|NCT02963805|Experimental|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
16547959|NCT02963805|Experimental|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
16547960|NCT02963805|Experimental|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
16547961|NCT02963805|No Intervention|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
16547962|NCT02963792|Experimental|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.
~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
16547963|NCT02963792|Experimental|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.
~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.
~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
16547964|NCT02963779|Experimental|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
16547965|NCT02963779|Experimental|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
16547966|NCT02963779|Placebo Comparator|Placebo (Part A)|Placebo administered orally in healthy participants
16547967|NCT02963779|Active Comparator|Apremilast (Part B)|Oral dose of apremilast in healthy participants
16547968|NCT02963766|Experimental|Dose 1 Dulaglutide|Dulaglutide given subcutaneously (SC).
16547969|NCT02963766|Experimental|Dose 2 Dulaglutide|Dulaglutide given SC.
16547970|NCT02963766|Placebo Comparator|Placebo|Placebo given SC.
16547971|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
16547972|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
16547973|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
16547974|NCT02963727|Experimental|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
16547975|NCT02963714|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16547976|NCT02963714|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
16547977|NCT02963701|Experimental|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
16547978|NCT02963701|Active Comparator|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
16547979|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
16547980|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
16547981|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
16547982|NCT02963662|Experimental|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
16547983|NCT02963662|Experimental|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
16547984|NCT02963662|No Intervention|Normal BMI group|no intervention
16547985|NCT02963649|Experimental|drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.
16547986|NCT02963649|Active Comparator|Standard angioplasty balloon|standard PTA balloon
16547987|NCT02963636|Experimental|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
16547988|NCT02963610|Experimental|Pembrolizumab, Lenalidomide|"Phase I The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. The dose of lenalidomide will depend upon the patient cohort. Cohort 1 will receive 10mg, Cohort II will receive 15mg and cohort 3 will receive 20mg of lenalidomide.
~Phase II The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. Maximum Tolerated Dose (MTD) of lenalidomide as determined by the Phase I study will be given in Phase II study."
16547989|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
16547990|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
16547991|NCT02963584|Experimental|intervention group|Patients in this group will receive CTO Choice (decision aid).
16547992|NCT02963584|No Intervention|control group|Patients in this group will receive usual primary care.
16547993|NCT02963571|Experimental|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
16547994|NCT02963558|Experimental|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
16547995|NCT02963558|No Intervention|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
16547996|NCT02963545|Experimental|Patients presenting cerebral infarction|no intervention of health product administration,
16547997|NCT02963545|Other|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
16547998|NCT02963519|Experimental|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
16547999|NCT02963519|Active Comparator|Dressings|Dressings Adapted to the case
16548000|NCT02963506|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
16548001|NCT02963506|Experimental|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
16548002|NCT02963506|Experimental|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
16548003|NCT02963506|Experimental|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
16548004|NCT02963506|Experimental|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
16548005|NCT02963493|Experimental|melphalan flufenamide (melflufen) + dexamethasone|Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
16548006|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
16548007|NCT02963480||SIRS|Patients, who developed postoperative SIRS
16548008|NCT02963467|Other|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
16548009|NCT02963467|Other|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
16548010|NCT02963467|Other|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
16548090|NCT02963077|Placebo Comparator|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
16548011|NCT02963454|Experimental|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).
~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
16548012|NCT02963454|Active Comparator|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.
~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
16548013|NCT02963428|No Intervention|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
16548014|NCT02963428|Experimental|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:
~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
16548015|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
16548016|NCT02963402||Tocilizumab treated|
16548017|NCT02963402||Anti-TNF treated|
16548018|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
16548019|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
16548020|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
16548021|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
16548022|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
16548023|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
16548024|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
16548025|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
16548026|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
16548027|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
16548028|NCT02963363|Experimental|Interventional|"Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :
~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks"
16548029|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
16548030|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
16548031|NCT02963324|Experimental|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
16548032|NCT02963311|Experimental|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by >70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
16548033|NCT02963298|Active Comparator|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
16548034|NCT02963298|No Intervention|control|Repetitive testing of blood Glutamate levels without CRRT
16548035|NCT02963285||0 to 6 months|
16548036|NCT02963285||7 months to less than 1 year|
16548037|NCT02963285||1 to less than 2 years|
16548038|NCT02963285||2 to less than 6 years|
16548039|NCT02963285||6 to 12 years|
16548042|NCT02963259||SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system|Subjects will be implanted with SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
16548043|NCT02963246|Experimental|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
16548044|NCT02963246|No Intervention|Control Group|Treatment-as-usual control
16548045|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
16548046|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
16548047|NCT02963220|Experimental|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
16548048|NCT02963207|Experimental|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
16548049|NCT02963207|Active Comparator|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
16548050|NCT02963194|Experimental|Oxytocin|Oxytoxin nasal spray
16548051|NCT02963194|Placebo Comparator|Placebo|Placebo nasal spray
16548052|NCT02963181|Experimental|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
16548053|NCT02963181|Experimental|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
16548054|NCT02963168|Experimental|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
16548055|NCT02963155|Experimental|Metastatic prostate cancer blood samples|
16548056|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.
~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
16548057|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.
~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
16548058|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.
~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
16548059|NCT02963129|Experimental|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
16548060|NCT02963129|Placebo Comparator|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
16548061|NCT02963116|Experimental|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
16548062|NCT02963116|Experimental|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
16548063|NCT02963116|Experimental|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
16548064|NCT02963116|Experimental|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
16548065|NCT02963116|Experimental|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
16548066|NCT02963103|Experimental|Tacrolimus group|oral
16548067|NCT02963090|Active Comparator|Topotecan|Topotecan IV at 1265mg/m^2 Days 1-5 of every 21 day cycle
16548068|NCT02963090|Experimental|Pembrolizumab|Pembrolizumab IV 200mg infusion Day 1 of every 21 day cycle
16548069|NCT02963077|Experimental|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
16548070|NCT02963077|Experimental|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
16548071|NCT02963077|Experimental|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
16548072|NCT02963077|Experimental|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
16548073|NCT02963077|Experimental|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
16548074|NCT02963077|Placebo Comparator|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
16548075|NCT02963077|Placebo Comparator|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
16548076|NCT02963077|Placebo Comparator|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
16548077|NCT02963077|Placebo Comparator|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
16548078|NCT02963077|Placebo Comparator|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
16548079|NCT02963077|Experimental|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
16548080|NCT02963077|Placebo Comparator|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
16548081|NCT02963077|Experimental|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
16548082|NCT02963077|Placebo Comparator|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
16548083|NCT02963077|Experimental|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
16548084|NCT02963077|Placebo Comparator|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
16548085|NCT02963077|Experimental|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
16548086|NCT02963077|Active Comparator|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
16548087|NCT02963077|Experimental|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
16548088|NCT02963077|Placebo Comparator|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
16548089|NCT02963077|Active Comparator|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
16548092|NCT02963077|Placebo Comparator|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
16548093|NCT02963064|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
16548094|NCT02963051|Experimental|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)
~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
16548095|NCT02963051|Experimental|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)
~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
16548096|NCT02963051|Experimental|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases
~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
16548097|NCT02963038|Experimental|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
16548098|NCT02963025|Other|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
16548099|NCT02963025|Other|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
16548100|NCT02962999|Experimental|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
16548101|NCT02962999|Placebo Comparator|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
16548102|NCT02962986|Active Comparator|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
16548103|NCT02962986|Active Comparator|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
16548104|NCT02962973|Experimental|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
16548105|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
16548106|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
16548107|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
16548108|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
16548109|NCT02962947|Placebo Comparator|PLACEBO|Placebo will be taken daily during the study period
16548110|NCT02962947|Active Comparator|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
16548111|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
16548112|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
16548113|NCT02962921|Experimental|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.
~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
16548114|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
16548115|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
16548116|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
16548117|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
16548118|NCT02962895|Experimental|VAY736 dose 1|VAY736 low
16548119|NCT02962895|Experimental|VAY736 dose 2|VAY736 medium
16548120|NCT02962895|Experimental|VAY736 dose 3|VAY736 high
16548121|NCT02962895|Placebo Comparator|Placebo|Placebo control
16548122|NCT02962882|Experimental|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
16548123|NCT02962882|Experimental|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
16548124|NCT02962869|Experimental|BAY987517|All subjects are patched with the same product
16548125|NCT02962856|Experimental|BAY987517|All subjects are patched with the same product.
16548126|NCT02962843|Experimental|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
16548127|NCT02962843|No Intervention|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
16548128|NCT02962830|Experimental|Sufentanil|
16548264|NCT02961829|No Intervention|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
16548129|NCT02962817|Experimental|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.
~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
16548130|NCT02962817|Active Comparator|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
16548131|NCT02962804|Experimental|Nivolumab plus radiation|Nivolumab plus radiation
16548132|NCT02962791|Experimental|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
16548133|NCT02962791|Active Comparator|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
16548134|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
16548135|NCT02962752|Experimental|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
16548136|NCT02962752|Placebo Comparator|Placebo|Sugar, flavour and volume matched placebo control drink.
16548137|NCT02962739|Active Comparator|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
16548138|NCT02962739|Active Comparator|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
16548139|NCT02962739|Active Comparator|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
16548140|NCT02962739|Active Comparator|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
16548141|NCT02962739|Active Comparator|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
16548142|NCT02962739|Active Comparator|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
16548143|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
16548144|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
16548145|NCT02962713|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
16548146|NCT02962713|Experimental|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
16548147|NCT02962700|Experimental|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
16548148|NCT02962700|Active Comparator|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.
~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
16548149|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
16548150|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
16548151|NCT02962674|Other|Treatment|
16548152|NCT02962661|Experimental|Arm I (hMSCs IV)|Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
16548153|NCT02962661|Experimental|Arm II (hMSCs transendocardially)|Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
16548154|NCT02962661|Active Comparator|Arm III (standard of care)|Patients receive standard of care treatment for heart failure.
16548155|NCT02962648|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
16548156|NCT02962635||Hemodialysis patients|"A total of 30 patients
~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
16548157|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients
~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
16548158|NCT02962622|Experimental|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
16548159|NCT02962622|Experimental|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
16548160|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
16548161|NCT02962609|Experimental|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
16548162|NCT02962583|Experimental|Probiotic|Daily probiotic consumption
16548163|NCT02962583|Placebo Comparator|Placebo|Daily placebo consumption
16548164|NCT02962570|Experimental|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped
~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped
~Repeat until the end of the surgical procedure"
16548165|NCT02962557|No Intervention|Control|The control group will receive no prompts by the recorded voice.
16548166|NCT02962557|Experimental|Experimental|The experimental group will receive playback of recorded verbal prompts to breathe with an optional shoulder shake.
16548167|NCT02962544|Active Comparator|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
16548168|NCT02962544|Active Comparator|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
16548169|NCT02962531|Experimental|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
16548170|NCT02962531|Experimental|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
16548171|NCT02962531|Experimental|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
16548172|NCT02962518|Active Comparator|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
16548173|NCT02962518|Experimental|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
16548174|NCT02962492|Active Comparator|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
16548175|NCT02962492|Active Comparator|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
16548176|NCT02962492|Placebo Comparator|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
16548177|NCT02962492|Active Comparator|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
16548178|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
16548179|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
16548180|NCT02962479||TNF blocker-naïve nrSpA patients|
16548181|NCT02962479||TNF blocker-exposed nrSpA patients|
16548182|NCT02962479||Healthy Participants|
16548183|NCT02962466|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
16548184|NCT02962466|No Intervention|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
16548185|NCT02962466|No Intervention|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
16548186|NCT02962453|Experimental|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
16548187|NCT02962453|Active Comparator|Ground Walker|Rehabilitation using walker for 5days.
16548188|NCT02962440|Experimental|Somapacitan|
16548189|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
16548190|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
16548892|NCT02957929|Experimental|Cohort 1b, Period F|Single oral dose under fed conditions, crossover
16548192|NCT02962401|Experimental|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab
~Cycle 1 :
~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15
~Cycle 2 - 6 :
~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1
~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
16548193|NCT02962388|Active Comparator|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
16548194|NCT02962388|Experimental|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.
~Maximum dose 25 mg BID."
16548195|NCT02962375|Experimental|Active Treatment|100% orange juice with orange pomace fiber
16548196|NCT02962375|Placebo Comparator|Control Treatment|100% orange juice
16548197|NCT02962336|Experimental|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
16548198|NCT02962336|Active Comparator|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
16548199|NCT02962323|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
16548200|NCT02962323|Active Comparator|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
16548201|NCT02962310|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
16548202|NCT02962310|Active Comparator|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
16548203|NCT02962297|Experimental|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
16548204|NCT02962297|Placebo Comparator|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
16548205|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
16548206|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
16548207|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
16548208|NCT02962258|Experimental|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
16548209|NCT02962258|Active Comparator|Reference|Tribenzor of Daichi Sankyo Inc., USA
16548210|NCT02962245|Active Comparator|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
16548211|NCT02962245|Placebo Comparator|regular treatment group|regular treatment untill recurrence in one year
16548212|NCT02962232|Experimental|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
16548213|NCT02962232|Active Comparator|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
16548214|NCT02962219|Experimental|Intervention|A pre-operative personalised exercise programme (my-PEP).
16548215|NCT02962219|Other|Control|Standard care
16548216|NCT02962206|Active Comparator|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
16548217|NCT02962206|Experimental|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
16548218|NCT02962180|Experimental|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
16548219|NCT02962167|Experimental|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
16548220|NCT02962167|Experimental|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
16548221|NCT02962167|Experimental|Disseminated Recurrent Medulloblastoma|Patients must have disseminated recurrent medulloblastoma (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
16548222|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable
~They will undergo the following:
~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
16548265|NCT02961829|Experimental|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
16548223|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder
~They will undergo the following:
~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
16548224|NCT02962141|Experimental|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
16548225|NCT02962141|Active Comparator|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
16548226|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
16548227|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
16548228|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
16548229|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
16548230|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg PO/NGT/OGT daily x 5 days
16548231|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil daily x 5 days
16548232|NCT02962089|Placebo Comparator|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
16548233|NCT02962089|Active Comparator|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
16548234|NCT02962063|Experimental|Esophageal Cancer|This is a phase Ib/II trial of durvalumab (MEDI4736), a monoclonal antibody against programmed death ligand-1 (PD-L1)), and tremelimumab, an anti-CTLA-4 antibody, in combination with chemoradiation for patients with locally advanced (TanyN+M0 or T3-4NanyM0) esophageal or gastroesophageal (GE) junction adenocarcinoma.
16548235|NCT02962050||ALS|Participants enrolled will complete the following tests: Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, reflexive cough testing, Pulmonary Function Testing; Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
16548236|NCT02962037|No Intervention|Base line|the subject will take the tests in the morning and the evening
16548237|NCT02962037|Experimental|After treatment|the subject will take the tests in the morning and the evening
16548238|NCT02962024|Active Comparator|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
16548239|NCT02962024|Placebo Comparator|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
16548240|NCT02962011|Experimental|Knotless barbed suture|
16548241|NCT02962011|Active Comparator|polyglactin 910|Vicryl
16548242|NCT02961998|Experimental|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
16548243|NCT02961998|Active Comparator|Control group|Patients take sorafenib only.
16548244|NCT02961972|Placebo Comparator|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
16548245|NCT02961972|Experimental|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
16548246|NCT02961959|Experimental|Surgery|Arthrodesis of SI-joint/s, physiotherapy
16548247|NCT02961959|Active Comparator|Non-surgery|Non-surgery, physiotherapy
16548248|NCT02961946|Active Comparator|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
16548249|NCT02961946|Active Comparator|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
16548250|NCT02961946|Active Comparator|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
16548251|NCT02961933|Experimental|Apneic oxygenation|
16548252|NCT02961933|Active Comparator|non-apneic oxygenation|
16548253|NCT02961920|Experimental|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
16548254|NCT02961920|Active Comparator|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
16548255|NCT02961907|No Intervention|Control|"The usual routine course includes :
~a clinico-biological evaluation of infertility causes
~a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy
~collection of blood and sperm samples"
16548256|NCT02961907|Experimental|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
16548257|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
16548258|NCT02961881|Experimental|blinatumomab|
16548259|NCT02961868|Experimental|Prospective cohort|3 years follow-up
16548260|NCT02961855|Experimental|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
16548261|NCT02961855|Active Comparator|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
16548262|NCT02961842|Experimental|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
16548263|NCT02961842|Active Comparator|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
16548266|NCT02961829|Experimental|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
16548267|NCT02961829|Experimental|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
16548268|NCT02961829|Experimental|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
16548269|NCT02961829|Experimental|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
16548270|NCT02961816|Experimental|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
~Panobinostat daily from Day -9 to -2.
~Gemcitabine administered on Days -8 and -3.
~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
~Melphalan on Days -3 and -2.
~Rituximab on Day -9 for participants with CD20+ tumors.
~Dexamethasone twice a day from Day -8 AM to Day -2 PM.
~Caphosol oral rinses 30 mL four times a day used from Day -8.
~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
~Pyridoxine three times a day from Day -1.
~Stem cells administered by vein on Day 0.
~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
16548271|NCT02961816|Experimental|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
~Panobinostat daily from Day -9 to -2.
~Gemcitabine administered on Days -8 and -3.
~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
~Melphalan on Days -3 and -2.
~Rituximab on Day -9 for participants with CD20+ tumors.
~Dexamethasone twice a day from Day -8 AM to Day -2 PM.
~Caphosol oral rinses 30 mL four times a day used from Day -8.
~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
~Pyridoxine three times a day from Day -1.
~Stem cells administered by vein on Day 0.
~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
16548272|NCT02961816|Experimental|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
~Panobinostat daily from Day -9 to -2.
~Gemcitabine administered on Days -8 and -3.
~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
~Melphalan on Days -3 and -2.
~Rituximab on Day -9 for participants with CD20+ tumors.
~Dexamethasone twice a day from Day -8 AM to Day -2 PM.
~Caphosol oral rinses 30 mL four times a day used from Day -8.
~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
~Pyridoxine three times a day from Day -1.
~Stem cells administered by vein on Day 0.
~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
16548273|NCT02961803|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
16548274|NCT02961803|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
16548275|NCT02961790|Experimental|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
16548276|NCT02961790|Placebo Comparator|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
16548277|NCT02961790|Experimental|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
16548278|NCT02961790|Placebo Comparator|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
16548279|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
16548280|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
16548281|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
16548282|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
16548283|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
16548284|NCT02961751|Other|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
16548285|NCT02961738|Active Comparator|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
16548286|NCT02961738|Experimental|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
16548287|NCT02961725|Experimental|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
16548288|NCT02961712|Experimental|cell therapy|NK cells and amniotic epithelial cells
16548289|NCT02961699|Experimental|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
16548290|NCT02961699|Active Comparator|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
16548325|NCT02961413||cohort 4|Silibinin capsules
16548326|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
16548291|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
16548292|NCT02961673|Experimental|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
16548293|NCT02961673|Active Comparator|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
16548294|NCT02961660|Experimental|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
16548295|NCT02961660|Experimental|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
16548296|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
16548297|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
16548298|NCT02961634|Experimental|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.
~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
16548299|NCT02961634|Active Comparator|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
16548300|NCT02961621|Experimental|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
16548301|NCT02961621|No Intervention|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
16548302|NCT02961608|Experimental|study group|
16548303|NCT02961595|No Intervention|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
16548304|NCT02961595|Active Comparator|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
16548305|NCT02961582|Experimental|Sacral Neuromodulation|
16548306|NCT02961582|Other|Personalized Conservative Treatment|
16548307|NCT02961569|Other|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
16548308|NCT02961556|Experimental|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
16548309|NCT02961543|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
16548310|NCT02961543|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
16548311|NCT02961530|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
16548312|NCT02961530|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
16548313|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
16548314|NCT02961504|Experimental|HLCM051 (MultiStem)|single dose of 1.2 billion HLCM051 cells
16548315|NCT02961504|Placebo Comparator|Placebo|a single dose of placebo
16548316|NCT02961478|Experimental|Iohexol plasmatic clearance|
16548317|NCT02961465||Sacral Neuromodulation (SNM)|
16548318|NCT02961452||Peanut allergic children|
16548319|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
16548320|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
16548321|NCT02961426|Experimental|sofosbuvir + ravidasvir|12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients
16548322|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
16548323|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
16548324|NCT02961413||cohort 3|Bicyclol
16548328|NCT02961400|Experimental|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
16548329|NCT02961400|Experimental|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
16548330|NCT02961400|Other|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
16548331|NCT02961387|Experimental|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
16548332|NCT02961387|Sham Comparator|Oxygen-making machine treatment|Inhalation of oxygen.
16548333|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
16548334|NCT02961361|Experimental|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
16548335|NCT02961361|Experimental|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
16548336|NCT02961348|Active Comparator|Early start of NOAC|Day 1 to day 4 after ischemic stroke onset
16548337|NCT02961348|Active Comparator|Late start of NOAC|Day 5 to day 10 after ischemic stroke onset
16548338|NCT02961335|Experimental|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
16548339|NCT02961322|Experimental|lobo isthmectomy|
16548340|NCT02961309|Experimental|Active THC|5.6% THC via smoked marijuana cigarette
16548341|NCT02961309|Experimental|Placebo|Placebo THC via smoked cigarette
16548342|NCT02961283|Experimental|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
16548343|NCT02961283|Experimental|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
16548344|NCT02961283|Experimental|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
16548345|NCT02961283|Experimental|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
16548346|NCT02961270|Experimental|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
16548347|NCT02961257|Experimental|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).
~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel."
16548348|NCT02961257|Experimental|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
16548349|NCT02961244|No Intervention|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
16548350|NCT02961244|Active Comparator|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
16548351|NCT02961231|Active Comparator|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
16548352|NCT02961231|Active Comparator|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
16548353|NCT02961231|Experimental|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
16548354|NCT02961231|Experimental|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
16548355|NCT02961218|Placebo Comparator|Placebo|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
16548356|NCT02961218|Experimental|ACZ885|Monthly doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
16548359|NCT02961192|No Intervention|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
16548360|NCT02961192|Experimental|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
16548361|NCT02961192|Experimental|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
16548362|NCT02961192|Experimental|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
16548363|NCT02961179|Experimental|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
16548364|NCT02961179|Placebo Comparator|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
16548365|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
16548893|NCT02957929|Experimental|Cohort 2|Multiple oral doses
16548366|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
16548367|NCT02961140|Experimental|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
16548368|NCT02961140|Active Comparator|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
16548369|NCT02961127||group 1|no drugs were used in our study
16548370|NCT02961127||group 2|
16548371|NCT02961114|Experimental|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
16548372|NCT02961114|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
16548373|NCT02961114|Experimental|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
16548374|NCT02961101|Experimental|Anti-PD-1 antibody+decitabine|Decitabine will be administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 200mg on day8 IV Q3 weeks until progression.
16548375|NCT02961101|Experimental|Anti-PD-1 antibody|Anti-PD-1 antibody 200mg IV Q3 weeks until progression.
16548376|NCT02961101|Experimental|Anti-PD-1 antibody+chemotherapy|Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
16548377|NCT02961075|Experimental|Cricothyroid|local surface anesthesia by Cricothyroid
16548378|NCT02961075|Experimental|Laryngeal tube|local surface anesthesia by Laryngeal tube
16548379|NCT02961062|Experimental|Treatment Sequence 1|
16548380|NCT02961062|Placebo Comparator|Treatment Sequence 2|
16548381|NCT02961049|Active Comparator|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
16548382|NCT02961049|Active Comparator|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
16548383|NCT02961049|Active Comparator|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
16548384|NCT02961049|Active Comparator|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
16548385|NCT02961036|Experimental|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
16548386|NCT02961036|Active Comparator|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
16548387|NCT02961036|Active Comparator|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
16548388|NCT02961036|Active Comparator|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
16548389|NCT02961036|Active Comparator|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
16548390|NCT02961036|Experimental|Group A reminder|One survey reminder at 14 days
16548391|NCT02961036|Active Comparator|Group B reminders|Two survey reminders 14 days and 28 days
16548392|NCT02961023|Active Comparator|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
16548393|NCT02961023|Other|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
16548394|NCT02961010|Experimental|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
16548395|NCT02961010|No Intervention|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
16548396|NCT02960997|Experimental|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
16548397|NCT02960997|Placebo Comparator|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
16548398|NCT02960984|Experimental|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
16548399|NCT02960984|No Intervention|Baseline|No intervention is planned
16548400|NCT02960945|Experimental|CTP-543|Tablet, single oral dose
16548401|NCT02960945|Active Comparator|Jakafi|Tablet, single oral dose
16548402|NCT02960932|Experimental|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
16548428|NCT02960776|Experimental|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
16548403|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1A|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
16548404|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1B|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
16548405|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4A|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
16548406|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4B|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
16548407|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
16548408|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2B|"ccRCC molecular subgroup 2 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
16548409|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3B|"ccRCC molecular subgroup 3 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
16548410|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
16548411|NCT02960893|Experimental|Troriluzole|"Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.
~Troriluzole/Troriluzole - Extension Phase: Participants received Troriluzole 140 mg capsules orally QD for 48 weeks."
16548412|NCT02960893|Placebo Comparator|Placebo|"Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.
~Placebo/Troriluzole - Extension Phase: Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks."
16548413|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
16548414|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
16548415|NCT02960854|Experimental|Nivolumab 1|Dose 1
16548416|NCT02960854|Experimental|Nivolumab 2|Dose 2
16548417|NCT02960841|Experimental|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
16548418|NCT02960841|Active Comparator|Conventional treatment|Conventional treatment active comparator
16548419|NCT02960828|Experimental|"Intervention-Device:_Laser"|"Subthreshold focal photocoagulation
~Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
16548420|NCT02960828|No Intervention|Control|Contralateral eye
16548421|NCT02960815|Active Comparator|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
16548422|NCT02960815|Experimental|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
16548423|NCT02960815|Experimental|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
16548424|NCT02960802|Active Comparator|kidney transplant patient|kidney transplantation is intervention
16548425|NCT02960802|No Intervention|healthy control|no intervention
16548426|NCT02960789|Experimental|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.
~Interventions:
~Undertake and record a formalized clinical assessment of hydration status
~Take a measurement of body weight on calibrated scales
~RF wristband hydration status measurement
~Measure capillary refill time with manual stopwatch
~CRT device hydration status measurement"
16548427|NCT02960776|No Intervention|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
16548498|NCT02960399|Active Comparator|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
16548429|NCT02960763|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
16548430|NCT02960763|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
16548431|NCT02960763|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
16548432|NCT02960763|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
16548433|NCT02960763|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
16548434|NCT02960750|Experimental|Intervention group|Had access to the W@WS website program during 19 weeks.
16548435|NCT02960750|Active Comparator|Active comparison group|Maintained habitual behavior.
16548436|NCT02960737|Experimental|Intervention group|Intensive training with oral screen (intervention group) and traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
16548437|NCT02960737|No Intervention|Control group|Traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
16548438|NCT02960724|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
16548439|NCT02960711|Experimental|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
16548440|NCT02960711|Placebo Comparator|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
16548441|NCT02960711|Experimental|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
16548442|NCT02960711|Placebo Comparator|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
16548443|NCT02960698|Active Comparator|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
16548444|NCT02960698|Active Comparator|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
16548445|NCT02960698|Placebo Comparator|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
16548448|NCT02960646|Experimental|Treatment (peripheral blood stem cell transplantation)|Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
16548449|NCT02960633|Active Comparator|THA with Collar|THA with Collar
16548450|NCT02960633|Active Comparator|THA without Collar|THA without Collar
16548451|NCT02960607|Experimental|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
16548452|NCT02960594|Experimental|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548453|NCT02960594|Experimental|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548454|NCT02960594|Experimental|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548455|NCT02960594|Experimental|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548456|NCT02960594|Experimental|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548457|NCT02960594|Experimental|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548458|NCT02960594|Experimental|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548459|NCT02960594|Experimental|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548460|NCT02960594|Experimental|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548461|NCT02960594|Experimental|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
16548462|NCT02960581|Experimental|Group 1A|HIV-uninfected participants
16548463|NCT02960581|Experimental|Group 1B|HIV-uninfected participants
16548464|NCT02960581|Experimental|Group 1C|HIV-uninfected participants
16548465|NCT02960581|Experimental|Group 2A|HIV-infected on ART, (<50 cp/ml)
16548466|NCT02960581|Experimental|Group 2B|HIV-infected on ART, (<50 cp/ml)
16548467|NCT02960581|Experimental|Group 2C|HIV-infected on ART, (<50 cp/ml)
16548468|NCT02960581|Experimental|Group 3A|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
16548469|NCT02960581|Experimental|Group 3B|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
16548470|NCT02960581|Experimental|Arm 1D|HIV-uninfected participants
16548473|NCT02960555|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.
16548474|NCT02960542|Experimental|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
16548475|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
16548476|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
16548477|NCT02960503|Active Comparator|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
16548478|NCT02960503|Placebo Comparator|Placebo arm|Control arm: placebo three times a week for 6 months
16548479|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
16548480|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
16548481|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
16548482|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
16548483|NCT02960477|Experimental|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
16548484|NCT02960477|Active Comparator|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
16548485|NCT02960464|Active Comparator|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
16548486|NCT02960464|Sham Comparator|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
16548487|NCT02960451|Experimental|PRIME care|Specialized care in the PRIME clinic
16548488|NCT02960451|Active Comparator|Usual care|Usual care in the community
16548489|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
16548490|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
16548491|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
16548492|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
16548493|NCT02960425|Experimental|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
16548494|NCT02960425|Experimental|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
16548495|NCT02960412|Experimental|furosemide|furosemide 10mg (1mL) IV push for one dose
16548496|NCT02960412|Placebo Comparator|placebo|normal saline 1mL IV push for one dose
16548497|NCT02960399|Experimental|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
16548578|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (2a)|
16548499|NCT02960386|Other|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
16548500|NCT02960373|Active Comparator|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
16548501|NCT02960373|Experimental|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
16548502|NCT02960373|Experimental|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
16548503|NCT02960373|Experimental|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
16548504|NCT02960347|Experimental|Active tDCS|open label active tDCS treatment
16548505|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
16548506|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
16548507|NCT02960308||Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
16548508|NCT02960295|Experimental|Virtual visit|"Self-monitoring of blood glucose (four times daily).
~Self-weighing (weekly).
~Self-checking of blood pressure (weekly).
~Checking fetal heart rate (weekly).
~Visits with caregivers."
16548509|NCT02960282||Ancillary-Correlative (gut microbiome analysis)|Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.
16548510|NCT02960269|Experimental|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
16548511|NCT02960256||Patients admitted to an internal medicine department due to an|
16548512|NCT02960243|Sham Comparator|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
16548513|NCT02960243|Experimental|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
16548514|NCT02960243|Experimental|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
16548515|NCT02960243|Experimental|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
16548516|NCT02960230|Experimental|Stratum A: Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
16548517|NCT02960230|Experimental|Stratum B: Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
16548518|NCT02960230|Experimental|Stratum C: Newly Diagnosed DIPG or other Midline Glioma|Newly diagnosed children with DIPG or other midline gliomas (excluding primary spinal cord tumors) who are positive for HLA-A2 (02:01) and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Nivolumab will also be given via IV. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks. Nivolumab will continue to be given every 3 weeks throughout all of treatment.
16548519|NCT02960217|Experimental|Double-Blind UX007 Followed by Placebo|"Participants will first receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks.
~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
16548579|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (2b)|
16548580|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3a)|
16548520|NCT02960217|Experimental|Double Blind Placebo Followed by UX007|"Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks.
~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
16548521|NCT02960204|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
16548522|NCT02960204|Active Comparator|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
16548523|NCT02960204|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
16548524|NCT02960204|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
16548525|NCT02960191|Other|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
16548526|NCT02960191|Other|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
16548527|NCT02960191|Other|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
16548528|NCT02960178|Experimental|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
16548529|NCT02960178|Active Comparator|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
16548530|NCT02960165|Experimental|Virtual interface group A|Older adults that started the practice on the virtual interface
16548531|NCT02960165|Experimental|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
16548532|NCT02960165|Active Comparator|Real interface group A|Older adults that started the practice on the virtual interface
16548533|NCT02960165|Active Comparator|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
16548534|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
16548535|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
16548536|NCT02960152||Control|interview and periodontal full-mouth examination
16548537|NCT02960139|Experimental|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
16548538|NCT02960139|No Intervention|Control- Standard of Care|Control group is standard closure of anastomosis.
16548539|NCT02960126|Active Comparator|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
16548540|NCT02960126|Experimental|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
16548541|NCT02960113|Experimental|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
16548542|NCT02960113|Experimental|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
16548543|NCT02960113|Experimental|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
16548544|NCT02960100|Experimental|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
16548545|NCT02960100|Active Comparator|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
16548546|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
16548547|NCT02960087|Active Comparator|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
16548548|NCT02960074|Experimental|Non-antibiotics Arm|The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
16548549|NCT02960074|Experimental|Antibiotics Arm|An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
16548550|NCT02960061|Experimental|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
16548551|NCT02960061|Sham Comparator|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
16548581|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3b)|
16548582|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4a)|
16548583|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4b)|
16548584|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5a)|
16548585|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5b)|
16548552|NCT02960048|Active Comparator|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .
~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.
~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .
~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
16548553|NCT02960048|Experimental|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .
~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .
~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
16548554|NCT02960035|Experimental|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
16548555|NCT02960035|Experimental|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
16548556|NCT02960035|Placebo Comparator|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
16548559|NCT02960009|Experimental|Anode HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
16548560|NCT02960009|Experimental|Cathode HD-tDCS|The center cathode is fixed on the contralesional primary motor cortex and the 4 surrounding anode electrodes will be placed about 6 cm to the center.
16548561|NCT02960009|Placebo Comparator|Sham HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
16548562|NCT02959996|Placebo Comparator|Placebo|Normal saline will be infiltrated
16548563|NCT02959996|Active Comparator|Intervention|Liposomal bupivacaine will be infiltrated
16548564|NCT02959983|Active Comparator|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
16548565|NCT02959983|Placebo Comparator|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
16548566|NCT02959970|Experimental|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
16548567|NCT02959970|Experimental|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
16548568|NCT02959957|Experimental|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
16548569|NCT02959957|Active Comparator|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
16548570|NCT02959944|Experimental|Ibrutinib + Prednisone|"Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 [CYP] inhibitors or hepatic dysfunction as applicable.
~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
16548571|NCT02959944|Placebo Comparator|Placebo + Prednisone|"Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity.
~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
16548572|NCT02959931|Experimental|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~2400 mg of dietary potassium.
16548573|NCT02959931|Active Comparator|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~540 mg of dietary potassium.
16548574|NCT02959918|Experimental|SEL-037 Pegsiticase LD(low dose) alone|
16548575|NCT02959918|Experimental|SEL-037 Pegsiticase HD(high dose) alone|
16548576|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (1a)|
16548577|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (1b)|
16548588|NCT02959905|Experimental|medium dose of preparative regimen|Patients will receive medium dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
16548589|NCT02959905|Experimental|low dose of preparative regimen|Patients will receive low dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
16548590|NCT02959905|Experimental|no preparative regimen|Patients will only receive TSA-CTL.
16548591|NCT02959892|Experimental|TAK-041 20 mg|[11C] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
16548592|NCT02959892|Experimental|TAK-041 40 mg|[11C] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
16548593|NCT02959879|Experimental|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
16548594|NCT02959879|Experimental|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
16548595|NCT02959879|Active Comparator|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.
~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
16548596|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
16548597|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
16548598|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
16548599|NCT02959840|No Intervention|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
16548600|NCT02959840|Active Comparator|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
16548601|NCT02959840|Experimental|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
16548602|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
16548603|NCT02959801|Experimental|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
16548604|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
16548605|NCT02959775|Experimental|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
16548606|NCT02959775|Experimental|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
16548607|NCT02959775|No Intervention|Control|Receive no vaccination during the study period
16548608|NCT02959762|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
16548609|NCT02959762|Active Comparator|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
16548610|NCT02959762|Active Comparator|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
16548611|NCT02959749|Active Comparator|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
16548612|NCT02959749|Experimental|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
16548613|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
16548614|NCT02959736||Spectrum|Music Therapy (MATADOC)
16548615|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
16548616|NCT02959710|Experimental|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
16548617|NCT02959710|Experimental|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
16548618|NCT02959710|Experimental|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
16548619|NCT02959697|Experimental|Subcut. + Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
16548683|NCT02959229|Active Comparator|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
16548894|NCT02957929|Experimental|Cohort 3|Multiple oral doses
16548620|NCT02959697|Sham Comparator|Subcut. + Sham Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.
16548621|NCT02959671|Experimental|Lower Anterior EXD-952 Self-ligating Brackets|
16548622|NCT02959658|Active Comparator|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
16548623|NCT02959658|Placebo Comparator|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
16548624|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
16548625|NCT02959645||Healthy control|Healthy Volunteers
16548626|NCT02959632|Experimental|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).
~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
16548627|NCT02959619|Experimental|Ensartinib|Escalating dose of ensartinib was orally given once er day
16548628|NCT02959606|Experimental|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.
~Other Name: Anplone SR"
16548629|NCT02959606|Active Comparator|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.
~Other Name: Plavix"
16548630|NCT02959593|Experimental|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
16548631|NCT02959593|Experimental|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
16548632|NCT02959580|Experimental|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
16548633|NCT02959580|Active Comparator|surgical|lesion extended excision
16548634|NCT02959567|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
16548635|NCT02959554|Experimental|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
16548636|NCT02959554|Active Comparator|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
16548637|NCT02959541|Other|Calciumfolinat 60 mg/m²|Intravenous infusion of Calciumfolinat 60 mg/m²given to patients with colon cancer at the time for the operation of the colon cancer.
16548638|NCT02959541|Other|Calciumfolinat 200 mg/m²|Intravenous infusion of Calciumfolinat 200 mg/m² given to patients with colon cancer at the time for the operation of the colon cancer.
16548639|NCT02959541|Other|Calciumfolinat 500 mg/ m²|Intravenous infusion of Calciumfolinat 500 mg/ m² given to patients with colon cancer at the time for the operation of the colon cancer.
16548640|NCT02959528|Active Comparator|Control|ADHD group treated with visual-perceptual training
16548641|NCT02959528|Experimental|Experiment|ADHD group treated with working memory training
16548642|NCT02959515|Active Comparator|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
16548643|NCT02959515|Active Comparator|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
16548644|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
16548645|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
16548646|NCT02959489|Active Comparator|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
16548647|NCT02959489|Experimental|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
16548648|NCT02959476|Experimental|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
16548649|NCT02959476|Placebo Comparator|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
16548650|NCT02959463|Experimental|Cohort 1 (hemithoracic radiation therapy, pembrolizumab)|Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16548895|NCT02957929|Experimental|Cohort 4|Multiple oral doses in presence of CYP probe substrates
16604653|NCT02582216|Experimental|Open label|3D augmented reality
16548651|NCT02959463|Experimental|Cohort 2 (palliative radiation therapy, pembrolizumab)|Patients undergo palliative radiation therapy over 1-3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax). After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16548652|NCT02959450|Experimental|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
16548653|NCT02959450|No Intervention|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
16548654|NCT02959437|Experimental|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
16548655|NCT02959437|Experimental|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
16548656|NCT02959437|Experimental|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
16548657|NCT02959411|Experimental|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
16548658|NCT02959411|Active Comparator|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
16548659|NCT02959398|Active Comparator|standard mammography|standard mammography
16548660|NCT02959398|Experimental|standard mammography and tomosynthesis|standard mammography and tomosynthesis
16548661|NCT02959385|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
16548662|NCT02959385|Active Comparator|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
16548663|NCT02959372|Experimental|lung ultrasound group|lung ultrasound results
16548664|NCT02959372|Placebo Comparator|control group|The attending physician will not have the result of the lung ultrasound
16548665|NCT02959359|Other|DAA treatment arm|Active DAA treatment ('Ledipasvir 90mg/Sofosbuvir 400 mg plus Ribavirin' ) for HCV-HCC patients after curative resection or ablation.
16548666|NCT02959346|Sham Comparator|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
16548667|NCT02959346|Experimental|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
16548668|NCT02959333|Experimental|hAEC treatment|hAEC: human amniotic epithelial cells 3-5*10^7 /5 ml
16548669|NCT02959320|Active Comparator|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
16548670|NCT02959320|Active Comparator|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
16548671|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
16548672|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
16548673|NCT02959294|Experimental|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
16548674|NCT02959294|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
16548675|NCT02959294|Experimental|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
16548676|NCT02959281|Experimental|Hemodynamic data available|Providing caring physicians with hemodynamic variables measured using the NICAS system.
16548677|NCT02959281|No Intervention|Hemodynamic data not available|Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
16548678|NCT02959268|Other|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
16548679|NCT02959255|Active Comparator|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
16548680|NCT02959255|Active Comparator|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
16548681|NCT02959229|Experimental|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
16548682|NCT02959229|Experimental|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
16548684|NCT02959216|Experimental|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
16548685|NCT02959216|Placebo Comparator|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
16548686|NCT02959190|Experimental|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
16548687|NCT02959190|Experimental|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
16548688|NCT02959190|Experimental|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
16548689|NCT02959190|Experimental|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
16548690|NCT02959190|Experimental|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
16548691|NCT02959190|Experimental|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
16548692|NCT02959177|Experimental|120 milligrams (mg) Galcanezumab|120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
16548693|NCT02959177|Experimental|240 mg Galcanezumab|120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
16548694|NCT02959177|Placebo Comparator|Placebo|Placebo administered SC once a month for 6 months.
16548695|NCT02959164|Experimental|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.
~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
16548696|NCT02959151|Experimental|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
16548697|NCT02959138|Experimental|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of lanraplenib
16548698|NCT02959138|Experimental|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of lanraplenib
16548699|NCT02959138|Experimental|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of lanraplenib
16548700|NCT02959125|Experimental|Intervention|"Intervention
~NutFish based supplementation for 60 days
~Multiple micro nutrient for 60 days
~Health education in pregnancy class"
16548701|NCT02959125|Active Comparator|Control|"Control
~Government food supplementation for 60 days
~Iron Folic acid for 60 days
~Health education in pregnancy class"
16548702|NCT02959112|Active Comparator|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
16548703|NCT02959112|Placebo Comparator|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
16548704|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
16548705|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
16548706|NCT02959086||1|Patients were diagnosed since January 2002.
16548707|NCT02959060|Experimental|BMS-986177 and Rifampin|
16548708|NCT02959047|Experimental|Alirocumab|Alirocumab 150mg SQ every 2 weeks
16548709|NCT02959047|Placebo Comparator|Placebo|Matched placebo
16548710|NCT02959034||BMI > 95%|No Intervention
16548711|NCT02959034||Healthy Weight Siblings|Control
16548712|NCT02959034||Healthy Weight Unrelated|Control
16548713|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
16548714|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
16548715|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
16548716|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.
~Hypertension group will measure TOI and BP."
16548717|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
16605563|NCT02576340|No Intervention|control|no drug administered
16548718|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
16548719|NCT02958982|Experimental|RP3128|RP3128, A CRAC channel modulator
16548720|NCT02958982|Placebo Comparator|Placebo|Placebo
16548721|NCT02958969|Experimental|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
16548722|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
16548723|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
16548724|NCT02958943|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
16548725|NCT02958943|No Intervention|No Alert|Each provider in the non-alert group will receive no such notification.
16548726|NCT02958930|Experimental|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
16548727|NCT02958917|Placebo Comparator|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
16548728|NCT02958917|Active Comparator|Placebo|The placebo will be visually similar to pirfenidone.
16548729|NCT02958878|Experimental|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
16548730|NCT02958878|Placebo Comparator|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
16548741|NCT02958852|Active Comparator|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
16548742|NCT02958852|Experimental|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
16548743|NCT02958852|Other|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
16548744|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
16548745|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
16548746|NCT02958826||No Smoke Evacuation|No Smoke Evacuation Group, anonymous questionnaire administered
16548747|NCT02958826||Smoke Evacuation|Smoke Evacuation Group, anonymous questionnaire administered
16548748|NCT02958813|Experimental|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
16548749|NCT02958813|Placebo Comparator|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
16548750|NCT02958800|Experimental|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
16548751|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
16548752|NCT02958774|Experimental|Hypofractionated Radiation Therapy|Daily for 4 weeks
16548819|NCT02958423|Experimental|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
16548896|NCT02957903|Experimental|Treatment A|"Injection around the lateral femoral cutaneous nerve:
~8 ml Ropivacaine 0.75 %."
16606706|NCT02568865||Major Depressive Disorder|
16548753|NCT02958761|Experimental|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
16548754|NCT02958761|Active Comparator|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
16548755|NCT02958748||ARDS|Patients admitted to ICU with diagnosis of ARDS,which happened in 48hours.
16548756|NCT02958748||Control|Heathy vonlunteers
16548757|NCT02958735|No Intervention|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
16548758|NCT02958735|Experimental|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
16548759|NCT02958735|Experimental|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
16548760|NCT02958722|Active Comparator|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
16548761|NCT02958722|Active Comparator|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
16548765|NCT02958696|Active Comparator|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
16548766|NCT02958696|Active Comparator|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
16548767|NCT02958696|Active Comparator|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
16548768|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
16548769|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
16548770|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
16548771|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
16548772|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
16548773|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
16548774|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
16548775|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
16548776|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
16548777|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
16548778|NCT02958670|Experimental|18F-AV-1451-PET|All subjects receive a Scan for assessment of TAU with the radiotracer 18-F-AV-1451
16548779|NCT02958657|Experimental|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
16548780|NCT02958657|No Intervention|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
16548781|NCT02958644|Experimental|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
16548782|NCT02958644|Placebo Comparator|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.
~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
16548783|NCT02958631|Experimental|Fimasartan|Fimasartan 60mg, QD
16548784|NCT02958631|Active Comparator|Losartan|Losartan 50mg, QD
16548785|NCT02958618|Experimental|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
16548786|NCT02958618|Experimental|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
16548787|NCT02958618|Experimental|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
16548788|NCT02958605|Experimental|Smartphone|Smartphone application
16548789|NCT02958605|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
16548790|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
16548791|NCT02958579||Obesity|Body mass index (BMI) score > 25.2 kg/m2 for women and > 27.3 kg/m2 for men or Waist circumference > 90 cm
16548792|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;
~Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)
~Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test
~Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)
~Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;
~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
16548793|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
16548794|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
16548795|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of <40 mg/dL for men, <50 mg/dL for women,
16548796|NCT02958566|Active Comparator|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.
~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
16548797|NCT02958566|Experimental|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
16548798|NCT02958553|Other|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
16548799|NCT02958540|Experimental|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
16548800|NCT02958540|Experimental|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
16548801|NCT02958540|Placebo Comparator|placebo|12 subjects receiving placebo
16548802|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
16548803|NCT02958514|Other|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
16548804|NCT02958514|Experimental|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
16548805|NCT02958501|Active Comparator|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
16548806|NCT02958501|Active Comparator|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
16548807|NCT02958488|Experimental|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
16548808|NCT02958475|Experimental|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
16548809|NCT02958475|Active Comparator|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
16548810|NCT02958475|Active Comparator|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
16548811|NCT02958462|Other|Potential Premyeloid Cancer or Bone Marrow Failure Patients|Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies
16548812|NCT02958449|Experimental|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
16548813|NCT02958449|No Intervention|Control - Standard Closure|Standard closure with no intervention
16548814|NCT02958436|Experimental|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
16548815|NCT02958436|Experimental|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
16548816|NCT02958436|Experimental|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
16548817|NCT02958436|Experimental|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
16548818|NCT02958436|Experimental|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
16548820|NCT02958423|Experimental|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
16548821|NCT02958423|Experimental|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
16548822|NCT02958423|Experimental|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
16548823|NCT02958410|Experimental|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16548824|NCT02958397|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16548825|NCT02958384|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16548826|NCT02958371|Experimental|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
16548827|NCT02958358|Experimental|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
16548828|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
16548829|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
16548830|NCT02958332|Experimental|video game program|Participants will play video games during 30 min , all along 5 sessions.
16548831|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
16548832|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
16548833|NCT02958306|Experimental|platelet rich plasma|autologous blood product
16548834|NCT02958306|No Intervention|no platelet rich plasma|control
16548835|NCT02958293||December admission|The elective surgery group of people whose admission was the end of the calendar year (December) corresponding with insurance deductible year-end.
16548836|NCT02958293||Non-December admission|The elective surgery group of people whose admission was between January and November.
16548837|NCT02958280|Experimental|Brief Advice Plus the Fit&Sober App|"Phase 1 (app development & Open Pilot) will consist of: 1) development of the Fit&Sober prototype; 2) series of usability studies with patients with AUDs; and 3) An open pilot of a 12-week trial (n=20) to test the feasibility and acceptability of the Fit&Sober app with patients with AUDs in early recovery.
~Phase 2: RCT of the Fit&Sober app with 160 patients with AUD"
16548838|NCT02958280|Active Comparator|Brief Advice for Physical Activity|Phase 2: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
16548839|NCT02958267|Experimental|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
16548840|NCT02958267|Active Comparator|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
16548841|NCT02958228|Experimental|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, & Shah, 2009) and clinical (e.g. Blackwell & Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
16548842|NCT02958228|Active Comparator|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
16548843|NCT02958228|Active Comparator|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
16548844|NCT02958215|Placebo Comparator|Group A|This group will include patients with orthostatic hypotension and will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
16548845|NCT02958215|Active Comparator|Group B|This group will include patients with orthostatic hypotension and will be managed with prophylaxis single dose of phenylephrine, 50 ug IV, will be administered immediately before the spinal block then the patients will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
16548846|NCT02958202|Experimental|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
16548847|NCT02958202|Experimental|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
16548848|NCT02958202|Experimental|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
16548888|NCT02957929|Experimental|Cohort 1a, Period B|single oral dose, crossover
16548889|NCT02957929|Experimental|Cohort 1a, Period C|single oral dose
16548849|NCT02958189|Experimental|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
16548850|NCT02958189|Active Comparator|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
16548851|NCT02958176|Experimental|HRV Biofeedback|At home HRV biofeedback using mobile device
16548852|NCT02958176|Experimental|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
16548853|NCT02958176|No Intervention|Wait List|Wait list control
16548854|NCT02958163|Active Comparator|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.
~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.
~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
16548855|NCT02958163|Experimental|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.
~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.
~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
16548856|NCT02958150|Experimental|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
16548857|NCT02958150|Active Comparator|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
16548858|NCT02958137||Isolated CMC|Arthroscopic Resection Arthroplasty of isolated CMC joint OA. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
16548859|NCT02958137||Pantrapezial|Arthroscopic Resection Arthroplasty of simultaneous ARA of both the CMC and the STT joints. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
16548860|NCT02958111|Experimental|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
16548861|NCT02958111|No Intervention|Observation|Clinical follow-up and surveillance only
16548862|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
16548863|NCT02958098||Stroke|Individuals with stroke before age 50 years
16548864|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
16548865|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
16548866|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
16548867|NCT02958085|Experimental|NNC0174-0833|
16548868|NCT02958085|Placebo Comparator|Placebo|
16548869|NCT02958072|Experimental|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
16548870|NCT02958072|Active Comparator|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
16548871|NCT02958059|Experimental|Treatment|The intervention group
16548872|NCT02958059|Placebo Comparator|Comparator|The comparator group
16548873|NCT02958046|Experimental|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
16548874|NCT02958033|Experimental|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
16548875|NCT02958033|Placebo Comparator|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
16548876|NCT02958007|Experimental|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
16548877|NCT02958007|Active Comparator|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
16548878|NCT02957994|Experimental|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
16548879|NCT02957981|Experimental|Web-Based Counseling|Genetic information provided via an individually tailored website.
16548880|NCT02957981|Active Comparator|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
16548881|NCT02957968|Experimental|Cohort A: Triple Negative Breast Cancer (TNBC)|Triple Negative Breast Cancer (Cohort A): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin.
16548882|NCT02957968|Experimental|Cohort B: HER2-negative hormone receptor-positive tumors|HER2-negative hormone receptor-positive tumors (Cohort B): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel.
16548883|NCT02957955|Experimental|Interventional|Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
16548884|NCT02957955|No Intervention|Non interventional|Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
16548885|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
16548886|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
16548887|NCT02957929|Experimental|Cohort 1a, Period A|single intravenous dose, crossover
16548897|NCT02957903|Placebo Comparator|Treatment B|"Injection around the lateral femoral cutaneous nerve:
~8 ml isotonic Saline."
16548898|NCT02957890|Experimental|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
16548899|NCT02957890|Placebo Comparator|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
16548900|NCT02957877|Experimental|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
16548901|NCT02957877|Active Comparator|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
16548902|NCT02957864|Experimental|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
16548903|NCT02957864|Active Comparator|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
16548904|NCT02957851|Placebo Comparator|Oxygen/Nitrogen (22%/78%)|Medical Air
16548905|NCT02957851|Active Comparator|Nitrous Oxide/Oxygen (50%/50%)|EMONO
16548906|NCT02957838|Experimental|Non-diabetics|Non-diabetic volunteers with HbA1c < 6.5%. Subjects will be treated with C18:0 supplementation or mock.
16548907|NCT02957838|Experimental|Type 2 Diabetics|Type 2 Diabetes according to common definitions, but we exclude insulin-treated Type 2 diabetics because nutritional intervention is more difficult/risky. Subjects will be treated with C18:0 supplementation or mock.
16548908|NCT02957825|No Intervention|Control|Routine monitoring
16548909|NCT02957825|Experimental|Continuous wireless monitoring|Continuous wireless monitoring
16548910|NCT02957812|Experimental|Orthotics|Custom made orthotic provided for study
16548911|NCT02957812|No Intervention|Control|Wearing own footwear
16548912|NCT02957799|Experimental|Accountable Condition- 8 clinics|In the Accountable Condition, the intervention includes mothers who will receive home visits from government-funded CHW who will be trained once under Philani and receive ongoing monitoring and supervision.
16548913|NCT02957799|Experimental|Control Condition- 8 clinics|The Control Condition will include mothers who receive home visits from government-funded CHW who will be trained once under Philani and receive supervision and monitoring consistent with local government practices.
16548914|NCT02957786|Experimental|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).
~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.
~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
16548915|NCT02957786|Active Comparator|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).
~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.
~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
16548916|NCT02957773|Experimental|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
16548917|NCT02957773|Experimental|Art activities|Art activities and daily activities group for 90 minutes.
16548918|NCT02957773|Experimental|Qigong|A Qigong and daily activities group for 90 minutes
16548919|NCT02957773|Other|Daily activities|A daily activities group for 90-minutes.
16548920|NCT02957747|Experimental|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
16548921|NCT02957747|No Intervention|Control|Participants randomized to this arm will receive referrals to VA and community resources
16548922|NCT02957734|Experimental|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
16548923|NCT02957721|Other|Behavioral self-management|Eligible patients who are registered on the practice EHR linked portal will be invited to join the study. Following informed consent, enrollment and randomization, participants in the treatment group will receive the type 2 diabetes behavioral self-management education intervention; comprised of 9 modules derived from Medline Plus.
16548924|NCT02957721|No Intervention|Usual Care|Usual care includes whatever care and services the patient's clinical provides as well as generic type 2 diabetes education built into the patient's EHR linked portal.
16548925|NCT02957708|Experimental|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
16548926|NCT02957708|Active Comparator|Control|conventional occupational therapy
16548927|NCT02957695|Placebo Comparator|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
16548928|NCT02957695|Active Comparator|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
16548929|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
16548930|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
16606707|NCT02568865||Healthy Volunteers|
16548931|NCT02957669|Experimental|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
16548932|NCT02957669|Active Comparator|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
16548933|NCT02957656|Experimental|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
16548934|NCT02957656|Experimental|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
16548935|NCT02957656|Experimental|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
16548936|NCT02957656|Experimental|University of Rochester URMC 13-001 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
16548937|NCT02957656|Experimental|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
16548938|NCT02957643|Placebo Comparator|pregnant women|iron dosage 1 per day for 3 months
16548939|NCT02957643|Experimental|pregnant women with anemia|iron dosage 1 per day for 6 months
16548940|NCT02957630|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
16548941|NCT02957630|Active Comparator|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
16548942|NCT02957630|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
16548943|NCT02957617|Experimental|BIIB074|BIIB074 orally twice daily
16548944|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), who were exposed to Evolocumab (Repatha) during pregnancy
16548945|NCT02957604||Comparison Group I|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH) who were not exposed to Evolocumab during pregnancy
16548946|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), and who were not exposed to Evolocumab during pregnancy.
16548947|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to Evolocumab (Repatha) but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
16548948|NCT02957591|Experimental|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
16548949|NCT02957591|Placebo Comparator|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
16548950|NCT02957578|Experimental|Solo TTD|Placement of tympanostomy tube with Solo TTD
16548951|NCT02957565|Experimental|Video 1: No EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
16548952|NCT02957565|Experimental|Video 1: No EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
16548953|NCT02957565|Experimental|Video 2: With EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
16548954|NCT02957565|Experimental|Video 2: With EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
16548955|NCT02957552|Experimental|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10^6 MSCs/kg body weight:
~first administration intraoperatively via intraportal infusion
~second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)
~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
16548956|NCT02957539|No Intervention|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
16548976|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
16548977|NCT02957396|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
16548978|NCT02957396|Experimental|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
16548957|NCT02957539|Experimental|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
16548958|NCT02957539|Experimental|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
16548959|NCT02957526|Experimental|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
16548960|NCT02957526|Active Comparator|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
16548961|NCT02957513|Experimental|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
16548962|NCT02957513|Experimental|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
16548963|NCT02957513|Active Comparator|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:
~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.
~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.
~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
16548964|NCT02957500|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
16548965|NCT02957500|No Intervention|No treatment|standard treatment for surgery
16548966|NCT02957474|Experimental|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
16548967|NCT02957474|Experimental|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
16548968|NCT02957474|Experimental|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
16548969|NCT02957474|Experimental|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
16548970|NCT02957461||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
16548971|NCT02957461||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
16548972|NCT02957448|Experimental|BMS 986141 and Rifampin|
16548973|NCT02957435|Experimental|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
16548974|NCT02957422|Experimental|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
16548975|NCT02957422|Active Comparator|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
16548979|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
16548980|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
16548981|NCT02957383|Experimental|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
16548982|NCT02957383|Experimental|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
16548983|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
16548984|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
16548985|NCT02957344||Text without context|
16548986|NCT02957344||Text with context|
16548987|NCT02957344||Map without context|
16548988|NCT02957344||Map with context|
16548989|NCT02957331|Experimental|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
16548990|NCT02957331|No Intervention|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
16548991|NCT02957318|Experimental|FiberBind|
16548992|NCT02957318|Experimental|RG-I fiber|
16548993|NCT02957318|Placebo Comparator|Placebo|
16548994|NCT02957305|Active Comparator|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
16548995|NCT02957305|Experimental|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
16548998|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
16548999|NCT02957279||Healthy control group|Healthy volunteers.
16549000|NCT02957266|Active Comparator|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
16549001|NCT02957266|Experimental|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.
~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
16549002|NCT02957253|Experimental|Intervention (CI)|Compensated intervention (CI). Nurse-led clinic one time per year. Focus on Life style and risk factors.
16549003|NCT02957253|No Intervention|Control (CC)|Compensated Control (CC)
16549004|NCT02957253|Experimental|Intervention (DI)|Decompensated intervention (DI). Nurse-led clinic two times every month to every third month. Focus on Lifestyle, risk factors, nutrition, selfcare and psychosocial needs
16549005|NCT02957253|No Intervention|Control (DC)|Decompensated Control (DC)
16549006|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
16549007|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
16549008|NCT02957227||1|cohort 1: Older adults with memory impairment
16549009|NCT02957227||2|cohort 2: Age matched healthy controls
16549010|NCT02957214|Experimental|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
16549011|NCT02957201|Other|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
16549012|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
16549013|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
16549014|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
16549015|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
16549016|NCT02957162|Other|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
16549017|NCT02957149|Experimental|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
16549018|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
16549104|NCT02956512|Experimental|Dexibuprofen 300mg - Fasting|Fasting condition
16549019|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
16549020|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.
~30 patients with organic brain syndrome will receive auto-M2-BFs with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days."
16549021|NCT02957097|Experimental|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
16549022|NCT02957097|Placebo Comparator|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
16549023|NCT02957058|Active Comparator|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
16549024|NCT02957058|Active Comparator|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
16549025|NCT02957045|Experimental|Cough|
16549026|NCT02957032|Experimental|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
16549027|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):
~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.
~Phase II (Activity Evaluation):
~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
16549028|NCT02956993|Active Comparator|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
16549029|NCT02956993|Placebo Comparator|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
16549030|NCT02956980|Experimental|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
16549031|NCT02956980|Experimental|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
16549032|NCT02956967||Patients receiving Nivestim|
16549033|NCT02956954|Experimental|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
16549034|NCT02956954|Sham Comparator|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
16549035|NCT02956941|Experimental|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
16549036|NCT02956941|No Intervention|Control cluster|Control group will receive routine dietary practices.
16549037|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
16549038|NCT02956902|No Intervention|Waiting list control|
16549039|NCT02956902|Experimental|Intervention|Clinician-supported smartphone application intervention
16549040|NCT02956889|Experimental|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
16549041|NCT02956876|Experimental|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
16549042|NCT02956876|Other|Standard consultation|standard chemotherapy for colorectal cancer
16549043|NCT02956863|Active Comparator|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
16549044|NCT02956863|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
16549045|NCT02956850|Experimental|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
16549046|NCT02956850|Experimental|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (100 mg, 140 mg, and 170 mg as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
16549047|NCT02956850|Experimental|Part II: CHB Participants|CHB participants will receive RO7020531 (150 mg and 170 mg as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41, unless in Cohort 4 in case of QW dosing as dose modification.
16549048|NCT02956837|Experimental|GSK3003891A vaccine formulation 1 Group|Subjects in this group received a single 30 micrograms (µg) dose injection of the investigational GSK3003891A vaccine at Day 0.
16549049|NCT02956837|Experimental|GSK3003891A vaccine formulation 2 Group|Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.
16549105|NCT02956499|Experimental|Cohort 1|single intravenous dose
16549050|NCT02956837|Experimental|GSK3003891A vaccine formulation 3 Group|Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.
16549051|NCT02956837|Placebo Comparator|Control Group|Subjects in this group received a single placebo injection at Day 0.
16549052|NCT02956811|Active Comparator|Active|Dapagliflozin 10mg once daily for 12 months
16549053|NCT02956811|Placebo Comparator|Placebo|Placebo 10mg once daily for 12 months
16549054|NCT02956798|Experimental|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
16549055|NCT02956785|Active Comparator|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
16549056|NCT02956785|Active Comparator|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
16549057|NCT02956785|Active Comparator|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
16549058|NCT02956772|Experimental|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
16549059|NCT02956772|Active Comparator|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
16549060|NCT02956759|Experimental|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
16549061|NCT02956759|Active Comparator|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
16549062|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
16549063|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
16549064|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
16549065|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
16549066|NCT02956733|Active Comparator|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
16549067|NCT02956733|Active Comparator|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
16549068|NCT02956720|Experimental|single arm|
16549069|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.
~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.
~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
16549070|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
16549071|NCT02956694|Experimental|Professional training|Professional e-learning program on shared decision making including two components: (1) a self-directed e-learning activity on shared decision making, lasting about 1 hour, that participants could complete in several sittings; and (2) five evidence summaries named Decision Boxes (DBs).
16549072|NCT02956681|Active Comparator|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
16549073|NCT02956681|Active Comparator|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
16549074|NCT02956668|Experimental|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.
~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.
~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.
~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
16549106|NCT02956499|Experimental|Cohort 2|single intravenous dose
16549107|NCT02956499|Experimental|Cohort 3|single intravenous dose
16549108|NCT02956499|Experimental|Cohort 4|single intravenous dose
16549075|NCT02956668|Active Comparator|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.
~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
16549076|NCT02956655|Experimental|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
16549077|NCT02956655|Active Comparator|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
16549078|NCT02956642|Experimental|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
16549079|NCT02956642|Active Comparator|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
16549080|NCT02956629|Experimental|HCV GT1|Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
16549081|NCT02956629|Experimental|HCV GT2|Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
16549082|NCT02956629|Experimental|HCV GT3|Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
16549083|NCT02956629|Experimental|HCV GT4|Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
16549084|NCT02956629|Experimental|HCV GT5|Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
16549085|NCT02956629|Experimental|HCV GT6|Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
16549086|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
16549087|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
16549091|NCT02956590|Active Comparator|Pitavastatin|Study Drug
16549092|NCT02956590|Placebo Comparator|Placebo|Placebo
16549093|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
16549094|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
16549095|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
16549096|NCT02956564|Other|exposure group|subjects in this group are those who accept intrauterine intervention
16549097|NCT02956564|No Intervention|control group|subjects in this group are those who do not accept intrauterine intervention
16549098|NCT02956551|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
16549099|NCT02956538|Experimental|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
16549100|NCT02956538|Active Comparator|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
16549101|NCT02956525|Experimental|Dexibuprofen 200 mg - Fed|Fed condition
16549102|NCT02956525|Experimental|Dexibuprofen 200 mg - Fasting|Fasting condition
16549103|NCT02956512|Experimental|Dexibuprofen 300mg - Fed|Fed condition
16549115|NCT02956486|Experimental|Core Study: Elenbecestat 50 mg|Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
16549116|NCT02956486|Placebo Comparator|Core Study: Placebo|Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
16549117|NCT02956486|Experimental|Open-label Extension Phase: Elenbecestat 50 mg|Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.
16549118|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed
~Supine MRI will be performed
~Participant will receive mammography and ultrasound
~Breast Radiologist will take a brief survey.
~Patients will undergo upfront surgery or receive Neoadjuvant Therapy per standard of care
~Standard of care will be performed"
16549119|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
16549120|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
16549121|NCT02956447|Experimental|Kisspeptin Bolus|Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.
16549122|NCT02956447|No Intervention|Baseline|Blood sampling every 10 minutes
16549123|NCT02956447|Experimental|Pulsatile kisspeptin|Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
16549124|NCT02956434|Experimental|Brief family intervention|Participants will receive the BFI in this arm of the study. The BFI is a 2-session intervention for family members of Veterans who are beginning PTSD treatment.
16549125|NCT02956434|No Intervention|No intervention|Participants will not receive the BFI in this arm of the study. They will be eligible for any usual support or programming for the families of Veterans.
16549126|NCT02956421|Active Comparator|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
16549127|NCT02956421|Experimental|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
16549128|NCT02956408|Active Comparator|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
16549129|NCT02956408|Experimental|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
16549130|NCT02956395|Active Comparator|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
16549131|NCT02956395|No Intervention|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
16549132|NCT02956382|Experimental|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg
~Each medication is taken daily. Treatment cycles are 28 days long."
16549133|NCT02956382|Experimental|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg
~Each medication is taken daily. Treatment cycles are 28 days long."
16549134|NCT02956382|Experimental|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg
~Each medication is taken daily. Treatment cycles are 28 days long."
16549135|NCT02956382|Experimental|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg
~Each medication is taken daily. Treatment cycles are 28 days long."
16549136|NCT02956382|Experimental|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
16549137|NCT02956369|Placebo Comparator|Control|10 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
16549138|NCT02956369|Active Comparator|SATIOSTAT|10 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
16549139|NCT02956356|Placebo Comparator|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
16549140|NCT02956356|Active Comparator|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
16549141|NCT02956356|Placebo Comparator|Control treatment + meal intake|Control treatment as preload followed by a test meal
16549142|NCT02956356|Active Comparator|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
16549143|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
16549144|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
16549145|NCT02956330||CLS1003-201|Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.
16549146|NCT02956317|Active Comparator|STP705|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
16549147|NCT02956317|Placebo Comparator|Placebo|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
16549148|NCT02956304|Other|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
16549149|NCT02956304|Other|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
16549150|NCT02956304|Other|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
16549151|NCT02956304|Other|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
16549152|NCT02956304|Other|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
16549153|NCT02956304|Other|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
16549154|NCT02956291|Experimental|Newly Diagnosed Brain Tumors|Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
16549155|NCT02956291|Experimental|Treated tumors with possible recurrence|Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
16549156|NCT02956278|Placebo Comparator|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
16549157|NCT02956278|Experimental|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
16549158|NCT02956278|Experimental|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
16549159|NCT02956265|Experimental|Patients - Suffering from carcinomatous or polymorphous skin|
16549160|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
16549161|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
16549162|NCT02956239|Experimental|Thermocoagulation (device)|VIA Positive women will be treated by the new device for thermocoagulation
16549163|NCT02956239|Active Comparator|Cryotherapy (device)|VIA positive women will be treated by cryotherapy
16549164|NCT02956239|Active Comparator|LEEP (device)|VIA Positive women not suitable for thermo-coagulation or cryotherapy will be treated by LEEP
16549165|NCT02956226|Experimental|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
16549166|NCT02956226|Placebo Comparator|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
16549167|NCT02956226|Experimental|Cannabinoids - whole plant extract|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
16549168|NCT02956213|Experimental|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
16549169|NCT02956213|Active Comparator|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
16549170|NCT02956200|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
16549171|NCT02956200|No Intervention|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
16549172|NCT02956187|Experimental|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
16549173|NCT02956187|Active Comparator|Fiber supplementation|Constipation will be treated by a fiber supplement
16549174|NCT02956174|Experimental|Co-Cr single crown|Co-Cr single crown
16549175|NCT02956174|Active Comparator|Contralateral sound tooth|Contralateral sound tooth
16549176|NCT02956161|Experimental|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
16549177|NCT02956161|Experimental|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
16549178|NCT02956161|Sham Comparator|No stimulation|The device is worn without any auditory stimulations delivered.
16549179|NCT02956148|Experimental|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.
~The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
16549180|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
16549181|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
16549182|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
16549183|NCT02956109|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
16549184|NCT02956109|Experimental|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
16549185|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
16549186|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
16549231|NCT02955875|No Intervention|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
16549298|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
16549187|NCT02956096|Active Comparator|tDCS device and Treatmill|The stimulation is accomplished with a direct current-tDCS Stimulator Plus device, via two surface electrodes sponge (non-metallic) 5-7 cm2 in saline moistened with a 2mA current during 20 minutes after hemodinamic analysis is performed for 15 minutes and then made only training treadmill for 20 minutes. Placebo tDCS will follow the same procedures, but the tDCS device will only be switched on for 20 seconds. The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve (MACKO , 2005).
16549188|NCT02956096|Sham Comparator|1- tDCS|1. Who received stimulation transcranial direct current active will receive Sham stimulation and who received the placebo stimulation receive active stimulation and then the two groups will do the workout on the treadmill
16549189|NCT02956083|Active Comparator|Lipid based artificial tears|Patients use lipid based artificial tears
16549190|NCT02956083|Active Comparator|Non-lipid based artificial tears|patients use non-lipid based artificial tears
16549191|NCT02956083|Placebo Comparator|Saline|patients use saline
16549192|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
16549193|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
16549194|NCT02956057|Active Comparator|PEG1D|Polyethylene glycols single dose a day before colonoscopy
16549195|NCT02956057|Active Comparator|PEG2D|Polyethylene glycols split dose
16549196|NCT02956057|Active Comparator|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
16549197|NCT02956057|Active Comparator|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
16549198|NCT02956057|Active Comparator|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
16549199|NCT02956057|Active Comparator|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
16549200|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
16549201|NCT02956044|Active Comparator|Group 1: Metformin alone|
16549202|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
16549203|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
16549204|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
16549205|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
16549206|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
16549207|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
16549208|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
16549209|NCT02956031||HIV pos|those who serologically tested positive for HIV
16549210|NCT02956031||HIV neg|those who serologically tested negative for HIV
16549211|NCT02956031||HIV unk|those with no available serological test for HIV
16549212|NCT02956005|Other|Envarsus|Open Label; Envarsus XR started at the time of transplant. Initial dosing of 0.17mg/kg. Target trough level of 8-10 ng/mL
16549213|NCT02955992|No Intervention|standard of care|
16549214|NCT02955992|Experimental|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.
~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.
~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:
~Preparation for the death : Prepare the relative for the patient's imminent death
~During the dying and death process: The physician enters the patient's room at least once to check on the relatives
~After the patient's death: the physician and the nurse meet the relative"
16549215|NCT02955979||CT scan with iodinated contrast agents|Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
16549216|NCT02955966|Experimental|Patient with invasive pulmonary aspergillosis|Blood collection and imaging 18F-FDG-PET/CT
16549217|NCT02955953|Experimental|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
16549218|NCT02955953|Experimental|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
16549219|NCT02955940|Experimental|Ruxolitinib|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
16549220|NCT02955940|Experimental|Ruxolitinib plus background cancer therapy|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
16549221|NCT02955940|Experimental|Background cancer therapy alone|Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.
16549222|NCT02955927|Experimental|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
16549223|NCT02955927|Active Comparator|ortho-k|participants will receive treatment of ortho-k alone
16549224|NCT02955914||Optimism|Based on quality of life assessment
16549225|NCT02955914||Pessimism|Based on quality of life assessment
16549226|NCT02955901|Active Comparator|3-day low residue diet|Group A - 3 day low residue diet prior to the colonoscopy
16549227|NCT02955901|Placebo Comparator|1-day low residue diet|Group B - 1 day low residue diet prior to the colonoscopy
16549228|NCT02955888|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
16549229|NCT02955888|Placebo Comparator|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
16549230|NCT02955875|Experimental|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
16607950|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
16549232|NCT02955862|Other|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months."
16549233|NCT02955849|Experimental|SLT laser group|"selective laser trabeculoplasty for 360 degrees the study eye.
~Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;
~Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.
~Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)."
16549234|NCT02955849|No Intervention|Standard care group|"Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).
~Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.
~Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.
~Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)"
16549235|NCT02955849|No Intervention|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
16549236|NCT02955823|Experimental|1 arm for all patient: Ritux-Dexame-Lena|Rituximab-Dexamethasone-Lenalidomide
16549237|NCT02955810|Experimental|CyBorD-DARA|
16549238|NCT02955797|Experimental|Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
16549239|NCT02955797|Experimental|Group 2 (Meningococcal Vaccine-Naive): Nimenrix®|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
16549240|NCT02955797|Experimental|Group 3 (MenC-Primed): MenACYW Conjugate Vaccine|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
16549241|NCT02955797|Experimental|Group 4 (MenC-Primed): Nimenrix®|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
16549242|NCT02955784|Experimental|Sinasprite Mobile App|Mobile App
16549243|NCT02955771|Experimental|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
16549244|NCT02955771|Experimental|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
16549245|NCT02955771|Other|Stenting|Endoscopic or percutaneous stenting alone will be performed.
16549246|NCT02955758|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
16549247|NCT02955732|Experimental|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
16549248|NCT02955719|Experimental|Enrolled Cases|"Integrated Care Pathway with different treatment interventions
~Interventions include:
~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
16549249|NCT02955719|No Intervention|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
16549250|NCT02955706|Experimental|Active|Acetyl-L-carnitine (DongA ST)
16549251|NCT02955706|Placebo Comparator|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
16549252|NCT02955693|Other|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
16549253|NCT02955693|Other|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
16549254|NCT02955693|Other|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
16549255|NCT02955693|Other|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
16549256|NCT02955680|Experimental|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
16549257|NCT02955680|Active Comparator|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
16549258|NCT02955667|Experimental|invivo microscopy group|patients receive invivo micro-colposcopy examination and do not have to receive the biopsies
16549259|NCT02955667|Other|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
16549260|NCT02955654|Experimental|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
16549261|NCT02955654|Active Comparator|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
16549262|NCT02955654|Other|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
16549297|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
16549263|NCT02955641|Active Comparator|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
16549264|NCT02955641|Active Comparator|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
16549265|NCT02955641|Active Comparator|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
16549266|NCT02955641|Active Comparator|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
16549267|NCT02955628|Experimental|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
16549268|NCT02955615|Experimental|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
16549269|NCT02955615|Placebo Comparator|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
16549270|NCT02955602|Experimental|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
16549271|NCT02955602|Experimental|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
16549272|NCT02955602|Experimental|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
16549273|NCT02955589|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
16549274|NCT02955576|Placebo Comparator|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
16549275|NCT02955576|Active Comparator|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
16549276|NCT02955576|Experimental|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
16549277|NCT02955563|Experimental|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
16549278|NCT02955563|No Intervention|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
16549279|NCT02955550|Experimental|PNK-007 and rhIL-2|Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 7 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
16549280|NCT02955537|No Intervention|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
16549281|NCT02955537|Experimental|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
16549282|NCT02955524|Experimental|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.
~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
16549283|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:
~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
16549284|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:
~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
16549285|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:
~Inscope DL-blade size 3.5"
16549286|NCT02955498|Experimental|R-T|First period: administration of reference drug, Second period: administration of test drug
16549287|NCT02955498|Experimental|T-R|First period: administration of test drug, Second period: administration of reference drug
16549288|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
16549289|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
16549290|NCT02955472|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
16549291|NCT02955472|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
16549292|NCT02955459|Experimental|VNRX-5133|IV infusion
16549293|NCT02955459|Placebo Comparator|Placebo|IV infusion
16549294|NCT02955433|Experimental|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
16549295|NCT02955433|No Intervention|Control|The control arm will receive an appointment reminder, but no free transportation offer.
16549296|NCT02955420|Experimental|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:
~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.
~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).
~Part B:
~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose < 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.
~Part C:
~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
16549299|NCT02955394|Placebo Comparator|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
16549300|NCT02955394|Experimental|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
16549301|NCT02955381|Experimental|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
16549302|NCT02955381|Placebo Comparator|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
16549303|NCT02955368|Experimental|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
16549304|NCT02955368|Active Comparator|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
16549305|NCT02955368|Active Comparator|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
16549306|NCT02955355|Experimental|HYQVIA|Subjects will continue to receive HYQVIA/HyQvia infusions every 2, or 3, or 4 weeks (±3 days) following the same dose and dosing regimen of the Phase 3 pivotal study (Study 161403).
16549307|NCT02955329|Experimental|Tobacco Arm|Participants will vape tobacco leaves with nicotine out of the PAX device.
16549308|NCT02955329|Experimental|Cannabis Arm|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
16549309|NCT02955329|Experimental|Combined Cannabis and Tobacco Arm|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
16549310|NCT02955303|Experimental|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
16549315|NCT02955277|Experimental|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by six weekly sessions (of 60 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
16549316|NCT02955277|No Intervention|standard care|Participants will receive standard medical care with no TECH protocol.
16549317|NCT02955277|Active Comparator|active standard care|Partivipans will receive six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.
16549318|NCT02955264|Experimental|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
16549319|NCT02955251|Experimental|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
16549320|NCT02955251|Experimental|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
16549321|NCT02955251|Experimental|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
16549322|NCT02955251|Experimental|Arm 2|ABBV-428 plus nivolumab.
16549323|NCT02955238|Experimental|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
16550259|NCT02949323||children without urinary stones|children without urinary stones
16549324|NCT02955238|No Intervention|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
16549325|NCT02955225|Experimental|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
16549326|NCT02955225|Active Comparator|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
16549327|NCT02955212|Placebo Comparator|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
16549328|NCT02955212|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
16549329|NCT02955199|Experimental|Mothering From the Inside Out|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
16549330|NCT02955199|Active Comparator|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
16549331|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
16549332|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
16549333|NCT02955173|Experimental|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
16549334|NCT02955173|Experimental|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
16549335|NCT02955173|Experimental|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
16549336|NCT02955173|Experimental|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
16549337|NCT02955160|Experimental|Multivalent|Pneumococcal conjugate vaccine
16549338|NCT02955160|Active Comparator|Tdap|Tetanus, diphtheria, and pertussis vaccine
16549339|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
16549340|NCT02955134|Experimental|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
16549341|NCT02955134|Placebo Comparator|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
16549342|NCT02955121|Active Comparator|Pharmacogenetic Results Available to Provider|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
16549343|NCT02955121|No Intervention|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
16549344|NCT02955108|Experimental|music first then no music|
16549345|NCT02955108|Experimental|no music first then music|
16549346|NCT02955095|Experimental|Current cigarette smoker|
16549347|NCT02955082|Experimental|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
16549348|NCT02955069|Experimental|PDR001|Subjects with advanced or metastatic, well-differentiated, NET of pancreatic, GI, or thoracic origin or poorly-differentiated GEP-NEC, that have progressed on prior treatment were treated with 400mg PDR001 administered via intravenous infusion once every 4 weeks.
16549349|NCT02955056|Experimental|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
16549350|NCT02955056|No Intervention|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
16549351|NCT02955043|Experimental|Behavioral intervention|Participants will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. The intervention will be delivered in three 45-60 minute face-to-face sessions at approximately 3-4, 8, and 12 weeks post-HSCT with brief telephone coaching calls scheduled between sessions. Participants will be encouraged to use the behavioral strategies from hospital discharge through 18 weeks post-HSCT. Participants will be asked to complete a daily checklist indicating which intervention strategies they used. Participants will also receive standard medical care following HSCT.
16549352|NCT02955043|No Intervention|Usual care|Participants will receive standard medical care following HSCT.
16549353|NCT02955030|Experimental|NSV0001(Cohort1)|15 µg of hemagglutinin [HA] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
16549354|NCT02955030|Experimental|NSV0001(Cohort2)|30 µg of hemagglutinin[HA] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
16549355|NCT02955030|Experimental|NSV0001(Cohort3)|60 µg of hemagglutinin[HA] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
16550260|NCT02949310|Placebo Comparator|Control|Placebo use instead of nefopam
16549356|NCT02955030|Placebo Comparator|Placebo|0 µg of hemagglutinin[HA] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
16549357|NCT02955030|Active Comparator|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
16549358|NCT02955017|Active Comparator|Traditional follow-up|
16549359|NCT02955017|Experimental|"Distance follow-up new technologies"|
16549360|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks
16549361|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks
16549362|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks
16549363|NCT02954978|Placebo Comparator|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
16549364|NCT02954978|Active Comparator|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
16549365|NCT02954978|Active Comparator|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
16549366|NCT02954965|Experimental|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
16549367|NCT02954965|Experimental|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
16549368|NCT02954965|No Intervention|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
16549369|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
16549370|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
16549371|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
16549372|NCT02954939|Active Comparator|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
16549373|NCT02954939|Placebo Comparator|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
16549374|NCT02954926|Experimental|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
16549375|NCT02954926|No Intervention|Control|No intervention
16549376|NCT02954913|Experimental|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
16549377|NCT02954900|Other|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
16549378|NCT02954887|Experimental|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.
~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
16549379|NCT02954874|Experimental|Arm I (observation)|Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
16549380|NCT02954874|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
16549381|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
16549382|NCT02954848|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
16549383|NCT02954848|Experimental|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
16549384|NCT02954835|Active Comparator|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
16549385|NCT02954835|Active Comparator|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
16549386|NCT02954822|Experimental|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
16549387|NCT02954822|Experimental|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
16549388|NCT02954809|Experimental|Experimental|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
16549389|NCT02954809|Active Comparator|Attention Control|Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
16549390|NCT02954796|Experimental|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
16549391|NCT02954783|Experimental|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
16549392|NCT02954783|Active Comparator|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
16549393|NCT02954770||Fitbit® challenger|The residents who participated a Fitbit® challenge study about one year ago
16549394|NCT02954757|Experimental|Treatment arm|HIFU treatment
16549395|NCT02954744|Experimental|Treatment arm|HIFU treatment
16549396|NCT02954731|Experimental|UP-CBT|"The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions."
16549397|NCT02954731|Active Comparator|Standard-CBT|Group CBT following Danish versions of diagnosis specific manuals (Social Anxiety Disorder (SAD) Group; Depression (DEP) Group; Agoraphobia/Panic Disorder (Ag/PD) (standard-CBT). The original elements of psychoeducation, cognitive restructuring, and exposure/activity scheduling are present in the applied manuals. Standard-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
16549398|NCT02954718|Experimental|1|patient-centered task oriented activity training in real life
16549399|NCT02954718|Experimental|2|patient-centered video-based task oriented activity training
16549400|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
16549401|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).
~10 milliliter of blood are collected from these donors"
16549402|NCT02954692|Experimental|Insulin glargine (U300)|Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.
16549403|NCT02954666|Experimental|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
16549404|NCT02954666|Experimental|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
16549405|NCT02954653|Experimental|Dose Escalation|Single agent PF-06747143 dose escalation
16549406|NCT02954653|Active Comparator|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
16549407|NCT02954653|Active Comparator|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
16549408|NCT02954653|Experimental|Cohort 3|PF-06747143 dose expansion as a single agent.
16549409|NCT02954640|Other|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.
~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.
~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
16549410|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
16549411|NCT02954614|Experimental|Intervention group|Active play in after school programs (ASP). Training program for ASP staff.
16549412|NCT02954614|No Intervention|Control group|ASP as usual.
16549413|NCT02954601|Active Comparator|Placebo|Placebo (fish oil)
16549414|NCT02954601|Active Comparator|Dose1|Dose 1 ORMD-0801 (qd)
16549415|NCT02954601|Active Comparator|Dose2|Dose 2 ORMD-0801 (bid)
16549416|NCT02954601|Active Comparator|Dose 3|Dose 3 ORMD-0801 (tid)
16549417|NCT02954588|Active Comparator|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
16549418|NCT02954588|Active Comparator|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
16549419|NCT02954588|Placebo Comparator|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
16549420|NCT02954575|Experimental|All patients|All patients will receive Wilate for prophylactic treatment
16549421|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
16549422|NCT02954549|Active Comparator|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, >30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
16549423|NCT02954549|Experimental|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of < 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
16549424|NCT02954549|Experimental|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of <30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
16549425|NCT02954536|Experimental|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
16549488|NCT02954068|Active Comparator|IM administration|Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml
16549426|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.
~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).
~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).
~There is no limit to the number of cycles a patient can receive.
~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
16549428|NCT02954497|Experimental|Jarvik 2015 Device VAD|New, experimental continuous flow VAD
16549429|NCT02954484|Active Comparator|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
16549430|NCT02954484|Placebo Comparator|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
16549431|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
16549432|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
16549433|NCT02954445|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16549434|NCT02954419||IgA nephropathy group|Eligible biopsy-proven primary IgA nephropathy patients.
16549435|NCT02954406|Experimental|Dose Escalation Phase Cohort A:TAK-659 + Bendamustine|TAK-659 60 milligram (mg), immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 milligram per square meter (mg/m^2), infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
16549436|NCT02954406|Experimental|Dose Escalation Phase Cohort B:TAK-659+Bendamustine+Rituximab|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
16549437|NCT02954406|Experimental|Dose Escalation Phase Cohort C: TAK-659 + Gemcitabine|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
16549438|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 + Lenalidomide|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
16549439|NCT02954406|Experimental|Dose Escalation Phase Cohort E: TAK-659 + Ibrutinib|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
16549440|NCT02954406|Experimental|Safety Expansion Phase Cohort B:TAK-659+Bendamustine+Rituximab|TAK-659 TBD, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants with advanced ollicular lymphoma (FL) or marginal zone lymphoma (MZL). The TAK-659 dose will be the MTD / maximally administered dose (MAD)/ RP2D as determined in the dose escalation phase. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
16549441|NCT02954393|Placebo Comparator|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
16549442|NCT02954393|Active Comparator|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
16549443|NCT02954393|Active Comparator|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
16549444|NCT02954380|Experimental|ZIO/ILR|THe Zio ILR arm will already have an ILR implanted for standard of care and will receive the Zio patch
16549445|NCT02954367|Experimental|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
16549446|NCT02954367|Placebo Comparator|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
16549447|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
16549448|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
16549449|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
16549450|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
16549451|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
16549452|NCT02954328|Experimental|tDCS|"The active tDCS condition will consist of 4 visit:
~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:
~Sham
~motor M1 area
~motor M1 + Dorsolateral Prefrontal cortex
~Dorsolateral Prefrontal cortex.
~The tDCS condition will be randomized and double blinded"
16549453|NCT02954315|Experimental|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
16549454|NCT02954315|No Intervention|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
16549455|NCT02954302|Experimental|PrPD with RGA|Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
16549456|NCT02954302|Experimental|conventional PrPD|Patients who will undergo conventional PrPD.
16549457|NCT02954289|Other|Dietary intervention|Dietary intervention
16549458|NCT02954276|Experimental|75 mg Omexa sumatriptan sublingual tablet|
16549459|NCT02954276|Active Comparator|100 mg Imitrex oral tablet|
16549460|NCT02954263|Experimental|TD-1439|Capsule formulation
16549461|NCT02954263|Placebo Comparator|Placebo|Capsule formulation
16549462|NCT02954250|No Intervention|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
16549463|NCT02954250|Experimental|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
16549466|NCT02954211|Experimental|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
16549467|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
16549468|NCT02954198|Active Comparator|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
16549469|NCT02954185|Experimental|WellClub Device|Hand held device that patients use for home therapy
16549470|NCT02954185|Active Comparator|Standard Therapy|Standard care therapy for should pain
16549471|NCT02954172|Experimental|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
16549472|NCT02954172|Active Comparator|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
16549473|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
16549474|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
16549475|NCT02954146|Active Comparator|CBT only|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT only) sessions for anger management.
16549476|NCT02954146|Experimental|CBT + Connectd mobile health app|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT) sessions for anger management. In addition, veterans in this group will also receive instructions for using Connectd mobile health app with a family member or friend that will provide data for the CBT clinician.
16549477|NCT02954133|Experimental|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
16549478|NCT02954133|Experimental|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
16549479|NCT02954133|Experimental|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
16549480|NCT02954133|Experimental|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
16549481|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
16549482|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
16549483|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
16549484|NCT02954120||(PCOS+CP+)|PCOS participants with CP
16549485|NCT02954107||Absence epilepsy|Children aged 6-12 years of age primarily presenting with episodes of brief loss of consciousness (absences) in an otherwise normal child in the previous 2 years. With an EEG showing 3 Hz (2.5-4.5 Hz) generalized rhythmic spike-and-wave complexes with a discharge duration of at least 3 seconds on a present or former EEG.
16549486|NCT02954107||Controls|Overall healthy children aged 6-12 years of age following a regular school without major problems.
16549487|NCT02954068|Active Comparator|IV Infusion|Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU
16549489|NCT02954055|Active Comparator|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
16549490|NCT02954055|Experimental|Arm B|"Metronomic VEX:
~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
16549491|NCT02954042|Experimental|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
16549492|NCT02954042|Placebo Comparator|Placebo Probe|Placebo probe
16549493|NCT02954029|Experimental|Study group (transradial cohort)|device-assisted compression with ezClot pad
16549494|NCT02954029|Experimental|Study group (transfemoral cohort)|manual compression with ezClot pad
16549495|NCT02954029|Active Comparator|Control group (transradial cohort)|Rotary compression device
16549496|NCT02954029|Active Comparator|Control group (transfemoral cohort)|manual compression with BloodSTOP ix pad
16549497|NCT02954016|Experimental|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
16549498|NCT02954003|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
16549499|NCT02953990|Experimental|MOMS Program|The MOMS Program involves: (1) mindfulness of symptoms and goal-setting through a nurse-participant partnership, and (2) 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home activity. Participants will engage in 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home practice.
16549500|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
16549501|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
16549502|NCT02953964|Experimental|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
16549503|NCT02953964|Experimental|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
16549504|NCT02953964|Active Comparator|Behavioral : control group|Participants receive cognitive stimulation intervention
16549505|NCT02953951||Stored Blood Cells|"Blood transfusion:
~Stored blood cells transfused patients"
16549506|NCT02953951||Autologous Salvaged Blood|"Blood transfusion:
~Autologous salvaged blood transfused patients"
16549507|NCT02953951||Control|"Blood transfusion:
~No transfusion patients"
16549508|NCT02953938|Active Comparator|mono therapy|ranibizumab alone
16549509|NCT02953938|Experimental|combination therapy|ranibizumab with Grid&Direct short pulse laser photocoagulation
16549510|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
16549511|NCT02953912|Experimental|Reciproc single-file.|The Reciproc is a single-file nickel-titanium systems used in reciprocating motion, made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue .
16549512|NCT02953912|Active Comparator|One Shape single-file .|One Shape is single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue. with electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
16549513|NCT02953899|Experimental|Contingency Management|This is a treatment where participants earn points for treatment attendance and for providing evidence of gambling abstinence. These points are added to study accounts that can be redeemed for goods and services available at a variety of on-line businesses (e.g., Amazon, Walmart, etc.). Submission of evidence of gambling behaviour or non-attendance at an on-line counselling session re-sets subsequent points to the starting level. The CM procedure is implemented as part of the CBT counselling session.
16549514|NCT02953899|Active Comparator|Cognitive Behavioural Therapy|"CBT is currently considered best practice for the treatment of problem gambling, as noted in the National Health and Medical Research Council (Australia) endorsed Clinical Guidelines for problem and pathological gambling treatment (Problem Gambling Research and Treatment Centre, 2011). CBT is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling and substance use. Techniques include psychoeducation, behavioural interventions, and cognitive strategies. Participants are expected to attend on-line counselling sessions three times a week for approximately 12 weeks. All participants will receive individual counselling from an experienced counsellor/therapist."
16549515|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
16549516|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
16549517|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
16549518|NCT02953847|Other|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
16549519|NCT02953847|Other|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
16549520|NCT02953847|Other|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
16549556|NCT02953652|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
16549521|NCT02953847|Other|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
16549522|NCT02953847|Other|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
16549523|NCT02953847|Other|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
16549524|NCT02953834|Experimental|Kisspeptin and Insulin Resistance Test|intravenous administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
16549525|NCT02953834|Placebo Comparator|Placebo and Insulin Resistance Test|intravenous administration of IV fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
16549526|NCT02953821|Experimental|Acthar Gel|Participants receive Acthar Gel every other day for 4 weeks, and then twice per week for 20 weeks
16549527|NCT02953821|Placebo Comparator|Placebo Gel|Participants receive Placebo Gel every other day for 4 weeks, and then twice per week for 20 weeks
16549528|NCT02953808|Experimental|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
16549529|NCT02953808|Experimental|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
16549530|NCT02953808|Experimental|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
16549531|NCT02953808|Experimental|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
16549532|NCT02953808|Placebo Comparator|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
16549533|NCT02953782|Experimental|Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).
16549534|NCT02953782|Experimental|Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549535|NCT02953782|Experimental|Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549536|NCT02953782|Experimental|Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both were given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549557|NCT02953639|Placebo Comparator|Placebo|Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
16549558|NCT02953639|Experimental|Basmisanil 80mg BID|Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
16549559|NCT02953639|Experimental|Basmisanil 240mg BID|Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
16549560|NCT02953626|Experimental|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
16549619|NCT02953262|Experimental|Encouragement Arm 2|Participants in this encouragement condition will receive the same brochure and training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
16549537|NCT02953782|Experimental|Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549538|NCT02953782|Experimental|Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced colorectal cancer (CRC) who are KRAS wild type (KRASwt) and are refractory to anti-EGFRmAb therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549539|NCT02953782|Experimental|Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRAS mutation (KRASm) who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549540|NCT02953782|Experimental|Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRASm who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approx. 3 hours) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approx. 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
16549541|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
16549542|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
16549543|NCT02953756||Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery (GKRS)
16549544|NCT02953743|Experimental|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
16549545|NCT02953743|Experimental|Lenvatinib 8 mg|Participants weighing < 60 kg will be enrolled in this arm.
16549546|NCT02953730|Experimental|PEG-rhG-CSF|
16549547|NCT02953717|Active Comparator|Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery
16549548|NCT02953717|Active Comparator|Whole Brain Radiation Therapy (WBRT)|Whole Brain Radiation Therapy
16549549|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
16549550|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
16549551|NCT02953691|Experimental|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
16549552|NCT02953691|Placebo Comparator|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
16549553|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
16550261|NCT02949310|Experimental|Nefopam|Intraoperative use of nefopam 40 mg
16549561|NCT02953626|No Intervention|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
16549562|NCT02953613||Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
16549563|NCT02953600|Experimental|Standard Dose Spirulina Platensis|Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
16549564|NCT02953600|Active Comparator|Zero Spirulina Platensis|Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
16549565|NCT02953600|Active Comparator|Double Dose Spirulina Platensis|same as usual, non pill taken
16549566|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) NJ/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
16549567|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) NJ/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
16549568|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) PO/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
16549569|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) PO/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
16549570|NCT02953574|Experimental|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.
~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
16549571|NCT02953574|No Intervention|usual nursing care|
16549572|NCT02953561|Experimental|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16549573|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
16549574|NCT02953535|Experimental|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
16549575|NCT02953535|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16549576|NCT02953535|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16549577|NCT02953522|Other|191 mcg/day of Folate|Diet with 191 mcg/day of Folate
16549578|NCT02953522|Other|90 mcg/day of Folate|Diet with 90 mcg/day of Folate
16549584|NCT02953496|Experimental|vonapanitase|
16549585|NCT02953483|Experimental|Acellular first|Lung preservative solution without red blood cells will be used for perfusion in the initial 2 hours followed by addition of red blood cells for the next two hours
16549586|NCT02953483|Experimental|Cellular first|Lung preservative solution will contain red blood cells for the first two hours followed by acellular perfusate for the next two hours
16550795|NCT02945566|Active Comparator|Standard TME surgery|Radical total mesorectal excision
16549587|NCT02953470|Experimental|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
16549588|NCT02953470|Active Comparator|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
16549589|NCT02953457|Experimental|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
16549590|NCT02953444|No Intervention|Wait List Control|Participants receive daily email surveys for two weeks before being given access to the brief-mindfulness-practice training materials.
16549591|NCT02953444|Experimental|Thirty-Second Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a thirty-second mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
16549592|NCT02953444|Active Comparator|Three-Minute Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a three minute mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
16549593|NCT02953431|Placebo Comparator|Sham CPAP|Participants will be randomized to Sham CPAP
16549594|NCT02953431|Active Comparator|CPAP 10|Participants will be randomized to CPAP 10
16549595|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
16549596|NCT02953392|Active Comparator|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
16549597|NCT02953392|Active Comparator|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
16549598|NCT02953392|Active Comparator|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
16549599|NCT02953392|Active Comparator|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
16549600|NCT02953379|Experimental|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
16549601|NCT02953379|Active Comparator|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
16549602|NCT02953366|Experimental|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
16549603|NCT02953366|Active Comparator|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
16549604|NCT02953353|Active Comparator|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
16549605|NCT02953353|Sham Comparator|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
16549606|NCT02953340|Experimental|Docetaxel +Cyclophosphamide+ SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)
~Supplied in prefilled single-use syringes for subcutaneous injection
~Administered on Day 2 of each cycle"
16549607|NCT02953340|Active Comparator|Docetaxel +Cyclophosphamide+ Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta®)
~Single-dose subcutaneous injection on Day 2 of each cycle."
16549608|NCT02953327|Experimental|Intervention arm|Intervention arm, these participants will receive BCG vaccination.
16549609|NCT02953327|Placebo Comparator|Placebo arm|The placebo arm will receive BCG solvent.
16549610|NCT02953314|Experimental|Part A|"Participants weighing <25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.
~Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days."
16549611|NCT02953314|Experimental|Part B|"Participants weighing <40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.
~Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks."
16549612|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
16549613|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
16549614|NCT02953288||Benign thyroid nodules|Benign thyroid nodules
16549615|NCT02953288||Thyroid Carcinoma|Thyroid Carcinoma
16549616|NCT02953275|Experimental|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
16549617|NCT02953275|Placebo Comparator|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
16549618|NCT02953262|Experimental|Encouragement Arm 1|Participants in this encouragement condition will receive a mailed brochure with basic My HealtheVet content and a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
16549620|NCT02953262|Experimental|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (brochure, training guide, and group training offer) but will also be offered a one-on-one My HealtheVet training session.
16549621|NCT02953262|Other|Brochure Only Comparison Arm|The Comparison condition will only receive a mailed brochure with basic My HealtheVet content during the trial. (The training guide will be mailed to them after completion of the interview at the end.)
16549622|NCT02953249||Study group|The study group will include 30 subjects with type 1 diabetes mellitus who require extraction of 1 or more erupted teeth
16549623|NCT02953249||Control group|The control group will include 30 healthy subjects, without diabetes mellitus, in need of tooth extraction
16549624|NCT02953236|Experimental|Instrumented massage|
16549625|NCT02953236|Active Comparator|Manual massage|
16549626|NCT02953210|Experimental|GF general free|pre induction midazolam 50ug.kg-1, clonidine 1ug.kg induction dexter ketamine 0.2mg.kg, lidocaine 1.5mg.kg, propofol 2mg.kg,rocuronium 0.6mg.kg maintenance isoflurane 1 CAM, lidocaine 2mg.kg.h
16549627|NCT02953210|Active Comparator|GBal general balanced|pre induction with midazolam 50 ug.kg induction fentanyl 3ug.kg, propofol 2mg.kg, rocuronium 0.6mg.k maintenance isoflurane 1 CAM and fentanyl as needed
16549628|NCT02953197|Experimental|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
16549629|NCT02953184|Active Comparator|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
16549630|NCT02953184|Experimental|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
16549631|NCT02953171|Experimental|Raw sauerkraut+Probiotic capsule|75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
16549632|NCT02953171|Experimental|Raw sauerkraut+placebo capsule|75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
16549633|NCT02953171|Experimental|Pasteurized sauerkraut+Probiotic capsule|75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
16549634|NCT02953171|Placebo Comparator|Pasteurized sauerkraut+Placebo capsule|75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
16549635|NCT02953158|Experimental|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
16549636|NCT02953158|Active Comparator|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
16549637|NCT02953145|Experimental|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
16549638|NCT02953145|No Intervention|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
16549639|NCT02953132|Experimental|Single ascending dose, MT-4129 or Placebo|
16549640|NCT02953132|Experimental|Multiple ascending dose, MT-4129 or Placebo|
16549641|NCT02953119|Experimental|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:
~5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)
~Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series
~Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
16549642|NCT02953119|No Intervention|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
16549643|NCT02953106|Active Comparator|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
16549644|NCT02953106|Placebo Comparator|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
16549645|NCT02953093|Other|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
16549646|NCT02953093|Other|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
16549647|NCT02953080|Active Comparator|Call for Life Mobile phone support|"The intervention is Call for life mHealth adherence support tool  through basic mobile phone-based interactive voice response."
16549648|NCT02953080|No Intervention|Standard of Care|No call for life Uganda: Patients are randomized to standard of Care
16549649|NCT02953067|Active Comparator|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
16549650|NCT02953067|Active Comparator|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
16549825|NCT02951988|Placebo Comparator|Placebo|Rapastinel 450 mg IV once a week during OLTP followed by placebo-matching rapastinel 450 mg IV once a week during DBTP.
16549651|NCT02953067|Active Comparator|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
16549652|NCT02953054|Active Comparator|DMTS|DMTS applied to the upper arm
16549653|NCT02953054|Placebo Comparator|Placebo|Placebo patches to match DMTS applied to the upper arm
16549654|NCT02953041|Experimental|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
16549655|NCT02953041|Experimental|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
16549656|NCT02953041|Experimental|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
16549657|NCT02953028|Active Comparator|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
16549658|NCT02953028|Active Comparator|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
16549659|NCT02953015|Experimental|Manipulative articulatory and myofascial techniques Group|Manipulative and myofascial techniques
16549660|NCT02953015|Active Comparator|Transcutaneous Electrical Nerve Stimulation Group|Electrical Nerve Stimulation
16549661|NCT02952989|Experimental|SGN-2FF|Dose escalation and dose expansion
16549662|NCT02952989|Experimental|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
16549663|NCT02952976|Active Comparator|Abthera|Patients with open abdomen submitted to treatment with the Abthera dressing
16549664|NCT02952976|Active Comparator|Barker|Patients with open abdomen submitted to treatment with the Baker dressing
16549665|NCT02952963|Experimental|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
16549666|NCT02952963|Experimental|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
16549667|NCT02952950|Other|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
16549668|NCT02952950|No Intervention|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
16549669|NCT02952937|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
16549670|NCT02952937|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
16549671|NCT02952924|Placebo Comparator|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
16549672|NCT02952924|Experimental|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
16549673|NCT02952924|Placebo Comparator|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.
16549674|NCT02952924|Experimental|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
16549675|NCT02952924|Placebo Comparator|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
16549676|NCT02952924|Experimental|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
16549677|NCT02952924|Experimental|Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)|Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
16549678|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort B)|Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
16549679|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort C)|Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.
16549680|NCT02952911|Experimental|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
16549681|NCT02952911|Other|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
16549682|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
16549683|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
16549684|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
16549685|NCT02952885|Experimental|Pegvisomant|Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.
16549686|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
16549687|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
16549688|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
16549689|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
16549690|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
16549691|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
16549692|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
16549693|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
16549694|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
16549695|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
16549696|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
16549697|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
16549698|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
16549699|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
16549700|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
16549701|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
16549702|NCT02952859||historic control group|Work-up and follow-up of the historic control will be performed through similar means by contacting primary care physicians and/or medical oncologists, if information cannot be received, the patient will be directly contacted. In case the patient cannot be reached and no other information can be received on patients outcome, the death registry will be contacted.
16549703|NCT02952859||comparator group|All patients with potentially and borderline resectable pancreatic cancer are potentially candidates for IRE and will be considered for this treatment. Patient will be recruited/referred through daily clinical practice from the Inselspital Bern. Final inclusion into the study will be performed by the responsible investigators at the Inselspital Bern. Patients will be included according to the inclusion/exclusion criteria mentioned.
16549704|NCT02952846|No Intervention|Before algorithm|Observational
16549705|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
16549706|NCT02952833|Experimental|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
16549707|NCT02952833|Experimental|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
16549708|NCT02952833|Experimental|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
16549709|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
16549710|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
16551123|NCT02943369|Experimental|Cangrelor|Ticagrelor will be followed by Cangrelor
16549711|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
16549712|NCT02952807|Active Comparator|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
16549713|NCT02952807|Active Comparator|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
16549714|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
16549715|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
16549716|NCT02952768|Other|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
16549717|NCT02952755|Experimental|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
16549718|NCT02952755|Experimental|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
16549719|NCT02952742|Experimental|Black Cohosh Therapy|Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
16549720|NCT02952742|Placebo Comparator|Placebo|Subjects will take 2 capsules, identical to the Black Cohosh capsules, by mouth each. Subject's will remain on this study arm for 8 weeks.
16549721|NCT02952729|Experimental|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
16549722|NCT02952716|Experimental|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
16549723|NCT02952716|Placebo Comparator|control group|hyperbaric oxygen
16549724|NCT02952703|Active Comparator|First Breath|brief pre-natal smoking cessation counseling
16549725|NCT02952703|Experimental|Striving to Quit|Additional pre-natal counseling (in-person and telephonic); post delivery counseling (in-person and telephonic) and incentives
16549726|NCT02952690|Active Comparator|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
16549727|NCT02952690|Experimental|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
16549728|NCT02952677|Experimental|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
16549729|NCT02952677|Sham Comparator|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
16549730|NCT02952677|Other|Control|Participants receive usual care only during the intervention period.
16549731|NCT02952664|Experimental|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
16549732|NCT02952651|Experimental|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
16549733|NCT02952638||Healthy|BMI is between 20 and 25
16549734|NCT02952638||Overweight|BMI is between 25 and 30
16549735|NCT02952638||Obese|BMI is between 30 and 40
16549736|NCT02952625|Other|Single arm imaging study|Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
16549737|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
16549738|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase
~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase
~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
16549739|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase
~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase
~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
16549740|NCT02952573|Experimental|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.
~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).
~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
16549741|NCT02952573|Experimental|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.
~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).
~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
16549742|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
16549743|NCT02952547|Experimental|Test / Reference Drug|DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
16549744|NCT02952547|Experimental|Reference / Test Drug|Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
16549745|NCT02952534|Experimental|Rucaparib|Oral rucaparib (monotherapy)
16549746|NCT02952521||Epithelial ovarian cancer|"Whole blood sample collection
~Up to 3 fresh tumor tissue core biopsies
~Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
16549747|NCT02952508|Experimental|CLR 131, intravenous administration WM|CLR 131 in Waldenstroms Macroglobulinemia
16549748|NCT02952508|Experimental|CLR 131, intravenous administration MM|CLR 131 in Multiple Myeloma
16549749|NCT02952508|Experimental|CLR 131, intravenous administration CNS Lymphoma|CLR 131 in Central Nervous System Lymphoma
16549750|NCT02952508|Experimental|CLR 131 intravenous administration NHL [CLOSED]|CLR 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma
16549751|NCT02952495|Experimental|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
16549752|NCT02952495|No Intervention|No intervention|Participants will NOT Participate in the online alcohol education class.
16549753|NCT02952482||newborns testing for ALD|newborns testing for ALD
16549754|NCT02952469|Experimental|(68Ga)PSMA-HBED-CC|Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen
16549755|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
16549756|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
16549757|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
16549758|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
16549759|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
16549760|NCT02952430||Frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of greater than or equal to five.
~This group will then be observed after intervention to review outcomes."
16549761|NCT02952430||Not frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of less than five.
~This group will then be observed after intervention to review outcomes."
16549762|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
16549763|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
16549764|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
16549765|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
16549766|NCT02952391||Parkinson's disease patients|patients with Parkinson's disease, between the ages of 45 and 65, with a disease duration of 3 - 10 years
16549767|NCT02952391||healthy control subjects|Healthy control subjects, between the ages of 45 and 65
16549768|NCT02952378|Experimental|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
16549769|NCT02952378|Experimental|Healthy individuals|Healthy individuals without allergies.
16549770|NCT02952365|Other|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
16549771|NCT02952352|Experimental|Diabetes Intervention|Diabetes Prevention Program
16549772|NCT02952352|Other|Delayed Intervention|Diabetes Prevention Program
16549773|NCT02952339|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
16549774|NCT02952339|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
16549775|NCT02952326|Experimental|XP Endo Finisher|
16549776|NCT02952326|Active Comparator|Conventional needle irrigation|
16549777|NCT02952313|Other|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
16549778|NCT02952300|Experimental|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
16549779|NCT02952300|Active Comparator|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
16549780|NCT02952287|Experimental|Study Participants|4D PC MRI acquisition
16549781|NCT02952274|Active Comparator|locater attachment|mandibular overdenture retained with single midline implant using locator attachment
16549782|NCT02952274|Active Comparator|ball attachment|mandibular overdenture retained with single midline implant using ball attachment
16549783|NCT02952261|Other|CT-guided localization|This group of participants received conventional CT-guided lung nodule localization.
16551124|NCT02943369|Active Comparator|Ticagrelor|Ticagrelor only
16549784|NCT02952261|Experimental|template-guided localization|Three-dimensional printed template was customized based on participant's computed tomography information. Participants received template-guided lung nodule localization.
16549785|NCT02952248|Experimental|BI 754091|
16549786|NCT02952235|Other|SPF50+|SPF 50+ assigned to Left side of face SPF 100+ assigned to Right side of face
16549787|NCT02952235|Other|SPF100+|SPF 100+ assigned to Left side of face SPF 50+ assigned to Right side of face
16549790|NCT02952209|No Intervention|No Treatment|Tooth extraction with no bone graft.
16549791|NCT02952209|Active Comparator|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
16549792|NCT02952196|Placebo Comparator|placebo|
16549793|NCT02952196|Experimental|cannabinoid dose 1|
16549794|NCT02952196|Experimental|cannabinoid dose 2|
16549795|NCT02952183|Experimental|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
16549796|NCT02952170|Experimental|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
16549797|NCT02952157|Sham Comparator|Control|Normal saline will be applied to the endotracheal tube.
16549798|NCT02952157|Active Comparator|Lidocaine|Lidocaine jelly will be applied to the endotracheal tube.
16549799|NCT02952144|Experimental|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
16549800|NCT02952144|No Intervention|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
16549801|NCT02952131|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
16549802|NCT02952131|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
16549803|NCT02952131|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
16549804|NCT02952118|Experimental|one night with the device and one night without the device.|"The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the Forrest epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the Forrest epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home."
16549805|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
16549806|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
16549807|NCT02952092|Experimental|ASP1517 Group|Subjects will take the study drug at two- or three-day intervals.
16549808|NCT02952092|Experimental|Darbepoetin alfa Group|Subjects will take the study drug once a week.
16549809|NCT02952079|Active Comparator|BlephEx treatment|Treatment with the BlephEx instrument (lid margin exfoliation)
16549810|NCT02952079|Active Comparator|MiBoFlo treatment|Treatment with the MiboFlo equipment (heat therapy to eyelids)
16549811|NCT02952066|Experimental|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
16549812|NCT02952053|Experimental|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
16549813|NCT02952053|Active Comparator|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
16549814|NCT02952040|Experimental|ASP1517 alone period preceding group|Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
16549815|NCT02952040|Experimental|ASP1517+lanthanum period preceding group|Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
16549816|NCT02952027|Experimental|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
16549817|NCT02952027|Placebo Comparator|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
16549818|NCT02952014|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
16549819|NCT02952014|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
16549820|NCT02952014|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
16549821|NCT02952001||4 mg CLS-TA Suprachoriodal Injection|Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
16549822|NCT02952001||Sham procedure|Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
16549823|NCT02951988|Experimental|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) once a week during OLTP followed by rapastinel 450 mg IV once a week during DBTP.
16549824|NCT02951988|Experimental|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV once a week during OLTP followed by rapastinel 450 mg IV once every 2 weeks during DBTP.
16551125|NCT02943356|Experimental|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
16549826|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
16549827|NCT02951962|Experimental|Twynsta 80/5mg|Day 1 ~ Day 9 : Twynsta 80/5mg / Day 10 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
16549828|NCT02951962|Experimental|Crestor 20mg|Day 1 ~ Day 5 : Crestor 20mg / Day 6 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
16549829|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
16549830|NCT02951936|Experimental|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.
~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
16549831|NCT02951936|Sham Comparator|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
16549832|NCT02951923|Experimental|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
16549833|NCT02951923|Active Comparator|Soy powder|8 weeks of Soy powder, 60g per day
16549834|NCT02951910|Experimental|Intervention|Patients receiving zinc-hyaluronate eye drop
16549835|NCT02951897|Active Comparator|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
16549836|NCT02951897|Placebo Comparator|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
16549837|NCT02951897|Placebo Comparator|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
16549838|NCT02951897|Active Comparator|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
16549839|NCT02951897|Placebo Comparator|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
16549840|NCT02951897|Placebo Comparator|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
16549841|NCT02951884|Experimental|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
16549842|NCT02951884|Experimental|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
16549843|NCT02951884|No Intervention|Control|Participants assigned to this arm receive no injection or aspiration therapy.
16549844|NCT02951871||LP: Lymphoma Progression|
16549845|NCT02951871||TRM: Treatment Related Mortality|
16549846|NCT02951871||NHM: Non hematologic malignancy|
16549847|NCT02951871||OC: Other Cause|
16549848|NCT02951858|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
16549849|NCT02951858|Active Comparator|Control Group|The participants only receive the materials about the harm of substance use.
16549850|NCT02951845|Experimental|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram [mg], Fasted) then Treatment B1 (Direct Compression Tablets, 5*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549851|NCT02951845|Experimental|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549852|NCT02951845|Experimental|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549853|NCT02951845|Experimental|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549854|NCT02951845|Experimental|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549855|NCT02951845|Experimental|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549856|NCT02951845|Experimental|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549857|NCT02951845|Experimental|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549858|NCT02951845|Experimental|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16551126|NCT02943330||Hemodialysis|Hemodialysis patients
16549859|NCT02951845|Experimental|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549860|NCT02951845|Experimental|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549861|NCT02951845|Experimental|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
16549862|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
16549863|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
16549864|NCT02951806|Active Comparator|(R) Rapid spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 15 seconds then 10 mg hyperbaric bupivacaine.
16549865|NCT02951806|Active Comparator|(S) Slow spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
16549866|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C>4)
16549867|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
16549868|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
16549869|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
16549870|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
16549871|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
16549872|NCT02951780|Experimental|LY3185643|LY3185643 administered subcutaneous (SC)
16549873|NCT02951780|Experimental|rGlucagon|rGlucagon administered subcutaneous (SC)
16549874|NCT02951767|Experimental|Cohort 1: Treatment-naive Cisplatin Ineligible Participants|Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
16549875|NCT02951754|Experimental|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
16549876|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
16549877|NCT02951728|Experimental|Decitabine plus R-CHOP|"Rituximab 375 mg/m2 IV d6; Cyclophosphamide 750mg/m2 IV d7; Doxorubicin 50mg/m2 IV d7; Vincristine 1.4 mg/m2 IV d7; Prednisone 60 mg/m2 PO d7-11;
~Decitabine will be administered intravenously at dose levels as follow in Phase 1:
~Dose level 1: Decitabine 10 mg/m2 days 1-5; Dose level 2: Decitabine 15 mg/m2 days 1-5; Dose level 3: Decitabine 20 mg/m2 days 1-5 and determine the maximum tolerated dose.
~In phase 2, Decitabine will be administered intravenously at MTD."
16549878|NCT02951715|Experimental|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
16549879|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
16549880|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
16549881|NCT02951689|Experimental|Probiotic|Multi-strain probiotic
16549882|NCT02951689|Placebo Comparator|Placebo|Maltodextrin placebo
16549883|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.
~Amoxicillin 250 mg , three times daily for five days."
16549884|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
16549885|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
16549886|NCT02951663|Experimental|Protein Supplement|Ready to drink blinded protein supplement
16549887|NCT02951663|No Intervention|Control|Control group
16549888|NCT02951650|Experimental|Cyberonics VNS|Cyberonics VNS
16549889|NCT02951637|Experimental|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
16549890|NCT02951637|Experimental|Group B|Patient will be administrated with gefitinib
16549891|NCT02951624|Experimental|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
16549892|NCT02951624|Experimental|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
16549893|NCT02951624|Experimental|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
16549894|NCT02951624|Experimental|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
16549895|NCT02951611|Sham Comparator|Sham stimulation|Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.
16549926|NCT02951455|Experimental|CBP- PF|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Peer Facilitator (PF)
16608223|NCT02558842|No Intervention|Routine|Routine hospital assistance
16549896|NCT02951611|Experimental|Treatment: Acupuncture stimulation|Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.
16549897|NCT02951598|Other|MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
16549898|NCT02951598|Other|Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
16549899|NCT02951598|Other|MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
16549900|NCT02951598|Other|Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
16549901|NCT02951585|Experimental|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
16549902|NCT02951585|Placebo Comparator|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
16549903|NCT02951572|Other|Patients with RLD initiating NIV|Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation
16549904|NCT02951559|Experimental|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
16549905|NCT02951546|Experimental|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;
~Aerobic exercise training for a 4-month period;"
16549906|NCT02951546|Experimental|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;
~Aerobic exercise training for a 4- month period;"
16549907|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
16549908|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
16549909|NCT02951520|Experimental|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
16549910|NCT02951507|Active Comparator|Conventional partial denture|Intervention will be O T unilateral attachment
16549911|NCT02951507|Active Comparator|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
16549912|NCT02951494|Active Comparator|AlterG Anti-gravity treadmill|cont. aerobic exercise training with lower body weight support
16549913|NCT02951494|No Intervention|Exercise without body weight support|cont. aerobic exercise training without lower body weight support
16549914|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
16549915|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
16549916|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
16549917|NCT02951455|Experimental|CD-LC|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Licensed Clinician (LC).
16549918|NCT02951455|Experimental|CBP- LC|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Licensed Clinician (LC)
16549919|NCT02951455|Experimental|QLW- LC|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life Wheel, Licensed Clinician (LC)
16549920|NCT02951455|Experimental|CD & CBP- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
16549921|NCT02951455|Experimental|CD & QLW- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
16549922|NCT02951455|Experimental|QLW & Capacity Building ProjectCBP- LC|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks. Licensed Clinician (LC)
16549923|NCT02951455|Experimental|QLW & CD & CBP-LC|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
16549924|NCT02951455|Experimental|LC|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes.Licensed Clinician (LC)
16549925|NCT02951455|Experimental|CD- PF|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Peer Facilitator (PF)
16550051|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
16549927|NCT02951455|Experimental|QLW-PF|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life wheel, Peer Facilitator (PF)
16549928|NCT02951455|Experimental|CD & CBP- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions. Peer Facilitator (PF)
16549929|NCT02951455|Experimental|CD & QLW- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
16549930|NCT02951455|Experimental|QLW & CBP- PF|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks.Peer Facilitator (PF)
16549931|NCT02951455|Experimental|CD & QLW & CBP- PF|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
16549932|NCT02951455|Experimental|PF|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes. Peer Facilitator (PF)
16549933|NCT02951442|Experimental|Renal Transplant|
16549934|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
16549935|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
16549936|NCT02951416||Idiopathic Pulmonary Fibrosis (IPF)|"IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646).
~Patient registry (observation and biomaterial sampling)."
16549937|NCT02951416||Non-specific interstitial pneumonia|"Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern.
~Patient registry (observation and biomaterial sampling)."
16549938|NCT02951416||Cryptogenic organising pneumonia (COP)|"COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces.
~Patient registry (observation and biomaterial sampling)."
16549939|NCT02951416||Acute interstitial pneumonia (AIP)|"Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction.
~Patient registry (observation and biomaterial sampling)."
16549940|NCT02951416||Lymphoid interstitial pneumonia (LIP)|"Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sjögren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)).
~Patient registry (observation and biomaterial sampling)."
16549941|NCT02951416||respiratory bronchiolitis-ILD (RB-ILD)|Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).
16549942|NCT02951416||Desquamative Interstitial Pneumonia|"Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution.
~Patient registry (observation and biomaterial sampling)."
16549943|NCT02951416||Hypersensitivity Pneumonitis|"Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas.
~Patient registry (observation and biomaterial sampling)."
16549944|NCT02951416||Sarcoidosis|"Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL.
~Patient registry (observation and biomaterial sampling)."
16549945|NCT02951416||Lung Cancer|"Histological confirmation of Lung Cancer. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
16549946|NCT02951416||Chronic Obstructive Pulmonary Disease|"Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
16549947|NCT02951416||Pulmonary Hypertension|"Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
16549948|NCT02951416||Sleep Apnea|"Sleep Apnea diagnosed by polysomnography. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
16549949|NCT02951416||Asthma|"Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
16549950|NCT02951416||Control/Health Individuals|Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).
16549951|NCT02951403|Experimental|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
16549952|NCT02951403|Other|Conservative treatment|Patients to whom special physiotherapy will be advised.
16549953|NCT02951390|Active Comparator|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
16549954|NCT02951390|No Intervention|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
16549955|NCT02951377|No Intervention|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
16549956|NCT02951377|Experimental|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
16549958|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
16549959|NCT02951351|Experimental|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
16549960|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.
~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
16549961|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
16549962|NCT02951325|No Intervention|Standard|"Surgery +/- chemotherapy only
~Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.
~Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.
~No radiation therapy will be given."
16549963|NCT02951325|Experimental|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention
~Radiation Therapy:
~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.
~Dose Prescription:
~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.
~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
16549964|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
16549965|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
16549966|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
16549967|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
16549968|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
16549969|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
16549970|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
16549971|NCT02951299|Experimental|pentoxifylline group|Received oral pentoxifylline (400 mg) three times a day for 14 days.
16549972|NCT02951299|No Intervention|no treatment group|No intervention.
16549973|NCT02951286|Experimental|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
16549974|NCT02951286|Experimental|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
16549975|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
16549976|NCT02951260|Experimental|Metformin|17 days metformin treatment
16549977|NCT02951260|Placebo Comparator|Placebo|17 days placebo treatment
16549978|NCT02951234|Experimental|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
16549979|NCT02951234|Active Comparator|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
16549980|NCT02951221|Experimental|Cohort 1|Treatment sub groups A and B
16549981|NCT02951221|Experimental|Cohort 2|Treatment sub groups C and D
16550262|NCT02949297|Other|Ovation Alto Abdominal Stent Graft System|Endovascular repair of AAA using the Ovation Alto Abdominal Stent Graft System.
16549982|NCT02951208|Experimental|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
16549983|NCT02951208|Sham Comparator|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
16549984|NCT02951195|Placebo Comparator|Part 1: Placebo|
16549985|NCT02951195|Experimental|Part 1 Cohort 1A: TC|
16549986|NCT02951195|Experimental|Part 1 Cohort 1B: TC|
16549987|NCT02951195|Experimental|Part 1 Cohort 1C: TC|
16549988|NCT02951195|Active Comparator|Part 2 Cohort 2A: TEZ/IVA|
16549989|NCT02951195|Experimental|Part 2 Cohort 2A: TC|
16549990|NCT02951195|Active Comparator|Part 2 Cohort 2B: TEZ/IVA|
16549991|NCT02951195|Experimental|Part 2 Cohort 2B: TC|
16549992|NCT02951182|Placebo Comparator|Part 1: Placebo - Cohort 1A and 1B Combined|Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
16549993|NCT02951182|Experimental|Part 1 Cohort 1A: Triple Combination (TC)|Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
16549994|NCT02951182|Experimental|Part 1 Cohort 1B: TC Low Dose|Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
16549995|NCT02951182|Experimental|Part 1 Cohort 1B: TC High Dose|Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
16549996|NCT02951182|Active Comparator|Part 2: TEZ/IVA|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
16549997|NCT02951182|Experimental|Part 2: TC-2|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
16549998|NCT02951156|Experimental|Phase 1b Arm A|avelumab/utomilumab/rituximab
16549999|NCT02951156|Experimental|Phase 1b Arm B|avelumab/utomilumab/azacitidine
16550000|NCT02951156|Experimental|Phase 1b Arm C|avelumab/rituximab/bendamustine
16550001|NCT02951156|Experimental|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
16550002|NCT02951156|Active Comparator|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
16550003|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
16550004|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
16550005|NCT02951143|Experimental|1.3 mg/g Concentration|Participants in this arm will experience the 1.3 mg/g Concentration
16550006|NCT02951143|Experimental|2.4 mg/g Concentration|Participants in this arm will experience the 2.4 mg/g Concentration
16550007|NCT02951143|Experimental|5.2 mg/g Concentration|Participants in this arm will experience the 5.2 mg/g Concentration
16550008|NCT02951143|Experimental|15.8 mg/g Concentration|Participants in this arm will experience the 15.8 mg/g Concentration
16550011|NCT02951117|Experimental|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily [QD]) and dexamethasone (40 mg once weekly [Q1W]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
16550012|NCT02951117|Experimental|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).
~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
16550013|NCT02951104|Experimental|USCOM|
16550014|NCT02951091||biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets [Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
16550015|NCT02951091||control group|
16550016|NCT02951078|Experimental|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
16550017|NCT02951078|Active Comparator|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
16550018|NCT02951065|Experimental|Bristle-less brush|Subjects will be assigned to use a bristle-less manual tooth brush with short, rubbery cones for one year twice daily
16550019|NCT02951065|Active Comparator|Soft bristle brush|Subjects will be assigned to use a soft, nylon-bristled tooth brush for one year twice daily
16550052|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
16550020|NCT02951052|Experimental|CAB LA + RPV LA every 4 weeks|Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
16550021|NCT02951052|Active Comparator|Current antiretroviral regimen|Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
16550022|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
16550023|NCT02951026||0.03mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.03mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
16550024|NCT02951026||0.07mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.07mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
16550025|NCT02951026||0.23mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.23mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
16550026|NCT02951026||Placebo (previously injected)|"Subjects in this group received a single intra-articular injection of placebo into the target knee during the parent study prior to enrolling in this observational study."
16550027|NCT02951013|Experimental|restrictive group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.
16550028|NCT02951013|Active Comparator|liberal group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.
16550029|NCT02951000|Active Comparator|platysma suture|running suture of the platysma with 3/0 polyglactin
16550030|NCT02951000|Active Comparator|no platysma suture|no platysma suture
16550031|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants
~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
16550032|NCT02950974|Active Comparator|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
16550033|NCT02950974|Experimental|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
16550034|NCT02950961|Other|Arm 1: nonrandomized stepped wedge|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In the context of the nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) at a site makes her/his first referral to the CCWV care manager. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
16550035|NCT02950948|Experimental|Progesterone|25 mg of progesterone will be administered daily by subcutaneous injection.
16550036|NCT02950948|Placebo Comparator|Placebo|25 mg of progesterone will be administered daily by subcutaneous injection.
16550037|NCT02950935|Experimental|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
16550038|NCT02950935|Placebo Comparator|Placebo|placebo will be administered twice à day until the 12th week of gestation.
16550039|NCT02950922|Experimental|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
16550040|NCT02950922|Experimental|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
16550041|NCT02950922|Placebo Comparator|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
16550042|NCT02950909|Experimental|Emphasized exercise group|Patients in the emphasized exercise group performed exercises emphasizing the deep cervical extensor muscles applying a resistance at the level of the vertebral arch of C4 either therapeutically with the therapist's fingers or as a home exercise with the aid of a towel or belt. These exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, a dynamic exercise was added moving the head from maximal flexion to maximal extension keeping the gaze fixed at an object lying between both elbows hoping to activate more the extensors in the lower cervical spine.
16550043|NCT02950909|Experimental|General exercise group|Patients in the general exercise group performed exercises targeting all cervical extensor muscles including the superficial ones applying resistance at the head pushing against a wall or the therapist's hand or as a home exercise with the aid of a towel. As in the other group, these exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, the same dynamic exercise was added as in the other group with the only difference that the gaze was fixed at an object lying between both hands hoping to activate all cervical extensors
16550044|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
16550045|NCT02950883|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
16550046|NCT02950883|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
16550047|NCT02950870|Experimental|group treated|this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.
16550048|NCT02950870|No Intervention|group untreated|Control group
16550049|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
16550050|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
16551127|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
16550053|NCT02950818|Experimental|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
16550054|NCT02950818|No Intervention|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
16550055|NCT02950805|Experimental|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
16550056|NCT02950805|Experimental|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
16550057|NCT02950792|Experimental|ViewRay MRI-IGART|"ViewRay MRI-Image-Guided Adaptive Radiation Therapy (IGART):
~Daily MRI on ViewRay 5 days per week for 4 weeks in combination with weekly standard of care chemo-radiation.
~Daily MRI on ViewRay during Week 5 in combination with Stereotactic Body Radiation Therapy boost for daily for up to 1 week.
~Continued standard of care consolidation chemotherapy every 21 days for 3 cycles, beginning 4 - 6 weeks after completion radiation therapy, ."
16550058|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor
~Neovax is a combination of Poly-ICLC and Neoantigen Peptides
~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22
~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20
~Ipilimumab will be injected within 1 cm of each NeoVax administration"
16550059|NCT02950766|Experimental|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor
~Neovax is a combination of Poly-ICLC and Neoantigen Peptides
~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22
~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
16550060|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
16550061|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
16550062|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
16550063|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
16550064|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
16550065|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
16550066|NCT02950727|Experimental|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
16550067|NCT02950727|Active Comparator|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
16550068|NCT02950714|Experimental|LIN_NOW|Participants from CaNIOS centres randomized to the NOW group will be provided immediate access to the lupus interactive navigator (LIN), a web-based program developed to promote engagement and self-care in lupus.
16550069|NCT02950714|Active Comparator|LIN_WAIT|Participants from CaNIOS centres randomized to the WAIT group will have usual care for three months prior to crossing over to access to the LIN.
16550070|NCT02950688|Experimental|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
16550071|NCT02950688|Placebo Comparator|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
16550072|NCT02950675||Normal Adult|Control:Normal Adult
16550073|NCT02950675||Burn Patient|The burn patient will be identified according to the diagnoses (ICD-9-CM code: 940-949).
16550074|NCT02950662|Active Comparator|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
16550075|NCT02950662|Active Comparator|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
16550076|NCT02950649|Experimental|Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
16550077|NCT02950649|Active Comparator|No Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
16550078|NCT02950636|Experimental|Restorative Yoga|Subjects will participate in a structured restorative yoga program. Subjects will attend a 60 minute restorative yoga class twice a week for 8 weeks in a yoga studio.
16550079|NCT02950623|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
16550080|NCT02950623|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
16550081|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
16550082|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
16550083|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
16550084|NCT02950584|Experimental|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
16550085|NCT02950584|Placebo Comparator|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
16550086|NCT02950571|Active Comparator|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
16550188|NCT02949869|Experimental|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
16550189|NCT02949856|Experimental|Tapered|Mallinckrodt, COVIDIEN
16550087|NCT02950571|Experimental|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.
~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.
~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
16550088|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
16550089|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
16550090|NCT02950545|Experimental|Placebo, Spherical, then Toric Lenses|Crossover order 1
16550091|NCT02950545|Experimental|Placebo, Toric, then Spherical Lenses|Crossover order 2
16550092|NCT02950545|Experimental|Spherical, Placebo, then Toric Lenses|Crossover order 3
16550093|NCT02950545|Experimental|Spherical, Toric, then Placebo Lenses|Crossover order 4
16550094|NCT02950545|Experimental|Toric, Placebo, then Spherical Lenses|Crossover order 5
16550095|NCT02950545|Experimental|Toric, Spherical, then Placebo Lenses|Crossover order 6
16550096|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
16550097|NCT02950519|Active Comparator|As needed Cuff Pressure Checks|Cuff pressure checks upon intubation and after any manipulation of ET tube
16550098|NCT02950519|Experimental|Cuff Pressure checks every 8 hrs|Cuff pressure checks upon intubation, after manipulation of ET tube, and minimum of 8 hr interval
16550099|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
16550100|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
16550101|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
16550102|NCT02950480|Experimental|Zafirlukast|Zafirlukast
16550103|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
16550104|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
16550105|NCT02950454|Experimental|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
16550106|NCT02950454|Active Comparator|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
16550107|NCT02950441|Experimental|Nicotinamide Riboside|1000mg (2x250mg tablets twice daily)
16550108|NCT02950441|Placebo Comparator|Placebo|Two tablets twice daily
16550109|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
16550110|NCT02950415|Other|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
16550111|NCT02950415|Other|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
16550112|NCT02950415|Other|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
16550113|NCT02950415|Other|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
16550114|NCT02950402|Experimental|Two Dried Plums per day|Two Dried Plums per day is approximately 14 g.
16550115|NCT02950402|Experimental|Six Dried Plums per day|Six Dried Plums per day is approximately 42 g.
16550116|NCT02950389|Experimental|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
16550117|NCT02950389|Experimental|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
16550118|NCT02950376||Group1：amphetamine abusers|
16550119|NCT02950376||Group2: health control|
16550120|NCT02950376||Group3: norm of assessment system|
16550121|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
16550122|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
16550123|NCT02950337|Experimental|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
16550124|NCT02950337|Experimental|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
16550125|NCT02950337|Experimental|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
16550126|NCT02950324|Experimental|Prehabilitation|Patients in this (intervention) arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'.
16550190|NCT02949856|Active Comparator|Cylindrical|Endotracheal tube, Unomedical
16610573|NCT02543788|Other|Controls|healthy volunteers
16550127|NCT02950324|Active Comparator|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
16550128|NCT02950311|Experimental|Intranasal xylitol spray|Two sprays each nostril, twice a day.
16550129|NCT02950311|Placebo Comparator|Intranasal saline spray|Two sprays each nostril, twice a day.
16550130|NCT02950285|Experimental|Baseline alert|For patients randomly selected for the baseline alert arm, their physicians will be alerted via email that a patient(s) under their care has atrial fibrillation, is at high risk of stroke, and is not currently anticoagulated. Physicians will also be asked to complete a survey related to anticoagulation for each patient and will be provided with educational resources and consultation services.
16550131|NCT02950285|No Intervention|3-month alert arm|For patients randomly selected for the 3-month alert arm, their physicians will not be notified during the 3-month study follow-up period. Instead, PCPs will be sent alerts after 3-months via email for these patients.
16550132|NCT02950259|Experimental|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
16550133|NCT02950259|Experimental|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
16550134|NCT02950246|Experimental|2% alcoholic chlorhexidine group|"Skin preparation Use of 10 ml of 2% alcoholic Chlorhexidine drug for disinfection in place of povidone iodine without scrubing device Wait at least 30 secondes for drying Perineural catheterization implementation Ultrasonography use"
16550135|NCT02950246|Active Comparator|povidon iodine group|"Skin preparation Use of 10 ml of povidone iodine drug for disinfection with scrubing device Wait at least 30 seondes for drying Perineural catheterization implementation Ultrasonography use"
16550136|NCT02950233|Experimental|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
16550137|NCT02950233|Experimental|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).
~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
16550138|NCT02950233|Experimental|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
16550139|NCT02950233|Placebo Comparator|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).
~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
16550140|NCT02950220|Experimental|Arm 1|
16550141|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
16550142|NCT02950181|Experimental|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
16550143|NCT02950168||Edoxaban|All patients treated with edoxaban with a planned or unplanned diagnostic or interventional procedure
16550144|NCT02950155|Experimental|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
16550145|NCT02950155|Sham Comparator|Sodium Chloride solution|A single infusion with sodium chloride solution.
16550146|NCT02950142|Experimental|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
16550147|NCT02950142|Active Comparator|CPOE without order sets|Physicians who use CPOE without order sets.
16550148|NCT02950129|Other|measurements of gait|all subjects will undergo 6 tests to assess gait before and after SIJ; SIJ pain diagnostic tests
16550149|NCT02950116|Active Comparator|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
16550150|NCT02950116|Active Comparator|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
16550151|NCT02950116|Active Comparator|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
16550152|NCT02950103|Experimental|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
16550153|NCT02950090|Experimental|MobilWise|MobilWise will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) via Fitabase to: allow a remote coach to view and collect physical activity data generated by the personal monitor, and use that data to formulate and provide tailored behavioral support, using motivational interviewing. The coach has a phone conversation weekly x 12 using motivational interviewing with participants to set goals and encourage activity. Coaches mention patient use of treatment elements (accountability) and will be positively reinforcing for adherent participants, or will include positive statements for those who are not adherent (supportive).Participants are also encouraged to use all the features of Fitbit (social networking, challenges, email reminders).
16550154|NCT02950090|Active Comparator|Fitbit Only|will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) to monitor their own progress and physical activity level without coaching support. Participants are again encouraged to use all the features of Fitbit (social networking, challenges, email reminders) to achieve activity levels.
16550155|NCT02950090|No Intervention|Waitlist Control|Participants in the waitlist arm have exposure to the usual wellness supports provided by the company: Motiva is the internal corporate wellness program that is under the direction of the Chief Medical Officer. Initiated in 2000, Motiva is staffed by two full- time health professionals and two full-time healthy lifestyle professionals. Motiva provides wellness programming year round on a BCBSIL intranet web page plus an individual page called myMotiva, where self- assessment of health risks, including weight and physical activity behavior, is encouraged. Participating in myMotiva allows individuals to earn up to $200 per year in an incentive program called Wellness Rewards
16550156|NCT02950077|Experimental|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
16550157|NCT02950064|Experimental|BTP-114|Intravenous (IV) treatment n 21-day cycles
16550158|NCT02950051|Active Comparator|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)
~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
16550159|NCT02950051|Experimental|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
16550160|NCT02950051|Experimental|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
16550161|NCT02950051|Experimental|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.
~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
16550162|NCT02950038|Experimental|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.
~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
16550163|NCT02950025|Active Comparator|Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)
~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments
~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site
~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
16550164|NCT02950025|Experimental|Arm B: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)
~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments
~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site
~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day
~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
16550167|NCT02949999|Experimental|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
16550168|NCT02949999|Experimental|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
16550169|NCT02949999|Experimental|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
16550170|NCT02949999|Experimental|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
16550171|NCT02949999|Placebo Comparator|Placebo voclosporin|placebo BID
16550172|NCT02949986|Experimental|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
16550173|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg twice daily (BID)
16550174|NCT02949960|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
16550175|NCT02949960|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
16550176|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.
~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
16550177|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.
~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
16550178|NCT02949934|Active Comparator|Tolcapone|Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days
16550179|NCT02949934|Placebo Comparator|Placebo|Placebo three times per day for eight days
16550180|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
16550181|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
16550182|NCT02949908||Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)|
16550183|NCT02949895|Experimental|Dose Escalation Dose 1|BMS-986012 Dose Escalation Dose 1
16550184|NCT02949895|Experimental|Dose Escalation Dose 2|BMS-986012 Dose Escalation Dose 2
16550185|NCT02949895|Experimental|Chemotherapy Combination|BMS-986012 + Cisplatin + Etoposide
16550186|NCT02949882|Experimental|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
16550187|NCT02949882|Active Comparator|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
16550258|NCT02949323||children with urinary stones|children with urinary stones
16550191|NCT02949843|Experimental|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
16550192|NCT02949843|Experimental|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
16550193|NCT02949843|Experimental|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
16550195|NCT02949817|Experimental|IMU sensor training group(intervention group)|video-game based rehabilitation therapy system training group
16550196|NCT02949817|Active Comparator|Conventional OT group (control group)|conventional training group (control group)
16550197|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
16550198|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
16550199|NCT02949791|Active Comparator|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
16550200|NCT02949791|Experimental|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
16550201|NCT02949778|Active Comparator|Ropivacaine 3.75mg/mL|QL-block using 20 mL ropivacaine 3.75mg/mL
16550202|NCT02949778|Placebo Comparator|Sodium chloride 9 mg/mL|QL-block using 20 mL sterile sodium chloride 9 mg/mL
16550203|NCT02949765|Active Comparator|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
16550204|NCT02949765|Experimental|Iron-rich diet|Iron-rich diet recommendations are given
16550205|NCT02949752|Experimental|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
16550206|NCT02949739|Active Comparator|Intensive lifestyle modification|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study (Index cases). Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).
~Intensive lifestyle modification follows clinically accepted, evidence based strategies to achieve >7% reduction in weight through improved diet and increased physical activity, and is delivered as 9 face-face and 13 telephone contact sessions over 12 months.
~Index cases will be followed for three years to identify new-onset T2D."
16550207|NCT02949739|No Intervention|Usual Care|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study.
~Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).
~Usual care group will comprise one diabetes prevention session and written material."
16550208|NCT02949726|Other|Cancer-treated patients receiving NIRFLI|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
16550209|NCT02949713|Experimental|Text messaging-motivational interviewing|Participants will register their phone numbers into an automated SMS software (provided by WelTel.org). Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, 10, 14, and 24. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
16550210|NCT02949713|No Intervention|Usual standard of care|Usual standard of care
16550211|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.
~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
16550212|NCT02949687|Experimental|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
16550213|NCT02949674|Experimental|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
16550214|NCT02949674|Experimental|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
16550215|NCT02949674|No Intervention|Control|No application of anesthetic
16550216|NCT02949661|Experimental|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block using levobupivacaine
16550217|NCT02949661|Active Comparator|Local wound infiltration|Patients will receive local wound infiltration with levobupivacaine after the conclusion of surgery
16550218|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
16550219|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
16550220|NCT02949622|Experimental|Multimodal intervention program|The intervention program will be in group format, with a size of 10 to 12 patients per group and with an extension of 12 sessions. The treatment program will feature sessions with psychoeducation of metabolic syndrome and treatment model, problem solving, stress management, anger management, social skills, self-efficacy and social support.
16550221|NCT02949622|Active Comparator|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
16550222|NCT02949609|Experimental|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
16550223|NCT02949609|Active Comparator|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
16550224|NCT02949583|Experimental|Punica granatum Linn.|The childrens used the mouthwash contain pomegranate 6,25% twice daily for 14 days.
16550225|NCT02949583|Active Comparator|chlorhexidine|The childrens used the mouthwash contain chlorhexidine 0.12% twice daily for 14 days.
16550226|NCT02949570|Experimental|Treatment|
16550227|NCT02949557|Active Comparator|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
16550228|NCT02949557|Active Comparator|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
16550229|NCT02949544|Other|water immersion|patients with heart failure will be immersed to the neck for 15 minutes
16550230|NCT02949531|Active Comparator|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
16550231|NCT02949531|Active Comparator|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
16550232|NCT02949531|Active Comparator|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
16550233|NCT02949518|Experimental|Enhanced Recovery Pathway for Spine|
16550234|NCT02949518|No Intervention|Usual Care|
16550235|NCT02949505|Experimental|Intervention arm|12-week home prehabilitation program
16550236|NCT02949492|Experimental|IL-2 arm|Liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
16550237|NCT02949479|Other|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
16550238|NCT02949466|Experimental|triamcinolone and hyaluronic acid group|combined triamcinolone (Triamcinolone 10 mg 1cc) and hyaluronic acid (2 cc) injections: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
16550239|NCT02949466|Active Comparator|hyaluronic acid group|hyaluronic acid (2cc) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
16550240|NCT02949453|Experimental|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
16550241|NCT02949440|Experimental|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
16550242|NCT02949440|Active Comparator|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
16550243|NCT02949414|Experimental|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
16550244|NCT02949401|No Intervention|Standard of Care|"No research intervention to be administered.
~Participants will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time."
16550245|NCT02949401|Experimental|Virtual Reality|The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
16550246|NCT02949388|Placebo Comparator|Placebo|Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days
16550247|NCT02949388|Active Comparator|300 mg (150 mg BID)|Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days
16550248|NCT02949388|Active Comparator|400 mg (200 mg BID)|Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days
16550249|NCT02949375|Placebo Comparator|Placebo Arm|Gel capsule containing Placebo to be taken once per day
16550250|NCT02949375|Active Comparator|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
16550251|NCT02949375|Active Comparator|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
16550252|NCT02949362|Experimental|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
16550253|NCT02949349|Experimental|MMF 500mg|Mycophenolate mofetil 500mg, PO BID
16550254|NCT02949349|Experimental|MMF 750mg|Mycophenolate mofetil 750mg, PO BID
16550255|NCT02949349|Active Comparator|AZA|Azathioprine 1mg/kg, PO BID
16550256|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
16550257|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
16550263|NCT02949284|Experimental|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
16550264|NCT02949284|Active Comparator|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
16550265|NCT02949284|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
16550266|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
16550267|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
16550268|NCT02949258|Experimental|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
16550269|NCT02949245||Groups/Cohorts|"Surgical treatment
~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
16550270|NCT02949232|Experimental|Prednisolone|Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
16550271|NCT02949232|Placebo Comparator|Placebo Oral Tablet|Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
16550272|NCT02949219|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16550273|NCT02949206|Experimental|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
16550274|NCT02949206|Experimental|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
16550275|NCT02949206|Experimental|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
16550276|NCT02949206|Experimental|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
16550277|NCT02949206|Experimental|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
16550278|NCT02949206|Experimental|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
16550279|NCT02949206|Experimental|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
16550280|NCT02949206|Experimental|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
16550281|NCT02949206|Experimental|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
16550282|NCT02949206|Experimental|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
16550283|NCT02949193|Experimental|evogliptin|evogliptin 5mg qd add-on to metformin
16550284|NCT02949193|Active Comparator|sitagliptin|sitagliptin 100mg qd add-on to metformin
16550285|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
16550286|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
16550287|NCT02949167|Experimental|MyHealth intervention arm|Nurse-led follow-up
16550288|NCT02949167|No Intervention|MyHealth Control condition|Physician-led follow-up
16550289|NCT02949154||Metastatic melanoma patients|All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
16550290|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
16550355|NCT02948634|Sham Comparator|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
16550291|NCT02949128|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.
~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first."
16550292|NCT02949115|Experimental|70 mL red beetroot juice|70 mL red beetroot juice naturally containing 300 mg nitrate.
16550293|NCT02949115|Active Comparator|70 mL placebo drink plus potassium nitrate|70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.
16550294|NCT02949115|Active Comparator|70 mL red beetroot juice without nitrate|70 mL red beetroot juice per day without nitrate.
16550295|NCT02949115|Placebo Comparator|70 mL placebo drink|70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.
16550296|NCT02949102|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
16550297|NCT02949102|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
16550298|NCT02949089|Experimental|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
16550299|NCT02949076|Experimental|Exercise|Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
16550300|NCT02949050|Experimental|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
16550301|NCT02949050|No Intervention|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
16550302|NCT02949037|Experimental|Intervention|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
16550303|NCT02949037|No Intervention|Control|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
16550304|NCT02949024|Experimental|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
16550305|NCT02949024|Experimental|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
16550306|NCT02949011|Experimental|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
16550307|NCT02949011|Active Comparator|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
16550308|NCT02949011|Placebo Comparator|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
16550309|NCT02948998|No Intervention|control|The participants in control group do not take spironolactone.
16550310|NCT02948998|Experimental|spironolactone|The participants in spironolactone group take 10-20mg spironolactone orally and daily.
16550311|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
16550312|NCT02948972|Experimental|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
16550313|NCT02948972|Active Comparator|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
16550316|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
16550317|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
16550318|NCT02948920|Experimental|Ephedrine|Intravenous 9 mg of ephedrine (3 ml) given at finishing local anesthetic administration for spinal anesthesia
16550319|NCT02948920|Placebo Comparator|NSS|Intravenous normal saline 3 ml given at finishing local anesthetic administration for spinal anesthesia
16550320|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
16550321|NCT02948894|Experimental|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
16550322|NCT02948894|Placebo Comparator|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
16550323|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
16550324|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
16550325|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:
~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
16550486|NCT02947724|Active Comparator|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
16611618|NCT02536807|Experimental|Hyaluronan|Hyaluronan gel injection
16550326|NCT02948842|Experimental|Treatment Group|Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.
16550327|NCT02948842|Placebo Comparator|Control Group|On day of treatment, patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of injectable normal saline. The depth and location of the needle will be determined pre-procedurally with urethral ultrasonography with the needle in a semi-parallel manner into the plaque as to avoid perforation into nearby structures. Injections will be performed at a single site.
16550328|NCT02948829|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
16550329|NCT02948816|Experimental|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
16550330|NCT02948816|Experimental|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
16550331|NCT02948816|Active Comparator|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
16550332|NCT02948803|Experimental|Intervention group|smartphone based intervention with Active Coach app: participants in the intervention group will use a newly developed smartphone app in combination with a Fitbit Charge activity tracker for 9 weeks. The app aims to promote an active lifestyle.
16550333|NCT02948803|No Intervention|control group|participants in the control groups only receive a flyer with standard information about an active lifestyle
16550337|NCT02948764|Other|single-arm study|This project is designed as a one-armed diagnostic study. Every patient included in the study will undergo the same diagnostic test, the vacuum-assisted biopsy, after NACT and before surgery according to guidelines.
16550338|NCT02948738|Experimental|Interactive Education|Interactive asthma education
16550339|NCT02948738|Active Comparator|Standard Education|Standard asthma education
16550340|NCT02948725|Experimental|cross-education + standard rehabilitation|The cross-education group will engage in strength training of the non-paretic hand in addition to standard rehabilitation. Cross-education will be progressive in nature, beginning with 2 sets of 8 repetitions and increasing up to a maximum of 6 sets of 8 repetitions of maximal voluntary effort isometric handgrip contractions as tolerated. Grip training will be performed using standard grip trainers (Digi-Flex Grip trainers) to train both finger flexors and full hand and wrist isometric contractions. In addition, patients will perform controlled dynamic wrist flexion and extension training of the non-paretic hand using exercise tubing with the same prescription. Patients will be asked to complete exercises 3 times per week for 26 weeks, and to record adherence in a training log. An average of one session per week will be considered 'trained'.
16550341|NCT02948725|No Intervention|standard rehabilitation|Standardized rehabilitation involves several strategies tailored to the patient and remains somewhat based on clinician preference. These therapies may involve functional electrical stimulation, neuro-facilitation, strengthening, range of motion (ROM), mirror therapy, and force-use therapy (e.g., CIMT). Patients engage in therapy 5 days per week as inpatients, and 2 days per week as outpatients with additional home exercises. Specific therapies for each patient will be tracked using a therapy log.
16550342|NCT02948712|Experimental|Survivor Distress|This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.
16550343|NCT02948699|Experimental|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
16550344|NCT02948699|No Intervention|Regular diet|Regular diet without other nutritional intervention.
16550345|NCT02948686|Active Comparator|SET (Self-Etching)|55 teeth will receive restorations using Self-Etching Application Strategy
16550346|NCT02948686|Experimental|SEE (Selective Enamel Etching)|55 teeth will receive restorations using Enamel Etching Application Strategy
16550347|NCT02948686|Experimental|SETT (Self-Etching, more time)|55 teeth will receive restorations using Self Etching with Extended time Application Strategy
16550348|NCT02948686|Experimental|SETL (Self-Etching, more layers)|55 teeth will receive restorations using Self Etching with Extended layers number Strategy
16550349|NCT02948673|Placebo Comparator|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
16550350|NCT02948673|Active Comparator|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
16550351|NCT02948660|Other|acute consciousness disorders group|"Duration time of coma <= 3 weeks.
~This group will receive sleep EEG monitoring, serum melatonin and orexin level testing, and Zolpidem Tartrate Tablets or melatonin treatment."
16550352|NCT02948660|Other|chronic consciousness disorders group|"Duration time of coma > 3 weeks.
~This group received sleep EEG monitoring, serum melatonin and orexin testing, and Zolpidem Tartrate Tablets or melatonin treatment."
16550353|NCT02948647|No Intervention|Control Group|Will receive standard of care, which is general dietary advice
16550354|NCT02948647|Experimental|Intervention Group|Will receive standard of care as well as sugar-reduction education
16550356|NCT02948634|Active Comparator|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
16550357|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
16550358|NCT02948595|Experimental|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
16550359|NCT02948595|Experimental|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
16550360|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
16550361|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
16550362|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
16550363|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
16550364|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
16550365|NCT02948582|Placebo Comparator|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
16550366|NCT02948569|Experimental|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.
16550367|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
16550368|NCT02948543|Experimental|Treatment (Arm B):Intravesical BCG + MMC|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.
~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.
~Dosage of Mitomycin (MMC) fixed at 40mg per instillation."
16550369|NCT02948543|Other|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.
~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
16550370|NCT02948517|Experimental|Time restricted feeding|Time restricted feeding
16550371|NCT02948517|No Intervention|Control|No intervention
16550372|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
16550373|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
16550374|NCT02948491|Experimental|Music therapy|First. Recording of the voice of the mother singing the song to the child. (To choose this option, the song must be sung to the child during pregnancy at least 2 to 3 times per week. Second. The mother's favorite song, obtained externally. (To choose this option, the mother must bring the song that she that she listened to frequently, at least 5 times per week). Third. Pre-determined lullaby. (This option refers only to the lullaby melody or Brahms lullaby, edited to obtain stable volumes and normalization of the audio, with the effect of progressively appearing and fading for the first and last 10 seconds of the intervention with music therapy, so there are no drastic acoustic changes in the intervention. Audacity editing software will be used.)
16550375|NCT02948491|No Intervention|Without sound emission|"The infant does not receive any sound emission because the baffle will be turned off.
~One of the three intervention options are chosen. The parents are told that their child may be randomly assigned to either the therapeutic or control group."
16550376|NCT02948478||Precarious patients|Precarious patients - exposed - will be those identified as precarious by at least one of the three scores (EPICES, Pascal, European Deprivation Index)
16550377|NCT02948478||Non precarious patients|Non precarious patient - non exposed - will be all the patients identified as non-precarious by the three scores (EPICES, Pascal, European Deprivation Index)
16550378|NCT02948452||Anorexia|fMRI: reward task, anxiety provocation
16550379|NCT02948452||Mild anxiety comparison group|fMRI: reward task, anxiety provocation
16550380|NCT02948439|Experimental|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
16550381|NCT02948439|No Intervention|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
16550382|NCT02948426|Experimental|Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml)|Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
16550487|NCT02947724|Active Comparator|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
16612372|NCT02531815|Experimental|Cohort 6 (IV) PF-06741086, Placebo|
16550383|NCT02948426|Experimental|Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
16550384|NCT02948426|Experimental|Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
16550385|NCT02948426|Experimental|Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml)|Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
16550386|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the maximum tolerated dose (MTD)
16550387|NCT02948413||Single Group of patients with Cancer|Patients with cancer (lymphoma, leukemia, prostate cancer, and mesothelioma) on clinical trials at the NIH Clinical Center.
16550388|NCT02948400|Experimental|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
16550389|NCT02948400|Active Comparator|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
16550390|NCT02948374||Delirium positive|Patients with a positive CAM-ICU test
16550391|NCT02948374||Delirium negative|Patient without delirium determined with the CAM-ICU test
16550392|NCT02948361|Experimental|QT Ultrasound breast scan|
16550393|NCT02948348|Experimental|Nivolumab & Ipilimumab(Only Cohort D)|chemoradiotherapy with capecitabine+ Nivolumab + Ipilimumab(Only Cohort D) + surgical therapy
16550394|NCT02948322|Experimental|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
16550395|NCT02948322|Active Comparator|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
16550396|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
16550397|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
16550398|NCT02948283|Experimental|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.
~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16550399|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
16550400|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
16550401|NCT02948244|Active Comparator|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
16550402|NCT02948244|Active Comparator|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
16550403|NCT02948231|Experimental|Mistral|
16550404|NCT02948218|Active Comparator|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
16550405|NCT02948218|Active Comparator|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
16550406|NCT02948218|Active Comparator|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
16550407|NCT02948218|Active Comparator|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
16550408|NCT02948205|Experimental|3D group|infertility patient get TU-LESS by 3D Laparoscopy
16550409|NCT02948205|Other|normal group|infertility patient get normal laparoscopic surgery
16550410|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
16550411|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
16550412|NCT02948179|Experimental|Preimplantation genetic diagnosis group|ADPKD patients will complete the whole process of preimplantation genetic diagnosis with healthy baby without pathogenic gene inheritance.
16550413|NCT02948179|No Intervention|Natural pregnancy group|ADPKD patients, pathogenic mutations in PKD1, have natural pregnancy without preimplantation genetic diagnosis.The investigators will perform genetic tests on the blood or umbilical cord blood of infants born between January 2014 and June 2020.
16550414|NCT02948166|Active Comparator|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
16551298|NCT02942251|Experimental|immunology|A group patients with significant high risk of immune disturbance.
16550415|NCT02948166|Experimental|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
16550416|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
16550417|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
16550418|NCT02948140|Experimental|Stroke|
16550419|NCT02948127|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
16550420|NCT02948127|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
16550421|NCT02948114|Active Comparator|Control: Cow milk-based infant formula|Cow milk-based infant formula
16550422|NCT02948114|Experimental|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
16550423|NCT02948114|Experimental|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
16550424|NCT02948114|Experimental|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
16550425|NCT02948114|No Intervention|Human Milk Reference|Human Milk Reference
16550426|NCT02948101|Experimental|Treatment (PD 0360324, cyclophosphamide)|Patients receive anti-CSF1 monoclonal antibody anti-CSF1 monoclonal antibody PD 0360324 IV over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide PO QD. Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16550427|NCT02948075|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x [GFR (ml/min) + 25] on Day 7 up to 6 cycles.
16550428|NCT02948036|Experimental|MMT|Mobile-device, plasticity-based adaptive cognitive treatment
16550429|NCT02948023|No Intervention|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
16550430|NCT02948023|Active Comparator|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
16550431|NCT02948010|Active Comparator|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
16550432|NCT02948010|Active Comparator|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
16550433|NCT02948010|Active Comparator|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
16550434|NCT02948010|Active Comparator|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
16550435|NCT02948010|Active Comparator|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
16550436|NCT02948010|Active Comparator|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
16550437|NCT02948010|Active Comparator|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
16550438|NCT02948010|Active Comparator|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
16550439|NCT02948010|Active Comparator|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
16550440|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
16550441|NCT02947984|Experimental|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
16550442|NCT02947984|Experimental|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
16550443|NCT02947971|Experimental|OFDI Imaging|Experimental OFDI Imaging
16550444|NCT02947958|Experimental|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
16550445|NCT02947958|Active Comparator|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
16550446|NCT02947945|Other|Open-Label|all subjects will receive the study medication- reslizumab.
16550447|NCT02947932|Experimental|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
16550448|NCT02947932|Active Comparator|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
16550449|NCT02947919|Experimental|Intervention|Music in the perioperative period
16550450|NCT02947919|No Intervention|Control|Usual treatment
16550451|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
16550452|NCT02947906||Control Group|Healthy participants
16550453|NCT02947893|Placebo Comparator|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
16550554|NCT02947256|Experimental|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
~Operative procedure of by RI approach:"
16550454|NCT02947893|Active Comparator|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
16550455|NCT02947880|Experimental|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
16550456|NCT02947880|Placebo Comparator|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
16550457|NCT02947867|Experimental|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
16550458|NCT02947867|Experimental|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
16550459|NCT02947867|Placebo Comparator|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
16550460|NCT02947854|Experimental|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol [poly-ICLC]) followed by light application.
16550461|NCT02947854|Experimental|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
16550462|NCT02947854|Experimental|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
16550463|NCT02947841|Placebo Comparator|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
16550464|NCT02947841|Active Comparator|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
16550465|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
16550466|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
16550467|NCT02947815|Experimental|NABOTA|Single-dose
16550468|NCT02947815|Active Comparator|BOTOX|Single-dose
16550469|NCT02947802|Experimental|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
16550470|NCT02947802|Experimental|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
16550471|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
16550472|NCT02947776|Active Comparator|USUAL|Usual care
16550473|NCT02947776|Experimental|PEER|Usual care + peer-befriending
16550474|NCT02947763|Active Comparator|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
16550475|NCT02947763|No Intervention|single visit|single visit root canal treatment without any intra-canal medication
16550476|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
16550477|NCT02947750|Active Comparator|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
16550478|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
16550479|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
16550480|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
16550481|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
16550482|NCT02947737|Experimental|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
16550483|NCT02947737|Active Comparator|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
16550484|NCT02947724|No Intervention|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
16550485|NCT02947724|No Intervention|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
16612373|NCT02531815|Experimental|Cohort 7 (IV) PF-06741086, Placebo|
16550488|NCT02947711|Experimental|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
16550489|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
16550490|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
16550491|NCT02947685|Experimental|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
16550492|NCT02947685|Active Comparator|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
16550493|NCT02947672|Active Comparator|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
16550494|NCT02947672|Active Comparator|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
16550495|NCT02947646|Experimental|BabyGentleStick™ ON|Experimental intervention to be compared to the Active Comparator.
16550496|NCT02947646|Active Comparator|BabyGentleStick™ OFF|Active Comparator intervention to be compared to the Experimental Treatment.
16550497|NCT02947633|Experimental|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
16550498|NCT02947633|Active Comparator|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
16550499|NCT02947620|Active Comparator|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
16550500|NCT02947620|Placebo Comparator|Metformin|Metformin, QD
16550501|NCT02947620|Placebo Comparator|Atorvastatin|Atorvastatin, QD
16550502|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
16550503|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
16550504|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
16550507|NCT02947568||CKD|chronic kidney disease
16550508|NCT02947568||DM|diabetes mellitus
16550509|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
16550510|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
16550511|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
16550512|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
16550513|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
16550514|NCT02947542|Experimental|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
16550515|NCT02947542|Experimental|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
16550516|NCT02947542|Active Comparator|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
16550517|NCT02947529|Experimental|Hemiarthroplasty|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
16550518|NCT02947529|Experimental|Intramedullary nail|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
16550519|NCT02947516|Active Comparator|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
16550520|NCT02947516|Experimental|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
16550521|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin HCL 850 CF (1-3 times daily) added to usual care from start of the diagnosis GDM.
~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.
~Intervention: metformin HCF 850 CF (1-3 times daily) on top of usual care."
16550522|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.
~Intervention: usual care."
16550523|NCT02947490|Sham Comparator|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
16551359|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
16550524|NCT02947490|Placebo Comparator|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week & arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
16550525|NCT02947490|Active Comparator|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse & supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
16550526|NCT02947477|Experimental|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
16550527|NCT02947477|No Intervention|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
16550528|NCT02947464|Active Comparator|Control|Standard clinical practice
16550529|NCT02947464|Experimental|Intervention|Standard clinical practice + Rapid Maxillary Expansion
16550530|NCT02947451|Experimental|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
16550531|NCT02947451|Experimental|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
16550532|NCT02947438|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU
~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
16550533|NCT02947438|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU
~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
16550534|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
16550535|NCT02947399|Other|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
16550537|NCT02947373|Other|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
16550538|NCT02947360|Experimental|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
16550539|NCT02947347|Experimental|(Part 1 : Arm A) ibrutinib + rituximab|"Subjects will receive 560mg of ibrutinib and rituximab 375mg/m^2 weekly x4 with maintenance.
~In Part 1, Arm A to Arm B ratio is 3:1"
16550540|NCT02947347|Placebo Comparator|(Part 1 : Arm B) placebo + rituximab|"Subjects will receive placebo and rituximab 375mg/m^2 weekly x4 with maintenance.
~In Part 1, Arm A to Arm B ratio is 3:1"
16550541|NCT02947347|Experimental|(Part 2 : Arm A1) ibrutinib|"Subjects will receive 560mg of ibrutinib
~Part 1 Arm A subjects will be re-randomized 1:1 into Part 1 Arm A1 or Arm A2"
16550542|NCT02947347|Placebo Comparator|(Part 2 : Arm A2) placebo|"Subjects will receive placebo
~Part 1 Arm A subjects will be re-randomized 1:1 into Part 2 Arm A1 or Arm A2"
16550543|NCT02947334|Experimental|Bococizumab|Bococizumab Q2wks
16550544|NCT02947334|Placebo Comparator|Placebo|Bococizumab placebo Q2wks
16550545|NCT02947321|Experimental|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
16550546|NCT02947321|Sham Comparator|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
16550547|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
16550548|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
16550549|NCT02947282|Active Comparator|Intervention|Educational Workshop
16550550|NCT02947282|No Intervention|Control|They will continue regular prenatal care as planned
16550551|NCT02947269|Experimental|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
16550552|NCT02947269|Placebo Comparator|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
16550553|NCT02947256|Active Comparator|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
16550670|NCT02946528|Experimental|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
16550555|NCT02947243|Active Comparator|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
16550556|NCT02947243|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
16550557|NCT02947230|Experimental|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
16550558|NCT02947230|No Intervention|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
16550559|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
16550560|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
16550561|NCT02947204|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
16550562|NCT02947204|Experimental|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
16550563|NCT02947191|Experimental|Collagen membrane + HUC-MSCs|
16550564|NCT02947178|Active Comparator|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
16550565|NCT02947178|Active Comparator|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
16550566|NCT02947165|Experimental|NIS793|
16550567|NCT02947165|Experimental|NIS793 + PDR001|
16550568|NCT02947152|Experimental|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
16550569|NCT02947152|Experimental|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
16550570|NCT02947152|Experimental|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
16550571|NCT02947139|Experimental|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
16550572|NCT02947139|Experimental|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
16550573|NCT02947126|Experimental|Cystic Fibrosis (HS, IS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day,
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
16550574|NCT02947126|Experimental|Cystic Fibrosis (IS, HS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day.
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
16550575|NCT02947126|Experimental|Parents of CF subjects|"Ages 18 and older, biological parent of a CF patient who is also enrolled in the study
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)"
16550576|NCT02947126|Experimental|non CF controls|"Ages 18 and older with no history of lung disease
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)."
16550577|NCT02947113|Experimental|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
16550578|NCT02947100|Experimental|SCD-Omegatex™|single arm
16550579|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
16550580|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
16550581|NCT02947074|No Intervention|Control|Waiting list
16550582|NCT02947074|Experimental|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
16550583|NCT02947061|Experimental|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
16550584|NCT02947061|Active Comparator|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
16550585|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
16550586|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
16550587|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
16550588|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
16550589|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
16550590|NCT02947035|Experimental|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
16550591|NCT02947035|Experimental|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
16550592|NCT02947022|Experimental|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
16550671|NCT02946528|Active Comparator|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
16612374|NCT02531815|Experimental|Cohort 8 (subcutaneous [SC]) PF-06741086|
16550593|NCT02947009|Experimental|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.
~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
16550594|NCT02947009|Active Comparator|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.
~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
16550595|NCT02946996|Experimental|OPC|Subjects will take one OPC capsule at the same time each morning and evening, approximately 12 hours apart during weeks 1-12.
16550596|NCT02946983|Active Comparator|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
16550597|NCT02946983|Active Comparator|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
16550598|NCT02946983|Placebo Comparator|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
16550599|NCT02946983|Placebo Comparator|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
16550600|NCT02946970|Placebo Comparator|Control|Intragastric infusion
16550601|NCT02946970|Experimental|Quinine hydrochloride|Intragastric infusion
16550602|NCT02946957|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
16550603|NCT02946957|Active Comparator|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
16550604|NCT02946944|Experimental|double drug therapy|
16550605|NCT02946944|Active Comparator|mono drug therapy|
16550606|NCT02946931||Prizbind|patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
16550607|NCT02946918|Experimental|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
16550608|NCT02946918|Experimental|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
16550609|NCT02946905||SCD participant|No intervention
16550610|NCT02946905||Non-SCD participant|No intervention
16550611|NCT02946892|Experimental|Carvedilol|Study participants will receive carvedilol for 12 weeks
16550612|NCT02946892|Experimental|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
16550613|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
16550614|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
16550615|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
16550616|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
16550617|NCT02946853|Active Comparator|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
16550618|NCT02946853|Experimental|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
16550619|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
16550620|NCT02946827|Experimental|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
16550621|NCT02946827|Active Comparator|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
16550622|NCT02946814|Active Comparator|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
16550623|NCT02946814|Experimental|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
16550624|NCT02946814|Sham Comparator|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
16550625|NCT02946801|Active Comparator|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
16550626|NCT02946801|Experimental|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
16550627|NCT02946801|Sham Comparator|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
16550628|NCT02946788|Experimental|BPX-01 1%|BPX-01 1% minocycline topical gel
16550629|NCT02946788|Experimental|BPX-01 2%|BPX-01 2% minocycline topical gel
16550630|NCT02946762|Other|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
16550631|NCT02946749||Shanghai First Maternity and Infant Hospital|
16550632|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
16550633|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
16550634|NCT02946749||The Sixth people's hospital of Shanghai|
16550635|NCT02946736|Experimental|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
16550636|NCT02946736|Experimental|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
16550637|NCT02946723|Experimental|US group|lead implantation surgery for SNM using ultrasound guided technique
16550638|NCT02946723|Sham Comparator|X-ray group|lead implantation surgery for SNM using X-ray guided technique
16550792|NCT02945592|Experimental|Intervention|"adaptive, therapeutic cueing during reading tasks
~adaptive, therapeutic cueing during visuo spatial tasks"
16550639|NCT02946697|No Intervention|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
16550640|NCT02946697|Experimental|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
16550641|NCT02946684|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
16550642|NCT02946684|Active Comparator|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
16550643|NCT02946671|Experimental|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
16550644|NCT02946671|Experimental|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
16550645|NCT02946671|Experimental|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
16550646|NCT02946658|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
16550647|NCT02946658|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
16550648|NCT02946658|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
16550649|NCT02946645|Active Comparator|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
16550650|NCT02946645|Active Comparator|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
16550651|NCT02946645|Placebo Comparator|Placebo|TMD placebo group.
16550652|NCT02946632|Experimental|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
16550653|NCT02946632|Active Comparator|Stepwise add-on therapy group|"Participants were started on metformin 1000mg once daily after screening & assignment
~At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
16550654|NCT02946619|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
16550655|NCT02946619|Experimental|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
16550656|NCT02946619|Experimental|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
16550657|NCT02946606|Experimental|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
16550658|NCT02946606|Experimental|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
16550659|NCT02946606|Experimental|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
16550660|NCT02946593|Experimental|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
16550661|NCT02946593|Active Comparator|Control|Participants in the control group will receive written information about preventing outdoor falls.
16550662|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
16550663|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
16550664|NCT02946567|Experimental|Noisy City|Participant will play the Noisy City game developed by this project.
16550665|NCT02946567|Placebo Comparator|Control|Participant will play a generic game.
16550666|NCT02946554|Other|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.
~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
16550667|NCT02946554|Other|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
16550668|NCT02946541|Experimental|evogliptin 5mg|evogliptin 5mg QD
16550669|NCT02946541|Placebo Comparator|placebo|Placebo QD
16550672|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
16550673|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
16550674|NCT02946502|Experimental|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
16550675|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
16550676|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
16550677|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
16550678|NCT02946463|Experimental|Ravulizumab|"Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.
~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
16550679|NCT02946463|Active Comparator|Eculizumab|"Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.
~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
16550680|NCT02946450||Not applicable-observational study|Not applicable-observational study
16550681|NCT02946437|Experimental|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.
~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
16550682|NCT02946437|Active Comparator|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
16550683|NCT02946437|Other|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
16550684|NCT02946424|Experimental|Simvastatin treatment|Simvastatin for one year time period
16550685|NCT02946424|Placebo Comparator|Placebo treatment|Placebo for one year time period
16550686|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
16550687|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
16550688|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
16550689|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
16550690|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
16550691|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
16550692|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
16550693|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
16550694|NCT02946372|Experimental|ILMT|internal limiting membrane autologous transplantation (ILMT)
16550695|NCT02946359|Experimental|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
16550696|NCT02946359|Experimental|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
16550793|NCT02945592|No Intervention|Control|- unspecific neglect treatment
16550697|NCT02946359|Experimental|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
16550698|NCT02946346|Experimental|Vaginal and blood sampling|
16550699|NCT02946333||Patient with MM who are not candidates for ASCT|Patients with newly diagnosed MM who are not candidates for ASCT and who are going to start drug treatment for the study disease and patient who is capable of understanding and filling in the study questionnaires At least 450 patients will be enrolled in a 2-year period. Patients must meet all of the inclusion criteria and none of the exclusion criteria and must have previously granted their informed consent in writing.
16550700|NCT02946320|Active Comparator|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
16550701|NCT02946320|Experimental|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
16550702|NCT02946320|Experimental|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
16550703|NCT02946307|Experimental|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter>2.00 mm） in small vessel cohort
16550704|NCT02946307|Active Comparator|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
16550705|NCT02946307|Other|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
16550706|NCT02946294|Active Comparator|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
16550707|NCT02946294|Active Comparator|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
16550708|NCT02946281|Experimental|Intervention|
16550709|NCT02946281|No Intervention|Care as usual|
16550710|NCT02946268|Experimental|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
16550711|NCT02946268|Experimental|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
16550712|NCT02946268|Experimental|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
16550713|NCT02946255|Experimental|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
16550714|NCT02946255|Experimental|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
16550715|NCT02946255|Active Comparator|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
16550716|NCT02946242|Other|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
16550717|NCT02946229|Other|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
16550718|NCT02946203|Active Comparator|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
16550719|NCT02946203|Active Comparator|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
16550720|NCT02946190|Experimental|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
16550926|NCT02944656|Experimental|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
16550721|NCT02946190|Active Comparator|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
16550722|NCT02946177|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
16550723|NCT02946177|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
16550724|NCT02946164|No Intervention|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
16550725|NCT02946164|Active Comparator|Intervention: 'Stick To It' Intervention|Behavioral intervention.
16550726|NCT02946151|Experimental|Implantation|Implantation of a subcutaneous electrode and connection to the external logging device
16550727|NCT02946138|Experimental|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
16550728|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
16550729|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
16550730|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
16550731|NCT02946112||Shoulder pain|volleyball players with shoulder pain
16550732|NCT02946112||No shoulder pain|volleyball players without shoulder pain
16550733|NCT02946099|Experimental|Reciproc file|Reciproc files in reciprocating motion
16550734|NCT02946099|Active Comparator|ProTaper Next file|ProTaper Next files in continuous rotary motion
16550735|NCT02946086|Experimental|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
16550736|NCT02946086|Active Comparator|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
16550737|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
16550738|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
16550739|NCT02946060|Sham Comparator|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
16550740|NCT02946060|Active Comparator|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
16550741|NCT02946060|Experimental|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
16550742|NCT02946047|Experimental|Treatment group|Patients will be given at least one treatment cycle of Ixazomib.
16550743|NCT02946034|Experimental|Treatment 1|12 week therapy with Viekira Pak ± ribavirin
16550744|NCT02946034|Experimental|Treatment 2|12 week therapy with Mavyret
16550745|NCT02946021|Experimental|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
16550746|NCT02946021|Experimental|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
16550747|NCT02946008|Experimental|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
16550748|NCT02945982|Placebo Comparator|Entecavir/Carvedilol|Tablet with Entrcavir and Carvedilol
16550749|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
16550750|NCT02945969|Experimental|Low Sodium Diet|Behavioral modification to decrease dietary sodium intake to ≤2,300 mg/day for 24 weeks. The intervention program consists of two phases. An initial 12-week intensive phase will include weekly individual and group sessions. This will be followed by a 12-week maintenance phase that includes telephone counseling sessions every 2 weeks.
16550751|NCT02945969|No Intervention|Usual Diet|No dietary intervention.
16550752|NCT02945956|Placebo Comparator|Entecavir|Tablet with Entrcavir
16550753|NCT02945956|Experimental|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
16550754|NCT02945943|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
16550755|NCT02945943|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
16550756|NCT02945891|Experimental|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
16550757|NCT02945865|Experimental|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
16550758|NCT02945865|No Intervention|Control arm: No treatment|Treatment us usual
16550759|NCT02945852|Experimental|refractory SCLC|Patients receive apatinib 500mg/d until progressive Disease(PD).
16550760|NCT02945839|Active Comparator|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
16550794|NCT02945579|Experimental|Treatment (whole breast irradiation, EBRT)|Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation.
16550761|NCT02945839|Active Comparator|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
16550762|NCT02945826|Experimental|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
16550763|NCT02945813|Experimental|Arm A: Metformin|"Metformin - 850mg PO BID; 48 weeks
~Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
16550764|NCT02945813|Active Comparator|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
16550765|NCT02945800|Experimental|Combination Therapy|Participants will receive nab-Paclitaxel and Gemcitabine on days 1, 8, and 15 of each 28 day cycle, for up to 12 cycles.
16550766|NCT02945787|Experimental|Extended Self-help|Spanish-Language Version of the Stop Smoking for Good: The Extended Self-help condition will comprise the 11 Stop Smoking for Good booklets and 9 supportive My Story pamphlets transcreated for Spanish speaking smokers.
16550767|NCT02945787|Active Comparator|Usual Care (UC)|NCI-Produced Spanish-language Self-help Booklet: The UC control condition enhances the external validity of the study by providing a comparison to an existing, credible intervention that a smoker could receive in a medical setting or elsewhere.
16550768|NCT02945774|Experimental|(18F)-FEPPA|
16550769|NCT02945761|Active Comparator|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
16550770|NCT02945761|Active Comparator|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
16550771|NCT02945735|Experimental|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
16550772|NCT02945735|Placebo Comparator|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
16550773|NCT02945722|Active Comparator|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
16550774|NCT02945722|Placebo Comparator|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
16550775|NCT02945709|Experimental|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
16550776|NCT02945709|Active Comparator|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
16550777|NCT02945709|Placebo Comparator|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
16550778|NCT02945696|No Intervention|Local port site injection|
16550779|NCT02945696|No Intervention|Ultrasound-guided nerve blocks|
16550780|NCT02945696|Experimental|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
16550781|NCT02945683|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
16550782|NCT02945683|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 3 months
16550783|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
16550784|NCT02945644|Placebo Comparator|Placebo|pill filled with inert material
16550785|NCT02945644|Active Comparator|Trazodone 50mg|
16550786|NCT02945644|Active Comparator|Trazodone 100mg|
16550787|NCT02945631|Experimental|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
16550788|NCT02945618|Experimental|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.
~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
16550789|NCT02945618|Active Comparator|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
16550790|NCT02945605|Experimental|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
16550791|NCT02945605|Active Comparator|Standard of Care|Participants in this group will receive standard care as directed by their physician.
16612537|NCT02530853|Experimental|Group A|Laser acupuncture
16550796|NCT02945566|Experimental|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
16550797|NCT02945566|Experimental|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
16550798|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
16550799|NCT02945553|Active Comparator|Microstimulation|Microstimulation
16550800|NCT02945527|Active Comparator|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
16550801|NCT02945527|Active Comparator|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
16550802|NCT02945527|No Intervention|No additional anti-edema treatment|No additional treatment
16550803|NCT02945501|Experimental|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
16550804|NCT02945501|Sham Comparator|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
16550805|NCT02945488|Experimental|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
16550806|NCT02945488|Experimental|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
16550807|NCT02945488|Experimental|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
16550808|NCT02945488|Active Comparator|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
16550809|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
16550810|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2
16550811|NCT02945475||overweight|Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2
16550812|NCT02945462|Experimental|autologous mesenchymal stem cells|"Intervention:
~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
16550813|NCT02945449|Experimental|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
16550814|NCT02945436|Active Comparator|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
16550815|NCT02945436|Experimental|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
16550816|NCT02945436|Experimental|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
16550817|NCT02945436|Experimental|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
16550818|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
16550819|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
16550820|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
16550821|NCT02945397|Active Comparator|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
16550822|NCT02945397|Active Comparator|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
16550823|NCT02945384|Experimental|Creating Connections|Dual-generation intervention: child component delivered in classroom setting, parent component delivered in small-group setting
16550824|NCT02945384|No Intervention|Head Start as usual|Regular Head Start curriculum
16550825|NCT02945371|Experimental|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.
~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.
~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
16550826|NCT02945371|Active Comparator|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
16550827|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
16550828|NCT02945332|Experimental|Required supervised walking|Device: Fitbit Flexes
16550829|NCT02945332|Active Comparator|Non-required supervised walking|Device: Fitbit Flexes
16550830|NCT02945306|Experimental|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
16550831|NCT02945306|Active Comparator|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
16550832|NCT02945293||Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
16550833|NCT02945280|Experimental|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
16550834|NCT02945267|Experimental|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
16550835|NCT02945267|Active Comparator|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
16550836|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
16550837|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
16550838|NCT02945241|Experimental|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
16550839|NCT02945241|Other|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
16550840|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
16550841|NCT02945215|Experimental|IBI301|
16550842|NCT02945215|Active Comparator|Rituximab|
16550843|NCT02945202|Other|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
16550844|NCT02945189||Peri menopausal|Participants aged 41-55 years
16550845|NCT02945189||post menopausal|participants aged 56-65 years
16550846|NCT02945176|Experimental|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.
~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation
~Accessories: MESOGRAPH reading device, Implant Injector"
16550847|NCT02945163|Experimental|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
16550848|NCT02945163|Active Comparator|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
16550849|NCT02945150|Experimental|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor
~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
16550850|NCT02945124|Experimental|Normal children with K Tape|
16550851|NCT02945124|No Intervention|Normal children without K Tape|
16550852|NCT02945124|Experimental|DCD with K Tape|
16550853|NCT02945124|No Intervention|DCD without K Tape|
16550854|NCT02945111|Experimental|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
16550855|NCT02945111|Active Comparator|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
16550856|NCT02945098|No Intervention|Control group|No intervention. Remained five minutes at rest.
16550857|NCT02945098|Placebo Comparator|Placebo group|Apply Kinesio Taping without tension.
16550858|NCT02945098|Experimental|KT group|Apply Kinesio Taping application with tension.
16550859|NCT02945085|Experimental|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
16550860|NCT02945085|Active Comparator|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
16550861|NCT02945072|Active Comparator|Sevoflurane group|general anesthesia will be maintained with sevoflurane
16550862|NCT02945072|Experimental|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
16550863|NCT02945059|Experimental|1|Patients will undergo reversible PVE before major hepatic resection.
16550864|NCT02945046|Placebo Comparator|Placebo|Participants will receive placebo administered via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injection at Weeks 4 and 8, respectively.
16550865|NCT02945046|Experimental|Fremanezumab 675 mg/Placebo/Placebo|Participants will receive placebo as an approximately 1-hour intravenous infusion followed by fremanezumab at 675 milligrams (mg) administered as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 and placebo administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
16550866|NCT02945046|Experimental|Fremanezumab 900/225/225 mg|Participants will receive fremanezumab at 900 mg administered via an approximately 1-hour intravenous infusion followed by 3 placebo subcutaneous injections at Week 0 and fremanezumab at 225 mg administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
16550867|NCT02945033|Experimental|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
16550868|NCT02945033|Placebo Comparator|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
16550869|NCT02945020|Experimental|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
16550870|NCT02945007|Experimental|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
16550871|NCT02945007|Experimental|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).
~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
16550872|NCT02945007|Experimental|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).
~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
16550873|NCT02945007|Experimental|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).
~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
16550874|NCT02945007|Experimental|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).
~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
16550875|NCT02945007|Experimental|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).
~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
16550876|NCT02945007|Experimental|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).
~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
16550877|NCT02945007|Experimental|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).
~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
16550878|NCT02944994|Experimental|Unified Protocol|Unified Protocol-psychotherapy
16550879|NCT02944994|Experimental|Routine Care|Routine Care psychotherapy comparison
16550880|NCT02944981|Experimental|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
16550881|NCT02944981|Placebo Comparator|Placebo|Patient receiving oral placebo tablet preoperatively
16550882|NCT02944968|Experimental|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
16550883|NCT02944955|Experimental|BLEX 404 Oral Liquid|"Part I:
~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.
~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.
~Part II:
~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.
~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
16550884|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
16550885|NCT02944929|Experimental|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
16550886|NCT02944929|No Intervention|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
16550887|NCT02944916|Experimental|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
16550888|NCT02944890|Experimental|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
16550889|NCT02944890|Active Comparator|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
16550890|NCT02944877|Experimental|intervention|experimental
16550891|NCT02944877|Other|control|Other
16550892|NCT02944864|Experimental|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16550893|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
16550927|NCT02944656|Placebo Comparator|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
16550928|NCT02944643|Experimental|Active group|Will get the mindfulness and support groups
16550929|NCT02944630|Experimental|Experimental:|Receiving psychotherapy and medical treatment.
16550930|NCT02944630|No Intervention|Control|Awaiting group: Receiving medical treatment.
16550931|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
16550894|NCT02944838|Active Comparator|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
16550895|NCT02944838|Active Comparator|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
16550896|NCT02944825|Active Comparator|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
16550897|NCT02944825|Active Comparator|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
16550898|NCT02944812|Experimental|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
16550899|NCT02944799|Active Comparator|Alendronate|Continues treatment with alendronate, 70mgs oral tablet once every week
16550900|NCT02944799|Placebo Comparator|Placebo|Placebo tablets, one every week
16550901|NCT02944786|Experimental|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
16550902|NCT02944786|No Intervention|Control|Standard care
16550903|NCT02944773|Experimental|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
16550904|NCT02944773|No Intervention|without FTD|20 infants use not a FTD in the procedure of daily weight
16550905|NCT02944760|Experimental|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
16550906|NCT02944760|Placebo Comparator|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
16550907|NCT02944747|Experimental|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
16550908|NCT02944747|Experimental|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
16550909|NCT02944747|Experimental|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
16550910|NCT02944747|No Intervention|Comparison|The participants will not receive any of the interventions that are focused in this study.
16550911|NCT02944734|Experimental|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
16550912|NCT02944734|Experimental|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
16550913|NCT02944734|Experimental|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
16550914|NCT02944734|Experimental|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
16550915|NCT02944734|Experimental|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
16550916|NCT02944734|Experimental|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
16550917|NCT02944734|Experimental|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
16550918|NCT02944734|Experimental|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
16550919|NCT02944721|Other|Transversal study|Patients who had surgery for breast cancer for 2 years or less
16550920|NCT02944721|Other|Longitudinal study|Patients that must be operated for a breast cancer
16550921|NCT02944708|Active Comparator|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
16550922|NCT02944708|Experimental|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
16550923|NCT02944708|Experimental|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
16550924|NCT02944682|Experimental|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
16550925|NCT02944682|No Intervention|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
16612538|NCT02530853|Sham Comparator|Group B|Simulation Laser acupuncture
16550932|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
16550933|NCT02944604|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
16550934|NCT02944578|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 12 weeks.
16550935|NCT02944578|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of a placebo once a week for 12 weeks.
16550936|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
16550937|NCT02944552|Experimental|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
16550938|NCT02944552|Experimental|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
16550939|NCT02944552|Active Comparator|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
16550940|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
16550941|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
16550942|NCT02944526|Experimental|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.
~3 successive blocks are realized at 1 week interval."
16550943|NCT02944526|Placebo Comparator|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.
~3 successive blocks are realized at 1 week interval."
16550944|NCT02944513|Experimental|Experimental|Subjects will receive the Quell device
16550945|NCT02944513|No Intervention|Control|Subjects will not receive the Quell device
16550946|NCT02944500|Experimental|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
16550947|NCT02944500|Experimental|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
16550948|NCT02944487|Experimental|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
16550949|NCT02944487|Experimental|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
16550950|NCT02944487|Placebo Comparator|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
16550951|NCT02944487|Placebo Comparator|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
16550952|NCT02944474|Experimental|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
16550953|NCT02944474|Experimental|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
16550954|NCT02944474|Experimental|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
16550955|NCT02944474|Experimental|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
16550956|NCT02944474|Placebo Comparator|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
16550957|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
16550958|NCT02944448|Active Comparator|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
16550959|NCT02944448|Active Comparator|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
16550960|NCT02944448|Active Comparator|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
16550961|NCT02944448|Placebo Comparator|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
16550962|NCT02944435|Experimental|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
16550963|NCT02944435|Active Comparator|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
16550964|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
16550965|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
16550966|NCT02944396|Experimental|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
16550967|NCT02944396|Experimental|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
16550968|NCT02944383|Experimental|Gemcabene 300 mg|Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
16550969|NCT02944383|Experimental|Gemcabene 600 mg|Participants received 600 mg Gemcabene orally, once daily for 12 weeks.
16550970|NCT02944383|Placebo Comparator|Placebo|Participants received matching placebo orally, once daily for 12 weeks.
16551085|NCT02943603|Experimental|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
16550971|NCT02944370|Experimental|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
16550972|NCT02944357|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo cystectomy during course 8.
~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
16550973|NCT02944344|Experimental|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
16550974|NCT02944344|Other|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
16550975|NCT02944318|Experimental|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
16550976|NCT02944318|No Intervention|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
16550977|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
16550978|NCT02944292|Experimental|All enrolled patients|"Study population:
~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned
~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
16550979|NCT02944279||Peking University Third Hospital|
16550980|NCT02944279||Beijing Friendship Hospital|
16550981|NCT02944279||Beijing Shijitan Hospital|
16550982|NCT02944279||Beijing Xiyuan Hospital|
16550983|NCT02944279||China-Japan Friendship Hospital|
16550984|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of > 50%, iii.Left ventricular end diastolic area of < 10 cm2 iv. VTI variation with respiration of < 12.5%, are grouped under the hypovolaemia group .
16550985|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
16550986|NCT02944253|Experimental|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates for 8 weeks.
16550987|NCT02944253|Experimental|Low energy diet 100 gram carbohydrates|isocaloric (4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 100 gram carbohydrates for 8 weeks.
16550988|NCT02944253|Experimental|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates for 8 weeks.
16550989|NCT02944227|Experimental|Lucentis|Lucentis fixed treatment
16550990|NCT02944214|Experimental|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
16550991|NCT02944214|Experimental|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
16550992|NCT02944201|Experimental|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
16550993|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
16550994|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
16550995|NCT02944175|Experimental|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
16550996|NCT02944175|Active Comparator|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
16550997|NCT02944162|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
16550998|NCT02944149|Active Comparator|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
16550999|NCT02944149|Experimental|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
16551086|NCT02943590|Placebo Comparator|Placebo|Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
16551002|NCT02944123|Other|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
16551003|NCT02944123|Experimental|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
16551004|NCT02944123|Experimental|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
16551005|NCT02944110|Active Comparator|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
16551006|NCT02944110|Placebo Comparator|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
16551007|NCT02944110|Active Comparator|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
16551008|NCT02944110|Placebo Comparator|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
16551009|NCT02944097|Experimental|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
16551010|NCT02944097|Experimental|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
16551011|NCT02944084|Experimental|Rice bran extract|2 g of unprocessed rice bran extract
16551012|NCT02944084|Experimental|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
16551013|NCT02944084|Experimental|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
16551015|NCT02944058|Active Comparator|Philos plate|Intervention is surgery with Philos plate
16551016|NCT02944058|Active Comparator|Multiloc nail|Intervention is surgery with Multiloc nail
16551017|NCT02944045|Placebo Comparator|Placebo|Saline serum, same volume as in the Experimental arm.
16551018|NCT02944045|Experimental|Steroids|"Methylprednisolone intra veinous
~Day 1 to 5 : 30mg twice per day
~Day 6 to 10 : 30mg per day
~Day 11 to 21 : 20mg per day"
16551019|NCT02944032|Experimental|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
16551020|NCT02944032|Active Comparator|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
16551021|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
16551022|NCT02943993||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
16551023|NCT02943980|Experimental|CMAC Videolaryngoscope|tracheal intubation using CMAC
16551024|NCT02943980|Experimental|Macintosh laryngoscope|tracheal intubation using Macintosh laryngoscope
16551025|NCT02943967|Active Comparator|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.
~Both procedures will have the same post operative treatment :
~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
16551026|NCT02943967|Active Comparator|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.
~Both procedures will have the same post operative treatment :
~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
16551027|NCT02943954|Other|Angiography guided PCI|Revascularisation of non-culprit lesions guided by PCI
16551028|NCT02943954|Other|FFR guided PCI|Revascularisation of non-culprit lesions guided by FFR measurement
16551029|NCT02943941|Other|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
16551587|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
16551030|NCT02943928|Experimental|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis.
16551031|NCT02943928|Experimental|Traditional method by experience|Operator inserted the double lumen tube by experience
16551032|NCT02943915|Experimental|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
16551033|NCT02943915|Active Comparator|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
16551034|NCT02943915|No Intervention|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
16551035|NCT02943902|Experimental|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
16551036|NCT02943902|Experimental|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
16551037|NCT02943902|Experimental|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
16551038|NCT02943902|Experimental|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
16551039|NCT02943902|Active Comparator|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
16551040|NCT02943902|Active Comparator|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
16551041|NCT02943889|Experimental|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
16551042|NCT02943889|No Intervention|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
16551043|NCT02943876|No Intervention|Control|Serves as a control group, receiving generic information about depression and self-help.
16551044|NCT02943876|Experimental|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
16551045|NCT02943863|Active Comparator|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
16551046|NCT02943863|Active Comparator|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
16551047|NCT02943850|Experimental|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
16551048|NCT02943837|Active Comparator|EUS-FNA|Device: 22G FNA needle
16551049|NCT02943837|Experimental|EUS-FNB|Device: 20G FNB needle
16551050|NCT02943824|Experimental|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
16551051|NCT02943824|Active Comparator|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
16551052|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
16551053|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
16551054|NCT02943798|Experimental|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
16551055|NCT02943798|Experimental|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
16551056|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet for transitioning at end of treatment. Dosing must follow the locally approved label.
16551057|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
16551058|NCT02943772|Experimental|Local hypothermia|Local application of a brick cooled to -20(celsius)
16551059|NCT02943772|Sham Comparator|Control|Local application of a brick in room temperature
16551060|NCT02943759|Experimental|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
16551061|NCT02943759|Active Comparator|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
16551087|NCT02943590|Experimental|Atorvastatin|Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
16551088|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16551128|NCT02943317|Experimental|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
16551064|NCT02943733|Experimental|TAS-102 and TMZ|"Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ). Treatment cycles are 28 days, with TAS-102 administered orally twice daily days 1-5 and 8-12, and TMZ administered orally days 8-12. No treatment medications administered days 13-28 of each cycle. Growth factor support is required during Part 1 and should be dosed per institutional standards.
~Part 2: expansion phase to evaluate preliminary efficacy of MTD. Subjects treated with the recommended phase 2 drug doses determined in part 1. Treatment will continue for up to 13 cycles (approx. 12 months). Growth factor support is allowed during Part 2 and should be dosed per institutional standards."
16551065|NCT02943720|Placebo Comparator|placebo|5 SC injections in 2 months
16551066|NCT02943720|Experimental|AllerT 50 ug|5 SC injections in 2 months
16551067|NCT02943720|Experimental|AllerT 10 ug|5 SC injections in 2 months
16551068|NCT02943707|Experimental|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
16551069|NCT02943707|Active Comparator|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
16551070|NCT02943694|Experimental|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
16551071|NCT02943681|Experimental|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
16551072|NCT02943681|No Intervention|Control|Nothing
16551073|NCT02943668|Experimental|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
16551074|NCT02943655|Active Comparator|combined oral contraceptives|oral second generation pills one tablet daily
16551075|NCT02943655|Active Comparator|medroxyprogesterone acetate|oral 5 mg daily
16551076|NCT02943655|Active Comparator|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
16551077|NCT02943642|Experimental|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
16551078|NCT02943642|Active Comparator|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
16551079|NCT02943642|Experimental|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
16551080|NCT02943629|Experimental|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
16551081|NCT02943629|Other|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
16551082|NCT02943629|Experimental|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
16551083|NCT02943629|Other|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
16551084|NCT02943616|Experimental|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
16551122|NCT02943382|Experimental|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
16551089|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16551090|NCT02943564|Experimental|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16551091|NCT02943564|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16551092|NCT02943564|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16551093|NCT02943551|Other|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.
~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
16551094|NCT02943551|Other|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.
~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
16551095|NCT02943538|Experimental|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
16551096|NCT02943538|Experimental|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
16551097|NCT02943538|Active Comparator|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
16551098|NCT02943525|Experimental|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
16551099|NCT02943525|No Intervention|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
16551100|NCT02943512|Experimental|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
16551101|NCT02943512|No Intervention|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
16551102|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
16551103|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
16551104|NCT02943486|Experimental|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
16551105|NCT02943486|Active Comparator|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
16551106|NCT02943486|Active Comparator|Fitostimoline|Topical application of fitostimoline every other day
16551107|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
16551108|NCT02943460|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
16551109|NCT02943460|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
16551110|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
16551111|NCT02943460|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
16551112|NCT02943447|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
16551113|NCT02943447|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
16551114|NCT02943447|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
16551115|NCT02943447|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
16551116|NCT02943434|Other|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
16551117|NCT02943434|Other|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
16551118|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
16551119|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
16551120|NCT02943395|Experimental|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
16551121|NCT02943395|Active Comparator|light cured adhesive resin cement|resin cement that only get activated by light
16612686|NCT02529917|Experimental|Hemp powder|Hemp powder supplement
16551129|NCT02943317|Experimental|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
16551130|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
16551131|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
16551132|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
16551133|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
16551134|NCT02943278|Placebo Comparator|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
16551135|NCT02943278|Active Comparator|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
16551136|NCT02943265|Experimental|Complex Care Survivors|Patients eligible for the study who will receive Care Coordination Strategies.
16551137|NCT02943252|Experimental|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
16551138|NCT02943239|Experimental|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
16551139|NCT02943239|Experimental|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
16551140|NCT02943239|Experimental|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
16551141|NCT02943239|Experimental|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
16551142|NCT02943239|Experimental|Panel E|REGN2477 (Regimen 5) or placebo
16551143|NCT02943239|Experimental|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
16551144|NCT02943239|Experimental|Panel G|REGN2477 (Regimen 7) or placebo
16551145|NCT02943226|Experimental|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
16551146|NCT02943226|Active Comparator|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
16551147|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
16551148|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
16551149|NCT02943187|Experimental|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
16551150|NCT02943174|Experimental|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 6 to 12 participants).
~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
16551151|NCT02943174|Other|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
16551152|NCT02943161|Experimental|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
16551153|NCT02943135|Active Comparator|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
16551154|NCT02943135|Placebo Comparator|placebo|Self-administered gel 10 min before intrauterine device insertion
16551155|NCT02943109|Experimental|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
16551156|NCT02943109|Experimental|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
16551157|NCT02943109|Experimental|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
16551158|NCT02943109|Experimental|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
16551159|NCT02943096|Active Comparator|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
16551160|NCT02943096|Placebo Comparator|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
16551161|NCT02943083|Experimental|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
16551162|NCT02943083|Active Comparator|Home Intervention|Only perform relaxation exercise at home
16551163|NCT02943083|No Intervention|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
16551164|NCT02943083|No Intervention|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
16551165|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
16551166|NCT02943057|Experimental|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
16551167|NCT02943031|Experimental|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
16551168|NCT02943018||anovaginal distance variation|3 measurements
16551299|NCT02942251|Experimental|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
16551169|NCT02943005|Active Comparator|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
16551170|NCT02943005|Experimental|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
16551171|NCT02942992|No Intervention|Control|Usual Care Group
16551172|NCT02942992|Other|Intervention|Intervention Group
16551173|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
16551174|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
16551175|NCT02942966|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
16551176|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
16551177|NCT02942940|Active Comparator|mobile app|
16551178|NCT02942940|Active Comparator|in-person|
16551179|NCT02942927|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:
~Medication reconciliation
~Identification of patient priorities for care
~Identification of medications that are potentially appropriate for discontinuation/dose reduction
~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
~Identification of medications for trial of discontinuation/dose reduction (shared decision making)
~Pause of medication and clinical monitoring"
16551180|NCT02942927|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
16551181|NCT02942914|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
16551182|NCT02942914|Placebo Comparator|Placebo|Placebo (sterile saline) administered SC.
16551183|NCT02942914|Active Comparator|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
16551184|NCT02942888|Active Comparator|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
16551185|NCT02942888|Experimental|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
16551186|NCT02942875|Experimental|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
16551187|NCT02942875|Active Comparator|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
16551188|NCT02942823|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
16551189|NCT02942823|No Intervention|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
16551190|NCT02942810|Experimental|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
16551191|NCT02942797||NRS 2002 score ≥ 3|
16551192|NCT02942797||NRS 2002 score < 3|
16551193|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
16551194|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
16551195|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
16551196|NCT02942771|Experimental|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
16551197|NCT02942771|Placebo Comparator|Placebo|No drug intervention.
16551198|NCT02942758|Experimental|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
16551199|NCT02942758|Active Comparator|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
16551200|NCT02942745|Placebo Comparator|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
16551201|NCT02942745|Experimental|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
16551202|NCT02942732|Other|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
16551203|NCT02942732|Other|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
16551261|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
16551204|NCT02942732|Other|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
16551205|NCT02942732|Other|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
16551206|NCT02942719||Shanghai First Maternity and Infant Hospital|
16551207|NCT02942719||Dalian Maternity and Child Health Hospital|
16551208|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
16551209|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
16551210|NCT02942719||The Children and Women's Healthcare of Laiwu City|
16551211|NCT02942719||Suzhou Municipal Hospital|
16551212|NCT02942719||Wenling Women's and Children's Hospital|
16551213|NCT02942719||First Affiliated Hospital of Kunming Medical University|
16551214|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
16551215|NCT02942719||Xinxiang Maternity and Child Health Hospital|
16551216|NCT02942719||Yanshi People's Hospital|
16551217|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
16551218|NCT02942719||Northwest Women and Children's Hospital|
16551219|NCT02942719||Suining Central Hospital|
16551220|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
16551221|NCT02942719||Fujian Province Maternity and Child Health Hospital|
16551222|NCT02942719||Qinghai Red Cross Hospital|
16551223|NCT02942719||Xinjiang Maternity and Child Health Hospital|
16551224|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
16551225|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
16551226|NCT02942706|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
16551227|NCT02942706|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
16551228|NCT02942693|Experimental|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
16551229|NCT02942693|Experimental|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
16551230|NCT02942680|Experimental|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
16551231|NCT02942680|Other|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
16551232|NCT02942667||Subjects undergoing high quality MRI Scans|
16551233|NCT02942654|Experimental|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
16551234|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
16551235|NCT02942641|Experimental|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
16551236|NCT02942641|Experimental|Clean intermittent catheterization (CIC)|CIC as the intervention .
16551237|NCT02942628|Experimental|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
16551238|NCT02942628|Active Comparator|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
16551239|NCT02942615|Experimental|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
16551240|NCT02942615|No Intervention|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
16551241|NCT02942602|Experimental|Atorvastatin 20 mg|lipid lowering treatment
16551242|NCT02942602|Experimental|Cholestyramine 8 g|lipid lowering treatment
16551243|NCT02942602|Experimental|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
16551244|NCT02942602|Experimental|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
16551245|NCT02942602|Active Comparator|Life style modification for management of dyslipidemia|
16551246|NCT02942589|Experimental|100% Portions|Meal portion size: 100%
16551247|NCT02942589|Experimental|125% Portions|Meal portion size: 125%
16551248|NCT02942589|Experimental|150% Portions|Meal portion size: 150%
16551249|NCT02942589|Experimental|175% Portions|Meal portion size: 175%
16551250|NCT02942576|Experimental|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
16551251|NCT02942576|Active Comparator|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
16551252|NCT02942563|Experimental|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
16551253|NCT02942550|Active Comparator|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
16551254|NCT02942550|Placebo Comparator|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
16551255|NCT02942537|Experimental|Intervention|Microwave treatment
16551256|NCT02942537|Active Comparator|Control|Uterine artery embolization
16551257|NCT02942524|Experimental|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
16551258|NCT02942498|Experimental|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
16551259|NCT02942498|Placebo Comparator|Placebo|Placebo solution
16551260|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
16551297|NCT02942251|Experimental|Psycho-social|A group patients with significant high risk of psycho-social problems.
16551262|NCT02942459|Experimental|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).
~A Manual is created and trained with the Music Therapists, which distinguishes between
~Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,
~Essential but not Unique Principles,
~Acceptable but not necessary Principles,
~Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
16551263|NCT02942459|Active Comparator|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.
~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
16551264|NCT02942446|Experimental|Headgear|Investigative Headgear with CPAP mask
16551265|NCT02942433|Experimental|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
16551266|NCT02942433|Other|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
16551267|NCT02942420|Experimental|Dose Group A|Bucillamine 300 mg/day
16551268|NCT02942420|Experimental|Dose Group B|Bucillamine 600 mg/day
16551269|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
16551270|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
16551271|NCT02942381|Active Comparator|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
16551272|NCT02942381|Placebo Comparator|Placebo|Placebo and supportive treatment
16551273|NCT02942368|Experimental|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
16551274|NCT02942355|Experimental|Cohort A: First-line therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
16551275|NCT02942355|Experimental|Cohort B: Maintenance therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
16551276|NCT02942329|Experimental|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
16551277|NCT02942316|Experimental|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
16551278|NCT02942303|Active Comparator|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
16551279|NCT02942303|Active Comparator|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
16551280|NCT02942290|Experimental|Venetoclax + Azacitidine|
16551281|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
16551282|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
16551283|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
16551284|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
16551285|NCT02942277|Experimental|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
16551286|NCT02942277|Experimental|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
16551287|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
16551288|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
16551289|NCT02942277|Active Comparator|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
16551290|NCT02942277|Active Comparator|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
16551291|NCT02942277|Active Comparator|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
16551292|NCT02942264|Experimental|Phase I Arm 1 Dose Dense Temozolomide plus Zotiraciclib (TG02)|dose dense (dd) Temozolomide (TMZ) 125 mg/m^2 x 7 days on / 7 days off plus Zotiraciclib (TG02) dose escalation
16551293|NCT02942264|Experimental|Phase I Arm 2 Metronomic Temozolomide Plus Zotiraciclib (TG02)|metronomic Temozolomide (TMZ) 50 mg/ m^2 daily plus Zotiraciclib (TG02) dose escalation
16551294|NCT02942264|Experimental|Phase II Arm 1 Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) Plus Temozolomide (TMZ)|"Maximum tolerated dose (MTD) of Zotiraciclib (TG02) from phase I plus and winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I"
16551295|NCT02942264|Active Comparator|Phase II Arm 2 Metronomic Temozolomide (TMZ)|"winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I alone"
16551296|NCT02942251|Experimental|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
16551300|NCT02942251|Experimental|Comorbidity|A group patients with physical or mental disorders comorbidities.
16551301|NCT02942251|Experimental|Treatment as usual|Control group.
16551302|NCT02942238|Experimental|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
16551303|NCT02942238|Active Comparator|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
16551304|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
16551305|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
16551306|NCT02942212|Experimental|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.
~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
16551307|NCT02942212|Active Comparator|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.
~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
16551308|NCT02942212|Experimental|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.
~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.
~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
16551309|NCT02942199|Experimental|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
16551310|NCT02942173|No Intervention|CD45RA-|
16551311|NCT02942173|Experimental|CD45RA+|
16551312|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
16551313|NCT02942147|Active Comparator|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
16551314|NCT02942147|Active Comparator|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
16551315|NCT02942147|Active Comparator|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
16551316|NCT02942121|Experimental|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
16551317|NCT02942108|Active Comparator|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
16551318|NCT02942108|Experimental|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
16551319|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.
~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
16551320|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.
~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
16551321|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.
~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
16551322|NCT02942082|Experimental|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
16551323|NCT02942082|Placebo Comparator|glycrin|glycrin will be applied on tooth before and /or after bleaching.
16551324|NCT02942056|Experimental|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
16551325|NCT02942056|Placebo Comparator|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
16551326|NCT02942043|Experimental|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
16551327|NCT02942043|Experimental|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
16551328|NCT02942043|Experimental|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
16551329|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
16551330|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
16551331|NCT02942017|Placebo Comparator|Placebo|Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
16551332|NCT02942017|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
16551333|NCT02942004|Placebo Comparator|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
16551334|NCT02942004|Experimental|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
16551335|NCT02942004|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
16551336|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
16551337|NCT02941978|Experimental|Subject on Motivational Interview|"Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician for an interactive session and will be given an educational leaflet. Both methods will aim to educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.
~Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient, aiming to improve adherence to OAC."
16551338|NCT02941978|Active Comparator|Subject Control|Patients assigned to the control group will receive usual treatment and will be contacted via telephone for a pre-specified interview at 1 year after discharge for outcome assessment.
16551339|NCT02941965|Experimental|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
16551340|NCT02941965|Experimental|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.
~A maximum of 2 embryos will be transferred for each treatment cycle."
16551341|NCT02941939|Active Comparator|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
16551342|NCT02941939|Experimental|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
16551344|NCT02941913|Experimental|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
16551345|NCT02941913|Experimental|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
16551346|NCT02941900||Non-melanoma skin cancers (NMSCs)|
16551347|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
16551348|NCT02941874||Healthy volunteers IRAP measurement|
16551349|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
16551350|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
16551351|NCT02941848|Experimental|Group1|"C → A + B
~A : HGP0816 B : HGP1404 C : HCP1306"
16551352|NCT02941848|Experimental|Group2|"A + B → C
~A : HGP0816 B : HGP1404 C : HCP1306"
16551353|NCT02941835|Other|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
16551354|NCT02941822|Experimental|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:
~Day 1-7, 60 mg
~Day 8-14, 120 mg
~Day 15-21, 180 mg
~Day 22-28, 300 mg
~Day 29-186, 420 mg"
16551355|NCT02941809|Experimental|Open-Label Placebo (OLP)|Participants who are randomly assigned to group OLP will receive placebo pills. In Phase 1 of the study (first two weeks), participants in this group are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), OLP participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. OLP participants will meet with the study team at five time points: at baseline (entry into treatment), 2 weeks post-baseline, and 1-, 2- and 3-months post-baseline.
16551356|NCT02941809|No Intervention|Treatment as Usual (TAU)|Participants assigned to TAU will not be given placebo pills, but all interactions with the study team (5 meetings total) will be matched in frequency and length.
16551357|NCT02941796|Experimental|Sequence 1|"T → R
~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
16551358|NCT02941796|Experimental|Sequence 2|"R → T
~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
16551360|NCT02941770|No Intervention|Control group|"Clinic standard care protocol:
~Baseline evaluation session with a Pediatrician for initial screening;
~Appointment with a Dietitian;
~A brochure with physical activity guidelines for youth with examples of physical exercises."
16551361|NCT02941770|Experimental|Intervention group I|"Clinic standard care protocol;
~Physical activity consultation (Physical activity behavior change);"
16551362|NCT02941770|Experimental|Intervention group II|"Clinic standard care protocol;
~Physical activity consultation;
~2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
16551363|NCT02941757|Experimental|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
16551364|NCT02941757|No Intervention|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
16551365|NCT02941744|Experimental|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
16551366|NCT02941731|Experimental|Sequence 1|HIP1403→HGP0919
16551367|NCT02941731|Experimental|Sequence 2|HGP0919→HIP1403
16551368|NCT02941718|Experimental|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.
~Smoking Cessation intervention components include:
~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)
~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.
~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
16551369|NCT02941718|Active Comparator|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.
~Smoking Cessation intervention components include:
~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)
~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.
~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
16551370|NCT02941705|Active Comparator|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
16551371|NCT02941705|Placebo Comparator|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
16551372|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
16551373|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
16551374|NCT02941679|Experimental|HCP1202|Test
16551375|NCT02941679|Active Comparator|HGP1011|Control
16551376|NCT02941679|Active Comparator|HCP0910|Control
16551377|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
16551378|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
16551379|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
16551380|NCT02941653|Active Comparator|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
16551381|NCT02941653|Experimental|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
16551382|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
16551383|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
16551384|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
16551385|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
16551386|NCT02941627|Experimental|Cochlear Implant|Neuro Cochlear Implant System
16551387|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
16551388|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
16551389|NCT02941601|Experimental|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
16551390|NCT02941601|Experimental|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
16551391|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
16551392|NCT02941575|Active Comparator|Control|Implant superstructure crown: All ceramic, IPS Emax
16551393|NCT02941575|Experimental|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
16551394|NCT02941562|Experimental|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
16551395|NCT02941562|Active Comparator|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
16551396|NCT02941549|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
16612687|NCT02529917|Active Comparator|Soy powder|Soy powder supplement
16551397|NCT02941549|Experimental|500 mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
16551398|NCT02941549|Experimental|1000 mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
16551399|NCT02941536|Other|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
16551400|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:
~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
16551401|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.
~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
16551402|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.
~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
16551403|NCT02941510|Experimental|Budesonide|Will participate in all study activities but will receive budesonide.
16551404|NCT02941510|Placebo Comparator|Placebo|Will participate in all study activities but will receive placebo.
16551405|NCT02941497|Experimental|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
16551406|NCT02941497|Experimental|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
16551407|NCT02941484|Experimental|1 early oral intake|early oral intake since postoperative day 1.
16551408|NCT02941484|Experimental|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
16551409|NCT02941471|Experimental|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
16551410|NCT02941471|Active Comparator|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
16551411|NCT02941458||Non-small cell lung cancer|patients treated for a non small cell lung cancer
16551412|NCT02941458||Small cell lung cancer|patients treated for a small cell lung cancer
16551413|NCT02941458||Mesotelioma|patients treated for a mesotelioma
16551414|NCT02941458||timic cancer|patients treated for a timic cancer
16551415|NCT02941458||carcinoid cancer|patients treated for a carcinoid cancer
16551416|NCT02941445|Experimental|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
16551417|NCT02941445|Experimental|MET (metformin)|metformin 1000 mg BID
16551418|NCT02941432|Other|Black tea|Black tea compress treatment
16551419|NCT02941419|Experimental|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
16551420|NCT02941406||Healthy subjects|"Men and Women aged 18 and older
~Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
~Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
16551421|NCT02941406||Age-related macular degeneration patients|"Men and Women aged 18 and older
~Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
16551422|NCT02941393|Active Comparator|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
16551423|NCT02941393|Active Comparator|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
16551424|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
16551425|NCT02941367|Experimental|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
16551426|NCT02941367|Active Comparator|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
16551427|NCT02941354|Experimental|Turoctocog alfa|
16551428|NCT02941328|Experimental|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
16551429|NCT02941328|Placebo Comparator|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
16551430|NCT02941315|Experimental|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
16551465|NCT02941081|Active Comparator|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
16551431|NCT02941315|Placebo Comparator|etiology unconfirmed without acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
16551432|NCT02941315|Placebo Comparator|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
16551433|NCT02941315|Experimental|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
16551434|NCT02941302|Experimental|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
16551435|NCT02941289|Experimental|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
16551436|NCT02941289|Active Comparator|Control patient|patient with MMSE score equal or > 27
16551437|NCT02941276|Experimental|Group A|Active electrostimulator device
16551438|NCT02941276|Sham Comparator|Group B|Sham electrostimulator device
16551439|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with AMD.
16551440|NCT02941250|Experimental|treatment|patients receiving ISSD emulator
16551441|NCT02941237|Other|Healthcare worker measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
16551442|NCT02941237|Other|Expert measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
16551443|NCT02941224|Experimental|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
16551444|NCT02941211|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
16551445|NCT02941198|Active Comparator|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
16551446|NCT02941198|Active Comparator|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
16551447|NCT02941185|Other|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
16551448|NCT02941185|Active Comparator|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
16551449|NCT02941185|Active Comparator|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
16551450|NCT02941172|Other|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
16551451|NCT02941172|Other|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
16551452|NCT02941172|Other|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
16551453|NCT02941159|Active Comparator|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
16551454|NCT02941159|Placebo Comparator|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
16551455|NCT02941146|Experimental|Zeltiq Dual Sculpting Treatment Group|All subjects treated with CoolSculpting System using the CoolAdvantage and CoolAdvantage Plus applicators simultaneously on the abdomen.
16551456|NCT02941133|Experimental|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
16551457|NCT02941133|Experimental|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
16551458|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
16551459|NCT02941107|Experimental|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
16551460|NCT02941107|Placebo Comparator|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
16551461|NCT02941094|Active Comparator|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
16551462|NCT02941094|Active Comparator|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
16551463|NCT02941094|Active Comparator|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
16551464|NCT02941081|Experimental|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
16551466|NCT02941081|Placebo Comparator|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
16551467|NCT02941068|Experimental|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
16551468|NCT02941068|No Intervention|Empirical group|
16551469|NCT02941055|Experimental|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
16551470|NCT02941055|Active Comparator|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
16551471|NCT02941042|Experimental|NNC9204-1177|
16551472|NCT02941042|Placebo Comparator|Placebo|
16551473|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
16551474|NCT02941016|Experimental|Lipid lowering|
16551475|NCT02941003|Experimental|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
16551476|NCT02941003|Experimental|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
16551477|NCT02940990|Placebo Comparator|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
16551478|NCT02940990|Experimental|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
16551479|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
16551480|NCT02940964|Experimental|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
16551481|NCT02940964|Active Comparator|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
16551482|NCT02940951|Other|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
16551483|NCT02940951|Experimental|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) to document, monitor and address the quality of life concerns of patients and family caregivers.
16551484|NCT02940938|Experimental|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
16551485|NCT02940925|Experimental|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT)."
16551486|NCT02940925|Active Comparator|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
16551487|NCT02940912|Active Comparator|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
16551488|NCT02940912|Placebo Comparator|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
16551489|NCT02940899|Active Comparator|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
16551490|NCT02940899|Active Comparator|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
16551491|NCT02940886|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
16551492|NCT02940886|Active Comparator|Iron sucrose|Administered IV
16551493|NCT02940873|Experimental|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
16551494|NCT02940873|Active Comparator|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
16551495|NCT02940860|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
16551496|NCT02940860|Active Comparator|Iron sucrose|Administered IV
16551536|NCT02940587|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
16551497|NCT02940847|Active Comparator|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
16551498|NCT02940847|Active Comparator|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
16551499|NCT02940834||patients with sodium imbalance|
16551500|NCT02940834||patients without sodium imbalance|
16551501|NCT02940821|Active Comparator|Whitening and Dentifrice|
16551502|NCT02940821|Active Comparator|Whitening Dentifrice|
16551503|NCT02940821|Active Comparator|Dentifrice|
16551504|NCT02940808|Other|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
16551505|NCT02940808|Other|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
16551506|NCT02940795|Experimental|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
16551507|NCT02940795|Experimental|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
16551508|NCT02940782|Experimental|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
16551509|NCT02940782|Active Comparator|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
16551510|NCT02940769|Experimental|light glasses|Study subjects will wear light glasses
16551511|NCT02940769|Sham Comparator|sham glasses (placebo)|Study subjects will wear sham glasses
16551512|NCT02940756|Experimental|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
16551513|NCT02940756|Experimental|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
16551514|NCT02940756|Experimental|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
16551515|NCT02940743|Active Comparator|Education (Edu)|
16551516|NCT02940743|Active Comparator|Edu + Self-Monitoring (SM)|
16551517|NCT02940743|Active Comparator|Edu + SM + Social Cognitive Theory (SCT)|
16551518|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
16551519|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
16551520|NCT02940717|Experimental|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
16551521|NCT02940717|Active Comparator|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
16551522|NCT02940704|Experimental|Reciproc|"Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.
~Size: R40 (40/0.06)"
16551523|NCT02940704|Active Comparator|One Shape|"One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.
~Size: 25/0.06"
16551524|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
16551525|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
16551526|NCT02940665||Conventional|Conventional group received conventional care.
16551527|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
16551528|NCT02940639||Cohort 1|Participants with advanced/metastatic renal cell cancer (RCC) starting nivolumab monotherapy after prior therapy
16551529|NCT02940639||Cohort 2|Participants with advanced/metastatic RCC starting 1st line therapy with nivolumab and ipilimumab combination therapy, in intermediate/poor risk participants
16551530|NCT02940626|Placebo Comparator|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
16551531|NCT02940626|Experimental|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
16551532|NCT02940613|Experimental|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
16551533|NCT02940613|No Intervention|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
16551534|NCT02940600|Experimental|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
16551535|NCT02940600|Active Comparator|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
16551537|NCT02940587|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
16551538|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
16551539|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
16551540|NCT02940561|Experimental|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
16551541|NCT02940561|Active Comparator|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
16551542|NCT02940548|Active Comparator|Nifedipine GITS|Nifedipine GITS 30~60mg/day
16551543|NCT02940548|Active Comparator|Amlodipine besylate|Amlodipine besylate 5~10mg/day
16551544|NCT02940535|Experimental|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
16551545|NCT02940535|Active Comparator|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
16551546|NCT02940522|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector
16551547|NCT02940522|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle
16551548|NCT02940509|Active Comparator|Ketamine plus Magnesium sulfate|Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
16551549|NCT02940509|Placebo Comparator|Placebo|Normal Saline (NaCl 0.9%)
16551550|NCT02940496|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
16551551|NCT02940496|Experimental|Arm B (pembrolizumab, elbasvir/grazoprevir, ribavirin)|Patients receive pembrolizumab as in arm A. Patients also receive elbasvir/grazoprevir orally PO QD and ribavirin PO QD on days 1-28. Treatment continues for 12-16 weeks in the absence of disease progression or unacceptable toxicity.
16551552|NCT02940483|Experimental|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
16551553|NCT02940470|Experimental|Calorie restricted diet plus exercise|See Intervention Description
16551554|NCT02940470|Active Comparator|Weight management classes|See Intervention Description
16551555|NCT02940457|Experimental|Verum tDCS|prefrontal anodal stimulation
16551556|NCT02940457|Experimental|Sham tDCS|sham stimulation, same electrode positions
16551557|NCT02940444|Experimental|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
16551558|NCT02940444|Active Comparator|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
16551559|NCT02940431|Experimental|High Autonomy|Children will choose active video games for use during the study.
16551560|NCT02940431|Experimental|Low Autonomy|Children will be assigned active video games for use during the study.
16551561|NCT02940418|Active Comparator|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.
~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
16551562|NCT02940418|Active Comparator|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.
~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
16551563|NCT02940405|Experimental|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
16551564|NCT02940405|Placebo Comparator|placebo tablet|One tablet of a placebo one hour before endodontic treatment
16551565|NCT02940392|Experimental|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
16551566|NCT02940379|Experimental|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
16551567|NCT02940379|Experimental|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
16551568|NCT02940366|Experimental|Pitavastatin 4 mg orally daily|
16551569|NCT02940366|Placebo Comparator|Atorvastatin 20 mg orally daily|
16551570|NCT02940353|Other|Treatment with Trefoil concept|Treatment
16551571|NCT02940314|Experimental|sequence 1|HGP1103→HIP1503
16551572|NCT02940314|Experimental|Sequence 2|HIP1503→HGP1103
16551573|NCT02940301|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
16551574|NCT02940288|Experimental|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
16551575|NCT02940288|Sham Comparator|Control|Participants will be randomized to receive bilateral sham acupuncture.
16551576|NCT02940275||Hypertension|
16551577|NCT02940275||Diabetes mellitus|
16551578|NCT02940275||Hypertension and diabetes mellitus|
16551579|NCT02940275||End stage kidney disease|
16551580|NCT02940275||Kidney transplant recipient|
16551581|NCT02940275||Coronary artery disease|
16551582|NCT02940275||Peripheral arterial occlusive disease|
16551583|NCT02940262|Experimental|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
16551584|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
16551585|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
16551586|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
16551588|NCT02940236||Multimodal analgesia|Patients scheduled for general surgery and requiring multimodal analgesia in preoperative period.
16551589|NCT02940223|Experimental|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
16551590|NCT02940223|Experimental|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
16551591|NCT02940223|Experimental|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
16551592|NCT02940210|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
16551593|NCT02940210|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
16551594|NCT02940197|Experimental|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
16551595|NCT02940197|Experimental|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
16551596|NCT02940184|Experimental|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)
~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
16551597|NCT02940184|Experimental|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
16551598|NCT02940171||Early surgery|Early Excision of full thickness burn First excision surgery of full -thickness burn performed within 48 hours from burn injury
16551599|NCT02940171||Late surgery|Late Excision of full thickness burn First excision surgery of full -thickness burn performed after 48 hours from burn injury
16551600|NCT02940158|Other|1/2 cup|1/2 cup serving size arm
16551601|NCT02940158|Other|1/4 cup|1/4 cup serving size arm
16551602|NCT02940145|Experimental|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.
~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
16551603|NCT02940145|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
16551604|NCT02940132|Experimental|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
16551605|NCT02940119|Active Comparator|Active PBMT|The volunteers received active phototherapy in each session.
16551606|NCT02940119|Placebo Comparator|Placebo PBMT|The volunteers received placebo phototherapy in each session.
16551607|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
16551608|NCT02940106|Active Comparator|open device|New cryopreservation system.
16551609|NCT02940093||Stem cell transplant recipient|
16551610|NCT02940093||Stem cell donor|
16551611|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
16551612|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
16551613|NCT02940067|Experimental|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
16551614|NCT02940067|No Intervention|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
16551615|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:
~diarrhea
~nocturnal diarrhea
~body weight loss (>5%)
~abdominal pain
~perianal lesions."
16551616|NCT02940028|Experimental|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
16551617|NCT02940028|Other|Control writing intervention|The control group will receive a control writing condition (fact based writing).
16551618|NCT02940015||Anonymous Sample Collection - Adults (ASCA)|Healthy Volunteers ages 18 and older
16551619|NCT02940002|Experimental|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
16551620|NCT02940002|Experimental|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
16551621|NCT02940002|Experimental|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
16551622|NCT02940002|Experimental|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
16551623|NCT02940002|Active Comparator|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
16551624|NCT02940002|Active Comparator|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
16551811|NCT02938689|Experimental|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
16551627|NCT02939976|Active Comparator|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
16551628|NCT02939976|Experimental|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
16551629|NCT02939976|Experimental|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
16551630|NCT02939963|Experimental|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC
16551631|NCT02939963|Experimental|pressure support 7 cm H2O PEP 4 cm H2O then ATC|ventilator is set to pressure support ventilation mode at set pressure 7 cm H2O above PEEP level of 4 cm H2O
16551632|NCT02939950|Experimental|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
16551633|NCT02939950|Active Comparator|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
16551634|NCT02939937|Experimental|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
16551635|NCT02939937|Experimental|placebo|patients received placebo 100 mg three time daily for 3 months
16551636|NCT02939924|Experimental|DCB treatment|Patient treated with Kanshas DCB
16551637|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
16551638|NCT02939898|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
16551639|NCT02939898|Active Comparator|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
16551640|NCT02939872|Experimental|DAPT|Dual antiplatelet therapy : aspirin and clopidogrel
16551641|NCT02939872|Active Comparator|Clopidogrel only|Clopidogrel monotherapy
16551642|NCT02939859|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
16551643|NCT02939859|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
16551644|NCT02939859|Experimental|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
16551645|NCT02939846|Experimental|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
16551646|NCT02939833|Experimental|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
16551647|NCT02939833|Placebo Comparator|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
16551648|NCT02939807|Experimental|advanced HCC, tumor progression with sorafenib|Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.
16551649|NCT02939794|Active Comparator|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
16551650|NCT02939794|Placebo Comparator|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
16551651|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
16551652|NCT02939768|Experimental|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
16551653|NCT02939768|No Intervention|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
16551654|NCT02939755|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
16551730|NCT02939248|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
16551732|NCT02939235|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
16551655|NCT02939755|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
16551656|NCT02939742|Experimental|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
16551657|NCT02939742|Placebo Comparator|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
16551658|NCT02939729|Experimental|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
16551659|NCT02939729|No Intervention|Standard Care|This group will receive standard preoperative information and education only.
16551660|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
16551661|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
16551662|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
16551663|NCT02939703|Active Comparator|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
16551664|NCT02939703|Experimental|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
16551665|NCT02939690|Experimental|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
16551666|NCT02939690|Active Comparator|UVC and Birth weight based formula|UVC insertion depth=[(3× birth weight (Kg) + 9)/2+1)] cm
16551667|NCT02939677|Other|Targeted exercise|Targeted exercise intervention
16551668|NCT02939677|No Intervention|care as usual|home based exercises
16551669|NCT02939664|Active Comparator|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
16551670|NCT02939664|Active Comparator|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
16551671|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
16551672|NCT02939638|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
16551673|NCT02939638|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
16551674|NCT02939625|Active Comparator|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
16551675|NCT02939625|Active Comparator|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
16551676|NCT02939625|Active Comparator|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
16551677|NCT02939612|Experimental|App for Stress management|Participants will get access to two modules per week for five weeks (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
16551678|NCT02939612|No Intervention|Waitlist control group|Participants will get treatment as usual during the study. After the one year study follow up they will receive the stress management app.
16551679|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg
~-active patients will continue at the dose they finished on the QCC374X2201 study"
16551680|NCT02939586|Active Comparator|Haemodialysis|regular convectional haemodialysis 3times/weekly
16551681|NCT02939586|Active Comparator|Haemodiafiltration|post-dilution haemodiafiltration
16551682|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
16551683|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
16551684|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
16551685|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
16551686|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
16551687|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
16551688|NCT02939521|Experimental|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
16551689|NCT02939508|Experimental|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
16551731|NCT02939248|Active Comparator|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
16551810|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
16551690|NCT02939508|Active Comparator|Non-colon originated|"NCOG met one of the two following criteria:
~History of nerve damage that could affect colon movement (colon [-innervating] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;
~Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
16551691|NCT02939495|Experimental|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
16551692|NCT02939482|Active Comparator|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
16551693|NCT02939482|Experimental|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
16551694|NCT02939469|Experimental|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
16551695|NCT02939456|Other|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
16551696|NCT02939443|Other|cross-sectional study|
16551697|NCT02939430|Active Comparator|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
16551698|NCT02939430|Experimental|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
16551699|NCT02939417|Experimental|using grape seed extract|Grape seed extract as collagen cross-linking agent
16551700|NCT02939417|Active Comparator|without uing grape seed extract|
16551702|NCT02939391|Experimental|KW-6356 Low Dose|Oral administration
16551703|NCT02939391|Experimental|KW-6356 High Dose|Oral administration
16551704|NCT02939391|Placebo Comparator|Placebo|Oral administration
16551705|NCT02939378|Experimental|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
16551706|NCT02939378|Other|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
16551707|NCT02939365|Experimental|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.
~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
16551708|NCT02939352|Experimental|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
16551709|NCT02939352|Experimental|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
16551710|NCT02939339|Experimental|real treatment|continuous theta burst stimulation (real) will be delivered
16551711|NCT02939339|Sham Comparator|sham treatment|continuous theta burst stimulation (sham) will be delivered
16551712|NCT02939326|Placebo Comparator|Placebo|"Intervention: Drug: Placebo
~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area."
16551713|NCT02939326|Active Comparator|EB-001 Dose 1 (1X)|"Intervention: Drug: EB-001
~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
16551714|NCT02939326|Active Comparator|EB-001 Dose 2 (3X)|"Intervention: Drug: EB-001, 3X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
16551715|NCT02939326|Active Comparator|EB-001 Dose 3 (9X)|"Intervention: Drug: EB-001, 9X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
16551716|NCT02939326|Active Comparator|EB-001 Dose 4 (12X)|"Intervention: Drug: EB-001, 12X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
16551717|NCT02939326|Active Comparator|EB-001 Dose 5 (16X)|"Intervention: Drug: EB-001, 16X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
16551718|NCT02939326|Active Comparator|EB-001 Dose 6 (21X)|Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
16551719|NCT02939326|Active Comparator|EB-001 Dose 7 (28X)|"Intervention: Drug: EB-001, 28X Dose 1
~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
16551720|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
16551721|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
16551722|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
16551723|NCT02939300|Experimental|Combination Of Nivolumab with Ipilimumab|"All patients will be treated with the combination regimen of Nivolumab at pre-determine dose with Ipilimumab at a pre-determine dose.This will be followed by Nivolumab Monotherapy.
~Each treatment Cycle will last 6 weeks"
16551724|NCT02939287|Active Comparator|Aprepitant|aprepitant plus standard anti-emetic regimen
16551725|NCT02939287|Experimental|Olanzapine|olanzapine plus standard anti-emetic regimen
16551726|NCT02939287|Experimental|Aprepitant plus olanzapine|aprepitant and olanzapine plus standard anti-emetic regimen
16551727|NCT02939274|Other|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
16551728|NCT02939261|Active Comparator|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
16551729|NCT02939261|Experimental|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
16551733|NCT02939235|Active Comparator|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
16551734|NCT02939222|Other|Routine implant placement|No comparison needed
16551735|NCT02939209|Experimental|Hydromorphone|Patients will be given 2 mg hydromorphone (immediate release) in the post anesthetic care unit.
16551736|NCT02939209|Placebo Comparator|Placebo|Patients will be given placebo in the post anesthetic care unit.
16551737|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
16551738|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
16551739|NCT02939183|Experimental|Part 1 Arm 1|Oprozomib (Immediate Release) plus dexamethasone
16551740|NCT02939183|Experimental|Part 1 Arm 2|Oprozomib (Gastro-retentive) plus dexamethasone
16551741|NCT02939183|Experimental|Part 2 Arm 1|Oprozomib (Immediate release) plus pomalidomide and dexamethasone
16551742|NCT02939183|Experimental|Part 2 Arm 2|Oprozomib (Gastro-retentive) plus pomalidomide and dexamethasone
16551743|NCT02939170|Experimental|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
16551744|NCT02939170|Active Comparator|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
16551745|NCT02939144|Experimental|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
16551746|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
16551747|NCT02939131|Active Comparator|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
16551748|NCT02939105|Experimental|CoolSculpting Treatment in the Upper Arm|"Subjects in the study were treated with the CoolSculpting System with one of two vacuum applicator types for bilateral fat reduction in the upper arms. Applicators were used concurrently, with an applicator on each arm. Each subject received 1 or 2 cooling cycles on each arm for 35 minutes at protocol-defined temperatures.
~The Investigator selected the applicator for each subject based on the intended fat volume of the treatment area."
16551749|NCT02939092|Experimental|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
16551750|NCT02939092|Active Comparator|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
16551751|NCT02939079|Experimental|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
16551752|NCT02939079|Active Comparator|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
16551753|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
16551754|NCT02939040|Experimental|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
16551755|NCT02939040|No Intervention|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
16551756|NCT02939027|Experimental|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
16551757|NCT02939027|Experimental|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
16551758|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
16551759|NCT02939001|Experimental|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
16551760|NCT02938988|Experimental|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
16551761|NCT02938988|Active Comparator|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
16551762|NCT02938975|Placebo Comparator|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
16551763|NCT02938975|Active Comparator|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.
~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.
~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
16551764|NCT02938975|Active Comparator|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.
~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft
~Placebo lotion: liposome lotion with no DEET"
16551765|NCT02938975|Active Comparator|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.
~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
16551766|NCT02938962|Active Comparator|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
16551767|NCT02938962|Active Comparator|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
16551768|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
16551769|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
16551770|NCT02938936|Experimental|Scheduling Intervention|Pre-natal visit scheduling
16551771|NCT02938936|No Intervention|Control|
16551772|NCT02938923|Experimental|Exercise + Testosterone (EX + T)|Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
16551773|NCT02938923|Placebo Comparator|Exercise + Placebo (EX + P)|Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.
16551774|NCT02938923|Other|Enhanced Usual Care (EUC)|Home exercise program 3 times per week and monthly health education modules, both for six months duration.
16551775|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
16551776|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
16551777|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
16551778|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
16551779|NCT02938897|Experimental|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
16551780|NCT02938897|Active Comparator|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
16551781|NCT02938884|Active Comparator|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.
~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
16551782|NCT02938884|No Intervention|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
16551783|NCT02938871|Active Comparator|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
16551784|NCT02938871|Placebo Comparator|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
16551785|NCT02938858||ATRA-chimio|according to usual practice center
16551786|NCT02938858||ATRA-ATO|according to usual practice center
16551787|NCT02938845|Experimental|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
16551788|NCT02938845|Experimental|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
16551789|NCT02938832|Active Comparator|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
16551790|NCT02938832|Active Comparator|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
16551791|NCT02938819|Experimental|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
16551792|NCT02938819|Active Comparator|Control group|Patients in the control group received a standard upper limb intervention
16551793|NCT02938806||Obese/overweight children with T1D|No intervention
16551794|NCT02938806||Normal weight children with T1D|No intervention
16551795|NCT02938806||Obese/overweight children, no diabetes|No intervention
16551796|NCT02938806||Healthy, normal weight children|No intervention
16551797|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.
16551798|NCT02938780|Placebo Comparator|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
16551799|NCT02938780|Experimental|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
16551800|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
16551801|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
16551802|NCT02938754|Experimental|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
16551803|NCT02938754|Active Comparator|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
16551804|NCT02938741|Experimental|r-ATG Immunosuppressive agents|"Rabbit Anti-human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.
~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
16551805|NCT02938741|Placebo Comparator|placebo|"Rabbit Anti-human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.
~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
16551806|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
16551807|NCT02938715|Experimental|Feedback group (teledermatology)|
16551808|NCT02938715|No Intervention|Control group (phone only)|
16551809|NCT02938702||Active surveillance|Group with active surveillance of their PTC
16551812|NCT02938689|Active Comparator|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
16551813|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
16551814|NCT02938650|Other|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
16551815|NCT02938624|Experimental|cohort1|Pembrolizumab 200 mg I.V single dose
16551816|NCT02938624|Experimental|Cohort II|Pembrolizumab 200 mg I.V Twice interval 21 days
16551817|NCT02938624|Experimental|Cohort III|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
16551818|NCT02938624|Experimental|COHORT -1|Pembrolizumab 100 mg I.V single dose
16551819|NCT02938611||The study population|Persons with stage >=4 chronic kidney disease.
16551820|NCT02938598|Experimental|A|Engagement On - Problem Solving High - Motivation On
16551821|NCT02938598|Experimental|B|Engagement On - Problem Solving Low - Motivation On
16551822|NCT02938598|Experimental|C|Engagement On - Problem Solving High - Motivation Off
16551823|NCT02938598|Experimental|D|Engagement On - Problem Solving Low - Motivation Off
16551824|NCT02938598|Experimental|E|Engagement Off - Problem Solving High - Motivation On
16551825|NCT02938598|Experimental|F|Engagement Off - Problem Solving Low - Motivation On
16551826|NCT02938598|Experimental|G|Engagement Off - Problem Solving High - Motivation Off
16551827|NCT02938598|Experimental|H|Engagement Off - Problem Solving Low - Motivation Off
16551828|NCT02938585|Experimental|Prophylactic treatment|
16551829|NCT02938585|Experimental|On-demand treatment|
16551830|NCT02938572|Experimental|NNC0143-0406|
16551831|NCT02938572|Active Comparator|Insulin aspart|
16551832|NCT02938559|Experimental|Cognitive Therapy plus Memory Support|
16551833|NCT02938559|Active Comparator|Cognitive Therapy-as-usual|
16551834|NCT02938546|Active Comparator|before therapy|18F-FDG PET/CT performed before therapy
16551835|NCT02938546|Experimental|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
16551836|NCT02938546|Experimental|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
16551837|NCT02938533|No Intervention|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
16551838|NCT02938533|Experimental|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
16551839|NCT02938520|Experimental|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
16551840|NCT02938520|Active Comparator|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
16551841|NCT02938507|Experimental|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
16551842|NCT02938507|Experimental|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
16551843|NCT02938494|Experimental|IDP-123 Lotion|Lotion
16551844|NCT02938494|Active Comparator|Tazorac Cream|Cream
16551845|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
16551846|NCT02938494|Active Comparator|Vehicle Cream|Cream
16551847|NCT02938468|Active Comparator|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
16551848|NCT02938468|Experimental|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
16551849|NCT02938442|Active Comparator|Control Arm|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
16551850|NCT02938442|Experimental|Chemo+Vaccine Arm|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
16551851|NCT02938429|Other|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.
~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).
~Participants will complete a questionnaire to access factors that can affect endothelial function."
16551900|NCT02938065|Other|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
16551852|NCT02938429|Other|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.
~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).
~Participants will complete a questionnaire to access factors that can affect endothelial function."
16551853|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
16551854|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
16551855|NCT02938403|Experimental|In vivo group|Those who receive in vivo counseling and Nicotine Replacement Therapy (NRT)
16551856|NCT02938403|Active Comparator|Controls|Standard smoking cessation counseling and Nicotine Replacement Therapy (NRT)
16551857|NCT02938377|Active Comparator|No dx of alcohol use disorder, panic or depre|Computerized Brief Intervention (CBI)- a video about alcohol abuse
16551858|NCT02938377|Active Comparator|Risky drinking, no dx of AUD, has panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy
16551859|NCT02938377|Active Comparator|Dx of AUD with or without panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy plus a recommendation for Alcohol Pharmacotherapy (APT). The drugs recommended in the APT are all standard of care drugs for alcohol treatment and are not under study in this protocol.
16551860|NCT02938364|Experimental|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
16551861|NCT02938364|Experimental|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
16551862|NCT02938364|Placebo Comparator|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
16551863|NCT02938351|Experimental|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
16551864|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
16551865|NCT02938325||No intervention: General Anesthesia|"Thirty patients undergoing elective surgery under general anesthesia who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the surgery, patients will be questioned for awareness under anesthesia by Modified Brice Questionnaire.
~There will be no intervention. Patients will be anesthetized with general anesthesia as they were supposed to be for their elective surgery. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
16551866|NCT02938325||No intervention: Sedation|"Fourty patients undergoing elective cardiac catheterization under conscious sedation who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the procedure, patients will be questioned for awareness under sedation by Modified Brice Questionnaire.
~There will be no intervention. Patients will be anesthetized with sedation as they were supposed to be for their elective cardiac catheterization. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
16551867|NCT02938325||No Intervention - Awake Volunteers|EEG and BIS will be recorded in twenty volunteers, for 10 minutes, in supine position, while their eyes are closed. This recording will be utilized as for positive control for recall.
16551868|NCT02938312|Active Comparator|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
16551869|NCT02938312|Experimental|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
16551870|NCT02938299|Experimental|Arm 1: neoadjuvant + surgery|"Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors of a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks (or until all injectable tumors have disappeared, or intolerance to study treatment or in the opinion of the investigator immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first).
~Newly occurring injectable melanoma lesions within the 4 weeks treatment period will also be treated as described. Surgical resection of all existing metastases will follow within 4 weeks after end of treatment. Surgery will be performed after the safety evaluation carried out at week 5 and, if indicated, may be carried out on the same day of the safety evaluation."
16551871|NCT02938299|Active Comparator|Arm 2: surgery alone|Patients in Arm 2 will receive directly surgical resection of melanoma tumor lesions within 4 weeks after randomization.
16551872|NCT02938286|Experimental|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
16551873|NCT02938286|Experimental|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
16551901|NCT02938065|Other|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
16551874|NCT02938286|Experimental|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
16551875|NCT02938286|Experimental|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
16551876|NCT02938273|Experimental|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
16551877|NCT02938260||Diltiazem|
16551878|NCT02938260||Metoprolol|
16551879|NCT02938247|Experimental|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
16551880|NCT02938234|Experimental|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
16551881|NCT02938221|Experimental|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
16551882|NCT02938208|Experimental|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
16551883|NCT02938195|Experimental|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
16551884|NCT02938182|Experimental|clopidogrel|clopidogrel tablet 75mg daily for three months
16551885|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise
~walking exercise: treadmill gait with tolerable gait speed
~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
16551886|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise
~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.
~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
16551887|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise
~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.
~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.
~walking exercise:treadmill gait with tolerable gait speed"
16551888|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)
~Only educate the flexibility exercise(stretching exercise)
~Don't educate the walking exercise method and stabilization exercise method"
16551889|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
16551890|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
16551891|NCT02938130|Other|Wellness Programs|Community Partners and Community LIFE programs
16551892|NCT02938117|Experimental|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
16551893|NCT02938117|Experimental|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
16551894|NCT02938104|Experimental|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:
~Receive a personalized physical exercise program
~Receive nutritional counselling with whey protein isolate powder
~Receive relaxation techniques"
16551895|NCT02938104|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
16551896|NCT02938091|Experimental|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
16551897|NCT02938091|Experimental|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
16551898|NCT02938078|Experimental|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
16551899|NCT02938078|No Intervention|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
16551902|NCT02938065|Other|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
16551903|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).
~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
16551904|NCT02938039|Active Comparator|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
16551905|NCT02938039|Active Comparator|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
16551906|NCT02938026|No Intervention|Control|Usual care
16551907|NCT02938026|Experimental|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
16551908|NCT02938026|Experimental|Bariatric surgery|Bariatric surgery
16551909|NCT02938013|Experimental|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
16551910|NCT02938013|Active Comparator|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
16551911|NCT02938013|Active Comparator|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
16551912|NCT02938000|Experimental|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
16551913|NCT02938000|Placebo Comparator|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
16551914|NCT02937987||Group 1|non-obese type 2 DM
16551915|NCT02937987||Group 2|obese type 2 DM
16551916|NCT02937974|Experimental|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
16551917|NCT02937974|Placebo Comparator|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
16551918|NCT02937961|Experimental|Early SLED|
16551919|NCT02937961|Active Comparator|Late SLED|
16551920|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
16551921|NCT02937935|Experimental|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
16551922|NCT02937935|Active Comparator|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow >200 mL/min and a dialysate flow >500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
16551923|NCT02937922|Active Comparator|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
16551924|NCT02937922|Active Comparator|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
16551925|NCT02937922|Active Comparator|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
16551926|NCT02937909|Experimental|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
16551927|NCT02937909|No Intervention|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
16551928|NCT02937896|Experimental|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
16551929|NCT02937896|Active Comparator|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
16551930|NCT02937883|Experimental|empowerment intervention|Empowerment intervention
16551931|NCT02937883|No Intervention|regular care|Regular care, care as usual
16551932|NCT02937870|Experimental|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
16551933|NCT02937870|Experimental|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
16551934|NCT02937870|Active Comparator|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
16551935|NCT02937870|Other|Negative Control|
16551936|NCT02937857|Active Comparator|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
16551937|NCT02937857|Experimental|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
16551938|NCT02937844|Experimental|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
16551939|NCT02937831||All Study Participants|
16551940|NCT02937818|Experimental|ARM A|
16551941|NCT02937818|Experimental|ARM B|
16551942|NCT02937818|Experimental|ARM C|
16551943|NCT02937805|Experimental|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
16551944|NCT02937805|Active Comparator|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
16551945|NCT02937805|No Intervention|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
16551946|NCT02937792|No Intervention|CONTROL|one with intrathecal 12.5 mg bupivacaine
16551947|NCT02937792|Experimental|experimental|one group with intrathecal 15 mg bupivacaine
16551948|NCT02937779|Experimental|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.
~No treatment for negative HBe Ag women"
16551949|NCT02937766|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
16551950|NCT02937766|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
16551951|NCT02937740|Other|Naive patients - ARM 1|"NATESTO Testosterone Nasal Gel administered intranasally to patients with no prior TRT experience. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.
~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
16551952|NCT02937740|Other|Non-naive patients - ARM 2|"NATESTO Testosterone Nasal Gel administered intranasally to patients who had prior TRT. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.
~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
16551953|NCT02937727|Experimental|MRI compatible and LFP recordable implantable stimulator|
16551954|NCT02937714|Experimental|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
16551955|NCT02937714|No Intervention|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
16551956|NCT02937701|Experimental|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.
~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
16551957|NCT02937701|Active Comparator|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.
~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
16551958|NCT02937675|Experimental|Tomivosertib (eFT-508) Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
16551959|NCT02937675|Experimental|Tomivosertib (eFT-508) Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas
16551960|NCT02937662|Experimental|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
16551961|NCT02937662|Active Comparator|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
16551962|NCT02937649|Experimental|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
16551963|NCT02937649|Active Comparator|Laparoscopic sleeve gastrectomy using standard care bougie|Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
16551964|NCT02937636|Experimental|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
16551965|NCT02937636|Active Comparator|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
16551966|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
16551967|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
16551968|NCT02937597|Active Comparator|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
16551969|NCT02937597|Active Comparator|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
16551970|NCT02937597|Experimental|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
16551971|NCT02937584|Experimental|GP MDI (PT001) 14.4 μg|Glycopyrronium
16551972|NCT02937584|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
16551973|NCT02937571|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone|"Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.
~Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
~Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days
~Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23
~Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23"
16551974|NCT02937558|Experimental|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
16551975|NCT02937558|Placebo Comparator|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
16551976|NCT02937558|Experimental|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
16551977|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
16551978|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
16551979|NCT02937532|Placebo Comparator|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
16551980|NCT02937532|Active Comparator|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
16551981|NCT02937519|Experimental|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
16551982|NCT02937519|Other|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
16551983|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
16551984|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
16551985|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
16551986|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
16551987|NCT02937480|Experimental|Experimental group|Task-specific training
16551988|NCT02937480|Sham Comparator|Control group|Global stretching, memory exercises, health care orientation
16551989|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
16551990|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
16551991|NCT02937428|Experimental|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
16551992|NCT02937428|Active Comparator|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
16551993|NCT02937428|Experimental|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
16551994|NCT02937428|Active Comparator|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
16552039|NCT02937207|Placebo Comparator|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
16551995|NCT02937415|Experimental|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
16551996|NCT02937415|Active Comparator|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
16551997|NCT02937402|Experimental|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
16551998|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
16551999|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
16552000|NCT02937363|Experimental|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
16552001|NCT02937363|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
16552002|NCT02937350|Experimental|Study Population|D6-25-hydroxyvitamin D3
16552003|NCT02937337|Experimental|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
16552004|NCT02937337|Active Comparator|Blind|Laryngeal mask insertion using standard index finger-guided technique
16552005|NCT02937324|Active Comparator|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
16552006|NCT02937324|Experimental|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
16552007|NCT02937311|Experimental|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
16552008|NCT02937311|Experimental|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
16552009|NCT02937311|Experimental|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
16552010|NCT02937298|Experimental|Control Meal|Control meal using standard breakfast foods.
16552011|NCT02937298|Experimental|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
16552012|NCT02937298|Experimental|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
16552013|NCT02937298|Experimental|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
16552014|NCT02937285|Active Comparator|Standard care|Interferon alone
16552015|NCT02937285|Experimental|Experimental group|Mitoxantrone for 6 month followed by interferon
16552016|NCT02937272|Experimental|LY3200882 Schedule 1 Escalation|
16552017|NCT02937272|Experimental|LY3200882 Schedule 2 Escalation|
16552018|NCT02937272|Experimental|LY3200882 Schedule 1 Expansion|
16552019|NCT02937272|Experimental|LY3200882 Schedule 2 Expansion|
16552020|NCT02937272|Experimental|LY3200882 + LY3300054|
16552021|NCT02937272|Experimental|LY3200882 + Gemcitabine + nab-Paclitaxel|
16552022|NCT02937272|Experimental|LY3200882 + Cisplatin + Radiation|
16552023|NCT02937272|Experimental|Japanese Arm LY3200882|
16552024|NCT02937259|Experimental|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
16552025|NCT02937246|Experimental|the intervention group|Partial covered double bare metal stent
16552026|NCT02937246|Active Comparator|the control group|Uncovered double bare metal stent
16552027|NCT02937233|Experimental|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
16552028|NCT02937233|Experimental|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
16552029|NCT02937233|Experimental|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
16552030|NCT02937220|Experimental|Monolithic zirconia crowns|New crown material to restore dental implants
16552031|NCT02937220|Active Comparator|metal ceramic crowns|conventional crown material for restoring dental implants
16552032|NCT02937207|Experimental|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552033|NCT02937207|Placebo Comparator|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552034|NCT02937207|Experimental|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552035|NCT02937207|Placebo Comparator|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552036|NCT02937207|Experimental|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552037|NCT02937207|Placebo Comparator|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552038|NCT02937207|Experimental|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
16552040|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
16552041|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
16552042|NCT02937181|Experimental|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
16552043|NCT02937168|Experimental|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
16552044|NCT02937168|Experimental|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
16552045|NCT02937168|Placebo Comparator|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
16552046|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
16552047|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
16552048|NCT02937142|Experimental|Cognitive behavior group therapy|Cognitive behavior group therapy in weekly 1,5 hour sessions during 12 weeks, 8 participants and 2 therapists per group, in addition to education on ADHD, and ADHD medication if indicated.
16552049|NCT02937142|Other|Controls|Treatment as usual: Education on ADHD, and ADHD medication if indicated.
16552050|NCT02937116|Experimental|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.
~Drug: IBI308"
16552051|NCT02937116|Experimental|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308"
16552052|NCT02937116|Experimental|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308"
16552053|NCT02937116|Experimental|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308"
16552054|NCT02937116|Experimental|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308/Cisplatinum/Pemetrexed"
16552055|NCT02937116|Experimental|Phase 1b Cohort E|"Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308\gemcitabine\cisplatin"
16552056|NCT02937116|Experimental|Phase 1b Cohort F|"Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308\oxaliplatin\capecitabine"
16552057|NCT02937116|Experimental|Phase 1b Cohort G|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308\etoposide\cisplatin"
16552058|NCT02937116|Experimental|Phase 1b Cohort H|"Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308\irinotecan\5-FU"
16552059|NCT02937103|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16552060|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.
~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):
~chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);
~total or free T levels above the reference interval and/or excessive facial hair, acne;
~transvaginal ultrasound with polycystic ovaries.
~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
16552061|NCT02937090||Control|Women matched for age and BMI.
16552062|NCT02937064||Controls|Controls
16552063|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
16552064|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
16552065|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
16552066|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
16552073|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
16552074|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
16552075|NCT02937025|Experimental|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
16552076|NCT02937012|Experimental|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
16552077|NCT02937012|Placebo Comparator|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
16552078|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
16552079|NCT02936973|Experimental|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
16552080|NCT02936973|Sham Comparator|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
16552081|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
16552082|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.
~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
16552083|NCT02936934|Active Comparator|Morphine|Multimodal analgesia to morphine
16552084|NCT02936934|Experimental|Oxycodone|Multimodal analgesia to oxycodone
16552085|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
16552086|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
16552087|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
16552088|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
16552089|NCT02936895|Experimental|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
16552090|NCT02936895|Placebo Comparator|Placebo|Placebo (same size and shape) for 2 days
16552091|NCT02936882|Other|Preoperative gastric ultrasonography|
16552092|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
16552093|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
16552094|NCT02936856|Experimental|After Hepatic Arteriography|
16552095|NCT02936856|Active Comparator|Before Hepatic Arteriography|
16552096|NCT02936843|Experimental|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
16552097|NCT02936843|Placebo Comparator|Comparator|Placebo for Salsalate, 2 tablets by mouth, 3 times daily for 12 months
16552098|NCT02936830|Placebo Comparator|Control|21 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
16552099|NCT02936830|Active Comparator|Fluoride group|21 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
16552100|NCT02936830|Experimental|Nanohydroxyapetite|21 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
16552101|NCT02936817|Other|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
16552102|NCT02936804|Experimental|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
16552103|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
16552104|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
16552105|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
16552106|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
16552107|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
16552108|NCT02936765|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
16552109|NCT02936765|Active Comparator|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
16552110|NCT02936752|Experimental|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
16552111|NCT02936739|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
16552112|NCT02936739|Active Comparator|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
16552113|NCT02936726|Active Comparator|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.
~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
16552114|NCT02936726|Experimental|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.
~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)
~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
16552115|NCT02936713|Experimental|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
16552116|NCT02936713|Experimental|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
16552117|NCT02936700|Other|Control group|Add on relaxation group
16552118|NCT02936700|Experimental|Therapy ACT|Add on ACT group
16552123|NCT02936674|Experimental|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
16552124|NCT02936674|Active Comparator|Light 2|Light 2 will be a standard LED bulb.
16552125|NCT02936661|Experimental|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
16552126|NCT02936661|Placebo Comparator|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
16552127|NCT02936648|Experimental|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
16552128|NCT02936635|Experimental|Delayed Start Treatment|The Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
16552129|NCT02936635|Experimental|Early Start Treatment|The Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
16552130|NCT02936622|Experimental|Stent 1|Zilver® PTX Stent
16552131|NCT02936622|Experimental|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
16552132|NCT02936622|Experimental|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
16552133|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
16552134|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
16552137|NCT02936583|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16552138|NCT02936570|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16552176|NCT02936271|Active Comparator|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
16552139|NCT02936557|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16552140|NCT02936544|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16552141|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
16552142|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
16552143|NCT02936518|Experimental|Intervention|
16552144|NCT02936505|Active Comparator|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
16552145|NCT02936505|Experimental|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
16552146|NCT02936492|Experimental|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
16552147|NCT02936492|Placebo Comparator|Placebo|Topical treatment using matching amount of placebo
16552148|NCT02936492|Active Comparator|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
16552149|NCT02936479|Experimental|Berinert treatment|
16552150|NCT02936466|Experimental|Interventional group|Bipolife group
16552151|NCT02936466|No Intervention|Control group|No specific intervention, treatment as usual
16552152|NCT02936453|Experimental|All patients|"Patients will participate during 8-12 months, during which there will be :
~Pre-implant evaluations (6-8 weeks)
~Device implantation and stimulation optimization (6-8 weeks)
~Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.
~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
16552153|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
16552154|NCT02936427|No Intervention|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
16552155|NCT02936427|Experimental|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
16552156|NCT02936427|Experimental|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
16552157|NCT02936414|Experimental|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
16552158|NCT02936414|Placebo Comparator|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
16552159|NCT02936401|Experimental|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
16552160|NCT02936401|Experimental|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
16552161|NCT02936388|Experimental|Arm A|SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)
16552162|NCT02936388|Active Comparator|Arm B|DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)
16552163|NCT02936375|Experimental|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
16552164|NCT02936375|Active Comparator|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
16552165|NCT02936362|Other|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
16552166|NCT02936362|Other|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
16552167|NCT02936336|No Intervention|Control|without exercise intervention
16552168|NCT02936336|Experimental|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
16552169|NCT02936323|Experimental|PEN-221|intravenous administration of PEN-221
16552170|NCT02936310|Experimental|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.
~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
16552171|NCT02936297|Placebo Comparator|Lactose free placebo|Lactose free placebo pill
16552172|NCT02936297|Active Comparator|Low dose Gluten (0.5g)|Low dose gluten pill
16552173|NCT02936297|Active Comparator|High Dose Gluten (2.0g)|High dose gluten pill
16552174|NCT02936284|Experimental|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
16552175|NCT02936284|Active Comparator|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
16552177|NCT02936271|Placebo Comparator|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
16552178|NCT02936258|Other|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
16552179|NCT02936258|Active Comparator|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
16552180|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
16552181|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
16552182|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
16552183|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
16552184|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
16552185|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
16552186|NCT02936206|Experimental|Fulvestrant|750 mg injection in 3 divided doses
16552187|NCT02936206|Active Comparator|Tamoxifen|20mg orally
16552188|NCT02936193|Experimental|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
16552189|NCT02936193|Active Comparator|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
16552190|NCT02936180|Active Comparator|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
16552191|NCT02936180|Active Comparator|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
16552192|NCT02936167|Experimental|Ringer Lactate|fluid
16552193|NCT02936167|Experimental|Plasmalyte|fluid
16552194|NCT02936154|Experimental|300 mg|
16552195|NCT02936154|Placebo Comparator|placebo|
16552196|NCT02936141|Experimental|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
16552197|NCT02936128|Experimental|TruSkin®|Cryopreserved skin allograft
16552198|NCT02936128|Active Comparator|Wound Cover|Active Comparator for Venous Leg Ulcers
16552199|NCT02936115|Experimental|TruSkin®|Cryopreserved skin allograft
16552200|NCT02936115|Active Comparator|Wound Cover|Active Comparator for Diabetic Foot Ulcers
16552201|NCT02936102|Experimental|FAZ053 single agent|
16552202|NCT02936102|Experimental|FAZ053 + PDR001|
16552203|NCT02936089|Experimental|Risk Stratification-directed Therapy|AE AML patients first received IA or DA induction therapy, and then received two courses of IDAC (Ara-C 1-2 g/m2 q12 h ×6 cycles). Subsequently, different subgroups of AE AML received different treatment based on risk stratification. For low-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or autologous HSCT. For intermediate-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or allogeneic HSCT. High-risk AE AML all received allogeneic HSCT.
16552204|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
16552205|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
16552206|NCT02936063|Experimental|Surgical staples|Skin closure with surgical staples
16552207|NCT02936063|Experimental|Sutures|Skin closure with subcuticular sutures
16552208|NCT02936050|Other|Intervention|"Experimental: Addition of diagnostic ultrasound performed by nurses at the outpatient heart failure clinic. Interpretation by specialist per telemedicine.
~No Control arm"
16552209|NCT02936037|Placebo Comparator|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
16552210|NCT02936037|Experimental|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
16552211|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
16552212|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
16552529|NCT02934022|Other|Maraviroc|
16552213|NCT02936011|Other|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
16552214|NCT02935998|Experimental|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
16552215|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.
~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.
~Participants will be assessed (clinically or by telephone) over a period of 180 days."
16552216|NCT02935972|Active Comparator|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
16552217|NCT02935972|Active Comparator|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
16552218|NCT02935972|Active Comparator|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
16552219|NCT02935959|Active Comparator|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
16552220|NCT02935959|Active Comparator|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
16552221|NCT02935959|Active Comparator|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
16552222|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
16552223|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
16552224|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
16552225|NCT02935933|Active Comparator|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
16552226|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
16552227|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
16552228|NCT02935920|Experimental|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
16552229|NCT02935920|No Intervention|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
16552230|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
16552231|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.
~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
16552232|NCT02935881|Active Comparator|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
16552233|NCT02935881|Sham Comparator|Placebo Arm|Stretta device used but RFA will not be generated.
16552234|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
16552235|NCT02935868||Control Group|Patients without systemic diseases
16552236|NCT02935855|Active Comparator|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
16552237|NCT02935855|Active Comparator|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
16552238|NCT02935855|Active Comparator|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
16552239|NCT02935855|Active Comparator|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
16552240|NCT02935842|Experimental|Specific SL-therapy for PD (with and without DBS)|Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
16552241|NCT02935842|Active Comparator|rBMT for PD (with and without DBS)|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
16552242|NCT02935842|No Intervention|PD (with and without DBS); no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
16552243|NCT02935842|No Intervention|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
16552244|NCT02935829|Experimental|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16552245|NCT02935829|Experimental|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
16552246|NCT02935829|Experimental|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16552247|NCT02935829|Experimental|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16552248|NCT02935829|Experimental|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
16552249|NCT02935829|Experimental|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
16552250|NCT02935803|Other|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
16552251|NCT02935803|Other|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
16552252|NCT02935790|Experimental|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
16552253|NCT02935777|Experimental|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules
~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
16552254|NCT02935777|Placebo Comparator|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
16552255|NCT02935764|Experimental|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
16552256|NCT02935764|Active Comparator|IRINOTECAN|irinotecan
16552257|NCT02935738|Experimental|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
16552258|NCT02935738|Experimental|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
16552259|NCT02935738|No Intervention|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
16612897|NCT02528396|Active Comparator|Humalog®|
16552260|NCT02935738|No Intervention|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
16552261|NCT02935725|Experimental|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
16552262|NCT02935725|Experimental|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
16552263|NCT02935725|Placebo Comparator|Placebo + Ketamine|Placebo + ketamine
16552264|NCT02935725|Placebo Comparator|Placebo + Saline|Placebo + saline
16552265|NCT02935712|Experimental|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
16552266|NCT02935712|Experimental|Part B|Subjects received 2 treatments (AZD8601+Placebo)
16552267|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
16552268|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
16552274|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
16552275|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
16552276|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
16552277|NCT02935660|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
16552278|NCT02935647|Experimental|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
16552279|NCT02935634|Active Comparator|Nivolumab (nivo) and Ipilimumab (ipi) Combination|
16552280|NCT02935634|Experimental|Nivo and Relatlimab Combination|
16552281|NCT02935634|Experimental|Nivo and BMS-986205 Combination|
16552282|NCT02935634|Experimental|Nivo and Rucaparib Combination|
16552283|NCT02935634|Experimental|Ipi with Rucaparib Combination|
16552284|NCT02935634|Experimental|Nivo with Ipi and rucaparib|
16552285|NCT02935621|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
16552286|NCT02935621|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
16552287|NCT02935608|Experimental|BIIB074 high dose|Administered twice daily (BID)
16552288|NCT02935608|Experimental|BIIB074 low dose|Administered BID
16552289|NCT02935608|Placebo Comparator|Placebo|Placebo administered BID
16552290|NCT02935595|Experimental|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
16552291|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
16552292|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
16552293|NCT02935569|Experimental|Compression Headband|a compression headband, placed only at the time of irradiation
16552294|NCT02935556||post partum pre-eclampsia|women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
16552295|NCT02935556||controls|women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
16552296|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
16552297|NCT02935530|Experimental|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
16552298|NCT02935530|Active Comparator|LMWH|4250 I.U. subcutaneous injection for 5-10 days
16552299|NCT02935530|Experimental|Argatroban|20mg, injection for 5-10 days
16552300|NCT02935517|Experimental|Group 1: 4.0 x 10^10 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16552301|NCT02935517|Experimental|Group 2: 1.2 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16552302|NCT02935517|Experimental|Group 3: 3.6 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16614610|NCT02516995|Experimental|Patients with prostate cancer|
16552303|NCT02935517|Experimental|Group 3a: 3.6 x 10^11 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16552304|NCT02935517|Experimental|Group 4: 1.1 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16552305|NCT02935517|Experimental|Group 4a: 1.1 x 10^12 vg/mL of AGTC-402|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16552306|NCT02935517|Experimental|Group 5: 3.2 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
16552307|NCT02935517|Experimental|Group 6: MTD of AGTC-402|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGA3 study drug determined by Groups 1-5.
16552308|NCT02935504|Experimental|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
16552309|NCT02935504|Active Comparator|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
16552310|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
16552311|NCT02935478|Experimental|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
16552312|NCT02935465|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
16552313|NCT02935465|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
16552314|NCT02935452|Active Comparator|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
16552315|NCT02935452|No Intervention|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
16552316|NCT02935439|Active Comparator|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
16552317|NCT02935439|No Intervention|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
16552318|NCT02935426|Experimental|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
16552319|NCT02935426|Active Comparator|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
16552320|NCT02935413|Active Comparator|tDCS|group receiving complete treatment of transcranial direct current stimulation
16552321|NCT02935413|Active Comparator|Standard rehabilitation|Standard rehabilitation procedures
16552322|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
16552323|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
16552324|NCT02935387|Experimental|Taper methotrexate, then golimumab|Taper methotrexate 25>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50>0mg/month during 24 weeks.
16552325|NCT02935387|Active Comparator|Taper golimumab, then methotrexate|Taper golimumab 50>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25>0mg/wk during 24 weeks.
16552326|NCT02935374|Active Comparator|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
16552327|NCT02935374|Active Comparator|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
16552328|NCT02935374|No Intervention|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
16552329|NCT02935374|Other|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
16552330|NCT02935361|Experimental|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16552331|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
16552332|NCT02935322|Active Comparator|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
16552333|NCT02935322|Active Comparator|0.2 % NaF mouthrinse|A mouthrinse containing NaF
16552334|NCT02935322|Active Comparator|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
16552335|NCT02935322|Placebo Comparator|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
16552336|NCT02935309|Experimental|Pre-Surgery Chemotherapy/Radiotherapy|Pre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
16552337|NCT02935296|No Intervention|Control|Standard of Care
16552338|NCT02935296|Experimental|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
16552339|NCT02935283||OTCD participants|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD who can undergo MRI and behavioral testing
16552340|NCT02935283||Normal controls|Healthy males or females without known medical or metabolic disorder (control group) who can undergo MRI and behavioral testing
16552341|NCT02935283||HA recovery group|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD or participants with CPS-1 who have had a recent hyperammonemic episode who can undergo MRI and behavioral testing
16552342|NCT02935283||Distal UCD|Males and females with ASSD and ASLD who can undergo MRI and behavioral testing
16552343|NCT02935270||Stroke Survivors|Individuals who have experienced a unilateral hemispheric stroke
16552344|NCT02935257|Experimental|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
16552345|NCT02935231|Experimental|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
16552346|NCT02935231|Experimental|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
16552347|NCT02935231|Experimental|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
16552348|NCT02935231|Active Comparator|Control|This control group receives a health warning leaflet.
16552349|NCT02935218|Other|Parenting Skills for Mothers with BPD|single-arm study
16552350|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16552351|NCT02935192|Experimental|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
16552352|NCT02935192|Placebo Comparator|Placebo Arm|Phosphate buffered saline
16552353|NCT02935179|Placebo Comparator|Control Group|Normal diet with 1500~2000 kcal
16552354|NCT02935179|Experimental|Treatment Group|White sweet potato diet with 1500~2000 kcal
16552355|NCT02935166|Placebo Comparator|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
16552356|NCT02935166|Active Comparator|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
16552357|NCT02935166|Active Comparator|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
16552358|NCT02935153|Experimental|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16552359|NCT02935127|Experimental|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
16552360|NCT02935127|Experimental|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
16552361|NCT02935114|Experimental|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)
~37% Carbamide Peroxide application (2 sessions of 45 minutes)
~Tooth sensitivity (Verbal and visual scale) and color evaluation"
16552362|NCT02935114|Active Comparator|35% Hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)
~35% Hydrogen Peroxide application (2 sessions of 45 minutes)
~Tooth sensitivity (Verbal and visual scale) and color evaluation"
16552363|NCT02935101|Experimental|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
16552364|NCT02935101|Placebo Comparator|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
16552365|NCT02935075|Experimental|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
16552366|NCT02935075|Active Comparator|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
16552367|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
16552368|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
16552369|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
16552370|NCT02935036|Experimental|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
16552371|NCT02935036|Placebo Comparator|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
16552372|NCT02935023|Experimental|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
16552373|NCT02935010|Experimental|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
16552374|NCT02935010|Active Comparator|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
16552375|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
16552376|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
16552377|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
16552378|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
16552379|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
16552380|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
16552381|NCT02934958|Active Comparator|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
16552382|NCT02934958|Experimental|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
16552383|NCT02934945|Other|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
16552384|NCT02934945|Other|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
16552385|NCT02934932|Experimental|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
16552386|NCT02934932|Experimental|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
16552387|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
16552388|NCT02934919|Experimental|nalmefene|
16552389|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
16552390|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
16552391|NCT02934893|Experimental|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
16552392|NCT02934893|Active Comparator|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
16552393|NCT02934893|No Intervention|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
16552394|NCT02934880|Experimental|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
16552395|NCT02934880|Active Comparator|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
16552396|NCT02934867|Experimental|CONTARM|Protocol phone advice
16552397|NCT02934867|Other|CONTHAB|Usual phone advice
16552398|NCT02934854||Observation|Patients with the Creatine Deficiency Syndromes or high-grade suspicion for the Creatine Deficiency Syndromes
16552399|NCT02934841|Experimental|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
16552400|NCT02934841|Sham Comparator|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
16552401|NCT02934828|Experimental|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
16552402|NCT02934828|Active Comparator|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
16552403|NCT02934815|Experimental|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
16552404|NCT02934815|No Intervention|Control group|No intervention
16552405|NCT02934789|Active Comparator|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
16552406|NCT02934789|Active Comparator|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
16552407|NCT02934776|Experimental|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
16614634|NCT02516852|Experimental|Intervention|
16552408|NCT02934763|Placebo Comparator|Placebo|Saline solution by target controlled infusion
16552409|NCT02934763|Active Comparator|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
16552410|NCT02934763|Active Comparator|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
16552411|NCT02934750|Experimental|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
16552412|NCT02934750|No Intervention|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
16552413|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.
~Interventions:
~Self sample from vagina using Rover's Evalyn Brush
~Self sample from the oral cavity using COPAN's FloqSwab
~Questionnaire"
16552414|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine
~Interventions:
~Self sample from vagina using Rover's Evalyn Brush
~Self sample from the oral cavity using COPAN's FloqSwab
~Questionnaire"
16552415|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
16552416|NCT02934685|Experimental|hypofraction|70 Gy in 28 fractions over 5.6 weeks
16552417|NCT02934685|Active Comparator|convention|80Gy in 40 fractions over 8 weeks
16552418|NCT02934659|Experimental|Investigational|Intervention - Atlas Knee System device for medial knee osteoarthritis
16552419|NCT02934646|Experimental|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
16552420|NCT02934633|Experimental|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
16552421|NCT02934633|Active Comparator|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
16552422|NCT02934620|Experimental|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
16552423|NCT02934620|Active Comparator|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
16552424|NCT02934607|Active Comparator|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
16552425|NCT02934607|Experimental|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
16552426|NCT02934607|Active Comparator|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
16552427|NCT02934607|Experimental|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
16552428|NCT02934594||Group A|Motor function intact group: received palliative decompression
16552429|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
16552430|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
16552431|NCT02934568|Experimental|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
16552432|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
16552433|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
16552434|NCT02934542|No Intervention|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
16552435|NCT02934542|Experimental|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
16552436|NCT02934529|Active Comparator|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab
~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.
~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
16552437|NCT02934529|Experimental|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab
~Administration every 2 weeks for a maximum of 12 cycles
~Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,
~Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
16552438|NCT02934529|Experimental|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.
~Folinic acid, 5-FU, Bevacizumab
~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.
~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
16552569|NCT02933762|Experimental|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (<=) 600 mg] of JNJ-54175446, to be determined.
16614635|NCT02516852|No Intervention|Control|
16552439|NCT02934529|Active Comparator|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013
~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice
~Administration until progression occurs in the third line or unacceptable toxicity"
16552440|NCT02934529|Experimental|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly
~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity
~or depending on the patient's general condition and the study physician's decision
~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
16552441|NCT02934516|Experimental|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
16552442|NCT02934516|Active Comparator|Classic push method|Cesarean section with push method
16552443|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.
~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.
~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.
~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
16552444|NCT02934490|Experimental|Treatment group|
16552445|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
16552446|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
16552447|NCT02934464|Experimental|ARM A|"RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle
~PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
16552448|NCT02934464|Active Comparator|ARM B|"FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.
~mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.
~XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
16552449|NCT02934438|Active Comparator|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
16552450|NCT02934438|Placebo Comparator|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
16552451|NCT02934425|Placebo Comparator|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
16552452|NCT02934425|Experimental|High pork protein breakfast|High pork protein breakfast
16552453|NCT02934412|Experimental|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
16552454|NCT02934412|Experimental|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
16552455|NCT02934412|Experimental|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
16552456|NCT02934412|Experimental|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
16552457|NCT02934412|Experimental|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
16552458|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
16552459|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.
~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control
~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
16552460|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.
~Study subjects: Subjects with established primary (adrenal) AI"
16552461|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.
~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
16552570|NCT02933762|Experimental|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (<= 600 mg) of JNJ-54175446, to be determined.
16552462|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.
~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.
~Study subjects: Subjects with suspected PHA."
16552463|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.
~Study subjects: Adult subjects with established clinical and biochemical GHD."
16552464|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.
~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
16552465|NCT02934386|Experimental|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
16552466|NCT02934373|Active Comparator|A New Sound Processor|Sound Processor is the next generation sound processor.
16552467|NCT02934373|No Intervention|Subject's own sound processor|
16552468|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
16552469|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
16552470|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
16552471|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
16552472|NCT02934334||MDD|Major Depressive Disorder
16552473|NCT02934321|Active Comparator|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
16552474|NCT02934321|Experimental|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
16552475|NCT02934308|Experimental|ICU patients|
16552476|NCT02934295|Experimental|Pregnant women|
16552477|NCT02934269|Experimental|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
16552478|NCT02934269|Experimental|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
16552479|NCT02934269|Experimental|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
16552480|NCT02934269|Experimental|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
16552481|NCT02934269|Experimental|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
16552482|NCT02934269|Experimental|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
16552483|NCT02934256|Experimental|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
16552484|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
16552485|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
16552486|NCT02934230|Experimental|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
16552487|NCT02934230|No Intervention|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
16552488|NCT02934217|Experimental|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
16552489|NCT02934217|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
16552490|NCT02934204|Experimental|MTX and Temozolomide|"Induction therapy:
~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles
~Consolidation therapy:
~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
16552491|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
16552492|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
16552493|NCT02934178|Experimental|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
16552494|NCT02934178|Experimental|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
16552495|NCT02934178|Experimental|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
16552496|NCT02934178|Experimental|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
16552497|NCT02934178|Placebo Comparator|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
16552498|NCT02934178|Placebo Comparator|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
16552499|NCT02934178|Placebo Comparator|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
16552500|NCT02934178|Placebo Comparator|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
16552501|NCT02934165|Experimental|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
16552502|NCT02934165|Active Comparator|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
16552503|NCT02934152|Experimental|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
16552504|NCT02934152|Experimental|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
16552505|NCT02934152|Active Comparator|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
16552506|NCT02934139|Experimental|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
16552507|NCT02934139|Experimental|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
16552508|NCT02934139|Experimental|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
16552509|NCT02934139|Experimental|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
16552510|NCT02934139|Placebo Comparator|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
16552511|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
16552512|NCT02934113|No Intervention|Control|
16552513|NCT02934113|Experimental|iOTA and HWPP|
16552514|NCT02934113|Experimental|HWPP|
16552515|NCT02934100|Active Comparator|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
16552516|NCT02934100|Active Comparator|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
16552517|NCT02934100|Active Comparator|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
16552518|NCT02934100|Sham Comparator|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
16552519|NCT02934087|Active Comparator|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
16552520|NCT02934087|Active Comparator|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
16552521|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
16552522|NCT02934061|Experimental|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
16552523|NCT02934061|Active Comparator|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
16552524|NCT02934048|Experimental|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
16552525|NCT02934048|Experimental|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
16552526|NCT02934048|Experimental|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
16552527|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
16552528|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
16552530|NCT02934009|Experimental|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement. The measurement will be repeated on three different days with each patient.
16552531|NCT02934009|Experimental|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
16552532|NCT02933996|Experimental|TEAS+GA group|"The patients of TEAS+GA group will receive TEAS therapy in perioperative period.
~GA: general anesthesia"
16552533|NCT02933996|Sham Comparator|Sham TEAS+GA group|The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
16552534|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
16552535|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
16552536|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
16552537|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
16552538|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).
~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
16552539|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
16552540|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
16552541|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
16552542|NCT02933918|Experimental|Probiotics|
16552543|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
16552544|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
16552545|NCT02933892|Active Comparator|Transradial Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the arm access site (transradial access).
16552546|NCT02933892|Active Comparator|Transfemoral Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the inner thigh access site (transfemoral access).
16552547|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
16552548|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
16552549|NCT02933866|Experimental|DSXS topical|applied once daily for 28 days
16552550|NCT02933866|Placebo Comparator|Vehicle topical|applied once daily for 28 days
16552551|NCT02933853|Experimental|Faster Aspart|
16552552|NCT02933853|Active Comparator|Insulin Aspart|
16552553|NCT02933840|Experimental|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
16552554|NCT02933840|No Intervention|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
16552555|NCT02933827|Experimental|Low dose:|ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)
16552556|NCT02933827|Experimental|Middle dose|ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)
16552557|NCT02933827|Experimental|High dose|ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)
16552558|NCT02933814|No Intervention|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
16552559|NCT02933814|Experimental|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
16552560|NCT02933801|Experimental|Arm A: ODM-201|600mg ODM-201 BID (twice daily) and Best Supportive Care until progression
16552561|NCT02933801|Placebo Comparator|Arm B: Placebo|Placebo BID (twice daily) and Best Supportive Care until progression
16552562|NCT02933788|Experimental|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
16552563|NCT02933788|Active Comparator|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
16552564|NCT02933775|Experimental|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
16552565|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
16552566|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
16552567|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
16552568|NCT02933762|Experimental|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
16553504|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
16552571|NCT02933762|Experimental|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
16552572|NCT02933762|Experimental|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
16552573|NCT02933762|Experimental|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
16552574|NCT02933762|Experimental|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
16552575|NCT02933762|Experimental|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
16552576|NCT02933762|Experimental|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
16552577|NCT02933762|Experimental|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
16552578|NCT02933749|Active Comparator|The sitting|The sitting position Device sCtO2 Device BIS
16552579|NCT02933749|Active Comparator|The prone|The prone position Device sCtO2 Device BIS
16552580|NCT02933736|Experimental|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:
~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection
~Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection
~Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection"
16552581|NCT02933723|Experimental|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
16552582|NCT02933723|Active Comparator|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
16552583|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
16552584|NCT02933697|Active Comparator|Apixaban|2.5 mg apixaban twice daily for 6 to 60 months
16552585|NCT02933697|Active Comparator|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 6 to 60 months
16552586|NCT02933684|Experimental|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
16552587|NCT02933684|Placebo Comparator|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
16552588|NCT02933671|Experimental|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
16552589|NCT02933671|Placebo Comparator|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
16552590|NCT02933658|Experimental|Reference1|single(Reference1) -> combination(Reference1+Reference2)
16552591|NCT02933658|Experimental|Reference2|single(Reference2) -> combination(Reference1+Reference2)
16552592|NCT02933645|Active Comparator|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
16552593|NCT02933645|Placebo Comparator|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.
~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
16552594|NCT02933632|Active Comparator|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
16552595|NCT02933632|Active Comparator|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
16552596|NCT02933606|Experimental|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
16552597|NCT02933606|Experimental|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
16552598|NCT02933606|Experimental|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
16552599|NCT02933606|Placebo Comparator|Placebo b.i.d.|Suspension administered orally for 12 weeks.
16552600|NCT02933593|Active Comparator|labetalol|labetalol
16552601|NCT02933593|Active Comparator|hydralazine|Hydralazine
16552602|NCT02933593|Active Comparator|nifedipine|nifedipine
16552603|NCT02933580|Experimental|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.
16552604|NCT02933580|Experimental|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.
16552605|NCT02933580|Experimental|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.
16552606|NCT02933580|Experimental|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.
16552607|NCT02933567|Experimental|CSC OnDemand Pilo|Pilot Intervention
16552608|NCT02933554|Experimental|NASH- Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
16552609|NCT02933528|Experimental|Dsxs topical product|treatment with DSXS once daily for 28 days
16552610|NCT02933515|Experimental|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
16552611|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
16552612|NCT02933489|Experimental|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
16552613|NCT02933489|Experimental|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
16552614|NCT02933476|Experimental|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
16552615|NCT02933463|Experimental|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
16552616|NCT02933463|Active Comparator|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
16552617|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
16552618|NCT02933450|No Intervention|Standard of Care group|Standard of Care
16552619|NCT02933437|Experimental|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
16552620|NCT02933424|No Intervention|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
16552621|NCT02933424|Experimental|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
16552622|NCT02933424|Experimental|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
16552623|NCT02933424|Experimental|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
16552624|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
16552625|NCT02933398|Active Comparator|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
16552626|NCT02933398|Active Comparator|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
16552627|NCT02933385|Experimental|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
16552628|NCT02933385|Experimental|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
16552629|NCT02933385|Experimental|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
16552630|NCT02933385|Experimental|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
16552631|NCT02933385|No Intervention|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
16552632|NCT02933372|Experimental|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
16552633|NCT02933372|Experimental|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
16552634|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups [7].
16552635|NCT02933333|Experimental|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
16552636|NCT02933333|Experimental|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
16552637|NCT02933333|Experimental|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
16552638|NCT02933320|Experimental|Part A: Arm 1: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).
16552639|NCT02933320|Experimental|Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase|Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).
16552640|NCT02933320|Experimental|Part B: Arm1: BI-1206 single agent expansion phase|Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
16552641|NCT02933320|Experimental|Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase|Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
16552642|NCT02933307|No Intervention|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
16552643|NCT02933307|Experimental|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
16552644|NCT02933307|Experimental|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
16553505|NCT02927522|Placebo Comparator|Control|Placebo was administrated
16552645|NCT02933294|Active Comparator|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
16552646|NCT02933294|Active Comparator|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
16552647|NCT02933281|Experimental|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
16552648|NCT02933281|Experimental|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
16552649|NCT02933281|Experimental|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
16552650|NCT02933281|Experimental|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
16552651|NCT02933281|Experimental|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
16552652|NCT02933281|Experimental|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
16552653|NCT02933281|Experimental|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
16552654|NCT02933281|Experimental|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
16552655|NCT02933281|Active Comparator|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
16552656|NCT02933268|Active Comparator|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality > 300 mOsmo/kg
16552657|NCT02933268|Active Comparator|High water intake|Personalised daily water intake prescription to achieve target urine osmolality < 270 mOsm/kg.
16552658|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F every 2 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo sigmoidoscopies on week 9 and restaging scans on week 12. If no PD, option to continue treatment every 2 weeks until intolerance or progression. Option to extend nivolumabinterval to 4 weeks after 1 year
16552659|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo prostatectomy on week 9.
16552660|NCT02933242|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy
16552661|NCT02933229|Experimental|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.
~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
16552662|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
16552663|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
16552664|NCT02933190|Other|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
16552665|NCT02933177|Experimental|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
16552666|NCT02933177|Experimental|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
16552667|NCT02933164|Experimental|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
16552668|NCT02933151|Other|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
16552669|NCT02933151|Other|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
16552670|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
16552671|NCT02933125|Experimental|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
16552672|NCT02933125|Active Comparator|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
16552673|NCT02933112|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
16552674|NCT02933099|Experimental|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
16552675|NCT02933099|Active Comparator|Control arm|palonosetron+dexamethasone
16552676|NCT02933086|Experimental|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
16552677|NCT02933086|Experimental|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
16552678|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
16552679|NCT02933060|Experimental|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
16552680|NCT02933060|Sham Comparator|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
16552681|NCT02933047|Active Comparator|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
16552682|NCT02933047|Placebo Comparator|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
16552683|NCT02933034|Experimental|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
16552684|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
16552685|NCT02933008|Experimental|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
16552686|NCT02933008|Sham Comparator|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
16552687|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
16552688|NCT02932969|Experimental|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
16552689|NCT02932969|Experimental|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
16552690|NCT02932969|Experimental|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
16552691|NCT02932956|Experimental|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
16552692|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16552693|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
16552694|NCT02932930|Active Comparator|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.
~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
16552695|NCT02932930|Placebo Comparator|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.
~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
16552696|NCT02932917|Experimental|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
16552697|NCT02932904|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
16552698|NCT02932904|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
16552699|NCT02932904|Active Comparator|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
16552700|NCT02932904|Placebo Comparator|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
16552701|NCT02932891|Experimental|DSXS topical|active treatment
16552702|NCT02932878|Experimental|DSXS topical|administered twice daily for 28 days
16552703|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
16552704|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
16552705|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
16552706|NCT02932852|Active Comparator|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
16552707|NCT02932852|Active Comparator|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
16552708|NCT02932852|Active Comparator|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
16552709|NCT02932839|Experimental|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
16552710|NCT02932826|Experimental|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
16552711|NCT02932826|Active Comparator|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
16552712|NCT02932813|Experimental|Intervention Group|"THINK intervention:
~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
16552713|NCT02932813|No Intervention|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
16552714|NCT02932800|Active Comparator|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
16552715|NCT02932800|Active Comparator|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
16552716|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
16552717|NCT02932787|No Intervention|Control|
16552718|NCT02932774|Experimental|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
16552719|NCT02932774|Active Comparator|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
16552720|NCT02932774|Placebo Comparator|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
16552721|NCT02932761|Experimental|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
16552722|NCT02932761|Placebo Comparator|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
16552723|NCT02932748|Experimental|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
16552724|NCT02932748|Experimental|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
16552725|NCT02932748|Active Comparator|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
16552726|NCT02932722|Sham Comparator|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
16552727|NCT02932722|Active Comparator|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
16552728|NCT02932722|Active Comparator|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
16552729|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
16552730|NCT02932696|Experimental|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.
~Intervention: Cardiac training program"
16552731|NCT02932696|No Intervention|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
16552732|NCT02932683|Experimental|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
16552733|NCT02932683|No Intervention|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
16552734|NCT02932670|Active Comparator|costoclavicular inflaclavicular block|costoclavicular block with similar volume
16552735|NCT02932670|Experimental|costoclavicular block|costoclavicular block with decreasing volume
16552736|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
16552737|NCT02932631|Active Comparator|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:
~stretching, strengthening and/or mobilization;
~functional training of the affected muscles;
~functional training of the paretic limb."
16552738|NCT02932631|Experimental|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
16552739|NCT02932618|Experimental|On-demand Treatment|Participants will receive treatment for non-surgical bleeding episodes over a 12 to 18-month period.
16552740|NCT02932618|Experimental|Elective Surgery|12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
16552741|NCT02932618|Experimental|Emergency Surgery|Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
16552742|NCT02932605|Experimental|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
16552743|NCT02932605|Placebo Comparator|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
16552744|NCT02932592|Experimental|Dysglycemic group|"Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.
~Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus."
16552745|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
16552746|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
16552747|NCT02932566|Active Comparator|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
16552748|NCT02932566|Placebo Comparator|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
16552749|NCT02932553|Experimental|BVS and OMT|Optimal medical treatment + BVS implantation
16552750|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
16552751|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
16552752|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
16552753|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
16552754|NCT02932527|Experimental|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
16552755|NCT02932527|Other|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
16552756|NCT02932514|Experimental|Eversense (Senseonics) CGM System|
16552757|NCT02932501||MRONJ|"Patients diagnosed of medication-related osteonecrosis of the jaw (MRONJ). Treatment strategies vary depending on the stage of MRONJ and can be of different nature as:
~Conservative treatment Surgical treatment Adjuvant non-surgical treatment"
16552758|NCT02932488|Experimental|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.
~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
16552759|NCT02932475|Active Comparator|Treatment|Metformin 1000 mg twice a day
16552760|NCT02932475|Sham Comparator|Placebo|Placebo, identical to Metformin
16552761|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
16552762|NCT02932462|Placebo Comparator|Placebo|Vehicle
16552763|NCT02932436|Experimental|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
16552764|NCT02932436|Experimental|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
16552765|NCT02932423|Other|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
16552766|NCT02932423|Other|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
16552769|NCT02932397|Active Comparator|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
16552770|NCT02932397|Placebo Comparator|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
16552771|NCT02932384|Active Comparator|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
16552772|NCT02932384|Experimental|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
16552773|NCT02932371|Experimental|Cardiac Surgery|
16552774|NCT02932358|Active Comparator|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
16552775|NCT02932358|Active Comparator|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
16552776|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
16552777|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
16552778|NCT02932332|Active Comparator|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
16552779|NCT02932332|Active Comparator|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
16552780|NCT02932332|Sham Comparator|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
16552962|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
16552781|NCT02932332|Sham Comparator|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
16552782|NCT02932319|Active Comparator|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
16552783|NCT02932319|Sham Comparator|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
16552784|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
16552785|NCT02932306|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
16552786|NCT02932293|Experimental|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is <500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is >500 IU/ml.
16552787|NCT02932293|Experimental|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is <500 IU/ml or (b) 8 weeks if HCV VL on day 2 is >500 IU/ml.
16552788|NCT02932280|Experimental|Neratinib|There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
16552789|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
16552790|NCT02932254|Active Comparator|Magnesium Sulfate|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.
~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.
~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
16552791|NCT02932254|Placebo Comparator|Saline Solution|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.
~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.
~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
16552792|NCT02932241|Experimental|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
16552793|NCT02932241|No Intervention|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
16552794|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
16552795|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
16552796|NCT02932215|Experimental|All participants|All participants will receive open label lorcaserin
16552797|NCT02932202|Experimental|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
16552798|NCT02932202|Placebo Comparator|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
16552799|NCT02932189|No Intervention|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
16552800|NCT02932189|Experimental|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.
~Device: K5 Power Breath"
16552801|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
16552883|NCT02931734|Active Comparator|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
16552809|NCT02932137|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
16552810|NCT02932137|No Intervention|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
16552811|NCT02932124||1|manual chest compressions
16552812|NCT02932124||2|mechanical chest compression
16552813|NCT02932111|Experimental|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
16552814|NCT02932111|Placebo Comparator|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
16552815|NCT02932098|Experimental|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
16552816|NCT02932098|Active Comparator|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
16552817|NCT02932085|Active Comparator|rTMS + Wash-out period + Sham|"Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)
~Two weeks wash-out period
~Five consecutive daily sham stimulation sessions"
16552818|NCT02932085|Sham Comparator|Sham + Wash-out period + rTMS|"Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)
~Two weeks wash-out period
~Five consecutive daily repetitive transcranial magnetic stimulation sessions"
16552819|NCT02932059|Experimental|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
16552820|NCT02932059|Experimental|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
16552821|NCT02932059|Experimental|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
16552822|NCT02932059|Experimental|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
16552823|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
16552824|NCT02932033|Active Comparator|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
16552825|NCT02932033|Experimental|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
16552826|NCT02932020|Experimental|Group A|"Randomized 10 subjects
~Visit 1:
~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
16552827|NCT02932020|Other|Group B|"Randomized 10 subjects
~Visit 1:
~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).
~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
16552828|NCT02932007|Experimental|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
16552829|NCT02931994|No Intervention|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
16552830|NCT02931994|Active Comparator|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
16552831|NCT02931994|Active Comparator|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
16552832|NCT02931994|No Intervention|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
16552833|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
16552834|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.
~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
16552835|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.
~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
16552957|NCT02931227|Experimental|PICCO group|
16552836|NCT02931955||Control Group|"The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.
~The patients will receive usual standard of care and no intervention."
16552837|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
16552838|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
16552839|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
16552840|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
16552841|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
16552842|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
16552843|NCT02931929|Other|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
16552844|NCT02931916||healthy group|recruited for evaluation of system reliability
16552845|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
16552846|NCT02931903|Experimental|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
16552847|NCT02931903|Active Comparator|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
16552848|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
16552849|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
16552850|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
16552851|NCT02931877|Experimental|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
16552852|NCT02931877|Active Comparator|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
16552853|NCT02931864|No Intervention|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
16552854|NCT02931864|Experimental|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
16552855|NCT02931864|Active Comparator|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
16552856|NCT02931864|Active Comparator|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
16552857|NCT02931851|Placebo Comparator|Placebo|Standard Information
16552858|NCT02931851|Active Comparator|Intervention|Professionally developed website for relatives of ICU patients
16552859|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
16552860|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
16552861|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
16552862|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
16552863|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
16552864|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
16552865|NCT02931825|Experimental|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
16552866|NCT02931825|No Intervention|Control|No intervention (what is done currently)
16552867|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
16552868|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
16552869|NCT02931812||Healthy subjects|30 healthy subjects to compare
16552870|NCT02931799|Experimental|Nurse Follow-Up and Electronic Monitoring|
16552871|NCT02931799|Active Comparator|Minimal Intervention|
16552872|NCT02931786|Active Comparator|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
16552873|NCT02931786|Active Comparator|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
16552874|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
16552875|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
16552876|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
16552877|NCT02931760|Active Comparator|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
16552878|NCT02931760|Active Comparator|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
16552879|NCT02931747|Placebo Comparator|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
16552880|NCT02931747|Active Comparator|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
16552881|NCT02931747|Active Comparator|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
16552882|NCT02931734|Active Comparator|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
16552958|NCT02931214|Experimental|GMI-1359|Dose escalation
16552884|NCT02931734|Active Comparator|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
16552885|NCT02931734|Active Comparator|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
16552886|NCT02931734|Active Comparator|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
16552887|NCT02931734|Active Comparator|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
16552888|NCT02931734|Active Comparator|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
16552889|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
16552890|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
16552891|NCT02931708|Experimental|DFES group|"Diaphragm Functional Electrical Stimulation:
~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.
~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
16552892|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum
~ECG
~circulating sex hormones levels"
16552893|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum
~ECG
~circulating sex hormones levels"
16552894|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
16552895|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
16552896|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
16552897|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
16552898|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
16552899|NCT02931656|Experimental|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
16552900|NCT02931656|Active Comparator|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
16552901|NCT02931643|Placebo Comparator|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
16552902|NCT02931643|Experimental|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
16552903|NCT02931630|Experimental|HP/HF|Whey protein powder / High fiber bread
16552904|NCT02931630|Experimental|HP/LF|Whey protein powder / Low fiber bread
16552905|NCT02931630|Experimental|LP/HF|Maltodextrin powder / High fiber bread
16552906|NCT02931630|Experimental|LP/LF|Maltodextrin powder / Low fiber bread
16552907|NCT02931617|Active Comparator|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
16552908|NCT02931617|Experimental|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
16552909|NCT02931604|Experimental|Sinus irrigation|Sinus irrigation intervention
16552910|NCT02931591|Active Comparator|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
16552911|NCT02931591|Placebo Comparator|GH+Placebo|Children will be given both GH and Placebo for 6 months
16552912|NCT02931578|Active Comparator|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
16552913|NCT02931578|Active Comparator|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
16552914|NCT02931578|Active Comparator|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
16552915|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
16552916|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
16552917|NCT02931552|Experimental|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
16552918|NCT02931552|No Intervention|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
16552919|NCT02931539|Experimental|Maribavir Treatment|Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.
16552920|NCT02931539|Active Comparator|Investigator-Assigned Treatment|Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
16552921|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
16552922|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
16552923|NCT02931513||PBC patients|Patients with primary biliary cholangitis
16552959|NCT02931214|Experimental|Placebo|Dose escalation
16552960|NCT02931201|Experimental|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
16552961|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
16552924|NCT02931487|Experimental|Attentional Bias Modification|ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
16552925|NCT02931487|Sham Comparator|Sham comparator|Sham condition without modification of attentional bias. These trials are identical in structure to the ABM trials with the exception that target probes replaced negative and positive images with equal frequency.
16552926|NCT02931474|Placebo Comparator|Placebo|Salt Water Solution
16552927|NCT02931474|Experimental|Tesamorelin|Growth Hormone-Releasing
16552928|NCT02931461|Experimental|needle Procore ®|
16552929|NCT02931461|Active Comparator|needle Cook®|
16552930|NCT02931435|Active Comparator|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
16552931|NCT02931435|Sham Comparator|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
16552932|NCT02931422|Experimental|Low Financial Incentive|Conditional cash transfer upon HIV testing
16552933|NCT02931422|Experimental|Medium Financial Incentive|Conditional cash transfer upon HIV testing
16552934|NCT02931422|Experimental|High Financial Incentive|Conditional cash transfer upon HIV testing
16552935|NCT02931409|Experimental|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
16552936|NCT02931409|Active Comparator|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
16552937|NCT02931396|Experimental|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
16552938|NCT02931396|No Intervention|Control|Participants will be asked to continue their activities of daily living as usual.
16552939|NCT02931383|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
16552940|NCT02931383|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
16552941|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
16552942|NCT02931357|Experimental|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
16552943|NCT02931357|Active Comparator|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
16552944|NCT02931344|Experimental|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
16552945|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
16552946|NCT02931318|Experimental|Nevsehir|People Living in the City Center of Nevşehir
16552947|NCT02931305|Experimental|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
16552948|NCT02931305|Placebo Comparator|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
16552949|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
16552950|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
16552951|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
16552952|NCT02931240|Experimental|Treatment|Treatment with the Revivent TC System
16552953|NCT02931240|No Intervention|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
16552954|NCT02931227|Experimental|Brain-injured group|
16552955|NCT02931227|Experimental|Hypothermia group|
16552956|NCT02931227|Experimental|Hyperthermia group|
16552963|NCT02931175|Experimental|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
16552964|NCT02931175|Experimental|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
16552965|NCT02931162|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
16552966|NCT02931162|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
16552967|NCT02931149|Experimental|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
16552968|NCT02931136|Active Comparator|treatment group|Huperzine A treatment.
16552969|NCT02931136|Placebo Comparator|Placebo group|The placebo in 52 weeks.
16552970|NCT02931123|No Intervention|standard|
16552971|NCT02931123|Experimental|treatment|rifaximine and lattulose plus low proteine diet
16552972|NCT02931110|Experimental|CBL0137 Dose Escalation|"Dose Level 1: 150mg/m2, IV
~Dose Level 2: 180mg/m2, IV
~Dose Level 3: 240mg/m2, IV
~Dose Level 4: 320mg/m2, IV
~Dose Level 5: 400mg/m2, IV
~Dose Level 6: 540mg/m2, IV
~Dose Level 7: 650mg/m2, IV
~Dose Level 8: 780mg/m2, IV
~Dose Level 9: 950mg/m2, IV
~Dose Level 10: 1150mg/m2, IV
~Dose Level 11: 1400mg/m2, IV
~Dose Level 12: 1700mg/m2, IV
~Dose Level 13: 2000mg/m2, IV
~Dose Level 14: 2400mg/m2, IV
~Dose Level 15: 2900mg/m2, IV
~Dose Level 16: 3500mg/m2, IV"
16552973|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
16552974|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
16552975|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
16552976|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
16552977|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
16552978|NCT02931071|Experimental|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
16552979|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
~The knee-extension resistance training exercise is performed with an elastic exercise band."
16552980|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
~The knee-extension resistance training exercise is performed with an elastic exercise band."
16552981|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
~The knee-extension resistance training exercise is performed with an elastic exercise band."
16552982|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
16552983|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
16552984|NCT02931032|Experimental|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.
~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
16552985|NCT02931019|Experimental|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.
~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
16552986|NCT02931019|Experimental|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
16552987|NCT02931006|Placebo Comparator|control|
16552988|NCT02931006|Active Comparator|experimental|
16552989|NCT02930993|Experimental|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.
~CAR T dosage ranging from 5×10^4 /kg to 1×10^7 /kg will be tested ."
16552990|NCT02930980|Experimental|Investigational Software|Investigational Software loaded on Micra device
16552991|NCT02930967|Experimental|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.
~CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested."
16552992|NCT02930954|Active Comparator|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
16552993|NCT02930954|Experimental|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
16552994|NCT02930954|Experimental|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
16552995|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
16552996|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
16552997|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
16552998|NCT02930902|Active Comparator|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
16552999|NCT02930902|Experimental|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
16553000|NCT02930889|Experimental|Prostate Artery Embolization|Prostate Artery Embolization
16553001|NCT02930876|Experimental|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
16553002|NCT02930876|Experimental|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
16553003|NCT02930876|No Intervention|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
16553004|NCT02930863|Active Comparator|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
16553005|NCT02930863|Experimental|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
16553006|NCT02930850|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter sensor for measurement of hemoglobin.
16553007|NCT02930837|Experimental|alteplase|
16553008|NCT02930824|Experimental|Adult Genotype guided treatment|For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
16553009|NCT02930824|No Intervention|Adult Conventional treatment|For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
16553010|NCT02930824|Experimental|Pediatric Genotype guided treatment|For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
16553011|NCT02930824|No Intervention|Pediatric Conventional treatment|For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
16553012|NCT02930811|Experimental|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
16553013|NCT02930811|Placebo Comparator|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
16553014|NCT02930798|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16553015|NCT02930785|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16553016|NCT02930772|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16553017|NCT02930759|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16553018|NCT02930746|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16553019|NCT02930733|Active Comparator|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
16553020|NCT02930733|Placebo Comparator|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
16553021|NCT02930707|Active Comparator|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
16553022|NCT02930707|Placebo Comparator|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
16553113|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
16553506|NCT02927522|Experimental|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
16553023|NCT02930694|Experimental|Group 1: Treatment Sequence AB|Participants will receive Treatment A [JNJ-54175446, 50 milligram (mg) capsule] on Day 1 of period 1 followed by Treatment B [JNJ-54175446, 50 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
16553024|NCT02930694|Experimental|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
16553025|NCT02930694|Experimental|Group 2: Treatment Sequence CD|Participants will receive Treatment C [JNJ-54175446, 100 mg capsule] on Day 1 of period 1 followed by Treatment D [JNJ-54175446, 100 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
16553026|NCT02930694|Experimental|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
16553027|NCT02930681|Placebo Comparator|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
16553028|NCT02930681|Experimental|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
16553029|NCT02930681|Experimental|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
16553030|NCT02930668|Placebo Comparator|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.
~Subjects will take 2 capsules three times a day, 30 mins before meals."
16553031|NCT02930668|Experimental|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg
~Subjects will take 2 capsules three times a day, 30 mins before meals."
16553032|NCT02930668|Experimental|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg
~Subjects will take 2 capsules three times a day, 30 mins before meals."
16553033|NCT02930655|Experimental|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
16553034|NCT02930655|Experimental|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
16553035|NCT02930642|Experimental|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
16553036|NCT02930642|Active Comparator|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
16553037|NCT02930642|No Intervention|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
16553038|NCT02930616|Experimental|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
16553039|NCT02930616|Active Comparator|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
16553040|NCT02930603||Control|Control: Healthy child
16553041|NCT02930603||Experimental|Patients with Developmental Disabilities
16553042|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
16553043|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
16553044|NCT02930590|Active Comparator|Standard mattress|basic foam
16553045|NCT02930564|Experimental|a milk fat or gluten challenge|patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.
16553046|NCT02930551|Active Comparator|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
16553047|NCT02930551|Placebo Comparator|Isotonic Saline|Isotonic Saline 2 ml Injection
16553048|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
16553049|NCT02930525|Active Comparator|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
16553050|NCT02930525|Experimental|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
16553051|NCT02930512||patients with idiopathic Parkinson's disease|
16553052|NCT02930499|Experimental|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
16553053|NCT02930499|Active Comparator|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
16553054|NCT02930486|Active Comparator|ZipTight|ZipTight suture endobutton
16553055|NCT02930486|Active Comparator|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
16553056|NCT02930473|Experimental|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
16553057|NCT02930473|Active Comparator|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
16553058|NCT02930447|Experimental|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
16553059|NCT02930447|No Intervention|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
16553060|NCT02930434|Active Comparator|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
16553061|NCT02930434|Active Comparator|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
16553114|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
16553062|NCT02930421|Experimental|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
16553063|NCT02930421|No Intervention|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
16553064|NCT02930395||professional rugby players|
16553065|NCT02930382|Experimental|BAROREFLEX|
16553066|NCT02930369|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
16553067|NCT02930369|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
16553068|NCT02930356|Experimental|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
16553069|NCT02930356|Experimental|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
16553070|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
16553071|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
16553072|NCT02930330|Experimental|Interval|"2x / week INT
~2x / week CONT"
16553073|NCT02930330|Active Comparator|Continuous|4x / week CONT
16553074|NCT02930317|Experimental|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
16553075|NCT02930317|Experimental|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
16553076|NCT02930304|Experimental|first physiotherapy|cold pack, TENS, exercise
16553077|NCT02930304|Experimental|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
16553078|NCT02930304|Experimental|third physiotherapy|cold pack, TENS, ESWT, exercise
16553079|NCT02930265|Active Comparator|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
16553080|NCT02930265|No Intervention|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
16553081|NCT02930252|Experimental|Niti-S Biliary ComVi Stent|"Device:
~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
16553082|NCT02930252|Active Comparator|Niti-S Stent (D-type)|"Device:
~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.
~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
16553083|NCT02930239|Experimental|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
16553084|NCT02930239|Active Comparator|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
16553085|NCT02930226|Experimental|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
16553086|NCT02930226|Experimental|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
16553087|NCT02930226|Experimental|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
16553088|NCT02930226|Experimental|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
16553089|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
16553090|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
16553091|NCT02930200|Active Comparator|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
16553092|NCT02930200|Active Comparator|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
16553093|NCT02930200|Experimental|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
16553094|NCT02930174|Active Comparator|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
16553095|NCT02930174|Active Comparator|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
16553096|NCT02930161|Experimental|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
16553097|NCT02930161|Experimental|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
16553098|NCT02930161|Placebo Comparator|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
16553099|NCT02930148|Experimental|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
16553100|NCT02930148|No Intervention|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
16553101|NCT02930135|Experimental|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite
~Local anesthesia administration
~Isolation of tooth with rubber dam
~Opening of the cavity and the removal of undermined enamel
~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed
~Partial removal of carious dentin on the pulp wall.
~Washing the cavity and dryness
~Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)
~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
16553102|NCT02930135|Active Comparator|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite
~Local anesthesia administration
~Isolation of tooth with rubber dam
~Opening of the cavity and the removal of undermined enamel
~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed
~Partial removal of carious dentin on the pulp wall.
~Washing the cavity and dryness
~Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)
~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
16553105|NCT02930109|Experimental|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour
~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.
~Phase II: maximum tolerated dose. given as a 1 hour infusion
~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
16553106|NCT02930096||pulsatility index mesured with doppler ultrasound|
16553107|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA>=2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
16553108|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA<2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
16553109|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA>=2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
16553110|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA<2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
16553111|NCT02930057|Experimental|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
16553112|NCT02930057|Other|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
16553115|NCT02930031|Experimental|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
16553116|NCT02930031|Active Comparator|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
16553117|NCT02930018|Placebo Comparator|Placebo|Drug vehicle only
16553118|NCT02930018|Experimental|Nerinetide (NA-1), 2.6 mg/kg|
16553119|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
16553120|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
16553121|NCT02929992|Experimental|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
16553122|NCT02929992|Experimental|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
16553123|NCT02929992|Active Comparator|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
16553124|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
16553125|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
16553126|NCT02929966|Placebo Comparator|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
16553127|NCT02929966|Experimental|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
16553128|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.
~chart review"
16553129|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
16553130|NCT02929940||PiZZ|Observational
16553131|NCT02929940||PiMZ|Observational
16553132|NCT02929940||Other AATD variants|Observational
16553133|NCT02929940||PiMM (Control)|Observational
16553134|NCT02929927|Experimental|Control group|Rubber dam isolation, tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, then take the sample again, drying the canal and fill the canal with a commercial calcium hydroxide-based paste. After 2 weeks, the canals were filled with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
16553135|NCT02929927|Experimental|Experimental group|Rubber dam isolation，tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO for 1 min, then 17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, drying the canal, aPDT, then take the sample again. then dried the canals and filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
16553136|NCT02929914|Experimental|Control|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, dentin washed with sodium 0.9% saline, sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
16553137|NCT02929914|Experimental|PDT+CH|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, disinfect the remaining dentin with antimicrobial photodynamic therapy (DENFOTEX PADplus), sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
16553138|NCT02929901|Active Comparator|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
16553139|NCT02929901|Active Comparator|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
16553140|NCT02929901|Active Comparator|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
16553141|NCT02929901|Placebo Comparator|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
16553142|NCT02929888|Experimental|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
16553143|NCT02929888|Active Comparator|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
16553748|NCT02926079||Pregnant women diagnosed with gestational diabetes|
16553144|NCT02929875|Experimental|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:
~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
16553145|NCT02929875|No Intervention|Control (No intervention)|No educational intervention provided to subjects in control group
16553146|NCT02929862|Experimental|Single Agent 55716|
16553147|NCT02929849|Experimental|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
16553148|NCT02929849|Active Comparator|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
16553149|NCT02929849|Placebo Comparator|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
16553150|NCT02929836|Active Comparator|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
16553151|NCT02929836|Active Comparator|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
16553152|NCT02929836|Active Comparator|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
16553153|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
16553154|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
16553155|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
16553156|NCT02929810|Experimental|sleep extension|
16553157|NCT02929810|Active Comparator|sleep maintenance|
16553158|NCT02929797|Experimental|AKT + gemcitabine|gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
16553159|NCT02929797|Active Comparator|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
16553160|NCT02929784|Experimental|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
16553161|NCT02929784|Sham Comparator|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
16553162|NCT02929784|No Intervention|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
16553163|NCT02929771|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
16553164|NCT02929771|Active Comparator|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
16553165|NCT02929758|Active Comparator|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
16553166|NCT02929758|Active Comparator|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
16553167|NCT02929758|Other|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
16553168|NCT02929758|Other|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
16553169|NCT02929745|Experimental|10 HLA-Cw6+|HLA-Cw6+ patients will donate blood and skin samples
16553170|NCT02929745|Experimental|10 HLA Cw6-|HLA-Cw6- patients will donate blood and skin samples
16553171|NCT02929745|Experimental|Healthy Skin|Healthy patients will donate blood and skin samples
16553172|NCT02929732|Experimental|Willis-Ekbom disease patients (CASE)|
16553173|NCT02929732|Experimental|Healthy volunteers (CONTROL)|
16553174|NCT02929719|Experimental|Test Gel 5%|Topical, twice daily on the face for 84 days.
16553175|NCT02929719|Active Comparator|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
16553176|NCT02929719|Placebo Comparator|Placebo Gel|Topical, twice daily on the face for 84 days
16553177|NCT02929706|Experimental|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
16553178|NCT02929706|No Intervention|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
16553179|NCT02929693|Experimental|combination|YYJD plus gefitinib
16553180|NCT02929693|Placebo Comparator|controll|placebo plus gefitinib
16553749|NCT02926079||Pregnant women with normal pregnancy|
16553181|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
16553182|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
16553183|NCT02929654|Active Comparator|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
16553184|NCT02929654|Experimental|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
16553185|NCT02929654|Experimental|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
16553186|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
16553187|NCT02929628|Experimental|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
16553188|NCT02929628|Sham Comparator|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
16553189|NCT02929615|Experimental|Treatment group|
16553190|NCT02929589|Experimental|Opioid naïve patients-Group A|"Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
~."
16553191|NCT02929589|Experimental|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
16553192|NCT02929589|Placebo Comparator|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
16553193|NCT02929589|Experimental|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
16553194|NCT02929576|Experimental|Double-blind enzalutamide with paclitaxel|
16553195|NCT02929576|Placebo Comparator|Double-blind placebo with paclitaxel|
16553196|NCT02929576|Experimental|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
16553197|NCT02929563|Experimental|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
16553198|NCT02929563|Placebo Comparator|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
16553199|NCT02929550||Well-controlled cohort (LDL-C ≤ 1.8 mmol/L)|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation with well-controlled LDL-cholesterol
16553200|NCT02929550||Non-controlled cohort|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation and with not well-controlled LDL-C
16553201|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
16553202|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
16553203|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
16553204|NCT02929524|Experimental|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
16553205|NCT02929524|Placebo Comparator|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
16553206|NCT02929511|Experimental|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
16553207|NCT02929511|Experimental|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
16553208|NCT02929511|Active Comparator|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
16553209|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
16553210|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
16553211|NCT02929485|Experimental|Experimental: Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
16553212|NCT02929485|Placebo Comparator|Comparator: Placebo|Drug: Placebo for tolcapone administered at study visit
16553213|NCT02929485|Experimental|Experimental: Bromocriptine|Drug: Bromocriptine 1.25mg (single dose) administered at study visit
16553778|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
16553214|NCT02929472|Experimental|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
16553215|NCT02929472|Other|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
16553216|NCT02929459|Experimental|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
16553217|NCT02929459|Experimental|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
16553218|NCT02929459|Placebo Comparator|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
16553219|NCT02929446|Experimental|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
16553220|NCT02929446|No Intervention|Control|No mobilisation or breathing exercises until discharge or maximum 6 hours
16553221|NCT02929446|Experimental|Mobilisation and breathing exercises (PEP)|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
16553222|NCT02929433|Experimental|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
16553223|NCT02929433|No Intervention|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
16553224|NCT02929420|Experimental|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
16553225|NCT02929420|Placebo Comparator|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.
~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
16553226|NCT02929407|Experimental|FE 204205|
16553227|NCT02929407|Placebo Comparator|Placebo|
16553228|NCT02929394|Active Comparator|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
16553229|NCT02929394|No Intervention|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
16553230|NCT02929381|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
16553231|NCT02929381|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
16553232|NCT02929368|Active Comparator|Fluoroscopy|PICC Implantation under x-ray
16553233|NCT02929368|Active Comparator|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
16553234|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
16553235|NCT02929342|Experimental|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
16553236|NCT02929342|Experimental|[14C]-Pitolisant|[14C]-Pitolisant, oral single dose administration at Day8.
16553237|NCT02929329|Experimental|Omecamtiv Mecarbil|Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations < 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and < 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and < 1000 ng/mL maintained a 25 mg BID dosing regimen.
16553238|NCT02929329|Placebo Comparator|Placebo|Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.
16553239|NCT02929316|Experimental|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
16553240|NCT02929290|Experimental|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.
~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
16553241|NCT02929277|Other|single arm study|
16553242|NCT02929264|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
16553243|NCT02929264|Placebo Comparator|Placebo|Placebo, capsules, single dose
16553244|NCT02929264|No Intervention|Control|No Intervention
16553245|NCT02929251|Active Comparator|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
16553246|NCT02929251|Experimental|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
16553247|NCT02929251|Experimental|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
16553248|NCT02929238|Experimental|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
16553249|NCT02929238|Experimental|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
16553250|NCT02929225|Experimental|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
16553251|NCT02929225|Placebo Comparator|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
16553252|NCT02929212|Other|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
16553253|NCT02929212|Other|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
16553254|NCT02929212|Other|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
16553255|NCT02929212|Other|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
16553256|NCT02929199|Active Comparator|group A|Pressable E- max, an all ceramic crown
16553257|NCT02929199|Experimental|Group B|BIO-Hpp hybrid crown
16553258|NCT02929186|Experimental|Opt-In|Opt-In Outreach
16553259|NCT02929186|Experimental|Opt-Out|Opt-Out Outreach
16553260|NCT02929173|Active Comparator|Group 2|E-max is un allceram crown
16553261|NCT02929173|Experimental|Group 1|Bio HPP crown is a hybrid crown
16553262|NCT02929160|Experimental|PCN|Percutaneous nephrostomy
16553263|NCT02929160|Experimental|JJ Stent|Retrograde ureteric JJ stent
16553264|NCT02929147|Experimental|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
16553265|NCT02929147|Experimental|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
16553266|NCT02929147|Active Comparator|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
16553267|NCT02929134|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
16553268|NCT02929134|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
16553269|NCT02929121|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
16553270|NCT02929121|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
16553271|NCT02929108|No Intervention|Enhanced Usual Care|This group will receive usual hospice care which has been enhanced as the staff have been trained in shared decision making.
16553272|NCT02929108|Experimental|Facebook|This group only participates in the Facebook groups, not in the shared decision making
16553273|NCT02929108|Experimental|ACCESS|This group participates in facebook and web conferencing for shared decision making
16553274|NCT02929095|Experimental|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
16553275|NCT02929095|Active Comparator|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
16553276|NCT02929082|Experimental|Group 1 : volunteer patient|Group 1 will be constituted of 20 volunteer patients coming for abdominal MRI with no known hepatic disease, in order to determine the feasibility of FRM . A 5-minute- additional sequence to measure FRM will be done for the volunteers.
16553277|NCT02929082|Experimental|Group 2 : patient with resectable HCC|"Group 2 will be constituted of 60 patients with resectable HCC eligible for surgery. This group will enable to evaluate the gold standard.
~A 5-minute- additional sequence to measure FRM will be done while MRI sequence."
16553278|NCT02929082|Experimental|Group 3 : patient with HCC eligible for TACE|"Group 3 will be constituted of 50 patients with HCC eligible for transplant with transcatheter arterial chemoembolization (TACE) treatment as pending treatment before transplant. This groups will enable to evaluate the efficiency of TACE through the necrosis percentage in treated HCC.
~A 5-minute- additional sequence to measure FRM will be done while MRI sequence"
16553279|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
16553280|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
16553281|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
16553282|NCT02929056|Placebo Comparator|SOC alginate dressing|SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
16553283|NCT02929056|Experimental|AmnioExCel dressing|AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
16553284|NCT02929043||Dentine hypersensitivity subjects|
16553285|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
16553286|NCT02929017|Other|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
16553287|NCT02929017|Other|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
16553288|NCT02929004|Experimental|Vibrasens|"In addition of classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction, this group will follow a local vibration training, using small and portable vibrator device.
~Training programme: vibration training 3/week from Day 1 to Day 60"
16553289|NCT02929004|No Intervention|Usual activities|Usual activities from day 1 to Day 60 during their classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction.
16553290|NCT02928991|Experimental|Acquired Aplastic Anemia (AA)|Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.
16553291|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.
16553292|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.
16553293|NCT02928978|Experimental|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
16553294|NCT02928978|Placebo Comparator|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
16553295|NCT02928965|Experimental|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the remainder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
16553296|NCT02928965|Placebo Comparator|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
16553297|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
16553298|NCT02928952|No Intervention|DSME alone|Usual care control
16553299|NCT02928939||Multimorbid patients|
16553300|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
16553301|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
16553302|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
16553303|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
16553304|NCT02928900|Experimental|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
16553305|NCT02928900|No Intervention|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
16553306|NCT02928887|Experimental|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
16553307|NCT02928887|No Intervention|Ambient light|Exposure to ambient, white fluorescent light
16553308|NCT02928874|Experimental|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
16553309|NCT02928874|Experimental|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
16553310|NCT02928861|Experimental|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
16553311|NCT02928848|Experimental|Real tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
16553312|NCT02928848|Sham Comparator|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
16553313|NCT02928835|Experimental|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
16553314|NCT02928835|No Intervention|Control group|Control group received standardized physical therapy intervention.
16553315|NCT02928822|Experimental|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
16553316|NCT02928822|Active Comparator|Control Group|Conventional aphasia therapy.
16553317|NCT02928809|No Intervention|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
16553318|NCT02928809|Experimental|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
16553319|NCT02928809|No Intervention|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
16553320|NCT02928809|Experimental|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
16553321|NCT02928809|Placebo Comparator|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
16553322|NCT02928809|Placebo Comparator|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
16553323|NCT02928796||Trainees|Registrar Cardiologists
16553324|NCT02928796||Trainers|Consultant Cardiologists
16553325|NCT02928783|Experimental|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
16553326|NCT02928783|No Intervention|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
16553327|NCT02928770|Experimental|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
16553328|NCT02928757|Experimental|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
16553329|NCT02928757|No Intervention|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
16553330|NCT02928744|Experimental|COPD|
16553331|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.
~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
16553332|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.
~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
16553333|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
16553334|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
16553335|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
16553336|NCT02928692|Placebo Comparator|Placebo|Placebo administered before surgery
16553337|NCT02928692|Experimental|Minocycline|Minocycline was administrated before surgery
16553338|NCT02928692|No Intervention|Volunteers|Health people for calculate the incidence of POCD
16553339|NCT02928679|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
16553340|NCT02928679|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
16553341|NCT02928666|Experimental|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
16553342|NCT02928666|No Intervention|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
16553343|NCT02928653|Active Comparator|Sucrose Sweetened Beverage|100-140 g sucrose/day
16553344|NCT02928653|Experimental|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
16553345|NCT02928653|Experimental|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
16553346|NCT02928653|Experimental|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
16553347|NCT02928653|Experimental|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
16553348|NCT02928640|Experimental|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
16553349|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
16553350|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
16553351|NCT02928614|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
16553352|NCT02928614|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
16553353|NCT02928601|Experimental|Ondansetron|
16553354|NCT02928601|Active Comparator|Saline|
16553355|NCT02928575|Experimental|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
16553356|NCT02928562|No Intervention|Control|TKA patients without exercise intervention
16553357|NCT02928562|Experimental|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
16553358|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
16553359|NCT02928523|Experimental|Autologous Fecal Microbiota Transplantation|Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.
16553360|NCT02928510||Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
16553361|NCT02928497|Experimental|WATCHMAN (Device)|WATCHMAN LAAC Device implant including modified post-implant drug regimen.
16553362|NCT02928497|Active Comparator|Control|Single antiplatelet therapy or no therapy (Control) at the discretion of the study physician for the duration of the trial.
16553363|NCT02928484|Active Comparator|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
16553364|NCT02928484|Placebo Comparator|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
16553365|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
16553366|NCT02928458|Active Comparator|Omnipaque|Arm 1
16553367|NCT02928458|Active Comparator|MD-Gastroview|Arm 2
16553368|NCT02928445|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
16553369|NCT02928445|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
16553370|NCT02928432|Experimental|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
16553371|NCT02928419|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
16553372|NCT02928419|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
16553374|NCT02928393|Experimental|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
16553375|NCT02928393|Placebo Comparator|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
16553376|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
16553377|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
16553378|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
16553379|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
16553380|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
16553381|NCT02928354|Experimental|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
16553382|NCT02928354|Experimental|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
16553383|NCT02928354|Experimental|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
16553384|NCT02928341|No Intervention|No intervention|Current water supply access
16553385|NCT02928341|Experimental|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
16553386|NCT02928328|Experimental|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
16553387|NCT02928328|Experimental|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
16553388|NCT02928328|Experimental|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
16553389|NCT02928315|Active Comparator|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
16553390|NCT02928315|Placebo Comparator|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
16553391|NCT02928302|Experimental|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
16553392|NCT02928302|No Intervention|no screening|no TVU CL screening
16553393|NCT02928289|Active Comparator|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
16553394|NCT02928289|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
16553395|NCT02928276|Experimental|All patients|All eligible patients
16553396|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
16553397|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
16553398|NCT02928250|Active Comparator|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
16553399|NCT02928250|Placebo Comparator|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
16553400|NCT02928237|Active Comparator|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
16553401|NCT02928237|Placebo Comparator|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
16553402|NCT02928224|Experimental|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
16553403|NCT02928224|Experimental|Doublet Arm|Encorafenib + cetuximab.
16553404|NCT02928224|Active Comparator|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
16553405|NCT02928211|Experimental|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
16553406|NCT02928198|Active Comparator|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
16553407|NCT02928198|Active Comparator|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
16553408|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
16553409|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
16553410|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
16553411|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
16553412|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
16553413|NCT02928159|Experimental|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
16553414|NCT02928146|Active Comparator|Lichtenstein technique|Lichtenstein inguinal hernia repair
16553415|NCT02928146|Active Comparator|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
16553416|NCT02928146|Active Comparator|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
16553417|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
16553418|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
16553419|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
16553420|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
16553421|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
16553422|NCT02928107|Experimental|At-Home Telephone Screening (Tele-HS)|Subjects receive printed educational materials about hearing loss and access to at-home Tele-HS
16553423|NCT02928107|Experimental|PCP Encouragement, At-Home Tele-HS|Subjects receives encouragement from primary care provider (PCP) or hearing screening, printed materials and access to at-home Tele-HS.
16553424|NCT02928107|Experimental|PCP Encouragement, In-Office Tele-HS|Subjects receives PCP encouragement for hearing screening, printed materials and access to Tele-HS while in clinic.
16553425|NCT02928107|No Intervention|CHEER Cohort (non-randomized)|Participants will complete a one page questionnaire related to Red Flag conditions during a routine Otolaryngology appointment for suspected hearing loss. The audiologist will be complete a questionnaire about the participants audiological assessment including Red Flag conditions. The Otolaryngology provider will complete a questionnaire about the participants otoscopic exam findings, Red Flag conditions, and indicate if any other conditions exist that me be considered a medical contraindication to hearing aid fitting.
16553426|NCT02928094|Experimental|A: Ad5FGF-4|Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.
16553427|NCT02928094|Placebo Comparator|B: Placebo|Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.
16553428|NCT02928081|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
16553429|NCT02928081|Other|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
16553430|NCT02928068|Experimental|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
16553431|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
16553432|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
16553433|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
16553434|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
16553435|NCT02928029|Experimental|Phase1, arm1: 33 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
16553436|NCT02928029|Experimental|Phase1, arm2: 55 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
16553437|NCT02928029|Placebo Comparator|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
16553438|NCT02928029|Experimental|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
16553439|NCT02928016|Experimental|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
16553440|NCT02928016|Experimental|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
16553441|NCT02928016|Experimental|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
16553442|NCT02928016|Experimental|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
16553443|NCT02928016|Experimental|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
16553444|NCT02928016|Experimental|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
16553445|NCT02928003|Experimental|Lung Surgery|
16553446|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
16553447|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
16553448|NCT02927977|Active Comparator|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
16553449|NCT02927977|Experimental|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
16553450|NCT02927964|Experimental|Treatment (radiation therapy, TLR9 agonist SD-101, ibrutinib)|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also receive ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity.
16553451|NCT02927951|Experimental|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
16553452|NCT02927951|Placebo Comparator|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
16553453|NCT02927938|Other|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)
~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:
~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)
~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)
~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
16553454|NCT02927938|Other|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)
~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:
~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)
~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)
~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
16553455|NCT02927938|No Intervention|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
16553456|NCT02927938|No Intervention|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:
~Lack the immunophenotype of interest,
~Cytarabine based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit or refusal)] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)
~HMA-based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit, lack of donor, refusal)] and do not receive HCT
~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.
~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
16553457|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
16553458|NCT02927912|Experimental|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
16553459|NCT02927899|Experimental|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
16553460|NCT02927886|Experimental|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
16553461|NCT02927886|Placebo Comparator|Intrapyloric injection of botulinum toxin|
16553468|NCT02927847|Experimental|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
16553469|NCT02927847|Active Comparator|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
16553470|NCT02927834|Active Comparator|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
16553471|NCT02927834|Active Comparator|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
16553472|NCT02927834|Active Comparator|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
16553473|NCT02927821|Experimental|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
16553474|NCT02927821|No Intervention|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
16553475|NCT02927808|Experimental|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
16553476|NCT02927808|No Intervention|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
16553477|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
16553478|NCT02927782|Active Comparator|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
16553479|NCT02927782|Experimental|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
16553480|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
16553481|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
16553482|NCT02927743|Active Comparator|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
16553483|NCT02927743|No Intervention|control|GPs will register data without receiving online feed-back
16553484|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
16553485|NCT02927730||negative retainted placenta histology|
16553486|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
16553487|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
16553488|NCT02927691|Experimental|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
16553489|NCT02927691|Other|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
16553490|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
16553491|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
16553492|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery & Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
16553493|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
16553494|NCT02927639|No Intervention|Control|This group will receive the usual standard of care for 6 months.
16553495|NCT02927626|Experimental|Yang Yin Fu Zheng therapy|
16553496|NCT02927626|Placebo Comparator|Routine medical care|
16553497|NCT02927600|Experimental|Low GI Rice Breakfast|Intake of low GI breakfast
16553498|NCT02927600|Experimental|High GI rice Breakfast|Intake of High GI breakfast
16553499|NCT02927600|Experimental|Low GI Rice Dinner|Intake of low GI dinner
16553500|NCT02927600|Experimental|High GI Rice Dinner|Intake of High GI dinner
16553501|NCT02927587|Experimental|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
16553502|NCT02927587|Other|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
16553503|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
16553507|NCT02927496|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
16553508|NCT02927496|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
16553509|NCT02927483|Experimental|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
16553510|NCT02927483|Active Comparator|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
16553511|NCT02927470|Experimental|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
16553512|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
16553513|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
16553514|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
16553515|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
16553516|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
16553517|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
16553518|NCT02927444|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
16553519|NCT02927444|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
16553520|NCT02927431|Experimental|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
16553521|NCT02927431|Experimental|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
16553522|NCT02927431|Placebo Comparator|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
16553523|NCT02927418|Experimental|Strength & Conditioning|Supervised S & C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
16553524|NCT02927418|Active Comparator|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
16553525|NCT02927405|Placebo Comparator|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
16553526|NCT02927405|Experimental|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
16553527|NCT02927392|Experimental|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
16553528|NCT02927392|No Intervention|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
16553529|NCT02927379|Active Comparator|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
16553530|NCT02927379|Active Comparator|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
16553531|NCT02927379|Placebo Comparator|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
16553532|NCT02927366|Experimental|QCC374|Adult patients with pulmonary arterial hypertension (PAH) on QCC374. All patients were initiated at 0.03 mg BID (Day 1-3), and were up-titrated to next higher dose 0.06 mg BID (Day 4) and increased to 0.12 mg BID (Day 7-14).
16553533|NCT02927366|Placebo Comparator|Placebo|Adult patients with pulmonary arterial hypertension (PAH) on placebo matching to QCC374 doses (0.03 mg BID (Day 1-3), 0.06 mg BID (Day 4) and 0.12 mg BID (Day 7-14)).
16553534|NCT02927353|Experimental|DMB-3113|adalimumab biosimilar
16553535|NCT02927353|Active Comparator|adalimumab|adalimumab
16553536|NCT02927340|Experimental|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
16553537|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.
~Zero Echo Time (ZTE) scan for head attenuation"
16553538|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.
~PET/MR Q Static (Q. MRAC)"
16553539|NCT02927314|Placebo Comparator|Placebo|Placebo tablets orally q12h
16553540|NCT02927314|Active Comparator|CF102 12.5mg|CF102 tablets orally q12h
16553541|NCT02927314|Active Comparator|CF102 25mg|CF102 tablets orally q12h
16553542|NCT02927301|Experimental|Atezolizumab|Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
16553543|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
16553544|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
16553545|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
16553546|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
16553547|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
16553548|NCT02927275|Experimental|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
16553549|NCT02927275|Experimental|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
16553550|NCT02927275|Experimental|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
16553551|NCT02927275|Other|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
16553552|NCT02927262|Experimental|ASP2215|Subjects will be treated with ASP2215 once daily (continuously for up to 2 years).
16553553|NCT02927262|Placebo Comparator|Placebo|Subjects will be treated with matching placebo tablets once daily (continuously for up to 2 years).
16553554|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
16553555|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
16553556|NCT02927236|Experimental|Cocaine - Active (EFS)|designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
16553557|NCT02927236|Sham Comparator|Cocaine - Sham (EFS)|To test the efficacy of the iTBS.
16553558|NCT02927236|Other|Healthy Control-Main (EFS)|Population comparison of acute experimental iTBS.
16553559|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
16553560|NCT02927223|Experimental|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
16553561|NCT02927210|Placebo Comparator|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
16553562|NCT02927210|Experimental|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
16553563|NCT02927197|Experimental|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
16553564|NCT02927197|No Intervention|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
16553565|NCT02927184|Placebo Comparator|Placebo|Placebo capsule
16553566|NCT02927184|Experimental|VK2809 (5mg)|5mg VK2809 capsule
16553567|NCT02927184|Experimental|VK2809 (10mg)|10mg VK2809 capsule
16553568|NCT02927184|Experimental|VK2809 (10mg QOD)|10mg VK2809 capsule
16553569|NCT02927171|No Intervention|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
16614676|NCT02516605|Placebo Comparator|Placebo|
16553570|NCT02927171|Experimental|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
16553571|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
16553572|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.
~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
16553573|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0
~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
16553574|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
16553575|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
16553576|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.
~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
16553577|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
16553578|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
16553579|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
16553580|NCT02927132|Experimental|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
16553581|NCT02927132|Experimental|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
16553582|NCT02927132|Experimental|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
16553583|NCT02927132|Experimental|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
16553584|NCT02927132|No Intervention|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
16553585|NCT02927132|Experimental|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
16553586|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
16553587|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
16553588|NCT02927106||Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
16553589|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
16553590|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
16553591|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg|ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
16553592|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
16553593|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
16553594|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg|ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
16553595|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg|ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
16553596|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg|ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
16553846|NCT02925403|Placebo Comparator|Group 3|Saline injection on days 0, 28, and 56.
16553597|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Tibialis Anterior (TA)|"Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.
~Drug: Placebo Normal saline
~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.
~Drug: ACE-083 Recombinant fusion protein"
16553598|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.
~Drug: ACE-083 Recombinant fusion protein
~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.
~Drug: ACE-083 Recombinant fusion protein"
16553599|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Biceps Brachii (BB)|"Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.
~Drug: Placebo Normal saline
~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.
~Drug: ACE-083 Recombinant fusion protein"
16553600|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.
~Drug: ACE-083 Recombinant fusion protein
~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.
~Drug: ACE-083 Recombinant fusion protein"
16553601|NCT02927067|Experimental|Maribavir/ Placebo|Participants will receive 400 milligrams (mg) of maribavir (2*200 mg tablets) twice daily (BID) orally along with a placebo matched to valganciclovir for 8 weeks.
16553602|NCT02927067|Active Comparator|Valganciclovir/ Placebo|Participants will receive 900 mg of valganciclovir (2*450 mg tablets) BID orally along with a placebo matched to maribavir for 8 weeks. Valganciclovir dose may be adjusted to 450 mg BID or 450 mg QD during the study for renal function impairment or neutropenia.
16553603|NCT02927054|Other|Internal Medicine Residents|Sepsis education provided to internal medicine residents
16553604|NCT02927054|Other|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
16553605|NCT02927054|Other|Orthopedic Residents|Sepsis education provided to orthopedic residents
16553606|NCT02927054|Other|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
16553607|NCT02927054|Other|General Surgery Residents|Sepsis education provided to general surgery residents
16553608|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
16553609|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
16553610|NCT02927028|Other|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
16553611|NCT02927015|Experimental|Purple Majesty potato chips|Purple Majesty potato chips
16553612|NCT02927015|Experimental|Mountain Rose potato chips|Mountain Rose potato chips
16553613|NCT02927015|Experimental|White potato chips|White potato chips
16553614|NCT02927015|Experimental|Crackers|Crackers
16553615|NCT02927002|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
16553616|NCT02927002|Sham Comparator|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
16553617|NCT02926989|Experimental|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
16553618|NCT02926989|Active Comparator|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
16553619|NCT02926976|Active Comparator|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
16553620|NCT02926976|Active Comparator|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
16553621|NCT02926976|Active Comparator|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.
16553622|NCT02926976|Active Comparator|clozapine|only clozapine, dosage and frequency:300~600 mg/d;
16553623|NCT02926976|Active Comparator|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
16553624|NCT02926976|Active Comparator|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
16553625|NCT02926963|Experimental|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
16553843|NCT02925416|Other|One dose oritavancin, one dose placebo|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, a placebo (D5W) will be administered.
16553626|NCT02926950|Experimental|Sotagliflozin 400 mg + Metformin|Following a 2-week run-in period, sotagliflozin 400 mg was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
16553627|NCT02926950|Placebo Comparator|Placebo + Metformin|Following a 2-week run-in period, matching placebo was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
16553628|NCT02926937|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 400 milligrams (mg) administered as two 200 mg tablets, once daily (QD), before the first meal of the day in the double-blind treatment period for up to 26 weeks.
16553629|NCT02926937|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 Sotagliflozin tablet and 1 matching placebo tablet, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
16553630|NCT02926937|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
16553631|NCT02926924|Active Comparator|Wound Vac|Wound vac
16553632|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
16553633|NCT02926911|Active Comparator|Surgery|DCIS - Surgery +/- radiation choice for endocrine therapy (MMG q 12 months x 5 years usual care for recurrent disease)
16553634|NCT02926911|Experimental|Active Monitoring|DCIS - Choice for endocrine therapy (MMG q 6 months x 5 years GCC for invasive progression)
16553635|NCT02926898|Experimental|ZX008 - 0.2 mg/kg/day - Cohort 1|"ZX008 0.2 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.
~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
16553636|NCT02926898|Experimental|ZX008 - 0.4 mg/kg/day - Cohort 1|"ZX008 - 0.4 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.
~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
16553637|NCT02926898|Experimental|ZX008 - 20 mg/day maximum - Cohort 2|"ZX008 - 20 mg/day maximum dose is supplied as an oral solution administered twice a day day (BID) in equally divided doses with food. Dose to be determined based on based on Cohort 1 .
~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
16553638|NCT02926898|Placebo Comparator|Matching Placebo - Cohort 2|Matching placebo will be administered twice a day (BID) in equally divided doses with food.
16553639|NCT02926885|Active Comparator|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
16553640|NCT02926885|Experimental|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
16553641|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
16553642|NCT02926859|Experimental|Cannabidiol|Cannabidiol as add-on to individualized pharmacological treatment
16553643|NCT02926859|Placebo Comparator|Placebo|Placebo as add-on to individualized pharmacological treatment
16553644|NCT02926846|Experimental|Lavage arm|Intravenous vancomycin & gentamicin with adjunctive lavage
16553645|NCT02926846|Active Comparator|Standard treatment arm|Intraperitoneal vancomycin & gentamicin
16553646|NCT02926833|Experimental|KTE-C19 + ATZ|Participants will receive conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days. Treatment with ATZ will begin 21 days following KTE-C19 (Phase 1 Cohort 1), 14 days following KTE-C19 (Phase 1 Cohort 2), and 1 day following KTE-C19 (Phase 1, Cohort 3 & Phase 2).
16553647|NCT02926820|Experimental|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
16553648|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
16553649|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
16553650|NCT02926794|Experimental|SA and II|Combined self-affirmation and implementations intention arm
16553651|NCT02926794|Experimental|SA and No II|Self-affirmation and control intentions condition
16553652|NCT02926794|Experimental|No SA and II|Implementation intentions intervention and control writing task
16553653|NCT02926794|Experimental|No SA and No II|Control writing task and control intentions condition
16553654|NCT02926781|Experimental|osteotome technique|transcrestal sinus floor elevation using osteotomes
16553655|NCT02926781|Active Comparator|drills|transcrestal sinus floor elevation using drills
16553656|NCT02926768|Experimental|Daily dose of CK-101|Daily oral dose of CK-101
16553657|NCT02926755|Experimental|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
16553658|NCT02926729|Experimental|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
16553659|NCT02926729|Active Comparator|Control|Standard lumpectomy without nonlinear microscopy imaging.
16553660|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
16553661|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
16553662|NCT02926690|Experimental|OTS167PO|
16553663|NCT02926677|Experimental|Cue-Centered Therapy (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
16553664|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
16553665|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
16553670|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
16553671|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
16553672|NCT02926625|Active Comparator|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
16553673|NCT02926625|Experimental|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
16553674|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
16553675|NCT02926599|Experimental|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).
~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
16553676|NCT02926599|No Intervention|Control|"No particular training.
~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
16553677|NCT02926586|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.
16553678|NCT02926586|Active Comparator|high-dose cytarabine|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
16553679|NCT02926573|Active Comparator|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
16553680|NCT02926573|Placebo Comparator|Placebo|Placebo liquid by mouth or Per Tube twice a day
16553681|NCT02926547||CCIS|
16553682|NCT02926547||invasive breast cancer|
16553683|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
16553684|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
16553685|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
16553686|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
16553687|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
16553688|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
16553847|NCT02925377|Experimental|Neuromuscular|Neuromuscular warm-up
16553689|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
16553690|NCT02926508|Experimental|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
16553691|NCT02926508|Placebo Comparator|Placebo|Maltodextrin
16553692|NCT02926495|Active Comparator|Treatment (ON)|
16553693|NCT02926495|Sham Comparator|Control (OFF)|
16553694|NCT02926482|No Intervention|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
16553695|NCT02926482|Experimental|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
16553696|NCT02926469|No Intervention|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
16553697|NCT02926469|Experimental|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
16553698|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.
16553699|NCT02926443|Active Comparator|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
16553700|NCT02926443|Experimental|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
16553701|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
16553702|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
16553703|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
16553704|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
16553705|NCT02926430|Experimental|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
16553706|NCT02926404||Pediatric patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) <18Years old
16553707|NCT02926404||Adult patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) >18Years old
16553708|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
16553709|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
16553710|NCT02926378|Experimental|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
16553711|NCT02926365|Experimental|ICBT|Therapist-supported internet-delivered CBT
16553712|NCT02926352|Experimental|Extinction Training with LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear domain. 15 minutes after fear extinction, participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system; to stimulate the vmPFC). Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
16553713|NCT02926352|Active Comparator|Extinction Training with Sham LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear. 15 minutes after fear extinction, participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
16553844|NCT02925403|Active Comparator|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
16553714|NCT02926352|Experimental|LLLT alone|Participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). F3 corresponds with the left dorsolateral prefrontal cortex and F4 corresponds with the right dorsolateral prefrontal cortex. Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
16553715|NCT02926352|Sham Comparator|Sham LLLT alone|Participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
16553716|NCT02926339|Experimental|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
16553717|NCT02926339|No Intervention|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
16553718|NCT02926326|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1
~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
16553719|NCT02926313|No Intervention|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
16553720|NCT02926313|Experimental|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
16553721|NCT02926287|Experimental|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
16553722|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure <100 will receive up to 6 units of whole blood when available.
16553723|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure <100, as well as adult male patients with systolic blood pressure <100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
16553724|NCT02926248|Experimental|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
16553725|NCT02926248|Placebo Comparator|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
16553726|NCT02926235|Experimental|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
16553727|NCT02926235|Placebo Comparator|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
16553728|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
16553729|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
16553730|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
16553731|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
16553732|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
16553733|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
16553734|NCT02926183|Experimental|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
16553735|NCT02926170|Experimental|rivaroxaban|Rivaroxaban 20 mg per day
16553736|NCT02926170|Active Comparator|acenocumarol|INR adjusted dose
16553737|NCT02926157|Experimental|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
16553738|NCT02926157|No Intervention|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
16553741|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
16553742|NCT02926118|Experimental|Low glycemic load|Low glycemic load
16553743|NCT02926118|Experimental|High glycemic load|High glycemic load
16553744|NCT02926105|Experimental|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
16553745|NCT02926105|Experimental|Otago|Individually tailored exercise programme
16553746|NCT02926105|Active Comparator|Helsana booklet|Helsana recommendations and exercises
16553747|NCT02926092||Arm 1|Observation of progression of disease over time.
16553750|NCT02926066|Experimental|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect
~Dosage form: Aqueous solution Dose(s): 1.81x10^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
16553751|NCT02926053|Experimental|Patient group|"All patients receive the same treatment.
~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.
~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.
~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.
~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
16553752|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
16553753|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
16553754|NCT02926014|Experimental|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.
~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
16553755|NCT02926014|Other|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
16553756|NCT02925988|Other|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
16553757|NCT02925975|Other|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
16553758|NCT02925975|Experimental|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
16553759|NCT02925975|Experimental|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
16553760|NCT02925975|Active Comparator|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
16553761|NCT02925962|Experimental|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.
~CDSS overview:
~The study MDs order CKD triple marker tests
~Patients will go to the lab as per usual clinical care
~Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines
~Results will also be sent to the Study MD's for monitoring
~At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP
~If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
16553762|NCT02925962|Experimental|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.
~CDSS Plus overview:
~At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit
~The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit
~On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance
~A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
16553763|NCT02925962|No Intervention|Usual Care|Patients continue to receive usual care by their provider.
16553764|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
16553765|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
16553766|NCT02925936|Active Comparator|Cathode|Thyroid facing the cathode end of xray machine
16553767|NCT02925936|Active Comparator|Anode|Thyroid facing the anode end of xray machine
16553768|NCT02925923|Active Comparator|Ticagrelor|crushed ticagrelor (180 mg); (n=50 patients)
16553769|NCT02925923|Active Comparator|Eptifibatide bolus+clopidogrel|Eptifibatide bolus (180 mcg/kg x 2 boluses) + clopidogrel 600 mg and heparin low-dose (n=50 patients)
16553770|NCT02925910|Other|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
16553771|NCT02925910|Other|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
16553772|NCT02925897|Experimental|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
16553773|NCT02925897|No Intervention|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
16553774|NCT02925884|Experimental|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
16553775|NCT02925884|No Intervention|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
16553777|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
16553779|NCT02925845|Experimental|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
16553780|NCT02925845|No Intervention|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
16553781|NCT02925832|Experimental|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
16553782|NCT02925832|Experimental|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
16553783|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
16553784|NCT02925806||ER/LA opioids included in the class REMS|
16553785|NCT02925806||IR Opioids|
16553786|NCT02925806||Celecoxib|
16553787|NCT02925806||Benzodiazepines|
16553788|NCT02925793|Experimental|1% DS107 cream|Participants in this group will receive 1% DS107 cream twice daily.
16553789|NCT02925793|Experimental|5% DS107 cream|Participants in this group will receive 5% DS107 cream twice daily.
16553790|NCT02925793|Placebo Comparator|Vehicle cream|Participants in this group will receive matching placebo cream twice daily.
16553791|NCT02925780|Experimental|Resin infiltration|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated using the resin infiltrant Icon (DMG, Germany). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
16553792|NCT02925780|Active Comparator|Microabrasion|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated by microabrasion using the microabrasive material Opalustre (Ultradent, USA). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
16553793|NCT02925767|Experimental|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
16553794|NCT02925767|Active Comparator|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
16553795|NCT02925741|Experimental|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
16553796|NCT02925741|No Intervention|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
16553797|NCT02925728|Experimental|Nutrition with Finger-Food|Nutrition with Finger-Food
16553798|NCT02925728|Active Comparator|Nutrition without Finger-Food|Nutrition without Finger-Food
16553799|NCT02925715|Experimental|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
16553800|NCT02925715|Experimental|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
16553801|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks IV
16553802|NCT02925676|Experimental|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
16553803|NCT02925663|Experimental|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
16553804|NCT02925650|Experimental|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
16553805|NCT02925650|Experimental|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
16553806|NCT02925650|Experimental|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
16553807|NCT02925650|Placebo Comparator|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
16553808|NCT02925637|Experimental|FACoT group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
16553809|NCT02925637|No Intervention|control group|control group receiving standard care - cognitive and functional assesment
16553810|NCT02925624|Experimental|CLOSE guided PVI and insertable cardiac monitor|
16553811|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
16553812|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
16553813|NCT02925598|Experimental|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
16553814|NCT02925598|Experimental|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
16553815|NCT02925598|Experimental|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
16553816|NCT02925585||Pre/post pelvic floor surgery imaging|
16553817|NCT02925572|Experimental|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
16553818|NCT02925572|Experimental|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
16553819|NCT02925559|Experimental|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
16553820|NCT02925559|Active Comparator|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
16553842|NCT02925416|Experimental|Two doses oritavancin|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL D5W will be administered.
16553821|NCT02925546|Experimental|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
16553822|NCT02925546|Experimental|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
16553823|NCT02925546|Experimental|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
16553824|NCT02925546|Experimental|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
16553825|NCT02925546|Experimental|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
16553826|NCT02925546|Experimental|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
16553827|NCT02925533|Experimental|B-701 and Pembrolizumab|"B-701 will be administered every 3 weeks intravenously
~Pembrolizumab will be administered every 3 weeks intravenously"
16553828|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
16553829|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
16553830|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
16553831|NCT02925494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
16553832|NCT02925481|Experimental|Low dose Yoga|12 week online yoga for 60 minutes per week
16553833|NCT02925481|Experimental|Moderate dose Yoga|12 week online yoga for 150 minutes per week
16553834|NCT02925481|Active Comparator|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
16553835|NCT02925468|Experimental|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
16553836|NCT02925468|No Intervention|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
16553837|NCT02925455|Experimental|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
16553838|NCT02925455|Active Comparator|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
16553839|NCT02925442|Experimental|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
16553840|NCT02925442|Experimental|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
16553841|NCT02925442|Sham Comparator|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
16553845|NCT02925403|Active Comparator|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
16553848|NCT02925377|Active Comparator|Control|Standard warm-up
16553849|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
16553850|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
16553851|NCT02925351|Experimental|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
16553853|NCT02925325|Experimental|Music Therapy|Music therapy 8 weekly sessions
16553854|NCT02925325|Active Comparator|Usual Treatment|It is the usual medical treatment.
16553855|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
16553856|NCT02925312|No Intervention|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
16553857|NCT02925299|Experimental|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
16553858|NCT02925299|Active Comparator|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
16553859|NCT02925286|Experimental|Intervention group|Five organizations will get the intervention during fall/winter 2016.
16553860|NCT02925286|No Intervention|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
16553861|NCT02925273|Other|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
16553862|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria
~Ileal pouch reservoir in situ
~Greater than three years since closure of ileostomy
~Normal pouch function as defined by Orësland score of <4
~Never had a diagnosis of pouchitis
~Never had treatment for pouchitis
~No evidence of pouchitis on rigid pouchoscopy
~CRP <10"
16553863|NCT02925247|Other|patient with atrial fibrillation|
16553897|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with tolvaptan or already treated with tolvaptan will be eligible.
16553898|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
16553899|NCT02925195|Experimental|Active Treatment|
16553900|NCT02925195|Placebo Comparator|Placebo|Placebo
16553901|NCT02925182|Experimental|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
16553902|NCT02925182|Placebo Comparator|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
16553903|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
16553904|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
16553905|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
16553906|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
16553907|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
16553908|NCT02925143|Experimental|E-learning course|
16553909|NCT02925130|Experimental|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
16553910|NCT02925130|Experimental|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
16553911|NCT02925130|Placebo Comparator|Placebo|Acute oral intake of a placebo
16553912|NCT02925117|Placebo Comparator|Placebo|Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
16553913|NCT02925117|Experimental|Upadacitinib 7.5 mg|Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
16553914|NCT02925117|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
16553915|NCT02925117|Experimental|Upadacitinib 30 mg|Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
16553916|NCT02925104|Experimental|INC280|
16553917|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
16553918|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
16553919|NCT02925065|Experimental|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
16553920|NCT02925065|Experimental|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
16553921|NCT02925052|Experimental|GTG|Gastric tube placement using the Gastric Tube Guide
16553922|NCT02925052|Other|Conventional|Gastric tube placement using a conventional method, according to local protocol.
16553923|NCT02925039|Experimental|Experimental|Sit to stand training augmented with technology delivered movement feedback
16553924|NCT02925039|Active Comparator|Control|Sit to stand training as per normal practice
16553925|NCT02925026|Experimental|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
16553926|NCT02925026|Placebo Comparator|Placebo|rice flour
16553927|NCT02925013|Experimental|Study group|Pregnant women at delivery
16553928|NCT02925013|Other|Control group|Women in fertility age not pregnant
16553929|NCT02925000|Experimental|TLC178|Liposomal Vinorelbine
16553930|NCT02924987|Other|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
16553931|NCT02924974|Sham Comparator|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
16553932|NCT02924974|Experimental|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
16553933|NCT02924961|Experimental|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
16553934|NCT02924961|Active Comparator|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
16553935|NCT02924948|No Intervention|Conventional insertion|EUS will be inserted with conventional method.
16553936|NCT02924948|Experimental|Balloon inflated insertion|EUS will be inserted with balloon inflated method
16553937|NCT02924935|Experimental|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
16553938|NCT02924922|Active Comparator|Laparoscopic partial nephrectomy|"Inclusion criteria fulfilled:
~Baseline Abdomen CT/MRI
~Patient Age, Weight, Height, Co-Medication
~Informed Consent
~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)
~During hospitalization, one day before laparoscopic partial nephrectomy:
~eGFR
~sCreatinine
~Hemoglobin
~After surgery:
~Assessment of eGFR 4 days after operation
~Hb assessment every 6 H in the first 48 H
~Assessment of adverse events
~Histological Results
~6, 12, 24 months after intervention:
~Creatinine Clearance (only performed at 6 months follow-up)
~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)
~eGFR
~Assessment of adverse events
~Assessment of possible recurrence
~Assesment of kidney volume variation"
16553939|NCT02924922|Active Comparator|Robot assisted partial nephrectomy|"Inclusion criteria fulfilled:
~Baseline Abdomen CT/MRI
~Patient Age, Weight, Height, Co-Medication
~Informed Consent
~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)
~During hospitalization, one day before robot assisted partial nephrectomy:
~eGFR
~sCreatinine
~Hemoglobin
~After surgery:
~Assessment of eGFR 4 days after operation
~Hb assessment every 6 H in the first 48 H
~Assessment of adverse events
~Histological Results
~6, 12, 24 months after intervention:
~Creatinine Clearance (only performed at 6 months follow-up)
~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)
~eGFR
~Assessment of adverse events
~Assessment of possible recurrence
~Assesment of kidney volume variation"
16553940|NCT02924909|Experimental|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
16553941|NCT02924896|Other|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
16553942|NCT02924896|Other|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
16553943|NCT02924896|Other|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
16553944|NCT02924896|Other|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
16553945|NCT02924896|Other|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
16553946|NCT02924896|Other|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
16553947|NCT02924883|Experimental|Trastuzumab Emtansine + Atezolizumab|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
16553948|NCT02924883|Active Comparator|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
16553949|NCT02924870|Active Comparator|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
16553950|NCT02924870|Experimental|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
16553951|NCT02924857|Experimental|Test Group (Chocolate Touch)|"The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.
~The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.
~If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
16553952|NCT02924857|Active Comparator|Control Group (Lutonix Drug Coated Balloon)|"Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.
~The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).
~If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.
~Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
16553953|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
16553954|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
16553955|NCT02924831|Experimental|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
16553956|NCT02924831|Experimental|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
16553957|NCT02924831|Placebo Comparator|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
16553958|NCT02924831|Experimental|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
16553959|NCT02924831|Experimental|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
16553960|NCT02924818|Experimental|Chronic Obstructive Pulmonary disease (COPD)|
16553961|NCT02924818|Experimental|Cystic Fibrosis (CF)|
16553962|NCT02924818|Experimental|bronchiectasis|
16553965|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
16553966|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
16553967|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
16553968|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
16553969|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
16553970|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
16553971|NCT02924766|Experimental|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
16553972|NCT02924753|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
16553973|NCT02924740|Active Comparator|control|pelvic floor muscle training
16553974|NCT02924740|Experimental|intervention|vaginal tampon training.
16553975|NCT02924727|Experimental|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).
~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.
~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
16553976|NCT02924727|Active Comparator|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).
~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.
~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
16553977|NCT02924714|Other|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
16553978|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
16553979|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16553980|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16553981|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16553982|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16553983|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16553984|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16553985|NCT02924675|Experimental|pregabalin group|
16553986|NCT02924675|Placebo Comparator|Placebo group|
16553987|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
16553988|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
16553989|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
16553990|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
16553991|NCT02924649|Experimental|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
16553992|NCT02924649|No Intervention|Standard care group|The standard care group will receive daily mobilisation to the seated position.
16553993|NCT02924636|Experimental|Intervention|personalized and online intervention. The intervention website will provide secure communication with dietician and lifestyle coaches. Women will receive emails and monthly newsletters with new content and reminder.
16553994|NCT02924636|No Intervention|Control|standard care with oral information about the goal of nutritional needs during pregnancy and gestational weight gain guidelines according to BMI
16619881|NCT02481843||Hyperoxia|2-hours of hyperoxia (FiO2 = 1.0)
16553995|NCT02924597|Experimental|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
16553996|NCT02924597|Active Comparator|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
16553997|NCT02924571|Experimental|Bone Marrow Aspirate Concentrate (BMAC)|
16553998|NCT02924571|Active Comparator|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|
16553999|NCT02924558|Experimental|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
16554000|NCT02924558|Placebo Comparator|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
16554001|NCT02924532||Patients with total thiroidectomy|
16554002|NCT02924506|Other|Fixed Core|Cervical arthroplasty with fixed core prothesis
16554003|NCT02924506|Other|Movable Core|Cervical arthroplasty with movable core prothesis
16554004|NCT02924493|Experimental|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
16554005|NCT02924493|Placebo Comparator|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
16554006|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
16554007|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
16554008|NCT02924467|No Intervention|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
16554009|NCT02924467|Experimental|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
16554010|NCT02924467|Experimental|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
16554011|NCT02924467|Experimental|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
16554012|NCT02924454|Experimental|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
16554013|NCT02924454|Experimental|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
16554014|NCT02924454|Experimental|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
16554015|NCT02924454|Experimental|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
16554016|NCT02924441|Experimental|Right Breast Lidocaine and calming music|Group 1 - right breast lidocaine & calming music
16554017|NCT02924441|Experimental|Right Breast Lidocaine and no music|Group 2 - right breast lidocaine & no calming music
16554018|NCT02924441|Experimental|Left Breast Lidocaine and calming music|Group 3 - left breast lidocaine & calming music
16554019|NCT02924441|Experimental|Left Breast Lidocaine and no music|Group 4 - left breast lidocaine & no calming music
16554020|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.
~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.
~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
16554021|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.
~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
16554022|NCT02924415|Experimental|Tele-care support|Online psychoeducation treatment using new technologies
16554023|NCT02924415|Active Comparator|Control group|Standard care
16554026|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
16554027|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
16554031|NCT02924363||Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- & post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
16554032|NCT02924350|Experimental|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
16554033|NCT02924350|Active Comparator|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
16554034|NCT02924337|Experimental|Imeglimin therapeutic dose|Tablet, oral, single dose
16554035|NCT02924337|Experimental|Imeglimin supratherapeutic dose|Tablet, oral, single dose
16554036|NCT02924337|Placebo Comparator|Placebo|Tablet, oral, single dose
16554037|NCT02924337|Active Comparator|Moxifloxacin|Tablet, oral, single dose (400 mg)
16554038|NCT02924324|Active Comparator|propofol alone|1st Bone Marrow procedure (BM) Intervention A: propofol alone. Crossover for second BM procedure propofol & ropivacaine
16554039|NCT02924324|Experimental|propofol and ropivacaine|1st BM procedure: Intervention B: propofol & ropivacaine. Crossover for second BM procedure propofol alone
16554040|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
16554041|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
16554042|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
16554043|NCT02924298|Experimental|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate > 60 mL/min/1.73m^2, to undergo SLIMM intervention
16554044|NCT02924298|Experimental|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to < 60 mL/min/1.73m^2, to undergo SLIMM intervention
16554045|NCT02924285|Active Comparator|Procedure|Radiofrequency catheter ablation
16554046|NCT02924285|Active Comparator|Antiarrhythmic Drug|Amiodarone
16554047|NCT02924272|Experimental|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until ixazomib is available to the participant through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
16554048|NCT02924259|Experimental|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
16554049|NCT02924246|Placebo Comparator|Control group|Regular cholera vaccination
16554050|NCT02924246|Active Comparator|Raw milk|Cholera vaccination - raw milk
16554051|NCT02924246|Active Comparator|Pasteurized milk|Cholera vaccination - pasteurized milk
16554052|NCT02924246|Active Comparator|UHT milk|Cholera vaccination - UHT milk
16554053|NCT02924233|Experimental|Sym004 + nivolumab|"Phase 1b, dose-escalation:
~Dose Level 1: Sym004 + nivolumab (Q2W)
~Dose Level 2: Sym004 + nivolumab (Q2W)
~Dose Level -1: Sym004 + nivolumab, if needed"
16554054|NCT02924233|Experimental|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:
~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
16554055|NCT02924233|Active Comparator|Nivolumab|"Phase 2b, dose-expansion:
~Receiving nivolumab monotherapy (Q2W)"
16554058|NCT02924207|Experimental|Intervention|Path Electronic decision support arm
16554059|NCT02924194|Experimental|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
16554119|NCT02923856|Experimental|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
16554060|NCT02924194|Experimental|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
16554061|NCT02924181|Active Comparator|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
16554062|NCT02924181|Active Comparator|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
16554063|NCT02924181|Active Comparator|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
16554064|NCT02924181|Active Comparator|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
16554065|NCT02924168|Experimental|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density [EFD] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
16554066|NCT02924168|Sham Comparator|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
16554067|NCT02924155|Experimental|SJP002|single/repeated administration
16554068|NCT02924155|Placebo Comparator|SJP002 placebo|single/repeated administration
16554069|NCT02924142|Experimental|Intervention|Mandibular removable partial denture with OT Cap attachment
16554070|NCT02924142|No Intervention|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
16554073|NCT02924116|Experimental|Bioboosti|Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
16554074|NCT02924116|Experimental|Sustained Efficacy|"Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia.
~Subjects will use it once a day for about one hour, before habitual sleep time."
16554075|NCT02924116|Experimental|Insomnia and migraine|Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.
16554076|NCT02924103|Active Comparator|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.
~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
16554077|NCT02924103|Active Comparator|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
16554078|NCT02924090|Active Comparator|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
16554079|NCT02924090|Active Comparator|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
16554080|NCT02924090|Active Comparator|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
16554081|NCT02924090|Active Comparator|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
16554082|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
16554083|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
16554084|NCT02924051|Experimental|Motivational Interview (MI)|Intervention group participants receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse
16554085|NCT02924051|Active Comparator|Cooking Skills/Nutritional Education|Participants in this arm receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
16554120|NCT02923856|Experimental|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
16554121|NCT02923843|Experimental|intervention|Comprehensive Geriatric Assessment
16554122|NCT02923843|No Intervention|control|Standard care
16554086|NCT02924038|Experimental|IMA950/poly-ICLC subcutaneous (subQ) + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
16554087|NCT02924038|Experimental|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
16554088|NCT02924025|Experimental|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
16554089|NCT02924025|No Intervention|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
16554090|NCT02924012|Experimental|active video game|An active game session lasting 40 minutes
16554091|NCT02924012|Other|sedentary video game|An sedentary game session lasting 40 minutes
16554092|NCT02924012|Other|walking|An walking lasting 40 minutes
16554093|NCT02923999|Experimental|Dose cohort 1|P2G12 0.125g
16554094|NCT02923999|Experimental|Dose cohort 2|P2G12 0.25g
16554095|NCT02923999|Experimental|Dose cohort 3|P2G12 0.5g
16554096|NCT02923986|Experimental|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
16554097|NCT02923986|Experimental|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
16554098|NCT02923973|Experimental|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
16554099|NCT02923973|No Intervention|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
16554100|NCT02923960|Active Comparator|Standard ONS|liquid oral nutritional supplement
16554101|NCT02923960|Experimental|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
16554102|NCT02923960|Active Comparator|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
16554103|NCT02923947|Experimental|Normal renal function|For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.
16554104|NCT02923947|Experimental|Severe renal impairment|For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance <30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.
16554105|NCT02923934|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
16554106|NCT02923921|Experimental|Pegilodecakin + FOLFOX|Pegilodecakin 5 microgram per kilogram (μg/kg) dosed as one of the following 2 fixed doses: 0.4 milligram (mg) for participants weighing ≤80 kg or 0.8 mg for participants weighing>80 kg on Days 1-5 and Days 8-12 subcutaneously (SC) plus FOLFOX [dl-Leucovorin (dl-LV) 400 milligram per meter square (mg/m2) and oxaliplatin 85 mg/m2 followed by bolus 5-fluorouracil (5-FU) 400 mg/m2 and a 46 to 48 hour infusion of 5- FU 2400 mg/m2] initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression. After discontinuation of FOLFOX in the absence of tumor progression [that is (i.e., completion of the planned 12 cycles or unacceptable FOLFOX related toxicity], Pegilodecakin 10µg/kg maintenance treatment administered as one of the 2 fixed doses, either 0.8 mg for participants weighing ≤80 kg or 1.6 mg for participants weighing>80 kg.
16554107|NCT02923921|Active Comparator|FOLFOX|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression.
16554108|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
16554109|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
16554110|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
16554111|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
16554112|NCT02923869|Active Comparator|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
16554113|NCT02923869|Active Comparator|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
16554114|NCT02923856|Experimental|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
16554115|NCT02923856|Experimental|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
16554116|NCT02923856|Experimental|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
16554117|NCT02923856|Experimental|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
16554118|NCT02923856|Experimental|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
16554123|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
16554124|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
16554125|NCT02923817|Experimental|Treatment|
16554126|NCT02923804|Experimental|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
16554127|NCT02923804|Placebo Comparator|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
16554128|NCT02923791|Experimental|Filgrastim Hospira|
16554129|NCT02923791|Active Comparator|US-Approved Neupogen|
16554130|NCT02923778|Experimental|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy at weeks 2-6.
16554131|NCT02923765|Active Comparator|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
16554132|NCT02923765|No Intervention|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
16554133|NCT02923765|No Intervention|healthy participant (HP)|healthy control
16554134|NCT02923739|Active Comparator|Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16554135|NCT02923739|Experimental|Arm II (paclitaxel, bevacizumab, emactuzumab)|Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16554136|NCT02923726|Active Comparator|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
16554137|NCT02923726|Experimental|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
16554138|NCT02923700|Experimental|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
16554139|NCT02923700|Experimental|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
16554140|NCT02923687|Active Comparator|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
16554141|NCT02923687|Placebo Comparator|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
16554142|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.
~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
16554143|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.
~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
16554144|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.
~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).
~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
16554145|NCT02923661|Experimental|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
16554146|NCT02923661|Active Comparator|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
16554147|NCT02923648||Very/extremely prematurely born with BPD|Very/extremely prematurely born (gestational age [GA]< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-23 years
16554148|NCT02923648||Very/extremely prematurely born without BPD|Very/extremely prematurely born (GA< 32 weeks) without BPD in the neonatal period, age 18-23 years
16554149|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA> 37 weeks), age 18-23 years
16554150|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA>37 weeks), age 18-23 years
16554151|NCT02923635|Active Comparator|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
16554152|NCT02923635|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
16554153|NCT02923622||Traditional Chinese and Western medicine combined group|
16554154|NCT02923622||Traditional Chinese medicine group|
16554155|NCT02923622||Western medicine group|
16554156|NCT02923609|Experimental|SC Group|In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).
16554157|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
16554158|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
16554159|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
16554160|NCT02923583|Experimental|M834|M834 (abatacept biosimilar candidate)
16554161|NCT02923583|Active Comparator|US Orencia®|US-sourced Orencia® (abatacept)
16554162|NCT02923583|Active Comparator|EU Orencia®|EU-sourced Orencia® (abatacept)
16554163|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
16554164|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
16554165|NCT02923557|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
16554166|NCT02923557|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
16554168|NCT02923531|Experimental|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study treatment will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
16554169|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
16554170|NCT02923518||Control group|Those without a positive score on the two scores listed above.
16554171|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
16554172|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
16554173|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
16554174|NCT02923492|Experimental|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
16554175|NCT02923492|Experimental|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
16554176|NCT02923492|No Intervention|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
16554177|NCT02923479|Experimental|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:
~General Rehabilitation
~Specific ankle rehabilitation by ARBOT device"
16554178|NCT02923479|Other|Control Group|"The patients in the Control Group underwent to following interventions:
~General Rehabilitation
~Specific ankle rehabilitation performed by physiotherapist
~Specific ankle rehabilitation by Biodex System 3 dynamometer
~Specific ankle rehabilitation by ProKin PK254 platform."
16554179|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
16554180|NCT02923466|Experimental|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
16554181|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.
~Avelumab will be administered intravenously every 2 weeks starting on day 1."
16554182|NCT02923453|Placebo Comparator|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
16554183|NCT02923453|Active Comparator|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
16554184|NCT02923440|Experimental|Congenital heart defects|
16554185|NCT02923427|Active Comparator|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
16554186|NCT02923427|Experimental|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
16554187|NCT02923414|Active Comparator|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
16554188|NCT02923414|Active Comparator|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
16554189|NCT02923401|Experimental|High-Intensity Interval Training (HIIT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.
~Participants receive written materials and instructions on how to perform their exercises.
~Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.
~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.
~One (1) time each month, participant attends a motivational session."
16554190|NCT02923401|Experimental|Moderate-Intensity Continuous Training (MICT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.
~Participants receive written materials and instructions on how to perform their exercises.
~Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.
~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.
~One (1) time each month, participant attends a motivational session."
16554191|NCT02923401|Active Comparator|Control Group|"Participants receive written materials and counseling by an exercise physiologist.
~Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals.
~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.
~One (1) time each month, participant attends a motivational session."
16554192|NCT02923388|Active Comparator|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
16554606|NCT02920632|Experimental|Online cognitive training 1 (N=70)|Eight-week, three times a week during 45 minutes cognitive training
16554193|NCT02923388|Placebo Comparator|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
16554194|NCT02923375|Experimental|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
16554195|NCT02923375|Experimental|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
16554196|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
16554197|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
16554198|NCT02923349|Experimental|INCAGN01949|
16554199|NCT02923336|Other|Smart pill|Single group, before and after, the same group is going to be its own control
16554200|NCT02923323|Experimental|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
16554201|NCT02923323|Active Comparator|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
16554202|NCT02923310|Experimental|Osteoarthrits G II and III|Group of treatment
16554203|NCT02923310|Experimental|Osteoarthrits GIV|Group of treatment
16554204|NCT02923297|Other|Parkinson's disease patients|blood sampling
16554205|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
16554206|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
16554207|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.
~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
16554208|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.
~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
16554209|NCT02923258|Experimental|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
16554210|NCT02923258|Active Comparator|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
16554211|NCT02923245|Experimental|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
16554212|NCT02923245|No Intervention|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
16554213|NCT02923232|Experimental|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
16554214|NCT02923219|Experimental|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
16554215|NCT02923206|Experimental|Phase 0 - healthy volunteers|Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
16554216|NCT02923206|Experimental|Phase A - preeclampsia patients|Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
16554217|NCT02923206|Experimental|Phase B - preeclampsia patients|Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
16554218|NCT02923193|Experimental|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
16554219|NCT02923193|Active Comparator|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
16554220|NCT02923180|Experimental|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
16554222|NCT02923154|Experimental|MT-3995|
16554223|NCT02923154|Placebo Comparator|Placebo|
16554224|NCT02923141|Active Comparator|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
16554225|NCT02923141|Active Comparator|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
16554226|NCT02923128|Active Comparator|Dexmedetomidine+routine PCIA|Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
16554227|NCT02923128|Sham Comparator|Routine PCIA|Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
16554228|NCT02923115|Experimental|DS-1040b|Participants who are randomized to receive DS-1040b as a single, continuous intravenous infusion (initial loading dose 3-6 mg). All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
16554229|NCT02923115|Placebo Comparator|Placebo|Participants who are randomized to receive placebo as a single, continuous intravenous infusion. All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
16554230|NCT02923102|Active Comparator|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
16554231|NCT02923102|Placebo Comparator|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
16554232|NCT02923089|Experimental|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
16554233|NCT02923089|Experimental|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
16554234|NCT02923089|Placebo Comparator|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
16554235|NCT02923089|Experimental|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
16554236|NCT02923089|Experimental|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
16554237|NCT02923089|Placebo Comparator|Potato Soup|Soup: 25g available carbohydrate from potato
16554238|NCT02923089|Experimental|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
16554239|NCT02923089|Experimental|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
16554240|NCT02923089|Placebo Comparator|Rice Chili|Chili: 25g available carbohydrate from rice
16554241|NCT02923076|Experimental|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
16554242|NCT02923063|Experimental|Combined Aerobic and Resistance Exercise|"Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Aerobic intervention sessions of 30-minute duration will target 60-80% of the maximal heart rate (or rating of perceived exertion of 13 on a scale of 6-20). We will encourage adherence to 50% ambulatory based and 50% cycling based aerobic exercise each session targeting the same goal heart rate.
~Resistance exercises occur 3 times weekly. The load will be adjusted for each exercise as needed on successive sets to ensure that subjects achieved momentary failure in the target repetition range. The load will be increased based on the supervising researcher's assessment of what would be required to reach momentary failure in the desired loading range; if less than 8 repetitions were accomplished, the load was similarly decreased. All routines will be directly supervised by the research team to ensure proper performance of the respective routines."
16554243|NCT02923063|No Intervention|Usual Care|"The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
16554244|NCT02923050|No Intervention|Waitlist control|
16554245|NCT02923050|Experimental|10-week family meals program|
16554246|NCT02923037|Experimental|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
16554247|NCT02923024|No Intervention|Usual Care|This arm will be usual care and there will be no intervention.
16554248|NCT02923024|Experimental|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
16554451|NCT02921529|Experimental|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
16554249|NCT02923024|Experimental|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
16554250|NCT02923011|Active Comparator|MRgFUS|Magnetic resonance-guided focused ultrasound ablation
16554251|NCT02923011|Active Comparator|CTgRFA|Computed tomography-guided radiofrequency ablation
16554252|NCT02922985|Placebo Comparator|Placebo Control Group|Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.
16554253|NCT02922985|Active Comparator|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications: Patients will receive the pre-operative dose of IV acetaminophen 1 g within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of either 20 mL of bupivacaine 0.25% after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive 60 mg of IM ketorolac.
16554254|NCT02922972|Experimental|Platelet Rich Plasma|Interventions: Four injections of PRP: The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
16554255|NCT02922959|Active Comparator|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.
~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
16554256|NCT02922959|Experimental|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.
~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
16554257|NCT02922946|Experimental|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.
~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
16554258|NCT02922946|Experimental|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.
~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.
~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
16554259|NCT02922933|Active Comparator|Omeprazole|"Treatment A: 5mg entinostat on Day 1
~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
16554260|NCT02922933|Active Comparator|Famotidine|"Treatment C: 5mg entinostat on Day 1
~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
16554261|NCT02922933|Active Comparator|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water
~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
16554262|NCT02922920|Experimental|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
16554263|NCT02922920|Placebo Comparator|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
16554264|NCT02922907|Experimental|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
16554265|NCT02922907|Placebo Comparator|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
16554266|NCT02922894|Experimental|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
16554267|NCT02922894|Experimental|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
16554268|NCT02922894|Experimental|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
16554269|NCT02922881|Experimental|Ulcerative Colitis Diet|Participants will receive a structured 12-week diet with a step down phase.
16554270|NCT02922868|Experimental|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
16554271|NCT02922868|Active Comparator|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
16554272|NCT02922855|No Intervention|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
16554273|NCT02922855|Active Comparator|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
16554274|NCT02922855|Experimental|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
16554275|NCT02922855|Experimental|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
16554276|NCT02922842|Active Comparator|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
16554277|NCT02922842|Active Comparator|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
16554278|NCT02922842|Sham Comparator|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
16554281|NCT02922803|Active Comparator|Vitamin D insufficient|Subjects with Vitamin D level in blood > 25 nmool/L < 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
16554282|NCT02922803|Active Comparator|Vitamin D deficient|Subjects with Vitamin D level in blood < 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
16554283|NCT02922790|Active Comparator|Control|"Subjects will review standard health information on the health consequences of smoking.
~Subjects will have blood drawn but it will not be tested for DNA damage."
16554284|NCT02922790|Active Comparator|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.
~Subjects will have blood drawn and the feedback will be presented at Visit 2."
16554285|NCT02922790|Active Comparator|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.
~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
16554286|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
16554292|NCT02922751||All Subjects|All subjects will be recruited from the Children parent studies: LOGIC (NCT00571272), BASIC (NCT00345553) and PROBE (NCT00061828) and will undergo Liver Stiffness Measurement (LSM). Subjects in these studies have one or more of the following conditions: biliary atresia (BA), Alpha1 Anti-trypsin Deficiency (A1AT) or Alagille Syndrome (ALGS).
16554293|NCT02922738|Experimental|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
16554294|NCT02922738|No Intervention|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
16554295|NCT02922725|Active Comparator|Depressed patients receiving study drug|Participants diagnosed with MDD
16554296|NCT02922725|Placebo Comparator|Depressed patients receiving placebo|Participants diagnosed with MDD
16554297|NCT02922725|No Intervention|Healthy Control|
16554298|NCT02922712|Experimental|NISE 100mg|Nise 100mg given BD for 3 weeks
16554299|NCT02922699|Experimental|Omeprazole 40mg|Omez 40mg OD
16554300|NCT02922699|Active Comparator|Omeprazole 80 mg|Omez 80mg OD
16554301|NCT02922686|Active Comparator|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
16554302|NCT02922686|Placebo Comparator|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
16554303|NCT02922673|Experimental|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
16554304|NCT02922673|Active Comparator|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
16554305|NCT02922673|Placebo Comparator|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
16554306|NCT02922660|Experimental|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
16554307|NCT02922660|Experimental|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
16554308|NCT02922647|Experimental|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
16554309|NCT02922647|Active Comparator|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
16554310|NCT02922634||older surgical patients|Older surgical patients presenting for elective spine surgery
16554444|NCT02921568|Other|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
16554311|NCT02922595|Active Comparator|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
16554312|NCT02922595|Experimental|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
16554313|NCT02922582|Experimental|DepoTXA 400mg|400mg Intracapsular at the end of surgery one time
16554314|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
16554315|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
16554316|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 g of IV TXA at the end of surgery
16554317|NCT02922569|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
16554318|NCT02922569|Active Comparator|Active Comparator|Commercially available computerized training and traumatic brain injury information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
16554319|NCT02922556|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
16554320|NCT02922556|Active Comparator|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
16554321|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
16554322|NCT02922530|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
16554323|NCT02922530|Active Comparator|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
16554324|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
16554325|NCT02922517||controls|patients without HCM
16554326|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
16554327|NCT02922504|Experimental|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use before the procedure
16554328|NCT02922504|Active Comparator|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
16554329|NCT02922491|Experimental|Group 1|"400 mg Vitamin E of synthetic source
~1 once daily during 2 months"
16554330|NCT02922491|Experimental|Group 2|"400 mg Vitamin E of natural source
~1 once daily during 2 months"
16554331|NCT02922491|Placebo Comparator|Group control|"400 mg of starch
~1 once daily during 2 months"
16554332|NCT02922491|No Intervention|No intervention|Without intervention
16554333|NCT02922465|Experimental|K-877 & Clopidogrel|K-877 & Clopidogrel orally
16554334|NCT02922452|Experimental|BMS-986141 and Dilitazem|
16554335|NCT02922439|Experimental|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
16554336|NCT02922439|Active Comparator|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
16554337|NCT02922426|Experimental|ALKS 3831|Oral, bilayer tablet
16554338|NCT02922426|Active Comparator|Olanzapine|Oral, bilayer tablet
16554339|NCT02922426|Placebo Comparator|Placebo|Oral, bilayer tablet
16554340|NCT02922413|Experimental|Hemin for injection|Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
16554341|NCT02922413|Placebo Comparator|Placebo|A double blind dose of saline.
16554342|NCT02922400|Experimental|Social Cognition Assessment and Training|Assessment and training program to enhance social function
16554343|NCT02922387|Experimental|Varenicline + Behavioral support|varenicline and behavioral support
16554344|NCT02922387|Active Comparator|Behavioral support|behavioral support
16554345|NCT02922374|Experimental|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
16554346|NCT02922348|Experimental|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
16554347|NCT02922348|Experimental|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
16554348|NCT02922335|Experimental|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
16554445|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
16554349|NCT02922335|Active Comparator|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
16554350|NCT02922322|Active Comparator|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
16554351|NCT02922322|No Intervention|Control Group|The control group was composed by 15 participants that received no intervention
16554352|NCT02922309|Experimental|experimental|Vocal Training via Telepractice
16554353|NCT02922309|Active Comparator|control|Vocal Training via face-to-face practice
16554354|NCT02922283|Experimental|IL2-PET scan|[18F]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
16554355|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
16554356|NCT02922244|No Intervention|Standard skin care|standard skin care
16554357|NCT02922244|Placebo Comparator|Control|Moisture Cream
16554358|NCT02922244|Active Comparator|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
16554359|NCT02922244|Active Comparator|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
16554360|NCT02922244|Active Comparator|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
16554361|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
16554362|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
16554363|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
16554364|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
16554365|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
16554366|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
16554367|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
16554368|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
16554369|NCT02922166|Experimental|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
16554370|NCT02922166|Placebo Comparator|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
16554371|NCT02922153|Experimental|Cryoanalgesia + Standard of Care (SOC)|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
16554372|NCT02922153|Active Comparator|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
16554373|NCT02922140|No Intervention|control group|will receive standard care by physician in attendance
16554374|NCT02922140|Active Comparator|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
16554375|NCT02922127|Other|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
16554376|NCT02922127|Other|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
16554377|NCT02922114|Experimental|Ultrasonography|B-mode and power Doppler Ultrasonography examination
16554378|NCT02922101|Experimental|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
16554379|NCT02922101|Active Comparator|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
16554380|NCT02922075|Placebo Comparator|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
16554381|NCT02922075|Experimental|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
16554382|NCT02922075|Experimental|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
16554383|NCT02922062|Experimental|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
16554384|NCT02922062|Active Comparator|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
16554446|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
16554447|NCT02921542||Homogenous Lesions|
16554448|NCT02921542||Heterogenous Lesions|
16554449|NCT02921542||Calcific Lesions|
16554450|NCT02921542||Restenotic Lesions|
16554385|NCT02922049|Other|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.
~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
16554386|NCT02922036|Experimental|Treatment|WiSE System therapy ON with Guideline Directed Medical Therapy
16554387|NCT02922023|Active Comparator|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
16554388|NCT02922023|Active Comparator|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
16554389|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
16554390|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
16554391|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
16554392|NCT02921984|Experimental|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
16554393|NCT02921984|Experimental|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
16554394|NCT02921984|Experimental|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
16554395|NCT02921971|Experimental|SAR156597|SAR156597 will be given on a specific time period
16554396|NCT02921971|Placebo Comparator|Placebo|Placebo will be given on a specific time period
16554397|NCT02921945|Experimental|SCT800|
16554398|NCT02921932|Active Comparator|Intervention|"In the interventional arm, patients will be given:
~A 'Threshold' Inspiratory Muscle Trainer
~A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).
~Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.
~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
16554399|NCT02921932|No Intervention|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
16554400|NCT02921919|Experimental|Talazoparib|
16554401|NCT02921906|Experimental|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
16554402|NCT02921906|Active Comparator|Non-diabetic controls|People without diabetes.
16554403|NCT02921906|Active Comparator|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
16554406|NCT02921880|Experimental|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
16554407|NCT02921880|No Intervention|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
16554408|NCT02921867|Experimental|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
16554409|NCT02921867|No Intervention|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
16554410|NCT02921854|Experimental|All included patients|3 times Blood withdrawal for each patient (25ml each)
16554411|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
16554412|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
16554413|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
16554414|NCT02921815||Patients with myeloid leukemia|All del(5q) Myelodysplastic syndrome (MDS) patients in the all-case surveillance in whom transformation to acute myeloid leukemia has not been documented at the end of the observation period of the all-case surveillance.
16554415|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
16554452|NCT02921529|Sham Comparator|false stimulation|Attach electrodes without electric current
16554418|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.
~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.
~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
16554419|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.
~Intervention is usability tasks with the VidaTalk app"
16554420|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
~Intervention will be receipt of VidaTalk tablet application."
16554421|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.
~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
16554422|NCT02921776|No Intervention|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.
~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
16554423|NCT02921763||Dydrogesterone|Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.
16554424|NCT02921750|Experimental|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
16554425|NCT02921750|Active Comparator|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
16554426|NCT02921737|Experimental|Treatment Arm|TAS-102
16554427|NCT02921724|Experimental|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
16554428|NCT02921711||LVIS®|
16554429|NCT02921698||FRED®|
16554430|NCT02921685|Experimental|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
16554431|NCT02921672|Active Comparator|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
16554432|NCT02921672|Active Comparator|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
16554433|NCT02921672|Experimental|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
16554434|NCT02921659|Placebo Comparator|Placebo|placebo, 500 mg, 2x/day for 6 weeks
16554435|NCT02921659|Active Comparator|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
16554436|NCT02921646|Other|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
16554437|NCT02921633|Experimental|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
16554438|NCT02921633|No Intervention|Control|No centrally-sent invitation letter.
16554439|NCT02921620|Experimental|PRX-102|PRX-102 infusions every 2 weeks
16554440|NCT02921620|Placebo Comparator|Placebo|Placebo infusions every 2 weeks
16554441|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
16554442|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
16554443|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
16554453|NCT02921516|Experimental|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
16554454|NCT02921516|Active Comparator|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
16554455|NCT02921516|Placebo Comparator|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
16554456|NCT02921503|Experimental|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
16554457|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
16554458|NCT02921477|Experimental|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
16554459|NCT02921464||Group A|Group A - without known pre-existing SIHD
16554460|NCT02921464||Group B|Group B - with known pre-existing SIHD.
16554461|NCT02921451|Other|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
16554462|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
16554463|NCT02921425|Experimental|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
16554464|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
16554465|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
16554466|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
16554467|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
16554468|NCT02921386|Other|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
16554469|NCT02921386|Other|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
16554470|NCT02921386|Other|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
16554471|NCT02921386|Other|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
16554472|NCT02921386|Other|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
16554473|NCT02921373|Experimental|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.
~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
16554474|NCT02921373|Experimental|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.
~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
16554475|NCT02921360|Experimental|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
16554476|NCT02921360|No Intervention|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
16554477|NCT02921347|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
16554478|NCT02921347|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
16554479|NCT02921334|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
16554480|NCT02921334|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
16554481|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
16554482|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
16554483|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
16554484|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
16554485|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
16554486|NCT02921269|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16554490|NCT02921243||Stool Sample Collection|
16554491|NCT02921243||Prebiotic|
16554492|NCT02921230|Experimental|ELUVIA Stent Implantation|Peripheral stenting
16554493|NCT02921230|Active Comparator|control Bare Metal Stent Implantation|Peripheral stenting
16554494|NCT02921217|Experimental|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
16554495|NCT02921217|Experimental|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
16554496|NCT02921217|Placebo Comparator|Control|Control
16554497|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
16554498|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
16554499|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
16554500|NCT02921165|Active Comparator|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
16554501|NCT02921165|Experimental|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
16554502|NCT02921165|Experimental|Group 3|Non Hypertensive Intervention: On normal saline rinses.
16554503|NCT02921152|Other|all|All patients with early breast cancer
16554504|NCT02921139|Experimental|Arm I|Stereotactic ablative radiotherapy (SABR)
16554505|NCT02921139|Active Comparator|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
16554506|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
16554507|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
16554508|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
16554509|NCT02921100|Other|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
16554510|NCT02921100|Other|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
16554511|NCT02921087|Other|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
16554512|NCT02921087|Other|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
16554513|NCT02921074|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
16554514|NCT02921074|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
16554515|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.
~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.
~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
16554516|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
16554517|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
16554518|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
16554519|NCT02921022|Experimental|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
16554520|NCT02921022|Experimental|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
16554521|NCT02921009|Experimental|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
16554522|NCT02920996|Experimental|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
16554523|NCT02920996|Experimental|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
16554524|NCT02920983|Active Comparator|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
16554525|NCT02920983|Active Comparator|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
16554526|NCT02920983|Active Comparator|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
16554527|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
16554528|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
16554529|NCT02920957|Active Comparator|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
16554530|NCT02920957|Active Comparator|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
16554531|NCT02920944|Experimental|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
16554532|NCT02920944|Active Comparator|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
16554533|NCT02920931|Experimental|A|"st period: Tenofovir disoproxil fumarate
~nd period: Tenofovir Disoproxil"
16554534|NCT02920931|Active Comparator|B|"st period: Tenofovir disoproxil
~nd period: Tenofovir Disoproxil fumarate"
16554535|NCT02920918|Active Comparator|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
16554536|NCT02920918|Active Comparator|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
16554537|NCT02920905|Experimental|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
16554538|NCT02920905|Experimental|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
16554539|NCT02920905|Experimental|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
16554540|NCT02920892|Experimental|AFQ056 group with language intervention|12 month treatment phase during which subjects are randomized to AFQ056. The initial dose of AFQ056 will be 25 mg BID. If the subject has no side effects the dose will be titrated (mandatory titration if no side effects) to the next level, 50 mg BID, 75 mg BID and 100 mg BID in order. A flexible dose design will mimic practice, and allow use of maximum tolerated dose (MTD) which is likely to be most effective. The dose can be adjusted weekly through week 7. After 7 weeks the dose will be fixed, and at the 2 month visit all subjects will initiate the language intervention, remaining on a stable AFQ056/placebo dose for the next 6 months.
16554541|NCT02920892|Placebo Comparator|Placebo group with language intervention|12-month treatment phase during which subjects are randomized to placebo. At the 2 month visit (language intervention baseline visit) all subjects will initiate the language intervention, remaining on placebo dose for the next 6 months.
16554542|NCT02920879|Other|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
16554543|NCT02920879|Other|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
16554544|NCT02920879|Other|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
16554545|NCT02920879|Other|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
16554548|NCT02920853|Experimental|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
16554549|NCT02920853|Active Comparator|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
16554550|NCT02920840|Active Comparator|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
16554551|NCT02920840|Experimental|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
16554552|NCT02920840|Active Comparator|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
16554553|NCT02920827|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
16554554|NCT02920827|Placebo Comparator|Placebo Vaginal Ring|Placebo vaginal ring
16554555|NCT02920814|Experimental|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
16554556|NCT02920801|Experimental|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
16554557|NCT02920801|Active Comparator|metformin group|metformin group consumed metformin 1500mg per day for 12 week
16554558|NCT02920788|Experimental|Veteran Mild TBI Group - GOALS Intervention|Veterans ages 18+ with chronic mild TBI, to undergo GOALS cognitive training as an intervention.
16554559|NCT02920788|Active Comparator|Veteran Mild TBI - Treatment as Usual|Veterans ages 18+ with chronic mild TBI, matched by demographic and clinical criteria to the GOALS group, to receive the standard clinical care.
16554560|NCT02920788|No Intervention|Veteran Non TBI - No Treatment|Veterans ages 18+ with no history of TBI, to undergo Neuropsychologic evaluation and MR Imaging with no intervention.
16554561|NCT02920775||Pain|
16554562|NCT02920775||PCP|
16554563|NCT02920775||Dentist|
16554564|NCT02920775||Surgery|
16554565|NCT02920775||Emergency Medicine|
16554566|NCT02920775||Oncology|
16554567|NCT02920775||Hospice and Palliative Medicine|
16554568|NCT02920775||Anesthesiology|
16554569|NCT02920775||Neurology|
16554570|NCT02920775||Nurse Practitioners|
16554571|NCT02920775||Pediatrics|
16554572|NCT02920775||Physical Medicine & Rehabilitation|
16554573|NCT02920775||Physician Assistant|
16554574|NCT02920775||Rheumatology|
16554575|NCT02920775||All Other Specialties|
16554576|NCT02920762||Buprenorphine|
16554577|NCT02920762||Fentanyl|
16554578|NCT02920762||Hydromorphone HCl|
16554579|NCT02920762||Morphine Sulfate|
16554580|NCT02920762||Morphine Sulfate Beads|
16554581|NCT02920762||Oxycodone HCl|
16554582|NCT02920762||Oxymorphone HCl|
16554583|NCT02920762||Tapentadol|
16554584|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
16554585|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
16554586|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
16554587|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
16554588|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
16554589|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
16554590|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
16554591|NCT02920723|Experimental|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
16554592|NCT02920723|Other|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
16554593|NCT02920710|Experimental|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
16554594|NCT02920697|Experimental|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
16554595|NCT02920697|Experimental|Chronic Lymphocytic Leukaemia (CLL)|
16554596|NCT02920684|Active Comparator|Passive legs mobilisation|A physiotherapist performs passive legs movement
16554597|NCT02920684|Active Comparator|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
16554598|NCT02920684|Active Comparator|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
16554599|NCT02920684|Active Comparator|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
16554600|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
16554601|NCT02920671||Obese|BMI > 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
16554602|NCT02920671||Normal Weight & Overweight|BMI 18.5 - < 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
16554603|NCT02920658|Experimental|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
16554604|NCT02920658|Active Comparator|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
16554605|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
16554607|NCT02920632|Active Comparator|Online cognitive training 2 (N=70)|Eight-week, three times a week during 45 minutes cognitive activities
16554608|NCT02920632|No Intervention|Healthy control subjects (N=30)|Reference group to compare cognitive training effects to
16554609|NCT02920606|Active Comparator|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.
~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
16554610|NCT02920606|Experimental|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
16554611|NCT02920593|Experimental|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
16554612|NCT02920593|No Intervention|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
16554613|NCT02920580|Active Comparator|Extubation|Extubation by removal of endotracheal tube.
16554614|NCT02920580|Active Comparator|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
16554615|NCT02920567|Experimental|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
16554616|NCT02920567|Placebo Comparator|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
16554617|NCT02920554|Active Comparator|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
16554618|NCT02920554|Active Comparator|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
16554619|NCT02920541|Experimental|S 055746|
16554620|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
16554621|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
16554622|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
16554623|NCT02920515|Experimental|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
16554624|NCT02920515|Active Comparator|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
16554625|NCT02920515|No Intervention|blank group|without therapy
16554626|NCT02920502|Placebo Comparator|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
16554627|NCT02920502|Experimental|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
16554628|NCT02920502|Experimental|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
16554629|NCT02920502|Experimental|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
16554630|NCT02920489|Experimental|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
16554631|NCT02920489|Active Comparator|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
16554632|NCT02920476|Experimental|Treatment arm|TAS-102
16554633|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
16554634|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
16554635|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
16554636|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
16554637|NCT02920450|Experimental|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
16554638|NCT02920437|Experimental|Intervention group|Four-week weekly intervention to reduce salt intake.
16554639|NCT02920437|Other|Control group|Usual government pamphlets.
16554640|NCT02920424|Experimental|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 [4 active: 1 placebo]).
16554641|NCT02920424|Experimental|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 [5 active: 1 placebo]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
16554642|NCT02920411|Experimental|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:
~Pediatopic treatment cream during acute stages of atopic dermatitis and
~Pediatopic body lotion during stable stages"
16554643|NCT02920398|Experimental|N8-GP pivotal|
16554644|NCT02920398|Active Comparator|N8-GP commercial|
16554645|NCT02920385|Experimental|Levothyroxine/SNAC/Placebo/Semaglutide|
16554646|NCT02920372|Experimental|EPOETIN ALFA|
16554647|NCT02920359|Experimental|LEUPRORELIN ACETATE|
16554718|NCT02919852|Other|laparoscopic retrovesical colpopectinopexia|new operative technic
16554648|NCT02920333|Experimental|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
16554649|NCT02920333|Experimental|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
16554650|NCT02920333|Sham Comparator|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
16554651|NCT02920320|Experimental|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink & Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
16554652|NCT02920320|No Intervention|Waiting control group|
16554653|NCT02920307|Experimental|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
16554654|NCT02920307|Active Comparator|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
16554655|NCT02920307|Experimental|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
16554656|NCT02920307|Active Comparator|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
16554657|NCT02920294|Active Comparator|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
16554658|NCT02920294|Active Comparator|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
16554659|NCT02920294|Placebo Comparator|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
16554660|NCT02920268|Experimental|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
16554661|NCT02920268|No Intervention|Controls|No intervention
16554662|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
16554663|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
16554664|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
16554665|NCT02920242|Experimental|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
16554666|NCT02920242|Active Comparator|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
16554667|NCT02920242|Placebo Comparator|Placebo|Patients received placebo tablet 3 times per day for 3 days.
16554668|NCT02920229|Experimental|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
16554669|NCT02920216|Experimental|eligible patient for a salvage surgery|
16554670|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
16554671|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
16554672|NCT02920190|Experimental|Liraglutide Group|Participants in this group will receive the Liraglutide intervention for 12 months
16554673|NCT02920177|Experimental|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
16554674|NCT02920177|Active Comparator|Kenalog 10 mg/mL Injectable Suspension|corticosteroid injection into the head-neck junction of the hip joint
16554675|NCT02920164|Active Comparator|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
16554676|NCT02920164|Placebo Comparator|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
16554677|NCT02920164|No Intervention|Standard therapy|No intervention, just observation
16554678|NCT02920151|Experimental|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
16554679|NCT02920151|No Intervention|CONTROL GROUP|usual routine
16554680|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
16554681|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
16554682|NCT02920125|Active Comparator|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.
~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
16554683|NCT02920125|Placebo Comparator|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
16554684|NCT02920112|Experimental|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
16554685|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
16554686|NCT02920086|Experimental|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
16554687|NCT02920086|Experimental|Decision Support Program|Decision support education for family members of an elderly critically ill patient
16554688|NCT02920086|No Intervention|Usual Care|No intervention
16554689|NCT02920060|Experimental|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
16554690|NCT02920060|Active Comparator|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
16619882|NCT02481843||Control|2-hours control without hyperoxia
16554691|NCT02920047|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)
~There will be a washout of 14 days between the each period."
16554692|NCT02920047|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)
~There will be a washout of 14 days between the each period."
16554693|NCT02920047|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)
~There will be a washout of 14 days between the each period."
16554694|NCT02920034|Active Comparator|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
16554695|NCT02920034|Experimental|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
16554696|NCT02920034|Experimental|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
16554697|NCT02920021|Experimental|ANB020|ANB020, administration of ANB020
16554698|NCT02920021|Placebo Comparator|Placebo|Placebo, administration of Placebo
16554699|NCT02920008|Experimental|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m2 in 28-day cycles (delayed as necessary to allow blood count recovery).
16554700|NCT02920008|Active Comparator|Treatment Choice (TC)|"High intensity
~Low intensity
~Best supportive care (BSC)."
16554701|NCT02919995|Experimental|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
16554702|NCT02919995|Experimental|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
16554703|NCT02919995|Placebo Comparator|Placebo|Inhaled placebo dose
16554704|NCT02919969|Experimental|Pembrolizumab|"Pembrolizumab is administered every 3 week intravenously
~Dosage to be determine by physician"
16554705|NCT02919956||Group I: CBF-I Single Ventricles|The 1st group (cohort group) will be patients who were enrolled in the original NIH CBF grant. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
16554706|NCT02919956||Group II: Prospective Single Ventricles|The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
16554707|NCT02919956||Group III: CBF-I Normal Controls|The 3rd group (cohort group) will be normal controls who were enrolled in the original CBF grant. These patients will have Neurodevelopmental Testing. The data from these patients' MRI from CBF-I (original CBF grant) will be used.
16554708|NCT02919956||Group IV: Prospective Normal Controls|The 4th group (cross sectional group) will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for clinically indicated MRIs and found to have structurally normal cardiac and brain anatomy. These patients will have an abbreviated research MRI, lasting 15-20 minutes, added onto their clinically-indicated MRI at CHOP. They will also have Neurodevelopmental Testing.
16554709|NCT02919956||Volunteer Group|There will also be a volunteer group of one to five volunteers that will be enrolled prior to enrollment in the other four study groups. These volunteers will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for a clinically-indicated MRI and consent to have an additional 15-20 minutes of research MRI scanning. The purpose will be to ensure that the brain MRI sequences run correctly and produce useful information before the patient and normal control enrollment begins. The volunteers will not undergo neurodevelopmental testing.
16554710|NCT02919930|Other|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
16554711|NCT02919930|Other|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
16554712|NCT02919917|Experimental|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.
~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).
~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
16554713|NCT02919917|Experimental|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.
~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).
~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
16554714|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
16554715|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
16554716|NCT02919878|Experimental|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).
~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.
~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
16554717|NCT02919865|Other|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
16554719|NCT02919826|Experimental|DBT Group|Adapted Dialectical Behaviour Therapy
16554720|NCT02919826|No Intervention|Control Arm|People in this group will receive treatment as usual
16554721|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
16554722|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
16554723|NCT02919800|Experimental|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life [t1/2] ~10 h, terminal t1/2 ~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 ~1 h, terminal t1/2 ~10 h) (Fares et al., 1992).
16554724|NCT02919800|Placebo Comparator|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
16554725|NCT02919787|Active Comparator|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
16554726|NCT02919787|Experimental|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
16554727|NCT02919774|Experimental|POMA 40 mg BID|40 mg BID for 10 days
16554728|NCT02919774|Experimental|POMA 160 mg BID|160 mg BID for 10 days
16554729|NCT02919774|Placebo Comparator|Placebo|Placebo BID for 10 days
16554730|NCT02919761|Experimental|Part 1: All Enrolled Participants|All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
16554731|NCT02919761|Experimental|Part 2: Acthar Gel|Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
16554732|NCT02919761|Placebo Comparator|Part 2: Placebo|Participants receive Placebo 1 mL twice weekly for an additional 12 weeks
16554733|NCT02919748|Experimental|Intervention arm|Choral Singing
16554734|NCT02919748|Active Comparator|Control arm|General Health Education Program and Group Activities
16554735|NCT02919735|Experimental|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
16554736|NCT02919735|Placebo Comparator|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
16554737|NCT02919722|Experimental|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
16554738|NCT02919709|Experimental|thoracic or abdominal aortic aneurysm|
16554739|NCT02919696|Experimental|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
16554740|NCT02919696|Experimental|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
16554741|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks
~Ipilimumab to be delivered at a pre-determine dose for one week
~Blood Sample Collected
~Standard of Care Surgery"
16554742|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks
~Blood Sample Collected
~Standard of Care Surgery"
16554743|NCT02919670|Experimental|Enterade and Standard Supportive Care|"Two 8 oz. bottles of Enterade will be administered daily
~Enterade will be given orally from admission until day +14 or until discharge
~Standard Supportive Care will be administered according to institution's practice"
16554744|NCT02919670|Placebo Comparator|Placebo and Standard Supportive Care|"Two 8 oz. bottles of Placebo will be administered daily
~Placebo will be given orally from admission until day +14 or until discharge
~Standard Supportive Care will be administered according to institution's practice"
16554745|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.
~Intervention: Weekly blood draws will determine the effect on blood protein levels."
16554746|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.
~Intervention: Weekly blood draws will determine the effect on blood protein levels."
16554747|NCT02919644|Experimental|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
16554748|NCT02919631|Active Comparator|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
16554749|NCT02919631|Placebo Comparator|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
16554750|NCT02919618|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
16554751|NCT02919605|Experimental|Single dose of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
16554752|NCT02919605|Experimental|Two doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
16554753|NCT02919605|Experimental|Three doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.
16554754|NCT02919592|Experimental|Primary Breast Augmentation|Participants who meet the requirements for primary breast augmentation (have not had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
16554887|NCT02918955|Active Comparator|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
16620093|NCT02480348|Experimental|Polymer-free DES (Drug Eluting Stent)|
16554755|NCT02919592|Experimental|Revision Breast Augmentation|Participants who meet the requirements for revision breast augmentation (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast implants
16554756|NCT02919592|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
16554757|NCT02919592|Experimental|Revision Breast Reconstruction|Participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
16554758|NCT02919592|Active Comparator|Other Aesthetic Surgery|Participants who meet the requirements for other aesthetic surgery procedures, which may not include silicone implants (breast or otherwise)
16554759|NCT02919579|Experimental|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3.
16554760|NCT02919579|Experimental|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
16554761|NCT02919579|Experimental|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
16554762|NCT02919579|Experimental|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
16554763|NCT02919579|Experimental|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
16554764|NCT02919579|Experimental|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
16554765|NCT02919579|Experimental|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
16554766|NCT02919553|Experimental|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
16554767|NCT02919553|Active Comparator|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
16554768|NCT02919540|Experimental|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
16554769|NCT02919540|No Intervention|control group|routine care will be implemented
16554770|NCT02919527|Experimental|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
16554771|NCT02919527|Active Comparator|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
16554772|NCT02919527|No Intervention|Control|No Intervention
16554773|NCT02919514|Active Comparator|Physical training on hard surface|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
16554774|NCT02919514|Experimental|Physical training on sand surface|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
16554775|NCT02919514|Experimental|Physical training on soft surface|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
16554776|NCT02919501|Experimental|IV vortioxetine|
16554777|NCT02919501|Placebo Comparator|IV placebo|
16554778|NCT02919488|Experimental|Exercise Condition|
16554779|NCT02919488|Active Comparator|Control Condition|
16554780|NCT02919475|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
16554781|NCT02919475|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
16554782|NCT02919475|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
16554783|NCT02919475|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
16554784|NCT02919475|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
16554785|NCT02919462|Experimental|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.
~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
16554786|NCT02919462|Active Comparator|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.
~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).
~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
16554787|NCT02919449|Experimental|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
16554788|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
16554789|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
16554790|NCT02919423|Active Comparator|10 Hz TMS|active TMS will be administered
16554791|NCT02919423|Active Comparator|1 Hz TMS|active TMS will be administered
16554792|NCT02919410|Active Comparator|Surgery performed using iodophor-impregnated adhesive drapes|
16554793|NCT02919410|Other|Surgery performed without iodophor-impregnated adhesive drapes|
16554794|NCT02919397|Experimental|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
16554795|NCT02919397|Active Comparator|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
16554796|NCT02919384|Experimental|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
16554797|NCT02919384|No Intervention|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
16554798|NCT02919371|Experimental|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
16554799|NCT02919358|Experimental|Music|Exposure to music, twice per day for the study period
16554800|NCT02919358|Other|Control|No intervention; standard care.
16554801|NCT02919345|Experimental|Dapagliflozin|Dapagliflozin 10 mg in addition to Metformin 1500 mg
16554802|NCT02919345|Active Comparator|Glibenclamide|Glibenclamide 5mg in addition to Metformin 1500 mg
16554803|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
16554804|NCT02919319|Experimental|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
16554805|NCT02919319|Experimental|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
16554806|NCT02919319|Experimental|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
16554807|NCT02919319|Experimental|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
16554808|NCT02919319|Experimental|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
16554809|NCT02919306|Experimental|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.
16554810|NCT02919306|Placebo Comparator|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
16554811|NCT02919293|Experimental|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
16554812|NCT02919293|Active Comparator|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
16554813|NCT02919280||No treatment|This is an observational study. No intervention / treatment involved.
16554814|NCT02919267|Other|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
16554815|NCT02919267|Other|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
16554816|NCT02919254|Active Comparator|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
16554817|NCT02919254|Active Comparator|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
16554818|NCT02919254|Placebo Comparator|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
16554819|NCT02919241|Experimental|Diagnostic interview|Intervention for this group include diagnostic interview. Oral health Impact Profile (OHIP 14) and Spielberg State and Trait Anxiety (STAI-1) questionnaires and behaviour analyses are used in diagnostic interview.
16554820|NCT02919241|Experimental|Combined interview and treatment|Intervention for this group include both the diagnostic interview and one session treatment.
16620293|NCT02479022|Experimental|Level 1-7 escalating doses|
16554821|NCT02919228|Experimental|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554822|NCT02919228|Experimental|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554823|NCT02919228|Experimental|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554824|NCT02919228|Experimental|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554825|NCT02919228|Experimental|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554826|NCT02919228|Experimental|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554827|NCT02919228|Experimental|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554828|NCT02919228|Experimental|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
16554829|NCT02919215|Experimental|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
16554830|NCT02919215|No Intervention|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
16554831|NCT02919202|Experimental|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
16554832|NCT02919202|Active Comparator|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
16554833|NCT02919189|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554834|NCT02919189|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554835|NCT02919189|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554836|NCT02919189|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554837|NCT02919189|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554838|NCT02919189|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554839|NCT02919189|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554888|NCT02918955|Experimental|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
16554840|NCT02919189|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554841|NCT02919176|Active Comparator|Mirabegron|Mirabegron 50 mg/day
16554842|NCT02919176|Active Comparator|Pioglitazone|Pioglitazone 30 mg/day
16554843|NCT02919176|Experimental|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
16554844|NCT02919163|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554845|NCT02919163|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554846|NCT02919163|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554847|NCT02919163|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554848|NCT02919163|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554849|NCT02919163|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554850|NCT02919163|Experimental|Visible light exposure White 30 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554851|NCT02919163|Experimental|Visible light exposure White 120 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16554852|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.
~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
16554853|NCT02919137|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554854|NCT02919137|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554855|NCT02919137|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554856|NCT02919137|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554857|NCT02919137|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554858|NCT02919137|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554859|NCT02919137|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554889|NCT02918929|Experimental|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
16554890|NCT02918929|Experimental|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
16554860|NCT02919137|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
16554861|NCT02919124|Experimental|Echoclip device|Ultrasonography using the echoclip device
16554862|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
16554863|NCT02919098|Experimental|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
16554864|NCT02919098|Placebo Comparator|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.
~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
16554865|NCT02919085|Experimental|Mobilization|
16554866|NCT02919072|Experimental|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
16554867|NCT02919072|Active Comparator|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
16554868|NCT02919059|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
16554869|NCT02919059|Active Comparator|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
16554870|NCT02919046|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
16554871|NCT02919033|Placebo Comparator|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
16554872|NCT02919033|Experimental|Self-management|"BP tele-monitor & App based self-management supports
~Patient proficiency training"
16554873|NCT02919033|Experimental|PCTM intervention|"BP tele-monitor & App-based self-management supports
~Patient proficiency training
~PCP & cardiologist training of using Web-based analytics
~Proactive and interactive care by PCPs and cardiologists"
16554874|NCT02919020|Experimental|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
16554875|NCT02919020|Experimental|resistance exercise|Resistance exercise to strengthen lower limbs
16554876|NCT02919007|Experimental|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
16554877|NCT02918994|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
16554878|NCT02918981|Active Comparator|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
16554879|NCT02918981|Experimental|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
16554880|NCT02918981|Experimental|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
16554881|NCT02918981|Experimental|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
16554882|NCT02918981|Sham Comparator|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
16554883|NCT02918968|Experimental|Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT|Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
16554884|NCT02918968|Experimental|Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT|Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
16554885|NCT02918955|Active Comparator|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
16554886|NCT02918955|Experimental|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
16554891|NCT02918929|Placebo Comparator|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
16554892|NCT02918929|Placebo Comparator|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
16554893|NCT02918916|Experimental|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).
~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.
~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
16554894|NCT02918916|Placebo Comparator|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.
~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
16554895|NCT02918916|No Intervention|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
16554896|NCT02918903|Experimental|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
16554897|NCT02918903|Active Comparator|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
16554898|NCT02918890|Experimental|CIMT|Procedure: Constraint-Induced Movement Therapy 90 hours Other Name: CIT, CI Therapy, restraint therapy, PT, OT, rehab
16554899|NCT02918890|Experimental|HABIT|Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) 90 hours Other Name: HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
16554900|NCT02918877|Experimental|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
16554901|NCT02918877|Active Comparator|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
16554902|NCT02918864|Experimental|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
16554903|NCT02918864|Active Comparator|Facilitated Play|The active comparison condition is a facilitated play therapy group.
16554904|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
16554905|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
16554906|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
16554907|NCT02918838|Experimental|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
16554908|NCT02918838|Experimental|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
16554909|NCT02918838|Active Comparator|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
16554910|NCT02918825|Experimental|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
16554911|NCT02918825|Active Comparator|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
16554912|NCT02918812|Experimental|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
16554913|NCT02918812|Active Comparator|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
16554914|NCT02918799|Other|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
16554915|NCT02918786|Active Comparator|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
16554916|NCT02918786|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
16554917|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
16620322|NCT02478749|Experimental|Infant|patients aged younger than 1year
16554918|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
16554919|NCT02918760|Experimental|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
16554920|NCT02918760|Placebo Comparator|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
16554921|NCT02918747|Experimental|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.
~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.
~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
16554922|NCT02918747|Active Comparator|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1; Pegaspargase 2000U/m2 im，day 2 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.
~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
16554923|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
16554924|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
16554925|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
16554926|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
16554927|NCT02918708|Active Comparator|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
16554928|NCT02918708|Active Comparator|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
16554929|NCT02918682|Experimental|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
16554930|NCT02918682|No Intervention|Control Group|Participants from the control group will not perform any kind of physical exercise.
16554931|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
16554932|NCT02918656|Experimental|Infographics|Infographic presentation of health information
16554933|NCT02918656|Active Comparator|Plain Language Summary|PLS presentation of health information
16554934|NCT02918656|Active Comparator|Scientific abstract|Scientific abstract presentation of health information
16554935|NCT02918643|Active Comparator|Application|7 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
16554936|NCT02918643|Sham Comparator|Control|7 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
16554937|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
16554938|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
16554939|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16554940|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16554941|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16554942|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16554943|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16554944|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16555029|NCT02918136|Experimental|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
16555030|NCT02918136|Active Comparator|cortisone injection|ultrasound guided injection of cortisone
16554945|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
16554946|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
16554947|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
16554948|NCT02918604|Other|B : veinsite access|infrared technology vein access
16554949|NCT02918604|Active Comparator|A: control group|conventional vein access
16554950|NCT02918591|Experimental|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
16554951|NCT02918578|Experimental|"Phone group"|see intervention description
16554952|NCT02918578|Experimental|"Phone and SMS group"|see intervention description
16554953|NCT02918578|Active Comparator|"single writing group"|see intervention description
16554954|NCT02918565|Experimental|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
16554955|NCT02918565|Experimental|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
16554956|NCT02918565|Experimental|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
16554957|NCT02918565|Experimental|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
16554958|NCT02918565|No Intervention|Control|12 weeks of text message assessments without any feedback
16554959|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
16554960|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
16554961|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
16554962|NCT02918526|Experimental|Laryngeal Mask|laryngeal mask (LMA)
16554963|NCT02918526|Active Comparator|Oro Tracheal Intubation|oro tracheal intubation
16554964|NCT02918513|Experimental|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
16554965|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
16554966|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
16554967|NCT02918487|Experimental|Active|[Formoterol + Fluticasone] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
16554968|NCT02918487|Placebo Comparator|Placebo|[Formoterol + Fluticasone] conventional along with inert similar looking placebo capsules
16554969|NCT02918474|Experimental|Supportive care (decision making tool)|Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
16554970|NCT02918461|Experimental|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
16554971|NCT02918448|Experimental|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
16554972|NCT02918448|No Intervention|control group|control group that did not perform any type of physical exercise
16554973|NCT02918435|No Intervention|Usual Care-Control|Participants in the usual care group will receive standard pediatric care.
16554974|NCT02918435|Experimental|On-site WE CARE implementation arm|"WE CARE will be implemented in the study site using a facilitated on-site strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via an on-site team which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room."
16554975|NCT02918435|Experimental|Self-directed web-based WE CARE implementation arm|WE CARE will be implemented in the study site using a web-based implementation strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via web-based tools (e.g., web-based seminar) which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room
16554976|NCT02918422|Experimental|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
16554977|NCT02918422|Experimental|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
16554978|NCT02918422|Experimental|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
16554979|NCT02918422|Experimental|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
16554980|NCT02918409|Active Comparator|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
16554981|NCT02918409|Active Comparator|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
16554982|NCT02918409|Active Comparator|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
16554983|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
16554984|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
16554985|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
16554986|NCT02918383|Other|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
16554987|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
16554988|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
16554989|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
16554990|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
16554991|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
16554992|NCT02918331|Experimental|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram [mg/kg]) will be administered by intravenous [IV] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.
~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
16554993|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
16554994|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
16554995|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
16554996|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
16554997|NCT02918305|Sham Comparator|PRDS-001 Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using PRDS-001 System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
16554998|NCT02918305|Sham Comparator|Sham Procedure|Randomization will occur following the diagnostic renal angiography. For blinded patients randomized to control, the diagnostic renal angiography will be considered the sham procedure.
16554999|NCT02918292|Experimental|Haplo Bone Marrow HSCT|Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.
16555000|NCT02918279|Experimental|Liraglutide|
16555001|NCT02918279|Placebo Comparator|Placebo|
16555002|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
16555031|NCT02918123|Experimental|Treatment|"FURESTEM-CD Inj. 5.0x10^7 cells
~FURESTEM-CD Inj. 1.0x10^7 cells
~FURESTEM-CD Inj. 2.0x10^8 cells"
16555003|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555004|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555005|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555006|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555007|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555008|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555009|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555032|NCT02918110|Experimental|Cytotec|orally administrated solution of misoprostol (Cytotec®)
16555033|NCT02918110|Experimental|Misodel|vaginal slow release misoprostol (Misodel®)
16555119|NCT02917512|Placebo Comparator|Placebo(without main component)|"Placebo
~1 drop b.i.d at 12 hour interval for 12 weeks"
16555010|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555011|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555012|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
16555013|NCT02918253|Experimental|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
16555014|NCT02918253|Active Comparator|No tumour visible on MRI|Whole-gland HDR Brachytherapy
16555015|NCT02918240|Experimental|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
16555016|NCT02918240|Experimental|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
16555017|NCT02918240|Experimental|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
16555018|NCT02918240|Experimental|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
16555019|NCT02918227|Experimental|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
16555020|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
16555021|NCT02918201|Experimental|topical tranexamic acid|tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
16555022|NCT02918201|Placebo Comparator|placebo control|Saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
16555023|NCT02918188|Experimental|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
16555024|NCT02918175|Other|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
16555025|NCT02918175|No Intervention|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
16555026|NCT02918162|Experimental|Pembrolizumab|"All study subjects will receive standard of care chemotherapy regimen for 3 cycles prior to and 3 cycles following surgery in combination with Pembrolizumab with an additional cycle of Pembrolizumab (4 total) in the pre-operative period. Additionally subjects will complete 12 months of maintenance Pembrolizumab (14 additional doses to complete 17 post-operative cycles) following completion of post-operative chemotherapy.
~Standard of care combination chemotherapy regimen has a 21-day cycle."
16555027|NCT02918149|Other|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
16555028|NCT02918149|Experimental|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
16620323|NCT02478749|Experimental|Child|patients aged 1year to 5years
16555034|NCT02918097|Experimental|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.
~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.
~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.
~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.
~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step
~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
16555035|NCT02918084|Sham Comparator|ARM A|Adjuvant chemotherapy → Aromatase inhibitors x 5 yrs (sequential arm)
16555036|NCT02918084|Experimental|ARM B|Adjuvant chemotherapy + Aromatase inhibitors x 5 yrs (concurrent arm)
16555037|NCT02918071|Experimental|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
16555038|NCT02918058|Active Comparator|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
16555039|NCT02918058|Active Comparator|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
16555040|NCT02918058|Active Comparator|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
16555041|NCT02918045|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
16555042|NCT02918045|Active Comparator|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
16555043|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
16555044|NCT02918019|Experimental|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
16555045|NCT02918019|Experimental|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
16555046|NCT02918019|Experimental|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
16555047|NCT02918019|Placebo Comparator|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
16555048|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
16555049|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
16555050|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
16555051|NCT02917993|Experimental|Itacitinib + osimertinib|
16555052|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
16555053|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
16555054|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
16555055|NCT02917967|Experimental|BTX injection group|Botulinum toxin injection group
16555056|NCT02917954|No Intervention|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
16555057|NCT02917954|Experimental|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.
~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
16555058|NCT02917941|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.
16555059|NCT02917928|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
16555060|NCT02917928|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
16555115|NCT02917525|Placebo Comparator|Placebo|22 patients will receive placebo during 18 months.
16555116|NCT02917512|Experimental|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)
~1 drop b.i.d at 12 hour interval for 12 weeks"
16555117|NCT02917512|Experimental|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)
~1 drop b.i.d at 12 hour interval for 12 weeks"
16555118|NCT02917512|Active Comparator|Restasis|"Restasis(Cyclosporine 0.05%)
~1 drop b.i.d at 12 hour interval for 12 weeks"
16555061|NCT02917915|Experimental|New Canadian Standardized PR|"Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress & anxiety, nutrition, leisure & travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.
~Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
16555062|NCT02917915|Active Comparator|Traditional PR|"Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies & pulmonary function tests, health and air quality, healthier eating, travel, stress management & relaxation, tips to remember/summary of content.
~Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
16555063|NCT02917902|Experimental|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
16555064|NCT02917902|Other|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
16555065|NCT02917889|Experimental|Caffeine protocol|300 mg in pills
16555066|NCT02917889|Experimental|Placebo protocol|300 mg in pills
16555067|NCT02917863|Experimental|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).
~Dosage in children with hypothyroidism:
~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die
~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die
~Dosage in adults:
~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).
~Dosage will be adjusted according to TSH level."
16555068|NCT02917863|Active Comparator|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).
~Dosage in children with acquired hypothyroidism:
~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area
~Dosage in adults:
~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).
~Dosage will be adjusted according to TSH level."
16555069|NCT02917850|Active Comparator|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
16555070|NCT02917850|Active Comparator|Control|Patients who benefit from a conventional rehabilitation program
16555071|NCT02917837|Active Comparator|Usual QCNL report group|Physicians receive the usual Quality of Care Newfoundland and Labrador utilization report: This reports ranks the physician on a figure of their peers according to the total number of tests ordered in a one-year period.
16555072|NCT02917837|Experimental|Usual QCNL report plus detailing.|This group receives the usual QCNL report described above. Shortly after the reports are sent, this group will be contacted at least three times to attempt to arrange a single in-person detailing session.
16555073|NCT02917837|Experimental|New utilization report|This group will receive a new type of report that shows individual physician ordering per 100 patients compared to the mean of all physicians, adjusted for patient complexity (age, sex, comorbidity, education, income, rurality).
16555074|NCT02917837|Experimental|New utilization report plus detailing|New type of report plus detailing as described above.
16555075|NCT02917824|Experimental|High-intensity IMT|Participants enrolled in this arm received high-intensity IMT
16555076|NCT02917824|Active Comparator|Low-intensity IMT|Participants enrolled in this arm received low-intensity IMT
16555077|NCT02917811||ICU patients|
16555078|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
16555079|NCT02917785|Experimental|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
16555080|NCT02917785|No Intervention|Control|
16555081|NCT02917772|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy
~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
16555082|NCT02917759||Hepatocellular cancer|Surgical waste tissue will be collected after removal of a liver tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
16555083|NCT02917759||Cholangiocarcinoma|Surgical waste tissue will be collected after removal of a biliary tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
16555084|NCT02917746|Experimental|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
16555085|NCT02917746|Active Comparator|Standard treatment arm|Treatment by large loop excision of the transformation zone.
16555086|NCT02917733|Experimental|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
16555154|NCT02917252|Active Comparator|Intervention|Subjects drink 3-hydroxybuturate
16555087|NCT02917720|Experimental|TKI-stop, pre-treatment with nilotinib|"Treatment after unsuccessful 1st or 2nd discontinuation at least two year with nilotinib (300 mg/bid). In total, retreatment with TKI for at least 3 years before entering screening for stopping phase is warranted. Clinical monitoring every 3 months during this 2 years.
~Patients who re-achieved and maintained MR4 for at least 12 months and MR4.5 for at least 6 months can enter screening phase for TFR .If MR4.5 is confirmed by an validated laboratory, patient may enter stopping phase of the study. Patient not fulfilling these criteria can be screened again every 3 months until month 48. After TKI-stop hematological monitoring and quantitative PCR of BCR/ABL1 (month 1-6 after stopping: monthly; month 7-12 after stopping: every 1.5 months, thereafter once every three months, for 3 years in total.
~Relapse is defined as BCR-ABL1 > 0.1% on IS at a single time point (loss of MMR) In case of relapse restart of TKI. In general, the same TKI (nilotinib) as before second stop is recommended"
16555088|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
16555089|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
16555090|NCT02917707||liver metastasis tissues|liver metastasis tissues
16555091|NCT02917681|Experimental|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
16555092|NCT02917668|Active Comparator|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
16555093|NCT02917668|Active Comparator|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
16555094|NCT02917655|Experimental|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
16555095|NCT02917655|Other|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.
~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
16555096|NCT02917642|Experimental|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
16555097|NCT02917642|Active Comparator|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
16555098|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
16555099|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
16555100|NCT02917616|Experimental|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
16555101|NCT02917616|Active Comparator|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
16555102|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
16555103|NCT02917603|No Intervention|Control|These family and residents will receive usual care
16555104|NCT02917590|Experimental|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
16555105|NCT02917590|Sham Comparator|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
16555106|NCT02917577|Active Comparator|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
16555107|NCT02917577|Active Comparator|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
16555108|NCT02917564|Sham Comparator|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.
~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected."
16555109|NCT02917564|Active Comparator|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.
~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down."
16555110|NCT02917551|Active Comparator|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
16555111|NCT02917551|Active Comparator|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
16555112|NCT02917538|Experimental|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
16555113|NCT02917538|Active Comparator|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
16555114|NCT02917525|Experimental|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
16555120|NCT02917499|Experimental|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
16555121|NCT02917499|No Intervention|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
16555122|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
16555123|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
16555124|NCT02917473|Other|Control|"Education and counseling as commonly delivered to the patients in clinical practice.
~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
16555125|NCT02917473|Experimental|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.
~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
16555126|NCT02917460|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
16555127|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
16555128|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
16555129|NCT02917434|Active Comparator|Patients with PsA and obesity|Very Low Energy Diet (VLED)
16555130|NCT02917434|Other|Patients with obesity|Very Low Energy Diet (VLED)
16555131|NCT02917421|Experimental|Cohort 1|"(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
~Radiation therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
16555132|NCT02917421|Experimental|Cohort 2|"In addition to receiving radiation to the original tumor bed, patients will also receive radiation to Level III axillary nodes and Supraclavicular nodes: 3D-CRT or IMRT at 2.7 Gy X 15 fraction (40.50 Gy)
~Radiation Therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
16555133|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
16555134|NCT02917395|Experimental|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.
~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
16555135|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
16555136|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
16555137|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
16555138|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
16555139|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
16555140|NCT02917356|Experimental|Spiritual laying on of hands group|"Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)
~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
16555141|NCT02917356|Active Comparator|Non-spiritual Laying on of Hands group|"Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)
~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
16555142|NCT02917356|Sham Comparator|Control Group (CG)|"Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)
~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
16555143|NCT02917343|Experimental|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
16555144|NCT02917330|Experimental|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
16555145|NCT02917330|No Intervention|Control group|Treatment as usual
16555146|NCT02917304|Experimental|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
16555147|NCT02917291|Experimental|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (8 patients)
16555148|NCT02917291|Other|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
16555149|NCT02917291|Experimental|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
16555152|NCT02917265|Experimental|TENS for vagus stimulation|A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
16555153|NCT02917265|Sham Comparator|TENS for sham stimulation|A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
16555156|NCT02917226|Experimental|Clinical decision support and monitoring system|
16555157|NCT02917226|No Intervention|Control Group|
16555158|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction < 45% in the first 24-72 h after symptoms onset.
~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.
~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
16555159|NCT02917200|Active Comparator|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
16555160|NCT02917200|Experimental|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
16555161|NCT02917200|Experimental|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
16555162|NCT02917200|Experimental|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
16555163|NCT02917200|Experimental|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
16555164|NCT02917200|Experimental|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
16555165|NCT02917200|Experimental|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
16555166|NCT02917200|Experimental|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
16555167|NCT02917200|Experimental|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
16555168|NCT02917200|Experimental|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
16555169|NCT02917200|Experimental|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
16555170|NCT02917200|Other|CTRL|Negative control, tid, 7 days
16555171|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
16555172|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
16555173|NCT02917174|Experimental|mobile management|use mobile management to improve asthma control
16555174|NCT02917174|Other|Traditional management|use Traditional management to improve asthma control
16555175|NCT02917161|Experimental|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
16555176|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
16555177|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
16555178|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
16555181|NCT02917109|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
16555182|NCT02917096|Experimental|Treatment (ruxolitinib phosphate, chemotherapy,allogeneic HCT)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5, melphalan IV over 20 minutes on day -4, and ruxolitinib phosphate PO BID on days -3 to 30 with a taper for 2-3 weeks in the absence of disease progression or unacceptable toxicity. Patients being treated with ruxolitinib phosphate prior to allogeneic HCT as standard therapy may continue receiving ruxolitinib phosphate.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -3 and convert to PO daily when the patient is able to tolerate and absorb oral medications. Patients also receive sirolimus PO daily beginning on day -3. Treatment continues in the absence of GVHD.
~STEM CELL TRANSPLANT: Patients undergo allogeneic HCT on day 0."
16555183|NCT02917083|Experimental|CD30.CAR T Cells|"Each patient will receive one infusion of CAR modified T cells.
~Unless post autologous transplant, patients will receive Cyclophosphamide and Fludarabine to induce lymphopenia.
~Patients post autologous stem cell transplantation will receive T cell infusion starting at least 14 days after the date of transplant, unless there is clear evidence of relapse, then T-cell infusion can occur at any time after transplant. No lymphodepleting chemotherapy will be given to these patients."
16555184|NCT02917070||Patients|Patients who have chronic kidney diseases
16555185|NCT02917070||Healthy controls|Healthy subjects
16555186|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
16555187|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
16555188|NCT02917044|Active Comparator|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
16555189|NCT02917044|Experimental|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
16555190|NCT02917031|Active Comparator|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
16555191|NCT02917031|Active Comparator|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
16555192|NCT02917031|Placebo Comparator|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
16555193|NCT02917018|Active Comparator|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
16555194|NCT02917018|Active Comparator|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
16555195|NCT02917018|Active Comparator|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
16555196|NCT02917005|Experimental|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
16555197|NCT02917005|Active Comparator|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
16555198|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
16555199|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
16555200|NCT02916979|Other|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
16555201|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
16555202|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
16555203|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
16555204|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
16555205|NCT02916953|Experimental|Treatment|All subjects who meet the inclusion and exclusion criteria will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) treatment
16555206|NCT02916940|Experimental|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
16555207|NCT02916940|No Intervention|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
16555208|NCT02916927|Experimental|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
16555209|NCT02916927|Active Comparator|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
16555210|NCT02916914|Other|Q2 feeding|feeding intervals: 2 hours
16555211|NCT02916914|No Intervention|Q3feeding|feeding intervals: 3 hours
16555212|NCT02916901|Experimental|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
16555213|NCT02916901|Placebo Comparator|Placebo|placebo
16555214|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
16555215|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
16555216|NCT02916862|Experimental|Soluble Corn Fiber (SCF) + Calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
16555217|NCT02916862|Active Comparator|Soluble Corn Fiber (SCF) without calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
16555218|NCT02916862|Placebo Comparator|Placebo|This group will receive a similar supplement without SCF or calcium, administered twice a day
16555219|NCT02916862|Placebo Comparator|Placebo + calcium|This group will receive a similar supplement without SCF + 600 mg/d of elemental calcium carbonate, administered twice a day
16555220|NCT02916849|Experimental|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
16555221|NCT02916849|Active Comparator|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
16555222|NCT02916849|Experimental|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
16555223|NCT02916849|Experimental|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
16555258|NCT02916615|Active Comparator|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
16555224|NCT02916849|Active Comparator|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
16555225|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
16555226|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
16555227|NCT02916810|Active Comparator|Active rTMS stimulation|Real active rTMS stimulation.
16555228|NCT02916810|Sham Comparator|Sham rTMS stimulation|Sham repetitive TMS stimulation.
16555229|NCT02916797|Experimental|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
16555230|NCT02916797|No Intervention|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
16555231|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
16555232|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
16555233|NCT02916771|Experimental|Ixazomib|"Cycles 1-9
~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle
~Lenalidomide is administered orally on days 1-21 on a 28 days cycle
~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle
~Cycle 10-24
~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle
~Lenalidomide is administered orally on days 1-21 on a 28 days cycle
~Supportive measures consistent with optimal patient care may be given throughout the study"
16555234|NCT02916758|Experimental|Let's Go Community Mobility Program|Participation in 4 week program
16555235|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
16555236|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
16555237|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
16555238|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
16555239|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
16555240|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
16555241|NCT02916719|Experimental|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
16555242|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
16555243|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
16555244|NCT02916693|Experimental|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
16555245|NCT02916680|Experimental|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
16555246|NCT02916667|Active Comparator|CNdiet|CNdiet includes chrono nutritional dietary guidelines
16555247|NCT02916667|Placebo Comparator|GDMdiet|GDMdiet includes regular GDM diet
16555248|NCT02916654|Active Comparator|sulphate iron|patients administered with sulphate iron
16555249|NCT02916654|Experimental|sucrosomial iron|patients administered with sucrosomial iron
16555250|NCT02916641|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
16555251|NCT02916641|Active Comparator|Monotherapy|UDCA monotherapy
16555252|NCT02916628|Experimental|Group 1|auricular acupressure + group counseling
16555253|NCT02916628|Placebo Comparator|Group 2|placebo acupressure + group counseling
16555254|NCT02916628|No Intervention|Group 3|self-help smoking cessation
16555255|NCT02916628|No Intervention|Group 4|Non-smokers
16555256|NCT02916615|Active Comparator|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
16555257|NCT02916615|Placebo Comparator|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
16555259|NCT02916602|Experimental|Treatment|HCP1401
16555260|NCT02916602|Active Comparator|Reference|HCP0605
16555261|NCT02916589|Placebo Comparator|Baseline|The subjects will start with one week eating their normal diet.
16555262|NCT02916589|Active Comparator|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
16555263|NCT02916576|Experimental|Blood glucose measurement|
16555264|NCT02916563|Experimental|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
16555265|NCT02916550|Experimental|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
16555266|NCT02916537|Experimental|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
16555267|NCT02916537|Experimental|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).
~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
16555268|NCT02916524|Experimental|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
16555269|NCT02916524|Active Comparator|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
16555270|NCT02916524|No Intervention|Sub-Study: Computational Modeling for Bilingual Dementia and Semantic Decline|This is a sub-study aimed at building a computational model to simulate bilingual dementia and semantic decline.
16555271|NCT02916511|Experimental|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.
~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.
~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5"
16555272|NCT02916498|Active Comparator|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
16555273|NCT02916498|Experimental|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
16555274|NCT02916485|Experimental|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
16555275|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
16555276|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
16555277|NCT02916459|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
16555278|NCT02916459|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
16555279|NCT02916446|Experimental|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
16555280|NCT02916446|Placebo Comparator|Placebo|Placebo patch, daily administration
16555281|NCT02916433|No Intervention|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
16555282|NCT02916433|Experimental|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
16555283|NCT02916420|Experimental|Treatment|Pomalidomide plus low-dose Dexamethasone
16555284|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
16555285|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
16555286|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
16555287|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
16555288|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
16555289|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
16555290|NCT02916381|Experimental|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
16555291|NCT02916381|Sham Comparator|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
16555292|NCT02916368||with surgery|
16555293|NCT02916368||with chemotherapy or radiotherapy|
16555294|NCT02916355|Experimental|Normal BMI|Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
16555295|NCT02916355|Experimental|Overweight|Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
16555296|NCT02916342|Active Comparator|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
16555297|NCT02916342|Experimental|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
16555298|NCT02916329|Experimental|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
16555299|NCT02916329|Experimental|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
16555300|NCT02916329|Experimental|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
16555301|NCT02916329|Experimental|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
16555302|NCT02916329|Experimental|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
16555303|NCT02916329|Experimental|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
16555304|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
16555305|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
16555306|NCT02916290|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
16555307|NCT02916290|Active Comparator|Monotherapy|UDCA monotherapy
16555308|NCT02916264|Active Comparator|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose < 3 mg/kg, is performed by an anesthesiologist.
16555309|NCT02916264|No Intervention|no scalp block|An anesthesiology will pretend to perform the scalp block,
16555310|NCT02916251|Experimental|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
16555311|NCT02916251|Active Comparator|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
16555312|NCT02916238|Experimental|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
16555313|NCT02916238|Active Comparator|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
16555314|NCT02916225|Active Comparator|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
16555315|NCT02916225|Placebo Comparator|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
16555316|NCT02916212|Experimental|Experimental|Hospital units where alarms have been optimized
16555317|NCT02916212|No Intervention|Control|Hospital units where alarms remain unchanged
16555318|NCT02916199|Experimental|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis
~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
16555319|NCT02916199|Active Comparator|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis
~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
16555320|NCT02916186|Experimental|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
16555321|NCT02916186|Active Comparator|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
16555322|NCT02916173|Experimental|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
16555323|NCT02916173|Active Comparator|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
16555324|NCT02916160|Experimental|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
16555325|NCT02916147|Experimental|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
16555326|NCT02916147|Active Comparator|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
16555327|NCT02916134|Active Comparator|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
16555328|NCT02916134|Experimental|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
16555329|NCT02916121|Experimental|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
16555330|NCT02916121|Placebo Comparator|placebo|placebo
16555331|NCT02916108||Concussion|"Study group include up to 30 children with history of concussion in the last 24 hours before admitting to emergency department.
~Reading EEG."
16555332|NCT02916108||Isolated limb injury|"Cohort group include up to 30 children with history of isolated limb injury in the last 24 hours before admitting to emergency department.
~Reading EEG."
16555333|NCT02916095|Experimental|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
16555334|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
16555335|NCT02916069|Active Comparator|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
16555336|NCT02916069|No Intervention|Group 2|Patients will be monitored without any interference based on such monitors
16555337|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
16555338|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
16620324|NCT02478749|Experimental|Adult|adult patients
16555339|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
16555340|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
16555341|NCT02916017||Participants receiving adalimumab|Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
16555342|NCT02916004|Other|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
16555343|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
16555344|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
16555345|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
16555346|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
16555347|NCT02915965|Experimental|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
16555348|NCT02915952|Active Comparator|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
16555349|NCT02915952|Active Comparator|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
16555350|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
16555351|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
16555352|NCT02915926|Active Comparator|OT|standard OT
16555353|NCT02915926|Experimental|OT+OPC|occupational performance coaching
16555354|NCT02915913|Experimental|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
16555355|NCT02915913|Experimental|Resistance training|One session for 30-60 minutes of resistance exercise
16555356|NCT02915913|Experimental|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
16555357|NCT02915913|Placebo Comparator|Non-exercise|Non-exercise
16555358|NCT02915900|Experimental|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
16555359|NCT02915900|Active Comparator|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
16555360|NCT02915887|Experimental|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
16555361|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:
~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;
~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
16555362|NCT02915874|No Intervention|Control|Subjects randomized to not receive treatment.
16555363|NCT02915861||EXPa|Scrub typhus patients: Group A
16555364|NCT02915861||EXPb|Scrub typhus patients: Group B
16555365|NCT02915861||EXPc|Scrub typhus patients: Group C
16555366|NCT02915861||EXC|Control group
16555367|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
16555368|NCT02915835|Active Comparator|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
16555369|NCT02915835|Placebo Comparator|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
16555370|NCT02915822|Experimental|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
16555371|NCT02915822|Active Comparator|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
16555372|NCT02915809|Experimental|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
16555373|NCT02915809|Active Comparator|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
16555374|NCT02915796|Experimental|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
16555375|NCT02915796|Active Comparator|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
16555376|NCT02915796|Placebo Comparator|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
16555377|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
16555378|NCT02915770|Experimental|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
16555379|NCT02915770|Active Comparator|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
16555380|NCT02915757|Experimental|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
16555381|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
16555382|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
16555383|NCT02915718|Experimental|experimental group|protein A immunoadsorption for 5 days
16555384|NCT02915718|No Intervention|control group|non intervention
16555385|NCT02915705|Experimental|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
16555386|NCT02915705|Active Comparator|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
16555387|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
16555388|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
16555389|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:
~81 depressed patients admitted after a recent suicidal act (<8 days)
~81 depressed subjects with a past history of suicidal act (>1month)
~80 depressed subjects without any personal history of suicidal behaviour"
16555390|NCT02915666|Experimental|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
16555391|NCT02915653|No Intervention|Control|Control: not receiving any intervention
16555392|NCT02915653|Experimental|Intervention 1|Receiving educational materials on a new diagnostic service
16555393|NCT02915653|Experimental|Intervention 2|Receiving educational materials on a new diagnostic service
16555394|NCT02915640|Experimental|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
16555395|NCT02915640|No Intervention|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
16555396|NCT02915627|Active Comparator|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
16555397|NCT02915627|Active Comparator|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
16555398|NCT02915627|Active Comparator|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
16555399|NCT02915614|Active Comparator|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
16555400|NCT02915614|Experimental|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
16555401|NCT02915601|Experimental|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
16555402|NCT02915601|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
16555403|NCT02915588|Active Comparator|Primary Active|Early postoperative isometric activation of the rotator cuff
16555404|NCT02915588|Active Comparator|Primary Passive|Standard postoperative passive movement rehabilitation protocol
16555405|NCT02915575|Other|Control Arm (usual care)|Participants will be discharged as per usual ward discharge protocols.
16555406|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
16555407|NCT02915562|Active Comparator|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
16555408|NCT02915562|Active Comparator|Non-depressive Group|GDS 15 (Geriatric Depression Score) <5 Points at baseline
16555409|NCT02915549|Experimental|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
16555410|NCT02915549|Active Comparator|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
16555411|NCT02915523|Active Comparator|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on D1 and D8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
16555412|NCT02915523|Placebo Comparator|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on D1 and D8 of each cycle.
16555413|NCT02915510|Experimental|GMP|Single arm designed, 3 day baseline, 28day on GMP
16555414|NCT02915497|No Intervention|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
16555415|NCT02915497|Experimental|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
16555416|NCT02915484|Experimental|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
16555417|NCT02915484|Experimental|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
16555418|NCT02915471|Experimental|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
16555419|NCT02915471|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
16555420|NCT02915445|Experimental|CAR-T cells recognizing EpCAM|Autologous T cells from patient are engineered to expressing a special chimeric antigen receptor to recognizing EpCAM by lentiviral vector. The engineered T cells were then endowed cytotoxicity to the tumor cells and hold the potential to inhibit the advance of tumors.
16555421|NCT02915432|Experimental|3 mg/kg anti-PD-1 mAb JS001 Q2W|Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.
16555422|NCT02915432|Experimental|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
16555423|NCT02915432|Experimental|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death
16555424|NCT02915419|Active Comparator|group A|prp revascularization
16555425|NCT02915419|Experimental|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
16555426|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
16555427|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
16555428|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
16555429|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
16555430|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
16555431|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
16555432|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
16555433|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
16555434|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
16555435|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
16555436|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
16555437|NCT02915354|Experimental|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
16555438|NCT02915328|Experimental|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
16555439|NCT02915328|Experimental|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
16555440|NCT02915328|Experimental|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
16555441|NCT02915328|Experimental|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
16555442|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
16555443|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
16555444|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
16555445|NCT02915302|Active Comparator|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
16555446|NCT02915302|Experimental|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
16555447|NCT02915289|Active Comparator|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
16555448|NCT02915289|Active Comparator|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
16555449|NCT02915276|Active Comparator|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
16555450|NCT02915276|Active Comparator|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
16555451|NCT02915263|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
16555452|NCT02915263|Experimental|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
16555453|NCT02915250|Experimental|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
16555454|NCT02915250|Active Comparator|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
16555455|NCT02915250|Active Comparator|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
16555456|NCT02915237|Experimental|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
16555457|NCT02915237|Experimental|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
16555458|NCT02915237|Experimental|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
16555459|NCT02915237|Placebo Comparator|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
16555460|NCT02915237|Placebo Comparator|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
16555461|NCT02915237|Placebo Comparator|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
16555462|NCT02915224||Obinutuzumab|Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
16555463|NCT02915211|Experimental|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
16555464|NCT02915198|Experimental|Metformin|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
16555465|NCT02915198|Placebo Comparator|Placebo|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
16555466|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
16555467|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
16555468|NCT02915172|Experimental|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.
~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.
~All participants receive the same dose of Capecitabine.
~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.
~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.
~All participants receive the same dose of Capecitabine."
16555469|NCT02915159|Experimental|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
16555470|NCT02915159|Placebo Comparator|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
16555471|NCT02915146|Active Comparator|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
16555472|NCT02915146|Active Comparator|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
16555473|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
16555502|NCT02914938|Experimental|ME-401 Alone|This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
16555503|NCT02914938|Experimental|ME-401 in Combination with Rituximab|The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
16555474|NCT02915120|Active Comparator|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at < 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
16555475|NCT02915120|Sham Comparator|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
16555476|NCT02915107|Experimental|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
16555477|NCT02915107|Active Comparator|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
16555478|NCT02915081|Experimental|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
16555479|NCT02915081|No Intervention|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
16555480|NCT02915068|No Intervention|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
16555481|NCT02915068|Experimental|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
16555482|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
16555483|NCT02915042|Experimental|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
16555484|NCT02915042|Placebo Comparator|Placebo group|Intervention group 2: placebo
16555485|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:
~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
16555486|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
16555487|NCT02915016|Experimental|Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.
16555488|NCT02915016|Experimental|Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
16555489|NCT02915016|Experimental|Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
16555490|NCT02915016|Experimental|Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
16555491|NCT02915016|Experimental|Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
16555492|NCT02915016|Experimental|Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
16555493|NCT02915016|Experimental|Group 7: Placebo + Protein/AS01B|Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
16555494|NCT02915016|Placebo Comparator|Group 8: Placebo|Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.
16555495|NCT02915003|Experimental|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
16555496|NCT02915003|No Intervention|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
16555497|NCT02914990|Experimental|BPI-15086|BPI-15086, orally administered daily
16555498|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
16555499|NCT02914964|Experimental|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
16555500|NCT02914964|Experimental|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
16555501|NCT02914951|Experimental|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
16555504|NCT02914938|Experimental|ME-401 in Combination with Zanubrutinib|The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).
16555505|NCT02914925|Experimental|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
16555506|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
16555507|NCT02914899|Active Comparator|Pilot RCT Control Group|Eligible NYC Chinese livery drivers will receive written materials only
16555508|NCT02914899|Experimental|Pilot RCT CHW Intervention Group|Eligible NYC Chinese livery drivers will receive written materials and navigation for shared decision making (SDM) and lung cancer screening (LCS).
16555509|NCT02914899|Experimental|Focus Group|The investigators conducted a series of 4-6 focus groups with Chinese livery drivers who (currently, or in the past) smoke.
16555510|NCT02914899|Experimental|In-Depth Interview Group|12-15 in-depth interviews with livery base management and staff, and with 12-15 primary care physicians (PCPs), clinic directors, hospital CFOs, heads of financial services and counseling, and heads of radiology facilities serving the Chinese community.
16555511|NCT02914899|Experimental|Pre-pilot Group|Approximately 10 Chinese livery drivers who smoke or who quit smoking with the past 15 years and have a 30 pack-year history of smoking
16555512|NCT02914886|Experimental|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
16555513|NCT02914886|Active Comparator|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
16555514|NCT02914873|Active Comparator|Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and curative treatment are performed according to the urologist's judgement.
16555515|NCT02914873|Experimental|Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
16555516|NCT02914860|Experimental|Volunteers|Healthy volunteers
16555517|NCT02914860|Active Comparator|PAF|Patients with paroxysmal atrial fibrillation
16555518|NCT02914860|Active Comparator|Pers AF|Patients with persistent atrial fibrillation
16555519|NCT02914860|Active Comparator|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
16555520|NCT02914847|Experimental|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
16555521|NCT02914847|No Intervention|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
16555522|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
16555523|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
16555524|NCT02914821|No Intervention|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
16555525|NCT02914821|Experimental|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
16555526|NCT02914821|Experimental|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
16555527|NCT02914821|Experimental|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
16555528|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
16555529|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria
16555530|NCT02914769|Placebo Comparator|placebo|patients receiving a passive placebo
16555531|NCT02914769|Experimental|Ayahuasca|patients receiving Ayahuasca
16555532|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
16555533|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
16555534|NCT02914743|Experimental|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
16555535|NCT02914743|Experimental|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
16555536|NCT02914743|No Intervention|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
16555537|NCT02914704|Experimental|Patients treated with MRI-HIFU|
16555538|NCT02914691|Active Comparator|Active|Dapagliflozin 10 mg once daily tablet treatment
16555539|NCT02914691|Placebo Comparator|Placebo|Identical once daily tablet treatment
16555540|NCT02914678|No Intervention|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
16555541|NCT02914678|Experimental|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
16555542|NCT02914665|Experimental|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
16555543|NCT02914665|Placebo Comparator|Placebo|Placebo once daily for 7 consecutive days
16555544|NCT02914652|Experimental|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
16555545|NCT02914652|Experimental|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
16555546|NCT02914652|Experimental|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
16555547|NCT02914639|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
16555548|NCT02914639|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
16555549|NCT02914626|Experimental|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
16555550|NCT02914626|Sham Comparator|Control|Standard of care therapy
16555551|NCT02914613|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
16555552|NCT02914613|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
16555558|NCT02914587|Experimental|ARTAS System|Implantation with the ARTAS System.
16555559|NCT02914587|Active Comparator|Manual Implantation|Implantation manually.
16555560|NCT02914574|Other|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
16555561|NCT02914561|Experimental|Filgotinib 200 mg (Induction Study)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
16555562|NCT02914561|Experimental|Filgotinib 100 mg (Induction Study)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 10 weeks
16555563|NCT02914561|Placebo Comparator|Placebo (Induction Study)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
16555564|NCT02914561|Experimental|Maintenance Study|Participants who meet response or remission criteria at Week 10 will continue into the Maintenance Study and receive filgotinib and/or placebo for 48 weeks.
16555565|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
16555566|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
16555567|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
16555568|NCT02914535|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
16555569|NCT02914535|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
16555570|NCT02914535|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
16555571|NCT02914535|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 336 weeks
16555572|NCT02914535|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 336 weeks
16555573|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 200 mg|Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
16555574|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 100 mg|Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
16555575|NCT02914522|Placebo Comparator|Induction Study (Cohort A): Placebo|Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
16555576|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 200 mg|Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
16555577|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 100 mg|Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
16555578|NCT02914522|Placebo Comparator|Induction Study (Cohort B): Placebo|Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
16555579|NCT02914522|Experimental|Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
16555580|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
16555581|NCT02914522|Experimental|Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
16555582|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
16555583|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Placebo|Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
16555584|NCT02914509|Experimental|OTX-TP (sustained release travoprost) Intracanalicular Depot|OTX-TP (sustained release travoprost) Intracanalicular Depot
16555585|NCT02914509|Placebo Comparator|PV (Placebo Vehicle) Intracanalicular Depot|PV (Placebo Vehicle) Intracanalicular Depot
16555586|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
16555587|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
16555588|NCT02914483|Other|Enhanced Usual Care (EUC)|
16555589|NCT02914483|Other|Stress Management|
16555591|NCT02914457|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
16555592|NCT02914431|Experimental|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
16555593|NCT02914431|No Intervention|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
16555594|NCT02914418|Experimental|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
16555595|NCT02914418|Sham Comparator|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
16555596|NCT02914405|Experimental|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:
~Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)
~Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)
~Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
16555597|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
16555598|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
16555599|NCT02914379|Experimental|[¹⁴C]-LY3337641|Oral dose of LY3337641 containing 120 microcuries of radioactivity.
16555600|NCT02914366|Experimental|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by ~3mg/kg to a dose of 1050 mg/day (~l5 mg/kg/day).
16555601|NCT02914366|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
16555602|NCT02914353|Experimental|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg
~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
16555603|NCT02914353|Placebo Comparator|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;
~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
16555604|NCT02914340|Experimental|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
16555605|NCT02914327|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
16555606|NCT02914314|Experimental|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
16555607|NCT02914301|Active Comparator|Babyscripts Prenatal App|For patients allocated to the study group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients who were allocated to the intervention arm, the clinician will told that they are in intervention group and therefore will be receiving regular app-based education and clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
16555608|NCT02914301|Placebo Comparator|Placebo|For patients cared for by clinicians allocated to the usual care arm, the clinician will discuss the management options and scheduling procedures with the parent in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.
16555609|NCT02914275|Experimental|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
16555610|NCT02914275|Experimental|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
16555611|NCT02914275|Active Comparator|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
16555612|NCT02914275|Active Comparator|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
16555613|NCT02914262|Experimental|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
16555614|NCT02914262|Placebo Comparator|Placebo:Cohort 1-6|"Intervention Placebo:
~Two subjects per cohort will receive single oral doses of placebo"
16555615|NCT02914249|Experimental|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
16555616|NCT02914249|No Intervention|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
16555617|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
16555618|NCT02914223|Experimental|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
16555619|NCT02914223|Experimental|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
16555620|NCT02914210|Other|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
16555621|NCT02914210|Other|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
16555622|NCT02914197|Experimental|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:
~Decision aid
~YouTube video
~Group information session"
16555623|NCT02914197|No Intervention|Control|Standard information leaflet for breast screening from Cancer Care Ontario
16555624|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
16555625|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
16555626|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
16555627|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
16555628|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
16555629|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
16555630|NCT02914158|Experimental|Goserelin and aromatase inhibitors|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.
~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
16555631|NCT02914158|Active Comparator|Goserelin and tamoxifen|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.
~Tamoxifen: 20mg oral for every day, for 5 years."
16555632|NCT02914145|Other|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
16555633|NCT02914132|Other|Seraph 100 Filter|Renal replacement patient with bacteremia.
16555634|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
16555696|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
16555635|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
16555636|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
16555637|NCT02914093|Experimental|IMT-feasibility|Single arm intervention
16555638|NCT02914067|Experimental|Cohort 1|"Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later.
~Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time"
16555639|NCT02914067|Experimental|Cohort 2|"Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 3 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient.
~Patients in Cohort 1 will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 3 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans)."
16555640|NCT02914067|Experimental|Cohort 3|"During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.
~rsfcMRI will be obtained annually for total of 3 rsfcMRIs for each patient."
16555641|NCT02914054|Active Comparator|Conventional Prednisone receiving group|Patients in PDN arm received PDN
16555642|NCT02914054|Active Comparator|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
16555643|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD >0 cm.
16555644|NCT02914028|Active Comparator|Tramadol and paracetamol|subjects were administered intravenous analgesia (control group) Tramadol 100 mg and paracetamol 1000 mg at the end of the surgery
16555645|NCT02914028|Active Comparator|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
16555646|NCT02914015|Experimental|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
16555647|NCT02914015|Active Comparator|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
16555648|NCT02914002|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
16555649|NCT02914002|No Intervention|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
16555650|NCT02914002|No Intervention|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
16555651|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
16555652|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
16555653|NCT02913976|Experimental|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
16555654|NCT02913976|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
16555655|NCT02913963|Active Comparator|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
16555656|NCT02913963|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
16555657|NCT02913937|Active Comparator|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
16555658|NCT02913937|Experimental|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
16555659|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
16555660|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
16555661|NCT02913911|Experimental|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
16620430|NCT02478008|Experimental|CardiAQ TMVI System (Transapical DS)|
16555662|NCT02913911|Sham Comparator|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
16555663|NCT02913898|Experimental|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
16555664|NCT02913898|Placebo Comparator|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
16555665|NCT02913885|Active Comparator|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
16555666|NCT02913885|Experimental|Group 1|fluoride varnish inhibit progression of white spot lesion
16555667|NCT02913859|Experimental|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
16555668|NCT02913859|Active Comparator|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
16555669|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
16555670|NCT02913833|Experimental|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
16555671|NCT02913833|No Intervention|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
16555672|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
16555673|NCT02913807|Placebo Comparator|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
16555674|NCT02913807|Experimental|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
16555675|NCT02913781|Experimental|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
16555676|NCT02913768|Active Comparator|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
16555677|NCT02913768|Placebo Comparator|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
16555678|NCT02913755|Experimental|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
16555679|NCT02913755|Active Comparator|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
16555680|NCT02913742|Experimental|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
16555681|NCT02913729|Experimental|radiotherapy in arm 1|pre-operative accelerated partial breast irradiation
16555682|NCT02913729|Active Comparator|radiotherapy in arm 2|post-operative accelerated partial breast irradiation
16555683|NCT02913716|Experimental|Defactinib treatment|Single dose of 400 mg [14C]-defactinib, oral suspension
16555684|NCT02913703|Experimental|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
16555685|NCT02913703|Experimental|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
16555686|NCT02913703|Experimental|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
16555687|NCT02913703|Experimental|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
16555688|NCT02913703|Experimental|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
16555689|NCT02913703|Experimental|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
16555690|NCT02913690|Placebo Comparator|Control group|Control group will be supplemented with placebo for 12 months.
16555691|NCT02913690|Active Comparator|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
16555692|NCT02913677|Active Comparator|group 1|prolonged minimal enteral nutrition
16555693|NCT02913677|Placebo Comparator|group 2|slowly advancing enteral nutrition
16555694|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
16555695|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
16555697|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
16555698|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
16555699|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
16555700|NCT02913625|Experimental|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
16555701|NCT02913625|Active Comparator|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
16555702|NCT02913612|Experimental|Intervention Group|Subjects assigned to this arm will be randomized to either 0.25% Timolol or 0.5% Timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol, if on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin alternative treatment.
16555703|NCT02913612|No Intervention|Non-Intervention Group|Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.
16555704|NCT02913573|Experimental|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
16555705|NCT02913573|No Intervention|GA only|Patients will receive standard general anesthesia.
16555706|NCT02913547|Experimental|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.
~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
16555707|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
16555708|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
16555709|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
16555710|NCT02913508|Experimental|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
16555711|NCT02913508|Experimental|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
16555712|NCT02913508|Experimental|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
16555713|NCT02913508|Experimental|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
16555714|NCT02913508|Experimental|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
16555715|NCT02913495|Experimental|Vaginal Progesterone|200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery
16555716|NCT02913495|Active Comparator|Intramuscular Progesterone|250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.
16555717|NCT02913482|Experimental|Part 1 (Dose Finding): Risdiplam (RO7034067)|Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
16555718|NCT02913482|Experimental|Part 2 (Confirmatory): Risdiplam (RO7034067)|Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
16555719|NCT02913469|Experimental|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
16555720|NCT02913469|Active Comparator|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
16555721|NCT02913469|Sham Comparator|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
16555722|NCT02913469|Placebo Comparator|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
16555723|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
16555724|NCT02913443|Experimental|Introductory Cohort - 400 μg RO7051790|Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
16555725|NCT02913443|Experimental|Dose Escalation - 1000 μg RO7051790|1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
16555726|NCT02913443|Experimental|Dose Escalation - 1300 μg RO7051790|1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
16555727|NCT02913443|Experimental|Dose Escalation - 1900 μg RO7051790|1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
16555728|NCT02913430|Active Comparator|Arm A|fulvestrant administered 500mg IM Q28 days plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
16555858|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
16555729|NCT02913430|Active Comparator|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
16555730|NCT02913417|Experimental|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
16555731|NCT02913404|Experimental|ACL Reconstruction|"Surgical Protocol
~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
16555732|NCT02913404|Experimental|ACL Recon. extra-articular-tenodesis|"Surgical Protocol
~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
16555733|NCT02913391|Experimental|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
16555734|NCT02913391|Active Comparator|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
16555735|NCT02913378|Experimental|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
16555736|NCT02913378|Active Comparator|Conservative|Conservative treatment with sling and rehabilitation
16555737|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
16555738|NCT02913352|Active Comparator|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
16555739|NCT02913352|Experimental|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
16555740|NCT02913339|Experimental|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be > 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
16555741|NCT02913339|Active Comparator|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:
~If the CHW calculates the risk of CVD to be > 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
16555742|NCT02913326|Experimental|Dabigatran etexilate|
16555743|NCT02913326|Active Comparator|Warfarin|
16555744|NCT02913313|Experimental|Part 1A: Dose Escalation Monotherapy (BMS-986207)|
16555745|NCT02913313|Experimental|Part 1B: Dose Escalation Combination Therapy (BMS-986207 + nivolumab)|
16555746|NCT02913313|Experimental|Part 2A: Expansion Monotherapy (BMS-986207)|
16555747|NCT02913313|Experimental|Part 2B: Expansion Combination Therapy (BMS-986207 + nivolumab)|
16555748|NCT02913313|Experimental|Part 1C: Triplet Cohort (BMS-986207 + nivolumab + ipilimumab)|
16555749|NCT02913313|Experimental|Part 2C: Triplet Expansion (BMS-986207 + nivolumab + ipilimumab)|
16555750|NCT02913300|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
16555751|NCT02913300|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
16555752|NCT02913287|Placebo Comparator|Placebo|Maltodextrin
16555753|NCT02913287|Experimental|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
16555754|NCT02913274|Experimental|"DEB arm"|dilation by a high-pressure conventional angioplasty balloon (sized to fit the reference native vein diameter) until disappearance of the stenotic obstructive area and achievement of technical success (possibility of changing balloon size or dilation pressure) then dilation by a DEB.
16555755|NCT02913274|Active Comparator|"conventional angioplasty arm"|dilation will be performed by a conventional high-pressure balloon until technical success is achieved (possibility of changing balloon size or dilation pressure), then by a sham balloon i.e a conventional low-pressure balloon (placebo)
16555756|NCT02913261|Active Comparator|Ruxolitinib|Ruxolitinib 10 mg Bis In Diem (BID)
16555757|NCT02913261|Active Comparator|Best Available Therapy (BAT)|As selected by the investigator
16555758|NCT02913248|Experimental|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
16555759|NCT02913235|Experimental|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
16555859|NCT02912507|Experimental|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
16555760|NCT02913222|Experimental|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
16555761|NCT02913222|Active Comparator|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
16555762|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
16555763|NCT02913196|Experimental|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
16555764|NCT02913183|Experimental|young Fresh Frozen Plasma|"Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.
~Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
16555765|NCT02913183|Placebo Comparator|old Fresh Frozen Plasma|"Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.
~Old plasma exchange over a course of 3 consecutive days after stroke onset.
~Patients will receive usual care and drug use in hospital."
16555766|NCT02913170|Experimental|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
16555767|NCT02913170|Placebo Comparator|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
16555768|NCT02913157|Experimental|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
16555769|NCT02913131|Experimental|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
16555770|NCT02913131|Experimental|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
16555771|NCT02913118|Experimental|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
16555772|NCT02913118|Placebo Comparator|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
16555773|NCT02913105|Experimental|LMB763|Oral dose once daily for 12 weeks (84 days)
16555774|NCT02913105|Placebo Comparator|Placebo|Oral dose once daily for 12 weeks (84 days)
16555775|NCT02913092|Experimental|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed and responded to (e.g. outreach worker contacts the participant for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide asthma education over the phone
16555776|NCT02913092|No Intervention|Usual Care|Usual care group will receive the electronic tracker but the sensor-generated alerts will not be delivered. If the usual care group rescue inhaler data reveals frequent use of rescue medication (daily use for >3 days) investigators will reach out (via app or phone call) to advise the participant to see their physician
16555777|NCT02913079|Experimental|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
16555778|NCT02913079|Placebo Comparator|Sitting|During this condition, participants will work in the sitting position only.
16555779|NCT02913066|Experimental|Single drug|S-1 concurrent Radiotherapy
16555780|NCT02913066|Active Comparator|Double drug|S-1 plus cisplatin concurrent Radiotherapy
16555781|NCT02913053|Active Comparator|Aerobic exercise|
16555782|NCT02913053|Active Comparator|Stretching and Toning|
16555783|NCT02913053|No Intervention|Usual care: Control Group|
16555784|NCT02913040|Experimental|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
16555785|NCT02913040|Active Comparator|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
16555786|NCT02913027|No Intervention|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
16555787|NCT02913027|Active Comparator|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
16555788|NCT02913014|Active Comparator|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
16555789|NCT02913014|No Intervention|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
16555790|NCT02913001|Experimental|Low Glycemic Load Diet|Participants received a diet education to follow a low glycemic load diet and received some low glycemic load staple foods.
16555791|NCT02913001|Active Comparator|Usual Eating Plan|Participants received a diet education to continue with their usual diet.
16555792|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:
~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
16555793|NCT02912988|No Intervention|Control group|"Standard treatment:
~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
16555794|NCT02912975|Experimental|Mirror treatment|Five minutes treatment period twice a day for three weeks
16555795|NCT02912975|Active Comparator|Tactile treatment|Tactile massage twice a day for three weeks
16555796|NCT02912962|Experimental|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.
~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
16555797|NCT02912962|Experimental|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
16555798|NCT02912949|Experimental|Part 2 Pancreatic cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
16555799|NCT02912949|Experimental|Part 2 NSCLC cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
16555800|NCT02912949|Experimental|Part 2 Solid tumour (basket) harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
16555801|NCT02912936|Experimental|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
16555802|NCT02912936|Placebo Comparator|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
16555803|NCT02912923|Experimental|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
16555804|NCT02912923|Experimental|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
16555805|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
16555806|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
16555807|NCT02912897|Experimental|Cellular therapy with EBV specific autologous CTL infusion|
16555808|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
16555809|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
16555810|NCT02912871|Experimental|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
16555811|NCT02912858|Experimental|geko plus R-2|neuromuscular electrostimulation
16555812|NCT02912845|Experimental|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
16555813|NCT02912832|Experimental|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.
~Operators were blinded to all other results for a sample upon data entry."
16555814|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
16555815|NCT02912793|Active Comparator|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
16555816|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
16555817|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
16555818|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
16555819|NCT02912754|Experimental|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
16555820|NCT02912754|No Intervention|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
16555821|NCT02912741|Experimental|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
16555822|NCT02912741|Active Comparator|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
16555823|NCT02912728|Active Comparator|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
16555824|NCT02912728|Active Comparator|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.
~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.
~Participants will be instructed to use the CGM as per the FDA labeling."
16556004|NCT02911480|Experimental|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
16555825|NCT02912728|No Intervention|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
16555826|NCT02912715|Experimental|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
16555827|NCT02912702|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
16555828|NCT02912702|Active Comparator|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
16555829|NCT02912689|Experimental|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
16555830|NCT02912689|Active Comparator|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
16555831|NCT02912676|Experimental|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
16555832|NCT02912663|Experimental|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
16555833|NCT02912663|Placebo Comparator|Placebo|Control group will receive saline only
16555834|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
16555835|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
16555836|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
16555837|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
16555838|NCT02912637||CF patients|Hyperpolarized Xenon MRI
16555839|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
16555840|NCT02912611|Other|Moderate and High risk for AKI|
16555841|NCT02912598|Active Comparator|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
16555842|NCT02912598|Active Comparator|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
16555843|NCT02912598|Experimental|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
16555844|NCT02912598|Active Comparator|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
16555845|NCT02912585|Experimental|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
16555846|NCT02912585|Placebo Comparator|Placebo|Oropharyngeal administration of sterile water.
16555847|NCT02912585|Active Comparator|Donor human milk|Oropharyngeal administration of donor human milk.
16555848|NCT02912572|Experimental|Pole Mutated Endometrial Cancer|Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
16555849|NCT02912572|Experimental|MSS Endometrial Cancer|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
16555850|NCT02912572|Experimental|MSS Avelumab/Talazoparib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
16555851|NCT02912572|Experimental|MSS Avelumab/Axitinib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Axitinib will be administered twice per day by mouth
16555854|NCT02912546|Active Comparator|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
16555855|NCT02912546|Active Comparator|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
16555856|NCT02912533|Experimental|JR-131|
16555857|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
16555860|NCT02912507|Active Comparator|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
16555861|NCT02912494|Experimental|JR-131|
16555862|NCT02912494|Active Comparator|Darbepoetin alfa|
16555863|NCT02912481|Experimental|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
16555864|NCT02912481|Active Comparator|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
16555865|NCT02912481|Active Comparator|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
16555866|NCT02912468|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
16555867|NCT02912468|Experimental|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
16555868|NCT02912455|Active Comparator|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
16555869|NCT02912455|Placebo Comparator|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
16555870|NCT02912442||Infertile women study 1|
16555871|NCT02912442||Infertile women study 2|
16555872|NCT02912442||Repeated pregnancy loss|
16555873|NCT02912429|Other|Inlay|specific technical type of patellofemoral arthroplasty
16555874|NCT02912429|Other|Onlay|specific technical type of patellofemoral arthroplasty
16555875|NCT02912416|Experimental|Probiotics|Capsule with probiotics
16555876|NCT02912416|Placebo Comparator|Placebo|Capsule with placebo
16555877|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
16555878|NCT02912390|Active Comparator|Cerclage|- Macdonald cerclage placed in standard fashion
16555879|NCT02912390|Active Comparator|Expectant management|- Patient is placed on activity restrictions
16555880|NCT02912377|Experimental|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
16555881|NCT02912377|Experimental|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
16555882|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
16555883|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
16555884|NCT02912338|Experimental|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
16555885|NCT02912338|Active Comparator|Control Group|not change lifestyle
16555886|NCT02912325|Other|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
16555887|NCT02912312|Experimental|Arm I: Hypofractionated Regional Nodal Irradiation (RNI)|Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
16555888|NCT02912312|Active Comparator|Arm II: Standard Regional Nodal Irradiation (RNI)|Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
16555889|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
16555890|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
16555891|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
16555892|NCT02912286|Active Comparator|conventional needle irrigation|side-vented needle used for endodontic irrigation
16555893|NCT02912286|Experimental|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
16555894|NCT02912286|Experimental|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
16555895|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
16555896|NCT02912260|Experimental|MGL-3196|Study Drug
16555897|NCT02912260|Placebo Comparator|Placebo|Matching Placebo
16555898|NCT02912247|Experimental|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
16555899|NCT02912247|Active Comparator|adalimumab|adalimumab 40mg administered subcutaneously once
16555900|NCT02912234|Experimental|Apixaban and Clarithromycin|
16555901|NCT02912221|No Intervention|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
16555902|NCT02912221|Active Comparator|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
16555903|NCT02912208|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
16555904|NCT02912208|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
16555905|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.
~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
16555906|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.
~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
16555907|NCT02912182|Placebo Comparator|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
16555908|NCT02912182|Active Comparator|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
16555909|NCT02912182|Active Comparator|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
16555910|NCT02912169|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
16555911|NCT02912156|Experimental|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
16555912|NCT02912156|Active Comparator|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
16555913|NCT02912143||newly diagnosed children with hemophilia|no intervention
16555914|NCT02912130|No Intervention|Control|No Intervention
16555915|NCT02912130|Experimental|Exercise|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
~Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
16555916|NCT02912130|Experimental|Exercise+Nutrition|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
~Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
16555917|NCT02912130|Experimental|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
16555918|NCT02912104|Experimental|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of primary ovarian insufficiency(POI) patients
16555919|NCT02912078|Experimental|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
16555920|NCT02912078|Active Comparator|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
16555921|NCT02912052|Experimental|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
16555922|NCT02912052|Active Comparator|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
16555923|NCT02912026|Experimental|Intravenous|Intravenous AUC0-infinity
16555924|NCT02912026|Experimental|Oral|Oral AUC0-infinity
16555925|NCT02912013|Experimental|Me mini|Subjects treated with Me mini device
16555926|NCT02912000|Experimental|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
16555927|NCT02912000|No Intervention|Control|Care as usual: No electronic tablet in waiting room
16555928|NCT02911987|Experimental|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
16555929|NCT02911987|Experimental|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
16555930|NCT02911987|Experimental|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
16555931|NCT02911987|Experimental|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
16555932|NCT02911987|Active Comparator|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
16555933|NCT02911974|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
16555934|NCT02911974|Active Comparator|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
16555935|NCT02911961|Experimental|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
16555936|NCT02911961|No Intervention|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
16555937|NCT02911948|Experimental|Insulin degludec/liraglutide|
16555938|NCT02911948|Active Comparator|Insulin degludec|
16555939|NCT02911935|Active Comparator|Oral azithromycin|Oral Azithromycin
16555940|NCT02911935|Placebo Comparator|Placebo|Oral Placebo
16555941|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.
~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
16555975|NCT02911714|Experimental|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
16555942|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.
~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
16555943|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
16555944|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
16555945|NCT02911883||Normal|Not having glaucoma or retinal pathology
16555946|NCT02911883||Glaucoma|Having glaucoma.
16555947|NCT02911883||Retina|Having retinal pathology
16555948|NCT02911870|Experimental|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
16555949|NCT02911870|Placebo Comparator|Part A, placebo|Single dose at corresponding dose levels.
16555950|NCT02911870|Experimental|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
16555951|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
16555952|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
16555953|NCT02911831|Experimental|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.
~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
16555954|NCT02911831|Placebo Comparator|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.
~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
16555955|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
16555956|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
16555957|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
16555958|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
16555959|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
16555960|NCT02911805|Active Comparator|Aerobic Exercise|Exercise 3 times a week
16555961|NCT02911805|Placebo Comparator|Balance Training|Group balance training 3 times a week
16555962|NCT02911792|Experimental|Dapagliflozin|Subjects will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization we will add Dapagliflozin to current metformin.
16555963|NCT02911792|Active Comparator|Metformin|Subjects who Drug naïve we will give Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization we will add Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
16555964|NCT02911779|Other|change of medilateral angle line|change of medilateral angle line during crowning of the head
16555965|NCT02911766|Active Comparator|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,
~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
16555966|NCT02911766|Experimental|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse
~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
16555967|NCT02911766|Experimental|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.
~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
16555968|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
16555969|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
16555970|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
16555971|NCT02911740|Experimental|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
16555972|NCT02911740|No Intervention|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
16555973|NCT02911727|Experimental|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
16555974|NCT02911727|No Intervention|Standard discharge|Discharge at least 48 hours after elective cesarean section.
16555976|NCT02911714|Experimental|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
16555977|NCT02911701|Experimental|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
16555978|NCT02911701|Active Comparator|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
16555979|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
16555980|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
16555981|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
16555982|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
16555983|NCT02911662|Experimental|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
16555984|NCT02911662|Active Comparator|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
16555985|NCT02911649|Experimental|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
16555986|NCT02911649|Experimental|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
16555987|NCT02911649|Experimental|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
16555988|NCT02911649|No Intervention|Control Group|Participants in this group will receive usual care
16555989|NCT02911636|Experimental|Arm 1|Pelvic SABR with intra-prostatic SABR
16555990|NCT02911623|Experimental|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
16555991|NCT02911610|Experimental|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
16555992|NCT02911610|Other|volar plate|surgery of wrist fractures with volar plate
16555993|NCT02911597|Experimental|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.
~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
16555994|NCT02911597|Experimental|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.
~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
16555995|NCT02911584|Active Comparator|Sacral colpopexy|Laparoscopic procedure
16555996|NCT02911584|Active Comparator|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
16555997|NCT02911571|Experimental|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
16555998|NCT02911532|Experimental|Optical Coherence tomography|
16555999|NCT02911519|Experimental|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
16556000|NCT02911519|Active Comparator|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
16556001|NCT02911493|Experimental|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
16556002|NCT02911493|Active Comparator|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
16556003|NCT02911480|Experimental|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
16556005|NCT02911480|Experimental|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
16556006|NCT02911480|Experimental|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
16556007|NCT02911480|Experimental|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
16556008|NCT02911467|Experimental|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
16556009|NCT02911454|Experimental|Healthy infants: fully or partly formula fed|
16556010|NCT02911441|Experimental|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
16556011|NCT02911441|No Intervention|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
16556012|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
16556013|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
16556014|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
16556015|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
16556016|NCT02911389|Active Comparator|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
16556017|NCT02911389|Active Comparator|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
16556018|NCT02911389|Active Comparator|outpatient PT|outpatient physical therapy
16556019|NCT02911363|Active Comparator|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
16556020|NCT02911363|Active Comparator|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
16556021|NCT02911350|Experimental|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:
~Lupron / Flutamide
~Zoladex/ Flutamide
~Lupron/ Casodex
~Zoladex/ Casodex
~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday & Wednesday or Tuesday & Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) & 45 mg/m2 (dose level VI).
~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
16556022|NCT02911337|Experimental|Lifestyle modification|Lifestyle modification
16556023|NCT02911324|Experimental|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
16556024|NCT02911324|Experimental|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
16556025|NCT02911311|Experimental|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
16556026|NCT02911311|Active Comparator|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
16556027|NCT02911298|Experimental|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
16556028|NCT02911298|Active Comparator|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
16556029|NCT02911285|Experimental|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
16556030|NCT02911285|Placebo Comparator|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
16556031|NCT02911272|Active Comparator|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
16556032|NCT02911272|Experimental|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
16556033|NCT02911259|Experimental|Group 1|Post-operative suction is set to -2 cmH2O.
16556034|NCT02911259|Active Comparator|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
16556035|NCT02911220|Other|blood sample for genetic evaluation|a blood sample is collected once for genetic analysis
16556036|NCT02911207|Experimental|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
16556037|NCT02911207|Active Comparator|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
16556038|NCT02911194|Experimental|Treatment|a2 milk intervention period
16556039|NCT02911194|Placebo Comparator|Control|a1 containing milk (normal) intervention period
16556040|NCT02911168|Active Comparator|Proximal Intercostal Block|See Intervention Section
16556041|NCT02911168|Active Comparator|Paravertebral Block|See Intervention Section
16556042|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
16556043|NCT02911142|Experimental|1|Lenalidomide, Rituximab, Prednisone, Etopiside, Doxorubicin, Vincristine and Cyclophosphamide
16556044|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
16556045|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
16556046|NCT02911116|Experimental|Cohort 1 (Subcutaneous Only)|Subcutaneous injections of Ustekinumab at baseline.
16556047|NCT02911116|Experimental|Cohort 2 (IV and Subcutaneous)|Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
16556048|NCT02911103|Experimental|Active|single arm study
16556049|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SE Addictions Unit.
16556051|NCT02911051|Experimental|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
16556052|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
16556053|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
16556054|NCT02910999||NSCLC patients with squamous tumor histology|
16556055|NCT02910999||NSCLC patients with non-squamous tumor histology|
16556056|NCT02910986|No Intervention|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
16556057|NCT02910986|Active Comparator|Enhanced|Usual Care plus a written educational brochure
16556058|NCT02910986|Active Comparator|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
16556059|NCT02910973|Active Comparator|Vagus Nerve Stimulation|Device: Vagus nerve stimulation Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
16556060|NCT02910973|Sham Comparator|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
16556061|NCT02910960|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
16556062|NCT02910960|Active Comparator|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
16556063|NCT02910947|Experimental|quadratus lumborum|
16556064|NCT02910947|Experimental|TAP(Transversus abdominis plane)|
16556065|NCT02910934|Experimental|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
16556066|NCT02910934|No Intervention|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
16556067|NCT02910895|Other|single arm|single tumor biopsy
16556068|NCT02910882|Experimental|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:
~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).
~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);
~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:
~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
16556069|NCT02910869||Successful weight loss|Patients who have lost =>5% of their weight after completing MOVE! or TeleMOVE!
16556070|NCT02910869||Unsuccessful weight loss|Patients who have lost <5% of their weight after completing MOVE! or TeleMOVE!
16556071|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.
~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.
~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
~External beam Radiotherapy
~Surgery"
16556072|NCT02910817|Experimental|Metformin-treated group|51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
16556073|NCT02910817|Placebo Comparator|Placebo|A cohort of fifty-one cross matched PCOS women
16556074|NCT02910804|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
16557194|NCT02902874|Experimental|Patients treated for anaplastic large cell lymphoma ( ALCL )|
16556078|NCT02910778|Experimental|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
16556079|NCT02910778|Placebo Comparator|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
16556080|NCT02910765|Active Comparator|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
16556081|NCT02910765|Placebo Comparator|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
16556082|NCT02910752|Experimental|"CLAM|PBSC"|CLAM chemotherapy with mobilized PBSC infusion: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
16556083|NCT02910739|Experimental|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
16556084|NCT02910739|Active Comparator|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
16556085|NCT02910739|Experimental|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
16556086|NCT02910739|Active Comparator|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
16556087|NCT02910726|Experimental|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
16556088|NCT02910713|Experimental|Intranasal Application|Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
16556089|NCT02910713|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
16556090|NCT02910700|Experimental|Arm A (NDT, CLOSED)|Patients receive nivolumab IV over 30 minutes on day 1, dabrafenib PO BID on days 1-28, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
16556091|NCT02910700|Experimental|Arm B (NT, closed to accrual)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
16556092|NCT02910700|Experimental|Arm C (NEB)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, encorafenib PO QD on days 1-28, and binimetinib PO BID on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
16556093|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
16556094|NCT02910674|Other|One Arm|This is a comparative diagnostic study, no interventional actions are being taken.
16556095|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine & CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
16556096|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh & Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. & 15- 17 y.)
16556097|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
16556098|NCT02910648|Experimental|Approach/Inhibit group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.
~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.
~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
16556099|NCT02910648|Sham Comparator|Sham sound cues group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.
~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.
~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
16556100|NCT02910648|Sham Comparator|Sham go/no-go group|"Participants in the control sham go/no-go group will complete a modified Go/No-Go Task with sham approach and inhibit items.
~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.
~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
16556101|NCT02910635|Experimental|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
16556102|NCT02910635|Experimental|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
16556103|NCT02910635|Active Comparator|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
16556104|NCT02910635|Placebo Comparator|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
16556105|NCT02910635|Placebo Comparator|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
16556106|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
16556107|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
16556108|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
16556109|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
16556110|NCT02910596|Experimental|A|"Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day
~In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.
~Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
16556111|NCT02910596|Experimental|B|"Early bladder training Start on 3rd - 5th postoperative day
~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
16556112|NCT02910596|Experimental|C|"Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day
~should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.
~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
16556113|NCT02910596|Other|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
16556114|NCT02910583|Experimental|MRD Cohort Randomized ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity
16556115|NCT02910583|Placebo Comparator|MRD Cohort Randomized Placebo to match ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive matching ibrutinib placebo capsules orally once daily on a continuous schedule until MRD-positive relapse, clinical disease progression or unacceptable toxicity.
16556116|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules and venetoclax 400 mg tablets orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity.
16556117|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous scheduled until clinical disease progression or unacceptable toxicity.
16556118|NCT02910583|Experimental|Fixed Duration Cohort - Open Label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
16556119|NCT02910570|Experimental|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
16556120|NCT02910570|Placebo Comparator|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
16556121|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
16556154|NCT02910245|Active Comparator|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
16556155|NCT02910245|Placebo Comparator|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
16556122|NCT02910531|Experimental|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.
~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.
~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
16556123|NCT02910531|Placebo Comparator|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.
~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.
~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
16556124|NCT02910518|Experimental|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
16556125|NCT02910518|Active Comparator|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
16556126|NCT02910505|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
16556127|NCT02910492|Experimental|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
16556128|NCT02910479|Experimental|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
16556129|NCT02910466|Experimental|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
16556130|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
16556131|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
16556132|NCT02910440|Experimental|DCL-101|
16556133|NCT02910440|Active Comparator|GoLytely|
16556134|NCT02910427|Placebo Comparator|Na salt|regular salt
16556135|NCT02910427|Active Comparator|K salt|potassium-enriched salt
16556136|NCT02910427|Active Comparator|K/Mg salt|potassium and magnesium-enriched salt
16556137|NCT02910414|Experimental|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
16556138|NCT02910414|Sham Comparator|Renal Angiography Only (Sham Procedure)|The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).
16556139|NCT02910401|Active Comparator|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
16556140|NCT02910401|Active Comparator|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
16556141|NCT02910401|Active Comparator|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
16556142|NCT02910388|Experimental|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
16556143|NCT02910388|Active Comparator|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
16556144|NCT02910375|Other|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (<80 kg) or 100mg (>80 kg body weight)
16556145|NCT02910375|Other|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (<80 kg) or 100mg every 4 weeks (>80 kg body weight)
16556146|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
16556147|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
16556148|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
16556149|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
16556150|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
16556151|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
16556152|NCT02910310|No Intervention|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
16556153|NCT02910310|Experimental|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
16556156|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
16556157|NCT02910219|Experimental|Treatment|Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.
16556158|NCT02910219|No Intervention|Control|Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.
16556159|NCT02910206|Experimental|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
16556160|NCT02910206|Experimental|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
16556161|NCT02910193||alcohol-dependent patients|
16556162|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
16556163|NCT02910193||healthy control subjects|
16556164|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
16556165|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
16556166|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
16556167|NCT02910154|Experimental|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.
~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
16556168|NCT02910154|No Intervention|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
16556169|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
16556170|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
16556171|NCT02910128|Experimental|School intervention|chiquichefs education innovation
16556172|NCT02910128|No Intervention|control school|A primary schools will function as control schools.
16556173|NCT02910115|Other|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
16556174|NCT02910115|Experimental|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.
~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
16556175|NCT02910102|Other|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
16556176|NCT02910102|Other|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
16556177|NCT02910089|Other|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
16556178|NCT02910089|No Intervention|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
16556179|NCT02910076|Experimental|Healthy volunteers|
16556180|NCT02910076|Experimental|Diabetes patients|
16556181|NCT02910063|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
16556182|NCT02910050|Experimental|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
16556183|NCT02910037|Experimental|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
16556184|NCT02910024|Active Comparator|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
16556185|NCT02910024|Sham Comparator|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
16556186|NCT02910011|Experimental|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
16556212|NCT02909803|Experimental|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
16556213|NCT02909803|Active Comparator|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
16556187|NCT02909985|Experimental|Visual response to IR|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source
~10 colorblind participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source
~For both groups, as intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
16556188|NCT02909985|Experimental|Electroretinography|"5 healthy participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR
~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
16556189|NCT02909985|Experimental|Visual Evoke Potential Test|"5 healthy participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR
~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
16556190|NCT02909972|Experimental|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
16556191|NCT02909972|Experimental|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
16556192|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.
~The weight-based dosing schedule is as follows:
~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
16556193|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
16556194|NCT02909946|Active Comparator|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
16556195|NCT02909946|No Intervention|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
16556196|NCT02909933|Experimental|liraglutide|liraglutide 3 mg QD for 12 weeks
16556197|NCT02909933|Experimental|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
16556198|NCT02909920|Experimental|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
16556199|NCT02909920|Active Comparator|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
16556200|NCT02909907|Experimental|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
16556201|NCT02909907|Experimental|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
16556202|NCT02909894|Experimental|Prolonged Sitting|
16556203|NCT02909894|Active Comparator|Light intensity arm ergometry breaks|
16556204|NCT02909881|Experimental|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
16556205|NCT02909868|Experimental|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
16556206|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
16556207|NCT02909842|Experimental|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
16556208|NCT02909842|Placebo Comparator|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
16556209|NCT02909829|Experimental|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
16556210|NCT02909829|Experimental|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
16556211|NCT02909829|Active Comparator|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
16556214|NCT02909790|Experimental|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
16556215|NCT02909790|Sham Comparator|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
16556216|NCT02909777|Experimental|CUDC-907|"CUDC-907 orally administered
~CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing
~Dose level assigned at registration
~Pre-dose pharmacokinetic blood sample will be collected
~Dose escalation will follow a standard 3+3 design"
16556217|NCT02909764|No Intervention|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
16556218|NCT02909764|Experimental|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
16556219|NCT02909751|Active Comparator|Neoadjuvant chemotherapy|"HER2 negative:
~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv
~HER2 positive:
~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
16556220|NCT02909751|Experimental|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:
~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.
~Daily: Tocotrienol 300 mg x 3
~HER2 positive:
~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.
~Daily: Tocotrienol 300 mg x 3"
16556221|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
16556222|NCT02909725|Experimental|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( >50 minutes) of sedentary time.
16556223|NCT02909725|Experimental|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
16556224|NCT02909725|Active Comparator|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
16556225|NCT02909712|Active Comparator|sulfadoxine-pyrimethamine (SP)|"Group 1 (50 CareStart™ RDT-positive women)
~Group 2 (50 CareStart™ RDT-negative women)
~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
16556226|NCT02909712|Experimental|dihydroartemisinin-piperaquine (DHA-PQP)|"Group 3 (50 CareStart™ RDT-positive women)
~Group 4 (50 CareStart™ RDT-negative women)
~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
16556227|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
16556228|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
16556229|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
16556230|NCT02909686|Experimental|Boswellia Serrata|400-800mg in capsule form by mouth every day
16556231|NCT02909686|Experimental|Curcumin|1000-2000mg in capsule form by mouth every day
16556232|NCT02909686|Experimental|Epimedium|1000-2000mg in capsule form by mouth every day
16556233|NCT02909686|Experimental|Fisetin|200-800mg in capsule form by mouth every day
16556234|NCT02909686|Experimental|Luteolin|200-400mg in capsule form by mouth every day
16556235|NCT02909686|Experimental|Nettle|435-1305mg in capsule form by mouth every day
16556236|NCT02909686|Experimental|Pycnogenol|200-400mg in capsule form by mouth every day
16556237|NCT02909686|Experimental|Reishi Mushroom|1600-3200mg in capsule form by mouth every day
16556238|NCT02909686|Experimental|Resveratrol|200-600mg in capsule form by mouth every day
16556239|NCT02909686|Placebo Comparator|Placebo|in capsule form by mouth every day
16556240|NCT02909673|Experimental|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
16556241|NCT02909673|No Intervention|Control|Control: Treatment as usual (standard health class curriculum)
16556242|NCT02909660|Experimental|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
16556243|NCT02909660|Active Comparator|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
16556244|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
16556245|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
16556246|NCT02909621|Active Comparator|Group A|Group A: FLEXOFYTOL® high dosage
16556247|NCT02909621|Active Comparator|Group B|Group B: FLEXOFYTOL® low dosage
16556248|NCT02909621|Placebo Comparator|Group C|Group C: PLACEBO
16556249|NCT02909608||Controls|
16556250|NCT02909608||Children With Pulmonary Hypertension|
16556251|NCT02909595|Experimental|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
16556252|NCT02909595|Active Comparator|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
16556429|NCT02908347|Experimental|Placebo|"Placebo to MP1032:
~2 capsules of Placebo are provided orally twice daily for 42 days"
16556253|NCT02909582|No Intervention|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
16556254|NCT02909582|Experimental|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
16556255|NCT02909569|Experimental|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
16556256|NCT02909556|Experimental|ACURATE neo AS|
16556257|NCT02909530|Active Comparator|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
16556258|NCT02909530|Active Comparator|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
16556259|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
16556260|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
16556261|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
16556262|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
16556263|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
16556264|NCT02909504|Other|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
16556265|NCT02909491||Cases|Inpatient with severe behavioural disorders
16556266|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
16556267|NCT02909478|Experimental|Aprepitant arm|Aprepitant + Tropisetron
16556268|NCT02909478|Active Comparator|Control arm|Dexamethasone+ Tropisetron
16556269|NCT02909465|Placebo Comparator|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
16556270|NCT02909465|Experimental|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
16556271|NCT02909465|Experimental|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
16556272|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
16556273|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
16556274|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
16556275|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
16556276|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
16556277|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.
~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
16556278|NCT02909413|Experimental|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
16556279|NCT02909413|Active Comparator|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
16556280|NCT02909400|Experimental|Treatment A|Oral administration of 100 mg KH176 twice daily
16556281|NCT02909400|Placebo Comparator|Treatment B|Oral administration of matching placebo twice daily
16556282|NCT02909387|Experimental|Stratum A|This group will be the first to receive the Project UPLIFT intervention, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by phone for one hour once a week for 8 weeks.
16556283|NCT02909387|Active Comparator|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10-week waiting period.
16556284|NCT02909374|Experimental|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
16556285|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
16556286|NCT02909335|Active Comparator|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
16556287|NCT02909335|Experimental|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
16556288|NCT02909322|Active Comparator|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
16556289|NCT02909322|Experimental|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
16556290|NCT02909309|Other|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.
~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
16556291|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
16556292|NCT02909270|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
16556293|NCT02909270|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
16556294|NCT02909257|Experimental|same dose|patient is exposed to the same previously successful dose
16556295|NCT02909257|Experimental|lower dose|patient is exposed to a lower concentration dose
16556296|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
16556297|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
16556298|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
16556299|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
16556300|NCT02909218|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
16556301|NCT02909218|Experimental|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
16556302|NCT02909205|Other|control|First phase : before training / sensitization / booklet delivery
16556303|NCT02909205|Other|post intervention|Second phase : after training / sensitization / booklet delivery
16556304|NCT02909192|Active Comparator|Bright light therapy|Participants will be treated twice daily with bright light therapy.
16556305|NCT02909192|Active Comparator|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
16556306|NCT02909179|Experimental|mCARE-II|mCARE-II supported service provision through existing community health workforce.
16556307|NCT02909179|No Intervention|Comparison|Standard of care, paper-based service provision through existing community health workforce.
16556308|NCT02909166|Active Comparator|aliskiren|Aliskiren 300 once a day (q.d)
16556309|NCT02909166|Placebo Comparator|placebo|Placebo once a day (q.d)
16556310|NCT02909153|Experimental|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
16556311|NCT02909153|Experimental|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
16556312|NCT02909140|Experimental|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
16556313|NCT02909140|Experimental|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
16556314|NCT02909140|Experimental|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
16556315|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
16556316|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
16556317|NCT02909114|Experimental|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
16556318|NCT02909101|Experimental|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
16556319|NCT02909101|Sham Comparator|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
16556320|NCT02909088|Experimental|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
16556321|NCT02909088|Experimental|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
16556322|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
16556374|NCT02908711|Active Comparator|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).
~Patients randomized to this group will receive the block at the end of the surgery."
16556323|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
16556324|NCT02909049|Active Comparator|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
16556325|NCT02909049|Experimental|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
16556326|NCT02909036|Experimental|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
16556327|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
16556328|NCT02909010|Active Comparator|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
16556329|NCT02909010|Placebo Comparator|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
16556330|NCT02908997|Experimental|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
16556331|NCT02908997|Experimental|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
16556332|NCT02908997|Experimental|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
16556333|NCT02908984|Experimental|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a period of 4 weeks and recommendations for further training.
16556334|NCT02908984|Active Comparator|Standard primary health care|This represents individualized therapy administered by the primary physician.
16556335|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
16556336|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
16556337|NCT02908958|Experimental|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
16556338|NCT02908958|Experimental|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
16556339|NCT02908945|Experimental|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
16556340|NCT02908945|Experimental|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
16556341|NCT02908945|Other|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
16556342|NCT02908932|Experimental|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
16556343|NCT02908932|Placebo Comparator|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
16556344|NCT02908919|Active Comparator|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
16556345|NCT02908919|Active Comparator|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
16556346|NCT02908919|Active Comparator|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
16556347|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), IV every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4 to evaluate additional doses.
16556348|NCT02908893|Experimental|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.
~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.
~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
16556427|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
16556349|NCT02908893|Active Comparator|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.
~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.
~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
16556350|NCT02908893|No Intervention|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
16556351|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
16556352|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
16556353|NCT02908854|Experimental|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
16556354|NCT02908841|Other|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
16556355|NCT02908841|Other|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
16556356|NCT02908828|Experimental|Calanus oil|4 capsules of 500 mg Calanus oil once every day
16556357|NCT02908828|Placebo Comparator|Placebo|4 capsules of 500 mg dietary oil once every day
16556358|NCT02908815|Experimental|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
16556359|NCT02908815|Experimental|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
16556360|NCT02908815|Sham Comparator|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
16556361|NCT02908815|Sham Comparator|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
16556362|NCT02908802|Active Comparator|Probiotic|Probiotic capsules: two capsules twice a day
16556363|NCT02908802|Placebo Comparator|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
16556364|NCT02908789|Other|Antimicrobial photodynamic therapy (aPDT)|The technique consists of a basic protocol of two steps: the use of a photosensitizer and the laser application. In the first step, the cavity was dried and then 0.01% methylene blue solution (Formula & Ação, São Paulo, Brazil) was applied to the entire cavity using a carpule in order to keep in contact with all the walls. It remained in the cavity for a pre-irradiation period of 5 minutes. In the second step, the excess of 0.01% methylene blue solution was removed and the cavity was irradiated with an Indium Gallium Aluminum Phosphorus diode laser (InGaAlP) (Laser DUO®, MM Optics, São Carlos, São Paulo, Brazil) with a wavelength of 660 nm (visible red), a spot area of 3mm2, and fixed output power of 100 mW. We adopted the following parameters: energy of 9 J with 90 seconds of exposure time. The irradiation was applied in continuous mode and the laser array was positioned, in contact, directly over the central part of the cavity.
16556365|NCT02908776|Experimental|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
16556366|NCT02908776|Placebo Comparator|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
16556367|NCT02908763|Experimental|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg <1000 IU/ mL and HBV DNA<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
16556368|NCT02908763|No Intervention|Observing Group|Only observing and following up in this group.
16556369|NCT02908750|Experimental|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
16556370|NCT02908737|Experimental|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
16556371|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
16556372|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
16556373|NCT02908711|Active Comparator|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).
~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
16556375|NCT02908698|Experimental|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:
~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
16556376|NCT02908698|Placebo Comparator|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
16556377|NCT02908685|Experimental|Part 1 Group A: Adolescents and Adults (Risdiplam)|Adolescent and adult participants aged 12-25 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
16556378|NCT02908685|Placebo Comparator|Part 1 Group A: Adolescents and Adults (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
16556379|NCT02908685|Placebo Comparator|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
16556380|NCT02908685|Experimental|Part 1 Group B: Children (Risdiplam)|Children aged 2-11 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
16556381|NCT02908685|Placebo Comparator|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants will be switched to risdiplam (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20) in a blinded manner and participants will continue with treatment until Month 24. After Month 24, participants will be offered the opportunity to enter the open-label phase.
16556382|NCT02908685|Experimental|Part 2: Risdiplam|Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20 kg), for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label phase.
16556383|NCT02908672|Experimental|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
16556384|NCT02908672|Experimental|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
16556385|NCT02908646|Experimental|microcoil|patients who plan for microcoil localization
16556386|NCT02908646|Placebo Comparator|hookwire|patients who plan for hookwire localization
16556387|NCT02908633|Active Comparator|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
16556388|NCT02908633|Active Comparator|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
16556389|NCT02908633|Active Comparator|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
16556390|NCT02908620|Experimental|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
16556391|NCT02908620|Experimental|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
16556428|NCT02908347|Experimental|MP1032|"Test Product:
~100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days"
16556666|NCT02906683|Placebo Comparator|Placebo|
16556392|NCT02908620|Experimental|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
16556393|NCT02908620|Experimental|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
16556394|NCT02908607|Experimental|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
16556395|NCT02908594|Experimental|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
16556396|NCT02908594|No Intervention|control group|The control group received routine care
16556397|NCT02908581|Active Comparator|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
16556398|NCT02908581|Experimental|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
16556399|NCT02908568|Experimental|Spring device|Brisk dilatation of fhe mouth.
16556400|NCT02908568|Sham Comparator|Mandible stimulator|Stimulation of fhe mouth.
16556401|NCT02908555||no intervention|Descriptive study without groups
16556402|NCT02908529|Placebo Comparator|Placebo|Placebo 2 hours before bedtime
16556403|NCT02908529|Active Comparator|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
16556404|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
16556405|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
16556406|NCT02908503|Other|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
16556407|NCT02908503|Other|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
16556408|NCT02908503|Other|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
16556409|NCT02908503|Other|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
16556410|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
16556411|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
16556412|NCT02908477|Experimental|De-escalated Adjuvant Radiation Therapy|Docetaxel 15 mg/m2 days 1, 8 + Radiation Therapy (RT) 30 Gy/1.5 Gy fractions twice daily (b.i.d.) days 1-12 only (intermediate risk) or 36 Gy/1.8 Gy b.i.d. fractions (high risk)
16556413|NCT02908477|Active Comparator|Standard of Care Treatment|RT 60 Gy/2 Gy fractions daily (qday) days 1-40. For high risk, add weekly Cisplatin 40 mg/m2 (Around days 1, 8, 15, 22, 29, 36)
16556414|NCT02908464|Experimental|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
16556415|NCT02908464|No Intervention|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
16556416|NCT02908451|Experimental|AbGn-107|AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
16556417|NCT02908438|Experimental|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
16556418|NCT02908438|No Intervention|control group|Control group receive only the routine LPS.
16556419|NCT02908425|Other|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
16556420|NCT02908412|Experimental|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
16556421|NCT02908412|Experimental|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
16556422|NCT02908399|Experimental|Thermal Imaging|Imaging using a thermal camera
16556423|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
16556424|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
16556425|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
16556426|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD> 50).
16620472|NCT02477722|Sham Comparator|Sham-NF|Placebo
16556430|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
16556431|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
16556432|NCT02908321|Active Comparator|CBT|
16556433|NCT02908321|No Intervention|WL|
16556434|NCT02908308|Active Comparator|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
16556435|NCT02908308|Experimental|Hypothermia|Targeted temperature management to 33°C for up to 28h.
16556436|NCT02908295|Experimental|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
16556437|NCT02908295|Placebo Comparator|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
16556438|NCT02908282|Other|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
16556439|NCT02908282|Other|C (control)-group|Povidone: Usage according to instructions for use.
16556440|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
16556441|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to < 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
16556442|NCT02908269|Experimental|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
16556443|NCT02908256|Experimental|PVI group|Monitoring of the PVI during the surgical intervention
16556444|NCT02908256|Active Comparator|Delta PP group|Monitoring of the deltaPP during the surgical intervention
16556445|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
16556446|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
16556447|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
16556448|NCT02908230|Placebo Comparator|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
16556449|NCT02908230|Active Comparator|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
16556450|NCT02908230|Experimental|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
16556451|NCT02908217|Experimental|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
16556452|NCT02908217|Placebo Comparator|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
16556453|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
16556454|NCT02908204||Traditional surgery|Patients underwent traditional surgery
16556455|NCT02908191|Experimental|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
16556456|NCT02908191|Experimental|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
16556457|NCT02908191|Experimental|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
16556458|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.
~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
16556459|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.
~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
16556460|NCT02908165|Experimental|Group A- continuous schedule|Subjects with HCC randomized to group A
16556461|NCT02908165|Active Comparator|Group B- sequential schedule|Subjects with HCC randomized to group B
16556462|NCT02908152|Active Comparator|curcumin|curcumin
16556463|NCT02908152|Placebo Comparator|placebo|
16556464|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
16556465|NCT02908126|Experimental|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
16556466|NCT02908126|Experimental|Oxytocin tablet|single dose of oxytocin tablet
16556467|NCT02908113|Other|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
16556468|NCT02908113|Other|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
16556469|NCT02908100|Placebo Comparator|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
16557220|NCT02902653|Active Comparator|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
16556470|NCT02908100|Experimental|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
16556471|NCT02908100|Experimental|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
16556472|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
16556473|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
16556474|NCT02908074|Experimental|Experimental: Regimen 1|Drug: BGS649 Dose 1 weekly
16556475|NCT02908074|Experimental|Experimental: Regimen 2|Drug: BGS649 Dose 2 weekly
16556476|NCT02908074|Experimental|Experimental: Regimen 3|Drug: BGS649 Dose 3 weekly
16556477|NCT02908061|Active Comparator|Surgery (Usual approach group)|standard surgery
16556478|NCT02908061|Experimental|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
16556479|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
16556480|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
16556481|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
16556482|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
16556483|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
16556484|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
16556485|NCT02908035|Placebo Comparator|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
16556486|NCT02908022|Experimental|Interaction|"Phase 1:
~Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.
~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
16556487|NCT02908022|Experimental|No Interaction|"Phase 1:
~The clinician and the patient will first be introduced at the MRI sessions.
~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
16556488|NCT02908022|Experimental|Longitudinal|"Phase 2:
~Prior to first MRI session, both clinician and patient will go through a training visit.
~During the first MRI session, the patient will receive experimental pressure pain to the left leg via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief.
~Following the first MRI session, the patient will attend biweekly acupuncture treatment sessions with the clinician (6 treatments total). During the first session the clinician will be introduced to the patient and do a general intake in addition to the acupuncture treatment.
~The final MRI session will be identical to the first. The patient will receive experimental pressure pain via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief."
16556489|NCT02907996||Sofosbuvir|Adult Korean participants with genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean participants aged 12 to <18 years with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens
16556490|NCT02907983|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
16556491|NCT02907983|Sham Comparator|Saline|Saline injection
16556492|NCT02907957|Active Comparator|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
16556493|NCT02907957|Sham Comparator|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
16556494|NCT02907944|No Intervention|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
16556495|NCT02907944|Experimental|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
16556496|NCT02907931|Experimental|Subjects|Lower Body Negative Pressure
16556497|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles
~Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
16621035|NCT02473874||Skin Spect dermoscope|Skin mole
16556498|NCT02907905|Other|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
16556499|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
16556500|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
16556501|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
16556502|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
16556503|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
16556504|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
16556505|NCT02907853|Experimental|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
16556506|NCT02907840|Experimental|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
16556507|NCT02907827|Experimental|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
16556508|NCT02907827|Experimental|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
16556509|NCT02907814|Experimental|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
16556510|NCT02907814|Experimental|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
16556511|NCT02907801|Experimental|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
16556512|NCT02907788||Cystic Fibrosis patients|Patient with cystic fibrosis diagnosed by Heel-prick screening
16556513|NCT02907788||non-CF patients|Children who undergo bronchoscopy for another reason, without CF: eg gastro-esophageal reflux.
16556514|NCT02907775|Active Comparator|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
16556515|NCT02907775|Active Comparator|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
16556516|NCT02907749|Active Comparator|Carvedilol|Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
16556517|NCT02907749|Experimental|Spironolactone and carvedilol|"Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
~Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose"
16556518|NCT02907723|Experimental|Continuous Sleep Recording|Continuous Sleep Recording in Patients
16556519|NCT02907710|Experimental|concurrent chemoradiotherapy + endostar|"Drug: Endostar
~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy
~Drug: DDP
~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles
~Radiation: IMRT
~IMRT:70-74Gy"
16556520|NCT02907710|Active Comparator|concurrent chemoradiotherapy|"Drug: DDP
~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles
~Radiation: IMRT
~IMRT:70-74Gy"
16556521|NCT02907697|Experimental|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
16556522|NCT02907697|Active Comparator|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
16556523|NCT02907684|Experimental|Almonds|Almond snacks
16556524|NCT02907684|Placebo Comparator|Control muffins/crackers|Muffin/Cracker snacks
16556525|NCT02907671|Active Comparator|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
16556526|NCT02907671|Active Comparator|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
16557575|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
16556527|NCT02907658|Experimental|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
16556528|NCT02907658|No Intervention|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
16556529|NCT02907645|Experimental|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
16556530|NCT02907645|Experimental|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
16556531|NCT02907645|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
16556532|NCT02907632|Experimental|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
16556533|NCT02907632|Placebo Comparator|Placebo|Blind and randomized allocation to placebo
16556534|NCT02907619|Experimental|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
16556535|NCT02907593|Experimental|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
16556536|NCT02907593|Experimental|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
16556537|NCT02907593|Experimental|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
16556538|NCT02907593|Experimental|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
16556539|NCT02907580|Experimental|Local educational data|Local-based educational handout
16556540|NCT02907580|Experimental|National educational data|National-based educational handout
16556541|NCT02907580|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
16556542|NCT02907567|Active Comparator|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
16556543|NCT02907567|Active Comparator|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
16556544|NCT02907567|Placebo Comparator|Placebo|4 subjects randomized to matching placebo of CT1812
16556545|NCT02907554|Placebo Comparator|control group|control group receives a placebo
16556546|NCT02907554|Experimental|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
16556547|NCT02907541|Experimental|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
16556548|NCT02907541|Active Comparator|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
16556549|NCT02907541|Active Comparator|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
16556550|NCT02907528|Placebo Comparator|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
16556551|NCT02907528|Active Comparator|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
16556552|NCT02907528|Experimental|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
16556553|NCT02907515|Experimental|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
16556554|NCT02907515|Active Comparator|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
16556555|NCT02907502|Experimental|Experimental formula|Young-child formula with low protein content
16556556|NCT02907502|Active Comparator|Control formula|Young-child formula with protein content similar to that of cow's milk
16556557|NCT02907489|No Intervention|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
16556558|NCT02907489|Other|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
16556559|NCT02907476|Experimental|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
16556560|NCT02907476|Active Comparator|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
16556561|NCT02907450|Experimental|Clinical evaluation of the tolerance of the orthosis|
16556562|NCT02907437|Active Comparator|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
16556563|NCT02907437|Placebo Comparator|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
16556564|NCT02907424|Active Comparator|BP-100|standard treatment
16556565|NCT02907424|Experimental|Num Trey|locally produced RUTF
16556566|NCT02907411|Experimental|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
16556569|NCT02907385|Experimental|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
16556570|NCT02907385|No Intervention|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
16556571|NCT02907372|Other|cognitive tests|
16557221|NCT02902653|Active Comparator|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
16556572|NCT02907359|Experimental|Guadecitabine|Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
16556573|NCT02907359|Active Comparator|Treatment Choice|"Best Supportive Care.
~Low dose cytarabine.
~Standard Intensive Chemotherapy."
16556574|NCT02907346|Experimental|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
16556575|NCT02907333|Active Comparator|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
16556576|NCT02907333|No Intervention|Control group|Women who are not contacted with advise to use condoms
16556577|NCT02907320|Experimental|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
16556578|NCT02907320|Active Comparator|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
16556579|NCT02907320|Placebo Comparator|placebo|MPFF = Micronized Purified Flavonoid Fraction
16556580|NCT02907307|Experimental|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
16556581|NCT02907307|Experimental|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
16556582|NCT02907307|Active Comparator|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
16556583|NCT02907294|Experimental|PBF-999|
16556584|NCT02907294|Placebo Comparator|Placebo|
16556585|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
16556586|NCT02907281||Healthy volunteers|Healthy volunteers
16556587|NCT02907268|Active Comparator|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
16556588|NCT02907268|Active Comparator|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
16556589|NCT02907255|Experimental|Oximetry monitor|"Standard care plus
~Wireless respiratory monitoring
~Covidien
~Alarm triggers:
~SpO2 ≤89% (heart rate) HR < 50 or > 120"
16556590|NCT02907255|No Intervention|Standard of Care|"• Standard care:
~1:4 patient to nurse ratio
~Vital signs every 4 hours
~Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
16556591|NCT02907242|No Intervention|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
16556592|NCT02907242|Other|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5
16556593|NCT02907229|Experimental|Treatment group|neuroendovascular therapy(NCVC-CS1)
16556594|NCT02907216|Experimental|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
16556595|NCT02907216|Active Comparator|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
16556596|NCT02907190|Experimental|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
16556597|NCT02907190|Active Comparator|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
16556598|NCT02907177|Experimental|Ponesimod|Ponesimod
16556599|NCT02907177|Placebo Comparator|Placebo|Placebo
16556600|NCT02907164|Active Comparator|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
16556601|NCT02907164|Experimental|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
16556602|NCT02907164|Experimental|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
16556603|NCT02907164|Experimental|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
16556604|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
16556605|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
16556606|NCT02907138|Experimental|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
16556607|NCT02907138|Active Comparator|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
16556667|NCT02906670|Experimental|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
16556608|NCT02907125|Experimental|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.
~This intervention will be delivered in each school over the academic year."
16556609|NCT02907125|Experimental|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.
~This intervention will be delivered in each school over the academic year."
16556610|NCT02907125|Active Comparator|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
16556611|NCT02907112|No Intervention|Control|Participants to continue on their habitual diet for 4 weeks
16556612|NCT02907112|Experimental|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
16556613|NCT02907099|Experimental|Treatment (CXCR4 antagonist BL-8040, pembrolizumab)|Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16556614|NCT02907086||colorectal cancer|
16556615|NCT02907086||melanoma|
16556616|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
16556617|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
16556618|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
16556619|NCT02907060|Experimental|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
16556620|NCT02907060|Active Comparator|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
16556621|NCT02907047|Active Comparator|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
16556622|NCT02907047|Other|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
16556623|NCT02907034|Experimental|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
16556624|NCT02907034|Active Comparator|Group 2|First, classical narrative approach (CN), then virtual reality approach
16556625|NCT02907021|Experimental|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
16556626|NCT02906995|Experimental|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
16556627|NCT02906995|Active Comparator|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
16556628|NCT02906982|Experimental|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
16556629|NCT02906982|Experimental|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
16556668|NCT02906670|Experimental|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
16556630|NCT02906982|No Intervention|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
16556631|NCT02906969|Experimental|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
16556632|NCT02906969|Placebo Comparator|Control|Non-colonoscopy video as a control.
16556633|NCT02906956|Experimental|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
16556634|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
16556635|NCT02906930|Experimental|3 mg oral semaglutide|
16556636|NCT02906930|Experimental|7 mg oral semaglutide|
16556637|NCT02906930|Experimental|14 mg oral semaglutide|
16556638|NCT02906930|Placebo Comparator|Placebo|
16556639|NCT02906917|Experimental|IDegAsp|
16556640|NCT02906917|Active Comparator|IGlar + IAsp|
16556641|NCT02906904|Experimental|CASE (adult sleepwalking patients)|
16556642|NCT02906904|Experimental|CONTROL (adult healthy volunteers)|
16556643|NCT02906891|Experimental|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
16556644|NCT02906839|Experimental|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
16556645|NCT02906839|No Intervention|Control group|No SAS screening will be performed in this group before the end of the 2 year follow up period.
16556646|NCT02906826|No Intervention|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
16556647|NCT02906826|Active Comparator|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
16556648|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
16556649|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
16556650|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
16556651|NCT02906800|Experimental|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
16556652|NCT02906787|Experimental|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
16556653|NCT02906787|Placebo Comparator|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
16556654|NCT02906761|Experimental|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
16556655|NCT02906761|Placebo Comparator|Placebo|Placebo (2 tablets) twice daily for 6 months
16556656|NCT02906748|Experimental|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
16556657|NCT02906748|Active Comparator|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
16556658|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
16556659|NCT02906722|Experimental|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
16556660|NCT02906722|Active Comparator|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
16556661|NCT02906709|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
16556662|NCT02906709|Experimental|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
16556663|NCT02906696|Experimental|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16556664|NCT02906683|Experimental|TAS-303 3mg|
16556665|NCT02906683|Experimental|TAS-303 6mg|
16556669|NCT02906670|Experimental|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
16556670|NCT02906670|Experimental|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
16556671|NCT02906670|Experimental|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
16556672|NCT02906670|Experimental|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
16556673|NCT02906670|Experimental|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
16556674|NCT02906670|Experimental|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
16556675|NCT02906670|Experimental|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
16556676|NCT02906670|Experimental|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
16556677|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
16556678|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
16556679|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
16556680|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
16556681|NCT02906657|Experimental|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
16556682|NCT02906657|No Intervention|Control|Usual Care
16556683|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
16556684|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
16556685|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
16556686|NCT02906618|Experimental|LY3039478 - Oral|LY3039478 given once, orally
16556687|NCT02906618|Experimental|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
16556688|NCT02906605|Experimental|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
16556689|NCT02906605|Experimental|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
16556690|NCT02906579|Experimental|IW-1973|Placebo taken once daily Day 1-Day 3; 10 mg IW-1973 take once daily Day 4-Day 6; 20 mg IW-1973 taken once daily Day 7-Day 9; 30 mg IW-1973 taken once daily Day 10-Day 12; 40 mg IW-1973 taken once daily Day 13-Day 15; 50 mg IW-1973 taken once daily Day 16-Day 18
16556691|NCT02906566|Other|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
16556692|NCT02906566|No Intervention|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
16556693|NCT02906553|Experimental|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
16621036|NCT02473874||Spatially modulated quantitative|Skin mole
16556694|NCT02906553|Placebo Comparator|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
16556695|NCT02906540|Experimental|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
16556696|NCT02906540|Experimental|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
16556697|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
16556698|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
16556699|NCT02906514|Experimental|Hydroxyethyl starch 130/0.4|
16556700|NCT02906514|Placebo Comparator|Sodium Chloride 0.9%|
16556701|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
16556702|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
16556703|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
16556704|NCT02906488||Patients with Parkinson's Disease|
16556705|NCT02906475|Other|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
16556706|NCT02906475|No Intervention|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
16556707|NCT02906462|Other|Usual Practices|Usual Practices
16556708|NCT02906462|Other|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
16556709|NCT02906449|Experimental|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
16556710|NCT02906449|Active Comparator|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
16556711|NCT02906436|Experimental|ExVivo lung reconditioning|
16556712|NCT02906423||Allina health patients|
16556713|NCT02906410|No Intervention|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
16556714|NCT02906410|Experimental|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
16556715|NCT02906410|Experimental|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
16556716|NCT02906410|No Intervention|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
16556717|NCT02906410|Experimental|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
16556718|NCT02906410|Experimental|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
16556720|NCT02906384|No Intervention|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
16556721|NCT02906384|Experimental|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin<9Gy Dmax<16Gy.
~Radiation technique: VMAT."
16556722|NCT02906371|Active Comparator|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
16556723|NCT02906371|Active Comparator|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
16556724|NCT02906358|Active Comparator|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
16556725|NCT02906358|Active Comparator|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
16556726|NCT02906345|No Intervention|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
16556727|NCT02906345|Active Comparator|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
16556728|NCT02906345|Active Comparator|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
16556729|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.
~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.
~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
16556730|NCT02906306|Experimental|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
16623197|NCT02459613|Experimental|Imaging|99mTc Annexin V-128 SPECT
16556731|NCT02906306|Experimental|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
16556732|NCT02906293||Healthy Participants|Potential participants will self-refer.
16556733|NCT02906280|Experimental|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
16556734|NCT02906280|Active Comparator|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
16556735|NCT02906267|Other|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
16556736|NCT02906267|Other|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
16556737|NCT02906267|Other|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
16556738|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:
~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
16556739|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:
~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
16556740|NCT02906241|Experimental|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
16556741|NCT02906241|No Intervention|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
16556742|NCT02906241|Other|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
16556743|NCT02906228|Experimental|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
16556744|NCT02906228|Experimental|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
16556745|NCT02906228|Experimental|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
16556746|NCT02906215|Experimental|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
16556747|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
16556748|NCT02906176|Experimental|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
16556749|NCT02906176|Experimental|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
16556750|NCT02906163|Experimental|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
16556751|NCT02906163|Experimental|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
16556752|NCT02906163|Active Comparator|SoC (tyrosine kinase inhibitor)|12 months
16556753|NCT02906150|Experimental|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
16556754|NCT02906150|Active Comparator|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
16556755|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:
~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling
~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling
~10 subjects will have both a gastroscopy and a coloscopy"
16556756|NCT02906137|Other|Uninfected-controls|"30 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:
~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling
~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling
~10 subjects will have both a gastroscopy and a coloscopy"
16556757|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
16556758|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
16556759|NCT02906111|Active Comparator|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
16556760|NCT02906111|Active Comparator|Control group, no estriol treatment|Procedure: vaginal surgery
16556761|NCT02906098|Experimental|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
16556992|NCT02904408|No Intervention|Control|control group (awaiting group) (receiving medical/surgical treatment)
16556762|NCT02906098|Active Comparator|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
16556763|NCT02906085|Experimental|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
16556764|NCT02906085|Placebo Comparator|Placebo|Intravenous infusion of placebo (isotonic saline)
16556765|NCT02906072|Experimental|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
16556766|NCT02906072|Other|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
16556767|NCT02906059|Experimental|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)
~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks
~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks
~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks
~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
16556768|NCT02906046|Placebo Comparator|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
16556769|NCT02906046|Other|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
16556770|NCT02906046|Other|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
16556771|NCT02906033|Experimental|Intervention group|New perioperative practice model.
16556772|NCT02906033|No Intervention|Control group|Traditional practice model.
16556773|NCT02906020|Experimental|GZ/SAR402671|Part 1: Increasing dose of GZ/SAR402671 will be administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) will be administered once per day.
16556774|NCT02906020|Placebo Comparator|Placebo|A matching placebo for Parts 1 and 2 will be administered once per day.
16556775|NCT02906007|Experimental|Bedaquiline (BDQ)|Participants will receive bedaquiline (BDQ) once a day for 2 weeks. For the next 22 weeks, participants will take BDQ 3 times a week on Monday, Wednesday, and Friday.
16556776|NCT02905994|Experimental|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3
~Cytarabine continuous infusion days 1-7
~Idarubicin IV bolus on days 1, 2, and 3.
~Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8
~Patients will receive Standard Anti Fungal and Standard Antibiotic during induction
~A bone marrow biopsy will be performed according to standard practice on day 14"
16556777|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
16556778|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
16556779|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
16556780|NCT02905968|Experimental|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
16556781|NCT02905968|No Intervention|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
16556782|NCT02905955|Other|Prevena|
16556783|NCT02905942|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
16556784|NCT02905942|Active Comparator|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
16556785|NCT02905929|Experimental|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
16556786|NCT02905929|Active Comparator|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
16556787|NCT02905916|Experimental|PEG-rhG-CSF|
16556788|NCT02905903|Other|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
16556789|NCT02905890|Experimental|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
16556790|NCT02905890|Active Comparator|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
16556791|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
16556792|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
16556793|NCT02905877||Healthy control|Healthy age matched controls
16556794|NCT02905864|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
16556795|NCT02905864|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
16556796|NCT02905851|Placebo Comparator|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
16556797|NCT02905851|Active Comparator|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.
~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:
~Continue current dose
~Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.
~Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
16556798|NCT02905838|Active Comparator|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
16556799|NCT02905838|Active Comparator|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
16556800|NCT02905825|Experimental|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
16556801|NCT02905812|Active Comparator|RGI & Massage|"relaxation and guided imagery with background music (RGI) (40 min, headphones)
~a brief moderate pressure massage session (massage: 15 min)"
16556802|NCT02905812|No Intervention|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
16556803|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
16556804|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
16556805|NCT02905773|Other|postoperative pain|postoperative pain
16556806|NCT02905773|Other|intensity|intensity
16556807|NCT02905760|Experimental|Furosemide|Furosemide and Placebo filling (Glucose 5%).
16556808|NCT02905760|Active Comparator|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling
~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
16556809|NCT02905747|Experimental|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
16556810|NCT02905734|Experimental|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
16556811|NCT02905734|Placebo Comparator|placebo patch|Single administration of a placebo patch
16556812|NCT02905721|Experimental|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
16556813|NCT02905708|Active Comparator|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.
~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
16556814|NCT02905708|Active Comparator|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
16556815|NCT02905695|Experimental|Group A|Chirocaine
16556816|NCT02905695|Placebo Comparator|Group B|Placebo
16556817|NCT02905682|Experimental|Desmopressin|Desmopressin ODT
16556818|NCT02905682|Placebo Comparator|Placebo|Placebo ODT
16556819|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
16556820|NCT02905656|Placebo Comparator|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
16556821|NCT02905656|Experimental|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
16556822|NCT02905656|Experimental|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
16556823|NCT02905656|Experimental|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
16556824|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
16556825|NCT02905630|Experimental|Exercise training|High intensity aerobic exercise training
16556826|NCT02905630|No Intervention|No training|No exercise training, only ordinary daily life activities.
16556827|NCT02905617||Primary Augmentation|
16556828|NCT02905617||Revision Augmentation|
16556829|NCT02905604|Experimental|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
16556830|NCT02905604|Sham Comparator|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
16556831|NCT02905591|Experimental|ChemoRT + Ascorbate|Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
16556832|NCT02905578|Experimental|Ascorbate group|"Each cycle is 4 calendar weeks
~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
16556833|NCT02905578|Active Comparator|Control|"Each cycle is 4 calendar weeks
~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
16556834|NCT02905565|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
16556835|NCT02905565|Active Comparator|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
16556836|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
16556837|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS
~Patient will be paired to index case by:
~Hospital site
~Age
~Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
16556838|NCT02905539|Experimental|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
16556839|NCT02905539|Active Comparator|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
16556840|NCT02905526|Experimental|Intervention|App plus the contraceptive instant messages
16556841|NCT02905526|Placebo Comparator|Control|App only
16556842|NCT02905513|Experimental|Intervention|App plus the contraceptive instant messages
16556843|NCT02905513|Placebo Comparator|Control|App only
16556844|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
16556845|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
16556846|NCT02905474|Experimental|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
16556847|NCT02905474|Active Comparator|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
16556848|NCT02905461|Experimental|Intervention|Contraceptive text messages
16556849|NCT02905461|Placebo Comparator|Control|Text messages not about contraception
16556850|NCT02905448|Experimental|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
16556851|NCT02905435|Experimental|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
16556852|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
16556853|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
16556854|NCT02905409|Active Comparator|4PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.
16556855|NCT02905409|Experimental|2PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.
16556856|NCT02905396|Experimental|Spinal cord stimulation|implantation of spinal cord stimulator
16556993|NCT02904369|Experimental|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
16556857|NCT02905383|Experimental|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
16556858|NCT02905383|No Intervention|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
16556861|NCT02905357||MINOCA|OCT and CMR imaging
16556862|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
16556863|NCT02905344||1|Control, no anatomical model used for description
16556864|NCT02905344||2|Anatomical model used for description
16556865|NCT02905331|Experimental|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
16556866|NCT02905331|Experimental|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
16556867|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
16556868|NCT02905305|Experimental|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
16556869|NCT02905305|Active Comparator|Contour Advance|Standard Contour Advance electrode array
16556870|NCT02905279|Active Comparator|Biofeedback|Biofeedback Relaxation Training
16556871|NCT02905279|Active Comparator|Standard Exposure|Exposure Therapy
16556872|NCT02905279|Experimental|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
16556873|NCT02905279|Experimental|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
16556874|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
16556875|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
16556876|NCT02905253|Experimental|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
16556877|NCT02905253|Placebo Comparator|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
16556878|NCT02905253|Experimental|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
16556879|NCT02905253|Placebo Comparator|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
16556880|NCT02905253|Experimental|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
16556881|NCT02905240|Experimental|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
16556882|NCT02905240|Other|Saline|Saline control
16556883|NCT02905227|Experimental|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
16556884|NCT02905227|Experimental|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
16556885|NCT02905227|Experimental|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
16556886|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
16556887|NCT02905188|Experimental|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
16556888|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
16556889|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
16556890|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
16556891|NCT02905149|Experimental|Serrato|Standard anesthesia+serratus plane block.
16556892|NCT02905149|Placebo Comparator|Control|Standard anesthesia
16556893|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :
~with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)
~or uncharacterized antibodies"
16556894|NCT02905123|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
16556895|NCT02905123|No Intervention|Control|No Intervention Control
16556994|NCT02904369|Experimental|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
16623685|NCT02456480|Placebo Comparator|Vehicle gel|
16556897|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
16556898|NCT02905071|Experimental|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
16556899|NCT02905071|Experimental|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
16556900|NCT02905071|Experimental|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
16556901|NCT02905071|Experimental|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
16556902|NCT02905058|Experimental|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
16556903|NCT02905058|Placebo Comparator|Placebo|women will take one placebo tablet one hour before the procedure
16556904|NCT02905045|Active Comparator|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
16556905|NCT02905045|Placebo Comparator|Placebo|women will take one tablet placebo one hour before the procedure
16556906|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
16556907|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
16556908|NCT02905019|Active Comparator|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
16556909|NCT02905019|Active Comparator|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
16556910|NCT02905019|Active Comparator|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
16556911|NCT02905019|No Intervention|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
16556912|NCT02905019|No Intervention|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
16556913|NCT02905019|No Intervention|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
16556914|NCT02905019|Active Comparator|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
16556915|NCT02905019|No Intervention|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
16556916|NCT02905019|Active Comparator|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
16556917|NCT02905006|Placebo Comparator|Placebo|
16556918|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
16556919|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
16556920|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
16556921|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
16556922|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
16556923|NCT02904993|Other|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
16556924|NCT02904993|Active Comparator|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
16556925|NCT02904980|Experimental|Technical Training Group|15 children diagnosed with DCD
16556926|NCT02904980|Experimental|Quiet Eye Training Group|15 children diagnosed with DCD
16556927|NCT02904967|Experimental|patients with recurrent VTE|
16556928|NCT02904967|Active Comparator|patients with only one episode of VTE|
16556929|NCT02904954|Experimental|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
16556930|NCT02904954|Experimental|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
16556931|NCT02904941|Experimental|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
16556932|NCT02904941|Active Comparator|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
16556933|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
16556934|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
16556935|NCT02904902|Experimental|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
16556936|NCT02904889|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
16556937|NCT02904889|Active Comparator|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
16556995|NCT02904369|Active Comparator|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
16556938|NCT02904876|Experimental|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
16556939|NCT02904863|Experimental|patients with HUS|
16556940|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
16556941|NCT02904837|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
16556942|NCT02904837|Active Comparator|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
16556943|NCT02904824|Experimental|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
16556944|NCT02904824|Active Comparator|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
16556945|NCT02904811|Experimental|Intervention group|"Testing for Ct infection immediately
~Participants will perform self-taken vaginal samples.
~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
16556946|NCT02904811|Experimental|Control group|Testing for Ct infection at the end of the study
16556947|NCT02904798|Experimental|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.
~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
16556948|NCT02904785|Experimental|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
16556949|NCT02904785|Sham Comparator|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
16556950|NCT02904772|Other|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
16556951|NCT02904772|Other|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
16556952|NCT02904759|Experimental|Desmopressin 25 µg|Desmopressin ODT
16556953|NCT02904759|Experimental|Desmopressin 50 µg|Desmopressin ODT
16556954|NCT02904759|Placebo Comparator|Placebo|Placebo ODT
16556955|NCT02904746|Experimental|Intervention|Participants receiving the Make It! intervention
16556956|NCT02904746|No Intervention|Control|Care as usual
16556957|NCT02904733|Experimental|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
16556958|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
16556959|NCT02904668|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-management program and manual therapy program
16556960|NCT02904668|Active Comparator|Control group|"The intervention consisted of 45-minute manual therapy sessions. Manual therapy included hands-on muscular mobilization techniques (aimed at improving soft tissue function), specific articular mobilization techniques (to improve overall joint function and decrease any restrictions in movement at single or multiple segmental levels in the cervical spine), and coordination or stabilization techniques (to improve postural control, coordination, and movement patterns by using the stabilizing cervical musculature)"
16556961|NCT02904655|Active Comparator|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
16556962|NCT02904655|No Intervention|control diet|Participants were instructed to consume their usual diet.
16556963|NCT02904642|No Intervention|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
16556964|NCT02904642|Experimental|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
16556996|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
16556997|NCT02904343|Experimental|Group of domestic hemodialysis machine|
16556998|NCT02904343|Active Comparator|Group of imported hemodialysis machine|
16557706|NCT02898818||vaginal discharge|vaginal and oral swab sample, questionnaire
16556965|NCT02904642|Experimental|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
16556966|NCT02904629|Experimental|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
16556967|NCT02904629|Other|Control|"The control program includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
16556968|NCT02904616|Experimental|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.
~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
16556969|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
16556970|NCT02904577||Training and validation cohort|"One cohort: from this cohort 2/3 of patients will be randomly separated after registration in training sample, to develop a prognostic model, and 1/3 in test sample, to validate the prognostic score obtained from the prognostic model.
~The training cohort aims to develop a prognostic model and a resulting score, on the basis of clinical, biochemical and blood count parameters, in patients with non-follicular indolent lymphomas.
~Intervention: any treatment, watch and wait policy included
~The validation cohort is aims to assess the prognostic score on a collected set of data in parallel but independently of the sample training.
~Intervention: any treatment, watch and wait policy included"
16556971|NCT02904564|Experimental|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
16556972|NCT02904564|Placebo Comparator|MMP with saline infusion|MMP with saline infusion using tattoo device
16556973|NCT02904551|Experimental|Experimental|Free gingival grafts
16556974|NCT02904551|Active Comparator|Control|Oral prophylaxis
16556975|NCT02904538|Experimental|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
16556976|NCT02904538|Experimental|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
16556977|NCT02904525|Experimental|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
16556978|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
16556979|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
16556980|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
16556981|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
16556982|NCT02904486|Experimental|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
16556983|NCT02904486|Experimental|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
16556984|NCT02904473|Experimental|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
16556985|NCT02904473|No Intervention|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
16556986|NCT02904473|No Intervention|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
16556987|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
16556988|NCT02904421||Group 1|the placebo group
16556989|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
16556990|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
16556991|NCT02904408|Experimental|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
16556999|NCT02904330|Experimental|Single dose|The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
16557000|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
16557001|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
16557002|NCT02904304|Experimental|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.
~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
16557003|NCT02904304|Placebo Comparator|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.
~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
16557004|NCT02904278|Experimental|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.
~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.
~Duration of participation: up to 12 months post heart transplantation."
16557005|NCT02904278|Other|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.
~Duration of participation: up to 12 months post heart transplantation."
16557006|NCT02904265|Active Comparator|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
16557007|NCT02904265|Experimental|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
16557008|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
16557009|NCT02904226|Experimental|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
16557010|NCT02904226|Experimental|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
16557011|NCT02904226|Experimental|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
16557012|NCT02904226|Experimental|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
16557013|NCT02904226|Experimental|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
16557014|NCT02904226|Experimental|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
16557015|NCT02904226|Experimental|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
16557016|NCT02904226|Experimental|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
16557017|NCT02904213|Experimental|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
16557018|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
16557019|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
16557020|NCT02904187|Other|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
16557021|NCT02904187|Other|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
16557022|NCT02904174|Experimental|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
16557023|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
16557024|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
16557025|NCT02904148|Experimental|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
16557026|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
16557027|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
16557028|NCT02904122|Other|Teleconsultation|Teleconsultation using a specific camera SoproCare®6
16557029|NCT02904109|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
16557030|NCT02904109|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
16557031|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
16557032|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
16557033|NCT02904083|Experimental|specific training of professionals|patients from centers where professionals have received specific training
16557034|NCT02904083|Active Comparator|control training of professionals|patients from centers where professionals have received control training
16557035|NCT02904070|Experimental|Threat of premature delivery|"Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;
~Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
16557036|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
16557037|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
16557038|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
16557039|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
16557040|NCT02904031|Experimental|FOLFOX plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;
~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
16557041|NCT02904031|Experimental|5FU/LV plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
16557042|NCT02904005|Other|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
16557044|NCT02903979|Experimental|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
16557045|NCT02903979|Active Comparator|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
16557046|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
16557047|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
16557048|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
16557049|NCT02903940|Experimental|CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
16557050|NCT02903927|Experimental|CT LUCIA|
16557051|NCT02903927|Active Comparator|Acrysof IQ Sn60WF|
16624925|NCT02448641|Sham Comparator|Sham Control|Sham surgery
16557060|NCT02903901|Placebo Comparator|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
16557061|NCT02903901|Active Comparator|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
16557062|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
16557063|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
16557064|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
16557065|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
16557066|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
16557067|NCT02903862|Experimental|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
16557068|NCT02903862|Other|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
16557069|NCT02903849|Experimental|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
16557070|NCT02903849|Experimental|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
16557071|NCT02903836|Experimental|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
16557072|NCT02903836|Experimental|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
16557073|NCT02903836|Active Comparator|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
16557074|NCT02903823|Experimental|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
16557075|NCT02903810|Experimental|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
16557076|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
16557077|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
16557078|NCT02903784|Other|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
16557079|NCT02903784|Other|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
16557080|NCT02903771|Experimental|Part A and Part B|"Part A (Dose Escalation):
~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.
~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.
~Part B (Expansion Cohort):
~An expansion cohort of an additional 12 patients will be recruited at the MTD."
16557081|NCT02903719|Other|Group A|"st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml
~nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
16557082|NCT02903719|Other|Group B|"st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml
~nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
16557083|NCT02903680|Active Comparator|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
16557084|NCT02903680|Placebo Comparator|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
16557085|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
16557086|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
16557087|NCT02903641|No Intervention|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
16557088|NCT02903641|Experimental|Personalized information only|Household received the personalized information about the index child's height.
16557089|NCT02903641|Experimental|Labeled cash transfer only|Household received the labeled cash transfer.
16557090|NCT02903641|Experimental|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
16557091|NCT02903628|Experimental|eye health education|
16557092|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
16557093|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
16557188|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
16557286|NCT02902185|Experimental|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
16557094|NCT02903602|Experimental|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.
~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
16557095|NCT02903602|Active Comparator|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.
~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
16557096|NCT02903576|Active Comparator|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
16557097|NCT02903576|Active Comparator|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
16557098|NCT02903537|Experimental|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
16557099|NCT02903537|Experimental|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
16557100|NCT02903537|Experimental|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
16557101|NCT02903537|Experimental|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
16557102|NCT02903524|Active Comparator|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
16557103|NCT02903524|Experimental|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
16557104|NCT02903511|Experimental|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
16557105|NCT02903511|Placebo Comparator|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
16557106|NCT02903498|Experimental|UFT treatment|Uracil and Tegafur
16557107|NCT02903498|No Intervention|comparator|no treatment, follow-up at regular time
16557108|NCT02903485|Experimental|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
16557109|NCT02903485|Active Comparator|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
16557110|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
16557111|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
16557112|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
16557113|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
16557114|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
16557115|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
16557116|NCT02903446|Active Comparator|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
16557117|NCT02903446|No Intervention|Control|Standard urate lowering therapy
16557118|NCT02903433|Experimental|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
16557119|NCT02903433|Active Comparator|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
16557120|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
16557121|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
16557189|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
16557190|NCT02902913|Active Comparator|Ibuprofen|Ibuprofen, 400 mg
16557707|NCT02898818||atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
16557122|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
16557123|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
16557124|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.
~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
16557125|NCT02903368|Experimental|Arm 1A: AAPL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:
~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 6 months
~Pts x weeks to RP"
16557126|NCT02903368|Experimental|Arm 1B: APL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:
~APL: Abiraterone acetate (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/day orally) for 6 months"
16557127|NCT02903368|Experimental|Arm 2A: AAPL Adjuvant Therapy [Part 2]|"Eligible Participants will be randomized to receive:
~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 12 months"
16557128|NCT02903368|No Intervention|Arm 2B: Observation [Part 2]|
16557129|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
16557130|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
16557131|NCT02903342|Experimental|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
16557132|NCT02903342|No Intervention|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
16557133|NCT02903329|Active Comparator|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
16557134|NCT02903329|Active Comparator|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
16557135|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
16557136|NCT02903303|Other|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
16557137|NCT02903290|Other|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
16557138|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
16557139|NCT02903264||Control|Healthy non-pregnant females
16557140|NCT02903251|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.
~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
16557141|NCT02903251|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.
~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
16557142|NCT02903238|Experimental|Placebo|placebo capsule
16557143|NCT02903225|No Intervention|Usual Care|usual care and no changes in their previous physical activity
16557144|NCT02903225|Active Comparator|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
16557145|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
16557146|NCT02903199|Experimental|Whey Protein|Whey protein (18g) experimental supplement
16557147|NCT02903199|Experimental|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
16557148|NCT02903199|Placebo Comparator|Placebo|Water placebo supplement
16557149|NCT02903186|Experimental|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
16557191|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
16557192|NCT02902887|Experimental|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
16557193|NCT02902887|No Intervention|Observation|No intervention, just observation
16557150|NCT02903186|Active Comparator|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
16557151|NCT02903173||Women who undergo cesarean delivery|
16557152|NCT02903160|Experimental|Intensive, Non-Cross Reactive Therapy|Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223
16557153|NCT02903147|Experimental|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
16557154|NCT02903147|Active Comparator|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
16557155|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI>30) or normal weight (BMI<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
16557156|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
16557157|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
16557158|NCT02903108|Active Comparator|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
16557159|NCT02903108|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
16557160|NCT02903095|Experimental|TD-1439|Capsule formulation
16557161|NCT02903095|Placebo Comparator|Placebo|Capsule formulation
16557162|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
16557163|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
16557164|NCT02903069|Experimental|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT
~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
16557165|NCT02903069|Experimental|Stage 1: Adjuvant Treatment|MRZ + TMZ
16557166|NCT02903069|Experimental|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ
~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
16557167|NCT02903069|Experimental|Optune Arm|MRZ + TMZ + Optune
16557168|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
16557169|NCT02903056||Control-normal|Healthy people
16557170|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
16557171|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
16557172|NCT02903030|Experimental|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
16557173|NCT02903030|Placebo Comparator|Placebo, Then Visbiome|Placebo matched to probiotic.
16557174|NCT02903017|Active Comparator|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
16557175|NCT02903017|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
16557176|NCT02903004|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
16557177|NCT02903004|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
16557178|NCT02902978|Experimental|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
16557179|NCT02902978|Experimental|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
16557180|NCT02902965|Experimental|Ibrutinib+ Bortezomib+ Dexamethasone|
16557181|NCT02902952|Experimental|Physical Exercise Condition|An eight week physical exercise intervention
16557182|NCT02902952|Active Comparator|Control Condition|An eight week control condition consisting of sedentary activities
16557183|NCT02902939|No Intervention|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
16557184|NCT02902939|Active Comparator|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
16557185|NCT02902926|Experimental|Low FODMAPs Diet|"Instructed to low FODMAPs diet when patients signed the informed consent.
~Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
16557186|NCT02902926|Placebo Comparator|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
16557187|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
16626721|NCT02436486|Active Comparator|Moxifloxacin 400 mg|Positive Control
16557195|NCT02902861|Active Comparator|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
16557196|NCT02902861|Placebo Comparator|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
16557197|NCT02902835|Active Comparator|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
16557198|NCT02902835|Experimental|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
16557199|NCT02902822|Active Comparator|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
16557200|NCT02902822|Experimental|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
16557201|NCT02902809|Experimental|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
16557202|NCT02902796|Active Comparator|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
16557203|NCT02902796|Active Comparator|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
16557204|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
16557205|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
16557206|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
16557207|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
16557208|NCT02902757|Experimental|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
16557209|NCT02902744|Experimental|ILUVIEN 0.19 MG|
16557210|NCT02902731|Placebo Comparator|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
16557211|NCT02902731|Experimental|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.
~Intervention Anakinra in add on Therapy."
16557212|NCT02902718|Experimental|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
16557213|NCT02902705|Experimental|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
16557214|NCT02902705|Other|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
16557215|NCT02902692|Experimental|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
16557216|NCT02902679|Experimental|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
16557217|NCT02902666|Experimental|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.
~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
16557218|NCT02902666|Active Comparator|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
16557219|NCT02902653|Experimental|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
16557222|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
16557223|NCT02902627|Experimental|Metastatic cancer|
16557224|NCT02902614|Experimental|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
16557225|NCT02902614|Experimental|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
16557226|NCT02902601|Experimental|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
16557227|NCT02902601|Experimental|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
16557228|NCT02902601|Placebo Comparator|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
16557229|NCT02902588|Experimental|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
16557230|NCT02902588|Other|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
16557231|NCT02902588|Experimental|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
16557232|NCT02902575|Experimental|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
16557233|NCT02902562|Other|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
16557234|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
16557235|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
16557236|NCT02902536||Normal Controls|Patients without myasthenia
16557237|NCT02902523|Active Comparator|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
16557238|NCT02902523|Experimental|HUG116 tablet 245mg|Tenofovir disoproxil
16557239|NCT02902510|Experimental|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
16557240|NCT02902510|No Intervention|Wait List Control|There was no intervention during the WLC.
16557241|NCT02902484|Experimental|Nintedanib Monotherapy|"One cycle of Nintedanib monotherapy followed by a total of eight cycles of both Nintedanib and the chemotherapeutic agents, or until disease progression, whichever comes first.
~Nintedanib dose escalation: 150, 200 mg PO BID
~Nab-paclitaxel: 125 mg/m2 day 1,8,15 every 28 days
~Gemcitabine: 1000 mg /m2 day 1,8,15 every 28 days"
16557242|NCT02902471|Experimental|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
16557243|NCT02902458|Experimental|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
16557244|NCT02902458|No Intervention|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
16557245|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
16557246|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.
~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.
~oral swab for polymorphism exploration"
16557247|NCT02902432|Placebo Comparator|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
16557248|NCT02902432|Experimental|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
16557249|NCT02902419|Active Comparator|1|Wound dressing removal was performed between 12-30 hours postoperatively.
16557250|NCT02902419|Active Comparator|2|Wound dressing removal was performed between 30-48 hours postoperatively.
16557251|NCT02902406||normal oral mucosa|
16557252|NCT02902406||oral precancerous lesion or oral cancer|
16557253|NCT02902393||Success of revascularisation|
16557254|NCT02902380|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
16557255|NCT02902380|Placebo Comparator|Control Group|0.9% saline infusion
16557256|NCT02902367|Experimental|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
16557257|NCT02902367|Other|Control group|Usual care; no restriction for exercise, Three months
16557258|NCT02902354|Other|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
16557259|NCT02902341|Active Comparator|Control|Standard protocol nutrition.
16557260|NCT02902341|Experimental|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
16557261|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
16557287|NCT02902185|Placebo Comparator|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
16557288|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
16630612|NCT02411500|Experimental|Formulation E|
16557262|NCT02902315|Active Comparator|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
16557263|NCT02902315|Active Comparator|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
16557264|NCT02902315|Active Comparator|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
16557265|NCT02902315|Active Comparator|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
16557266|NCT02902302|Experimental|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
16557267|NCT02902302|Active Comparator|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
16557268|NCT02902289|Experimental|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
16557269|NCT02902289|Active Comparator|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
16557270|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
16557271|NCT02902250|Active Comparator|vertebroplasty|vertebroplasty for compression fracture
16557272|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
16557273|NCT02902224|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
16557274|NCT02902224|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
16557275|NCT02902224|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
16557276|NCT02902211|Experimental|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
16557277|NCT02902211|Active Comparator|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
16557278|NCT02902198|Placebo Comparator|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
16557279|NCT02902198|Placebo Comparator|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
16557280|NCT02902198|Active Comparator|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
16557281|NCT02902198|Active Comparator|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
16557282|NCT02902198|Active Comparator|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
16557283|NCT02902198|Active Comparator|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
16557284|NCT02902198|Active Comparator|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
16557285|NCT02902198|Active Comparator|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
16557708|NCT02898818||no atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
16557289|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
16557290|NCT02902159|Experimental|BWW|Free access to online peer support through BWW for 6 months
16557291|NCT02902159|Experimental|MZ|Access to NHS Moodzone Information Only
16557292|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
16557293|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
16557294|NCT02902133|Other|Acetazolamide Arm|Acetazolamide 500 mg twice per day for 5 consecutive days post standard-of-care endoscopic skull base surgery
16557295|NCT02902120|Experimental|Post-transplant|This arm will evaluate the treatment of patients with HCV and chronic kidney disease (GFR <50) who have had a kidney transplant using grazoprevir and elbasvir.
16557297|NCT02902094|Experimental|Experimental|Drug eluting angioplasty balloons
16557298|NCT02902094|Active Comparator|Control|Non-drug eluting balloons
16557299|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
16557300|NCT02902081|Experimental|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
16557301|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
16557302|NCT02902055|Active Comparator|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
16557303|NCT02902055|Active Comparator|Isotonic saline|
16557304|NCT02902042|Experimental|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
16557305|NCT02902042|Experimental|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
16557306|NCT02902029|Experimental|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib [960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.
~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).
~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
16557307|NCT02902029|Experimental|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.
~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.
~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
16557308|NCT02902016|Experimental|Lactase expression induction by GED|
16557309|NCT02902003|No Intervention|Control|Not eligible for program services
16557310|NCT02902003|Active Comparator|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
16557311|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
16557312|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
16557313|NCT02901977|Experimental|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
16557314|NCT02901977|Active Comparator|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
16557315|NCT02901964|Experimental|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
16557316|NCT02901964|Active Comparator|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
16557317|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
16557318|NCT02901938|Experimental|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
16557319|NCT02901938|Experimental|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
16557320|NCT02901925|Experimental|ABY-029|ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
16557321|NCT02901912||Active|Women who perform at least 3h of physical activity per week
16557322|NCT02901912||Sedentary|Women who did not perform any kind of exercise
16557323|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16557364|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
16557365|NCT02901587|Experimental|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
16557366|NCT02901587|Experimental|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
16557367|NCT02901587|Experimental|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
16557403|NCT02901327|Experimental|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
16557324|NCT02901886|Experimental|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.
~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.
~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.
~The participants will note their tobacco and NRT consumption in a smoking diary."
16557325|NCT02901886|No Intervention|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
16557326|NCT02901873|Active Comparator|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
16557327|NCT02901873|Active Comparator|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
16557328|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
16557329|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
16557330|NCT02901847|Other|Intervention|PAD tailored care
16557331|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
16557332|NCT02901821||Concussion|Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.
16557333|NCT02901808||NOMI|Patients suffering from NOMI
16557334|NCT02901808||No-NOMI|Patients not suffering from NOMI
16557335|NCT02901782|Experimental|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
16557336|NCT02901769|Experimental|Depressed suicide attempters|20 subjects
16557337|NCT02901769|Experimental|Depressed patients with past history of|20 subjects
16557338|NCT02901769|Experimental|Depressed patients with no history of|20 subjects
16557339|NCT02901769|Placebo Comparator|Healthy controls|20 subjects
16557340|NCT02901743|Active Comparator|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
16557341|NCT02901743|Active Comparator|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
16557342|NCT02901730|Experimental|532nm laser group|LPI with 532nm laser.
16557343|NCT02901730|Experimental|561nm laser group|LPI with 561nm laser.
16557344|NCT02901717|Active Comparator|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
16557345|NCT02901717|Experimental|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
16557346|NCT02901704|Experimental|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
16557347|NCT02901704|Sham Comparator|Sham procedure|Renal anigography
16557348|NCT02901691|Experimental|Deaf children|
16557349|NCT02901691|Placebo Comparator|healthy volonteer children|
16557350|NCT02901678|Active Comparator|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
16557351|NCT02901678|Experimental|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
16557352|NCT02901665|No Intervention|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
16557353|NCT02901665|Active Comparator|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
16557354|NCT02901652|Active Comparator|NIPPV|"noninvasive respiratory support devices
~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
16557355|NCT02901652|Active Comparator|BİPAP|"noninvasive respiratory support devices
~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
16557356|NCT02901639|Experimental|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
16557357|NCT02901639|No Intervention|NO counseling|will not receive any counseling about contraceptive methods
16557358|NCT02901626|Experimental|Pessary|Arabin pessary. Participants where local standard of care includes vaginal progesterone will also receive progesterone.
16557359|NCT02901626|No Intervention|No Pessary|Participants that do not receive a pessary will receive the usual standard of care, including vaginal progesterone if that is the local standard.
16557360|NCT02901613|No Intervention|Retrospective|Standard dry sterile dressing
16557361|NCT02901613|Experimental|Prospective|Negative-pressure wound therapy
16557362|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
16557363|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
16557368|NCT02901574|Active Comparator|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
16557369|NCT02901574|Sham Comparator|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
16557370|NCT02901561|Experimental|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
16557371|NCT02901561|Active Comparator|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
16557373|NCT02901535|Active Comparator|Control|Spirometry in baseline Spirometry - 20 weeks
16557374|NCT02901535|Experimental|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
16557375|NCT02901522|Active Comparator|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
16557376|NCT02901522|Experimental|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
16557377|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
16557378|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
16557379|NCT02901496|Experimental|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
16557380|NCT02901496|Experimental|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
16557381|NCT02901496|Experimental|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
16557382|NCT02901496|Placebo Comparator|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
16557383|NCT02901496|Experimental|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
16557384|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.
~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
16557385|NCT02901457|Experimental|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
16557386|NCT02901457|No Intervention|Control group|Students do not receive the intervention program.
16557387|NCT02901431|Placebo Comparator|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
16557388|NCT02901431|Experimental|Balovaptan (RO5285119) 10 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
16557389|NCT02901431|Experimental|Balovaptan (RO5285119) 4 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
16557390|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
16557391|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
16557392|NCT02901405|Experimental|Negative Pressure Wound Therapy|120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
16557393|NCT02901405|Active Comparator|Standard dressings|Absorbant dressings applied in a standard fashion, i.e. only changed as necessary
16557394|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
16557395|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
16557396|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
16557397|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
16557398|NCT02901379|Experimental|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
16557399|NCT02901379|Active Comparator|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
16557400|NCT02901366|Experimental|14C-FYU-981|14C-FYU-981, (Oral single dosing)
16557401|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index>5.0 and ≤8.0cm.
~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
16557402|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
16557491|NCT02900664|Experimental|PDR001+ trametinib in NSCLC|
16557404|NCT02901327|Active Comparator|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
16557405|NCT02901314|Experimental|MyRoad|Receives usual care heart failure education before discharge AND a card at discharge that provided pre-recorded audio messages that can be played back on-demand on 4 themes: heart failure signs/symptoms assessment, medications, activity and exercise and diet and a general message about the importance of follow-up post discharge and following the plan of care.
16557406|NCT02901314|No Intervention|Usual care|Receives usual care heart failure education before discharge
16557407|NCT02901301|Experimental|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
16557408|NCT02901288|Experimental|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.
~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
16557409|NCT02901288|Experimental|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
16557410|NCT02901288|Active Comparator|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).
~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).
~."
16557411|NCT02901275|Placebo Comparator|Placebo + Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
16557412|NCT02901275|Active Comparator|Hydromorphone (oral) 4mg + Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
16557413|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
16557414|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
16557415|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.
16557416|NCT02901262||qEEG patients|All the patients with continuous EEG (>24 hours) in teh two study units
16557417|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.
~Second step: Sertraline 200mg + lithium (900mg-1500mg)
~Non responsive patients: 3rd step.
~Third step: Nortriptyline 100mg
~Non responsive patients: 4th step.
~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)
~Non responsive patients : 5th step
~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients
~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
16557418|NCT02901236|Active Comparator|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
16557419|NCT02901236|Active Comparator|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
16557420|NCT02901223|Active Comparator|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
16557421|NCT02901223|Active Comparator|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
16557422|NCT02901210|Experimental|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
16557423|NCT02901197|Active Comparator|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
16557424|NCT02901197|Active Comparator|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
16557425|NCT02901184|Active Comparator|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.
16557426|NCT02901184|Placebo Comparator|Standard care alone|Patients in the control arm will get the standard care alone
16557427|NCT02901171|Experimental|Combined Treatment|ACT group treatment combined with smartphone application
16557428|NCT02901171|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT group treatment
16557429|NCT02901171|Active Comparator|Behavioural Support Programme|Group based Behavioural Support Programme
16557430|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
16557431|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
16557432|NCT02901145|Experimental|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
16557433|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
16557434|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
16557435|NCT02901119|Experimental|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
16557436|NCT02901119|Active Comparator|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
16557437|NCT02901106|Experimental|Patient with recurring-remitting MS|
16557438|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
16557439|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
16557440|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
16557441|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.
~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
16557442|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
16557443|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
16557444|NCT02901028|Experimental|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
16557445|NCT02901028|Sham Comparator|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
16557446|NCT02901015|Other|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
16557447|NCT02901015|Other|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
16557448|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
16557449|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
16557450|NCT02900989|Other|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
16557451|NCT02900989|Other|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if >=15 yo and the SIQ-Fr Junior composed of 15 items if <15 yo
16557452|NCT02900976|Experimental|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a complete response (CR) after induction receive additional rituximab or biosimilar as in induction.
16557453|NCT02900976|Experimental|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who do not achieve a CR to induction, all relapsed patients after induction, and all patients with refractory disease who received rituximab or biosimilar within 90 days according to institutional guidelines, receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Cycle continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first cycle of cycle allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional cycle.
16557454|NCT02900963|Other|Nutrition state determination|"Determination of nutritional state and inflammatory status:
~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
16557455|NCT02900950|Experimental|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:
~Anterior surface of the pancreas (yellow);
~Posterior surface of the pancreas (orange);
~Superior mesenteric/portal vein groove (blu);
~Superior mesenteric artery margin (retroperitoneal margin) (red);
~Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
16557456|NCT02900950|Other|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
16557457|NCT02900937|Experimental|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
16557458|NCT02900911|Experimental|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
16557459|NCT02900911|Active Comparator|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
16557492|NCT02900664|Experimental|PDR001+EGF816 in NSCLC|
16557493|NCT02900664|Experimental|PDR001+canakinumab in CRC|
16557494|NCT02900664|Experimental|PDR001+ CJM112 in CRC|
16557495|NCT02900664|Experimental|PDR001+trametinib in CRC|
16557460|NCT02900898|Experimental|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.
~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
16557461|NCT02900898|Experimental|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
16557462|NCT02900898|Experimental|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
16557463|NCT02900898|Active Comparator|Control|This group will not carry out interventions.
16557464|NCT02900820|Experimental|Novel intervention group|Discontinuing antibiotic therapy.
16557465|NCT02900820|Experimental|Usual intervention group|Usual strategy of continuing antibiotic treatment.
16557466|NCT02900794|Other|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
16557467|NCT02900794|Other|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
16557468|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
16557469|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
16557470|NCT02900768|Experimental|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
16557471|NCT02900768|No Intervention|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
16557472|NCT02900755|Experimental|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
16557473|NCT02900742|Experimental|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
16557474|NCT02900742|Placebo Comparator|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
16557475|NCT02900729|Experimental|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
16557476|NCT02900729|Active Comparator|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
16557477|NCT02900716|Experimental|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
16557478|NCT02900716|Experimental|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
16557479|NCT02900716|Experimental|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:
~daily x 21 days every 28 days"
16557480|NCT02900703||PATIENT|
16557481|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
16557482|NCT02900690||Standard care|without use of the Novoseven
16557483|NCT02900677|Experimental|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
16557484|NCT02900677|No Intervention|Control|usual care
16557485|NCT02900664|Experimental|PDR001+canakinumab in TNBC|
16557486|NCT02900664|Experimental|PDR001+CJM112 in TNBC|
16557487|NCT02900664|Experimental|PDR001+trametinib in TNBC|
16557488|NCT02900664|Experimental|PDR001+EGF816 in TNBC|
16557489|NCT02900664|Experimental|PDR001+canakinumab in NSCLC|
16557490|NCT02900664|Experimental|PDR001+CJM112 in NSCLC|
16557500|NCT02900651|Experimental|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
16557501|NCT02900638|Experimental|Intervention (Mentor/Mentee)|
16557502|NCT02900638|No Intervention|Wait list control|
16557503|NCT02900612|Experimental|WA (Water Aerobics Training)|Water aerobics training.
16557504|NCT02900612|Experimental|WR (Water Resistance Training)|Resistance aquatic training.
16557505|NCT02900612|Active Comparator|CG (Control Group)|Control Group.
16557506|NCT02900560|Active Comparator|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
16557507|NCT02900560|Active Comparator|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
16557508|NCT02900560|Active Comparator|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
16557509|NCT02900560|Active Comparator|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
16557510|NCT02900534|Experimental|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
16557511|NCT02900534|No Intervention|Waiting control group|
16557512|NCT02900508|Experimental|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
16557513|NCT02900508|Active Comparator|Control training|Participants in the control training group received a 4-week conventional training.
16557514|NCT02900495|Experimental|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
16557515|NCT02900495|Experimental|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
16557516|NCT02900495|Experimental|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
16557517|NCT02900495|Placebo Comparator|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
16557518|NCT02900482||case group|Patients with a history of congenital hip dislocation
16557519|NCT02900482||control group|Patients with no history of congenital hip dislocation
16557520|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
16557521|NCT02900469|Experimental|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection
~Surgery: 2-4 weeks after denosumab"
16557522|NCT02900443|Experimental|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
16557523|NCT02900443|Active Comparator|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
16557524|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
16557525|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
16557526|NCT02900417|Experimental|sitagliptin|All the patients will receive sitagliptin 100mg daily.
16557527|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
16557528|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
16557529|NCT02900378|Experimental|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
16557530|NCT02900378|Active Comparator|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
16557531|NCT02900365|Experimental|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery & IOL implantation"
16557532|NCT02900365|Experimental|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery & IOL implantation."
16557533|NCT02900352|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
16557534|NCT02900352|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
16557535|NCT02900339|Experimental|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
16557536|NCT02900326|Placebo Comparator|Control patients with no intervention|group without intervention
16557537|NCT02900326|Experimental|Endurance training program (8 weeks) group|only physical training group
16557538|NCT02900326|Experimental|MBSR group (mindfulness-based-stress-reduction)|only mental training group(8 weeks)
16557539|NCT02900326|Experimental|Endurance training program combined with MBSR sessions|Endurance training program combined with MBSR sessions, during 8 weeks (mindfulness-based-stress-reduction)
16557540|NCT02900313|Other|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
16557541|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
16557542|NCT02900235|Experimental|MT-3995|[14C]-MT-3995 after a single oral dose
16557543|NCT02900222|Experimental|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
16557544|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
16557545|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
16557546|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
16557547|NCT02900196|Experimental|1 - Test|
16557548|NCT02900196|Placebo Comparator|2 - Placebo|
16557549|NCT02900183|Experimental|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
16557550|NCT02900157|Experimental|MEDI9090|
16557551|NCT02900144|Experimental|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
16557552|NCT02900144|Active Comparator|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
16557553|NCT02900131|Experimental|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
16557554|NCT02900131|Experimental|trial group 2|Participants will receive Jaungo twice a day for three weeks.
16557555|NCT02900131|Placebo Comparator|control group|Participants will receive placebo twice a day for three weeks.
16557556|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
16557557|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
16557558|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
16557559|NCT02900105|Experimental|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
16557560|NCT02900092|Experimental|Ganaxolone|Participants received ganaxolone
16557561|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
16557562|NCT02900053|Active Comparator|Arm 1|Cerebral modulation using tDCS (transcranial Direct-Current Stimulation) associated with repetitive traumatic exposure using a personal traumatic script
16557563|NCT02900053|Placebo Comparator|Arm 2|Placebo cerebral modulation using sham-tDCS associated with repetitive traumatic exposure using a personal traumatic script
16557564|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
16557565|NCT02900027|Experimental|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
16557566|NCT02900027|Placebo Comparator|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
16557567|NCT02900014|Experimental|Children with cleft|
16557568|NCT02900001|Active Comparator|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
16557569|NCT02900001|Experimental|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
16557570|NCT02899988|Experimental|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
16557571|NCT02899988|Experimental|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
16557572|NCT02899988|Experimental|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
16557573|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC Q8W.
16557574|NCT02899975|Other|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
16557576|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
16557577|NCT02899936|Active Comparator|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
16557578|NCT02899936|Experimental|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
16557579|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
16557580|NCT02899910|Experimental|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
16557581|NCT02899910|Active Comparator|Health education|Standardized health education for weight loss
16557582|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
16557583|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
16557584|NCT02899871||case|aetiology of joint symptoms
16557585|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
16557586|NCT02899845|Experimental|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
16557587|NCT02899845|Active Comparator|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
16557588|NCT02899832||NIRS|Near Infra Red Spectroscopy.
16557589|NCT02899819|Experimental|meconium|The meconium will be sampled in the first 2 days of life
16557590|NCT02899806|Placebo Comparator|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
16557591|NCT02899806|Experimental|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
16557592|NCT02899793|Experimental|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
16557593|NCT02899780|Experimental|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
16557594|NCT02899754|Experimental|Intervention Group|Participants in this arm will use the lung cancer screening decision aid (LCSDecTool)
16557595|NCT02899754|Active Comparator|Control Group|Content that provides general information on disease prevention and health promotion unrelated to lung cancer. The information will be delivered on the same modality and take a similar amount of time to administer.
16557596|NCT02899741|Experimental|Omega-3|One group of this study. Omega-3 will be administered for thee months.
16557597|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.
~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.
~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
16557598|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
16557599|NCT02899702|Experimental|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
16557600|NCT02899702|Placebo Comparator|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.
~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
16557601|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
16557602|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
16557603|NCT02899676|Experimental|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
16557604|NCT02899676|Experimental|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
16557605|NCT02899676|Experimental|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
16557606|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
16557607|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
16557608|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
16557609|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
16557610|NCT02899637|Experimental|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
16557611|NCT02899637|Sham Comparator|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
16557612|NCT02899624|Experimental|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
16557613|NCT02899624|Active Comparator|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
16557614|NCT02899624|Active Comparator|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
16557709|NCT02898818||lichen planus|vaginal and oral swab sample, questionnaire, papa smear
16558225|NCT02895334|No Intervention|Standard of Care|Caregivers will complete 4 follow up assessments.
16557615|NCT02899611|Experimental|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
16557616|NCT02899598|Experimental|Pregnant women|
16557617|NCT02899585|Experimental|Group A|Elaboration of the questionnaires
16557618|NCT02899585|Experimental|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
16557619|NCT02899572|Experimental|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
16557620|NCT02899572|No Intervention|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
16557621|NCT02899559|Experimental|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
16557622|NCT02899559|Experimental|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
16557623|NCT02899559|Experimental|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
16557624|NCT02899533||FES PET/CT scan|All subjects will receive an [18F]FES PET/CT scan.
16557625|NCT02899520|Active Comparator|Group A|Reference method
16557626|NCT02899520|Experimental|Group B|CMP ® method (Knowledge and Control of Perineum)
16557627|NCT02899507|Experimental|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
16557628|NCT02899507|No Intervention|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
16557629|NCT02899494|Other|Group A|Antenatal classes
16557630|NCT02899494|Experimental|Group B|Physical and psychic preparation
16557631|NCT02899481|Experimental|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
16557632|NCT02899481|No Intervention|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
16557633|NCT02899468|Experimental|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
16557634|NCT02899468|Other|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
16557635|NCT02899455|Experimental|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
16557636|NCT02899455|Active Comparator|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
16557637|NCT02899455|Active Comparator|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
16557638|NCT02899442|No Intervention|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.
~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:
~Information about health risks for night workers
~Dietetic intake
~Leisure physical activities
~Sleep and alertness
~Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)
~That's a current practice in France for Occupational physicians."
16557639|NCT02899442|Experimental|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
16557640|NCT02899403|Experimental|healthy subjects|
16557641|NCT02899390|Experimental|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
16557642|NCT02899377|Experimental|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
16557643|NCT02899377|Experimental|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of <=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
16557676|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16557704|NCT02898831|Experimental|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
16557644|NCT02899364|Experimental|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
16557645|NCT02899364|Placebo Comparator|Sodium chloride 0.9%|50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
16557646|NCT02899351||Infants less than 12 months|intubated infants in ICU
16557647|NCT02899338|Experimental|BI695501 Autoinjector|
16557648|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
16557649|NCT02899299|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
16557650|NCT02899299|Active Comparator|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
16557651|NCT02899286|Experimental|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
16557652|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
16557653|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
16557654|NCT02899260|No Intervention|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
16557655|NCT02899260|Experimental|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
16557656|NCT02899247|Experimental|No Surface Sealant|Resin composite only
16557657|NCT02899247|Active Comparator|With surface Sealant|Resin composite with surface sealant application
16557658|NCT02899234|Active Comparator|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
16557659|NCT02899234|Active Comparator|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
16557660|NCT02899221|Experimental|Treatment (high dose rate brachytherapy, hyperthermia)|Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.
16557661|NCT02899195|Experimental|Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion. After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
16557662|NCT02899182|Placebo Comparator|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
16557663|NCT02899182|Experimental|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
16557664|NCT02899169|Experimental|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
16557665|NCT02899169|Active Comparator|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
16557666|NCT02899156|Active Comparator|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
16557667|NCT02899156|Placebo Comparator|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
16557668|NCT02899143|Experimental|Group 5-days|5-days targeted antibiotic therapy
16557669|NCT02899143|Other|Group 10-days|10-days targeted antibiotic therapy
16557670|NCT02899130|Experimental|Polyherbal|Combination of 3 whole herbs in a capsule
16557671|NCT02899130|Placebo Comparator|Matching placebo|Similar looking inert capsules
16557672|NCT02899117|Experimental|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
16557673|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
16557674|NCT02899091|Experimental|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
16557675|NCT02899091|Placebo Comparator|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
16557677|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
16557678|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
16557680|NCT02899039|Experimental|IgG4-related disease|Subjects suffering from IgG4-related disease
16557681|NCT02899039|Active Comparator|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
16557682|NCT02899039|Active Comparator|Healthy controls|Healthy subjects
16557683|NCT02899026|Experimental|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
16557684|NCT02899026|Experimental|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
16557685|NCT02899026|Placebo Comparator|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
16557686|NCT02899000|Experimental|Acne treatment|"Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)
~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)"
16557687|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
16557688|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
16557689|NCT02898961|Experimental|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.
~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
16557690|NCT02898922|Experimental|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
16557691|NCT02898922|Active Comparator|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
16557692|NCT02898909|Experimental|16 pieces fragmentation|
16557693|NCT02898909|Active Comparator|8 pieces fragmentation|
16557694|NCT02898896|Other|HIV-infected patients|HIV-infected patients >= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA < 50 copies >= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
16557695|NCT02898883|Experimental|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
16557696|NCT02898883|No Intervention|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
16557697|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
16557698|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
16557699|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
16557700|NCT02898844|No Intervention|Control Condition|Neither roommate dieted.
16557701|NCT02898844|Experimental|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
16557702|NCT02898844|Experimental|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
16557703|NCT02898831|No Intervention|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
16557705|NCT02898818||symptomless|vaginal and oral swab sample, questionnaire
16557710|NCT02898805|Experimental|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
16557711|NCT02898805|Active Comparator|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
16557712|NCT02898792|Experimental|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
16557713|NCT02898792|Experimental|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
16557714|NCT02898792|Experimental|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
16557715|NCT02898779|Experimental|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.
~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
16557716|NCT02898779|Experimental|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.
~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
16557717|NCT02898766|Active Comparator|Enteral Nutrition Formula 1|Enteral Nutrition Formula
16557718|NCT02898766|Active Comparator|Enteral Nutrition Formula 2|Enteral Nutrition Formula
16557719|NCT02898753|Experimental|VAL-1221 3 mg/kg|"Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.
~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data."
16557720|NCT02898753|Experimental|VAL-1221 10 mg/kg|"Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.
~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data."
16557721|NCT02898753|Experimental|VAL-1221 30 mg/kg|"Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions.
~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week."
16557722|NCT02898753|Active Comparator|rhGAA|"Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme.
~Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week."
16557723|NCT02898740|Experimental|Exercise|Structured exercise
16557724|NCT02898740|Active Comparator|Health Education|Health education
16557725|NCT02898727|Other|Local Therapy|"The local therapy offered will be determined by the participant's doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases.
~Neurosurgery: The surgery may be performed up to 6 weeks before participant being registered on the trial or up to 4 weeks after registration.
~Sometimes stereotactic radiosurgery is required to be delivered to the cavity left after the metastasis has been removed (Cavity Boost).
~Stereotactic Radiosurgery: Treatment is to commence within 4 weeks of study registration. The size, number and location of the brain metastasis will determine the dose and fractionation schedule of radiotherapy."
16557726|NCT02898701|Active Comparator|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
16557727|NCT02898701|Experimental|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
16557728|NCT02898701|Active Comparator|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
16557729|NCT02898688|Other|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
16557730|NCT02898688|Experimental|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
16557731|NCT02898688|Experimental|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
16557732|NCT02898688|Experimental|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
16557733|NCT02898675|Experimental|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
16557734|NCT02898675|Active Comparator|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
16630613|NCT02411500|Experimental|Formulation F|
16557735|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
16557736|NCT02898662|Placebo Comparator|Placebo|Matching placebo
16557737|NCT02898649|Experimental|IRE|The intervention group
16557738|NCT02898610|Active Comparator|Colchicine treatment|Colchicine 0.5mg/day plus usual care for 60 months
16557739|NCT02898610|No Intervention|Usual Standard of care alone|Normal standard of care remains for these patients
16557740|NCT02898597|Experimental|Video|Video-call delivered cognitive behavioral therapy
16557741|NCT02898597|Active Comparator|Voice|Voice-call delivered cognitive behavioral therapy
16557742|NCT02898584|Other|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
16557743|NCT02898571|Placebo Comparator|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
16557744|NCT02898571|Experimental|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
16557745|NCT02898571|Experimental|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
16557746|NCT02898558|Experimental|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
16557747|NCT02898545|Other|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
16557748|NCT02898545|No Intervention|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
16557749|NCT02898532|Active Comparator|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
16557750|NCT02898532|No Intervention|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
16557751|NCT02898506|Active Comparator|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
16557752|NCT02898506|Placebo Comparator|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
16557753|NCT02898480|Experimental|Remote ischemic conditioning|
16557754|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
16557755|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
16557756|NCT02898454|Experimental|Dupilumab 300 mg q2w|Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
16557757|NCT02898454|Experimental|Dupilumab 300 mg q2w then q4w|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
16557758|NCT02898454|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
16557759|NCT02898441|Active Comparator|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
16557760|NCT02898441|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care
16557761|NCT02898428||New mothers|New mothers with type 1 diabetes
16557762|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
16557763|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
16557764|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
16557765|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
16557766|NCT02898376|Experimental|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
16557767|NCT02898376|Active Comparator|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
16557768|NCT02898350|Active Comparator|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
16557769|NCT02898350|Active Comparator|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
16557770|NCT02898350|Active Comparator|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
16557771|NCT02898350|Active Comparator|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
16557772|NCT02898337||Methadone-induced QTc interval prolongation|
16557773|NCT02898337||Methadone-treated patients, no QT interval prolongation|
16557774|NCT02898324|Experimental|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
16557775|NCT02898324|Experimental|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
16557835|NCT02897895|Active Comparator|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
16557776|NCT02898324|No Intervention|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
16557777|NCT02898298|Experimental|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
16557778|NCT02898298|Active Comparator|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
16557779|NCT02898285|Active Comparator|Personal time condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
16557780|NCT02898285|Experimental|Individual sport condition|People randomized to this group will select an individual sport. They will be asked to participate in this individual sport for three months.
16557781|NCT02898285|Experimental|Team sport condition|People randomized to this group will select a team sport. They will be asked to participate in the team sport for three months (length of the team sport season).
16557782|NCT02898259|Experimental|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
16557783|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).
~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.
~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.
~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
16557784|NCT02898233|Active Comparator|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
16557785|NCT02898233|Sham Comparator|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
16557786|NCT02898233|Other|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
16557787|NCT02898207|Experimental|Treatment (olaparib and onalespib)|Patients receive olaparib PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients receive olaparib PO BID on days 1-28 and onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16557788|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
16557789|NCT02898181|Experimental|Tragus Stimulation|In this group patients will receive tragus stimulation for 8 hours per day during hospital stay.
16557790|NCT02898181|No Intervention|Control group|No tragus stimulation will be done
16557791|NCT02898168|Experimental|WA|
16557792|NCT02898168|Active Comparator|Control|
16557793|NCT02898142|Experimental|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
16557794|NCT02898142|Experimental|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
16557795|NCT02898129|Experimental|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
16557796|NCT02898129|Experimental|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
16557797|NCT02898129|Experimental|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
16557798|NCT02898129|Experimental|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
16557799|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
16557800|NCT02898103|Experimental|Active Current then Sham then Active Current|Electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes; then sham/placebo for 5 minutes; and then active electrical current for the following 2-4 weeks
16557801|NCT02898103|Active Comparator|Sham then Active Current|Sham/placebo will be introduced to the insulated percutaneous lead(s) for 5 minutes; then active electrical current for the following 2-4 weeks
16557802|NCT02898077|Experimental|8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel|"8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.
~Participants may continue on treatment until discontinuation criteria were met."
16557803|NCT02898077|Experimental|Placebo + 80 mg/m² Paclitaxel|"Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.
~Participants may continue on treatment until discontinuation criteria were met."
16557804|NCT02898064|Other|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
16557805|NCT02898064|Other|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
16557806|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.
~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
16557807|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.
~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
16557808|NCT02898038|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
16557809|NCT02898025|Active Comparator|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
16557810|NCT02898025|Active Comparator|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
16557811|NCT02898025|Active Comparator|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
16557812|NCT02898025|Placebo Comparator|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
16557813|NCT02898012|Experimental|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
16557814|NCT02897999|Experimental|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
16557815|NCT02897999|Experimental|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
16557816|NCT02897999|Experimental|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
16557817|NCT02897999|Experimental|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
16557818|NCT02897999|Experimental|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
16557819|NCT02897999|Experimental|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
16557820|NCT02897999|Experimental|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
16557821|NCT02897999|Experimental|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
16557822|NCT02897999|Experimental|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
16557823|NCT02897999|Experimental|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
16557824|NCT02897986|Experimental|patients with refractory/relapsing solid tumors|
16557825|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
16557826|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
16557827|NCT02897973||Controls|Able-bodied individuals without amputation
16557828|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
16557829|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
16557830|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
16557831|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.
~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
16557832|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
16557833|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
16557834|NCT02897895|Experimental|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
16557837|NCT02897869|Experimental|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
16557838|NCT02897869|Experimental|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
16557839|NCT02897856|Active Comparator|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
16557840|NCT02897856|Active Comparator|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
16557841|NCT02897843|Sham Comparator|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
16557842|NCT02897843|Experimental|tDCS|20 minute tDCS sessions
16557843|NCT02897830|Experimental|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
16557844|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
16557845|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
16557846|NCT02897804|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
16557847|NCT02897804|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
16557848|NCT02897804|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
16557849|NCT02897804|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
16557850|NCT02897804|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
16557851|NCT02897804|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
16557852|NCT02897804|Experimental|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
16557853|NCT02897804|Experimental|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16557854|NCT02897804|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
16557855|NCT02897804|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
16557856|NCT02897804|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
16557857|NCT02897804|Experimental|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
16557858|NCT02897804|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
16557859|NCT02897804|Experimental|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
16557860|NCT02897804|Experimental|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
16557861|NCT02897804|Experimental|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16557862|NCT02897804|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
16557863|NCT02897804|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
16557864|NCT02897804|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
16557865|NCT02897804|Experimental|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16557866|NCT02897804|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
16557867|NCT02897804|Experimental|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
16557868|NCT02897804|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
16557869|NCT02897804|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16557870|NCT02897804|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
16557871|NCT02897804|Experimental|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
16632557|NCT02398188|Experimental|LIPO-202|Experimental arm
16557872|NCT02897804|Experimental|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
16557873|NCT02897804|Experimental|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16557874|NCT02897804|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
16557875|NCT02897804|Experimental|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
16557876|NCT02897804|Experimental|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
16557877|NCT02897804|Experimental|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
16557878|NCT02897791|Experimental|Impaired Rt. Hemisphere patients|20 first stroke patients
16557879|NCT02897791|Experimental|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
16557880|NCT02897778|Active Comparator|Entinostat|15 patients will be randomized to receive a single, supratherapeutic dose of entinostat
16557881|NCT02897778|Placebo Comparator|Placebo|15 patients will be randomized to receive a single dose of placebo
16557882|NCT02897765|Experimental|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
16557883|NCT02897752|Experimental|WalkAide|
16557884|NCT02897752|Active Comparator|Usual gait Training|
16557885|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
16557886|NCT02897739||Health Volunteers|Participants who have normal hearts.
16557887|NCT02897726|Experimental|NVP-1402|NVP-1402 was administered once a day for 24 hours
16557888|NCT02897726|Active Comparator|NVP-1402R|Active comparator was administered twice a day for 24 hours
16557889|NCT02897713|Experimental|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
16557890|NCT02897713|Active Comparator|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
16557891|NCT02897700|Experimental|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.
~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
16557892|NCT02897700|Experimental|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.
~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
16557893|NCT02897700|Placebo Comparator|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
16557894|NCT02897687|Experimental|Facebook Group|Social skills training within an online group.
16557895|NCT02897687|Active Comparator|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
16557896|NCT02897674|Experimental|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
16557897|NCT02897674|Experimental|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
16557898|NCT02897661|Experimental|Early WMT and EEN|WMT (day1), EEN (day1-15)
16557899|NCT02897661|Experimental|Late WMT and EEN|WMT (day8), EEN (day1-15)
16557900|NCT02897635|Experimental|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
16557901|NCT02897622|Other|Case management|Case management
16557902|NCT02897609||A simple questionary filled|
16557903|NCT02897596|Experimental|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
16557904|NCT02897596|Experimental|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
16557905|NCT02897583|Experimental|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
16557906|NCT02897583|Sham Comparator|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
16557907|NCT02897570|Active Comparator|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
16557908|NCT02897570|Experimental|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
16557909|NCT02897570|Experimental|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
16557910|NCT02897570|Experimental|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
16557911|NCT02897557|Experimental|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
16557912|NCT02897544|Experimental|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
16557913|NCT02897531|Active Comparator|ES anastomosis|Stapled end-to-side anastomosis
16557914|NCT02897531|Active Comparator|SS anastomosis|Stapled side-to-side anastomosis
16557915|NCT02897518|Experimental|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
16557916|NCT02897518|Active Comparator|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
16557917|NCT02897505|Experimental|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
16557918|NCT02897479|Experimental|Savolitinib|Pulmonary Sarcomatoid Carcinomas
16557919|NCT02897466|Experimental|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.
~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
16557920|NCT02897466|No Intervention|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.
~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
16557921|NCT02897453||The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
16557922|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
16557923|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
16557924|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants fill out a survey and undergo collection of blood and oral rinse samples.
~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, collection of oral rinse sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, penile exam, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, ultrasound, and blood sample collection once every year for 5 years. Select participants will provide oral rinse sample by mail every six months."
16557925|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
16557926|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
16557927|NCT02897414||Overall group that includes all prescription opioids except|
16557928|NCT02897414||Comparator Group taking benzodiazepines|
16557929|NCT02897414||Comparator Group taking IR hydrocodone|
16557930|NCT02897401|Experimental|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
16557931|NCT02897401|Experimental|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
16557932|NCT02897401|Experimental|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
16557933|NCT02897401|Placebo Comparator|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
16557934|NCT02897388|No Intervention|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
16557935|NCT02897388|Experimental|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
16557936|NCT02897375|Experimental|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16557937|NCT02897375|Experimental|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16557938|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
16557939|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
16557940|NCT02897349|Experimental|linagliptin|
16557941|NCT02897349|Placebo Comparator|Placebo|
16557942|NCT02897336|Experimental|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
16557943|NCT02897336|Active Comparator|interlaminar|interlaminar epidural corticosteroid injection
16557944|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
16557945|NCT02897284|Experimental|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
16557946|NCT02897284|Active Comparator|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
16557947|NCT02897284|No Intervention|Control|waiting list
16557948|NCT02897258||Without anticoagulant/antiplatelet|
16557949|NCT02897258||Treated with antiplatelet only|
16557950|NCT02897258||Treated with anticoagulant only|
16557951|NCT02897258||With antiplatelet/anticoagulant|
16557952|NCT02897245||Patient with intentionally stop|
16557953|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
16557954|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
16557955|NCT02897219|Experimental|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
16557956|NCT02897219|Placebo Comparator|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
16557957|NCT02897219|Experimental|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
16557958|NCT02897206|Experimental|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
16557959|NCT02897206|Placebo Comparator|Placebo group|Identical placebo administered in identical dosage, timing and duration.
16557960|NCT02897193|Active Comparator|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
16557961|NCT02897193|Experimental|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
16557962|NCT02897180|Placebo Comparator|Placebo|Subjects will receive a total of 14 capsules with Placebo
16557963|NCT02897180|Experimental|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
16557964|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.
~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
16557965|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.
~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
16557966|NCT02897167||Controls|Healthy subjects without psychotic disorder.
16557967|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
16557968|NCT02897141|Placebo Comparator|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
16557969|NCT02897115|Experimental|Treat-to-Target (T2T)|Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
16557970|NCT02897115|Active Comparator|Standard of Care (SOC)|Participants received treatment as prescribed by their physician according to the local standard of care.
16557971|NCT02897102|Active Comparator|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
16557972|NCT02897102|Experimental|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
16557973|NCT02897089|No Intervention|acid-etch|Acid etch+fissure sealant
16557974|NCT02897089|Other|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
16557975|NCT02897089|Other|All Bond universal|All Bond universal adhesive agent+fissure sealant
16557976|NCT02897089|Other|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
16557977|NCT02897089|Other|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
16557978|NCT02897089|Other|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
16557979|NCT02897089|Other|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
16557980|NCT02897089|Other|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
16557981|NCT02897076|Active Comparator|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.
~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.
~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
16558013|NCT02896855|Experimental|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m^2), administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
16558014|NCT02896842|No Intervention|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
16632558|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
16557982|NCT02897076|Placebo Comparator|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.
~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.
~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
16557983|NCT02897063|Experimental|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
16557984|NCT02897063|Experimental|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
16557985|NCT02897050|Experimental|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
16557986|NCT02897050|Active Comparator|T followed by FEC|Docetaxel 100mg/m2, iv, d1 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
16557987|NCT02897037|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
16557988|NCT02897037|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
16557989|NCT02897024|Active Comparator|Usual weekly|Usual weekly physical therapy is 1 hours of therapy one day per week for 40 weeks.
16557990|NCT02897024|Experimental|High intensity periodic|High intensity periodic physical therapy is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
16557991|NCT02897011|Sham Comparator|Group 1: MTX continue|Group will continue MTX after vaccination
16557992|NCT02897011|Experimental|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
16557993|NCT02896998|Other|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
16557994|NCT02896998|Experimental|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
16557995|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
16557996|NCT02896972|Active Comparator|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
16557997|NCT02896972|Active Comparator|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
16557998|NCT02896959|Experimental|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
16557999|NCT02896959|Experimental|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
16558000|NCT02896959|Experimental|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
16558001|NCT02896946|Experimental|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
16558002|NCT02896933||patients with multiple sclerosis|recruited in a former study
16558003|NCT02896933||healthy control subjects|
16558004|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
16558005|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16558006|NCT02896894|Experimental|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
16558007|NCT02896894|Other|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
16558008|NCT02896894|Experimental|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
16558009|NCT02896894|No Intervention|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
16558010|NCT02896868|Experimental|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
16558011|NCT02896868|Placebo Comparator|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
16558012|NCT02896855|Active Comparator|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg/m^2]), administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
16558015|NCT02896842|Active Comparator|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage < 1000 ng/ml
16558016|NCT02896842|Experimental|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage < 1000 ng/ml
16558017|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
16558018|NCT02896816|Experimental|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.
~Surface EMG, MRI and PET scan will be performed at baseline."
16558019|NCT02896816|Active Comparator|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
16558020|NCT02896803|Experimental|Experimental|mFLOX
16558021|NCT02896790||Stage 1|Patients without therapeutic education
16558022|NCT02896790||Stage 2|Patients with therapeutic education
16558023|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
16558024|NCT02896777|Experimental|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
16558025|NCT02896777|Experimental|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
16558026|NCT02896764|Experimental|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
16558027|NCT02896751|Experimental|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
16558028|NCT02896725|Experimental|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
16558029|NCT02896725|Active Comparator|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
16558030|NCT02896712|Active Comparator|ACT plus CM|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered to help decrease experiential avoidance while increasing acceptance and willingness to experience unpleasant thoughts, feelings, and physical symptoms.
16558031|NCT02896712|Active Comparator|ACT plus CM, with Placebo|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
16558032|NCT02896712|Experimental|ACT plus CM, with Modafinil|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
16558033|NCT02896712|Active Comparator|DC plus CM|Drug Counseling and Contingency Management for cocaine use will be administered to help educate patients about important concepts in addiction recovery.
16558034|NCT02896712|Active Comparator|DC plus CM, with Placebo|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
16558035|NCT02896712|Experimental|DC plus CM, with Modafinil|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
16558036|NCT02896699|Experimental|PrEP Intervention Group|Group training session including HIV Education, PrEP Education, Following the training session Booster phone calls HIv and syphillis testing
16558037|NCT02896699|Active Comparator|Control Group|Group HIV risk vignettes
16558038|NCT02896686|Active Comparator|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
16558039|NCT02896686|Experimental|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.
~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.
~The skin will be closed using a subcutaneous purse-string closure"
16558040|NCT02896673|Experimental|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.
~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
16558041|NCT02896660|Experimental|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
16558042|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
16558043|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
16558044|NCT02896634||group with none|Selection of samples from biobank with groups with none
16558045|NCT02896634||group with both|Selection of samples from biobank with groups with both.
16558046|NCT02896621|Experimental|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.
~A capsule with both drugs was taken once daily in the morning for eight weeks."
16558047|NCT02896621|Active Comparator|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
16558048|NCT02896608||Dravet syndrome - HCN1 channel mutation|early infantile epileptic encephalopathy with HCN1 channel mutation
16558049|NCT02896608||control with epilepsy|
16558050|NCT02896608||control without epilepsy|
16558051|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
16635447|NCT02378688|Placebo Comparator|Placebo|
16558052|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
16558053|NCT02896582|Experimental|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
16558054|NCT02896569|Experimental|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
16558055|NCT02896569|No Intervention|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
16558056|NCT02896556|Experimental|Resin infiltrate|This is a single-arm study. Resin infiltration technique will be performed to all patients.
16558057|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
16558058|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
16558059|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
16558060|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
16558061|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
16558062|NCT02896491|Experimental|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
16558063|NCT02896491|Experimental|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:
~exposure with TETRA (6W/kg)"
16558064|NCT02896491|Sham Comparator|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
16558065|NCT02896465|Active Comparator|ORS+ZINC|Oral rehydration solution + Zinc
16558066|NCT02896465|Experimental|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
16558067|NCT02896465|Placebo Comparator|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
16558068|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
16558069|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
16558070|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
16558071|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
16558072|NCT02896439|Experimental|Neurophysiological monitoring|
16558073|NCT02896426|Experimental|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
16558074|NCT02896426|Active Comparator|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
16558075|NCT02896413|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
16558076|NCT02896413|Placebo Comparator|Control Group|0.9% saline infusion
16558077|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
16558078|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
16558079|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
16558080|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
16558081|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
16558082|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
16558083|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
16558084|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
16558085|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
16558086|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
16558087|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
16558088|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
16558089|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
16558090|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
16558091|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
16558092|NCT02896400|No Intervention|Control|Control arm, no intervention
16558093|NCT02896374|Experimental|Patients|Treated or hospitalized patients for schizophrenia.
16558094|NCT02896374|Experimental|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
16558095|NCT02896361|Experimental|Stimulation order 1|"Stimulations delivered in following order:
~Standard burst
~Burst Microdosing 1
~Burst Microdosing 2"
16558096|NCT02896361|Experimental|Stimulation order 2|"Stimulations delivered in following order:
~Burst Microdosing 1
~Burst Microdosing 2
~Standard burst"
16558097|NCT02896361|Experimental|Stimulation order 3|"Stimulations delivered in following order:
~Burst Microdosing 2
~Standard burst
~Burst Microdosing 1"
16558098|NCT02896348|Experimental|SynPhNe therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities.
~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system."
16558099|NCT02896348|Active Comparator|Conventional therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities.
~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage."
16558101|NCT02896322|Experimental|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
16558102|NCT02896309|Experimental|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
16558103|NCT02896309|Active Comparator|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
16558104|NCT02896309|No Intervention|No treatment|No treatment
16558105|NCT02896296|Experimental|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.
~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
16558106|NCT02896283|Experimental|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
16558107|NCT02896283|Placebo Comparator|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
16558108|NCT02896270|Experimental|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).
~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).
~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
16558109|NCT02896257|Other|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
16558110|NCT02896257|No Intervention|Usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
16558111|NCT02896231|Experimental|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
16558112|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
16558113|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
16558114|NCT02896205|Experimental|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
16558115|NCT02896205|Placebo Comparator|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
16558116|NCT02896192|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
16558117|NCT02896192|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
16558118|NCT02896179|Experimental|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
16558153|NCT02895867|Experimental|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
16558119|NCT02896179|Active Comparator|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
16558120|NCT02896166|Experimental|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
16558121|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
16558122|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
16558123|NCT02896127|Experimental|Secukinumab|"Secukinumab 150 mg s.c.
~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16"
16558124|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
16558125|NCT02896101|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
16558126|NCT02896101|Active Comparator|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
16558127|NCT02896101|Placebo Comparator|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
16558128|NCT02896088|Other|test tooth groups|test tooth groups
16558129|NCT02896088|Other|control tooth groups|control tooth groups
16558130|NCT02896075|Experimental|Randomized cross-over approach|"The main study was conducted using a randomized controlled cross-over approach. Participants made three visits each for the two video watching interventions. The interventions were separated by a minimum of
~1week as a washout. Each intervention included one day of inducing muscle soreness in one leg through eccentric muscle contractions; a second day of testing muscle soreness and pain tolerance and watching a 30-min video (either a comedy or documentary); and a third day of testing muscle soreness and pain tolerance again to see if the effects of the video viewing persisted the next day (i.e., 24 h after the video viewing)."
16558131|NCT02896062|Experimental|Treatment group|In the treatment phase subjects receive a sleep-coaching
16558132|NCT02896062|Active Comparator|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
16558133|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
16558134|NCT02896036|Experimental|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
16558135|NCT02896036|Active Comparator|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
16558136|NCT02896023|Active Comparator|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
16558137|NCT02896023|Active Comparator|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
16558138|NCT02896010|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
16558139|NCT02896010|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
16558140|NCT02895997|Experimental|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
16558141|NCT02895984|Experimental|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
16558142|NCT02895984|No Intervention|Natural History Control (NHC)|Students in the NHC group will receive no contact.
16558143|NCT02895958|Other|Administration of Zepatier|
16558145|NCT02895932|Experimental|Case|Patients with diagnosed Parkinson's disease
16558146|NCT02895932|Experimental|Control|Healthy adults
16558147|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
16558148|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
16558149|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
16558150|NCT02895893|Experimental|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
16558151|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
16558152|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
16558189|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
16558190|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
16558154|NCT02895867|Experimental|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
16558155|NCT02895867|Other|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
16558156|NCT02895854|Active Comparator|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
16558157|NCT02895854|Active Comparator|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
16558158|NCT02895841|No Intervention|Standard of Care|Patients will continue with their normal Standard of Care for their condition
16558159|NCT02895841|Experimental|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
16558160|NCT02895828|Experimental|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
16558161|NCT02895828|Experimental|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
16558162|NCT02895815|Experimental|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
16558163|NCT02895815|Experimental|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system.
16558164|NCT02895815|No Intervention|Control Group|Participants will undergo observations without surgery.
16558165|NCT02895802|Other|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
16558166|NCT02895802|Other|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
16558167|NCT02895802|Other|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
16558168|NCT02895802|Other|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
16558169|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
16558170|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
16558171|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
16558172|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
16558173|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
16558174|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
16558175|NCT02895750|Experimental|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
16558176|NCT02895750|Experimental|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
16558177|NCT02895750|Experimental|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
16558178|NCT02895737|Other|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
16558179|NCT02895737|Other|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
16558180|NCT02895737|Other|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
16558181|NCT02895737|Other|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
16558182|NCT02895724|Experimental|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
16558183|NCT02895724|No Intervention|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
16558184|NCT02895711||Patients with urolithiasis|To record the effective radiation dose to the patient during endourologic procedures to treat urolithiasis
16558185|NCT02895698|Active Comparator|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
16558186|NCT02895698|Other|Control group|stretching exercise + active dorsiflexion without cupping
16558187|NCT02895685|Experimental|Dyad training|Participants randomized to train in pairs during the whole 6-week course
16558188|NCT02895685|No Intervention|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
16558191|NCT02895659|Active Comparator|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
16558192|NCT02895659|Active Comparator|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
16558193|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
16558194|NCT02895646||Control|No specific clinical investigation for control subjects
16558195|NCT02895633|Experimental|Patients with bone or peripheral soft-tissue tumor|
16558196|NCT02895620|Other|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
16558197|NCT02895555|Active Comparator|Allograft group, standard treatment|Control group, standard treatment. Aprox 50 g pr level fused.
16558198|NCT02895555|Experimental|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Aprox 5 ml pr level fused.
16558199|NCT02895542||Oral Anti-Cancer Agent|No intervention
16558200|NCT02895529|Experimental|Itraconazole|
16558201|NCT02895529|Active Comparator|Caspofungin|
16558202|NCT02895516|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
16558203|NCT02895503|Experimental|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
16558204|NCT02895503|Active Comparator|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
16558205|NCT02895490|Experimental|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
16558206|NCT02895490|Active Comparator|Arm II (control)|Patients receive information about the LINC group.
16558207|NCT02895477|Experimental|Intervention group|Hearing aid
16558208|NCT02895477|Experimental|Test group|Hearing aid
16558209|NCT02895464|Experimental|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
16558210|NCT02895464|Other|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
16558213|NCT02895438|Experimental|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
16558214|NCT02895438|Active Comparator|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
16558215|NCT02895412|Experimental|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.
~Donor-derived WT1-CTL and P-CTL.
~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.
~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
16558216|NCT02895386|Active Comparator|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
16558217|NCT02895386|Sham Comparator|Control Group B|Sham procedure and continuing current antihypertensive medications.
16558218|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
16558219|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
16558220|NCT02895360|Experimental|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
16558221|NCT02895360|Experimental|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
16558222|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
16558223|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
16558224|NCT02895334|Experimental|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
16558226|NCT02895321|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense and Colgate Protection Caries and Placebo gel.
~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.
~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
16558227|NCT02895308|Experimental|Online|The Online psychoeducation is presented on on a webpage.
16558228|NCT02895308|Active Comparator|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
16558229|NCT02895295|Active Comparator|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and will be provided with a list of resources available in the community to help them choose a prescription drug plan.
16558230|NCT02895295|Experimental|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
16558231|NCT02895295|Active Comparator|Individual Analysis|"Participants randomized to Individual Analysis arm will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
16558232|NCT02895269|Experimental|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
16558233|NCT02895269|Active Comparator|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
16558234|NCT02895243|Experimental|Prehabilitation|
16558235|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
16558236|NCT02895217|Experimental|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
16558237|NCT02895217|Experimental|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
16558238|NCT02895204|Experimental|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
16558239|NCT02895204|Placebo Comparator|Placebo group|Placebo supplementation
16558240|NCT02895191|Experimental|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
16558241|NCT02895191|Experimental|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
16558242|NCT02895191|Experimental|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
16558243|NCT02895191|Placebo Comparator|control group|Placebo
16558244|NCT02895178|Experimental|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
16558245|NCT02895178|No Intervention|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
16558246|NCT02895178|Sham Comparator|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
16558247|NCT02895152|Experimental|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
16558248|NCT02895152|No Intervention|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
16558249|NCT02895139|Experimental|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
16558250|NCT02895139|Other|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
16558251|NCT02895139|Other|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
16558252|NCT02895126|Experimental|"Appui Parental program (44 cases)"|
16558253|NCT02895126|Other|Regular parental support (44 cases)|Usual intervention
16558254|NCT02895113|Experimental|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
16558255|NCT02895113|Placebo Comparator|Placebo|Patients will be treated with placebo for one year
16558260|NCT02895087||Cohort 1: Diurnal Variation Group|Cohort recruitment - open to recruitment
16558261|NCT02895087||Cohort 2: External Stress Group|Cohort recruitment - closed to recruitment
16558262|NCT02895074|Experimental|femtosecond laser-assisted cataract surgery group|
16558263|NCT02895074|Experimental|conventional phacoemulsification surgery group|
16558264|NCT02895061|Experimental|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
16558265|NCT02895061|Experimental|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
16558266|NCT02895048||Chronic heart failure|
16558267|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
16558268|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
16558269|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
16558270|NCT02895022|Experimental|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
16558271|NCT02895009|Other|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
16558272|NCT02895009|Experimental|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
16558273|NCT02894996|Other|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
16558274|NCT02894983|Other|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
16558275|NCT02894983|Other|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
16558276|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
16558277|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
16558278|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
16558279|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
16558280|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
16558281|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
16558282|NCT02894957|Experimental|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.
~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
16558283|NCT02894957|Active Comparator|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
16558284|NCT02894944|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
16558285|NCT02894931|Sham Comparator|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
16558286|NCT02894931|Active Comparator|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
16558287|NCT02894931|Experimental|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
16558288|NCT02894931|Experimental|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
16558289|NCT02894931|Experimental|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
16558290|NCT02894931|Experimental|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
16558291|NCT02894931|Experimental|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
16558292|NCT02894931|Experimental|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
16558293|NCT02894931|Experimental|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
16558294|NCT02894931|Experimental|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
16558295|NCT02894931|Experimental|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
16558296|NCT02894931|Experimental|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
16558297|NCT02894931|Experimental|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
16558862|NCT02890758|Active Comparator|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
16558298|NCT02894931|Experimental|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
16558299|NCT02894931|Experimental|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
16558300|NCT02894918|Experimental|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
16558301|NCT02894918|No Intervention|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
16558302|NCT02894905|Experimental|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2*400-mg tablets).
16558303|NCT02894905|Experimental|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
16558304|NCT02894905|Experimental|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
16558305|NCT02894905|Experimental|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
16558306|NCT02894892|Active Comparator|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
16558307|NCT02894892|Active Comparator|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
16558308|NCT02894892|Active Comparator|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
16558309|NCT02894892|Active Comparator|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
16558310|NCT02894892|Active Comparator|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
16558311|NCT02894892|Active Comparator|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
16558312|NCT02894892|Other|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
16558313|NCT02894879|Experimental|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
16558314|NCT02894879|Sham Comparator|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
16558315|NCT02894866|Experimental|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
16558316|NCT02894866|No Intervention|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
16558317|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
16558318|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
16558319|NCT02894827||EMS|
16558320|NCT02894827||Control|
16558321|NCT02894814|Active Comparator|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
16558322|NCT02894814|Active Comparator|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
16558323|NCT02894814|No Intervention|Observational part of the study|Data collection on patients under the traditional medication system
16558324|NCT02894788||ICU|patients postoperatively admitted to ICU
16558325|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
16558326|NCT02894775||included in a clinical trial|
16558327|NCT02894775||not included in a clinical trial|
16558328|NCT02894749|No Intervention|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
16558329|NCT02894749|Experimental|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
16558330|NCT02894736|Experimental|Active tDCS|Soterix tDCS machine is used to administer active stimulation
16558331|NCT02894723|Active Comparator|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
16558332|NCT02894723|Placebo Comparator|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
16558333|NCT02894710|Experimental|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
16558334|NCT02894710|Placebo Comparator|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
16558335|NCT02894697|Active Comparator|Angiography-guidance|
16558336|NCT02894697|Experimental|OCT-guidance|
16558459|NCT02893709|Experimental|Omeprazole|A course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
16558337|NCT02894684|Experimental|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
16558338|NCT02894684|Active Comparator|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
16558339|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
16558340|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
16558341|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
16558342|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
16558343|NCT02894658|Experimental|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
16558344|NCT02894658|Active Comparator|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
16558345|NCT02894645|Other|Standard Risk (SR)|
16558346|NCT02894645|Other|Intermediate Risk (IR)|
16558347|NCT02894645|Other|High risk (HR)|
16558348|NCT02894632|Experimental|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
16558349|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
16558350|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
16558351|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16558352|NCT02894593|Active Comparator|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16558353|NCT02894593|Placebo Comparator|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16558354|NCT02894593|Experimental|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
16558355|NCT02894567|Experimental|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
16558356|NCT02894554|Placebo Comparator|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
16558357|NCT02894554|Active Comparator|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
16558358|NCT02894541|Experimental|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
16558359|NCT02894541|Experimental|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
16558360|NCT02894541|Experimental|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
16558361|NCT02894541|Experimental|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
16558362|NCT02894528|Experimental|Ridge Preservation (Test Group)|
16558363|NCT02894528|Active Comparator|Ridge Preservation (Control Group)|
16558364|NCT02894515|Experimental|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
16558365|NCT02894515|Experimental|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
16558366|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
16558367|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
16558368|NCT02894502|No Intervention|Control group|This Group will receive the usual care
16558369|NCT02894489|Experimental|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
16558370|NCT02894489|Experimental|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
16558371|NCT02894437||patients|SCI recruited Physical Medicine and Nantes University Hospital Rehabilitation. Recruitment will try to balance the number of people in four sub-groups followed and complicated (= history of pelvic pressure sores), not followed and uncomplicated, monitored and uncomplicated, not followed and complicated
16558372|NCT02894437||health professionals|those involved in the chain of care Spinal Cord concerning various professions (including medical, paramedical and administrative) decision and variable influence on the organization of the die care of spinal injuries.
16558373|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
16558374|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
16558488|NCT02893449|Other|CG group: Control Group|No supplementary support
16558375|NCT02894398|Experimental|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
16558376|NCT02894385|Experimental|Part 1 - Subjects with severe renal impairment|Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
16558377|NCT02894385|Experimental|Part 1 - Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
16558378|NCT02894385|Experimental|Part 1 - Healthy subjects|Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
16558379|NCT02894372|Experimental|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
16558380|NCT02894372|Experimental|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
16558381|NCT02894359||CD patients|10 patients with a cervical dystonia
16558382|NCT02894359||control subjects|10 healthy patients
16558383|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
16558384|NCT02894333||Patients with Parkinson's disease|
16558385|NCT02894320||Parkinson's disease|
16558386|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
16558387|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
16558388|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
16558389|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
16558390|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
16558391|NCT02894268|Experimental|Regimen A|esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg
16558392|NCT02894268|Active Comparator|Regimen B|two sensitivity antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg
16558393|NCT02894255|Experimental|PCI and CABG|
16558394|NCT02894242|Experimental|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
16558395|NCT02894229|No Intervention|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
16558396|NCT02894229|Active Comparator|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
16558397|NCT02894229|Active Comparator|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
16558398|NCT02894203|Experimental|Mindfulness|
16558399|NCT02894203|Active Comparator|Hatha Yoga|
16558400|NCT02894203|No Intervention|Wait-list|
16558401|NCT02894177|Experimental|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
16558402|NCT02894151|Active Comparator|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.
~It was inserted only first time entry in the study."
16558403|NCT02894151|Active Comparator|DMPA|DMPA was given in trimonthly intramuscular injection.
16558404|NCT02894138|Experimental|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
16558405|NCT02894138|Placebo Comparator|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
16558406|NCT02894138|No Intervention|Observational|10 patients with IMR <30 will undergo the same follow-up as the randomised patients
16558407|NCT02894125||old subject|
16558408|NCT02894112|Experimental|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
16558409|NCT02894112|Experimental|High fat tolerance test|single high fat load determined by body weight.
16558410|NCT02894099|Experimental|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
16558411|NCT02894099|Experimental|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
16558412|NCT02894099|Experimental|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
16558413|NCT02894099|Experimental|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
16558414|NCT02894073|No Intervention|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
16558415|NCT02894073|Experimental|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
16558416|NCT02894060|Experimental|blood|blood tests
16558417|NCT02894021|Active Comparator|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
16558418|NCT02894021|Experimental|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
16558419|NCT02894008|Experimental|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
16558420|NCT02894008|Experimental|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
16558421|NCT02893995|Experimental|Slow Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
16558489|NCT02893436||Curarized patients|
16558422|NCT02893995|Experimental|Rapid Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.
16558423|NCT02893982|Experimental|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
16558424|NCT02893969|Experimental|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
16558425|NCT02893969|Sham Comparator|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
16558426|NCT02893956|Experimental|echocardiography with postural support then standard condition|the first echocardiography (ultrasound) is performed with a postural support then the second echocardiography is performed with standard condition
16558427|NCT02893956|Active Comparator|echocardiography with standard condition then support postural|the first echocardiography (ultrasounds) is performed with standard condition (usual) and the second echocardiography is performed with a postural support
16558428|NCT02893943|Active Comparator|Probiotics|1 capsule per day containing probiotics
16558429|NCT02893943|Placebo Comparator|Placebo|1 capsule per day without probiotics
16558430|NCT02893930|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16558433|NCT02893904|Experimental|Propofol|General anesthesia by TCI Propofol and Remifentanil guided by BIS EEG monitoring intervention
16558434|NCT02893904|Experimental|Sevoflurane|General anesthesia by Sevoflurane and Remifentanil guided by BIS EEG monitoring intervention
16558435|NCT02893891|Active Comparator|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
16558436|NCT02893891|Active Comparator|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
16558437|NCT02893891|Active Comparator|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
16558438|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
16558439|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
16558440|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
16558443|NCT02893852|Active Comparator|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
16558444|NCT02893852|Experimental|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
16558445|NCT02893839|Other|Prick to prick|
16558446|NCT02893826|Experimental|EG-1962 Group|1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
16558447|NCT02893826|Active Comparator|Enteral Nimodipine Group|Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)
16558448|NCT02893800|Other|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
16558449|NCT02893800|Other|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
16558450|NCT02893787||Patients treated with anthracyclines in childhood|
16558451|NCT02893787||Healthy volunteers|
16558452|NCT02893774|Experimental|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
16558453|NCT02893748|Active Comparator|1: HyGIeaCare Prep and Colonoscopy|"Patients will receive:
~HyGIeaCare Prep
~Colonoscopy"
16558454|NCT02893748|Active Comparator|2: Split-dose PEG Prep and Colonoscopy|"Patients will receive:
~Split-dose PEG
~Colonoscopy"
16558455|NCT02893735|Active Comparator|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
16558456|NCT02893735|Active Comparator|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
16558457|NCT02893722|Experimental|atosiban|"Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute.
~Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg.
~Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg."
16558458|NCT02893722|Placebo Comparator|0.9% salain|intravenous injection of 0.9% saline in one minute before transfer. Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
16558460|NCT02893696|Active Comparator|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
16558461|NCT02893696|Active Comparator|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
16558462|NCT02893670|Other|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:
~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
16558463|NCT02893618|Experimental|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
16558464|NCT02893618|Experimental|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
16558465|NCT02893618|Experimental|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
16558466|NCT02893618|Experimental|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
16558467|NCT02893618|Experimental|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
16558468|NCT02893605||Cases|Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
16558469|NCT02893605||Controls|Controls correspond to spouses/partners of patients.
16558470|NCT02893579|Experimental|Early Intervention|Stress reduction intervention 1 time a month
16558471|NCT02893579|Experimental|Delayed Intervention|Wait list Control
16558472|NCT02893566|Experimental|Mi Band Step Challenge|
16558473|NCT02893553|Experimental|Study 1|Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
16558474|NCT02893553|Experimental|Study 2|Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
16558475|NCT02893540|Experimental|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
16558476|NCT02893540|Active Comparator|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
16558477|NCT02893527|Experimental|"Group intervention"|Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
16558478|NCT02893527|No Intervention|"Group standard"|conventional support
16558479|NCT02893514|Placebo Comparator|Screening Only (SO)|
16558480|NCT02893514|Experimental|Substance Use Screening and Intervention Tool (SUSIT)|
16558481|NCT02893488|Experimental|SEQUENCE ABCDE|Participants will receive treatment A in period 1, treatment B in period 2, treatment C in period 3, treatment D in period 4 and treatment E in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with zero mineral content (ZMC) water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 milliliter (mL) stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 minutes(mins), re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
16558482|NCT02893488|Experimental|SEQUENCE BCDEA|Participants will receive treatment B in period 1, treatment C in period 2, treatment D in period 3, treatment E in period 4 and treatment A in period 5 (one treatment per period). Where A= EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
16558483|NCT02893488|Experimental|SEQUENCE CDEAB|Participants will receive treatment C in period 1, treatment D in period 2, treatment E in period 3, treatment A in period 4 and treatment B in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
16558484|NCT02893488|Experimental|SEQUENCE DEABC|Participants will receive treatment D in period 1, treatment E in period 2, treatment A in period 3, treatment B in period 4 and treatment C in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
16558485|NCT02893488|Experimental|SEQUENCE EABCD|Participants will receive treatment E in period 1, treatment A in period 2, treatment B in period 3, treatment C in period 4 and treatment D in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
16558486|NCT02893449|Other|SICRPPD group|(Specific Individual Cognitive Remediation Program in Parkinson's Disease). Group of patients profiting from a structured program of preoperative cognitive remediation
16558487|NCT02893449|Other|ICM group: Intensive Care Management|Group of patients profiting from a preoperative non structured support
16558490|NCT02893423|Active Comparator|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
16558491|NCT02893423|Active Comparator|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
16558492|NCT02893423|No Intervention|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
16558493|NCT02893397|Experimental|Group I (supervised exercise)|Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
16558494|NCT02893397|Experimental|Group II (fitbit)|Patients wear a fitbit.
16558495|NCT02893384|Experimental|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.
~Local Anesthetic Injection above the serratus anterior"
16558496|NCT02893384|No Intervention|Control Arm|Retrospective control group who have not had the new injection technique.
16558497|NCT02893358|Active Comparator|Active treatment|Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP<130/80 mmHg, and daytime BP <135/85 mmHg, and nighttime BP <120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.
16558498|NCT02893358|Placebo Comparator|Placebo|Placebo tablets are identical to the active study drugs, with a similar schedule of administration.
16558499|NCT02893345|Experimental|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
16558500|NCT02893345|Active Comparator|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
16558501|NCT02893332|Active Comparator|TKI without SBRT|"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.
~The oligometastatic disease will not receive SBRT"
16558502|NCT02893332|Experimental|TKI with SBRT|"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.
~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions."
16558503|NCT02893319|No Intervention|Breastfeeding|control group
16558504|NCT02893319|Active Comparator|5 oz bottle|Subject will feed infant with 5oz medela bottle
16558505|NCT02893319|Active Comparator|8 oz bottle|Subject will feed infant with 8oz medela bottle
16558506|NCT02893306|Experimental|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
16558507|NCT02893293|Active Comparator|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
16558508|NCT02893293|Sham Comparator|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
16558509|NCT02893267|Experimental|PNS + PT|The PNS+PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
16558510|NCT02893267|Active Comparator|PNS + sham-PT|The PNS + sham-PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of sham outpatient physical therapy not focused on shoulder pain over the same four week period.
16558511|NCT02893267|Active Comparator|sham-PNS + PT|The sham-PNS + PT Group will receive sham peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
16558512|NCT02893254|Experimental|IBI303|IBI303 40mg administered subcutaneously every other week, 12cycles
16558513|NCT02893254|Active Comparator|Adalimumab|Adalimumab 40mg administered subcutaneously every other week
16558514|NCT02893241||Cohort A|Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
16558515|NCT02893241||Cohort B|Patients, who undergo caesarean section under spinal anaesthesia
16558516|NCT02893228|Experimental|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
16558517|NCT02893228|Active Comparator|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
16558614|NCT02892513|Experimental|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
16558518|NCT02893215||Heart failure|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
16558519|NCT02893215||Diabetes mellitus II|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
16558520|NCT02893202|Experimental|Ride On Center for Kids (ROCK) facility|8-week therapeutic horseback riding
16558521|NCT02893202|Experimental|Triple H Equitherapy Facility|8-week therapeutic horseback riding
16558522|NCT02893202|Experimental|Rainer Therapeutic Riding facility|8-week therapeutic horseback riding
16558523|NCT02893202|Experimental|REACH Therapeutic Riding facility|8-week therapeutic horseback riding
16558524|NCT02893202|Experimental|Courtney Cares Riding facility|8-week therapeutic horseback riding
16558525|NCT02893189|Experimental|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
16558526|NCT02893176|Placebo Comparator|Placebo|10mg will be administered one time daily
16558527|NCT02893176|Active Comparator|Active|10mg macitentan will be administered one time daily
16558528|NCT02893163|Experimental|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
16558529|NCT02893163|Active Comparator|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
16558530|NCT02893150|Active Comparator|TAU (treatment as usual)|The Treatment as Usual (TAU) will be considered as following: 1) In the cases of individuals presenting overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, primary care teams propose the improvement of the life style (more physically active, and with a better eating behaviour) in order to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²). 2) For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities (psycho-education), it is evaluated the need for individual dietary prescription by a nutritionist.
16558531|NCT02893150|Active Comparator|TAU+MBHP|"The Mindfulness-based Health Promotion (MBHP) developed by our research group (generic protocol) will be adapted from the Mindfulness-based Stress Reduction program (MBSR), It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems], which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice."
16558532|NCT02893150|Experimental|TAU+MB-EAT|The Mindfulness-based Eating Awareness (MB-EAT) protocol consists in ten weekly sessions of 2,5 hour to improve compulsive eating, and to promote conscious eating.
16558533|NCT02893137|Experimental|Craniectomy and Optune|Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
16558534|NCT02893124|Experimental|PEG-IFN group|HBeAg-negative CHB patients with HBsAg <1000 IU/ mL and HBV DNA<100 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
16558535|NCT02893124|No Intervention|NAs group|CHB patients do not need to change their NAs treatment.
16558536|NCT02893111|Experimental|Bortezomib (Velcade)|A proteasome inhibitor
16558537|NCT02893098|Experimental|Humia inj.|Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.
16558538|NCT02893098|Active Comparator|High Hyal Plus inj.|Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks
16558539|NCT02893085||patients with malignant biliary stricture|
16558540|NCT02893085||patients with benign biliary diseases|
16558541|NCT02893072|Experimental|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
16558542|NCT02893046||Population at Risk|Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.
16558543|NCT02893046||Prison population|"Proposal of participation to a  consultation arrivants  by the staff of medical units correctional"
16558544|NCT02893033|Experimental|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
16558545|NCT02893033|Sham Comparator|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
16558615|NCT02892513|Sham Comparator|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
16558670|NCT02892071|Active Comparator|22% TCA peel|22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
16558863|NCT02890745|Experimental|Empagliflozin|One tablet 25 mg empagliflozin every morning for 14 days
16558546|NCT02893007|Experimental|Brief family-centered care program|The Brief family-centered care (BFCC) program was developed and provided for hospitalized patients with BPD and their family caregivers.The BFCC protocol is outlined as 4 treatment sessions, specific goals, and example questions. Four 90-minute in-depth sessions for each dyad were initially held in a quiet interview room to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
16558547|NCT02893007|No Intervention|treatment-as-usual (TAU)|All patients were given the standard hospital-provided services: psychiatric nursing care, occupational therapy, and pharmacotherapy. All of the family caregivers were only to attend a routine 60-minute family discussion group about violence and suicide prevention without any specific patient-family dyad interview.
16558548|NCT02892994|Experimental|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm^2 and 100% duty cycle on each masseter muscle.
16558549|NCT02892994|Placebo Comparator|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
16558550|NCT02892981|Other|Pulmonary hypertension patients|All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests
16558551|NCT02892968|Experimental|U/S Guided Regional Anesthesia|"Fascia-Iliaca Block(FIB) Femoral Nerve Block(FNB)
~All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. EPs will then be trained to use two approaches to ultrasound (U/S) guided regional anesthesia, the fascia iliaca and femoral nerve blocks. Which block that will be used will be randomly determined at the individual patient level"
16558552|NCT02892968|No Intervention|Current Local Standard Analgesia|"All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. Physicians who are in the control group will provide current local standard of analgesic care for hip fracture patients such as the use of IV opiods with supplemental acetaminophen and non-steroidal anti-inflammatory agents until they receive training."
16558553|NCT02892955|Experimental|HeartMate 3 LVAS (HM3 LVAS)|The study will be a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
16558554|NCT02892942|Active Comparator|Control Group|"Background therapy which is the usual COH treatment:
~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,
~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®."
16558555|NCT02892942|Experimental|NATOS Group|"Background therapy which is the usual COH treatment:
~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,
~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®.
~GnRH antagonist treatment (Cetrotide®, MerckSerono Pharmaceuticals) will be reinforced and patients will receive 1.5 mg/day (6 ampoules of 0.25 mg), S.C., starting on day 1 (S1) of Gonal-F® treatment until dhCG"
16558556|NCT02892929|Experimental|Motivational Interviewing|The motivational interview is a style of care that evokes the patient their motivations to make behavioral changes in the interests of their own health. It is a technique centered in patient to explore and resolve their ambivalence to modify unhealthy behavior.
16558557|NCT02892929|Active Comparator|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation. In this type of consultation the health professional who plans the action plan for the patient and determines how it will be the patient's lifestyle modification.
16558558|NCT02892916|Experimental|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
16558559|NCT02892916|Placebo Comparator|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
16558560|NCT02892903|No Intervention|Conventional angiography|Routine angiography will be performed according to local best practice
16558561|NCT02892903|Experimental|Routine Measurement of FFR|Additional investigation with the measurement of FFR in all major vessels
16558562|NCT02892890|Experimental|patients with CIDP|
16558563|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
16558564|NCT02892877||Invasive mole|
16558565|NCT02892877||Choriocarcinoma|
16558566|NCT02892877||Post-molar neoplasia|
16558567|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
16558568|NCT02892864|Active Comparator|Control arm|Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
16558569|NCT02892864|Experimental|Experimental Virtual Arm|Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
16558570|NCT02892851|Experimental|Deep brain stimulation (DBS)|Deep brain stimulation of the subthalamic nuclei (STN-DBS)
16558571|NCT02892838|Experimental|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
16558572|NCT02892838|Active Comparator|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
16558573|NCT02892825|Experimental|music group|music listening
16558574|NCT02892825|Active Comparator|no music group|no music listening
16558575|NCT02892812|Experimental|LBVE013|13-valent pneumococcal conjugate vaccine
16558576|NCT02892812|Experimental|LBVE014|14-valent pneumococcal conjugate vaccine
16558577|NCT02892812|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
16558578|NCT02892799|Active Comparator|Standard of Care|Patients randomized to the usual care arm will be treated almost the same as if they do not enroll in the study. They will be managed in accordance with best ICU (intensive care unit) practices, with treatment decisions made by the treating team. Often this will include blood draws (often 2 teaspoons once or twice per day, but sometimes exceeding this), assessments of cardiac function, assessments of fluid status, and other measures as dictated by the presenting illness (this is broad and will include antibiotics, diuretics, cardiac medications, ventilator and oxygen management, etc.). Patients in the usual care arm will not have diuresis managed by NICOM.
16558579|NCT02892799|Experimental|NICOM-Guided Diuresis|"Within 4 hours, patients will have their blood pressure obtained, a NICOM-based assessment of PLR (passive leg raise)-induced change in cardiac index, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7 am). This will allow determination of the fluid goal over the next 4 hours. Patients will receive furosemide to achieve the goal fluid balance, if needed as described in the accompanying protocol. Monitoring of electrolytes and renal function will be at the discretion of the treating physician.
~Following the initial evaluation, at set times spaced every 4 hours apart, patients will have an ongoing evaluation of the day's fluid balance, hourly urinary output, and PLR/NICOM values. This diuresis protocol will continue for a total of seven 24-hour periods or until the primary means of oxygenation/ventilation has been withdrawn, whichever occurs first. Patients will be followed for a total of 60 days to evaluate outcome data."
16558580|NCT02892786|Experimental|experimental|
16558581|NCT02892773|Other|Incentive Spirometry Group|"Participant will be asked to take 10 deep breaths through the mouthpiece of an incentive spirometer, followed by a 60 second pause.
~This cycle will be repeated two more times.
~A Respiratory Therapist will coach participants three times per day.
~Each duration of Incentive Spirometry will last about 15 minutes."
16558582|NCT02892773|Active Comparator|EzPAP® Positive Airway Pressure Group|"Participant will be coached by a Respiratory Therapist to breathe through the mouthpiece of an EzPAP® device for 10 breaths, followed by a 60 second pause.
~This cycle will be repeated two more times.
~The Respiratory Therapist will coach participants three times per day.
~Each duration of EzPAP® therapy will last about 15 minutes."
16558583|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
16558584|NCT02892747|Experimental|Educational Program for prevention of malnutrition|In addition to the usual nutritional assessment, the patients in the experimental arm benefit of a personalized educational program for prevention of malnutrition. This program aims to monitor energy and protein intake in addition to managing sodium intake, notably by offering personalized menu ideas and recipes.
16558585|NCT02892747|No Intervention|Control|In the control arm, patients are followed-up by the cardiologist and the nutritionist, and did not benefit of the personalized educational program for prevention of malnutrition.
16558586|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
16558587|NCT02892721|No Intervention|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
16558588|NCT02892721|Other|Training with feedback|See intervention description
16558589|NCT02892708|Active Comparator|Surgery|Surgical resection followed by radiation therapy
16558590|NCT02892708|Experimental|radiotherapy alone|radiotherapy after a brain biopsy
16558591|NCT02892695|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
16558592|NCT02892682|Other|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
16558593|NCT02892682|Other|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
16558594|NCT02892682|Other|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
16558595|NCT02892682|Other|ARM 4 US|Arm of superficial nettle rashes: blood test
16558596|NCT02892669||patients admitted to the intensive care department|
16558597|NCT02892643|Experimental|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
16558598|NCT02892643|Active Comparator|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
16558599|NCT02892630||Pregnant ITP women|Pregnant women more than 18 years old, with primary ITP diagnosis before pregnancy
16558600|NCT02892630||Control ITP Women (Non pregnant)|Primary ITP women more than 18 years old, at more than one year from a precedent pregnancy
16558601|NCT02892630||De novo ITP pregnant women|Pregnant women more than 18 years old, with newly diagnosed thrombocytopenia during pregnancy
16558602|NCT02892617||Group 1|Patients with low back pain lasting for more than 6 months, debilitating, with the presence of type 1 Modic disc disease on MRI at the operated disc, eligible for a disc prosthesis or arthrodesis anterior approach
16558603|NCT02892617||Group 2|Patients underwent surgery for nerve root pain by disc herniation on MRI viewable with a radio-clinical concordance with or without Modic 1 disc disease in the operated disc
16558604|NCT02892604|Experimental|insulin delivery driven by inControl|"Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.
~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data."
16558605|NCT02892591|Experimental|Cannabis|Medium dose THC, single administration, vaporized
16558606|NCT02892591|Active Comparator|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
16558607|NCT02892591|Placebo Comparator|Placebo|No active study drug
16558608|NCT02892578|Experimental|electrocardiogram|Patient will take an electrocardiogram in order to detect atrial fibrillation
16558609|NCT02892565|Experimental|Cases|Patients with SLE and/or APL and first vein thrombosis episode
16558610|NCT02892565|Other|Controls|age-matched; Patients with SLE and/or APL
16558611|NCT02892552|Experimental|Cone Beam|Patients included will have first a MultiSlice Computed tomography (MSCT) as usual and then a Cone Beam Computed Tomography (CBCT)
16558612|NCT02892526||Vital wounds|from abdominoplasty of alive persons
16558613|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
16558616|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
16558617|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
16558618|NCT02892487|Experimental|Early active swallowing therapy|
16558619|NCT02892487|No Intervention|Usual care|
16558620|NCT02892474||Hybrid Coronary Revascularization (HCR)|Patients who are scheduled to have the hybrid coronary revascularization (HCR) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
16558621|NCT02892474||Coronary Artery Bypass Grafting (CABG)|Patients who are scheduled to have the coronary artery bypass grafting (CABG) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
16558622|NCT02892461|Experimental|Umbilical cord milking|The cord will be cut at 25 cm from the umbilical stump within 30 seconds after the infant is taken out from the uterus and its blood will be milked to the infant gently and thoroughly in 30 seconds during resuscitation on the radiant warmer, and then the cord will be cut at 2 to 3 cm from the umbilical stump.
16558623|NCT02892461|No Intervention|Routine clinical treatment and care|The cord will be dealt with routine clinical method, which means it will be cut twice within 1minute after the infant is taken out from the uterus, the first cut is on the operating table, while the second cut is on the radiant warmer.
16558624|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
16558625|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
16558626|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
16558627|NCT02892435|Experimental|Prevena arm|patients underwent to contaminated/dirty surgery who positioned incisional negative pressure wound therapy and kept for six days
16558628|NCT02892435|Active Comparator|Control arm|patients underwent to contaminated/dirty surgery who positioned conventional dressing
16558629|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
16558630|NCT02892409|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
16558631|NCT02892409|Experimental|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
16558632|NCT02892396||COPD patients & conventional cigarettes|COPD patients regular smokers of conventional cigarettes with no desire to quit smoking habit.
16558633|NCT02892396||COPD patients & electronic cigarettes|COPD patients who had been users of electronic cigarettes for at least 8 weeks. They will be provided with an specific type of electronic cigarette and the same dosage of inhaled nicotine.
16558634|NCT02892370|Experimental|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
16558635|NCT02892370|Experimental|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
16558636|NCT02892357|Experimental|Treatment group|Participants in this group take the herbal compound of Jianpi Qinghua granules and half-dose omeprazole tablet.Jianpi Qinghua granule:one bag after 1 hour of breakfast and supper(twice a day) for 4 weeks.Half-dose omeprazole tablet:1 tablet of real omeprazole (10mg) and 1 tablet of Sham(10mg),once a day before breakfast for 4 weeks.
16558637|NCT02892357|Active Comparator|Control group|Participants in this group take the sham herbal granules twice a day as treatment group and two pieces of real omeprazole tablet(10mg each) once a day before breakfast for 4 weeks.
16558638|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
16558639|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
16558640|NCT02892331|No Intervention|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
16558641|NCT02892331|Experimental|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
16558642|NCT02892331|Experimental|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
16558643|NCT02892318|Experimental|Cohort A1: Safety Cohort (Relapsed/refractory AML)|An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams [mg] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter [mg/m^2] subcutaneously [SC] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
16558864|NCT02890745|Placebo Comparator|Placebo|One tablet placebo every morning for 14 days
16558644|NCT02892318|Experimental|Cohort A2: Expansion Cohort (Relapsed/refractory AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
16558645|NCT02892318|Experimental|Cohort A3: Safety Cohort (Previously Untreated AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
16558646|NCT02892318|Experimental|Cohort A4: Expansion Cohort (Previously Untreated AML)|If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
16558647|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
16558648|NCT02892279|Experimental|Diesel exhaust exposure|A single arm study in which first a baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute diesel exhaust will start.
16558649|NCT02892266||Adolescent Transplant Recipients|"Questionnaire battery at enrollment (Participants and their parents/guardians)
~Clinical data from patient's chart (6 months of retrospective data & 6 months of prospective tacrolimus trough level data)"
16558650|NCT02892253|Experimental|NIR+ group|"Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND).
~Parathyroid identification was done with the use of NIR (intervention group, NIR+ group)"
16558651|NCT02892253|No Intervention|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
16558652|NCT02892227|Experimental|JET ECHO|Transmitral flow estimation
16558653|NCT02892227|No Intervention|NO JET ECHO|no bedside echocardiography
16558654|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
16558655|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
16558656|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
16558657|NCT02892201|Experimental|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation
~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
16558658|NCT02892162|Experimental|With additional LAAW linear ablation|Patients who undergo CPVI+LA roof linear ablation+/ MI linear ablation, and additional LAAW linear ablation using ThermoCool SmartTouch catheter.
16558659|NCT02892162|Active Comparator|Without additional LAAW linear ablation|Patients who undergo CPVI+LA roof +/ MI linear ablation using ThermoCool SmartTouch catheter, without LAAW linear ablation.
16558660|NCT02892149|Experimental|Vadadustat|
16558661|NCT02892149|Active Comparator|darbepoetin alfa|
16558662|NCT02892123|Experimental|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
16558663|NCT02892110|Experimental|Varenicline|2 mg daily
16558664|NCT02892110|Placebo Comparator|Placebo|2 mg daily
16558665|NCT02892097|Active Comparator|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
16558666|NCT02892097|Active Comparator|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
16558667|NCT02892097|Sham Comparator|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
16558668|NCT02892084|Experimental|Uphill COMa training|Walking on an inclined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
16558669|NCT02892084|Experimental|Downhill COMa training|Walking on a declined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
16558865|NCT02890732|Experimental|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
16558671|NCT02892071|Active Comparator|CO2 laser|CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
16558672|NCT02892071|Active Comparator|Qs-NdYAG laser|Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
16558673|NCT02892045||MMG versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus Mechanomyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg.
16558674|NCT02892045||TOFWatch versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus TOF-Watch Acceleromyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg
16558675|NCT02892032|Experimental|Attention Modification Training|ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful
16558676|NCT02892032|Placebo Comparator|No Attention Modification Training|There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen.
16558677|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
16558678|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
16558679|NCT02892006|Experimental|Intervention|All participants in the study will participate a 6 week improv intervention.
16558680|NCT02891993|Experimental|IMPROVED Intervention|"Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.
~The clinical team will view reports detailing their patients' symptom burden
~Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
16558681|NCT02891993|Active Comparator|Usual Care|"Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer
~Patients will report their symptoms to their clinicians as they usually would
~Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
16558682|NCT02891980|Experimental|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
16558683|NCT02891980|Experimental|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
16558684|NCT02891980|Experimental|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
16558685|NCT02891980|Experimental|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
16558686|NCT02891967|Other|Bulk full composite (3M)|bulk fill composite in posterior class one cavities
16558687|NCT02891967|Other|Incremental packing composite resin|Nano resin composite (K Z350 xt) restoration in class one cavities
16558688|NCT02891954|Experimental|Single arm|Healthy volunteers will receive canagliflozin to assess pharmacodynamic responses to drug.
16558689|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
16558690|NCT02891928|Experimental|with rocker sole|patient were wearing the rocker soles shoes during investigation
16558691|NCT02891928|Placebo Comparator|without rocker sole|patient were wearing normal shoes during investigation
16558692|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
16558693|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
16558694|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
16558695|NCT02891850|Experimental|Riociguat|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
16558696|NCT02891850|Active Comparator|PDE-5i|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
16558697|NCT02891837|Experimental|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;
~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;
~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;
~9 mg/kg/hr continuous infusion for up to 48 hours."
16558698|NCT02891837|Placebo Comparator|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;
~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;
~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;
~9 mg/kg/hr continuous infusion for up to 48 hours."
16558699|NCT02891824|Placebo Comparator|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:
~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
16558700|NCT02891824|Experimental|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:
~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression
~."
16558701|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
16558702|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
16558866|NCT02890719|Experimental|Genotype 1B|treatment 12 weeks
16558867|NCT02890719|Experimental|Genotype 1A and 4|treatment 16 weeks
16558703|NCT02891798|Experimental|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
16558704|NCT02891798|Active Comparator|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
16558705|NCT02891785|Experimental|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
16558706|NCT02891785|No Intervention|standard care|Standard care will be described as part of the study.
16558707|NCT02891772||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
16558708|NCT02891759|Experimental|Group A: Alloderm RTU|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.
~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group A will receive Alloderm RTU
~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
16558709|NCT02891759|Experimental|Group B: Cortiva 1mm Allograft Dermis|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.
~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis
~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
16558710|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
16558711|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
16558712|NCT02891720|Active Comparator|ARM A: Proteus Sensor System (PSS) First|ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
16558713|NCT02891720|No Intervention|ARM B: SOC First|ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
16558714|NCT02891707|Active Comparator|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
16558715|NCT02891707|Active Comparator|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
16558716|NCT02891694||recurrent corneal erosion|
16558717|NCT02891694||control patients (refractive surgery)|
16558718|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.
~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.
~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
16558719|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.
~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.
~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
16558720|NCT02891668||Hypothyroid|Levothyroxine treatment
16558721|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
16558722|NCT02891655||surgery for keratoconus|
16558723|NCT02891655||refractive surgery (control patients)|
16558724|NCT02891642||Malignancy, Serous effusion|Analysis of serous effusion through immunomagnetic detection device
16558725|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
16558726|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
16558727|NCT02891616|Experimental|FDG-PET/CT + FLT-PET/CT + PET/MR|"-Baseline, Week 3 (between days 14-20), Week 6 (between days 35-41)
~FDG-PET/CT - Patients required to fast for at least 4 hours prior to FDG administration. Roughly 60 minutes prior to PET/CT imaging, FDG will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.
~FLT-PET/CT - Patients required to fast for at least 4 hours prior to FLT administration. Roughly 80 minutes prior to PET/CT imaging, FLT will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.
~PET/MR - A limited whole body scan performed immediately following PET/CT imaging when possible. Should be performed at least once at each time-point. This scan will be of a more limited area and be performed for no more than 30 minutes."
16558762|NCT02891408|Experimental|Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
16558900|NCT02890472||prenatal diagnosis of a fetal 22q11 deletion syndrome|
16558728|NCT02891603|Experimental|Pacritinib with Sirolimus and Tacrolimus|"Pacritinib added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).
~Pacritinib will begin the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant.
~Sirolimus will be given the day before transplant and continued daily for at least one year.
~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
16558729|NCT02891590|Experimental|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
16558730|NCT02891564|Placebo Comparator|Control Arm (R 33)|a mobile 3D video game to be used as placebo.
16558731|NCT02891564|Experimental|Intervention Arm (R 33)|a mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
16558732|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
16558733|NCT02891538|Experimental|epigallocatechin gallate (EGCG)|Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.
16558734|NCT02891538|No Intervention|Observation Only|Standard of care surgical resection followed by standard of care colonoscopy at year.
16558735|NCT02891525|Active Comparator|50g glucose intragastric|50g glucose dissolved in 250mL tap water given via nasogastric tube
16558736|NCT02891525|Active Comparator|25g fructose intragastric|25g glucose dissolved in 250mL tap water given via nasogastric tube
16558737|NCT02891525|Active Comparator|220mg acesulfame-K intragastric|220mg acesulfame-K dissolved in 250mL tap water given via nasogastric tube
16558738|NCT02891525|Placebo Comparator|250mL tap water intragastric|250mL tap water given via nasogastric tube
16558739|NCT02891512|Experimental|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
16558740|NCT02891512|Placebo Comparator|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
16558741|NCT02891499|Experimental|LLLT + immediate force|Use of Low-level laser therapy and not mediate orthodontic force application (150 gF the day of the implantation).
16558742|NCT02891499|Experimental|LLLT + mediate force|Use of Low-level laser therapy and mediate orthodontic force application (150 gF 4 weeks after the day of the implantation).
16558743|NCT02891499|No Intervention|Immediate force application|Not mediate orthodontic force application (150 gF the day of the implantation), without use of Low-level laser therapy.
16558744|NCT02891499|Experimental|Mediate force application|Mediate orthodontic force application (150 gF 4 weeks after the day of the implantation), without use of Low-level laser therapy.
16558745|NCT02891486||Incidence of surgical site infection|The number of spinal surgery patients with surgical site infections.
16558746|NCT02891473|Experimental|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
16558747|NCT02891473|Active Comparator|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
16558748|NCT02891460|Experimental|40 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
16558749|NCT02891460|Experimental|80 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
16558750|NCT02891447|Experimental|Treatment (mitomycin, cisplatin)|Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.
16558751|NCT02891434|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
16558752|NCT02891434|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
16558753|NCT02891434|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
16558754|NCT02891434|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
16558755|NCT02891434|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
16558756|NCT02891434|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
16558757|NCT02891421|Other|Therapeutic Horseback Riding|Therapeutic Horseback Riding: Veterans were matched to a horse by the instructor and occupational therapist for best fit and the same horse was ridden each week
16558758|NCT02891421|Other|Standard Care|Participants received standard care.
16558759|NCT02891408|Experimental|Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg|Participants with mild hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
16558760|NCT02891408|Experimental|Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
16558761|NCT02891408|Experimental|Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg|Participants with moderate hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
16558763|NCT02891408|Experimental|Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg|Participants with severe hepatic impairment will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
16558764|NCT02891408|Experimental|Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
16558765|NCT02891408|Experimental|Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg|Participants with mild hepatic impairment will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
16558766|NCT02891408|Experimental|Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg|Matched normal hepatic function participants to mild hepatic impairment participants, will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
16558767|NCT02891395|Experimental|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.
~Salvage phase:
~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
16558768|NCT02891382|Experimental|Individual incentives - Arm 1|This arm receives diabetes education + goal setting + individual rewards
16558769|NCT02891382|Experimental|Mixed incentives (Altruism) - Arm 2|This arm receives diabetes education + goal setting + companion support + individual rewards
16558770|NCT02891382|Experimental|Mixed Incentives (Cooperation) - Arm 3|This arm receives diabetes education + goal setting + companion support + shared rewards
16558771|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
16558772|NCT02891343|Experimental|Healthy volunteers|
16558773|NCT02891330|Experimental|Dietary and nutritional recommendations|Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse
16558774|NCT02891330|No Intervention|Standard of care|Postoperative standard of care
16558775|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
16558776|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
16558777|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
16558778|NCT02891304||Quarterly Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive objective feedback every 3-months on trainee overall performance including learning curves on ACE tool performance, performance relative to de-identified anonymous peers on each of the individual skills (e.g. fine tip control), and the global assessment for technical and cognitive skill achievement. For those skills which are not advanced/superior - trainees will additionally receive links to online didactic videos which teach these skills.
16558779|NCT02891304||Annual Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive learning curves at the end of each training year. Learning curves, relative to de-identified anonymous peers will be provided to program directors annually (June).
16558780|NCT02891278|Experimental|Sertraline with cytosine arabinoside|"All subjects will receive the following:
~Induction phase
~Sertraline, twice daily at one of the pre-defined dose levels
~Cytosine arabinoside, on days 1 and 10
~Consolidation phase
~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:
~Allogeneic SCT and off study
~Repeat cycle of oral sertraline and cytosine arabinoside IV infusion
~Maintenance phase with sertraline for cycles of 28 days in length"
16558781|NCT02891265|No Intervention|Group A|Group A - smoking cessation with no assistance
16558782|NCT02891265|Placebo Comparator|Group B|Group B - smoking cessation with the addition of a smoking cessation patch
16558783|NCT02891252|Active Comparator|outpatient|outpatient
16558784|NCT02891252|No Intervention|inpatient|inpatient
16558785|NCT02891239|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
16558786|NCT02891226|Experimental|Mirikizumab Dose Level 1|"Period 1 (Weeks 0 -12) Mirikizumab dose level 1
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 1 or dose level 4 or dose level 3
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
16558787|NCT02891226|Experimental|Mirikizumab Dose Level 2|"Period 1 (Weeks 0 -12) Mirikizumab dose level 2
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 2 or dose level 4 or dose level 3
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
16558788|NCT02891226|Experimental|Mirikizumab Dose Level 3|"Period 1 (Weeks 0 -12) Mirikizumab dose level 3
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3 or dose level 4
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
16558789|NCT02891226|Placebo Comparator|Placebo|"Period 1 (Weeks 0 -12) Placebo
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
16558860|NCT02890771|Experimental|SRP with turmeric massaging|SRP with turmeric massaging on half arch
16558790|NCT02891213||LE (Lupus Erythematosus) group|"Samples of the LE (Lupus Erythematosus) group from a specimen collection : Lupus BioBanque du Rhin Supérieur (LBBR UF 9882).
~It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank Lupus BioBanque du Rhin Supérieur (project : LBBR UF 9882)."
16558791|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
16558792|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
16558793|NCT02891187|Active Comparator|Outpatient Clinic Visits|Outpatient clinic visits for postoperative care is currently the standard of care. Patients who undergo surgery for a pelvic floor disorder will be scheduled appointments in the outpatient clinic at 1-2 weeks, 6 weeks, and 3 months where they will be evaluated by a physician.
16558794|NCT02891187|Active Comparator|Telephone Follow-up|Patients will be called instead of returning to clinic for postoperative care at 1-2 weeks, 6 weeks, and 3 months.
16558795|NCT02891174|Active Comparator|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
16558796|NCT02891174|Active Comparator|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
16558797|NCT02891161|Experimental|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
16558798|NCT02891161|Experimental|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
16558799|NCT02891148|Experimental|BI 690517|
16558800|NCT02891135|No Intervention|Standard|Patients randomized to the standard arm will receive standard procedures for initiating antiretroviral therapy for HIV.
16558801|NCT02891135|Experimental|Intervention|Patients randomized to the intervention arm will be offered immediate treatment initiation under the intervention algorithm (SLATE).
16558802|NCT02891109||patients group|Adults patients with chronic immune thrombocytopenia
16558803|NCT02891109||control group|Adults without immune thrombocytopenia
16558804|NCT02891083|Experimental|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
16558805|NCT02891083|Experimental|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
16558806|NCT02891083|Other|Control group|Surgery alone
16558807|NCT02891070|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
16558808|NCT02891070|Active Comparator|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
16558809|NCT02891057|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16558810|NCT02891044|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16558811|NCT02891031|Active Comparator|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
16558812|NCT02891031|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
16558813|NCT02891018|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
16558814|NCT02891018|Experimental|paclitaxel release coronary balloon catheter|Patients treated with paclitaxel release coronary balloon catheter
16558815|NCT02891005|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
16558816|NCT02891005|Experimental|common balloon catheter|Patients treated with common balloon catheter
16558817|NCT02890992|Experimental|Cohort 1 - Alirocumab 30 mg Q2W: <50 kg|"Period 1: Participants with body weight less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT).
~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
16558818|NCT02890992|Experimental|Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg|"Period 1: Participants with body weight greater than or equal to (>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
16558819|NCT02890992|Experimental|Cohort 2 - Alirocumab 40 mg Q2W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT.
~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still < 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
16558861|NCT02890758|Experimental|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
16558820|NCT02890992|Experimental|Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130."
16558821|NCT02890992|Experimental|Cohort 3 - Alirocumab 75 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT.
~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
16558822|NCT02890992|Experimental|Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
16558823|NCT02890992|Experimental|Cohort 4 - Alirocumab 150 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT.
~Period 2: Participants with body weight < 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48."
16558824|NCT02890992|Experimental|Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48."
16558825|NCT02890979|Experimental|Screening (cytology collection)|Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.
16558826|NCT02890966|Experimental|Cohort 1|1mg SHR4640 or placebo
16558827|NCT02890966|Experimental|Cohort 2|2.5mg SHR4640 or placebo
16558828|NCT02890966|Experimental|Cohort 3|5mg SHR4640 or placebo
16558829|NCT02890966|Experimental|Cohort 4|10mg SHR4640 or placebo
16558830|NCT02890953|Placebo Comparator|Control|Control group receives placebo medication (normal saline)
16558831|NCT02890953|Experimental|MSC group|MSC group receives mesenchymal stem cells transplantation (Pneumostem)
16558832|NCT02890940|Experimental|Pet Therapy|
16558833|NCT02890927|Experimental|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
16558834|NCT02890927|No Intervention|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
16558835|NCT02890914|No Intervention|Standard Education|These residents received their standard residency education and experience.
16558836|NCT02890914|Experimental|DVD Intervention|These residents received a one-hour long DVD lecture in addition to standard residency education and experience.
16558837|NCT02890888|Experimental|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
16558838|NCT02890875|Active Comparator|Ethanol lock|70% ethanol
16558839|NCT02890875|Active Comparator|Heparin lock|Heparinized saline (100 U/mL)
16558840|NCT02890862||20 healthy volunteers|
16558841|NCT02890862||Dupuytren disease|10 patients dupuytren disease
16558842|NCT02890862||Tendon pathology|10 patients with tendon pathology
16558843|NCT02890862||wrist osteoarthritis|10 patients with wrist osteoarthritis
16558844|NCT02890849|Experimental|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
16558845|NCT02890836||Pregnant women with pre-existing diabetes|Inclusion of 400 women is anticipated.
16558846|NCT02890836||Healthy pregnant women|Inclusion of 100 women is anticipated
16558847|NCT02890823|Experimental|EIAEDs-1000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
16558848|NCT02890823|Experimental|EIAEDs-3000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
16558849|NCT02890823|Experimental|EIAEDs-6000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
16558850|NCT02890823|Active Comparator|non-EIAEDs-1000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
16558851|NCT02890823|Active Comparator|non-EIAEDs-3000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
16558852|NCT02890823|Active Comparator|non-EIAEDs-6000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
16558853|NCT02890810|Experimental|Verum Electroacupuncture|Active Intervention
16558854|NCT02890810|Placebo Comparator|Placebo Electroacupuncture|Validated Control
16558855|NCT02890797|Other|Bronchiolitis children|Under two years old patient with bronchiolitis will have thoracic radiology
16558856|NCT02890784|Active Comparator|A. Standard arm|100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)
16558857|NCT02890784|Experimental|B. Study arm|100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)
16558858|NCT02890771|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice
16558859|NCT02890771|Experimental|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
16558868|NCT02890706|Other|Patients|Each patient undergo the same CT protocol. Theobservers will observe the detection of the perfusion defects in two different techniques.
16558869|NCT02890693|Experimental|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
16558870|NCT02890693|No Intervention|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
16558871|NCT02890680|Experimental|Platelet-rich fibrin group|Use platelet-rich fibrin after mandibular third molar extraction
16558872|NCT02890680|Placebo Comparator|Control group|mandibular third molar extraction
16558873|NCT02890667||Beneficiaries|Incident cancer for Beneficiaries present in the EGB on January 1, 2012.
16558874|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :
~First time measure : 1 month before the scoliosis surgery
~Second time measure : 3 months after the scoliosis surgery
~Third time measure : 1 year after the scoliosis surgery"
16558875|NCT02890641||drug resistant epilepsy|Sequencing of paired blood-brain DNA samples
16558876|NCT02890628||pregnant/post-natal adolescents (<20 years)|12-24 individual with pregnant or postnatal adolescent girls (<20 years) will be interviewed.
16558877|NCT02890628||non-pregnant female adolescents (<20 years)|1 Focus group discussion of 6-10 non-pregnant female adolescents (<20 years)
16558878|NCT02890628||male adolescents (<20 year)|1 Focus group discussion of 6-10 adolescent men (<20 years)
16558879|NCT02890628||SMRU health staff of antenatal clinics (ANC)|1 Focus group discussion of 6-10 Shoklo Malaria Research Unit antenatal clinic staff
16558880|NCT02890615|Experimental|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.
~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
16558881|NCT02890615|No Intervention|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
16558882|NCT02890602|Experimental|Darbepoietin alfa|Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
16558883|NCT02890589|Experimental|SYNERGY Stent|The SYNERGY™ stent is a Device marked CE (European Conformity), platinum chromium coronary stent, currently developped by Boston Scientific™. This stent has been designed with the goal of providing optimal and rapid healing within the vessel using a bioabsorbable polymer to elute everolimus.
16558884|NCT02890589|Experimental|BVS device|The ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold (BVS 1.1, Abbott Vascular, California, USA, CE approved) is Device marked CE, currently the most studied PLA (Polylactic acid) based scaffold. It consists of PLLA (Poly I-lactic acid) backbone with 1:1 PDLLA (Poly-DL Lactic Acid) drug surface coating and a total strut thickness of 156 μm.
16558885|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
16558886|NCT02890563|No Intervention|No Compression|Patients in this group will not receive any compression after treatment.
16558887|NCT02890563|Active Comparator|Compression|Patients in this group will use compression stockings for seven days after treatment (2 days continuously and 5 days during daytime).
16558888|NCT02890550||30 Patients Alström syndrome|
16558889|NCT02890550||60 Related patients Alström syndrome|
16558890|NCT02890537|Experimental|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
16558891|NCT02890537|Active Comparator|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
16558892|NCT02890524|Experimental|Night guard|the night guard made of EVA
16558893|NCT02890524|Placebo Comparator|Placebo night guard|Placebo night guard made of EVA
16558894|NCT02890511|Experimental|DHP107(Oral paclitaxel)|"Phase I (determining MTD) The patients diagnosed with either advanced or metastatic solid cancers were enrolled. The administered dose was escalated in a step-wise manner by an increment of 2 x 50 mg/m2 at each dose level. Three patients were treated for toxicity evaluation for each dose level.
~Phase IIa (efficacy evaluation) The safety and efficacy of the corresponding dose was investigated more closely by increasing the patient number to 6 or more patients in the dose tentatively determined as recommended dose for phase IIa clinical trial."
16558895|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
16558896|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
16558897|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
16558898|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
16558899|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
16558901|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
16558902|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
16558903|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
16558904|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
16558905|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
16558906|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
16558907|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
16558908|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
16558909|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
16558910|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
16558911|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
16558912|NCT02890446|Experimental|External Focus (EF)|"Participants received arm training using the InMotion2 robot under external focus practice conditions and instructions. Participants practiced arm reaching by playing a simple video game.
~EF instructions: Focus on moving the yellow ball on the screen in a smooth, straight line at a constant speed; Move the yellow ball toward the blinking red/orange light; and Hit the center of the target and try not to overshoot the target"
16558913|NCT02890446|Experimental|Internal Focus (IF)|"Participants received arm training using the InMotion2 robot without the video game interface. Participants were instructed to think about how they were moving their arm while completing the arm training tasks.
~IF instructions:
~think about how you're moving your arm; push your arm away from you; pull your arm toward you; move your arm to the right/left"
16558914|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
16558915|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
16558916|NCT02890394|Experimental|2 minutes Group|The group was perform the technique inhibition suboccipital two minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
16558917|NCT02890394|Experimental|4 minutes Group|The group was perform the technique inhibition suboccipital four minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
16558918|NCT02890394|Experimental|8 minutes Group|The group was perform the technique inhibition suboccipital eight minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
16558919|NCT02890394|No Intervention|not intervention Group|The not intervention group will be asked to lie supine on the table for ten minutes, collecting data by measuring with algometer and test repositioning of the head before and after laying.
16558920|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
16558921|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
16558922|NCT02890368|Experimental|TTI-621 Monotherapy Escalation|TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
16558923|NCT02890368|Experimental|TTI-621 Monotherapy (Single Lesion)|TTI-621 Single Lesion Injection Expansion Cohort
16558924|NCT02890368|Experimental|TTI-621 Monotherapy (Multiple Lesions)|TTI-621 Multiple Lesion Injections Expansion Cohort
16558925|NCT02890368|Experimental|TTI-621 + PD-1/PD-L1 Inhibitor|Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
16558926|NCT02890368|Experimental|TTI-621 + Pegylated Interferon-α2a|Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
16558927|NCT02890368|Experimental|TTI-621 + T-Vec|Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
16558928|NCT02890368|Experimental|TTI-621 + Radiation|Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy
16558929|NCT02890355|Experimental|Arm I (veliparib and mFOLFIRI)|Patients receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
16558930|NCT02890355|Active Comparator|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
16558931|NCT02890342||Affected Patients with Propionic Acidemia|Patients with Propionic Acidemia, standard adult, parental permission
16558932|NCT02890342||Healthy Volunteers|Healthy Volunteers, standard adult, parental permission
16558933|NCT02890342||Unaffected Family Members|Unaffected family members
16558934|NCT02890329|Experimental|Arm A (decitabine, ipilimumab)|"PRIMING PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.
~INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
16558935|NCT02890329|Experimental|Arm B (decitabine, ipilimumab)|"PRIMING PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.
~INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
16558936|NCT02890316|Experimental|Radiation therapy with Homeopathy|Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
16559250|NCT02888106|Experimental|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
16558937|NCT02890316|Placebo Comparator|Radiation therapy with placebo|Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
16558938|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
16558939|NCT02890290|Active Comparator|Intervention|Marine protein hydrolysate pills (3000mg)
16558940|NCT02890290|Placebo Comparator|Control|Placebo pills (gum arabicum)
16558941|NCT02890277|Experimental|Treatment group|
16558942|NCT02890238|Active Comparator|sildenafil citrate|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
16558943|NCT02890238|Placebo Comparator|placebo group|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
16558944|NCT02890225|Other|3|Patients in 3 days
16558945|NCT02890225|Other|10|Patients in10ys
16558946|NCT02890225|Experimental|30|Patients in10ys
16558947|NCT02890212|Experimental|selenium|subjects resistant to treatment of major depression with sertraline who were randomized and ingest selenium pills (400 microgram) during six weeks
16558948|NCT02890212|Placebo Comparator|placebo|subjects resistant to treatment of major depression with sertraline who were randomized and ingest placebo pills
16558949|NCT02890199|Active Comparator|Lidocaine group|0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy
16558950|NCT02890199|Experimental|Bupivacaine liposomal group|1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy
16558951|NCT02890186|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
16558952|NCT02890186|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
16558953|NCT02890173|Experimental|CS-3150 2.5 mg|CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
16558954|NCT02890173|Experimental|CS-3150 5.0 mg|CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
16558955|NCT02890173|Active Comparator|Eplerenone|Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks
16558956|NCT02890160|Experimental|Firesorb|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
16558957|NCT02890160|Active Comparator|XIENCE|Implantation of the XIENCE Everolimus Eluting Coronary Stent System
16558958|NCT02890108|Experimental|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
16558959|NCT02890108|Experimental|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
16558960|NCT02890095|Experimental|Arm A = Breast Cancer surgery|Arm A : women undergoing breast cancer surgery.
16558961|NCT02890095|Other|Arm B = Control (plastic surgery)|Arm B : women undergoing breast surgery for the purpose of plastic surgery
16558962|NCT02890082|Experimental|Tamoxifen stim in early follicular phase|Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
16558963|NCT02890082|Other|Tamoxifen stim in late follicular phase|Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
16558964|NCT02890082|Other|Tamoxifen stim in luteal phase|Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
16558979|NCT02890056|Experimental|H2GO! intervention|H2GO! is a community-based behavioral intervention to reduce sugar-sweetened beverage consumption and promote water intake among school-age youth and parents.The intervention consists of 6 weekly group-based sessions (1-hour sessions twice a week) that target beverage knowledge, attitudes, and behaviors through interactive activities, youth-produced narratives, and parent-child activities. The intervention is delivered through a youth-based community setting (Boys and Girls Clubs of America) by trained Boys and Girls Club staff.
16558980|NCT02890056|No Intervention|Comparison|Usual care will take place at the comparison site (standard programming at the Boys and Girls Club comparison site).
16558981|NCT02890043|Experimental|Robot|Intervention: Surgery: robot-assisted spine surgery, device: TiRobot surgery system
16558982|NCT02890043|Active Comparator|Free-hand|Intervention: Surgery: free-hand surgery
16558983|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
16558984|NCT02890017|Experimental|Hotel-Ambu|Outpatient surgery with a patient-hotel night
16558985|NCT02890017|Other|conventional hospitalization|conventional hospitalization
16558986|NCT02889991|Experimental|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
16558987|NCT02889991|Experimental|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
16558988|NCT02889991|Experimental|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
16558989|NCT02889991|Sham Comparator|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
16558990|NCT02889978||Cancer arm|Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
16558991|NCT02889978||Non-cancer arm|Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
16558992|NCT02889965||Radiologically Isolated Syndromes (RIS)|
16558993|NCT02889965||Clinically Isolated Syndromes (RIS)|
16558994|NCT02889965||Primary progressive MS (PPMS)|
16558995|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
16558996|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
16558997|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
16558998|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
16558999|NCT02889939|Other|UC + ETT|"An enriched comprehensive task-specific therapy (ETT) program combining intensive and task-specific therapy with the sensory-motor, social, and cognitive stimulation inherent to environmental enrichment.
~The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control."
16559000|NCT02889926|Experimental|a swab according to the method of Levine|
16559001|NCT02889926|Experimental|Bacteriological referred to biopsy|
16559002|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
16559003|NCT02889887||preterm|infants who born before 37 completed weeks
16559004|NCT02889874|No Intervention|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
16559005|NCT02889874|Experimental|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
16559006|NCT02889861|Experimental|Regimen 1|IMCgp100 (77 kDa bi-specific protein) weekly dosing regimen (QW)
16559007|NCT02889848|Sham Comparator|Saline only|Injection of saline to assess the injection procedure
16559008|NCT02889848|Experimental|1.16 mg EN3835|Injection of maximum marketed dose of EN3835 regardless of fibroid size
16559009|NCT02889848|Experimental|Dose 1|Injection of 0.05 mg EN3835 per cm3 fibroid
16559010|NCT02889848|Experimental|Dose 2|Injection of 0.1 mg EN3835 per cm3 fibroid
16559011|NCT02889848|Experimental|Dose 3|Injection of 0.2 mg EN3835 per cm3 fibroid
16559012|NCT02889835|Active Comparator|Universal Composite|Supreme Universal Restorative
16559013|NCT02889835|Experimental|Flowable Composite|Supreme Flowable Restorative
16559014|NCT02889835|Experimental|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
16559015|NCT02889822|Experimental|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd
~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
16559016|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
16559017|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
16559018|NCT02889796|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
16559019|NCT02889796|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
16559020|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
16559021|NCT02889796|Experimental|Placebo to Filgotinib 200 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
16559022|NCT02889796|Experimental|Placebo to Filgotinib 100 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
16559023|NCT02889796|Placebo Comparator|Placebo Never Received Filgotinib|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
16559024|NCT02889757|Experimental|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
16559025|NCT02889757|Experimental|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
16559026|NCT02889757|Placebo Comparator|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
16559027|NCT02889744|Active Comparator|36-TH|Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
16559028|NCT02889744|Active Comparator|33-TH|Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
16559029|NCT02889718|Experimental|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
16559030|NCT02889692|Experimental|TCM granules plus EGFR-TKIs|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day，until progression or unacceptable toxicity."
16559031|NCT02889692|Placebo Comparator|Placebo granules plus EGFR-TKIs|Placebo granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day until progression or unacceptable toxicity.
16559032|NCT02889679|Experimental|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
16559033|NCT02889679|Active Comparator|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
16559034|NCT02889666|Experimental|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
16559035|NCT02889666|Experimental|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
16559036|NCT02889666|Experimental|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
16559037|NCT02889666|Experimental|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
16559038|NCT02889666|Experimental|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
16559039|NCT02889666|Experimental|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
16559040|NCT02889666|Experimental|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
16559041|NCT02889666|Placebo Comparator|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
16559042|NCT02889640|No Intervention|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
16559043|NCT02889640|Experimental|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
16559044|NCT02889640|Experimental|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
16559045|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo repeated FMT with ~50ml microbiota suspension.
16559046|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
16559251|NCT02888106|Experimental|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
16559047|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
16559048|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
16559049|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.
~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
16559050|NCT02889549|Experimental|Ticagrelor 22.5 mg|Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
16559051|NCT02889549|Experimental|Ticagrelor 45 mg|Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
16559052|NCT02889549|Experimental|Ticagrelor 90 mg|Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
16559053|NCT02889549|Active Comparator|Clopidogrel|Clopidogrel (75mg, once daily, oral) treatment for 1 month.
16559054|NCT02889536||Focus group interview, stoma clinics|Qualitative data collection. Patients attending stoma clinics in the capital region
16559055|NCT02889536||Focus group interview, referred|Qualitative data collection. Patients referred to repair surgery at a specific hospital in the capital region
16559056|NCT02889523|Experimental|DLBCL cohort|"RCHOP + tazemetostat:
~- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days
~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
~Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
16559057|NCT02889523|Experimental|FL cohort|"RCHOP + tazemetostat:
~Induction
~RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):
~6 cycles, every 21 days
~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
~Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID
~Maintenance
~Tazemetostat : 6 months (every 8 weeks)
~Rituximab : 24 months (every 8 weeks)"
16559058|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
16559059|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
16559060|NCT02889497|Experimental|300 subjects receive the first batch vaccine|300 subjects will be randomly received the first batch vaccine
16559061|NCT02889497|Experimental|300 subjects receive the second batch vaccine|300 subjects will be randomly received the second batch vaccine
16559062|NCT02889497|Experimental|300 subjects receive the third batch vaccine|300 subjects will be randomly received the third batch vaccine
16559063|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
16559064|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
16559065|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
16559066|NCT02889471|Experimental|ERCP with nasobiliary catheter|
16559067|NCT02889471|Active Comparator|ERCP only|
16559068|NCT02889458||Case|"Inclusion Criteria
~Female
~aged 18 or above
~Chinese
~Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)
~Able to speak Cantonese
~Newly diagnosed with breast cancer or DCIS in 24 weeks
~Exclusion Criteria
~- Undergoing treatment for any non-breast cancer
~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
16559069|NCT02889458||Control|"Inclusion Criteria
~Female
~aged 18 or above
~Chinese
~Usually residing in Hong Kong
~Able to speak Cantonese
~Exclusion Criteria
~- History of any cancer
~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
16559070|NCT02889432|Experimental|Melatonin|Oral Melatonin 10mg Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
16559071|NCT02889432|Placebo Comparator|Placebo|Placebo tabs Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
16559072|NCT02889419|Experimental|Evaluation of underwear Selfia®|Every patient is his own control.
16559073|NCT02889406|Experimental|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.
~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
16559074|NCT02889406|No Intervention|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
16559118|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
16559075|NCT02889393|Experimental|Standard of Care followed by Teduglutide|"Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.
~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure."
16559076|NCT02889393|Experimental|Teduglutide followed by Standard of Care|"Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.
~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure"
16559077|NCT02889380||Cetrotide|This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome.
16559078|NCT02889367|Experimental|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
16559079|NCT02889367|Experimental|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
16559080|NCT02889367|Experimental|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
16559081|NCT02889354|Experimental|Cognitive-behavioral therapy|
16559082|NCT02889341|Placebo Comparator|Placebo|Placebo
16559083|NCT02889341|Active Comparator|500 mg DHA/day|500 mg DHA/day
16559084|NCT02889341|Active Comparator|1g DHA/day|1g DHA/day
16559085|NCT02889341|Active Comparator|2g DHA/day|2g DHA/day
16559086|NCT02889328|Experimental|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
16559087|NCT02889302|Experimental|KPS-0373|
16559088|NCT02889302|Placebo Comparator|Placebo|
16559089|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
16559090|NCT02889276|Active Comparator|Control|Unsupervised activity
16559091|NCT02889276|Experimental|Functional Resistance Training (FRT)|Supervised, group-based functional resistance training
16559092|NCT02889250|Experimental|Open Label DBS|6 months of DBS
16559093|NCT02889237|No Intervention|Standard care|Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
16559094|NCT02889237|Active Comparator|Calcium|Immediate administration of daily calcium supplementation (1000 mg calcium)
16559095|NCT02889237|Active Comparator|Calcium and low dose vitamin D|Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
16559096|NCT02889237|Active Comparator|Calcium and high dose vitamin D|Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
16559097|NCT02889237|No Intervention|Already on treatment with Calcium or vitamin D|Patients who are already treated with Calcium or Vitamin D.
16559098|NCT02889224|Active Comparator|Obese|Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
16559099|NCT02889224|Experimental|Hypercortisolism|Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
16559100|NCT02889224|Experimental|Hydrocortisone|Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
16559101|NCT02889224|Experimental|Control|Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
16559102|NCT02889211|Active Comparator|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
16559103|NCT02889211|Experimental|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
16559104|NCT02889211|Experimental|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
16559105|NCT02889211|Experimental|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
16559106|NCT02889198|Experimental|Intervention group|Centers in this group will be granted immediate access to the Go NAP SACC website following randomization with minimal support from a local technical assistance provider. The center director will have 4 months to use Go NAPSACC tools.
16559107|NCT02889198|No Intervention|Control group|During the study, centers in this group will receive no intervention. However, they will be granted delayed access to the Go NAP SACC website and technical assistance support after post-intervention measures are collected.
16559108|NCT02889185|Experimental|Adaptative optics retinal camera|
16559109|NCT02889172|Experimental|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
16559110|NCT02889172|No Intervention|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
16559111|NCT02889159|Other|Candida albicans antigen|useful in measuring the capacity of a person to manifest a delayed-type hypersensitivity response
16559112|NCT02889159|Other|histamine phosphate|useful to assess type I IgE-mediated hypersensitivity reactions
16559113|NCT02889159|Other|imiquimod 5% cream|direct stimulator of TLR-7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response
16559114|NCT02889159|Other|tape stripping|to create alterations in key inflammatory mediators involved in both the innate and adaptive immune responses
16559115|NCT02889159|No Intervention|Control|control sample from both sun exposed and non-sun exposed skin
16559116|NCT02889146|Active Comparator|Control group|Conventional Physical Therapy: motor physical therapy delivered by the intensive care unit physical therapists, according to his own criteria, without following any protocol. Respiratory therapy.
16559117|NCT02889146|Experimental|Protocol group|Early and progressive mobilization program: motor physical therapy delivered by a trained physical therapist according to the mobilization protocol, in which patient progress according to his performance. Respiratory therapy.
16559252|NCT02888106|Experimental|Arm D|Myrcludex B 2 mg for 48 weeks
16559119|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
16559120|NCT02889107|No Intervention|standard care|Patients received standard listening strategies for 10 weeks
16559121|NCT02889107|Experimental|intervention|Patients received an assistive listening device (personal frequency modulated systems) for 10 weeks
16559122|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
16559123|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
16559124|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
16559125|NCT02889068||Intellectual disability|
16559126|NCT02889042|Experimental|Volunteers repeated drug poisoning|performing MRI and a biological assessment
16559127|NCT02889042|Other|Volunteers single drug poisoning|performing MRI and a biological assessment
16559128|NCT02889042|Other|alcoholic|performing MRI and a biological assessment
16559129|NCT02889042|Other|volunteers|performing MRI and a biological assessment
16559130|NCT02889029|Experimental|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
16559131|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
16559132|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
16559133|NCT02889003|Experimental|CML patients following molecular response loss|
16559134|NCT02888990|Experimental|Treatment Arm|standard treatment + dasatinib
16559135|NCT02888964|Experimental|ACTOS treatment|Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events
16559136|NCT02888951||Diabetic Group|A group of diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
16559137|NCT02888951||Non-Diabetic Group|A group of non-diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
16559138|NCT02888938||Patients suspected of SpA|
16559139|NCT02888925|Other|Epilepsy|Patients do face specific tests during conventional pre-lobectomy intercritical assessment hospitalization (inclusion, day 0) and after 6 and 18 months from anterior temporal lobectomy
16559140|NCT02888925|Other|Control|Control individuals do face specific tests during inclusion visit (day 0) and after X months (X = time from day 0 and lobectomy of matched patient + 6 months)
16559141|NCT02888912|Active Comparator|EQUIA|randomly applied
16559142|NCT02888912|Active Comparator|Gradia Direct Posterior|randomly applied
16559143|NCT02888899|Experimental|Standard treatment|
16559144|NCT02888899|Experimental|PTNS in addition to standard treatment|
16559145|NCT02888886|Experimental|COPD|
16559146|NCT02888873|Active Comparator|Charisma|applied randomly
16559147|NCT02888873|Active Comparator|Charisma classic|applied randomly
16559148|NCT02888860||Group 1|Patients with candidemia
16559149|NCT02888860||Group 2|Patients without colonization during follow up
16559150|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
16559151|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
16559152|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
16559153|NCT02888847|Active Comparator|Philips Zoom! White Speed whitening lamp|Philips Zoom! White Speed whitening lamp
16559154|NCT02888847|Sham Comparator|Philips Zoom! Advanced power lamp|Philips Zoom! Advanced power whitening lamp
16559155|NCT02888834||Adverse drug reaction|Patients aged over 65 years who presented a serious adverse drug reaction notified to the Regional Pharmacovigilance Center of Champagne-Ardenne between January and May 2013 were included in the study.
16559156|NCT02888821|Experimental|CLS-FUERTE|Families will receive the CLS-FUERTE intervention in the fall of the 2016-2017 school year. CLS-FUERTE includes caretaker, child and teacher components implemented during a 6 week period. All content of group sessions will be derived from the manualized CLS-FUERTE treatment protocol developed by the PI and study staff.
16559157|NCT02888821|Other|Business as Usual (BAU) Waitlist Control|Families will receive school services as usual while on a waitlist to receive CLS-FUERTE in the spring of the 2016-2017 school year.
16559158|NCT02888808||Erosive GERD|Gastroscopy examination.
16559159|NCT02888808||Control population|Gastroscopy examination.
16559160|NCT02888795|Experimental|hypertonic dextrose prolotherapy|
16559161|NCT02888782|Experimental|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
16559162|NCT02888782|No Intervention|Control|Receive regular physician follow up
16559163|NCT02888769|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week.
16559164|NCT02888769|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
16559165|NCT02888756|Experimental|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
16559166|NCT02888756|Active Comparator|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
16559167|NCT02888756|Placebo Comparator|Placebo|Water for injection 3 vaccinations, two weeks interval
16559168|NCT02888743|Experimental|Arm A (tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.
16559169|NCT02888743|Experimental|Arm B (tremelimumab, Durvalumab, RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
16559170|NCT02888743|Experimental|Arm C (tremelimumab, durvalumab, and RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
16559171|NCT02888730|Experimental|Tobramycin nebulized nasally|Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
16559172|NCT02888730|Placebo Comparator|Physiologic serum nebulized nasally|Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days
16559173|NCT02888717|Experimental|OSNA stadification during surgery|The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and will be analysis both by histological analysis and OSNA analysis
16559174|NCT02888704|Experimental|intervention: Biological: ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.
~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
16559175|NCT02888691|Experimental|Low Carbohydrate Diet|< 100 grams of carbohydrate per day
16559176|NCT02888691|Experimental|High Carbohydrate Diet|> 250 grams of carbohydrate per day
16559177|NCT02888678|Experimental|ES + HIV Prevention|"Economic Strengthening + HIV prevention education combined intervention consists of 2 parts.
~Impumelelo: This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
~Vhutshilo 2.2: . This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy."
16559178|NCT02888678|Experimental|ES only|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
16559179|NCT02888678|Experimental|HIV only|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
16559180|NCT02888678|No Intervention|No intervention (control)|The control group will not receive the ES or HIV prevention interventions. They will receive the basic package of services available to all beneficiaries of Future Families.
16559181|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
16559182|NCT02888613|Other|Mini laparotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with transperitoneal approach
16559183|NCT02888613|Other|Mini lumbotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with retroperitoneal approach
16559184|NCT02888600|Active Comparator|Mindfulness Training|The Mindfulness Meditation Program consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily mindfulness meditation homework.
16559185|NCT02888600|Active Comparator|Health Education|The Health Education Program also consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily health practice homework
16559186|NCT02888587||Control group|no gastrointestinal symptoms
16559187|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
16559188|NCT02888574|Experimental|Intranasal Oxytocin|Oxytocin nasal spray delivered bi-daily over a 14-day period at 24-IU per dose
16559189|NCT02888574|Placebo Comparator|Placebo|Placebo nasal spray containing the same ingredients as the active nasal spray minus the oxytocin and packaged in an identical bottle. To be delivered bi-daily over a 14-day period at 24-IU per dose
16559190|NCT02888548|Experimental|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
16559191|NCT02888548|Experimental|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
16559192|NCT02888509||healthy control|Well mathed with patients in age, gender, education
16559193|NCT02888509||major depression disorder|patients with major depression disorder
16559194|NCT02888509||anxiety disorder|patients with anxiety disorder
16559195|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
16559196|NCT02888496||PMR patients|Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
16559197|NCT02888496||Healthy controls|Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease
16559198|NCT02888457|Other|AOM (acute otitis media)|Infants (6-30 months of age) with acute otitis media
16559199|NCT02888457|Other|DCC (day-care centers)|Healthy infants (6-30 months of age) attending day-care centers
16559200|NCT02888444|Active Comparator|Varenicline plus behavioural support|12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
16559201|NCT02888444|Placebo Comparator|Placebo plus behavioural support|12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support
16559202|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
16559203|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
16559204|NCT02888418|Experimental|One dose of HPV vaccine in women aged 18 to 30|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 18 to 30.
16559205|NCT02888418|Placebo Comparator|Placebo in women aged 18 to 30|Placebo in women aged 18 to 30.
16559249|NCT02888106|Active Comparator|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
16635692|NCT02377024|Placebo Comparator|placebo|placebo
16559206|NCT02888418|Experimental|One dose of HPV vaccine in women aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 9 to 17.
16559207|NCT02888418|Placebo Comparator|Placebo in women aged 9 to 17|Placebo in women aged 9 to 17.
16559208|NCT02888418|Experimental|One dose of HPV vaccine in men aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in men aged 9 to 17.
16559209|NCT02888418|Placebo Comparator|Placebo in men aged 9 to 17|Placebo in men aged 9 to 17.
16559210|NCT02888405|Experimental|High-carbohydrate diet|Single day of 9 g/kg body weight consumption of carbohydrate. Isocaloric to very low-carbohydrate condition.
16559211|NCT02888405|Experimental|Very low-carbohydrate diet|Single day of 1 - 1.5 g/kg body weight consumption of carbohydrate. Isocaloric to high-carbohydrate condition.
16559212|NCT02888392|Experimental|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
16559213|NCT02888392|Active Comparator|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
16559214|NCT02888379|Experimental|TOP1288 200 mg Rectal Solution|TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks
16559215|NCT02888379|Placebo Comparator|Placebo Rectal Solution|Placebo (for TOP1288) Rectal Solution Once Daily for 4 Weeks
16559216|NCT02888366||1|Breath samples taken, no treatment given.
16559217|NCT02888353|Experimental|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).
~Patients will not be pre-screened prior to hospital visit."
16559218|NCT02888340|Experimental|Acupuncture|One session of acupuncture prior to receiving pain medications after arriving to the emergency department with pain as a symptom.
16559219|NCT02888340|No Intervention|Usual Care|Usual care for pain, without intervention, after arriving to the emergency department with pain as a symptom.
16559220|NCT02888327|Other|Oseltamivir and AL-794|Oseltamivir alone and with AL-794 over fourteen days.
16559221|NCT02888327|Other|Digoxin, Midazolam, and AL-794|Single doses of Digoxin and Midazolam with and without AL-794 over seventeen days.
16559222|NCT02888327|Other|Pitavastatin and AL-794|Single doses of Pitavastatin with and without AL-794 over seventeen days.
16559223|NCT02888327|Other|JNJ-63623872 and AL-794|JNJ-63623872 alone and with AL-794 over fourteen days.
16559224|NCT02888301||Basic science (18F-clofarabine biodistribution)|Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
16559225|NCT02888288|Experimental|Mental Health Intervention|This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
16559226|NCT02888288|Active Comparator|Standard of Care|This arm includes standard medical care and adherence counseling with routine education prior to the start of the HIV youth clinic from which participants are recruited.
16559227|NCT02888275|Experimental|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
16559228|NCT02888275|Active Comparator|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
16559229|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
16559230|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
16559231|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
16559232|NCT02888249|Experimental|Cigarette W|"Altered composition cigarettes
~moisture = 12.20 %, tar = 10.40 mg/cigarette, total particulate matter = 12.0 mg/cigarette, high sugar content"
16559233|NCT02888249|Experimental|Cigarette X|"Altered composition cigarettes
~moisture = 12.10 %, tar = 8.60 mg/cigarette, total particulate matter = 9.60 mg/cigarette, low sugar content"
16559234|NCT02888249|Experimental|Cigarette Y|"Altered composition cigarettes
~moisture = 13.20 %, tar = 9.10 mg/cigarette, total particulate matter = 10.10 mg/cigarette, low sugar content"
16559235|NCT02888249|Experimental|Cigarette Z|"Altered composition cigarettes
~moisture = 13.60 %, tar = 8.10 mg/cigarette, total particulate matter = 9.10 mg/cigarette, low sugar content"
16559236|NCT02888236|Experimental|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
16559237|NCT02888236|Placebo Comparator|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
16559238|NCT02888223|Experimental|Group A|a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)
16559239|NCT02888223|Experimental|Group B|a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)
16559240|NCT02888210|Experimental|MD-15|Investigational intraocular lens
16559241|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
16559242|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
16559243|NCT02888158|Active Comparator|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.
~Intervention: Pelvic Trainer"
16559244|NCT02888158|Experimental|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.
~Intervention: Robotic assistance
~Intervention: Pelvic Trainer"
16559245|NCT02888132|Experimental|Hypertrophic Obstructive Cardiomyopathy|
16559246|NCT02888119|Active Comparator|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
16559247|NCT02888119|Active Comparator|Mild Osteoarthritis|
16559248|NCT02888119|Active Comparator|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
16559253|NCT02888106|Experimental|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
16559254|NCT02888106|Experimental|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
16559255|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
16559256|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
16559257|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
16559258|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
16559259|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.
~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
16559260|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.
~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
16559261|NCT02888054|Experimental|Sequence ABBA|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
16559262|NCT02888054|Experimental|Sequence BABA|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
16559263|NCT02888054|Experimental|Sequence ABAB|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
16559264|NCT02888054|Experimental|Sequence BAAB|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
16559265|NCT02888041|Experimental|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
16559266|NCT02888041|Active Comparator|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
16559267|NCT02888028|Active Comparator|ICD remote monitoring|Active Comparator: ICD remote monitoring additionally to regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement
16559268|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
16559269|NCT02888015|Other|Upper extremity exercise|Five upper extremity exercises will be provided to each of the 10 participants to complete on a daily basis. Exercises included shoulder flexion, elbow flexion/extension, shoulder abduction, internal/external rotation
16559270|NCT02888002|Experimental|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
16559271|NCT02888002|Experimental|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
16559272|NCT02887989|Experimental|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
16559273|NCT02887989|Sham Comparator|'Health and Wellness Channel'|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
16559274|NCT02887976|Experimental|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)
16559275|NCT02887950|Active Comparator|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
16559276|NCT02887950|Experimental|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.
~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
16559277|NCT02887950|Experimental|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.
~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
16559278|NCT02887937||Breast Mass 4a-cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
16559279|NCT02887937||Breast Mass 4a- non cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
16559280|NCT02887937||Breast Mass 4b|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
16559281|NCT02887937||Breast Mass 4c|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
16559282|NCT02887924|Active Comparator|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
16559283|NCT02887924|Placebo Comparator|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
16559284|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
16559285|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
16559286|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
16559287|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
16559288|NCT02887898|Active Comparator|Carb counting and bolus calculator|Education in carb counting and the use of an automated bolus calculator
16559289|NCT02887898|Placebo Comparator|Carb counting|Education in carb counting and manual calculation of insulin bolus
16559290|NCT02887872|Experimental|Pilot data|Four participants with chronic stroke participated in a 45-minute combined electrical stimulation-dynamic hand orthosis regimen using the affected upper extremity (UE) 5X/week for 6 weeks.
16559291|NCT02887859|Experimental|HAV Treatment|Human Acellular Vessel (HAV)
16559292|NCT02887846|Active Comparator|group 1|Heated humidified high-flow nasal cannula therapy device for post extubation
16559293|NCT02887846|Active Comparator|group 2|Nasal continuous positive airway pressure for post extubation
16559294|NCT02887833||XRT for Cancer induced bone pain|Will have community based assessment before and after radiotherapy to assess feasibility of using a clinical biomarker (thermal sensory testing) to predict treatment response
16559295|NCT02887820|Other|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
16559296|NCT02887807|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
16559297|NCT02887807|Placebo Comparator|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
16559298|NCT02887794|Experimental|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
16559299|NCT02887768|Experimental|Treatment|Epicardial Infarct Repair with CorMatrix-ECM in addition to coronary artery bypass grafting
16559300|NCT02887755|Experimental|Amputee Group|In this study n=20 returning US military combatants between 18 and 45 years of age who have unilateral transtibial or transfemoral amputation will be asked to perform two aerobic exercise tests while we4aring the NIRS sensor. Subjects must be medically cleared and able to complete approximately 30 minutes of physical activity.
16559301|NCT02887703|Experimental|Sensory Augmentation Group 1|Each subject in Group 1 will undergo 6 weeks of balance training with sensory augmentation followed by 6 weeks of balance training without sensory augmentation.
16559302|NCT02887703|Experimental|Sensory Augmentation Group 2|Each subject in Group 2 will undergo 6 weeks of balance training without sensory augmentation followed by 6 weeks of balance training with sensory augmentation.
16559303|NCT02887690|Experimental|Modular Prosthetic Limb|The Defense Advanced Research Projects Agency's (DARPA) advanced upper limb prosthesis, the Modular Prosthetic Limb (MPL)
16559304|NCT02887677|Active Comparator|Dapagliflozin|Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
16559305|NCT02887677|Placebo Comparator|Placebo|Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
16559306|NCT02887664||Blood test in Mothers of SGA Infants|In mothers of Small for Gestational Age (SGA) Infants, maternal and cord blood test will be performed
16559560|NCT02885597|Placebo Comparator|placebo group|participants should administrate both Juanbi pill placebo and Methotrexate
16559307|NCT02887664||Blood test in Mothers of AGA infants|In mothers of Appropriate for Gestational Age (AGA) Infants, maternal and cord blood test will be performed
16559308|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
16559309|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
16559310|NCT02887638|Experimental|headache|Patients diagnosed (neurologist - anesthesiologist - manual therapist) with tension-type and/or cervicogenic headache. During a first phase the sitting-posture, dura mater profile and pain-profile of the Headache-group will be analyzed. In a second phase, the patients will be sub-classified according to the data-analysis and receive intervention (Individual Profile Analysis +Physical therapy Intervention)
16559311|NCT02887638|No Intervention|asymptomatic controls|Asymptomatic controls, matched for gender and age. During a first phase the sitting-posture, dura mater profile and pain-profile of the control-group will be analyzed.
16559312|NCT02887625|Experimental|Combination Therapy|pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week
16559313|NCT02887625|Active Comparator|Insulin Therapy|"insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) <110 mg/dl.
~and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c <7.0% and postprandial plasma glucose (PPG) <140 mg/dl"
16559314|NCT02887599|Other|Patient Group|Pancreatic cancer patients
16559315|NCT02887599|Other|Control Group|Healthy people without evidence of malignancy
16559316|NCT02887586|Experimental|Auricular Needling group|Patients will receive auricular needling for 4 weeks .
16559317|NCT02887586|No Intervention|control group|This group will receive no treatment. Subjects will be assessed at baseline and the 2th, 4th and 8th week.
16559318|NCT02887573|Experimental|Free-residue nutrients+PEG|"Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.
~Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.
~Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy."
16559319|NCT02887573|Experimental|Low fiber diet+PEG|"Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.
~Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.
~Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.
~Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy."
16559320|NCT02887560|Experimental|All patient|Only one arm has been specified for the protocol. This arm included all study patient (33) for which the intervention is to be administered
16559321|NCT02887547|No Intervention|Control|Control group, with traditional orthodontic mechanics for anterior retraction. Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
16559322|NCT02887547|Experimental|Acceleration|Group with micro-osteoperforation for accelerated tooth movement during anterior retraction, Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
16559323|NCT02887534|Experimental|Arm 1|three times medication; SPARC1401-low dose
16559324|NCT02887534|Experimental|Arm 2|three times medication; SPARC1401-mid dose
16559325|NCT02887534|Experimental|Arm 3|three times medication; SPARC1401-high dose
16559326|NCT02887534|Active Comparator|Active comparator|Reference1401; To be administered 3 times a day
16559327|NCT02887534|Placebo Comparator|Arm 5|Placebo1401 - 3 three times a day
16559328|NCT02887521|Experimental|Pulmonary Rehabilitation (PR)|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
16559329|NCT02887521|Active Comparator|Standard of Care|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
16559330|NCT02887508|Experimental|HINTS Intervention|The HINTS intervention consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills related to a specific topic relevant to online partner seeking and transmission risk reduction, including Internet safety and communication, condom negotiation, and serostatus disclosure.
16559331|NCT02887508|Active Comparator|Healthy Living Control|The Healthy Living Control condition consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills to address non-sexual health-related topics particularly relevant to individuals living with HIV, such as nutrition, healthy eating, portion control, exercise and staying active, and stress reduction.
16559332|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
16559333|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
16559334|NCT02887469|Active Comparator|Intermittent bolus group|"<<Within 6hr>>
~Moderately Severe : 3% saline 2ml/kg over 20min *1 (unknown bwt 100ml)
~Severe :3% saline 2ml/kg over 20min *2 (unknown bwt 100ml)
~<additional treatment> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief
~<<During 6-24hr>>
~- Moderately Severe or Severe
~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief
~<<During 24-48hr>>
~Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief"
16559335|NCT02887469|Active Comparator|slow continuous infusion group|"<<Within 24hr>>
~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)
~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)
~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)
~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na
~if △ Na inc <0.5mmol/hr or △ Na inc <3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped
~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr
~: maintain infusion rate
~<<During 24-48hr>>
~- Moderately Severe and Severe
~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)
~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief
~: stop 3% saline infusion regardless of △ Na
~if △ Na inc <1.5mmol/6hr
~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped
~if △ Na inc ≥ 1.5mmol/6hr
~: maintain infusion rate"
16559336|NCT02887456|Active Comparator|Vitapex|Endodontic treatment using Vitapex
16559337|NCT02887456|Experimental|MTA paste|Endodontic treatment using MTA paste
16559338|NCT02887430|Experimental|intervention|Participants will be received 8 sessions of foot reflexology therapy, 30 minutes each (2 sessions per week of 4 weeks) and low back pain standard care
16559339|NCT02887430|No Intervention|control|participants will be received standard care in general practice
16559340|NCT02887417||patients|glioblastoma patients
16559341|NCT02887417||controls|healthy controls
16559342|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).
~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).
~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
16559343|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).
~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).
~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
16559344|NCT02887391||Conventional Hemodialysis|Control group 4 hours of hemodialysis 3x per week (12 hours hemodialysis/week)
16559345|NCT02887391||In-Centre Nocturnal Hemodialysis|8 hours of hemodialysis 3x per week (24 hours hemodialysis/week)
16559346|NCT02887378|Experimental|hot clamps|reusable hot biopsy forceps
16559347|NCT02887378|Active Comparator|normal clamps|normal clamps
16559348|NCT02887365|Experimental|tegafur-uracil|tegafur-uracil treatment in patients with stage II MSI-L or MSS colon cancer
16559349|NCT02887365|No Intervention|Observation|Observation for one year
16559350|NCT02887339|Experimental|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
16559351|NCT02887339|Experimental|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
16559352|NCT02887326||age 15-25 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
16559353|NCT02887326||age 25-35 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
16559354|NCT02887326||age 35-45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
16559355|NCT02887326||> age 45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
16559356|NCT02887313|Experimental|Locally advanced rectal cancer|Locally advanced rectal cancer receiveing total neoadjuvant treatment
16559357|NCT02887300|No Intervention|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:
~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
16559358|NCT02887300|Experimental|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.
~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:
~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
16559359|NCT02887261|Other|Power Port|patients who received power injectable port
16559360|NCT02887261|Active Comparator|Conventional Port|patients who received conventional port ( not power injectable)
16559361|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.
~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
16559362|NCT02887235|No Intervention|Standard of Care (SOC) Meals|Patient assigned in this arm will receive standard of care nutritional services including nutrition consult, evaluation, and as needed follow-ups.
16559363|NCT02887235|Active Comparator|Medically tailored meals|Patient assigned in this arm will receive home delivered, medically tailored meals (HDMTM) in addition to the standard nutritional care.
16559364|NCT02887222|Active Comparator|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16559365|NCT02887222|Active Comparator|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16559366|NCT02887222|Active Comparator|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16559367|NCT02887222|Active Comparator|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16559368|NCT02887222|Active Comparator|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16559369|NCT02887222|Active Comparator|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16559370|NCT02887209|Experimental|CBT-I|This is a single arm study in which all participants receive the intervention (cognitive behavioural therapy for insomnia)
16559371|NCT02887183|Other|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).
~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
16559372|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).
~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia
~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.
~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
16559373|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.
~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.
~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.
~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
16559374|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:
~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.
~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.
~Ocular and systemic health data will be extracted from the study participant's medical record."
16559375|NCT02887144|Experimental|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:
~SenSura test product
~SenSura"
16559376|NCT02887144|Experimental|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:
~SenSura
~SunSura test product"
16559377|NCT02887131|Experimental|Healthy volunteers|
16559378|NCT02887131|Experimental|Arthritis|
16559379|NCT02887131|Experimental|Instability|
16559380|NCT02887118||Common arm|Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated
16559381|NCT02887105||Patients with cerebrovascular accident|
16559382|NCT02887066||Patients with thoracic pain and suspicion of ACS|
16559383|NCT02887053|Experimental|All subjects|All subjects will have an MRI examination
16559384|NCT02887040|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
16559385|NCT02887040|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
16559386|NCT02887027|Experimental|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
16559387|NCT02887027|Experimental|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
16559388|NCT02887027|Experimental|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
16559389|NCT02887014|Experimental|Group A|Participants getting SPECIFIC VERBAL INSTRUCTIONS before starting bowel preparation (Group A).
16559390|NCT02887014|No Intervention|Group B|Participants getting ordinary instructions as usual in each of the participating centers (Group B).
16559391|NCT02887001|Other|BMO|
16559392|NCT02886988|Experimental|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
16559393|NCT02886988|Placebo Comparator|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
16559394|NCT02886975|Experimental|low protein diet plus α-keto acid|A comparison of normal diet and low protein diet plus α-keto acid after intervention in the same individual
16559395|NCT02886962|Experimental|No anticoagulation|No oral anticoagulation, and no monitoring of the INR.
16559396|NCT02886962|Active Comparator|Oral anticoagulation with vitamin K antagonists|"VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.
~Antiplatelet therapy will be provided only if recent acute coronary syndrome (< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population."
16559397|NCT02886936|Experimental|iFIT Group|This is a feasibility and effectiveness study to assess the iFIT transtibial and transfemoral prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
16559398|NCT02886923|Experimental|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
16559399|NCT02886923|Active Comparator|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
16559400|NCT02886910|Experimental|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
16559401|NCT02886910|Active Comparator|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
16559402|NCT02886897|Experimental|D-CIK and anti-PD-1 Immunotherapy|D-CIK was incubated with anti-PD-1 antibody before infused back into participants
16559403|NCT02886884|Experimental|20 million allogeneic hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
16559404|NCT02886884|Experimental|100 million hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
16559405|NCT02886871|Experimental|Personalized Steps Goal|Step Goal Delivery by Smartphone
16559406|NCT02886871|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
16559407|NCT02886858|Experimental|tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
16559408|NCT02886858|Sham Comparator|Sham tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
16559409|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
16559410|NCT02886845||healthy controls|Woman without breast cancer
16559411|NCT02886832|Experimental|Prostate Health formulation|Prostate Health formulation
16559412|NCT02886819|Experimental|WBV group|whole-body vibration (WBV) group
16559413|NCT02886806|Experimental|high risk vascular surgery|Patients scheduled for high risk vascular surgery under automated total closed loop intravenous anesthesia and fluid management
16559414|NCT02886793|Experimental|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
16559415|NCT02886780|Experimental|Concentrated Exposure Treatment (cET)|Please refer to:Havnen, A., Hansen, B., Öst, L.-G. & Kvale, G. Concentrated ERP delivered in a group setting: An effectiveness study. Journal of Obsessive Compulsive and Related Disorders 3, 319-324 (2014)
16559416|NCT02886780|Active Comparator|Self-help|"The self-help condition (SH):
~Foa, E.B. & Kozak, M.J. Mastery of obsessive-compulsive disorder: Client workbook, (Graywind Publications, New York, 1997)."
16559417|NCT02886780|No Intervention|Wait list|
16559418|NCT02886767|Experimental|skin-to-skin contact (SSC)|Experimental: a daily skin-to-skin contact (SSC) at least 15 minutes in length
16559419|NCT02886767|No Intervention|Control: hospital routine care|As the hospital routine. Allow the father to visit the neonate, touching the neonate
16559420|NCT02886754|Active Comparator|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
16559421|NCT02886754|Active Comparator|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
16559422|NCT02886754|Experimental|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
16559423|NCT02886741|Other|Quality Improvement Campaign|"IHI designed and encouraged implementation of a five-component enhanced surgical site infection (SSI) prevention bundle with three relatively new evidence-based practices and two Surgical Care Improvement Program (SCIP) practices.
~The campaign recruited state organizations to share information about evidence-based practices and publicize IHI activities and intervention materials (a How-to Guide, evidence reviews, a summary of the business case for interventions, and tip sheets for surgeons, other providers, patients and families). A project website and email listserv offered learning opportunities including webinar calls, faculty-led office hours, and town hall meetings."
16559424|NCT02886741|No Intervention|Comparison|Matched state pairs received no campaign intervention and experienced usual care
16559425|NCT02886728|Experimental|Filgotinib 200 mg + MTX|Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
16559426|NCT02886728|Experimental|Filgotinib 100 mg + MTX|Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
16559427|NCT02886728|Experimental|Filgotinib 200 mg Monotherapy|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
16559428|NCT02886728|Active Comparator|MTX Monotherapy|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
16559429|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
16559430|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
16559431|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
16559432|NCT02886702|Experimental|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
16559433|NCT02886702|Active Comparator|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
16559434|NCT02886702|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
16559435|NCT02886689||1|patients will be those receiving any biotherapy
16559436|NCT02886689||2|patients will be those not receiving biotherapy : non indication, refusal, contraindication.
16559437|NCT02886676|Experimental|Spirulina capsules and scaling & root planing|Patients in test group will be provided with Spirulina capsules 2gm daily, after meals for 1 month
16559438|NCT02886676|Active Comparator|Placebo capsules and scaling & root planing|Patients in test group will be provided with placebo capsules after meals for 1 month
16559439|NCT02886663|Experimental|immediate rehabilitation|
16559440|NCT02886663|Other|delayed rehabilitation|
16559441|NCT02886650|Experimental|Thermocoagulation|
16559442|NCT02886637||Acinetobacter baumannii infection|Critically ill patients infect with Acinetobacter baumannii
16559443|NCT02886624|Experimental|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
16559444|NCT02886598||Firmagon®|Treatment according to standard clinical practice.
16559445|NCT02886585|Experimental|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases
~Baseline Brain MRI and PET CT
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.
~Brain MRI and PET/CT"
16559446|NCT02886585|Experimental|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases
~Baseline Brain MRI and PET CT
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.
~Brain MRI and PET/CT"
16559447|NCT02886585|Experimental|Neoplastic Meningitis-Cohort C|"Neoplastic Meningitis
~Histologically confirmed solid malignancy
~Positive Cytology
~Baseline Brain MRI
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.
~Brain MRI and PET/CT"
16559448|NCT02886585|Experimental|1-4 Brain Metastases from Melanoma Cohort D|"1-4 Brain Metastases from Melanoma
~Clinical indication for stereostatic radiosurgery
~Evaluable extracranial focus
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.
~Brain MRI and PET CT"
16559449|NCT02886572|Experimental|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
16559450|NCT02886559|Experimental|DCCAG|Chidamide 30mg twice for one week decitabine 20mg/m^2 for 5 days
16559451|NCT02886520|Active Comparator|PVDF transobturator tape|Transobturator tension-free suburethral tape made of polyvinylidene fluoride.
16559452|NCT02886520|Active Comparator|PP transobturator tape|Transobturator tension-free suburethral tape made of polypropylene.
16559453|NCT02886507|Active Comparator|NSK-SD (nattokinase)|One capsule (100 mg) nattokinase/day for the 8-week study duration.
16559454|NCT02886507|Placebo Comparator|Placebo|One capsule placebo/day for the 8-week study duration.
16559455|NCT02886494|Active Comparator|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
16559456|NCT02886494|Placebo Comparator|Matched vehicle|Matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
16559457|NCT02886468|Experimental|ultrasound images|ultrasound images of the anterolateral aspect of the mid-right thigh
16559458|NCT02886455|Experimental|Cohort 4|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin at two different time points (4 and 24 hours).
~There are two visits:
~Visit 1:
~Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 4 hours before being removed
~Visit 2: Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 24 hours before being removed"
16559459|NCT02886442|Experimental|Cohort 3|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.
~There are two kinds of visits:
~Visit 1:
~Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.
~Visit 2:
~Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.
~Visit 2:"
16559460|NCT02886429|Active Comparator|Group A|Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
16559461|NCT02886429|Active Comparator|Group B|Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
16559462|NCT02886403|Experimental|Cohort 02|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.
~There are two visits:
~The first visit:
~Two adhesive strips (standard adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not.
~The second visit:
~Two adhesive strips (new adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not."
16559463|NCT02886390|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
16559464|NCT02886390|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
16559465|NCT02886377||NMOSD-ON|NMOSD-ON included patients who met the established diagnostic criteria for NMO or NMOSD published by Wingerchuk et al,with AQP4 seropositive according to the results of the AQP4-Ab test.
16559466|NCT02886377||MS-ON|MS-ON group patients included typical acute demyelinating ON with brain lesions fulfilling the revised McDonald criteria or clinical isolate syndrome (CIS), with AQP4 seronegative according to the results of the AQP4-Ab test.
16559467|NCT02886377||Healthy controls|Age- and gender- matched healthy controls.
16559468|NCT02886364|Other|Women delivered at AAC Hospital|The intervention is only being implemented at the Ángel Albino Corzo Hospital due to limited funding. The site was selected by the Ministry of Health in Chiapas as a hospital that would benefit from improved quality of care around childbirth. There are no other arms in this study.
16559469|NCT02886351|Experimental|nitrous oxide|Administration of high concentration of nitrous oxygen in pediatric dentistry
16559470|NCT02886338|Experimental|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
16559471|NCT02886299|Active Comparator|Fenofibrate group|Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
16559472|NCT02886299|Active Comparator|Simvastatin group|Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).
16559473|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
16559474|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
16559475|NCT02886273||Group 1|SCA with first MI (n = 43)
16559476|NCT02886273||Group 2|SCA with AMI and previous MI (n = 10)
16559477|NCT02886273||Group 3|SCA without AMI and without former heart disease (n = 3)
16559478|NCT02886273||Group 4|SCA without AMI and with known heart disease (n = 18)
16559479|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
16559480|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
16559481|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
16559482|NCT02886221|Other|HV patients|patients with symptomatic Hallux Valgus treated my Reverdin-Isham Osteotomy
16559483|NCT02886208|Experimental|Intervention|This study has a single arm. All participants in a summer employment program at an urban farm in Indianapolis, IN are invited to participate.
16559484|NCT02886195|Experimental|PC plus erlotinib|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy
16559485|NCT02886195|Active Comparator|erlotinib|"erlotinib 150mg/d until progress disease"
16559486|NCT02886195|Active Comparator|PC|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles
16559487|NCT02886182||group A|pregnants who were positivity for serum HBsAg for more than 6 months and HBeAg , HBV DNA >106IU/mL, alanine aminotransferase (ALT) below 35 IU/mL (ULN=40IU/mL) and no received nucleoside analogue antiviral therapy were enrolled into group A
16559488|NCT02886182||group B|the CHB infection pregnants with undetectable HBVDNA were enrolled into group B(control group)
16559489|NCT02886169|Experimental|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
16559490|NCT02886169|Placebo Comparator|unsupplemented group|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
16559491|NCT02886156|Experimental|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
16559492|NCT02886156|Active Comparator|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
16559493|NCT02886143|Experimental|Active Voiding Trial (instillation of sterile saline)|Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.
16559494|NCT02886143|Active Comparator|Passive Voiding Trial|For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.
16559495|NCT02886130|Placebo Comparator|Placebo|Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
16559496|NCT02886130|Experimental|Alpha-GPC|Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
16559497|NCT02886104|Active Comparator|CRLM resection group|Resection of both primary and secondary tumors in SCRLM and resection of MCRLM. Interventions: Simultaneous resection of both primary and secondary tumors in SCRLM and resection of MCRLM.
16559498|NCT02886104|Experimental|CRLM ablation group|"Ablation of CRLM after resection of primary tumor in SCRLM and ablation of MCRLM.
~Interventions: Ablation of liver metastasis within 30 days after resection of primary tumor in SCRLM and ablation of MCRLM."
16559499|NCT02886078|Experimental|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
16559500|NCT02886078|Active Comparator|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
16559501|NCT02886065|Experimental|PVX-410 + Citarinostat|"Participants will receive:
~6 biweekly doses of PVX-410
~6 biweekly doses of Hiltonol
~3 monthly cycles of Citarinostat"
16559502|NCT02886065|Experimental|PVX-410 + Citarinostat + Lenalidomide|"Participants will receive:
~6 biweekly doses of PVX-410
~6 biweekly doses of Hiltonol
~3 monthly cycles of Citarinostat
~3 monthly cycles of Lenalidomide"
16559503|NCT02886052|Experimental|ICBT for insomnia|Therapist guided Internet-CBT for insomnia
16559504|NCT02886052|Active Comparator|Active control|Written information on sleep, insomnia, and sleep hygiene
16559505|NCT02886039|Other|patients|Patient with cardiac arrest benefiting an electroencephalogram
16559506|NCT02886026|Active Comparator|Inpatient TUR-BT|Transurethral bladder tumor resection in operating theatre as inpatient.
16559507|NCT02886026|Experimental|laser bladder tumor destruction|Outpatient laser mediated destruction of bladder tumors (LMD-BT)
16559508|NCT02886013||Mexican adolescents|"Students without known disease, between 14 and 18 years from the Lic. Adolfo Lopez Mateos Preparatory school of the Autonomous University of the State of Mexico (UAEMex)."
16559509|NCT02885987|No Intervention|Standard Colonoscopy|AmplifEYE will not be used.
16559510|NCT02885987|Experimental|Colonoscopy with AmplifEYE|AmplifEYE accessory device will be attached to the colonoscope prior to starting the procedure
16559511|NCT02885974|Experimental|Celecoxib plus Gemcitabine/Cisplatin chemo|Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy
16559512|NCT02885961|Other|Dabigatran|"All patients will be entered into the arm, i.e. this is a single arm study. All patients will complete 2 FDG PET scans. All patients will receive dabigatran (direct thrombin inhibitor) at a dose of 110mg twice daily (oral).
~The drug will be given for 24 days (+/-3 days). The variation in duration reflects that scans are completed Monday to Friday only."
16559513|NCT02885948|Experimental|Naloxone|"The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.
~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution."
16559514|NCT02885948|Placebo Comparator|Saline|The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.
16559515|NCT02885935|Experimental|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
16559516|NCT02885935|Experimental|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
16559517|NCT02885909|Active Comparator|Insulin protocal with CGM|Insulin protocal with continue glucose monitor
16559518|NCT02885909|Active Comparator|Insulin protocal|Insulin protocal with convential glucose monitor
16559519|NCT02885909|No Intervention|Convential treatment|Convential insulin treatment and glucose monitor
16559520|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
16559561|NCT02885584|Experimental|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
16559521|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
16559522|NCT02885883|Active Comparator|a control group|
16559523|NCT02885883|Experimental|patients with paroxysmal or persistent AF|
16559524|NCT02885883|Experimental|patients with permanent AF|
16559525|NCT02885870|Experimental|Patient|"Patient with :
~Spinal muscular atrophy (n=25)
~X-linked spinobulbar muscular atrophy (n=25)
~Amyotrophic lateral sclerosis (n=25)"
16559526|NCT02885870|Experimental|Healthy subject|Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
16559527|NCT02885857|Experimental|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
16559528|NCT02885844|Experimental|INVERTED VISION|inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
16559529|NCT02885844|Active Comparator|NORMAL VISION|During normal vision trials, subject's field of view will be restricted by goggles without lenses (see below) in order to be equivalent to the inverted vision one.
16559530|NCT02885831||A - Abduction splintage|Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
16559531|NCT02885831||B - Surveillance|No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients
16559532|NCT02885805|Experimental|SPF evaluation + Control|Fair-skinned subjects in good health with Skin Types I, II or III.
16559533|NCT02885792|Experimental|Debuting and chronic schizophrenia|"ILLNESS HISTORY:
~Existing psychiatric and somatic diagnosis and treatment
~Charlson co-morbidity
~MEASURE OF SOCIAL CONDITIONS
~- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.
~MEASURE OF PSYCHIATRIC CONDITION::
~Positive and Negative Syndrome Scale (PANSS)
~Clinical Global Impression Scale (CGI)
~Columbia Suicide Severity Rating Scale (C-SSRS)
~Beck Cognitive Insight Scale
~Birchwood Insight Scale
~CARDIOVASCULAR MEASUREMENT:
~CT Coronary angiography (CT-CAG)
~Echocardiography
~Heart rate variability (HRV)
~Pulmonary function test (PFT)
~Toe blood pressure (TBP)
~Blood test
~Body composition analysis
~CT scan of upper abdomen
~Cardiovascular magnetic resonance imaging (CMR)
~Adipose tissue biopsy"
16559534|NCT02885792|Active Comparator|Matched controls|"CARDIOVASCULAR MEASUREMENT:
~CT Coronary angiography (CT-CAG)
~Echocardiography
~Heart rate variability (HRV)
~Pulmonary function test (PFT)
~Toe blood pressure (TBP)
~Blood test
~Body composition analysis
~CT scan of upper abdomen
~Cardiovascular magnetic resonance imaging (CMR)
~Adipose tissue biopsy"
16559535|NCT02885779||Patient having an operating indication of adnexa surgery|Patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy
16559536|NCT02885766|Experimental|PF-114|"PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.
~When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.
~Orally, once daily"
16559537|NCT02885753|Experimental|Experimental arm with oxaliplatin intra-arterial|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intra-arterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
16559538|NCT02885753|Active Comparator|Reference arm with oxaliplatin intravenous|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
16559539|NCT02885740|Experimental|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
16559540|NCT02885740|Active Comparator|Control|Patients having a junctional supraventricular tachycardia in normal heart
16559541|NCT02885727|Experimental|Durvalumab + Radiation therapy|"Durvalumab (MEDI4736) 750 mg (or 10mg/kg if the patient weighs <30 kg) IV Q2W over 1 hour for all patients + Radiation therapy
~First lesion to receive 25 Gy / 5 daily consecutive fractions of 5 Gy
~Second lesion to receive15 Gy / 5 daily consecutive fractions"
16559544|NCT02885701|Experimental|No splint|
16559545|NCT02885701|Experimental|Removable Splint|
16559546|NCT02885701|Experimental|Non-removable Splint|
16559547|NCT02885688|Other|Standard-of-Care Treatment for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment alone for up to 7 days.
16559548|NCT02885688|Experimental|Standard-of-Care Treatment Plus Liquid Nutrition for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment plus plus liquid nutrition for up to 7 days.
16559549|NCT02885675||ARDS|
16559550|NCT02885675||Healthy control|
16559551|NCT02885662|Experimental|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
16559552|NCT02885649|Experimental|Treatment (enzalutamide, nephrectomy)|Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.
16559553|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
16559554|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
16559555|NCT02885610|Placebo Comparator|Placebo Comparator|Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
16559556|NCT02885610|Experimental|RC18 80 mg plus standard therapy|RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
16559557|NCT02885610|Experimental|RC18 160 mg plus standard therapy|RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
16559558|NCT02885610|Experimental|RC18 240 mg plus standard therapy|RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses
16559559|NCT02885597|Experimental|Juanbi group|participants should administrate both Juanbi pill and Methotrexate
16559562|NCT02885584|No Intervention|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
16559563|NCT02885571|Active Comparator|MAD for subjective compliance|MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
16559564|NCT02885571|Experimental|MAD for objective compliance|MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.
16559565|NCT02885558|Experimental|L + T-type|8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
16559566|NCT02885558|Active Comparator|L-Type|8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
16559567|NCT02885545|Experimental|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
16559568|NCT02885545|Active Comparator|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
16559569|NCT02885519|No Intervention|Control|Standard treatment and standard vocational rehabilitation
16559570|NCT02885519|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
16559571|NCT02885519|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
16559572|NCT02885506|Experimental|Cohort 1|Oral administration of P218 capsules 10 mg
16559573|NCT02885506|Experimental|Cohort 2|Oral administration of P218 capsules 30 mg
16559574|NCT02885506|Experimental|Cohort 3|Oral administration of P218 capsules 100 mg
16559575|NCT02885506|Experimental|Cohort 4|Oral administration of P218 capsules 250 mg
16559576|NCT02885506|Experimental|Cohort 5|Oral administration of P218 capsules 500 mg
16559577|NCT02885506|Experimental|Cohort 6|Oral administration of P218 capsules 750 mg
16559578|NCT02885506|Experimental|Cohort 7|Oral administration of P218 capsules 1000 mg
16559579|NCT02885506|Placebo Comparator|Cohort 8 - Pooled Placebo|Oral administration of P218 matching placebo
16559580|NCT02885506|Experimental|Fed - Fasted|Oral administration of P218 capsules 250 mg Under fed then fasted conditions.
16559581|NCT02885506|Experimental|Fasted - Fed|Oral administration of P218 capsules 250 mg Under fasted then fed conditions.
16559582|NCT02885493||Falls is <or = 1 year|Patients whose number of falls is <or = 1 year
16559583|NCT02885493||falls is> 1 year|Patients whose numbers falls is> 1 year
16559584|NCT02885467|Active Comparator|Control|Standard total knee arthroplasty performed through medial parapatellar approach
16559585|NCT02885467|Experimental|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
16559586|NCT02885454|Experimental|OC + AL-335 + ODV + 3-DAA combination|Participants will receive single dose of 3 milligram (mg) drospirenone/0.02 mg ethinylestradiol [OC] on Day 1, AL-335 800 mg once daily on Days 5 and 6, a single dose of AL-335 800 mg + a single dose of OC on Day 7, ODV 25 mg once daily on Days 12 to 24, followed by a single dose of ODV 25 mg and a single dose of OC on Day 25, followed by ODV 25 mg + AL-335 800 mg + simeprevir (SMV) 75 mg [3-DAA combination] once daily on Days 26 to 31, followed by a single dose of 3-DAA combination and a single dose of OC on Day 32.
16559587|NCT02885441|Experimental|Ketorolac|Ketorolac,10 mg, 3 times daily from time of enrollment until 72 hours from enrollment for up to a maximum of 9 doses, along with the standard medical treatment
16559588|NCT02885441|No Intervention|Control|The standard medical treatment
16559589|NCT02885402|Experimental|Osteoarthritis patient|
16559590|NCT02885402|Placebo Comparator|Healthy volunteers|
16559591|NCT02885376|Experimental|Dentoxol|Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. Subjects will use Dentoxol® mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
16559592|NCT02885376|Placebo Comparator|Placebo|The placebo rinse will be identical in color, taste and consistency as the Dentoxol rinse and will be packaged in identical bottles with the same labels. Subjects will use placebo mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
16559593|NCT02885363|Experimental|Patients with newly diagnosed Left Ventricular Non Compaction|Patient newly diagnosed with Left Ventricular Non Compaction (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
16559594|NCT02885363|Active Comparator|Patients with Idiopathic Dilated Cardiomyopathy|Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
16559595|NCT02885350|Active Comparator|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
16559596|NCT02885350|Experimental|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
16559597|NCT02885350|Active Comparator|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
16559598|NCT02885350|Experimental|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
16559599|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.
~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
16559600|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.
~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.
~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.
~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.
~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
16559601|NCT02885324|Experimental|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
16559602|NCT02885311|Other|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
16559603|NCT02885311|Other|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
16559604|NCT02885311|Other|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy [MBSCT]) adapted from our two prior protocols. These participants will also receive follow up assessments.
16559605|NCT02885311|Other|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
16559606|NCT02885298||Supine intubations (0-10 degrees)|Intubations performed with patient positioned 0-10 degrees. Patient supine.
16559607|NCT02885298||Inclined (11-44 degrees)|Intubations performed with 11-44 degrees of elevation.
16559608|NCT02885298||Upright (45 degrees or greater)|intubations performed with patient elevated to 45 degrees or greater
16559609|NCT02885285|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16559610|NCT02885285|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16559611|NCT02885285|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16559612|NCT02885285|Active Comparator|No Exercise Class|Subjects randomly selected for the no class group will not participate in the study exercise classes. Subjects will still complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
16559613|NCT02885272|Experimental|Diagnostic (PET/CT)|Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
16559614|NCT02885259|Experimental|HyQvia|human immunoglobulin and one vial of recombinant human hyaluronidase (rHuPH20
16559615|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
16559616|NCT02885233|Active Comparator|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
16559617|NCT02885233|Placebo Comparator|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
16559618|NCT02885220|Active Comparator|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
16559619|NCT02885220|Experimental|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
16559620|NCT02885207|Other|Focal epilepsy of unknown cause|
16559621|NCT02885194|Other|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
16559622|NCT02885181|Experimental|GS-9876 - 30 mg|GS-9876 30 mg + filgotinib placebo for 12 weeks
16559623|NCT02885181|Experimental|GS-9876 - 10 mg|GS-9876 10 mg + filgotinib placebo for 12 weeks
16559624|NCT02885181|Experimental|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
16559625|NCT02885181|Placebo Comparator|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
16559626|NCT02885168|Experimental|Shock + Treatment|Patients treated with activated protein C
16559627|NCT02885168|Other|Shock|Patients not treated with activated protein C
16559628|NCT02885155||Patients with pulmonary arterial hypertension|
16559629|NCT02885142|Experimental|Transanal endoscopic microsurgery group|
16559630|NCT02885142|Active Comparator|endoscopic submucosal dissection group|
16559631|NCT02885116|Placebo Comparator|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
16559632|NCT02885116|Active Comparator|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
16559633|NCT02885103|Placebo Comparator|inhalation with nebulizer|inhalation with an nebulizer via mouth
16559634|NCT02885103|Active Comparator|inhalation with nebulizer and NHF|inhalation with combination of nebulizer and nasal high flow (NHF) via nasal cavity
16559635|NCT02885090|Experimental|RTT patient|Blood sampling
16559636|NCT02885090|Experimental|Parents|Blood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
16559637|NCT02885077|Experimental|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
16559638|NCT02885077|Sham Comparator|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
16559639|NCT02885051|Experimental|preterm newborn|Newborns hospitalized in the neonatal or Neonatal Resuscitation unit of Brest University Hospital and born before 36 weeks of gestation who will have recording of skin conductance and heart rate variability.
16559640|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:
~Broccoli Sprout Extract + Nasal Fluticasone
~Broccoli Sprout Extract + normal saline nasal spray
~Placebo Pill + Nasal Fluticasone
~Placebo Pill + normal saline nasal spray"
16559641|NCT02885025|Active Comparator|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:
~Broccoli Sprout Extract + Nasal Fluticasone
~Broccoli Sprout Extract + normal saline nasal spray
~Placebo Pill + Nasal Fluticasone
~Placebo Pill + normal saline nasal spray"
16559642|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:
~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
16559643|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:
~Broccoli Sprout Extract + Nasal Fluticasone
~Broccoli Sprout Extract + normal saline nasal spray
~Placebo Pill + Nasal Fluticasone
~Placebo Pill + normal saline nasal spray"
16559644|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
16559645|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
16559646|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
16559647|NCT02884986|Active Comparator|Etoricoxib|120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
16559648|NCT02884986|Placebo Comparator|Placebo|120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
16559649|NCT02884960|Experimental|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
16559650|NCT02884960|Active Comparator|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
16559651|NCT02884921|Active Comparator|Preemptive Paracetamol|Preemptive Paracetamol
16559652|NCT02884921|Active Comparator|Post surgery Paracetamol|Post surgery Paracetamol
16559653|NCT02884921|Placebo Comparator|Placebo|Placebo
16559654|NCT02884908|Experimental|Pregabalin + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
16559655|NCT02884908|Experimental|Pregabalin + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
16559656|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
16559657|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
16559658|NCT02884895|Experimental|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
16559659|NCT02884895|Active Comparator|Direct Laryngoscopy|Direct Laryngoscopy
16559660|NCT02884882|Other|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
16559661|NCT02884882|Placebo Comparator|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
16559662|NCT02884869|Experimental|Intubating laryngeal Mask|Intubating laryngeal Mask
16559663|NCT02884869|Active Comparator|Direct laryngoscopy|Intubating laryngeal Mask
16559664|NCT02884856||Females observers (F)|those with female gender characteristics
16559665|NCT02884856||Male observers (M)|those with male gender characteristics
16559666|NCT02884843|Active Comparator|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
16559667|NCT02884843|Active Comparator|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
16559668|NCT02884830|Placebo Comparator|Sham CPAP|Sham continuous positive airway pressure is a CPAP given at too low pressure to have any physiological effect on upper airways patency and on lung volumes
16559669|NCT02884830|Active Comparator|Efficace CPAP|Continuous positive airway pressure is a CPAP given at effective pressure to decrease the work of breathing in COPD patients
16559670|NCT02884817|Experimental|Listerine prof.gum.ther|"The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson & Johnson,USA).
~Intervention; Rinsing 30 sec with test solution twice daily for 21 days"
16559671|NCT02884817|Placebo Comparator|21.6% hydroalcoholic|"a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.
~Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days"
16559672|NCT02884817|Sham Comparator|Plain sterile water|"Plain sterile water.
~Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days"
16559673|NCT02884791|Experimental|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
16559674|NCT02884791|Experimental|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
16559675|NCT02884778|Experimental|NoL index in response to stimulation|"There is only one arm in this study. The intervention is not a drug, but it is the stimulus applied to the patient such as intubation and a standardized electrical stimulus applied on the forearm of the anesthetized patient. There are several stimuli that are the so-called interventions and the NoL index and the classical vital signs (heart rate, mean blood pressure, BISspectral index) are registered in response to these stimuli in an observational manner."
16559676|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
16559677|NCT02884739||schizophrenia|
16559678|NCT02884739||chronic psychiatric disorder other than schizophrenia|
16559679|NCT02884726|Experimental|BMS-986148 intravenous infusion|
16559680|NCT02884713|Experimental|Levofloxacin and Doxycycline and Esomeprazole|The rescue treatment was given for ten days consisting of levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily
16559681|NCT02884700||Severe legionellosis cases|Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
16559682|NCT02884674|Active Comparator|active Transcranial Magnetic Stimulation|Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
16559683|NCT02884674|Placebo Comparator|Placebo|Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
16559684|NCT02884661||Hospitalization in Cardiology department|Patients cared by the Cardiology department
16559685|NCT02884661||Hospitalization in Geriatric unit|Patients cared by the Geriatric unit
16559686|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
16559687|NCT02884635|Experimental|ASP1707|ASP1707 will be orally administered for 12 weeks.
16559688|NCT02884635|Placebo Comparator|Placebo|Placebo will be orally administered for 12 weeks.
16559689|NCT02884622|Other|CF patients|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added and blood sampling will be collected for this study
16559690|NCT02884583|Experimental|Pulmonary function test|Patients hospitalized for Oral Food Challenge realize pulmonary function test
16559691|NCT02884557|Other|PSC + IBD group|collection of gut biopsies collection of blood samples in patients with PSC and IBD
16559692|NCT02884557|Other|IBD alone group|collection of gut biopsies collection of blood samples in patients with IBD alone
16559693|NCT02884544|Experimental|HLD100 10mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
16559694|NCT02884544|Experimental|HLD100 20mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
16559695|NCT02884544|Experimental|HLD100 30mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
16559696|NCT02884544|Experimental|HLD100 40mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)
16559697|NCT02884531|Experimental|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
16559698|NCT02884531|Active Comparator|Patient Education|Patients will only participate in Patient Education
16559699|NCT02884518|Experimental|patient group|The patient group recruits subjects diagnosed with first episode psychosis which occurred within 2 years and having been treated with antipsychotics for 1 year. Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity. And patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
16559700|NCT02884518|Other|healthy control group|Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
16636247|NCT02373423|No Intervention|Control|No intervention program
16559701|NCT02884505||Patients with Hypersomnolence|Patients referred for polysomnography and multiple sleep latency test
16559702|NCT02884492|Experimental|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
16559703|NCT02884492|Active Comparator|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
16559704|NCT02884479|Experimental|PT-112 + Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
16559705|NCT02884466|Experimental|Intervention group|The intervention group will receive a multidisciplinary rehabilitation intervention consisting of: 1) a pre-admission day, 2) two weeks of home-based activities, 3) two-week inpatient period, 4) four weeks of home-based activities, 5) 1st two-days inpatient follow-up, 6) six weeks of home-based activities and 7) 2nd two-days inpatient follow-up.
16559706|NCT02884466|Active Comparator|Usual care group|The usual care group will receive a four-week inpatient multidisciplinary rehabilitation intervention.
16559707|NCT02884453|Experimental|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
16559708|NCT02884440|Experimental|TAP block ropivacaine|Bilateral ultrasound guided with 15 ml ropivacaine 5mg/ml on each side under general anesthesia at the end of the intervention
16559709|NCT02884440|Placebo Comparator|TAP block placebo|Bilateral ultrasound guided with 15 ml saline on each side under general anesthesia at the end of the intervention
16559710|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
16559711|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
16559712|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
16559713|NCT02884414|Experimental|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
16559714|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
16559715|NCT02884388|Experimental|experimental group|Combined nerve block will be used, involving lower lumbar plexus, sciatic nerve, and paraspinal nerve L1-2.
16559716|NCT02884388|Experimental|control group|General anesthesia will be used in this group.
16559717|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
16559718|NCT02884349|Experimental|RoM assessment|All patients recruited to the study.
16559719|NCT02884323|Experimental|geko device arm|
16559720|NCT02884310|Experimental|SPI group|"Remifentanil titration before tracheal intubation and skin incision according to the SPI gradient obtained after a nociceptive test using a tetanic stimulus of 100 Hz, 60 milliamperes during 30 seconds performed at a 3 ng/ml level of the remifentanil concentration.
~During surgery, the effect site remifentanil concentration was either increased or decreased by 1 ng/ml to maintain SPI below 40 or above 20, respectively."
16559721|NCT02884310|Active Comparator|Control group|"The remifentanil concentration before tracheal intubation and skin incision was fixed at 4 ng/ml.
~During surgery, the remifentanil concentration was adapted according to the hemodynamic answer of the patient. It was changed by 1 ng/ml stepwise variations to maintain heart rate and mean blood pressure within 20% of the patient reference hemodynamic values."
16559722|NCT02884297|Experimental|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
16559723|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
16559724|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
16559725|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
16559726|NCT02884258||Control Group|1. Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age. 2. non-operated severely obese women
16559727|NCT02884245|Experimental|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
16559728|NCT02884245|No Intervention|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
16559729|NCT02884232||Workers exposed to wood dust|
16559730|NCT02884219|Active Comparator|Early Treatment with cyclooxygenase inhibitors|Treatment of PDA that starts within the first 3 days of life using cyclooxygenase-inhibitors (Ibuprofen or Indomethacin)
16559731|NCT02884219|Sham Comparator|Expectative Treatment|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
16559734|NCT02884193|Experimental|Brief Cooling (Quick Icing)|Group receiving the application of cold on the ventral side of the dominant forearm for 30 seconds, using the technique of ice beakers dynamically.
16559735|NCT02884193|Active Comparator|Prolonged Cold|"Group receiving the intervention of ice bag for a period of 5 and a half minutes from 1 minute, on the ventral side of the dominant forearm"
16559736|NCT02884193|Sham Comparator|Control|"Group receives a placebo application through an ice bag empty. The bag will be applied from 1 minute to 6 and a half minutes, as the group of prolonged cold"
16559737|NCT02884180|Active Comparator|Treatment A|Dexamethasone 24 mg i.v. after start of anaesthesia
16559738|NCT02884180|Placebo Comparator|Treatment B|Saline isotonic i.v. after start of anaesthesia
16559739|NCT02884167||Patients with constipation|
16559740|NCT02884167||Healthy individuals without constipation|
16559741|NCT02884154|Other|Arm who will undergo EUS-FNB|
16559742|NCT02884141||Patients|"Patients with documented fibromuscular dysplasia (see inclusion criteria).
~Non-usual care added acts:
~blood sampling
~urine sampling
~renal echography"
16559743|NCT02884128|Experimental|PEP02 + 5-FU/LV|The initial starting dose of PEP02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-FU and LV were given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. PEP02 was administered on Day 1; 5-FU/LV was started after the end of PEP02 infusion on Day 1 and also on Day 8.
16559744|NCT02884115|Active Comparator|Retreatment group|Serofast early syphilis cases retreated with three doses benzathine penicillin
16559745|NCT02884115|No Intervention|Control group|Absence of any retreatment
16559746|NCT02884089|Placebo Comparator|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
16559747|NCT02884089|Experimental|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
16559748|NCT02884089|Placebo Comparator|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
16559749|NCT02884089|Experimental|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
16559750|NCT02884076||Symptomatic Hemorrhoid|Consecutive patients with symptomatic hemorrhoids presenting to our clinic
16559751|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
16559752|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
16559753|NCT02884050|Experimental|Topiramate|single, 100mg oral dose of topiramate
16559754|NCT02884050|Placebo Comparator|Placebo|matched inactive placebo
16559755|NCT02884037||1|Rifaxmin group
16559756|NCT02884037||2|placebo group
16559757|NCT02884024||lean|healthy subject undergoing routine screening colonoscopy, BMI< or = 25
16559758|NCT02884024||mildly obese|healthy subject undergoing routine screening colonoscopy, BMI 30-33.9
16559759|NCT02884024||moderate-to-severe obese|healthy subject undergoing routine screening colonoscopy, BMI 34+
16559760|NCT02884011||No chronic antihypertensives|not on either a chronic β-blocker or ACE-Inhibitor
16559761|NCT02884011||β-blocker|on chronic β-blocker
16559762|NCT02884011||ACE-Inhibitor|on chronic ACE-Inhibitor
16559763|NCT02884011||Both β-blocker and ACE-inhibitor|on both chronic β-blocker and ACE-inhibitor
16559764|NCT02883998|Active Comparator|Outpatient Physical Therapy Group|Once the patient is cleared for discharged from the hospital, the patient will be given a prescription for outpatient physical therapy to attend 3 times per week for 6 weeks.
16559765|NCT02883998|Experimental|Home Base Physical Therapy Group|Patients will be provided a packet of exercises and equipment to perform the home based physical therapy program. Patients will attend a single session of outpatient physical therapy prior to surgery no more than 4 weeks prior to the procedure to teach the patient how to perform the exercises.
16559766|NCT02883985|Experimental|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
16559767|NCT02883972|Experimental|Intervention letter and reminder|Behavioural insights informed invitation letter and SMS/email reminder message
16559768|NCT02883972|Experimental|Intervention letter|Behavioural insights informed invitation letter only
16559769|NCT02883972|Experimental|Control letter and reminder|Control invitation letter and SMS/email reminder message
16559770|NCT02883972|Active Comparator|Control letter|Control invitation letter only
16559771|NCT02883959|Experimental|music therapy|Music therapy
16559772|NCT02883959|No Intervention|control arm|No music
16559773|NCT02883946||hairy-cell leukemia|Patients with hairy-cell leukemia.
16559774|NCT02883933||melanoma|Patients with melanoma.
16559775|NCT02883920||workers of Champagne vineyard|
16559776|NCT02883907||Healthy volunteers|
16559777|NCT02883907||Osteoarthritis patients|
16559778|NCT02883894||bullous pemphigoid|Patients with bullous pemphigoid.
16559779|NCT02883881||No eye rubbing|
16559780|NCT02883881||with eye rubbing|
16559781|NCT02883868||patients treated with CXL|
16559782|NCT02883842|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
16559783|NCT02883842|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
16559784|NCT02883829|Experimental|Peer-Based Delivery|The Peer-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a peer will be the spokesperson delivering the intervention content.
16559823|NCT02883569|Experimental|LSS w/ instability - NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
16559785|NCT02883829|Experimental|Provider-Based Delivery|The Provider-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a healthcare provider will be the spokesperson delivering the intervention content.
16559786|NCT02883816|Experimental|cystic fibrosis|assessment of lung function in newborns screened for cystic fibrosis
16559787|NCT02883803|Experimental|MSC|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.
16559788|NCT02883803|Sham Comparator|Placebo|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.
16559789|NCT02883790|Experimental|Somnage|Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
16559790|NCT02883790|Placebo Comparator|Placebo|Oral administration o.d.
16559791|NCT02883777|Experimental|High Protein and Low Glycemic Index Diet|A protocol of a high protein and low glycemic index diet.
16559792|NCT02883777|Active Comparator|Conventional Diet|A protocol of a conventional diet.
16559793|NCT02883751|Active Comparator|Control group|Control group - gold standard: Conventional ulcer treatment with Rayon® and essential fatty acids (Dersani®). Cleaning of the surgical wound will be performed with saline solution. The wound will then be covered with a sterile polyethylene film, over which the LED plate will be positioned for placebo treatment (emission of sound, but with the device switched off). After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
16559794|NCT02883751|Experimental|LED group|LED group: Cleaning of the surgical wound will be performed with saline solution and the wound will be covered with a sterile polyethylene film, over which the LED plate will be positioned for active treatment with the device switched on. After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
16559795|NCT02883738|Experimental|upper limb tremor|
16559796|NCT02883725||Esophageal atresia|
16559797|NCT02883699|Active Comparator|Endurance Training Group 1|Standard endurance training
16559798|NCT02883699|Experimental|Endurance Training Group 2|Polarized endurance training
16559799|NCT02883699|Active Comparator|Resistance Training Group 1|Standard resistance training
16559800|NCT02883699|Experimental|Resistance Training Group 2|Daily undulating periodization resistance training
16559801|NCT02883686|Experimental|Alma Mentoring plus usual care|Alma peer-mentoring
16559802|NCT02883686|No Intervention|Enhanced Usual Care|Usual care for depression within the Kaiser Permanente of Colorado healthcare system plus study monitoring of depression symptoms and feedback.
16559803|NCT02883673|Experimental|Intervention|Jada System for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
16559804|NCT02883660||Cases|"patients who had empirically defined increased AEs on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
16559805|NCT02883660||Controls|"patients who did not have empirically defined increased AEs with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were nonresponders to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
16559806|NCT02883647||retreatment|"Patients with HBV DNA > 2000 IU/ml and ALT ≥ 5×ULN;
~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have clinical symptoms.
~Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again."
16559807|NCT02883647||non-retreatment|"Patients with HBV DNA ≤ 2000 IU/ml;
~Patients with HBV DNA > 2000 IU/ml and ALT ≤ 2×ULN;
~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have no clinical symptoms."
16559808|NCT02883634|Experimental|specific manipulation|"Participants allocated to group specific manipulation, will have their lumbar spine manipulated according to the previous clinical examination."
16559809|NCT02883634|Experimental|non-specific manipulation|"Participants allocated to group non-specific manipulation will have their upper thoracic spine manipulated (also known as global manipulation) regardless of the previous clinical examination."
16559810|NCT02883621|Active Comparator|Group A|subjects receive standard upper endoscopy
16559811|NCT02883621|Experimental|Group B|subjects receive cap assisted upper endoscopy
16559812|NCT02883608|Experimental|Initial cap assisted endoscopy|undergo initial cap assisted forward-viewing endoscope then side-viewing duodenoscope
16559813|NCT02883608|Active Comparator|Initial standard endoscopy|undergo initial side-viewing duodenoscope then cap assisted forward-viewing endoscope
16559814|NCT02883595|Experimental|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
16559815|NCT02883595|Placebo Comparator|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
16559816|NCT02883582|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
16559817|NCT02883582|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
16559818|NCT02883569|Active Comparator|HIVD-OP|open or endoscopic discectomy
16559819|NCT02883569|Experimental|HIVD-NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
16559820|NCT02883569|Active Comparator|LSS w/o instability -OP|decompression, instrumentation and fusion
16559821|NCT02883569|Experimental|LSS w/o instability -NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
16559822|NCT02883569|Active Comparator|LSS w/ instability - OP|decompression, instrumentation and fusion
16559824|NCT02883569|Active Comparator|No intervention group|exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
16559825|NCT02883569|Experimental|Intervention group|epidural block, epidural adhesiolysis
16559826|NCT02883556|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
16559827|NCT02883543|Experimental|icotinib plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy.
16559828|NCT02883543|Active Comparator|icotinib|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
16559829|NCT02883543|Active Comparator|chemotherapy plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy.
16559830|NCT02883530||Biomarker optimised patients|Optimised biomarker/Th2 low n=40
16559831|NCT02883530||non -optimised/Th2 low patients|Patients identified in clinic with FeNO <30 ppb. Those who at screening demonstrate FeNO <30 ppb and blood eosinophil count ≤0.20 x109/L will be considered to be non-optimised biomarker-low patients (Th2-low) and will proceed to bronchoscopy n=80
16559832|NCT02883530||corticosteroid-resistant biomarker|Patients identified in clinic with FeNO >45 ppb who have failed to suppress their FeNO during FeNO suppression testing. These patients are considered adherent to inhaled corticosteroids. Those who at screening also demonstrate blood eosinophils of >0.3x109/L n=40
16559833|NCT02883517||Aggressive primary cutaneous lymphomas|"Mycosis fungoides ≥ T2b
~Primary cutaneous T helper follicular lymphoma ≥ T2
~Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome."
16559834|NCT02883504|Experimental|Echocardiography|
16559835|NCT02883478|Active Comparator|Treatment group A|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 3 milliwatt/cm² (mW/cm²) for 30 minutes.
~Device: UV-X 1000 irradiator (3 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
16559836|NCT02883478|Active Comparator|Treatment group B|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 9 mW/cm² for 10 minutes.
~Device: UV-X 2000 irradiator (9 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
16559837|NCT02883465|Other|Single arm|
16559838|NCT02883452|Active Comparator|Cohort 1: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
16559839|NCT02883452|Experimental|Cohort 2: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
16559840|NCT02883452|Experimental|Cohort 3: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
16559841|NCT02883452|Experimental|Cohort 4: CT-P13 SC 240 mg|CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
16559842|NCT02883452|Experimental|Arm 1: CT-P13 SC 120/240 mg|CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
16559843|NCT02883452|Active Comparator|Arm 2: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)
16559844|NCT02883439|Experimental|Investigational product|MP29-02 137
16559845|NCT02883439|Active Comparator|Non-investigational product|fluticasone propionate
16559846|NCT02883426|Experimental|Group 1: H3N2v Seronegative Adults: H3N2v LAIV|Participants will receive one dose of H3N2v LAIV on Day 0 (study entry). They will then receive one dose of H3N2v IIV on Day 84.
16559847|NCT02883426|Experimental|Group 2: H3N2v Seropositive Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
16559848|NCT02883426|Placebo Comparator|Group 2: H3N2v Seropositive Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
16559849|NCT02883426|Experimental|Group 3: H3N2v Seronegative Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
16559850|NCT02883426|Placebo Comparator|Group 3: H3N2v Seronegative Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
16559851|NCT02883426|Experimental|Group 4: Children: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
16559852|NCT02883426|Placebo Comparator|Group 4: Children: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
16559853|NCT02883413|Experimental|CRT +Teach the Parent|The Teach the Parent (TtP) addition to CRT is designed to increase parental understanding of their adolescents' thinking styles. We hypothesize that by doing so, parents will be more likely to challenge eating disorder behaviors and be less likely to accommodate behavioral symptoms of the eating disorder (e.g., make something low-fat for dinner because it will be easier). In this arm, adolescents will explain what they learned during CRT and walk their parents though at least 4 tasks during each TtP session. Parents and child will not be permitted to speak about the eating disorder during these sessions. TtP sessions will occur 3-4 times during hospitalization and will be guided by the adolescent.
16559971|NCT02882542|Experimental|Visible light exposure Orange 120 lux|The participants will be exposed to orange LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16560621|NCT02877940|Active Comparator|Group I|i-gel will be inserted in mechanically ventilated patients undergoing elective surgeries..
16559854|NCT02883413|Active Comparator|CRT + Family Fun Time|In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
16559855|NCT02883413|No Intervention|Treatment as Usual (TAU)|Adolescents in this condition will not receive any additional treatment. They will have a standard hospital stay with all normal contact with health professionals.
16559856|NCT02883400|No Intervention|SOC-Standard of care|standard of care, nontreatment
16559857|NCT02883400|Experimental|spironolactone|spironolactone
16559858|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
16559859|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
16559860|NCT02883374|Experimental|Chidamide|Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
16559861|NCT02883361|Experimental|Treatment|Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
16559862|NCT02883361|Placebo Comparator|Control|Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
16559863|NCT02883322||Initial|Patients answering the initial translation
16559864|NCT02883322||Committee-only|Patients answering the translation modified by an expert committee
16559865|NCT02883322||BT-only|Patients answering the translation modified with the use of a back-translation
16559866|NCT02883322||Both|Patients answering the translation modified by an expert committee with the use of a back-translation
16559867|NCT02883296|Experimental|Patients with perianal fistulizing Crohn's disease|
16559868|NCT02883283|Active Comparator|Epidural Catheter Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
16559869|NCT02883283|Experimental|Epidural Needle Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural needle prior to catheter placement. Epidural loading dose via epidural needle.
16559870|NCT02883270|Experimental|RAGT treatment group|Robotic-assisted gait training （RAGT）is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation after some neuropathy. The investigators use LokoHelp for training, which is provided to the feet and the patient actively controls the knee and hip joints. The participants of RAGT treatment group receive 30 min conventional rehabilitation and 30 min robotic-assisted gait training daily for 8 weeks.
16559871|NCT02883270|Placebo Comparator|controls|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
16559872|NCT02883257|Experimental|Cognitive Behavioral Therapy|"20 individual 60-minute appointments over the course of 16 weeks
~Consistent with Beck, Rush, Shaw, and Emery (1979)"
16559873|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
16559874|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
16559875|NCT02883218||Comunity-acquired severe sepsis patients|Patients with new-onset community-acquired severe sepsis within 24h without confounding factors in immune status
16559876|NCT02883218||Non-severe sepsis patients|Patients between 18 and 90 years of age and be admitted to the ICU without a diagnosis of severe sepsis.
16559877|NCT02883218||Healthy controls|Heathy vonlunteers between 18 and 90 years of age.
16559878|NCT02883192|Experimental|ondansetron|ondansetron
16559879|NCT02883192|Placebo Comparator|Placebo|Placebo
16559880|NCT02883179|Active Comparator|lidocaine injection|5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
16559881|NCT02883179|Experimental|lidocaine-prilocaine cream|5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing
16559882|NCT02883166|Other|group 1|1000mg abiraterone fasted followed by 500 mg with breakfast
16559883|NCT02883166|Other|group 2|500 mg abiraterone with breakfast followed by 1000mg fasted
16559884|NCT02883153|Experimental|Zirconium-89 girentuximab PET/CT|A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
16559885|NCT02883127||The study group|Receives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
16559886|NCT02883127||The control group|Was given the same routine care with the same treatment goals, but without motivational interviewing.
16559887|NCT02883114|Experimental|single cohort|single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
16559888|NCT02883101|Active Comparator|Pulmonary rehabilitation group|"Participants randomised to the PR group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.
~The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.
~The Rehabilitation Programme will include the following:
~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
16559972|NCT02882542|Experimental|Visible light exposure Cyan 30 lux|The participants will be exposed to cyan LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559889|NCT02883101|No Intervention|Standard care group|"Candidates randomized to the standard care group will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training."
16559890|NCT02883088||LAD-group|Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).
16559891|NCT02883075|Sham Comparator|Supine position|Supine position Supine position after placement of spinal anesthetic
16559892|NCT02883075|Active Comparator|Right lateral position|Right lateral position Right lateral after placement of spinal anesthetic
16559893|NCT02883075|Active Comparator|Left lateral position|Left lateral position Left lateral after placement of spinal anesthetic
16559894|NCT02883062|Active Comparator|Arm A (carboplatin, paclitaxel, mastectomy, lumpectomy)|Patients receive carboplatin IV over 30 minutes Q3W and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16559895|NCT02883062|Experimental|Arm B (atezolizumab, carboplatin, paclitaxel, breast surgery)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV over 30 minutes Q3W, and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16559896|NCT02883049|Experimental|DS HR B-ALL (RER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.
~See outline for details."
16559897|NCT02883049|Experimental|DS HR B-ALL (SER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.
~See outline for details."
16559898|NCT02883049|Experimental|Group I Arm A (HR B-ALL)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
16559899|NCT02883049|Experimental|Group I Arm B (HR B-ALL) (CLOSED 03/19/2018)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
16559900|NCT02883049|Active Comparator|Group II Arm A (VHR B-ALL - Control Arm)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
16559901|NCT02883049|Experimental|Group II Arm B (VHR B-ALL - Exp Arm1) (CLOSED 02/15/2017)|"Patients receive consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
16559902|NCT02883049|Experimental|Group II Arm C (VHR B-ALL - Exp Arm 2) (CLOSED 09/12/2014)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
16559903|NCT02883049|Experimental|Group III PH-like predicted TKI-sensitive kinase mutation|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.
~See outline for details."
16559904|NCT02883036||Patients with chronic myeloid leukemia|100 adult patients(age>18 years),with chronic myeloid leukemia defined by the World Health Organization(WHO) criteria
16559905|NCT02883036||Healthy volunteers|Healthy volunteers
16559906|NCT02883023|Experimental|Electrosclerotherapy|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will be treated with electrosclerotherapy
16559907|NCT02883023|Active Comparator|Intralesional bleomycin injections|One region of interest in the capillary malformation will be treated with intralesional bleomycin injections without electroporation
16559908|NCT02883023|No Intervention|No treatment|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will not be treated.
16559909|NCT02883010|Experimental|PICO|Single use NPWT (PICO Softport V1.6)
16559910|NCT02883010|Other|Standard care|Gauze dressing, Film dressing, foam dressing, skin glue, no dressing
16559911|NCT02882997|Experimental|Duck Duck Punch|"Community dwelling stroke survivors: Stroke survivors will install an interactive computer game in their home. Subjects will be instructed to play the computer game as much as you want to every day for 7 days. Inpatient stroke patients: The interactive computer game will be installed at a local inpatient stroke rehabilitation hospital. Subjects will be instructed to play this game as much as you want to during non-therapy hours (evenings and weekends) over the next 7 days."
16559912|NCT02882997|Active Comparator|Standard activities|"Community dwelling stroke survivors: Subjects will receive a hard-copy handout of an arm home exercise program and given the instructions to do these exercises as many times as you can daily. Inpatient stroke patients: Subjects will be encouraged to participate in standard evening/weekend recreational activities and to remember to use the paretic arm as much as you can."
16559913|NCT02882984|Active Comparator|WBRT along with TKI|"Drug: EGFR-TKI
~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
~Other Name: Gefitinib/Tarceva/Icotinib
~Radiation: whole brain radiotherapy
~3750Gy/15F
~Other Name: WBRT"
16559914|NCT02882984|Experimental|HFSRS with EGFR TKI|"Drug: EGFR-TKI
~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
~Other Name: Gefitinib/Tarceva/Icotinib
~Radiation: whole brain radiotherapy
~25 to 40 Gy/5F
~Other Name: HFSRS"
16559915|NCT02882945||Group A|150 healthy blood donors without a family history of diabetes mellitus
16559916|NCT02882945||Group B|200 cases of type 2 DM without complications (group B), there were 62 males and 108 females, aged 29-53, with an average age of 42 ± 9 years
16559917|NCT02882945||Group C|120 cases of type 2 DM with macroangiopathy complication (group C), there were 70 males and 50 females, aged 40-53, with an average age of 47 ± 6 years. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD
16559918|NCT02882932|Other|Super Oxidized Solution|Procedure/Surgery: Super Oxidized Solution(SOS) in group I - SOS with normal saline solution was used
16559919|NCT02882932|Other|normal saline|"Procedure/Surgery: normal saline
~In group II - patients underwent normal saline wash and bacterial load was noted."
16560622|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
16559920|NCT02882919|Experimental|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
16559921|NCT02882919|No Intervention|Usual care|In the usual care group, patients are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors
16559922|NCT02882893|Experimental|DWP450|Single-dose
16559923|NCT02882893|Active Comparator|Botox|Single-dose
16559924|NCT02882880|Other|Started|Intervention: Treatment with the Luco Hybrid OSA Appliance (LHOA) Group 1, fitted with LHOA Group 2: LHOA removed for 48 hours
16559925|NCT02882880|Active Comparator|Completed|Intervention: The LUco Hybrid OSA APpliance The subjects that actually completed the study in both groups. Group 1 n = 32, in Group 2 n=19
16559926|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
16559927|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
16559928|NCT02882841|Other|Single-arm study|
16559929|NCT02882828|Experimental|DBS (dried blood spots) collection|In this study, we make a switch from Prograf® to Envarsus®. Patients will be trained to collect their blood from a finger prick on filter paper. DBS will be done at home, collected on filter paper and mailed by the patients to a centralized laboratory (Department of Pharmacology, Toxicology and Pharmacovigilance at Limoges University Hospital), where tacrolimus concentration will be determined by HPLC-MS/MS
16559930|NCT02882815|Other|IrisFIT PFO Occluder|Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
16559931|NCT02882802|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
16559932|NCT02882802|Active Comparator|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
16559933|NCT02882789|Experimental|LCB01-0371 200mg|LCB01-0371 IV 200 mg
16559934|NCT02882789|Experimental|LCB01-0371 400mg|LCB01-0371 IV 400 mg
16559935|NCT02882789|Experimental|LCB01-0371 800mg|LCB01-0371 IV 800 mg
16559936|NCT02882776|Other|Ginger drink once daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water once a day for continuous 5 days.
16559937|NCT02882776|Other|Ginger drink twice daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water twice a day for continuous 5 days.
16559938|NCT02882763|Experimental|Parents As Teachers (PAT)|c.f. intervention
16559939|NCT02882763|No Intervention|control group condition|Families in the control group condition did not receive the home visiting program PAT, but were informed about support services in their community. The use of these services was permitted for ethical reasons; however, parents were regularly asked about the nature and intensity of the retrieved services. Additionally, all parents received incentives, such as greeting cards, small birthday presents, and monetary reimbursements.
16559940|NCT02882750||Surgical Patients|Early stage NSCLC patients submitted to Surgical Resection
16559941|NCT02882750||SABR Patients|Early stage NSCLC patients submitted to SABR
16559942|NCT02882737|Experimental|Exercise and glucagon before exercise|"120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.
~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.
~When exercise is ended a single subcutaneous bolus of 0.2 ml saline is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
16559943|NCT02882737|Active Comparator|Exercise and glucagon after exercise|"120 minutes after breakfast; a single subcutaneous bolus of 0.2 ml saline is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.
~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.
~Low-dose glucagon phase: When exercise is ended or when hypoglycemia occurs (≤3.9 mmol/l); a single subcutaneous bolus of 200μg glucagon is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
16559973|NCT02882542|Experimental|Visible light exposure Cyan 120 lux|The participants will be exposed to Cyan LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559974|NCT02882542|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16560623|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
16559944|NCT02882737|Active Comparator|Resting and glucagon after resting|"120 minutes after breakfast; a single subcutaneous bolus of 200μg placebo is administered.
~Resting: After placebo injection the patient will be resting on a hospital bed for 45 minutes. The patient do not know if placebo or glucagon is administered.
~Low-dose glucagon phase: After 45 minutes of resting or when hypoglycemia occurs, a single subcutaneous bolus of 200μg glucagon is administered.
~Safety issues: If plasma glucose drops < 2.5 mmol/l at two consecutive measurements with 5 min interval or the patient experiences unbearable symptoms of hypoglycemia even after glucagon administration, 20 g carbohydrate is given orally. If plasma glucose drops< 2.3 mmol/l or doesn't raise sufficient after oral glucose, we will give intravenøs glucose to the patient. The study will then end and a new study day will be planned."
16559945|NCT02882724|Experimental|Exercise training|
16559946|NCT02882724|Experimental|Control|Control group did not do any exercise training.
16559947|NCT02882711|Experimental|ketamine|
16559948|NCT02882698|Experimental|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
16559949|NCT02882698|Experimental|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
16559950|NCT02882698|Active Comparator|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
16559951|NCT02882698|Active Comparator|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
16559952|NCT02882685|Active Comparator|RYGB|Roux-en-Y gastric bypass
16559953|NCT02882685|Active Comparator|SAGB|Single anastomosis gastric bypass
16559954|NCT02882672|Experimental|Experimental|experimental group did 8 weeks exercise training
16559955|NCT02882672|Experimental|Control|Control group did not do any exercise training.
16559956|NCT02882659|Experimental|Dendritic Killer Cell (DKC)|All enrolled patients received one treatment cycle of DKC cell therapy, which consists of 5 infusion cycles approximately 23 days apart. There were 3 dose levels: 5 x 10^6, 1 x 10^7, and 5 x 10^7 cells, and the protocol followed a traditional 3+3 dose escalation design.
16559957|NCT02882646|Experimental|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.
~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
16559958|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
16559959|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
16559960|NCT02882620|Experimental|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
16559961|NCT02882620|Experimental|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
16559962|NCT02882620|Experimental|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
16559963|NCT02882607|Experimental|Intervention group|Reproductive Health Peer Groups
16559964|NCT02882607|No Intervention|Control group|no intervention
16559965|NCT02882594||CIBA Study Cohort|Patients aged 1 to 13 years undergoing inhalation inductions for general anesthesia
16559966|NCT02882581|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
16559967|NCT02882568|Other|investigational|Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
16559968|NCT02882555|Experimental|Children|"12 concentrations of caspaicin are administered: - 0.6, 1.2, 2.4, 4.8, 9.8, 19.5, 39, 78.1, 156.2, 312.5, 625, 1250 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.
~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline
~At least 1-hour-interval (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
16559969|NCT02882555|Active Comparator|Adults|"As reference for more precise assessment of effects of development.
~12 concentrations of caspaicin are administered: 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.
~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline
~At least 1-hour-interval (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
16559970|NCT02882542|Experimental|Visible light exposure Orange 30 lux|The participants will be exposed to orange LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16560033|NCT02882217|Active Comparator|XC8 10mg|Cohort 1: 8 subjects will be randomized in a 3:1 ratio to be treated either with 10mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
16559975|NCT02882542|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559976|NCT02882529|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559977|NCT02882529|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559978|NCT02882529|Experimental|Visible light exposure Yellow 30 lux|The participants will be exposed to yellow LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559979|NCT02882529|Experimental|Visible light exposure Yellow 120 lux|The participants will be exposed to yellow LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559980|NCT02882529|Experimental|Visible light exposure Violet 30 lux|The participants will be exposed to violet LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559981|NCT02882529|Experimental|Visible light exposure Violet 120 lux|The participants will be exposed to violet LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559982|NCT02882516|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559983|NCT02882516|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559984|NCT02882516|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559985|NCT02882516|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559986|NCT02882516|No Intervention|darkness|The participants will not be exposed to any light but stay in darkness for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
16559987|NCT02882503|Experimental|EUS-RFA|monopolar radiofrequency probe (1.2 mm Habib endoscopic ultrasound - radiofrequency ablation (EUS-RFA) catheter) and 19 or 22 gauge fine needle aspiration (FNA) needle
16559988|NCT02882490|Experimental|Parent training (PT)|The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
16559989|NCT02882490|Experimental|Supportive Therapy (ST)|The ST arm receives a 10-week supportive group treatment. Parents are invited to discuss relevant problems that have occurred during the previous week. A therapist moderate the discussion but does not provide information about the behavioral techniques included in the PT group. Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
16559990|NCT02882477|Experimental|Deferiprone and Acetylcystein|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200 mg divided in 2 doses 5 months duration
16559991|NCT02882477|Experimental|Deferiprone and Acetylcystein with Sitagliptin and Metformin|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200mg divided in 2 doses PO Januet 50/500 if BW < 30kg and 50/850 if BW> 30kg *2/D 5 months duration
16559992|NCT02882464|Experimental|2PRF+CAF|"Two tubes of blood samples were centrifuged by PC-02 Centrifuged device. This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France). PRF were prepared for patients in 2 layer platelet rich fibrin membrane with coronally advanced flap group (2PRF+CAF).
~Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 2PRF+CAF group: two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flpa is positioned coronally."
16559993|NCT02882464|Experimental|4PRF+CAF|Four tubes of blood samples were centrifuged by PC-02 Centrifuged device,four layers of PRF membranes were prepared for patients in 4 layer platelet rich fibrin membrane with coronally advanced flap.(4PRF+CAF). This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France) Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 4PRF+CAF group: four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flap is coronally positioned.
16560028|NCT02882269|Experimental|Neoadjuvant chemotherapy|Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.
16560029|NCT02882256|Experimental|Intervention|Patients will receive video discharge instructions in addition to standard written discharge instructions.
16560030|NCT02882256|No Intervention|Control|Patients will receive standard written discharge instructions.
16560031|NCT02882230||exposition to the drugs|patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
16559994|NCT02882464|Active Comparator|CTG+CAF|"The surgical technique in coronally advanced flap with subepithelial connective tissue graft (CTG+CAF) group was envelope technique as described by Raetzke. The papillae were dis epithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. The connective tissue graft was harvested from the palate using trap-door technique described by Edel. Epithelial layer was elevated with a horizontal and two vertical incisions. The connective tissue graft was harvested as 1 mm by using a standard caliper, then epithelial layer was sutured by resorbable suture. The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ."
16559995|NCT02882451|Experimental|pinaverium bromide|take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally
16559996|NCT02882451|Placebo Comparator|Vitamin C|take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally
16559997|NCT02882438|Active Comparator|Infected group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
16559998|NCT02882438|Placebo Comparator|Control group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
16559999|NCT02882425|Experimental|Intravenous selexipag (Pilot phase)|Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
16560000|NCT02882425|Experimental|Sequence A-B (Main phase)|Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
16560001|NCT02882425|Experimental|Sequence B-A (Main phase)|Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.
16560002|NCT02882412||patient group|
16560003|NCT02882399|Experimental|Shortystrap|
16560004|NCT02882386|Placebo Comparator|Milk 1%|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
16560005|NCT02882386|Experimental|Whey protein concentrate 80 (WPC-80)|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
16560006|NCT02882386|Experimental|Microparticulated whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
16560007|NCT02882386|Experimental|Hydrolyzed whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
16560008|NCT02882386|Experimental|Native whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
16560009|NCT02882373|Experimental|Group I (arginine)|Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
16560010|NCT02882373|Placebo Comparator|Group II (placebo)|Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
16560011|NCT02882360|Experimental|Elective LSCS--Kerlix AMD|Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
16560012|NCT02882360|Placebo Comparator|Elective LSCS--Placebo|Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
16560013|NCT02882360|Experimental|Labouring LSCS--Kerlix AMD|Kerlix-AMD applied to wound post-operatively for 2 weeks
16560014|NCT02882360|Placebo Comparator|Labouring LSCS--Placebo|Normal gauze applied to wound post-operatively for 2 weeks
16560015|NCT02882347|Experimental|somatostatin group|The investigators administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time < 50% and serum total bilirubin > 2.9mg/dl after liver resection) until recovery from liver failure.
16560016|NCT02882334|Experimental|Finger individuation training|Finger Force Manipulandum
16560017|NCT02882334|Active Comparator|control|conventional physiotherapy
16560018|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.
~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
16560019|NCT02882308|Experimental|Monotherapy with olaparib|Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
16560020|NCT02882308|Experimental|Combination of cisplatin and olaparib|Patients in the cisplatin - olaparib combination arm will receive treatment until the 5th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day.
16560021|NCT02882308|No Intervention|No treatment arm|"Patients in the no treatment arm will wait to be operated or have a second biopsy on the 23rd - 29th day.Optionally, patients who have a baseline FDG-PET/CT scan may be re-examined on the 22nd -28th day by the same modality to assess metabolic response."
16560022|NCT02882308|Experimental|Combination of durvalumab and olaparib|Patients in the durvalumab - olaparib combination arm will receive treatment until the 21th-28th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
16560023|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
16560024|NCT02882295||control|age and gender matched
16560025|NCT02882282|Active Comparator|Arm A (observation)|Patients undergo observation.
16560026|NCT02882282|Experimental|Arm B (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16560027|NCT02882269|Active Comparator|Postoperative chemotherapy|Patients receive 6 months of chemotherapy after surgery.
16560034|NCT02882217|Active Comparator|XC8 50mg|Cohort 2: 8 subjects will be randomized in a 3:1 ratio to be treated either with 50mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
16560035|NCT02882217|Active Comparator|XC8 200mg|Cohort 3: 16 subjects will be randomized in a 3:1 ratio to be treated either with 200mg XC8 (12 subjects) or placebo (4 subjects, see placebo arm)
16560036|NCT02882217|Placebo Comparator|Placebo|Placebo comparator arm consists of 2 subjects in the cohorts 1 and 2 each and 4 subjects in the cohort 3.
16560037|NCT02882204||First Episode Patients|First episode patients new to the PEPP program.
16560038|NCT02882204||Chronic Patients|Existing patients who have been enrolled in the PEPP program for >3 years
16560039|NCT02882204||Healthy Controls|Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
16560040|NCT02882204||Cliniucal High Risk patients|Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
16560041|NCT02882191|Experimental|LevoCept IUD|LevoCept IUD placement
16560042|NCT02882165|Experimental|Intervention arm|Participants receive a comprehensive medical review by a Respiratory Clinical Fellow.
16560043|NCT02882165|No Intervention|Control arm|Participants receive usual care as required via their primary care practice.
16560044|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
16560045|NCT02882152|Active Comparator|Morphine|intrathecal morphine
16560046|NCT02882139||Electrical storm|Documentation of 3 or more episodes of sustained ventricular arrhythmia within 24h or documentation of sustained ventricular tachycardia lasted at least 12h
16560047|NCT02882126|Experimental|Subcutaneous Treprostinil|Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
16560048|NCT02882113|Experimental|Expressor|CYP3A5 expressor; containing CYP3A5*1 wild-type allele(*1/*1 type & *1/*3 type) intervention: Advagraf conversion
16560049|NCT02882113|Active Comparator|Non-expressor|CYP3A5 non-expressor: without CYP3A5*1 allele( *3/*3 type) intervention: Advagraf conversion
16560050|NCT02882100|Experimental|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
16560051|NCT02882100|Active Comparator|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
16560052|NCT02882087|Experimental|Placebo Comparator|Placebo SC plus MTX. Patients received placebo SC weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
16560053|NCT02882087|Experimental|Experimental: RC18 160 mg plus MTX|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
16560054|NCT02882074|Other|Human albumin|Human albumin 5% during surgery.
16560055|NCT02882074|Other|Hydroxyethyl starch|Hydroxyethyl starch 6% (130/0.4) solution during surgery
16560056|NCT02882061|Experimental|CTDT positive|All subjects with a positive cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
16560057|NCT02882061|Active Comparator|CTDT negative|All subjects with a negative cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
16560058|NCT02882048|Experimental|Medication management & NADA Protocol|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens, and NADA protocol administered biweekly
16560059|NCT02882048|Active Comparator|Medication management|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens.
16560060|NCT02882035|Experimental|OFA (opioid free anesthesia)|"All drugs were given IV. Induction in the opioid free group began with a loading dose of clonidine (0.2 mcg kg-1), a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).
~General anesthesia was maintained with sevoflurane (MAC: 1) (adapted according to hemodynamic stability).
~Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups. A bolus of ketamine (0.2mg kg -1) was given if necessary in the opioid free group (up to three bolus max. were permitted).
~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.
~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
16560061|NCT02882035|No Intervention|OA (opioid anesthesia)|"All drugs were given IV. Induction in the opioid group began with remifentanil TCI, a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).
~General anesthesia was maintained with sevoflurane (MAC: 1). Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups.
~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.
~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
16560062|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
16560063|NCT02882009|Experimental|Gantenerumab + Placebo|Participants will be randomized to receive gantenerumab HCLF and placebo solution via SC injection according to different sequences for the site of administration and different injection speeds.
16560101|NCT02881788||Control|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have not recently sustained any brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as subjects who have had a non-trauma related brain injury.
16560268|NCT02880657|Experimental|SODB®-physical training|This arm receives daily two capsules of SODB® 40mg containing 560 UI of superoxide dismutase, associated with standardized physical training
16560064|NCT02881996|Experimental|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
16560065|NCT02881996|Active Comparator|No IV tylenol|Same as above without IV tylenol.
16560066|NCT02881983||STA group|Short-term alcohol abstinent patients (after 1 month of withdrawal)
16560067|NCT02881983||LTA group|Long-term alcohol abstinent patients (at least 6 months of abstinence)
16560068|NCT02881983||Control group|Healthy subjects
16560069|NCT02881970|Experimental|Neonatal hypoxic-ischaemic encephalopathy|
16560070|NCT02881957|Placebo Comparator|Control|Placebo control (simple oral syrup)
16560071|NCT02881957|Experimental|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
16560072|NCT02881944|Experimental|Low FODMAP (modified healthy) Diet|Low FODMAP diet for 3 weeks. Veterans will be provided a diet containing foods low in FODMAP.
16560073|NCT02881944|Experimental|High FODMAP (typical healthy) Diet|High FODMAP diet for 3 weeks. Veterans will be provided a typically healthy diet following US Dietary Guidelines, containing foods high in FODMAPs
16560074|NCT02881931||Pre-Manifest HDGEC Participant|
16560075|NCT02881931||Early-Manifest HDGEC Participant|
16560076|NCT02881931||Corresponding HDGEC participant Companion|
16560077|NCT02881918||squamous cell carcinoma|Patients affected by Head & Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
16560078|NCT02881905|Active Comparator|ball attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment
16560079|NCT02881905|Experimental|CM LOC attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment
16560080|NCT02881879|Experimental|Allergovac depot with HDM extract|Extract of mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae (50:50) adsorbed onto aluminum hydroxide 0.33%.
16560081|NCT02881866|Active Comparator|Air Hunger|"Previous studies have shown that inhaled furosemide relieves 'air hunger'.
~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.
~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. ."
16560082|NCT02881866|Experimental|Work Effort|Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .
16560083|NCT02881853|Experimental|Part A1|XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
16560084|NCT02881853|Experimental|Part A2|XmAb7195 for SC injection; dose level 1; 4 once weekly doses
16560085|NCT02881853|Experimental|Part A3|XmAb7195 for SC injection; dose level 2; 4 once weekly doses
16560086|NCT02881853|Experimental|Part A4|XmAb7195 for SC injection; dose level 3; 4 once weekly doses
16560087|NCT02881853|Experimental|Part A5|XmAb7195 for SC injection; dose level 4; 4 once weekly doses
16560088|NCT02881853|Experimental|Part B6|XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
16560089|NCT02881853|Experimental|Part B7|XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
16560090|NCT02881853|Experimental|Part B8|XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
16560091|NCT02881853|Experimental|Part B9|XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
16560092|NCT02881840|Experimental|14C-APD421|
16560093|NCT02881827|Active Comparator|Infrared Laser|Using a laser in the infrared wave spectrum (780 nm)
16560094|NCT02881827|Active Comparator|Red Laser|Using laser red wave spectrum (662 nm)
16560095|NCT02881827|Placebo Comparator|Placebo|Simulation of treatment with the device switched off
16560096|NCT02881827|Active Comparator|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied
~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two ( statistically ) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug , which serves to prevent bias and isolating effects of such drugs."
16560097|NCT02881814|Experimental|Lung ultrasound and clinical decision|Clinical assessment and choice of chest physiotherapy treatmetn performed by the clinical physiotherapist, followed by a comprehensive lung and diaphragm ultrasonography. After ultrasonography, the clinical physiotherapist is asked what CPT treatment he was going finally to implement, and explain the reasons for change, if any.
16560098|NCT02881814|Experimental|Mechanically ventilated patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
16560099|NCT02881788||Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a traumatic brain injury. We are hoping to find patterns that may indicate a TBI in the data we collect.
16560100|NCT02881788||Non-Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a non-trauma related brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as healthy controls.
16560157|NCT02881385||E5 Esense autocycle|PSV mode using E5 ventilator with Esense Auto cycle
16560102|NCT02881775|Experimental|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
16560103|NCT02881775|Sham Comparator|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
16560104|NCT02881762|Active Comparator|Immediate start maraviroc|To start maraviroc immediately after randomization.
16560105|NCT02881762|Active Comparator|Delayed start maraviroc|To start maraviroc 8 weeks after enrollment.
16560106|NCT02881749|Experimental|TSEBT & mechlorethamine gel 0.016%|All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
16560107|NCT02881736|Experimental|Pateint with chronic stroke|
16560108|NCT02881736|Active Comparator|Healthy volunteer|
16560109|NCT02881723|Experimental|Treatment for oropharyngeal cancer by surgery|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery
16560110|NCT02881723|Experimental|Treatment for oropharyngeal cancer by radio-chemotherapy|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy
16560111|NCT02881697||Obese insulin-resistant subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery
16560112|NCT02881697||Lean insulin-sensitive controls|Adipose tissue sampling in normal weight patients (BMI < 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery
16560113|NCT02881697||Obese diabetic subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; diabetic, scheduled for elective bariatric surgery
16560114|NCT02881684|Experimental|Treatment|"Intervention:
~Device: Aspiration Therapy (AspireAssist)
~- Subjects randomized to the treatment group will undergo an endoscopic procedure to have the experimental device (i.e. the A-tube) inserted. This will be followed by regular follow up visits and lifestyle therapy matched to the control group. The device will be removed at the end of one year and this group will be observed for one year more to determine if there is any legacy effect.
~Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy"
16560115|NCT02881684|Active Comparator|Control|"Intervention:
~(1) Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy
~- Subjects randomized to the control group will receive lifestyle management matched to the treatment group in the first year. At the end of one year, they will be crossed over to treatment and the A-tube will be inserted. They will then follow up the same follow up schedule of the treatment group during the first year."
16560116|NCT02881671||Patients with congenital atrioventricular block|Patient with congenital atrioventricular block
16560117|NCT02881671||relatives with congenital atrioventricular block|Normal relatives of patients with congenital atrioventricular block
16560118|NCT02881671||Patients with progressive Cardiac Conduction Disease|Patients with progressive Cardiac Conduction Disease,
16560119|NCT02881671||relatives with progressive Cardiac Conduction disesae|Normal relatives of patients with progressive Cardiac Conduction Disease
16560120|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
16560121|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
16560122|NCT02881645||Best practices|Assessment of critical incidents linked to nursing with a best practices protocol
16560123|NCT02881645||Common practices|Assessment of critical incidents linked to nursing in common practices
16560124|NCT02881632||Healthy infants aged 0-2|Healthy infants aged 0-2 year with no respiratory diseases to provide a reference values. A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person.
16560125|NCT02881632||Infants aged 0-1 with Bronchiolitis|Infants admitted to hospital within last 24hrs (AVB participants only). A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person
16560126|NCT02881619|Placebo Comparator|Placebo|Placebo - (inert content)
16560127|NCT02881619|Experimental|Experimental -|400 mg of NAISE etodolac
16560128|NCT02881606|Active Comparator|Naso-alveolar molding (NAM)|Active plates and nasal stents (Grayson method)
16560129|NCT02881606|Active Comparator|Computer aided design NAM (CAD/NAM)|Computer aided design active plates and nasal stents
16560130|NCT02881567|Experimental|Daclizumab|
16560131|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.
~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.
~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
16560132|NCT02881541|Experimental|Patients having Enhanced Support|"A preoperative consultation with a nurse. This time will be dedicated to the preparation of returning home: explanation of the clinical pathway, realization of postoperative wound care, information on pain management and answer any questions the patient.
~A nurse call on D + 1, the day after the operation to ensure the smooth running of returning home, assess postoperative pain, the correct performance of local care, answer questions from the patient, and provide advice to to limit pain .. A reminder to J2 / J3 will be produced at the request of the patient or on FDI initiative if particular difficulties are reported"
16560133|NCT02881541|Experimental|Patients having usual care|no intervention will be made for this group. Patients will receive usual care respecting intern procedure
16560134|NCT02881528|Experimental|Metformin Hydrochloride|"Metformin Hydrochloride Ph Eur oral solution (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).
~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
16560135|NCT02881528|Placebo Comparator|Placebo|"Placebo (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).
~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
16560136|NCT02881515|Experimental|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
16560137|NCT02881515|Experimental|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
16560138|NCT02881502||healthy control group|Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
16560139|NCT02881502||mild and moderate asthma group|Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
16560140|NCT02881502||severe asthma group|Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
16560141|NCT02881489|Experimental|Autologous BM-MSCs injection|Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
16560142|NCT02881476|Experimental|Allogeneic WJ-MSCs injection|Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
16560143|NCT02881463|Experimental|Home Exercise Program|8- week therapeutical exercise program performing at home for women with knee joint osteoarthritis
16560144|NCT02881437|Experimental|IgHy10 (HyQvia)|"Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:
~The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose
~During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).
~At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose."
16560145|NCT02881424||alcohol-dependent patients|a group of 34 alcohol-dependent patients, currently abstinent
16560146|NCT02881424||healthy controls|a group of control subjects, without neurologic or psychiatric disease, matched for age and sex with the alcohol-dependent participants
16560147|NCT02881411|Active Comparator|Self-soft tissue therapy|Intervention group: Fibromyalgia coping skills programme plus self-soft tissue therapy (SSTT) SSTT consists of MTrP therapy on TrP sites in either the lower leg/foot or forearm/hand. MTrP therapy will be administered by the researcher for only two sessions which will include training to teach the participant how to do SSTT on themselves. All participants in the intervention group will also receive an advice booklet for SSTT.
16560148|NCT02881411|Active Comparator|Fibromyalgia coping skills programme|Control group:Fibromyalgia coping skills programme only. The FCSP is a non-pharmacological, multidisciplinary exercise and education group programme. Its main aims are to provide condition-specific, patient centred, self-management education and advice, in line with national drivers for long-term conditions and international FMS clinical guidelines.
16560149|NCT02881398|Experimental|mHealth|Each participant randomized to a mHealth assessment were evaluated with: (1) structural abnormalities with handheld-echocardiography (Vscan®, General Electric Healthcare); (2) vital signs with smartphone-connected oxymetry and blood pressure monitors (iHealthLabs®); (3) functional assessments on a 6-minute walk test with a trial-axial activity monitor (Ozeri®); (4) cardiac rhythm abnormalities with smartphone-connected- iECG (AliveCor®) and; (5)point-of-care testing with fingerstick B-type natriuretic peptide (Alere). All study participants then underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
16560150|NCT02881398|Active Comparator|Standard-Care|Each participant randomized to a standard-assessment were evaluated with the resource available at the institution including a physical examination,12 lead-ECG, radiographic, laboratory testing as clinically required. All study participants underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
16560151|NCT02881385||E5 Esense 10%|PSV mode using E5 ventilator with Esense 10%
16560152|NCT02881385||E5 Esense 30%|PSV mode using E5 ventilator with Esense 30%
16560153|NCT02881385||E5 Esense 50%|PSV mode using E5 ventilator with Esense 50%
16560154|NCT02881385||Servo-I Esense 10%|PSV mode using Servo-I ventilator with Esense 10%
16560155|NCT02881385||Servo-I Esense 30%|PSV mode using Servo-I ventilator with Esense 30%
16560156|NCT02881385||Servo-I Esense 50%|PSV mode using Servo-I ventilator with Esense 50%
16560158|NCT02881372|Experimental|Oral food desensitization|All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
16560159|NCT02881359||LifeSeal® Kit|creation of a coloanal or colorectal anastomosis
16560160|NCT02881346||Enstilar®|Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.
16560169|NCT02881307|Experimental|Dietary Supplement|
16560170|NCT02881307|Active Comparator|Dietary Counseling|
16560171|NCT02881294|Active Comparator|Food Effect|SUVN-G3031 tablets single dose
16560172|NCT02881294|Active Comparator|Gender Effect|SUVN-G3031 tablets single dose
16560173|NCT02881294|Active Comparator|Age Effect|SUVN-G3031 tablets single dose
16560174|NCT02881281|Other|Education|Education program
16560175|NCT02881281|Other|Control Group|no intervention
16560176|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
16560177|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
16560178|NCT02881255|Other|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
16560179|NCT02881255|Other|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
16560180|NCT02881242|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
16560181|NCT02881229||Women in the Vulvar Specialty Clinic|Information will be collected from all patients presenting with vulvar complaints who have been seen by Dr. Schlosser in the Vulvar Mucosal Specialty Clinic at Northwestern Medical Group.
16560182|NCT02881216|Other|Common DES|Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
16560183|NCT02881216|Other|Synergy Stent|Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
16560184|NCT02881203|Experimental|Breathe Well + RPM|Participants will receive Breathe Well audiovisual feedback in addition to the RPM system
16560185|NCT02881203|Active Comparator|RPM|Varian's RPM system is the current standard of care at Royal North Shore Hospital where this trial is to be run.
16560186|NCT02881190|Experimental|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.
16560187|NCT02881177|Experimental|Oxytocin|Oxytocin 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
16560188|NCT02881177|Placebo Comparator|Placebo|Placebo 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
16560189|NCT02881164|Experimental|Low glycemic index breakfast|Low glycemic index breakfast (GI=45)
16560190|NCT02881164|Active Comparator|High glycemic index breakfast|High glycemic index breakfast (GI=80)
16560191|NCT02881151|Experimental|Treatment|Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.
16560192|NCT02881138|Experimental|RC48-ADC|Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
16560266|NCT02880683|Experimental|Single arm, transvenous cardiac autonomic nerve stimulation|
16560193|NCT02881125|Experimental|Treatment (paclitaxel, nortriptyline hydrochloride)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride PO QD on days 1-7, BID on days 8-14, and TID on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16560194|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
16560195|NCT02881099||Recent diagnosis (P3)|Primary cohort; participants recruited if diagnosed within the last three years
16560196|NCT02881099||Early diagnosis (P50)|Participants recruited if diagnosed before the age of 50 years old
16560197|NCT02881099||Relatives (R)|Siblings of existing participants
16560198|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
16560199|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
16560200|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
16560201|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
16560202|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
16560203|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
16560204|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
16560205|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
16560206|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
16560207|NCT02881073|No Intervention|Control|"Eligible women at participating centres prior to roll-out of PlGF testing (as per stepped wedge trial design) will be managed according to HSE/Institute of Obstetrician and Gynaecologists' National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia or by NICE guidelines for Management of Hypertension in Pregnancy for those in Northern Ireland."
16560208|NCT02881073|Active Comparator|Maternal plasma PlGF quantification|"Women in the interventional arm will have an additional point of care test performed at the time of enrolment for immediate PlGF quantification. The PlGF measurement will be reported as the absolute value in pg/ml with the following ranges given:
~PlGF <12 pg/ml: Very low
~PlGF ≥12 and <100 pg/ml: Low
~PlGF ≥100 pg/ml: Normal
~All hospitals will follow National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia with the additional integration of PlGF results as indicated in the algorithm."
16560209|NCT02881060|Active Comparator|Ethanol|Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
16560210|NCT02881060|Placebo Comparator|Non-ethanol|Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
16560211|NCT02881047|Experimental|rAblative Fractional Laser for Sclerotic GVHD-Associated Joint|"Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
16560212|NCT02881034||Hepatitis C patients|Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir
16560213|NCT02881021|Experimental|Rehabilitation program and kinesiotaping.|"Each patient will attend 10 physiotherapy sessions over six. Patients from the Experimental group (KT group) will receive the same standardized rehabilitation program as control group (No-KT group) including manual therapy, movement training, stretching, muscular strengthening, and patient education.
~Only KT-group (experimental) will receive therapeutic KT added to the rehabilitation program.
~Kinesio® Tex Classic will be applied using a combination of techniques designed for RCTe and underlying symptoms following the instructions and principles described by Kase et al (2003).
~Kinesiotaping strips will be weaned gradually, according to the individual improvements of deficits evaluated weekly by the physiotherapist treating."
16560214|NCT02881021|Active Comparator|Rehabilitation program.|"Each patient will attend 10 physiotherapy sessions over six. Patients allocated at the control group (No-KT group) will receive only the rehabilitation program, including manual therapy, movement training, stretching, muscular strengthening, and patient education.
~The rehabilitation program will be exactly the same applied to the experimental group (KT group)."
16560215|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
16560216|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
16560217|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
16560218|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg daily for 24 weeks
16560219|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
16560220|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
16560221|NCT02880995|Experimental|patient group|"50 Drug-naïve patients with first episode psychosis (We anticipate the non-responder rate will be 30% of the patients)
~Drug-naïve
~Diagnosed as first episode psychosis
~The total score of PANSS>70
~No co-morbid psychiatric illness (including drug dependence/abuse)
~They will also undergo PET scan at the baseline. And the investigators are going to determine treatment response after 6 weeks of treatment with amisulpride. Also they should complete clinical scales at 0, 2, 4, 6, and 8 week."
16560267|NCT02880670|Experimental|Single dose of radiolabeled BMS-986142|
16560222|NCT02880995|Other|healthy control group|"12 healthy volunteers
~No history of psychiatric disorder (including drug dependence/abuse)
~No history of physical illness
~No contra-indication to scanning
~They will also undergo PET scan at the baseline"
16560223|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
16560224|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
16560225|NCT02880969|Experimental|Patient with end stage renal disease undergoing dialysis|
16560226|NCT02880956|Experimental|Group 2|Dose 2 ABBV-8E12
16560227|NCT02880956|Experimental|Group 3|Dose 3 ABBV-8E12
16560228|NCT02880956|Experimental|Group 1|Dose 1 ABBV-8E12
16560229|NCT02880956|Placebo Comparator|Group 4|Placebo for ABBV-8E12
16560230|NCT02880943|Experimental|Group A|"Group A: patients with bone disease mainly will be treated with XOFIGO® alone.
~Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A."
16560231|NCT02880943|Experimental|Group B|Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
16560232|NCT02880930|Experimental|Vitamin D supplement (Cholecalciferol)|Participants will be given oral Fultium-D3 drops (Internis) contain 400 IU cholecalciferol/day for a period of 3 months. Daily vitamin D3 supplementation dose will be increased to 1,000 IU for an additional 3 months if plasma 25(OH)D still below 75 nmol/L.
16560233|NCT02880917|Active Comparator|Cognitive training + tDCs-Active|tDCs active left dorsolateral prefrontal cortex (2mA,20 min) and Cognitive training (20min) at the same time.
16560234|NCT02880917|Sham Comparator|Cognitive training+ tDCs-Sham|tDCs Sham dorsolateral prefrontal cortex ((2mA,20 min) and Cognitive training (20min) at the same time.
16560235|NCT02880891|Experimental|splinted|splinted crown
16560236|NCT02880891|No Intervention|non-splinted|single crown
16560237|NCT02880878|Experimental|Early Surgical Hematoma Evacuation|Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
16560238|NCT02880878|No Intervention|Medical Management|Subjects will receive standard of care medical management for ICH.
16560239|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
16560240|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
16560241|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
16560242|NCT02880839|Experimental|Partial cervical lamina excision group|Patients in the cervical lamina partial excision group underwent partial cervical lamina excision and cervical pedicle screw internal fixation.
16560243|NCT02880839|Experimental|Pipeline-dredge discharge group|Patients in the pipeline-dredge discharge group underwent pipeline-dredge discharge and cervical pedicle screw internal fixation.
16560244|NCT02880839|Experimental|Digital navigation group|Patients in the digital navigation group underwent digital navigation-assisted cervical pedicle placement.
16560245|NCT02880813|Experimental|Gastric|gastric infusion
16560246|NCT02880813|Experimental|Duodenal|Duodenal infusion
16560247|NCT02880800|Experimental|Analgesia, patient controlled|Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of either morphine or hydromorphone.
16560248|NCT02880800|Active Comparator|Analgesia, as per needed|Patients will receive intravenous (IV) opioids as per needed.
16560249|NCT02880787|Other|Adult population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
16560250|NCT02880787|Other|Adult population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
16560251|NCT02880787|Other|Pediatric population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
16560252|NCT02880787|Other|Pediatric population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
16560253|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
16560254|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
16560255|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
16560256|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
16560257|NCT02880748|Experimental|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum.
16560258|NCT02880748|Active Comparator|Air insufflation (AI) method|Air insufflation (AI) method was used for insertion to the cecum.
16560259|NCT02880735|Experimental|Non Invasive Ventilation.|"It will provide noninvasive mechanical ventilation with the following specifications:
~Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months."
16560260|NCT02880722||IBS patients|IBS according to Rome IV criteria.
16560261|NCT02880722||Healthy control group|Healthy volunteers without abdominal complaints fulfilling Rome IV criteria for IBS.
16560262|NCT02880709|Experimental|Special diet|Special diet with taste, energy-and protein content adjusted according to previous finding
16560263|NCT02880709|No Intervention|Usual diet|Patients habitual diet
16560264|NCT02880696|Experimental|Test (Regular)|Regular stimulation sequence & DCS
16560265|NCT02880696|Active Comparator|Control (Random)|Random stimulation sequence & DCS
16560269|NCT02880657|Experimental|Placebo-physical training|This arm receives daily two capsules of Placebo containing excipients only, associated with standardized physical training
16560270|NCT02880605||appropriate in appropriate indications|
16560271|NCT02880605||inappropriate in appropriate indications|
16560272|NCT02880605||appropriate in inappropriate indications|
16560273|NCT02880605||inappropriate in inappropriate indications|
16560274|NCT02880592|Experimental|Fresh amniotic membrane/standard of care|This group will receive the Affinity Allograft and standard of care.
16560275|NCT02880592|Active Comparator|Standard of Care|This group will receive standard of care for diabetic foot ulcers that includes offloading of the diabetic foot ulcer, debridement, and infection management using the appropriate dressings.
16560276|NCT02880566|Experimental|Treatment|Full scalp block performed with a total of 30 ml of levobupivacaine 0.33 %.
16560277|NCT02880566|Placebo Comparator|Control|Full scalp block performed with a total of 30 ml of normal saline.
16560278|NCT02880540|Active Comparator|Control Group|Fentanyl 50 micrograms IV every 15 minutes up to 3 doses in postanesthesia recovery room and Morphine 2mg IV every 2 hours for 2days on hospital floor
16560279|NCT02880540|Experimental|Dexmedetomidine Treated|Dexmedetomidine IV bolus 1.5microgram/kilogram and a continuous infusion starting at 0.1 microgram/kilogram/hour during surgery
16560280|NCT02880527||patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis will be used:
~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;
~general practitioners
~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )
~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
16560281|NCT02880514|Experimental|PROPEL Mini Sinus Implant|Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
16560282|NCT02880514|Active Comparator|Balloon Sinus Dilation Alone|In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement
16560283|NCT02880501|Experimental|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.
16560284|NCT02880475|Experimental|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
16560285|NCT02880475|Experimental|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
16560286|NCT02880462|Active Comparator|high dose sulforaphane|The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
16560287|NCT02880462|Active Comparator|low dose sulforaphane|The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
16560288|NCT02880462|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
16560289|NCT02880449|Experimental|Intervention|The intervention will be conducted in pre-existing older women's groups based in community centres. The intervention will consist of three educational sessions, encouragement to enlist the support of a partner or 'buddy' (e.g. a spouse, partner or friend), an information pack (containing information on the local area, walking routes, points of interest) and the option of weekly telephone contact. Participants will be given the opportunity to discuss their progress and share feedback with the rest of the group at weekly meetings.
16560290|NCT02880449|No Intervention|Control|Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
16560291|NCT02880423|Other|salpingectomy group I|salpingectomy during cesarean section for sterilization
16560292|NCT02880423|Active Comparator|tubal ligation group II|tubal ligation in cesarean section
16560293|NCT02880410|Experimental|LITT Treatment w/radiation therapy and temozolomide|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System in combination with radiation therapy and temozolomide
16560294|NCT02880397|Active Comparator|Garcinia Mangostana|The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
16560295|NCT02880397|Placebo Comparator|Placebo gel|The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.
16560296|NCT02880384|Experimental|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
16560297|NCT02880371|Experimental|Phase 1b/Part A|Patients in Part A will receive escalating doses of single-agent ARRY-382 in combination with 2 mg/kg pembrolizumab.
16560298|NCT02880371|Experimental|Phase 2|Patients in Phase 2 will receive the MTD/RP2D dose of ARRY-382 determined during Part A in combination with 200mg pembrolizumab.
16560299|NCT02880345|Active Comparator|Cohort 1 - 8 Gy x 3 fractions|8 Gy x 3 fractions
16560300|NCT02880345|Active Comparator|Cohort 2 - 17 Gy x 1 fractions|17 Gy x 1 fraction
16560301|NCT02880332|Active Comparator|Usual care + Extra care|This group will receive usual care and one additional session; extra care.
16560302|NCT02880332|Experimental|Usual care + PNE|Next to usual care, this group will also receive pain neuroscience education.
16560303|NCT02880319|Experimental|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine
~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.
~Dosage will be determined by physician"
16560304|NCT02880319|Experimental|Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine
~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.
~Dosage will be determined by physician"
16560305|NCT02880306||RA cohort|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria.
16560306|NCT02880306||Non-RA cohort|Participants who were ≥18 years of age, without a RA diagnosis
16560307|NCT02880293|Experimental|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
16560308|NCT02880280|Experimental|Human Menopausal Gonadotropin|Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
16560309|NCT02880280|Experimental|Human Chorionic Gonadotropin|Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation
16560310|NCT02880267|Other|CGM Users|Glucose challenge during a clinic sessions to assess performance of CGM compared to reference measurement
16560311|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
16560312|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
16560313|NCT02880241|Experimental|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
16560314|NCT02880241|Experimental|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
16560315|NCT02880241|Experimental|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
16560316|NCT02880241|Experimental|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
16560317|NCT02880241|Experimental|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
16560318|NCT02880241|Experimental|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
16560319|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
16560320|NCT02880215|Experimental|Attention Bias Modification|Behavioral intervention designed to improved negative attention bias.
16560321|NCT02880215|Experimental|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
16560322|NCT02880215|No Intervention|Assessment Only|Assessment only with no active intervention.
16560323|NCT02880202|Other|Massage Therapy|Massage therapy for hospice patients.
16560324|NCT02880189|Other|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
16560325|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.
~Subjects will use Fitbit Zip to track step counts"
16560326|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
16560327|NCT02880150|Other|Elite climbers|Elite climbers selected in a national group for their previous performances at high altitude
16560328|NCT02880150|Other|Sea level sportsmen|Control group with similar anthropometric, age, gender and maximal normoxic oxygen consumption that the elite climber group
16560329|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
16560330|NCT02880124|Experimental|Maple syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
16560331|NCT02880124|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
16560332|NCT02880124|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
16560432|NCT02879422|Other|Diabetic patients with non proliferative diabetic retinopathy|
16636989|NCT02368483|Experimental|Neuromuscular training|
16560333|NCT02880124|Active Comparator|Sport drink|A Gatorade (TM) solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
16560334|NCT02880124|Placebo Comparator|Trace|A solution containing stevia (sugar substitute) and trace amounts of glucose (3g) labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
16560335|NCT02880111||group 1|CF patients with Pseudomonas aeruginosa chronic colonization.
16560336|NCT02880111||group 2|CF patients without a Pseudomonas aeruginosa chronic colonization.
16560337|NCT02880072|Experimental|refeeding syndrome|6 patients with head and neck cancer and refeeding syndrome, 4 different of preparations of phosphate orally
16560338|NCT02880072|Experimental|no refeeding syndrome|6 patients with head and neck cancer without refeeding syndrome, 4 different of preparations of phosphate orally
16560339|NCT02880046||Melanoma (LyteloMel)|
16560340|NCT02880046||Lung cancer (TeloCap)|
16560341|NCT02880046||Renal carcinoma (EMIR)|
16560342|NCT02880033|Active Comparator|Parkinson's disease|ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
16560343|NCT02880033|Active Comparator|Amyotrophic lateral sclerosis|ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
16560344|NCT02880033|Placebo Comparator|healthy age and sex matched controls|ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
16560345|NCT02880020|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16560346|NCT02880020|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes every 6 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16560347|NCT02880007|Experimental|ARM A|Dose Optimization in 3D Pulsed Dose Rate Brachytherapy
16560348|NCT02879994|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
16560349|NCT02879981||Pediatric Participants With Acute Bronchitis|Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label will be observed for safety.
16560350|NCT02879968||Head and Neck squamous cell carcinoma|"A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.
~The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).
~The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula."
16560351|NCT02879955|Experimental|10 gastric bypass operated patients|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
16560352|NCT02879955|Experimental|10 healthy control subjects|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
16560353|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
16560354|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
16560355|NCT02879916|Placebo Comparator|Placebo|NaCl 0.9% 3ml perineural stellate ganglion injection
16560356|NCT02879916|Active Comparator|Stellate ganglion block|Levobupivacaine 3ml perineural stellate ganglion injection
16560357|NCT02879903|Experimental|biofilm tobacco effect|Group smokers - patients will receive periodontal treatment and biofilm will be collected.
16560358|NCT02879903|Experimental|biofilm non smoker effect|Group Non Smokers - patients will receive periodontal treatment and biofilm will be collected.
16560359|NCT02879877|Experimental|UCB7858 (intravenous)|Various single doses, administered to various cohorts.
16560360|NCT02879877|Placebo Comparator|Placebo (intravenous)|Single dose placebo comparator for each cohort of iv administration.
16560361|NCT02879877|Experimental|UCB7858 (subcutaneous)|Various single doses, administered to various cohorts.
16560362|NCT02879877|Placebo Comparator|Placebo (subcutaneous)|Single dose placebo comparator for each cohort of sc administration.
16560363|NCT02879864|Experimental|Light therapy|Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes. Light therapy begins immediately after receipt of the luminometer. The total duration of daily outpatient therapy program is 6 months. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24. They will complete the same day or the day before, and / or before any chemotherapy. A follow-up visit will be performed 1 month after the end of therapy (week 28).
16560571|NCT02878291|Experimental|low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,20μg/dose
16560364|NCT02879864|Active Comparator|usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
16560365|NCT02879838||Occupational Asthma|
16560366|NCT02879838||Work Aggravated Asthma|
16560367|NCT02879838||Non-Work-Related Asthma|
16560368|NCT02879825|Experimental|Group A|Mitral valve prolapse without mitral regurgitation
16560369|NCT02879825|Experimental|Group B|Mitral valve prolapse with trivial mitral regurgitation
16560370|NCT02879825|Experimental|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
16560371|NCT02879825|Experimental|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
16560372|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
16560373|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
16560374|NCT02879799|Experimental|Implement Family Integrated Care|Dynamic education and support intervention for families of preterm infants.
16560375|NCT02879799|No Intervention|Monitor Standard Practices|Standard nursing care of preterm infants and their families.
16560376|NCT02879786|Experimental|Phonological dyslexia|Children with phonological dyslexia
16560377|NCT02879786|Experimental|Visuo-attentional dyslexia|Children with visuo-attentional dyslexia
16560378|NCT02879786|Other|Control|Control children, age-matched
16560379|NCT02879773||Lung cancer|Patients undergoing thoracic surgery for suspected or confirmed lung cancer; including wedge resection, segmentectomy, lobectomy, bilobectomy or pneumonectomy. CTPVe will be modelled to predict postoperative lung function.
16560380|NCT02879773||Emphysema|Patients undergoing assessment of emphysema/chronic obstructive pulmonary disease (COPD) for potential surgical intervention; including lung volume reduction surgery, endobronchial valve insertion or endobronchial coil insertion. CTPVe will be modelled to predict postoperative lung function.
16560381|NCT02879773||Interstitial lung disease|Patients undergoing assessment or treatment of suspected or confirmed interstitial lung disease. CTPVe will be modelled to aid diagnosis of the subtype of interstitial lung disease confirmed by histological diagnosis.
16560382|NCT02879760|Experimental|Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab|"Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.
~MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 & 18 at 1x 10e10 pfu.
~Cohort 2: Days 15 & 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22."
16560383|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
16560384|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
16560385|NCT02879734|No Intervention|Without Omentopexy|Patients that did not undergo prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter
16560386|NCT02879734|Experimental|With Omentopexy|Patients that underwent prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter. Intervention = Prophylactic laparoscopic omentopexy
16560387|NCT02879721|No Intervention|no drug|No drug and no intervention
16560388|NCT02879721|Active Comparator|AT1R-antagonist|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily
16560389|NCT02879721|Active Comparator|ACE-inhibitor|Angiotensin converting enzyme inhibitor, (enalapril) 5 mg once daily
16560390|NCT02879708|No Intervention|Control|40 (of 120) randomly selected villages receive no intervention
16560391|NCT02879708|Other|Information Only|"40 randomly selected villages are assigned to the information only arm where households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village."
16560392|NCT02879708|Other|Information and Facilitation|The remaining 40 villages will receive similar information as the villages in the Information Only Arm, but will also have facilitators present that ensure the existence of the VHSNC at the village level as well as the occurrence of VHSNC monthly meetings.
16560394|NCT02879682|Active Comparator|nTMS|presurgical motor mapping by nTMS and fusion with intraoperative neuronavigation
16560395|NCT02879682|Sham Comparator|non-nTMS|presurgical motor mapping by nTMS without access of the surgeon to these data
16560396|NCT02879669|Experimental|ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)|ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
16560397|NCT02879669|Active Comparator|Pemetrexed/cisplatin (carboplatin)|Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
16560398|NCT02879656|Other|Cohort 1|"Early ustable fracture:
~Phase 1:
~After closed reduction, if satisfactory reduction is not achieved fulfilling the inclusion criteria, the patient is allocated to Cohort 1. The patient is randomized to either non-operative (=Arm 1) or operative treatment (=Arm 2). Patients allocated to non-operative treatment will undergo a standard treatment protocol. Patients allocated to operative treatment will undergo a surgery with volar locking plate with modified Henry's volar approach."
16560399|NCT02879656|Other|Cohort 2|"Early stable fracture:
~Phase 1:
~After closed reduction, if satisfactory position is achieved, the patient is allocated to Cohort 2 and conservative treatment is performed as usually.
~Phase 2:
~Patients allocated to Cohort 2, will visit orthopedic outpatient clinic in 1 week in the hospital where the treatment was initially started. If reduction is maintained the patient will undergo standard follow-up visits. If reduction is lost to fulfill the inclusion criteria for surgery the patient is asked to participate to phase 2 of this study. After the patient´s enrollment has been confirmed and informed consent is signed, the patient is randomized to either non-operative (=Arm 3N) or operative treatment (=Arm 3O). If allocated to non-operative treatment patient will undergo the same protocol as those in the Arm 1. Patients allocated to operative treatment will undergo surgery with volar locking plate with standard volar approach."
16560400|NCT02879643|Experimental|Cohort A: Marqibo and UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.
~Dexamethasone orally twice daily on days 1-5 and 15-19.
~Mitoxantrone: given by intravenous (IV) infusion on days 1 and 2.
~PEG-asparaginase: given as an injection into the muscle on says 3 and 17.
~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
16560401|NCT02879643|Experimental|Cohort B: Marqibo and lower intensity UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.
~Dexamethasone orally twice daily on days 1-5 and 15-19.
~PEG-asparaginase: given as an injection into the muscle on days 3 and 17.
~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
16560402|NCT02879643|Experimental|Cohort C: Marqibo and maintenance regimen|"Marqibo®: given by intravenous (IV) infusion on day 1
~Dexamethasone orally twice daily on days 1-5
~Methotrexate: given orally on days 1 and 8
~Mercaptopurine: given orally daily on days 1-13"
16560403|NCT02879630||Obese Patients|Obese patients (patients whose weight is >190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
16560404|NCT02879630||Non-obese Patients|Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
16560405|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
16560406|NCT02879604|Experimental|Compensatory cognitive training|Compensatory cognitive training
16560407|NCT02879604|Placebo Comparator|usual treatment|usual treatment for shizophrenai
16560408|NCT02879591|Experimental|Patients with schizophrenia|Patients with schizophrenia
16560409|NCT02879591|Placebo Comparator|Healthy volunteers|Healthy volunteers
16560410|NCT02879578|Experimental|Valbenazine (Children)|Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
16560411|NCT02879578|Experimental|Valbenazine (Adolescents)|Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
16560412|NCT02879578|Experimental|Valbenazine (Adults)|Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
16560413|NCT02879565|Other|qualitative and neuroimaging research|
16560414|NCT02879552||Traditional upper blepharoplasty|Patients with an odd total number of letters in their first name received traditional upper blepharoplasty.
16560415|NCT02879552||Brassiere suture with blepharoplasty|The rest of the patients received orbicularis oculi muscle fixation to periosteum (brassiere sutures)
16560416|NCT02879539|Experimental|MP3000-ACE strategy|MP3000 sound coding strategy or ACE strategy with lower stimulation rate
16560417|NCT02879526|Experimental|C-CPT|
16560418|NCT02879513|Active Comparator|Switch to CEF|Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
16560419|NCT02879513|Experimental|Continue the neoadjuvant regimen|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
16560420|NCT02879513|Experimental|Pathological complete response group with chemotherapy|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
16560421|NCT02879513|No Intervention|Pathological complete response group with no chemotherapy|
16560422|NCT02879487|Active Comparator|Coagulation mode|Colpotomy will be performed by monopolar needle electrode using coagulation mode
16560423|NCT02879487|Active Comparator|Cut mode|Colpotomy will be performed by monopolar needle electrode using cut mode
16560424|NCT02879474||Patient with melanoma|
16560425|NCT02879461|Active Comparator|Lumbar Decompression plus Physical Therapy|First group will be submitted to lumbar decompression L3 to S1 and physical therapy with exercise Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
16560426|NCT02879461|Active Comparator|Physical Therapy|Second group physical therapy alone, with exercises Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
16560427|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
16560428|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
16560429|NCT02879435|Experimental|bupivacaine|Intervention
16560430|NCT02879435|Placebo Comparator|Placebo|Control
16560431|NCT02879422|Other|Diabetic patients with proliferative diabetic retinopathy|
16560433|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl
~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
16560434|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl
~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
16560435|NCT02879396|Experimental|Study Participants|A maximum of 50 participants will be enrolled in the study per the inclusion and exclusion criteria. The participants will be residents of SLH who are 55 years old or older. They will have had one or more EMS calls made, ED visit or hospital admission in the past year, as determined by the incidence report at SLH. The study participants will receive PA4LE program.
16560436|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
16560437|NCT02879383|Sham Comparator|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
16560438|NCT02879370|Experimental|TICRANT|Transanal Inspection and management of low ColoRectal Anastomosis
16560439|NCT02879357|Experimental|Trained Clinicians|Training in Serious Illness Communication Guide
16560440|NCT02879357|No Intervention|Untrained Clinicians|No training in Serious Illness Communication Guide
16560441|NCT02879344|Other|Patient undergoing ECMO|
16560442|NCT02879331|Active Comparator|10 coils in upper lobes|10 coils in upper lobes
16560443|NCT02879331|Experimental|15 coils in upper and lower lobes|15 coils in upper and lower lobes
16560444|NCT02879318|Active Comparator|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 8, 15 Q28 days.
16560445|NCT02879318|Experimental|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.
~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
16560446|NCT02879305|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
16560447|NCT02879305|Active Comparator|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
16560448|NCT02879279|Experimental|Robotic rehabilitation|In the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
16560449|NCT02879279|Active Comparator|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
16560450|NCT02879266|Experimental|TetraVax-DV TV005|Participants will receive a subcutaneous injection of TetraVax-DV TV005 at study entry (Day 0).
16560451|NCT02879266|Placebo Comparator|Placebo|Participants will receive a subcutaneous injection of placebo at study entry (Day 0).
16560452|NCT02879240|Other|Group animated cartoon-black screen (AB)|In this group, children will be exposed to a animated cartoon during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to a black screen in the same conditions for one other week.
16560453|NCT02879240|Other|Group black screen - animated cartoon (BA)|In this group, children will be exposed to a black screen during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to an animated cartoon in the same conditions for one other week.
16560454|NCT02879227|Active Comparator|Arm Cisplatin|Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
16560455|NCT02879227|Experimental|Arm Oxaliplatin|Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
16560456|NCT02879214|Experimental|SIDE cervical trial|To Maximal downstage locally advanced squamous cell cervical cancer before minimal invasive surgical resection. The SIDE study is to use both RT dose escalation to the biological target defined by PET and Chemo dose escalation composited with two drugs to achieve maximal reduction of tumor burden, providing feasibility of minimal invasive surgical resection.
16560457|NCT02879201|Active Comparator|Slow efficiency dialysis|SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
16560458|NCT02879201|No Intervention|Continuous renal replacement therapy|CRRT is a kind of therapy involved continuos dialysis throughout 24 hours by using Edward Delivery system (Edward Life Science) as continuous venovenous hemodiafiltration (CVVHDF) mode using Aquamax HF 12 dialyzer. Blood flow rate was kept from 100-200 mL/hr and target effluent rates of 20 mL/hr . The substitution fluid was infused at a rate of 1,000 ml/hr with ultrafiltration rate at 100-300 mL/hr.Intervention here is the different mode of dialysis
16560572|NCT02878278|Experimental|Chidamide BIW|Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
16560459|NCT02879188|Experimental|Ambulation|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
16560460|NCT02879188|Active Comparator|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
16560461|NCT02879162|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
16560462|NCT02879149||Group 1|Standard Rigid Fixation plus autograft
16560463|NCT02879149||Group 2|Standard rigid fixation plus AUGMENT® Bone Graft
16560464|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
16560465|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
16560466|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
16560467|NCT02879110|Experimental|Sulforaphane group|The patients will take sulforaphane for 12 weeks.
16560468|NCT02879110|Placebo Comparator|Placebo group|The patients will take placebo for 12 weeks.
16560469|NCT02879097|Experimental|CBT124 arm|CBT124 plus carboplatin and paclitaxel
16560470|NCT02879097|Active Comparator|EU Sourced Avastin® arm|EU-sourced Avastin® plus carboplatin and paclitaxel
16560471|NCT02879058|No Intervention|Without Ultrasound|Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
16560472|NCT02879058|Experimental|With Ultrasound|Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography
16560473|NCT02879045|Experimental|elasticity Belly® oil|Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil
16560474|NCT02879019|Sham Comparator|Stretching exercise group|Patients will receive two session per week of stretching classes.
16560475|NCT02879019|Experimental|Walking training group|Patients will perform two walking sessions per week.
16560476|NCT02879006|Active Comparator|Chinese Herbal Medication|
16560477|NCT02879006|Placebo Comparator|Placebo|
16560478|NCT02878993||Intubated infants|Recording of diaphragm EMG
16560479|NCT02878980|Experimental|Arm I (exercise intervention)|Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
16560480|NCT02878954|Other|No intervention|160 men and women with PAD will be recruited.
16560481|NCT02878954|Other|Control session|40 patients (men and women) will complete this session.
16560482|NCT02878954|Other|Exercise session|40 patients (men and women) will complete this session.
16560483|NCT02878941|Other|Elbow Fracture|Patients with an intraarticular elbow fracture and/or dislocation. Synovial fluid from the injured elbow will be obtained during the subject's emergency department encounter by one of the Chief Residents or Attending surgeon as part of standard of care procedures for pain control-related injection and aspiration. Patients with an intraarticular elbow fracture and/or dislocation receive an intraarticular elbow injection with anesthetic (i.e. lidocaine or marcaine) to provide analgesia for elbow range of motion testing and orthopaedic reduction maneveuers as the current standard of care. The patients would be asked to consent for 2 elbow joint aspirations: 1.Aspiration of the injured elbow at time of surgical fracture fixation; 2.Aspiration of the uninjured elbow at time of surgical fracture fixation.
16560484|NCT02878928|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|Medical providers for IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
16560485|NCT02878928|No Intervention|Control Group|Medical providers for the Control Group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
16560486|NCT02878915|Active Comparator|Ultrasound guided femoral puncture|
16560487|NCT02878915|No Intervention|palpation guided femoral puncture|
16560488|NCT02878902||Before implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2012 to December 31, 2013"
16560489|NCT02878902||Post implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2014 to December 31, 2015"
16560490|NCT02878889|Experimental|Arm 1|S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
16560491|NCT02878876|Experimental|Sequence A1-A2|Dietary Supplement: Oral consumption of milk with sequence A1-A2
16560492|NCT02878876|Experimental|Sequence A2-A1|Dietary Supplement: Oral consumption of milk with sequence A2-A1
16560493|NCT02878863|Experimental|Paeoniflorin + phosphatidylcholine or silymarin|Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin
16560494|NCT02878863|Active Comparator|Phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin
16560495|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
16560496|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
16560497|NCT02878837|Active Comparator|DEX|Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.
16560498|NCT02878837|Active Comparator|MDZ|Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1
16560499|NCT02878824||HK-Children|This is a group of typically-developing children ages 7-12 years old who are of Chinese ethnicity, born and raised in Hong Kong (n=32).
16560500|NCT02878824||FHK-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity; either born, migrated and/or raised in Hong Kong (n=32).
16560501|NCT02878824||FU-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in an urban area in the Philippines (n=32).
16560502|NCT02878824||FR-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in a rural area in the Philippines (n=32).
16560503|NCT02878798|Placebo Comparator|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
16560504|NCT02878798|Experimental|Topiramate|Oral topiramate
16560505|NCT02878785|Experimental|Phase 1: Decitabine and Talazoparib Combo|"Phase 1:
~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28.
~The 'outer layer' of this nested dose escalation trial will escalate the dose of the two drugs by sequentially going through dose levels 1-6 in the table found in the protocol. The standard algorithm of the 3+3 design will be applied."
16560506|NCT02878785|Experimental|Phase 2: Decitabine and Talazoparib Combo|"Phase 2:
~Recommended Phase 2 Dose (RP2D) The MTD of the combination of decitabine with a dose of talazoparib of at least 0.25 mg is defined as the maximal tolerated dose of decitabine studied - and for that dose level, combined with the maximum dose of talazoparib for which the incidence of DLT was less than 33% in 6 participants treated and this will be chosen as the recommended Phase 2 dose (RP2D). Among potential combined dose levels at MTD, available pharmacodynamic data (PARP trapping) will also be considered in the choice of RP2D, as will any significant indications of differences in clinical efficacy"
16560507|NCT02878785|Active Comparator|Phase 2 Arm A|Adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy
16560508|NCT02878785|Active Comparator|Phase 2 Arm B|Adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment
16560509|NCT02878785|Active Comparator|Phase 2 Arm C|Adult patients previously treated with a DNA methyltransferase inhibitor (decitabine, azacitidine or guadecitabine)
16560510|NCT02878772|Active Comparator|vinpocetine group|Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
16560511|NCT02878772|Placebo Comparator|Control group|Patients will receive aspirin only.
16560512|NCT02878759|Experimental|Wristbot|WristBot will be used as diagnostic tool to evaluate the novel technology and the associated protocol for proprioception quantification during rehabilitation. The main objective is to provide clinicians with a reliable instrument able to overcome the limitations in proprioceptive measurement by current clinical methodologies.
16560513|NCT02878746|Experimental|Robotic mirror therapy|For 30 min per day for two weeks (10 sessions)
16560514|NCT02878746|Active Comparator|Conventional mirror therapy|For 30 min per day for two weeks (10 sessions)
16560515|NCT02878733||Albumin|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
16560516|NCT02878733||Crystalloid Only|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
16560517|NCT02878720|Experimental|Robotic therapy and real tVNS|This group receives REAL vagus nerve stimulation during robotic rehabilitation.
16560518|NCT02878720|Active Comparator|Robotic therapy and sham tVNS|This group receives SHAM VNS during robotic rehabilitation. Sham VNS is not effective. Both groups receive the same amount of robotic rehabilitation.
16560519|NCT02878707|Experimental|DEX|Intraoperative intravenous infusion of dexmedetomidine
16560520|NCT02878707|Placebo Comparator|Control|Intraoperative intravenous infusion of 0.9% saline
16560521|NCT02878694|Experimental|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections
16560522|NCT02878681|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab for six months
16560523|NCT02878681|Experimental|Group 2|Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.
16560524|NCT02878681|Experimental|Group 3|Monthly injections of 2 mg aflibercept for six months
16560525|NCT02878616|Experimental|LFG316 + IVIG|
16560526|NCT02878616|Experimental|LFG316 alone|
16560527|NCT02878603|Experimental|caplacizumab|Initial i.v. dose followed by daily s.c. injections for a maximum period of 6 months
16560528|NCT02878590|Experimental|BONGO DEVICE|All participants that qualify will receive the intervention of the Bongo device
16560529|NCT02878577||EEG fMRI TBI Mild/Moderate-Severe severity|patient population who suffered a brain trauma (traumatic brain injury, TBI). with a Glasgow Coma Scale between 3-15
16560530|NCT02878577||EEG fMRI Control group|healthy subjects with out a traumatic brain injury
16560531|NCT02878564|Experimental|Praziquantel treatment|Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.
16560532|NCT02878551|Experimental|Prehabilitation program|Multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
16560533|NCT02878538|Active Comparator|deferiprone|Deferiprone will be administered three times a day (25mg/kg). Total dose per day will depend on participants' body weight for one, three month block.
16560534|NCT02878538|Placebo Comparator|Placebo Phase|Placebo tablets with inactive substance will be used. Total number of placebo tablets will be equivalent to the active tablets administered depending on participants' body weight for two, three month blocks.
16560535|NCT02878525|Experimental|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
16560536|NCT02878525|Active Comparator|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
16560573|NCT02878278|Experimental|Chidamide QD|Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
16560574|NCT02878265|Placebo Comparator|Vitamin A|A single dose of 20,000IU Vitamin A for the whole study period
16560575|NCT02878265|Active Comparator|Vitamin A and zinc|A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months
16560749|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
16560537|NCT02878512|Active Comparator|PCNL under General Anesthesia|Patients were premedicated with Inj. Atropine 0.06 mg intramuscularly half an hour prior to surgery, IV ranitidine 1mg kg-1, IV ondansetron 0.08mg kg-1 IV midazolam 0.02mg kg-1 and Pentazocine 0.3 mg/kg. Anaesthesia was induced with IV Thiopentone sodium 3-5 mg kg-1 and Vecuronium 0.1mg kg-1.and then intubated. Anaesthesia was maintained on 50 %:50% nitrous oxide and oxygen, vecuronium and propofol infusion . At the end of the surgery postoperative analgesia was given with IV tarmadol and local nfiltration with 0.25% bupivacaine at the surgical site. Patients were reversed with IV glycopyrrolate 0.008mg kg-1 and IV neostigmine 0.06mg kg-1 and extubated.
16560538|NCT02878512|Experimental|PCNL under Segmental epidural Anesthesia|epidural space was located at T12 -L1 or L1-L2 space .The epidural catheter was inserted cephalad 5 cm upwards in the epidural space (tip approximately at T8 to T9). and test dose of 3 ml of 2% Adrenalized Lignocaine was administered..loading dose of 0.5% Bupivacaine, approximately 8 to 10 ml was injected epidurally with regular negative aspiration to block T6- T12 segments, if desired level was not achieved then additional dose of 1 to 1.5 ml 0.5% bupivacaine per spared segment was given to achieve the desired level.Motor blockade of the lower limbs was checked and noted before lithotomy, before prone and at the end of the surgery using Bromage scale. After two segment regression of sensory level epidural top up with 1/4th of initial dose 2 to 3 ml of 0.5% Bupivacaine was given. At the end of the surgery 8ml of 0.125% Bupivacaine was administered for postoperative analgesia and the catheter was removed.
16560539|NCT02878499|Other|ASD|
16560540|NCT02878486|Experimental|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
16560541|NCT02878486|Active Comparator|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
16560542|NCT02878473|Experimental|Liver transplantation|The intervention will consist of liver transplantation
16560543|NCT02878460|Experimental|monitoring with ORI + SpO2|"Patients receive the regular monitoring with SpO2, but in this group, the ORI parameters is shown on the scope.
~Lower and upper SpO2 limits are prescribed for each patient."
16560544|NCT02878460|Other|monitoring with SpO2|"Patients receive the regular monitoring; the ORI parameters is not shown (but it is recorded each time a blood gas is drown).
~Lower and upper SpO2 limits are prescribed for each patient."
16560545|NCT02878447|Experimental|External Beam Radiotherapy|Patients will receive radiotherapy (3.5Gy weekly for 5 fractions to a maximum of 17G) prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue
16560546|NCT02878447|No Intervention|Control|Patients will receive best medical care.
16560547|NCT02878434||Study group|
16560548|NCT02878434||control group|
16560549|NCT02878421|Active Comparator|tobacco cigarette|Intervention: tobacco cigarettes min 15/day
16560550|NCT02878421|Active Comparator|e.cigarettes + 16mg nicotine & flavor|Intervention: One flavoured electronic cigarette 16mg nicotine/day
16560551|NCT02878421|Active Comparator|e.cigarettes + 0mg nicotine & flavour|Intervention: One electronic cigarette with flavour +0mg nicotine/day
16560552|NCT02878408|Other|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
16560553|NCT02878408|Other|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
16560554|NCT02878408|Other|stable Bipolar disorder|blood sampling and data collection (only one visit)
16560555|NCT02878408|Other|stable Schizophrenia|blood sampling and data collection (only one visit)
16560556|NCT02878408|Other|healthy control|blood sampling and data collection (only one visit)
16560557|NCT02878395||Crohn's disease|
16560558|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
16560559|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
16560560|NCT02878356|Active Comparator|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
16560561|NCT02878356|Active Comparator|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
16560562|NCT02878356|Active Comparator|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
16560563|NCT02878343|Active Comparator|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
16560564|NCT02878343|Active Comparator|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
16560565|NCT02878343|Active Comparator|Incentive and environmental strategies|A combination of incentives and environmental strategies
16560566|NCT02878343|No Intervention|Usual care|Standard employee wellness benefits
16560567|NCT02878330|Placebo Comparator|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
16560568|NCT02878330|Experimental|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
16560569|NCT02878317||Malnourished participants|"Presence of malnutrition will be assessed by using the Subjective Global Assessment.
~Once the identified malnourished participants have given their informed consent, they will receive intensive dietitian supervised nutritional support with the aim of improving their malnutrition. In addition, participants will receive standard dietary advice for people on dialysis based on the Nutritional Guidelines in CKD published by the Renal Association in March 2010 in the UK (Wright and Jones, 2010) and will include the following: energy (35 kcal/kg/day) and protein intake (1.2 g/kg/day), as well as potassium, phosphate and sodium restriction, according with biochemical blood parameters."
16560570|NCT02878291|Experimental|High dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,40μg/dose
16560750|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
16560576|NCT02878265|Active Comparator|Vitamin A , Zinc and Multivitamin|A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months
16560577|NCT02878239||Early OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with early knee osteoarthritis because their Kellgren-Lawrence Scores were Grade I.
16560578|NCT02878239||Moderate OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade II.
16560579|NCT02878239||Severe OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade III/IV.
16560580|NCT02878239||Asymptomatic Participants|The asymptomatic participants（>35 years） has no history of knee pain, trauma, surgery, or obvious gait abnormalities. They are set as controls in the study.
16560581|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
16560582|NCT02878200|Experimental|reactive treatment|Household members; defined as those sharing the same sleeping area, in the intervention villages, will be treated with a full course of dihydroartemisinin-piperaquine (DHAP)
16560583|NCT02878200|No Intervention|standard care|In control villages, no household treatment will be done
16560584|NCT02878187||placenta previa|all women managed by conservative surgical techniques during cesarean section after intraoperative hemorrhage due to placenta previa/accreta
16560585|NCT02878187||healthy controls|women delivered by Cesarean for any other indication with no intraoperative hemorrhage or any additional surgical techniques performed during Cesarean
16560586|NCT02878174|Active Comparator|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
16560587|NCT02878174|Experimental|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
16560588|NCT02878161|Experimental|A group|Infliximab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
16560589|NCT02878161|Experimental|B group|Etanercept plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
16560590|NCT02878161|Experimental|C group|Adalimumab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
16560591|NCT02878148|Experimental|Patients with suspected acute uncomplicated renal colic|Diagnostic imaging
16560592|NCT02878135|Experimental|fast vulsellum|rapid ratchet of the vulsellum
16560593|NCT02878135|Active Comparator|slow vulsellum|Placement of the tenaculum over 7-10 seconds and not allowing the vulsellum to ratchet audibly.
16560594|NCT02878122||Patients with epithelial ovarian cancer|Cancer treatment
16560595|NCT02878109||Post-treatment phase group|29 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE).
16560596|NCT02878109||Pre-treatment phase group|11 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before treatment (if any).
16560597|NCT02878096|Experimental|[14C]-SK-1404|
16560598|NCT02878083|Experimental|VEDOLIZUMAB|300 mg IV
16560599|NCT02878070|Experimental|Peer Health Coaching|Calls from a Peer Health Coach for 6 months
16560600|NCT02878070|No Intervention|Usual Care|
16560601|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
16560602|NCT02878044|Experimental|Implementation Arm|
16560603|NCT02878031|Experimental|Oral amoxicillin for CI pneumonia|Community management of chest indrawing pneumonia using oral amoxicillin by CHWs
16560604|NCT02878018||TCM intervention|Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
16560605|NCT02878018||WM conventional intervention|The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
16560606|NCT02878005|Active Comparator|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
16560607|NCT02878005|Active Comparator|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
16560608|NCT02877992|Active Comparator|Donors|Oocyte donors without infertility problems
16560609|NCT02877992|Experimental|PCOS|Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria
16560610|NCT02877992|Experimental|Endometriosis|Patients with endometriosis (I-IV)
16560611|NCT02877992|Experimental|Age|Patients with advanced maternal age (38 years or more)
16560612|NCT02877992|Experimental|Low ovarian response|Patients with low ovarian response according to Bologna criteria
16560613|NCT02877979|Experimental|DS003 vaginal tablet|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
16560614|NCT02877979|Placebo Comparator|placebo|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
16560615|NCT02877966|Experimental|Arm A|Amixea- patented stoechiometrical mixture of EAA & AA
16560616|NCT02877966|Placebo Comparator|Arm B|Placebo
16560617|NCT02877953|No Intervention|Control group|The conventional care was performed for the patients of control group
16560618|NCT02877953|Experimental|Intervention group|the prevention of complications post-TIPS
16560619|NCT02877940|Active Comparator|ProSeal Laryngeal mask airway|ProSeal will be inserted in mechanically ventilated patients undergoing elective surgeries.
16560620|NCT02877940|Active Comparator|Laryngeal Tube Suction- Disposable|LTS-D will be inserted in mechanically ventilated patients undergoing elective surgeries.
16560624|NCT02877901|Active Comparator|tolterodine-treated group|they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
16560625|NCT02877901|Placebo Comparator|placebo-control group|they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated
16560626|NCT02877888|Experimental|drug fluoride varnish /strength 22600ppm|intervention: drug :fluoride varnish 22600ppm topical application every 6 months for a total period of 2 years
16560627|NCT02877888|No Intervention|placebo comparator|placebo:use of routine dental advice
16560628|NCT02877875|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC;Chorpita & Weisz, 2009), and (2) a youth monitoring and feedback system (MFS).
16560629|NCT02877875|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
16560630|NCT02877862|Experimental|Intervention|Receive 7-day mAGIC app intervention and handout
16560631|NCT02877862|No Intervention|Control|Handout only
16560632|NCT02877849||Individuals with Alcohol Use Disorder|Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
16560633|NCT02877849||Healthy Volunteers|Healthy volunteers with comparable age and gender to the patient group will be recruited through community advertisements. We will collect brain imaging data, this is an observational study.
16560634|NCT02877836|Other|Segmentary dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
16560635|NCT02877836|Other|Hemidystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
16560636|NCT02877836|Other|Generalized dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
16560637|NCT02877836|Other|Healthy control subjects|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
16560638|NCT02877823|Experimental|Treatment|"Home delivery of bottled water supplying 48 oz. /day for the child and 24 oz. /day per other household members (up to 6 family members).
~Child pedometer use and activity tracking to encourage child physical activity/goal setting and engage parents in monitoring their child's health behavior.
~Family Navigator Services by telephone with the parent to help engage and empower parents in child healthy lifestyle changes. They will also be able to assist with resource needs for the household (food/housing services).
~Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks daily and limit fruit juice to one hundred percent real fruit juice."
16560639|NCT02877823|Active Comparator|Control|Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks and limit fruit juice to one hundred percent real fruit juice.
16560640|NCT02877810|Experimental|Telemedicine|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telemedicine, a live, interactive, audiovisual teleconferencing system, from a pediatric critical care physician.
16560641|NCT02877810|Active Comparator|Telephone|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telephone, from a pediatric critical care physician..
16560642|NCT02877797|No Intervention|standard Esophagogastroduodenoscopy|standard Esophagogastroduodenoscopy
16560643|NCT02877797|Experimental|cap assisted Esophagogastroduodenoscopy|cap assisted Esophagogastroduodenoscopy
16560644|NCT02877784||Screening|Participants enrolled will undergo testing of the swallowing mechanism
16560645|NCT02877771|Experimental|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses CGM values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
16560646|NCT02877758|Experimental|Experimental|Tomorrowlabs cosmeceutical formulation is applied to the face of the subjects twice daily for 3 consecutive months.
16560647|NCT02877758|Sham Comparator|Control|Tomorrowlabs cosmeceutical formulation without the active ingredient is applied to the face of the subjects twice daily for 3 consecutive months.
16560648|NCT02877745||no SDB|apnea-hyponea index <15/hour
16560649|NCT02877745||SDB|apnea-hyponea index >=15/hour
16560650|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
16560651|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
16560652|NCT02877719||Children from low-income families|Children from low-income families were invited to fill in a set of questionnaires.
16560653|NCT02877719||Children from high income families|Children from high-income families were invited to fill in a set of questionnaires.
16560654|NCT02877693|Other|Thoracic MRI Scan|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
16560655|NCT02877680|Experimental|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
16560751|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
16560656|NCT02877680|No Intervention|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
16560657|NCT02877667|Experimental|Open label device treatment|Up to four passes with Q-Switched laser alternating with acoustic wave device
16560658|NCT02877654|Experimental|Irritable Bowel Syndrome|
16560659|NCT02877641|Active Comparator|Control arm (multivitamin, placebo)|Patients receive a placebo and multivitamin orally each day for 52 weeks.
16560660|NCT02877641|Experimental|Supplementation arm (multivitamin, cholecalciferol)|Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.
16560661|NCT02877615|Experimental|S 44819 150 mg twice a day|
16560662|NCT02877615|Experimental|S 44819 300 mg twice a day|
16560663|NCT02877615|Placebo Comparator|Placebo|
16560664|NCT02877602||Experience of liver disease|This is defined as either those who have had direct experience of liver disease as sufferers, or the carers of those who have had liver disease. Each individual receives an MRI (LiverMultiScan), with many also receiving a FibroScan.
16560665|NCT02877589||solid tumor|Patients receiving chemotherapy for solid tumors in Ambulatory Medicine Unit of the Reims University Hospital (France) between May 14, 2012 and July 31, 2013.
16560666|NCT02877576|Experimental|Epileptic patient|micro-electrode recordings interventions: Implantation of mixed intracerebral electrodes Face detection Face individualization
16560667|NCT02877563||Patients with PAD|Patients with PAD who are to undergo surgical or percutaneous revascularization.
16560668|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:
~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)
~Part B - dose expansion:
~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD
~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
16560669|NCT02877537|Experimental|Asthma child|
16560670|NCT02877537|Experimental|Control adult|
16560671|NCT02877537|Experimental|Control child|
16560672|NCT02877524|Experimental|Adaptive support ventilation|Adaptive support ventilation during NIV for acute exacerbation of COPD
16560673|NCT02877524|Active Comparator|Pressure support ventilation|Pressure support ventilation during NIV for acute exacerbation of COPD
16560674|NCT02877511|Experimental|Arm 1|2/3 of subjects testing the test article
16560675|NCT02877511|Active Comparator|Arm 2|1/3 of subjects testing the marketed control
16560676|NCT02877498|Experimental|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
16560677|NCT02877498|Active Comparator|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
16560678|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
16560679|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
16560680|NCT02877472|Experimental|Experimental group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression and porous tantalum rod implantation (experimental group).
16560681|NCT02877472|Experimental|Control group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression (control group).
16560682|NCT02877459|Experimental|AeriSeal System|Subjects will be treated with AeriSeal Foam.
16560683|NCT02877433|Active Comparator|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
16560684|NCT02877433|Experimental|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
16560685|NCT02877420|Experimental|Non-Technical Skills Training Curriculum|This group will receive 4 hours of small-group and hands-on sessions and 1 hour of didactic NTS sessions. Participants will watch a video that demonstrates ideal endoscopic performance. They will use the E-NTS Checklist during the integrated scenario training. This checklist targets NTS. The group will be given 7 hours of expert-assisted instruction on the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (6 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist who will demonstrate techniques, answer questions and provide individualized performance feedback with a focus on NTS. The last three hours on the high fidelity simulator will be an integrated scenario (IG) featuring standardized patient (SP) and standardized nurse (SN). Feedback will be given after each IG by the instructor, SP and SN. Participants can view the E-NTS Checklist before and after each case.
16560686|NCT02877420|Active Comparator|Conventional Simulation Training Group|This group will receive 4 hours of small-group and hands-on sessions on colonoscopy theory from an expert endoscopist. The core curriculum is designed on the basis of the American Society for Gastrointestinal Endoscopy colonoscopy curriculum and an endoscopic training textbook. This curriculum has been shown to be effective when compared to self-regulated learning on the simulator. The sessions will be interlaced with eight hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and on the high-fidelity VR simulator (7 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist. The expert will demonstrate techniques, answer questions and provide feedback on global performance. Feedback, in the form of performance metrics, will be provided by the simulator upon completion/failure of each module.
16560687|NCT02877407|Other|laparoscopic/robotic-assisted hysteropexy|patient who undergo laparoscopic/robotic-assisted hysteropexy
16560688|NCT02877407|Other|vaginal hysterectomy|patient who undergo vaginal hysterectomy
16560689|NCT02877394|Experimental|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
16560690|NCT02877394|Sham Comparator|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
16560691|NCT02877381|Active Comparator|Single IV Dose|• 1 gram IV TXA administered at time of prepping and draping
16560692|NCT02877381|Active Comparator|Double Dose IV|"1 gram IV TXA administered at time of prepping and draping
~1 gram IV TXA administered prior to tourniquet deflation"
16560693|NCT02877381|Active Comparator|IV + Topical|"1 gram IV TXA administered at time of prepping and draping
~1 gram topical TXA injected intra-articular following closure of the arthrotomy"
16560694|NCT02877381|Active Comparator|Repeated Oral Dose|• Three 650 mg tablets of TXA administered two hours prior surgery with a second dose given 6 hours postoperatively and a final dose given the morning of postoperative day 1
16560695|NCT02877368||gastrointestinal stromal tumours|Patients with advanced or high-risk resected gastrointestinal stromal tumours (GIST) .
16560696|NCT02877355|Experimental|Semaglutide|
16560697|NCT02877342||Pre-intervention|All injured patients arriving by ambulance (to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving without notification buy ambulance service
16560698|NCT02877342||Post-Intervention|All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
16560699|NCT02877329|Experimental|Internet-delivered ACT|Guided Internet-delivered Acceptance and commitment therapy for 8 weeks
16560700|NCT02877329|No Intervention|Wait list control|No treatment during 8 weeks
16560701|NCT02877316|Experimental|MYPLAN app|MYPLAN app (safety plan) as part of treatment
16560702|NCT02877316|Active Comparator|Safety plan on paper|Safety plan on paper as part of treatment
16560703|NCT02877303|Experimental|Treatment (blinatumomab, inotuzumab, combination chemotherapy)|See detailed description.
16560704|NCT02877290|Experimental|cycling test first with NIV, then without NIV|patients in this arm will perform their first constant work rate test while using NIV and the second constant work rate test without NIV
16560705|NCT02877290|Experimental|cycling test first without NIV, then with NIV|patients in this arm will perform their first constant work rate test without NIV and the second constant work rate test with NIV
16560706|NCT02877277|Experimental|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
16560707|NCT02877277|Placebo Comparator|Placebo|Oral intake of placebo tablet daily for 56 days
16560708|NCT02877264|Experimental|Vapendavir Capsule, 264 mg|Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules
16560709|NCT02877264|Experimental|Vapendavir Tablets, 264 mg|Vapendavir free base tablets containing 264 mg of vapendavir
16560710|NCT02877264|Experimental|Vapendavir Oral Suspension, 264 mg|Vapendavir free base as a 24 mg/mL oral suspension
16560711|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
16560712|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
16560713|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
16560714|NCT02877238|Active Comparator|Group A|Sevoflurane plus remote ischemic preconditioning anesthesia will be induced and maintain with sevoflurane in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
16560715|NCT02877238|Active Comparator|Group B|anesthesia will be induced and maintain with total intravenous anesthesia (propofol, midazolam plus fentanyl) during plus remote ischemic preconditioning in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
16560716|NCT02877225|Experimental|Treatment Sequence 1 : ABAB|Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
16560717|NCT02877225|Experimental|Treatment Sequence 2 : BABA|Participants will receive (Treatment B) Period 1, then Treatment A in Period 2, then Treatment B in Period 3 and then followed by Treatment A in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
16560718|NCT02877212|Experimental|Study subjects|Steroid refractory ITP patients will be given Eltrombopag to investigate the association of treatment outcome with Fc Receptor polymorphism and THPO expression in responders and non responders following comparison correlation with ITP patients treated with standard IST as control group
16560719|NCT02877199||HCV triple therapy|Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
16560720|NCT02877186|Experimental|Diet Soda|Consumption of diet soda three times daily for one week
16560721|NCT02877186|Placebo Comparator|Carbonated Water|Consumption of plain, unsweetened, carbonated water three times daily for one week
16560722|NCT02877173|Experimental|Alprostadil Liposomes for Injection|Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
16560723|NCT02877173|Active Comparator|Alprostadil Injection|Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
16560724|NCT02877160|Experimental|Reference Formulation Fasted|150 mg of AL-794 study drug in suspension dosed in a fasted condition
16560725|NCT02877160|Experimental|Test Formulation Fasted|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition
16560726|NCT02877160|Experimental|Test Formulation Fed|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition
16560727|NCT02877147|Experimental|$60 SEBTC Benefit Group|Households received $60 per summer month when school was not in session for each eligible child (Summers 2011-2013).
16560728|NCT02877147|Experimental|$30 SEBTC Benefit Group|Households received $30 per summer month when school was not in session for each eligible child (Summer 2013 only).
16560729|NCT02877147|No Intervention|No Intervention Group|Households with eligible children were not issued SEBTC benefits (Summers 2011 and 2012)
16560737|NCT02877108||Adasuve|These patients will receive Adasuve for treatment of agitation.
16560738|NCT02877108||Haloperidol/Lorazepam|These patients will receive haloperidol/lorazepam for treatment of agitation.
16560739|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
16560740|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
16560741|NCT02877069|Experimental|VYC-12 Injectable Gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection on Day 0 in the face and if applicable neck areas. Participants are eligible to receive up to 3 treatments including an optional top-up and an optional second treatment.
16560742|NCT02877056||Colorectal Cancer|Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
16560743|NCT02877043||patients undergoing lung resection|
16560744|NCT02877030|Experimental|Test control group|Start the sensorimotor exercises protocol with video game immediately after the first evaluation
16560745|NCT02877030|Active Comparator|Control test group|Start of sensorimotor exercises with video game protocol after ten weeks
16560746|NCT02877030|No Intervention|comparison group|No intervention
16560747|NCT02877017|No Intervention|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
16560748|NCT02877017|Experimental|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
16560752|NCT02876991|Other|Sodium fluoride PET|"Before inclusion, patients undergo choline PET to assess an occult recurrence of prostate cancer.
~After inclusion, they undergo sodium fluoride PET."
16560753|NCT02876978|Experimental|CAR-GPC3 T cells|"Intravenous infusion with escalating dose is adopted in this study.
~Total dosage: 1 x 10^5 - 2 x 10^9 CAR-GPC3 T cells/kg
~The next dose and interval depends on the response of the subject to previous dose.
~Lymphodepletion:
~Fludarabine: 30 mg/m^2/day x 4 days; Cyclophosphamide: 500 mg/m^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response."
16560754|NCT02876965|Active Comparator|Physical Exercise|Aerobic physical exercise protocol of moderate intensity, for 12 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
16560755|NCT02876965|Experimental|Muscle Stretching|Stretching program on the main muscle groups of the body, for 12 weeks, 1sessions per week, about 45 minutes.
16560756|NCT02876952|Active Comparator|Attention Control Group (AC)|Moderate to high- intensity physical activity and Mediterranean Diet recommendations
16560757|NCT02876952|Experimental|HV-HIIT|"Supervised high volume and high intensity interval training exercise group with Mediterranean Diet recommendations.
~High-intensity [heart rate (HR) values up to second ventilatory threshold (VT2) to peak intensity] interval training and high-volume increasing gradually from 20 to 40 min and alternating high and moderate [HR values between first ventilatory threshold (VT1) and VT2] intensities at different protocols."
16560758|NCT02876952|Experimental|LV-HIIT|"Supervised low volume and high intensity interval training exercise group with Mediterranean Diet recommendations.
~High-intensity (HR values up to VT2 to peak intensity) interval training and low-volume (20 min) alternating high and moderate (HR values between VT1 and VT2) intensities at different protocols."
16560759|NCT02876939|Experimental|HSAN III|
16560760|NCT02876939|Active Comparator|Control Subjects|
16560761|NCT02876926|Experimental|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
16560762|NCT02876926|Active Comparator|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
16560763|NCT02876926|Sham Comparator|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
16560764|NCT02876913||Group Nasotracheal Intubation|Patients who are scheduled for nasotracheal intubation for general anesthesia
16560765|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
16560766|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
16560767|NCT02876900|Placebo Comparator|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
16560768|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
16560769|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
16560770|NCT02876874||the patients group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
16560771|NCT02876874||the health group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
16560772|NCT02876861|Active Comparator|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.
~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
16560773|NCT02876861|Experimental|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group
~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):
~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
~Surgery:
~2-3weeks after Neoadjuvant chemotherapy
~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.
~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
16560774|NCT02876848|Experimental|Intervention Site|"The hospital that will be the intervention site will have access to the OPTIMUM e-health tool. The intervention site cancer care team will receive the following OPTIMUM e-health alerts:
~An electronic alert of increased Adjuvant Endocrine Therapy discontinuation risk.
~An adherence to Adjuvant Endocrine Therapy monitor.
~An electronic discontinuation occurrence alert"
16560775|NCT02876848|No Intervention|Control Site|The hospital that will be the control site will not have access to the OPTIMUM e-health tool. The cancer care team will continue to deliver care according to standard processes.
16560776|NCT02876835|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
16560777|NCT02876835|Active Comparator|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
16560778|NCT02876822|Experimental|Vitamin D|Enrolled subjects will receive one observed oral vitamin D dose (based on current vitamin D status and rounded to the nearest 5000IU) within 2 weeks prior to their HSCT.
16560779|NCT02876796|Experimental|50 mg GS-0976 (Cohort 1)|"Sequence 1:
~Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
~Sequence 2:
~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution"
16560780|NCT02876796|Experimental|200 mg GS-0976 (Cohort 2)|"Sequence 3:
~Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
~Sequence 4:
~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution"
16560848|NCT02876276|Placebo Comparator|saline filler group|with saline same protocol was performed as mentioned in test group
16560781|NCT02876796|Experimental|20 mg GS-0976 (Cohort 3)|"Sequence 5:
~Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
~Sequence 6:
~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution"
16560782|NCT02876770|Experimental|Melatonin|
16560783|NCT02876770|Placebo Comparator|Placebo|
16560784|NCT02876757||5ARI Users|
16560785|NCT02876757||Non 5ARI users|
16560786|NCT02876731|Other|single group|PET-CT MRI
16560787|NCT02876718||Rivaroxaban, BAY59-7939|It is a single-arm study in which only patients who switched from a VKA to a NOAC treatment will be included.
16560788|NCT02876705|Experimental|Pain Patterns|In this vein, we tend to study and delineate individualized pain and discomfort patterns in exercise.
16560789|NCT02876679|Experimental|Cyclophosphamide|50mg/Kg/day cyclophosphamide (day +3 and +4)
16560790|NCT02876679|Active Comparator|Anti-Thymocyte Globulin|2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)
16560791|NCT02876666|Experimental|Coach Intervention|
16560792|NCT02876666|No Intervention|Usual Care|
16560793|NCT02876653|Other|Severe OSA|Patients with severe OSA (AHI > 30)
16560794|NCT02876653|Other|Moderate OSA|Patients with moderate OSA (5 < AHI ≤ 30)
16560795|NCT02876653|Other|Healthy volunteers|Healthy volunteers (AHI ≤ 5)
16560796|NCT02876640|Experimental|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery.
16560797|NCT02876627|Experimental|breast cancer|Effect of exercise training on breast cancer patient
16560798|NCT02876601|Active Comparator|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
16560799|NCT02876601|Placebo Comparator|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
16560800|NCT02876601|Other|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
16560801|NCT02876601|Other|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
16560802|NCT02876588|Active Comparator|Unrestricted|"Users have unrestricted access to open up to a maximum of 4 patient records at a time in the EHR"
16560803|NCT02876588|Active Comparator|Restricted|"Users have restricted access to open a maximum of 1 patient record at a time in the EHR"
16560804|NCT02876575|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
16560805|NCT02876562|Experimental|root coverage with collagen matrix|evaluation of root coverage achieved by collagen matrix in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
16560806|NCT02876562|Active Comparator|root coverage with connective tissue graft|evaluation of root coverage achieved by connective tissue graft in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
16560807|NCT02876549|Experimental|G6PD Normal|
16560808|NCT02876549|Experimental|G6PD Deficient|
16560809|NCT02876536|Experimental|TNES with sending electrical impulses|The MS patients will receive electrical impulses by TENS device for 30 minutes a day, for 5 days a week and in 6 weeks
16560810|NCT02876536|Sham Comparator|TENS without sending electrical impulses|The MS patients will use the TENS device for 30 minutes a day, for 5 days a week and in 6 weeks without receiving any electrical impulses
16560811|NCT02876523||Patients with a hilar biliary stricture requiring a drainage|Drainage performed by endoscopy, echo-endoscopy or percutaneously
16560812|NCT02876510|Experimental|IMA101 product only (Cohort 1)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~Infusion of the IMA101 T-cell product(s)
~Post-infusion administration of low-dose recombinant human interleukin-2"
16560813|NCT02876510|Experimental|IMA101 product + atezolizumab (Cohort 2)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~Infusion of the IMA101 T-cell product(s)
~Post-infusion administration of low-dose recombinant human interleukin-2
~Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year"
16560814|NCT02876497|Experimental|Study arm|
16560815|NCT02876484|Experimental|Placebo|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.
~25 ml water"
16560816|NCT02876484|Experimental|Chenodeoxycholic Acid|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt
16560817|NCT02876484|Experimental|Colesevelam|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
16560818|NCT02876484|Experimental|Colesevelam x 2|plus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
16560819|NCT02876471|No Intervention|OSA group|100 severe OSA patients without hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS),demographic and anthropometric data The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated
16560901|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
16560820|NCT02876471|Other|OSA with hypertension|100 severe OSA patients with hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS), antihypertensive medicine demographic and anthropometric data. The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated.Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood pressure control, the investigators would give one-night CPAP.
16560821|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
16560822|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
16560823|NCT02876445|Other|Caregiver Evaluation|ZARIT Burden Interview
16560824|NCT02876432|Experimental|Device: Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.
~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
16560825|NCT02876432|Sham Comparator|Device: Sham Electroacupuncture|In sham electroacupuncture (Sham) the investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
16560826|NCT02876432|Active Comparator|Drug: Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
16560827|NCT02876393||Cases|Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
16560828|NCT02876393||Control definition|Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
16560829|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
16560830|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
16560831|NCT02876367||Acute scrub typhus (Group 1)|Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using <1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
16560832|NCT02876367||Scrub typhus serosurvey (Group 2)|Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
16560833|NCT02876354|Experimental|Menaquinone 360|All patients in the study will be assigned to receive menaquinone 360 μg /d for 4 weeks.
16560834|NCT02876341||No chronic antihypertensives|Not on either a chronic β-blocker or ACE-Inhibitor
16560835|NCT02876341||Chronic antihypertensives|On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
16560836|NCT02876328|Experimental|Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost|Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.
16560837|NCT02876328|Placebo Comparator|Placebo (0.5 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
16560838|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.
16560839|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.
16560840|NCT02876328|Placebo Comparator|Placebo (1 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
16560841|NCT02876315|Experimental|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
16560842|NCT02876315|Placebo Comparator|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
16560843|NCT02876302|Experimental|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively
~16 patients will be randomized from the Run-In 7 days of Ruxolitinib
~The drug will be administered at a pre-determine dosage"
16560844|NCT02876302|Experimental|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively
~16 patients will be randomized from the Run-In 7 days of Ruxolitinib
~The drug will be administered at a pre-determine dosage"
16560845|NCT02876302|Experimental|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively
~32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel
~The drug will be administered at a pre-determine dosage"
16560846|NCT02876289||patients treated with Perampanel|
16560847|NCT02876276|Active Comparator|HA filler group|6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
16560849|NCT02876263||Study group|Elective and emergency surgery for aneurysm or dissections of the ascending aorta, operated under extracorporeal circulation, protective deep therapeutic hypothermia and circulatory arrest.
16560850|NCT02876263||On-pump CABG Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease under extracorporeal circulation
16560851|NCT02876263||OPCAB Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease with a beating heart
16560852|NCT02876250|Experimental|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
16560853|NCT02876250|Placebo Comparator|Control|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
16560854|NCT02876237|Experimental|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later.
~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
16560855|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 1: SRP)|Stage 1 Safety Run-in Phase (SRP): Approximately 12 participants will receive cobimetinib 60 milligrams (mg) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 milligrams per kilogram (mg/kg) administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to Stage 2: dose expansion phase. If the results from the safety run-in phase require dose reduction in cobimetinib, then an additional Stage 1 cohort will be opened. Treatment will continue until the participant has disease progression according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
16560856|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: BC)|Stage 2 Biopsy Cohort (BC): Approximately 7 evaluable participants in the biopsy cohort in expansion phase will receive bevacizumab 5 mg/kg IV on Cycle 1 Days 1 and 15 (tumor biopsy on Cycle 1 Day 8) and cobimetinib (at dose determined during safety run-in phase) orally on Cycle 1 Day 15 to Cycle 2 Day 14 (tumor biopsy on Cycle 1 Day 22). From Cycle 2 onwards, participants will follow the same treatment regimen for bevacizumab and atezolizumab (optional tumor biopsy on Cycle 2 Day 22) as those in the safety run-in phase and expansion cohort, and for cobimetinib cycles start at Day 15 and will continue 21 days to Day 7 of next cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Biopsies must be collected before the initiation of cobimetinib and atezolizumab. Treatment will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, decision to withdraw, or pregnancy, whichever occurs first.
16560857|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: EC)|Stage 2 Expansion Cohort (EC): Approximately 14 participants will receive cobimetinib (at dose determined during safety run-in phase) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 mg/kg administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Treatment will continue until the participant has disease progression according to RECIST v1.1, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
16560858|NCT02876211|Experimental|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week & epoetin
16560859|NCT02876211|Placebo Comparator|placebo plus epoetin beta|Placebo 2 capsules/three times per week & epoetin
16560860|NCT02876198||Patients treated with anti-VEGF|
16560861|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
16560862|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.
16560863|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
16560864|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
16560865|NCT02876146|Other|Hepatic alveolar echinococcosis|"Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)
~Standardized earlier withdrawal of benzimidazole :
~Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)
~Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)"
16560866|NCT02876133|Experimental|Narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
16560867|NCT02876133|Placebo Comparator|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
16560868|NCT02876120|Other|Pre- and post-implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.
~Post-implementation phase: during the post-implementation phase the GPs and PTs will treat persons with hip or knee osteoarthritis according to the START treatment model including providing information/patient education program, supervised exercise and advice/support to loose weight and other non-surgical evidence based treatments modalities prior to being referred to an orthopaedic surgeon"
16560869|NCT02876107|Experimental|Group A (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 1 hour on day 1 of cycle 0 and over 30 minutes on days 1, 8, and 15 of cycles 1-4. Patients also receive paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1 of cycles 1-4. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
16560870|NCT02876107|Experimental|Group B (paclitaxel, carboplatin)|Patients receive paclitaxel, carboplatin, doxorubicin, and cyclophosphamide as in Group A. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
16560902|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
16560871|NCT02876094|Experimental|Open-label|All patients will be treated at each dose of oral once daily celecoxib (40, 80 and 160 mcg/kg) for a period of two weeks, for a total of 6 weeks (42 days) of treatment.
16560872|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
16560873|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.
~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
16560874|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
16560875|NCT02876029|Other|Reference|White wheat bread
16560876|NCT02876029|Other|Test product|Pasta
16560877|NCT02876016|Experimental|awake brain surgery|Exploration of the cortical area of the brain awake surgery
16560878|NCT02876003|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
16560879|NCT02875990|Experimental|patients with invasive cervical cancer|Blood sample
16560880|NCT02875977|Experimental|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
16560881|NCT02875977|Active Comparator|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
16560882|NCT02875964|Experimental|registration of intracerebral activity|epileptic patient receiving implantation of intracranial electrodes
16560883|NCT02875951||ER positive, HER2 negative breast cancer patients|Postmenopausal patients with hormone receptor positive, HER2 receptor negative breast cancer
16560884|NCT02875938|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
16560885|NCT02875925|Experimental|MTM|Patients will receive MTM at an individualized frequency for 1 year.
16560886|NCT02875925|No Intervention|Control|Patients enrolled in the control group will not experience any change in their medical care.
16560887|NCT02875912|No Intervention|Usual Care|Family members are surveyed at enrollment, day 5 (if patient is still in ICU), and 90 days post ICU discharge for symptoms of PTSD, depression, and anxiety as well as for concordance of care at enrollment and ICU day 5. Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed to establish baseline data
16560888|NCT02875912|Experimental|Family Care Rituals Intervention|At enrollment, family members are given a handout/pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so. The families are then surveyed in the same way as they were during the usual care, with nursing completing the same surveys as well to compare against the baseline data
16560889|NCT02875886|Active Comparator|Diuretic treatment|Patients receive amiloride and hydrochlorothiazide
16560890|NCT02875886|Active Comparator|Low-sodium diet|Patients are put on a low-sodium diet (60 mmol/day)
16560891|NCT02875873|Experimental|Plasma-Lyte, Slow Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
16560892|NCT02875873|Experimental|Plasma-Lyte, Fast Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
16560893|NCT02875873|Experimental|Saline 0.9%, Slow Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
16560894|NCT02875873|Experimental|Saline 0.9%, Fast Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
16560895|NCT02875860|Other|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
16560896|NCT02875860|Experimental|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
16560897|NCT02875847|Active Comparator|HMO1|Daily bolus of HMO1
16560898|NCT02875847|Active Comparator|HMO2|Daily bolus of HMO2
16560899|NCT02875847|Placebo Comparator|Dextropur|Daily bolus of dextropur
16560900|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
16560903|NCT02875821|Experimental|Group IMP|Group IMP (Ipragliflozin with Metformin with Pioglitazone)
16560904|NCT02875821|Active Comparator|Group MP|Group MP (Metformin with Pioglitazone)
16560905|NCT02875808||patients|patients with an external ventricular drainage
16560906|NCT02875795|Experimental|speech intelligibility|speech intelligibility is registered by an automatic speech processing tool
16560907|NCT02875782|Experimental|DM intervention|Subjects will receive a patient-centered motivational intervention with two components: (1) the stage-matched smoking cessation intervention and (2) the relationship between smoking and diabetic complications. All subjects will receive a self-help cessation manual with DM components and take the exhaled carbon monoxide test. The total counseling process will take about 20 minutes. Three consecutive (3-, 6- and 12-month) follow ups will be conducted. Also, the counselor will further the progress of their action plan and barriers encountered in the behavioral change process as well as engage them in the process, enhance their self-efficacy, and identify individual barriers and facilitators.
16560908|NCT02875782|Placebo Comparator|Control group|Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
16560909|NCT02875769|Experimental|Test: Mouthwash CPC+Zn+F|To rinse with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
16560910|NCT02875769|Active Comparator|Positive control: Mouthwash CHX|To rinse with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
16560911|NCT02875769|Placebo Comparator|Negative control A: No rinsing|No rinsing with pre-procedural mouthwash + full mouth dental prophylaxis using ultrasonic scaler.
16560912|NCT02875769|Placebo Comparator|Negative control B: Water|To rinse with pre-procedural mouthwash containing water from a three-way syringe (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
16560913|NCT02875756|Experimental|10 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
16560914|NCT02875756|Active Comparator|20 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
16560915|NCT02875743|Experimental|Posaconazole|
16560916|NCT02875730|Experimental|CMRI Pulse Sequence|Patients will have late gadolinium cardiac magnetic resonance images of the individual pulmonary veins acquired with the standard and the cylindrical navigator preparatory pulse sequences for comparison.
16560917|NCT02875717||Control|
16560918|NCT02875717||Acetylsalicylic acid|Patients that were on medication with Acetylsalicylic acid on the date of shockwave lithotripsy
16560919|NCT02875717||Low Molecular weight heparin|Patients that were on medication with low molecular heparin on the date of shockwave lithotripsy
16560920|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
16560921|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
16560922|NCT02875691|Active Comparator|green tea extract|Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
16560923|NCT02875691|Placebo Comparator|Placebo|Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
16560924|NCT02875678|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
16560925|NCT02875678|Placebo Comparator|Placebo|Placebo, capsules, single dose
16560926|NCT02875665|Experimental|geko device arm|geko™ devices (acting on the posterior tibial nerve) to be used on alternate days over seven days, for an hour per day
16560927|NCT02875652|Experimental|Blood sampling|
16560928|NCT02875639|Experimental|tonifying qi group|tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)
16560929|NCT02875639|Experimental|activating blood group|which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)
16560930|NCT02875639|Experimental|qi and blood group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)
16560931|NCT02875639|Active Comparator|QISHEN YIQI DRIPPING PILLS group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)
16560932|NCT02875639|Sham Comparator|placebo group|which treated by the simulation of Chinese patent medicine (major components:excipient)
16560933|NCT02875626|Experimental|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
16560934|NCT02875613|Experimental|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
16560935|NCT02875600|Experimental|Nutri drink|MRI flow measurements of mesenterial vessels and portal vein before and after stimulation with nutritional drink
16560936|NCT02875587|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
16560937|NCT02875587|Experimental|Calcium gluconate infusion group|Calcium gluconate is administered starting on the day of HCG administration.
16560938|NCT02875574||All participants|
16560939|NCT02875561|Active Comparator|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
16560940|NCT02875561|Experimental|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
16560941|NCT02875548|Experimental|Open-label Tazemetostat|Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.
16560942|NCT02875535|No Intervention|Usual Care|Standard school nurse care for suicide prevention.
16560943|NCT02875535|Experimental|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
16560944|NCT02875522|Experimental|Patients with COPD|Stable patients with COPD participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
16560945|NCT02875522|Active Comparator|Healthy Controls|Age, sex, BMI and activity matched controls participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
16560946|NCT02875496||Healthy aging|Subjects meeting criteria for healthy aging No intervention administered
16560947|NCT02875496||Early Alzheimer Disease|Subjects meeting criteria for Early Alzheimer Disease No intervention administered
16560948|NCT02875496||Depression|Subjects meeting criteria for Depression No intervention administered
16560949|NCT02875496||MCI-Mild Cognitive Impairment|Subjects meeting criteria for MCI-Mild Cognitive Impairment No intervention administered
16560950|NCT02875496||General Arm|Subjects not meeting criteria for any of the other arms (Healthy, Early Alzheimer's, Depression, or MCI)
16560951|NCT02875483|Placebo Comparator|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
16560952|NCT02875483|Experimental|Expedited Scheduling|Group allocated to expedited scheduling practices
16560953|NCT02875470|Experimental|Intensiv Perio Set|Root planing with diamond burs
16560954|NCT02875470|Active Comparator|Gracey curette|Root planing with Gracey curettes
16560955|NCT02875457|Experimental|Arm A|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
16560956|NCT02875457|Placebo Comparator|Arm B|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.
16560957|NCT02875444||"group abdominal aortic aneurysm"|Patients with non-operated abdominal aortic aneurysm with angio-CT realized between 01/01 2010 au 04/15/2012
16560958|NCT02875431||ACDF or cervical vertebral body replacement|
16560959|NCT02875418|Experimental|EUM and tocodynamometry|Pregnant women with gestational age 24+0/7 to 33+6/7 weeks of gestation and contractions, cramping, pelvic pressure or backache.
16560960|NCT02875405|Experimental|Received pericardiotomy|Patient will receive a posterior left pericardiotomy at the time of surgery
16560961|NCT02875405|No Intervention|No Pericardiotomy|Patient will not receive posterior left pericardiotomy.
16560962|NCT02875392|Experimental|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
16560963|NCT02875392|Placebo Comparator|placebo pills|placebo capsule 6 per day (before breakfast and supper)
16560964|NCT02875379|Experimental|HME|Passive humidification with heat and moisture exchanger, Y-piece circuit.
16560965|NCT02875379|Experimental|HH33|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
16560966|NCT02875379|Experimental|HH37|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
16560967|NCT02875379|Experimental|NoH|Passive humidification, double tube circuit
16560968|NCT02875366|Placebo Comparator|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
16560969|NCT02875366|Experimental|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
16560970|NCT02875353|Other|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
16560971|NCT02875353|Experimental|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
16560972|NCT02875340|Experimental|VAL401 treatment|Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
16560973|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.
~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
16560974|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.
~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:
~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
16561009|NCT02875080|Experimental|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
16637455|NCT02365363|Experimental|Bagel with pea flour|Pea flour (30%)
16560975|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.
~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.
~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
16560976|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
16560977|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
16560978|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
16560979|NCT02875288|Experimental|Liposomal Bupivicaine arm|"Post procedure, infiltrate wounds with liposomal bupivacaine
~Liposomal Bupivacaine (Brand name Exparel) 266 milligram (mg)/20 mL to be diluted to 30 mL with normal saline
~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
16560980|NCT02875288|Active Comparator|Plain Bupivicaine|"Post procedure, infiltrate wounds with plain bupivicaine
~Plain Bupivacaine 0.25%, volume of 30 mL
~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
16560981|NCT02875275|No Intervention|Glucose Solution only|Control drink containing 50 g carbohydrate
16560982|NCT02875275|Active Comparator|Glucose with grass jelly solution|Control drink plus 3.12 g grass jelly powder
16560983|NCT02875275|Active Comparator|Glucose with grass jelly (solid)|Control drink plus 3.12 g grass jelly powder in solid form
16560984|NCT02875275|No Intervention|Porridge and juice only|Control breakfast containing 50 g carbohydrate.
16560985|NCT02875275|Active Comparator|Porridge and juice with coconut oil|Control breakfast, plus 25g coconut oil
16560986|NCT02875275|Active Comparator|Porridge and juice with coconut oil gel|Control breakfast, plus 25g coconut oil gel
16560987|NCT02875262|Experimental|Treatment|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day. duration 3 days
16560988|NCT02875262|Placebo Comparator|placebo|NaCl 0.9% in similar dosis to treatment arm
16560989|NCT02875236|Placebo Comparator|Control|Ringer-acetat
16560990|NCT02875236|Active Comparator|Intervention|OctaplasLG®
16560991|NCT02875223|Experimental|CC-90011 Administration|Subjects will administer CC-90011 orally once weekly in each 4 -week (28 day) Cycle. Alternative dosing schedules may be implemented based on the review of clinical safety and laboratory data by the SRC. CC-90011 will be administered with at least 240 mL of water. Subjects should fast for a minimum of 4 hours in both Parts A and B prior to CC-90011 administration and refrain from any food intake for up to 1 hour after dosing
16560992|NCT02875210|Experimental|Patient with anterior cruciate ligament rupture|Anterior laxity of patient was measure with 4 laximeters:Telos, reference laximeter and with three other instruments called, KT-1000, GnrB and Rolimeter.
16560993|NCT02875197||Healthy Controls|"Males and females 18-50 years old
~Up to 20 able-bodied sex, age, height, and weight-matched subjects"
16560994|NCT02875197||Lower Extremity Amputees|"Males & females 18-50 years old
~Must have a unilateral, transtibial amputation & must have been prescribed a running-specific prosthesis
~Subject with amputations resulting from trauma, congenital reasons, or cancer treatment unless cancer is in remission or treatments do not impact gait function
~Physician approval to run
~4 months experience using a running-specific prosthesis"
16560995|NCT02875184||Psoriatic arthritis patients treated with apremilast|Psoriatic arthritis patients who are treated with apremilast according to daily practice
16560996|NCT02875171||Anthracycline therapy|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
16560997|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
16560998|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
16560999|NCT02875145||Keratoplasty with cataract surgery|Patients who underwent keratoplasty who also underwent a cataract surgery during follow up.
16561000|NCT02875145||Keratoplasty without cataract surgery|Patients who underwent keratoplasty who never underwent cataract surgery.
16561001|NCT02875132|Experimental|pembrolizumab|
16561002|NCT02875119|Experimental|Griffithsin Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer Griffithsin Gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
16561003|NCT02875119|Placebo Comparator|Placebo Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer placebo gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
16561004|NCT02875106||Atrial Fibrillation Patients|Adult female and male patients with diagnosed atrial fibrillation
16561005|NCT02875106||Sinus Rhythm Patients|Adult female and male patients with diagnosed sinus rhythm
16561006|NCT02875093|Other|ADI-PEG 20 Plus Low Dose Cytarabine|This is a phase 1, open label trial of ADI-PEG 20 (18 and 36 mg/m2) weekly in combination with low-dose cytarabine (20 mg BID [twice daily] for 10 days, every 28 days)
16561007|NCT02875080|Experimental|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
16561008|NCT02875080|Experimental|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
16637456|NCT02365363|Experimental|Bagel with pea fibre|Pea fibre (11g)
16561010|NCT02875067|Experimental|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions
~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
16561011|NCT02875054|Active Comparator|Continued Casting|Participants with 24 hour cast wear (continued casting) for the entire duration of the constraint portion of camp (2 initial weeks).
16561012|NCT02875054|Active Comparator|Intermittent Casting|Participants who wear a univalve cast for 3 hours of constraint camp with home exercise program of 2 hours cast wear on the weekends (intermittent casting).
16561013|NCT02875041|Experimental|Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy|TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
16561014|NCT02875041|Active Comparator|MAGSTIM Rapid2 Therapy System|MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
16561015|NCT02875028|Experimental|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
16561016|NCT02875028|Placebo Comparator|Placebo|subjects will be treated with 4 empty lactose-starch capsules
16561017|NCT02875015|Experimental|Liposomal Bupivacaine|20mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
16561018|NCT02875015|Active Comparator|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
16561019|NCT02875002|Experimental|All subjects|Subjects have relapsed and refractory aggressive B- and T-cell lymphomas and will receive both Belinostat and Volasertib.
16561020|NCT02874989|Experimental|Dasatinib + Quercetin|
16561021|NCT02874989|Placebo Comparator|Placebo|
16561022|NCT02874976|Experimental|Experimental: Group A|"Active and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group A, received program 1 before aerobic training, and the same program 1 after training"
16561023|NCT02874976|Experimental|Experimental: Group B|"Active and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 1 before aerobic training, and program 2 after training."
16561024|NCT02874976|Experimental|Experimental: Group C|"Placebo and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group C, received program 2 before aerobic training, and program 1 after training."
16561025|NCT02874976|Experimental|Experimental: Group D|"Placebo and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
16561026|NCT02874963|Active Comparator|Surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Non-Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Intervention:
~Procedure: Surgery (Tooth Extraction)"
16561027|NCT02874963|Active Comparator|Surgical and non-surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Non-Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Interventions:
~Procedure: Surgery (Tooth Extraction)
~Procedure: Non-surgical periodontal therapy-full mouth scaling and root planing (FM-SRP) with ultrasonic device and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus, post operative rinsing thrice a day for 3 weeks."
16561028|NCT02874950|Experimental|Office exercise training|A package of exercise raining was defined by the researcher and one of the intervention group did it for 6 months.
16561029|NCT02874950|Experimental|Ergonomic modification|The ergonomic group, followed 6 months ergonomic modification.
16561030|NCT02874950|Experimental|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months ergonomic modification.
16561031|NCT02874950|Experimental|Control|Control group did not do any exercise and did not follow any ergonomic modification.
16561032|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
16561033|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
16561034|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
16561035|NCT02874911|Experimental|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
16561036|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
16561037|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
16561038|NCT02874885||Ancillary-Correlative (biospecimen collection)|Patients and healthy participants undergo collection of blood sample at baseline. Patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back.
16561076|NCT02874599|Experimental|Patients|Patients who require multiple dental restorations. Teeth will be restored with commercial restorative composites
16561077|NCT02874586|Experimental|Plasma exchange combination of immunosuppressive regimens|Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
16561234|NCT02873559|Experimental|Testosterone|A testosterone group given 20 weeks on testosterone injections without training
16561039|NCT02874872|Experimental|OASIS Collaborative|The nursing homes in this arm will receive facilitated implementation of two tools aimed at minimizing unnecessary antibiotic use. Facilitated implementation includes coaching of the nursing home staff on use of the tools. In addition, nursing home management will be coached on how to monitor implementation fidelity, antibiotic utilization, and consequences to over- and under-utilization of antibiotics as feedback on the effectiveness of the intervention. Finally, nursing home management will receive coaching on how to develop and implement a sustain plan for the OASIS intervention.
16561040|NCT02874872|No Intervention|Control|The nursing homes in this arm will continue care as usual, with no tools or facilitated implementation.
16561041|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
16561042|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
16561043|NCT02874833|Experimental|Exercise Group|Experimental arm type will assess whether a newly developed, supervised 8-week individualized, internet-based exercise therapy is effective in reducing depressive symptoms.
16561044|NCT02874833|No Intervention|Treatment as usual group|Treatment as usual. Other form of therapy (e.g. antidepressive medication) will not be affected.
16561045|NCT02874820|Experimental|Patient Group|Baseline PET scan followed by a blocked PET scan
16561046|NCT02874807|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg once daily for four days
16561047|NCT02874807|Placebo Comparator|Placebo|Treatment with Placebo once daily for four days
16561048|NCT02874794|Experimental|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
16561049|NCT02874794|Active Comparator|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
16561050|NCT02874768|Experimental|dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
16561051|NCT02874768|Active Comparator|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
16561052|NCT02874755|Experimental|Tuberculosis Program (PPIA)|Half of the 300 participants were randomly selected to be sensitized and engaged into the program, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if networked into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free and/or subsidized diagnostic testing and referrals to providers for free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests; training opportunities, and access to a referral network.
16561053|NCT02874755|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining half of the sample in Mumbai selected randomly will be phased into the program at least a year after the PPIA arm. However, during the year of the study, they will not be networked into the program.
16561054|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
16561055|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
16561056|NCT02874729||Healthy donors|No interventions
16561057|NCT02874729||Cancer patients|No interventions
16561058|NCT02874716|Experimental|Tuberculosis Program (PPIA)|In Patna, 171 of the 321 participants were randomly selected to be sensitized and engaged into the program in Phase 1, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if engaged into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free or subsidized diagnostic testing and free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests and anti-TB treatment; financial incentives to providers based on certain indicators; training opportunities, and access to a referral network.
16561059|NCT02874716|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining part of the sample in Patna selected randomly will be phased into the program at least a year after the PPIA arm in Phase 2. However, during the year of the study, they will not be engaged into the program.
16561060|NCT02874703||HIV-positive|
16561061|NCT02874703||HIV-negative|
16561062|NCT02874690|Placebo Comparator|Placebo|Placebo pill received
16561063|NCT02874690|Experimental|Methylphenidate|
16561064|NCT02874677|No Intervention|Control|Routine activities
16561065|NCT02874677|Experimental|Experimental|Effort reeducation program : 3 sessions of 20 minutes per week during 6 weeks
16561066|NCT02874664|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
16561067|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
16561068|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
16561069|NCT02874638|Experimental|BASE egg protein|0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
16561070|NCT02874638|Experimental|BCAA-enriched egg protein|branched-chain amino acid-enriched egg protein
16561071|NCT02874638|Experimental|small amount of essential amino acids|small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
16561072|NCT02874638|Experimental|large amount of essential amino acids|large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
16561073|NCT02874625|Active Comparator|Treatment 1|Dental restoration performed with glass-ionomer materials.
16561074|NCT02874625|Experimental|Treatment 2|Dental restoration performed with resin-based composites.
16561075|NCT02874612||Young Adults with Type 1 Diabetes Mellitus|All YA (ages 18-24) who are seen in the Cincinnati Children's Hospital Medical Center Diabetes Clinic and have recently (< 4 months) completed the Transition Readiness assessment tool as part of their standard clinical care is eligible for the study.
16561078|NCT02874573|Active Comparator|Treatment Group|Subjects in the tocilizumab group will receive a 4 mg/kg infusion at baseline, and weeks 4 and 8, as per the recommended starting dosing for rheumatoid arthritis
16561079|NCT02874573|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the tocilizumab group) at baseline, and weeks 4 and 8.
16561080|NCT02874560||Schizophrenia|350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).
16561081|NCT02874547|Experimental|Intervention|Patients will receive five visits with a CHW during a 6 month period (two in-person and three by telephone). At the first visit, patients will meet the CHW who is trained in motivational interviewing techniques to deliver coaching to work on behavioral changes and introduce a 60 minute Digital Video Disc of five patient stories of individuals who have managed to control their hypertension.
16561082|NCT02874547|Other|Delayed Intervention|Patients will receive print materials at time of consent and randomization. Four to six months after randomization, DI patients will receive an invitation to schedule an in-person visit at the health center to begin receiving the intervention protocol.
16561083|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
16561084|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
16561085|NCT02874521|Experimental|Intra-dialytic LF-EMS|Performed twice weekly whilst seated on a standard dialysis chair. Delivered by adhesive electrodes in a neoprene garment, applied bilaterally to the quadriceps and hamstrings. Cardiovascular stimulus via rapid, rhythmical, sub-tetanic contractions. Short bursts of four pulses repeatedly delivered by stimulator at a frequency of 4Hz. Current amplitude adjustable from 40 - 200 mA with inbuilt controller. Conducted for one hour at the maximum tolerable intensity. Five minute warm-up and cool down at a lower frequency (3 Hz).
16561086|NCT02874521|Experimental|Intra-dialytic cycle training|Semi-recumbent cycling performed twice weekly whilst seated on a standard dialysis chair. Performed for up to one hour per session, initially at a workload (Watts) equivalent to that achieved at 40-60% VO2 reserve during cardiopulmonary exercise test. Exercise intensity regulated using a combination of heart rate and rating of perceived exertion (12-14). Workload adjusted weekly and controlled with a combination of pedal resistance and cadence to provide a personalised exercise prescription. Five minute warm-up and cool down each session.
16561087|NCT02874521|No Intervention|Usual care|Continuation of dialysis treatment without the addition of an intra-dialytic exercise intervention.
16561088|NCT02874495||Healthy volunteers|22 persons.
16561089|NCT02874495||Patients with Crohn's disease|22 patients.
16561090|NCT02874482||Patients with schizophrenia|30 patients with schizophrenia (diagnosis based on the standard DSM criteria)
16561091|NCT02874482||Controls|30 healthy controls without any psychiatric or neurological diagnosis
16561092|NCT02874469|No Intervention|Control group (first period)|Patients treated as recommended with usual care in a center.
16561093|NCT02874469|Experimental|Group with diary (second period)|Intervention group = On top of usual care, an intensive care unit diary will be implemented for patients within the first 8 hours following their admission.
16561094|NCT02874456|Experimental|virus detection|detection of ZIKA virus in blood and sperm
16561095|NCT02874443|Experimental|Intervention centers|"Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.
~Intervention centers will receive knowledge translation of labor management guidelines"
16561096|NCT02874443|No Intervention|Control centers|No intervention at control centers
16561097|NCT02874430|Experimental|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16561098|NCT02874417|Experimental|Psychoeducation|The program was designed to dispel exaggerated thoughts surrounding the danger of the experience of anxiety symptoms, specifically focusing on fears regarding feelings of cognitive dyscontrol. The psychoeducation portion contains video animation and audio narration throughout, as well as some interactive features . Participants are provided with corrective information about the experience of anxiety-related sensations, with a particular focus on dispelling myths commonly held by individuals with high anxiety sensitivity cognitive concerns . Participants are taught that anxiety-related sensations are not dangerous and that they may have developed a conditioned fear to these symptoms of arousal.
16561099|NCT02874417|Placebo Comparator|Health and Wellness|The controlled condition consisted Physical Health Education Training (PHET), a computerized presentation which focuses on information on general healthy living. The PHET program contains information on nutrition, alcohol, water consumption, exercise, sexual health, hygiene, stress management, life organization, social support, positive outlook, and sleep.
16561100|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16561141|NCT02874196|Experimental|Patients with painful prosthesis|
16561235|NCT02873559|Experimental|Training|A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
16561101|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16561102|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16561103|NCT02874391||AV fistula group|
16561104|NCT02874391||Control group|
16561105|NCT02874378|Experimental|study group|Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
16561106|NCT02874378|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
16561107|NCT02874365|Experimental|Crohn disorder|arm composed by 30 patients with Crohn disorder
16561108|NCT02874365|Experimental|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
16561109|NCT02874365|Experimental|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
16561110|NCT02874365|Sham Comparator|witness|arm composed by 30 patients with no intestinal disorders
16561111|NCT02874352|Other|intensive care patients|intensive care patients with tracheostomy/ high resolution impedance manometry with Automated Impedance Manometry analysis
16561112|NCT02874352|Other|healthy volunteers|control group with healthy volunteers/ high resolution impedance manometry with Automated Impedance Manometry analysis
16561113|NCT02874339|Experimental|Optiflow Group|High flow nasal oxygen therapy
16561114|NCT02874339|Active Comparator|NIV group|
16561115|NCT02874326|Experimental|Active comparator: Octreotide LAR|Sandostatin LAR Sandostatin LAR 20 mg will be administered once every 4 weeks as a intramuscular injection
16561116|NCT02874313|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
16561117|NCT02874313|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin
16561118|NCT02874300|No Intervention|Control|The control arm will comprise the offer of an assessment by a standard community falls prevention service.
16561119|NCT02874300|Other|High intensity supervision arm|high-intensity supervision
16561120|NCT02874300|Other|Moderate intensity supervision arm|Moderate intensity supervision
16561121|NCT02874287|Other|Hydroxychloroquine|Subjects are treated with hydroxychloroquine sulfate tablets.All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
16561122|NCT02874287|Other|placebo|Subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
16561123|NCT02874274|Active Comparator|100 Non-Homebound Subjects|outpatient healthcare utilization and self-reported illness.
16561124|NCT02874274|Active Comparator|60 Homebound Subjects|Will test the feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
16561125|NCT02874261|Experimental|Whole Body Periodic Acceleration|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation is 120 cycles/minute; cpm) as well as a distance traveled 16 mm."
16561126|NCT02874248|Active Comparator|Group 1: 15 mg E4/3 mg DRSP (n=10)|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
16561127|NCT02874248|Placebo Comparator|Group1: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
16561128|NCT02874248|Active Comparator|Group 2: 30 mg E4/6 mg DRSP (n=10)|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
16561129|NCT02874248|Experimental|Group 2: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
16561130|NCT02874248|Active Comparator|Group 3: 60 mg E4/12 mg DRSP (n=10)|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
16561131|NCT02874248|Placebo Comparator|Group 3: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
16561132|NCT02874248|Active Comparator|Group 4: 75 mg E4/15 mg DRSP (n=9)|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
16561133|NCT02874248|Placebo Comparator|Group 4: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
16561134|NCT02874235|Experimental|Music therapy treatment|35 patients receiving each 16 sessions of Receptive music therapy
16561135|NCT02874235|Active Comparator|Standard treatment|35 patients receiving each 16 sessions of Psychological treatment
16561136|NCT02874222||Caucasian|surveys completed by subject n=600, nationally
16561137|NCT02874222||African-American|surveys completed by subject n=200, nationally
16561138|NCT02874222||Asian|surveys completed by subject n=200, nationally
16561139|NCT02874209|Experimental|Patient with amyotrophic lateral sclerosis|ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium
16561140|NCT02874209|Placebo Comparator|Healthy volunteer|Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium
16561142|NCT02874183|Experimental|Pharmacist intervention group|"The intervention group will receive:
~A phone call 48h-72h after discharge from the hospital to ensure that the patient filled their prescriptions and started taking their medication.
~A phone call five to seven days after discharge to reinforce the education using the teach back technique1. Patients will be asked about their medications, what are they for, how to use them, and what side effects to watch for, based on the education and information that was provided to them at discharge."
16561143|NCT02874183|No Intervention|usual care group|The control group will receive the usual standard care available at West Kendall Baptist Hospital.
16561144|NCT02874170|Experimental|drepanocytose affected patient|
16561145|NCT02874170|Other|Healthy volunteers|
16561146|NCT02874144|Experimental|AZ Compound|40 mg 12 weeks TID po
16561147|NCT02874144|Placebo Comparator|Placebo|40 mg 12 weeks TID po
16561148|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
16561149|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
16561150|NCT02874118|Experimental|HIV Patient population over 50 years old|
16561151|NCT02874105|Experimental|experimental group|Dynamic Humeral Centering
16561152|NCT02874105|Active Comparator|control group|Conventional physiotherapy
16561155|NCT02874079|Experimental|bullous pemphigoid|patients with bullous pemphigoid
16561156|NCT02874079|Active Comparator|no bullous pemphigoid|patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
16561157|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
16561158|NCT02874053||Healthy|Healthy Volunteers
16561159|NCT02874040|Experimental|Experimental|endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar
16561160|NCT02874027||TBI Patients with depression|All the patients should be diagnosed by CCMD-3(evaluation of depression)
16561161|NCT02874027||TBI Patients without depression|
16561162|NCT02874014|Experimental|Hypofractionation Proton beam therapy|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
16561163|NCT02873988||patients with COPD|patients with COPD
16561164|NCT02873988||patients without COPD|patients without COPD
16561165|NCT02873975|Experimental|Homologous Repair (HR) Deficiency|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
16561166|NCT02873975|Experimental|Replicative Stress|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
16561167|NCT02873975|Experimental|CCNE1 Amplification|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
16561168|NCT02873962|Experimental|Nivolumab with Bevacizumab|Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
16561169|NCT02873962|Experimental|Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
16561170|NCT02873949|Other|1. Periodontitis patients|30 patients consulting at Odontology department for periodontal treatment
16561171|NCT02873949|Other|2. Control|10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
16561172|NCT02873936|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
16561173|NCT02873936|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
16561174|NCT02873936|Placebo Comparator|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
16561175|NCT02873923||Patients with a metastatic soft tissue sarcoma|All patients included in eligible clinical trials of the meta-analysis
16561176|NCT02873910|Experimental|IQP-AS-119|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
16561177|NCT02873910|Placebo Comparator|Placebo|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
16561178|NCT02873897|Other|"Group meals on wheels at home"|
16561179|NCT02873897|Other|"Group residents of old people's homes - EHPAD"|
16561180|NCT02873884||case-management|Patients will meet the case-manager 5 times per month during 1h30 in community living
16561181|NCT02873884||traditional nursing|Patients will meet the case-manager 2 times per month during 1h00 in hospital
16561182|NCT02873871|Other|Control group|Standardized compressive dressing
16561183|NCT02873871|Experimental|Intervention group|Hemostasis with TerumoBand®
16561184|NCT02873858|Active Comparator|1.independent patients|
16561185|NCT02873858|Experimental|2. less mobile patients|
16561186|NCT02873858|Experimental|patient in a residence|
16561187|NCT02873858|Experimental|patients in a home for the elderly (EHPAD)|
16561188|NCT02873845||PATIENT|Patients with colon cancer
16561189|NCT02873845||THE SPOUSE/PARTNER|The spouse/partner of patients with colon cancer
16561190|NCT02873832||MPS|
16561191|NCT02873832||Control|
16561232|NCT02873572|Experimental|no gamer subjects|Recruitment by poster.
16561233|NCT02873559|No Intervention|Controls|A control group, which is 20 weeks with placebo injections without training.
16561192|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
16561193|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
16561194|NCT02873806|Other|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost
~Intervention:
~Implantation of two iStent inject micro-bypass stents
~Tobramycin
~Dexamethasone"
16561195|NCT02873793||7/8 cases pure seminomas|
16561196|NCT02873793||5 cases of non-seminoma|
16561197|NCT02873793||3 cases of composite tumours seminoma/non-seminoma.|
16561198|NCT02873767|Placebo Comparator|Placebo|Single dose placebo comparator for each active arm
16561199|NCT02873767|Experimental|UCB4019 Dose 1|Dose 1 calculated based on body weight
16561200|NCT02873767|Experimental|UCB4019 Dose 2|Dose 2 calculated based on body weight
16561201|NCT02873767|Experimental|UCB4019 Dose 3|Dose 3 calculated based on body weight
16561202|NCT02873767|Experimental|UCB4019 Dose 4|Dose 4 calculated based on body weight
16561203|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
16561204|NCT02873741||Validation Study|Participants will undergo a perianal and digital anorectal exam, a high resolution anoscopy, and cervical and anal swabs to determine the best method to identify women at high risk for anal cancer.
16561205|NCT02873728|Experimental|RIC|In the study group, a blood pressure cuff will be inflated to 50 mmHg above systolic blood pressure while the performing investigator examines the radial pulse to ensure complete blood flow obstruction. Ischemia will be performed for 3 cycles of 5 min each and 10 min resting between cycles.
16561206|NCT02873728|Sham Comparator|Control|In the control group, a blood pressure cuff will be inflated to 10 mmHg (Sham procedure) for 3 cycles of 5 min each and 10 min resting between cycles.
16561207|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
16561208|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two yeart study
16561209|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
16561210|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
16561211|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
16561212|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
16561213|NCT02873689|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
16561214|NCT02873689|Experimental|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
16561215|NCT02873676|Experimental|nutritional intervention|This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
16561216|NCT02873676|Experimental|resistance training program|This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
16561217|NCT02873676|Experimental|lifestyle modification project|This group receive multi-dimensional intensive nutritional intervention and resistance training program.
16561218|NCT02873676|Placebo Comparator|control|This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
16561219|NCT02873663|Experimental|heavy drinkers|Plasma and head hair collection
16561220|NCT02873663|Experimental|teetotalers|Plasma and head hair collection
16561221|NCT02873650|Experimental|Group 1 - Control group|
16561222|NCT02873650|Experimental|Group 2-Moderate hepatic impairment|
16561223|NCT02873650|Experimental|Group 3-Severe hepatic impairment|
16561224|NCT02873637|Experimental|under sartorial catheter|catheter under sartorial
16561225|NCT02873637|Other|femoral catheter|femoral catheter
16561226|NCT02873611|Experimental|MRI scanning and the genicular ablation|patients undergoing both MRI scanning and the genicular ablation procedure. additional MRI testing of apprx. 0.5-1 hour
16561227|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane
16561228|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
16561229|NCT02873572|Experimental|online poker gamblers|Recruitment by forums of online poker gamblers: an explanation of the research is sent with the dedicated link of the research.
16561230|NCT02873572|Experimental|casino gamblers|Recruitment to the casino gates: an explanation of the research is sent with the dedicated e-link of the research and they could answer directly to the questionnaire (1st step) on sites.
16561231|NCT02873572|Experimental|MMORPG gamers|Recruitment by forums of MMORPG (as guilds): an explanation of the research is sent with the dedicated link of the research.
16561236|NCT02873559|Experimental|Testosterone and training|A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
16561237|NCT02873546|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
16561238|NCT02873546|Sham Comparator|sham tDCS on left DLPFC (F3)|Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
16561239|NCT02873533|Other|A-Elderly patients with cancer|geriatric care and longitudinal follow up
16561240|NCT02873520|Experimental|Precision Cells combined with Chemotherapy treatment:|Precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
16561241|NCT02873520|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
16561242|NCT02873507|Experimental|MRI of donor liver|MRI evaluation of graft steatosis in donor liver prior to transplantation
16561243|NCT02873494||PHYSIOFLOW PF05 Lab1TM|Impedance cardiography
16561244|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
16561245|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
16561246|NCT02873468|Experimental|Florence 30|
16561247|NCT02873468|Experimental|Florence 60|
16561248|NCT02873468|Experimental|Florence 90|
16561249|NCT02873468|Placebo Comparator|Placebo|
16561250|NCT02873455|Experimental|watching video|Short video clip including the circumstance of operation theater, and surgeon's interview
16561251|NCT02873442|Experimental|Precision cells combined with TACE|"Transcatheter Arterial Chemoembolization:
~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
16561252|NCT02873442|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
16561253|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
16561254|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
16561255|NCT02873416|Experimental|Precision cells combined with Chemotherapy treatment:|Once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
16561256|NCT02873416|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
16561257|NCT02873403|Experimental|KNEEMO knee brace & Popular knee brace|Patients having medial knee osteoarthritis
16561258|NCT02873403|Experimental|Popular knee brace &KNEEMO knee brace|Patients having medial knee osteoarthritis
16561259|NCT02873390|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
16561260|NCT02873377|Experimental|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling & Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
16561261|NCT02873377|Active Comparator|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
16561262|NCT02873364|Active Comparator|Vitamin D3 (Low dose)|Daily 600 unites of vitamin D + Cetirizine 10mg twice a day
16561263|NCT02873364|Experimental|Vitamin D3 (High dose)|Daily 4000 unites vitamin D + Cetirizine 10mg twice a day
16561264|NCT02873351|Experimental|carbidopa-levodopa 25-100 mg|Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
16561265|NCT02873351|Placebo Comparator|Placebo for carbidopa-levodopa 25-100 mg|Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
16561293|NCT02873156|Placebo Comparator|Placebo|Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.
16561329|NCT02872896|Experimental|ClearSight device|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.
16637545|NCT02364856||Children with cerebral palsy|
16561269|NCT02873312|Experimental|StimRouter Treatment|The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months.
16561270|NCT02873312|Sham Comparator|StimRouter Control|The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months.
16561271|NCT02873299|No Intervention|Treatment as usual|Treatment as usual, wait list control group
16561272|NCT02873299|Active Comparator|rTMS at 10Hz|10 Hz rTMS of the right dorsolateral prefrontal cortex
16561273|NCT02873299|Active Comparator|rTMS at 20Hz|20 Hz rTMS of the right dorsolateral prefrontal cortex
16561274|NCT02873286|Experimental|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
16561275|NCT02873286|Experimental|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
16561276|NCT02873286|Experimental|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
16561277|NCT02873286|Experimental|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
16561278|NCT02873286|Experimental|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
16561279|NCT02873273|Experimental|Dexamethasone delivery system|
16561280|NCT02873260|Experimental|TetraVax-DV-TV005 + rDEN3Δ30|Participants will receive the TetraVax-DV-TV005 vaccine at Day 0 and the rDEN3Δ30 virus at Day 180.
16561281|NCT02873260|Placebo Comparator|Placebo + rDEN3Δ30|Participants will receive placebo at Day 0 and the rDEN3Δ30 virus at Day 180.
16561282|NCT02873234||Traditional Chinese Medicine|Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
16561283|NCT02873234||TCM plus antidepressants|This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
16561284|NCT02873234||Antidepressants|Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
16561285|NCT02873221|Active Comparator|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
16561286|NCT02873221|Experimental|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
16561287|NCT02873221|Experimental|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
16561288|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
16561289|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16561290|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16561291|NCT02873182|Experimental|Autonomic nervous system monitoring|During standard intraoperative neuromonitoring, additional smooth muscle free-running and stimulated EMG will be recorded from corporal tissues (corpus spongiosum) of male and female genitalia from all patients who consent to participate in the study. EMG data and additional demographics and clinical data (e.g. operative time, adverse events) will be collected for each patient.
16561292|NCT02873156|Experimental|E2027|"Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:
~Part A Cohort 1: 50 mg (1 × 50 mg capsule)
~Cohort 2: 100 mg (2 × 50 mg capsules)
~Cohort 3: 200 mg (4 × 50 mg capsules)
~Cohort 4: 400 mg (8 × 50 mg capsules)
~Cohort 6: 25 mg (5 × 5 mg capsules) Part B
~Cohort 5: 400 mg (8 × 50 mg capsule)
~Part C:
~• Cohort 7: 50 mg (1 × 50 mg capsules)
~Part D:
~Cohort 8: 5 mg (1 × 5 mg capsules)
~Cohort 9: 10 mg (2 × 5 mg capsules)"
16561328|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
16561365|NCT02872649|Active Comparator|control group|Phenprocoumon dosage according to INR
16561294|NCT02873143||The APA2011 cohort|In September 2011, students at 4 upper secondary schools in Aalborg were invited to answer an online questionnaire and to be part of the APA2011 cohort. From 2846 potential responders, 2200 adolescents responded to the questionnaire, corresponding to a response rate of 77%. A total of 504 adolescents indicating knee pain at least monthly were successfully contacted (a response rate of 83% of those who reported their telephone numbers) and were asked standardized questions on the telephone. This forms the cohort of 504 adolescents with knee pain. In addition a random selected group of adolescents without knee pain in 2011 will be contacted and asked the same questions as those with knee pain.
16561295|NCT02873130|Experimental|Behavioral: Telepractice Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) through West Chester University's Desire 2 Learn (D2L) software program. Synchronous and asynchronous learning opportunities are provided through D2L over a four week period. The GVPM includes vocal hygiene, vocal education, and vocal training.
16561296|NCT02873130|Experimental|Behavioral: In-person Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) at West Chester University in-person. The GVPM will meet for 2 hours once a week for four weeks. The GVPM includes vocal hygiene, vocal education, and vocal training.
16561297|NCT02873130|Sham Comparator|Behavioral: Telepractice, Vocal Hygiene and Vocal Education|Participants will complete Vocal Hygiene and Vocal Education through West Chester University's Desire 2 Learn (D2L) software program. Asynchronous learning opportunities are provided through D2L over a one week period.
16561298|NCT02873117||5 alpha reductase inhibitor|
16561299|NCT02873117||Any other drug for benign prostate hyperplasia|
16561300|NCT02873104|Active Comparator|Treatment|truSculpt rf device, therapeutic settings
16561301|NCT02873104|Sham Comparator|Sham|truSculpt rf device, non-therapeutic settings
16561302|NCT02873091|Active Comparator|CEI|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose
16561303|NCT02873091|Active Comparator|PIEB 1|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose
16561304|NCT02873091|Active Comparator|PIEB 2|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose
16561305|NCT02873078|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of cognitive behavior therapy (CBT). Parents will also receive 10 weekly modules. Main components in the children's modules are exposure for abdominal symptoms, feared stimuli and situations in which the children are afraid of having symptoms. The parental receive information on how they can support their children in the treatment and how to reinforce health y behaviors and decrease attention to pain behaviors. Therapist support is provided through written messages within the secure platform.
16561306|NCT02873078|No Intervention|Waiting list|This is a wait-list control where the children and parents are allowed to carry on with any contacts within the health-care system, exempt for psychological treatments.
16561307|NCT02873065|Experimental|Ilaprazole|Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.
16561308|NCT02873065|Active Comparator|Esoprazole|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.
16561309|NCT02873026|No Intervention|Standard care|The patient will receive the standard care given to all patients that have received a vitrectomy following open globe trauma.
16561310|NCT02873026|Experimental|Triamcinolone acetonide|Triamcinolone Acetonide 4mg/0.1ml intravitreal cavity and 40mg/1ml subtenons to be injected at the time of the vitrectomy. Patients will then receive standard care following operation.
16561311|NCT02873013||Prostate Cancer|About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
16561312|NCT02873000|No Intervention|Routine Care Group|Routine Care (R): Standard of care therapy based on admitting diagnosis
16561313|NCT02873000|Experimental|Experimental Group|"Intervention 1 (E1): addition of incentive spirometry every hour while awake;
~There will be a computerized protocol with specific instructions documenting:
~compliance
~patient position while using [sitting up vs laying flat in bed]
~inspiratory volume attained
~effort, motivation and compliance will subjectively be documented using a visual analogue 0-5 point scale."
16561314|NCT02872987||B-ALL/NHL|
16561315|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
16561316|NCT02872974||Exposed|Offspring of woman with GDM
16561317|NCT02872974||Not exposed|Offspring of woman without GDM
16561318|NCT02872961||SIBO Positive|Positive small bowel aspirate culture and/or positive glucose breath test
16561319|NCT02872961||SIBO Negative|Negative small bowel aspirate culture and negative glucose breath test
16561320|NCT02872948||70 euploïdes foeti samples|"Patients with foetus euploïde (no sick)"
16561321|NCT02872948||30 trisomies 21 samples|"Patients with foetus reached(affected) by trisomy 21 (sick)"
16561322|NCT02872935|Placebo Comparator|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
16561323|NCT02872935|Experimental|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
16561324|NCT02872922|Active Comparator|Endothelial function after CWUT|Endothelial function of the all patients before and after application continuous waveform of ultrasound therapy (CWUT) measured by technique flow-mediated dilation (FMD).
16561325|NCT02872922|Active Comparator|Endothelial function after PWUT|Endothelial function of the all patients before and after application pulsed waveform of ultrasound therapy (PWUT) measured by technique flow-mediated dilation (FMD).
16561326|NCT02872922|Active Comparator|Endothelial function after PLACEBO|In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off. Endothelial function of the all patients before and after application placebo waveform of ultrasound therapy measured by technique flow-mediated dilation (FMD)
16561327|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED portable PDT treatment
16561366|NCT02872636|Experimental|Treatment Group|
16561330|NCT02872896|Sham Comparator|Non-ClearSight|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.
16561331|NCT02872883|Experimental|Expectant management and minimal vaginal examinations|Expectant management up to approximately 96hours and vaginal examinations only when necessary during active labour
16561332|NCT02872883|Experimental|Expectant management and routine vaginal examinations|Expectant management up to approximately 96hours and routine vaginal examinations during active labour
16561333|NCT02872883|Experimental|Active management and minimal vaginal examinations|Induction of labour at approximately 24hours and vaginal examinations only when necessary during active labour
16561334|NCT02872883|Active Comparator|Active management and routine vaginal examinations|Induction of labour at approximately 24hours and routine vaginal examinations
16561335|NCT02872870||Control adults|lexical tests and electroencephalogram (EEG).
16561336|NCT02872870||Dyslexic patients|lexical tests
16561337|NCT02872870||Dysphasic patients|lexical tests
16561338|NCT02872857|Placebo Comparator|Placebo|
16561339|NCT02872857|Experimental|8mg galantamine twice daily|
16561340|NCT02872857|Experimental|12mg galantamine twice daily|
16561341|NCT02872831|Active Comparator|22G SharkCore™ needle|Covidien has recently released a novel SharkCore™ Fine Needle Biopsy (FNB) system for EUS-guided tissue acquisition of solid gastrointestinal lesions. With its unique bevel design, this needle has shown promising results to acquire histologic tissue as per oral communication with physicians around the country
16561342|NCT02872831|Active Comparator|22G BNX EUS-FNA needle|The standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle is routinely used for the evaluation of solid mass lesions in the pancreas and gastrointestinal tract.
16561343|NCT02872818|Active Comparator|Control group|Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
16561344|NCT02872818|Active Comparator|Metformin group|Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
16561345|NCT02872818|Active Comparator|Medroxyprogesterone acetate group|Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
16561346|NCT02872805|Active Comparator|PEPFAR Enhanced Standard of Care (PESCA)|This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites. We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care
16561347|NCT02872805|Experimental|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
16561348|NCT02872792|Experimental|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
16561349|NCT02872792|Active Comparator|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
16561350|NCT02872779|Experimental|Patients Treated for Metastatic Colorectal cancer|Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer
16561351|NCT02872766|Experimental|Corneal cross linking (CXL)|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
16561352|NCT02872753|Experimental|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
16561353|NCT02872753|Other|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
16561354|NCT02872740|Experimental|Embolization of Left Gastric Artery|These patients will have their left gastric artery embolized
16561355|NCT02872740|Experimental|Embolization of Gastroepiploic Artery|These patients will have their gastroepiploic artery embolized
16561356|NCT02872727||Air France Company's Employees Working|Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations
16561357|NCT02872714|Experimental|Cohort A-ID (Intermittent Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
16561358|NCT02872714|Experimental|Cohort A-CD (Continuous Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
16561359|NCT02872714|Experimental|Cohort B Pemigatinib|Pemigatinib in subjects with other FGF/FGFR alterations.
16561360|NCT02872701|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
16561361|NCT02872688|Experimental|GanedenBC30|
16561362|NCT02872675|Experimental|HOST-DM059 (Prebiotic)|HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics. HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g. The β-Galacotosidase Enzyme, & Bifidobacterium Bifidum). The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria. HOST-DM059 encourages the growth and development of Bifidobacteria. Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
16561363|NCT02872675|Placebo Comparator|Maltodextrin|Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
16561364|NCT02872649|Experimental|study medication|Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate >80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
16561367|NCT02872623|Experimental|experimental group|patients clinically suspected of having a tumor of the small intestine
16561368|NCT02872610|Experimental|Self-help Online|6 weeks of internet-based self-help intervention
16561369|NCT02872610|No Intervention|Wait-list|Waiting list control condition
16561370|NCT02872597|Experimental|Treatment|Inhaled ipratropium bromide 250mcg given via nebulization every 6 hours for up to 5 days
16561371|NCT02872597|Placebo Comparator|Placebo|Inhaled normal saline 1.25mL given via nebulization every 6 hours for up to 5 days
16561372|NCT02872584||Prednisone|Patients with dermatological conditions requiring high dose long term glucocorticoid treatment
16561373|NCT02872571|Experimental|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
16561374|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:
~The study coordinator will provide the decision aid for the parent/clinician dyad.
~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.
~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.
~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.
~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
16561375|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
16561376|NCT02872545|Experimental|forward tilted|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in forward tilted position
16561377|NCT02872545|Other|semi sitting|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in semi sitting
16561378|NCT02872545|Other|dorsal decubitus|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in dorsal decubitus
16561379|NCT02872532|Experimental|Testicular tissue|Children faced with a fertility threatening diagnosis or treatment plan will be offered testicular tissue cryopreservation, particularly if pre-pubescent and without other options to preserve fertility.
16561380|NCT02872519|Experimental|Experimental|Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).
16561381|NCT02872506|Active Comparator|medical treatment by Anti TNF|The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time
16561382|NCT02872506|Active Comparator|ileocecal resection|The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy
16561383|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
16561384|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
16561385|NCT02872480|Experimental|ACTIVE Training|Healthy participants will be progressed from 60-80% of their VO2max as determined by the progressive exercise test over the course of 6 30-minute training sessions. Concussed participants will begin 30-minute training sessions at 60% of the VO2 achieved at symptom exacerbation of the exercise test. Intensity will be progressed as tolerated by the participant and training sessions will continue until the participant is asymptomatic for 24 consecutive hours (total number of sessions variable based on clinical recovery).
16561386|NCT02872480|No Intervention|Control|Healthy controls will be asked to follow their normal routine for rest and physical activity. Concussed controls will be asked to follow the guidance for rest and activity as prescribed by the physicians and athletic trainers overseeing their clinical care.
16561387|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
16561388|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
16561389|NCT02872454|Experimental|Text Messaging|
16561390|NCT02872441|Experimental|diagnosis of disease associated with IgG4|patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
16561391|NCT02872428|Experimental|Valproic acid (Depacon)|Valproic acid by IV infusion over one hour
16561392|NCT02872428|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
16561393|NCT02872415|Experimental|The forearm as blood puncture site|The child receives a puncture blood on the forearm
16561394|NCT02872415|Placebo Comparator|Fingers like blood puncture site|Premature receiving a puncture blood on the finger
16561395|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.
~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
16561396|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
16561397|NCT02872389|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
16561398|NCT02872389|Experimental|Desflurane|Anesthesia was maintained with desflurane.
16561399|NCT02872376||Anemic|Anemic patients
16561440|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
16640027|NCT02347956|Experimental|Reduced port group|
16561400|NCT02872363|No Intervention|Control|The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
16561401|NCT02872363|Experimental|Intervention A - Behavioural Regulation|Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
16561402|NCT02872363|Experimental|Intervention B - Priority|Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
16561403|NCT02872350|Experimental|Premature with necrotizing enterocolitis|
16561404|NCT02872337|Experimental|Experimental (Intervention): PreopPT Group|This group will undergo the group preoperative education session. Following this session (intervention) this group underwent a one-time, one-on-one preoperative PT session. They also were given access to a web-based microsite which was customized to surgeon
16561405|NCT02872337|Placebo Comparator|Control (standard of care): No PreopPT Group|This group underwent the current of standard of care at our institution. This only includes the group preoperative education session. No further preoperative education was given.
16561406|NCT02872324|Experimental|Sessions of Mindfulness Based Cognitive Therapy (MBCT)|
16561407|NCT02872311|Active Comparator|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
16561408|NCT02872311|Active Comparator|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
16561409|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
16561410|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
16561411|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
16561412|NCT02872298|Experimental|Treatment|Treatment: Targeted Lung Denervation (TLD)
16561413|NCT02872285|Experimental|LYC-30937-EC 25 mg PO once daily (QD)|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
16561414|NCT02872285|Placebo Comparator|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
16561415|NCT02872272|Experimental|Treatment with Amikacin|Dressing impregnated by administration of amikacin
16561416|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week
~Treatment until disease progression, or unacceptable toxicity"
16561417|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.
~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily
~Treatment until disease progression, or unacceptable toxicity"
16561418|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week
~Treatment until disease progression, or unacceptable toxicity"
16561419|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily
~Treatment until disease progression, or unacceptable toxicity"
16561420|NCT02872246|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
16561421|NCT02872233|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
16561422|NCT02872220|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products compared to that of a negative control [0.9% NaCl] were tested simultaneously on each subject.
16561423|NCT02872207|Experimental|Suncare agent 1 + control|Application of control and test product into one of the subjects two eyes.
16561424|NCT02872207|Experimental|Suncare agent 2 + control|Application of control and test product into one of the subjects two eyes.
16561425|NCT02872194|Experimental|Suncare agent A + control|Application of control and test product into one of the subjects two eyes.
16561426|NCT02872194|Experimental|Suncare agent B + control|Application of control and test product into one of the subjects two eyes.
16561427|NCT02872194|Experimental|Suncare agent C + control|Application of control and test product into one of the subjects two eyes.
16561428|NCT02872181|Experimental|BMI <30|Pregnant women undergoing C/S with BMI <30
16561429|NCT02872181|Experimental|BMI 30-40|Pregnant women undergoing C/S with BMI 30-40
16561430|NCT02872181|Experimental|BMI >40|Pregnant women undergoing C/S with BMI >40
16561431|NCT02872155|Experimental|Oral hydratation|
16561432|NCT02872155|Active Comparator|Endovenous hydratation|
16561433|NCT02872142|Experimental|Albutein 5%|Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
16561434|NCT02872129||166 women with FM/CWP|166 women with Fibromyalgia (FM) or Chronic Widespread Pain (CWP) that participated in an Randomised Controlled Trial called GAU in western Sweden 2004-2005.
16561435|NCT02872116|Experimental|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy
~Enrollment is closed for this arm"
16561436|NCT02872116|Active Comparator|XELOX (Oxaliplatin + Capecitabine)|
16561437|NCT02872116|Active Comparator|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
16561438|NCT02872116|Experimental|Nivolumab + XELOX|
16561439|NCT02872116|Experimental|Nivolumab + FOLFOX|
16640741|NCT02343211|Experimental|immunoglobulin|
16561441|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
16561442|NCT02872090|Experimental|Arm 1|The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo
16561443|NCT02872090|Experimental|Arm 2|The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol
16561444|NCT02872090|Experimental|Arm 3|The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,
16561445|NCT02872090|Experimental|Arm 4|The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium
16561446|NCT02872077|Active Comparator|Auricular Acupuncture|Study subjects randomized to this group will receive auricular acupuncture: the investigator will evaluate the infant using an ear point locator to determine active sites, and will place acupuncture needles in the active sites found in one ear. Acupuncture sites will be alternated every 3 days between right and left ear.
16561447|NCT02872077|No Intervention|Control|The subjects randomized to the control group will have NO interventions, and will continue to receive routine care for NAS, pharmacologic and non-pharmacologic, per NICU protocol.
16561448|NCT02872064|Experimental|Treatment with PDT|A single intravenous injection of Verteporfin (0.4mg/kg) will be administered, at least 60minutes and up to 90 minutes before laser activation. A 690nm red laser light will be delivered with a diffuser laser fibre inserted through the skin into the breast tissue, with light dose escalation after every three patients. All patients will have fixed dose of the photosensitizer but variable light dose.
16561449|NCT02872051|No Intervention|Control|Standard treatment and standard vocational rehabilitation
16561450|NCT02872051|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
16561451|NCT02872051|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
16561452|NCT02872038|Experimental|Treatment|Cefepime intraperitoneal continuous dosing
16561453|NCT02872038|Active Comparator|Control|Cefazolin plus Ceftazidime intraperitoneal continuous dosing
16561454|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
16561455|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
16561456|NCT02872025|Experimental|Pembrolizumab intralesional (IL) x 2 doses + intralesional mRNA 2752 x 2-4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab and intralesional mRNA 2752 injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
16561457|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
16561458|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
16561459|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
16561460|NCT02872012|Experimental|Cryoanesthesia Device -7 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
16561461|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
16561462|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
16561463|NCT02872012|Active Comparator|Lidocaine|"Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.
~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye."
16561464|NCT02871999|Active Comparator|Control group|This group receives normal treatment after surgery,with no acupuncture.
16561465|NCT02871999|Experimental|Experimental group|This group receives acupuncture therapy besides normal treatment after surgery. The acupuncture therapy starts after 24 hours of surgery, 1 time a day, 30 minutes every time, until the fifth day.
16561466|NCT02871986||Individuals with hypogonadism|Individuals with hypogonadism requiring pubertal induction. Participants will receive oestrogen therapy in the form of transdermal oestrogen patch, which is standard care.
16561467|NCT02871973|Experimental|SDP|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visit.
16561468|NCT02871973|Active Comparator|CDC Handout|Families in the control group will receive the Center for Disease Control and Prevention (CDC) Handout at enrollment.
16561469|NCT02871960|Experimental|Robotic colectomy|Patients undergoing robotic colectomy for colorectal cancer
16561470|NCT02871960|Active Comparator|Laparoscopic colectomy|Patients undergoing laparoscopic colectomy for colorectal cancer
16561471|NCT02871934|Experimental|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
16561472|NCT02871934|Experimental|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
16561473|NCT02871921|Experimental|Conversational Engagement|Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months). Under an exploratory aim, a limited number of participants will be further followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from topic options. Participants will also receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions.
16561474|NCT02871921|No Intervention|Control Group|Participants will receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions
16561475|NCT02871908|Experimental|L reuteri DSM 17938|L reuteri DSM 17938 2 x 10^8 twice daily
16561476|NCT02871908|Placebo Comparator|Controls|Identically appearing placebo twice daily
16561477|NCT02871882|Active Comparator|Ox bile extract|Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
16561478|NCT02871882|Placebo Comparator|Placebo|Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
16561479|NCT02871869|Active Comparator|Control group A|Control group A was treated with single R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
16561480|NCT02871869|Experimental|Trial group A|Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
16561481|NCT02871869|Active Comparator|Control group B|Control group B was treated with single CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
16561482|NCT02871869|Experimental|Trial group B|Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
16561483|NCT02871856|Other|Single|Single arm only, CT screening of lung
16561484|NCT02871843|Experimental|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
16561485|NCT02871830|Experimental|Physical activity intervention group|
16561486|NCT02871830|No Intervention|Control group|
16561487|NCT02871817||Normal Vision|Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
16561488|NCT02871817||Age-related macular degeneration|Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
16561489|NCT02871817||Diabetic retinopathy|Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
16561490|NCT02871804|Active Comparator|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
16561491|NCT02871804|Experimental|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
16561492|NCT02871791|Experimental|Palbociclib, Everolimus, Exemestane|"Palbociclib will be administered orally, once daily for 21 consecutive days followed by a 7-day rest (28-day cycle)
~Everolimus will be administered orally, once daily on a 28 day schedule
~Exemestane will be administered orally, once daily on a 28 day schedule
~Participants will be treated with increasing/decreasing doses of palbociclib and everolimus to establish MTD(s)/RP2D for both drugs in the setting of the triple combination of palbociclib, everolimus and exemestane"
16561493|NCT02871778|Experimental|VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor|"Part A/ Treatment Period 1: VX-371 in Hypertonic Saline
~Part A/ Treatment Period 2: Hypertonic Saline
~Part B/ Treatment Period 3: Hypertonic Saline + Ivacaftor"
16561494|NCT02871778|Experimental|HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor|"Part A/ Treatment Period 1: Hypertonic Saline
~Part A/ Treatment Period 2: VX-371 in Hypertonic Saline
~Part B/ Treatment Period 3: VX-371 in Hypertonic Saline + Ivacaftor"
16561495|NCT02871778|Experimental|VX-371, then Placebo, then Placebo + Ivacaftor|"Part A/ Treatment Period 1: VX-371
~Part A/ Treatment Period 2: Placebo
~Part B/ Treatment Period 3: Placebo + Ivacaftor"
16561496|NCT02871778|Experimental|Placebo, then VX-371, then VX-371 + Ivacaftor|"Part A/ Treatment Period 1: Placebo
~Part A/ Treatment Period 2: VX-371
~Part B/ Treatment Period 3: VX-371 + Ivacaftor"
16561497|NCT02871765|Experimental|education group|In education group, each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department by researchers. Three months later, participants in the education group received a follow-up phone call in order to clarify any questions related to the brochure. All participants completed posttest at 6-month follow-up.
16561498|NCT02871765|No Intervention|control group|The control group received the brochure only.
16561532|NCT02871596|Experimental|Flavonoids+Prebiotics,Flavonoids,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
16561533|NCT02871583|Active Comparator|lichtenstein|lichtenstein procedure
16561499|NCT02871752|Experimental|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
16561500|NCT02871752|Active Comparator|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
16561501|NCT02871739|Experimental|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
16561502|NCT02871739|Experimental|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
16561503|NCT02871739|Experimental|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
16561504|NCT02871739|Experimental|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
16561505|NCT02871726|Experimental|TRUS-Robot and TRUS|TRUS and TRUS-Robot will be used during prostate biopsy
16561506|NCT02871726|Active Comparator|Routine TRUS/Fusion biopsy|Just Uronav will be used during prostate biopsy
16561507|NCT02871713|Active Comparator|Intrathecal morphine|Intrathecal morphine 100 mcg
16561508|NCT02871713|Experimental|Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg)
16561509|NCT02871713|Experimental|Intrathecal morphine + Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg) + Intrathecal morphine 100 mcg
16561510|NCT02871700|Experimental|Action observation therapy (AOT)|Action observation therapy (AOT)
16561511|NCT02871700|Experimental|Mirror therapy (MT)|Mirror therapy (MT)
16561512|NCT02871700|Active Comparator|Control group|Customary bilateral UE training
16561513|NCT02871687|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
16561514|NCT02871687|Active Comparator|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
16561515|NCT02871687|Active Comparator|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.
16561516|NCT02871674|Experimental|Intervention group|Participants in the intervention group will receive behavioural training by psychologists in three sessions over three weeks
16561517|NCT02871674|No Intervention|Control group - usual care|Participants in the control group will receive usual care. They will also attend their usual appointments with the psychiatrists. They will not receive any intervention.
16561518|NCT02871661|Active Comparator|Amitriptyline|This group will be treated with medication alone (amitriptyline hydrochloride, 25 mg) for chronic vulvar pain (vulvodynia).
16561519|NCT02871661|Active Comparator|Amitriptyline plus kinesiotherapy|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus pelvic floor exercises such as Kegel contractions and stretching of pelvic floor muscles with patients own hands.
16561520|NCT02871661|Active Comparator|Amitriptyline plus IC (Quark)|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus electrical stimulation with Interferential Current (manufacturer: Quark Medical; Model: Dualpex 961 - program number 42): two electrodes put into the perineal surface area emitting interferential current, once a week for twenty minutes each, for eight weeks long.
16561521|NCT02871648|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
16561522|NCT02871648|Active Comparator|Fludrocortisone|Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
16561523|NCT02871648|Active Comparator|Epleronone|Subjects will receive 100 mg of epleronone on one of three study days.
16561524|NCT02871635|Experimental|BI 695501|
16561525|NCT02871635|Active Comparator|HUMIRA + BI 695501|
16561526|NCT02871609||Patients with longterm ureteral stent|
16561527|NCT02871596|Experimental|Placebo,Flavonoids,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
16561528|NCT02871596|Experimental|Placebo,Flavonoids+Prebiotics,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
16561529|NCT02871596|Experimental|Flavonoids,Placebo,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
16561530|NCT02871596|Experimental|Flavonoids,Flavonoids+Prebiotics,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
16561531|NCT02871596|Experimental|Flavonoids+Prebiotics,Placebo,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
16561534|NCT02871583|Active Comparator|Kugel|Kugel procedure
16561536|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
16561537|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
16561538|NCT02871544|Sham Comparator|Low BNP and Low NGAL Group|BNP≤100pg/ml and NGAL≤153pg/ml
16561539|NCT02871544|Active Comparator|High BNP and Low NGAL Group|BNP>100pg/ml and NGAL≤153pg/ml
16561540|NCT02871544|Active Comparator|Low BNP and High NGAL Group|BNP≤100pg/ml and NGAL>153pg/ml
16561541|NCT02871544|Active Comparator|High BNP and High NGAL Group|BNP>100pg/ml and NGAL>153pg/ml
16561542|NCT02871531|Experimental|Pneumatic retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy
16561543|NCT02871531|Experimental|Vitrectomy|Patients with retinal detachment allocated to vitrectomy
16561544|NCT02871518|Experimental|Two cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
16561545|NCT02871518|Active Comparator|Three cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
16561546|NCT02871505|Experimental|Molecular subtyping (14d/f) of Treponema pallidum|Benzathine Penicillin G treatment
16561547|NCT02871505|Experimental|Molecular subtyping (others) of Treponema pallidum|Benzathine Penicillin G treatment
16561548|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
16561549|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
16561550|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
16561551|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
16561552|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
16561553|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
16561554|NCT02871466|Experimental|stem cells infusion|
16561555|NCT02871453|Experimental|Acupuncture combined rehabilitation|"Scalp acupuncture treatment
~Rehabilitation treatment"
16561556|NCT02871453|Experimental|Rehabilitation|Rehabilitation treatment
16561557|NCT02871440|Experimental|Eye drop 1|Omega 3
16561558|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
16561559|NCT02871440|Active Comparator|Eye drop 3|Optive
16561560|NCT02871427|Experimental|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
16561561|NCT02871414|Experimental|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
16561562|NCT02871414|Experimental|REST - Late Group|Control - No treatment for 7 weeks, then provided 7 weeks of sleep skills education provided in group and one-on-one format
16561563|NCT02871401|Experimental|Valganciclovir|Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
16561564|NCT02871401|Placebo Comparator|Placebo|Placebo, 2 pills by mouth one time per day x 12 weeks
16561565|NCT02871388|Experimental|CONECT|12 week program with additional follow up at 24 weeks.
16561566|NCT02871388|No Intervention|Control|Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
16561567|NCT02871375|Other|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
16561568|NCT02871375|Other|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
16561569|NCT02871362|Experimental|IQP-AS-118|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
16561570|NCT02871362|Placebo Comparator|Placebo|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
16561571|NCT02871349|Experimental|Propanolol and MRI|Participants will receive propranolol via oral capsule, crushed tablet, or liquid daily. The drug dosage will be titrated slowly to ensure the drug is tolerated well. Those aged 15-24 will have an MRI before starting drug.
16561572|NCT02871349|Placebo Comparator|Placebo and MRI|Participants will receive placebo via oral capsule, crushed tablet, or liquid daily. Those aged 15-24 will have an MRI before starting drug.
16561573|NCT02871323|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with SD, no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses.
16561574|NCT02871310|Experimental|IQP-AS-118|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
16561575|NCT02871310|Placebo Comparator|Placebo|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
16561576|NCT02871297|Experimental|Vortioxetine tablets|Vortioxetine tablets for 26 weeks
16561577|NCT02871297|Experimental|Vortioxetine|Single dose of vortioxetine oral drops (only a subset of patients)
16561578|NCT02871284|Experimental|Sensorimotor training (EI)|The participants of the experimental intervention arm will take part in a 45 minutes sensorimotor training class two times a week for a maximum of 24 weeks at the NCT (National Center for Tumor Diseases). Highly qualified exercise therapists will guide the class. Class size will be no bigger than 8 patients to ensure adequate individual supervision and guidance. Additionally, participants will be asked to perform one weekly 15 minutes home-based sessions without supervision. Participants who are not able to come to the NCT Heidelberg 2x/week will be offered a home-based sensorimotor program including the same exercises. At the beginning, participants will receive an appointment for an individual face-to-face counseling session at the NCT. During this appointment, the patient will receive an exercise manual for individualized home-based sensorimotor training and a practical introduction by the exercise therapist.
16561615|NCT02871037|Experimental|Part 1_Cohort 2_Placebo|Single dose of Placebo
16561616|NCT02871037|Experimental|Part 2_Active|Repeated, escalating doses of PF-05221304
16561617|NCT02871037|Placebo Comparator|Part 2_Placebo|Repeated doses of placebo
16561618|NCT02871037|Experimental|Part 3|Single dose of PF-05221304 with and without food
16641421|NCT02338739|Active Comparator|REC; Navigator if Failure|
16561579|NCT02871284|Active Comparator|machine-based resistance training (AC)|Participants of the active control arm will receive machine-based resistance training. The supervised resistance exercise program will be undertaken twice weekly in small groups (not more than 12 people per group) of participants and will be guided by an exercise physiotherapist over a maximum of 24 weeks. All sessions will start with a warm-up and finish with a cool-down (comprising exercise on a cycle ergometer or treadmill at a relatively low intensity and stretching activities) and will take approximately 45 minutes. Additionally, participants will be asked to perform a weekly 15 minutes home-based resistance training session without supervision
16561580|NCT02871284|No Intervention|usual care|Participants will receive usual care with no additional exercise training or intervention
16561581|NCT02871271|Experimental|IQP-AS-121|To be taken once daily dosing of 1 tablet in the morning.
16561582|NCT02871258|Other|The MetaNeb® System Treatment|Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
16561583|NCT02871245|Active Comparator|Comparator Group|Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.
16561584|NCT02871245|Experimental|Acupuncture Therapy Group|Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row
16561585|NCT02871232||Intentional exposures among adolescents and adults|
16561586|NCT02871232||Unintentional exposures among infants and children|
16561587|NCT02871219|Experimental|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
16561588|NCT02871206|Experimental|Adjuvanted Influenza Vaccine|Fluad
16561589|NCT02871206|Active Comparator|Quadrivalent Influenza Vaccine|Fluzone
16561590|NCT02871193|Sham Comparator|Group C（Control）|Group C received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml combined with general anesthesia and intravenous patient controlled analgesia pump.
16561591|NCT02871193|Experimental|Group R(Ropivacaine)|Group R received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20 ml combined with general anesthesia and intravenous patient controlled analgesia pump.
16561592|NCT02871193|Experimental|Group D(Dexamethasone)|Group D received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg combined with general anesthesia and intravenous patient controlled analgesia pump.
16561593|NCT02871180|Other|With late night snack|At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.
16561594|NCT02871180|Other|Without late night snack|Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..
16561595|NCT02871167|Experimental|Oocyte/embryo cryopreservation|"Controlled ovarian hyperstimulation (COH)
~Oocyte/embryo freezing"
16561596|NCT02871154|Experimental|Delay|Delaying oocyte pick up beyond 39 hours post hCG
16561597|NCT02871141||ECT group|Patients with a major depressive episode treated with ECT. Patients will be investigated (i) prior to the 1st ECT session, (ii) after the 4th ECT session, (iii) after the 12th ECT session, and (iv) 6 months after the 1st ECT session.
16561598|NCT02871141||Antidepressant group|Patients with a major depressive episode treated with antidepressants. Patients will be investigated (i) prior to treatment, (ii) after 10 days of treatment, (iii) after 4 weeks of treatment, and (iv) after 6 months.
16561599|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
16561600|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
16561601|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
16561602|NCT02871115|Experimental|Pharmacy Intervention|"Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will
~Perform detailed medication reconciliation
~Obtain allergy and vaccination history
~Evaluate and document polypharmacy (number of medications)
~Document their findings in the medical record and discuss their recommendations (in-person, phone call, email) with each patient's oncology team"
16561603|NCT02871115|Active Comparator|Usual Care|"Participants receiving Usual Oncology Care will not meet with the pharmacist unless indicated as part of their routine clinical care
~Study staff will obtain all patient-reported measures from the patient.
~Remind participant to complete self-report measures"
16561604|NCT02871102|Experimental|Intervention Arm|
16561605|NCT02871089|Experimental|24/7 Closed loop delivery|Unsupervised home use of day and night automated closed-loop insulin delivery system FlorenceM (Medtronic 640G insulin pump, guardian 3 CGM and Android smartphone) of CamAPS FX (Dana insulin pump, Dexcom G6 CGM and App on Android smartphone) until 24 months after diagnosis
16561606|NCT02871089|Active Comparator|Multiple Daily Injections|Participants will apply standard insulin therapy using multiple daily injections via insulin pens during the 24 months control period
16561607|NCT02871076|Experimental|Verum Acupuncture|Patients will receive verum acupuncture twice weekly for twelve weeks.
16561608|NCT02871076|Placebo Comparator|Sham Placebo Acupuncture|Patients will receive sham placebo acupuncture twice weekly for twelve weeks.
16561609|NCT02871063||High altitude ARDS|ARDS diagnosed at altitudes greater than 1500 meters above sea level
16561610|NCT02871063||Sea level ARDS|ARDS diagnosed at altitudes below 1500 meters above sea level
16561611|NCT02871050||Castleman Disease Patients|Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
16561612|NCT02871037|Experimental|Part 1_Cohort 1_Active|Single, escalating dose of PF-05221304
16561613|NCT02871037|Placebo Comparator|Part 1_Cohort 1_Placebo|Single dose of Placebo
16561614|NCT02871037|Experimental|Part 1_Cohort 2_Active|Single, escalating dose of PF-05221304
16561619|NCT02871024|Experimental|Intervention arm|Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart
16561620|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
16561621|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
16561622|NCT02870998|Experimental|Active learning|Educational strategies will be used to foster active learning.
16561623|NCT02870998|Active Comparator|Passive learning|Traditional educational strategies (lecture) will be used.
16561624|NCT02870985|Experimental|BIOTRONIK Orsiro SES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the experimental arm will be implanted with BIOTRONIK sirolimus eluting coronary stent(Orsiro).
16561625|NCT02870985|Active Comparator|Abbott Xience Prime™ EES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the comparator arm will be implanted with Abbott everolimus eluting coronary stent(Xience Prime™).
16561626|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
16561627|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
16561628|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
16561629|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
16561630|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
16561631|NCT02870946|Experimental|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced.
16561632|NCT02870946|Experimental|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
16561633|NCT02870933|Experimental|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
16561634|NCT02870933|No Intervention|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
16561635|NCT02870920|Active Comparator|Best Supportive Care|Best supportive care available
16561636|NCT02870920|Experimental|Durvalumab plus Tremelimumab and Best Supportive Care|Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care
16561637|NCT02870907|Experimental|Low risk group|
16561638|NCT02870907|Experimental|Intermediate risk sub group 1|2 cycles (4 courses): 2 courses of etoposide and Carboplatin from D1 to D5 and Vincristin at D22 and D26- Cyclophosphamide from D22 to D26.
16561639|NCT02870907|Experimental|Intermediate risk sub group 2|2 courses of Vincristin and Carboplatin
16561640|NCT02870907|Experimental|High risk group|"Orbital irradiation
~3 cycles of two different types of alternating chemotherapy courses (id 6 courses) :
~Etoposide (100 mg/m²/d) and Carboplatin (160 mg/m²/d) with intrathecal Thiotepa injection.
~Vincristin (1,5 mg/m²/d) - Cyclophosphamide (1000 mg/m²/d)
~Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamide.
~High dose chemotherapy :
~Carboplatin (AUC : 7/d) - etoposide (250 mg/m²/d) - Thiotepa (300 mg/m²/d)
~Peripheral bood stem cell transplantation."
16561641|NCT02870868|Experimental|Slow breathing with exhale greater than inhale|
16561642|NCT02870868|Experimental|Slow breathing with exhale equal to inhale|
16561643|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
16561644|NCT02870855|No Intervention|Control group|blastocyst transfer
16561645|NCT02870842|Placebo Comparator|Control|Perform recruitment maneuver with fraction of inspired oxygen (FiO2) of 1.0 after intubation under lung ultrasound guidance and maintain FiO2 of 0.6 during the general anesthesia.
16561646|NCT02870842|Active Comparator|Low FiO2|Perform recruitment maneuver with low FiO2 of 0.3 after intubation under lung ultrasound guidance and maintain FiO2 of 0.3 during the general anesthesia.
16561647|NCT02870829|Experimental|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
16561648|NCT02870829|No Intervention|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
16561649|NCT02870816|Active Comparator|Tissue engineered skin substitute|Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
16561650|NCT02870816|Experimental|Amnionic membrane graft|Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
16561651|NCT02870790|Experimental|treatment|A single open-label arm. All participants receive daily oral pill containing TDF/FTC
16561652|NCT02870777|Experimental|MRD-directed therapy|
16561653|NCT02870764|Active Comparator|Dan-shen extract|Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.
16561654|NCT02870764|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.
16561655|NCT02870751|Experimental|ST-only ETEC strain TW11681 or TW10722|Oral inoculum of several doses of bacteria to establish range to achieve diarrhea attack rate in around 70% of volunteers.
16561656|NCT02870738|Active Comparator|Pelvic Floor Physical Therapy|One hour of pelvic floor physical therapy twice weekly for 8 weeks
16561657|NCT02870738|Active Comparator|Bladder Instillations|Bladder instillation of lidocaine, kenalog, heparin sulphate, and bicarbonate twice weekly for 8 weeks
16561658|NCT02870725|No Intervention|Control Group (Treatment As Usual)|Individuals randomized into the control condition will not receive any active treatment but will have access to customary, community-based supportive services. These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of comparison for those in the other arm of the study.
16561659|NCT02870725|Experimental|CBT Individual Psychotherapy (Treatment)|Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
16561660|NCT02870712|Experimental|suture directed|The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
16561661|NCT02870712|Active Comparator|systematic suture|systematic suture tears following current recommendations
16561662|NCT02870699|Experimental|ARM A|"Evonail film forming solution : 1 daily application on the left hand
~Placebo excipient : 1 daily application on the right hand"
16561663|NCT02870699|Active Comparator|ARM B|"Evonail film forming solution : 1 daily application on the right hand
~Placebo excipient : 1 daily application on the left hand"
16561664|NCT02870686|Active Comparator|ERCP without the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to the EUS guided ERCP without fluoroscopy clear all of the bile duct stones.
16561665|NCT02870686|Active Comparator|ERCP with the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to underwent ERCP with the use of fluoroscopy to clear all of the bile duct stones.
16561666|NCT02870673|Active Comparator|Injection of Shincort 0.5 ml and Xylocaine 0.5ml mixture|"In the first week of recruitment, this group will receive the local injection around the distal wrist crease with mixture of Shincort Inj(10mg/ml) 0.5 ml and xylocaine(20mg/ml) 0.5 ml only one time.
~The ultrasound-guided procedure is performed by the orthopedic physician."
16561667|NCT02870673|Experimental|sham electroacupuncture|"In this group, the participants receive acupuncture treatment and only 2 minutes electrical stimulation.
~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant. After 2 minutes, the stimulator will turn off spontaneously and the participant will not be informed.
~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
16561668|NCT02870673|Experimental|electroacupuncture|"In this group, the participants receive acupuncture treatment and 20 minutes electrical stimulation.
~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant.
~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
16561669|NCT02870647|Other|Single arm study|only 1 arm - no comparison nor randomization in this study
16561670|NCT02870634|Experimental|Cu(II)ATSM|Cu(II)ATSM capsules, administered orally once daily
16561671|NCT02870608|Experimental|preterm labor group|Pregnant women hospitalized for preterm labor
16561672|NCT02870608|Other|control group|Pregnant women with a normal pregnancy
16561673|NCT02870595|Active Comparator|Parallel lidocaine injection|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
16561674|NCT02870595|Sham Comparator|Parallel|In the sham comparator, the device will be placed on the skin, but not turned on. Digit block anesthesia will progress in usual fashion as with active comparator, except without the vibratory device engaged.
16561675|NCT02870582|Experimental|Donafenib|Donafenib 300mg bid on 1-21 days of each 28 days cycle.
16561676|NCT02870582|Placebo Comparator|Placebo|Placebo 300mg bid on 1-21days of each 28 days cycle.
16561677|NCT02870569|Experimental|Donafenib1|This is the lower dose group. Donafenib 200mg bid
16561678|NCT02870569|Active Comparator|Donafenib2|This is the higher dose group. Donafenib 300mg bid
16561679|NCT02870556|Experimental|EP, Cervical epidural group|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive cervical epidural analgesia in addition to the standard general anesthesia (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) Cervical epidural technique: epidural needle will be inserted at C 6-C7 or C7-T1 under fluoroscopy in prone position, 6 ml of 0.125% bupivacaine and fentanyl 2 mic/ ml will be administered before skin incision followed by 4 ml of the same injectate, will be infused continously for 2 days
16561680|NCT02870556|Active Comparator|GA, General anesthesia|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive standard general anesthesia only (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) in addition to postoperative analgesia through patient controlled intravenous morphine analgesia (PCA), that involve 1 mg continuous infusion and 2 mg boluses with lockout interval 10 min
16561682|NCT02870543|Active Comparator|Phytolacca decandra|The Phytolacca decandra with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
16561683|NCT02870543|Active Comparator|Melissa officinalis|The Melissa officinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
16561684|NCT02870543|Experimental|Phyt.decandra + Melissa offic.|The combination of Phytolacca decandra with Melissa offcicinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
16561685|NCT02870530|Experimental|division-less gastric bypass|
16561686|NCT02870530|Active Comparator|mini-gastric bypass|
16561687|NCT02870517|Experimental|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
16561688|NCT02870517|Active Comparator|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
16561689|NCT02870504|Experimental|corneoscleral limbus group|Laser spot locates on the corneoscleral limbus.
16561690|NCT02870504|Experimental|One spot group|Laser spot locates on one spot away from the corneoscleral limbus
16561691|NCT02870504|Experimental|Two spots group|Laser spot locates on two spots away from the corneoscleral limbus
16561692|NCT02870491|No Intervention|Control|Existing standard of care.
16561693|NCT02870491|Experimental|Free Distribute+Preemptive Delivery|Community health workers (CHWs) will deliver oral rehydration salts (ORS) and zinc for free to all households in their catchment area with a child under 5-years-old at the beginning of the study.
16561694|NCT02870491|Experimental|Cost Sharing + Preemptive Delivery|CHWs will visit all households with a child under 5-years-old at the beginning of the study and offer to sell ORS and zinc to caretakers at the time of the visit for them to store in their homes.
16561695|NCT02870491|Experimental|Free Distribution Upon Retrieval|CHWs will visit all households with a child under 5-years-old at the beginning of the study and inform caretakers that they have ORS and zinc available for free that caretakers can retrieved from the CHWs home if needed.
16561696|NCT02870478|Active Comparator|0.01% atropine daily|Nightly dosing of 0.01% atropine
16561697|NCT02870478|Experimental|0.01% atropine twice per week|Atropine dosed twice per week
16561698|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
16561699|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
16561700|NCT02870452|Experimental|Hypnosis|Hypnosis for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
16561701|NCT02870452|Experimental|Cognitive-Behavioral Therapy|Cognitive Behavioral Therapy for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
16561702|NCT02870452|No Intervention|Control Group|No psychological intervention - standard Haemophilia care
16561703|NCT02870439|Experimental|patients with at least 20% of wounded burns body|
16561704|NCT02870439|Experimental|patients with at least 5% of wounded burns body|
16561705|NCT02870439|Experimental|patients with post-surgical wounds with skin resection|
16561706|NCT02870426||Group 1A:|Donors after brainstem death (DBDs) undergoing solid organ donation
16561707|NCT02870426||Group 1B:|Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
16561708|NCT02870426||Group 2:|Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
16561709|NCT02870413|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 12 weeks post-partum. Services will be available through mobile phone app.
16561710|NCT02870413|No Intervention|Usual care|Participants in the control arm will receive care as usual.
16561711|NCT02870400|Experimental|REGN2477|Cohorts 1 - 5 will receive REGN2477
16561712|NCT02870400|Experimental|Placebo|Cohorts 1 - 5 will receive placebo
16561713|NCT02870387|Active Comparator|Usual Inpatient Care|Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
16561714|NCT02870387|Experimental|Comprehensive Care with Inpatient Consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
16561715|NCT02870361|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
16561716|NCT02870361|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
16561717|NCT02870348|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg administered weekly via intravenous administration
16561718|NCT02870335|Experimental|Manual Therapy|The objective of treatment is to restore esta possible limitation of global mobility to major lower limb joints and remove any tensions from the musculature involved in a relevant way in this sport.
16561719|NCT02870335|Active Comparator|Proprioceptive neuromuscular facilitation|It is a stretching technique with the aim of increasing the ROM. It includes passive static stretching and contract-relax.
16561737|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
16561720|NCT02870322|Active Comparator|Fruit and Vegetable CSA Prescription|"Study participants randomized to the CSA group will be expected to pick up their weekly CSA box at University Health Services and to commit to using and consuming as much of the produce as they are able. CSA group participants will also be required to attend two cooking and food preparation classes coordinated by Slow Food UW. The classes will teach study participants how to properly clean and prepare the fruits and vegetables from a weekly CSA box, and also offer techniques and show them how to cook the foods in a healthy manner. These classes will also educate study participants on the benefits of eating fruits and vegetables and buying them from local farmers. These two classes will only exist for study participants in this fruit and veggie CSA group. Participants in the CSA group will also be required to take a field trip to the farm providing their CSA share, which will offer the opportunity for participants to gain a better understanding of from where their food comes."
16561721|NCT02870322|Active Comparator|Bikeshare Prescription|"Study participants randomized to the bikeshare group will be expected to use B-cycle bikes for transportation and/or recreation as much as is safe and appropriate. Bikeshare group participants will be required to attend one bicycle use/safety course. This course will introduce the B-cycle program, demonstrate use of the B-cycle station, provide information use of helmets and safety gear, and provide information on the basics of cycling and keeping yourself safe and comfortable while riding in traffic. The study participants in this group will also be required to attend a class on the benefits of exercise, including bicycling, among other forms of physical activity. This class will be offered by the University Health Services Wellness program. B-cycle usage, including estimated distance traveled and frequency of use, will be tracked via the B-cycle Madison website."
16561722|NCT02870322|No Intervention|Control|"Study participants in the control group will receive continued usual care from University Health Services providers, which includes educational brochures on healthy eating and exercising, plus a cash payment. Control group participants are not part of a wait-list group."
16561724|NCT02870296|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
16561725|NCT02870296|Experimental|Intervention|Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
16561726|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
~Group (A) Started Lithium (900mg-1500mg)
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.
~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).
~Non responsive patients: 3rd step.
~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).
~Non responsive patients: 4th step.
~Fourth step: Association with risperidone (1-6mg)"
16561727|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
~Group (B) Started Valproic Acid (1000mg-1500mg).
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.
~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.
~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.
~Fourth step: Association with risperidone (1-6mg)"
16561728|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
~Group (C) Started Carbamazepine (600mg-1200mg).
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.
~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.
~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.
~Fourth step: Association with risperidone (1-6mg)"
16561729|NCT02870270||Head and neck cancer patients|Patients with head and neck cancer who were ≥ 18 years old and had ≥ 16 teeth and no removable prosthesis or dental implants consisting of more than one teeth were included
16561730|NCT02870257|Experimental|Progressive overload strengthening group|"Strengthening protocol with progressive load
~Strengthening muscle exercises for the shoulder and scapular with progressive increase of load during 10 weeks (20 sessions)"
16561731|NCT02870257|Active Comparator|Strengthening group|"Strengthening protocol without progressive load
~Strengthening muscle exercises for the shoulder and scapular without increase of load (minimal load) during 10 weeks (20 sessions)"
16561732|NCT02870244|Experimental|Escalating Doses|Three patients will be treated at the first & each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level & an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.
16561733|NCT02870231|Experimental|NNC9204-0530 / Placebo and Liraglutide 1.8|
16561734|NCT02870231|Active Comparator|NNC9204-0530 /Placebo and Liraglutide 3.0|
16561735|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
16561736|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
16562363|NCT02865954|No Intervention|Standard Care|Standard Care - control group
16561738|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
16561739|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
16561740|NCT02870218|Experimental|Halo G6 & Tribeca e-liquid|"Difference detection assessments.
~Nicotine discrimination thresholds"
16561741|NCT02870218|Experimental|Spectrum Research Cigarette|"Difference detection assessments.
~Nicotine discrimination thresholds"
16561742|NCT02870205|Experimental|GSP 301 NS|
16561743|NCT02870205|Active Comparator|GOM-NS|
16561744|NCT02870205|Active Comparator|GMM-2 NS|
16561745|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
16561746|NCT02870192|Experimental|Rectal Prolapse|Patients with rectal prolapse, who will underwent laparoscopic ventral mesh rectopexy. The implemented mesh may be synthetic or biological.
16561747|NCT02870179||Healthy volunteer|Smoker or non-smoker
16561748|NCT02870153|Experimental|SOX(oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
16561749|NCT02870153|Active Comparator|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
16561750|NCT02870140|Experimental|SUPRAFLEX|Percutaneous Coronary Intervention with the SUPRAFLEX Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
16561751|NCT02870140|Active Comparator|XIENCE|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
16561752|NCT02870101|Other|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
16561753|NCT02870088|Active Comparator|Prolonged Sitting|Participants sat on a chair during the trial.
16561754|NCT02870088|Experimental|Breaking Sitting|Participants walked regularly during the trial.
16561755|NCT02870075|Active Comparator|Fed exercise|Fed prior to exercise
16561756|NCT02870075|Active Comparator|Fasted exercise|Fasted prior to exercise
16561757|NCT02870062|Experimental|Chlorhexidine|Intervention: daily baths with chlorhexidine wipes, oral spray and shampoo. This arm will receive daily bathing with chlorhexidine wipes at 2% (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México) plus an oral spray application of chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied.
16561758|NCT02870062|Placebo Comparator|Placebo|Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
16561759|NCT02870049|Experimental|Inreach strategy|This consists of a community health worker-delivered in clinic education regrading CRC screening with a fecal immunochemical test (FIT) kit, and telephone reminders.
16561760|NCT02870049|Experimental|Outreach strategy|This consists of mailed invitations to complete screening with an enclosed fecal immunochemical test (FIT) kit and telephone reminders.
16561761|NCT02870049|Experimental|Both Inreach and Outreach strategies|This is a combination of the above two strategies: Inreach and Outreach combined.
16561762|NCT02870049|Active Comparator|Usual care|Usual care in the clinic using the fecal immunochemical test (FIT) kit.
16561763|NCT02870036|Experimental|Pharmacokinetic data investigation of Simmitecan|To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors
16561764|NCT02870036|Experimental|Dose escalation study of Simmitecan combined therapy|To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor
16561765|NCT02870036|Experimental|Dose extension study of Simmitecan monotherapy|To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)
16561766|NCT02870036|Experimental|Dose extension study of Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D
16561767|NCT02870036|Experimental|Dose escalation&extension Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with gastrointestinal tumors, and to determine RP2D and MTD
16561768|NCT02870036|Experimental|Dose extension study of Simmitecan combined therapy|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with specific tumors
16561769|NCT02870023|Experimental|Balance training|"All sessions will start with a ten minute warm-up on either a treadmill or a cycle.
~The balance intervention will be conducted in stations/domains where balance is challenged in the five different functions: standing, walking, sit to stand, stepping, and a station that exercises vestibular and gaze control.
~Progression is achieved by adding exercises with increased balance requirements and by adding additional motoric and cognitive tasks to the exercises-dual-tasking.
~Intensity of the exercises is defined from an error-rate where an adequate level is 20-40 percent.
~The intervention is conducted according to a standardized framework that describes examples of exercises and progressions."
16561808|NCT02869763|Experimental|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.
~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
16562058|NCT02867943||respiratory rate is 12 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
16561770|NCT02870023|Experimental|Strength training|"All sessions will start with a ten minute warm-up on a stationary bicycle, followed by strength training of primary muscle synergies in the lower extremities. All exercises will be performed on machines with patients sitting or lying, adequately supported. The exercises are leg press, knee extension, hip flexion, hamstring curl, and hip extension. Exercises are performed with a fast concentric phase and a slow eccentric phase..
~Set, repetition, and load:
~Weeks 1 and 2, 3 sets of 10 repetitions at a load of 15 repetitions maximum (RM)
~Weeks 3 and 4, 3 sets of 12 repetitions at a load of 12RM
~Weeks 5 and 6, 4 sets of 12 repetitions at a load of 12RM
~Weeks 7 and 8, 4 sets of 10 repetitions at a load of 10RM
~Weeks 9 and 10, 4 sets of 8 repetitions at a load of 8RM."
16561771|NCT02870023|No Intervention|Control group|On a waitlist. After ten weeks of waiting, and intervention that contains 50 percent strength training and 50 percent balance training begins.
16561772|NCT02870010|Experimental|non-metastatic hepatocellular carcinoma|"Radiation : Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
~Biological : blood samples (5 ml) will be taken"
16561773|NCT02869997|Experimental|Single arm|arm wherein all patients Suppression Ratio evaluated by BIS will be collected
16561774|NCT02869984|Experimental|Treatment|ramosetron treatment for 4 weeks from 1mo after anterior resection for rectal cancer
16561775|NCT02869984|No Intervention|Control|No treatment
16561776|NCT02869971|Experimental|Embolization|Prostatic Arteries Embolization
16561777|NCT02869971|Active Comparator|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
16561778|NCT02869958|Active Comparator|1: Written action plan|Written action plan
16561779|NCT02869958|Experimental|2: Digital action plan|Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
16561780|NCT02869945|Other|COMT HH|COMT HH gene
16561781|NCT02869945|Other|COMT HL|COMT HL gene
16561782|NCT02869945|Other|COMT LL|COMT LL gene
16561783|NCT02869932|Other|Atypical and classic cystic fibrosis|Lung CT scan without injection
16561784|NCT02869919||Patients with AKI|critically ill patients with acute kidney injury
16561785|NCT02869919||Patients without AKI|critically ill patients without acute kidney injury
16561786|NCT02869906||FFR and iFR|The investigators compare FFR and iFR values in the acute phase of STEMI and in the subacute phase, 5-7 days after STEMI.
16561787|NCT02869893|Other|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
16561788|NCT02869880|Active Comparator|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial.
16561789|NCT02869880|Experimental|Enhanced Pre-consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
16561790|NCT02869867|No Intervention|Qutenza® without refrigerated cushion|Qutenza® without refrigerated cushion
16561791|NCT02869867|Experimental|Qutenza® with refrigerated cushion|Qutenza® with refrigerated cushion
16561792|NCT02869854|Active Comparator|PAP only|This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
16561793|NCT02869854|Active Comparator|Mindfulness only|Mindfulness. This group will receive a group course in mindfulness during 8 weeks once a week, and with 20 minutes of daily personal training. Three and six months after inclusion they will answer a new set of surveys and fasting blood samples.
16561794|NCT02869854|Experimental|Combination of the two groups|Mindfulness and physical activity prescription. This group will get a combination of the two other groups. PAP will be prescribed during the first meeting and another one after 3 months. During the first 8 weeks once a week they will participate in a mindfulness training group and also preform 20 minutes of daily training. The same surveys as the other groups and fasting blood samples
16561795|NCT02869841|Active Comparator|Continuous rectus sheath analgesia|Local anesthetic continuous infusion with infusion pumps
16561796|NCT02869841|Active Comparator|Bolus rectus sheath analgesia|Bolus administration of local anesthetic
16561797|NCT02869841|Active Comparator|Single dose rectus sheath analgesia|single dose administration of local anesthetic
16561798|NCT02869841|Placebo Comparator|Placebo|no rectus sheath analgesia
16561799|NCT02869828|Other|monitoring by arterial catheter and Spot-on|
16561800|NCT02869828|Other|monitoring by oesophagus tube and Spot-on|
16561801|NCT02869815||ICG+Methylene Blue|"ICG+Methylene Blue:
~Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery."
16561802|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy at baseline and an optional tumour biopsy at disease progression.
~Participants will undergo serial collection of plasma and serum samples."
16561803|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.
~Participants will undergo serial collection of plasma and serum samples."
16561804|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
16561805|NCT02869776|Experimental|Rapid finger stick|HIV and HCV testing through rapid finger stick. Behavioral questionnaires will also be administered.
16561806|NCT02869776|Experimental|Standard venipuncture|HIV and HCV testing through venipuncture. Behavioral questionnaires will also be administered.
16561807|NCT02869763|Experimental|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.
~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
16561849|NCT02869412|Active Comparator|Group II (passive website)|Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
16561809|NCT02869763|Placebo Comparator|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
16561810|NCT02869750||Obese PCOS|PCOS patients with BMI more than 25 kg/m2
16561811|NCT02869750||Lean PCOS|PCOS patients with BMI less than 25 kg/m2
16561812|NCT02869750||PCOS with normal HOMA2-1R|PCOS without Insuline resistance
16561813|NCT02869750||PCOS with elevated HOMA2-IR|PCOS with Insuline resistance
16561814|NCT02869724|Active Comparator|Weekly divided delivery|Hospitalized for voluntary drug intoxications.
16561815|NCT02869724|Active Comparator|Monthly divided delivery|Hospitalized for voluntary drug intoxications.
16561816|NCT02869698|Experimental|Evaluation of cognitive functions by Spectral Dynamic Imaging|Evaluation of cognitive functions by SDI will be conducted during the exploration SEEG (which usually lasts from 1 to 3 weeks), and started a few days after implantation of intracranial electrodes
16561817|NCT02869685|Other|a prospective, open,phase I clinical study|We have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
16561818|NCT02869672|Experimental|age of 18-50 years old, experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
16561819|NCT02869672|Active Comparator|age of 18-50 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
16561820|NCT02869672|Experimental|age of 7-17 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
16561821|NCT02869672|Active Comparator|age of 7-17 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
16561822|NCT02869672|Experimental|age of 2-6 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
16561823|NCT02869672|Active Comparator|age of 2-6 years old,control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
16561824|NCT02869659|Active Comparator|Control/Delayed Weight Loss Group|"Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program.
~No outcome data will be collected at the end of the delayed weight loss phase."
16561825|NCT02869659|Experimental|Weight Loss Group|"Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study.
~This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day.
~Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity.
~Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start."
16561828|NCT02869633|Experimental|Treatment (ibrutinib)|Beginning between 60-90 days post donor stem cell transplant, patients receive ibrutinib PO QD until 1 year post donor stem cell transplant in the absence of disease progression or unacceptable toxicity.
16561829|NCT02869620||Patients with thyroid cancer diagnosis|
16561830|NCT02869607||Patients with breast cancer diagnosis|
16561831|NCT02869594||Patients with prostate cancer diagnosis|
16561832|NCT02869581||Patients with diagnosis of Pancreatic neoplasms|
16561833|NCT02869568||Patients with ovarian cancer diagnosis|
16561834|NCT02869555||Patients with multiple myeloma diagnosis|
16561835|NCT02869542||Patients with lymphoma diagnosis|
16561836|NCT02869529||Chronic lymphatic leukemia diagnosis|
16561837|NCT02869516||Patient with new diagnosis of Acute Leukemia|
16561838|NCT02869503||Patients with colorectal cancer diagnosis|
16561839|NCT02869490||Patients with cervical cancer diagnosis|
16561840|NCT02869477||Patients with cardia cancer diagnosis|
16561841|NCT02869464||Patients presenting with IA|These patients will undergo an abdominal ultrasound (Imaging - Ultrasound) to test for abdominal aortic aneurysm(s). RNA, DNA testing will be planned on banked samples
16561842|NCT02869464||Patients presenting with AAA|These patients will undergo a non-contrast enhanced magnetic resonance angiogram (MRA) (Imaging - MRA) to test for intracranial aneurysm(s). RNA, DNA testing will be planned on banked samples
16561843|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
16561844|NCT02869438|Experimental|Benralizumab arm|Benralizumab administered subcutaneously
16561845|NCT02869438|Placebo Comparator|Placebo arm|Placebo administered subcutaneously
16561846|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
16561847|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
16561848|NCT02869412|Experimental|Group I (BCG website)|Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
16561880|NCT02869165|Experimental|Apricot kernel oil|One teaspoonful per vagina every night for 3 months.
16561850|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
16561851|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
16561852|NCT02869386|Experimental|STEMO deployment|STEMO is a specialized stroke ambulance providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
16561853|NCT02869386|Active Comparator|Regular care|Regular prehospital care consists of an ambulance. In suspected life-threatening cases an emergency physician is sent to the emergency scene in parallel.
16561854|NCT02869373|Experimental|Exercise|spinal stabilization exercise program was applied
16561855|NCT02869373|No Intervention|Control|
16561856|NCT02869360||Multiple Sclerosis (MS) patients|4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
16561857|NCT02869360||Healthy Controls|4 Healthy volunteers aged between 18-60 years of age
16561858|NCT02869347|Active Comparator|Conestat alfa|Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
16561859|NCT02869347|Placebo Comparator|Sodium chloride 0.9%|Intravenous injection of sodium chloride 0.9%.
16561860|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
16561861|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
16561862|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
16561863|NCT02869321|Experimental|Fentanyl|"Administration of Morphine Sulfate Placebo and Fentanyl
~Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy
~+
~Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy
~Administration 1+2 if pain after 4 hours from gastrostomy"
16561864|NCT02869321|Placebo Comparator|Morphine Sulfate|"Administration of Morphine Sulfate and Fentanyl Placebo
~Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy
~+
~Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy
~Administration 1+2 if pain after 4 hours from gastrostomy"
16561865|NCT02869308|Other|Myocardial angioscintigraphy|
16561866|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
16561867|NCT02869282||Prospective cohort|Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
16561868|NCT02869269||Early stage|patients who diagnosed as TNM stage 1 and 2
16561869|NCT02869269||Late stage|patients who diagnosed as TNM stage 3 and 4
16561870|NCT02869243|Experimental|hrBMP4|Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium
16561871|NCT02869230|Other|Radioguided occult lesion localization|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
16561872|NCT02869230|Experimental|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
16561873|NCT02869217|Experimental|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.
~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.
~TBI-1301 cells will be infused on Day 0 at a dose of 5x10^9 cells.
~*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
16561874|NCT02869217|Experimental|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.
~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.
~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10^9 cells."
16561875|NCT02869204|Experimental|Leucocyte - Platelet rich Plasma and Dietary Supplements|"An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.
~A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30"
16561876|NCT02869204|No Intervention|Treatment as usual|Patients are treated as usual.
16561877|NCT02869191||blood cultures|Admitted patients in critical care who need blood cultures
16561878|NCT02869191||blood cultures Getafe|Data collection of patients included in study
16561879|NCT02869165|Experimental|Conjugated equine estrogen topical cream|The conjugated equine estrogen topical vaginal cream 0.5 grams per vagina two times per week at nights for 3 months.
16561881|NCT02869152|Experimental|Intraoperative sentinel lymph node mapping|Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
16561882|NCT02869139|Experimental|Package of mentholated measures|Package of mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
16561883|NCT02869139|Active Comparator|Package of non-mentholated measures|Package of non-mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
16561884|NCT02869126|Experimental|Patients|Patients with abnormalities of myocardial perfusion detected with stress tomoscintigraphy, undergo double isotope myocardial tomoscintigraphy using Thallium-201 and 99mTc-sestamibi and traditional myocardial tomoscintigraphy using 99mTc-sestamibi with a semiconductor camera
16561885|NCT02869113|Experimental|Sunscreen agent A + control|Application of control and test product into one of the subjects two eyes.
16561886|NCT02869113|Experimental|Sunscreen agent B + control|Application of control and test product into one of the subjects two eyes.
16561887|NCT02869113|Experimental|Sunscreen agent C + control|Application of control and test product into one of the subjects two eyes.
16561888|NCT02869100|Experimental|Spondyloarthritis Patients|
16561889|NCT02869087|Experimental|Single Group|Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold
16561890|NCT02869074||VWD Spanish Cohort|"Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.
~Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene"
16561891|NCT02869061|Experimental|ADRC injection|Subjects will be undergone liposuction under local anesthesia. Adipose-derived regenerative cells (ADRC) will be isolated from lipoaspirate by enzymatic digestion. Transurethral bladder neck resection followed by the injection of ADRC suspension will be performed. This is a single arm study with no control. All patients receive cell therapy.
16561892|NCT02869048||ALS patients|Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
16561893|NCT02869048||Control group with patients with other neurological disease|Patients referred to hospital with symptoms of acute or chronic headache.
16561894|NCT02869048||Neurologically healthy control group|Patients having orthopaedic surgery performed in spinal anaesthesia.
16561895|NCT02869035|Experimental|Treatment of MDD patients|Treatment of MDD patients with escitalopram
16561896|NCT02869035|No Intervention|Healthy controls|No treatment.
16561897|NCT02869035|Experimental|Shift of treatment for MDD patients|Treatment of MDD patients with duloxetine
16561898|NCT02869022|Experimental|Custodiol-N|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
16561899|NCT02869022|Active Comparator|Custodiol|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
16561900|NCT02869009|Experimental|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
16561901|NCT02869009|Experimental|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
16561902|NCT02868996|Experimental|Low dose (Part A)|Recombinant human tissue kallikrein
16561903|NCT02868996|Experimental|Medium low dose (Part A)|Recombinant human tissue kallikrein
16561904|NCT02868996|Experimental|Medium high dose (Part A)|Recombinant human tissue kallikrein
16561905|NCT02868996|Experimental|High dose (Part A)|Recombinant human tissue kallikrein
16561906|NCT02868996|Experimental|Subcutaneous (Part B)|Recombinant human tissue kallikrein
16561907|NCT02868996|Experimental|IV (Part B)|Recombinant human tissue kallikrein
16561908|NCT02868983|Experimental|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:
~A. Identification B. Assessment C. Treatment D. Surveillance"
16561909|NCT02868983|No Intervention|Co-Location|A Behavioral Health Clinician (BHC) such as a psychologist or counselor is housed in or near the primary care practice.
16561910|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
16561911|NCT02868957|Active Comparator|Impression data from reference scanner|desktop scanner was used as a reference scanner. According to the data of the manufacturer, the accuracy is less than 20 µm and the scan points more than 100,000.
16561912|NCT02868957|Experimental|Trios|"Trios is a scanner with real time rendering type adopting the confocal principle, and scans the object while showing the scanned area on a screen.
~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of Trios intra-oral scanner."
16561913|NCT02868957|Experimental|iTero|"iTero captures teeth and periodontal soft tissue using a red laser beam and parallel confocal imaging technology. This system with a focal depth of 300 can capture up to 100,000 of laser points, and each of such laser points is separated at a 50 mm gap.
~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of iTero intra-oral scanner."
16561914|NCT02868944|Experimental|experimental group|sequential combined spinal epidural with local anesthetic injection associated with morphine
16561915|NCT02868944|Active Comparator|control group|sequential combined spinal epidural with local anesthetic injection alone
16561953|NCT02868697|Active Comparator|A|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of of all Hemodialysis sessions and during all interdialytic periods
16561916|NCT02868931|Experimental|INPUT|INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump. Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life. Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
16561917|NCT02868931|No Intervention|Waiting list|Patients are randomly assigned to the waiting list. After completion of the 6-month follow-up, these patients will also receive training with INPUT.
16561918|NCT02868918|Experimental|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
16561919|NCT02868918|Active Comparator|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
16561920|NCT02868905|Other|Control group|Control group
16561921|NCT02868905|Other|Obese group|Obese group
16561922|NCT02868905|Other|Non-obese AD group|Non-obese AD groups
16561923|NCT02868905|Other|Obese AD group|Obese AD group
16561924|NCT02868892|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
16561925|NCT02868879||Schizophrenia|
16561926|NCT02868879||Normal controls.|
16561927|NCT02868866|Experimental|Immediate intervention|Training of church committee followed by 12 months of technical assistance phone calls.
16561928|NCT02868866|No Intervention|Delayed intervention|20 churches are followed but receive no intervention.
16561929|NCT02868853|Experimental|Photo App|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile dietary tracking application(Photo App). This Photo App allows participants to track meals by taking photos.
16561930|NCT02868853|Active Comparator|Diet App|Participants in this group will receive podcasts twice weekly in conjunction with an app (Diet App) to track their diet by entering in foods and beverages consumed.
16561931|NCT02868840|Experimental|Tai Chi group|Tai Chi exercise, twice a week, one hour per session. participated in Tai Chi either while seated or standing upon their comfort level.
16561932|NCT02868840|Active Comparator|Symptom management group|manage stroke symptom through phone and text message along with other rehabilitation therapy.
16561933|NCT02868827|Experimental|Cholecalciferol|This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
16561934|NCT02868827|Placebo Comparator|Placebo|This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
16561935|NCT02868814|Experimental|330mg/day|330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
16561936|NCT02868814|Experimental|495mg/day|495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
16561937|NCT02868814|Placebo Comparator|Placebo|1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
16561938|NCT02868801|Placebo Comparator|Placebo|placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
16561939|NCT02868801|Experimental|Pregabalin SR tablet 165mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
16561940|NCT02868801|Experimental|Pregabalin SR tablet 330mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
16561941|NCT02868801|Experimental|Pregabalin SR tablet 660mg/day|2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
16561942|NCT02868788|Other|high fat high calorie|Subjects in this arm will receive high fat high calorie meal
16561943|NCT02868788|Experimental|high fat high calorie plus fiber|Subjects in this arm will receive high fat high calorie meal plus dietary fiber supplementation
16561944|NCT02868775||Interstitial cystitis/bladder pain syndrome|These are the patients that will be evaluated in this study.
16561945|NCT02868749|Experimental|Hyaluronic Acid filler 1 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery
~Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery"
16561946|NCT02868749|Active Comparator|Hyaluronic Acid filler 2 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery
~Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery"
16561947|NCT02868736||Suspected Periprosthetic Joint Infection|Individuals who are suspected of having Periprosthetic Joint Infection (PJI)
16561948|NCT02868723|No Intervention|Control; standard of care|All the subjects enrolled in this arm will receive counseling as the usual standard of care by the stroke neurologists. These will include procedures and guidelines as approved by American Heart Association (AHA), follow up and guidance as offered by Hamad General Hospital's policies.
16561949|NCT02868723|Active Comparator|Intervention; Lifestyle counselling: Behavioural|Subjects in this group will receive a more detailed guidance on rigorous management of stroke and will be provided assistance from a stroke trained nurse and pharmacist additional to the counseling offered by the Stroke Neurologist.
16561950|NCT02868710|Experimental|Individualized method|"3 days a week of exercise at the following intensity and energy expenditure:
~Week 1: HR > VT1; 5.6 kcal/kg/wk Week 2: HR > VT1; 8.4 kcal/kg/wk Week 3: HR > VT1; 11.2 kcal/kg/wk Week 4: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 5-6: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 7: HR ≥ VT1 to <VT2; 12.6 kcal/kg/wk Week 8: HR ≥ VT1 to <VT2; 14 kcal/kg/wk Week 9-10: HR ≥ VT2; 14 kcal/kg/wk Week 11-12: HR ≥ VT2; 15.4 kcal/kg/wk"
16561951|NCT02868710|Experimental|Standardized method|"3 days a week of exercise at the following intensity and energy expenditure:
~Week 1: 40-45% HRR; 5.6 kcal/kg/wk Week 2: 40-45% HRR; 8.4 kcal/kg/wk Week 3: 40-45% HRR; 11.2 kcal/kg/wk Week 4: 50-55% HRR; 11.2 kcal/kg/wk Week 5-6: 55-60% HRR; 11.2 kcal/kg/wk Week 7: 55-60% HRR; 12.6 kcal/kg/wk Week 8: 55-60% HRR; 14 kcal/kg/wk Week 9-10: 60-65% HRR; 14 kcal/kg/wk Week 11-12: 60-65% HRR; 15.4 kcal/kg/wk"
16561952|NCT02868710|No Intervention|Control|"non-exercise control group
~Testing at baseline and post-program (12 weeks)"
16561954|NCT02868697|Experimental|B|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of the first two session only per week and during first two interdialytic periods then TauroLock U 25000at the end of third session before week end, (over the week end).
16561955|NCT02868684||mild traumatic brain injury|
16561956|NCT02868684||Healthy controls|
16561957|NCT02868671|Experimental|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), RN4 (Guan Yuan), ST36 (Zusanli) (front treatment) or Du20, GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 6 required points, acupuncturist will be allowed to choose 4 more points. The 4 supplemental points may be chosen from the following: LR2 (Xin Jian), HT7 (Shenmen), PC6 (Neiguan), GB34 (Yang Ling Quan), GB39 (Xuan Zhong), SI3 (Hou Xi), RN6 (Qi Hai), RN24 (Cheng Jiang),KI 3 (Taixi), KI 6 (Zhao Hai), ST40 (Feng Long), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL19 (Dan Shu), BL20 (Pi Shu), BL60 (Kun Lun). Auricular acupuncture will be employed.
16561958|NCT02868671|Sham Comparator|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. In the sham procedure, a needle guiding tube will be tapped on the surface of the skin near, but not on, each of the 10 acupuncture points that would have been selected for true acupuncture. The needle guiding tube will be used to create sensations that mimic needle manipulation.
16561959|NCT02868671|No Intervention|No Intervention|All participants in this study will receive usual care. For those assigned to true acupuncture and sham acupuncture, the usual care will be in addition to their acupuncture.
16561960|NCT02868658|Experimental|Health-care workers|Health-care workers recruited in the study will have blood sampling and naso-pharyngeal bottle-brush sampling
16561961|NCT02868645|Experimental|Patients with bone fibrous dysplasia|Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
16561962|NCT02868645|No Intervention|Control subjects|Control subjects will have no intervention
16561963|NCT02868632|Experimental|Cohort A: MEDI4736 + SBRT|MEDI4736 10 mg/kg IV every 2 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
16561964|NCT02868632|Experimental|Cohort B:Tremelimumab + SBRT|Tremelimumab 10 mg/kg IV every 4 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
16561965|NCT02868632|Experimental|Cohort C: MEDI4736 + Tremelimumab + SBRT|MEDI4736 + Tremelimumab (recommended phase 2 IV dose for combination) plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 16 Subjects
16561966|NCT02868619|Other|Healthy controls|Non obese adolescents without Binge Eating Disorder (BED)
16561967|NCT02868619|Other|Patients with BED|Obese adolescents with BED with Binge Eating Disorder (BED)
16561968|NCT02868606||Historical control group (H)|Winthrop patients with diabetes hospitalized between August 1, 2010 and March 31, 2011
16561969|NCT02868606||Intervention group (I)|Winthrop patients with diabetes hospitalized between August 1, 2011 and March 31, 2012
16561970|NCT02868606||Parallel control group (P-sub-H)|Patients with diabetes hospitalized between August 1, 2010 and March 31, 2011 at 7 control hospitals located in the New York City metropolitan region
16561971|NCT02868606||Parallel control group (I-sub-H)|Patients with diabetes hospitalized between August 1, 2011 and March 31, 2012 at 7 control hospitals located in the New York City metropolitan region
16561972|NCT02868593|Experimental|Patient with clinical meningitis or meningo-encephalitis|
16561973|NCT02868580|Experimental|Single arm open label|All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg
16561974|NCT02868567|Experimental|Ampyra|Ampyra open label
16561975|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
16561976|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
16561977|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
16561978|NCT02868541||Haaj pilgrim|Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
16561979|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
16561980|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
16561981|NCT02868515|Experimental|Oatmeal containing beta-glucan|43 g cereal containing 3g fiber per serving
16561982|NCT02868502||Trabeculectomy|Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
16561983|NCT02868502||Ahmed Glaucoma Valve implantation|Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
16561984|NCT02868502||Cyclophotocoagulation|Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
16561985|NCT02868502||Ocular hypotensive eye drops|"Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.
~IOP measurement in different positions."
16561986|NCT02868502||Ocular Hypertension|"Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..
~IOP measurement in different positions."
16561987|NCT02868502||Control|"Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.
~IOP measurement in different positions."
16562020|NCT02868177|Experimental|Totum-63|The studied active product is a food supplement formula in shape of capsule which contains Totum-63 (a patented mixture of dry extracts from 5 plants), active ingredient of Valedia
16562021|NCT02868177|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging in which all ingredients are replaced by maltodextrin.
16561988|NCT02868489|Experimental|Proprietary Blend - LactoWise®|After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
16561989|NCT02868489|Placebo Comparator|Control|For the control group, prior to surgery and after consenting to enroll in the study participants will also be asked to complete the Gastrointestinal Quality of Life Index. Participants of the control group will be administered their supply of a matching placebo. They will be required to take 1 capsule per day at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
16561990|NCT02868450|Experimental|Patients with HLA-DQB1 06 and/or HLA-DRB 13|
16561991|NCT02868437|Active Comparator|Group 1|The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure
16561992|NCT02868437|No Intervention|Group 2|The patients who are having curettage for retained product after second trimester abortion will receive no intervention
16561993|NCT02868424|Experimental|fRPE cells|Subretinal transplantation of fRPE cells in experimental eye
16561994|NCT02868411|Experimental|Patients admitted for traveller's fever|
16561995|NCT02868385|Active Comparator|Control group (A)|1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
16561996|NCT02868385|Experimental|Intervention group (B)|4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.
16561997|NCT02868372|Active Comparator|Betadine group|Subcutaneous tissues of cesarean section wounds are swabbed with10% undiluted Povidone Iodine solution without mobbing before closure of subcutaneous tissues
16561998|NCT02868372|No Intervention|No intervention group|No swabbing of subcutaneous tissue of cesarean section wounds
16561999|NCT02868359||Pregabalin / Other analgesics|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
16562000|NCT02868359||Other analgesics|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
16562001|NCT02868346|Experimental|Patients admitted for sexually transmitted infection|
16562002|NCT02868320|Experimental|Intervention group|This group received a diabetes instruction booklet in addition to daily educational SMS messages and weekly reminders
16562003|NCT02868320|Active Comparator|Control group|This group only received a diabetes instruction booklet
16562004|NCT02868307|Experimental|Patient prsenting schizophrenia|
16562005|NCT02868294|Experimental|Patient receiving the Fassier-Duval Nail|Implementation of a telescopic system intramedullary
16562006|NCT02868281|Experimental|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for >=3 months then step-down the treatment; if ACT score >=20, <25 or ACT=25 for <3 months then there will be no change and if ACT score less than (<=) 19 then step-up the treatment.
16562007|NCT02868281|Active Comparator|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
16562008|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
16562009|NCT02868255||Ascites|"30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
16562010|NCT02868255||Resections|"30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
16562011|NCT02868255||blood samples|"blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
16562012|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
16562013|NCT02868229|Experimental|COR-001|
16562014|NCT02868229|Placebo Comparator|Placebo|
16562015|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
16562016|NCT02868216|No Intervention|Without management training|No anger management training
16562017|NCT02868203|Active Comparator|OCT at 3 months|OCT at 3 months and 12 OCT at 3 months
16562018|NCT02868203|Active Comparator|OCT at 6months|OCT at 6 months and 12 OCT at 3 months
16562019|NCT02868190|Other|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
16562022|NCT02868164|Experimental|Fecal Microbiota Transplantation (FMT)|
16562023|NCT02868164|Active Comparator|Weight Reduction|
16562024|NCT02868151|No Intervention|GROUP A|Standard treatment followed in the regional cancer center for prevention and treatment of oral mucositis during chemo radiotherapy of cancers. 20% Benzocaine 15grms. twice daily for the entire treatment period
16562025|NCT02868151|Experimental|GROUP B|"Ascorbic acid oral supplementation 1g four times daily for the entire treatment period of 30 days and after treatment by tapering the dose of the drug to half for another month. The drug has to be started 2 days prior to initiation of treatment of cancer.
~Subdivided into 2 groups , 30 patients in each : sub group 1: only radiotherapy patients, subgroup 2 includes concurrent chemo-radiotherapy patients."
16562026|NCT02868151|Experimental|GROUP C|Zinc acetate tablets 50mg orally
16562027|NCT02868112|Experimental|Transdisciplinary Intervention|"Patients randomized to the Transdisciplinary Intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool.
~-Investigators will test a two-visit Transdisciplinary Intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit."
16562028|NCT02868112|Active Comparator|Usual Care|Participants receiving Usual Oncology Care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
16562029|NCT02868099|Placebo Comparator|Placebo|Subjects received placebo for injection treatment will be administered subcutaneously once a week
16562030|NCT02868099|Experimental|Drug|Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week
16562031|NCT02868086|Experimental|Tested patients|Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography
16562032|NCT02868086|Active Comparator|Control patients|Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans
16562033|NCT02868073|Experimental|H1N1 (high dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
16562034|NCT02868073|Experimental|H1N1 (low dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
16562035|NCT02868073|Placebo Comparator|Placebo Tablets|Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
16562036|NCT02868060|Experimental|1 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
16562037|NCT02868060|Experimental|3 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
16562038|NCT02868047||Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination with suspected chronic pancreatitis
16562039|NCT02868047||NOT Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination without suspected chronic pancreatitis.
16562040|NCT02868034|Experimental|SMT Only|Patients receive 2 sessions on SMT during week 1, no additional treatment.
16562041|NCT02868034|Experimental|SMT extended|2 sessions of SMT in week 1 and 6 additional sessions of SMT during weeks 2-4.
16562042|NCT02868034|Experimental|SMT with Activation Exercises|2 sessions of SMT during week 1 and 6 additional sessions of lumbar multifidus activating exercises during weeks 2-4.
16562043|NCT02868034|Experimental|SMT with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of spinal mobilizing exercises during weeks 2-4.
16562044|NCT02868034|Experimental|SMT with Mobilizing and Activation Exercises|2 sessions of SMT during week 1; 6 sessions of lumbar multifidus activating exercises and spinal mobilizing exercises during weeks 2-4.
16562045|NCT02868034|Experimental|SMT extended with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and spinal mobilizing exercises during weeks 2-4.
16562046|NCT02868034|Experimental|SMT extended with Activation Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and lumbar multifidus activating exercises during weeks 2-4.
16562047|NCT02868034|Experimental|SMT extended with Activation and Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT, multifidus activating and spinal mobilizing exercises during weeks 2-4.
16562048|NCT02868021|Placebo Comparator|NO-EX group|Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.
16562049|NCT02868021|Experimental|EX-BFR group|Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.
16562050|NCT02868008|Experimental|fMRI guided AVM resection|fMRI guided microsurgical resection of brain AVMs
16562051|NCT02867995|No Intervention|Control|No glaucoma drop aid control
16562052|NCT02867995|Active Comparator|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
16562053|NCT02867982|Other|Subcrestal|implants that are placed below the alveolar ridge
16562054|NCT02867982|Other|Paracrestal|implants that are placed flush to the alveolar ridge
16562055|NCT02867969|Other|Motor training|The motor training comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
16562056|NCT02867956|Experimental|Apatinib + Etoposide|"Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles."
16562057|NCT02867943||respiratory rate is 10 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
16641422|NCT02338739|Active Comparator|SMS; Outreach if Failure|
16562059|NCT02867943||respiratory rate is 14 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
16562060|NCT02867943||respiratory rate is 16 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
16562061|NCT02867930|Active Comparator|Group D|Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
16562062|NCT02867930|Active Comparator|Group KF|Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
16562063|NCT02867917|Other|Total group|Volcolon sugar free & Metamucil Orange & Psyllium Orange in a randomized order.
16562064|NCT02867904|Placebo Comparator|Group A|After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
16562065|NCT02867904|Experimental|Group B|After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.
16562066|NCT02867891||Chemotherapy alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
16562067|NCT02867891||Chemotherapy/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
16562068|NCT02867891||Sorafenib alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
16562069|NCT02867891||Sorafenib/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
16562070|NCT02867878|Experimental|Adenosine|Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
16562071|NCT02867878|Placebo Comparator|Saline solution|Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
16562072|NCT02867865|Active Comparator|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.
~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
16562073|NCT02867865|Experimental|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.
~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
16562074|NCT02867852|Experimental|Abiraterone acetate|Abiraterone acetate 1 g/day must be taken as four 250-mg tablets daily on an empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Prednisone (prednisolone when prednisone is not available) 5 mg will be given orally twice a day.
16562075|NCT02867839|Experimental|A: postoperative Oxaliplatin plus S-1|"Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.
~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40~60mg bid, po, d1~14, q3W (6 months)"
16562076|NCT02867839|Active Comparator|B: postoperative S-1 only|"Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.
~S-1: 40~60mg bid, po, d1~14, q3W (12 months)"
16562077|NCT02867826|Experimental|Cap-assisted endoscopy|forward-viewing endoscope with a Cap attached at the tip
16562078|NCT02867813|Experimental|evolocumab (AMG 145)|All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.
16562079|NCT02867800|Experimental|Standard GVHD Prophylaxis + Abatacept|"Subjects will receive
~premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)
~immunosuppression (Alemtuzumab, or Thymoglobulin)
~conditioning regimen (Fludarabine, Thiotepa, and Melphalan)
~GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0."
16562080|NCT02867787|Experimental|Botox arm|intramuscular injection of botulinum toxin
16562081|NCT02867774|Experimental|Intervention|This pilot study will enroll 25 women age 18-65 with greater than six months of noncyclic pelvic pain. Subjects will participate in an 8-week physical activity program specifically designed for patients with chronic pain and supervised by personal trainers and exercise physiologists in a rehab-focused, medically-based fitness center. Subjects will complete web-based assessment tools at the start of the program, immediately after completion of the 8-week program and four weeks after the conclusion of the program (at the 12-week time point).
16562082|NCT02867761|Active Comparator|Indacaterol/Glycopyrrolate|indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily for 12 weeks
16562083|NCT02867761|Placebo Comparator|Placebo|Placebo 27.5/15.6 mcg inhaled twice daily for 12 weeks
16562084|NCT02867748|Experimental|1|TVT-Abbrevo
16562085|NCT02867748|Experimental|2|Serasis
16562086|NCT02867735|Experimental|LKA651|
16562087|NCT02867735|Sham Comparator|Sham Comparator|
16562088|NCT02867722|Experimental|Daylight PDT|Patients will receive daylight-PDT treatment (aminolevulinic acid)
16562089|NCT02867709|Experimental|Ubrogepant 25 mg|1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
16562090|NCT02867709|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
16562157|NCT02867215|Active Comparator|Barley bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
16562091|NCT02867709|Placebo Comparator|Placebo|1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
16562092|NCT02867696|Active Comparator|Standard Care|Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
16562093|NCT02867696|Experimental|Technology-based Intervention (TECH)|TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.
16562094|NCT02867683|Experimental|Vibrotactile Feedback|Balance exercises completed while vibration was applied to the trunk (anterior, posterior, right, and left) if postural sway exceeded a pre-determined threshold during the exercise.
16562095|NCT02867683|No Intervention|Without Vibrotactile Feedback|Balance training without feedback
16562096|NCT02867670||Transcranial Magnetic Stimulation of Motor Cortex|All study participants will receive real TMS stimulation over the primary motor cortex in order to collect physiological measures which will later be correlated with measures of neuroplasticity. There is NO placebo stimulation.
16562097|NCT02867670||Transcranial Magnetic Stimulation of Language Cortex|All study participants will receive real TMS stimulation over the language cortex and a control site (i.e. vertex). Transient changes in speech production will be recorded and compared to measures of neuroplasticity. There is NO placebo stimulation.
16562098|NCT02867657|Experimental|Mindfulness in nature|A five day mindfulness retreat in nature
16562099|NCT02867657|Active Comparator|Mindfulness indoor|A five day mindfulness retreat indoor
16562100|NCT02867657|No Intervention|Wait list control|A wait list control group, that 6 months later is offered a two-day mindfulness retreat in nature
16562101|NCT02867644|Active Comparator|standard care|
16562102|NCT02867644|Experimental|standard care+conversational hypnosis|
16562103|NCT02867631|No Intervention|Enhanced control|Regular care as provided by the community based organization from which the convenience sample is recruited with one year of assessments only
16562104|NCT02867631|Experimental|Intervention|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
16562105|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
16562106|NCT02867605|Other|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
16562107|NCT02867592|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16562108|NCT02867579|Other|women with denial pregnancy|women with denial pregnancy
16562109|NCT02867579|Other|women without denial pregnancy|women without denial pregnancy
16562110|NCT02867566|Experimental|IBI301|IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
16562111|NCT02867566|Active Comparator|Rituximab|Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
16562112|NCT02867553|Experimental|Rituximab by intravenous|attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
16562113|NCT02867553|Active Comparator|multi-field radiotherapy|multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
16562114|NCT02867540|Experimental|experimental group|Patient's with Crohn's disease who have had ileocolic resection
16562115|NCT02867514|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
16562116|NCT02867514|Sham Comparator|sham tDCS on left DLPFC (F3)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
16562117|NCT02867514|Active Comparator|anodal tDCS on right DLPFC (F4)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
16562118|NCT02867514|Sham Comparator|sham tDCS on right DLPFC (F4)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
16562119|NCT02867501||Aneurysmatic disease|Patients with dilatative arteriopathy (DA) the aortic diameter must be > 3 cm or the popliteal artery diameter > 1.5 cm
16562120|NCT02867501||Peripheral arterial occlusive disease|Patients with arterial occlusive disease (PAOD) defined with an Ankle brachial index (ABI) < 0.9 and positive criteria in the Edinburgh questionnaire.
16562121|NCT02867501||Healthy|Control group of age matched persons without PAOD (ABI > 0.9) and without DA.
16562122|NCT02867475|Other|A|Physical activity motivation
16562123|NCT02867462|Other|A-Standard Care|standard care
16562124|NCT02867462|Experimental|B-manipulator consultation radiotherapy added to standard care|manipulator consultation radiotherapy added to standard care
16562125|NCT02867449|Experimental|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
16562126|NCT02867449|Experimental|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
16562127|NCT02867436|Experimental|Gluten-free diet|Gluten-free diet
16562128|NCT02867436|No Intervention|Conventional diet|Conventional diet
16562129|NCT02867423|Other|A - CK boost radiation|CK boost radiation
16562130|NCT02867397|Other|Teysuno (S1) in combination with epirubicin and oxaliplatin|
16562158|NCT02867215|Active Comparator|Wheat bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
16562362|NCT02865954|Experimental|iball intervention|Use of iball pelvic floor training mhealth application for 16 weeks.
16562131|NCT02867384|Active Comparator|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.
~Premedication with histamine blockers and acetaminophen will be provided
~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
16562132|NCT02867384|Sham Comparator|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.
~Premedication with histamine blockers and acetaminophen will be provided
~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
16562133|NCT02867371|Experimental|-Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
16562134|NCT02867358|Active Comparator|High dose of KT07 capsule|It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).
16562135|NCT02867358|Active Comparator|Low dose of KT07 capsule|It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).
16562136|NCT02867358|Placebo Comparator|Placebo|It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.
16562137|NCT02867345||Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
16562138|NCT02867345||Comparable group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 wild-type T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
16562139|NCT02867332|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
16562140|NCT02867332|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment."
16562141|NCT02867319|Experimental|age of 18-50 years old|
16562142|NCT02867319|Experimental|age of 7-17 years old|
16562143|NCT02867319|Experimental|age of 2-6 years old|
16562144|NCT02867306|Experimental|ASP1707 and methotrexate (MTX)|On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadministered on Day 8.
16562145|NCT02867293|Active Comparator|Preop-drainage|ascites drained over the pre-operative week through multiple ultrasound guided paracentesis
16562146|NCT02867293|Active Comparator|Op-drainage|ascetic fluid drained through an abdominal incision after anesthesia
16562147|NCT02867280|Experimental|Sorafenib|Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
16562148|NCT02867280|No Intervention|Control|No use of Sorafenib (Nexavar). Regular treatment.
16562149|NCT02867267|Experimental|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
16562150|NCT02867267|Placebo Comparator|Placebo|1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
16562151|NCT02867254||Groups1|15 patients with type 2 diabetes mellitus with periodontal endodontic lesions
16562152|NCT02867254||Groups 2|15 non-diabetics with periodontal endodontic lesions
16562153|NCT02867241|Experimental|Intervention|"Motivational interviews (3 visits) + supportive phone calls
~Feedback of child hair nicotine levels
~Feedback of home air quality (PM2.5)
~New Media (Website and/or Facebook with information and parental forum)"
16562154|NCT02867241|Other|Control Regular|This group will get no intervention during the study period. Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
16562155|NCT02867241|Other|Control Expanded|This group will get no intervention during the study period. However, participants will fill out a detailed questionnaire on parental perceptions of exposure and risk, as well as questions on social norms, self-efficacy, and knowledge Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
16562156|NCT02867228|Other|Single Observational Group|Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.
16562159|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
16562160|NCT02867202|Experimental|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
16562161|NCT02867189|Experimental|atlas of micro-instrument|anterior chamber cell counts and visual and intraocular pressures on postoperative days 1,3,7,14 by atlas of micro-instrument training method.
16562162|NCT02867189|No Intervention|traditional training|anterior chamber cell counts and visual and intraocular pressures on postoperative days1,3,7,14 by traditional training method.
16562163|NCT02867176|Other|Corneal collagen CXL epi-off|For the epithelium-off procedure, the corneal epithelium is removed with a 10-minute soak time with isotonic riboflavin 0.1% solution and 4 minutes of exposure with 30 mw/cm2 ultraviolet-A irradiation.
16562164|NCT02867176|Other|Corneal collagen CXL epi-on|For the epithelium-on procedure, riboflavin is applied for a total soak of 4 minutes; the cornea is then completely rinsed with additional riboflavin for a total of 6 minutes. The ultraviolet-A irradiation is performed for 2 minutes and 40 seconds at 45mw/cm2.
16562165|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
16562166|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
16562167|NCT02867137||Mild TBI patients|
16562168|NCT02867124|Experimental|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
16562169|NCT02867124|Active Comparator|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
16562170|NCT02867111|Other|ICSI Control|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with no intervention of the Sperm Selection Assay
16562171|NCT02867111|Placebo Comparator|ICSI + SSA placebo|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with control solution (culture medium)
16562172|NCT02867111|Experimental|ICSI + SSA Attractant substance|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with attractant solution (attractant diluted in culture medium at 10 pM)
16562173|NCT02867098|Experimental|Cohort 1|Dose Level 1 XmAb5871 given SC Q14days X 3
16562174|NCT02867098|Experimental|Cohort 2|Dose Level 2 XmAb5871 given SC Q14days X 3
16562175|NCT02867098|Experimental|Cohort 3|Dose Level 3 XmAb5871 given SC Q14days X 3
16562176|NCT02867098|Experimental|Cohort 4|Dose Level 4 XmAb5871 given IV Q14days X 3
16562177|NCT02867098|Experimental|Cohort 5|Dose Level 5 XmAb5871 given SC Q7days X 3
16562178|NCT02867085||Group 1 (MDS group)|
16562179|NCT02867085||Group 2 (control group)|
16562180|NCT02867072|Active Comparator|Open appendectomy|Subjects that underwent open surgery for appendicitis
16562181|NCT02867072|Active Comparator|Laparoscopic appendectomy|Subjects that underwent laparoscopic surgery for appendicitis
16562182|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
16562183|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
16562184|NCT02867046|Experimental|medial approach group|
16562185|NCT02867046|Active Comparator|lateral approach group|
16562186|NCT02867033|Other|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
16562187|NCT02867020|Active Comparator|Abiraterone acetate + Prednisone + ADT (Goserelin)|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)
~Prednisone administered at a 5 mg twice daily oral dose
~Goserelin administered as subcutaneous injections of 10.8mg every 3 months"
16562188|NCT02867020|Experimental|APALUTAMIDE monotherapy|o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)
16562189|NCT02867020|Experimental|Abiraterone acetate + Prednisone + APALUTAMIDE|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)
~Prednisone administered at a 5 mg twice daily oral dose
~APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)"
16562190|NCT02867007|Experimental|KHK2455 + Mogamulizumab|"Part 1 (Dose Escalation Part): Will identify the MTD for the KHK2455 monotherapy run-in and for the combination regimen (KHK2455 monotherapy [Cycle 0] followed by KHK2455 +mogamulizumab combination [Cycle 1]).
~Part 2 (Expansion Part): Subjects with a selected tumor type will be enrolled and treated with the recommended dose of KHK2455 established in Part 1 in combination with mogamulizumab."
16562191|NCT02866994|Experimental|Project Connect Online (PCO)|Creation of personal website to share breast cancer experience with friends and family
16562192|NCT02866994|Experimental|PCO PLUS|Creation of personal website to share breast cancer experience with friends and family, as well as other women diagnosed with breast cancer
16562193|NCT02866981|Experimental|Observation|Patients that meet all inclusion and exclusion criteria are monitored every 2 months for two years or until a therapeutic intervention is warranted.
16562194|NCT02866968|Experimental|Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|All patients included will undergo FLAPS in one eye.
16562195|NCT02866955|Other|GROUP E (Estramustine)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine
16562196|NCT02866955|Other|GROUP T (Tamoxifen)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen
16562197|NCT02866942|Experimental|Asthma|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
16562198|NCT02866929|Active Comparator|Conventional orthodontic treatment|Patients that will receive conventional orthodontics
16562199|NCT02866929|Experimental|Orthodontics with decortication|Patients that will receive orthodontic treatment with selective alveolar decortication
16562200|NCT02866929|Experimental|Orthodontics decortication and Mucograft|Orthodontic treatment, selective alveolar decortication and Mucograft® on the mandibular anterior segment
16562201|NCT02866929|Experimental|Orthodontics and Mucograft®|Patients that will receive orthodontic treatment and Mucograft® on the mandibular anterior segment
16562202|NCT02866916|Experimental|Dose escalation|"The standard method 3+3 will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01.
~Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent.
~Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase."
16562203|NCT02866903|Experimental|Patients with peritoneal carcinosis|Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
16562204|NCT02866890|Experimental|Laryngeal Tube Suction size 1|Measurement of leak pressure
16562205|NCT02866890|Experimental|Laryngeal Tube Suction size 2|Measurement of leak pressure
16562206|NCT02866890|Experimental|Laryngeal Tube Suction size 2.5|Measurement of leak pressure
16562207|NCT02866877||Subarachnoid Hemorrhage|
16562208|NCT02866864||Subjects with animal allergy|Subjects who suffer from allergic symptom during contact with animal
16562209|NCT02866864||Subjects without animal allergy|Subjects who do not suffer from allergic symptom during contact with animal
16562210|NCT02866851|Experimental|Monitoring by Web application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
16562211|NCT02866838|Experimental|Tranexamic acid|Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.
16562212|NCT02866838|Placebo Comparator|Placebo|Saline 0.9% given in identical dosage as experimental
16562213|NCT02866825|Active Comparator|IFX-1|dose escalating single i.v. administration of IFX-1 (verum)
16562214|NCT02866825|Placebo Comparator|Placebo|dose escalating mimicing single i.v. administration of placebo
16562215|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
16562216|NCT02866799|Experimental|Multi-PAP intervention|Complex intervention with general practitioners and patients
16562217|NCT02866799|Active Comparator|Usual care|Patients will receive the usual clinical care
16562218|NCT02866786|Active Comparator|OCP only arm|OCP containing 35 microgram ethinyl estradiol and 2 milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
16562219|NCT02866786|Active Comparator|Metformin arm|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
16562220|NCT02866773|Experimental|PA1:Education sessions, Reminders, Whataps group|The intervention includes Physical activity knowledge enhancement session, Physical activity anti-inertia Reminders , Physical activity ambassadors' electronic communication group.
16562221|NCT02866773|Active Comparator|PA2:Education sessions, Reminders|The intervention includes Physical activity knowledge enhancement session and Physical activity anti-inertia Reminders
16562222|NCT02866773|Active Comparator|PA3:Education sessions, Whataps group|The intervention includes Physical activity knowledge enhancement session and Physical activity ambassadors' electronic communication group.
16562223|NCT02866773|Active Comparator|PA4:Education sessions|The intervention includes Physical activity knowledge enhancement session only.
16562224|NCT02866773|Experimental|HD1:Education sessions, Reminders, Whataps group|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , Health diet ambassadors' electronic communication group.
16562225|NCT02866773|Active Comparator|HD2:Education sessions, Reminders|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , and Health diet ambassadors' electronic communication group.
16562226|NCT02866773|Active Comparator|HD3:Education sessions, Whataps group|The intervention includes Health diet knowledge enhancement session and Health diet ambassadors' electronic communication group.
16562227|NCT02866773|Active Comparator|HD4:Education sessions|The intervention includes Health diet knowledge enhancement session only.
16562228|NCT02866747|Active Comparator|Arm A: radiation therapy alone|Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.
16562229|NCT02866747|Experimental|Arm B: combined treatment|"hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.
~* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I."
16562230|NCT02866734|Active Comparator|Free screening group|Subjects in this group receive free diabetic retinopathy screening.
16562231|NCT02866734|Active Comparator|Pay screening group ($150)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$150.
16562232|NCT02866734|Active Comparator|Pay screening group ($300)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$300.
16562233|NCT02866721|Experimental|Human Allogeneic Mesenchymal Stem Cells|"One time IV Infusion of up to 5 x 10^6 allogeneic hMSCs/kg of body weight. A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
16562234|NCT02866708|Experimental|Intermittent negative pressure (INP) therapy|"At baseline, the participants will be randomized into 2 groups: 1) INP therapy or 2) control with no INP therapy.
~The 1) patients randomized to INP therapy will start with 8 weeks INP therapy two hours per day divided into timed sections (1-3 times per day or use the device as many times as practical for the individual as long as the total time is two hours). After 8 weeks of INP therapy, final measures will be performed at the Vascular lab before the participants starts their 8-week control period."
16562235|NCT02866708|No Intervention|Control|The participants randomized to control will continue their usual wound care for 8 weeks without INP therapy. The control group will start INP therapy after 8 weeks. After 8-weeks without intervention, the participants allocated to the control-group will be asked to start with INP therapy for 8 weeks before a final examination. The participants in the control group will receive vascular assesment at baseline, week 8 (end of control).
16562236|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
16562237|NCT02866682|Other|Brand Tacrolimus Only : Prograf|Arm 1 will receive brand tacrolimus for the entire study
16562238|NCT02866682|Other|Generic A Only|Arm 2 will receive specific generic tacrolimus for the entire study
16562239|NCT02866669|Active Comparator|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
16562240|NCT02866669|Experimental|Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
16562241|NCT02866669|Experimental|Peer coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
16562242|NCT02866669|Experimental|Peer coach and Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. The patients will also be matched with peer advisors who will work with the participants for 12 months.
16562243|NCT02866656|Experimental|control group|patients were given Conventional conservative treatment；
16562244|NCT02866656|Experimental|therapeutic ultrasound group|patients were given Conventional conservative treatment and low intensity ultrasonic treatment ；
16562245|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
16562246|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
16562247|NCT02866630||Cardiopulmonary bypass (Sevoflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of sevoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
16562248|NCT02866630||Cardiopulmonary bypass (Desflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of desflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
16562249|NCT02866617|Experimental|Conventional|T1-T2 : VFR constructed on conventional study model T2-T3 : VFR constructed on 3D reconstructed study model
16562250|NCT02866617|Experimental|3D|T1-T2 : VFR constructed on 3D reconstructed study model T2-T3 :VFR constructed on conventional study model
16562251|NCT02866604|Active Comparator|Strerofundin|Days of intervention: 3 days
16562252|NCT02866604|Active Comparator|0.9% saline|Days of intervention: 3 days
16562253|NCT02866591|Experimental|Arm A|Patients have a mammography performed by themselves according to auto-compression procedure. The radiologist leads the compression at a minimum threshold of 40 Newton, then leaves the control of the compression to the patient. The radiologist treats only the positioning of the breast on the sensor.
16562254|NCT02866591|Active Comparator|Arm B|Patients have a mammography performed by the radiologist according to standard procedure.
16562255|NCT02866578|Experimental|Open lung protective ventilation|"Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.
~PEEP at 8 cmH2O.
~Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.
~Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
16562256|NCT02866578|No Intervention|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
16562257|NCT02866565|Experimental|Diabetic foot ulcer|
16562258|NCT02866552|Placebo Comparator|PLACEBO|Patients will receive an injection of placebo
16562259|NCT02866552|Experimental|DRUG : Stromal Vascular Fraction|Patients will receive an injection of Stromal Vascular Fraction injection
16562260|NCT02866539|Active Comparator|Polyherbal capsule|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
16562261|NCT02866539|Placebo Comparator|Placebo|Placebo will contain an inert substance
16562262|NCT02866526||group1|adolescents (14-17 years old)
16562263|NCT02866526||group 2|young adults (20-29 years old)
16562264|NCT02866513|Other|Patient mechanically ventilated with APRV mode|
16562265|NCT02866500|Experimental|oral cancer|
16562266|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history
~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
16562267|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
16562268|NCT02866474|Other|- Puteaux or Paris for elderly persons|
16562269|NCT02866474|Other|-Two EHPAD in Lyon for elderly persons living|
16562270|NCT02866461||Fibromyalgia|No treatment
16562271|NCT02866448|Placebo Comparator|Vehicle control|"Subjects will consume
~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid
~1 x 75mg cellulose pill"
16562272|NCT02866448|Experimental|Isoquercetin|"Subjects will consume
~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid
~1 x 75mg cellulose pill"
16562273|NCT02866448|Active Comparator|Aspirin|"Subjects will consume
~1 x 75mg dispersible aspirin
~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid"
16562274|NCT02866448|Experimental|Isoquercetin plus Aspirin|"Subjects will consume
~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid
~1 x 75mg dispersible aspirin"
16562275|NCT02866435|Experimental|Euglycemia pre-conditioning|Participants will undergo two euglycemia (normal blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where the target glucose during the clamp will be 95 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
16562276|NCT02866435|Experimental|Hypoglycemia pre-conditioning|Participants will undergo two hypoglycemia (low blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where target glucose during the clamp will be 50 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
16562277|NCT02866422||OCD|
16562278|NCT02866422||Healthy Controls|
16562279|NCT02866409|Experimental|Bupivacaine,dexmedetomidine scalp block|Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept < 2 mg /kg for scalp block
16562280|NCT02866409|Active Comparator|bupivacaine dexmedetomidine infiltration|The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
16562281|NCT02866409|Active Comparator|bupivacaine infiltration|The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
16562282|NCT02866396||Pregabalin patients|Same dose of preoperative pregabalin 1h after surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration (PACU if NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
16562283|NCT02866396||Naive patients|Pregabalin 150mg PO initiated 1h before surgery and associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
16562284|NCT02866383|Experimental|Nivolumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT and then every 2 weeks (q2w), for a maximum of 52 weeks
16562285|NCT02866383|Experimental|Nivolumab & Ipilimumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT. Thirty minutes after the completion of nivolumab infusion patients will receive ipilimumab 1 mg/kg over 90 minutes IV as an IV infusion. Nivolumab will be given every 2 weeks (q2w) and ipilimumab every 6 weeks (q6w), respectively for a maximum of 52 weeks
16562286|NCT02866370|Experimental|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously
16562287|NCT02866370|Active Comparator|Chemotherapy|"Ovarian Cancer Patients:
~Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days
~Endometrial Cancer Patients:
~Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days
~Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
16562320|NCT02866149|Other|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.
~One tumor sampling.
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
16562321|NCT02866149|Other|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
16562322|NCT02866149|Other|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib
~Timing of blood sampling:
~Inclusion day (2 samples)
~after #2 weeks of therapy
~after #4 weeks of therapy
~at progression."
16562288|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
16562289|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
16562290|NCT02866331|Experimental|CB + G-CSF|
16562291|NCT02866331|Placebo Comparator|CB + placebo|
16562292|NCT02866331|Experimental|G-CSF|
16562293|NCT02866331|Placebo Comparator|Placebo|
16562294|NCT02866318||Novice practitioners|Residents in Emergency department who has no experiences of echocardiography prior to the study.
16562295|NCT02866305|Experimental|HRCT with bullae, treatment conservative|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
16562296|NCT02866305|Experimental|HRCT no bullae, treatment conservative|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
16562297|NCT02866305|Experimental|HRCT with bullae, treatment VATS.|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
16562298|NCT02866305|Experimental|HRCT no bullae, treatment VATS.|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
16562299|NCT02866292||non-pregnant nulliparous|Nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
16562300|NCT02866292||primigravid|Pregnant women on her first pregnancy and gestational age above 14 weeks. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
16562301|NCT02866279|Experimental|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
16562302|NCT02866279|Experimental|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
16562303|NCT02866279|Active Comparator|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
16562304|NCT02866266||All commercially insured patients in the HIRD|
16562305|NCT02866266||All Medicaid patients in a participating state Medicaid plan|
16562306|NCT02866253|Experimental|DHEA Group|DHEA 25mg t.i.d. for more than 12weeks
16562307|NCT02866253|No Intervention|Control Group|patients without any DHEA
16562308|NCT02866240|Experimental|Single arm|Cathodal Transcranial Direct Current Stimulation (tDCS)
16562309|NCT02866227|Experimental|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
16562310|NCT02866227|Experimental|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
16562311|NCT02866214|Experimental|Group I|This Group of Patients will receive Febuxostat Drug along with their Standard Treatment.
16562312|NCT02866214|Placebo Comparator|Group II|This Group of Patients will receive Placebo along with their standard Treatment.
16562313|NCT02866201|Experimental|Patient suffering from traveler's diarrhoea|Patient suffering form traveler's diarrhoea during a stay (up to 3 months) outside metropolitan France
16562314|NCT02866175|Experimental|Edoxaban Regimen|Participants will be randomized to receive edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5 mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) used.
16562315|NCT02866175|Active Comparator|Vitamin K Antagonist Regimen|Participants will be randomized to receive VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) and aspirin (100 mg once-daily, for a minimum of 1 month and up to 12 months duration.
16562316|NCT02866162||patients with neutropenia|
16562317|NCT02866149|Other|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.
~Timing of blood sampling:
~inclusion
~after #8 weeks on therapy
~at progression or 6 months from inclusion for patient without progressive disease
~if toxicity grade 3 or 4, or grade 2 until 1 month."
16562318|NCT02866149|Other|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).
~Timing of blood sampling:
~inclusion
~after 1 cycle of therapy (weeks 3-4)
~up to 2 other samples, timepoints decided by the investigator"
16562319|NCT02866149|Experimental|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).
~One tumor sampling.
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
16562323|NCT02866149|Other|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
16562324|NCT02866149|Other|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
16562325|NCT02866149|Other|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.
~Blood sampling at 4 timepoints."
16562326|NCT02866149|Other|"Cohort 10 - Palbociclib II"|"Monitoring of patient with a metastatic breast cancer treated by palbociclib.
~Timing of blood sampling:
~Inclusion
~after #4 weeks of therapy
~at the first tumoral evaluation (month 3 or 4)
~at progression."
16562327|NCT02866149|Other|Cohort 11 - Sarcomas|The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.
16562328|NCT02866149|Other|Cohort 12 - Faslorad|"Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.
~Timing of blood sampling:
~Inclusion
~after #3-5 weeks of therapy
~at the first tumoral evaluation (month 2 or 3)
~at progression."
16562329|NCT02866149|Other|Cohort 13 - MUm|"The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).
~Timing of blood sampling:
~J1C1
~J2C1
~J1C2
~J1C5 (first tumoral evaluation)."
16562330|NCT02866149|Other|Cohort 14 - CNBC Snipe|"This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.
~One tumour sampling.
~Timing of blood sampling:
~before treatment
~at W8 of treatment (after radiological examination)
~at W12 of treatment
~at progression or 18 months after the beginning of treatment"
16562331|NCT02866149|Other|Cohort 15 - Breast CLI|"This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.
~Timing of blood sampling:
~At inclusion
~After biopsy post inclusion (or in 15 days after)
~after 1 or 2 months of treatment
~at progression or 18 months after inclusion"
16562332|NCT02866136|Other|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).
~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
16562333|NCT02866136|Other|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.
~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
16562334|NCT02866136|Other|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
16562335|NCT02866123|Experimental|patient with insertion of an NGT|
16562336|NCT02866110|Experimental|Treatment group|25 patients with BPD. In a diagnostic session, diagnostics of psychiatric disorders are conducted. For BPD diagnosis, the International Personality Disorder Examination (IPDE) is used and symptom severity is assessed with the Borderline Symptom List. The Treatment group will receive fMRI amygdala neurofeedback training (3 sessions within 2 weeks). Patients in regular psychotherapeutic treatment (treatment-as-usual) will not be excluded.
16562337|NCT02866097|Experimental|Intervention|mHealth inventory management and referrals via text messaging plus supportive supervision of CHWs via an mHealth strategy
16562338|NCT02866097|Placebo Comparator|Control|ICCM current standard of care with CHWs operating under standard conditions without enhanced inventory management or supportive supervision by mHealth
16562339|NCT02866084|Experimental|Device|Neuromodulation
16562340|NCT02866071|Active Comparator|Ketamine|50mg IN Ketamine Hydrochloride
16562341|NCT02866071|Placebo Comparator|Placebo|50mg IN placebo
16562342|NCT02866058||Cesarean|Mothers delivered by cesarean section
16562343|NCT02866058||Vaginal|Mothers delivered by vaginal delivery
16562344|NCT02866045|Active Comparator|EUS-guided Fine Needle Biopsy|EUS-FNB is performed using a 22 or 25 G SharkCore biopsy needle with a minimum of 3 passes into the lesion.
16562345|NCT02866045|Experimental|Single incision needle knife biopsy|SINK biopsy is performed under direct endoscopic visualization via EGD with a minimum of 3 biopsy samples obtained.
16562346|NCT02866032|Experimental|MOB015B|
16562347|NCT02866032|Active Comparator|Ciclopirox 80 mg/g|
16562348|NCT02866019|Experimental|CLS2702C/CLS2702D|
16562349|NCT02866006|Experimental|BVAC-C mono(High dose)|BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)
16562350|NCT02866006|Experimental|BVAC-C mono(Intermediate dose)|BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)
16562351|NCT02866006|Experimental|BVAC-C + Topo Combi|BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks
16562352|NCT02865993|Other|Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
16562353|NCT02865993|Other|No Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
16562354|NCT02865980|Experimental|inflammation|The effect of washing with betadine and clove extract on incidence of inflammation place logging shaldon catheter in the hemodialysis patients
16562355|NCT02865980|Experimental|infection|The effect of washing with betadine and clove extract on incidence of infection place logging shaldon catheter in the hemodialysis patients
16562356|NCT02865967|Experimental|Block1_Intervention|Usual care + a-GPS
16562357|NCT02865967|Other|Block1_Control|Usual Care
16562358|NCT02865967|Experimental|Block2_Intervention|Usual care + a-GPS
16562364|NCT02865941|Experimental|5 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.
~Routine fortifier will be added to breast milk batches.
~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
16562365|NCT02865941|Experimental|1 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.
~Routine fortifier will be added to breast milk batches.
~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
16562366|NCT02865928|Experimental|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivacaine HCl.
16562367|NCT02865928|Placebo Comparator|Normal Saline|Placebo injection on operated side, same technique as experimental group.
16562368|NCT02865915|Placebo Comparator|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
16562369|NCT02865915|Experimental|MLE4901|Plain, round, biconvex, white film-coated tablets administered twice per day
16562370|NCT02865902|Experimental|Test Group|In Test group, the free gingival graft donor sites of each experimental group received low-level laser therapy by Ezlase; Biolase® at doses of 8.6 J/cm2.
16562371|NCT02865902|Sham Comparator|Control Group|In Control Group, the low-level laser therapy by Ezlase; Biolase® was performedin a same manner with test group at free gingival graft donor sites. However, no irradiation was occurred because of not pushing the start button.
16562372|NCT02865889||Uterine oncologic Indications for surgery|
16562373|NCT02865876|Experimental|Accelerated Corneal Cross-linking|Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.
16562374|NCT02865876|Sham Comparator|Sham Accelerated Corneal Cross-linking|"Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted the impregnation phase applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged."
16562375|NCT02865863|Experimental|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
16562376|NCT02865863|Placebo Comparator|Placebo|
16562377|NCT02865850|Experimental|Vadadustat|
16562378|NCT02865850|Active Comparator|darbepoetin alfa|
16562379|NCT02865837|Experimental|ARM 1|
16562380|NCT02865824|Active Comparator|Continue thienopyridine|Patients continue dual antiplatelet therapy (DAT) before colonoscopy and all polyps are removed by cold snare polypectomy.
16562381|NCT02865824|Experimental|Discontinue thienopyridine|Patients discontinue thienopyridines for 1 week before colonoscopy and all polyps are removed by cold snare polypectomy.
16562382|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.
~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.
~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)
~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV
~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
16562383|NCT02865785|Active Comparator|Study Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20% (100 mL of intralipid 20% diluted in 250 mL sterile i.v. saline administered i.v. over two hours), once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
16562384|NCT02865785|Placebo Comparator|Placebo Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
16562385|NCT02865772||observational|healthy newborns
16562386|NCT02865759|Experimental|Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, in a brochure and at a website. The practice is described as spending 15 minutes every day from gestational week 28 to get to know the fetal movement pattern. The fetus must be awake when she practice Mindfetalness and the woman is suggested to lay on her left side when she observe the fetal movements. In the brochure as well at the website the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek health-care without unnecessary delay.
16562387|NCT02865759|No Intervention|Routine Care|No activities will take place in the antenatal clinics randomized to routine care.
16562388|NCT02865746|Active Comparator|Group betamethasone|Active Comparator: betamethasone disodium phosphate at a concentration of 4 mg / ml - dosage of 0.05 mg / kg
16562389|NCT02865746|Placebo Comparator|Group placebo|sterile saline solution (sodium chloride 0.9% - 1 ml ampoules) - dosage of 0.05 mg / kg
16562390|NCT02865733|Experimental|Remodulin Injection|Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
16562391|NCT02865733|Placebo Comparator|Distilled water group|Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours
16562392|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
16562393|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
16562394|NCT02865707|Experimental|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
16562395|NCT02865707|Placebo Comparator|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
16562396|NCT02865681|Active Comparator|Conventional IVF|Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
16562397|NCT02865681|Experimental|IVF protocol using nasal gonadotropins|Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
16562398|NCT02865668|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16562399|NCT02865668|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16562400|NCT02865668|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16562401|NCT02865668|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16562402|NCT02865655||CSD-TVU|Cesarean Section Scar Evaluation by TVU
16562403|NCT02865655||CSD-MRI|Cesarean Section Scar Evaluation by MRI
16562404|NCT02865655||CSD-MRI with saline|Cesarean Section Scar Evaluation by MRI with saline
16562405|NCT02865655||CSD-Hysteroscopic|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy
16562406|NCT02865642|Experimental|Serotonin Uptake Inhibitors|"Treatment 1: Starting with Escitalopram 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage increase of 5mg/day till target dose of Escitalopram 20mg/day.
~Subjects will remain on Escitalopram 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by dosage reduction of Escitalopram 10mg/day for one week."
16562407|NCT02865642|Placebo Comparator|Placebo|"Treatment 2: Starting with Placebo 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage of 5mg/day till target dose of Placebo 20mg/day.
~Subjects will remain on Placebo 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by Placebo 10mg/day for one week."
16562408|NCT02865629|Experimental|N-acetyl cysteine|Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
16562409|NCT02865616|Experimental|MET-2 Capsules|"Patients will be on vancomycin to control symptoms up until the time of the treatment.
~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.
~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.
~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..
~All patients will be followed up for 120 days after the last treatment has been received."
16562410|NCT02865603|Experimental|PAX Good Behavior Game|The intervention is delivered by teachers within the normal school curriculum. Teachers from intervention classes completed 3-day training and were supported by the mentor, who visited their class during the 2016/17 school year and provided counseling via e-mail and phone. During the second year (2017/18) teachers could use the PAX GBG methods, but they did not receive additional support from the mentors.
16562411|NCT02865603|No Intervention|Waitlist control group|Control group continue their normal activities without intervention. After a post-test assessment in spring 2018 the control group teachers will be trained and supported to implement PAX GBG.
16562412|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
16562413|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
16562414|NCT02865577||Adult asthma|"Adult asthma subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.
~Participants will undergo following study assessments:
~Clinical History
~Health status and disease control questionnaires
~Focused physical examination
~Electrocardiogram (ECG)
~Blood test
~Spirometry
~Echocardiogram
~Cardiac magnetic resonance (CMR) imaging
~CMR survey"
16562415|NCT02865577||Adult COPD|"Adult COPD subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.
~Participants will undergo following study assessments:
~Clinical History
~Health status and disease control questionnaires
~Focused physical examination
~Electrocardiogram (ECG)
~Blood test
~Spirometry
~Echocardiogram
~Cardiac magnetic resonance (CMR) imaging
~CMR survey"
16562416|NCT02865577||Healthy participants|"Healthy participants with no past history of cardiovascular or respiratory disease.
~Participants will undergo following study assessments:
~Clinical History
~Focused physical examination
~Electrocardiogram (ECG)
~Blood test
~Spirometry
~Echocardiogram
~Cardiac magnetic resonance (CMR) imaging
~CMR survey"
16562417|NCT02865564|Active Comparator|Intervention group|The intervention group will receive 5 drops, a minimum of 100 million live Lactobacillus reuteri DSM 17938 a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
16562418|NCT02865564|Placebo Comparator|Placebo group|Placebo group will receive 5 drops of maltodextrin in the some oil suspension a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
16562419|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
16562420|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
16562421|NCT02865538|Placebo Comparator|BAY3427080 Placebo|
16562422|NCT02865538|Experimental|50mg BAY3427080|
16562423|NCT02865538|Experimental|100mg BAY3427080|
16562424|NCT02865538|Experimental|150mg BAY3427080|
16562425|NCT02865538|Experimental|300mg BAY3427080|
16562426|NCT02865512|Active Comparator|supine position|thoracic epidural catheterization with supine position
16562427|NCT02865512|Active Comparator|flexed lateral position|thoracic epidural catheterization with flexed lateral position
16562428|NCT02865499|Experimental|acarbose|all participants will receive acarbose
16562429|NCT02865486|Experimental|Lipid emulsion: visit 2|One of four randomly assigned lipid emulsions
16562430|NCT02865486|Experimental|Lipid emulsion: visit 3|One of four randomly assigned lipid emulsions
16562431|NCT02865486|Experimental|Lipid emulsion: visit 4|One of four randomly assigned lipid emulsions
16562432|NCT02865473|No Intervention|primary open angle glaucoma patients|
16562433|NCT02865473|No Intervention|patients with primary angle closure|
16562434|NCT02865473|No Intervention|patients with neovascular glaucoma|
16562435|NCT02865473|No Intervention|PEX glaucoma patients|
16562436|NCT02865473|No Intervention|glaucoma patients with filtering bleb|
16562437|NCT02865473|Experimental|healthy volunteers|instillation of antiglaucoma treatment in the study eye
16562438|NCT02865460|Experimental|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
16562439|NCT02865460|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x 200 mg for 4 months) with food each morning-upon waking
16562440|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
16562441|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562442|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562443|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562444|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562445|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562446|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562447|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562448|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562449|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
16562474|NCT02865252|Sham Comparator|MWM sham|The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
16562475|NCT02865239|Placebo Comparator|Supine position|3.0 tesla MRI in supine position
16562476|NCT02865239|Active Comparator|Prone position|3.0 tesla MRI in prone position
16562450|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
16562451|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
16562452|NCT02865421|Experimental|Stem cells|adipose tissue derived stromal vascular fraction was used
16562453|NCT02865421|Experimental|platelet rich plasma|platelet rich plasma isolated after centrifugation from the pt was transplanted
16562454|NCT02865408|Active Comparator|Group 1: Peptamen 1.5% via enteral only|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard EN Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d
16562455|NCT02865408|Active Comparator|Group 2: Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive the same enteral feeding as group 1 (Peptamen 1.5) but in addition will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/d
16562456|NCT02865408|Active Comparator|Group 3: Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids (Prosol 20%) in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/day.
16562457|NCT02865395|Experimental|Pre-operative Suppository|A B&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
16562458|NCT02865395|Active Comparator|Post-operative Suppository|A B&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
16562459|NCT02865395|Placebo Comparator|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
16562460|NCT02865382|Active Comparator|Group A|white light was used for both insertion and withdrawal of the colonoscope
16562461|NCT02865382|Experimental|Group B|Insertion to cecum was performed under white light and once the cecum was reached,the OE mode was swithed on during withdrawal of endoscope for complete colonic examination
16562462|NCT02865369||Daclatasvir plus Asunaprevir treatment|Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography
16562463|NCT02865356|Experimental|Cyclosporine 5% Solution|"SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.
~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
16562464|NCT02865356|Placebo Comparator|Placebo|"SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.
~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
16562465|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
16562466|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
16562467|NCT02865317||Study group|Patients with obstetrical brachial plexus injury involving upper trunk (C5-6)
16562468|NCT02865304|Experimental|endostar; taxane|Endostar was administered at 7.5 mg/m2, d1-14, q21d and was continued until progressive disease, unacceptable toxicity, consent withdrawal, or completion of 24 months. In the same time,Taxane-based chemotherapy was continued until progressive disease, unacceptable toxicity, consent withdrawal, or up to 8 cycles.
16562469|NCT02865291|Experimental|ForConti device|Use the device up to 12 hours/day for 4 weeks
16562470|NCT02865278|Experimental|Polyphenol-rich drink|The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
16562471|NCT02865278|Placebo Comparator|Placebo drink|The participants consume the control drink.After 3 hours they consume a standard meal to evaluate the metabolic response after a placebo.
16562472|NCT02865265||Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.
~An ultrasound-guided ipsilateral PaB was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
16562473|NCT02865252|Active Comparator|MWM treatment|"Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.
~MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range."
16562477|NCT02865226|Experimental|experimental group|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
16562478|NCT02865226|Active Comparator|control group|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual)
16562479|NCT02865213|Experimental|Miniplates + OBA|"The intrusion of posterior teeth using Miniplates + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniplates.
~The miniplates are for Jeil Dual top® anchor system, Jeil medical corporation, #702,kolon science valley 2nd, 811, Guro-Dong, Guro-Gu, Seoul, 152-050, Korea. Tel: 82.2.850.3500. Fax: 82.2.850.3537. homepage: www.jeilmed.co.kr/ E-mail: mktg@jeilmed.co.kr"
16562480|NCT02865213|Experimental|Miniscrews + OBA|"The intrusion of posterior teeth using Miniscrews + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniscrews.
~The miniscrews are for Denxy ® dental orthodontic products, Denxy technology co, limited . 404,Lihuabuilding,Furongroad, Changsha, Hunan, China. Tel: 0086-731-89717339. Fax: 0086-731-82237315. Homepage: www.denxy-orthodontic.com/email: DENXYDENTALBOSS@126.COM"
16562481|NCT02865213|Experimental|Only OBA|The intrusion of posterior teeth using OBA only will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth only.
16562482|NCT02865200|Experimental|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique. The needles were kept on the body for 20 minutes and at the 10th minute, the needle was rolled and re-stimulation was enabled. The treatment was applied twice a week, which is equal to 6 sessions in total.
16562483|NCT02865200|Experimental|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again. The period of treatment was 6 sessions in total with 25 minutes of each.
~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
16562484|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
16562485|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
16562486|NCT02865174|Active Comparator|Topical tranexamic acid|Intraarticular application of tranexamic acid Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
16562487|NCT02865174|Active Comparator|Floseal®|"Floseal® was applied on potential bleeding sites before prosthesis implantation.
~Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay"
16562488|NCT02865174|Placebo Comparator|Control group|No intervention before closure of joint capsule. Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
16562489|NCT02865161||NISELAT|Amtolmetin guacil should be taken in fasting conditions. The recommended dose is 600 mg b.i.d. Maximum daily dose - 1800 mg
16562490|NCT02865148|Experimental|Cognitive behavioral therapy (CBT) group|Participants will receive 4 sessions that lasts approximately 50 mins. The sessions will teach patients to manage their symptoms.
16562491|NCT02865148|No Intervention|Waitlist control (WLC) group|The WLC group receives standard usual care before being offered the same CBT protocol and assessment thereafter.
16562492|NCT02865135|Experimental|DPX-E7 Vaccine|Subjects will 2 priming doses of DPX-E7 at a pre-determine dosage 3 weeks apart followed by a predetermine booster dose every 8 weeks until clinical progression.
16562493|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
16562494|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
16562495|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
16562496|NCT02865083|Active Comparator|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
16562497|NCT02865083|No Intervention|Standard|Patients will receive use of the standard of care option which is the montgomery straps
16562498|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
16562499|NCT02865070||10 babies (full term, ages 37-42 weeks)|
16562500|NCT02865070||5 babies (premature, ages 34-37 weeks)|
16562501|NCT02865070||5 babies (premature, ages 31-34 weeks)|
16562502|NCT02865070||5 babies (premature, ages 28-31 weeks)|
16562503|NCT02865070||5 babies (premature, ages 25-28 weeks)|
16562504|NCT02865070||5 babies (premature, ages 23-25 weeks)|
16562505|NCT02865070||30 babies (any gestational age under 6 months)|
16562506|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
16562507|NCT02865057||3rd year Residents|3rd year Ob, Gyn Residents
16562508|NCT02865057||4th Year Residents|4th year Ob, Gyn Residents
16562509|NCT02865044|Active Comparator|Wax Ester Marine Oil|Active: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules)
16562510|NCT02865044|Other|Ethyl Ester Marine Oil|Control: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule)
16562511|NCT02865031|Experimental|Decorin|Intravitreal injection of 200-400 ug of Decorin.
16562512|NCT02865018|Experimental|cetirizine|10mg oral each day
16562513|NCT02865005|Active Comparator|Dapsone 5.0% Gel (Allergan)|Dapsone 5.0% Gel applied twice daily for 84 days
16562514|NCT02865005|Experimental|Dapsone 5.0% Gel (SEEGPharm)|Dapsone 5.0% Gel applied twice daily for 84 days
16562515|NCT02865005|Placebo Comparator|Placebo|Vehicle of Experimental Gel applied twice daily for 84 days
16562516|NCT02864992|Experimental|Tepotinib|
16562517|NCT02864966|Other|Other|This is a safety study where a marketed product will be placed on healthy adult skin.
16562656|NCT02864069|Experimental|Walking Intervention|
16562518|NCT02864953|Experimental|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
16562519|NCT02864953|Placebo Comparator|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
16562520|NCT02864940|Experimental|Intervention Arm|Using the cognitive exercises on Lumosity for 10 weeks
16562521|NCT02864940|Active Comparator|Control Arm|Using online crossword puzzles for 10 weeks.
16562522|NCT02864927|Experimental|Menactra Group 1|Participants aged 9 to 23 months will receive 2 doses of Menactra
16562523|NCT02864927|Experimental|Menactra Group 2|Participants aged 2 to 55 years will receive 1 dose of Menactra
16562526|NCT02864901|Experimental|KSL-W 30 mg|3 times per day over 4 treatment days
16562527|NCT02864901|Placebo Comparator|Chewing Gum Placebo|3 times per day over 4 treatment days
16562528|NCT02864888|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
16562529|NCT02864888|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 24 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
16562530|NCT02864875|No Intervention|Control|Not to receive an early replacement of fibrinogen
16562531|NCT02864875|Experimental|Intervention|Receive early replacement through fibrinogen concentrate (50mg per kg of body weight)
16562532|NCT02864862|Active Comparator|Immediate implant|Immediate implant alone
16562533|NCT02864862|Active Comparator|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
16562534|NCT02864862|Active Comparator|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
16562535|NCT02864849|Experimental|TNT|"Patients with MRI defined high-risk rectal cancer will receive chemotherapy before and after chemoradiation, and will not receive adjuvant treatment. This arm is called total neoadjuvant treatment (TNT). The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX (Capecitabine+Oxaliplatin) over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.
~Finally, patients will receive TME (Total mesorectal excision) following TNT if no metastasis occurs."
16562536|NCT02864836||Patients with head or neck cancer|Samples collection
16562537|NCT02864836||Patients with lymphoma|Samples collection
16562538|NCT02864836||Patients without tumoral pathology|Samples collection
16562539|NCT02864823|Experimental|Perichondrium|Perichondrium Autografts
16562540|NCT02864810|Experimental|[18F]GP1 PET/CT imaging|"Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).
~Intravenous injection and PET/CT scanning of [18F]GP1"
16562541|NCT02864797|Experimental|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software.
16562542|NCT02864784|Experimental|Amorphous calcium carbonate|Subjects in this arm of the study will receive AMOR-1 tablets, containing 200 mg elemental calcium in addition to the standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
16562543|NCT02864784|Placebo Comparator|Placebo|Subjects in this arm of the study will receive Placebo tablets in addition to standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
16562544|NCT02864771||1|Derivation cohort (n=474); may be analyzed separately or combined with cohort #2 to enhance statistical power
16562545|NCT02864771||2|Validation cohort (patient #475 and after); may be combined with cohort #1 to enhance statistical power
16562546|NCT02864758||Group 1|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with rivaroxaban
16562547|NCT02864758||Group 2|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin k anatognists
16562548|NCT02864758||Group 3|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with dabigatran
16562549|NCT02864745|Experimental|Early rehabilitation arm|These patients will receive very early (<48 hours after ICU admission), protocolised, intensive rehabilitation, which will include functional electrical stimulation-assisted cycle ergometry.
16562550|NCT02864745|Active Comparator|Standard-of-care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
16562551|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
16562552|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
16562553|NCT02864719|Experimental|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
16562554|NCT02864706|Experimental|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
16562555|NCT02864706|Active Comparator|Control|patients received standard CsA, MMF and corticosteroids
16562556|NCT02864693|Active Comparator|Configuration A (Kinnex)|
16562557|NCT02864693|Active Comparator|Configuration B (Pacifica LP)|
16562558|NCT02864680|Other|Cannabis users|
16562559|NCT02864680|Other|Healthy volunteers, not cannabis/tobacco users|
16562560|NCT02864680|Other|Healthy volunteers, tobacco users|
16562561|NCT02864680|Other|Schizophrenia patients|
16562562|NCT02864654|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate Adipose-derived regenerative cells (ADRC). After isolation 10 mL of autologous ADRC suspension will be injected intramuscularly, close to the site of muscle injury. 10 to 20 injections will be performed so as to infiltrate the injured muscle
16562563|NCT02864641|Experimental|TX Group: Planet K Treatment|Participants in the TX Group will receive access to Planet K. Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Adolescent and young adult participants will then receive a mobile phone preloaded with the Planet K app and a brief orientation to the app and associated website.
16562564|NCT02864641|No Intervention|CO Group: Treatment-as-usual|A national sample of CKD participants will be recruited. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet K app and website but will receive email reminders to complete surveys online at each time point.
16562565|NCT02864628|Experimental|Group 1|≥55 year old healthy subjects, receiving either 5x10E7 TCID50 MVA-BN-RSV or Placebo intranasal application
16562566|NCT02864628|Experimental|Group 2|≥55 year old healthy subjects, receiving either 1x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
16562567|NCT02864628|Experimental|Group 3|≥55 year old healthy subjects, receiving either 5x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
16562568|NCT02864628|Experimental|Group 4|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intranasal and intramuscular application
16562569|NCT02864628|Experimental|Group 5|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intramuscular application
16562570|NCT02864615|Experimental|Stereotactic Body Radiation Therapy|Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
16562571|NCT02864602|Experimental|Dexamethasone 2mg|The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
16562572|NCT02864602|Experimental|Dexamethasone 4mg|The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
16562573|NCT02864602|Experimental|Dexamethasone 8mg|The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
16562574|NCT02864589|Experimental|I-HRT|Internet-delivered habit reversal training
16562575|NCT02864589|Experimental|I-ERP|Internet-delivered exposure and response prevention
16562576|NCT02864576|Experimental|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:
~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.
~Aerobic Exercise:
~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
16562577|NCT02864576|Active Comparator|Cognitive Remediation_Health Promotion|"Cognitive Remediation:
~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.
~Health Promotion:
~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
16562578|NCT02864563|Experimental|Prospective cohort|Experimental arm, prospective cohort
16562579|NCT02864550|Experimental|Doxycycline arm|Participants in this intervention group will receive doxycycline 100mg orally daily, which is available as a 100mg capsule. This single daily dose was chosen to maximize adherence, given the common use of once-daily Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), as well as its efficacy as once-daily prophylaxis against malaria and its utility as dosing as infrequent as once weekly for another spirochete infection, leptospirosis.
16562580|NCT02864550|Placebo Comparator|Placebo arm|Participants in this control group will receive a placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group.
16562581|NCT02864537|No Intervention|Conventional treatment|Conventional anticoagulation treatment Before enrolment
16562582|NCT02864537|Experimental|Self-management|Trained to monitor INR and dose warfarin
16562583|NCT02864524|Experimental|Manipulative and Massage Therapy|"Ten sessions (2/week):
~High speed and low amplitude technique to lower cervical spine (C3-C4).
~Dog technique flexion for high thoracic area (T1-T4).
~Dog technique flexion for mid-thoracic area (T5-T8).
~Dog technique flexed to low thoracic (T6-T12).
~Classic Massage Therapy during 40 minutes (2 time / week):"
16562584|NCT02864524|Active Comparator|Exercise Program|Ten sessions (2 time/ week): Initial heating and continuing with aerobic and muscle stretching exercises.
16562585|NCT02864511|Experimental|Intervention group|
16562586|NCT02864498|Experimental|1g Oral DS107|1g Oral DS107 to be administered once-daily for 8 weeks.
16562587|NCT02864498|Experimental|2g Oral DS107|2g Oral DS107 to be administered once daily for 8 weeks.
16562588|NCT02864498|Placebo Comparator|Placebo|Placebo orally administered once-daily for 8 weeks.
16562589|NCT02864485|Experimental|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
16562590|NCT02864472|Other|combination Tx|combination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
16562591|NCT02864472|Other|mono Tx|Ranibizumab (at 4 weeks interval) *3 (M0-2) + ranibizumab PRN (M3-6)
16562592|NCT02864459|Experimental|Muscular ultrasound|
16562593|NCT02864433||Controls for non-cholera diarrhea cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
16562594|NCT02864433||Non-cholera diarrhea cases|- Cases of acute watery diarrhea that present for healthcare at the study sites, but that test negative for cholera
16562595|NCT02864433||Controls for cholera cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
16562596|NCT02864433||Cholera cases|- Those with cholera-related diarrhea who present to healthcare at the study sites.
16562597|NCT02864420|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vitals and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
16562598|NCT02864420|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
16562599|NCT02864407||Vahelva group|Korean patients with COPD who are newly prescribed with Vahelva Respimat
16562600|NCT02864394|Experimental|Pembrolizumab|Participants with NSCLC receive pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
16562601|NCT02864394|Experimental|Docetaxel|Participants with NSCLC receive Docetaxel 75 mg/m^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue, or consent withdrawal.
16562602|NCT02864381|Experimental|Andecaliximab + Nivolumab|Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
16562603|NCT02864381|Active Comparator|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
16562604|NCT02864368|Experimental|5-day TMZ|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
16562605|NCT02864368|Experimental|21-day TMZ|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
16562606|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
16562607|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
16562608|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
16562609|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
16562610|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
16562611|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
16562612|NCT02864303|Other|Patients with Alzheimer disease|Saliva samples were collected on this patients
16562619|NCT02864277|No Intervention|No Intervention Conventional Strategy|Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
16562620|NCT02864277|Experimental|ERAS Group|ERAS (enhanced recovery after surgery)
16562621|NCT02864264|Experimental|Single Ascending Dose (SAD) - IV Panel|Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
16562622|NCT02864264|Experimental|Single Ascending Dose (SAD) - SC Panel|Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
16562623|NCT02864264|Experimental|Multiple Ascending Dose (MAD) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
16562624|NCT02864264|Experimental|Proof of Mechanism (POM) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
16562625|NCT02864251|Experimental|Nivolumab+Platinum doublet chemotherapy|
16562626|NCT02864251|Experimental|Nivolumab + Ipilimumab|Enrollment is closed for this arm
16562627|NCT02864251|Active Comparator|Platinum doublet chemotherapy|
16562628|NCT02864238||Pre intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2013 prior to the institution of the electronic milestone pathway
16562629|NCT02864238||post intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2014 after the electronic milestone pathway had been instituted
16562630|NCT02864225|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
16562631|NCT02864212||Glucose monitoring|Glucose will be monitor in patients using fast-acting insulin.
16562632|NCT02864212||Depth of anesthesia monitoring|Depth of anesthesia will be monitor in patients undergoing cardiac surgery.
16562633|NCT02864212||Blood pressure monitoring|Invasive blood pressure will be monitor in patients undergoing cardiac surgery.
16562634|NCT02864199|Experimental|Group A: Moderate Renal Impairment|Participants with CrCl 30 to 50 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 micrograms (mcg) via subcutaneous (SC) injection once weekly, in combination with ribavirin, 600 milligrams (mg) orally (PO) daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
16562635|NCT02864199|Experimental|Group B: Severe Renal Impairment|Participants with CrCl <30 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 400 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
16562636|NCT02864199|Experimental|Group C: Hemodialysis/ESRD|Participants requiring hemodialysis will receive 12 weeks of peginterferon alfa-2a, 135 mcg via SC injection once weekly, in combination with ribavirin, 200 mg PO every morning. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
16562637|NCT02864199|Experimental|Group D: Normal Renal Function|Participants with CrCl >80 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 800 to 1200 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
16562638|NCT02864186|Active Comparator|control|Women wont use support bra for six months
16562639|NCT02864186|Active Comparator|surgical support bra|Women will use surgical support bra 24 hours a day for six months
16562640|NCT02864186|Active Comparator|common support bra|Women will use common support bra 24 hours a day for six months
16562641|NCT02864160|Experimental|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
16562642|NCT02864160|Active Comparator|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
16562643|NCT02864147|Experimental|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
16562644|NCT02864147|Active Comparator|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
16562645|NCT02864147|No Intervention|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
16562646|NCT02864121|Experimental|arm 1|all patients included in IDAHO study
16562647|NCT02864108||Those with trisomy 21|People aged 6 months to 89 years old who have some form of trisomy 21.
16562648|NCT02864108||Controls|People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
16562649|NCT02864095|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
16562650|NCT02864095|Experimental|Topical epinephrine|Topical epinephrine
16562651|NCT02864095|Active Comparator|Control|No epinephrine
16562652|NCT02864082|Experimental|PAT-001 0.1%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
16562653|NCT02864082|Experimental|PAT-001 0.2%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
16562654|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.1% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
16562655|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.2% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
16562660|NCT02864056|Experimental|Tai Chi|Completes 50 hours of Tai Chi, a combination of in-class and at-home practise.
16562661|NCT02864043|Other|EGD with NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe following standard of care endoscopy
16562662|NCT02864030|Other|Single arm with Eribulin mesylate|
16562663|NCT02864017|Experimental|L-Citrulline group|Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
16562664|NCT02864017|Placebo Comparator|Control group|Enteral nutrition 5-day placebo treatment
16562667|NCT02863991|Experimental|ONC201|Single agent ONC201.
16562668|NCT02863978|Experimental|Digi-NewB Cohort|Multimodal signal acquisitions
16562669|NCT02863965||High definition endoscopy and optic enhancement|All the patients underwent routine preparation before the procedure. The detected lesions in high definition endoscopy were observed with optic enhancement mode. The endoscopist was required to give the real-time descriptions of surface pit patterns of the lesions, based on surface pattern classification. After that, biopsy specimens will be obtained respectively by forceps from each detected lesion recorded for histologic diagnosis.
16562670|NCT02863952|Other|EARLY POST-STRESS EF CHANGE|There is only a single arm. All patients undergoing the routine myocardial perfusion SPECT study will also have additional (earlier) image acquisition in order to assess the relation of early wall motion abnormalities to the severity of myocardial ischemia.
16562671|NCT02863939|Other|NICAS|There is only one arm - a single cohort. All patients undergoing the nuclear stress test will also have the NICAS evaluation.
16562672|NCT02863926|Experimental|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
16562673|NCT02863926|Experimental|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
16562674|NCT02863926|Experimental|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
16562675|NCT02863913|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
16562676|NCT02863913|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.
~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
16562677|NCT02863900|Experimental|Experimental arm|subtypes of BC (namely luminal A and luminal B, HER2+, TN)
16562678|NCT02863887|Experimental|Weight loss intervention|Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.
16562679|NCT02863887|Experimental|Delayed Treatment Control Group|Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.
16562680|NCT02863874|Active Comparator|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
16562681|NCT02863874|Active Comparator|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
16562682|NCT02863861|Experimental|Group PK|Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed.
16562683|NCT02863861|Experimental|Group DK|Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required
16562684|NCT02863848|Placebo Comparator|Placebo|Maltodextrin 2g, twice per day, 6 weeks
16562685|NCT02863848|Active Comparator|Inulin-type fructans|Orafti inulin-type fructans 2g, twice per day, 6 weeks
16562686|NCT02863835|Experimental|Intervention 1|"A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.
~Each participant will then have continuous assessment of the following whilst self venting:
~Spirometry - FEV1, FVC, MVV
~Muscle strength measurements: MIP, MEP, SNIP
~Borg scale, mMRC, Visual Analogue Scale for breathlessness
~Electrical impedance tomography
~EMGpara
~Transcutaneous measurement of CO2 and 02 level
~End-tidal CO2 monitoring
~Pneumotachography"
16562687|NCT02863822|Experimental|Low FODMAP|Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.
16562688|NCT02863822|Active Comparator|Choose My Plate|Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
16562689|NCT02863809|Experimental|Active Treatment Arm|De-epithelialized corneas cross-linked with riboflavin 0.1% and dextran 20% solution AND ultraviolet A light (UVA Light Source).
16562690|NCT02863809|Active Comparator|Control Treatment Arm|De-epithelialized corneas will be exposed to only riboflavin 0.1% with dextran 20% solution (NO ultraviolet A light).
16562691|NCT02863783|Experimental|Fiducial Placement|EUS with Fiducial Placement into Tumor
16562692|NCT02863770|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
16562693|NCT02863757||CHB Group|Patients with chronic hepatitis B
16562694|NCT02863757||CHB/NAFLD Group|Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
16562695|NCT02863757||NAFLD Group|Patients with nonalcoholic fatty liver disease
16562696|NCT02863744|Experimental|CAF+SCTG|
16562697|NCT02863731|Experimental|Alternating postures: first day|Alternating body postures on the first day of measurement. Sitting body posture on the second day of measurement.
16562698|NCT02863731|Experimental|Alternating postures: second day|Alternating body postures on the second day of measurement. Sitting body posture on the first day of measurement.
16562699|NCT02863731|No Intervention|Control group|Sitting body posture on both days of measurement.
16562700|NCT02863718|No Intervention|Watch & wait|Watch & wait
16562701|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
16562702|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
16562703|NCT02863705|Experimental|COMBIGAN®|One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
16562704|NCT02863705|Experimental|COMBIGAN® + LUMIGAN® 0.01%|LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
16562705|NCT02863679|Experimental|Tetracaine hydrochloride gel group|Patients in getracaine hydrochloride gel group were covered with a gauze with tetracaine hydrochloride gel on the cervix after hysteroscopic insertion of utrauterine balloon stent.
16562706|NCT02863679|Placebo Comparator|Control group|Patients in control group were covered with a gauze with saline on the cervix after hysteroscopic insertion of utrauterine balloon stent.
16562707|NCT02863640||Exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
16562708|NCT02863640||Non exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
16562709|NCT02863627|Experimental|Newborn Care Pathway|two telephone interviews conducted after the emergency department visit will be used to gather data to meet the objectives of this study.
16562710|NCT02863614|Experimental|Ibuprofen+Lorazepam|Oral ibuprofen (600 mg) + lorazepam (1 mg); one hour before endometrial scratching.
16562711|NCT02863614|Active Comparator|Ibuprofen|Oral ibuprofen (600 mg) + Placebo; one hour before endometrial scratching.
16562712|NCT02863614|Placebo Comparator|Placebo|Placebo + Placebo; one hour before endometrial scratching.
16562713|NCT02863588|Experimental|seropositive for Toxoplasma gondii|
16562714|NCT02863575|Experimental|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
16562715|NCT02863575|Active Comparator|Ibuprofen|Ibuprofen 400 mg
16562716|NCT02863575|Placebo Comparator|Placebo|Placebo comparator
16562717|NCT02863562|Experimental|Group 1|"This group included 16 subjects. They received kinesio taping for both ankle joints and and performed proprioceptive exercises.
~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training."
16562718|NCT02863562|Experimental|Group 2|"This group received placebo kinesio taping for ankle joint (no tension) and performed proprioceptive exercises.
~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training in the same way as before but with no tension. It was removed on the second day of training."
16562719|NCT02863562|Experimental|Group 3|This group received kinesio taping for ankle joint. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training.
16562720|NCT02863536|Other|Polybactum®|"Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.
~Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis."
16562721|NCT02863523|Experimental|Integrated Behavioral Intervention|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
16562722|NCT02863523|No Intervention|Usual Care|Patients receive usual care
16562723|NCT02863510|Experimental|Renal Denervation|Participation receiving renal sympathetic denervation
16562724|NCT02863497|Active Comparator|Mindfulness Intervention|For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
16562725|NCT02863497|No Intervention|No Intervention|For those who are not in the intervention group they will simply be asked to fill the initial questionnaire and the 3 month post questionnaire. They will not participate in any other questionnaires.
16562726|NCT02863484|Active Comparator|Conventional surgery intra-dural|This arm will be surgically operated by direct attack of the tumour after opening the dura
16562727|NCT02863484|Experimental|Pealing surgery extra-dural|This arm the pealing of the outer layer of the lateral wall of the cavernous sinus will be done before the dura is opened. After the pealing is completed, the middle meningeal artery will be divided at the foramen spinosum. Then, the dura will be opened and the tumour attacked.
16562728|NCT02863471|Experimental|Gemcitabine|1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes
16562729|NCT02863445|Active Comparator|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
16562730|NCT02863445|Experimental|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
16562731|NCT02863419|Experimental|Oral Semaglutide|
16562732|NCT02863419|Active Comparator|Liraglutide|
16562733|NCT02863419|Placebo Comparator|Placebo|
16562734|NCT02863406|Experimental|Healthy volunteers|Bronchoalveolar lavage in healthy volunteers
16562735|NCT02863406|Experimental|Patients suffering from sarcoidosis|Bronchoalveolar lavage in patients suffering from sarcoidosis
16562736|NCT02863393|Experimental|Diaphragmatic breathing exercise|The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.
16562737|NCT02863380|Experimental|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.
~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
16562738|NCT02863380|Active Comparator|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
16562739|NCT02863380|Active Comparator|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
16562740|NCT02863367|Experimental|Treatment group|Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
16562741|NCT02863354|Experimental|Q4WKS|"Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections) through week 48. Following week 48, aflibercept 2 mg every 12 weeks through week 96.
~If NV or PDR are worse per pre-specified criteria at week 60, or at any study visit thereafter, the subject will be treated every 4 weeks through the end of the study."
16562742|NCT02863354|Experimental|Q12WKS|"Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval through week 48. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.
~At week 52, aflibercept 2 mg every 4 weeks (defined as 28 days (+ 7 days) and at least 21 days between injections) for subjects with visible retinal non-perfusion. If retinal non-perfusion has completely resolved at week 72, aflibercept every 12 weeks through end of study. For subjects without retinal non-perfusion at week 52, aflibercept 2 mg every 12 weeks through the end of study."
16562743|NCT02863341|Experimental|naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
16562744|NCT02863341|No Intervention|naive Wait-list Control arm|
16562745|NCT02863341|Experimental|non-naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
16562746|NCT02863341|No Intervention|non-naive Wait-list Control arm|
16562747|NCT02863328|Experimental|14 mg oral semaglutide|
16562748|NCT02863328|Active Comparator|25 mg empagliflozin|
16562749|NCT02863315|Experimental|tsDCS|In the tsDCS group, anodal tsDCS will be applied for 20 minutes.
16562750|NCT02863315|Placebo Comparator|sham|In sham tsDCS group, the current of anodal tsDCS will be discontinued after 30 s while the power indicator remained on for 20 minutes.
16562751|NCT02863302|Experimental|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment until the end of hospitalization.
16562752|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
16562753|NCT02863276|Experimental|Intensified insulin group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
16562754|NCT02863276|No Intervention|Control group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses
16562755|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
16562756|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
16562878|NCT02862366||Primary Myelofibrosis (PMF)|Blood sampling during routine visit
16562879|NCT02862366||Essential thrombocytosis (ET)|Blood sampling during routine visit
16562757|NCT02863250||Massively transfused patients|Patients (18+ years) who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red cells in any 4 hour period)
16562758|NCT02863237||weaning failure group|Patients reconnected to the ventilator within 48 hours after SBT will be designated the weaning failure group
16562759|NCT02863237||weaning success group|Patients who pass the SBT and breathing without ventilator support within 48 hours are designated the weaning success group
16562760|NCT02863224||Healthy control|
16562761|NCT02863224||Ocular hypertension|
16562762|NCT02863224||Primary open angle glaucoma|
16562763|NCT02863224||Normal tension glaucoma|
16562764|NCT02863211||Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease|One-thousand women 55 years of age or older will be recruited to be screened through the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
16562765|NCT02863198|Active Comparator|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
16562766|NCT02863198|No Intervention|non endometrial injury|non endometrial injury was done only for patient of the control group
16562767|NCT02863185|Experimental|Pitavastatin group|Use of 2mg or 4mg Pitavastatin
16562768|NCT02863185|Active Comparator|Atorvastatin group|Use of 10mg or 20mg Atorvastatin
16562769|NCT02863172||Consenting Proband Group|Questionnaires completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
16562770|NCT02863172||Family Members (MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
16562771|NCT02863172||Family Members (Not MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
16562772|NCT02863159|Active Comparator|Treatment Group 1|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +3.25D (ZLB00) in their non-dominant eye.
16562773|NCT02863159|Active Comparator|Treatment Group 2|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +4.00D (ZMB00) in their non-dominant eye.
16562774|NCT02863133|Experimental|Easyx Liquid Embolic|embolization of intracranial malformations and fistulas and brain tumours with Easyx Liquid Embolic
16562775|NCT02863120|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants
16562776|NCT02863120|Active Comparator|Adductor canal and tibial nerve block|Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour
16562777|NCT02863107||Observational (questionnaire, biospecimen collection)|"PATIENTS: Patients complete questionnaires over 30-50 minutes about work, family history, medical history, health habits, and experience as a cancer survivor (quality of life, well-being, concerns, types of health care, and follow-up care received). Patients also undergo collection of blood or saliva samples. Active patients, who have undergone treatment at MD Anderson Cancer Center within the past year, complete additional questionnaires at enrollment, 6 months, 12 months after treatment completion, and then every years for up to 6 years. Also, active patients who are consented to the study more than 5 years from surgery, they may complete the survivorship questionnaire once. Patients medical records are also reviewed.
~FAMILY MEMBERS: Participants complete questionnaires over 10-15 minutes. Participants also undergo collection of blood or saliva samples once."
16562778|NCT02863094|Active Comparator|Real Stimulation|The continuous theta burst stimulation (cTBS) protocol lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. In the cTBS session, this 40s protocol was repeated for three times (1800 pulses in total) separated by two 15 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
16562779|NCT02863094|Sham Comparator|Placebo Stimulation|The procedure of this protocol was performed by a placebo coil. Each session lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first sham TBS session and after the last sham TBS session.
16562780|NCT02863081||Healthcare providers|All healthcare providers working in the participating LTACH will be asked to complete 2 surveys and invited to participate in focus group meetings
16562781|NCT02863081||Patients|81 LTACH patients will be enrolled over the course of a 9 month period. Each patient and their LAR will be interviewed at the time of LTACH admission to garner information about their pre hospitalization physical, functional, and cognitive health status. Each day enrolled patients will undergo daily symptom assessments and medical record reviews. At the time of LTACH discharge all enrolled patients will be interviewed again to garner information about their discharge physical, functional, and cognitive health status.
16562782|NCT02863068|Placebo Comparator|control|patients will receive placebo and standard of care
16562783|NCT02863068|Experimental|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
16562784|NCT02863055|Experimental|Nintedanib|200 mg twice a day per os
16562785|NCT02863055|Placebo Comparator|Placebo|Placebo match twice a day per os
16562786|NCT02863042|Experimental|Deltoid Tendon Repaired|Repair Deltoid Tendon
16562787|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|
16562880|NCT02862366||Polycythemia vera (PV)|Blood sampling during routine visit
16562881|NCT02862353||patients with thrombocytopenia drug|
16562788|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
16562789|NCT02863016||Concentrate SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)
16562790|NCT02863016||Concentrate SelectBag Citrate|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)
16562791|NCT02862990||Pre menopausal women with breast cancer|Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy
16562792|NCT02862977|Experimental|EMS association|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h.
16562793|NCT02862977|Active Comparator|Miosan Caf®|The patient will take 2 tablets (combination of Cyclobenzaprine and caffeine), oral, per day, each 12h.
16562794|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
16562795|NCT02862951||Term pregnancy (>37 weeks gestation)|Term pregnancy (>37 weeks gestation)
16562796|NCT02862938|Experimental|NT-501 ECT Implant|"On eligible participants that are randomized to this group, the NT-501 Investigational product will be implanted in the study eye, and participants will be followed for 24 months.
~The investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary neurotrophic factor (CNTF) receptor after intraocular implantation."
16562797|NCT02862938|Sham Comparator|Sham|To maintain masking, participants randomized to this group receive sham surgery and will be followed for 12 months. Following analysis of the 6 month data, if the open label extension (OLE) is not triggered, patients in the control group will continue on the original study schedule timeline trough month 24. If OLE is triggered participants will be offered the NT-501 ECT investigational product and will followed for additional 12 months.
16562798|NCT02862925|No Intervention|Pre-Intervention|A consecutive sample of 350 patients will be collected. After informed consent, data will be abstracted from the patient's record including day and time of delivery, method of delivery, parity, gestational age, meconium presence, heart rate abnormality and induction methods. For CD, the following data will be collected: decision-to-delivery time, Partogram adherence, time of each FSST, Apgar score, date and time of delivery and Comorbidities such as: Hypertension-spectrum disorders, Malaria, Postpartum Hemorrhage, Macrosomia, History of CD, Diabetes, Sickle Cell, and HIV status.
16562799|NCT02862925|Experimental|Post-intervention|The study will take place on the labor ward at KCMC in Moshi, Tanzania. It will involve women who present to the labor ward in labor or who undergo an induction of labor. A consecutive sample of 350 patients will be collected. Study investigators will be present for 24 hours a day, 7 days a week on a rotating schedule during the enrollment period. All patients who fit inclusion and exclusion criteria will be approached if they are deemed medically stable.
16562800|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
16562801|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
16562802|NCT02862899|Experimental|Heating cable|
16562803|NCT02862886|Other|N°1|
16562804|NCT02862873|Experimental|Ondansetron|
16562805|NCT02862873|Placebo Comparator|Saline solution|
16562806|NCT02862860|Experimental|patients with type-1 diabetes|
16562807|NCT02862860|Placebo Comparator|Controls|
16562808|NCT02862847||gastroenteritis|
16562809|NCT02862847||control|
16562810|NCT02862834||patients with poikiloderma|
16562811|NCT02862821|Experimental|validation of EEfRT task|20 healthy volunteers will be recruted to validate motivation EEfRT task which is adaptated to HR-EEG
16562812|NCT02862821|Experimental|biomarkers identification|20 addict online poker gamblers and 20 non-addict online poker gamblers will be recruted : After standardized questionnaires to define the socio-demographic data, the diagnosis of gambling addiction (Diagnostic and Statistical Manual of Mental Disorder 5th edition DSM-5), screening for comorbidities addictive, the level of anxiety and impulsivity, brain acvtivity will be registred (by randomisation between the 2 tasks) with HR-EEG: during the performance of a task of motivation evaluation laboratory (EEfRT) adaptated for high-resolution electroencephalography AND during a laboratory task that assesses decision making in conditions of uncertainty (IGT) with its version for high-resolution electroencephalography has already been validated in a previous study (Giustiniani et al., 2015).
16562813|NCT02862821|Experimental|biomarkers validation|13 online poker gamblers will be recruted, independently of their dependance profile and they will realize the same task that in precedent arm (quaestionnaires and 2 tasks adaptated to HR-EEG).
16562814|NCT02862795|Other|HPV detection in anal canal samples|
16562815|NCT02862782|Experimental|hCG|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono)
16562816|NCT02862782|Experimental|hCG + GnRH agonist|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono) and GnRH agonist - Gonadotropin - releasing hormone (Decapeptyl 0.2mg - Ferring Gmgh)
16562817|NCT02862769|Experimental|Lidocaine infusion|first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion
16562818|NCT02862769|Placebo Comparator|Saline Infusion|The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.
16562819|NCT02862756|Experimental|patient with endovascular treatment|
16562820|NCT02862743|Experimental|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
16562882|NCT02862340|Other|Autistic disorder|Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
16562883|NCT02862327|Active Comparator|intravenous dexamethasone|intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
16562821|NCT02862730|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
16562822|NCT02862730|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
16562823|NCT02862730|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
16562824|NCT02862730|Active Comparator|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
16562825|NCT02862717||Hemodialysis (HD)|HD patients in MOH dialysis centres notified to NRR.
16562826|NCT02862717||Continuous ambulatory peritoneal dialysis (CAPD)|CAPD patients in MOH dialysis centres notified to NRR.
16562827|NCT02862704|Experimental|MG7-CART|A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance. The dose is 1-6x108 MG7-CAR positive T cells. The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
16562828|NCT02862691|Active Comparator|Oral analgesic|2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
16562829|NCT02862691|Experimental|Injectable local anesthetic|local injection or nerve block with bupivicaine 0.5%
16562830|NCT02862678|Experimental|Patients with head and neck squamous cell carcinoma|
16562831|NCT02862665|Experimental|IV iron|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
16562832|NCT02862665|Placebo Comparator|Control|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
16562833|NCT02862652|Experimental|children with acute lymphoblastic leukemia|
16562834|NCT02862639|Experimental|injection of viscosupplementation and corticosteroid|experimental group
16562835|NCT02862639|Active Comparator|injection of corticosteroid|control group
16562836|NCT02862613|Experimental|Precision Cells|"Precision Cells combined with Transcatheter Arterial Chemoembolization:
~Transcatheter Arterial Chemoembolization:
~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
16562837|NCT02862613|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
16562838|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
16562839|NCT02862587|Experimental|Precision Cells|"precision cells combined with Chemotherapy treatment:
~Chemotherapy:
~once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods."
16562840|NCT02862587|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
16562841|NCT02862574|Experimental|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
16562842|NCT02862574|Experimental|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
16562843|NCT02862574|Placebo Comparator|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
16562844|NCT02862574|Experimental|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
16562845|NCT02862561|Experimental|Precision Cell Immunotherapy|"Precision Cells combined with Chemotherapy treatment: Chemotherapy:
~once a week with a total of six times before 60 days prior to the start of drawing blood. Precision Cells：once per 3 weeks with a total of three periods."
16562846|NCT02862561|Active Comparator|Chemotherapy|"Chemotherapy:
~once a week with a total of six times before 60 days prior to the start of drawing blood."
16562847|NCT02862548|Experimental|TAF|TAF for 48 weeks
16562848|NCT02862548|Active Comparator|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
16562849|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF for an additional 144 weeks.
16562850|NCT02862535|Experimental|Cohort 1: ADX|Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
16562851|NCT02862535|Experimental|Cohort 2: ADX + S-1 + Cisplatin|Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
16562884|NCT02862327|Placebo Comparator|intravenous placebo|intravenous injection of 2ml of NaCl 0.9% during regional anesthesia
16562885|NCT02862314|Experimental|procalcitonin group|The procalcitonin concentration is measured at inclusion.
16562852|NCT02862535|Experimental|Cohort 3: ADX + S-1 + Oxaliplatin|Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.
16562853|NCT02862535|Experimental|Cohort 4: ADX + Nivolumab|Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
16562854|NCT02862522||Women With CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
16562855|NCT02862522||Women Without CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
16562856|NCT02862509|Experimental|Budesonide nasal instillation|budesonide(0.5mg/2ml) 1 respule plus normal saline solution 120ml instilled in vertex to floor position daily
16562857|NCT02862509|Placebo Comparator|Normal saline nasal instillation|Normal saline solution instilled in vertex to floor position daily
16562858|NCT02862496||hyperemesis gravidarum|hyperemesis gravidarum group consisting of 30 pregnant women between 7-20 weeks of gestation with diagnosed hyperemesis gravidarum.
16562859|NCT02862496||Control group|control group consisting of 30 health pregnant women between 7-20 weeks of gestation with excluded hyperemesis gravidarum.
16562860|NCT02862483|Experimental|Experimental|Tamsulosin 0.2mg and Tadalafil 5mg
16562861|NCT02862483|Active Comparator|Comparator|placebo for Tamsulosin 0.2mg and Tadalafil 5mg
16562862|NCT02862457|Experimental|Epacadostat (Epacad)|Cycle 1 is a dose escalation study in which participants will receive 25 or 100 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 with a washout on Days 6 and 7. On Day 8 of Cycle 1 participants will receive a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 or 100 mg of epacadostat orally BID on Days 8-28. For Cycles 2 through 35 participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25 or 100 mg of epacadostat orally BID on Days 1-21.
16562863|NCT02862457|Experimental|Epacad+Pembrolizumab (Pembro)|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25 or 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles.
16562864|NCT02862457|Experimental|Epacad+Pembro+Cisplatin+Pemetrexed|"For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of 75 mg/m^2 Cisplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.
~With protocol amendment 02, treatment with epcadostat stopped, and participants continued treatment with pembrolizumab, cisplatin and pemetrexed."
16562865|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Pemetrexed|"For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of Area Under the Curve (AUC) 5 Carboplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.
~With protocol amendment 02, treatment with epcadostat stopped, and participants continued treatment with pembrolizumab, carboplatin and pemetrexed."
16562866|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Paclitaxel|"For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of AUC6 Carboplatin and 200 mg/m^2 Paclitaxel on Day 1 for the first 4 cycles.
~With protocol amendment 02, treatment with epcadostat stopped, and participants continued treatment with pembrolizumab, carboplatin and paclitaxel."
16562867|NCT02862444||intervention group|Culturally Appropriate Intervention
16562868|NCT02862431|Experimental|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
16562869|NCT02862431|Experimental|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
16562870|NCT02862431|Experimental|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
16562871|NCT02862431|Experimental|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
16562872|NCT02862418||Pulmonary disease|UTE MRI
16562873|NCT02862418||Control|UTE MRI
16562874|NCT02862405||Patients with loss of central vision|Patients coming in ophthalmic consultation will be selected for the study. The diagnosis of this disease is based on clinical examination, and imaging of the retina.Patients with only loss of central vision will be selected.
16562875|NCT02862405||Patients with loss of peripheral vision|Patients coming in ophthalmic consultation will be selected for the study. Patients with loss of peripheral vision will be selected on the bases of presence of tunnel vision.
16562876|NCT02862405||Control group|Patients without loss of vision.
16562877|NCT02862379|Experimental|Elderly patients that fall|Personalized rehabilitation program for elderly patients that fall for the first time. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors.
16562886|NCT02862314|No Intervention|control group|Concentrations of procalcitonin are not measured. .
16562887|NCT02862301|Other|Control group|Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
16562888|NCT02862301|Experimental|CIS group|patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.
16562889|NCT02862288|Experimental|Renal tumor|Microwave ablation of renal tumor
16562890|NCT02862288|Experimental|Lung tumor|Microwave ablation of lung tumor
16562891|NCT02862288|Experimental|Bone tumor|Microwave ablation of bone tumor
16562892|NCT02862275|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity.
16562893|NCT02862262|Experimental|Blinded, Prospective Arm (1)|Clinical performance of the ARIES Bordetella Assay for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.
16562894|NCT02862262|Experimental|Blinded, Pre-selected Arm (2)|In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance of the ARIES Bordetella Assay will be tested using banked, pre-selected, positive clinical specimens.
16562895|NCT02862262|Experimental|Blinded, Contrived Arm (3)|Contrived specimens will be tested using the ARIES Bordetella Assay to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.
16562896|NCT02862249|Experimental|Faecal microbiota transplantation|Faecal microbiota transplantation.
16562897|NCT02862249|Placebo Comparator|Placebo|Placebo solution.
16562898|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 250 mg)|
16562899|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 500 mg)|
16562900|NCT02862223|Experimental|Neoprinol|
16562901|NCT02862210|Experimental|Lithium carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
16562902|NCT02862210|Placebo Comparator|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.
16562903|NCT02862197||study group|hemodialysis treated patients as described in the inclusion of the study
16562904|NCT02862171|Experimental|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
16562905|NCT02862158|Experimental|Experimental|FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss
16562906|NCT02862145|Experimental|Treatment with MRX34|Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
16562907|NCT02862132|Experimental|Vedolizumab|IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks
16562908|NCT02862119|Experimental|FFR Treatment Arm|"Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of >0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued.
~Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study."
16562909|NCT02862119|Active Comparator|Conservative Treatment Arm|Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
16562910|NCT02862106|Experimental|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
16562911|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
16562912|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
16562913|NCT02862106|No Intervention|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
16562914|NCT02862106|No Intervention|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
16562915|NCT02862106|No Intervention|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
16562916|NCT02862093|Active Comparator|Deep rTMS|The intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
16562917|NCT02862093|Placebo Comparator|Placebo|The sham stimulation consisted of rTMS sessions without an effective instrument operation.
16562947|NCT02861872||IP Patients|women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy will be studied.
16562979|NCT02861612||Nerve Transfer|This is an observational study that looks at function and quality of life in patients before and after nerve transfer surgery.
16562918|NCT02862080|Experimental|no intervention; then no intervention; then cathode tsDCS + Ekso; then Ekso; then cathode tsDCS+Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.
~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
16562919|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then cathode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.
~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
16562920|NCT02862080|Experimental|no intervention; then no intervention; then anode tsDCS + Ekso; then Ekso; then anode tsDCS + Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.
~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
16562921|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then anode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.
~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
16562922|NCT02862054|Experimental|Splenectomy|Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
16562923|NCT02862041|Active Comparator|Group Echogenic|Ultrasound guided infraclavicular brachial plexus block with Pajunk sonoplex echogenic needle
16562924|NCT02862041|Placebo Comparator|Group Nonechogenic|Non echogenic needle group, ultrasound guided infraclavicular brachial plexus block with Stimuplex Braun non echogenic needle
16562925|NCT02862028|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
16562926|NCT02862015|Experimental|Oncothermia|Patients with oncothermia treatment and palliative chemotherapy
16562927|NCT02862015|Active Comparator|Control|Patients with palliative chemotherapy only
16562928|NCT02862002|Experimental|"Therapeutic Patient Education (E.T.P)of type caratif"|Patients in arm E.T.P benefit of the nursing consultation E.T.P,
16562929|NCT02862002|Active Comparator|standard care|patients receiving standard care of cancer pain.
16562930|NCT02861989||Osteoporotic women|women over 50 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
16562931|NCT02861989||At risk women|women over 50 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
16562932|NCT02861989||Osteoporotic men|Men over 60 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
16562933|NCT02861989||At-risk men|Men over 60 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
16562934|NCT02861989||General practitioners|General practitioners from the Rhône area, France
16562935|NCT02861963|Experimental|Right ventricle outflow tract reconstruction|RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure
16562936|NCT02861963|Active Comparator|Systemic-to-pulmonary artery shunts|systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)
16562937|NCT02861950|Active Comparator|Caudal block|Patients will receive a caudal block with 0.75-1ml/kg of 0.2% ropivacaine.
16562938|NCT02861950|Active Comparator|Penile Nerve Block|Patients will receive a dorsal penile nerve block with up to 0.75ml/kg of 0.25% bupivacaine.
16562939|NCT02861937|No Intervention|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
16562940|NCT02861937|Active Comparator|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)
~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)
~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
16562941|NCT02861937|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.
~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
16562942|NCT02861924|Experimental|microcirculatory responses|"Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).
~A pressure is applied to the subject's arm. this causes a localized ischemia. the measures responses to this ischemia will be made by the imager speckle (LSCI) give the microvascular perfusion data."
16562943|NCT02861911|Sham Comparator|Control group|The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
16562944|NCT02861911|Active Comparator|Active NMES group|Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).
16562946|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
16562948|NCT02861859|Placebo Comparator|Placebo Comparator|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4).
~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle,), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4)."
16562949|NCT02861859|Active Comparator|Olanzapine|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO, OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4).
~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4)."
16562950|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
16562951|NCT02861833||Patients with a cancerous wound|major patients followed in a cancer ward and holders of a cancerous wound.
16562952|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:
~Complete a diagnostic screening interview at baseline.
~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.
~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.
~Complete 9 follow-up phone calls to assess for relapse."
16562953|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:
~Complete a diagnostic screening interview at baseline.
~Complete questionnaires and computer tasks at baseline and 2 month time points.
~Complete MRI brain imaging data collection at the baseline and 2 month time points."
16562954|NCT02861807|Experimental|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
16562955|NCT02861807|Sham Comparator|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
16562956|NCT02861794|Other|GMK Sphere|Patients receive a GMK Sphere Total Knee Replacement.
16562957|NCT02861781||Type 2 diabetes|Type 2 diabetes according to ADA criteria
16562958|NCT02861781||Insulin resistance non diabetes|HOMA-IR criteria ≥ 3
16562959|NCT02861781||Insulin sensitivity non diabetes|HOMA-IR criteria < 3
16562960|NCT02861768|Experimental|diagnosis of M.tuberculosis infection|
16562961|NCT02861755|Experimental|Arm 1|The MARIGOLD positive emotions course plus a blend of enhancements to include: 5-minutes of weekly facilitator contact, online discussion board, or gamification through virtual flower badges.
16562962|NCT02861755|Experimental|Arm 2|Emotion reporting control condition. Reporting daily emotions for the same duration of the online emotions course.
16562963|NCT02861742|Other|Study procedure|Delivery of questionnaires, Questionnaire T1 to fill, Questionnaire T2 to fill, Questionnaire T3 to fill, Questionnaire T4 to fill, Questionnaire T5 to fill
16562964|NCT02861729|Experimental|Suprinity|Vita Suprinity® (VITA Zahnfabrik H. Rauter GmbH & Co.KG- Germany) Zirconia reinforced lithium silicate PCRs
16562965|NCT02861729|Active Comparator|e.max|IPS-e.max® CAD (Ivoclar Vivadent AG, Schaan - Liechtenstein) lithium disilicate PCRs
16562966|NCT02861716|Experimental|fentanyl and dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl and dexmedetomidine in 2ml volume will be injected slowly over 20 seconds.
16562967|NCT02861716|Active Comparator|dexmedetomidine and placebo for fentanyl|intrathecal bupivacaine (0.5%) 0.4mg/kg plus dexmedetomidine 0.2 μg/kg in 2ml volume and placebo (for fentanyl 0.2 μg/kg) it will be injected slowly over 20 seconds.
16562968|NCT02861716|Active Comparator|fentanyl and placebo for dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl 0.2 μg/kg in 2ml volume and placebo (for dexmedetomidine 0.2 μg/kg) it will be injected slowly over 20 seconds.
16562969|NCT02861703|Experimental|Online lifestyle intervention|"A weekly psychosocial intervention (Online Lifestyle Intervention) delivered in an online group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
16562970|NCT02861690|Experimental|Treatment group|patients received Liposomal Paclitaxel and Nedaplatin every 21 days until the presence of progressive disease or unacceptable toxicity
16562971|NCT02861677|No Intervention|Control group|The control group will receive the usual medical care by physicians and nurses
16562972|NCT02861677|Experimental|Intervention group|the intervention group will receive clinical pharmacy services
16562973|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
16562974|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
16562975|NCT02861638|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
16562976|NCT02861638|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
16562977|NCT02861625||Group A|letter of condolence offering to the reliable person a post-death consultation with the reference physician (sent between J15 and J30 post death)
16562978|NCT02861625||Group B|no intervention, i.e without a letter of condolence proposing a consultation with the reference physician
16563022|NCT02861404||Imiquimod|patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)
16563023|NCT02861404||5-Fluoro-Uracil|patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)
16563024|NCT02861404||Cryotherapy|patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)
16563025|NCT02861404||placebo|patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)
16563000|NCT02861560|Experimental|dHACM|Dehydrated human amnion/chorion membrane (dHACM)
16563001|NCT02861547||Traumatic brain injury|
16563002|NCT02861534|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
16563003|NCT02861534|Placebo Comparator|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
16563004|NCT02861521|Experimental|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
16563005|NCT02861521|Sham Comparator|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
16563006|NCT02861508|Active Comparator|Usual care|Usual care as determined by treating team. Ultrasound may still be part of the workup per the treating team's discretion.
16563007|NCT02861508|Experimental|Early POCUS|Point-of-care ultrasound protocol will involve cardiac views (for pericardial effusion, left ventricular function, left and right ventricular equality, aortic root dilation, and inferior vena cava status), lung views (for pneumothorax, signs of alveolar interstitial syndrome), abdominal views for free fluid, and a view of the abdominal aorta for aneurysm.
16563008|NCT02861495|Experimental|humeral nail|Surgical fixation with a humeral compression/distraction nail.
16563009|NCT02861482|Experimental|Bakri Ballon|All the enrolled patients who would undergo the laying of Bakri Balloon
16563010|NCT02861469||Main carers|Individual semi-structured interviews
16563011|NCT02861469||General practitioners|Individual semi-structured interviews
16563012|NCT02861456|Active Comparator|Standard Care Group|Patient in the treatment arm will receive the Standard Model of Care as prescribed for their condition by their physician including but not limited to Advanced imaging, Rest, Bracing, Physical Therapy, and Medication.
16563013|NCT02861456|Experimental|Functional Progression Group|Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
16563014|NCT02861430||Patients|
16563015|NCT02861417|Experimental|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
16563016|NCT02861417|Experimental|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
16563017|NCT02861417|Experimental|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score > 3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
16563018|NCT02861417|Experimental|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score >3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
16563019|NCT02861417|Experimental|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
16563020|NCT02861417|Experimental|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
16563021|NCT02861404||Salicylate ointment|patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)
16563026|NCT02861391|Experimental|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed in urodynamic testing intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
16563027|NCT02861378|Experimental|Phentolamine mesylate|Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
16563028|NCT02861378|Placebo Comparator|Water|Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).
16563029|NCT02861352|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 10 mg/d and 25 mg supplemental zinc/d
16563030|NCT02861339|Experimental|Keratoconus and IBD|Opthalmologic measure with DM OPD scan III (Nidek)
16563031|NCT02861326|Other|Patients|Non-surgical periodontal treatment has performed to patients. Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
16563032|NCT02861313|Experimental|CM LOC attachment|CM LOC attachment other names: resin matrix attachment
16563033|NCT02861313|Active Comparator|ball attachment|ball attachment other names metallic ball attachment
16563034|NCT02861300|Experimental|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
16563035|NCT02861287||Study cohort|patients with Multiple Myeloma who underwent PBSC mobilization since December 2009 and who received plerixafor in line with inclusion criteria
16563036|NCT02861287||Historical cohort|patients with Multiple Myeloma who underwent PBSC mobilization immediately prior to marketing authorization and clinical utilization of Plerixafor which is before December 2009 (over the 2007-2009 period)
16563037|NCT02861274|Active Comparator|electrophysiological testing|Patients will receive a pacemaker.
16563038|NCT02861274|No Intervention|control group|These subjects will receive cardicor® (beta blockers).
16563039|NCT02861261|Experimental|Group A|
16563040|NCT02861261|Experimental|Group B|
16563041|NCT02861261|Experimental|Group C|
16563042|NCT02861261|Placebo Comparator|Group D|
16563043|NCT02861248|Experimental|Laser treatment|Fractional micro-plasma radiofrequency treatment given to 95 patients with non-hypertrophic burn scar.
16563044|NCT02861235|Experimental|1. stress thallium-201 tomoscintigraphy|
16563045|NCT02861235|Experimental|2. stress technetium-99m tomoscintigraphy 1|
16563046|NCT02861235|Experimental|3. stress technetium-99m tomoscintigraphy 2|
16563047|NCT02861235|Experimental|4. stress technetium-99m tomoscintigraphy 3|
16563048|NCT02861235|Experimental|5. rest thallium-201 tomoscintigraphy|
16563049|NCT02861235|Experimental|6. rest technetium-99m tomoscintigraphy|
16563050|NCT02861222|Experimental|MYOCET|2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.
16563051|NCT02861209|No Intervention|Non-care pathway|"This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months.
~The decision to start with an oral anticancer therapy depends solely on the treating physician."
16563052|NCT02861209|Experimental|Care Pathway|"This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months.
~The decision to start with an oral anticancer therapy depends solely on the treating physician."
16563053|NCT02861196|Experimental|Therapy Arm|Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
16563054|NCT02861183|Experimental|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
16563055|NCT02861183|Placebo Comparator|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
16563056|NCT02861170|Experimental|Brief Mindfulness-Based Intervention|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety as well as a 10-minute mindfulness-based intervention called a body scan at 3 different time-points (T1 - 1 week prior to surgery, T2 - within 4 hours before surgery, and T3 - approximately 24 hours after transfer from recovery to the orthopedic floor).
16563057|NCT02861170|No Intervention|Education|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety.
16563058|NCT02861157|Experimental|TX Condition: Planet T1D Intervention|Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.
16563087|NCT02860923|Experimental|Exenatide|Treatment with exenatide at the initial dose of 5 µg x 2/day (subcutaneously administered) during 4 weeks, and treatment with 10 µg x 2/day during 5 months.
16563059|NCT02861157|No Intervention|CO Condition: Treatment-As-Usual|A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.
16563060|NCT02861144|Other|Intervention|"Patient participants in the intervention arm will receive diabetes self-management program, Ma ka hana ka ̒ike which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 4.5 months. After 4.5 months, the patient will receive 4 monthly boosters by mail that will reinforce information from the Ma ka hana ka ̒ike program. Completion of diabetes process and glycemic outcomes will trigger the modest financial incentives.
~Health care provider participants in the intervention arm will receive educational resources, Hanapū Provider Toolbox to guide their patients to optimal glycemic control.They will receive modest financial incentives when their patients complete clinical tests and achieve glycemic target."
16563061|NCT02861144|No Intervention|Usual Care|"Patient participants in the usual care arm will receive 5 mail-out diabetes self management education booklets endorsed by the American Diabetes Association (ADA) and the National Institute for Diabetes, Digestive and Kidney disease for 4.5 months. Patients will see their doctor according to usual care practice. After 4.5 months, the patients will receive 4 monthly boosters in mail reinforcing the previous mail-out diabetes self-management program materials.
~Health care provider participants in the usual care arm will receive the latest ADA guidelines to use in their treatment plan of their patients."
16563062|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
16563063|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
16563064|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
16563065|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
16563066|NCT02861105|Active Comparator|LMWH supplementation|40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
16563067|NCT02861105|Placebo Comparator|0.9% saline solution|0.9% saline injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
16563068|NCT02861079|Experimental|Propess with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
16563069|NCT02861079|Active Comparator|Propess vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
16563070|NCT02861066|Experimental|Mindfulness-based Intervention|6 week, abbreviated group MBI treatment for depression and anxiety
16563071|NCT02861053|Experimental|chronic quiet inflammatory bowel disease patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with regular and moderate physical activity
16563072|NCT02861053|Sham Comparator|chronic quiet inflammatory bowel disease Patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with no regular and moderate physical activity more than usual
16563073|NCT02861040|Experimental|Treatment (volasertib, vincristine sulfate liposome)|Patients receive volasertib IV over 1 hour on day 1 and vincristine sulfate liposome IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression, development of an inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw or treating investigator determines that the patient should be taken off treatment for any reason.
16563074|NCT02861027|Active Comparator|PPTHA|Control Group performs the PPTHA.
16563075|NCT02861027|Experimental|FES and PPTHA|The Intervention Group performs the PPTHA associated with FES.
16563076|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
16563077|NCT02861001|Active Comparator|bronchoscopic guidance|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
16563078|NCT02861001|Experimental|tube mounted camera guidance|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
16563079|NCT02860988|Experimental|MCCC Treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
16563080|NCT02860988|No Intervention|MCCC Comparison|Participants in this condition did not receive reentry services related to responsible parenting, economic stability and mobility, or healthy marriage and relationships.
16563081|NCT02860975|Experimental|Inhaled Nitrogen|A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
16563082|NCT02860962|Active Comparator|Dextromethorphan|2 doses of Dextromethorphan 75mg oral (PO), separated by 4 hours
16563083|NCT02860962|Placebo Comparator|Placebo|2 doses of placebo (oral/PO), separated by 4 hours
16563084|NCT02860949|Experimental|LAI with PCI|Local anesthetic infiltration with posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area, Lateral gutter area and Posterior capsular area)
16563085|NCT02860949|Active Comparator|LAI without PCI|Local anesthetic infiltration without posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area and Lateral gutter area)
16563086|NCT02860936|Experimental|Lenvatinib|24 mg of lenvatinib will be administered daily to patients until progression of disease or intolerable toxicity or other criteria for discontinuation is met.
16563088|NCT02860923|Placebo Comparator|Placebo|Patients will be maintained on placebo (injected subcutaneously, twice a day) with the same dose and frequency than exenatide arm.
16563089|NCT02860910|Experimental|Cognitive Behavioral Group Therapy|"The six CBGT sessions are outlined in the manual entitled: Managing Hot Flushes with Group Cognitive Behaviour Therapy: An Evidenced-Based Treatment Manual for Health Care Professionals (Hunter & Smith, 2015) as follows:
~Session 1: Psycho-education and the cognitive behavioural model Session 2: Stress management, improving wellbeing and identifying precipitants Session 3: Managing hot flushes using a cognitive behavioural approach Session 4: Managing night sweats and improving sleep (part one) Session 5: Managing night sweats and improving sleep (part two) Session 6: Review and maintaining changes (One alteration: Open discussion about mood disorders, anxiety and the psychological impact instead of the psychological impact of breast cancer)"
16563090|NCT02860897|Experimental|Vaginal estrogen cream|
16563091|NCT02860897|Experimental|Vaginal estrogen tablet|
16563092|NCT02860884||simple fatty liver|patients with fatty liver disease
16563093|NCT02860884||NASH|patients with nonalcoholic steatohepatitis
16563094|NCT02860858|Experimental|Aflibercept|
16563095|NCT02860845|Experimental|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
16563096|NCT02860845|Active Comparator|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
16563097|NCT02860819|Experimental|Gemcitabine, Carboplatin, Veliparib|Gemcitabine 800mg/m2 day 1 and 8 every 3 weeks; Carboplatin AUC = 4, day 1, every 3 weeks, Veliparib 250mg bid day continuously.
16563098|NCT02860806|Experimental|Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)|Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
16563099|NCT02860806|Experimental|Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
16563100|NCT02860806|Experimental|Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
16563101|NCT02860806|Experimental|Part 2: Group 1 (EFG)|Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
16563102|NCT02860806|Experimental|Part 2: Group 2 (FGE)|Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
16563103|NCT02860806|Experimental|Part 2: Group 3 (GEF)|Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
16563104|NCT02860806|Experimental|Part 2: Group 4 (GFE)|Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
16563105|NCT02860806|Experimental|Part 2: Group 5 (FEG)|Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
16563106|NCT02860806|Experimental|Part 2: Group 6 (EGF)|Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
16563107|NCT02860806|Experimental|Part 3: JNJ-63623872 300 mg|Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
16563108|NCT02860793|Experimental|AML patients at diagnosis|
16563109|NCT02860780|Experimental|Part A: prexasertib + ralimetinib|"Cohort 1: 60 milligrams (mg) prexasertib (LY2606368) given intravenously (IV) and 100 mg ralimetinib given orally.
~Cohort 2: 60 mg prexasertib (LY2606368) given intravenously (IV) and 200 mg ralimetinib given orally."
16563110|NCT02860780|Experimental|Part B1: prexasertib + ralimetinib (colorectal cancer)|60 mg prexasertib (LY2696368) given IV and 200 mg ralimetinib given orally. Participants receive prexasertib IV on Days 1 and 15 and ralimetinib every 12 hours (Q12H) Days 1 and 14 of a 28 day cycle.
16563111|NCT02860754|Other|Six-minute walk test|All patients will perform six-minute walk test before surgery, in the preoperative clinic
16563112|NCT02860741|Experimental|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
16563113|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
16563114|NCT02860728|Experimental|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
16563115|NCT02860715|Experimental|Cohort 1|GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
16563116|NCT02860715|Experimental|Cohort 2|GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
16563117|NCT02860715|Experimental|Cohort 3|GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
16563118|NCT02860702|Experimental|Exclusive Human Milk|All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery
16563119|NCT02860702|Active Comparator|Human/Bovine Milk|All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery
16563120|NCT02860676|Experimental|Cirmtuzumab|
16563121|NCT02860663|Active Comparator|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
16563122|NCT02860663|Active Comparator|Vitamin D2|10 ug/d of vitamin D2 for 6 weeks
16563124|NCT02860650|Experimental|Group 1: AD26.Filo/MVA-BN-Filo or Placebo|Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
16563125|NCT02860650|Experimental|Group 2: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.
16563126|NCT02860650|Experimental|Group 3: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.
16563127|NCT02860650|Experimental|Subset of Group 3: AD26.Filo or Placebo|The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.
16563128|NCT02860650|Experimental|Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
16563129|NCT02860624|Experimental|10 mg ilaprazole|
16563130|NCT02860624|Active Comparator|40 mg esomeprazole|
16563131|NCT02860611||Type 1 Diabetes|Patients with type 1 diabetes
16563132|NCT02860611||Type 2 Diabetes|Patients with type 2 diabetes
16563133|NCT02860611||Control|Healthy volunteers
16563134|NCT02860598||Group 1|Patient with AML de novo or secondary myelodysplasia, in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy
16563135|NCT02860598||Group 2|Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, myeloma, myeloproliferative syndrome (MDS)) and candidate for blood marrow or stem cell or placental blood transplantation.
16563136|NCT02860572|Experimental|follow-up without intervention|No intervention to increase the urine output within 2 hours will be done.
16563137|NCT02860572|Active Comparator|Standard group - fluid bolus|Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
16563138|NCT02860559|Experimental|TBX-1400 treatment|Single intravenous infusion of TBX-1400
16563139|NCT02860546|Experimental|TAS-102 + Nivolumab|Participants received a dose of 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).
16563140|NCT02860533|Experimental|Blood pressure measurement|six repetitive blood pressure measurements with iPhone and conventional oscillometric cuff device during stress testing will be performed
16563141|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
16563142|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
16563143|NCT02860494|Experimental|Topical everolimus 0.1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
16563144|NCT02860494|Experimental|Topical everolimus 0.5%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
16563145|NCT02860494|Experimental|Topical everolimus 1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
16563146|NCT02860494|Placebo Comparator|Topical placebo|Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
16563147|NCT02860481|Other|first cohort : first 100 patients|first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type
16563148|NCT02860481|Other|second cohort : 100 patients|Patients with breast cancer of with ovarian and/or endometrial cancer
16563149|NCT02860468|Experimental|Cranberry juice consumption|participants in this arm will be provided cranberry juice to consume for 21 days in total
16563150|NCT02860468|Placebo Comparator|Placebo juice consumption|participants in this arm will be provided placebo juice to consume for 21 days in total
16563151|NCT02860455|Other|SpCO and COHb measurement|"SpCO measurement (Experimental) : Non invasive pulse CO-oximetry will be carried out in all patients simultaneously with venous blood sampling for standard laboratory blood gas analysis, at time of prehospital management by emergency medical services
~COHb measurement (Active comparator) : Blood carboxyhemoglobin testing will be carried out in all patients"
16563152|NCT02860442|Experimental|Smartphone brief intervention (SP-BI)|
16563153|NCT02860442|Placebo Comparator|Enhanced Usual Care (EUC)|
16563154|NCT02860429|Experimental|Cinobufacini injection|"Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
~Duration:6 chemotherapy cycles."
16563155|NCT02860429|Other|Control group|Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
16563156|NCT02860403|Experimental|C6-C7 patients|C6-C7 patients able to recover tenodesis grasp.
16563157|NCT02860403|Experimental|C5-C6 patients|C5-C6 patients for whom surgery for rehabilitation of an upper limb is indicated with a upper limit of one year after trauma, and after complete clinical and functional evaluation
16563158|NCT02860403|No Intervention|Control group|a control group (n=6) matched on age and sex to C6-C7 without medical history or neurological disorder
16563159|NCT02860390|No Intervention|Adolescent - Control|Usual care arm of subjects aged 13-19 years old
16563160|NCT02860390|Experimental|Adolescent - SMS|Subjects aged 13-19 years and receiving Denver Health Asthma Management Program (text messaging intervention)
16563161|NCT02860390|Experimental|Adolescent - SMS plus support person|Subjects aged 13-19 years, Denver Health Asthma Management Program (text messaging intervention) sent to subjects and subjects' chosen Person of Support.
16563162|NCT02860390|No Intervention|Adult - Control|Usual care arm of subjects aged 20-40 years old.
16563163|NCT02860390|Experimental|Adult - SMS|Subjects aged 20-40 years and receiving Denver Health Asthma Management Program (text messaging intervention).
16563164|NCT02860377|Active Comparator|stranger's voice|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
16563165|NCT02860377|Experimental|maternal voice|At the end of surgery, patients were stimulated to wake up by recorded maternal voice, which was recorded before the operation.
16563166|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
16563167|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
16563168|NCT02860338||GROUP 1- CNS Protocol|"Patients in a specialized dementia practice. Evaluated and treated for hypoxia, elevated BNP, hyperhomocysteinemia, B 12 deficiency as measured by elevated methymalonic acid, Vitamin D 25-OH deficiency, elevated CRP, and decreased IGF-1, and other metabolic abnormalities.
~Treated with maximal doses of acetylcholinesterase inhibitors, memantine, methylfolate/methylB12/N-acetylcysteine, dextromethorphan/quinidine, and SSRI's; dose and duration based on protocol."
16563169|NCT02860338||GROUP 2- Community Care|Patients referred to a neuropsychology practice for cognitive evaluation and treated for MCI or dementia by their primary care clinician or non-dementia specialist according to specific provider's usual practice pattern.
16563170|NCT02860325|Experimental|NIV-NAVA|Patients allocated to non-invasive NAVA
16563171|NCT02860325|Active Comparator|Conventional|Patients allocated to nasal CPAP or non-synchronized nasal IPPV
16563172|NCT02860312|Active Comparator|Exercisers|Intradialytic exercise on stationary bicycles
16563173|NCT02860312|Placebo Comparator|Non Exercisers|No intradialytic exercise
16563174|NCT02860299|Experimental|Citrate lock|
16563175|NCT02860299|Active Comparator|Heparin lock|
16563176|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
16563177|NCT02860273|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO at 21%
~Constant Treadmill Load Test (CTLT) using HFNCO at 21%"
16563178|NCT02860273|Other|Control Group|"Incremental Load Treadmill Test (ILTT) at Room Air
~Constant Treadmill Load Test (CTLT) at Room Air"
16563179|NCT02860260|Experimental|Patients with fibrinolysis|
16563180|NCT02860260|Placebo Comparator|Patients without fibrinolysis|
16563181|NCT02860234||Group A:Clinical complete response (cCR)|Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
16563182|NCT02860234||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
16563183|NCT02860234||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).
16563184|NCT02860221|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
16563185|NCT02860221|Experimental|Topical epinephrine|Topical epinephrine
16563186|NCT02860221|Active Comparator|Control|No epinephrine
16563187|NCT02860208||3 years follow-up|all patients who received surgical treatment for peri-implantitis during a Randomized and Controlled Trial registered in ClinicalTrials.gov NCT NCT01857804
16563188|NCT02860195|Experimental|healthy volunteers|
16563189|NCT02860182||experimental|patients with acute type A dissection
16563190|NCT02860182||control|patients without any pathology of the ascending aorta, but having the same characteristics as the sick patients, in terms of age and vascular risk factors including high blood pressure
16563191|NCT02860169|Experimental|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
16563192|NCT02860169|Placebo Comparator|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
16563193|NCT02860156||HIV+/DD+|Subjects are HIV positive and have diastolic dysfunction
16563194|NCT02860156||HIV+/DD-|Subjects are HIV positive and do not have diastolic dysfunction
16563195|NCT02860156||HIV-/DD+|Subjects do not have HIV and have diastolic dysfunction
16563196|NCT02860143||studying ventilation during sedation|Comparing ventilation during sedation with capnography
16563197|NCT02860130|Experimental|Prismocitrate 18|
16563198|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
16563199|NCT02860117|Active Comparator|Ketatamine|Ketamine continuous infusion 0,2mg/kg/h
16563200|NCT02860117|Placebo Comparator|Placebo|Placebo in continuous infusion
16563203|NCT02860078|Active Comparator|Ultrasound|The group I will be subjected to epidural infiltration using methylprednisolone acetate diluted in ropivacaine 0.1%. Initially the sacral hiatus is identified by palpation. After, the ultrasound device is used (USG) for the puncture, with a linear transducer of high frequency. At the end of corticosteroid administration, the placement of the needle tip will be checked with fluoroscopy and noted.
16563204|NCT02860078|Active Comparator|Radioscopy|The group II will be subjected to infiltration using methylprednisolone acetate diluted in ropivacaine 0.1% . However, only radioscopy be used to guide the puncture.
16563205|NCT02860065|Experimental|CPC-201|combination of solifenacin and high doses of donepezil
16563206|NCT02860052|Experimental|SB208 2%|Apply once daily to one or both feet for 14 days
16563207|NCT02860052|Experimental|SB208 4%|Apply once daily to one or both feet for 14 days
16563208|NCT02860052|Experimental|SB208 16%|Apply once daily to one or both feet for 14 days
16563209|NCT02860052|Placebo Comparator|Vehicle Gel|Apply once daily to one or both feet for 14 days
16563210|NCT02860039|Experimental|Group 1 - High Dose HD-TIV|Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.
16563211|NCT02860039|Active Comparator|Group 2 - Standard Dose QIV|Patients receive standard dose QIV IM on day 0 and day 28.
16563212|NCT02860026|Active Comparator|Control|Marketed cow's milk-based infant formula
16563213|NCT02860026|Experimental|Investigational|Cow's milk-based infant formula with added nutrients
16563214|NCT02860013|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling heart failure in general. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
16563215|NCT02860013|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with heart failure are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). Heart failure patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing heart failure. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in heart failure and definitely not on call
16563216|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
16563217|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16563218|NCT02859987|Active Comparator|Landmark Technique|Blinded method for catheter placement
16563219|NCT02859987|Experimental|Ultrasound-guided Technique|Use sonography for catheter placement
16563220|NCT02859974|Experimental|Respiratory retraining for PVFMD|Single arm study
16563221|NCT02859961|Experimental|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
16563222|NCT02859961|Experimental|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
16563223|NCT02859961|Experimental|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
16563224|NCT02859948|Experimental|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
16563225|NCT02859935|No Intervention|Control group|The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
16563226|NCT02859935|Other|Intervention group|The intervention group will receive -besides standard care- additional questionnaires depending on their baseline questionnaires and in case of an indication for mental health problems, feedback and referral to relevant mental health and addiction care will be provided.
16563227|NCT02859922|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
16563228|NCT02859922|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
16563229|NCT02859909|Experimental|2 day treatment schedule|Patients will receive a dosage of 1 g/kg bw per day of BT595 for 2 consecutive days
16563230|NCT02859909|Experimental|5 day treatment schedule|Patients will receive a dosage of 0.4 g/kg bw per day of BT595 for 5 consecutive days
16563231|NCT02859896|Experimental|Hectorol|Hectorol (Doxercalciferol) will be administered orally two to three times weekly dependent on patient age. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
16563232|NCT02859896|Active Comparator|Rocaltrol|Rocaltrol (Calcitriol) will be administered orally seven days/week. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
16563233|NCT02859857|Experimental|Rising dose; safety and tolerance|Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.
16563234|NCT02859857|Experimental|Solid tumor patients|Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
16563235|NCT02859857|Experimental|Glioblastoma Multiforme patients|Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
16563236|NCT02859857|Experimental|Gastrointestinal tumor patients|Cohort of patients with Gastrointestinal tumors as defined in the protocol and administered BXQ-350 at the 2.4 mg/kg dose level.
16563573|NCT02857595|Experimental|Online Weight Loss Program + Nomogram + Bite Counter|
16563237|NCT02859857|Experimental|Ependymoma tumor patients|Cohort of patients with ependymoma administered BXQ-350 at the 2.4 mg/kg dose level.
16563238|NCT02859857|Experimental|Solid tumor patients other than HGG|Cohort of patients with advanced solid tumors other than HGG administered BXQ-350 at the 2.4 mg/kg dose level.
16563239|NCT02859844|Experimental|TTNS ON|Transcutaneous tibial nerve stimulation
16563240|NCT02859844|Sham Comparator|TTNS OFF|Sham/placebo stimulation
16563241|NCT02859831||with construction work|
16563242|NCT02859831||without construction work|
16563243|NCT02859818|Other|adolescents with type 1 diabetes|adolescents with type 1 diabetes following their participation in therapeutic education program
16563244|NCT02859792|Placebo Comparator|Placebo|
16563245|NCT02859792|Experimental|Experimental|
16563246|NCT02859779|Other|mediterranean adolescents with type 1 diabetes|
16563247|NCT02859766|Experimental|Abicipar Pegol_Repeat Dose|Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. [Day 1, Weeks 4 and 8]
16563248|NCT02859766|Experimental|Abicipar Pegol_Single Dose|Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.
16563249|NCT02859753|Experimental|RFA|
16563250|NCT02859753|Active Comparator|MCT|
16563251|NCT02859740||permanent prosthesis|
16563252|NCT02859740||Temporary prosthesis|
16563253|NCT02859727|Experimental|CDZ173|140mg/day
16563254|NCT02859714||colorectal adenoma|
16563255|NCT02859701|Experimental|AK002|AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses
16563256|NCT02859701|Placebo Comparator|Placebo|Placebo administered as anl IV infusion
16563257|NCT02859688||SRS patient|
16563258|NCT02859688||father SRS patient|
16563259|NCT02859688||control patient|
16563260|NCT02859675||Crohn and anti-TNF treatment|Tests at 3 or 4 weeks after the beginning of anti-TNF treatment
16563261|NCT02859675||Crohn and without anti-TNF treatment|tests performed according to patient availability
16563262|NCT02859675||Control|tests performed according to patient availability
16563263|NCT02859649|Experimental|healthy volunteers|
16563264|NCT02859610|Other|cirrhotic patients|We prospectively included 90 cirrhotic patients .
16563265|NCT02859610|Other|healthy volunteers|The pilot cohort was compared with 10 healthy volunteers.
16563266|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
16563267|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
16563268|NCT02859584|Other|no serious acute hepatitis|
16563269|NCT02859584|Other|Serious acute hepatitis|
16563270|NCT02859584|Other|Healthy volunteers|
16563271|NCT02859584|Other|Surrenal insufficiency|
16563272|NCT02859571|Active Comparator|Continuous oxytocin|oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery.
16563273|NCT02859571|Experimental|intermittent oxytocin|oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group.
16563274|NCT02859558|Experimental|Arm 1: Fiebig I II|Participants enrolled during Fiebig stages I-II will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
16563275|NCT02859558|Experimental|Arm 2: Fiebig III IV|Participants enrolled during Fiebig stages III-IV will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
16563276|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stages V will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
16563277|NCT02859545|Experimental|Validation Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to validate which is provided by the research assistant.
16563278|NCT02859545|Placebo Comparator|Education Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to ask questions about treatments, which is provided by the research assistant.
16563279|NCT02859532|Experimental|Diagnosis of deep vein thrombosis|All subjects with proximal DVT will have quantitative elastography SWIRE, thrombin generation test and rotational thromboelastometry test.
16563280|NCT02859519|Experimental|MOB015B|Subjects will treat all affected fingernails and/or toenails with MOB015B for 48 weeks once daily at bedtime.
16563281|NCT02859519|Placebo Comparator|MOB015B Vehicle|Subjects will treat all affected fingernails and/or toenails with MOB015B Vehicle for 48 weeks once daily at bedtime.
16563282|NCT02859506|Experimental|liver transplant|
16563283|NCT02859506|Active Comparator|kidney transplant|
16563284|NCT02859506|Placebo Comparator|control|
16563285|NCT02859506|Active Comparator|stable liver damage|
16563286|NCT02859493|Active Comparator|Saccharomyces cerevisiae|Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
16563287|NCT02859493|Placebo Comparator|Maize starch and magnesium stearate|Placebo presented in a vaginal capsule. 1 capsule a day for 14 days
16563288|NCT02859480|Experimental|Rosuvastatin 5mg|Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention
16563289|NCT02859480|Active Comparator|Rosuvastatin 20mg|Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention
16563290|NCT02859467|Experimental|Kinesio Taping and Inhibitory Treatment Techniques|"During each session participants will receive the application kinesio taping in trapezius, infraspinatus and paravertebral muscles.
~Inhibitory Treatment Techniques:
~Release Technique of the trapezius muscle.
~Release Technique for scalene muscles.
~Technique suboccipital inhibition.
~Technique hands crossed for induction dorsal superficial fascia."
16563291|NCT02859467|Active Comparator|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
16563292|NCT02859454|Experimental|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
16563293|NCT02859441|Experimental|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
16563294|NCT02859428||Patients with hereditary spastic paraplegia (HSP)|Patients with hereditary spastic paraplegia types 3A, 4 and 31.
16563295|NCT02859415|Experimental|Phase I|Escalating doses of Mithramycin
16563296|NCT02859415|Experimental|Phase II|Mithramycin administered at MTD
16563297|NCT02859402|Experimental|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
16563298|NCT02859376|Active Comparator|sucrose24% 2 minutes before|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure
16563299|NCT02859376|Experimental|sucrose24% 2minutes before and during|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure
16563300|NCT02859363||Young stroke|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing for the 26 common Fabry mutation types in Taiwan.
16563301|NCT02859350|Experimental|Group 1a (PfSPZ Vaccine)|18-35 years; n= 20; 3 doses of 2.7x10^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
16563302|NCT02859350|Placebo Comparator|Group 1a (normal saline)|18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
16563303|NCT02859350|Experimental|Group 1b (PfSPZ CVac)|18-35 years; n=20; 3 doses of 1.0x10^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
16563304|NCT02859350|Placebo Comparator|Group 1b (normal saline)|18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
16563305|NCT02859350|Experimental|Group 2 (PfSPZ Vaccine)|36-65 years; n=12; 3 doses of 2.7x10^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
16563306|NCT02859350|Placebo Comparator|Group 2 (normal saline)|36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
16563307|NCT02859350|Experimental|Group 3 (PfSPZ Vaccine)|11-17 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
16563308|NCT02859350|Placebo Comparator|Group 3 (normal saline)|11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
16563309|NCT02859350|Experimental|Group 4 (PfSPZ Vaccine)|6-10 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
16563310|NCT02859350|Placebo Comparator|Group 4 (normal saline)|6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
16563311|NCT02859350|Experimental|Group 5 (PfSPZ Vaccine)|1-5 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
16563312|NCT02859350|Placebo Comparator|Group 5 (normal saline)|1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
16563313|NCT02859350|Experimental|Group 6a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 9.0x10^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
16563314|NCT02859350|Experimental|Group 6b (PfSPZ Vaccine)|6-11 months; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
16563315|NCT02859350|Placebo Comparator|Group 6b (normal saline)|6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
16563316|NCT02859337|Active Comparator|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
16563317|NCT02859337|Experimental|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
16563318|NCT02859337|Other|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
16563319|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
16563320|NCT02859311|Experimental|Withdrawal of therapy|Gradual, supervised withdrawal of medical therapy over 4-16 weeks
16563321|NCT02859311|No Intervention|Control|Continuation of usually prescribed pharmacological therapy
16563322|NCT02859298|Experimental|Suspicion of threat of premature delivery|10 consecutive patients arriving at the Brugmann maternity with suspicion of a threat of premature delivery will be encouraged to participate in this study, before the onset of any tocolytic treatment. The patient will receive an standard examination of the cervix and at the same time a polarimetric measurement.
16563323|NCT02859298|Active Comparator|Normal pregnancy|10 control patients, with the same term of pregnancy, will be benefit from the same measurements.
16563360|NCT02859025|Experimental|C:MSCs+liac|Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.
16563681|NCT02856750|Experimental|gabapentin|gabapentin 300 mg three times daily x 30 d
16563324|NCT02859285|Active Comparator|Estradiol vulvar cream|"The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.
~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
16563325|NCT02859285|Placebo Comparator|Placebo cream|"The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.
~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
16563326|NCT02859259|Experimental|Treatment A: reference extended-release (ER) 1 tablet at 600mg|A single dose of BMS-663068 administered orally as specified
16563327|NCT02859259|Experimental|Treatment B: low-dose ER 4 tablets at 150mg|A single dose (4 tablets) of BMS-663068 administered orally as specified
16563328|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
16563329|NCT02859233|No Intervention|Control group|Routine advices about the interest of increase fluid after lumbar puncture to prevent PDPH will be transmitted: 2 liters will be provided to be drunk in 2 hours.
16563330|NCT02859233|Experimental|Interventional group|Lack of hyperhydration : no particular advices will be transmitted about the interest of oral hyperhydration. 500 milliliters will be provided in case of thirst, according to patient's convenience.
16563331|NCT02859220|Other|group 1|group 1 : Roche Elecsys intact PTH
16563332|NCT02859220|Other|group 2|group 2 : PTH 1-84 complete (PAC) report and CAP / PTH 7-84 (CIP), Duo PTH IRMA Scantibodies
16563333|NCT02859207|Experimental|Cohort 1|Participants with mild hepatic impairment (Child-Pugh class A).
16563334|NCT02859207|Experimental|Cohort 1C|Healthy participants (control) matched to participants in Cohort 1.
16563335|NCT02859207|Experimental|Cohort 2|Participants with moderate hepatic impairment (Child-Pugh class B)
16563336|NCT02859207|Experimental|Cohort 2C|Healthy participants (control) matched to participants in Cohort 2
16563337|NCT02859194|Experimental|Veno-veno-arterial ECMO group|
16563338|NCT02859181|Experimental|Active, Adolescent males|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
16563341|NCT02859155|Other|Multiviceral resection colorectal cancer|Multiviceral resection surgery of 2 or more intrabdominal organs en bloc with colorectal cancer
16563342|NCT02859142|Experimental|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.
~Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions
~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
16563343|NCT02859142|Active Comparator|Standard Treatment w/ placebo|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits in addition to placebo pills identical in appearance to varenicline
~Placebo pills (identical to varenicline)
~NicodermCQ (Nicotine Patches): Administered according to package insert directions
~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
16563344|NCT02859129|Experimental|Rosuvastatin|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
16563345|NCT02859129|Experimental|Epanova®|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)
16563346|NCT02859129|Experimental|Epanova® + Crestor®|Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24
16563347|NCT02859129|Active Comparator|Vascepa®|Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).
16563348|NCT02859116||Collection of digestive tissues|Digestive tissues will be collected from participants undergoing scheduled (non-emergent) gastrointestinal surgery.
16563349|NCT02859103|Active Comparator|Treatment|Patients in this arm will receive treatment with desvenlafaxine for 8 weeks.
16563350|NCT02859103|No Intervention|Healthy Control|Patients in this arm are healthy controls and will not receive any medication.
16563351|NCT02859090|Experimental|patient|
16563352|NCT02859077|Experimental|EGFR-TKI and Chemotherapy|NSCLC patients
16563353|NCT02859064|Experimental|Lanreotide/Y-90 microspheres|"Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy.
~Y-90 (Yttrium-90) microspheres [SIR-Spheres therapy]: dose and treatment day to be determined by treating radiation oncologist."
16563354|NCT02859051|No Intervention|control|No intervention
16563355|NCT02859051|Experimental|robot|Humanoid robot interacts with child, teaching breathing and coping strategies.
16563356|NCT02859038|Experimental|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy.
16563357|NCT02859038|Active Comparator|Neoadjuvant chemotherapy|neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy.
16563358|NCT02859025|Active Comparator|A:Iiac|Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.
16563359|NCT02859025|Experimental|B:MSCs+LRCP|Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect
16563361|NCT02859012|Experimental|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
16563362|NCT02859012|Active Comparator|observation|Observation. if disease progression is detected, cross-over will be permitted.
16563363|NCT02858999|Experimental|treatment|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles PAD-VCD
16563364|NCT02858986|Experimental|3D laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 3D laparoscopic system
16563365|NCT02858986|Experimental|4K laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 4K laparoscopic system
16563366|NCT02858973|Experimental|Q203|Q203 tablets
16563367|NCT02858973|Placebo Comparator|Placebo|Placebo tablets
16563368|NCT02858960|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO
~Constant Treadmill Load Test (CTLT) using HFNCO"
16563369|NCT02858960|Active Comparator|The Venturi Mask|"Incremental Load Treadmill Test (ILTT) using venturi mask
~Constant Treadmill Load Test (CTLT) using venturi mask"
16563370|NCT02858947|Active Comparator|Aelite Flo|Microhybrid flowable composite
16563371|NCT02858947|Active Comparator|x-tra base|Bulk-fill flowable composite
16563372|NCT02858934|Experimental|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
16563373|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
16563374|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
16563375|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
16563376|NCT02858908|Experimental|Cohort 1 - Tideglusib|1000 mg tideglusib, orally, once daily
16563377|NCT02858908|Experimental|Cohort 2 - Tideglusib|400 mg tideglusib, orally, once daily
16563378|NCT02858895|Experimental|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).*
~*Subjects may be eligible to receive a second administration of MDNA55."
16563379|NCT02858882||Swimmers|Screening of elite athletes
16563380|NCT02858869|Experimental|Arm A (pembrolizumab, SRS 6 Gy, CLOSED):|Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat Q3W for at least 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo 5 SRS fractions between days 2-15 of course 1.
16563381|NCT02858869|Experimental|Arm B (pembrolizumab, SRS 9 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 3 SRS fractions between days 2-15 of course 1.
16563382|NCT02858869|Experimental|Arm C (pembrolizumab, SRS 18-21 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 1 SRS fraction between days 2-3 of course 1.
16563383|NCT02858856|Experimental|A group|Take Sipjeondaebo-tang on 0~2 week, 3~5 week of clinical trial period, total of 4 weeks
16563384|NCT02858856|Experimental|B group|Take Sipjeondaebo-tang on 6~8 week, 9~11 week of clinical trial period, total of 4 weeks
16563385|NCT02858843|Experimental|Lumacaftor-ivacaftor|Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.
16563386|NCT02858830|Other|Group 1: Healthy Subject|Healthy Subject (Control) will undergo assessments before and after ingesting a high fat mixed meal.
16563387|NCT02858830|Other|Group 2: FPL Subject|FPL Subject will undergo assessments before and after ingesting a high fat mixed meal.
16563388|NCT02858817|Experimental|51,200 PfSPZ|Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
16563389|NCT02858817|Experimental|150,000 PfSPZ|Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
16563390|NCT02858817|Placebo Comparator|Placebo|Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
16563391|NCT02858804|Experimental|Etoposide|50 mg/m2, IV, d1-4
16563392|NCT02858804|Experimental|Doxorubicin|10 mg/m2, IV, d1-4
16563393|NCT02858804|Experimental|Dexamethasone|30 mg/d, d1-5
16563394|NCT02858804|Experimental|Vincristine|0.4 mg/m2, IV, d1-4
16563395|NCT02858804|Experimental|Cyclophosphamide|750 mg/m2 ,d5
16563396|NCT02858804|Experimental|Cytarabine|2g/m2, q12h, d1
16563397|NCT02858804|Experimental|Cisplatin|100mg/ m2,IV, d1
16563398|NCT02858804|Experimental|Rituximab|375 mg/m2 IV, d1
16563399|NCT02858804|Experimental|Thalidomide|50-150mg/d, po, d1-28
16563400|NCT02858804|Experimental|Prednisone|0.5mg/Kg, po, qod
16563401|NCT02858791||Healthy Controls|"Subjects are made up of healthy adults
~Interventions:
~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
16563402|NCT02858791||Affected|"Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease
~Interventions:
~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
16563403|NCT02858778|Experimental|Interventional group (Ig)|The interventional group (Ig) will have an early palliative care consultation ordered during their stay in the emergency department.
16563404|NCT02858778|No Intervention|Control group (Cg)|The control group will be treated as standard of care. Palliative care consultations may or may not be ordered at the attending physician's discretion.
16563405|NCT02858765|Experimental|white polychromatic light A|
16563406|NCT02858765|Experimental|white polychromatic light B|
16563407|NCT02858765|Experimental|white polychromatic light C|
16563409|NCT02858752|Experimental|Healthy Children|Memory and Attention in healthy children will be assessed non-invasively through behavioral and electrophysiological measures while participants will perform passive or active computer task involving auditory and/or visual perception.
16563410|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
16563411|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
16563412|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
16563413|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
16563414|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
16563415|NCT02858713|No Intervention|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
16563416|NCT02858700|Experimental|umbilical cord blood procalcitonin|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
16563417|NCT02858687|Experimental|Patients with clinical diagnosis of tonsillitis|
16563418|NCT02858674|Experimental|Active Alerting Mechanism|Traditional Pop Up Alert used in Epic
16563419|NCT02858674|Active Comparator|Passive Alerting Mechanism|Noninterruptive alert that sits in the checklist
16563420|NCT02858661|Experimental|Patients diagnosed with clinical meningitis|Patients admitted in emergency rooms for clinical meningitis, for which a nasopharyngeal swab will be performed in order to confirm the etiological diagnosis of meningitis
16563421|NCT02858648|Experimental|Behavior intervention with smart phone based self-monitoring|Patients in this group were asked to attend 11 group and 1 individual session over 6 months, and received a smartphone with two downloaded applications to monitor diet, physical activity, weight, and blood glucose (connected with a blue tooth glucometer) throughout 6 months.
16563422|NCT02858648|Experimental|Behavior intervention with paper diary based self-monitoring|Patients in this group were asked to attend 11 group sessions and 1 individual session over 6 months, and received paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer to monitor diet, physical activity, weight, and blood glucose throughout 6 months.
16563423|NCT02858648|No Intervention|Usual care|Patients in this group received no intervention, they continue to receive usual diabetes care and education from the recruitment clinic.
16563424|NCT02858635|Experimental|Suicide attempters|Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
16563425|NCT02858622|Active Comparator|dual TAB group|22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
16563426|NCT02858622|Sham Comparator|control group|22 patients who will not receive dual TAB block
16563427|NCT02858609|Experimental|Patients with Diarrhoea|Patients admitted in emergency room with Diarrhoea
16563428|NCT02858596|Experimental|Semi-solid feed group|Given semi-solid feed protocol
16563429|NCT02858596|Placebo Comparator|Liquid feed group|Given liquid feed protocol
16563430|NCT02858583|Experimental|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI."
16563431|NCT02858583|Active Comparator|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
16563432|NCT02858570|Experimental|MenCC-BIO Vaccine|Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old)For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
16563433|NCT02858570|Active Comparator|combined - CRM197|Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
16563434|NCT02858557|Experimental|Group A|Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
16563435|NCT02858557|Experimental|Group B|Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
16563436|NCT02858544||Group1 - Validation Group|n=890 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
16563437|NCT02858544||Group 2 - Cross Validation Group|n=900 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
16563438|NCT02858531||patients < 24 months or 60 years with bronchiolitis or ARF|ARF = Acute Renal Failure
16563439|NCT02858518||patients with atrial fibrillation with anticoagulant treatment|
16563440|NCT02858505|Active Comparator|27 mg elemental iron group|received 27 mg elemental iron once daily starting at 12 weeks until 36 weeks
16563441|NCT02858505|Active Comparator|54 mg elemental iron group|received 54 mg elemental iron once daily starting at 12 weeks until 36 weeks
16563442|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
16563443|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
16563449|NCT02858453|Experimental|AQX-1125 100 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
16563450|NCT02858453|Experimental|AQX-1125 200 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
16563451|NCT02858453|Placebo Comparator|Placebo|2 placebo tablets, by mouth, once per day for 12 weeks; followed by randomization to 100 mg or 200 mg AQX-1125 for a 52-week Extension Period
16563452|NCT02858440|Experimental|DTPa-IPV/Hib Group|All subjects receive three doses of primary vaccination of the study vaccine, Infanrix-IPV/Hib (DTPa-IPV/Hib), at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
16563453|NCT02858427|Experimental|depressed with suicide attempt (SA)|elderly depressed patients with a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
16563454|NCT02858427|Experimental|depressed without a history of SA|elderly depressed patients without a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
16563455|NCT02858414|Experimental|blood sample|
16563456|NCT02858401|Experimental|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
16563457|NCT02858401|Experimental|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
16563458|NCT02858401|Experimental|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
16563459|NCT02858401|Experimental|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
16563460|NCT02858401|Experimental|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
16563461|NCT02858401|Experimental|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
16563462|NCT02858401|Experimental|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
16563463|NCT02858401|Experimental|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
16563464|NCT02858401|Experimental|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
16563465|NCT02858401|Placebo Comparator|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
16563466|NCT02858388|Active Comparator|SN45|Sinuclean Nebules 45
16563467|NCT02858388|Placebo Comparator|Sal|Saline solution
16563468|NCT02858362|Experimental|Cohort 1: SMT C1100 Formulation 1|Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
16563469|NCT02858362|Experimental|Cohort 2: SMT C1100 Formulation 2|Participants received 1 g SMT C1100 formulation 2 orally twice-daily for at least 48 weeks.
16563470|NCT02858362|Experimental|Cohort 3: SMT C1100 Formulation 1|Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
16563471|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
16563474|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
16563475|NCT02858310|Experimental|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin
16563476|NCT02858310|Experimental|Arm 2: Phase II|1 x 10 e11 E7 Cells that was determined in Phase I + aldesleukin
16563477|NCT02858297|Experimental|Glucosamine/Corticosteroid 4|Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
16563478|NCT02858297|Experimental|Glucosamine/Corticosteroid 2|Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
16563479|NCT02858297|Active Comparator|Corticosteroid|Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
16563480|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
16563481|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
16563482|NCT02858271|Experimental|AKB-9778|Single dose of [14C]-radiolabeled subcutaneous (SC) injection of AKB-9778 in the morning of Day 1
16563483|NCT02858258|Active Comparator|Standard Arm A|"R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
~Drug: R-CHOP/R-DHAP
~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM"
16563484|NCT02858258|Experimental|Experimental Arm A+I|"R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)
~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM
~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)"
16563485|NCT02858258|Experimental|Experimental Arm I|"R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)
~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)"
16563486|NCT02858245||Commercial MitraClip® patients|Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
16563487|NCT02858232|Experimental|solid tumor|Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
16563488|NCT02858219|Experimental|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).
~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
16563489|NCT02858219|Placebo Comparator|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
16563490|NCT02858206|Experimental|Neoadjuvant nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.
~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
16563491|NCT02858206|Active Comparator|Neoadjuvant chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.
~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
16563492|NCT02858206|Experimental|Radical nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
16563493|NCT02858206|Active Comparator|Radical chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
16563494|NCT02858193|Experimental|1.35 g SCMC- lys powder|1.35 g of SMC L-lysine monohydrate salt powder for solution
16563495|NCT02858193|Experimental|Fluifort® syrup|Fluifort® syrup 90 mg SCMC-lys/mL
16563496|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)
~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
16563497|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)
~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
16563498|NCT02858167|Experimental|FDG-PET|
16563499|NCT02858154|Other|HFNC and low flow oxygen by nasal cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)
16563500|NCT02858115||one lung ventilation lung|patients requiring one lung ventilation lung resection.
16563501|NCT02858102|Active Comparator|Active treatment group|Physical activity program: 36 sessions of physical activity lasting between 30-60 minutes for 12 weeks, three days per week.
16563502|NCT02858102|No Intervention|Control group|No physical activity program
16563503|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
16563504|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
16563505|NCT02858063||Pending chemotherapy +/- trastuzumab|In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
16563506|NCT02858063||pending trastazumab +/- hormone therapy|In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
16563507|NCT02858063||pending hormone therapy alone|In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
16563508|NCT02858063||pending afercare period|In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
16563509|NCT02858050||MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
16563510|NCT02858050||MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
16563511|NCT02858037|Experimental|HIV Open-label Prevention|"Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women
~MTN-020:NCT01617096 MTN-025: NCT02858037"
16563512|NCT02858024|Active Comparator|Cohort I|In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
16563513|NCT02858024|Active Comparator|Cohort II|In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
16563514|NCT02858011|Active Comparator|Control and comparison group -cash transfer program|The program is implemented during 48 months. During the first 36 months the control group does not receive any intervention. During the last 12 months eligible beneficiaries receive cash transfer and accompanying information sessions on health, child nutrition, household economics every three months (identical to experimental group).
16563515|NCT02858011|Experimental|Jigisemejiri cash transfer program|Unconditional cash is distributed every 3 months to beneficiaries of the Jigisemejiri program. During cash handouts, information sessions on health, child nutrition, households economics and education are organized by local NGOs.
16563516|NCT02858011|Experimental|Jigisemejiri - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women receiving rations of fortified flour (PNP) during the last 12 months of the project
16563517|NCT02858011|Active Comparator|Control and comparison group - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women
16563518|NCT02857998|Experimental|HMPL-523|Oral administration, at dose of 200, 400, 600 and 800 mg once daily;at dose of 200,300, 400mg twice daily at Dose-escalation stage; At Dose-expansion stage, if patients dosing at 600mgQD.
16563519|NCT02857985|Experimental|Patient with Myocardial Infarction|
16563520|NCT02857972|Experimental|Wondaleaf®|This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
16563521|NCT02857959|Experimental|single dose benzathine penicillin G.|single dose benzathine penicillin G.
16563522|NCT02857959|Active Comparator|three doses of benzathine penicillin G.|three doses of benzathine penicillin G.
16563523|NCT02857946|Experimental|A Test|Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin
16563524|NCT02857946|Active Comparator|B Reference|Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin
16563525|NCT02857933|Other|Frequency Level 1 - Daily Therapy|Level 1 daily physical therapy is 2 hours of one-on-one physical therapy per day for 20 straight weekdays
16563526|NCT02857933|Other|Frequency Level 2 - Intermediate Therapy|Level 2 intermediate physical therapy is 2 hours of therapy per day 3 days per week for 6.6 weeks
16563527|NCT02857933|Other|Frequency Level 3 - Usual Therapy|Level 3 usual weekly physical therapy is 2 hours of therapy one day per week for 20 weeks.
16563528|NCT02857920|Experimental|Bevacizumab and NK immunotherapy|In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16563529|NCT02857920|Active Comparator|Bevacizumab|In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16563530|NCT02857907||ATG group|Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
16563531|NCT02857907||anti-CD25 group|Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
16563532|NCT02857881|Experimental|Evolutive keratoconus|
16563533|NCT02857868|Experimental|ABL001|
16563534|NCT02857855|Experimental|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
16563535|NCT02857855|Active Comparator|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
16563536|NCT02857842|Experimental|Blood eosinophil guided prednisolone treatment|Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood <0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.
16563537|NCT02857842|Active Comparator|Standard of care|Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days
16563538|NCT02857829|Placebo Comparator|Placebo|
16563539|NCT02857829|Active Comparator|Caffeine-alone|The effects of the combination will be compared to both placebo and caffeine-alone, to test the hypothesis that the blend of ingredients will enhance cognitive measures greater than the most commonly used cognitive enhancer, caffeine.
16563540|NCT02857829|Experimental|CAF+|
16563541|NCT02857816|Other|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
16563542|NCT02857803|Experimental|Virtual Reality|The Virtual Reality group will perform personalised activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
16563682|NCT02856750|No Intervention|placebo|no gabapentin administered to this arm.
16563543|NCT02857803|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalised to their deficits and generated automatically through a Task Generator.
16563544|NCT02857803|Active Comparator|Conventional Therapy|The Conventional Therapy group will perform the activities offered by the public health system, which are motor-focused.
16563545|NCT02857777|Experimental|Cohort 1: Japanese elderly subjects (Esketamine)|Subjects will receive Treatment A (28 milligram [mg] of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0) in Period 1, Treatment B (56 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0 and 5 minutes) in Period 2 and then Treatment C (84 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0, 5, and 10 minutes) in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
16563546|NCT02857777|Active Comparator|Cohort 2: Japanese healthy subjects (Esketamine)|Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
16563547|NCT02857764||Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users|Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
16563548|NCT02857764||Canagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.
16563549|NCT02857764||Dapagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
16563550|NCT02857764||Empagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
16563551|NCT02857764||First-time Non-SGLT2i AHA New Users|Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
16563552|NCT02857751||Surf therapy cohort 1|The first cohort of participants to enroll in the study (i.e., participants in the first 6-week program)
16563553|NCT02857751||Surf therapy cohort 2|The second cohort of participants to enroll in the study (i.e., participants in the second 6-week program)
16563554|NCT02857751||Surf therapy cohort 3|The third cohort of participants to enroll in the study (i.e., participants in the third 6-week program)
16563555|NCT02857751||Surf therapy cohort 4|The fourth cohort of participants to enroll in the study (i.e., participants in the fourth 6-week program)
16563556|NCT02857751||Surf therapy cohort 5|The fifth cohort of participants to enroll in the study (i.e., participants in the fifth 6-week program)
16563557|NCT02857738|Experimental|SPF evaluation|Subjects with Good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
16563558|NCT02857725|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were considered for SPF testing.
16563559|NCT02857712|Experimental|Axitinib|Axitinib will be administered at 5 mg BID (starting dose); in case of no adverse events above CTCAE version 4.0 Grade 2 for a consecutive 2-week periods, the dose may be increased to 7 mg BID and further to 10 mg BID using the same criteria until tumor progression, unacceptable toxicity or other criteria for discontinuation is met.
16563560|NCT02857686|Active Comparator|arm intravenous regional anesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
16563561|NCT02857686|Experimental|forearm intravenous regional anesthesia|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
16563562|NCT02857673|Experimental|Intervention Group|The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
16563563|NCT02857673|Active Comparator|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers. The study team member will not be trained in CAPPS and will adhere to a case management model consistent with resources available in the medical home, checking in with control families and offering to help identify existing clinic and community resources as needed.
16563564|NCT02857660|Experimental|Whole-Body Electromyostimulation and Protein|16 weeks of whole-body intervention 1.5 x 20 min week with bipolar current up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
16563565|NCT02857660|Active Comparator|Protein supplementation|up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
16563566|NCT02857660|No Intervention|sedentary Control Group|No protein supplementation or WB-EMS-application, but up to 800 IU/d Vitamin D-Supplementation
16563567|NCT02857647|Experimental|The experimental group|"Participants who will assigned to the experimental group will be asked to watch an information video of 30 minutes 1-2 weeks prior to the surgery date.
~n=100."
16563568|NCT02857647|No Intervention|The control group|"Participants who will assigned to the control group will receive standard care and will not asked to watch a videotaped lecture prior to the surgery.
~n=100."
16563569|NCT02857634||Bladder tumor resection|
16563570|NCT02857608|Experimental|Lymphoseek - 0.5 mCi, 50 ug|A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
16563571|NCT02857595|Active Comparator|Online Weight Loss Program|
16563572|NCT02857595|Experimental|Online Weight Loss Program + Nomogram|
16563574|NCT02857582|Active Comparator|Vancomycin|Secondary treatment for relapse of Clostridium difficile infection.
16563575|NCT02857582|Experimental|Cultured human intestinal microbiota1|Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
16563576|NCT02857582|Experimental|Cultured human intestinal microbiota2|Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.
16563577|NCT02857569|Experimental|Experimental IT Arm|"ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response, eradication of all injectable sites, disease progression or toxicity, for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).
~nivolumab: 1mg/kg, IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
16563578|NCT02857569|Active Comparator|Standard Arm|"ipilimumab: 3mg/kg, IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.
~nivolumab: 1mg/kg, IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
16563579|NCT02857556|Other|group with stage 3 kidney failure (diabetic or not)|
16563580|NCT02857556|Other|group with stage 5 kidney failure (diabetic or not)|
16563581|NCT02857543|Active Comparator|plant-based diet|Plant-based diet with as few added oils and fats as possible
16563582|NCT02857543|Active Comparator|American Heart Association|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation.
16563583|NCT02857543|Active Comparator|Mediterranean|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, with more emphasis on fish and extra virgin olive oil and/or nuts.
16563584|NCT02857530|Experimental|rhTPO|rhTPO injection
16563585|NCT02857530|Placebo Comparator|control|without rhTPO injection
16563586|NCT02857517|Experimental|intravitreal 0.05ml conbercept for ICNV|0.05ml conbercept ,1 injection with PRN
16563587|NCT02857504|Other|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
16563588|NCT02857504|Other|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
16563589|NCT02857491|Experimental|ranibizumab|Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.
16563590|NCT02857491|Sham Comparator|control|Sham intravitreal injection one week before vitrectomy.
16563591|NCT02857478|Experimental|Safety of a Sunscreen product|Sunscreen product safety evaluation under supervised out-door conditions on sport users.
16563592|NCT02857465|Experimental|Epidural analgesia + DEXAMETHASONE|Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
16563593|NCT02857465|Placebo Comparator|Epidural analgesia + PLACEBO|Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
16563594|NCT02857452||Lupus|
16563595|NCT02857439|Other|MD as first examiner|Patients will be examined according to a standardized physical examination item list
16563596|NCT02857439|Other|Triage nurse as first examiner|Patients will be examined according to a standardized physical examination item list
16563597|NCT02857426|Experimental|Nivolumab for population with PCNSL|Specified dose on specified days
16563598|NCT02857426|Experimental|Nivolumab for population with PTL|Specified dose on specified days
16563599|NCT02857400|Other|Arm A (standard)|
16563600|NCT02857400|Experimental|Arm B (experimental)|
16563601|NCT02857387|Experimental|acute coronary syndrome|
16563602|NCT02857374|Experimental|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
16563603|NCT02857361|Experimental|Treatment A: Simultaneous Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
16563604|NCT02857361|Experimental|Treatment B: Sequential Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
16563605|NCT02857348|Experimental|Adventure video game|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for one hour.
16563606|NCT02857348|Active Comparator|Educational Module|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least one hour on the combined tasks.
16563607|NCT02857335|Other|study group|patients with benign intracranial hypertension ages 8-16 years
16563608|NCT02857322|Other|subjects with documented psychiatric pathology|
16563609|NCT02857309|Other|Device implant|Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
16563610|NCT02857309|Active Comparator|Optimal medical therapy|Patients randomized to the control group will receive optimal medical therapy for heart failure.
16563611|NCT02857283|Experimental|Filtered Air, then Ozone|Participants in this arm will first receive filtered clean air followed by ozone
16563612|NCT02857283|Experimental|Ozone, then Filtered Air|Participants in this arm will first receive ozone followed by filtered clean air
16563613|NCT02857270|Experimental|LY3214996 Dose Escalation|LY3214996 given orally once a day (or twice a day) for 21 days.
16564005|NCT02854631|Placebo Comparator|Prednisolone|Selonsertib placebo + prednisolone for 28 days
16563614|NCT02857270|Experimental|LY3214996 + Midazolam|"(Preliminary Drug-Drug Interactions [DDI])
~LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days)."
16563615|NCT02857270|Experimental|LY3214996 Dose Expansion|LY3214996 given orally (once a day) during each 21 day cycle.
16563616|NCT02857270|Experimental|LY3214996 + Abemaciclib|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.
16563617|NCT02857270|Experimental|LY3214996 + Nab-Paclitaxel + Gemcitabine|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.
16563618|NCT02857270|Experimental|LY3214996 + Encorafenib + Cetuximab|Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.
16563619|NCT02857270|Experimental|Japan Part 1|LY3214996 given orally.
16563620|NCT02857270|Experimental|Japan Part 2|LY3214996 given orally and abemaciclib given orally.
16563621|NCT02857257|Experimental|Treatment arm|Only one treatment arm. Patients are allocated under disease condition and later treated with ACHIM. The post-treatment disease progression is monitored.
16563622|NCT02857244|Other|Open-Label Treatment Arm|"Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week.
~After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week.
~Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil."
16563623|NCT02857218|Experimental|Diagnostic (ferumoxytol, MRI)|Patients receive ferumoxytol IV over 15 minutes and then undergo ferumoxytol-enhanced MRI (Magnetic Resonance Imaging) after 24-36 hours and before surgery at week 12.
16563624|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
16563625|NCT02857192|Experimental|Horton|
16563626|NCT02857192|Placebo Comparator|control|
16563627|NCT02857166|Experimental|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
16563628|NCT02857153|Experimental|Low-level MAP|According to grouping, MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
16563629|NCT02857153|Experimental|High-level MAP|According to grouping, MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
16563630|NCT02857127|Experimental|Intervention Group|A group of people who participated in the walking program during a six month period. This group also received an educational material and attended meetings for behavioral change strategies.
16563631|NCT02857127|No Intervention|Control Group|A group of people who did not receive the educational material and did not participated in any of the activities offered by the research team, such as walking classes and meetings for behavioral change.
16563632|NCT02857114|Other|massage|
16563633|NCT02857088|Experimental|depressed patients|patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
16563634|NCT02857088|Experimental|non depressed subject|subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
16563635|NCT02857075||Rhesus positive individuals|Red cell concentrates from RH1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
16563636|NCT02857075||Rhesus negative individuals|red cell concentrates from RH-1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
16563637|NCT02857062|Experimental|E45 Eczema Repair Emollient|Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
16563638|NCT02857049|Experimental|Geriatric patients administered with ONS|Oral nutritional supplements (ONS) degustation
16563639|NCT02857036|Experimental|responder|responder to antidepressant treatment
16563640|NCT02857036|Experimental|non responder|non responder to antidepressant treatment
16563641|NCT02857023|Experimental|Cogmed intervention|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
16563642|NCT02857023|Experimental|Cogmed-waitlist control|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
16563643|NCT02857010|Experimental|Allogenic Mesenchymal stem cells|Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
16563644|NCT02857010|Placebo Comparator|Placebo|Solution without cells on days 1, 4, 11 and 18
16563645|NCT02856997|Experimental|Chidamide with ICE regimen|"Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours during Ifosfamide transfusion, ivg, d1-4; Carboplatin AUC=4, d2,ivg; etoposide 65mg/m 2, d1-4, ivg. 3 weeks as 1 course, for 6 courses.
~if the effect is PR or better than PR, go to auto-stem cell transplantation, no further treatment with Chidamide is needed.
~If the effect is PR or better than PR and no auto-stem cell transplantation available,Chidamide 20mg orally, twice every week, till the end of the trial."
16563646|NCT02856984||ZIKV infected women|The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.
16564006|NCT02854618|Experimental|Everolimus treatment|
16563647|NCT02856984||Control (uninfected women)|The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.
16563648|NCT02856958|Experimental|Operative|Peroneal nerve decompression
16563649|NCT02856958|Active Comparator|Non-operative|Physical therapy
16563650|NCT02856932|Experimental|Glass Ionomer with Glass Hybrid technology|Intervention
16563651|NCT02856932|Active Comparator|Conventional high viscosity Glass Ionomer|Comparator
16563652|NCT02856919|Other|Mirvaso® gel|Mirvaso® gel (5 mg/g brimonidine tartrate)
16563653|NCT02856906|Experimental|Occlusal adjustment group|Patients in this group will receive treatment of occlusal adjustment based on the clinical and lab examination results.
16563654|NCT02856893|Experimental|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
16563655|NCT02856893|Experimental|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
16563656|NCT02856893|Active Comparator|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
16563657|NCT02856880|Experimental|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
16563658|NCT02856880|Experimental|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
16563659|NCT02856880|Active Comparator|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
16563660|NCT02856880|Active Comparator|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
16563661|NCT02856880|Active Comparator|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
16563662|NCT02856867|Active Comparator|mFOLFOX6 + Nintedanib|"Patients will receive nintedanib in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).
~Dose modification of nintedanib and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
16563663|NCT02856867|Placebo Comparator|mFOLFOX6 + Placebo|"Patients will receive placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).
~Dose modification of placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
16563664|NCT02856854|Experimental|EMB-001 (oral)|EMB-001 will be orally administered for 7 consecutive days, twice daily for 6 days followed on the last day by one EMB-001 oral dose (QD) in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
16563665|NCT02856854|Placebo Comparator|Placebo (oral)|PLB-to-match EMB-001 will be orally administered for 7 consecutive days, BID for 6 days, followed on the last day by one PLB oral dose in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
16563666|NCT02856841||optimum cytoreduction|without any gross tumor residue after surgery
16563667|NCT02856841||Suboptimum cytoreduction|with any gross tumor residue after surgery
16563668|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
16563669|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
16563670|NCT02856815|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 12 times(5 treatments at a frequency of once per week, followed by 5 treatments every 2 weeks, and finally 2 treatments every 4 weeks.
16563671|NCT02856815|No Intervention|Non-treatment group|Non-treatment
16563672|NCT02856802|Experimental|DFN-02|Participants self-administered a single-dose of DFN-02 (sumatriptan 10-mg/100 μL nasal spray) intranasally within one hour of an acute migraine pain episode.
16563673|NCT02856802|Other|Placebo|Participants self-administered a single-dose of DFN-02 placebo nasal spray matching DFN-02 intranasally within one hour of an acute migraine pain episode.
16563674|NCT02856789||Healthy volunteers (HV)|"HV without any known treatment, without any coagulation trouble and with normal hemostasis results.
~FS and TEG will be processed to define the most relevant parameters for normal range and the correlation between both assays.
~Tests performed on HV :
~Routine hemostasis tests
~Fibrin structure (FS)
~Thromboelastography (TEG)
~Specialized hemostasis tests"
16563675|NCT02856789||Patients without coagulation disorder|"Hospitalized patients without coagulation disorder or abnormal hemostasis and hematological results and witout ongoing treatment (mainly anticoagulant treatment). FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.
~Tests performed on patients :
~Routine hemostasis tests
~Fibrin structure (FS)
~Thromboelastography (TEG)"
16563676|NCT02856789||Patients with coagulation disorders|"Hospitalized patients with coagulation disorders, mainly trauma patients or abnormal hemostasis and hematological results, mainly decreased fibrinogen level . FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.
~Tests performed on patients :
~Routine hemostasis tests
~Fibrin structure (FS)
~Thromboelastography (TEG)"
16563677|NCT02856776|Experimental|Arm 1: 600 IU vitamin D|Subject will receive 600 IUs of vitamin D3/day for 24 weeks.
16563678|NCT02856776|Experimental|Arm 2: 4,000 IU vitamin D|Subject will receive 4,000 IUs of vitamin D3/day for 24 weeks
16563679|NCT02856776|Experimental|Arm 3: 10,000 IU vitamin D|Subjet will receive 10,000 IUs of vitamin D3/day for 24 weeks
16563680|NCT02856776|Experimental|Arm 4: Mixed vitamin D dosages|Subject will receive 600 IUs of vitamin D3/day for the first 8 weeks, 4,000 IUs of vitamin D3/day for the next 8 weeks, and 10,000 IUs of vitamin D3/day for the final 8 weeks.
16563683|NCT02856737|Experimental|Earplugs and eye masks (to be used concurrently)|Group will include patients consented to the use of earplugs and eye masks. Patients will participate in the intervention nightly
16563684|NCT02856724|Experimental|Early amniotomy and PGE2|10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
16563685|NCT02856724|Active Comparator|PGE2|10 mg PGE2 vaginal ovul(Propess)
16563686|NCT02856711|Experimental|Trauma-informed group|These groups will use the enhanced Centering Pregnancy curriculum.
16563687|NCT02856711|No Intervention|Control group|These groups will use the standard CenteringPregnancy curriculum.
16563688|NCT02856698|Experimental|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
16563689|NCT02856698|Active Comparator|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
16563690|NCT02856685|Experimental|PLM60|Mitoxantrone Hydrochloride Liposome
16563691|NCT02856672|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
16563692|NCT02856672|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
16563693|NCT02856646||Population with Condition|Community Sample
16563694|NCT02856633||Vitaliti System|
16563695|NCT02856620||Moderate AS with HF|
16563696|NCT02856620||Severe AS with HF|
16563697|NCT02856620||Moderate AS without HF|
16563698|NCT02856620||Severe AS without HF|
16563699|NCT02856620||HFpEF without AS|
16563700|NCT02856620||Normal age-matched controls|
16563701|NCT02856607||Group I|patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
16563702|NCT02856607||Group II|patients secondary addressed to a referent center with cardiac surgery
16563703|NCT02856607||Group III|patients for which the totality medical care are performed in non-referent health center
16563704|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
16563705|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
16563706|NCT02856581|Experimental|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
16563707|NCT02856581|Placebo Comparator|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
16563708|NCT02856568|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, ricolinostat)|Patients receive cisplatin IV followed by gemcitabine hydrochloride IV on days 1 and 8, and ricolinostat PO on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16563709|NCT02856555|Experimental|Firsocostat 5 mg|Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
16563710|NCT02856555|Experimental|Firsocostat 20 mg|Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
16563711|NCT02856555|Experimental|Placebo|Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
16563712|NCT02856529|Experimental|Intervention|A BICSL certified trainer conduct the intervention. It includes hand on training session standardized in a scientific way. The participants trained on hand hygiene and use of PPE. Also, it includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator.
16563713|NCT02856529|Active Comparator|Control|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
16563714|NCT02856516|Experimental|Boost Glucose Control (A)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
16563715|NCT02856516|Experimental|Boost Glucose Control (B)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
16563716|NCT02856516|Active Comparator|Boost Original|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.
16563717|NCT02856503|Experimental|Phase 1 - Group A - VD 3 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.
16563718|NCT02856503|Active Comparator|Phase 1 - Group B - VD 4 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks
16563719|NCT02856503|Active Comparator|Phase 1 - Group C - VD 5 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.
16563720|NCT02856503|Experimental|Phase 2 - VD|Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.
16563721|NCT02856477|Experimental|adapted treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
16563722|NCT02856477|Experimental|non-adaptated treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
16563723|NCT02856464|Experimental|Experimental|
16563724|NCT02856464|Other|Control|
16563725|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
16563726|NCT02856425|Experimental|NSCLC of adenocarcinoma tumor hist|
16563727|NCT02856425|Experimental|NSCLC of squamous cell tumor histo|
16563728|NCT02856425|Experimental|Urothelial cancer|
16563729|NCT02856425|Experimental|Renal Cell cancer (RCC)|
16563730|NCT02856425|Experimental|Colo Rectal Cancer|
16563731|NCT02856425|Experimental|Ovarian cancer (OC)|
16563732|NCT02856425|Experimental|Hepatocellular (HCC)|
16563733|NCT02856425|Experimental|Mesothelioma (MPM)|
16564007|NCT02854605|Experimental|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
16563736|NCT02856386|Experimental|polyphenol supplement|Dietary supplement administered 8 mL once daily
16563737|NCT02856373|Other|CPVT|catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
16563738|NCT02856373|Other|long QT syndrome|long QT syndrome patients
16563739|NCT02856373|Other|ARVC|arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
16563740|NCT02856373|Other|HCM|hypertrophic cardiomyopathy (HCM) patients
16563741|NCT02856373|Other|DCM|dilated non-ischemic cardiomyopathy (DCM) patients
16563742|NCT02856373|Other|ICM|ischemic cardiomyopathy (ICM) patients
16563743|NCT02856360|Experimental|Moderate Stiffness|Shoe condition that has moderate stiffness
16563744|NCT02856360|Active Comparator|High Stiffness|Shoe condition that has high stiffness
16563745|NCT02856347|Other|PET 18-FDOPA|"18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).
~PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).
~Other series of images will be done 50 min after tracer injection. Images will be interpreted."
16563746|NCT02856334||Chronic pelvic pain|Women with chronic pelvic pain
16563747|NCT02856334||Control group|Healthy women
16563748|NCT02856308|Experimental|Hairstetics hair implant device|Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject. The implantation will be carried out according to the device IFU.
16563749|NCT02856295|Active Comparator|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight < 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, >170kg-100mg.
16563750|NCT02856295|Active Comparator|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
16563751|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
16563752|NCT02856269|Active Comparator|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
16563753|NCT02856269|Active Comparator|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
16563754|NCT02856256|Experimental|RedBull® energy drink|
16563755|NCT02856230|Experimental|Ranger SL DEB angioplasty|patients filling general and angiographic inclusion/exclusion criteria will have an BTK angioplasty using one or several Ranger SL drug-eluting balloons
16563756|NCT02856217|Active Comparator|tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal tunneling in SCP: creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum.
16563757|NCT02856217|Active Comparator|non-tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal non-tunneling group in SCP: incised and sutured peritoneum between vaginal apex and sacrum
16563758|NCT02856204||Diagnostic (collection of blood samples)|Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
16563759|NCT02856191|Other|Septic shock|
16563760|NCT02856178|Experimental|F901318 + Caspofungin|"Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:
~Day 1: 4.0 mg/kg i.v. b.i.d.
~Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.
~Day after last i.v. application: 2.0 mg/kg oral q.d.
~Concomitant medication:
~For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:
~Chemo day 4: Caspofungin 70 mg i.v. q.d.
~Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.
~All patients will undergo chemotherapy for acute leukaemia according to local clinical standard."
16563761|NCT02856165|Experimental|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher&Paykel (F&P), NZ)
16563762|NCT02856165|Active Comparator|Low-flow oxygen therapy|Low-flow oxygen therapy with standard nasal canula
16563763|NCT02856152|Experimental|Treatment A Then B Then D Then C|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment A on Day 1 of first intervention period, followed by Treatment B on Day 1 of second intervention period, followed by Treatment D on Day 1 of third intervention period, and then Treatment C on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
16563791|NCT02855983|Other|B (Standard of care initially)|"B PATHWAY -
~Intervention: standard of care (observation) for the first year, followed by autologous fat grafting to the foot
~Observation visit will occur first, next the subject will have two Observation visits V1 (Month 2) and V2 (Month 6). The subject will then crossover to Pathway A. The subject will be assessed by the PI his/her for continued study eligibility. Once the continued eligibility has been determined, the subject will have the interventional fat graft procedure and subsequent post-operative follow up visits (V1-V4). After completion of Post-op V4 (Month 6), the subject will have completed study participation."
16563792|NCT02855970|Experimental|patient|
16563764|NCT02856152|Experimental|Treatment B, Then C, Then A, Then D|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment B on Day 1 of first intervention period, followed by Treatment C on Day 1 of second intervention period, followed by Treatment A on Day 1 of third intervention period, and then Treatment D on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
16563765|NCT02856152|Experimental|Treatment C, Then D, Then B, Then A|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment C on Day 1 of first intervention period, followed by Treatment D on Day 1 of second intervention period, followed by Treatment B on Day 1 of third intervention period, and then Treatment A on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
16563766|NCT02856152|Experimental|Treatment D, Then A, Then C, Then B|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment D on Day 1 of first intervention period, followed by Treatment A on Day 1 of second intervention period, followed by Treatment C on Day 1 of third intervention period, and then Treatment B on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
16563767|NCT02856139||1 (MB- and VL-)|without mottled fluorescent band (MB) and vascular leakage (VL)
16563768|NCT02856139||2 (MB+ and VL-)|with mottled fluorescent band (MB), without vascular leakage (VL)
16563769|NCT02856139||3 (MB-/+ and VL+)|with or without mottled fluorescent band (MB), with vascular leakage (VL)
16563770|NCT02856126|Experimental|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
16563771|NCT02856126|Active Comparator|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
16563772|NCT02856113|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
16563773|NCT02856113|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
16563774|NCT02856100||Patients with CRPC, evidence of metastases, planned treatment|
16563775|NCT02856087|Placebo Comparator|group LR|low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
16563776|NCT02856087|Active Comparator|group HR|High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
16563777|NCT02856087|Experimental|group HR-N|remifentanil infusion at 4ng/ml of Ce with naloxone infusion
16563778|NCT02856074|Experimental|Ischemic stroke patients|
16563779|NCT02856061|Other|PRT|Children with ASD who are currently receiving PRT treatment.
16563780|NCT02856061|No Intervention|Wait List / Non-Treatment Control|Children with ASD who are not currently receiving PRT treatment.
16563781|NCT02856061|No Intervention|Typically Developing|Children without ASD or developmental delay.
16563782|NCT02856048|Experimental|Triptorelin (GnRHa) + Chemotherapy|Triptorelin LP 3 mg (DECAPEPTYL LP 3 mg, IPSEN) 3 mg every 28±3 days, intramuscular during chemotherapy
16563783|NCT02856048|No Intervention|Chemotherapy alone|Patient having a chemotherapy without drug injection for fertility preservation
16563784|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.
~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
16563785|NCT02856022|Experimental|Electrical ilioinguinal nerve stimulation|
16563786|NCT02856022|Active Comparator|Intravesical Irrigation|
16563787|NCT02856009|Experimental|patient|
16563788|NCT02855996|Experimental|Intervention|"Fathers will be randomly assigned to participate in the Fathers in Action/Padres Activos (FA/PA) intervention program to support fathers' healthy relationships with their children and support their co-parenting skills."
16563789|NCT02855996|No Intervention|Control|"Fathers waitlisted for participation in the Fathers in Action/Padres Activos (FA/PA) program."
16563790|NCT02855983|Experimental|A (Fat grafting initially)|"A PATHWAY -
~Intervention: autologous fat grafting to the foot, occur first
~Fat graft study intervention procedure to occur first, next post-operative follow up visits (V1-V4). The Subject will after Month 6 (V4) crossover to Pathway B to complete Observation visits V1 (Month 2) and V2 (Month 6). After completion of V2 (Month 6), the subject will have completed study participation."
16563793|NCT02855957|Other|Blood sample|A blood collection is carry out in the three populations of patients during the day of their enrolment.
16563794|NCT02855944|Experimental|Rucaparib|"Drug: Oral rucaparib
~600 mg BID Other Names: •CO-338
~PF 01367338
~AG 14699
~Rubraca"
16563845|NCT02855619|Active Comparator|Cader|A threshold-based IMT is performed like used by Cader in a randomized trial in 2012, in a view of inspiratory endurance increase.
16564055|NCT02854293||control group|"Conventional palliative management
~76 patients"
16563795|NCT02855944|Active Comparator|Chemotherapy|"Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision."
16563796|NCT02855931|Experimental|Middle turbinate resection|Resection of one middle turbinate
16563797|NCT02855931|No Intervention|Middle turbinate preservation|Preservation of one middle turbinate
16563798|NCT02855918|Other|Blood sample for genetic purpose|"All the participants performed the same evaluations and blood analysis.
~The study is composed of 3 groups :
~depressed patients with an history of suicide attempt
~depressed patients without any history of suicide attempt
~healthy controls without any history of psychopathology"
16563799|NCT02855905|Experimental|Coronary artery disease patients|Coronary artery disease patients are exposed to brief cold exposure (-15 C for 30 min) mainly subjected to facial region during which their cardiovascular responses are registered. Exposure was repeated 4 times: rest and exercise in 22 C and rest and exercise in -15 C.
16563800|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
16563801|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
16563802|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
16563803|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration
~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
16563804|NCT02855879||CAD patients|
16563805|NCT02855866|Experimental|cryotherapy|
16563806|NCT02855866|Active Comparator|Cortisone aerosol|
16563807|NCT02855866|Placebo Comparator|Management|
16563808|NCT02855853|Experimental|serious game|
16563809|NCT02855853|Placebo Comparator|control|
16563810|NCT02855840||systemic lupus erythematous|
16563811|NCT02855840||systemic sclerosis|
16563812|NCT02855840||inflammatory myopathy|
16563813|NCT02855801|Experimental|constant exercise without cryotherapy|constant exercise without cryotherapy
16563814|NCT02855801|Experimental|constant exercise with cryotherapy|constant exercise with cryotherapy
16563815|NCT02855801|Experimental|intermittent exercise, no cryotherapy|intermittent exercise without cryotherapy
16563816|NCT02855801|Experimental|intermittent exercise and cryotherapy|intermittent exercise with cryotherapy
16563817|NCT02855788|Experimental|POLF regimen|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
16563818|NCT02855775|Experimental|Bevacizumab|Bevacizumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
16563819|NCT02855775|Experimental|Trastuzumab|Trastuzumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
16563820|NCT02855762|Other|Dietary Intervention Group|Subject will be guided to eat a high polyunsaturated fatty acid diet.
16563821|NCT02855749|No Intervention|landmark group|percutaneous tracheostomy with traditional landmark technique
16563822|NCT02855749|Active Comparator|ultrasound-guided long axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided in plane technique
16563823|NCT02855749|Active Comparator|ultrasound-guided short axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided out of plane technique
16563824|NCT02855736|Experimental|Intervention group|Positive Psychology (gratitude journal)
16563825|NCT02855736|Placebo Comparator|Control group|Alimentary list
16563826|NCT02855723|Active Comparator|GS strategy|sentinel node biopsy
16563827|NCT02855723|Other|Classic strategy|systematic lymphadenectomy
16563828|NCT02855710|Other|No training|Parkinsonian Patients with no Rhythm Workers training perceptive timing and senrorimotor timing
16563829|NCT02855710|Other|Perceptive timing training|Parkinsonian Patients with Rhythm Workers training perceptive timing
16563830|NCT02855710|Other|Sensorimotor timing training|Parkinsonian Patients with Rhythm Workers training sensorimotor timing
16563831|NCT02855710|Other|Healthy volunteers|Healthy people with Rhythm Workers training perceptive timing
16563832|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
16563833|NCT02855684|Experimental|Toujeo - insulin glargine (U300)|Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
16563834|NCT02855684|Active Comparator|Lantus - insulin glargine|Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
16563835|NCT02855671||Healthy volunteers|
16563836|NCT02855671||Sepsis|
16563837|NCT02855671||Severe sepsis/septic shock|
16563838|NCT02855658|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
16563839|NCT02855658|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
16563840|NCT02855645|Experimental|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
16563841|NCT02855645|Placebo Comparator|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
16563842|NCT02855632|Experimental|G-CSF|G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
16563843|NCT02855632|Placebo Comparator|Normal saline|equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
16563844|NCT02855619|Active Comparator|Martin|A threshold-based IMT is performed like used by Martin in a randomized trial in 2011, in a view of inspiratory strength increase.
16563846|NCT02855619|Experimental|EDRIC|A new threshold-based IMT is performed, in a view of both inspiratory strength and endurance increase.
16563847|NCT02855593||Physicians|Physicians who perform acupuncture
16563848|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
16563849|NCT02855580||PGX Testing Based Treatment|Treatment will be administered based on the results that are obtained from the pharmacogenomics testing. Results from testing will be provided two weeks after specimen collection.
16563850|NCT02855580||Standard of Care Treatment|Treatment will be based off of the standard of care. Results from pharmacogenomics testing will be provided at the end of the study.
16563851|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
16563852|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
16563853|NCT02855554|Experimental|Additional 5 minute research MR scan of heart.|The purpose of this is to evaluate new, faster MR scans
16563854|NCT02855541|Experimental|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
16563855|NCT02855528|Experimental|Reduction of radiation dose and diagnostic accuracy|Reduction of radiation dose during coronary artery calcium scoring with the use of a tin filter system.
16563856|NCT02855515|Experimental|Short-time diagnostic anaesthesia|The study population will consist of patients with obstructive sleep apnoea, which will be classified as mild, moderate, severe (patients who failed or refused primary CPAP treatment). The patients will undergo a short-time general anaesthesia in order to diagnose OSA when relaxed.
16563857|NCT02855502|Active Comparator|Prednisolone|dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
16563858|NCT02855502|Placebo Comparator|Placebo|placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
16563859|NCT02855489|Experimental|Attitudes Only|The attitudes condition targeted cognitive and affective attitudes by pairing attitudinal messages with pictures, and included an evaluative conditioning task.
16563860|NCT02855489|Experimental|Norms Only|The norms condition utilized a group-affirmation exercise, personalized feedback, and group norms in an attempt to greater condom use norms.
16563861|NCT02855489|Experimental|Perceived Behavioral Control Only|The PBC condition included a condom application video, lubrication instructions, condom negotiation videos, and a detailed description regarding purchasing condoms.
16563862|NCT02855489|Experimental|Intentions Only|The intentions condition utilized implementation intentions in order to create condom use intentions.
16563863|NCT02855489|Experimental|Three Constructs|A three construct condition, which included attitudes, norms, and perceived behavioral control represented the core components of the TPB that are thought to work through intentions to result in behavior change.
16563864|NCT02855489|Experimental|Four Constructs|"A four construct condition (i.e., attitudes, norms, PBC, and intentions) was designed to represent the full TPB model intervention which we expected would be more successful than either the three-construct intervention or any of the single construct interventions."
16563865|NCT02855489|No Intervention|No-Treatment, Control|A no-treatment control condition, which solely consisted of pretest and posttest assessments, was included. This allowed us to obtain important information about how the theoretical constructs in the TPB change over time (or do not) in the absence of an experimental manipulation.
16563866|NCT02855476||Early Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD
16563867|NCT02855476||Late Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort
16563868|NCT02855476||Early Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD
16563869|NCT02855476||Moderate Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD
16563870|NCT02855476||Late Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD
16563871|NCT02855476||Controls|Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.
16563872|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
16563873|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
16563874|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
16563875|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
16563876|NCT02855424|No Intervention|control|traditional rehabilitation merely, no ergocycling training
16563877|NCT02855424|Experimental|the low-intensity exercise group|traditional rehabilitation plus the low-intensity ergocycling exercise training
16563878|NCT02855424|Experimental|the moderate-intensity exercise group|traditional rehabilitation plus the moderate-intensity ergocycling exercise training
16563879|NCT02855411|Experimental|0.15 mg PF-04958242|Participants received 0.15 mg oral capsule, twice daily (BID) for 12 weeks
16563880|NCT02855411|Experimental|0.5 mg PF-04958242|Participants received 0.5 mg oral capsule, twice daily (BID) for 12 weeks
16563881|NCT02855411|Placebo Comparator|Placebo|Participants received matching placebo oral capsule, twice daily (BID) for 12 weeks
16563882|NCT02855385||Patient group|This are patients who have current or previous history of rectal bleeding
16563883|NCT02855385||General Practitioner group|This are General practitioner who are in public or private hospitals who treat patients with rectal bleeding
16563884|NCT02855372||Lung transplanted patients|
16563885|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
16563886|NCT02855359|Experimental|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
16563887|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
16563888|NCT02855359|Active Comparator|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
16563889|NCT02855346|Experimental|200 mg of DPV|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
16563890|NCT02855346|Experimental|200 mg of DPV + 320 mg LNG|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
16563891|NCT02855333||Merendino Group (MER)|Patients who underwent merendino procedure for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
16563892|NCT02855333||Control Group (CON)|Patients who underwent alternative surgery for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
16563893|NCT02855320|Experimental|PE (patient education)|Nurse-led self-management education intervention : The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
16563894|NCT02855320|No Intervention|Standard|The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
16563895|NCT02855307|Active Comparator|Unannounced exercise|The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
16563896|NCT02855307|Active Comparator|Announced exercise with pre-meal full bolus|The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
16563897|NCT02855307|Active Comparator|Announced exercise with reduced insulin bolus|The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.
16563898|NCT02855294|Active Comparator|Oral contraceptive pills users|The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
16563899|NCT02855294|No Intervention|control|no drugs
16563900|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
16563901|NCT02855268|Experimental|lademirsen (SAR339375)|Eligible participants will receive subcutaneous injection every week for 48 weeks
16563902|NCT02855268|Placebo Comparator|Placebo|Eligible participants will receive subcutaneous injection every week for 48 weeks
16563903|NCT02855255|Active Comparator|NHS smoking cessation|NHS 1-1 smoking cessation programme. One thirty minute session followed by up to five shorter sessions (approx.10/15minutes) comprising Cognitive Behavioural Therapy/Motivational Interviewing to assist with smoking cessation.
16563904|NCT02855255|Active Comparator|Allen Carr's Easyway smoking cessation|Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
16563905|NCT02855242|Other|Intervention Program Group|Lifestyle Counseling
16563906|NCT02855242|Active Comparator|Controls Group|No lifestyle counseling
16563907|NCT02855229||Phase 1 Participants [No Study Drug]|Phase 1 participants are not being assigned to any study drug.
16563908|NCT02855229||Phase 2 Participants [Placebo]|Phase 2 participants that are randomly assigned to the placebo.
16563909|NCT02855229||Phase 2 Participants [Methylphenidate]|Phase 2 participants that are randomly assigned to take methylphenidate.
16563910|NCT02855229||Phase 2 Participants [Modafinil]|Phase 2 participants that are randomly assigned to take modafinil.
16563911|NCT02855216|Experimental|Manual technique of sub-occipital inhibition|"The technique applied to Manual Group was performed with the patient supine position. Physiotherapist in a sitting position at the head of the subject with forearms resting on the table . Suboccipital region was located , and flexing the metacarpophalangeal joints 90º a pressure was made ventrally , relaxing the rest of the head in the heel of the hand.
~The technique was performed for 5 minutes"
16563912|NCT02855216|Experimental|Self-treatment by way of Occipivot®|The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
16563913|NCT02855203|Experimental|SABR + Pembrolizumab|SABR treatment (18Gy-20Gy/1#) followed by 200mg pembrolizumab IV once every 3 weeks for a total of 8 cycles
16564008|NCT02854605|Experimental|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
16563914|NCT02855190|Experimental|68Ga-citrate and 18F-FDG PET scans|The recruited subject with surgery/pathology proved periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.
16563915|NCT02855177|Placebo Comparator|Placebo|Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
16563916|NCT02855177|Experimental|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
16563917|NCT02855164|Experimental|LJN452 10 μg|Tropifexor (LJN452) Part A
16563918|NCT02855164|Experimental|LJN452 30 μg|Tropifexor (LJN452) Part A
16563919|NCT02855164|Experimental|LJN452 60 μg|Tropifezor (LJN452) Parts A + B
16563920|NCT02855164|Experimental|LJN452 90 μg|Tropifexor (LJN452) Parts A + B
16563921|NCT02855164|Placebo Comparator|Placebo A+ B|Placebo Parts A + B
16563922|NCT02855164|Experimental|LJN452 140 μg|Tropifexor (LJN452) Part C
16563923|NCT02855164|Experimental|LJN452 200 μg|Tropifexor (LJN452) Part B
16563924|NCT02855164|Placebo Comparator|Placebo C|Placebo Part C
16563925|NCT02855138|Active Comparator|study group|The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
16563926|NCT02855138|No Intervention|control group|The control group of this study was pretreatment period of the same volunteer patients.
16563927|NCT02855125|Active Comparator|Combination Therapy (TAS-114/S-1) versus Monotherapy (S-1).|Treatment cycle of the experimental arm (TAS-114/S-1) and control arm (S-1 alone) will be 21 days: 14 days of treatment and 7 days recovery.
16563928|NCT02855125|Active Comparator|Monotherapy (S-1)|Treatment cycle of the active control arm (S-1) be 21 days: 14 days of treatment and 7 days recovery
16563929|NCT02855112|No Intervention|Control|A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.
16563930|NCT02855112|Experimental|Adipose derived Mesenchymal Stem cell|A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks.
16563931|NCT02855099|Active Comparator|CR group|patients will be referred to our rehabilitation centre at the following week after the procedure, and assigned to a personalized rehabilitation program for duration of 3 month.
16563932|NCT02855099|No Intervention|conservative group|No intervention
16563933|NCT02855086|Experimental|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.
~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
16563934|NCT02855086|Experimental|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.
~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
16563935|NCT02855073|Experimental|ReJoinTM Group|Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.
16563936|NCT02855073|Active Comparator|Sodium Hyaluronate Group|subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.
16563937|NCT02855060|Experimental|Pelvic Binder|Commercially available device used to stabilize the pelvis
16563938|NCT02855060|No Intervention|No Binder|Standard of care
16563939|NCT02855034|Other|Blood sample|All the patients performed the same blood samples for dosage: copeptin, S-100B, GFAP, NFL and UCHL-1 proteins
16563940|NCT02855021|Other|Parkinson disease|Patients with a Parkinson disease with clinical diagnosis made for at least 5 years
16563941|NCT02855008|Experimental|STEPS|Experimental: Individuals with ID and residential staff in group homes receive 6 one-hour STEPS sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games to build group cohesiveness, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice social problem-solving skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
16563942|NCT02855008|Active Comparator|Food for Life|Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
16563943|NCT02854995|Other|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce.
16563944|NCT02854995|Other|preputioplasty with intralesional injection of triamcinolone|(ii) preputioplasty with intralesional injection of triamcinolone: longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile.
16563945|NCT02854982||Prostate Cancer|Group drawn of the case group of the case control study, entitled EPICAP
16563946|NCT02854982||No Prostate Cancer|Group drawn of the control group of the case control study, entitled EPICAP
16563947|NCT02854969|No Intervention|epinephrine auto-injector|3 months using the epinephrine auto-injector alone, and after that 3 more months using the epinephrine auto-injector + medical device
16563948|NCT02854969|Experimental|epinephrine auto-injector + medical device|"Device: Anapphylaxis is a medical device with a case for an epinephrine autoinjector that connects via Bluetooth to a mobile application
~3 months using the epinephrine auto-injector + medical device , and after that 3 more months using the epinephrine auto-injector alone"
16563949|NCT02854956|Other|X-linked Mental retardation|This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.
16563950|NCT02854956|Other|Control Group|This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.
16563951|NCT02854943||Critically ill patients|Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018.
16563952|NCT02854917||Memantine Alone|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine for a period of 28 weeks."
16563953|NCT02854917||Memantine plus Individualized Management of AD|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine plus individualized management of AD for a period of 28 weeks."
16563954|NCT02854904|Experimental|Dexmedetomidine intervention|Dexmedetomidine (1 ug/kg/hr) during anesthesia.
16563955|NCT02854904|Placebo Comparator|Placebo|Infusion of normal saline during anesthesia.
16563956|NCT02854878|Experimental|treatment|
16563957|NCT02854865||Echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
16563958|NCT02854852||Patients undergoing general anesthesia|Patients ASA 1-3, undergoing different types of general anesthesia, in supine position, with standard or advanced hemodynamic monitoring.
16563959|NCT02854839|No Intervention|The Control Group|Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.
16563960|NCT02854839|Experimental|The Treatment Group (MG4101)|Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
16563961|NCT02854826||UCLA Ronald Reagan Medical Center|"Site 1 (UCLA Regan Medical Center): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
16563962|NCT02854826||Huntington Hospital|"Site 2 (Huntington Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research Council/ Evidence Based Practice will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
16563963|NCT02854826||Torrance Memorial Hospital|"Site 3 (Torrance Memorial Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/ Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
16563964|NCT02854813||Group 1|Patients with a OAB-V8 score ≥8
16563965|NCT02854813||Group 2|Patients with a OAB-V8 score <8
16563966|NCT02854800|Experimental|Weekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
16563967|NCT02854800|Experimental|Biweekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once bi-weekly. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
16563968|NCT02854800|Experimental|Monthly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per month. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
16563969|NCT02854787|Active Comparator|Phenylephrine|A bolus of 100 mcg
16563970|NCT02854787|Active Comparator|Norepinephrine|A bolus of 0,2 mcg/kg
16563971|NCT02854774|Active Comparator|Knee muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of knee extensor muscles.
16563972|NCT02854774|Active Comparator|Hip muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of hip extensor muscles.
16563973|NCT02854761|Experimental|SC administration|Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
16563974|NCT02854761|Experimental|IM administration|Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
16563975|NCT02854748|Experimental|Empagliflozin / Lobeglitazone / Empa.+Lobe.|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
16564003|NCT02854644|Experimental|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
16563976|NCT02854748|Experimental|Empagliflozin / Empa.+Lobe. / Lobeglitazone|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
16563977|NCT02854748|Experimental|Lobeglitazone / Empagliflozin / Empa.+Lobe.|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
16563978|NCT02854748|Experimental|Lobeglitazone / Empa.+Lobe. / Empagliflozin|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
16563979|NCT02854748|Experimental|Empa.+Lobe. / Empagliflozin / Lobeglitazone|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
16563980|NCT02854748|Experimental|Empa.+Lobe. / Lobeglitazone / Empagliflozin|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
16563981|NCT02854735||Head and neck neoplasm|Patients with stage III-IV head and neck cancer (squamous cell carcinoma) patient undergoing CCRT
16563982|NCT02854722|Experimental|Deferasirox and calcium-vitamin D3|"Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.
~Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy."
16563983|NCT02854722|Placebo Comparator|Calcium-vitamin D3|Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
16563984|NCT02854709|No Intervention|Control|Continue with habitual sleep duration
16563985|NCT02854709|Experimental|Intervention|Sleep extension
16563986|NCT02854696|Experimental|Islet graft|Patients who receive islet graft Intervention : Procedure/Surgery
16563987|NCT02854696|Active Comparator|Best medical care|Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment
16563988|NCT02854683|Experimental|Normal Saline|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
16563989|NCT02854683|Experimental|Oral rehydration solution|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
16563990|NCT02854670|Experimental|Capsaicin patch|Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.
16563991|NCT02854657|Experimental|skin self-examination|"Participants from the treatment arms of the original RCT. It is anticipated that 228 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study. These subjects received Skin Self- examination structured training.
~The subject are being followed for an additional period of time after receiving an educational intervention."
16563992|NCT02854657|Experimental|Skin Self- examination:Distance (remote) learning|Participants receive the Skin Self- examination structured training with partner assistance educational intervention via mailed workbook while under the customary care of their own dermatologists. It is anticipated that 50 new participant dyads will be recruited and randomized to this group.
16563993|NCT02854657|Active Comparator|Active control|"Participants from the control arm of the original RCT. It is anticipated that 100 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study.
~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the Skin Self- examination structured training with partner assistance."
16563994|NCT02854657|Placebo Comparator|Assessment-only control|"Participants who receive customary care from their own dermatologists. It is anticipated that 150 new participant dyads will be recruited and randomized to this group.
~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the structured training in skin self-examination with partner assistance."
16563995|NCT02854657|No Intervention|Observational study 1|"Feasibility of wearing 2 sensors No intervention. At the conclusion of the study, participants receive a report of their UV exposure and physical activity over the 7 days of the study.
~N= 10"
16563996|NCT02854657|No Intervention|Observational study 2|"Feasibility of completing online daily survey. The research team will strive to integrate event level data in real -time No intervention. At the conclusion of the study, participants receive an event level reports of their daily UV exposure and physical activity over the 7 days of the study.
~N= 30"
16563997|NCT02854657|No Intervention|Relationship Factors Study Observational Study|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.
~No intervention- Control group. n=144 Results pending*"
16563998|NCT02854657|Active Comparator|Relationship Factors Study- Skin Self Examination|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.
~Intervention= Skin self-examination training n=197 Results Pending*"
16563999|NCT02854657|Active Comparator|Comparison of distance (remote) learning vs in-person learning|Controls re-enrolled from the original study (n=38) and newly enrolled in the distance (remote) learning (n=106) are compared with participants receiving the workbook in-person in the original study and re-enrolled (n=134) and participants newly enrolled in distance (remote) learning, who had the workbook mailed to them (n=63). Online surveys assessed SSE knowledge, confidence, anxiety and performance. Electronic health record review identified biopsies of concerning moles and the number of melanomas identified.
16564000|NCT02854644|Experimental|glioma|1 additional blood sample for patients with glioma and without treatment
16564001|NCT02854644|Experimental|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
16564002|NCT02854644|Experimental|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
16564004|NCT02854631|Experimental|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
16564009|NCT02854605|Placebo Comparator|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
16564010|NCT02854592||rtPA|Intravenous rt-PA thrombolysis shall be administered within 4.5 h after symptom onset, at a dose of 0.9 mg/kg body weight (maximum, 90 mg), with 10% of the dose given as a bolus over 1 min and the remaining 90% infused over 60 min.
16564011|NCT02854592||urokinase|1,000,000-1,500,000 units of urokinase intravenous infused over 30 minutes within 4.5 h of stroke onset .
16564012|NCT02854579|Experimental|Neural progenitor cell|Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
16564013|NCT02854579|Experimental|Paracrine factors|Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy
16564014|NCT02854579|Experimental|Progenitor cell and paracrine factors|Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
16564015|NCT02854579|No Intervention|Routine therapy|neonates only receive routine therapy
16564016|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
16564017|NCT02854553|Experimental|TAP|Transversus abdominis plane block
16564018|NCT02854553|Experimental|TAP and rectus sheath block|Transversus abdominis plane block with rectus sheath block
16564019|NCT02854553|No Intervention|control|no truncal blocks, conventional analgesia
16564020|NCT02854540|Experimental|Hand A (iontophoresis) vs. Hand B (no treatment)|During the treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device. Participants will also be asked to leave the other hand untreated.
16564021|NCT02854527|Experimental|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
16564022|NCT02854527|Experimental|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
16564023|NCT02854527|Experimental|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
16564024|NCT02854527|Experimental|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
16564025|NCT02854527|Experimental|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
16564026|NCT02854514||aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated with endometrial secretion then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
16564027|NCT02854501||Uncomplicated pregnancies|
16564028|NCT02854501||Preeclampsia|
16564029|NCT02854501||Isolated IUGR|
16564030|NCT02854501||Any complication|
16564031|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
16564032|NCT02854475|Experimental|Proband group|Raman spectroscopy and venous blood collection
16564033|NCT02854462|Experimental|Language comprehension intervention|The intervention will run for 4 weeks. Caregivers will be provided with storybooks (e.g., Percy the Park Keeper) that have been amended to include inference-eliciting questions. Caregivers will be trained (with a video) to ask these questions and respond to their children's answers during shared reading sessions. They will be asked to read one book per day. Caregivers will keep a reading diary.
16564034|NCT02854462|Active Comparator|Counting intervention|The intervention will run for 4 weeks. Caregivers will be provided with a book 'At home with counting' that is made up of age appropriate maths exercises. Caregivers will trained (with a video) to work through one page of the book per day. This should take the same amount of time as the activity in the language intervention condition. Caregivers will keep a counting diary.
16564035|NCT02854436|Experimental|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
16564036|NCT02854423||biodegradable polymer|
16564037|NCT02854423||durable-polymer|
16564038|NCT02854410|Experimental|Sodium nitrate supplementation|Patients will receive Sodium nitrate supplementation from 7 days before radiotherapy to one month after the end of radiotherapy
16564039|NCT02854410|Placebo Comparator|Placebo Comparator(sodium chloride)|Patients will receive placebo from 7 days before radiotherapy to one month after the end of radiotherapy
16564040|NCT02854397||patients with hereditary angioedema|A blood sample will be performed in crisis and 7 days after the crisis.
16564041|NCT02854397||patients with angioedema resulting of mast cell activation|A blood sample will be performed in crisis and 7 days after the crisis.
16564042|NCT02854397||healthy patients, without angioedema|A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.
16564043|NCT02854384||Epilepsy Patients|males and females whose age more than 18 years, diagnosed with epilepsy, regardless of whether symptomatic,idiopathic ,focal or generalized
16564044|NCT02854384||Healthy Control|males and females whose age more than 18 years
16564045|NCT02854371|Experimental|CLD and LC|Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
16564046|NCT02854358|Active Comparator|control|In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
16564047|NCT02854358|Experimental|intervention|Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks
16564048|NCT02854345|Experimental|Tomoscintigraphic parathyroid imaging on a CZT camera|Tomoscintigraphic parathyroid imaging on a CZT camera
16564049|NCT02854332|Active Comparator|MRI by rTMS|Patients which received an MRI study of cortical plasticity by rTMS.
16564050|NCT02854332|Active Comparator|MRI by tDCS|Patients which received an MRI study of cortical plasticity by tDCS.
16564051|NCT02854319|Experimental|LOTUS Edge Valve System|Transcatheter aortic valve implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
16564052|NCT02854306|Active Comparator|Surgery|Obese patient without mindfulness program in parallel.
16564053|NCT02854306|Active Comparator|Surgery with mindfulness program|Obese patient following a mindfulness program in parallel.
16564056|NCT02854280|Active Comparator|Chronic Obstructive Pulmonary Disease (COPD)|18 patients
16564057|NCT02854280|Active Comparator|Sleep Apnea Obstructive (OSA)|18 patients
16564058|NCT02854280|Active Comparator|Healthy Volunteers|36 control patients
16564059|NCT02854267||group without guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all registered situations of brain death patients on the database (nationwide) minus the situations occuring in the group with guide (22 intensive care units forming the 'RESEAU NORD FRANCILIEN' network). The period before the diffusion of the guide is from 1st of july 2012 to 30th of june 2014
16564060|NCT02854267||group without guide, after guide's diffusion|For this group, only the primary objective (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all the registered situations of brain death patients on the database minus the situations occuring in the group with guide ('RESEAU NORD FRANCILIEN'). The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
16564061|NCT02854267||Group with guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018.
16564062|NCT02854267||Group with guide, after guide's diffusion|For this group, the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database. The secondary endpoints (level of anxiety of the caregivers before the meeting with the next of kins as measured by the french short version of Spielberger test and compliance to the guide) will be assessed by the datasheet prospectively filled by the caregivers. The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
16564063|NCT02854254|Experimental|PICC|peripherally inserted central catheter
16564064|NCT02854254|Other|Control|peripherally venous access
16564065|NCT02854241|Experimental|LC group|LC group under surveillance of biannual ultrasonography and annual noncontrast liver MRI. Six month after the last MRI, contrast enhanced liver CT is performed to investigate presence of HCC.
16564066|NCT02854215|Other|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
16564067|NCT02854202|Experimental|Arm 1-Whey protein|In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey
16564068|NCT02854202|Active Comparator|Arm 2 Breakfast- other proteins|In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast
16564069|NCT02854202|Placebo Comparator|Arm 3 Breakfast- low protein|In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast
16564070|NCT02854189|Other|patients with genu recurvatum|The medial osteoarthritis knees with genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
16564071|NCT02854189|Other|patients without genu recurvatum|The medial osteoarthritis knees without genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
16564072|NCT02854176|Experimental|Somatosensory electrical stimulation|
16564073|NCT02854176|Sham Comparator|Control|
16564074|NCT02854163|Experimental|Secukinumab|"Secukinumab will be given to all 20 patients registered (Secukinumab group). All doses will be given subcutaneously using the following schedule: 4 weekly injections of 150 or 300 mg subcutaneous injections depending the severity of skin involvement, followed by 11 monthly subcutaneous injections of 150mg.
~Patients will continue to use their normal DMARDs treatment."
16564075|NCT02854137|Experimental|Sunscreen / Arm 1|Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.
16564076|NCT02854137|Other|Control|A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or steriled dropper.
16564077|NCT02854124||Patients with stage Ib and II melanoma|Melanoma and peritumoral skin excision
16564078|NCT02854111|Active Comparator|oral glucose tolerance test|75-g glucose A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink a sweet liquid containing 75 g-glucose. Blood samples will be collected at timed intervals of 1 and 2 hours after you drink the glucose. This is a standard method for diagnosis of diabetes mellitus that called oral glucose tolerance test or OGTT.
16564079|NCT02854111|Experimental|ice cream|A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink ice cream that contained carbohydrate 73.9 g. Blood samples will be collected at timed intervals of 1 and 2 hours after you eat the ice cream.
16564080|NCT02854098||with functional constipation|n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
16564081|NCT02854098||without functional constipation|n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
16564082|NCT02854085|Experimental|Art Therapy|Art Therapy, 24 sessions
16564083|NCT02854085|Experimental|Music Reminiscence Activity|Music Reminiscence Activity, 24 sessions
16564084|NCT02854085|No Intervention|Control|Participants will not participate in either of the interventions and will continue life as usual.
16564085|NCT02854072|Experimental|GV1001 + gemcitabine/capecitabine|
16564086|NCT02854072|Active Comparator|gemcitabine/capecitabine|
16564087|NCT02854059|Experimental|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
16564088|NCT02854059|Experimental|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
16564089|NCT02854046||Calciphylaxis Cases|Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
16564090|NCT02854046||Witness cases|"Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging"
16564094|NCT02854020||An asian airline|
16564095|NCT02854007||Coronary stenosis treated with Absorb|Patients with ischemic heart disease who have undergone percutaneous coronary revascularization with Absorb according to standard clinical practice. One thousand revascularized patients will be recruited at 40 siteS.
16564096|NCT02853981|Active Comparator|Harmonic scalpel group|group of donors whom will undergo liver transection using harmonic scalpel.
16564097|NCT02853981|Active Comparator|clamp-crush group|group of donors whom will undergo liver transection using Kelly clamp.
16564098|NCT02853968||Castleman's Patients|Castleman's patients with HHV8 negative multicentric MCD
16564099|NCT02853968||Related Disease Controls|Controls with inflammatory diseases similar to idiopathic multicentric Castleman's: i.e. HHV8+ MCD, HLH, Hodgkin disease
16564100|NCT02853968||Healthy Donor Controls|Healthy subjects used for controls. These healthy subjects have no history of autoimmune disorders.
16564101|NCT02853942|Experimental|Stem cell therapy group|Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.
16564102|NCT02853942|Experimental|Neurotrophic drugs treatment group|Patients were treated with routine drug therapy，do not inject stem cell to the facial nerve of patient
16564103|NCT02853929|Experimental|dTpa Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
16564104|NCT02853929|Active Comparator|Control Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
16564105|NCT02853916|Active Comparator|500 mg InSea2®|
16564106|NCT02853916|Active Comparator|250 mg InSea2®|
16564107|NCT02853916|Placebo Comparator|Placebo|
16564108|NCT02853903|Experimental|Allogenic NK immunotherapy|In this group, the patients will receive more than 4 times of allogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564109|NCT02853903|Active Comparator|Autogenic NK immunotherapy|In this group, the patients will receive more than 4 times of autogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564110|NCT02853890||pregnant woman|
16564111|NCT02853877|Experimental|Weekly Incentive|Participants in the Weekly Incentive arm will be asked to weigh in each week during a 12 week intervention period. They will receive tailored messages and have an opportunity to win a financial reward each week they meet their weight loss goal. Participants will be asked to complete a final weight measurement at week 24.
16564112|NCT02853877|No Intervention|Weekly Weigh-In|Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
16564113|NCT02853864|Placebo Comparator|Propofol and 0.0 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
16564114|NCT02853864|Experimental|Propofol and 0.4 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
16564115|NCT02853864|Experimental|Propofol and 0.6 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
16564116|NCT02853864|Experimental|Propofol and 0.8 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
16564117|NCT02853851||France|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
16564118|NCT02853851||Italy|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
16564119|NCT02853851||spain|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
16564120|NCT02853851||montreal|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
16564121|NCT02853838|Experimental|Prolonged slow expiration+provoked coughing+ST|Prolonged slow expiration+provoked coughing+Standard Therapy
16564122|NCT02853838|Active Comparator|Manual chest wall vibration+ST|Manual chest wall vibration+Standard Therapy
16564123|NCT02853825|No Intervention|Wait List Control Group|No interventions given, this is a wait list control group.
16564124|NCT02853825|Experimental|Intervention Group|Receive relationship skill enhancement classes with access to parenting, employment services, and financial services.
16564125|NCT02853812|Other|single sided tinnitus|patients with single sided tinnitus on which functional brain MRI is assessed
16564126|NCT02853799|Other|Continuous Enteral Feeding|"Crossover Study:
~Randomized to continuous enteral feeding first then crossed over to receive versus intermittent enteral feeding next."
16564127|NCT02853799|Other|intermittent enteral feeding|"Crossover Study:
~Randomized to intermittent enteral feeding first then crossed over to receive versus continuous enteral feeding next."
16564128|NCT02853786|Experimental|LENA and advices|With the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
16564129|NCT02853786|Active Comparator|LENA without advices|Regular speech therapy follow blindly the results of LENA
16564130|NCT02853773|Experimental|Artificial sweetener|Effects of co-ingestion of artificially sweetened beverage on the response to a test meal
16564131|NCT02853773|Active Comparator|Sugar|Effects of co-ingestion of sugar-sweetened beverage on the response to a test meal
16564132|NCT02853773|Active Comparator|Water|Effects of co-ingestion of water on the response to a test meal
16564133|NCT02853760|Experimental|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).
~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
16564134|NCT02853760|Active Comparator|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.
~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
16564135|NCT02853760|No Intervention|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
16564136|NCT02853734|Experimental|SEVERE PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
16564137|NCT02853734|Other|NO PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
16564138|NCT02853721|Experimental|Experimental group|iPTH at 6 hours after surgery
16564139|NCT02853721|Other|Control group|no dosage of iPTH
16564140|NCT02853682||presence of a vascular dysfunction|plasma
16564141|NCT02853682||absence of vascular dysfunction|plasma
16564142|NCT02853669|Experimental|group (A) lumber plexus block|Ultrasound-guided Lumber plexus Block (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation.
16564143|NCT02853669|Experimental|Group (B) adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
16564144|NCT02853643|Experimental|25 mg Dose|Single dose of 25 mg ASN002
16564145|NCT02853643|Experimental|50 mg Dose|Single dose of 50 mg ASN002
16564146|NCT02853643|Experimental|100 mg Food effect cross over|100 mg single dose under both fasted and fed conditions in a cross over fashion
16564147|NCT02853630|Active Comparator|Metformin|Tablet Metformin 1000 - 2500 mg/day for 96 weeks
16564148|NCT02853630|Experimental|Vildagliptin|Tablet Vildagliptin 100mg/day for 96 weeks
16564149|NCT02853617|Experimental|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
16564150|NCT02853617|Experimental|AV0328 - Cohort 2|Cohorts 2 will receive 30 µg to be given as an IM injection
16564151|NCT02853617|Experimental|AV0328 - Cohort 3|Cohorts 3 will receive 75 µg to be given as an IM injection
16564152|NCT02853617|Experimental|AV0328 - Cohort 4|Cohorts 4 will receive 150 µg to be given as an IM injection
16564153|NCT02853604|Placebo Comparator|Reference Treatment Group (Arm A)|Placebo Arm A
16564154|NCT02853604|Experimental|Experimental Treatment Group (Arm B)|"ADXS11-001
~1:2 Arm A to Arm B"
16564155|NCT02853591|Active Comparator|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
16564156|NCT02853591|Experimental|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
16564157|NCT02853591|Experimental|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
16564158|NCT02853591|Experimental|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
16564159|NCT02853578|Experimental|Busonid (budesonide 200mcg and 400mcg)|"It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.
~Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.
~The duration of treatment may be 12 weeks."
16564160|NCT02853565|Experimental|CAN008|CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
16564161|NCT02853539|Experimental|Denosumab|One per 6 months subcutaneous injection of Denosumab (2 doses in total)
16564162|NCT02853539|No Intervention|No Denosumab|No intervention, just observation of HPN patients
16564163|NCT02853526|Experimental|TIPS arm|Transjugular intrahepatic portosystemic shunt(TIPS) is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension.TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (also called p-TIPS or modified TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
16564164|NCT02853526|Active Comparator|conservative treatment arm|Conservative treatment including endoscopic therapy，non-selective beta blockers (propranolol)and anticoagulation therapy (warfarin).
16564165|NCT02853500|Experimental|TACE Procedure With Surefire|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Surefire.
~Patients will undergo structural follow-up for a timeframe of one year post treatment
~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
16564166|NCT02853500|Active Comparator|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.
~Patients will undergo structural follow-up for a timeframe of one year post treatment
~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
16564167|NCT02853487||Cluster headache patients|Episodic cluster headache patients in- and outside of bout will wear an actigraph and fill out a diary for 2 weeks.
16564168|NCT02853487||Control group|Healthy, headache-free controls will wear an actigraph and fill out a diary for 2 weeks.
16564169|NCT02853474|Sham Comparator|Arm A: Chemotherapy (CT) alone|"The medical oncologists (or gastro enterologist physician) are in charge of the patient for CT administration, and for the management of symptoms related to the disease and/or the treatment, in accordance with professional practices. If needed (any time), a PC (Palliative consultation) visit could be performed.
~Interventions are :
~EORTC-QLQ-C30 questionnaire for the assessment of quality of life
~HADS score for anxiety and depression assessment"
16564170|NCT02853474|Experimental|Arm B: CT + Early Palliative care(EPC)|"Standard oncology care as for arm A plus early PC visits.
~Interventions are :
~EORTC-QLQ-C30 questionnaire for the assessment of quality of life
~HADS score for anxiety and depression assessment
~Early palliative care visits"
16564171|NCT02853448|Experimental|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
16564172|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
16564173|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
16564174|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
16564175|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
16564176|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
16564177|NCT02853435|Experimental|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
16564178|NCT02853435|Experimental|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
16564179|NCT02853396|Experimental|Cognitive behavioural therapy|Cognitive behaviour therapy
16564180|NCT02853396|Active Comparator|Psychoeducation|psychoeducation
16564181|NCT02853370|Experimental|Bendamustine and Rituximab|"Induction Phase (Cycle 1 to Cycle 3 ):
~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1**
~Extended Phase (Cycle 4 to Cycle 6):
~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1
~From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles
~*Or days 2-3 according to institutional/patient/physician preference
~**Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)"
16564182|NCT02853357|Sham Comparator|Control|The control group includes randomized participants that will receive a sham manipulation. Participants will also complete the standard set of core strengthening exercises.
16564183|NCT02853357|Experimental|Manipulation|The manipulation group includes randomized participants that will receive a thoracic spine thrust manipulation. Participants will also complete the standard set of core strengthening exercises.
16564186|NCT02853331|Experimental|Pembrolizumab+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
16564187|NCT02853331|Active Comparator|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
16564188|NCT02853318|Experimental|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
16564189|NCT02853305|Experimental|Pembrolizumab + ST Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS standard therapy (ST) chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin at an area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
16564190|NCT02853305|Experimental|Pembrolizumab (Pembro)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses.
16564191|NCT02853305|Active Comparator|ST Chemotherapy (Chemo)|Participants receive ST chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin at AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
16564192|NCT02853292||amoxicillin crystalluria|
16564193|NCT02853279|Experimental|Interval exercise training|Supervised exercise training undertaking interval exercise twice per week for 30 min each visit over 12 weeks.
16564194|NCT02853279|Active Comparator|Continuous exercise training|Supervised exercise training undertaking continuous exercise twice per week for 30 min each visit over 12 weeks.
16564195|NCT02853266||patients KD|adults with a history of KD in childhood
16564196|NCT02853266||control group|healthy adults volunteers
16564197|NCT02853253|Experimental|SMOF|parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
16564198|NCT02853253|Active Comparator|Medialipide®|parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
16564199|NCT02853240|Experimental|Children with spastic CP receiving toxin injections|Children with spastic cerebral palsy receiving toxin injections
16564200|NCT02853227||BCS|Photographs og consecutive group of 346 patients operated with breast conserving surgery were used to investigate cosmetic outcomes.
16564201|NCT02853227||DIEP|Photographs og consecutive group of 30 patients operated with DIEP-flap were used to assess cosmetic results
16564202|NCT02853214|Experimental|Identification of genetic factors in dysglobulinemia cases|
16564203|NCT02853188|Experimental|cancer of lung|
16564204|NCT02853175||Patients with both CF and ABPA|"Patients with both cystic fibrosis and allergic broncho-pulmonary aspergillosis (ABPA).
~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
16564205|NCT02853175||Patients with CF and no ABPA|"Patients with both cystic fibrosis and no allergic broncho-pulmonary aspergillosis (ABPA).
~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
16564206|NCT02853162|Experimental|ARREST-study|SBRT renal cell carcinoma 5 times 7Gy
16564207|NCT02853149|Experimental|Spinal Cord Injury (SCI)|Experimental: Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) for Spinal Cord injury individuals enrolled with their caregivers, can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
16564208|NCT02853149|Active Comparator|Caregiver Intervention(CCC)|Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
16564252|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group E (Fasting)|Participants will receive single dose of ASP2151 assigned to Group E on day 1
16565328|NCT02845115|Experimental|laser velocimetry|optimized implantation of laser velocimetry
16564209|NCT02853149|Placebo Comparator|Caregiver Control (CC)|Placebo: This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life. The control group intervention will test benefits of exercise alone while controlling for investigator contact.
16564210|NCT02853136|Experimental|Reference Treatment (pilot phase)|BI 409306 low dose
16564211|NCT02853136|Experimental|Test Treatment (pilot phase)|Fluvoxamin and low dose of BI 409306
16564212|NCT02853136|Experimental|Reference Treatment (main phase)|BI 409306 medium or high dose
16564213|NCT02853136|Experimental|Test Treatment (main phase)|Fluvoxamin and medium or high dose of BI 40930
16564214|NCT02853123|Experimental|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
16564215|NCT02853123|Active Comparator|Tiotropium|
16564216|NCT02853110|Experimental|Hypo-FLAME|External beam radiotherapy, 5 additional MRI scans, blood sampling
16564217|NCT02853097||Ancillary-Correlative (blood collection)|Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.
16564218|NCT02853084|Experimental|HL2351|
16564219|NCT02853071|Experimental|Estramustine|560 mg per day
16564220|NCT02853071|Active Comparator|Standard practice center|"Standard treatment center choice.
~Excepted: anthracyclines, taxanes, capecitabine and eribulin"
16564221|NCT02853058|Active Comparator|normal PI|Uterine artery PI expresserd in MoM is <95e percentile
16564222|NCT02853058|Active Comparator|pathological PI|Uterine artery PI expressed in Multiple of Mediane (MoM) is >=95e percentile
16564223|NCT02853045|Experimental|period with drug (trade name) then period with generic|Period of 6 weeks.
16564224|NCT02853045|Experimental|period with generic then period with drug (trade name)|Period of 6 weeks.
16564225|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
16564226|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
16564227|NCT02853019|Sham Comparator|Healthy volunteers|Healthy volunteers
16564228|NCT02853019|Experimental|Patients with schizophrenia|Patients with schizophrenia
16564229|NCT02853006|Other|Group 1 lung cancer in stage 1-2|Group 1 : patient with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery
16564230|NCT02853006|Other|Group 2 lung cancer in stage 3-4|Group 2 : patient with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies.
16564231|NCT02853006|Other|Group 3 : control patients|Group 3 control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco.
16564232|NCT02852993||Transfused patients|A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
16564233|NCT02852980||gestational diabetes women|Women who had childbirth in the Hospital center Rene Dubos and who had gestational diabetes.
16564239|NCT02852954||study group1|20 paraffin embedded blocks which was diagnosed endometrial cancer
16564240|NCT02852954||control group|20 paraffin embedded blocks of healthy women
16564241|NCT02852954||study group2|20 paraffin embedded blocks which was diagnosed endometrial hyperplasia
16564242|NCT02852941||Patients after kidney transplantation|The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.
16564243|NCT02852941||Healthy subjects|Medical staff: medical doctors, nurses
16564244|NCT02852915|Experimental|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
16564245|NCT02852915|No Intervention|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
16564246|NCT02852889||fluid responders|Patients whose stroke volume index increase by >10% in response to a 500-ml fluid bolus was defined as fluid responders.
16564247|NCT02852889||fluid non-responders|Patients whose stroke volume index increase by <10% in response to a 500-ml fluid bolus was defined as fluid non-responders.
16564248|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group A (Fasting)|Participants will receive single dose of ASP2151 assigned to Group A on day 1
16564249|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group B (Fasting)|Participants will receive single dose of ASP2151 assigned to Group B on day 1
16564250|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group C (Fasting)|Participants will receive single dose of ASP2151 assigned to Group C on day 1
16564251|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group D (Fasting)|Participants will receive single dose of ASP2151 assigned to Group D on day 1
16564398|NCT02851849|Active Comparator|LGD-6972-10 mg|10 mg LGD-6972 QD
16564253|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group F (Fasting)|Participants will receive single dose of ASP2151 assigned to Group F on day 1
16564254|NCT02852876|Placebo Comparator|Part 1: Placebo Single Ascending Dose (Fasting)|Participants will receive single dose of matching placebo on day 1
16564255|NCT02852876|Experimental|Part 2: ASP2151 (Fasting)|Participants will receive a single dose of ASP2151 under fasted conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
16564256|NCT02852876|Experimental|Part 2: ASP2151 (Fed)|Participants will receive a single dose of ASP2151 under fed conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
16564257|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group G (Fasting)|Participants will receive single dose of ASP2151 assigned to Group G on day 1
16564258|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group H (Fasting)|Participants will receive single dose of ASP2151 assigned to Group H on day 1
16564259|NCT02852863|Experimental|Ultrasound (case only)|Subjects will fast for a minimum of 8 hours. Ultrasound assessment of gastric volume and content will determine basal conditions. Next, subjects will chew gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
16564260|NCT02852850||Molecular Imaging With IFX-FITC|Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
16564261|NCT02852837|Experimental|Part 1: Dose Escalation Part|Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
16564262|NCT02852837|Experimental|Part 2: Pharmacokinetic (PK) Expansion Part|Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
16564263|NCT02852837|Experimental|Part 3: Safety Expansion Part|Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.
16564264|NCT02852824|Experimental|BI 655130|
16564265|NCT02852824|Placebo Comparator|Placebo|
16564266|NCT02852811|Other|group education|To measure improvement of menopause symptoms and depression all participating women answered a baseline questionnaire and a follow-up questionnaire four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
16564267|NCT02852811|No Intervention|control group|The control group did not obtain any group education or any other intervention. Women answered at baseline questionnaire and four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
16564268|NCT02852785||Asymptomatic volleyball attackers|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
16564269|NCT02852785||Asymptomatic bilateral overhead athletes|Asymptomatic swimmers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
16564270|NCT02852785||Asymptomatic non-athletes|Asymptomatic persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers),
16564271|NCT02852785||Asympt. athletes / scapula dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
16564272|NCT02852785||Symptom. athletes / scapula dyskinesis|Volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis and complaints of shoulder pain and disability
16564273|NCT02852772||PLHIV with microalbuminuria|Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years
16564274|NCT02852772||PLHIV without microalbuminuria (control)|Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years
16564275|NCT02852759|Experimental|intervention group|Add Selective Cold and Electroacupuncture treatment to the existing treatment for patients with insulin resistance.
16564276|NCT02852759|No Intervention|Intensive Care group|continue the existing management of insulin resistance in these patients. They will receive the same follow up, examinations etc as intervention group.
16564277|NCT02852746||Asympt. athletes / scapular dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
16564278|NCT02852746||Symptom. athletes / scapular dyskinesis|Symptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
16564279|NCT02852733||Residents in end-of-life situation|"Residents in end-of-life situation the day of the survey, as determined by the physician coordinator of nursing homes (we will use the definition of terminal condition contained in the guide of the CNSA (coding PATHOS - April 2011))."
16564280|NCT02852733||dead residents|dead residents in the quarter preceding the date of the survey
16564281|NCT02852720|Experimental|Pharmacokinetics|A bilateral TAP block will be performed with 20 ml levobupivacaine 0,25% and epinephrine (5ug/ml). After the blockade, venous blood samples will be taken on predefined times.
16564282|NCT02852707||Unilateral overhead throwing athletes|Volleyball attackers involved in competitive events ≥ 2 years, ≥18 years of age
16564283|NCT02852707||Bilateral overhead athletes|Swimmers involved in competitive events ≥ 2 years, ≥18 years of age
16564284|NCT02852707||Non-athletes|Persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers), ≥18 years of age
16564285|NCT02852694|Active Comparator|High Risk Group|subcutaneous methotrexate versus subcutaneous adalimumab
16564286|NCT02852694|Active Comparator|Low risk group|subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine
16564287|NCT02852694|Other|Ancillary|the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
16564288|NCT02852681|Other|15 mg E4/3 mg DRSP without food|Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).
16564289|NCT02852681|Other|15 mg E4l/3 mg DRSP with food|Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)
16564290|NCT02852668|Experimental|Power Training Group|Physical exercises. Strength training performed quickly
16564291|NCT02852668|Experimental|Strength Training Group|Physical exercises. Strength training performed in moderate speed
16564292|NCT02852668|No Intervention|Control Group|This group maintained the same physical activity level during the intervention period.
16564293|NCT02852655|Experimental|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.
~Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.
~MK-3475 will be administered intravenously"
16564294|NCT02852655|Active Comparator|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.
~Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.
~MK-3475 will be administered intravenously"
16564295|NCT02852642|Experimental|Exercise|Power training model based in the potentiation of the stretch-shortening cycle.
16564296|NCT02852642|No Intervention|Control|Maintaining daily activities
16564297|NCT02852616|Active Comparator|Narrative Exposure Therapy|Participants with a PTSD diagnosis
16564298|NCT02852616|No Intervention|no / standard treatment|Participants with a PTSD diagnosis / other mental health problems / no mental health problems
16564299|NCT02852603||thoracic aortic aneurysm and dissection|Patients with thoracic aortic aneurysm and/or dissection are recruited in the study.
16564300|NCT02852577|Active Comparator|Clonazepam|Treatment with clonazepam
16564301|NCT02852577|Active Comparator|Paroxetine|Treatment with paroxetine
16564302|NCT02852564|Experimental|Enrolled Participants|Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor [TURBT])
16564303|NCT02852551|Experimental|PAT-1251 Single Dose|Oral solution of PAT-1251, 150 - 4000 mg administered once
16564304|NCT02852551|Placebo Comparator|Placebo Single Dose|Matching placebo solution administered once
16564305|NCT02852551|Experimental|PAT-1251 Multiple Dose|Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days
16564306|NCT02852551|Experimental|Placebo Multiple Dose|Matching placebo tablets administered daily for 7 days
16564307|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
16564308|NCT02852525|Other|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
16564309|NCT02852512|Active Comparator|Laparoscopic sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be laparoscopic
16564310|NCT02852512|Active Comparator|Robotic assisted Sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be robotic assisted
16564311|NCT02852499||Mothers|Pregnant women.
16564312|NCT02852499||Fathers|Futur fathers.
16564313|NCT02852499||Children|Children after childbirth.
16564314|NCT02852486|Experimental|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
16564315|NCT02852473|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP) will be administered using FDA-approved equipment.
16564316|NCT02852460|Experimental|Experimental group|rapid recovery
16564317|NCT02852460|No Intervention|Controlled group|non-rapid recovery
16564318|NCT02852434|Experimental|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
16564319|NCT02852434|Active Comparator|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
16564320|NCT02852421|Active Comparator|Multiple injection paravertebral blocks|"Patients in this group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
16564321|NCT02852421|Experimental|Single injection paravertebral block|"Patients in single injection group will receive single injection paravertebral blocks at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections."
16564322|NCT02852408||Study|liver cauterized during laparoscopic cholecystectomy.
16564323|NCT02852408||Control|liver not-cauterized during laparoscopic cholecystectomy.
16564324|NCT02852395|Experimental|Part 1 Single Dose|Part 1 single daytime oral dose of JNJ-48816274 or placebo. Doses of JNJ-48816274 will start at 5 milligram (mg) and increase sequentially to a maximum dose of 250 mg.
16564325|NCT02852395|Experimental|Part 2 Crossover Sleep Study|Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
16564399|NCT02851849|Active Comparator|LGD-6972-15 mg|15 mg LGD-6972 QD
16564400|NCT02851849|Placebo Comparator|Placebo|Placebo QD
16564326|NCT02852395|Experimental|Part 3 Repeated Dose (Optional)|Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
16564327|NCT02852382|Active Comparator|scalp block|In this arm, after general anesthesia, before surgery and head pin placement, scalp block will be applied. Scalp block will be performed with bupivacaine (Marcaine 5 mg/mL, 0,5% bupivacaine); nervus supraorbitalis, nervus supratrochlearis, n. auriculotemporalis, nervus zygomaticotemporalis, nervus occipitalis majoris and minoris will be bilaterally blocked with 2-3 ml bupivacaine.
16564328|NCT02852382|Active Comparator|local infiltration|In this arm, after general anesthesia, before surgery, 20 ml 0,5% bupivacaine (Marcaine 5 mg/ml, 0,5% bupivacaine) will be infiltrated to head pin points and skin incision area.
16564329|NCT02852382|Placebo Comparator|control|In this arm, neither scalp block, nor local infiltration will be performed.
16564330|NCT02852369|Experimental|Task Oriented Training|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.
~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
16564331|NCT02852356|No Intervention|Control Incubator|Standard Incubator
16564332|NCT02852356|Experimental|MIRI-TL Timelapse Incubator|Timelapse incubator
16564333|NCT02852356|Experimental|Culture Coin Dish|Culture Coin dish for embryo culture
16564334|NCT02852356|No Intervention|Control dish|Control Dish for embryo culture
16564335|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
16564336|NCT02852317||Spina bifida patient|
16564337|NCT02852317||Patients with multiple sclerosis|
16564338|NCT02852317||Patients with spinal cord injury|
16564339|NCT02852317||Patients with overactive bladder|
16564340|NCT02852291|Experimental|Parents Make the Difference|Parents Make the Difference (Caregivers attend 10 group parent training sessions)
16564341|NCT02852291|Experimental|Parents Make the Difference Plus|Parents Make the Difference Plus (Caregivers attend 10 group parent training sessions and receive 3 home visits)
16564342|NCT02852291|No Intervention|Waitlist Control|No parenting intervention until the end of the study period
16564343|NCT02852265|Experimental|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
16564344|NCT02852239|Experimental|Group 1 - Normal renal function|Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight.
16564345|NCT02852239|Experimental|Group 2 - Severe renal function|Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline.
16564346|NCT02852239|Experimental|Group 3 - End stage renal disease (ESRD)|Subjects with end stage renal disease (ESRD), defined as GFR of <15 mL/min at baseline.
16564347|NCT02852226|Experimental|Study Intervention|Assess PrEP among women in the study. Assess the characteristics of women who enroll in the PrEP study. Assess the referral sources of women who enroll in the PrEP study
16564349|NCT02852200||SEGAm|Elderly community-dwelling people
16564350|NCT02852187|Active Comparator|MOBIS PEEK|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS PEEK Cage
16564351|NCT02852187|Active Comparator|MOBIS II ST|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS II ST Cage
16564352|NCT02852174|Experimental|Mindfulness group|The treatment groups will participate in a mindfulness intervention training that will meet for 2 hours once a week for eight weeks. The 8-week program provides participants with 2-hour weekly instruction designed to teach specific skills and how to apply them during stressful situations (e.g., when caring for or advocating for the veteran).Mindfulness training also requires that participants engage in daily home practice for 30 to 40 minutes. Participants will be required to record the duration of the meditation in log sheets.
16564353|NCT02852174|No Intervention|Control|Participants in the control may receive the mindfulness training after the wait period ends at which point they may receive the treatment as described above.
16564354|NCT02852161|Experimental|MACE|MACE procedure
16564355|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
16564356|NCT02852148|Experimental|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
16564357|NCT02852135|Experimental|LMA Proseal group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Prosealgroup,LMA Proseal was inserted into each patient after anesthesia induction.
16564358|NCT02852135|Experimental|LMA Supreme group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Supreme group,LMA Supreme was inserted into each patient after anesthesia induction.
16564359|NCT02852122|Experimental|C-11 choline|
16564360|NCT02852109||experimental group|patients who was firstly diagnosed as diffuse axonal injury
16564361|NCT02852109||control group|patients negative for magnetic resonance examination with no trauma
16564362|NCT02852096|Experimental|Dual or Multiple Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
16564363|NCT02852096|Active Comparator|One Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
16564364|NCT02852083|Experimental|A: Biomodulatory treatment|treosulfan 250 mg p.o. twice daily, pioglitazone 45 mg p.o. once daily, clarithromycin 250 mg p.o. twice daily until progression or no clinical benefit observed, whichever comes first.
16564365|NCT02852083|Active Comparator|B: Standard Treatment|Nivolumab, 3 mg per kilogram of body weight every 2 weeks until disease progression according to RECIST 1.1 or unacceptable toxicity
16564366|NCT02852070|Active Comparator|control group|Bronchoscopy examination with 120ml sterile saline solution for bronchoalveolar lavage
16564367|NCT02852070|Experimental|observation group|Bronchoscopy examination with 60ml sterile saline solution for bronchoalveolar lavage
16564368|NCT02852057|Experimental|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
16564369|NCT02852044|Active Comparator|Rest|Remain rested prior to the oral glucose tolerance test
16564370|NCT02852044|Experimental|Exercise|Complete exercise prior to the oral glucose tolerance test
16564371|NCT02852031||Hypoplastic Left Heart Syndrome|Infants diagnosed with Hypoplastic Left Heart Syndrome (HLHS)
16564372|NCT02852018||Appropriate treatment|Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
16564373|NCT02852018||No event|Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.
16564374|NCT02852005|Experimental|Group 1: MVA/HIV62B + Placebo|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
16564375|NCT02852005|Experimental|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
16564376|NCT02852005|Experimental|Group 3: MVA/HIV62B + Placebo|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
16564377|NCT02852005|Experimental|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
16564378|NCT02852005|Experimental|Group 5: Placebo + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
16564379|NCT02851992|Other|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
16564380|NCT02851979|Experimental|S0 - S1 - S2|S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
16564381|NCT02851979|Experimental|S0 - S2 - S1|S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
16564382|NCT02851979|Experimental|S1 - S0 - S2|S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
16564383|NCT02851979|Experimental|S1 - S2 -S0|S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
16564384|NCT02851979|Experimental|S2 - S0 - S1|S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
16564385|NCT02851979|Experimental|S2 - S1 - S0|S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation
16564386|NCT02851966|Other|TEX101|This is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
16564387|NCT02851953|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
16564388|NCT02851940|Experimental|A (Rubber Band Ligation)|15 patients
16564389|NCT02851940|Experimental|B (Hypertonic Saline Infusion)|15 patients
16564390|NCT02851927|Experimental|Mini Thoracoscopy|Thoracoscopy procedure shall be performed using the Rigid Mini Thoracoscope
16564391|NCT02851927|Active Comparator|Semirigid Thoracoscopy|Thoracoscopy procedure shall be performed using the SemiRigid Thoracoscope
16564392|NCT02851914|Active Comparator|Arm 1 - TCA|"The Tricyclic Antidepressant (TCA) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
16564393|NCT02851914|Active Comparator|Arm 2 - SSRI|"The Selective Serotonin Reuptake Inhibitor (SSRI) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
16564394|NCT02851888|Experimental|Iliac Fascia Block (Ropivacaine)|These patients will receive a preoperative iliac fascia block performed as a single shot in the standard fashion prior to hip arthroscopy with general anesthesia.
16564395|NCT02851888|Sham Comparator|Control (Normal Saline Sham Injection)|These patients will receive a preoperative sham block of normal saline in the same fashion as a standard singl shot iliac fascia block prior to hip arthroscopy with general anesthesia.
16564396|NCT02851862||Late Onset GM2 Gangliosidosis|10-15 subjects with Late Onset GM2 Gangliosidosis
16564397|NCT02851849|Active Comparator|LGD-6972-5 mg|5 mg LGD-6972 QD
16564401|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
16564402|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
16564403|NCT02851797|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
16564404|NCT02851797|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
16564405|NCT02851784|Active Comparator|MWA only|The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
16564406|NCT02851784|Experimental|MWA combined with immunotherapy|The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
16564407|NCT02851771|Experimental|Pneumonia Patients|Patient admitted at hospital with pneumonia, who need a microbiological diagnosis
16564408|NCT02851758|Experimental|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
16564409|NCT02851745|Experimental|Linagliptin|Linagliptin 5 mg daily for 48 weeks
16564410|NCT02851745|Placebo Comparator|Placebo|Placebo 5 mg daily for 48 weeks
16564411|NCT02851732|No Intervention|Control|"Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: Admission, 06 months, and 12 months. Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes."
16564412|NCT02851732|Experimental|Intervention|Educational multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Health care professionals from each institution one being a physician (acting as a local leader) and the other being a research nurse (acting as a case manager) must attend the training course for high cardiovascular risk patients that will take place at HCor.
16564413|NCT02851719|Experimental|BF group|24 outpatient sessions of the PFMT (twice a week) using manometric-based BF equipment and daily home PFMT exercises.
16564414|NCT02851719|Active Comparator|PFMT group|24 outpatient sessions (twice a week) of PFMT without BF and daily home PFMT exercises.
16564415|NCT02851706||1/Patients with CNS Tumors|Patients with CNS tumors (or a history) including those with undiagnosed imaging abnormalities in the CNS; and patients with known genetic syndromes at high risk of developing CNS Cancers.
16564416|NCT02851693|Experimental|Optical Coherence Tomography (OCT)|
16564417|NCT02851680|Experimental|Fongitell test|
16564418|NCT02851680|Active Comparator|serum galactomannan|
16564419|NCT02851667|Experimental|Training group|Resident training programs such as talks, day camp and thematic activities were delivered in training group.
16564420|NCT02851654||Dry eye syndrome|Meibomian gland dysfunction responsible of moderate to severe dry eye syndrome
16564421|NCT02851641||Nasolacrimal duct obstruction|
16564422|NCT02851628|Experimental|Alternative sizing model trial mask|In this arm participants who are randomized to the alternative sizing model based mask will be given the alternative sizing model based mask to use in home for the duration of this arm.
16564423|NCT02851628|Active Comparator|Prototype Full Face Mask (PFFM)|In this arm, participants who are randomized to the PFFM will be given the PFFM to use in-home for the duration of this arm.
16564424|NCT02851615|Other|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
16564425|NCT02851615|No Intervention|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
16564426|NCT02851602|Experimental|Obese|
16564427|NCT02851602|Placebo Comparator|control|
16564428|NCT02851589|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
16564429|NCT02851576|Experimental|Infusion of ADV specific T cells|This one arm study consists in ADV-specific T cell infusion after HSCT from a (M)MUD or, for the first time, from a haploidentical donor for patients having undergone previous UCB transplantation, in the event of refractory ADV infection or disease. Specific anti-ADV immune reconstitution was observed in all patients, and viral load clearance in all but one.
16564430|NCT02851524|Experimental|posturography|
16564431|NCT02851511|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
16564432|NCT02851511|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
16564433|NCT02851511|Experimental|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
16564434|NCT02851511|Experimental|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
16564435|NCT02851498|Experimental|Novel high-protein pasta and cereal|High-protein pasta (orzo and fusilli) enriched with gluten and egg white protein (%energy: 27/30/43 for protein/fat/carbohydrate) and high-protein flaked breakfast cereal enriched with gluten (%energy: 30/35/35 for protein/fat/carbohydrate) were manufactured by Zone Inc.(Boston, MA). The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as control meals.
16564471|NCT02851238|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 6mL/kg of ideal body weight and positive end expiratory ventilation of 5cmH2O during one-lung ventilation
16564436|NCT02851498|Sham Comparator|Control pasta and cereal|Commercial gluten-free pasta (Barcilla orzo and fusilli; %energy: 13/24/63 for protein/fat/carbohydrate) and commercial flaked cereal (Post Honey Bunches of Oats; %energy: 6/18/76 for protein/fat/carbohydrate) were used as the control foods. The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as experimental foods.
16564437|NCT02851485|Experimental|GLPG1972 600 mg oral solution fasted|600 mg GLPG1972 administered as oral solution after overnight fasting
16564438|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fasted|600 mg GLPG1972 administered as oral tablet after overnight fasting
16564439|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fed|600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast
16564440|NCT02851472|Experimental|Inhaled Nitric Oxide|iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
16564441|NCT02851472|Active Comparator|Placebo|Placebo gas (nitrogen) will be given continuous, via inhalation at the same ppm, before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
16564442|NCT02851459|Experimental|Morally Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations.
16564443|NCT02851459|Experimental|Morally Non-Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations.
16564444|NCT02851459|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
16564445|NCT02851446||DS|
16564446|NCT02851446||no DS|
16564447|NCT02851433|Experimental|Sevoflurane Group|
16564448|NCT02851433|Active Comparator|Propofol Group|
16564449|NCT02851420|Placebo Comparator|control|
16564450|NCT02851420|Experimental|patient|
16564451|NCT02851407|Experimental|Defibrotide|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT
16564452|NCT02851407|Other|Best Supportive Care|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable
16564453|NCT02851394|Active Comparator|Levobupivacaine group|
16564454|NCT02851394|Experimental|Levobupivacaine + tramadol group|
16564455|NCT02851381|Other|FG-3019|Treatment of Pancreatic Cancer with FG-3019
16564456|NCT02851368|Other|Near Infrared Fluorescence Imaging with Indocyanine Green|Patients will receive an injection of indocyanine green (ICG) 1 day prior to surgery. Near infrared fluorescence imaging (NIFI) will be used to identify pulmonary nodules during the surgical biopsy and/or resection procedure.
16564457|NCT02851342||MS|patients with multiple sclerosis
16564458|NCT02851342||CO|matched control subjects
16564459|NCT02851316|Experimental|Whole Body Vibration|The WBV intervention consists of 6 bouts of 60 seconds vibration with 2 minutes of rest in between (30Hz, 2g acceleration) while participants stand on a vibrating platform with their knees bent.
16564460|NCT02851316|No Intervention|Control|The control intervention consists of 6 bouts of 60 seconds with 2 minutes of rest in between while participants stand with their knees bent (no vibration applied).
16564461|NCT02851303|Active Comparator|Morphine|"Dose given q 3 - 4 hrs with feeds; do not exceed 4 hrs between doses Morphine (0.04mg/0.1ml)
~Score Dose For Initiation 0-8 0 None 9-12 0.04 mg/dose 13-16 0.08 mg/dose 17-20 0.12 mg/dose 21-24 0.16 mg/dose 25 or above 0.20mg/dose
~Morphine Maintenance/Escalation
~Maintain dose if score 0-8
~Increase dose by 0.02 if score is 9-12 (rescore before dosing) • Increase dose by 0.04 if score 13-16
~Increase score by 0.06 if score 17-20
~Weaning Instructions:
~Maintain on dose 48 hrs before starting weaning
~Wean 0.02 mg morphine every day for a score is 0-8 • Defer wean for score 9-12
~Re-escalation
~If neonate scores 9-12 re-score as described for initiation,
~If second score is in 9-12 increase morphine 0.01 mg q3-4 hrs • If 2 consecutive scores 13-16, increase 0.02 mg q3-4 hrs
~If 2 consecutive scores in 17-20, increase 0.04 mg q3-4 hrs etc"
16564462|NCT02851303|Active Comparator|Methadone|Step 1: 0.7 mgs/Kg/24 hrs. divided by into six doses (q 4 hrs) is starting dose Step 2: Decrease dose by half, which is 50% of starting dose, EVERY 4 hours. Step 3: Same dose which is 50% of starting dose EVERY 6 hours. Step 4: Same dose which is 50% of starting dose EVERY 8 hours. Step 5: Same dose which is 50% of starting dose EVERY 12 hours. Step 6: Decrease dose by half, which is 25% of starting dose EVERY 12 hours. Step 7: Same dose which is 25% of starting dose q 24 hours
16564463|NCT02851290|Experimental|Caudal block|Local anesthetic will be administered into the caudal space
16564464|NCT02851290|Active Comparator|Dorsal penile nerve block|Local anesthetic will be administered around the dorsal penile nerve
16564465|NCT02851277|Experimental|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
16564466|NCT02851277|Experimental|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
16564467|NCT02851277|Placebo Comparator|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
16564468|NCT02851277|Experimental|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
16564469|NCT02851277|Placebo Comparator|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
16564470|NCT02851264||Optical enhancement technology examination|After routine examination by white-light endoscopy,the imaging mode will be switched to optical enhancement.Suspicious area will be recorded in detail. Then all enrolled patients will have their esophagus sprayed with iodine solution. Suspicious area will be also recorded in detail.After that biopsy specimens will be obtained respectively by forceps from each suspicious lesion recorded for histologic diagnosis.
16564472|NCT02851238|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
16564473|NCT02851225|Experimental|telemedicine transmission|telemedicine transmission of biological results in the treatment of transfusion supportive care
16564474|NCT02851225|No Intervention|without telemedicine transmission|no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care
16564475|NCT02851212|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with two Extended Release (XR) tablets of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 Extended Release (XR) fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin XR two tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564476|NCT02851212|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564477|NCT02851212|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564478|NCT02851212|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564479|NCT02851199|Active Comparator|study group 1|1. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the prone position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. Finally the participants will performed additional 3 minutes of hyperventilation in the sitting position
16564480|NCT02851199|Active Comparator|study group 2|2. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the sitting position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. . Finally the participants will performed additional 3 minutes of hyperventilation in the
16564481|NCT02851186|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|Subjects in the treatment group will receive EA combined with AA two hours before operation, immediately post-operation and once a day for the subsequent 5 days.
16564482|NCT02851186|Sham Comparator|Sham acupuncture|Subjects in the control group will receive non-invasive sham procedure in the same schedule as the treatment group.
16564483|NCT02851173|Experimental|LLLT|Six weekly sessions of LLLT. The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each laser stimulation session will consist of total 8 min, with eight 1 min/cycle treatments alternating between two locations on the right forehead.
16564484|NCT02851173|Active Comparator|Placebo|The control group will undergo the same procedure as the treatment group, but will receive brief (5-s) stimulation to the intended site on the forehead, followed by 55 s of no stimulation, for each 1-min cycle. Thus the control group will receive approximately 1/12th of the cumulative energy density as the treatment group. This is sufficient to provide a brief sensation of slight heat (as active placebo) at the onset of each one-minute cycle, using a fraction of the energy received by the experimental group.
16564485|NCT02851160||Patients requiring lung cancer chemotherapy|30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment having a semi-structured interview conducted by a clinical psychologist
16564486|NCT02851160||Family of lung cancer patients receiving chemotherapy|30 Family of lung cancer patients receiving chemotherapy having a semi-structured interview conducted by a clinical psychologist
16564487|NCT02851160||doctors caring for lung cancer patients receiving chemotherapy|15 doctors caring for lung cancer patients receiving chemotherapy 15 have a semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
16564488|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
16564489|NCT02851134||Crohn disease subject|Crohn disease affected subject
16564490|NCT02851134||family control subject|family control unaffected subject
16564491|NCT02851121|Other|Healthy volunteers|
16564492|NCT02851108|Experimental|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
16564493|NCT02851108|Active Comparator|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
16564494|NCT02851095|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with two Extended Release (XR) tablet of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D of (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and 1 metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with 2 metformin (XR) tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564495|NCT02851095|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564860|NCT02848326|Experimental|Atogepant 30 mg BID|Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
16564496|NCT02851095|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564497|NCT02851095|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16564498|NCT02851082|Experimental|Haemophilia A patients|Patients will perform endurance training program on 6 consecutive weeks
16564499|NCT02851069||Participants with Hepatitis C Virus Genotype 1 (HCV + GT1)|ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] with or without dasabuvir [250 mg twice daily]), and with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks in HCV + GT1 participants.
16564500|NCT02851056|Experimental|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
16564501|NCT02851043|Experimental|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
16564502|NCT02851043|No Intervention|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
16564503|NCT02851030|Experimental|Move, Play, Learn! Intervention|This arm will receive the 10-week Move, Play, Learn! intervention immediately.
16564504|NCT02851030|No Intervention|Waitlist Control|This arm will receive the 10-week intervention once follow-up measures on the primary outcome have been collected for both groups.
16564505|NCT02851017|Experimental|Exergaming group (XBOX Kinect|Kinect™ exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total).
16564506|NCT02851017|Experimental|Traditional gym based exercise group|Traditional gym based (TGB) exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total). Those in the TGB group performed exercises that were matched for sequence, intensity, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading as required in the Kinect™ group.
16564507|NCT02851004|Experimental|BBI608 + Pembrolizumab|BBI608 and Pembrolizumab
16564508|NCT02850991|Experimental|High-dose|"concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.
~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
16564509|NCT02850991|Active Comparator|Standard-dose|"concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.
~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
16564510|NCT02850978||Spiolto|Patient with COPD to received Spiolto
16564511|NCT02850965|Experimental|BI 695501|
16564512|NCT02850965|Active Comparator|Humira|
16564513|NCT02850952|Experimental|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
16564514|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
16564515|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
16564516|NCT02850926|Experimental|Soccer head gear|Subjects who are wearing soccer head gear during the practices and games during the soccer season.
16564517|NCT02850926|No Intervention|Control|Subjects who are not wearing soccer head gear during the practices and games during the soccer season.
16564518|NCT02850913|Active Comparator|Doxycycline|"115 participants will be randomized to oral Doxycycline 100 mg daily for six weeks.
~Each capsule contains doxycycline hyclate equivalent to 100 mg of doxycycline base.
~Treatment will be initiated in hospital but will be continued at home.
~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
16564519|NCT02850913|Placebo Comparator|Placebo|"115 participants will be randomized to the placebo arm for matching capsules containing no active ingredients daily for six weeks.
~Placebo will be initiated in hospital but will be continued at home.
~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
16564520|NCT02850900|Experimental|Internet Survey|Subject will receive an electronic survey weekly to complete
16564521|NCT02850900|No Intervention|No Survey|No intervention
16564522|NCT02850887|Active Comparator|general endotracheal anesthesia|an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
16564523|NCT02850887|Active Comparator|deep sedation without endotracheal intubation|local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.
16564558|NCT02850614|Experimental|Intervention|Fifty participants will be randomized to the intervention condition, which will use a gaming application to encourage physical activity, as physical activity goal achievement will translate into rewards in the game. Physical activity will be tracked using a FitBit activity monitor and in order to encourage intervention condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
16564559|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
16564560|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
16564524|NCT02850874|Experimental|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
16564525|NCT02850874|Other|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
16564526|NCT02850861|Experimental|The experimental group|In this group, the condylar reductor was applied in the surgical treatment of mandibular condylar fractures.
16564527|NCT02850861|No Intervention|The control group|In this group, traditional surgical instruments were applied in the surgical treatment of mandibular condylar fractures.
16564528|NCT02850848|Experimental|Entigin Film Coated Tablet 0.5mg|Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets
16564529|NCT02850848|Active Comparator|Baraclude 0.5mg Tablets|Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets
16564530|NCT02850835|Experimental|Video Decision Aid|This group will be shown a video decision aid along with their standard of care.
16564531|NCT02850835|No Intervention|Standard Care|This group will not see the video decision aid and will only receive standard of care.
16564532|NCT02850822||Therapy pre-transplantation|Chemotherapy regimen and/or demethylation drugs(such as decitabine) were given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
16564533|NCT02850822||No Therapy pre-transplantation|No therapy (chemotherapy or demethylation drugs) was given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
16564534|NCT02850809||patients|Treated by percutaneous image-guided radiofrequency for renal tumor
16564535|NCT02850796|Experimental|Kg-Free|Kg-free is a manualized acceptance, mindfulness & compassionate-based group intervention for women struggling with their weight. It comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups (ranging from 10 to 12 participants).
16564536|NCT02850796|Other|Treatment as Usual (TAU)|nutritional treatment for weight loss in primary care units and Hospitals from Coimbra's district that includes dietary and physical activity support
16564537|NCT02850783|Experimental|SLN identification with 89-zirconium-nanocoll|Submucosal injection of 2.5 mBq, 0.4 ml 89-Zirconium-Nanocoll and subsequently SLN identification
16564538|NCT02850770|Other|Control|Pedometers and walking logs
16564539|NCT02850770|Experimental|Phone Messaging|Phone Messaging
16564540|NCT02850770|Experimental|Phone Messaging + Family/Friend Support|Phone Messaging + Family/Friend Support
16564541|NCT02850757|Experimental|U shaped Guedl's airway|
16564542|NCT02850757|Experimental|Modified William's airway(Fekry airway )|
16564543|NCT02850744|Other|Single-arm|Open label, single arm including patients with progressive glioblastoma during or after temozolomide chemotherapy obtaining PQR309 80mg capsules.
16564544|NCT02850731|Experimental|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
16564545|NCT02850731|No Intervention|supervision by a therapist|an adapted physical activity program under supervision of a therapist
16564546|NCT02850718|Experimental|Period 1: Sublingual wafer|Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.
16564547|NCT02850718|Active Comparator|Period 2: Oral comparator|Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.
16564548|NCT02850692|Experimental|Cystic fibrosis with portal hypertension|Mucoviscidosis with portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
16564549|NCT02850692|Experimental|Muco without portal hypertension|Mucoviscidosis without portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
16564550|NCT02850692|Experimental|Portal hypertension without muco|Portal hypertension without Mucoviscidosis. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
16564551|NCT02850692|Experimental|Healthy volunteers|Healthy volunteers. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®).
16564552|NCT02850666|Experimental|Interdisciplinary Process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
16564553|NCT02850653|Other|Endophthalmitis sufferers|Patients hospitalized for diagnostic and therapeutic evaluation of a post-operative acute endophthalmitis.
16564554|NCT02850653|Other|Healthy control patient|Patients hospitalized in the context of a scheduled surgery with sampling of aqueous humour.
16564555|NCT02850627|Experimental|Tongguan capsule|Tongguan capsule (0.5 g tid. for 6 months)
16564556|NCT02850627|Placebo Comparator|placebo capsule|same volume/day of placebo capsule (0.5 g tid. for 6 months)
16564557|NCT02850614|Active Comparator|Control|Fifty participants in the control condition will each receive a FitBit to track their physical activity. Instead of interfacing with a gaming app on their Chromebooks to track physical activity, control condition participants will interface with a minimalist activity tracker showing them only how many minutes of MVPA they've done over the course of the day. It is expected that after several weeks of baseline use, control condition participants will no longer find the FitBit novel. In order to encourage control condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
16564561|NCT02850588||TCAR treatment|All high risk surgical patients undergoing transcarotid revascularization with a carotid stent during carotid artery flow reversal in hospitals that participate in the Carotid Artery Stent Registry of the Society for Vascular Surgery Patient Safety Organization
16564562|NCT02850588||CEA treatment|All patients undergoing carotid endarterectomy in hospitals that participate in the Carotid Endarterectomy Registry of the Society for Vascular Surgery Patient Safety Organization
16564563|NCT02850562|Active Comparator|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
16564564|NCT02850562|Experimental|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
16564565|NCT02850549|Other|physical therapy|Physical Therapy intervention provided by therapists in phase one without training in following a neck classification system and in phase two after being trained to follow a neck pain classification system.
16564567|NCT02850523|Experimental|Experimental|After an initial assessment, the experimental group will receive 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety (n=6 per group) for perinatal anxiety. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
16564568|NCT02850523|No Intervention|Waitlist Control|After an initial assessment, the wait-list control group will not receive any treatment for 6 weeks. They will then be re-assessed after 6 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety
16564569|NCT02850510|Experimental|Brief Incredible Years parent training|Parent training
16564570|NCT02850510|No Intervention|No parent training|No parent training
16564571|NCT02850497|Active Comparator|CRE8 stent|Treatment with CRE8 stent implantation and evaluated with optical coherence tomography at 6 months
16564572|NCT02850497|Active Comparator|Biomatrix stent|Treatment with Biomatrix stent implantation and evaluated with optical coherence tomography at 6 months
16564573|NCT02850497|Active Comparator|patients treated with Xience stent|Treatment with Xience stent implantation and evaluated with optical coherence tomography at 6 months
16564574|NCT02850484|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
16564575|NCT02850484|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
16564576|NCT02850484|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
16564577|NCT02850471|Experimental|TEAS group|Before anesthesia, patients in this group treated with Transcutaneous Electric Acupoint Stimulation (TEAS) which is an electroacupuncture on Feishu, Hegu, Chize half an hour before the surgery, using the device Hua Tuo SDZ-II Acupoint Stimulator. The stimulus parameters set as 2/100Hz, 2V, 30min.
16564578|NCT02850471|No Intervention|controlled group|Patients in controlled group treated without TEAS or other placebo.
16564579|NCT02850458||implant retained-overdentures with the attachment of bar|patients treated with implant-retained overdentures,and the attachment is bar
16564580|NCT02850458||implant retained-overdentures with the attachment of magnet|patients treated with implant-retained overdentures,and the attachment is magnet
16564581|NCT02850445|Experimental|Integrated Treatment|
16564582|NCT02850445|Active Comparator|antipsychotic medication alone treatment|
16564583|NCT02850432|Active Comparator|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
16564584|NCT02850432|Active Comparator|Conservative treatment|rehabilitation with medical therapy
16564585|NCT02850419|Experimental|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
16564586|NCT02850406|Experimental|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:
~Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)
~Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)
~Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)
~Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)"
16564587|NCT02850393|Experimental|patients with obsessive compulsive disorder|Functional magnetic resonance imaging behavioral measures physiological measurements
16564588|NCT02850393|Experimental|healthy participants|Functional magnetic resonance imaging behavioral measures physiological measurements
16564589|NCT02850380|Other|spatial orientation in weightlessness|"subjects will be asked to flip a series of switches into the off position. On Earth, the off position corresponds to down in all three reference frames: the visual allocentric, the non-visual allocentric as well as the egocentric frames. We expect that flip direction will be dominated by visual allocentric cues when those are available, will be delayed and more variable when confirmatory gravitational cues are absent, and will be biased towards the egocentric reference when tactile cues are added"
16564590|NCT02850367|Active Comparator|Acute intake|Evaluation after acute intake of the food supplement.
16564591|NCT02850367|Active Comparator|Chronic intake|Evaluation before and after chronic intake of the food supplement.
16565365|NCT02844894|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation
16564592|NCT02850354|Experimental|anti-g maneuvers|"Before the first parabola, pulmonary function will be evaluated. Then during each weightlessness period the subject will be instructed either to stay at rest (control condition) or to perform anti-g maneuvers (4 times each): intermittent exhalation on exertion, lower limbs and abdomen muscular contraction, combined maneuver ('intermittent exhalation on exertion' + 'muscle contraction'). Before, the exhalation on exertion, the subject will close the airway after the mouthpiece by pushing on a button actuating a pneumatic valve.
~Each subject will be tested during 15 parabola where the anti-g maneuvers will be performed in randomized order. After the 15th parabola, pulmonary function will be again evaluated."
16564593|NCT02850341|Experimental|Intervention group|Patients receive a pedometer and instructions how to raise their physical activity
16564594|NCT02850341|No Intervention|Control group|Patients receive treatment-as-usual
16564595|NCT02850328|Other|high-load resistance training for long term space flights|"Short duration electrical will be delivered and the resulting EMG will be recorded. Intensity of electrical stimulation will be progressively increased until we observed a maximal EMG response.
~Finally an ultrasound probe (similar to that used for prenatal diagnostic imaging) will be fixed behind your calf in order to visualize muscle."
16564596|NCT02850302|Other|FDG PET + exome analysis before treatment and after|Participants will performed one PET with FDG an tumor exome analysis before treatment is started.After 6 cycles of chemotherapy a second PET with FDG and a second tumor exome analysis will be performed
16564597|NCT02850289||Pegylated Interferon (PEG-IFN) alfa-2a and Ribavirin|Participants with hepatitis C who were to be treated with combination of pegylated interferon (PEG-IFN) alfa-2a and ribavirin, within 7 days of baseline, with ongoing management at investigator's discretion.
16564598|NCT02850276|Experimental|Pyridostigmine|30mg PO three times a day
16564599|NCT02850263||Cohort 1 / Anti-VEGF treatment naïve patients|Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
16564600|NCT02850263||Cohort 2 / Anti-VEGF treatment non-naïve patients|Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
16564601|NCT02850263||Cohort 3 / Total study population|Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
16564602|NCT02850224|Experimental|Motivational interviewing to elicit PCO in pediatrics|"Providers will be randomized into a patient-centered outcomes (PCO) education course or standard of care. The PCO education course will educate and test providers on patient-centered outcomes of interest and appropriate methods to deliver PCO care.
~Providers randomized into the intervention arm will be required to take a brief, one-hour, webinar describing the background, problem, results from focus groups we conducted, and a training program on motivational interviewing. After completing the course, providers will be required to complete an evaluation."
16564603|NCT02850224|No Intervention|No Intervention|Standard care
16564604|NCT02850211|Experimental|Celecoxib|1 capsule of 200mg Celebrex twice a day for 14 days
16564605|NCT02850211|Active Comparator|Traditional NSAIDs|1 tablet of 385mg Ibuprofen twice a day for 14 days
16564606|NCT02850211|Active Comparator|Opioid drug|1 tablet of 50mg Tramadol twice a day for 14 days
16564607|NCT02850198|Experimental|Scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
16564608|NCT02850198|Sham Comparator|Sham scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. with shame electroacupuncture. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
16564609|NCT02850185|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
16564610|NCT02850185|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
16564611|NCT02850172|Experimental|Walk, eat, & breathe group|"Participants in the experimental group will receive Walk, Eat, & Breathe at initiation of CCRT and ends before curative surgery."
16564612|NCT02850172|No Intervention|Control group|Participants in the control group received usual care.
16564613|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
16564614|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
16564615|NCT02850146|Experimental|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 4 time points over a 4.5 year period.
16564616|NCT02850133|Experimental|Spinal cord injury|Cardio-pulmonary exercise testing and aerobic exercise training
16564617|NCT02850120||Unconfounded|"All hospital admissions including Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with:
~no concomitant procedures,
~any concomitant procedures which were considered unlikely to have an effect on outcomes from their mesh insertion, or
~only other concomitant procedures which were considered likely to be rescue procedures treating complications caused by the mesh insertion procedure itself."
16564618|NCT02850120||Confounded|All hospital admissions for insertion of Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with concomitant procedures likely to affect outcomes.
16564619|NCT02850107|Other|Non-randomized|"Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects.
~DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™.
~Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU.
~Medtronic IN.PACT® Admiral® DCB will be used after DA.
~Volcano Visions® PV .014 IVUS catheter required to assess lesion in each procedure.
~Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required."
16564620|NCT02850094|Experimental|Financial Bonuses|For two weeks following enrollment, subjects are monitored via their FitBit accelerometer to monitor their pre-intervention physical activity levels. For a twenty-four week period following the observational period, participants are eligible for financial bonuses based on their increased activity. Participants enroll as teams and are eligible for additional financial bonuses based on their team's performance.
16564621|NCT02850081|No Intervention|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.
16564622|NCT02850081|Experimental|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin <40mg without amlodipine and <20mg with amlodipine; Atorvastatin (<80mg) or Rosuvastatin (<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.
16564623|NCT02850081|Experimental|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA
16564624|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
16564625|NCT02850055|Experimental|Specific Manual Therapy Group|Conventional Physiotherapy and Specific manual therapy, six one hour treatment sessions. An hour for week.
16564626|NCT02850055|Active Comparator|Multimodal Group|Conventional Physiotherapy, six one hour treatment sessions. An hour for week.
16564627|NCT02850042|Experimental|Occupation-based practice|Occupation-based intervention (OBP) is a form of activity-based therapy consisting of client-directed occupations that match client-identified goals. OBP group will participate in activities such as wood working, scrap booking, higher level dressing (don/doffing a bra, zipping coat), hair care, opening doors, using bathroom stalls, typing, cooking, tying shoes, washing dishes, carrying dirty dish carts, clearing dirty dishes and raking. Repetition of the tasks are not the focus in the OBP group. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
16564628|NCT02850042|Active Comparator|Modified-constraint induced therapy|Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
16564629|NCT02850029||critically ill patients|Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.
16564630|NCT02850016|Experimental|Group A|Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
16564631|NCT02850016|Experimental|Group B|Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .
16564632|NCT02850003|Experimental|IDP-120 Gel|Gel
16564633|NCT02849990|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
16564634|NCT02849977||Cohort 1|If the subject has a history of hyperphagia, early onset obesity and/or clinical characteristics known to be related to mutations in the MC4R pathway and related to obesity (1.4 times 95th percentile in children).
16564635|NCT02849977||Cohort 2|If the subject has exponentially high BMI (≥50 to 59), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.5 - 1.6 times 95th percentile in children).
16564636|NCT02849977||Cohort 3|If the subject has exponentially high BMI (≥60), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.6 times 95th percentile in children).
16564637|NCT02849977||Cohort 4|If the subject has had or is undergoing bariatric surgery, who represents a refractory population of severely obese individuals whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.4 times 95th percentile in children and adolescents aged 12 and older).
16564638|NCT02849964||First time renal replacement therapy|Patients beginning renal replacement therapy by renal dialysis or preemptive kidney transplant.
16564639|NCT02849951|Experimental|LT-02|1.6 g PC in LT-02 BID
16564640|NCT02849951|Placebo Comparator|LT-02 Placebo|0 g PC in LT-02 Placebo BID
16564641|NCT02849938|No Intervention|Control Group|Usual care
16564642|NCT02849938|Experimental|Telemedicine Group|TytoCare Device
16564643|NCT02849925|Experimental|Glass Ionomer Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
16565366|NCT02844894|Experimental|Esmolol|0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
16564644|NCT02849925|Active Comparator|Resin Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of resin sealant, Clinpro (3M-ESPE) in first permanent molars
16564645|NCT02849899|Active Comparator|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
16564646|NCT02849899|Placebo Comparator|Placebo|Group 2 will be treated with placebo according to the same dosage.
16564647|NCT02849886|Experimental|LT icasp9 ΔCD19 (cohort1)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 Gene Modified Cells (GMC)/kg).
16564648|NCT02849886|Experimental|LT iCASP9 ΔCD19 & GvHD (cohort2)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 GMC/kg). Patients who develop GVHD after administration of Gene Modified Cells (GMC) will be treated with dimerizer drug (AP1903)
16564649|NCT02849873|Experimental|IDp-123 Lotion|Lotion
16564650|NCT02849873|Active Comparator|Tazorac Cream|Cream
16564651|NCT02849860|Experimental|IDP-121 Lotion|Lotion
16564652|NCT02849834|Active Comparator|healthy volunteers|
16564653|NCT02849834|Experimental|Patients with resistant pain|
16564654|NCT02849821|Other|hypobaric pressure chamber|The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
16564655|NCT02849808||Keratoplasty patients|All patients who underwent one or more keratoplasties since january 1983.
16564656|NCT02849795|Experimental|Psoriasis and arthritic psoriasis|additional blood sample for biological analyses bone densitometry questionnaires
16564657|NCT02849782|Experimental|Fampridine responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).
~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner."
16564658|NCT02849782|Active Comparator|Fampridine non responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).
~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner."
16564659|NCT02849769||Patients implanted with an MR-conditional Tachy device system|Patients implanted with an MR-conditional Tachy device system in the routine care
16564660|NCT02849756||older in intensive care unit|older (age superior at 85 years) hospitalized in intensive care unit. A follow-up until 6 months after hospitalization will determine the evolution of the quality of life and others secondary outcomes.
16564661|NCT02849743|Experimental|Syntocinon (= Oxytocin), then Placebo|"Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
~Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks) *Dose Escalation, as appropriate, at 2 Weeks"
16564662|NCT02849743|Experimental|Placebo, then Syntocinon (= Oxytocin)|"Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
~Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)"
16564663|NCT02849730||Young adults|Patients aged 20 to 39 who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
16564664|NCT02849730||Elderly patients|Patients aged 70 and over who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
16564665|NCT02849717|No Intervention|Standard Care|Subjects are advised to maintain their normal level of activity
16564666|NCT02849717|Active Comparator|Home-Based Exercise|Progressive walking and resistance exercise treatment
16564667|NCT02849704|Experimental|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.
~Subjects will take Creon36™ for 9 days.
~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
16564668|NCT02849704|No Intervention|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
16564669|NCT02849691||Quartile 1|Quartile 1 of plasma DPP4 activity
16564670|NCT02849691||Quartile 2|Quartile 2 of plasma DPP4 activity
16564671|NCT02849691||Quartile 3|Quartile 3 of plasma DPP4 activity
16564672|NCT02849691||Quartile 4|Quartile 4 of plasma DPP4 activity
16564736|NCT02849249|Active Comparator|Rapid schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in a rapid Schedule.The initation phase includes 3 weekly increasing doses till the maintenance dose of 0.5 mL is reached.
16564673|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.
~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
16564674|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
16564675|NCT02849665|Experimental|Kangaroo Position|The newborn remains in a vertical position, with limbs flexed, dressed in light clothes, maintaining skin-to-skin contact and the face on the adult's thorax.
16564676|NCT02849665|No Intervention|Not Kangaroo Position|The newborns will be not placed in the position Kangaroo.
16564677|NCT02849652|Experimental|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
16564678|NCT02849652|Other|Usual Care|Usual Care is the typical guideline based smoking cessation intervention
16564679|NCT02849639|Placebo Comparator|Placebo|"Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.
~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
16564680|NCT02849639|Active Comparator|Medication Therapy Management (MTM)|"Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.
~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
16564681|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
16564682|NCT02849613|Experimental|Adipose derived Stem Cells ADSC|ADSC, single IV, 1.106 cells/kg
16564683|NCT02849613|Sham Comparator|Vehicle media|IV infusion of cell excipients, 1ml/kg
16564684|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will receive cannabis with placebo THC
16564685|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will receive cannabis with 5.9% THC
16564686|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will receive cannabis with 13.4% THC
16564687|NCT02849561|Active Comparator|Favourable neurological evolution after cardiac arrest|MGOS 4-5
16564688|NCT02849561|Active Comparator|Unfavourable neurological evolution after cardiac arrest|MGOS 1-3
16564689|NCT02849548|Experimental|suvorexant|10 to 20 mg to be administered after an evening written trauma narrative exposure session.
16564690|NCT02849548|Placebo Comparator|Placebo pill|A pill without active ingredients
16564691|NCT02849535|Experimental|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
16564692|NCT02849535|No Intervention|Standard of care|In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.
16564693|NCT02849522||PAE patients|Men who have undergone PAE and are in the UK ROPE Register
16564694|NCT02849522||Comparator treatment patients|Men who have undergone TURP, Open Prostatectomy or laser ablation/enuclation of the prostate, and are on the UK ROPE Register.
16564695|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
16564696|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
16564699|NCT02849483|Experimental|Ramosetron|2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
16564700|NCT02849483|Placebo Comparator|Control|dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA
16564701|NCT02849470|Active Comparator|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
16564702|NCT02849470|Active Comparator|ARM 2|"Experimental: HD-PRP + Emulsified AD-tSVF;
~Intervention:
~Platelet Rich Plasma
~Adipose Derived Stem/Stromal Cells
~Intradermal injections of hair loss"
16564703|NCT02849470|Experimental|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss
~Platelet Rich Plasma
~Adipose Derived Stem/Stromal Cells
~Stem/Stromal Cell Isolation
~Intradermal injections of hair loss"
16564704|NCT02849457|Placebo Comparator|Vigabatrin or Placebo|Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
16564737|NCT02849236|Placebo Comparator|Control group|PECS block performed with Saline solution instead of local anesthetic
16564738|NCT02849236|Experimental|PECS group|PECS block performed with Ropivacaine 3.75mg/mL
16564705|NCT02849457|Other|Vigabatrin|Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
16564706|NCT02849457|No Intervention|Control Group|Enrolled subjects who never develop EEG abnormalities or clinical seizures
16564707|NCT02849444||Moderate kidney failure|30 ≤ CrCl < 50 mL/min/1.73 m2
16564708|NCT02849444||Severe kidney failure|CrCl < 30 mL/min/1.73 m2
16564709|NCT02849431|Experimental|Mindfulness-based intervention|
16564710|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
16564711|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
16564712|NCT02849405|Other|Arteriosclerosis|Hyperspectral camera for arteriosclerosis Diagnostic
16564713|NCT02849405|Other|Healthy controls|Hyperspectral camera for healthy control Diagnostic
16564714|NCT02849392|Experimental|Pistachio|Pistachio added 20% of kcals to diet
16564715|NCT02849392|No Intervention|No Pistachio|No pistachios in diet (control)
16564716|NCT02849379|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564717|NCT02849379|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564718|NCT02849366|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564719|NCT02849366|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564720|NCT02849353|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564721|NCT02849353|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564722|NCT02849340|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564723|NCT02849340|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564724|NCT02849327|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564725|NCT02849327|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564726|NCT02849314|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564727|NCT02849314|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564728|NCT02849301|Experimental|Cervical pessary|Arabin cervical pessary
16564729|NCT02849301|No Intervention|Standard care|No treatment
16564730|NCT02849288|Experimental|Intervention|Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
16564731|NCT02849275|Placebo Comparator|Lactose free 1% milk|Diet will be recorded with a 7-day diet record and participants will include an isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
16564732|NCT02849275|Experimental|Probiotic treatment|Diet will be recorded with a 7-day diet record and participants will include an isocaloric fermented milk (probiotic), consumed once daily, over 4-5 weeks.
16564733|NCT02849262|Experimental|Omiganan (CLS001)|CLS001 Topical Gel, 2.5%
16564734|NCT02849262|Placebo Comparator|Vehicle|Vehicle Topical Gel
16564735|NCT02849249|Active Comparator|One day schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in one day schedule. The maintenance dose (0.5 mL) is reached in one day.
16565367|NCT02844894|Placebo Comparator|Placebo|20 ml normal saline infused in 5 minutes before intubation
16564739|NCT02849223|Experimental|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
16564740|NCT02849223|Sham Comparator|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
16564741|NCT02849210|Experimental|Allergovac depot|Allergovac depot with Olea europaea pollen extract
16564742|NCT02849197||Primary Closure|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.
~Technique: primary closure. Technical details: An elliptical incision was made, and the excision included sinus openings at the median line and extended down to the pre-sacral fascia. One suction drain was placed in the wound cavity. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and skin was closed with interrupted 2-0 silk suture."
16564743|NCT02849197||Limberg Flap Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.
~Technique: Limberg Flap Technique. Technical details: A rhomboid incision was made as to include all sinus openings, and an excision was made down to the pre-sacral fascia. A bisector drawn in the rhombohedron was extended laterally to a length similar to that of a corner of the rhombohedron. Then, the flap was prepared by removing gluteal muscle with its fascia. One suction drain was placed at the wound cavity. The base of the flap was approximated with the presacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable sutures, and the skin was closed with interrupted 3-0 prolene suture."
16564744|NCT02849197||Modified Limberg Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.
~Technique: Modified Limberg Flap Technique. Technical details: As in Limberg flap technique, a rhomboid incision was made. Upper and lower corners of the excision were lateralized 2 cm away from the midline in order to keep the suturing line at the inferior from overlapping the midline. An excision was made down to the pre-sacral fascia. One suction drain was placed at the wound cavity, and the base of the flap was approximated with the pre-sacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and the skin was closed with 3-0 prolene."
16564745|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
16564746|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
16564747|NCT02849171|Experimental|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
16564748|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
16564749|NCT02849145|Experimental|Biological/Vaccine|
16564750|NCT02849132|Experimental|Treatment group|entecavir oral，0.5mg daily for 8 years
16564751|NCT02849119|Experimental|Transperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through transperitoneal approach
16564752|NCT02849119|Experimental|Retroperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through retroperitoneal approach
16564753|NCT02849106|Experimental|biopsy to obtain a chemogram|
16564754|NCT02849093||Dry Eye Syndrome Patients|Patients who have been diagnosed clinically with Sjögren's will have an OCT image of their lacrimal glands and buccal mucosa taken. Imaging from patients found to have Sjögren's clinically diagnosed following examination of buccal mucosa under the microscope will be compared with images from patients without dry eye syndrome to see of any obvious differences can be identified.
16564755|NCT02849093||Epiphora Patients|Pre and post-operative OCT images of patients undergoing punctoplasty or conjunctivoplasty will be compared to images of the same structures in people without watery eyes.
16564756|NCT02849093||Asymptomatic Patients|OCT images will be captured of the cornea, conjunctiva, lacrimal gland and buccal mucosa to establish normal appearance in asymptomatic patients.
16564757|NCT02849080|Experimental|Semaglutide flexible dosing (3, 7 or 14 mg)|
16564758|NCT02849080|Active Comparator|Sitagliptin 100 mg|
16564759|NCT02849067|Experimental|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
16564760|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
16564761|NCT02849054|Experimental|4, 5, 6ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 5ml/kg, 6ml/kg. Measurement of PTPdi
16564762|NCT02849054|Experimental|4, 6, 5ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 6ml/kg, 5ml/kg. Measurement of PTPdi
16564763|NCT02849054|Experimental|5, 4, 6ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 4ml/kg, 6ml/kg. Measurement of PTPdi
16564764|NCT02849054|Experimental|5, 6, 4ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 6ml/kg,4ml/kg. Measurement of PTPdi
16564765|NCT02849054|Experimental|6, 5, 4ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 5ml/kg, 4ml/kg. Measurement of PTPdi
16564766|NCT02849054|Experimental|6, 4, 5ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 4ml/kg, 5ml/kg. Measurement of PTPdi
16564858|NCT02848326|Experimental|Atogepant 10 mg QD|Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
16565397|NCT02844660|Experimental|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
16564767|NCT02849041|Experimental|Screening program|Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
16564768|NCT02849028||TBI Patients with sleep disorder|All the patients should be diagnosed by polysomnographic (PSG)
16564769|NCT02849028||health people|The people have a normal sleep
16564770|NCT02849015|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive liver cryosurgery first to destroy big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564771|NCT02849015|Active Comparator|Cryosurgery|In this group, the patients will receive liver cryosurgery to destroy big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16564772|NCT02849002|Experimental|Interventional Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the brain motion caused by pulsatile blood flow from the cardiac cycle.
~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile blood flow. The system is powered by rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
16564773|NCT02848989|Experimental|Qigong Mind-Body Exercise (QMBE)|"After the screening procedures confirm that you are eligible to participate in the research study:
~Breast cancer survivors with persistent post-surgical pain (PPSP) into a 12-week program of Qigong mind-body exercise (QMBE).
~Outcome assessments related to pain, function, and quality of life"
16564774|NCT02848976||IA group|EDSS (Expanded Disability Status Scale) below 6 with RE
16564775|NCT02848976||IB group|EDSS (Expanded Disability Status Scale) below 6 with no RE
16564776|NCT02848976||IIA group|EDSS (Expanded Disability Status Scale) betwin 6 and 8 with RE
16564777|NCT02848976||IIB group|EDSS (Expanded Disability Status Scale) below 6 with RE
16564778|NCT02848963|Active Comparator|ketamine-propofol mixture 5/1|Ketamine-propofol mixture will be compare for every groups.
16564779|NCT02848963|Active Comparator|ketamine-propofol mixture 10/1|Ketamine-propofol mixture will be compare for every groups.
16564780|NCT02848963|Active Comparator|Ketamine-propofol mixture 6,7/1|Ketamine-propofol mixture will be compare for every groups
16564781|NCT02848950|Active Comparator|treatment|drug: metformin
16564782|NCT02848950|No Intervention|control|without metformin
16564783|NCT02848937||Bath with citrate|"Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM.
~•Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study"
16564784|NCT02848937||Bath with citrate and Ca_eq|"Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials:
~Filter high permeability (Kuf> 20ml/mmHg);
~Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.
~All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study."
16564785|NCT02848911|Experimental|AFM11|IV (intravenous) infusion, dose escalation
16564786|NCT02848898|Experimental|Equistasi Group|arm treated with application of devices
16564787|NCT02848898|Placebo Comparator|Placebo Group|arm treated with application of inactivated devices
16564788|NCT02848885|Experimental|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
16564789|NCT02848885|Experimental|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
16564790|NCT02848872||NSCLC patients|Resected patients
16564791|NCT02848859|Active Comparator|Intervention: Go! to Sleep|We are using a web-based cognitive behavioral therapy program called Go! to Sleep. Go! to Sleep is an interactive online program developed by specialists in Cleveland Clinic's Wellness Institute and Sleep Disorders Center. The program is a 6 week self-help program that uses cognitive behavioral therapy techniques that have been proven to be effective in decreasing symptoms of insomnia.
16564792|NCT02848859|Placebo Comparator|General Sleep Hygiene Education|General Sleep Hygiene Education is the first step in the treatment of any sleep disorder. Both arms will have access to a Harvard sleep education web site that provides general information about sleep as well as sleep hygiene.
16564793|NCT02848846|Experimental|Robotic Hand|The two patient enrolled will perform the task requiring the use of the robotic hand.
16564794|NCT02848833||JARDIANCE|T2DM with JARDIANCE
16564859|NCT02848326|Experimental|Atogepant 30 mg QD|Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
16564795|NCT02848820|Experimental|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:
~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.
~Pain medication according to national protocol."
16564796|NCT02848820|Active Comparator|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
16564797|NCT02848807|Active Comparator|NUTRIDRINK Compact Protein|NUTRIDRINK Compact Protein Oral nutritional supplement Dietary advice
16564798|NCT02848807|No Intervention|without oral nutritional supplements|Dietary advice alone
16564799|NCT02848794|Experimental|Apatinib+Irinotecan|Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
16564800|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
16564801|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
16564802|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
16564803|NCT02848742|Experimental|Treatment with cryotherapy device|To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
16564804|NCT02848729|Experimental|Treatment A: Oral Acetaminophen|Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
16564805|NCT02848729|Experimental|Treatment B: IV Acetaminophen|Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
16564806|NCT02848716|Active Comparator|Standard of care arm|Standard chemoradiation based on FluoroDeoxyGlucose-Positon Emission Tomography (FDG-PET) imaging status of the pelvic nodes
16564807|NCT02848716|Experimental|Experimental arm|Pretherapeutic paraaortic lymphadenectomy followed by tailored chemoradiation. Pretherapeutic lymphadenectomy will be performed via the laparoscopic extraperitoneal or transperitoneal approach
16564808|NCT02848703|Experimental|healthy volunteers|
16564809|NCT02848690|Experimental|Educational Intervention Group|Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
16564810|NCT02848690|Sham Comparator|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
16564811|NCT02848677|Active Comparator|intervention group|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
16564812|NCT02848677|Sham Comparator|control group|usual care of hypertensive patients.
16564813|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
16564814|NCT02848651|Experimental|Atezolizumab|Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
16564815|NCT02848625|Experimental|Group A|Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
16564816|NCT02848625|No Intervention|Group B|Patients who are not randomized to yoga sessions will continue with their usual care and usual activities
16564817|NCT02848599|Active Comparator|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
16564818|NCT02848599|Active Comparator|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
16564819|NCT02848586|Active Comparator|ECIGS|Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
16564820|NCT02848586|Active Comparator|Usual brand|Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
16564821|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
16564822|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
16564823|NCT02848547||Intervention - SMS|Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period.
16564824|NCT02848547||Control - Standard Care|Participants in the control group received standard one time advice at entry in the study.
16564825|NCT02848508|Experimental|moderate impairment, CKD stage 3a|(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day
16564826|NCT02848508|Experimental|moderate impairment, CKD stage 3a)|(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day
16564827|NCT02848508|Experimental|severe impairment|(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day
16564828|NCT02848482|Active Comparator|Control group|Plastic curette will be used to perform the mechanical debridement. Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
16564829|NCT02848482|Experimental|Test group|Plastic curette will be used to perform the mechanical debridement. Then, the addition photodynamic therapy (PDT) will be performed. This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
16564830|NCT02848469|Active Comparator|Omega-3 fatty acids|Subjects will receive food supplements in the form of 200ml juice drinks, containing either the active component, 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid, or matching placebo for a duration of six months. Neither the active nor the placebo food supplements taste of fish, so the subject will be blind to whether he/she is receiving the active intervention or placebo.
16564831|NCT02848469|Placebo Comparator|placebo 200ml juice drinks|200ml juice drinks
16564832|NCT02848456|Active Comparator|Spinal Manipulation SM|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
16564833|NCT02848456|Active Comparator|Max Voluntary Isometric Contraction MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
16564834|NCT02848456|Active Comparator|SM+MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
16564835|NCT02848443|Experimental|S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)|
16564836|NCT02848430|Experimental|Humulus lupulus|Spent hop extract; 2 gelatin capsules (59.5 mg extract) per day for 14 days
16564837|NCT02848417|Experimental|Curcumin|12 weeks 400mg orally twice a day
16564838|NCT02848417|Experimental|Liposomal Glutathione|12 weeks 630mg orally twice a day
16564839|NCT02848417|Experimental|Placebo Liquid or Capsules|"Placebo liquid for Glutathione 120 ml per/ bottle 420 mg/5 ml
~Placebo capsules for Curcumin 60 capsules per bottle 400 mg /cap"
16564840|NCT02848404|Experimental|Categorical Language Fluency Smartphone Application|Smartphone game application specifically aimed at training categorical language fluency
16564841|NCT02848391|Experimental|healthy subjects|three hour flight simulation
16564842|NCT02848391|Experimental|COPD normocapnic|three hour flight simulation
16564843|NCT02848391|Experimental|COPD hypercapnic|three hour flight simulation
16564844|NCT02848378||Chronic periodontitis group|Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression
16564845|NCT02848378||Gingivitis group|Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at >50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis
16564846|NCT02848378||Periodontally healthy group|Subjects who have no sites with PD >3mm and CAL >0 mm, a BOP score of <15% at the examination and no alveolar bone loss.
16564847|NCT02848365|Active Comparator|Glidescope|
16564848|NCT02848365|Active Comparator|Macintosh laryngoscope|
16564849|NCT02848365|Active Comparator|Bonfill's rigid scope|
16564850|NCT02848365|Active Comparator|Air traq|
16564851|NCT02848365|Active Comparator|C -Mac scope|
16564852|NCT02848365|Active Comparator|flexible fiberoptic scope|
16564853|NCT02848352|Experimental|Positive placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
16564854|NCT02848352|Experimental|Negative placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
16564855|NCT02848352|Placebo Comparator|Placebo control group|Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
16564856|NCT02848352|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
16564857|NCT02848326|Placebo Comparator|Placebo|Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
16564861|NCT02848326|Experimental|Atogepant 60 mg QD|Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
16564862|NCT02848326|Experimental|Atogepant 60 mg BID|Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
16564863|NCT02848313|Experimental|Intermediate AMD - HRD without GA|"Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy [GA]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen.
~Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
16564864|NCT02848313|Experimental|Intermediate AMD with NCGA|"Participants had 1 eye with intermediate AMD with noncentral geographic atrophy [NCGA]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area[DA]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography [SD-OCT]).
~Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
16564865|NCT02848300|Experimental|All Participants|Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
16564866|NCT02848287|Placebo Comparator|Normal Saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
16564867|NCT02848287|Experimental|Ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
16564868|NCT02848261|Experimental|Developmental Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
16564869|NCT02848261|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
16564870|NCT02848261|Experimental|Remote Monitoring|Optimize the use of remote monitoring by focusing on situational demands and problem solving.
16564871|NCT02848261|Experimental|Fear of Hypoglycemia|Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
16564872|NCT02848261|Placebo Comparator|No Intervention|Serves as the control group comparator. No intervention provided.
16564873|NCT02848248|Experimental|SGN-CD123A|SGN-CD123A every 3 weeks
16564874|NCT02848235|No Intervention|Group 1 (Standard of Care)|Participants in group 1 will receive the standard of care for the Prevention of Mother to Child Transmission (PMCTC) of HIV from the clinic's Mentor Mothers.
16564875|NCT02848235|Experimental|Group 2 (Standard of Care + EMMA)|Participants in group 2 will receive the standard of care for Prevention of Mother to Child Transmission (PMCTC) of HIV plus study-specific enhanced care interventions from the clinic's Mentor Mothers.
16564876|NCT02848222|Experimental|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
16564877|NCT02848222|Experimental|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
16564878|NCT02848222|Sham Comparator|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
16564879|NCT02848209|No Intervention|Control|No peeling applied on the skin flap
16564880|NCT02848209|Experimental|Drug: TCA 20% Peeling|Trichloroacetic acid 20% applied on the skin flap until even frosting for 2-4 minutes.
16564881|NCT02848209|Experimental|Drug: TCA 40% Peeling|Trichloroacetic acid 40% applied on the skin flap until even frosting for 2-4 minutes.
16564882|NCT02848209|Experimental|Drug: Phenol/croton oil Peeling|Phenol/croton oil applied on the skin flap occluded with silicone tape for 24 hours and not neutralized.
16564883|NCT02848196|Experimental|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
16564884|NCT02848183|Experimental|Pediatric de novo acute myeloid leukemia|"I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide
~II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning"
16564885|NCT02848170|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks
16564886|NCT02848170|Active Comparator|olmesartan medoxomil|olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks
16564887|NCT02848157|Experimental|DR|dexmedetomidine 0.3mcg/kg and 0.25% ropivacaine 0.3ml/kg
16564888|NCT02848157|Placebo Comparator|PR|0.25% ropivacaine 0.3ml/kg
16564889|NCT02848144|Other|Children with infectious shock|Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
16564890|NCT02848144|Other|Control group: healthy children|Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
16564891|NCT02848131|No Intervention|Group 1: Observational|Observational Only
16564892|NCT02848131|Active Comparator|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
16564893|NCT02848118|Experimental|A nasal-oral cannula of capnography|Start bronchoscopy when the nasal-oral capnography shows hypoventilation during bronchoscopic sedation.
16564894|NCT02848118|Active Comparator|Sedation scale|Start bronchoscopy when Observer Assessment of Alertness and Sedation scale (OAAS)=3~2 during bronchoscopic sedation.
16564895|NCT02848105|Experimental|VPA+Methyl|VPA added to standard methylpredisonlone treatment for aGVHD
16564896|NCT02848092|Experimental|FOCAL+Training|
16564897|NCT02848092|Sham Comparator|Rules of the Road Training|
16564898|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|"Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional 3+3 design. The subjects in Part 2 were treated with dose level 3.
~Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle."
16564899|NCT02848066||Gastric Cancer patients|This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.
16564900|NCT02848066||Cancer-free healthy volunteers|This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.
16564901|NCT02848053||Tianqi group|used Tianqi Capsule in the REDUCES study
16564902|NCT02848053||Placebo group|used placebo in the REDUCES study
16564903|NCT02848040|Experimental|Single Arm|All patients will receive the same interventions. Single are only
16564904|NCT02848027|Experimental|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
16564905|NCT02848014|Experimental|Expectation|Participants are asked to think and write about ways how they can positively influence/control the stress during stress induction. They also can think of strategies they used in their past. The purpose of this arm is to improve participants' personal control expectations.
16564906|NCT02848014|Experimental|Emotion|Participants in this group are asked to write a gratitude-letter to a person they want to thank. The purpose of this arm is to foster positive emotions.
16564907|NCT02848014|Active Comparator|Control|Participants in this group are asked to do a neutral writing task. The task is to write a protocol of yesterday's to-dos.
16564910|NCT02847988|Active Comparator|Neuro-muscular electrical stimulation|"Intervention:Neuromuscular electrical stimulation (NMES)
~NMES stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering NMES"
16564911|NCT02847988|Sham Comparator|Sham stimulation|"Intervention: sham stimulation
~Sham stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering sham-NMES"
16564912|NCT02847975|Experimental|Sodium nitrate|Sodium nitrate will be administered orally and functional sympatholysis assessed before and after treatment
16564913|NCT02847962|No Intervention|Control (No FBF)|FBF provided after the intervention period
16564914|NCT02847962|Active Comparator|Corn Soy Blend Plus (CSB+)|Consumed Corn Soy Blend Plus (CSB+)
16564915|NCT02847962|Experimental|Corn Soy Blend 14 (CSB14)|Consumed Corn Soy Blend 14 (CSB14)
16564916|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 1|Consumed White Sorghum Cowpea Blend Variety 1
16564917|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 2|Consumed White Sorghum Cowpea Blend Variety 2
16564918|NCT02847962|Experimental|Red Sorghum Cowpea Blend|Consumed Red Sorghum Cowpea Blend
16564919|NCT02847962|Experimental|White Sorghum Soy Blend|Consumed White Sorghum Soy Blend
16564920|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
16564921|NCT02847936|Active Comparator|VICRYL PLUS|triclosan-coated sutures
16564922|NCT02847936|Active Comparator|VICRYL|non antibacterial coated sutures
16564923|NCT02847923|Experimental|Group Experimental|All the volunteers will use the software and then answer the questionnaire. They will be familiar with the software interface, performs an initial test to learn how to use the software, run a test script and answer the questionnaire.
16564924|NCT02847910|Experimental|experimental group|device： High-tech disposable tissue suction set for uterine cavity tissue is produced by Xi'an Mejiajia Medical Equipment Company ; The participants will be use the disposable tissue suction set during the induced abortion procedure.
16564925|NCT02847910|Experimental|control group|device： Traditional metal instruments for induced abortion procedure; The participants will be use traditional metal instruments during induced abortion procedure.
16564926|NCT02847897|Experimental|CO2 AcuPulse Laser treatment|Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
16564927|NCT02847871|Other|Multimodal Intervention|The multimodal intervention on mobility will consist of the implementation of a care pathway dedicated in primary care. It will include awareness and training of general practitioners for easy identification, a care associating a dedicated geriatric consultation to rule out underlying pathology, teaching exercises by MAPA (+/- taken care in the presence of MAPA) and nutritional counseling by a dietician. Close collaboration between general practitioners, geriatrician, MAPA and dietician will be established.
16564928|NCT02847871|No Intervention|Non interventional|Patients received treatment as part of their standard care: at the discretion of the general practitioner patients
16564929|NCT02847858|Experimental|Health-E You App Participants|
16564930|NCT02847858|No Intervention|Control Group|
16564931|NCT02847845|Experimental|Red ginseng powder capsule|People in this group take a red ginseng powder capsule.
16564932|NCT02847845|Placebo Comparator|Placebo powder capsule|People in this group take a placebo powder capsule.
16564933|NCT02847819||Vocal cords movement assessment by airway USG.|Preoperatively patients undergoing thyroid surgery will be scanned by airway ultrasound and graded for vocal cord movement, the same group of patients will be again scanned and graded by airway ultrasound at 4th post operative hours.
16564934|NCT02847806|Experimental|Estradiol|dosage used in the study: 1 patch / 3-4 days dosed at 25, 37.5 or 50 mg / 24h titration according to the plasma level, with the objective of a physiological level of estradiol (25-40 pg / ml ) - During 4 weeks
16565398|NCT02844660|Active Comparator|Standard of Care|Weekly application of moist wound therapy and offloading
16564935|NCT02847806|Experimental|Testosterone|dosage used : from 25 to 75 mg / day of testosterone (ie 2.5 to 7.5 g / day transdermal gel) according to the plasma level, with the goal of a physiological level of testosterone (5-8 ng / ml) - During 4 weeks
16564936|NCT02847806|Experimental|Testosterone + Estradiol|Testosterone + Estradiol During 4 weeks
16564937|NCT02847793|Active Comparator|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial
16564938|NCT02847793|Placebo Comparator|Placebo intervention|Using a matching procedure (i.e., yoked control group), participants are required to maintain their gaze in a given picture (e.g., a happy face), for the same average time that their counterparts in the Gaze training group (i.e. Experimental group)
16564939|NCT02847780|Active Comparator|C-Mac video laryngoscope.|Active Comparator: C-Mac Videolaryngoscope for vocal cord movement assessment.
16564940|NCT02847780|Experimental|Airway Ultrasound|Experimental: Airway Ultrasound for vocal cord movement assessment.
16564941|NCT02847767|Experimental|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.
16564942|NCT02847754|Experimental|A|A patients in arm A carry out daily physical Training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home. exercise tailored isometric physical exercise
16564943|NCT02847754|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min progressive muscle relaxation starting from day one of radiotherapy.
16564944|NCT02847741|Other|Major depressive episode|Depressive patients will be assessed by interview (psychiatrists), questionnaires and blood sampling, as the inpatients's routine care
16564945|NCT02847728||Single Arm Design|The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
16564946|NCT02847715|No Intervention|Audit phase|In the audit-phase, a group of 59 patients will be recruited and followed over a 12 month period. Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
16564947|NCT02847715|Experimental|Intervention (pilot-phase)|In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
16564948|NCT02847702|Experimental|VM902A 200 mg|VM902A 200-mg Capsules
16564949|NCT02847702|Experimental|VM902A 400 mg|VM902A 400-mg Capsules (2 x 200-mg capsules)
16564950|NCT02847702|Active Comparator|Naproxen|Naproxen 500-mg Capsules
16564951|NCT02847702|Placebo Comparator|Placebo|Placebo
16564952|NCT02847689|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
16564953|NCT02847689|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
16564954|NCT02847676||No previous surgery, adhesions present.|Patients have had no previous abdominal surgery. Inspection shows peritoneal adhesions.
16564955|NCT02847676||No previous surgery, no adhesions present.|Patients have had no previous abdominal surgery. Inspection shows no peritoneal adhesions.
16564956|NCT02847676||Previous surgery, adhesions present.|Patients have had previous abdominal surgery. Inspection shows peritoneal adhesions.
16564957|NCT02847676||Previous surgery, no adhesions present.|Patients have had previous abdominal surgery. Inspection shows no peritoneal adhesions.
16564958|NCT02847663|Experimental|Whole-body cryotherapy|The effects of whole-body cryotherapy (-135°C for 2 minutes) are investigated after a muscle damage protocol.
16564959|NCT02847663|Other|Cold-water immersion|The effects of cold-water immersion (10°C for 15 minutes) are investigated after a muscle damage protocol.
16564960|NCT02847650|Placebo Comparator|Placebo|
16564961|NCT02847650|Experimental|PF-06649751|
16564962|NCT02847637|Experimental|A: Emicizumab 1.5 mg/kg/week|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
16564963|NCT02847637|Experimental|B: Emicizumab 3 mg/kg/2 weeks|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 3 mg/kg/2 weeks emicizumab subcutaneously until the end of study (maximum up to 6 years).
16564964|NCT02847637|Active Comparator|C: No Prophylaxis|Participants who received episodic treatment with FVIII prior to study entry will be randomized to continue episodic FVIII treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.
16564965|NCT02847637|Experimental|D: Emicizumab 1.5 mg/kg/week (Pre-study FVIII Prophylaxis)|Participants who received FVIII prophylaxis prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
16564966|NCT02847624||ADPKD|
16564967|NCT02847611|Experimental|Jamar then Labin|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
16564968|NCT02847611|Experimental|Labin then Jamar|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
16564969|NCT02847598|Experimental|Part A: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with systemic lupus erythematosus [SLE] with active skin manifestations and joint involvement.
16564970|NCT02847598|Placebo Comparator|Part A: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with [SLE] with active skin manifestations and joint involvement.
16564971|NCT02847598|Experimental|Part B: BIIB059 50 mg|BIIB059 50 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active cutaneous lupus erythematosus [CLE] with or without systemic manifestations.
16564972|NCT02847598|Experimental|Part B: BIIB059 150 mg|BIIB059 150 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
16564973|NCT02847598|Experimental|Part B: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
16564974|NCT02847598|Placebo Comparator|Part B: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
16564975|NCT02847585|Experimental|Open label|water-soluble ubiquinol
16564976|NCT02847572|Other|Surgery Patient|All patients to be implanted bilaterally with a Tecnis Extended Range Lens in the Dominant eye and a Low Add Multifocal in the non dominant
16564977|NCT02847559|Experimental|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16564978|NCT02847533|Other|resistant depression|patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
16564979|NCT02847533|Other|non resistant depression|patients in remission from unipolar depressive disorder
16564980|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
16564981|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
16564982|NCT02847481|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
16564983|NCT02847481|Placebo Comparator|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
16564984|NCT02847481|Experimental|FMT after antibiotic pretreatment v1|fecal microbiota transplantation after antibiotic pretreatment
16564985|NCT02847481|Experimental|FMT after antibiotic pretreatment v2|fecal microbiota transplantation after antibiotic pretreatment
16564986|NCT02847468|Experimental|FDG and FCH PET|Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.
16564987|NCT02847455|Experimental|5 mg ilaprazole|
16564988|NCT02847455|Experimental|10 mg ilaprazole|
16564989|NCT02847455|Active Comparator|10mg Rabeprazole|
16564990|NCT02847442|Experimental|Opicapone (BIA 9-1067) 50 mg|Total duration of trial participation and treatment: three months. All subjects will start treatment with 50 mg opicapone (OPC) once daily for a 3-month period in addition to their current treatment with levodopa/dopa decarboxylase inhibitor (L-dopa/DDCI)
16564991|NCT02847429|Experimental|Crenolanib Arm|Investigational product (crenolanib)
16564992|NCT02847429|Placebo Comparator|Placebo Arm|Matching placebo
16564993|NCT02847416|Experimental|Inspiratory group|the subjects will be instructed to inspire as deeply as possible with steady flow rate for 3 seconds with end-inspiratory pause for 2-3 seconds through the inspiratory circuit and follow by passive exhalation
16564994|NCT02847416|Experimental|expiratory group|the subjects will be instructed to inspire as deeply as possible through the nose with end-inspiratory pause for 2-3 seconds and partially forced exhalation with reach to 1/3 of expiratory reserve volume (ERV) for at least 3 seconds through expiratory circuit
16564995|NCT02847403|Experimental|exenatide|long-acting exenatide 2 mg subcutaneously once-weekly
16564996|NCT02847403|Placebo Comparator|placebo|no drug assigned
16564997|NCT02847390||Pre-implementation group|"The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes education intervention to our staff over a 6-month time frame from August 2016-January 2017. The investigators will use a before and after study design to assess the impact of the educational intervention on hospital-wide hypoglycemia and hyperglycemia.
~Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/16 to 6/30/16)."
16564998|NCT02847390||Post-implementation group|Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/17 to 6/30/17).
16564999|NCT02847377|Experimental|[18F]-ODS2004436|Two TEP will be performed with the radiotracer [18F]-ODS2004436
16565000|NCT02847364|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
16565001|NCT02847364|No Intervention|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
16565002|NCT02847351|Placebo Comparator|Control Diet (CD)|Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
16565003|NCT02847351|Experimental|Arabinoxylan Diet (AXD)|Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
16565004|NCT02847338|Experimental|Mono-therapy group|"The monotherapy group will be treated with the following treatments:
~A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone
~Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA."
16565005|NCT02847338|Experimental|Dual-therapy arm|"The dual-therapy group will be treated with the following treatments:
~A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg
~Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB."
16565006|NCT02847325|Experimental|AC0058TA|Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA
16565007|NCT02847325|Placebo Comparator|Placebo capsules|Drug: Placebo capsules
16565008|NCT02847312|Active Comparator|High avenanthramide, phenolic acid|66.8g Pepsico Oatmeal + 60g Oat cake
16565009|NCT02847312|Active Comparator|Low avenanthramide, medium phenolic acid|17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast
16565010|NCT02847312|Placebo Comparator|Control|69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast
16565011|NCT02847299|Experimental|Astral ventilator|instrumental increase of cough peak flow with air stacking
16565012|NCT02847299|Experimental|Astral ventilator - mode kiné|instrumental increase of cough peak flow with hyperinsufflation
16565013|NCT02847286|Active Comparator|Treatment A|Dapivirine Ring-004 for 28 days
16565014|NCT02847286|Active Comparator|Treatment B|Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
16565015|NCT02847286|Active Comparator|Treatment C|Clotrimazole, 5 g per day for 7 days
16565016|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
16565017|NCT02847247|Experimental|CCRE|20,000 EU of CCRE (Clinical Center Reference Endotoxin)
16565018|NCT02847208||cystic fibrosis women|It was a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry.
16565019|NCT02847195|Experimental|pediatric intensive care|"When aspiration is planned, pain assessment will be performed thrice :
~3-5 minutes before aspiration, during aspiration, and 3-5 minutes after aspiration.
~Pain assessment will be performed with both methods:
~COMFORT B scale (routinely performed by nurses, and lasts less than one minute)
~Simultaneously pupillometry is assessed using the device (Neurolight) (one measurement per eye, this also lasts less than one minute) These measurements can occur at any time during stay in ICU, and can be repeated."
16565020|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
16565021|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
16565022|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
16565023|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
16565024|NCT02847156|Other|cystic fibrosis infants|1 year follow-up in CF infants
16565025|NCT02847143|Experimental|secure|healthy adult male with secure attachement
16565026|NCT02847143|Experimental|avoidant|healthy adult male with avoidant attachement
16565027|NCT02847143|Experimental|enmeshed/fearfull|healthy adult male with enmeshed/fearfull attachement
16565028|NCT02847143|Experimental|dual style|healthy adult male with dual attachement style
16565029|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia [FN], chemotherapy induced nausea and vomiting [CINV], fertility preservation [FP]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.
~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.
~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
16565030|NCT02847117|Other|Mastiha|
16565031|NCT02847104||dynamic insulin protocol|patients received intravenous insulin infusion according to a dynamic insulin protocol
16565032|NCT02847104||static insulin protocol|patients received intravenous insulin infusion according to a static insulin protocol
16565033|NCT02847091|Experimental|Ipragliflozin Group|Ipragliflozin will be administered orally for 24 weeks.
16565080|NCT02846766|Experimental|Lenvatinib|The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.
16565034|NCT02847078|Experimental|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
16565035|NCT02847078|Other|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
16565036|NCT02847039||Early repolarization syndrome|Patients with an aspect of early repolarization syndrome or belonging to a family in which the diagnosis of early repolarization was identified.
16565037|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
16565038|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
16565039|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
16565040|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
16565041|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
16565042|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
16565043|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
16565044|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
16565045|NCT02847013|Placebo Comparator|Placebo- Tap block w normal saline|After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
16565046|NCT02847013|Experimental|Intervention-Tap block w Liposomal bupivacaine|After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
16565047|NCT02847000|Experimental|Decitabine + Tetrahydrouridine|Tetrahydrouridine (THU) is supplied as 250 mg/capsule, Decitabine (Dec) as 5 mg/capsule.
16565048|NCT02846987|Experimental|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
16565049|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
16565050|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
16565051|NCT02846961||Crohn's disease|Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
16565052|NCT02846961||Ulcerative colitis|Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
16565053|NCT02846948|No Intervention|Non-echo group|Patients get the standard monitoring and treatment based on Good medical practice. Extended monitoring by focused echocardiography is not applied for this group.
16565054|NCT02846948|Experimental|Focussed echocardiography group|The extended cardiac monitoring by focused assessed transthoracic echocardiography is applied.
16565055|NCT02846935|Experimental|Decitabine + Tetrahydrouridine|"oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.
~Treatment on protocol monitoring continues for 52 weeks."
16565056|NCT02846922||catheter ablation group|atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
16565057|NCT02846922||rate control group|atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
16565058|NCT02846909|Active Comparator|Vaginal progesterone group|Will receive progesterone pessaries 400 mg once daily vaginally
16565059|NCT02846909|No Intervention|No progesterone group|Will receive nothing
16565060|NCT02846883|Active Comparator|Intravenous infusion of 1 million allogenic MSC's/Kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
16565081|NCT02846753|Experimental|Implantation of Venus P-Valve™|Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
16565082|NCT02846740|Experimental|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
16565061|NCT02846883|Active Comparator|Intravenous infusion of 3 million allogeneic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
16565062|NCT02846883|Placebo Comparator|Intravenous infusion of Plasmalyte A (placebo)|In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
16565063|NCT02846870|Active Comparator|Standard Education|Patients receive standard-of-care prostate cancer radiation oncology consultation.
16565064|NCT02846870|Experimental|Visually Enhanced Education|Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.
16565065|NCT02846857|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
16565066|NCT02846857|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
16565067|NCT02846857|Active Comparator|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
16565068|NCT02846844||Group A|"Whole body vibration training
~manuelle therapy
~exercises for power and coordination
~performance training as needed"
16565069|NCT02846844||Group B|"manuelle therapy
~Exercises for power and coordination
~Performance training as needed"
16565070|NCT02846831|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
16565071|NCT02846831|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
16565072|NCT02846818|Experimental|Low mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
16565073|NCT02846818|Experimental|High mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
16565074|NCT02846805|No Intervention|complete dentures|complete dentures will be provided for all subjects according to the standardized treatment protocol
16565075|NCT02846805|Experimental|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible ,and continue wearing their complete denture in the maxilla
16565076|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16565077|NCT02846779|Active Comparator|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
16565078|NCT02846779|Experimental|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
16565079|NCT02846779|Experimental|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
16565167|NCT02846155|Experimental|simethicone combined with pronase group|the patients drink 900ml clear water and 15ml simethicone and 20，000iu pronase before checking
16565083|NCT02846740|Sham Comparator|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
16565084|NCT02846727||Sepsis Group|This group will consist of surgical intensive care patients with diagnosis of sepsis, severe sepsis, or septic shock.
16565085|NCT02846727||Control Group|This group will consist of patients that serve as controls who do not have diagnosis of sepsis, severe sepsis, or septic shock.
16565086|NCT02846714|Experimental|FLARE intervention|All FLARE participants enrolled will receive the intervention
16565087|NCT02846701|Other|patient treated by duloxetine|
16565088|NCT02846675|Experimental|SVF treatment (random knee)|A random knee (left or right) of subjects will be treated with autologous SVF.
16565089|NCT02846675|Placebo Comparator|placebo treatment (the other knee)|The other knee of subjects will be treated with placebo.
16565090|NCT02846662|Experimental|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an applicative for smartphones (CONEMO), which encourages them to be more active and to incorporate more activities in their everyday life.
~Primary care nurses will train participants to use the CONEMO app, monitor patients' adherence to CONEMO, calling patients when they are non-adherent, and give technical support when necessary. They will be supervised by clinical psychologists.
~Primary care teams are informed of participants' depression level and deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication."
16565091|NCT02846662|No Intervention|ENHANCED USUAL CARE|The primary care teams are informed of the participants' depression level and can deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication. This is considered enhanced usual care because the teams are notified about participants' level of depressive symptomatology, which otherwise might go undetected, and then decide about the best way to handle with patients' needs related to their depressive symptomatology.
16565092|NCT02846649|Experimental|PIER Intervention|The program will help participants learn to recognize the presence of craving and how it can be reduced through environmental, self-regulatory and mood management. Each day, the PIER1 program sends (1) a morning reflection focused on positive thinking, (2) two random prompts assessing severity of craving, (3) feedback specific to managing withdrawal symptoms, mood management, and environmental triggers that are affecting craving, (4) evening assessments of drug use with feedback, (5) goal commitment prompt with feedback, and (6) user-triggered craving assessments with feedback
16565093|NCT02846623|Experimental|Cohort I (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.
16565094|NCT02846623|Experimental|Cohort II (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.
16565095|NCT02846610||regional anesthesia|surgical patients (age: 0-100 years) having regional anesthesia along with the procedure and postoperative course
16565096|NCT02846610||systemic analgesia|surgical patients (age: 0-100 years) having systemic analgesia along with the procedure and post procedure course
16565097|NCT02846597|No Intervention|Control|Infants in this group will not receive sustained lung inflation in the delivery room and will be put immediately on CPAP at a pressure of 5 cm H2O.
16565098|NCT02846597|Active Comparator|High pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
16565099|NCT02846597|Active Comparator|High pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
16565100|NCT02846597|Active Comparator|Low pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
16565101|NCT02846597|Active Comparator|Low pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
16565102|NCT02846584|Experimental|CD19 or CD20 CAR T cells briging HSCT|lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.
16565103|NCT02846571|Other|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
16565104|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
16565105|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
16565106|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
16565107|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
16565108|NCT02846545|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).
16565109|NCT02846545|Placebo Comparator|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
16565110|NCT02846532|Experimental|Rivaroxaban|
16565111|NCT02846532|Experimental|Acetylsalicylic Acid|
16565112|NCT02846519|Experimental|Esketamine|Participants in Cohort 1 (Han Chinese participants), Cohort 2 (Korean participants) and Cohort 3 (Japanese participants ) will receive 100-microliter (mcL) spray of 14 percent (%) esketamine solution (14 milligram [mg]) into each nostril at Time 0 and 5 minutes later for a total dose of 56 milligram (mg) in Period 1.
16565113|NCT02846519|Experimental|Esketamine+Rifampin|Participants in Cohort 4 (Caucasian participants) will receive a 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 1 followed by rifampin from Day -6 to Day -1 of treatment Period 2 and followed by 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 2.
16565114|NCT02846506|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16565115|NCT02846506|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16565116|NCT02846506|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16565117|NCT02846506|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16565118|NCT02846493|Active Comparator|bromocriptine group|Rectal bromocriptine (2.5 mg, qd) for 7 days
16565119|NCT02846493|Experimental|dexamethasone group|Oral take dexamethasone(3mg,qd)for 7 days
16565120|NCT02846480|Experimental|surgical treatment+behavior therapy+physical therapy|Including POP surgical treatment, and pre- post physical therapy to aim the posture, PFM awareness and the strengthening. They will be also informed and instructed on hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
16565121|NCT02846480|Experimental|surgical treatment+behavior therapy|Including POP surgical treatment, and information and instruction about hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
16565122|NCT02846467|Experimental|Portable video media|Patients who receive informed consent trough portable video media around 10 minutes
16565123|NCT02846467|Active Comparator|Traditional IC|Patients who receive traditional IC (written consent) during 10 to 15 minutes
16565124|NCT02846454|Experimental|inulin|Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
16565125|NCT02846454|No Intervention|non inulin and arabinoxylan|investigating the satiating effects of a control drink (2.6g/d maltodextrin)
16565126|NCT02846454|Experimental|arabinoxylan|Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
16565127|NCT02846428|Active Comparator|5-Fluorouracil + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
16565128|NCT02846428|Experimental|Capecitabine + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
16565129|NCT02846415|Experimental|PID group|Experimental group receiving the Play Intervention for Dementia
16565130|NCT02846415|No Intervention|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
16565131|NCT02846402|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
16565202|NCT02845934|Experimental|Mucormycosis|blood sample
16565132|NCT02846402|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
16565133|NCT02846402|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
16565134|NCT02846389|Experimental|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
16565135|NCT02846389|No Intervention|Control Group|No exercise
16565136|NCT02846376|Experimental|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34
~Dose level 1: 1 mg/kg
~Dose level 2: 3 mg/kg"
16565137|NCT02846376|Experimental|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16
~Dose level 1: 0.3 mg/kg
~Dose level 2: 1.0 mg/kg
~Dose level 3: 3.0 mg/kg"
16565138|NCT02846376|Experimental|Group C - Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34
~Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16
~Dose level 1: 0.3 mg/kg
~Dose level 2: 0.6 mg/kg
~Dose level 3: 1.0 mg/kg"
16565139|NCT02846363||Patients included in the Rhône region from France|public awareness campaign
16565140|NCT02846363||Patients included in the control region (Isère, France)|
16565141|NCT02846350|Active Comparator|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
16565142|NCT02846350|No Intervention|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
16565143|NCT02846337|Experimental|ULTRAFILTRATION|The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (>1 session per week) or isolated ultrafiltration (>1 session per week). Ultrafiltration technique could change throughout the care
16565144|NCT02846337|Other|ENHANCED MEDICAL TREATMENT|"The control group called enhanced medical treatment will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration). These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration."
16565145|NCT02846324|Experimental|GBT440 600 mg Dose|Parts A and B
16565146|NCT02846324|Experimental|GBT440 900 mg Dose|Part A
16565147|NCT02846324|Experimental|GBT440 1500 mg Dose|Part B
16565148|NCT02846324|Placebo Comparator|Placebo|Parts A and B
16565149|NCT02846311||Group with support that will be usually performed|"During the first phase (before), the assumption will be that usually achieved.
~The doctor continues to support according to information it has and according to good practice and service protocols."
16565150|NCT02846311||Group with a flu test|"During the second phase (after), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.
~The doctor continues to support according to information it has and according to good practice and service protocols."
16565151|NCT02846272|Experimental|Observational cohort|Observing MRI changes in subjects.
16565152|NCT02846246|Experimental|Intervention|The experimental group will be introduced to a person-centred care model that involves shared decision making where the person with home care service and family together with contact nurse prioritise care content and make rearrangements to make sure the provided home care service maximises health.
16565153|NCT02846246|Sham Comparator|Control|A usual care paradigm will guide the control units, i.e. a continuation with practice as usual.
16565154|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
16565155|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
16565156|NCT02846220|Experimental|Health coaching|"Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions
~Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets"
16565157|NCT02846220|No Intervention|Usual care|
16565158|NCT02846207|Experimental|Yiqi huoxue group|Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
16565159|NCT02846207|Experimental|Yiqi group|Astragalus 60g. Oral administration, twice one day, for 12weeks.
16565160|NCT02846207|Experimental|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
16565161|NCT02846207|Placebo Comparator|placebo group|dextrin, Oral administration, twice one day, for 12weeks.
16565162|NCT02846194|Experimental|brief guided imagery|The study group of our research will go through six Brief Guided Imagery sessions. These sessions will be completed within two months and will last one hour each.
16565163|NCT02846194|No Intervention|control group|
16565164|NCT02846181|Experimental|Healthy|
16565165|NCT02846155|Placebo Comparator|clear water group|the patients only drink 1000ml clear water before checking
16565166|NCT02846155|Experimental|simethicone group|the patients drink 950ml clear water and 15ml simethicone before checking
16565168|NCT02846142|Active Comparator|SAD PTI-428|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
16565169|NCT02846142|Placebo Comparator|SAD placebo|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
16565170|NCT02846142|Active Comparator|MAD PTI-428|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
16565171|NCT02846142|Placebo Comparator|MAD placebo|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
16565172|NCT02846142|Experimental|OC (ethinyl estradiol and levonorgestrel) DDI Period A|Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).
16565173|NCT02846142|Active Comparator|OC (ethinyl estradiol and levonorgestrel) DDI Period B|Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
16565174|NCT02846142|Placebo Comparator|OC (ethinyl estradiol and levonorgestrel) DDI|Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
16565175|NCT02846116|Active Comparator|lithium disilicate|The intervention will be: Prosthetic crown
16565176|NCT02846116|Active Comparator|Vita suprinity|The intervention will be: Prosthetic crown
16565177|NCT02846103|Experimental|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.
~Tumor tissues will be collected if available."
16565178|NCT02846090|Experimental|D50 Dexmedetomidine 50 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
16565179|NCT02846090|Experimental|D25 Dexmedetomidine 25 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine + 4.5 ml of 2% lidocaine +0.5ml of 25 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
16565180|NCT02846090|Placebo Comparator|control|peribulbar block was given using 10 ml of a mixture of local anesthetics without Dexmedetomidine. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml with 150 IU hyaluronidase.
16565181|NCT02846077||College students|College students will be monitored and will complete online surveys, install apps on their mobile phones, wear physiological sensors and provide saliva samples for later assay.
16565182|NCT02846064|Other|Ovarian tissue cryopreservation|
16565183|NCT02846051|Other|intensive sport practice|"intensive sport practice
~the subject must practice for more than six months a drive of at least 8 hours / week, intense, above the ventilatory threshold, or 60-70% of maximum consumption oxygen or 70-80% of maximum heart rate, ie beyond a moderate slowdown. If stopping the intensive sport practice, the duration of the stop at the time of the study should be less practice time.
~volunteers,
~from 18 to 80 years,
~free to consent.
~covered by social security.
~reported in the national register of healthy volunteers.
~The intervention is a lower limb venous examination = venous mapping"
16565184|NCT02846051|Other|control group|"&) Volunteers who do not have intensive sport practice as it is defined in the group intensive sport practice 2) from 18 to 80 years, 3) free to consent. 4) covered by social security. 5) reported in the national register of healthy volunteers.
~The intervention is a lower limb venous examination = venous mapping"
16565185|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
16565186|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
16565187|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
16565188|NCT02846025|Other|Folate|diet rich in folate
16565189|NCT02846025|Other|placebo|placebo
16565190|NCT02846025|Other|diet antioxidant|diet antioxidant
16565191|NCT02846025|Other|Hazelnut Oil|hazelnut oil capsule
16565192|NCT02846012|No Intervention|CSCM Control|Control medium
16565193|NCT02846012|Experimental|CSCM2|New Formulation medium
16565194|NCT02845999|Experimental|Allogenic NK cells transfer|Patients will be treated with a conditioning chemotherapy including 60 mg/kg intravenous cyclophosphamide, 25 mg/m2 intravenous fludarabine for 5 consecutive days and cetuximab. A lymphapheresis from an haploidentical related donor will be performed and T cells will be depleted . Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol (three doses with at least three patients per cohort)to define the dose-limiting toxicity (DLT). T
16565195|NCT02845986|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed laparoscopic spleen-preserving No.10 lymph node dissections.After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
16565196|NCT02845973||test cohort|The test cohort was from Fudan University Shanghai Cancer Center (August 2016 to December 2016) and ECRJ-East Campus of Renji hospital (January 2012 to March 2017);
16565197|NCT02845973||validation cohort|The validation cohort was from Shanghai Tenth People's Hospital (October 2015 to November 2016) and WCRJ-West Campus of Renji hospital (July 2016 to March 2017)
16565198|NCT02845960||Experimental group|rapid recovery
16565199|NCT02845960||Controlled group|no rapid recovery
16565203|NCT02845921|Placebo Comparator|Group C Control|Patient will be shifted to operation theatre. Electrocardiography (ECG), pulse oximeter and non-invasive blood pressure (NIBP) monitors will be attached. Baseline vitals will be noted. Intravenous access will be secured and crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs will be neither elevated or wrapped. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube.
16565204|NCT02845921|Experimental|Group E Leg elevation|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs are elevated and supported on a stand making an angle of 30 degree to the horizontal. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Stand will be removed and legs will be brought to horizontal position 10 minutes after intubation.
16565205|NCT02845921|Experimental|Group W Leg wrapping|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.
16565206|NCT02845908|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
16565207|NCT02845908|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
16565208|NCT02845908|Active Comparator|FOLFOX|The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
16565209|NCT02845895||Neuroscience pole|Patient hospitalized in the department of medicine-surgery-obstetric of the neuroscience pole department
16565210|NCT02845895||Respiratory tracts pole|Patient hospitalized in the department of medicine-surgery-obstetric of the respiratory tracts pole department
16565211|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
16565212|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
16565213|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
16565214|NCT02845869|Experimental|Light Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Light Therapy treatment with the THOR laser LX2 system.
16565215|NCT02845869|Sham Comparator|Sham Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Sham Therapy.
16565216|NCT02845856|Experimental|Cetuximab and NK immunotherapy|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565217|NCT02845856|Active Comparator|Cetuximab|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565218|NCT02845843|Experimental|Combination of Lopinavir /Ritonavir and IntErferon Beta 1B|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
16565219|NCT02845843|Placebo Comparator|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
16565220|NCT02845830||Participants in early stage of dementia|Subjects with any type of dementia at an early phase diagnosed in the last 12 months with MMSE score 20-25 points
16565221|NCT02845830||Participants without dementia|Subjects without dementia with MMSE score 26-30 points
16565222|NCT02845817|Other|Qualitative research|Semi-structured interviews
16565223|NCT02845804||Alpine|The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
16565224|NCT02845791|No Intervention|Control|The control participants will not receive the educational intervention but will be provided with a detailed advice leaflet for themselves and their parents/guardians.
16565225|NCT02845791|Other|Intervention|The educational intervention participants will receive the eight 90 minute sessions of an interactive family based lifestyle programme.
16565226|NCT02845778|Experimental|melatonin niosomes oral gel 2.5 mg|apply onto oral mucosa as single use
16565227|NCT02845778|Experimental|melatonin niosomes oral gel 5 mg|apply onto oral mucosa as single use
16565228|NCT02845778|Experimental|melatonin niosomes oral gel 10 mg|apply onto oral mucosa as single use
16565451|NCT02844270|Experimental|Galaxy stent|The galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System will be implanted in all subjects.
16565229|NCT02845765||Patients with erectile dysfunction|Patients with erectile dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline and 6 months after therapy with Phosphodiesterase type 5 Inhibitor (PDE5I).
16565230|NCT02845765||Subject healthy volunteers|Patients without erectile dysfunction or ocular disease. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline
16565231|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
16565232|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
16565233|NCT02845739|Experimental|kidney transplanted patient|
16565234|NCT02845726||Patients with temporary ureteral stent|Assessment of patients transiently undergoing ureteral stenting.
16565235|NCT02845713|Active Comparator|Single IDA dose W. bancrofti positive|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
16565236|NCT02845713|Active Comparator|Single IDA dose W. bancrofti negative|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
16565237|NCT02845700|Active Comparator|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
16565238|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
16565239|NCT02845687||Participants|All participants are patients within the Quit at Duke Smoking Cessation Program. This is an observational study with no interventions.
16565240|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
16565241|NCT02845661|Experimental|group 1|patients in group 1, aged 20~60, were accepted an initial dose of 0.9μg/kg dexmedetomidine over 15 min.
16565242|NCT02845661|Experimental|group 2|patients in group 2, aged 20~60, were accepted an initial dose of 1.0μg/kg dexmedetomidine over 15 min.
16565243|NCT02845661|Experimental|group 3|patients in group 3, aged 20~60, were accepted an initial dose of 1.1μg/kg dexmedetomidine over 15 min.
16565244|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
16565245|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
16565246|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
16565247|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
16565248|NCT02845622|Experimental|30g peeled hazelnuts cream|Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
16565249|NCT02845622|Experimental|30g unpeeled hazelnuts cream|Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
16565250|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts|Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
16565251|NCT02845622|Experimental|snack w/ 2.5g cocoa powder|Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
16565252|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts+2.5g cocoa|Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
16565253|NCT02845622|Placebo Comparator|empty snack|Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
16565254|NCT02845609|Experimental|Intervention|Sialic acid-Extended release 2000 mg, three times per day (TID) for 3 months
16565255|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
16565256|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
16565257|NCT02845583||Retrospective cohort|150 oncologic patients belonging to major complexity DRGs
16565258|NCT02845583||Perspective cohort|150 oncologic patients belonging to major complexity DRGs
16565259|NCT02845570|Experimental|68Ga-DOTANOC PET/MRI|Comparison between 68Ga-DOTANOC PET/MRI and 18F-FDG PET/MRI scans
16565288|NCT02845375|Experimental|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
16565289|NCT02845362|Experimental|Dysphagia assessment|
16565552|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
16565260|NCT02845557||Control subjects without diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.
~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;
~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
16565261|NCT02845557||Subjects with type 2 diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.
~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;
~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
16565262|NCT02845544|Experimental|Experimental group - Pilates|A Pilates-based exercises program of 6 weeks' duration
16565263|NCT02845544|No Intervention|Control group - no exercises|
16565264|NCT02845531|Experimental|ICD implantation and optimal medical therapy|
16565265|NCT02845531|Active Comparator|optimal medical therapy|
16565266|NCT02845518|Experimental|no arms|"All patients included will undergo a cardiac Magnetic Resonance Imaging (cMRI) at the baseline visit (V1), at 3- or 6-month follow up visit (V2 or V3), at 24-month follow up visit and in case of clinical worsening during the first 24-month of follow up.
~All patients will complete a questionnaire on the acceptability and tolerability of cMRI and right heart catheterization at V1, V2 or V3 and V9, right heart catheterization being performed as a routine test in pulmonary arterial hypertension.
~Depending on patient agreement, 22 ml of peripheral venous blood will be taken at visits V1, V2 or V3 and V9. On one of these 3 visits a blood sample of 5 ml will be taken from the pulmonary artery during the right cardiac catheterization."
16565267|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
16565268|NCT02845492|Experimental|Qigong intervention|Qigong meditative exercise intervention meets three times a week for 10 weeks. The qigong group (n=30) will meet at the Women's Medicine Collaborative, Miriam Hospital (146 W. River St., Providence, RI) for Qigong classes. The lesson will be taught by a validated Qi Gong master with over forty years of experience and the interventional protocol will be validated. Two and a half hours of weekly outside personal practice will also be required of participants.
16565269|NCT02845492|Active Comparator|CHIP healthy wellness-exercise class|The Complete Health Improvement Program is a validated set of weekly classes designed to promote gentle exercise and wellness related activities in a supportive group setting led by an experienced trainer.
16565270|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
16565271|NCT02845466|Experimental|Becaplermin/Promagran Dressing|Topical Becaplermin with a protease inhibitor wound dressing.
16565272|NCT02845466|Active Comparator|Becaplermin/Placebo Dressing|Topical Becaplermin with a placebo wound dressing.
16565273|NCT02845453|Experimental|Quetiapine|Quetiapine
16565274|NCT02845453|Placebo Comparator|Placebo|Placebo
16565275|NCT02845440|Active Comparator|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.
16565276|NCT02845440|Experimental|AD + CHW|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.
~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
16565277|NCT02845440|Experimental|AD Alone|Participants who are randomized to this condition will only not be offered additional Community Health Worker services; however, the participant's primary care clinic will receive Academic Detailing as described above.
16565278|NCT02845440|Experimental|CHW Alone|Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
16565279|NCT02845427|Active Comparator|A(drain group)|patients of primary THA will have closed suction drain introduced intraoperative at surgical site
16565280|NCT02845427|Placebo Comparator|B(No drain group)|patients of primary THA will have the surgical wound be closed with no suction drain
16565281|NCT02845414|Experimental|Intravenous Infusion of dCD133KDEL|
16565282|NCT02845401|Experimental|HBeAg-CHB patients who stop NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that stop treatment.
~Intervention: Cases will stop antiviral therapy"
16565283|NCT02845401|No Intervention|HBeAg-CHB patients continue NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that continue to stay on treatment.
~Intervention: None. Controls will continue antiviral therapy."
16565284|NCT02845388|Active Comparator|estradiol valerate|estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
16565285|NCT02845388|Active Comparator|Sildenafil citrate and estradiol valerate|Sildenafil citrate 25 mg every 6 hours orally in combination with estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
16565286|NCT02845375|Placebo Comparator|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
16565287|NCT02845375|Other|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
16565290|NCT02845349|Experimental|Drug-Vortioxetine|The treatment group will receive vortioxetine 10 mg per day, which will be increased to 20 mg or decreased to 5 mg, if deemed clinically necessary, at week 4 or 8.
16565291|NCT02845349|Placebo Comparator|Placebo|Matching placebo will be used.
16565292|NCT02845336|Experimental|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
16565293|NCT02845336|Active Comparator|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
16565296|NCT02845310|Experimental|Restricted fluid therapy group|Patients will receive restricted fluid management guided by concomitant SVV monitoring. GDT protocol
16565297|NCT02845310|Placebo Comparator|Control group|Patients will receive standard fluid management.
16565298|NCT02845297|Experimental|Safety Run In Phase (only Cohort 1):|The treatment of relapsed and refractory AML patients.
16565299|NCT02845297|Experimental|Cohort 2|The treatment of newly diagnosed AML patients (≥ 65 years) who are not candidates for intensive induction chemotherapy.
16565300|NCT02845284|No Intervention|Routine Care|Group education/counseling from Antenatal clinic midwives, routine PMTCT, HIV C&T and family planning C&T services on request.
16565301|NCT02845284|Experimental|Routine Care plus group support|Routine Care plus enhanced group support
16565302|NCT02845284|Experimental|Routine Care plus individual support|Routine Care plus enhanced individual support
16565303|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
16565304|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
16565305|NCT02845245|Active Comparator|Standard of Care|Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
16565306|NCT02845245|Experimental|Intervention|A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.
16565307|NCT02845232||Intensive chemotherapy|First group: 68 patients receiving a combination of intermediate-dose cytarabine and an anthracycline. One patient with acute promyelocytic leukaemia (APL) also received all-trans retinoic acid (ATRA).
16565308|NCT02845232||Lower-intensity treatments|The second study group comprised 70 patients who were treated on frontline by lower-intensity treatments [LD-AraC(39 patients), azacitidine (16 patients), decitabine (11 patients),tipifarnib (3 patients), or ATRA (1 patient)]. Patients received LD-AraC 20 mg once or twice daily (according to physician'schoice) by subcutaneous injection for 10 consecutive days. Azacitidine was given at the dose of 75 mg/m2/day for 7 consecutive days by sc injection. Decitabine was administered by intravenous route once daily at 20 mg/m2 for 5 consecutive days. Tipifarnib was given at 600 mg administered orally twice daily for 21 consecutive days in 4-week cycles. ATRA was given at 45 mg/m2until CR achievement followed by maintenance combining 6-mercaptopurine with methotrexate.
16565309|NCT02845232||Best Supportive Care|The last study group comprises 76 patients: 31 patients received supportive care, while 36 patients also received hydroxyurea and 9 patients received 6-mercaptopurine.
16565310|NCT02845219|Experimental|Oral contraceptive/SNAC/Oral Trial drug|
16565311|NCT02845206|Experimental|Patient Specific Cutting Blocks|For the bespoke individualised cutting blocks to be manufactured, the patients will undergo a preoperative CT scan under a set protocol. The CT radiation dose will be considerably less than a conventional diagnostic CT scan.
16565312|NCT02845206|Active Comparator|Conventional Cutting Blocks|The patients in this arm will be operated on using conventional instruments.
16565313|NCT02845193|Experimental|Modified Nasoalveolar molding group|This group will receive nasoalveolar molding appliance in addition to taping for 3 Months with follow-up every 2 weeks.
16565314|NCT02845193|Experimental|Taping group|Tape will be used alone in this group on the upper lip segments for 3 months with follow-up every 2 weeks.
16565315|NCT02845193|No Intervention|Control group|This group will not receive any treatment.
16565316|NCT02845193|Experimental|CAD/NAM group|Computer Aided Designed Nasoalveolar molding and 3D printed.
16565317|NCT02845180|Experimental|3 Mo. Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 3 months.
16565318|NCT02845180|Experimental|6 Month Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
16565319|NCT02845167|No Intervention|Usual-care only|Patients will receive usual-care only during the preoperative period.
16565320|NCT02845167|Experimental|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods.
16565321|NCT02845154|Active Comparator|Control (bolus purge)|The portal vein clamp will be totally released after end of portal vein anastomosis and all graft and portal blood contents are allowed free and complete access to the systemic circulation via the inferior vena cave
16565322|NCT02845154|Experimental|Intermittent Purge|The portal clamp will be released in situ for 5 seconds to allow purge of the graft and portal contents into the systemic circulation, followed by 30 seconds of portal clamping again. This will be followed by another two cycles of 5 seconds declamping and 30 seconds clamping , then, the portal clamp will be completely released.
16565323|NCT02845141|Experimental|Actifuse|Actifuse to fill bone tunnel
16565324|NCT02845141|Active Comparator|bone graft|bone graft to fill bone tunnel
16565325|NCT02845128||HFNC failure|requiring intubation and invasive mechanical ventilation
16565326|NCT02845128||HFNC success|not requiring intubation nor invasive mechanical ventilation
16565327|NCT02845115|Other|control|standard care : usual technique for implanting
16565553|NCT02843412||group 1|choose one tumor tissue paraffin blocks
16565329|NCT02845102|Experimental|Pre-Post Feasibility Testing|The pre-post feasibility testing/ intervention includes the use of tablet technology and cognitive behavioral therapy (CBT) for depression and self-management education for patients with chronic illness and/or chronic pain and depression. The pre-post feasibility testing phase will include 25 subjects. The total duration of pre-post feasibility testing will be 6 weeks upon the retrieval of the RA-CBT tablet and the inclusion of follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview.
16565330|NCT02845089||Advanced/Metastatic NSCLC patients from UAE and KSA|A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)
16565331|NCT02845076|Active Comparator|Decrease in duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered. When a patient reaches without the presence of any reinstitution criteria, the duration of NIV use as 4 hours per 16 hours during daytime, it will be liberated definitively from NIV.
16565332|NCT02845076|Active Comparator|Decrease in pressure and duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. The level of pressure support will be decreased by 2-4 cmH2O per 4 hours during daytime in patients with good tolerance, with no change at night time. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered, based on the vitals and ABGs recorded at 8 pm (see above), with gradual decrease of at least 2 hrs/night. When a patient reaches without the presence of any reinstitution criteria, the level of PS of 8 cmH20, it will be liberated definitively from NIV.
16565333|NCT02845076|Active Comparator|Abrupt discontinuation of NIV|Patients will be disconnected from NIV and oxygenated with a nasal cannula. Oxygen flow will be limited to a maximum of 5L/min.
16565334|NCT02845063|Experimental|concentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
16565335|NCT02845063|Experimental|eccentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
16565336|NCT02845063|Active Comparator|concentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
16565337|NCT02845063|Active Comparator|eccentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
16565338|NCT02845050|Experimental|Vinflunine+Cisplatin+radical cystectomy|neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
16565339|NCT02845037|Experimental|2 mg or placebo|BIA 5-453 or placebo
16565340|NCT02845037|Experimental|10 mg or placebo|BIA 5-453 or placebo
16565341|NCT02845037|Experimental|20 mg or placebo|BIA 5-453 or placebo
16565342|NCT02845037|Experimental|50 mg or placebo|BIA 5-453 or placebo
16565343|NCT02845037|Experimental|100 mg or placebo|BIA 5-453 or placebo
16565344|NCT02845037|Experimental|200 mg or placebo|BIA 5-453 or placebo
16565345|NCT02845037|Experimental|400 mg or placebo|BIA 5-453 or placebo
16565346|NCT02845037|Experimental|600 mg or placebo|BIA 5-453 or placebo
16565347|NCT02845037|Experimental|900 mg or placebo|BIA 5-453 or placebo
16565348|NCT02845037|Experimental|1200 mg or placebo|BIA 5-453 or placebo
16565349|NCT02845024|Active Comparator|oral doxycycline|Oral capsules of doxycycline 100 mg were used
16565350|NCT02845024|Placebo Comparator|oral placebo capsule|oral placebo capsule were used
16565351|NCT02845011|Experimental|Audiovisual compression feedback|Cardiopulmonary resuscitation according to international guidelines with chest compressions performed with real-time audiovisual feedback using the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) device.
16565352|NCT02845011|Active Comparator|Standard chest compression|Cardiopulmonary resuscitation according to international guidelines with standard manual chest compression
16565353|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
16565354|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
16565355|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
16565356|NCT02844985||Addict Group|In-patient and out-patient adult men and women who meet diagnostic criteria for sexual addiction.
16565357|NCT02844985||Control Group|Individuals from the general community and college student populations who have no history of identifiable psychopathology.
16565358|NCT02844946|Experimental|ACT on Life|One day workshop aimed at providing Veterans with new tools and skills needed to pursue valued goals and directions in the face of life's challenges. Mindfulness, acceptance, values clarification, and goal-setting will be taught.
16565359|NCT02844946|No Intervention|Treatment as Usual|Veterans will continue receiving care as usual.
16565360|NCT02844933|Experimental|Cannabidiol|Cannabidiol oral solution (40 mg/kg/day) divided into two daily doses with a standard meal
16565361|NCT02844933|Placebo Comparator|Placebo|Matching placebo solution divided into two daily doses with a standard meal
16565362|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
16565363|NCT02844907|Experimental|Hyperglycemic clamp + Exendin (9-39)|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
16565364|NCT02844907|Experimental|Dexamethasone|Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
16565554|NCT02843412||group 2|choose two tumor tissue paraffin blocks
16565368|NCT02844881|Experimental|Apatinib+MASCT|Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma
16565369|NCT02844868|Experimental|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
16565370|NCT02844868|Sham Comparator|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
16565371|NCT02844855|Active Comparator|patients with Alzheimer disease|Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
16565372|NCT02844855|Active Comparator|patients with Parkinson disease|Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
16565373|NCT02844855|Sham Comparator|healthy controls|Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
16565374|NCT02844842||1 day initiation schedule|The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.
16565375|NCT02844842||Rapid initiation schedule|The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.
16565376|NCT02844829|Other|MRI and biomarkers|Prostate MRI. Blood and urine biomarkers. Both prior to biopsy. Tissue samples during prostatectomy.
16565377|NCT02844816|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.
16565378|NCT02844803|Other|Active drug-> Placebo|Metformin + S. Baicalensis --> Metformin + Placebo
16565379|NCT02844803|Other|Placebo -> Active drug|Metformin + Placebo --> Metformin + S. Baicalensis
16565380|NCT02844790|Experimental|IDegAsp|
16565381|NCT02844777|Placebo Comparator|Placebo|Excipeint alone
16565382|NCT02844777|Experimental|5% VDA-1102|Active study medication
16565383|NCT02844777|Experimental|10% VDA-1102|Active study medication
16565384|NCT02844764|Experimental|StroMed + Platelet Rich plasma [PRP]|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product by direct injection to affected joints.
16565385|NCT02844751|Experimental|Cohort 1|Interventions assigned by Principal Investigator
16565386|NCT02844751|Experimental|Cohort 2|Interventions assigned by Principal Investigator
16565387|NCT02844738|Experimental|StroMed + platelet rich plasma (PRP)|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
16565388|NCT02844725|Experimental|VVZ-149 injection|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
16565389|NCT02844725|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
16565390|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
16565391|NCT02844699|Experimental|Mobilan (M-VM3) on both Day 1 and on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
16565392|NCT02844699|Experimental|Placebo on Day 1 and Mobilan (M-VM3) on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
16565393|NCT02844699|Placebo Comparator|Placebo on both Day 1 and Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
16565394|NCT02844686|Experimental|Cardiac Dynamic SPECT|
16565395|NCT02844673|Active Comparator|Standard monitoring (SM) arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) with standard monitoring. Standard monitoring is defined as a follow-up visit two weeks after initiation of therapy and monthly follow-ups thereafter
16565396|NCT02844673|Experimental|mDOT arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) and Mobile Directly Observed Therapy (mDOT) consisting of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Participants will receive alerts on their cell phone at pre-arranged times to remind them to take their medications. Participants will be followed-up at two weeks after initiation of therapy and monthly thereafter.
16565399|NCT02844647|Experimental|MRI w/ Hyperpolarized Pyruvate (13C)|"Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI."
16565400|NCT02844634|Experimental|Immediate doxycycline 100mg PO daily|"Individuals will receive tenofovir/emtricitabine one tablet daily in an open-label fashion.
~Subjects are randomized to immediate (12 months duration) doxycycline 100mg PO daily."
16565401|NCT02844634|Active Comparator|Deferred doxycycline 100mg PO daily|Individuals will receive daily tenofovir/emtricitabine one tablet daily and will begin doxycycline 100mg PO daily after 6 months for a total duration of 6 months
16565402|NCT02844621|Experimental|Healthy subjects|
16565403|NCT02844608|Other|Quality of Life|Administration of Quality of Life questionnaires
16565404|NCT02844595|Active Comparator|Standard cognitive-behavioural smoking cessation treatment|
16565405|NCT02844595|Active Comparator|Standard smoking cessation treatment and behavioral activation|
16565406|NCT02844595|No Intervention|Control group|It will be a delayed treatment control group for a period of 3 months.
16565407|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16565408|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
16565409|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
16565410|NCT02844556|Other|SMILE surgery|Small incision lenticule extraction (SMILE) has become a novel and effective method for the correction of myopia and myopic astigmatism. It is a micro-invasive and flapless refractive procedure that has been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
16565411|NCT02844556|Other|FS-LASIK surgery|FS-LASIK surgery is femtosecond laser assisted- conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
16565412|NCT02844543|Experimental|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
16565413|NCT02844530|Experimental|RIT|The experimental treatment will consist on 2 injections of 370 MBq/m2 of 90Y-epratuzumab tetraxetan fractionated RIT at day 1 and day 8. The first infusion of 90Y-epratuzumab tetraxetan will be co-injected for the six first patients in Nantes with 111In-epratuzumab tetraxetan for dosimetry purpose.
16565414|NCT02844530|Active Comparator|chemotherapy/ immunotherapy|"chemotherapy/ immunotherapy regimen will be assigned per investigator's choice to one of the following chemotherapy/ immunotherapy regimens:
~FLAG +- anthracycline based regimen For subject's >60 years : idarubicin 5 mg/m2 day 1,3, fludarabine 20 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5.
~Clofarabine or clofarabine based regimens. Clofarabine use as a single agent should follow the recommended prescribing information. Clofarabine combination based regimens should use >=20mg/m2/day for up to 5 days.
~Hyper-C-VAd regimen: hyperfractionated cyclophosphamide 300 mg/m2 intravenously(i.v.) every 12 hours for 6 doses Days 1 to 3 + vincristine 2 mg i.v.Days 4 and 11; doxorubicin 50 mg/m2 i.v. over 24 hours via central venous catheter Day 4; and dexa-methasone 40 mg daily Days 1 to 4 and 11 to 14.
~Blinatumomab (Blincyto®) : 28-day continuous infusion (9µg/d for days 1-7; 28µg/d thereafter, followed by 2 weeks of rest for up to 2 cycles."
16565415|NCT02844517|Experimental|Artificial Pancreas|The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
16565416|NCT02844504|Experimental|Low Intensity Exercise Training 1|Cancer survivors will receive low intensity handgrip exercise training.
16565417|NCT02844504|Experimental|Low Intensity Exercise Training 2|Cancer survivors will receive low intensity handgrip exercise training different than other arm.
16565418|NCT02844504|No Intervention|Control|This group will receive no training.
16565419|NCT02844491||Cohort A|"In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.
~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab
~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab"
16565420|NCT02844491||Cohort B|"For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.
~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage
~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months"
16565421|NCT02844478|Active Comparator|SBP ENGLISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in English
16565422|NCT02844478|Experimental|SBP SPANISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in Spanish
16565423|NCT02844465|Experimental|Treatment|Visualase MRI-guided laser ablation procedure
16565424|NCT02844452|Experimental|Verum Acupuncture 1|The participants with atopic dermatitis in the acupuncture group 1 will attend twelve acupuncture sessions over 4 weeks: 3 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
16565450|NCT02844283|Sham Comparator|control group|0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery
16565585|NCT02843165|Active Comparator|CBI|Checkpoint blockade immunotherapy (CBI)
16565425|NCT02844452|Experimental|Verum Acupuncture 2|The participants with atopic dermatitis in the acupuncture group 2 will attend eight acupuncture sessions over 4 weeks: 2 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
16565426|NCT02844452|Sham Comparator|Sham Acupuncture|The participants in the sham acupuncture group will visit eight acupuncture sessions over 4 weeks. The acupuncture treatment will be conducted on six control points. The acupressure will be applied with ring-sham press tack needles on three control points. Unlike the acupuncture group 2, partially-individualized manual acupuncture according to the patient's symptoms will not be given but the questions about symptoms will be questioned to patients.
16565427|NCT02844452|No Intervention|Healthy Control|The participants will go through the screening test. The included subjects will complete questionnaires and their blood sample will be obtained.
16565428|NCT02844439|Experimental|Glioblastoma|The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
16565429|NCT02844426|Placebo Comparator|Placebo|patients allowed to take maltodextrin by the experienced doctor.
16565430|NCT02844426|Experimental|synbiotic|patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .
16565431|NCT02844413|Experimental|study group|implementation of aerobic interval training
16565432|NCT02844413|No Intervention|control group|control group
16565433|NCT02844400||Adjuvant and Curative Chemotherapy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
16565434|NCT02844400||Palliative Chemoteraphy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
16565435|NCT02844387|Experimental|Arginine|In the Arginine arm patients will receive 10 mg of L-arginine hydrochloride solution oral supplementation (in 200 ml of flavoured drinking water solution) administered twice a day prior to the radiation therapy fraction
16565436|NCT02844387|Placebo Comparator|Placebo|In the Placebo arm patients will receive 200 ml of flavoured drinking water oral solution administered twice a day prior to the radiation therapy fraction
16565437|NCT02844374|Other|Partial Epilepsy Drug Resistant|Patients with partial Epilepsy Drug Resistant , justifying a SEEG exploration.
16565438|NCT02844361|Experimental|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
16565439|NCT02844361|Active Comparator|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
16565440|NCT02844348|No Intervention|Standard pain control|Classical pain assessment and drug treatment at each dialysis session.
16565441|NCT02844348|Experimental|Hypnosis|Besides the classical pain assessment and drug treatment, hypnosis sessions during 2 periods of one week of dialysis sessions.
16565442|NCT02844335|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565443|NCT02844335|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565444|NCT02844322|Experimental|Bortezomib|Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
16565445|NCT02844322|Experimental|rituximab|Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
16565446|NCT02844309|Experimental|Thalidomide|thalidomide 50-150mg per night
16565447|NCT02844296|Experimental|exercise group|"A free handgrip (strength 15 kg) will be given to the subject and some short-bout exercise will be introduced to the subjects for reliving the cravings for smoking through a short video. After the video, the counselor will install a smartphone application which is about exercise in the subject's mobile phone to set up exercise reminder schedule for 4 weeks. 20-30 reminders on exercise and quitting tips via the App for 4 weeks. Subjects will be requested o record a daily diary on smoking.
~A leaflet with exercise instruction and motivation messages based on the Health Action Process Approach (HAPA) will be given to the participant. 2-month, 6 -month and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
16565448|NCT02844296|Experimental|diet group|"Subjects will view a short video on healthy diet only. After the video, the counselor will also install another smartphone application which is about healthy diet in the subject's mobile phone to set up healthy die reminder schedule for 4 weeks.
~A leaflet on healthy diet will be given to the subjects, and 20-30 reminders on healthy diet and quitting tips via the App for 4 weeks.2-,6- and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
16565449|NCT02844283|Experimental|treatment group|Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery
16565452|NCT02844244|Experimental|training group|Two two-hour training sessions for the participants. It aimed to train lay resident leaders to be peer health promoters. The peer health promoters were taught either to independently implement or to assist social workers to conduct a series of community-based family well-being activities.
16565453|NCT02844231|Other|Sleepwalker, SW episode|Sleepwalker patients undergo single-photon emission computed tomography during a sleepwalking episode.
16565454|NCT02844231|Other|Sleepwalkers, slow wave sleep|Sleepwalker patients undergo single-photon emission computed tomography during slow-wave sleep.
16565455|NCT02844231|Other|Control group|Control subjects undergo single-photon emission computed tomography during slow-wave sleep.
16565456|NCT02844218||Intensive chemotherapy group|Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
16565457|NCT02844218||Lower intensity treatment group|Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
16565458|NCT02844218||personalized treatment group|"Group 3: patients who had received, starting in 2007, more personalized treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician."
16565459|NCT02844179|Experimental|dose escalation|Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally
16565460|NCT02844166|Experimental|viscoelastic group|viscoelastic surface support
16565461|NCT02844166|Active Comparator|pyramidal foam group|pyramidal foam surface support
16565462|NCT02844153||6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)|All patients with type 2 diabetes seen for the first time by a nephrologist.
16565463|NCT02844140|Experimental|Scans|Patients included in the trial will receive DE-CT in stead of SE-CT's.
16565464|NCT02844127|Other|Apex First|Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
16565465|NCT02844127|Other|Septum First|Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
16565466|NCT02844114|Experimental|Ganoderma lucidum spore & Chemotherapy|Ganoderma lucidum spore 1500mg tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
16565467|NCT02844114|Placebo Comparator|Placebo & Chemotherapy|Placebo tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
16565468|NCT02844101|Other|non-blinded group|The non-blinded subjects will be informed that the accelerometer device (GT3X Actigraph accelerometer) is an accelerometer that assessed physical activity levels and patterns
16565469|NCT02844101|Other|blinded group|The blinded subjects will be informed that they will test the reliability of a new device for body posture assessment and these youngsters will not receive any information with regards to physical activity.
16565470|NCT02844088|Experimental|vaccinated group|evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
16565471|NCT02844088|Other|unvaccinate group|Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
16565472|NCT02844075|Experimental|pembrolizumab|
16565473|NCT02844062|Experimental|anti-EGFRvIII CAR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg
16565474|NCT02844049|Active Comparator|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
16565475|NCT02844049|No Intervention|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
16565476|NCT02844036|Experimental|Patients with a pulmonary hypertension|Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.
16565477|NCT02844023|Other|Patient with giant gells arteritis|50 patients with giant gells arteritis
16565478|NCT02844023|Other|Control patients|50 control patients : blood from French national blood service (EFS)
16565479|NCT02844010||patients with pneumonia|
16565480|NCT02843997|Other|Healthy volunteers|Members of a family
16565481|NCT02843984|No Intervention|A - untreated|The patients will be not treated with vaginal lactoferrin
16565482|NCT02843984|Active Comparator|B - 4 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
16565483|NCT02843984|Active Comparator|C - 12 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 12 hours prior to mid-trimester genetic amniocentesis.
16565484|NCT02843971|Experimental|Healthy volunteers|
16565485|NCT02843958|Other|Healthy volunteers and patients under Vitamin K antagonist|
16565486|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
16565487|NCT02843932|Experimental|Psychogenic disorders|Psychogenic movement disorders and seizures
16565488|NCT02843919|Other|Healthy volunteers|Adults healthy volunteers
16565489|NCT02843906|Active Comparator|BD/CD +|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
16565490|NCT02843906|Active Comparator|BD/CD -|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
16565491|NCT02843906|Active Comparator|a-MCI|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
16565492|NCT02843893|Other|Intubated and Mechanically Ventilated Patients|Intubated and Mechanically Ventilated Patients receiving by continuous intravenous an hypnotic sedation (midazolam or propofol) associate with a morphine type drug (fentanyl, sufentanil, rémifentanil, or morphine) since at least 6 hours and for a predictable duration over 24 hours.
16565493|NCT02843880||Septic shock patients|Septic shock patients staying over 3 days mechanically ventilated in the ICU
16565494|NCT02843841|Other|ATG group|"Renal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of polyclonal antilymphocyte globulin (ATG-Fresenius®) as recommended.
~Intervention = blood and fecal sample"
16565495|NCT02843841|Other|Anti-CD25 group|"PRenal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of anti-CD25 monoclonal antibodies (basiliximab SIMULECT®) as recommended.
~Intervention = blood and fecal sample"
16565496|NCT02843828|Experimental|Samsung Hip Assist v1|gait rehabilitation with Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
16565497|NCT02843828|Active Comparator|Conventional gait training|gait rehabilitation without Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
16565498|NCT02843815|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565499|NCT02843815|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565500|NCT02843802|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565501|NCT02843802|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565502|NCT02843789|Experimental|Adiponectin evaluation|Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
16565503|NCT02843763|Other|Renal transplant with 1rst cancer|"Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).
~Intervention : blood sample"
16565504|NCT02843763|Other|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.
~Intervention : blood sample"
16565505|NCT02843763|No Intervention|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
16565506|NCT02843763|Other|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
16565507|NCT02843763|Other|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
16565508|NCT02843763|Other|Rt patients without cancer apparied to RT skin cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.
~Intervention : blood sample"
16565509|NCT02843750|Experimental|Inspiratory Muscle Training-Rehabilitation|Patients will start the IMT-R, following their consent and within 2 weeks of their scheduled surgery: 10 sessions lasting about 90 minutes. Participants who completed their initial IMT greater than 2 weeks prior to surgery will have an additional visit prior to surgery. Participants will receive a Participant Manual demonstrating and explaining the rehabilitation process. Participants will also receive a log for recording their efforts and notes. A DVD of the rehabilitation is available to the participant. Participants will complete questionnaires at baseline and 3 months.
16565510|NCT02843724|Active Comparator|Control (Conventional) Arm|Treatment of Type 2 Diabetes according to the Canadian Diabetes Association guidelines. Participants' other health concerns to be addressed as per usual care by practitioners at Wise-Elephant Family Health Team.
16565511|NCT02843724|Active Comparator|Integrative (Naturopathic + Conventional) Arm|In addition to conventional care, participants will receive free naturopathic care at Brampton Naturopathic Teaching Clinic (located within the Brampton Civic Hospital). Senior student clinicians will provide care under the direct supervision of licensed naturopathic doctors. A naturopathic menu of treatment options have been designed to reflect naturopathic practice and vetted by 3 licensed naturopathic doctors and experts in the field. Participants' other health concerns will be addressed as per naturopathic doctors' discretion.
16565512|NCT02843711||Adenocarcinoma|Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
16565513|NCT02843698|Experimental|Dexmedetomidine group|Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
16565514|NCT02843698|Placebo Comparator|Control group|Patients will receive normal saline
16565515|NCT02843672|Active Comparator|TWO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.
~Triple´s Weil osteotomy is performed."
16565516|NCT02843672|Active Comparator|DMMO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.
~Distal metatarsal minimally invasive osteotomy is performed."
16565517|NCT02843659|Experimental|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
16565518|NCT02843659|Experimental|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
16565519|NCT02843659|Placebo Comparator|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
16565550|NCT02843438|Other|Subjects suspected of toxoplasmosis chorioretinitis infection|Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
16565551|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
16565520|NCT02843646|Experimental|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
16565521|NCT02843646|Placebo Comparator|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
16565522|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
16565523|NCT02843620|Placebo Comparator|Placebo|The placebo arm will take a pill each day containing only excipients
16565524|NCT02843620|Experimental|b-2Cool|The b-2Cool arm will take a pill each day containing 40 mg of b-2Cool and excipients
16565525|NCT02843607|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565526|NCT02843607|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
16565527|NCT02843594|Active Comparator|LEEP Intervention C1|Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
16565528|NCT02843594|Active Comparator|LEEP Intervention C2|Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
16565529|NCT02843594|Placebo Comparator|Control Phaco C2|Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
16565530|NCT02843581|Experimental|Cryosurgery and NK immunotherapy|We use comprehensive cryosurgery to destroy big tumors, and use multiple (more than 6 times) NK immunotherapy to destroy small tumors
16565531|NCT02843581|Active Comparator|Cryosurgery|We use comprehensive cryosurgery to destroy big tumors
16565532|NCT02843568|Active Comparator|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.
~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
16565533|NCT02843568|Experimental|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
16565534|NCT02843555||Leukodystrophy of unknown etiology|Subjects who may have an undiagnosed form of leukodystrophy
16565535|NCT02843542|Other|Control Group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT)
16565536|NCT02843542|Other|Study group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT) and in addition will also undergo the PET-MR
16565537|NCT02843529|Experimental|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers
~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
16565538|NCT02843529|Experimental|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers
~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
16565539|NCT02843516||patients with stroke|patients with stroke
16565540|NCT02843516||patients without stroke|patients without stroke
16565541|NCT02843503|Experimental|Arterialized-venous reference YSI|CGM monitoring performance per arterialized venous reference measurement (YSI)
16565542|NCT02843503|Experimental|Venous reference samples YSI|CGM monitoring performance per venous reference measurement (YSI)
16565543|NCT02843490|Experimental|Ranibizumab treatment of nAMD patients|nAMD patients will be treated with Ranibizumab (0.5 mg injection) 3 times within three months followed by individual therapy interval based on the clinical progress (PRN) up to 7 times. Analysis of specific biomarker.
16565544|NCT02843490|No Intervention|healthy subjects|Analysis of specific biomarker.
16565545|NCT02843477||Fluid loading group|Spontaneously breathing patients before induction of general anesthesia who receive fluid loading
16565546|NCT02843464|Experimental|long-term RIPC group|routine treatment + once RIPC/day for a year. Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
16565547|NCT02843464|No Intervention|control group|routine treatment.
16565548|NCT02843451|Experimental|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
16565549|NCT02843451|Placebo Comparator|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
16565555|NCT02843399||Exenatide once weekly (EQW)|EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.
16565556|NCT02843399||Insulin Glargine (IG)|IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015
16565557|NCT02843386|Experimental|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
16565558|NCT02843386|Other|B : Surveillance|Intensive surveillance
16565559|NCT02843373||rTMS|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered to the left DLPFC as assessed by either the 5cm rule or F3 site. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
16565560|NCT02843347||Biorepository substudy participants|Participants from the main study who give consent for the genetic testing substudy.
16565561|NCT02843334||Population of adult patients undergoing chronic renal dialysis|Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)
16565562|NCT02843321|Experimental|T-cell infusion|Infusion of donor-derived T cells. Non randomised, prevention study arm
16565563|NCT02843308|Experimental|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
16565564|NCT02843308|Experimental|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
16565565|NCT02843308|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
16565566|NCT02843295|Experimental|Population of the study|3 stratification groups: Group 1: High immunologic risk Patients receiving a ≥ 2nd graft and/or Panel Reactive Antibody ≥ 30% and/or Human Leukocyte Antigen (HLA) mismatches ≥ 4 Group 2: High non-immunologic risk Donors over 60 years of age and/or Donor between 50 to 59 years of age who have died of stroke, or had a history of high blood pressure, or at the time of death had a creatininemia ≥ 135 µmol/L Group 3: Low risk Patients not included in Groups 1 or 2
16565567|NCT02843282|Experimental|Cognitive training|Advanced reasoning training
16565568|NCT02843269|Active Comparator|Multi-component lifestyle intervention 1|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
16565569|NCT02843269|Active Comparator|Multi-component lifestyle intervention 2|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
16565570|NCT02843269|Active Comparator|Multi-component lifestyle intervention 3|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
16565571|NCT02843256||Patients receiving intravenous nutrition|Patients will blow into a bag that will capture 500 mL of their exhaled air daily for 7 days or the length of the parenteral nutrition, whichever is shorter. The Isomark Canary will analyze the air to generate a breath delta value.
16565572|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).
~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.
~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
16565573|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).
~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.
~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
16565574|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).
~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.
~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
16565575|NCT02843217|Experimental|Text Messaging|
16565576|NCT02843204|Experimental|Pembrolizumab and NK immunotherapy|In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565577|NCT02843204|Active Comparator|Pembrolizumab|In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565578|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
16565579|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
16565580|NCT02843178|Experimental|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
16565581|NCT02843178|Active Comparator|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
16565582|NCT02843178|Active Comparator|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
16565583|NCT02843178|Active Comparator|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
16565584|NCT02843165|Experimental|CBI plus SBRT|Checkpoint blockade immunotherapy (CBI) plus stereotactic body radiation therapy (SBRT)
16565586|NCT02843139||Children group|Children recruiters were categorized into three groups: obesity, overweight and normal control based on World Health Organization child growth standards.
16565587|NCT02843139||Adults group|Adults with type 2 diabetes were defined if the individual had a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L.
16565588|NCT02843126|Experimental|Trastuzumab and NK immunotherapy|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565589|NCT02843126|Active Comparator|Trastuzumab|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565590|NCT02843113|Experimental|4 Your Child Program|Program integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
16565591|NCT02843113|Experimental|4 Your Child + Case Management|Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
16565592|NCT02843113|No Intervention|Waiting list control|Individuals who are randomly assigned to this condition will receive no treatment for a period of months in parallel with the experimental intervention conditions. Data will be gathered from them, and they will be randomly assigned to a treatment condition when possible.
16565593|NCT02843100|Experimental|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) phases 2 & 3 for 24 weeks
16565594|NCT02843100|Active Comparator|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 24.
16565595|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565596|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565597|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565598|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565599|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565600|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565620|NCT02842957|No Intervention|Usual Care|The Usual Care arm will continue to receive the current standard of care involving all the services provided at a contemporary nephrology practice in Western Massachusetts
16565601|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565602|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565603|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565604|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
16565606|NCT02843061|Experimental|Rituximab and NK immunotherapy|In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565607|NCT02843061|Active Comparator|Rituximab|In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
16565608|NCT02843048|Experimental|Exercise training|Exercise training plus standard medical follow-up care
16565609|NCT02843048|Active Comparator|Standard medical care|Standard medical follow-up care only
16565610|NCT02843035|Experimental|Open label (OL) venglustat|Administered once a day orally for 260 weeks. Patients will continue their usual dose of Cerezyme throughout study.
16565611|NCT02843022|Active Comparator|Usual care|Participant will receive the usual care provided by the nursing staff at Catholic Medical Center. A lactation consultant or childbirth educator attempts to call each patient within 2-3 weeks prior to discharge. Only one call is made, and a message left if the patient would like to call back.
16565612|NCT02843022|Experimental|Message Only|Participant will receive the usual care, and in addition, will receive four standardized electronic messages weekly for six months postpartum. These will be one-way messages without the option to respond.
16565613|NCT02843022|Experimental|Message and Nurse|"Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond yes to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week."
16565614|NCT02843009|Placebo Comparator|Safflower Oil plus Resistance Exercise Training|3.0g of safflower oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
16565615|NCT02843009|Active Comparator|Fish Oil plus Resistance Exercise Training|3.0g of fish oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
16565616|NCT02842996||Patient and carer study group|Patients having undergone hip fracture surgery and their care givers.
16565617|NCT02842983|Experimental|Esmolol|After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.
16565618|NCT02842983|No Intervention|Control|Patients received conventional management of septic shock
16565619|NCT02842957|Experimental|Lifestyle intervention|Behavioral: The Lifestyle arm is the experimental group that will be exposed to an intensive, individualized approach aimed at assisting these CKD patients to adhere to lifestyle changes that are expected to be beneficial to their health and wellbeing. Patients will receive direction to implement a plant based diet, along with more physical activity in their lives. They will be assisted with the optimal use of their prescribed medications by pharmacy professionals and they will receive behavioral counseling by experts in that area.
16565621|NCT02842944|Experimental|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
16565622|NCT02842944|Active Comparator|Routine care|"Connect and start Beacon with advice disabled
~Standardized routine care"
16565623|NCT02842931|Active Comparator|R-DA-EPOCH-21|Protocol involves 6 cycles.
16565624|NCT02842931|Active Comparator|R-DA-EPOCH-21 + auto-SCT|Protocol involves 6 cycles. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
16565625|NCT02842931|Active Comparator|R-mNHL-BFM-90|"Course A:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 25 mg/m2/day IV 1, 2 days, Vincristine 2 mg IV 1 day, Cytarabine 100 mg/m2/day IV 1 h 4, 5 days.
~Course B:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Doxorubicin 25 mg/m2/day IV 4, 5 days, Vincristine 2 mg IV 1 day. Protocol involves 6 cycles : A-B-A-B-A-B. One cycle continues 21 days."
16565626|NCT02842931|Active Comparator|R-mNHL-BFM-90 + auto-SCT|Protocol involves 6 cycles R-mNHL-BFM-90: A-B-A-B-A-B. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
16565627|NCT02842918|Active Comparator|Spinal Manual Therapy|Supine thoracic spine manipulation located between the levels of T4-T7
16565628|NCT02842918|Sham Comparator|Spinal Range of Motion|Supine thoracic spine sham manipulation located between the levels of T4-T7; identical procedure as the active treatment intervention but without the delivery of high velocity low amplitude thrust
16565629|NCT02842905|Active Comparator|Control Group|Fitting Audiologist completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
16565630|NCT02842905|Experimental|Test Group|Participant's physician completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
16565631|NCT02842892|Other|Squat Jump|
16565632|NCT02842892|Other|Drop Jump|
16565633|NCT02842892|Other|Countermovement Jump|
16565634|NCT02842879|Experimental|Outpatient Foley cervix priming|Patients randomized to outpatient cervix priming will have the insertion of the catheter in the same conditions defined by the Department protocol for inpatient cervix priming. They will be discharged after a reassuring cardiotocogram following the introduction of the Foley catheter. When discharged, the patients will be instructed to apply manual traction to the catheter every 6 hours and they will be given a written document with all the information that should bring them back to hospital.
16565635|NCT02842879|No Intervention|Inpatient Foley cervix priming|The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
16565636|NCT02842866|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
16565637|NCT02842866|Active Comparator|Group 2: Menomune® Vaccine|Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
16565638|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 1|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 1a) and adults aged 18 to 55 years (Group 1b) received a single dose of MenACYW conjugate vaccine from lot 1 on Day 0.
16565639|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 2|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 2a) and adults aged 18 to 55 years (Group 2b) received a single dose of MenACYW conjugate vaccine from lot 2 on Day 0.
16565640|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 3|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 3a) and adults aged 18 to 55 years (Group 3b) received a single dose of MenACYW conjugate vaccine from lot 3 on Day 0.
16565641|NCT02842853|Active Comparator|Menactra®|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 4a) and adults aged 18 to 55 years (Group 4b) received a single dose of Menactra® on Day 0.
16565642|NCT02842840|Experimental|Patients based intervention|A multifaceted intervention program will use to improve adherence and clinical outcomes in Stroke patients. This intervention focus on behavioral treatment in the patients.
16565643|NCT02842840|Experimental|Family based intervention|Patients and their families will receive a series of educational/motivational interventions.
16565644|NCT02842840|Active Comparator|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 30 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
16565645|NCT02842827|Experimental|Multiple ascending dose|MAD Cohorts using IMG-7289 alone
16565646|NCT02842827|Experimental|Combination Therapy|IMG-7289 in combination with all-trans retinoic acid (ATRA)
16565647|NCT02842827|Experimental|Ascending duration|Treatment duration extension Cohorts using IMG-7289 alone
16565648|NCT02842814|Experimental|Full withdrawal|Intervention: 'Drug free'.
16565649|NCT02842814|Experimental|GC withdrawal|Intervention: 'HCQ' .
16565650|NCT02842814|Experimental|No withdrawal|Intervention: 'GC+HCQ' .
16565651|NCT02842801|Other|Hip Manipulation|Hip manipulation: high velocity low amplitude thrust mobilization
16565652|NCT02842788||ARDS patients receiving invasive mechanical ventilation in ICU|"ARDS criteria (Berlin definition) fulfilled the day of the study, whatever the ARDS stage. The onset of ARDS could have been established at any time between ICU admission and study day but ARDS criteria must be still present the day of the study. The ARDS criteria are listed below
~Within 1 week of a known clinical insult or new or worsening respiratory symptoms
~Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules
~Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
~PaO2/FIO2 ≤ 300 with Positive end-expiratory pressure (PEEP) ≥ 5 cmH2O
~Age ≥ 18 years
~Intubated or tracheotomized and mechanically ventilated"
16565653|NCT02842775|Experimental|Dynamic balance exercise group|balance perturbation training
16565654|NCT02842775|No Intervention|Control group|No intervention
16565655|NCT02842762|Sham Comparator|Non-paced|"cardiac surgery
~3D TEE measurements of systolic dyssynchrony
~right ventricular epicardial pacemaker lead (off)"
16565656|NCT02842762|Experimental|Paced|"The patient is randomized to the order of measurements taken, and serves as his own control.
~cardiac surgery
~3D TEE measurements of systolic dyssynchrony
~right ventricular epicardial pacemaker lead (on)"
16565657|NCT02842749|Experimental|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
16565658|NCT02842736|Experimental|Endometrial Cryoablation|
16565659|NCT02842723|Experimental|Protontherapy|
16565660|NCT02842710|Experimental|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
16565661|NCT02842697|Experimental|Single arm study|"Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.
~Intervention: Procedure: HVPG measurement"
16565662|NCT02842684|Experimental|Traumacad software|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . The recent TraumaCad system ( Brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric hip parameters
16565663|NCT02842684|No Intervention|without digital planning|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise
16565664|NCT02842671|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the the procedure will serve as our intervention group. The participants will be assigned an Ambassador throughout the procedure and will complete a patient satisfaction survey afterwards. The investigators hope to enroll 25 controls.
16565665|NCT02842671|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
16565666|NCT02842658|Active Comparator|A high-intensity interval exercise group|Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
16565667|NCT02842658|Other|An attention-control group|Patients will receive counseling regarding physical activity during chemotherapy. Patients will receive a weekly phone call to maintain physical activity during chemotherapy and compliance will be verified using physical activity diaries and pedometers.
16565668|NCT02842645||Control|Children born at term and not exposed to drugs during pregnancy
16565669|NCT02842645||Case|Case = Children exposed to drugs during pregnancy
16565670|NCT02842632|Other|A virtual teaching|Group A will be introduced to the virtual TEE online (http://pie.med.utoronto.ca/TEE/)
16565671|NCT02842632|Other|B simulator|Group B will be introduced to the simulator (CAE Vimedix Simulator)
16565672|NCT02842632|Other|C hands on OR|group C will be introduced to the TEE training in the operation room.
16565673|NCT02842619|Experimental|Intervention Arm|1 Arm - IMP treatment arm
16565674|NCT02842606|Experimental|Fiber-enriched pasta|The participants consume whole wheat pasta with added fiber (fiber 12 g fiber/100 g).
16565675|NCT02842606|Active Comparator|Control pasta|The participants consume pasta made from durum wheat semolina (fiber 2.7g/100g).
16565676|NCT02842593|Experimental|Resistance exercise training|Whole-body resistance exercise training 4x/week for 12 weeks. Either 'lower-repetition, heavier-load' or 'higher-repetition, lighter-load' intervention.
16565677|NCT02842593|No Intervention|Non-exercising control|Continue habitual physical activity for 12 weeks.
16565678|NCT02842580|Active Comparator|Standard arm (escalation strategy - arm A)|LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
16565679|NCT02842580|Experimental|Experimental arm (de-escalation strategy -arm B)|(4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine
16565680|NCT02842567|Experimental|TREATED GROUP|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
16565681|NCT02842567|Placebo Comparator|PLACEBO GROUP|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
16565682|NCT02842554|Other|DPA|Drug Placebo Administration
16565683|NCT02842554|Other|C|Control
16565684|NCT02842554|Other|EPT|Evoked Pain Training
16565685|NCT02842541|Experimental|Single dose arm|Subjects will receive a single intravitreal dose of EBI-031
16565686|NCT02842541|Experimental|Repeat dose arm|Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months
16565687|NCT02842528|Experimental|Alcohol-dependent patients|
16565688|NCT02842528|Active Comparator|First-degree relatives of alcohol-dependent probands|
16565689|NCT02842528|Active Comparator|Healthy Controls|
16565690|NCT02842515||Patients requiring dental avulsion|Patients requiring dental avulsion
16565691|NCT02842502|Experimental|Skin graft pellet|This group concerns patients who are recruited for skin graft procedure leading to the collection of supernumerary biopsies.
16565692|NCT02842489|Experimental|left lateral tilt-down position|patients will be positioned on left lateral tilt-down position during colonoscopy until sigmoid-descending junction were examined, and then patients will be positioned on the left lateral horizontal position during colonoscopy
16565693|NCT02842489|Active Comparator|left lateral horizontal body position|patients will be positioned on the left lateral horizontal position during colonoscopy insertion
16565694|NCT02842476||Disposable Sensor|Adhesive based Pulse Oximeter Probes, Model S0136J
16565695|NCT02842476||Reusable Sensor|Reusable Pulse Oximeter Probes, Model S0080D
16565696|NCT02842476||Control Pulse Oximetry|Reference CO-Oximeters ABL80 Flex OSM (Radiometer), # 302125, 307205 IL682 (Instrumentation Laboratories), # 012511B (ILH), #012511A (ILG)
16565697|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.
~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
16565698|NCT02842450||training with typical definitions established + photos|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
16565699|NCT02842450||Training only with definitions|Interns will receive typical definitions of LAP stages
16565700|NCT02842437|Experimental|Dexmedetomidine|25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
16565701|NCT02842437|Placebo Comparator|Placebo|25 patients receive matching placebo （normal saline）
16565702|NCT02842424|Experimental|Ramipril Treatment|6 months treatment with the medication Ramipril
16565703|NCT02842411||chronic constipation|patients with chronic constipation based on Rome Ⅳ
16565704|NCT02842398|Experimental|Balance Master Training|Children receive one weekly Balance Master training session, in addition to their weekly physical therapy sessions. During Balance Master training, children practice balance on a Balance Master device that simulates crossing a city street.
16565705|NCT02842398|Active Comparator|Customary Care|Children received their customary scheduled physical therapy sessions, without Balance Master training
16565706|NCT02842385|Active Comparator|Nonsubmerged thick group|Nonsubmerged type of implants placed with thick (>3 mm) soft tissue
16565707|NCT02842385|Active Comparator|Nonsubmerged thin group|Nonsubmerged type of implants placed with thin (<3 mm) soft tissue
16565708|NCT02842385|Active Comparator|Submerged thick group|Submerged type of implants placed with thick (>3 mm) soft tissue
16565709|NCT02842385|Active Comparator|Submerged thin group|Submerged type of implants placed with thin (<3 mm) soft tissue
16565710|NCT02842372||Ectoin Dermatitis Cream 7%|Cream for symptomatic treatment and relief of skin redness and itching experienced with various types of inflammatory dermatoses.
16565711|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
16565712|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
16565713|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
16565714|NCT02842333|Experimental|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).
~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
16565715|NCT02842320|Experimental|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
16565716|NCT02842307|Active Comparator|A(senior acupuncturists)|Manual acupuncture implemented by senior acupuncturists (clinical experience >15 years)
16565717|NCT02842307|Active Comparator|B(junior acupuncturists)|Manual acupuncture implemented by junior acupuncturists (clinical experience <5 years)
16565718|NCT02842307|Active Comparator|C(P6 points)|Manual acupuncture on P6 points by junior acupuncturists (clinical experience <5 years)
16565719|NCT02842307|No Intervention|D(no acupuncture)|No acupuncture treatment
16565720|NCT02842294||irinotecan based chemotherapy|patients having a 1st line doublet chemotherapy including irinotecan
16565721|NCT02842294||oxaliplatin based chemotherapy|patients having a 1st line doublet chemotherapy including oxaliplatin
16565722|NCT02842294||triplet chemotherapy|patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
16565723|NCT02842281|Active Comparator|Fructan|Fructans will be provided for 72 hours.
16565724|NCT02842281|Placebo Comparator|Maltodextrin|Maltodextrin will be provided for 72 hours.
16565725|NCT02842268|Experimental|BAY987517|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams.Subject should sweat profusely.
16565726|NCT02842255|Experimental|Healthy volunteers|
16565727|NCT02842242|Experimental|Open Label|MYK-461
16565728|NCT02842229||Patients with Haematologic Neoplasms|"Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01).
~Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).
~Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01)."
16565729|NCT02842190|Active Comparator|NIPPV|NIPPV after ekstubation
16565730|NCT02842190|No Intervention|BIPAP|BIPAP after ekstubation
16565731|NCT02842177|Active Comparator|Group I (classic method)|
16565732|NCT02842177|Active Comparator|uterine sound sparing group|
16565733|NCT02842164|Other|Foley Catheter Balloon with Tension group|a 16 French transcervical Foley catheter balloon will be advanced to or past the internal os and the balloon will be filled. Then catheter will be placed on gentle traction by taping the distal tip to the medial thigh for maximum 24 hours. To maintain gentle traction, periodic repositioning of the distal tip on the thigh will be necessary.
16565734|NCT02842164|Other|Foley Catheter Balloon without tension group|The Foley catheter balloon will be just supported by simple taping to the thigh.
16565735|NCT02842151|Other|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
16565736|NCT02842138|Experimental|CD19 CAR T cells|A standard dose escalation approach aimed to assess the safety and efficacy of autologous anti-CD19 CAR T cells will be applied.
16565766|NCT02841982|Active Comparator|IPCA|postoperative IPCA is given alone
16567036|NCT02833038|Experimental|Magnesium group|Intravenous administration of Magnesium Sulfate
16565737|NCT02842125|Experimental|Ad-p53 with Xeloda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
16565738|NCT02842125|Experimental|Ad-p53 with Keytruda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
16565739|NCT02842125|Experimental|Ad-p53 with Opdivo 33.3% of patients|Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
16565740|NCT02842112||CD34+ CD38-|A first cell population, which expressed the CD34 antigen and lacked CD38 (CD34+ CD38-), and often contained very few events requiring to be tightly clustered in a forward light scatter /side light scatter (FSC/ SSC) and CD45/SSC plot;
16565741|NCT02842112||CD34+ CD38low|A second population characterized by expression of the CD34 antigen and by a low density of CD38 antigen (CD34+ CD38low)
16565742|NCT02842112||CD34+ CD38+|A third population characterized by a large density of CD38 and CD34 antigens (CD34+ CD38+). Antigens were expressed as percent positively stained cells as well as intensity of the fluorescence signal quantified as mean fluorescence intensity (MFI) from CD34+ gated cells and from CD45low/SSC total immature cells
16565743|NCT02842099|Experimental|TA or TAC plus X|Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
16565744|NCT02842099|Active Comparator|TA or TAC|Standard chemotherapy (TA or TAC) followed by no more chemotherapy
16565745|NCT02842086|Experimental|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
16565746|NCT02842086|Experimental|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
16565747|NCT02842086|Experimental|Open-label|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.
16565748|NCT02842086|Experimental|Open-Label Extension|Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 144 weeks.
16565749|NCT02842073|Experimental|Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
16565750|NCT02842060|Experimental|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
16565751|NCT02842060|Active Comparator|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
16565752|NCT02842047|Experimental|End of Life Care with Meditation|The intervention has two content components: end of life planning education (using end of life planning videos) and strategies and kindness based meditation (using the Stop, Breathe & Think™ app). The activities comprising these components work together to improve both analytic neural processing (e.g. improving knowledge about goal setting and EOL planning, learning self-monitoring of EOL values and goals of care, and self-regulation skills of monitoring symptoms of distress and anxiety) and emotional neural processing (e.g. teaching participants to experience the moment non-judgmentally and directing thoughts to think positive thoughts and feel positive feelings like kindness and compassion.
16565753|NCT02842047|Active Comparator|Meditation Only|This arm has the single content component of kindness based meditation delivered by using the Stop, Breathe & Think™ application. This group will also be instructed to view 3 caregiver wellness videos.
16565754|NCT02842034|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
16565755|NCT02842034|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
16565756|NCT02842021|Active Comparator|S2G6T-1|Topical cream
16565757|NCT02842021|Active Comparator|S2G6T-2|Topical Cream
16565758|NCT02842021|Active Comparator|S2G6T-3|Topical Cream
16565759|NCT02842021|Placebo Comparator|S2G6T-4|Topical Cream
16565760|NCT02842008|Experimental|Exercise group|Wheelchair basketball players participating in home therapeutic exercise program that use the protocol of postural hygiene.
16565761|NCT02842008|No Intervention|Control group|Wheelchair basketball players that not participate in home therapeutic exercise program and use a protocol of postural hygiene provided.
16565762|NCT02841995|Experimental|belumosudil 200 mg QD|Two 100 mg capsules or one 200 mg tablet (200 mg) of belumosudil once daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal.
16565763|NCT02841995|Experimental|belumosudil 200 mg BID|Two 100 mg capsules or one 200 mg tablet (200 mg) of belumosudil twice daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal and 2 capsules or 1 tablet with their evening meal or within 5 minutes of completing a meal.
16565764|NCT02841995|Experimental|belumosudil 400 mg QD|Four 100 mg capsules or two 200 mg tablets (400 mg) of belumosudil once daily. Subjects should take 4 capsules or 2 tablets with their morning meal or within 5 minutes of completing a meal.
16565765|NCT02841982|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
16565767|NCT02841969|Active Comparator|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
16565768|NCT02841969|Experimental|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
16565769|NCT02841956|Experimental|Electronic Screen + Education (Phase 1)|Electronic screening of participants and targeted education of providers according to standard EDAPT model.
16565770|NCT02841956|Active Comparator|Targeted Provider Education (Phase 1)|Targeted education of providers according to standard EDAPT model.
16565771|NCT02841956|Experimental|Community Mobile Engagement (Phase 2)|Clinical intake interviews take place via videoconference at a location in the community convenient for the participant.
16565772|NCT02841956|Active Comparator|Clinic based Engagement (Phase 2)|Clinical intake interviews take place at the EDAPT clinic.
16565773|NCT02841930|Experimental|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
16565774|NCT02841930|No Intervention|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
16565775|NCT02841917||Transcatheter Aortic Valve Replacement|ROS Post TAVR
16565776|NCT02841917||Surgical Aortic Valve Replacement|ROS Post SAVR
16565777|NCT02841904|Other|CLE|CLE assessed by the pathologist
16565778|NCT02841904|Active Comparator|Biopsy|Histology assessed by the pathologist
16565779|NCT02841891|Experimental|Test|Test group will receive Sylys® Surgical Sealant as an adjunct to standard closure of stapled anastomosis in colectomy procedure.
16565780|NCT02841891|Active Comparator|Control|Control group will receive standard of care closure of stapled anastomosis in colectomy procedure without Sylys® Surgical Sealant.
16565781|NCT02841878|Other|analysis on colorectal biopsy|"Proteases activity (cystein and serin proteases)
~Proteases inhibitors genes expression (Serpins A1 / E1)
~Colonic biopsies permeabilityTight junctions genes expression
~Cytokines genes expression (TNFalpha, interleukines)
~Cellularity on histologic sections"
16565782|NCT02841839|Experimental|2-step system|Subjects are to brush with 2-step system for 4 weeks; stannous fluoride
16565783|NCT02841826|Other|Group I: IUD without uterine sound group|Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding.
16565784|NCT02841826|Other|Group II: IUD with uterine sound|Intrauterine contraceptive device inserted by classic method
16565785|NCT02841813||The normal mothers group|No intervention
16565786|NCT02841813||The normal full-term infants group|No intervention
16565787|NCT02841813||The preterm mothers group|No intervention
16565788|NCT02841813||The preterms group|No intervention
16565789|NCT02841800|Experimental|Intra-luminal radiofrequency ablation|Intra-luminal radiofrequency ablation Admission for endoscopic retrograde cholangiopancreatography (ERCP) and stent placement after radiofrequency ablation. ERCP should be performed for 2 times with an interval of two months.
16565790|NCT02841787|Experimental|Individual Internet Intervention (III)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.
~(iCBT for late life depression without social network included.)"
16565791|NCT02841787|Experimental|Internet Intervention+Peer Supp.(II+PS)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.
~(iCBT for late life depression with social network included.)"
16565792|NCT02841787|No Intervention|Waitlist Control (WLC)|Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.
16565793|NCT02841774|Active Comparator|Moderate Intensity Group|pravastatin 40mg daily for 12 weeks
16565794|NCT02841774|Experimental|High Intensity Group|rosuvastatin 20 - 40 mg daily for 12 weeks
16565795|NCT02841761|Experimental|Treatment A (Midazolam)|Single dose of Midazolam 8 mg on Day 1
16565796|NCT02841761|Experimental|Treatment B1 (ACT-132577)|Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.
16565797|NCT02841761|Experimental|Treatment B2 (Midazolam + ACT-132577)|Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6
16565798|NCT02841748|Experimental|Pembrolizumab|200mg, every three weeks, iv, x 1 year
16565799|NCT02841748|Experimental|Placebo|iv, every 3 weeks, x 1 year
16565800|NCT02841735||Smartphone breathalyzer device & app|This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
16565801|NCT02841735||BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
16565802|NCT02841735||Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.
16565803|NCT02841722|Other|Biological samples|Only one arm in this pilot study. All patient will have a follow up and treatment as per standard care for this pathology. Specifically for the study all patients will have 8 additional blood samples to be drawn during the first 2 cycles of treatment (1 cycles is 21 days).
16565804|NCT02841709|Experimental|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
16565805|NCT02841709|Experimental|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
16565806|NCT02841709|Experimental|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
16565807|NCT02841709|Experimental|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
16565808|NCT02841709|Experimental|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
16565809|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
16565810|NCT02841683|Active Comparator|Lifestyle counseling|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
16565811|NCT02841683|No Intervention|Current practices|Current practices of smoking cessation in France
16565812|NCT02841644||Traumatic Arthrotomy- Treated Nonoperatively|Patient diagnosed with traumatic arthrotomy treated nonoperatively.
16565813|NCT02841644||Traumatic Arthrotomy- Treated Operatively|Patient diagnosed with traumatic arthrotomy treated operatively.
16565814|NCT02841631||Post-Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
16565815|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks
16565816|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks
16565817|NCT02841605|Other|AD group|AD group: rectosigmoidospcopy with biopsies of colon
16565818|NCT02841605|Other|PD group|PD group: rectosigmoidospcopy with biopsies of colon
16565819|NCT02841605|Other|PSP group|PSP group: rectosigmoidospcopy with biopsies of colon
16565820|NCT02841605|Other|Patient eligible for colorectal cancer screening|Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon
16565821|NCT02841592|Active Comparator|Non-rebreather|This group will have a non-rebreather mask applied to the face and they will receive the flush rate oxygen intervention
16565822|NCT02841592|Active Comparator|Bag-valve-mask|With each inspiration from the subject, the ventilation bag will be gently squeezed to provide positive pressure and augment the amount of oxygen that is received by the subject for each breath. This group will receive the flush rate oxygen with assist intervention.
16565823|NCT02841579|Experimental|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.
16565824|NCT02841566||Problem glambers|The group of problem gamblers will consist of patients already included in the cohort EVALADD [favorable opinion of GNEDS 06/09/2012; CNIL authorization No. 912631 of 10.09.2013], and the data will be extracted directly from the database EVALADD
16565825|NCT02841566||Non-problem gamblers|The subjects of this group will be matched on sex, age and education level with the group problem gamblers. They will be recruited over the Internet and using the volunteer base [normal declaration with the CNIL: No. 1761543 of 21/05/2014].
16565826|NCT02841540|Experimental|H3B-8800 (Dose Escalation and Expansion)|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
16565827|NCT02841527|Active Comparator|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
16565828|NCT02841527|Active Comparator|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
16565829|NCT02841527|Active Comparator|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
16565830|NCT02841514|Experimental|treatment group|the operator will administer the Y10 whitening toothpaste in to the attachable mouthpiece and place it in the subject's mouth and turn on the device RF. After treating the patients for 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
16565831|NCT02841514|Placebo Comparator|placebo group|the operator will administer an off the shelf regular toothpaste in to the attachable mouthpiece and place it in the subject's mouth. At this point the operator will switch on the device but the RF will not be activated. After 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
16565832|NCT02841501||Candidemia patients|These patients are included in the study after the reception of a positive blood culture for Candida sp.
16565833|NCT02841501||Control patients|"These patients are matched on case patients on the following criteria:
~Age+/-5 years
~length of hospitalisation
~type of ward
~type of surgery for surgical patients
~IGS2 for intensive care patients"
16565834|NCT02841488|Active Comparator|Continuous nerve block|Continuous peripheral sciatic nerve block through popliteal perineural catheter with ropivacaine
16565835|NCT02841488|Active Comparator|Systemic analgesia|Intravenous fentanyl patient controlled analgesia device
16565836|NCT02841462|Experimental|Bursitis|Intra-bursal thermal ablation
16565837|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
16565838|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
16565839|NCT02841436|Experimental|irreversible electroporation (IRE)|IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
16565840|NCT02841423|Experimental|INTRAVENOUS ANESTHESIA|neuropsychological test battery
16565841|NCT02841423|Experimental|CLOSED LOOP ANESTHESIA|neuropsychological test battery
16565842|NCT02841410|Other|Healthy Volunteer|
16565843|NCT02841384|Other|Group taping McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
16565844|NCT02841384|Other|Group placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
16565845|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
16565846|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
16565847|NCT02841358|Other|Psychiatric adults patients presenting psychologic disorders|
16565848|NCT02841345|Other|Bipolar|bipolar patients type I or II (DSM-IV TR), euthymic phase
16565849|NCT02841345|Other|Schizophrenic|schizophrenic loss or paranoid or undifferentiated patients
16565850|NCT02841345|Other|Control|control group (paired in age and sex for patients)
16565851|NCT02841332|Experimental|Patients with glioblastoma|"Patient with histologically proved glioblastoma diagnostic will receive the following interventions :
~Cerebral magnetic resonance imagery
~Tomography emission positron with F-MISO
~Bevacizumab administration
~Clinical examination"
16565852|NCT02841319|Experimental|Intervention|Virtual reality exercises using Hand Tutor for 8 weeks
16565853|NCT02841319|No Intervention|Control|Home exercises for 8 weeks
16565854|NCT02841306|Active Comparator|3-5 hours|Duration between oral UDCA intake and surgery of 3-5 hours.
16565855|NCT02841306|Active Comparator|6-8 hours|Duration between oral UDCA intake and surgery of 6-8 hours.
16565856|NCT02841306|Active Comparator|9-12 hours|Duration between oral UDCA intake and surgery of 9-12 hours.
16565857|NCT02841306|Active Comparator|> 12 hours|Duration between oral UDCA intake and surgery of >12 hours.
16565858|NCT02841306|No Intervention|Control|No medication
16565859|NCT02841293|Experimental|Arm with biological mesh|The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)
16565860|NCT02841293|Active Comparator|Arm with primary perineal wound closure|The intervention consists of perinal reconstruction by primary perineal wound closure
16565861|NCT02841280|Experimental|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
16565862|NCT02841280|Placebo Comparator|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
16565863|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
16565864|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
16565865|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
16565866|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
16565867|NCT02841228|Experimental|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
16565868|NCT02841215|Experimental|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
16565869|NCT02841215|Active Comparator|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
16565870|NCT02841202|Active Comparator|oral contraceptive pills group|healthy women using oral contraceptive pills for only contraception for more than one year was called OCP group
16565871|NCT02841202|No Intervention|control group|The second group was called control group consisting 20 healthy women and using no drug
16565872|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
16565873|NCT02841176|Experimental|Experimental|Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)
16565977|NCT02840461|Active Comparator|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
16565874|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
16565875|NCT02841150|Experimental|Treatment Sequence 1|Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
16565876|NCT02841150|Experimental|Treatment Sequence 2|Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
16565877|NCT02841137|Experimental|progesterone 5 mg|progesterone 5 mg tablet
16565878|NCT02841137|Experimental|progesterone 10 mg|progesterone 10 mg tablet
16565879|NCT02841137|Experimental|progesterone 20 mg|progesterone 20 mg tablet
16565880|NCT02841137|Active Comparator|progesterone 100 mg|progesterone 100 mg capsule
16565881|NCT02841124|Other|Qualitative research|Semi-structured interviews
16565882|NCT02841098|Experimental|Carotid endarterectomy combined with optimal medical therapy|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
16565883|NCT02841098|Active Comparator|Optimal medical therapy (OMT)|Optimal medical therapy (OMT)
16565884|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
16565885|NCT02841059||Laparoscopic subtotal hysterectomy|women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.
16565886|NCT02841059||Laparoscopic CLSH|women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.
16565887|NCT02841059||Laparoscopic AVH|women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.
16565888|NCT02841046|Other|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
16565889|NCT02841046|Experimental|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
16565890|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
16565891|NCT02841020|No Intervention|Control SOC|Standard of care is followed
16565892|NCT02841020|Experimental|Experimental additional biopsy|Additional biopsy
16565893|NCT02841007|Experimental|geko device arm|Patients consenting to take part will receive the geko device prior to surgery to internally fixate their fractured ankle, to reduce and prevent oedema
16565894|NCT02840994|Experimental|CV301 + Pembrolizumab|CV301 + Pembrolizumab (Phase 1b portion of the trial)
16565895|NCT02840994|Experimental|CV301 + Nivolumab|CV301 + Nivolumab (Phase 1b portion of the trial)
16565896|NCT02840955|Active Comparator|Staphefekt SA.100|Staphefekt SA.100 cream, twice daily on (lesional) skin during 12 weeks
16565897|NCT02840955|Placebo Comparator|Placebo|Placebo (Gladskin cream without the Staphefekt protein), twice daily on (lesional) skin during 12 weeks
16565898|NCT02840942|No Intervention|Non-robot|Patients will interact with Child Life as per usual routine, no robot condition
16565899|NCT02840942|Experimental|Coping Robot|Robot will play coping game with children. Robot will speak and child will respond by touching tablet. Child life still present.
16565900|NCT02840942|Experimental|Non-coping Robot|Robot will play distraction only game, in addition to Child Life and routine cares
16565901|NCT02840929|Experimental|Second-look OGD group|"Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.
~OGD will be offered if signs of rebleeding present)"
16565902|NCT02840929|Active Comparator|Standard care group|Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present
16565903|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
16565904|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
16565905|NCT02840903||Setting 1 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
16565906|NCT02840903||Setting 2 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
16565907|NCT02840903||Setting 3 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
16565908|NCT02840903||Setting 4 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
16565909|NCT02840903||Setting 5 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
16565910|NCT02840903||Setting 6 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
16565911|NCT02840903||Setting 7 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
16565912|NCT02840903||Setting 8 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
16565913|NCT02840890|Experimental|experimental|Patients will have a visceral osteopathic technique perform with continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
16565914|NCT02840890|Placebo Comparator|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
16565915|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
16565916|NCT02840864|Experimental|Arm 1|Sonographically assisted breast surgery
16565917|NCT02840864|Active Comparator|Arm 2|Conventional breast surgery
16565918|NCT02840851||Healthy young women|Healthy young women between the age of 20-34 years.
16565919|NCT02840851||Healthy young men|Healthy young men between the age of 20-34 years.
16565920|NCT02840851||Healthy older women|Healthy older women between the age of 50-64 years.
16565921|NCT02840851||Healthy older men|Healthy older men between the age of 50-64 years.
16565922|NCT02840812|Experimental|Renal function impaired|Subject with Severe Impaired Renal Function. Nemonoxacin Malate Capsules 500mg single dose oral
16565923|NCT02840812|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
16565924|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
16565925|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.
~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
16565926|NCT02840786|Active Comparator|Intervention: Stents|Stents group
16565927|NCT02840786|Active Comparator|Intervention: Atherectomy|directional atherectomy group
16565928|NCT02840773|Active Comparator|Test group-baseline|Press-fit implant connection was monitored at baseline
16565929|NCT02840773|Active Comparator|Test group-12 month|Press-fit implant connection was monitored at 12 month after prosthesis delivered.
16565930|NCT02840773|Active Comparator|Control group-baseline|Screw-retained connection was monitored at baseline
16565931|NCT02840773|Active Comparator|Control group-12 month|Screw-retained connection was monitored at 12 month after prosthesis delivered.
16565932|NCT02840760|Active Comparator|tardive dyskinesia group|tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.
16565933|NCT02840760|No Intervention|Healthy control group|
16565934|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
16565935|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
16565936|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
16565937|NCT02840734|Experimental|Kinesio taping|All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
16565938|NCT02840734|Placebo Comparator|Placebo taping|Placebo tapes (3M tape) were applied with same method with Kinesio taping.
16565939|NCT02840734|No Intervention|No taping|In case of the no taping condition, the subject was treated along the same procedure which was closed subject's eyes with eye mask and covered the legs with clothes although applied anything on their legs. It might be able to minimize the error, because the researchers did not realize which condition the subject had.
16565940|NCT02840721|Experimental|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
16565941|NCT02840708|Active Comparator|125mcg|SK-1401 125mcg single inhalation
16565942|NCT02840708|Active Comparator|250mcg|SK-1401 250mcg single inhalation
16565943|NCT02840708|Active Comparator|500mcg|SK-1401 500mcg single inhalation
16565944|NCT02840695||AS patients|Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
16565945|NCT02840669|Other|Friedreich's Ataxia|
16565946|NCT02840669|Other|Healthy Volunteers (Controls)|
16565947|NCT02840656||healthy adult subject|oropharyngeal and rectal swabbing to collect Gram-negative bacilli
16565948|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
16565978|NCT02840461|Placebo Comparator|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
16565979|NCT02840448||Case|Subjects with WS/SVAS
16565980|NCT02840448||Controls|Healthy Volunteers
16565981|NCT02840435|Active Comparator|North Carolina Quit Line: Quit for Life|Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
16565949|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
16565950|NCT02840630|No Intervention|Non-diabetic group|Non-diabetic volunteers will be recruited for baseline data. They will only be required to provide dried blood samples (DBS) samples and information at week 0. They have to collect finger prick DBS, weigh themselves and fill in food frequency questionnaire only at one time point.
16565951|NCT02840630|No Intervention|Diabetic control intervention group|The diabetic control group will provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16. This group will not be receiving tinned mackerel and will be asked to continue with their habitual diet and lifestyle.
16565952|NCT02840630|Active Comparator|Diabetic fish intervention group|This intervention group will receive two 125 g portion of tinned mackerel fish (containing 7.8 g n-3 LCPUFA) per week from week 0 until 16 and a mackerel recipe book each. They will be required to provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16.
16565953|NCT02840617|Experimental|ICG injection group|ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
16565954|NCT02840604||patient with all types of solid malignant tumors not treatable|In the treatment or assessment of metastatic solid tumor malignancies not curable it can be offered to patients to establish the profile of their tumor by next generation sequencing (NGS). This technique permits the sequencing of millions of fragments in parallel in a short time and allows to identify rapidly somatic or constitutional mutations known or yet unknown. The establishment of the genetic profile of the tumor coupled to the available clinical data can help clinicians to predict patient outcome in terms of survival or progression to disease, but may also provide key clues to adapt the management and patient treatment.
16565955|NCT02840591|Experimental|Drug Treatment|"First 5 consecutive subjects: Ramelteon 8 mg daily at 8 pm for 5 days
~Next 5 consecutive subjects: Citicoline 250 mg daily at 8 pm for 2 days, followed by citicoline 500 mg daily at 8 pm for 3 days
~All subjects: Standard medical care"
16565956|NCT02840591|No Intervention|Observation-Only|Standard medical care
16565957|NCT02840565|Experimental|BIA 5-453 25 mg or placebo|Multiple oral doses of BIA 5-453 25 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
16565958|NCT02840565|Experimental|BIA 5-453 50 mg or placebo|Multiple oral doses of BIA 5-453 50 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
16565959|NCT02840565|Experimental|BIA 5-453 100 mg or placebo|Multiple oral doses of BIA 5-453 100 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
16565960|NCT02840565|Experimental|BIA 5-453 200 mg or placebo|Multiple oral doses of BIA 5-453 200 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
16565961|NCT02840565|Experimental|BIA 5-453 400 mg or placebo|Multiple oral doses of BIA 5-453 400 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
16565962|NCT02840565|Experimental|BIA 5-453 600 mg or placebo|Multiple oral doses of BIA 5-453 600 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
16565963|NCT02840552|Experimental|FCH-PET/CT|18F-Fluoromethylcholine (18F-FCH) PET/CT
16565964|NCT02840539|Experimental|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
16565965|NCT02840526|Experimental|PVB group|Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
16565966|NCT02840526|Other|GEN group|Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
16565967|NCT02840513|Experimental|Smartphone app/CO self-monitoring|The app offers a coaching function where users receive personalized messages to encourage smoking cessation and advice for behavioural changes. For the first 4 weeks of the intervention, individuals will also be asked to blow daily into a breath carbon monoxide monitor before going to sleep. Depending on the results of the breath test, individualized messages will be delivered by the Smokelyzer feedback app to either enhance maintenance of abstinence or increase the motivation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at least twice a week until the end of the 6-month study. The app will react with positive feedback in individuals doing well with smoking cessation and messages to encourage individuals with difficulties quitting to smoke.
16565968|NCT02840513|No Intervention|Control|Participants in the control group will be managed according to usual care as regularly provided by their SHCS physicians. Physicians will motivate patients to quit, emphasise the advantage of quitting, and provide patients with an information card that contains short advices how to quit and addresses of stop smoking clinics. The Swiss HIV Cohort Study study nurse will enter past or current use as well as of nicotine replacement therapy or use of other pharmaceutical support to quit smoking in the online study form
16565969|NCT02840500||Breakthrough Cancer Pain|No intervention (Non-interventional study)
16565970|NCT02840487|Experimental|Group 1|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
16565971|NCT02840487|Experimental|Group 2|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
16565972|NCT02840487|Experimental|Group 3|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
16565973|NCT02840487|Experimental|Group 4|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
16565974|NCT02840474|Experimental|Part A: VRC01LS (40 mg/kg)|VRC-HIVMAB080-00-AB (VRC01LS) - (40 mg/kg) - administered intravenously (IV) at Day 0
16565975|NCT02840474|Experimental|Part B: VRC07-523LS (40 mg/kg)|VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0
16565976|NCT02840461|Experimental|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
16565982|NCT02840435|Experimental|Sit to Quit|Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
16565983|NCT02840409|Active Comparator|Arm A|68 weeks of single agent Vinblastine administered once weekly IV
16565984|NCT02840409|Experimental|Arm B|68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
16565985|NCT02840396|Experimental|rTMS|
16565986|NCT02840396|Sham Comparator|Sham rTMS|
16565989|NCT02840370|Experimental|transcranial direct current stimulation|tDCS
16565990|NCT02840370|Sham Comparator|Sham tDCS|S-tDCS
16565991|NCT02840357|Experimental|Treatment Group|Purple Wheat Convenience Bars The treatment group will consume 4 servings /day of bran-enriched purple wheat convenience bars (40g/ serving)
16565992|NCT02840357|Placebo Comparator|Control Group|Control Wheat Convenience Bars The control group will consume 4 servings /day of bran-enriched ordinary wheat convenience basr (40g/ serving)
16565993|NCT02840344|Experimental|Couples MBSR|"Young breast cancer survivors and their partners take part in an 8-week Couples Mindfulness-Based Stress reduction (C-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor and partner will be asked to watch a video module, together, each week for a total of 8 weeks. The C-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.
~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
16565994|NCT02840344|Active Comparator|Individual MBSR|"Young breast cancer survivors take part in an 8-week Individual Mindfulness-Based Stress reduction (I-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor will be asked to watch a video module each week for 8 weeks in a row. The I-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.
~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
16565995|NCT02840331|Experimental|St. John's Wort & PDD, PDT|St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
16565996|NCT02840318|Experimental|Compassion Intervention|Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
16565997|NCT02840305|Other|Expérience 1|Brain bases of spatial frequencies treatment 30 young adults, 20 old adults 20 children between 4 and 6 years, 20 children between 6 and 12 years and 20 young adults
16565998|NCT02840305|Other|Expérience 2|Brain bases of Computer to Film (CtF) analysis 30 young adults, 20 old adults
16565999|NCT02840305|Other|Expérience 3|Part of parahippocampal gyrus in Computer to Film (CtF) analysis 30 young adults, 20 old adults.
16566000|NCT02840292||Cases|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal hemoglobin < 11gm/dl
16566001|NCT02840292||Controls|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal haemoglobin ≥ 11gm/dl
16566002|NCT02840279|Experimental|BPN14770|An oral dose of BPN14770
16566003|NCT02840279|Placebo Comparator|Placebo|An oral dose of placebo matching BPN14770
16566004|NCT02840253|Experimental|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
16566005|NCT02840240|Experimental|Gabapentin enacarbil|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
16566006|NCT02840240|Placebo Comparator|Placebo|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days
16566007|NCT02840227|Experimental|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
16566008|NCT02840227|Experimental|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
16566009|NCT02840214|Active Comparator|tDCS rescue group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
16566010|NCT02840214|Placebo Comparator|Sham Treatment Group|Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
16566011|NCT02840214|Active Comparator|tDCS prevent group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
16566012|NCT02840188||Radius tilt angle|Children 0-16 years of age positive for distal forearm fracture and positive history of goalkeeper's fracture (to catch a ball).
16566013|NCT02840188||Normal control group|Children 0-16 years of age without radius fracture and no history of catching a ball.
16566128|NCT02839356|Experimental|Drug: epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
16566014|NCT02840175|Experimental|Experimental|"Day 0 at Weeks 24 : Increase the interval between 2 doses of the biological agent (etanercept, adalimumab, tocilizumab, abatacept)
~Weeks 24 at Weeks 72: Stop the biological agent if inactive disease is maintained."
16566015|NCT02840175|Active Comparator|Control|"Day 0 at Weeks 24: Maintain the biological agent (etanercept, adalimumab, tocilizumab, abatacept) at the same dose.
~Weeks 24 at Weeks 48 : Increase the interval between 2 doses of the biological agent.
~Weeks 48 at Weeks 72: Stop the biological agent if inactive disease is maintained."
16566016|NCT02840162|Active Comparator|Celecoxib|Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
16566017|NCT02840162|Placebo Comparator|Placebo|Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth
16566018|NCT02840149|Other|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients
16566019|NCT02840136|Experimental|Standard of care|Sputum is collected from patients receiving standard of care therapy with IV piperacillin-tazobactam, ceftazidime or meropenem
16566020|NCT02840123|Experimental|Autologous dendritic cells|
16566021|NCT02840110||Post-ACTR|Subjects who have previously been treated with an ACTR T cell product
16566022|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
16566023|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
16566024|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
16566025|NCT02840084|Experimental|Treatment Patients|In stage I, 10 women aged 22 years or older who have received silicone or saline breast implants for subglandular or submuscular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.
16566026|NCT02840071|Experimental|Intervention|Psychological therapy.
16566027|NCT02840058|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.
~Peripheral blood mononuclear cells (PBMC) and plasma will be collected.
~Available tumor tissues will be collected."
16566028|NCT02840045|Experimental|Alzheimer patients|Cerebral measurements from high-density electroencephalography are recorded in Alzheimer patients. The same protocol is applied in the 3 arms
16566029|NCT02840045|Experimental|patients with a depressive disorder|Cerebral measurements from high-density electroencephalography are recorded in patients with a depressive disorder. The same protocol is applied in the 3 arms
16566030|NCT02840045|Active Comparator|Healthy controls|Cerebral measurements from high-density electroencephalography are recorded in healthy controls
16566031|NCT02840019|Experimental|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.
~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
16566032|NCT02840019|Experimental|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.
~The research MRI sequences will also be tested during the add-on research MRI scan."
16566033|NCT02840006|Active Comparator|General anesthesia only|Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1
16566034|NCT02840006|Active Comparator|General anesthesia associated spinal anesthesia|spinal anesthesia using bupivacaine 0,5% hyperbaric 20 mg, morphine 200 mcg, set trendeleburg for 10 minutes, sensitive test in T1. Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1.
16566035|NCT02839993|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
16566036|NCT02839993|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
16566037|NCT02839980||orthopedics (gr1) surgery|parient admitted to the orthopedics (gr1) surgery ward for an elective or semi-emergent surgical procedure.
16566038|NCT02839980||thoracic (gr2) surgery|parient admitted to the thoracic (gr2) surgery ward for an elective or semi-emergent surgical procedure.
16566039|NCT02839980||abdominal (gr3) surgery|parient admitted to the abdominal (gr3) surgery ward for an elective or semi-emergent surgical procedure.
16566040|NCT02839980||ICU (gr4)|patients admitted to the ICU with an antcipated length of stay of 3 days or more
16566041|NCT02839967|Experimental|Photobiomodulation group|For the purposes of photobiomodulation is used a portable cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), and 1 905 nm diode LASER, 4 875 nm LED diodes and 4 670 nm diodes LED, 4 cm2 beam, emitting an energy of 39.27 J.
16566042|NCT02839967|Placebo Comparator|Photobiomodulation placebo group|"To provide the blinding of the participants of the study we will use two identical photobiomodulation equipment supplied by the manufacturer, being an active and another a placebo, but both have identical light and sound device (do not send energy and heat, non-coherent light without biological effect). The devices are named in X and Y for a researcher who does not participate in treatment and assessments."
16566043|NCT02839954|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
16566044|NCT02839941|Experimental|experiment|
16566045|NCT02839941|Sham Comparator|Control|
16566046|NCT02839928|Experimental|Treatment|The experimental arm consists of children given intranasal Ketamine 1 mg/kg, once
16566129|NCT02839356|Placebo Comparator|Drug: normal saline|20-mL irrigation with physiological saline over the entire papilla
16566047|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - < 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
16566048|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
16566049|NCT02839902|Experimental|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
16566050|NCT02839902|Experimental|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
16566051|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
16566052|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
16566053|NCT02839876|Experimental|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
16566054|NCT02839876|Active Comparator|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
16566055|NCT02839850|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty
16566056|NCT02839837|Experimental|Depressed and non-depressed controls|All participants will participate in three different conditions: Low intensity aerobic exercise and paired associative stimulation, high intensity aerobic exercise and paired associative stimulation, no exercise control and paired associative stimulation. The order of conditions will be randomized.
16566057|NCT02839811|Experimental|immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
16566058|NCT02839798|Experimental|sTMS active|Treatment with the NEST Device
16566059|NCT02839785|Experimental|Ibuprofen|Active ibuprofen
16566060|NCT02839785|Placebo Comparator|Placebo|Placebo of ibuprofen
16566061|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
16566062|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
16566063|NCT02839759|Experimental|TELLYHealth Group|Subjects will receive the standard of care in hearing aid education and the TELLYHealth intervention for use over an 8 to12-week period and will be followed by their audiologist for 8 to 12 weeks.
16566064|NCT02839759|No Intervention|Standard of Care Group|Subjects will receive the standard of care in hearing aid education and will be followed by their audiologist for 8 to 12 weeks.
16566065|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
16566066|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
16566067|NCT02839733||Healthy Volunteers|Children and young adults healthy volunteer
16566068|NCT02839720|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
16566072|NCT02839694|Experimental|Dose escalation cohort|dose escalation cohort
16566073|NCT02839694|Experimental|Expansion cohort|expansion cohort at MTD
16566074|NCT02839694|Active Comparator|expansion cohort with celecoxib|expansion cohort at MTD with celecoxib
16566075|NCT02839681|Experimental|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
16566076|NCT02839681|Experimental|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansine at the recommended phase 2 dose (dose level 1 if no more than 1 dose limiting toxicity (DLT) occurred in the safety run-in arm, or at dose level -1 otherwise)
16566077|NCT02839668|Experimental|Sevoflurane|The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
16566098|NCT02839538|Active Comparator|local Infiltration|"Induction of General Anesthesia with Propofol(2mg/Kg) and Atracurium(0,5mg/Kg) . Pulmonary ventilation with laryngeal mask and Propofol infusion ( 100mcg/Kg/min.) After , Infiltration of 0.75% ropivacaine (10 ml) each side block injection of local anesthetic at perianal.
~If necessary, fentanyl endovenous injection (50 mcg)."
16566236|NCT02838654||cervical epidural injection group|cervical epidural injection group
16566078|NCT02839668|Active Comparator|Sevoflurane+Lidocaine|The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
16566079|NCT02839668|Experimental|TIVA-TCI|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.
16566080|NCT02839668|Active Comparator|TIVA-TCI+lidocaine|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.
16566081|NCT02839655|Experimental|Da Vinci Xi|
16566082|NCT02839642|Active Comparator|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.
~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
16566083|NCT02839642|Placebo Comparator|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
16566084|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
16566085|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
16566086|NCT02839590||HiFu (ultrasound)|Manufacturer Name Eyehope Principle intended use Surgical treatment of uncontrolled glaucoma and OHT The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study.
16566087|NCT02839590||Baerveldt implant|"Manufacturer Name Abbott Medical Optics Inc., Abbott Laboratories Inc., Abbott Park, Illinois, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
16566088|NCT02839590||Ahmed Implant|"Manufacturer Name New World Medical, Inc., 10763 Edison Court, Rancho Cucamonga, CA 91730, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
16566089|NCT02839590||STARflo|"Manufacturer Name iSTAR Medical SA, Parc Créalys, Rue Phocas Lejeune, Bâtiment Regain 25/3, 5032 Isnes, Belgium.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
16566090|NCT02839590||Hydrus Microstent implant|"Manufacturer Name Ivantis, Inc., 38 Discovery, Suite 150, Irvine, CA 92618, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
16566091|NCT02839590||iStent implant|"Manufacturer Name Glaukos Corporation, 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
16566092|NCT02839590||Kahook Dual Blade|Manufacturer: New World Medical. Inc. Single use, ophthalmic blade Utilizes ab interno approach through a clear cornea micro incision Dual blades positioned for precise parallel incisions of the trabecular meshwork with minimal residual leaflets Maintains natural physiologic outflow pathways
16566093|NCT02839577|Active Comparator|High Volume injection (HVI) with corticosteroid|"10 mls 0.5% bupivacaine hydrochloride
~20 mg of Depomedrol (40 mg/ml methylprednisolonacetat)
~40 mls saline (NaCl)
~HVI with corticosteroid is injected one time at baseline and compared to HVI without corticosteroid."
16566094|NCT02839577|Active Comparator|High Volume injection (HVI) without corticosteroid|"10 mls 0.5% bupivacaine hydrochloride
~40 mls saline (NaCl)
~HVI with corticosteroid is injected one time at baseline and compared to HVI with corticosteroid."
16566095|NCT02839564|Experimental|Adhesiolysis group|Patients underwent laparoscopic adhesiolysis
16566096|NCT02839564|Placebo Comparator|Placebo group|Patients underwent diagnostic laparoscopy alone
16566097|NCT02839551|Experimental|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
16566099|NCT02839538|Other|Subarachnoidal block|"Sedation with midazolam 2 mg. After , Spinal block with 10 mg of hyperbaric 0.5% bupivacaine. Injection of anesthetic at subarachnoidal space with Quincke needle 27G.
~If pain, local infiltration with lidocaine 1% (5 ml) in wound."
16566100|NCT02839525|Placebo Comparator|Omega 3|"3000mg of olive oil
~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
16566101|NCT02839525|Placebo Comparator|Isolate whey protein|"23g of maltodextrin
~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
16566102|NCT02839525|Placebo Comparator|Omega 3 and Isolate whey protein|"3000mg of olive oil and 23g of maltodextrin
~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
16566103|NCT02839512|Experimental|Jejunal to Ileal Diversion|All subjects who receive jejunal to ileal diversion endoscopic procedure
16566104|NCT02839499|Experimental|mixed food|experimental group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
16566105|NCT02839499|Other|normal texture food|control group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
16566106|NCT02839486||vancomycin and cefoxitin pharmacokinetics|This is surgical prophylaxis and cefoxitin/vancomycin have to be administered to each patient of the study, before surgery
16566107|NCT02839473|Experimental|Hydrosorb® arm|Hydrogel Hydrosorb®
16566108|NCT02839473|Placebo Comparator|Placebo arm|Castalie water spray
16566109|NCT02839460||subjects with sarcopenia|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)
~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)
~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
16566110|NCT02839460||healthy, physically-active controls|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)
~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)
~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
16566111|NCT02839447||Normal Semen|"Semen that meet the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
16566112|NCT02839447||Abnormal Semen|"Semen that fail to achieve one or more of the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
16566113|NCT02839434||Treated with oral anticoagulants|Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.
16566114|NCT02839421|Experimental|Scaling and Root Planing plus moxifloxacin|The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.The experimental treatment group consist of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days.One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the MOX group will be extensively informed about the intake of the prescribed medication.
16566115|NCT02839421|Active Comparator|Scaling and Root Planing plus amox-metro|"The active comparator is Scaling and Root Planing (SRP) combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days. The active comparator group consist of SRP combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days.
~One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the amox-metro group will be extensively informed about the intake of the prescribed medication."
16566116|NCT02839421|Placebo Comparator|Scaling and Root Planing plus placebo|Scaling and Root Planing (SRP) + placebo once daily for 7 days. The placebo comparator group consist of SRP combined with systemically administered placebo once daily for 7 days. One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The placebo agent will start at the SRP visit. Subjects in the placebo group will be extensively informed about the intake of the prescribed medication.
16566117|NCT02839408|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
16566118|NCT02839408|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months.
16566119|NCT02839408|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500mg Azithromycin
16566120|NCT02839395|Active Comparator|base line|First night is the base line- no exposure to computer screen illumination.
16566121|NCT02839395|Experimental|Acute|Second night is the acute exposure to computer screen illumination.
16566122|NCT02839395|Experimental|Chronic|Chronic is the effect after five nights of exposure to computer screen light illumination.
16566123|NCT02839382|Active Comparator|Coaching|External facilitation by a practice coach for 15 months
16566124|NCT02839382|Active Comparator|Educational Outreach|Academic detailing phone calls to support implementation of a cardiovascular risk calculator/estimator in each clinic
16566125|NCT02839382|Active Comparator|Site Visit|"Site visits made by practices to 'exemplar practices to learn innovative approaches to quality improvement"
16566126|NCT02839382|Active Comparator|Educational Outreach and Site Visit|In this arm of the study, practices will be offered both educational outreach and an opportunity for a site visit
16566127|NCT02839369||children|post Traumatic Brain Injury With Cerebral Palsy Typically developed
16566132|NCT02839330|Experimental|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
16566133|NCT02839330|Experimental|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
16566134|NCT02839330|Experimental|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
16566135|NCT02839330|Placebo Comparator|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
16566136|NCT02839317||Biological in pediatric CD|75 pediatric-onset CD Biological
16566137|NCT02839317||Biological in pediatric controls|75 pediatric controls matched on gender, age and area of residence Biological
16566138|NCT02839317||Biological in elderly CD|75 elderly-onset CD Biological
16566139|NCT02839317||Biological in elderly controls|75 elderly controls matched on gender, age and area of residence Biological
16566140|NCT02839304|Experimental|Catheter Ablation Treatment|Cryoablation System: Atrial Fibrillation Ablation
16566141|NCT02839291|Experimental|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
16566142|NCT02839278|Experimental|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
16566143|NCT02839265|Experimental|SBRT + FLT3 Ligand Immunotherapy|"Patients will be treated with stereotactic body radiotherapy (SBRT) to a single pulmonary or extrapulmonary lesion as well as FLT3 immunotherapy.
~FLT3 Ligand Therapy (CDX-301)
~Daily subcutaneous injections of CDX-301 (75 ug/kg) will be administered for 5 days, beginning on the first day of SBRT.
~Additional cycles of SBRT (to distinct lesions) and CDX-301 may be administered every 2-4 months to subjects who demonstrate evidence of clinical benefit (lack of treatment-related toxicity and no disease progression).
~Study therapy will be discontinued in cases of treatment-related toxicity or disease progression."
16566144|NCT02839252|Experimental|Intervention Group|After the baseline tools have been completed, the child will be given the Iggy Comic Book and trading cards. Parents and their children will then watch a 12-minute Iggy Video. At the completion of the video and prior to going home, the child and parent will complete the same 2 measures on asthma knowledge and self-efficacy. At 1-month after this clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
16566145|NCT02839252|No Intervention|Control Group|After the baseline tools have been completed, the parent and child will go home. At 1-month after the initial study clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
16566146|NCT02839239|Experimental|Drops with lactobacilli and vitamin D3|Exclusive breast feeding plus L. rhamnosus 19070-2 and L. reuteri DSM 12246 in a dose of 125 x 106 CFU (both strains) with 1,667 mg fructooligosaccharides and 2,5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
16566147|NCT02839239|Placebo Comparator|Drops with vitamin D3|Exclusive breast feeding plus 2.5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
16566148|NCT02839226|Active Comparator|AR/101|AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
16566149|NCT02839226|Placebo Comparator|Placebo|placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
16566150|NCT02839213|Active Comparator|group A (Hyoscine Butyl bromide group)|The women will be given Hyoscine Butyl bromide
16566151|NCT02839213|Active Comparator|group B (Saline group)|The women will be given saline
16566152|NCT02839200|Experimental|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
16566153|NCT02839200|Experimental|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
16566154|NCT02839200|Experimental|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
16566155|NCT02839200|Experimental|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
16566156|NCT02839200|Active Comparator|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
16566157|NCT02839200|Placebo Comparator|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
16566158|NCT02839187|Experimental|Patients with Alzheimer Disease|Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography
16566159|NCT02839187|Active Comparator|Controls patients|Controls will have neuroimaging by AV45-positron emission tomography
16566160|NCT02839161|Experimental|Low-dose (0,2,4 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
16566310|NCT02838095|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants had the chance to take a daytime nap from 14:00 to 15:00.
16566161|NCT02839161|Experimental|Low-dose (0,2,6 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
16566162|NCT02839161|Experimental|Medium-dose (0,2,4 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
16566163|NCT02839161|Experimental|Medium-dose (0,2,6 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
16566164|NCT02839161|Experimental|High-dose (0,2,4 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
16566165|NCT02839161|Experimental|High-dose (0,2,6 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
16566166|NCT02839161|Active Comparator|Comparator (0,2,4 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
16566167|NCT02839161|Active Comparator|Comparator (0,2,6 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.
16566168|NCT02839148|Experimental|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
16566169|NCT02839148|Experimental|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
16566170|NCT02839135|Experimental|Reformulated scopolamine patch|Participants will receive reformulated scopolamine Transdermal Delivery System (TDS) patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
16566171|NCT02839135|Active Comparator|Marketed scopolamine patch|Participants will receive currently marketed scopolamine TDS patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area, with delivery of approximately 1.0 mg over 72 hours.
16566172|NCT02839122|Experimental|Dutasteride, Tadalafil|
16566173|NCT02839122|Experimental|Tadalafil, Dutasteride|
16566174|NCT02839096|Other|Once Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and placebo in the evening
16566175|NCT02839096|Other|Twice Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and 325mg of ferrous sulfate in the evening
16566176|NCT02839083|Placebo Comparator|Thoracic Paravertebral group|Ultrasound guided thoracic paravertebral block
16566177|NCT02839083|Active Comparator|Pecs II group|Ultrasound guided Pecs II block
16566178|NCT02839070|Experimental|Regular Schedule|Participant will be on a regular sleep/wake schedule
16566179|NCT02839070|Experimental|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
16566180|NCT02839057||Surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated with surgical fracture stabilisation
16566181|NCT02839057||Non-surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated non-surgically
16566182|NCT02839044|Experimental|Vitamin K|One group receives tablets of 360 microgram menaquinone-7 daily
16566183|NCT02839044|Placebo Comparator|Placebo|One group receives placebo tablets daily
16566184|NCT02839031|Experimental|"CBT group"|
16566185|NCT02839031|Sham Comparator|Control group|
16566186|NCT02839018||Central nervous system (CNS) group|n=50 patients with presumed low prevalence of ICU-AW
16566187|NCT02839018||Severe sepsis/shock group|n=50 patients with presumed high prevalence of ICU-AW
16566188|NCT02839005|Active Comparator|suture with polyglecaprone 25|
16566189|NCT02839005|Active Comparator|suture with polyamide (nylon)|
16566190|NCT02838992|Experimental|ATG, Cy and cord blood transfusion group|"ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.
~Intervention:
~Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion"
16566191|NCT02838992|Active Comparator|ATG and CSA group|ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA
16566192|NCT02838979|Experimental|Oral L-Glutamine (0.4mg/kg/day)|Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses. Duration 2 weeks
16566193|NCT02838979|Placebo Comparator|Maltodextrin|Identical appearing maltodextrin powder.
16566194|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 1|1 can per day for 5 days prior to surgery
16566195|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 2|2 cans per day for 5 days prior to surgery
16566196|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 3|3 cans per day for 5 days prior to surgery
16566197|NCT02838966|Active Comparator|Nestle Boost High Protein Drink - Control Arm|4 cans per day for 5 days prior to surgery
16566198|NCT02838953|Experimental|COPD patients|COPD patients submitted to Pulmonary Rehabilitation according to the ATS/ERS statement.
16566199|NCT02838953|No Intervention|Control|"Healthy individuals who will undergo the same COPD's evaluation protocol. As healthy individuals they will not participate to the Pulmonary Rehabilitation."
16566200|NCT02838940|Experimental|cesarean in different indications|Women that are about to undergo an elective cesarean in different indications.
16566201|NCT02838927||Hypoparathyroidism|No intervention.
16566202|NCT02838914|Experimental|patients with AF|Before radiofrequency ablation (RFCA)
16566203|NCT02838914|Experimental|Assigned Comparisons|After radiofrequency ablation (RFCA)
16566204|NCT02838901|Experimental|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
16566205|NCT02838901|Placebo Comparator|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
16566206|NCT02838888||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
16566207|NCT02838875|Experimental|Pregnant women at risk population|women who arrived to the delivery room at Lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because of their affiliation to the at-risk population.
16566208|NCT02838862||Response to Therapy|
16566209|NCT02838862||No therapy response|
16566210|NCT02838849|Sham Comparator|Fiber|Participants were treated with 2 sachets of fiber orally a day for 14 days, after baseline characterization of bowel habit and stool features.
16566211|NCT02838849|Active Comparator|Fiber and Water|Participants were treated with 2 sachets of fiber orally a day and ingested 2 liters of water a day for 14 days, after baseline characterization of bowel habit and stool features.
16566213|NCT02838823|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
16566214|NCT02838810|Experimental|Experimental|CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1000 IU/mL and Hepatitis B virus DNA <100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
16566215|NCT02838810|Other|Control|Patients do not need to change their NAs treatment.
16566216|NCT02838797|Placebo Comparator|Placebo|"For the single ascending dose study, subjects will receive a single dose of oral acetate buffer on a single day.
~For the multiple ascending dose study, subjects will receive a single daily dose of oral acetate buffer each day for 14 days."
16566217|NCT02838797|Experimental|RQ-00000010|"For the single ascending dose study, subjects will receive a single dose of either:
~2 micrograms, 50 micrograms or 200 micrograms of RQ-00000010 on a single day.
~For the multiple ascending dose study, subjects will receive single daily doses of either 10 micrograms, 50 micrograms or 100 vs. 200 micrograms of RQ-00000010 each day for 14 days."
16566218|NCT02838784|Experimental|Artacent Human Amniotic Membrane|Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
16566219|NCT02838784|Active Comparator|Lower Extremity Ulcer Standard of Care|Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
16566220|NCT02838771|Experimental|Research group participants|"Research group consisted of 171 elderly nursing home residents and 82 outpatients of the Hospital of Lithuanian University of Health Sciences.
~The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening)."
16566221|NCT02838771|Other|Control group participants|Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
16566222|NCT02838758|Experimental|Cryoablation|Ultrasound guided perineural cryoablation. The mechanism of therapeutic cryoablation involves using short and repeated cycles of freezing and thawing to cause axonal degeneration and disrupt neuronal activity without damage to epineurium and perineurium.
16566223|NCT02838758|Active Comparator|Lidocaine|Ultrasound guided perineural lidocaine injection. Under ultrasound guidance, roughly 3cc of 2% lidocaine will be injected near the neuroma.
16566224|NCT02838758|Placebo Comparator|Saline|Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
16566225|NCT02838745|Experimental|Pemetrexed and Cisplatin|• Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
16566226|NCT02838732|Experimental|vegetarian|oral L-carnitine for one month
16566227|NCT02838732|Sham Comparator|omnivore|oral L-carnitine for one month
16566228|NCT02838719|Experimental|Perineural group|Group 1: perineural dexamethasone acetate added to bilateral transverse abdominis plane block with levobupivacaine
16566229|NCT02838719|Active Comparator|Intravenous group|Group 2: Intravenous dexamethasone acetate added with bilateral transverse abdominal plane block with levobupivacaine
16566230|NCT02838706||Elderly with hip fracture|The subjects are patients age ≥ 65 years requiring surgery for a hip fracture
16566231|NCT02838693||APT-2D (Normoglycemic)|800 Normoglycemic
16566232|NCT02838693||APT-2D (Pre-Diabetic)|1,500 Pre-Diabetic
16566233|NCT02838680|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
16566234|NCT02838667|No Intervention|Standard of Care|If participants are randomized into the non-intervention group, the participants' information during the study period will be collected. Participants will be managed by a care provider as per the standard of care. Participants may receive nephrology consultation as indicated clinically.
16566235|NCT02838667|Experimental|Standard of Care plus Nephrology Care|If participants are randomized into the intervention group, participants' information will be checked by the study investigators daily for 7 days (2 days pre-op and 5 days post-op). When appropriate, investigators may give suggestions to minimize the participants' risk(s) for AKI. Participant's primary care providers may take the suggestions into consideration. Participants' primary care providers are not obligated to carry out the suggestions that are given.
16566237|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 5)|Participants were applied 50 milligrams (mg) of KX2-391 Ointment 1% topically on face or scalp in 25 centimeter square (cm^2) treatment area, once daily for 5 consecutive days.
16566238|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 3)|Participants were applied 50 mg of KX2-391 Ointment 1% topically on face or scalp in 25 cm^2 treatment area, once daily for 3 consecutive days.
16566239|NCT02838615|Active Comparator|epidural steroid injection|TF epidural steroid (dexamethasone) injection
16566240|NCT02838615|Active Comparator|IL epidural steroid injection|PS interlaminar epidural steroid(dexamethasone) injection
16566241|NCT02838602|Experimental|Carbon ions therapy|Radical and exclusive carbon ions radiotherapy
16566242|NCT02838602|Active Comparator|Conventional radiotherapy|Radical radiotherapy by Xrays and / or protons
16566243|NCT02838589|Active Comparator|Byetta|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
16566244|NCT02838589|Placebo Comparator|Isotonic saline|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
16566245|NCT02838576|Experimental|Conjugated Equine Estrogen|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.
~The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.
~During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug."
16566246|NCT02838576|Placebo Comparator|Placebo|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.
~The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.
~During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo."
16566247|NCT02838563||Patient living in nursing home|Patient with an Alzheimer Disease or related disorder living in nursing home.
16566248|NCT02838550|Experimental|MOI and PEDOMETER|Accessing to a motivational online intervention and wearing an unblinded pedometer (in order to receive feedback of the steps taken).
16566249|NCT02838550|Experimental|MOI (without PEDOMETER)|Accessing to a motivational online intervention and wearing a blinded pedometer (in order to not receive feedback of the steps taken).
16566250|NCT02838550|No Intervention|CONTROL|Wearing a blinded pedometer (in order to not receive feedback of the steps taken).
16566251|NCT02838537||Triptan Arm|"Users of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
16566252|NCT02838537||Ergot Arm|"Users of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
16566253|NCT02838511||Non-cardiac surgery|Hopkins Frailty Score (HFS) or Modified Frailty Index (MFI) will be obtained during during pre anesthesia evaluation
16566254|NCT02838498|Experimental|Intensive EMS training group|"Device: ERCP mechanical simulator training EMS group was coached (by JWL) on how to use the EMS, and then practiced with supervision by a senior surgeon biliary endoscopist (WBM). Trainees practiced for a total of 20 hours performing basic maneuvers including scope insertion 2 hours, scope positioning 6 hours, selective guide wire cannulation of common bile duct (CBD) stricture or pancreatic duct (PD) 10 hours and placement of a biliary stent 2 hours.
~All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over."
16566255|NCT02838498|No Intervention|Routine ERCP training group|Other: Routine ERCP training group All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over.
16566256|NCT02838485|Experimental|Amputees|The subjects will receive both mirror and imagery treatments in a cross-over design.
16566257|NCT02838446|Experimental|Cognitive Therapy|Graded motor imagery program was applied in only intervention group for 8 weeks.
16566258|NCT02838446|Active Comparator|Control|Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
16566259|NCT02838433|Experimental|Biological samples|"Blood samples will be collected :
~at baseline,
~6 months after the first-line therapy or at disease progression (if occurs first).
~In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected :
~at baseline
~3 months after the initiation of immunotherapy or targeted therapy
~at disease progression Tumor tissues will be collected if available."
16566260|NCT02838420|Experimental|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
16566261|NCT02838420|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
16566262|NCT02838407|Other|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
16566263|NCT02838394|Experimental|Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
16566264|NCT02838394|Sham Comparator|Sham Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.
16566265|NCT02838381|Other|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.
~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
16566266|NCT02838355|Active Comparator|Standard Respiration Monitoring|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring throughout their stay in the ICU.
16566267|NCT02838355|Experimental|Standard Respiration Monitoring + Continuous ETCO2-NC|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring and continuous end-tidal capnography monitoring via nasal cannula (ETCO2-NC) throughout their stay in the ICU.
16566268|NCT02838342|Experimental|Metronomic cyclophosphamide and interferon-alpha|
16566269|NCT02838329|Active Comparator|room temperature - RT|Ropivacaine used for Epidural top-up administered at room temperature
16566270|NCT02838329|Experimental|body temperature BT|Ropivacaine used for Epidural top-up administered warmed to body temperature
16566271|NCT02838316|Experimental|150 x 106 dosage|10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR
16566272|NCT02838316|Experimental|300 x 106 dosage|10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR
16566273|NCT02838303|Other|Group A|Initial spray session: organophosphate. Crossover spray session: placebo
16566274|NCT02838303|Other|Group B|Initial spray session: placebo. Crossover spray session: organophosphate
16566275|NCT02838290|Experimental|Induction|
16566276|NCT02838290|Other|Control group|
16566277|NCT02838277||Lipedema|Women with all stages of lipedema
16566278|NCT02838277||Dercum's disease|Men and women with nodular, mixed and diffuse Dercum's disease
16566279|NCT02838277||Control|Sex, age and BMI matched controls.
16566280|NCT02838277||Familial Multiple Lipomatosis|Women and men with multiple lipomas and/or angiolipomas
16566281|NCT02838277||Madelung's disease|Men and women with different types of Madelung's disease.
16566282|NCT02838264|Experimental|Cohort 1|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
16566283|NCT02838264|Experimental|Cohort 2|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
16566284|NCT02838264|Experimental|Cohort 3|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
16566285|NCT02838264|Experimental|Cohort 4|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive the highest safe dose (mg) of PF-06463922 as a single-dose Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
16566286|NCT02838238|Experimental|X|Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
16566287|NCT02838238|Placebo Comparator|Placebo|Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
16566288|NCT02838225|Experimental|DA|docetaxel 75 mg/m², iv, day 1, doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1, every 3 weeks for 6 cycles
16566289|NCT02838225|Active Comparator|DAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
16566290|NCT02838212||Drug-related deaths|fatal adverse drug reactions
16566291|NCT02838212||non drug-related deaths|deaths for other causes different as drugs
16566292|NCT02838199|Experimental|TAVR|Transcatheter aortic valve replacement with SAPIEN 3
16566293|NCT02838199|Active Comparator|SAVR|Surgical aortic valve replacement
16566294|NCT02838186|Active Comparator|right colon in retroflexion|"polyp/adenoma detection
~feasibility"
16566295|NCT02838186|Active Comparator|right colon in forward view|polyp/adenoma detection
16566296|NCT02838173|Experimental|SPB|Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision
16566297|NCT02838173|Active Comparator|tissue infiltration|tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision
16566298|NCT02838160|Experimental|booklet Group|
16566299|NCT02838160|Experimental|Oral presentations group|
16566300|NCT02838160|Experimental|Clinical teaching in bedside Group|
16566301|NCT02838147|Experimental|Normal OGTT (Oral Glucose Tolerance Test)|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
16566302|NCT02838147|Experimental|Pathological OGTT - 1 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
16566303|NCT02838147|Experimental|Pathological OGTT - 2 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
16566304|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
16566305|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
16566306|NCT02838121|Experimental|Aclasta|Aclasta IV once annual for 2 years
16566307|NCT02838121|Placebo Comparator|Placebo|Placebo group
16566308|NCT02838108||patients with COPD|
16566309|NCT02838095|No Intervention|No nap|After each night with a 5-hour sleep opportunity, participants did not have a daytime nap opportunity, but instead watched documentaries.
16566311|NCT02838082|Experimental|Sleep Hygiene Protocol|Participants in this arm will undergo a 4 week sleep hygiene protocol
16566312|NCT02838082|Active Comparator|Standard of Care Protocol|Participants will undergo 4 weeks of current inpatient standard of care procedures in a rehabilitation facility
16566313|NCT02838069|Experimental|2x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
16566314|NCT02838069|Experimental|10x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
16566315|NCT02838069|Placebo Comparator|Placebo|0.5% glucose in saline with 4.5% albumin
16566316|NCT02838056|Experimental|epidural injection|epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
16566317|NCT02838043|Experimental|Participant|All participants will be experimental and receive Probio'Stick.
16566318|NCT02838030|Experimental|acetylsalicylic acid and L-arginine|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
16566319|NCT02838030|Placebo Comparator|acetylsalicylic acid and placebo|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
16566320|NCT02838017|Experimental|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
16566321|NCT02838017|Active Comparator|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
16566322|NCT02838004|Experimental|Single arm receiving Mini WELL Ready IOL|IOL implantation for cataract
16566323|NCT02837991|Experimental|CDX-014|"During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
~The planned dose of CDX-014 depends on the cohort assigned at enrollment."
16566324|NCT02837978|Experimental|Tacrolimus group|RA patients treated with tacrolimus, without MTX
16566325|NCT02837978|Active Comparator|Tacrolimus + MTX group|RA patients treated with tacrolimus and MTX
16566326|NCT02837965||diagnosed bullous pemphigoid|
16566327|NCT02837952|Active Comparator|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
16566328|NCT02837952|Placebo Comparator|Placebo|Placebo
16566329|NCT02837939|Experimental|Active|Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.
16566330|NCT02837939|Placebo Comparator|Control|Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm
16566331|NCT02837926|Experimental|women attending for cervical cancer screening|
16566332|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
16566333|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
16566334|NCT02837900|Placebo Comparator|Previous LT TX knee and right placebo|Previous left treated knee will have placebo treatment in this protocol.
16566335|NCT02837900|Placebo Comparator|Previous RT TX knee and left placebo|Previous right treated knee will have placebo treatment in this protocol.
16566336|NCT02837900|Active Comparator|Both TX with Active|Both knees with receive Active
16566337|NCT02837887|Experimental|Group I (immediate treatment)|Patients undergo computerized cognitive behavior therapy consisting of 45-60 minute sessions once per week for 8 weeks. Patients also complete the PHQ-9 and GAD7 at weeks 1, 3, 5, 7 and 8 and complete other questionnaires for 15-30 minutes each that assess psychosocial and physical symptoms.
16566338|NCT02837887|Experimental|Group II (wait-list)|Patients are placed on an 8-week wait-list and then undergo computerized cognitive behavior therapy and receive questionnaires as in Group I.
16566339|NCT02837874|Active Comparator|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
16566340|NCT02837874|Experimental|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
16566341|NCT02837861|Experimental|Experimental Group|Routine Nutritional Support plus supplemental IV amino acids, to begin within 24h of injury. (Target approximately 1.5-2g protein/kg/day)
16566342|NCT02837861|Active Comparator|Control Group|Routine Nutritional Support (i.e. enteral nutrition as tolerated, to begin as early as medically feasible)
16566343|NCT02837848|Experimental|Coactivation strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
16566344|NCT02837848|Active Comparator|Regular strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
16566345|NCT02837835|Experimental|continuous administration of ceftazidime|
16566346|NCT02837835|Experimental|intermittent administration of ceftazidime|
16566347|NCT02837822|Active Comparator|Stimulation Off|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn Off during the experiment."
16566348|NCT02837822|Active Comparator|Stimulation On|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn On during the experiment."
16566349|NCT02837809|Experimental|Intervention|Low Dose CT, annual or biennial, associated with primary prevention and pulmonary function test evaluation.
16566350|NCT02837809|No Intervention|Control|Program of primary prevention with pulmonary function test evaluation
16566351|NCT02837796|Active Comparator|inside-outside group|inside-out transobturator tape approach
16566352|NCT02837796|Active Comparator|outside-inside group|outside-in transobturator tape approach
16566353|NCT02837783|Experimental|290 μg linaclotide|Linaclotide Oral, once daily
16566354|NCT02837783|Placebo Comparator|Matching Placebo|Matching Placebo Oral, once daily
16566477|NCT02836886||Sézary syndrome|Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
16566355|NCT02837770|Active Comparator|Pacebo pill and Diclofenac Eye Drops|Pacebo pill will be administered 4 hours before the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
16566356|NCT02837770|Active Comparator|Oral Diclofenac and Diclofenac Eye Drops|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
16566357|NCT02837770|Placebo Comparator|Pacebo pill and Artificial Tears|Pacebo pill will be administered 4 hours before the IVI and one drop Artificial Tears will be instilled 45' prior to the IVI.
16566358|NCT02837757|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.
~Available tumor tissues samples will be collected."
16566359|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
16566360|NCT02837731|Experimental|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of < 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
16566361|NCT02837731|No Intervention|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
16566362|NCT02837718|Other|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
16566363|NCT02837705||carriers of a mutation in the Prion gene|Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status.
16566364|NCT02837705||family members of carriers of a mutation in the Prion gene|Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
16566365|NCT02837692|Experimental|Cohort 1|Participants assigned to Cohort 1 group A (elderly non-Asian), group B (young healthy non-Asian) and group C (healthy Japanese) will receive JNJ-42847922 10 mg, 3 hours after completing dinner.
16566366|NCT02837692|Experimental|Cohort 2|Participants assigned to Cohort 2 group A, group B and group C will receive JNJ-42847922 20 mg, 3 hours after completing dinner.
16566367|NCT02837692|Experimental|Cohort 3|Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
16566368|NCT02837692|Experimental|Cohort 4|Participants assigned to Cohort 4 group B will receive JNJ-42847922 60 or 80 mg, 3 hours after completing dinner.
16566369|NCT02837679|Experimental|Intervention|Geriatric follow up
16566370|NCT02837679|No Intervention|Control|Usual care
16566371|NCT02837666|Active Comparator|Exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group with exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
16566372|NCT02837666|Active Comparator|No exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group without exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
16566373|NCT02837653|Experimental|Experimental|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home, and a personalized Physical Activity Counseling based on the Cardiovascular Risk of Each Patient
16566374|NCT02837653|Active Comparator|Control|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home.
16566375|NCT02837640|Experimental|Treatment|"This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.
~patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months."
16566376|NCT02837614|Active Comparator|Group A (intramuscular dexamethasone)|In Group A patients, 1 ml of dexamethasone (4mg) administered in the deltoid muscle before commencement of surgical procedure
16566377|NCT02837614|Experimental|Group B (submucosal dexamethasone)|In Group B patients, 1 ml of dexamethasone was administered in submucosa after local anesthesia
16566378|NCT02837614|Placebo Comparator|Group C (control)|Group C patients continued without receiving any preoperative medication.
16566379|NCT02837601|Other|LOW AIS Pressure AirSeal®|AIS with an insufflation pressure target of 9mmHg ±1mmHg
16566380|NCT02837601|Other|HIGH AIS Pressure AirSeal®|AIS with an insufflation pressure target of 15mmHg ±1mm
16566381|NCT02837588|Active Comparator|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
16566382|NCT02837588|No Intervention|CONTROL|No intervention with radiofrequency treatment, only evaluation to usual drug treatment
16566383|NCT02837575|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses
16566384|NCT02837575|Placebo Comparator|Phosphate-buffered saline, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses
16566385|NCT02837562||Interventional Cardiology/Cath Lab Staff|"This is considered to be the case or group under study. These are Interventional Cardiology/ Cardiac Cath lab staff that are exposed to radiation as a result of their role as Cardiac Cath lab staff.
~Intervention: Slit lamp eye examination"
16566386|NCT02837562||Non-Interventional Cardiology/ Controls|"This is considered to be the control or comparison group. These are non-interventional cardiology/ non-cardiac cath lab staff that are not exposed to radiation as they do no operate/ work in the Cardiac Cath Lab.
~Intervention: Slit lamp eye examination"
16566387|NCT02837549|Experimental|Occupational therapy treatment|"Participants will undergo the following as appropriate:
~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations
~Application of the Physiotouch (a low-intensity negative pressure device)
~Passive Range of Motion
~Active Range of Motion
~Functional Activities"
16566388|NCT02837536|Active Comparator|Horizontal iCare|In the horizontal iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the horizontal position first and then their IOP measured with the iCare tonometer held in the vertical position.
16566389|NCT02837536|Active Comparator|Vertical iCare|In the vertical iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the vertical position first and then their IOP measured with the iCare tonometer held in the horizontal position.
16566390|NCT02837523||Observation|Patients with a Cystinosis disease or high-grade suspicion for Cystinosis disease
16566391|NCT02837510|Other|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
16566392|NCT02837497|No Intervention|Control|Standard ICU resuscitation practices
16566393|NCT02837497|Experimental|ICU-RESUS CPR Improvement Bundle|ICU-RESUS bundle implementation: 1) point-of-care bedside CPR training; and 2) post-cardiac arrest debriefings.
16566394|NCT02837484|Other|NuTech Affinity™ Membrane|Sharp dissection of the defect will be performed being careful not to violate the subchondral bone sparing the calcified cartilage layer. After hemostasis is reached, the defect will be treated with an Affinity™ patch stabilized with fibrin glue.
16566395|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
16566396|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
16566397|NCT02837458|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16566398|NCT02837458|Sham Comparator|Sham Stimulation|Electrodes are placed over the arm for a 30 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
16566399|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
16566400|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
16566403|NCT02837406||Doctors|specialists and general practitioners by ich territory
16566404|NCT02837406||Health professionals|"pharmacists
~nurses
~physiotherapists
~Medical and social professionals: social workers, psychologists, educators ..."
16566405|NCT02837406||Medical-social institutes|"Hospital,
~Healthcare structure,
~Local Centre of Information and Gerontological Coordination ..."
16566406|NCT02837393||History of Kidney Stones|Participants with a history of kidney stones who will be undergoing kidney surgery.
16566407|NCT02837393||No History of Kidney Stones|Participants without a history of kidney stones who will be undergoing kidney surgery.
16566408|NCT02837380|Experimental|FF/UMEC/VI|Subjects will receive single combination dose of FF/UMEC/VI 100/62.5/25 mcg via a DPI in the morning for 7 days.
16566409|NCT02837367|Experimental|Adult intervention|"The intervention will consist Administration of supplements containing methyl-donors (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
16566410|NCT02837367|Placebo Comparator|Adult placebo|"The intervention will consist of the Administration of supplements containing methyl-donors (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
16566411|NCT02837367|Experimental|Children intervention|"The intervention will consist of the Administration of supplements containing methyl-donors (as syrup) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
16566412|NCT02837367|Placebo Comparator|Children Placebo|"The intervention will consist of Administration of supplements containing methyl-donors (as syrup) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
16566413|NCT02837367|No Intervention|Adults genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.
16566478|NCT02836873|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
16566414|NCT02837367|No Intervention|Children genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.
16566415|NCT02837341|Other|Volunteers|Monitoring of respiratory rates via camera-based System Monitoring of respiratory rate by Philips®Vital Sign Device - Camera-based system (Prototype) and capnography simultaneously.
16566416|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
16566417|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
16566418|NCT02837315|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS was described to participants as the College Adjustment Session and the session was conducted using an MI plus personalized feedback approach."
16566419|NCT02837315|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students were asked about their reaction to the relaxation techniques and were provided with relaxation training handouts.
16566420|NCT02837315|No Intervention|Assessment|Participants fill out a battery of measures and receive no intervention.
16566421|NCT02837302|Active Comparator|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
16566422|NCT02837302|No Intervention|General nutritional support|General nutritional support
16566423|NCT02837289|Other|Treatment|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
16566424|NCT02837289|Other|Placebo|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
16566425|NCT02837263|Experimental|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
16566426|NCT02837250|Experimental|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
16566427|NCT02837250|Active Comparator|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
16566428|NCT02837237|Experimental|KBP-5074|Single oral dose
16566429|NCT02837224||Preimplementation: Situate Locate System|Subjects/surgeries performed before implementation of the Situate Detection System.
16566430|NCT02837224||Implementation|Subjects/surgeries performed after implementation of the Situate Detection System.
16566431|NCT02837211|Experimental|Tapered Diet|
16566432|NCT02837211|Active Comparator|Traditional Low Calorie Diet|
16566433|NCT02837198|Experimental|Uric acid-overproduction Type|FYU-981
16566434|NCT02837198|Experimental|Uric acid- underexcretion Type|FYU-981
16566435|NCT02837198|Experimental|Uric acid-overproduction Type (combination)|FYU-981 , Topiroxostat
16566436|NCT02837198|Experimental|Uric acid- underexcretion Type2|FYU-981
16566437|NCT02837185|Experimental|Cervical Dystonia|'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
16566438|NCT02837185|Other|Healthy controls|No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.
16566439|NCT02837172||Parkinson's disease from UAB|MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, Diffusion Weighted Imaging (DWI), and neurological examination.
16566440|NCT02837172||Parkinson's disease from PPMI dataset|Obtain retrospective and prospective de-identified data from the The Parkinson's Progression Markers Initiative (PPMI) dataset on Parkinson's disease (PD) subjects that have the following characteristics: within 2 years of diagnosis, positive DaTscan, and not (at study entry) on any PD related medication.
16566441|NCT02837172||Controls from PPMI dataset|Obtain retrospective and prospective de-identified DTI imaging and data from the PPMI dataset
16566442|NCT02837159|Experimental|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
16566443|NCT02837159|No Intervention|Usual care|Usual care
16566444|NCT02837146|Experimental|Tocilizumab (TCZ) + Methotrexate (MTX)|"Induction phase:
~From week 0 to week 24, all subjects will receive TCZ and MTX
~Maintenance phase:
~From week 24 to week 54, all subjects will receive MTX"
16566445|NCT02837133|Experimental|other techniques group|theory and practice of pair massage with tapping, stretching of the ankle and neck, and autogenic training
16566593|NCT02836054|Other|Patients without cognitive disorders|lumbar punction + brain MRI
16566446|NCT02837107|Active Comparator|Supplement|The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
16566447|NCT02837107|Placebo Comparator|Placebo|A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
16566448|NCT02837094|Experimental|C19-A3 GNP (Gold Nanoparticles)|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold. Solution For Injection The dose given will be equivalent to 10ug of C19A3 peptide at 3 dispensing visits, which are 4 weeks apart. Total 30ug.
16566449|NCT02837081|Active Comparator|Preauthorization group|Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.
16566450|NCT02837081|Experimental|Prospective audit|Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
16566451|NCT02837068|Experimental|Wheelchair handrail compensator|When a patient sitting on the wheelchair, the physiotherapist put the paralysis upper limb on the handrail compensator and keep the limb in normal position for at least 60 minutes one day.
16566452|NCT02837068|Active Comparator|Ordinary wheelchair|When a patient sitting on the wheelchair, the paralysis upper limb was put on the ordinary handrail for at least 60 minutes one day.
16566453|NCT02837055|Experimental|VivaSight intubation|Patients are intubated with the VivaSight-SL endotracheal tube
16566454|NCT02837055|Active Comparator|conventional intubation|Patients are intubated with a conventional endotracheal tube
16566455|NCT02837042|Experimental|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
16566456|NCT02837029|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16566457|NCT02837016|Experimental|Experimental 1|Wearable biofeedback device + Relaxation Training
16566458|NCT02837016|Active Comparator|Experimental 2|Relaxation Training only
16566459|NCT02837003||Experimental: Aspirin|Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
16566460|NCT02837003||Experimental: Thienopyridine|Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
16566461|NCT02836990|Active Comparator|Prevena|Prevena Incision Management System for vascular surgical groin wounds
16566462|NCT02836990|Active Comparator|Dermabond|Dermabond for vascular surgical groin wounds
16566463|NCT02836977|Experimental|maintenance therapy|Patients will receive oral tegafur-uracil 400mg/day (100mg/Cap., 2 capsules each time, twice a day), combined with oral folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day), and continue for one year.
16566464|NCT02836977|Active Comparator|observation arm|Patients will be observed following adjuvant oxaliplatin-based regimen.
16566465|NCT02836964|Active Comparator|Loading of Dental Implants after 4 weeks|"A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar. for this group.
~After 4 weeks definitive crown will be placed."
16566466|NCT02836964|Active Comparator|Loading of Dental Implants after 3 months|A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar for this group. After 3 months definitive crown will be placed
16566467|NCT02836951||Patient|This group consists of patients that are hospitalized due to a head injury. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
16566468|NCT02836951||Healthy controls|This group consists of healthy volunteers. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
16566469|NCT02836938||Severe|Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
16566470|NCT02836938||Mild|Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
16566471|NCT02836938||Control|Bronchiolitis obliterans syndrome (BOS), stage 0
16566472|NCT02836925|Experimental|Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir|The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
16566473|NCT02836912|No Intervention|Regular education|Regular education for COPD, including percussion and posture drainage.
16566474|NCT02836912|Experimental|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group.
16566475|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
16566476|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
16566479|NCT02836873|Placebo Comparator|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
16566480|NCT02836860|Other|Healthy Controls|Effects of tactile stimulation on lumbar multifidus activation in healthy adults without LBP.
16566481|NCT02836860|Other|Low Back Pain|Effects of tactile stimulation on lumbar multifidus activation in adults with LBP.
16566482|NCT02836847|Experimental|target therapy|The patients wil receive conventional chemotherapy(GEMOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
16566483|NCT02836847|Other|GEMOX|The patients wil receive conventional chemotherapy(GEMOX).
16566484|NCT02836834|Experimental|Dose Escalation Cohort|JS001
16566485|NCT02836834|Experimental|Expanded cohort 1|The subjects of expanded cohort 1 will use repeated doses every 2 weeks like multiple dose cohorts
16566486|NCT02836834|Experimental|Expanded cohort 2|The subjects of expanded cohort 2 will use repeated doses every 2 weeks like multiple dose cohorts
16566487|NCT02836821|Experimental|Apatinib|subjects receiving a single 750 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then rifampicin capsules 600 mg/day orally for 10 days with a single 750 mg oral dose of apatinib mesylate tablets co-administered on day 8 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
16566488|NCT02836808|No Intervention|Control|Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area
16566489|NCT02836808|Experimental|CAIPaDi|Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day
16566490|NCT02836795|Experimental|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
16566491|NCT02836782||Naive patients|Patients who begin their first antiretroviral regimen. Blood sample withdrawal
16566492|NCT02836782||Experienced patients|"Patients with a history of antiretroviral treatment, switching to a new regimen.
~Blood sample withdrawal"
16566493|NCT02836769|Experimental|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
16566494|NCT02836743|Experimental|Circadin 2mg|low-dose (2mg) slow-release melatonin for 1 month.
16566495|NCT02836743|Experimental|Circadin 6mg|high-dose (6mg) slow-release melatonin for 1 month.
16566496|NCT02836743|Placebo Comparator|Placebo|Administer placebo pills with identical morphology
16566497|NCT02836730||Lumbar disc herniation|Patients with surgery for lumbar disc herniation;
16566498|NCT02836730||Spinal stenosis|Patients with surgery for lumbar spinal stenosis
16566499|NCT02836730||No surgery|Patients with no surgery for lumbar disc herniation; patients with no surgery for lumbar spinal stenosis;
16566500|NCT02836704|Active Comparator|Standard initial dose of insulin glargine|Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
16566501|NCT02836704|Experimental|Higher initial dose of insulin glargine|Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
16566502|NCT02836691|Active Comparator|EKG to Control subjects|healthy controls without asthma or other respiratory disease.
16566503|NCT02836691|Active Comparator|EKG monitoring Mild asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
16566504|NCT02836691|Active Comparator|EKG monitoring severe control asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
16566505|NCT02836691|Active Comparator|EKG monitoring severe uncontrolled asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
16566506|NCT02836678|Active Comparator|Control group|Ridge splitting, immediate implantand PRF.
16566507|NCT02836678|Experimental|Test group|Ridge splitting, immediate implant, Nanobone with PRF.
16566508|NCT02836665|No Intervention|A: Control group|Patients of group A wait routinely until the dermatological investigator in charge arrives at the emergency room. Once the dermatological investigator is on site, he gives a diagnosis and proposes a therapy.
16566509|NCT02836665|Experimental|B: Telemedicine for dermatological emergency patients|"For Patients of group B study-related photographs of the skin lesion and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal."
16566510|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
16566511|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
16566512|NCT02836639|Experimental|Busulfan, Etoposide, Bendamustine|All patients will receive the conditioning regimen followed by autologous stem cell transplantation.
16566513|NCT02836626|Experimental|Deep Fascial Mobilization|
16566514|NCT02836626|Experimental|Superficial Fascial Mobilization|
16566515|NCT02836613|Active Comparator|Galcanezumab Reference|Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
16566516|NCT02836613|Experimental|Galcanezumab Test|Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
16566517|NCT02836600|Experimental|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
16566518|NCT02836587|Experimental|interventional|Experimental group will undergo balance training for 8 weeks.
16566519|NCT02836587|No Intervention|control|Control group will have no assigned intervention.
16566520|NCT02836574|Experimental|Immediate Treatment|Renal Autologous Cell Therapy (REACT) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
16566521|NCT02836574|Active Comparator|Delayed Treatment|Renal Autologous Cell Therapy (REACT) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after REACT product is made available before receiving 2 injections of REACT.
16566522|NCT02836561|Experimental|Intervention Message|Participants who are randomized to the intervention message will receive contraception information in advance of their appointment that may be helpful in their decision-making.
16566523|NCT02836561|No Intervention|Control Message|Participants who are randomized to the control message will receive appointment logistic information that may be a helpful reminder.
16566524|NCT02836548|Experimental|vorinostat|Vorinostat 360 mg once daily
16566525|NCT02836535||patients with complications|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential. The interview will examine the impact of complications utilizing a semi-structured script specific to each group
16566526|NCT02836535||patients without Complications (control group)|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential.
16566527|NCT02836509|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
16566528|NCT02836509|Experimental|Ibuprofen group|Second Group: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
16566529|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
16566530|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
16566531|NCT02836483|Experimental|Group 1|LCB01-0371 800mg, QD
16566532|NCT02836483|Experimental|Group 2|LCB01-0371 400mg, BID
16566533|NCT02836483|Experimental|Group 3|LCB01-0371 800mg, BID
16566534|NCT02836483|Active Comparator|Group 4|Tubes 3~5Tablet, QD
16566535|NCT02836483|Active Comparator|Group 5|Zyvox 600mg, BID
16566536|NCT02836483|Experimental|Group 6|LCB01-0371 1200mg, QD
16566537|NCT02836470|Experimental|LB1148|Active
16566538|NCT02836470|Placebo Comparator|Placebo|Placebo
16566539|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
16566540|NCT02836431|Experimental|DEX 1 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
16566541|NCT02836431|Experimental|DEX 2 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
16566542|NCT02836431|Experimental|DEX 1 mcg/kg Intravenous|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
16566543|NCT02836418|Experimental|ATYR1940|All patients will receive ATYR1940 at the highest tolerated dose received in the parent study for 12-weeks. After 12 weeks, if the patient is demonstrating good tolerability, theATYR1940 dose may be increased on a patient-specific basis at the Investigator's discretion, in consultation with the Sponsor and Medical Monitor. ATYR1940 dose increases to >3.0 mg/kg are not permissible.
16566544|NCT02836405||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder (ASD) will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
16566545|NCT02836405||Healthy Control|Typically developing individuals without a history of autism will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
16566546|NCT02836379||Breakthrough Cancer Pain|No intervention (Non-interventional study)
16566547|NCT02836353|No Intervention|Observational only|Oral glucose tolerance test, neurocognitive questionnaire tasks only.
16566548|NCT02836353|Experimental|Somatostatin|Oral glucose tolerance test after 100mcg Somatostatin
16566549|NCT02836353|Experimental|Antibiotics|Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth
16566550|NCT02836340|Experimental|2-Iminobiotin|Increasing dosage of study drug
16566551|NCT02836327||Multiple sclerosis|Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
16566552|NCT02836327||Neuromyelitis optica spectrum disorders|Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
16566553|NCT02836327||Health control|Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.
16566554|NCT02836314|Experimental|PRF and ABBM|Intervention: Anorganic Bovine Bone Mineral and Platelet Rich fibrin is applied to the periodontal intrabony defects
16566555|NCT02836314|Active Comparator|Anorganic Bovine Bone Mineral|Intervention: Anorganic Bovine Bone Mineral is applied to the periodontal intrabony defects
16566556|NCT02836301|Active Comparator|Testimonials-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
16566557|NCT02836301|Active Comparator|Testimonials-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
16566618|NCT02835859|Experimental|Group 1- Oral solution|Participants will be randomly assigned to drink two oral solutions made of different combinations of saccharin, lactisole, acetaminophen, 3-O-methyl glucose, or glucose.
16566558|NCT02836301|Active Comparator|Testimonials-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
16566559|NCT02836301|Experimental|Documentary-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
16566560|NCT02836301|Experimental|Documentary-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
16566561|NCT02836301|Experimental|Documentary-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
16566562|NCT02836288|Experimental|Ketamine|Oral ketamine 1.0 mg/kg mixed with syrup
16566563|NCT02836288|Placebo Comparator|Placebo|Oral placebo (syrup)
16566564|NCT02836288|Experimental|Ketamine after placebo|Optional oral Ketamine 1.0 mg/kg mixed with syrup for patients on placebo arm after 12 week treatment is completed.
16566565|NCT02836275|Experimental|Perfusion and diffusion-weighted MRI|
16566566|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
16566567|NCT02836249|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
16566568|NCT02836249|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
16566569|NCT02836249|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
16566570|NCT02836236|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
16566571|NCT02836236|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
16566572|NCT02836236|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
16566573|NCT02836223|Experimental|Interdental device|Water Flosser
16566574|NCT02836223|Other|Toothbrush|Control
16566575|NCT02836210|Active Comparator|Angled incision|Patients in this arm will undergo 27-gauge vitrectomy wound construction using angled (tunnel-like) incisions for trocar entry.
16566576|NCT02836210|Active Comparator|Straight Incision|Patients in this arm undergo 27-gauge vitrectomy wound construction using straight (perpendicular) incisions for trocar entry.
16566577|NCT02836197|Experimental|Experimental group|This group of 30 physicians will immediately attend the intervention communication skills training program (experimental group).For this experimental group, the first assessment will take place before the first training session and the second recording after the last session. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
16566578|NCT02836197|No Intervention|Waiting-list group|This group of 30 physicians will attend the intervention communication skills training in a delayed manner (control group). For this control group, the first and the second recording will take place with a four-month interval. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
16566579|NCT02836184|Active Comparator|control group|Group treated with calcium carbonate for 6 weeks first,then switch to nicotinic acids treatment after 2 week of wash-out.
16566580|NCT02836184|Experimental|nicotinic acids group|Group treated with nicotinic acids for 6 weeks first,then switch to calcium carbonate treatment after 2 week of wash-out.
16566581|NCT02836171|Experimental|Treatment|subjects receiving a single 250 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then Itraconazole capsules 100 mg/day orally for 6 days with a single 250 mg oral dose of apatinib mesylate tablets co-administered on day 4 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
16566582|NCT02836158|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
16566583|NCT02836132|Active Comparator|Weight Watchers Online|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform.
16566584|NCT02836132|Experimental|Weight Watchers Online + Experience Success|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
16566585|NCT02836106|Experimental|Healthy|Lean subjects (BMI<25) with a waist circumference of <94 cm for men and<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
16566586|NCT02836106|Experimental|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
16566587|NCT02836093||evaluations/assessments|
16566588|NCT02836080|Experimental|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services [EMYS]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
16566589|NCT02836080|Active Comparator|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.
~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
16566590|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:
~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
16566591|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:
~Questionnaires Blood Draw Bronchoscopy"
16566592|NCT02836054|Other|Patients with cognitive disorders|lumbar punction + brain MRI
16566594|NCT02836041||Pediatrics cancer patients|Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.
16566595|NCT02836028|Experimental|talazoparib|Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
16566596|NCT02836028|Active Comparator|talazoparib + temozolomide|Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
16566597|NCT02836015|Experimental|Shared Medical Visit Groups|All patients will be enrolled in the experimental group and will be involved in shared medical visits.
16566598|NCT02836002|Experimental|Group 1 - SP low/SP high|"Group 1 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.
~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).
~Group 1 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
16566599|NCT02836002|Experimental|Group 2 - SP low/Pip high|"Group 2 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.
~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).
~Group 2 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
16566600|NCT02836002|Experimental|Group 3 - Pip low/Pip high|"Group 3 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.
~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).
~Group 3 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
16566601|NCT02836002|Experimental|Group 4 - Pip low/SP high|"Group 4 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.
~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).
~Group 4 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
16566602|NCT02835989|Experimental|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.
~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
16566603|NCT02835989|No Intervention|Control|Usual Care
16566604|NCT02835976|Experimental|Olesoxime|Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
16566605|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
16566606|NCT02835937|No Intervention|Transfuse|Patients will receive a transfusion under standard care
16566607|NCT02835937|Experimental|No-Transfuse|Patients will not receive a transfusion
16566608|NCT02835924|Active Comparator|Arm A|160 mg/day 3w on/1w off
16566609|NCT02835924|Experimental|Arm B|120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
16566610|NCT02835924|Experimental|Arm C|160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
16566611|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
16566612|NCT02835898||Test Group|Patients with periodontal disease that need conventional periodontal treatment
16566613|NCT02835898||Control Group|Periodontally-healthy individuals.
16566614|NCT02835885|Experimental|Active tVNS Stimulation|Stimulating electrode will be placed on left tragus of subject. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied.The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
16566615|NCT02835885|Sham Comparator|Sham tVNS Stimulation|Stimulating electrode will be placed on left ear lobe of subject for sham tVNS stimulation condition. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied. The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
16566616|NCT02835872|Placebo Comparator|Cellulose control|3 g Insoluble Fiber (Cellulose)/d contained within drinks and crackers
16566617|NCT02835872|Active Comparator|Soluble fiber treatment|3 g soluble dietary fiber test ingredient contained within drinks and crackers
16567037|NCT02833038|Placebo Comparator|Control group|Intravenous administration of normal saline
16566619|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
16566620|NCT02835833|Experimental|Nintedanib 150 mg + Bevacizumab 15 mg/kg|"The first three patients on study will be treated with 150 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
~If one dose limiting toxicity occurs in the first cohort, then three more patients will be treated at that same starting dose and assessed for toxicity after cycle two. If two or more patients have dose limiting toxicity, then dose escalation will end and the maximum tolerated dose will be reached."
16566621|NCT02835833|Experimental|Nintedanib 200 mg + Bevacizumab 15 mg/kg|If no patients experience dose limiting toxicity, then three additional patients will be treated with 200 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
16566622|NCT02835820|Experimental|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
16566623|NCT02835820|No Intervention|Patient Choice Diet|Control.
16566624|NCT02835807|Experimental|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
16566625|NCT02835807|Active Comparator|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
16566626|NCT02835794|Experimental|Arm 1|Omacetaxine - escalating doses subcutaneous twice daily on Days 1-5 and 8-12 Azacitidine 50 mg/m2 subcutaneous/intravenous daily on Days 8-12 G-CSF 5mcg/kg subcutaneous daily on Days 15-19 and 22-26
16566627|NCT02835781||Acellular dermal matrix arm|The females undergoing breast reconstruction surgery after breast removal because of breast cancer. The breast reconstruction will be performed using acellular dermal matrix implantation.
16566628|NCT02835768|Experimental|Intervention|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Participants will be given an additional leaflet about the domestic safety website with address link and brief introductory information.
16566629|NCT02835768|No Intervention|Control|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Only this booklet serves as the anticipatory guidance to mothers about domestic safety.
16566630|NCT02835755|Active Comparator|Group I (Control)|Patients receive standard information about HPV and HPV vaccine, such as the VIS, on a mobile-friendly website study portal.
16566631|NCT02835755|Experimental|Group II (mHealth HPV vaccine)|Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail.
16566632|NCT02835742|Active Comparator|Group1|Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
16566633|NCT02835742|Placebo Comparator|Group2|Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
16566634|NCT02835729|Experimental|Phase 1a|"Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
~All current subjects will transition from indoximod freebase capsules over to indoximod HCL F2 tablets. All new subjects enrolled will also receive indoximod HCL F2 tablets."
16566635|NCT02835729|Experimental|Phase 1b (CLOSED TO ACCRUAL)|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL F1 formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
16566636|NCT02835703|Active Comparator|Deep hypothermic arrest|Surgical repair of coarctation of aorta under deep hypothermic circulatory arrest
16566637|NCT02835703|Active Comparator|Selective antegrade cerebral perfusion|Surgical repair of coarctation of aorta using selective antegrade cerebral perfusion
16566638|NCT02835703|Active Comparator|Double arterial cannulation|Surgical repair of coarctation of aorta using cerebral antegrade perfusion with descending aortic cannulation
16566639|NCT02835690|Experimental|Pembrolizumab 2 mg/kg|Participants receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
16566640|NCT02835690|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
16566641|NCT02835690|Experimental|Pembrolizumab 200 mg Fixed Dose|Participants receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
16566642|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
16566643|NCT02835664|Experimental|Nicotinamide Riboside|Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
16566884|NCT02834039|Active Comparator|Tidal volume 6 ml/kgBW|Tidal volume 6 ml/kgBW was given to patients after endotracheal tube was inserted properly
16566644|NCT02835664|Placebo Comparator|Placebo|Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
16566645|NCT02835651|Experimental|Palmitic acid|Diet rich in palmitic acid
16566646|NCT02835651|Experimental|Stearic acid|Diet rich in stearic acid
16566647|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)
~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
~Women selected for further assessment (positive screening exam) will be recalled."
16566648|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
16566649|NCT02835612|Experimental|Early stimulation|skin-to skin care by mother (kangaroo care) plus massage therapy by mothers.
16566650|NCT02835612|Active Comparator|Conventional care|skin-to skin care by mother (kangaroo care).
16566651|NCT02835586|Experimental|paclitaxel delivery in femoropopliteal artery|
16566652|NCT02835573||Sepsis-induced myocardial injury group|Patients admitted to the hospital with the diagnosis of Sepsis-induced myocardial injury
16566653|NCT02835573||Blank control group|Patients admitted to the hospital without the diagnosis of Sepsis-induced myocardial injury
16566654|NCT02835560|Experimental|Experimental|Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid
16566655|NCT02835560|Active Comparator|Active Comparator|"Esoprazole
~Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid"
16566656|NCT02835547||Systemic lupus erythematosus|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
16566657|NCT02835547||Rheumatoid arthritis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
16566658|NCT02835547||Psoriasis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
16566659|NCT02835547||Scleroderma|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
16566660|NCT02835547||Hematopoietic stem cells transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
16566661|NCT02835547||Kidney transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
16566662|NCT02835534|Experimental|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
16566663|NCT02835534|Active Comparator|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
16566664|NCT02835521|Experimental|Intervention Group|Patients will receive the reception treatment before the joint injection
16566665|NCT02835521|Active Comparator|Control Group|patient will receive a joint injection
16566666|NCT02835508|Experimental|Treatment A|Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
16566667|NCT02835508|Experimental|Treatment B|Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets*60 mg) on Day 1.
16566668|NCT02835508|Experimental|Treatment C|Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets*60 mg) on Day 1.
16566669|NCT02835495|Experimental|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention
~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
16566670|NCT02835495|Active Comparator|Enhanced Usual Care|"Behavioral: Individual Education Program
~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
16566671|NCT02835482|Experimental|Patient with glaucoma|Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
16566672|NCT02835482|Other|Patient without glaucoma|Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.
16566673|NCT02835469||Menopur® Multidose|Treatment according to routine clinical practice.
16566674|NCT02835456|Active Comparator|Group A: Sharklet Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
16566675|NCT02835456|Active Comparator|Group B: Silicone Foley Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
16566676|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
16566677|NCT02835430|Experimental|Coronally advanced flap and PRF with DFDBA|Coronally advanced flap and platelet-rich fibrin membrane with demineralized freeze-dried bone allograft.
16566678|NCT02835430|Active Comparator|Coronally advanced flap and PRF without DFDBA|Coronally advanced flap and Platelet-rich fibrin membrane without demineralized freeze-dried bone allograft.
16566679|NCT02835404|Experimental|Concurrent radiochemotherapy Group|Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
16566680|NCT02835404|Active Comparator|Radiotherapy Group|patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.
16566681|NCT02835391|Active Comparator|PerClot|PerClot® Polysaccharide Hemostatic System (PerClot) is a medical device composed of absorbable polysaccharide particles (AMPs) and delivery applicators. Investigators will have the option to choose 3g or 5g dependent on the requirements of the patient
16566682|NCT02835391|Active Comparator|Usual Care|Usual care will consist of any other haemostat the Investigator would normally use in the control of bleeding i.e arista, Floseal, surgical, surgiflo. If the Investigator would not normally use a haemostat to control bleeding then electrocautery or diathermy may be used in this arm
16566683|NCT02835378||Bilateral upper limb amputation|Bilateral upper limb amputees, with amputation from the short transverse hand (hand completely non-functional) to complete arm, whatever their age
16566684|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
16566685|NCT02835352|Experimental|Essential oils then oil massages|Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
16566686|NCT02835352|Experimental|Oil then essential oils massages|Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days
16566687|NCT02835339|Active Comparator|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
16566688|NCT02835339|Experimental|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
16566689|NCT02835326|Experimental|Exercise and Dietary Weight Loss|For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
16566690|NCT02835326|Active Comparator|Walk with Ease|The Arthritis Foundation's (AF) WWE is a self-management program for symptoms of arthritis (pain, fatigue, stiffness,etc.) through exercise. It is a 6 week program involving 3 sessions per week each lasting about 60 minutes. The WWE sessions are comprised of walking, stretching and strengthening exercises, and health education lectures. These group classes will be lead by an AF instructor. Each participant will complete 2 consecutive WWE classes for a total of 12 weeks in the program. During the final week of the program, participants will be trained and transitioin to the self-directed version of WWE for maintenance of exercise. To aid in retention efforts, phone contacts are provided to participants on a monthly basis from 4-12 months and bi-monthly from 12 to 24 months
16566691|NCT02835313|Experimental|FAST+SAM|Subjects participate in fast walking training in combination with a step activity monitoring program
16566692|NCT02835313|Active Comparator|FAST|Subjects participate in fast walking training
16566693|NCT02835313|Active Comparator|SAM|Subjects participate in a step activity monitoring program
16566694|NCT02835300|Experimental|CampAir Intervention|Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
16566695|NCT02835300|Active Comparator|Information and Referral Control|Adolescents assigned to the information-and-referral control condition will be provided access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will receive access to CampAir.
16566696|NCT02835287|Experimental|Protocol-based Integrated Care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
16566697|NCT02835287|Active Comparator|Enhanced Control|A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
16566698|NCT02835274|Experimental|Ring mode followed by Unrestricted mode|omni-directional stimulation followed by unrestricted Mode stimulation
16566699|NCT02835274|Active Comparator|Unrestricted mode followed by ring mode|Unrestricted Mode stimulation followed by omni-directional stimulation
16566700|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
16566701|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
16566702|NCT02835248||Primary|Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/).
16566703|NCT02835235|Experimental|NNC9204-0530|Dose-escalation within the cohort before reaching final dose
16566704|NCT02835235|Placebo Comparator|Placebo|
16566738|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:
~Pembrolizumab 200mg intravenously (IV);
~Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);
~Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);
~Carboplatin IV area under the curve (AUC) of 6."
16566739|NCT02834962|Experimental|single bundle ACLR|patients undergo single bundle ACL reconstruction
16566740|NCT02834962|Active Comparator|double bundle ACLR|patients undergo double bundle ACL reconstruction
16566885|NCT02834039|Active Comparator|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to patients after endotracheal tube was inserted properly.
16566705|NCT02835222|Experimental|Arm 2 (Selinexor) cytarabine, daunorubicin and selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Have had a response, completed all planned consolidation, have not gone to transplant receive selinexor on Days 1 and 8 for cycle 1 only, then Day 1 for cycles 2-4; Day 1 of every 4th cycle. Treatment continues until progression or unacceptable toxicity."
16566706|NCT02835222|Active Comparator|Standard of Care - Cytarabine and daunorubicin|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
16566707|NCT02835209||Work of breathing during SBT|Ventilated premature infants born 24 to 34+6 weeks gestational age.
16566708|NCT02835196||Optical Elastography Assessment of Skin Thickness|
16566709|NCT02835196||Visual Assessment of Skin Thickness|
16566710|NCT02835183|Experimental|Insulin pump followed by iDECIDE|Participants will be randomly assigned to 4 weeks of using their insulin pump to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing.
16566711|NCT02835183|Experimental|iDECIDE followed by insulin pump|Participants will be randomly assigned to 4 weeks of using iDECIDE to receive recommendations for insulin dosing and then 4 weeks of using their insulin pump to decide insulin boluses.
16566712|NCT02835170|Experimental|Autologous immunoglobulin|Intramuscular injection of autologous immunoglobulin (IgG)
16566713|NCT02835170|Placebo Comparator|Placebo|Intramuscular injection of normal saline
16566716|NCT02835144|Experimental|TIQAAM_therapy|Individuals in this group will receive units from the TIQAAM treatment program
16566717|NCT02835144|Active Comparator|active_control|Individuals in this group will receive units of psychoeducation
16566718|NCT02835118|Experimental|Surotomycin 0.5 g|Two oral doses of 0.25 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
16566719|NCT02835118|Experimental|Surotomycin 1 g|Two oral doses of 0.5 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
16566720|NCT02835118|Experimental|Surotomycin 2 g|Two oral doses of 1 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
16566721|NCT02835118|Placebo Comparator|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
16566722|NCT02835105|Experimental|Surotomycin 0.5 g|A single oral dose of 0.5 g surotomycin in hard gelatin capsules
16566723|NCT02835105|Experimental|Surotomycin 1 g|A single oral dose of 1 g surotomycin in hard gelatin capsules
16566724|NCT02835105|Experimental|Surotomycin 2 g|A single oral dose of 2 g surotomycin in hard gelatin capsules
16566725|NCT02835105|Experimental|Surotomycin 4 g|A single oral dose of 4 g surotomycin in hard gelatin capsules
16566726|NCT02835105|Placebo Comparator|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
16566727|NCT02835092|Active Comparator|Self-directed Control|
16566728|NCT02835092|Experimental|Take Shape For Life Program|
16566729|NCT02835092|Experimental|Medifast Direct Program|
16566730|NCT02835079|Other|open label study|one arm open label study
16566731|NCT02835066||Ancillary-Correlative (HRQOL, fitness and psychosocial health)|Patients scheduled for surgery, radiation therapy, or chemotherapy complete the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-core 30 (C30) and QLQ-Lung Cancer 13 (LC13) in addition to psychosocial health and smoking status questions from baseline up to 2 weeks prior to the start of treatment, 5-6 weeks after treatment begins, and 5-6 months from the start of treatment. During the same time points, patients also undergo function/fitness assessments including standard health measurements, short physical performance battery (SPPB), 6 minute walk test (6MWT), and a grip strength test.
16566732|NCT02835053||Emergency General Surgery|All patients having emergency general surgery procedures as defined by Scott et al (JAMA Surgery 2016)
16566733|NCT02835040|Experimental|CAP Service|
16566734|NCT02835040|Active Comparator|Usual care|
16566735|NCT02835014||Adolescents with T1DM|Adolescents with type I Diabetes Mellitus diagnosed for at least one year will be screened for mental health symptoms with the PHQ9, SCARED and UCLA PTSD. Self-efficacy regarding self-care and diabetes management will be assessed by using the SEDM. Parenting styles will be assessed by administering the Parenting Styles and Dimensions Questionnaire (PSDQ).
16566736|NCT02835001|Other|Patient with severe emphysema|Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
16566737|NCT02834988||SLND Patients|Patients scheduled to have their sentinel lymph nodes removed, as part of standard of care.
16566741|NCT02834949|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the College Adjustment Session and the session will be conducted using an MI plus personalized feedback approach."
16566742|NCT02834949|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
16566743|NCT02834949|No Intervention|Assessment|Participants will fill out a battery of measures and receive no intervention.
16566744|NCT02834936|Experimental|pyrotinib treatment|
16566745|NCT02834923|Active Comparator|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change. CTH utilizes web-based interactive behavior change technology, based on a logic model of behavior and maintenance that is informed by social-cognitive and social ecological theories. Prior to diabetes visits with a clinician, health educator, or care manager, patients complete a pre-visit CTH assessment at their practice through a tablet computer or computer kiosk. CTH assesses multiple diabetes management behaviors (diet, physical activity, medication adherence, alcohol and tobacco use, stress, mood) using brief assessment measures, each with cut-points highlighting areas of deficit. Action planning plays a central role, through a web-based platform that allows the patient and health care team to select and set goals collaboratively.
16566746|NCT02834923|Experimental|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
16566747|NCT02834910||Case group|patients with Extended-Spectrum Beta-lactamase producing Enterobacteriaceae carrying a qnr gene isolate
16566748|NCT02834910||control-group|patients with Enterobacteriaceae isolate without qnr gene
16566749|NCT02834897|Experimental|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
16566750|NCT02834884||RP-1828 IMMUcan|"The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.
~Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary"
16566751|NCT02834884||RP-1759 AYA/TYA|"The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials.
~Tumor type: CNS"
16566752|NCT02834884||RP-1843 Arcagen|"This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.
~Tumor types: all 10 EURACAN domains"
16566753|NCT02834871|Other|patients with cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients with cervical dystonia
16566754|NCT02834871|Other|patients without cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients without cervical dystonia
16566755|NCT02834858|Experimental|Umbilical Cord Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells Infusion.
16566756|NCT02834858|Placebo Comparator|saline|saline injection
16566757|NCT02834845|Experimental|Sevoflurane|
16566758|NCT02834845|Experimental|Desflurane|
16566759|NCT02834832||Control|The patients will be given removable dentures with no coatings. These dentures are part of the standard of care to treat their edentulism.
16566760|NCT02834832||PECVD Coatings|The patients will be given removable partial dentures with PECVD coatings on both the tissue surface of the dentures and the acrylic denture teeth.
16566761|NCT02834819|Experimental|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
16566762|NCT02834819|No Intervention|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
16566763|NCT02834806|Experimental|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
16566764|NCT02834793|Experimental|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.
~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
16566800|NCT02834585||Ultrasound|Patients undergoing Ultrasound
16566801|NCT02834585||Magnetic Resonance Imaging|Patients undergoing Magnetic Resonance Imaging
16566802|NCT02834572|Experimental|All About Me|assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach
16566803|NCT02834572|Active Comparator|Control|HIV testing information
16566765|NCT02834793|Placebo Comparator|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.
~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
16566767|NCT02834767|Experimental|Group 1 Primary Snoring Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
16566768|NCT02834767|Placebo Comparator|Group 2 Primary Snoring Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
16566769|NCT02834767|Experimental|Group 3 Primary OSA Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
16566770|NCT02834767|Placebo Comparator|Group 4 Primary OSA Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
16566771|NCT02834754|Experimental|Vedolizumab|Vedolizumab infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
16566772|NCT02834754|Placebo Comparator|placebo|Placebo infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
16566773|NCT02834741|Placebo Comparator|SAD Phase|"Up to 36 subjects: 50 - 1200 mg NYX-2925, Up to 12 subjects: placebo
~6 additional subjects will receive a fed dose of NYX-2925, 2 additional subjects will receive a fed dose of placebo (Food Effect Cohort)
~6 additional subjects will receive 1 dose of 50 mg NYX-2925 followed by a lumbar puncture at 1 and 4 (3 subjects) or 2 and 8 (3 subjects) hours post dose"
16566774|NCT02834741|Placebo Comparator|MAD Phase|"Up to 24 subjects : 150 - 600 mg NYX-2925 daily for 7 days, up to 6 subjects : placebo daily for 7 days
~6 additional subjects will receive 300 mg NYX-2925 daily for 7 days and undergo lumbar puncture on Day 6 in order to have two CSF samples taken (CSF Cohort)."
16566775|NCT02834728||Frail elderly people|A group of elderly people hospitalised in medical wards via emergency department
16566776|NCT02834715|Experimental|Stevia|Once-daily oral intake of 240 mg of Stevia liquid extract for 30 days as food supplement.
16566777|NCT02834715|No Intervention|Control|No intervention, similar follow up as experimental arm to control for trial effect
16566778|NCT02834702|Experimental|Sinew acupuncture|Sinew acupuncture
16566779|NCT02834702|Sham Comparator|Sham acupuncture|Sham acupuncture
16566780|NCT02834689|Experimental|Walking|Walking on a treadmill at 3.5 metabolic equivalents (METS) for 50 minutes
16566781|NCT02834689|Experimental|Seated Control|Sitting for 50 minutes
16566782|NCT02834676||Chemonucleolysis by Gelified Ethanol|Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy. Written informed consent was obtained from all participants.
16566783|NCT02834663|Experimental|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
16566784|NCT02834650|Experimental|Group 1a|Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
16566785|NCT02834650|Experimental|Group 1b|"Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.
~A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County."
16566786|NCT02834650|Experimental|Group 2|Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.
16566787|NCT02834650|Experimental|Group 3|Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.
16566788|NCT02834637|Active Comparator|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
16566789|NCT02834637|Active Comparator|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
16566790|NCT02834637|Active Comparator|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
16566791|NCT02834637|Active Comparator|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
16566792|NCT02834637|Active Comparator|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
16566793|NCT02834637|Active Comparator|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
16566794|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
16566795|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
16566796|NCT02834611|Experimental|Ceramide NanoLiposome|Dose escalation of Ceramide NanoLiposome
16566797|NCT02834598|Experimental|Rocking movement|Participant is lying in a hammock with a rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
16566798|NCT02834598|Active Comparator|Lying position|Participant is lying in a hammock with no rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
16566799|NCT02834598|Active Comparator|Seated position|Participant is sitting on a chair. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
16566804|NCT02834559|Active Comparator|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
16566805|NCT02834559|Placebo Comparator|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
16566806|NCT02834546||Patients with HCC treated with sorafenib|
16566807|NCT02834533|Active Comparator|column heading in tables.|The group 1 (G1, n=20) underwent Lokomat-Nanos training. Each patient underwent 40 1h-training sessions (for 3 times a week). Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
16566808|NCT02834533|Active Comparator|row and column in table|The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions. The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
16566809|NCT02834520||oral lichen planus|30 patients suffering from reticular, erosive and atrophic oral lichen planus
16566810|NCT02834520||control subjects|30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.
16566811|NCT02834507|Placebo Comparator|Placebo|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
16566812|NCT02834507|Experimental|Nebicapone 75 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
16566813|NCT02834507|Experimental|Nebicapone 150 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
16566814|NCT02834507|Active Comparator|Entacapone 200 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
16566815|NCT02834494|Other|3D Shear Wave Elastography (SWE)|
16566816|NCT02834481|Other|: ventilated children|ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE
16566817|NCT02834468|Experimental|Treatment group|DEX Combined With RTX, CSA and IVIG All patients are assigned to receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
16566818|NCT02834455|Active Comparator|CE-CT scanning|Contrast-enhanced CT scan of the thorax and abdomen.
16566819|NCT02834455|Active Comparator|PET-CT scanning|Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
16566820|NCT02834442|Experimental|Single ascending dose, MT-7117 or Placebo|
16566821|NCT02834442|Experimental|Multiple ascending dose, MT-7117 or Placebo|
16566822|NCT02834429||endoscopy patients|We will recruit patients (n=1000) from the endoscopy department at the Royal Hallamshire Hospital, Sheffield, United Kingdom (UK).
16566823|NCT02834416|Experimental|Group-Supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
16566824|NCT02834416|Experimental|Home-Based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
16566826|NCT02834390|Experimental|Quizartinib 20 mg/day|"Participants who received 20 mg quizartinib once daily in the morning under fasting conditions.
~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.
~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
16566886|NCT02834026|Experimental|Intervention|The intervention group held two months of training in hemodialysis a physical therapy protocol with cycle ergometer
16566827|NCT02834390|Experimental|Quizartinib 40 mg/day|"Participants who received 40 mg quizartinib once daily in the morning under fasting conditions.
~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.
~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
16566828|NCT02834377|Experimental|Treatment algorithm|Patients allocated to the study group will be connected to a cardiac output monitor. An initial haemodynamic assessment will be performed at the beginning of surgery and at regular time intervals (every 15 minutes) during surgery. The personal cardiac output value is targeted.
16566829|NCT02834377|No Intervention|Standard of Care|Patients allocated to the control group will receive the standard care of the hospital.
16566830|NCT02834364|Experimental|single arm|Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
16566831|NCT02834351|Active Comparator|Peripheral artery diseased group|pad Patients referred for femoro popliteal bypass Muscle biopsy during surgery
16566832|NCT02834351|Sham Comparator|Cardiac group|Patients referred for saphenous withdrawal for coronary bypass Muscle biopsy during surgery
16566833|NCT02834338|No Intervention|Laparoscopic surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
16566834|NCT02834338|Active Comparator|Laparoscopic surgery, intervention|activity tracking for autofeedback
16566835|NCT02834338|No Intervention|Open surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
16566836|NCT02834338|Active Comparator|Open surgery, intervention|activity tracking for autofeedback
16566837|NCT02834325||exit|HFNC with no need for mechanical ventilation
16566838|NCT02834325||failure|HFNC with need for mechanical ventilation
16566839|NCT02834312|Experimental|2.5 mg estetrol|
16566840|NCT02834312|Experimental|5 mg estetrol|
16566841|NCT02834312|Experimental|10 mg estetrol|
16566842|NCT02834312|Experimental|15 mg estetrol|
16566843|NCT02834312|Placebo Comparator|placebo|
16566844|NCT02834299|Experimental|DBT Guided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and receive six brief therapy sessions via video-calling."
16566845|NCT02834299|Experimental|DBT Unguided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and asked to follow the manual on their own."
16566846|NCT02834299|Active Comparator|Self-Esteem-Focused Unguided Self-Help|"Participants will be provided with the self-help manual Self-Esteem by McKay & Fanning (2016) as asked to follow the manual on their own."
16566847|NCT02834286|Experimental|Rituximab, eltrombopag and dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4
16566848|NCT02834273|Experimental|Therapeutic Workshop|Therapeutic Workshop (patients following therapeutic education workshops during their hospitalization)
16566849|NCT02834273|No Intervention|Usual care|
16566850|NCT02834260|Experimental|ozurdex group|Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
16566851|NCT02834247|Experimental|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
16566852|NCT02834247|Experimental|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If >=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
16566853|NCT02834247|Experimental|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
16566882|NCT02834052|Experimental|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:
~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)
~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg
~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.
~Participants may receive treatment for 1 year (~17 cycles)."
16566887|NCT02834026|Experimental|Control|The control group was reassessed after two months of the initial evaluation
16566946|NCT02833623|Active Comparator|conventional education group|Patients only receive oral and written education before H. pylori eradication therapy.
16566854|NCT02834247|Experimental|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
16566855|NCT02834247|Experimental|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
16566856|NCT02834234||Peritoneal mesothelioma specimens|"The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.
~The CGH arrays will be realized on frozen samples (for the comparative genomic analysis)."
16566857|NCT02834221|Experimental|Real-time ultrasound-guided puncture|Cannulate each femoral veins with two wires with real-time ultrasound-guided method.
16566858|NCT02834221|Other|Anatomical landmark guided puncture|Cannulate each femoral veins with two wires with the anatomical landmark guided method.
16566859|NCT02834208|Experimental|Schizophrenia subjects|35 patients suffering from schizophrenia
16566860|NCT02834208|Other|Healthy siblings|35 healthy siblings of the patients suffering from schizophrenia
16566861|NCT02834208|Other|Healthy controls|"35 healthy controls patients"
16566862|NCT02834182|Experimental|Bipolar Disorder patients and Schizophrenic patients|
16566863|NCT02834182|Active Comparator|Healthy Controls|
16566864|NCT02834169||pseudomyxoma peritonei|Data from pseudomyxoma peritonei cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566865|NCT02834169||peritoneal mesothelioma|Data from peritoneal mesothelioma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566866|NCT02834169||desmoplastic small round cell tumor|Data from desmoplastic small round cell tumor cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566867|NCT02834169||psammocarcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566868|NCT02834169||primary peritoneal serous carcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566869|NCT02834169||diffuse peritoneal leiomyomatosis|Data from diffuse peritoneal leiomyomatosis cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566870|NCT02834169||appendiceal mucinous neoplasms|Data from appendiceal mucinous neoplasms cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
16566871|NCT02834156|Other|LP in a seated position then LP in a lying position|Patients will have first a lumbar puncture (LP) in a seated position then a LP in a lying position
16566872|NCT02834156|Other|LP in a lying position then LP in a seated position|Patients will have first a lumbar puncture (LP) in a lying position then a LP in a seated position
16566873|NCT02834130|Other|children from 2 to 10 years with haemophilia or allied HBD, wh|
16566874|NCT02834117|Other|Natural cycle|Ovulation is not induced by drugs
16566875|NCT02834117|Experimental|Moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
16566876|NCT02834104|Experimental|Myocardial fibrosis|
16566877|NCT02834078|Experimental|BGG|Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
16566878|NCT02834078|Placebo Comparator|Placebo|Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
16566879|NCT02834065|Active Comparator|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
16566880|NCT02834065|Active Comparator|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
16566881|NCT02834065|Active Comparator|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
16566883|NCT02834052|Experimental|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.
~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (~17 cycles)."
16566890|NCT02834000|No Intervention|Standard Care|We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. The control group will compose of patients supervised in a standard way.
16566891|NCT02834000|Experimental|LiDCO rapid™ CNAP monitoring|Young, healthy adult patients (ASA I and II) undergoing elective orthopaedic surgery under general anaesthesia will be included in to this study. We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. We will use in the LiDCO rapid™ CNAP monitoring group, the continuous real time haemodynamic monitoring through non-invasive arterial pressure waveform. The monitor LiDCO rapid™ CNAP permits, through analysis the arterial blood pressure trace, to acquire information about CO, SVR, HR variability, SV and BIS.
16566892|NCT02833987||Treated with direct oral anticoagulants (DOACs)|Patients who received a new prescription for a DOAC (apixaban, dabigatran, or rivaroxaban) in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
16566893|NCT02833987||Treated with warfarin|Patients who received a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
16566894|NCT02833974|Experimental|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
16566895|NCT02833974|Placebo Comparator|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
16566896|NCT02833961|Experimental|ISCHEMIC STROKE|ischemic stroke admitted in the Pitié Salpêtrière Stroke unit in Paris
16566897|NCT02833961|Active Comparator|HEALTHY SUBJECTS|Age and gender-matched healthy volunteers
16566898|NCT02833948|Active Comparator|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
16566899|NCT02833948|Experimental|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
16566900|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
16566901|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
16566902|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
16566903|NCT02833909|Experimental|HS|
16566904|NCT02833909|Experimental|Controls|
16566905|NCT02833896||endometrial cancer|
16566906|NCT02833896||Control|
16566907|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
16566908|NCT02833870|Experimental|Musical intervention|
16566909|NCT02833870|Experimental|Non-musical (cooking) intervention|
16566910|NCT02833870|Active Comparator|Control with no intervention|
16566911|NCT02833857|Experimental|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
16566912|NCT02833844|Experimental|Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
16566913|NCT02833844|Placebo Comparator|Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
16566914|NCT02833831|Experimental|Part 1: Group 1|Participants will receive Treatment A (a single dose of ALS-008176 1,500 mg) or Treatment B (a single dose of placebo) under fasted conditions.
16566915|NCT02833831|Experimental|Part 1: Group 2|Participants will receive Treatment C (a single dose of ALS-008176 2,500 mg) or Treatment D (a single dose of placebo) under fasted conditions.
16566916|NCT02833831|Experimental|Part 1: Group 3|Participants will receive Treatment E (a single dose of ALS-008176 3,000 mg) or Treatment F (a single dose of placebo) under fasted conditions.
16566917|NCT02833831|Experimental|Part 2: Sequence GHI|Participants will receive Treatment G (a single dose of ALS-008176 3,000 mg + a single dose of moxifloxacin placebo under fasted conditions) then Treatment H (a single dose of ALS-008176 placebo + a single dose of moxifloxacin 400 mg under fasted conditions) then Treatment I (a single dose of ALS-008176 placebo + a single dose of moxifloxacin placebo under fasted conditions). There will be a washout period of at least 14 days between subsequent treatments.
16566918|NCT02833831|Experimental|Part 2: Sequence HIG|Participants will receive Treatment H then Treatment I and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
16566919|NCT02833831|Experimental|Part 2: Sequence IGH|Participants will receive Treatment I then Treatment G and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
16566920|NCT02833831|Experimental|Part 2: Sequence IHG|Participants will receive Treatment I then Treatment H and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
16566921|NCT02833831|Experimental|Part 2: Sequence HGI|Participants will receive Treatment H then Treatment G and then Treatment I. There will be a washout period of at least 14 days between subsequent treatments.
16566922|NCT02833831|Experimental|Part 2: Sequence GIH|Participants will receive Treatment G then Treatment I and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
16566923|NCT02833818|Experimental|CAKE-intervention|Increased nutrition and dietary consultations. Growth rate followed by clinical nutritionists that supply high protein and energy if growth rate deviates from 17g/kg/day
16566924|NCT02833818|Active Comparator|CAKE-control|nutrition according to established procedures in the neonatal intensive care unit (NICU)
16566925|NCT02833805|Experimental|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
16566926|NCT02833792|Experimental|Stem Cells|Stem cells
16566927|NCT02833792|Placebo Comparator|Placebo|Lactated Ringer's Solution
16566928|NCT02833779|Active Comparator|Group Therapy Exercises|Patients will be taught exercises in groups of six persons, on a daily basis for twelve sessions.
16566929|NCT02833779|Active Comparator|Individual Manual Therapy Exercises|Patients will be taught the same exercises as in a Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering
16566930|NCT02833766|Experimental|anti-EGFR-IL-dox|Metastatic, non resectable, EGFR positive TNBC patients treated in first-line
16566931|NCT02833753|Experimental|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.
~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients will receive dose level 3. The fourth cohort of 3 patients will receive dose level 2."
16566932|NCT02833740|Other|Click-MUAC & regular MUAC tape screening|"Each child will have nutritional status classified 11 times:
~3 times with each of the 3 Click-MUAC prototypes by the mother/caregiver
~1 time with a regular MUAC tape by the mother/caregiver
~3 times with each of the 3 Click-MUAC prototypes by the case-finding/programme staff
~1 time with a regular MUAC tape by the case-finding/programme staff
~3 times with a regular MUAC tape by the data collection team (gold standard)"
16566933|NCT02833727||Asthmatic smokers (AS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) < 8 mg/ml with a diagnosis of asthma made by a respirologist.
~Smokers or ex smokers will be defined by a smoking history of ≥ 10 pack/year."
16566934|NCT02833727||Asthmatic non-smokers (ANS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a PC20 < 8 mg/ml with a diagnosis of asthma made by a respirologist.
~Never smokers will have a life-long history without smoking."
16566935|NCT02833701|Experimental|Treatment (bevacizumab and ascorbic acid)|Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16566936|NCT02833688|Experimental|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
16566937|NCT02833688|Placebo Comparator|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
16566938|NCT02833675||bradykinin angioedema|Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
16566939|NCT02833675||Histaminergic angioedema|Allergic and non allergic angioedema
16566940|NCT02833675||Control group|Patients with abdominal pain
16566941|NCT02833662|Other|Patients suspected to present a Sleep Apnea Syndrom|"Record nocturnal respiratory and cardiac parameters before and after surgery :
~Severity of sleep respiratory disorders and relationship with cardiac rhythm abnormalities will be assessed in patients suspected to present Sleep Apnea, before and after surgery under general anesthesia."
16566942|NCT02833649|Experimental|Toric Implantable contact Lens|The Visian implantable collamer lens (Staar Surgical AG, Nidau, Switzerland), is a monoblock single-piece plate haptic lens made of collamer (an extremely hydrophilic and highly biocompatible flexible collagen copolymer with a refractive index of 1.452 that is permeable to oxygen and nutrients
16566943|NCT02833636||Successful CTO-PCI group|low ACEF score <1.215 (n = 79), intermediate ACEF score from 1.215 to 1.493 (n=70), and high ACEF score≥1.493 (n=72)
16566944|NCT02833636||Failed/non-attempted CTO-PCI group|low ACEF score<1.215 (n=45), intermediate ACEF score from 1.215 to 1.493 (n=57), and high ACEF score≥1.493 (n=54).
16566945|NCT02833623|Experimental|Short-message-based Re-education group|"Patients receive oral and written education before H. pylori eradication therapy at first, then they receive short message re-education twice per day during therapy.
~Both the content of the oral and written education and the short message re-education are same."
16566947|NCT02833610|Experimental|Denosumab Injection|Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.
16566948|NCT02833584|Experimental|Paracetamol|Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
16566949|NCT02833584|Placebo Comparator|Placebo|Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
16566950|NCT02833558|Experimental|PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
16566951|NCT02833558|Other|Standard Electrocautery|Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
16566952|NCT02833545|Experimental|OZONE|injection of ozone gas
16566953|NCT02833545|Active Comparator|control|injeciton of steroids intra articularly
16566954|NCT02833532|Experimental|Volus|Maxium: 22ml
16566955|NCT02833532|Active Comparator|Powerfill|Maxium: 22ml
16566956|NCT02833519|No Intervention|control group|Standard care, mentally vulnerable women
16566957|NCT02833519|Active Comparator|group exercise|Supervised Group training
16566958|NCT02833506|Active Comparator|Cohort I (NY-ESO-1 protein with MIS416)|Patients receive NY-ESO-1 protein with MIS416 vaccine SC on days 1, 15, 29, 57, 85, and 113 in the absence of disease progression or toxicity.
16566959|NCT02833506|Experimental|Cohort II (NY-ESO-1 protein with MIS416, sirolimus)|Patients receive NY-ESO-1 protein with MIS416 vaccine as in Cohort I. Patients also receive sirolimus PO daily for 2 weeks followed by 2 weeks off starting on days 1, 29, 57, and 85.
16566960|NCT02833480|Experimental|Fluticasone group|Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
16566961|NCT02833480|Experimental|Budesonide group|Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
16566962|NCT02833480|Active Comparator|Formoterol group|Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
16566963|NCT02833454|Active Comparator|direct insertion single bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using single bundle technique.
16566964|NCT02833454|Experimental|anatomical double bundle ACLR|Patients with ACL rupture undergo double bundle anterior cruciate ligament reconstruction.
16566965|NCT02833454|Experimental|anatomical single bundle ACLR|Patients with ACL rupture undergo single bundle anterior cruciate ligament reconstruction.
16566966|NCT02833454|Active Comparator|direct insertion double bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using double bundle technique.
16566967|NCT02833441|Experimental|Peer Support Intervention|Adolescents/young adults in the Peer Support Intervention arm will be referred to a Peer Support Intervention support group within their own or nearby community. This support group will meet monthly and will be facilitated by a professional HIV counsellor together with a Peer Support Intervention counselor. The Peer Support Intervention counsellors will provide regular counselling to their allocated participants through home visits and SMS messages. Each participant will be visited once a week in their home. Whatsapp messages will be delivered daily to each participant by the Community Adolescent Treatment Supporters. The agreed messages will briefly enquire about the participant's well-being without specifically making reference to HIV or ARVs. In addition, participants' caregivers will be invited to a 3-session intervention to build knowledge, skills and confidence to better support their adolescents.
16566968|NCT02833441|No Intervention|Standard of Care Practice|"Participants in the standard of care group will receive adherence evaluations and counseling at the clinic as per the current standard of care. Current procedures involve a group counseling session given on Monday morning during which topics are discussed that are relevant to adolescents. In general children aged between 13-19 years attend these sessions. After the group counseling, adolescents also receive an individual counseling session before being evaluated by the clinic doctor. Youth are also encouraged to complete a self reported adherence questionnaire and may periodically undergo pill counts by the clinic counselors.
~The adolescents may belong to peer support groups in their communities, however these activities are not part of the clinic program. No interventions are typically targeted at their caregivers."
16566969|NCT02833428|Experimental|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
16566970|NCT02833415|Experimental|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
16566971|NCT02833415|Placebo Comparator|Placebo|Placebo one tablet daily for 3 months
16566972|NCT02833402||UUI patients undergoing SNM|Urine specimens, questionnaire, and medical data will be collected from subjects that have UUI and are undergoing InterStim placement (SNM).
16566973|NCT02833389|Experimental|Cohort A - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 1|Participants with 0.8-6.0 centimeters square (cm^2) index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 1 for 12 weeks (a total of 4 doses).
16566974|NCT02833389|Experimental|Cohort B - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
16566975|NCT02833389|Experimental|Cohort C - UTTR1147A, 0.8-6.0 cm^2, Mild Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
16566976|NCT02833389|Experimental|Cohort D - UTTR1147A, 1.5-6.0 cm^2, Mild Infection - Dose 2|Participants with 1.5-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
16567032|NCT02833064||Acute Liver Injury|- biological sampling
16567033|NCT02833064||Acute on Chronic Hepatic Injury|- biological sampling
16566977|NCT02833389|Experimental|Cohort E - UTTR1147A, 0.8-6.0 cm^2, No infection - Dose 3|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 3 for 12 weeks (a total of 4 doses).
16566978|NCT02833389|Placebo Comparator|Placebo|Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).
16566979|NCT02833376|Experimental|Alcohol group|Patients allocated to this group will receive skin antisepsis with alcohol 70% prior spinal anesthesia
16566980|NCT02833376|Experimental|Chlorhexidine group|Patients allocated to this group will receive skin antisepsis with alcoholic solution of chlorhexidine 0.5% prior spinal anesthesia
16566981|NCT02833363||patients with non-atrophic gastritis|
16566982|NCT02833363||Patients with gastritis|
16566983|NCT02833363||Patients with intestinal metaplasia|
16566984|NCT02833363||Patients with intrepithelial neoplasia|
16566985|NCT02833363||Patients with non-cardia gastric cancer|
16566986|NCT02833350|Experimental|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566987|NCT02833350|Experimental|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566988|NCT02833350|Experimental|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566989|NCT02833350|Active Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566990|NCT02833350|Placebo Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566991|NCT02833350|Experimental|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566992|NCT02833350|Placebo Comparator|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
16566993|NCT02833324|Experimental|Fitbit with ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. In addition to being educated on the importance of postoperative ambulation, this arm will have 5 alarms every day reminding them to ambulate.
16566994|NCT02833324|Active Comparator|Fitbit without ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. Participants will be educated on the importance of postoperative ambulation but will not have ambulation reminder alarms.
16566995|NCT02833311|Active Comparator|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
16566996|NCT02833311|Active Comparator|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
16566997|NCT02833311|Active Comparator|Standard Treatment Control Group|Participants are prescribed an exercise program and given information on healthy eating.
16566998|NCT02833298|Experimental|Automated reminders|Patient will be contacted for automated reminders within one month before the six-month interval indicating they are due for HCC screening.
16566999|NCT02833298|Experimental|Patient navigation|The patient navigator will coordinate with the provider and subject to schedule the appropriate office visit and imaging for HCC screening as needed within one month before the test is due.
16567000|NCT02833272|Experimental|EMPOWER Educational Brochure|This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.
16567001|NCT02833246|Experimental|SMS/MMS text messaging|Patients will be able to tailor their SMS/MMS reminders with respect to when (i.e., what time of day) they wish to receive the reminders, as well as how often the messages are sent (e.g., morning and evening).
16567002|NCT02833246|Active Comparator|usual care|This includes physician and nursing assessment and intervention for any identified AEs. Of note, there is not currently standard follow-up that patients receive from nursing or physician staff while on an OAM treatment. Patients are encouraged to call their physician's office with any questions or changes in their medical status but are not called routinely by MSK staff.
16567003|NCT02833233|Experimental|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
16567004|NCT02833220||Healthy volunteers|"Healthy adults between the ages of 18-65 are eligible.
~Participants will receive non-invasive brain stimulation by way of single-pulse transcranial magnetic stimulation to the motor cortex"
16567005|NCT02833207|Experimental|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
16567006|NCT02833207|Experimental|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
16567007|NCT02833207|Experimental|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
16567008|NCT02833207|Experimental|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
16567009|NCT02833194||Leiden Group|Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
16567010|NCT02833194||aP1Ab-positive|"Inclusion in the aP1Ab Group:
~Initially positive for aP1Ab
~Second positive aP1Ab test six months later"
16567011|NCT02833194||Thrombophilia-negative|Women with completely negative thombophilia screening results.
16567012|NCT02833181||Awake patients|Awake patients
16567013|NCT02833181||Sedated patients|
16567014|NCT02833181||Sedated and curarized patients|
16567015|NCT02833168||1|Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.
16567016|NCT02833168||2|Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.
16567017|NCT02833168||3|Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.
16567018|NCT02833155|Experimental|Entinostat and Exemestane|"Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.
~Exemestane wil be orally administered once daily for up to six months."
16567019|NCT02833142|Experimental|BIIB033-A|Staggered single dosing schema
16567020|NCT02833142|Experimental|BIIB033-B|Staggered single dosing schema
16567021|NCT02833116|Experimental|Group Betamethasone|One ampule containing 12 mg of betamethasone in a syringe of 10 ml
16567022|NCT02833116|Active Comparator|Group Dexamethasone|One ampule containing 4 mg of dexamethasone in a syringe os 10 ml
16567023|NCT02833103|Experimental|Pinaverium Bromide group|Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
16567024|NCT02833103|Active Comparator|Danshu group|Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
16567025|NCT02833090|Other|Group 1|Control group had biomarkers.
16567026|NCT02833090|Experimental|Group 2|Biomarkers
16567027|NCT02833090|Experimental|Group 3|Biomarkers
16567028|NCT02833090|Experimental|Group 4|Biomarkers
16567029|NCT02833077|Experimental|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
16567030|NCT02833077|Other|No Treatment then JUVÉDERM VOLUMA® XC|No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
16567031|NCT02833064||Acute Liver Failure|"biological sampling
~MRI scanning for patients with paracetamol induced acute liver failure"
16567038|NCT02833012|Experimental|Group 1|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
16567039|NCT02833012|Experimental|Group 2|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
16567040|NCT02833012|Experimental|Group 3|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
16567041|NCT02833012|Experimental|Group 4|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
16567042|NCT02832999|Experimental|sub cutaneous liraglutide|once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
16567043|NCT02832999|Active Comparator|Oral Vildagliptin|Once daily oral 100mg of Vildagliptine for two weeks
16567044|NCT02832986||Patients in frailty consultation|Patients consulting in frailty consultation, at this occasion they will complete a medical questionary for the collection of study data
16567045|NCT02832973|Experimental|Spironolactone, Furosemide Amiloride|Spironolactone 25 mg qd, Furosemide 20 mg qd, Furosemide 40 mg qd, Amiloride 5 mg qd
16567046|NCT02832973|Active Comparator|Ramipril, Bisoprolol|Ramipril 5 mg qd, Ramipril 10 mg qd, Bisoprolol 5 mg qd, Bisoprolol 10 mg qd
16567047|NCT02832960|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
16567048|NCT02832960|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
16567049|NCT02832947|Other|Rivaroxaban Arm|
16567050|NCT02832934|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
16567051|NCT02832934|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
16567052|NCT02832921|Experimental|VR cognitive tasks + treadmill|This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.
16567053|NCT02832921|Active Comparator|VR cognitive tasks - treadmill|This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.
16567054|NCT02832921|Sham Comparator|scientific TV documentary + treadmill|This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.
16567055|NCT02832921|No Intervention|Passive control|This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.
16567056|NCT02832908|Other|Patients + parents|Patients with severe head trauma
16567057|NCT02832895|Experimental|Transcranial Doppler examination|Transcranial Doppler examination
16567058|NCT02832882|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
16567059|NCT02832882|Active Comparator|Conventional tumor puncture RFA arm|Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
16567060|NCT02832869|Experimental|short message service|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
16567061|NCT02832869|Experimental|Wechat|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
16567062|NCT02832869|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
16567063|NCT02832856|Placebo Comparator|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
16567064|NCT02832856|Experimental|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks.
16567065|NCT02832856|Experimental|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
16567066|NCT02832843||NTM lung disease|Patients with NTM lung disease satisfying American Thoracic Society guidelines
16567067|NCT02832843||Healthy control|The age-, sex-matched control subjects without pulmonary diseases
16567068|NCT02832830|Experimental|A|intensity modulated radiotherapy (IMRT) 10 x 3 Gy
16567069|NCT02832830|Active Comparator|B|fractionated conventional external beam RT 10×3 Gy
16567070|NCT02832804|Experimental|anodal stimulation|10 person The patients treated by anodal stimulation (2mA) for 20 minutes
16567071|NCT02832804|Active Comparator|cathodal stimulation|10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
16567072|NCT02832804|Sham Comparator|sham stimulation|10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
16567073|NCT02832791|Active Comparator|QUADRICEPS TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING QUADRICEPS TENDON
16567074|NCT02832791|Active Comparator|HAMSTRING TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING HAMSTRING TENDON
16567075|NCT02832778|Experimental|Stage 1 London|"Stage 1, London:
~Phase 1 (2 weeks): tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily
~Phase 2 (12 weeks): tenofovir/emtricitabine or tenofovir /lamivudine or zidovudine/lamivudine) plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)"
16567076|NCT02832778|Experimental|Stage 2 Kampala|Tenofovir/emtricitabine or lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥ 50 kg or rifampicin 450 mg and isoniazid 300 mg if <50kg).
16567077|NCT02832765|Experimental|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions
16567078|NCT02832765|Experimental|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis
16567079|NCT02832765|Experimental|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions
16567080|NCT02832765|Experimental|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis
16567081|NCT02832752|Active Comparator|ECPR Region|The ECPR region has incorporated ECPR therapy into the out-of-hospital cardiac arrest algorithm. Within the ECPR Protocol, full standard advanced cardiac life support treatments will continue up until the time of ECMO initiation. The anticipated enrolment in this group is 70 patients. All eligible patients in the region will be enrolled, regardless of whether the ECPR protocol is activated or whether the patient is actually treated with ECPR.
16567082|NCT02832752|No Intervention|Control Region|"The control region will continue usual care as per current protocols which include standard advanced cardiac life support. Patients will be enrolled in the control region group at the same juncture of study eligibility. The anticipated enrolment in this group is 350 patients.
~Within BCEHS practice, transport to hospital without prior return of spontaneous circulation is rare. Termination of resuscitation must be approved by an on-call physician and cannot occur prior to 30 minutes of resuscitation efforts."
16567083|NCT02832739|Experimental|SENACA - self-management support system|Use of enhanced SENACA - ICT based self-management support system prototype by study participants at home for 75-100 days
16567084|NCT02832726|Active Comparator|cyano-hydroxo B12|Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given.
16567085|NCT02832726|Active Comparator|Cyano-B12 doses|Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given.
16567086|NCT02832713|Experimental|Intra-articular injection of botulinum toxin A|
16567087|NCT02832713|Active Comparator|Intra-articular injection of hyaluronic acid|
16567088|NCT02832700|Active Comparator|Casein glycomacropeptide (CGMP)|During 4 weeks a daily oral intake of CGMP-protein-shake.
16567089|NCT02832700|Placebo Comparator|Placebo|During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.
16567090|NCT02832687|Active Comparator|normal saline|Patients will receive 100 milliliters of normal saline with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses in 24 hours. Blinded medication will be prepared by research pharmacist.
16567091|NCT02832687|Experimental|acetaminophen|Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients <50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline
16567092|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
16567093|NCT02832648|Experimental|selenase 200mcg|selenium as selenase 200mcg once daily, oral
16567094|NCT02832648|Experimental|selenase 50mcg|selenium as selenase 50mcg once daily, oral
16567095|NCT02832648|Placebo Comparator|placebo|matched placebo, once daily, oral
16567096|NCT02832635|Experimental|WBRT|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
16567097|NCT02832635|Experimental|WBRT with avoidance of hippocampus|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
16567098|NCT02832635|Experimental|WBRT with TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.
16567099|NCT02832635|Experimental|WBRT with avoidance of hippocampus and TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.
16567100|NCT02832622||MPP Programming|This post-market study was designed to characterize the real-world use of MPP technology in patients indicated for CRT device implant. Therefore in order to adequately characterize MPP, data from subjects with MPP programmed continuously or for at least 3 months prior to the final follow-up are reported as the MPP programming group.
16567101|NCT02832609|No Intervention|sitting position|measurement in the sitting position
16567102|NCT02832609|Active Comparator|supine position|measurement in the sitting position
16567103|NCT02832596|No Intervention|Control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
16567104|NCT02832596|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
16567105|NCT02832583|Experimental|Mesotherapy of PRP-HA into the cheeks|Three sessions of PRP-HA prepared with RegenKit BCT-HA Cellular Matrix into each cheek separated by 1 month interval.
16567106|NCT02832570|Experimental|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
16567107|NCT02832570|Placebo Comparator|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
16567108|NCT02832557||MCHAT-R Positive|Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
16567109|NCT02832544|Experimental|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n ~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
16567110|NCT02832544|Active Comparator|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n ~ 2250); VKA titrated to achieve an INR of 2.0-3.0
16567111|NCT02832531|Experimental|Rivaroxaban (15 mg)|Rivaroxaban 15 mg od (n ~ 1000)
16567112|NCT02832531|Active Comparator|Aspirin (ASA)|Aspirin 100 mg od (n~1000)
16567113|NCT02832518||patients under hemodialysis|
16567114|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).
~No intervention but only observational."
16567115|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).
~No intervention but only observational."
16567116|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).
~No intervention but only observational."
16567117|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
16567118|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
16567119|NCT02832453|Other|Lifestyle counseling|This group will receive lifestyle counselling but not supervised exercise training sessions
16567120|NCT02832453|Experimental|Aerobic interval training|This group will receive lifestyle counselling plus supervised high intensity (80%VO2max) interval exercise training sessions
16567121|NCT02832453|Active Comparator|Traditional continous training|This group will receive lifestyle counselling plus supervised moderate intensity (60%VO2max) continous exercise training sessions
16567122|NCT02832440|Other|Intradialytic exercise|Exercise during hemodialysis
16567123|NCT02832440|Other|Home-based exercise|Exercise at home
16567124|NCT02832414|No Intervention|Regular program|
16567125|NCT02832414|Active Comparator|Intensive weight loss program|
16567126|NCT02832401|Active Comparator|Caffeine|200 mg of caffeine powder administered in capsules
16567127|NCT02832401|Placebo Comparator|Placebo|Cellulose powder administered in capsules
16567128|NCT02832388||Primary aldosteronism patients for cardiac MRI|A subgroup of primary aldosteronism (PA) patients perform a cardiac MRI, including stress-testing with adenosine, and are compared to a sex- and age-matched group of healthy controls who perform the same MRI procedure
16567129|NCT02832388||Healthy controls|Healthy controls that are age-and sex-matched to the subgroup of PA patients performing cardiac MRI, perform MRI including adenosine as stress-test.
16567130|NCT02832388||Primary aldosteronism patients diagnosed from 2013 onwards|"All PA patients diagnosed or subtyped at Haukeland University from 2013 onwards are asked for inclusion in the main observational PA-study.
~From 2020 onwards, PA patients diagnosed or subtyped at Oslo University hospital will also be included."
16567131|NCT02832375|Experimental|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million [ppm] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
16567132|NCT02832375|Active Comparator|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
16567133|NCT02832362|Experimental|Carbomer 980|Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
16567134|NCT02832362|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
16567135|NCT02832349|Experimental|EA group (Educational Actions)|Epileptic patients participating to the educational actions program
16567136|NCT02832349|No Intervention|Control group|Epileptic patients with standard follow-up
16567137|NCT02832336|Experimental|Caffeine|"Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.
~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants."
16567138|NCT02832336|Placebo Comparator|Fiber|Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
16567139|NCT02832323|Other|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
16567140|NCT02832297|Other|Vectra DA (Arm A)|Treatment intensification with non-biologic DMARDS guided by Vectra DA
16567141|NCT02832297|Other|Usual care (Arm B)|Treatment intensification by usual care without using Vectra DA
16567142|NCT02832284|Experimental|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
16567143|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
16567144|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
16567205|NCT02831829|Active Comparator|Land-based exercise training group|"Patients randomized to the land-based exercise training group will undergo exercise training which will include two aerobic and calisthenic exercise session per day, six days of a week, lasting 30 minutes"
16567238|NCT02831582|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
16567145|NCT02832258||Children with urinary tract infection due to E-ESBL|In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with E-ESBL UTI (febrile UTI or cystitis) were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. We used the Kaplan-Meier method to estimate the time to apyrexia and length of hospital stay, and Log-rank test to assess equality of survivor functions. We also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
16567146|NCT02832232|Experimental|Mobilization Group|translational dorsal glide mobilization technique grade III and Protocolized Physiotherapy
16567147|NCT02832232|Experimental|Maintained pressure Group|pressure maintained suboccipital inhibition technique and Protocolized Physiotherapy
16567148|NCT02832232|Other|Control Group|Protocolized Physiotherapy
16567149|NCT02832219|Experimental|Molecular hydrogen|Molecular hydrogen, tablet, 2 g/day, 4 weeks
16567150|NCT02832219|Placebo Comparator|Placebo|Cellulose, tablet, 2 g/day, 4 weeks
16567151|NCT02832206||hybrid ablation|60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation
16567152|NCT02832193||Study group|"POCD data of study patients of the following studies:
~Phydelio - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 ReCosa - EA1/056/13 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 Pain-Long-EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
16567153|NCT02832193||Control group I|"POCD data of prospective control subjects/patients (ASA I+II+III) and POCD data of control subjects/patients of the following studies:
~Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 Phydeliostudie - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 BioCog-Studie - EA2/092/14 REACT-Studie - EA2/091/15 PAINLONG-Studie - EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
16567154|NCT02832180|Experimental|Daily single dose of OC containing EE and NET|Daily single dose of OC Containing EE and NET alone.
16567155|NCT02832180|Experimental|Daily single dose of OC in combination with BMS-986142|Daily single dose of OC containing EE and NET in combination with BMS-986142.
16567156|NCT02832167|Experimental|Nivolumab|
16567157|NCT02832154|Experimental|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
16567158|NCT02832141||Group A|Group A: immediate effects: T0, Grade 3 central thoracic mobilization from posterior-to-anterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
16567159|NCT02832141||Group B|Group B: immediate effects: T0, 3 central thoracic mobilization from anterior-to-posterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
16567160|NCT02832128|Experimental|AUT00063 - Placebo|AUT00063 (800 mg/day) for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with placebo
16567161|NCT02832128|Experimental|Placebo - AUT00063|Placebo for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with AUT00063 (800 mg/day)
16567162|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
16567163|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
16567164|NCT02832102||Retrospective cohort|"A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.
~Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN."
16567165|NCT02832102||Prospective cohort|"A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.
~Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments."
16567166|NCT02832089|Experimental|active arm|single arm study with one group given oral carvedilol.
16567167|NCT02832076|Experimental|group a|This arm will receive subcutaneous negative suction drain for the midline wound for 10 days.
16567168|NCT02832076|Active Comparator|group b|This arm will receive closure of the midline wound without a subcutaneous drain.
16567169|NCT02832063|Active Comparator|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
16567170|NCT02832063|Placebo Comparator|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
16567206|NCT02831829|No Intervention|Control group (usual care)|Control group: patients randomized in control group will have usual care with no exercise
16567207|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
16567208|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
16567209|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
16567239|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
16567171|NCT02832050|Experimental|Intervention|"The play therapy intervention consists of a standard of care delivered by a play specialist. The play specialist delivers interventions aimed in assisting the child through the process of undergoing procedures. The intervention is semi-structured in order to facilitate a systematic approach which remains individualised and child-centred.
~The intervention requires patients to be classified as 'high risk' or 'low risk' for procedure-related anxiety. This is assessed for all patients at baseline based on parent and clinician opinion. The play specialist may re-classify patients at the initial assessment or at any point whilst working with the child. If this occurs, clear documentation of the rationale for this will be recorded. Patients classified as high risk receive additional preparation sessions as detailed in the standard of care."
16567172|NCT02832050|Placebo Comparator|Comparator|The comparator group will receive standard care of patients having blood tests within the Trust, which does not include the specific intervention of a play therapist routinely. As part of standard care if a child becomes particularly distressed a clinician may make a decision to refer the child for play therapy. If this occurs during the study period the child will be referred to the play specialist delivering the intervention for the study. The child will then receive play therapy as in the described intervention. They will be excluded from the main analysis but data will still be collected and analysed descriptively.
16567173|NCT02832037|Experimental|BI 425809 dose 1|
16567174|NCT02832037|Experimental|BI 425809 dose 2|
16567175|NCT02832037|Experimental|BI 425809 dose 3|
16567176|NCT02832037|Experimental|BI 425809 dose 4|
16567177|NCT02832037|Placebo Comparator|Placebo|
16567178|NCT02832024|Active Comparator|Intervention: Stents|Stents group
16567179|NCT02832024|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
16567180|NCT02832024|Active Comparator|Intervention: Balloon|Balloon group
16567181|NCT02832011|Active Comparator|olive oil|After randomization, Investigators will give human milk fortiﬁed with olive oil
16567182|NCT02832011|Active Comparator|Eoprotin|After randomization, Human milk fortiﬁed with Eoprotin according to the recommendations of the manufacturer (1g per 30ml milk)
16567183|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
16567184|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
16567185|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
16567186|NCT02831985|Experimental|general practice follow-up|post-surgery follow-up by general practitioner
16567187|NCT02831985|Active Comparator|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
16567188|NCT02831972|Experimental|Period 1|A single oral dose of AG-120 will be administered at Hour 0 followed by PK sampling for 504 hours (21 days).
16567189|NCT02831972|Experimental|Period 2|In Period 2, multiple oral doses of itraconazole will be administered once daily (QD) for 18 consecutive days (Days -4 to 14) with a single oral dose of AG-120 coadministered at Hour 0 on Day 1. PK sampling for AG-120 will be taken for 504 hours (21 days) following AG-120 dosing on Day 1. PK sampling will also be collected for itraconazole and its metabolite, hydroxy-itraconazole, from Day -2 up to Day 13.
16567192|NCT02831946|Experimental|MODIFIED VICRYL PLUS|The intra-cuticular layer will closed with with VICRYL PLUS suture
16567193|NCT02831946|Experimental|DERMABOND GLUE|The intra-cuticular layer will closed with with DERMABOND GLUE
16567194|NCT02831933|Experimental|Experimental|"ADV/HSV-tk (5 x 1011 viral particles) in a 2-mL total volume will be injected intratumorally on day 0 of the study.
~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days. Valacyclovir treatment will be administered 24 hours after the gene vector injection from day 1 to day 15 of the study.
~SBRT of 30 gray (Gy; 6 Gy X 5 fractions) will be administered over 2 weeks from day 2 to day 16 of the study.
~Nivolumab (480 mg) will be administered intravenously over 30 minutes every 4 weeks starting on day 17 of the study and continuing until disease progression, unacceptable toxicity, or up to 12 months in patients without disease progression."
16567195|NCT02831920|Experimental|Single Arm|every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies. Every patient is therefore its own control.
16567196|NCT02831907||Cardiac surgery patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
16567197|NCT02831894|Sham Comparator|0% Hypnotic Medication Taper|In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
16567198|NCT02831894|Active Comparator|25% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
16567199|NCT02831894|Active Comparator|10% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.
16567200|NCT02831868|Experimental|EXP|Implantation of a HAVAI device to correct HVA without osteotomy
16567201|NCT02831855|Experimental|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
16567202|NCT02831855|Placebo Comparator|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
16567203|NCT02831842||mCRC Participants|Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.
16567204|NCT02831829|Active Comparator|Water-based exercise training group|"Intervention: Patients randomized to the water-based exercise training group will undergo water-based exercise training. The immersed exercise will include two session of aerobic (water-based) and calisthenic exercise per day, six days of a week, each lasting 30 minutes."
16567237|NCT02831582|Active Comparator|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid supplementation PO QD for 6 months.
16567210|NCT02831803|Experimental|Intervention|All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
16567211|NCT02831790|Experimental|Educational Intervention|Participants in the intervention group will have access to the 3 teaching videos, ~3:30-5:00 minutes in duration each, beginning several weeks prior to the preadmission clinic (as soon as written consent is obtained).
16567212|NCT02831790|No Intervention|Usual Care|Participants in the usual care will not be offered an intervention and will not be made aware of the existence of the teaching videos.
16567215|NCT02831751|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
16567216|NCT02831751|Experimental|60 µg/strain of Quadrivalent VLP Vaccine|
16567217|NCT02831751|Active Comparator|FluLaval® Tetra (15 µg/strain)|
16567218|NCT02831751|Active Comparator|Fluzone® High-Dose (60 µg/strain)|
16567219|NCT02831738|Experimental|Active Treatment|Polydextrose 12 g
16567220|NCT02831738|Placebo Comparator|Control Treatment|No polydextrose
16567221|NCT02831712|Other|Iron supplement|Ferrous Fumarate tablet 200 mg
16567222|NCT02831699||Febrile Rash|
16567223|NCT02831699||Household|
16567224|NCT02831699||Guillain-Barré prospective|
16567225|NCT02831699||Prior Guillain-Barré|
16567226|NCT02831686|Experimental|Selinexor (KPT-330), Ixazomib, and Dexamethasone|"Patients with relapsed and/or refractory MM will be treated with ixazomib, selinexor, and dexamethasone, all of which will be administered orally.Ixazomib will be given on Days 1, 8, and 15 on a 28 day cycle.
~Selinexor will be given twice weekly for three weeks, then there will be 1 week off (Days 1,3, 8,10, 15, 17) This study will follow a 3-by-3 dose escalation design.
~Dexamethasone will be given on all days of Selinexor but will also be given on the week off from Selinexor (Days 1, 3, 8, 10,15, 17, 22, 24)."
16567229|NCT02831660|Experimental|idarucizumab|
16567230|NCT02831647|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PRAGUE for a period of 9 days.
16567231|NCT02831634|Other|Blood sampling|
16567232|NCT02831621|Active Comparator|diet (usual care)|All participants will receive a hypocaloric diet based on the individual resting metabolic rate. Resting metabolic rate (RMR) will be estimated using the WHO formula or measured using indirect calorimetry. Total energy expenditure will be calculated by multiplying RMR with a physical activity level (PAL). The used physical activity level will be 1.3. A hypocaloric diet with an energy deficit of 500 kcal/day will be prescribed. Participants will see a skilled dietician two-weekly the first month and on a monthly basis the next five months to discuss problems and solutions or coping strategies. The first consultation will have a duration of 60 minutes, the next consultations will have a duration of approximately 30 minutes. Each visit, nutritional compliance will be recorded on a 0 to 10 numeric rating scale. The usual care group will be asked to continue with their normal physical activity during the six-month intervention period.
16567233|NCT02831621|Experimental|diet+exercise|"For participants of this group, usual care will be supplemented with a prescribed exercise program. For this exercise program the participants will be referred to a local fitness club near home, free of charge. Aerobic training will be done at an intensity of 90-95% of the heart rate achieved at the RCP. Aerobic training will have a duration of 30 to 45 minutes, according to the training stage. Cardio training will be performed on different cardio devices and strength training will be done on isotonic strength training devices. Each training day, core stability training will be completed with four strength exercises for large muscle groups. Each exercise will be done in two sets of 15 repetitions with the goal to achieve better muscular strength endurance.
~This combined training will be done individually during six months, three times/week.
~In this study, an effort is made to reach a uniform manner of guidance to the physical activity program."
16567234|NCT02831608|Experimental|Drug: influenza vaccine|Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
16567235|NCT02831608|Placebo Comparator|Drug: placebo|Saline administered as a deep subcutaneous injection at one occasion per subject.
16567236|NCT02831595||Patients undergoing unilateral TKA|
16567240|NCT02831556||Emergency Department Subjects|Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.
16567241|NCT02831556||Non-patient volunteers|Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.
16567242|NCT02831543|Experimental|Motireb 5/100 mg t.i.d|Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
16567243|NCT02831543|Active Comparator|Mosapride citrate t.i.d|Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d
16567244|NCT02831543|Placebo Comparator|Placebo t.i.d|Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
16567245|NCT02831530|Experimental|Abemaciclib|Patients randomized to the treatment arm will start treatment from 15 days before the surgery (day 1 of the study) to receive the last dose of treatment the day before the surgical procedure (day 14 of the study). Abemaciclib will be taken orally at a dose of 150 mg/ twice a day (Every 12h +/- 2h) on day 1 to day 14. The treatment should be taken in the morning and evening with a big glass of water (250ml) at approximately the same time.
16567246|NCT02831530|No Intervention|No treatment|
16567247|NCT02831517|Experimental|Part 1|48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
16567248|NCT02831517|Experimental|Part 2|16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
16567249|NCT02831504||Myotonic Dystrophy type 1 (DM1) patients|Natural History Study
16567250|NCT02831491|Experimental|Ramucirumab + Docetaxel|Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.
16567251|NCT02831478|Experimental|BAY987517|2/3 of subjects testing the test article
16567252|NCT02831478|Active Comparator|Sunscreen Lotion|1/3 of subjects testing the marketed control
16567253|NCT02831465|Experimental|healthy subjects|Subjects with normal lung function between 40 and 70 years old.
16567254|NCT02831452||non-pregnant nulliparous|nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
16567255|NCT02831452||primigravid on 1º trimester|"nulliparous women on her first pregnancy and gestational age until 13 weeks and 6 days.
~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
16567256|NCT02831452||primigravid on 2º trimester|"nulliparous women on her first pregnancy and gestational age between 14 weeks and 27 weeks.
~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
16567257|NCT02831452||primigravid on 3º trimester|nulliparous women on her first pregnancy and gestational age above 28 weeks. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
16567258|NCT02831439|Experimental|Intervention|Participating health systems in Wisconsin. Interventions include: Basic public reporting and the enhanced intervention (app)
16567259|NCT02831439|Other|Control|Health systems in comparison states. Control includes: Cost savings comparison
16567260|NCT02831426|Active Comparator|ADM two-stage reconstruction|Two-stage with Acellular Dermal Matrix (CELLIS® Breast). Tissue Expander A, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by ADM
16567261|NCT02831426|Experimental|TCPM two-stage reconstruction|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra). Tissue Expander B, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by TCPM
16567262|NCT02831413|Placebo Comparator|Control|Control group members will receive an alternate curriculum that is not related to relationship education. Family Bridges has identified a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
16567263|NCT02831413|Experimental|RS+|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
16567264|NCT02831413|Experimental|RS+ with enhanced facilitator support|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
16567265|NCT02831400|Experimental|IFABP assessment (1 study group)|30 elderly volunteers
16567266|NCT02831387|Experimental|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
16567267|NCT02831387|Placebo Comparator|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
16567268|NCT02831374|Experimental|Use of platelet rich plasma (Group A)'|Local anesthesia, surgical extraction of impacted third molar, Preparation of PRP gel, Placing platelet Rich plasma and suturing, Postoperative medication
16567269|NCT02831374|Placebo Comparator|surgical extraction (Group B)|Local anesthesia, surgical extraction of impacted third molar, Suturing, Postoperative medication
16567270|NCT02831361|Experimental|Gemigliptin 50mg|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
16567271|NCT02831361|Placebo Comparator|Gemigliptin 50mg placebo|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
16567272|NCT02831348||Uncontrolled asthma|Indicated by an asthma control test (ACT) score of <20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
16567273|NCT02831348||Controlled asthma|Indicated by an ACT score of >19, or spirometry results within 10% of year's best value (based on FEV1).
16567274|NCT02831348||Pneumonia|Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
16567275|NCT02831348||Controlled allergic rhinitis|Indicated by a rhinitis control assessment test (RCAT) score of >= 21.
16567276|NCT02831348||Uncontrolled allergic rhinitis|Indicated by an RCAT score of <21.
16567277|NCT02831348||Cystic fibrosis (exacerbated)|Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
16567278|NCT02831348||Cystic fibrosis (stable)|Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
16567279|NCT02831348||Control|Indicated by a negative history of any of the conditions characterizing the other groups.
16567280|NCT02831335||Group 1|normal 21-35 years old participants
16567281|NCT02831335||Group 2|normal 36-50 years old participants
16567282|NCT02831335||Group 3|normal 51-65 years old participants
16567283|NCT02831335||Group 4|normal 66- 80 years old participants
16567284|NCT02831322|Experimental|radial artery occlusion|Radial artery occlusion was the absence of a flow signal by Doppler ultrasound examination.
16567285|NCT02831322|Other|radial artery normal|Radial artery normal was blood flow signal by Doppler ultrasound
16567286|NCT02831309|Sham Comparator|Sedentary Condition|Forty minutes of screen time. Standardized meals provided.
16567287|NCT02831309|Active Comparator|Light-Intensity Condition|Forty minutes of light-intensity activity. Standardized meals provided.
16567288|NCT02831309|Active Comparator|Moderate-Intensity Condition|Forty minutes of moderate-intensity activity. Standardized meals provided.
16567289|NCT02831309|Active Comparator|High-Intensity Condition|Forty minutes of high-intensity activity. Standardized meals provided.
16567290|NCT02831296||Affected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)
~The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy."
16567291|NCT02831296||Unaffected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger who are not affected with SMA
~The unaffected group will undergo the same assessments as the affected group."
16567292|NCT02831296||Unaffected Family Members|"Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.
~The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy."
16567293|NCT02831296||Affected Subjects >36 Mos. of Age|"Children and adults >36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.
~The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects."
16567294|NCT02831283|Experimental|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
16567295|NCT02831283|Active Comparator|No cognitive impairment|Normal aging
16567296|NCT02831270||Control Group|Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB
16567297|NCT02831270||Active Comparator: Acute normovolemic hemodilution group|Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
16567298|NCT02831257|Experimental|AZD2014|"18 patients will be enrolled in this study in a single stage.
~AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.
~One cycle will consist of 28 days (1 cycle = 28 days)."
16567299|NCT02831244|Other|Agili-CTM|Intervention
16567300|NCT02831231|Active Comparator|Xanomeline plus placebo|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
16567301|NCT02831231|Experimental|Xanomeline plus trospium|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
16567302|NCT02831218|Experimental|QCA and Aspirin alone|
16567303|NCT02831218|Experimental|QCA and Clopidogrel alone|
16567304|NCT02831218|Active Comparator|Imaging guided and Aspirin alone|
16567305|NCT02831218|Active Comparator|Imaging guided and Clopidogrel alone|
16567306|NCT02831205|Experimental|ABSORB BVS|
16567307|NCT02831205|Active Comparator|XIENCE EES|
16567308|NCT02831192|Experimental|MST（microtransplantation）|
16567309|NCT02831179|Experimental|Treatment (capecitabine, temozolomide, veliparib)|Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
16567310|NCT02831166|Active Comparator|Transradial approach|Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=125).
16567311|NCT02831166|Active Comparator|Transfemoral approach|Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=125).
16567312|NCT02831153|Active Comparator|normal coronary anatomy|coronary angiography will be performed by transfemoral or transradial route.
16567313|NCT02831153|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
16567314|NCT02831153|Active Comparator|slow coronary flow|coronary angiography will be performed by transfemoral or transradial route.
16567315|NCT02831153|Active Comparator|nonobstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
16567316|NCT02831153|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
16567317|NCT02831140|Other|Common arm : for both groups :|"In preoperative phase
~In peroperative phase
~In postoperative phase"
16567318|NCT02831140|Experimental|FTR protocol group (A)|"A. Experimental : FTR protocol group :
~Early exercises after a thoracic surgery : removing urinary probe and all catheters as well as alimenting ."
16567319|NCT02831140|No Intervention|Control group (B)|Traditional, conventional care group with first get up and alimentation permission in 24 hours at the postoperative.
16567320|NCT02831127|Experimental|short message service group|Patients in this arm received conventional instructions plus short message reminder.
16567321|NCT02831127|Active Comparator|conventional group|Patients in this arm just received conventional instructions.
16567322|NCT02831114|Experimental|Intervention|The nine participants in the intervention arm will receive 18 acupuncture treatments over the course of 12 weeks (2 treatments per week for 6 weeks and 1 treatment per week for 6 weeks). They will undergo assessments at baseline, 6 weeks, and 12 weeks through the use of questionnaires and blood tests. The participants will also be allowed to continue their conventional therapy for TIPN.
16567323|NCT02831114|No Intervention|Control|The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
16567324|NCT02831101|Experimental|Sufentanil|Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study
16567325|NCT02831101|Other|Placebo|Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study
16567326|NCT02831101|No Intervention|Propofol|Open administration using a separate target controlled infusion system and the PK/PD model by Schnider. Initial effect-site concentration 0.5 mcg/ml increased by 0.5 mcg/ml until LOC
16567327|NCT02831088|Experimental|Neu2000KWL High-dose group|
16567328|NCT02831088|Experimental|Neu2000KWL Low-dose group|
16567329|NCT02831088|Placebo Comparator|Placebo|
16567330|NCT02831075|Experimental|Adipose-derived stem cell|Mesenchymal stem cells derived from adipocyte transplantation
16567331|NCT02831075|Placebo Comparator|saline|saline injections
16567332|NCT02831062|No Intervention|ad lib diet|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients will be asked to continue on their regular diet and the protein and caloric ingestion will be recorded at each visit.
16567333|NCT02831062|Experimental|Low Protein Diet + Ketosteril|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients in this arm will be prescribed a low protein diet (LPD) and +Ketosteril supplementation, containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose). Protein and caloric ingestion will be recorded.
16567337|NCT02831036|Experimental|trial group|subjects in trial group will be following the experimental protocol (VO2max tests and spatial orientation tests) while performing a training program during the trial (3 months).
16567338|NCT02831036|Other|control group|following the experimental protocol (VO2max tests and spatial orientation tests)without performing additional exercise.
16567339|NCT02831023|Active Comparator|SP-AQ only|Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
16567340|NCT02831023|Experimental|SP-AQ plus PQ|Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
16567341|NCT02831023|Active Comparator|DP only|Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
16567342|NCT02831023|Experimental|DP plus MB|Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).
16567343|NCT02831010||encephalopathy of prematurity|infants with encephalopathy of prematurity showed on MRI at term-equivalent age
16567344|NCT02831010||no encephalopathy of prematurity|infants with no encephalopathy of prematurity showed on MRI at term-equivalent age
16567345|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
16567346|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
16567347|NCT02830984|Experimental|EST+LBD+ENBD group|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
16567348|NCT02830984|Active Comparator|EST+LBD group|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
16567349|NCT02830971|Other|Clinical specific education|Providing clinical skills conditions
16567350|NCT02830958|Experimental|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
16567351|NCT02830958|Placebo Comparator|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
16567352|NCT02830945|Other|Control Brochure Arm|Control Arm households receive a culturally tailored Stroke and CVD brochure for prevention.
16567353|NCT02830945|Experimental|Motivational Interviewing Intervention Arm|The MI intervention households receive three aspects of the intervention: digital stories, motivational interviewing talking circle and the option to receive text messages to adhere to the action plan.
16567354|NCT02830932|Experimental|VXA-RSV-f Tablets (high dose)|Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
16567355|NCT02830932|Experimental|VXA-RSV-f Tablets (low dose)|Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
16567459|NCT02829996|Active Comparator|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
16567356|NCT02830932|Placebo Comparator|VXA Placebo Tablets|Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
16567357|NCT02830919|Experimental|Glucosamine and chondroitin sulfate combination (Eurofarma)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
16567358|NCT02830919|Active Comparator|Glucosamine and chondroitin sulfate combination (Zodiac)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
16567359|NCT02830906|Experimental|ramosetron group|Patients received 0.3 mg of intravenous ramosetron before spinal anesthesia and intrathecal morphine
16567360|NCT02830906|Active Comparator|ondansetron group|Patients received 8 mg of intravenous ondansetron before spinal anesthesia and intrathecal morphine
16567361|NCT02830893|Experimental|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
16567362|NCT02830893|Active Comparator|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
16567363|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
16567364|NCT02830854|Experimental|Molecular Hydrogen|Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks
16567365|NCT02830841|Experimental|DR-RIPC (donor and recipient RIPC group)|Both donors and recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm(donor) or right lower limb(recipient) and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
16567366|NCT02830841|Sham Comparator|S-RIPC (sham RIPC)|Patients had a deflated cuff placed on the right upper arm or right lower limb for 30 min
16567367|NCT02830841|Experimental|R-RIPC (recipient RIPC group)|Recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right lower limb and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
16567368|NCT02830841|Experimental|D-RIPC (donor RIPC group)|Donors receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
16567369|NCT02830828||Patients|Patients fulfilling inclusion/exclusion criteria referred to the PI with suspected carpal tunnel syndrome.
16567370|NCT02830828||Controls|"Healthy volunteers fulfilling inclusion/exclusion criteria with no symptoms of carpal tunnel syndrome.
~Mid-study, it was elected to also match patients to their own contralateral disease-free hand to act as a control."
16567371|NCT02830802|Experimental|Group A|Active Agent
16567372|NCT02830802|Placebo Comparator|Group B|Placebo
16567373|NCT02830789|Experimental|Calcium Carbonate|1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3
16567374|NCT02830789|Experimental|Calcium Citrate|2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3
16567375|NCT02830776|Experimental|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
16567376|NCT02830763|Experimental|Medium-chain Fatty Acid (CNT-02)|
16567377|NCT02830737|Active Comparator|Traditional RFA|Using Traditional RFA for the treatment of small hepatocellular carcinoma
16567378|NCT02830737|Experimental|No-touch RFA|Using No-touch RFA for the treatment of small hepatocellular carcinoma
16567379|NCT02830724|Experimental|1/Phase I|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
16567380|NCT02830724|Experimental|2/Phase II|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
16567381|NCT02830685|Active Comparator|Direct-To-Implant A|DTI with Acellular Dermal Matrix (CELLIS® Breast), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of an Acelluar Dermal Matrix (ADM)
16567382|NCT02830685|Experimental|Direct-To-Implant B|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of a titanium coated polypropylene mesh
16567383|NCT02830672|Active Comparator|Open surgical release A1 Pulley|
16567384|NCT02830672|Active Comparator|Ultrasound guided close release A1 pulley|
16567385|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC
16567386|NCT02830633|Experimental|LNTME|Laparoscopy-assisted nerve-preserved TME (LNTME) is conducted in rectal cancer patients
16567387|NCT02830633|Active Comparator|OTME|Open TME (OTME) is conducted in rectal cancer patients
16567388|NCT02830620|Other|groupe1|cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines
16567389|NCT02830620|Other|groupe2|cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines
16567390|NCT02830620|Other|groupe3|pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines
16567391|NCT02830620|Other|groupe4|unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines
16567392|NCT02830607|Experimental|Xiaomi Mi Band|participants will wear Xiaomi Mi Band .the device measures their daily steps number before and after epidural steroid injection for treatment of low back pain.
16567482|NCT02829801|Other|control group|Cognitive stimulation and rehabilitation of social tie.
16567393|NCT02830594|Experimental|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Cycles repeat every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity."
16567394|NCT02830568||couples kidney living donor - receiver|"Three groups for each technique of taking of kidney :
~open donor nephrectomy
~standard and hand-assisted laparoscopic donor nephrectomy
~laparoscopic robotic-assisted nephrectomy"
16567395|NCT02830542|Experimental|SER-262|SER-262 [Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs]
16567396|NCT02830542|Placebo Comparator|Placebo|Placebo
16567397|NCT02830529|Experimental|MAD DASH|Mindfulness based stress reduction and diet education delivered in 8 sessions lasting 2.5 hours each. Mindfulness conducted by a certified trainer. Participants were given homework and meditation CD. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
16567398|NCT02830529|Experimental|DASH diet education|Dietary approaches to stop hypertension sessions were delivered by a registered dietitian in 8 sessions lasting 1 hour each. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
16567399|NCT02830529|No Intervention|Usual Care-DASH Pamphlet Only|Dietary approaches to stop hypertension pamphlet was mailed to each participant. They continued receiving usual care from their health care provider.
16567400|NCT02830516||Lung elastance - transpulmonary pressure|Lung elastance and transpulmonary pressure measured by tidal esophageal pressure variations and by performing a PEEP step
16567401|NCT02830503|Experimental|Intervention|Feeding tube daily replacement
16567402|NCT02830503|No Intervention|Control|Feeding tubes replaced as normal practice in the department (normally once a week).
16567403|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
16567404|NCT02830438|Experimental|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
16567405|NCT02830412|Experimental|PONV Reminder|After patient has non-cardiac surgery, the subject will have Post-Operative Nausea and Vomiting Reminder display
16567406|NCT02830412|No Intervention|No PONV Reminder|After patient has non-cardiac surgery, the subject will not have Post-Operative Nausea and Vomiting Reminder display
16567407|NCT02830399|Active Comparator|active rTMS-ECT|5 active high frequency rTMS before 5 bilateral ECT
16567408|NCT02830399|Placebo Comparator|sham rTMS-ECT|5 sham rTMS before 5 bilateral ECT
16567409|NCT02830386||LVIS stents group|The patients with ruptured intracranial saccular aneurysm wil be treated with a LVIS stent without coils.
16567410|NCT02830373||LVIS stents group|patients with unruptured intracranial saccular aneurysms which located in the internal carotid artery or vertebra-basilar artery will be treated with a LVIS stent with coils
16567411|NCT02830360|Active Comparator|VT catheter ablation|Catheter ablation of ventricular tachycardia
16567412|NCT02830360|Active Comparator|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
16567413|NCT02830347||Amoxicillin|No randomization is performed. Patients who are prescribed antibiotics by the clinician performing the tooth extraction ( based on case complexity and intra operative judgement) are recruited into this group.The principal investigator is not involved in the decision to prescribe antibiotics or not.
16567414|NCT02830347||No Amoxicillin|Patients who do not receive antibiotics after extractions are recruited into this group.
16567415|NCT02830321||case|"Pregnant women who suffered from hyperemesis gravidarum and admitted in the hospital
~Age: 18-40 years old
~Gestational age: less than 16 weeks confirmed by pelvic u/s
~Excessive pregnancy - related nausea and /or vomiting that prevent adequate intake of food and fluids.
~All pregnant (case and control) were asked to bring a stool sample in a clean container. Collected samples were tested in a laboratory (Ain Shams Univerisity hospital).
~Stool samples were be tested by using one step H.pylori stool antigen test (CER TEST BIOTEC) for the detection of H. pylori antigen."
16567416|NCT02830321||control|Control patients which are selected from pregnant women presenting to the outpatient clinics for routine antenatal care of the same gestational age, same age range and same socioeconomic standard as cases.
16567418|NCT02830295|Experimental|Basic Body Awareness Therapy|The Basic Body Awareness Therapy is usual therapy of physiotherapy in health mental in nord of europe. BBAT is based in twelve movements and massage that improve the movement quality of patient, also BBAT improves others movement qualities like biomechanical, physiologic, socio-cultural and existential.
16567419|NCT02830295|No Intervention|control|the patients which below receive the treatment as usual, according the clinic guidelines of Health government
16567420|NCT02830243|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
16567421|NCT02830243|Experimental|Desflurane|Anesthesia was maintained with desflurane.
16567422|NCT02830230|Experimental|Intervention group/Case|"women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.
~women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.A cervico-vaginal swab shall be taken for Lab diagnosis of RTIs along with HPVDNA test on day 1.Women shall be treated with Tab Azithromycin 1gm and Tab Cefixime 400mg stat along with barrier contraception advised.The women will be followed up after 7-14 days .A repeat cervicovaginal swab and HPVDNA shall be repeated."
16567423|NCT02830230|No Intervention|Control group|Women without signs and symptoms of cervicitis or cervico-vaginitis.No intervention will be done in this group
16568316|NCT02823769|Experimental|SI-R21204 resin composite|Fillings made with a new dental filling material
16567424|NCT02830217||STEMI patients having primary PCI|Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
16567425|NCT02830204|Experimental|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
16567426|NCT02830178||Any Paracetamol|Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
16567427|NCT02830178||Ibuprofen|Participants with age 18 and over who received a first prescription of single-ingredient ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
16567428|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
16567429|NCT02830152|Experimental|Left Atrial Appendage Occlusion (LAAO)|The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
16567430|NCT02830152|Active Comparator|Medical Therapy|The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
16567431|NCT02830139|Sham Comparator|Radical colorectal resection without HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and postoperative chemotherapy (XELOX)
16567432|NCT02830139|Experimental|Radical colorectal resection with HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (XELOX)
16567433|NCT02830126|No Intervention|Anesthesiology Control Tower Control|Patients managed by anesthesia teams without feedback alerts from the ACT
16567434|NCT02830126|Experimental|Anesthesiology Control Tower Feedback|Patients managed by anesthesia teams with feedback alerts from the ACT
16567435|NCT02830113|Experimental|non-surgical periodontal treatment|One session of non-surgical periodontal treatment consisting of a complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution.
16567436|NCT02830100|Other|Healthy volunteers|
16567437|NCT02830087|Active Comparator|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
16567438|NCT02830087|Active Comparator|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
16567439|NCT02830087|Active Comparator|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
16567440|NCT02830087|Active Comparator|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
16567441|NCT02830087|Active Comparator|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
16567442|NCT02830087|Active Comparator|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
16567443|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + patient Education + ongoing Support and Training)
16567444|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
16567445|NCT02830061||TYAC|Teenagers and young adults who have received a cancer diagnosis which puts them at moderate-to-high risk of fertility impairment. Semi-structured interviews will take place with each individual participant.
16567446|NCT02830048|Experimental|Glibenclamide dose titration|Increasing doses of glibenclamide oral suspension from 0.3mg/day to 6mg/day.
16567447|NCT02830035|Active Comparator|Anatomical Landmark Technique|Traditional anatomical landmark technique based paramedian spinal anesthesia
16567448|NCT02830035|Active Comparator|Real-time Ultrasound-guided Technique|Ultrasound-guided paramedian spinal anesthesia Intervention: Ultrasound-guided Technique
16567449|NCT02830022|Experimental|Patients|Children from 8 to 18 years with autism without without intellectual disabilities (IQ > 70), verbals and responding to classification CIM 10-DSM IV.
16567450|NCT02830022|Experimental|Healthy volunteers|Paired for age, gender, IQ and and the practice of a physical activity strictly within the school context.
16567451|NCT02830009|Other|Primary Hyperoxaluria patient|
16567452|NCT02830009|Other|Primary Hyperoxaluria patient's siblings|
16567453|NCT02830009|Other|Idiopathic hypercalciuria patients|
16567454|NCT02830009|Other|Healthy volunteers|
16567455|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
16567456|NCT02829996|Experimental|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
16567457|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
16567458|NCT02829996|Active Comparator|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
16567460|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
16567461|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
16567462|NCT02829970|Experimental|SUCCEEDS Program|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will be engaged about personalized alcohol feedback and identify life values and specific activities important to those values.
16567463|NCT02829970|Active Comparator|Living a Healthy College Lifestyle|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
16567464|NCT02829957|Active Comparator|Rivaroxaban|
16567465|NCT02829957|Active Comparator|Apixaban|
16567466|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
16567467|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
16567468|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.
~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
16567470|NCT02829892|Other|Light therapy|Innovative ambient lighting
16567471|NCT02829879|Experimental|arginine|25 volunteers with dentin sensitivity
16567472|NCT02829879|Active Comparator|potassium nitrate|25 volunteers with dentin sensitivity
16567473|NCT02829853||sporadic cases (SP)|Sporadic cases are defined as patients diagnosed for sarcoidosis, for which the familial history did not reveal any other cases, whatever the relative degree is: 1, 2, 3 or 4. The clinical follow-up and the genetic studies performed in the frame of this project are the same as for the familial group. During the regular follow-up, patients are regularly questioned about the putative occurrence of the disease in their family, and if such a situation occurred, the patient (and his relative) may change from the SP to the familial (FAM) group. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
16567474|NCT02829853||familial cases (FAM)|Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
16567475|NCT02829840|Experimental|Cohort #1|"Cohort #1: Participants with no previous leukemia therapy (including no previous FLT3 inhibitor therapy) for either: a) front-line treatment of elderly (age 65 and greater) FLT3-mutated AML patients, or b) patients unable or unwilling to receive standard intensive therapy.
~Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.
~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
16567476|NCT02829840|Experimental|Cohort #2|"Cohort #2: Participants with relapsed/refractory FLT3-mutated AML that have not received prior FLT3 inhibitor therapy.
~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.
~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
16567477|NCT02829840|Experimental|Cohort #3|"Cohort #3: Participants with relapsed/refractory FLT3-mutated AML, that have received previous FLT3 inhibitor therapy (including, but not limited to, quizartinib, crenolanib, sorafenib, other FLT3 inhibitors).
~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant will continue on to Part 2 of study.
~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
16567478|NCT02829827|Experimental|Radiprodil|Each subject will enter an individualized dose titration schedule.
16567479|NCT02829814|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
16567480|NCT02829814|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
16567481|NCT02829801|Experimental|AAT arm|AAT and cognitive stimulation and rehabilitation of social tie.
16567483|NCT02829788||Digestive peritoneal carcinomatosis staging|All patients underwent laparoscopic followed by laparotomic surgical staging.
16567484|NCT02829775|Experimental|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
16567485|NCT02829762|Experimental|Interventional arm PS-DR|The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
16567486|NCT02829762|No Intervention|Reference Arm|In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.
16567487|NCT02829749|Experimental|NeoChord DS1000 Artificial Chordae Delivery System|Subjects randomized to the experimental group will undergo the NeoChord implantation
16567488|NCT02829749|Other|Control|traditional mitral valve repair performed under cardiac arrest
16567489|NCT02829736|Active Comparator|Chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard post-operative chest tube.
16567490|NCT02829736|Experimental|No chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
16567491|NCT02829723|Experimental|BLZ945 single agent|
16567492|NCT02829723|Experimental|BLZ945 + PDR001|
16567493|NCT02829710||group 1 : pre implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between January 2013 and December 2013.
~Prior to implementation of the protocol, analgesia and sedation were managed by the attending physician's order."
16567494|NCT02829710||group 2 : post implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between May 2014 and March 2015.
~Nurses managed analgesia and sedation following an algorithm, including COMFORT-B scale."
16567495|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 2.5 mL|Perineural injection of ropivacaine 0.2 %, 2,5 mL
16567496|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
16567497|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
16567498|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
16567499|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
16567500|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
16567501|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
16567502|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
16567503|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
16567504|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 30 mL|Perineural injection of ropivacaine 0.2 %, 30 mL
16567505|NCT02829671|Other|Patients with major depressive disorders|
16567506|NCT02829658||Psychiatric patients group|Patient groups were composed with: BPD, other PD and assessed Psychologic test
16567507|NCT02829658||Control group|Matched controls (age, sex) composed the 3rd and 4th group (BPD control and other PD control). They were randomly chosen in the health database insurance previously used. They had no intervention.
16567508|NCT02829645|Other|Eating disorders|
16567509|NCT02829632|Experimental|Experimental: Group Sessions|Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
16567510|NCT02829632|Experimental|Active Comparator: Self-Monitoring|Active Comparator: Self-monitoring Participants will record diet, activity and weight as described above in the participant's smartphone app to assist the participant in losing weight.
16567511|NCT02829632|Experimental|Experimental: Feedback|"Participants will be sent via the participant's smartphone between
~1 and 4 feedback messages a day about whether the participant has been self monitoring, or the amount of calories, fat or sugar the participant has consumed."
16567512|NCT02829606|Active Comparator|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
16567513|NCT02829606|Active Comparator|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
16567514|NCT02829593|Experimental|type 1 diabetes|type 1 diabetes >5 years duration
16567515|NCT02829593|Placebo Comparator|healthy controls|
16567516|NCT02829580|Experimental|Sickle group|Children with major sickle cell syndrome will have an usual Echocardiography
16567517|NCT02829580|Active Comparator|Control group|Children recruited in a previous study and who had an usual Echocardiography
16567518|NCT02829567|Experimental|Oral hygiene counseling and motivational interviewing|This group will receive a session of oral hygiene counseling and a single session of motivational interviewing to increase the readiness of change.
16567519|NCT02829567|No Intervention|Oral hygiene counseling|
16567520|NCT02829554||Respondents|US residents recruited to an on-line questionnaire through Amazon mTurk.
16567521|NCT02829541|Experimental|Cohorts 1|6 participants randomized (4:2) to receive a single-ascending dose (SAD) administered orally in tablet
16567522|NCT02829541|Experimental|Cohort 2|6 participants randomized (4:2) to receive a SAD administered orally in tablet(s)
16567523|NCT02829541|Experimental|Cohort 3|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
16567524|NCT02829541|Experimental|Cohort 4|8 participants randomized (6:2) to receive a SAD administered orally in tablet
16567525|NCT02829541|Experimental|Cohort 5|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
16567526|NCT02829541|Experimental|Cohort 6|14 participants (all active) to receive a SAD administered orally in tablet(s)
16567527|NCT02829528|Experimental|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
16567528|NCT02829502|Active Comparator|Byetta|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
16567529|NCT02829502|Placebo Comparator|Normosaline|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
16567530|NCT02829476|Experimental|patients with AIS|Patients will have 'Osteoblast sample'
16567531|NCT02829476|Experimental|control patients|
16567532|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
16567533|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
16567534|NCT02829450||PD|"Patients with CHF and chronic renal disease which started the treatment with peritoneal ultrafiltration.
~The patients will be follow up every 3 months for assesment of symptoms, QOL questionary, routine blood and urine tests and also for assesment of residual renal function and peritoneal membrane function: monitoring of clinical symptoms of fluid overload, hospital admissions, UF rate, peritoneal membrane damage parameters (cell-free DNA in peritoneal effluent, peritoneal equilibration test) and residual renal function markers (eGFR creatinine or cystatin C based , KT/V, urinary markers) at the start of the treatment, each 3 months during the treatment and at each change of prescription. Complications of all kinds will be recorded."
16567535|NCT02829450||Control|Patients with CHF and chronic renal disease which preferred to continue their regular treatment or choose other then peritoneal ultrafiltration type of renal replacement therapy (data from medical records): clinical symptoms of fluid overload, hospital admissions, urine volume,residual renal function markers (eGFR creatinine)
16567536|NCT02829437||Retrospective Observational Group|Patients who received treatment for EST Patients with EST diagnosis prior August 2016
16567537|NCT02829437||Prospective Observational Group|Patients who will receive treatment for EST Patients with EST diagnosis after August 2016
16567538|NCT02829424|Active Comparator|Experimental group|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the control group and according to the Summary of Product Characteritics (SmPC) MTX: 15 mg a week orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX will be initiated within 7 days after the start of the anti TNF alpha agent
16567539|NCT02829424|Placebo Comparator|Control group|"Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent
~All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the experimental group and according to the SmPC Placebo-MTX orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX-placebo will be initiated within 7 days after the start of the anti TNF alpha agent"
16567540|NCT02829411|Active Comparator|Employment Services only|'Workforce Readiness Program'. job readiness workshop, organized into ten daily sessions over two weeks. The main content of these sessions will be a program-developed workforce readiness training, developed with funding from a DOL Career Pathways Bridge grant.
16567541|NCT02829411|Experimental|Employment Services with HMRE content|'Workforce Readiness Program supplemented with Relationship Education': job readiness workshop, organized into ten daily sessions over two weeks. Program will add approximately 17 hours of content from the Within My Reach relationship education curriculum to the two-week job readiness workshop - and add up to eight additional one-hour relationship skills education sessions that customers can attend in the five weeks after completing the initial two-week job readiness workshop
16567542|NCT02829398|Experimental|Patients with subarachnoid hemorrhage|Patients with subarachnoid hemorrhage will have CerebroSpinal fluid and plasma sample.
16567543|NCT02829398|Active Comparator|Control subjects|healthy controls from a previous study with a CerebroSpinal fluid and plasma sample
16567544|NCT02829385|Experimental|Apatinib combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)
~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
16567545|NCT02829372|Experimental|GBR 1302|Dose escalation
16567546|NCT02829359|Experimental|Entecavir therapy|Patients who received entecavir (zhengda Tianqing Co., Ltd, Lianyungang, Jiangsu Province, China; 0.5 mg/d) were submitted to antiviral group. Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month. No immunological therapy in perioperative period will be submitted to any included patients.
16567547|NCT02829359|No Intervention|No antiviral therapy|Patients who did not receive any antiviral therapies were submitted as non-antiviral group. Patients in the non-antiviral group who underwent HBV reactivation will receive entecavir therapy. No immunological therapy in perioperative period will be submitted to any included patients.
16567548|NCT02829346|Experimental|Peri-articular group|Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
16567549|NCT02829346|Active Comparator|Intravenous group|Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.
16567550|NCT02829333|Other|Group GA|22 patients receive general anesthesia and patient controlled intravenous analgesia
16567551|NCT02829333|Other|Group SA|22 patients receive spinal anesthesia and continuous postoperative epidural analgesia
16567552|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
16567553|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
16567554|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
16567555|NCT02829281|Experimental|Botulinum toxin group|Patients will receive a intervention with joint injection of 100 units of botulinum toxin
16567556|NCT02829281|Active Comparator|Corticosteroid group|Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
16567557|NCT02829281|Placebo Comparator|Saline Group|Patients will receive a joint injection of 2ml of normal saline
16567558|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
16567559|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
16567560|NCT02829255|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
16567561|NCT02829242||Prostatic Surgery|Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
16567562|NCT02829242||Colorectal Surgery|Patient scheduled for a robotic assisted laparoscopic colorectal surgery.
16567563|NCT02829229|No Intervention|Usual care (UC)|Usual postpartum WIC care
16567564|NCT02829229|Experimental|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
16567565|NCT02829203||No-Frailty|Patients without frailty score submitted to a cardiac surgery
16567566|NCT02829203||Pre-Frailty|Patients with pre-frailty score submitted to a cardiac surgery
16567567|NCT02829190|Experimental|Healthy volunteers|Magnetic Resonance Imaging (MRI)
16567568|NCT02829190|Experimental|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
16567569|NCT02829190|Experimental|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
16567570|NCT02829190|Experimental|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
16567571|NCT02829177|Active Comparator|Allopurinol|400 mg once daily, tablet treatment
16567572|NCT02829177|Placebo Comparator|Placebo|Identical tablet treatment
16567573|NCT02829151|Experimental|Triple antiplatelet therapy group|Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol
16567574|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) A|Patient group with dual antiplatelet therapy using aspirin and clopidogrel
16567575|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) B|Patient group with angioplasty using aspirin and cilostazol
16567576|NCT02829138|Placebo Comparator|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
16567577|NCT02829138|Experimental|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
16567579|NCT02829086|Experimental|Group I|Participants in Group I will receive the following interventions: Intro to Relationship Enhancement (8 hours), Family Stress and Conflict Management (8 hours), and case management
16567580|NCT02829086|Experimental|Group II|Participants in Group II will receive the following interventions: Intro to Relationship Enhancement (8 hours), RE & Financial Management (8 hours), and case management
16567581|NCT02829086|No Intervention|Group III|Participants in Group III will receive the the standard care of all participants, case management ONLY
16567582|NCT02829073|Experimental|Oasis™ device|Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.
16567583|NCT02829073|Placebo Comparator|Placebo device|Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.
16567634|NCT02828683|Experimental|Ultimaster, Drug Eluting Stent|Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster
16567584|NCT02829060|Active Comparator|1a: Indwelling drains (48 hr)|"This group has indwelling urinary tubes/drains and a negative urine culture
~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
16567585|NCT02829060|Active Comparator|1b: Indwelling drains (7d)|"This group has indwelling urinary tubes/drains and a negative urine culture
~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
16567586|NCT02829060|Active Comparator|2a: +UCx with Oral Options (48hr)|"This group has a positive pre-operative urine culture with oral antibiotic options
~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery
~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
16567587|NCT02829060|Active Comparator|2b: +UCx with Oral Options (7d)|"This group has a positive pre-operative urine culture with oral antibiotic options
~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery
~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
16567588|NCT02829060|Active Comparator|3a: +UCx No Oral options (48hr)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities
~48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)
~Gentamicin (80 mg) preferred if sensitive
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
16567589|NCT02829060|Active Comparator|3b: +UCx No Oral options (7d)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities
~7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)
~Gentamicin (80 mg) preferred if sensitive
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
16567590|NCT02829047|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
16567591|NCT02829034|Active Comparator|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
16567592|NCT02829034|Placebo Comparator|Placebo|Placebo by mouth twice per day
16567593|NCT02829021|Other|Thermography and mammography|"All participants will be examined with
~Dynamic infrared thermography (FLIR ThermaCAM P-65)
~Mammography, clinical examination and if necessary breast tissue biopsy to diagnose breast cancer."
16567594|NCT02829008|Experimental|low-dose-bevacizumab/Pemetrexed|Low-dose-bevacizumab is given at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and every three weeks are a treatment cycle .Pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too. The pretreatment of pemetrexed should be conducted within the study.
16567595|NCT02829008|Active Comparator|Treatment of physician' choice|Treatment of physician's choice can be any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. It can be drugs like taxanes,capecitabine, gemcitabine, cisplatin, everolimus or even nutrient solution,et al.
16567596|NCT02828995||Comprehensive Diabetes Stigma Survey|Participants in the END STIGMA study will be adult patients who have been receiving diabetes-related medical care for a minimum of 12 months in the Vanderbilt University Medical Center Diabetes Clinic and who take at least 1 medication to manage their diabetes.
16567597|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
16567598|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
16567599|NCT02828969|Other|Children and adolescents with conduct disorders|Girls and boys having less than 18 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
16567600|NCT02828943|Active Comparator|IMT with Low Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. For the comparator group, EMT will be set to 5 cm H2O, the lowest setting on the device. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with low resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training.
16567601|NCT02828943|Experimental|IMT with High Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. EMT training loads in the experimental group will be set to 30% of maximal expiratory pressure. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with high resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training. At two weeks, participants will have a follow-up office visit to monitor progress and those that have completed 80% of their training sessions will increase their training to 40% of maximum inspiratory and expiratory pressures as tolerated.
16567632|NCT02828709|Experimental|Irreversible electroporation (IRE)|"IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called nanopores, resulting in increased permeability of the cell and subsequent cell death."
16567633|NCT02828696|Other|No prep|"No prep treatment of worn dentition with CAD-CAM composite (PICN)"
16567602|NCT02828930|Experimental|Idasanutlin|On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg [14C]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of [13C]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
16567603|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
16567604|NCT02828904||Primary Cases|"Primary cases are women
~aged 15 to 49 years
~with a new VTE diagnosis within the study period
~current user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
16567605|NCT02828904||Secondary Cases|"Secondary cases are women
~aged 15 to 49 years
~with a new VTE diagnosis within the study period
~using any HC other than CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg, or not using any HC at all"
16567606|NCT02828904||Primary Controls|"Primary controls are women
~aged 15 to 49 years
~matched to a primary case by age (+/- 1 year) and region of residence
~current or recent past user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
16567607|NCT02828904||Secondary Controls|"Secondary controls are women
~aged 15 to 49 years
~matched to a primary case by age (+/- 1year) and region of residence
~current or recent past user of other COCs (not containing CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg)"
16567608|NCT02828891|Experimental|Experimental|Intervention: transcranial Doppler device will be utilized to measure CSF pressure.
16567609|NCT02828878|Experimental|ApoGraft|ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
16567610|NCT02828865|Experimental|irreversible electroporation (IRE)|irreversible electroporation (IRE) (AngioDynamics, NY) To use 2 to 6 unipolar electrodes of IRE in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
16567611|NCT02828852|Experimental|Pregnancy|Blood sample
16567612|NCT02828852|Experimental|No pregnancy|Blood sample
16567613|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
16567614|NCT02828826|Experimental|telephone coaching|"Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.
~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.
~Data from the telephone coaching will be recorded in the eCRF."
16567615|NCT02828826|No Intervention|Without telephone coaching|
16567616|NCT02828813||Normal|healthy subjects
16567617|NCT02828813||CogImpair|persons with cognitive impairments
16567618|NCT02828813||MotorDeficits|persons with motor deficits
16567619|NCT02828787|Experimental|Urticaria|15 patients with urticaria
16567620|NCT02828787|Experimental|Psoriasis|15 patients with psoriasis
16567621|NCT02828787|Other|healthy|15 healthy control subjects
16567624|NCT02828748|Experimental|active UC|patients with clinically active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
16567625|NCT02828748|Experimental|remission UC|patients with clinically non active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
16567626|NCT02828748|Experimental|active CD|patients with clinically active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
16567627|NCT02828748|Experimental|remission CD|patients with clinically non active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
16567628|NCT02828735|Other|Respiration assessment|
16567629|NCT02828722|Experimental|Controlled light, noise and nutrition|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the nutrition protocol corresponding to the daily rhythm will be applied.
16567630|NCT02828722|Experimental|Controlled light and noise|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the continuous nutrition (in accordance with the clinical trial site's standard practice) will be applied.
16567631|NCT02828722|No Intervention|Control|The treatment of the study subject will be performed based on the clinical trial site's standard practice without environmental simulation or changes in the nutrition protocol.
16568317|NCT02823769|Active Comparator|Nanohybrid resin composite|Fillings made with nanohybrid resin composite (Clearfil Majesty)
16567635|NCT02828683|Active Comparator|Kaname, Bare metal stent|Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname
16567636|NCT02828670||patient|
16567637|NCT02828670||control|
16567638|NCT02828644|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
16567639|NCT02828644|Active Comparator|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
16567640|NCT02828631|Active Comparator|Macintosh laryngoscope|Nasotracheal intubation by Macintosh laryngoscope
16567641|NCT02828631|Experimental|McGrath videolaryngoscope|Nasotracheal intubation by McGrath videolaryngoscope
16567642|NCT02828631|Experimental|Pentax videolaryngoscope|Nasotracheal intubation by Pentax videolaryngoscope
16567643|NCT02828618|Active Comparator|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
16567644|NCT02828618|Experimental|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
16567645|NCT02828605|No Intervention|Control Group|Only receive surveys.
16567646|NCT02828605|Experimental|Experimental Group|Receive VIP Transplant App and surveys.
16567647|NCT02828592|Experimental|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
16567648|NCT02828579||Group 1|Patient with morbid obesity defined as a BMI above 40kg/m2 or 35kg/m2 with comorbidities who are qualified for bariatric surgery.
16567649|NCT02828566|Experimental|IN ketamine and IV saline|Ketamine, single dose, 10 mg/kg (0.1 mL/kg) of 100 mg/mL solution delivered intranasally using an atomizer and divided to both nares to a maximum of 800 mg (8 mL) AND 0.9% normal saline (NS) 0.02 to 0.03 mL/kg delivered intravenously to a maximum of 2.4 mL
16567650|NCT02828566|Active Comparator|IV ketamine and IN saline|Ketamine, single dose, 1 to 1.5 mg/kg (0.02 to 0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 120 mg (2.4 mL) AND 0.9% normal saline (NS) 0.1 mL/kg delivered intranasally using an atomizer and divided to both nares, to a maximum of 8 mL
16567651|NCT02828553||Control Group - Usual Care|At the start of the study, subjects will be enrolled in usual care when admitted to the heart failure unit following standard protocols.
16567652|NCT02828553||Intervention Group - Aggressive Ambulation|After a washout period and transition to a new aggressive ambulation protocol, subjects will be enrolled to usual care + aggressive planned ambulation with a trained mobility aide.
16567653|NCT02828540|Experimental|HT047 High-dose group|three times a day dosing schedule 3 tablets per dose
16567654|NCT02828540|Experimental|HT047 Low-dose group|three times a day dosing schedule 3 tablets per dose
16567655|NCT02828540|Placebo Comparator|Placebo|three times a day dosing schedule 3 tablets per dose
16567656|NCT02828501|Experimental|Lumbar manipulation group|Spinal Manipulation
16567657|NCT02828501|Experimental|Cervical manipulation group|Spinal Manipulation
16567658|NCT02828501|No Intervention|Control group|This group will receive a 2 minute supine rest between measurements
16567659|NCT02828475||CALYPSO-augmented|Patients' postoperative care will be augmented with the CALYPSO platform.
16567660|NCT02828475||Historical Control|Patients' postoperative care was performed using standard practice, before adopting the CALYPSO platform
16567661|NCT02828462||Experimental|Patients using the device
16567662|NCT02828462||Control|Patients not using the device
16567663|NCT02828449|Experimental|therapeutic education program|therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer
16567664|NCT02828436|Experimental|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
16567665|NCT02828436|Other|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
16567666|NCT02828423|Active Comparator|Control group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) alone
16567667|NCT02828423|Experimental|Test group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) and Biphasic Calcium phosphate (BC)
16567668|NCT02828410|Experimental|SBI|Serum bovine immunoglobulin protein isolate (SBI)
16567669|NCT02828397|Experimental|Reference Drug|REGN2222 Reference Formulation
16567670|NCT02828397|Experimental|Test Drug|REGN2222 Test Formulation
16567671|NCT02828384|Active Comparator|low fodmap diet|Subjects receive formalized teaching in low fodmap diet by a dietician
16567672|NCT02828384|Active Comparator|psyllium|subjects receive 7.1 g of psyllium daily
16567673|NCT02828371|Experimental|Erigo|Single daily sessions of verticalization, using a tilt table with an integrated robotic stepping device (Erigo. Hocoma AG, Switzerland) located in the ICU room. Sessions were performed five times per week (Monday-Friday) for three consecutive weeks (a total of 15 sessions per patient). On the same days the patients received conventional physiotherapy for 30 minutes a day. Before the verticalization period the experimental group received conventional in-bed physiotherapy for 60 minutes a day.
16567674|NCT02828371|Active Comparator|Conventional|treated with conventional in-bed physiotherapy for 60 minutes a day, from Monday to Friday, throughout the ICU stay.
16567676|NCT02828332|Other|Patient with autism disorder|Interview with a psychologist who do Vineland II (VABS -II) and evaluate Quality of life and comorbidities
16567677|NCT02828319|Experimental|Z-213|
16567678|NCT02828306||Patients with skull defects|Patients with skull defects after craniotomy for example tumor resection, head trauma, stroke which need a Patient Specific Implant.
16567679|NCT02828293||GMK Sphere|Patients who underwent total knee replacement using GMK Sphere implants. Patients underwent surgery before the inclusion in the study.
16568318|NCT02823756|Experimental|Physical Therapy|Treatment arm: manipulation, exercise, and education
16567680|NCT02828293||GMK PS Fixed Bearing|Patients who underwent total knee replacement using GMK PS Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
16567681|NCT02828293||GMK UC Fixed Bearing|Patients who underwent total knee replacement using GMK UC Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
16567682|NCT02828280||NuMask|Pt's randomized to Numask first will be ventilated for 10 breaths with the NuMask device first, followed by 10 breaths with the traditional face mask
16567683|NCT02828280||Traditional mask|patients randomized to traditional mask first will receive 10 breaths by traditional mask, followed by 10 breaths with NuMask
16567684|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
16567685|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
16567686|NCT02828267|Active Comparator|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive the 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
16567687|NCT02828267|Active Comparator|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
16567688|NCT02828241|Experimental|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
16567689|NCT02828241|Placebo Comparator|Placebo Ointment|Placebo Ointment
16567690|NCT02828228|Experimental|Vitamin D 1200 IU|Supplementation with vitamin D (1200 IU) once a day for 26 weeks
16567691|NCT02828228|Placebo Comparator|Placebo|Placebo once a day for 26 weeks
16567692|NCT02828189|Active Comparator|Physical Exercise|"The protocol consists in:
~Physical Exercise according to their preferences.
~Therapeutic Education related to Health Habits and Physical Exercise."
16567693|NCT02828189|Experimental|Therapeutic Exercise-Physiotherapy|"The protocol consists in:
~Cardiovascular exercise.
~Force-Resistance Exercises of the principals muscle groups of the lower limbs, upper limbs and trunk.
~Muscle Stretches.
~Therapeutic Education related to Health Habits and Physical Exercise."
16567694|NCT02828163|Experimental|Autologous Platelet rich plasma|Autologous platelet-rich plasma (PRP) is autologous plasma that has platelet concentration above the baseline. 1 millilitre of autologous platelet-rich plasma will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
16567695|NCT02828163|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide is an effective treatment for oral erosions of pemphigus vulgaris patients. 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
16567696|NCT02828150|Experimental|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements
16567697|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
16567698|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
16567699|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
16567700|NCT02828124|Experimental|Dose Escalation Monotherapy|
16567701|NCT02828124|Experimental|Dose Expansion Monotherapy|
16567702|NCT02828124|Experimental|Dose Escalation Combination Therapy|
16567703|NCT02828124|Experimental|Dose Expansion Combination Therapy|
16567704|NCT02828111|Experimental|Patidegib gel 2% - Cohort 1|Patidegib gel 2%, applied topically, once daily for 12 weeks (Cohort 1)
16567705|NCT02828111|Experimental|Patidegib gel 4% - Cohort 2|Patidegib gel 4%, applied topically, once daily for 12 weeks (Cohort 2)
16567706|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 1|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 1)
16567707|NCT02828111|Experimental|Patidegib gel 2% - Cohort 3|Patidegib gel 2%, applied topically, twice daily for 12 weeks (Cohort 3)
16567708|NCT02828111|Experimental|Patidegib gel 4% - Cohort 4|Patidegib gel 4%, applied topically, twice daily for 12 weeks (Cohort 4)
16567709|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 2|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 2)
16567710|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 3|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 3)
16567711|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 4|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 4)
16567712|NCT02828098|Experimental|Part 1: BO-112 IT|BO-112 dose 1 (starting dose) intratumoral injection. BO-112 dose 2, 3 and 4 are expected to be tested, upon confirmation of the safety profile of the starting dose.
16567713|NCT02828098|Experimental|Part 2: BO-112 IT|"Combination treatment of BO-112 intratumoral injections with standard of care nivolumab intravenous treatment
~Or Combination treatment of BO-112 intratumoral injections with standard of care pembrolizumab intravenous treatment"
16567714|NCT02828085|Other|Infective Pericarditis|In patient prescribed with a pericardite kit for an etiological diagnosis of a pericardial syndrome, an additional nasal swab will be performed in order to perform a specific diagnosis with PCR technique.
16567715|NCT02828072|Experimental|Sky|Sky treatment foe 15 days
16567716|NCT02828072|Sham Comparator|control|standard medical therapy
16567717|NCT02828046|Placebo Comparator|Placebo|Placebo
16567718|NCT02828046|Experimental|M281|M281
16567719|NCT02828033|Experimental|Rilonacept|A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
16567720|NCT02828020|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
16567721|NCT02828020|Experimental|Ubrogepant 100 mg|2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
16567722|NCT02828020|Placebo Comparator|Placebo|2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
16567723|NCT02828007|Experimental|Treatment/Intervention|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
16567724|NCT02827994|Experimental|Education and exercise|The intervention included neurophysiology of pain education and exercises.
16567725|NCT02827994|No Intervention|No intervention|This group received no intervention as participants were students that were not seeking treatment for their pain.
16567726|NCT02827968|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1, 2.5, 5 and 10 mg/kg weekly.
16567727|NCT02827955|Experimental|bilateral thalamotomy radiosurgery|Gamma Knife radiosurgery bilateral
16567728|NCT02827942|Experimental|Dual therapy|Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
16567729|NCT02827942|Active Comparator|Triple therapy|Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
16567730|NCT02827929|Experimental|educated group|Subjects who is diagnosed as COPD or asthma by their physicians were recruited from 43 primary clinic and had been visiting each primary clinic over one year or more will be provided education of 3 times for one months about disease, inhaler use technics and action plans about exacerbation
16567731|NCT02827916|Experimental|All patients|Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
16567732|NCT02827903|Experimental|Group I|Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
16567733|NCT02827903|Active Comparator|Group II|Metformin + placebo, Dosing to Type II DM with Dyslipidemia
16567734|NCT02827903|Active Comparator|Group III|Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
16567735|NCT02827890|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Januvia Tab. 100mg)*1T/day for 5 days, QD, PO.
~Period 2: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.
~Each treatment period was separated by a washout period of at least 10 dyas."
16567736|NCT02827890|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.
~Period 2: Treatment A(Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO.
~Each treatment period was separated by a washout period of at least 10 dyas."
16567737|NCT02827877|Experimental|Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)|Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
16567738|NCT02827864|Experimental|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1 lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
16567739|NCT02827864|Experimental|apply tDCS concurrently|"For the participants in the CON group, sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS.
~Similar to the SEQ group, the participants will also practice functional tasks for 30 minutes after MT."
16567740|NCT02827864|Sham Comparator|MT with sham tDCS|For the SHAM group, the training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
16567741|NCT02827851|Experimental|SVF injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
16567742|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
16567743|NCT02827812|Experimental|Participants Telemedicine Care (PTE)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).
~B. Physical Intervention at home for 60 minutes 3 days/week for three months
~C. Home-Based telemedicine program:"
16567744|NCT02827812|Active Comparator|Participants Usual Care (PUC)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).
~B. Physical Intervention at home for 60 minutes 3 days/week for three months"
16567745|NCT02827799|Placebo Comparator|Heart Failure Self-Management Education|This treatment includes participation in 4 one hour biweekly face-face sessions of education on heart failure self-management, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
16567746|NCT02827799|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
16567747|NCT02827786|Experimental|Electromagnetic Acoustic Imaging|
16567975|NCT02826148|Other|Patients with autism disorder|The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
16567748|NCT02827773|Experimental|Received Talking Pill Bottles|Patients received anti-hypertensives over 90 day period in Talking Pill Bottle which contained summary of pharmacy counselling session.
16567749|NCT02827773|No Intervention|Usual Care|Patients received oral summary of pharmacy counselling session.
16567750|NCT02827760|Placebo Comparator|Maltodextrin DE19|Placebo
16567751|NCT02827760|Active Comparator|Prebiotic Synergy1|Effective prebiotic
16567752|NCT02827747|Placebo Comparator|Placebo with Dietary Sources of Vitamins|Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.
16567753|NCT02827747|Active Comparator|Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum|Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.
16567754|NCT02827747|Active Comparator|Antioxidants (Vitamins A,C, E) plus GSH|Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.
16567755|NCT02827747|Active Comparator|Placebo plus Centrum|Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.
16567756|NCT02827734||interstitial lung disease|patients with known or suspected ILD such as idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, sarcoidosis, granulomatosis with polyangiitis
16567757|NCT02827734||pulmonary healthy controls|patients without known or suspected pulmonary disease
16567758|NCT02827721||COPD|Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
16567759|NCT02827721||pulmonary healthy controls|Patients without known or suspected pulmonary disease
16567760|NCT02827708|Experimental|Semaglutide|
16567761|NCT02827708|Placebo Comparator|Placebo|
16567762|NCT02827695|Experimental|SMASK|Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.
16567763|NCT02827695|Other|EnhancedSC|Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.
16567764|NCT02827682|Experimental|study group|Using Angel-6000D Multiparameter Anesthesia Monitor to maintain the Hemodynamic stability during surgery. Keep IoC1 40 to 60 while IoC2 30-50.Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when IoC1<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when IoC2>50 but was decreased by 1 ng/ml per adjustment when IoC2<30, with the maintenance value between 30 and 50.
16567765|NCT02827682|Placebo Comparator|control group|Using BIS VISTA Monitor to maintain the Hemodynamic stability during surgery. Keep BIS 40 to 60.The doses of propofol and remifentanil were adjusted by the anesthetists according to BIS. Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when BIS<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when BIS>60 but was decreased by 1 ng/ml per adjustment when BIS<40, with the maintenance value between 40 and 60.
16567766|NCT02827669|Experimental|One Drop Experts Program|Participants will be able to use the One Drop mobile app and One Drop Experts program on their smartphones. The One Drop mobile app is a diabetes management platform that allows users to track and log their blood glucose levels, medications, food, and activities. One Drop Experts is a diabetes education and coaching program delivered entirely through the One Drop mobile application.
16567767|NCT02827669|Experimental|One Drop Experts Program + Apple Watch|An Apple Watch will be provided to study participants in this arm. In addition to using the One Drop mobile app and One Drop Experts program on their smartphones, participants will also be able to engage with the app and program on their Apple Watch.
16567768|NCT02827656|Experimental|Decapeptyl support|S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
16567769|NCT02827656|Active Comparator|hCG luteal support|S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
16567770|NCT02827643|Active Comparator|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
16567771|NCT02827643|Other|TDF/3TC or FTC/EFV|the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
16567772|NCT02827630|Active Comparator|DH-4|Subjects will use Proteus Discover, the digital health offering (DH) for 4 weeks
16567773|NCT02827630|Active Comparator|DH-12|Subjects will use Proteus Discover, the digital health offering (DH) for 12 weeks
16567774|NCT02827630|Other|Usual Care|Subjects received usual medical care including all normal interventions such as medication titration, adherence counseling, lifestyle coaching, and additional clinic visits per their providers' discretion.
16567775|NCT02827617||TP53 mutated CLL|
16567776|NCT02827578|Experimental|Tamsulosin + Solifenacin|Tamsulosin and Solifenacin
16567777|NCT02827578|Active Comparator|Tamsulosin + Solifenacin Placebo|Tamsulosin and Solifenacin placebo
16567778|NCT02827565|Experimental|CircuLOR-1|KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
16567779|NCT02827552|Other|ARPEGE BioM|N/A (not a randomized study)
16567780|NCT02827539|Other|Research|If the patient is randomized to the Research Arm, the physician will begin the procedure utilizing LessRay enhanced fluoroscopic images.
16567781|NCT02827539|Other|Control|For patients in the control arm standard fluoroscopy will be used with the C-arm set to the conventional full dose setting
16567782|NCT02827526|Active Comparator|Ketamine|Patients in the ketamine arm will receive an intraoperative and postoperative infusion of ketamine
16567783|NCT02827526|Placebo Comparator|Control|Patients in the control arm will receive an intraoperative and postoperative infusion of dextrose
16567784|NCT02827513|Experimental|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
16567785|NCT02827513|Experimental|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
16567786|NCT02827513|Experimental|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
16567787|NCT02827513|Experimental|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
16567788|NCT02827500|Active Comparator|ivabradine|Active Comparator: ivabradine
16567789|NCT02827500|Placebo Comparator|usual care|Placebo Comparator: usual care
16567790|NCT02827487|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
16567791|NCT02827487|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
16567792|NCT02827487|Placebo Comparator|Placebo 1|Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
16567793|NCT02827474||Patient Participants|Patient participants will participate in two patient interviews.
16567794|NCT02827474||Physician Participants|Provider participants will participate in one provider interview.
16567795|NCT02827461||MZ|Monozygotic twins
16567796|NCT02827461||DZ|Dizygotic twins
16567797|NCT02827435|Experimental|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
16567798|NCT02827409|Active Comparator|Short Delay Cord Clamping|Subject will have umbilical cord clamped and cut by 1 minute of life.
16567799|NCT02827409|Active Comparator|Extended Delay Cord Clamping|Subject will have umbilical cord clamped and cut after at least 5 minutes of delayed cord clamping. Duration of cord clamping after 5 minutes will depend on if the subject is breathing and/or if the cord has stopped pulsating
16567800|NCT02827396|Experimental|Psycho-social intervention|Experimental group: The intervention group will get Psycho social Training Intervention which will be developed during the third phase of the study.
16567801|NCT02827396|No Intervention|TAU intervention|Wait-list (controlled) group: The waiting list (control) group will continue getting the general health education (TAU) that is done at disability clinics in the existing sites.
16567802|NCT02827383|Experimental|Stair Climbing 4x/day|Participants use the stair climber 4 times per day, for 4 minutes at a time. Total dose = 16 minutes.
16567803|NCT02827383|Experimental|Stair Climbing 8x/day|Participants use the stair climber 8 times per day, for 2 minutes at a time. Total dose = 16 minutes.
16567804|NCT02827370|Experimental|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
16567805|NCT02827344||Stage IV non-small cell lung cancer|"Intervention to be done are :
~- Blood sample collection for CTC and MDSC analysis"
16567806|NCT02827331||Patients exposed to benzodiazepines|"Data to be collected are :
~Administrative and medical data
~Exposition to hypnotics or anxiolytics benzodiazepines"
16567807|NCT02827331||Patients not exposed to benzodiazepines|"Data to be collected are :
~Administrative and medical data
~Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics"
16567808|NCT02827331||Control group|"Data to be collected are :
~Administrative and medical data
~Medical consultation without prescription of interest"
16567809|NCT02827318|Active Comparator|75g glucose|75g of glucose dissolved in 500ml provided in a clear plastic tumbler.
16567810|NCT02827318|Experimental|75g isomaltulose|75g of isomaltulose dissolved in 500ml provided in a clear plastic tumbler.
16567811|NCT02827318|Placebo Comparator|Sweetened water|500ml water sweetened with sucralose provided in a clear plastic tumbler.
16567812|NCT02827305|Experimental|group 1|scaling and Gotukola mouthwash intervention- 1.Scaling 2.Gotukola mouthwash , 10ml twice daily to be rinsed for 60 seconds
16567813|NCT02827305|Active Comparator|group 2|Scaling
16567814|NCT02827305|Active Comparator|group 3|Intervention- Gotukola mouthwash only is advised to be used two times a day, each time 10ml rinsed for 60 seconds (morning and evening ) after the food.
16567815|NCT02827292|Experimental|Laparoscopic Surgery without music|Intervention: Headphones without music (Silent). A headphone will be applied peroperatively but no music will be played. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
16567816|NCT02827292|Experimental|Laparoscopic Surgery with music|Intervention: peroperative music via head phones. A headphone will be applied peroperatively and music will be played for the entire duration of the surgical procedure. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
16567817|NCT02827279|Other|Patients|Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
16567818|NCT02827279|Other|Healthy volunteers|Mesure of emotional induction by eye tracking on People without disorders
16567819|NCT02827266|Experimental|Epoetin beta|Participants will receive epoetin beta over an 8-week correction phase and a 4-week extension or continuation phase, for a total exposure of up to 12 weeks.
16567820|NCT02827253||Predialysis|Patients with CKD (4 and 5 stages by KDOQI guidelines) underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A MRI 6 months after starting haemodialysis will be performed to analyze changes in gray and white matter of the brain.
16567821|NCT02827253||Haemodialysis|Patients with end stage of renal disease (ESRD) in haemodialysis underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A one year follow up MRI will be performed to analyze the changes in gray and white matter of the brain.
16567822|NCT02827240|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
16567823|NCT02827240|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
16567824|NCT02827240|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
16567825|NCT02827227||Primary HIV- Infected patients|Primary HIV- Infected patients with a minimum of 2 years of effective cART.
16567826|NCT02827214||Surgical treatment|"Several surgical treatments exist to treat the fractures included in the study. The following section describes the different surgical treatment modalities in more detail
~Approaches:
~Open short segment surgical fixation (1 level above and below the fracture level) with or without posterior decompression
~Open long segment posterior fixation (2 or more levels above, 2 or more levels below) with or without posterior decompression
~Posterior short or long fixation with posterolateral corpectomy and reconstruction
~Anterior alone instrumentation
~Combined Anterior Posterior (AP) instrumentation
~Percutaneous posterior fixation combined with anterior instrumentation
~Percutaneous posterior fixation with or without vertebroplasty"
16567827|NCT02827214||Non-surgical treatment|"Non-surgical treatment is defined as bed rest followed by immobilization with:
~Custom-molded or prefabricated total body contact thoracolumbosacral orthosis (TLSO)
~Thermoplastic removable brace
~Jewett hyperextension braces
~Anterior hyperextension brace (ASH)
~Taylor-Knight brace
~Plaster of Paris (POP)"
16567828|NCT02827201|Experimental|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :
~2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)
~follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
16567829|NCT02827201|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
16567830|NCT02827188|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
16567831|NCT02827188|No Intervention|Control-waitlist group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
16567832|NCT02827175|Experimental|fevers of the travelers|
16567833|NCT02827162||Case D1|Subject having experienced a Virologically confirmed dengue infection, from the first injection until the end of the active phase, excluding Case D3 subjects
16567834|NCT02827162||Case D3|Subject having experienced a Virologically confirmed dengue infection, from 28 days after the third injection until the end of the Active Phase of the proof of concept (PoC) efficacy study
16567835|NCT02827162||Control I|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and belonging to the PoC efficacy study immunogenicity subset
16567836|NCT02827162||Control E|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and not belonging to the PoC efficacy study immunogenicity subset
16567837|NCT02827136|Experimental|Patch group|Lidocaine patch and Hypafix
16567838|NCT02827136|Placebo Comparator|Control group|Just Hypafix
16567839|NCT02827123|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
16567840|NCT02827123|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
16567841|NCT02827110|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope
16567842|NCT02827110|Experimental|fiberoptic bronchoscope with pentax-AWS|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope with pentax-AWS
16567843|NCT02827097|Experimental|Rectus sheath block group|"administration of denogan
~rectus sheath block with 0.375% ropivacaine"
16567844|NCT02827097|Placebo Comparator|Control group|just administration of denogan
16567845|NCT02827084|Experimental|Kinesio Taping|Apply the Kinesio Taping with tension in the vatus mediallis
16567846|NCT02827084|Placebo Comparator|Placebo|Apply the Kinesio Taping without tension in the vatus mediallis
16567847|NCT02827084|No Intervention|Control|It will not apply Kinesio.
16567848|NCT02827071||Retina abnormalities|Subjects with various retina vascular disorders
16567849|NCT02827058|Experimental|G25 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
16567850|NCT02827058|Active Comparator|G27 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle
16567851|NCT02827045||Depressive phase|Vestibular test
16567852|NCT02827045||Maniac phase|Vestibular test
16567853|NCT02827045||Euthimic phase|Vestibular test
16567854|NCT02827045||Healthy subject|Vestibular test
16567855|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
16567856|NCT02827006|Active Comparator|Bone graft|Bone graft from iliac crest as gapfiller
16567857|NCT02827006|Experimental|Calcium phosphate bone cement|CaP bone cement as gapfiller
16567858|NCT02826993|Experimental|CCE in incomplete Colonoscopies|Patients in which colonoscopy is not possible are invited for CT colonography and those patients are examined by Camera Capsule Endoscopy the day before the CT colonography and the two different examinations are compared.
16567859|NCT02826967|Experimental|Colonic Irrigation|A designated health professional will administer to the patient the colonic irrigation procedure -using the Hydro-San Plus colon therapy system, an FDA approved and ISO certified device for colonic irrigation and cleansing before endoscopic procedures (FDA #2027347).
16568217|NCT02824510|Active Comparator|Patients under MDI.|Patients under multiple daily injection regimen. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart and glargine or detemir).
16567860|NCT02826954||COPD patients|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.
~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
16567861|NCT02826954||Healthy subjects|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.
~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
16567862|NCT02826941|Experimental|Hypothermia|If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.
16567863|NCT02826941|Placebo Comparator|Normothermia|If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.
16567864|NCT02826928|Experimental|patients with small-intestine neuroendocrine tumors|
16567865|NCT02826928|Experimental|control subjects with irritable bowel syndrome|
16567866|NCT02826902|Active Comparator|TIVA group|
16567867|NCT02826902|Active Comparator|Inhalation anesthesia group|
16567868|NCT02826889|Experimental|Fluid loading group|
16567869|NCT02826876|Placebo Comparator|Ropivacaine|Topical use of Ropivacaine
16567870|NCT02826876|Placebo Comparator|Placebo|Topical use of placebo
16567871|NCT02826863|Experimental|Experimental: ZX008 - 0.8 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
16567872|NCT02826863|Experimental|Experimental: ZX008 - 0.2 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 0.2 mg/kg/day ZX008 will be administered twice a day (BID) in equally divided doses with food.
16567873|NCT02826863|Placebo Comparator|Placebo Comparator: Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
16567874|NCT02826850|Sham Comparator|Genicular nerves|Neurotomy by radiofrequency of genicular nerves knee guided by fluoroscopy
16567875|NCT02826850|Active Comparator|Saphenous Nerve|Neurotomy of saphenous nerve by radiofrequency on the distal third of the thigh, guided by ultrasound
16567876|NCT02826837|Experimental|LEAC-102 and FOLFOX+Bevacizumab/Cetuximab|"The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.
~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.
~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day
~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
16567877|NCT02826798|Experimental|VBI-1501A: 0.5µg with adjuvant|0.5µg CMV vaccine with adjuvant
16567878|NCT02826798|Experimental|VBI-1501A: 1.0µg with adjuvant|1.0µg CMV vaccine with adjuvant
16567879|NCT02826798|Experimental|VBI-1501A: 2.0 µg with adjuvant|2.0 µg CMV vaccine with adjuvant
16567880|NCT02826798|Experimental|VBI-1501: 1.0µg without adjuvant|1.0µg CMV vaccine without adjuvant
16567881|NCT02826798|Placebo Comparator|Placebo|Buffer/sucrose used for VBI-1501 suspension
16567882|NCT02826785|Experimental|Cognitive strategy training|The cognitive strategy training intervention consists of 6 weekly ~1 hour sessions. It is delivered in an individual, face-to-face format in the client's home. It is a behavioral intervention that teaches people metacognitive, problem-solving and other compensatory strategies to address self-identified cognitive performance problems, and it uses practice and homework to promote strategy learning, retention and transfer.
16567883|NCT02826772|Experimental|Phase 1 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
16567884|NCT02826759||serum sphingolipid metabolites in healthy subjects|Healthy subjects are classified according to BMI into three subgroups: healthy normal weight subjects, healthy overweight subjects and healthy subjects with obesity. Age and sex are matched among three subgroups. serum sphingolipid metabolites including sphingosine-1-phosphate will be compared.
16567885|NCT02826759||serum sphingolipid metabolites in diabetic subjects|Diagnosed diabetic patients are divided into three subgroups: diabetic patients with normal weight, overweight and obesity. age and sex are matched.
16567886|NCT02826759||serum sphingolipid metabolites in the progression of diabetes|serum sphingolipid metabolites are compared among three age-, sex- and body mass index-matched subgroups: healthy subjects, subjects with pre-diabetes, subjects with diabetes
16567887|NCT02826759||serum sphingolipid metabolites and HbA1c|diabetic subjects are divided by HbA1c level. the cut-offs are 7% and 9%. serum sphingolipid metabolites will be tested among diabetic patients with HbA1c <7%, 7%-9% and >9%
16567888|NCT02826759||serum sphingolipid metabolites in insulin-resistant subjects|comparison of serum sphingolipid metabolites in newly diagnosed insulin-resistant subjects and age-, sex- and BMI-matched healthy controls.
16567889|NCT02826746|Experimental|Magnesium group|intravenous administration of Magnesium Sulfate
16567890|NCT02826746|Placebo Comparator|Control group|intravenous administration of normal saline
16567891|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).
~EEG NIRS MRI"
16567892|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .
~EEG NIRS MRI"
16567893|NCT02826720||HP+|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
16567894|NCT02826720||HP-|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
16567895|NCT02826720||NP+|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
16567896|NCT02826720||NP-|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
16567897|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
16567898|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
16567899|NCT02826694|Other|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
16567900|NCT02826694|Other|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
16567901|NCT02826681|Active Comparator|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
16567902|NCT02826681|Placebo Comparator|Normal Saline|Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.
16567903|NCT02826668|No Intervention|Control|Baseline ultrasound only, with no markings placed. No ultrasound prior to epidural placement.
16567904|NCT02826668|Experimental|Ultrasound|Baseline and pre-puncture ultrasound with markings placed.
16567905|NCT02826655|Active Comparator|Healthy Controls|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
16567906|NCT02826655|Experimental|Subjects with diabetic retinopathy|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
16567907|NCT02826642|Experimental|Arm 1: Medically fit for induction|IDH305 + Standard of care for patients that are medically fit for induction.
16567908|NCT02826642|Experimental|Arm 2 Medically unfit for induction|IDH305 + Standard of care for patients that are medically unfit for induction.
16567909|NCT02826629|Other|Schizophrenia|40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
16567910|NCT02826629|Other|Healthy sibling|25 healthy siblings
16567911|NCT02826629|Other|Ultra high risk for developing Schizophrenia|15 patients with ultra high risk for developing Schizophrenia
16567912|NCT02826629|Other|Controls|-25 age and gender-matched healthy controls
16567913|NCT02826616|Experimental|Trimetazidine group|Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery
16567914|NCT02826616|No Intervention|The control group|placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery
16567915|NCT02826603|Experimental|Secukinumab|Secukinumab
16567916|NCT02826603|Active Comparator|Ustekinumab|Ustekinumab
16567917|NCT02826590|Experimental|Neck passive mobilizations|Neck passive mobilizations
16567918|NCT02826590|Placebo Comparator|Manual contact|Manual contact
16567919|NCT02826577|Active Comparator|Pregnenolone 175mg|- Single dose of 175mg
16567920|NCT02826577|Active Comparator|Pregnenolone 400mg|- Single dose of 400mg
16567921|NCT02826577|Placebo Comparator|Placebo|- Single dose of placebo
16567922|NCT02826577|No Intervention|Matched healthy controls|- No intervention
16567923|NCT02826564|Experimental|Sequential|Stereotactic body radiotherapy prior to pembrolizumab treatment
16567924|NCT02826564|Experimental|Concurrent|Stereotactic body radiotherapy concurrent with pembrolizumab treatment
16567925|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.
~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
16567926|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.
~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
16567927|NCT02826538|Experimental|patient specific guides|fracture fixation with 3D planning and use of patient-specific instruments
16567928|NCT02826538|Active Comparator|standard procedure|standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments
16567929|NCT02826525|Experimental|Treatment|Subjects in this arm will receive AZD4076
16567930|NCT02826525|Placebo Comparator|Control|Subjects in this arm will receive placebo
16567932|NCT02826499|Active Comparator|Fluoroscopy|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy.
16567933|NCT02826499|Experimental|Fluoroscopy and Pediguard|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy, with the Pediguard system.
16568246|NCT02824276|Experimental|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
16567934|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.
~Combination therapy period begins following monotherapy treatment and consists of:
~Pembrolizumab 200mg once every three weeks.
~Beginning on Day 10, BL-8040 three times a week"
16567935|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®) plus Onivyde chemo|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.
~Combination therapy period begins following monotherapy treatment and consists of:
~IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.
~Pembrolizumab 200mg once every three weeks.
~Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
16567936|NCT02826473|Experimental|Intervention-Group|
16567937|NCT02826473|No Intervention|Control-Group|
16567938|NCT02826460||Liver Transplant Recipients|
16567939|NCT02826447||Patients|500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
16567940|NCT02826447||Healthcare workers|50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
16567941|NCT02826434|Experimental|PVX-410 and Durvalumab|"Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.
~The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections.
~The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions."
16567942|NCT02826421|Experimental|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
16567943|NCT02826421|Active Comparator|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
16567944|NCT02826421|Active Comparator|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
16567945|NCT02826421|Active Comparator|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
16567946|NCT02826408|Active Comparator|Active group|Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)
16567947|NCT02826408|Placebo Comparator|Placebo group|Will receive Folic acid 5 mg once daily
16567948|NCT02826382|Experimental|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
16567949|NCT02826382|Experimental|Whole body dosimetry group|Determination of human dosimetry of the investigation drug [68Ga]P15-041
16567950|NCT02826369|Experimental|3.0 Tesla in Magnetic Resonance Imaging|
16567951|NCT02826343|Other|COPD Advair|"Subjects will undergo hyperpolarized xenon MRI with perfusion imaging, before and after a 90 day course of Adair.
~All subjects belong to one arm and will receive same treatment. Then they are compared at baseline and 3 month post intervention (described below) for within same-subject changes.
~Subjects will be administered with
~Hyperpolarized Xenon129 inhalation during MRI twice (at baseline and post 3 month Advair)
~Gadolinium intravenous contrast during MRI twice (at baseline and post 3 month Advair)
~Advair diskus: strength 250mcg/50mcg, one puff twice a day for 3 months."
16567952|NCT02826330||case Crohn disease|60 cases with Crohn's Disease
16567953|NCT02826330||first relative healthy|2 healthy relatives per CD case (total 120)
16567954|NCT02826330||controls|60 controls matched on gender and age with CD cases
16567955|NCT02826304|Active Comparator|VH|Vaginal Hysterectomy for uteri larger than 280gm
16567956|NCT02826304|Active Comparator|LAVH|Laparoscopic assisted vaginal hysterectomy for uteri larger than 280gm
16567957|NCT02826291||RD-100i, OSNA|SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging
16567958|NCT02826278||Healthy female newborns|Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
16567959|NCT02826265||pulmonary disease|patients with known or suspected pulmonary disease
16567960|NCT02826252||Ventavis|The study will be conducted in patients who are enrolled in the German Ventavis patient support program Ventaplus.
16567961|NCT02826239||pulmonary healthy controls|patients without known pulmonary disease
16567962|NCT02826239||pulmonary disease|patients with known or suspected pulmonary disease
16567963|NCT02826226||obstructive ventilation disorder|patients with known or suspected obstructive ventilation disorder and clinical indication for bronchodilator testing
16567964|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
16567965|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
16567966|NCT02826200|Experimental|Group 1 (SOC+OAT)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving single antiplatelet therapy plus oral anticoagulant therapy.
16567967|NCT02826200|Active Comparator|Group 2 (SOC)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving standard of care therapy.
16567968|NCT02826187||Patients with acetabular implant|"Data to be collected are :
~Early complications data related to implant or procedure of implantation
~Late stage complications data
~Efficacity of treatment with HIP score
~Patient satisfaction
~Radiographic evaluation during standard follow-up"
16567969|NCT02826174|Experimental|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
16567970|NCT02826174|Active Comparator|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
16567971|NCT02826174|Other|Anti-Rejection Agents|Anti-Rejection Agents for both groups
16567972|NCT02826174|Other|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
16567973|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
16567974|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
16568309|NCT02823808|Active Comparator|GMPD+MET|Group who takes Glimepiride 2mg+Metformin 500mg, once daily.
16567976|NCT02826135|Experimental|Pediatric patients with hypovolemic state|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output or decreased central venous pressure. Changes of blood pressure during abdominal compression is continuously recorded.
16567977|NCT02826122|Active Comparator|FitBit APP|FitBit Zip APP registers and give feed-back on number of steps per day, distance and calories burned.
16567978|NCT02826122|Experimental|Pai APP|Mio Pai APP registers duration and intensity of the Activity and give feed back as activity Points.
16567979|NCT02826109|Experimental|Interventional: Cyanoacrylate Application|Application of cyanoacrylate adhesive to one quadrant of mouth
16567980|NCT02826109|No Intervention|Control: Absence of Cyanoacrylate Application|No application of cyanoacrylate adhesive to the other quadrant of mouth
16567981|NCT02826096|Experimental|biofeedback group|biofeedback therapy
16567982|NCT02826096|No Intervention|medication group|only medication treament
16567983|NCT02826083|Experimental|XXS|
16567984|NCT02826083|Placebo Comparator|Placebo|
16567985|NCT02826070|Other|Off-treatment|Patients who had stopped treatment during EFFORT extension study could receive 2-year off-treatment follow-up. All the patients in Part I will be followed up at the interval of 12 weeks. For these patients, if they have hepatitis flare during follow-up, they will be re-treated with telbivudine combined with adefovir for the left study period ( the total study period is 2 years) and followed up at the interval of 12 weeks. Hepatitis flare is defined as HBV DNA>4 Log10 copies/mL with either ALT≥5 times upper limit of normal (ULN) or TBIL≥2×ULN，or 2 ≤ALT ≤5 ×ULN (at two consecutive visits at least 2 weeks apart) and total bilirubin (TBIL) <2×ULN.
16567986|NCT02826070|Other|On-treatment|Patients with continuous treatment during EFFORT extension study will continue treatment, without off-treatment rule in the further extension study. The treatment strategy is depended on the HBV DNA level of each individual, that is, for patients with negative HBV DNA level (defined as HBV DNA <20 IU/mL) will continue their previous treatment strategy; and for patients with positive HBV DNA level (defined as HBV DNA>=20 IU/mL) will receive the combination therapy of telbivudine and adefovir, irrespective of their previous treatment strategy. All the patients in Part II will be followed up at the interval of 24 weeks until they complete the 2-year on-treatment follow-up. Patients will be conducted liver biopsy at the sixth year of treatment. All the patients with telbivudine monotherapy will be switched to telbivudine plus adefovir once confirmed HBV DNA breakthrough developed.
16567987|NCT02826057|Active Comparator|24 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
16567988|NCT02826057|Experimental|48 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
16567989|NCT02826044|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
16567990|NCT02826044|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
16567991|NCT02826044|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
16567992|NCT02826031|Experimental|Sodium Hyaluronate Injection + DICL-SR|"Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group.
~From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID） daily"
16567993|NCT02826031|Active Comparator|DICL-SR|From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID daily）. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.
16567994|NCT02826018|Active Comparator|ALN-HBV|
16567995|NCT02826018|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16567996|NCT02826005|Experimental|cirrhotic patients|if positive for 3 bio-markers- will be followed by MRI for HCC diagnosis
16567997|NCT02826005|No Intervention|non cirrhotic patients|control group - 3 bio-markers will be measured only
16567998|NCT02825992|Other|AcQMap System|All patients who underwent catheter ablation using the AcQMap System
16567999|NCT02825979|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
16568000|NCT02825979|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
16568001|NCT02825966|Other|AUDICOR then LifeVest then AUDICOR|First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
16568002|NCT02825953|Active Comparator|Nebulized surfactant|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV), and than premature babies with RDS breathing spontaneously will be administered surfactant by nebulizer.
16568310|NCT02823795|Experimental|sPATH|Motivational Interviewing in five sessions post hospital discharge
16568003|NCT02825953|Active Comparator|Endotracheal bolus application|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The investigators will administer surfactant via fundamental method.
16568004|NCT02825953|Active Comparator|Minimally invasive surfactant therapy|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). After randomisation, the investigators will administer surfactant via minimally invasive surfactant therapy (MIST) method which is recently very popular method
16568005|NCT02825940|Experimental|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
16568006|NCT02825940|Experimental|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
16568007|NCT02825927|Experimental|Intervention group|Intensive training with oral screen for 5 weeks.
16568008|NCT02825927|No Intervention|Control group|The control group is not offered any intervention.
16568009|NCT02825914|Active Comparator|Casein glycomacropeptide (CGMP)|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.
16568010|NCT02825914|Placebo Comparator|Placebo|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.
16568011|NCT02825901|Active Comparator|Djulis-Buckwheat & Placebo|Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
16568012|NCT02825901|Active Comparator|Buckwheat & Placebo|Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
16568013|NCT02825901|Experimental|Djulis-Buckwheat & Buckwheat|Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
16568014|NCT02825888||Non-obese|Body Mass index less than 30 kg/m2
16568015|NCT02825888||Obese|Body Mass index more than 30 kg/m2
16568016|NCT02825875||adenocarcinoma of the prostate|
16568017|NCT02825862|No Intervention|Replication group|Replication group - this group will complete the entire questionnaire, in order to replicate the findings of O'Carroll et al (2011)
16568018|NCT02825862|Active Comparator|Omit affective attitudes|Omitting affective attitudes The intervention is the omission of all questions on affective attitudes. This group will complete a similar questionnaire to the replication group, with the same number of questionnaire items, but affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
16568019|NCT02825862|Active Comparator|Omit negatively-worded items|Omitting negatively-worded affective attitudes. This intervention is the omission of a subset of negatively-worded affective attitudinal items. This group will complete a similar questionnaire to the replication group, with the same number of items, but all negatively-worded affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
16568020|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
16568021|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
16568022|NCT02825836|Experimental|TL-895 80/160 mg QD|Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568023|NCT02825836|Experimental|TL-895 300 mg QD|Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568024|NCT02825836|Experimental|TL-895 600 mg QD|Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568025|NCT02825836|Experimental|TL-895 300 mg BID|Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568026|NCT02825836|Experimental|TL-895 900 mg QD|Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568027|NCT02825836|Experimental|TL-895 100 mg BID|Participants received TL-895 100 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568028|NCT02825836|Experimental|TL-895 150 mg BID|Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
16568029|NCT02825823|Experimental|Ketone Salts|Acute dose of beta-hydroxybutyrate potassium/sodium salt (0.2g beta-hydroxybutyrate/kg, 0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
16568030|NCT02825823|Placebo Comparator|Placebo|Acute dose of taste-matched placebo (0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
16568031|NCT02825810|Experimental|Cervical motor control group|
16568032|NCT02825810|No Intervention|Control group|
16568218|NCT02824484|Experimental|Guided Written Disclosure Protocol|GWDP consists of three 20-minutes writing sessions. Participants write every two weeks at home following the specific instructions for each session.
16568033|NCT02825797|Experimental|Group 1A|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
16568034|NCT02825797|Experimental|Group 1B|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
16568035|NCT02825797|Experimental|Group 1C|HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
16568036|NCT02825797|Experimental|Group 2|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
16568037|NCT02825797|Experimental|Group 3|HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.
16568038|NCT02825784|Experimental|Renastart|"Compared to cows' milk and/or standard pediatric enteral feeds, Renastart has the following additional nutritional features that are beneficial in children with CKD: lower phosphorus, calcium and vitamin A. The powder presentation allows flexibility with dilutions to facilitate the provision of adequate energy and protein to support growth in children with CKD.
~For each subject, the recommended daily intake of Renastart is determined by the dietitian in collaboration with the local PI and primary nephrologist based on individual nutritional requirements, specifically dietary intake of potassium and serum potassium levels.
~Renastart is to be given by the clinician and based on clinical and nutritional needs. Standard preparation guidelines can be found on the Renastart label."
16568039|NCT02825771|Experimental|Usual Care + Caring Contacts messages|Usual care services plus caring contacts messages
16568040|NCT02825771|Active Comparator|Usual Care|Usual care services provided in that community following identification of suicidal ideation or behavior.
16568041|NCT02825758|Experimental|ZestiVits|"Supplement for use in ketogenic and restricted therapeutic diets, from the age of 11.
~Daily use for 7 days. Daily intake level for each subject will be determined and prescribed by a dietitian."
16568042|NCT02825745|Other|Betashot|"Children:will take Betashot as a proportion of their daily energy requirements calculated from the dietary information obtained during Visit A for up to 12 weeks.
~Adults:will introduce Betashot and increase the amount taken in ml incrementally for up to 12 weeks."
16568043|NCT02825719|Experimental|Ulipristal|Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
16568044|NCT02825719|Placebo Comparator|Placebo|Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
16568045|NCT02825706|Experimental|Experimental group|The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding. Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved. In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week. The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk. Low-intensity exercises with 20-25 repetitions were included.
16568046|NCT02825706|No Intervention|Control group|The patients in the control group did not receive any educational sessions and did no exercise at all at home.
16568047|NCT02825693|Active Comparator|Femtosecond laser cataract surgery|Cataract surgery with femtosecond laser treatment for corneal incisions, astigmatic keratotomies, capsulotomy and nuclear fragmentation
16568048|NCT02825693|Active Comparator|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery
16568049|NCT02825680|Active Comparator|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
16568050|NCT02825680|Experimental|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
16568051|NCT02825667|Experimental|Experimental group|"Patients included in this group will receive treatment over a period of three weeks, receiving 3 physiotherapy sessions lasting approximately 30 minutes each.
~The treatment program includes 8 maneuvers that must be administered bilaterally: maneuver longitudinal sliding on the fascial surface plant, maneuver induction of the plantar fascia, maneuver longitudinal surface sliding on the anterolateral compartment of the leg, induction maneuver ankle anterior compartment, maneuver pressure and sliding on the posterior region of the leg, technical release of the popliteal fascia, maneuver induction sural triceps, and lower extremity telescopic technique."
16568052|NCT02825667|No Intervention|Control group|Patients included in this group will not receive any physiotherapy treatment. However, will be evaluated under the same conditions that patients in the experimental group (pretreatment evaluation, post-treatment and follow-up).
16568053|NCT02825654||Post-9/11 Gulf War Era Veterans|Military personnel who deployed to Central Asia, Southwest Asia, and Africa during the Post-9/11 Gulf War Era
16568054|NCT02825641|Active Comparator|Expectant Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions."
16568055|NCT02825641|Active Comparator|Expectant Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions."
16568311|NCT02823795|No Intervention|Control|Care as usual
16568056|NCT02825641|Experimental|Active Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions."
16568057|NCT02825641|Experimental|Active Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions."
16568058|NCT02825628|Experimental|Osteodex 3.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
16568059|NCT02825628|Experimental|Osteodex 6.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
16568060|NCT02825628|Experimental|Osteodex 9.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
16568061|NCT02825615|Active Comparator|Conventional method (CM)|Radial artery cannulation has been done using the conventional method. Cannulation failure with this technique were tried with USG technique secondarily.
16568062|NCT02825615|Experimental|Ultrasound guided method (USG)|Radial artery cannulation is done with ultrasound guidance for this group of patients. Cannulation failure with this technique were tried with Conventional technique secondarily.
16568063|NCT02825602||Vietnam War Theater Veterans|Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
16568064|NCT02825602||Blue Water Navy Vietnam Veterans|Blue Water Navy Veterans are defined as Veterans who served aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975 and who never served ashore or on inland waterways of Vietnam.
16568065|NCT02825602||Vietnam era Veterans|Vietnam era Veterans served in locations around the world OTHER than on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos or aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975.
16568066|NCT02825602||Non-military U.S. public|Non-military U.S. public are individuals who were born before 1958, never served in the U.S. military, and are age- and gender-matched (by the study investigators) to Vietnam War Theater Veterans.
16568067|NCT02825589|Experimental|BIA-guided|Assessment of target dry weight guided by using bioelectrical impedance analysis (BIA).
16568068|NCT02825589|No Intervention|Standard clinical guided|Assessment of target dry weight guided by clinical evaluation eg. jugular venous pressure, blood pressure, edema etc.
16568069|NCT02825576|Active Comparator|Sugammadex group|Sugammadex 2mg/kg intravenously at completion of surgery.
16568070|NCT02825576|Active Comparator|Neostigmine/Glycopyrrolate group|Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.
16568071|NCT02825563|Experimental|Anlotinib(In the fasting state)|In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
16568072|NCT02825563|Experimental|Anlotinib(In the high fat diet state)|In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
16568073|NCT02825550|Experimental|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
16568074|NCT02825537|Experimental|With use of compression stocking|Use of compression stocking during 3 consecutives days
16568075|NCT02825537|Other|Without use of compression stocking|No use of compression stocking during 3 consecutives days
16568076|NCT02825524|Experimental|Endobiliary radiofrequency|
16568077|NCT02825511||A cohort of basal cell carcinoma|A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
16568078|NCT02825498|Experimental|Operator guided by contact force|Operator has full access to contact force parameters including force time integral (FTI).
16568079|NCT02825498|No Intervention|Operator blinded to contact force|Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
16568080|NCT02825485|Other|Control Group|The control patients will be the patients with antenatal hydronephrosis who get a routine VCUG to evaluate for vesicoureteral reflux, as part of routine care.
16568081|NCT02825485|No Intervention|Observation Group|Receives no intervention
16568082|NCT02825472|Active Comparator|Exercise training program|Six-months sports participation, three times per week for 30 minutes in the target heart rate zone
16568083|NCT02825472|No Intervention|No exercise training program|no exercise training program, usual care
16568084|NCT02825459|Experimental|Abstinence from e-cigarettes|Participants abstain from e-cigarettes and other nicotine/tobacco products for 6 days
16568085|NCT02825459|No Intervention|E-cigarette use|Participants use e-cigarettes and continue to abstain from tobacco/nicotine products as they normally would.
16568086|NCT02825446|Active Comparator|angioplasty tibial arteries|
16568087|NCT02825446|Experimental|radio frequency denervation popliteal artery by the use|"radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon"
16568088|NCT02825433||Patients receiving procedural sedation|The investigators collected ventilation data for each breath (respiratory rate, tidal volume, and end-tidal CO2) for all patients receiving procedural sedation for endoscopy.
16568089|NCT02825407|Experimental|main study|
16568090|NCT02825394||apixaban initiation|N=20
16568091|NCT02825394||apixaban on-treatment|N=20
16568092|NCT02825394||dabigatran initiation|N=20
16568093|NCT02825394||dabigatran on-treatment|N=20
16568094|NCT02825394||rivaroxaban initiation|N=20
16568095|NCT02825394||rivaroxaban on-treatment|N=20
16568096|NCT02825394||edoxaban initiation|N=20
16568097|NCT02825394||edoxaban on-treatment|N=20
16568098|NCT02825368|Experimental|Homeopathic vaccine group|"Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.
~Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo."
16568099|NCT02825368|Active Comparator|Conventional vaccine group|"One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)
~One subcutaneous dose of MMR (measles, mumps, rubella)
~Sugar pellets as placebo."
16568100|NCT02825368|Placebo Comparator|Control group|"Sugar pellets oral dose
~Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo"
16568101|NCT02825355||Patients with cervical cancer|All patients receive sentinel node mapping as the conventional treatment.
16568102|NCT02825355||Patients with endometrial cancer|All patients receive sentinel node mapping as the conventional treatment.
16568103|NCT02825342|No Intervention|GERD with PPI's therapy|Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
16568104|NCT02825342|Active Comparator|PPI's and SSRI's therapy|Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
16568105|NCT02825342|Active Comparator|SSRI's therapy|Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks
16568106|NCT02825316|Experimental|Group A|Patients with active Crohn's disease that will be allocated to the Mediterranean diet group.
16568107|NCT02825316|Experimental|Group B|Patients with active Crohn's disease that will be allocated to the low residue diet group.
16568108|NCT02825303|Experimental|Novel workplace - first half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
16568109|NCT02825303|Experimental|Novel workplace - second half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the second half of the study. Traditional workstation within the frist half of the study.
16568110|NCT02825303|No Intervention|Control group|Control group subjects did not encounter any changes in their regular office environments. Traditional workstation for both halves of the study.
16568111|NCT02825290|Experimental|Study group|hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer & GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.
16568112|NCT02825290|No Intervention|Control group|The usual progesterone only luteal phase support.
16568113|NCT02825277|Other|pathological group|pregnant women with preeclampsia and/or IUGR pregnancy with a planned or semi-urgent caesarean section or vaginal delivery will be recruited into this study.
16568114|NCT02825277|Other|physiological group|pregnant women with normal pregnancy with a planned caesarean section or vaginal delivery will be recruited into this study
16568115|NCT02825264||STARflo|Patients who have been implanted with STARflo implant
16568116|NCT02825251|Experimental|Faster-acting insulin aspart CSII|
16568117|NCT02825251|Active Comparator|NovoRapid® CSII|
16568118|NCT02825238|No Intervention|Control|Control group, did not undergo intervention.
16568119|NCT02825238|Experimental|Exercise group|Experimental, exercise group, underwent intervention
16568120|NCT02825225|Experimental|20 core-biopsy fragments|Patients submitted to experimental intervention (extended sextant biopsy with 20 cores) compared to current standard biopsy protocol (extended sextant biopsy with 12 cores) guided by transrectal ultrasound.
16568121|NCT02825225|Experimental|Base and apex local anesthesia|Patients submitted to experimental intervention in prostate-biopsy anesthetic protocol (prostate base and prostate apex bilateral local anesthetic injection) compared to participants submitted to current standard anesthetic protocol in institution (prostate base bilateral local anesthesia) guided by transrectal ultrasound. guided by transrectal ultrasound.
16568122|NCT02825212|Experimental|Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|"Participants treated with either Harvoni or Epclusa
~Harvoni 90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.
~Epclusa 400mg/100mg 400mg/100mg FDC once daily"
16568123|NCT02825199|Experimental|Caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
16568124|NCT02825199|Placebo Comparator|Non caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received placebo capsule (maize starch). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
16568125|NCT02825186|Experimental|Loteprendol|Topical Loteprendol used after strabismus surgery
16568126|NCT02825186|Experimental|Dexamethasone|Topical Dexamethasone used after strabismus surgery
16568127|NCT02825173|Experimental|Seal-G|A surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
16568128|NCT02825160||Ventavis|Ventavis treatment group
16568129|NCT02825147|Experimental|MESA|stage I/II: methotrexate 1000mg/m2,d1 dexamethasone 40mg,d2-d4 etoposide 100mg,d2-d4 pegaspargase 2500U/m2,d5 a cycle of every 21 days with totally 4 cycles Radiotherapy at least 50Gy in dose for the involved local focus is sandwiched after 2 cycles.
16568130|NCT02825134|Experimental|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
16568131|NCT02825134|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
16568132|NCT02825121|Experimental|Monitoring Neuromuscular Blockade|Monitoring Neuromuscular Blockade the Flexor Hallucis and adductor of the thumb.
16568133|NCT02825108|Experimental|experimental group|The patients who receive 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
16568134|NCT02825108|Placebo Comparator|placebo group|The patients who receive only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
16568135|NCT02825108|Other|control group|The patients for whom the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups
16568136|NCT02825095|Active Comparator|Talc Pleurodesis|"For patients in this group, chest tube type PIGTAIL 10 - 14 Fr will be inserted by by chest ultrasound guided and under local anesthesia, allowing good draining of the hemithorax, in case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed, chest tube will be removed 24 - 48 hours later on. the patient will be admitted in the hospital during the whole procedure course.
~If the patient developed non expanded - trapped lung post chest tube insertion, or if he had persistence high chest tube output for more than 10 days, then the patient will remain with the PIGTAIL as an Indwelling Pleural Catheter."
16568137|NCT02825095|Active Comparator|Indwelling Pleural Catheter|"All patients from this group will have Indwelling Pleural Catheter insertion type PLEURAX inserted by ultrasound guided and under local anesthesia.
~the patient and his/her family will be instructed and educated about the proper way of using the catheter, and how to perform pleural draining at home.
~the duration of treatment with the Pleurax depends on the rate and amount of pleural effusion draining."
16568138|NCT02825069|Experimental|Intervention group|Early introduction of solid foods starting at the age of 4 months, with foodstuff from all major groups in diet by the age of 6 months (vegetables and fruits, wheat and other grains, meat, fish, egg, dairy products). Babies presenting with mild symptoms are encouraged to continue the symptom-eliciting food.
16568139|NCT02825069|No Intervention|Control group|Families are advised to follow the official Finnish Nutrition Recommendations, including exclusive breastfeeding until the age of 6 months.
16568140|NCT02825056|Active Comparator|Bupivacaine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%).
16568141|NCT02825056|Experimental|Bupivacaine + Morphine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%) and 250 microgram of preservative free Morphine (VERMOR).
16568142|NCT02825043|Experimental|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
16568143|NCT02825030|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568144|NCT02825017|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568145|NCT02825004|Experimental|Psychological Intervention|All the professionals workers involved in the experimental group will attend three intensive psychological meetings about emotional exhaustion, depersonalisation, low personal accomplishment and how to improve coping skills.
16568146|NCT02825004|No Intervention|Control Group|There is not any intervention.
16568147|NCT02824991|Experimental|Deep Dry Needling|"Deep Dry Needling (DN) with the purpose of obtaining local twitch responses (LTRs). Description: Latent MTrPs were identified in both MG using according the presence of a palpable taut band and hypersensitive spot in the palpable taut band as diagnostic criteria.
~The deep DN was administered by a physical therapist with three years of experience in the technique. The ultrasound video (SonoSite Titan; Sonosite, Bothell, WA, USA) was recorded at 60 frames per second captured through an external capture device from Epiphan Systems Inc. (Ottawa, Ontario, Canada). According to the perception of the physical therapist and the ultrasound assessment, the filament needle was inserted into the MTrP to achieve three LTRs. Posterior to DN application, the ROMs of the MG and HA were measured"
16568148|NCT02824965|Experimental|Pembrolizumab+1x10^9 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
16568149|NCT02824952|Experimental|Tagrisso 80 mg|80 mg of Tagrisso(AZD9291) will be given every day for 6 or 12 weeks.
16568150|NCT02824939|Experimental|Transversus Abdominis Plane group|
16568151|NCT02824939|Experimental|Quadratus Lumborum group|
16568152|NCT02824939|No Intervention|Control group|
16568153|NCT02824926|Experimental|Dapaconazole|(cream; 2%; topical)
16568154|NCT02824926|Active Comparator|Ketoconazole|(cream; 2%; topical)
16568155|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
16568156|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
16568157|NCT02824900|Experimental|Vibration stimuli to neck|Vibration stimuli to contralesional neck muscles, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
16568158|NCT02824900|Active Comparator|Vibration stimuli to hand|Vibration stimuli to contralesional hand, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
16568159|NCT02824887||Exposed group|Long term curative effect of electroacupuncture treatment of lumbar intervertebral disc herniation in exposure group
16568160|NCT02824887||control group|Long term efficacy of conventional treatment of lumbar disc herniation in the control group
16568161|NCT02824874|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO
~Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO
~Each treatment period was separated by a washout period of at least 10 dyas."
16568162|NCT02824874|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO
~Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO
~Each treatment period was separated by a washout period of at least 10 dyas."
16568163|NCT02824861|Experimental|Text Intervention|Participants receive text messages to a personal cell phone over 8 weeks, wear a fitbit to monitor physical activity, and communicate with a health coach intermittently over 2 weeks
16568164|NCT02824861|Active Comparator|Active Control|Participants receive and wear a fitbit only for 8 weeks
16568312|NCT02823782|Experimental|Laminar HP|Structural and functional MRI markers
16568165|NCT02824848|Active Comparator|Passive Stretching|Passive Stretching intervention components include static passive stretching, active assistive range of motion, assisted stretching of the involved cervical musculature, and associated strengthening activities aimed to elicit head righting in developmentally appropriate positions and during developmentally appropriate movement transitions. Intervention is progressed by increasing head tilt angles, duration of head righting, and frequency and number of repetitions.
16568166|NCT02824848|Active Comparator|Perception-Action Approach|P-A Approach intervention components include environmental set-up for activity and participation in play, and manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions. Both components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing environmental supports provided to the infant's body parts, and by removing the therapist's hands from the infant's body to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
16568167|NCT02824835||adenoma group|Patients with adenoma. Biopsies are taken before endoscopic resection.
16568168|NCT02824835||cancer group|Patients with colorectal cancer. Biopsies are taken before surgical resection.
16568169|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
16568170|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
16568171|NCT02824796|Experimental|Schema Parent Behavioral Training|An enhanced protocol which combines a Schema Focused Therapy (SFT) and Behavioral Parent Training (PBT)
16568172|NCT02824796|Active Comparator|Parent Behavioral Training|Usually medication & The usual PBT treatment
16568173|NCT02824770|Active Comparator|Usual Care|After a major abdominal surgery, the control group will receive the usual postoperative care including continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) in the surgical intensive care unit.
16568174|NCT02824770|Experimental|Dimming of lights and decreasing noise|After a major abdominal surgery, the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed and will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) as in the control group. The study intervention will include dimming of lights and decreasing noise. The lights will be dimmed to 40 lux. The doors of the side-rooms will be closed decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m.
16568175|NCT02824757||known diabetes|Participants have been diagnosed diabetes.
16568176|NCT02824757||known prediabetes|Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.
16568177|NCT02824757||normal glucose tolerance|Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.
16568178|NCT02824757||unclear glucose tolerance condition|Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.
16568179|NCT02824744|Active Comparator|treatment by 2l/min/kg in HFNC|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
16568180|NCT02824744|Experimental|treatment by 3l/min/kg in HFNC|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
16568181|NCT02824731|Active Comparator|supratentorial, grade III/IV, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
16568182|NCT02824731|Experimental|supratentorial, grade III/IV, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
16568183|NCT02824731|Active Comparator|supratentorial, grade I/II, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
16568184|NCT02824731|Experimental|supratentorial, grade I/II, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.
16568185|NCT02824731|Active Comparator|infratentorial, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
16568186|NCT02824731|Experimental|infratentorial, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
16568187|NCT02824731|Active Comparator|pre-radiation, photon|> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
16568188|NCT02824731|Experimental|pre-radiation, proton|> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
16568189|NCT02824718|Experimental|rh PTH(1-34)|40 µg/day rhPTH(1-34) (teriparatide or FORSTEO® 20 µg twice daily) over 7 to 8 weeks (52±3 days).
16568190|NCT02824718|Active Comparator|Thiazide + potassium sparing diuretic|hydrochlorothiazide 25 mg/day (ESIDREX®) + amiloride 5 mg/day (MODAMIDE®) + 0.5 µg/day alfacalcidol (ALFACALCIDOL®) over 7 to 8 weeks (52±3 days).
16568191|NCT02824679|Active Comparator|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
16568192|NCT02824679|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
16568193|NCT02824679|Placebo Comparator|Saline|They received two ml of normal saline intravenously as a placebo
16568194|NCT02824666|Experimental|0.5 mg/kg|• Cohort 1: ATI-9242 - Single IV bolus dose of 0.5 mg/kg
16568195|NCT02824666|Experimental|ATI-9242 1.0 mg/kg|• Cohort 2: ATI-9242 - Single IV bolus dose of 1.0 mg/kg
16568196|NCT02824653|Experimental|Mesenchymal Stem Cells|The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells
16568219|NCT02824484|Placebo Comparator|Control|Control condition consists of three 20-minutes writing sessions. Participants write every two weeks at home following the instructions. Their task is constructed to be emotionally neutral.
16568220|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
16568221|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
16568197|NCT02824640|Active Comparator|Patient Navigation|"The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
~Health Promotion Sessions: PNs will deliver 4 standardized health promotion sessions to all patients either individually or within a group.
~Optional Weekly Support Groups: Subjects randomized to the PN arm will be offered weekly support groups led by Peers."
16568198|NCT02824640|Active Comparator|modified Directly Observed Therapy|"OAT clinic setting: Observation of HCV medications will be linked to methadone visits among patients receiving methadone. Patients will be receiving methadone as part of routine clinical care for opioid addiction and not as an intervention related to this study. The schedule of five days per week will be considered modified DOT (mDOT). Subjects will initiate HCV treatment on Mondays if feasible. Take home medications will be packed in a weekly electronic blister pack.
~Community health clinic setting: This intervention is considered modified DOT (mDOT) since between 3-5 weekly doses will be directly observed. A minimum of one dose will be observed in person by clinic/study staff. For the remaining observed doses, the research staff and provider will present the participant with a menu of options and determine what will work best for that participant."
16568199|NCT02824627|Experimental|Oxytocin|Subjects weighing >40kg will receive a total of 24 IU of oxytocin delivered as 2- 6 IU puffs to each nostril once daily. Subjects weighing < 40kg will receive a total of 12 IU of oxytocin delivered as 1- 6 IU puff to each nostril daily. Subjects will receive 14 to 21 days of daily oxytocin administration.
16568200|NCT02824627|Placebo Comparator|Placebo|Subjects weighing>40kg will 2 puffs of placebo to each nostril daily. Subjects weighing <40kg will receive 1 puff per day. Subjects will receive 14-21 days of placebo administration.
16568201|NCT02824614|No Intervention|Control|20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
16568202|NCT02824614|Active Comparator|E967-Xylitol|20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
16568203|NCT02824614|Active Comparator|E968-Erythritol|20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
16568204|NCT02824601|Experimental|One-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
16568205|NCT02824601|Experimental|Two-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. In the following, 14-day inter-appointment medication with Ca(OH)2 + SSL was placed in the root canal. After 14 days with intracanal medication, the tooth was isolated for surgery and disinfection, including removal of provisional restoration. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
16568206|NCT02824588|Experimental|Intervention|Working Memory Training
16568207|NCT02824588|Active Comparator|Control|Internet use
16568208|NCT02824575|Experimental|Arm A1-2: Paclitaxel plus Rebastinib.|"Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.
~Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
16568209|NCT02824575|Experimental|Arm B1-2: Eribulin plus Rebastinib.|"Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.
~Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
16568210|NCT02824562|Other|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
16568211|NCT02824562|Other|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
16568212|NCT02824536|Experimental|Group 1|Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
16568213|NCT02824536|Experimental|Group 2|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
16568214|NCT02824536|Experimental|Group 3|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
16568215|NCT02824523||High-dose aspirin|
16568216|NCT02824510|Active Comparator|Patients under insulin pump therapy.|Patients under insulin pump therapy. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart).
16568222|NCT02824458|Experimental|Gefitinib + Apatinib|"(Part A) Phase I, Open-label, Dose-escalation Study Escalating doses(500mg, 750mg, or 250mg) of Apatinib in combination with 250mg Gefitinib daily orally. Participants may continue to receive treatment until progress or intolerable.
~(Part B)Multicenter, Randomized, Double-Blind Study Apatinib (dose determined from Part A of study) in combination with 250mg Gefitinib."
16568223|NCT02824458|Placebo Comparator|Gefitinib + Placebo|"(Part A) Not Applicable
~(Part B) Placebo in combination with 250mg Gefitinib. Participants may continue to receive treatment until progress or intolerable."
16568224|NCT02824445|Sham Comparator|Sham|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
16568225|NCT02824445|Experimental|Treatment|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
16568226|NCT02824432|Experimental|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered once a day immediately after meal.
16568227|NCT02824432|Experimental|TAK-085 4g|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered twice a day immediately after meal.
16568228|NCT02824419|Experimental|C11-methionine|To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
16568229|NCT02824419|Experimental|68Ga-Dotanoc|To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
16568230|NCT02824406||Patients|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
16568231|NCT02824406||Controls|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
16568232|NCT02824393|Experimental|Mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
16568233|NCT02824393|No Intervention|Control patients|The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.
16568234|NCT02824380|Experimental|Sequence A|Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)
16568235|NCT02824380|Experimental|Sequence B|Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)
16568236|NCT02824367|Other|Parkinsonian|Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
16568237|NCT02824367|Other|Dystonic|Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
16568238|NCT02824354|Placebo Comparator|placebo|"The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side."
16568239|NCT02824354|Experimental|Nalmefene|"Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate).
~Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.
~The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food."
16568240|NCT02824341|Other|Parkinson's disease patients with RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
16568241|NCT02824341|Other|Parkinson's disease without RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
16568242|NCT02824341|Other|Healthy volunteers|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
16568243|NCT02824315|Experimental|AL-335+Simeprevir (SMV)+Odalasvir (ODV)|Participants will receive AL-335 800 milligram (mg) once daily from day 1-3; SMV 75 mg once daily from Day 4-13; loading dose of ODV 150 mg on Day 14, followed by ODV 50 mg once daily from Day 15 to 23; ODV 50 mg once daily + AL-335 800 mg once daily from day 24-26; ODV 50 mg once daily + SMV 75 mg once daily from Day 27-33 and ODV 50 mg once daily + SMV 75 mg once daily + AL-335 800 mg once daily from Day 34 to 36.
16568244|NCT02824289|Experimental|Sun Safe Workplaces Program|Program promoting the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers and in-person training of outdoor workers by research staff over two years.
16568245|NCT02824289|Active Comparator|Attention Control|Program promoting occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff.
16568247|NCT02824276|Placebo Comparator|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
16568248|NCT02824263|No Intervention|CPAP (Usual care)|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
16568249|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
16568250|NCT02824250|Experimental|MBSR + Usual Care|8-week standard Mindfulness-Based Stress Reduction (MBSR) course + standard of care
16568251|NCT02824250|No Intervention|Usual Care|Standard of care
16568252|NCT02824237|Experimental|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
16568253|NCT02824224|Experimental|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
16568254|NCT02824224|Placebo Comparator|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
16568255|NCT02824211|Experimental|Right Dose System|Use of automated oxygen titration during exertion
16568256|NCT02824198|Experimental|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
16568257|NCT02824198|Placebo Comparator|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
16568258|NCT02824185|Experimental|FCH-PET/MRI|FCH-PET/MRI exam performed in addition to the usual examinations for monitoring hepatocellular carcinoma.
16568259|NCT02824172|Experimental|Cast immobilization|36 patients in the experimental cast immobilization
16568260|NCT02824172|Active Comparator|complete sport rest|36 patients in the complete sport rest group
16568261|NCT02824159||Patient with haematologic malignancies|"Interventions to be administrated are :
~Clinical examinations
~Biological statement
~Blood samples for pharmacokinetics exploration
~Imagery with positron emission tomography scan or resonance magnetic imagery
~Saliva samples for genetics analyses
~Blood samples for treatment mutation resistance search
~Quality of life scale questionary
~Detection of adverse events"
16568262|NCT02824146|No Intervention|Control group|Patients received standard protective mechanical ventilation during all surgery, with tidal volumen 6 ml/kg and positive end-expiratory pressure (PEEP) level of 5 (centimeter of water) cmH2O.
16568263|NCT02824146|Experimental|Recruitment maneuver group|"Patient received a lung recruitment maneuver after pneumoperitoneum insufflation.
~The recruitment maneuver consists in 10 breaths at 30/15 cmH2O of plateau pressure and PEEP, respectively. Then, the ventilatory settings back to protective ventilation but adding 8 cmH2O of PEEP to keep the lungs open."
16568264|NCT02824133|Experimental|AZD4547|AZD4547: intake of 80mg bd (160mg/day), on a continuous schedule.
16568265|NCT02824120|Experimental|Comedy|patients in this group will watch a comedy film that will not exceed 30 minutes
16568266|NCT02824120|Experimental|Documentary|patients in this group will watch a documentary film that will not exceed 30 minutes.
16568267|NCT02824107|Experimental|patients with myocardial infarction|
16568268|NCT02824107|Experimental|patients with stroke|
16568269|NCT02824081|Other|Depressive patients|Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
16568270|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 15 mg; then RO5545965 5mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
16568271|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 5 mg; then RO5545965 15 mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
16568272|NCT02824055|Experimental|RO5545965 15 mg first; then Placebo; then RO5545965 5 mg|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
16568273|NCT02824055|Experimental|RO5545965 15 mg first; then RO5545965 5 mg; then Placebo|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
16568274|NCT02824055|Experimental|RO5545965 5 mg first; then Placebo; then RO5545965 15 mg|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
16568275|NCT02824055|Experimental|RO5545965 5 mg first; then RO5545965 15 mg; then Placebo|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
16568313|NCT02823782|Experimental|Complex HP|Structural and functional MRI markers
16568276|NCT02824042|Experimental|Anetumab ravtansine|The evaluation of multiple ECG parameters and the drug-drug interaction (DDI) potential of anetumab ravtansine parameters when administered alone and together with itraconazole 100 mg oral capsules will be conducted in 2 sequential parts. On Cycle 1 Day 1, anetumab ravtansine will be given alone at a dose of 6.5 mg/kg in Part 1 and Part 2. On Cycle 2 Day 1, anetumab ravtansine will be given together with itraconazole at a dose of 0.6 mg/kg in Part 1, and at a dose of 6.5 mg/kg (planned) in Part 2.
16568277|NCT02824029|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16568278|NCT02824016|Active Comparator|with supraclavicular irradiation|Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
16568279|NCT02824016|Active Comparator|without supraclavicular irradiation|Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
16568280|NCT02824003|Experimental|ISIS-GCGRRx|ISIS-GCGRRx once weekly dosing for 13 weeks
16568281|NCT02824003|Placebo Comparator|Placebo|once weekly dosing for 13 weeks
16568282|NCT02823990|Experimental|Treatment TG4010 + nivolumab|Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16568283|NCT02823977|Experimental|Ketamine / Dexmedetomidine|Ketamine 0.25 mg/kg bolus followed by 0.5 mg/kg per hour AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
16568284|NCT02823977|Placebo Comparator|Placebo / Dexmedetomidine|Normal saline, as a 500 mL infusion bag, to represent placebo AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
16568285|NCT02823964|Experimental|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
16568286|NCT02823951||Rebif - 1 year MRI cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline and at 12 months
16568287|NCT02823951||Rebif - 1 year clinical cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline
16568288|NCT02823951||Rebif - early discontinuation cohort - tolerability|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
16568289|NCT02823951||Rebif - early discontinuation cohort - adverse events|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
16568290|NCT02823951||Rebif - early discontinuation cohort - disease activity|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
16568291|NCT02823951||Tecfidera - 1 year MRI cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline and at 12 months
16568292|NCT02823951||Tecfidera - 1 year clinical cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline
16568293|NCT02823951||Tecfidera - early discontinuation cohort - tolerability|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
16568294|NCT02823951||Tecfidera - early discontinuation cohort - adverse events|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
16568295|NCT02823951||Tecfidera - early discontinuation cohort - disease activity|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
16568296|NCT02823912|Experimental|Capsaicin|75 mg capsaicin every 12 hours for 90 days
16568297|NCT02823912|Placebo Comparator|Control|75 mg magnesia calcinada every 12 hours for 90 days
16568298|NCT02823899|Experimental|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
16568299|NCT02823899|Active Comparator|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
16568300|NCT02823886|Experimental|STEMI patients|
16568301|NCT02823873||Normotensive|Normotensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
16568302|NCT02823873||Hypertensive|Hypertensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
16568303|NCT02823860|Other|Biospecimens and Quality of Life (QoL)|Only if patient's consent is obtained, biospecimens, including tumor and/or peripheral blood are collected.
16568304|NCT02823847|Experimental|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
16568305|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
16568306|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
16568307|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
16568308|NCT02823808|Experimental|ALO+PIO|Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.
16568314|NCT02823782|Experimental|ADHD|Structural and functional MRI markers
16568319|NCT02823743|Experimental|Low dose aspirin|75 mg aspirin orally daily from gestational week 7-35
16568320|NCT02823743|Placebo Comparator|Placebo|Placebo pill orally daily from gestational week 7-35
16568321|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
16568322|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
16568323|NCT02823691|Experimental|Lanreotide and Metformin|"Dose and Treatment Regimen:
~LANREOTIDE ATG 120 mg/28 days (equivalent to 1 cycle), deep subcutaneous injection (SC) in combination with METFORMIN 2550 mg daily (maximum dose), oral administration (OS).
~Metformin starting dose 850 mg/day to be increased up to 1700 mg/day at day 14, 2550 mg/day at day 28, (maximum dose), if well tolerated."
16568324|NCT02823678||Pancreatectomy|Patients scheduled to undergo a pancreatectomy
16568325|NCT02823665|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
16568326|NCT02823665|Experimental|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
16568327|NCT02823652|Experimental|Group I (internet-based intervention)|Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
16568328|NCT02823652|Active Comparator|Group II (usual care control)|Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
16568329|NCT02823652|Experimental|Group III (genetic counseling)|Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.
16568330|NCT02823639|Active Comparator|Transcranial direct current stimulation|tDCS with varying intensity, location and polarity
16568331|NCT02823639|Placebo Comparator|Sham stimulation|Double blind sham stimulation with sham mode of neuroConn device
16568332|NCT02823626||Intervention|Spironolactone and patiromer
16568333|NCT02823613|Experimental|Healthy male test subjects 1-5|High salt diet followed by low salt diet
16568334|NCT02823613|Experimental|Healthy male test subjects 6-10|Low salt diet followed by high salt diet
16568335|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
16568336|NCT02823587|Experimental|Bronchiectasis Pulmonary Rehabilitation|The volunteers will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
16568337|NCT02823587|Experimental|Healthy Pulmonary Rehabilitation|In this arm, the volunteers healthy will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
16568338|NCT02823587|Sham Comparator|Bronchiectasis Group Control|The volunteers with bronchiectasis will be informed only about the benefits of physical activities
16568339|NCT02823587|Sham Comparator|Healthy Group Control|Volunteers healthy will be informed only about the benefits of physical activities
16568340|NCT02823574|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
16568341|NCT02823574|Active Comparator|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
16568342|NCT02823561|Active Comparator|Garcinia mangostana (treatment group)|Balanced low-calorie diet and regular exercise in combination with integration
16568343|NCT02823561|Other|Control group|balanced low-calorie diet and regular exercise
16568344|NCT02823548|Experimental|Droglican|Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.
16568345|NCT02823548|Placebo Comparator|Placebo|Patients take one sacchet of Placebo once a day during 6 months.
16568346|NCT02823535|Experimental|Iwin: Individual Well-Being Navigator|Iwin intervention during 6-month intervention period plus study assessments at baseline, 6, and 9 months.
16568347|NCT02823535|No Intervention|Control group|Study assessments at baseline, 6 months, and 9 months, plus two short surveys unrelated to the study behaviors at 4 and 5 months.
16568348|NCT02823509|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568349|NCT02823496|Experimental|Arm 1|All subjects are patched with the same product
16568350|NCT02823483|Experimental|Arm 1|All subjects are patched.
16568351|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
16568352|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
16568353|NCT02823457|Other|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
16568354|NCT02823444||Peripheral Vascular Disease|Gender distribution will be approximately equal. The age range is 18-95, with increased prevalence in the elderly population.
16568355|NCT02823444||Control|In the initial sequence optimization stage, healthy volunteers will also be recruited.
16568356|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
16568357|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
16568358|NCT02823418||No neuraxial labor analgesia|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
16568688|NCT02821104||Healthy Adolescents|Healthy non Hispanic white adolescents
16568359|NCT02823418||Neuraxial labor analgesia|For patients who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
16568360|NCT02823405|Experimental|X4P-001 + Pembrolizumab|X4P-001 alone, then adding pembrolizumab
16568361|NCT02823379|Experimental|Physical Activity|A culturally relevant physical activity promotion program delivered using a Smartphone application.
16568362|NCT02823379|Active Comparator|Wellness Contact Control|A wellness contract control condition delivered using a Smartphone application.
16568363|NCT02823366|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
16568364|NCT02823366|Active Comparator|Monotherapy|UDCA alone
16568365|NCT02823353|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
16568366|NCT02823353|Active Comparator|Monotherapy|UDCA alone
16568367|NCT02823340|Experimental|Fractional Microneedle Radiofrequency Treatment|Fractional Microneedle Radiofrequency Treatment
16568368|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
16568369|NCT02823314|Experimental|Intervention group|One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes.
16568370|NCT02823314|Placebo Comparator|Placebo group|Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area.
16568371|NCT02823301|Experimental|VAMOS group|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
16568372|NCT02823301|No Intervention|Control group|Group that will not receive the VAMOS program as intervention.
16568373|NCT02823288|Experimental|Sonke CHANGE intervention condition|This arm (n=9 clusters) will receive the Sonke CHANGE intervention for 12 months.
16568374|NCT02823288|No Intervention|Control condition|In this arm (n=9 clusters), no activities will take place during the trial period outside of data collection.
16568375|NCT02823275|Active Comparator|Functional mobilisation|
16568376|NCT02823275|Experimental|plaster cast fixation|
16568377|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation
~Including background questionnaire and randomization into Decision Aid Group or Control Group:
~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.
~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.
~Assessment at One week after participants surgical consultation and five months after surgical consultation"
16568378|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation
~Including background questionnaire and randomization into Decision Aid Group or Control Group:
~Participant will receive Usual Care assistance when making treatment decisions.
~Assessment at One week after participants surgical consultation and five months after surgical consultation"
16568379|NCT02823249|Active Comparator|1.56 g L-Tryptophan|"1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
16568380|NCT02823249|Active Comparator|1.56 g L-Leucine|"1.56 g L-Leucine in 300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
16568381|NCT02823249|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water given via nasogastric tube
16568382|NCT02823249|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water given via nasogastric tube
16568383|NCT02823249|Placebo Comparator|75 g Glucose and mixed liquid meal|"75 g Glucose in 300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
16568384|NCT02823249|Placebo Comparator|Tap water and mixed liquid meal|"300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
16568385|NCT02823236|Active Comparator|Intralesional Triamcinolone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
16568386|NCT02823236|Experimental|Topical Pirfenidone|Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
16568387|NCT02823236|Experimental|Triamcinolone + Pirfenidone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
16568388|NCT02823223|Experimental|ELVR with Endobronchial Valves|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Endobronchial Valves (Zephyr valve) inserted into the target lobe of the lung with the aim of complete lobar exclusion.
16568389|NCT02823223|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice
16568390|NCT02823197|Experimental|active transport lesson|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations.
16568429|NCT02822950|Other|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
16568391|NCT02823197|Experimental|active transport lesson and Facebook group|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
16568392|NCT02823197|No Intervention|control group|Participants in the control group do not receive the active transport lesson or the Facebook group.
16568393|NCT02823184||Patients|ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available
16568394|NCT02823171|Experimental|Sequence I|Sequence I: treatment A/B
16568395|NCT02823171|Experimental|Sequence II|Sequence II: treatment B/A
16568396|NCT02823158|Experimental|GPi DBS and best medical treatment|
16568397|NCT02823158|Active Comparator|Best medical treatment|
16568398|NCT02823145|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
16568399|NCT02823132||patients who develop a fungal infection|
16568400|NCT02823132||patients without fungal infection|
16568401|NCT02823119|Experimental|Mini-hysteroscopy|A rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm.
16568402|NCT02823119|Active Comparator|Conventional Office Hysteroscopy|A rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm
16568403|NCT02823106|Experimental|Verapamil and Citicoline|10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
16568404|NCT02823106|Placebo Comparator|Placebo|The control group will receive saline only.
16568405|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
16568406|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
16568407|NCT02823067||Nursing home patients|Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
16568408|NCT02823054|No Intervention|Standard group|bi lung ventilation usual practice
16568409|NCT02823054|Experimental|EZ-Blocker group|one lung ventilation 'EZ-Blocker'
16568410|NCT02823041|Experimental|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
16568411|NCT02823041|Active Comparator|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
16568412|NCT02823028|Active Comparator|NRT + Web Guide|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges)
16568413|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Coed|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group
16568414|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Women|Experimental: NRT + Web Guide + Tweet2Quit-Women NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a women-only Tweet2Quit group
16568415|NCT02823015||Study population|The study population consists of adult surgery patients, scheduled for breast cancer surgery at St-Luc University Hospital.
16568416|NCT02823002|Experimental|Slow, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
16568417|NCT02823002|Experimental|Rapid, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
16568418|NCT02823002|Experimental|Slow, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
16568419|NCT02823002|Experimental|Rapid, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
16568420|NCT02823002|Experimental|Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
16568421|NCT02823002|Placebo Comparator|Non-Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
16568422|NCT02822989|Active Comparator|Vagus Nerve Stimulation|Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
16568423|NCT02822989|Sham Comparator|Sham Vagus Nerve Stimulation|Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
16568424|NCT02822976||Critically Ill Patient HbA1c<6.5|Patients admitted to an intensive care unit with a HbA1c <6.5.
16568425|NCT02822976||Critically Ill Patient HbA1c≥6.5|Patients admitted to an intensive care unit with a HbA1c ≥6.5.
16568426|NCT02822963||A|Non anticoagulant and/or antiplatelet users.
16568427|NCT02822963||B|Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
16568428|NCT02822963||C|Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
16568689|NCT02821091|No Intervention|Control young adults|Healthy adults, age between 20 to 59 yeas old
16568430|NCT02822937|Experimental|Placebo, Methylphenidate, Triazolam|The participants will receive placebo on the first day, 40mg Methylphenidate on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
16568431|NCT02822937|Experimental|Placebo, Triazolam, Methylphenidate|The participants will receive placebo on the first day, 0.375mg Triazolam on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
16568432|NCT02822937|Experimental|Methylphenidate, Placebo, Triazolam|The participants will receive 40mg Methylphenidate on the first day, placebo on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
16568433|NCT02822937|Experimental|Methylphenidate, Triazolam, Placebo|The participants will receive 40mg Methylphenidate on the first day, 0.375mg Triazolam on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
16568434|NCT02822937|Experimental|Triazolam, Placebo, Methylphenidate|The participants will receive 0.375mg Triazolam on the first day, placebo on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
16568435|NCT02822937|Experimental|Triazolam, Methylphenidate, Placebo|The participants will receive 0.375mg Triazolam on the first day, 40mg Methylphenidate on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
16568436|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
16568437|NCT02822911|Other|Alcohol Used Disorders Identification Test (AUDIT C)|Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
16568438|NCT02822898|Active Comparator|Isotonic Maintenance Fluid|Isotonic Maintenance Fluid
16568439|NCT02822898|Active Comparator|Hypotonic Maintenance Fluid|Hypotonic Maintenance Fluid
16568440|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
16568441|NCT02822872||infertile couples|"couples addressing IVF treatment due to known infertility will fill questionnaire in order to assess their stress level (as mentioned above), after filling the questionnaire scalp hair sample will be taken to assess chronic cortisol secretion.
~during the IVF treatment the stress level will be assessed every 3 month by using the same system (in order to find match between the stress level and cortisol secretion with the fertility treatment"
16568442|NCT02822859|Active Comparator|Wright|Methacholine challenge performed using the Wright nebulizer
16568443|NCT02822859|Active Comparator|Bennett-Twin|Methacholine challenge performed using the Bennett-Twin nebulizer
16568444|NCT02822859|Active Comparator|Aeroneb Solo|Methacholine challenge performed using the Aeroneb Solo nebulizer
16568445|NCT02822833|Experimental|Sentinel lymph node mapping|Sentinel lymph node mapping with indocyanine green injection to cervix in endometrial cancer patients operated laparoscopically
16568446|NCT02822820|Active Comparator|Advanced bipolar (Ligasure-Covidien)|Devices with advanced bipolar energy (Ligasure-Covidien) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
16568447|NCT02822820|Active Comparator|Conventional bipolar (RoBi forceps-Karl Storz)|Devices with conventional bipolar energy (RoBi rotating bipolar forceps-Karl Storz) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
16568448|NCT02822807|Other|Q fever without valvular disease|Q fever without valvular disease
16568449|NCT02822807|Other|Q fever with valvular disease|Q fever with valvular disease
16568450|NCT02822807|Other|Q fever infective endocarditis|Q fever infective endocarditis
16568451|NCT02822807|Other|Other Coxiella burnetii infections (including pregnant women)|Other Coxiella burnetii infections (including pregnant women)
16568452|NCT02822794|Experimental|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
16568453|NCT02822794|Experimental|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
16568454|NCT02822768|Active Comparator|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
16568455|NCT02822768|Placebo Comparator|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
16568488|NCT02822534|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
16568541|NCT02822105|Experimental|H3N2 M2SR monovalent influenza vaccine|This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
16568456|NCT02822755|Experimental|Video Recording Group|The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
16568457|NCT02822755|Active Comparator|Conventional Printed Group|The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs
16568458|NCT02822742|Other|DE-117 ophthalmic solution and Latanoprost|DE-117 is Experimental. Latanoprost is Active Comparator.
16568459|NCT02822729|Experimental|DE-117 ophthalmic solution (Group1)|Monotherapy
16568460|NCT02822729|Experimental|DE-117 ophthalmic solution (Group2)|Monotherapy
16568461|NCT02822729|Other|DE-117 ophthalmic solution + Timolol (Group3)|Concomitant Use
16568462|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
16568463|NCT02822703|Experimental|Active 20Hz|The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil. Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds. In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
16568464|NCT02822703|Sham Comparator|Sham|The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device. There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil. In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
16568465|NCT02822690||University Medical Center Groningen|all patients that died on one of the wards with the exception of children; on several wards the Hospice care will be introduced as an intervention
16568466|NCT02822690||Martini Ziekenhuis|all patients that died on one of the wards with the exception of children
16568467|NCT02822690||Ommelander ZorgGroep|all patients that died on one of the wards with the exception of children
16568468|NCT02822664|Other|Pedophiles patients|Adults diagnosed with pedophilia
16568469|NCT02822664|Other|Healthy subjects|Healhy subjects (not diagnosed with pedophilia)
16568470|NCT02822651|Experimental|Vitamin D status|The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.
16568471|NCT02822638||STEMI PATIENT Cohort|STEMI PATIENT Cohort
16568472|NCT02822625|Experimental|arm 1|Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.
16568473|NCT02822625|Active Comparator|arm 2|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.
~Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message"
16568474|NCT02822625|Placebo Comparator|arm 3|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.
~Patients will receive QUTENZA® according to standard procedure with a music therapy"
16568475|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
16568476|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
16568477|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
16568478|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
16568479|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
16568480|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
16568481|NCT02822586|Experimental|Cohort A (Stage IB and Stage IIA to IIIB [if N0-1])|"(Eligible patients with Stage IB, IIA, IIB, and IIIA [if N0-1])
~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.
~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week."
16568482|NCT02822586|Experimental|Cohort B(Stage IIA to IIIB; IVA;transformed CTCL)|"(Eligible patients with Stage IIA, IIB, IIIA [if N2-3]; IIIB; Stage IVA; and transformed CTCL)
~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.
~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week.
~Continuation of brentuximab every 3 weeks until disease progression or unacceptable toxicity or for up to 2 years as a study participant, (whichever occurs first)."
16568483|NCT02822573|Active Comparator|Donepezil|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
16568484|NCT02822573|Placebo Comparator|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
16568485|NCT02822560|Active Comparator|pEVAR|percutaneous femoral access using a suture-mediated closure system
16568486|NCT02822560|Active Comparator|open femoral access|cutdown to femoral artery and surgical closure
16568487|NCT02822547|Experimental|Peginterferon alfa-2a|
16568542|NCT02822105|Experimental|placebo|This group will receive saline administered intranasally.
16568489|NCT02822534|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
16568490|NCT02822534|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
16568491|NCT02822521|Experimental|Mobile Application + Population Manager|This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
16568492|NCT02822521|No Intervention|No Mobile Application|This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.
16568493|NCT02822508|Experimental|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
16568494|NCT02822508|Experimental|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
16568495|NCT02822508|Experimental|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
16568496|NCT02822508|Placebo Comparator|BLI801 Placebo|BLI801 Placebo
16568497|NCT02822482|Experimental|Copanlisib + Cetuximab|All patients will be treated by Copanlisib in association with Cetuximab.
16568498|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
16568499|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
16568500|NCT02822456|Experimental|Individual 3D-printed guided tube|IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat
16568501|NCT02822456|Active Comparator|traditional IOE tube|classic IOE tube feeding using nelaton tube only whenever they eat
16568502|NCT02822456|Active Comparator|nasogastric tube|nasogastric tube feeding using levin tube always
16568503|NCT02822443|Experimental|TAU - EFT|This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions. 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
16568504|NCT02822443|Experimental|TAU - SR|This arm focuses on the training of self-regulation strategies (SR; Carver & Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU). 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
16568505|NCT02822430||Patients|"Patients with psychiatric disorders will be assessed using five evaluation of pain scales :
~Visual analogic scale pain
~Pain behaviour scale
~Short-FormHealth Survey (SF-36)
~Global Clinical Impression (GCI) for severity and improvement
~Mini International Neuropsychiatric Interview (MINI)"
16568506|NCT02822417||patients after general anesthesia|Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia
16568507|NCT02822404|Experimental|Urinary and blood sample|Urinary and blood samples for cystatin C dosage
16568508|NCT02822391||Stroke-group|Screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 15. They were excluded if they presented with acute pain in the oro-facial sphere (nominal question) or an additional neuro-muscular disease.
16568509|NCT02822391||Control-group|Similar to stroke group in regard to age, gender and dental state. no stroke
16568510|NCT02822378|Experimental|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
16568511|NCT02822378|Experimental|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
16568512|NCT02822378|Experimental|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
16568513|NCT02822365||Diagnostic (PET/CT)|Patients undergo a PET/CT scan as part of their standard clinical care. While still positioned for the clinical scan, patients undergo additional research PET/CT scans in a smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single bed position CTAC.
16568514|NCT02822352|No Intervention|High Definition White Light|Surveillance colonoscopy using High Definition White Light alone
16568515|NCT02822352|Active Comparator|High Definition Virtualchromoendoscopy|High Definition Virtualchromoendoscopy
16568516|NCT02822339|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568517|NCT02822326|Experimental|CD19-CAR-T2 T Cells|The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells). These CD19-CAR-T2 T cells will be infused over 10-15 minutes on days Day 1, 2 and 3 tentatively according to the response to infusion.
16568518|NCT02822313|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568519|NCT02822300|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568520|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
16568521|NCT02822274|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568522|NCT02822261|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568523|NCT02822248|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16568524|NCT02822235||Crohn's Disease|Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
16568525|NCT02822235||Ulcerative Colitis|Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
16568526|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
16568527|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
16568528|NCT02822209|Experimental|Coordinating nurse added to the personalized care program|"The coordinating nurse (CN) is dedicated to the newly diagnosed patient to optimize their personalized care program.
~The CN is the connection between the medical team and the patient. They act according to the instructions from the multidisciplinary staff in charge of bronchopulmonary cancer patients.:
~e.g. Schedule an exam or an hospitalization, collect and share results of useful information to correct treatment's side effects etc
~Main contact of the patient, the general practitioner and the patient's relatives, they give practical information for the patient's case
~Quality of life questionnaires - EORTC QLQ-C30 and EORTC QLQ-LC13 - completed by the patient throughout the study.
~2 Satisfaction questionnaires completed :
~satisfaction questionnaire - patient,
~satisfaction questionnaire - general practitioner or home nurse"
16568529|NCT02822209|Active Comparator|Personalized care program as routine practice|"A personalized care program is decided for the newly diagnosed patient by the multidisciplinary team in charge of lung cancer.
~The care provided will be organized by the medical team, and besides the oncologist, no principal coordinating contact will be in charge of the patient.
~The quality of life questionnaire - EORTC QLQ-C30 and QLQ-LC13 - will be completed by the patient throughout the study.
~2 Satisfaction questionnaires completed :
~satisfaction questionnaire - patient,
~satisfaction questionnaire - general practitioner or home nurse"
16568530|NCT02822196|Experimental|Serratus Anterior Muscle Plane Block|The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi, teres major and serratus muscles will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.
16568531|NCT02822196|Active Comparator|Thoracic Paravertebral Block|The spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down.The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.
16568532|NCT02822170|Experimental|IV amino acids and in-bed cycle ergometry|"Beginning within 96 hours of ICU admission, participants will receive the following combined intervention:
~IV amino acids (15% solution) delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day.
~In-bed cycle ergometry exercise delivered in 45-minute sessions 5 days per week according to a detailed specific protocol that includes a safety check and gradual increases in resistance if the participant is actively cycling."
16568533|NCT02822157|Experimental|Olaparib|olaparib 300mg oral tablets twice daily for 28 days in 28-day cycles
16568534|NCT02822157|Active Comparator|Chemotherapy|physician's choice chemotherapy
16568535|NCT02822144|Experimental|general anesthesia|General anesthesia with etomidate, succinylcholine, propofol and remifentanil
16568536|NCT02822144|Experimental|sedation|Sedation with remifentanil and local anesthesia with lidocaine
16568537|NCT02822131|Other|low phosphate|low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.
16568538|NCT02822131|Other|high phosphate|high phosphate diet will be induced by oral supplementation with sodium phosphate.
16568539|NCT02822118|Experimental|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe for 8 weeks.
16568540|NCT02822118|Placebo Comparator|Placebo|Patients in this group were administered the placebo for 8 weeks.
16568649|NCT02821468|Experimental|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
16568650|NCT02821468|Experimental|Control|Untreated arm
16568543|NCT02822092||Patients with Psychotic Disorders taking Risp. or Arip.|Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
16568544|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
16568545|NCT02822066|Experimental|IRE for refractory neoplasms in liver and pancreas|To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
16568546|NCT02822053|Experimental|US-guided laser ablation for refractory neoplasms|The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50*10E9/L and PT ≤ 20s. Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
16568547|NCT02822040||Experimental group|All patients who have initial and final records qualify in the experimental group.
16568548|NCT02822027|Experimental|human gamma globulin|human gamma globulin for infants with encephalopathy of prematurities
16568549|NCT02822027|Active Comparator|non-human gamma globulin|non-human gamma globulin for infants with encephalopathy of prematurities
16568550|NCT02822014|Other|FDG-PET/CT arm|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical evolution of patients.
16568551|NCT02821988|Experimental|Nonstress test|"Subjects will undergo weekly nonstress tests beginning at 32 weeks until delivery in addition to monitoring fetal kick counts.
~A nonstress test is a test in which an external fetal monitor is placed on the mother to defect the fetal heart rate for 20 to 40 minutes. A test is considered reactive if there are more than 2 accelerations in fetal heart rate defined as an increase of at least 15 beats per minute lasting at least 15 seconds in a 20 minute period."
16568552|NCT02821988|Experimental|Biophysical profile|Subjects will undergo weekly biophysical profile testing beginning at 32 weeks until delivery in addition to monitoring fetal kick counts. A Biophysical profile is a test using real time ultrasonography to determine the presence of absence of certain components of fetal well being. There components include: an episode of fetal breathing lasting at least 30 seconds, 3 or more discrete body movements, 1 or more episodes of extension of a fetal extremity with return to flexion, and determination of amniotic fluid volume to detect a maximum vertical pocket of >2cm. The duration of this test is no more than 30 minutes.
16568553|NCT02821988|No Intervention|Kick counts only|Subjects will monitor fetal kick counts only.
16568554|NCT02821975|Experimental|Cognitive computer training|This is the intervention group receiving cognitive computer training three times a week for three months.
16568555|NCT02821975|No Intervention|cogntrol group|The control group do not receive cognitive computer training for three months
16568556|NCT02821962|Experimental|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
16568557|NCT02821962|No Intervention|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
16568558|NCT02821949||Patients|Patients with Non Small Cells Lung Cancer PCT dosage
16568559|NCT02821936|Experimental|Parametric Imaging|"one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy.
~Two PET scans at 3 months and one year after inclusion"
16568560|NCT02821923|No Intervention|Control|no treatment
16568561|NCT02821923|Active Comparator|E967-Xylitol|24g xylitol/d
16568562|NCT02821923|Active Comparator|E968-Erythritol|36g erythritol/d
16568563|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
16568564|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
16568565|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
16568566|NCT02821897|Experimental|Target-controlled Intravenous Anaesthesia|Patients have a target controlled intravenous anaesthesia to implant the spinal cord stimulation lead with active cooperation during the surgery.
16568567|NCT02821897|Active Comparator|Total anesthesia|Patients have a total anaesthesia to implant the spinal cord stimulation lead without active cooperation during the surgery.
16568568|NCT02821884|Experimental|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes.
16568569|NCT02821884|Active Comparator|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation.
16568570|NCT02821884|Sham Comparator|Combination of sham tDCS and sham NMES|"Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Shame tDCS is started in a ramp-like fashion but fade out slowly after 30 seconds.
~Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation."
16568571|NCT02821871|Active Comparator|SP2086|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
16568572|NCT02821871|Other|high fat diet|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
16568573|NCT02821858|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) 50 milligram (mg) (n=8) or placebo (n=2) on Day 1.
16568574|NCT02821858|Experimental|Panel 1: Treatment B|Participants will receive ODV 100 mg (n=8) or placebo (n=2) on Day 1.
16568575|NCT02821858|Experimental|Panel 1: Treatment C|Participants will receive ODV 300 mg (n=8) or placebo (n=2) on Day 1.
16568576|NCT02821858|Experimental|Panel 2: Treatment D|Participants will receive AL-335 400 mg (n=8) or placebo (n=2) on Day 1 of Period 1. Each treatment period will be separated by a washout period of 7 days.
16568577|NCT02821858|Experimental|Panel 2: Treatment E|Participants will receive AL-335 800 mg (n=8) or placebo (n=2) on Day 1 of Period 2. Each treatment period will be separated by a washout period of 7 days.
16568578|NCT02821858|Experimental|Panel 2: Treatment F|Participants will receive AL-335 1,200 mg (n=8) or placebo (n=2) on Day 1 of Period 3. Each treatment period will be separated by a washout period of 7 days.
16568579|NCT02821845||Control|Individuals with no spinal cord injury or other neurological deficits.
16568580|NCT02821845||Untrained and Trained SCI Hip and Knee|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Untrained individuals will complete 3 baseline measures and then complete eccentric training which will focus on rehabilitation of the hip joint or knee joint.
16568584|NCT02821819|Experimental|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
~Interventions:
~Random start ovarian stimulation
~Gonadotrophins: Urinary FSH 150-225 IU/d
~GnRH antagonists: Cetrorelix 0,25 mg/d
~GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
16568585|NCT02821806||Cohort 1|Healthy Volunteers
16568586|NCT02821793||Elderly patient (70 years and older)|
16568587|NCT02821793||Young patient (18 years - 69 years)|
16568589|NCT02821754|Experimental|1/A1|Durvalumab + Tremelimumab
16568590|NCT02821754|Experimental|2/A2|Durvalumab + Tremelimumab + TACE
16568591|NCT02821754|Experimental|3/A3|Durvalumab + Tremelimumab+ RFA
16568592|NCT02821754|Experimental|4/A4|Durvalumab + Tremelimumab+ Cryo
16568593|NCT02821741|Experimental|Cymba Conchae|Mild electrical stimulation is applied to the cymba conchae of the left ear, and thermal stimulation is applied to the arms.
16568594|NCT02821741|Active Comparator|Ear Lobe|Mild electrical stimulation is applied to the earlobe of the left ear, and thermal stimulation is applied to the arms.
16568595|NCT02821728|Experimental|Normal diet|No dietary intervention
16568596|NCT02821728|Experimental|Dietary intervention|3 portions of broccoli soup per week
16568597|NCT02821715|Active Comparator|Modafinil + placebo|3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks
16568598|NCT02821715|Experimental|THN102 300/3|3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks
16568599|NCT02821715|Experimental|THN102 300/27|3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks
16568600|NCT02821702|Experimental|Post surgery and embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
16568601|NCT02821702|Active Comparator|Control group|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
16568602|NCT02821702|Active Comparator|Post surgery with accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
16568603|NCT02821702|Active Comparator|Post surgery without accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
16568604|NCT02821702|Active Comparator|Normal Vaginal Delivery - no suspected accreta|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
16568605|NCT02821689|Experimental|pirfenidone|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
16568606|NCT02821689|No Intervention|Blank|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
16568607|NCT02821676|Experimental|PEC1/SPB Block|
16568608|NCT02821676|Active Comparator|Intercostal Block|
16568609|NCT02821663|Experimental|Vocal intervention|Vocal intervention
16568610|NCT02821650|Experimental|Intervention|Intervention arm will be administered with improved cook stoves (TEJ- Traditional stove to Efficient stove in Jhuggi).
16568611|NCT02821650|No Intervention|control|control arm will continue using traditional cook stoves (chulha) or a combination of the traditional stove and the kerosene/diesel stove.
16568651|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
16568652|NCT02821442|Experimental|Acupuncture|Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).
16568612|NCT02821637|Other|Effort rehabilitation program|"An effort rehabilitation program designed for obese and overweight children or teens : 13 weekly sessions of 1hour30 then 1 session 2 months, 6 months and 12 months later.
~This program is part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse.
~Child Health Questionnaire (CHQ) of quality of life are completed by parents and children on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session.
~Eurofit tests of Physical Fitness performed on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session."
16568613|NCT02821624|Experimental|Cohort 1|G1T38 or placebo
16568614|NCT02821624|Experimental|Cohort 2|G1T38 or placebo
16568615|NCT02821624|Experimental|Cohort 3|G1T38 or placebo
16568616|NCT02821624|Experimental|Cohort 4|G1T38 or placebo
16568617|NCT02821624|Experimental|Cohort 5|G1T38 or placebo
16568618|NCT02821624|Experimental|Cohort 6|G1T38 or placebo
16568619|NCT02821624|Experimental|Cohort 7|G1T38 or placebo
16568620|NCT02821624|Experimental|Cohort 8|G1T38 or placebo
16568621|NCT02821624|Experimental|Cohort 9 - Food Effect|G1T38
16568622|NCT02821624|Experimental|Cohort 10|G1T38 or placebo
16568623|NCT02821624|Experimental|Cohort 11|G1T38 or placebo
16568624|NCT02821624|Experimental|Cohort 12|G1T38 or placebo
16568625|NCT02821611|Experimental|Meditation Group|Participants in the experimental group are practicing a mantra-based meditation twice daily for 20 minutes over the 8 week intervention period to reduce stress and blood pressure and enhance quality of sleep.
16568626|NCT02821611|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
16568627|NCT02821598|Experimental|Upper limb pattern|Upper Limb pattern with flexion - abduction - external rotation
16568628|NCT02821598|Experimental|Lower limb pattern 1|Lower Limb pattern with flexion - adduction - external rotation with knee flexion;
16568629|NCT02821598|Experimental|Lower limb pattern 2|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion;
16568630|NCT02821598|Experimental|Lifting to the right|
16568631|NCT02821598|Active Comparator|Sit to Stand|Sit to Stand task
16568632|NCT02821585|Active Comparator|Mediterranean Diet|Participants will receive nutritional lessons on the principles of the Mediterranean diet. This type of diet is defined with a carbohydrate intake of 45-55% of total energy intake, 15-20% of proteins, 30-35% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
16568633|NCT02821585|Placebo Comparator|Low Fat Diet|Participants will receive nutritional lessons on the principles of the low fat diet. This type of diet is defined with a carbohydrate intake greater than 45% of total energy intake, 15-20% of proteins, less than 30% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
16568634|NCT02821572||patient|
16568635|NCT02821572||control|
16568636|NCT02821559|Experimental|triweekly then biweekly|The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).
16568637|NCT02821559|Experimental|biweekly then triweekly|The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.
16568638|NCT02821546|Placebo Comparator|standard hydration|Patients underwent first-time ERCP to receive standard fluid hydration with Lactated Ringer's solution at a rate calculated by the Holliday-Segar method given peri-procedurally starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
16568639|NCT02821546|Active Comparator|aggressive hydration|Patients underwent first-time ERCP to receive aggressive fluid hydration with Lactated Ringer's solution at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
16568640|NCT02821533|Other|TACE using a high dose of cisplatin|Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.
16568641|NCT02821520|Experimental|Initial PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.
~PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.
~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.
~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
16568642|NCT02821520|Active Comparator|Delayed PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.
~PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.
~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.
~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
16568643|NCT02821507|Experimental|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
16568644|NCT02821494|Experimental|Hespecta|Four dose groups of Hespecta
16568645|NCT02821481|Experimental|Beta-alanine and muscular endurance exercise|Receive 3.2 g/day beta-alanine and 3 days per week of endurance resistance training for 12 weeks
16568646|NCT02821481|Experimental|Beta-alanine without muscular endurance training|Receive 3.2 g/day beta-alanine with no endurance resistance training for 12 weeks
16568647|NCT02821481|Placebo Comparator|Placebo and muscular endurance exercise|Receive similar dextrose placebo and 3 days per week of endurance resistance training for 12 weeks
16568648|NCT02821481|Placebo Comparator|Placebo without muscular endurance training|Receive similar dextrose placebo with no endurance resistance training for 12 weeks
16568653|NCT02821442|Sham Comparator|Sham Acupuncture|Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.
16568654|NCT02821429||Patient with mechanical ventilation|Patient will be followed with combined Thoracic Echography Record
16568655|NCT02821416|Experimental|Benralizumab|Benralizumab administered subcutaneously
16568656|NCT02821416|Placebo Comparator|Placebo|Placebo administered subcutaneously
16568657|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
16568658|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
16568659|NCT02821390|Active Comparator|Nepafenac 0.1% Eye Drops|One drop of Nepafenac 0.1% Eye Drops will be instilled to the eye's cul de sac prior to the intravitreal injection.
16568660|NCT02821390|Placebo Comparator|Artificial Tears|One drop of Artificial Tears will be instilled to the eye's cul de sac prior to the intravitreal injection.
16568661|NCT02821377|Experimental|intravenous furosemide|intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix
16568662|NCT02821377|Experimental|intravenous hypertonic saline solutions|small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified
16568663|NCT02821377|Active Comparator|seriated paracentesis|no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge
16568664|NCT02821364|Other|Advanced Life Support|ALS providers are trained and able to perform certain procedures such as intubation with endotracheal tubes and placement of intravenous catheters. Endotracheal intubation is often performed by pre-hospital providers in critically ill trauma patients because it is believed that it allows for protection of the airway and better delivery of oxygen. However, most studies actually show that intubation does not provide a survival advantage to this patient population and actually could result in worse outcomes. Intravenous catheter placement and administration of intravenous fluids is also routinely performed however, studies have shown that it is also not helpful.
16568665|NCT02821364|No Intervention|Basic Life Support|Subjects randomized to the study group will receive basic life support (BLS) level care. This means that pre-hospital procedures such as endotracheal intubation and intravenous fluid administration will not be carried out. However, passive oxygen and needle thoracostomy, if required for tension pneumothorax, will be permitted if medically necessary.
16568666|NCT02821351|Experimental|DiamondTemp|Bilateral pulmonary vein isolation by RF ablation using DiamondTemp temperature controlled catheter and RF generator/pump system
16568667|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
16568668|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
16568669|NCT02821325||MRI|Radiology
16568670|NCT02821312|Active Comparator|Active in Group A1~A7|In each of Groups A1 to A7, 8 subjects will receive DA-8010.
16568671|NCT02821312|Placebo Comparator|Placebo in Group A1~A7|In each of Groups A1 to A7, 2 subjects will receive placebo.
16568672|NCT02821312|Active Comparator|Active in Group B1~B4|In each of Groups B1 to B4, 8 subjects will receive DA-8010.
16568673|NCT02821312|Placebo Comparator|Placebo in Group B1~B4|In each of Groups B1 to B4, 2 subjects will receive placebo.
16568674|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
16568675|NCT02821273|Experimental|Modified INSURE|Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
16568676|NCT02821273|Active Comparator|INSURE|INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant.
16568677|NCT02821247||Aflibercept|Adult wet Age Related Macular degeneration (AMD) treatment naïve partcipants were treated with intravitreal aflibercept injection
16568678|NCT02821234|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
16568679|NCT02821234|Experimental|Control group|Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
16568680|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
16568681|NCT02821182|Experimental|Anti-PD1 treatment in combination with SBRT|Patients receiving anti-PD1 treatment will be treated with high-dose radiotherapy to one lesion in 3 fractions prior to the second cycle of systemic therapy.
16568682|NCT02821169|Placebo Comparator|saline solution 0.9%|injection of saline solution in the sphenopalatine area in both nasal fossa
16568683|NCT02821169|Active Comparator|ropivacaine (2mg/ml)|injection of ropivacaine in the sphenopalatine area in both nasal fossa
16568684|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
16568685|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
16568686|NCT02821130||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis
16568687|NCT02821117|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
16568690|NCT02821091|No Intervention|Control old adults|Healthy adults, age between 60 to 80 yeas old
16568691|NCT02821091|Experimental|Exercise old adults|Healthy adults, age between 60 to 80 yeas old received interactive dynamic balance training
16568692|NCT02821078|Experimental|Participants|"In addition to the standard clinical MR protocol, 2 added sequences:
~4D flow imaging sequence
~standard 2D-PhaseContrast at portal trunk level as reference"
16568693|NCT02821065|Experimental|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse receives and reviews the data electronically and will follow-up with the patient.
16568694|NCT02821052||insulin degludec/insulin aspart|
16568695|NCT02821026|Experimental|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
16568696|NCT02821013|Active Comparator|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
16568697|NCT02821013|Active Comparator|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
16568698|NCT02821000|Experimental|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
16568699|NCT02820987|Active Comparator|MEROPENEM|After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.
16568700|NCT02820987|Active Comparator|PIPERACILLIN-TAZOBACTAM|After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
16568701|NCT02820987|Active Comparator|CEFEPIME|After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
16568702|NCT02820974||Healthy control|Healthy women of child bearing age (25-39) with regular cycles.
16568703|NCT02820974||Perimenopause|Women at the age of 40-54 with irregular cycles filling in th criteria of perimenopause.
16568704|NCT02820974||Menopause|Women at the age of over 55 without normal cycles filling in th criteria of menopause.
16568705|NCT02820961|Active Comparator|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
16568706|NCT02820961|Active Comparator|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
16568707|NCT02820948|Experimental|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
16568708|NCT02820948|No Intervention|No Vitamin E ointment application|No vitamin E ointment was performed.
16568709|NCT02820935|Experimental|Part 1, Period 1: CC-220|Single dose of 0.6mg CC-220
16568710|NCT02820935|Experimental|Part 1, Period 2: itraconazole with CC-220|Multiple does of 200 mg itraconazole alone, with a single dose of 0.6 mg CC-220 plus itraconazole
16568711|NCT02820935|Experimental|Part 2, Period 1: CC-220|Single dose of 0.6mg CC-220
16568712|NCT02820935|Experimental|Part 2, Period 2: rifampin with CC-220|Multiple doses of 600 mg rifampin alone, with a single dose of 0.6 mg CC-220 plus rifampin
16568713|NCT02820922||Orthopedic emergency surgery|Patients of all ages who have undergone emergency orthopedic surgery The analysis of medical data with regard to age, sex, the American Society of Anesthesiologists (ASA) score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
16568714|NCT02820909|Experimental|Ultrasound guidance|46 patients in the experimental ultrasound group
16568715|NCT02820909|Active Comparator|Anatomical guidance|46 patients in the anatomical group
16568716|NCT02820896|Placebo Comparator|Multiple Dose Placebo IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses.
16568717|NCT02820896|Experimental|Multiple Dose RO7105705 IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses.
16568718|NCT02820896|Experimental|Single Dose RO7105705 SC|Healthy participants will receive a single dose of RO7105705 SC on Day 1.
16568719|NCT02820896|Placebo Comparator|Single dose Placebo IV|Healthy participants will receive a single dose of placebo IV on Day 1.
16568720|NCT02820896|Experimental|Single dose RO7105705 IV|Healthy participants will receive a single dose of RO7105705 IV on Day 1.
16568721|NCT02820883|Experimental|High dosage vaccine|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
16568722|NCT02820883|Experimental|Middle dosage vaccine|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
16568723|NCT02820883|Experimental|Low dosage vaccine|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
16568724|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
16568955|NCT02819362||Prospective cohort - MRI|Patients with pathological nipple discharge
16568725|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
16568726|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
16568727|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
16568728|NCT02820844|Experimental|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
16568729|NCT02820844|Placebo Comparator|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
16568730|NCT02820805|Experimental|Meal skipping|No meal given
16568731|NCT02820805|Experimental|Mashed potatoes|Carbohydrate Test Meal (50 g of available carbohydrates)
16568732|NCT02820805|Experimental|French fries|Carbohydrate Test Meal (50 g of available carbohydrates)
16568733|NCT02820805|Experimental|Hash browns|Carbohydrate Test Meal (50 g of available carbohydrates)
16568734|NCT02820805|Experimental|Rice|Carbohydrate Test Meal (50 g of available carbohydrates)
16568735|NCT02820805|Experimental|Beans|Carbohydrate Test Meal (50 g of available carbohydrates)
16568736|NCT02820792|Active Comparator|LMA ProtectorTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
16568737|NCT02820792|Active Comparator|Ambu AuraGainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
16568738|NCT02820779|Experimental|WILLIS|Patients undergo WILLIS intracranial covered stent interventional treatment
16568739|NCT02820766||Journey II BCS Knee|Physical Therapy Observational
16568740|NCT02820766||All Other Posterior Stabilized Knees|Physical Therapy Observational
16568741|NCT02820753|No Intervention|Enhanced Usual Care|"Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.
~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles)."
16568742|NCT02820753|Active Comparator|Text or Portal|Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.
16568743|NCT02820740|Other|NeuroBlate LITT Treatment|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
16568744|NCT02820714|Experimental|BLI801 Laxative|BLI801 oral laxative
16568745|NCT02820701|No Intervention|Control|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
16568746|NCT02820701|Experimental|Treatment|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. Participants in the Treatment group will receive OMT to address sacral base asymmetry after the initial ultrasound assessment.
16568747|NCT02820688|Active Comparator|Concentrated|Infraclavicular nerve block under guidance of ultrasonography will be performed using an undiluted solution of 45mg bupivacaine and 180mg prilocaine (bupivacaine 0.25% and prilocaine 1%, 18mL in total) to patients in this group
16568748|NCT02820688|Active Comparator|Diluted by 33%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 33% (bupivacaine 0.167% and prilocaine 0.66%, 27mL in total) to patients in this group
16568749|NCT02820688|Active Comparator|Diluted by 50%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 50% (bupivacaine 0.125% and prilocaine 0.5%, 36mL in total) to patients in this group
16568750|NCT02820675|Other|intervention|all hospitals participating in the icosmos trial will be supported in implenatation of the two main interventions.
16568751|NCT02820662|Experimental|RETCAM|
16568752|NCT02820649|Experimental|Exercise training|7 weeks of exercise training
16568753|NCT02820649|Sham Comparator|Control|Sedentary group
16568754|NCT02820636|Experimental|InVita|Participants receive the Socio-Cognitive Behavior Therapy (S-CBT) treatment.
16568755|NCT02820636|Active Comparator|Treatment as Usual|Intensive outpatient therapy of standard care for adolescents and their parents
16568781|NCT02820415||infertile couples undergoing ICSI for PGS/PGT|patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).
16568756|NCT02820623|Experimental|Self-report|Therapists randomized to this condition will complete a brief self-report measure, the Therapy Process Observational Coding System for Child Psychotherapy Strategies Scale-Self Report version (TPOCS-SR) for each of the recorded clinical encounters with enrolled youth. The TPOCS-SR will be a self-report version of the Therapy Process Observational Coding System for Child Psychotherapy-Strategies Scale (TPOCS-S) and will be created in collaboration with the instrument developer (McLeod). In this condition, the investigators will (a) provide an operational definition for each item on the TPOCS-SR (e.g., cognitive education: teaches client the cognitive model (e.g., thoughts influence behavior)/identifies how the cognitive model applies to a specific aspects of the client's life), and (b) provide therapists with a 30-minute training session that includes sample vignettes of particular behaviors and information about how those vignettes should be rated.
16568757|NCT02820623|Experimental|Chart Stimulated Recall|"Therapists randomized to this condition will be asked to bring the charts of three enrolled youth to the chart-stimulated recall interview. A trained interviewer will ask the therapists how well they recall the encounter (rating of memory quality) followed by an open-ended question (Talk me through your last session with your client. Tell me what you did.). While the therapists are speaking, the interviewer will note any elements that represent a prescribed CBT strategy. The interviewer will go through a list of cognitive-behavioral strategies based upon the TPOCS-S and probe to determine if the therapists completed any of the strategies. Follow-up questions will be used to explore to what degree an element was used and how skillfully and responsively the strategies were used."
16568758|NCT02820623|Experimental|Behavioral Rehearsal|"Therapists randomized to this condition will be asked to engage in role-plays demonstrating the CBT strategies used with the three enrolled youth. The investigators will provide therapists with a list of the TPOCS-S CBT strategies and ask them to identify the CBT strategies used in their recorded encounter. The investigators will randomly select one of the strategies they report for each role-play. The investigators will then tell them, Please role-play how you used this strategy in session with your client, with the trained actor in front of you. Later, an independent rater will rate therapists' adherence and skill based on established scoring criteria."
16568759|NCT02820610|Active Comparator|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
16568760|NCT02820610|Active Comparator|Magnesium sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
16568761|NCT02820610|Placebo Comparator|Control group|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
16568762|NCT02820597|Experimental|Intervention|Cryoablation with the ClariFix device
16568763|NCT02820584|Experimental|GSC-loaded autologous dendritic cells|DC-GSC immunotherapy. Six vaccinations are envisaged. The first three vaccinations will be performed every two weeks; subsequent three vaccinations every month. The first vaccination will be performed using 20 million DC, the second and third with 10 million DC; and from the 4th vaccine 5 million DC
16568764|NCT02820558|Experimental|Substance P - 1nmol/kg|Substance P 1nmol/kg intra-celiac artery, single treatment
16568765|NCT02820558|Experimental|Substance P - 5nmol/kg|Substance P 5nmol/kg intra-celiac artery, single treatment
16568766|NCT02820558|Experimental|Substance P - 15nmol/kg|Substance P 15nmol/kg intra-celiac artery, single treatment
16568767|NCT02820558|Experimental|Substance P - 45nmol/kg|Substance P 45nmol/kg intra-celiac artery, single treatment
16568768|NCT02820545||Sociological interview|Patients will take a sociological interview with a sociologist during their hospital stay
16568769|NCT02820545||Self-administrated questionnaire|Patients will take a self-administrated questionnaire at the end of their hospital stay and one week after they left hospital
16568770|NCT02820532|Other|Tracking|The volunteers will be placed on the treatment couch. Their respiratory motion will be measured and the treatment couch will be moved accordingly. During the couch motion experiment the heartbeat, the skin humidity, the respiratory characteristics and the pupil motion will be additionally measured.
16568771|NCT02820519|Experimental|Loxapine|Loxapine Capsules 10 mg Day 1- 14: 10 mg b.i.d Day 15-28: 10 mg t.i.d Day 29-42: 20 mg b.i.d. Day 43-56: 20 mg t.i.d. Dosages will be escalated according to analgesic efficacy and tolerability.
16568772|NCT02820506|Other|High risk endometrial cancer|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
16568773|NCT02820506|Other|Cervical cancer tumor size 2-4 cm|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
16568774|NCT02820493|Other|single arm study|Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.
16568775|NCT02820480||Patients/health professionals|Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
16568776|NCT02820467|Experimental|patients with suspicion of CLI|patients presenting with peripheral artery disease and suspicion of critical limb ischemia as assessed by TASK II consensus 30 patients will be enrolled and will benefit of measures of TcPO2, too systolic blood pressure and skin perfusion pressure and in the same time angiography with fluorescence (Indocyanine grey 0.05 mg/kg by intravenous injection
16568777|NCT02820454|Experimental|AGuIX and radiotherapy|"Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.
~Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg"
16568778|NCT02820441|Experimental|ZOPICLONE|Zopiclone 3.5 mg capsule by mouth daily for 2 weeks
16568779|NCT02820441|Placebo Comparator|PLACEBO|Placebo 3.5 mg capsule by mouth daily for 2 weeks
16568780|NCT02820428|Other|Healthy participants|Submission of the scale 'Evaluation of behaviour in Parkinson's Disease' to healthy subjects
16568782|NCT02820389||Optical colonoscopy|Patients with suspected colorectal cancer will undergo optical colonoscopy as the initial imaging modality.
16569144|NCT02818036|Placebo Comparator|sugar pill|single sugar pill
16571427|NCT02802410|Experimental|Kinesiotape|Kinesiotape application on leg muscles
16568783|NCT02820389||CT Colonography|Patients with suspected colorectal cancer will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan.
16568784|NCT02820376|Other|All patients|"Differential renal function assessment by 4D CT:
~All patients will undergo both CT and SPECT assessment of differential renal function; each patient will be his own comparator"
16568785|NCT02820363|Experimental|Test|"Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s)."
16568786|NCT02820363|Active Comparator|Control|Tibial fracture fixation with IM nail.
16568787|NCT02820337||non comparative|Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal
16568788|NCT02820324|Experimental|Treatment 1 Oliceridine|
16568789|NCT02820324|Experimental|Treatment 2 Oliceridine|
16568790|NCT02820324|Experimental|Treatment 3 Oliceridine|
16568791|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
16568792|NCT02820324|Active Comparator|Treatment 5 Morphine|
16568793|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
16568794|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
16568795|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
16568796|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
16568797|NCT02820298|Experimental|Group 1 - Bexagliflozin dosed in fed state, then in fasted state|Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
16568798|NCT02820298|Experimental|Group 2 - Bexagliflozin in fasted state, then in fed state|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
16568799|NCT02820285|Other|Morbid obese patients|
16568800|NCT02820285|Other|Control patients|
16568801|NCT02820285|Other|Patients with overweight, steatosis and steatohepatitis|
16568802|NCT02820272|Experimental|NPWT with cold water|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change.
16568803|NCT02820272|Active Comparator|NPWT with normal saline room temp|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change.
16568804|NCT02820272|Placebo Comparator|NPWT without other intervention|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was no injection of any liquids into sponge before dressing change.
16568805|NCT02820246||hospitalised patients|all patients present in a hospital ward during the morning shift
16568806|NCT02820220||Patient/patient attendants|"Study subjects will be females.
~Age at enrolment should be more than 18 years.
~Attending Department of Paediatrics OPD/emergency/well-baby clinics/immunisation clinics OR Department of Gynaecology and Obstetrics OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.
~Written informed consent to participate in the study."
16568807|NCT02820220||Students,nursing|"Pursuing Bsc Nursing(in their final year) or intern of college of nursing LHMC
~Written informed consent to participate in the study"
16568808|NCT02820220||In-service nurses|"Posted in Department of Paediatrics indoor/OPD/well-baby clinics/immunisation clinics or Department of Gynaecology and Obstetrics indoor/OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.
~Written informed consent to participate in the study."
16568809|NCT02820207||Vulnerable plague|The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
16568810|NCT02820194|Active Comparator|Stereotactic body radiation therapy|Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
16568811|NCT02820194|Active Comparator|Microwave Ablation|Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.
16568812|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
16568813|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
16568814|NCT02820155|Placebo Comparator|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
16568815|NCT02820155|Experimental|RGN1016_50mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
16568816|NCT02820155|Experimental|RGN1016_100mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
16568817|NCT02820155|Experimental|RGN1016_200mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
16568818|NCT02820155|Experimental|RGN1016_400mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
16568819|NCT02820155|Experimental|RGN1016_800mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
16568820|NCT02820142||Bacteremia with Sepsis group|Patients aged 20 years or older with a diagnosis of bacteremia will be eligible for inclusion in the study.
16568821|NCT02820129|Experimental|Wallet Card Group|"The intervention arm is comprised of:
~Patients from the TAPER study who receive a medication wallet card with their medications and medical conditions listed."
16568822|NCT02820129|Placebo Comparator|Control Group|"Standard of care as well as wait list control. These participants will receive a reminder wallet card which states, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
16568823|NCT02820116|Experimental|Icotinib|Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
16568925|NCT02819570|Experimental|cefuroxime|I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days
16571428|NCT02802410|Experimental|No-Tape|No-Tape on leg muscles
16568824|NCT02820103|Active Comparator|Information leaflet (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
16568825|NCT02820103|Experimental|Text+Visual BCT-based intervention (Intervention Group 1)|Participants in the visual intervention group will receive the control condition specified above PLUS a specifically developed Text+Visual BCT-based intervention, comprising the 12 BCTs identified earlier in a Systematic Review and expert consensus study. The BCTs are Problem solving; Action planning; Social support (practical); Social support (emotional); Instruction on how to perform the behaviour; Information about health consequences; Salience of health consequences; Prompts/cues; Credible source; Pro's & Con's; Comparative imagining of future outcomes; Mental rehearsal of successful performance
16568826|NCT02820103|Experimental|Text-only BCT-based intervention (Intervention Group 2)|Information leaflet (usual care) plus text-only BCT-based intervention (Intervention group 2) Participants in the text-only BCT-based intervention group will receive the control condition specified above plus a text-only BCT-based intervention. This was developed in the same way as the text+visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen instead.
16568827|NCT02820090||Success with SBT|The patient have a success in SBT.
16568828|NCT02820090||Success with mechanical ventilation|Weaning from mechanical ventilation is successful
16568829|NCT02820090||failure with SBT|The patient have a failure in SBT.
16568830|NCT02820090||failure with mechanical ventilation|Weaning from mechanical ventilation is failed
16568831|NCT02820077|Experimental|Hemospray|Patients treated with hemostatic powder
16568832|NCT02820077|No Intervention|Clinical support|Patients treated with optimal clinical management, as it is been advised by the latest guidelines
16568833|NCT02820064|Other|only one arm|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
16568834|NCT02820051|Active Comparator|Midazolam|"In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
~Intervention: Transcutaneous CO2 monitor"
16568835|NCT02820051|Experimental|Propofol|"In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
~Intervention: Transcutaneous CO2 monitor"
16568836|NCT02820038|Active Comparator|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
16568837|NCT02820038|Experimental|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
16568838|NCT02820038|Experimental|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
16568839|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
16568840|NCT02820025|Experimental|doxapram group|the doxapram group iv doxapram 1mg/kg,
16568841|NCT02820025|Placebo Comparator|Controlled group|the controlled group given equal volume of saline with the doxapram group.
16568842|NCT02820012|Other|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.
~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.
~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .
~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
16568843|NCT02819999|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
16568844|NCT02819999|Experimental|Rovalpituzumab Tesirine followed by Cisplatin, Etoposide|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion
16568845|NCT02819999|Experimental|Rovalpituzumab Tesirine with Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion
16568846|NCT02819999|Experimental|Rovalpituzumab Tesirine following Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
16568847|NCT02819986|Experimental|Progressive Goal Attainment Program|10 one hour weekly therapy sessions focused on behavioural interventions
16568848|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
16568849|NCT02819973|Experimental|Educational Video 2|Caucasian Video
16568850|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
16568926|NCT02819570|Active Comparator|ampicillin|I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days
16568851|NCT02819960|Active Comparator|active probiotic formula|"Intervention: Probiotic formula PROBIO-FIX INUM® will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.
~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
16568852|NCT02819960|Placebo Comparator|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).
~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
16568853|NCT02819934|Experimental|Arm1|experimental group
16568854|NCT02819921|Experimental|Desvenlafaxine succinate 100mg|Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
16568855|NCT02819921|Experimental|Desvenlafaxine succinate 50mg|50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
16568856|NCT02819921|Placebo Comparator|Placebo|50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.
16568857|NCT02819908|Active Comparator|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
16568858|NCT02819908|Active Comparator|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
16568859|NCT02819895|Experimental|Intervention|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive their usual care (an immunization card). In addition they will received automated text, calls and emails (if applicable) reminders through a customized windows® software application when their child's immunization visit is due.
16568860|NCT02819895|No Intervention|Control|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive usual care (an immunization card)
16568861|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
16568862|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
16568863|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
16568864|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
16568865|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
16568866|NCT02819869|Experimental|Taking both statin and metformin Group|The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.
16568867|NCT02819869|No Intervention|Non- taking both statin and metformin Group|Non- taking both statin and metformin.
16568868|NCT02819856|Placebo Comparator|SPI-1000 Capsule 0mg Ebselen Placebo|0mg Ebselen SPI-1000 bid po x 21d
16568869|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x1|200mg SPI-1005 bid po x 21d Low Dose Arm
16568870|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x2|400mg SPI-1005 bid po x 21d Mid Dose Arm
16568871|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x3|600mg SPI-1005 bid po x 21d High Dose Arm
16568872|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.
16568873|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
16568874|NCT02819830|Experimental|Intervention group|"Participants, who have been randomly assigned to the intervention group, will take part in a six-week supervised exercise training programme. This programme takes place in a rehabilitation gymnasium. The exercise programme consists of two group sessions per week (scheduled for evenings, after typical working hours, approximately 12 patients per session). Each session lasts for approximately 70 minutes and includes a 5 minute warm up, 30 minutes of aerobic cycling exercise, 30 minutes of strength training, and a 5 minute cool down.
~Participants will also perform a 30 minute walk each weekend as part of the intervention."
16568875|NCT02819830|No Intervention|Control group|Participants who have been randomly assigned to the control group will not undertake the exercise intervention. These participants are instructed to maintain their usual lifestyle.
16568876|NCT02819817|Experimental|Aloe Vera Gel|Experimental gel placed in identical opaque tube as placebo gel.
16568877|NCT02819817|Placebo Comparator|Ultrasound Gel|Placebo placed in identical opaque tube as experimental gel.
16568878|NCT02819817|No Intervention|Standard care|Standard care
16568879|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16568880|NCT02819791|Active Comparator|Control group|
16568881|NCT02819791|Experimental|Intervention group|
16568882|NCT02819778|Other|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
16568883|NCT02819778|Other|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
16568884|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
16568885|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
16568886|NCT02819739|Experimental|normoxia|During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
16568887|NCT02819739|Active Comparator|hyperoxia|During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
16568888|NCT02819726|Experimental|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
16568889|NCT02819726|Active Comparator|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
16568890|NCT02819726|Active Comparator|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
16568891|NCT02819713|Placebo Comparator|ultrasound gel|
16568892|NCT02819713|Active Comparator|Instillagel|
16568893|NCT02819687|Experimental|RDX5791 10mg QD (SAD phase)|10mg of RDX5791 administered once daily PO fasting
16568894|NCT02819687|Experimental|RDX5791 50mg QD (SAD phase)|50mg of RDX5791 administered once daily PO fasting
16568895|NCT02819687|Experimental|RDX5791 150mg QD (SAD phase)|150mg of RDX5791 administered once daily PO fasting
16568896|NCT02819687|Experimental|RDX5791 450mg QD (SAD phase)|450mg of RDX5791 administered once daily PO fasting
16568897|NCT02819687|Experimental|RDX5791 900mg QD (SAD phase)|900mg of RDX5791 administered once daily PO fasting
16568898|NCT02819687|Experimental|RDX5791 3mg QD (MAD phase)|3mg of RDX5791 administered once daily PO fasting
16568899|NCT02819687|Experimental|RDX5791 10mg QD (MAD phase)|10mg of RDX5791 administered once daily PO fasting
16568900|NCT02819687|Experimental|RDX5791 30 mg QD (MAD phase)|30mg of RDX5791 administered once daily PO fasting
16568901|NCT02819687|Experimental|RDX5791 100 mg QD (MAD phase)|100mg of RDX5791 administered once daily PO fasting
16568902|NCT02819674||early-onset hypertension|early-onset hypertension patients recruited in Chinese multiple centers
16568903|NCT02819661|Active Comparator|women BMI<30 POD 1|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
16568904|NCT02819661|Active Comparator|women BMI≥30 POD 1|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
16568905|NCT02819661|Active Comparator|women BMI<30 POD4|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
16568906|NCT02819661|Active Comparator|women BMI≥30 POD 4|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
16568907|NCT02819648|Experimental|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France); administered 30 minutes before endodontic treatment
16568908|NCT02819648|Placebo Comparator|Control|Milk tablet administered 30 minutes before endodontic treatment
16568909|NCT02819635|Placebo Comparator|Placebo|Administered once daily.
16568910|NCT02819635|Experimental|Updacitinib (ABT-494) Dose A|Administered once daily.
16568911|NCT02819635|Experimental|Updacitinib (ABT-494) Dose B|Administered once daily.
16568912|NCT02819635|Experimental|Updacitinib (ABT-494) Dose C|Administered once daily.
16568913|NCT02819635|Experimental|Updacitinib (ABT-494) Dose D|Administered once daily.
16568914|NCT02819622||Control group|control (no disease)
16568915|NCT02819622||central serous retinopathy group|Central serous retinopathy (with CSCR disease) by exam and OCT
16568916|NCT02819609||Myomectomy|Women with uterine fibroids who underwent myomectomy as their index procedure as part of their routine clinical care
16568917|NCT02819609||Endometrial ablation|Women with uterine fibroids who underwent endometrial ablation as their index procedure as part of their routine clinical care
16568918|NCT02819609||Uterine artery embolization|Women with uterine fibroids who underwent uterine artery embolization as their index procedure as part of their routine clinical care
16568919|NCT02819609||MRI-guided focused ultrasound ablation|Women with uterine fibroids who underwent MRI-guided focused ultrasound ablation as their index procedure as part of their routine clinical care
16568920|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
16568921|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
16568922|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
16568923|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
16568924|NCT02819583|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
16568927|NCT02819557|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
16568928|NCT02819544|Active Comparator|Ropivacaine|Ropivacaine 7.5 mg/mL administration
16568929|NCT02819544|Placebo Comparator|Sodium chloride|NaCl 0.9% administration
16568930|NCT02819531|Active Comparator|Rotational atherectomy|RA protocol: After IVUS protocol, patients who are randomized to RA will undergo coronary wiring of the target lesion and subsequent advancement of the RA burr. The RA system is performed using standard technique under intravenous infusion of heparin. The atherectomy burr size will be determined by the operator.
16568931|NCT02819531|Active Comparator|Orbital atherectomy|OAS protocol: After IVUS protocol, patients who are randomized to OAS will undergo coronary wiring of the target lesion and subsequent advancement of the OAS according to the manufacturer's guidelines.
16568932|NCT02819531|Active Comparator|Scoring balloon system|SBS protocol: After IVUS protocol, patients who are randomized to SBS will undergo coronary wiring of the target lesion and balloon inflation with SBS performed by standard technique under intravenous infusion of heparin. SBS will be used according to the manufacturer's guidelines.
16568938|NCT02819505|Experimental|Beta-alanine supplementation|Participants will be supplemented with 6.4g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets four times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
16568939|NCT02819505|Placebo Comparator|Placebo supplementation|Participants will be supplemented with 6.4g·d-1 placebo (maltodextrin; NAI, USA).
16568940|NCT02819492||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
16568941|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
16568942|NCT02819466||volunteers|Healthy volunteers over the age of 18 years employed by Amiens University Hospital 3D echography
16568943|NCT02819453||prior corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) by two clinicians on the first day of hospital admission (not receiving corticosteroids yet)
16568944|NCT02819453||after corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) after corticosteroids treatment
16568945|NCT02819440|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
16568946|NCT02819440|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
16568947|NCT02819427||epilepsy|children with absence epilepsy presenting either typical or atypical seizures
16568948|NCT02819414|Placebo Comparator|Control Group|Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
16568949|NCT02819414|Active Comparator|Treatment Group|Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
16568950|NCT02819388|Experimental|Intervention|Contraceptive counseling
16568951|NCT02819388|No Intervention|Control|Control group without counseling
16568952|NCT02819375|Active Comparator|Group Propofol|anesthesia will induced 1 mg/kg propofol
16568953|NCT02819375|Active Comparator|Group propofol/remifentanil|anesthesia will induced 0.5 mg/kg propofol and 1 µg/kg remifentanil
16568954|NCT02819375|Active Comparator|Group propofol/ketamine|anesthesia will induced propofol 0.5 mg/kg and ketamine 0.5 mg/kg
16568956|NCT02819349|Experimental|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. The intervention will include an online interface for clinicians and an automated text messaging program for patients. Firstly, patients and providers will meet in an intake session, to identify the patient's personal early warning signs from a pre-identified list. Using the online interface, providers will enter additional warning signs or personalize the wording of the messages as requested by the patient. The patient also will determine the threshold at which the provider will be alerted about a possible relapse and whether additional contact people should be alerted.
16568957|NCT02819349|No Intervention|Treatment-As-Usual Control|The control group will be a treatment as usual comparison group. For the majority of individuals with schizophrenia/SAD in care at JHCPP, this involves meeting with their therapist every 2 to 4 weeks and meeting with their psychiatrist at least once every 90 days or more frequently as clinically indicated. All routine appointments are scheduled, but individuals can walk in or call if they do not feel well between sessions.
16568958|NCT02819336|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions within 21 days)
~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)
~20 minutes duration with middle frequency (30 Hz) of electrical stimulation
~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
16568959|NCT02819336|Sham Comparator|Park sham (PS) group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions within 21 days)
~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)
~20 minutes duration with undelivered electrostimulation of middle frequency (30 Hz)
~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
16568960|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
16568961|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
16568962|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
16568963|NCT02819310|Experimental|BLI400 Laxative|BLI400 Laxative
16568964|NCT02819297|Experimental|BLI400 Laxative|BLI400 Laxative
16568965|NCT02819297|Placebo Comparator|Placebo|BLI400 placebo
16568966|NCT02819284|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
16568967|NCT02819284|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
16568968|NCT02819271|Experimental|CXL-1427 (BMS-986231)|Experimental
16568969|NCT02819271|Placebo Comparator|Placebo|Placebo
16568970|NCT02819258|Other|Endodontic treatment for a tooth with a periapical pathology|
16568971|NCT02819245|Other|Age before and after 18 years old|Surgical treatment before and after skeletal maturity
16568972|NCT02819232|Other|Patient with a prescription of a microbiologic diagnostic of|Patient with a prescription of a microbiologic diagnostic of keratitis
16568973|NCT02819219|Placebo Comparator|Placebo|Participants will receive a flavored water placebo supplement. Part of the supplemental intervention. This, and all groups, simultaneously took part in the exercise intervention.
16568974|NCT02819219|Experimental|ElevATP|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
16568975|NCT02819219|Experimental|ElevATP w/Caffeine|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts), a 180 mg blend of caffeine (caffeine anhydrous, pterostilbene-bound caffeine), and 38mg B vitamins. Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
16568976|NCT02819206|Other|Uveitis|Patient with a prescription of a microbiologic diagnostic of uveitis
16568977|NCT02819193||exposed group : early raw mother's own milk|"The use of raw MOM is considered as early when it begins before day 7."
16568978|NCT02819193||unexposed group : no use of raw mother's own milk|Neonates who receive, or not, raw MOM before day 7.
16568979|NCT02819180||Healthy adults group|Healthy men and women between 18 and 59 years of age.
16568980|NCT02819180||Elderly group|Elderly over 60 years old.
16568981|NCT02819167|Other|neurologic and neuropsychological evaluation|
16568982|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
16568983|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
16568984|NCT02819128|Other|Homeless people|Populations of homeless households in Marseille.
16568985|NCT02819115||Healthy adults group|Healthy adults aged 18 to 59 years
16568986|NCT02819115||Elderly group|Elderly over 60 years old.
16568987|NCT02819102|Experimental|Metabolic Probes and BCX7353|"Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.
~Day 2: a single oral dose of 2 mg midazolam. Days 3 to 9: 350 mg BCX7353 once a day. Day 10: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, 30 mg dextromethorphan and 350 mg BCX7353, orally.
~Day 11: a single oral dose of 2 mg of midazolam along with 350 mg BCX7353."
16568988|NCT02819089|Active Comparator|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
16568989|NCT02819089|Placebo Comparator|NSS|NSS loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
16568990|NCT02819076||Painless Children|30 children
16568991|NCT02819076||Painful Children|70 children
16568992|NCT02819050|Experimental|Sprinting|Take off NCPAP twice daily for 3hours (day 1), Take off NCPAP twice daily for 6hours (day 2), Take off NCPAP twice daily for 9hours (day 3), Placed back on NCPAP for 24hours (day 4), Switch to nasal cannula at a flow rate of 1.5-2 L/min (day 5)
16571455|NCT02802241|Experimental|double-blind peppermint oil|
16568993|NCT02819050|Active Comparator|Non-Sprinting|"If the infant was on NCPAP 6, Infant was weaned down to CPAP 5 for 96 hours. If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC.
~If the infant was on NCPAP 5, the infant was continued on CPAP 5 for 96 hours If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC."
16568994|NCT02819037|Experimental|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
16568995|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
16568996|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
16568997|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
16568998|NCT02818998|Experimental|Aflibercept 2 mg fixed|Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
16568999|NCT02818998|Experimental|Aflibercept 2 mg flexible|Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
16569000|NCT02818998|Experimental|Aflibercept 2 mg PRN|Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
16569001|NCT02818985|Active Comparator|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
16569002|NCT02818985|Active Comparator|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
16569003|NCT02818985|Placebo Comparator|Control|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
16569004|NCT02818972|Experimental|RelayPro|Endovascular treatment with the investigational device.
16569005|NCT02818959|Experimental|Transcatheter Aortic Valve Replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.
16569006|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
16569007|NCT02818933||Aim 1|This group follows a crossover design where adolescents 12-17 years old (n=10) complete a diet recall using one of the two methods (interviewer-administered vs web-based), and then does another diet recall using the other method about a week later. Participants are randomly assigned to the order in which they complete each method of diet recall.
16569008|NCT02818933||Aim 2, interviewer-administered recall|This group of adolescents 12-17 years old (n=10) completes an interviewer-administered diet recall once a week for 6 weeks.
16569009|NCT02818933||Aim 2, web-based recall|This group of adolescents 12-17 years old (n=10) completes a web-based self-administered diet recall once a week for 6 weeks.
16569010|NCT02818920|Experimental|Pembrolizumab prior to and after surgery|
16569011|NCT02818907|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.
~Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.
~Tumor tissue will be collected during surgery."
16569012|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
16569013|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
16569014|NCT02818881|Experimental|High-speed then low-speed yoga|Subjects received a single session of High-speed yoga and within one week a single session of Low-speed yoga
16569015|NCT02818881|Experimental|Low-speed then high-speed yoga|Subjects received a single session of Low-speed yoga and within one week a single session of High-speed yoga
16569016|NCT02818855|Experimental|Collagen Matrix plus coronally advanced flap (CAF)|A new collagen matrix (Mucograft) associated to coronally advanced flap
16569017|NCT02818855|Active Comparator|Subepithelial connective tissue graft plus CAF|Subepithelial connective tissue graft associated to coronally advanced flap
16569018|NCT02818842||Pregnant Women|"Medical and personal data will be collected for all the pregnant women who want to participate.
~The source of data are :
~Primary Health Insurance Fund data
~Prenatal Diagnostic Center of Toulouse University Hospital data
~Mother and child protection data collection
~Medicalisation Program of Information Systems data"
16569019|NCT02818829||Cohort|Collection of biological samples
16569020|NCT02818816|Experimental|Brimonidine Tartrate 0.2% (2mg/mL)|One (I) drop of brimonidine tartrate 0.2% (2mg/mL) will be placed in the randomized eye preoperatively thirty minutes before robotic-assisted radical laparoscopic prostatectomy (RALP)
16569021|NCT02818816|Placebo Comparator|Carboxymethylcellulose Eye Drops|One drop of Carboxymethylcellulose eye drops will be placed in the randomized eye half an hour before RALP
16569022|NCT02818803|Experimental|Propolis|Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days
16569023|NCT02818803|Active Comparator|Miconazole|Miconazole 20mg/g oral gel,3 times a day, for 14 days
16569024|NCT02818790|No Intervention|Group 1. Control|
16569025|NCT02818790|Experimental|Group 2. Intervention 1|
16569026|NCT02818790|Experimental|Group 2. Intervention 2|
16569027|NCT02818777|Experimental|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).
~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
16569028|NCT02818764||Delirium|"Subjects undergoing elective total joint arthroplasty determined to have delirium by post operative 3D-CAM.
~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.
~CSF collected for biomarkers. Blood colelcted for biomarkers."
16569029|NCT02818764||Non-delirium|"Subjects undergoing elective total joint arthroplasty determined not to have delirium by post oeprative 3D-CAM.
~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.
~CSF collected for biomarkers. Blood colelcted for biomarkers."
16569030|NCT02818751|Experimental|Escitalopram|Patients being randomized to receive escitalopram, at an initial dose of 5 mg (oral) daily for 2 days. On day 3, escitalopram will be increased to 10 mg daily and continued for 7 days. Then, on day 10, escitalopram will be increased to 15 mg. At the week 4 visit, the dose of escitalopram may be increased to 20 mg, based on the investigator's clinical judgment and if significant anxiety symptoms are still present.
16569031|NCT02818751|Placebo Comparator|Placebo|Patients will receive placebo (sugar pill) at an initial dose of 5 mg daily for 2 days. On day 3, placebo will be increased to 10 mg daily and continued for 7 days to match the experimental group.
16569032|NCT02818751|No Intervention|Healthy Controls|Healthy adolescents will receive fMRI scans at the same time points, which will provide assessments of the stability of neurophysiologic measures and will be used to adjust and interpret comparisons within the patients (i.e., whether patient values are changing toward or away from those of healthy adolescents).
16569033|NCT02818738|Experimental|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
16569034|NCT02818738|Placebo Comparator|Placebo|matching verum
16569035|NCT02818725|Active Comparator|Chemotherapy|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin
16569036|NCT02818725|Experimental|Arm B: chemotherapy + panitumumab|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab
16569037|NCT02818712||Patients with IPF|
16569038|NCT02818699|Placebo Comparator|Placebo Capsule|Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
16569039|NCT02818699|Experimental|EMIQ Capsule|Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
16569040|NCT02818686|Experimental|TD-1473 low dose|10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days
16569041|NCT02818686|Experimental|TD-1473 mid dose|10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days
16569042|NCT02818686|Experimental|TD-1473 high dose|10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days
16569043|NCT02818686|Placebo Comparator|Placebo|10 subjects will be randomized to receive placebo orally daily for 28 days
16569044|NCT02818673|Experimental|Ascites in Patients With Cirrhosis|Patients will be further classified according to the refractory or sensitive ascitis
16569045|NCT02818660|Experimental|Synacthen|The patient get Synacthen to stimulate the adrenals to produce cortisol
16569046|NCT02818647|Active Comparator|COLD-DISSECTION|Cold Dissection Technique
16569047|NCT02818647|Active Comparator|HOT-DISSECTION|Needle Electrocautery Dissection Technique
16569048|NCT02818634|Active Comparator|Muscle-sparing|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
16569049|NCT02818634|Active Comparator|Muscle-cutting|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were cut with Monopolar electrocautery at (25 watts).
16569050|NCT02818621|Active Comparator|Group Dex|"The Dex group received 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure.
~Interventions:
~◦Drug: Dexmedetomidine"
16569051|NCT02818621|Placebo Comparator|Group Placebo|"The Placebo group received equal amount of normal saline.
~Interventions:
~◦Drug: Normal saline"
16569052|NCT02818608|Active Comparator|Functional electrical stimulation (FES)|Chronic stroke patients submitted to functional electrical stimulation (FES).
16569053|NCT02818608|Experimental|Combination of transcranial direct current stimulation and FES|Chronic stroke patients submitted to transcranial direct current stimulation (tDCS) and functional and to functional electrical stimulation (FES).
16569054|NCT02818595|Experimental|Normal children|Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological
16569055|NCT02818595|Experimental|Abnormal children|Every child meet the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological as intraventricular hemorrhage .
16569056|NCT02818582|Active Comparator|1|Active
16569057|NCT02818582|Placebo Comparator|2|Placebo
16569058|NCT02818569|Experimental|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
16569059|NCT02818569|Experimental|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
16569060|NCT02818556|Other|Restylane Right, Belotero Left|Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)
16569061|NCT02818556|Other|Restylane Left, Belotero Right|Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)
16569062|NCT02818543|Experimental|Cohort 1|LYC-30937 25 mg single oral dose
16569063|NCT02818543|Experimental|Cohort 2|LYC-30937 100 mg single oral dose
16569064|NCT02818530|Experimental|IOP by tomoneter and ultrasound|Intraocular pressure will be measured by electronic tomometer (tonopen) at different point of time after induction of anaesthesia in patients undergoing robotic assisted surgery under steep Trendelenberg position. Anterior chamber depth will be measured by ultrasound at the same time intervals.
16569065|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
16569066|NCT02818504|Experimental|Repeatability and reproducibility study|"Monitoring of system (Wize MIrror) measurements with changes in environmental conditions (fasting state, light, temperature)"
16571456|NCT02802241|No Intervention|no additional treatment|
16569067|NCT02818504|Experimental|Validation study|"Longitudinal monitoring of cardiometabolic risk factors through an user---friendly, unobtrusive, personalized system for lifestyle self---management (the Wize Mirror)"
16569068|NCT02818491|Placebo Comparator|Control group|Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls
16569069|NCT02818491|Active Comparator|Dex 1|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls
16569070|NCT02818491|Active Comparator|Dex 2|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls
16569071|NCT02818491|Active Comparator|Dex 3|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls
16569072|NCT02818491|Active Comparator|Dex 4|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls
16569073|NCT02818478|Other|RA; at home first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
16569074|NCT02818478|Other|RA; outpatient clinic first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
16569075|NCT02818478|Other|AxSpa; at home first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
16569076|NCT02818478|Other|AxSpa; outpatient clinic first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
16569077|NCT02818465|Experimental|Patients|
16569078|NCT02818452|Experimental|Oatmeal containing beta-glucan|27 g oatmeal
16569079|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 1|27.72g oatmeal
16569080|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 2|28.43g oatmeal
16569081|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 3|29.86g oatmeal
16569082|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 4|32.72g oatmeal
16569083|NCT02818452|Placebo Comparator|Hot Cereal - Cream of Rice|20g oatmeal
16569084|NCT02818426|Experimental|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.
~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
16569085|NCT02818413||U.S. Olympic Team and elite athletes|Biospecimens will be collected from and questionnaires will be administered to U.S. Olympic team members and other elite athletes
16569086|NCT02818400|Experimental|Composite tissue allotransplantation|
16569087|NCT02818387|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
16569088|NCT02818387|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
16569089|NCT02818387|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by midazolam 0.015 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.
~Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary."
16569090|NCT02818374|Experimental|Disabled People with behavioral trouble|
16569091|NCT02818361|Experimental|topical TwHF gel group|Topical TwHF gel recipe composes Tripterygium wilfordii Hook F, Mangxiao (Mirabilite), Chuanxiong (Rhizoma Ligustici), Ruxiang (Olibanum), Moyao (M yrrh) (prescription proportion is 4:4:2:2:1).Each gel is 20 gram(g). TwHF gel is applied for 1st to 5th metacarpophalangeal joints, 1st to 5th proximal interphalangeal joints, wrists, knees and ankles 20g for 1 hour, once per day from week 0 through week 4 and 10g for 1 hour, once per day from week 5 through week 8.
16569092|NCT02818361|Placebo Comparator|placebo group|Placebo recipe composes viscous agent which matches by the sucrose. The usage and dosage of topical TwHF and placebo are the same.
16569093|NCT02818348|Experimental|DRV cohort|Darunavir/Cobicistat 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
16569094|NCT02818348|Experimental|ETR cohort|Etravirine 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
16569095|NCT02818335|Experimental|LY3023414 Reference Fasted|Single oral dose of LY3023414 (Reference) on day one fasting.
16569096|NCT02818335|Experimental|LY3023414 Test Fasted|Single oral dose of LY3023414 (Test) on day one fasting.
16569097|NCT02818335|Experimental|LY3023414 Test Fed|Single oral dose of LY3023414 (Test) on day one after a meal.
16569098|NCT02818322|Experimental|telemedical monitoring ( T)|Home care by a nurse trained in the management of diabetic foot lesions with transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion every week
16569099|NCT02818322|Active Comparator|classic monitoring|Home care by a nurse trained in the management of diabetic foot lesions without transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion
16569100|NCT02818309|Experimental|Lesogaberan|Lesogaberan
16569101|NCT02818309|Placebo Comparator|Placebo|Placebo
16569102|NCT02818296|Experimental|Active IU CBM-I|This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
16569103|NCT02818296|Sham Comparator|Control CBM-I|This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.
16569104|NCT02818283|Experimental|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
16569105|NCT02818283|Active Comparator|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
16569106|NCT02818283|Placebo Comparator|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
16569107|NCT02818270|Experimental|Drug depositions|Aerosol drug deposited delivered on the inhaled and exhaled filters and protective filters were evaluated. Salbutamol and Acetylcysteine were delivered by a jet nebulizer through a mechanical ventilator.
16569108|NCT02818257|Experimental|Strip A (wet)|Six strips of Strip A are applied on skin wetted with two different buffers (3 strips each)
16569109|NCT02818257|Experimental|Strip A (dry)|Six strips of Strip A are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
16569110|NCT02818257|Experimental|Strip B (wet)|Six strips of Strip B are applied on skin wetted with two different buffers (3 strips each)
16569111|NCT02818257|Experimental|Strip B (dry)|Six strips of Strip B are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
16569112|NCT02818257|Experimental|Strip C (wet)|Six strips of Strip C are applied on skin wetted with two different buffers (3 strips each)
16569113|NCT02818257|Experimental|Strip C (dry)|Six strips of Strip C are applied on skin that is either dry (3 strips) or wetted with buffer (3 strips)
16569114|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
16569115|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
16569116|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
16569117|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
16569118|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
16569119|NCT02818231||NON EXPOSED|"Male, >50 years, unexposed to wood dust, without any nasal pathology, without known tumor
~-> Brushing of the olfactory cleft"
16569120|NCT02818231||EXPOSED|"Male, >50 years, exposed to wood dust, without any nasal pathology, without known tumor
~-> Brushing of the olfactory cleft"
16569121|NCT02818205||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation
16569122|NCT02818205||Typically Developing Children|Typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
16569123|NCT02818179|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures
16569124|NCT02818166|Experimental|Endoaortic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and endoaortic balloon clamp
16569125|NCT02818166|Active Comparator|Transthoracic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and transthoracic clamp.
16569126|NCT02818153|Experimental|questionnaire for allergic rhinitis control|Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
16569127|NCT02818140|Active Comparator|Ropivacaine TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
16569128|NCT02818140|Placebo Comparator|Placebo TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%
16569129|NCT02818127|Active Comparator|normal coronary artery|coronary angiography will be performed by transfemoral or transradial route.
16569130|NCT02818127|Active Comparator|coronary slow flow|coronary angiography will be performed by transfemoral or transradial route.
16569131|NCT02818127|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
16569132|NCT02818127|Active Comparator|non-obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
16569133|NCT02818127|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
16569134|NCT02818114|Experimental|PEET|Peer support interventions as an adjunct to prolonged exposure
16569135|NCT02818101|No Intervention|Control group|No hypnosis session before the coronary angiography
16569136|NCT02818101|Experimental|Hypnotised group|Hypnosis session before the coronary angiography
16569137|NCT02818088|Experimental|Cognitive Training|Cognitive Training - n Back.
16569138|NCT02818075|Experimental|Mobile Phone Based Peer Support|Mobile phone-based peer support (MPPS)
16569139|NCT02818075|Active Comparator|Usual Care|Standard community prenatal and postpartum support services
16569140|NCT02818062||Endophthalmitis|The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound).
16569141|NCT02818062||Cataract (Control)|Controls were patients who underwent cataract surgery.
16569142|NCT02818049|Experimental|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
16569143|NCT02818036|Experimental|naltrexone|single 50mg dose of naltrexone
16569145|NCT02818023|Experimental|Pembrolizumab plus vemurafenib and Cobimetinib|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.
~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
16569146|NCT02818010||exposed = patient practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire)
~A patient is defined as practicing physical activity (exposed) when he meets one of the conditions following:
~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week
~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week
~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.
~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
16569147|NCT02818010||unexposed = patient not practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire(Global Physical Activity Questionnaire)
~A patient is defined as unexposed if he does not fulfill any of these conditions :
~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week
~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week
~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.
~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
16569148|NCT02817984|Experimental|Treatment Group|Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.
16569149|NCT02817971|Experimental|Enhanced feedback|"Monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators
~Two-monthly written feedback on multiple quality of paediatric care indicators
~Clinical network promoting clinical leadership linked to mentorship and peer to peer support
~Improved use of health information on service delivery"
16569150|NCT02817971|Active Comparator|Standard feedback|"Two-monthly written feedback on multiple quality of paediatric care indicators
~Clinical network promoting clinical leadership linked to mentorship and peer to peer support
~Improved use of health information on service delivery"
16569151|NCT02817958|Experimental|A-Adjuvant Chemotherapy TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days
16569152|NCT02817958|Experimental|B-Neoadjuvant Chemotherapy TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
16569153|NCT02817945|Experimental|68Ga-NOTA-3P-TATE-RGD PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-3P-TATE-RGD in one dose intravenously and underwent PET/CT scan 45-60 min later.
16569154|NCT02817932|Experimental|Group 1 (Korean, 375 mg)|Group 1 (Korean, 375 mg): Ranolazine PR 375 mg
16569155|NCT02817932|Experimental|Group 2 (Korean, 500 mg):|Group 2 (Korean, 500 mg): Ranolazine PR 500 mg
16569156|NCT02817932|Experimental|Group 3 (Korean, 750 mg):|Group 3 (Korean, 750 mg): Ranolazine PR 750 mg
16569157|NCT02817932|Experimental|Group 4 (Caucasian, 375mg)|Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg
16569158|NCT02817932|Experimental|Group 5 (Caucasian, 750mg)|Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg
16569159|NCT02817906|Experimental|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.
16569160|NCT02817906|Placebo Comparator|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
16569161|NCT02817880|Experimental|rTMS (repetitive transcranial magnetic stimulation)|rTMS (repetitive transcranial magnetic stimulation)
16569162|NCT02817880|Experimental|tDCS (transcranial direct-current stimulation)|tDCS (transcranial direct-current stimulation)
16569163|NCT02817880|Experimental|tsDCS (transcutaneous spinal Direct Current Stimulation)|tsDCS (transcutaneous spinal Direct Current Stimulation)
16569164|NCT02817867|Active Comparator|tDCS|Patients who will be treated with Transcranial direct-current stimulation (tDCS) in the ipsilesional motor cortex.
16569165|NCT02817867|Active Comparator|rTMS|Patients who will be treated with Magnetic brain stimulation (rTMS) in the contralesional motor cortex.
16569166|NCT02817867|Experimental|tDCS + rTMS|Patients who will be treated with the association between Transcranial direct-current stimulation (tDCS) and magnetic brain stimulation (rTMS), in the ipsilesional and contralesional motor cortex, respectively.
16569167|NCT02817854||Patients with acute diverticulitis|Patients admitted in emergency setting for acute diverticulitis
16569168|NCT02817841|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
16569169|NCT02817828|Experimental|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
16569170|NCT02817815|Active Comparator|Group 1|Volunteers
16569171|NCT02817815|Experimental|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
16569172|NCT02817815|Experimental|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
16569173|NCT02817815|Experimental|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
16569174|NCT02817815|Experimental|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
16569175|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
16569176|NCT02817789|Active Comparator|Standard group|154 patients
16569177|NCT02817789|Experimental|Ticagrelor group|154 patients
16569178|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
16569179|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
16569180|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
16569181|NCT02817750|Experimental|zolpidem hemitartarate (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
16569182|NCT02817750|Experimental|zolpidem hemitartarate (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
16569183|NCT02817737||CT|Measured with computed tomography
16569184|NCT02817737||plain Radiography|Measured with plain Radiography
16569185|NCT02817724|Active Comparator|m-Health group|BENECA System: The m-health group will use the BENECA app for 8 weeks.
16569186|NCT02817724|Experimental|Integral Group|BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
16569187|NCT02817698|Experimental|Drug of dependence|There is only one arm to the study. All subjects will receive their drug of dependence in this study. Nicotine dependent subjects will receive tobacco cigarettes, cannabis dependent subjects will receive cannabis cigarettes, and cocaine dependent subjects will receive IV cocaine.
16569188|NCT02817685||1|Chronic Hepatitis B patient
16569189|NCT02817685||2|Chronic Hepatitis B patient
16569190|NCT02817685||3|cirrhotic patient
16569191|NCT02817685||4|cirrhotic patient
16569192|NCT02817685||5|ultrasound-difficult patient
16569193|NCT02817685||6|ultrasound-difficult patient
16569194|NCT02817672|Active Comparator|PRIME 1.0|8 weeks use of PRIME 1.0 (current version). Mobile application designed to improve psychosocial functioning and motivational deficits.
16569195|NCT02817672|Experimental|PRIME 2.0|8 weeks use of PRIME 2.0 (version with the NLP-powered dashboard). Mobile application designed to improve psychosocial functioning and motivational deficits.
16569196|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
16569197|NCT02817646||Intensive care patients|Patients admitted to the intensive care unit for 4 days or more with a computed tomography scan made for clinical reasons early during intensive care stay and who receive enteral and/or parenteral nutrition as per hospital protocol
16569213|NCT02817620|Experimental|Spirulysat®|Food supplement packaged in 10 ml vials called Spirulysat®. This product is a phycocyanin concentrated fresh spirulina water extract (Spirulina Platensis). 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
16569214|NCT02817620|Placebo Comparator|Placebo|Placebo with the same characteristics, appearance, packaging and composition as the active formula except for active ingredient (Spirulina) replaced by a classical blue food colorant used to colour desserts. 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
16569215|NCT02817607|Experimental|Surgery|
16569216|NCT02817594||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
16569217|NCT02817568||Aggressive Periodontitis (case)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention.(Drawing Blood)
16572300|NCT02796443||Elective laparoscopic cholecystectomy|Biliary colic with no acute cholecystitis
16569218|NCT02817568||Healthy (Control)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention. (Drawing Blood)
16569219|NCT02817555|Active Comparator|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
16569220|NCT02817555|Active Comparator|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.
~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.
~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
16569221|NCT02817542||STEMI TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention with TA
16569222|NCT02817542||STEMI without TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention without TA
16569223|NCT02817529|Experimental|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
16569224|NCT02817529|Active Comparator|RC-Cornet|The RC-Cornet is a device that provides oscillatory positive expiratory pressure (OPEP) therapy for the detachment and removal of pulmonary secretions. Through variable pressure settings and optional aerosolized medication delivery, patients realize maximum efficacy specific to their unique clinical needs.The RC-Cornet uses the patient's full expired air volume to produce pressure and oscillatory vibrations. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
16569225|NCT02817516|Experimental|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter [mg/mL] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
16569226|NCT02817516|Experimental|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
16569227|NCT02817516|Experimental|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
16569228|NCT02817516|Experimental|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
16569229|NCT02817516|Experimental|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
16569230|NCT02817516|Experimental|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
16569231|NCT02817516|Placebo Comparator|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
16569232|NCT02817516|Placebo Comparator|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
16569233|NCT02817503|Experimental|Standard BP control|"SBP within 140 - <150 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.
~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
16569234|NCT02817503|Active Comparator|Moderate BP control|"SBP within 130 - <140 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.
~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
16569235|NCT02817503|Active Comparator|Intensive BP control|"SBP <130 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.
~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
16569236|NCT02817490||Patients with hypermobility type Ehlers-Danlos Syndrome|Patients with hypermobility type Ehlers-Danlos Syndrome participating to one out of the three patient education sessions included in the study.
16569237|NCT02817490||Caregivers|Caregivers participating to one out of the three patient education sessions included in the study.
16569238|NCT02817477|Experimental|IN Ketamine|A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
16569239|NCT02817477|Active Comparator|IM Morphine|A single administration of 0.15 mg/kg intramuscular morphine
16569240|NCT02817477|Active Comparator|IV Morphine|A single administration of 0.1 mg/kg slow intravascular bolus of morphine.
16569241|NCT02817464|Experimental|TV-46046 - 1|
16569242|NCT02817464|Experimental|TV-46046 - 2|
16569243|NCT02817464|Experimental|TV-46046 - 3|
16569244|NCT02817451|Experimental|Study Group A|HIV exposed and infected infants
16569245|NCT02817451|Experimental|Study Group B|HIV exposed and uninfected infants
16569465|NCT02816008|Active Comparator|Passive control group|Passive/conventional cognitive training at home.
16569246|NCT02817438|Experimental|Online Intervention|Participants randomized to the online intervention arm will be given access to the Good Days Ahead program for 12 weeks.
16569247|NCT02817438|No Intervention|Waitlist|Participants randomized to the waitlist arm will wait for 12 weeks without doing an online intervention.
16569248|NCT02817425|Active Comparator|SOX Sequential S-1 Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 6 months and sequential S-1 for 6 months"
16569249|NCT02817425|Active Comparator|SOX Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 12 months"
16569250|NCT02817425|Experimental|TEGAFOX Sequential S-1|"Patients received chemotherapy with TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)  for 6 months and sequential S-1 for 6 months"
16569251|NCT02817412|Experimental|Go/No-Go Training|In the go/no go training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. They are told to press response keys as quickly as possible to indicate the side of presentation (go-trials). On half of the trials, the rectangular frame surrounding the image is not solid but hatched, which is a signal for them to withhold their response (no-go trials). This training is divided into 4 blocks of 50 trials.
16569252|NCT02817412|Experimental|Stop-Signal Training|In the stop signal training, participants are shown images in either a dark blue or light gray border. They are told to press the space bar as quickly as possible when the border is blue (go trials) and to withhold a response when the border is gray (no-go trials). This training is divided into 20 blocks of 32 trials.
16569253|NCT02817412|Experimental|Dot-Probe Training|In the dot-probe training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. Immediately after the images disappear, a small dot probe appears in the location of one of the images. Participants are told to press response keys as quickly as possible to indicate whether a visual probe appeared behind the left or right image during the trials. The probe appears in the location occupied by a high-calorie food image 10% of the time and in the location occupied by a low-calorie food image 90% of the time. This training is divided into 6 blocks of 40 trials.
16569254|NCT02817412|Placebo Comparator|Generic Training|In the generic training, participants complete a generic go/no-go training that uses images of flowers and office supplies instead of the images of high-calorie and low-calorie food images. This generic go/no go training is identical in duration and contact time to the go/no-go food training.
16569255|NCT02817399|Active Comparator|Neuro-muscular electrical stimulation|Active exercises & Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
16569256|NCT02817399|Experimental|Functional electrical stimulation|Active exercises & Functional electrical stimulation while walking.
16569257|NCT02817386||POD and Non-POD;|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The assessment of post deliriu (POD) was performed once per day between 8:00 AM to 10:00 AM. Patient notes were not reviewed for episodes of delirium which could occur outside the time of assessment. The clinical research assistants who performed the delirium assessments in this study had good training and went through quality control procedures. We used state-of-the-art delirium detection methods, which tend to report a higher incidence of delirium. The interview included the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS).
16569258|NCT02817373|Other|transvaginal ultrasound study|Patients with a well established infertility requiring IVF treatment and who are <40. Cohort will consist of patients going through a fresh day 5 transfer with a planned transfer of a single good quality embryo. Patients will go thorough a Ultrasound scan performed through a vaginal probe on the morning of the embryo transfer.
16569259|NCT02817360|Experimental|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
16569260|NCT02817360|Other|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
16569261|NCT02817347|Experimental|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
16569262|NCT02817347|Experimental|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
16569263|NCT02817347|Experimental|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
16569264|NCT02817347|Experimental|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
16569265|NCT02817347|Experimental|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
16569266|NCT02817334|Experimental|indocyanine green|"As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
~Intervention: Drug: indocyanine green"
16569267|NCT02817321|Experimental|Single-injection TPVB +continuous TPVB|Single-injection of TPVB is given preoperatively followed with continuous infusion+ postoperative IPCA.
16569268|NCT02817321|Active Comparator|IPCA|postoperative IPCA is given alone
16569269|NCT02817308|Experimental|Patients|"Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.
~intervention: samples of blood, saliva and urine"
16569270|NCT02817308|Other|Control|"Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.
~intervention: samples of blood, saliva and urine"
16569271|NCT02817295||elderly|patients underwent bariatric surgery and are above 65 years old
16569272|NCT02817295||non-elderly|patients underwent bariatric surgery and are below 65 years old
16569273|NCT02817282|Other|Hand hygiene implementation strategy|The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).
16569364|NCT02816697|Experimental|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)
~Tobacco Use Survey (Baseline,1- 6 Months)
~Biochemical verification"
16569365|NCT02816697|Active Comparator|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services
~100 patients in usual care
~Exit Interview and Tobacco Use Survey"
16569274|NCT02817269|Experimental|Manual palpation group|For the manual palpation group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut band tried to elicit local twitch response and referred pain in the infraspinatus area. First, three attempts will be made to elicit an local twitch response (LTR) using snapping palpation if a response will be obtained. After LRT, referred pain could also be evoked by palpation.
16569275|NCT02817269|Experimental|Deep dry needling group|For the deep dry needling group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut before making the needle insertion. Sterile stainless steel needles (length 40mm/caliber 0.32 with a cylindrical plastic guide) will be used.
16569276|NCT02817256|Active Comparator|Group A, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.
~Ergocalciferol 300,000 IM - Every 3 months Oral Vitamin B12 tablets daily (500mcg) Calcium /D Tab 600-200mg Centrium -1 Tablet Daily
~Mineral:
~Iron preparation - Daily (47mg)"
16569277|NCT02817256|Active Comparator|Group B, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.
~Centrium - 1 Tablet daily Ergocalciferol 50000 IU once every two weeks Vitamin B12 1000mcg IM every three months Calcium /D Tab 600-200mg
~Minerals:
~Iron preparation - Daily (47mg)"
16569278|NCT02817243|Other|SP2086 and Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
16569279|NCT02817230||Patients|Patients referred to the out-patient clinic with LDL levels >4.9 mmol/l
16569280|NCT02817230||Controls|Matched normocholesterolemic control subjects
16569281|NCT02817217|Other|SP2086 and Valsartan|
16569282|NCT02817204|Experimental|Aerobic Exercise group|Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
16569283|NCT02817204|Other|Health Education Group|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise
16569284|NCT02817191|Experimental|Hylo-Comod|The patients used Hylo-Comod eye drop after phaco+IOL in this group.
16569285|NCT02817191|Experimental|Tears Naturale Forte|The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
16569286|NCT02817178|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, at 1 month, at 3 months, and 1 month after surgery (if applicable).
~Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected. Tissue tumor is collected during surgery if applicable."
16569287|NCT02817165|Experimental|Probiotic (BioK+)|Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
16569288|NCT02817165|Placebo Comparator|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
16569289|NCT02817152|Sham Comparator|Periodontal ultrasonic debridement|Periodontal pockets received ultrasonic periodontal debridement intervention.
16569290|NCT02817152|Active Comparator|Low-level laser therapy|Periodontal pockets received ultrasonic periodontal debridement plus low-level laser therapy intervention.
16569291|NCT02817139|Active Comparator|active tDCS over primary motor cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
16569292|NCT02817139|Experimental|active tDCS over prefrontal cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
16569293|NCT02817139|Placebo Comparator|sham tDCS over primary motor cortex|Duration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
16569294|NCT02817126|Experimental|Robot-assisted surgery|Patients undergo robot-assisted resections.
16569295|NCT02817126|Active Comparator|Laparoscopic surgery|Patients undergo laparoscopic resections.
16569296|NCT02817113|Experimental|NC-6004, Cetuximab and 5-FU|Cetuximab will be administered before the start of chemotherapy at a loading dose of 400 mg/m2 given, followed by a subsequent weekly doses of 250 mg/m2; NC-6004 will be administered on Day 1 every 3 weeks, and 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
16569297|NCT02817100|Experimental|BAY1817080|Study Part 1: Dose 1 to 7 of BAY1817080 (increasing dose levels; redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]); Study part 2: Dose 1 to 4 of BAY1817080 together with an American breakfast (increasing dose levels; redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
16569298|NCT02817100|Placebo Comparator|Placebo|Study Part 1: Placebo Dose 1 to 7 of BAY1817080; Study Part 2: Placebo Dose 1 to 4 of BAY1817080
16569299|NCT02817087|Active Comparator|repetitive Transcranial Magnetic Stimulation -On|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.
16569300|NCT02817087|Sham Comparator|repetitive Transcranial Magnetic Stimulation -Off|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.
16569301|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
16569302|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
16569366|NCT02816697|No Intervention|Clinician and Staff Survey|- Interview clinicians and support staff (40)
16569303|NCT02817061|Experimental|NIR brain stimulation|"An Omnilux device will be used to put NIR light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.
~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
16569304|NCT02817061|Sham Comparator|Sham|"An Omnilux Device will be used at a safe wavelength not associated with photobiomodulation, putting sham light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.
~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
16569305|NCT02817048|Active Comparator|Tubeless|Interventions: VATS without chest tube placement
16569306|NCT02817048|Active Comparator|Chest tube|VATS with chest tube placement
16569307|NCT02817035|Experimental|noninvasive mechanical ventilation|To investigate the change of the neural inspiratory time and expiratory delay noninvasive mechanical ventilation ,in comparison to spontaneous breathing
16569308|NCT02817022|Other|developmentally supportive care|enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B
16569309|NCT02817009|No Intervention|Nutrition Group|This group will go through standard of care and visit the nutritionist on a monthly basis for the three months that they are a part of the study.
16569310|NCT02817009|Experimental|Healthy Families Group|Participants and their families will attend a weekly nutrition session, social support session and physical activity session for 12 weeks.
16569311|NCT02816996|Experimental|Hand-holding|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
16569312|NCT02816996|Experimental|Stress Ball|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
16569313|NCT02816996|No Intervention|Nothing|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
16569314|NCT02816983||SBRT for oligometastatic prostate cancer|
16569315|NCT02816970|Experimental|A Test|Test drug (Gliptus) 1 tablet contains 50 mg vildagliptin
16569316|NCT02816970|Active Comparator|B Reference|Reference drug (Galvus) 1 tablet contains 50 mg vildagliptin
16569317|NCT02816957|Active Comparator|patients receiving Nigella|40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
16569318|NCT02816957|No Intervention|patients not received nigella as controls|40 patients in the control group will not receive nigella sativa and continued on the usual chelators
16569319|NCT02816944|Experimental|EUS-guided laser ablation for refractory neoplasms|
16569320|NCT02816918|Experimental|Extraluminal use of Univent Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .
~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
16569321|NCT02816918|Experimental|Innerluminal use of Univent Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
16569322|NCT02816905|Active Comparator|Group A|20 eyes that received topical 0.1% Dexamethasone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
16569323|NCT02816905|Active Comparator|Group B|20 eyes that received topical 0.1 % Fluorometholone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
16569324|NCT02816905|Active Comparator|Group C|40 eyes that received topical 1% Rimexolone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
16569325|NCT02816892||Rupture group|Rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity.
16569326|NCT02816892||Covert rupture group|Covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities.
16569327|NCT02816892||Acute dissection group|Acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed.
16569328|NCT02816892||Chronic dissection group|Chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations.
16569329|NCT02816892||Ectatic aneurysm group|Ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal
16569330|NCT02816879|Experimental|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
16569331|NCT02816866|Experimental|empowered primary care model|"patients receive an individualized prescription for survivorship care prepared by a cancer survivor specialist to be implemented by the primary care doctor"
16569332|NCT02816866|Experimental|specialty survivor clinic|patient attends a specialty survivor clinic at Yale for survivorship care
16572375|NCT02796001|Active Comparator|RV39|volunteers re-challenged with RV39
16569333|NCT02816853|Experimental|Sequence 1|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
16569334|NCT02816853|Experimental|Sequence 2|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
16569335|NCT02816853|Experimental|Sequence 3|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
16569336|NCT02816853|Experimental|Sequence 4|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
16569337|NCT02816840|Experimental|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
16569338|NCT02816840|Experimental|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
16569339|NCT02816840|No Intervention|Computed Tomography|Patients in this arm take radiotherapy positioning with CT.
16569340|NCT02816827|Experimental|E-AG-01|550 mg of 2 capsules having AG-01 and AG-07 will be administered orally twice daily for one day.
16569341|NCT02816827|Experimental|E-AG-02|550 mg of 2 capsules having AG-05 and AG-06 will be administered orally twice daily for one day.
16569342|NCT02816827|Experimental|E-AG-03|550 mg of 2 capsules having AG-01 and AG-05 will be administered orally twice daily for one day.
16569343|NCT02816827|Experimental|E-AG-04|550 mg of 2 capsules having AG-06 and AG-07 will be administered orally twice daily for one day.
16569344|NCT02816814|Active Comparator|Love Diet|Overweight females (BMI > 25) in menopause
16569345|NCT02816814|Experimental|LωVE diet|Overweight females (BMI > 25) in menopause
16569346|NCT02816801|Experimental|Intervention|Access to Butler-Program 2.0
16569347|NCT02816801|No Intervention|Waitlist|
16569348|NCT02816788|Experimental|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
16569349|NCT02816775|Active Comparator|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
16569350|NCT02816775|Active Comparator|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
16569351|NCT02816762|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
16569352|NCT02816762|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
16569353|NCT02816749|Experimental|Maggot debridement therapy(MDT)|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
16569354|NCT02816749|Active Comparator|Conventional Dressing Therapy(CDT)|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
16569355|NCT02816736|Active Comparator|LCZ696 (Entresto) + placebo|LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
16569356|NCT02816736|Active Comparator|valsartan + placebo|valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
16569357|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
16569358|NCT02816723|Active Comparator|Brain Health|Brain Health education class
16569359|NCT02816710|Experimental|IVC Preoperative group|Conbercept injection before vitrectomy
16569360|NCT02816710|Experimental|IVC Postoperative group|Conbercept injection at the end of vitrectomy
16569361|NCT02816710|Experimental|IVC Pre- and Post-operative group|First conbercept injection before vitrectomy and second at the end of operation.
16569362|NCT02816697|Active Comparator|Cease-Aim 1|"Cease Implementation
~100 Patients after CEASE Implementation
~Exit Interview and Tobacco Use Survey"
16569363|NCT02816697|Active Comparator|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)
~Tobacco Use Survey (Baseline,1- 6 Months)
~Biochemical verification"
16569510|NCT02815774|Active Comparator|severe renal insufficiency|this group patients were given SP2086 50mg only one time.
16569367|NCT02816684|Active Comparator|SET-C|Social Effectiveness Therapy for Children (SET-C; Beidel et al., 2000) includes social skills training, peer generalization experiences, and in vivo exposure.
16569368|NCT02816684|Experimental|Pegasys-VR|SET-C SST and individual exposure sessions are the same as the active comparator. Peer generalization sessions are replaced by a virtual environment, known as Pegasys School. children engage with artificially intelligent avatars throughout the school.
16569369|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
16569370|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
16569371|NCT02816645|Experimental|<5 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
16569372|NCT02816645|Experimental|Between 5 and 10 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
16569373|NCT02816645|Experimental|Between 10 and 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
16569374|NCT02816645|Experimental|> 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
16569375|NCT02816632|Experimental|healthy volunteers|
16569376|NCT02816619|Experimental|APA+|APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)
16569377|NCT02816619|Other|APA-|APA- : patients will do free practice of physical activity during 3 months.
16569378|NCT02816606||Standard Reconstruction Technique|ACL reconstruction using hamstring autograft Using 30-degree arthroscope Using rigid femoral tunnel reamer (Rigid Reamers)
16569379|NCT02816606||Alternative Reconstruction Group|ACL reconstruction using hamstring autograft Using 30-degree and 70-degree arthroscopes Using flexible femoral tunnel reamer (Flexible Reamers)
16569380|NCT02816593|Experimental|Group 1 - HP 6%|Group 1: Experimental: Office; hydrogen peroxide 6%,
16569381|NCT02816593|Experimental|Group 2 - HP 15%|Group 2: Experimental: Office; hydrogen peroxide 15%,
16569382|NCT02816593|Active Comparator|Group 3 - CP 10%|Group 3: Control: Homemade; Carbamide Peroxide 10%,
16569383|NCT02816580|Experimental|elderly subjects|
16569384|NCT02816567|Experimental|NMBA group|
16569385|NCT02816567|Placebo Comparator|placebo group|
16569386|NCT02816554|Experimental|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1.0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12days
16569387|NCT02816554|Experimental|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
16569388|NCT02816554|Experimental|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
16569389|NCT02816554|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
16569390|NCT02816541|Experimental|Pelvis Retroverted|Pilates-based therapeutic exercises performed with a posterior pelvic tilt
16569391|NCT02816541|Experimental|Pelvis in Neutral Position|Pilates-based therapeutic exercises performed with a neutral position of the pelvis
16569392|NCT02816541|Active Comparator|Control Group|Aerobic exercise performed on a treadmill
16569393|NCT02816528||Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
16569394|NCT02816528||Nothing|Not Trained Physicians
16569395|NCT02816515||Ectoin® mouth wash|The treatment will be started on the first day of radio- and/or chemotherapy, before development of mucositis
16569396|NCT02816515||Ectoin mouth wash|The treatment will be started after oral mucositis development in patients receiving radio- and/or chemotherapy
16569397|NCT02816515||Supersaturated electrolyte mouth rinse|The treatment will be started after oral mucositis development in patients receiving radio and/or chemotherapy
16569398|NCT02816502|Experimental|Stress Management Skill Building Program A|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
16569399|NCT02816502|Active Comparator|Stress Management Skill Building Program B|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
16569400|NCT02816489|Experimental|Group I|"will be treated using passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA).
~Intervention: Device: passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA)."
16569401|NCT02816489|Experimental|Group II|"will be treated using conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA).
~Intervention: Device: conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA)."
16569402|NCT02816476|Experimental|Daratumumab|Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
16569403|NCT02816463|Experimental|Ambu AuraGain (Group A)|Laryngeal mask Ambu AuraGain will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
16569404|NCT02816463|Active Comparator|LMA Supreme (Group S)|Laryngeal mask Supreme will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
16569405|NCT02816450|Experimental|HIGH|Increase water intake to 2.5 liters per day for 4 days
16569406|NCT02816450|Experimental|LOW|Decrease water intake to 0.5 liter per day for 4 days
16569407|NCT02816437|Experimental|OpenBiome FMT retention enema|OpenBiome Fecal Microbiota Transplantation retention enema, one rectal application.
16569511|NCT02815774|Active Comparator|end-stage renal insufficiency|this group patients were given SP2086 50mg only one time.
16569512|NCT02815748|Other|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
16569513|NCT02815735|Experimental|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
16569408|NCT02816424|Experimental|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
16569409|NCT02816424|No Intervention|Control|
16569410|NCT02816411|Experimental|Protein|Milk protein isolate supplementation: orally, 20g of protein immediately post-exercise and then 20g every 3h on 3 occasions (+3, +6, +9), on the exercise day. The remaining 8 days, 20g daily with breakfast.
16569411|NCT02816411|Active Comparator|Placebo|Placebo administration: orally 500 ml, immediately post-exercise as well as at +3, +6 and +9 hours, on the exercise day. The remaining 8 days, 500 ml daily with breakfast.
16569412|NCT02816398|Experimental|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
16569413|NCT02816385|Active Comparator|Antegrade Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
16569414|NCT02816385|Experimental|Retrograde Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
16569415|NCT02816372|Experimental|Tidal volume 4 ml/kg Predicted Body Weight (PBW)|
16569416|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
16569417|NCT02816346|Experimental|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
16569418|NCT02816346|Experimental|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
16569419|NCT02816346|Experimental|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
16569420|NCT02816346|Experimental|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
16569421|NCT02816346|Experimental|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
16569422|NCT02816333||Type B aortic dissection|Patients with Type B aortic dissection requiring TEVAR
16569423|NCT02816320||Inpatient stays|All patients who were hospitalized in participating hospitals in France during the study period were eligible for inclusion.
16569424|NCT02816307|Experimental|Infective endocarditis|
16569425|NCT02816294|Experimental|Housing Prescription|Participants in the intervention group will be referred to the Care Coordinator at Project Hope, who will conduct case management with the family to stabilize their housing. The Care Coordinator will refer families all families to benefit maximization services and complete Problem Solving Education. The Care Coordinator will also refer families as necessary to Medical-Legal Partnership Boston for pro-bono legal services and/or the Boston Housing Authority for priority on a subsidized housing waitlist.
16569426|NCT02816294|No Intervention|Resource List|At present, for families facing housing insecurity, Children's HealthWatch offers paper resources with contact information for local social service agencies that may assist with housing stability.
16569463|NCT02816021|Experimental|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.
~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
16569427|NCT02816281||Reasons of case cancellation|"will be recorded and categorized into 6 groups including
~patient issue such as surgery refusal, no show on the day of surgery, transport problems
~facility such as equipment needs, improper estimate case time, case bumps
~Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively
~anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error
~medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure
~miscellaneous."
16569428|NCT02816268|Other|Conventional Pulmonary vein isolation|Conventional pulmonary vein isolation was gained by using an irrigated tip ablation catheter
16569429|NCT02816268|Other|Contact force pulmonary vein isolation|Contact force was meassured by using the SMART-Touch ablation catheter (Biosense-Webster®)
16569430|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
16569431|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
16569432|NCT02816242|Experimental|intervention|teaching anatomy by concept map
16569433|NCT02816242|Sham Comparator|placebo|teaching anatomy by traditional method
16569434|NCT02816229|Experimental|Insertion of endobronchial valve|Patients in this group will have one or more EBV inserted into the relevant lung regions to manage the haemoptysis via flexible bronchoscopy.
16569435|NCT02816229|No Intervention|Best care|Patients will receive best medical care.
16569436|NCT02816216|Other|End User Iterative Testing - CampAir|To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability.
16569437|NCT02816203|Experimental|Primary Hemostatic Intra-Uterine suction cup|Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
16569438|NCT02816177|Experimental|Telemedicine|Usual care and telemedicine consultations during12 months.
16569439|NCT02816177|Active Comparator|Usual care alone|Usual care during12 months.
16569440|NCT02816164|Active Comparator|Neupogen for 5 days|Neupogen injection for 5 days
16569441|NCT02816164|Active Comparator|Neupogen for 7 days|Neupogen injection for 7 days
16569442|NCT02816164|Active Comparator|Neupogen for 10 days|Neupogen injection for 10 days
16569443|NCT02816151|Experimental|Group 1|
16569444|NCT02816151|Experimental|Group 2|
16569445|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
16569446|NCT02816125|Active Comparator|Habitual supplemented|habitual diet with 1.2 g EPA+DHA in capsule form/day.
16569447|NCT02816125|Experimental|Low-fat supplemented|Reduce dietary fat to less than 20% energy, add 1.2 g EPA+DHA in capsule form/day.
16569448|NCT02816112|Active Comparator|Ciprofloxacin|Oral tablet taken twice a day at home starting 5 days after chemotherapy for 14 days for every cycle of TC
16569449|NCT02816112|Active Comparator|G-CSF|Daily injection at home for the number of days as chosen by the treating physician
16569450|NCT02816099|Experimental|Type-1 diabetes patients|
16569451|NCT02816099|Other|Controls|
16569452|NCT02816086|No Intervention|Standard care|The study participants receives standard care in the ward, this does not include a pharmacist.
16569453|NCT02816086|Experimental|Intervention|Interdisciplinary collaboration structure
16569454|NCT02816073|Active Comparator|1,700|Patients receive 1,700 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
16569455|NCT02816073|Active Comparator|2,500|Patients receive 2,500 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
16569456|NCT02816060|Experimental|neural tensionner exercise|This group will receive a specific tensionner nerve exercise to provide mechanical stress across the median nerve. This technique have two positions, start and end. It consists on going from one to the other position constantly, controlling the speed of the technique to be constant. In the start position, the subject will be supine lying on a couch with the following parameters: contralateral cervical side bending, shoulder depression, shoulder abduction and external rotation to 90°, elbow flexion to 90º, and forearm supination. In the final position, the therapist will perform full elbow extension while maintaining all the joints previously situated as described above until the patients feel tension, then return to the start position.
16569457|NCT02816060|Placebo Comparator|sham neural tensionner exercise|The control group will receive a sham technique (ST) with minimal mechanical stress across the median nerve. Patients will be placed in neutral cervical spine position with no shoulder depression, shoulder abduction and external rotation to 45°, 45° of elbow extension, and forearm pronation.. This technique will be passively repeated from elbow flexion to extension in the same way than the NTE group
16569458|NCT02816034|Experimental|Experimental Explicit|Cannabis user performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
16569459|NCT02816034|Active Comparator|Control Explicit|Healthy subject performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
16569460|NCT02816034|Experimental|Experimental Implicit|Cannabis user performs visuo-motor rotation tasks without being informed of the explicit strategy
16569461|NCT02816034|Active Comparator|Control Implicit|Healthy subject performs visuo-motor rotation tasks without being informed of the explicit strategy
16569462|NCT02816021|Experimental|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.
~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
16569464|NCT02816008|Experimental|Cognitive rehabilitation group|Cognitive rehabilitation training with RGS in the clinic.
16569466|NCT02815995|Experimental|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.
~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
16569467|NCT02815995|Experimental|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.
~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
16569468|NCT02815995|Experimental|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
16569469|NCT02815995|Experimental|Synovial Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
16569470|NCT02815995|Experimental|Osteosarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
16569471|NCT02815995|Experimental|Other Sarcomas Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
16569472|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
16569473|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
16569474|NCT02815969||Healthy volunteers|If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
16569475|NCT02815969||Patients|Patients are asked for a vena punction and urine collection, if not already done because of medical care.
16569476|NCT02815956|Experimental|percutaneous tibial nerve stimulation (ST)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.
~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.
~The protocol of stimulation is the same, that the one performed for fecal incontinence."
16569477|NCT02815956|Placebo Comparator|placebo (P)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.
~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.
~The device delivers ineffective impulses."
16569478|NCT02815943|Other|Before DBP-DS surgery|
16569479|NCT02815943|Experimental|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
16569480|NCT02815943|Other|Before SG surgery|
16569481|NCT02815943|Experimental|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
16569482|NCT02815930||HCUs|Newly incident seniors with annual total healthcare expenditures in the top 5% of Ontarians
16569483|NCT02815930||Non-HCUs|Seniors with annual total healthcare expenditures below the top 5% of Ontarians
16569506|NCT02815787|Active Comparator|Glyburide and SP2086|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days.In this group,the subjects was given the drugs from B sequence to the A sequence.
16569507|NCT02815774|Active Comparator|health volunteers|this group patients were given SP2086 50mg only one time.
16569508|NCT02815774|Active Comparator|mild renal insufficiency|this group patients were given SP2086 50mg only one time.
16569484|NCT02815917|Experimental|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
16569485|NCT02815917|Experimental|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
16569486|NCT02815917|Experimental|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic [18F]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
16569487|NCT02815917|Experimental|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the [18F]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
16569488|NCT02815904|Experimental|Yakson touch and Kinesthetic stimulation|"Yakson touch (YT) The therapist will relax arms and shoulder muscles for 1 minute and will do deep breathing to accumulate Ki energy on the palms. The Therapist will apply Yakson on the neonate.
~Kinesthetic stimulation (KS) For giving kinesthetic stimulation the neonate will be placed in supine position. There will be six passive flexion and extension movements. Each of the movement will each last for approximately 10 seconds. The movements will be performed in the following order -right arm, left arm, right leg, left leg, both legs simultaneously"
16569489|NCT02815904|Active Comparator|Conventional Handling and KMC|"Conventional Handling (CH) The neonates in control group will receive developmental positioning(positioning of preterm infants for optimal physiological development) for 20 minutes per hour for 5 days.
~Kangaroo mother care (KMC) Holding the neonate skin to skin by mother for one hour a day"
16569490|NCT02815878|Experimental|Group 1: Intervention with Disability|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
16569491|NCT02815878|Active Comparator|Group 2: Intervention without Disability|Participants without a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
16569492|NCT02815878|No Intervention|Group 3: No intervention|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older complete pre and post outcome assessments.
16569493|NCT02815865|Active Comparator|Foley catheter and pitocin|Intervention: Foley catheter and pitocin Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
16569494|NCT02815865|Active Comparator|Foley catheter and dinoprostone|Intervention: Foley catheter and dinoprostone Foley catheter will be inserted through the cervix and inflated with 80 ml saline dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
16569495|NCT02815865|Active Comparator|Dinoprostone|Intervention: Dinoprostone 3 mg will be inserted to the posterior fornix
16569496|NCT02815839|Experimental|Cohort 1|2.5-mg SHR4640 or placebo
16569497|NCT02815839|Experimental|Cohort 2|5-mg SHR4640 or placebo
16569498|NCT02815839|Experimental|Cohort 3|7.5-mg SHR4640 or placebo
16569499|NCT02815839|Experimental|Cohort 4|10-mg SHR4640 or placebo
16569500|NCT02815839|Experimental|Cohort 5|20-mg SHR4640 or placebo
16569501|NCT02815826||Barefoot training|16 weeks of progressive barefoot running training
16569502|NCT02815813|Experimental|PeerFIT|PeerFIT is a group-based lifestyle intervention enhanced by mobile health technology and social media designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
16569503|NCT02815813|Active Comparator|BEAT|BEAT involves basic education in fitness and nutrition supported by a wearable activity tracking device designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
16569504|NCT02815800|Experimental|ETHNODYNE VISIO|Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease
16569505|NCT02815787|Active Comparator|SP2086 and Glyburide|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days. In this group,the subjects was given the drugs from A sequence to the B sequence.
16569509|NCT02815774|Active Comparator|moderate renal insufficiency|this group patients were given SP2086 50mg only one time.
16569514|NCT02815735|Active Comparator|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
16569515|NCT02815722|Active Comparator|SP2086 and Simvastatin|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from A stage to B stage.
16569516|NCT02815722|Active Comparator|Simvastatin and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from B stage to A stage.
16569517|NCT02815709|Experimental|Treatment 1 Oliceridine|
16569518|NCT02815709|Experimental|Treatment 2 Oliceridine|
16569519|NCT02815709|Experimental|Treatment 3 Oliceridine|
16569520|NCT02815709|Placebo Comparator|Placebo|
16569521|NCT02815709|Active Comparator|Morphine|
16569522|NCT02815696|Experimental|lumbar spine segmental instability|Patients with a segmental instability of the lumbar spine having undergone surgery. Lumbar spine instability diagnosis is based on imaging (Magnetic resonance imaging, standard radiography, and EOS imaging). Surgical treatment is indicated if the pain is relieved by wearing a brace during at least three months.
16569523|NCT02815670|Experimental|Idarucizumab|
16569524|NCT02815657|Active Comparator|SP2086 and Valsartan|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.
16569525|NCT02815657|Active Comparator|Valsartan and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from B stage to A stage.
16569526|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
16569527|NCT02815631|Experimental|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.
~First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.
~Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.
~Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.
~The patients involvement will then be finished in the study and will be cared for as per clinical practice.
~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
16569528|NCT02815631|Active Comparator|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:
~A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.
~Maximal hyperaemia FFR will be recorded during adenosine infusion.
~An FFR ratio of <0.80 will be regarded as a positive result."
16569529|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
16569530|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
16569531|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
16569532|NCT02815592|Experimental|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
16569533|NCT02815592|Experimental|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
16569534|NCT02815592|Experimental|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
16569535|NCT02815592|Active Comparator|Active Comparator Arm 3B|Platinum/Etoposide
16569536|NCT02815579|Experimental|Intervention|The Shamba Maisha Intervention includes: a) a microcredit loan (~$140) from a well-established Kenyan bank for purchasing agricultural implements and commodities; b) agricultural implements to be purchased with the microcredit loan including the KickStart treadle pump, seeds, fertilizers and pesticides; and c) education in financial management and sustainable farming practices occurring in the setting of patient support groups.
16569537|NCT02815579|No Intervention|Control|Participants in the control arm will receive the standard of care.
16569538|NCT02815566|Experimental|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
16569539|NCT02815566|Active Comparator|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
16569540|NCT02815553|Experimental|Cardiac tumors|
16569541|NCT02815540|Other|Observational|This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
16569542|NCT02815527||Fresubin Intensive|Adult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
16572521|NCT02795091|Other|Manual clean|clean the rag and floor towel manually
16569543|NCT02815514||Aortic valve procedures|"percutaneous transfemoral aortic valve implantation
~percutaneous transapical aortic valve implantation
~percutaneous transaortic aortic valve implantation
~aortic valve valvuloplasty
~surgical aortic valve replacement
~conservative treatment"
16569544|NCT02815501||women|"attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery
~Blood samples"
16569545|NCT02815488|Experimental|CHF6297 Active|
16569546|NCT02815488|Placebo Comparator|Placebo|
16569547|NCT02815475|Placebo Comparator|Placebo|Starch filled capsule
16569548|NCT02815475|Experimental|Curcumin|400mg of Curcumin via capsule to be consumed every other day
16569549|NCT02815475|Active Comparator|Turmeric powder|2 teaspoons of dried turmeric powder to be consumed every other day
16569550|NCT02815462|Experimental|Intervention|FAM-FACE-SG risk score + decision making algorithm
16569551|NCT02815462|Active Comparator|Control|Usual Care
16569552|NCT02815449|Experimental|Low stabilizer level|Meals prepared with iron fortified cube with low stabilizer level
16569553|NCT02815449|Experimental|Medium stabilizer level|Meals prepared with iron fortified cube with medium stabilizer level
16569554|NCT02815449|Experimental|High stabilizer level|Meals prepared with iron fortified cube with high stabilizer level
16569555|NCT02815436|Active Comparator|Telephone reminder|subjects in this arm will receive a telephone reminder
16569556|NCT02815436|Active Comparator|SMS reminder|Subjects in this arm will receive a SMS reminder
16569557|NCT02815436|No Intervention|No reminder|usual care, where no additional intervention will be offered
16569558|NCT02815423|Experimental|UCMSCs|Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.
16569559|NCT02815423|Placebo Comparator|Placebo|The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.
16569560|NCT02815410|Other|Levetiracetam|Newly diagnosed histologically proven supratentorial glioblastoma patients received levetiracetam during and after their CCRT
16569561|NCT02815397|Experimental|Single arm, open label|Metformin added to standard of care treatment for all patients
16569562|NCT02815371|Experimental|Needle Acupuncture|Sterile, disposable needles were inserted into specific acupoints until Deqi sensation was elicited. The needles were retained for 25 minutes before and after embryo transfer.
16569563|NCT02815371|Experimental|Laser Acupuncture|Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
16569564|NCT02815371|Sham Comparator|Sham Laser Acupuncture|However, support staff uninvolved in the design of the trial or analysis of the data disarmed the machine, such that no laser irradiation was emitted. This system created an illusion for both the patient and the acupuncturist, and allowed for a truly double blinded control group.
16569565|NCT02815371|No Intervention|No Treatment|This control group was not exposed to any additional physical contact or acupuncture related protocol. They were only exposed to dim light and calming music before and after embryo transfer, mimicking the natural waiting room and procedure room setting for all patients undergoing embryo transfer.
16569566|NCT02815358|Experimental|Segmental Stabilization Group|Patients receiving segmental stabilization exercises.
16569567|NCT02815358|Active Comparator|Control Group|Patients receiving home exercises.
16569568|NCT02815345|Experimental|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.
~Some included neonates will also have rhinomanometry measurements."
16569569|NCT02815332|Placebo Comparator|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
16569570|NCT02815332|Experimental|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
16569571|NCT02815332|Experimental|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
16569572|NCT02815319|Active Comparator|Standard of care|Physician's treatment recommendation for dexamethasone premedication
16569573|NCT02815319|Active Comparator|8mg PO dexamethasone|8mg PO dexamethasone premedication
16569574|NCT02815306|Experimental|Brace goup|The infants who were brace group treated by braces which were designed and made by us.
16569575|NCT02815293|Experimental|AGN-195263|
16569576|NCT02815293|Placebo Comparator|Vehicle|
16569577|NCT02815280|Experimental|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
16569578|NCT02815280|Placebo Comparator|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
16569579|NCT02815267|Experimental|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
16569580|NCT02815267|Placebo Comparator|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
16569581|NCT02815254|Active Comparator|Low dose exercise intervention|
16569582|NCT02815254|Experimental|High dose exercise intervention|
16569583|NCT02815241|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16569584|NCT02815228|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16569585|NCT02815215|Experimental|Intervention group|Minimally Invasive Carroll's Technique
16569586|NCT02815215|Active Comparator|Control group|Ponseti method
16569587|NCT02815202|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16569715|NCT02814305|Experimental|Educational intervention only|Patient receives educational (narrative) intervention only
16569588|NCT02815189|Experimental|Post operative Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg taken a week after. Incidence of flare ups after a single vs multiple visits root canal treatments.
16569589|NCT02815189|Experimental|Flare up|Acetaminophen 325 mg for Flare Up. Taken second day after. Incidence of Post operative pain after root canal treatment in one vs two visits.
16569590|NCT02815176||Central serous chorioretinopathy|De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
16569591|NCT02815176||Polypoidal choroidal vasculopathy|De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
16569592|NCT02815176||Epiretinal membrane|Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
16569593|NCT02815163|No Intervention|comparison group|The CG received no extra care; they could receive the usual routine care for THR in the unit as they had before participation in the study. The routine care included oral instruction by nurses follow by the handout. Also, a brochure was provided of the structure of hip, the risk factors of THR, care before and after THR, complications, care of discharge, and demonstration of rehabilitation with pictures) of THR designed by researchers in this study. Five orthopedics health care experts independently reviewed and rated each item in the brochure on a five-point Likert-type scale in terms of relevance, representativeness, specificity, and clarity.
16569594|NCT02815163|Experimental|Empowerment education group|"The 5 times total, 12-week EE intervention was aimed to empower older patients with THR to develop their own self-management program to meet their needs. This empowerment education intervention based on 6 empowerment components: Partnership, listening, dialogue, reflection, action, feedback and 5-step empowerment strategies: motivating patients self-awareness, assessing the causes of the problem, goal setting, individual self-care plan development, and checking whether goals or plans have been achieved who modified from Freire's 3-stage methodology. The difference between this program and the other health educations for patients with THR are that this program encourages them to explore their needs and worries, their own ability and power to meet their needs, and their capacity to seek and use their social support and resources etc."
16569595|NCT02815150|Experimental|Treatment group|Preoperative oral carbohydrate drink: patients drink 5% glucose solution 250ml 2-3 hours before surgery.
16569596|NCT02815150|No Intervention|Control group|Patients undergo 6-8 hours of preoperative fasting.
16569597|NCT02815137|Other|XPO1 E571K mutation detection|Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy
16569598|NCT02815124|Active Comparator|Standard of Care|Cochlear Implant programming using standard of care
16569599|NCT02815124|Experimental|Image-Guided Cochlear Implant Programming|Cochlear Implant programming using Image-Guided Cochlear Implant Programming
16569600|NCT02815111||Control Group|Intensivists will proceed with analgesia utilizing conventional opioid based pain order sets.
16569601|NCT02815111||Study Group|The investigators plan to study an analgesic regimen of Ketamine and lidocaine as infusions with Neurontin and Acetaminophen delivered orally for postoperative analgesia and the subsequent effect on ventilator days and ICU stay.
16569602|NCT02815085|Experimental|RecoverLINK technology|RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.
16569603|NCT02815059|Experimental|Ibrutinib, Dasatinib and prednisone, all patients|
16569604|NCT02815033|Other|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
16569605|NCT02815020|Other|Boot Camp Translation|"Boot Camp Translation is rolled out in a stepped wedge design across participating PBRNs to assist practices with SMS implementation. The Boot Camp Translation intervention initiates practices to review and begin uptake and implementation of tools from the AHRQ Self-Management Support tool library."
16569606|NCT02815007|Experimental|Chidamide with EGFR-TKI|"Chidamide: Per Os, 30mg (5mg*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast.
~EGFR-TKI:
~Taken according to the instruction book"
16569607|NCT02814994|Experimental|tidal volume guided by respiratory system compliance|effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
16569608|NCT02814994|Experimental|low tidal volume|Ventilated patients with low tidal volume
16569609|NCT02814968|Experimental|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
16569610|NCT02814955||referred for paroxysmal atrial fibrillation with fluindione|
16569611|NCT02814955||referred for paroxysmal atrial fibrillation with previscan|
16569612|NCT02814955||referred for paroxysmal atrial fibrillation with apixaban|
16569613|NCT02814955||referred for paroxysmal atrial fibrillation with rivaroxaban|
16569614|NCT02814955||referred for paroxysmal atrial fibrillation with dabigatran|
16569615|NCT02814942||Heart Failure receiving CRT|Heart failure patients with QRS > 120ms receiving CRT
16569616|NCT02814929||Demographic and Prenatal Characteristics|Gender, multiple pregnancy antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis will be compared among infants with and without ROP
16569617|NCT02814929||Neonatal Characteristics of infants|Neonatal characteristics: GA, BW, SGA, resuscitation in delivery room, RDS, duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant PDA, early/late sepsis, NEC, number of blood transfusions, BPD, breastfeeding and weight gain at postnatal 28th day will be compared among infants with and without ROP.
16569618|NCT02814929||Incidence of any ROP and severe ROP|Incidence of any ROP, severe ROP and its treatment in relation to BW and GA will be evaluated. The same parameters will also be evaluated in preterm babies of refugees.
16569619|NCT02814916|Experimental|Dalbavancin, single dose|
16569620|NCT02814916|Experimental|Dalbavancin, two doses|
16569621|NCT02814916|Active Comparator|Comparator|
16569622|NCT02814903||Planned cardiac surgery. POAF occurence or not|The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) < 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.
16569623|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
16569624|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
16569625|NCT02814864|Experimental|Mesenchymal Stromal Cell (MSC)|Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)
16569626|NCT02814851|Experimental|Non valvular cardiac surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
16569627|NCT02814838|Experimental|Ladarixin|Ladarixin oral capsule
16569628|NCT02814838|Placebo Comparator|Placebo|Placebo oral capsule
16569629|NCT02814825||ViviGen|Patients undergoing a two or three level ACDF using ViviGen Cellular Bone Matrix in conjunction with cervical allograft spacers and DePuy Synthes anterior cervical plate systems.
16569630|NCT02814812|Experimental|pancreatic surgery|
16569631|NCT02814799||bone donors|
16569632|NCT02814786|Experimental|Equinus cohort|"15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.
~Interventions: MRI scanner and gait analysis"
16569633|NCT02814786|Experimental|Control cohort|"In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.
~Interventions: MRI scanner and gait analysis"
16569634|NCT02814773||AD group|group suffering from Alzheimer-type dementia (mild to moderate dementia)
16569635|NCT02814760||Pre-intervention group (Control group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.
~Patients of this group are included before the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
16569636|NCT02814760||Post-intervention group (Training course group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.
~Patients of this group are included after the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
16569637|NCT02814747|Experimental|quantitive study: 500 patients likely to be candidates for HTS|quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.
16569638|NCT02814747|Experimental|qualitative study: 30 patients who have benefited from HTS and|qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.
16569639|NCT02814721|No Intervention|Standard cannulation|The standard cannulation protocol of the center was defined as using 17 gauge needles for the first 3 dialysis sessions, followed by 16 gauge for the next 3, and finally 15 gauge for subsequent sessions.
16569640|NCT02814721|Active Comparator|Ultrasound guided cannulation|The study protocol involved similar up titration of needle size over a 3-week period, except that a pre-cannulation evaluation of the fistula was performed using the Sonic Window ultrasound device. The device was used to evaluate and identify the optimal site of cannulation (image 1). Depending upon the cannulator's preference, real-time guidance could be employed during cannulation (image 2, 3). The cannulations were performed by 4 selected personnel trained in device use and successfully completed a competency evaluation on simulator models and a mature dialysis fistula.
16569641|NCT02814708|Experimental|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
16569642|NCT02814708|Experimental|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
16569643|NCT02814708|Experimental|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
16569644|NCT02814708|Experimental|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
16569645|NCT02814708|Experimental|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
16569646|NCT02814708|Experimental|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
16569647|NCT02814708|Placebo Comparator|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
16569652|NCT02814669|Experimental|Cohort 1: ATZ + R-223-D (Concurrent)|Participants will receive concurrent radium-223 dichloride and atezolizumab for a single-cycle, 28-day dose limiting toxicity (DLT) assessment. If the combination is initially found to be safe and tolerable, additional participants will be randomized to Arms A, B, and C.
16569653|NCT02814669|Experimental|RT Arm A: ATZ + R-223-D (Concurrent)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm (randomized treatment [RT]) to receive concurrent radium-223 dichloride and atezolizumab.
16572522|NCT02795091|Other|machine clean|clean the rag and floor towel by machine
16569654|NCT02814669|Experimental|RT Arm B: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
16569655|NCT02814669|Experimental|RT Arm C: ATZ + R-223-D (Staggered, 28-Day ATZ Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive atezolizumab in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
16569656|NCT02814669|Experimental|Cohort 2: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is not tolerable, Arms A, B, and C will not be introduced and additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab in Cycle 2. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward). If, at Cycle 2, Cohort 2 regiment is not tolerable, additional participants will be enrolled in Cohort 3.
16569657|NCT02814669|Experimental|Cohort 3: ATZ + R-223-D (Staggered, 56-Day R-223-D Run-In)|If Cohort 2 regimen is not tolerable, additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab in Cycle 3. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab from Cycle 3 onward). If, at Cycle 3, Cohort 3 regiment is not tolerable, no additional participants will be enrolled in this study.
16569658|NCT02814656|Experimental|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
16569659|NCT02814656|Experimental|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
16569660|NCT02814656|Experimental|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
16569661|NCT02814643|Experimental|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
16569662|NCT02814643|Placebo Comparator|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
16569663|NCT02814630|Other|Open-label Xolair|"The patients will receive one subcutaneous injection of omalizumab at a dose of 300 mg on Days 1, 30, and 60.
~There is no control drug."
16569664|NCT02814617|Experimental|Cordyceps sinensis mycelium culture extract|Cordyceps sinensis mycelium culture extract 1.68 g
16569665|NCT02814617|Placebo Comparator|Placebo|Placebo
16569666|NCT02814604|Experimental|Traffic Light|"Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.
~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
16569667|NCT02814604|Experimental|Health Star Rating System|"Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall healthy rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.
~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
16569668|NCT02814604|No Intervention|Control|Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.
16569669|NCT02814604|Experimental|High-in Warning Label|"Participants in this group will download an app which features the nutrition information of the selected product in a 'high-in' warning label format (i.e. stop signs for each of saturated fat, sugar, and sodium; according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.
~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
16569670|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
16569671|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
16569672|NCT02814591||Cohort 3: Patients with osteoarthritis (OA)|40 patients with OA. Patients must have been clinically diagnosed with OA. Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database.
16569673|NCT02814591||Cohort 4: Patients with osteoporosis (OI)|40 patients with OI receiving treatment with bisphosphonates. Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment. 20 Adults and 20 Children. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed.
16569674|NCT02814591||Cohort 5: Patients with osteoporosis (OP) (2 treatment groups)|Patients must have been clinically diagnosed with OP. The first group will have been prescribed with bisphosphonate anti-resorptive treatment; the second with anabolic agents. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed. Bone mineral density (BMD) will be confirmed with DXA. Where possible measurements will be acquired prior to the start of treatment and then up to 4 follow up visits at flexible time points to allow scheduling to coincide with hospital appointments. Minimum time between vistis should be 2 months.
16569716|NCT02814305|Experimental|Both interventions|Patient receives both educational and financial interventions
16569675|NCT02814591||Cohort 6: Patients with rickets and osteomalacia|10-15 participants with rickets and 10-15 participants with osteomalacia. Patients must have been clinically diagnosed with rickets/osteomalacia. Blood tests for 25-hydroxyvitamin D should be less than or equal to 25 nmol/L. Once participants are on treatment further measurements will be made 6 months afterwards. Participants for rickets and osteomalacia groups will be recruited to give a total of 10 complete sets of data per group.
16569676|NCT02814591||Cohort 7: 5 patients with suspected bone infection.|Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
16569677|NCT02814578|Experimental|Optical coherent tomography|Optical coherent tomography provides more detailed information about the morphology of scaffolds, microstructures and coronary vasculature based on tissue characteristics as compared to conventional IVUS. In spite of angiographic success in BVS placement, further scaffold optimization was required in over a quarter of cases based on OCT findings due to malapposition or scaffold under expansion.
16569678|NCT02814578|Active Comparator|IntraVascular UltraSound|Intravascular ultrasound guidance has been associated with improved event-free survival compared with angiographic guidance after DES placement.
16569679|NCT02814565|Experimental|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
16569680|NCT02814565|Placebo Comparator|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
16569681|NCT02814552|Other|High Blood Pressure Consented|Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples. Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
16569682|NCT02814552|No Intervention|De-identified historical data|De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications. The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
16569683|NCT02814539||congenital heart disease|children with severe congenital heart disease who undergo open heart surgery during infancy
16569684|NCT02814539||healthy controls|
16569685|NCT02814526|Experimental|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
16569686|NCT02814526|Active Comparator|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
16569687|NCT02814513|Experimental|ANDAGO|ANDAGO
16569688|NCT02814500|Experimental|A group|Amlodipine and Rosuvastatin, DP-R212
16569689|NCT02814500|Experimental|B group|DP-R212, Amlodipine and Rosuvastatin
16569690|NCT02814474|Placebo Comparator|SALINE|Infusion of saline (0.9 %)
16569691|NCT02814474|Experimental|KETONE|Infusion of Na-3-Hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
16569692|NCT02814461|Experimental|Axitinib|Combined axitinib and radiotherapy (fixed strength)
16569693|NCT02814448|Active Comparator|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
16569694|NCT02814448|Active Comparator|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
16569695|NCT02814448|Active Comparator|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
16569696|NCT02814448|Active Comparator|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
16569697|NCT02814448|Experimental|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
16569698|NCT02814435||Patients|Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.
16569699|NCT02814435||Normal controls|Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.
16569700|NCT02814409|Active Comparator|Alteplase - standard care|Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
16569701|NCT02814409|Experimental|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
16569702|NCT02814383||ELBW Infants|This study seeks to collect data on premature ELBW infants (less than or equal to 2.2 lbs) at high risk of developing brain injury.
16569703|NCT02814357|Placebo Comparator|Control (market standard)|100 g wheat flour (atta)
16569704|NCT02814357|Active Comparator|High fibre 1|81% wheat flour (atta) + 15% chickpea + 4% guar gum
16569705|NCT02814357|Active Comparator|High fibre 2|80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley
16569706|NCT02814357|Active Comparator|High fibre 3|77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley
16569707|NCT02814344||pregnant women not in labour|"from 24 weeks of gestation until term, provided that they are not in labour
~Electrohysterography"
16569708|NCT02814344||women in labour|Electrohysterography
16569709|NCT02814331||symptomatic partial epilepsy|whose brain MRI is abnormal multimodal high-resolution EEG-NIRS
16569710|NCT02814331||not symptomatic partial epilepsy|whose brain MRI is normal multimodal high-resolution EEG-NIRS
16569711|NCT02814318||IV Vancomycin|GBS positive laboring women who are allergic to penicillin and clindamycin and are treated using IV vancomycin.
16569712|NCT02814318||IV Penicillin|GBS positive laboring women who are not allergic to penicillin and are treated using IV penicillin.
16569713|NCT02814305|No Intervention|Control|Patient receives neither educational nor financial interventions
16569714|NCT02814305|Experimental|Financial intervention only|Patient receives financial (pharmacy offer) intervention only
16569717|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
16569718|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
16569719|NCT02814266|Other|difficult intubation|Intubation difficulty score >5
16569720|NCT02814266|Other|Easy intubation|Intubation difficulty score >5
16569721|NCT02814253||Community Based Group|Patients who regularly present with exacerbations of COPD and have chronically-elevated CO2 levels. These patients are supported intensively in an out-patient setting (case-managed) and are potentially eligible for the community-based group.
16569722|NCT02814253||Acute Admissions Group|Patients who are admitted to hospital with an acute exacerbation of COPD. These patients are potentially eligible for the acute admission group.
16569723|NCT02814240|Experimental|Pituitary gland failure|
16569724|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
16569725|NCT02814214||ECG+IEGM|Surface ECG and intracardiac electrogram recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy settings
16569726|NCT02814201||Parkinson best-On|two hours after taking two tablets of 125 mg dispersible Modopar®
16569727|NCT02814201||Parkinson worst-off|after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)
16569728|NCT02814201||Huntington|
16569729|NCT02814201||Control|Data collected from the existing database
16569730|NCT02814188|Experimental|Carbohydrate Beverage|
16569731|NCT02814188|Placebo Comparator|Placebo Beverage|
16569732|NCT02814175|Active Comparator|Part 1: MTX Escalated Dose|Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
16569733|NCT02814175|Experimental|Part 1: ADA + MTX|Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
16569734|NCT02814175|Active Comparator|Part 2: MTX Escalated Dose|Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
16569735|NCT02814175|Active Comparator|Part 2: ADA + MTX Escalated Dose|Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
16569736|NCT02814175|Experimental|Part 2: ADA|Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
16569737|NCT02814175|Experimental|Part 2: ADA ew + MTX|Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
16569738|NCT02814149|Active Comparator|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
16569739|NCT02814149|Active Comparator|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
16569740|NCT02814136|Active Comparator|WACA|wide area circular ablation
16569741|NCT02814136|Active Comparator|EWACA|extra-wide area circular ablation
16569742|NCT02814123|Active Comparator|Rapid Insulin-alone closed-loop delivery|Rapid Insulin will be delivered by subcutaneous infusion. Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine)
16569743|NCT02814123|Experimental|Rapid Insulin-plus-pramlintide closed-loop delivery|"Rapid insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).
~Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine) Drug: Pramlintide"
16569744|NCT02814123|Experimental|Regular Insulin-plus-pramlintide closed-loop delivery|"Regular insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).
~Interventions: 24-hour inpatient intervention Drug: Regular Insulin (humulin R) Drug: Pramlintide"
16569745|NCT02814110|Other|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy
16569746|NCT02814097|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
16569747|NCT02814097|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
16569748|NCT02814084|Active Comparator|Bilateral Internal Mammary Artery grafts|Standard care wound dressings used as part of coronary artery bypass graft operation
16569749|NCT02814084|Experimental|Prevena|Prevena dressing used as part of coronary artery bypass graft operation.
16569750|NCT02814071|No Intervention|Fasting with intravenous fluids|The child will be kept fasted. Intravenous fluids will be at a rate and type as directed by the treating clinician. A low fat oral diet will be commenced once abdominal pain resolves and serum amylase/lipase levels decrease from the peak levels as per treating clinician. In the event that the patient is unable to tolerate oral feeding, tube feeding or parenteral nutrition may be commenced based on the clinical decision of the treating clinician(s). This will be recorded as an adverse event. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled as per treating clinician's discretion
16569797|NCT02813772|Experimental|group 1|Patients with infantile colics who will receive the milk formula NAN Sensitive, Nestlè
16569798|NCT02813772|Active Comparator|group 2|Patients with infantile colics who will receive the milk formula NAN Optipro, Nestlè
16569799|NCT02813759|Experimental|Sucralose|14 mg sucralose (Zero K sucralose powder, IANSA®) an 200 mL of water
16569800|NCT02813759|Placebo Comparator|Water|200 mL of water
16569840|NCT02813499||CARE Rule|Evaluation of the clinical suspicion of myocardial infarction and calculation of CARE rule.
16569751|NCT02814071|Experimental|Early enteral feeding|Patients will commence on an unrestricted oral diet within 24 hours of presentation, meeting 50% of EER with a regular diet and no fat restriction for the first 24 hours of enteral feeding. A 75-100% EER is targeted ≥ 24 hours of enteral feeding.If the targeted EER is not met orally, a nasogastric tube will be inserted to provide bolus feeds of a standard formula with standard fat content. If the patient fails to tolerate both oral and bolus nasogastric tube feeding, continuous nasogastric tube feeding will be provided. If all fails, enteral nutrition by nasojejunal tube feeding or parenteral nutrition may be commenced based on the clinical decision. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled.
16569752|NCT02814058|Experimental|Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
16569753|NCT02814058|Experimental|Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
16569754|NCT02814045||Alzheimer with OSA|Alzheimer with OSA after PSG
16569755|NCT02814045||Alzheimer without OSA|Alzheimer without OSA after PSG
16569756|NCT02814032||PTC group 1|papillary thyroid carcinoma patients with cervical lymph node metastasis
16569757|NCT02814032||PTC group 2|papillary thyroid carcinoma patients without cervical lymph node metastasis
16569758|NCT02814032||Positive control group|benign disease
16569759|NCT02814032||Negative control group|histologically normal
16569760|NCT02814019|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
16569761|NCT02814019|Placebo Comparator|placebo|matching placebo tablets
16569762|NCT02814006|Experimental|every other day|participants will visualize educational video with timed intercourse as recommended by NICE and ASRM
16569763|NCT02814006|Experimental|fertile window|participants will visualize educational video with timed intercourse as recommended by well-know evidence of better conception rates when using this strategy
16569764|NCT02814006|No Intervention|CG|participants will respond to questionnaire with no knowledge of intervention
16569765|NCT02813993|Experimental|Intervention Group|A five-minute video concerning age-related fertility decline, fertility risk factors, success of infertility treatments and emotional consequences of childlessness
16569766|NCT02813993|No Intervention|Control|No intervention
16569767|NCT02813980||High SUDEP-7 score|Patients with epilepsy who have a high SUDEP-7 score
16569768|NCT02813980||Low SUDEP-7 score|Patients with epilepsy who have a low SUDEP-7 score
16569769|NCT02813967|Experimental|chemoradiotherapy|Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
16569770|NCT02813967|Active Comparator|Radiotherapy 60 Gy|Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.
16569771|NCT02813954|Experimental|Study Group|Neonates with respiratory distress
16569772|NCT02813954|No Intervention|Control Group|Healthy Infants
16569773|NCT02813941|Experimental|Alternative GRADE SoF table|Two SoF tables (alternative GRADE SoF table and EPC SoF table) will be used in this randomized controlled non-inferiority trial as an intervention. The alternative GRADE SoF table format will be developed from a user-testing survey.
16569774|NCT02813941|Experimental|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published.
16569775|NCT02813941|Active Comparator|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
16569776|NCT02813928|Experimental|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
16569777|NCT02813915||Use of Cheetah medical NICOM|For those who consent to the study, the Cheetah NICOM will be used to obtain cardiac output, stroke volume, and fluid responsiveness.
16569778|NCT02813902|Active Comparator|Heliocare|240 mg administered orally daily
16569779|NCT02813902|Placebo Comparator|Sugar pill|a sugar pill matching the Heliocare tablet in look and weight will be administered orally daily
16569781|NCT02813876|Experimental|Enhanced recovery|Enhanced recovery protocol for nursing, diet and analgesic regimen
16569782|NCT02813876|No Intervention|Standard care|Standard care arm
16569783|NCT02813863|Experimental|SP2086 and Metformin|In the first day,the subject takes metformin 1000mg once,and from Day 4 to Day 7 they need to take SP2086 100mg everyday. In Day 8,they will be given SP2086 100mg and metformin 1000mg.
16569784|NCT02813850|No Intervention|control|standard medical care
16569785|NCT02813850|Experimental|oxygen therapy|
16569786|NCT02813837|Experimental|single arm|Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
16569787|NCT02813824|Active Comparator|Aspirin300|Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
16569788|NCT02813824|Placebo Comparator|Placebo300|Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
16569789|NCT02813824|Active Comparator|Aspirin100|Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
16569790|NCT02813824|Placebo Comparator|Placebo100|Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
16569791|NCT02813798|Experimental|Mild Renal Impairment|A single dose of IV Rivipansel over 20 minutes
16569792|NCT02813798|Experimental|Moderate Renal Impairment|A single dose of IV Rivipansel over 20 minutes
16569793|NCT02813798|Experimental|Severe Renal Impairment|A single dose of IV Rivipansel over 20 minutes
16569794|NCT02813798|Experimental|Normal Renal Functions|A single dose of IV Rivipansel over 20 minutes
16569801|NCT02813746||Obese non smoker vs Normoweight non smoker|Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO). Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9 kg/m2). The modifications in the miRNAs expression will be studied. After the weight loss, new EF will be collected from these patients.
16569802|NCT02813746||Normoweight smoker vs Normoweight non-smoker|EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
16569803|NCT02813733||Thyroid surgery|All patients who underwent a thyroid procedure in 5 high volume referral centers in France were eligible for inclusion.
16569804|NCT02813720||Patients with peripheral PsA|
16569805|NCT02813720||Patients with psoriatic nail onycholysis|
16569806|NCT02813720||Patients with PsO only|
16569807|NCT02813720||Healthy match control subjects|
16569808|NCT02813694|Experimental|lefamulin|oral lefamulin, 600mg
16569809|NCT02813694|Active Comparator|Moxifloxacin|oral moxifloxacin, 400mg
16569810|NCT02813681|Active Comparator|US-epidural SVD|US-epidural SVD group - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
16569811|NCT02813681|Sham Comparator|(US sham- epidural SVD)|US sham- epidural SVD group- participants who received US examination process but with the monitor turned off.
16569812|NCT02813681|Placebo Comparator|SVD without an Epidural|Spontaneous vaginal delivery without an Epidural group The purpose of the control group is to serve as a baseline.
16569813|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
16569816|NCT02813642|Experimental|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
16569817|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
16569818|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
16569819|NCT02813629|Active Comparator|SS-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
16569820|NCT02813629|Sham Comparator|SS-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
16569821|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
16569822|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
16569823|NCT02813629|Active Comparator|SC-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
16569824|NCT02813629|Sham Comparator|SC-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
16569825|NCT02813603||Study Product (19-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
16569826|NCT02813603||Control Intervention (22-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
16569827|NCT02813590||Patients with liver cirrhosis and with SBP|
16569828|NCT02813590||Patients with liver cirrhosis and without SBP|
16569829|NCT02813577|Other|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
16569830|NCT02813564|Experimental|Training group|This group of children will receive the software based intervention program (CAVINS) and will train at home during the training phase.
16569831|NCT02813564|No Intervention|Control group|This group of children will play video-games-as-usual and return in about 3 weeks for their next assessment appointment.
16569832|NCT02813564|Experimental|fMRI-training group|"This sub-group of children from the Training group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and train on CAVINS (the intervention) during the training phase."
16569833|NCT02813564|No Intervention|fMRI-Control group|"This sub-group of children from the Control group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and play video-games-as-usual until their next assessment appointment (after about 3 weeks)."
16569834|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
16569835|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
16569836|NCT02813538||IGC and thromboelastometry|Patients that have hyper, normo o hypcoagulability measured by tromboelastometry and anticoagulant proteins levels early after major liver resection and clinical evolution and patients with liver funcion impairment or without it, measured by indocyanine green clearance early after surgery and clinical evolution
16569837|NCT02813525||IUGR group|estimated fetal weight <10th percentile associated with an abnormal umbilical artery Doppler with IP>95th percentile or a confirmation of placental vascular disease by histological examination
16569838|NCT02813525||CONTROL group|non IUGR fetuses for gestational age (normal for weight, Doppler, and structural analyse)
16569839|NCT02813512|Experimental|GXNPC1|Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.
16569841|NCT02813486|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
16569842|NCT02813486|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
16569843|NCT02813460|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.
16569844|NCT02813460|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.
16569845|NCT02813460|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.
16569846|NCT02813460|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.
16569847|NCT02813460|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.
16569848|NCT02813460|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.
16569849|NCT02813460|Experimental|Session 2: Sequence 1|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).
16569850|NCT02813460|Experimental|Session 2: Sequence 2|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).
16569851|NCT02813460|Experimental|Session 2: Sequence 3|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).
16569852|NCT02813460|Experimental|Session 2: Sequence 4|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).
16569853|NCT02813460|Experimental|Session 2: Sequence 5|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).
16569854|NCT02813460|Experimental|Session 2: Sequence 6|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).
16569855|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
16569856|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
16569857|NCT02813434|Experimental|Florbetapir|
16569858|NCT02813421|Experimental|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
16569859|NCT02813421|No Intervention|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
16569860|NCT02813408||Participants with Prostate Cancer (abiraterone acetate)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.
16569861|NCT02813408||Participants with Prostate Cancer (enzalutamide)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.
16569862|NCT02813395|No Intervention|Control group|Volunteers remained at rest before and after the fatigue protocol.
16569863|NCT02813395|Placebo Comparator|Placebo group|Volunteers were subjected to laser application simulation for approximately four minutes with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
16569864|NCT02813395|Experimental|Laser before|Volunteers received effective application of laser before fatigue protocol.
16569865|NCT02813395|Experimental|Laser after|Volunteers received effective application of laser after fatigue protocol.
16569866|NCT02813382||B-group|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
16569867|NCT02813382||C-group|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
16569868|NCT02813382||P-group|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
16569869|NCT02813369||naloxegol|patients exposed to naloxegol
16569870|NCT02813369||non-PAMORA laxative|patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
16569871|NCT02813356||naloxegol|patients exposed to naloxegol
16569872|NCT02813356||non-PAMORA|patients exposed to non-peripherally acting mu-opioid antagonist
16569873|NCT02813343|Experimental|Immediate Treatment Group|The Immediate Treatment group will receive access to the study intervention - BlueStar app, immediately after consenting for a total duration of 6 months.
16569874|NCT02813343|Other|Delayed Treatment Group|The Delayed Treatment group will receive access to the study intervention - BlueStar app, 3 months after consenting for a total duration of 3 months.
16569875|NCT02813330|Experimental|Sterile Water injection|Subcutenous injection at low back portion during labor pain
16569876|NCT02813330|Experimental|saline injection|Subcutenous injection at low back portion during labor pain
16569877|NCT02813304|Experimental|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
16569917|NCT02813018|Experimental|preemptive group|Group who will be received ropivacaine bolus and continous infusion 5 minutes before skin incision.
16569878|NCT02813304|Active Comparator|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap and a towel cloth. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
16569879|NCT02813291|Experimental|Stimulation group (Young Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
16569880|NCT02813291|Experimental|Stimulation group (Elderly Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
16569881|NCT02813291|Sham Comparator|Sham group (Young Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
16569882|NCT02813291|Sham Comparator|Sham group (Elderly Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
16569883|NCT02813278|Experimental|simo decoction and acupuncture with vitamin B1|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection for 5 days or until flatus.
16569884|NCT02813278|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection for 5 days or until flatus.
16569885|NCT02813278|No Intervention|empty control|Patients only receive best support care.
16569886|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
16569887|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
16569888|NCT02813252||JCAR015-treated|Patients who received previous treatment with JCAR015
16569889|NCT02813239||HCG triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG when at least 2 follicles had a mean diameter of 17 mm.
16569890|NCT02813239||HCG + GnRH agonist triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG and GnRH agonist when at least 2 follicles had a mean diameter of 17 mm.
16569891|NCT02813226|Other|Imaging|Molecular Imaging
16569892|NCT02813213|Active Comparator|Standard skin graft|"This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard tie over dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day."
16569893|NCT02813213|Experimental|Skin micro graft|"This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use Xpansion micro-autografting system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution."
16569894|NCT02813200|Experimental|Group 1|
16569895|NCT02813200|Experimental|Group 2|
16569896|NCT02813200|Experimental|Group 3|
16569897|NCT02813174|Experimental|Automated online Compassionate Mind Training|
16569898|NCT02813135|Experimental|ARM A. Ribociclib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
16569899|NCT02813135|Experimental|ARM C. AZD1775 + Carboplatin|AZD1775 capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
16569900|NCT02813135|Experimental|ARM D. Olaparib + Irinotecan|Olaparib tablets orally BID on Day 1-10 of a 21 day cycle; Irinotecan iv QD Day 4-8 of a 21 day cycle.
16569901|NCT02813135|Experimental|Arm I. Enasidenib|Enasidenib orally on a continuous dosing once daily (QD) per 28 day cycle.
16569902|NCT02813135|Experimental|Arm J. Lirilumab + Nivolumab|Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Lirilumab iv QD every 4 weeks of a 28 day cycle (Day 1)
16569903|NCT02813122||with x-ray|patients underwent bariatric surgery and underwent x-ray
16569904|NCT02813122||without x-ray|patients underwent bariatric surgery and did not underwent x-ray
16569905|NCT02813096|Experimental|folfox4 chemotherapy regimen|"details in the Intervention Description"
16569906|NCT02813096|Placebo Comparator|Placebo|"details in the Intervention Description"
16569907|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
16569908|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
16569909|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
16569910|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
16569911|NCT02813057|Active Comparator|Stoppa repair|Stoppa inguinal hernia repair
16569912|NCT02813057|Experimental|TEP repair|Total extraperitoneal inguinal hernia repair
16569913|NCT02813044|Experimental|TIVA group|Anesthesia is maintained with propofol during surgery
16569914|NCT02813044|Active Comparator|inhalation anesthesia group|Anesthesia is maintained with sevoflurane during surgery
16569915|NCT02813031|Experimental|Functional meat products with healthy lipids from olive oil|Healthy people consuming 300g/week of functional meat products with high diglyceride lipid from olive oil
16569916|NCT02813031|Placebo Comparator|Traditional meat products|Healthy people consuming the same amount of traditional meat products
16569918|NCT02813018|Placebo Comparator|saline group|Group who will be received saline bolus and continous infusion 5 minutes before skin incision
16569919|NCT02813005|Experimental|Jet ventilation/ group A|Frequency : 120-200/min Pressure : 1-2 bars Inspiratory fraction of oxygen : 100% and 50% if Expiratory pressure : 5 -10 cmH2O
16569920|NCT02813005|Sham Comparator|Standard ventilation/ group B|Apnea made by the anesthesiologist to the request of the radiologist.
16569921|NCT02812992|Active Comparator|GO-GO arm|Nab-paclitaxel 125 mg/m^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m^2 on days D1, D8, D15 of a 28-day cycle.
16569922|NCT02812992|Active Comparator|SLOW-GO arm|Gemcitabine 1000 mg/m^2 i.v. on days D1, D8, D15 of a 28-day cycle.
16569923|NCT02812992|Active Comparator|FRAIL arm|Best supportive care as determined by the investigator.
16569924|NCT02812979|Experimental|Airvo2 with Aerogen Solo|"AIRVOTM2 will be set to deliver air (21% oxygen concentration ) at a rate of 30 L / min at 100 % relative humidity at 37 ° C.
~Nebulization of salbutamol will be effected by means of a nebulizer to the vibrating screen (Aerogen® Solo, Aerogen , Galway, Ireland ) which is a nebulizing device for single use, commonly used in invasive and non invasive mechanical ventilation.
~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
16569925|NCT02812979|Active Comparator|Mask|"During nebulization in the usual way ( oral facial mask ) , it will be used a pneumatic nebulizer powered by a 6 L / min air flow rate ( usual method ).
~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
16569926|NCT02812979|Placebo Comparator|arm control Airvo2 without nebulization of salbutamol|control procedure is to be placed under humidified high flow nasal alone
16569927|NCT02812966|Active Comparator|Lutonix DCB|Lutonix 035 Drug coated Balloon PTA Catheter
16569928|NCT02812966|Active Comparator|IN.PACT DCB|IN.PACT Admiral Paclitaxel-Coated PTA Balloon Catheter
16569929|NCT02812940|Experimental|Everolimus as part of GvHD prophylaxis after allogeneic SCT|Everolimus from day +5 to day +100
16569930|NCT02812927|Other|Standard infusion line|The standard insulin infusion system consisted in regular human insulin administration through a six-stopcock manifold connected to the distal line of a multilumen central venous catheter by 150 cm tubing. Insulin was systematically infused by syringe pump on the patient proximal port of the manifold. Carrier was infused via pump through the manifold. All others medicines were infused through the other five stopcocks.
16569931|NCT02812927|Experimental|Optimised infusion line|The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
16569932|NCT02812914|Experimental|Phase 1|In Phase I, 25 pregnant women will receive a low-cost gas stove and will be taught by peer educators in group classes how to safely use gas stoves and how to reduce exposure to air pollution.
16569933|NCT02812914|Experimental|Phase 2|In Phase 2, the investigators will assess a more resource-intensive behavioral intervention approach with a different group of 25 women who will follow the same study procedures described in Phase I.
16569934|NCT02812901|Other|morning group|cardiac surgery scheduled in the morning
16569935|NCT02812901|Other|afternoon group|cardiac surgery scheduled in the afternoon
16569936|NCT02812888||Hyperthyroid Patients|Patients with hyperthyroidism
16569937|NCT02812888||NC group|Normal control subjects
16569938|NCT02812875|Experimental|CA-170|Taken orally in a once or twice daily schedule.
16569939|NCT02812862||treatment group|"50 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.
~Ultibro/ Breezhaler combination therapy"
16569940|NCT02812862||control group|50 male and female patients suffering from chronic heart failure but not COPD and NOT receiving LAMA/ LABA
16569941|NCT02812849||Suspected cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
16569942|NCT02812849||Known cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
16569943|NCT02812849||Other inflammatory cardiac disease|Cu-64 DOTATATE PET/CT or PET/MRI
16569944|NCT02812836|Other|Manometry|All patients will be investigated by anorectal manometry and after the procedure with balloon expulsion test as previously described.
16569945|NCT02812823|Other|High resolution anorectal manometry|All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
16569946|NCT02812810|Experimental|active rTMS|
16569947|NCT02812810|Placebo Comparator|placebo rTMS|
16569948|NCT02812771|Experimental|Efinaconazole|Efinaconazole
16569949|NCT02812758||patients|All sedated, intubated, mechanically ventilated adult patients admitted for elective cardiac surgery, monitored for sedation depth (with the BIS) and for preload dependence indices (SVV, PPV and PVI) transthoracic echocardiography
16569950|NCT02812745||patients|"patients presenting an indication for general anaesthesia during elective cardiac surgery and being monitored for sedation depth
~recording of cardiac output
~other parameters"
16569951|NCT02812732|Other|Intervention|Providers at each clinic will receive the intervention (DOSE HPV) on a rolling basis. Vaccination rates will be compared pre- and post-intervention at each clinic, and changes in rates will be compared across clinics.
16569952|NCT02812719|Active Comparator|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.
~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
16569953|NCT02812719|Experimental|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.
~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
16569954|NCT02812706|Experimental|Isatuximab|Isatuximab will be administered intravenously (IV) once every week (QW) for 4 weeks followed by once every other week (Q2W)
16569955|NCT02812693|Experimental|Treatment (pembrolizumab, imatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and imatinib mesylate orally PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16569956|NCT02812680||Esophageal Cancer Patients - Blood Draw|Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.
16569957|NCT02812680||Healthy volunteers - Blood Draw|Comparators for the esophageal cancer group
16569958|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
16569959|NCT02812654|Experimental|Doxorubicin, Ifosfamide, radiotherapy|Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
16569960|NCT02812641|Experimental|BPF-CCRT (Run-in Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil
~Chemotherapy:
~Bevacizumab(B): 10 mg/kg on day 1
~Cisplatin(P): 75 mg/m2 on day 1
~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4
~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
16569961|NCT02812641|Experimental|BPF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil
~Chemotherapy:
~Bevacizumab(B): 10 mg/kg on day 1
~Cisplatin(P): 75 mg/m2 on day 1
~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4
~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
16569962|NCT02812641|Active Comparator|PF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Cisplatin and 5-fluorouracil
~Chemotherapy:
~Cisplatin(P): 75 mg/m2 on day 1
~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4
~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
16569963|NCT02812628|Active Comparator|Conventional LAPR|Patients undergoing conventional laparoscopic abdominoperineal resection (LAPR).
16569964|NCT02812628|Experimental|LAPR-TILT|Patients undergoing LAPR with transabdominal individualized levator transection (TILT).
16569965|NCT02812615|Experimental|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
16569966|NCT02812602|Experimental|Lidocaine patch|The patients was randomly assigned to experimental group or placebo group. In this arm, lidocaine patches will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
16569967|NCT02812602|Placebo Comparator|Placebo|The patients was randomly assigned to experimental group or placebo group. In this arm, a placebo patch will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
16569968|NCT02812589|Experimental|Diffusion tensor imaging (DTI) in breast MRI|
16569969|NCT02812550|Other|full-spectrum colonoscopy|Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)
16569970|NCT02812550|Other|standar forward-viewing colonoscopy|Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)
16569971|NCT02812537||patients with conduct disorders|Girls and boys having less than 16 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
16569972|NCT02812524|Experimental|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
16569973|NCT02812511|Experimental|Skin biopsy|
16569974|NCT02812498|Experimental|Teleconsultation|Teleconsultation for patients affected by type 1 diabetes mellitus
16569975|NCT02812498|Other|Control|Standard visit in outpatient clinic for the same type of patients
16569976|NCT02812472|Experimental|treadmill training with functional electrical stimulation|Subjects in the experimental group received additional treadmill training with functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
16569977|NCT02812472|Active Comparator|treadmill training without functional electrical stimulation|Subjects in the control group received additional treadmill training without functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
16569978|NCT02812459|Experimental|Kinesio taping plus exercise|Kinesio taping application for low back plus back exercises.This protocol will be administered three a week for 4 weeks.
16569979|NCT02812459|Active Comparator|Electrical stimulation plus exercise|Electrical stimulation for control pain applied in low back plus exercises.This protocol will be administered three a week for 4 weeks.
16569980|NCT02812446||IAI patients group|patients with Staphylococcus aureus of implant-associated infections
16569981|NCT02812446||control group|patients with Staphylococcus aureus nasal carriage
16569982|NCT02812433|Active Comparator|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
16569983|NCT02812433|Placebo Comparator|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
16569984|NCT02812420|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1 of weeks 1 and 4. Beginning 4-6 weeks after the last infusion, patients undergo cystectomy with pelvic lymph node dissection surgery.
16570040|NCT02812043|Experimental|Amorolfine+Long-pulsed Nd:YAG|This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
16569985|NCT02812407|Experimental|Mucosal Impedance|"Patient's having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.
~During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it."
16569986|NCT02812394|Experimental|CVT-301|"CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.
~CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.
~Sinemet® (carbidopa/levodopa)"
16569987|NCT02812381|Active Comparator|SCS (Jones tecnique)|18 patients were treatment with straincounterstrain
16569988|NCT02812381|Sham Comparator|KT Kinesiotaping|18 patients were treatment with neuromuscular bandage
16569989|NCT02812368|Experimental|Clonidine|Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
16569990|NCT02812368|Placebo Comparator|Placebo (for clonidine)|Taken once a day at bedtime
16569991|NCT02812355|Experimental|half heparinization|heparin I.V. 150 U/kg
16569992|NCT02812355|Active Comparator|full heparinization (300 U/kg)|heparin I.V. 300 U/kg
16569993|NCT02812342|Experimental|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
16569994|NCT02812329|Experimental|HIV prevention videogame|Participants will play PlayForward on a tablet computer for 1 hour, two times per week for 3 weeks.
16569995|NCT02812316|Experimental|Scleral lenses|Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.
16569996|NCT02812303||Population Health Coordinator Support|"8 practices received the support of central population health coordinators (PHCs). PHCs utilized a population health management (PHM) information technology (IT) tool and performed administrative tasks including appointment scheduling, ordering overdue laboratory testing, chart reviews, and obtaining outside tests/labs. In addition, PHCs regularly met with physicians to review those patients who required clinical intervention to develop an action plan.
~The network did not have sufficient resources to implement a PHC in all of the 18 network practices. So PHCs were allocated by responses from the practice leader, baseline quality scores, size of the practice, nature of the practice (health center vs not), and location of the practice. These decisions were made in a way that sought to equitably distribute available PHC resources within the practice network as a way to get network buy-in and maximize the impact of the program, both for practices with and without PHCs."
16569997|NCT02812303||No Population Health Coordinator Support|Ten practices without PHC support were provided training on how to use the PHM IT tool. The staff in these practices remained primarily responsible for managing administrative tasks.
16569998|NCT02812277||Anastrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted anastrozole therapy with the completed follow-up data.
16569999|NCT02812277||letrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted letrozole therapy with the completed follow-up data.
16570000|NCT02812264|Experimental|API App|use of API weight loss mobile application for 12 months, plus fitness tracker and scale.
16570001|NCT02812264|Active Comparator|Attention Control|use of non-API app for weight loss over 12 months, plus fitness tracker and scale.
16570002|NCT02812251|Experimental|Part 1: Cohort 1|Participants will receive 1 milligram (mg) JNJ-61393215 or placebo.
16570003|NCT02812251|Experimental|Part 1: Cohort 2|Participants will receive 5 mg JNJ-61393215 or placebo.
16570004|NCT02812251|Experimental|Part 1: Cohort 3|Participants will receive 15 mg JNJ-61393215 or placebo.
16570005|NCT02812251|Experimental|Part 1: Cohort 4|Participants will receive 30 mg JNJ-61393215 or placebo.
16570006|NCT02812251|Experimental|Part 1: Cohort 5|Participants will receive 45 mg JNJ-61393215 or placebo.
16570007|NCT02812251|Experimental|Part 1: Cohort 6|Participants will receive 60 mg JNJ-61393215 or placebo.
16570008|NCT02812251|Experimental|Part 1: Cohort 7|Participants will receive 90 mg JNJ-61393215 or placebo.
16570009|NCT02812251|Experimental|Part 1: Cohort 8|Participants will receive 120 mg JNJ-61393215 or placebo.
16570010|NCT02812251|Experimental|Part 2|Participants will receive JNJ-61393215 (dose to be determined).
16570011|NCT02812251|Experimental|Part 3|Participants will receive JNJ-61393125 (dose to be determined) or placebo under fed conditions.
16570012|NCT02812238|Experimental|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
16570013|NCT02812238|Experimental|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
16570014|NCT02812225|Experimental|BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
16570015|NCT02812212|Experimental|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
~Diuretic renography to measure the cortical transit time"
16570016|NCT02812199|Experimental|pilot study group 1|Patients in pilot study group 1 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in pilot study group scheduled for 6 follow up visits at 1,2,3,4,6 and 12 weeks after implantation and for tampon removal at day 2 - 3 after FESS surgery. Stent will be removed between 14 and 28-day implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
16570165|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
16570017|NCT02812199|Experimental|study group 2|Patients in study group 2 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in 2nd study group scheduled for 4 follow up visits at 2, 4, 6 and 12 weeks after implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
16570018|NCT02812199|No Intervention|control group 3|control group patients will undergo post-FESS bilateral Standard of Care (tampon) placement into middle meatus as standard of care. Frontal tampon will be placed to stop bleeding. Patients in control group scheduled for 3 follow up visits at 2, 6 and 12 weeks after surgery and for tampon removal at day 2 - 3 after FESS surgery.
16570019|NCT02812186|Other|Deep to Moderate NMB|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
16570020|NCT02812186|Other|Moderate to Deep NMB|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
16570021|NCT02812173|Active Comparator|suprapubic tube ex 2 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 2th day after the surgery
16570022|NCT02812173|Active Comparator|suprapubic tube ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 5th day after the surgery
16570023|NCT02812173|Active Comparator|transurethral catheter ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a transurethral catheter, which was withdrawn on the 5th day after the surgery
16570024|NCT02812160|Active Comparator|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
16570025|NCT02812160|No Intervention|Control|Dietary and Exercise counselling
16570026|NCT02812147|Active Comparator|L-DOPS|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
16570027|NCT02812147|Placebo Comparator|Placebo|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
16570028|NCT02812134||anorexic|
16570029|NCT02812121|Experimental|Group MSC-1|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.
16570030|NCT02812121|Experimental|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.
16570031|NCT02812121|No Intervention|Group Control|Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis).
16570032|NCT02812108||HARET|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
16570033|NCT02812095|Experimental|The refeeding group|Refeeding is initiated when 120mL/kg/day of enteral feed reaches or stoma loss exceeds more than 40ml/kg/day after operation.
16570034|NCT02812095|No Intervention|The control group|
16570035|NCT02812082|Experimental|video web-based patient education application|This is a single-arm design. Development of the web-based application will occur over a 6 month period. Patient accrual will not occur until development of the program is complete. Controlled usability testing during the development/design process of the computer program will not be employed as we do not aim to assess the mechanics of patient use, but rather overall time spent interacting with the application in an uncontrolled environment. Following completion of the tool, patient accrual will occur over a six month time period in order to meet our target sample size of up to 50 participants. Participants will be directed to complete a pre-test questionnaire at the time of accrual and will have 3 months to use the program before being directed to complete the post-test questionnaire.
16570036|NCT02812069|Other|minor to moderate surgical procedure|The ThermaZone® Device will be used for 30 minutes to warm the cervical spine during
16570037|NCT02812056|Experimental|Alisertib + TAK-228|"Dose Escalation Phase:
~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.
~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.
~Dose Expansion Phase:
~Alisertib and TAK-228 taken at the maximum tolerated dose from Dose Escalation Phase."
16570038|NCT02812043|Experimental|Amorolfine|This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month
16570039|NCT02812043|Experimental|Long-pulsed Nd:YAG|This group of patients will receive only the long-pulsed Nd:YAG (Cynergy®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
16570041|NCT02812030||aflibercept in real world|Patients receiving aflibercept for diabetic macular oedema at Bristol Eye Hospital or Gloucestershire Hospitals NHS Foundation Trust
16570042|NCT02812017|Experimental|1 - Intervention|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the Thirty Million Words-Well Baby intervention, which consists of educational, multimedia modules at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
16570043|NCT02812017|Placebo Comparator|2 - Neutral|The Neutral Video group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the neutral videos about car safety at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
16570044|NCT02812017|No Intervention|3 - Usual care|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will receive care as usual at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
16570045|NCT02812004|Experimental|Study Eye|Ultra Q Reflex YAG laser (Ellex)
16570046|NCT02812004|Sham Comparator|Contralateral Eye|Short light impulse is simulated
16570047|NCT02811991|Active Comparator|Experimental:Paracetamol Injection|325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment
16570048|NCT02811991|Placebo Comparator|Placebo:Normal Saline Injcetion|32.5mLor 50mL iv q6h according to assignment.
16570049|NCT02811978|Experimental|Group 1 : Intravenous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib intravenously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
16570050|NCT02811978|Experimental|Group 2 : Subcutaneous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib subcutaneously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
16570051|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
16570052|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
16570053|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
16570054|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
16570055|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
16570056|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
16570057|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
16570058|NCT02811952||study group|Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
16570059|NCT02811952||control group|Patients that need cystoscopy due to others reasons than malignancy.
16570060|NCT02811939|Experimental|Active THC and Placebo Pregnenolone|
16570061|NCT02811939|Experimental|Active THC and Active Pregnenolone|
16570062|NCT02811939|Experimental|Placebo THC and Active Pregnenolone|
16570063|NCT02811939|Placebo Comparator|Placebo THC and Placebo Pregnenolone|
16570064|NCT02811926||Ileostomy or colostomy|Patients with a ileostomy or colostomy in the Capital Region of Denmark
16570065|NCT02811913|Other|High frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 5 Hz rTMS
16570066|NCT02811913|Other|Low frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 1 Hz rTMS
16570067|NCT02811913|Other|Sham rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was sham rTMS
16570068|NCT02811887|Active Comparator|Usual care|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
16570069|NCT02811887|Experimental|SMS-messages|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period
16570070|NCT02811874|Experimental|diabetes education|Four community health workers receive a one-month diabetes education program (intervention group, patients n= 62)
16570071|NCT02811874|Active Comparator|education in other areas|Four community health workers receive an education course in other health issues (control group, patients n= 56).
16570072|NCT02811861|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily
16570073|NCT02811861|Experimental|Lenvatinib 20 mg plus pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks
16570074|NCT02811861|Active Comparator|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment
16570075|NCT02811848||Barbers|Barbers that service African American clientele mainly will be recruited for this study; there is no intervention.
16570076|NCT02811835||Renal Transplant Recipients|Renal Transplant Recipients that were more than 1 year post-transplantation
16570077|NCT02811835||Healthy Controls|Healthy subjects being evaluated as potential living kidney donors
16570078|NCT02811822|Experimental|Dose 1|
16570079|NCT02811822|Experimental|Dose 2|
16570080|NCT02811822|Experimental|Dose 3|
16570081|NCT02811822|Experimental|Dose 4|
16570082|NCT02811809|Experimental|Apalutamide + IHT|Participants will be treated with 240 mg (4-60 mg tablets) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently.
16570083|NCT02811809|Active Comparator|IHT only|Participants will receive 22.5 mg 3-month depot intramuscular leuprolide until PSA progression, then they will crossover to Apalutamide + IHT
16570084|NCT02811796||angio-based FFR estimation|The investigators will include all patients receiving successful coronary stent implantation. In these patients the investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
16570087|NCT02811770||children with HSN|
16570088|NCT02811757|Experimental|tenodesis|
16570089|NCT02811757|Active Comparator|tenotomy|
16570090|NCT02811744|Experimental|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
16570091|NCT02811744|Other|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and LP and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
16570092|NCT02811731|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
16570093|NCT02811731|Experimental|CKD-330|CKD-330 16/5mg - B, PO, 1days or 22days
16570094|NCT02811718|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
16570095|NCT02811718|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
16570096|NCT02811705||PFAPA group|Life quality for PFAPA patient report by themselves or parent
16570097|NCT02811705||FMF group|Life quality for FMF patient report by themselves or parent
16570098|NCT02811692||BAY86-5321|Anti-Vascular Endothelial Growth Factor (VEGF) - naive patients starting intravitreal Aflibercept injection treatment for Neovascular age-related macular degeneration (AMD), macular edema following Branch Retinal Vein Occlusion (BRVO), macular edema following central retinal vein occlusion (CRVO), and diabetic macular edema (DME)
16570099|NCT02811679|Experimental|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
16570100|NCT02811666|Experimental|Patients operated for liver or pancreas cancer|
16570101|NCT02811653|Experimental|Alzheimer disease|Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
16570102|NCT02811653|Active Comparator|control|"Healthy age- and gender-matched volunteers will be recruited into the study from the general population.
~Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation"
16570103|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
16570104|NCT02811627|Experimental|Memantine and Magnetic Resonance Imaging|"Subjects will be started on memantine post the imaging session.
~Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills). Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks."
16570105|NCT02811614|Experimental|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
16570106|NCT02811614|Experimental|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
16570107|NCT02811614|Active Comparator|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
16570109|NCT02811588||Phase1:Screening phase: normocapnic group|Normocapnic COPD patients
16570110|NCT02811588||Phase1;Screening phase: hypercapnic group|Hypercapnic COPD patients
16570111|NCT02811588||Phase1:Treatment phase: control group|Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.
16570112|NCT02811588||Phase1:Treatment phase: non-invasive ventilation group|Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.
16570113|NCT02811575||Patients with diabetes|Patients with type 2 diabetes will have biopsy during coloscopy.
16570114|NCT02811575||Control|Patients without type 2 diabetes will have biopsy during coloscopy.
16570115|NCT02811562|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in manikin using fiberoptic bronchoscope
16570116|NCT02811562|Experimental|fiberoptic bronchoscope with pentax-airwayscope|Tracheal intubation in manikin using fiberoptic bronchoscope with pentax-airwayscope
16570162|NCT02811276|Experimental|High-Protein Diet Group|Those assigned to the High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®).
16570163|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
16570117|NCT02811549|Experimental|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults who have severe to profound sensorineural hearing loss in one ear, and up to moderate sensorineural hearing loss in the other ear (asymmetric hearing loss).
16570118|NCT02811536||Diabetic retinopathy|Patients with various degrees of diabetic retinopathy
16570119|NCT02811536||Retinal detachment|Patients with a history of retinal detachment
16570120|NCT02811536||Retinal vein occlusion|Patients with a history of retinal vein occlusion
16570121|NCT02811536||Arterial hypertension|Patients with a history of arterial hypertension
16570122|NCT02811536||Carotid artery occlusion|Patients with a history of carotid artery occlusion
16570123|NCT02811536||Age related macular degeneration|Patients with a history of Age related macular degeneration
16570124|NCT02811536||Macroaneurysms|Patients with a history of retinal macroaneurysms
16570125|NCT02811536||Central serous chorioretinopathy|Patients with a history of central serous chorioretinopathy
16570126|NCT02811523|Experimental|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570127|NCT02811523|Experimental|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570128|NCT02811523|Experimental|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570129|NCT02811523|Experimental|Doxorubicin 11 mcg/ml|Doxorubicin 11mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570130|NCT02811523|Experimental|Doxorubicin 13 mcg/ml|Doxorubicin 13mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570131|NCT02811523|Experimental|Doxorubicin 15 mcg/ml|Doxorubicin 15mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570132|NCT02811523|Experimental|Doxorubicin 17 mcg/ml|Doxorubicin 17mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570133|NCT02811523|Experimental|Doxorubicin 20 mcg/ml|Doxorubicin 20mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
16570134|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
16570135|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
16570136|NCT02811497|Experimental|Azacitidine and Durvalumab|"Azacitidine will be given by mouth at a fixed dose of 300 mg daily for 14 consecutive days of every 28 day cycle for 3 cycles.
~Durvalumab will be given intravenously (by vein) at a fixed dose of 1500 mg (over 1 hour) on Day 1 of every 28 day cycle for 12 months or until disease progression."
16570137|NCT02811484|Other|Group 1|Insulin titration and behavioral therapy.
16570138|NCT02811484|Placebo Comparator|Group 2|Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.
16570139|NCT02811484|Experimental|Group 3|Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.
16570140|NCT02811458|Experimental|Transdiagnostic CBT|Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012)
16570141|NCT02811458|No Intervention|Treatment-as-usual|Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up.
16570142|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
16570143|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
16570144|NCT02811432|Experimental|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
16570145|NCT02811432|Active Comparator|Standard care|Incubator or radiant warmer
16570146|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
16570147|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
16570148|NCT02811406|Experimental|Receives IV albumin infusion|IV albumin 20% 50 mL for every 1L of ascitic fluid drained
16570149|NCT02811406|Placebo Comparator|Do not receive IV albumin infusion|No IV albumin infusion
16570150|NCT02811393||Bariatric surgery|Women who have been submitted to a Roux-en-Y Gastric Bypass Surgery for at least 2 years
16570151|NCT02811393||Unoperated|Women with similar characteristics to control group (age, body mass index, physical activity level), but they have not been submitted to bariatric surgery
16570152|NCT02811380|Experimental|BIP CVC|Bactiguard Infection Protection Central Venous Catheter
16570153|NCT02811380|Placebo Comparator|Uncoated standard CVC|Uncoated standard Central Venous Catheter
16570154|NCT02811367|Experimental|HPV self-test|Women will perform the HPV self-test.
16570155|NCT02811354|Experimental|AZD9291|Patient will be treated with AZD9291 at a starting dose of 80mg once a day until the patient completes the study, withdraws from the study or closure of the study. A cycle of treatment is defined as 28 days of once daily AZD9291 treatment. Patients may continue to receive AZD9291 until objective disease progression (determined by RECIST 1.1) or if the subject is no longer receiving clinical benefit in the Investigator's opinion.
16570156|NCT02811341|Placebo Comparator|A group|Using normal saline before pcle examination
16570157|NCT02811341|Experimental|B group|Using Scopolamine Hydrobromide before pcle examination
16570158|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
16570159|NCT02811289|Experimental|Mirabegron|Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.
16570160|NCT02811289|Active Comparator|Cold exposure|Cold exposure protocol using a water-conditioned cooling suit will be applied
16570161|NCT02811276|No Intervention|Control Group|Those assigned to the Control Group will receive a eucaloric diet (a diet designed to meet the person's energy needs and maintain body weight) composed of 55% of carbohydrate, 15% of protein, and 30% of lipid.
16570164|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
16570166|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
16570167|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
16570168|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
16570169|NCT02811237|Other|HESTIA group|
16570170|NCT02811237|Other|sPESI group|
16570171|NCT02811224||Ovarian Cancer|
16570172|NCT02811224||Benign Neoplasm|
16570173|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
16570174|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
16570175|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
16570176|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
16570177|NCT02811185|Other|PET/CT Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
16570178|NCT02811185|Other|PET Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
16570179|NCT02811172||Healthy pregnant women|Healthy pregnant women
16570180|NCT02811172||Risk pregnant women|Hypertensive, obese and diabetic women
16570181|NCT02811159|Experimental|Telapristone Acetate 12 mg|Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).
16570182|NCT02811146|Experimental|Cardiopulmonary exercise testing|Assess whether people who wore noninvasive ventilation during aerobic exercise have greater functional capacity than those who did not wear.
16570183|NCT02811146|Experimental|ADL Glitre test|Check that people who wore noninvasive ventilation during aerobic exercise have greater submaximal functional capacity than those who did not wear. Compare a ventilatory metabolic response of the ADL Glitre test with an six-minute walk test. .
16570184|NCT02811146|Experimental|Minnesota Living with Heart Failure|Check if people undergoing heart rehabilitation has improved quality of life.
16570185|NCT02811146|Experimental|Bioimpedance balance|Check if people undergoing heart rehabilitation has improved the body composition.
16570186|NCT02811146|No Intervention|Six-minute walk test|Compare a ventilatory metabolic response of the six-minute walk test with an ADL Glitre test.
16570187|NCT02811146|Experimental|Metabolic ventilatory response|"To verify if non-invasive ventilation during aerobic exercise modifies the ventilatory metabolic response in patients with heart failure.
~Check the metabolic ventilatory response during the Glittre ADL test and six-minute walk test."
16570188|NCT02811133|Experimental|Inositol|Subjects will receive inositol
16570189|NCT02811120||single arm|single venepuncture
16570190|NCT02811107||Patients in preoperative area|Patients in preoperative area before surgery or interventional procedure will complete questionnaires on tablet computers
16570191|NCT02811094|Other|Adult patients with Systemic LupusErythematosus (SLE)|Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.
16570192|NCT02811081|Experimental|Control|Passive deflation of residual carbon dioxide
16570193|NCT02811081|Experimental|Normal Saline Instillation|Instillation of isotonic normal saline in the sub-diaphragmatic region
16570194|NCT02811081|Experimental|Combined Intervention|Normal Saline Instillation + Pulmonary Recruitment
16570195|NCT02811068||Venepuncture|Collection of single blood sample to assess antibody persistence over time
16570196|NCT02811055|Experimental|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
16570197|NCT02811055|Placebo Comparator|Administration of placebo|Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
16570198|NCT02811042|Active Comparator|Oropharyngeal leak pressure|Ambu AuraOnce
16570199|NCT02811042|Experimental|Fiberoptic position|Ambu AuraGain
16570200|NCT02811029|Experimental|premature infants less than 32 weeks of age|measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
16570201|NCT02811016|Experimental|budesonide 200|inhaled budesonide 200 µg bid
16570202|NCT02811016|Experimental|budesonide 800|inhaled budesonide 800 µg bid
16570203|NCT02811016|Placebo Comparator|placebo|inhaled placebo bid
16570204|NCT02811003|Experimental|Treatment|Treatment with Rotation Medical Bioinductive Implant
16570205|NCT02810990|Experimental|Bosutinib treatment|
16570206|NCT02810964|Experimental|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
16570207|NCT02810964|Placebo Comparator|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
16570242|NCT02810717|Sham Comparator|sham TBS|40 patients with TRD will receive sham stimulation using a MagPro X1000 between the two PET measurements. After the second PET scan they will receive active TBS
16570268|NCT02810509||Short-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)
~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
~TTR evaluable days < 90 days"
16570209|NCT02810925|Experimental|PENS T6 and 1200 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
16570210|NCT02810925|Active Comparator|PENST6 + Normocaloric 2000 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a normocaloric 2000 Kcal/day diet.
16570211|NCT02810925|Placebo Comparator|TENS T11/ T12 + 1200 Kcal/day diet|Patients undergo 12 sessions of transcutaneous electrical stimulation of dermatomes T11-T12 , weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
16570212|NCT02810925|Active Comparator|1200 Kcal/day diet|Patients follow only a hypocaloric 1200 Kcal/day diet.
16570213|NCT02810912||Supraglottic airway device-based anesthesia|Investigators planned to enroll 200 cases who will receive scheduled surgery under supraglottic airway device-based general anesthesia.
16570214|NCT02810899|Experimental|Dexmedetomidine group|A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
16570215|NCT02810899|Placebo Comparator|Control group|Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
16570216|NCT02810886|Experimental|Single, arm exploratory|Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
16570217|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
16570218|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
16570219|NCT02810860|Other|Open Label|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
16570220|NCT02810847|Experimental|I-BiT Plus|6 weeks of I-Bit treatment plus (at least 30 mins/day, 6 days/week)
16570221|NCT02810847|No Intervention|Control|Refractive adaption or observation
16570222|NCT02810834|Experimental|Walking/Running Program|Walking/running/jogging program; school-based.
16570223|NCT02810834|Experimental|Classroom activity break program|Classroom physical activity break program; school-based.
16570224|NCT02810834|No Intervention|Control|Control/Delayed Intervention
16570225|NCT02810821||male|
16570226|NCT02810821||female, premenopause|Women with regular menstrual cycles in normal range (22-35 days) for the previous three cycles.
16570227|NCT02810821||female, perimenopause|Women with variability in menstrual cycle length, defined as a persistent difference of 7 days or more in the length of consecutive cycles, or amenorrhea of at least 60 days but no longer than 12 months.
16570228|NCT02810821||female, postmenopause|Women with amenorrhea of at least 12 consecutive months.
16570229|NCT02810808|Experimental|Ranibizumab 0.5 mg 1+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab
16570230|NCT02810808|Active Comparator|Ranibizumab 0.5 mg 3+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.
16570231|NCT02810782|Experimental|Phenobarbital|Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
16570232|NCT02810782|Active Comparator|Chlorpromazine|Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
16570233|NCT02810782|Active Comparator|Morphine|Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
16570234|NCT02810769|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
16570235|NCT02810769|Experimental|Juiced berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
16570236|NCT02810769|Experimental|Powdered berry drink|Berry drink made up from a powdered concentrate. each drink will be standardised to contain 500mg of polyphenols
16570237|NCT02810756|Experimental|Treated patients|
16570240|NCT02810730|Other|Single arm|Pancreatic MRI in the 6 months following the first consultation
16570241|NCT02810717|Experimental|active TBS|40 patients with TRD will receive active theta-burst stimulation using a MagPro X1000 between the two PET measurements
16570243|NCT02810704|Experimental|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
16570244|NCT02810704|Experimental|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
16570245|NCT02810704|Experimental|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
16570246|NCT02810691|Active Comparator|Soluble fiber, dose #1|Soluble fiber supplementation with dose #1 (smaller dose) of psyllium fiber.
16570247|NCT02810691|Active Comparator|Soluble fiber, dose #2|Soluble fiber supplementation with dose #2 (bigger dose) of psyllium fiber.
16570248|NCT02810691|Placebo Comparator|Placebo|A 250 ml placebo solution of orange-flavored water will be drink at breakfast.
16570249|NCT02810678|No Intervention|Control|No Intervention: Program runs as per usual. Minimal interference and visits from study staff. Main study outcomes evaluated in first and last 6 months of trial. Minimal visits to collect information on costing at control sites.
16570250|NCT02810678|Active Comparator|Intervention|Latent Tuberculosis Infection program evaluation & diagnosis: In intervention health facilities the current Latent Tuberculosis Infection program will be evaluated and gaps in the Latent Tuberculosis Infection cascade of care will be identified. Gaps in the current cascade will be quantified and solution proposed that are unique to the problems identified in each site. In phase 2 of the study low cost solutions will be implemented and the Latent Tuberculosis Infection program scaled up and improved. Study outcomes are evaluated in the first and last 6 months of trial. Costing evaluations are done throughout the trial.
16570251|NCT02810665||Normal vision group|Individuals with VA 20/20 to 20/25
16570252|NCT02810665||Impaired vision group|Individuals with impaired vision: VA of 20/32 to 20/200 due to either cataract, diabetic macular edema, or age-related macular degeneration
16570253|NCT02810652|Experimental|Perioperative Geriatrics Intervention|Evaluation with a board-certified geriatric clinician, both pre- and post-operatively.
16570254|NCT02810652|Active Comparator|Standard Care|Usual care participants will not meet with a geriatric clinician perioperatively, but may receive a geriatric consult upon request or at the discretion of their treating clinician(s).
16570255|NCT02810626|No Intervention|Control|Control Group (surgical standard of care): Subjects 18 years and younger diagnosed with a pediatric brain tumor, and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
16570256|NCT02810626|Other|Interventional|Interventional Group (involvement of all BrightMatter™ products): Subjects 18 years and younger diagnosed with a pediatric brain tumor and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol and will be sent to the interventional technology (BrightMatter Bridge) for quality control. The QC'ed images will then be sent to a pre-operating planning software (BrightMatter Plan) for planning the surgical approach. Surgery will be carried out with guidance from the exported plan and the intra-operative neuro-navigation software, BrightMatter Guide, with the use of post-processing DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
16570257|NCT02810587||Topical antibiotics group|Those who receive topical antibiotics after intravitreous injection as home medication for 7 days.
16570258|NCT02810587||No topical antibiotics group|Those who does NOT receive topical antibiotics after intravitreous injection as home medication.
16570259|NCT02810574|Active Comparator|Active noninvasive brain stimulation and cognitive training|In active condition, subject will receive stimulation during all the 30-minute stimulation period combined with cognitive training.
16570260|NCT02810574|Sham Comparator|Sham noninvasive brain stimulation|In sham condition, subject will receive stimulation only during the first 30 seconds of the 30-minute stimulation period combined with cognitive training.
16570261|NCT02810548|Placebo Comparator|OFD alone|Control group: including 15 defects that will receive open flap debridement (OFD).
16570262|NCT02810548|Active Comparator|PRF + OFD|Test group (1): including 15 defects that will receive platelet rich fibrin (PRF) with open flap debridement (OFD).
16570263|NCT02810548|Active Comparator|Bone + OFD|Test group (2): including 15 defects that will receive nanohydroxyapatite bone graft with open flap debridement OFD).
16570264|NCT02810548|Active Comparator|PRF + Bone + OFD|Test group (3): including 15 defects that will receive nanohydroxyapatite bone graft with platelet rich fibrin (PRF) after open flap debridement (OFD).
16570265|NCT02810535|Active Comparator|Allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and positive prick test for house dust mite
16570266|NCT02810535|Experimental|Non-allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and negative prick test for house dust mite
16570267|NCT02810535|Other|Healthy Control|Clinical observation of 20 subjects without nasal symptoms and with negative prick test
16570294|NCT02810340|Experimental|MCV-5 with adjuvant|Received a single intramuscular injection of Adjuvanted MCV-5.
16570269|NCT02810509||Long-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)
~long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
~TTR evaluable days ≥ 90 days"
16570270|NCT02810496|Experimental|patient|
16570271|NCT02810483|Experimental|Arm 1: Topiramate|Topiramate Arrow 50 mg hard capsules
16570272|NCT02810483|Placebo Comparator|Arm 2: Placebo Comparator|50 mg hard capsules with the same shape, color and taste than the active product
16570273|NCT02810470|Experimental|Cream appreciation tests|
16570274|NCT02810470|Experimental|Beverages appreciation tests|
16570275|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:
~15 mg/kg IV infusion on Day 1 of each 21-day cycle.
~Drug: Paclitaxel:
~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
~Drug: Carboplatin:
~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
16570276|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|"Drug: Avastin:
~15 mg/kg IV infusion on Day 1 of each 21-day cycle.
~Drug: Paclitaxel:
~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
~Drug: Carboplatin:
~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
16570277|NCT02810444|Experimental|BT595|Subjects will receive BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.
16570278|NCT02810418|Experimental|Arm A1, Dose Level 1 (Phase 1, short infusion) 100µg/kg LMB-100|"Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 +125mg/m^2 nab-paclitaxel
~Dose level 1 (DL1) Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving short infusion LMB-100+nabpaclitaxel"
16570279|NCT02810418|Experimental|Arm A1, Dose Level-1 (Phase 1, short infusion) 65µg/kg LMB-100|Arm A1, DL-1, Ph I Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel
16570280|NCT02810418|Experimental|Arm A2 (Phase 2, short infusion) 65µg/kg LMB-100|"Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel
~Efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel"
16570281|NCT02810418|Experimental|Arm B1, Dose Level 2 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL2, 48-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving continuous infusion LMB-100 as single agent
16570282|NCT02810418|Experimental|Arm B1, Dose Level 1 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL1, 48-hr Continuous Infusion Single Agent Lead-in 65µg/kg/day LMB-100
16570283|NCT02810418|Experimental|Arm B1, Dose Level 3R Phase I (Continuous infusion single agent lead-in)|Arm B1, DL3R, 24-hr Continuous Infusion Single Agent Lead-in 100µg/kg LMB-100
16570284|NCT02810418|Experimental|Arm B2 Phase I (continuous infusion combination therapy)|Subjects with pancreatic cancer receiving continuous infusion LMB-100 combination therapy
16570285|NCT02810405||1/Patient Samples|Patients treated at NCI with available tissue samples
16570286|NCT02810392|Active Comparator|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
16570287|NCT02810392|Placebo Comparator|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
16570288|NCT02810379|Placebo Comparator|written informed consent|participants read the written informed consent documents befor ERCP
16570289|NCT02810379|Experimental|video+written informed consent|participants watch a video about the ERCP and read the written informed consent documents before ERCP
16570290|NCT02810366|Active Comparator|Physician Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the electronic Verbal Autopsy (eVA) instrument.
~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a short checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness, followed by a free-text narrative.
~Cause of death for these VAs will be assigned by trained physicians using the MDS physician coding system; this includes dual, independent coding of VA records, disagreements resolved by reconciliation, and remaining cases by adjudication by a third physician. The assignment of cause of deaths will be in line with the international classification of disease version 10 (ICD-10)."
16570291|NCT02810366|Experimental|Computer Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the Extended Symptom List (ESL) VA instrument.
~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a long checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness. This VA instrument does not contain a free-text narrative.
~The cause of death for these VAs will be independently assigned by five leading computer-coding VA algorithms. The assignment of cause of deaths will be in line with 17 broad cause of death categories."
16570292|NCT02810353|Experimental|Expander with differential opening group|The experimental group will comprise 25 patients who will be submitted to rapid maxillary expansion using the expander with differential opening. The expander will be composed by two 11-mm screws, one anteriorly and the other posteriorly positioned on the palate (Great lakes Orthodontics Ltd, NY, EUA).
16570293|NCT02810353|Active Comparator|Hyrax group|The control group will be comprised by 25 patients who will undergo rapid maxillary expansion using the conventional Hyrax expander. The expander will be composed by one 11-mm screw centrally positioned on the palate (Dentaurum, Ispringen, Germany).
16570295|NCT02810340|Experimental|MCV-5 without adjuvant|Received a single intramuscular injection of Non-Adjuvanted MCV-5.
16570296|NCT02810340|Active Comparator|Menactra®|Received a single intramuscular injection of Menactra.
16570297|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
16570298|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
16570299|NCT02810314|Experimental|Clinical measures|MS patients recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works for each group and all MS patients will also complete a comprehensive neuropsychological battery including cognitive and behavioural tests of interest in MS
16570300|NCT02810314|Other|Control measures|Healthy participants recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works
16570301|NCT02810301|Experimental|Treatment (Probiotic ES1)|Capsules containing 1 billion CFU of B. longum ES1 per capsule. One capsule taken before and after consuming 2 slices of bread for 7 days.
16570302|NCT02810301|Placebo Comparator|Placebo|Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
16570303|NCT02810288||Expert|Anaesthesiologist with large paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
16570304|NCT02810288||Non-experts|Anaesthesiologist with little paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
16570305|NCT02810275|Experimental|Folinic Acid|Folinic acid group received 5 mg daily during four weeks
16570306|NCT02810275|Placebo Comparator|Placebo|Placebo group received a tablet daily during four weeks
16570307|NCT02810262||First bone metastasis of adenocarcinoma lung cancer|Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.
16570308|NCT02810249||African American YMSM|
16570309|NCT02810236|Active Comparator|No ultrasound|No ultrasound recommended. Discussion with radiologist.
16570310|NCT02810236|Active Comparator|Ultrasound|Ultrasound recommended.
16570311|NCT02810223|Experimental|Single dose of CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
16570312|NCT02810210||Cohort 1|Monitoring of children born without congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
16570313|NCT02810210||Cohort 2|Monitoring of children born with congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
16570314|NCT02810210||Cohort 3|Monitoring of children born without congenital anomalies to mothers with no biologically confirmed ZIKV's infection during the pregnancy
16570315|NCT02810197|Experimental|Exposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
16570316|NCT02810197|Experimental|unexposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
16570317|NCT02810184|Other|CBCT arm|all participating patients receive an additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
16570318|NCT02810171|Active Comparator|Cognitive Behavioral Therapy|
16570319|NCT02810171|Other|Relaxation Therapy|
16570320|NCT02810171|No Intervention|No Intervention: Healthy youth only|Healthy control participants, matched to gender and age with anxiety patients, will be enrolled. These healthy participants will be scanned with fMRI before and after ~16 weeks, but without any intervention (i.e., no therapy).
16570321|NCT02810158||Patients with suspected OSA|Persons with clinical suspicion of obstructive sleep apnoea syndrome (OSA)
16570322|NCT02810145||TBI with GCS <or= 8|Adult patients admitted to the surgical intensive care unit with traumatic brain injury and a Glasgow coma score less than or equal to 8.
16570323|NCT02810132|Active Comparator|Metformin|Drug: Metformin Target dose: 1000 mg x 2 (if eGFR 30-60 ml/min: 500 mg x 2) Other name: Glucophage XR 500
16570324|NCT02810132|Placebo Comparator|Placebo|Drug: Placebo
16570325|NCT02810119|Experimental|LO2A|Sodium Hyaluronate
16570326|NCT02810119|Placebo Comparator|Placebo-Controlled Saline|Placebo
16570327|NCT02810093||Breast cancer patients between 2000 and 2016|Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
16570328|NCT02810067|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
16570329|NCT02810067|Experimental|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
16570330|NCT02810054|Sham Comparator|Control Group (MIST without EMD)|Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .
16570331|NCT02810054|Experimental|Test Group (MIST with EMD)|Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .
16570332|NCT02810041|Experimental|yoghurts enriched with XXS|
16570333|NCT02810041|Placebo Comparator|yoghurts non enriched with XXS|
16570334|NCT02810028|Experimental|ACT + Standard Medical Care (SMC)|This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
16570335|NCT02810028|No Intervention|Standard Medical Care (SMC)|All participants will receive SMC. As such, they will receive all the treatment and support they would otherwise receive outside of a research trial including a personalised assessment from the physiotherapist.
16570369|NCT02809755|Placebo Comparator|Placebo Saline|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
16572523|NCT02795065|Active Comparator|Enoxaparin 40 mg subcutaneous once daily|
16570336|NCT02810015|Experimental|Botulinum Toxin A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
16570337|NCT02810002|Experimental|DEFINITE-REGULATOR|Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel
16570338|NCT02810002|Active Comparator|modified Belleville 390 TROP|Standard issue infantry boot
16570339|NCT02809989||Ovaleap®|Single group prospective treatment cohort
16570340|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
16570341|NCT02809963|Active Comparator|Eplerenone|Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
16570342|NCT02809963|Placebo Comparator|placebo|sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
16570343|NCT02809950|Experimental|oral carbohydrate beverage group|
16570344|NCT02809950|Placebo Comparator|control group|
16570345|NCT02809937|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
16570346|NCT02809937|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
16570347|NCT02809924|Experimental|Simulation-based just-in-time training|Viewing a short video showing the neonatal glottis of similar gestational age to the patient that is being intubated followed by practice on a mannequin (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada) with supervision and feedback from a senior provider (low fidelity simulation).
16570348|NCT02809924|Active Comparator|Video training|5 minutes video regarding endotracheal intubation
16570349|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
16570350|NCT02809911|Other|Active Provant|Active Provant Treatment
16570351|NCT02809885|Experimental|Transplanted patients|All patients included are in the same arm.
16570352|NCT02809872||Study Group|Study Group with Pleural effusion for any cause and receiving chest CT scan and thoracic Ultrasounds.
16570353|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
16570354|NCT02809846|Active Comparator|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
16570355|NCT02809846|Sham Comparator|Sham Quell Device|Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.
16570356|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
16570357|NCT02809820|Active Comparator|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
16570358|NCT02809820|Active Comparator|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
16570359|NCT02809807|Experimental|Baseline|Without a gas mask. We measure baseline respiratory index, parameters and the comfort.
16570360|NCT02809807|Experimental|Assessment with gas mask and canister A|With a gas mask, the measurement have been done with a high resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
16570361|NCT02809807|Experimental|Assessment with gas mask and canister B|With a gas mask, the measurement have been done with a low resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
16570362|NCT02809794|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
16570363|NCT02809781|Experimental|Intravenous infusion of MSCs|Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
16570364|NCT02809781|Active Comparator|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
16570365|NCT02809768|Experimental|Avatrombopag plus fluconazole|Part A: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, fluconazole (400-mg) will be administered once daily on Days 1 to 16, and a single dose of avatrombopag (20-mg) on Day 7 in Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
16570366|NCT02809768|Experimental|Avatrombopag plus itraconazole|Part B: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, itraconazole (200-mg) will be administered twice daily on Day 1 and 200-mg once daily on Days 2 to 16. A single dose of avatrombopag (20-mg) will be administered on Day 7 of Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
16570367|NCT02809768|Experimental|Avatrombopag plus rifampin|Part C: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, rifampin (600-mg) will be administered once daily on Days 1 to 16. In order to avoid a food-effect on rifampin absorption, each dose will be administered 1 hour before participants consume a meal. On Day 7 of Treatment Period 2, rifampin (600-mg) and avatrombopag (20-mg) will be administered 1 hour before meal and 30 minutes after starting meal consumption.
16570368|NCT02809755|Experimental|4% lidocaine|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
16570370|NCT02809742||Epidural group|Epidural : automatic intermittent boluses ( 8-12 mL per hour) + patient controlled bolus (4 mL evrey 20 min) using ropivacaine
16570371|NCT02809729|Placebo Comparator|placebo|The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction
16570372|NCT02809729|Active Comparator|cefazolin|The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction
16570374|NCT02809690|Experimental|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
16570375|NCT02809677|Other|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
16570376|NCT02809651|Experimental|Ischemic stroke|patients suffering from ischemic stroke diagnosed by clinical examination and CT-scan
16570377|NCT02809651|Experimental|Brain tumor|patients diagnosed with a brain tumor diagnosed by clinical examination and CT-scan or MRI
16570378|NCT02809651|Experimental|Brain surgery|patients that have undergone brain surgery
16570379|NCT02809651|Active Comparator|Intracranial hemorrhage|patients with intracranial hemorrhage diagnosed by clinical examination and CT-scan
16570380|NCT02809651|Experimental|Headache|patients with headache complaints and a normal CT-scan of the brain
16570381|NCT02809651|Experimental|Headtrauma|patients with head trauma and a normal CT-scan of the brain
16570382|NCT02809638||DVT of the lower limbs|patients with first suspected episode of unprovoked DVT of the lower limbs and patients with episode of unprovoked DVT of the lower limbs at third month of follow-up
16570383|NCT02809612|Experimental|Internet-based intervention|"Patients randomized to the internet-based intervention will be given access to the information in the internet-based platform directly after randomization. During the first 6 weeks, information will be offered in a structured way, with a theme changing weekly. After this time-point, the patients will have the possibility to navigate through all information. The platform encompasses internet-based training including information on the disorder, psycho-education and information of simple self-implemented intervention strategies cope with vulvodynia and ameliorate dyspareunia. The platform will also include videos where team members will describe their role in treating patients with the disorder, but also short videos from former patients willing to share their individual stories."
16570384|NCT02809612|No Intervention|Control group|Patients randomized to the control group through the platform will immediately be informed about the fact that there is available information and resources on the internet and that they will be called for a visit to the physiotherapist-midwife at due time, according to the present guidelines of care followed in the respective clinic (Uppsala, Falun, Gävle).
16570385|NCT02809599|No Intervention|Pre-intervention|Patients in hospitals that have not received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess BPPV processes at the ED Index visit. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
16570386|NCT02809599|Experimental|Post-intervention|Patients in hospitals that have received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess the main study outcome, behavior change in medical providers. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
16570387|NCT02809586|Active Comparator|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
16570388|NCT02809586|Active Comparator|SMI|A Social Media Intervention (SMI) condition
16570389|NCT02809586|No Intervention|Control|An Attention-Control E-News (CONTROL) condition
16570390|NCT02809573|Experimental|study drugs|Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.
16570391|NCT02809560|Experimental|Asthmatic children|Induced sputum method using hypertonic serum
16570392|NCT02809560|Sham Comparator|Control children|Induced sputum method using hypertonic serum
16570393|NCT02809547|Active Comparator|In Clinic monitoring|70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
16570394|NCT02809547|Experimental|At Home monitoring|30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.
16570395|NCT02809534|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16570396|NCT02809521|Other|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
16570397|NCT02809508|Experimental|Oily fish|
16570398|NCT02809508|Experimental|Poultry (control)|
16570403|NCT02809469|Experimental|Dose reduction|Eligible patients with apixaban levels persistently above 170ng/mL on two occasions, 2 weeks apart, will undergo apixaban dose reduction.
16570404|NCT02809456|Experimental|Nicorandil|Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral. Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
16570405|NCT02809456|Active Comparator|observation|regular radiotherapy as our protocol
16570406|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
16570407|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
16570408|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
16570409|NCT02809417||LICORNE platform|
16570410|NCT02809417||Control|
16570411|NCT02809391|Active Comparator|Orthotic|Recruited participants will be asked to wear the customizable foot orthotic, from baseline testing to a follow-up at 6 weeks post-baseline. Outcome measures at 6 weeks will be compared to those at baseline.
16570412|NCT02809391|Active Comparator|Orthotic+Textured Top Cover|At 6 weeks post-baseline, participants will received a different orthotic which has a textured material used as its top cover. Testing at 6 weeks post-baseline will determine if acute changes occur as a result of wearing the orthotic with textured top cover. Testing at 12 weeks post-baseline will determine if long-term changes occur as a result of the orthotic with textured top cover.
16570413|NCT02809378|Experimental|Sevoflurane|anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
16570414|NCT02809378|Experimental|sevoflurane, remifentanil, and propofol|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
16570415|NCT02809378|Experimental|Sevoflurane, remifentanil, propofol, and palonosetron|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
16570416|NCT02809365|Other|Libre|FreeStyle Libre users: FreeStyle Libre Flash Glucose Monitoring System is an interstitial glucose monitoring system intended to be replacement for the capillary blood glucose measurement. The system contains several features that distinguish it from exiting sensor technology including no user calibration during 14 days of wear. The sensor is applied to the upper arm of the patient and the hand-held reader is used to scan the sensor to receive glucose result along with historic results with a 15 min frequency for up to 8 hours.
16570417|NCT02809365|Other|SMBG|Self monitoring blood glucose: patients in this arm will measure blood glucose with personal glucometer
16570418|NCT02809352||women tested positive for hrHPV|All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
16570419|NCT02809339||Epithelial ovarian cancer|
16570420|NCT02809326|Experimental|17 week Trauma Management Therapy (TMT)|TMTconsists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups. Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy. Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
16570421|NCT02809326|Experimental|3 week Trauma Management Therapy (TMT)|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
16570422|NCT02809326|Active Comparator|17 week Exposure Therapy Control Arm|The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
16570423|NCT02809313|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct probiotic containing one sachet Lactobacillus rhamnosus per day during 3 month
16570424|NCT02809313|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct placebo containing one sachet placebo (talc power) per day during 3 month
16570425|NCT02809300|Experimental|ankylosing spondylarthritis|
16570426|NCT02809287||study group|patients with left lateral position plus jackknife posture when perform laparoscopic hepatectomy
16570427|NCT02809274||Patients with PV, not newly diagnosed|"Patients with clinically overt PV treated with watchful waiting (with or without aspirin), Phlebotomy (PHL), Hydrea or any other treatment.
~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
16570428|NCT02809274||Newly diagnosed patients with PV|"Patients with clinically overt PV, newly diagnosed, before any treatment and before phlebotomy initiation.
~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
16570429|NCT02809261|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
16570430|NCT02809261|Placebo Comparator|Perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.
16570431|NCT02809248|Active Comparator|coated stent|the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
16570432|NCT02809248|Active Comparator|uncoated stent|the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
16570433|NCT02809235|Experimental|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
16570434|NCT02809222|Other|Patients with MDS at diagnosis|The intervention, specific to the study, is to take blood samples on patients with MDS at diagnosis. A quality of life questionnaire will also be used to monitor patients
16570435|NCT02809222|Other|Patients with MDS in treatment|The intervention, specific to the study, is to take blood samples on patients with MDS receiving treatment. A quality of life questionnaire will also be used to monitor patients
16570436|NCT02809222|Other|Healthy volunteers|The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
16570437|NCT02809196|Active Comparator|1: Tailored, friend and mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Friend and mother are invited to participate."
16570438|NCT02809196|Active Comparator|2: Standardized, friend and mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Friend and mother are invited to participate."
16570439|NCT02809196|Active Comparator|3:Tailored, friend and not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Friend is invited to participate but not mother."
16570440|NCT02809196|Active Comparator|4: Standardized, friend and not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Friend is invited to participate but not mother."
16570441|NCT02809196|Active Comparator|5:Tailored, mother and not friend|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Mother is invited to participate but not friend."
16570442|NCT02809196|Active Comparator|6: Standardized, mother and not friend|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Mother is invited to participate but not friend."
16570443|NCT02809196|Active Comparator|7:Tailored, not friend, not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Neither friend nor mother is invited to participate."
16570444|NCT02809196|Active Comparator|8: Standardized, not friend, not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Mother is invited to participate but not friend. Neither friend nor mother is invited to participate."
16570445|NCT02809196|Other|9: No SMS program|Control Group; no SMS-based educational program
16570446|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
16570447|NCT02809183|Experimental|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
16570448|NCT02809183|Experimental|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
16570449|NCT02809183|Experimental|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
16570450|NCT02809183|Experimental|TRC101 (6g QD)|Administered once daily (QD) for 14 days
16570451|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
16570452|NCT02809170|Active Comparator|Arginine|Endothelial function will be assessed before and after arginine supplementation
16570453|NCT02809170|Active Comparator|Citrulline|Endothelial function will be assessed before and after citrulline supplementation
16570454|NCT02809144|Other|Nerve block|One novel nerve block combination
16570455|NCT02809131|Experimental|Saline irrigation|Saline irrigation
16570456|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
16570457|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
16570458|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
16570459|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
16570460|NCT02809105|Experimental|Part I ASP0456|ASP0456 will be administered orally for 4 weeks.
16570461|NCT02809105|Placebo Comparator|Part I Placebo|Placebo will be administered orally for 4 weeks.
16570462|NCT02809105|Experimental|Part II ASP0456|ASP0456 will be administered orally.
16570463|NCT02809092|Experimental|NK Cells + Chemotherapy Starting|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.
~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
16570464|NCT02809079|Experimental|Mycophenolate mofetil plus prednisone|Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd
16570465|NCT02809066|Experimental|Interventional group|8-week follow- up with dietary sufficient calcium intake
16570466|NCT02809066|No Intervention|Control group|8-week follow- up with no specific diet
16570467|NCT02809053|Experimental|SAIT101|
16570468|NCT02809053|Active Comparator|MabThera®|
16570469|NCT02809040||Hypertensive Heart Disease|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
16570470|NCT02809040||Volunteer subjects|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
16570471|NCT02809040||Diagnosed Hypertension|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
16570472|NCT02809027|Active Comparator|Ginger|Ginger capsule (500 mg), oral form, 2 capsules 3 time after meal for 3 days
16570473|NCT02809027|Sham Comparator|Placebo|Placebo capsule, oral form, 2 capsules 3 time after meal for 3 days
16570474|NCT02809014|Placebo Comparator|Placebo|Dentifrice without fluoride and tara gum.
16570475|NCT02809014|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
16570476|NCT02809014|Placebo Comparator|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
16570477|NCT02809014|Experimental|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
16570478|NCT02809014|Experimental|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
16570479|NCT02809001|Experimental|Experimental: Fat grafting|Autologous fat graft transplantation subdermally to expanded skin.
16570480|NCT02809001|No Intervention|Control|Expansion was discontinued until the early signs of complication disappeared.
16570481|NCT02808988|Active Comparator|group A|periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
16570482|NCT02808988|Active Comparator|group B|periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection
16570483|NCT02808988|Active Comparator|group C|no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
16570484|NCT02808988|Active Comparator|group D|no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection
16570485|NCT02808975|Placebo Comparator|Placebo|"Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week
~Period B: Weeks 13-14- 1 SC injection each week
~Period C: Weeks 15-23- 1 SC injection each week"
16570486|NCT02808975|Active Comparator|Adalimumab|"Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week
~Period B: Weeks 13-14- 1 SC 40 mg injection each week
~Period C: Weeks 15-23- 1 SC 40 mg injection each week"
16570487|NCT02808962|Other|Cooled Radiofrequency Ablation|"This is a single arm, prospective observational study. All subjects enrolled are patients that meet the inclusion criteria, as deemed by a physician.
~Typical standard of care for these patients is an initial visit followed by two diagnostic blocks ((0.5ml) of 1% Lidocaine per level). Subjects are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve."
16570488|NCT02808949|Experimental|Age Groups|Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
16570489|NCT02808936|Experimental|RIPC group|remote ischemic conditioning group with three cycles of ischemia (5 min) / reperfusion (5 min) of upper or lower limb available with automated RIPC machine using blood pressure cuff
16570490|NCT02808936|Sham Comparator|Control group|No remote ischemic conditioning, but blood pressure cuff applied to the upper or lower limb available
16570491|NCT02808923|Experimental|Foam rolling|"Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6 diameter x 36 length."
16570492|NCT02808923|Experimental|Static stretching|Participants in the static stretching group will perform sustained static hamstring stretching for 2 repetitions of 1 minute bouts for the same leg before switching sides using moderate pressure in supine against the wall. Subjects will rest for 15 seconds between repetitions and adjust distance from the wall to perceive moderate intensity.
16570493|NCT02808923|No Intervention|Control|The control group will perform their regular baseline activities without the addition of a specific lower extremity flexibility program. If the subjects are currently performing stretching of any mode at baseline, they will be allowed to continue with that activity.
16570494|NCT02808910|Experimental|Salt nudge|The following changes will be made in the cafeteria: Salt will be placed in a corner of the buffet, rather than on each dining table. Other spices, without sodium, will be provided on the table. A sign will be placed on the table that nudges participants to try the other spices. Food in the buffet that is high in salt will be labeled with a negative-appearing symbol, and food in the buffet that is low in salt will be labeled with a positive symbol.
16570495|NCT02808910|Experimental|Vegetable nudge|The following changes will be made in the cafeteria: Names of the vegetable dishes in the buffet will be made more attractive. Signs will be placed with reminders to eat more vegetables. Signs will be placed with a visual indication of the percentage of a meal that should consist of vegetables.
16570496|NCT02808910|Experimental|Portion size nudge|The following changes will be made in the cafeteria: Smaller plates will replace the regular plates. Verbal and visual nudges to reduce portion size will be given. Utensils for self-serving calorie-dense foods in the buffet will be smaller than normal.
16570497|NCT02808910|Experimental|Combined nudge|All three nudges are combined in this intervention.
16570498|NCT02808910|No Intervention|Control groups|No changes are made to the cafeteria, compared to the pre-study situation. One control group participates after each of the nudges to control for effects of time of the year.
16570499|NCT02808897|Active Comparator|Standard drainage|The control arm consist of consecutively enrolled cardiac surgery patients receiving < four (4) commercially available standard chest tubes.
16570500|NCT02808897|Experimental|Active Clearance Technology drainage|The test arm consists of consecutively enrolled cardiac surgery patients receiving < two (2) PleuraFlow® chest tubes with Active Clearance Technology® and < two (2) other commercially available standard chest tubes.
16570501|NCT02808884|Experimental|Circulating tumor DNA assay- First test - Negative result|Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
16570502|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Negative result|Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
16570503|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Positive result|Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.
16570504|NCT02808871|Experimental|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
16570505|NCT02808871|Placebo Comparator|Placebo|Placebo for 52 weeks
16570506|NCT02808845||microalbuminuria with eGFR≥60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
16570507|NCT02808845||normal-albuminuria group with eGFR≥60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
16570508|NCT02808845||microalbuminuria group with eGFR<60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
16570509|NCT02808845||normal-albuminuria group with eGFR<60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
16570510|NCT02808832|Experimental|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
16570511|NCT02808832|No Intervention|Usual care|Usual care
16570512|NCT02808819|Other|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
16570513|NCT02808819|Other|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
16570514|NCT02808806|Active Comparator|real-time audio-visual feedback|real-time audio-visual feedback to caregivers (i.e. both in- and outside the hospital) bringing the patient to the location where IVT/IAT is administered . The real time audio-visual feedback consists in information on the actual TSD for a particular patient and whether or not this exceeds pre-set median time delay. The feedback is provided by handhelds in the ambulance and by pre-set monitors on different locations in the participating hospitals.
16570515|NCT02808806|No Intervention|regular care|no real-time audio-visual feedback
16570516|NCT02808793|Experimental|AK002|IV dose of AK002
16570519|NCT02808767|Experimental|Patients treated with Prasugrel|Prasugrel Loading dose: 60 mg Maintenance dose: 10 mg once-daily; patients >75 years of age or < 60 kg of weight receive a maintenance dose of 5 mg o.d.
16570520|NCT02808767|Experimental|Patients treated with ticagrelor|Ticagrelor Loading dose: 180 mg Maintenance dose: 90mg twice-daily
16570521|NCT02808754|No Intervention|Usual Care|Patients in the usual care arm will undergo CEA without RIPC.
16570522|NCT02808754|Experimental|Remote Ischemic Preconditioning|Patients in the RIPC arm will undergo CEA with RIPC.
16570523|NCT02808741|Experimental|F901318 SDD|Liquid formulation
16570524|NCT02808741|Experimental|F901318 IR|Solid formulation
16570525|NCT02808741|Experimental|F901318 IR Fasting|Fasting solid formulation
16570526|NCT02808741|Experimental|F901318 IR Fed|Fed solid formulation
16570527|NCT02808728|Active Comparator|Pain Cocktail with Ropivacaine|"patients given the standard intra-articular pain cocktail injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
~given in one single dose"
16570528|NCT02808728|Experimental|Pain Cocktail with Exparel|"patients given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel, 20cc of 1.3% Exparel, to total 100cc.
~given in one single dose"
16570529|NCT02808702|Experimental|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
16570530|NCT02808689|Active Comparator|Asthma Center|"Use of Currently Accepted Asthma Care Guidelines:
~Assessment and monitoring: the use of objective measures of lung function to assess severity of asthma and to monitor the course of therapy,
~Control of factors contributing to symptom exacerbation: environmental control measures to avoid or eliminate factors that precipitate asthma symptoms or exacerbations,
~Pharmacotherapy: comprehensive pharmacologic therapy for long-term management, and
~Education for partnership in care: patient education that fosters a partnership among the patient, his/her family, and clinicians."
16570531|NCT02808689|Active Comparator|Asthma Center plus Functional Medicine|"All the factors in the Asthma Center Arm plus:
~Address lifestyle factors such as nutrition and exercise that influence long-term health and chronic diseases. The intention is to reduce ongoing biologic imbalances from deficiencies in dietary oxidants/antioxidants via vitamin supplementation, hormonal imbalances through evaluation and management, and the need for medications with unwarranted side effects that compound the chronic medical conditions and adverse effects (e.g. excess use of antibiotics), and to systematically evaluate intolerances to certain foods and additives."
16570532|NCT02808676|Experimental|Exercises+CognitiveTraining+Vitamin D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks."
16570533|NCT02808676|Experimental|Exercises+CognitiveTraining+Placebo D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks."
16570534|NCT02808676|Experimental|Exercises+Control CogTraining+Vitamin D3|Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
16570535|NCT02808676|Experimental|Exercises+Control CogTraining+Placebo D3|Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
16570536|NCT02808676|Placebo Comparator|Placebo exercise+Control Cog+Placebo D3|This will be the comparator arm with control/placebo activities.
16570537|NCT02808663|Experimental|Severe Alcoholic Hepatitis|
16570538|NCT02808650|Experimental|Treatment (prexasertib)|Patients receive prexasertib IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
16570539|NCT02808637|Experimental|Manual Pressure|
16570540|NCT02808637|Experimental|Rapid Injection without Aspiration|
16570541|NCT02808637|Experimental|Manual Pressure + Rapid Injection without Aspiration|
16570542|NCT02808637|Experimental|Control|
16570543|NCT02808624|Experimental|Treatment group|this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
16570544|NCT02808624|No Intervention|Control group|This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
16570545|NCT02808611|Active Comparator|Propranolol|Propranolol is a beta-blocker
16570546|NCT02808611|Placebo Comparator|Placebo|Placebo
16570547|NCT02808598|Experimental|Clinical Trials Education Program|Breast Cancer Clinical Trials Education program is offered to women in the experimental arm. This program was designed to promote increased clinical trials literacy among African American and Hispanic American women. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among these two groups of women who are traditionally underrepresented in breast cancer clinical trials.
16570548|NCT02808598|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of African American and Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
16570549|NCT02808585|Experimental|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
16570550|NCT02808585|Experimental|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
16570551|NCT02808585|Experimental|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
16570552|NCT02808585|Experimental|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
16570553|NCT02808585|Placebo Comparator|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
16570554|NCT02808572|Experimental|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
16570555|NCT02808559|Experimental|Bodystudio ATBM|The PASI of the patients will be evaluated by two dermatologists then by the bodystudio ATBMs.
16570556|NCT02808546||Case Group|All the patients who were diagnosed as gallbladder stone disease with definite clinical symptoms and underwent cholecystectomy in Cheju Halla General Hospital, Jeju, Korea during 2009-2013
16570557|NCT02808546||Control Group|Control group was determined as 1:1 age-sex matched subjects selected from the participants without GBS among Health Promotion Center in the same institute and periods.
16570558|NCT02808533|Experimental|Topiramate|Topiramate will be dispensed on a biweekly basis, and pill counts conducted at each visit.
16570559|NCT02808533|Placebo Comparator|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
16570560|NCT02808520||Hodgkin-lymphoma|Children and adolescents aged 10-18 years
16570561|NCT02808507|Experimental|Facility-based screening|This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
16570562|NCT02808507|Experimental|Contact screening|"This arm is comprised of two sub-arms:
~In the household contact screening sub-arm, a mobile field team visits the household of each consenting newly diagnosed pulmonary TB index case. Each visit consists of a household census, consent of all eligible household members for TB screening, administration of a brief questionnaire, sputum collection for testing with Xpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) and the offer of HIV testing.
~In the incentive-based contact screening sub-arm, all consenting newly diagnosed active TB cases are provided with 10 coupons for free TB screening to give to close contacts. When a contact presents at clinic with a coupon, they and the index case each receive a small amount of money. If the contact is diagnosed with active TB and starts treatment, the index case receives an additional larger amount of money. Each contact receives a brief questionnaire, TB symptom screen, optional HIV testing, and sputum sample collection for Xpert MTB/RIF."
16570563|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia or fetal growth restriction.
16570564|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia or fetal growth restriction.
16570565|NCT02808468|Active Comparator|Brief Cognitive Intervention|One in person session (90 minutes) of trauma focused cognitive therapy followed by 4 weekly coaching calls (20 minutes each) with the same study therapist
16570566|NCT02808468|No Intervention|Assessment Only|Assessment session followed by weekly completion of assessment measures
16570567|NCT02808455|Experimental|Sequence I: A/B|Treatment A: pacritinib 400 mg capsule
16570568|NCT02808455|Experimental|Sequence II: B/A|Treatment B: pacritinib 80 mg solution
16570569|NCT02808442|Experimental|UCART19|
16570570|NCT02808429|Experimental|Placebo|
16570571|NCT02808429|Experimental|Atacicept 25 mg|
16570572|NCT02808429|Experimental|Atacicept 75 mg|
16570573|NCT02808416|Experimental|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
16570574|NCT02808403||Evolocumab exposed|Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.
16570575|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
16570576|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
16570577|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
16570578|NCT02808377|Active Comparator|SPOP|This arm will have the soft silicone pessary inserted post operatively and it will remain in-situ for 3 weeks.
16570579|NCT02808377|No Intervention|Non Intervention|Routine post operative care
16570580|NCT02808364|Experimental|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
16570581|NCT02808351|Experimental|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
16570582|NCT02808351|No Intervention|Blank control|Blank control of berberine administration
16570583|NCT02808338|Active Comparator|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.
~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
16570584|NCT02808338|Experimental|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
16570585|NCT02808338|Active Comparator|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:
~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
16570586|NCT02808338|Active Comparator|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:
~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
16570587|NCT02808325|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
16570588|NCT02808325|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
16570589|NCT02808312|Experimental|Cohort 1: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
16570590|NCT02808312|Experimental|Cohort 1: Normal Hepatic Function|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
16570591|NCT02808312|Experimental|Cohort 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
16570592|NCT02808312|Experimental|Cohort 2: Normal Hepatic Function|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
16570593|NCT02808312|Experimental|Cohort 3: Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
16570594|NCT02808312|Experimental|Cohort 3: Normal Hepatic Function|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
16570595|NCT02808299||all the antigen and antibody of HBV are negative|Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.
16570877|NCT02806531|Experimental|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
16570596|NCT02808299||HBV infection history|One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.
16570597|NCT02808299||HBV carriers|One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.
16570598|NCT02808286|Experimental|Hybrid|"The hybrid emotion-focused treatment consists of 10-15 individual 1/1,5 hour sessions. It includes the following stages (examples of methods in parathesis)
~Stage I. Analysis of emotions and pain (Validation, Compassion, Chain analysis, Values & goals).
~Stage II. Developing skills (Dialectics, Self-validation, Self-compassion, emotion regulation skills).
~Stage III. Exposure training (Exposure for emotionally sensitive stimuli, exposure in vivo for avoided movements).
~Stage IV. Maintenance (Identifying key elements, Planning for flare-ups)."
16570599|NCT02808286|Active Comparator|internet Cognitive Behavior Therapy (iCBT)|CBT pain treatment, delivered via the internet consists of 8, weekly, modules and includes topics such as pain education, pain coping strategies (e.g. pacing), relaxation, cognitive restructuring, problem solving, stress and sleep management, conflict resolution. Patients read materials included in each module and do homework tasks on which they report back to the therapist via the internet. The therapist gives written feedback and guidance after each module. See reference for details.
16570600|NCT02808273||Retrospective control|Patients who had received enoxaparine as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
16570601|NCT02808273||Prospective Cohort|Patients who will receive bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
16570602|NCT02808247|Experimental|Experimental arm (arm A): Nintedanib|Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.
16570603|NCT02808247|Active Comparator|Standard arm (arm B): Ifosfamide|Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.
16570604|NCT02808234|Other|Nucel treatment group|One or two level lumbar interbody fusion surgery with Nucel
16570605|NCT02808208|Experimental|Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)
16570606|NCT02808208|No Intervention|No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Patients receive standard of care.
16570607|NCT02808208|Experimental|Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF
16570608|NCT02808208|Experimental|AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF
16570609|NCT02808208|Placebo Comparator|Placebo treatment in brachiobasilic arteriovenous fistula|Subjects will receive placebo at first and second stage of BBF
16570610|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
16570611|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
16570612|NCT02808182|Other|A0: PET/scan with [11C] palmitate|A bolus of 180 MBq of [11C]-acetate at time 90min and PET acquisition
16570613|NCT02808182|Other|A1: PET/scan with [11C] palmitate|A bolus injection of 180 MBq of [11C]-acetate at time 90min, followed by PET acquisition
16570614|NCT02808182|Other|B0: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.
16570615|NCT02808182|Other|B1: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA followed by a PET acquisition at time 90 min.
16570616|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
16570617|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
16570618|NCT02808143|Experimental|Treatment (pembrolizumab, BCG solution)|"PRE-INDUCTION PHASE: Patients receive pembrolizumab intravesically once on day -14.
~INDUCTION PHASE: Patients receive BCG solution intravesically once weekly for 6 weeks at weeks 0-5 and pembrolizumab intravesically every 2 weeks at weeks 0, 2, and 4.
~MAINTENANCE PHASE: Beginning 2 weeks after the last dose of BCG solution, patients receive pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then receive pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses."
16570619|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
16570620|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
16570621|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
16571457|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
16570622|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
16570623|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
16570624|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
16570625|NCT02808117||Targeted initially|Children who were in the Haiti villages and targeted by the MFI program with MNP delivery initially.
16570626|NCT02808117||Targeted later|Children who were in the Haiti villages and not targeted by the MFI program with MNP delivery until later.
16570627|NCT02808104|Experimental|Mazindol Controlled Release|Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
16570628|NCT02808104|Placebo Comparator|Placebo|Matching placebo
16570629|NCT02808091|Experimental|Early stage (IB or bulky disease - II)|who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
16570630|NCT02808091|Experimental|Advanced stage (III - IV)|will receive only chemotherapy alone
16570631|NCT02808078|Experimental|Augmented reality training|Gait training with augmented reality
16570632|NCT02808078|Active Comparator|Standard training|Gait training without augmented reality
16570633|NCT02808065||Tacrolimus + Mycophenolate mofetil|
16570634|NCT02808052|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
16570635|NCT02808039||DAPT patients|Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.
16570636|NCT02808026|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
16570637|NCT02808013|Experimental|NDS-446|NDS-446
16570638|NCT02808013|Placebo Comparator|Placebo|Placebo
16570639|NCT02808000|Active Comparator|Group 1 (also called Group A )|Group 1/A will use standard catheter during the first ~6 months (observational period 1). Then the patients in this group will switch to the noble metal alloy urinary catheter (BIP Foley catheter of latex or silicone produced by Bactiguard AB) and be observed for another ~6 months (the second observational period).
16570640|NCT02808000|Experimental|Group 2 (also called Group B)|Group 2/B will use the BIP Foley (latex or silicone) during the first ~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another ~6 months (the second observational period).
16570641|NCT02807987|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
16570642|NCT02807974|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
16570643|NCT02807961|Placebo Comparator|Placebo|Placebo comparator arm
16570644|NCT02807961|Active Comparator|Active treatment|ELX-02, active comparator
16570645|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
16570646|NCT02807935|Other|OCT imaging of surgical/pharmacological/laser branch|"to evaluate the effect on the conventional outflow pathway, and specifically on the Schlemm's canal (SC) anatomy in the surgical branch:
~Before and after trabeculotomy
~Before and after cataract surgery
~Before and after vitrectomy surgery
~Before and after XEN™ Gel Stent implant
~pharmacological branch-
~Before and during the treatment with prostaglandins analogs
~Before and during the treatment with alpha blockers
~Before and during the treatment with beta blockers
~Before and during the treatment with carbonic anhydrase inhibitor
~laser branch-
~Before and after trabeculoplasty
~Before and after laser iridotomy
~Before and after yag capsulotomy laser"
16570647|NCT02807922|Active Comparator|Zopiclone|Zopiclone six nights
16570648|NCT02807922|Placebo Comparator|Placebo|Placebo six nights
16570649|NCT02807909|Experimental|BMS-986177 and Itraconazole|Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days
16570650|NCT02807909|Experimental|BMS-986177 and Diltiazem|Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days
16570651|NCT02807896||pancreatic cancer|pancreatic cancer 88
16570652|NCT02807896||bile duct cancer|bile duct cancer 101
16570653|NCT02807896||stomach cancer|stomach cancer 9
16570654|NCT02807896||colon cancer|colon cancer 5
16570655|NCT02807896||normal group|normal group 29
16571458|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of D5W
16570656|NCT02807883|Experimental|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
16570657|NCT02807870|Experimental|Methylphenidate-psychoeducational group|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
16570658|NCT02807870|Experimental|Parental training-placebo pill|Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
16570659|NCT02807870|Placebo Comparator|Psychoeducational group-placebo pill|Weekly psychoeducational groups for parents and placebo pill during 8 weeks.
16570660|NCT02807857|Other|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
16570661|NCT02807844|Experimental|Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W
16570662|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W
16570663|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W
16570664|NCT02807844|Experimental|Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W
16570665|NCT02807844|Experimental|Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W
16570666|NCT02807844|Experimental|Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W
16570667|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)
16570668|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)
16570669|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)
16570670|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)
16570671|NCT02807831|Experimental|Executive functions training|
16570672|NCT02807831|Experimental|Language skills training|
16570673|NCT02807831|Active Comparator|Regular school curriculum|
16570674|NCT02807818|Experimental|Nurse home visits|Nurse biweekly home visit.
16570675|NCT02807818|No Intervention|Usual care|Usual care.
16570676|NCT02807805|Experimental|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
16570677|NCT02807792|Experimental|Perianal access device|
16570678|NCT02807779|Experimental|Dexamethasone|Patients randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
16570679|NCT02807779|Active Comparator|Drug Coated Balloon|Patients randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
16570680|NCT02807766|Experimental|Sensory Integration Training|Behavior modification and Sensory Integration Training
16570681|NCT02807766|Experimental|applied behavioral analysis|Behavior modification and applied behavioral analysis.
16570682|NCT02807766|Experimental|TEACCH|Behavior modification and TEACCH.
16570683|NCT02807766|Other|Behavior modification|Behavior modification.
16570684|NCT02807766|No Intervention|healthy control group|No intervention.
16570685|NCT02807753||Severe Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every 6 months.
~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
16570686|NCT02807753||Mild/Moderate Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every year.
~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
16570687|NCT02807740|Experimental|Virtual Reality|Patients will be treated with a virtual reality rehabilitation program
16570688|NCT02807740|Other|Conventional Rehabilitation Program|Patients will be treated with a conventional rehabilitation program.
16570689|NCT02807727|Active Comparator|Intralipid 20%|Intravenous single bolus of 1.5 ml/kg of Intralipid 20% over 3 minutes.
16570690|NCT02807727|Placebo Comparator|Modified Ringers Lactate|Intravenous single bolus of 1.5 ml/kg of MRL over 3 minutes.
16570691|NCT02807714||No CAD|Patients scheduled for elective cardiac catheterization for evaluation of suspected CAD that are found to not have CAD
16570692|NCT02807714||Obstructive CAD (non-ACS) Group|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have obstructive CAD requiring intervention.
16570693|NCT02807714||Stable CAD, no intervention required|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have non-obstructive CAD not requiring intervention.
16570694|NCT02807714||Acute Coronary Syndrome (ACS)|Patients who undergo an emergent cardiac catheterization for evaluation of known or suspected STEMI, NSTEMI, Unstable Angina (UA).
16570695|NCT02807701|Active Comparator|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy Under general anesthesia, the patient is placed in a supine position with the legs abducted. Carbon dioxide pneumoperitoneum is established using an open technique through a 10-mm trocar over the umbilicus. A 30 telescope is inserted to examine the peritoneal cavity, liver, stomach, and mesentric vessels.Then 4 to 6 more trocars are inserted under direct vision in the epigastrium and upper quadrants
~dissection
~reconstruction"
16570753|NCT02807337|Experimental|Caphosol rinse group|Caphosol consists of two solutions (A and B) which are mixed immediately before use. Caphosol mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
16571550|NCT02801682||Bacterial Sepsis (Bacteremia)|
16571551|NCT02801682||ICU patients without infectious disease|
16570696|NCT02807701|Active Comparator|Open pancreaticoduodenectomy|"Open pancreaticoduodenectomy Abdomen is opened from the Bilateral Subcostal incision. (Chevron's Incision) 2. Abdominal cavity is explored for metastasis especially in liver, base of mesentary, mesocolon and pelvis.
~Dissection Reconstruction Pancreaticogastrostomy Hepaticojejunostomy is next- Done in single layer and can be performed in interrupted or continuous fashion.
~Gastrojejunostomy is the final step of reconstruction."
16570697|NCT02807688|Experimental|Intervention|"Health Promotion Intervention package including elements of psychoeducation on healthy lifestyles and practical sessions of physical activity, with the use of motivational techniques."
16570698|NCT02807688|No Intervention|Control|Control subjects receive treatment as usual at the Community Mental Health Services of the Department of Mental Health.
16570699|NCT02807675|Experimental|CVT-301, levodopa inhalation powder (LIP)|designed to deliver l-dopa to the lung using the CVT-301 inhaler.
16570700|NCT02807675|Placebo Comparator|Placebo|Administered in the same way as the investigational product, except that it does not contain l-dopa.
16570701|NCT02807662|Experimental|Experimental|Intervention mothers receive adapted Seeking Safety intervention delivered by prenatal care advocate over 8 sessions
16570702|NCT02807662|No Intervention|No intervention|Treatment as usual mothers receive usual services of a prenatal care advocate
16570703|NCT02807649|Placebo Comparator|Placebo|Placebo: Methyl cellulose and dextrose
16570704|NCT02807649|Active Comparator|Low dose|This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day
16570705|NCT02807649|Active Comparator|High dose|This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day
16570709|NCT02807623|Experimental|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
16570710|NCT02807623|Placebo Comparator|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
16570711|NCT02807623|Experimental|Compound Exercise of Push-ups|Randomized study participants assigned to Group C will perform an exercise intervention of push-ups immediately after influenza vaccine receipt.
16570712|NCT02807610|Experimental|IV Propofol and IV Etomidate lipuro|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group P Patients received IV Propofol 2mg kg-1 slowly over 60 seconds till Entropy of 40 as a comparator agent in patients undergoing Medical termination of pregnancy(MTP) and Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP
16570713|NCT02807610|Active Comparator|IV Etomidate Lipuro and Placebo|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP and placebo group received normal saline
16570714|NCT02807597|Experimental|Phase I Dose Level 1: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
16570715|NCT02807597|Experimental|Phase I Dose Level 2: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
16570716|NCT02807597|Experimental|Phase I Dose Level 3: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
16570717|NCT02807597|Experimental|Phase I Dose Expansion: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)
~9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
16570718|NCT02807597|Experimental|Phase II: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
16570719|NCT02807584|Experimental|ELECT|Adhesive Foam Dressing
16570720|NCT02807558|Experimental|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6mg/m2/day orally divided into twice a day dosing.
16570721|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with azacitidine|"SY-1425 days 8-28 of a 28-day cycle at 6mg/m2/day orally divided into twice a day dosing.
~Azacitidine 75 mg/m2/day IV or SC days 1-7 of a 28-day cycle in combination with SY-1425."
16570722|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with daratumumab|"SY-1425 during a 7-day lead-in and days 1-28 of a 28 day cycle at 6mg/m2/day orally divided into twice a day dosing.
~Daratumumab at 16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425."
16572524|NCT02795065|Experimental|Bemiparin 3500 IU subcutaneous once daily|
16570723|NCT02807545|Experimental|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.
~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.
~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
16570724|NCT02807545|No Intervention|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
16570725|NCT02807532||atrial fibrillation group|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
16570726|NCT02807532||non-atrial fibrillation group|Patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
16570727|NCT02807519||Oncological patients|Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy . Collection of salivary cytokines will be performed in this group.
16570728|NCT02807519||Control group|Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel. Collection of salivary cytokines will be performed in this group.
16570729|NCT02807506|Experimental|Clinicians, Caregivers and Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept, 2nd mobile base, and 3rd mobile base with arm in daily supportive tasks
16570730|NCT02807493|Experimental|Occlusal Support Device|Support device for women in labor
16570731|NCT02807493|Placebo Comparator|Control|No device given for women in labor
16570732|NCT02807480|Experimental|Exposure-based therapy|Participants will complete 10, 90-minute sessions of Exposure-based therapy, conducted using a group format. Each group will include 8-12 participants. Exposure-based therapy seeks to increase abilities to manage anxiety through repeated practice in facing the situations or thoughts that are the focus of worry or fear. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
16570733|NCT02807480|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen negative mood. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
16570734|NCT02807467|Experimental|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
16570735|NCT02807467|Active Comparator|Propofol|Standard therapy for ICU delirium.
16570736|NCT02807454|Experimental|Daratumumab Plus Durvalumab Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle
~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
16570737|NCT02807454|Experimental|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle
~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward
~oral POM at 4mg/day on days 1 to 21
~oral/IV dex at 40mg/day (>75 years old) or 20mg/day (>75 years old) on days 1, 8, 15 and 22"
16570738|NCT02807441|No Intervention|No aspirin|Patients will not be given any Acetylsalicylic acid in the perioperative period.
16570739|NCT02807441|Experimental|Low-dose aspirin|Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.
16570740|NCT02807441|Experimental|High-dose aspirin|Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.
16570741|NCT02807428|Experimental|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
16570742|NCT02807428|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
16570743|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
16570744|NCT02807389|Experimental|MSC Fistula plug: Single Treatment Group|All patients received treatment of a stem cell coated fistula plug.
16570745|NCT02807376|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
16570746|NCT02807376|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
16570747|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
16570748|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
16570749|NCT02807363|Active Comparator|Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
16570750|NCT02807363|Experimental|Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
16570754|NCT02807337|Active Comparator|0,9% NaCl group.|0,9% NaCl consists of two solutions (A and B). Two vials of 0.9% NaCl will be mixed to maintain blinding. The study mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
16570755|NCT02807324||Controls|Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)
16570756|NCT02807324||Early PE with IUGR|These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
16570757|NCT02807324||Early PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
16570758|NCT02807324||Late PE with IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
16570759|NCT02807324||Late PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
16570760|NCT02807324||HELLP syndrome|Cases consist of women (18 years or older) with HELLP syndrome in the current pregnancy (defined as (1) the presence of microangiopathic hemolytic anemia with abnormal blood smear, low serum haptoglobin and elevated lactate dehydrogenase (LDH) levels, (2) aspartate transaminase (ASAT) above 70 IU/L and lactate dehydrogenase (LD) above 600 IU/L or bilirubin more than 1.2 mg/dL, (3) platelet count below 100 x 10^9 L-1 )
16570761|NCT02807298|Active Comparator|2% Lignocaine (lidocaine)|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine (adrenaline)
16570762|NCT02807298|Experimental|4% Articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine (adrenaline)
16570763|NCT02807272|Experimental|Tipifarnib, Oral|Single arm
16570764|NCT02807259|Experimental|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
16570765|NCT02807259|Other|Control|The intervention will rolled out to all participating villages after 24 months.
16570766|NCT02807246|Active Comparator|Probiotic|Experimental: Breast milk+ Probiotics(Maflor®, Mamsel Pharmaceuticals, Turkey) The study group will be fed with probiotics at a dose of 1x109 CFU/day (Lactobacillus rhamnosus GG 109colony ). Probiotic is in a liquid drop form at a dose of 5 drops a day and is used orally for 10 days.
16570767|NCT02807246|Active Comparator|Saline|Active Comparator: Breast milk+five drops of saline The control group will be given Breast milk without the addition of probiotics
16570768|NCT02807220|Experimental|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
16570769|NCT02807207|Experimental|Sequence I|treatment sequence: A/B/C
16570770|NCT02807207|Experimental|Sequence II|treatment sequence: A/C/B
16570771|NCT02807207|Experimental|Sequence III|treatment sequence: B/A/C
16570772|NCT02807207|Experimental|Sequence IV|treatment sequence: B/C/A
16570773|NCT02807207|Experimental|Sequence V|treatment sequence: C/A/B
16570774|NCT02807207|Experimental|Sequence VI|treatment sequence: C/B/A
16570775|NCT02807194|Experimental|general anesthesia|'lumbar disc herniation'
16570776|NCT02807194|Experimental|spinal anesthesia|'lumbar disc herniation'
16570777|NCT02807181|Active Comparator|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
16570778|NCT02807181|Experimental|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
16570779|NCT02807168|No Intervention|Usual care|Control Group
16570780|NCT02807168|Experimental|Usual care plus NT-proBNP|Experimental Group
16570781|NCT02807155|No Intervention|Non-Intervention Control|No intervention will be delivered.
16570782|NCT02807155|Experimental|Continuity Group|"Continuity Group participants aged 20-21 (i.e. the last year of the LEAP Program) will be seen at one of the 2 study centers - 1) the newly established LAC+USC Diabetes Transition Clinic; or 2) Children's Hospital Los Angeles Pediatric Endocrinology Clinic, and will receive the full 1-year Transition Empowerment Program - Continuity Group"
16570804|NCT02807025||Tuberculosis(TB)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
16572591|NCT02794649||healthy|Individuals without a history of kidney or bowel disease
16570783|NCT02807155|Experimental|Rescue Group|"Rescue Group participants aged 21-25 will be connected to a diabetes healthcare home (medical clinic or doctor's office) in Los Angeles County based on geography and personal preference. Those individuals connected to the LAC+USC Diabetes Transition Clinic will receive the full 1-year Transition Empowerment Program - Rescue Group (TEP-RG). Those assigned to other providers in LA County will have access to the web-based curriculum."
16570784|NCT02807142|Experimental|NC 1 cell therapy|All patients will be treated with the same treatment: NC1 cell therapy
16570785|NCT02807129|Experimental|patients|
16570786|NCT02807116|Experimental|Pacritinib and Rifampin|On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Days 8 through 17, following a 7-day washout period, 600-mg oral doses of rifampin were administered QD. It was anticipated that steady-state concentrations of rifampin would be achieved by Day 17. On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
16570787|NCT02807103|Experimental|Rituximab with FFS=0|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.
~Patients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment"
16570788|NCT02807103|Placebo Comparator|Conventional therapy with FFS=0|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.
~Patients with FFS=0 will receive placebo-rituximab at day 1 and day 15."
16570789|NCT02807103|Experimental|Rituximab with FFS≥1|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.
~Patients with FFS≥1 will receive a total of 9 pulses :
~1 gram of rituximab at day 1 and day 15 as induction treatment
~placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.
~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
16570790|NCT02807103|Active Comparator|Conventional therapy with FFS≥1|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.
~Patients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
16570791|NCT02807090|Experimental|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
16570792|NCT02807090|Experimental|Circular Dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
16570793|NCT02807077|Experimental|Subjects with mild renal impairment|Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
16570794|NCT02807077|Experimental|Subjects with moderate renal impairment|Group 2, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
16570795|NCT02807077|Experimental|Subjects with severe renal impairment|Group 3, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
16570796|NCT02807077|Experimental|Subjects with ESRD|Group 4, will consist of patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.
16570797|NCT02807077|Experimental|Healthy subjects|Group 5, will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.
16570798|NCT02807064|Active Comparator|Bifidobacteria mixture 0.5 ml|Bifidobacteria 0.5 ml per os all days for 2 months
16570799|NCT02807064|Placebo Comparator|placebo|Placebo 0.5 ml per os all days for 2 months
16570800|NCT02807051|Experimental|Pacritinib and Clarithromycin|Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
16570801|NCT02807038|Experimental|Lung function test|Pregnant women performed one spirometry at each trimester of pregnancy
16570802|NCT02807025||Idiopathic Pulmonary Fibrosis(IPF)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
16570803|NCT02807025||Sarcoidosis|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
16571552|NCT02801669|Experimental|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
16570805|NCT02807025||Chronic Obstructive Pulmonary Disease|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
16570806|NCT02807025||Asthma|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
16570807|NCT02807025||Healthy|Nasal, tracheal and bronchial sampling of MLF in patients from healthy controls for comparative data.
16570808|NCT02807012|Experimental|Nursing educational intervention|The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
16570809|NCT02807012|No Intervention|Usual care|The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.
16570810|NCT02806999|Experimental|Berberine; Insulin|"Follow the previous administration program，participants will continue to receive intensive insulin therapy; Besides injecting insulin, participants will receive 500mg berberine twice a day for 8 days.
~Drug: Berberine; Insulin"
16570811|NCT02806999|Active Comparator|Insulin|"Besides receiving intensive insulin therapy, participants will take a placebo twice a day for 8 days.
~Drug: Insulin"
16570812|NCT02806986|Experimental|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
16570813|NCT02806973|Experimental|Nasal Glucagon (NG) - Treatment 1|One dose of 3 milligram (mg) NG administered in one of four study periods.
16570814|NCT02806973|Experimental|NG - Treatment 2|Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.
16570815|NCT02806973|Experimental|NG - Treatment 3|Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.
16570816|NCT02806973|Experimental|NG - Treatment 4|Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.
16570817|NCT02806960|Experimental|Treatment 1|Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).
16570818|NCT02806960|Experimental|Treatment 2|Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.
16570819|NCT02806960|Experimental|Treatment 3|Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.
16570820|NCT02806960|Experimental|Treatment 4|Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.
16570821|NCT02806947|Experimental|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
16570822|NCT02806947|Active Comparator|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
16570823|NCT02806921|Active Comparator|ZenLens with Low limbal clearance|Scleral contact lens designed to provide approximately 25 microns of limbal clearance.
16570824|NCT02806921|Active Comparator|ZenLens with High limbal clearance|Scleral contact lens designed to provide approximately 80 microns of limbal clearance.
16570825|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
16570826|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
16570827|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
16570828|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
16570829|NCT02806882|Experimental|Ceftaroline fosamil|600mg 1 hour intravenous infusion ZINFORO
16570830|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
~Washout period of at least 7 days
~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
16570831|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
~Washout period of at least 7 days
~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
16570832|NCT02806856|Active Comparator|Active tDCS|
16570833|NCT02806856|Sham Comparator|Sham|
16570834|NCT02806843|Experimental|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
16570835|NCT02806830|Experimental|Optive after the second anti-VEGF injection|Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)
16570836|NCT02806817|Experimental|Bevacizumab + ME-344|"Bevacizumab single dose (15 mg/kg infused IV) on day 1. ME-344 will be administered at 10 mg/kg infused IV over 30 minutes on days 8, 15 and 22 (arm 1).
~ME-344 will be suspended in 250 mL sterile saline."
16570837|NCT02806817|Placebo Comparator|Bevacizumab + normal saline|Bevacizumab single dose (15 mg/kg infused IV) on day 1. Placebo: will be administered normal saline 250 mL infused IV over 30 minutes on days 8, 15 and 22 (arm 2).
16570838|NCT02806804|Experimental|one dose test vaccine|One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
16570839|NCT02806804|Experimental|one dose commercially available trivalent influenza vaccine|One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
16570840|NCT02806804|Experimental|One dose quadrivalent influenza virus vaccine|One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
16570841|NCT02806778||Hypoxic brain injury|Consecutive out-of-hospital, post-cardiac arrest patients who remain comatose after successful resuscitation, admitted on ICU of University Hospital Ostrava. The patients will undergo BIS monitor-guided sedation and jugular bulb catheterisation.
16570842|NCT02806765|Experimental|Dietary Supplement|This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol below the upper tolerable limit
16570843|NCT02806765|Experimental|Control|This experimental arm reflects administration of placebo in softgel capsule
16570844|NCT02806752|Experimental|Ranibizumab + Triamcinolone Acetonide|intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg
16570845|NCT02806752|Active Comparator|Ranibizumab|intravitreal injection: Ranibizumab 0.5mg
16570846|NCT02806739|Experimental|Soy Group (Soy Protein + Isoflavones)|"Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones.
~Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet."
16570847|NCT02806739|Placebo Comparator|Control Group (Minimize Soy Intake)|Control Group will avoid soy supplements and minimize intake of soy foods.
16570848|NCT02806726|Experimental|iDesign 1.3-PRESBY|iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
16570849|NCT02806726|Active Comparator|iDesign 1.3|iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
16570850|NCT02806713|Placebo Comparator|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
16570851|NCT02806713|Experimental|phenazopyridine|Patients receiving phenazopyridine
16570852|NCT02806700|No Intervention|Twitter Diabetes Control|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys
16570853|NCT02806700|Experimental|Twitter Diabetes Intervention|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys. This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
16570856|NCT02806674|Experimental|Successful treatment|
16570857|NCT02806674|Experimental|Refractory infection of H.pylori|
16570858|NCT02806661|Experimental|VPRDG for AGC|Vagus nerve-preserving Robot-assisted distal subtotal gastrectomy (VPRDG) with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
16570859|NCT02806661|Active Comparator|CRDG FOR AGC|Conventional Robot-assisted distal subtotal gastrectomy (CRDG) with D2 lymphadenectomy without preserving vagus nerve will be performed for the treatment of patients assigned to this group.
16570860|NCT02806648|Experimental|Palbociclib|Palbociclib
16570861|NCT02806635|No Intervention|Waitlist|Participants are assessed start, during, and end wait list; however, no active intervention is given.
16570862|NCT02806635|Experimental|OurRelationship|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s).
16570863|NCT02806635|Experimental|PREP Online|The PREP Online program is based on the in-person Prevention and Relationship Enhancement Program. The PREP Online program consists of seven sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour.
16570864|NCT02806622||Division II Collegiate Athletes|Student athletes (18-45) currently enrolled and participating on a sports team.
16570865|NCT02806609|Other|Group 1|Cold water immersion, with 10 degrees, for 10 minutes
16570866|NCT02806609|Other|Group 2|immersion in water at room temperature
16570867|NCT02806609|Other|Group 3|active recovery - running
16570868|NCT02806609|Other|Group 4|rest in the chair
16570869|NCT02806596|Other|sevoflurane|"induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde)
~intervention : titration of inspired sevoflurane concentration until targeted bispectral index"
16570870|NCT02806583|Experimental|intervention|telephone based structured support groups
16570871|NCT02806583|No Intervention|control|Active Comparator: Usual care (intervention as experimental group after 3 month (after T1)
16570872|NCT02806570|Experimental|AccuCinch® Ventricular Restoration System|
16570873|NCT02806557||High risk group|"Defined as risk of severe neutropenia >20% or risk of neutropenic infective complications >10%, with severe neutropenia defined as absolute neutrophil count <1.0 x10^9/L.
~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
16570874|NCT02806557||Frequently given regimens|"Defined as high number of cases of neutropenia, but risk of severe neutropenia <5%.
~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
16570875|NCT02806557||Prophylactic GCSF|"Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).
~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
16570876|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
16570878|NCT02806518||Women scheduled for DIEP|Women scheduled for DIEP breast reconstruction after mastectomy due to breast cancer are examined with DIRT, hand-held Doppler and CTA
16570879|NCT02806505|Experimental|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
16570880|NCT02806505|Experimental|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
16570881|NCT02806492|Experimental|Patient for cardiac surgery|All patient undergo the 5 different intervention in a randomised matter.
16570882|NCT02806479||Case: Hypertrophic cardiomyopathy|HCM patients at high risk for ventricular arrhythmia
16570883|NCT02806479||Control I: Healthy|Healthy Controls
16570884|NCT02806479||Control II: Post-MI with arrhythmogenic substrate|Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy
16570885|NCT02806479||Control III: VT/VF-free ischemic cardiomyopathy|Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life
16570886|NCT02806466|Active Comparator|Asthmatic children|
16570887|NCT02806466|Sham Comparator|Non-asthmatic children|
16570888|NCT02806453|Active Comparator|Group A|Group A: Mg alginate/thickened formula
16570889|NCT02806453|Active Comparator|Group B|Group B: thickened formula/Mg alginate
16570890|NCT02806440|Active Comparator|Low dose naltrexone|Low dose naltrexone 4.5 mg/tablet, 1 tablet a day for 21 days
16570891|NCT02806440|Placebo Comparator|Placebo|"Placebo tablet
~1 tablet a day for 21 days"
16570892|NCT02806427||enterally fed adults|Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days.
16570893|NCT02806414|Experimental|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
16570894|NCT02806401|Experimental|landmark|landmark method_subclavian venous cannulation
16570895|NCT02806401|Active Comparator|US_Ax|ultrasound guided axillary venous cannulation
16570896|NCT02806388||tumor tissue for molecular profiling|
16570897|NCT02806375|Experimental|PTCy and ruxolitinib|
16570898|NCT02806362|Experimental|Ombitasvir/paritaprevir/ritonavir (12 weeks)|Ombitasvir/paritaprevir/ritonavir (25/50/100mg once daily) for 12 weeks
16570899|NCT02806349|Placebo Comparator|Control|3g/d Cornstarch and 14g/d wheat bran control
16570900|NCT02806349|Experimental|K-GB&AG|3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend
16570901|NCT02806336|Experimental|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
16570902|NCT02806336|Active Comparator|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
16570903|NCT02806323|Experimental|Yoga Practice|12 week yoga intervention; 45 minutes/weekly practice Participants will be encouraged to practice their prescribed program of yoga at home, daily, for 20 minutes each day.
16570904|NCT02806310||Prospective|Group A: Patients with known BAV who are scheduled to have a cardiac MRI.
16570905|NCT02806310||Historic|Group B: Patients with known BAV who have already had an MRI within the past year
16570906|NCT02806297|Experimental|Early cholecystectomy with IOC|The experimental arm will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
16570907|NCT02806297|Active Comparator|Late cholecystectomy with IOC|The comparator will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
16570908|NCT02806284|Active Comparator|Neurotrauma|Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
16570909|NCT02806284|Active Comparator|Neurosurgery|Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
16570910|NCT02806284|Active Comparator|Control|All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
16570911|NCT02806271|Experimental|Worry Postponement|Two weeks of daily worry postponement
16570912|NCT02806271|Active Comparator|Worry Monitoring|Two weeks of daily worry monitoring
16570913|NCT02806271|No Intervention|Assessment Only Control|No intervention, participants will complete three assessment time points
16570914|NCT02806258|Active Comparator|Arm A|6-8 cycles of Primary systemic therapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
16570915|NCT02806258|Experimental|Arm B|The patients will receive 3D conformal or other modality (eg IMRT, VMAT) APBI during their PST sequence. APBI will be planned sequentially between the Primary systemic therapy cycles, 2 weeks after the 3rd/6 or the 4th/8 cycle of PST.
16571553|NCT02801669|Placebo Comparator|Placebo group|Placebo orally administered once daily.
16570916|NCT02806245|Experimental|Biventricular pacing|Patients will be randomized pre-operatively to either the pacing group or to the control group. Patients randomized to receive pacing will 1st undergo an acute pacing phase where the order of the pacing mode will be randomized and then will continue to an extended pacing phase of biventricular pacing.
16570917|NCT02806245|No Intervention|Control|Controls will receive standard of care treatment consisting of placement of 2 pacing leads (right atrial and right ventricular), monitoring of the study outcomes, monitoring of oxygen consumption and echocardiography, but no pacing.
16570918|NCT02806232|Experimental|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
16570919|NCT02806232|Experimental|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
16570920|NCT02806232|Experimental|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
16570921|NCT02806232|Experimental|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
16570922|NCT02806232|Experimental|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
16570923|NCT02806232|Experimental|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
16570924|NCT02806232|Experimental|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
16570925|NCT02806232|Experimental|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
16570926|NCT02806232|Experimental|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
16570927|NCT02806219|Active Comparator|Certolizumab Pegol injection by prefilled syringe|
16570928|NCT02806219|Experimental|Certolizumab Pegol injection by e-Device|
16570929|NCT02806206|Experimental|Drug: Prucalopride|A single 2 mg dose of prucalopride before ingesting the capsule endoscopy pill.
16570930|NCT02806206|Placebo Comparator|Drug: Placebo|A placebo pill just before ingesting the capsule endoscopy pill.
16570931|NCT02806193||Cardiovascular Magnetic Resonance Imaging|Cardiovascular imaging techniques (other subsidiary techniques such as CT and ECG will also be followed)
16570932|NCT02806180|Experimental|Single-Operator|For the 'Single Operator Ultrasound Guided IV placement' arm the RN operator will use the ultrasound probe to identify the target vein, and continue to hold and adjust the probe while placing the IV.
16570933|NCT02806180|Experimental|Dual-Operator|For the 'Dual Operator Ultrasound Guided IV placement' arm the RN operator will use the US to identify the target vein, at which time the study coordinator will hold the ultrasound probe in position. The RN operator will then place the IV.
16570934|NCT02806167|Experimental|Clinical algorithm|This is a single arm study. All eligible patients will be subject to our clinical algorithm.
16570935|NCT02806154||Elderly cancer patients|Elderly cancer patients treated with chemotherapy will have DEXA
16570936|NCT02806141|Experimental|Aerosolized plus intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
16570937|NCT02806141|Active Comparator|Intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
16570938|NCT02806128|Experimental|Treatment group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .
~Patients need to complete laboratory tests within a specified time."
16570939|NCT02806128|Experimental|Control group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .
~Patients need to complete laboratory tests within a specified time."
16570940|NCT02806115|Experimental|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
16570941|NCT02806102||High-risk|"Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:
~Age ≥ 65 years
~Diabetes mellitus requiring medication
~Documented history of a second prior presumed spontaneous MI (>1 year ago)
~Documented history of angiographic evidence of multivessel coronary artery disease
~Chronic, non-end stage renal dysfunction"
16570942|NCT02806102||Low-risk|Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
16570943|NCT02806089|Experimental|Muscle strength|"single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by Voorrips score questionnaire), inflammatory and nutritional status."
16570944|NCT02806076|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
16570945|NCT02806076|Active Comparator|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
16570946|NCT02806063|Other|Intraoperative samples|During this study of health care procedure evaluating microbiological setting in PJI prior prosthesis implantation with one stage surgery, 3 additional perioperative samples will be performed prior prosthesis implantation for every patient.
16570947|NCT02806050|Experimental|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
16571172|NCT02804373|Active Comparator|24 IU of oxytocin every 3 days|24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days
16570948|NCT02806024|Experimental|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
16570949|NCT02806024|Placebo Comparator|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
16570950|NCT02806011||no Intervention|Long-term follow up of no intervention group
16570951|NCT02806011||1-time injection group|Long-term follow up of 1-time injection group
16570952|NCT02806011||2-time injection group|Long-term follow up of 2-time injection group
16570953|NCT02805998|Experimental|Web-based CBT-I|Sleepio delivers CBT-I through 6 weekly web-sessions (www.sleepio.com). Treatment content is based on CBT for insomnia manuals (Espie et al., 2007, 2008) and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
16570954|NCT02805998|Other|Treatment as Usual|Our control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy. Use of non-study treatment will be tracked.
16570955|NCT02805985|Experimental|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
16570956|NCT02805972|Experimental|Naloxone|4 mg / 0.1 ml naloxone
16570957|NCT02805972|Placebo Comparator|Placebo|0.1 ml saline
16570958|NCT02805959||Constipated, Elderly|Investigation with MTS for motility
16570959|NCT02805959||Constipation, Young|Investigation with MTS for motility
16570960|NCT02805959||Normal Bowel, Elderly|Investigation with MTS for motility
16570961|NCT02805959||Normal Bowel, Young|Investigation with MTS for motility
16570962|NCT02805946|Other|intravenous followed by oral|"Start with posaconazole IV 300mg BID on the first day. Posaconazole will be infused over a period of 90 minutes.
~Days 2-7 patients will receive posaconazole IV 300mg QD.
~Days 8-12 patients will receive posaconazole PO 300mg QD.
~Days 13-16 patients will receive posaconazole PO 200mg QD.
~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
16570963|NCT02805946|Other|oral followed by intravenous|"Start with posaconazole PO 300mg BID on the first day.
~Days 2-7: patients will receive posaconazole PO 300mg QD.
~Days 8-12: patients will receive posaconazole IV 300mg QD. Posaconazole will be infused over a period of 90 minutes.
~Days 13-16 patients will receive posaconazole IV 200mg QD.
~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
16570964|NCT02805920|Active Comparator|GROUP 1 : G20|Postoperative pain for ACLR : G20 : received ACB with 20 ml 0.25% Bupivacaine
16570965|NCT02805920|Active Comparator|GROUP 2 : G25|Postoperative pain for ACLR : G25: received ACB with 25 ml 0.25% Bupivacaine
16570966|NCT02805920|Active Comparator|GROUP 3 : G30|Postoperative pain for ACLR : G30 received ACB with 30 ml 0.25% Bupivacaine
16570967|NCT02805907|Experimental|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
16570968|NCT02805907|Placebo Comparator|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
16570969|NCT02805894|Experimental|NBTXR3 activated by IMRT only|"Part I Dose Escalation
~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:
~- EBRT delivered as 45 Gy in 25 fractions of 1.8 Gy each; to the prostate and seminal vesicles, followed by 34.2 Gy in 19 fractions to the prostate and proximal seminal vesicles , over 9-10 weeks, utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT A)"
16570970|NCT02805894|Experimental|NBTXR3 activated by Brachytherapy & IMRT|"Part I Dose Escalation
~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:
~- Brachytherapy Boost and EBRT delivered as a single fraction of 15 Gy in one day to the prostate by High Dose Rate Brachytherapy followed by EBRT (initiated within 2-4 weeks after completion of Brachytherapy), delivered as 45 Gy in 25 fractions of 1.8 Gy to the prostate and seminal vesicles utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT B)"
16570971|NCT02805881|Experimental|Neurolief System treatment|Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks
16570972|NCT02805868|Experimental|Treatment (siltuximab)|Patients receive siltuximab IV over 60 minutes on day 1. Patients also undergo bone marrow biopsy and aspiration at baseline and at the end of treatment (within 30 days of last siltuximab dose) or as clinically indicated. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are responding after 6 courses may receive additional siltuximab treatment for up to 1 year at the discretion of the study doctor.
16570973|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
16570974|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
16570975|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
16570976|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
16570977|NCT02805842|Active Comparator|Tacrolimus BID|20 patients receiving twice daily (BID) Tacrolimus
16570978|NCT02805842|Active Comparator|Advagraf QD|40 patients randomized to receive once daily (QD) Advagraf
16570979|NCT02805829|Experimental|Trastuzumab + NK cells|"On Cycle 1,day -2, patients will receive IV loading dose 8mg/Kg trastuzumab, followed by collection blood on day 0. After NK expansion and verification that the resulting NK cells meet release criteria, NK cells were washed and resuspended in isotonic sodium chloride for intravenous transfusion on day 14.
~NK cellular therapy conduct 2 cycles per year. The maintenance dose of trastuzumab monotherapy is 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress."
16570980|NCT02805816||Study group|Children with suspicion of CD based on positive serology (TG2 >2 times upper limit of normal) and classical clinical manifestations or belonging to high risk groups, who underwent gastroscopy with intestinal biopsies.
16570981|NCT02805816||Control group|Children without suspicion of CD who underwent gastroscopy and duodenal biopsies for other reasons (abdominal pain, failure to thrive, vomiting, eg)
16570982|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:
~SF12
~Beck
~WOMAC"
16570983|NCT02805790|Experimental|Elamipretide, Then Placebo|Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.
16570984|NCT02805790|Placebo Comparator|Placebo, Then Elamipretide|Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.
16570985|NCT02805777|Experimental|Washing procedure 1|this group will apply washing technique 1
16570986|NCT02805777|Experimental|Washing procedure 2|this group will apply washing technique 2
16570987|NCT02805764|Experimental|Homeoblock functional dental appliance|Removable functional dental appliance to be used at during sleep for one year.
16570988|NCT02805751|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have weight-bearing as tolerated from day 0. They are also instructed to perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
16570989|NCT02805751|Experimental|Early loading|The patients in the early loading group are also allowed to have weight-bearing as tolerated from day 0 and perform tendon strain exercises 3 times each day from 2 weeks after the rupture. The patients in this group will also remove the walker twice a day and use a special training pedal for 5 weeks (until walker removal).
16570990|NCT02805738|Experimental|Experimental Group|once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
16570991|NCT02805738|Active Comparator|Active comparator Group|once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
16570992|NCT02805725|Experimental|Phase 1: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
16570993|NCT02805725|Experimental|Phase 2: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
16570994|NCT02805712|Active Comparator|Control|Participant will receive usual care for Heart Failure patients, which include standard written material on Advanced Care planning and supportive cardiology/palliative care consult if ordered by attending.
16570995|NCT02805712|Experimental|Verbal Information and Discussion|Participants will participate in a guided goals of care conversation and the support of a Palliative Care Social Worker who is working closely with the patients' primary cardiology team. Social worker has ongoing clinical review of participants with a Palliative Care physician who will provide a full medical consult if appropriate.
16570996|NCT02805699|Experimental|Baofeikang Granule|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,cough,give BaoFeikang Granules(by Beijing KangRentang Pharmaceutical Co., Ltd.), 1 bag, twice each day.
16570997|NCT02805699|Placebo Comparator|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,coughand give Chinese medicine placebo (by Beijing Kang Rentang Pharmaceutical Co., Ltd., requirements and Chinese medicine BaoFeikang Granules in appearance and taste similar),1bag，twice each day.
16570998|NCT02805686|Experimental|"En face OCT (C-scan)"|
16570999|NCT02805673|Experimental|OSTEO group|usual medical treatment + 6 osteopathic interventions
16571000|NCT02805673|No Intervention|witness group|usual medical treatment
16571001|NCT02805660|Experimental|Phase 1: Dose Escalation - 50 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
16571002|NCT02805660|Experimental|Phase 1: Dose Escalation - 70 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
16571003|NCT02805660|Experimental|Phase 1: Dose Escalation - 90 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
16571004|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 1|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with no/low programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
16571005|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 2|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with high programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
16571006|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 3|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent with clinical benefit response followed by progression of disease were included in this cohort.
16571007|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 4|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent who had progression of disease ≤ 16 weeks after initiation of treatment were included in this cohort.
16571008|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
16571173|NCT02804360|Experimental|therapy|Dexamethasone injection
16572592|NCT02794649||primary hyperoxaluria|Patients diagnosed with type I PH by genetic testing
16571009|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
16571010|NCT02805634|Experimental|Multiple sclerosis|Patients with multiple sclerosis, followed by Dr Dachy within the CHU Brugmann Hospital.
16571011|NCT02805634|Other|Control group|Control group without neurological pathology
16571012|NCT02805621||Subject|Patients with know or suspected coronary artery disease, who underwent both CT angiography and invasive coronary angiography including invasive FFR measurements.
16571013|NCT02805608|Experimental|uPAR PET/CT and FDG PET/MR|One injection of 68Ga-NOTA-AE105 followed by PET/CT and on a separate day one injection of 18F-FDG followed by PET/MRI. Both scans will be evaluated for possible regional lymph node metastases.
16571014|NCT02805595|Experimental|Hypertonic Saline|23.4% Hypertonic Saline injection(s) with a maximum of 0.6cc per treatment. If necessary every two weeks, with a maximum of three treatments.
16571015|NCT02805595|Placebo Comparator|Saline (Placebo)|"If a patient has two active HS sites with fistulas or sinus tracts, patients will be their own control.
~Injection with normal saline (placebo) in one site randomly allocated by side. The subject and ultrasound operator will be blinded to the treatment allocation."
16571016|NCT02805582|Active Comparator|Anterior musculus serratus block|"Proximal nerve block above the second intercostal space between Musculus serratus anterior and Musculus pectoralis minor.
~Intervention: 10ml ropivacain 0.5%"
16571017|NCT02805582|Active Comparator|Subpectoral block|"Distal nerve block under the Musculus pectoralis major at the medial border of the axillary triangle.
~Intervention: 10ml ropivacain 0.5%"
16571018|NCT02805569|Active Comparator|Group A|articulating stylet
16571019|NCT02805569|Active Comparator|group C|conventional stylet
16571020|NCT02805556|Experimental|Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529|Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529
16571021|NCT02805543||diabetes group|34 T2DM patients without vascular complications as diabetes group
16571022|NCT02805543||control group|32 healthy people were recruited as control group
16571023|NCT02805530|Experimental|single arm|"Patients with synchronous metastases at Central Nervous System (CNS), evaluated in less than one week by the Multidisciplinary Committee at National Cancer Institute of Mexico to define the initial treatment. Patients with metastases at other sites than CNS will receive first line systemic treatment, in those EGFR-mutated with tyrosine kinase inhibitors (TKI) and in patients without a driver mutation with first line duplet of chemotherapy based on platin. The type of TKI or chemotherapy will be at discretion of the treating physician.
~After 4 cycles of treatment, patients with stable disease or partial response will be evaluated by de Multidisciplinary Committee to establish the type of radical treatment to the primary and to the metastases, radiation therapy and chemoradiotherapy."
16571027|NCT02805491||with hypospadias|parent-child triads as cases (male newborns with hypospadias)
16571028|NCT02805491||without hypospadias|parent-child triads as controls (male newborns without hypospadias)
16571029|NCT02805465|Experimental|HBP Group|CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.
16571030|NCT02805465|Active Comparator|BiVP Group|CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.
16571031|NCT02805452|Experimental|Succinate of Solifenacin|1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.
16571032|NCT02805452|Placebo Comparator|Placebo of Succinate of Solifenacin|1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.
16571033|NCT02805439|Experimental|S47445 15mg|
16571034|NCT02805439|Experimental|S47445 50mg|
16571035|NCT02805439|Placebo Comparator|Placebo|
16571036|NCT02805426|Experimental|Tranexamic acid|1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
16571037|NCT02805426|Placebo Comparator|Placebo|oral placebo + 800 mcg sublingual misoprostol
16571038|NCT02805413|Other|DETERMINATION OF BLOOD PRESSURE|"determination and comparison of blood pressure by/with :
~Pulse Curve Analysis
~Inert gas re-breathing
~Central blood pressure device
~Vascular ultrasound device
~Thoracic Impedance (ICG) - Electrocardiography (ECG) - Phonocardiography (Phono) - Carotid plethysmography (Pneumo)"
16571039|NCT02805400|Other|Neurocognitive performance|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.
~For these methods only commercially available CE marked devices will be used."
16571040|NCT02805387|No Intervention|no treatment|Dystocic women where no bicarbonate was given
16571041|NCT02805387|Experimental|Treatment|Dystocic women where bicarbonate was ingested
16571042|NCT02805374|Experimental|ASP1517 fasting then fed|Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
16571043|NCT02805374|Experimental|ASP1517 fed then fasting|Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
16571044|NCT02805348||Chronic kidney disease|Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
16571045|NCT02805335|No Intervention|Control group|Group with the sutureless device actually used
16571046|NCT02805335|Experimental|Innovative group|Group with the new device ( KTFIX PLUS)
16571047|NCT02805322|Experimental|Temporal Temperature Measurement|Infrared Temporal Temperature Measurement using the ARC InstaTemp MD in three different age groups with a specified percentage reporting as febrile.
16571048|NCT02805322|Active Comparator|Tympanic and/or Sublingual Temperature|"Tympanic and/or Sublingual Temperature Measurement using one or both of two widely used reference clinical thermometers in three different age groups with a specified percentage reporting as febrile.
~Choice between Tympanic and/or Sublingual is determined based on standard of care in study site
~Reference Thermometer 1 - Covidien Genius 2 Tympanic Thermometer
~Reference Thermometer 2 - Welch Allen SureTemp Plus Sublingual Thermometer"
16571049|NCT02805309|Experimental|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
16571050|NCT02805309|Experimental|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
16571051|NCT02805309|Active Comparator|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
16571052|NCT02805296|Active Comparator|Double light|"High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below.
~Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm"
16571053|NCT02805296|Active Comparator|Single light|High-intensity phototherapy with blue LED light from above. Intervention: Light irradiance: 66 µW/cm2/nm
16571054|NCT02805283||Dapagliflozin, dapagliflozin/met ER|Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
16571055|NCT02805283||Sulfonylurea|Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
16571056|NCT02805270|Experimental|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
16571057|NCT02805270|No Intervention|usual care|Usual care provided by ward pharmacist, nurses and doctors in the ward
16571058|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
16571059|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
16571060|NCT02805244|Experimental|JTZ-951, 14C-JTZ-951|Single oral administration on Day 1; 10 mg JTZ-951, 100 μCi of 14C-JTZ-951
16571061|NCT02805231||primary open-angle glaucoma patients|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
16571062|NCT02805231||randomly age-matched people|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
16571063|NCT02805218|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
16571064|NCT02805205|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
16571065|NCT02805192|Other|one Arm: size measurement by Smart phone App|
16571066|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
16571067|NCT02805166|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
16571068|NCT02805153|Experimental|Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
16571069|NCT02805153|Active Comparator|Active Comparator/rhG-CSF|patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day. Injections on day 3 after chemotherapy and continued daily until an ANC of at least 10.0 X 10^9/L was documented after the expected nadir, or for a maximum of 14 days
16571070|NCT02805140|Experimental|Virtual exercise and mobile apps|Participants randomized to the intervention arm will join a virtual group convenient for them. They will plan and participate in 8 weeks (every week day) of virtual exercise sessions. Sessions will all be under 30 minutes and include a brief check in amongst participants. The investigators will provide links to information on physical activity and links to online resources for being active.
16571071|NCT02805140|Active Comparator|Exercise resources and information|The investigators will provide links to information on physical activity and links to online resources for being active. Women will be invited to join the exercise groups at the end of the 8 weeks.
16571072|NCT02805127||Patients with COPD and Asthma .|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.
~All clinical diagnoses and treatments will be performed according to the department's protocols.
~This is an observational study with no interventions"
16571073|NCT02805114||Asthma and COPD patients|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken from the subjects with at least two minutes recording before the first spirometry assessment.
~All clinical diagnoses and treatments will be performed according to the department's protocols.
~This is an observational study with no interventions"
16571074|NCT02805101|Experimental|Biodentine|The perforation area of the root is going to be covered by Biodentine
16571075|NCT02805101|Active Comparator|MTA|The perforation area of the root is going to be covered by MTA.
16571076|NCT02805088|Experimental|Bipolar Disorder patients|
16571077|NCT02805088|Experimental|Schizophrenia patients|
16571078|NCT02805088|Experimental|Healthy Volunteers|
16571079|NCT02805075|Experimental|Supportive care (Fructooligosaccharide)|Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
16571080|NCT02805062||Pleural Effusion|Malignant pleural effusion patients requiring investigation with thoracoscopy.
16571081|NCT02805049|Experimental|The study population|The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).
16571082|NCT02805036||30 cmH20 for 30 seconds|"plateau pressure is hold on at 30 cmH20 pour 30 seconds. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.
~echocardiography - arterial oximetry"
16571083|NCT02805036||10 cmH20 above|"plateau pressure is hold on at 10 cmH20 above. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.
~echocardiography - arterial oximetry"
16571084|NCT02805023|Placebo Comparator|Placebo|Intramuscular injection of control medium only
16571085|NCT02805023|Experimental|BGC101|Intramuscular injection of BGC101 (autologous EnEPC preparation)
16571086|NCT02805010|Experimental|Subcutaneous(SC) Abatacept|
16571087|NCT02805010|Placebo Comparator|Placebo|
16571088|NCT02804984||ICUS|idiopathic cytopenia of undetermined significance (ICUS)
16571089|NCT02804958||STEMI treated with primary PCI|Patients diagnosed with acute ST-segment elevation myocardial infarction and treated with primary percutaneous coronary intervention were consecutively registered.
16571090|NCT02804945|Experimental|Mesenchymal Stem Cells|"Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).
~Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
16571091|NCT02804932|Experimental|Beetroot crystals (nitrate)|Participants will receive a nitrate rich beetroot powder (10g/day) for 8 weeks.
16571092|NCT02804932|Placebo Comparator|Placebo (beetroot powder, no nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 8 weeks.
16571093|NCT02804919|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
16571094|NCT02804906|Experimental|Home-Based Physical Therapy|
16571095|NCT02804906|Active Comparator|Control-30-minute counseling session|Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge.
16571096|NCT02804893|Active Comparator|VATS GROUP|VATS lobectomy or segmentectomy
16571097|NCT02804893|Active Comparator|RATS GROUP|Robotic lobectomy or segmentectomy
16571098|NCT02804880|Experimental|Group A|HAR + AWARD + Referral Card + A4 leaflet
16571099|NCT02804880|Experimental|Group B|LTM + AWARD + Referral Card + A4 leaflet
16571100|NCT02804880|Active Comparator|Group C|Brief advice + 12-page booklet
16571101|NCT02804867||Depression|
16571102|NCT02804867||Bipolar disorder|
16571103|NCT02804867||Control|
16571104|NCT02804854|Experimental|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
16571105|NCT02804841|Experimental|Intervention|Healthy, Community Dwelling; Aged 60-80 years; Cholecalciferol -Vitamin D3, 4000 international units (IU) on alternating days.
16571106|NCT02804841|Placebo Comparator|Placebo|Healthy, Community Dwelling; Aged 60-80 years; Placebo -gel capsule containing no vitamin D on alternating days.
16571107|NCT02804828|Active Comparator|Arm 1|
16571108|NCT02804828|Sham Comparator|Arm 2|
16571109|NCT02804815|Active Comparator|Aspirin 100mg|Aspirin 100mg
16571110|NCT02804815|Placebo Comparator|Placebo 100mg|100mg Placebo
16571111|NCT02804815|Active Comparator|Aspirin 300mg|Aspirin 300mg
16571112|NCT02804815|Placebo Comparator|Placebo 300mg|300mg Placebo
16571113|NCT02804776|Experimental|Gefitinib|Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery
16571114|NCT02804763|Placebo Comparator|Placebo|Placebo in a specified sequence for a total of 24 weeks
16571115|NCT02804763|Experimental|DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
16571116|NCT02804763|Experimental|DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
16571117|NCT02804763|Experimental|DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
16571118|NCT02804750|Experimental|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
16571119|NCT02804750|Experimental|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
16571120|NCT02804737||Web Group|Patients given web site (aiddly) instructions for colonoscopy
16571121|NCT02804737||Paper Group|Patients given paper instructions for colonoscopy
16571122|NCT02804724||Newly diagnosed individuals with HIV|Individuals newly diagnosed with HIV in Grampian between January 2009 and December 2014
16571123|NCT02804711|Experimental|Four doses of low dose vaccine|four doses of 15µg/0.6ml per dose
16571124|NCT02804711|Experimental|Four doses of middle dose vaccine|four doses of 30µg/0.6ml per dose
16571125|NCT02804711|Experimental|Four doses of high dose vaccine|four doses of 60µg/0.6ml per dose
16571126|NCT02804711|Experimental|Three doses of low dose vaccine and one dose of placebo|three doses of 15µg/0.6ml per dose and one dose of placebo
16571127|NCT02804711|Experimental|Three doses of middle dose vaccine and one dose of placebo|three doses of 30µg/0.6ml per dose and one dose of placebo
16571128|NCT02804711|Experimental|Three doses of high dose vaccine and one dose of placebo|three doses of 60µg/0.6ml per dose and one dose of placebo
16571129|NCT02804711|Placebo Comparator|Four doses of placebo|four doses of placebo
16571168|NCT02804399|Experimental|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
16571169|NCT02804386|Experimental|treatment|Sofosbuvir, 400 mg OD for 6 months
16571170|NCT02804373|Placebo Comparator|placebo daily|daily administration of placebo during 28 days : placebo continuous
16571171|NCT02804373|Active Comparator|24 IU of oxytocin daily|24 IU of daily oxytocin administration during 28 days : oxytocin continuous
16571130|NCT02804698|Experimental|Meta Salud Diabetes-Intervention|"Attend the thirteen weekly educational classes and physical activity group (prior physician approval) that are part of the Meta Salud Diabetes program.
~Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.
~Respond to a survey about your nutrition and physical activity habits on three separate occasions (at the start of the 13-week program, just after you finish the program, and nine months after you finish the program).
~You may also be invited to participate in a follow-up interview, where you will be asked about your experience during and after the Meta Salud Diabetes program."
16571131|NCT02804698|No Intervention|Meta Salud Diabetes-Comparison Group|"Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.
~Respond to a survey about your nutrition and physical activity habits on three separate occasions (you will answer the first survey as soon as you finish reading and agree to participate by signing this form, the second survey will be three months from now, and the third survey will be 12 months from now)."
16571132|NCT02804685|No Intervention|Control|It consists on only a regular training performance
16571133|NCT02804685|Experimental|Experimental|It consists on performing the protocol which includes 6 strength, agility and balance exercises together with the regular training. The exercise program has to be performed twice a week during 6 weeks
16571134|NCT02804646|Experimental|endostar and chemotherapy group|recombinant human endostatin(endostar) injection was continuous intravenous transfusion for 7 days,with the dose of 15mg/m2 per one day,every 21 days of a cycle,combined with pemetrexed plus cisplatin or carboplatin.
16571135|NCT02804646|Active Comparator|chemotherapy group|pemetrexed injection was intravenous with the dose of 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin,without recombinant human endostatin.
16571136|NCT02804633|Active Comparator|IV acetaminophen group|In addition to PCA (morphine or hydromorphone) all patients receive 1 gram of IV acetaminophen (100 ml ) 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge.
16571137|NCT02804633|Placebo Comparator|Placebo Group|In addition to PCA (morphine or hydromorphone) all patients received placebo (100 ml normal saline) given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge
16571138|NCT02804620|Experimental|PLEASED|The PLEASED intervention arm will receive peer leader who is patients with diabetes that has been gone through our trainings. Also, they will receive three free health screenings (baseline, 3 months, 12 months) and monetary compensation for their time and effort.
16571139|NCT02804620|No Intervention|Wait List|The wait list will receive three free health screening (at baseline, 3months, 12 months) and monetary compensation for their time and effort.
16571140|NCT02804607||skin lesion|severe skin traumatism occurring during childhood and which had required an initial graft.
16571141|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
16571142|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
16571143|NCT02804581|Experimental|Gum Arabic|Oral intake of 30 gram of Gum Arabic daily for 12 weeks
16571144|NCT02804568|Experimental|Group 1|Olanzapine/samidorphan 10 mg/10 mg
16571145|NCT02804568|Experimental|Group 2|Olanzapine/samidorphan 20 mg/10 mg
16571146|NCT02804555|Active Comparator|Oxygen support|5 liter / minute oxygen has given to the mothers on face mask.
16571147|NCT02804555|No Intervention|Room air|Oxygen support has not given to the mothers.
16571148|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
16571149|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
16571150|NCT02804529|Experimental|Meng's Point entry|Meng's entry involved a 0.2 cm horizontal or vertical incision using the Veress needle in the cross of lateral border of the left rectus abdominis and rib arch.
16571151|NCT02804529|Experimental|Palmer's Point entry|Palmer's entry involved a 0.2 cm horizontal or vertical incision with the Veress needle in the left midclavicular line approximately 3 cm caudal to the 10th rib
16571152|NCT02804529|Experimental|Periumbilllicus entry|Periumbilllicus entry involved a 0.2 cm horizontal or vertical midline incision using the Veress needle in the lower or uper border of the umbilicus.
16571153|NCT02804516|Experimental|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
16571154|NCT02804516|Experimental|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
16571155|NCT02804503|Experimental|Calorie Labels|A menu with rank ordered calorie labels and a statement on the energy needs per meal.
16571156|NCT02804503|Experimental|Exercise Labels|A menu with rank ordered exercise labels showing minutes of brisk walking necessary to burn the food calories.
16571157|NCT02804503|Active Comparator|No Labels|A menu with no labels
16571158|NCT02804490|Placebo Comparator|White maize|Conventional maize flour
16571159|NCT02804490|Experimental|Biofortified maize|Provitamin A carotenoid biofortified maize flour
16571160|NCT02804490|Active Comparator|Fortified maize|Retinyl palmitate fortified maize flour
16571161|NCT02804451|Experimental|Intubation without chest compression|normal airway, without chest compression during intubation.
16571162|NCT02804451|Experimental|Intubation with uninterrupted chest compression|normal airway, with continuous chest compressions
16571163|NCT02804425|Experimental|"actor-spectator group"|actor at least once during the immersive simulation session
16571164|NCT02804425|No Intervention|"spectator-only group"|observer during the whole one-day session but participation in the debriefing part of the four scenarios
16571165|NCT02804412|Active Comparator|Control group|Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
16571166|NCT02804412|Experimental|CIAT-group|Patients received constraint-induced aphasia therapy.
16571167|NCT02804412|Active Comparator|communication treatment group (CTG)|Patients received aphasia group therapy without constraints
16571396|NCT02802592|Active Comparator|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
16571174|NCT02804347||Patient|Patients will be receiving either ECT or iTBS as a depression management. Olfactory functioning will be assessed at pre-treatment and 6 weeks later at post-treatment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
16571175|NCT02804347||Control|Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
16571176|NCT02804334||Healthy Volunteers|Participants with no current or lifetime psychiatric disorders
16571177|NCT02804334||Untreated Bipolar Disorder|Participants who meet criteria for current bipolar disorder but who are not currently taking any psychotropic medications
16571178|NCT02804308|No Intervention|Group Control with breast cancer and without breast cancer|Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months
16571179|NCT02804308|Experimental|Combined Training with breast cancer and without breast cancer|Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
16571180|NCT02804295|Other|Collaborative Care Intervention|All enrolled participants received the collaborative care intervention over 6 months.
16571181|NCT02804282|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
16571182|NCT02804269||Healthy Volunteer|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
16571183|NCT02804269||Dilated Cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
16571184|NCT02804269||Hypertrophic cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
16571185|NCT02804269||Ischemic heart disease with reduced EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
16571186|NCT02804269||Ischemic heart disease with normal EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
16571187|NCT02804243|Active Comparator|nasal high flow therapy|In this group, patients have undergone rehabilitation under the nasal high flow therapy (FiO2 100%, oxygen flow from 30 to 60 L/min) during four weeks.
16571188|NCT02804243|No Intervention|oxygen therapy|In this group, patients have undergone rehabilitation under the oxygen therapy via a nasal canula (6 L/min) during four weeks.
16571190|NCT02804204||Anti-TNF|
16571191|NCT02804191|Experimental|LO2A|Sodium Hyaluronate
16571192|NCT02804191|Placebo Comparator|Placebo-Controlled|Saline.
16571193|NCT02804178|Experimental|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.
16571194|NCT02804165|Other|Target high-risk subjects or subpopulations for T1D|Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
16571195|NCT02804152|Other|CBT for Chronic Pain|single arm open-label design
16571196|NCT02804139|Active Comparator|Standard care|Standard Care after C-section with no additional physical therapy.
16571197|NCT02804139|Experimental|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization
16571198|NCT02804126|Experimental|TAP (transversus abdominis plane)|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
16571199|NCT02804126|Experimental|QL (quadratus lumborum)|Ultrasound-guided quadratus lumborum block at the end of cesarean section
16571200|NCT02804113|Experimental|Supera Peripheral Stent System|
16571203|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
16571204|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
16571205|NCT02804061|Active Comparator|Full NELIP|This group will receive the full Nutrition and Exercise Lifestyle Intervention Program (two behavior changes) from enrollment until birth and serves as the comparator control (Group A).
16571206|NCT02804061|Experimental|Nutrition followed by Exercise (N+E)|Intervention - Nutrition component only (one behaviour) until 24 week assessment, then the addition of the second behavior change (Exercise component) at 25 weeks, with both behaviours followed until birth (Group B).
16571207|NCT02804061|Experimental|Exercise followed by Nutrition (E+N)|Intervention - Exercise component only (one behaviour) until 24 week assessment, after which there will be the addition of the second behaviour change (Nutrition component), with both behaviours followed until birth (Group C).
16571208|NCT02804048|Experimental|Pelvic Floor Muscle Training|"superficial heat pelvic floor muscle intra vaginal manual therapy. PERFECT scale is applied in 5 sessions and based on the result of each assessment is performed the treatment plan with exercises of the pelvic floor muscles.
~It is performed manual therapy in iliopsoas, diaphragm and piriformis. From the fourth session, initiate treatment with electromyographic biofeedback based on the result of PERFECT scale."
16571209|NCT02804048|Placebo Comparator|Low back|superficial heat low back Manual therapy in piriform, lumbar, iliopsoas and diaphragm.
16571397|NCT02802592|Placebo Comparator|Normal Saline|250 ml normal saline infused over 1 hr
16571210|NCT02804035|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
16571211|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
16571212|NCT02803996|Active Comparator|Part A- Single Dose- 400 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
16571213|NCT02803996|Active Comparator|Part A- Single Dose- 600 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
16571214|NCT02803996|Placebo Comparator|Part A-Single Dose-Placebo|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
16571215|NCT02803996|Active Comparator|Part B-Multiple Dose-400 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
16571216|NCT02803996|Active Comparator|Part B-Multiple Dose-600 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
16571217|NCT02803996|Placebo Comparator|Part B-Multiple Dose-Placebo|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
16571218|NCT02803983||Pediatric hip plate|The children were treated with pediatric hip plate.
16571219|NCT02803983||Cannulated screw|The children were treated with cannulated screw.
16571220|NCT02803957|Experimental|Treatment Group|Subjects with degenerative mitral valve insufficiency treated with artificial chordae implanted using the NeoChord DS1000
16571221|NCT02803957|Active Comparator|Control Group|Subjects with degenerative mitral valve insufficiency treated with standard surgical mitral valve repair
16571222|NCT02803944||Cystic fibrosis patients taking azithromycin|Cystic fibrosis patients taking azithromycin continuously for two years.
16571223|NCT02803931|Experimental|Cardiogoniometry|Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI. The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
16571224|NCT02803931|Active Comparator|12-lead ECG|For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
16571225|NCT02803918|Experimental|Lixisenatide|Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
16571226|NCT02803918|Placebo Comparator|Placebo|Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
16571227|NCT02803905|Active Comparator|standard procedure: intrahepatic|Liver infusion: the islet mixture is delivered slowly via injection through a syringe attached to the catheter in the portal vein or portal vein tributary. Access to the portal vein is achieved by percutaneous transhepatic access under fluoroscopic, ultrasonographic, or real-time CT guidance. Alternatively access to a mesenteric or omental venous tributary of the portal vein can be obtained by mini-laparotomy under general anesthesia (transplant site preference or in the extremely rare circumstance that percutaneous access cannot be achieved). At a minimum, portal pressure will be monitored before and after infusion of the islet product. Portal pressure measurements will be documented in the medical record. Gel foam plugs and/or collagen/thrombin paste will be used to embolize the entire peripheral catheter tract immediately before the catheter is withdrawn, to reduce the chances of bleeding.
16571228|NCT02803905|Experimental|experimental procedure: omentum|Omentum infusion: briefly, islets are spread in the surface of the omentum, in a single omental pouch site. Transplanting in a single site will reduce risks. A single dose of at least 5000 IEQ/KG will be transplanted. The investigators should be able to achieve a meaningful metabolic improvement and prevention of severe hypoglycemia, as previously seen in experience with intraportal islet transplants. Recombinant human thrombin is added to the islets placed on the omentum to promote formation of a gel clot and facilitate adherence to the surface of the omentum. A pouch is then created by folding the omentum. The pouch is secured inn place with stitches.
16571229|NCT02803892|Placebo Comparator|Group 1: Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks
16571230|NCT02803892|Experimental|Group 2: Rapamycin plus Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks
16571231|NCT02803892|Experimental|Group 3: Rapamycin plus Vildagliptin|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks
16571232|NCT02803879|Experimental|Cardiogoniometry (CGM)|All patients attending clinic for follow up appointments following the implantation of a CRT device will be eligible for inclusion in the study. If they consent for enrolment in the study each patient will undergo a series of 4 CGM recordings whilst in their follow up appointment. They will undergo each of these during different pacemaker settings. These are: 1) No pacing, 2) Paced from the right ventricular lead; 3) Paced from the left ventricular lead and 4) Paced from both ventricular leads. After this has been done the participants involvement in the study will have finished.
16571233|NCT02803866||Parents of preterm newborns (25-32 weeks of gestation)|Parents (mother or mother+father) of preterm newborns admitted at the Gregorio Marañón Hospital from birth, recruited during the first 10 days of preterm newborn hospitalization and receiving the training program CAP-PREM
16571234|NCT02803853|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
16571235|NCT02803853|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
16571236|NCT02803840|Other|Experimental|DLBCL patients with indication for palliative radiotherapy
16571237|NCT02803827|Experimental|Rapid diagnostics and probiotic|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
16571238|NCT02803827|Other|Rapid diagnostics and placebo|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.
16571239|NCT02803827|Other|No rapid diagnostics and probiotic|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
16571240|NCT02803827|Placebo Comparator|No rapid diagnostics and placebo|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.
16571241|NCT02803814|Experimental|Superior mesenteric artery approach|Initial approach of the superior mesenteric artery to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
16571242|NCT02803814|Active Comparator|Classic approach|Classic approach to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
16571243|NCT02803801|Experimental|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
16571244|NCT02803788|Active Comparator|Group O|this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.
16571245|NCT02803788|Experimental|Group R|this group will receive inj. ramosetron 0.3mg iv stat just before extubation.
16571246|NCT02803775|Active Comparator|Paced|Paced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
16571247|NCT02803775|Active Comparator|Sensed|Sensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
16571248|NCT02803762|Experimental|Investigational: [14C] Pacritinib|All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg [14C]pacritinib (containing 100 μCi radioactivity).
16571249|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
16571250|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
16571251|NCT02803736|Experimental|Real acupuncture group|Patients in the real acupuncture group will receive true acupuncture 3 times a week for 4 weeks (12 sessions). A standardized prescription of six acupuncture points is used unilaterally. Needles are inserted and manipulated manually until needling sensation (de qi) is obtained, and are retained for 20 minutes with manual manipulation at 10 minutes. Acupuncturists are trained to inquire about specific needle sensations when providing true acupuncture.
16571252|NCT02803736|Sham Comparator|Sham acupuncture group|Patients in the sham acupuncture group will receive sham acupuncture 3 times a week for 4 weeks (12 sessions).
16571253|NCT02803723|Experimental|Holding-cuddling + Sucrose|The Holding-cuddling is started 5 minutes before and the sucrose administration is started 2 minutes before blood sampling.
16571254|NCT02803723|Active Comparator|Sucrose alone|The sucrose administration is started 2 minutes before blood sampling.
16571255|NCT02803710||Case group|patients with decreased susceptibility to carbapenems Enterobacteriaceae isolate
16571256|NCT02803710||Control-group|patients with Enterobacteriaceae isolate without decreased susceptibility to carbapenems
16571257|NCT02803697||Patients|All patients who underwent surgery for a NFPA in Reims university hospital between 01/01/1991 and 31/12/2004
16571258|NCT02803684|Experimental|Single arm|Whole cohort
16571259|NCT02803671|Experimental|patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
16571260|NCT02803671|Experimental|without patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
16571261|NCT02803671|Experimental|patent ductus arteriosus + cardiac or respiratory therapy|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
16571262|NCT02803658|Experimental|infertile couples|smoking behavior
16571263|NCT02803658|Active Comparator|Fertile couples|smoking behavior
16571264|NCT02803645|Experimental|healthy|blood sample
16571265|NCT02803632|Experimental|suicide attempt|questionnaires actigraphic recording
16571266|NCT02803606||hypothermia|Preterm neonates less than 32 weeks of gestational age admitted at birth to the Neonatal Medicine unit
16571267|NCT02803593|No Intervention|Control|165 Asian American breast cancer survivors (55 per sub-ethnic group) who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS). Participants are asked to use the online ACS resources for 3 months.
16571268|NCT02803593|Experimental|Intervention (TICAA)|165 Asian American breast cancer survivors (55 per sub-ethnic group) who use the intervention (TICAA) and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors. Participants are asked to use the TICAA program for 3 months.
16571269|NCT02803567|Experimental|Intervention|Those in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education on substance use. Content in the intervention will focus on health promotion and will deliver positive messages about health.
16571270|NCT02803567|No Intervention|Control|Those in the control arm will receive treatment as usual.
16571271|NCT02803554|Experimental|Young donor plasma|An infusion of plasma derived from donors aged 25 years or younger
16571272|NCT02803541|Experimental|12 day mainstream summer camp experience|The 12 day mainstream camp experience involves increased exercise from baseline at home. Can this exercise and peer contact improve physical endurance as measured by the 6 minute walk test and self concept as measured by a modified Harter scale
16571273|NCT02803528|Experimental|Biodentine|The exposed area of the pulp is going to be covered with Biodentine.
16571274|NCT02803528|Active Comparator|MTA|The exposed area of the pulp is going to be covered with MTA
16571275|NCT02803515|Experimental|Patient with HIPEC|
16571276|NCT02803515|Sham Comparator|Patient without HIPEC|
16571277|NCT02803502|Experimental|hemophilia|Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII
16571278|NCT02803489|Experimental|medical device intervention|
16571279|NCT02803476||Cases|Polycystic ovary syndrome (PCOS) female patients. 20-35 years of age.
16571280|NCT02803476||Controls|Non-PCOs female subjects. 20-35 years of age.
16571281|NCT02803463|Active Comparator|Peritoneal Closure|open appendectomy with peritoneal closure
16571282|NCT02803463|Active Comparator|Peritoneal Non Closure|open appendectomy without peritoneal closure
16571283|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Needle|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via epidural needle followed by catheter placement.
~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.
~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
16571284|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Catheter|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via the epidural catheter administration following catheter placement.
~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.
~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
16571285|NCT02803450|Active Comparator|Low Volume, High Concentration via Epidural Catheter|"Standard of Care Epidural Administration Epidural loading: Participants will receive 10ml of 0.125% bupivacaine with fentanyl 2mcg/ml in 5 ml increments 5 minutes apart via the epidural catheter following epidural catheter placement, per standard of care.
~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.0625% bupivacaine with 2mcg/ml fentanyl. The infusion rate will be set at 10ml/hr basal rate and 4ml every 15 minutes on demand with lockout of 26ml/hr.
~For inadequate analgesia: One additional 5ml boluses of the standard 0.125% bupivacaine with 2mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
16571287|NCT02803424|Experimental|Volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
16571288|NCT02803424|Active Comparator|Autoflow-volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, Autoflow-volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
16571289|NCT02803398|Experimental|Patient at risk of venous thrombosis|
16571290|NCT02803385|Active Comparator|Continous Epidural Analgesia|Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes
16571291|NCT02803385|Active Comparator|Patient Controlled Epidural Analgesia|Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .
16571292|NCT02803372|Experimental|Intervention group|In addition to routine monitoring, invasive LiDCOrapid is used to monitor mean arterial pressure (MAP), stroke volume variation (SVV) and cardiac index (CI). Intraoperative goal-directed circulatory management is performed, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery.
16571293|NCT02803372|Active Comparator|Control group|Routine monitoring is performed, which includes invasive blood pressure and urine output. Intraoperative routine circulatory management is performed, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h.
16571294|NCT02803359|Experimental|Planned Procedure|Endoscope will be connected to a camera and monitor. Needle electrodes will then be positioned into the false vocal fold mucosa bilaterally, under direct visualization of the needle tip on the monitor, but the needles will be passed trans-orally in the operating room. For those participating during an open-neck surgery, the surgery will commence as planned and once exposure of the superior laryngeal nerve is obtained, the surgeon will insert the electrodes directly into the nerve trunk for the purposes of recording. In Surgery or cervical lymphadenectomy, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold.
16571295|NCT02803359|Experimental|Routine Laryngoscopy|Nasolaryngoscopy will be performed in the office in the standard fashion with the use of oxymetazoline for topical decongestion of the nasal mucosa, In both settings, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold
16571296|NCT02803346||septic shock patients|
16571297|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
16571298|NCT02803320|Experimental|SPF 50 Y65 110|All subjects received baseline skin evaluation and 1 day of sun exposure.
16571299|NCT02803307|Experimental|6 mg TLC599|6 mg DSP with 50 μmol PL
16571300|NCT02803307|Experimental|12 mg TLC599|12 mg DSP with 100 μmol PL
16571301|NCT02803294|Experimental|Aortic Stenosis/regurgitation|Transcatheter aortic valve replacement
16571302|NCT02803281||Lung Cancer - Frialty Assessment|Patients who will undergo surgery for lung cancer
16571303|NCT02803281||Esophageal Cancer - Frailty Assessment|Patients who will undergo esophagectomy for esophageal cancer
16571304|NCT02803268|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
16571305|NCT02803268|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
16571306|NCT02803268|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
16571307|NCT02803255|Experimental|Assist-As-Needed Control|"Subjects in this group will interact with a robotic exoskeleton, the MAHI Exo-II, programmed with an adaptive mode. In this mode, the robot will continuously assist motion along pre-defined trajectories, but will employ an assist-as-needed protocol.
~Here, the amount of assistance provided by the robot will not be always the 100% of that required to complete the task (as in the position control mode), but only a fraction of it. The robot will continuously estimate the residual movement capabilities of the subject, depending on the specific joint addressed in the movement, and will estimate the remaining contribution needed to complete the movement following a predefined trajectory, thus avoiding to over-support motion."
16571308|NCT02803255|Active Comparator|Subject-Triggered Control|Subjects in group B will interact with a robotic exoskeleton, the MAHI Exo-II, controlled via the subject-triggered mode, as in a previous clinical trial with the MAHI Exo II robotic system. In the subject triggered mode, the MAHIExo II is commanded to regulate joints motion following a position-control control scheme, and using as desired trajectories standardized single-joints profiles that require motion of one of the axes of the exoskeleton (i.e. elbow flexion and extension, forearm pronation and supination, wrist radial and ulnar deviation, wrist flexion and extension). The switch to position control of the exoskeleton is triggered by the application of sufficient force by the subject, in a previous phase where the robot implements a virtual wall.
16571309|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
16571310|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
16571311|NCT02803216|Experimental|standard triple region|The patients in this group were given 10-day standard triple therapy.
16571312|NCT02803216|Active Comparator|standard triple region +2-week TCM|The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.
16571313|NCT02803216|Active Comparator|standard triple region +4-week TCM|The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.
16571314|NCT02803203|Experimental|osimertinib and bevacizumab|"Phase 1:
~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks
~Phase 2:
~Use MTD determined during phase 1"
16571315|NCT02803190|Experimental|ICG- integrated care group|Integraded Care Group
16571316|NCT02803190|Experimental|MTG- muscle training group|Muscle Traing Group
16571317|NCT02803177|Experimental|BMC2012 + beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical standard, filled with a clinically established scaffold (beta-TCP Chronos® Synthes), and loaded with 1.3 x 10E6 BMC/ml TCP per 1 ml beta-TCP in situ.
16571318|NCT02803177|Placebo Comparator|beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical Standard and filled with a clinically established scaffold (beta-TCP Chronos® Synthes).
16571319|NCT02803164|Other|Vacuum-assisted dressing|Eligible subjects will receive negative pressure wound therapy during surgery.
16571320|NCT02803164|Other|Historical control group for comparison|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
16571321|NCT02803151|Experimental|Stereotactic ablative radiotherapy|Image-guided stereotactic ablative radiotherapy
16571322|NCT02803138||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
16571323|NCT02803125|Active Comparator|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
16571324|NCT02803125|Placebo Comparator|Support group control|This is the comparison group
16571325|NCT02803099|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571326|NCT02803086||1|To date, around 700 patients, who were treated with Radiotherapy for Prostate Cancer, have been enrolled. 34% of them underwent radiotherapy with radical intent, whereas the others were post-prostatectomy patients (29% adjuvant, 37% salvage). Various techniques of irradiation were used (1% 3DCRT, 6% SF-IMRT, 52% VMAT, 41% Tomotherapy) in conventional (42%, 1.7-2.0 Gy/fr.) and hypofractionated (58%, 2.1-2.7 Gy/fr.) settings. EQD2(alpha/beta=3) to prescribed PTV ranged between 64 and 93 Gy. Limph nodes were treated in the 98% of cases.
16571327|NCT02803073|Experimental|Testosterone Replacement|The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.
16571328|NCT02803073|Placebo Comparator|Control|Patients in the control group will receive intramuscular normal saline injections.
16571398|NCT02802579|Active Comparator|A: standard protocol|Standard dual-source computed tomography coronary angiography protocol
16572593|NCT02794649||enteric hyperoxaluria|Patients with Roux-en-Y-gastric-bypass.
16571329|NCT02803060|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571330|NCT02803047|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571331|NCT02803034|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571332|NCT02803021|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571333|NCT02803008|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571334|NCT02802995|Experimental|Treatment arm|Subjects receiving the study drug which is PRP/thrombin mixture
16571335|NCT02802995|No Intervention|Control arm|Subjects receiving the standard of care for chronic venous wounds
16571336|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
16571337|NCT02802956|Experimental|intervention group|Daily Life Promotion Program
16571338|NCT02802956|Experimental|control group|general rehabilitation treatment
16571339|NCT02802943|Experimental|Peptide Vaccine MRD +|MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
16571340|NCT02802943|Experimental|Peptide Vaccine MRD-|MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow <10-4 6-10 weeks after the end of first line treatment)
16571341|NCT02802930|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products (SPF 50 Y65 110,SPF 50 Y51 002, and SPF 15 V27 l 04 compared to that of a negative control [0.9% NaCl]) were tested simultaneously on each subject.
16571342|NCT02802917|Experimental|SPF 50 Y49 091|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
16571343|NCT02802917|Experimental|SPF 50 X15 158|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
16571344|NCT02802917|Experimental|SPF 50 X15 160|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
16571345|NCT02802917|Experimental|SPF 50 X57 162|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
16571346|NCT02802904|Experimental|Palm olein IV 64|Palm olein IV 64, n= 15, 4 weeks intervention
16571347|NCT02802904|Experimental|Cocoa butter|Cocoa butter, n= 15, 4 weeks intervention
16571348|NCT02802904|Experimental|Virgin olive oil|Virgin olive oil, n= 15, 4 weeks intervention
16571349|NCT02802891||Recruitment group|"Group of individuals (aged 6 to 18 years old) recruited for the JOIN project. Consent was obtained from legal guardians for individuals under 18.
~Exclusion criteria:
~Individuals who refused to partake in the clinical assessment, despite the legal guardians consent.
~Individuals who provided an insufficient amount of sample (ex: low volume of EBC)"
16571350|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.
~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
16571351|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
16571352|NCT02802865|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
16571353|NCT02802865|Experimental|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
16571354|NCT02802852|Experimental|Calf Compression, Filgrastim injection|All patients enrolled in the study will undergo pneumatic calf compression though use of the Art Assist device as well as stem cell mobilization through administration of Filgrastim 10 mcg/kg subcutaneously, every 3rd day for 30 days.
16571355|NCT02802839|Experimental|Sperimental|The patient will be shown the headset for VR and a selection of age appropriate virtual realities to immerge in by the nurse not performing the procedure. There will be two lists of VRs to choose from, one for age 6 to 12 and one for age 12 to 18 with the following themes: amusement rides /carousel, space rides, zoo, safari, dinosaurs, city touring, landscapes, caverns. Once the patient is ready to wear the headset the application will start and 120 seconds later the procedure will take place. The nurse performing venipuncture will be a different one than the one handling distraction. Once the procedure ends the video will last for one more minute or up to the child' s desire. Only the first venipuncture attempt will be observed.
16571399|NCT02802579|Experimental|B: enhanced protocol|enhanced dual-source computed tomography coronary angiography protocol
16571356|NCT02802839|No Intervention|Observational|Control intervention When arriving to the CF centre for routine visit that implies also the taking of blood samples, after having obtained the informed consent, a trained nurse of the CF Centre, will apply to each child recruited -in the presence of the parent, who may hold the child- the anesthetic cream. Only the first venipuncture attempt will be observed.
16571357|NCT02802826|Experimental|Tailored Exercise Prescription|"Participants will have a discussion on the 'My Exercise Prescription' booklet on the benefits of increasing levels of physical activity. They will be encouraged to read this in more detail and guided through its completion. The participant will receive an exercise prescription using the Pre-Intervention Assessment Tool (PIAT) and following discussion with the participant on a realistic and achievable starting point.
~The booklets provided will guide participants through the exercise programme which is a graduated walking-based activity intervention. Both booklets provide participants with a suggested starting point for walking distance per week based on their PIAT score as well as motivational and behaviour change strategies to encourage participation."
16571358|NCT02802826|No Intervention|Standard Care|No sham or placebo conditions will be used in the study. At visit 1 standard care participants will be given the Standard Care Information Sheet and asked to simply continue with standard care.
16571359|NCT02802813|Active Comparator|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
16571360|NCT02802813|Placebo Comparator|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
16571361|NCT02802800|Experimental|Water|Plyometric Training in water, twice per week for 6 weeks.
16571362|NCT02802800|Experimental|Land|Plyometric training on land, twice per week for 6 weeks.
16571363|NCT02802787|Experimental|Camp Discovery|One week activity based camp
16571364|NCT02802774|Active Comparator|Plaster Splint|
16571365|NCT02802774|Active Comparator|Velcro Brace|
16571366|NCT02802774|Active Comparator|Soft Dressing|
16571367|NCT02802748|Experimental|Metronomic Vinorelbine + Letrozole|"Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
~Letrozole: 2.5mg daily, for 3 weeks"
16571368|NCT02802748|Active Comparator|Letrozole alone|Letrozole: 2.5mg daily, for 3 weeks
16571369|NCT02802748|Active Comparator|Metronomic Vinorelbine alone|Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
16571370|NCT02802735|Experimental|Part 1: Apremilast 20 mg|A single oral dose of 20 mg apremilast.
16571371|NCT02802735|Experimental|Part 1: Apremilast 30 mg|A single oral dose of 30 mg apremilast.
16571372|NCT02802735|Experimental|Part 1: Apremilast 40 mg|A single oral dose of 40 mg apremilast.
16571373|NCT02802735|Experimental|Part 2: Apremilast 30 mg BID|30 mg apremilast orally twice a day (BID) for 14 days.
16571374|NCT02802735|Placebo Comparator|Part 2: Placebo|Matching placebo orally twice a day for 14 days.
16571375|NCT02802722|Active Comparator|Immediate supplementation|Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
16571376|NCT02802722|Placebo Comparator|Delayed supplementation|Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
16571377|NCT02802709|Experimental|SB-061|SB-061
16571378|NCT02802709|Placebo Comparator|Placebo|Placebo
16571379|NCT02802696|Experimental|Furosemide|Diuretic
16571380|NCT02802696|Placebo Comparator|Placebo|Normal saline
16571381|NCT02802683|Experimental|"BUPI,P"|patients who received hyperbaric bupivacaine and continous infusion of phenylephrine
16571382|NCT02802683|Placebo Comparator|"BUPI,N"|patients who received hyperbaric bupivacaine and continous infusion of normal saline
16571383|NCT02802683|Experimental|"LEVO,P"|patients who received isobaric levobupivacaine and continous infusion of phenylephrine
16571384|NCT02802683|Active Comparator|"LEVO,N"|patients who received isobaric levobupivacaine and continous infusion of normal saline
16571385|NCT02802670|Experimental|GDC-0810|GDC-0810 300-mg dose administered as oral solution, containing approximately 100 microcuries of [14C]-labeled GDC-0810.
16571386|NCT02802657|Experimental|Conbercept 0.5mg Treat-and-Extend regimen|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and Treat-and-Extend Regimen of the same dose guided by BCVA stabilization and optical coherence tomography (OCT) in the extension treatment period.
~Intervention: Drug: Conbercept"
16571387|NCT02802657|Active Comparator|Conbercept 0.5mg Pro Re Nata|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period.
~Intervention: Drug: Conbercept"
16571388|NCT02802644|Experimental|DPP-4 Inhibitor|Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
16571389|NCT02802644|Active Comparator|Non DPP-4 Inhibitor|Oral anti-diabetic medication except DPP-4 inhibitor
16571390|NCT02802631|Experimental|Minocin for Injection (minocycline)|Minocin (minocycline for injection) for will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg. Within each cohort, subjects will receive a single dose on Day 1, followed by 7 days of multiple-doses (Days 4-10, given every 12 hours), followed by a single dose on Day 11.
16571391|NCT02802631|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo is in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection USP). Dosing is to the same schedule as subjects randomized to Minocin (minocycline) for Injection.
16571392|NCT02802618|Experimental|Interactive 3D visualization technique|"The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with 3D technique.
~Patients randomized into education by 3D technique."
16571393|NCT02802618|No Intervention|Conventional technique|The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with conventional technique. Patients randomized into education by conventional technique.
16571394|NCT02802605|Experimental|Bemiparin|Bemiparin 3.500 U, once a day during hospitalization
16571395|NCT02802605|No Intervention|No drug|Clinical practice as usual
16571400|NCT02802579|Experimental|C: enhanced obesity protocol|enhanced obesity-mode dual-source computed tomography coronary angiography protocol
16571401|NCT02802566|Experimental|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
16571402|NCT02802566|Active Comparator|Control|Standard prenatal vitamin provided by the study
16571403|NCT02802553|Experimental|Integrated Imaging Goggles|Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle. Viewed by Smart Googles and compare lesions detected by commercial FDA approved near infrared camera device (SPY Elite/Quest/PDE) in addition to those detected by gamma probe and blue dyes.
16571404|NCT02802540|Experimental|Nabilone|Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.
16571405|NCT02802540|Placebo Comparator|placebo|Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.
16571406|NCT02802527|Other|Bronchoscopy Guided|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
16571407|NCT02802527|Other|Direct Laryngoscopy|Performing percutaneous tracheostomy by placing the tube higher up, near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
16571408|NCT02802514|Experimental|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
16571409|NCT02802514|Experimental|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
16571410|NCT02802514|Experimental|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
16571411|NCT02802514|Experimental|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
16571412|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
16571413|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
16571414|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
16571415|NCT02802488|Experimental|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
16571416|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
16571417|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
16571418|NCT02802462|Experimental|High intensity-interval (HIT)|
16571419|NCT02802462|Experimental|moderate intensity-continuous (MCT)|
16571420|NCT02802462|No Intervention|control (CTL)|
16571421|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
16571422|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
16571423|NCT02802436|Experimental|Extraction with socket graft and GEM21|"Intervention - Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Test site (active arm) will be injected with Bioactive Agent (PDGF - Platelet derived growth factor). At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd.
~Bioactive agent - GEM21S (Growth factor enhanced matrix) Dosage - one cup containing 0.5 cc of ß-TCP particles (0.25 to 1.0 mm); and one syringe containing a solution of 0.5 mL rhPDGF-BB (0.3 mg/mL)"
16571424|NCT02802436|Other|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Normal saline will be used and no growth factor to maintain the volume in control sites
16571425|NCT02802423|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
16571426|NCT02802410|Experimental|IQ-Tape|IQ-application on leg muscles muscles
16571429|NCT02802397|Other|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.
~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
16571430|NCT02802397|Other|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.
~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
16571431|NCT02802384||Cases|People with active Paget's Disease of Bone
16571432|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
16571433|NCT02802371|No Intervention|control group|Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.
16571434|NCT02802371|Active Comparator|Psychosocial intervention|Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
16571435|NCT02802371|Experimental|Pharmaceutical care and psychosocial support|Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
16571436|NCT02802358||Hip fracture|Patients with a hip fracture due to an accidental fall
16571437|NCT02802358||Wrist fracture|Patients with a wrist fracture due to an accidental fall
16571438|NCT02802345|Experimental|Nintedanib + placebo matching sildenafil|
16571439|NCT02802345|Active Comparator|Nintedanib + Sildenafil|
16571440|NCT02802332|Active Comparator|Footlength Card|Pregnant women will receive a card that enables them to measure the length of their baby's foot. The card contains a phone number to pre-recorded message that provides basic information/advice regarding care of preterm and/or low birth weight babies
16571441|NCT02802332|No Intervention|No Footlength Card|Women in this group do receive any footlength card.
16571442|NCT02802319|Experimental|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
16571443|NCT02802319|Active Comparator|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
16571444|NCT02802306|Experimental|Tack Implant|Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.
16571445|NCT02802293|Active Comparator|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
16571446|NCT02802293|Active Comparator|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
16571447|NCT02802293|Active Comparator|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
16571448|NCT02802280|Other|Cardiovascular risk in HCV patients|"Intervention:
~The only intervention to be carried out along the study will consist of a complete evaluation of cardiovascular risk of HCV patients both at baseline (pre-treatment) and after HCV treatment, through performing different tests (see below)
~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied at different times before and after the end of the treatment.
~The participation in the study will not influence neither the indication to treat nor the treatment used.
~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
16571449|NCT02802267|Experimental|inecalcitol|Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.
16571450|NCT02802267|Placebo Comparator|placebo|Two tablets of placebo 2mg each (total 4mg) taken orally every other day
16571451|NCT02802254|Experimental|Pedometer+physical-activity-feedback|At cardiac consultation patients receive a patient-targeted individual physical-activity-feedback.
16571452|NCT02802254|Active Comparator|Pedometer-only|Patients use a Pedometer in order to measure their daily step number
16571453|NCT02802241|Experimental|open-label placebo|
16571454|NCT02802241|Experimental|double-blind placebo|
16571459|NCT02802215|Active Comparator|Metformin group|40 women will receive metformin in dose of 1500 mg per day orally (500 mg every 8 hrs in the middle of meal) starting from 12th week of gestation till delivery.
16571460|NCT02802215|Placebo Comparator|control group|40 women will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet.
16571461|NCT02802202||Fibromyalgia|Individuals who met the criteria for a diagnosis of FM based upon the ACR diagnostic criteria.
16571462|NCT02802202||Myofascial Pain Syndrome|Individuals with a diagnosis of MPS that does not meet the American College of Rheumatology (ACR) diagnostic criteria for FM.
16571463|NCT02802202||Control|Individuals with no current or prior diagnosis consistent with MPS or FM.
16571464|NCT02802189|Experimental|exercise and INIT group|The first group (experimental) followed the exersice programme in combination with the integrated neuromuscular inhibition technique (INIT).
16571465|NCT02802189|Active Comparator|exercise group|"The protocol for this group was identical to the previous group with the sole difference that the application of INIT was not included.
~At the end of the exercise programme, relaxing breathing exercise and gentle stretching was applied for 15 min"
16571466|NCT02802176|Experimental|Intra-vaginal culture - INVOcell device|3 day intra-vaginal incubation using the INVOcell device
16571467|NCT02802176|Active Comparator|Traditional IVF culture|3 day traditional IVF incubation
16571468|NCT02802163|Experimental|Combination Therapy|Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
16571469|NCT02802150|Active Comparator|Zanthoxylum schinifolium seed Oil|Zanthoxylum schinifolium seed Oil 100% (4g/day)
16571470|NCT02802150|Placebo Comparator|soy bean oil|soy bean oil 99.9%, edible dyes 0.01% (4g/day)
16571471|NCT02802137|Active Comparator|Tafluprost drops|Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
16571472|NCT02802137|Active Comparator|Tafluprost and dorzolamide/timolol drops|Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
16571473|NCT02802124|Experimental|carbon-ion radiotherapy for tumor away from GI|For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels [55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx] are planned within the Phase I part.
16571474|NCT02802124|Experimental|carbon-ion radiotherapy for tumor adjacent to GI|"For tumor location which is adjacent to gastrointestine (less than 1 cm).We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.
~Three dose levels (carbon 60GyE/15Fx, carbon 67.5GyE/15Fx, carbon 75GyE/15Fx) are planned within the Phase I part."
16571475|NCT02802111|Experimental|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
16571476|NCT02802111|Experimental|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
16571477|NCT02802098|Experimental|Bevacizumab + Durvalumab|Treatment with DURVALUMAB 10 mg/kg Q2W IV infusion plus Bevacizumab 10 mg/ Kg Q2W, IV infusion for a maximum duration of treatment of 12 months. Study treatment should be discontinued prior to 12 months if there is confirmed PD (unless the investigator considers the subject to continue to receive benefit from treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue study treatment occur.
16571478|NCT02802085||Knee Arthroplasty|Vega Knee Arthroplasty
16571479|NCT02802072|Experimental|Enterprise stent implantation group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive Enterprise stent implantation in combination with antiplatelet medication for carotid artery stenosis.
16571480|NCT02802072|Experimental|Only aspirin medication group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive only antiplatelet medication for carotid artery stenosis.
16571481|NCT02802059|Experimental|EcN-Suspension|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension
16571482|NCT02802059|Placebo Comparator|Placebo|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo
16571483|NCT02802046||FFR≦0.8|FFR is a score of 0 to 1, FFR < 0.75, has proved almost always accompanied by myocardial ischemia.
16571484|NCT02802046||FFR>0.8|FFR > 0.80 almost never associated with myocardial ischemia.
16571485|NCT02802020|Experimental|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
16571486|NCT02802007|Experimental|Elipse Intragastric Balloon|Patients seeking weight loss received the Elipse Intragastric Balloon.
16571487|NCT02801994|Experimental|Ventilator settings, PAV|"A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.
~The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min."
16572658|NCT02794272|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
16571488|NCT02801981|Experimental|Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
16571489|NCT02801981|Experimental|Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
16571490|NCT02801981|Experimental|Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg|Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
16571491|NCT02801981|Experimental|Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg|Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
16571492|NCT02801968|Experimental|Tap block|Tap block with ropivacaine 2 mg/kg at the end of cesarean delivery. Postoperative analgesia with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
16571493|NCT02801968|Active Comparator|control group|Postoperative analgesia after cesarean delivery with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
16571494|NCT02801955||tumor marker|serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
16571495|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
16571496|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
16571497|NCT02801929|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16571498|NCT02801916|Other|Study subjects|Each healthy subject will receive each of the interventions in randomized order.
16571499|NCT02801903|Experimental|SB204 4%|Topically Once Daily (AM)
16571500|NCT02801890|Experimental|AD-MSC|The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
16571501|NCT02801890|Placebo Comparator|Placebo|The patients with ultra filtration failure (UFF) underwent Placebo injection.
16571502|NCT02801877|Experimental|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
16571503|NCT02801877|Experimental|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
16571504|NCT02801877|Experimental|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
16571505|NCT02801877|Experimental|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
16571506|NCT02801864|Experimental|Combined real tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. The stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. For the experimental group, the stimulation will be ramped up for 45 seconds and stay there for 20 min. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
16571507|NCT02801864|Sham Comparator|Combined sham tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. For the sham group, the stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. The stimulation will be ramped up for 45 seconds and then ramp down after the initial 45 seconds. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
16571508|NCT02801851|Experimental|Intervention SCREEN-ED|This is the arm that will receive the SCREEN-ED. SCREEN-ED is an innovative, yet practical intervention that combines screening with informing clinicians of the results and provides a checklist for delirium management that is tailored to the time-limited ED setting.
16571509|NCT02801838|Experimental|Ventilator settings, morphine titration|First, ventilator settings optimization and when the clinician judges necessary (remains discomfortable), opioid titration with a maximum of 10mg of morphine
16571510|NCT02801825|Experimental|Axillary artery.|Cannulation of the axillary artery.
16571511|NCT02801825|Experimental|Femoral artery.|Cannulation of the femoral artery.
16571512|NCT02801812||Systemic Lupus Erythematosus|patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.
16571513|NCT02801812||Healthy controls|subjects ≥18 years fulfilling the definition proposed in the protocol.
16571514|NCT02801799|Active Comparator|Infusion group 1|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 12 mL/h. This infusion rate is normal clinical practice when administering a perineural infusion of ropivacaine."
16571515|NCT02801799|Experimental|Infusion group 2|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 60 mL/h. This infusion rate is experimental."
16571516|NCT02801799|Experimental|Infusion group 3|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 300 mL/h. This infusion rate is experimental."
16572659|NCT02794272|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
16571517|NCT02801799|Experimental|Infusion group 4|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 600 mL/h. This infusion rate is experimental."
16571518|NCT02801799|Active Comparator|Infusion group 5|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 1800 mL/h. This infusion rate is normal clinical practice when administering a perineural bolus of ropivacaine."
16571519|NCT02801786|Placebo Comparator|Placebo|Five capsules containing placebo
16571520|NCT02801786|Experimental|Tamoxifen|Five capsules containing 20mg of tamoxifen.
16571521|NCT02801786|Experimental|Lidocaine|One sachet containing lidocaine gel at 4%
16571522|NCT02801773|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and adjunct probiotic one lozenge containig Lactobacillus reuteri per day during 3 month
16571523|NCT02801773|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and one lozenge containig placebo (mint lozenge) per day during 3 month
16571524|NCT02801760||Subjects Currently or Previously Enrolled in ATN 110/ATN 113|Younger and older YMSM and transgender women who have sex with men, ages 15 through 22 years, inclusive, at the time of consent into the ATN 110 or ATN 113 study.
16571525|NCT02801760||Sub-Sample of Subjects to Complete Qualitative Interview|A sub-sample of subjects who completed the web-based survey and indicated willingness to complete the qualitative interview.
16571526|NCT02801747|Experimental|Condition 1|Receives a core intervention session and the navigation intervention component (long duration; that is, up to 6 months).
16571527|NCT02801747|Experimental|Condition 2|Receives a core intervention session, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
16571528|NCT02801747|Experimental|Condition 3|Receives a core intervention session, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
16571529|NCT02801747|Experimental|Condition 4|Receives a core intervention session, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
16571530|NCT02801747|Experimental|Condition 5|Receives a core intervention session, the pre-adherence preparation component, and the navigation intervention component (short duration, that is, up to 3 months).
16571531|NCT02801747|Experimental|Condition 6|Receives a core intervention session, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
16571532|NCT02801747|Experimental|Condition 7|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
16571533|NCT02801747|Experimental|Condition 8|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
16571534|NCT02801747|Experimental|Condition 9|Receives a core intervention session, the Motivational Interviewing sessions component, and the navigation intervention component (short duration, that is, up to 3 months).
16571535|NCT02801747|Experimental|Condition 10|Receives a core intervention session, the Motivational Interviewing sessions component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
16571536|NCT02801747|Experimental|Condition 11|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
16571537|NCT02801747|Experimental|Condition 12|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
16571538|NCT02801747|Experimental|Condition 13|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, and the navigation intervention component (long duration, that is, up to 6 months).
16571539|NCT02801747|Experimental|Condition 14|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
16571540|NCT02801747|Experimental|Condition 15|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
16571541|NCT02801747|Experimental|Condition 16|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
16571542|NCT02801734|Experimental|Intervention|"Participants in the EQUIP intervention group will individually receive four face-to-face sessions with a palliative care nurse.
~For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate."
16571543|NCT02801734|No Intervention|Control|For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate.
16571544|NCT02801721|Active Comparator|Stimulation|Stimulation group received psycho social stimulation. In the stimulation there were anemic and non anemic children. All anemic children received iron(syrup) supplementation.
16571545|NCT02801721|No Intervention|No stimulation|No stimulation group did not receive any stimulation. In the no stimulation group there were anemic and non anemic children. All anemic children received iron (syrup) supplementation
16571546|NCT02801695|Experimental|L-Citrulline|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
16571547|NCT02801695|Placebo Comparator|Lactose|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
16571548|NCT02801682||Healthy Controls|
16571549|NCT02801682||Invasive Candidiasis|
16571554|NCT02801656|Experimental|Fecal Microbiota Transplantation|Oral, encapsulated fecal microbiota transplantation
16571555|NCT02801656|Active Comparator|Vancomycin|125 mg po qid x 10 days
16571556|NCT02801630|Sham Comparator|Sham Crossover|"After the enrollment and lead in period, subjects will be given a sham device to sleep with every night for a month. They will be asked to fill out their pain and analgesic use logs, and undergo the bi weekly assessments. After a month they will be crossed over to an active Painshield SAW patch device and will continue to complete their pain and analgesic use logs as well as undergo biweekly assessments for months two and 3."
16571557|NCT02801630|Active Comparator|Active Device|After the enrollent and lead in period, subjects will be given an active PainSHield SAW Patch device to sleep with every night. They will be asked to fill out their pain and analgesic use logs, and undergo bi weekly assessments. They will continue to use the device while completing their logs and undergoing assessments for 3 months.
16571558|NCT02801617|Experimental|Sequence 1 (PRO-067)|"study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
~Washout period: 21 hours"
16571559|NCT02801617|Active Comparator|Sequence 2 (GAAP Ofteno®)|"study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
~Washout period: 21 hours"
16571560|NCT02801591||GH AQ|
16571561|NCT02801578|Experimental|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.
~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
16571562|NCT02801565|Experimental|GH AQ|Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
16571563|NCT02801552|Experimental|Regenerative Endodontic Procedure + PRF|Visit 1: root canal dressing with triple antibiotic paste. Visit 2: a 5 ml sample of whole blood was drawn intravenously from the patient's forearm. The blood sample is centrifuged at 400 g for 10 min. The prepared PRF membrane is cut into segments, the fragments are placed into the canal space. The coronal is sealed mineral trioxide aggregate and composite resin.
16571564|NCT02801552|No Intervention|Regenerative Endodontic Procedure|Regenerative Endodontic Procedure Visit 1: root canal dressing with triple antibiotic paste. Visit 2: Blood clot formation is induced in the root canal after disinfection. No PRF was used in this group. Then the canal access is sealed with mineral trioxide aggregate and composite resin.
16571565|NCT02801539|Experimental|Respiratory muscle training (RMT)|Subjects in the experimental arm will be given an inspiratory and expiratory RMT device to use during Duke-based and home-based RMT therapy.
16571566|NCT02801539|Sham Comparator|Sham-RMT|Subjects in control arm will be given an inspiratory and expiratory sham-device and will complete Duke-based and home-based sham-RMT therapy.
16571567|NCT02801526|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
16571568|NCT02801526|Experimental|CKD-330|CKD-330 16/5mg - A, PO, 1days or 22days
16571569|NCT02801513|Experimental|Brief Mindfulness Training|The brief mindfulness training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to engage in formal meditation practice for about 25 minutes twice per day on six out of seven days of each week using recorded guided meditations. Practices were shorter in duration than the practices in Mindfulness-Based Cognitive Therapy (MBCT, Segal et al., 2002) in order to allow for more flexibility in scheduling the practices, but followed the standard sequence of mindfulness-based interventions.
16571570|NCT02801513|Active Comparator|Resting Control Training|The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
16571571|NCT02801500|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
16571572|NCT02801500|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
16571573|NCT02801487|Experimental|CIRT with concurrent chemo arm|Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m^2, weekly).
16571574|NCT02801474|Experimental|direct reduction|Intervention: The posterior and lateral malleoli were accessed via a posterolateral approach with the patients in prone position. The fibular fracture was exposed and reduced anatomically in the first place. The posterior malleolus was then exposed between the fiexor halluces longus and peroneus longus interval. The posterior malleolar fragment was then reduced with reference to the typical metaphyseal-diaphyseal spike of the posterior malleolus. One-third tubular plate, reconstruction plate, or distal radius plate were applied spanning the fracture in a buttress mode. Cannulated screws could also be used.
16571575|NCT02801474|Experimental|indirect reduction|Intervention: After open reduction and internal fixation of lateral and medial malleolar fractures, the posterior malleolus was then reduced through ligamentotaxis with the ankle in dorsiflexion. One or two 4.0 mm cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
16571576|NCT02801461|Experimental|Three-sessions of ESWT|ESWT was given once a week for 3 weeks.
16571577|NCT02801461|Active Comparator|One-session of ESWT|Single ESWT was given.
16571578|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
16571579|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
16571610|NCT02801305|Experimental|Diltiazem Gel 2%|About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
16571580|NCT02801435|Experimental|Cohort 1-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571581|NCT02801435|Placebo Comparator|Cohort 1-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571582|NCT02801435|Experimental|Cohort 2-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571583|NCT02801435|Placebo Comparator|Cohort 2-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571584|NCT02801435|Experimental|Cohort 3-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571585|NCT02801435|Placebo Comparator|Cohort 3-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571586|NCT02801435|Experimental|Cohort 4-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571587|NCT02801435|Placebo Comparator|Cohort 4-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
16571588|NCT02801422||Cannabis Dependence|ages 18-40
16571589|NCT02801422||Healthy control subjects|socio-demographically matched
16571590|NCT02801409|Active Comparator|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
16571591|NCT02801409|Experimental|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
16571592|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
16571593|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
16571594|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
16571595|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
16571596|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
16571597|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
16571598|NCT02801383|Active Comparator|Treatment group|received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
16571599|NCT02801383|Placebo Comparator|controlled group|received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
16571600|NCT02801370|Experimental|OTO-201|
16571601|NCT02801370|Sham Comparator|Control|
16571602|NCT02801357|Experimental|lofexidine with tapering buprenorphine|Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
16571603|NCT02801344|Experimental|Normal protein intake|participants will receive the controlled-diet containing 0.8 g protein /kg/day and the test drink containing 0.14 g protein/kg/d.
16571604|NCT02801344|Experimental|Moderate protein intake|participants will receive the controlled-diet containing 1.20 g protein /kg/day and the test drink containing 0.40 g protein/kg/d.
16571605|NCT02801344|Experimental|High protein intake|participants will receive the controlled-diet containing 1.83 g protein /kg/day and the test drink containing 1.03 g protein/kg/d.
16571606|NCT02801331|Experimental|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth. SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed). Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
16571607|NCT02801331|No Intervention|Treatment as Usual (TAU)|Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS. Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
16571608|NCT02801318|Other|Polysomnography|
16571609|NCT02801305|Placebo Comparator|Vaseline|About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
16572660|NCT02794259|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
16571611|NCT02801305|Experimental|Nitroglycerin Ointment 2%|About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
16571612|NCT02801292|Other|administering of ketamine|adjuvant to standard of care
16571613|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
16571614|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
16571615|NCT02801266|Experimental|Intervention|The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.
16571616|NCT02801266|No Intervention|No intervention|The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.
16571617|NCT02801240|Experimental|Nutrition Support Product|Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
16571618|NCT02801227|Experimental|Oxytocin|
16571619|NCT02801227|Experimental|Prostaglandin E2|
16571620|NCT02801214||Recreational Cannabis Use|ages 18-40
16571621|NCT02801214||Healthy control subjects|socio-demographically matched
16571622|NCT02801201|Active Comparator|sedation|Midazolam : 0,10 mg/kg
16571623|NCT02801201|Active Comparator|spinal anesthesia|Bupivacain 10 mg
16571624|NCT02801188|Placebo Comparator|Bupivacaine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
16571625|NCT02801188|Active Comparator|Mixture of bupivacaine and dexmedetomidine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
16571626|NCT02801175||RF|Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation
16571627|NCT02801175||Cryoballoon|Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation
16571628|NCT02801162|Active Comparator|Conventional ABG analyser|
16571629|NCT02801162|Experimental|Proxima 3® arterial blood gas|
16571630|NCT02801149|No Intervention|No further imaging|Patients randomised to this group will receive standard care, i.e. will not undergo additional imaging scans at A&E/Urgent Care Centre.
16571631|NCT02801149|Experimental|Wrist Magnetic Resonance Imaging (MRI)|Patients randomised to this group will undergo an additional 3-sequence wrist MRI during the initial A&E/Urgent Care Centre episode.
16571632|NCT02801136|Experimental|ReACT for PNES|ReACT consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
16571633|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
16571634|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
16571635|NCT02801123|Experimental|Preference: MBCR (im)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to immediate treatment
16571636|NCT02801123|Experimental|Preference: TCQ (im)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to immediate treatment
16571637|NCT02801123|Active Comparator|Preference: MBCR (wl)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to waitlist
16571638|NCT02801123|Active Comparator|Preference: TCQ (wl)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to waitlist
16571639|NCT02801123|Experimental|No Preference: MBCR (im)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - immediate
16571640|NCT02801123|Experimental|No Preference: TCQ (im)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - immediate
16571641|NCT02801123|Active Comparator|No Preference: MBCR (wl)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - waitlist
16571642|NCT02801123|Active Comparator|No Preference: TCQ (wl)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - waitlist
16571643|NCT02801097|Experimental|RRx-001 + Irinotecan|Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.
16571644|NCT02801084|Experimental|Float|One arm only: restricted environmental stimulation
16571645|NCT02801071|Experimental|L-citrulline|15 g L-citrulline p.o. per day (3x 5g) for 24 weeks
16571646|NCT02801071|Placebo Comparator|Placebo|L-citrulline Placebo 3 times daily p.o. for 24 weeks
16571647|NCT02801058|No Intervention|Control|Simple observation
16571648|NCT02801058|Sham Comparator|Shame|Light touch manipulative simulation
16571649|NCT02801058|Experimental|Treatment|Osteopathic manipulative techniques on the abdominal diaphragm
16571650|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
16571651|NCT02801032|Active Comparator|Active Treatment|Tadalafil 20 mg Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
16571652|NCT02801032|Placebo Comparator|Control|Placebo Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
16571653|NCT02801019|Experimental|E-XLPE|E-poly
16571654|NCT02801019|Active Comparator|C-XLPE|ArComXL
16571655|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
16572296|NCT02796456||Obese women with gestational diabetes|BMI more than 30 kg/m2 and with gestational diabetes
16571656|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
16571657|NCT02800980||Drainage and sclerotherapy.|Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.
16571658|NCT02800980||Drainage alone.|Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.
16571659|NCT02800967|Active Comparator|Pure Aronia juice|Participants will consume 100 ml of pure Aronia juice per day for 28 days
16571660|NCT02800967|Active Comparator|Aronia juice-based beverage|Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
16571661|NCT02800967|Placebo Comparator|Placebo beverage|Participants will consume 100 ml of Placebo beverage per day for 28 days
16571662|NCT02800954|Experimental|multiple myeloma group|case group = patients with multiple myeloma
16571663|NCT02800954|Experimental|MGUS group|monoclonal gammopathy of undetermined significance
16571664|NCT02800954|Other|healthy control group|control group = healthy subjects
16571665|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
16571666|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
16571667|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
16571668|NCT02800915|Experimental|Intervention, telemedicine and interdisciplinary cooperation|The intervention group will be offered regular interdisciplinary outpatient follow-up via telemedicine.
16571669|NCT02800915|Active Comparator|Control, interdisciplinary guidance on request.|The control group will receive guidance based on existing routines, and based on initiative taken by the local healthcare service/ patient/ next of kin.
16571670|NCT02800902|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
16571671|NCT02800902|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
16571672|NCT02800902|Active Comparator|group 3|SRP followed by 1.2% Atorvastatin (ATV) gel
16571673|NCT02800889|Experimental|Treatment: Pixantrone|Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment. At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts. The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity. During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced. Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
16571674|NCT02800876||asymptomatic not ruptured aneurysm|Patients with asymptomatic not ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
16571675|NCT02800876||symptomatic not ruptured aneurysm|Patients with symptomatic aortic aneurysms greater than 3 cm who received a clinical indicated CT
16571676|NCT02800876||symptomatic ruptured aneurysm|Patients with symptomatic ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
16571677|NCT02800876||patients with small aneurysms|Patients with small aortic aneurysms approximately 5.5 cm, ruptured and not ruptured, who received a clinical indicated CT
16571678|NCT02800863||Dorsal Root Ganglion (DRG) Stimulation|
16571679|NCT02800850|Experimental|Bright Light Group|Bright Light Exposure
16571680|NCT02800850|Placebo Comparator|Control Group|Placebo Light Exposure
16571681|NCT02800824|Experimental|Budesonide rectal foam|
16571682|NCT02800824|Active Comparator|Uceris rectal foam|
16571683|NCT02800811|Experimental|Part 1: Cohort A, Group 1, FR104|Dose: single 0.005 mg/kg.
16571684|NCT02800811|Experimental|Part 1: Cohort A, Group 2, FR104|Dose: single 0.05 mg/kg.
16571685|NCT02800811|Experimental|Part 1: Cohort A, Group 3, FR104|Dose: single 0.2 mg/kg.
16571686|NCT02800811|Experimental|Part 1: Cohort A, Group 4, FR104|Dose: single 0.5 mg/kg.
16571687|NCT02800811|Placebo Comparator|Part 1: Cohort A, placebo|Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).
16571688|NCT02800811|Experimental|Part 1: Cohort B, Group 7, FR104|Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
16571689|NCT02800811|Experimental|Part 1: Cohort B, Group 8, FR104|Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
16571690|NCT02800811|Experimental|Part 1: Cohort B, Group 9, FR104|Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
16571691|NCT02800811|Experimental|Part 1: Cohort B, Group 9 bis, FR104|Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.
16571692|NCT02800811|Placebo Comparator|Part 1: Cohort B, placebo|placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)
16571693|NCT02800811|Experimental|Part 2: Group 10, FR104|Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.
16571694|NCT02800811|Experimental|Part 2: Group 11, FR104|Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.
16571695|NCT02800811|Placebo Comparator|Part 2: placebo|placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.
16571696|NCT02800798||High risk for OSA|High risk OSA defines as Stop-bang score ≥ 3
16571697|NCT02800798||Low risk for OSA|Low risk OSA defines as Stop-bang score < 3
16571717|NCT02800655|Experimental|DHFS with IS-ARV|Digital Health Feedback System (DHFS) with either IS- Odefsey®, IS- Genvoya®, IS-Biktarvy®, IS- Tivicay® and Truvada® or IS- Tivicay® and Descovy ® (IS-co-encapsulated with ingestion sensor) -1 or 2 capsules daily (QD), depending on the treatment regimen, administered orally for 16 weeks.
16571718|NCT02800642|Experimental|Intravitreal (IVT) aflibercept|Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
16571719|NCT02800629|Active Comparator|Intervention|Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
16571698|NCT02800785|Active Comparator|Antibiotics Therapy Arm|Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
16571699|NCT02800785|Active Comparator|Appendectomy Arm|Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.
16571700|NCT02800772|Experimental|acetic acid|spray 50ml acetic acid to duodenal bulb
16571701|NCT02800772|Placebo Comparator|saline|spray 50ml saline to duodenal bulb
16571702|NCT02800759|Active Comparator|100% of JOINTRUS®|After randomization, 100% dose of JOINTRUS® is taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
16571703|NCT02800759|Active Comparator|80% of JOINTRUS®|After randomization, 80% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
16571704|NCT02800759|Active Comparator|62.4% of JOINTRUS®|After randomization, 62.4% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
16571705|NCT02800759|Placebo Comparator|Starch 100%|After randomization, starch 100% was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
16571706|NCT02800746|Experimental|Experimental group|Ferric carboxymaltose
16571707|NCT02800746|Placebo Comparator|Control Group|Placebo
16571708|NCT02800733|Experimental|saffron|450 mg of saffron capsule once a day for 6 weeks
16571709|NCT02800733|Placebo Comparator|placebo|placebo capsule once a day for 6 weeks
16571710|NCT02800720|Experimental|Meditation Awareness Training|"Target Intervention Arm:
~8-week meditation intervention"
16571711|NCT02800720|Active Comparator|Cognitive Behavioural Therapy for Groups|"Active Comparator Arm:
~8-week CBT-based intervention"
16571712|NCT02800707|Active Comparator|Sucralose|Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
16571713|NCT02800707|Active Comparator|Stevia|Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
16571714|NCT02800681||Asperger syndrome|"Expert panel evaluation for identification of participants with typical symptoms
~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum
~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being
~Other general interviewer ratings for assessing functioning and severity of psychopathology"
16571715|NCT02800681||Schizotypal disorder|"Expert panel evaluation for identification of participants with typical symptoms
~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum
~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being
~Other general interviewer ratings for assessing functioning and severity of psychopathology"
16571716|NCT02800668||DJBL implant-group|"T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.
~The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR <50 ml/min), pregnancy or breast feeding."
16571720|NCT02800629|Placebo Comparator|Control|Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
16572661|NCT02794259|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
16571721|NCT02800616|Experimental|Full intervention group|The full intervention ('The Healthy Primary School of the Future') is implemented in two schools involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years.
16571722|NCT02800616|Experimental|Partial intervention group|The partial intervention ('The Physical Activity School') is implemented in two other schools: involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years. Hence, this intervention only differs from the full intervention on the absence of nutritional intervention. Instead, children bring their own food from home, as they normally do.
16571723|NCT02800616|No Intervention|Control group|Four primary schools will function as control schools. The control schools have a representative Dutch school environment in terms of lifestyle education, school hours and amount of Physical Education (PE) lessons.
16571724|NCT02800603|Experimental|Family Check Up|FCU Intervention: All 280 participants will undergo screening and a baseline FCU assessment before randomization. Once randomized, the FCU group (n=140) will be provided with a feedback visit and up to 6 optional sessions of the EDP curriculum over 16 weeks.
16571725|NCT02800603|No Intervention|Community Control|The Community Control group (n=140) will receive general information that includes a list of all the relevant services available in Hamilton. As such, the community control group would be provided with all the information needed to obtain standard care.
16571726|NCT02800590|Experimental|ABP-700 30 μg/kg/min|Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
16571727|NCT02800590|Experimental|ABP-700 40 μg/kg/min|Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
16571728|NCT02800590|Experimental|ABP-700 45 μg/kg/min|Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
16571729|NCT02800577|Other|All participants|Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
16571730|NCT02800564|Experimental|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months plus interactive voice response systems (IVRS) and monthly open community meetings.
16571731|NCT02800564|Experimental|Passive mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months
16571732|NCT02800551|Experimental|SBRT (Arm A)|"dose-intensified image-guided SBRT using simultaneous integrated boost:
~in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.
~In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively."
16571733|NCT02800551|Active Comparator|Conventional Radiation Therapy (Arm B)|"External 3-dimensional conformal radiotherapy (3D-CRT):
~Homogeneous irradiation of the affected vertebra delivering either
~20 Gy in 5 fractions or
~30 Gy in 10 fractions."
16571734|NCT02800551|Experimental|SBRT (prospective observational)|Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.
16571735|NCT02800538|Experimental|Lauric acid|the nutrient that can be widely found in daily food.
16571736|NCT02800538|Experimental|Palmitic acid|the nutrient that can be widely found in daily food.
16571737|NCT02800538|Experimental|Capric acid|the nutrient that can be widely found in daily food.
16571738|NCT02800538|Placebo Comparator|Saline|physiological salt water
16571739|NCT02800525|Experimental|Picosecond laser|"The pigmented lesions on this half-side of the face would be treated with picosecond laser.
~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.
~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
16571740|NCT02800525|Active Comparator|Q-switched Nd:YAG laser|"The pigmented lesions on this half-side of the face would be treated with q-switched Nd:YAG laser.
~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.
~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
16571741|NCT02800512|Active Comparator|Sacrocolpopexy|Robotic sacrocolpopexy
16571742|NCT02800512|Active Comparator|HUSLS|Vaginal high uterosacral ligament suspension
16571743|NCT02800499||KOCOSS|The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional observational study within the Korean COPD patients
16571744|NCT02800486|Experimental|Intra-arterial Cetuximab with Re-Irradiation|Mannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
16571745|NCT02800473|Other|Experimental|"Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.
~Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.
~24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects"
16571746|NCT02800460|Other|Deep brain stimulation with fMRI-3T|Patients will have a 3T-fMRI before their usual MRI-1,5T
16571747|NCT02800447|Experimental|Treatment|baseline BEACOPP regimen
16571748|NCT02800447|Active Comparator|controlled group|ABVD regimen
16571749|NCT02800434|Experimental|hand allograft|
16571750|NCT02800421||no organ damage|no evidence of HLI and CI-AKI
16571751|NCT02800421||CI-AKI only|CI-AKI, but no HLI
16571752|NCT02800421||HLI only|HLI, but no CI-AKI
16571753|NCT02800421||combined CI-AKI and HLI|Both CI-AKI and HLI
16571754|NCT02800408|Experimental|Whole grain high-BCX maize|Whole grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
16571755|NCT02800408|Experimental|Refined grain high-BCX maize|Refined (degermed) grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
16571756|NCT02800408|Placebo Comparator|Whole grain white maize|Whole grain, white maize (low in beta-cryptoxanthin) will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
16571757|NCT02800395|Other|Nutritional evaluation|
16571758|NCT02800382|Other|Lung Malignancy|"Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
~The samples (fine-needle aspiration biopsy and fine-needle aspiration cytology) were diagnosed by pathological examination."
16571759|NCT02800382|Other|Lung bening Diseases|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
16571760|NCT02800369|Experimental|ZFN-603 and ZFN-758|Subjects will receive suppository with ZFN-603 or ZFN-758
16571761|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
16571762|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
16571763|NCT02800343||Cardiovascular surgery|All adult patients undergoing elective or emergency cardiovascular surgery at the study site
16571764|NCT02800330|Other|Arm A (e.g. sequence phase A-B-C)|In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
16571765|NCT02800330|Other|Arm B (e.q. sequence phase C-B-A)|In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
16571766|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
16571767|NCT02800265|Experimental|Avmacol during week 2 for 3 days|"Buccal cells line the inner cheek, and will be collected from the inner right cheek with a cytobrush (a q-tip like swab) by a trained investigator.
~During the second week the participant will take 8 Avmacol tablets every evening for 3 evenings (Day 2, 3, 4), and record the time of each dose in the provided diary. Research blood collection: on days 1 and 5. Overnight urine collection."
16571768|NCT02800252|Placebo Comparator|Control Group|Full-mouth periodontal debridement and placebo
16571769|NCT02800252|Active Comparator|Test 1|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
16571770|NCT02800252|Active Comparator|Test 2|omega-3 plus aspirin before periodontal therapy
16571771|NCT02800239|Experimental|Active, adolescent females|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
16571772|NCT02800226|Experimental|10Hz|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
16571773|NCT02800226|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
16571774|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
16571775|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
16571776|NCT02800200|Experimental|Platelet rich plasma|The ultrasoud-guided injection with Platelet rich plasma (3cc) was perfomed in both groups.
16571777|NCT02800200|Experimental|Active shock wave|One-session active shock wave 2 weeks later after PRP injection was performed in intervention group.
16571778|NCT02800200|Placebo Comparator|Sham shock wave|One-session sham shock wave 2 weeks later after PRP injection was performed in control group.
16571779|NCT02800187|Experimental|three-sessions of ESWT|Active three-sessions of ESWT ( once a week for 3 weeks) was given.
16571780|NCT02800187|Active Comparator|one-session of ESWT|One-session of ESWTactive ESWT was given.
16571781|NCT02800187|Active Comparator|Night splint|The night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study. Another 3 sessions of sham ESWT was given.
16571782|NCT02800174|Experimental|Smart nitinol stent implantation group|The Smart nitinol stent system was used (import product registration number YZB/USA 0115-2008; Nitinol stent system, trade name SMART Control). The stent system comprises a self-expanding stent and a delivery system. The self-expanding stent is composed of a nickel titanium alloy and the ends of the stent are equipped with tantalum radiopaque markers. The Smart nitinol stent system is sterilized with ethylene oxide gas and is intended for single use only.
16571783|NCT02800174|Active Comparator|Antiplatelet drug group|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
16571784|NCT02800161|Active Comparator|Trehalose|Trehalose 70g/die
16571785|NCT02800161|Placebo Comparator|Placebo|Maltose 70g/die
16571786|NCT02800148|Experimental|Azelaic acid foam|
16571787|NCT02800148|Active Comparator|Finacea Foam|
16571788|NCT02800148|Placebo Comparator|Placebo Foam|
16571789|NCT02800135|Experimental|Furosemide stress test|
16571790|NCT02800122||Patients with acute dyspnea|"Patients with acute dyspnea treated by a medical team of emergencies of CHRU of Nancy.
~All patients admitted to the emergencies in the last 5 years matching the inclusion criteria will be evaluated. About 4,000 patients will be affected, including more than 800 patients with acute heart failure. (Figures based on export of ICD X codes (R06.0: Dyspnea) of patients cared in extra-hospital for acute dyspnea (diagnosis Dyspnea + Heart Failure) over the last 5 years)."
16572297|NCT02796443||Early laparoscopic cholecystectomy (ELC)|Operation within 72 hours after onset of symptoms
16571791|NCT02800096|Active Comparator|Gambling Internet intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
16571792|NCT02800096|Experimental|Gambling Internet intervention + MoodGYM|The G+MH intervention condition will consist of the G-only intervention and an online intervention for depression and anxiety. The mental health intervention chosen is MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
16571793|NCT02800083|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
16571794|NCT02800083|Placebo Comparator|Placebo|placebo
16571795|NCT02800070|Experimental|Treatment Arm|Patients will receive Health Canada approved transduced autologous CD34+ cell product.
16571796|NCT02800044|Experimental|Wearing glucose sensor|The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..
16571797|NCT02800031|Experimental|Participants|"Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).
~Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method.
~Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes.
~Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy.
~All specimens will be examined histopathologically."
16571798|NCT02800005|Other|BMI group (Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
16571799|NCT02800005|Experimental|AFA group(Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.
16571800|NCT02799992|Active Comparator|Half Dose Photodynamic Therapy|Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
16571801|NCT02799992|Experimental|689 nm Laser Treatment|A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
16571802|NCT02799979||Case|Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months
16571803|NCT02799979||Control|Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline
16571804|NCT02799966|Other|Early Treatment Group|Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury
16571805|NCT02799966|Other|Late Treatment Group|Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury
16571806|NCT02799953|Experimental|Technology-based self-management model|Participants randomized to the intervention group will be given a tablet-based, interactive touch-screen self-monitoring system free of charge to perform disease self-monitoring in their homes.
16571807|NCT02799953|No Intervention|Conventional self-management|Participants randomized to the usual care group will not be provided access to tablet computers but a 2-in-1 blood pressure and blood glucose monitor and a paper-based log book to perform conventional self-monitoring.
16571808|NCT02799940||Computed tomography in acute respiratory distress syndrome|The lung on computed tomography (CT) in patients with acute respiratory distress syndrome (ARDS) has revealed a heterogeneous pattern of lung injury, with areas of normal lung interspersed with altered regions: ground-glass opacification and consolidation among the most frequent. It has been performed quantitative assessments of ARDS by means of CT, thus enabling a correlation of such pathologic details with physiologic, clinical parameters and with patient outcomes. Therefore, the primary objective of the study is to determine the correlation between the extent of oxygenation (PaO2/FiO2) and the degree of consolidation (total CO) in the CT. The secondary objectives are to determine: the correlation between the driving pressure, ventilator variables and the total CO; the independent variables associated with total CO; differences in the CT with respect to the total lung-disease score (total CO plus total value of ground-glass opacification) between survivors and nonsurvivors.
16571809|NCT02799927|Experimental|Biodentine|"Biodentine (Septodont, Saint-Maur-des-Fosses, France) has been recently introduced and marketed as a bioactive dentin substitute. The Biodentine powder contains tricalcium silicate, dicalcium silicate and calcium oxide, while its liquid consists of calcium chloride and a carboxylate-based hydrosoluble polymer (water-reducing agent).
~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the preparation of Biodentine liner (a mix of powder and liquid), following the manufacturers' instructions, and its placement over the remanent carious dentin layer."
16571810|NCT02799927|Active Comparator|Ultra-Blend plus (Calcium hydroxide)|"Ultra-Blend plus® (Ultradent Products Inc., South Jordan, UT, USA). This material is a light-activated calcium hydroxide based-liner. Calcium hydroxide has demonstrated to reduce and promote immediate deactivation of the residual microorganisms after IPT.
~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the placement of Ultra-Blend plus liner over the remanent carious dentin layer, using a dycal metallic applicator. Finally, the liner is cured through light exposure during 20 seconds ."
16571811|NCT02799901|Experimental|Patient|patient with Advanced melanoma
16571812|NCT02799888|Experimental|Maraviroc + standard GVHD prophylaxis|Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.
16571813|NCT02799875|Active Comparator|Higher permissive hypercapnia|Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 75mmHg; pH < 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
16571814|NCT02799875|Active Comparator|Lower permissive hypercapnia|Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 55mmHg; pH < 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
16571815|NCT02799849|Other|Narcoleptic patients|
16571816|NCT02799849|Other|hypersomnic patients|
16571817|NCT02799836|Experimental|Light deprived study subjects|Study subjects who are blindfolded for 48 hours
16571818|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
16571819|NCT02799797|Active Comparator|short axis (SAX) placement of adductor canal catheters|Procedure: Ultrasound guided short axis (SAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a PAJUNK Contiplex S catheter along the short axis of the middle part of adductor canal
16571820|NCT02799797|Experimental|long axis (LAX) placement of adductor canal catheters|Procedure: Ultrasound guided long axis (LAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a catheter along the long axis of the middle part of adductor canal
16571821|NCT02799784|Experimental|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
16571822|NCT02799784|Experimental|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
16571823|NCT02799758|Experimental|NK-104-CR|NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.
16571824|NCT02799758|Active Comparator|Livalo® IR|Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.
16571825|NCT02799745|Active Comparator|Enzalutamide|Taken once daily
16571826|NCT02799745|Other|Active Surveillance (AS)|AS arm will not receive any study drug
16571827|NCT02799706|Active Comparator|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.
~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.
~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
16571828|NCT02799706|Experimental|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.
~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
16571829|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
16571830|NCT02799680|Experimental|allogeneic CART-33|infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
16571831|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
16571832|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
16571833|NCT02799641|Placebo Comparator|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
16571834|NCT02799641|Experimental|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
16571941|NCT02798835|Active Comparator|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
16571835|NCT02799628|Active Comparator|intervention|"Give the physical therapy of low back pain educational video + therapist introduction and recommendation video, at the first time of clinic visit.
~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
16571836|NCT02799628|Placebo Comparator|placebo|"Give the physical therapy of low back pain educational video, at the first time of clinic visit.
~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
16571837|NCT02799602|Experimental|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
16571838|NCT02799602|Placebo Comparator|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
16571839|NCT02799589|Experimental|Remifentanil-dexmedetomidine and caudal|Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
16571840|NCT02799576|Experimental|Curved needle|This will utilize the curved block needle of performance of regional block
16571841|NCT02799576|No Intervention|Traditional needle|This will utilize the traditional block needle of performance of regional block
16571842|NCT02799563|Experimental|Cohort A: Coach, Preselected number of cases|Cohort A completed the DKA simulator cases during two one-hour coached sessions. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
16571843|NCT02799563|Experimental|Cohort B: Coach, Self-selected number of cases|Cohort B completed the DKA simulator cases during two one-hour coached sessions. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
16571844|NCT02799563|Experimental|Cohort C: No coach, Preselected number of cases|Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
16571845|NCT02799563|Experimental|Cohort D: No coach, Self-selected number of cases|Cohort D completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
16571846|NCT02799550|Experimental|allogeneic CART-19|infusions of allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
16571847|NCT02799537|Experimental|Intervention|Participants in the intervention arm complete the Stanford letter advance directive
16571848|NCT02799537|Active Comparator|Control|Participants in the control arm complete the California state traditional advance directive
16571849|NCT02799511|Other|protein expression|
16571850|NCT02799498|Active Comparator|A-etanercept (ENBREL®) by auto-injector|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
16571851|NCT02799498|Other|B-etanercept (ENBREL®) by Manual injection|Single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
16571852|NCT02799485|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
16571853|NCT02799472|Experimental|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
16571854|NCT02799472|Placebo Comparator|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
16571855|NCT02799459||General anaesthesia|this group will allow us to compare the results like it is the treatment used in current practice ie general anesthesia.
16571856|NCT02799459||Hypnosis in conization|This group is the treatment being tested , where hypnosis is used in the conization
16571857|NCT02799446|Experimental|Reslizumab|Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
16571858|NCT02799446|Placebo Comparator|Placebo|Matching placebo.
16571859|NCT02799433|Active Comparator|Usual Services|This group of child care centers receives standard services from the San Francisco Department of Public Health Child Care Health Program. CCHP offers services to child care centers annually. The standard services include nurse consultation, health education, monitoring of nutrition and physical activity resource need, vision, hearing, oral health, and height and weight screenings.
16571860|NCT02799433|Experimental|Usual services + HAP|This group of child care centers receives all the standard services plus invitation to participate in the voluntary Healthy Apple Program (HAP). The Healthy Apple program involves child care provider self-assessment, followed by an iterative process of goal setting, technical assistance/training, and re-assessment.
16571861|NCT02799420|Experimental|pCLE group|The intervention group
16571862|NCT02799420|Active Comparator|WLE group|The control group
16571863|NCT02799407|No Intervention|Traditional Long Form Consent|Participants will receive the traditional long-form consent form.
16571864|NCT02799407|Experimental|ResearchKit Consent|Participants will receive the Apple ResearchKit consent form.
16571865|NCT02799394|Experimental|Activity modification, exercises and gradual return to sport|
16571866|NCT02799381|Active Comparator|Optimized Medical Treatment (OMT)|Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
16571899|NCT02799082|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
16571867|NCT02799381|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
16571868|NCT02799368|Experimental|CJ Plasma Solution A Injection|Before contrast media administration : CJ Plasma Solution A Injection (3mL/kg for 1 hour) After contrast media administration : CJ Plasma Solution A Injection (1.5 mL/kg/h for 4 hours)
16571869|NCT02799368|Active Comparator|CJ 0.9% Normal Saline Injection|Before contrast media administration : CJ 0.9% Normal Saline Injection (3mL/kg for 1 hour) After contrast media administration : CJ 0.9% Normal Saline Injection (1.5mL/kg/h for 4 hours)
16571870|NCT02799316|Other|rheumatic disease with HBs-ag positive|• HBV core antibodies testing. • Real time PCR testing.
16571871|NCT02799303|Experimental|Multi-parametric MRI|Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
16571872|NCT02799303|Active Comparator|PSA Only|"Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.
~Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician."
16571873|NCT02799290|No Intervention|CONTROL|No intervention
16571874|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
16571875|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
16571876|NCT02799277|Experimental|Testosterone|14mg testosterone will be administered intranasally in a 1milliliter aqueous solution
16571877|NCT02799277|Placebo Comparator|Placebo|1ml blank (containing no drug) aqueous solution will be administered intranasally
16571878|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence AB (fasted followed by fed)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive a single tablet of cabotegravir 30 mg,(micronized 500 mg core weight) orally under fasted condition with at least 10 hours of prior fast. In Period 2, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
16571879|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence BA (fed followed by fasted)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. In Period 2, eligible subjects will receive a single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally under fasted condition with at least 10 hours of prior fast. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
16571880|NCT02799251||Collection of plasma cell rate|Post operative infections and their association with lymphopenia are assessed in this study for patients over 18 years of age undergoing digestive or thoracic cancer surgery under general anesthesia.
16571881|NCT02799238|Active Comparator|Radiotherapy in combination with Temozolomide (TMZ)|radiotherapy combined with TMZ treatment followed by adjuvant TMZ
16571882|NCT02799238|Experimental|ALECSAT + Radiotherapy in combination with TMZ|3 doses of ALECSAT /4 weeks followed by ALECSAT every 3 months
16571883|NCT02799225||Enterobacteria|
16571884|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
16571885|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
16571886|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
16571887|NCT02799173|Experimental|Systemic lupus erythematosus|RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
16571888|NCT02799147|Experimental|280 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.
16571889|NCT02799147|Experimental|200 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv
16571890|NCT02799147|Experimental|140 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4: Bendamustine 70 mg/m2/day iv.
16571891|NCT02799134|Experimental|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
16571892|NCT02799134|Placebo Comparator|group2|take Vitamin C at 22:00 on the first day, 0.5mg
16571893|NCT02799134|Other|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
16571894|NCT02799121|Experimental|ReGenerCell™|Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading
16571895|NCT02799108|Experimental|patients|children with drug-resistant partial epilepsy, in whom preoperative assessment is indicated
16571896|NCT02799095|Experimental|ALKS 4230|
16571897|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
16571898|NCT02799082|Placebo Comparator|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
16571940|NCT02798835|Active Comparator|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
16571900|NCT02799069|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
16571901|NCT02799069|Active Comparator|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
16571902|NCT02799069|Placebo Comparator|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
16571903|NCT02799043|Active Comparator|Standard PVI|Standard catheter ablation including pulmonary vein isolation (PVI) procedure.
16571904|NCT02799043|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by PVI.
16571905|NCT02799030|Placebo Comparator|BF-200 ALA 0%|Topical application of matched placebo gel without containing 5-ALA. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
16571906|NCT02799030|Experimental|BF-200 ALA 1%|Topical application of BF-200 ALA gel containing 0.78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
16571907|NCT02799030|Experimental|BF-200 ALA 3%|Topical application of BF-200 ALA gel containing 3.8 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
16571908|NCT02799030|Experimental|BF-200 ALA 10%|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
16571909|NCT02799017|Experimental|Intensive Phonology Treatment|"The participants in the experimental group will receive an hour of phonology treatment, an hour of group therapy, and an hour of reading. They will work on writing, generative naming during group time focusing on self-cueing with the sounds they learn during the individual session. They will be read to or read aloud depending on their level.
~The participants in the experimental group will be taught all consonants and vowels over the course of 16 weeks."
16571910|NCT02799017|Active Comparator|Intensive SFA Treatment|The participants in the control group will receive an hour of individual therapy, an hour of reading and an hour of group therapy in a traditional setting. They will work on writing, generative naming during group time following the semantic feature analysis to retrieve the name.They will be read to or read aloud depending on their level.
16571911|NCT02799004||Patients in acute pain|
16571912|NCT02798991|Experimental|10 mg of GSK3179106 QD-Cohort 1|Eligible six subjects will receive 10 mg oral dose once daily for 14 days
16571913|NCT02798991|Experimental|50 mg of GSK3179106 QD-Cohort 2|Eligible six subjects will receive 50 mg oral dose once daily for 14 days
16571914|NCT02798991|Experimental|200 mg of GSK3179106 QD-Cohort 3|Eligible six subjects will receive 200 mg oral dose once daily for 14 days
16571915|NCT02798991|Experimental|400 mg of GSK3179106 QD-Cohort 4|Eligible six subjects will receive 400 mg oral dose once daily for 14 days
16571916|NCT02798991|Experimental|25 mg of GSK3179106 BID-Cohort 5|Eligible six subjects will receive 25 mg oral dose twice daily for 14 days
16571917|NCT02798991|Experimental|200 mg of GSK3179106 BID-Cohort 6|Eligible six subjects will receive 200 mg oral dose twice daily for 14 days
16571918|NCT02798991|Placebo Comparator|Matching placebo QD-Cohort 1, 2, 3, 4|Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days
16571919|NCT02798991|Placebo Comparator|Matching placebo BID-Cohort 5, 6|Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days
16571920|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
16571921|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
16571922|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
16571923|NCT02798965|Other|Control|patients with goiter or nodule
16571924|NCT02798965|Experimental|Graves' disease|patients with Graves' disease
16571925|NCT02798952|Experimental|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
16571926|NCT02798939||cirrhotic patients|
16571927|NCT02798926||with the use of a polyethylene bag|
16571928|NCT02798926||without the use of a polyethylene bag|
16571929|NCT02798913|Experimental|Short DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
16571930|NCT02798913|Experimental|Long DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
16571931|NCT02798900|Experimental|Functional task-training and Ultrasound|This group will receive 16 sessions of functional task-training program and therapeutic ultrasound will be applied prior to functional task-training.
16571932|NCT02798900|Active Comparator|Functional task-training|This group will receive 16 sessions of functional task-training program.
16571933|NCT02798887|Experimental|Ridge preservation membrane|Positive control Patients will receive ridge preservation intrasocket allograft and overlay xenograft resorbable with membrane
16571934|NCT02798887|Experimental|Ridge preservation no membrane|test patients will receive ridge preservation intrasocket allograft and overlay xenograft with no membrane
16571935|NCT02798874|Experimental|Ticagrelor Group|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
16571936|NCT02798874|Active Comparator|Clopidogrel Group|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
16571937|NCT02798861||CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
16571938|NCT02798848|Experimental|Assistive technology: tablet computer|iPad tablet computers
16571939|NCT02798848|Active Comparator|Standard optical low vision devices|standard optical devices including magnifiers, telescopes, CCTV
16571942|NCT02798835|Active Comparator|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
16571943|NCT02798822|Active Comparator|RME on upper first permanent molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 35 ± 6 days for Gr6, and the average treatment time was 12 ± 1.3 months.
16571944|NCT02798822|Active Comparator|RME on upper second deciduous molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 41 ± 8 days, and the average treatment time was 12 ± 1.3 months.
16571945|NCT02798809||GeOrGS cohort|Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy)
16571946|NCT02798796|Experimental|MRI Group|MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
16571947|NCT02798796|No Intervention|Control Group|Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
16571948|NCT02798783||Diagnosed with EVA|Self-reported Enlarged Vestibular Aqueduct (EVA), or, when available, radiological diagnosis of EVA will be used to define the cohort.
16571949|NCT02798770||Stroke Center Basel|
16571950|NCT02798757|Experimental|Dapagliflozin|All patients will take dapagliflozin, the intervention does not refer to a drug or device but to the specific 1HNMR test spectroscopy
16571951|NCT02798744|Experimental|Empagliflozin 25mg once daily|Empagliflozin (Jardiance™) 25mg once daily (orally)
16571952|NCT02798744|Experimental|Empagliflozin 25mg once daily + diet|Empagliflozin (Jardiance™) 25mg once daily (orally) + energy restriction diet
16571953|NCT02798744|Placebo Comparator|Placebo once daily|Placebo once daily (orally)
16571954|NCT02798744|Active Comparator|Placebo once daily + diet|Placebo once daily (orally) + energy restriction diet
16571955|NCT02798718|Active Comparator|lactose digesters|Participants in arm 1 are grouped as lactose digesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is less than 20 ppm.
16571956|NCT02798718|Active Comparator|lactose maldigesters|Participants in arm 2 are also grouped as lactose maldigesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is not less than 20 ppm.
16571957|NCT02798692|Active Comparator|Low dose HB-101 group|Intervention:Three administrations of a low dose of HB-101
16571958|NCT02798692|Active Comparator|Medium dose HB-101 group|Intervention:Three administrations of a middle dose of HB-101.
16571959|NCT02798692|Active Comparator|High dose HB101 group|Intervention:Three administrations of a high dose of HB-101.
16571960|NCT02798692|Placebo Comparator|Placebo group|Intervention:Three administrations of placebo (diluent)
16571961|NCT02798666|Experimental|High intensity exercise training|The participants exercised for 40 minutes, twice a week, under supervision of two physiotherapists for in total 10 weeks. Each training session included a warming up, a sprint interval block [10 minutes], continuous aerobic exercise [10 minutes], another sprint interval block [10 minutes] and cooling down. For the first 5 weeks, each sprint interval block consisted of 10 sprint bouts [>100 r/min] of 15 seconds at a cycling resistance matching with the ventilatory threshold [VTR], alternated with 45 seconds relative rest [50 r/min at VTR]. Starting from week 6 until week 10, the intensity of sprinting and relative rest was increased up to 110% of VTR.
16571962|NCT02798666|Active Comparator|Continuous exercise training|The comparative group performed a continuous aerobic training [CAT] for 10 weeks, twice a week and 40 minutes per session [volume and frequency is equal to HIIT]. The protocol of the CAT group consisted of warming up [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes], continuous aerobic exercise training [3 times 10 minutes] and cooling down [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes]. During the continuous aerobic protocol [cycling or stepping] participants exercised for 10 minutes at a HR similar to the HR at VT [60 r/min], which was increased to 110% of VT from week 6 onwards.
16571963|NCT02798653|Experimental|Choriomon®|subjects receive 1,500 IU of hCG (Choriomon®; IBSA) intramuscular (IM) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
16571964|NCT02798653|Experimental|Choriomon®+Endometrin ®|patients will receive 1,500 IU of hCG (Choriomon®; IBSA) (IM) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
16571965|NCT02798653|Experimental|Endometrin ®|patients will receive only Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
16571966|NCT02798640|Active Comparator|Active|Subject wearing Celliant garment
16571967|NCT02798640|Placebo Comparator|Control|Subject wearing non-celliant control garment
16571968|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
16571969|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
16571970|NCT02798614|Active Comparator|10-day cast|Removal of plaster cast 10 Days after reduction
16571971|NCT02798614|No Intervention|1-month cast|Removal of plaster cast 1 month after reduction
16572054|NCT02798042||Patient population|Patients undergoing bariatric surgery
16571972|NCT02798601|Experimental|Hypernatremia|Serum sodium between 150 - 155 milliequivalent/L. 7,5% sodium chloride (2 ml/kg every 4 hours), with controls of serum sodium every 4 hours, to achieve a goal of serum sodium between 150 - 155 milliequivalent/L. If after 4 doses of 7.5% sodium chloride the serum sodium is below the target, a bolus of 1 ml/kg of 12% sodium chloride will be used every 4 hours. The goal of serum sodium will be maintained for 48 hours.
16571973|NCT02798601|No Intervention|Normonatremia|Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
16571974|NCT02798588|Experimental|Comatose patients in ICU|
16571975|NCT02798562|Experimental|Native and dynamic contrast-enhanced CT|Patients will undergo a native high-resolution and a dynamic contrast-enhanced CT, both sides respectively.
16571976|NCT02798549|Other|Viraemic|
16571977|NCT02798549|Other|Remission|
16571978|NCT02798536|Experimental|A1/LMB-100 dose escalation (closed)|De-escalating doses of LMB-100 in up to 18 subjects
16571979|NCT02798536|Experimental|A2/LMB-100 dose expansion (closed)|Fixed dose of LMB-100 as determined in Arm A1 in up to 16 subjects
16571980|NCT02798536|Experimental|B1/LMB-100+ nab- paclitaxel dose escalation|De-escalating doses of LMB-100 + fixed dose of nab-paclitaxel in up to 12 subjects
16571981|NCT02798536|Experimental|B2/LMB-100+ nab- paclitaxel dose expansion|Fixed dose of LMB-100 as determined in Arm B1 + fixed dose of nab-paclitaxel in up to 16 subjects
16571982|NCT02798523|Experimental|Group A|Following collection of a 3-mm skin punch biopsy sample and a preinfusion whole-blood sample, volunteers will receive a single intravenous dose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes, and a single application of topical methylprednisolone 0.1% to a small area (2 x 2 cm) of the skin. Whole blood samples will then be obtained serially, at 2 and 4 hours after the start of drug administration. A second skin punch biopsy will be performed 4 hours after the start of drug administration, in the area of skin where topical methylprednisolone was applied.
16571983|NCT02798523|Experimental|Group B|Following collection of a pre-infusion whole- blood sample, volunteers will receive a single intravenousdose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes. Whole-blood samples will then be obtained serially, at 1 and 2 hours after the start of drug administration.
16571984|NCT02798510|Experimental|Arm 1|Patients in arm 1 will receive adjuvant chemotherapy followed by concurrent chemoradiotherapy. Patients will receive four cycles of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330mg/m2 per day) and radiotherapy (50.4Gy/28fx to regional lymphatics with or without tumor bed)
16571985|NCT02798510|Active Comparator|Arm 2|Patients in arm 2 will receive six cycles chemotherapy of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days
16571986|NCT02798497|Other|staphylococcus aureus PVL-|patients with staphylococcus aureus PVL-
16571987|NCT02798497|Other|staphylococcus aureus PVL+|patients with staphylococcus aureus PVL+
16571988|NCT02798484|Experimental|Breast cancer|Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.
16571989|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.
~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
16571990|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
16571991|NCT02798458|Experimental|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
16571992|NCT02798458|Experimental|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
16571993|NCT02798445|Experimental|tapirs|this group will have surgery with endovascular laser treatment (EVLT) in the axial vein and foam sclerotherapy echo-guided in perforator veins and veins in relation with the ulcer, after the surgery the patients will have conventional wound care plus juxta cure system that give a continuous compression in the leg.
16571994|NCT02798445|Active Comparator|multilayer bandage|multilayer bandage and conventional wound care (grade 1A) recommendation in management of vein ulcers. gold standard
16571995|NCT02798432|Experimental|Hybrid NEXGEN LPS|Noncemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
16571996|NCT02798432|Sham Comparator|Cemented NEXGEN LPS|Cemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
16571997|NCT02798419|Experimental|DFD05 Cream|DFD05 Cream
16571998|NCT02798419|Active Comparator|Active01 Cream|Active01 Cream
16571999|NCT02798406|Experimental|DNX-2401 + pembrolizumab|Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.
16572000|NCT02798393|Sham Comparator|HL-Sham|The placebo device (also referred to as the HL-SHAM device) will have an identical appearance to the HL-NIR device. Though the HL-NIR device will be applied, there will be no treatment administered.
16572055|NCT02798029|Experimental|Treatment (FFSRT)|Patients undergo FFSRT daily over 30 minutes for 3-5 days.
16572001|NCT02798393|Experimental|HL-NIR|The device referred to as the HL-NIR device includes both a podiatric or foot and leg component, similar to a loose fitting boot, that is easily applied to all subjects (one size fits all). Application of the device is snug but comfortable without risk for constriction of soft tissue.
16572002|NCT02798380|Experimental|HTS-519 Insert|Active treatment
16572003|NCT02798367|Experimental|CBT-I plus Melatonin 3 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 3mg. Melatonin 3mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.
~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
16572004|NCT02798367|Experimental|CBT-I plus Melatonin 5 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 5mg. Melatonin 5mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.
~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
16572005|NCT02798367|Other|CBT-I plus placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo. The participants shall administer the placebo tablets to enable the double-blind study. Placebo will be dispensed to 65 (first stage) and 56 (second stage) participants of this group and shall administer 01 tablet orally every 24 hours one hour before bedtime for 21(±2) days.
~Sleep hygiene is a psychoeducational intervention that teaches patients to prevent external or environmental factors generate adverse effects and harmful to sleep. The stimulus control technique is based on five instructions that encourages the patient to establish a proper sleep-wake rhythm and strengthens the links between the way for a quick and well consolidated sleep. The CBT-I guidelines are standardized in clinical protocol."
16572006|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.
~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
16572007|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.
~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
16572008|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.
~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
16572009|NCT02798328||Reference Range|Healthy Subjects
16572010|NCT02798328||DOAC Pivotal|DOAC Eligible Subjects
16572011|NCT02798315||Participants With Hepatitis C Virus (HCV) Genotype 1 or 4|"Participants with HCV genotype 1 or 4 receiving paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
16572012|NCT02798302|Active Comparator|Non rebreather|
16572013|NCT02798302|Active Comparator|Bag valve mask without leak|
16572014|NCT02798302|Active Comparator|Bag valve mask with simulated mask leak|
16572015|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
16572016|NCT02798276|Experimental|AGTP-treatment|Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.
16572017|NCT02798276|Other|Control|Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
16572018|NCT02798263|Experimental|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
16572019|NCT02798263|Experimental|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
16572020|NCT02798263|Experimental|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
16572021|NCT02798250|Active Comparator|Dual-hormone CL with overestimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
16572022|NCT02798250|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 35g of carbohydrates.
16572056|NCT02798016|Experimental|Platelet-Rich Plasma alone|The scars will be injected with Platelet-Rich Plasma alone.
16572057|NCT02798016|Active Comparator|Platelet-Rich Plasma with micro-needling|The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma
16572298|NCT02796443||Intermediate cholecystectomy (ILC)|Operation within 14 days after onset of symptoms
16572023|NCT02798237|Experimental|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.
~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
16572024|NCT02798237|Sham Comparator|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program.
16572028|NCT02798211|Active Comparator|Group 1|secukinumab 300mg s.c. injection
16572029|NCT02798211|Active Comparator|Group 2|secukinumab 150 mg s.c. injection
16572030|NCT02798211|Placebo Comparator|Group 3|Placebo s.c. injection
16572031|NCT02798198||Diabetes group|37 T2DM adults (diabetes group) without DKD
16572032|NCT02798198||Control group|33 healthy adults (control group)
16572033|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
16572034|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
16572035|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
16572036|NCT02798172|Experimental|Alogliptin+metformin|Alogliptin (alogliptin benzoate) is the most recent DPP-4 inhibitor; it entered the market in 2006. It is a potent and highly selective DPP-4 inhibitor with oral antidiabetic activity; Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
16572037|NCT02798172|Experimental|metformin|Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
16572038|NCT02798159|Experimental|Part A- Arm 1|Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
16572039|NCT02798159|Experimental|Part A- Arm 2|Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
16572040|NCT02798159|Experimental|Part A- Arm 3|Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
16572041|NCT02798159|Experimental|Part A- Arm 4|Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
16572042|NCT02798159|Experimental|Part B- Arm 1|"Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.
~Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month"
16572043|NCT02798159|Active Comparator|Part B- Arm 2|Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month
16572044|NCT02798146|Other|hormonal levels|Blood samples are collected for analysis of LH, E2, hCG and progesterone.
16572045|NCT02798133|Experimental|OLA|recruitment maneuver + individualized PEEP
16572046|NCT02798133|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
16572047|NCT02798120|Experimental|SB204 4%|SB204 4% once daily
16572048|NCT02798107||All patients treated with idarucizumab|
16572049|NCT02798094||Depressed Participants|No intervention
16572050|NCT02798094||Healthy Control Participants|No intervention
16572051|NCT02798081|Experimental|Single arm study|A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
16572052|NCT02798068|Active Comparator|Solu - Medrol|Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
16572053|NCT02798068|Placebo Comparator|Placebo|NaCl 0,9% 100ml IV once single administration
16572058|NCT02798003||Cachectic cancer patients|Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
16572059|NCT02798003||Non-cachectic cancer patients|Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
16572060|NCT02798003||Cachectic COPD patients|Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
16572061|NCT02798003||Non-cachectic COPD patients|Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
16572062|NCT02797977|Experimental|Standard-Dose Triplet Combination|SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
16572063|NCT02797977|Experimental|Low-Dose Gemcitabine Combination|SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
16572064|NCT02797964|Experimental|Open label|
16572065|NCT02797951|Experimental|Galcanezumab|Galcanezumab given subcutaneously (SQ) up to once a month.
16572066|NCT02797938|Experimental|Taper guard tube|Taper guard tube was intubated in 26 patients
16572067|NCT02797938|Active Comparator|Cylindrical tube|Cylindrical tube was intubated in 26 patients
16572068|NCT02797925||Tendinopathy|Long slow strength training for 3 months that are performed at home or gym. Participants receive initial guidance to the exercises from a physiotherapist assigned to Bispebjerg H.
16572069|NCT02797925||Healthy|No intervention. No training
16572070|NCT02797912||CF children and young people|Observational study involving clinical procedures: lung function testing, respiratory muscle strength testing, body composition analysis & exercise tolerance.
16572071|NCT02797899|Active Comparator|Palatal donor site received PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and received platelet rich fibrin and periodontal pack as assigned randomly by a flip of coin during the screening visits.
16572072|NCT02797899|Active Comparator|Palatal donor site NOT receiving PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and sutured followed by periodontal pack application.
16572073|NCT02797886|Experimental|FES+VOL|Electrical stimulation (FES) in concert with volitional effort. The subject is visually cued to initiate the movement and when they begin the movement (as ascertained by EMG response), the stimulation is immediately applied until the completion of the trial.
16572074|NCT02797886|Active Comparator|FES|Electrical stimulation alone. The subject is asked to do nothing as electrical stimulation initiates and completes the movement for them.
16572075|NCT02797886|Active Comparator|VOL|Volitional effort alone. When cued, the subject initiates and completes the movement on their own until the completion of the trial. There is no electrical stimulation in this group.
16572076|NCT02797873|Experimental|EIP|"Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.
~Interventions:
~fMRI - Stroop task
~fMRI - MID task
~Stop Signal task
~Structural T1 MRI scan
~Structural T2 MRI scan
~DTI MRI scan
~Resting state MRI scan
~FEFA 2
~SCID-II
~SDQ
~ASRS
~AQ
~TAS-20
~Raven's SPM
~Reading ability
~Ishihara's tests for colour deficiency
~Additional questionnaire
~Brown-ADD
~MFQ
~STAI-T
~BIS
~DAWBA
~STAI-S
~Sleepiness rating x 6
~Motivation rating x 6"
16572077|NCT02797873|Experimental|Healthy controls|"Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).
~Interventions:
~fMRI - Stroop task
~fMRI - MID task
~Stop Signal task
~Structural T1 MRI scan
~Structural T2 MRI scan
~DTI MRI scan
~Resting state MRI scan
~FEFA 2
~SCID-II
~SDQ
~ASRS
~AQ
~TAS-20
~Raven's SPM
~Reading ability
~Ishihara's tests for colour deficiency
~Additional questionnaire
~Brown-ADD
~MFQ
~STAI-T
~BIS
~DAWBA
~STAI-S
~Sleepiness rating x 6
~Motivation rating x 6"
16572078|NCT02797860||transabdominal cervicoisthmic cerclage|Second Stage of Labor pregnant women who are scheduled for transabdominal cervicoisthmic cerclage due to incompetent internal os of cervix
16572079|NCT02797860||control|women of childbearing age between 20 and 45
16572080|NCT02797847|Active Comparator|ALN-TTRSC02|
16572081|NCT02797847|Placebo Comparator|Sterile normal saline 0.9% for SC administration|
16572082|NCT02797834||Patients Endometrial Fluid|"Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days).
~This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30)."
16572083|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
16572084|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
16572085|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
16572086|NCT02797808|Experimental|Children with OCD|Children with obsessive compulsive disorder, not currently on medication for OCD
16572087|NCT02797808|Active Comparator|Healthy Control Children|Children without obsessive compulsive disorder
16572088|NCT02797795|Experimental|NEV801|"Part A - Dose escalation and de-escalation for the determination of the Maximum tolerated dose. All subjects will receive NEV801 intravenously on days 1, 8, 15 and 22 during each 28-day cycle.
~Part B - Subjects will receive NEV801 at or below the highest tolerable dose from Part A."
16572089|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
16572090|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
16572091|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
16572092|NCT02797756||Case|CC/GER+ presence of chronic cough and presence of GER evidenced by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
16572093|NCT02797756||Control|CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
16572094|NCT02797743||Whole blood from all ages and gender|- Ages from 0 to Adults (18 yrs of age or older)
16572095|NCT02797730|Experimental|art-therapy sessions|Caregivers will receive 6 art-therapy sessions
16572096|NCT02797730|No Intervention|no art-therapy sessions|Caregivers will not receive 6 art-therapy sessions during the evaluation period
16572097|NCT02797717|Other|"A-COPDAC-28"|"standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.
~drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8."
16572098|NCT02797717|Experimental|"B- DECOPDAC-21"|"DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.
~Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:
~Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1"
16572099|NCT02797704|Experimental|SC Aflibercept|The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
16572100|NCT02797691|Experimental|CaCBT plus Treatment As Usual|"Receiving CaCBT intervention in addition to the Treatment as usual"
16572101|NCT02797691|Active Comparator|Treatment As Usual (TAU)|Receiving Treatment as usual
16572102|NCT02797678|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week. Participants will then be crossed over and will wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week
16572103|NCT02797678|Sham Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week. Participants will then wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week.
16572104|NCT02797665|Active Comparator|Steroids group|The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
16572105|NCT02797665|Active Comparator|Stent group|The patients will be treated with oral corticosteroids and biliary stent.
16572106|NCT02797652||Neoadjuvant chemotherapy|ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
16572107|NCT02797652||Surgery|ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
16572108|NCT02797639|Experimental|Co-PID|Eight collaborative consultation meetings between occupational therapist to each teacher in purpose of enhancing participation of students in class
16572109|NCT02797639|Active Comparator|In-service|Three in- service meetings to all homeroom teachers together, in purpose of enhancing participation of students in class
16572110|NCT02797626|Other|Primary RPNLD|
16572111|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
16572112|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
16572113|NCT02797600||ARM I|Woman residing in Appalachian counties who have prevalent invasive cervical cancer. Invasive cervical cancer cases participants will include women previously and currently treated for ICC during the past 10 years. Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. Biological samples will be collected during a scheduled visit with the research staff.
16572114|NCT02797600||ARM II|Woman residing in Appalachian counties who are newly diagnosed with invasive cervical cancer(ICC). Newly diagnosed with ICC, and currently being treated for ICC. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected during a scheduled clinic visit.
16572115|NCT02797600||ARM III|Healthy controls (women without a diagnosis of any type of cancer. Healthy controls will be women who are coming into one of the participating clinic or physician practice for a routine Pap test. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected at the time of the clinical Pap smear.
16572116|NCT02797587|Active Comparator|Varenicline + Nicotine Replacement Therapy placebo|Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
16572117|NCT02797587|Placebo Comparator|Varenicline placebo + Nicotine Replacement Therapy|Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
16572118|NCT02797587|Active Comparator|Cytisine + Nicotine Replacement Therapy placebo|Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
16572119|NCT02797587|Placebo Comparator|Cytisine placebo + Nicotine Replacement Therapy|Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
16572120|NCT02797574|Active Comparator|Vitiligo Diagnosed Group|Clinically diagnosed with non-segmental vitiligo
16572121|NCT02797574|Active Comparator|Healthy Control Group|20 normally pigmented control subjects who are between the ages of 18 and 50
16572122|NCT02797561||Tandem lesion evaluated by FFR|
16572123|NCT02797548|Experimental|Aspirin only|
16572124|NCT02797548|Active Comparator|No antiplatelet therapy|
16572125|NCT02797535|Other|GI fluids samples collection|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
16572126|NCT02797522|Experimental|NHV Participants: Cohort 1|NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.
16572127|NCT02797522|Experimental|NHV Participants: Cohort 2|NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.
16572128|NCT02797522|Experimental|NHV Participants: Cohort 3|NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.
16572129|NCT02797522|Experimental|NHV Participants: Cohort 4|NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.
16572130|NCT02797522|Experimental|NHV Participants: Cohort 5|NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.
16572131|NCT02797522|Experimental|NHV Participants: Cohort 6|NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.
16572132|NCT02797522|Placebo Comparator|NHV Participants: Placebo|NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.
16572133|NCT02797522|Experimental|CHB Participants: Cohort 3b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
16572134|NCT02797522|Experimental|CHB Participants: Cohort 4b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
16572135|NCT02797522|Experimental|CHB Participants: Cohort 3c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.
16572136|NCT02797522|Experimental|CHB Participants: Cohort 4c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.
16572137|NCT02797509|Experimental|Psychosocial Skills-Based Intervention|Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.
16572138|NCT02797509|No Intervention|Minimally Enhanced Usual Care (MEUC)|Those in the MEUC will continue with their current care. This may include meeting with nurses, physical therapist, medical doctors, and other members of the stroke patient's medical team. Treatment as usual may also involve administration of Selective Serotonin Reuptake Inhibitors (SSRIs) to those patients with motor problems. They will also received a pamphlet with educational information on stroke and recovery
16572139|NCT02797496|Experimental|Asymmetric Motor Strengthening|
16572140|NCT02797496|Active Comparator|Conventional Therapy|
16572141|NCT02797483|Experimental|Test Fat Blue|16 weeks interventions
16572142|NCT02797483|Experimental|Test Fat Green|16 weeks interventions
16572143|NCT02797483|Experimental|Test Fat Red|16 weeks interventions
16572144|NCT02797470|Experimental|Treatment (anti-HIV gene transduced CD34+ cells)|Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.
16572145|NCT02797457|Other|Allograft|Bilateral allograft of the hands and forearms.
16572146|NCT02797457|Other|Prostheses|Prosthetic forehands
16572147|NCT02797431|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
16572148|NCT02797431|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
16572149|NCT02797431|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
16572150|NCT02797418|Experimental|Cognitus and Me|Cognitus & Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
16572151|NCT02797418|Active Comparator|control group|the control management that involves fine motor skills and research computer information,management control is usually done
16572152|NCT02797405|Other|Standard treatment|The patients will receive standard treatment according to international recommendations depending on their type of cancer.
16572186|NCT02797158|Experimental|Interventional Arm|
16572153|NCT02797392|Experimental|Lifestyle intervention|All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
16572154|NCT02797379|Other|Immediate start|This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later.
16572155|NCT02797379|Other|Delayed start|This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8.
16572156|NCT02797366|Other|Proton radiotherapy|Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
16572157|NCT02797353|Experimental|Intervention Arm|Antenatal Care, Post natal care, Skilled birth attendance, recognition and referrals of complicated cases, immunization
16572158|NCT02797353|No Intervention|Control|This arm will receive the standard MNCH services as outlined in the MNCH policy of Government of Pakistan
16572159|NCT02797340|Experimental|Interventional|All participants
16572160|NCT02797314|Other|Type 2 diabetic population|Bone biopsies
16572161|NCT02797314|Other|Non-diabetic control population|Bone biopsies
16572162|NCT02797301|Experimental|synthetic test & computerised test|Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
16572163|NCT02797301|Experimental|computerised test & synthetic test|Sixteen preschool children (G2), with no motor impairments, from a private school. The children in G2 performed the computerised test before the synthetic test.
16572164|NCT02797301|Experimental|computerised test|Seven volunteers (G3), two males and five females, with moderate mobility impairment, patients from the Physical Therapy and Rehabilitation Clinic.
16572165|NCT02797275|Experimental|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
16572166|NCT02797275|Experimental|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
16572167|NCT02797262|Experimental|Intervention|"Building on the available Proteus devices, the investigators will design and create a Proteus digital health feedback (PDHF) system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
~The investigators will test overall utility (including feasibility, acceptability and sustainability) of the PDHF system, its accuracy for measuring adherence and its impact on enhancing patients' level of adherence and the effect on virologic and clinical outcomes (exploratory), the retention of its impact on keeping up with adherence and improvement of plasma HIV RNA and CD4 cell count after the 16-week usage of the PDHF system."
16572168|NCT02797262|No Intervention|Control|UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment. Eligible patients will be randomized to one of the two conditions using a stratified urn randomization procedure to increase the likelihood of balanced allocation of prognostic variables at baseline.
16572169|NCT02797249|Experimental|aspirin|Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
16572170|NCT02797249|Other|blank|Routine examination during pregnancy.
16572171|NCT02797236|Experimental|vaccine dose 1|SF2a-TT15 vaccine, 2 μg
16572172|NCT02797236|Experimental|vaccine dose 1+ adjuvant|SF2a-TT15 vaccine, 2 μg + alum
16572173|NCT02797236|Experimental|vaccine dose 2|SF2a-TT15 vaccine, 10 μg
16572174|NCT02797236|Experimental|vaccine dose 2 + adjuvant|SF2a-TT15 vaccine, 10 μg + alum
16572175|NCT02797236|Placebo Comparator|Placebo|Tris buffer
16572176|NCT02797236|Placebo Comparator|Placebo + adjuvant|Tris buffer + Alum
16572177|NCT02797210|Experimental|Sham then Active Stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
16572178|NCT02797210|Experimental|Active then Sham Stimulation|Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
16572179|NCT02797197|Experimental|patient undergoing to chemotherapy during 6 months|
16572180|NCT02797184|Experimental|Aim 1. KNO3 dose response|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
16572181|NCT02797171|Experimental|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
16572182|NCT02797171|Experimental|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
16572183|NCT02797171|Experimental|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
16572184|NCT02797171|Experimental|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
16572185|NCT02797171|Experimental|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
16572187|NCT02797145|Active Comparator|Intensive Group|Dose adjusted digoxin by the recommended range for the serum digoxin: 0.5-0.9 nanogram/mL
16572188|NCT02797145|Placebo Comparator|Conventional|Use digoxin as recommended by the guidelines.
16572189|NCT02797132|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A (<14 kg): Participants weighing less than (<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.
~Part A (>=14 kg): Participants weighing greater than or equal to (>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.
~Part B (<14 kg): Participants weighing <14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.
~Part B (>=14 kg): Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B."
16572190|NCT02797119|Experimental|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.
~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
16572191|NCT02797119|Experimental|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
16572192|NCT02797119|Placebo Comparator|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
16572193|NCT02797119|No Intervention|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
16572194|NCT02797106||health care professionals|health care professionals potentially involved in assessment and/or treatment of drooling in children with Cerebral Palsy.
16572195|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
16572196|NCT02797080|Experimental|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
16572197|NCT02797067|Experimental|Indomethacin|Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
16572198|NCT02797067|Placebo Comparator|Glycerin|Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.
16572199|NCT02797054|Experimental|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
16572200|NCT02797054|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
16572201|NCT02797054|Other|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
16572202|NCT02797028|Placebo Comparator|Placebo capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule
16572203|NCT02797028|Experimental|Anthocyanidins capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.
16572204|NCT02797028|Experimental|Allopurinol|The experimental group taking allopurinol.
16572205|NCT02797015|Experimental|1 mg RPC1063|1 mg RPC1063 oral capsule daily
16572206|NCT02797015|Experimental|0.5 mg RPC1063|0.5 mg RPC1063 oral capsule daily
16572207|NCT02797002||Chronic non specific neck pain|Experiencing neck pain for at least 3 months in the last year
16572208|NCT02797002||Without neck pain (asymptomatic)|No history of neck pain
16572209|NCT02796989|Active Comparator|Healthy - Wheat Bran|Wheat bran 20 g each day
16572210|NCT02796989|Placebo Comparator|Healthy - Placebo|Placebo 20 g each day
16572211|NCT02796989|Active Comparator|Obese - Wheat bran|Wheat bran 20 g each day
16572212|NCT02796989|Placebo Comparator|Obese - Placebo|Placebo 20 g each day
16572213|NCT02796976|No Intervention|healthy older active|only cross-sectional
16572214|NCT02796976|No Intervention|healthy older sedentary|only cross-sectional
16572215|NCT02796976|Active Comparator|older sedentary at risk|cross-sectional and training or control condition
16572216|NCT02796963|Experimental|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
16572217|NCT02796963|Experimental|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
16572218|NCT02796950|Experimental|Acipimox|Administration of acipimox 250 mg p.o.
16572219|NCT02796950|No Intervention|Control|No intervention.
16572220|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
16572221|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
16572222|NCT02796911|No Intervention|Corticotomy alone|Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
16572223|NCT02796911|Experimental|Corticotomy + xenograft|group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
16572224|NCT02796911|Experimental|Corticotomy + bioactive glass|group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
16572225|NCT02796898|Experimental|Treated Group|"SM88 is a combination therapy consisting of 4 agents. One agent, the tyrosine isomer will be increased in each of 2 dose cohorts as follows:
~Cohort 1:
~Tyrosine isomers - 230 mg qd
~Phenytoin - 50 mg qd.
~Methoxsalen - 10 mg qd
~Sirolimus - 0.5 mg qd
~Cohort 2:
~Cohort 2 has increasing tyrosine isomer from q.d. to b.i.d.
~Expansion Cohort:
~The optimum dose will be expanded in 2nd stage of the study to 30 subjects."
16572226|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
16572227|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
16572228|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
16572229|NCT02796872|Placebo Comparator|mother's breast milk.|mother's breast milk.
16572230|NCT02796872|Active Comparator|other GOS|Commercial infant formula containing 4% w/w FOS:GOS (1:3)
16572231|NCT02796872|Experimental|B-GOS 3%|Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
16572232|NCT02796872|Experimental|B-GOS 2%|Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
16572233|NCT02796859|Active Comparator|Treatment Group|Subjects in the siltuximab group will receive an 11 mg/kg infusion at baseline, and weeks 3 and 6, as per the recommended dosing for multicentric Castleman's disease
16572234|NCT02796859|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the siltuximab group) at baseline, and weeks 3 and 6.
16572235|NCT02796846||CPAP prescription group|Patients with a CPAP prescription (both compliant and noncompliant)
16572236|NCT02796846||Without a CPAP prescription|Patients without a CPAP prescription to satisfy our primary goals/objectives.
16572237|NCT02796833|Other|SMOF/Intralipid|"Patients that are randomized to receive for the first 6 months SMOF as a lipid emulsion in their PN, and for the next 6 month (after 28 days of active washout on Intralipid) Intralipid, which is the standard lipid emulsion used in the hospital. SMOF is approved by Health Canada.
~The parenteral nutrition bags are compounded individually for each patient based on their specific needs."
16572238|NCT02796833|Other|Intralipid/SMOF|Patients that are randomized to receive Intralipid, which is the standard lipid emulsion used in the hospital for the first 6 months, and for the next 6 month (after 28 days of active washout on Intralipid) SMOF as a lipid emulsion in their PN. SMOF is approved by Health Canada.The parenteral nutrition bags are compounded individually for each patient based on their specific needs.
16572239|NCT02796820|Experimental|Huaier Granule|Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
16572240|NCT02796820|No Intervention|Regular follow-up observation|Regular follow-up observation after surgery.
16572241|NCT02796807|Experimental|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
16572242|NCT02796794|Active Comparator|Genistein|Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
16572243|NCT02796794|Other|control|Control group are the patients receiving enteral nutrition
16572244|NCT02796781|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
16572245|NCT02796768||Participants|"Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:
~BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.
~FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,
~1 2D US scanning session of right and left hip by Specialist 1,
~1 2D US scanning session of right and left hip by Specialist 2."
16572246|NCT02796755|Experimental|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
16572247|NCT02796755|Placebo Comparator|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
16572248|NCT02796742||Group MSSA|
16572249|NCT02796742||Group MRSA|
16572250|NCT02796742||Group PVL-negative strains|
16572251|NCT02796742||Group PVL-positive strains|
16572252|NCT02796729|Experimental|dynamic glucose enhanced MRI after D-glucose injection|"IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.
~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.
~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec."
16572253|NCT02796703|Placebo Comparator|Control Group|Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
16572254|NCT02796703|Active Comparator|Treatment Group|"Dietary Supplement: Heat Inactivated Probiotics
~1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula."
16572255|NCT02796690||Group Methicillin susceptible Staphylococcus aureus (MSSA)|
16572256|NCT02796690||Group methicillin resistant Staphylococcus aureus (MRSA)|
16572257|NCT02796677|Experimental|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
16572258|NCT02796677|Experimental|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
16572259|NCT02796677|Experimental|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
16572260|NCT02796677|Experimental|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
16572261|NCT02796664|Experimental|Ginseng|
16572262|NCT02796664|Placebo Comparator|Placebo|
16572299|NCT02796443||Delayed LC (DLC)|Operation after 6-12 weeks
16572263|NCT02796651|Experimental|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
16572264|NCT02796651|Experimental|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
16572265|NCT02796651|Experimental|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
16572266|NCT02796651|Placebo Comparator|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
16572267|NCT02796651|Experimental|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
16572268|NCT02796651|Experimental|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
16572269|NCT02796638|Experimental|Minute Ventilation Adaptive Servo-Ventilation plus SOC|Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
16572270|NCT02796638|No Intervention|Standard of Care (SOC)|Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
16572271|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
16572272|NCT02796612|Active Comparator|No intervention|Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
16572273|NCT02796612|Experimental|Intervention group|"Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
~Additionally, delivery of a take-home brochure to the patients during the first visit is planned. The biopsy is explained to the patient and performed by a psychological trained physician. Patient care by a psychologically trained physician is performed in the sense that patients are informed about their biopsy result by a specifically trained physician."
16572274|NCT02796599|Experimental|CWLT with facial mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
16572275|NCT02796599|Experimental|CWLT with nasal mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
16572276|NCT02796586|Placebo Comparator|Individual Contraceptive Counseling|Performed by a medical provider and planned to simulate a typical clinic visit addressing contraception.
16572277|NCT02796586|Experimental|Group Contraceptive Counseling|Performed by a bicultural study staff member who speaks the primary languages of participants and had been formally trained in contraception counseling.
16572278|NCT02796573|Experimental|B-CBT|6 face-to-face consultations plus 6 online modules.
16572279|NCT02796573|Active Comparator|Face-to-Face CBT|12 face-to-face consultations.
16572280|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
16572281|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
16572282|NCT02796547|Experimental|Levobupivacaine|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with Levobupivacaine. This is the only intervention specific to the study, as compared to the standard of care.
16572283|NCT02796547|Placebo Comparator|Placebo|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with physiological serum.This is the only intervention specific to the study, as compared to the standard of care.
16572284|NCT02796521|Other|control group|The control group will receive usual dietary counseling for enrichment.
16572285|NCT02796521|Other|workshop group|The workshop group will have informations about interest of foods. They will enrich a meal with foods which can easily be added without cooking.
16572286|NCT02796508|Experimental|Non-action video game training|Experimental: Non-action video game training 16 1-hour training sessions with 10 non-action video game training selected games from Lumosity.
16572287|NCT02796508|Active Comparator|Non-cognitive video game training|Active Control: Non-cognitive social video game training 16 1-hour training sessions with non-cognitive video game training with social games from The Sims.
16572288|NCT02796495|Experimental|Operation of hand prosthesis with direct nerve stimulation|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in one or two amputees:
~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)
~TIME-4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)
~Sensorized Hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)
~Prosthetics sensorized hand for amputees DLR/HIT Hand II (Wessling Robotics)
~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand
~The EPIONE Psychophysical Testing Platform software for stimulator control"
16572289|NCT02796482|Other|EnergieShake 1.5 kcal Complete Intervention|Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
16572290|NCT02796469||Pentoxifylline + Corticosteroid|Association of treatment by pentoxifylline and corticosterone during 28 days
16572291|NCT02796469||Corticosteroid|treatment by corticosteroid during 28 days
16572292|NCT02796469||Pentoxifylline|treatment by pentoxifylline during 28 days
16572293|NCT02796469||Placebo|
16572294|NCT02796456||Normal weight women|BMI between 18.5 and 25 kg/m2 and without gestational diabetes
16572295|NCT02796456||Obese women without gestational diabetes|BMI more than 30 kg/m2 and without gestational diabetes
16572301|NCT02796430||Mechanically ventilated patients|Ease of use will be assessed by analysing the time needed to start indirect calorimetry measurement, and results of indirect calorimetry measurements by both the new indirect calorimeter and the currently used calorimeters at each study center.
16572302|NCT02796417|Experimental|Rehacop group|Cognitive rehabilitation
16572303|NCT02796417|Active Comparator|Control group|Occupational activities
16572304|NCT02796404|Experimental|Homebased cardiac rehabilitation program|Homebased Cardiac rehabilitation program with monitoring vest and mixed surveillance.
16572305|NCT02796404|Other|Traditional cardiac rehabilitation|Multidisciplinary program in a cardiac rehabilitation gym. Routine clinical practice
16572306|NCT02796391|Experimental|Study 1: Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mb nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction.
~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
16572307|NCT02796391|Experimental|Study 1: Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).
~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
16572308|NCT02796391|Experimental|Study 2: Targeted/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
16572309|NCT02796391|Experimental|Study 2: Targeted/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
16572310|NCT02796391|Experimental|Study 2: Generic/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
16572311|NCT02796391|Experimental|Study 2: Generic/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
16572312|NCT02796378|Active Comparator|Training+Simvastatin+Q10-placebo|Training+Simvastatin+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day and Q10-placebo.
16572313|NCT02796378|Placebo Comparator|Training+Simvastatin-placebo+Q10-placebo|Training+Simvastatin-placebo+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week, Simvastatin-placebo and Q10-placebo.
16572314|NCT02796378|Active Comparator|Training+Simvastatin+Q10|Training+Simvastatin+Q10. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day in combination with 400 mg of oral supplementation with Q10.
16572315|NCT02796365|Experimental|Exercise|Patients will participate in a 10 week outpatient cardiac rehabilitation program. Exercise will consist of 3 days per week of interval training on a treadmill or bike at an intensity between 50-90% of heart rate reserve. Additionally patients will perform resistance exercises 1-2 days per week and attend 8 nutrition and lifestyle classes.
16572316|NCT02796365|No Intervention|Usual care|Control group will not be instructed on exercise, but encouraged to follow standard medical advice.
16572317|NCT02796352|Experimental|High dose bolus interleukin-2 (HD IL2)|
16572318|NCT02796339|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
16572319|NCT02796339|Placebo Comparator|Placebo|This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
16572320|NCT02796326|Experimental|Dilatation|Patients undergoing tracheal dilatation with the study device
16572321|NCT02796313|Experimental|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $35 credit for groceries.
16572322|NCT02796313|Active Comparator|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $35 credit for groceries.
16572323|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
16572324|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
16572325|NCT02796287|Experimental|Patients with Ictus amnesic|Patients admitted in the hospital as part of their medical care with amnesic Ictus episode
16572326|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
16572327|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
16572328|NCT02796235|Other|Spinal cord injury (SCI) patient|
16572329|NCT02796222||Hemophilia A patients on rFVIIIFc|Patients with hemophilia A who switch from on-demand or prophylactic treatment with rFVIII to rFVIIIFc
16572330|NCT02796222||Hemophilia A patients on rFVIII|Patients with hemophilia A who remain on on-demand or prophylactic treatment with rFVIII
16572331|NCT02796222||Hemophilia B patients on rFIXFc|Patients with hemophilia B who switch from on-demand or prophylactic treatment with rFIX to rFIXFc
16572332|NCT02796222||Hemophilia A patients on rFIX|Patients with hemophilia B who remain on on-demand or prophylactic treatment with rFIX
16572333|NCT02796209|Experimental|Atomexetine|Following the dose optimization phase, investigators will stratify the treatment assignment by Atomexetine dose (10mg or 19mg twice a day)
16572334|NCT02796209|Placebo Comparator|Placebo|The placebo capsules will be of identical color, size, and approximate weight to provide an authentic blinded effect. The capsule contents will be a microcrystalline cellulose, NF (PH-105), which should not produce any adverse effects. It is a common pharmaceutical capsule filler used in the industry.
16572335|NCT02796196||Supportive care (monitoring device, medical chart review)|Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
16572336|NCT02796183|Other|Diabetic macular edema|Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
16572337|NCT02796170|Active Comparator|Dapagliflozin|This arm will undergo 6 weeks of Dapagloflozin then 6 weeks of placebo
16572338|NCT02796170|Other|Sulfonylurea|This arm will be open label, participants will receive usual care for 6 weeks, then be provided a sulfonylurea medication for 6 weeks.
16572339|NCT02796170|Active Comparator|Placebo|This arm will undergo 6 weeks of placebo then 6 weeks of Dapagloflozin
16572340|NCT02796157|Active Comparator|absorb arm|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
16572341|NCT02796157|Experimental|Xience arm|PCI with Xience everolimus-eluting metallic stent
16572342|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
16572343|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
16572344|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
16572345|NCT02796131|Experimental|30 mg bid|30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).
16572346|NCT02796131|Experimental|30 mg tid|30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).
16572347|NCT02796131|Experimental|60 mg bid|60 mg of RDX5791 administered two times daily (120 mg total dose/day).
16572348|NCT02796131|Experimental|15 mg bid|15 mg of RDX5791 administered two times daily (30 mg total dose/day).
16572349|NCT02796131|Experimental|30 mg QD|30 mg of RDX5791 administered once daily (30 mg total dose/day).
16572350|NCT02796131|Experimental|Escalating dose bid|15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.
16572351|NCT02796131|Experimental|30 mg bid with psyllium|30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).
16572352|NCT02796118|Experimental|ASP2151 Low dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
16572353|NCT02796118|Experimental|ASP2151 High dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
16572354|NCT02796118|Experimental|ASP2151 Low dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
16572355|NCT02796118|Experimental|ASP2151 High dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
16572356|NCT02796118|Placebo Comparator|Placebo in non-elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
16572357|NCT02796118|Placebo Comparator|Placebo in elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
16572358|NCT02796105|Experimental|Progevera|Progevera 10 mg
16572359|NCT02796105|Active Comparator|Orgalutran|Orgalutran 0.25 mg
16572360|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
16572361|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
16572362|NCT02796079|Experimental|Autologous Bone Marrow Stem Cell|Mesenchymal stem cells derived from bone marrow infusion
16572363|NCT02796079|Placebo Comparator|saline|saline injections
16572364|NCT02796066|Placebo Comparator|Vehicle|Vehicle gel
16572365|NCT02796066|Experimental|Low Dose Active|Low Dose of TSN2898
16572366|NCT02796066|Experimental|Mid Dose Active|Mid Dose of TSN2898
16572367|NCT02796066|Experimental|High Dose Active|High Dose of TSN2898
16572368|NCT02796053|Placebo Comparator|Placebo|Placebo to TAB08
16572369|NCT02796053|Experimental|TAB08 Dose 1|Drug: TAB08 biologic
16572370|NCT02796040|Experimental|patients with ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
16572371|NCT02796040|Other|patients without ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
16572372|NCT02796027|Experimental|Experimental: BRIDGE|Subjects assigned to this arm would receive an integrated HIV service model
16572373|NCT02796027|No Intervention|Pre-implementation|Subjects assigned to this arm would receive standard care (treatment as usual) and would not be exposed to the integrated HIV service model.
16572374|NCT02796001|Active Comparator|RV16|volunteers re-challenged with RV16
16572376|NCT02795988|Experimental|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
16572377|NCT02795988|Experimental|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
16572378|NCT02795988|Experimental|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
16572379|NCT02795962|Active Comparator|Transfer to an Endovascular Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center.
16572380|NCT02795962|No Intervention|Transfer to the Local Stroke Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol.
16572381|NCT02795949|Experimental|Antipseudomonal beta-lactam antibiotic|"Ampicillin 2g IV/6h
~Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h
~Cefuroxime 750-1000 mg IV/8h
~Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h
~Amoxicillin/clavulanate 1000/125 mg IV/8h
~Ciprofloxacin 400 mg IV/12h
~Ertapenem 1-2g/24h."
16572382|NCT02795949|Active Comparator|De-escalation(short-spectrum antibiotic)|"Piperacillin/tazobactam 4/0.5 g IV/8h
~Meropenem 1-2 g IV/8h
~Imipenem 0.5 g IV/6h - 1g IV/6h
~Aztreonam 1-2 g IV/8h
~Ceftazidime 1-2 g IV/8h
~Cefepime 2 g IV/8-12h"
16572383|NCT02795936|Active Comparator|Institutional based rehabilitation|Conduct cardiac rehabilitation exercise protocol within the hospital
16572384|NCT02795936|Active Comparator|Home based rehabilitation|Conduct cardiac rehabilitation exercise protocol at home
16572385|NCT02795936|Placebo Comparator|Observational arm|No prescribed exercises, followed up monthly
16572386|NCT02795910|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions
16572387|NCT02795910|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will receive no outreach education training.
16572388|NCT02795884|Experimental|Intercalation arm|"Intercalation phase (Duration: 3wks x 4 cycles = 12 wks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Erlotinib 150mg D8-21 q3wks
~Maintenance phase (Duration: 1 year) Erlotinib 150mg D1-28"
16572389|NCT02795884|Active Comparator|Chemotherapy alone arm|Duration: 3wks x 4 cycles = 12 wks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3wks
16572390|NCT02795871|Experimental|Group D+ 1|Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
16572391|NCT02795871|Experimental|Group D+ 2|Girls and boys affected by CAH and treated in utero by Dexamethasone.
16572392|NCT02795871|Active Comparator|: Group D - 1|Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
16572393|NCT02795871|Active Comparator|Group D - 2|Girls and boys affected by CAH and not treated in utero by Dexamethasone.
16572394|NCT02795871|Other|Group D - 3|Girls and boys enrolled in school closed to Lyon
16572395|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with Ramucirumab at a pre-determined dose intravenously every 14 days of a 28-day treatment cycle.
~Patients will receive treatment with a Somatostatin Analog at a pre-determined dose.
~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
16572396|NCT02795845|Experimental|Primary prevention- probiotic capsules|"patients with normal vaginal flora in the experimental arm will be treated with Probiotic capsules (containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus, Bifidobacterium bifidum and B. Lactis).
~one capsule twice a day until delivery."
16572397|NCT02795845|Placebo Comparator|Primary prevention - Placebo|patients with normal vaginal flora in the placebo arm will be treated with a capsule without active ingredient, one capsule twice a day until delivery.
16572398|NCT02795845|Experimental|Secondary prevention - probiotic capsules|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given probiotic capsules.
16572399|NCT02795845|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given placebo without active ingredient.
16572400|NCT02795832|Experimental|Cohort 1a|ZPL-5212372 1% w/w Ointment BID
16572401|NCT02795832|Placebo Comparator|Cohort 1b|Placebo Ointment BID
16572402|NCT02795832|Experimental|Cohort 2a|ZPL-5212372 1% w/w Ointment BID
16572403|NCT02795832|Placebo Comparator|Cohort 2b|Placebo Ointment BID
16572404|NCT02795832|Experimental|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
16572405|NCT02795832|Placebo Comparator|Cohort 3b|Placebo Ointment BID
16572406|NCT02795819|Experimental|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
16572407|NCT02795819|Experimental|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
16572408|NCT02795819|Experimental|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
16572409|NCT02795819|Experimental|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
16572410|NCT02795819|Experimental|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
16572411|NCT02795819|Experimental|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
16572412|NCT02795819|Experimental|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
16572413|NCT02795806||1|Everybody for whom a clinical narrative report is created.
16572414|NCT02795793|Experimental|Non-operative management group (NOM)|Children in the NOM group will receive intravenous Piperacillin with Tazobactam (Tazocin) 100mg/kg/dose every 8 hours for at least 24 hours, and they will be observed and reassessed within 24 hours after randomisation. A further 24 hours of intravenous Piperacillin with Tazobactam therapy will be offered to children in invariable condition. A clinical decision will be made by the attending surgeon to offer OM if a patient's condition deteriorates at any time, or if a patient has failed to improve after 48 hours of intravenous antibiotic therapy. Once the patient is clinically improving and tolerating oral intake, the antibiotic regimen will be changed to oral Amoxicillin plus Clavulanic acid (Augmentin) 22.5mg/kg/dose twice per day to complete a total seven day course of antibiotics. Oral Ciprofloxacin 15mg/kg/dose twice daily and oral Metronidazole 10mg/kg/dose twice daily will be offered to children who are known to have an intolerance or allergy to Amoxicillin or Clavulanic acid.
16572415|NCT02795793|Active Comparator|Appendectomy group (Operative management, OM)|Children allocated to OM may receive preoperative antibiotic prophylaxis as clinically indicated. Appendicectomy will be performed laparoscopically, or via open surgery according to the surgeon's standard practice. Postoperative antibiotic treatment will be determined on the basis of intraoperative findings in accordance with the institutional practice. The appendix specimen will be examined by a paediatric pathologist, and the formal histopathology report will be recorded.
16572416|NCT02795780|Experimental|Follow-up Flortaucipir PET Scan|
16572417|NCT02795767|Experimental|Cohort A: 1.5 mg/kg Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
16572418|NCT02795767|Experimental|Cohort B: 3 mg/kg Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
16572419|NCT02795767|Experimental|Cohort C: 6 mg/kg Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
16572420|NCT02795754|Experimental|GSK2838232 PIB (50 mg+100 mg+200 mg)+Placebo|During Part 1A, subjects will receive QD single dose of either GSK2838232 50 mg, 100 mg or 200 mg or placebo in each of the four visits (one treatment per visit).Subjects will also receive RTV along with all the doses and QD RTV for 48hours (2 doses) before all doses of GSK2838232 and placebo.
16572421|NCT02795754|Experimental|GSK2838232 PIB+IR1+IR2|During Part 1B, subjects will receive either GSK2838232 PIB, GSK2838232 IR1 or IR2 in each of the three visits (one treatment per visit) after at least 10 hours fasting and IR1 or IR2 after fat meal at visit 4.
16572422|NCT02795754|Experimental|GSK2838232 PIB (20mg/50 mg/100 mg/200 mg)/Placebo|During Part 2, subjects will receive repeated QD doses of either GSK2838232 (20 mg, 50 mg, 100 mg or 200 mg) or placebo for 11 days. Subjects will also receive RTV along with all the doses of GSK2838232 and placebo.
16572423|NCT02795741|Experimental|Cooling Bolero|All participants will use the Cooling Bolero for one month
16572424|NCT02795728|Experimental|Experimental arm|Fuji type VII is a GIC based sealant with an additional property of high fluoride release
16572425|NCT02795728|Active Comparator|Resin based sealant|Helioseal F is a resin based sealant
16572426|NCT02795715|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
16572427|NCT02795715|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
16572428|NCT02795702|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
16572429|NCT02795702|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
16572430|NCT02795676|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 infusion every 2 weeks
16572431|NCT02795676|Active Comparator|agalsidase beta|agalsidase beta infusion every 2 weeks
16572432|NCT02795663|Experimental|parkinson's patient stimulated at STN level|15 parkinson's disease patients stimulated at STN level NIRS EEG HR recording
16572433|NCT02795663|Experimental|non STN|5 Parkinson's Disease patients who received stimulation in another target that the STN NIRS EEG HR recording
16572434|NCT02795663|Experimental|control|20 control patients undergoing DBS for the treatment of OCD NIRS EEG HR recording
16572435|NCT02795650|Experimental|Experimental arm|Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.
16572436|NCT02795650|Active Comparator|Control|Investigators are allowed to chose the best option of standard treatment for patients.
16572437|NCT02795637|Experimental|dasotraline|dasotraline 8mg capsule/day
16572438|NCT02795624||Flight attendants|Flight attendants
16572439|NCT02795611|Experimental|Treatment group|Patients who receive 'family-centered occupational therapy' in our hospital
16572440|NCT02795611|Active Comparator|Control group 1|Patients who receive regular occupational therapy in our hospital
16572441|NCT02795611|Other|Control group 2|Patients who don't receive intervention in our hospital
16572442|NCT02795598|Active Comparator|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
16572443|NCT02795598|Active Comparator|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
16572444|NCT02795585||QFR group|Patients with stable angina pectoris and indication for FFR.
16572445|NCT02795572|Experimental|Intervention Group|The intervention group will receive a daily dose of Vitamin D 2000 IU, Vitamin B6 100 mg, Vitamin B12 100 mcg and Omega-3 Fatty Acids 2700 mg [900 mg TID (600 mg EPA, 300 mg DHA)].
16572446|NCT02795572|No Intervention|Reference Group|Reference group will receive usual care.
16572447|NCT02795559|Other|Lean|Subjects within the range of desirable body weight (BMI<25)
16572448|NCT02795559|Other|OWO|Subjects who are overweight or obese (BMI between 25 and 40)
16572449|NCT02795546|Experimental|Test group|400µg Alendronate sodium+ β-TCP + saline. 400µg alendronate sodium is combined with beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
16572450|NCT02795546|Active Comparator|Control group|β-TCP + saline Beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
16572451|NCT02795533||Clinical follow-up|As part of the regular follow-up of aSAH patients at Oslo University Hospital patients with as aSAH in 2011-2012 will be invited to a clinical interview, medical examination and neuropsychological test. Patients will also be asked to answer Quality of Life Questionnaires.
16572452|NCT02795520|Experimental|OTS167IV|
16572453|NCT02795507|Experimental|Device with feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in this specialized motion control apparatus which allows movement of the non involved hand while receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).
~5 days per week for 3 weeks, 1 hour per day."
16572454|NCT02795507|Active Comparator|Device without feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in a specialized motion control apparatus which allows movement of the non involved hand but without receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).
~5 days per week for 3 weeks, 1 hour per day."
16572455|NCT02795494||Perthes Group|Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
16572456|NCT02795494||Fracture Control Group|Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
16572457|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
16572458|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
16572459|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
16572460|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
16572461|NCT02795481||Traumatic brain injury patients|10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.
16572462|NCT02795468|Active Comparator|Palpation group|The operator will use the pulsation of the radial artery as a guide for the cannulation.
16572463|NCT02795468|Experimental|Ultrasound group|The ultrasound guided technique will be used to find a radial artery and insert a radial arterial catheter.
16572464|NCT02795455|Experimental|Interoceptive Exposure (IE)|IE is an exposure-based intervention that involves consuming a food in session and tolerating uncomfortable feelings around eating.
16572465|NCT02795455|Active Comparator|Family Based Therapy-Weight Gain Control (FBT-WG)|Family-based therapy uses parent(s) to help modify disordered eating and develop contingencies to motivate eating.
16572466|NCT02795455|No Intervention|Healthy Controls (HC)|HC participants will only participate in the pre and post-intervention visits and not in the intervention sessions.
16572467|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
16572468|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
16572469|NCT02795429|Experimental|INC280+PDR001|PDR001 + INC280 treatment in Phase II
16572470|NCT02795429|Experimental|PDR001 single agent|PDR001 single agent treatment in Phase II
16572471|NCT02795416|Experimental|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.
~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
16572472|NCT02795403|Experimental|Viraemic|
16572473|NCT02795403|Experimental|responder group|
16572474|NCT02795390|Experimental|Chinese herbal medicine|MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
16572475|NCT02795390|Placebo Comparator|Placebo|Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.
16572476|NCT02795377||male subjects with arterial hypertension|Measurements will be taken at baseline.
16572477|NCT02795377||male subjects without arterial hypertension and no CAD|Measurements will be taken at baseline.
16572478|NCT02795377||male subjects with hypertensive crises|Measurements will be taken before and after 4 hours and normalization of arterial blood pressure by urapidil.
16572479|NCT02795377||male subjects with stable CAD|Measurements will be taken before and after transfemoral coronary diagnostic angiography.
16572480|NCT02795364|Active Comparator|Structural Image Guidance|In this arm, the patients will receive maximum resection of the tumor with the MRI T1W-enhanced image guidance, in addition to the standard therapy
16572662|NCT02794259|Sham Comparator|Sham tDCS|Sham stimulation during resting state fMRI
16572663|NCT02794246|Experimental|Single Arm|
16572481|NCT02795364|Experimental|Metabolic Image Guidance|In this arm, the patients will receive quantitative resection of the tumor with both the MRI T1W-enhanced and the MRS Cho-to-NAA index (CNI) image guidance, in addition to the standard therapy.
16572482|NCT02795351|Experimental|Active|Sildenafil 100 mg single dose
16572483|NCT02795351|Placebo Comparator|Placebo|Placebo capsule
16572484|NCT02795325|Experimental|PH Patients|
16572485|NCT02795325|Experimental|Healthy Volunteers|
16572486|NCT02795312|Experimental|Smoking Cessation Training Program|Participants will take part in a 9-week Smoking Cessation Program class curriculum consisting of weekly 2.5 hour classes and complete pre and post questionnaires
16572487|NCT02795299|Active Comparator|Gerilimzumab 5/2 mg/Methotrexate/folate|• 5 mg gerilimzumab loading dose followed by 2 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
16572488|NCT02795299|Active Comparator|Gerilimzumab 10/5mg/Methotrexate/folate|• 10 mg gerilimzumab loading dose followed by 5 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
16572489|NCT02795299|Active Comparator|Gerilimzumab 20/10mg/Methotrexate/folate|• 20 mg gerilimzumab loading dose followed by 10 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
16572490|NCT02795299|Placebo Comparator|Placebo/Methotrexate/folate|• Placebo every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
16572491|NCT02795286|Experimental|ASIST A|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
16572492|NCT02795286|Experimental|ASIST B|Artis Haemodialysis Machine w/ ASIST Software - Isotonic
16572493|NCT02795286|Active Comparator|Conventional HD|Artis Haemodialysis Machine w/o ASIST Software
16572494|NCT02795273|Experimental|Grass-SPIRE|Eight intradermal injections of Grass-SPIRE
16572495|NCT02795273|Placebo Comparator|Placebo|Eight intradermal injections of Placebo
16572496|NCT02795260|Experimental|ESAT6-CFP10 in the right arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.
16572497|NCT02795260|Experimental|ESAT6-CFP10 in the left arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.
16572498|NCT02795247|Active Comparator|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
16572499|NCT02795247|Active Comparator|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
16572500|NCT02795247|Active Comparator|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
16572501|NCT02795234|Other|Participants with Vitamin D deficiency|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
16572502|NCT02795234|Other|Participants with sufficient Vitamin D Level|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
16572503|NCT02795208|No Intervention|Control group|Patients received standard protective ventilation along the protocol.
16572504|NCT02795208|Experimental|Recruitment maneuver group|Patient received a lung recruitment maneuver after cardiopulmonary bypass. The recruitment maneuver consists in 10 breaths at 40/20 cmH2O of plateau pressure and PEEP, respectively. Then, the .ventilatory settings back to protective ventilation but adding 10 cmH2O of PEEP to keep the lungs open.
16572505|NCT02795195|Experimental|CIRT Arm (3GyE per fraction)|Patients included in this arm were treated with carbon ion radiotherapy with a fraction size of 3GyE.
16572506|NCT02795182|Other|BGB-3111 and BGB-A317|Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tiselisumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
16572507|NCT02795156|Experimental|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
16572508|NCT02795156|Experimental|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
16572509|NCT02795156|Experimental|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
16572510|NCT02795156|Experimental|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
16572511|NCT02795143|Experimental|Isotretinoin|"Isotretinoin will be given at the following dosage:
~Dosing will be as listed on the table below.
~Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg"
16572512|NCT02795143|Placebo Comparator|Placebo|Subjects will be given placebo capsules twice a day.
16572513|NCT02795130|Experimental|8-0 polyglactin 910|
16572514|NCT02795130|Experimental|6-0 plain gut suture|
16572515|NCT02795117|Experimental|Test product|
16572516|NCT02795117|Active Comparator|Reference product|
16572517|NCT02795117|Placebo Comparator|Placebo product|
16572518|NCT02795104|Experimental|ARM I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
16572519|NCT02795104|Experimental|ARM II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
16572520|NCT02795104|Experimental|ARM III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
16572525|NCT02795052|Active Comparator|Arm 1 - Intravenous BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously.
16572526|NCT02795052|Active Comparator|Arm 2- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
16572527|NCT02795039|Experimental|Fulvestrant 50mg/mL (Fresenius Kabi)|5 mL intramuscular injection
16572528|NCT02795039|Active Comparator|Fulvestrant 50 mg/mL (Faslodex®)|5 mL intramuscular injection
16572529|NCT02795026|Active Comparator|Manual therapy|Intervention to be administered is manual therapy with myofascial release of trigger points for pelvic floor muscles, pelvis and abdominal musculature.
16572530|NCT02795026|Active Comparator|Dry needling & manual therapy|Intervention to be administered is Trans-perineal trigger point dry needling, done externally to target the trigger points in the pelvic floor muscles along with dry needling of the pelvis and abdominal musculature.Manual therapy will only be used in areas difficult to reach with the acupuncture needles.
16572531|NCT02795013||Participants with Hodgkin Lymphoma|Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.
16572532|NCT02795013||Family Members without Hodgkin Lymphoma|Those unaffected by HL will serve as a control group to compare with those with HL.
16572533|NCT02795000||Primary Ovarian insufficiency group|"amenorrhea one year or more than one year
~amenorrhea more than 4 months and FSH≥40IU/L
~≤42 years old and AMH≤0.071"
16572534|NCT02795000||The normal group|"normal regular menorrhea
~≤42 years old
~normal FSH and AMH level"
16572535|NCT02794987||Classification group|Group of endoscopists that will use the previous classification to select the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes
16572536|NCT02794987||No classification group|Group of endoscopists that will classified the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes without using the classification.
16572537|NCT02794974|Experimental|with perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
16572538|NCT02794974|Experimental|without perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
16572539|NCT02794961|Experimental|CD22 CAR-T|Enrolled patients will receive three escalating doses of autologous CAR-T.
16572540|NCT02794948|Experimental|Chinese Medicine intervention|Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months
16572541|NCT02794948|Active Comparator|Western intervention|DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.
16572542|NCT02794935|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
16572543|NCT02794935|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
16572544|NCT02794922|Experimental|Interventional|Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
16572545|NCT02794922|Placebo Comparator|Placebo|Capsule containing 250mg corn starch
16572546|NCT02794909|Experimental|CPUS group|The group of patients in the CPUS group will be those who receive a cardiopulmonary ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has received specific training in the CPUS protocol.
16572547|NCT02794909|No Intervention|Control group|The group of patients in the control group will be those who do not receive an ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has not received specific training in the CPUS protocol.
16572548|NCT02794896|Experimental|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
16572549|NCT02794896|Experimental|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
16572550|NCT02794883|Active Comparator|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
16572551|NCT02794883|Active Comparator|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
16572552|NCT02794883|Experimental|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16572553|NCT02794870|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
16572554|NCT02794870|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
16572555|NCT02794857|Experimental|NP001|NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
16572556|NCT02794857|Placebo Comparator|Placebo|Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
16572557|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
~No other ARM will be studied."
16572558|NCT02794831||patient|Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
16572559|NCT02794831||control|Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site
16572560|NCT02794818||Participating Patients|Participating patients will receive a prescription for weekly CSA produce boxes with nutritional education
16572561|NCT02794818||Participating Providers|Participating providers will be surveyed at the end of the pilot to evaluate their perceived program efficacy, the benefit of the program to their patients, and elicit program feedback.
16572562|NCT02794805|Experimental|HCC positive|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
16572563|NCT02794805|Experimental|HCC negative|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
16572564|NCT02794792|Active Comparator|Metformin and placebo|Participants will receive daily dosage of Metformin and Placebo as single tablets.
16572565|NCT02794792|Experimental|Metformin and Ipragliflozin|Participants will receive daily dosage of Metformin and Ipragliflozin (2 dose strengths) as single tablets.
16572566|NCT02794792|Other|Metformin, placebo and Ipragliflozin|Participants will receive daily dosage of Metformin, placebo and Ipragliflozin (1 dose strength) as single tablets.
16572567|NCT02794779|Experimental|Rule of three|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
16572568|NCT02794779|Active Comparator|Continuous infusion|Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.
16572569|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
16572570|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
16572571|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
16572572|NCT02794753|Experimental|True intervention|Working memory training on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
16572573|NCT02794753|Active Comparator|Active control|Similar time spent playing on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
16572574|NCT02794740|Experimental|X0002 First Dose|Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.
16572575|NCT02794740|Experimental|X0002 Second Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
16572576|NCT02794740|Placebo Comparator|Placebo Second Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
16572577|NCT02794740|Experimental|X0002 Third Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
16572578|NCT02794740|Placebo Comparator|Placebo Third Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
16572579|NCT02794740|Experimental|X0002 Fourth Dose|8 Subjects,Single Dose,Once,Double-Blind.
16572580|NCT02794740|Placebo Comparator|Placebo Fourth Dose|2 Subjects,Single Dose,Once,Double-Blind.
16572581|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
16572582|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
16572583|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
16572584|NCT02794714|Experimental|deep neuromuscular blockade|Rocuronium will be administered to achieve PTC 1-2 throughout surgery.
16572585|NCT02794714|Active Comparator|moderate neuromuscular blockade|Rocuronium will be administered to achieve TOFC 2 throughout surgery
16572586|NCT02794701||people with silicosis|
16572587|NCT02794688||Ductal lavage group|The patients will receive ductal lavage therapy every other day for two weeks, and will be followed up for one year.
16572588|NCT02794675|Experimental|Cesium 131 brachytherapy|Cesium 131 is the radioactive isotope in the protocol. The prescribed dose will range from 50-80 Gy at maximal delivery. It comes in 0.5 cm seeds that will be placed in the tumor resection bed at 1cm intervals. They are implantable seeds that do not require removal.
16572589|NCT02794662|Experimental|Oxygen Environment|Blended oxygen delivered by servo-controlled incubator
16572590|NCT02794662|Active Comparator|Nasal cannula oxygen|Blended oxygen delivered by nasal cannula
16572594|NCT02794649||calcium oxalate stone formers|History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment.
16572595|NCT02794636||IFN Treatment|Adult (age ≥ 18 years) patients identified as having stage III melanoma and no other primary or secondary cancer who initiated treatment with IFN between 1/1/2007 and 12/31/2011. Patients are required to have continuous pharmaceutical benefit enrollment for 180 days before (pre-index) and after (post-index) IFN initiation and no evidence of treatment with systemic chemotherapy during the pre- or post-index period
16572596|NCT02794623|Experimental|Cochlear Implant Recipients|
16572597|NCT02794610|Experimental|Topical tacrolimus|Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.
16572598|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
16572599|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
16572600|NCT02794584|Active Comparator|Off-pump hybrid closure|Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.
16572601|NCT02794584|Placebo Comparator|Control|Control group: Conventional closure of ventricular septal defects was aided with cardiopulmonary bypass.
16572602|NCT02794571|Experimental|Phase Ia Dose-Escalation Stage: Tiragolumab|Cohorts of at least 3 participants each will be treated with escalating doses of tiragolumab.
16572603|NCT02794571|Experimental|Phase Ia Dose-Expansion Stage: Tiragolumab|Participants will be treated with tiragolumab at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.
16572604|NCT02794571|Experimental|Phase Ib Q3W Dose-Escalation Stage: Tiragolumab+Atezolizumab|A minimum of 3 participants will be treated for each dose level of tiragolumab in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
16572605|NCT02794571|Experimental|Phase Ib Q3W Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 3 weeks (Q3W) with tiragolumab at or below the MTD or MAD in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
16572606|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A|In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and tiragolumab intravenous (IV) infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab in combination with pemetrexed on Day 1 of each 21-day cycle.
16572607|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B|In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle (participants enrolled under protocol version 4) or Day 1 of each 28-day cycle (participants enrolled under protocol version 5).
16572608|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C|In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 28-day cycle.
16572609|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort D|In Cohort D, participants will receive atezolizumab and tiragolumab on Day 1 and capecitabine on Day 1-14 of each 21-day cycle.
16572610|NCT02794571|Experimental|Phase Ib Q4W Sequential Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 4 weeks (Q4W) with fixed doses of tiragolumab and atezolizumab with tiragolumab being administered prior to atezolizumab.
16572611|NCT02794571|Experimental|Phase Ib Q4W Coinfusion Expansion Cohort Tiragolumab+Atezolizumab|Participants will be treated Q4W with fixed doses of tiragolumab and atezolizumab mixed and administered in one IV bag.
16572612|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC1|In Cohort NC1, participants will receive atezolizumab and tiragolumab in combination with bevacizumab on Day 1 of each 21-day cycle.
16572613|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC2|In Cohort NC2, participants will receive tiragolumab in combination with pembrolizumab on Day 1 of each 21-day cycle.
16572614|NCT02794558|Experimental|Treatment Arm|Subjects in this arm are treated once with MRgFUS device
16572615|NCT02794545|Experimental|Recent infection patient|The patient who infected with HIV-1 and screened out by P24 ELISA, and they would receives early cART course.
16572616|NCT02794532|No Intervention|Pre oxygenation with 100% oxygen via tight fitting mask|Pre Oxygenation will be done using a tight mask
16572617|NCT02794532|Experimental|Pre oxygenation with 100% oxygen in high-flow nasal cannula|Pre Oxygenation will be done using high-flow nasal canula
16572618|NCT02794519|Experimental|Sirukumab 50 mg/mL administered subcutaneously every 4 weeks|Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
16572619|NCT02794519|Placebo Comparator|Placebo administered subcutaneously every 4 weeks|Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
16572620|NCT02794506|Experimental|Propolis|400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
16572621|NCT02794506|Placebo Comparator|Placebo|Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
16572622|NCT02794493|Experimental|Arm I|Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
16572623|NCT02794493|Placebo Comparator|Arm II|Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
16572624|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
16572625|NCT02794480|Experimental|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
16572626|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
16572627|NCT02794480|Experimental|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
16572628|NCT02794467|Experimental|Epelsiban 75 mg|Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration
16572629|NCT02794467|Experimental|Epelsiban 200 mg|Approximately 24 subjects will receive 200 mg of epelsiban TID via oral administration
16572630|NCT02794467|Placebo Comparator|Placebo|Approximately 24 subjects will receive a matching placebo TID via oral administration
16572631|NCT02794454|Active Comparator|HeezOn Ultra-1|HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
16572632|NCT02794454|Active Comparator|HeezOn Ultra-2|HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
16572633|NCT02794454|Placebo Comparator|Placebo|Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
16572634|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
16572635|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
16572636|NCT02794428|Active Comparator|Eflornithine|
16572637|NCT02794428|Placebo Comparator|Eflornithine Placebo|
16572638|NCT02794415|Other|Community-based exercise|
16572639|NCT02794402|Active Comparator|Bydureon|s.c. once Weekly
16572640|NCT02794402|Placebo Comparator|Placebo|s.c. once Weekly
16572641|NCT02794389|Experimental|N-acetyl cysteine|1200mg for 2 days 2400mg for 7 days
16572642|NCT02794389|Placebo Comparator|Placebo|Magnesium stearate capsules
16572643|NCT02794376|Experimental|Immediate Treatment Group|Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments.
16572644|NCT02794376|Other|Delayed Treatment Group|Waiting period plus Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments after the waiting period has finished.
16572645|NCT02794363|Other|Autologous platelet rich plasma|Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms
16572646|NCT02794350||Cohort|
16572647|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
16572648|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
16572649|NCT02794324|Experimental|Voluntary deep-inspiratory breath hold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
16572650|NCT02794324|Active Comparator|Active-breathing-controlled deep-inspiratory breathhold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
16572651|NCT02794324|Active Comparator|Prone treatment|Stage 1B: Optimised supine DIBH vs prone position
16572652|NCT02794298|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
16572653|NCT02794298|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
16572654|NCT02794298|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
16572655|NCT02794285|Experimental|Anifrolumab|Anifrolumab
16572656|NCT02794285|Placebo Comparator|Placebo|Placebo
16572657|NCT02794272|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
16572664|NCT02794233|Experimental|PD patients with implanted DBS|Impedance measurements at different time points.
16572665|NCT02794220|Experimental|CN Electronic cigarette 10 mg|"10 mg strength
~- Administration once every hour for a total of 4 hours."
16572666|NCT02794220|Experimental|CN Electronic cigarette 15 mg|"15 mg strength
~- Administration once every hour for a total of 4 hours."
16572667|NCT02794220|Active Comparator|Nicorette Inhalator 15 mg|"15 mg strength
~- Administration once every hour for a total of 4 hours."
16572668|NCT02794220|Active Comparator|Cigarette|"Subjects will all smoke the same brand.
~- Administration once every hour for a total of 4 hours."
16572669|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
16572670|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
16572671|NCT02794194|No Intervention|Control group|No intervention
16572672|NCT02794194|Experimental|Vibration group|Proprioceptive training on a whole body vibration platform. Participants in the Vibration group trained with a BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
16572673|NCT02794194|Experimental|Non-vibration group|Proprioceptive training with the BOSU® on the floor. Participants in the Non-Vibration group trained with a BOSU® on the floor.
16572674|NCT02794168|Experimental|VAS203 (Ronopterin)|Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg
16572675|NCT02794168|Placebo Comparator|Saline|Intravenous infusion of physiological saline over 48 hours
16572676|NCT02794155|Experimental|Test Group|HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period
16572677|NCT02794155|Active Comparator|Control Group|Insulin Lispro subcutaneous, Pre-prandial dosing, 26 week treatment period
16572678|NCT02794142|Experimental|HD patient|
16572679|NCT02794142|Other|Healthy volunteers|
16572680|NCT02794129|Experimental|Bipolar Disorder patients|
16572681|NCT02794129|Experimental|Healthy Controls|
16572682|NCT02794116|Active Comparator|Control group: Sound teeth|"20 first permanent molars sound, that not affected by MIH will be included.
~The teeth were treated with conventional sealants to prevent caries lesion"
16572683|NCT02794116|Experimental|Test: Hypomineralized teeth|"20 first permanent molars affected by MIH will be included.
~The MIH teeth were treated with a resin sealants."
16572684|NCT02794103|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
16572685|NCT02794090|Active Comparator|Usual care, individual visits|Usual care according to regular treatment routines at the clinic during 18 months. The Child and parent(s) at regular visits to the nurse at the clinic.
16572686|NCT02794090|Active Comparator|Telephone coaching|Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
16572687|NCT02794077|Experimental|Cyclophosphamide|Patients receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progression or unacceptable toxicity.
16572688|NCT02794064|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes. Imaging time: Approximately 30 minutes
16572689|NCT02794051|Experimental|Unified Protocol for Children|Child participants with behavior problems between the ages of 8-12 and their caregivers will participate in a transdiagnostic group therapy protocol.
16572690|NCT02794038|Active Comparator|Soberlink Cellular Device|BAC reading with Soberlink Cellular Device
16572691|NCT02794038|Active Comparator|BACtrack S80 Pro|BAC reading with BACtrack S80 Pro
16572692|NCT02794025|Experimental|esmolol group|patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
16572693|NCT02794025|Sham Comparator|control group|Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
16572694|NCT02794012||At-Risk Rheumatoid Arthritis subjects|
16572695|NCT02794012||Early Rheumatoid Arthritis subjects|
16572696|NCT02794012||Healthy Controls|
16572697|NCT02794012||Non-Rheumatoid Arthritis Autoimmune Controls|
16572698|NCT02793986|Experimental|dexmedetomidine sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h.
16572699|NCT02793986|Experimental|propofol sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
16572700|NCT02793973|Active Comparator|80% discrepancy lift height correction|Each participant will be given 80% discrepancy shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
16572701|NCT02793973|Experimental|optimal lift height correction|Each participant will be given the optimal shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
16572702|NCT02793960|Experimental|Topical BPM31510 3.0% Cream|Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
16572724|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
16572725|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
16572992|NCT02791984|Experimental|Fluid challenge with 250 ml of Ringer Lactate|
16572703|NCT02793947|Experimental|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
16572704|NCT02793947|No Intervention|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
16572705|NCT02793934||1st phase|"In the 1st phase of the study the staff of the medical organizations continue to work in the familiar old scheme, but using the set of scales."
16572706|NCT02793934||2nd phase|"In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program ICF-reader will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales."
16572707|NCT02793921|Experimental|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
16572708|NCT02793921|No Intervention|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
16572709|NCT02793908|Experimental|Pleyris|Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days
16572710|NCT02793908|Active Comparator|Crinone8|Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days
16572711|NCT02793895|Experimental|Enhanced cardiac rhythm monitoring|Subjects in this group will receive up to 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
16572712|NCT02793895|Active Comparator|Usual care|Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
16572713|NCT02793869||Total cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
16572714|NCT02793869||Anterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
16572715|NCT02793869||Interior cataracts group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
16572716|NCT02793869||Posterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
16572717|NCT02793856|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
16572718|NCT02793856|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
16572719|NCT02793856|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
16572720|NCT02793843|Active Comparator|Ondansetron|
16572721|NCT02793843|Experimental|Ondansetron+ dexamethasone|
16572722|NCT02793830|Experimental|Mobile App Group|Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
16572723|NCT02793830|Active Comparator|Control Group|The control group will receive the same educational materials, but no daily reminder.
16572726|NCT02793804|No Intervention|Control|All HIV testing and counselling services will be conducted as currently.
16572727|NCT02793804|Experimental|HIV Self-Testing|Community-based distribution agents (CBDA), including Voluntary Male Medical Circumcision (VMMC) mobilisers, will deliver OraQuick® HIV Self-Tests (Orasure Technologies, Thailand). The kits will also be available at the health facility.
16572728|NCT02793791|Experimental|Ablation|
16572729|NCT02793791|No Intervention|Observation|
16572730|NCT02793778|Experimental|CROWN|CROWN: A nutritionally based therapy with a high protein content, formulated as a powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
16572731|NCT02793778|Placebo Comparator|CROWN Placebo|Placebo: An appearance and volume matched formulated powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
16572732|NCT02793765|Experimental|Docetaxel & Sipuleucel-T|75 mg/m2 docetaxel IV over 1-hour every 21 days x 6 cycles; 28 day rest then Sipuleucel-T IV over 1-hour every 14 days for 3 doses
16572733|NCT02793752||Mitochondrial Activity of Cumulus Cells|One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
16572734|NCT02793752||Competence to Blastocyst|The percentage of fertilized eggs that develop to the blastocyst stage.
16572735|NCT02793739|Experimental|20 subjects|20 subjects will be enrolled to take part in this study and followed for a period of 12 months. Subjects will receive hyaluronic acid filler injection in the dorsal fingers (2-4 syringes) at the initial visit for volume restoration. If warranted, subjects will receive touch-up of hyaluronic acid at day 14 (1-2 syringes). The investigators expect volume restoration to last 9-12 months.
16572736|NCT02793726||Symptomatic|Patients with pain and or other sign of prothesis failure
16572737|NCT02793726||Asymptomatic|Patients with regular clinical and radiographic evolution of the implant. No pain
16572738|NCT02793687|Experimental|Mexidol|"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.
~The use of the study drug is held with basic therapy."
16572739|NCT02793687|Placebo Comparator|Placebo|"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.
~The use of a placebo is held with basic therapy."
16572740|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
16572741|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
16572742|NCT02793661|Experimental|RenalGuard Arm|In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.
16572743|NCT02793661|Active Comparator|Control Arm|Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.
16572744|NCT02793648|Experimental|Treatment|Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks
16572745|NCT02793648|Placebo Comparator|Placebo|colloidal Silica 200mg twice a day for twelve weeks
16572746|NCT02793635|Experimental|SCI Patients|"10 subjects with complete or incomplete SCI (> 1 year post-injury) with preserved LE function will be recruited.
~No control group"
16572747|NCT02793622|Active Comparator|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
16572748|NCT02793622|Active Comparator|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
16572749|NCT02793609|Other|Outpatient group|After insertion of double balloon induction catheter of labor, women are discharged overnight to home. Intervention is to let patient to go home.
16572750|NCT02793609|Other|Inpatient group|After insertion of double balloon induction catheter of labor, women are observed in the prenatal ward. Intervention is to observe women in the ward.
16572751|NCT02793596|Experimental|Obstetrical patients|Obstetrical patients requiring epidural analgesia for delivery
16572755|NCT02793557|Placebo Comparator|Placebo|Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.
16572756|NCT02793557|Experimental|FOL-005: Solution 1|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
16572757|NCT02793557|Experimental|FOL-005: Solution 2|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
16572758|NCT02793557|Experimental|FOL-005: Solution 3|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
16572759|NCT02793557|Experimental|FOL-005: Solution 4|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
16572760|NCT02793544|Active Comparator|Regimen A (RIC: Flu/Cy/TBI)|"Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2
~Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
~Total Body Irradiation (TBI) 200cGy on Day -1
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
16572761|NCT02793544|Active Comparator|Regimen B 2a (FIC: Bu/Cy)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)
~Cyclophosphamide 50mg/kg/day IV on Days -2,-1
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
16572762|NCT02793544|Active Comparator|Regimen B 2b (FIC: Bu/Flu)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)
~Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
16572763|NCT02793544|Active Comparator|Regimen C (FIC: Cy/TBI)|"Cyclophosphamide 50mg/kg/day IV on Days -5,-4
~Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
16572764|NCT02793531|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
16572765|NCT02793531|Experimental|Cancer subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
16572766|NCT02793518|Experimental|Bipolar Disorder patients|
16572767|NCT02793518|Experimental|Healthy Controls|
16572768|NCT02793505||Pregnant patient exposed to metformin|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)).
16572769|NCT02793505||Reference group|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to any drug not known as a major teratogen or fetotoxicant and different than metformin, insulin or any other hypoglycaemic agent.
16572771|NCT02793479||BE|Patients presenting Barrett's Esophagus as a complication of a gastroesophageal reflux disease.
16572772|NCT02793466|Experimental|Durvalumab; MEDI4736|Open label
16572773|NCT02793453|Other|Diseased|Patients suffering of moderate to severe chronic periodontitis
16572774|NCT02793453|Other|Healthy|Healthy Patients not suffering of any periodontal disease a
16572775|NCT02793440|Active Comparator|cortivazol|anti-inflammatory therapy and epidural
16572776|NCT02793440|Experimental|Traction arm|Medical treatment associated with 5 lumbar traction sessions
16572777|NCT02793427|Experimental|Type 1 diabetes|
16572778|NCT02793427|Experimental|control|
16572779|NCT02793414||Malaria patients|
16572780|NCT02793414||Febrile controls|
16572781|NCT02793401|Active Comparator|HILT group|71 of the patients were in the HILT group
16572782|NCT02793401|Active Comparator|US Group|70 of the patients were in the US group.
16572783|NCT02793388|Active Comparator|Supervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure. Supervision of primaquine is done on alternate days at home (attended by a home visitor) or at the health centre.
16572784|NCT02793388|Active Comparator|Unsupervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure for self administration.
16572785|NCT02793375|Placebo Comparator|Control|Patients receiving placebo preoperatively (blinded)
16572786|NCT02793375|Experimental|Study group|Patients receiving montelukast preoperatively (blinded)
16572787|NCT02793362||Normal subjects without stroke|"subjects who can walk independent without any difficult
~subjects without history of CNS or PNS lesion
~Modified ranking scale (MRS) <=2
~Functional ambulation category (FAC) >=2"
16572788|NCT02793362||Post stroke patients with sarcopenia(by sarcopenia index)|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
16572789|NCT02793362||Post stroke patients without sarcopenia(by sarcopenia index)|patients who do not satisfy the value of DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
16572790|NCT02793362||Post stroke patients with sarcopenia(by lean body mass)|Existence of sarcopenia will be determined by DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
16572791|NCT02793362||Post stroke patients without sarcopenia(by lean body mass)|patienst who do not satisfy the value of DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
16572792|NCT02793349|Experimental|Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
16572826|NCT02793102|Experimental|Auditory workshop + Somesthesia workshop|Auditory workshop, Twenty extracts of music tracks. Somesthesia workshop, time for moving the body, Talk Time
16572926|NCT02792400|Placebo Comparator|A1: GRA-placebo + MEAL + DPP4-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo
16572793|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
16572794|NCT02793323|Experimental|Superficial cervical block|Patients will receive superficial cervical nerve block in which we inject 5 ml of local anaesthetic mixture. Each 17 ml of the mixture contain: 6 ml lidocaine 2%, 6 ml lidocaine 2% with adrenaline 5 µg/ml, and 5 ml bupivacaine 0.5. Patients will also receive 100 ml IV saline.
16572795|NCT02793323|Placebo Comparator|NSAID|Patients will receive 100 mg (100 ml) IV NSAIDs (Profenid) before induction of anesthesia. Superficial cervical nerve block containing 5 ml placebo will be performed.
16572796|NCT02793310|Active Comparator|DMEK|The intervention group will receive cornea transplantation by DMEK
16572797|NCT02793310|Active Comparator|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
16572798|NCT02793297|Experimental|refined wheat crisp bread|refined wheat crisp bread was served as part of a complete standardized breakfast
16572799|NCT02793297|Experimental|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread was served as part of a complete standardized breakfast
16572800|NCT02793297|Experimental|unfermented rye crisp bread|Unfermented rye crisp bread was served as part of a complete standardized breakfast
16572801|NCT02793284|Experimental|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
16572802|NCT02793271|Active Comparator|PRIME|The behavioral intervention will be the PRIME/mhGAP training. This is standard mental health training for prescribers (primary care workers who can prescribe psychotropic medication, e.g., health assistants) and non-prescribers (primary care workers who cannot prescribe medications, e.g., auxilliary nurse midwives). For prescribers, training includes introduction to psychosocial techniques and mhGAP. For non-prescribers, training includes psychosocial techniques.
16572803|NCT02793271|Experimental|PRIME+RESHAPE|The behavioral intervention will be the PRIME/mhGAP training plus the RESHAPE training adjunct. This is the PRIME training plus social contact component in which mental health service users participate as training co-facilitators. The intended goal of the additional component is to reduce stigma against persons with mental illness.
16572804|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.
~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
16572805|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.
~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
16572806|NCT02793245|Experimental|Studied population|Patients will be questioned about their main characteristics (age, gender, height, weight, smoking), they will also perform a simplified a pulmonary function test (if possible).
16572807|NCT02793232|Experimental|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
16572808|NCT02793232|Experimental|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
16572809|NCT02793232|Experimental|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
16572810|NCT02793219|Experimental|Sipuleucel-T then Docetaxel|Sipuleucel-T IV over 1-hour every 14 days for 3 doses; 28 day rest; 75 mg/m2 docetaxel IV over 1-hour every 21 days for 6 cycles
16572811|NCT02793193|Experimental|Active (rifaximin/B.longum 1714)|
16572812|NCT02793193|Experimental|Placebo|
16572813|NCT02793167|No Intervention|Usual care|patients will receive standard clinical care by the doctor in charge.
16572814|NCT02793167|Experimental|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
16572815|NCT02793154|Experimental|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
16572816|NCT02793154|Experimental|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
16572817|NCT02793154|Active Comparator|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.
~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
16572818|NCT02793141||ICU Nosocomial Pneumonia|Nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ward patients (= or > 48 hours after hospital admission) that due to deterioration are subsequently admitted to ICU or nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ICU patients (= or >48 hours after hospital admission) or ventilator-associated pneumonia with onset = or > 48 hours after intubation. No intervention will be administered.
16572819|NCT02793128|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
16572820|NCT02793115|Experimental|Arm 1|Disclosure Letter-RISKS
16572821|NCT02793115|Experimental|Arm 2|Disclosure Letter-BENEFITS
16572822|NCT02793115|Experimental|Arm 3|Disclosure Letter-RISKS AND BENEFITS
16572823|NCT02793115|Experimental|Arm 4|Disclosure Letter-NO RISKS OR BENEFITS
16572824|NCT02793115|Placebo Comparator|Arm 5|Letter-APPOINTMENT REMINDER
16572825|NCT02793102|Experimental|Olfactory workshop + Somesthesia workshop|Olfactory workshop, Twenty odorants. Somesthesia workshop, time for moving the body, Talk Time
16572919|NCT02792465|Experimental|Cohort B|CFI-402257 capsules will be taken orally, once a day, every day.
16572827|NCT02793089||First quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
16572828|NCT02793089||Second quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
16572829|NCT02793089||Third quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
16572830|NCT02793089||Fourth quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
16572831|NCT02793076|Experimental|Bollywood Dance|Bollywood dance is a routine that doubles as both physical and mental exercise.
16572832|NCT02793063||BBD Consortium Contact Registrants|Osteogenesis Imperfecta patients who have self-registered at the Brittle Bone Disorders Consortium (BBD) Consortium Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
16572833|NCT02793050||Trabectedin|Trabectedin give according the market authorization for advanced soft tissue sarcoma
16572834|NCT02793037|Experimental|A proof of concept of using zirconia bonded bridge|
16572835|NCT02793024|Experimental|Arm 1 - Intervention|Counties will be randomized to receive the intervention or act as a delayed control. Students in the intervention arm will receive the 12-week intervention to improve shopping choices.
16572836|NCT02793024|No Intervention|Arm 2 - Intervention|Control adolescents will not receive the intervention and will receive routine information normally distributed through schools.
16572837|NCT02793011|Experimental|Dexamethasone|Liquid or capsule dexamethasone - to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
16572838|NCT02793011|Placebo Comparator|Placebo|Placebo liquid or capsule to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
16572839|NCT02792998|Experimental|IW-1701|IW-1701 tablets administered orally in multiple ascending dose.
16572840|NCT02792998|Placebo Comparator|Placebo|Matching placebo tablets administered orally.
16572841|NCT02792985|Experimental|Multisensory stimulation protocol|The Experimental group will follow an intervention protocol.
16572842|NCT02792985|Active Comparator|Control protocol|The Control group will follow the current protocol for patients in PTA at the Institut Guttmann.
16572843|NCT02792972|Active Comparator|Acmella oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers 3 minutes before the venipuncture
16572844|NCT02792972|Placebo Comparator|alcohol 70%|70% alcohol were used in the volunteers 3 minutes before the venipuncture
16572845|NCT02792959|Experimental|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
16572846|NCT02792946|Experimental|Sulfolase CR (200mg, QD)|for 7 days with or without meal
16572847|NCT02792946|Active Comparator|Sulfolase Capsule (100mg, BID)|for 7 days with or without meal
16572848|NCT02792933|Active Comparator|air in epidural space|When the ALOR epidural localization technique will be used, an intermittent pressure with fast movements will be exerted on the plunger of the syringe while the Tuohy needle will be inserted until loss of resistance was felt.
16572849|NCT02792933|Experimental|saline in epidural space|When the SLOR technique is used, a continuous pressure will be exerted on the plunger of the Tuohy needle until loss of resistance was felt.
16572850|NCT02792920|Other|CoCr-EES|
16572851|NCT02792907|Experimental|Compressive Stockings group|Patients with compressive stockings at the operated foot for 4 weeks
16572852|NCT02792907|No Intervention|No compressive stockings group|Patients with no compressive stockings at the operated foot
16572853|NCT02792894|No Intervention|Enhanced Usual Care (EUC)|Enhanced Usual Care comprises of normal routine visits conducted by the local community health workers / Lady Health Workers (LHWs). Care is enhanced in 2 ways: (a) LHWs in the EUC arm will receive training in identifying children with developmental disorders and delays, as well as making referrals to their primary care physicians for treatment using the WHO mhGAP training program for developmental disorders and (b) The primary care physicians will receive the training in WHO mental health GAP(mhGAP) program developmental disorders module, by WHO Collaborating Center in Rawalpindi, Pakistan.
16572854|NCT02792894|Experimental|Family Networks program|Intervention is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO Parent Skills Training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
16572855|NCT02792881|Experimental|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
16572856|NCT02792868||patient|patient with cardiovascular risk (moderate)
16572857|NCT02792855|Experimental|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
16572858|NCT02792855|Experimental|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
16572859|NCT02792842|Experimental|ART-123 (3-day ART)|
16572860|NCT02792842|Experimental|ART-123 (1-day ART)|
16572861|NCT02792842|Placebo Comparator|Placebo|
16572862|NCT02792829|Experimental|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:
~Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)
~Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
16572863|NCT02792829|Experimental|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:
~Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE
~Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER
~Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE
~Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
16572864|NCT02792829|Experimental|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:
~Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation
~Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
16572865|NCT02792816||Kawthaung Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Kawthaung is one of the sentinel site and located at the Southern Myanmar.
16572866|NCT02792816||Myawaddy Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Myawaddy is one of the sentinel site and located at the northern part of the Southern Myanmar.
16572867|NCT02792816||Thanbyuzayat Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Thanbyuzayat is one of the sentinel site and located at the northern part of the Southern Myanmar.
16572868|NCT02792816||Shwegyin Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Shwegyin is one of the sentinel site and located at the southern part of the central Myanmar.
16572869|NCT02792816||Magway Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Magway is one of the sentinel site and located at the middle part of the central Myanmar.
16572870|NCT02792816||Rakhine Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Rakhine is one of the sentinel site and located at the western Myanmar.
16572871|NCT02792803|Experimental|Xalatan --> Apo-/Co-Latanoprost|Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
16572872|NCT02792803|Experimental|Apo-/Co-Latanoprost --> Xalatan|Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
16572873|NCT02792790||Patients with carpal tunnel syndrome.|Patients undergoing carpal tunnel release surgery.
16572874|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
16572875|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
16572876|NCT02792764||Port|Subjects receiving chemotherapy through a port
16572877|NCT02792764||Peripheral Intravenous (PIV) Lines|Subjects receiving chemotherapy through a peripheral IV
16572878|NCT02792751|Active Comparator|Group R (Ramsey)=25 patients|Propofol infusion was administered to provide Ramsey Sedation Scale 3-4 in Group R
16572879|NCT02792751|Experimental|Group B (BIS)=25 patients|Propofol infusion was given to maintain the Bispectral index monitorisation (BIS) levels between 60 and 85 in Group B.
16572880|NCT02792738|Experimental|hypnosis, visual distraction|"This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction.
~For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used.
~For visual distraction, subject will be watching the movie la marche des empereurs"
16572881|NCT02792712|Experimental|STEMI_MRI_Ticagrelor|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm
16572882|NCT02792712|Active Comparator|STEMI_MRI_Clopidogrel|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm
16572883|NCT02792699|Experimental|ABP 798 / ABP 798|Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
16572920|NCT02792465|Experimental|Cohort C|CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
16572884|NCT02792699|Active Comparator|Rituximab (US) / ABP 798|Participants received rituximab (United States [US] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
16572885|NCT02792699|Active Comparator|Rituximab (EU) / Rituximab (EU)|Participants received rituximab (European Union [EU] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
16572886|NCT02792686|Experimental|ABX464|50, 100, 150 or 200 mg once a day / Single Administration
16572887|NCT02792673|Active Comparator|"Embryo Glue®"|Hyaluronan-enriched medium
16572888|NCT02792673|Active Comparator|"Global Total®"|30% Protein-supplemented Culture Medium
16572889|NCT02792673|Experimental|Autologous Follicular Fluid|a novel technique
16572890|NCT02792660|Experimental|Injeq IQ-Needle|Lumbar puncture is performed using Injeq IQ-Needle
16572891|NCT02792647|Placebo Comparator|Placebo|Placebo
16572892|NCT02792647|Experimental|Experimental: IX-01|2 different dose groups 1,600 mg and 2,400 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
16572893|NCT02792621|Experimental|active oral supplement|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
16572894|NCT02792621|Placebo Comparator|placebo supplement|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
16572895|NCT02792608|Experimental|Mindfulness-based Therapy|5 week, manual-based group MBI treatment for depression
16572896|NCT02792595|Sham Comparator|Negative Control|Untreated area will be irradiated using a sun simulator with UV irradiation increment of 1.25 to detect MED of the unprotected skin.
16572897|NCT02792595|Active Comparator|Positive Control|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, positive control will be applied. The dose of positive control will be measured in accordance to the application volume (2 milligram (mg)/centimeter (cm)^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Positive control will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 seconds (s). After waiting for 15 to 30 minutes (min), the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the SPF of positive control, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572898|NCT02792595|Experimental|Test Product A|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572899|NCT02792595|Experimental|Test Product B|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572900|NCT02792595|Experimental|Test Product C|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572901|NCT02792595|Experimental|Test Product D|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572921|NCT02792426|Active Comparator|Group 1 AB|Smoker subject's own brand of combustion cigarette
16572922|NCT02792426|Active Comparator|Group 1 BA|Smoker subject's own brand of combustion cigarette
16572923|NCT02792426|Active Comparator|Group 2|E-cigarette user's own brand of electronic nicotine delivery system (ENDS)
16572924|NCT02792413|Experimental|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
16572925|NCT02792413|Placebo Comparator|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
16572902|NCT02792595|Experimental|Test Product E|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572903|NCT02792595|Experimental|Test Product F|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572904|NCT02792595|Experimental|Test Product G|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572905|NCT02792595|Experimental|Test Product H|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
16572906|NCT02792582|Active Comparator|Tumor-Surgery|"Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups.
~If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups."
16572907|NCT02792582|Active Comparator|Tumor-No Surgery|Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
16572908|NCT02792569|Experimental|Biopsy at Right side|Biopsy of ovarian cortical tissue (50% right side)
16572909|NCT02792569|Experimental|Biopsy at Left side|Biopsy of ovarian cortical tissue (50% left side)
16572910|NCT02792556||patient having a drug abortion|Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
16572911|NCT02792543|Active Comparator|parenteral nutrition|Parenteral nutrition consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
16572912|NCT02792543|Experimental|chyme reinfusion|Chyme reinfusion consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
16572913|NCT02792530|Other|arm 1|Unuric hemodialytic patients who accumulate above 2.5 (4%) in intradialytic intervals before the nutritional intervention.
16572914|NCT02792517|Experimental|Erenumab + Estrogen/Progestin Contraceptive|"Participants received a combination oral contraceptive for 3 28-day cycles during the study.
~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider."
16572915|NCT02792491|Experimental|Reduced dose R-CHOP|"Reduced dose R-CHOP is regimen including Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
~In this study, Rituximab 375 mg/m2, Cyclophosphamide 600 mg/m2, Doxorubicin 30 mg/m2 and Vincristine fixed dose of 1mg will be administrated through intravenous on day 1. and Prednisone 40mg will be administrated orally on day 1-5. This chemotherapy will be repeated every 21 days."
16572916|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.
16572917|NCT02792478||Patient RAS WT|As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.
16572918|NCT02792465|Experimental|Cohort A|CFI-402257 capsules will be taken orally, once a day, every day.
16572927|NCT02792400|Placebo Comparator|A2: GRA-active + MEAL + DPP4-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo
16572928|NCT02792400|Active Comparator|A3: GRA-placebo + MEAL + DPP4-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
16572929|NCT02792400|Active Comparator|A4: GRA-active + MEAL + DPP4-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
16572930|NCT02792400|Placebo Comparator|B1: GRA-placebo + MEAL + SGLT2-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
16572931|NCT02792400|Placebo Comparator|B2: GRA-active + MEAL + SGLT2-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
16572932|NCT02792400|Active Comparator|B3: GRA-placebo + MEAL + SGLT2-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
16572933|NCT02792400|Active Comparator|B4: GRA-active + MEAL + SGLT2-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
16572934|NCT02792374||Dental patients group|Psychological measurement is done when they refer to a dental clinic.
16572935|NCT02792374||Control group|Psychological measurement is done when they refer to a dental clinic.
16572936|NCT02792361|No Intervention|Control Group|Subjects who did not have a suction drain placed post-operatively following a Pterional Craniotomy.
16572937|NCT02792361|Experimental|Treatment Group|Subjects who did have a suction drain placed post-operatively following a Pterional Craniotomy at the location of surgical incision.
16572938|NCT02792348||children with congenital urine flow impairment|this group contain children with an unilateral urinary tract dilatation diagnosed by prenatal ultrasonography
16572939|NCT02792348||control group|this group contains children, between 1 and 3 months of age, without nephrological or urological anomaly
16572940|NCT02792335||patients naive to oral anticoagulant treatment|NVAF patients naïve to oral anticoagulant treatment (Naïve)
16572941|NCT02792335||patients with prior warfarin therapy|NVAF patients with prior warfarin therapy (Warfarin treated)
16572942|NCT02792322|Other|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
16572943|NCT02792309|Experimental|MotherWise Programming|Three components: (1) 18 hours of core workshop sessions using the Within My Reach relationship education curriculum supplemented with content on mother-infant relationships; (2) case management services; and (3) optional relationship education workshops for couples.
16572944|NCT02792309|No Intervention|Control|No program services
16572945|NCT02792296|Experimental|Daily measurement|This arm will be asked to use the Project: EVO Monitor once a day for four weeks..
16572946|NCT02792296|Experimental|Multiple times per day measurement|This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.
16572947|NCT02792296|Experimental|Weekly measurement|This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.
16572948|NCT02792283|Experimental|patients undergoing hemodialysis|
16572949|NCT02792270|Experimental|Caloric Restriction Diet|"Patients will meet with the Registered Dietitian to discuss calorie, protein and fluid needs.The dietitian will calculate calorie needs.
~Calorie needs will then be reduced to 30%.
~Protein needs will be estimated based on 0.8g/kg BW and then reduced by 70%.
~Dietitian will educate participants on electrolytes and fluid intake based on the reduced food intake."
16572950|NCT02792270|No Intervention|Normal Diet|Participant will follow a normal diet.
16572951|NCT02792257|Experimental|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
16572952|NCT02792257|Placebo Comparator|Placebo|Placebo medication will be administered twice daily.
16572953|NCT02792231|Experimental|OMG 20 mg|"Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1
~,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily"
16572954|NCT02792231|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
16572955|NCT02792218|Experimental|OMB 20 mg|Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
16572956|NCT02792218|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
16572987|NCT02792023|Other|Upper endoscopy followed by colonoscopy|In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination
16572988|NCT02792010|Experimental|T1rho MRI|Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
16572989|NCT02791997|Experimental|Brain-damaged patients|
16572990|NCT02791997|Experimental|Control participants|
16572961|NCT02792179|Experimental|[18F]RO6958948|Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
16572962|NCT02792166|Active Comparator|BPD-DS|BPD-DS involves creating a sleeve gastrectomy and creation of a Roux-en-Y bypass involving a Roux limb (150cm) which is anastomosed to the transected first-stage of the duodenum and a short common channel (100cm).
16572963|NCT02792166|Experimental|SADI-S|SADI-S involves creating a sleeve gastrectomy but simplifies the bypass part of the BPD-DS by a single anastomosis of a loop of jejunum at 250cm from the ileocecal valve (longer common channel) to the transected first-stage of the duodenum instead of the Roux-en-Y construct.
16572964|NCT02792153|Experimental|Estrogen|AN participants receive a course of transdermal estradiol treatment.
16572965|NCT02792140|No Intervention|Baseline|reporting of dreams
16572966|NCT02792140|Experimental|Naltrexone|daily administration of 50mg Naltrexone, reporting of dreams
16572967|NCT02792140|Placebo Comparator|Placebo|daily administration of Placebo, reporting of dreams
16572968|NCT02792127|Experimental|Experimental|These participants will be given access to a six-month online program for social anxiety.
16572969|NCT02792127|No Intervention|Wait List Control|These participants will not be given an intervention until after they have completed the study.
16572970|NCT02792114|Experimental|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen & diphenhydramine, & administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
16572971|NCT02792088|Experimental|Besifovir|Besifovir 150 mg q.d.
16572972|NCT02792088|Active Comparator|Tenofovir|Tenofovir 300 mg q.d.
16572973|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
16572974|NCT02792075||OCT|Patients with Optical coherence tomography
16572975|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
16572976|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
16572977|NCT02792062|Experimental|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
16572978|NCT02792062|Experimental|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
16572979|NCT02792062|Experimental|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
16572980|NCT02792062|Experimental|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
16572981|NCT02792062|Experimental|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
16572982|NCT02792062|Experimental|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
16572983|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
16572984|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
16572985|NCT02792036|Experimental|Treatment|"Participants with retinoblastoma that is refractory or has relapsed inside the eye.
~Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy."
16572986|NCT02792023|Other|Colonoscopy followed by upper endoscopy|In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination
16572993|NCT02791971|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
16572994|NCT02791971|Active Comparator|Alcohol Control Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
16572995|NCT02791958|Experimental|CV Fixed Dose Combination Pill AAR|Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
16572996|NCT02791958|Active Comparator|Atorvastatin|Atorvastatin 40 mg (Lipitor®).
16572997|NCT02791958|Active Comparator|Ramipril|Ramipril 10 mg (Altace®).
16572998|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
16572999|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
16573000|NCT02791932|Experimental|Exercise|The intervention will last 8-10 months depending on when during pregnancy the participant is randomized. The intervention will consist of three components (i.e., telephone, print materials, and exercise log/goal setting) designed to increase exercise. Social Cognitive Theory (SCT) and Self-Determination Theory will guide the exercise intervention. The counseling sessions will be a collaboration between the counselor and participants on how to best integrate exercise into the participant's daily routine. Participants will receive 15 intervention phone calls lasting approximately 15-20 minutes each. There will be a one-month intensive phase (weekly contacts), followed by bi-weekly contacts for two months, and then monthly until delivery. Beginning at 6 weeks postpartum, bi-weekly contacts will resume through 3 months postpartum.
16573001|NCT02791932|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard of care as suggested by their healthcare provider. Participants will complete the same assessments and incentives as the active interventions but will not receive the exercise counseling sessions. Following completion of the nine-month follow-up, the usual care arm can choose to receive a six-month version of the exercise intervention.
16573002|NCT02791919|Experimental|Treatment (AZD1775, FLAG chemotherapy)|Patients receive filgrastim IV or SC daily, fludarabine intravenously IV over 30 minutes, cytarabine IV over 1-3 hours and wee1 kinase inhibitor AZD1775 PO on days 1-5. Patients who meet criteria for CR, CRp or PR may receive a second course of therapy. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16573003|NCT02791906|Experimental|ISMN Only|Patients receive only ISMN
16573004|NCT02791906|Experimental|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
16573005|NCT02791893|Experimental|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
16573006|NCT02791893|Placebo Comparator|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
16573007|NCT02791880||TAVR patients|The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
16573008|NCT02791867|Active Comparator|Active|AphoelineBrake administration
16573009|NCT02791867|Placebo Comparator|Placebo|Placebo Administration
16573010|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
16573011|NCT02791841|Experimental|RRT|Rhythmic Reading Training, administered for 13 hours over 9 days (two 45-minute training sessions per day).
16573012|NCT02791841|Experimental|VHSS+AVG|Visual Hemispheric-Specific Stimulation + Action Video Games, administered for 13 hours over 9 days (two 45-minute training sessions per day).
16573013|NCT02791841|Experimental|AVG|Action Video Games only, administered for 13 hours over 9 days (two 45-minute training sessions per day).
16573014|NCT02791815|Experimental|Sequence AB|Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
16573015|NCT02791815|Experimental|Sequence BA|Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
16573016|NCT02791802||Group A: Lipoprotein apheresis subjects|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.
~Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP)."
16573051|NCT02791516|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a month for 6 months.
16573017|NCT02791802||Group B: Control group|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.
~The control group will not undergo a sham apheresis procedure. It is an open trial."
16573018|NCT02791789|Other|Autism Spectrum Disorder|clinical exam, speech and language therapy and neuropsychological evaluations, Training to the SEMATIC serious game
16573019|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.
~collection of patient's radiographic and clinical parameters"
16573020|NCT02791763|Experimental|Daprodustat in ND participants|Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams [mg] as recommended) dose once daily for 52 weeks.
16573021|NCT02791763|Active Comparator|Epoetin beta pegol in ND participants|Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram [µg] as recommended) dose once every 2 or 4 weeks for 52 weeks.
16573022|NCT02791763|Experimental|Daprodustat in PD participants|Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
16573023|NCT02791750||Observational|Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
16573024|NCT02791737|Experimental|Supportive care (otago exercise programme)|Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
16573025|NCT02791724|Experimental|Desiconnect|Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
16573026|NCT02791724|Active Comparator|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
16573027|NCT02791711|Other|High Flow Nasal Cannula|Use of High Flow Nasal Cannula
16573028|NCT02791685||Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
16573029|NCT02791685||Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
16573030|NCT02791685||Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
16573031|NCT02791672||Same Day Discharge|Following a Latissimus Dorsi flap reconstruction patients will be offered discharge at 24 hours. Patients successfully discharged within 24 hours of their surgery will be included in the cohort group.
16573032|NCT02791659|Active Comparator|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
16573033|NCT02791659|Experimental|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
16573034|NCT02791646|Experimental|PCST-Full|PCST-full will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
16573035|NCT02791646|Experimental|PCST-Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
16573036|NCT02791620|Experimental|A nanofractional radiofrequency device|
16573037|NCT02791581|Experimental|Breast Cancer Patients|"Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.
~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.
~Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment."
16573038|NCT02791581|Experimental|Non-Cancer Controls|"Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.
~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities."
16573039|NCT02791568||Pilot Study|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection"
16573040|NCT02791568||Main Study- Control Group|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection"
16573041|NCT02791568||Main Study- Study Group|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection"
16573042|NCT02791568||Main Study- Ferumoxytol Group|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection
~Ferumoxtyol Infusion"
16573043|NCT02791555||Pradaxa|20 men and 20 women on Pradaxa for non valvular atrial fibrillation
16573044|NCT02791555||Warfarin|20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
16573045|NCT02791542||Asthma|Participants with a history of asthma
16573046|NCT02791542||Healthy controls|Participants without a history of asthma
16573047|NCT02791542||Asthma Bronchoscopy sub-group|Participants with a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
16573048|NCT02791542||Healthy Bronchoscopy sub-group|Participants without a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
16573049|NCT02791529|Active Comparator|Scalpel|Skin incision performed by scalpel
16573050|NCT02791529|Experimental|Electrocautery|Skin incision performed by electrocautery
16573227|NCT02790177|Experimental|HiB|This group will receive the compound for the reduction of adhesions
16573052|NCT02791516|Experimental|Romosozumab|Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
16573053|NCT02791503|Experimental|IRE group|FOLFIRINOX + IRE For patients diagnosed with LAPC, a combination of chemotherapy plus local tumor destruction using irreversible electroporation (IRE), a novel tumor ablation technique, has recently shown great promise. IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
16573054|NCT02791503|Active Comparator|SABR group|FOLFIRINOX + SABR Focal therapy using external beam radiation therapy (EBRT) may further improve survival, but outcome remains poor. Stereotactic ablative radiotherapy (SABR) is a form of EBRT that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
16573055|NCT02791490|Experimental|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day [b.i.d.]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
16573056|NCT02791490|Placebo Comparator|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
16573057|NCT02791477|Other|Attune FB PS|Attune FB PS knee arthroplasty
16573058|NCT02791464|No Intervention|wait list control|Waitlist control subjects interested in learning the TM program will be asked to wait for 4 months before learning if they were randomly assigned to this comparison group. Controls will receive usual medical care during 4 month intervention period.
16573059|NCT02791464|Experimental|Transcendental Meditation|The TM technique is a simple, effortless, mental technique to reducing stress which allows the mind to experience finer levels of the thinking process to achieve a state of restful alertness. The Transcendental Meditation program will be taught as a standard seven-step program over five consecutive days.
16573060|NCT02791451|Experimental|Telemonitoring|Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.
16573061|NCT02791438|Experimental|Azilsartan 2.5 - 20 mg (Weight < 50 kg)|Following a 2-week placebo run-in period, azilsartan 2.5 mg (titrated as needed to the highest dose of 20 mg) was administered orally once daily before or after breakfast, for the participants weighing < 50 kg.
16573062|NCT02791438|Experimental|Azilsartan 5 - 40 mg (Weight ≥ 50 kg)|Following a 2-week placebo run-in period, azilsartan 5 mg (titrated as needed to the highest dose of 40 mg) was administered orally once daily before or after breakfast, for the participants weighing ≥ 50 kg.
16573063|NCT02791425|Experimental|Brain Computer Interface (BCI) device|The patient uses the Brain Computer Interface (BCI) device in the ICU for communication for 2 hours a day for 3 consecutive days. The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
16573064|NCT02791412||unprotected left main|undergone percutaneous coronary intervention or coronary artery bypass graft
16573065|NCT02791399|No Intervention|Control|Treatment as usual
16573066|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
16573067|NCT02791386||Chinese Patients With CHB and Drug Resistance to NA Therapy|
16573068|NCT02791373|Active Comparator|Mobilisation Chemotherapy: Vinorelbine|Vinorelbine is given at a standard dose of 35mg/m2 i.v. at day 1 as an infusion over 10 minutes, on an ambulatory basis.
16573069|NCT02791373|Experimental|Mobilisation Chemotherapy: Gemcitabine|Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
16573070|NCT02791360|Other|MRI evaluation|Patient pretreated for brain tumor and witness
16573071|NCT02791347|No Intervention|Control|"Upon discharge from the medical center, patients would be advised on a qualitative, neutropenic diet. Participants' quality of life, physical activity level, functional and nutritional status would be assessed at days +30, +60 and +100 post transplantation.
~These participants will not receive nutritional counseling by the dietitian as outpatients except if referred by the medical team."
16573072|NCT02791347|Experimental|Nutrition Intervention Group|"Upon discharge from the medical center, NIG patients will receive tailored nutrition counseling with the provision of patient education material and oral nutritional supplements if needed. Patients will be advised on a diet high in energy and proteins and tailored to their medical condition in the hospital before discharge.
~Patients will be followed up at days +30, +60 and +100 post transplantation. Compliance will be measured at each visit by comparing patients caloric and protein needs to their actual protein and energy intake. Compliance will be reinforced to meet patients' goals using nutritional tips, oral supplementation, and artificial nutrition use."
16573073|NCT02791334|Experimental|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
16573074|NCT02791334|Experimental|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
16573075|NCT02791334|Experimental|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
16573076|NCT02791334|Experimental|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
16573077|NCT02791334|Experimental|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
16573078|NCT02791334|Experimental|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
16573079|NCT02791334|Experimental|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
16573080|NCT02791334|Experimental|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
16573081|NCT02791334|Experimental|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
16573082|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
16573083|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
16573084|NCT02791334|Experimental|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
16573085|NCT02791321|Other|Patients with ADS-MR|Patients presenting Autism Spectrum Disorder and mental retardation who are evaluated for their ADS severity, their adaptative and intellectual functioning, psychiatric and somatic comorbidities
16573086|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
16573087|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
16573088|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
16573089|NCT02791295|Experimental|Diet and physical activity program|Diet and physical activity program with individual coaching
16573090|NCT02791295|No Intervention|control|standard care
16573091|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Patients with clinical suspicion for CTEPH, scheduled for SPECT
16573092|NCT02791269|Experimental|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
16573093|NCT02791269|Experimental|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
16573094|NCT02791256|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day [mg/day] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.
16573095|NCT02791243|Experimental|Finasteride 0.25%|approximately 0.2 ml of P-3074 (0.25% finasteride)
16573096|NCT02791243|Placebo Comparator|Placebo for Finasteride 0.25%|approximately 0.2 ml of the vehicle cutaneous solution
16573097|NCT02791243|Other|Negative Control|approximately 0.2 ml of 0.9% aqueous NaCl
16573098|NCT02791230|Experimental|Tafamidis|Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg
16573099|NCT02791217||Diffused Large B cell Lymphoma|
16573100|NCT02791217||Follicular Lymphoma|
16573101|NCT02791217||Multiple Myeloma|
16573102|NCT02791217||Hodgkin Lymphoma|
16573103|NCT02791217||Healthy individuals|
16573104|NCT02791204|Experimental|Participants with PAD|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
16573105|NCT02791204|Active Comparator|Controls|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
16573106|NCT02791191|Experimental|Dose 1 LY3202626|3 mg LY3202626 given orally once daily for 52 weeks.
16573107|NCT02791191|Experimental|Dose 2 LY3202626|12 mg LY3202626 given orally once daily for 52 weeks.
16573108|NCT02791191|Experimental|Placebo|Placebo given orally once daily for 52 weeks.
16573109|NCT02791178||STEMI patients|"The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.
~All patients to do Optical Coherence Tomography (OCT), Index of Microcirculatory Resistance (IMR) and Cardiac MRI."
16573110|NCT02791139||Control|Healthy Volunteers will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Hand-Grip Strength Measurement Body Fat Mass Analysis
16573111|NCT02791139||Ageing|"Ageing cohort will undergo the following studying procedures:
~Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Body Fat Mass Analysis"
16573112|NCT02791126||Heart Failure|"Patients presented to hospital with a primary diagnosis of Heart Failure or are attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either resulted in a hospital admission (primary diagnosis) or was treated in out-patient clinic.
~Cardiovascular Magnetic Resonance and Echocardiogram will be performed."
16573113|NCT02791100|No Intervention|No promotion of chicken eggs|The community receives no chickens and therefore has no additional eggs or egg shell powder for children
16573114|NCT02791100|Experimental|Promotion of Chicken eggs for children|The community receives chickens so that each study child receives 2 eggs a day and also receives some egg shell daily (1/4 bottle cap which provides 500 mg Ca). The community receives information on using the egg and eggshell, and has help in caring for the chickens.
16573115|NCT02791087||Coronary Artery Disease for CABG|Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.
16573116|NCT02791087||Stable/Unstable Angina|Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.
16573117|NCT02791074||Control|"Healthy Volunteers will undergo the following studying procedures:
~Echocardiography Arterial tonometry"
16573118|NCT02791074||Heart Failure Patients|"Patients will undergo the following studying procedures:
~NTproBNP Echocardiography Arterial tonometry"
16573119|NCT02791061||Control|"Healthy Volunteers will undergo the following studying procedures:
~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
16573120|NCT02791061||Congenital Disease|"Patients will undergo the following studying procedures:
~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
16573121|NCT02791048|Experimental|Experimental Group|Music therapy for up to 45 minutes twice a week for three weeks, in addition to usual care from the hospice multidisciplinary team.
16573122|NCT02791048|No Intervention|Control Group|Usual care only from the hospice multidisciplinary team. The dose and frequency of usual care will be as deemed appropriate by the hospice practitioner in charge of their treatment.
16573123|NCT02791035|Experimental|Ipragliflozin|Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks
16573124|NCT02791009||Diagnosed Heart Failure [Prior]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
16573125|NCT02791009||Control [Prior]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
16573126|NCT02791009||Control [New]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
16573127|NCT02791009||Diagnosed Heart Failure [New]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
16573128|NCT02790996|Experimental|Vancomycin - Optimised Regimen|"A single loading dose of 25 mg/kg followed by a maintenance dose of:
~Postmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly"
16573129|NCT02790996|Active Comparator|Vancomycin - Standard Regimen|Postmenstrual age < 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly
16573130|NCT02790970|Experimental|PReDicT Test|To determine whether use of the PReDicT Test to direct antidepressant treatment results in an increased proportion of depressed patients showing a response to treatment at week 8
16573131|NCT02790970|Placebo Comparator|Treatment as usual|Treat patients as usual without using the predict test to determine treatment.
16573132|NCT02790957|Experimental|Plerixafor|Single subcutaneous injection of Plerixafor (0.24 mg/kg)
16573133|NCT02790957|Placebo Comparator|Placebo|Single injection of an equal volume of NaCl solution
16573134|NCT02790931|Experimental|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months.
16573135|NCT02790931|No Intervention|Control Group|Patients will not receive any exercise treatment, will not have acess to the software, but they will keep their recommended clinical treatment.
16573136|NCT02790918||Diagnosed Pulmonary Hypertension|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
16573137|NCT02790918||Healthy Volunteer|Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
16573138|NCT02790892|Other|Art therapy - pre and post test measures|20 young adults aged 15-24 years with diabetes (10 with type 1 diabetes and 10 with type 2 diabetes) receiving 12 weeks of group art therapy. Participants serve as their own controls.
16573139|NCT02790879||Transition|Patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.
16573140|NCT02790866|Experimental|LuCaS Decision Aid|Access to LuCaS, a web-based lung cancer screening decision aid
16573141|NCT02790866|Active Comparator|NCI Website|Access to NCI website on lung cancer screening
16573142|NCT02790853|Experimental|Diagnostic (multimodal imaging, biopsy)|Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
16573143|NCT02790840|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days
16573144|NCT02790827|Experimental|CETA|Participants in the experimental arm will receive the CETA intervention. The intervention period will last for approximately 4 months with weekly sessions. There will be separate groups for men, women, and children. Each group will have approximately six participants. Individuals who cannot attend group therapy (e.g., conflicting work schedules) may be offered the therapy individually.
16573145|NCT02790827|Active Comparator|Treatment as usual|There is no standard of care for domestic violence or alcohol use problems in Zambia. We will track any treatment or care that families receive during the course of the study. The active comparator arm will not receive any formal services provided by the study.
16573146|NCT02790814|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
16573147|NCT02790814|Active Comparator|Hand-held fetoscope|Intermittent fetal heart rate monitoring
16573148|NCT02790801||1 group|observation of patients with chronic heart failure and atrial fibrillation
16573149|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
16573150|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
16573151|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 1|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1
16573228|NCT02790177|Placebo Comparator|Normal saline|This group will just receive normal saline to ensure blinding.
16573152|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 2|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2
16573153|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 3|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3
16573154|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 4|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4
16573155|NCT02790762|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
16573156|NCT02790749|Experimental|PAO with adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) with adjunctive hip arthroscopy.
16573157|NCT02790749|Active Comparator|PAO WITHOUT adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) WITHOUT adjunctive hip arthroscopy.
16573158|NCT02790736|Experimental|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
16573159|NCT02790736|Placebo Comparator|placebo capsule|Placebo capsule, given once after fear activation procedure
16573163|NCT02790710|Experimental|Propanolol|Propranolol 40 mg capsule, given once after fear reactivation procedure
16573164|NCT02790710|Placebo Comparator|Placebo capsule|Placebo capsule, given once after fear reactivation procedure
16573165|NCT02790697||Mechanically ventilated ICU patient|Indirect calorimetry measurements will be conducted using the new calorimeter and the mass spectrometer system at the same time for all enrolled patients.
16573166|NCT02790684|Experimental|DS-8500a|
16573167|NCT02790671|Experimental|single study arm|DS-8500a and itraconazole
16573168|NCT02790658|Other|Grumixama Juice|"Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight.
~The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice."
16573169|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
16573170|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
16573171|NCT02790645|Other|Group 1b. Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
16573172|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).
16573173|NCT02790632|Experimental|EG-1962 Group|"1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg
~Up to 21 days of placebo capsules/tablets"
16573174|NCT02790632|Active Comparator|Enteral Nimodipine Group|"1 dose of intraventricular normal saline
~Up to 21 days of oral nimodipine capsules/tablets"
16573175|NCT02790619|Active Comparator|Meditation and Active Stimulation 1|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 1 milliamp(mA) stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
16573176|NCT02790619|Active Comparator|Meditation and Active Stimulation 2|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 2 mA stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
16573177|NCT02790619|Sham Comparator|Meditation and Sham Stimulation|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.The participants in the sham study will receive Sham tDCS (no stimulation) with Anode over F8 and cathode over left supraorbital area with intervention administration delivered by Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
16573178|NCT02790606|Experimental|Covera(TM) Vascular Covered Stent|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
16573179|NCT02790593|Experimental|Juxta-Cures™|Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
16573180|NCT02790593|Active Comparator|Standard compression|Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
16573181|NCT02790580|Active Comparator|Dose-dense doxorubicin/cyclophosphamide|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after doxorubicin/cyclophosphamide
16573182|NCT02790580|Experimental|Dose-dense doxorubicin/cyclophosphamide + sunitinib|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide, Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0), Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
16573226|NCT02790190|No Intervention|Conventional radiotherapy|2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.
16573183|NCT02790567||HIT study group|The HIT study group will include all patients admitted in our surgical intensive care unit (ICU) during the study period if the clinician in charge of the patient suspects the diagnosis of HIT. The HEP score, the 4Ts score, the immuno-diffusion particle gel immunoassay (ID-PaGIA) and the HIT-Ab(PF4-H) test will be done for each patient the day the diagnosis of HIT will be suspected.
16573184|NCT02790554|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
16573185|NCT02790554|Active Comparator|Hand-held Doppler|Intermittent fetal heart rate monitoring
16573186|NCT02790541|Experimental|Treatment|Hyperbaric Oxygen Therapy: 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
16573187|NCT02790541|Other|Control/Crossover|Hyperbaric Oxygen Therapy: 3 months control period (no treatment) followed by 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
16573188|NCT02790528|Experimental|Atorvastatin|20mg QD
16573189|NCT02790528|Placebo Comparator|Placebo|
16573190|NCT02790515|Experimental|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.
~Cells for infusion are prepared using the CliniMACS System."
16573191|NCT02790502|Other|Intervention|Intervention Group
16573192|NCT02790489|Experimental|Valedia|Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses
16573193|NCT02790476|Experimental|Letter intervention|The intervention arm will involve letters sent to prescribers in San Diego County.
16573194|NCT02790476|No Intervention|Control|The control group will involve prescribers not receiving letters
16573195|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
16573196|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
16573197|NCT02790450|Experimental|Benzbromarone|1x200mg Benzbromarone
16573198|NCT02790437|Experimental|Treatment IdeS|IdeS intravenous infusion
16573199|NCT02790424|Experimental|Patients|Imaging devices
16573200|NCT02790411|Experimental|healthy volunteers|Imaging devices New Non Invasive Devices
16573201|NCT02790398|Experimental|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol.
16573202|NCT02790398|Active Comparator|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol that includes a component aimed at the regulation of PA.
16573203|NCT02790385|Experimental|NPWT|subjects will undergo negative pressure wound therapy
16573204|NCT02790385|Active Comparator|Standard Gauze|standard method of using gauze and dressing will be utilized
16573205|NCT02790372|No Intervention|Control nursing homes|Nursing homes carries out usual care
16573206|NCT02790372|Active Comparator|Intervention nursing homes|Nursing homes that carries out regularly case conferencing
16573207|NCT02790359|Active Comparator|Patient group 1|Air
16573208|NCT02790359|Active Comparator|Patient group 2|Carbon dioxide
16573209|NCT02790346|Experimental|arthrodesis talonavicular|arthrodesis talonavicular in addition to tendon gestures
16573210|NCT02790346|Active Comparator|tendon gestures|tendon gestures only
16573211|NCT02790333|Experimental|Tri-Staple reloads|Tri-Staple reloads were used for pancreatic stump texture
16573212|NCT02790333|Active Comparator|traditional reloads|the traditional reloads were used for pancreatic stump texture
16573213|NCT02790320||Patients with locally recurrent or metastatic breast cancer|Patients received 1.4 mg/m2 eribulin, administered intravenously on day 1 and 8 of each 21 day cycle until disease progression or unmanageable toxicity, per routine clinical practice.
16573214|NCT02790307|Experimental|Daily stimulation (30mins/day)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
16573215|NCT02790307|Experimental|Weekly stimulation (30mins/week)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
16573216|NCT02790294|Experimental|Postoperative Magnetic Resonance Imaging|Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
16573217|NCT02790268||Lens Subluxation|Pediatric eyes with lens subluxation undergoing Cionni Ring Bag fixation with in-the-bag IOL Implantation
16573218|NCT02790255|Experimental|Cold air|Subjects to be seated in an airtight chamber at an ambient temperature between 16 to 20 degrees Celsius for 1 hour.
16573219|NCT02790255|Experimental|Cold water|Subjects to be seated in an airtight chamber at an ambient temperature of 24 degrees Celsius, with their hands and feet fully immersed in cold water for 5 minutes.
16573220|NCT02790229|Experimental|anti-gravity treadmill arm|Treatment with anti-gravity treadmill (alter G®)
16573221|NCT02790229|Other|control arm|Treatment with standardized physiotherapy
16573222|NCT02790216||Brachytherapy|men eligible for monotherapy seed implant brachytherapy
16573223|NCT02790203|Experimental|Celecoxib|"Celecoxib will be given orally to patients participating in the study and allocated to the treatment group, for an intervention period of 6 days, starting from the day of surgery.
~Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses, a dose which is within the recommended and a widely used dosage and is expected to induce a significant inhibition of prostaglandin synthesis by the COX2 pathway. Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses."
16573224|NCT02790203|Placebo Comparator|Placebo|"Placebo will be given orally to patients participating in the study and allocated to the control group that will receive placebo, for an intervention period of 6 days, starting from the day of surgery.
~Placebo will be given throughout the intervention period of the study orally in capsules that resemble the drug, twice a day."
16573225|NCT02790190|Experimental|Individualized Adaptive radiotherapy|GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.
16573229|NCT02790164|Experimental|Rocuronium|Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.
16573230|NCT02790164|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
16573231|NCT02790151|Active Comparator|Standard Therapy|Learning and practicing memory strategies
16573232|NCT02790151|Experimental|Experimental Intervention|Computerbased working memory training and Recollection training
16573233|NCT02790138|Placebo Comparator|Placebo IV|Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
16573234|NCT02790138|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
16573235|NCT02790125|Experimental|Dose Panel 1|"BMS-986166 or Placebo matching BMS-986166
~Single oral dose of solution as specified"
16573236|NCT02790125|Experimental|Dose Panel 2|"BMS-986166 or Placebo matching BMS-986166
~Single oral dose of solution as specified"
16573237|NCT02790125|Experimental|Dose Panel 3|"BMS-986166 or Placebo matching BMS-986166
~Single oral dose of solution as specified"
16573238|NCT02790125|Experimental|Dose Panel 4|"BMS-986166 or Placebo matching BMS-986166
~Multiple ascending solid dose formulation as specified"
16573239|NCT02790125|Experimental|Dose Panel 5a/b/c|"BMS-986166
~Single oral solid dose formulation under fasting/fed/fasting with famotidine conditions"
16573240|NCT02790112|Other|GnRHas - Not GnRHas patients|Compared long term outcome of treated and untreated patients with idiopathic central precocious puberty : hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
16573241|NCT02790112|Other|GnRHas - controls patients|Compared long term outcome of treated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
16573242|NCT02790112|Other|Not GnRHas - Controls patients|Compared long term outcome of untreated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
16573243|NCT02790099|Experimental|Rectus sheath block only|Patient will be given surgical rectus sheath block postoperatively with 40ml of bupivacaine (2.5mg/mL) and 0.1ml of normal saline will be injected intrathecally at time of spinal anaesthesia.
16573244|NCT02790099|Active Comparator|Intrathecal morphine group|0.1mg preservative free morphine will be injected intrathecally at time of spinal anesthesia and 40ml of normal saline will be injected as rectus sheath block.
16573245|NCT02790099|Active Comparator|Both intervention|Patient will be given 0.1mg preservative free morphine intrathecally at time of spinal anaesthesia and surgical rectus sheath block with 40ml of bupivacaine (2.5mg/ml).
16573246|NCT02790073|Other|SNF472|SNF472 for calciphylaxis
16573247|NCT02790047|Active Comparator|Home-base exercise|"Patients will receive intervention as following
~A home-base exercise program
~Health education
~Breathing strategies for self secretion clearance
~The medication following the COPD GOLD guidelines (2015)"
16573248|NCT02790047|Experimental|Home-base exercise with a PEP mask|"Patients will receive intervention as following
~A home-base exercise program with using a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise
~Health education
~Breathing strategies for self secretion clearance
~The medication following the COPD GOLD guidelines (2015)"
16573249|NCT02790034|Active Comparator|Sarizotan|Between 2 to 10 mg bid based on age and weight criteria.
16573250|NCT02790034|Placebo Comparator|Placebo|Placebo bid respectively
16573251|NCT02790021|No Intervention|Complex decongestive therapy|Group A will continue complex decongestive therapy consisting of skin care, manual lymphatic drainage, and compression therapy using compression stockings.
16573252|NCT02790021|Experimental|Lymphaticovenous anastomosis (LVA)|Group B will undergo an LVA procedure under local anesthesia in surgical daycare setting. Patients are not allowed to wear compression stockings or have decongestive therapy for four weeks after the surgery.
16573253|NCT02790008||Aortic valve disease|Patients with aortic stenosis referred to surgery. Exclusion criteria are concomitant heart valve disease, congenital heart disease, hemodynamic instability, previous cardiac surgery, history of myocardial infarction and coronary artery disease.
16573254|NCT02789995|Experimental|Patients with and without sepsis|"Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.
~Human biological samples collected for research :
~Blood sample
~Muscle biopsy
~Bone marrow sample (mesenchymal stem cells)"
16573255|NCT02789982|Experimental|Reconsolidation blockade|β-adrenergic blocker propranolol 1 mg / kg to each of the 6 treatment sessions
16573256|NCT02789982|Active Comparator|Treatment as usual|Treatment as usual like SSRIs, psychotherapy, ...
16573257|NCT02789969|Experimental|Hydromorphone 15mcg/kg IV|Patient randomly assigned to hydromorphone
16573258|NCT02789969|Experimental|Fentanyl 1.5 mcg/kg IV|Patient randomly assigned to fentanyl
16573259|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
16573260|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
16573261|NCT02789917|Experimental|Dual therapy (incl. NOAC)|Apixaban plus Clopidogrel
16573262|NCT02789917|Active Comparator|Triple therapy (incl. VKA)|Phrenprocoumon plus Clopidogrel plus ASA
16573263|NCT02789904||Chest pain patients in DEM|Recruitment done at SGH DEM. Blood taking will be done at 0, 1 and 2 hr.
16573264|NCT02789891|Experimental|D2 Lymphadenectomy including No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
16573265|NCT02789891|Active Comparator|D2 lymphadenectomy excluding No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
16573266|NCT02789878|Experimental|ADT and Abiraterone|"Goserelin 10.8 mg, single dose, subcutaneously.
~Abiraterone 1,000 mg, once daily, orally for 3 months.
~Prednisone 5 mg, once daily, orally for 3 months."
16573267|NCT02789878|Experimental|ADT, Abiraterone and Apalutamide|"Goserelin 10.8 mg, single dose, subcutaneously.
~Abiraterone 1,000 mg, once daily, orally for 3 months.
~Prednisone 5 mg, once daily, orally for 3 months.
~Apalutamide 240 mg, once daily, orally for 3 months."
16573268|NCT02789865|Active Comparator|Antibiotic therapy group|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
16573269|NCT02789865|Experimental|ERAT group|The patients will receive emergent endoscopic retrograde appendicitis therapy (ERAT).
16573270|NCT02789865|Active Comparator|Appendectomy group|The patients will receive laparoscopic appendectomy according to standard routines.
16573271|NCT02789852|Experimental|Orthosis Group|Will use the night orthosis for interphalangeal in the treatment of OA hand.
16573272|NCT02789852|No Intervention|Control Group|wait for treatment
16573273|NCT02789839|Experimental|Healthy volunteer|Blood test Medullar test
16573274|NCT02789826|Experimental|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
16573275|NCT02789826|Active Comparator|Open gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group
16573276|NCT02789813|Experimental|Valproic Acid and fear reactivation|This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.
16573277|NCT02789813|Active Comparator|Valproic Acid and no fear reactivation|This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.
16573278|NCT02789813|Placebo Comparator|Placebo and fear reactivation|This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.
16573279|NCT02789813|Placebo Comparator|Placebo and no fear reactivation|This group will receive once Placebo (oral solution) before exposure therapy.
16573280|NCT02789800|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
16573281|NCT02789800|No Intervention|Group B|Control group (n = 163)
16573282|NCT02789800|No Intervention|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
16573283|NCT02789787||Maxillary protraction|Early adolescents (11 - 14 yrs) with cleft lip and palate and Cl III malocclusion
16573284|NCT02789787||Orthognathic surgery|Late adolescents to young adults (16-21 years) with cleft lip and palate and Cl III malocclusion
16573285|NCT02789774|Experimental|Surgical treatment|Stabilization of odontoid fracture with posterior fusion C1-C2
16573286|NCT02789774|Active Comparator|Conservative treatment|External stabilization of odontoid fracture with a rigid cervical collar for 3 months.
16573287|NCT02789761|Active Comparator|High-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
16573288|NCT02789761|Placebo Comparator|Low-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately <1 mg of (-)-epicatechin for 2-weeks (14 days)
16573289|NCT02789748|Experimental|Treatment ON|Kinesthetic stimulation administered during one night
16573290|NCT02789748|No Intervention|Treatment OFF|NO kinesthetic stimulation administered during one night
16573291|NCT02789735|Active Comparator|Device: LiteCure LCT-1000®|Treatment with 10 J/cm²
16573292|NCT02789735|Sham Comparator|Device: Sham LiteCure|Sham i.e. visible red light
16573293|NCT02789722|Experimental|Yerba Mate Extract 750 mg|Yerba Mate Extract - Capsules: daily dose of 2.250 g, distributed in 3 doses of 750 mg, for 28 days.
16573294|NCT02789722|Placebo Comparator|Placebo|Starch - Capsules: 3 times daily for 28 days.
16573295|NCT02789709||Non metastatic colon cancer patients|Consecutive patients undergoing elective surgery for non-metastatic colon or rectal cancer with curative intent.
16573296|NCT02789696|Other|Acromegaly|Diagnosis of acromegaly
16573297|NCT02789683|Experimental|Fine emulsion|Emulsion with small lipid droplet size served together with white bread
16573298|NCT02789683|Experimental|Coarse emulsion|Emulsion with large lipid droplet size served together with white bread
16573299|NCT02789683|Experimental|Control|Non-emulsified oil and water served together with white bread
16573300|NCT02789670||MS patients|MS patient group is composed by 20 Individuals with inflammatory brain lesions seen in MRI (Radiologically Isolated syndrome) 20 patients with only one clinically isolated syndrome (CIS) 20 patients with relapsed remittent Multiple sclerosis (RRMS) 20 patients with primary progressive Multiple Sclerosis (PPMS)
16573301|NCT02789670||Control group patients|"Control patient cohort is composed by 20 patients suffering from inflammatory neurological disease other than MS Devic syndrome, Neurosarcoidosis, Neurobehcet... (autoimmune disease control group with neurological disease) 20 patients with systemic sclerosis (autoimmune disease control group) without neurological disease)
~40 healthy subjects"
16573302|NCT02789657|Experimental|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
16573303|NCT02789657|Experimental|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
16573304|NCT02789657|Experimental|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
16573305|NCT02789657|Experimental|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
16573306|NCT02789644|Experimental|Ursodeoxycholic acid 400mg|Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
16573307|NCT02789644|Experimental|Ursodeoxycholic acid 800mg|Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
16573308|NCT02789631||chronic neck pain|experiencing neck pain for at least 3 months in the last year
16573309|NCT02789631||without neck pain (asymptomatic)|no history of neck pain
16573310|NCT02789618|Active Comparator|A01|Toothpaste containing calcium silicate and Sodium Monofluorophosphate (1450ppm F) and a gel containing sodium fluoride (1450ppm F)
16573311|NCT02789618|Active Comparator|B99|Toothpaste containing Stannous Fluoride and a dentinal bonding agent
16573312|NCT02789618|Placebo Comparator|M89|Toothpaste containing sodium fluoride (1450ppm F)
16573313|NCT02789605|Experimental|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months
16573314|NCT02789605|Placebo Comparator|Placebo|Patient receiving placebo, orally taken, 4 times a day, during 3 months
16573315|NCT02789592|Experimental|Group 1|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
16573316|NCT02789592|Experimental|Group 2|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
16573317|NCT02789592|Experimental|Group 3|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
16573318|NCT02789592|Experimental|Group 4|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
16573319|NCT02789592|Experimental|Group 5|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
16573320|NCT02789592|Experimental|Group 6|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
16573321|NCT02789579|Experimental|levofloxacin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 3 days before Minimally invasive upper tract lithotomy.
16573322|NCT02789579|Experimental|nitrofurantoin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 3 days before Minimally invasive upper tract lithotomy.
16573323|NCT02789579|Experimental|cefuroxime group|There are 150 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and does not receive oral antibiotics 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
16573324|NCT02789579|Experimental|levofloxacin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 7 days before Minimally invasive upper tract lithotomy.
16573325|NCT02789579|Experimental|nitrofurantoin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 7 days before Minimally invasive upper tract lithotomy.
16573326|NCT02789566|Experimental|Regimen|Primaquine (PQ) 30 mg base single dose
16573327|NCT02789553|Experimental|Meal with glucose syrup|Meal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
16573328|NCT02789553|Experimental|Starch meal|Starch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
16573329|NCT02789527|Experimental|Healthy volunteers in Ethiopia|Phenotype and genotype of enzymes involved in drug metabolism in Ethiopia population
16573330|NCT02789527|Experimental|Healthy volunteers in Oman|Phenotype and genotype of enzymes involved in drug metabolism in Oman population
16573331|NCT02789527|Experimental|Healthy volunteers in the Czech Republic|Phenotype and genotype of enzymes involved in drug metabolism in Czech Republic population
16573332|NCT02789527|Experimental|Healthy volunteers in Greece|Phenotype and genotype of enzymes involved in drug metabolism in Greek population
16573333|NCT02789514||children|Investigators give observation to the patients who need esophagogastroduodenoscopic procedures.
16573334|NCT02789501|Active Comparator|Control|Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
16573335|NCT02789501|Experimental|Test|"TauroLock™ based lock solution regimen:
~Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval).
~TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin.
~TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase."
16573336|NCT02789488|Other|Furocyst|Furocyst one caps BID
16573337|NCT02789475|Experimental|amplodipine group|Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days
16573338|NCT02789475|Experimental|rosuvastatin group|Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days
16573339|NCT02789462||Patients undergoing laser-assisted PCI|Patients of VAMC centers who undergone laser-assisted percutaneous coronary interventions.
16573340|NCT02789449||precapillary|patients with PH and PAWP<12mmHg
16573341|NCT02789449||postcapillary|patients with PH and PAWP>18mmHg
16573443|NCT02788786|No Intervention|No oral rinse|No rinse provided in this group
16573447|NCT02788760|Other|12 weeks|This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)
16573342|NCT02789436|Experimental|L. reuteri Prodentis® lozenges|"15 subjects
~Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). Probiotic lozenges are used twice daily for 28 days."
16573343|NCT02789436|Placebo Comparator|Placebo lozenges|"15 subjects
~Placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.Placebo lozenges are taken twice daily for 28 days."
16573344|NCT02789423|Active Comparator|Dycal|Intervention: drug: Dycal, Other names: Calcium Hydroxide. Intervention Description:DPC using Dycal for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria evaluated were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility. Radiographic criteria:Defective restoration/Recurrent caries,Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
16573345|NCT02789423|Active Comparator|Biodentine|Intervention: drug: Biodentine, Other names: Calcium Silicate. Intervention Description:DPC using Biodentine for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility.Radiographic criteria:Defective restoration/Recurrent caries, Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
16573346|NCT02789410|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
16573347|NCT02789410|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
16573348|NCT02789397|Active Comparator|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
16573349|NCT02789397|Placebo Comparator|Placebo|IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
16573350|NCT02789384|Experimental|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
16573351|NCT02789371|Other|Arm A|the first pass is made with 5ml suction technique
16573352|NCT02789371|Other|Arm B|the first pass is made with modified wet suction technique
16573353|NCT02789358|Active Comparator|Control Arm|"Conventional protocol for cryoablation:
~At least 2 applications of 180s each"
16573354|NCT02789358|Experimental|Study Arm|"Experimental protocol for cryoablation:
~Time to effect + 1 minute and a bonus application of 120s"
16573355|NCT02789345|Experimental|Ramucirumab + Osimertinib|"Dose Finding: Ramucirumab given intravenously (IV) on day 1 every 2 weeks (Q2W) and osimertinib given orally daily during each 14 day cycle.
~Expansion: Ramucirumab given IV on day 1 Q2W and osimertinib given orally daily during each 14 day cycle."
16573356|NCT02789345|Experimental|Necitumumab + Osimertinib|"Dose Finding: Necitumumab given IV on days 1 and 8 every 3 weeks (Q3W) and osimertinib given orally daily during each 21 day cycle.
~Expansion: Necitumumab given IV on days 1 and 8 Q3W and osimertinib given orally daily during each 21 day cycle."
16573357|NCT02789332|Active Comparator|Paclitaxel with Carboplatin (PwCb)|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
16573358|NCT02789332|Experimental|Paclitaxel with Olaparib (PwO)|"paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)
~followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery."
16573359|NCT02789319|Other|FreeStyle Lite|Blood Glucose Meter type
16573360|NCT02789319|Other|Contour Next|Blood Glucose Meter type
16573361|NCT02789319|Other|OneTouch Ultra2|Blood Glucose Meter type
16573362|NCT02789319|Other|ACCU-CHEK AVIVA Plus|Blood Glucose Meter type
16573363|NCT02789319|Other|Prodigy Auto Code|Blood Glucose Meter type
16573364|NCT02789319|Other|Walmart ReliOn Prime|Blood Glucose Meter type
16573365|NCT02789319|Other|Embrace|Blood Glucose Meter type
16573366|NCT02789319|Other|True Result|Blood Glucose Meter type
16573367|NCT02789319|Other|True Track|Blood Glucose Meter type
16573368|NCT02789319|Other|Walmart ReliOn Confirm|Blood Glucose Meter type
16573369|NCT02789319|Other|Advocate Redi-Code +|Blood Glucose Meter type
16573370|NCT02789319|Other|CVS Advanced|Blood Glucose Meter type
16573371|NCT02789319|Other|OneTouch Verio|Blood Glucose Meter type
16573372|NCT02789319|Other|Contour|Blood Glucose Meter type
16573373|NCT02789319|Other|Accu-Chek Nano|Blood Glucose Meter type
16573374|NCT02789319|Other|Walmart ReliOn Ultima|Blood Glucose Meter type
16573375|NCT02789319|Other|Gmate Smart|Blood Glucose Meter type
16573376|NCT02789319|Other|SolusV2|Blood Glucose Meter type
16573377|NCT02789306||Peri-implantitis|"Peri-implantitis' - Loss radiographic bone beyond the biological bone remodeling at baseline (after prosthesis delivery) from the implant neck
~Early:> 4 mm probing depth; <25% radiographic bone loss
~Moderate:> 6mm probing depth; <50% radiographic bone loss
~Severa:> 8 mm probing depth; > 50% radiographic bone loss"
16573378|NCT02789306||Healthy|No signs of inflammation and otherwise no bone loss beyond the biological bone remodeling
16573379|NCT02789293|Experimental|Focused Ultrasound treatment|Ultrasound ciliary pasty (UCP) using focused ultrasound
16573444|NCT02788773|Experimental|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
16573445|NCT02788773|Experimental|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
16573380|NCT02789280|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
16573381|NCT02789280|Active Comparator|Wait List|Participants will be asked to wait for a week until they receive the behavioral activation condition
16573382|NCT02789267|No Intervention|Control|"Group of patients with standard of care: the nutritional support is conducted by physicians.
~No systematic dietary support"
16573383|NCT02789267|Experimental|Regular dietary support|Group of patients will benefit from a systematic and regular dietary support. Patients will be followed by a dietitian 1 month and 3 month after radiotherapy in hospital. Then, dietitian will realize a telephon interview 2 and 5 months after radiotherapy
16573384|NCT02789254|Experimental|Experimental: FLYSYN|IV infusion over a 3-hr duration
16573385|NCT02789241|Experimental|Endotoxin (LPS)|The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
16573386|NCT02789241|Placebo Comparator|Placebo|The trial will consist of 4 groups each group will have 2 subjects receiving Placebo (normal saline)].
16573387|NCT02789228|Experimental|Group A|"Group A includes patients who have undergone an allogeneic hematopoietic stem cell transplant (HSCT) as part of their prior therapy.
~Group A patients (post allogeneic HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first."
16573388|NCT02789228|Experimental|Group B|"Group B includes patients who have undergone conventional (standard) therapy which does not include an allogeneic HSCT. Within group B, a cohort of patients with relapsed or refractory Wilms tumor will be enrolled and receive a lymphodepleting chemotherapy regimen followed by TAA-T.
~Group B patients (no prior allogeneic HSCT): TAA-T will be infused any time >1 week after completing most recent course of conventional (non-investigational) therapy for their disease. Patients receiving lymphodepletion will be >2 weeks from most recent course of conventional therapy and have nadired and recovered before beginning protocol therapy."
16573389|NCT02789215|Experimental|Intervention|Receive new CACFP menu pattern
16573390|NCT02789215|No Intervention|Control|Follow existing CACFP menu pattern
16573391|NCT02789202|Experimental|Silver Diamine Fluoride|Control treatment
16573392|NCT02789202|Active Comparator|Fluoride Varnish|Test treatment
16573393|NCT02789189|Experimental|nedaplatin combined with gemcitabine|
16573394|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They were contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They were asked to take part in all prospective follow up surveys at 12, 18, & 24 months of age.
16573395|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, & completed the follow surveys at 12, 18, & 24 months of age.
16573396|NCT02789150|Experimental|MAP 65-70|Goal MAP of 65-70
16573397|NCT02789150|Active Comparator|MAP greater than or equal to 85|MAP greater than or equal to 85
16573398|NCT02789124|Experimental|Carotid Artery Flow Time|Patients with radial aline and flotrac vigileo will have carotid dopper measured for carotid flow time and a passive leg raise
16573399|NCT02789111|Active Comparator|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
16573400|NCT02789111|Placebo Comparator|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
16573401|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
16573402|NCT02789085|No Intervention|Control|without tens stimulation
16573403|NCT02789085|Experimental|Test|with tens stimulation
16573404|NCT02789072|Other|Microgravity|effect of microgravity on central aortic blood pressure.
16573405|NCT02789059|Experimental|muscle oxygenation|assesment of muscle oxygenation and gas exchanges
16573406|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
16573407|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
16573408|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
16573409|NCT02789020|Experimental|Rasagiline|This group will receive a 1 mg rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
16573410|NCT02789020|Placebo Comparator|Placebo|This group will receive a placebo tablet in the same forum as the rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
16573411|NCT02789007|Other|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
16573446|NCT02788760|Other|6 weeks|This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
16573448|NCT02788747|Experimental|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
16573412|NCT02788994|Experimental|Endovis BA2 Nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.
~The system has been designed to allow:
~stable fracture synthesis for fast rehabilitation and early mobilization
~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)
~This is a one off surgical fixation."
16573413|NCT02788994|Active Comparator|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.
~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
16573414|NCT02788981|Experimental|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
16573415|NCT02788981|Placebo Comparator|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
16573416|NCT02788968|Other|Adolescents|MRI 11-15 years
16573417|NCT02788968|Experimental|Young adults|MRI 19-25 years
16573418|NCT02788955|Active Comparator|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
16573419|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
16573420|NCT02788942|No Intervention|Umbilical|The cholecystectomy material will be removed from umbilical port as usual. This will be control group. Port site infection rates will be measured.
16573421|NCT02788942|Experimental|Epigastric|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured.
16573422|NCT02788929|Active Comparator|Fitbit Charge HR|"Use of the Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
~All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback."
16573423|NCT02788929|No Intervention|No Device|No Fitbit used and no feedback on exercise goal adherence. All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback.
16573424|NCT02788916||Cohort 1|Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
16573425|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
16573426|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
16573427|NCT02788890|Active Comparator|Control Group (T0)|The supragingival scaling without LA
16573428|NCT02788890|Experimental|Test Group 1 (T1)|The simple restoration under LA
16573429|NCT02788890|Experimental|Test Group 2 (T2)|The simple exodontia under LA
16573430|NCT02788877|Experimental|treat-and-extend|Aflibercept 2mg is injected into the vitreous cavity. An injection is given every 4 weeks five times and then the Treat-and-Extend process begins. If 1mm central subfield macular thickness (CSMT) improved (10% or more reduction) compared to the previous visit, the next treatment will be performed at the same interval. If CSMT is maintained (less than 10% changes), the next interval will be extended by two weeks (up to 12 weeks). If CSMT is worsened (10% or more increase), the next interval will be shortened by two weeks (minimum 4 weeks). If CSMT is stable two times at 12 weeks-interval, the injection will be deferred, and the next visit will be 8 weeks later. These process will be continued for 2 years.
16573431|NCT02788864|Active Comparator|Arterakine|Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
16573432|NCT02788864|Placebo Comparator|Placebo|Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
16573433|NCT02788851|Active Comparator|Medication only|Stimulant or non-stimulant medication only - Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine. Investigators will be using a product approved for clinical use in Canada), with dose optimized for each participant based on report of efficacy and side effects. Once on an optimal dose of stimulant or non-stimulant medication they will attend 8 weekly education sessions about ADHD.
16573434|NCT02788851|Experimental|Aerobic Exercise only|Participants attend a structured aerobic exercise class, twice a week for 8 weeks.
16573435|NCT02788851|Active Comparator|Combination Group|Participants assigned to this group will be optimally medicated (either stimulant or non-stimulant medication - approved for clinical use in Canada) and will attend a structured aerobic exercise class, twice a week for 8 weeks.
16573436|NCT02788812|Active Comparator|Open modified Lichtenstein repair|
16573437|NCT02788812|Active Comparator|Laparoscopic TAPP inguinal hernia repair|
16573438|NCT02788799||Control|
16573439|NCT02788799||Intervention|
16573440|NCT02788786|Experimental|chlorhexidine|0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks
16573441|NCT02788786|Experimental|cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks
16573442|NCT02788786|Active Comparator|Salt and Water|Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks
16573449|NCT02788747|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
16573450|NCT02788747|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
16573451|NCT02788734||INC Contact Registry|INC Contact Registry will complete the online questionnaires
16573452|NCT02788721|Experimental|GLPG2451 single dose|Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order
16573453|NCT02788721|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension
16573454|NCT02788708|Experimental|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16573455|NCT02788695||Group 1 - aged 20-90 years|25 participants from each decade from 20-90. Those from 50+ will be recruited from the NICOLA study and retinal/lens images assessed to confirm normality.
16573456|NCT02788695||Group 2: aged 60 years|Group 2: 250 participants NICOLA participants aged 60 will be invited to participate; only those whose ocular images confirm normality will be included.
16573457|NCT02788682||Patients|WT+ Diplotype
16573458|NCT02788682||Controls|WT- Diplotype
16573459|NCT02788656|Experimental|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
16573460|NCT02788656|Active Comparator|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.
~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
16573461|NCT02788630|Experimental|Intervention group|Arm: Experimental: Intervention group Field workers trained in sleep hygiene counseling will advice the mothers randomly allocated to the intervention group. The intervention will be delivered at the child household and will include information on: Normal sleep behaviors during the first year of life; ideal conditions to promote sleep onset like environmental improvements that ensure restful sleep (no screen media, low noise and light); calming naptime routines and avoiding stimulating or stressing children just before naptime; practices that promote child self-regulation of sleep, including putting infants to sleep drowsy but awake; and how to handle nighttime awakenings. A booklet with the intervention content to aid the mother in implementing the intervention will be used.
16573462|NCT02788630|No Intervention|Control group|Mothers randomly allocated to the control group will be visited at home following the same schedule as the intervention group. The control group will receive a written material describing the advantages of breastfeeding over maternal and child health. No advice in relation to child sleep hygiene will be delivered to the mothers from the control group.
16573463|NCT02788617||Non treatment group|This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.
16573464|NCT02788604|Experimental|Experimental Group|Participants in this arm will have a summary of their family's psychosocial risk factors provided to the treatment team. This will occur twice: once shortly after diagnosis (within 2-4 weeks) and once approximately 6 months following diagnosis.
16573465|NCT02788604|Active Comparator|Control Group|Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
16573466|NCT02788591|Other|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
16573467|NCT02788591|Other|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
16573468|NCT02788552|Active Comparator|Acute Symptomatic WKS- 300mg|Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
16573469|NCT02788552|Active Comparator|Acute Symptomatic WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
16573470|NCT02788552|Active Comparator|Acute Symptomatic WKS - 1500mg|Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
16573471|NCT02788552|Active Comparator|High-risk subclinical WKS- 100mg|Thiamine Hydrochloride 100mg once daily for 3 days.
16573472|NCT02788552|Active Comparator|High-risk subclinical WKS- 300mg|Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
16573473|NCT02788552|Active Comparator|High-risk subclinical WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
16573474|NCT02788539|No Intervention|Science Cafe|One time event, Group discussion for 30 participants who are chronic pain stakeholders on pain in their community.
16573475|NCT02788539|Experimental|Cohort 1- Pilot OWL Study|Participants will pilot test a website- Our Whole Lives website for nine weeks in order to determine if it will help with their chronic pain management.
16573476|NCT02788526|Experimental|Adjuvant TACE|Adjuvant TACE were performed 4-6 weeks after surgery
16573477|NCT02788526|Other|Follow-up|Routine follow-up were performed instead of adjuvant TACE
16573478|NCT02788513|Experimental|BI 425809 dose 1|
16573479|NCT02788513|Experimental|BI 425809 dose 2|
16573480|NCT02788513|Experimental|BI 425809 dose 3|
16573481|NCT02788513|Experimental|BI 425809 dose 4|
16573482|NCT02788513|Placebo Comparator|Placebo|
16573483|NCT02788500||Swedish para-athletes|The total population of athletes in the Swedish Paralympic program, which covers candidates for the Paralympic Summer or Winter Games, will be invited by mail to participate in the study and report their incidence of sports-related injuries and illnesses
16573484|NCT02788487|Active Comparator|CPAP1 use and TRD 2use|Wash-in period 1 week and Continuous positive airway pressure (CPAP) is used for 3 weeks then wash-out 1 week and Tongue retaining device (TRD) is used for another 3 weeks
16573485|NCT02788487|Experimental|TRD1 use and CPAP2 use|Wash-in period 1 week and Tongue retaining device (TRD) is used for 3 weeks then Wash-out period 1 week and Continuous positive airway pressure (CPAP) is used for another 3 weeks
16573486|NCT02788474|Placebo Comparator|placebo|
16573488|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
16573489|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
16573490|NCT02788448|Experimental|VIVASURE CLOSURE DEVICE|Large hole closure device
16573491|NCT02788435|No Intervention|Control|Patients in the control arm will undergo a graduated prescription of voice use immediately following surgery.
16573492|NCT02788435|Experimental|Absolute Voice Rest|Patients in the experimental arm will undergo 7 days of absolute voice rest following surgery.
16573493|NCT02788422|Experimental|Video|Video discharge instructions developed using Easy Sketch Pro3TM software (Easy Sketch Pro, United Kingdom). It was created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
16573494|NCT02788422|Active Comparator|Standard of care|This is a one-page paper handout created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
16573495|NCT02788409||Medicare CRPC|Men in the US older than 65 years old having CRPC
16573496|NCT02788370|Sham Comparator|Sham-PEP breathing|Patients will perform a constant work load cycling test with sham-positive expiratory pressure breathing util symptom limit.
16573497|NCT02788370|Experimental|Conical-PEP breathing|Patients will perform a constant work load cycling test with positive expiratory pressure breathing using a conical positive expiratory pressure device until symptom limit.
16573498|NCT02788357|Experimental|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
16573499|NCT02788357|Placebo Comparator|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
16573500|NCT02788331||Hospitals with increasing activity|Hospitals experiencing an increase in the volume of surgical procedures over the study period
16573501|NCT02788331||Hospitals with decreasing activity|Hospitals experiencing a decrease in the volume of surgical procedures over the study period
16573502|NCT02788331||Hospitals with stable activity|Hospitals experiencing no change in the volume of surgical procedures over the study period
16573503|NCT02788318||diagnostic of SUDEP|patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.
16573504|NCT02788318||Control 1|Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.
16573505|NCT02788318||Control 2|Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.
16573506|NCT02788305||non obese|BMI<30. Misoprostol is given for induction of labour according to Bishop score
16573507|NCT02788305||obese|BMI>30. Misoprostol is given for induction of labour according to Bishop score
16573508|NCT02788292|Experimental|Acetylcysteine (NAC)|NAC added to tumescent solution for liposuction and eventual fat grafting.
16573509|NCT02788292|No Intervention|Control|Just tumescent solution for liposuction and fat grafting.
16573510|NCT02788279|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
16573511|NCT02788279|Experimental|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
16573512|NCT02788279|Active Comparator|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
16573513|NCT02788266|Active Comparator|connective tissue graft+composite resin|connective tissue graft plus composite resin
16573514|NCT02788266|Active Comparator|connective tissue graft+ glass ionomer|connective tissue graft plus resin modified glass ionomer cement
16573515|NCT02788266|Active Comparator|connective tissue graft+giomer|connective tissue graft plus giomer
16573516|NCT02788240|Experimental|Peg GCSF with standard medical therapy|
16573517|NCT02788240|Active Comparator|Placebo with standard medical therapy|
16573520|NCT02788214||Advanced intestinal metaplasia|"H. pylori strains from patients with:
~Complete-type intestinal metaplasia with extension to corpus, or
~Incomplete-type intestinal metaplasia of any extent"
16573521|NCT02788214||Non-atrophic gastritis|H. pylori strains from patients with non-atrophic gastritis
16573522|NCT02788214||Gastric cancer|H. pylori strains from patients with gastric cancer
16573523|NCT02788201|Experimental|Treatment Regimen|Treatment regimen selected by CO eXpression ExtrapolatioN (COXEN) model
16573524|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
16573525|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
16573526|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
16573527|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
16573528|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
16573529|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
16573530|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
16573531|NCT02788175|Experimental|HIV-infected Adults on cART|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia
16573532|NCT02788162|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16573533|NCT02788149|Experimental|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
16573534|NCT02788149|Active Comparator|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
16573535|NCT02788136|Experimental|Klinefelter syndrome|13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)
16573536|NCT02788136|Active Comparator|Control|12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)
16573537|NCT02788123|Experimental|bismuth tripotassium dicitrate and pantoprazole|Participants will receive bismuth tripotassium dicitrate (twice daily) and pantoprazole (once daily) as single tablets
16573538|NCT02788123|Active Comparator|pantoprazole|Participants will receive pantoprazole (once daily) as single tablet
16573539|NCT02788110|Other|NIV NAVA then NIPPV|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
16573540|NCT02788110|Other|NIPPV then NIV NAVA|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIPPV then NIV NAVA.
16573541|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
16573542|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
16573543|NCT02788084||B cell Non-Hodgkin Lymphoma|18 years of age or older with new diagnosis of non-Hodgkin lymphoma with FFPE specimen demonstrating enough tissue for elucidation of lymphoma specific variant and immunoglobulin clonotype, willing to provide baseline and follow up bloodwork to look for presence of variant and clonotype.
16573544|NCT02788071|Experimental|FMT capsules|FMT capsules
16573545|NCT02788071|Placebo Comparator|FMT placebo|Placebo capsules
16573546|NCT02788058|Experimental|EGFR-TKI|Patients take EGFR-TKI alone till tumor progression
16573547|NCT02788058|Active Comparator|EGFR-TKI+hypofractionated radiotherapy|After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
16573552|NCT02788032|Other|EnergieShake Intervention|Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
16573553|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
16573554|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
16573555|NCT02788006|Experimental|Regorafenib 160 mg|
16573556|NCT02787993|Active Comparator|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
16573557|NCT02787993|No Intervention|Treatment as usual|Treatment as usual
16573558|NCT02787980|Other|Patients = premature newborns|"Patients will consist of all premature babies (<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood"
16573559|NCT02787980|Other|"Controls = children born full term"|"For controls the participation to research would be proposed to parents of children born full term, just after each patient child included.
~Additional taking blood"
16573560|NCT02787967|Experimental|NEXThaler® 35/4µg|CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg
16573561|NCT02787967|Active Comparator|Reference treatment|Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
16573593|NCT02787785|Active Comparator|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
16573562|NCT02787954||Transcatheter Chemoembolization or TACE|A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.
16573563|NCT02787954||Yittrium 90 or Y-90|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.
16573564|NCT02787954||Microwave Ablation or MWA|Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
16573565|NCT02787954||electroporation|Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.
16573566|NCT02787941|Experimental|Intervention group|The intervention group will receive the pharmacist-delivered multifaceted intervention with two counselling sessions in addition to usual care.
16573567|NCT02787941|No Intervention|Control group|The control group will receive usual care without the pharmacist-delivered multifaceted intervention.
16573568|NCT02787928|Experimental|Intrathecal Dilaudid|This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
16573569|NCT02787915|Experimental|dendritic cell vaccine|DC1-CTL cellular therapy
16573570|NCT02787902|Experimental|Communication|Behavioral weight loss program with communication skills training
16573571|NCT02787902|Active Comparator|Standard|Standard behavioral weight loss program
16573572|NCT02787889|Experimental|Uneven Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks.Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
16573573|NCT02787889|Experimental|Even Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks. Each participant will consume 33% of total protein consumed each meal
16573574|NCT02787876|Experimental|Chemotherapy induced neutropenia|Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle
16573575|NCT02787863|Experimental|COPD with Prevenar-13 (1)|33 patients with COPD. Standard therapy with Prevenar-13.
16573576|NCT02787863|Experimental|Asthma with Prevenar 13 (2)|34 patients with asthma. Standard therapy with Prevenar 13.
16573577|NCT02787863|Experimental|COPD with Pneumo-23 (3)|25 patients with COPD. Standard therapy with Pneumo-23.
16573578|NCT02787863|Experimental|Asthma with Pneumo-23 (4)|25 patients with asthma. Standard therapy with Pneumo-23.
16573579|NCT02787863|Experimental|COPD with Pneumo-23/Prevenar-13 (5)|32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).
16573580|NCT02787863|Experimental|Asthma with Pneumo-23/Prevenar-13 (6)|18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
16573581|NCT02787863|Experimental|COPD with Prevenar-13/Pneumo-23 (7)|25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
16573582|NCT02787863|Experimental|Asthma with Prevenar-13/Pneumo-23 (8)|27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
16573583|NCT02787850|Experimental|CoolSculpting Treatment Cohort A|"Cohort A will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 60 minutes using the CoolMax applicator without the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with the Crown Cooling Insert at a second protocol-defined temperature for 45 minutes.
~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
16573584|NCT02787850|Active Comparator|CoolSculpting Treatment Cohort B|"Cohort B will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 45 minutes using the CoolMax applicator with the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with a second protocol-defined temperature for 60 minutes with the Crown Cooling Insert.
~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
16573585|NCT02787837||Abiraterone Acetate|Abiraterone Acetate 1000 mg/24h plus Prednisone 5mg/12h
16573586|NCT02787824|Experimental|continuous iv administration of iron sucrose|Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).
16573587|NCT02787824|Active Comparator|intermittent iv administration of iron sucrose|Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
16573588|NCT02787811|Active Comparator|Pregnant|women with positive serum beta HCG done 14 days after Intrauterine insemenation
16573589|NCT02787811|Active Comparator|Nonpregnant|women with negative serum beta HCG done 14 days after Intrauterine insemenation
16573590|NCT02787798|Experimental|Entresto|"Stop of all angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor during 2 days.
~valsartan/sacubitril 100 mg tablets (51 and 49 mg) during 2 to 4 weeks twice a day.
~valsartan/sacubitril 200 mg tablets (103 and 97 mg) during 2 to 4 weeks twice a day.
~Microneurography recording of sympathetic activity in muscle destiny (MSNA)"
16573591|NCT02787798|Placebo Comparator|Control|"Hearth failure treatment as usual (angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor)
~Microneurography recording of sympathetic activity in muscle destiny (MSNA) will be done"
16573592|NCT02787785|No Intervention|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
16573594|NCT02787772|Experimental|Elective Hernia Repair|Elective abdominal wall hernia surgery was performed in randomized cirrhotic patients.
16573595|NCT02787772|No Intervention|Clinical follow up|"Cirrhotic patients were kept in clinical follow up concerning their abdominal wall hernia.
~If a complication occured at the hernia site (such as skin rupture, bowel strangulation,..) the patient underwent emergency hernia repair."
16573596|NCT02787759|Active Comparator|Hands-Free Walking|Body-weight supported treadmill training
16573597|NCT02787759|Experimental|Challenge Based plus Hands-Free|9 different balance and locomotor challenges applied during walking while not holding onto anything
16573598|NCT02787746|Other|donepezil|This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.
16573599|NCT02787733|Experimental|Citrus flavonoid|Citrus peel extract containing >90% flavonoids
16573600|NCT02787733|Placebo Comparator|Placebo|Identical looking placebo
16573601|NCT02787720|Experimental|Family centered empowerment model|The Family-Centered Empowerment Model (FCEM)
16573602|NCT02787720|Experimental|Continuous care model|The Continuous Care Model
16573603|NCT02787707|Active Comparator|intervention|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
16573604|NCT02787707|Placebo Comparator|control|2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.
16573605|NCT02787694|Experimental|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
16573606|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
16573607|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat. During the first two weeks of the intervention,
16573608|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
16573609|NCT02787655|Experimental|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
16573610|NCT02787655|Active Comparator|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
16573611|NCT02787642|Experimental|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
16573612|NCT02787629|Experimental|Simultaneous|Simultaneous Intubation with GlideScope and ETT inserted simultaneously
16573613|NCT02787629|Active Comparator|Control Standard|Standard Intubation with GlideScope inserted first and ETT inserted after the GlideScope view is obtained
16573614|NCT02787616||Rosacea Group|
16573615|NCT02787616||Non-Rosacea Group|
16573616|NCT02787603|Experimental|group A|Interruption of antibiotic treatment due to PCT measurement
16573617|NCT02787603|No Intervention|group B|Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.
16573620|NCT02787577|Experimental|Sleep Lengthening|The intervention group will receive a personalised sleep consultation session to lengthen sleep by 1-1.5 hours per night by targeting sleep hygiene using behaviour change techniques for 4 weeks.
16573621|NCT02787577|No Intervention|Control|The control group will be asked to resume their normal lifestyle.
16573622|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
16573623|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
16573624|NCT02787551|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.
~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
16573625|NCT02787551|Active Comparator|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily [BID], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
16573744|NCT02786732|Experimental|210mg Brodalumab|Administered by subcutaneous injection until Week 12
16573626|NCT02787538|Experimental|US-ANSWER-2 decision aid|The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
16573627|NCT02787538|Active Comparator|Control group (Online medication guide)|The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
16573628|NCT02787525||A: patients on anticoagulation|Questionnaire to patients with non-valvular atrial fibrillation on OAC or NOAC
16573629|NCT02787525||B: patients treated by LAA-Closure|Questionnaire to patient with non-valvular atrial fibrillation who underwent LAAC between 2009 and 2014 at the University hospitals Bern or Zurich
16573630|NCT02787512|Active Comparator|Plastic stent|10 Fr plastic stent (Percuflex Amsterdam® or C-flex pigtail® or Advanix® Biliary stent)
16573631|NCT02787512|Experimental|Uncovered metal stent|Uncovered metal stent (WallFlex® Biliary RX stent)
16573632|NCT02787499|No Intervention|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load <1,000 copies/mL at repeat testing will be retained on first-line therapy.
16573633|NCT02787499|Experimental|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
16573634|NCT02787486||Aneuploidy Arm|Includes pregnant women at high risk for fetal chromosome aneuploidy for serum screening
16573635|NCT02787486||TORCH Arm|Infectious disease arm: Toxoplasmosis, other viruses, rubella, cytomegalovirus, and herpes simplex virus (TORCH). Includes pregnant women at low-risk for fetal aneuploidy that may be at increased risk for fetal infection for serum screening
16573636|NCT02787473|Experimental|pemetrexed+carboplatin/cisplatin+radiation therapy->docetaxel|Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.
16573637|NCT02787460|Experimental|Behavioral Text Messages|Couples assigned to a treatment group will receive weekly behavioral theory-based messages encouraging them to attend the sessions.
16573638|NCT02787460|No Intervention|Simple Reminder Text Messages|"Couples in the control group will receive simple reminder text messages that include the date, time, and location of their next group session"
16573639|NCT02787447|Experimental|1|After 3 mos TKI, patients showed stable disease take TKI, radiotherapy and thymosin alpha 1 till tumor progression.
16573640|NCT02787434|Experimental|PCSPrep decision aid|All participants recruited to the trial will receive the decision aid. This a one-group study with a quasi-experiemental pre/post evaluation design.
16573641|NCT02787421|Experimental|Functional Rhinoplasty|Participants undergoing functional rhinoplasty for nasal valve compromise and obstruction at the Emory Aesthetics Center.
16573642|NCT02787408|Experimental|EW Tricuspid Transcatheter Repair System|Edwards (EW) Tricuspid Transcatheter Repair System
16573643|NCT02787395|Experimental|Milch|modified Milch technique for self reduction
16573644|NCT02787395|Experimental|Boss Holtzach|Boss Holtzach technique for self reduction
16573645|NCT02787395|Experimental|Stimson|Stimson technique for self reduction
16573646|NCT02787382|Experimental|Pregnant women with CMV infection|"An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).
~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography)."
16573647|NCT02787382|Experimental|Pregnant women with suspected CMV infection|"The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).
~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group."
16573648|NCT02787369|Experimental|Combination of ACY-1215 With Ibrutinib|ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
16573649|NCT02787369|Experimental|Combination of ACY-1215 With Idelalisib|ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
16573650|NCT02787356|Experimental|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic with trained skin graders and images of skin
16573651|NCT02787356|Experimental|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD with trained skin graders and images of skin
16573652|NCT02787330|Active Comparator|Control Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
16573653|NCT02787330|Experimental|Experimental Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program which focuses on education, therapeutic problem solving, and social support. Each intervention session is structured by theme relevant to the cancer experience and themes are addressed through fun activities, games, arts, and crafts.To maximize the therapeutic effect of the intervention fun work (homework) will be assigned after each session. Training for the EG facilitators requires reading and studying the manual to become fully familiarized with the intervention approaches, observing group sessions through a one-way mirror prior to participation as a group facilitator, and participating as a group facilitator assistant for the intervention program.
16573654|NCT02787317|Active Comparator|heparin|For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.
16573655|NCT02787317|Experimental|not prolong infusion Bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .
16573656|NCT02787317|Experimental|prolong infusion bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.
16573657|NCT02787304|Experimental|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
16573658|NCT02787304|Experimental|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
16573659|NCT02787304|Experimental|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
16573660|NCT02787304|Placebo Comparator|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
16573661|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
16573662|NCT02787278|Experimental|SP-8203 High dose group|SP-8203 160mg (80mg/dose twice a day for three days)
16573663|NCT02787278|Experimental|SP-8203 Low dose group|SP-8203 80mg (40mg/dose twice a day for three days)
16573664|NCT02787278|Placebo Comparator|Placebo group|Placebo group: twice a day for three days
16573665|NCT02787265||spinal cord stimulation|Failed back surgery syndrome patients will receive high density spinal cord stimulation
16573666|NCT02787252|Experimental|HF DRG|HF DRG Implants
16573667|NCT02787239|Experimental|HLX01|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
16573668|NCT02787239|Active Comparator|Rituximab|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
16573669|NCT02787226|Active Comparator|TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
16573670|NCT02787226|Active Comparator|Reverse TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
16573671|NCT02787226|Active Comparator|TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
16573672|NCT02787226|Active Comparator|Reverse TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.
16573673|NCT02787213||Women with preterm delivery|
16573674|NCT02787213||Women without preterm delivery|
16573675|NCT02787187|Active Comparator|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
16573676|NCT02787187|Experimental|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
16573677|NCT02787174|No Intervention|Control|Participants will receive routine clinical treatment care.
16573678|NCT02787174|Experimental|Intervention|Participants will receive interactive tailored asthma medication adherence education on an iPad.
16573679|NCT02787161|Active Comparator|Hemodialysis|Patients who are treated with high flux hemodialysis will continue the same treatment with high flux hemodialysis.
16573680|NCT02787161|Experimental|Hemodiafiltration|Patients who are treated with high flux hemodialysis will be switched to hemodiafiltration for 6 months.
16573681|NCT02787148|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for Major Depression
16573682|NCT02787148|No Intervention|Waitlist group|Waitlist group to control for repeated physiological measures and fluctuations over time
16573683|NCT02787135|Active Comparator|CBTd-E|Experimental: emotion-oriented Cognitive Behavior Therapy focused on delusions for patients with schizophrenia-spectrum disorders and delusions. The therapeutical intervention follows a treatment-manual consisting of two modules. Patients work on two modules every week for 25 weeks in a row. Module I comprises psychoeducation on emotions, training radical acceptance of emotions and mindfulness, cognitive and behavioral strategies in order to change negative emotions and in order to foster positive emotions and suggestions for life-style changes (positive activities, sports, stress reduction). In the second module, the focus is on self-acceptance. Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
16573684|NCT02787135|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait-list receive treatment as usual (regular visits to a physicist every third month and antipsychotic medication). After six month the waiting list patients receive the treatment specified above.
16573685|NCT02787122|Active Comparator|CBT-E|"Emotion-focussed Cognitive behavior therapy:
~Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy. Interventions are behavioral activation, training of emotion regulation strategies, improvement of self-esteem and relapse prevention."
16573686|NCT02787122|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait list are required to wait for half a year, while they receive standardized care (antipsychotic medication). After half a year, they receive CBT-E, as well.
16573687|NCT02787109|Experimental|CTH522-CAF01|"CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)
~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
16573688|NCT02787109|Experimental|CTH522-Al(OH)3|"CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)
~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
16573689|NCT02787109|Placebo Comparator|Placebo|Saline for IM and In administrations
16573690|NCT02787096|Experimental|laxIRM|Patients will have dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
16573691|NCT02787083|Experimental|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
16573692|NCT02787083|Placebo Comparator|Placebo|These patients will receive placebo tablets daily for 12 weeks.
16573693|NCT02787070|Active Comparator|Primaquine supervised|14 days of supervised primaquine treatment (0.5mg/kg/day).
16573694|NCT02787070|Active Comparator|Primaquine unsupervised|14 days of unsupervised primaquine treatment (0.5mg/kg/day).
16573695|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
16573696|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
16573697|NCT02787044|Experimental|High Dose Influenza Vaccine|High Dose Influenza Vaccine
16573698|NCT02787044|Active Comparator|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
16573699|NCT02787031||Neuraxial anesthesia|Participants in this group will be those who had a spinal or epidural anesthetic without concurrent general anesthesia
16573700|NCT02787031||General anesthesia|Participants in this group will be those who had general anesthesia, including those who had a general plus a concurrent spinal or epidural anesthetic.
16573701|NCT02787018|Placebo Comparator|Block with Ropivacaine and Normal saline|Patients will receive brachial plexus block with 20 ml 0.5% ropivacaine with 1ml normal saline: Total volume 21 ml
16573702|NCT02787018|Active Comparator|Block with Ropivacaine and Dexamethasone|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 4mg (1ml) dexamethasone: Total volume 21 ml
16573703|NCT02787018|Experimental|Block with Ropivacaine and Dexmedetomidine|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 50mcg (1ml) dexmedetomidine: Total volume 21 ml
16573704|NCT02787005|Experimental|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
16573705|NCT02787005|Experimental|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
16573706|NCT02787005|Experimental|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
16573707|NCT02787005|Experimental|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
16573708|NCT02787005|Experimental|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
16573709|NCT02786992|Active Comparator|Misoprostol + Oxytocin|400 ug sublingual misoprostol + 10 IU Oxytocin IVI
16573710|NCT02786992|Active Comparator|Carbetocin|100 ug Carbetocin IV
16573711|NCT02786979|Experimental|Beraprost sodium tablet and Aspirin combination group|Oral
16573712|NCT02786979|Experimental|Aspirin Group|Oral
16573713|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
16573714|NCT02786953|Experimental|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
16573715|NCT02786953|No Intervention|Usual Care|Usual Care
16573716|NCT02786940|Experimental|Live Remote Cardiac Monitoring|Patients in this arm will receive the Cardiophone device, a live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
16573717|NCT02786940|Active Comparator|Usual Care|Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
16573718|NCT02786927|Experimental|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
16573719|NCT02786927|Experimental|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
16573720|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
16573721|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
16573722|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
16573723|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
16573724|NCT02786901|Placebo Comparator|Vehicle Gel|Vehicle
16573725|NCT02786888||conventional needle|conventional needle used
16573726|NCT02786888||fenestrated needle|fenestrated needle used
16573745|NCT02786732|Experimental|140mg Brodalumab|Administered subcutaneous injection until Week 12
16573727|NCT02786875|Experimental|Group A (high intensity program):|"Diet: low glycemic index (GI) Mediterranean diet. All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
~Moderate physical activity: brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
~Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D."
16573728|NCT02786875|Active Comparator|Group B (lower intensity program)|"Diet: general recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
~Basic physical activity: general recommendations to avoid sedentary behaviour. Vitamin D supplement (cholecalciferol) will be given only if vitamin D insufficiency is detected to reach blood levels of 30 ng/ml of 25(OH)D."
16573729|NCT02786862|Experimental|Ventilation|Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
16573730|NCT02786849|Experimental|Group of high frequency and intensity|Group realized high frequency and intensity neuromuscular electrical stimulation
16573731|NCT02786849|Experimental|Group of low frequency and intensity|Group realized neuromuscular electrical stimulation of low frequency and intensity
16573732|NCT02786836|Experimental|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness <26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
16573733|NCT02786823|Experimental|Folic acid|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
16573734|NCT02786823|Experimental|Vitamin B12|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
16573735|NCT02786823|Experimental|"Folic acid and Vitamin B12"|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
16573736|NCT02786823|Active Comparator|Control|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation
16573737|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
16573738|NCT02786797|Experimental|MBSR(BC) 6 Week Program|Participants who are randomized to MBSR(BC) program will receive of educational material; group practice of mindfulness meditation (MM) and homework assignments; and group processes related to the practice of MM and supportive group interaction. Participants who receive MBSR will receive training in (1) sitting meditation anchored to the breath; (2) body scan (observing body sensations from the toes to the head); (3) Gentle Yoga (postures and stretches that increase awareness and balance; and (4) walking meditation. Through this arm of the study the goal is to enhance executive cognition through training in self-regulation of attention and acceptance of experience.
16573739|NCT02786797|Active Comparator|BCES Education Support Program|Participants who are randomized to the BCES program will be scheduled for 6 weekly, 2-hour sessions. BCES compared to MBSR(BC) meets the following criteria: (1) professional contact and group support time matched equally to the MBSR(BC) program; and (2) the content or activities of the BCES program does not include meditation or attention, relaxation, yoga, body scan, or walking meditation. This program is as an active control condition that accounts for nonspecific effects related to attention from the leader and favorable outcome expectancy, the educational materials provided and supportive interaction between group members and is matched for homework activity time over the 6 months. This group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
16573740|NCT02786797|No Intervention|Usual Care|Participants who are randomized to the Usual Care (UC) or control group will continue to receive standard post-treatment medical and nursing clinic visits that will not be modified by study participation. The UC participants will participate in their standard care appointments and will not be required to alter their UC regimen; however, they will be asked not to initiate a mindfulness program during the study period. The UC group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
16573741|NCT02786784|Other|healthy control|patients with patellofemoral pain
16573742|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
16573743|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
16573746|NCT02786732|Active Comparator|Ustekinumab|Administered subcutaneous injection until Week 52
16573747|NCT02786732|Placebo Comparator|Placebo|Administered subcutaneous injection until Week 12
16573748|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
16573749|NCT02786706||Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
16573750|NCT02786693||FUO and SII patients|Patients with fever > 38,3°C for more than a week, OR CRP> 5mg/L, without diagnosis after a first step clinical examination and paraclinical exams.
16573751|NCT02786680|Experimental|stroop test in condition DBS off|Condition 1 : On Med /Off Stim
16573752|NCT02786680|Active Comparator|stroop test in condition DBS on|Condition 2 : On Med /On Stim
16573753|NCT02786667|Experimental|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
16573754|NCT02786667|Placebo Comparator|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
16573755|NCT02786641|Active Comparator|Group A|low risk NPC treated with concurrent chemoradiotherapy
16573756|NCT02786641|Active Comparator|Group B|high risk NPC treated with concurrent chemoradiotherapy
16573757|NCT02786641|Experimental|Group C|high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy
16573758|NCT02786628||Solid tumor malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
16573759|NCT02786628||Hematologic malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
16573760|NCT02786628||Hematopoietic cell transplantation|15 patients. Will participate in physical performance testing and patient-generated health data.
16573761|NCT02786615|Experimental|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
16573762|NCT02786615|No Intervention|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
16573763|NCT02786589|Experimental|Blood-stage infection of P. vivax|This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.
16573764|NCT02786576||Participants receiving adalimumab|Hidradenitis Suppurativa (HS) participants receiving adalimumab
16573765|NCT02786563||Participants with RA receiving adalimumab|This group contains participants in China with RA receiving adalimumab
16573766|NCT02786550|Experimental|Botulinum Toxin|"Immediately after lower blepharoplasty surgery 3 injections of 2.5U of botulinum toxin over lateral part of orbicularis oculi muscle.
~Intervention: Botulinum toxin injection"
16573767|NCT02786550|Placebo Comparator|Normal saline|"Immediately after lower blepharoplasty surgery 3 injections of same amount of normal saline over lateral part of orbicularis oculi muscle.
~Intervention: Normal saline injection"
16573768|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir) with RBV|Patients received 1 EBR/GZR (elbasvir/grazoprevir) (Zepatier) tablet (50/100mg) once daily for 12 to 16 weeks (provider discretion) with Ribavirin (RBV) 200 mg/tablet, 1-3/day, taken 1-2 times per day (dosage at discretion of provider).
16573769|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir)|Patients received 1 EBR/GZR (elbasvir/grazoprevir) tablet (50/100 mg) once daily for 12 to 16 weeks (provider discretion) (without Ribavirin)
16573770|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir) with RBV|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) (Harvoni) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (at discretion of provider). RBV taken as 200 mg/tablet(capsule), 1-3 pills/day, 1-2 times/day.
16573771|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir)|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
16573772|NCT02786537|Active Comparator|PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) with RBV (Phase 1 only)|"Patients received Pr0D (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) orally daily with food for 12 to 24 weeks with RBV (Ribavirin). Ombitasvir/Paritaprevir/Ritonavir (12.5/75/50 mg/tablet) -2 tablets once daily with food for 12 to 24 weeks and 1 dasabuvir tablet (250 mg) twice daily with food for 12 to 24 weeks.
~RBV (200 mg/pill) 1-3 pills/day, 1-2 times/day (use and dosage at provider discretion). Total daily RBV dosage ranged from 200 to 1200 mg."
16573773|NCT02786537|Active Comparator|PrOD (ombitasvir/paritaprevir/ritonavir and dasabuvir)|Patients received 2 ombitasvir/paritaprevir/ritonavir tablets (12.5/75/50 mg) once daily and 1 dasabuvir (250 mg) tablet twice daily with food for 12 to 24 weeks without Ribavirin (as per provider instructions)
16573774|NCT02786524|No Intervention|Standard of Care|Patients randomized to this arm receive standard symptom management care by their primary gynecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each visit, every 3-4 weeks.
16573775|NCT02786524|Experimental|Symptom Management and Supportive Care|Patients randomized to this arm are referred to a specialized symptom management and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recommended by the symptom management providers, and at each visit they will complete the ESAS-r and NCCN distress thermometer and return their responses either in person or by mail to the study team in a pre-addressed postage paid envelope.
16573776|NCT02786511||Subjects with multiple myeloma|Subjects treated with ex vivo gene therapy in a bluebird bio sponsored trial who agree to participate in this study.
16573777|NCT02786498|Experimental|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
16573778|NCT02786498|Experimental|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
16573779|NCT02786498|Experimental|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
16573780|NCT02786498|Placebo Comparator|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
16573863|NCT02785887|No Intervention|Oncological care|Routine oncological care only
16573864|NCT02785874|Experimental|Statin(Crestor) taken|Subjects take Statin(Crestor) 10mg per day for a- year
16573781|NCT02786485|Experimental|Rivogenlecleucel & Rimiducid|"All subjects will receive 3 courses of rivogenlecleucel (BPX-501 T cells) infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.
~Escalating doses of rimiducid (AP1903) (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after rivogenlecleucel infusion."
16573782|NCT02786472|Active Comparator|Haven|"Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are personalized and reflective and incorporate the student's unique perspectives and experiences. This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training."
16573783|NCT02786472|Active Comparator|AlcoholEdu|Online Substance Abuse Training or AlcoholEdu provides confidential substance abuse education course which uses a science-based approach to educate students about alcohol and its effects. Whether the student drinks or not, the course will help them make informed decisions about alcohol and better deal with drinking behavior that may occur around them. AlcoholEdu is used by more than 500 colleges nationwide through EVERFi.
16573784|NCT02786472|Experimental|ConnectEd|In-person Combination Training provides Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming to develop ConnectED. The intentional coordination between substance abuse and violence prevention programming would include in-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystander behaviors and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; and, in-depth skill building activities to prepare participants to safely intervene in problem situations.
16573785|NCT02786472|Experimental|GreenDot|"In-person Bystander Training provides Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions. While a Popular Opinion Leader strategy has been used in prior training, for this trial all incoming students randomized to this condition will be offered intensive bystander training.
~NOTE: Green Dot Speeches will be supplemental to Intensive Green Dot Bystander training. These speeches will continue to occur as usual. As the aim of this study is to compare bystander intensive training, we will not attempt to limit participation to Green Dot Speeches."
16573786|NCT02786459|Experimental|Post Radical Prostatectomy|"Up to n=30 evaluable male patients, between ages 30-75, who were previously diagnosed with PCa, have undergone a RP at least 6 months before imaging and who experience rising PSA (biochemical failure). The RP group (n=30) will be stratified into PSA subgroups <0.005, 0.005-<0.2, >0.2.
~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI."
16573787|NCT02786459|Active Comparator|Active Surveillance|"Up to n=10 men, between ages 30-75, on active surveillance with known prostate adenocarcinoma diagnosis and multiple positive biopsies.
~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
16573788|NCT02786459|Experimental|Multiple Negative Biopsies|"Up to n=20 men, between ages 30-75, who have previously undergone one/or multiple negative biopsies, with elevated PSA (≥4 ng/mL) and/or an abnormal digital rectal exam suspicious for prostate cancer with a planned sextant prostate biopsy but who do not have a definitive PCa diagnosis.
~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
16573789|NCT02786446|Active Comparator|Lidocaine gel|20 grams Lidocaine gel 2 % will be applied to corresponding lumber area of the patients 30 minutes before undergoing ESWL for renal stone.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
16573790|NCT02786446|Active Comparator|Naproxen Sodium|Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
16573791|NCT02786446|Active Comparator|Lidocaine Gel and Naproxen Sodium|Oral Naproxen sodium 55o mg and locally applied 2 % lidocaine gel to patients before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
16573792|NCT02786433|Active Comparator|GROUP CONTROL|"Participants in the control group only underwent conventional physiotherapy. Conventional therapy includes stretching and strengthening exercises with cane aid, leggings , elastic band and overball for upper and lower limbs , in addition to gait and balance training.
~The intervention for the control group was applied for five weeks with sessions of 60 minutes twice a week"
16573793|NCT02786433|Experimental|EXPERIMENTAL GROUP|The subjects in the experimental group underwent conventional physiotherapy (The same applied in the control group) associated with virtual reality , performed with the console X -Box Kinect® of Microsoft. Durante the achievement of the virtual reality practice, Kinect and Kinect games Adventures® Dance® demanded the anterior movements players -posterior and lateral , as well as jumps and squats to get rid of the game obstacles. They Kinect Dance® game were all required movements of the previous game more dance . The intervention lasted five weeks , with two weekly sessions lasting 30 minutes to conventional therapy and 30 minutes to virtual reality.
16573794|NCT02786420||Observational|Pregnant women
16573795|NCT02786407|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
16573796|NCT02786407|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
16573865|NCT02785874|No Intervention|non Statin(Crestor) taken|non Statin(Crestor) taken as a reference for experimental group.
16573797|NCT02786394|Experimental|REACH Participant Course|This study will run twice a week over 8 weeks with 6 REACH sessions 8 optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
16573798|NCT02786368|Other|Control group|For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
16573799|NCT02786368|Experimental|EHFP group|Households will receive training and inputs for an Enhanced Homestead Food Production (EHFP) package. Participants will also receive educational components through inter-personal behavioural change communication on nutrition (Essential Nutrition Actions), Water Sanitation and Hygiene (WASH), gender, and business/marketing.
16573800|NCT02786355|Other|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
16573801|NCT02786355|Other|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
16573802|NCT02786342||Advanced HCC patients treated with sorafenib|
16573803|NCT02786329|Active Comparator|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.
~Interventions: TIVA+lidocaine"
16573804|NCT02786329|Placebo Comparator|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
16573805|NCT02786329|Placebo Comparator|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).
~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
16573806|NCT02786329|Active Comparator|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.
~Intervention: sevoflurane anesthesia+ lidocaine infusion"
16573807|NCT02786316|Experimental|intervention group|Hit program for the rehabilitation of persons with nonspecific chronic low backpain
16573808|NCT02786316|Active Comparator|Control group|a conventional rehabilitation program for persons with nonspecific chronic low backpain
16573809|NCT02786303|Other|arm whole-body MRI|
16573810|NCT02786290|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
16573811|NCT02786277|No Intervention|Usual Care|No alert will be fired
16573812|NCT02786277|Experimental|Alert|An alert informing the provider of acute kidney injury will be fired.
16573813|NCT02786264||Propofol-dominant Sedation|Patients receiving propofol infusion for TAVR as the primary drug for sedation.
16573814|NCT02786264||Dexmedetomidine-dominant Sedation|Patients receiving dexmedetomidine infusion for TAVR as the primary drug for sedation.
16573815|NCT02786264||Fentanyl and/or Midazolam Sedation|Patients receiving fentanyl +/- midazolam as the primary drugs for sedation for TAVR
16573816|NCT02786251|Other|BAT+|Individuals with significant amounts of BAT (>20 ml)
16573817|NCT02786251|Other|BAT-|Individuals with no/minimal amounts of BAT (<20 ml)
16573818|NCT02786238|Active Comparator|Standard Behavioral Treatment (SBT)|For the Standard Behavioral Treatment (SBT) condition, participants will participate in the standard behavioral weight loss programming, which utilizes strategies from existing obesity treatments (e.g., the Diabetes Prevention Program). These features include the following: 1) nutritional education, 2) diet and physical activity, 3) expectations for daily self-monitoring of calorie intake and activity, 4) stimulus control, behavior shaping, behavior analysis, and relapse prevention strategies, and 5) social support.
16573819|NCT02786238|Experimental|Acceptance-Based Treatment (ABT)|"The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., urge-surfing). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430)."
16573820|NCT02786225|Experimental|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a Vanderbilt University Medical Center (VUMC) perinatologist and a Vanderbilt University School of Nursing (VUSN) nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
16573821|NCT02786225|Active Comparator|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
16573822|NCT02786212|Experimental|dexmedetomidine|Patients receiving intraoperative dexmedetomidine infusion. Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
16573823|NCT02786212|Placebo Comparator|control|control group, receiving same volume of normal saline infusion.
16573824|NCT02786199||Hepatocellular carcinoma|patients HCC who are going to receive surgical resection
16573825|NCT02786186||Secikinumab|Patients treated with secukinumab
16573826|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
16573827|NCT02786160|Active Comparator|HMO1|Daily bolus of HMO1
16573828|NCT02786160|Active Comparator|HMO2|Daily bolus of HMO2
16573829|NCT02786160|Placebo Comparator|Dextropur|Daily bolus of Dextropur
16574163|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
16573830|NCT02786147||Patient Initiated|Patients randomized into this group will receive a standard handout explaining their result, which includes information on how to obtain cancer genetics services through Winship. However, neither the patient nor their ordering clinician will be directly contacted regarding the B-RST result.
16573831|NCT02786147||Physician Notification|Patients randomized into this group will also receive the standard handout explaining their result. In addition, their primary care physician or ordering physician will be notified via Emory Electronic Medical Record (EeMR) that the patient screened positive on the B-RST. The note will provide specific instructions on how to refer the patient for cancer genetic counseling services.
16573832|NCT02786147||Automatic Follow-Up By Genetic Counseling Staff|Patients randomized into this group will also receive the standard handout explaining their result. Within 1-2 weeks after their mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment. This call may take up to 10 - 15 minutes.
16573833|NCT02786134|Experimental|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
16573834|NCT02786134|Experimental|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
16573835|NCT02786108|Experimental|left gastric artery embolization|Patients undergoing left gastric artery embolization
16573836|NCT02786108|Active Comparator|healthy diet and exercise|Patients undergoing healthy diet and exercise
16573837|NCT02786095||Code-AF registry|
16573838|NCT02786082|Experimental|Group I|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group I, half are male and half are female, will take Azilsartan tablet 20mg orally on fasting.
~For Pharmacokinetics Studies of Azilsartan with Multiple-dose oral administration, 12 subjects in group I will take 20mg Azilsartan orally once daily for 7 day (day 3~day 9) after completing the last time blood sample collection (in day 2, 48h) of the first time administration (day 1)"
16573839|NCT02786082|Experimental|Group II|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group II, half are male and half are female, will take Azilsartan tablet 40mg orally on fasting.
~For The effects of diet for pharmacokinetic study: The 12 healthy subjects, in group II (in single-dose administration study), after 7-day washout period after the first administration (at day 1, 40mg) will receive Azilsartan tablet 40mg after high-fat diet at day 8"
16573840|NCT02786069|Experimental|Single arm|
16573841|NCT02786056|Experimental|Lung MRI examination|
16573842|NCT02786043|Experimental|Single arm|
16573843|NCT02786030|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions.
16573844|NCT02786030|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will not receive outreach education training.
16573845|NCT02786017|Sham Comparator|Conventional therapy|
16573846|NCT02786017|Experimental|Injectable Collagen Scaffold + HUC-MSCs|
16573847|NCT02786004|Experimental|Full Field Digital Mammography|2-dimensional breast imaging
16573848|NCT02786004|Experimental|Digital Breast Tomosynthesis|3-dimensional breast imaging
16573849|NCT02785978|Experimental|Parkinson Disease Patients Group #1|PD patients with programmed levodopa challenge
16573850|NCT02785978|Experimental|Parkinson Disease Patients Group #2|PD patients without programmed levodopa challenge
16573851|NCT02785978|Experimental|Healthy volunteers|Healthy volunteers
16573852|NCT02785965|Experimental|acupuncture & lifestyle modification|Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
16573853|NCT02785965|Active Comparator|lifestyle modification|diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
16573854|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16573855|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16573856|NCT02785939|Experimental|Arm I - Palbociclib|"Participants receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Closed to accrual 09/01/2016"
16573857|NCT02785939|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.
~Closed to accrual 12/18/2015"
16573858|NCT02785939|Experimental|Arm III - Palbociclib re-reg|"Participants in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Closed to accrual 09/01/2016"
16573859|NCT02785913|Experimental|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16573860|NCT02785900|Experimental|33A + HMA|33A plus azacitidine or decitabine
16573861|NCT02785900|Active Comparator|placebo + HMA|placebo plus azacitidine or decitabine
16573862|NCT02785887|Experimental|Oncological and geriatrician review|Routine oncological care plus geriatric intervention
16573866|NCT02785861|Experimental|supervised practice|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.
~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.
~Each patient of supervised walking group will meet the student each session"
16573867|NCT02785861|Experimental|distance supervised physical activity|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.
~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.
~Each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions"
16573868|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
16573869|NCT02785822|Active Comparator|Fostipur|
16573870|NCT02785822|Experimental|Meriofert|
16573871|NCT02785796|Experimental|CV4|The practitioner will contact the participant's occiput (lateral to the external occipital protuberances, but medial to the occipital-mastoid suture) with his or her thenar eminences. When no cranial mobility will be found, operators will be free to use any kind of technique to enhance the cranial movement before CV4 procedure. Once the practitioner will detect the CRI, the practitioner will resist the flexion phase of the CRI and exaggerate the extension phase. This compressive pressure will be maintained until the CRI stopped, and the still-point is reached. The still-point will be held until the CRI return, at which point the compressive pressure will be slowly release
16573872|NCT02785796|Placebo Comparator|sham technique|"The operator will overlap the hands so that the thumbs formed a V. The operator's thenar eminences will contact the occiput very lightly well below the positioning used in the CV4 procedure but with no pressure on the occiput between the occipitomastoid sutures. Once placement will be achieved, the operator's hands will remain motionless for 10 min. Finally, the practitioner's hands will be gently removed and the participant's head will be placed on the table for both procedures"
16573873|NCT02785796|No Intervention|Control|The control group will not receive ant type of treatment: subject just stay quietly in supine position in ambulatory room for ten minutes
16573874|NCT02785783|Active Comparator|Standard colonoscopy|A standard colonoscope will be used to complete the procedure
16573875|NCT02785783|Active Comparator|EndoRings™|An EndoRings™ device will be placed at the distal end of a standard colonoscope
16573876|NCT02785770|Experimental|PF-04447943 low dose|25 mg of PF-04447943
16573877|NCT02785770|Experimental|PF-04447943 high dose|100 mg of PF-04447943
16573878|NCT02785770|Placebo Comparator|Placebo|Matching placebo for PF-04447943
16573879|NCT02785770|Active Comparator|Moxifloxacin|400 mg of moxifloxacin
16573880|NCT02785757|Experimental|Patients with adenocarcinoma|60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy
16573881|NCT02785744||Patients receiving DEXA Scan|Gaucher patients referred for dual energy X-ray absorptiometry (DEXA scan), who were found to have T-score <-1.0.
16573882|NCT02785731||Women with a pelvic mass|Women diagnosed with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled for a laparotomy or laparoscopy for removal of the pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 60 days prior to surgery.
16573883|NCT02785718|Experimental|Patients with FXI or FXII deficiency|12 patients with FXI deficiency and 6 patients with FXII deficiency
16573884|NCT02785705|Experimental|cIPV-bOPV-bOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two bivalent types 1 and 3 oral poliovirus vaccine sequentially.
16573885|NCT02785705|Experimental|cIPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
16573886|NCT02785705|Experimental|cIPV-cIPV-bOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one bivalent types 1 and 3 oral poliovirus vaccine sequentially.
16573887|NCT02785705|Experimental|cIPV-cIPV-tOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
16573888|NCT02785705|Experimental|cIPV-cIPV-cIPV poliovirus vaccine|Participants would be vaccine with three shots of trivalent conventional inactivated poliovirus vaccine.
16573889|NCT02785705|Experimental|tOPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with three times of trivalent types 1, 2 and 3 oral poliovirus vaccine .
16573890|NCT02785692||Combined Radiation/ Surgery|All patients treated with combined radiotherapy and surgery at Balgrist University Hospital and University Hospital Zurich
16573891|NCT02785679|No Intervention|Exclusive breast feeding|Exclusive breast feeding
16573892|NCT02785679|No Intervention|Exclusive CMF feeding|Exclusive CMF feeding
16573893|NCT02785679|Active Comparator|Breast feeding with small amount of CMF|Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
16573894|NCT02785679|Active Comparator|Breast feeding with one meal of CMF|Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
16573895|NCT02785666|Experimental|Treatment and behavioural intervention:|"Treatment intervention: Patients with a replicating GT 1 and/or 4 HCV infection without or with cirrhosis will be treated with grazoprevir/elbasvir (100mg/50mg) for 12 weeks. GT 1a infected patients with baseline RAV's and GT 4 infected patients with a history of prior HCV treatment failure without or with cirrhosis will be treated with the same regimen for 16 weeks, in combination with weight-adjusted ribavirin.
~Behavioural Intervention: Participants with inconsistent condom use with occasional partners will receive the behavioral Intervention and in addition standard of care written and oral information on prevention of HCV reinfection. Study participants with consistent condom use or those reporting inconsistent condom use with occasional partners but not willing to participate in the intervention will receive standard of care written and oral information on prevention of HCV reinfection only"
16573920|NCT02785497|Sham Comparator|Control group|"For the control group the unit is turned on, the time will pass but will not be given intensity
~50min, 100Hz, Intensity according to the sensitivity patient"
16573921|NCT02785484|Experimental|Label with constituent disclosure message|
16573896|NCT02785653|Experimental|sevoflurane and rocuronium|After induction of general anaesthesia, patients in the sevoflurane group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen with 2% inspired concentration of sevoflurane. After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
16573897|NCT02785653|Active Comparator|rocuronium|After induction of general anaesthesia, patients in the control group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen . After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
16573898|NCT02785640|Experimental|Prompt group|Following feedback on their baseline sitting behaviour and an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered via Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing
16573899|NCT02785640|No Intervention|Control group|The control group will receive the same education session as the prompt group, as well as feedback on their baseline sitting behaviour. However, the will not receive prompts on their PC.
16573900|NCT02785627||Group A: ADT|Men with non-metastatic prostate cancer, about to start or within 2 weeks of starting ADT
16573901|NCT02785627||Group B: ADT + chemotherapy|Men with newly diagnosed hormone sensitive metastatic prostate cancer, starting ADT and who will have chemotherapy
16573902|NCT02785627||Group C: Controls|Healthy age matched men
16573903|NCT02785614|Experimental|II-1|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:
~R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days."
16573904|NCT02785614|Experimental|II-2|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:
~T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days."
16573905|NCT02785601|Experimental|I-1|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
16573906|NCT02785601|Experimental|I-2|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
16573907|NCT02785601|Experimental|I-3|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
16573908|NCT02785601|Experimental|I-4|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
16573909|NCT02785588|Other|3.0 T Neonatal MRI scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
16573910|NCT02785575|Active Comparator|HeProCalc|This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.
16573911|NCT02785575|No Intervention|Traditional calculations|This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)
16573912|NCT02785562|Other|Assessment of PDL1 expression|Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.
16573913|NCT02785549|Experimental|Symptomatic treatment with NSAID|1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
16573914|NCT02785549|Active Comparator|Antibiotic+symptomatic treatment with NSAID|875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
16573915|NCT02785536|Active Comparator|Standard Treatment|The standard treatment was a well-established, manual-driven, multicomponent CBT for tobacco dependence that has been delivered in multiple modalities (i.e., group, individual, and telephone), used in numerous studies, and considered intensive, comprehensive, and consistent with the Public Health Service Clinical Practice Guideline.
16573916|NCT02785536|Experimental|RITCh Treatment|The RITCh treatment is an adaptation of the standard treatment which proactively addresses the needs and experiences of a diverse group of lower SES smokers as well as ensures that the treatment is culturally congruent and experientially resonant for African Americans while maintaining the same amount of treatment contact (i.e., six one-hour sessions).
16573917|NCT02785523|Experimental|G. SPORE LIPIDS|"Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy.
~Duration: 6 chemotherapy cycles."
16573918|NCT02785523|Placebo Comparator|Placebo|"Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy.
~Duration: 6 chemotherapy cycles."
16573919|NCT02785497|Experimental|Treatment group|"Chronic ulcer patients will be treated with 50 minutes of the high-voltage current or 10 minutes of the diadynamic current. To burn patients 50 minutes high voltage current in the donor area. For both group the metal electrodes will be sterilized and the negative polarity in the active electrode.
~50 min, 100Hz, intensity according to the sensitivity patient - High Voltage; 10 min, intensity according to the sensitivity patient - Diadynamic"
16573923|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
16573924|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
16573925|NCT02785458|No Intervention|Usual Care|Subjects will receive the current standard of care.
16573926|NCT02785458|Experimental|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
16573927|NCT02785445|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
16573928|NCT02785432|Sham Comparator|Sham low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 0 watts for a total of 0 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint. The contact head applicator will be used if soft tissue contact is tolerable. Otherwise, the non-contact head will be utilized.
16573929|NCT02785432|Active Comparator|Active low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. This equates to standard acceptable dosing of 6-10 j/cm2 over the larger area of treatment. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Areas for administration and contact will otherwise be consistent with the sham group.
16573930|NCT02785419|Experimental|Arm Training with Action Selection|Task-oriented, functional arm training with the addition of action selection cues to practice. All participants receive the same arm training intervention.
16573931|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
16573932|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
16573933|NCT02785393|Placebo Comparator|Sugar Pill|
16573934|NCT02785393|Active Comparator|Doxazosin|
16573935|NCT02785380|Experimental|laparoscopic surgery(LS)|For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
16573936|NCT02785380|Active Comparator|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).
16573937|NCT02785367|Experimental|Cord blood samples|8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml washed with Heparin.
16573938|NCT02785354||NOAC|New oral anticoagulant groups
16573939|NCT02785354||VKA|VKA group
16573940|NCT02785341|Other|Immediate adaptated physical activity (Group A)|"Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.
~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
16573941|NCT02785341|Other|Without immediate adaptated physical activity (Group B)|"Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.
~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
16573942|NCT02785328|Experimental|obstructive sleep apnoea|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from obstructive sleep apnoea syndrome.
16573943|NCT02785328|Experimental|narcolepsy|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from narcolepsy.
16573944|NCT02785328|Experimental|BECTS (Benign epilepsy with centro-temporal spikes)|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from BECTS.
16573945|NCT02785328|Experimental|high intellectual potential|The objective of this task is to evaluate the sleep-dependent consolidation abilities in children with high intellectual potential.
16573946|NCT02785328|Experimental|healthy children|The objective of this task is to evaluate the sleep-dependent consolidation abilities in healthy children.
16573947|NCT02785315|Experimental|rehabilitation & remediation approach|The intervention group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention with various compensatory strategies. Investigators will use group discussion to discuss everyday situations with memory problem and specific strategies (internal and external) related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
16574164|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
16573948|NCT02785315|Active Comparator|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
16573949|NCT02785302||Adolescents and Young Adults:|Behaviorally-infected, HIV-positive, adolescents and young adults enrolled in ATN 125, aged 18 through 24, inclusive who are transition eligible. All subjects with available endpoint data will be included in the analysis.
16573950|NCT02785302||AMTU and Adult Clinic Staff|Clinical staff at the Adolescent Medical Trials Units (AMTUs) and at adult clinics where the AMTUs refer their transitioning patients will be recruited to complete quantitative surveys and semi-structured interviews.
16573951|NCT02785289|Experimental|Flocked|Patients will perform vaginal cell collection beginning with the flocked swab, followed by the coton swab.
16573952|NCT02785289|Experimental|Coton|Patients will perform vaginal cell collection beginning with the coton swab, followed by the flocked swab.
16573953|NCT02785276|Experimental|Ropivacaine infusion|Following the insertion of the 2mm fenestrated catheter, the wound catheter will be connected to the 270mL AutoFuser Pain Pump. The intraperitoneal infusion with ropivacaine (0.2%) at 4 mL/hour will start immediately and continue for 68 hours post-operatively uninterrupted.
16573954|NCT02785276|Placebo Comparator|Placebo infusion|In the same manner as described for the ropivacaine infusion arm, 0.9% Normal Saline will be administered over 68 hours.
16573955|NCT02785263|Other|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
16573956|NCT02785263|Other|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
16573957|NCT02785263|Other|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
16573958|NCT02785250|Experimental|Arm 1|DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)
16573959|NCT02785250|Experimental|Arm 2|DPX-Survivac, Cyclophosphamide (in Phase 2 only)
16573960|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in first lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
16573961|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in first lesion|Patients with Ultimaster® Drug-eluting stent in first lesion
16573962|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in second lesion|Patients with with Ultimaster® Drug-eluting stent in first lesion
16573963|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in second lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
16573964|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
16573965|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
16573966|NCT02785211|Experimental|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
16573967|NCT02785211|Placebo Comparator|control group|"For the control group, participants will receive regular physical examinations and education by village doctors weekly during the 8 week intervention.The weekly visits for every old people whose age above 65 by country doctors are not arranged by our study, it is the country doctors routine work by government health policy. This study was permitted by the local community health center, the director with specific responsibility will inform all country doctors to support our study."
16573968|NCT02785198|No Intervention|Control group|A control group receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
16573969|NCT02785198|Experimental|Passive training group|An Intervention group doing passive exercise for 8 weeks in knee extensor machine, and receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
16573970|NCT02785185|Experimental|IDP-122 Lotion|Lotion
16573971|NCT02785185|Active Comparator|Ultravate Cream|Cream
16573972|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
16573973|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
16573974|NCT02785172|Experimental|IDP-118 Lotion|Lotion
16573975|NCT02785172|Active Comparator|Ultravate Cream|Cream
16573976|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
16573977|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
16573978|NCT02785159|Experimental|IDP-118 Lotion|Lotion
16573979|NCT02785159|Active Comparator|Tazorac Cream|Cream
16573980|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
16573981|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
16573982|NCT02785146|Experimental|mFOLFOX6 + Huaier Granule|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
16573983|NCT02785146|Active Comparator|mFOLFOX6|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).
16574039|NCT02784730|Active Comparator|Long term implantable device|Port-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
16574040|NCT02784717||Rivaroxaban (Xarelto, BAY 59-7939)|Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.
16573984|NCT02785133|Experimental|Treatment group|Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.
16573985|NCT02785120|Experimental|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
16573986|NCT02785120|Experimental|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
16573987|NCT02785120|Experimental|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
16573988|NCT02785107|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
16573989|NCT02785107|No Intervention|Control|Participants exercised on their own without receiving any instructions.
16573990|NCT02785094||A|Group of High Education level
16573991|NCT02785094||B|Group of Low/Non Education level
16573992|NCT02785094||C|Group has Accessibility to Social Media
16573993|NCT02785094||D|Group has not Accessibility to Social Media
16573994|NCT02785068|Experimental|Phase 1b/2a|"Phase 1b: Safety Evaluation - MM-151 (weekly dosing) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400mg/m2 every two weeks.
~Phase 2a: Expansion - MM-151 (Maximum Tolerated Dose or Recommended Phase 2 Dose) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2."
16573995|NCT02785055|Active Comparator|Ultrasound-Assisted|Ultrasound assisted marking of the thoracic spine on the skin for Thoracic Epidural Placement
16573996|NCT02785055|Active Comparator|Palpation|Palpation marking of the thoracic spine on the skin for Thoracic Epidural Placement
16573997|NCT02785042|Experimental|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
16573998|NCT02785029|Experimental|Normal healthy Volunteers|OCT imaging
16573999|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
16574000|NCT02785003|Experimental|Ketamine Infusion|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the ketamine solution at a calculated dose of 0.25 mg/kg. A continuous infusion of ketamine will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
16574001|NCT02785003|Placebo Comparator|Saline Placebo|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the saline solution at a calculated dose of 0.25 mg/kg. A continuous infusion of saline will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
16574002|NCT02784990||Patient|
16574003|NCT02784977||Obstructive Sleep Apnea (OSA)|Patients with apnea hypopnea index of at least 5 events per hour. Intervention with positive airway pressure, or intraoral device, or uvuloplasty, or conservative treatment.
16574004|NCT02784977||No-OSA|Patients with apnea hypopnea index less than 5 events per hour. No intervention.
16574005|NCT02784964|Experimental|Elixcyte 8mL|ADSC 6.4*10^7 cells, allogeneic injection, one time injection on Day 1
16574006|NCT02784964|Active Comparator|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
16574007|NCT02784964|Experimental|Elixcyte 4mL|ADSC 3.2*10^7 cells, allogeneic injection, one time injection on Day 1
16574008|NCT02784964|Experimental|Elixcyte 2mL|ADSC 1.6*10^7 cells, allogeneic injection, one time injection on Day 1
16574009|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
16574010|NCT02784938|Experimental|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
16574011|NCT02784938|No Intervention|Wait-list Control|Services as usual
16574012|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
16574013|NCT02784899|Experimental|iloprost group|iloprost inhalation group
16574014|NCT02784899|Placebo Comparator|control group|normal saline inhalation group
16574015|NCT02784873|No Intervention|Usual care|"Usual care cardiac rehabilitation with exercise training as per current guidelines
~Warm up: 15 mins, < 40% heart rate reserve (HRR) Cardiovascular component: progress towards 20 - 40 mins continuous cardiovascular exercise at 40-70% HRR.
~Muscular strength and endurance programme. Cool down: 10 mins, < 40% HRR. Initial duration based on participant's previous and current physical activity (PA) levels and cardiopulmonary exercise test (CPEX) performance.
~Duration and workload of cardiovascular component adjusted, as tolerated, within the above parameters, in response to exercising heart rate (HR), participant reported rating of perceived exertion (RPE) and symptoms."
16574041|NCT02784704|Experimental|Eravacycline|
16574042|NCT02784704|Active Comparator|Meropenem|
16574043|NCT02784691|Experimental|Patients|
16574016|NCT02784873|Experimental|High intensity interval training|"High intensity interval training within a standard cardiac rehabilitation programme.
~Warm up: 15 mins total, 10 mins <40-70% HRR, 5 mins <70% HRR. Cardiovascular component: exercise bike interval training: 10 x high @ 85-90% peak power output (PPO) from CPEX, 10 x low @ 20-25% PPO (exercise intensity will not to be prescribed from gas exchange data i.e. %VO2 peak). Change in intensity from low to high achieved by altering cadence (rpm).
~Muscular strength and endurance programme. Cool down: 10 mins, <40% HRR. Duration of intervals and total programme duration increased in a standardised fashion.
~Workload increased bi-weekly in response to participant reported RPE (only after the full 10 x 1 protocol has been achieved). If RPE < 17 then workload will be increased."
16574017|NCT02784860|Active Comparator|Lidocaine|Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
16574018|NCT02784860|Placebo Comparator|Placebo|Placebo Administration of normal saline: same volume of saline as lidocaine.
16574019|NCT02784847|Other|treatment arm|pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
16574020|NCT02784834|Experimental|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.
~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.
~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
16574021|NCT02784821|Other|Antibiotics Control|"These neonates have a clinical indication to receive antibiotics, such as maternal chorioamnionitis with fetal tachycardia. The standard of care antibiotics include Ampicillin and Gentamicin or Cefotaxime and as part of standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.
~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
16574022|NCT02784821|Other|No Antibiotics Control|"These neonates show no signs of respiratory distress(RDS) or have no indications of maternal chorioamnionitis. Antibiotics is not indicated for this group as standard of care.
~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins."
16574023|NCT02784821|Other|Randomized to pre-emptive antibiotics|"This group will be randomized to receive standard of care antibiotics which include Ampicillin and Gentamicin or Cefotaxime. Standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.
~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
16574024|NCT02784821|Other|Randomized to no pre-emptive antibiotics|This group will be randomized not to receive standard of care antibiotics. Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins.
16574025|NCT02784808||Biologic DMARDs|Participants who received biologic DMARDs as per standard of care were included in this arm.
16574026|NCT02784808||Non-biological DMARDs|Participants who received non-biologic DMARDs as per standard of care were included in this arm.
16574027|NCT02784795|Experimental|LY3039478 + Taladegib|LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.
16574028|NCT02784795|Experimental|LY3039478 + LY3023414|LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
16574029|NCT02784795|Experimental|LY3039478 + Abemaciclib|LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.
16574030|NCT02784795|Experimental|LY3039478 + Cisplatin/Gemcitabine|LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.
16574031|NCT02784795|Experimental|LY3039478 + Gemcitabine/Carboplatin|LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.
16574032|NCT02784782|Experimental|Orthesis|Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
16574033|NCT02784782|Active Comparator|No Orthesis|"Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol.
~Control: The patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes."
16574034|NCT02784769|Experimental|aneurysm diameter of below 75 mm|
16574035|NCT02784769|Experimental|aneurysm diameter above 75 mm|
16574036|NCT02784756|Other|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
16574037|NCT02784743|Experimental|albendazole and ivermectin|Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).
16574038|NCT02784730|Experimental|Iterative PICC placement|New PICC placement at each chemotherapy cycle (removed after treatment administration)
16574044|NCT02784678|Experimental|closed reduction group|Patients will be assigned to C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws (experimental group).
16574045|NCT02784678|Experimental|open reduction group|Patients will be assigned to open reduction (palmar and dorsal incisions) and internal fixation with titanium plate (control group).
16574046|NCT02784665|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
16574047|NCT02784665|Active Comparator|577-TL|"577nm Traditional laser(577-TL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area."
16574048|NCT02784652|Experimental|RT & Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions, Zoleronic acid: every 4 weeks, 6 times, 4.0 mg iv
16574049|NCT02784639|Other|determination of KRAS mutation|circulating cell free DNA (ccfDNA) plasma analysis
16574050|NCT02784626|Experimental|Dexmedetomidine|Patients who received dexmedetomidine during the operation
16574051|NCT02784626|Experimental|Propofol|Patients who received propofol during the operation
16574052|NCT02784613|Experimental|Ospemifene open label|60 mg ospemifene daily for 20 weeks
16574054|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
16574055|NCT02784561|Experimental|Busulfan/FLAG conditioning regimen|"All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).
~The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously [i.v.], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days
~-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2)."
16574056|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
16574057|NCT02784535|Placebo Comparator|placebo|placebo capsules
16574058|NCT02784535|Active Comparator|atomoxetine|atomoxetine capsules 10 mg or 18 mg
16574059|NCT02784522|Experimental|locking compression plate group|In the experimental group, patients will undergo closed reduction via a lateral approach to the shoulder followed by locking compression plate fixation using a minimally invasive technique.The locking compression plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
16574060|NCT02784522|Active Comparator|conventional locking plate group|Patients in the control group will be subjected to closed reduction via a lateral approach to the shoulder followed by conventional steel plate fixation using a minimally invasive technique. The conventional locking plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
16574061|NCT02784496|Experimental|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
16574062|NCT02784483|Experimental|Atezolizumab (1200mg via IV infusion)|
16574063|NCT02784470|Experimental|gastrojejunostomy arm|
16574064|NCT02784470|Active Comparator|gastroduodenal stent placement|
16574065|NCT02784457|Active Comparator|GnRHant|women who received GnRH antagonist
16574066|NCT02784457|No Intervention|Control|women who did not receive GnRH antagonist
16574067|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
16574068|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
16574069|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
16574070|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
16574071|NCT02784431|Experimental|Contour Neurovascular System placement|Treatment of intracranial aneurysm with the Contour Neurovascular System device.
16574072|NCT02784418|Active Comparator|PCI of CTO|Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.
16574073|NCT02784418|Sham Comparator|Sham Procedure|"Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a Sham procedure, wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months."
16574074|NCT02784392|Experimental|Active|Ulimorelin
16574075|NCT02784392|Active Comparator|Comparator|Metoclopramide
16574076|NCT02784379||The breast with mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast with mastalgia.
16574077|NCT02784379||The breast without mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast without mastalgia.
16574078|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
16574079|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
16574080|NCT02784353|Active Comparator|Conventional|No intervention; conventional perioperative management without perioperative rehabilitation program
16574081|NCT02784353|Experimental|Intervention - PReHeBP|conventional perioperative management with preoperative and postoperative rehabilitation program
16574082|NCT02784340|Active Comparator|IV dexamethasone|40 women received 16 mg Dexamethasone IV drip.
16574083|NCT02784340|Active Comparator|Local dexamethasone|40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
16574084|NCT02784340|Placebo Comparator|placebo|Placebo in the form of IV fluids 500 cc saline infusion
16574085|NCT02784327|Experimental|PRF110- oily solution|Post-operative application of new extended release PRF110- oily solution (Ropivacaine)
16574086|NCT02784314|Experimental|Robotic-Assisted Radical Prostatectomy|Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
16574087|NCT02784314|Active Comparator|Laparoscopic Radical Prostatectomy|Standard laparoscopic Radical Prostatectomy
16574088|NCT02784301|Experimental|Belly breathing with biofeedback app|
16574089|NCT02784301|No Intervention|Standard of Care|
16574090|NCT02784301|Active Comparator|Belly breathing without biofeedback app|
16574091|NCT02784301|Active Comparator|Belly breathing + visual distraction|
16574095|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
16574096|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
16574097|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
16574098|NCT02784275|Placebo Comparator|Dose D|Placebo
16574099|NCT02784262|Experimental|botox injection|"Preoperative medication: Paracetamol 1,5g oral, diclofenac 50mg (evt ibuprofen 600mg) oral and/or diazepam 5-10 mg oral.
~Skin and tissue inside the projected injection canal will be infiltrated with 5-10ml Marcain-Adrenalin (5mg/ml + 5microg/ml) for local anaesthesia.
~Localization will be confirmed with help of navigation before the medication will be given. Intravascular injection will be prevented by control of aspiration."
16574100|NCT02784249|Experimental|Goniotomy|Procedure: Goniotomy and trabecular excision in combination with planned cataract extraction via Phaco and PCIOL implant.
16574101|NCT02784249|Active Comparator|Trabecular Micro-Bypass Stent|Procedure: Device implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
16574102|NCT02784236|Other|pre-post evaluation|All patients undergo the condition of telemedicine.
16574103|NCT02784223|Experimental|PET-CT with F18-choline|PET-CT with F18-choline examination will be performed before surgery
16574106|NCT02784197|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
16574107|NCT02784184||1 year follow-up group|1 year follow-up group including 6 measurements
16574108|NCT02784184||40 days diaper study subgroup|"Subgroup of the 1 year follow-up group including 15 girls undergoing daily measurement of urinary hormone excretion"
16574109|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
16574110|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
16574111|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
16574112|NCT02784145|Other|RS|Resistant starch supplementation (5 g twice a day)
16574113|NCT02784145|Other|No RS|PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition)
16574114|NCT02784132|Other|Study Arm A|Right eye examined first with video diversion then left eye examined without video diversion
16574115|NCT02784132|Other|Study Arm B|Right eye examined first without video diversion then left eye examined with video diversion
16574116|NCT02784132|Other|Study Arm C|Left eye examined first with video diversion then right eye examined without video diversion
16574117|NCT02784132|Other|Study Arm D|Left eye examined first without video diversion then right eye examined with video diversion
16574118|NCT02784119|Experimental|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
16574119|NCT02784119|No Intervention|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
16574120|NCT02784106|Placebo Comparator|Placebo: Double-Blind Treatment Period|
16574121|NCT02784106|Experimental|M2951: Double-Blind Treatment Period|
16574122|NCT02784106|Experimental|Placebo/M2951: Open Label Extension Period|
16574123|NCT02784106|Experimental|M2951/M2951: Open Label Extension Period|
16574124|NCT02784093|Experimental|Exposure Group|Participants were allocated to receive 100 mL of Gastrograﬁn orally once daily for 6 consecutive days.
16574125|NCT02784093|Placebo Comparator|Control Group|Participants were allocated to receive enemas twice daily for 6 consecutive days.
16574126|NCT02784080||HLA-alloantibodies exposure|Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.
16574127|NCT02784067|Experimental|Treatment|Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
16574128|NCT02784067|Placebo Comparator|Placebo|Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
16574161|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
16574162|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
16574129|NCT02784054|Experimental|Intracranial NGGCT|"Six cycles of chemotherapy with carboplatin, etoposide, bleomycin (CEB) and cyclophosphamide, etoposide, bleomycin (CyEB) regimen.
~Peripheral blood stem cell collection during the first cycle of chemotherapy.
~Surgery, if there is residual tumor after chemotherapy.
~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation (auto-SCT)
~1st HDCT: Carboplatin, thiotepa, etoposide
~2nd HDCT: Cyclophosphamide, melphalan
~Reduced dose of radiotherapy"
16574130|NCT02784041|Experimental|single adductor-canal-block|Patients in this group will receive ultrasound guided single adductor-canal- block with 0.35% ropivacaine 25ml.
16574131|NCT02784041|Experimental|periarticular infiltration|patients in this group will receive periarticular infiltration of local anesthetic.
16574132|NCT02784028|Experimental|SGM-101|6 dose levels of SGM-101 (5mg/patient, 7.5mg/patient, 10 mg/patient, 12.5mg/patient , 15 mg/patient - 24 h prior surgery and 15 mg/patient - 48h prior surgery
16574133|NCT02784015|Experimental|Unresectable localized soft tissue sarcoma|"Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen.
~Surgery, if possible
~Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan)
~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy.
~1st HDCT: carboplatin, thiotepa, etoposide
~2nd HDCT: cyclophosphamide, melphalan"
16574134|NCT02784002|Experimental|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
16574135|NCT02784002|Active Comparator|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
16574136|NCT02783989|Active Comparator|White wine|Two glasses of a market white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14 g in women). It is estimated that wine will contain about 8-9 mg/l of tyrosol. Therefore the dose of tyrosol ingested in two glasses would be 2-2.5 mg (1-1.25 mg in women).
16574137|NCT02783989|Experimental|White wine plus tyrosol capsules|Two glasses of white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14g in women), in combination with capsules of 25 mg of TYR (each one to be ingested with a glass of wine), two capsules along the day for men (at lunch and at dinner) and one for woman (at lunch).
16574138|NCT02783989|No Intervention|Water|Drinking water along with meals
16574139|NCT02783976||Sovaldi-based regimens|Adult patients with chronic HCV infection living in Mexico who take Sovaldi as part of routine clinical care at a participating clinical site.
16574140|NCT02783963|Other|MI with nonobstructive CAD at coronary angiography|MI with nonobstructive CAD investigated by means of OCT and CMR
16574141|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
16574142|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
16574143|NCT02783937|Active Comparator|Filgrastim arm|Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days
16574144|NCT02783937|Placebo Comparator|Placebo arm|Intervention: Injection of saline SC injection twice daily for five consecutive days.
16574145|NCT02783924|Active Comparator|Cholecalciferol|Vitamin d (as a 20.000 IU capsule) will be given i a dose of 40.000 IU per week for two months
16574146|NCT02783924|Placebo Comparator|Placebo|two capsules (identical looking to the vitamin D capsules) will be given per week for two months
16574147|NCT02783911|Experimental|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (< 1gm) will be placed on pulp orifice once for the life of the primary teeth
16574148|NCT02783911|Experimental|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
16574149|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
16574150|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
16574151|NCT02783872||Loss of control|30 overweight or obese (BMI≥85th %ile) youth endorsing loss of control eating within the past 3 months
16574152|NCT02783872||Overweight control|30 overweight or obese controls without any history of loss of control eating
16574153|NCT02783872||Normal-weight control|15 normal-weight controls without any history of loss of control eating
16574154|NCT02783859|Experimental|Active arm: Amoxicillin-clavulanic Acid|8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)
16574155|NCT02783859|Placebo Comparator|Placebo arm|8 days of oral placebo (equivalent volume as the active arm)
16574156|NCT02783846|Placebo Comparator|Group control|24 eligible patients are received equal volumes of saline intravenously for 10 minutes
16574157|NCT02783846|Active Comparator|Group dexmedetomidine 0.5 µg/kg|24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
16574158|NCT02783846|Active Comparator|Group dexmedetomidine 1.0 µg/kg|25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
16574159|NCT02783833|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
16574160|NCT02783833|Experimental|MMV390048 dose to be determined mg|MMV390048 dose to be determined mg, tablets, single dose
16574165|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
16574166|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
16574167|NCT02783807|Experimental|Eyenez Retinal Camera v200|Retinal images from Eyenez Retinal Camera v200 of healthy and diseased subjects
16574168|NCT02783807|Active Comparator|Volk Pictor Ret 1|Retinal images from Volk Pictor Ret 1 of healthy and diseased subjects
16574169|NCT02783794|Experimental|BP-C1|Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
16574170|NCT02783794|Placebo Comparator|Placebo|Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
16574171|NCT02783781||Cardiac surgery|All patients (planned and urgent) needed cardiac surgery, and agreed to participate
16574172|NCT02783768|Experimental|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
16574173|NCT02783768|Experimental|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
16574174|NCT02783755|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
16574175|NCT02783742|Experimental|Intervention|Providers in this arm will receive a communication coaching intervention immediately post-randomization.
16574176|NCT02783742|Other|Waitlist Control|Providers assigned to this arm will be offered the option of receiving the communication coaching intervention after follow up data collection is complete.
16574177|NCT02783729|Experimental|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
16574178|NCT02783729|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
16574179|NCT02783729|Active Comparator|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
16574180|NCT02783729|Placebo Comparator|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
16574181|NCT02783716|Active Comparator|Cardiac Resynchronization Therapy (CRT)|Participants will be undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure
16574182|NCT02783716|Active Comparator|Control Group|Participants will undergo device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block.
16574183|NCT02783703|Experimental|MCT|Medium chain triglyceride (MCT) oil ingested daily for 6 weeks
16574184|NCT02783690|No Intervention|Conventional Fractionation|50.0 Gy (RBE) in 25 daily fractions
16574185|NCT02783690|Experimental|Hypofractionation|40 Gy (RBE) in 15 daily fractions
16574186|NCT02783677||DM with PAD before angioplasty|Diabetic patients diagnosed with peripheral artery disease via vascular Duplex.
16574187|NCT02783677||DM without PAD|Diabetic patients diagnosed without peripheral artery disease via vascular Duplex.
16574188|NCT02783677||Healthy volunteers|Healthy volunteers
16574189|NCT02783677||DM with PAD after angioplasty|Diabetic patients diagnosed with PAD underwent balloon-angioplasty
16574190|NCT02783664||Questionnaires to Evaluate Patient Stress Levels|
16574191|NCT02783651||No treatment 1|It is planned to have 20-30 sites participating on the trial for chart review of approximately 200-235 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
16574192|NCT02783651||No Treatment 2|Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
16574193|NCT02783638|Experimental|YHD1119 (Pregabalin 300mg)|YHD1119 (Pregabalin 300mg)
16574194|NCT02783638|Active Comparator|Lyrica (Pregabalin 150mg)|Lyrica (Pregabalin 150mg)
16574195|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
16574196|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
16574197|NCT02783612|Experimental|glucose application|Regular high risk pregnancy clinic surveillance in addition to a Smart phone application for registering the Blood glucose levels and submitting via email every 3-5 days to the High risk Doctor involved in the trial.
16574198|NCT02783612|No Intervention|Regular monitoring|Regular high risk pregnancy clinic surveillance
16574199|NCT02783599|Experimental|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle).
~Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle).
~Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles)."
16574200|NCT02783599|Experimental|Olaratumab + Radiotherapy Addendum|"Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy.
~Radiotherapy addendum was not implemented."
16574201|NCT02783586|Experimental|Quadratus Lumborum Block type II|Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
16574202|NCT02783586|Active Comparator|Transversus Abdominalis Plane Block|Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle
16574203|NCT02783573|Experimental|Lanabecestat 20 milligrams (mg)|Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
16574204|NCT02783573|Experimental|Lanabecestat 50 mg|Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156.
16574205|NCT02783573|Experimental|Placebo/ Lanabecestat 20 mg|Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156.
16574206|NCT02783573|Experimental|Placebo/ Lanabecestat 50 mg|Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156.
16574207|NCT02783560|Experimental|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
16574208|NCT02783560|Active Comparator|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
16574209|NCT02783547|Experimental|SyB C-1101 and Azacytidine|
16574210|NCT02783534|Experimental|Verum acupuncture|Participants will receive verum acupuncture plus usual care. Participants will receive acupuncture treatment start from the 5th or 7th day before the estimated first day of menstrual cycle, and for each cycle, participants will receive one session of treatment each day for 5 consecutive days, totally be treated with 15 sessions.Verum needles will be inserted into the skin and manipulated manually until deqi occurs. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and manipulates the needles to maintain the intensity of deqi. Participants will receive the same usual care as those in the usual care group.
16574211|NCT02783534|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.
16574212|NCT02783534|Placebo Comparator|Usual care|Participants will not receive acupuncture treatment besides health education as a control group.
16574213|NCT02783521|Experimental|Intervention|Includes changing eating behaviors, increasing physical activity, and attending regular in-person weight loss meetings for 12 weeks. To support additional weight loss/weight maintenance, participants will receive bi-weekly phone calls across a 12 week follow-up.
16574214|NCT02783521|Other|Wait List Control|Wait-list control participants will not receive any intervention for the first 12 weeks. After 12 weeks, participants will receive the weight loss intervention plus mHealth technology support.
16574215|NCT02783508|Active Comparator|IV Meperidine|Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.
16574216|NCT02783508|Active Comparator|Inhaled Nitrous Oxide|Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.
16574217|NCT02783495|Experimental|Device: iPad|Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
16574218|NCT02783482|Experimental|GC5107|GC5107 Immune globulin intravenous (human) solution, 10% liquid
16574219|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
16574220|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
16574221|NCT02783456|Active Comparator|Noise and silence|Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.
16574222|NCT02783456|Active Comparator|silence and noise|Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes
16574223|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
16574224|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
16574225|NCT02783430|Experimental|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
16574226|NCT02783430|Active Comparator|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
16574227|NCT02783417|Experimental|Training with vascular occlusion|Strength Training: intensity of 30% of 1RM, with vascular occlusion pressure in members.
16574228|NCT02783417|Experimental|Traditional strength training|Strength Training: intensity of 80% of 1RM, without vascular occlusion pressure in members
16574229|NCT02783417|No Intervention|Control|Subject untrained.
16574230|NCT02783404|No Intervention|Control|Receiving no prophylaxis
16574231|NCT02783404|Active Comparator|Amoxicillin|"Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation
~Intervention: Drug: Amoxicillin"
16574232|NCT02783404|Experimental|Amoxicillin-Potassium Clavulanate|"Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation
~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
16574233|NCT02783391|Experimental|BRAINSPEAK|Electrocorticographical (ECoG) and intracortical electrodes
16574234|NCT02783378|Other|Gaviscon syrup|"Gaviscon will be given to threat patients with reflux after first 24 hours of oesophagal pH-monitoring.
~This is a syrup and will be given after every meal. dosage depends from age between 1ml and 5ml after every meal"
16574235|NCT02783365|Experimental|Intervention|The intervention uses photo-elicitation and online group support (via Facebook) to improve patients' overall experience of chronic pain and patient-identified areas of function. This intervention was informed by the Photovoice methodology developed by Wang and Burris (1994). Photovoice participants will utilize cameras that enable them to record issues related to their experiences, and subsequently display them in office visits with their physician or mid-level clinician.
16574236|NCT02783365|No Intervention|Control|Patients in the control practices will receive usual care and will be eligible to participate in the intervention after their participation in the study is completed at 12 months.
16574237|NCT02783352|Experimental|treatment group|arthroscopic rotator cuff repair + injection of autologous micro-fragmented adipose tissue (10 mL)
16574238|NCT02783352|Other|control group|arthroscopic rotator cuff repair only
16574239|NCT02783326|Experimental|COPD Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
16574240|NCT02783326|Active Comparator|Control Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
16574241|NCT02783313|Experimental|PR-plasma-PCs|Pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)
16574242|NCT02783313|Active Comparator|Plasma-PCs|Pooled buffy coat-derived plasma-stored platelet concentrates (plasma-PCs)
16574243|NCT02783300|Experimental|Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet|Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).
16574244|NCT02783300|Experimental|Part 2: Disease-Specific Expansion cohort|Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme [GBM]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.
16574245|NCT02783300|Experimental|Part 3: GSK3326595 in combination with pembrolizumab|Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.
16574246|NCT02783287|Experimental|Medication text message|Once daily text message reminder.
16574247|NCT02783287|Experimental|Exercise text message|4x daily text message reminder.
16574248|NCT02783287|No Intervention|Usual care, medication adherence|Usual care for medication adherence.
16574249|NCT02783287|No Intervention|Usual care, exercise regimen|Usual care for exercise regimen.
16574250|NCT02783274|Other|Actis Total Hip System|The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
16574251|NCT02783261||Post Y90 hypertrophy measurement|All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
16574252|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.
~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.
~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.
~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.
~Patients in the study will receive an annual monitoring as recommended, independently of the study."
16574253|NCT02783235|Other|cervical cancer|cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
16574254|NCT02783222|Active Comparator|Arm B|Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks
16574255|NCT02783222|Experimental|Arm A|Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
16574256|NCT02783209|Other|Cataract surgery|Patient acts as his own control
16574257|NCT02783196|Experimental|Liraglutide (LIR)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with Liraglutide ( IR) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with placebo (PLA)
16574258|NCT02783196|Placebo Comparator|Placebo (PLA)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with placebo ( PLA) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with Liraglutide ( LIR)
16574259|NCT02783183|Experimental|YHD1119|Pregabalin 300mg
16574260|NCT02783183|Active Comparator|Lyrica|Pregabalin 150mg
16574261|NCT02783170|Other|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
16574262|NCT02783170|Other|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
16574263|NCT02783157|Experimental|Transcutaneous low-level vagal nerve stimulation (LLVNS)|n=100 patients will be randomized to transcutaneous low-level vagal nerve stimulation (LLVNS), via a clip applied to the ear. Stimulation will be delivered throughout the procedure.
16574264|NCT02783157|Sham Comparator|Sham LLVNS|n=100 patients will be randomized to sham LLVNS, with the clip applied but no stimulation delivered.
16574265|NCT02783144|Experimental|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, 4 mg of Dexamethasone are added to 20 ml of 0,375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
16574266|NCT02783144|Placebo Comparator|TAP Block and Saline|After general anesthesia and before the beginning of surgery, 2 ml of saline are added to 20 ml of 0.375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
16574267|NCT02783144|Active Comparator|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, 20 ml of 0,375% Levobupivacaine are used in Ultrasound-guided Tranversus Abdominis Plain Block. In this group 4 mg of dexamethasone are injected intravenously.
16574268|NCT02783131|Experimental|MedNav|Team getting taught to use mednav, and using mednav in simulation managing Post partum Haemorrhage.
16574269|NCT02783131|No Intervention|non MedNav|Team undergoing routine simulation training in Post Partum Haemorrhage.
16574270|NCT02783118|Experimental|Healthy sample, active intervention|Healthy participants will be testing a depression prevention app employing a self administered online CBT intervention, for 4 weeks.
16574271|NCT02783118|No Intervention|Healthy sample, delayed intervention|Healthy participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
16574272|NCT02783118|Experimental|Mild depression, active intervention|Mildly depressed participants will be testing a depression prevention app, employing a self administered online CBT intervention, for 4 weeks.
16574273|NCT02783118|No Intervention|Mild depression, delayed intervention|Mildly depressed participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
16574274|NCT02783105|Experimental|Musical intervention|"Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.
~Both have inverted U shape."
16574275|NCT02783105|Sham Comparator|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
16574276|NCT02783092|Experimental|Cannabidiol|Concentration unit: 200mg/ml; 5 - 25 mg/Kg/day ; Oral solution
16574277|NCT02783092|Placebo Comparator|Placebo|Oral solution
16574278|NCT02783079|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT)
16574279|NCT02783079|Active Comparator|Arm 2|Mindfulness Based Stress Reduction (MBSR)
16574280|NCT02783066|Experimental|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
16574281|NCT02783053|Other|Metformin use|The investigators compare the use of metformin vs no metformin
16574282|NCT02783053|No Intervention|Lean or Obese|The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
16574283|NCT02783040|Experimental|single dose cocktail (Midazolam, Warfarin, Omeprazole)|
16574284|NCT02783040|Experimental|single dose Midazolam|
16574285|NCT02783040|Experimental|single dose Digoxin|
16574286|NCT02783040|Experimental|multiple dose BI 425809|
16574287|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
16574288|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
16574289|NCT02782988||CMV symptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
16574290|NCT02782988||CMV asymptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
16574291|NCT02782988||Healthy controls|olfactory tests, otoacoustic emissions (OAE)
16574292|NCT02782975|Experimental|aducanumab IV|Infusion of aducanumab over approximately 1 hour
16574293|NCT02782975|Experimental|aducanumab SC|Subcutaneously via injection
16574294|NCT02782962||Cohort|Patients with acute vertigo/unsteadiness
16574295|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
16574296|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
16574297|NCT02782936|Experimental|Baseline|Randomised baseline without and with gas mask.
16574298|NCT02782936|Experimental|Induced Hypoxemia|Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
16574299|NCT02782936|Experimental|Effort|Randomised effort without and with gas mask
16574300|NCT02782923|Experimental|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
16574301|NCT02782923|Experimental|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
16574302|NCT02782923|Experimental|CDR with STISIM|Cervical disc replacement
16574303|NCT02782923|Experimental|PCLF with STISIM|Posterior laminectomy and fusion
16574304|NCT02782923|Experimental|PCD with STISIM|Posterior cervical decompression procedure
16574305|NCT02782923|Sham Comparator|Control Group with STISIM|
16574306|NCT02782910|Experimental|SBAA+|Upon exceeding pre defined SBAA-threshold limits during the randomisation phase the treating physician is alerted (+) to this signal and required to contact the patient so as to assess the current mental status and collaboratively discuss the potential need for medical/psychiatric treatment with the patient.
16574307|NCT02782910|No Intervention|SBAA|Continuous monitoring will occur analogous to SBAA+. Exceeding the pre defined SBAA-threshold will not result in any action taken.
16574308|NCT02782897|Experimental|IVIg group|Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.
16574309|NCT02782897|Other|Control group|Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.
16574310|NCT02782884||Outpatient general surgery operation|Patients undergoing outpatient general surgical operations They will be given a specified number of narcotic pills based on our retrospective analysis of patient post-operative opioid use
16574311|NCT02782884||Inpatient general surgical patients|Inpatients who are being discharged They will be given a specified number of narcotic pills based on the number of pills they took in the 24 hrs prior to discharge
16574312|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
16574313|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
16574314|NCT02782858|Experimental|Dose 1 GNbAC1|Monthly IV repeated dose
16574315|NCT02782858|Experimental|Dose 2 GNbAC1|Monthly IV repeated dose
16574316|NCT02782858|Experimental|Dose 3 GNbAC1|Monthly IV repeated dose
16574317|NCT02782858|Placebo Comparator|Placebo|Monthly IV repeated dose
16574318|NCT02782845|Experimental|Pegfilgrastim|Participants will receive CT or ICT for 6 cycles on Days 1-6, as per standard of care. Protocol does not specify any choice of CT or ICT drugs. Participants will receive pegfilgrastim at a fixed dose of 6 mg subcutaneously, 24 hours after the last dose of CT or ICT in each treatment cycle. CT or ICT cycles of 21 days, as per standard of care.
16574319|NCT02782819|Placebo Comparator|Crystalloid|Isotonic crystalloid solution resuscitation
16574320|NCT02782819|Active Comparator|Crystalloid plus Colloid|Colloid solution resuscitation
16574321|NCT02782806|Experimental|Test group|All subjects are enrolled into the test group and receive Masimo Rad-67 Pulse Oximeter for measurement of hemoglobin.
16574322|NCT02782793||Patient's with complex colon polyps|
16574323|NCT02782780|Experimental|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
16574324|NCT02782780|No Intervention|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
16574325|NCT02782767|Active Comparator|Epidural catheter infusion|epidural catheter in the thoracic vertebra level to provide local anesthetic infusion
16574326|NCT02782767|Experimental|Wound catheter infusion|A multiorificed wound infusion catheter kept within the incision site to provide continuous local anesthetic infusion
16574327|NCT02782754|Experimental|Intracranial germinoma|"Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen
~Reduced dose of radiotherapy
~Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site
~With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site"
16574328|NCT02782741|Experimental|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
16574329|NCT02782741|Active Comparator|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
16574330|NCT02782728|Active Comparator|TIPS-Basic|Providers receive tailored scripts based on the patient's responses to the questions administered via tablet.
16574331|NCT02782728|Experimental|TIPS-Plus|Patients receive tailored messages in addition to the scripts given to providers.
16574332|NCT02782715|Experimental|Radiotherapy & Microwave Ablation|"3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:
~Dose level I: 6 Gy x 5 fractions
~Dose level II: 8 Gy x 5 fractions
~Dose level III: 10 Gy x 5 fractions
~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.
~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.
~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration)."
16574333|NCT02782702|Experimental|Botulism Toxin treatment|Injection of 50 UI Botulism toxin for the treated zone
16574334|NCT02782689|Experimental|Kit Biflex|The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
16574335|NCT02782689|Active Comparator|Profore|The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.
16574336|NCT02782676|Experimental|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
16574337|NCT02782676|Active Comparator|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
16574338|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
16574339|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose B|Open label dose B QD
16574340|NCT02782650||Survey and interviews|"* part one * (quantitative)
~Survey on:
~A) prenatal counseling at the limits of viability, both current and preferred, within three domains of interest:
~organization of prenatal counseling
~content of prenatal counseling
~decision-making in prenatal counseling
~B) treatment options at the limits of viability against the background of the Dutch guideline
~* part two * (qualitative)
~Focus groups interviews (qualitative) to in-depth explore preferences in prenatal counseling
~insight in the specific preferred content of prenatal counseling.
~study influencing factors on preferences in the domains of organization and decision-making."
16574341|NCT02782637||Survey and interviews|"*part one* (quantitative)
~Survey on:
~A. prenatal counseling at the limits of viability, within three domains of interest:
~organization of prenatal counseling
~content of prenatal counseling
~decision-making in prenatal counseling Domains used to evaluate current counseling and counseling preferences
~B. decision-making at the limits of viability: evaluation of the made decision (decisional conflict and regret)
~*part two* (qualitative)
~Individual interviews (qualitative) to in-depth explore preferences in prenatal counseling
~insight in the specific preferred content of prenatal counseling.
~study influencing factors on preferences in the domains of organization and decision-making."
16574342|NCT02782624|Experimental|Treatment A: Empagliflozin|5 mg bid
16574343|NCT02782624|Experimental|Treatment B: Empagliflozin|10 mg qd
16574344|NCT02782611|Experimental|Treatment|ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
16574345|NCT02782611|No Intervention|Waiting Group Control|The waiting group control will complete the same assessments as the experimental group but without receiving the intervention.
16574346|NCT02782598|Experimental|CRT+NAVH|Surface ECG and pressure-volume loop recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings at the device implant procedure
16574347|NCT02782585|Experimental|Experimental group 1|Cervical Manipulation
16574348|NCT02782585|Experimental|Experimental group 2|Cervical lateral glide
16574349|NCT02782585|Placebo Comparator|Control group|Cervical Mobilisation
16574350|NCT02782572|Experimental|Exercise with Non-invasive ventilation|Patients with acute haert failure who performed aerobic exercise with non-invasive ventilation. This group also received conventional medical treatment.
16574351|NCT02782572|Sham Comparator|Exercise|Patients with acute haert failure who performed aerobic exercise with placebo of non-invasive ventilation. This group also received conventional medical treatment.
16574352|NCT02782572|Other|Control|Patients who receiveid only conventional medical treatment and not performed exercise during protocol.
16574353|NCT02782559|Experimental|Sildenafil|Sildenafil 40mg oral tablet three times a day from randomization until delivery
16574354|NCT02782559|Placebo Comparator|Placebo|Matched to oral capsule of active treatment three times a day from randomization until delivery
16574355|NCT02782546|Experimental|Recipient|"Standard of care reduced conditioning regimen on Day -1
~Graft cell infusion on Day 0
~Post-transplant cyclophosphamide on Days +3 and +4
~GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD
~G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines
~The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.
~ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses"
16574356|NCT02782546|Experimental|Donor|"Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.
~Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.
~On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
16574357|NCT02782533|Experimental|DBS V3|Deep Brain Stimulation V3
16574358|NCT02782520|Active Comparator|Ringer Lactate|Ringer Lactate group
16574359|NCT02782520|Experimental|Hypertonic saline|Hypertonic saline group
16574360|NCT02782494||Dialysis group|Patient receiving long term dialysis
16574361|NCT02782481|Experimental|ND0612 High dose (Levodopa/Carbidopa solution)|High dose ND0612 SC infusion over 24 h
16574362|NCT02782481|Experimental|ND0612 Low dose (Levodopa/Carbidopa solution)|Low dose ND0612 SC infusion over 24 h
16574363|NCT02782481|Placebo Comparator|Placebo|Placebo SC infusion over 24 h
16574364|NCT02782468|Experimental|Arm 1, Cohort 1: Pevonedistat 25 mg/m^2|Pevonedistat, 25 milligram per square meter (mg/m^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
16574365|NCT02782468|Experimental|Arm 1, Cohort 2: Pevonedistat 44 mg/m^2|Pevonedistat, 44 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
16574366|NCT02782468|Experimental|Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 10 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
16574367|NCT02782468|Experimental|Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
16574368|NCT02782455|Experimental|CDobi|Calcium dobesylate is given in this group
16574369|NCT02782455|Active Comparator|Flavono|Flavonoids are given in this group
16574370|NCT02782442|Experimental|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
16574371|NCT02782442|Active Comparator|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
16574372|NCT02782429|Experimental|Ketamine|This group received ketamine in a dose 0.5 mg / in anesthesia, in addition to other drugs used for induction, which will be standardized.
16574373|NCT02782429|Placebo Comparator|Placebo|This group received the equivalent volume of saline, in addition to other drugs used for induction, which will be standardized.
16574374|NCT02782416|No Intervention|Waiting for renal transplant_no screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination but no LTBI check
16574375|NCT02782416|Placebo Comparator|Not waiting for renal transplant|Dialysis patients who are not waiting for renal transplant
16574376|NCT02782416|Other|Status post renal transplant|patients who have received renal transplant
16574377|NCT02782416|Experimental|Waiting for renal transplant_ screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination in addition to LTBI check
16574378|NCT02782403|Experimental|Treatment (alternating therapy)|Patients with chronic phase CML receive either bosutinib PO QD or axitinib PO BID alone for 3 months. Patients then switch to the other drug for 3 months and alternate between the two every 3 months in the absence of disease progression or unacceptable toxicity.
16574407|NCT02782208|Placebo Comparator|Placebo/GH substitution|Drug: Placebo tablets Continue GH substitution as usually.
16574379|NCT02782403|Experimental|Treatment (combined therapy)|Patients with accelerated or blastic phase CML receive bosutinib PO QD and axitinib PO BID for 3 months. Courses repeat every 3 months in the absence of disease progression or unacceptable toxicity.
16574380|NCT02782390|Experimental|Hall Technique|single placement of stainless dental crowns on atypical cavities
16574381|NCT02782390|Active Comparator|Composite Resin|single placement of composite resin on atypical cavities
16574382|NCT02782377||Pelvic Floor Dysfunction|"Observational study where patients with pelvic floor dysfunction undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed
~Note, that initial inclusion of Squeeze parameters was detailed in error, these were not compared in this study and were compared in previous study"
16574383|NCT02782364||Faecal Incontinence: fast-fill measurement first|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
16574384|NCT02782364||Faecal Incontinence: step-wise measurement first.|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will have step-wise measurement first.
16574385|NCT02782351|Experimental|CAR-T|In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.
16574386|NCT02782325|Active Comparator|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
16574387|NCT02782325|Placebo Comparator|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
16574388|NCT02782312|Experimental|ICS+LABA Group|Seretide 250，inhalation，twice daily，one year
16574389|NCT02782312|Active Comparator|Control Group|routine therapy for one year
16574390|NCT02782299|No Intervention|Control|This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
16574391|NCT02782299|Experimental|Decision Aid|This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.
16574392|NCT02782286|Active Comparator|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
16574393|NCT02782286|Active Comparator|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
16574394|NCT02782273|Active Comparator|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
16574395|NCT02782273|Active Comparator|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
16574396|NCT02782260|Experimental|Active|"Dipyridamole eye drops 8.48 mg in 100ml
~1 drop three times a day for 1 year"
16574397|NCT02782260|Placebo Comparator|Placebo|"Fluorescein in Active Vehicle
~1 drop three times a day for 1 year"
16574398|NCT02782247||Short term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who are planning to start antiviral therapy will be enrolled. Patients will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
16574399|NCT02782247||Medium term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who have been successfully treated in the past 3 or 5 years (+/- 3 months). Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
16574400|NCT02782247||Hepatitis B Patients|60 patients with chronic hepatitis B and cirrhosis will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients who have started treatment past 3 or 5 years (+/- 3 months) will also be tested. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
16574401|NCT02782234|No Intervention|not contract management|monthly follow-up phone or family visit completed as regulation, and instruct them proper healthy training.
16574402|NCT02782234|Experimental|Contract management|In accordance with the contract content, researchers and participants should manage and maintain the liquid balance of the participants. Signed doctors and nurses should undergo the follow-up phone or family visit on time, instruct them proper healthy training, and provided necessary information data. By telephone, SMS, wechat, remind and urge the participants to take the lifestyle and behavior regulate in the contract. Participants should supervise and manage the fluid unbalance (Edema, hypertension, heart failure, and fluid imbalance of intake and output etc.), and feedback the Management and supervision to researchers according to contract.
16574403|NCT02782221|Active Comparator|Growth hormone|Subjects are receiving growth hormone
16574404|NCT02782221|Placebo Comparator|Placebo|Subjects are receiving pegvisomant to block the action of growth hormone
16574405|NCT02782208|Active Comparator|Acipimox/GH substitution|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
16574406|NCT02782208|Active Comparator|Acipimox/GH pause|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
16574408|NCT02782208|Placebo Comparator|Placebo/GH pause|Drug: Placebo tablets Pause GH substitution to days prior to the study day.
16574409|NCT02782182|Experimental|FOLFIRINOX+surgery|4 cycles of pre-operative FOLFIRINOX, followed by surgery, followed by 2 more cycles of FOLFIRINOX
16574410|NCT02782169|Active Comparator|Pregabalin|
16574411|NCT02782169|Placebo Comparator|Placebo|
16574412|NCT02782130|Active Comparator|Intervention Group|Subjects randomized to the Epic Allies Intervention will download and install the intervention branch of the Epic Allies app and receive a tour of the app guided by site staff. During the 26-week intervention phase, intervention arm subjects will receive daily adherence reminders set up through Epic Allies with tailored feedback for encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all features of Epic Allies and will receive supportive messages from other subjects on the intervention arm.
16574413|NCT02782130|Placebo Comparator|Control Group|Subjects randomized to the control arm will download and install the control branch of the Epic Allies app (phone-based notifications only) and be provided with instructions on using the app. During the 26-week intervention phase, the control arm subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
16574414|NCT02782117|Experimental|Treatment Regimen A|Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.
16574416|NCT02782091|Experimental|Schizophrenia Patient|
16574417|NCT02782091|Experimental|Control Subject|
16574418|NCT02782078|Other|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
16574419|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
16574420|NCT02782052|Experimental|Nebulized ipratropium bromide|Administration in a random order nebulized ipratropium bromide at V3 or V4 or V5
16574421|NCT02782052|Experimental|Nebulized combination ipratropium bromide with salbutamol|Administration in a random order combination Ipratropium bromide and Salbutamol at V3 or V4 or V5
16574422|NCT02782052|Placebo Comparator|Placebo|Administration in a random order placebo at V3 or V4 or V5
16574423|NCT02782026|Experimental|idiopathic PAH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
16574424|NCT02782026|Experimental|heritable PAH with BMPR2 mutation|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
16574425|NCT02782026|Experimental|chronic thromboembolic PH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
16574426|NCT02782026|Experimental|Controls|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
16574427|NCT02782000|Experimental|Long-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
16574428|NCT02782000|Active Comparator|Short-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 3 months.
16574429|NCT02781987||CP group|Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc..
16574430|NCT02781987||BD group|Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct.
16574431|NCT02781974|Experimental|Intervention|Intervention consists of strength and balance exercise in group sessions, twice a week for 12 weeks
16574432|NCT02781974|No Intervention|Control|"Participants allocated in the control group are instructed to live as usual"
16574433|NCT02781948||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
16574434|NCT02781948||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus
16574435|NCT02781922|Experimental|Autologous cardiac stem cells (JRM-001)|
16574436|NCT02781922|No Intervention|Usual care|
16574437|NCT02781909|Active Comparator|Control: Standard of Care TB treatment|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines; n=12
16574438|NCT02781909|Experimental|Ibuprofen-treated|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines plus ibuprofen (400mg/day/2 months); n=12
16574439|NCT02781896|Active Comparator|Right ventricular pacing|Rapid pacing during TAVI is provided by a temporary pacing catheter placed in the right ventricle. An additional venous vascular access is required.
16574440|NCT02781896|Experimental|Left ventricular pacing|Rapid pacing during TAVI is provided by the valve delivery guidewire inserted into the left ventricle using two alligator clamps. One clamp is attached directly to the skin at the femoral entry site, the other is attached to the body of the valve delivery guidewire. No additional venous vascular access is required.
16574441|NCT02781883|Experimental|Untreated AML|BP1001 in combination with Ventoclax plus decitabine
16574442|NCT02781883|Experimental|Refractory/Relapsed AML|BP1001 in combination with Ventoclax plus decitabine
16574443|NCT02781883|Experimental|Refractory/Relapsed AML (ventoclax-intolerant or resistant)|BP1001 + decitabine combination in patients who are resistant or intolerant of venetoclax-based treatment, or considered not optimal candidates for a venetoclax-based therapy.
16574444|NCT02781870|Other|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
16574445|NCT02781870|Experimental|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
16574446|NCT02781857||60 patients with lung cancer|"Group A: 30 patients with squamous cell carcinoma eligible for lung cancer surgery
~Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
16574447|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history and lung function testing.
16574448|NCT02781844|Experimental|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
16574449|NCT02781844|Experimental|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
16574450|NCT02781844|Experimental|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
16574451|NCT02781844|Experimental|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
16574452|NCT02781831|Active Comparator|Standard Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation program
16574453|NCT02781831|Experimental|Robot-assisted Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation as well as robot-assisted gait rehabilitation program
16574454|NCT02781818|Experimental|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
16574455|NCT02781818|Experimental|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
16574456|NCT02781818|Placebo Comparator|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
16574457|NCT02781805|Experimental|Alendronate|Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
16574458|NCT02781792|Experimental|Arm 1: Temozolomide morning|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).
~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
16574459|NCT02781792|Experimental|Arm 2: Temozolomide evening|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).
~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
16574460|NCT02781779|Active Comparator|Silverlon®|Subjects randomized to this arm will receive Silverlon® dressing postoperative.
16574461|NCT02781779|Active Comparator|AQUACEL® AG|Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.
16574462|NCT02781766|Other|One arm: patients with severe haemophilia A on prophylaxis|Patients with severe haemophilia A (FVIII < 1 IU/dl), currently on prophylactic therapy , having the same prophylaxis regimen in the last six months, aged between 2 (with a body weight ≥12.5 kg ) and 45 years , with adequate venous access, having patient's diary or equivalent regularly completed and able to give informed consent
16574463|NCT02781753|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.
16574464|NCT02781753|Active Comparator|Pegasys|Peginterferon 180 μg single dose S.C.
16574465|NCT02781740|Active Comparator|CPAP therapy|Continuation of the already established CPAP therapy.
16574466|NCT02781740|Sham Comparator|Sham CPAP therapy|Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
16574467|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
16574468|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
16574469|NCT02781714|Experimental|Two-way SMS|Pre-programmed SMS messages by partner track will be delivered twice weekly to participants in participants' preferred languages from enrollment to 6 months postpartum. They will include a question soliciting a response from the participant(s). Interactive SMS communication will be responded to and managed by the study nurse at each site. Content themes will include: general support/encouragement, postpartum visit reminders, postpartum pregnancy risk and benefits of birth spacing, postpartum contraceptive options and side effects, family planning misconceptions, and couple communication.
16574470|NCT02781714|No Intervention|Control|The control arm will receive standard education and counseling provided in antenatal care and in postnatal care.
16574471|NCT02781701|Experimental|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.
~Therefore, participants will work out about 20 minutes a day for 6 weeks."
16574472|NCT02781688|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks.
16574473|NCT02781675|Experimental|Western Diet|Dietary Intervention: 3 wks of a typical Western Diet
16574474|NCT02781675|Experimental|Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet
16574475|NCT02781675|Experimental|Modified Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet including full fat dairy products
16574476|NCT02781662|No Intervention|Control|No Intervention; Control Arm: Receives Written Medication Information
16574477|NCT02781662|Experimental|Intervention|Behavioral: Pharmacist Home-Visit
16574478|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
16574479|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
16574480|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
16574481|NCT02781636|Experimental|Chronic Tibial Implant Arm|StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
16574482|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
16574483|NCT02781610|Other|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
16574484|NCT02781610|Other|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
16574485|NCT02781610|Other|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
16574486|NCT02781610|Other|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
16574487|NCT02781597|Active Comparator|Tranexamic acid|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
16574488|NCT02781597|Placebo Comparator|Placebo|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
16574489|NCT02781584|Experimental|SEL (Cohort 1)|SEL (1 x 18 mg tablet) for 12 weeks
16574490|NCT02781584|Experimental|Firsocostat (Cohort 2)|"Firsocostat (2 x 10 mg capsules) for 12 weeks
~Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1."
16574491|NCT02781584|Experimental|Cilofexor (Cohort 3)|"Cilofexor (3 x 10 mg tablets) for 12 weeks
~Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2."
16574492|NCT02781584|Experimental|SEL+ Cilofexor(Cohort 4)|"SEL (1 x 18 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
~Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3."
16574493|NCT02781584|Experimental|SEL + Firsocostat(Cohort 5)|"SEL (1 x 18 mg tablet) + firsocostat (1 x 20 mg tablet) for 12 weeks
~Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4."
16574494|NCT02781584|Experimental|Firsocostat + Cilofexor(Cohort 6)|"Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
~Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5."
16574495|NCT02781584|Experimental|Firsocostat Cirrhotic (Cohort 7)|"Firsocostat (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)
~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
16574496|NCT02781584|Experimental|Cilofexor Cirrhotic (Cohort 8)|"Cilofexor (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)
~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
16574497|NCT02781584|Experimental|SEL + Firsocostat + Cilofexor (Cohort 9)|"SEL (1 x 18 mg tablet) + Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
~Enrollment into Cohort 9 will begin upon completion of enrollment for Cohort 6."
16574498|NCT02781584|Experimental|Firsocostat + Fenofibrate 48 mg (Cohort 10)|Pre-treatment with fenofibrate 48 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 48 mg tablet) for 24 weeks
16574499|NCT02781584|Experimental|Firsocostat + Fenofibrate 145 mg (Cohort 11)|Pre-treatment with fenofibrate 145 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 145 mg tablet) for 24 weeks
16574500|NCT02781584|Experimental|Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)|Pre-treatment with Vascepa® (2 x 1 g tablet twice daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + Vascepa® (2 x 1 g tablet twice daily) for 6 weeks
16574501|NCT02781584|Experimental|Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)|Pre-treatment with fenofibrate (1 x 145 mg tablet once daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + fenofibrate (1 x 145 mg tablet once daily) for 6 weeks
16574502|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
16574503|NCT02781558|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
16574504|NCT02781558|Experimental|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
16574505|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
16574506|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
16574507|NCT02781506|Experimental|Nivolumab and SABR|Nivolumab alone: IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.
16574508|NCT02781493|Experimental|Prucalopride group|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
16574509|NCT02781493|Placebo Comparator|Placebo group|2 mg Placebo plus 2 L Polyethylene Glycol regimen
16574991|NCT02778477|Placebo Comparator|Part A_Cohort 6_Placebo|Multiple dose of placebo
16574510|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
16574511|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
16574512|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
16574513|NCT02781467|Experimental|Cyclophosphamide + Fludarabine + PNK-007 + rhIL-2|Fludarabine Day -6 to -2 and Cyclophosphamide Day -5 and -4. On Day 0 PNK-007 at 4 varying dose levels followed by Human recombinant Interleukin-2 (rhIL-2) every other day, Day 0 to Day 10.
16574514|NCT02781454|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
16574515|NCT02781454|Active Comparator|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
16574516|NCT02781454|Placebo Comparator|Placebo|Placebo, by mouth per day for 4 weeks.
16574517|NCT02781441|Active Comparator|Control group|Patients will receive only the education brochure of GFM
16574518|NCT02781441|Experimental|General QPL group|Patients will receive the brochure and the newly developed QPL (general version)
16574519|NCT02781441|Experimental|Targeted QPL group|Patients will receive the brochure and the newly developed QPL (general version)
16574520|NCT02781415|Experimental|Acupuncture|Traditional Acupuncture Session:Patients in this group will benefit from a 30 minutes acupuncture session made by an experimented physician.
16574521|NCT02781415|Active Comparator|Titrated Morphine|Morphine Titration:Patients will receive an intravenous titration of morphine by a qualified nurse.
16574522|NCT02781402|Experimental|4 weeks of Aerobic Training for normal BMI group|4 weeks of aerobic training on treadmill 3 times per week.
16574523|NCT02781402|Experimental|4 weeks of Aerobic Training for overweight BMI group|4 weeks of aerobic training on treadmill 3 times per week.
16574524|NCT02781376|Experimental|CHICA-OSA|Two clinics will be randomized to receive the advanced CHICA-OSA computer decision support system designed to support PCPs in evidence-based identification and management of pediatric OSA. This module includes a snoring identification component (received by the control group).
16574525|NCT02781376|Other|Control|Two clinics will be randomized to receive a control computer decision support system module that automates screening for snoring and alerts the PCP, but does not provide any additional guidance on evidence-based diagnosis or management.
16574526|NCT02781363|Other|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
16574527|NCT02781363|Other|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
16574528|NCT02781350|Placebo Comparator|High fat high carbohydrate (HFHC) meal|Subjects will consume a HFHC meal. HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
16574529|NCT02781350|Experimental|HFHC meal plus Fiber|HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). Subjects will also receive FiberOne Original cereal 14 grams (half cup) before and after the HFHC meal. 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
16574530|NCT02781324|Experimental|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
16574531|NCT02781324|Active Comparator|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
16574532|NCT02781311|Experimental|Setipiprant|Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
16574533|NCT02781311|Placebo Comparator|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
16574534|NCT02781311|Active Comparator|Finasteride|Finasteride 1 mg tablet, orally, once daily for 24 weeks.
16574535|NCT02781298|Experimental|New Infant Cereal|amount ingested according to pediatricians recommendations
16574536|NCT02781298|Active Comparator|Multicereals Infant Cereal|amount ingested according to pediatricians recommendations
16574537|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
16574538|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
16574539|NCT02781285||3group three|patients take no Chinese Medicine
16574540|NCT02781272||Women with a pelvic mass|Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
16574541|NCT02781259|Experimental|Selective Lymph Node Dissection|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.
16574542|NCT02781246|Active Comparator|saline (Group A)|perineural ropivacaine
16574543|NCT02781246|Active Comparator|0.5 mcg/kg dexmedetomidine (Group B)|(perineural ropivacaine plus 0.5 mcg/kg dexmedetomidine),
16574544|NCT02781246|Active Comparator|1 mcg/kg dexmedetomidine (Group C)|(perineural ropivacaine plus 1 mcg/kg dexmedetomidine)
16574545|NCT02781246|Active Comparator|1.5 mcg/kg dexmedetomidine (Group D)|(perineural ropivacaine plus 1.5mcg/kg dexmedetomidine)
16574546|NCT02781246|Active Comparator|2 mcg/kg dexmedetomidine (Group E)|(perineural ropivacaine plus 2 mcg/kg dexmedetomidine)
16574547|NCT02781233|Experimental|Training group|Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
16574548|NCT02781233|Placebo Comparator|Control group|Usual daily activities
16574549|NCT02781220||Qualifying participants|All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
16574550|NCT02781194|Experimental|forced-air warming blanket|Forced-air warming blanket via 3M™ Bair Hugger™.
16574551|NCT02781194|Experimental|warmed, humidified insufflation|Warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
16574552|NCT02781194|Experimental|forced-air warming blanket & warmed, humidified insufflation|Combination of forced-air warming blanket via 3M™ Bair Hugger™ and warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
16574553|NCT02781181|Other|CAS with CPD|CAS performed under neuroprotection
16574554|NCT02781181|Active Comparator|CAS without CPD|CAS without neuroprotection
16574555|NCT02781168|Experimental|Use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
16574556|NCT02781168|Active Comparator|No use of earmuffs|No use of earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
16574557|NCT02781155|Other|Self administration of moxibustion|Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
16574558|NCT02781142|Experimental|Motor imagery training|Persons with multiple sclerosis
16574559|NCT02781142|No Intervention|Control group|Persons with multiple sclerosis
16574560|NCT02781142|No Intervention|Healthy controls|Healthy participants
16574561|NCT02781129|Experimental|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
16574562|NCT02781103|Experimental|Guided imagery plus active tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
16574563|NCT02781103|Sham Comparator|Guided imagery plus Sham tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
16574564|NCT02781090|Experimental|Positively Smoke Free on the Web+|Subjects will be assigned to the PSFW+ website and social network. They will also be offered a three-month supply of nicotine patches.
16574565|NCT02781090|Placebo Comparator|American Heart Assoc Getting Healthy|Subjects will be assigned to the AHA Getting Healthy website. They will also be offered a three-month supply of nicotine patches.
16574566|NCT02781064|Active Comparator|Atorvastatin 20mg|Atorvastatin to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
16574567|NCT02781064|Placebo Comparator|Placebo - Microcrystalline Cellulose|Placebo to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
16574568|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
16574569|NCT02781038|Experimental|Interventional|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given a teaching intervention and receive another attitude survey.
16574570|NCT02781038|Other|Control|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will receive another attitude survey.
16574571|NCT02781025||Oligometastatic Disease|Patients with oligometastatic cancer, defined as biopsy proven disease involving at least one organ other than the primary tumor organ. Regional lymph node metastases are not considered metastatic.
16574572|NCT02781012||Healthy|Healthy volunteers without any known pancreatic disease
16574573|NCT02781012||Healthy At-Risk|Healthy volunteers with no known benign or malignant pancreatic disease, AND with one first-degree relative with pancreatic cancer, OR two second-degree relatives with pancreatic cancer. These subjects also include those who have undergone surgery for suspected pancreatic cancer, and who are found to have a non-pancreatic cancer pathology upon final local site or central pathology review.
16574574|NCT02781012||Pancreatitis|Subjects diagnosed with acute or chronic pancreatitis
16574575|NCT02781012||Early Stage/Borderline/Locally Advanced|Subjects diagnosed with early stage pancreatic cancer who undergo surgery as standard of care therapy with or without preoperative (neoadjuvant) chemotherapy and/or radiation therapy; subjects diagnosed with borderline pancreatic cancer, or subjects diagnosed with locally advanced pancreatic cancer.
16574576|NCT02781012||Metastatic|Subjects diagnosed with metastatic pancreatic cancer and treated with any standard of care therapy/therapies.
16574577|NCT02780999|Experimental|Experimental group|It is a thumb orthotic that does not include wrist joint but includes the metacarpophalangeal joint.
16574578|NCT02780999|Active Comparator|Control group|It is a thumb orthotic that does not include wrist joint neither metacarpophalangeal joint.
16574579|NCT02780986|Active Comparator|Female entertainment worker intervention group|The intervention program for the female EE workers aims to increase STI/HIV prevention knowledge and develop their condom negotiation and application skills so as to increase condom use with both casual and paid partners. It consists of a total of 4 sessions: 2 on-site and 2 online sessions. For each on-site session, groups of 4 to 5 female EE workers will be gathered. The 2 on-site sessions would be delivered by peer educators. The 2 online sessions would be conducted via phone and other modes of network communication (e.g. SMS message or WhatsApp message) depending on the preference of each participant. In addition, all the intervention materials and video demonstrations will also be uploaded onto the web portal for the participant to access during their free time.
16574608|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
16574580|NCT02780986|No Intervention|Female entertainment worker control group|"The female EE workers in the control group will receive the same number of 2 onsite and 2 online sessions but covering healthy eating and physical activity.
~The following gives a summarised breakdown and content of each session:
~Session 1 (on-site immediately after baseline survey, 10 minutes):
~The peer educator will share information on healthy eating and physical activity using the educational pamphlets from the Health Promotion Board (HPB) with the participants.
~Session 2 (online 1-2 weeks after baseline survey, 5 minutes):
~The peer educator will share an app on healthy eating with the participants.
~Session 3 (online 3-4 weeks after baseline survey, 5 minutes):
~The peer educator will share an app on physical activity with the participants.
~Session 4 (onsite during follow-up survey, 10 minutes):
~The peer educator will reinforce information on healthy eating and physical activity based on the educational pamphlets from HPB with the participants."
16574581|NCT02780986|Active Comparator|Heterosexual men intervention group|The intervention program for heterosexual men patronising EEs will be a holistic non disease-centric, non-stigmatising and non-judgemental program addressing sexual well-being, avoidance of casual and paid sex if possible and safe sex such as condom use.
16574582|NCT02780986|No Intervention|Heterosexual men control group|There will be a simultaneous programme on healthy eating and physical activity at the control site at Tanjong Pagar. Health promoters will go around Tanjong Pagar and distribute pamphlets and brochures developed by the HPB on healthy eating and physical activity to the heterosexual men who step into or out of the EEs there. These health promoters have been trained to give simple health advice on healthy eating and physical activity if the heterosexual men wish to find out more information.
16574583|NCT02780973||Females|Female volunteers
16574584|NCT02780973||Males|Male volunteers
16574585|NCT02780960|Experimental|HPV self-testing|Patients will perform HPV self-testing at home, prior to their follow-up visit. At the colposcopy visit, the doctor or nurse will also perform HPV testing. This procedure will be repeated at 6 and 12 months following LEEP.
16574586|NCT02780947|Active Comparator|Prophylactic substrate ablation group|Prophylactic substrate ablation group will undergo substrate mapping and ventricular tachycardia substrate ablation
16574587|NCT02780947|No Intervention|Control group|Control group will undergo substrate mapping
16574588|NCT02780934|Active Comparator|Pressure Dressing|Participants randomized to this group will receive the standard post-operative dressing following their Mohs procedure: a pressure dressing consisting of high absorbency gauze and retention tape.
16574589|NCT02780934|Experimental|Simple Adhesive Dressing|Participants randomized to this group will receive the experimental post-operative dressing following their Mohs procedure: a simple adhesive dressing consisting of a non-adherent pad and transparent dressing.
16574590|NCT02780921|Experimental|Prehab Group|In the experimental group (Prehab group) compared to the control group, the main objective will be to demonstrate an improvement of the percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board
16574591|NCT02780921|Other|control group|The control group will be treated according to conventional care; will not receive any specific intervention before surgery except nutritional support and physiotherapy at the surgeon's discretion
16574592|NCT02780908|Experimental|Hypoxia at rest and exercise|The participants will perform a resting test, hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in normoxic condition ((HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m)
16574593|NCT02780908|Placebo Comparator|Normoxia at rest and exercise|The participants will perform a resting test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo)
16574594|NCT02780895|Experimental|Single Arm Study|stereotactic brain surgery of human stem cells (OK99)
16574595|NCT02780882|Experimental|Pasireotide|Each patient will be treated with pasireotide at an initial dose of 600 μg twice daily for one month. The dose will be further increased to 900 μg twice daily for month 2 and 3. After month 3, patients who continue to meet the inclusion and exclusion criteria will be entered into an additional 3 months of treatment.
16574596|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
16574597|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
16574598|NCT02780856|Other|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
16574599|NCT02780843|Experimental|Computerized Tomography|Patients will be examined with Computerized Tomography (CT) at admission
16574600|NCT02780843|Experimental|Magnetic Resonance Imaging|Patients will be examined with Magnetic Resonance Imaging (MRI) at admission
16574601|NCT02780830|Experimental|AZD2014 plus Ibrutinib Combination|AZD2014 and ibrutinib will be dosed together in the morning under fasting conditions. When possible, the morning doses of AZD2014 and ibrutinib should be taken at approximately the same time each day. The morning doses must be taken in a fasted state (water to drink only) from at least 2 hours prior to the dose to at least 1 hour post dose. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
16574602|NCT02780817|Experimental|Error enhancement|Arm reaching rehabilitation training with error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
16574603|NCT02780817|Other|Control group|Arm reaching rehabilitation training without error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
16574604|NCT02780804|Experimental|Treatment (entinostat)|Patients receive entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
16574605|NCT02780791|Active Comparator|Transplantation into pelvic wall|Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
16574606|NCT02780791|Active Comparator|Transplantation into the ovary|Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies
16574607|NCT02780778|Experimental|Treatment group|Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w
16574874|NCT02779140|Experimental|0.033 mg/kg NTM-1632|N=6 administered 0.033 mg/kg NTM-1632 IV, N=2 administered placebo IV
16574875|NCT02779140|Experimental|0.165 mg/kg NTM-1632|N=6 administered 0.165 mg/kg NTM-1632 IV, N=2 administered placebo IV
16574609|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
16574610|NCT02780752|Active Comparator|Oral hymecromone 400mg po three times per day|Participants will be administered oral hymecromone 400mg po three times per day (1200 mg)
16574611|NCT02780752|Active Comparator|Oral hymecromone 800 mg po three times per day (2400 mg)|Participants will be be administered oral hymecromone 800 mg po three times per day (2400 mg)
16574612|NCT02780752|Active Comparator|Oral hymecromone 1200 mg three times per day (3600 mg)|Participants will be administered oral hymecromone 1200 mg three times per day (3600 mg)
16574613|NCT02780739|Experimental|Cognitive Training - 48 sessions|56 hours of video game training with Mind Frontiers adaptive cognitive training software (48 70-min sessions distributed over 16 weeks)
16574614|NCT02780739|Experimental|Fitness, Cognitive Training, sham tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers adaptive cognitive training software with simultaneous sham tDCS (20 70-min sessions distributed over weeks 5-16)
16574615|NCT02780739|Experimental|Fitness, Cognitive Training, active tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers 1.0 adaptive cognitive training software with simultaneous active tDCS for a total of 10 hrs (20 70-min sessions distributed over weeks 5-16)
16574616|NCT02780739|Active Comparator|Active Control|56 hours of video game training with visual search and change detection tasks using open sesame software (48 70-min sessions distributed over 16 weeks)
16574617|NCT02780739|No Intervention|No Contact Control|Completed no study activities for 16 weeks after pre-assessment, then returned for post-assessment
16574618|NCT02780726|Experimental|ASP1517 Low Dose Group (ESA Untreated)|This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.
16574619|NCT02780726|Experimental|ASP1517 High Dose Group (ESA Untreated)|This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
16574620|NCT02780726|Experimental|ASP1517 ESAs Treated Group|This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
16574621|NCT02780713|Experimental|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.
~Treatment period 1 will assess AZD9496 Variant A: 100mg.
~Treatment period 2 will assess AZD9496 Reference: 100mg.
~Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.
~Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.
~Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
16574622|NCT02780700|Experimental|Nintedanib|
16574623|NCT02780700|Experimental|Nintedanib plus capecitabine|
16574624|NCT02780687|Experimental|Afatinib|
16574625|NCT02780674|Active Comparator|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
16574626|NCT02780674|Placebo Comparator|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
16574627|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
16574628|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
16574629|NCT02780648|Experimental|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
16574630|NCT02780635|Experimental|App + Couples Coach Intervention|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse. Those assigned to this arm will also receive mailed materials that are designed to help increase positive communication strategies.
16574631|NCT02780635|Active Comparator|App Alone|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse.
16574632|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
16574738|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
16574633|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
16574634|NCT02780609|Experimental|Selinexor Plus HDM HCT|The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.
16574635|NCT02780596|Experimental|Items1;3|Caregiver is randomly assigned to receive screening items 1 and 3. Item 1: Does CHILD NAME often wake one or more times during the night? Item 3: Do you think CHILD NAME's sleep is a problem?
16574636|NCT02780596|Experimental|Items1;4|Caregiver is randomly assigned to receive screening items 1 and 4. Item 1: Does CHILD NAME often wake one or more times during the night? Item 4: Does you think CHILD NAME has a sleep problem?
16574637|NCT02780596|Experimental|Items1;5|Caregiver is randomly assigned to receive screening items 1 and 5. Item 1: Does CHILD NAME often wake one or more times during the night? Item 5: Do you have any concerns about CHILD NAME's sleep?
16574638|NCT02780596|Experimental|Items2;3|Caregiver is randomly assigned to receive screening items 2 and 3. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 3: Do you think CHILD NAME's sleep is a problem?
16574639|NCT02780596|Experimental|Items2;4|Caregiver is randomly assigned to receive screening items 2 and 4. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 4: Does you think CHILD NAME has a sleep problem?
16574640|NCT02780596|Experimental|Items2;5|Caregiver is randomly assigned to receive screening items 2 and 5. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 5: Do you have any concerns about CHILD NAME's sleep?
16574641|NCT02780596|Experimental|Items3;5|Caregiver is randomly assigned to receive screening items 3 and 5. Item 3: Do you think CHILD NAME's sleep is a problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
16574642|NCT02780596|Experimental|Items4;5|Caregiver is randomly assigned to receive screening items 4 and 5. Item 4: Does you think CHILD NAME has a sleep problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
16574643|NCT02780583|Placebo Comparator|placebo|methylprednisolone intravenously, placebo shots every 6 hours
16574644|NCT02780583|Experimental|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
16574645|NCT02780570|Active Comparator|GBS patients|Small Volume Plasma Exchange
16574646|NCT02780570|No Intervention|non-GBS|non-GBS patients with central venous catheter
16574647|NCT02780557|Experimental|Contingent Reading Intervention|
16574648|NCT02780557|Other|Book Provision Control|
16574649|NCT02780544|Experimental|skin-to-skin contact + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in skin-to-skin position with a parent (intervention group) and one in the incubator (standard care). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination.
16574650|NCT02780544|Active Comparator|incubator + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in the incubator (standard care) and one in skin-to-skin position with a parent (intervention group). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination
16574651|NCT02780518|Experimental|Airvo|All patients scheduled for elective microlaryngeal surgery under general anaesthesia and subglottic high frequency jet ventilation
16574652|NCT02780505|Active Comparator|vitamin c|vitamin C supplement orally up to 250 mg per day for 6 weeks was prescribed. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study.
16574653|NCT02780505|Placebo Comparator|placebo|ُPlacebo prescribed to Group B. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study
16574654|NCT02780492||Ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
16574655|NCT02780492||Non-ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
16574656|NCT02780492||Healthy volunteers and Disease controls|A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
16574657|NCT02780479|Experimental|Dexamethasone|Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
16574658|NCT02780479|Active Comparator|Prednisone|Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
16574659|NCT02780466||Patients with septic shock|
16574660|NCT02780453|Experimental|Negative pressure dressing|Negative pressure dressing
16574661|NCT02780453|Active Comparator|Standard dressing|Standard wound dressing
16574662|NCT02780440||Control Group|Subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program.
16574663|NCT02780440||Experimental Group 1|Subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program
16574664|NCT02780440||Experimental Group 2|Subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.
16574665|NCT02780427|Active Comparator|1-6 months (Group 1)|
16574666|NCT02780427|Active Comparator|7-12 months (Group 2)|
16574667|NCT02780427|Active Comparator|13-18 months (Group 3)|
16574668|NCT02780427|Active Comparator|19-24 months (Group 4)|
16574669|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
16574670|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
16574671|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
16574672|NCT02780388|Placebo Comparator|Placebo|Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
16574673|NCT02780388|Experimental|VIB4920 75 mg|Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
16574674|NCT02780388|Experimental|VIB4920 500 mg|Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
16574675|NCT02780388|Experimental|VIB4920 1000 mg|Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
16574676|NCT02780388|Experimental|VIB4920 1500 mg|Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
16574677|NCT02780375||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
16574678|NCT02780362|Experimental|A Test|Test drug (Prodactariv)1 tablet contains 60 mg Daclatasvir
16574679|NCT02780362|Active Comparator|B Reference|Reference drug (Clatazev) 1 tablet contains 60 mg Daclatasvir
16574680|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
16574681|NCT02780336||Blepharospasm (BL)|Participants in this group should be diagnosed with blepharospasm, but may have dystonia in other body parts as well.
16574682|NCT02780336||Disease Control Group|Participants in this group should be diagnosed with a disorder affecting their eyes or face, such as hemifacial spasm, facial tics, or apraxia.
16574683|NCT02780336||Normal Control Group|Participants in this group should not have any neurologic problems or other disorders affecting patients eyes or face.
16574684|NCT02780323|Experimental|CELBESTA® and CELEBREX® placebo|CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks
16574685|NCT02780323|Active Comparator|CELEBREX®|CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks
16574686|NCT02780310|Experimental|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
16574687|NCT02780297||Primary Hyperoxaluria Patients|Patients with confirmed diagnosis of Primary Hyperoxaluria.
16574688|NCT02780297||Dent Disease Patients|Patients with confirmed diagnosis of Dent Disease.
16574689|NCT02780297||Cystinuria Patients|Patients with confirmed diagnosis of Cystinuria.
16574690|NCT02780297||APRT deficiency Patients|Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
16574691|NCT02780297||Lowe Syndrome or Dent 2 patients|Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
16574692|NCT02780297||Dent 1 carriers|Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
16574693|NCT02780297||Enteric Hyperoxaluria Patients|Patients with confirmed diagnosis enteric hyperoxaluria.
16574694|NCT02780284|Experimental|Physical activity intervention|Observation phase of usual activity and an intervention phase of regular physical activity
16574695|NCT02780271|Experimental|Arm A|Subjects will receive in-person education plus e-communication AND subjects will receive control intervention
16574696|NCT02780271|Experimental|Arm B|Subjects will receive e-communication alone AND subjects will receive control intervention
16574697|NCT02780271|Experimental|Arm C|Subjects will receive in-person education alone AND subjects will receive control intervention
16574698|NCT02780271|Active Comparator|Arm D|Subjects will receive control intervention
16574699|NCT02780258|Experimental|Restylane Silk Treated Hand|The dorsal aspect of one hand will be injected with Restylane Silk.
16574700|NCT02780258|No Intervention|Control Hand|The dorsal aspect of the hand that is not treated will be used for baseline comparison.
16574701|NCT02780245|Experimental|Group (X) Prophylactic Tranexamic Acid|Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
16574702|NCT02780245|Experimental|Group (Y) Intraoperative Uterine Cooling|Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].
16574703|NCT02780232|Experimental|Internet-based program|"Adolescents in the intervention will receive a tailored online program during 3 months.
~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links."
16574704|NCT02780232|No Intervention|Treatment as usual|-Waiting list control group.
16574705|NCT02780219|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
16574706|NCT02780219|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
16574769|NCT02779868|Experimental|Omega-3|Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
16574770|NCT02779868|Placebo Comparator|Olive oil|Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
16574876|NCT02779140|Experimental|0.33 mg/kg NTM-1632|N=6 administered 0.33 mg/kg NTM-1632 IV, N=2 administered placebo IV
16574707|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
16574708|NCT02780180|Experimental|QGC001|QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
16574709|NCT02780180|Placebo Comparator|Placebo|Placebo, capsule twice daily, for 28 days, oral use
16574710|NCT02780167|Experimental|Cohort 1|10 mg of PF-04965842 QD
16574711|NCT02780167|Experimental|Cohort 2|30 mg of PF-04965842 QD
16574712|NCT02780167|Experimental|Cohort 3|100 mg of PF-04965842 QD
16574713|NCT02780167|Experimental|Cohort 4|200 mg of PF-04965842 QD
16574714|NCT02780167|Placebo Comparator|Cohort 5|placebo QD
16574715|NCT02780154|Experimental|1600 7G8 PfSPZ|N= 7-9 participants will receive 1600 7G8 PfSPZ DVI in a volume of 500mcL
16574716|NCT02780154|Experimental|3200 7G8 PfSPZ|N= 9 participants will receive 3200 7G8 PfSPZ DVI in a volume of 500mcL
16574717|NCT02780154|Experimental|3200 NF54 PfSPZ|N= 5-6 participants will receive 3200 NF54 PfSPZ DVI in a volume of 500mcL
16574718|NCT02780154|Experimental|4800 7G8 PfSPZ|N= 2-3 participants will receive 4800 7G8 PfSPZ DVI in a volume of 500mcL
16574719|NCT02780154|Experimental|800 7G8 PfSPZ|N= 7-9 participants will receive 800 7G8 PfSPZ DVI in a volume of 500mcL
16574720|NCT02780141|Experimental|ASP1517 Low dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
16574721|NCT02780141|Experimental|ASP1517 High dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
16574722|NCT02780128|Other|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
16574723|NCT02780128|Experimental|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.
~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.
~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
16574724|NCT02780115|Experimental|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
16574725|NCT02780115|Experimental|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
16574726|NCT02780115|Experimental|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
16574727|NCT02780115|Experimental|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
16574728|NCT02780115|Experimental|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
16574729|NCT02780102|Experimental|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR): 20 sixty-minute sessions of cognitive-motor rehabilitation
16574730|NCT02780102|Experimental|Ritalin|2 to 3 doses of 10 mg Ritalin tablets per day during 8 week.
16574731|NCT02780102|Active Comparator|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
16574732|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
16574733|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
16574734|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
16574735|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
16574736|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
16574737|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
16574918|NCT02778867|Active Comparator|6-Food Elimination Diet (6FED)|Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
16574739|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
16574740|NCT02780076|Experimental|Functional training group|Participation in a functional training program in addition to usual care. The functional training program is initiated by the nurses and consists of walking, sit-to-stands, balance training, weight transfer training, knee squats. The program is performed 4 times a day for 3 weeks while at short-term stays.
16574741|NCT02780076|No Intervention|Control group|Usual care only. No participation in the functional training program while at short-term stays.
16574742|NCT02780063|Experimental|Lenstar Biometry|Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
16574743|NCT02780050|No Intervention|chest compression before physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.
~2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). Researchers record subject's chest compression depth and rate in 1st chest compression."
16574744|NCT02780050|Experimental|after core muscle activation using physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.
~After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.
~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 2nd chest compression."
16574745|NCT02780037|Experimental|Prevention|Regulatory frame: prevention
16574746|NCT02780037|Experimental|Promotion|Regulatory frame: promotion
16574747|NCT02780037|Sham Comparator|Neutral|Regulatory frame: not implied
16574748|NCT02780024|Experimental|Registered one arm study|Two weeks of neo-adjuvant Metformin+Temozolomide followed by accelerated hypofractionation using an IMRT technique+TMZ & Metformin followed by TMZ, and Metformin as adjuvant component.
16574749|NCT02780011|Experimental|Alsertib and Brentuximab Vedotin|Brentuximab vedotin at a fixed dose of 1.8 mg/kg will be administered by intravenous infusion on day 1 of every 21-day cycle. MLN8237 at a dose of 60 mg will be orally administered daily in 2 divided doses (30 mg qAM, 30 mg qPM) from days 1 to 7 of each 21-day cycle. MLN8237 dose will be escalated in 20-mg increments to the maximum dose of 100 mg (Level 2) or de-escalated in a 20-mg decrement to the minimum dose of 40 mg (Level -1).
16574750|NCT02779998|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute in order to maintain peripheral oxygen saturation (SpO2) above 94% during electrophysiology procedure under light sedation.
16574751|NCT02779998|Experimental|non invasive ventilation|non invasive ventilation (NIV) which associated positive end expiratory pressure (PEEP: 5 to 10 cmH2O) and pressure support ventilation (PSV: 5 to 15 cmH2O, to achieve total Pressure bellow 20cmH2O) will be delivered during electrophysiology procedure under light sedation. The patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
16574752|NCT02779985|Experimental|Lycium Barbarum mixed meal|Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
16574753|NCT02779985|Active Comparator|Control mixed meal|Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
16574754|NCT02779972||60's decade|60's decade Echo stress test
16574755|NCT02779972||70's decade|70's decade Echo stress test
16574756|NCT02779972||80's decade|80's decade Echo stress test
16574757|NCT02779959|Experimental|Buccal Prochlorperazine|Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline
16574758|NCT02779959|Active Comparator|Intravenous Prochlorperazine|Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
16574759|NCT02779946||CHD-positive|positive tested for coronary artery disease
16574760|NCT02779946||CHD-negative|negative tested for coronary artery disease
16574761|NCT02779920|Experimental|Per oral pylorotomy|Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
16574762|NCT02779907||Study Population|Children aged 4-6 years resident in Chikwawa District.
16574763|NCT02779894|No Intervention|Hospital group|Patients referred to the sleep unit and randomized to Hospital group. Participants will be diagnosed in the hospital either by Polysomnography , Respiratory Polygraphy or one night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the titration and adjustment of patient's will be accomplished at the hospital. This patient's will be monitored during 3 months of the study at the hospital.
16574764|NCT02779894|Other|ICT group|Patients referred to the sleep unit and randomized to intervention group. Participants will be diagnosed at home by 3 night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the adjustment will be performed at the CPAP supplier center, titration will be performed at home and patient's compliance and treatment will be controlled via remote. During the 3 months of the study patient's will be controlled via phono/video conferences and with a platform designed for the study.
16574765|NCT02779881||Healthy controls|Healthy controls
16574766|NCT02779881||Children at diagnosis of cow's milk allergy|Children at diagnosis of cow's milk allergy
16574767|NCT02779881||Subjects outgrown cow's milk allergy with formula+probiotic|Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
16574768|NCT02779881||Subjects outgrown cow's milk allergy assuming other formulas|Subjects tolerant with other formulas
16574772|NCT02779842|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16574773|NCT02779829|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16574774|NCT02779816|Experimental|Intervention (pen device)|Subjects will use the pen device when using their commercially available insulin pens
16574775|NCT02779816|No Intervention|Control|Subjects will use the commercially available insulin pens only (no adaptive pen device).
16574776|NCT02779777|Experimental|Tipifarnib, Oral|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
16574777|NCT02779764|Experimental|ASP1517 Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
16574778|NCT02779751|Experimental|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16574779|NCT02779751|Experimental|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16574780|NCT02779751|Experimental|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16574781|NCT02779751|Experimental|HR+, HER2- Locally Advanced or Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16574782|NCT02779738|Experimental|Merestinib Fasted|Single dose of merestinib administered in fasted state in one of three periods
16574783|NCT02779738|Experimental|Merestinib Standard Meal|Single dose of merestinib administered with a standard meal in one of three periods
16574784|NCT02779738|Experimental|Merestinib High-Fat Meal|Single dose of merestinib administered with a high-fat meal in one of three periods
16574785|NCT02779725|Active Comparator|Group 1 SCC/SSR|This arm includes self-care coaching (SCC) message during daily self-reported symptom severity report (SSR) calls to the automated system.
16574786|NCT02779725|Active Comparator|Group 2 NP/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. These alerts are monitored and follow-up care is given by a nurse practitioner.
16574787|NCT02779725|Active Comparator|Group 3 NP/DSS/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. Nurse practitioner follow-up calls utilize the evidenced based SCH decision support system (DSS) when symptoms exceed alert thresholds
16574788|NCT02779725|Active Comparator|Group 4 Full Intervention SSR/SCC/NP/DSS|Complete intervention with all components used in prior efficacy study (Symptom Severity Report (SSR)+Self Care Coaching (SCC) +Nurse Practitioner (NP) +Decision Support System (DSS))
16574789|NCT02779725|Active Comparator|Group 5 SSR/SCC/AT|Symptom severity reporting (SSR), automated self-care coaching (SCC) based on daily symptom reporting plus activity tracker (AT)
16574790|NCT02779712|Active Comparator|Remote Ischaemic Conditioning|Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (20mmHg above systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
16574791|NCT02779712|Sham Comparator|Control|Control: 4 cycles of alternating 5 minutes inflation (up to 30 mmHg) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
16574792|NCT02779699|Experimental|AL2846|AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16574793|NCT02779686||ARMD Free|Patient free of ARMD on clinical examination
16574794|NCT02779686||ARMD Positive|Patients with evidence of ARMD on clinical examination
16574795|NCT02779673|Experimental|Test group|Subjects randomized to the test group consumed yoghurt drink containing 3.4g plant stanol as ester for 1 per day for a period of 4 weeks.
16574796|NCT02779673|Placebo Comparator|Placebo group|Subjects randomized to the placebo group consumed yoghurt drink without plant stanol as ester for 1 per day for a period of 4 weeks.
16574797|NCT02779660|Experimental|RIPC-Group|After randomization patients will undergo 3 sessions of RIPC (Remote ischemic preconditioning) intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
16574798|NCT02779660|Placebo Comparator|Control-Group|After randomization patients will undergo 3 sessions of sham-intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
16574799|NCT02779647|Experimental|Study group|Consisting of 49 children who were recommended a programme of physical activity, play and nutritional advice, for both the children and their parents
16574800|NCT02779647|No Intervention|Control group|49 children, who received only nutritional advice
16574801|NCT02779634|Placebo Comparator|Placebo|Placebo three times daily
16574802|NCT02779634|Active Comparator|Active|Pills of 100 mg ubiquinol three times daily
16574803|NCT02779621|Experimental|Self-sampling|(Self-collecting a vaginal sample with a swab for HPV testing) Women in the experimental arm will have the option of vaginal self-sampling for HPV testing, in addition to the routine screening test. They can choose one of them.
16574804|NCT02779621|Active Comparator|Routine smear|(Collection of cervical sample for routine cervical screening) Women in the control arm will only receive the routine cervical screening invitation letter.
16574877|NCT02779127|Other|Intervention|"Subjects exposed to passive smoking at least 1 hour per day since 1 year, non active smokers, non exposed to passive smoking at home
~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
16574805|NCT02779608|Experimental|intraperitoneal docetaxel and oral S-1|"Docetaxel is diluted in 1litre normal saline and administered intraperitoneal（IP）at a dose of 60 mg/m2 over 1 hour on day 1. S-1 was administered orally twice daily at a dose of 40mg/m2 per day for 14 consecutive days, followed by 7 days of rest.
~Intervention: Drug: Intraperitoneal docetaxel Intervention：Drug：Oral S-1"
16574806|NCT02779595||Lung surgery|26 patients (up to 36) undergoing lung surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
16574807|NCT02779595||Flail chest|8 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
16574808|NCT02779582|Experimental|Progesterone|Oral micronized progesterone, 300 mg po daily, taken as three capsules daily before sleep for three months
16574809|NCT02779582|Placebo Comparator|Placebo|Placebo, each taken as three capsules daily before sleep for three months
16574810|NCT02779569|Experimental|Ultra-low-dose group|decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
16574811|NCT02779569|Active Comparator|Low-dose group|decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
16574812|NCT02779556|Other|Enhanced Usual Care|ADA Living Well with Diabetes Workbook, 15 minute in-person counseling, follow-up every 3 months
16574813|NCT02779556|Other|Intervention|ACP Living with Diabetes Guide, 15 minute in-person counseling , 15 minute follow-up counseling (3, 6, and 9 months), monthly phone calls after 3 months
16574814|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
16574815|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
16574816|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
16574817|NCT02779530|Experimental|Diclofenac|
16574818|NCT02779530|Placebo Comparator|Placebo|
16574819|NCT02779517||Focus groups- Patients|Subjects with or without an upper extremity disability will be asked to observe and interact with the mobile service robot.
16574820|NCT02779517||Focus Groups-clinicians|Clinicians with neuro-rehab experience.
16574821|NCT02779504||Agluna treated METS|Patient implanted with Agluna treated METS
16574822|NCT02779504||Untreated METS|Patient implanted with untreated METS
16574823|NCT02779491|Experimental|Intervention for two weeks|Receipt of the mobile phone application for two weeks
16574824|NCT02779491|No Intervention|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
16574825|NCT02779491|Experimental|Intervention for four weeks|Receipt of the mobile phone application for four weeks
16574826|NCT02779491|No Intervention|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
16574829|NCT02779465|Experimental|Vitamin D|Drug: Vitamin D3 800 IU daily besides the anti-virus treatment with nucleos(t)ide medicine
16574830|NCT02779465|No Intervention|Control|chronic hepatitis B patients with long term anti-virus therapy
16574831|NCT02779452||GDM newborns|Newborns from gestational diabetes mellitus pregnancy
16574832|NCT02779452||No GDM newborns|Newborn from a normal pregnancy
16574833|NCT02779439|Experimental|3rd party CTL infusion|Virus specific CTLs
16574834|NCT02779426|Experimental|Text Message Intervention + Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution as well as daily text messages with information about atopic dermatitis and treatment reminders. 1-2 times/week they will receive a message asking if they were able to complete their treatments in the last day. They will respond with 1=yes, 2=no, 3= I have questions about the treatment. Those who respond with 3 will be sent the contact information for the office. No other communications will be sent through text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
16574878|NCT02779127|Other|Control|"Subjects non expose to passive smoking at home or at work, non active smokers
~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
16574835|NCT02779426|No Intervention|Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution. They will not receive text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
16574836|NCT02779413||Insulin degludec|
16574837|NCT02779400|Experimental|Evaluation of the device perfomance|
16574838|NCT02779387|Experimental|GnRH-a|"patients treated with GnRH-a after surgery and Outpatient guidance
~."
16574839|NCT02779387|No Intervention|non GnRH-a|patients treated with outpatient guidance only.
16574840|NCT02779374|Experimental|Autologous bone marrow transplantation|autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up
16574841|NCT02779361|Experimental|Green tea|Green tea consumption along 7 days.
16574842|NCT02779348|Experimental|Nebicapone plus warfarin|BIA 3-202 200 mg tid + Warfarin 25 mg
16574843|NCT02779348|Experimental|Warfarin|Warfarin 25 mg
16574844|NCT02779335|Other|Enteral formula tube feeding|Enteral fed children, ages 1-13, with establish enteral feeding access
16574845|NCT02779322|Active Comparator|Minigastric bypass|Intervention(s): The patient will have done a Laparoscopic one anastomosis gastric bypass (minigastric bypass) at the time of the surgical procedure.
16574846|NCT02779322|Active Comparator|Gastric bypass|The patient will have a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
16574847|NCT02779309||Development Cohort|437,000 home care recipients who received services from January 1, 2007 to December 31, 2012.
16574848|NCT02779309||Validation Cohort|122,000 home care recipients who received services from January 1, 2013 to December 31, 2013.
16574849|NCT02779296|Experimental|2-Octyl Cyanoacrylate Glue|At the surgical site, a thin layer of cyanoacrylate glue will be applied over the sutures at the time of closure.
16574850|NCT02779296|No Intervention|No Glue|No cyanoacrylate glue will be applied.
16574851|NCT02779283|Experimental|Arm I (AML)|Patients receive cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 30 minutes on days 1-3.Patients receive cyclophosphamide IV over 3 hours twice daily (BID) on days 1-3, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV on day 4, dexamethasone PO on days 1-4 and 11-14, and rituximab IV on day 1 and 11 (day 11 only of course 1). Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
16574852|NCT02779283|Experimental|Arm II (ALL)|Patients receive cytarabine IV over 2 hours BID on days 2-3, methotrexate IV over 2-22 hours on day 1, methylprednisolone sodium succinate IV BID on days 1-3, leucovorin calcium IV every 6 hours until methotrexate level is < 0.05 uM and rituximab IV on days 1 and 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
16574853|NCT02779270|Experimental|BAY987518|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
16574854|NCT02779270|Active Comparator|Sunscreen control|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
16574855|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
16574856|NCT02779244|Experimental|Early Weight Bearing + Cam boot|
16574857|NCT02779244|Active Comparator|Standard Treatment Cam boot|
16574858|NCT02779231|Experimental|Texting group|This group will be enrolled in bi-directional texting to send back blood pressure.
16574859|NCT02779231|No Intervention|Standard of care group|
16574860|NCT02779218|Experimental|Sequence 1|"The patients will receive in order :
~Paired Associative Stimulation
~Paired Associative Stimulation + Motor Imagery exercises
~Placebo Paired Associative Stimulation + Motor Imagery exercises"
16574861|NCT02779218|Experimental|Sequence 2|"The patients will receive in order :
~Paired Associative Stimulation + Motor Imagery exercises
~Placebo Paired Associative Stimulation + Motor Imagery exercises
~Paired Associative Stimulation"
16574862|NCT02779218|Experimental|Sequence 3|"The patients will receive in order :
~Placebo Paired Associative Stimulation + Motor Imagery exercises
~Paired Associative Stimulation
~Paired Associative Stimulation + Motor Imagery exercises"
16574863|NCT02779205|Other|0-1 year old child|Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
16574864|NCT02779205|Other|>1-10 year old child|Adipose tissue sample in >1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
16574865|NCT02779192|Active Comparator|SPI-1005 200 mg|200 mg SPI-1005, capsule, bid, po, x7d
16574866|NCT02779192|Active Comparator|SPI-1005 400 mg|400 mg SPI-1005, capsule, bid, po, x7d
16574867|NCT02779192|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, bid, po, x7d
16574868|NCT02779179|Experimental|Immediate Periodontal treatment group|
16574869|NCT02779179|Active Comparator|Delayed Periodontal treatment Group|
16574870|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
16574871|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
16574872|NCT02779153|Experimental|Acthar low dose (40 U)|
16574873|NCT02779153|Experimental|Acthar high dose (80 U)|
16574879|NCT02779114|Other|Control group|After 1:1:1 randomization patients in the control group receive their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during 12 months of the study.
16574880|NCT02779114|Other|Reduction group 1|Patients in reduction group 1 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
16574881|NCT02779114|Other|Reduction group 2|Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
16574882|NCT02779101|Experimental|Single arm|pembrolizumab
16574883|NCT02779088|Experimental|Early exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the AB arm receive exercise and nutrition intervention first, followed by the education course.
16574884|NCT02779088|Active Comparator|Delayed exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the BA arm receive the education course first, followed by exercise and nutrition.
16574885|NCT02779075|Placebo Comparator|Saline|0.9% NaCL (saline) intravenously for 6 hours.
16574886|NCT02779075|Active Comparator|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
16574887|NCT02779049||MAC-LD|patients with MAC-LD Do Blood examination
16574888|NCT02779049||Control|controls without NTM or tuberculosis infection Do Blood examination
16574889|NCT02779049||Tuberculosis infection|patients with tuberculosis infection which diagnosis by culture or typical pathology Do Blood examination
16574890|NCT02779049||MAC colonization|patients with MAC pulmonary colonization by American Thoracic Society guideline Do Blood examination
16574891|NCT02779036|Experimental|Task-oriented Exercise|Structured, progressive, task-oriented, home exercise program
16574892|NCT02779036|Active Comparator|Usual Care|Usual Physiotherapy Care
16574893|NCT02779023|Experimental|ICHP + CBT-I|Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
16574894|NCT02779023|No Intervention|ICHP Only|Participants in this arm will receive the usual care (ICHP program).
16574895|NCT02779010|Experimental|Hand washing with soap|Hand washing with soap and health education every 2 weeks for 6 months
16574896|NCT02779010|No Intervention|Books and pens|Books and pens for every 2 months for 6 months
16574897|NCT02778984|Active Comparator|standard face masks|The standard mask is used in usual care
16574898|NCT02778984|Experimental|QuadraLite face masks|This study will compare tightness of 2 face masks during preoxygenation and after induction of anesthesia with propofol, sufentanil and rocuronium. During preoxygenation, a 10 l.min-1 fresh gas flow and 8 cm H2O PEEP will be applied. After induction of anesthesia, patients will receive pressure-controlled ventilation (fresh gaz flow 3 L.min-1, pressure set to obtain a 7 ml.kg-1 ideal body weight, 10 cpm, peep 5 cm H2O).
16574899|NCT02778971||Qualifying participants|All consented participants referred by a dementia expert physician to receive an amyloid PET scan with [18F]Flutametamol and meeting eligibility criteria will have visual and semi-quantitative software aided scan interpretation, complete care partner questionnaires and providers will document diagnosis, diagnostic confidence, and management plan before and after the scan.
16574900|NCT02778958|Experimental|ibuprofen and morphine|iv ibuprofen 800 mg infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
16574901|NCT02778958|Active Comparator|paracetamol and morphine|iv paracetamol 1 gram infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
16574902|NCT02778945|Experimental|Group D (Deep NMB group)|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
16574903|NCT02778945|Active Comparator|Group I (Intermediate NMB group)|Use NMB as conventional clinical usage Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
16574904|NCT02778932||Intubation|General anesthesia including intubation and muscle relaxation
16574905|NCT02778932||Laryngeal Mask|General anesthesia including laryngeal mask without muscle relaxation
16574906|NCT02778919|Experimental|KLH-2109, lowest dose|
16574907|NCT02778919|Experimental|KLH-2109, low dose|
16574908|NCT02778919|Experimental|KLH-2109, medium dose|
16574909|NCT02778919|Experimental|KLH-2109, high dose|
16574910|NCT02778919|Placebo Comparator|Placebo|First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
16574911|NCT02778919|Other|Leuprorelin acetate|Active reference
16574912|NCT02778906|Active Comparator|Abatacept|Abatacept 125 mg s.c. weekly
16574913|NCT02778906|Placebo Comparator|Placebo|Placebo (NaCl 0,9%) s.c. weekly
16574914|NCT02778893|Experimental|Conmana and Thalidomide|"Conmana(Icotinib Hydrochloride Tablets) and Thalidomide:
~Conmana(Icotinib Hydrochloride Tablets) will be administered at 125mg three times a day(TID）continuously; Thalidomide will be administered at 100mg one a day（QD)at night continuously,If can tolerance after 1 weeks to add to 200mg."
16574915|NCT02778880|Experimental|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
16574916|NCT02778880|Active Comparator|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
16574917|NCT02778867|Active Comparator|1-Food Elimination Diet (1FED)|Participants eliminate milk from the diet in Phase 1
16574954|NCT02778607||Progressive Supranuclear Palsy|Patients with a current clinical diagnosis of Progressive Supranuclear Palsy (PSP)
16574919|NCT02778867|Other|1FED Non-Responders (6FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
16574920|NCT02778867|Other|6FED Non-responders (SGC)|Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2
16574921|NCT02778854||cohort 1|Participants are recruited for diagnostic test
16574922|NCT02778854||cohort 2|participants are recruited for follow-up
16574923|NCT02778841|Experimental|XBox Kinact Exercise|Kinact game intervention group performed three times per week on non-consecutive days for eight weeks
16574924|NCT02778841|Experimental|conventional balance exercises|conventional balance exercises group performed three times per week on non-consecutive days for eight weeks
16574925|NCT02778841|Experimental|concurrent exercise group|Concurrent group performed mixed conventional balance and Xbox Kinact exercises three times per week on non-consecutive days for eight weeks
16574926|NCT02778841|No Intervention|control Group|There is no exercise for this group
16574927|NCT02778828|Experimental|Patients with Multi-Resistant Tb|
16574928|NCT02778815|Experimental|Kindness for Mums|An online self-help course designed to promote self-kindness and self-compassion in new mothers
16574929|NCT02778815|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help intervention once the RCT is complete.
16574930|NCT02778789||Tocilizumab|Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
16574931|NCT02778789||TNF-alpha Inhibitor|Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
16574932|NCT02778776|Experimental|Agave inulin + Metfomin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
16574933|NCT02778776|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
16574934|NCT02778776|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
16574935|NCT02778776|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
16574936|NCT02778763|Experimental|One injection of CBLB612 after Сhemo|One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)
16574937|NCT02778763|Experimental|One injection of CBLB612 prior Сhemo|One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)
16574938|NCT02778763|Placebo Comparator|Placebo|Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)
16574939|NCT02778750||Stable Group|
16574940|NCT02778750||Rapid Decliner Group|
16574941|NCT02778737|Experimental|ACT-based intervention|The Acceptance and Commitment Therapy + MTAU consists of an unpublished manual developed for the purposes of the project (Karekla et al., 2013). The 8, 90-min weekly group sessions focus in fostering psychological flexibility or the capacity to engage or change behaviors based on what a situation affords and an individual's goals, needs, and desires (Hayes et al., 2004). The ACT protocol involves helping patients to engage in values-based behaviors while remain in contact with pain, especially, when efforts to control or reduce it fail or contribute to suffering.
16574942|NCT02778737|Active Comparator|CBT-based intervention|The Cognitive Behavioral group + MTAU consists of an unpublished manual developed by Kalantzi-Azizi & Karademas (2003). It includes 8, 90-min weekly group session and primarily focuses on teaching patients to manage their pain by utilizing various techniques, such as activity pacing, muscle relaxation(i.e., progressive muscle relaxation, diaphragmatic breathing, guided imagery), pain recording, thought challenging, problem solving skills, relapse prevention, etc. The CBT protocol involves helping patients to learn to control their pain and to modify dysfunctional thoughts that accompany it.
16574943|NCT02778711|Experimental|Cosentyx|secukinumab (anti-IL-17)
16574944|NCT02778685|Experimental|Treatment (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16574945|NCT02778672||Infants with potential pneumonia|
16574946|NCT02778659|Experimental|Zolpidem Normoxia|Acute zolpidem intake at sea level
16574947|NCT02778659|Sham Comparator|Placebo Normoxia|Acute placebo intake at sea level
16574948|NCT02778659|Experimental|Zolpidem Hypoxia|Acute zolpidem intake at high altitude
16574949|NCT02778659|Sham Comparator|Placebo Hypoxia|Acute placebo intake at high altitude
16574950|NCT02778646||MINAP Audit|Individuals within this group are those that have been admitted into a United Kingdom (UK) based hospital following a major cardiac event. The FH status of individuals within this group is unknown.
16574951|NCT02778646||BCIS Audit|Individuals within this group are those who have undergone percutaneous coronary intervention in the United Kingdom (UK). The FH status of individuals within this group is unknown.
16574952|NCT02778633||Sepsis|Patients diagnosed with septic shock, admitted to the intensive care unit, with a good left ventricular ejection fraction without significant co-morbidity are highly eligible for this study. Patients must be equipped with a pulse-contour cardiac output (PICCO)-system with a central venous catheter which will be applied by the intensivist on admission.Patients will be subsequently connected to the hemodynamic monitoring device Navigator™. In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
16574953|NCT02778620||Aortic Valve Replacement|Post Anaesthetic Care Unit (PACU) patients treated with aortic valve replacement (AVR) are highly eligible for this study.These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
16575125|NCT02777723|Experimental|CKD-350|Xenobella
16574955|NCT02778607||Multiple System Atrophy|Patients with current clinical diagnosis of Multiple System Atrophy (MSA).
16574956|NCT02778607||Atypical Parkinsonian Syndrome|Atypical Parkinsonian Syndrome (APS) patients who do not fulfil existing criteria for PSP/CBD/MSA, but may represent variant clinical syndromes related to tau pathology including pure akinesia with gait freezing (PAGF), PSP-parkinsonism, overlap syndromes and atypical parkinsonian disorders not meeting clinical diagnostic criteria at entry
16574957|NCT02778607||Controls|Participants unaffected by neurological or psychiatric disease
16574958|NCT02778607||Corticobasal Degeneration|Patients with a current clinical diagnosis of Corticobasal Degeneration (CBD)
16574959|NCT02778594|Placebo Comparator|Placebo|Placebo (4 tablets) Simultaneously with the placebo dose, subjects were administered 1 capsule of Madopar® HBS 125
16574960|NCT02778594|Experimental|Nebicapone 50 mg|Nebicapone 50 mg (1 tablet of 50 mg plus 3 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
16574961|NCT02778594|Experimental|Nebicapone 100 mg|Nebicapone 100 mg (2 tablets of 50 mg plus 2 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
16574962|NCT02778594|Experimental|Nebicapone 200 mg|Nebicapone 200 mg (4 tablets of 50 mg). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
16574963|NCT02778581|Active Comparator|Lipidic Blend 1|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
16574964|NCT02778581|Active Comparator|Lipidic Blend 2|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
16574965|NCT02778581|Placebo Comparator|Placebo|Glass bottle with 45 ml of Olive oil. 1 bottle per day
16574966|NCT02778568|Experimental|Resistance Training|Patients performed resistance exercises
16574967|NCT02778568|Active Comparator|Control|Patients who performed flexibility exercise
16574968|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
16574969|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
16574970|NCT02778555||Sample 3|In Sample 3 (N=318), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14. In addition, assessments of pain, mood, activity, sleep, energy level, and positive affect were administered daily for the 14-day period.
16574971|NCT02778542|Active Comparator|Electronic Pill Bottle|Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication.
16574972|NCT02778542|Active Comparator|Bidirectional Text Messaging|Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
16574973|NCT02778542|No Intervention|Usual Care|Participants in this arm do not receive a medication reminder system.
16574974|NCT02778529|Other|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
16574975|NCT02778516|Active Comparator|Sodium Restriction 1500mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
16574976|NCT02778516|Active Comparator|Sodium Restriction 2400mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
16574977|NCT02778516|No Intervention|Control Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
16574978|NCT02778503|Active Comparator|High Cost|Restoration using a high-cost glass ionomer cement.
16574979|NCT02778503|Experimental|Low Cost|Restoration using a low-cost glass ionomer cement.
16574980|NCT02778477|Experimental|Part A_Cohort 1_Active|Multiple ascending dose of PF-06423264
16574981|NCT02778477|Placebo Comparator|Part A_Cohort 1_Placebo|Multiple dose of placebo
16574982|NCT02778477|Experimental|Part A_Cohort 2_Active|Multiple ascending dose of PF-06423264
16574983|NCT02778477|Placebo Comparator|Part A_Cohort 2_Placebo|Multiple dose of placebo
16574984|NCT02778477|Experimental|Part A_Cohort 3_Active|Multiple ascending dose of PF-06423264
16574985|NCT02778477|Placebo Comparator|Part A_Cohort 3_Placebo|Multiple dose of placebo
16574986|NCT02778477|Experimental|Part A_Cohort 4_Active|Multiple ascending dose of PF-06423264
16574987|NCT02778477|Placebo Comparator|Part A_Cohort 4_Placebo|Multiple dose of placebo
16574988|NCT02778477|Experimental|Part A_Cohort 5_Active|Multiple ascending dose of PF-06423264
16574989|NCT02778477|Placebo Comparator|Part A_Cohort 5_Placebo|Multiple dose of placebo
16574990|NCT02778477|Experimental|Part A_Cohort 6_Active|Multiple ascending dose of PF-06423264
16574992|NCT02778477|Experimental|Part A_Cohort 7_Active|Multiple ascending dose of PF-06423264
16574993|NCT02778477|Placebo Comparator|Part A_Cohort 7_Placebo|Multiple ascending dose of placebo
16574994|NCT02778477|Experimental|Part B_Cohort 1_Active|Multiple doses of PF-06423264
16574995|NCT02778477|Placebo Comparator|Part B_Cohort 1_Placebo|Multiple doses of placebo
16574996|NCT02778477|Experimental|Part B_Cohort 2_Active|Multiple doses of PF-06423264
16574997|NCT02778477|Placebo Comparator|Part B_Cohort 2_Placebo|Multiple doses of placebo
16574998|NCT02778464||Group A: Female IBD and RA (non-pregnant)|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
16574999|NCT02778464||Group B: Female IBD|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
16575000|NCT02778464||Group C: Female - Healthy Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
16575001|NCT02778464||Group D: Female - RA Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
16575002|NCT02778451|Other|Ultrasonography-experienced surgeons|Attending physicians and consultants in head and neck surgery using head and neck Ultrasonography on a daily basis.
16575003|NCT02778451|Other|Ultrasonography novices|Physicians participating in their one-year internship at other surgical or medical departments with no experience with head and neck US or head and neck surgery.
16575004|NCT02778425|Experimental|Secondary prevention-1|Endoscopic therapy+ beta blockers
16575005|NCT02778425|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
16575006|NCT02778425|Experimental|Primary prevention-1|Beta blockers
16575007|NCT02778425|Experimental|Primary prevention-2|Endoscopic therapy
16575008|NCT02778425|Experimental|Primary prevention-3|Endoscopic therapy+ PSE
16575009|NCT02778425|Experimental|Acute bleeding-1|Somatostatin+endoscopic therapy
16575010|NCT02778425|Experimental|Acute bleeding-2|Somatostatin+endoscopic therapy+PSE
16575011|NCT02778399|Experimental|OBE2109 dose 1|
16575012|NCT02778399|Experimental|OBE2109 dose 2|
16575013|NCT02778399|Experimental|OBE2109 dose 3|
16575014|NCT02778399|Experimental|OBE2109 dose 4|
16575015|NCT02778399|Experimental|OBE2109 dose 5|
16575016|NCT02778399|Placebo Comparator|Placebo / OBE2109 dose 6|
16575017|NCT02778386|Experimental|Cohort 1|6 subjects, male & female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
16575018|NCT02778386|Experimental|Cohort 2|6 subjects, male & female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
16575019|NCT02778386|Experimental|Cohort 3|8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
16575020|NCT02778386|Experimental|Cohort 4|8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
16575021|NCT02778373|Placebo Comparator|Placebo|Flavored Water
16575022|NCT02778373|Active Comparator|Low Molecular Weight Carbohydrate|low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
16575023|NCT02778373|Experimental|High molecular weight carbohydrate|high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
16575024|NCT02778360|Experimental|Neurofeedback NFT|"Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.
~Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home"
16575025|NCT02778360|Active Comparator|Methylphenidate MPH|"Methylphenidate long acting preparation.
~Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).
~Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day)."
16575026|NCT02778334|No Intervention|patients who return home|
16575027|NCT02778334|Experimental|patients who continued hospitalization in rehabilitation|
16575028|NCT02778321|Other|Uses of SpiderFlash monitor|"The intervention corresponds to the use of Spiderflash as Holter monitor. Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.
~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist."
16575029|NCT02778308|Active Comparator|chemotherapy group|6 cycles of Gemcitabine + Cisplatin as per the following schedule Injection Gemcitabine 1 gm/kgm2 intravenous over 30 min Day1 and Day8 Injection Cisplatin 70 mg/m2 intravenous on Day1
16575030|NCT02778308|No Intervention|control group|follow up
16575031|NCT02778295||Observation|Patients with Fabry disease or high-grade suspicion for Fabry disease
16575032|NCT02778282|No Intervention|Standard Care|Standard Care through office-based opioid treatment with buprenorphine/naloxone and weekly urine toxicology screening
16575033|NCT02778282|Experimental|Standard Care + MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents Standard Care plus MySafeRx™.
16575034|NCT02778269|Experimental|Study Treatment|The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
16575035|NCT02778256|Experimental|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
16575036|NCT02778256|Sham Comparator|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
16575037|NCT02778243|Experimental|Bladder cancer|▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
16575038|NCT02778243|Other|benign prostate hyperplasia|▪ Patients with benign prostate hyperplasia who justified a prostatectomy.
16575039|NCT02778230|Experimental|Pea Fiber|Two fiber snacks fortified with 5 g/each of pea fiber (Best Pea Fiber 200) will be consumed each day for a period of two weeks.
16575040|NCT02778230|Other|Control|Two control snacks will be consumed each day for a period of two weeks.
16575041|NCT02778217|No Intervention|Uninterrupted single embryo culture|The same single medium is used throughout the 5-6 days of culture with no replenishment on day 3.
16575042|NCT02778217|Experimental|Interrupted single medium culture|The single step medium is renewed on Day 3 of embryo culture.
16575043|NCT02778204|Experimental|Cohort 1 Stratum 1A|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; without in utero exposure to maternal efavirenz.
16575044|NCT02778204|Experimental|Cohort 1 Stratum 1B|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; with in utero exposure to maternal efavirenz.
16575045|NCT02778204|Experimental|Cohort 2 Stratum 2A|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; without in utero or breast milk exposure to maternal efavirenz.
16575046|NCT02778204|Experimental|Cohort 2 Stratum 2B|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; with in utero and breast milk exposure to maternal efavirenz
16575047|NCT02778191||Concomitant cisplatin|Patients treated with concomitant cisplatin
16575048|NCT02778191||Carboplatin plus 5-FU|Patients treated with carboplatin plus 5-FU
16575049|NCT02778178|Experimental|TAP block with ropivacaine|Bilateral single shot TAP block under ultrasound guidance: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
16575050|NCT02778178|Placebo Comparator|TAP block with placebo|Placebo administration: bilateral single shot TAP block under ultrasound guidance: 20 mL saline 0.9%, per side
16575051|NCT02778165|No Intervention|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
16575052|NCT02778165|Experimental|MyCaRe Android Application|The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Flex before leaving hospital. They will be asked to input data (pain, mood, wounds, activity) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
16575053|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
16575054|NCT02778139||youth smokers|
16575055|NCT02778139||non-smokers|
16575056|NCT02778126|Experimental|[¹⁴C]Prexasertib|170 milligrams (mg) of prexasertib containing approximately 50 μCi [¹⁴C] prexasertib radiotracer administered intravenously (IV) as a 1 hour continuous IV infusion.
16575057|NCT02778126|Experimental|Prexasertib|"105 milligrams per square meter (mg/m²) of prexasertib administered IV as a 1 hour continuous IV infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.
~Treatment for this arm was administered after ¹⁴C administration (¹⁴C was administered during first phase of the study)"
16575058|NCT02778113|Experimental|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
16575059|NCT02778113|Experimental|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
16575060|NCT02778113|Experimental|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
16575061|NCT02778113|Active Comparator|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
16575062|NCT02778100|Experimental|Nasal Glucagon (NG) - Common Cold|Cohort 1 - Nasal Glucagon (NG) administered once in participants with a common cold.
16575063|NCT02778100|Experimental|Nasal Glucagon (NG) - Symptom-Free|Cohort 1 - NG administered once in participants who have recovered from a common cold.
16575064|NCT02778100|Experimental|NG - Common Cold+Oxymetazoline|Cohort 2 - NG administered once in participants with a common cold who are taking oxymetazoline.
16575065|NCT02778087|Experimental|TAU plus 30 minutes of BT.|Intervention: Subjects randomized to the 30 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently two times per day in addition to their treatment as usual.
16575126|NCT02777723|Active Comparator|Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
16575066|NCT02778087|Experimental|TAU plus 60 minute of BT.|Intervention: Subjects randomized to the 60 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently four times per day in addition to their treatment as usual.
16575067|NCT02778087|Sham Comparator|TAU plus 30 minutes of sham BT.|Intervention: Subjects randomized to the control (sham) group will perform the above Sham Mirror Box Therapy intervention independently two times per day. The control group will be using a mirror box with an opaque surface as opposed to a reflective mirror.
16575068|NCT02778074|Experimental|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
16575069|NCT02778074|Placebo Comparator|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
16575070|NCT02778048||fecal incontinence patients (m/f)|patients suffering from fecal incontinence (m/f) are going to be assessed via MRI, US, FLIP, and HRAM
16575071|NCT02778035|Experimental|60 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 60 min).
16575072|NCT02778035|Experimental|30 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 30 min).
16575073|NCT02778035|Experimental|0 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 0 min).
16575074|NCT02778022|Experimental|Immediate PriCARE|Parent-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
16575075|NCT02778022|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual.
16575076|NCT02778009|Experimental|Fit Physician Group|"Subjects will receive activity monitor and will be required to attend monthly wellness lectures and weekly exercise intervention.
~Every subject will undergo an iDEXA scan to measure body mass composition"
16575077|NCT02778009|Active Comparator|Activity Monitor Only Group|"Subjects will receive an activity monitor without any intervention Every subject will undergo an iDEXA scan to measure body mass composition
~)"
16575078|NCT02778009|Other|Control Group|Subjects will not an activity monitor nor will they receive any intervention Every subject will undergo an iDEXA scan to measure body mass composition
16575079|NCT02777996|Active Comparator|Screening arm|Low Dose Computed Tomography offered at baseline and for 3 repeated rounds
16575080|NCT02777996|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care (in Europe lung cancer screening is not raccomended), according with the GP.
16575081|NCT02777983|Experimental|Education Group|This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
16575082|NCT02777983|No Intervention|Usual Care Group|Subjects randomized to usual care will receive a 1-page generic informational handout on general conditioning recommended for low back pain, in addition to whatever education the subject's PCP decides to provide.
16575083|NCT02777970|Experimental|Tramadol/Dexketoprofen|"Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;
~Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose."
16575084|NCT02777970|Active Comparator|Tramadol/Paracetamol|"Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;
~Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.
~."
16575085|NCT02777970|Placebo Comparator|Placebo|"Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;
~Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
16575086|NCT02777957||mPAP ≥ 25 mmHg|mean pulmonary artery pressure (mPAP) ≥ 25 mmHg (37 patients)
16575087|NCT02777957||mPAP < 25 mmHg|mean pulmonary artery pressure (mPAP) < 25 mmHg (28 patients).
16575088|NCT02777944|Experimental|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
16575089|NCT02777944|No Intervention|Control|Usual Care
16575090|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
16575091|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
16575092|NCT02777918|Experimental|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
16575093|NCT02777918|No Intervention|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
16575204|NCT02777151|Experimental|Cohort 1|REGN3470-3471-3479 dosing level 1 or placebo
16575205|NCT02777151|Experimental|Cohort 2|REGN3470-3471-3479 dosing level 2 or placebo
16575206|NCT02777151|Experimental|Cohort 3|REGN3470-3471-3479 dosing level 3 or placebo
16575094|NCT02777905|Experimental|MBCT intervention|"Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the centre local de services communautaires (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms."
16575095|NCT02777905|No Intervention|Control Group|Patients randomized to the control group will be offered literature on mental health promotion and will receive treatment as usual in the primary care health center setting. After the end of the study, the control group will be offered MBCT.
16575096|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
16575097|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC<70 and FEV1>50%)
16575098|NCT02777879||Control|No obstruction (FEV1/FVC<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
16575099|NCT02777866|Experimental|1: Bupivacaine 0.5%|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
16575100|NCT02777866|Placebo Comparator|2: 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs, who will be infiltrated in the total thickness of the abdominal wall with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound.
16575101|NCT02777853|Experimental|Active (green) tea|Tea to be ingested 3 times per day for 7 days.
16575102|NCT02777853|Placebo Comparator|Placebo tea|Tea to be ingested 3 times per day for 7 days.
16575103|NCT02777840|Active Comparator|Face mask group|Patients will be given oxygen via face mask as per routine practice, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
16575104|NCT02777840|Active Comparator|THRIVE group|Patients will be given oxygen via high flow oxygen in Optiflo, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
16575105|NCT02777827|Experimental|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
16575106|NCT02777827|Experimental|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
16575107|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
16575108|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
16575109|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
16575110|NCT02777827|Placebo Comparator|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
16575111|NCT02777814|Experimental|Prophylactic Entecavir|Entecavir is prophylactically used from the time of chemotherapy initiation at the dose of 0.5 mg p.o daily
16575112|NCT02777814|Active Comparator|Preemptive Entecavir|Entecavir is preemptively used from the time that hepatitis B virus DNA copies are more than 100 IU/ml at the dose of 0.5 mg p.o daily
16575113|NCT02777801|Experimental|Prophylactic Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the initiation of chemotherapy till 6 months after the end of chemotherapy.
16575114|NCT02777801|Active Comparator|Preemptive Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the time that the DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of chemotherapy.
16575115|NCT02777788|Active Comparator|chemotherapy|"Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.
~Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1."
16575116|NCT02777788|Experimental|TCM combined chemotherapy|TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21
16575117|NCT02777762|Experimental|Fun First|Strategies to promote enjoyment of physical activity
16575118|NCT02777762|Active Comparator|Close at Hand|Strategies to promote tracking of physical activity
16575119|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
~Adductor Canal Block (ACB)"
16575120|NCT02777749|Active Comparator|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
16575121|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
16575122|NCT02777736|Experimental|Arm A - Methotrexate i.v.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).
16575123|NCT02777736|Active Comparator|Arm B - Methotrexate i.t.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).
16575124|NCT02777736|No Intervention|Arm C - no Methotrexate|Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.
16575127|NCT02777710|Experimental|Combination Pexidartinib-Durvalumab|"DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca
~PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg.
~In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose."
16575128|NCT02777697||cancer patients|
16575129|NCT02777684||knee osteoarthritis|
16575130|NCT02777671|Experimental|Group A|Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide
16575131|NCT02777671|Experimental|Group B|Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide
16575132|NCT02777658||Primary Study Cohort|Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
16575133|NCT02777658||Secondary Study Cohort|Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
16575134|NCT02777645||Study group|Study group(n=50) included CP children with chewing disorder. Growth, feeding evaluation will be done.
16575135|NCT02777645||Control group|Control group(n=35)= healthy children without chewing disorder Growth, feeding evaluation will be done.
16575136|NCT02777632||HCV patients following living donor liver transplantation|single infection episode group
16575137|NCT02777632||patients following living donor liver transplantation|recurrent Infections episode group
16575138|NCT02777619|Placebo Comparator|Propofol and 0.0ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
16575139|NCT02777619|Experimental|Propofol and 0.4ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
16575140|NCT02777619|Experimental|Propofol and 0.6ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
16575141|NCT02777619|Experimental|Propofol and 0.8ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
16575142|NCT02777606|Experimental|Si-Ni-Tang (a Chinese Herbal Formula)|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015. Besides, 150ml of Si-Ni-Tang will be given by p.o. or a nasogastric tube once per day for 3 days in the treatment group.
16575143|NCT02777606|No Intervention|Control|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015.
16575144|NCT02777593|Other|Zone 2 Aortic aneurysm - CLOSED TO ENROLLMENT|Zone 2 Aortic Aneurysm
16575145|NCT02777593|Other|Zone 2 Non-aneurysm aortic lesions|Includes dissection, traumatic transection and other isolated lesion types
16575146|NCT02777580|Experimental|Pharmaco-invasive strategy|Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
16575147|NCT02777580|Active Comparator|Standard primary PCI|Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.
16575148|NCT02777554|Experimental|Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD|Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.
16575149|NCT02777554|Experimental|Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID|Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.
16575150|NCT02777554|Experimental|Part 2: Sequence 1|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:
~Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal."
16575151|NCT02777554|Experimental|Part 2: Sequence 2|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:
~Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal."
16575152|NCT02777554|Experimental|Part 2: Sequence 3|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:
~Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions."
16575153|NCT02777554|Experimental|Part 2: Sequence 4|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:
~Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions."
16575154|NCT02777541|Other|Early enteral nutrition|3 hours after PEG implantation
16575155|NCT02777541|Other|Late enteral nutrition|8 hours after PEG implantation
16575156|NCT02777528|Other|Zone 0/1 Aortic aneurysm|Zone 0/1 Aortic aneurysm
16575157|NCT02777528|Other|Zone 0/1 Non-aneurysm aortic lesions|Includes dissection and other isolated lesion types
16575158|NCT02777515|Other|Patients using electronic cigarette|The patients under the age of 35 followed at the consultation of rythmology for a cardiovascular assessment and already smoking the electronic cigarette and this since at least 1 month. The patient will receive a clinical examination, an electrocardiogram, a Holter-ECG and an echocardiogram before and after electronic cigarette consumption for 15 minutes.
16575159|NCT02777489|Experimental|Perindopril Bluepharma 8 mg|Each participant will have an at least 4-week run-in period, followed by a 6 weeks treatment period with Perindopril 8 mg.
16575160|NCT02777476|Experimental|procedure with B-Lite® Light Weight Breast Implant|
16575161|NCT02777450||Block group|Lumbar facet block. Levobupivacaine 0,25% and corticosteroids
16575162|NCT02777437|No Intervention|Laparoscopic surgery|Patients with T4 colon cancer receive laparoscopic surgery only.
16575163|NCT02777437|Experimental|Neoadjuvantive chemotherapy + Laparoscopic surgery|Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
16575164|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
16575165|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
16575166|NCT02777411|Experimental|Group A1|3 to 6 years
16575167|NCT02777411|Experimental|Group A2|3 to 6 years
16575168|NCT02777411|Experimental|Group A3|3 to 6 years
16575169|NCT02777411|Experimental|Group A4|3 to 6 years
16575170|NCT02777411|Experimental|Group B2|6 to 35 months
16575171|NCT02777411|Experimental|Group B3|6 to 35 months
16575172|NCT02777411|Experimental|Group B4|6 to 35 months
16575173|NCT02777398|Experimental|Trans-Quadrant Channel Surgery|Patients in the experimental arm (experimental group, i.e. microsurgery through trans-Quadrant channel pathway) will be operated using Quadrant channel system. All the tumor resection will be operated through the Quadrant channel with assistance of microsurgical techniques.
16575174|NCT02777398|Active Comparator|Conventional Open Surgery|Patients in the active comparator arm (control group, i.e. conventional open surgery) will be operated using the conventional open surgery. All the tumor resection will be operated directly with conventional procedures. More posterior structures of spine will be removed.
16575175|NCT02777385|Experimental|Arm 1|Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplating and radiation.
16575176|NCT02777385|Experimental|Arm 2|Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisp/radiation and given every 3 weeks
16575177|NCT02777372|Experimental|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMD group only) on arousal regulation across the menstrual cycle.
16575178|NCT02777359|Experimental|the closure group|In the closure group, the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA, in combination of clopidogrel(50mg/d, 3mon) and aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
16575179|NCT02777359|No Intervention|the medication group|In the medication group, in combination of clopidogrel (50mg/d, 3mon) and aspirin (0.1g/d, 6mon), current medication resumed, including conventional prescription for migraine as β-receptor blockers, calcium-ion antagonists, antiepileptics, antidepressants and non-steroid anti-inflammatory drugs (NSAID).
16575180|NCT02777346|Experimental|Absorbable|Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).
16575181|NCT02777346|Active Comparator|Non Absorbable|Suture material: Polypropylene thread (Prolene®, Ethicon Inc).
16575182|NCT02777333|Experimental|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
16575183|NCT02777333|No Intervention|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
16575184|NCT02777320|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
16575185|NCT02777320|Experimental|Ibuprofen group|Second Group: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
16575186|NCT02777307|Experimental|Hemopatch Sealing Hemostat|
16575187|NCT02777307|No Intervention|No Hemopatch Sealing Hemostat|
16575188|NCT02777294|Experimental|Online intervention|Therapist-facilitated, cognitive behavioral therapy
16575189|NCT02777294|Active Comparator|Psycho-educational website|Self-help, psycho-educational website
16575190|NCT02777281|Other|Shoulder pain and SCI|Manual wheelchair users with SCI
16575191|NCT02777281|Other|Shoulder pain and able bodies|No SCI or wheelchair use but presence of shoulder pain
16575192|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
16575193|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
16575194|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
16575195|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
16575196|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
16575197|NCT02777242|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg [Device: QuickShot® Testosterone (QST)]
16575198|NCT02777229|Experimental|Dolutegravir|Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
16575199|NCT02777229|Active Comparator|Efavirenz|Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
16575200|NCT02777216|Experimental|ConfidenHT system|ConfidenHT system
16575201|NCT02777190|Experimental|Oral misoprostol|oral misoprostol given 25 mcg every 2 hours
16575202|NCT02777190|Active Comparator|Vaginal misoprostol|vaginal misoprostol given 25 mcg every 4 hours
16575203|NCT02777164|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
16575207|NCT02777151|Experimental|Cohort 4|REGN3470-3471-3479 dosing level 4 or placebo
16575208|NCT02777138||Young males aged 20-35 years old|"Maintaining a normal daily living lifestyle
~Healthy
~Reasonably active- PAL: 1.4-1.9
~Non-obese- Fat mass index based on DEXA of 4-8kg/m2
~Weight stable for more than 3 months (±3% body mass)
~Non-smoker
~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders
~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription
~No medications that may influence lipid or carbohydrate metabolism or immune system function
~No known negative reaction to lidocaine
~No participation in heavy resistance training"
16575209|NCT02777138||Old males aged 65-85 years old|"Maintaining a normal daily living lifestyle
~Healthy
~Reasonably active- PAL: 1.4-1.9
~Non-obese- Fat mass index based on DEXA of 4-8kg/m2
~Weight stable for more than 3 months (±3% body mass)
~Non-smoker
~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders
~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription
~No medications that may influence lipid or carbohydrate metabolism or immune system function
~No known negative reaction to lidocaine
~No participation in heavy resistance training"
16575210|NCT02777125|Active Comparator|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
16575211|NCT02777125|Active Comparator|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
16575212|NCT02777112|Placebo Comparator|Control|This group will receive generic information about depression and serve as control
16575213|NCT02777112|Experimental|e-mental health program|This group will receive the developed e-mental health program
16575214|NCT02777112|Experimental|e-mental health program and job coaching|This group will receive the developed e-mental health program plus interactive job coaching through telephone.
16575215|NCT02777099|Experimental|RIPostC|Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning
16575216|NCT02777099|Sham Comparator|sham RIPostC|"Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure.
~Intervention:Procedure:Sham Remote Ischemic Postconditioning"
16575217|NCT02777086|Experimental|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
16575218|NCT02777086|No Intervention|Comparison|Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
16575219|NCT02777073|Active Comparator|liraglutide 1.8 mg|single dose of Victoza ( liraglutide) 1.8 mg
16575220|NCT02777073|Experimental|dapagliflozin 10|single dose of Farxiga ( dapagliflozin) 10 mg
16575221|NCT02777073|Placebo Comparator|Placebo|Single dose of placebo
16575222|NCT02777060|Experimental|Exergame|inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback. The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
16575223|NCT02777060|Active Comparator|Home based balance training|The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback. Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
16575224|NCT02777047|Experimental|Intervention|Complex Intervention including focused discharge medication reconciliation; structured handovers to family physician, community pharmacy, patient and family, home care, telehealth providers; virtual visit follow-up focused on anticoagulation monitoring.
16575225|NCT02777047|No Intervention|Control|Usual care. Patients will be provided with the URL to Thrombosis Canada website.
16575226|NCT02777034|Experimental|Enhanced Recovery|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.
~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.
~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
16575227|NCT02777034|Other|Unenhanced Recovery|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.
~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.
~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
16575228|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
16575265|NCT02776657|Active Comparator|Cohort 1 (Stable Angina)|20 patients with stable angina planned to undergo elective coronary angiography will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries.
16575229|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
16575230|NCT02777008|Experimental|CTP-543 Single Dose|Single oral dose
16575231|NCT02777008|Experimental|CTP-543 Multiple Dose|Multiple oral dose for 7 consecutive days
16575232|NCT02776995|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every 5 fraction of radiation, starting prior to the first radiation treatment, periodically, until the end of radiation therapy (a period of several weeks).
16575233|NCT02776982|Other|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
16575234|NCT02776956|Experimental|atorvastatin group|atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.
16575235|NCT02776956|Other|non-atorvastatin group|atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..
16575236|NCT02776943|Experimental|Mesenchymal stem cell treatment|Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.
16575237|NCT02776943|Active Comparator|Hyaluronic acid treatment|Administer hyaluronic acid (30 mg) in a single injection
16575238|NCT02776930||Return to Duty after Rehab from Injury|Patients deemed healthy enough to return to full duty without any restrictions after completing a course of rehabilitation for a lumbar/thoracic spine or lower extremity injury.
16575239|NCT02776917|Experimental|Cirmtuzumab + Paclitaxel|"Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
~Paclitaxel 80 mg/m^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle."
16575240|NCT02776904|Other|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
16575241|NCT02776904|Other|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
16575242|NCT02776891|Experimental|Gallium citrate|The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 millicurie (mCi) and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
16575243|NCT02776878|Experimental|Dasatinib|Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.
16575244|NCT02776865|Experimental|physical therapy and suprascapular nerve block|patient received ultrasound-guided suprascapular nerve block as well as physical therapy.
16575245|NCT02776865|Active Comparator|physical therapy only|patient received physical therapy only.
16575246|NCT02776852|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16575247|NCT02776839|Other|Mobile Sensing|This phase of the study is designed to develop the app. due to algorithms the app should lern to detect depressive symptoms
16575248|NCT02776813|Experimental|ACTR087, in combination with rituximab|
16575249|NCT02776800|Experimental|Allevyn Life|Foam Dressing
16575250|NCT02776800|Other|Foam Dressing|Standard Care - Foam Dressing
16575251|NCT02776787||Patients|Patients with diverticulitis
16575252|NCT02776787||Surgeons|Surgeons who perform elective colon resections
16575253|NCT02776761|Experimental|Hantaan Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
16575254|NCT02776761|Experimental|Puumala Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
16575255|NCT02776761|Experimental|Hantaan/Puumala Vaccine|The HTNV and PUUV vaccine will be combined (equal volumes) before use: 1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
16575256|NCT02776748|Other|FTC-TDF|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF
16575257|NCT02776735|Experimental|Sarilumab|Participants will receive one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose regimen once this is identified. Sarilumab will be given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for approximately 72 patients enrolled in dose-finding and second portions and 84 weeks for approximately 28 patients enrolled in third portion)
16575258|NCT02776709||Bile duct Stricture|Patients referred for the evaluation of indeterminate strictures.
16575259|NCT02776709||Common bile duct Stones|Patients referred for the removal of difficult stones.
16575260|NCT02776696|Experimental|Advanced HybridClosed Loop System (AHCL)|Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3 or 5 days in a camp setting and 21 days at home during segment 4.
16575261|NCT02776696|Experimental|Hybrid Closed Loop System (HCL)|"Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:
~36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3"
16575262|NCT02776683|Experimental|All patients|
16575263|NCT02776670|Experimental|SYSTANE BALANCE|Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
16575264|NCT02776670|Active Comparator|REFRESH OPTIVE|Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
16575477|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
16575478|NCT02775227|Experimental|Hydrocortisone|
16575479|NCT02775227|Active Comparator|Pasireotide|
16575266|NCT02776657|Active Comparator|Cohort 2 (Acute Coronary Syndrome)|20 patients diagnosed with acute coronary syndrome will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries. If thrombus is identified, participants will be asked to undergo a repeat MRI scan at one and three months.
16575267|NCT02776631|Experimental|Pinloc|Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
16575268|NCT02776631|Active Comparator|LIH (Hansson pins)|2 pins. An established method for fixation of femoral neck fractures.
16575269|NCT02776618|Experimental|Polyglactin 910|One half of excision site will be randomly assigned superficial closure with polyglactin 910 suture
16575270|NCT02776618|Experimental|poliglecaprone 25|One half of excision site will be randomly assigned superficial closure with poliglecaprone 25
16575271|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)
~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.
~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.
~HSCT (performed ideally within 1 month from the end of consolidation).
~Post HSCT therapy (MRD monitoring)"
16575272|NCT02776592|Experimental|Experimental|A cow's milk-based formula with added nutrients
16575273|NCT02776592|Active Comparator|Control|A cow's milk-based formula
16575274|NCT02776579|Experimental|Girls-only resistance training|8 weeks of 2-3x/week girls-only resistance training class with a female strength and conditioning specialist.
16575275|NCT02776579|No Intervention|No resistance training|8 weeks of usual activity.
16575276|NCT02776566|Active Comparator|Anticoagulation Clinic|"Usual care through pharmacist managed anticoagulation clinic
~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
16575277|NCT02776566|Experimental|Patient Self-Monitoring|"In home self-monitoring and pharmacist guided education
~Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages."
16575278|NCT02776553|Experimental|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
16575279|NCT02776553|Active Comparator|Control|nutritional intervention
16575280|NCT02776540|Active Comparator|900 mg Clopidogrel|67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
16575281|NCT02776540|Active Comparator|600 mg Clopidogrel|67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
16575282|NCT02776540|Placebo Comparator|400 mg Aspirin|67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
16575283|NCT02776527|Experimental|A group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
16575284|NCT02776527|No Intervention|B group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox
16575285|NCT02776514|Active Comparator|Triamcort (1 ml, 40 mg/ml)|30 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
16575286|NCT02776514|Active Comparator|Platelet-rich-plasma (PRP 3 ml)|30 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
16575287|NCT02776514|Active Comparator|Suplasyn1-shot (60 mg/ ml)|30 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
16575288|NCT02776514|Placebo Comparator|Placebo (Iopamiro 200)|30 patients receive intraarticular injection with contrast media only
16575289|NCT02776501|Experimental|BAY987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16575290|NCT02776488|Experimental|ELI Arm|Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI
16575291|NCT02776488|Placebo Comparator|Placebo|Placebo infusion of normal saline in Part 2 RCT
16575292|NCT02776475|Other|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
16575293|NCT02776462||Potential Traumatic Brain Injury|This group will consist of people admitted to the ER, Trauma Bay, or Neurosurgery for potential traumatic brain injury.
16575294|NCT02776449||Normal Tension Glaucoma|Patients with manifest normal tension glaucoma
16575295|NCT02776436|Experimental|Breast cancer|"Dose of prophylactic dexamethasone will be reduced as follows:
~STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)
~STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)
~STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)
~STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)
~STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)
~STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)"
16575325|NCT02776254|Experimental|FAST Track|In the FAST-TRACK model a pharmacy technician will dispense drugs) and lay health care workers will provide brief symptom screening to identify patients in need of higher-level care. If there is no need of higher-level care, then the clinic visit is over.
16575296|NCT02776436|Experimental|Prostate cancer|"Dose of prophylactic dexamethasone will be reduced as follows:
~STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)
~STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)
~STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)
~STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)"
16575297|NCT02776410|Experimental|Intervention group|Group receiving tailored messages promoting sustainable and healthy eating through an mobile-application together with six principles of sustainable healthy eating that will be included in the mobile application,
16575298|NCT02776410|No Intervention|Control group|Group who will not download the mobile application
16575299|NCT02776397|Active Comparator|Hp 2-2 Vitamin E|The Haptoglobin 2-2 group randomised to Vitamin E
16575300|NCT02776397|Placebo Comparator|Hp 2-2 Placebo|The Haptoglobin 2-2 group randomised to placebo
16575301|NCT02776397|Active Comparator|Non Hp 2-2 Vitamin E|The Non Haptoglobin 2-2 group randomised to Vitamin E
16575302|NCT02776397|Placebo Comparator|Non Hp 2-2 Placebo|The Non Haptoglobin 2-2 group randomised to placebo
16575303|NCT02776384||chronic heart failure|patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction
16575304|NCT02776371|Experimental|Modified non-clarithromycin triple therapy|H.pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
16575305|NCT02776371|Active Comparator|Sequential therapy|H.pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
16575306|NCT02776358|Experimental|High Fidelity Simulation|Students will receive a 1 hour High fidelity simulation session
16575307|NCT02776358|Experimental|Video Case|Students will receive a 1 hour assisted Video Case learning session
16575308|NCT02776345|Active Comparator|Ultrasound guided Needle Fragmentation|"Ultrasound guided Needle Fragmentation (Intervention):
~Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed."
16575309|NCT02776345|Active Comparator|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
16575310|NCT02776345|Placebo Comparator|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
16575311|NCT02776332|Active Comparator|3 day group|Manual expression for 3 days after delivery Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
16575312|NCT02776332|Active Comparator|7 day group|The 7 day group will manually express for 7 days after delivery. Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery follow up phone call at 5 days to encourage continued manual expression
16575313|NCT02776319|Experimental|Active|Non-invasive brain stimulation (active)
16575314|NCT02776319|Placebo Comparator|Sham/Placebo|Non-invasive brain stimulation (sham)
16575315|NCT02776306|Experimental|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
16575316|NCT02776306|No Intervention|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
16575317|NCT02776293|Active Comparator|Relaxation Group|The relaxation group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to sit undisturbed for 20 minutes.
16575318|NCT02776293|Experimental|Music Group|The music group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to listen to pre-recorded songs specifically composed for pregnancy.
16575319|NCT02776280|Placebo Comparator|Negative control|Meal prepared with non-fluoridated water and salt
16575320|NCT02776280|Experimental|Fluoridated water|Meal prepared with fluoridated water
16575321|NCT02776280|Experimental|Fluoridated salt|Meal prepared with fluoridated salt
16575322|NCT02776267|Experimental|Angiolite stent - 3-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
16575323|NCT02776267|Experimental|Angiolite stent - 6-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
16575324|NCT02776254|Experimental|START|The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing and results, streamlined adherence counseling, and quicker initiation of life-long ART to patients enrolling in HIV care and treatment services.
16575480|NCT02775214|No Intervention|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
16575326|NCT02776254|Experimental|CAG (intervention)|CAG intervention, consists of facilitated groups of six people based on geographic proximity of home address and patient preference. This group of six people, will meet monthly at a designated place in the community to provide support and receive medications. Each month one of the members will rotate visiting the clinic for their routine medical visit and will pick up medications for the entire CAG and bring them back to the community. This rotation schedule will recur every six months. Lay health care workers will provide brief symptom screening to identify patients in the group that need of higher-level care.
16575327|NCT02776254|Active Comparator|CAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
16575328|NCT02776254|Experimental|UAG (intervention)|Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
16575329|NCT02776254|Active Comparator|UAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
16575330|NCT02776241|No Intervention|water restriction|20 patients will be subjected to 3 hours of water restriction following MR scan of the kidneys.
16575331|NCT02776241|Active Comparator|high water intake|20 patients will be subjected to 1 hour of high water intake (20 ml/kg) following MR scan of the kidneys.
16575332|NCT02776228|Experimental|benzodiazepine|The patient which will be in the Experimental arm (after randomization) will receive 0.25 mg of Brotizolam (short acting benzodiazepine) for six weeks from the day of discharge.
16575333|NCT02776228|Placebo Comparator|placebo|The patient which will be in the placebo arm (after randomization) will receive placebo for six weeks from the day of discharge.
16575334|NCT02776215|Experimental|Pharmacokinetic Dosing|Single-dose pharmacokinetics of tasimelteon
16575335|NCT02776202|Experimental|Reduced-intensity conditioning regimen|"The HSCT preparative regimen will consist of
~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5
~Fludarabine: 35 mg/m2/day IV on Days -8 through -4
~Melphalan: 140 mg/m2 IV on Day -3
~Rest on Day -2 and -1
~Day 0 is the day of transplant
~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
16575336|NCT02776189|Experimental|Midazolam & Dexmedetomidine|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
16575337|NCT02776189|Active Comparator|Midazolam & Propofol|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous propofol 2 mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
16575338|NCT02776176|Experimental|ERAS group|Patients receive the Enhanced Recovery After Surgery program during the peri-operative period.
16575339|NCT02776176|Other|Traditional group|Patients receive the Traditional program during the peri-operative period.
16575340|NCT02776163|Experimental|Cisplatin Group|Intensity-modulated radiotherapy+concurrent chemotherapy with cisplatin for squamous carcinoma of salivary gland
16575341|NCT02776163|Experimental|Docetaxel+Cisplatin|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and cisplatin for adenogenous types carcinoma of salivary gland
16575342|NCT02776150||MGIT liquid culture+drug sensitivity test|MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
16575343|NCT02776150||Xpert-MTB/RIF|xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
16575344|NCT02776150||probe melting curve detection|Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.
16575345|NCT02776137|Experimental|Docetaxel Group|Concurrent Chemoradiotherapy With Docetaxel
16575346|NCT02776124|Experimental|ONS group|Individualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
16575347|NCT02776124|No Intervention|control group|Individualized dietary counseling during CRT
16575348|NCT02776111||Healthy Controls|Participants in this group will have a one time blood sample taken.
16575349|NCT02776111||Kidney Transplant Group|Participants in this group have had a kidney transplant and blood samples will be obtained as described in study plan
16575447|NCT02775448|Experimental|Diet + exercise + Carduus marianus 12cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
16575350|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
16575351|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
16575352|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
16575353|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
16575354|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
16575355|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
16575356|NCT02776072||dimethyl fumarate (DMF)|Participants who initiated DMF during the specified time period
16575357|NCT02776072||glatiramer acetate (GA)|Participants who initiated GA during the specified time period
16575358|NCT02776072||teriflunomide|Participants who initiated teriflunomide during the specified time period
16575359|NCT02776072||fingolimod|Participants who initiated fingolimod during the specified time period
16575360|NCT02776059|Experimental|prednisolone or pentoxifylline + pegfiltrastim|prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot
16575361|NCT02776059|Active Comparator|prednisolone or pentoxifylline|prednisolone or pentoxifylline for 28 days
16575362|NCT02776046|Experimental|High FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
~Postoperatively 3h with 0.8 FiO2 and individualized CPAP"
16575363|NCT02776046|Active Comparator|Conventional FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.3. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
~Postoperatively 3h with 0.3 FiO2 and individualized CPAP"
16575364|NCT02776033|Experimental|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
16575365|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
16575366|NCT02776033|Experimental|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
16575367|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
16575368|NCT02776020||Propofol sedated patients|Women undergoing a short trans vaginal ovum retrieval (TVOR) will be sedated with propofol , and monitored non-invasively for changes in blood propofol concentration levels. Propofol dosages will be adapted according to patients vital signs and their reaction to noxious stimuli exerted during the trans vaginal ovum retrieval (TVOR) procedure, irrespective to the proposed study in which these participants undergo.Those changes of administered propofol dosages will be observed by the anesthetic drug monitor (ADM). Propfol is administered by the anesthesiologist in a routine manner and according to anesthesiologist discretion .
16575369|NCT02776007|Experimental|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
16575370|NCT02776007|Active Comparator|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
16575371|NCT02775994|Experimental|Treatment Arm|Single dose of Canakinumab 4mg/kg
16575372|NCT02775981|Experimental|Active|RX0041-002
16575373|NCT02775955|Experimental|RX0041-002|Active
16575374|NCT02775942|Experimental|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
16575375|NCT02775942|Experimental|IPOVAC 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
16575376|NCT02775942|Experimental|IPOVAC 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
16575377|NCT02775942|Active Comparator|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
16575378|NCT02775929|Other|PrEP as a bridge to ART|FTC-TDF PrEP for HIV uninfected partners and ART for HIV infected partners
16575379|NCT02775916|Experimental|CDZ173|Capsule
16575380|NCT02775916|Placebo Comparator|Placebo|Capsule matching Placebo
16575481|NCT02775214|Active Comparator|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
16575381|NCT02775903|Experimental|Azacitidine + Durvalumab|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
16575382|NCT02775903|Active Comparator|Azacitidine Alone|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
16575383|NCT02775890||Eating lead-shot wild game|Hunters that have eaten lead-shot in the past week will have blood lead levels measured.
16575384|NCT02775890||Not eating lead-shot wild game|Hunters that have not eaten lead-shot in the past week will have blood lead levels measured.
16575385|NCT02775877|Experimental|letrozole and clomiphene|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and clomiphene100 mg tablet orally once a day from 11-15 day of menstrual cycle.
16575386|NCT02775877|Active Comparator|Letrozole and human menopausal gonadotropin (HMG)|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and HMG 75u once a day by intramuscular injection from 11-15day of menstrual cycle
16575387|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
16575388|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
16575389|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
16575390|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
16575391|NCT02775851|Experimental|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab.
16575392|NCT02775851|Active Comparator|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity.
16575393|NCT02775838|Experimental|kidney transplantation|Intravenous injection of Indocyanine Green in patients receiving kidney transplantation
16575394|NCT02775812|Experimental|Treatment (cisplatin, pembrolizumab, IMRT)|Patients receive cisplatin IV over 1-2 hours once weekly for weeks 1-6 and pembrolizumab IV over 30 minutes every 3 weeks in weeks 9, 12, 15, 18, and 21. Patients also undergo IMRT in weeks 1-6. Patients may also receive pembrolizumab IV over 30 minutes in weeks 3, 6, 24, and 27.
16575395|NCT02775786|No Intervention|Healthy Volunteers|Normal volunteers with no pancreas mass or risk factors for pancreas cancer will be recruited for MRI protocol optimization and nothing more. No intravenous contrast will be given. They will be asked to lie in the scanner for up to 1 hour and non-contrast imaging will be performed.
16575396|NCT02775786|Experimental|Pancreatic Mass or Risk Factors Group|Participants with pancreatic adenocarcinoma who are planning to undergo surgical resection. Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis .
16575397|NCT02775773|Experimental|arm A (TXA)|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
16575398|NCT02775773|Active Comparator|arm B (OXY)|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
16575399|NCT02775760|Experimental|Cardiovascular endurance|Participants will undergo cardiovascular endurance training. The trainer-supervised endurance training will involve walking on a treadmill at moderate intensity
16575400|NCT02775760|Active Comparator|Strength, balance, and flexibility|Participants will undergo Strength, balance, and flexibility training.
16575401|NCT02775747|Experimental|platelet rich plasma gel|Injection of Platelet rich plasma (PRP) gel in 64 cases at time of wound closure in women undergoing cesarean section for improving wound healing after fullfit to all the inclusion and exclusion craiteria
16575402|NCT02775747|Placebo Comparator|Saline|64 Controlled Women with recurrent cesarean section and fullfit to all the inclusion and exclusion craiteria will reseve saline injection at time of wound closure
16575403|NCT02775734|Active Comparator|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + LOD
16575404|NCT02775734|Active Comparator|NO N-acetyl-cysteine|Clomiphene citrate + LOD
16575405|NCT02775721|Other|Cohort A|"Head and Neck Cancer patients receiving Radiation Therapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts B and C.
~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.
~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.
~Nutritional therapy education and evaluation is assessed per the attending dietitian.
~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
16575406|NCT02775721|Other|Cohort B|"Head and Neck Cancer patients receiving Chemotherapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and C.
~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.
~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.
~Nutritional therapy education and evaluation is assessed per the attending dietitian.
~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
16575448|NCT02775448|Experimental|Diet + exercise + Carduus marianus 30cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
16575449|NCT02775448|Placebo Comparator|Diet + exercise + placebo|Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
16575407|NCT02775721|Other|Cohort C|"Head and Neck Cancer patients receiving Chemotherapy and Radiation therapy. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and B.
~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.
~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.
~Nutritional therapy education and evaluation is assessed per the attending dietitian.
~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
16575408|NCT02775708|Experimental|capsule endoscopy|open label arm ; up to 100 subjects indicated for capsule endoscopy (CE) procedure will undergo the CE procedure with the Pillcam endoscopy system
16575409|NCT02775695|Experimental|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
16575410|NCT02775682||patients with epilepsy|
16575411|NCT02775682||normal individuals without epilepsy|
16575412|NCT02775669||intracranial ICP monitoring|invasive intracranial ICP monitoring
16575413|NCT02775669||tranfontanel ICP monitoring|Noninvasive transfontanel ICP monitoring
16575414|NCT02775656||Prospective cohort|For a pregnancy to be enrolled in the prospective cohort, the pregnancy outcome cannot be known (ie, no prenatal diagnosis of a fetus with a congenital defect and the pregnancy is still ongoing at the time of consent).
16575415|NCT02775656||Retrospective cohort|For a pregnancy to be enrolled in the retrospective cohort, the pregnancy outcome must already be known (ie, a congenital defect has already been identified at the time of consent into the pregnancy follow-up study, or the pregnancy has been completed at the time of consent).
16575416|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
16575417|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
16575418|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
16575419|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..
~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
16575420|NCT02775604|Other|Home-Based Video|GoPro Camera
16575421|NCT02775604|Other|Paper Checklist|Homeowner Print Checklist
16575422|NCT02775591|Experimental|Motilitone arm|DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
16575423|NCT02775591|Placebo Comparator|Placebo arm|DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks
16575424|NCT02775578|Experimental|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
16575425|NCT02775578|Experimental|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
16575426|NCT02775578|Experimental|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
16575427|NCT02775552|Experimental|A&T intervention areas|
16575428|NCT02775552|Active Comparator|Comparison areas|(Receive standard government services)
16575429|NCT02775539|Active Comparator|Mirabegron|Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.
16575430|NCT02775539|Placebo Comparator|Placebo|Oral placebo, similarly titrated to ensure blindness.
16575431|NCT02775526|Active Comparator|TOT|TOT
16575432|NCT02775526|Active Comparator|TVT|TVT
16575433|NCT02775526|Active Comparator|Burch colposuspension|Burch colposuspension
16575434|NCT02775513||Mutation|Patients with functional mutation in ion channels
16575435|NCT02775513||Control|Matched control
16575436|NCT02775500||Apremilast-Exposed Cohort|Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
16575437|NCT02775500||Diseased Comparison Cohort|Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
16575438|NCT02775500||Healthy Comparison Cohort|Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
16575439|NCT02775500||Apremilast-Exposed Registry Group|Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
16575440|NCT02775487||COPD and air quality|Persons enrolled in the study will have been diagnosed with Stage III or IV COPD and samples of air taken from their home environment.
16575441|NCT02775474|Experimental|Methadone|Methadone used as anesthesia opioid: induction with 0,15 mg / kg intravenous methadone. Boluses of 0,05 mg / kg intravenous methadone as needed intraoperatively
16575442|NCT02775474|Active Comparator|Fentanyl|Fentanyl used as anesthesia opioid: induction with 6 mcg / kg intravenous fentanyl. Boluses of 2 mug / kg intravenous fentanyl as needed intraoperatively
16575443|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
16575444|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
16575445|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
16575446|NCT02775448|Experimental|Diet + exercise + Carduus marianus 6cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
16575450|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
16575451|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
16575452|NCT02775422|Experimental|Pregnant women|Pregnant women
16575453|NCT02775409|Active Comparator|Subcutaneous|Subcutaneous placement of tissue expander
16575454|NCT02775409|Active Comparator|Submuscular|Submuscular placement of tissue expander
16575455|NCT02775396|Experimental|Adult computer user|Wearing each of the two spectacle lens designs for one month in random sequence
16575456|NCT02775383||Longitudinal|Participants with MDS, MDS/MPN overlap disorder, AML <30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities
16575457|NCT02775383||Cross-sectional|Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only
16575458|NCT02775370|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
16575459|NCT02775357|Experimental|Enhanced HIV counseling and testing|In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
16575460|NCT02775357|Active Comparator|Standard HIV testing and counseling|Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
16575461|NCT02775344|Experimental|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
16575462|NCT02775344|No Intervention|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
16575463|NCT02775331|Experimental|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
16575464|NCT02775331|Experimental|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
16575465|NCT02775331|No Intervention|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
16575466|NCT02775318|Other|Stellate Ganglion Block|After diagnosis of vasospasm patients were administered ultrasound guided Stellate Ganglion block using 10 cc of 0.5% Inj Bupivacaine on the same side of vasospasm or the side contralateral to the focal neurological deficit.Patients were then assessed using transcranial Doppler and digital subtraction angiography after 30 minutes
16575467|NCT02775305|No Intervention|Not frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants do not meet criteria for frailty, baseline screening data will be used for comparative analysis as the no intervention arm.
16575468|NCT02775305|Experimental|Frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants meet criteria for frailty participants will be enrolled in the intervention arm. Participants who are ambulatory regardless of co-morbidities will not be excluded from the study.
16575469|NCT02775292|Experimental|Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.
~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.
~NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
~NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28.
~LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses."
16575470|NCT02775279||Acute coronary syndrome group|200 consecutive patients were recruited, who have diagnosed with acute coronary syndrom(ACS) by quantitative coronary angiography.
16575471|NCT02775279||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
16575472|NCT02775266|Active Comparator|ALA + Scaling and Root planing|Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)
16575473|NCT02775266|Placebo Comparator|Scaling and root planing only|Patients will receive scaling and root planning at baseline and 3 months(group A)
16575474|NCT02775253|Experimental|Chronic cold acclimation group|All patients will be conducted a chronic cold acclimation intervention for 33 days.
16575475|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
16575476|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
16575482|NCT02775201|Active Comparator|Plantaris release under ultrasound guidance|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris released under ultrasound guidance by a consultant radiologist
16575483|NCT02775201|Active Comparator|Plantaris excision surgically|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris excised in surgery by a consultant orthopaedic surgeon
16575484|NCT02775188|Experimental|Physical Therapy with InterACTION|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
16575485|NCT02775188|Other|Physical Therapy|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week
16575486|NCT02775175|No Intervention|Fasting as Usual|This group will continue to practice their usual fasting regimen during Ramadan
16575487|NCT02775175|Experimental|Modified Ramadan Fasting|This group will receive an educational intervention providing knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
16575488|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
16575489|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
16575490|NCT02775149||Reflux patients|Patients who are treated at the Clinic for Gastroenterology and Gastrointestinal Oncology and have a 24-hours pH monitoring or impedance measurement performed for medical reasons
16575491|NCT02775136|Experimental|HS-1000 recording|Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
16575492|NCT02775123|No Intervention|Control|Conventional cardio-pulmonary bypass
16575493|NCT02775123|Experimental|Cytosorb|Cytosorb added to cardio-pulmonary bypass
16575494|NCT02775110|Active Comparator|Immediate Discontinuation Group|Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
16575495|NCT02775110|Experimental|Taper-off Group|Patients will be administered two more natalizumab infusion, one at six weeks and the second at eight weeks (14 weeks from study entry), followed by six months natalizumab discontinuation. Another DMT will be initiated within two months after the last natalizumab infusion.
16575496|NCT02775097||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
16575497|NCT02775097||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus.
16575498|NCT02775084|Experimental|Healthy Fish Oil|8 grams fish oil
16575499|NCT02775084|Placebo Comparator|Olive Oil|8 grams olive oil
16575500|NCT02775058||patients|The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.
16575501|NCT02775045||Eosinophil esophagitis|Adult patients (>18 yr) will be recruited from the Gastroenterology clinic following a diagnostic endoscopy for esophageal dysfunction with predominant symptom(s) of solid food dysphagia and/or esophageal food impaction. Patients with esophageal biopsy showing greater than 15 eosinophil/hpf (pathology results typically available within three business days) despite greater than two months use of high dose proton pump inhibitor will be invited to participate and enroll in the study within 1 week of the endoscopy.
16575502|NCT02775019|Active Comparator|Lactobacillus reuteri lonzenges|2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
16575503|NCT02775019|Placebo Comparator|Placebo lozenges|2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
16575504|NCT02775006|Active Comparator|Docetaxel|Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
16575505|NCT02775006|Active Comparator|Docetaxel plus erlotinib|Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.
16575506|NCT02774993|Experimental|Doxycycline|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
16575507|NCT02774993|Placebo Comparator|Placebo|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
16575508|NCT02774967|Active Comparator|extended flap technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.
~Other Names:
~acellular dermal matrix extended flap technique"
16575509|NCT02774967|Experimental|tunnel technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.
~Other Names:
~acellular dermal matrix extended flap technique"
16575560|NCT02774564|Experimental|Nebicapone 200 mg|4 tablets of 50 mg concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
16575561|NCT02774564|Placebo Comparator|Placebo|4 tablets concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
16575596|NCT02774356||Native English speakers without experience of a tonal language|
16575510|NCT02774954|Experimental|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
16575511|NCT02774954|Active Comparator|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
16575512|NCT02774941|Active Comparator|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
16575513|NCT02774941|Experimental|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
16575514|NCT02774928||Chronic Obstructive Pulmonary Disease|Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
16575515|NCT02774928||Interstitial lung diseases|Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
16575516|NCT02774928||Obstructive sleep apnea (OSA)|"Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.
~These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
~OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome-also referred to as obstructive sleep apnea-hypopnea syndrome."
16575517|NCT02774902|Experimental|TAK-438 40 mg + Clarithromycin 500 mg|TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.
16575518|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.
~Fall prevention tips
~Fall prevention exercise videos noting technique and safety
~Guest expert videos and communication with expert
~Tools to set exercise goals, reminders and track progress
~Fall prevention specialist for feedback and group activities
~Discussion and messaging (1:1, small and large group)
~Fall prevention resources."
16575519|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
16575520|NCT02774876|Active Comparator|Carbohydrate meal|
16575521|NCT02774876|Active Comparator|Carbohydrate + fat meal|
16575522|NCT02774876|Active Comparator|Carbohydrate + protein meal|
16575523|NCT02774876|Active Comparator|Carbohydrate + fat + protein meal|
16575524|NCT02774863||"Group Maternal and Child Protection"|Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
16575525|NCT02774863||"Group Home passages"|A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.
16575526|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
16575527|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
16575528|NCT02774837|Experimental|combination|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
16575529|NCT02774837|Active Comparator|mono therapy|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
16575530|NCT02774824||CABG patients from protocol 003-03|"Patients who will agree to be followed for an additional 9 months, which include:
~2 phone calls at 6 and 9 months after coronary artery bypass graft surgery
~1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography)"
16575531|NCT02774811|Active Comparator|Selective laser trabeculoplasty|Selective laser trabeculoplasty
16575532|NCT02774811|Active Comparator|Prostaglandin analogue|Prostaglandin analogue topical medical therapy
16575533|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:
~Oxford Grades 1 & 2 - intra-rectal intussusception
~Oxford Grades 3 & 4 - intra-anal intussusception
~Oxford grade 5 - Overt Rectal Prolapse"
16575534|NCT02774785|Experimental|Device Arm|Randomized for MarginProbe device to be used during surgical procedure
16575535|NCT02774785|No Intervention|Control Arm|Randomized for surgical procedure to happen as per standard care
16575592|NCT02774382|Experimental|Vancomycin + rectal bacteriotherapy|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
16575593|NCT02774369|Experimental|Physical exercise|A 6-week individualised, aerobic intervention program elaborated by a kinesiologist following a complete assessment of the individual's physical condition.
16575536|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.
~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.
~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.
~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
16575537|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.
~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.
~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
16575538|NCT02774759|Active Comparator|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.
~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.
~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
16575541|NCT02774720|Experimental|Centre-based physical activity|People with Mild Cognitive Impairment (MCI) and early dementia will receive centre-based physical activity for one hour each week for three months, plus at-home prescribed exercise.
16575542|NCT02774720|Experimental|Home-based exercise|People with Mild Cognitive Impairment (MCI) and early dementia be prescribed at-home prescribed exercise and will received monthly support phone calls.
16575543|NCT02774694||observational cohort|patients undergoing interventional pain management procedures
16575544|NCT02774681|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
16575545|NCT02774668|Active Comparator|"Grab-and-Go meal plan"|"The intervention of this arm is to use a Grab-and-Go meal plan. This meal plan provides Atkins shakes and bars for breakfast, lunch, and snacks for 2 weeks. For dinner the subject is given a freshly-prepared meal. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
16575546|NCT02774668|Active Comparator|"Jump-Start meal plan"|"The intervention of this arm is to use a Jump Start meal plan. This meal plan provides Atkins frozen meals at breakfast, lunch and dinner for 2 weeks and these meals are supplemented with fresh salads and vegetables. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
16575547|NCT02774655|Experimental|PAI APP|personal activity index application
16575548|NCT02774655|Active Comparator|FitBit APP|
16575549|NCT02774642|Experimental|CBTI-PE|Integrates the core components of CBT-I and PE in 14 90-minute weekly sessions.
16575550|NCT02774642|Active Comparator|Hygiene-PE|Uses non-active sleep hygiene to account for the dose response of experimental condition before starting PE. Uses 14 90-minute weekly sessions.
16575551|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
16575552|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
16575553|NCT02774616|Other|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
16575554|NCT02774603|Active Comparator|Aquatic Locomotor Training|Aquatic Locomotor Training is a Locomotor Training technique utilizing an underwater treadmill to help increase a patient's independence and function. Aquatic Locomotor Training may require up to three people to obtain desirable gait kinematics: one at each of the patient's legs, and one at the patient's pelvis; however, typically with ambulatory patients, only one therapist is utilized. Therapists are highly trained, using their legs and feet to provide properly timed underwater cues throughout the gait cycle.
16575555|NCT02774603|Active Comparator|Land Locomotor Training|Locomotor Training encompasses a variety of interventions ranging from BWSTT to overground gait training to robotic-assisted walk training. Overground Locomotor Training, depending upon the technique used, can require up to four people to complete the intervention (one at each participant's leg, one at the participant's trunk and/or pelvis, and one monitoring the computer and/or treadmill).
16575556|NCT02774590|Experimental|Timolol to split face for 8 weeks|All 24 subjects will receive study drug and everyone will be randomized to which side of the face is treated with study drug first (right half-face versus left half-face). After 8 weeks of split-face treatment every night before bed, the subjects will be instructed to start treating both sides for another 8 weeks. Up to 30 subjects may be enrolled to ensure a target sample size of 24 (12 acne cases, 12 rosacea cases). This is an exploratory study. No part of this protocol will be considered routine care.
16575557|NCT02774577|Experimental|healthy young and elderly|young adults (20 to 30 years) compare to elderly (60 to 74 years)
16575558|NCT02774564|Experimental|Nebicapone 50 mg|1 tablet of 50 mg plus 3 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
16575559|NCT02774564|Experimental|Nebicapone 100 mg|2 tablets of 50 mg plus 2 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
16575562|NCT02774551|Experimental|Physical activity intervention group|The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse. The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
16575563|NCT02774551|No Intervention|Standard care control group|Patients follow their routine daily physical activity.
16575564|NCT02774538|Other|Experimental arm|
16575565|NCT02774525|Active Comparator|Treatment as Usual (TAU)|Outpatient substance-abuse treatment plus drug and alcohol screening plus brief support for personal goal setting
16575566|NCT02774525|Experimental|Contingency Management|Contingency management for drug and alcohol abstinence plus TAU
16575567|NCT02774525|Experimental|Parenting Intervention|Parenting intervention plus TAU
16575568|NCT02774525|Experimental|Parenting Intervention + Contingency Management|Parenting intervention plus contingency management for drug and alcohol abstinence plus TAU
16575569|NCT02774512|Experimental|Nilotinib|A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status. Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days. The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours). When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
16575570|NCT02774499|Experimental|Methadone|Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
16575571|NCT02774499|Placebo Comparator|Placebo|Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
16575572|NCT02774486|Experimental|IQP-AK-102|2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
16575573|NCT02774460|Active Comparator|Zestril® (Lisinopril)|Inhibition of angiotensin converting enzyme (ACE inhibitor). Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
16575574|NCT02774460|Active Comparator|Atacand® (Candesartan)|Angiotensin receptor blocker. Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
16575575|NCT02774460|Active Comparator|Norvasc® (Amlodipine)|Calcium channel blocker. Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
16575576|NCT02774460|Active Comparator|Hydrochlorothiazide® (Hydrochlorothiazide)|Diuretic agent. Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
16575577|NCT02774460|Active Comparator|Repeated treatment X|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.
~The repeated arms will be given with the same duration and dosing as the other arms."
16575578|NCT02774460|Active Comparator|Repeated treatment Y|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.
~The repeated arms will be given with the same duration and dosing as the other arms."
16575579|NCT02774460|Placebo Comparator|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
16575580|NCT02774447||Rectal cancer patients with ileostoma|"In association with anterior resection of rectal cancer these patients obtain loop-ileostoma in order to avoid complications. These are closed within a few months and according to previous studies the admission time is 3-5 days after operation. This study is a single-arm study. The arm include patients having had rectal cancer operation and who have obtained a loop-ileostoma and that meet the inclusion criteria.
~The operation procedure is standardized; shortly described by dissecting the ileostoma from the abdominal wall and everting the stoma ledges, which will be sutured or stapled. The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will be followed up."
16575581|NCT02774434|Experimental|JM-105|Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
16575582|NCT02774421|Experimental|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
16575583|NCT02774421|Experimental|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
16575584|NCT02774408|Other|CPAP|"Infants on CPAP will receive backup breafs whenever the SpO2 <88 % along with
~automated FiO2 controller. In the control period they will receive automated FiO2
~alone"
16575585|NCT02774408|Other|NIMV/NIPPV|"Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate
~of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%
~( max rate 100/min) in the reference period as compared to baseline (automated FiO2
~- control + unchanged SIPPV settings)"
16575586|NCT02774395||endometrioid adenocarcinoma grade I|
16575587|NCT02774395||endometrioid adenocarcinoma grade II|
16575588|NCT02774395||endometrioid adenocarcinoma garde III|
16575589|NCT02774395||healthy endometrioid|obtain after hysterectomia provided for
16575590|NCT02774382|Active Comparator|Vancomycin|"Oral vancomycin according to number of recurrences (Danish guidelines):
~First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days
~≥2 recurrences:
~capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by
~capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by
~capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by
~capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by
~capsule vancomycin 125 mg x 1 p.o. every third day for 14 days"
16575591|NCT02774382|Experimental|Vancomycin + fecal microbiota transplantation|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
16575594|NCT02774369|Active Comparator|Cognitive-behavioral therapy|A 6-week self-administered cognitive-behavioral therapy for insomnia composed of a 60-min video (DVD format) and 6 booklets.
16575597|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
16575598|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
16575599|NCT02774330||Minneapolis, Minnesota Customers|"Minneapolis, Minnesota has a policy in place whereby minimum quantities and varieties of healthy food are required for all licensed food stores. The policy is our intervention condition."
16575600|NCT02774330||St. Paul, Minnesota Customers|No policy exists in St. Paul, Minnesota. This is the control condition.
16575601|NCT02774317|Active Comparator|FFP|Patients receive FFP as clinically indicated (INR 1.5 or more)
16575602|NCT02774317|Experimental|FP24|Patients receive FP24 as clinically indicated (INR 1.5 or more)
16575603|NCT02774304|Active Comparator|arterial line|invasive haemodynamic monitoring
16575604|NCT02774304|Experimental|Cheetah®|non-invasive cardiac output
16575605|NCT02774291|Experimental|Treatment (mTCR, aldesleukin)|Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.
16575606|NCT02774278|Experimental|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
16575607|NCT02774265|Active Comparator|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
16575608|NCT02774265|Active Comparator|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
16575609|NCT02774252|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16575610|NCT02774239|Experimental|SC Treatment Period|"Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:
~1st week: 2-3 SCIG infusions of 10ml per site at four sites (total dose 16 to 24g)*
~2nd week: 2-3 SCIG infusions of 15ml per site at four sites (total dose 24 to 36g)*
~3rd week: 2-4 SCIG infusions of 20ml per site at four sites (total dose 32 to 64g)*
~4th week: 2-4 SCIG infusions of 25ml per site at four sites (total dose 40 to 80g)*
~Doses indicated are study recommended. Doses may be adjusted depending on tolerance and total dose required by the patient."
16575611|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
16575612|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
16575613|NCT02774200|Experimental|test group|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
16575614|NCT02774187|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
16575615|NCT02774187|Active Comparator|Sorafenib alone|Sorafenib alone
16575616|NCT02774174||METS Proximal Humeral system|Implanted with METS Proximal Humerus
16575617|NCT02774161|Experimental|Diagnostic (B-mode ultrasound imaging)|Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.
16575618|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
16575619|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
16575620|NCT02774135||direct occupational therapy intervention|group will be evaluated 4 times: on referral to waiting list for treatment, before and after 9-12 direct individual treatments of 45 minutes, and follow-up after 3 months.
16575621|NCT02774122|Active Comparator|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
16575622|NCT02774122|Experimental|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
16575623|NCT02774109|Experimental|Experimental group|Participants in the experimental group will take fish oil (five 1000mg fish oil soft capsules per day, each capsule containing 350mg EPA and 250mg DHA) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
16575624|NCT02774109|Placebo Comparator|Control group|Participants in the control group will take placebo (five 1000mg sunflower oil soft capsules per day) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
16575625|NCT02774096|No Intervention|Control group（Ascending aorta）|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
16575626|NCT02774096|Experimental|Xenon Post-conditioning|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
16575627|NCT02774083|Active Comparator|Feuerstein Program|The participants of the Intervention Group will participate in the Feuerstein mediated learning cognitive program.
16575628|NCT02774083|Placebo Comparator|Adler Program|The Control Group will participate in the program of the Adler Institute dealing with social and emotional development without specific cognitive skills training.
16575629|NCT02774070|Other|Symptomatic atlantoaxial joint affection|Undergo plain X-ray and magnetic resonance imaging
16575630|NCT02774070|Other|Asymptomatic atlantoaxial joint aff.|Undergo plain X-ray and magnetic resonance imaging
16575992|NCT02771665||Breast cancer women without recurrences|Breast cancer women without recurrences
16575631|NCT02774057|Experimental|Initial therapy with Captafer®|This arm will consist of 10 patients who will begin Captafer® therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Iron Sulfate therapy twice daily for an additional 6 weeks.
16575632|NCT02774057|Experimental|Initial therapy with Iron Sulfate|This arm will consist of 10 patients who will begin Iron Sulfate therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Captafer® therapy twice daily for an additional 6 weeks.
16575633|NCT02774044|Experimental|Cadisurf (goat lung surfactant extract)|Neonates in the intervention group will be intratracheally administered 100 mg/kg of GLSE (CADISURF®).
16575634|NCT02774044|Active Comparator|Survanta (Beractant)|
16575635|NCT02774031|Experimental|Aisys with Et control|the ventilation modus will be pressure control ventilation with volume guarantee (PCV-VG). Settings: tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR) 12 -14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP). Target for end expired desflurane concentration (F A des) is set to 4.2%, and target for end expired oxygen (F AO2) is set to 35%.
16575636|NCT02774031|Active Comparator|Aisys conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Aisys with PCV-VG'
16575637|NCT02774031|Experimental|Flow-i with ACG|the following parameters will be preset: FIO2= 40%; end expired gas concentration (FA des) to 4.2%; speed 6; and ventilation modus = pressure regulated volume control (PRVC) with tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR)12-14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP).
16575638|NCT02774031|Active Comparator|Flow-I conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Flow-i with ACG'
16575639|NCT02774018|Experimental|12 institutionalized elderly people|Mindfulness-Based Stress Reduction program.
16575640|NCT02774005|Experimental|Raxone|
16575641|NCT02773992||The IoT group|
16575642|NCT02773992||The routine management group|
16575643|NCT02773979|Active Comparator|Group 1: PfSPZ 51200 sporozoites/Placebo|Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
16575644|NCT02773979|Active Comparator|Group 2: PfSPZ 102400 sporozoites/Placebo|CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
16575645|NCT02773979|Active Comparator|Group 3: PfSPZ 102400 sporozoites|CQ/PfSPZ Challenge 102400 sporozoites N=9
16575646|NCT02773966|Experimental|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
16575647|NCT02773966|Active Comparator|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
16575648|NCT02773953|Experimental|CPAP + T4PTelemonitoring device|T4P® (Telemonitoring device) is added to CPAP at home. Sleep lab technical staff are connecting to the web portal 2 X/ week. In case of air leaks, persistant significant apnea-hypopnea index, use < 3h on three consecutive days, they have to call the patient .
16575649|NCT02773953|Active Comparator|CPAP standard care|After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
16575650|NCT02773940|Experimental|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
16575651|NCT02773927|Experimental|Agave inulin + Metformin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
16575652|NCT02773927|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
16575653|NCT02773927|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
16575654|NCT02773927|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
16575655|NCT02773914|Experimental|CGA intervention|The CGA intervention will include multidisciplinary teams consisting of physician, nurse (RN), physiotherapist (PT), occupational therapist (OT) and social worker (SW). The team will work according to CGA, and have the primary and continuing responsibility for planning of hospital care and discharge. CGA will include assessment of socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, as well as treatment and planning for discharge and follow-up.
16575656|NCT02773914|No Intervention|Control group|The control group receives usual hospital care, that is care given at an ordinary medical hospital ward, without the specialized multi-disciplinary team approach and CGA.
16575657|NCT02773901|Experimental|HS-1000 recording|ICP monitoring will be done with the HS-1000 to compare to CSF measurement from lumbar puncture (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals last 10 minutes.
16575658|NCT02773888|Experimental|HS-1000 recording|ICP readings will be recorded in parallel from both the invasive ICP monitor, and HeadSense's non-invasive ICP monitor. Each recording session will be done until an aggregate of at least 30 minutes worth of quality data is collected, depending on the patient's clinical condition. For each patient, two recording sessions will be completed for 30-60 minutes each for 120 minutes total.
16575659|NCT02773875|No Intervention|Sensor Augmented Pump (control)|Use sensor augmented pump (SAP) for 3 weeks.
16575660|NCT02773875|Experimental|Artificial Pancreas (intervention)|Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
16575755|NCT02773212|Active Comparator|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
16575661|NCT02773862|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an invasive monitoring device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 48 hours, continuously depending on the patient's clinical condition.
16575662|NCT02773849|Experimental|INSTILADRIN|Intravesical administration of INSTILADRIN into the bladder
16575663|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
16575664|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
16575665|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
16575666|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
16575667|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
16575668|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
16575669|NCT02773823|Active Comparator|Intervention|"Lifestyle intervention includes diet instruction and exercise intervention:
~Diet instruction: The children were asked to increase fruit/vegetables consumption, reduce high fat food, etc.
~Exercise intervention: The children participated sports 60 min/day,5d/week for 8 months."
16575670|NCT02773823|No Intervention|Control|"No intervention in the group with control."
16575671|NCT02773810|Experimental|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
16575672|NCT02773797|Placebo Comparator|IN-DEX 1.0 mcg/kg, intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
16575673|NCT02773797|Placebo Comparator|IN-DEX, 1.5 mcg/kg intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label IN-DEX intranasal 1.5 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
16575674|NCT02773797|Active Comparator|Placebo - Saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Placebo - Saline will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
16575675|NCT02773784||invasive breast cancer|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
16575676|NCT02773771|Placebo Comparator|Placebo + Vital HP|GROUP 1 will receive Placebo (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas.
16575677|NCT02773771|Experimental|B-hydroxy-B-methylbutyrate (HMB) + Vital HP|GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
16575678|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
16575679|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
16575680|NCT02773745|No Intervention|Standard of Care|Participant will receive standard of care and a brochure on healthy eating.
16575681|NCT02773745|Active Comparator|Aquatic Prehabilitation Group|The prehabilitation group will undergo 6-8 weeks of individualized aquatic exercise in a heated pool (60 min/session, 3 times per week). Aquatic equipment maybe used to challenge balance and trunk stabilization.
16575683|NCT02773719|Experimental|True biofield therapist|Subject will have a 40 minutes therapy with a real biofield therapist to treat the wart
16575684|NCT02773719|Placebo Comparator|Fake biofield therapist|Subject will have a 40 minutes therapy with a fake biofield therapist to treat the wart
16575685|NCT02773706|Experimental|Usual Subspecialty Care|"Once a subject is screened positive for anxiety or depression, the subspecialty provider is informed of the positive screen, and left to manage or refer the condition as per usual care by that provider.
~Intervention: Depression / anxiety screen + clinician informed."
16575993|NCT02771652|Active Comparator|e-training intervention|Resistance and endurance training
16575994|NCT02771652|Other|Control|no exercise
16575686|NCT02773706|Active Comparator|Integrated Psychology Care|"Once a subject is screened positive for anxiety or depression, an automated psychology referral occurs, in addition to any intervention determined by the subspecialty provider.
~Intervention: Depression / anxiety screen + clinician informed + automated psychologist visit."
16575687|NCT02773693|Active Comparator|CPT|Cognitive Processing Therapy-cognitive only version (typically labeled CPT-C, but labeled CPT in this grant for simplicity) is a type of Cognitive Therapy addressing daytime symptoms of PTSD. This arm will have 12 twice-weekly sessions, followed by 6 weekly sessions.
16575688|NCT02773693|Active Comparator|CBTin+CPT|Cognitive Behavioral Therapy of Insomnia and nightmares (CBTin) will be used to address nighttime symptoms of PTSD during 6 weekly sessions, followed by 12 twice-weekly sessions of CPT.
16575689|NCT02773693|Active Comparator|CPT+CBTin|12 twice-weekly sessions of CPT followed by 6 sessions of CBTin.
16575690|NCT02773680|Experimental|Study cohort 1|"electrical impedance tomography"
16575691|NCT02773654||Healthy Volunteers|Asymptomatic subjects: subjects without complaints or history of shoulder pain or obvious movement abnormalities.
16575692|NCT02773654||Symptomatic Volunteers|Symptomatic subjects: subjects with shoulder pain who have active range of motion beyond 120° of elevation.
16575693|NCT02773641|Active Comparator|Botulinum Toxin Type A|50 Allergan units (0.5 ml) injected in m bulbocavernosus twice with 3 months in between treatments
16575694|NCT02773641|Placebo Comparator|Sterile saline solution|0.5 ml of sterile saline injected in m bulbocavernosus twice with 3 months in between treatments
16575695|NCT02773628|Placebo Comparator|control group|stable asthmatics receiving an Acar'up placebo system
16575696|NCT02773628|Active Comparator|treatment group|stable asthmatics receiving Acar'up system
16575697|NCT02773602|Experimental|Dexamethasone|Dexamethasone has been used for adult epidurals and nerve blocks and in spine surgeries. It prolongs the duration of pain relief and causes less sedation. It is commonly administered to children during surgery to help decrease nausea and vomiting after surgery. It is also much cheaper than clonidine The patient will receive Ropivacaine plus 200 μgm/kg of dexamethasone in 1 ml saline
16575698|NCT02773602|Active Comparator|Clonidine|"Clonidine has been added to caudal analgesia for infants and children for many years. It increases the duration of pain relief of ropivicaine by itself, however, it may lead to prolonged sedation following the surgical procedure (an undesired effect) and it is expensive.
~The patient will receive Ropivacaine plus 2 μg/kg of clonidine in 1 ml saline."
16575699|NCT02773602|Placebo Comparator|Normal Saline|The patient only will receive Ropivacaine
16575700|NCT02773589|Experimental|Peroral endoscopic myotomy|
16575701|NCT02773576|Experimental|2x360 mg risperidone implant|2, 360 mg risperidone implants
16575702|NCT02773576|Experimental|3x300 mg risperidone implant|3, 300 mg risperidone implants
16575703|NCT02773563||EUS with CO2 insufflation|Patients undergoing EUS with CO2 insufflation
16575704|NCT02773563||EUS with air insufflation|Patients undergoing EUS with air insufflation
16575705|NCT02773550|Experimental|Velcadito|Bortezomib 1.3 mg/m2 days 1,4,8 and 11 first cycle, the 1.0 mg/m2 days 1 and 4. Melphalan 9 mg/m2 days 1 to 4 Prednisone 60 mg/m2 days 1 to 4 Cycles of 28 days
16575706|NCT02773537|Active Comparator|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
16575707|NCT02773537|Active Comparator|Randomization Group 2|Adductor canal catheter and selective tibial block
16575708|NCT02773537|Active Comparator|Randomization Group 3|Adductor canal catheter only
16575709|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
16575710|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
16575711|NCT02773511|Other|Bone healing|Bone healing in surgical or conservative treatment for children type 1 humeral condyle fracture
16575712|NCT02773511|Other|Fracture displacement|Fracture displacement in surgical or conservative treatment for children type 1 humeral condyle fracture
16575713|NCT02773498|Active Comparator|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
16575714|NCT02773498|Experimental|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
16575715|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
16575756|NCT02773212|Active Comparator|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
16575811|NCT02772874||Urge-predominant|All subjects who report fecal incontinence that is primarily urge-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
16575716|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
16575717|NCT02773472|Experimental|Electroacupuncture Group|In addition to morphine, patients will receive 4 sessions of electroacupuncture after surgery over four days, with each session lasting 30 minutes.
16575718|NCT02773472|Other|Morphine Group|Neither electroacupuncture nor sham acupuncture will be given. Patient use morphine for analgesia.
16575719|NCT02773459|Experimental|Phase 1 part|to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
16575720|NCT02773459|Experimental|Expansion part|to assess the efficacy (PFS) of MEK162+Capecitabine combination
16575721|NCT02773446|Experimental|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
16575722|NCT02773446|Experimental|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
16575723|NCT02773446|Experimental|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
16575724|NCT02773446|Experimental|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
16575725|NCT02773446|Experimental|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
16575726|NCT02773446|Experimental|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
16575727|NCT02773433|Experimental|PAV group|Using Proportional Assist Ventilation after failed Spontaneous Breathing Trial
16575728|NCT02773433|No Intervention|Control group|Using Volume Assist Control mode after failed SBT
16575729|NCT02773420|Experimental|HET application arm|Patients with grade I-II internal hemorrhoids will undergo HET application
16575730|NCT02773407|Active Comparator|Group A|Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)
16575731|NCT02773407|Active Comparator|Group B|Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)
16575732|NCT02773394||Group 1|Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
16575733|NCT02773381|Experimental|Semaglutide 3 mg, 7 mg, 14 mg|
16575734|NCT02773381|Placebo Comparator|Placebo|
16575735|NCT02773368|Experimental|IDegLira|
16575736|NCT02773368|Active Comparator|IGlar|
16575737|NCT02773355||Saxenda®|
16575738|NCT02773342||Pathological findings in chest CT|
16575739|NCT02773329|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive exercise program (game-based exercise) intervention twice a week for 6 weeks.
16575740|NCT02773329|Active Comparator|Intervention without game-based exercise|Subjects will be receiving non-technology based foot and ankle exercise twice a week for 6 weeks
16575741|NCT02773316|Experimental|MR902 50/0.5 mg|MR902 50/0.5 mg PR tablets, single dose oral
16575742|NCT02773316|Experimental|MR902 200/2 mg|MR902 200/2 mg PR tablets, single dose oral
16575743|NCT02773316|Active Comparator|IR morphine sulphate 10 mg/5mL solution|IR morphine sulphate 10 mg/5mL solution, single dose oral
16575744|NCT02773303|Active Comparator|Active|Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
16575745|NCT02773303|Sham Comparator|Control|Children not receiving neurofeedback based therapy, but receiving the Sham therapy
16575746|NCT02773290|Experimental|Romiplostim|Weekly Subcutaneous (SC) administration
16575747|NCT02773277|Experimental|Single intervention arm|All patients will be assigned the intervention arm and will receive head-impulse testing before and in the days after skull base surgery.
16575748|NCT02773264||UltraSound Patients|All patients will undergo next to the clinical indicated conventional US-examination, US Elastography after informed consent. After completion of these three examinations, the participation in the study is completed.
16575749|NCT02773251|Experimental|hyaluronic acid-carboxymethylcellulose treatment group|the HA/CMC treatment group after laparoscopic pelvic surgery
16575750|NCT02773251|No Intervention|control group|the HA/CMC non-treatment group after laparoscopic pelvic surgery
16575751|NCT02773238|Experimental|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or > 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
16575752|NCT02773225|Experimental|Eltrombopag + Ciclosporin A|"Eltrombopag, 75 mg film tablets, starting dose: 2 tablets (150 mg per day), daily, per os
~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
16575753|NCT02773225|Placebo Comparator|Placebo + Ciclosporin A|"Placebo for Eltrombopag 75 mg film tablets, 2 tablets, daily, per os
~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
16575754|NCT02773212|Experimental|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
16575805|NCT02772913||acute mesenteric ischemia|patients with abdominal pain and acute mesenteric ischemia
16575757|NCT02773199||Cohort 1- Morning Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in morning hours (until 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for 8 hours
16575758|NCT02773199||Cohort 2- Afternoon Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in afternoon hours (after 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for more than 12 hours
16575759|NCT02773173|Experimental|Individualized Pneumoperitoneum Pressure|In Individualized Pneumoperitoneum Pressure (IPP) group, measures to optimize and individualize intra-abdominal pressure (PIA) will be apply.
16575760|NCT02773173|Other|Standard Pneumoperitoneum Pressure|In Standard Pneumoperitoneum Pressure (SPP) group, a conventional operation without optimization measures and PIA preset to 12 mmHg will be conducted.
16575761|NCT02773160|Experimental|Sensor-based postural feedback|Subjects will receive visual feedback on a computer screen while practicing the motor control task. The feedback is based on information from from motion sensors that mointor the movements of the lumbar spine
16575762|NCT02773160|Experimental|Mirror Feedback|Subjects will receive feedback from a mirror while practicing the motor control task
16575763|NCT02773160|Active Comparator|control group|Subjects will receive no feedback while practicing the motor control task
16575764|NCT02773147|Experimental|Triobe|Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
16575765|NCT02773147|No Intervention|Control|
16575766|NCT02773134|Active Comparator|Brace Group|Patients in the brace group will be fitted by an orthotist postoperatively and will be instructed to wear a rigid molded Lumbosacral Orthosis (LSO) full time for 8 weeks except during hygiene and wound care followed by daytime wear for another 4 weeks. All patients will start wearing the brace 48 hours after the surgery following removal of the wound drain. All braces will be molded and fitted by the same experienced orthotist affiliated with the hospital. Self-compliance to brace wear will be noted every day for 3 months by each patient on a specific form.
16575767|NCT02773134|Experimental|Control Group|No brace prescription postoperatively. Patients in this group will be observed and results will be compared to the brace group.
16575768|NCT02773121|Experimental|Physical activity monitoring|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their physical activity level to at least 150 min of moderate-intensity physical activity per week. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
16575769|NCT02773121|Active Comparator|Flexibility and balance|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their balance and flexibility over the 12 week period of the intervention. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
16575770|NCT02773108||Hospitalized|Hospitalized psychiatric patients
16575771|NCT02773108||Daily hospital|
16575772|NCT02773108||Outpatients|
16575773|NCT02773095|Experimental|Intervention counties|In intervention counties, a Novartis Access portfolio of 15 medicines will be sold to local purchasers at a cost of 150 Kenyan Shillings (KES), around US$1.50, per monthly dose.
16575774|NCT02773095|No Intervention|Control counties|Control counties not exposed to the intervention.
16575775|NCT02773082|Experimental|Reclaim™ DBS Therapy|Procedure: Reclaim™ DBS Therapy The DBS lead is stereotactically introduced into the target in the brain (AIC) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region. This is performed by a neurosurgeon skilled in this technique, as the same procedure is routinely performed in patients with other diseases (using other brain targets).
16575776|NCT02773069|Experimental|Weight loss program|Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.
16575777|NCT02773056|Active Comparator|Socket 1 (Ischial Ramus Containment)|This arm included unilateral transfemoral amputees who were assessed while using the Ischial Ramus Containment socket.
16575778|NCT02773056|Active Comparator|Socket 2 (Dynamic Socket IRC)|This arm included unilateral transfemoral amputees who were assessed while using the Dynamic Socket Ischial Ramus Containment socket.
16575779|NCT02773056|Active Comparator|Socket 3 (Sub-Ischial Interface)|This arm included unilateral transfemoral amputees who were assessed while using the Sub-Ischial Interface socket.
16575780|NCT02773043|Other|non invasive imaging technique|
16575781|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
16575782|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
16575783|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
16575806|NCT02772913||non-acute mesenteric ischemia|patients with abdominal pain without mesenteric ischemia
16575807|NCT02772900|Active Comparator|Beetroot gel (dietary nitrate)|Beetroot-based nutritional gel containing approximately 10.0 mmol of nitrate per dose
16575808|NCT02772900|Active Comparator|Placebo gel (nitrate-depleted)|Nutritional gel nitrate-depleted
16575809|NCT02772887|Experimental|Citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
16575810|NCT02772887|Placebo Comparator|Placebo|Placebo, 3 grams once per day for 3 weeks.
16575784|NCT02773030|Experimental|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA.
~Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
~Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle."
16575785|NCT02773030|Experimental|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.
~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.
~Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle."
16575786|NCT02773030|Experimental|Cohort G1-CC-220 in combination with CFZ and DEX -Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
~Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle
~Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg"
16575787|NCT02773030|Experimental|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
~Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle
~Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg"
16575788|NCT02773030|Experimental|CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
16575789|NCT02773030|Experimental|CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above).
~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.
~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
16575790|NCT02773030|Experimental|CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle.
~Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.
~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
16575791|NCT02773017|Experimental|Youth female group|patients in the Youth female group, aged 20~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
16575792|NCT02773017|Experimental|Middle-aged female group|patients in the Middle-aged female group, aged 40~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
16575793|NCT02773017|Experimental|Elderly female group|Patient in the elderly female group, aged 65~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
16575794|NCT02773004|Other|EndoPredict (EP)clin testing|Once the patient is registered, the most representative block of the primary tumor from surgery (or 10 paraffin slides) are sent to the central analysis platform for EP clin testing. The EPclin method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.
16575795|NCT02772991|Experimental|Cases|All patients will be submmited to troponin measurements and CCTA. If CCTA shows coronary stenosis ≥ 50%, patient will initiate the ACS treatment and be hospitalized to have coronary cineangiography. If CCTA shows lesions < 50%, the patient will be discharged and monitored for 30 days. A second sampling of the troponin will be obtained from all patients three hours after the first collection in order to evaluate for an increase/decrease of troponin.
16575796|NCT02772978|Active Comparator|tolcapone arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
16575797|NCT02772978|Placebo Comparator|placebo arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
16575798|NCT02772965|Experimental|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.
~Folic Acid (1 mg) daily"
16575799|NCT02772965|Placebo Comparator|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.
~Folic Acid (1 mg) daily"
16575800|NCT02772952|Other|Control Group|a control group whose intervention will be to review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
16575801|NCT02772952|Experimental|Experimental Group|Experimental group whose intervention will be a Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program.
16575802|NCT02772939|Experimental|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
16575803|NCT02772926|Placebo Comparator|Placebo|450 g per pill, 2 pills per day to get 900 mg per day
16575804|NCT02772926|Active Comparator|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
16575812|NCT02772874||Passive-predominant|All subjects who report fecal incontinence that is primarily passive-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
16575813|NCT02772861|Experimental|Citrulline|Citrulline is a non-protein amino acid that is present in substantial amounts in watermelon (Citrullus vulgaris), with a mean content of 2.1 mg/g fresh weight, ranging from 0.5 to 3.6 mg/g according to variety. The oral dose can reach 20 g, which was administered orally in the present study in one single dose, followed by a washout period of one week Amino Acid Supplement - One dose
16575814|NCT02772861|Experimental|Glutamine|"L-glutamine is a protein amino acid found in proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient l-glutamine to meet physiological demands. However, there are conditions where the body cannot do so. Recently, l-glutamine has come to be regarded as one of the most important of the amino acids when the body is subjected to such metabolic stress situations as trauma (including surgical trauma), cancer, sepsis and burns. In the present study, glutamine was administered orally in one single dose of 20 g, followed by a washout period of one week.
~Amino Acid Supplement - One dose"
16575815|NCT02772861|Experimental|Arginine|"Arginine was administered orally in 20 g for one single dose, followed by a washout period of 1 week.
~Amino Acid Supplement - One dose"
16575816|NCT02772861|Experimental|3-Methyl-Histidine|"This amino acid is made by methylation of the actin and myosin peptide chains in the muscle. Metabolism after intravenous administration of L-3-methylhistidine involves excretion in the urine of 75% of the administered dose in 24 h and 95% in 48 h.
~3-Methyl-Histidine was administered orally in 120 mg for one single dose, followed by a washout period of 1 week."
16575817|NCT02772861|Placebo Comparator|Placebo|Dextrose (glucose) was used in a dose of 20 g in this study.
16575818|NCT02772835|Active Comparator|nHFOV|Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
16575819|NCT02772835|Active Comparator|nCPAP|Starting treatment mode: nCPAP with Medin-cno. Targeted oxygen saturation of 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the be-ginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A se-cond capillary BGA will be performed at the end of second period.
16575820|NCT02772822|Experimental|Experimental|SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
16575821|NCT02772822|Active Comparator|Active Comparator|Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
16575822|NCT02772809|Other|Stroke survivors with low and moderate motor deficits|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
16575823|NCT02772796|Experimental|SENS-218|2 x 10 mg administered once on Day 1.
16575824|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
16575825|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
16575826|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
16575827|NCT02772770||Non Operative: Rehabilitation, Bracing, Activity Restriction|
16575828|NCT02772770||Operative: Transphyseal|
16575829|NCT02772770||Operative: Partial Transphyseal|
16575830|NCT02772770||Operative: Physeal sparing by Anderson Technique|
16575831|NCT02772770||Operative: Physeal sparing by Micheli/Kocher Technique|
16575832|NCT02772757|Active Comparator|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
16575833|NCT02772757|Experimental|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
16575834|NCT02772757|Experimental|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
16575835|NCT02772744||Group 1: Easy to treat group|"Treatment naïve
~Total serum bilirubin ≤ 1.2 mg/dl
~Serum albumin ≥ 3.5 g/dl
~International normalized ratio ≤ 1.2
~Platelet count ≥ 150000 mm3
~This group will be receiving Sofosbuvir + daclatasvir for 12 weeks."
16575836|NCT02772744||Group 2: Difficult to treat group|"Peg interferon treatment experienced.
~Total serum bilirubin ≥ 1.2 mg/dl
~Serum albumin ≤ 3.5 g/dl
~International normalized ratio ≥ 1.2
~Platelet count ≤ 150000 mm3
~This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks."
16575837|NCT02772744||Group 3: Sofosbuvir resistant cases|This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.
16575838|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
16575839|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
16575840|NCT02772718|Experimental|Part 1 - single dose|Cohorts A, B, and C
16575841|NCT02772718|Experimental|Part 2 - multiple doses|Cohort 1
16575842|NCT02772705||Hyperthyroidism|Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
16575843|NCT02772705||Health Humans|Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
16575844|NCT02772692|Experimental|Squatting pan|Defecation using a squatting pan
16575845|NCT02772692|No Intervention|Toilet|defecation using a standard-sized toilet
16575847|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
16575848|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
16575849|NCT02772653||Severe trauma patients|"No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:
~Blood Lactate levels
~Blood Base Excess levels
~Blood B-type Natriuretic Peptide levels
~Blood Thromboelastometry (ROTEM) alterations
~Near-infrared spectroscopy alterations
~Sublingual videomicroscopy alterations
~All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission."
16575850|NCT02772640|Active Comparator|Arm I: R+E morning->evening|Rosuvastatin and Ezetimibe morning or evening administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the morning (8:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the evening hours (20:00).
16575851|NCT02772640|Active Comparator|ARM II: R+E evening->morning|Rosuvastatin and Ezetimibe evening or morning administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the evening (20:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the morning hours (8:00).
16575852|NCT02772627|Experimental|Nebicapone 100 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
16575853|NCT02772627|Experimental|Nebicapone 200 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
16575854|NCT02772627|Experimental|Nebicapone 300 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
16575855|NCT02772614|Experimental|Nebicapone (200 mg)|"Each subject was to receive one single dose of 2.5 MBq [14C]-labelled BIA 3-202 (200 mg) together with a total of 250 mL non-carbonated water.
~The study drug was given after an overnight fast of at least 10 hours after the in-house stay. During waking hours on Day 1, subjects had to have a fluid intake of at least 150 mL per hour starting 1 hour before study drug administration."
16575856|NCT02772601|Experimental|All patients|
16575857|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
16575858|NCT02772575||patients with primary liver or liver metastases|A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.
16575859|NCT02772562|Experimental|PROSTVAC-V/F|
16575860|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study all participants are subject to a set of three visual stimulus conditions.
~These are: Low ambient light; Self selected tinted light; White light"
16575861|NCT02772523|Other|Intervention|
16575862|NCT02772510|Experimental|Smart glove system with functional electrical stimulation|game-based virtual reality rehabilitation combined with functional electrical stimulation for upper extremity
16575863|NCT02772510|Active Comparator|Functional electrical stimulation|functional electrical stimulation on upper extremity
16575864|NCT02772497|Experimental|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks
16575865|NCT02772484|Experimental|HS-1000 recording|The recording session should be performed in a quiet environment with no disturbance to the patient for a total of up to 60 minutes.
16575866|NCT02772471|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and invasive ICP monitoring. HS-1000 ICP monitoring intervals will last at least 30 minutes, continuously depending on the patient's clinical condition.
16575869|NCT02772445|Experimental|STROKE-CARE Intervention|In STROKE-CARE, caregivers will learn a problem-solving strategy. Participants will receive approximately 10 sessions by an occupational therapist in the home over a 5 week process.
16575870|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
16575871|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
16575872|NCT02772419|Experimental|benralizumab A|Subcutaneous (SC) administration
16575873|NCT02772419|Experimental|benralizumab B|SC administration
16575874|NCT02772419|Placebo Comparator|Placebo|Placebo SC administration
16575875|NCT02772406|Experimental|Experimental group|(With LCI endoscopy and 1 month later with white light endoscopy) The patients will be evaluated by Linked Color Imaging and 1 month later evaluated by White Light endoscopy
16575876|NCT02772406|Active Comparator|Control group|(With white light endoscopy and 1 month later with LCI endoscopy) The patients will be evaluated by White Light endoscopy and 1 month later evaluated by Linked Color Imaging
16575877|NCT02772380|Experimental|VT/ VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and termination through use of a defibrillator, will be carried out as the intervention in all subjects undergoing study procedures.
16575878|NCT02772367||Breast Cancer Patients|In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.
16575879|NCT02772354|Experimental|Ablation|Standard radiosurgery ablation of premature ventricular complexes using navigation system.
16575880|NCT02772354|Active Comparator|Control|Antiarrhythmic therapy of premature ventricular complexes according to the guidlines
16575881|NCT02772341|Active Comparator|Salt room with halogenerator|Asthmatic patients sitting in a salt room with salt aerosol produced by a halogenerator.
16575882|NCT02772341|Placebo Comparator|Salt room without halogenerator|Asthmatic patients sitting in a salt room without salt aerosol
16575883|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
16575884|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
16575885|NCT02772315||Hypertensive patients|Diagnostic procedures in patients with hypertension applying omics results
16575886|NCT02772302|Experimental|Patients|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
16575887|NCT02772302|Experimental|Healthy Controls|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
16575888|NCT02772289|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
16575889|NCT02772289|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
16575890|NCT02772289|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
16575891|NCT02772276|Experimental|Normal-CKD Stage 2/QuantumLeap|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may receive different doses.
16575892|NCT02772276|Experimental|CKD Stage 3-4/QuantumLeap|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may receive different doses.
16575893|NCT02772276|Experimental|Normal-CKD Stage 2/Radiance|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575894|NCT02772276|Experimental|CKD Stage 3-5/Radiance|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575895|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance algorithm optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575896|NCT02772276|Experimental|CKD Stage 3-5/Brilliance algorithm optimization|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575897|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Sensor optimization of the Brilliance device will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575898|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor verification|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Verification of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575899|NCT02772276|Experimental|CKD Stage 3-5/Brilliance sensor verification|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Verification of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575900|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance final algorithm and sensor|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device will be tested. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm will receive two doses of MB-102, 12 hours apart.
16575901|NCT02772276|Experimental|CKD Stage 3-5/Brilliance final algorithm and sensor|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device will be tested. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
16575902|NCT02772263|Experimental|CHAP-EMS Intervention|Participants guided through a 15-20 minute defined risk assessment by a trained paramedic. Risk factors assessed were those related to cardiovascular and diabetes risk (blood pressure, diabetes-risk status, lifestyle factors), and potential for falls. Based on these, the paramedic provided education and developed an individualized action plan directing participants to use available community resources to assist them in addressing their risk factors. They were advised to return to CHAP-EMS sessions regularly for BP monitoring and follow-up. Each participant's information was faxed to his/her family physician once a month.
16575903|NCT02772250|Active Comparator|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by a investigator at 15:00-17:00 on the day before colonoscopy.
16575904|NCT02772250|Experimental|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
16575905|NCT02772237|Active Comparator|Treatment group|Riboflavin 400mg daily
16575906|NCT02772237|Placebo Comparator|Placebo group|Placebo
16575907|NCT02772224|Experimental|Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty
16575908|NCT02772224|Active Comparator|Conventional balloon angioplasty|Conventional balloon angioplasty
16575909|NCT02772211|Experimental|D-cycloserine|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
16575910|NCT02772211|Placebo Comparator|Placebo|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
16575911|NCT02772198|Experimental|Single Arm|All patients will be treated on this single arm
16575912|NCT02772185|Experimental|active tDCS plus real CT|Participants will receive active transcranial direct current stimulation and real cognitive training.
16575913|NCT02772185|Experimental|sham tDCS plus real CT|Participants will receive sham transcranial direct current stimulation and real cognitive training.
16575914|NCT02772185|Experimental|active tDCS plus placebo CT|Participants will receive active transcranial direct current stimulation and placebo cognitive training.
16575915|NCT02772185|Placebo Comparator|sham tDCS plus placebo CT|Participants will receive sham transcranial direct current stimulation and placebo cognitive training.
16575916|NCT02772172|Active Comparator|GuideMia surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
16575917|NCT02772172|Active Comparator|Control surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in control program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
16575918|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
16575919|NCT02772146|Experimental|Device: CLS UF|The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.
16575920|NCT02772133||STEMI patients|
16575921|NCT02772133||Healthy subjects|
16575922|NCT02772133||Unstable angina|
16575923|NCT02772120|Active Comparator|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
16575924|NCT02772120|Active Comparator|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
16575925|NCT02772107|Experimental|BSC group|Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. Radiotherapy was allowed. Follow-up until disease progression.
16575951|NCT02771912|Experimental|Propofol|"Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %).
~Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes.
~Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h."
16575926|NCT02772107|Experimental|TMZ group|"Patients will receive platinum-based first-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cyclesfor the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
~Re-staging will be performed every 2 cycles (every 8 weeks) during the study, radiotherapy was allowed."
16575927|NCT02772094|Experimental|Single arm, open-label|"Experimental:
~ADCTA-G total 10 doses, each dose (30+/-5 millions autologous dendritic cells plus 6+/-0.5 millions 100Gy-irradiated short-term cultured autologous GBM tumor cells) divided in 2 halves for subcutaneous injection into both axillar areas, in a course of 6 months (sequential series of weekly injections 4 times, bi-weekly injections twice; then monthly injections 4 times.
~Experimental: ADCTA-G total 10 doses, each dose (similar fore-mentioned numbers of 5:1 ratio of autologous dendritic cells and irradiated short-term cultured autologous GBM tumor cells) divided into 2 injections administered subcutaneously in both axillar areas, in a course of 8 months (sequential series of bi-weekly injections 4 times, then monthly injections 6 times)."
16575928|NCT02772081|Experimental|Curosurf LISA|"Single dose of poractant alfa 200 mg/kg via brief insertion of a thin catheter (CHF 6440) into the trachea in neonates with RDS.
~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.
~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
16575929|NCT02772081|Active Comparator|Curosurf Endotracheal Tube|"Single dose of poractant alfa 200 mg/kg via the conventional intubation with endotracheal tube in neonates with RDS.
~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.
~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
16575930|NCT02772068|Active Comparator|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
16575931|NCT02772068|Experimental|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
16575932|NCT02772055|Experimental|moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
16575933|NCT02772055|Experimental|smoke-free moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants and have a purification device at the top of the moxibustion to remove the moxa smoke.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
16575934|NCT02772042|Experimental|Intervention Group|Investigators will performed traction manipulation of those articulations of upper cervical spine with indication for this treatment. Before manipulation soft tissue techniques will be applied in order to prepare the joint. After manipulation the patient rest in supine position. The intervention will have a duration of 10 minutes.
16575935|NCT02772042|Other|Control Group|The patient of the control group maintain the supine position for 10 minutes.
16575936|NCT02772029|Experimental|Apatinib Mesylate Tablets|Apatinib (Apatinib Mesylate Tablets) 750 mg is administered orally daily, until disease progression or intolerable toxicity.
16575937|NCT02772016|Experimental|Intervention group|Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.
16575938|NCT02772016|No Intervention|Control group|Patients in control groups do not receive any intervention.
16575939|NCT02772003|Experimental|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
16575940|NCT02771990|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
16575941|NCT02771990|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
16575942|NCT02771977|No Intervention|Usual Care|No alert will be fired.
16575943|NCT02771977|Experimental|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
16575944|NCT02771964||All patients|All patients receive both types of quality of life assessment, thus serving as their own controls.
16575945|NCT02771951|Experimental|Special Intervention|Study participants randomized to receive Special Intervention receive a series of 7 group classes taught by trained clinic health educators; a series of phone calls; clinical visits with a mid-level provider; and a series of 6 booster group classes over 1 year.
16575946|NCT02771951|Placebo Comparator|Usual Care|Study participants randomized to receive Usual Care receive up to 2 visits with a usual care health educator over 1 year.
16575947|NCT02771938|Experimental|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
16575948|NCT02771938|Active Comparator|Radiotherapy after surgery|Mastectomy and DIEP flap reconstruction followed by radiotherapy (current standard treatment)
16575949|NCT02771925|Experimental|gabapentin|Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
16575950|NCT02771925|Placebo Comparator|Placebo|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
16575952|NCT02771912|Placebo Comparator|Intralipid|"Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion.
~Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes."
16575953|NCT02771899|Experimental|EOS + spineEOS software in adults|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
16575954|NCT02771899|Active Comparator|EOS in adults|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
16575955|NCT02771899|Experimental|EOS + spineEOS software in children|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
16575956|NCT02771899|Active Comparator|EOS in children|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
16575957|NCT02771886|Active Comparator|2-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 2nd week in the study. The duration of the study will be 6 weeks."
16575958|NCT02771886|Active Comparator|4-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 4th week in the study. The duration of the study will be 6 weeks."
16575959|NCT02771873|No Intervention|Usual care|Screening for CVD risk factors plus one time education regarding management of risk factors will be provided to all family members.
16575960|NCT02771873|Experimental|Life style Intervention and care coordination|Integrated cardiovascular disease risk management.
16575961|NCT02771860|Active Comparator|Experimental: denosumab|50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline.
16575962|NCT02771860|Placebo Comparator|Comparator|"50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks.
~Calcium and vit D supplementation will be installed at baseline"
16575963|NCT02771834||Experimental|women with osteoporosis
16575964|NCT02771834||Control|women without osteoporosis
16575965|NCT02771821|Experimental|Group Intervention|Individual routine consultation with the Family Health Unit team and participation in operative groups based on methodology of problematization
16575966|NCT02771821|No Intervention|Control Group|Individual routine consultation with the Family Health Unit team
16575967|NCT02771808||diabetic patients|obtain biomarker samples from diabetic patients and examine for 1-1 & 1-2 & 2-2 haptoglobin genotype
16575968|NCT02771795||Herceptin (trastuzumab)|Intravenous administration
16575969|NCT02771795||SB3 (proposed trastuzumab biosimilar)|Intravenous administration
16575970|NCT02771782|Experimental|BCG|Subjects are vaccinated with BCG vaccine (SSI) alone, 0,1ml intradermal
16575971|NCT02771782|Experimental|TDaP-IPV|Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular
16575972|NCT02771782|Experimental|BCG+TDaP-IPV|Subjects are vaccinated with BCG vaccine (SSI) (0.1ml intradermal) and TDaP-IPV vaccine Boostrix Polio (0.5ml intramuscular) simultaneously
16575973|NCT02771756|Experimental|test group|Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.
16575974|NCT02771756|Placebo Comparator|placebo group|Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.
16575975|NCT02771743|Experimental|High risk neuroblastoma|"Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen
~Upfront surgery or surgery after 6 cycles of chemotherapy
~Peripheral stem cell mobilization after 7 cycles of chemotherapy
~Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT)
~Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT
~Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT
~Radiotherapy after tandem HDCT
~Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin"
16575976|NCT02771730|Experimental|Vaccine A|Receive Ad4-mgag three times at 0,2,and 6 months with a boost at 8months
16575977|NCT02771730|Experimental|Vaccine B|Receive Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
16575978|NCT02771730|Experimental|Vaccine A & B|Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
16575979|NCT02771730|Placebo Comparator|Placebo|Receive placebo three times at 0,2,and 6 months with a boost at 8 months
16575980|NCT02771730|Experimental|Vaccine A & B (previously received study vaccine)|People who have previously had a study vaccine: Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
16575981|NCT02771717|Experimental|Budesonide (Pulmicort)|Low dose inhaled corticosteroid.
16575982|NCT02771717|Placebo Comparator|Placebo - dummy inhaler|Placebo - dummy inhaler
16575983|NCT02771704|Experimental|Silver diamine fluoride|Intervention: Silver diamine fluoride will be applied in vivo on carious dentine lesions
16575984|NCT02771704|Experimental|Potassium iodide|Potassium iodide will be applied in vivo on carious dentine lesions.
16575985|NCT02771704|Experimental|Chlorhexidine|Chlorhexidine will be applied in vivo on carious dentine lesions
16575986|NCT02771704|Experimental|Silver diamine fluoride+Potassium iodide|Silver diamine fluoride and potassium iodide mixture will be applied in vivo on carious dentine lesions
16575987|NCT02771704|Experimental|Saline|Sterile physiological saline will be applied in vivo on carious dentine lesions
16575988|NCT02771691|Experimental|MBT therapy plus treatment as usual|Mentalization based group treatment for adolescents plus standard care
16575989|NCT02771691|No Intervention|Treatment as usual alone|Standard care provided by local Child and Adolescent Mental Health Services
16575990|NCT02771678||Asthma|All participants will have an asthma-related crisis event due to an asthma exacerbation that resulted in A&E attendance and/or hospital admission.
16575991|NCT02771665||Breast cancer women with known recurrences|Breast cancer women with known recurrences (locoregional recurrence and distant metastasis)
16575995|NCT02771639||Femoral neck fractures|Patients admitted to Sundsvall hospital for a displaced femoral neck fracture and treated with a hip arthroplasty
16575996|NCT02771626|Experimental|CB-839 + Nivolumab Dose Escalation|Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).
16575997|NCT02771626|Experimental|Clear Cell RCC Naïve to Checkpoint Inhibitors|Cohort 1: CB-839/nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitors (TKI) but are treatment naive to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
16575998|NCT02771626|Experimental|Clear Cell RCC Recently Treated with Nivolumab|Cohort 2: CB-839/nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
16575999|NCT02771626|Experimental|Clear Cell RCC with Prior PD-1 Therapy|Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
16576000|NCT02771626|Experimental|Melanoma with Prior PD-1 Therapy|Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
16576001|NCT02771626|Experimental|NSCLC with Prior PD-1 Therapy|Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
16576002|NCT02771613||Active experience feedback|Multi professional, in situ simulation , with scenarios based on the adverse events analyzed in MMR : After analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
16576003|NCT02771613||Passive experience feedback|Large diffusion of information about discussions and decisions of Morbidity Mortality Reviews : after the analysis of adverse effects in Morbidity Mortality reviews, a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out.
16576004|NCT02771613||No experience feedback|MMR will be performed as usual, without any feedback to the medical staff
16576005|NCT02771600|Experimental|Buzzy|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
16576006|NCT02771600|Active Comparator|Standard Care (Maxilene)|Maxilene topical anaesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site
16576007|NCT02771587|Experimental|Alcohol and energy drink|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
16576008|NCT02771587|Active Comparator|Alcohol|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
16576009|NCT02771587|Active Comparator|Energy drink|3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
16576010|NCT02771587|Placebo Comparator|Placebo|"3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
~Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration."
16576011|NCT02771574|Experimental|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
16576012|NCT02771574|Experimental|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
16576013|NCT02771574|Experimental|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
16576014|NCT02771574|Experimental|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
16576015|NCT02771574|Experimental|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
16576016|NCT02771561|Other|Patent Foramen Ovale Closure|All eligible participants undergo a patent foramen ovale closure procedure
16576017|NCT02771548||Anterior Cruciate Ligament Reconstruction|Those who have undergone unilateral anterior cruciate ligament reconstructive surgery in the Sports Surgery Clinic.
16576018|NCT02771548||Control|Healthy volunteers with no previous knee injury, no current lower limb injuries and take part in regular multidirectional team sports.
16576019|NCT02771535|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
16576020|NCT02771535|Active Comparator|Health Training Group|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
16576021|NCT02771522|Other|Active post-othodontic lesions|Imaging with the Calcivis System
16576022|NCT02771509|Active Comparator|ANG-3777|Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
16576023|NCT02771509|Placebo Comparator|Normal Saline|The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
16576403|NCT02768974|Experimental|OPRX-106 8 mg|Open label, 1:1 randomization ration (up to 10 subjects)
16576024|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
16576025|NCT02771483||Suspected GCA (GCA final diagnosis)|
16576026|NCT02771483||Suspected GCA (alternative final diagnosis)|
16576027|NCT02771470|Experimental|Probiotic|Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
16576028|NCT02771470|Placebo Comparator|Placebo|Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
16576029|NCT02771457|Experimental|Infliximab at weeks 0,2, and 6|In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.
16576030|NCT02771457|Experimental|Infliximab at weeks 0,4, and 8|In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8
16576031|NCT02771457|Active Comparator|Infliximab at weeks 0, and 8|In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.
16576032|NCT02771444|Experimental|Tomo Assessment|Subjects will have a 4-view tomosynthesis examination with the study device.
16576033|NCT02771431|No Intervention|Standard|Group 1 will consist of patients receiving in-person attending-patient encounters while inpatients.
16576034|NCT02771431|Experimental|Tele-rounding|Group 2 will consist of patients receiving video-conference attending-patient encounters. The intervention is being seen via ipad
16576035|NCT02771418|Sham Comparator|TIVA with propofol|Induction and maintenance of general anesthesia using TIVA with propofol
16576036|NCT02771418|Active Comparator|VIMA with sevoflurane|Induction and maintenance of general anesthesia using VIMA with sevoflurane
16576037|NCT02771405|Experimental|Sofosbuvir +Ribavirin|Sofosbuvir 400 mg/day +ribavirin for 24 weeks
16576038|NCT02771405|Experimental|Sofosbuvir+Simeprevir±Ribavirin|Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
16576039|NCT02771405|Experimental|Sofosbuvir+Daclatasvir±Ribavirin|Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks
16576040|NCT02771405|Experimental|Sofosbuvir+Ledipasvir±Ribavirin|Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks
16576041|NCT02771392|Experimental|Tetracaine Group|Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
16576042|NCT02771392|Placebo Comparator|Normal Saline Group|Patients with the primary diagnosis of corneal abrasion will be treated with normal saline eye drops. Normal saline will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of normal saline. Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
16576043|NCT02771379||Patients who are treated with Raxone®|
16576044|NCT02771366|Experimental|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
16576045|NCT02771366|Placebo Comparator|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
16576046|NCT02771353|Active Comparator|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
16576047|NCT02771353|Active Comparator|VMAT_FB|Volumetric modulated arc therapy in free breathing.
16576048|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
16576049|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
16576050|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
16576051|NCT02771327|Experimental|CPAP plus gas|Treatment with Boussingnac valve CPAP during 6 hour, starting immediately after weaning
16576052|NCT02771327|Active Comparator|Usual treatment(ventimask plus gas)|ventimask
16576053|NCT02771314|Experimental|AZD9291|AZD9291
16576054|NCT02771301|Other|dendritic cell|Patients will receive autolgous IDH1R132H dendritic cells and cytotoxic lymphocytes treatment.
16576055|NCT02771288|Other|Kawasaki disease|
16576056|NCT02771275|Experimental|Harpoon Medical Device TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
16576057|NCT02771249|Experimental|Arm B|Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + RPT and INH once weekly (days 5-19).
16576058|NCT02771236||Affected Participants|Participants with inherited eye diseases
16576059|NCT02771236||Unaffected family members|Family members without eye disease
16576060|NCT02771223||Study group|patients scheduled for prolonged cardiac surgery (over 3 hours anticipated ECC time) with no known coagulation disorders
16576061|NCT02771210|Experimental|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
16576062|NCT02771210|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
16576063|NCT02771197|Experimental|Lymphodepletion plus Pembrolizumab|Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
16576064|NCT02771184|Other|Lung-Healthy|Subjects with no diagnosed lung disease. The intervention is the recording of lung sounds with the Lung Sound Recording System.
16576065|NCT02771184|Other|Pneumothorax|Subjects with pneumothorax. The intervention is the recording of lung sounds with the Lung Sound Recording System.
16576066|NCT02771184|Other|Pulmonary Fibrosis|Subjects with pulmonary fibrosis. The intervention is the recording of lung sounds with the Lung Sound Recording System.
16576067|NCT02771171||Age groups|The cohort is divided into on the basis of age
16576068|NCT02771158|Experimental|midodrine|randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
16576069|NCT02771158|Placebo Comparator|placebo|randomization to placebo control
16576070|NCT02771145|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
16576071|NCT02771132|Experimental|Intervention|"12-hour intervention IMPower empowerment self defense course for girls and 12-hour Source of Strength for boys+ 2 refresher sessions (at 2 hrs. per session)"
16576072|NCT02771132|Other|Standard of Care|1-2 hour course based on Ministry of Education life skills course (no refresher sessions)
16576073|NCT02771106||vision dysfunction|This group are subjects with mild TBI who have been diagnosed with profound oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist. These subjects will undergo neuro vision rehabilitation.
16576074|NCT02771106||control|This group are subjects with mild TBI who have no oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist
16576075|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
16576076|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
16576077|NCT02771067|Experimental|Pulse pressure variation|Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
16576078|NCT02771054|Experimental|TAF/emtricitabine (FTC)|All 20 patients will switch their nucleoside backbone, either ABC/3TC or TDF/FTC to TAF/FTC
16576079|NCT02771041|Experimental|Group with D-8 medical consultation|"A medical consultation 8 days before surgery would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
16576080|NCT02771041|No Intervention|Group without D-8 medical consultation|
16576081|NCT02771028|Experimental|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
16576082|NCT02771028|No Intervention|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
16576083|NCT02771015|Active Comparator|Mepilex Border®|Mepilex Border® wound dressing at patients after hip-knee or primary spine surgery
16576084|NCT02771015|Active Comparator|Cosmopor steril®|Standard wound dressing at patients after hip-knee or primary spine surgery
16576085|NCT02771002||septic shock patients|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until normalisation of lactate sonographic assesment of perfusion of solid organs once within 24h after admission
16576086|NCT02771002||patients rewarming after cardiac surgery|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until extubation
16576087|NCT02771002||healthy volunteers|measurements of peripheral perfusion including capillary refill time and peripheral perfusion index in ambient temperature and after cooling of extremity
16576088|NCT02770989|Experimental|Vimecon Laser CAI Cardiac Ablation|Ablation of the cardiac tissue by the use of the Vimecon Laser CAI (Cardiac Ablation Instrument).
16576089|NCT02770976|Experimental|NAVA|Seven increasing and decreasing NAVA levels (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0 and 0.5 cmH2O/uV) will applied to 20 preterm infants each for 10 minutes.
16576090|NCT02770963|Experimental|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.
~Huatuo Brand needle (0.3*75 mm) will be used for BL25 and Huatuo Brand needle (0.3*40mm) will be used for BL23, BL40 and BL57."
16576091|NCT02770963|Sham Comparator|Sham acupuncture|The acupoints will be the same as the acupuncture group. Specially designed sham needles (0.3*25 mm) will be used . The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
16576092|NCT02770950|Active Comparator|High dose group|"High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.
~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day."
16576093|NCT02770950|Active Comparator|Low dose group|"Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.
~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day."
16576094|NCT02770950|Active Comparator|Controlled group|Indometacin Cataplasms will be used topically on the knee for 24h per day
16576095|NCT02770937|Active Comparator|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
16576096|NCT02770937|Active Comparator|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on box trainer.
16576097|NCT02770937|No Intervention|Control|The control group will not receive further training.
16576098|NCT02770924|Experimental|AT LISA TRI TORIC|All patients will be undergo to phacoemulsification with IOL implantation bilateral
16576099|NCT02770924|Experimental|AT LISA TRI|All patients will be undergo to phacoemulsification with IOL implantation bilateral
16576123|NCT02770729|Active Comparator|Intracameral moxifloxacin|Intracameral injection of 0.5% moxifloxacin at conclusion of cataract surgery (150 micrograms)
16576100|NCT02770911|Experimental|"without Dog Ear group"|Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
16576101|NCT02770911|Active Comparator|"with Dog Ear group"|traditional double-stapled anastomosis was used for laparoscopic anterior resection
16576102|NCT02770898|Experimental|Brief Intervention|The brief intervention is individual focus and consists of three main components, which include enhancing the individual personal attributes such as participant's knowledge, values, and behaviors related to physical exercise. Second, the intervention will promote changes in behavioral attributes by providing opportunities and experience in goal setting, skills development in physical exercise and self-monitoring. Finally, the brief intervention promotes family relations and well-being by encouraging individuals to share their knowledge and increase physical activities with other family members. The brief intervention will be delivered by the probation officer during regular monthly consultation.
16576103|NCT02770898|Experimental|Combined Intervention|Participants allocated to the combined intervention will receive the individual brief intervention and participate in a community group program. The components in the brief intervention will also be reinforced in the group program. The group nature is designed to create an environment that is supportive of physical exercise, through role models, peer support, and encourages families to exercise with probationers.
16576104|NCT02770898|No Intervention|Care-as-usual|Participants allocated to Care-as-usual arm will receive their usual services. Participants will be offered the combined interventions upon completion of 3-months follow up assessment.
16576105|NCT02770885|Experimental|Verum first|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
16576106|NCT02770885|Placebo Comparator|Placebo first|Placebo: 0.5 ml normal saline (0.9% sodium chloride [0.9% sodium chloride (NaCl)]), injection sc via syringe once weekly for 3 weeks.
16576107|NCT02770872||Obese, normal|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2. Observation of SAA on apoB containing lipoproteins
16576108|NCT02770872||Obese, MetS|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2, blood pressure above 135/80, HDL less than 40 mg/dl, triglycerides greater the 150 mg/dl and fasting blood glucose greater than 100 mg/dl but less than 126 mg/dl. Observation of SAA on apoB containing lipoproteins
16576109|NCT02770872||Obese, diabetic|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2 and physician diagnosed diabetes mellitis. Observation of SAA on apoB containing lipoproteins
16576110|NCT02770846|Experimental|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
16576111|NCT02770846|Active Comparator|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
16576112|NCT02770833|Experimental|Salmon vs. veal and CHO with low or high GI|"In the first clinical study (Study 1), subjects will eat salmon or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:
~Meat balls with salmon served with tomato sauce and other accompaniments with low GI
~Meat balls with salmon served with tomato sauce and other accompaniments with high GI
~Meat balls with veal served with tomato sauce and other accompaniments with low GI
~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
16576113|NCT02770833|Experimental|Cod vs. veal and CHO with low or high GI|"In the second clinical study (Study 2), subjects will eat codfish or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:
~Meat balls with codfish served with tomato sauce and other accompaniments with low GI
~Meat balls with codfish served with tomato sauce and other accompaniments with high GI
~Meat balls with veal served with tomato sauce and other accompaniments with low GI
~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
16576115|NCT02770807|Experimental|EDS-EP dose range of ~5-10 mg DSP/infusion|"Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL.
~Other Names:
~EryDex System end product"
16576116|NCT02770807|Experimental|EDS-EP dose range of ~14-22 mg DSP/infusion|"Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
~Other Names:
~EryDex System end product"
16576117|NCT02770807|Placebo Comparator|Placebo EDS infusion|Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
16576118|NCT02770794|Experimental|All patients|Discontinue infliximab; Receive infliximab when relapse
16576119|NCT02770781|Experimental|Personal Trainer|All subjects will meet a set amount of times with a personal trainer over the course of the study to participate in an exercise regimen.
16576120|NCT02770768|Active Comparator|Flibanserin|"Drug: Flibanserin
~8 weeks
~100mg once daily at bedtime"
16576121|NCT02770768|Placebo Comparator|Placebo|Drug: Matching Placebo Matching placebo capsules taken in same amount of pills as the active medication (for 8 weeks once daily at bedtime)
16576122|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
16576124|NCT02770729|Sham Comparator|No injection of moxifloxacin|No injection of moxifloxacin at conclusion of cataract surgery
16576125|NCT02770716|Experimental|Terlipressin|"Participants will receive terlipressin intravenously as a bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (+/- 30 minutes), followed by a saline flush.
~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
16576126|NCT02770716|Placebo Comparator|Placebo|"Participants will receive 1 vial of matching placebo intravenously as a bolus injection of 1 vial over 2 minutes every 6 hours (+/- 30 minutes), followed by a saline flush.
~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
16576127|NCT02770703|Experimental|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
16576128|NCT02770703|Experimental|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
16576129|NCT02770703|Experimental|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
16576130|NCT02770690|Experimental|spray|apply the ethyl chloride spray before propofol injection
16576131|NCT02770690|Active Comparator|lidocaine|apply the lidocaine 0.5 mg/kg under the touniquette state before propofol injection
16576132|NCT02770690|Placebo Comparator|placebo|apply the saline before propofol injection
16576133|NCT02770677|No Intervention|Control group|Control group will be asked to continue their normal daily life without Yoga training
16576134|NCT02770677|Experimental|Yoga group|Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
16576135|NCT02770664|Experimental|LC28-0126 Dose A|
16576136|NCT02770664|Experimental|LC28-0126 Dose B|
16576137|NCT02770664|Experimental|LC28-0126 Dose C|
16576138|NCT02770664|Placebo Comparator|Placebo|
16576139|NCT02770651||Optical Coherence Tomography|To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.
16576140|NCT02770638|Experimental|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
16576141|NCT02770638|Active Comparator|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
16576142|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
16576143|NCT02770612|Other|Post-cesarean delivery mothers|"Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.
~After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)
~The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.
~A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc."
16576144|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
16576145|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
16576146|NCT02770586|Other|Breast PET|Breast PET
16576147|NCT02770573|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense; Kuraray Teethmate™ Desensitizer; Ghimas Dentin Desensitizer.
~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.
~The application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
16576148|NCT02770560||Chronic hemodialysis patients with a tunneled cuffed catheter|In case of thrombotic dysfunction of the dialysis catheter : administration of Urokinase (100 000 units in total) as locking solution in the dead space of the catheter lumen, interdialytic (between two dialysis sessions) or intradialytic (during the dialysis in case of complete obstruction of the dialysis catheter)
16576149|NCT02770547|Active Comparator|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
16576150|NCT02770547|Experimental|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
16576151|NCT02770534||Sickle patients in steady state|Well sickle cell patients attending the outpatient clinic
16576152|NCT02770534||Sickle cell patients admitted in crisis|Inpatients with acute vaso-occlusive crisis
16576153|NCT02770534||Sickle patients on transfusion program|Sickle patients managed on a regualar transfusion program
16576154|NCT02770534||Sickle patients on Hydroxycarbamide|Sickle cell patients managed on hydroxycarbamide and on a stable dose for at least 3 months
16576155|NCT02770534||Health controls|Well age and race matched individuals without a known diagnosis of sickle cell anaemia
16576156|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
16576157|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
16576158|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
16576159|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
16576160|NCT02770508|Experimental|Darunavir/ritonavir plus lamivudine|Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
16576161|NCT02770508|Active Comparator|Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)|Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
16576162|NCT02770495|Experimental|Postoperative endoscopic recurrence|Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection
16576163|NCT02770482|Experimental|AD Patients|
16576164|NCT02770469|Active Comparator|Standard Intervention|The standard intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship.
16576165|NCT02770469|Experimental|Enhanced Intervention|The enhanced intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship as well as cognitive-behavioral stress management.
16576166|NCT02770456|Experimental|High dose fish oil|Women will be offered 4 capsules per day containing fish oil
16576167|NCT02770456|Experimental|Low dose fish oil|Women will be offered 4 capsules per day containing mixed fish oil and olive oil
16576168|NCT02770456|Placebo Comparator|Control|Women will be offered 4 capsules per day containing olive oil
16576169|NCT02770443|Experimental|Treatment|Withdrawal of beta blockers and ACE inhibitors
16576170|NCT02770443|Placebo Comparator|control|no withdrawal, standard of care
16576171|NCT02770430|Active Comparator|conventional treatment|"After randomization, patients will be allocated to receive conventional treatment:
~Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.
~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
16576172|NCT02770430|Experimental|mesenchymal stem cells|Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg
16576173|NCT02770417|Active Comparator|COPD (beta-alanine)|
16576174|NCT02770417|Placebo Comparator|COPD (placebo)|
16576175|NCT02770417|Other|Healthy controls|
16576176|NCT02770404|Experimental|Nafithromycin|"Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.
~Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1"
16576177|NCT02770404|Placebo Comparator|Placebo|Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.
16576178|NCT02770391|Experimental|Apalutamide + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to Apalutamide 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. Apalutamide may be continued up to and including the day before
16576179|NCT02770378|Experimental|Temozolomide combined with 9 repurposed drugs|"After enrollment, the subject goes into the induction cycle, which lasts 35 days. The induction cycle consists of a drug-by-drug addition and up-dosing process.
~Hereafter, the subject will enter the treatment cycles (up to 12). During the induction cycle and the first 2 treatment cycles, regimen adjustments (dropping of certain drugs, dose modification of certain drugs) may be executed to accommodate to the patients' individual toxicity reactions that may occur during this period."
16576180|NCT02770365|Experimental|Test Product|estradiol cream
16576181|NCT02770365|Active Comparator|Reference Product|estradiol cream
16576182|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
16576183|NCT02770326|Experimental|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
16576184|NCT02770313|Experimental|Intermittent Fasting|Water-only Intermittent Fasting
16576185|NCT02770313|No Intervention|Control|ad libitum Usual Diet
16576186|NCT02770300|No Intervention|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.
~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
16576187|NCT02770300|Experimental|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
16576188|NCT02770300|Experimental|Automatic personalized robotic rehabilitation with ALEx RS|
16576189|NCT02770287|Experimental|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
16576190|NCT02770274|Experimental|Group Cilostazol|Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.
16576191|NCT02770274|Active Comparator|Group Aspirin|Patients receiving monotherapy with aspirin 100mg once daily for 12 months.
16576192|NCT02770261|Experimental|CR group|DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
16576193|NCT02770261|Active Comparator|CP group|DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
16576194|NCT02770261|Active Comparator|PR group|DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
16576195|NCT02770248|Experimental|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
16576196|NCT02770248|Active Comparator|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
16576197|NCT02770235|Experimental|DE assessment and AGE measurements|To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients
16576198|NCT02770222|Experimental|Part 1, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods.
16576199|NCT02770222|Experimental|Part 1, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
16576200|NCT02770222|Experimental|Part 2, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
16576201|NCT02770222|Experimental|Part 2, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
16576202|NCT02770209|Experimental|the experimental group|Patients in the experimental group will be treated with the biomimetic cartilage matrix combined with autologous chondrocytes. The entire course of treatment includes two surgeries. The first surgery will be performed to observe articular cartilage damage by arthroscopy and assess treatment potential. If the patient's condition meets the surgical requirement, we will extract cartilage from the fossa intercondylar non-weight-bearing area during the first surgery. Chondrocytes will be in vitro-amplified and inoculated into the cartilage scaffold. The fully prepared seeded scaffold will be implanted into the site of injury during the second surgery.
16576203|NCT02770209|Experimental|the control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
16576204|NCT02770196|Experimental|Group One (Two-year Intervention, 2016 Enrollment)|Group one intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2016 and 2017. During the 2016 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
16576205|NCT02770196|Experimental|Group Two (Delayed Two-year Intervention, 2016 Enrollment)|Group two intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2017 and 2018. During the 2017 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
16576206|NCT02770196|Experimental|Group Three (One-year Intervention, 2017 Enrollment)|Group three intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2017 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
16576207|NCT02770196|Experimental|Group Four (Delayed One-year Intervention, 2017 Enrollment)|Group four delayed intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2018 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
16576208|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.
~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
16576209|NCT02770170|Experimental|BI 655064 dose 1|
16576210|NCT02770170|Experimental|BI 655064 dose 2|
16576211|NCT02770170|Experimental|BI 655064 dose 3|
16576212|NCT02770170|Placebo Comparator|Placebo|
16576213|NCT02770157|Experimental|DA-3002|1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
16576214|NCT02770157|Active Comparator|Genotropin®|1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
16576215|NCT02770157|Other|Non-treatment control group|After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
16576216|NCT02770144|Experimental|Financial Coaching & Social Services Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
16576217|NCT02770144|Active Comparator|Access to Referrals to Social Services|Enrollment provides access to referrals to social services to meet basic needs.
16576218|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
16576219|NCT02770118|Experimental|PSR-TSD|Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
16576220|NCT02770118|Experimental|TSD-PSR|Total sleep deprivation (TSD) followed by partial sleep restriction (PSR). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
16576221|NCT02770092|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
16576222|NCT02770092|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
16576223|NCT02770092|Experimental|Congestive Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
16576224|NCT02770079||Gestational diabetes|10 women with gestational diabetes
16576225|NCT02770053|Experimental|Intervention|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with #35 K-files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
16576226|NCT02770053|Active Comparator|Control|In the control group, no foraminal enlargement will be performed.
16576230|NCT02770027|Placebo Comparator|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16576231|NCT02770027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16576232|NCT02770014|Experimental|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
16576233|NCT02769988||Project SHARE|
16576234|NCT02769975||Case Only|Children ages 0-18 with known or suspected endocrine or metabolism disorders.Family members ages 0-100. They may participate in the DNA part of the study
16576238|NCT02769936|Placebo Comparator|Healthy Adult - Placebo|Single dose placebo pill in healthy adults
16576239|NCT02769936|Experimental|Healthy Adult - D-cycloserine|Single 100 mg dose D-cycloserine pill in healthy adults
16576240|NCT02769936|Placebo Comparator|Schizophrenia - Placebo|Single dose placebo pill in schizophrenia patients
16576241|NCT02769936|Experimental|Schizophrenia - D-cycloserine|Single 100 mg dose D-cycloserine pill in schizophrenia patients
16576242|NCT02769923|Active Comparator|Arm A|Westpharma ID Adapter
16576243|NCT02769923|Active Comparator|Arm B|Star ID syringe
16576244|NCT02769923|Active Comparator|Arm C|BCG NS
16576245|NCT02769910|Other|Cowhage|Cowhage is used to induce non-histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hours and Qutenza Demo Patch.
16576246|NCT02769910|Other|Histamine|Histamine is used to induce histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hour and Qutenza Demo Patch.
16576247|NCT02769897|Experimental|Intervention group|The exercise program, nutritional counseling and oral health will last for five to six months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC). The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
16576248|NCT02769897|No Intervention|Control group|The control group did not receive the intervention.
16576249|NCT02769884|Experimental|MMPPC arm|Subjects in this arm will wear the experimental MMPPC algorithm artificial pancreas for 72 hours in a hotel/house setting. The study period will involve unannounced meals and exercise
16576250|NCT02769871|Active Comparator|Standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at the participant's initial interview. Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
16576311|NCT02769416||Family Members and Healthy Volunteers|Healthy volunteer controls or family members may be enrolled for identification of genetic mutations.
16576251|NCT02769871|Experimental|Neuroimages of stroke|Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
16576252|NCT02769858|Experimental|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
16576253|NCT02769845|Experimental|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
16576254|NCT02769845|Experimental|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
16576255|NCT02769832|Experimental|Nab-Paclitaxel with Gemcitabine|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days; Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
16576256|NCT02769819|Experimental|Intubation with a flexible fiberscope|Following induction of general anesthesia and administration of a neuromuscular blocking agent, intubation will be performed using a flexible fiberscope.
16576257|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
16576258|NCT02769793|Experimental|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
16576259|NCT02769793|Active Comparator|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
16576260|NCT02769767||Cases|Subjects with Relapsing-Remitting Multiple Sclerosis. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
16576261|NCT02769767||Controls|Healthy subjects. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
16576262|NCT02769767||Responders|Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of <1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
16576263|NCT02769767||No responders|Subjects with MS that have more than one relapse per year treated for at least two years, and who had ≥1 relapse(s) or an increase of 1.5 points on the EDSS (if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
16576264|NCT02769754|Placebo Comparator|Control|In the control group (group A) no additional treatment will be applied after performing the usual surgical hemostasis.
16576265|NCT02769754|Experimental|Hemopatch|Hemopatch will be apply in the treatment group (group B), once the standard surgical hemostasis is achieved
16576266|NCT02769741|Other|Crossover 1: Control Diet followed by Active Diet|Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts
16576267|NCT02769741|Other|Crossover 2: Active Diet followed by Control Diet|Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts
16576268|NCT02769728|Experimental|EndoBarrier|EndoBarrier will be implemented for 9 months.
16576269|NCT02769715|Active Comparator|cast removable partial denture|patients received cast removable partial dentures fabricated using traditional lost-wax casting technique.
16576270|NCT02769715|Experimental|laser-sintered removable partial denture|patients received removable partial dentures fabricated using laser-sintering.
16576271|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
16576272|NCT02769689|Experimental|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
16576273|NCT02769689|Placebo Comparator|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
16576274|NCT02769676|Experimental|3-week visit|Participants randomized to this arm will receive an additional visit at 3-weeks postpartum
16576275|NCT02769676|Active Comparator|usual care|Participants randomized to this arm will receive usual postpartum care, including the standard timing for a postpartum visit.
16576276|NCT02769663||OSA|Patients with newly diagnosed obstructive sleep apnea and no medical comorbidity affecting cognition.
16576277|NCT02769663||healthy controls|Participants with no sleep disorder or other medical comorbidity affecting cognition.
16576278|NCT02769650|Experimental|Stress-MRI + Chronic total occlusion PCI|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Coronary angioplasty with stenting of RCA CTO
16576279|NCT02769650|Active Comparator|Stress-MRI + Optimal medicamentous treatment|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Optimal medicamentous treatment
16576280|NCT02769637||ON PPI|Subjects on proton pump inhibitor (PPI) treatment
16576281|NCT02769637||OFF PPI|Subjects off proton pump inhibitor (PPI) treatment
16576400|NCT02768987|Experimental|Overweight|Sedentary adolescents with T1D and overweight
16576401|NCT02768987|Experimental|Normal Weight|Sedentary adolescents with T1D and normal weight
16576282|NCT02769624|Experimental|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
16576283|NCT02769624|Placebo Comparator|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
16576284|NCT02769611|Experimental|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
16576285|NCT02769611|Experimental|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
16576286|NCT02769611|Experimental|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
16576287|NCT02769598||ANI Index for Hospitalized children|"Each child will be registered upon arrival in the service and for a period of 24 hours. Registration will finish at the end of 24 hours or when the patient is discharged from the service. A FLACC scale (Face, Legs, Activity, Cry, Consolability scale) will be performed at the patient's input and then once every 4 hours corresponding to the patient's baseline. A FLACC scale will then be performed at each painful episode of the patient and 30 minutes after the end of production of analgesic treatment corresponding to the post-treatment painful condition of the patient.
~A measurement of blood pressure will be performed at each pain rating by the patient assisted by the nurse."
16576288|NCT02769585|Experimental|Self-hypnosis|Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.
16576289|NCT02769585|Active Comparator|CDE training|Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.
16576290|NCT02769572|Experimental|real moxibustion plus placebo gel|In subjects with osteoarthritis of the knee
16576291|NCT02769572|Active Comparator|diclofenac sodium gel plus sham moxibustion|In subjects with osteoarthritis of the knee
16576292|NCT02769559||Patients with macromasty|Female adult patients with symptomatic macromasty selected for elective reduction surgery
16576293|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
16576294|NCT02769507|Experimental|real tDCS|DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
16576295|NCT02769507|Sham Comparator|sham tDCS|"DC Stimulator PLUS (NeuroConn) The sham condition is identical to the real tDCS condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period."
16576296|NCT02769494|Experimental|Mesalazine Group|Mesalazine Sustained-Release Tablets and 0.02L glycerol mixed, 2.5% mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. Daily treatment time of the drug is 8 am,12 pm and 4 pm.
16576297|NCT02769494|Active Comparator|Riboflavin Sodium Phosphate Group|wipe the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. Daily treatment time of the drug is am,12 pm and 4 pm.
16576298|NCT02769481|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
16576299|NCT02769481|Active Comparator|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
16576300|NCT02769468|Active Comparator|The Back|The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.
16576301|NCT02769468|Active Comparator|Chest|The probe is placed on the chest, 1 cm above the left nipple.
16576302|NCT02769468|Active Comparator|Left Axilla|The probe is placed deep in the left axilla
16576303|NCT02769455|No Intervention|Control|The control group will not be exposed to any FOP nutrition labels
16576304|NCT02769455|Experimental|Front-of-pack labelling (Reference Intakes)|The second group will be exposed to a FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are presented in the form of a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
16576305|NCT02769455|Experimental|Front-of-pack labelling (5-CNL)|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.
~The format of the 5-CNL system therefore includes five categories of nutritional quality of food products, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the letter/colour corresponding to the product being enlarged."
16576306|NCT02769442|Experimental|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
16576307|NCT02769442|Active Comparator|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
16576308|NCT02769429||ultrasound-guided CISB|Group 1 will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
16576309|NCT02769429||nerve stimulator-guided CCPVB|Group 2 will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
16576310|NCT02769416||Spinal Cord and Traumatic Brain Injury Subjects|Patients with a history of spinal cord and/or traumatic brain injury will provide data and samples so that they may be queried for interventional studies.
16576402|NCT02768974|Experimental|OPRX-106 2 mg|Open label, 1:1 randomization ration (up to 10 subjects)
16576312|NCT02769403|Experimental|Treatment|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
16576313|NCT02769403|Active Comparator|Control|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The control participants will use it daily only for weeks 7-12. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
16576314|NCT02769390|No Intervention|Bupivacaine 0,166%|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% for hypospadia surgery
16576315|NCT02769390|Active Comparator|Clonidine 1 mcg/Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 1 mcg/ Kg of clonidine for hypospadia surgery
16576316|NCT02769390|Active Comparator|Clonidine 2 mcg/ Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 2 mcg/ Kg of clonidine for hypospadia surgery
16576317|NCT02769390|Active Comparator|Clonidine 3 mcg/Kg|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 3 mcg/ Kg of clonidine for hypospadia surgery
16576318|NCT02769377|No Intervention|Control|patients who decline or unable to do self-monitoring of blood glucose
16576319|NCT02769377|Active Comparator|Breeze2 glucometer|patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone
16576320|NCT02769377|Experimental|Breeze2 glucometer and H2|patients who do self-monitoring of blood glucose and transfer data via mobile-phone
16576321|NCT02769364||Participants treated with eribulin for at least 7 months|
16576322|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
16576323|NCT02769338|Experimental|QI with External Facilitation|Receive external facilitation to support implementation of the quality improvement program
16576324|NCT02769338|No Intervention|Control|Non-Intervention VA Medical Centers
16576325|NCT02769325|Experimental|Atropine|Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia
16576326|NCT02769325|Placebo Comparator|placebo|Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia
16576327|NCT02769312|Sham Comparator|Sham Stimulation|A sham coil is being used to compare against active coil.
16576328|NCT02769312|Active Comparator|Active Stimulation|An active coil is being used to compare against sham coil.
16576329|NCT02769286|Experimental|Osimertinib in cohort 1|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA
16576330|NCT02769286|Experimental|Osimertinib in cohort 2|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA
16576331|NCT02769260|No Intervention|No toothbrushing during experiment and Pyrosequencing|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope) and 16S DNA pyrosequencing.
16576332|NCT02769260|No Intervention|No toothbrushing during experiment|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
16576333|NCT02769260|Active Comparator|Toothbrushing during experiment|48hours-Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
16576334|NCT02769247|Experimental|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
16576335|NCT02769247|Experimental|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
16576336|NCT02769247|Experimental|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
16576337|NCT02769247|Experimental|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
16576338|NCT02769234||Alzheimer's disease|Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
16576339|NCT02769221|Experimental|Optiscope|Endotracheal intubation by rigid video stylet, manufactural named Optiscope.
16576340|NCT02769221|Active Comparator|McGrath|Endotracheal intubation by video laryngoscope, manufactural named McGrath.
16576341|NCT02769208|Active Comparator|Group A: Pre-Filter Only Intervention|Subjects in Group A start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which both the HEPA and ESP are removed, leaving only a pre-filter. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
16576342|NCT02769208|Active Comparator|Group B: Pre-filter + HEPA Intervention|Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
16576343|NCT02769182|Experimental|Monitoring and training using the system|
16576344|NCT02769182|Active Comparator|Standard of care|
16576345|NCT02769169|Experimental|double-dose|"double-dose
~Lucentis® (Raibizumab), 1mg, 3+prn"
16576346|NCT02769169|Active Comparator|regular-dose|"regular-dose
~Lucentis® (Raibizumab), 0.5mg, 3+prn"
16576347|NCT02769143|Experimental|Whole-Body Vibration Group (WBV)|Will be exposed to five minutes on a vibrating platform (Oscillating Platform Semi-Professional Horizontal - Arktus, Cascavel, Brazil), this type of platform vibrates through an anteroposterior axis, causing the right and left sides alternate horizontally denominated: alternating side vibration platforms, will be performed three times per week on alternate days (5 minutes). a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. The volunteers will be guided to stand on the platform with semi-flexed knees, barefoot and apart about hip width.
16576348|NCT02769143|Experimental|Pilates Group (PG)|Will be exposed to 60 minutes, held three times a week on alternate days. Pilates equipment used for the exercises are: Combo Chair, Cadillac Trapeze, Ladder Barrel, Reformer Universal, Step Barrel and Wall Unit. Will be selected for this study, 21 strengthening exercises and stretching to the main body segments. All exercises are performed in a series of ten repetitions with one minute interval between exercises. To determine the level of effort and consequently to changing loads, will be used verbal command according to the Borg CR10 scale. The level of effort will be maintained during the session heavy (Borg between 5 and 6).
16576349|NCT02769143|No Intervention|Control Group (CG)|The control group will be instructed to maintain their usual activities both in relation to their daily activities, dietary habits, failure to use drugs that can influence the increase in bone mass and participate in monthly meetings to address on issues osteoporosis and postmenopausal women. After the end of the interventions with WBV and GP groups, GC volunteers will be invited to also perform whole body vibration for six months. Exposure of vibration will be for five minutes on a vibrating platform, three times per week on alternate days. a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. Likewise which was offered for the WBV group.
16576350|NCT02769130|Experimental|Losartan|"Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.
~Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year."
16576351|NCT02769117|Active Comparator|Ultrasound on fractured bone|An ultrasound technique will be used to record the acoustic response of the fractured bone at each clinical visit until the fracture is healed. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm on either sides of the fracture. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fracture and on the unaffected (contralateral) bone as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
16576352|NCT02769117|Active Comparator|Ultrasound on contralateral intact bone|An ultrasound technique will be used to record the acoustic response of the intact bone as control at each clinical visit. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm or clavicle. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fractured forearm/clavicle and on the unaffected (contralateral) forearm/clavicle as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
16576353|NCT02769104|Experimental|AI+Chemo|aromatase inhibitors (Letrozole 2.5mg po. QD for 5 years) starts at the beginning of neoadjuvant treatment combined with chemotherapy (AC*4-T*4) in patients with postmenopausal hormone receptor-positive breast cancer
16576354|NCT02769104|Active Comparator|Chemo|chemotherapy (AC*4-T*4) as neoadjuvant treatment without aromatase inhibitors in patients with postmenopausal hormone receptor-positive breast cancer
16576355|NCT02769091|Experimental|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
16576356|NCT02769091|Placebo Comparator|Placebo|Matching placebo
16576357|NCT02769078||Patients who received dabigatran|Patients who received dabigatran
16576358|NCT02769078||Patients who received rivaroxaban|Patients who received rivaroxaban
16576359|NCT02769078||Patients who received apixaban|Patients who received apixaban
16576360|NCT02769078||Patients who received warfarin|Patients who received warfarin
16576361|NCT02769065|Placebo Comparator|SRD: Placebo Cohorts 1-6, 18 and 19|TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
16576362|NCT02769065|Experimental|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
16576363|NCT02769065|Experimental|SRD: Cohort 2: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
16576364|NCT02769065|Experimental|SRD: Cohort 3: TAK-071 9 mg|TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
16576365|NCT02769065|Experimental|SRD: Cohort 4: TAK-071 20 mg|TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
16576366|NCT02769065|Experimental|SRD: Cohort 5: TAK-071 40 mg|TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
16576367|NCT02769065|Experimental|SRD: Cohort 6: TAK-071 80 mg|TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
16576368|NCT02769065|Placebo Comparator|MRD: Placebo Cohorts 7-9|TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
16576369|NCT02769065|Experimental|MRD: Cohort 7: TAK-071 3 mg|TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
16576370|NCT02769065|Experimental|MRD: Cohort 8: TAK-071 9 mg|TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
16576371|NCT02769065|Experimental|MRD: Cohort 9: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
16576372|NCT02769065|Placebo Comparator|MRD: TAK-071 Placebo Cohorts 10-12+Donepezil|TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
16576373|NCT02769065|Experimental|MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg|TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
16576374|NCT02769065|Experimental|MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg|TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
16576375|NCT02769065|Experimental|MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg|TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
16576376|NCT02769065|Experimental|MRD: Placebo Cohorts 13-15|TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
16576377|NCT02769065|Experimental|MRD: Cohort 13: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
16576378|NCT02769065|Experimental|MRD: Cohort 14: TAK-071 9 mg|TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
16576379|NCT02769065|Experimental|MRD: Cohort 15: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
16576380|NCT02769065|Experimental|Cohort 16|
16576381|NCT02769065|Experimental|Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC|A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
16576382|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence BCA|B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
16576383|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence CAB|C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
16576384|NCT02769065|Experimental|SRD: Cohort 18: TAK-071 120 mg|TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
16576385|NCT02769065|Experimental|SRD: Cohort 19: TAK-071 160 mg|TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
16576386|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil Placebo|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
16576387|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
16576388|NCT02769065|Experimental|SRD: Cohort 20: TAK-071 40 mg+Donepezil|TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
16576389|NCT02769065|Experimental|SRD: Cohort 21: TAK-071 60 mg+Donepezil|TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
16576390|NCT02769065|Experimental|SRD: Cohort 22: TAK-071 80 mg+Donepizil|TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
16576391|NCT02769052|Active Comparator|Follow-up/Treatment - Control Group|Composed of two phases of 8 weeks each (follow-up - treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
16576392|NCT02769052|Active Comparator|Treatment Group|Composed of one phase of 8 weeks (treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
16576393|NCT02769039||Parkinson's Disease participants|People with early Parkinson's disease with mild-to-moderate severity of disease.
16576394|NCT02769039||Control participants|Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
16576395|NCT02769013||S. haematobium positives in Gabon|Asymptomatic volunteers infected with S. haematobium and living in Gabon
16576396|NCT02769013||S. haematobium negatives in Gabon|Volunteers not infected with S. haematobium and living in Gabon
16576397|NCT02769013||S. haematobium positives in Ghana|Asymptomatic volunteers infected with S. haematobium and living in Ghana
16576398|NCT02769013||S. haematobium negatives in Ghana|Volunteers not infected with S. haematobium and living in Ghana
16576399|NCT02769000|Experimental|Subjects 1-30|15 subjects in each RT dose schedule 10 GY in 5 daily fractions 20 GY in 10 daily fractions
16576404|NCT02768961|Experimental|Active treatment|"All HCV chronic infected patients will be treated with oral anti-HCV regimens containing sofosbuvir, ledipasvir (associated or not to ribavirin) according to clinical practice as indicated into the current guidelines (1)
~(1)European Association for Study of Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
16576405|NCT02768948|Experimental|telmisartan|treatment with telmisartan at doses of 80 mg / day for 6 months
16576406|NCT02768948|Experimental|losartan|Losartan at a dose of 100 mg / d for 6 months.
16576407|NCT02768935|Other|Diabetes|
16576408|NCT02768935|Other|normoglycaemic|
16576409|NCT02768922|Experimental|Aphasia telerehabilitation|Speech and language therapy is given by telemedicine to improve expressive language function. The therapy will include knowledge based tasks of aphasia rehabilitation including training of language forms and overall functional communication. A special emphasis will be put on naming training. The telerehabilitation will be given in a addition to standard face-to-face aphasia rehabilitation
16576410|NCT02768922|Active Comparator|Control|Control Group receives standard face-to-face aphasia rehabilitation
16576411|NCT02768909|Experimental|Pulmonary TB|"This arm will enroll 100 patients older than 15 years old, from Caracas, with pulmonary TB, culture proved.
~Intervention:
~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.
~Chest X-ray.
~Sputum samples for Ziehl Neelsen smear and Culture in L-J.
~Follow Up 5 days after beginning of Tx
~Follow Up 15 days after beginning of Tx
~Follow Up 30 days after beginning of Tx
~Follow Up 60 days after beginning of Tx"
16576412|NCT02768909|Active Comparator|Non - Pulmonary TB|"This arm will enroll 75 patients older than 15 years old, from Caracas, with non TB pulmonary infections, culture negative.
~Intervention:
~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.
~Chest X-ray.
~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
16576413|NCT02768909|Active Comparator|Healthy Individuals|"This arm will enroll 75 patients older than 15 years old, from Caracas, without any symptom or sign of lower track infection.
~Intervention:
~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.
~Chest X-ray.
~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
16576414|NCT02768896|No Intervention|Baseline|Patients will walk naturally with EEG measuring brain waves
16576415|NCT02768896|Experimental|Visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
16576416|NCT02768896|Experimental|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
16576417|NCT02768896|Experimental|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
16576418|NCT02768883|Experimental|Clinic + Home + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator
~Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls
~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
16576419|NCT02768883|Experimental|Clinic + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator
~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
16576420|NCT02768883|Experimental|Home + Community|"Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls
~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
16576421|NCT02768883|Active Comparator|Community only|Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook.
16576422|NCT02768870|Experimental|Harpoon Medical Device|This is a prospective, single arm, nonrandomised, multi-center EU study to demonstrate the performance and safety of the Harpoon Medical device in patients with degenerative MR.
16576423|NCT02768857|Experimental|Early sensorimotor reeducation intervention|The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
16576424|NCT02768857|Active Comparator|Traditional sensorimotor reeducation intervention|The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
16576425|NCT02768844|Experimental|SVS vs Control|Prospective, within-subject design. Compare effects of mattress SVS (ON) and Control (SVS OFF) on physiology in opioid-exposed newborns. SVS is alternated in intervals between continuous stimulation (ON) and no stimulation (OFF/Control) throughout inter-feed intervals. The order of the ON-OFF cycles is randomized across subjects and counterbalanced between feeding periods within subjects.
16576426|NCT02768831|Experimental|Cuffed ETT|
16576427|NCT02768818|Experimental|Intervention|Probiotic VIVOMIXX™
16576428|NCT02768818|Placebo Comparator|Control|Placebo
16576429|NCT02768805|Experimental|15 µg/strain of Quadrivalent VLP Vaccine|
16576430|NCT02768805|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
16576431|NCT02768805|Active Comparator|15 µg/strain of the licensed quadrivalent vaccine|
16576488|NCT02768337|Experimental|Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.
16576432|NCT02768792|Other|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
16576433|NCT02768779||HIV negative and positive individuals|HIV Negative or HIV positive individuals, aged 18 years or older, who have been taking their ARV medication for at least 3 months and are adherent based on blood plasma HIV RNA of <50 copies/mL or HIV negative status. Hair analysis.
16576434|NCT02768766|Experimental|Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles starting at a dose of 125mg. The doses to be studied on a 3 day on, 4 day off schedule are 100mg, 125mg, 150mg, 175mg, 200mg and 225mg as per the time to event continual reassessment (TITE-CRM) design.
16576435|NCT02768753|Experimental|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
16576436|NCT02768753|Experimental|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
16576437|NCT02768740|Active Comparator|200 mg group|Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
16576438|NCT02768740|Experimental|300 mg group|Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
16576439|NCT02768727|Experimental|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
16576440|NCT02768714|Experimental|Eurofarma's pegfilgrastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Eurofarma's pegfilgrastim (subcutaneous injection)
16576441|NCT02768714|Active Comparator|Neulastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)
16576443|NCT02768688|Experimental|Brain connectivity and physiology|Dexmedetomidine anesthesia on glymphatic flow in human subjects as visualized by diffusion tensor MRI.
16576444|NCT02768675|Experimental|LOADPRO arm|Participants will temporarily receive a LOADPRO device affixed to kyphotic corrective rods. The device will not be implanted and will be removed prior to surgery closure.
16576445|NCT02768662|Experimental|OTO-104|12 mg dexamethasone
16576446|NCT02768649|Experimental|Cohort 1|Eligible subjects received a test dose of 0.25 risperidone prior to dosing with RBP-7000. Fifteen eligible subjects then received low dose RBP-7000
16576447|NCT02768649|Experimental|Cohort 2|After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
16576448|NCT02768649|Experimental|Cohort 3|After safety and tolerability review of the data from Day 1 to Day 15 of the medium dose arm, 3 subjects were dosed in Cohort 3 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
16576449|NCT02768636|Experimental|Before and after omega-3 used|Before and after omega-3 used
16576450|NCT02768623|Active Comparator|Control Group|Patients in the control group will receive standard, dispensing services they currently receive from pharmacists. Control group pharmacists will continue to provide these services in accordance with the standards of practice adopted by the Ontario College of Pharmacists. They will not provide either of the 3 intervention components outlined above. Should a control group patient request additional information and/or services, the pharmacist will comply and provide these as deemed necessary for the particular patient. This could include the full range of educational and drug therapy optimization services outlined for the intervention group. If this occurs then the pharmacists will document all services provided in order for the research team to account for this in the analysis.
16576451|NCT02768623|Experimental|Intervention Group|"Pharmacists in the intervention group will provide patients with a comprehensive disease management program for asthma. The 3 major components of pharmacists' intervention are outlined below. The services delivered will be customized based on each patient's case.
~Medication review and drug therapy optimization
~Patient education
~Improving patient adherence"
16576452|NCT02768610|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine is administered before endotracheal intubation for 10 minutes
16576453|NCT02768610|Placebo Comparator|Normal Saline|
16576454|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
16576455|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
16576456|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
16576457|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
16576489|NCT02768337|Experimental|Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.
16576490|NCT02768324||sepsis with diarrhea|
16576491|NCT02768324||sepsis without diarrhea|
16576492|NCT02768311|Experimental|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system post-treatment pain after using neolix rotary system
16576458|NCT02768571|Experimental|Cerebrolysin|"Cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation
~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)
~Rehabilitation
~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day
~5 times/week for 3 weeks
~Duration of Treatment:
~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.
~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
16576459|NCT02768571|Placebo Comparator|Placebo|"Saline 100 ml/day * 21 days with rehabilitation
~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)
~Rehabilitation
~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day
~5 times/week for 3 weeks
~Duration of Treatment:
~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.
~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
16576460|NCT02768558|Experimental|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
16576461|NCT02768558|Placebo Comparator|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
16576462|NCT02768545|Experimental|Liver transplant candidates|Ezetimibe in a dose of 10 mg/d for 12 weeks.
16576463|NCT02768532|Experimental|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
16576464|NCT02768519|Experimental|OTS167IV|Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.
16576465|NCT02768519|Placebo Comparator|Placebo|Cherry syrup
16576466|NCT02768506||Gastric bypass|Subjects submitted to gastric bypass
16576467|NCT02768506||SADI-S|Subjects submitted to SADI-S
16576468|NCT02768493|Experimental|low dose group|Patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block.
16576469|NCT02768493|Active Comparator|high dose group|Patients in the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block.
16576470|NCT02768480|Active Comparator|Primary Care|Patients will be followed by primary care team exclusively.
16576471|NCT02768480|Experimental|Phone Calls Support and Primary Care|Patients will be followed by primary care team and supported by periodic nurse phone calls.
16576472|NCT02768467|Experimental|Tissue Matrix Graft Placement|After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
16576473|NCT02768467|Active Comparator|Without stitches|After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
16576474|NCT02768454||inpatient under broad-spectrum antibiotics|medical review
16576475|NCT02768441|Experimental|Study group|Participants receiving Dexamphetamine 60 mg SR
16576476|NCT02768428|Experimental|Video-Audio Media|watching the entire video in 15 mins
16576477|NCT02768428|No Intervention|Handbooks|study the hand book in 15 mins
16576478|NCT02768415|Experimental|lapatinib+oral vinorelbine|"apatinib 425/500mg qd, 21days/cycle
~oral vinorelbine 60mg/m2 d1, 8, 15 21days/cycle*3cycles, after 3 cycles: 80mg/m2 d1, 8, 15 21days/cycle"
16576479|NCT02768402|Experimental|Treatment Arm|All eligible patients will be in the treatment arm for the 'Caisson TMVR System' (transcatheter mitral valve replacement) procedure. No control or comparator in this study.
16576480|NCT02768389|Experimental|Modified Atkins Diet and Bevacizumab|Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
16576481|NCT02768376|Active Comparator|General anesthesia group|General anesthesia group: Standard anesthetic technique will be applied.Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response. Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
16576482|NCT02768376|Experimental|Spinal anesthesia group|While in sitting position; intrathecal injection using 25 G spinal needle using 3 mls of Bupivacaine 0.5% with 20 mic Fentanyl, at L 2-3 level the patient head will be lowered till sensory blockade of T6 obtained at least.
16576483|NCT02768363|Active Comparator|ProstAtak®|Patients randomized to the ProstAtak arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir
16576484|NCT02768363|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
16576485|NCT02768350|Experimental|Control group|All of the participants in control group will be treated with conventional treatment for 3 days, The conventional treatments consist of: (1) Passive chest mobilization, (2) Positioning, (3) Side lying (good lung down), (4) Vibration. The conventional treatment consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
16576486|NCT02768350|Experimental|Experimental group|All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
16576487|NCT02768337|Other|Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)|No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
16576493|NCT02768311|Experimental|waveone rotary system (reciprocating system)|Procedure: waveone rotary system post-treatment pain after using waveone rotary system
16576494|NCT02768311|Experimental|hand files k-files|Procedure: hand files post-treatment pain after using hand files
16576495|NCT02768298|Experimental|LCZ696|LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.
16576496|NCT02768298|Active Comparator|Enalapril|"Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.
~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
16576497|NCT02768285|Experimental|Intervention|Endodontic treatment was performed in posterior teeth with necrotic pulp and periapical periodontitis using a reciprocating single-file system (Reciproc). Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 2.5 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 K-files in patency group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills was done. The canals were obturated with gutta-percha and epoxy resin sealer. The treatments were carried out in one-visit.
16576498|NCT02768285|No Intervention|Control|In the control group, apical patency did not maintained.
16576499|NCT02768272|Experimental|Epidural analgesia|Randomized allocation to receive patient controlled epidural analgesia or programed intermittent epidural boluses
16576500|NCT02768272|Experimental|Epidural technique|Randomized allocation to be punctioned a conventional epidural or a combined spinal-epidural technique
16576501|NCT02768246|Active Comparator|Begin with BVGA|The volunteers will be asked to breathe 5 minutes of room air through the BVGA, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the BVGA. Then the same volunteers will be asked to repeat the protocol with the face mask.
16576502|NCT02768246|Active Comparator|Begin with Face-mask|The volunteers will be asked to breathe 5 minutes of room air through the face mask, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the face mask. Then the same volunteers will be asked to repeat the protocol with the BVGA.
16576503|NCT02768233|Experimental|Educational programme|Group 1: Educational programme + standard treatment
16576504|NCT02768233|No Intervention|Standard treatment|Standard treatment
16576505|NCT02768220|Active Comparator|Linagliptin|Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
16576506|NCT02768220|Experimental|Empagliflozin|Eligible patients were randomized empagliflozin 25mg daily for 30 days.
16576507|NCT02768207|Experimental|Treatment Phase: Vemurafenib+Cobimetinib|Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.
16576508|NCT02768194|Experimental|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
16576509|NCT02768194|Active Comparator|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
16576510|NCT02768194|Other|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
16576511|NCT02768181|Experimental|Arm 1: BCC+PNS+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with a lipid-based nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with a lipid-based nutrient supplement for children (CNS) aged 6m to 2 years.
16576512|NCT02768181|Experimental|Arm 2: BCC+PNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
16576513|NCT02768181|Experimental|Arm 3: BCC+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutrient supplement to children (CNS) 6m to 2 years.
16576576|NCT02767752|Placebo Comparator|Placebo + Gemcitabine + Capecitabine|"Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.
~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
16576514|NCT02768181|Experimental|Arm 4: BCC only|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
16576515|NCT02768181|No Intervention|Arm 5: comparison|No intervention will be provided by the study. The existing services delivered though government health systems will be continued. Government /NGO-led routine counseling and supplementary services available at Upazila and union levels, which include prenatal counseling, exclusive breastfeeding counseling, and maternal iron-folic acid supplementation and vitamin-A supplementation for children will continue. However, assessment of outcomes will be conducted in same frequency and schedule, alike in intervention arms, described in data collection section.
16576516|NCT02768168|Experimental|Group D|40 patients receive dezocine 0.1 mg/Kg
16576517|NCT02768168|Placebo Comparator|Group C|40 patients receive matching placebo （normal saline）
16576518|NCT02768155|Experimental|AF 4.0|Amniotic Fluid 4.0ml dose
16576519|NCT02768155|Experimental|AF 2.0|Amniotic Fluid 2.0ml dose
16576520|NCT02768155|Placebo Comparator|Placebo|Saline Placebo Control
16576521|NCT02768142|Experimental|Natural cesarean delivery|Placing the neonate on maternal chest immediately after the extraction from the uterus, and permitting breastfeeding during surgery.
16576522|NCT02768142|Active Comparator|Standard cesarean delivery|Presentation of the neonate to the mother during the operation.
16576523|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
16576524|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
16576525|NCT02768116|Experimental|ATP technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of non-left-main bifurcation lesion.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
16576526|NCT02768116|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Provisional T stenting technique in the treatment of non-left-main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
16576527|NCT02768103|Experimental|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
16576528|NCT02768090|Experimental|Skin Patch|Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry
16576529|NCT02768077|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
16576530|NCT02768077|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
16576531|NCT02768064|Experimental|Flexible screwed electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a flexible screwed electrode.
16576532|NCT02768064|Active Comparator|Stiff standard electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a stiff standard temporary electrode
16576533|NCT02768051|Experimental|AF Ablation Intervention|Subjects who are scheduled to undergo ablation procedure due to atrial flutter.
16576534|NCT02768025|Experimental|Intervention group|NRT, counselling, traditional & complementary medicine treatment (Body acupuncture, Ear acupuncture and aromatic therapy).
16576535|NCT02768025|Active Comparator|Control group|NRT, counselling
16576536|NCT02768012|Active Comparator|mindfulness-based cognitive therapy|The practice of mindfulness will be followed plus the basics of cognitive therapy given in small group format.
16576537|NCT02768012|No Intervention|waitlist|Women diagnosed with AISD randomised to wait list will receive no active treatment during the trial period.
16576538|NCT02767999|Experimental|Fluoxetine|One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI
16576539|NCT02767999|Placebo Comparator|Placebo|The other group will take a cellulose placebo per day from D0 to D90 and have fMRI
16576541|NCT02767973|Experimental|Woodsmoke Exposure|
16576542|NCT02767960||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
16576543|NCT02767960||NSTEMI group|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
16576608|NCT02767492|Active Comparator|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
16577017|NCT02764840|Experimental|experimental group elastic tube (GETE)|elastic tube brand LEMGRUBER 203
16576544|NCT02767960||UAP group|The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
16576545|NCT02767960||control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.
16576546|NCT02767947|Experimental|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
16576547|NCT02767947|Placebo Comparator|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
16576548|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
16576549|NCT02767921|Experimental|Treatment (recombinant EphB4-HSA fusion protein, surgery)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
16576550|NCT02767908|No Intervention|Usual Care|Participants in the usual care group will be offered and, if accepted, provided with smoking cessation support that meets the recommendations of NICE PH48 guidance including pharmacotherapy and behavioural support before leaving hospital, referral to NHS SSS for continued care after discharge, and ascertainment of smoking status at 4 weeks; participants will also be asked to consent to smoking status ascertainment at three months. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation. All will be asked at four weeks and 3 months to list the cessation support, in terms of pharmacotherapy and behavioural support from local or other services, delivered since the last contact.
16576551|NCT02767908|Active Comparator|Intervention|A home visit will be carried out as soon as practicable after discharge and typically within 48 hours, to deliver a multi-component intervention. Intervention components all have an existing evidence base proving or suggesting potential efficacy for smoking cessation and/or relapse prevention, though their feasibility and importance when delivered as a combined package have not been tested.
16576552|NCT02767895|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health
16576553|NCT02767895|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
16576554|NCT02767882|Active Comparator|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
16576555|NCT02767882|Experimental|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
16576556|NCT02767882|Placebo Comparator|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
16576557|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
16576558|NCT02767869|Placebo Comparator|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
16576559|NCT02767856|Experimental|Intense 12-hour IO-therapy Group|Participants wear 12-hour daily IO-therapy glasses for 4 weeks
16576560|NCT02767856|Active Comparator|Standard 4-hour IO-therapy Group|Participants wear 4-hour daily IO-therapy glasses for 12 weeks
16576561|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
16576562|NCT02767830|Experimental|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
16576563|NCT02767817|Sham Comparator|Stereotactic Hematoma Evacuation|
16576564|NCT02767817|Experimental|MSCs Transplantation|
16576565|NCT02767817|Experimental|Injectable Collagen Scaffold with MSCs Transplantation|
16576566|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
16576567|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
16576568|NCT02767791|Active Comparator|Acupuncture|Acupuncture wrist 6
16576569|NCT02767791|Active Comparator|Auriculotherapy|Auriculotherapy
16576570|NCT02767791|Experimental|Auriculotherapy and acupuncture|Auriculotherapy and acupuncture
16576571|NCT02767791|No Intervention|No treatment|No treatment
16576572|NCT02767778|Experimental|REAL Pulsed ELF-MF stimulation|Patients will receive REAL pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
16576573|NCT02767778|Sham Comparator|SHAM Pulsed ELF-MF stimulation|Patients will receive SHAM pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
16576574|NCT02767765|Experimental|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
16576575|NCT02767752|Experimental|T-ChOS + Gemcitabine + Capecitabine|"T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.
~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
16576639|NCT02767284|Experimental|UCST-V2|The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
16576577|NCT02767739|Experimental|Physical, social and cultural activities|"Physical Activity: The training program will be supervised by a physical activity specialist and will consiste of two aerobic exercise sessions per week, including walking and stretching exercises after walking. Each session will be 60 minutes and the size of groups will be from 15 to 30 participants. Additionally, participants will receive advice about the health benefits of PA and PHC nurses using different strategies to encourage the adherence of participants to the program.
~Social and cultural support activities. Activities will include: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons. These activities will be performed once a month."
16576578|NCT02767739|No Intervention|Control Group|No intervention. We will measure the variables at the begining and after 9 months.
16576579|NCT02767713|Experimental|Dexamethasone|Dexamethasone dose of 0.1 mg/kg was administered intravenously 10h before surgery
16576580|NCT02767713|Placebo Comparator|Control|Equal volume of normal saline (placebo) was administered intravenously 10h before surgery
16576581|NCT02767687|Experimental|Noninvasive ventilation (NIV)|Noninvasive mechanical ventilation is a resource used to treat respiratory failure or to reestablish respiratory comfort and function. It is commonly used in the ICU with a regular mechanical ventilator and is offered using an interface that connects the machine to the patient. The interface used for adults and in this study, was a silicon facial mask that covers the nose and mouth of the patient, allowing him or her to open the eyes.
16576582|NCT02767674|Experimental|R-GemOx|Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)
16576583|NCT02767674|Active Comparator|R-miniCHOP|Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Epirubicin 35 mg/m2 IV d1 vindesine 2 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)
16576584|NCT02767661|Experimental|Capecitabine+Aromatase inhibitor|Capecitabine, 625mg/m2, orally twice daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
16576585|NCT02767661|Active Comparator|Aromatase inhibitor|Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
16576586|NCT02767648||cholestasis|infant suffering from cholestasis proteomic urine analysis
16576587|NCT02767635|Experimental|Botox-Epic group|20 units of Botox injection into lateral epicondyle in Botox-Epic group
16576588|NCT02767635|Experimental|Botox-Tend group|20 units of Botox injected into tender point of muscles in Botox-Tend group
16576589|NCT02767635|Active Comparator|Steroid group|40mg of triamcinolone acetonide but not Botox injected into lateral epicondyle in Steroid group
16576590|NCT02767622||Patient Group|Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation.
16576591|NCT02767622||Control Group|Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness.
16576592|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
16576593|NCT02767596|Experimental|Lixisenatide|S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
16576594|NCT02767583|Experimental|Non diabetic obese|Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology.
16576595|NCT02767570|Experimental|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
16576596|NCT02767570|Experimental|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
16576597|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:
~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.
~Gemcitabine:
~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
~Nab-Paclitaxel:
~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
16576598|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:
~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
~Nab-Paclitaxel:
~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
16576599|NCT02767544|Experimental|ropivacaine group|Vaginal wound local analgesia by 10ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
16576600|NCT02767544|No Intervention|Control group|Vaginal wound no local analgesia by 10 ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
16576601|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
16576602|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
16576603|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
16576604|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
16576605|NCT02767505|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
16576606|NCT02767505|Active Comparator|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
16576607|NCT02767492|Experimental|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
16577018|NCT02764814|Active Comparator|Treatment|subjects receiving cryopreserved amniotic membrane
16576609|NCT02767479|Active Comparator|rabeprazole group|rabeprazole-based regimen. This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
16576610|NCT02767479|Active Comparator|esomeprazole group|'esomeprazole^based regimen. This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
16576611|NCT02767466||G|"All participants were randomly exposed to two different treatments:
~Conventional physical therapy (no specific device used)
~Robotic assisted gait training (Lokomat, Hocoma AG, Switzerland)
~We consider the study as observational, since the both interventions of the study (physical therapy, robotic assisted gait training) did not change in the patients' usual therapy plan, as they received both interventions daily.
~We only added diagnostic interventions to assess the affective responses."
16576612|NCT02767453|Active Comparator|TSA with drain placement|Hemovac drains are placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
16576613|NCT02767453|Active Comparator|TSA without drain placement|Hemovac drains will not be placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
16576614|NCT02767440|Experimental|Families on Track Intervention|This is a pre-post study. Enrolled parents will receive the Families on Track intervention plus usual care at the Healthy Lifestyles clinic at Duke University.
16576615|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
16576616|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
16576617|NCT02767414|Experimental|Respirio Flu Test and eLab Flu Test|"Upper respiratory tract samples from participants will be tested with:
~Respirio Flu Test; eLab Flu Test; and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)"
16576618|NCT02767401|Active Comparator|PCI using stenting or balloon expansion|Opening single CTO lesions using drug-eluting stents (such as Xience V and Prime, Endeavor Resolute, Taxus express and Libete, Excel, Partner, BUMA, YINYI, TIVOLI,Firebird2,FireHawk, and Coroflex) or balloon expansion plus optimal medical therapy. Intravascular ultrasound (IVUS),optimal coherence tomgraphy (OCT) or fractional flow reserve (FFR) is used if they are needed. Optimal medical therapy includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-angina therapy should be used if the patients have symptoms.
16576619|NCT02767401|No Intervention|Optimal medical therapy|Optimal medical therapy. It includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
16576620|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
16576621|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
16576622|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
16576623|NCT02767375|Active Comparator|HAIC treatment group|HAIC treatment after resection Intervention: Drug: Oxaliplatin, 5-fluorouracil (5-FU) Procedure/Surgery: Hepatic arterial catheter implantation
16576624|NCT02767375|No Intervention|No HAIC treatment group|Best support care and follow up
16576625|NCT02767362|Experimental|Single Arm|Patients will undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgery. At the time of hysterectomy and surgical staging, women will undergo repeat endometrial biopsy in the operating room under general anesthesia.
16576626|NCT02767349|Experimental|MNK-155|MNK-155, initial dose of two or three tablets followed by 2 tablets every 12 hours up to a maximum of five doses.
16576627|NCT02767336|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
16576628|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC (Aim1a)|excitatory rTMS applied over the DLPFC (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
16576629|NCT02767323|Experimental|Active or Sham rTMS over the Parietal cortex (Aim1b)|excitatory rTMS applied over the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
16576630|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC and the Parietal cortex (Aim1c)|excitatory rTMS applied over the DLPFC and the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
16576631|NCT02767310|Experimental|Test Product|Rosuvastatin 20 mg film-coated tablets
16576632|NCT02767310|Active Comparator|Reference product|Crestor 20 mg film-coated tablets
16576633|NCT02767297|Experimental|Part 1: Single dose (cross over)|FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
16576634|NCT02767297|Experimental|Part 2: Multiple dose (dose level 1)|FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
16576635|NCT02767297|Experimental|Part 2: Multiple dose (dose level 2)|FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
16576636|NCT02767297|Experimental|Part 2: Multiple dose (dose level 3)|FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
16576637|NCT02767297|Experimental|Part 3: Single dose|FDL169 test formulation administered as a single dose in CF subjects
16576638|NCT02767284|Experimental|UCST-V1|The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
16576710|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
16576640|NCT02767284|Experimental|UCST-V3|The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
16576641|NCT02767284|Experimental|Quick-CSF|The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
16576642|NCT02767284|Active Comparator|Pelli-Robson|The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
16576643|NCT02767284|Active Comparator|Optec 6500|The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
16576644|NCT02767271|Experimental|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
16576645|NCT02767271|Experimental|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
16576646|NCT02767258|Active Comparator|Sham Comparator: Eye drop|Eye drop LACRIBELL® - two drops each eye, two times a day, after eye cleansing.
16576647|NCT02767258|Experimental|VIDISIC® GEL|Ocular gel VIDISIC® GEL applied two times a day at the lower palpebra from medium line to the lateral border.
16576648|NCT02767245|Active Comparator|Thiamine|Thiamine intravenously 100 mg/day for 3 days
16576649|NCT02767245|No Intervention|No thiamine|No thiamine was given to the patient
16576650|NCT02767232|Active Comparator|Standard Anticoagulation Therapy|Anticoagulant therapy will be prescribed in accordance with 2012 ACCP Guidelines for children. Initial therapy generally will consist of low molecular weight heparin (LMWH) or unfractionated heparin (UFH), monitored to achieve and maintain a target anti-Xa activity of 0.5-1.0 IU/mL for LMWH and 0.35-0.7 IU/mL for UFH. Long-term therapy generally will consist of warfarin/coumadin, monitored to achieve and maintain a target INR of 2.0-3.0. The use of novel anticoagulants is permitted based on investigator preference.
16576651|NCT02767232|Experimental|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis (CDT) with intrathrombus delivery of Recombinant tissue plasminogen activator (rt-PA) (maximum allowable total dose 35 mg/24 hours) into the DVT over a period of up to 24 hours. CDT will be initiated within 72 hours of diagnosis. Two methods of initial rt-PA delivery will be used: 1.) AngioJet Thrombectomy System- maximum first-session rt-PA dose 25 mg; or 2.) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole catheter. Before and after CDT, patients will receive standard DVT therapy as in the standard anticoagulation group
16576652|NCT02767219|Other|Dexamethasone and 5-fluorouracil|The control arm consists of current standard therapy of subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of 5-fluorouracil as required for 4 consecutive weeks after entry into the trial.
16576653|NCT02767219|Active Comparator|Dexamethasone and Avastin|Subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of bevacizumab will be given for 4 consecutive weeks from time of entry into trial
16576654|NCT02767206||portal hypertension|Patients with cirrhosis or non-cirrhotic portal hypertension.
16576655|NCT02767193|Experimental|DCV3|Autologus differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus
16576656|NCT02767193|Experimental|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG-INF
16576657|NCT02767193|Placebo Comparator|CD placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded
16576658|NCT02767193|Placebo Comparator|CD placebo + PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG-INF
16576659|NCT02767180||Critical care survivors|Former ICU-patients recruited six months to three years after discharge from the ICU
16576660|NCT02767180||Matched controls|Control patients who have not been critically ill, matched for age and sex.
16576661|NCT02767167|Active Comparator|Milk treatment group|Semi-skimmed cow's milk + normal diet for 12 weeks
16576662|NCT02767167|No Intervention|Control group|Normal diet for 12 weeks
16576663|NCT02767154|Active Comparator|PrimECC|1250 ml of a priming solution based on the colloid Dextran 40 to use for extracorporeal circulation.
16576664|NCT02767154|Active Comparator|Ringer-Acetate/Mannitol|1250 ml of a priming solution based on the crystalloid Ringer-Acetate (1000ml) and Mannitol (250ml).
16576665|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
16576666|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
16576667|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
16576668|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
16576669|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
16576670|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
16576671|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
16576672|NCT02767115|Experimental|GSE mucoadhesive gel|2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
16576673|NCT02767115|Placebo Comparator|Control mucoadhesive gel|GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
16576674|NCT02767102|Experimental|Red wine with Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be enriched with 10 ng mL-1 MLT (MLT+) and used as experimental wine.
16576675|NCT02767102|Placebo Comparator|Red wine without Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be used as placebo treatment (PLC).
16576676|NCT02767089|Other|Sequence A|Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg
16576677|NCT02767089|Other|Sequence B|Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg
16576678|NCT02767089|Other|Sequence C|Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg
16576679|NCT02767089|Other|Sequence D|Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg
16576680|NCT02767089|Other|Sequence E|Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo
16576681|NCT02767089|Other|Sequence F|Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg
16576682|NCT02767089|Other|Sequence G|Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg
16576683|NCT02767076|Active Comparator|Conventional|conventional paramedian spinal anesthesia
16576684|NCT02767076|Experimental|Ultrasound|ultrasound guided paramedian spinal anesthesia
16576685|NCT02767063|Experimental|Experimental Arm_ACTOS|"TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
~PIOGLITAZONE (Actos®):
~30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE."
16576686|NCT02767063|No Intervention|controled Arm|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
16576687|NCT02767063|Experimental|Experimental Arm_AVELUMAB|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
16576688|NCT02767050||GROUP 1: CONTROL GROUPS|Patients with no habit history of tobacco are included in group 1.
16576689|NCT02767050||GROUP 2: SMOKING TOBACCO|Patients with a history of tobacco consumption in the form of smoking.
16576690|NCT02767050||GROUP 3: SMOKELESS TOBACCO|Patients with a history of tobacco consumption in the form of chewing.
16576691|NCT02767037|Active Comparator|Parkinson's disease (PD) patients|40 patients will be recruited. All will meet criteria for probable PD, according to the new MDS Clinical Diagnostic criteria. All participants will be 40 or older (young-onset PD includes many genetic causes, which often have normal autonomic function).
16576692|NCT02767037|Active Comparator|parkinsonsism (non-PD) patients|20 patients will also be recruited. These will include patients with progressive supranuclear palsy, multiple system atrophy, 'vascular parkinsonism' or corticobasal syndrome. All patients will have parkinsonism according to UK brain bank criteria, with a diagnosis of one of the above conditions made according to gold-standard expert evaluation. No patient will meet MDS Criteria for probable PD.
16576693|NCT02767037|Active Comparator|idiopathic REM sleep behavior disorder patient|40 patients will be recruited. All patients will have polysomnogram-confirmed RBD according to American Academy of Sleep Medicine Criteria. Patients will be free of parkinsonism and dementia according to neurological examination and will have no untreated sleep apnea, epilepsy, or other abnormalities that could cause dream enactment behavior.
16576694|NCT02767037|Placebo Comparator|Controls|40 controls will be age matched (within 5 years) and sex-matched (with >90% concordance). All controls will have an examination confirming the absence of parkinsonism, and will have no symptoms of REM sleep behavior disorder, as assessed with the RBD1Q and expert interview.
16576695|NCT02767024|Experimental|Sodium Nitroprusside|Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP > 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) > 2.2 L·min-1·m-2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
16576696|NCT02767024|Active Comparator|Dobutamine|Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI > 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
16576697|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
16576698|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
16576699|NCT02766998|Experimental|Preserved umbilical vein|Preserved umbilical vein as shunt/conduit
16576700|NCT02766985||FSHD|Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
16576701|NCT02766972|Experimental|RVP|
16576702|NCT02766959||PAV/PAV Tasters|Individuals homozygous for the taster allele of the TAS2R38 gene, PAV/PAV.
16576703|NCT02766959||AVI/PAV.|Individuals heterozygous for the taster allele of the TAS2R38 gene, AVI/PAV.
16576704|NCT02766959||AVI/AVI|Individuals homozygous for the non-taster allele of the TAS2R38 gene, AVI/AVI.
16576705|NCT02766946|Experimental|Mechanical Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Mechanical Ventilation
~Interventions :
~Ultrasound of the right diaphragm
~Ultrasound of the pectoral muscle
~Neuromyopathy score
~Respiratory performances"
16576706|NCT02766946|Active Comparator|Non-invasive Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Non-invasive Ventilation
~Interventions :
~Ultrasound of the right diaphragm
~Ultrasound of the pectoral muscle
~Neuromyopathy score
~Respiratory performances"
16576707|NCT02766946|Active Comparator|Spontaneous Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Spontaneous Ventilation
~Interventions :
~Ultrasound of the right diaphragm
~Ultrasound of the pectoral muscle
~Neuromyopathy score
~Respiratory performances"
16576708|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
16576709|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
16576711|NCT02766881||Patients with DCIS|Whether patients with DCIS receive radiotherapy based on Oncotype DX DCIS score, radiation oncologist treatment recommendation and patient's decision.
16576712|NCT02766868|Experimental|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
16576713|NCT02766855|Experimental|cysteamine eye drops|Patients used cysteamine eye drops every 2 hours while awake to both eyes.
16576714|NCT02766842|Active Comparator|EUS-FNB with ProCore needle|General anesthesia or conscious sedation will be started and an upper endoscopic ultrasound will be inserted into the participants mouth and advanced to the site of the lesion. The lesion will be punctured by the ProCore needle, then the stylet is completely removed, and negative suction pressure is applied using a 10 ml syringe for 30 seconds while the needle is stationary with the target. Then, the needle is moved back and forth several times within the target, utilizing the fanning technique. Finally, suction is released by closing the lock of the syringe and the needle is removed.
16576715|NCT02766842|Active Comparator|EUS-FNB with SharkCore needle|The procedure will be done in the same manner with same endoscopic technique and method of tissue procurement. The only difference will be using the SharkCore needle to acquire tissue.
16576716|NCT02766829|Experimental|CLSP Group|Those with cross leg sitting position: patients sit with both their knees flexed medially, hip flexed, resulting in pelvic leaning posteriorly and reducing lumbal lordosis.
16576717|NCT02766829|Active Comparator|TSP Group|Those with traditional sitting position: patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion.
16576718|NCT02766816|Experimental|Part 1 Study - BBio bOPV|
16576719|NCT02766816|Active Comparator|Part 1 Study - Licensed bOPV|
16576720|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 1|
16576721|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 2|
16576722|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 3|
16576723|NCT02766816|Active Comparator|Part 2 Study - Licensed bOPV|
16576724|NCT02766803|Active Comparator|Simvastatin + resveratrol|simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily
16576725|NCT02766803|Placebo Comparator|simvastatin+ placebo|simvastatin 20 mg daily Placebo
16576726|NCT02766790|Placebo Comparator|Placebo|Placebo taken once daily in the morning and once daily in the evening
16576727|NCT02766790|Active Comparator|TA-65MD 100 units Dose|TA-65MD 100 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
16576728|NCT02766790|Active Comparator|TA-65MD 250 units Dose|TA-65MD 250 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
16576729|NCT02766790|Active Comparator|TA-65MD 500 units Dose|TA-65MD 500 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
16576730|NCT02766790|Active Comparator|TA-65MD 250 units a.m. and p.m. Dose|Two TA-65MD 250 units capsules; one of them will be taken in the a.m. and one of them will be taken in the p.m.
16576731|NCT02766777|Experimental|Lubiprostone|Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
16576732|NCT02766764|Active Comparator|Study group|Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.
16576733|NCT02766764|Placebo Comparator|Placebo group|Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.
16576734|NCT02766751|Placebo Comparator|Health Education|The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
16576735|NCT02766751|Experimental|HIVPASS|Over 7 sessions, the interventionist and the participant will explore the relationship between pain, depressive symptoms, and HIV. General information about pain, HIV and depression will be discussed, as will avoidance of physical activity. Psychoeducation about these areas will be tied to the participant's stated life goals, and exposure exercises and goal lists will be developed. Later sessions will integrate continued efforts towards reaching goals and reducing avoidance. A release of information will be obtained from the participant to allow study session chart notes to be placed in the medical record at the participant's PCP office and to allow the PCP and the study interventionist to discuss treatment coordination.
16576736|NCT02766738|No Intervention|Control|All participants assigned to the control group will be given the option to engage in other activities that were offered by the facility during the 24-week intervention period. However, no specific resistance exercises were offered in these activities.
16576737|NCT02766738|Experimental|GrACE program|Participants in the exercise group will perform twice weekly training for 24 weeks. In brief, the program will include weight-bearing exercises and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. The following-weight bearing and resistance exercises: chair stands, chair dips, calf raises and hip flexor/abdominal lifts, trunk twists, and bicep curl and shoulder press. In total the sessions will be 45 minutes twice weekly.
16576738|NCT02766738|Experimental|GrACE + gait program|GrACE program as mentioned above plus focus on gait specific training will be one-hour training sessions for 24 weeks. Gait exercises will be a combination of exercises: heel and toe raises, stepping in different directions, single leg stand¬ing, step-ups, and task-specific balance work (e.g. reaching outward from the base of support while standing, sitting, and standing and turning). Gait exercises will be upgraded by: 1) reducing hand support and/or 2) narrowing the base of support, and/or 3) introducing a cognitive challenge (e.g. counting backwards while performing exercise) or perform¬ing exercise with the eyes closed.
16576772|NCT02766491|Active Comparator|conventional stretching|The control group will receive conventional stretching and strengthening exercises to the upper limb to assure that the same systemic physiological stimuli and a similar number of contact hours is received.
16576739|NCT02766725|Experimental|preparation F12 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
16576740|NCT02766725|Active Comparator|preparation F2 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
16576741|NCT02766725|Placebo Comparator|placebo gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
16576742|NCT02766712|Experimental|CA 1st Half of lesion|During each of the 15 pre-specified lesions, pacing will be initiated at a 500ms cycle length from a catheter in the coronary sinus or right ventricle prior to the start of the lesion. Pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Weckebach behavior continues, the pacing catheter will be moved to the right ventricle, which and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
16576743|NCT02766712|Experimental|CA 2nd Half of Lesion|During each of the 15 pre-specified lesions, pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Wenckebach behavior persists, the pacing catheter will be moved to the right ventricle and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
16576744|NCT02766699|Experimental|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10^9 or 8 x 10^9. All subjects will undergo an adapted dose escalation regime in the first cycle of treatment. For subsequent cycles all doses will be administered at full strength (5x10^9 or 8x10^9 EGFR(V)-EDV-Dox). Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
16576745|NCT02766686|Experimental|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
16576746|NCT02766686|Active Comparator|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
16576747|NCT02766686|Other|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
16576748|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
16576749|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
16576750|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
16576751|NCT02766660|Other|Thyroid ophthalmopathy|Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
16576752|NCT02766660|Other|Control|Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
16576753|NCT02766647|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
16576754|NCT02766647|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
16576755|NCT02766634|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
16576756|NCT02766634|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
16576757|NCT02766621|Placebo Comparator|Placebo injection SC/IV|Placebo for injection SC/IV
16576758|NCT02766621|Active Comparator|PF-06823859|Study Drug being used in the study
16576759|NCT02766608|Experimental|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
16576760|NCT02766608|Experimental|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
16576761|NCT02766608|Experimental|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
16576762|NCT02766608|Experimental|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
16576763|NCT02766608|Other|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
16576764|NCT02766595|Other|hyperventilation|Non-drug: performing hyperventilation while sitting up during routine EEG
16576765|NCT02766582|Experimental|Chemotherapy combined with pembrolizumab|"Single arm study:
~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 7 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
16576766|NCT02766556|Active Comparator|arm 1|received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
16576767|NCT02766556|Placebo Comparator|arm 2|received ISB with 8mL of ropivacaine with 1ml of normal saline
16576768|NCT02766543|Experimental|MRI-guided Transurethral Ultrasound Ablation Device|Magnetic resonance imaging-guided transurethral ultrasound ablation of whole-gland prostate tissue.
16576769|NCT02766530|Experimental|PETMR study|All the study participants will receive PET MR examinations before neoadjuvant chemotherapy and during neoadjuvant chemotherapy (during early cycle as well as during mid-cycle of chemotherapy treatment). There will be two groups of patients after completion of neoadjuvant chemotherapy, that is, responders versus non-responders. We will compare the PET MR imaging parameters before, during neoadjuvant chemotherapy between the two groups of patients.
16576770|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
16576771|NCT02766491|Experimental|Strengthening and stretching|The intervention group will follow a strengthening-stretching program of the calf muscles.
16576773|NCT02766478|Experimental|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
16576774|NCT02766478|Placebo Comparator|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
16576777|NCT02766452|Experimental|Pre-operative educational DVD preparation|"After their pre-assessment clinic (PAC) appointment, parents in the intervention group took the hospital's 20 minute surgical virtual tour in the hospital's family library. Parents in the intervention group also watched the 12 minute DVD entitled, You and Your Child in the RR. This pre-operative educational tool was developed and tested in a previous study (Chartrand 2014). It was designed to enable parents to gain knowledge about the equipment and procedures related to the RR, and about nurses' and parents' roles in supporting their child in the RR. The DVD also focused on potential reactions of children waking up after a general anesthesia and strategies parents can use to support their child in the RR. The DVD included images of RR equipment and positive nurse-family and parent-child interactions."
16576778|NCT02766452|Placebo Comparator|Standard pre-operative preparation|After their PAC appointment, parents in the control groups took the hospital's 20 minute surgical virtual tour in the hospital's family library.
16576779|NCT02766439||Rhupus syndrome, SLE without RA|Rhupus syndrome, SLE without RA
16576780|NCT02766426|Other|Lifestyle change intervention|Overweight/obese pregnant women enrolled in a healthy lifestyle change programm
16576781|NCT02766400|Experimental|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
16576782|NCT02766400|Active Comparator|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
16576783|NCT02766387|Experimental|2 minutes walk test|fast walk test during 2 minutes in first and the 10 meters walk test, the 6 minutes walk test and the 2 kilometers walk test
16576784|NCT02766387|Experimental|6 minutes walk test|comfortable walk test during 6 minutes in first and the 10 meters walk test, the 2 minutes walk test and the 2 kilometers walk test
16576785|NCT02766374|Experimental|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
16576786|NCT02766374|Placebo Comparator|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
16576787|NCT02766361|Experimental|Cognitive Behavioral Rehabilitation|12 sessions of new intervention of cognitive behavior therapy and cognitive rehabilitation
16576788|NCT02766361|Active Comparator|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
16576789|NCT02766348|Experimental|DC-CTL|After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment
16576790|NCT02766348|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
16576791|NCT02766335|Experimental|Arm I (MEDI4736 - closed to accrual 12/2015)|Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
16576792|NCT02766335|Active Comparator|Arm II (docetaxel - closed to accrual 4/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
16576793|NCT02766335|Experimental|Arm III (MEDI4736 retreatment)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
16577019|NCT02764814|No Intervention|Control|no intervention
16576794|NCT02766322||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
16576795|NCT02766322||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
16576796|NCT02766322||Sleeve gastrectomy longitudinal|Morbidly obese subjects undergoing sleeve gastrectomy surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight..
16576797|NCT02766322||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
16576798|NCT02766322||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
16576799|NCT02766322||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
16576800|NCT02766322||Non-surgical group|Subjects who are age and body mass index equivalent to gastric bypass (cross-sectional) and Sleeve gastrectomy (cross-sectional) but did not undergo any type of bariatric surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
16576801|NCT02766296|Experimental|Active Emotional Working Memory Training|Each participant will receive 15 sessions (each lasting 20 minutes) over a 5 week. This will be Internet-based cognitive training based on the adaptive dual n-back paradigm.
16576802|NCT02766296|Placebo Comparator|Control Working Memory Training|Participants in this condition will receive 15 sessions (each lasting 20 minutes) over a 5-week period. This will also be home-based training over the Internet. This training will be based on a fixed 1-back training program.
16576803|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
16576804|NCT02766270|Experimental|Chemoradiotherapy with Temozolomide|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses
16576805|NCT02766270|Active Comparator|Radiotherapy alone|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)
16576806|NCT02766257|Other|children undergoing ambulatory surgery|
16576807|NCT02766244|Experimental|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
16576808|NCT02766231||Physica CR|
16576809|NCT02766231||Physica PS|
16576810|NCT02766218||Behavioral: Lifestyle Intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
16576811|NCT02766218||No Intervention: Standard Care|
16576812|NCT02766192|Experimental|TIMBER-Ketamine arm|This arm received TIMBER psychotherapy and ketamine infusion.
16576813|NCT02766192|Placebo Comparator|TIMBER-placebo arm|This arm received TIMBER psychotherapy and placebo (normal saline) infusion.
16576814|NCT02766179|Active Comparator|CPAP Therapy|Continuous Positive Airway Pressure
16576815|NCT02766179|Experimental|Somnoguard|Somnoguard
16576816|NCT02766166||Predictive Monitoring|
16576817|NCT02766166||No Predictive Monitoring|
16576818|NCT02766153||patients|
16576819|NCT02766153||healthy volunteers|intrafamily marrow donors
16576820|NCT02766140|Experimental|SHR1020 plus Docetaxel|
16576821|NCT02766140|Placebo Comparator|Placebo plus Docetaxel|
16576822|NCT02766127|Experimental|Xerostomic Patients|"Patients with evident clinical signs of xerostomia who experienced dentinal hypersensitivity after undergoing radiation therapy due to head and neck cancer.
~The following dental materials will be used following the manufacturers' instructions: Veritise Flow; Universal Dentin Sealant; Clearfil Protect Bond, and Flor-Opal® Varnish. In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.
~the application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
16576861|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
16577663|NCT02760758|Experimental|Cohort 7A HV|CDI-31244 200 mg active or placebo MD
16576823|NCT02766114|Experimental|Issa1|After local anesthesia, through transverse approach on the middle of dorsal wrist crease the incision is made for 1.5 cm length, then the subcutaneous fat is dissected, soon we see the the palmaris longus tendon or its connection with the carpal ligament , take the ulnar side of the palmaris longus tendon and cut the carpal ligament axillary by scalpel, not going deep with the scalpel to avoid medial nerve injury, soon we see the nerve, we use the scissors to cut the proximal part then the distal part of the carpal ligament by enclosing it between the blades of the scissors, now the full released carpal tunnel most be observed, and one stitch is enough, in this operation most be an assistant exist.
16576824|NCT02766101|Experimental|Aerobic Exergaming PE|Progressive aerobic curriculum utilizing virtual reality exergaming stationary bicycles. Classes held 2 times per week for 30-40 minutes, aerobic exercise beginning at 10 minutes at moderate to vigorous intensity and building to 20 minutes plus.
16576825|NCT02766101|Active Comparator|Standard PE|Traditional PE focused on gross motor skill and sports skill acquisition, and team building. Typically non-aerobic.
16576826|NCT02766088|Experimental|Total Group|Subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia. The study population comprised household members and should include between 30% and 50% of adults (aged 18 years or above) per site.The appropriate recruitment strategy was selected by each participating site. Two approaches might be considered: a school-based approach and a community-based approach without school involvement The expected period for recruiting the target sample size was approximately three months.
16576827|NCT02766075|Experimental|Supervised TAVR Exercise Program (STEP)|Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
16576828|NCT02766075|No Intervention|Standard of Care|Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
16576829|NCT02766062|Active Comparator|propofol group|Patients with metabolic syndrome were randomly assigned to receive propofol anesthesia
16576830|NCT02766062|Active Comparator|sevoflurane group|Patients with metabolic syndrome were randomly assigned to receive sevoflurane anesthesia
16576831|NCT02766049|Active Comparator|(a) DC|Autologous dendritic cells (3x10e7)
16576832|NCT02766049|Active Comparator|(b) DC 10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
16576833|NCT02766049|Active Comparator|(c) DC 10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
16576834|NCT02766036|Active Comparator|Propolis|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
16576835|NCT02766036|Placebo Comparator|Placebo|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.
16576836|NCT02766023|Experimental|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
16576837|NCT02766023|Placebo Comparator|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
16576838|NCT02766010|Experimental|group A TensorTip|Male or female, age > 18
16576839|NCT02765997|Active Comparator|Unmanipulated UCB|Subjects will receive unmanipulated umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
16576840|NCT02765997|Experimental|StemRegenin-1 UCB|Subjects will receive StemRegenin-1 (SR-1) cultured umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
16576841|NCT02765984||normal placental site|women with normal implantation site at early trimester with normal placental site
16576842|NCT02765984||Low placental site|women with low implantation site at early trimester with low placental site
16576843|NCT02765971|Active Comparator|chewing gum group|180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval
16576844|NCT02765971|Active Comparator|laxatives group|180 women will receive laxatives after their operating room discharge by 3 hours
16576845|NCT02765971|Placebo Comparator|control|they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds
16576846|NCT02765958||Healthy|subjects without heart disease or arrhythmia, no evidence of obstructive sleep apnea
16576847|NCT02765958||OSA|obstructive sleep apnea
16576848|NCT02765932|Active Comparator|Placebo Therapy|Dummy Movements
16576849|NCT02765932|Experimental|Psychosensory Therapy|Will involve touch technique, havening.
16576850|NCT02765919|Experimental|Radiation HDR Brachytherapy 9 Gy|High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix
16576851|NCT02765919|Active Comparator|Radiation HDR Brachytherapy 7 Gy|High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix
16576852|NCT02765906|No Intervention|No intervention|No additional education
16576853|NCT02765906|Experimental|Graphic card|Education with graphic card
16576854|NCT02765906|Experimental|Video|Education with video
16576855|NCT02765893|No Intervention|Foley|Patients will have Foley in place overnight after completion of surgery, which is currently standard of care at our institution.
16576856|NCT02765893|Active Comparator|No Foley|Patients will have Foley catheter removed 6 hours post-op.
16576857|NCT02765880|Experimental|Healthy volunteer|
16576858|NCT02765880|Experimental|Patients with schizophrenia|
16576859|NCT02765880|Experimental|Patient with bipolar disorder|
16576860|NCT02765867|Experimental|RBP-6000|A single dose of RBP-6000 will be administered on Study Day 1
16576862|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
16576863|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
16576864|NCT02765841|Experimental|Lomitapide|
16576865|NCT02765828||Late-Onset Pompe Disease|
16576866|NCT02765828||Acquired/Hereditary Myopathy|
16576867|NCT02765828||Neuropathy|
16576868|NCT02765815|Active Comparator|Exparel plus multi-drug cocktail|Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.
16576869|NCT02765815|Active Comparator|Multi-drug cocktail alone|Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.
16576870|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
16576871|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
16576872|NCT02765789|Experimental|Immunoadsorption|Immunoadsoprtion (Immunosorba). All (anticipated) 8 participants will be treated with immunoadsorption
16576873|NCT02765763|Sham Comparator|Group 1 Sham|Null Formula of the Test System
16576874|NCT02765763|Active Comparator|Group 2 Treated|Full Formulas of Test System
16576875|NCT02765750|Experimental|BIS 40-60|Patient with intraoperative Bispectral Index (BIS) 40-60.
16576876|NCT02765750|Experimental|BIS 20-40|Patient with intraoperative Bispectral Index (BIS) 20-40.
16576877|NCT02765750|Placebo Comparator|Placebo|Placebo group
16576878|NCT02765737|Active Comparator|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
16576879|NCT02765737|Active Comparator|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
16576880|NCT02765724|Experimental|Group 1|Patients with mild hepatic impairment
16576881|NCT02765724|Experimental|Group 2|Patients with moderate hepatic impairment
16576882|NCT02765724|Experimental|Group 3|Patients with severe hepatic impairment
16576883|NCT02765724|Experimental|Group 4|Healthy subjects
16576884|NCT02765711||the use of ticagrelor in hospital|
16576885|NCT02765685|Experimental|ODRA|
16576886|NCT02765685|Active Comparator|usual care|
16576887|NCT02765672|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
16576888|NCT02765672|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
16576889|NCT02765672|Active Comparator|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
16576890|NCT02765672|Active Comparator|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
16576891|NCT02765672|Active Comparator|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
16576892|NCT02765672|Active Comparator|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
16576893|NCT02765659|Other|Community 1|Receives Mzake ndi Mzake T1 immediately after baseline
16576894|NCT02765659|Other|Community 2|Receives Mzake ndi Mzake T2 immediately after Post-T1 evaluation
16576895|NCT02765659|Other|Community 3|Receives Mzake ndi Mzake T3 immediately after Post-T2 Evaluation
16576896|NCT02765633|Experimental|Cangrelor|Cangrelor in up to four (4) dose cohorts consisting of a minimum of five participants in each cohort. One cohort of five participants will be enrolled at a time. Cohort 1 subjects will receive Cangrelor at 0.5 mcg/kg/min. Cohort 2 subjects will receive Cangrelor at 0.25 mcg/kg/min. Subsequent cohort dosing decisions are made at the completion of enrollment in each cohort.
16576897|NCT02765620||drug|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
16576898|NCT02765620||radiation|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
16576899|NCT02765594|Experimental|valsartan only:control group|valsartan (160mg/d)
16576900|NCT02765594|Experimental|hydroxychloroquine with valsartan:study group|valsartan (160mg/d) and Hydroxychloroquine Sulfate ( 400mg/d, twice daily)
16576901|NCT02765581|Experimental|Verum acupuncture (VA)|Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
16576956|NCT02765204|Experimental|DS-D-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
16576902|NCT02765581|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
16576903|NCT02765581|Placebo Comparator|Usual care (UA)|Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.
16576904|NCT02765568|Experimental|Moderate Intensity Continuous Exercise|Moderate Intensity Continuous Exercise Training
16576905|NCT02765568|Experimental|Nordic Walking|Nordic Walking
16576906|NCT02765568|Experimental|High Intensity Interval Training|High Intensity Interval Training
16576907|NCT02765555|Experimental|RBP-7000|All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
16576908|NCT02765542|Experimental|Automated phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
16576909|NCT02765529|Experimental|20-30 years|Blood sampling
16576910|NCT02765529|Experimental|45-55 years|Blood sampling
16576911|NCT02765529|Experimental|70-80 years|Blood sampling
16576912|NCT02765529|Experimental|Control|Blood sampling for standardization of technical procedures
16576913|NCT02765516|Active Comparator|Plant sterols|
16576914|NCT02765516|Placebo Comparator|Placebo|
16576915|NCT02765503|Active Comparator|Control|'Standard' external beam radiotherapy to deliver 66Gy in 33 fractions treating with 6 fractions a week.
16576916|NCT02765503|Experimental|HYPNO|The experimental regimen in which patients receive external beam radiotherapy to deliver 55Gy in 20 fractions treating 5 times a week.
16576917|NCT02765490|Experimental|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
16576918|NCT02765490|Experimental|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
16576919|NCT02765477||Angiogram Cohort w Acute Coronary Occlusion|Inclusion Criteria: Angiogram Cohort. Patients who present 1) directly through the study site Emergency Department (ED) OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1.Underwent urgent or emergent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to chest pain [CP] and/or shortness of breath [SOB]) AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, a group of patients will be identified who had angiographic evidence of ACO, defined as an acute lesion with TIMI flow 0 or 1 when evaluated by an experienced study-site adjudicator.
16576920|NCT02765477||Non-ACO Angiogram Cohort|Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
16576921|NCT02765477||Random ED Sample w Paced Rhythm but No AMI|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.
~Each study site will randomly select 5 unique encounters for every one 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.
~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.
~The primary control group selected from this search will be all patients in this group who do not meet criteria for acute myocardial injury, as defined by 1) all troponins below the 99th percentile or 2) Peak troponin < 3x the upper limit of normal AND no rise and/or fall of > 30%."
16576922|NCT02765477||ED Patients w Paced Rhythm Without AMI excluded|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.
~Each study site will randomly 5 unique encounters for every 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.
~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.
~The secondary control group will include patients in this group in whom Acute MI cannot be excluded because they either have at least 1 troponin > 3x the upper limit of normal or they have at least 1 troponin between 1x and 3x the ULN AND have a rise and/or fall of at least 30%."
16576923|NCT02765451|Active Comparator|A : 1 year of intervention|interventions of Cancéropôle Nord-Ouest during 1 year after an observational period of 2 years.
16576924|NCT02765451|Active Comparator|B : 2 years of intervention|interventions of Cancéropôle Nord-Ouest during 2 years after an observational period of 1 year.
16576925|NCT02765438|Experimental|BOBO|"Playing with the BOBO system."
16576926|NCT02765425|Experimental|Training Group|Subjects will receive the same outcome measures at baseline, after 3 months training and 6 months later. Intervention will comprise of three sessions seated at the AMES device. Each training session will include 15 min of training of each ankle. Training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
16576957|NCT02765204|Experimental|DS-DG-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
16576927|NCT02765425|No Intervention|Control Group|Subjects will receive no intervention. Subjects will receive all outcome measures at baseline and at 3 months post enrollment. Subjects will also receive a fall-incidence reporting form 9 months post enrollment. No other intervention - i.e. no treatment - is given.
16576928|NCT02765412||standard implementation|Webinar, Promotion, Tool Access, academic detailing + Audit and Feedback
16576929|NCT02765412||intensive implementation|Webinar, Promotion, and Tool Access, academic detailing + Audit and Feedback + LEAP
16576930|NCT02765399|Experimental|Liraglutide|"Liraglutide subcutaneous injection once daily with following dose escalation:
~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months."
16576931|NCT02765399|Placebo Comparator|Placebo|"Placebo subcutaneous injection once daily with following dose escalation:
~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months."
16576932|NCT02765386|Experimental|Cochlear Implant Recipients|Newly implanted cochlear implant recipients with post-implantation acoustic hearing.
16576933|NCT02765373||steroidal aromatase inhibitors(AIs)|Exemestane 25mg Qd for 5 years
16576934|NCT02765373||non-steroidal aromatase inhibitors(AIs)|Letrozole 2.5mg Qd or Anastrozole 1mg Qd for 5 years
16576935|NCT02765360|Experimental|Treatment|Each patient will be assigned to Continuous Positive Airway Pressure (CPAP), Pressure Support Ventilation (PSV) and Pressure Control Ventilation (PCV) modes in a random order with a 10 minute washout period modes.
16576936|NCT02765347|Other|Metformin and Insulin|MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks
16576937|NCT02765347|Other|Insulin|Accept insulin for 24 weeks
16576938|NCT02765334|Experimental|nBETTER and Conventional Therapy|Intervention: nBetter therapy
16576939|NCT02765321|Experimental|Physical activity and healthy eating promotion|
16576940|NCT02765308||Healthy volunteers|healthy age matched with cases volunteers as controls
16576941|NCT02765308||Uveitis with raised IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
16576942|NCT02765308||Uveitis with with normal IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
16576943|NCT02765295|Active Comparator|hydrogen inhalation|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
16576944|NCT02765295|Sham Comparator|oxygen inhalation|Oxygen will be generated by an instrument provided by the sponsor, that would be capable of generating oxygen equivalent to that generated by the MUNHO (3L/min mixed gas containing 33.3% oxygen). Usual care referred to mucolytics [[ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily)/ serrapeptase (10mg thrice daily), or carbocisteine (500mg thrice daily)] alone or in combination with chest physiotherapy.
16576945|NCT02765282|Experimental|DBS-Expert Programming First|These patients will be undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) first and then be programmed by a clinician within five days.
16576946|NCT02765282|Experimental|Traditional Programming First|These patients will be programmed by a clinician first and then undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) within five days.
16576947|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
16576948|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
16576949|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
16576950|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
16576951|NCT02765243|Experimental|effectiveness of Anti-GD2 CART|Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma
16576952|NCT02765217|Experimental|Study group 1|"Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).
~Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days."
16576953|NCT02765217|Placebo Comparator|Study group 2|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.
16576954|NCT02765217|Experimental|Study group 3|Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.
16576955|NCT02765217|Placebo Comparator|Study group 4|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.
16577016|NCT02764840|Experimental|experimental group isokinetic dynamometer (GEDI)|Isokinetic Biodex System Pro 4
16576958|NCT02765204|Experimental|D-DG-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
16576959|NCT02765204|Experimental|D-DS-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
16576960|NCT02765204|Experimental|DG-D-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
16576961|NCT02765204|Experimental|DG-DS-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
16576962|NCT02765191|Experimental|Study group|Subjects investigated according to protocol after administration of bolus of Ringer's Acetate
16576963|NCT02765178||Patients with Tourette Syndrome|The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
16576964|NCT02765178||Patients with Diabetes type 1|The primary caregiver will be asked to fill the Children's motivation Scale. Demographic data will also be collected for each study patient.
16576965|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1a|USL311, intravenous, once per week, starting at 60 mg/m˄2
16576966|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1b|USL311, oral, daily, starting at 40 mg
16576967|NCT02765165|Experimental|Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2|USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks
16576968|NCT02765165|Experimental|Dose-Expansion, USL311, GBM, Part 3|USL311, oral, daily, starting at dose determined in Part 1b
16576969|NCT02765165|Experimental|Dose-Expansion, USL311 with Lomustine, GBM, Part 4|USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2
16576970|NCT02765152|Active Comparator|Conventional Physical Therapy|Usual therapy: joint mobility exercises, stimulating joint movement of the main active components of the upper limb; major muscle groups stretching, especially in the affected muscles by tone impairment; manual resistance training according to the degree of the patient's muscle strength, prioritizing the functional specificity of the upper limb, so the majority of the exercises will be held in open chain; motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks.
16576971|NCT02765152|Experimental|discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
16576972|NCT02765152|Experimental|rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
16576973|NCT02765139|Experimental|EMAP Treatment|Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
16576974|NCT02765139|Other|Control|In the 15 control sites, the male participants will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
16576975|NCT02765126|Active Comparator|Group 1|Diphtheria-tetanus-acellular pertussis vaccine administered day 0, followed by seasonal influenza vaccination four weeks later. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week, 4 weeks, 4 weeks + 24 hours, 5 weeks, 8 weeks and 30 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
16576976|NCT02765126|Active Comparator|Group 2|Seasonal influenza vaccine administered on day 0, to be offered DTP vaccine at week 26. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
16576977|NCT02765126|Active Comparator|Group 3|Seasonal influenza vaccine and DTP vaccine administered together on day 0. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
16576978|NCT02765113|Active Comparator|Facial nerve combing|Facial nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
16576979|NCT02765113|Active Comparator|Facial and Trigeminal nerve combing|Facial nerve combing、trigeminal nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
16576980|NCT02765100|Experimental|Low CRP|Subjects have CRP > 3
16576981|NCT02765100|Experimental|High CRP|Subjects have CRP =/> 3
16576982|NCT02765087|Experimental|Pleural TB|"This group consist of patients with TB pleural effusion.
~Intervention:
~Inform Consent
~Medical History
~E-Nose Device
~Chest CT
~Cytomorphologic & Cytochemistry of pleural Fluid.
~Adenosine Deaminase value of pleural Fluid."
16576983|NCT02765087|Active Comparator|Control|"Patients with pleural effusion with different aetiologies than Tuberculosis.
~Intervention:
~Inform Consent
~Medical History
~E-Nose Device
~Chest CT
~Cytomorphologic & Cytochemistry of pleural Fluid.
~Adenosine Deaminase value of pleural Fluid."
16576984|NCT02765074|Experimental|Roactemra|subcutaneous tocilizumab
16576985|NCT02765048|Experimental|GAIN Program|Subjects randomly assigned to receive the GAIN Program intervention
16576986|NCT02765048|No Intervention|Usual Care|Subjects randomly assigned to receive community-based services as part of their usual care
16576987|NCT02765035|Experimental|C-Leg 3, then C-Leg 4|Participants are first fitted with a C-Leg 3, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 4, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
16576988|NCT02765035|Experimental|C-Leg 4, then C-Leg 3|Participants are first fitted with a C-Leg 4, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 3, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
16576989|NCT02765022|Experimental|Clip|Clip closure of mucosal defects after endoscopic mucosal resection.
16576990|NCT02765022|Active Comparator|No clip|No clip closure of mucosal defects after endoscopic mucosal resection. Observation.
16576991|NCT02765009|No Intervention|Control|Usual care provided according to the ward policy. Patients have to be weighed at least on admission (day 0), day 7 and day 14.
16576992|NCT02765009|Experimental|Strategy|Patients have to be weighed every day. Use of an algorithm based on weight changes from day 2 to day 14 in order to reduce weight gain (fluid overload) using diuretics, fluid restriction,albumin, and ultrafiltration (the latter when ongoing renal replacement)
16576993|NCT02764996|Experimental|Acupuncture for Migraine|Acupuncture treatments will be subject dependent, and points could include the N point (on scalp); various auricular points to include Shen Men, Point Zero, thalamus and Omega-2; body points to include Liver 2, Liver 3, Gall Bladder 20, bladder 10; and surface release over tense areas in the neck or shoulders
16576994|NCT02764983|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Driving safety professional, three x 1 hour sessions to discuss traffic safety, rules of the road, defensive driving, driving under influence, driver attitudes and safety. Additionally, the study will obtain real world driving data from the Department of Motor Vehicles (public records) which will include citations, violations, and recorded collisions/ crashes.
16576995|NCT02764983|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
16576996|NCT02764983|Active Comparator|Caregiver Control Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
16576997|NCT02764983|Active Comparator|Caregiver Experimental Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
16576998|NCT02764983|Other|Focus Group Discussion Interview Guide|This group will comprise of a subset of the control and experimental groups. A focus group with 8 participants (4 with Traumatic Brain Injury/Post Traumatic Stress Disorder and 4 with orthopedic conditions). The focus group will meet once for a discussion which will be guided with a semi-structured interview that will explore the driving behavior prior to war, during war and post-deployment. Responses will be outlined in an intervention matrix.
16576999|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
16577000|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
16577001|NCT02764957|Active Comparator|intervention|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
16577002|NCT02764957|Placebo Comparator|control|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
16577003|NCT02764944|Experimental|Intervention|simple non-exposure EFTR group (single arm study)
16577004|NCT02764931|Experimental|Oat meal 1|A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
16577005|NCT02764931|Placebo Comparator|Placebo meal|A single meal which does not contain oats before ingesting the SmartPill capsule. Dietary intervention: gluten-free oats and gastrointestinal health.
16577006|NCT02764931|Experimental|Oat meal 2|A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
16577007|NCT02764918||Children|
16577008|NCT02764918||Mothers|
16577009|NCT02764905||intensive cognitive-physical rehabilitation group|will include a 2 phase multi-disciplinary intervention. The 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies
16577010|NCT02764892|Experimental|V81444|Single oral dose of V81444
16577011|NCT02764879|Experimental|omega 3 group|scaling and root planing omega3 received 2 times daily-for 6 months
16577012|NCT02764879|Placebo Comparator|control group|scaling and root planing placebo soft gelatin capsules 2 times daily-for 6 months
16577013|NCT02764866|Experimental|Sleep testing|Enrolled patients with lung cáncer will undergo home sleep testing during their initial oncologic evaluation, prior to treatment.
16577014|NCT02764853|Experimental|STEP-AD (10 sessions)|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence."
16577015|NCT02764853|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive 1 session of Lifesteps and appropriate services and referrals as needed, followed by bi-weekly check-ins with a study research assistant.
16577020|NCT02764801|Experimental|Contrast ultrasound arm|Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
16577021|NCT02764788|Experimental|Specific auriculotherapy|Auriculotherapy on specific points with needles
16577022|NCT02764788|Sham Comparator|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
16577023|NCT02764788|Placebo Comparator|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
16577024|NCT02764775|Experimental|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
16577026|NCT02764749|Experimental|freeze dried powder whole cranberry dissolved in water|Dietary Supplement: freeze dried cranberry powder
16577027|NCT02764749|Placebo Comparator|freeze dried cranberry deprived powder dissolved in water|Placebo comparator: freeze dried cranberry deprived powder
16577028|NCT02764736|Experimental|atorvastatin|Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
16577029|NCT02764723|Active Comparator|Hyperbaric bupivacaine|12.5 mg of 0.5% hyperbaric bupivacaine
16577030|NCT02764723|Experimental|Isobaric ropivacaine|15 mg of 0.5% isobaric ropivacaine
16577031|NCT02764710|Experimental|Short treatment|Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
16577032|NCT02764710|Active Comparator|Long treatment|Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
16577033|NCT02764697|Other|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
16577034|NCT02764684|Experimental|HIV-infected patients|Probiotics (lactobacillus rhamnosus)
16577035|NCT02764671|Experimental|10μg/0.5ml recombinant HBV vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
16577036|NCT02764658|Experimental|Pulmonary recovery on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
16577037|NCT02764658|Other|Routine care on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
16577038|NCT02764658|Other|Routine care on the stable COPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
16577039|NCT02764645|Experimental|CardioGard group|"Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.
~2. The suction cannula of the 'Cardiogard cannula'."
16577040|NCT02764645|Active Comparator|Control group|Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
16577041|NCT02764632|Active Comparator|Didgital group|After induction of anesthesia, and after ensuring muscle relaxation, NGT will be inserted through the selected nostril and advanced for 12 cm then the NGT was advanced according to study group advancing. In control group; NGT was inserted with patient head flexed. In D group, after feeling the NGT in pharynx, with the head in neutral position,the index finger was used to support the NGT with slight direction towards the left side. This will prevent tube kinking at this point in front of the resistance offered by the inflated tube cuff or arytenoids cartilage. Also, this digital support reinforces the tube at the area weakened by its openings
16577042|NCT02764632|No Intervention|Control group|
16577043|NCT02764619|Active Comparator|Aldo group|Fixed dose of spironolactone, Spirix (Takeda Pharma A/S), 25 mg once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
16577044|NCT02764619|Placebo Comparator|Control group|Matched placebo, 1 pill once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
16577045|NCT02764606||Patients with a non-small cell lung cancer|Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
16577046|NCT02764593|Experimental|Arm 1 (Nivolumab + Cisplatin)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
16577047|NCT02764593|Experimental|Arm 2 (Nivolumab + High-dose Cisplatin)|Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
16577048|NCT02764593|Experimental|Arm 3 (Nivolumab + Cetuximab)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
16577049|NCT02764593|Experimental|Arm 4 (Nivolumab + IMRT)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
16577050|NCT02764567|Experimental|Aromatherapy|"The participants randomized to aromatherapy will be offered one of three essential oils, 'applied' to their smell zone via cotton ball that are known to have anti-anxiety effect. These are:
~ginger
~calming
~lavender The participant's choice will be documented in a database. The participant can chose an oil each time (i.e., they are not bound to use only the first choice oil). Pain and anxiety will be measured prior to receiving the essential oils and again after the phlebotomy procedure. Blood pressure and pulse will also be measured post-phlebotomy."
16577051|NCT02764567|No Intervention|Standard of Care|The participants randomized to standard of care will proceed to the outpatient phlebotomy room in the Heart Care Clinic as per usual care. Pain, anxiety, blood pressure and pulse will be assessed pre and post-procedure.
16577052|NCT02764554||Lenvatinib 4 milligram (mg) and 10 mg capsule|Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
16577053|NCT02764541|Experimental|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
16577054|NCT02764541|Experimental|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
16577055|NCT02764541|Experimental|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
16577056|NCT02764541|Experimental|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
16577057|NCT02764528|No Intervention|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
16577058|NCT02764528|Experimental|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
16577059|NCT02764528|Experimental|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
16577060|NCT02764528|Experimental|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
16577061|NCT02764515|Experimental|Kunxian capsule group|"Intervention:
~Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo."
16577062|NCT02764515|Active Comparator|Methotrexate group|"Intervention:
~Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks."
16577063|NCT02764502|Experimental|Pressure Gauge Manometer|Tuohy needle is introduced into intervertebral space at the level of L3-L4 up to the interspinous ligaments . The needle is advanced slowly using both hands while monitoring the manometer reading and is stopped when the pressure suddenly dropped ( the pressure usually drops by 5-10 mm Hg when the tip of the needle inters the epidural space ).
16577064|NCT02764489|Experimental|Part 1 Regular then reduced volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA reconstituted in regular volume then FEIBA reconstituted in 50% reduced volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
16577065|NCT02764489|Experimental|Part 1 Reduced then regular volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA Reconstituted in 50% Reduced Volume then FEIBA Reconstituted in Regular Volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
16577066|NCT02764476|Experimental|Virtual Reality Therapy|Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
16577067|NCT02764476|Active Comparator|Control|Eight 30 minute sessions of virtual reality therapy.
16577068|NCT02764463|Other|FRCFPDs|Fiber reenforced Composite Fixed Partial Dentures
16577069|NCT02764450|Experimental|Astralis 10 HPM|Polymerization High-power mode: 1300 mW/cm2 for 10 s
16577070|NCT02764450|Experimental|Astralis 10 RM|Polymerisation regular mode: 650 mW/cm2 for 20
16577071|NCT02764437||MRI-Bronch, PET-WLAC (Stress vs Control)|Subjects will have a functional MRI scan 24 hours before a bronchoscopy with segmental allergen challenge. 48 hours post segmental allergen challenge, the subject will have another MRI and bronchoscopy. 4-6 weeks later, subjects will have a PET scan and whole lung antigen challenge under a stress condition or control condition. 4-6 weeks later, subject will have another PET scan and whole lung antigen challenge under a stress condition or control condition (whatever they did not have the first time).
16577072|NCT02764424||Preterm or term newborns|Preterm or term newborns, hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France), who have to acute painful stimuli related to their care will be included in the study. This painful stress is made in the patient's usual care and is not modified by the protocol. Their stress due to the painful stimuli will be measured with different scales (2 PIPP (Premature Infant Pain Profile) and DAN (Newborn Acute Pain)) and compared with the index obtained with the NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®).
16577073|NCT02764411|Experimental|Onreltea ( Brimonidine)|All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).
16577074|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
16577075|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
16577076|NCT02764372|Experimental|Serious games|The experimental group received Serious Games-based upper extremity therapy through Kinect
16577077|NCT02764372|Active Comparator|Exergames|The control played the same amount of time with commercial exergames of the Wii
16577078|NCT02764359|Experimental|IV Vancomycin loading dose- higher|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
16577079|NCT02764359|Experimental|IV Vancomycin loading dose- lower|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
16577080|NCT02764346|Experimental|iCanCope app|iCanCope app
16577081|NCT02764346|Active Comparator|Attention control app|Control group: iCanCope attention control app
16577082|NCT02764333|Experimental|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
16577083|NCT02764320|Active Comparator|Discontinuation|Immediate discontinuation of the overused medication(s) and migraine preventive therapy
16577084|NCT02764320|Active Comparator|Preventive Therapy Only|Migraine preventive therapy without immediate discontinuation of the overused medication(s)
16577085|NCT02764307|Experimental|Aerosolized drug depositions|Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
16577086|NCT02764294|Active Comparator|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
16577087|NCT02764294|Active Comparator|Stress Ball Group|"Stress ball group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
16577088|NCT02764294|Active Comparator|DVD Group|DVD group was watched a DVD of their choice (documentaries, interesting and amazing videos, comedies) on a ceiling-mounted monitor positioned at a comfortable distance to the participant.
16577089|NCT02764294|No Intervention|Control Group|Participants received usual care from health professionals. They didn't receive any intervention.
16577090|NCT02764281|Experimental|MEDA/Auto-HSCT|Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).
16577091|NCT02764268|Experimental|Apatinib|
16577092|NCT02764255||embryoscope group|cases with embryos continuously monitored by the embryoscope followed by embryo selection based on a multivariable model
16577093|NCT02764255||control group|cases with embyos cultured in the standard incubator and evaluated only by morphology
16577094|NCT02764242|Other|insect sting allergy|"Skin prick tests to local and imported insect sting allergen with different concentration are performed.
~sIgE Measurement (to insect and the recombinant venom)"
16577095|NCT02764229|Experimental|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
16577096|NCT02764216|Experimental|EMI group|Elective mucosal irradiation
16577097|NCT02764203|Experimental|Chocolate consumption|Subjects will consume 50g of dark chocolate for 2 weeks and have their blood pressure compared before chocolate and after chocolate
16577098|NCT02764190|Experimental|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
16577099|NCT02764190|No Intervention|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
16577100|NCT02764177|Experimental|Protein|In this arm the subjects were provided with a PROTEIN drink to consume after exercise. This protein drink contained whey protein isolate that provided 0.3 g/ kg body mass of protein.
16577101|NCT02764177|Experimental|Carbohydrate|In this arm the subjects were provided with a CARBOHYDRATE drink to consume after exercise. This carbohydrate drink was energy matched to the protein drink in the other arm of the experiment.
16577102|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
16577103|NCT02764151|Experimental|PF-06840003|Daily Oral PF-06840003
16577104|NCT02764138|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.
~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
16577105|NCT02764138|No Intervention|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
16577106|NCT02764125|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
16577107|NCT02764125|Experimental|levodopa MR|Levodopa MR/carbidopa/ODM-104
16577108|NCT02764099|Experimental|Life Skills Training|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the intervention condition (n=280) will participate in the LST program concurrently during the weeks when they serve as peer court jurors."
16577165|NCT02763787|Experimental|100 mg|1 x 100 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577109|NCT02764086|Other|Trial Cohort Description|"Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.
~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort
~Cohort is extended to 12pts:
~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level & recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.
~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent & neo-adjuvant/no chemotherapy arms will be escalated independently of each other"
16577110|NCT02764060|Experimental|Tongue scraper|In this group the subjects are explained how to use a plastic loop-formed tongue cleaner (Halita® tongue cleaner (Dentaid, Spain)) to clean their tongues.
16577111|NCT02764060|Experimental|Toothbrush|In this group the subjects are explained how to use a toothbrush (Oral-B® Indicator® medium tooth brush) to clean their tongues.
16577112|NCT02764047|Placebo Comparator|Placebo|Placebo capsule
16577113|NCT02764047|Active Comparator|Probiotic|Probiotic capsule
16577114|NCT02764021|Experimental|1.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
16577115|NCT02764021|Active Comparator|2.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
16577116|NCT02764008|Active Comparator|Low thoracic paravertebral block|T8-T9 Ultrasound guided paravertebral block with 20 ml %0,25 bupivacaine
16577117|NCT02764008|Active Comparator|Peritubal infiltration|Peritubal infiltration with 20 ml %0,25 bupivacaine
16577118|NCT02764008|No Intervention|Control Group|No drug
16577119|NCT02763995|Experimental|Pharmaceutical care|Dader method. Health education for lifestyle modification. Improve adherence. Resolution of negative outcome associated with medication.
16577120|NCT02763982||G1|High or normal left ventricular ejection fraction
16577121|NCT02763982||G2|Moderate left ventricular ejection fraction
16577122|NCT02763982||G3|Reduced left ventricular ejection fraction
16577123|NCT02763969|Experimental|Part A: Single Ascending Dose|BMS-986202 or Placebo specified dose on specified days
16577124|NCT02763969|Experimental|Part B: Multiple Ascending Dose|BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
16577125|NCT02763969|Experimental|Part C: Multiple Ascending Dose-Japanese descent|BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent
16577126|NCT02763969|Experimental|Part D: Relative Bioavailability|BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days
16577127|NCT02763969|Experimental|Part E: Proof of Mechanism|BMS-986202 or Placebo + Ustekinumab specified dose on specified days
16577128|NCT02763956|Experimental|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
16577129|NCT02763956|Placebo Comparator|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
16577130|NCT02763930|Experimental|CONTROL (dairy-free)|6 weeks experimental diet with all meals and foods provided to participants. The diet contain 32% of fat, 11% of saturated fat (SFA), 13% of mono-unsaturated fat (MUFA), 8% of polyunsaturated fat (PUFA) and 15% of proteins.
16577131|NCT02763930|Experimental|MILK (low fat dairy)|6 weeks experimental diet with all meals and foods provided to participants including 3 servings/day of milk (1% fat) per 2500 kcal. The diet contain 32% of fat, 11% of SFA, 13% of MUFA, 8% of PUFA and 15% of proteins.
16577132|NCT02763930|Experimental|GABA-rich cheese (high-fat dairy )|6 weeks experimental diet with all meals and foods provided to participants including 50g/day of GABA-rich cheddar cheese (approximately 32% fat). The diet contain 32% of fat, 13% of SFA, 13% of MUFA, 6% of PUFA and 15% of proteins.
16577133|NCT02763917|Active Comparator|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
16577134|NCT02763917|Placebo Comparator|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
16577135|NCT02763904|Experimental|Intensive nutritional counseling|Dietary counseling + energy dense oral nutritional supplements
16577136|NCT02763904|Active Comparator|Dietary counseling|Dietary counseling
16577137|NCT02763891|Experimental|Intervention group|Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
16577138|NCT02763891|Sham Comparator|Control group|Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
16577139|NCT02763878|Experimental|uncut Roux-en-Y anastomosis|After distal gastrectomy, duodenal stump closure, side to side anastomosis was underwent on the remnant stomach and jejunum,which was 25cm from Treitz ligament. Then underwent side to side anastomosis between jejunum about 35cm distance from gastrojejunostomy and jejunum about 5cm from Triez ligament . close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis by using uncut Closure devices
16577140|NCT02763878|Sham Comparator|Billroth II anastomosis|After distal gastrectomy, duodenal stump closure, the investigators first underwent remnant stomach and upper jejunum side anastomosis. Then choose the jejunum about 25cm from Treitz ligament, premenstrual colon using a disposable cutting closure (or tubular stapling) in the rear wall of the stomach and jejunum anastomosis, common opening was closed with the (barbed wire) hand-stitched. After that, steps were same with the group A.
16577141|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
16577142|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
16577143|NCT02763852|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Madopar 125. BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
16577144|NCT02763852|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
16577145|NCT02763852|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
16577146|NCT02763852|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
16577147|NCT02763852|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
16577148|NCT02763839|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Sinemet 25/100 BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
16577149|NCT02763839|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
16577150|NCT02763839|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
16577151|NCT02763839|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
16577152|NCT02763839|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
16577153|NCT02763826|Experimental|Determine the Optimal tDCS current|We will invesitigate the optimal curent in range of 1 mA to 4 mA. We hypothesize that 4 mA is tolerable, safe and can induce the highest level of cortical excitability in the lesional motor cortex.
16577154|NCT02763826|Experimental|Determine the optimal tDCS electrode montage|We hypothesize that the bi-hemispheric stimulation with anodal stimulation on the lesional hemisphere and simultaneous cathodal stimulation on the non-lesional hemisphere induces more cortical excitability in the lesional hemisphere than either anodal stimulation on the affected hemisphere or cathodal stimulation on non-lesional hemisphere alone.
16577155|NCT02763813|Experimental|Propulsion type appliance (Herbst)|
16577156|NCT02763813|Active Comparator|Retention type appliance (ORM)|Retention type appliance
16577157|NCT02763800|Experimental|Group 1: BIA 3-202 50 mg/placebo|"Group 1: BIA 3-202 50 mg/placebo on Day 1; BIA 3-202 50 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 50 mg/placebo on Day 9.
~50 mg BIA 3-202: 5 x 10 mg BIA 3-202 tablets"
16577158|NCT02763800|Experimental|Group 2: BIA 3-202 100 mg/placebo|"Group 2: BIA 3-202 100 mg/placebo on Day 1; BIA 3-202 100 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 100 mg/placebo on Day 9.
~100 mg BIA 3-202: 1 x 100 mg BIA 3-202 tablet"
16577159|NCT02763800|Experimental|Group 3: BIA 3-202 200 mg/placebo|"Group 3: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.
~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
16577160|NCT02763800|Experimental|Group 4: BIA 3-202 200 mg/placebo|"Group 4: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo t.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.
~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
16577161|NCT02763787|Experimental|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577162|NCT02763787|Experimental|10 mg|1 x 10 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577163|NCT02763787|Experimental|30 mg|3 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577164|NCT02763787|Experimental|50 mg|5 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577166|NCT02763787|Experimental|200 mg|2 x 100 mg BIA 3-202 tablets
16577167|NCT02763787|Experimental|400 mg|4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577168|NCT02763787|Experimental|800 mg|8 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577169|NCT02763787|Experimental|Food Effect (fed/fasted)|400 mg BIA 3-202: 4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
16577170|NCT02763774|Experimental|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
16577171|NCT02763774|Experimental|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
16577172|NCT02763774|Experimental|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
16577173|NCT02763761|Experimental|Infliximab + Prednisone|Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days
16577174|NCT02763761|Experimental|Methylprednisolone + Prednisone|Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days
16577175|NCT02763748|Experimental|Laparoscopic surgery|Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.
16577176|NCT02763748|Experimental|laparoscopic and endoscopic|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
16577177|NCT02763748|Experimental|Single-arch laparoscopic and endoscopic|Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
16577178|NCT02763735||Pulmonary Arterial Hypertension|Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging.
16577179|NCT02763735||Subjects without cardiopulmonary disease|Subjects without known cardiopulmonary disease. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging
16577180|NCT02763722|Experimental|Emollient spray product|"Study design
~A 3 visits are planned:
~0 week (first visit) 2nd week (second visit) 4th week (third visit)
~B. During each visit will be made:
~The clinical examination (including an assessment of any adverse effects)
~Evaluation of transepidermal water loss (TEWL) and capacitance of outer areas of the stratum corneum as an indirect assessment of skin hydration,
~fill out questionnaires CDLQI (The Children's Dermatology Life Quality Index)
~will assess VAS (visual analogue scale)
~C. All patients will be instructed to use emollients spray the entire surface of the skin at least twice daily for four weeks."
16577181|NCT02763709||Cases|Children admitted in Pediatric ICU for more than 24 hours with Pediatric Risk of Mortality (PRISM) score III > 20
16577182|NCT02763696||normal women|Composition of Viginal flora of Child-Bearing women in normal woman
16577183|NCT02763696||vaginitis women|Women of childbearing age with vaginitis
16577184|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
16577185|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
16577186|NCT02763670|Other|Interventional|PRETICARD patient care management
16577187|NCT02763670|Other|Control|"Heterogenous as usual patient care management."
16577188|NCT02763657|Experimental|Brain activity during reasoning|
16577189|NCT02763644|Experimental|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
16577190|NCT02763644|Experimental|All SoC first|Standard of Care then LFG316 plus SoC
16577191|NCT02763631|Experimental|Run In Phase|Eligible patients will have 6-Minute Walk Test (6-MWT) on self ventilation and on CPAP
16577192|NCT02763631|Experimental|Treatment|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:
~Treatment arm - Patients will be setup onto portable CPAP during the day"
16577193|NCT02763631|Sham Comparator|Standard Care Arm|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:
~Control Arm - Standard care arm."
16577194|NCT02763618|Active Comparator|Group A: Theta/beta ratio Neurofeedback|"In this condition, participants will receive three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions.
~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
16577195|NCT02763618|Active Comparator|Group B: Theta/beta ratio Neurofeedback|"In this condition, participants will receive nine baseline sessions and continue with eight theta/beta ratio Neurofeedback sessions.
~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
16577196|NCT02763618|Placebo Comparator|Group C: Placebo Neurofeedback training|Three baseline sessions and continue with 14 placebo training sessions. The placebo training will be a previously recorded Neurofeedback session of a participant in group A (receiving 14 real Neurofeedback sessions). Before the participants in group C (placebo trainings) start, they will be matched to a participant in group A, and receive the exact same (prerecorded) feedback per session of their matched participant. In this way, participants in the placebo training are then made to think that the video and EEG feedback is their own, however they are actually not able to influence the continuation of the video.
16577197|NCT02763605||patients diagnosed with acanthamoeba keratitis|"Inclusion Criteria:
~- All patients presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016 with the tissue proven corneal AK will be included.
~Exclusion Criteria
~- Patients with tissue proven corneal AK during from Jun. 1st, 2003 to dec. 30th , 2016, but without in vivo confocal data, or complete chart records."
16577198|NCT02763592|Experimental|Lidocaine|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
16577199|NCT02763592|Placebo Comparator|placebo|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
16577200|NCT02763579|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
16577201|NCT02763579|Active Comparator|Placebo + Carboplatin + Etoposide|Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
16577206|NCT02763553|Experimental|Ketogenic Feed|A low-carbohydrate, high-fat enteral feed (Nutrison KetoCal 4:1) containing 0.4g of carbohydrate and 10g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
16577207|NCT02763553|Active Comparator|Standard Feed|Standard enteral feed (Nutrison ProteinPlus MF 1.28) containing 11.1g of carbohydrate and 3.8g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
16577208|NCT02763540|Other|Lung cryobiopsy|
16577209|NCT02763527|Experimental|Smoking reduction|"Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a booster intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers."
16577210|NCT02763527|Placebo Comparator|Smoking Cessation|"Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and booster intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group."
16577211|NCT02763514|Active Comparator|DHA-enriched oil|3 g PronovaPure 150:500 EE EU
16577212|NCT02763514|Active Comparator|EPA-enriched oil|3 g PronovaPure 500:200 EE EU
16577213|NCT02763514|Placebo Comparator|Placebo|3 g Olive oil
16577214|NCT02763501|Active Comparator|RCT|"patients operated with laparoscopic gastric bypass surgery within a register based RCT from May 1st 2010 until Nov 14th 2011.
~1:1 randomization to closure of mesenteric defects by running, non-absorbable sutures"
16577215|NCT02763501|Active Comparator|non-RCT|"patients operated with laparoscopic gastric bypass surgery outside of the RCT from May 1st 2010 until Nov 14th 2011.
~Intervention of mesenteric defects according to local tradition or choice of surgeon (non-randomized)"
16577216|NCT02763488|Active Comparator|Standard physical therapy|These individuals will conduct physical therapy for 12 sessions as per the institutional standard physical therapy protocol
16577217|NCT02763488|Experimental|Blood flow restriction|These individuals will conduct physical therapy for 12 sessions with the addition of blood flow restriction interventions to their standard physical therapy
16577281|NCT02763020|Placebo Comparator|Food bar without fruit|snack bar without fruit
16577282|NCT02763020|Experimental|Food bar with cranberry extract (0.5%)|Snack bar with cranberry extract (0.5% total weight)
16577283|NCT02763020|Experimental|Food bar with cranberry extract (1.0%)|Snack bar with cranberry extract (1.0% total weight)
16577664|NCT02760758|Experimental|Cohort 8A HV|CDI-31244 400 mg active or placebo MD
16577218|NCT02763475|Experimental|Natural Killer (NK) Cells + Chemotherapy|Starting on day -6, 60mg/Kg cyclophosphamide by vein will be administrated. Day -5 to -1 fludarabine administrated by vein at 25 mg/m2. 24-48 hours after chemotherapy completion, NK cell infusion will be injected (day 0). On day 7 a second NK cell infusion will be administrated. First infusion consist of 5x10^7/kg NK CD3-CD56+ NK cells. The second NK cell infusion will include up to 5x10^8 CD3-CD56+ cells if no treatment related toxicity occurred. Subcutaneous IL-2 (1x10^6 UI/m2) three times a week for two weeks will be administrated after first NK infusion.
16577219|NCT02763449|Experimental|Sedentary|Individuals will reduce their physical activity level for 14-days
16577220|NCT02763449|Experimental|Active|Individuals will increase their physical activity level for 14-days
16577221|NCT02763436|No Intervention|"Group immediate cord clamping (ICC)"|The cord will be clamped within the first minute after birth, afterwards the newborn will be placed on the mothers chest/abdomen. This corresponds to the present routine approach in Graz.
16577222|NCT02763436|Active Comparator|"Group physiological based cord clamping (PBCC)"|"The newborn will be placed on mother's chest/abdomen with intact cord. After the newborn has established stable breathing efforts (continuous regular breathing pattern and SpO2 values >25th percentile from Dawson et al reference range for oxygen saturation -minute 2>58%, minute 3>67%, minute 4>76%) the cord is clamped. This will need 2 - 4 minutes."
16577223|NCT02763423|Experimental|umbilical cord mesenchymal stem cell|single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients
16577224|NCT02763410||control group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery, with no renal failure at the 48th hour after surgery, based on the RIFLE classification, and regardless of the transfusion received after the H6 assessment.
16577225|NCT02763410||Renal failure group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery and who developed renal failure before H48 with no new transfusion prior to diagnosis of kidney failure.
16577226|NCT02763397|Experimental|NBM-DBS on|DBS is programmed to stimulate the NbM
16577227|NCT02763397|Placebo Comparator|DBS off|DBS is turned off, no stimulation will be exerted
16577228|NCT02763384|Experimental|Arm 1: BL-8040 and Nelarabine|"Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6
~Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5
~Treatment may be repeated every 21 days for up to 4 cycles"
16577229|NCT02763371|Experimental|Dietary: high GI lunch|High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
16577230|NCT02763371|Experimental|Dietary: low GI lunch|Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
16577231|NCT02763358|Other|Bites and Steps displayed|All subjects will be assigned to one arm-daily bites and steps displayed on Bite Counter device
16577232|NCT02763345|Active Comparator|Paper-based CCM (Standard Care)|Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
16577233|NCT02763345|Experimental|SL eCCM App + paper CCM|Health Surveillance Assistants use the Supporting LIFE electronic Community Case Management App (SL eCCM App) deployed on a smartphone and replicating paper-based CCM guidelines to assess and treat children in conjunction with standard care, for a minimum of 2-weeks and maximum of 7-weeks. Clinical data is recorded in both the SL eCCM App and Village Clinic Register.
16577234|NCT02763332|Experimental|Upper trunk group (UTG)|In the UTG, the bandage was applied over the superior fibbers of the trapezious and levator scapulae muscle using a strip in a 'Y' shape. The individuals were asked to remain in an upright sitting position and the base of the strip was attached to the skin beyond the acromion without any tension. Later, we placed the two straps of the bandage with a range of tension from 15 to 25%. The main goal of this shape is achieve muscular relaxation of the trapezius, scapula levator and supraspinatus.
16577235|NCT02763332|Active Comparator|Global trunk group (GTG)|In the GTG the bandage was applied parallel to the paravertebral muscles in a 'C' shape. The individuals were sit in the same position with the head in the neutral position. The strip was pasted with approximately 25% of tension all over the paravertebral musculature. The main goal was procuring a global mechanical correction of the superior part of the trunk.
16577236|NCT02763319|Experimental|Tafasitamab and bendamustine|Tafasitamab and bendamustine
16577237|NCT02763319|Active Comparator|Rituximab and bendamustine|Rituximab and bendamustine
16577238|NCT02763306|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
16577239|NCT02763293|Experimental|Manual Therapy|Cranial therapy (CT). Neuro-lymphatic reflexes treatment (NL) Viscerosomatic reflexes (VR) Induction myofascial Visceral osteopathic therapy (VOT)
16577240|NCT02763293|No Intervention|Control Group|Patients only came to make assessments, without receiving any treatment.
16577241|NCT02763280|Experimental|Ginseng extract 1g|Ginseng extract 1g
16577242|NCT02763280|Experimental|Ginseng extract 3g|Ginseng extract 3g
16577243|NCT02763280|Placebo Comparator|Placebo|Placebo
16577244|NCT02763267||Pregnant Women|Pregnant women with history of GDM or at risk for diabetes mellitus will enter study during first trimester (4-14 weeks) and receive an oral glucose tolerance test (OGTT) at baseline, mid-pregnancy, and at delivery.
16577245|NCT02763267||Nonpregnant Women|Nonpregnant women with a history of GDM will undergo an OGTT at baseline.
16577246|NCT02763254|Experimental|baltaleucel-T|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
16577247|NCT02763241|Experimental|Cleanoze®|"Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
16577248|NCT02763241|Active Comparator|Syringe irrigation|"Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe
~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
16577665|NCT02760758|Experimental|Cohort 1B HCV genotype (GT) 1|CDI-31244 400 mg active or placebo MD
16577249|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.
~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
16577250|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.
~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
16577251|NCT02763215||Total|
16577252|NCT02763202|No Intervention|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
16577253|NCT02763202|Experimental|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
16577254|NCT02763189|Active Comparator|Control|Control group will study the learning material independently. 'Self-study'.
16577255|NCT02763189|Experimental|Mentored|Mentored group will study the learning materials and then receive expert mentoring
16577256|NCT02763163||outdoor workers|Subjects with an excessive exposure to the sun on a daily basis
16577257|NCT02763163||office workers|Subjects who spend most of the day in a closed shaded room
16577258|NCT02763150|Experimental|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
16577259|NCT02763150|Active Comparator|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
16577260|NCT02763137|Active Comparator|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
16577261|NCT02763137|Experimental|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
16577262|NCT02763124|Experimental|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
16577263|NCT02763111|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
16577264|NCT02763111|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
16577265|NCT02763111|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
16577266|NCT02763111|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
16577267|NCT02763098|Experimental|Remi 0.1|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [(0.1), 0.2, 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
16577268|NCT02763098|Experimental|Remi 0.2|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, (0.2), 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-RoiFrance) for two minutes.
16577269|NCT02763098|Experimental|Remi 0.3|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, 0.2, (0.3) µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
16577270|NCT02763085|Experimental|Basic Filling Material|Fillings made with a new dental filling material.
16577271|NCT02763072|Experimental|Picosecond Q-switched Laser|12 subjects will receive one treatment with a dual wavelength 532 nm KTP and/or 1064 nm Nd: YAG picosecond pulse duration laser.
16577272|NCT02763072|Active Comparator|KTP Laser|12 subjects will receive up to four treatments with a dual wavelength 532nm KTP long pulsed laser and/or 1064 nm Nd: YAG.
16577273|NCT02763059|Active Comparator|Group 1- Received Ibuprofen (N=44)|
16577274|NCT02763059|Active Comparator|Group 2- Received Dexamethasone (N=44)|
16577275|NCT02763059|Placebo Comparator|Group 3 - Received Placebo (N=44)|
16577276|NCT02763046|Experimental|Secukinumab - delayed NSAID tapering|"Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind.
~NSAID tapering allowed from Week 4 (delayed tapering)."
16577277|NCT02763046|Experimental|Secukinumab - early NSAID tapering|"Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind.
~NSAID tapering allowed from Week 4 (early tapering)."
16577278|NCT02763046|Placebo Comparator|Placebo|"Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20).
~NSAID tapering allowed from Week 4."
16577279|NCT02763033|Experimental|Bob's Red Mill®|"Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.
~Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID."
16577280|NCT02763033|Placebo Comparator|Starch Placebo|Patients will receive an iso-caloric, non-resistant starch placebo.
16577284|NCT02763020|Experimental|Food bar w/ dried black raspberry (10%)|Snack bar with freeze-dried black raspberry(10% total weight)
16577285|NCT02763020|Experimental|Food bar w/ dried black raspberry (20%)|Snack bar with freeze-dried black raspberry (20% total weight)
16577286|NCT02763007|Experimental|alogliptin+pioglitazone|A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
16577287|NCT02763007|Active Comparator|alogliptin|A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
16577288|NCT02763007|Active Comparator|pioglitazone|A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
16577289|NCT02762994|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
16577290|NCT02762994|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
16577291|NCT02762994|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
16577292|NCT02762994|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
16577293|NCT02762981|Experimental|CORT125134 with nab-paclitaxel|"Part I - Dose Escalation:
~Patients will be treated with CORT125134 in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.
~Part 2 - Dose Expansion:
~Expansion cohorts in the Continuous-Dosing and Intermittent-Dosing Regimens will be enrolled to better characterize the antitumor activity in patients with specific tumor types and to better define the safety profile."
16577294|NCT02762968|Placebo Comparator|Placebo|Placebo capsules similar to the experimental treatments.
16577295|NCT02762968|Experimental|HMB|HMB capsules providing 3 g of calcium HMB per day.
16577296|NCT02762968|Experimental|HMB + BC30|Capsules providing 3 g calcium HMB per day plus Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
16577297|NCT02762955|Experimental|BCD-057 group|"BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.
~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa."
16577298|NCT02762955|Active Comparator|Humira® group|"Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.
~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.
~Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa."
16577299|NCT02762942|Active Comparator|Vaginal misoprostol alone|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols
16577300|NCT02762942|Experimental|Vaginal misoprostol + Foley catheter|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
16577301|NCT02762929|Experimental|Part A Cohort A|200 mg of HTX-011A via closed wound infiltration
16577302|NCT02762929|Experimental|Part A Cohort B|200 mg of HTX 011A via open wound infiltration
16577303|NCT02762929|Experimental|Part A Cohort C|200 mg of HTX-011B via closed wound infiltration
16577304|NCT02762929|Experimental|Part A Cohort D|200 mg of HTX 011B via open wound infiltration
16577305|NCT02762929|Active Comparator|Part A Cohort E|50 mg 0.5% bupivacaine hydrochloride injection via a closed wound infiltration
16577306|NCT02762929|Placebo Comparator|Part A Cohort F|Saline Placebo via a closed wound infiltration
16577307|NCT02762929|Experimental|Part B Cohort A|200 mg HTX 002 via closed wound infiltration
16577308|NCT02762929|Experimental|Part B Cohort B|200 mg HTX 002 via open wound infiltration
16577309|NCT02762929|Placebo Comparator|Part B Cohort C|Saline placebo via a closed and open wound infiltration
16577310|NCT02762929|Experimental|Part C Cohort A|120 mg of HTX-011B via closed wound infiltration
16577311|NCT02762929|Experimental|Part C Cohort B|120 mg of HTX-011B via open wound infiltration
16577312|NCT02762929|Experimental|Part C Cohort C|120 mg of HTX-011B local administration via instillation
16577313|NCT02762929|Placebo Comparator|Part C Cohort D|Saline placebo via open wound infiltration
16577314|NCT02762929|Experimental|Part D Cohort A|60 mg of HTX-011B via closed wound infiltration
16577315|NCT02762929|Experimental|Part D Cohort B|60 mg of HTX-011B via open wound infiltration.
16577316|NCT02762929|Placebo Comparator|Part D Cohort C|Saline placebo via open wound infiltration
16577317|NCT02762929|Experimental|Part E Cohort A|120 mg HTX 002 via closed wound infiltration
16577318|NCT02762929|Experimental|Part E Cohort B|120mg HTX 002 via open wound infiltration
16577319|NCT02762929|Placebo Comparator|Part E Cohort C|Saline placebo via closed and open wound infiltration
16577320|NCT02762929|Experimental|Part F Cohort A|HTX 009 via closed wound infiltration
16577321|NCT02762929|Experimental|Part F Cohort B|HTX 009 via open wound infiltration
16577322|NCT02762929|Placebo Comparator|Part F Cohort C|Saline placebo via closed and open wound infiltration
16577323|NCT02762929|Experimental|Part G Cohort A|30 mg of HTX 011B via closed wound infiltration
16577324|NCT02762929|Placebo Comparator|Part G Cohort B|Saline placebo via closed wound infiltration
16577325|NCT02762929|Experimental|Part H Cohort A|120 mg of HTX-011-056
16577326|NCT02762929|Experimental|Part H Cohort B|60 mg of HTX-011-056
16577327|NCT02762929|Placebo Comparator|Part H Cohort C|4.1 mL of normal saline
16577328|NCT02762916|Experimental|1- Telemedicine arm|"The intervention arm (IA), telehealth control, were followed up by himself helped by CONTECI program. They have to use every three months and if somethings was wrong the patient have to send mail to the doctor.
~The intervention consisted to use the CONTECI program (included test) for the following of the patients."
16577329|NCT02762916|No Intervention|2- Control arm|The Control Arm (CA) were followed up as usual every 6 months in outpatient vascular visits in the clinical hospital. If some patient have a complications or and emergency they have to do usual protocol, go to primary care or emergency.
16577330|NCT02762903|Active Comparator|Tenotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with tenotomy technique.
16577331|NCT02762903|Active Comparator|Osteotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with lesser tuberosity osteotomy technique.
16577332|NCT02762890|Experimental|Deep neuromuscular blockade|Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
16577333|NCT02762890|Active Comparator|Moderate neuromuscular blockade|Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
16577334|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
16577335|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
16577336|NCT02762864|Experimental|PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period. For patients in the PRU-target group with PRU ≥234 seconds, rescue medicine (ticagrelor) will be added to keep PRU<234 seconds.
16577337|NCT02762864|Active Comparator|non PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period, regardless the levels of PRU.
16577338|NCT02762851|Experimental|Influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.
16577339|NCT02762851|Placebo Comparator|Placebo vaccine|Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.
16577340|NCT02762838|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
16577341|NCT02762838|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
16577342|NCT02762825|Experimental|Higher Intensity Interval Training (HIIT)|
16577343|NCT02762825|Active Comparator|Moderate Continuous Training (MCT)|
16577344|NCT02762812|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
16577345|NCT02762812|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
16577346|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
16577347|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
16577348|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
16577349|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
16577350|NCT02762786|Experimental|Experimental|Participants in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation. The Music Children Foundation is a non-governmental organization established by a group of professional musicians with the objective of transforming children's lives and instils positive values in the entire community through music. It aims to provide free musical training to low-income children and children with chronic diseases, including those with Down's syndrome, mucopolysaccharidoses, skeletal dysplasia and visual impairment.
16577351|NCT02762786|No Intervention|Wait-list control group|Participants in the waitlist control group will receive the same training after the experimental group had completed the intervention.
16577352|NCT02762773|Experimental|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
16577353|NCT02762773|Placebo Comparator|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
16577354|NCT02762760|Experimental|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
16577355|NCT02762760|Experimental|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
16577356|NCT02762747|Experimental|Drain|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
16577357|NCT02762747|No Intervention|No-drain|No drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
16577666|NCT02760758|Experimental|Cohort 2B HCV GT 1|CDI-31244 600 mg active or placebo MD
16577358|NCT02762734|Experimental|MEDIA|"The patient will benefit of the usual care with additional text message (SMS or mail or other new media). The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt."
16577359|NCT02762734|No Intervention|CLASSIC|The patient will benefit of the usual care.
16577360|NCT02762708|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Subjects between the ages of 20-65 years of age seen for weight management in the Nutrition Clinic at Mayo Clinic, who have been approved for RYGB.
16577361|NCT02762708|Sham Comparator|Caloric restriction|Subjects between the ages of 20-65 years of age, with diagnosis of Type 2 diabetes mellitus or impaired fasting glucose. Subjects will undergo caloric restriction alone to mimic weight loss seen after gastric bypass surgery.
16577362|NCT02762708|Active Comparator|Exendin-9,39|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
16577363|NCT02762708|Placebo Comparator|Normal Saline|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
16577364|NCT02762695|Experimental|Case Management|
16577365|NCT02762695|Active Comparator|Control|Usual Care at Primary Health Care
16577366|NCT02762682||CASES OF ITS AND PRE ITS|"Either sex, age less than 3 years
~Clinical diagnosis of Infantile Tremor Syndrome as evidenced by the following features:
~[Developmental delay or regression WITH history of exclusive or predominant breast feeding WITH two or more of the following; skin pigmentation, hair depigmentation, tremors] ITS:1 and 2 plus tremors PreITS:1 and 2 without tremors"
16577367|NCT02762682||HEALTHY CONTROLS|Developmentally normal child not suffering from any acute or chronic neurological illness
16577368|NCT02762669|No Intervention|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
16577369|NCT02762669|Active Comparator|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
16577370|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
16577371|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
16577372|NCT02762669|Active Comparator|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
16577373|NCT02762669|Active Comparator|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
16577374|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
16577375|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
16577376|NCT02762656|Active Comparator|Lidocaine|Patients will receive Lidocaine drip during spine surgery
16577377|NCT02762656|Placebo Comparator|Placebo|Patients will receive placebo during spine surgery
16577378|NCT02762643|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
16577379|NCT02762643|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
16577380|NCT02762617|Experimental|TDF IVR group|"The Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core which contains the experimental drug, TDF, and sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).
~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
16577381|NCT02762617|Placebo Comparator|Placebo IVR group|"The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).
~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
16577382|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
16577383|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
16577384|NCT02762578|Experimental|IDegAsp BID|
16577385|NCT02762578|Active Comparator|BIAsp 30 BID|
16577386|NCT02762565|Experimental|breast scanner|
16577387|NCT02762552|Experimental|Transcranial-holter monitoring|Transcranial doppler in patient with ischemic stroke
16577388|NCT02762539|No Intervention|Control group|Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion
16577667|NCT02760758|Experimental|Cohort 3B HCV GT 1|CDI-31244 800 mg active or placebo MD
16577389|NCT02762539|Experimental|SMOF group|SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.
16577390|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
16577391|NCT02762500|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
16577392|NCT02762500|Placebo Comparator|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
16577393|NCT02762487|Experimental|LINX arm|Previous LSG patient will be treated with the LINX device and serve as their own control
16577394|NCT02762474|Experimental|nab-paclitaxel group|Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
16577395|NCT02762461||Exposed group|Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).
16577396|NCT02762461||Reference group 1|Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).
16577397|NCT02762461||Reference group 2|Women with medically treated endometriosis not undergoing ART.
16577398|NCT02762448||Daclatasvir + Asunaprevir|Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
16577399|NCT02762435|Placebo Comparator|control|No pressure applied to the 3 points
16577400|NCT02762435|Sham Comparator|sham|Light touch applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
16577401|NCT02762435|Experimental|acupressure|Moderate pressure applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
16577402|NCT02762422|Experimental|Phlebotomy plus normal saline|Four serial phlebotomy procedures followed by infusion of normal saline
16577403|NCT02762422|Experimental|Phlebotomy plus intravenous iron|Four serial phlebotomy procedures followed by infusion of intravenous iron sucrose
16577404|NCT02762422|Placebo Comparator|Sham Phlebotomy|Four serial sham phlebotomy procedures followed by infusion of normal saline
16577405|NCT02762409||patients exposed|Patients exposed will be estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015, and in 17 centers of the group control some study IPREA3 during October 2015
16577406|NCT02762409||patients non exposed|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015 and in 17 centers of the interventional group during October 2014"
16577407|NCT02762383|Experimental|Peginterferon Alfa-2a|Participants will receive a low dose of peginterferon alfa-2a for 18 months.
16577408|NCT02762370|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
16577409|NCT02762370|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
16577410|NCT02762357||Novosyn® Quick|episiotomy closure using suture material
16577411|NCT02762344||ACT < 150 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec
16577412|NCT02762344||ACT between 150 and 249 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec
16577413|NCT02762344||ACT >= 250 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec
16577414|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
16577415|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
16577416|NCT02762305|Experimental|RSVP Bone Builder group exercise|A group of older adults who are participating in the RSVP Bone Builder group exercise.
16577417|NCT02762292|Experimental|Patients|
16577418|NCT02762279|Experimental|Patients|"Patient baseline characteristics will be collected.
~Specific nasogastric tube installation: a specific nasogastric tube equipped with pressure transducers (Gaeltec® probe) will be installed.
~Connection of a pressure transducer to the existing chest-tube.
~Simultaneous recordings of PES (Gaeltec®), PPL, PAW, respiratory volume and flow (5 minutes).
~Removal of the Gaeltec® probe, and repositioning of the pre-existing nasogastric tube in the esophagus for PES measurement.
~Simultaneous recordings of PES (feeding tube), PPL, PAW, respiratory volume and flow (5 minutes).
~Repositioning of the nasogastric tube in the stomach, and disconnection of the different recording equipment."
16577419|NCT02762266|Active Comparator|Arm I (TACE)|Patients undergo TACE.
16577420|NCT02762266|Experimental|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
16577421|NCT02762253|Other|Riboflavin drops - epithelium on or off|Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax
16577422|NCT02762240|Active Comparator|DHQP 2016|This group consists of general practices allocated to undergo accreditation scheme in 2016.
16577423|NCT02762240|Placebo Comparator|DHQP 2018|This group consists of general practices allocated to undergo accreditation scheme in 2018.
16577455|NCT02761993|Active Comparator|Group 2|Group 2 received ST266 treatment 2x/week (with at least 1 day between treatments) for the first 3 months, and then monthly for 5 months (Days 120, 150, 180, 210, and 240).
16577668|NCT02760745||Febrile Shivering|
16577424|NCT02762227|Experimental|gallbladder polyps patients|"All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US, were enrolled in this study.
~Of these patients, we excluded: (1) gallbladder polyp with a diameter less than 10 mm. (2) lesions highly suspected to be cancer due to visible metastasis. (3) allergy to contrast agents and cannot received CT or CEUS examination. (4) women in pregnancy or lactation.
~All patients received transabdominal US, abdominal high resolution CT and contrast-enhanced ultrasonography (CEUS) before the cholecystectomy."
16577425|NCT02762214|Active Comparator|With Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.
16577426|NCT02762214|Experimental|Without Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.
16577427|NCT02762201|Experimental|PASI|PASI dental prosthesis delivery
16577428|NCT02762201|Active Comparator|PAC|PAC dental prosthesis delivery
16577429|NCT02762188|Experimental|wet ARMD patients|Patients with the wet form of ARMD who receive or have received in the past anti VEGF intra vitreal injections. Diagnosis of wet ARMD is made based on clinical data-visual acuity, fundus presence of subretinal fluid and/or haemorrhage and/or hard exudates, fundus photographs -color and red free, optical coherence tomography (SD-OCT), fluorescein angiography and indocyanine green angiography showing the presence and activity of subretinal neovascularisation.
16577430|NCT02762149|Active Comparator|0.1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
16577431|NCT02762149|Active Comparator|1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
16577432|NCT02762136|Placebo Comparator|placebo|Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
16577433|NCT02762136|Active Comparator|Xiang-sha-liu-jun granules|Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
16577434|NCT02762123|Experimental|Cohort 1 (BMS-986142: 200 mg)|200mg BMS-986142 administered orally once daily on specified days.
16577435|NCT02762123|Experimental|Cohort 2 (BMS-986142: 350 mg)|350mg BMS-986142 administered orally once daily on specified days.
16577436|NCT02762097|Experimental|intervention|All women would undergo saline sonography with normal saline. Women with endometrial polyps who consent to the removal of polyps will be offered polypectomy
16577437|NCT02762097|Placebo Comparator|control|All women would undergo saline sonography with normal saline. Women with endometrial polyps who do not consent to the removal would serve as controls
16577438|NCT02762084|Experimental|Patidegib gel 2%|Patidegib gel 2%, applied topically, twice daily for 26 weeks
16577439|NCT02762084|Experimental|Patidegib gel 4%|Patidegib gel 4%, applied topically, twice daily for 26 weeks
16577440|NCT02762084|Placebo Comparator|Vehicle gel|Vehicle gel, applied topically, twice daily for 26 weeks
16577441|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
16577442|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
16577443|NCT02762058|Experimental|Experimental Group|Patients receiving Virtual Reality Mirror Therapy
16577444|NCT02762058|Experimental|Control Group|Patients receiving Traditional Mirror Therapy
16577445|NCT02762045|Experimental|Low dose Ad5-gag or Placebo|1ml low dose Ad5-gag(2x10^9VP) or Preservation solution at weeks 0 and weeks 4.
16577446|NCT02762045|Experimental|Medium dose Ad5-gag or Placebo|1ml medium dose Ad5-gag(2x10^10VP) or Preservation solution at weeks 0 and weeks 4.
16577447|NCT02762045|Experimental|High dose Ad5-gag or Placebo|1ml high dose Ad5-gag(2x10^11VP) or Preservation solution at weeks 0 and weeks 4.
16577448|NCT02762032|Active Comparator|Arm 1|15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.
16577449|NCT02762032|Active Comparator|Arm 2|15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.
16577450|NCT02762032|Placebo Comparator|Arm 3|15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.
16577451|NCT02762019|Experimental|Laser therapy|Children are allocated to receive Laser therapy
16577452|NCT02762019|Sham Comparator|Sham therapy|Children are allocated to receive Sham therapy
16577453|NCT02762006|Experimental|Durvalumab + Tremelimumab with Nephrectomy|"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.
~Cohort 1: Durvalumab x 1 dose (n=6)
~Cohort 2: Durvalumab + Tremelimumab x 1 dose (n=6)
~Cohort 2a: Durvalumab + Tremelimumab x 1 dose (n=12)
~Cohort 3: Durvalumab + Tremelimumab x 1 dose (n=9)
~Cohorts 1 and 2: Adjuvant dosing of Durvalumab x 1 beginning 2-8 weeks after surgery.
~Cohort 2a: Durvalumab monotherapy until 1 year after nephrectomy.
~Cohort 3: Adjuvant dosing of durvalumab + tremelimumab x 1 beginning 2-8 weeks after surgery, then durvalumab monotherapy until 1 year after nephrectomy."
16577454|NCT02761993|Active Comparator|Group 1|Group 1 received ST266 treatment daily on Days 1 through 5, 8 through 12, 22, and 30, and then monthly for 7 months (Days 60, 90, 120, 150, 180, 210, and 240).
16577456|NCT02761993|Placebo Comparator|Group 3|Group 3 received commercially available sterile saline (0.9% sodium chloride) according to the same schedule as Group 1.
16577457|NCT02761980|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
16577458|NCT02761980|Active Comparator|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
16577459|NCT02761980|Active Comparator|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
16577460|NCT02761980|Placebo Comparator|Placebo|Single dose of 2 caplets of Placebo by mouth
16577461|NCT02761967|Experimental|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.
~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
16577462|NCT02761967|No Intervention|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.
~After the postpartum period, the women in the control group did not perform regulated physical activity."
16577463|NCT02761928||Epidural|Positive response (>50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)
16577464|NCT02761928||Selective nerve root block|Positive response (>50% pain relief) to selective nerve root block
16577465|NCT02761928||Facet injection|Positive response (>50% pain relief) to intra-articular facet injection
16577466|NCT02761928||Medial branch block|Positive response (>50% pain relief) to median branch nerve block
16577467|NCT02761928||Medial branch RFA|Positive response (>50% pain relief) to median branch nerve radiofrequency ablation
16577468|NCT02761928||SIJ injection|Positive response (>50% pain relief) to sacroiliac joint injection
16577469|NCT02761928||Lateral branch block|Positive response (>50% pain relief) to lateral branch nerve block for SIJ
16577470|NCT02761928||Greater trochanter injection|Positive response (>50% pain relief) to greater trochanteric bursa injection
16577471|NCT02761928||Piriformis injection|Positive response (>50% pain relief) to piriformis injection
16577472|NCT02761928||Trigger point injection|Positive response (>50% pain relief) to trigger point injection
16577473|NCT02761915|Other|Dose Level 1|Patients in Dose Level 1 will receive 1x10^7 1RG-CART/m^2 intravenously (IV) on Day 0.
16577474|NCT02761915|Other|Dose Level 2|Patients in Dose Level 2 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
16577475|NCT02761915|Other|Dose Level 3|Patients in Dose Level 3 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
16577476|NCT02761915|Other|Dose Level 4|Patients in Dose Level 4 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 IV on Day 0.
16577477|NCT02761915|Other|Dose Level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 IV which could be be split over two days (Day 0 and Day 1).
16577478|NCT02761915|Other|Patients who underwent leukapheresis but did not proceed to receive any IMP|Patients who were enrolled and underwent leukapheresis but who did not receive any IMP.
16577479|NCT02761902||Preschool group|3-6 years old
16577480|NCT02761902||school age group|7-12 years old
16577481|NCT02761902||Adolescence group|13-15 years old
16577482|NCT02761889|Experimental|IGRT 45 Gy in 5 fractions of 9 Gy|Patients will be treated using volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
16577483|NCT02761876|Experimental|Intervention (Participatory education)|Participatory education
16577484|NCT02761876|No Intervention|Control|Delayed participatory education
16577485|NCT02761863||CD74 - VEGF arm|
16577486|NCT02761837|Active Comparator|IVR call/text|Identify gaps in care and contact patients by IVR phone call or text
16577487|NCT02761837|Active Comparator|Email|Identify gaps in care and contact patients by email
16577488|NCT02761824|Experimental|Camp Discovery|One week activity based camp.
16577489|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
16577490|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
16577491|NCT02761798||Automated Mobile Interactive Audiometer, Test Retest|Each participant will act as his/her own control. The iPad audiogram will be compared to the audiogram in sound booth or to a second iPad audiogram.
16577492|NCT02761798||Automated Mobile Interactive Audiometer, Validation.|iPad testing will be compared to conventional audiometry in the sound booth.
16577493|NCT02761798||Automated Mobile Interactive Audiometer, Speech Recognition|Testing with NU-6 word lists will be conducted by the iPad and by an audiologist in the sound booth.
16577494|NCT02761798||Automated Mobile Interactive Audiometer, Cochlear Implant|Participants with cochlear implants will be tested using iPad against conventional audiometry (warble tone) in the sound booth.
16577495|NCT02761785||Celiacs with oat-related symptoms|Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats
16577496|NCT02761785||Celiacs without oat-related symptoms|Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats
16577497|NCT02761785||Healthy controls|Healthy controls (without celiac disease) who include oats in their diet
16577498|NCT02761785||Non-celiac gluten sensitive subjects|Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.
16577499|NCT02761772||PEP-A|See detailed description
16577500|NCT02761772||PEP-S|See detailed description
16577501|NCT02761746|Experimental|Intervention Condition (MESA)|MESA involves two sessions (ACASI assessment and intervention), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first MESA session is tailored based on how important and how confident the person feels about taking medications as prescribed. The participant is also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, the participant may engage in goal setting. The second MESA session focuses on adherence behavior over the previous month and the consequences (good or bad) of that behavior.
16577502|NCT02761746|No Intervention|Control Condition (SH)|The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
16577503|NCT02761733|Experimental|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
16577504|NCT02761733|No Intervention|Control|Treatment as usual
16577505|NCT02761720||MyPennMedicine (MPM)|Participants assigned to this arm downloaded only the MyPennMedicine mobile app.
16577506|NCT02761720||MPM and Ginger iO|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app.
16577507|NCT02761720||Lottery|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app. They were also given a lottery incentive if they completed 70% of the daily mood ratings.
16577508|NCT02761707||Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Parkinson's Disease. Must be Hoehn and Yahr stage 2 or less with a history of motor symptoms less than two years.
16577509|NCT02761707||Alzheimer's Disease|Non-smokers, ages 18-80, diagnosed with Alzheimer's Disease. Must meet the 2011 National Institute on Aging-Alzheimer's Association and the 1984 National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's disease and Related Disorders Association criteria for probable AD.
16577510|NCT02761707||Progressive Supranuclear Palsy|Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
16577511|NCT02761707||Essential Tremor|Non-smokers, ages 18-80, diagnosed with Essential Tremor.
16577512|NCT02761707||Drug-Induced Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Drug-Induced Parkinson's Disease.
16577513|NCT02761707||Myasthenia Gravis|Non-smokers, ages 18-80, diagnosed with Myasthenia Gravis.
16577514|NCT02761707||Multiple System Atrophy|Non-smokers, ages 18-80, who have been diagnosed with Multiple System Atrophy.
16577515|NCT02761707||Diffuse Lewy Body Disease|Non-smokers, ages 18-80, diagnosed with Diffuse Lewy Body Disease. Must meet the Consensus Criteria for the clinical diagnosis of DLBD.
16577516|NCT02761707||Healthy Controls|Non-smokers, ages 18-80, with no neurodegenerative disease, and no first-degree relatives with a neurodegenerative disease.
16577517|NCT02761707||Spinal Cord Injury|
16577518|NCT02761707||Asymptomatic Relatives|
16577522|NCT02761681|Experimental|ACT-CL Web-based guided self-help|Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
16577523|NCT02761681|Active Comparator|Control Web-based guided self-help|Behavioral: Control Web-based guided self-help program This intervention will be created for the current study. It will involve psycho-education on how students might get the most out of counseling. Counselors will go through the psycho-education session before inviting students to participate.
16577524|NCT02761668|Experimental|ParS+Ortho 4W|Orthodontic alignment starts 4 weeks post surgical
16577525|NCT02761668|Active Comparator|ParS+Ortho 6M|Orthodontic alignment starts 6 months post surgical
16577526|NCT02761655|No Intervention|Control Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement.
16577669|NCT02760745||Fever without Shivering|
16577527|NCT02761655|Experimental|Intervention Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement. The intervention group will further receive memory strategies training on encoding and retention, retrieval, as well as execution and monitoring.
16577528|NCT02761642|Experimental|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
16577529|NCT02761629|Experimental|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
16577530|NCT02761629|Active Comparator|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
16577531|NCT02761616||eBC treated participants|Participants with metastatic disease after previously being treated for eBC were observed for 24 months.
16577532|NCT02761603|Active Comparator|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
16577533|NCT02761603|Experimental|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
16577534|NCT02761590|Experimental|Circuit training protocol|"The CT protocol will be held in three sessions per week for 14 weeks. The volume of work is defined by the training section of time and intensity of effort by the heart rate response to exercise.
~The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. that concludes in favor of the organization of training adapted to the reality of the public to be trained."
16577535|NCT02761590|Active Comparator|Strength training protocol|"The strength training protocol was performed in three sessions per week for 14 weeks and divided into three levels.
~The initial load set for each exercise was based on the one repetition maximum test (1 RM). Strengthening exercises were performed in two sets of 15 repetitions, using 25% 1RM for hip adductors and abductors, and 50% 1RM for the quadriceps and hamstrings, using ankle weights. Exercises for the trunk were performed in 3 10-second series, increasing the duration when participants were able."
16577536|NCT02761590|No Intervention|Educational Protocol|In order to provide care, social interaction, and health education, an educational protocol was conducted. This protocol consisted in interactive presentations of 60 minutes, twice a month for 14 weeks, totaling 7 meetings. The topics addressed pathophysiology of osteoarthritis, and American College of Rheumatology (ACR) recommendations on nutrition, posture, and lifestyle.
16577537|NCT02761577|No Intervention|control|perorally 1500 ml water on the day of the procedure
16577538|NCT02761577|Experimental|Sodium bicarbonate|3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
16577539|NCT02761577|Experimental|N-acetylcysteine plus Sodium bicarbonate|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.
16577540|NCT02761564|Experimental|ScVO2 group|Anemia (<9g/dL) requiring blood transfusion Measure of ScvO2 : ScVO2 is measured using the central venous catheter placed in the superior vena cava. Transfusion is performed if the ScVO2 is inferior or equal to 65%.
16577541|NCT02761564|Other|Control group|Anemia (<9g/dL) requiring blood transfusion : Transfusion is performed following national guidelines for red blood cell transfusion
16577542|NCT02761551|No Intervention|Usual Care|Patients in this group will not receive any reminders for influenza vaccine.
16577543|NCT02761551|Experimental|1 notice|Patients in this group will receive one reminder for influenza vaccine across the 2016 influenza season.
16577544|NCT02761551|Experimental|2 notices|Patients in this group will receive up to two reminders for influenza vaccine across the 2016 season.
16577545|NCT02761551|Experimental|3 notices|Patients in this group will receive up to three reminders for influenza vaccine across the 2016 season.
16577546|NCT02761538|Experimental|AVIITAM Group|Utilization of the web platform Aviitam
16577547|NCT02761538|No Intervention|Control group|No utilization of web-platform Aviitam
16577548|NCT02761525|Experimental|gel silver nanoparticles|topic gel silver nanoparticles 12 ppm
16577549|NCT02761525|Placebo Comparator|placebo|topic innocuous gel
16577550|NCT02761512|Experimental|CJ-12420 50 mg QD|CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks
16577551|NCT02761512|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
16577552|NCT02761512|Active Comparator|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks
16577554|NCT02761486|Active Comparator|Aspirin|The subjects will receive 325 mg of aspirin once a day for 6 weeks followed by a 6-week washout.
16577555|NCT02761486|Placebo Comparator|Placebo|The subjects will receive placebo once a day for 6 weeks followed by a 6-week washout.
16577556|NCT02761473||Patients with Urticaria Pigmentosa|This group will undergo skin biopsy, blood and buccal swab analyses
16577557|NCT02761473||Family members of affected patients|This group will undergo blood and buccal swab analyses
16577558|NCT02761460|Experimental|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy,
16577590|NCT02761252|Active Comparator|Bilastine+placebo montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
16577559|NCT02761447|Experimental|Treatment Traditional and Motor Imaginary Program|"Amputees patients also conservative protocol will undergo physiotherapy techniques work Motor Imaginary Program, based on a system of two videos that allow the patient to recreate the normal way. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases. This protocol will be applied 3 days a week (25-30minutos) for one month."
16577560|NCT02761447|Active Comparator|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
16577561|NCT02761434|Active Comparator|Dehydration|Infusion of 3% sodium chloride for osmotic stimulation of vasopressin
16577562|NCT02761434|Placebo Comparator|Euhydration|Infusion of 0.9% sodium chloride that will induce similar expansion of plasma volume without any significant change in osmolality and vasopressin
16577563|NCT02761421||patients with IOPD|observation all patients with IOPD
16577564|NCT02761395|Experimental|Group 1: ALhijama|20 patients under went Al-hijamah procedure for iron chelation
16577565|NCT02761395|Experimental|Group 2: AL-hijama with deferasirox|20 patients receive deferasirox and Al-hijamah.
16577566|NCT02761395|Active Comparator|Group 3:deferasirox|20 patients already receiving deferasirox
16577567|NCT02761382|Experimental|Mindfulness-based treatment|"The mindfulness-based psychological treatment consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT) and Acceptance and commitment therapy (ACT). The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:
~mindfulness-training (including meditation and yoga),
~therapy based on ACT, and
~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
16577568|NCT02761382|Experimental|Non-specific treatment|"The non-specific general psychological treatment is matched the mindfulness-based psychological treatment and consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Client-centered therapy. The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:
~relaxation and physical training,
~therapy based on the non-specific factors of psychological treatment which emphasize a focus on the relation and alliance between the therapist and the client and the therapist being a warm empathic, non-directive and unconditionally accepting support, and
~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
16577569|NCT02761382|No Intervention|Waiting list control|Participants in this arm will be on the waiting list to participate in one of the two experimental treatments after a period of six months. Participants will receive medical treatment as usual in this period.
16577570|NCT02761369|Experimental|A PAS protocol, right-to-left, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the right DLPFC
16577571|NCT02761369|Experimental|A PAS protocol, left-to-right, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the left DLPFC
16577572|NCT02761369|Sham Comparator|A sham PAS protocol, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a sham PAS protocol, starting with the right DLPFC (@ 40% of individual MT)
16577573|NCT02761356||Tc99-MAA and SPECT-CT|26 of the patients were examined with Tc99-MAA and SPECT-C
16577574|NCT02761356||Tc99-MAA , SPECT-CT and PET-CT|24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT.
16577575|NCT02761343|Other|MRI scan|Post ablation MRI scan will be performed for all subjects who are clinically stable.
16577576|NCT02761330|Active Comparator|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
16577577|NCT02761330|Experimental|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
16577578|NCT02761330|Sham Comparator|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
16577579|NCT02761317|Active Comparator|GroupA：standard preparation|Subjects who are randomized into group A receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
16577580|NCT02761317|Experimental|Group B:low-volume preparation|Subjects who are randomized into group B receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure. ( 2L PEG-ELS and 10mg bisacodyl )
16577581|NCT02761317|Experimental|Group C：high-volume preparation|Subjects who are randomized into group C will receive 2L PEG-ELS at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure. (4 L PEG-ELS)
16577582|NCT02761304|Experimental|ultrasound results given to obstetrical practionnair|
16577583|NCT02761304|Other|ultrasound results shaded to obstetrical practionnair|
16577584|NCT02761291|Experimental|gemcitabine dose escalation|In three combined drugs used in nasopharyngeal carcinoma, the valproic acid and valganciclovir administration will be followed by indication to find the maximum tolerance dose of gemcitabine.
16577585|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression Before Polypectomy|A biopsy will taken in infertility patients with endometrial polyp before polypectomy
16577586|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression After Polypectomy|A biopsy will taken in infertility patients with endometrial polyp 1-3 months after polypectomy
16577587|NCT02761265|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
16577588|NCT02761265|Other|Control Group|Gait and balance testing to be administered once in healthy subjects
16577589|NCT02761252|Experimental|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
16577591|NCT02761252|Active Comparator|Montelukast+placebo bilastine|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
16577592|NCT02761239|Other|Cricopharyngeal muscle innervation|The recurrent laryngeal nerve (RLN), vagus nerve, external branch of the superior laryngeal nerve (EBSLN) and pharyngeal plexus were stimulated intraoperatively by the NIM 3.0 Nerve Monitoring System (Medtronic Xomed, Jacksonville, FL, USA). Responses were evaluated by visual observation of the cricopharyngeal muscle and electromyographies via needle electrodes inserted into the cricopharyngeal muscle.
16577593|NCT02761226|Experimental|Group A (Platform Matched Design)|10 Patients with missing tooth in upper posterior area will receive dental implant (implants with the same abutment diameter)
16577594|NCT02761226|Active Comparator|Group B (intervention - Platform Switching Design)|10 patients with missing tooth in upper posterior area will receive dental implant (implants with smaller diameter abutment)
16577595|NCT02761213|Experimental|Oral sulfate solution (OSS)|oral sulfate solution (OSS)
16577596|NCT02761213|Active Comparator|2-L PEG/Asc|low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)
16577597|NCT02761200||volunteer who completion of a recent ATI|
16577598|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
16577599|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
16577600|NCT02761174|Active Comparator|Brimonidine (Mirvaso cream)|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face (control) and 0.5 g of brimonidine (Mirvaso cream) to the randomized side of the face.
16577601|NCT02761174|Other|IPL+air-cooling|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face and IPL+air-cooling (control) are thereby compared to IPL+air-cooling+brimonidine (Mirvaso cream).
16577602|NCT02761161|No Intervention|Treatment as usual|TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation
16577603|NCT02761161|Active Comparator|Mianserin|10-30 mg of mianserin af sleep enhancing
16577604|NCT02761161|Active Comparator|Imagery Rehearsal Therapy|Therapy focusing on nightmares
16577605|NCT02761161|Active Comparator|mianserin and Imagery Rehearsal Therapy|Both mianserin and IRT
16577606|NCT02761148||Control|
16577607|NCT02761148||White matter hyperintensity|
16577608|NCT02761135||Side-fire|Using side-fire technique during transrectal ultrasound.
16577609|NCT02761135||End-fire|Using end-fire technique during transrectal ultrasound.
16577610|NCT02761122|Experimental|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.
~Human biological samples :
~Blood sample
~Skin or mucosal brushing
~Skin or mucosal biopsy"
16577611|NCT02761096|Experimental|Study group|The acupuncture intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). It will be given in addition to conventional treatments. All interventions will be performed by one Korean Medicine doctor with over 5 years of working experience with a college education of 6 years. This doctor will be trained in the study protocol before the start of the trial.
16577612|NCT02761096|Other|Control group|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery.
16577613|NCT02761083|Experimental|Novosyn® Quick|Eye surgery using suture material
16577614|NCT02761083|Active Comparator|Vicryl® Rapid|Eye surgery using suture material
16577615|NCT02761070|Active Comparator|Bevacizumab (BEV) alone|Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
16577616|NCT02761070|Experimental|Dose Dense Temozolomide Followed by BEV|Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
16577617|NCT02761057|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate PO on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
16577618|NCT02761057|Experimental|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
16577619|NCT02761057|Experimental|Arm III (crizotinib closed to accrual 12/5/18)|Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
16577620|NCT02761057|Experimental|Arm IV (savolitinib closed to accrual 12/5/18)|Patients receive savolitinib PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
16577621|NCT02761018|Experimental|Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
16577622|NCT02761018|Experimental|Fitness Tracker with Group Participation|will use a fitness tracker and will be able to see other member's daily and weekly results
16577623|NCT02761005|Experimental|23S rRNA wt|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
16577624|NCT02761005|Experimental|23S rRNA mutation|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains with mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,
16577625|NCT02760992|Active Comparator|Oral Baclofen|Subject will start baclofen at a 5 mg oral dose every 8 hours. Oral baclofen will be increased incrementally and self-administered over 13 days to a maximum dose of 20 mg every 8 hours. Following IV administration, subjects will be changed back to oral baclofen at a 15 mg dose self-administered every 8 hours and tapered off of baclofen over 15 days.
16577626|NCT02760992|Experimental|IV Baclofen|Subjects will be crossed over to 16 mg intravenous baclofen infused over 120 or 150 minutes every 8 hours for 11 doses.
16577627|NCT02760979|Active Comparator|Denosumab|Patients treated with Denosumab
16577628|NCT02760979|Placebo Comparator|Placebo|Patients treated with placebo
16577629|NCT02760966|Experimental|Alcohol 70º|Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
16577630|NCT02760966|Active Comparator|Soap|Umbilical cord care will be carried out using soap at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
16577631|NCT02760953|Experimental|TUR with Cryoablation|Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
16577632|NCT02760953|Active Comparator|TUR with instant instillation|Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
16577633|NCT02760940|Experimental|Oral liposomal iron treatment|Oral liposomal iron - 28 mg per day over 8 weeks
16577634|NCT02760927|Experimental|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
16577635|NCT02760914||Coronary heart disease|Patients with coronary heart disease undergoing planned coronary artery bypass surgery
16577636|NCT02760901|Active Comparator|Mannitol group|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
16577637|NCT02760901|Active Comparator|ACTZ group|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.
16577638|NCT02760901|Active Comparator|NAC group|patients received acetylcysteine NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.
16577639|NCT02760888|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
16577640|NCT02760888|Active Comparator|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
16577641|NCT02760888|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure
16577642|NCT02760875||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
16577643|NCT02760875||control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
16577644|NCT02760862|Active Comparator|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
16577645|NCT02760862|Active Comparator|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
16577646|NCT02760849|Experimental|Arm I (ISDO)|Patients undergo ISDO.
16577647|NCT02760849|Active Comparator|Arm II (RRSO)|Patients undergo RRSO.
16577648|NCT02760823|Active Comparator|Alpha Lipoic Acid|Subjects in this arm will receive ALA IV, as a dose of 600 mg/12 hours.
16577649|NCT02760823|Placebo Comparator|Non-Alpha Lipoic Acid|Subjects in this arm will to receive standard treatment only (without Alpha Lipoic Acid, instead they will receive placebo , which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment.
16577650|NCT02760810|Experimental|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
16577651|NCT02760797|Experimental|Part I (Dose-Finding Stage)|Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
16577652|NCT02760797|Experimental|Part II (Dose Expansion Stage)|Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
16577653|NCT02760784||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
16577654|NCT02760784||Control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
16577655|NCT02760771||with BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve
16577656|NCT02760771||without BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve
16577657|NCT02760758|Experimental|Cohort 1A HV|CDI-31244 20 mg active or placebo single dose (SD)
16577658|NCT02760758|Experimental|Cohort 2A HV|CDI-31244 50 mg active or placebo SD
16577659|NCT02760758|Experimental|Cohort 3A HV|CDI-31244 100 mg active or placebo SD
16577660|NCT02760758|Experimental|Cohort 4A HV|CDI-31244 200 mg active or placebo SD; food effect
16577661|NCT02760758|Experimental|Cohort 5A HV|CDI-31244 400 mg active or placebo SD
16577662|NCT02760758|Experimental|Cohort 6A HV|CDI-31244 200 mg active or placebo multiple dose (MD)
16577670|NCT02760732|Experimental|drug eluting balloon group|patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .
16577671|NCT02760732|Experimental|drug eluting stent group|patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R&D Center Co., Ltd. China) implantation.
16577672|NCT02760719|Experimental|hypertonic saline|4 ml of nebulized 3 % hypertonic saline + salbutamol 0,03 ml/kg every 8 hours for the time of hospitalisation and standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
16577673|NCT02760719|No Intervention|supportive care|Standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
16577674|NCT02760693||bipolar patients|unselected admissions of bipolar patients
16577675|NCT02760680|Placebo Comparator|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
16577676|NCT02760680|Active Comparator|Diagnostic Device (WatchPAT 200 (TM))|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
16577677|NCT02760667|Experimental|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
16577678|NCT02760654|Experimental|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
16577679|NCT02760654|No Intervention|Control|Treatment as usual
16577680|NCT02760641|Experimental|Egg-based diet (EBD)|This arm will provide ≤25% energy from CHO, 25% energy from protein, and ≥50% energy from fat. EBD participants will be asked to consume ≥2 eggs per day along with other protein sources including meat, fish, pork, and poultry. Carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day.
16577681|NCT02760641|Placebo Comparator|Carbohydrate-based diet (CBD)|The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
16577682|NCT02760628|Experimental|The First Twenty (TF20)|Participants in TF20 will be provided an online wellness program focused on fitness and nutrition tailored to firefighters. TF20 is interactive and involves health coaching.
16577683|NCT02760628|Placebo Comparator|Life Simple Seven (LS7)|Participants assigned to the LS7 arm will be directed to a website that contains information about health and wellness from the American Heart Association that was developed for the general population. No health coaching is present and the site is not tailored for the fire service.
16577684|NCT02760615|Other|Part 1: UC and CD Participants|Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
16577685|NCT02760615|Other|Part 1: Healthy Participants|Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
16577686|NCT02760615|Experimental|Part 2: Vedolizumab|Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
16577687|NCT02760602|Experimental|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
16577688|NCT02760602|Experimental|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
16577689|NCT02760589||ACL tear - conservative|conservative treatment
16577690|NCT02760589||ACL tear - ACL reconstruction|reconstruction of the ACL with autologous tendons
16577691|NCT02760589||ACL tear - Internal brace|augmentation of the ruptured ACL with Internal brace
16577692|NCT02760589||healthy subjects|control group of healthy subjects with no previous injury
16577693|NCT02760576|Experimental|BAY 987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16577694|NCT02760563|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16577695|NCT02760550||never smokers|who have never smoked at all
16577696|NCT02760550||ex-smokers|formerly smokers but currently do not smoke at all
16577697|NCT02760550||current smokers|current smokers who, at the time of the survey, smoke any tobacco product either daily or occasionally. Social smokers fall into this category and are defined as those who smoke less than one cigarette per week or smoke only in some occasions
16577731|NCT02760368|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
16578434|NCT02755857|Experimental|Lozanoc|65 mg, capsules, at least 2 capsules twice a day
16577698|NCT02760537|Experimental|Lay Health Worker Intervention|LHWs conducted phone interventions by reminding participants of a series of vaccinations at months 1, 2, and 5 among those assigned to the intervention group. Those who had health insurance were encouraged to complete vaccinations through their providers. If participants did not have health insurance, LHWs provided resources to help those in the intervention access vaccinations by referring them to free vaccine events in the community.
16577699|NCT02760537|Placebo Comparator|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
16577700|NCT02760524|Experimental|Intervention|Subjects will receive NET intervention treatment immediately
16577701|NCT02760524|Active Comparator|Control|Subjects will receive NET intervention treatment and serve as a wait-list control
16577702|NCT02760511|Placebo Comparator|Control|Intake of placebo capsules
16577703|NCT02760511|Active Comparator|20 mg|Daily intake of 20 mg anthocyanin
16577704|NCT02760511|Active Comparator|40 mg|Daily intake of 40 mg anthocyanin
16577705|NCT02760511|Active Comparator|80 mg|Daily intake of 80 mg anthocyanin
16577706|NCT02760511|Active Comparator|160 mg|Daily intake of 160 mg anthocyanin
16577707|NCT02760511|Active Comparator|320 mg|Daily intake of 320 mg anthocyanin
16577708|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously every 2 weeks.
16577709|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered intravenously every 2 weeks.
16577710|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously every 3 weeks.
16577711|NCT02760498|Experimental|Group 4|Patients with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] Cemplimab administered intravenously every 4 weeks.
16577712|NCT02760498|Experimental|Group 6|Patients with advanced CSCC (metastatic [nodal or distant] or locally advanced). Cemiplimab administered IV every 3weeks.
16577713|NCT02760485|Experimental|itacitinib + ibrutinib|
16577714|NCT02760472|Active Comparator|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
16577715|NCT02760472|Experimental|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
16577716|NCT02760459|Active Comparator|Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.
16577717|NCT02760459|Placebo Comparator|Placebo|The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
16577718|NCT02760446|Other|CAM-ICU.fr|CAM-ICU and ICDSC evaluation proceed by two investigators and a Neuropsychologist (Speech & language therapist specialized in neuropsychology)
16577719|NCT02760433|Experimental|Arm 1: Olokizumab q4w|"Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate
~Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)"
16577720|NCT02760433|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate
~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
16577721|NCT02760433|Placebo Comparator|Arm 3: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate
~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)
~Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group."
16577722|NCT02760420|Experimental|Placebo|250 mg of placebo (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
16577723|NCT02760420|Active Comparator|3 Days|250 mg amoxicillin (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
16577724|NCT02760407|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
16577725|NCT02760407|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate
~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
16577726|NCT02760407|Active Comparator|Arm 3: Adalimumab q2w|"Adalimumab 40mg q2w subcutaneous + Methotrexate
~Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
16577727|NCT02760407|Placebo Comparator|Arm 4: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate
~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
16577728|NCT02760394|Active Comparator|Treated group|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
16577729|NCT02760394|Other|Control group|Following 2 months of follow up the group will be crossed over to receive the same treatment as the treated group
16577730|NCT02760381|Experimental|Routine colonoscopy Cohort|Patients receiving routine colonoscopy receive the intervention: NBI + Acetic Acid (AA)
16577843|NCT02759718|Experimental|pancreatic neuroendocrine tumor|chromogranin A
16577732|NCT02760368|Experimental|Arm 2: Olokizumab q2w|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
16577733|NCT02760368|Placebo Comparator|Arm 3: Placebo|Placebo Subcutaneous q2w + Methotrexate (oral)
16577734|NCT02760355|Experimental|Active treatment|Ledipasvir 90 mg/Sofosbuvir 400 mg, one tablet once a day + b.w. dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks
16577735|NCT02760342|Experimental|ASP015K and Metformin|Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
16577736|NCT02760329||Chronic airways disease|Patients with suspected or primary diagnosis of asthma or COPD
16577737|NCT02760316|Experimental|AZD9567 oral suspension of 10 mg|Participants will receive oral supension of 10 mg dose strength
16577738|NCT02760316|Experimental|AZD9567 oral suspension of 20 mg|Participants will receive oral suspension of 20 mg dose strength
16577739|NCT02760316|Experimental|AZD9567 oral suspension of 40 mg|Participants will receive oral suspension of 40 mg dose strength
16577740|NCT02760316|Experimental|AZD9567 oral suspension of 80 mg|Participants will receive oral suspension of 80mg dose strength
16577741|NCT02760316|Active Comparator|Prednisolone oral capsules of 20 mg|Participants will receive oral capsules of 5 mg dose strength
16577742|NCT02760316|Experimental|AZD9567 oral suspension of 125 mg|Participants will receive oral suspension of 125 mg dose strength
16577743|NCT02760316|Experimental|AZD9567 oral suspension of 155 mg|Participants will receive oral suspension of 155 mg dose strength
16577744|NCT02760316|Active Comparator|Prednisolone oral capsules of 5 mg|Participants will receive oral capsules of 5 mg dose strength
16577745|NCT02760316|Active Comparator|Prednisolone oral capsules of 40 mg|Participants will receive oral capsules of 5 mg dose strength
16577746|NCT02760303|Experimental|Cognitive Behavioral Therapy|Hains' adaptation of cognitive behavioral therapy for adolescents and young adults with type 1 diabetes
16577747|NCT02760303|Experimental|Mindfulness Based Stress Reduction|Sabinga's adaptation of Mindfulness Based Stress Reduction for adolescents and young adults with type 1 diabetes
16577748|NCT02760303|Active Comparator|Diabetes Support and Education|Investigator developed peer support group and diabetes education
16577749|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
16577750|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
16577751|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
16577752|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
16577753|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
16577754|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
16577755|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
16577756|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
16577757|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
16577758|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
16577759|NCT02760251|Experimental|Romiplostim|Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
16577760|NCT02760238||Patients with a diagnosis of MPN|"Patients with a myeloproliferative neoplasm (MPN) diagnosis:
~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T"
16577761|NCT02760225|Experimental|89Zr-Pembrolizumab PET imaging|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
16577762|NCT02760212|Experimental|Group 1 - Radial Shockwave Therapy Group|Participants in Group 1 will receive RSWT to the most painful spot within each of the 3 most painful regions as described by the participant. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with treatment to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot.
16577763|NCT02760212|Placebo Comparator|Group 2 - Placebo Group|Participants in Group 2 will receive a placebo treatment with a soft rubber cap applied to the applicator, leaving air between the transmitter and the cap and the participant's skin so that no shockwave will be generated nor applied to the participant's skin. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with placebo treatment to the painful areas will be undertaken with 2000 placebo shocks (15 Hz) producing an audible sound but no therapeutic dosage to the most painful spot. Upon completion of the placebo treatment, participant's will be offered the experimental treatment but this data will not be used for comparison and analysis.
16577764|NCT02760199|Experimental|89Zr-AMG211 and 89Zr-AMG211 PET|
16577765|NCT02760186|Experimental|Altitude Exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
16577766|NCT02760173|Experimental|Single intervention arm|This is the only arm in this study, measuring verticality perception after prolonged roll-tilt over 5min.
16577767|NCT02760160|Other|Reconstituted grape powder|Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
16577768|NCT02760147|Other|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
16577769|NCT02760147|Other|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
16577770|NCT02760147|Other|PEEP Over Level|PEEP Level upward by 50%, 2 hours
16577771|NCT02760147|Other|PEEP Under Level|PEEP Level downward by 50%, 2 hours
16577772|NCT02760134|Other|SMP with F14 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F14 suction-evacuation sheath.
16577773|NCT02760134|Other|SMP with F12 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F12 suction-evacuation sheath.
16577774|NCT02760121|Experimental|Acetazolamide|Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
16577775|NCT02760121|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
16577776|NCT02760121|Placebo Comparator|Placebo|Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
16577777|NCT02760108||Index case|Patients with a family history of Parkinson's/parkinsonism, and/or early onset Parkinson's/parkinsonism. The first individual member from a family who is recruited to the study.
16577778|NCT02760108||Affected relatives|Patients with Parkinson's/parkinsonism who are first or second degree relatives of an Index Case.
16577779|NCT02760108||Unaffected relatives|Participants who do not have Parkinson's/parkinsonism and are first or second degree relatives of an Index Case.
16577780|NCT02760095||Children with EED|Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
16577781|NCT02760095||Children without EED|Children are placed in this arm if they screen negative for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
16577782|NCT02760082||Semi-structured interviews|20 participants (anticipated)
16577783|NCT02760082||Questionnaire survey|400 respondents (anticipated)
16577784|NCT02760082||Focus group interviews|3-5 focus group interviews (anticipated)
16577785|NCT02760069|Active Comparator|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
16577786|NCT02760069|Experimental|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
16577787|NCT02760069|Active Comparator|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
16577788|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
16577789|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
16577790|NCT02760043|Experimental|Dexamethasone|LIA mixture with the addition of 8mg Dexamethasone.
16577791|NCT02760043|Sham Comparator|Saline|LIA mixture with the addition of 2mL of 0.9% NaCl Saline.
16577792|NCT02760030|Experimental|Treatment (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16577793|NCT02760017|Placebo Comparator|placebo|capsules containing placebo for B forticata
16577794|NCT02760017|Experimental|B. forficata|capsules of B. forficata containing 200 mg of plant extracts
16577795|NCT02760004|Experimental|Prism Intervention|PRogram In Support of Moms (PRISM)
16577796|NCT02760004|Experimental|Enhanced Usual Care|Enhanced Usual Care group (Access to MCPAP for Moms)
16577797|NCT02759991|Active Comparator|HEV vaccine|Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
16577798|NCT02759991|Placebo Comparator|HBV vaccine|Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
16577799|NCT02759978||Suspicion NVE|Patients with suspicion of native valve endocarditis, infective endocarditis and no intracardiac prosthetic material in situ
16577800|NCT02759978||Suspicion (PVE)|Patients with a suspicion of prosthetic valve endocarditis (PVE), infective endocarditis and one or more prosthetic valves in situ
16577801|NCT02759978||Suspicion pacemaker/ICD related endocarditis|Patients with a suspicion of infective endocarditis and a pacemaker or implantable cardiac defibrillator (ICD) in situ
16577802|NCT02759939|Experimental|Arm 1|
16577803|NCT02759939|Experimental|Arm 2|
16577804|NCT02759939|Experimental|Arm 3|
16577805|NCT02759939|No Intervention|Arm 4|
16577806|NCT02759926|Active Comparator|Denatonium benzoate intragastric|1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
16577807|NCT02759926|Active Comparator|Quinine hydrochloride intragastric|10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
16577808|NCT02759926|Placebo Comparator|Tap water intragastric|An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.
16577809|NCT02759926|Active Comparator|Denatonium benzoate intraduodenal|1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
16577810|NCT02759926|Active Comparator|Quinine hydrochloride intraduodenal|10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
16577811|NCT02759926|Placebo Comparator|Tap water intraduodenal|An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
16577812|NCT02759913||Amyotrophic lateral sclerosis|Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
16577813|NCT02759913||ALS mimics|Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection
16577814|NCT02759900|Experimental|Non-thermal atmospheric plasma treatment|Device treatment
16577815|NCT02759900|Experimental|Indirect non-thermal atmospheric plasma treatment|A compound of non-thermal atmospheric plasma and medium is used to treat the target by direct application or by on-site generation of the compound
16577816|NCT02759887|Other|DS adult group|Consists of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
16577817|NCT02759887|Other|DS/AD group|Consists of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by DSM-IV criteria. Diagnoses will be by standard consensus review of all cases. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
16577818|NCT02759887|Other|NC adult|Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
16577819|NCT02759874|Experimental|Experimental|Intervention is pregnant women enrolled and using specialized breathalyzer device w face recognition technology linked to a cellphone
16577820|NCT02759874|No Intervention|Control Group|No intervention. No breathalyzer given. Access granted by participant to IHE to collect data from Alberta Health Services (medical records)
16577821|NCT02759861|Experimental|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
16577822|NCT02759848||with history of TB|
16577823|NCT02759848||without history of TB|
16577824|NCT02759835|Experimental|Arm 1|osimertinib followed by LAT followed by osimertinib
16577825|NCT02759835|Experimental|Arm 2|LAT followed by osimertinib
16577826|NCT02759822||Group A: Acute Lymphoblastic Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)
~Preferred conditioning:
~Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)
~Alternative conditionings:
~Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)
~Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)"
16577827|NCT02759822||Group B: Acute Myeloid Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200
~Alternative conditionings:
~Bu9,6 + Flu150 + TBI200
~Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF"
16577828|NCT02759809||Children previously assigned to donor milk in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive donor milk when mother's own breastmilk was unavailable. Donor milk was from a milk bank part of the Human Milk Banking Association of North America (HMBANA).
16577829|NCT02759809||Children previously assigned to formula in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive preterm formula when mother's own breastmilk was unavailable. Preterm formula was either Similac Special Care or Enfamil Premature depending on hospital contract with formula companies.
16577830|NCT02759796|Placebo Comparator|Clinical assessment of flap perfusion|Tailoring the flap according to clinical assessment of flap perfusion
16577831|NCT02759796|Experimental|Angiography assessment of flap perfusion|Tailoring the flap according to ICG Angiography assessment of flap perfusion
16577832|NCT02759783|Active Comparator|Standard of Care|Standard of care (SOC) is at the discretion of the local oncologist.
16577833|NCT02759783|Experimental|Standard of Care + SBRT|Patients randomised to SBRT will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC.
16577834|NCT02759770||ARDS|ARDS patients after cardiac surgery
16577835|NCT02759770||non-ARDS|non-ARDS patients after cardiac surgery
16577836|NCT02759770||propective group|patients of cardiac surgery including ARDS and non-ARDS patients
16577837|NCT02759757|Experimental|Kinesio Taping|"Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a I position bilaterally."
16577838|NCT02759757|Placebo Comparator|Placebo|Patient from this group will receive a 5cm-wide Micropore® tape from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae bilaterally.
16577839|NCT02759757|No Intervention|Control|Patients allocated will not receive any intervention.
16577840|NCT02759744|Experimental|1|ultrasound image-guided focal laser ablation device
16577841|NCT02759731|Experimental|Arm 1|Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a CR and there has not been a DLT, the dose will be remain at 2mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks, the dose will be decreased to 1mg daily, and will continue at this dose as tolerated. If there has been DLT at this dose (1 mg), patients will be taken off treatment.
16577842|NCT02759731|Experimental|Arm 2|If the response is a PR or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily. For patients who experience cGVHD progression at any time within the first 12 weeks on 2mg daily, the dose can be increased to 4mg daily until 24 weeks.
16577844|NCT02759692|Active Comparator|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
16577845|NCT02759692|Active Comparator|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
16577846|NCT02759679|Other|Lung cancer|Patients with lung cancer
16577847|NCT02759679|Other|Controls|Controls being either healthy or having other lung disease
16577848|NCT02759666|Experimental|SHR3162|"3 to 6 participants (traditional 3+3 design) will be enrolled in 6 dose levels. SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6."
16577849|NCT02759653||Symptomatic|Symptomatic carotid artery disease
16577850|NCT02759653||Asymptomatic|Asymptomatic carotid artery disease
16577851|NCT02759640|Experimental|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
16577852|NCT02759627|No Intervention|Conventional Training|Conventional physical therapy consisted of neurophysiological concepts such as Bobath and Brunnstrom.Training sessions focused on static and dynamic postural tasks, improving lower and upper extremity range of motion, strengthening and overground walking. During walking training, emphasis was on distance walked than on gait quality. Symmetrical weight distribution was encouraged through verbal and tactile cues and was made more difficult by the addition of arm activities or actions requiring trunk rotation. In an effort to improve rhythmic weight-shifting ability, subjects practiced shifting their weight in forward and backward directions and side to side while performing reaching tasks. A session lasted 45 minutes, for 5 days per week for 6 weeks.
16577853|NCT02759627|Experimental|Robotic-Assisted Gait Training|Lokomat (Hocoma) was used in Robotic-Assisted Gait Training group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait. Robotic-Assisted Gait Training sessions lasted 45-minute sessions, 2 days a week during 6 weeks.
16577854|NCT02759627|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
16577855|NCT02759614|Experimental|Bevacizumab and Erlotinib|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
16577856|NCT02759614|Active Comparator|Erlotinib|Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
16577857|NCT02759601|Other|Tefinostat|"This is an open label, dose escalating, phase I/II study of Tefinostat administered orally, once or twice daily in 28 day cycles of treatment in patients with advanced hepatocellular carcinoma.
~Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II."
16577858|NCT02759588|Experimental|GL-ONC1|
16577859|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
16577860|NCT02759562|Experimental|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
16577861|NCT02759562|Placebo Comparator|Placebo (Part 1)|Placebo weekly for 8 weeks
16577862|NCT02759562|Experimental|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
16577863|NCT02759562|Experimental|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
16577864|NCT02759562|Placebo Comparator|Placebo (Part 2)|Placebo weekly for 8 weeks
16577865|NCT02759562|Experimental|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
16577866|NCT02759549|Experimental|eSMART-MH|Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
16577867|NCT02759549|Other|Theater Testing|Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
16577868|NCT02759536|Experimental|Boronophenylalanine and IHNI-based BNCT|
16577869|NCT02759510|Active Comparator|phenylephrine|phenylejphrine (one bolus for 40 ug/ml)
16577870|NCT02759510|Experimental|norepinephrine|norepinephrine (one bolus for 2 ug/ml)
16577871|NCT02759497||Serum amyloid A level in SBP|serum amyloid A level
16577872|NCT02759497||Serum amyloid A level in cirrhosis|Serum amyloid A level
16577873|NCT02759484|Experimental|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
16577874|NCT02759484|Active Comparator|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
16577875|NCT02759471|Experimental|comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
16577876|NCT02759471|Active Comparator|comfilcon A sphere (control)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
16577935|NCT02759146|Experimental|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
16577879|NCT02759432|Experimental|Intervention|Participants in the intervention group will complete a 4-week school-based high-intensity interval exercise training programme. The intervention will take place twice per week, and comprise of 6-8 repetitions of 45 s maximal effort exercise (boxing, running, soccer and basketball drills), each interspersed with 90-s rest. Participants will be encouraged to work maximally during the 45-s repetitions.
16577880|NCT02759432|No Intervention|Control|Participants in the control group will be instructed not to change their lifestyle, dietary or physical activity habits during the intervention period, and maintain their normal school physical education routine
16577881|NCT02759419|Experimental|BAY63-2521|Single-arm, uncontrolled
16577882|NCT02759406|Experimental|Mach-5 Grooved|grooved
16577883|NCT02759406|Experimental|Mach 5 Bare Metal|bare metal
16577884|NCT02759393|Experimental|DEX group|receiving 8-week dexlansoprazole 60 mg per day
16577885|NCT02759393|Active Comparator|Double-dose PPI group|receiving 8-week lansoprazole 30 mg twice daily
16577886|NCT02759380|Experimental|Phytoestrogen-rich foods|"Introduced to the study by a dietitian.
~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).
~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.
~Called one time during the study and perform a 24-hour recall.
~The intervention continues until the day before the surgery (at least 6 weeks).
~The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
16577887|NCT02759380|No Intervention|Control group|"Introduced to the study by a dietitian.
~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).
~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.
~Called one time during the study and perform a 24-hour recall.
~The intervention continues until the day before the surgery (at least 6 weeks)."
16577888|NCT02759367|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
16577889|NCT02759367|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake.
16577890|NCT02759354|Experimental|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
16577891|NCT02759354|Active Comparator|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
16577892|NCT02759354|Experimental|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
16577893|NCT02759354|Active Comparator|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
16577894|NCT02759341|Other|Cardiac X Syndrome (CSX)|patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)
16577895|NCT02759341|Other|Takotsubo Cardiomyopathy (TTC)|Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)
16577896|NCT02759341|Other|Acute myocardial infarction (AMI)|Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)
16577897|NCT02759328|Experimental|Xbox Kinect™ training group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program plus 60 minutes/day, 5 days/week, 4 weeks (20 sessions) Xbox Kinect™ upper extremity training. Two games both of which require using upper extremities, were chosen and each game was played for 30 minutes per session.
16577898|NCT02759328|Active Comparator|Conventional rehabilitation group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program only. The treatment protocol was individualized according to the goals which were determined depending on each patient's needs and functional level.
16577899|NCT02759315|Experimental|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
16577900|NCT02759315|Experimental|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
16577901|NCT02759315|Experimental|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
16577902|NCT02759315|Experimental|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
16577903|NCT02759315|Experimental|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
16578017|NCT02758743|Experimental|Acetium Lozenge|Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.
16577904|NCT02759315|Experimental|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
16577905|NCT02759302||Patients with LGMD2N|Five patients over 18 years old with genetically verified LGMD2N
16577906|NCT02759289||Group A|Prediabetes glycohemoglobin test A1c 5.7-6.4%
16577907|NCT02759289||Group B|"T2D glycohemoglobin test= A1c 6.5-7.9% without T2D medications
~T2D glycohemoglobin test=A1c ≥ 8.0% with/without T2D medications"
16577908|NCT02759289||Group C|Control
16577909|NCT02759276||Resistant Hypertension (RH)|uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
16577910|NCT02759276||Stages 1 and 2 Hypertension (MMH)|According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
16577911|NCT02759276||Normotensive (CG)|Blood Pressure <140/90 mmHg and without comorbidities.
16577912|NCT02759263|Experimental|Working Memory Intervention|The group randomized to the Working Memory intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the adolescents' responses, time spent on each task, and evolution curves.
16577913|NCT02759263|No Intervention|Control group - Standard of Care|Adolescents randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, an adolescent in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like adolescents assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
16577914|NCT02759250|Experimental|adjuvant monotherapy|ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
16577915|NCT02759250|Experimental|metastatic/recurrent monotherapy|ARGX-110 5mg/kg once every three weeks until disease progression
16577916|NCT02759250|Experimental|metastatic/recurrent combination therapy|ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
16577917|NCT02759237||Patient Group|Patients identified for treatment of symptomatic aortic sten
16577918|NCT02759224|Other|Arm A (Lafutidine and Irsogladine maleate --> BRI-1501)|Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day
16577919|NCT02759224|Other|Arm B (BRI-1501 --> Lafutidine and Irsogladine maleate)|Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day
16577920|NCT02759211|Active Comparator|Forwards Walking Group (FWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
16577921|NCT02759211|Experimental|Backwards Walking Group (BWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
16577922|NCT02759198|Experimental|YH23537|YH23537 750/1500/3000mg
16577923|NCT02759198|Active Comparator|Celebrex|Celecoxib 200mg
16577924|NCT02759198|Placebo Comparator|Placebo|YH23537 Placebo
16577925|NCT02759185|Experimental|High THC cannabis|Provided up to 1.8 g of cannabis per day with more tetrahydrocannabinol than cannabidiol
16577926|NCT02759185|Experimental|High CBD cannabis|Provided up to 1.8 g of cannabis per day of marijuana with more cannabidiol than tetrahydrocannabinol
16577927|NCT02759185|Experimental|THC/CBD cannabis|Provided up to 1.8 g of cannabis per day with an approximately equal amount of tetrahydrocannabinol and cannabidiol
16577928|NCT02759185|Placebo Comparator|Placebo cannabis|Provided 1.8 g of cannabis per day with very low levels of tetrahydrocannabinol and cannabidiol
16577929|NCT02759172|Experimental|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
16577930|NCT02759172|No Intervention|Standard Care|Standard Care for pretrial jail detainees is assessment of risk and stabilization to the extent possible during their jail detention. No post-release community follow-up is typically provided. This study will augment standard care with regular assessment and emergency referral post-release, as well as provision of a list of community resources.
16577931|NCT02759159|Experimental|AD-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on AD patients"
16577932|NCT02759159|Sham Comparator|AD-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on AD patients"
16577933|NCT02759159|Experimental|Mild Cognitive Impairment(MCI)-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on MCI patients"
16577934|NCT02759159|Sham Comparator|MCI-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on MCI patients"
16577936|NCT02759146|Experimental|Meditative Practice|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
16577937|NCT02759146|No Intervention|Control|Control - no intervention
16577938|NCT02759133|Active Comparator|A - A standard Localization technique|A standard Localization technique : Metal wire as localization technique for breast cancer surgery
16577939|NCT02759133|Experimental|B - Experimental Localization technique|Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery
16577940|NCT02759120|Experimental|Antimicrobial therapy|Co-trimoxazole OR doxycycline
16577941|NCT02759120|Other|Standard of care|Standard of care for patients with IPF for comparison
16577942|NCT02759107|Experimental|LY3298176 (Part A)|Escalating doses of LY3298176 administered subcutaneously (SC) once in healthy participants.
16577943|NCT02759107|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants.
16577944|NCT02759107|Experimental|LY3298176 (Part B)|Escalating doses of LY3298176 administered SC once weekly for four weeks in healthy participants.
16577945|NCT02759107|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants.
16577946|NCT02759107|Active Comparator|Dulaglutide (Part B)|Dulaglutide administered SC once weekly for four weeks in healthy participants
16577947|NCT02759107|Experimental|LY3298176 (Part C)|Two dose levels of LY3298176 administered SC once weekly for four weeks in participants with T2DM.
16577948|NCT02759107|Placebo Comparator|Placebo (Part C)|Placebo administered SC once weekly for four weeks in participants with T2DM.
16577949|NCT02759094|Experimental|Treatment with RefluxStop device|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ at all time
16577950|NCT02759081|Active Comparator|water exchange|The air was turned off at the beginning of colonoscopy. Water was infused and suctioned at the same time during insertion. The air was turned on when the colonoscope reached the cecum.
16577951|NCT02759081|Experimental|cap-assisted water exchange|Cap was mounted to the tip of the colonoscope when water exchange was performed.
16577952|NCT02759068|Experimental|patients behavior|Behavior (motor reaction) to stimuli (sounds and odors)
16577953|NCT02759068|Active Comparator|healthy volunteers behavior|Behavior (motor reaction) to stimuli (sounds and odors)
16577954|NCT02759055|Experimental|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
16577955|NCT02759055|No Intervention|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
16577956|NCT02759029|Active Comparator|Susceptibility-guided group|Drugs according to antimicrobial susceptibility-guided treatment
16577957|NCT02759029|Sham Comparator|triple therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
16577958|NCT02759029|Sham Comparator|concomitant therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
16577959|NCT02759016|Experimental|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
16577960|NCT02759003|Active Comparator|inpatients group|"In-hospital nightime NIV initiation. For the inpatients Group, NIV was initiated in the respiratory wards of the two hospitals and continued during night for a minimum of 4 hours/night.
~Inpatients had a 24-h availability of health staff care. During the night, they had nurses and physicians available on-hand."
16577961|NCT02759003|Experimental|outpatients group|"Home nightime NIV initiation. For the outpatients group, diurnal NIV was initiated during a scheduled visit in a hospital dedicated room(at least 4 hours/day of care), the trial proceeded at home during the night with a personal caregiver.
~A minimum of 4 hours/night was required. No support during the night was provided to these patients."
16577962|NCT02758990|Experimental|Predictions: BMI vs. Broccoli|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577963|NCT02758990|Experimental|Predictions: BMI vs. Caffeine|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577964|NCT02758990|Experimental|Predictions: BMI vs. Coffee|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577965|NCT02758990|Experimental|Predictions: BMI vs. Spinach|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577966|NCT02758990|Experimental|Predictions: BMI vs. Vitamin A|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577967|NCT02758990|Experimental|Predictions: BMI vs. Vitamin C|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577968|NCT02758990|Experimental|Predictions: Headache vs. Vitamin B6|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577969|NCT02758990|Experimental|Predictions: Headache vs. Vitamin C|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16578018|NCT02758743|Placebo Comparator|Placebo|Identical in appearance with Acetium lozenge, placebo lozenges will be used in the same manner as in experimental arm.
16577970|NCT02758990|Experimental|Predictions: Headache vs. Nicotinamide|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577971|NCT02758990|Experimental|Predictions: Headache vs. Axon Eyewear|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577972|NCT02758990|Experimental|Predictions: Rhinitis vs Broccoli|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577973|NCT02758990|Experimental|Predictions: Rhinitis vs Caffeine|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577974|NCT02758990|Experimental|Predictions: Rhinitis vs Chocolate|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577975|NCT02758990|Experimental|Predictions: Rhinitis vs Coffee|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577976|NCT02758990|Experimental|Predictions: Rhinitis vs Vitamin A|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577977|NCT02758990|Experimental|Predictions: Insomnia vs Axon Eyewear|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577978|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin A|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577979|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin E|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577980|NCT02758990|Experimental|Predictions: Insomnia vs Nicotinamide|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577981|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin D3|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577982|NCT02758990|Experimental|Predictions: Joint pain vs Broccoli|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577983|NCT02758990|Experimental|Predictions: Joint pain vs Caffeine|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577984|NCT02758990|Experimental|Predictions: Joint pain vs Coffee|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577985|NCT02758990|Experimental|Predictions: Joint pain vs Spinach|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
16577986|NCT02758977|Experimental|ALPPS|"ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS)
~Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) is performed according to local practice in the respective centers. Preconditions to participation are experience with major liver resections and documentation of having performed at least 5 ALPPS cases prior to participation due to the learning curve with this quite complex procedure.
~The amount of transsection (in-situ split/liver partition) in Step 1 is left to the participating center, no minimal % of transsection is specified."
16577987|NCT02758977|Active Comparator|TWO STAGE HEPATECTOMY|"TWO STAGE HEPATECTOMY (TSH)
~Two-Stage Hepatectomy is defined as:
~Partial resection + portal vein ligation (RES PVL)
~Partial resection + secondary portal vein embolization (RES PVE). Followed by (extended) hemihepatectomy after an interval to induce hypertrophy of the liver.
~Conventional Two- Stage Hepatectomies will be standard procedures of the centers participating in the study."
16577988|NCT02758951|Experimental|Perioperative systemic therapy and CRS-HIPEC|"At the discretion of the treating physician, perioperative systemic therapy consists of either four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by either four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four (FOLFOX/FOLFIRI) neoadjuvant cycles.
~CRS-HIPEC is performed according to the Dutch protocol in all study centres."
16577989|NCT02758951|Active Comparator|Upfront CRS-HIPEC alone|CRS-HIPEC is performed according to the Dutch protocol in all study centres.
16577990|NCT02758938|Experimental|Patient Subjects|Patients that are part of the UW LUTD Program (n=30) will undergo 3 weekly biofeedback sessions each lasting 1 hour. All interactive biofeedback sessions will be conducted by American Family Children's Hospital nurses that are experienced in standard biofeedback techniques. After the patient has completed all of the biofeedback sessions, he/she will complete a feedback form about their satisfaction with the device.
16577991|NCT02758938|Experimental|Biofeedback Nurse Subjects|"The nurses (n=3) involved in the biofeedback portion of the UW LUTD Program will undergo a Nurse Training Session where they will be asked to think aloud while completing an outlined scenario. Their feedback will be used to update the software to make it more user friendly. After the session, they will be asked to complete the System Usability Scale (SUS). Additionally, after guiding patients through biofeedback sessions using the new software, they will be asked to complete the Nurse Feedback Form."
16577992|NCT02758938|Experimental|Biofeedback Physician Subject|The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
16577993|NCT02758938|Experimental|Focus Group Subjects|A Focus Group session will involve the physician involved in this study, an advisor on the project and staff involved in the project as well as three random individuals outside of the project (n=7). These individuals will provide feedback on the software that will be used to improve the software.
16577994|NCT02758925|Experimental|DLBCL patients|they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles
16577995|NCT02758912|Experimental|arm 1, Cardionat®|oral intake of study drug capsules at a dose of 1 g per day for 3 weeks.
16577996|NCT02758912|Experimental|arm 2, Cardionat®|oral intake of study drug capsules at a dose of 2 g per day for 3 weeks.
16577997|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
16577998|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
16577999|NCT02758886|Experimental|Stress reduction method|Participants randomized into the PYSA group engaged in a 10 minute direct interaction with the animals (dogs and cats) of the Pet Your Stress Away program
16578000|NCT02758886|Placebo Comparator|Control|Participants randomized into the Control group watched a 10 minute slide show of dog and cat photos
16578001|NCT02758886|No Intervention|Non-treatment|Participants randomized into the No-treatment group silently waited for 10 minutes without engaging in any physical or electronic social interactions.
16578002|NCT02758886|Placebo Comparator|Observation|Participants randomized into the observation group observed 10 minutes of others in the general PYSA program petting cats and dogs, while they 'waited in line' for there turn.
16578003|NCT02758873|Experimental|Personalised Medicine|If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.
16578004|NCT02758873|Active Comparator|Standard care|If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.
16578005|NCT02758847|Other|Critical Limb Ischemia (CLI) and Tissue Loss|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent
16578006|NCT02758821|Other|CRP-Control|The health care provider will manage the patient using standard guidelines. No CRP will be measured onsite
16578007|NCT02758821|Other|CRP-A|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
16578008|NCT02758821|Other|CRP-B|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
16578009|NCT02758795|Placebo Comparator|CONTROL|A placebo nutrient drink with no anti-inflammatory bioactivity (measure by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
16578010|NCT02758795|Active Comparator|NUTRIENT|A nutrient drink with confirmed anti-inflammatory bioactivity (measured by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
16578011|NCT02758782|Active Comparator|Golimumab monotherapy|Treatment with 50 mg Golimumab subcutaneous once monthly
16578012|NCT02758782|Active Comparator|Golimumab combined with Celecoxib|Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day
16578013|NCT02758769||ORENCIA with Exposure|ORENCIA with Exposure
16578014|NCT02758756|Active Comparator|Massage|Subjects assigned to Arm 1 will receive two massage treatments approximately two weeks apart.
16578015|NCT02758756|Experimental|Two Reiki Tx|Subjects assigned to Arm 2 will receive two Reiki treatments approximately two weeks apart.
16578016|NCT02758756|Experimental|Four Reiki Tx|Subjects assigned to Arm 3 will receive four Reiki treatments approximately 1 week apart.
16578019|NCT02758730|Experimental|AFFITOPE® PD01A + Adjuvant|3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
16578020|NCT02758730|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks
16578021|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
16578022|NCT02758704|Experimental|High-Stress (HS)|In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
16578023|NCT02758704|Active Comparator|Low-Stress (LS)|In the LS environment, there will be absence of audio (alarms), physical (third-party supervisor, nurse and respiratory therapist) and situational (unstable infant) stressors.
16578024|NCT02758691|Experimental|Intranasal Insulin|Healthy participants will self-administer 20 IU of Humulin® R U-100 with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
16578025|NCT02758691|Placebo Comparator|Saline Placebo|Healthy participants will self-administer a saline solution with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
16578026|NCT02758678||1-patients with operating tumor|"1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin.
~Will be compared concentration of P-selectin in 3 groups of patients.
~Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
16578027|NCT02758678||2-patients with advanced desease.|"2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy);
~In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:
~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above"
16578028|NCT02758678||3-patients with inoperable disease|"In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:
~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
16578029|NCT02758665|Experimental|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
16578030|NCT02758639|Experimental|W & W Intervention|Wonders & Worries Psychosocial intervention is a 6 week group or individual sessions for children who have a parent with cancer focusing on psycho-educational information about cancer, treatment and its side effects, feelings expression, positive coping strategies, and family communication about the illness.
16578031|NCT02758639|Other|Wait list control|Wait list group will complete baseline, 6 week and 8 week follow up measures and then will be enrolled to receive W & W intervention.
16578032|NCT02758626|Active Comparator|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
16578033|NCT02758626|Active Comparator|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
16578034|NCT02758613|Experimental|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
16578035|NCT02758613|Experimental|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
16578036|NCT02758613|Experimental|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
16578037|NCT02758613|Placebo Comparator|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
16578038|NCT02758600|Experimental|LVEF < 45%|Patients with left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
16578039|NCT02758600|Experimental|LVEF > 45%|Patients without left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
16578040|NCT02758587|Experimental|Dose - escalation|"Does-escalation in an all-comers phase I population, with treatment-refractory advanced solid malignancies, unselected by tumour type. Two cohorts of up to evaluable 6 patients in each:
~Cohort 1: 200mg (IV) pembrolizumab every 3 weeks; plus 200mg (oral) defactinib twice daily
~Cohort 2: 200mg (IV) pembrolizumab every 3 weeks; plus 400mg (oral) defactinib twice daily
~Interventions:
~Drug: Defactinib
~Drug: Pembrolizumab"
16578041|NCT02758587|Experimental|Pancreatic|Pancreatic expansion for response assessment (single arm). Optional paired biopsies prior to treatment and after 14 days of treatment. All would have concurrent therapy with pembrolizumab + defactinib (VS-6063) from the start (c.f. NSCLC & mesothelioma expansions below). 15 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 6
16578042|NCT02758587|Experimental|NSCLC|NSCLC paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and after around 14 days of treatment. 1:1 randomised split of patients having their mandatory on-treatment biopsy after concurrent therapy, or after a defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
16578043|NCT02758587|Experimental|Mesothelioma|Mesothelioma paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and around 14 days of treatment. 1:1 randomised split of patients having thier on-treatment biopsy after concurrent therapy, or after defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
16578044|NCT02758574|Active Comparator|CDT without ultrasound acceleration|Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus
16578045|NCT02758574|Experimental|CDT ultrasound accelerated|Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus
16578046|NCT02758561|No Intervention|Standard of care|Standard of care
16578047|NCT02758561|Experimental|Workshop|90 minute workshop on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (POP)
16578048|NCT02758548|Other|Capillary Blood Sampling|Capillary blood sampling, collected as two fingerprick samples with POCT device and two venous samples
16578049|NCT02758535|Experimental|Core needle biopsy with coaxial method|The patients undergo renal biopsy with a coaxial Tru-Cut needle
16578050|NCT02758535|Experimental|Core needle biopsy with noncoaxial method|The patients undergo renal biopsy with a noncoaxial Tru-Cut needle
16578051|NCT02758522|Active Comparator|Once-daily insulin|60% of total dose of insulin as NPH insulin in the once-daily regimen was administered subcutaneously before breakfast. Also, 40% in rapid insulin before meals (every 8 hours).
16578052|NCT02758522|Active Comparator|Twice-daily insulin|60% of total dose of insulin as NPH insulin in the twice-daily regimen it was given before breakfast and before dinner. Also, 40% in rapid insulin before meals (every 8 hours).
16578053|NCT02758522|Active Comparator|Triple-daily insulin|60% of total dose of insulin as NPH insulin in the triple daily regimen it was administered before each meal. Also, 40% in rapid insulin before meals (every 8 hours).
16578054|NCT02758509||PEG/RBV|Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)
16578055|NCT02758509||PEG/RBV+BOC or TVR|Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)
16578056|NCT02758509||IF-DAAs|"Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)
~Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks
~Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)
~Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks
~Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks"
16578057|NCT02758496||ASD Subjects|Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.
16578058|NCT02758496||Healthy Controls|Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group
16578059|NCT02758483|Other|Test diet|"Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
16578060|NCT02758483|Other|Control diet|"Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
16578061|NCT02758470|Experimental|Acetazolamide|Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
16578062|NCT02758470|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
16578063|NCT02758470|Placebo Comparator|Placebo|Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
16578064|NCT02758457|Active Comparator|metal-based restorations|single crown with a metal framework and pressed ceramic
16578065|NCT02758457|Experimental|zirconia-based restorations|single crown with a zirconia framework and pressed ceramic
16578066|NCT02758444|Active Comparator|Micronutrient Powder (MNP) + 15 mg Zn|1 sachet of Micronutrient Powder (MNP) + 15 mg Zn will be added to a single meal on study day 8
16578067|NCT02758444|Active Comparator|MNP + 10 mg Zn|1 sachet of MNP + 10 mg Zn will be added to a single meal on study day 8
16578068|NCT02758444|Active Comparator|MNP + 5 mg Zn|1 sachet of MNP + 5 mg Zn will be added to a single meal on study day 8
16578069|NCT02758444|Placebo Comparator|MNP without Zn|1 sachet of MNP without Zn will be added to a single meal on study day 8
16578073|NCT02758418|Experimental|Online Computerized Program group.|"Intervention group that uses TAO program."
16578074|NCT02758418|No Intervention|Waiting list control group.|Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
16578075|NCT02758405|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16578076|NCT02758405|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16578077|NCT02758405|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16578078|NCT02758405|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16578079|NCT02758392|Experimental|Dose 1: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.
16578080|NCT02758392|Experimental|Dose 2: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.
16578081|NCT02758392|Experimental|Dose 3: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.
16578082|NCT02758392|Experimental|Dose 4: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.
16578083|NCT02758392|Experimental|Dose 5: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.
16578084|NCT02758392|Experimental|Dose 6: JNJ-61178104 OR Placebo SC|Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.
16578085|NCT02758379|Experimental|Shockwave Coronary Lithoplasty System|Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
16578086|NCT02758366|Experimental|Doxorubicin|"Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.
~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)
~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).
~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).
~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day."
16578087|NCT02758353|Experimental|Community distribution of SP|All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.
16578088|NCT02758340|Experimental|M=misoprostol|Patients who would receive Only oral misoprostol{(50 micrograms) tab cytotec ¼ tablets (Searle)}. All patients in this group will be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes). If labor is not established within 4 hours of the administration of the fourth dose, induction will be considered to be failed
16578089|NCT02758340|Experimental|M+F=MISOPROSTOL+FOLEY'S BALLOON CATHETER|All patients in this group will be explained the technique of foley's catheter ballooning and informed consent will be taken. The cervix will be visualized with the help of Cusco's speculum. The balloon will be inflated with about 30 cc of sterile water. The catheter will be pulled down to bring the balloon into the cervical canal and will be tapped around the thigh. Patients will also be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes).
16578090|NCT02758327|Experimental|TheraTears Lubrication Drop|TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
16578091|NCT02758314||Cases / NSCLC patients|"Evaluation of PD-1/PDL-1 expression.
~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 150 NSCLC, free treatment by flow cytometry.
~Evaluate the expression of PD-1 / PD-L1 in tumor tissue obtained by biopsy of patients with NSCLC by immunohistochemistry.
~The patients for the enrollment have to be diagnosed with advanced Non-Small Cell Lung Adenocarcinoma (clinical stages IIIA, IIIB and IV), treated at the Instituto Nacional de Cancerología (INCan) who had not received radiotherapy and / or chemotherapy prior to obtaining samples to analyze. ECOG performance status 0-2 and present evidence of measurable disease."
16578092|NCT02758314||Control / Healthy subjects|"Evaluation of PD-1/PDL-1 expression.
~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 50 samples, by flow cytometry.
~Healthy subjects blood cells will be obtained from the blood bank at the Instituto Nacional de Cancerología (INCan)"
16578093|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
16578094|NCT02758288||New Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach
16578095|NCT02758288||Standard Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach
16578276|NCT02757144|Active Comparator|Cohort 7-10: Esomeprazole|Nexium®, orally, repeated dose administration(for 7days)
16578096|NCT02758275|Experimental|Teaching: Individual (5606)|People will receive an education session per month for a period of six months with an average duration of 30 minutes. These will be performed by nurses outside the collection of phase base line and follow-up measurements, previously trained for the purpose.
16578097|NCT02758275|No Intervention|Usual care|People will continue to receive usual care in the health center where they usually assist to medical controls.
16578098|NCT02758262|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the duration of the experimental session.
16578099|NCT02758262|Placebo Comparator|Noninvasive brain stimulation: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of the experimental session.
16578100|NCT02758249|Active Comparator|sevoflurane|patients under sevoflurane anesthesia
16578101|NCT02758249|Active Comparator|propofol|patients under propofol anesthesia
16578102|NCT02758223|Experimental|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
16578103|NCT02758210|Experimental|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
16578104|NCT02758197|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
16578105|NCT02758197|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
16578106|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
16578107|NCT02758184|No Intervention|Control Group|Patients who are randomized not to receive ROTEM
16578108|NCT02758171|Experimental|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
16578109|NCT02758171|Active Comparator|Empagliflozin+Linagliptin single tablets|
16578110|NCT02758158|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
16578111|NCT02758145|Active Comparator|Influenza vaccine information (G1)|During the recruitment visit at the occupational medicine unit between the 04/29/16 and the 10/31/16, the workers in this group (G1) in addition to their recruitment visit, will benefit from a short intervention given by the nurse concerning the flu, the advantages of the flu vaccination, and how they can be vaccinated in the institution. The nurse also transmits an information sheet concerning the benefits of the vaccination. 2 weeks after the beginning of the next flu vaccination campaign, they will receive a reminder letter to encourage vaccination.
16578112|NCT02758145|No Intervention|No information (G2)|Workers in the control group (G2) receive no intervention, only recruitment visit.
16578113|NCT02758132|Active Comparator|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
16578114|NCT02758132|Active Comparator|Standard of Care|Denosumab plus enzalutamide alone
16578115|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
16578116|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
16578117|NCT02758106|Active Comparator|HFCW oscillation|"HFCWO was performed using a Vest Airway Clearance System Model 105 (Hill-Rom, St. Paul, Minnesota). HFCWO was applied to each subject at a frequency of 10-12 Hz and a pulse pressure setting of 1-2 selected for 15 minutes. The patients receiving HFCWO were placed in a semi-upright sitting position. Following HFCWO, suction was performed immediately via an endotracheal tube.
~Changes to the initial ventilator settings during HFCWO were recorded before and at 5, 10 and 15 minutes. The variables included peak airway pressure, positive-end expiratory pressure, respiratory rate, fraction of inspired oxygen, inspiratory time, and sensitivity settings. Following HFCWO, suction was performed immediately via an endotracheal tube."
16578118|NCT02758106|Placebo Comparator|placebo intervention|the patients undergoing CCPT received cup-hand percussion with the hands positioned 3 inches from the chest, striking the chest with a waving movement while they were placed in right and left decubitus positions for 5-10 minutes each. Following CCPT, suction was performed immediately via an endotracheal tube.
16578119|NCT02758093|Experimental|Speed of Processing Training (10 hours)|Participants randomized to this arm will receive 10 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
16578120|NCT02758093|Experimental|Speed of Processing Training (20 hours)|Participants randomized to this arm will receive 20 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
16578121|NCT02758093|Sham Comparator|Internet Navigational (10 hours)|In this group, participants will receive 10 hours of Internet Navigation Training. Specifically, participants will be given instructional materials and exercises on how to navigate the Internet. For more computer savvy participants, they will be directed to the Thinks.com website. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
16578122|NCT02758080|Experimental|Matched|A molecular profile is identified using next generation sequencing. A participant in this arm is assigned to early clinical trial studying targeted agent, which is anticipated to have the best response rate.
16578123|NCT02758080|Other|Not matched|A participants in this arm is assigned to a clinical trial at physician's choice.
16578124|NCT02758067|Experimental|brexpiprazole|
16578125|NCT02758067|Experimental|risperidone|
16578126|NCT02758054|No Intervention|Usual Care|Participants will experience standard practice for lung cancer early detection.
16578127|NCT02758054|Experimental|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
16578128|NCT02758041|Experimental|Sebacia Microparticles|
16578129|NCT02758028|Other|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.
~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
16578130|NCT02758015|Active Comparator|Standardized Meal|Standardized meal given to patients.
16578131|NCT02758015|Experimental|Beatine PO (by mouth) 1500mg|Betaine (natural supplement)
16578132|NCT02758015|Experimental|Betaine PO (by mouth) 3000mg|Betaine (natural supplement)
16578133|NCT02758015|Experimental|Betaine PO (by mouth) 4500mg|Betaine (natural supplement)
16578134|NCT02758002|Experimental|Firm ablation for transitional AF rotors|All subjects will undergo this ablation, in addition to their standard PVI and Firm ablation for sustained AF rotors.
16578135|NCT02757989|Experimental|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
16578136|NCT02757989|No Intervention|Patients without donor|Patients without a matched donor
16578137|NCT02757976|Active Comparator|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging
16578138|NCT02757976|Experimental|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
16578139|NCT02757963|Other|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS >=8 and/or BPE/BPO questionnaire >=3 with a PSA >=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
16578140|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
16578141|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
16578142|NCT02757937|Experimental|Health & Wellness Website|Subjects will receive access to an interactive health & wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
16578143|NCT02757937|Other|Control Arm|Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
16578144|NCT02757924|Experimental|Infant formula supplemented with prebiotics|infant formula powder, feed ad libitum
16578145|NCT02757911|Experimental|open label|X vivo gene therapy
16578146|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
16578147|NCT02757885|Other|Bone Marrow Donor|Participants who are related marrow donors and are 2-4 (out of 8) human leukocyte antigen (HLA) antigen mismatched and towards whom the recipient does not have donor specific antibodies.
16578148|NCT02757885|Experimental|Bone Marrow Recipient|Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) matched donor.
16578153|NCT02757859|Active Comparator|Arm I (EIPL-S)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal saline EIPL-S lavage 10 times over 15 minutes.
16578154|NCT02757859|Active Comparator|Arm II (EIPL-D)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal distilled water EIPL-D lavage 10 times over 15 minutes
16578155|NCT02757859|Sham Comparator|ARM III (NO LAVAGE)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
16578156|NCT02757833|Other|Late Life Depressed Arm|Participants in the Late Life Depressed arm will have a confirmed diagnosis of late-life depression.
16578157|NCT02757833|Other|Healthy Control Arm|Participants in the Healthy Control Arm will have no history of mental illness.
16578158|NCT02757820|Active Comparator|LMA classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
16578159|NCT02757820|Active Comparator|I-gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
16578160|NCT02757820|Active Comparator|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
16578161|NCT02757807|Experimental|Utilization of Serenita for Relaxation|Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
16578162|NCT02757794|Active Comparator|Cognitive remediation parents|
16578163|NCT02757794|Placebo Comparator|Remediation standard|
16578164|NCT02757781|No Intervention|Control Group|Group of healthcare professionals that NOT receive the intervention (community of practice)
16578165|NCT02757781|Experimental|Intervention group|Group of healthcare professionals that receive the intervention (community of practice)
16578166|NCT02757768|Experimental|Mirabegron|Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
16578167|NCT02757768|Placebo Comparator|Placebo|Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
16578168|NCT02757755|Experimental|Cohort 10^8|AB-SA01 (10^8) and Placebo
16578169|NCT02757755|Experimental|Cohort 10^9|AB-SA01 (10^9) and Placebo
16578170|NCT02757742||Non-ischemic cardiomyopathy|Non-ischemic cardiomyopathy patients with baseline cardiac magnetic resonance LVEF≤35%
16578171|NCT02757729|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 8 weeks
16578172|NCT02757729|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 8 weeks
16578173|NCT02757729|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 8 weeks
16578174|NCT02757729|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 8 weeks
16578175|NCT02757716|Other|Sleeve Gastrectomy|Obese patients who undergo sleeve gastrectomy fill in questionnaire
16578176|NCT02757716|Other|Roux-en-Y-Gastric Bypass|Obese patients who undergo roux-en-y-gastric bypass fill in questionnaire
16578177|NCT02757716|Other|One anastomosis-Gastric Bypass|Obese patients who undergo one anastomosis gastric bypass fill in questionnaire
16578178|NCT02757703|Active Comparator|somatostatin group|Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.
16578179|NCT02757703|Placebo Comparator|terlipressin group|Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.
16578180|NCT02757690|Active Comparator|2-dimenasional distal pancreatectomy|device: 2 dimensional laparoscopy of Olympus
16578181|NCT02757690|Experimental|3-dimenasional distal pancreatectomy|device : 3 dimensional laparoscopy of Olympus
16578182|NCT02757677||Longitudinal arm|Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
16578183|NCT02757677||24-h Intraocular pressure (IOP) arm|Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
16578184|NCT02757677||Surgery arm|Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients
16578185|NCT02757664|Active Comparator|Shock wave plus eccentric exercises|Shock wave therapy associated with eccentric exercises rehabilitation program.
16578186|NCT02757664|Placebo Comparator|Placebo plus eccentric exercises|Placebo associated with eccentric exercises rehabilitation program.
16578277|NCT02757144|Experimental|Cohort 9: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
16578187|NCT02757651|Experimental|Radiotherapy + radiation sensitizer|Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer
16578188|NCT02757651|No Intervention|Radiotherapy alone|Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone.
16578189|NCT02757638|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
16578190|NCT02757638|Experimental|Obese subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~3 study days (one baseline, one pre-surgery, one post-surgery): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
16578191|NCT02757625|Experimental|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
16578192|NCT02757612|Active Comparator|Interventional|"Device Laser diode parameters: spot size of 0.04 mm2, average power (output) of 40 mW and 0.4 J per irradiation point, energy density of 10 J cm2, irradiation time of 10 seconds per point
~1 session per week during 4 session"
16578193|NCT02757612|Sham Comparator|Comparator|"laser probe inactive for similar duration as for the laser diode group; only a beep sound was produced by the laser machine
~1 session per week during 4 session"
16578194|NCT02757599|Other|Top-down (TD)|The group having the transvaginal ultrasound image top-down. During training and transfer test.
16578195|NCT02757599|Other|Bottom-up (BU)|The group having the transvaginal ultrasound image bottom-up. During training and transfer test.
16578196|NCT02757573|Experimental|Hypercarbia|Hypercarbia: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
16578197|NCT02757560|Experimental|SFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
16578198|NCT02757560|Experimental|MUFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
16578199|NCT02757560|Experimental|CARB versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
16578200|NCT02757547|Placebo Comparator|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
16578201|NCT02757547|Active Comparator|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
16578202|NCT02757521|Placebo Comparator|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
16578203|NCT02757521|Experimental|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
16578204|NCT02757508|Active Comparator|Control|Vitamins/minerals-200 mg premix
16578205|NCT02757508|Experimental|Group 1|Vitamins/minerals + Milk Protein (8.75 g)-the milk protein is a skim milk powder with the sugar lactose.
16578206|NCT02757508|Experimental|Group 2|Vitamins/minerals + Milk/plant Protein (8.75g)-the milk protein is a skim milk protein powder and the plant protein is a rice protein concentrate and the sugar lactose.
16578207|NCT02757508|Experimental|Group 3|Vitamins/minerals + Milk Protein (4.38g)-the milk protein is a skim milk protein powder with the sugar lactose.
16578208|NCT02757495|No Intervention|Traditional|This will utilize the traditional method of performance of single dose caudal epidural block
16578209|NCT02757495|Experimental|Caudal dexmedetomidine|In this arm, single dose caudal epidural injection will be done patients in this arm will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%
16578210|NCT02757482|Experimental|intervention|Patient training
16578211|NCT02757482|No Intervention|control|no patient training
16578212|NCT02757469|Experimental|Yasmin|Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.
16578213|NCT02757456|Other|Aerobic Exercise program|Intervention of aerobic exercise
16578214|NCT02757456|Other|Control|no aerobic exercise program
16578334|NCT02756663|Experimental|Arm B: PAN (20mg) + CFZ + Dex|Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
16578215|NCT02757443|Experimental|Phosphocreatine|"Participants randomly assigned to the phosphocreatine arm receive:
~after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);
~together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);
~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;
~immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV"
16578216|NCT02757443|Placebo Comparator|Control|"Participants randomly assigned to the placebo arm receive:
~after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;
~together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);
~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;
~immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes"
16578217|NCT02757417|Active Comparator|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
16578218|NCT02757417|Active Comparator|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
16578219|NCT02757404|Experimental|Ultrasonography guidance|Ultrasonography guidance injection of Meditoxin®.
16578220|NCT02757404|Experimental|Electrical stimulation guidance|Electrical stimulation guidance injection of Meditoxin®.
16578221|NCT02757404|Experimental|Manual needle placement|Manual needle placement injection of Meditoxin®.
16578222|NCT02757391|Experimental|Treatment (CD8 +T cell therapy, pembrolizumab)|Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide IV over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin SC BID on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15.
16578223|NCT02757378|Experimental|Neuroplasticity Education Group|Patients who receive manual physical therapy treatment with a neuroplasticity explanation of the basis for the technique
16578224|NCT02757378|Active Comparator|Biomechanical Education Group|Patients who receive manual physical therapy treatment with a traditional, biomechanical explanation of the basis for the technique
16578225|NCT02757365|Experimental|the NSAIDs group|Patients in the this Group will received the aspirin 100mg qd until the experiment finished
16578226|NCT02757365|Experimental|the antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks
16578227|NCT02757365|Experimental|the NSAIDs+antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks and aspirin 100mg qd until the experiment finished
16578228|NCT02757365|No Intervention|the control group|No treatment
16578229|NCT02757352|Experimental|Q2W Ixekizumab|"Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period.
~Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
16578230|NCT02757352|Experimental|Q4W Ixekizumab|"Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period.
~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44."
16578231|NCT02757352|Placebo Comparator|Placebo|"Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period.
~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
16578232|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 140 female patients with either DID or PTSD ages 18-89
16578233|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
16578234|NCT02757326|Experimental|Phase Ib/II|"For Phase Ib, the planned ABC294640 (Opaganib) doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.
~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
16578235|NCT02757313|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
16578236|NCT02757313|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
16578237|NCT02757300|Experimental|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.
~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
16578238|NCT02757300|Active Comparator|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.
~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
16578239|NCT02757287|Experimental|FSH-CTP + DESOGESTREL|Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation
16578306|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
16578240|NCT02757261|Experimental|Application of Low-level laser therapy.|The intervention will be twelve sessions (two per week). Laser parameters: wavelength - 786.94 nm; conventional tip; energy density - 25 J/cm²; intensity - 1.675 mW/cm²; output power - 70 mW (0.070 W); and exposure time - 20 seconds per point. The point application method will be used with direct contact with the skin (spot beam of 0.04 cm²), following the protocol suggested by Carvalho et al.50 and Venezian et al.44 A potentiometer will be used to determine the mean power of the laser equipment to ensure the safety of the operator.
16578241|NCT02757261|Experimental|Treatment with Occlusal splint.|The intervention will be a maxillary occlusal splint will be used on the maxilla with palatal and occlusal coverage. Following the protocol established by Hachmann et al., the children will only use the splint at night for two months, with weekly adjustments of a quarter turn.46
16578242|NCT02757261|Active Comparator|Placebo laser|Placebo laser will be performed using the same equipment.
16578243|NCT02757261|No Intervention|Children without bruxism|Control group
16578244|NCT02757248|Experimental|Cohort 1|Volasertib 75mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
16578245|NCT02757248|Experimental|Cohort 2|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
16578246|NCT02757248|Experimental|Cohort 3|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
16578247|NCT02757248|Experimental|Cohort 4|Volasertib 150mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
16578248|NCT02757248|Experimental|Cohort -1|Volasertib 50mg/m2 on days 1 and 8 Romidepsin 10mg/m2 on days 1, 8 and 15
16578249|NCT02757235|Active Comparator|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
16578250|NCT02757235|Active Comparator|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
16578251|NCT02757222|Active Comparator|Standard dose|Patients receive a radiation dose of 66Gy in 30 fractions to the planning target volume 1 (PTV1) and 54 Gy in 30 fractions to the PTV2 concurrent with platinum chemotherapy weekly
16578252|NCT02757222|Experimental|Escalated dose|Patients receive a radiation dose of 73.5 Gy in 30 fractions to the boost target volume (BTV), 63Gy in 30 fractions to PTV1 and 54 Gy in 30 fractions to PTV2 concurrent with platinum chemotherapy weekly
16578253|NCT02757209|Active Comparator|Spiromax Inhaler|"Evaluation of correct use of Spiromax inhaler - DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.
~Additional 8 weeks in one subgroup"
16578254|NCT02757209|Active Comparator|Turbohaler inhaler|"Turbohaler® - Symbicort® 160/4.5 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate). Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week.
~Additional 8 weeks in one subgroup"
16578255|NCT02757209|Active Comparator|Diskus Inhaler|"Diskus® inhaler - Seretide Diskus 50/250 mcg ® or 50/500 mcg (50 mcg salmeterol & 250/500 mcg fluticasone propionate). Dose of one inhalation twice a day for 1 week.
~Additional 8 weeks in one subgroup"
16578256|NCT02757196|Experimental|Rituximab plus methylprednisolone|Combination therapy with rituximab （1000mg IV day1, week 3, week 17 , and week 19）plus short-term methylprednisolone (1mg/kg, oral or IV; reduce to 50% of base dose at week 4, then reduce 8mg every 1 week until stopped).
16578257|NCT02757196|Active Comparator|Methylprednisolone|standard dose methylprednisolone alone (1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks).
16578258|NCT02757170|Experimental|I|Thromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
16578259|NCT02757170|Active Comparator|Group II|Thromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
16578260|NCT02757170|Experimental|Group III|Thromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
16578261|NCT02757170|Experimental|Group IV|Thromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
16578262|NCT02757157|Experimental|COPD (normal weight)|People with COPD (BMI 21 kg/m2 to 29 kg/m2)
16578263|NCT02757157|Experimental|COPD (obese)|People with COPD (BMI >/= 30 kg/m2)
16578264|NCT02757144|Experimental|Cohort 1: DWP14012 Amg|DWP14012 Amg, tablets, orally, single dose administration
16578265|NCT02757144|Experimental|Cohort 2: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single dose administration
16578266|NCT02757144|Experimental|Cohort 3: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single dose administration
16578267|NCT02757144|Experimental|Cohort 4: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, single dose administration
16578268|NCT02757144|Experimental|Cohort 5: DWP14012 Emg|DWP14012 Emg, tablets, orally, single dose administration
16578269|NCT02757144|Experimental|Cohort 6: DWP14012 Fmg|DWP14012 Emg, tablets, orally, single dose administration
16578270|NCT02757144|Placebo Comparator|Cohort 1-6: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
16578271|NCT02757144|Active Comparator|Cohort 1-6: Esomeprazole|Nexium® tablets, orally, single dose administration
16578272|NCT02757144|Experimental|Cohort 7: DWP14012 Amg|DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
16578273|NCT02757144|Experimental|Cohort 8: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
16578274|NCT02757144|Experimental|Cohort 9: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
16578275|NCT02757144|Placebo Comparator|Cohort 7-10: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
16578278|NCT02757131|Experimental|Intervention|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the Physical Therapy (PT) staff 3 times daily under the supervision of the dedicated ambulator PCNA.
~The ambulator will be trained by the physical therapy team on how to implement the protocol prior to initiation of the study."
16578279|NCT02757131|No Intervention|Control|"The cohort of patients randomized to usual care will not be seen by the dedicated ambulator, but will not otherwise be restricted in nursing's baseline ability to execute nursing specific recommendations placed by the PT team."
16578280|NCT02757118|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16578281|NCT02757118|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16578282|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
16578283|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
16578284|NCT02757092|Experimental|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
16578285|NCT02757092|Active Comparator|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
16578286|NCT02757079|Experimental|NPC-15 Granule|NPC-15 granule 1 mg, 2 mg or 4 mg once a day, administered orally before going to bed.
16578287|NCT02757066|Experimental|NPC-15 Granules Lower Dose|NPC-15 Granules Lower Dose group which is administered 1mg melatonin
16578288|NCT02757066|Experimental|NPC-15 Granules Higher Dose|NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
16578289|NCT02757066|Placebo Comparator|NPC-15 Placebo Granule|NPC-15 Placebo Granules group which is administered placebo melatonin
16578290|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
16578291|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
16578292|NCT02757040|Experimental|Ibrutinib combined with As2O3|Ibrutinib combined with As2O3
16578293|NCT02757040|Active Comparator|Ibrutinib|Ibrutinib only
16578294|NCT02757027|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16578295|NCT02757027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16578296|NCT02757014|Experimental|Coppertone (BAY987517)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16578297|NCT02756988|Experimental|Coppertone (BAY987704)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16578298|NCT02756975|Experimental|transperineal prostate biopsy with coaxial method|The patients undergo transperineal biopsy with a coaxial Tru-Cut needle (18-gauge Core Biopsy Instrument with a 17-gauge Disposable Coaxial Needle).
16578299|NCT02756975|Experimental|transperineal prostate biopsy with noncoaxial method|The patients undergo transperineal biopsy with a noncoaxial 18-gauge needle.
16578300|NCT02756962|Experimental|Cohort A: HiDAC|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq
~Patients who have clearance of their leukemia-associated mutations, defined as a LAM VAF <2.5% will be assigned to the high-dose cytarabine consolidation (HiDAC) arm.
~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.
~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
16578301|NCT02756962|Experimental|Cohort B: Investigator's choice (HiDAC, AlloSCT)|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq
~Patients who have persistent leukemia-associated mutations, defined as a LAM VAF ≥2.5% will be assigned to the investigator's choice arm.
~Patients assigned to this arm may received either HiDAC or AlloSCT.
~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.
~The source of stem cell product, donor selection, conditioning regimen, graft-versus-host-prophylaxis, and supportive care will be at the discretion of the treatment physician
~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
16578302|NCT02756949|Experimental|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
16578303|NCT02756949|No Intervention|Standard of care|Participants in this arm are randomised to receive standard of care services.
16578304|NCT02756936|Experimental|A Test|Test drug (Daclatasvir zeta)1 tablet contains 60 mg Daclatasvir
16578305|NCT02756936|Active Comparator|B Reference|Reference drug (Clatazev)) 1 tablet contains 60 mg Daclatasvir
16578335|NCT02756663|Active Comparator|Arm C: CFZ + Dex|Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
16578307|NCT02756897|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
16578308|NCT02756884|Experimental|LoFU and aADSC|Low Frequency Ultrasound LFUS will be delivered in a non-sterile manner using a custom modified LFUS combined imaging/therapy probe. Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area after the administration of the low frequency ultrasound
16578309|NCT02756884|Active Comparator|Adipose Derived Stem Cells|Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area without the administration of the low frequency ultrasound
16578310|NCT02756871|Experimental|Online guided self-help intervention|CBT based online guided self-help intervention. Intervention can be found at www.overcomingperfectionism.co.uk
16578311|NCT02756871|No Intervention|Control|No intervention.
16578312|NCT02756858|Experimental|ANAVEX2-73 Oral as assigned in ANAVEX2-73-002|
16578313|NCT02756845|Experimental|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to ≤ 21 years). Cohort B1 (age 2 to < 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to ≤ 21 years), Cohort B2 (age 2 to < 12 years).
16578314|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 (T2DM) who received alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) were observed for approximately 6 months.
16578315|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.
16578316|NCT02756806|Experimental|Picosecond Q-switched Laser|Treatment with investigational wavelengths of the Cutera enlighten laser for tattoo removal.
16578317|NCT02756793|Active Comparator|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:
~Continue with current systemic agent(s)
~Observation
~Switch to next-line treatment"
16578318|NCT02756793|Experimental|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
16578319|NCT02756780|Experimental|Tenovus Cancer Choir|Participants will be asked to attend 12 weeks of weekly choir rehearsals lasting approximately 1 hour. Following the first 12 weeks, participants will no longer be asked to attend rehearsals, but are welcome to do so. Whether or not they do and how many they attend will be measured as an outcome variable to assess whether initial 3-month involvement leads to long-term engagement.
16578320|NCT02756780|No Intervention|Control (no choir) Group|If eligible participants are unable to make the dates and times or live too far away but fulfil all the same criteria (including expressing an interest in singing) they will become part of the control group. This will involve the same data collection as the Cancer Choir Group but participants will not sing in a weekly choir.
16578321|NCT02756767||Completed subjects|Subjects will complete patient-reported outcomes assessments during and after radiation therapy.
16578322|NCT02756754|Experimental|Radiofrequency ablation|"Radiofrequency ablation (RFA) is a minimally invasive technique for eliminating both primary tumors and metastases.
~The needles that will be used are monopolar RFA, the LeVeen™ Needle Electrode Family with a generator RF 3000 by Boston Scientific. The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored."
16578323|NCT02756741|Active Comparator|STANDARD DOSE|Albumin 1.5gm/kg on day 1 and 1gm/kg on day 3
16578324|NCT02756741|Placebo Comparator|LOW DOSE|Albumin 20g/d for 5 days
16578325|NCT02756728|Active Comparator|HDM+ASCT|Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
16578326|NCT02756728|Experimental|BI-505|Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation
16578327|NCT02756715|Active Comparator|propofol group|The patient who anesthetized by using propofol.
16578328|NCT02756715|Active Comparator|Desflurane group|The patient who anesthetized by using sevoflurane.
16578329|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
16578330|NCT02756689|Active Comparator|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
16578331|NCT02756689|Active Comparator|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
16578332|NCT02756676|Experimental|Rehabilitative treatment (MIRT)|Rehabilitative treatment MIRT consist in daily sessions of: motor treatment, occupational therapy and language speech therapy
16578333|NCT02756663|Experimental|Arm A: PAN (10mg) + CFZ + Dex|Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
16578336|NCT02756650|Experimental|Canakinumab|Canakinumab was administered monthly
16578337|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
16578338|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
16578339|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
16578340|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
16578341|NCT02756611|Experimental|Venetoclax|"Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation.
~In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, determined on a case by case basis."
16578342|NCT02756598|Active Comparator|Sufentanil I|"Randomized arm moderate sufentanil I: bolus 1 microgram/kg propofol I: infusion 0.03 mg/kg/min"
16578343|NCT02756598|Active Comparator|Sufentanil II|"Randomized arm low sufentanil II bolus 0.5 microgram/kg propofol II: infusion 0.06 mg/kg/min"
16578344|NCT02756585|Other|ct perfusion|All participants will undergo the imaging protocol with CTP of head at the time of initial diagnostic imaging upon hospital arrival.
16578345|NCT02756572|Experimental|Treatment (chemotherapy, HCT)|See Detailed Description
16578346|NCT02756559||sepsis, severe sepsis and septic shock|Septic patients were divided into sepsis, severe sepsis and septic shock
16578347|NCT02756546|No Intervention|Control|Healthy volunteers
16578348|NCT02756546|Active Comparator|Patients|SLE patients further divided into mild and severe patients
16578349|NCT02756533|Experimental|Telemonitoring|Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
16578350|NCT02756533|Placebo Comparator|control|"Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.
~Phone calls to patient during the follow-up like false alerts for the blind procedure."
16578351|NCT02756520||Chronic kidney disease (pre-dialysis)|Observational study: supplemented protein-restricted diet
16578352|NCT02756507|Experimental|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
16578353|NCT02756507|Sham Comparator|wait list|The wait-list is a delayed treatment condition.
16578354|NCT02756494||Ischemic Stroke in Young Adults|Patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the Department of Beijing Chaoyang Hospital between January 1, 2016 and December 31, 2016. All patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain CT or MRI.
16578355|NCT02756494||matched control subjects|The age-, sex-, and time of enrollment-matched control cohort was randomly identified after eliminating the study subjects and those who had been given a diagnosis of any stroke at any time.
16578356|NCT02756481||NVAF Treatment patterns|"Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit.
~Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected:
~Type of treatment, start & stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable
~Type of therapy utilized (monotherapy/combination therapy)
~Total number of therapy changes or switches through the course of treatment
~Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR)
~Routine care (visits per month) by anticoagulation regimen"
16578357|NCT02756468||pts operated for pancreatic cancer|all pts operated of pancreatic resection for cancer in the involved units
16578358|NCT02756455||gastric cancer pts undergoing surgery|all pts receiving gastric resection for cancer, with anastomosis
16578359|NCT02756442|Experimental|pregnant women with gestational diabetes|
16578360|NCT02756442|Active Comparator|pregnant women without gestational diabetes|
16578361|NCT02756429|Experimental|atrial fibrillation|Patients with atrial fibrillation
16578362|NCT02756429|Experimental|Control|Patients without atrial fibrillation
16578363|NCT02756416|Experimental|ASL MRI and MRA|All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
16578364|NCT02756403|Active Comparator|Azithromycin|500 mg of Azithromycin
16578365|NCT02756403|Active Comparator|Doxycycline|200 mg of Doxycycline
16578366|NCT02756403|Active Comparator|Metronidazole|500 mg of Metronidazole
16578367|NCT02756403|Placebo Comparator|Placebo|Inactive Ingredient
16578368|NCT02756390|Experimental|Arm A (Sleep Hygiene & CBTI-CS)|Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions
16578369|NCT02756390|Other|Arm B (Telehealth Pilot of CBTI-CS)|Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.
16578370|NCT02756377|Active Comparator|cetylpyridinium chloride|mouthwash (cetylpyridinium chloride)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
16578371|NCT02756377|Active Comparator|Chlorhexidine mouthwash|mouthwash ( Alcohol-free chlorhexidine)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
16578372|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
16578373|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 4 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
16578374|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 30 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
16578375|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
16578376|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
16578377|NCT02756325|Experimental|MRI|
16578378|NCT02756312|Other|Intravenous anesthesia|Patients will receive total intravenous anesthesia undergoing brain tumor resection.
16578379|NCT02756312|Other|Inhalation anesthesia|Patients will receive volatile inhalational anesthesia undergoing brain tumor resection.
16578380|NCT02756299|Active Comparator|Device and Standard Care|Positive Airway Pressure Device and Standard Support
16578381|NCT02756299|Active Comparator|Device and Educational Care|Positive Airway Pressure Device and Educational Support
16578382|NCT02756286||ADHD: Adults with ADHD|NAT electroencephalography (EEG) test
16578383|NCT02756286||Controls: Healthy adults without ADHD|NAT electroencephalography (EEG) test
16578384|NCT02756273|Experimental|no bridge device|After the ileostomy creation, no bridge device was placed.
16578385|NCT02756273|Active Comparator|bridge device|A bridge device was placed after the stoma creation.
16578386|NCT02756247|Experimental|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.
~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration for 36 cycles, not exceeding 36 months on therapy."
16578387|NCT02756234||Qualifying CTP patients|A convenience sample of all qualifying patients for CTP procedure
16578388|NCT02756221|Experimental|Probiotics|Probiotics capsules, one capsule daily for 90 days.
16578389|NCT02756221|Placebo Comparator|Placebo|Starch capsules, one capsule daily for 90 days
16578390|NCT02756208|Experimental|0.25 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 75 mcg (0.25 mL) FLSC on study days 0, 28, 56 and 168.
16578391|NCT02756208|Placebo Comparator|0.25 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 0.25 mL placebo on study days 0, 28, 56 and 168.
16578392|NCT02756208|Experimental|0.5 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 150 mcg (0.5 mL) FLSC on study days 0, 28, 56 and 168.
16578393|NCT02756208|Placebo Comparator|0.5 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 0.5 mL placebo on study days 0, 28, 56 and 168.
16578394|NCT02756208|Experimental|1.0 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 300 mcg (1.0 mL) FLSC on study days 0, 28, 56 and 168.
16578395|NCT02756208|Placebo Comparator|1.0 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 1.0 mL placebo on study days 0, 28, 56 and 168.
16578396|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
16578397|NCT02756182|Experimental|Urodynamics with AC and WP|Patients underwent a conventional urodynamics study utilizing a single catheter technique
16578398|NCT02756169|Experimental|Intervention|One workshop during pregnancy Support for breastfeeding at immediate postpartum Telephonic support after delivery
16578399|NCT02756169|No Intervention|Control|Standar procedures of neonatal and pregnancy health care at the clinics or hospitals.
16578400|NCT02756143|No Intervention|Control Group|Non- supervised physical exercise program during pregnancy
16578401|NCT02756143|Experimental|Exercise Group|Supervised physical exercise program during pregnancy
16578402|NCT02756130|Experimental|Treatment (birinapant, carboplatin)|Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16578403|NCT02756117|Experimental|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at one study visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of L-lysine (10 g) in 100 ml water. This amount of lysine is equivalent to that which is found in a 10oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of 10 ml/hr to flush the canula prior to each blood draw.
~All subjects will undergo the same procedures and interventions."
16578404|NCT02756104|Other|Volunteers|Healthy People on each collecting blood for phenotyping Tcells
16578405|NCT02756104|Other|Patients with ALS|"Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.
~The patients who are deficient in Vitamin D will have supplementation in vitamin D"
16578406|NCT02756078|Active Comparator|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
16578407|NCT02756078|Active Comparator|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
16578408|NCT02756065||Control|Individuals between 18-30 years old No diagnosis of Bipolar Disorder or Schizophrenia No intervention used
16578409|NCT02756065||Bipolar Disorder|Individuals between 18-30 years old Diagnosis of Bipolar Disorder No intervention used
16578410|NCT02756065||Schizophrenia|Individuals between 18-30 years old Diagnosis of Schizophrenia or Schizoaffective Disorder No intervention used
16578411|NCT02756052|Sham Comparator|Medical Student - Sham tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).
~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
16578412|NCT02756052|Sham Comparator|General Surgery Resident - Sham tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).
~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
16578413|NCT02756052|Experimental|Medical Student - Anodal tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).
~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
16578414|NCT02756052|Experimental|General Surgery Resident - Anodal tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).
~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
16578415|NCT02756026|Experimental|Micronutrient supplementation|"On day 3, all mothers are given a commercial multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
~On day 4, all mothers are given two commercial multiple micronutrient supplements (Nutri-Fem) manufactured by Thorne, containing twice the Recommended Dietary Intake (RDA)."
16578416|NCT02756013|Experimental|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
16578417|NCT02756000|Experimental|complete PCI at initial hospitalization|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session during initial hospitalization for ST elevation myocardial infarction
16578418|NCT02756000|Experimental|complete PCI after 30 days|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session after 30 days from initial hospitalization for ST elevation myocardial infarction
16578419|NCT02756000|Active Comparator|Dobutamine stress testing|Revascularization by PCI or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using Dobutamin stress echocardiography
16578420|NCT02755961|No Intervention|Control group|No intervention was performed
16578421|NCT02755961|Experimental|Education group|Dietary education and education on phosphate binder use. Pharmacists instructed patients about how to take phosphate binders properly. Dietitians educated on dietary phosphate restriction.
16578422|NCT02755948|Experimental|RSV A Memphis 37|Half the participants will be inoculated with RSV Memphis 37 10(4) plaque forming units (PFU) in 1 milliliter (mL) 25% sucrose/Dulbecco's Modification of Eagle's Medium (DMEM) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
16578423|NCT02755948|Experimental|Influenza A/California/04/2009|Half the participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
16578424|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
16578425|NCT02755922|Experimental|Fractures with Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.
16578426|NCT02755922|No Intervention|Fractures without Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site.
16578427|NCT02755909|Other|Subjects|Pra-anesthetic education given to the subjects includes the anatomy of a normal heart, normal blood circulation, anatomy and pathophysiology of the disease in the respected subject, surgery procedures needed, anesthetic procedures needed for the surgery, and cardiopulmonary bypass procedures. Education and discussion were given repeatedly until subjects could repeat the materials given correctly.
16578428|NCT02755896|Other|Arm 1 - 600 cGY x 5 fractions|Patients will receive 600 cGY x 5 fractions of radiation therapy over 5 consecutive days.
16578429|NCT02755896|Other|Arm 2 - 800 cGY x 3 fractions|Patients will receive 800 cGY x 3 fractions of radiation therapy every other day for 3 days.
16578430|NCT02755883|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
16578431|NCT02755883|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
16578432|NCT02755870|Experimental|CNM-Au8|"CNM-Au8 is an orally administered, clean-surface gold nanocrystal suspension drug. It is atomically clean-surface elemental nanocrystals, free of any residual surface chemicals or surface-capping agents.
~CNM-Au8 15, 30, 60, 90mg as an oral suspension"
16578433|NCT02755870|Placebo Comparator|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
16578435|NCT02755844|Experimental|Olaparib, metformin and metronomic cyclophosphamide|"Phase 1: Dose escalation scheme: a continual reassessment method (CRM) will be used to guide inclusion of patients in drug dose levels pre-specified based on observations of dose-limiting toxicity.
~Phase 2 (expansion of cohort): once RP2D will be determined, additional patients will be enrolled, in order to obtain preliminary data about efficacy in a 2 stage Simon's design."
16578436|NCT02755831|Experimental|Sleep Study + CPAP group|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
16578437|NCT02755831|Other|Standard Prenatal Care group|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
16578438|NCT02755818||control|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
16578439|NCT02755818||chronic renal disease (CKD3b)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
16578440|NCT02755818||chronic renal disease (CKD4)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
16578441|NCT02755818||chronic renal disease (CKD5)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
16578442|NCT02755805|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
16578443|NCT02755805|Placebo Comparator|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
16578444|NCT02755792|Experimental|Calligraphy Training|This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
16578445|NCT02755792|Active Comparator|iPad Training|This group receives an iPad training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
16578446|NCT02755766||Clubfeet|Babies, ages 0-1, with a diagnosis with clubfoot or clubfeet who are beginning treatment with foot abduction bracing following casting treatment.
16578447|NCT02755766||Adolescent Idiopathic Scoliosis|Patients, ages 10-14, with a diagnosis of AIS who are beginning treatment with TLSO (initial bracing).
16578448|NCT02755766||Guardians (CF babies)|Clubfoot patients' guardians.
16578449|NCT02755753|Experimental|Study Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
~Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
16578450|NCT02755753|Placebo Comparator|Control Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
~Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
16578451|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
16578452|NCT02755727|Experimental|Platelet Rich Plasma injection|"In the outpatient setting a sample of venous whole blood will be taken from the patient (40mls), from the antecubital fossa using standard phlebotomy techniques. The Angel™ system will be in the available also in the outpatient clinic and will be used to separate the blood to yield a PRP sample (approximately 15 minutes preparation time). The PRP sample is then injected into the common extensor origin.
~2 injections will be used per patient over 2 weeks."
16578453|NCT02755727|Active Comparator|Open Surgical Release|Standardised surgical technique based on the Nirschl technique will be used. The patient will then have a small scar centred over the lateral epicondyle and the plane opened between ECRL (Extensor Carpi Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the damaged ECRB (Extensor Carpi Radialis Brevis) tendon. The amount of abnormal tendon will be documented and excised. EDC will also be inspected and any abnormal tissue documented then excised. The footprint of the excised ECRB +/- EDC is cleared of soft tissue and the bone scored with an osteotome to promote bleeding. The interval is closed with suture material and the skin wound closed.
16578454|NCT02755714|No Intervention|No Atrovent ®|NO INTERVENTION: The patient will not receive Ipratropium bromide spray (MDI) 20 μg ,(Atrovent ®) prior to CLE testing
16578455|NCT02755714|Experimental|Atrovent ®|INTERVENTION: Ipratropium bromide spray (MDI) 20 μg (Atrovent ®) prior to CLE testing
16578456|NCT02755701|Experimental|BCAA group|Branched-chain amino acid, 4.15g, Tid
16578457|NCT02755701|Placebo Comparator|Placebo group|Placebo, 4.15g, Tid
16578458|NCT02755688|Experimental|Thoracoscopic surgical ablation|Pulmonary vein isolation, ganglionic plexi ablation, left atrial appendage exclusion
16578459|NCT02755688|Active Comparator|Catheter ablation|Pulmonary vein isolation, linear lines
16578460|NCT02755675|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
16578461|NCT02755662|Active Comparator|Narval O.R.M CC™|First mandibular retention device : Narval O.R.M CC™
16578462|NCT02755662|Active Comparator|Narval O.R.M™ trad|Second mandibular retention device : Narval O.R.M TRAD™
16578490|NCT02755428|Experimental|retinal pigment epithelium transplantation|Subretinal transplantation of human embryonic stem cell derived retinal pigment epitheliums.
16578491|NCT02755415|Active Comparator|Static Standing Table Training|Patients in this group will receive standard hospital based rehabilitation as well as static standing table training
16578804|NCT02753335|Experimental|Desensitization|Tactile stimulation of the affected limb with different materials.
16578463|NCT02755649|Experimental|Placebo QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
16578464|NCT02755649|Experimental|Dupilumab 300 mg Q2W + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
16578465|NCT02755649|Experimental|Dupilumab 300 mg QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
16578466|NCT02755636|Experimental|PCPHC intervention|PCPHC intervention during 6-month intervention period plus study assessments at baseline, 6, and 12 months
16578467|NCT02755636|Active Comparator|Usual care|Usual primary care plus study assessments at baseline, 6, and 12 months
16578468|NCT02755623|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|low-frequency (1 Hertz) rTMS
16578469|NCT02755623|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|sham TMS
16578470|NCT02755610|Experimental|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
16578471|NCT02755610|No Intervention|Control|Standard care
16578472|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
16578473|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Venetoclax 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
16578475|NCT02755558|Experimental|Low energy density, small portion|Low milk energy density and small portion size
16578476|NCT02755558|Experimental|Low energy density, large portion|Low milk energy density and large portion size
16578477|NCT02755558|Experimental|High energy density, small portion|High milk energy density and small portion size
16578478|NCT02755558|Experimental|High energy density, large portion|High milk energy density and large portion size
16578479|NCT02755545|Active Comparator|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
16578480|NCT02755545|Active Comparator|Product B (salicylic acid)|Product B applied topically to the affected area of the skin 1 to 3 times daily.
16578481|NCT02755532|Active Comparator|Bupivacaine 0,25%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve) In the group bupicavaine 0.25%, 10 ml of 0.25% bupivacaine was injected into each nerve, for a total of 40 ml per patient.
16578482|NCT02755532|Active Comparator|Bupivacaine 0,5%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve). In the group bupivacaine 0.5% , 5 ml of 0.5% bupivacaine was injected into each nerve, for a total of 20 ml per patient.
16578483|NCT02755519||Primary Aldosteronism|"Those with hypertension, and with or without hypoglycemia;
~Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1"
16578484|NCT02755519||Non-Primary Aldosteronism|"Those with Primary Hypertension;
~Those with adrenal diseases except for Primary Aldosteronism"
16578485|NCT02755506|Experimental|patients with thoracic lesions|Patients with thoracic lesions is going to undergo endobronchial ultrasound elastography followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
16578486|NCT02755493|Experimental|Sleep Deprivation|Sleep deprivation
16578487|NCT02755480|Experimental|ultralow dose research|"An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.
~The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography."
16578488|NCT02755467|Experimental|Laser treatment|Each subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
16578489|NCT02755454|Other|open label|Perfusion CT Imaging
16578492|NCT02755415|Experimental|Robotic Gait Training|Patients in this group will receive standard hospital based rehabilitation as well as robot-assisted gait rehabilitation training
16578493|NCT02755402|Experimental|Rapid evaluation|Transient elastography, Xpert HCV Viral load, medical and nurse visits
16578494|NCT02755389|Placebo Comparator|0 L/min|These participants will receive 0 L/min oxygen via conventional nasal cannulae during the apneic period.
16578495|NCT02755389|Experimental|15 L/min|These participants will receive 15 L/min oxygen via conventional nasal cannulae during the apneic period.
16578496|NCT02755389|Experimental|60 L/min|These participants will receive 60 L/min oxygen via high-flow nasal cannulae during the apneic period.
16578497|NCT02755376|Active Comparator|ACL reconstruction only|only ACL reconstruction without any injection
16578498|NCT02755376|Experimental|ACL reconstruction + Cartistem(TM)|ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.
16578499|NCT02755376|Experimental|ACL reconstruction + Hyaluronic acid|ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy
16578500|NCT02755363|Active Comparator|osteopathic manual therapy (OMT group)|patients who will undergo manual osteopathic therapy.
16578501|NCT02755363|Placebo Comparator|control group (C group)|patients who will undergo manual therapy not aimed to decrease hyperinflation.
16578502|NCT02755350|Experimental|Truvada|Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.
16578503|NCT02755324|Experimental|Intervention|Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
16578504|NCT02755311|Experimental|liver resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
16578505|NCT02755311|Active Comparator|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
16578506|NCT02755298|Experimental|Acetazolamide|Twice a day 250 mg acetazolamide for 5 weeks
16578507|NCT02755298|Placebo Comparator|Placebo|Placebo capsule 250 mg (Mannitol) twice a day 5 weeks
16578508|NCT02755285|Experimental|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
16578509|NCT02755272|Experimental|Pembrolizumab with Standard Chemotherapy|Pembrolizumab plus standard chemotherapy using carboplatin and gemcitabine.
16578510|NCT02755272|Active Comparator|Standard Chemotherapy Alone|Standard chemotherapy alone using carboplatin and gemcitabine.
16578511|NCT02755259|Experimental|Acetazolamide|Diamox 500mg i.v. (1x)
16578512|NCT02755259|Placebo Comparator|Placebo|Placebo Saline injection (1x)
16578513|NCT02755246|Experimental|Polyamine supplementation|750 mg polyamine-rich plant extract per day
16578514|NCT02755246|Placebo Comparator|Placebo|750 mg potato starch per day
16578515|NCT02755233||Pulmonary function|Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated
16578516|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
16578517|NCT02755207||Suspected ACS group|Patients admitted to the hospital with the diagnosis of ACS
16578518|NCT02755207||Blank control group|Patients admitted to the hospital without the diagnosis of ACS
16578519|NCT02755194||Breastfeeding women on the study medications|The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)
16578520|NCT02755181||BPD|Borderline Personality Disorder as diagnosed by DSM-5
16578521|NCT02755181||normal volunteers|normal volunteers
16578522|NCT02755168|Other|External Pop-Out Cesarean Section|
16578523|NCT02755168|Other|Classic technique|
16578524|NCT02755155|Experimental|Continuous low dosage (CLD)|The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
16578525|NCT02755155|Active Comparator|Intermittent high dosage (IHD)|The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%
16578526|NCT02755142|Active Comparator|Dose level 1|0,2 mg/Kg
16578527|NCT02755142|Active Comparator|Dose level 2|2,0 mg/Kg
16578528|NCT02755142|Active Comparator|Dose level 3|20 mg/Kg
16578553|NCT02754960|Active Comparator|Thalidomide group|Patients were randomly assigned to the thalidomide group and received 100 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
16578554|NCT02754960|Placebo Comparator|Placebo group|Patients were randomly assigned to the placebo group and received 100 mg of thalidomide placebo (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
16578555|NCT02754921|Experimental|Ultra-perc|
16578529|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.
~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:
~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test
~Walking exercises - 4 Meter Gait Speed (4MGS) Test
~Walking Exercises - Five Times Sit to Stand (FTSTS) Test
~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
16578530|NCT02755116|Experimental|Olanzapine|10mg pill
16578531|NCT02755116|Placebo Comparator|Placebo|
16578532|NCT02755103|Experimental|Women receiving MBRP plus TAU|Women will receive the Mindfulness Based Relapse Prevention (MBRP) plus treatment as usual (TAU less trauma focused group).
16578533|NCT02755103|No Intervention|Women receiving TAU|Women will only receive treatment as usual (TAU less trauma focused group).
16578534|NCT02755090|Experimental|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
16578535|NCT02755090|No Intervention|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
16578536|NCT02755077|Experimental|Mask ventilation in rotated head position|Patient's head will be axially rotated 45 degrees to the right
16578537|NCT02755077|No Intervention|Mask ventilation in neutral head position|
16578538|NCT02755064|Experimental|Erythromycin lactobionate IV 2 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
16578539|NCT02755064|Active Comparator|Erythromycin lactobionate IV 3 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
16578540|NCT02755064|Placebo Comparator|Placebo IV|Saline was given as an initial bolus over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
16578541|NCT02755064|Experimental|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
16578542|NCT02755064|Placebo Comparator|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
16578543|NCT02755051|Experimental|CBT-CI-A Therapy|Participants in this group receive Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder (CBT-CI-A)
16578544|NCT02755038||premenopausal and postmenopausal women|One group will include 20 premenopausal women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 postmenopausal women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.
16578545|NCT02755025||Prospective cohort|This group will include ICU patients for the two month period after the automated SOFA score has been activated within the electronic patient care dashboard.
16578546|NCT02755012||Longitudinal|155 women enrolled in 2nd or 3rd trimester of pregnancy, and seen again, with their infant, at 0-6 wk postpartum, and 4-6 mo postpartum
16578547|NCT02755012||Early Postpartum|60 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
16578548|NCT02755012||Later Postpartum|56 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
16578549|NCT02754999|Experimental|SANGUINATE™|As Needed Dosing of SANGUINATE
16578550|NCT02754986|Experimental|measuring Holter electrocardiogram|Hotter ECG will be recorded continuously during hemodialysis
16578551|NCT02754973|Experimental|Experimental group|During hospitalization for cancer treatment, besides receiving usual care, participants in the experimental group will first receive a health education talk Participants will then be taught and encouraged to practice with some stretching and relaxing exercises during their hospitalization. After hospitalization, participants will receive an integrated experiential training program with coaching by nursing students through home visits.
16578552|NCT02754973|Placebo Comparator|Placebo Control group|Since participants in both groups are hospitalized in the same unit, to avoid contamination, participants in the placebo control group will receive the same intervention as those participants in the experimental group during their hospitalization. When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures.
16578557|NCT02754908|Experimental|Experimental group|In addition to medical follow-up, the subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation. Qualified orchestral performers will provide the musical training. Training will start at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song). The subjects will continue on to the next level if they successfully pass the relevant test; those who do not will be encouraged to repeat test.
16578558|NCT02754908|Placebo Comparator|Placebo Control group|"The subjects will receive medical follow-up according to the schedule of the oncology units.
~They will receive the same amount of time and attention as those in the experimental group but not in a way designed to have any specific effect on the outcome measures. They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks)."
16578559|NCT02754895|Experimental|PP-weekly|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week.
16578560|NCT02754895|Experimental|PP-daily|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day.
16578561|NCT02754895|Experimental|Shortened PP-weekly plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week.
16578562|NCT02754895|Experimental|Shortened PP-daily plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day.
16578563|NCT02754895|Experimental|PP-weekly with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
16578564|NCT02754895|Experimental|PP-daily with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
16578565|NCT02754895|Experimental|Shortened PP-weekly plus MI + boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
16578566|NCT02754895|Experimental|Shortened PP-daily plus MI with boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
16578567|NCT02754882|Active Comparator|Bevacizumab (Avastin)|Avastin® + Carboplatin/Paclitaxel
16578568|NCT02754882|Experimental|SB8 (A proposed bevacizumab biosimilar)|SB8 + Carboplatin/Paclitaxel
16578569|NCT02754869||Control Subject-Drug Study|The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra---patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
16578570|NCT02754869||Dysmotility Subjects-Drug Study|The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1---3 days reducing patient time off medication
16578571|NCT02754869||Reference Range Study|The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
16578572|NCT02754869||Desmotility Reversibility Study|The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11---16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes
16578573|NCT02754856|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
16578574|NCT02754843|Active Comparator|Naida Q90-SP|Phonak's commercial power Behind-The-Ear (BTE) device, type 1.
16578575|NCT02754843|Active Comparator|Naida Q90-UP|Phonak's commercial power Behind-The-Ear (BTE) device, type 2.
16578576|NCT02754830|Experimental|LY3303560|Single IV infusion or SC injection of LY3303560 on Day 1
16578577|NCT02754830|Placebo Comparator|Saline Solution|Single IV infusion of saline solution to match LY3303560 on Day 1
16578578|NCT02754817||Insulin degludec/liraglutide|
16578579|NCT02754804||PAD patients|Patients with grade 1 claudication Measurement of biomechanic parameters while walking on treadmill
16578580|NCT02754791|No Intervention|Monthly report|A monthly report will be submitted to department heads describing their departments rate of blood culture contamination and comparing it to blood culture contamination rate in previous months and to blood culture contamination rate of the hospital as a whole
16578581|NCT02754791|Experimental|Steripath|The Steripath device (Magnolia) will be used to take blood cultures in this arm instead of standard methods. This will be in addition to a departmental monthly report (described above).
16578582|NCT02754791|Experimental|Soluprep wipes|In this arm, skin sterilization will be achieved using Soluprep wipes (3M) instead of standard methods (alcohol wipes).This will be in addition to a departmental monthly report (described above).
16578583|NCT02754778|No Intervention|control group|no intervention, regular family life
16578584|NCT02754778|Active Comparator|intervention group|6 month of regular conditional workout 1-3 times a week
16578609|NCT02754648|Active Comparator|group B; laparoscopic ovarian endometrial stripping|Laparoscopic ovarian endometrial stripping will be done for thirty patients with ovarian endometriotic cyst.
16578873|NCT02752919|Experimental|Part B Galunisertib - 1 tablet|Single oral dose of galunisertib in non-Japanese participants
16578585|NCT02754765|Experimental|endTB regimen 1 (BeLiMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
16578586|NCT02754765|Experimental|endTB regimen 2 (BeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
16578587|NCT02754765|Experimental|endTB regimen 3 (BeDeLiLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
16578588|NCT02754765|Experimental|endTB regimen 4 (DeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
16578589|NCT02754765|Experimental|endTB regimen 5 (DeCMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
16578590|NCT02754765|Active Comparator|endTB regimen 6 (Control)|endTB regimen 6 is the control regimen.
16578591|NCT02754752|Experimental|Group I (electroacupuncture therapy)|Patients undergo electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions.
16578592|NCT02754752|Placebo Comparator|Group II (sham electroacupuncture therapy)|Patients undergo modified electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. Acupuncture needles are placed in different locations using a different technique than those used for Group I.
16578593|NCT02754752|Active Comparator|Group III (waitlist control)|Patients receive standard of care without any kind of acupuncture therapy.
16578594|NCT02754739|Experimental|Pravastatin|Pravastatin 40mg tablet by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
16578595|NCT02754739|Placebo Comparator|Placebo|Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
16578596|NCT02754739|Other|Open-label control|No medication. Only nutritional education was provided to participants by a nutritionist, and participants were instructed to follow the educated guideline.
16578597|NCT02754726|Other|single arm|open label using combination therapy
16578598|NCT02754713||Patients with acute pericarditis|300 patients with a first episode of acute pericarditis
16578599|NCT02754700|Experimental|Biofeedback Hip|Hip focused biofeedback with neuromuscular training
16578600|NCT02754700|Experimental|Biofeedback Knee|Knee focused biofeedback with neuromuscular training
16578601|NCT02754700|Active Comparator|Neuromuscular Training|Neuromuscular Training component
16578602|NCT02754687|Placebo Comparator|Placebo|Placebo
16578603|NCT02754687|Experimental|11βmethyl nortestosterone dodecylcarbonate|11β-MNTDC in doses of 100 mg, 200 mg, 400 mg, and 800 mg
16578604|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
16578605|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
16578606|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.
~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.
~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
16578607|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.
~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
16578608|NCT02754648|Active Comparator|Group A; laparoscopic ovarian endometrial aspiration|Laparoscopic ovarian endometrial aspiration will be done for thirty patients with ovarian endometriotic cyst. .
16578610|NCT02754648|Active Comparator|Group c laparoscopic ovarian endometrial de-roofing|Laparoscopic ovarian endometrial de-roofing and bed cauterization will be done for thirty patients with ovarian endometriotic cyst.
16578611|NCT02754635|Active Comparator|Induction of labour|Induction of labour at 38-39 weeks
16578612|NCT02754635|Active Comparator|Expectant management|Expectant management until 41 weeks.
16578613|NCT02754622||Observational Group|"2hours before planned physical rehabilitation patients will have their regular ventilator changed to the study ventilator by an ICU Consultant and patients will be clinical stable for 30mins prior to the start of the planned physical rehabilitation.
~Intended physical rehabilitation as planned will continue without change. This session will be observed by a member of the research team to ensure accurate documentation of the exact timing of performance of the physical rehabilitation activity.
~Patients will also undergo an assessment by the Medical Research Council Sum-score and maximal inspiratory pressure (all part of routine physiotherapy assessment).
~Following the physical rehabilitation session, the patient to rate their perceived exertion then patients will also undergo ultrasound assessment of peripheral skeletal muscle architecture.
~Patients return to their original ventilator after 30mins by an ICU Consultant."
16578614|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-10|A total of 40 participants week 0 and week 8 will have low dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 10 L3 in 200 microliter (uL) of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
16578615|NCT02754609|Placebo Comparator|Tabasco® Sauce|A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
16578616|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-20|A total of 10 participants at week 0 and week 8 will have medium dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 20 L3 in 200 uL of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
16578617|NCT02754596|Experimental|Travoprost Intraocular Implant, high elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
16578618|NCT02754596|Experimental|Travoprost Intraocular Implant, low elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
16578619|NCT02754596|Active Comparator|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol, a beta blocker, will be dosed twice daily
16578620|NCT02754583|Experimental|WASH arm (WUHA)|"WUHA I, Behavioral: Water, sanitation, and hygiene (WASH) intervention: Communities will receive the water, sanitation, and hygiene (WASH) intervention including community water point construction, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
~WUHA II, Behavioral and Treatment: WASH intervention communities will continue to receive the water, sanitation, and hygiene (WASH) intervention.
~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline."
16578621|NCT02754583|Other|Standard of care WASH arm (WUHA)|"WUHA I: Standard of care WASH intervention: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.
~WUHA II: Standard of care WASH intervention and treatment: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.
~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
~These communities will receive a WASH package at the conclusion of the SWIFT II study, including water point construction, hygiene and sanitation promotion, and educational materials."
16578622|NCT02754583|Experimental|Targeted antibiotics arm (TAITU)|Targeted antibiotic treatment: Communities will receive targeted antibiotic treatments for children testing positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21, and 24 months. Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
16578623|NCT02754583|Other|Delayed mass antibiotics arm (TAITU)|Delayed mass antibiotic treatment: Communities will receive no mass azithromycin treatment during the study period. Communities in this treatment group have previously received at least 8 rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program (azithromycin or tetracycline) after the completion of the study.
16578624|NCT02754583|Active Comparator|Mass antibiotics arm (TAITU)|Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all individuals aged 6 months and up (20mg/kg for children; 1 g for adults); those younger than 6 months, pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline.
16578625|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
16578626|NCT02754557|Experimental|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
16578627|NCT02754557|Experimental|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
16578628|NCT02754544|Experimental|Diagnostic (electrocorticography)|Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.
16578659|NCT02754284|Experimental|Autologous fat transplantation|
16578660|NCT02754284|Experimental|Functional collagen scaffold transplantation|
16578629|NCT02754531|Experimental|Subjects|USG was used to measure the internal transversal subglottic diameter on the crichoid cartilago level while the head was in sniffing position. After USG measurement was recorded, Cole formula was used to measure internal diameter of uncuffed endotracheal tube.
16578630|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
16578631|NCT02754505|Other|Early rehabilitation group|Directly after transfer to a general ward the early rehabilitation group started with an early rehabilitation program, as ordered by an experienced physiatrist. The applied intervention (early rehabilitation) is a combination out of different therapeutic modalities (for further information please see interventions).
16578632|NCT02754505|Other|Usual care group|The usual care group received single physical therapy sessions as ordered by the primary care team after transfer from the ICU to the general ward. The applied intervention (usual care) is a combination out of different therapeutic modalities (for further information please see interventions).
16578633|NCT02754492|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
16578634|NCT02754492|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
16578635|NCT02754492|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
16578636|NCT02754479|Experimental|Laser treatments|Each subject will receive a combination of 532 nm KTP and/or 1064 nm Nd:YAG laser treatment
16578637|NCT02754466|Experimental|Deep dentin lesions|Subjective vs objective criteria in selective excavation of carious lesions Group 1: selective carious dentin excavation using subjective criteria (standard protocol in Dentistry) Group 2: selective carious dentin excavation using objective criteria (polymer burs) All restorations performed using high-viscosity glass-ionomer.
16578638|NCT02754466|Experimental|Shallow and medium depth dentin lesion|Glass-ionomer vs Bulk fill composites in the ART approach All cavities excavated using hand-instruments only (ART approach) Group 1: restorations using high-viscosity glass-ionomer Group 2: restorations using self-etch adhesive and bulk fill composite
16578639|NCT02754453|Other|Behavioral|
16578640|NCT02754440|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
16578641|NCT02754440|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
16578642|NCT02754440|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
16578643|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
16578644|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
16578645|NCT02754414|Experimental|Healthy Volunteers|Autologous, cold stored, PAS/plasma suspended platelets stored for various periods (3 to 20 days).
16578646|NCT02754401|Other|group 1|non-periodontitis persons (PSI 0-2)
16578647|NCT02754401|Other|group 2|periodontitis persons (PSI 3-4)
16578648|NCT02754375|Experimental|Patient|Patient with resistant depression treated with rTMS
16578649|NCT02754362|Experimental|Block 1|
16578650|NCT02754362|Experimental|Block 2|
16578651|NCT02754362|Experimental|Block 3|
16578652|NCT02754349|Experimental|Validation|SphygmoCor version 7, AtCor Medical, Sydney, Australia
16578653|NCT02754336|Active Comparator|Cogmed Robomemo, working memory training|Robomemo working memory training, 25 sessions with 8 verbal and non-verbal tasks per session.
16578654|NCT02754336|Active Comparator|Othmer, neurofeedback|Othmer method neurofeedback, 25 sessions a 30 minutes.
16578655|NCT02754323|Other|apparatus CODESNA|correlation between job stress measurement by the Maslach Burnout INVENTORY and KARASEK questionnaires and measurement of chronic stress by CODESNA tool
16578656|NCT02754310|Active Comparator|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
16578657|NCT02754310|Experimental|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
16578658|NCT02754297|Experimental|Personalized PRRT (P-PRRT)|"177Lu-Octreotate (LuTate) P-PRRT will be administered as follows:
~Renal absorbed radiation dose will be prescribed for the 4-cycle induction course (23 Gy) and for each subsequent cycle (6 Gy), with a reduction in cases of impaired renal or bone marrow function, or significant toxicity from prior cycles.
~The personalized activity to be administered at each cycle will be derived from renal dose per unit of injected activity that is predicted by patient characteristics or renal dose delivered during prior cycle(s).
~Participants responding to the induction course of P-PRRT will be eligible to receive additional consolidation and/or maintenance cycles.
~Participants with prior PRRT exposure outside the trial may receive less induction cycles, or only consolidation/maintenance cycle(s)."
16578661|NCT02754271|Experimental|Intervention|A research-based film (Fit for Dialysis) and a 16-week exercise program involving activities during dialysis, at home, and in the community.
16578662|NCT02754271|No Intervention|Control|The 16-week exercise program involving activities during dialysis, at home, and in the community.
16578663|NCT02754258|Placebo Comparator|Placebo|60 day oral administration of sugar placebo twice per day before lunch and supper.
16578664|NCT02754258|Experimental|Methylphenidate (MPH)|60 day oral administration of active study drug (methylphenidate) twice per day before lunch and supper.
16578665|NCT02754245||JPS|study sample at JPS included for analysis
16578666|NCT02754245||BUMC Dallas|study sample at Baylor University Medical Center Dallas included for analysis
16578667|NCT02754245||BUMC at Gardin|study sample at Baylor University Medical Center Gardin included for analysis
16578668|NCT02754245||BUMC Waxahachie|study sample at Baylor University Medical Center Waxahachie included for analysis
16578669|NCT02754245||BUMC Carrolton|study sample at Baylor University Medical Center Carrolton included for analysis
16578670|NCT02754245||BUMC McKinney|study sample at Baylor University Medical Center McKinney included for analysis
16578671|NCT02754232|Active Comparator|Telemedical training|Patients in the intervention group will receive telemedical training 21 times, three times weekly for seven weeks. During the first three weeks the regional physiotherapists will be responsible for the training. Municipal occupational -and physiotherapists will manage the last four weeks' training.
16578672|NCT02754232|No Intervention|The usual training or no training|Patients in the control-group will receive no telemedical training. They will be discharged to the municipal sphere with a rehabilitation plan, where they have the possibility to receive training.
16578673|NCT02754219|Experimental|Evogliptin|Hepatic dysfunction, Healthy control
16578674|NCT02754206||Control|Subjects who are collegiate level athletes who do not have a concussion and are currently playing a contact-collision sport.
16578675|NCT02754206||Concussed|Subjects who have recently suffered a sports-related concussion and are currently a collegiate athlete playing a contact-collision sport.
16578676|NCT02754193|Experimental|Moderate hypothermia|Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
16578677|NCT02754193|No Intervention|Normothermia|Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
16578678|NCT02754180|Active Comparator|chemotherapy|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.
16578679|NCT02754180|Experimental|chemotherapy with chemoradiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
16578680|NCT02754167|Experimental|PRS-080#022-DP|Hepcidin antagonist, single administration, ascending doses
16578681|NCT02754167|Placebo Comparator|PRS-080-Placebo#001|Comparator treatment, single administration
16578682|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
16578683|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
16578684|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
16578685|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
16578686|NCT02754141|Experimental|Arm A-Monotherapy|BMS-986179, dose as specified
16578687|NCT02754141|Experimental|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
16578688|NCT02754141|Experimental|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
16578689|NCT02754128|Active Comparator|BeFAST|Motor learning-based program involving athletic lower extremity training of gait-related skills.
16578690|NCT02754128|Active Comparator|BeSTRONG|Lower limb strength training program involving progressive muscle resistance exercises.
16578691|NCT02754102|Experimental|Sunscreen Spray-Liquid|All subjects are patched with the same product
16578692|NCT02754089|Experimental|Rhus|500 mg twice daily after meal for 6 weeks
16578693|NCT02754089|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
16578694|NCT02754076|Experimental|AX 250|In Part 1, patients will receive up to 3 escalating doses of AX 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of AX 250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
16578695|NCT02754063|Active Comparator|ICP Management|
16578696|NCT02754063|Experimental|PbtO2 + ICP Management|
16578697|NCT02754050|Experimental|Polypectomy|When a 6-25mm polyp is identified the Tandem snare will be inserted through the colonoscope, remove and retrieve the polyp.
16578698|NCT02754024||Total shoulder arthroplasty (TSA)|Replacement of humeral head and glenoid
16578699|NCT02754024||Hemi shoulder arthroplasty (HSA)|Replacement of humeral head only
16578700|NCT02754011|Experimental|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
16578701|NCT02753998|Experimental|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
16578702|NCT02753998|Placebo Comparator|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
16578728|NCT02753842|Experimental|Thin, Then Standard, Then Fitted Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
16578729|NCT02753842|Experimental|Standard, Then Fitted, Then Thin Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
16579034|NCT02751866|Placebo Comparator|Placebo, Control|placebo powder, higher carbohydrate diet
16578703|NCT02753972|Experimental|Mindful Eating and Living|The goal of the Mindful Eating and Living (MEAL) intervention was to apply mindfulness to apply mindfulness to eating behavior. The content for the MEAL sessions included group discussion, mindfulness meditation, and group eating exercises. The course, based on the work of Kristeller, Baer, & Quillian-Wolever (31), emphasized brief daily meditation and pairing meditation with eating, but was more streamlined in terms of didactic content and course length. Participants examined hunger and satiety cues, the qualities of foods they crave, and emotional and cognitive states associated with eating. Each session included an eating exercise with a variety of foods. The monthly refresher sessions included a brief meditation, a brief eating exercise, and group discussion. (The MEAL curriculum is available from the authors.)
16578704|NCT02753972|Active Comparator|Active Control|The Active Control (CONT) group matched the MEAL group regarding schedule. The agenda for the CONT sessions involved giving each participant the opportunity to discuss issues such as food choices, activity levels, and caloric goals. The sessions began by having the participants check-in about their experiences with eating. Next, the clinical psychology graduate student led the participants in goal setting and finally there was a question and answer period when the registered dietician answered questions about food selection. The monthly refresher sessions had the same agenda as the initial weekly sessions.
16578705|NCT02753959|Experimental|Acute Intervention|Patients will need to be Clinically stable patients with established neuromuscular disease with clinical secretions or cough PEF <270 and history of chest infections. Patients are required to be stable for the preceding 4 weeks with no changes to medications or ventilator settings.
16578706|NCT02753959|Experimental|Stable Intervention|Patients with established neuromuscular disease admitted to either the Lane Fox Respiratory Unit or Critical Care at St Thomas' Hospital with acute respiratory deteriorations and with the need for respiratory physiotherapy for secretion management.
16578707|NCT02753946|Experimental|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
16578708|NCT02753946|Active Comparator|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
16578709|NCT02753933||MRI scan|Direct referral from Primary Care (GPs) to an MRI scan as the initial Secondary Care point of contact.
16578710|NCT02753933||Neurology Appointment|Referral from Primary Care (GPs) to Neurology Services in Secondary Care as the initial Secondary Care point of contact.
16578711|NCT02753920|Active Comparator|Retrograde fill voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.
~Catheter is removed
~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).
~The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).
~If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids <200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
16578712|NCT02753920|Active Comparator|Force of Stream (FAST) voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.
~Catheter is removed
~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).
~The patient will subjectively quantify their force of stream via VAS scale.
~If VAS scale >/=50 (>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR
~If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is <500cc, the patient will be discharged without a catheter; if PVR is >/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
16578713|NCT02753907|Experimental|Low LA (linoleic acid)|Individuals who replaced 10 mL soy oil with one apple
16578714|NCT02753907|No Intervention|Medium LA|Individuals who maintained their usual food intake
16578715|NCT02753907|Experimental|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9 g of soy oil as a supplement
16578716|NCT02753894|Experimental|4.5 g/day group|Three times a day
16578717|NCT02753894|Experimental|6.0 g/day group|Three times a day
16578718|NCT02753894|Experimental|7.5 g/day group|Three times a day
16578719|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
16578720|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
16578721|NCT02753868|Experimental|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
16578722|NCT02753868|Experimental|Hemodialysis with Exercise (1-st hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
16578723|NCT02753868|Experimental|Hemodialysis with Exercise (3-rd hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
16578724|NCT02753855|Experimental|Telavancin Administration|Single dose of telavancin administered as a 1-hour intravenous infusion
16578725|NCT02753842|Experimental|Fitted, Then Thin, Then Standard Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
16578726|NCT02753842|Experimental|Fitted, Then Standard, Then Thin Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
16578727|NCT02753842|Experimental|Thin, Then Fitted, Then Standard Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
16578874|NCT02752919|Experimental|Part B Galunisertib - 2 tablets|Single oral dose of galunisertib in non-Japanese participants
16578730|NCT02753842|Experimental|Standard, Then Thin, Then Fitted Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
16578731|NCT02753829|Experimental|Experimental group 1|Cardiovascular rehabilitation program using Kinect of Xbox, in home care context,virtual format
16578732|NCT02753829|Experimental|Experimental group 2|Cardiovascular rehabilitation program using paper manual, in home care context, conventional format
16578733|NCT02753829|Other|Control Group|Educational component
16578734|NCT02753816|Experimental|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
16578735|NCT02753816|Placebo Comparator|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
16578736|NCT02753803|Experimental|A group|Evogliptin Pioglitazone Evogliptin+Pioglitazone
16578737|NCT02753803|Experimental|B group|Pioglitazone Evogliptin Evogliptin+Pioglitazone
16578738|NCT02753803|Experimental|C group|Evogliptin Evogliptin+Pioglitazone Pioglitazone
16578739|NCT02753803|Experimental|D group|Pioglitazone Evogliptin+Pioglitazone Evogliptin
16578740|NCT02753803|Experimental|E group|Evogliptin+Pioglitazone Evogliptin Pioglitazone
16578741|NCT02753803|Experimental|F group|Evogliptin+Pioglitazone Pioglitazone Evogliptin
16578742|NCT02753790|Experimental|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
16578743|NCT02753764|No Intervention|Normal control|Health volunteers will be recruited as an additional control group.
16578744|NCT02753764|Other|Corticosteroid sensitive (CS) asthmatics|After the initial visit, asthmatics will be given oral prednisone for 1 week and patients will return for the spirometer assessment. Patients will be defined as CR if <10% improvement in FEV1 % predicted is observed and as CS in >12% improvement in FEV1% predicted is observed.
16578745|NCT02753764|Active Comparator|Corticosteroid resistant (CR) asthmatics active|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
16578746|NCT02753764|Placebo Comparator|Corticosteroid resistant (CR) asthmatics placebo|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
16578747|NCT02753751|No Intervention|Usual Care|No alert will be fired.
16578748|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
16578749|NCT02753738|Experimental|SSRI treatment|Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
16578750|NCT02753738|Placebo Comparator|Placebo treatment|Subjects will receive 21 days of placebo treatment while performing learning paradigms.
16578751|NCT02753725|Active Comparator|Fentanyl group|Fentanyl given at a dose of one micro gram per kilogram body weight
16578752|NCT02753725|Placebo Comparator|normal saline group|placebo arm will be given normal saline at a volume equivalent to Fentanyl dose as per body weight.
16578753|NCT02753712|Active Comparator|fluticasone/vilanterol DPI (Relvar Ellipta DPI)|Inhalation powder. 92/22µg, I inhalation od
16578754|NCT02753712|Experimental|Fluticasone/formoterol BAI|Pressurised suspension for inhalation 125/5µg, 2 inhalations bid
16578755|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
16578756|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
16578757|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
16578758|NCT02753686||Cohort 1: Endocrine Therapy (ET)|HR+ HER2- male, female pre/postmenopausal advanced breast cancer patients being treated with endocrine therapy
16578759|NCT02753686||Cohort 2: Endocrine Therapy (ET) plus Targeted Therapy (TT)|HR+ HER2- male, female pre/ postmenopausal advanced breast cancer patients being treated with endocrine therapy in combination with targeted therapy including CDK4/6 inhibitor therapy
16578760|NCT02753673||Breast Cancer|The assessments are all qualitative. The assessments include an in-person, open-ended qualitative interview, during which the interviewer will use an interview guide to ensure that all relevant topics are discussed. Participants will also complete the Patient Expectations with Breast Reconstruction questionnaire using the think-aloud technique in order to identify which questions reflect the expectations of BCT patients, which questions need modification to reflect the expectations of BCT patients and which questions are not appropriate for BCT patients. The responses to the expectations questionnaire for this portion of the interview will not be recorded or analyzed; only the participants' thoughts and opinions about the questions will be recorded.
16578761|NCT02753660|Active Comparator|Traditional sitting position|Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
16578762|NCT02753660|Experimental|Pendant position|Patients sit with both their underarms propped up on a metal prop, thus both arms hanging from the prop before spinal anesthesia begun.
16578763|NCT02753647|Experimental|Chidamide plus R-CHOP|Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Doxorubicin 50mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Chidamide 20mg/d PO d1, 4, 8, 11 Frequency every 21 days for 6 cycles
16578803|NCT02753335|Experimental|GMI and Desensitization|Left/right judgement, imagine movements of the affected area, mirror treatment and tactile stimulation of the affected limb with different materials.
16578764|NCT02753634|Experimental|Square-stepping exercise Intervention|Participant attend sessions 2 times per week for 24-weeks at a community location. An instructor demonstrated increasingly difficulty walking or stepping patterns across a gridded mat and participants are asked to try and remember and repeat the patterns. Social engagement is encouraged.
16578765|NCT02753634|No Intervention|Usual care wait-list control group|This group will be invited to participate in square-stepping exercise after final assessments are completed.
16578766|NCT02753621|Experimental|Singing Intervention|Twelve weekly group singing classes lasting 60-90 minutes under the direction of a professional choir director and a social worker with a music background.
16578767|NCT02753621|Active Comparator|Discussion/Support Group Intervention|Twelve weekly 60-90 minute discussion groups led by a facilitator trained in discussion group facilitation; occurring at the same time and in the same location (next door) as experimental intervention (group singing).
16578768|NCT02753608|Sham Comparator|No ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients without clinical signs of VAP
16578769|NCT02753608|Experimental|Ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients displaying clinical signs of VAP
16578770|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:
~Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m^2)) or
~Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m^2) or
~Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m^2)
~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed."
16578771|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
16578772|NCT02753595|Experimental|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m^2.
16578773|NCT02753582|Active Comparator|Intervention|SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
16578774|NCT02753582|Placebo Comparator|Placebo|Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
16578775|NCT02753543|Experimental|Chidamide plus previous chemotherapy|Chidamide 20mg/d Biw p.o. on d1,4,8,11 for of each cycle for 3 cycles
16578776|NCT02753530|Experimental|Arimoclomol|Participants will be asked to take 400mg arimoclomol three times a day.
16578777|NCT02753530|Placebo Comparator|Placebo|Participants will be asked to take 400mg placebo three times a day.
16578778|NCT02753517|Other|Extended hepatectomy|Hepatic Scintigraphy
16578779|NCT02753504|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
16578780|NCT02753504|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
16578781|NCT02753504|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
16578782|NCT02753491|Active Comparator|Intervention|In intervention group, three or four motivational short interview made with every participants.
16578783|NCT02753491|No Intervention|Control|non intervention group,
16578784|NCT02753478|Experimental|intracoronary hypothermia group|Patients who will receive intracoronary hypothermia before and during percutaneous coronary intervention
16578785|NCT02753465|Experimental|left colic artery group|Laparoscopic D3 Lymph Node Dissection with preservation of the left colic artery
16578786|NCT02753465|Active Comparator|High ligation group|Laparoscopic D3 Lymph Node Dissection with high ligation
16578787|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
16578788|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
16578789|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
16578790|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
16578791|NCT02753439|Experimental|3rd molar|Drug: Geistlich Bio Oss
16578792|NCT02753426|Other|Doxycycline-Placebo|Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.
16578793|NCT02753426|Other|Placebo-Doxycycline|Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.
16578794|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
16578795|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
16578796|NCT02753400|Experimental|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)
~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)
~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)
~Week 4- Four emixustat HCl tablets (Strength C)
~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
16578797|NCT02753400|Placebo Comparator|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
16578798|NCT02753387|Experimental|CHLORHEXIDINE|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of chlorhexidine
16578799|NCT02753387|Placebo Comparator|NaCl 0.9 %|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of NaCl 0.9%
16578800|NCT02753361|No Intervention|Traditional|This will utilize the traditional method of performance of regional block
16578801|NCT02753361|Experimental|US-guided|In this arm, regional block will be performed under the ultrasound guidance
16578802|NCT02753348||Newborns|Newborns (within 14 days from birth)
16578805|NCT02753322|Experimental|Dual-task training group|"Subjects in this group will have 30 minutes of dual-task training with simultaneously performing balance and walking exercise and attention demanding tasks, and 30 minutes of stretching exercises.
~The training program will last for 8 weeks with frequency of 2 sessions a week."
16578806|NCT02753322|Active Comparator|Single-task training group|"Subjects in this group will have single-task training with 30 minutes of balance and walking exercise and 30 minutes of attention demanding task performed separately.
~The training program will last for 8 weeks with frequency of 2 sessions a week."
16578807|NCT02753322|Active Comparator|Limbs exercise group|"Subjects in this group will have stretching and strengthening exercise for 60 minutes.
~The training program will last for 8 weeks with frequency of 2 sessions a week."
16578808|NCT02753309|Active Comparator|Rapamycin 0.5mg|Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
16578809|NCT02753309|Active Comparator|Rapamycin 2.0mg|Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
16578810|NCT02753309|No Intervention|Control|Subject will be apart of the control group and won't take the study drug being tested
16578811|NCT02753283|Experimental|Denosumab, then Zoledronic Acid|Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of Denosumab.
16578812|NCT02753283|Placebo Comparator|Placebo Group, then Zoledronic Acid|Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of placebo.
16578813|NCT02753270|Active Comparator|Short catheter|Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
16578814|NCT02753270|Experimental|Long catheter preceded by tumescence|Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
16578815|NCT02753244|Experimental|Intendu FBT inpatient|Other: Motion Based Cognitive Video Games Software
16578816|NCT02753244|Active Comparator|iPad games|Other: iPad apps
16578817|NCT02753244|Experimental|Intendu FBT community|Other: Motion Based Cognitive Video Games Software
16578818|NCT02753231|Experimental|Low physical activity program|Three Physical Education sessions / week
16578819|NCT02753231|Experimental|High physical activity program|Three Physical Education sessions / week (increased volume)
16578820|NCT02753231|Experimental|Low and High physical activity program|Three Physical Education sessions / week (increased volume and intensity)
16578821|NCT02753231|Active Comparator|Conventional physical activity program|One Physical Education sessions / week
16578822|NCT02753218|Experimental|Midazolam and LEO 32731|
16578823|NCT02753205|Experimental|Control|Infusion of normal saline
16578824|NCT02753205|Active Comparator|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
16578825|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
16578826|NCT02753179|Experimental|Bilateral vestibular hypofunction|Patients suffering from chronic bilateral vestibular hypofunction.
16578827|NCT02753166|Experimental|Dexamethasone|
16578828|NCT02753166|No Intervention|Control|
16578829|NCT02753153|Experimental|Mucograft®, Geistlich Biomaterials|A Mucograft membrane will be used in state of a connective tissue graft. The dimension of the Mucograft® will be previously calculated according to the site dimensions and inserted into buccal pouch and sutured to be stabilized on the buccal aspect. The membrane is then positioned to cover the socket and inserted and sutured in the palatal pouch by the means of vertical interrupted sutures
16578830|NCT02753153|Active Comparator|Soft tissue graft|
16578831|NCT02753140|Experimental|RT concurrent with cetuximab|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.To observe the curative effect of the treatment of the cetuximab
16578832|NCT02753140|Experimental|RT concurrent with TP|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy. To observe the curative effect of concurrent radiotherapy and chemotherapy
16578833|NCT02753127|Experimental|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
16578834|NCT02753127|Active Comparator|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
16578835|NCT02753114|Experimental|Intranasal Ketamine|Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
16578836|NCT02753114|Placebo Comparator|Placebo|"Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered."
16578837|NCT02753101|Experimental|Single Arm|[18F]-FTC-146
16578838|NCT02753088|Experimental|BCD-063 (glatiramer acetate)|Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day
16578839|NCT02753088|Active Comparator|Copaxone-Teva (glatiramer acetate)|Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day
16578840|NCT02753088|Placebo Comparator|Placebo|Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day
16578841|NCT02753075|Experimental|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
16578842|NCT02753075|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
16578843|NCT02753075|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
16578844|NCT02753062|Experimental|bendamustine, rituximab|Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
16578845|NCT02753049|Experimental|Peer led mHealth adherence intervention|Eligible participants enrolled will receive five, weekly-60 minute, 'ACCESS' sessions, delivered by a peer adherence coach via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
16578846|NCT02753036||Chemotherapy|patients with ovarian cancer and paclitaxel + carboplatin combination chemotherapy as well as patients with breast cancer and paclitaxel +/- carboplatin combination chemotherapy
16578847|NCT02753036||Healthy control|patients with benign gynecological tumors after laparoscopic surgical resection
16578848|NCT02753036||Tumor control|patients with breast cancer with anti-hormonal and/or localized radiation treatment but no chemotherapy
16578849|NCT02753023||acute coronary syndromes|No intervention related
16578850|NCT02753023||acute decompensated heart failure|No intervention related
16578851|NCT02753023||warfarin intoxication|No intervention related
16578852|NCT02753023||acute pulmonary edema|No intervention related
16578853|NCT02753023||acute aortic dissection|No intervention related
16578854|NCT02753023||chest pain|No intervention related
16578855|NCT02753023||pulmonary embolism|No intervention related
16578856|NCT02753023||syncope|No intervention related
16578857|NCT02753010||Acute hip fracture|Women preoperatively with acute hip fracture with gastric emptying of carbohydrate-rich beverage
16578858|NCT02753010||Elective hip replacement|Women on waiting list for elective hip replacement with gastric emptying of carbohydrate-rich beverage
16578859|NCT02753010||Healthy volunteers|Healthy female volunteers with gastric emptying of carbohydrate-rich beverage
16578860|NCT02752997|Experimental|Intervention|"Discharge medication services included:
~Discharge medication reconciliation
~Identification of medication discrepancies and resolution
~Medication counseling using health coaching techniques with short term goal setting and follow up phone call"
16578861|NCT02752997|No Intervention|Comparator|Current standard of care provided by nursing staff.
16578862|NCT02752984||PICC insertion|Peripherally Inserted Central Catheter insertion
16578863|NCT02752971|Experimental|Bupivacaine|A dilution of Bupivacaine 0,25% , 15 ml was infiltrated in surgical wound after close the aponeurosis
16578864|NCT02752971|Experimental|Bupivacaine, sodium diclofenac|A dilution of Bupivacaine 0,25% and sodium diclofenac 75 mgr, was infiltrated in surgical wound after close the aponeurosis
16578865|NCT02752971|Experimental|Sodium diclofenac|A dilution of sodium diclofenac 75 mgrs (3ml) and 12 ml of solution 0,9% was infiltrated in surgical wound after close the aponeurosis
16578866|NCT02752958|Experimental|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
16578867|NCT02752945|Experimental|One-day CBT workshop (+Usual Care)|"One-day CBT-based workshop (DISCOVER), followed by up to three brief telephone contacts to review goals set in workshop."
16578868|NCT02752945|Active Comparator|Usual care|Usual care afforded by local CAMHS services
16578869|NCT02752932|Other|HNSCC -PDX development|Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
16578870|NCT02752932|Other|RMHNSCC -PDX drug testing|Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
16578871|NCT02752919|Experimental|Part A Galunisertib - 1 tablet|Single oral dose of galunisertib in Japanese participants
16578872|NCT02752919|Experimental|Part A Galunisertib - 2 tablets|Single oral dose of galunisertib in Japanese participants
16578969|NCT02752204|Other|Stage 2|AZD 2014 oral tablets and rituximab infusion will be given to patients
16578875|NCT02752906|Experimental|MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine-primed adolescents (greater than or equal to [>=] 15 to less than [< ]18 years) or adults (>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.
16578876|NCT02752906|Active Comparator|Menactra®|Healthy, meningococcal- vaccine-primed adolescents (>= 15 to < 18 years) or adults (>= 18 years) received a single dose of Menactra ® vaccine on Day 0.
16578877|NCT02752880|Experimental|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
16578878|NCT02752880|Placebo Comparator|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
16578879|NCT02752867|Experimental|Jianpi Yishen Huatan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
16578880|NCT02752867|Placebo Comparator|The control group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
16578881|NCT02752854||Group A|Pain threshold measurement in high altitude
16578882|NCT02752854||Group B|Pain threshold measurement in low altitude
16578883|NCT02752841|Experimental|Intervention|Nutritional vitamin D repletion and maintenance
16578884|NCT02752828|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
16578885|NCT02752828|Active Comparator|insulin glargine|"Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
16578886|NCT02752815|Active Comparator|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days
~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
16578887|NCT02752815|Experimental|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days
~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
16578888|NCT02752802|Active Comparator|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
16578889|NCT02752802|Active Comparator|Control|The control group will include standard of care for diagnostic coronary angiograms.
16578890|NCT02752789||Pediatric Heart Transplant Recipients|CTOTC-04 (ClinicalTrials.gov ID NCT01005316) participants who consent to long-term follow-up as part of this study as well as candidates less than 21 years of age who are listed for isolated orthotopic heart transplantation at one of the participating sites
16578891|NCT02752776|Experimental|Secukinumab|All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
16578892|NCT02752763|Experimental|preservative free artificial tear drop|preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.
16578893|NCT02752763|Experimental|%40 Autologous serum(AS)|peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.
16578894|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
16578895|NCT02752750||HC_GROUP|Healthy controls
16578896|NCT02752724|Experimental|Ketamine Interventional Arm|1.0 mg/kg IV ketamine (experimental arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
16578897|NCT02752724|Active Comparator|Methohexital Control Arm|1mg/kg of methohexital (standard arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
16578898|NCT02752698|Experimental|Micro Hand S robotic group|Micro Hand S robotic surgery group
16578899|NCT02752698|Other|laparoscopic surgery|laparoscopic surgery group
16578900|NCT02752698|Other|da Vinci robotic group|da Vinci robotic robotic group
16578901|NCT02752685||triple negative breast cancer (TNBC)|
16578902|NCT02752685||hormone receptor (HR)-positive cohort|(currently not recruiting for this group)
16578903|NCT02752672||Psoriasis|Psoriasis patients treated with dithranol
16578904|NCT02752672||Non-Psoriasis|Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
16578905|NCT02752659|Experimental|Women with breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
16578906|NCT02752659|Experimental|Women at risk of breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
16578907|NCT02752646|Active Comparator|nepafenac 0.3%|Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
16578908|NCT02752646|Active Comparator|ketorolac 0.5%|Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
16578909|NCT02752633|Experimental|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
16578910|NCT02752620|Experimental|Osteopathic Manipulative Treatment|"We selected two types of osteopathic techniques for this study:
~Technical articulation: rhythmic technique with low speed in which the goal is the full gain range of motion.
~Myofascial techniques (Neuromuscular): techniques involving lateral stretching, linear, deep pressures and pulls of the origins and insertions aiming at a myofascial relaxation.
~Sacroiliac articulatory technique; Dorsal articulatory technique; Lumbar paraspinal muscles stretching technique; Lumbar myofascial technique (inhibitory)."
16578911|NCT02752620|Active Comparator|Exercise Therapy|"2 types of therapeutic exercises techniques were used:
~Stabilization exercises
~Stretches
~Stabilization exercises:
~Bridge on the ball 10 - 15 sec Side plank 10 - 15 sec Front board 10 - 15 sec active mobilization lumbopelvic 3 x 6 rep Squats with the ball on the wall 3 x 8 rep
~Static-passive stretch (2 x 30 sec):
~Paraspinal; Abdominals; Quadratus lumborum; Hip extenders; Hip flexors; Hip abductors; Hip adductors."
16578912|NCT02752594|Experimental|probiotic|2 mg of probiotic powder mixed in 10 ml of distilled water
16578913|NCT02752594|Placebo Comparator|placebo|10 ml of distilled water
16578914|NCT02752581|Other|Drain Group|Suction drain was applied to these patients after arthroscopic knee surgery.
16578915|NCT02752581|Other|Control Group|No suction drain was applied to this group, therefore used as a control group.
16578916|NCT02752568|Active Comparator|Endometrial scratch group|endometrial scratch controlled ovarian hyperstimulation
16578917|NCT02752568|Active Comparator|Assisted hatching group|assisted hatching controlled ovarian hyperstimulation
16578918|NCT02752568|Sham Comparator|ovarian stimulation only group|controlled ovarian hyperstimulation
16578919|NCT02752555|No Intervention|Antioxidant group|In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).
16578920|NCT02752555|Experimental|Antioxidant+modifiable lifestyle factors|In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
16578921|NCT02752542|Experimental|Psychotherapy|Cognitive Behavioral Therapy
16578922|NCT02752542|Experimental|Pharmacotherapy|Antidepressant medication
16578923|NCT02752529|Experimental|Tacrolimus/dose1|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
16578924|NCT02752529|Active Comparator|Tacrolimus/dose2|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
16578925|NCT02752516|Experimental|Anlotinib|
16578926|NCT02752503|Experimental|Nalmafene|
16578927|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
16578928|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
16578929|NCT02752477|Experimental|Opioid-free anesthetic (OFA) group|
16578930|NCT02752477|Active Comparator|Traditional Anesthesia (TA) group|
16578931|NCT02752464|Experimental|Feedback report plus peer counseling|Feedback report plus peer counseling Participants receive 12 sessions of behavioral counseling and a brief printed feedback report
16578932|NCT02752464|Active Comparator|Feedback report|Feedback report Participants receive a brief printed feedback report
16578933|NCT02752451|Other|CO|8 subjects who did not undergo arthroscopy simulation training prior to assessment on cadaveric specimens. These served as controls.
16578934|NCT02752451|Experimental|CBAT|8 Subjects who received 4 hours of simulation training on the Cigar Box Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
16578935|NCT02752451|Experimental|AKAT|8 Subjects who received 4 hours of simulation training on the Anatomic Knee Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
16578936|NCT02752438||Survived|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation and survived.
16578937|NCT02752438||Death|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation but died.
16578938|NCT02752425|Experimental|With visual feedback|Session of speech therapy conducted with the additional use of articulatory visual feedback based on ultrasound echography, which allows to visualize the patient's tongue in real time on a computer screen
16578939|NCT02752425|No Intervention|Without visual feedback|Session of speech therapy without use of ultrasound echography
16578940|NCT02752412|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Metformin will be continued."
16578941|NCT02752412|Active Comparator|insulin glargine|"Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.
~Metformin will be continued."
16578942|NCT02752386|Experimental|Biofeedback Training 1|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide pain relief when relaxation is achieved.
16578943|NCT02752386|Active Comparator|Biofeedback Training 2|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide a painful context in which to practice relaxing.
16578944|NCT02752386|Active Comparator|Biofeedback Training 3|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback.
16578945|NCT02752360|Experimental|BSA Group|Patients accept the management of Biodegradable Stenting Anastomoses for reconstruction in the surgery of Intestinal Anastomosis
16578946|NCT02752360|Experimental|DHS Group|Patients accept the management of Double-layer Hand Sutures for reconstruction in the surgery of Intestinal Anastomosis
16578947|NCT02752347|Experimental|unilateral crossbite|unilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
16578948|NCT02752347|No Intervention|control|the surface Electromyography (surface EMG device) device will be used to examine the muscle activities on normal patients
16578949|NCT02752347|Experimental|Bilateral crossbite|Bilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
16578950|NCT02752334|No Intervention|group Bupivacaine|patients will receive 23 mL of Bupivacaine HCL 0.5% (Marcaine, 5 mg per mL; Hospira, USA) in addition to 2 mL normal saline using Ultrasound-guided Supraclavicular Brachial Plexus Block
16578951|NCT02752334|Active Comparator|group Bupivacaine Magnesium|patients will receive 23 mL of Bupivacaine HCL 0.5% in addition to 2 mL (100 mg) Magnesium Sulphate (Magnesium Sulphate 50 %, 500 mg per mL; Hospira, USA) diluted with normal saline. using Ultrasound-guided Supraclavicular Brachial Plexus Block
16578952|NCT02752321|Experimental|eDischarge + Standard Discharge (SDeD)|"Patients in this arm will be enrolled in the eDischarge technology prior to hospital discharge. Upon hospital discharge, these patients will receive a personalized eDischarge, containing text and multimedia information, in addition to receiving the standard discharge process.
~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
16578953|NCT02752321|No Intervention|Standard Discharge (SD)|"Patients in this arm will receive the standard discharge process upon hospital discharge.
~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
16578954|NCT02752308|Active Comparator|General anesthesia + caudal block|Patients who receive general anesthesia plus caudal epidural block and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
16578955|NCT02752308|Active Comparator|General anesthesia only|Patients who receive only general anesthesia and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
16578956|NCT02752295|No Intervention|Waiting list, intervention after EOS|control group / waiting list one week stress-coping intervention planned after end of study (EOS) without one week stress-coping intervention AND without an additional two days follow-up care
16578957|NCT02752295|Active Comparator|Stress-coping week without follow-up|active comparator with one week stress-coping intervention BUT without an additional two days follow-up weekend
16578958|NCT02752295|Active Comparator|Stress-coping week with follow-up|active comparator with one week stress-coping intervention AND with an additional two days follow-up weekend
16578959|NCT02752282|Sham Comparator|Control Video|Participants in this study arm will be assigned to watch a short educational video about new pap screening guidelines for women. Intervention: Cancer Screening Guidelines.
16578960|NCT02752282|Active Comparator|Intervention Video|Participants in this group will be assigned to watch a short educational video providing anticipatory counseling on their LNG-IUS' side effects and expected changes in bleeding. Intervention: Anticipatory Counseling
16578961|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
16578962|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
16578963|NCT02752243|Experimental|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
16578964|NCT02752230|Active Comparator|Exparel (Bupivicaine Liposome)|Patient will have Exparel (Bupivicaine Liposome) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
16578965|NCT02752230|Active Comparator|Marcaine (Bupivicaine)|Patient will have Marcaine (Bupivicaine) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
16578966|NCT02752217|Experimental|Inspiratory Muscle Training (IMT)|"Subjects in the inspiratory muscle training (IMT) group will perform loaded deep breathing exercise at 6 breaths/min using BreatheMaxยฎ device. The IMT protocol at 6 breathing rate (inspiratory time = 4 seconds and expiratory time = 6 seconds) with load at 25 percent of MIP for eighth weeks.
~The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks"
16578967|NCT02752217|Placebo Comparator|Control|Subjects in the control (CON) group will perform breathing exercise with inspiratory load at 2 cmH2O at 6 breathing rate using one BreatheMAXยฎ device. The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks
16578968|NCT02752204|Other|Stage 1|AZD 2014 oral tablets will be given to patients
16578970|NCT02752191|Active Comparator|Ferumoxytol|Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
16578971|NCT02752191|Active Comparator|gadofosveset|gadofosveset, 0.03mmol/kg, one time bolus injection
16578972|NCT02752178||DEP+MA+|Incompletely responsive patients (approximately N ~100) who are currently depressed after greater than 6 weeks of treatment with one or more monoaminergic antidepressants
16578973|NCT02752178||DEP-MA+|Responsive patients (approximately N~50) who are not currently depressed after greater than 6 weeks of treatment with a monoaminergic antidepressant
16578974|NCT02752178||DEP+MA-|Untreated patients (approximately N~50) who are currently depressed but have not been treated with monoaminergic antidepressants in the previous 6 weeks
16578975|NCT02752178||DEP-MA-|Healthy volunteers (approximately N~50) who have no personal history of depression requiring treatment with either monoaminergic antidepressants or other clinical interventions including psychotherapy
16578976|NCT02752165|Experimental|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
16578977|NCT02752165|Active Comparator|Enhanced Usual Care|Report of symptoms to primary care physician
16578978|NCT02752152|Experimental|Computer-assisted counseling|Computer-assisted informational/educational interactive session followed by an interactive face-to-face session to discuss personal issues with a counselor as needed
16578979|NCT02752152|Experimental|On-demand counseling|The counselor asks whether the participant has any questions
16578980|NCT02752152|Active Comparator|Standard counseling|Interactive face-to-face counseling session
16578981|NCT02752152|Experimental|Appointment + reminder|Make appointment and send SMS reminder
16578982|NCT02752152|Experimental|Reminder only|Send SMS reminder only
16578983|NCT02752152|Active Comparator|No appointment and no reminder|No appointment and no SMS reminder sent
16578984|NCT02752139||patients with sleep disorders|
16578985|NCT02752139||normal individuals without sleep disorders|
16578986|NCT02752126|Active Comparator|Standard Palliative Radiation|Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
16578987|NCT02752126|Experimental|Esophageal Sparing IMRT|Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
16578988|NCT02752113|Active Comparator|Empagliflozin and Linagliptin|After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
16578989|NCT02752113|Active Comparator|Metformin and Insulin sc|Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
16578990|NCT02752100|Experimental|Interventional Therapy|Percutaneous transluminal angioplasty.
16578991|NCT02752100|No Intervention|Non-Interventional Therapy|
16578992|NCT02752087|Experimental|U-193 LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
16578993|NCT02752087|Active Comparator|U-95 LY900014 Reference|LY900014 reference dose administered via SC injection
16578994|NCT02752074|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
16578995|NCT02752074|Active Comparator|Pembrolizumab + Placebo|Pembrolizumab + Placebo
16578996|NCT02752061|Experimental|Kweneng East District|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in Kweneng East District during study period.
16578997|NCT02752061|No Intervention|All other districts|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in all other districts of Botswana (or Kweneng East prior to implementation of intervention).
16578998|NCT02752048|Experimental|TAS-205（Low dose group）|Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
16578999|NCT02752048|Experimental|TAS-205（High dose group）|High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
16579000|NCT02752048|Placebo Comparator|Placebo|Placebo group: Oral administration of tablets for 24 weeks, BID after meal
16579005|NCT02752022||Heavy smokers|Heavy smokers (continuous smoking of >10 cigarettes per day) for at least 6 months who will give up smoking and switch to nicotine containing e-cigarettes for 28 days to help them quit smoking.
16579032|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
16579033|NCT02751866|Active Comparator|Active supplement, low carbohydrate|Whole fruit berry powder, low carbohydrate diet
16579006|NCT02752009|Experimental|Axillary Lymph Node Sampling Clip|"Axillary Lymph Node Biopsy
~-- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes.
~Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed.
~Wire-localization of the clipped node on the day of surgery.
~Lymphatic mapping performed with either radiocolloid and/or blue dye.
~Sentinel lymph node biopsy will be performed on the day of surgery.
~--- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen.
~Axillary lymph node dissection as is the standard of care."
16579007|NCT02751996|Active Comparator|Part A Cohort 1: 25mg SB 9200|Part A Cohort 1: 25mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579008|NCT02751996|Placebo Comparator|Part A Cohort 1: 25mg Placebo|Part A Cohort 1: 25mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579009|NCT02751996|Active Comparator|Part A Cohort 2: 50mg SB 9200|Part A Cohort 2: 50mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579010|NCT02751996|Placebo Comparator|Part A Cohort 2: 50mg Placebo|Part A Cohort 2: 50mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579011|NCT02751996|Active Comparator|Part A Cohort 3: 100mg SB 9200|Part A Cohort 3: 100mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579012|NCT02751996|Placebo Comparator|Part A Cohort 3: 100mg Placebo|Part A Cohort 3: 100mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579013|NCT02751996|Active Comparator|Part A Cohort 4: 200mg SB 9200|Part A Cohort 4: 200mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579014|NCT02751996|Placebo Comparator|Part A Cohort 4: 200mg Placebo|Part A Cohort 4: 200mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579015|NCT02751996|Active Comparator|Part B: SB 9200 with tenofovir|Part B: SB 9200 selected dose from Part A administered in combination with tenofovir 300 mg qd. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579016|NCT02751996|Active Comparator|Part B: Tenofovir 300 mg|Part B: Tenofovir 300 mg qd monotherapy. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
16579017|NCT02751983|Experimental|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
16579018|NCT02751983|Active Comparator|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
16579019|NCT02751970|Active Comparator|3 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin.
16579020|NCT02751970|Experimental|2 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of an adhesive/primer step.
16579021|NCT02751970|Active Comparator|2 step SE & Dental restoration|Dental restoration with etching the dental substrates with acidic primer, followed by the application of adhesive resin.
16579022|NCT02751970|Experimental|1 step SE & Dental restoration|Dental restoration with etching and infiltrate the dental substrates with acidic primer/adhesive system.
16579023|NCT02751957|Experimental|Intervention|Receives caregiver coaching version of the Early Start Denver Model (ESDM) intervention, delivered by non-specialist workers. ESDM is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
16579024|NCT02751944|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 2 weeks
16579025|NCT02751944|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 2 weeks
16579026|NCT02751931|Experimental|Children (3 to < 12 Years)|Participants aged 3 to < 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg (milligram) [PED25]) on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50], orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 end-of-study (EOS) or end-of-treatment (EOT).
16579027|NCT02751931|Experimental|Adolescents (12 to < 18 Years)|Participants aged 12 to < 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight [PED25] on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50] orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT.
16579028|NCT02751918|Experimental|Anetumab ravtansine|Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.
16579029|NCT02751905|Experimental|BIIB074|Single oral dose on Day 1
16579030|NCT02751892|Experimental|Active Lifestyle Programme|Supervised exercises for 3 months and motivational interviewing to facilitate physical activity behaviour change. Supervised exercise sessions took place twice per week for the first four weeks. This was tapered off to once per week for the second four weeks. During the last month of the intervention participants continued with the exercise at home and were encouraged to achieve 150min of moderate to vigorous PA per week.
16579031|NCT02751892|No Intervention|Standard Care|Received usual care. Was offered the intervention after the completion of the study.
16579035|NCT02751853|Experimental|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
16579036|NCT02751853|Experimental|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
16579037|NCT02751853|Active Comparator|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
16579038|NCT02751840|Experimental|Caffeine|Caffeine capsule (200 mg) is taken prior to RMR measurement
16579039|NCT02751840|Placebo Comparator|Placebo|Placebo (starch) capsule is taken prior to RMR measurement
16579040|NCT02751840|Experimental|Coffee|Black coffee (9 grams) is consumed prior to RMR measurement
16579041|NCT02751840|Placebo Comparator|Decaffeinated|Decaffeinated Black coffee (9 grams) is consumed prior to RMR measurement
16579042|NCT02751827||Prospective cohort|"Prospective cohort involving patients treated in four distinct centers. Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).
~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.
~All eligible patients who have received at least one TKI administration were included in analysis."
16579043|NCT02751827||Retrospective cohort A|"Retrospective cohort of patients treated at the Institut Bergonié (Bordeaux, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).
~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.
~All eligible patients who have received at least one TKI administration were included in analysis."
16579044|NCT02751827||Retrospective cohort B|"Retrospective cohort of patients treated at the Centre Antoine Lacassagne(Nice, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).
~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.
~All eligible patients who have received at least one TKI administration were included in analysis."
16579045|NCT02751801||Adults and children with hypophosphatasia|Healthcare use interview
16579046|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated long-term opioid therapy or initiated ER/LA opioid therapy
16579047|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than one year
16579048|NCT02751749|Experimental|Unified Protocol|"CBT based Internet delivered treatment targeting transdiagnostic vulnerability and maintaining factors for chronic pain and emotional problems.
~Since this is a new target Group, a replicated single case design was used and participants are their own Control Group (no other treatment arms)."
16579049|NCT02751736|Experimental|Intervention|"2 g sachet (CJLP 243) once a day for 3 weeks
~10 billion lactic acid bacteria(lactobacillus plantarum CJLP243), maltodextrin, glucose(anhydrous)"
16579050|NCT02751736|Placebo Comparator|Control|"2g sachet (near identically appearing placebo) once day for 3 weeks
~maltodextrin, glucose(anhydrous)"
16579051|NCT02751723||lung cancer|validated questionnaires
16579052|NCT02751723||malignant melanoma|validated questionnaires
16579053|NCT02751723||cancer of the hepatobiliary system|validated questionnaires
16579054|NCT02751723||head and neck cancer|validated questionnaires
16579055|NCT02751723||breast cancer|validated questionnaires
16579056|NCT02751723||ovarian carcinoma|validated questionnaires
16579057|NCT02751723||pancreatic cancer|validated questionnaires
16579058|NCT02751723||stomach cancer|validated questionnaires
16579059|NCT02751723||oesophageal cancer|validated questionnaires
16579060|NCT02751723||colorectal cancer|validated questionnaires
16579061|NCT02751710|Experimental|Whole-body FDG PET-CT alone|
16579062|NCT02751710|No Intervention|Conventional breast cancer staging|Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen & pelvis
16579063|NCT02751671|Experimental|POCUS before clean catch sampling|The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is > 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is < 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches > 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
16579064|NCT02751671|Experimental|Standard clean catch sampling|Patients allocated to this arm will have a 20 minute feeding period either being breastfed or provided with formula intake appropriate to the infant's age and weight. If possible, the genital areas of the infant will be cleaned with warm water and soap and dried with sterile gauze prior to the feeding. The parents will let the diaper opened and will be will be ready to collect urine if the child voids during the feeding period. After the feeding, the stimulated clean-catch procedure will be performed without prior ultrasound
16579065|NCT02751658|Other|patients in the Otorhinolaryngology|patients in the Otorhinolaryngology department realization of a levy into the mouth swab on the day of admission to hospital and the day of release
16579066|NCT02751645|No Intervention|Standard of Care Control|This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
16579067|NCT02751645|Experimental|Acute Normovolemic Hemodilution|This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
16579068|NCT02751632|Experimental|Step 1-Regular SPS Therapy|Support and Problem Solving Therapy delivered to all study participants over a six-week period with a minimum of three sessions.
16579069|NCT02751632|Experimental|Responders- Monthly SPS Therapy|Participants are randomised to receive monthly Support and Problem Solving Therapy for up to 12 months.
16579070|NCT02751632|Experimental|Responders- 3-monthly monitoring|Participants are randomised to be monitored for risk every 3 months for up to 12 months.
16579071|NCT02751632|Experimental|Step 2- Regular SPS Therapy|Participants are randomised to receive regular sessions of Support and Problem Solving Therapy, with a minimum of six sessions delivered over an 18-week period.
16579072|NCT02751632|Experimental|Step 2- Regular CBCM|Participants are randomised to receive regular sessions of Cognitive Behavioural Case Management, with a minimum of six sessions delivered over an 18-week period.
16579073|NCT02751632|Experimental|Step 3- Regular CBCM + Fluoxetine|Participants are randomised to receive either Cognitive Behavioural Case Management plus an antidepressant medication for six months .
16579074|NCT02751632|Placebo Comparator|Step 3- Regular CBCM+ placebo|Participants are randomised to receive Cognitive Behavioural Case Management plus placebo medication for six months.
16579075|NCT02751619|Experimental|Lidocaine Group|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, PA, USA) measuring 10 x 14 cm and containing 700 mg of Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
16579076|NCT02751619|Active Comparator|Placebo Patch|A patch, that was identical in appearance to the active patch but did not contain Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
16579077|NCT02751606|Experimental|Breast and rectal cancer|Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.
16579078|NCT02751593|Experimental|dexamethasone|dexamethasone 40mg/d for 4 days
16579079|NCT02751580|Experimental|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
16579080|NCT02751567|Experimental|Arm 1|All subjects are patched with the same product
16579081|NCT02751541|Experimental|BAY987519|All subjects are patched
16579082|NCT02751528|Experimental|ETBX-021|Ad5 [E1-, E2b-]-HER2/neu Vaccine, Suspension for Injection
16579083|NCT02751515|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
16579084|NCT02751502|Experimental|Bimanual-to-unimanual device home training program|
16579085|NCT02751502|No Intervention|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
16579086|NCT02751489|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
16579087|NCT02751476|Active Comparator|standard SAM treatment (control group)|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure.
16579088|NCT02751476|Experimental|SAM treatment + flocculent-disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a flocculent-disinfectant for household level application.
16579089|NCT02751476|Experimental|SAM treatment + chlorine disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a chlorine disinfectant for household level application.
16579090|NCT02751476|Experimental|SAM treatment + ceramic water filter|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a ceramic water filter for household level application.
16579091|NCT02751463|Experimental|BAY987519|All subjects are patched .
16579092|NCT02751450|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
16579093|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
16579094|NCT02751437|No Intervention|Low Arginine unsupplemented|These infants identified as having low blood arginine levels will receive standard care.
16579095|NCT02751437|Experimental|Low Arginine supplemented|These infants identified as having low arginine levels will receive an additional arginine infusion between days 3 and 10 of life.
16579096|NCT02751437|No Intervention|Normal Arginine|These infants identified as having normal arginine levels will receive standard care.
16579097|NCT02751424|Experimental|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
16579098|NCT02751424|Placebo Comparator|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
16579122|NCT02751294|Experimental|TQ Control+ TQ SIL|Subjects received TQ Control product (2 tablets) and 30 mg TQ SIL solution orally with water after a meal.
16579123|NCT02751294|Experimental|TQ X + TQ SIL|Subjects received 2 tablets of Tafenoquine dissolution profile X and 30 mg TQ SIL solution orally with water after a meal.
16579124|NCT02751281|Active Comparator|pneumatic percutaneous nephrolithotomy|pneumatic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
16579099|NCT02751424|Experimental|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
16579100|NCT02751424|Placebo Comparator|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
16579101|NCT02751411|Experimental|micro-enema with Promelaxin|2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
16579102|NCT02751411|Active Comparator|Macrogol 4000|One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).
16579103|NCT02751398|Experimental|Dapagliflozin|Dapagliflozin 10mg/day
16579104|NCT02751398|Placebo Comparator|Placebo|
16579105|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
16579106|NCT02751372|Experimental|BAY 987517|All subjects are patched .
16579107|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
16579108|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
16579109|NCT02751346||Patients with Pain|Patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
16579110|NCT02751346||Patients without Pain|Patients without pain age and gender matched to patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
16579111|NCT02751333|Active Comparator|FCSEMS with Endostitching (ES)|General anesthesia or conscious sedation will be started and an upper endoscope will be inserted into the participants mouth and advanced into the stomach. Endoscopic stenting with a fully covered self-expanding metal stents (FCSEMS) will then be performed. Once the stent is in place, the endoscope will be withdrawn from the participant to set-up the endostitch device unto the endoscope. Bites are taken separately with the first on the esophageal mucosa followed by a second on the stent itself and finishing with a last bite on esophageal mucosa. A cinch is then used to secure the deployed suture. An attempt at placing 2 sutures will be performed. Stent removal will then be performed at 8-weeks post-stent insertion.
16579112|NCT02751333|Active Comparator|FCSEMS with No Suturing (NS)|The procedure will be done in the same manner with same endoscopic technique, stent deployment, and timing of stent removal. The only difference would be the lack of suturing and naturally the need for suture cutting at stent removal.
16579113|NCT02751320|Experimental|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
16579114|NCT02751320|Experimental|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
16579115|NCT02751320|Experimental|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
16579116|NCT02751320|Placebo Comparator|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
16579117|NCT02751320|Active Comparator|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
16579118|NCT02751320|Active Comparator|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
16579119|NCT02751307|Active Comparator|metformin 500 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
16579120|NCT02751307|Active Comparator|metformin 1000 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, 500 mg of metformin twice a day was administered. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
16579121|NCT02751307|Placebo Comparator|placebo; clozapine 100 mg|In the first week, one pill of placebo was given and in the second week, placebo BID was given. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
16579125|NCT02751281|Active Comparator|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
16579126|NCT02751268|Placebo Comparator|Control|placebo for the realization of infraorbital and infratrochlear block
16579127|NCT02751268|Active Comparator|Ropivacaine|ropivacaine for the realization of infraorbital and infratrochlear block
16579128|NCT02751255|Experimental|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
16579129|NCT02751242||Usual Care|All patients will receive a dose of intravenous furosemide.
16579130|NCT02751229|Experimental|Honest Open Proud|"The group program is about disclosure ('coming out') versus secrecy of one's mental illness. The groups are facilitated by peers (young adults with mental illness) and mental health professionals. Each group runs for three weeks, one meeting per week, and two hours per meeting.
~Fidelity to manual: rated by PhD student in each session as proportion of key topics covered"
16579131|NCT02751229|No Intervention|Control Group|treatment as usual (TAU)
16579132|NCT02751216|Experimental|spinal cord stimulation|
16579133|NCT02751203|Experimental|Make Safe Happen App Intervention|Pre- and post-test delivered to online survey panel participants. Instruction to download and use the intervention (Make Safe Happen Mobile App) for 1 week.
16579134|NCT02751203|No Intervention|Make Safe Happen App Control|A subset of online survey panel participants (n=200) will complete a pre- and post-test survey but will receive a non-safety app (e.g. a free recipe app). After the study, participants will be asked to download the intervention app.
16579135|NCT02751177|Experimental|OncoBEAM|KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.
16579136|NCT02751164||Weekday daytime|Admitted to the critical care unit Monday-Friday 08:00-17:59
16579137|NCT02751164||Weekend daytime|Admitted to the critical care unit Saturday-Sunday 08:00-17:59
16579138|NCT02751164||Weekday night|Admitted to the critical care unit Monday-Friday 18:00-07:59 the next day
16579139|NCT02751164||Weekend night|Admitted to the critical care unit Saturday-Sunday 18:00-07:59 the next day
16579140|NCT02751151|Experimental|1|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
16579141|NCT02751138||Isocitrate dehydrogenase - 1 mutated|Immunophenotype of Glioblastoma and correlation with outcome
16579142|NCT02751138||Isocitrate dehydrogenase - 1 wild type|Immunophenotype of Glioblastoma and correlation with outcome
16579143|NCT02751125|Experimental|Augmentation of new alveolar bone|Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
16579144|NCT02751112|Experimental|Couple donor / recipient|"Each couple will be treated the same way :
~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.
~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process."
16579145|NCT02751099||de novo renal transplanted patients|renal transplanted patients
16579146|NCT02751086||Robotic Gastrectomy|Patients who will be treated for gastric cancer with the assistance of the robotic surgical system
16579147|NCT02751086||Laparoscopic Gastrectomy|Patients who will be treated for gastric cancer through laparoscopic devices.
16579148|NCT02751086||Open Gastrectomy|Patients who will be treated for gastric cancer with traditional open surgery.
16579149|NCT02751060||patients with coronary heart disease symptoms|
16579150|NCT02751047|Placebo Comparator|Manual ventilation|During anesthetic induction, facemask ventilation is performed by manual bagging, after setting adjustable pressure limiting (APL) valve at 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
16579151|NCT02751047|Active Comparator|Pressure controlled mechanical ventilation|During anesthetic induction, facemask ventilation is performed with mechanical ventilator by pressure controlled mode, with inspiratory pressure of 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
16579152|NCT02751034|Experimental|Neuramis® Deep Lidocaine|Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
16579153|NCT02751034|Active Comparator|Restylane® PERLANE-L|Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
16579154|NCT02751021|Other|Sleep apnea diagnosis|The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
16579155|NCT02750995|Experimental|Vaccination|Azacitidine + NPMW-peptide vaccine
16579156|NCT02750982|Experimental|Laughter therapy|effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
16579157|NCT02750969|Experimental|1. lidoderm patches first|"29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.
~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
16579158|NCT02750969|Experimental|2. tegaderm patches first|"29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.
~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
16579159|NCT02750956||Group 1|Periodontal healthy individuals
16579160|NCT02750956||Group 2|Patients with chronic periodontitis
16579340|NCT02749812|Experimental|automatic Continuous Positive Airway Pressure|
16579161|NCT02750956||Group 3|the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
16579162|NCT02750943|Experimental|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
16579163|NCT02750943|Active Comparator|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
16579164|NCT02750930|Experimental|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
16579165|NCT02750917|Experimental|GROUP LORNOXICAM|Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours
16579166|NCT02750917|Active Comparator|GROUP ETORICOXIB|Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.
16579167|NCT02750904|Experimental|Experimental therapy|
16579168|NCT02750904|Active Comparator|Control Therapy|
16579169|NCT02750891|Experimental|DSP-7888|
16579170|NCT02750878|No Intervention|Control group|Participants will receive only the standard verbal TOT surgical consent counseling.
16579171|NCT02750878|Other|Intervention group|Participants will receive the standard verbal TOT surgical consent counseling plus a handout describing their surgical intervention
16579174|NCT02750852||Analysis group|Create an algorithm to predict blood loss using patients data
16579175|NCT02750852||Control group|The algorithm was applied to analyze sensitivity and specificity
16579176|NCT02750839||proximal humerus fracture|Patients with proximal humerus fracture treated with mini-invasive plate.
16579177|NCT02750826|Other|Arm 1: Health Education Program|Patients will receive a standardized intervention focusing on healthy living. This will include mailings at study entry and one year later describing healthy lifestyle behaviors. All participants will also receive a 2-year subscription to a health magazine. In addition, all study participants will be invited to join twice-yearly Webinars/teleconferences that focus on breast cancer and other health topics, such as treatment updates in breast cancer, management of menopausal side effects, general cancer screening, etc. Finally, the study will also provide birthday and holiday greeting cards and a twice-yearly study newsletter with study updates and other general breast cancer news.
16579178|NCT02750826|Other|Arm 2: Health Education Program + Weight Loss Intervention|Patients will receive a standardized intervention focusing on healthy living as described in the Arm 1 (Health Education Program). In addition, patients will utilize a standardized, 2-year, telephone-based weight loss intervention. The intervention will include individual weight loss, caloric restriction, and physical activity goals for each participant. It will be administered through semi-structured phone calls delivered by trained coaches at the BWEL call center and supplemented through print and on-line materials. The intervention will utilize a toolbox approach that will allow for tailoring for the individual participant.
16579179|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
16579180|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
16579181|NCT02750800||Adalimumab and AbbVie Care 2.0|Adalimumab administered via subcutaneous (SC) injection for 12 months according to the approved EMA label and Hungarian financial protocols and supportive services via the AbbVie Care 2.0 patient support program
16579182|NCT02750787|Experimental|Nutritional Study Product|A ready-to-drink peptide-based liquid formula for patients with impaired gastro-intestinal function.
16579183|NCT02750774|Experimental|Low-Glycemic Index Group|Women in the low- glycaemic index group received a dietary intervention based on 3 main meals and 3 snacks, with a precise macronutrient composition, and a physical activity counseling according to the ACOG and ACSM recommendations.
16579184|NCT02750774|Other|Standard Care Group|Women in the Standard Care Group received a simple nutritional booklet regarding lifestyle, which was in agreement with the Italian Guidelines for a healthy diet during pregnancy that included general advice regarding food consumption and physical activity.
16579185|NCT02750761|Experimental|Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 5 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
16579186|NCT02750761|Experimental|Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
16579187|NCT02750761|Experimental|Group 2 Cohort 1: Tedizolid IV 6 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 6 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
16579188|NCT02750761|Experimental|Group 2 Cohort 2: Tedizolid IV 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
16579189|NCT02750761|Experimental|Group 3: Tedizolid oral 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single dose of tedizolid phosphate oral suspension dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
16579190|NCT02750761|Experimental|Group 4: Tedizolid oral 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single dose of tedizolid phosphate oral suspension dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
16579191|NCT02750748|Experimental|4mg Intranasal Naltrexone|Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril
16579192|NCT02750748|Experimental|4mg Intranasal Naltrexone with Intravail|Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril
16579193|NCT02750748|Experimental|2mg Intramuscular Naltrexone|Administer 2 mg formulation intramuscularly
16579194|NCT02750748|Experimental|50mg Naltrexone|Administer 50mg formulation orally
16579195|NCT02750735||Retrospective NCWS patients|The clinical charts of NCWS patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca were retrospectively reviewed. Patients had all been diagnosed with NCWS between January 2001 and June 2011, by a DBPCC method, and included in a previously published study. These charts included specific sections for the presence of associated atopic diseases, including nickel allergy. In this way, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy. Incomplete clinical charts were excluded.
16579196|NCT02750735||Prospective NCWS patients|The investigators also prospectively surveyed adult patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS. The patients were recruited between December 2014 and March 2016 at 3 centers: the two already mentioned and the Gastroenterology Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the patients had been referred due to gastrointestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. Again, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy.
16579197|NCT02750735||Retrospective NCWS control patients|To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
16579198|NCT02750735||Prospective NCWS control patients|As for the retrospective study, to compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 patients with functional gastroenterological symptoms, was selected, with the same criteria adopted for the retrospective study.
16579199|NCT02750722|Experimental|Cycling in combination with Flutter® therapy|Participants perform 30 minutes of moderately intense cycling exercise in 4-min intervals at 75% of their maximal heart rate and interspersed with 2-min resting periods during which 6-8 breathing maneuvers are performed with the Flutter®.
16579200|NCT02750722|Active Comparator|Cycling without Flutter® therapy|Participants perform 30 minutes of continuous moderately intense cycling exercise at 75% of their maximal heart rate without additional Flutter® breathing maneuvers.
16579201|NCT02750709|Experimental|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579202|NCT02750709|Experimental|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579203|NCT02750709|Experimental|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579204|NCT02750709|Experimental|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579205|NCT02750709|Experimental|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579206|NCT02750709|Experimental|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579207|NCT02750696|Active Comparator|Co/ Ac|Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
16579208|NCT02750696|Experimental|Tr/ Ac|Tramadol/acetaminophen (37.5 mg/325 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of tramadol/acetaminophen (37.5 mg/325 mg) every 4 hours for 3 days.
16579209|NCT02750670|Experimental|GD2P|Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m^2 by IV for 1 hour all for a duration of 3 cycles
16579210|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
16579238|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
16579239|NCT02750488|Experimental|BAY987517|All subjects are patched with the same product
16579211|NCT02750644||High-risk|Patients with atherosclerotic carotid disease with (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
16579212|NCT02750644||Standard-risk|Patients with atherosclerotic carotid disease without (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
16579213|NCT02750631|Experimental|Triple Therapy|Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance
16579214|NCT02750618|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
16579217|NCT02750592|Experimental|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
16579218|NCT02750579|Active Comparator|Control group|control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)
16579219|NCT02750579|Experimental|experimental group|experimental group: early Percutaneous coronary intervention for revascularization intervention (<2 hours)
16579220|NCT02750566|Experimental|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
16579221|NCT02750566|Active Comparator|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
16579222|NCT02750553|Experimental|Pre-test|Three healthy male subjects were randomized in 2:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
16579223|NCT02750553|Experimental|Cohort 1|Eight healthy subjects were randomized in 3:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
16579224|NCT02750553|Experimental|Cohort 2|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 10 mg SHR0534 or matching placebo.
16579225|NCT02750553|Experimental|Cohort 3|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 25 mg SHR0534 or matching placebo.
16579226|NCT02750553|Experimental|Cohort 4|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 50 mg SHR0534 or matching placebo.
16579227|NCT02750553|Experimental|Cohort 5|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 100 mg SHR0534 or matching placebo.
16579228|NCT02750540|Active Comparator|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
16579229|NCT02750540|Active Comparator|Product B dose|Product B will contain tenofovir (TFV) *660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
16579230|NCT02750540|Active Comparator|Product C dose|Product C will contain tenofovir (TFV) *660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
16579231|NCT02750540|Placebo Comparator|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
16579232|NCT02750540|Placebo Comparator|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
16579233|NCT02750514|Active Comparator|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
16579234|NCT02750514|Experimental|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
16579235|NCT02750514|Experimental|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
16579236|NCT02750514|Experimental|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
16579237|NCT02750514|Experimental|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
16579241|NCT02750462|Experimental|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
16579242|NCT02750462|Active Comparator|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
16579243|NCT02750449|Experimental|Arm 1|All subjects are patched.
16579244|NCT02750436|Experimental|Ultrasound guided|Ultrasound guided sacral lateral branch block
16579245|NCT02750436|Active Comparator|Fluoroscopy guided|Fluoroscopically guided sacral lateral branch block
16579246|NCT02750423|Active Comparator|DHCA+RCP|Participants undergoing ascending aortic and hemiarch replacement will receive deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP).
16579247|NCT02750423|Active Comparator|MHCA+uSACP|Participants undergoing ascending aortic and hemiarch replacement will receive moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA+uSACP).
16579248|NCT02750410|Experimental|Dulaglutide|Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
16579249|NCT02750410|Placebo Comparator|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
16579250|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
16579251|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
16579252|NCT02750384|Experimental|50% SDD granules, fasting|50% spray dried dispersion granules, fasting
16579253|NCT02750384|Active Comparator|25% SDD powder for suspension, fasting|25% spray dried dispersion powder for suspension, fasting
16579254|NCT02750384|Experimental|50% SDD granules, fed|50% spray dried dispersion granules, fed
16579255|NCT02750371|Experimental|Patients with brain tumors treated by radiotherapy|"Patients with:
~- meningioma of the cavernous sinus for which radiotherapy is planned
~Or
~- a pituitary adenoma for which radiotherapy is planned"
16579256|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
16579257|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579258|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579259|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579260|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579261|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579262|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579263|NCT02750332|Experimental|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579264|NCT02750332|Experimental|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
16579265|NCT02750319|Placebo Comparator|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
16579266|NCT02750319|Experimental|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
16579267|NCT02750306|Experimental|Suvorexant|Participants will receive 1 suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' suvorexant dose may be increased to 20 mg if their Clinical Global Impression of Insomnia Severity (CGI-S) is ≥3 and investigators feel they can tolerate the increased dose.
16579268|NCT02750306|Placebo Comparator|Placebo|Participants receive 1 placebo-matching suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' placebo-matching dose can be increased to 20 mg if their CGI-S is ≥3 and investigators feel they can tolerate the increased dose.
16579269|NCT02750293|Active Comparator|cholecalciferol|vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
16579270|NCT02750293|Placebo Comparator|placebo|placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
16579271|NCT02750280|Experimental|Urinary Bladder matrix (UBM)|UBM covered with silicone foam dressing plus total contact cast
16579272|NCT02750280|Active Comparator|Standard Care|Silicone foam dressing plus total contact cast
16579273|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
16579274|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
16579275|NCT02750254|Experimental|Arm 1: Azacitidine|"Treating physician must choose from one of these conditioning regimens (will be given per standard of care)
~fludarabine and fractionated total body irradiation (Flu/FrTBI)
~fludarabine and busulfan (Flu/Bu4)
~fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)
~fludarabine and melphalan (Flu/Mel)
~reduced-intensity fludarabine and busulfan (Flu/Bu2)
~G-CSF from Day -5 through Day -1 per standard of care
~On Day 0, the allograft will be infused per standard of care.
~Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days
~Cyclophosphamide on Days +3 and +4 post-transplant"
16579276|NCT02750241|Experimental|Active video game-based intervention|This arm will receive the active video game-based intervention, which will include attending 12 weekly group sessions at the UTMB Breast Health Clinic, participate in self-paced home session, and monitor daily, weekly, and monthly steps using Wii Fit Meter. All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
16579277|NCT02750241|Active Comparator|Pedometer|This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
16579278|NCT02750215|Experimental|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.
~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
16579279|NCT02750202|Active Comparator|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
16579280|NCT02750202|Sham Comparator|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
16579281|NCT02750189||Mild Group|FEV₁/FVC <70% and FEV₁≥80% direct/indirect cost
16579282|NCT02750189||Moderate Group|FEV₁/FVC <70% and 50%≤FEV₁≤80% direct/indirect cost
16579283|NCT02750189||Severe Group|FEV₁/FVC <70% and 30%≤FEV₁≤50% direct/indirect cost
16579284|NCT02750189||Very Severe Group|FEV₁/FVC <70% and FEV₁<30% direct/indirect cost
16579285|NCT02750176|Experimental|CERCT|Closed chain exercises
16579286|NCT02750150|Experimental|Freezed-dried plasma|transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
16579287|NCT02750150|Active Comparator|Fresh-frozen plasma|transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
16579288|NCT02750124|Active Comparator|HPV self sampling test sent|A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
16579289|NCT02750124|Active Comparator|HPV self sampling test ordered|An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
16579290|NCT02750124|Active Comparator|Nurse navigator contact|An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
16579291|NCT02750124|Placebo Comparator|Control|The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
16579292|NCT02750098|Experimental|Diabetic patients|Diabetic patients planned to undergo elective cataract surgery
16579293|NCT02750085||2-point and 6-point PK sampling|
16579294|NCT02750072|Active Comparator|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
16579295|NCT02750072|Experimental|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
16579296|NCT02750059|Experimental|TDF/3TC/EFV + Telmisartan|The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
16579297|NCT02750059|Active Comparator|TDF/3TC/EFV only|Subjects will receive ART only
16579298|NCT02750046|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
16579299|NCT02750046|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
16579300|NCT02750033||Basal Cell Carcinoma (BCC)|Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
16579432|NCT02749097|Experimental|Cohort 1|Single oral dose of 10 mg SHR0534 or matching placebo
16579301|NCT02750033||Squamous Cell Carcinoma (SCC)|Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
16579302|NCT02750020||never smokers|Around 1667 never smokers will be required to answer a questionnaire via telephone.
16579303|NCT02750020||ex-smokers|Around 1667 ex-smokers will be required to answer a questionnaire via telephone.
16579304|NCT02750020||current smokers|Around 1667 current smokers will be required to answer a questionnaire via telephone.
16579305|NCT02750007|Experimental|Experimental|Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
16579306|NCT02749994|Active Comparator|R5|Rosuvastatin 5mg
16579307|NCT02749994|Active Comparator|R10|Rosuvastatin 10mg
16579308|NCT02749994|Active Comparator|R20|Rosuvastatin 20mg
16579309|NCT02749994|Experimental|R5/E10|Rosuvastatin 5mg/Ezetimibe 10mg
16579310|NCT02749994|Experimental|R10/E10|Rosuvastatin 10mg/Ezetimibe 10mg
16579311|NCT02749994|Experimental|R20/E10|Rosuvastatin 20mg/Ezetimibe 10mg
16579312|NCT02749981||Cefazolin|patients receiving cefazolin as part of routine clinical care
16579313|NCT02749968|Active Comparator|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
16579314|NCT02749968|Placebo Comparator|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
16579315|NCT02749955|Experimental|PS-PrEP Intervention Group|
16579316|NCT02749955|Active Comparator|PrEPLine Control Group|
16579317|NCT02749955|No Intervention|CDPH Prevention Projects|
16579318|NCT02749942|Active Comparator|AutoRIC: Remote Ischemic Conditioning|Daily cuff treatment of arm with 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG of pressure) on top of standard care.
16579319|NCT02749942|Sham Comparator|AutoRIC: Sham device treatment|Daily sham device treatment of arm, 4 cycles of 5 minute (0 mmHG of pressure) on top of standard care. No ischemia induced.
16579320|NCT02749929|Experimental|Low-Level Laser therapy|"After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the laser to make skin contact. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. The light from the laser is not visible to the eye, and will not give any perceptible stimulus.
~Low-Level Laser therapy (LLLT) will be given according to the recommended dosage from World Association of Laser Therapy (WALT). A LLLT dose of 3.6 Joules will be administered at two points over the fracture site."
16579321|NCT02749929|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the placebo laser to make skin contact. The placebo laser is identical in apperance to a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Since the light from the laser is invisible, neither the participant nor the therapist will know whether the laser is a placebo. The treatment time and number of treated points will be identical to group 1.
16579322|NCT02749916||Patients with acute or recent (within 3months) stroke|
16579324|NCT02749890|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
16579325|NCT02749890|Active Comparator|lixisenatide|"Lixisenatide (AVE0010) is injected subcutaneously (under the skin) once daily. It will be initiated with Dose 1 for 1 week and then continue with Dose 2 for 1 week followed by the maintenance dose of Dose 3 up to the end of treatment period.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
16579326|NCT02749877|Experimental|Cognitive Training|"This group will undergo a working memory training program (Training A). The children will receive individual memory training based on the computer program Cogmed RM and will be supervised by trained neuropsychologists. Its efficacy in the use with children with cancer has been recently published. The children will undergo 25 training sessions online; each session takes about 45 minutes and consists of a selection of various tasks that target the different aspects of working memory."
16579327|NCT02749877|Experimental|Physical Training|This group will receive a physical training that can be executed at home (Training B). The training will be based on xbox Kinect games and comprise games and activities such as jump'n'run games, physical training, and dance activities. One training session will last approximately 45 minutes and will be performed 3 days a week over a period of 8 weeks (in total 25 sessions).
16579328|NCT02749877|Active Comparator|Waiting Control Group|This group will serve as a waiting control group and will receive either the physical or the working memory training program after completion of the Neuropsychological Assessment II
16579329|NCT02749864||A: Age 20-34 yr|No intervention Cohort of subjects aged 20-34 years old.
16579330|NCT02749864||B: Age 35-49 yr|No intervention Cohort of subjects aged 35-49 years old.
16579331|NCT02749864||C: Age 50-79 yr|No intervention Cohort of subjects aged 50-79 years old.
16579332|NCT02749851||Non-smokers|Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.
16579333|NCT02749851||Smokers|Pregnant women that identify as smokers will receive the MRI Imaging intervention.
16579334|NCT02749851||High risk/Non-Smokers|Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.
16579335|NCT02749851||Confirmed IUGR|Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy
16579336|NCT02749825|Experimental|Trelstar|Per prescribing information
16579337|NCT02749825|Active Comparator|Lupron|Per prescribing information
16579338|NCT02749825|Active Comparator|Zoladex|Per prescribing information
16579339|NCT02749812|Experimental|Constant Continuous Positive Airway Pressure|
16579341|NCT02749799|Experimental|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
16579342|NCT02749786|Other|Control Group|Participants who do not have rosacea (control group)
16579343|NCT02749773|Active Comparator|Oocyte aspiration with 17G needle|Oocyte Aspiration with 17G needle.
16579344|NCT02749773|Active Comparator|Oocyte aspiration with (20-17G) needle|Oocyte Aspiration (20-17G) needle.
16579345|NCT02749760|Other|Minor league pitchers|Minor league pitchers from a single professional baseball organization. Strength tests of the elbows will be administered at spring training and end of season for 5 years. If strength correlates to injury, strengthening and exercise programs may be established to target the stabilizers of the elbows.
16579346|NCT02749747|Active Comparator|Sulpiride use|50mg sulpiride once a day use for 60 days
16579347|NCT02749747|Placebo Comparator|Placebo|50mg placebo once a day use for 60 days
16579348|NCT02749734|Experimental|hESC-RPE|Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums
16579349|NCT02749721|Other|Other - vortioxetine|Open-label vortioxetine
16579350|NCT02749708|Experimental|Dose level 1|IRX5183 50 mg daily
16579351|NCT02749708|Experimental|Dose level 2|IRX5183 75 mg daily
16579352|NCT02749695|Experimental|Group 1 (Melsmon)|20 women used placental extract Melsmon® (Japan), 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
16579353|NCT02749695|Placebo Comparator|Group 2 (placebo)|20 patients used placebo (normal saline solution): 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
16579354|NCT02749682||constipation & hernia group|The effect of constipation on study group whether there is a correlation between subgroups of operated patients on the view of direct and indirect hernias(Nyhuss classification).
16579355|NCT02749682||constipation & normal population|The level of constipation on normal population using constipation severity scale.
16579356|NCT02749669|Other|Qualitative research|Semi-structured interviews
16579357|NCT02749669|No Intervention|Economic evaluation|Questionnaire
16579358|NCT02749656|Experimental|0.25% Desoximetasone cream (Topoxy®)|"0.25% Desoximetasone cream (Topoxy®): apply on scalp psoriasis lesion twice a day for 8 weeks.
~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
16579359|NCT02749656|Active Comparator|0.25% Desoximetasone cream (Topicorte®)|"0.25% Desoximetasone cream (Topicorte®): apply on scalp psoriasis lesion twice a day for 8 weeks.
~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
16579360|NCT02749656|Placebo Comparator|Placebo|Placebo: apply on scalp psoriasis lesion twice a day for 8 weeks. (Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)
16579361|NCT02749643|Experimental|Vibrotactile feedback|Vibrotactile system - comprises of force sensors, attached to the fingertips of the prosthetic hand, and a set of 8 vibration actuators attached to a fabric arm cuff. When the subject applies force on the sensors with his prosthetic hand, he receives a vibration on the skin of his arm. The sensors and actuators are connected to an electronic control board, which transforms the resistance from the sensors to an electric signal that activates the vibration actuators.
16579362|NCT02749630|Experimental|Healthy Volunteer|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
16579363|NCT02749630|Experimental|Ulcerative Colitis|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
16579364|NCT02749630|Experimental|Crohn's Disease|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
16579365|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
16579366|NCT02749604|Active Comparator|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
16579367|NCT02749604|Experimental|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
16579368|NCT02749591|Experimental|Robot-assisted therapy (RT)|After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
16579369|NCT02749591|Experimental|Mirror therapy (MT)|After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
16579370|NCT02749591|Active Comparator|Control Intervention (CI)|After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
16579371|NCT02749578|Other|Treatment|Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
16579372|NCT02749565||asthmatic patients with OSA|
16579373|NCT02749565||asthmatic patients without OSA|
16579374|NCT02749552|Experimental|Acceptance and Commitment Therapy|ACT intervention
16579375|NCT02749539|Experimental|Kinesio tape|The first 3 kinesio tape application was inhibition technique for supraspinatus, deltoid and teres minor muscles. the fourth Kinesio tape was mechanical correction for the shoulder joint. in addition to active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
16579376|NCT02749539|Active Comparator|Physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
16579433|NCT02749097|Experimental|Cohort 2|Single oral dose of 25 mg SHR0534 or matching placebo
16579434|NCT02749097|Experimental|Cohort 3|Single oral dose of 50 mg SHR0534 or matching placebo
16579377|NCT02749526|Experimental|Endostar combined with MPFC|"Chemotherapy regimens (er degree + mPFC) :
~Endostar:
~degrees 30 mg civ24h d0-6;
~Liposo:
~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2
~Gimeracil and Oteracil Potassium (Tegafur):
~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
16579378|NCT02749513|Experimental|Itraconazole|Itraconazole 300 mg po bid for 14-17 days
16579379|NCT02749500|Active Comparator|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
16579380|NCT02749500|Experimental|OT + Device-assisted therapy|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy. The m2 BAT will enable repeated movement of the affected body part without the help of a therapist, providing the opportunity to maintain range-of motion in the affected limb to limit spasticity, contracture and the ensuing deformity, a major goal of rehabilitation therapy and produces movement in the affected limb from activating the patient's own brain, rather than from being acted on by an external powered source such as a robot.
16579381|NCT02749487||cured (c)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
16579382|NCT02749487||Died ( M)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
16579383|NCT02749474||Pregnant women diagnosed with cancer|Any pregnant woman diagnosed with any cancer within 6 weeks prior to their last menstrual period, or up to 6 months after the end of their pregnancy can be enrolled.
16579384|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
16579385|NCT02749435||Standard of Care + digital disease management cohort|Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
16579386|NCT02749435||Standard of Care cohort|Participants will have standard care with no access to the digital disease management tool.
16579387|NCT02749422|Active Comparator|Healthy Subjects|
16579388|NCT02749422|Experimental|Temporal Lobe Epilepsy Patients|
16579389|NCT02749409|Active Comparator|Control group|The control group will be given Morphine prn after admission
16579390|NCT02749409|Experimental|Experimental group|the experimental group will be given parecoxib after admission by intravenous method every 12 hours for 4 days. Then Morphine agent will be given prn usage
16579391|NCT02749396||IFN-β / Cohort 1|Exposure to IFN-β only
16579392|NCT02749396||IFN-β + other MSDMDs / Cohort 2|Women with MS exposed to IFN-β regardless of exposure to other MSDMDs
16579393|NCT02749396||No MSDMDs / Cohort 3|Women with MS exposed with no exposure to any MSDMDs
16579394|NCT02749396||No IFN-β + other MSDMDs / Cohort 4|Women with MS exposed to IFN-β exposure regardless of exposure to other MSDMDs
16579395|NCT02749396||Other MSDMDs / Cohort 5|Women with MS exposed to other MSDMD only excluding IFN-β or glatiramer acetate (Copaxone) or dimethyl fumarate (Tecfidera)
16579396|NCT02749396||Control / Cohort 6|Women from the general population without MS
16579397|NCT02749383|Experimental|PAC-14028 cream 0.3%|Twice daily for 4 weeks
16579398|NCT02749383|Experimental|PAC-14028 cream 1.0%|Twice daily for 4 weeks
16579399|NCT02749383|Placebo Comparator|PAC-14028 cream vehicle|Twice daily for 4 weeks
16579400|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
16579401|NCT02749357|Active Comparator|Control|"Intervention: Control group, with 30 training sessions in robotic orthosis with duration of 30 minutes during 6 weeks.
~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
16579402|NCT02749357|Experimental|Experimental|"Intervention: Experimental group, with 30 training sessions in robotic orthosis with duration of 60 minutes during 6 weeks.
~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
16579403|NCT02749344|Experimental|FET after endometrial preparation|Natural cycle/progesterone fortified endometrial preparation before embryo transfer
16579404|NCT02749331|Experimental|AdVince|"Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:
~10 000 000 000 virus particles
~100 000 000 000 virus particles
~300 000 000 000 virus particles
~1000 000 000 000 virus particles
~Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa."
16579405|NCT02749318|Experimental|Experimental Group|Consented patients who complete the initial Experimental Group Questionnaire, receive a prophylaxis, have the IL-1 genetic test for risk of severe periodontitis performed, their dental records monitored for 18 months post-enrollment, and answer a Study Completion Questionnaire 18 months post-enrollment.
16579406|NCT02749318|No Intervention|Usual Care Group|Consented patients who complete the initial Usual Care Group Questionnaire, receive a prophylaxis and have their dental records monitored for 18 months post-enrollment.
16579407|NCT02749305|Other|Preop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures preoperatively and annually postoperatively will occur with all metabolic and bariatric surgery patients scheduled for surgery at a participating center.
16579408|NCT02749305|Other|Postop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures annually postoperatively will occur with all metabolic and bariatric surgery patients who had surgery at a participating center within the preceding 12 months.
16579435|NCT02749097|Experimental|Cohort 4|Single oral dose of 100 mg SHR0534 or matching placebo
16579436|NCT02749097|Experimental|Cohort 5|Single oral dose of 200 mg SHR0534 or matching placebo
16579463|NCT02748967|Experimental|Group 6|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
16579409|NCT02749292|Active Comparator|B cell reconstitution|Subjects will no longer receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months for B cell return. Once peripheral B cells rise to ≥ 10cells/mm3 they will receive rituximab 1000 mg IV x 2 (doses spaced approx. 2-3 weeks apart). Subsequent dosing will be again based on B cell return (≥ 10 B cells/mm3), with patients seen in clinic and B cells monitored every 3 months.
16579410|NCT02749292|Active Comparator|Serologic ANCA flare|Subjects will not receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months in clinic. Re-dosing will occur once the subject's ANCA titer has risen above the predetermined treatment value (MPO treatment value defined as a 5-fold rise from baseline and a level greater than 4 times the cutoff value for the assay; PR3 treatment value defined as a 4-fold rise from baseline and a level greater than 2-fold above the cutoff for the assay). Subjects who meet this criteria will then be re-dosed with rituximab 1000 mg IV x2 (spaced 2-3 weeks apart). If the ANCA titer remains 2-fold above baseline and above a specified threshold (the cutoff value of the assay for PR3 and 4 times the cutoff value for MPO), subjects will then receive rituximab 1000mg IV every 6 months x 2 doses and a new ANCA titer baseline will be established. The cycle will then re-start.
16579411|NCT02749266|Experimental|Chiropractic Activator Adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
16579412|NCT02749266|Sham Comparator|Chiropractic sham adjustment|Participant will receive a sham (simulated) chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
16579413|NCT02749253|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
16579414|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program (Youth Empowerment Seminar, YES!) will be offered to at risk youth participating in programs or resources offered by Youth Opportunities Unlimited. The YES! program will be taught in two phases: (1) an active learning phase which consists of four consecutive days (3 hrs/day) of SEL skills taught in a multi-modality interactive format as well as SKY training, and (2) a reinforcement phase which involves weekly follow up sessions (75-90 mins each) for the 7 weeks following the active phase. Two certified instructors from the Art of Living Foundation (Spencer Delisle and Mark Frye) will deliver this training under supervision of Ronnie Newman (RN). After the initial 4 day training, participants will be asked to practice SKY daily for 20-25 minutes in addition to attending the weekly follow up sessions.
16579415|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
16579416|NCT02749214||Parkinson's Disease (PD)|Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
16579417|NCT02749214||Healthy Control|Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
16579418|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
16579419|NCT02749188|Other|bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes.
16579420|NCT02749175|Experimental|Cricoid force sensor monitor system|Nurse applied cricoid pressure with a sensor guided by monitoring Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons.
16579421|NCT02749175|Sham Comparator|Sham cricoid force sensor monitor system|Nurse applied pressure on a sham sensor with no monitor input. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
16579422|NCT02749175|No Intervention|Current standard|Nurse applied cricoid force according to memory. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
16579423|NCT02749162|Placebo Comparator|Group A|After the spinal anesthesia regressed, the investigators performed a single shot femoral block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
16579424|NCT02749162|Active Comparator|Group B|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg and 4 mg dexamethasone phosphate. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
16579425|NCT02749162|Active Comparator|Group C|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg+ lidocaine 1% 200 mg and 8 mg dexamethasone phosphate.After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
16579426|NCT02749149||Cardiac Surgery|Patients undergoing cardiac surgery: coronary artery bypass graft (CABG); valve replacement/repair; or transcatheter aortic valve implantation (TAVI) surgery
16579427|NCT02749136|Experimental|Perioperative chemotherapy|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles
~Postoperative gemcitabine, every 4 weeks, 3-6 cycles"
16579428|NCT02749123|Active Comparator|Lidocaine5% v Lidocaine3.6%,Menthol1.25%|Daily patch Q12 followed by Q12 of no patch
16579429|NCT02749123|Placebo Comparator|Lidocaine 3.6%, menthol 1.25% v placebo|Daily patch Q12 followed by Q12 of no patch
16579430|NCT02749110|Experimental|Self-sampling for HPV test|Invitation to participate to the screening process by means of the usual care (pap-test) or the provision of a vaginal self-sampling brush (Evalyn Brush°). Self-collected samples are mailed to a central lab for HPV testing.
16579431|NCT02749110|No Intervention|Usual care (Pap test)|Intervention: invitation to participate to the screening process by means of the usual care (pap-test).
16579437|NCT02749084|Experimental|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.
~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.
~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).
~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.
~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).
~Patients in the MTD study should be about 10, according to Fleming."
16579438|NCT02749071|Sham Comparator|Control Group|This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
16579439|NCT02749071|Experimental|Treatment Group|The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
16579440|NCT02749058|Other|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
16579441|NCT02749058|Other|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
16579442|NCT02749045|Other|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
16579443|NCT02749032|Active Comparator|Vildagliptin - stratum diet/exercise|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
~Mixed meal test were performed in the morning after an overnight fast."
16579444|NCT02749032|Active Comparator|Vildagliptin - stratum metformin|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
~Mixed meal test were performed in the morning after an overnight fast."
16579445|NCT02749032|Active Comparator|Sitagliptin - stratum diet/exercise|"The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
~Mixed meal test were performed in the morning after an overnight fast."
16579446|NCT02749032|Active Comparator|Sitagliptin - stratum metformin|"In patients treated with metformin, sitagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening.
~Mixed meal test were performed in the morning after an overnight fast."
16579447|NCT02749032|Placebo Comparator|Placebo - stratum diet/exercise|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
~Mixed meal test were performed in the morning after an overnight fast."
16579448|NCT02749032|Placebo Comparator|Placebo - stratum metformin|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
~Mixed meal test were performed in the morning after an overnight fast."
16579449|NCT02749019|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
16579450|NCT02749006|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
16579451|NCT02749006|Sham Comparator|Sham rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
16579452|NCT02748993|Experimental|PAC-14028 Cream 0.1%|PAC-14028 Cream 0.1%, Twice daily for 4 weeks
16579453|NCT02748993|Experimental|PAC-14028 Cream 0.3%|PAC-14028 Cream 0.3%, Twice daily for 4 weeks
16579454|NCT02748993|Experimental|PAC-14028 Cream 1.0%|PAC-14028 Cream 1.0%, Twice daily for 4 weeks
16579455|NCT02748993|Placebo Comparator|PAC-14028 Cream Vehicle|PAC-14028 Cream Vehicle, twice daily for 4 weeks
16579456|NCT02748980||Non- obstructive coronary artery disease, non- diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed without diabetes.
16579457|NCT02748980||Non- obstructive coronary artery disease, diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed with type 2 diabetes.
16579458|NCT02748967|Experimental|Group 1|Participants with age (greater than or equal to [>=] 20 to less than [<] 50 years) will receive single dose of 0.5 milliliter (mL) of ExPEC4V (4:4:4:4) or placebo on Day 1.
16579459|NCT02748967|Experimental|Group 2|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
16579460|NCT02748967|Experimental|Group 3|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
16579461|NCT02748967|Experimental|Group 4|Participants with age greater than or equal to [>=] 50 will receive single dose of 0.5 mL of ExPEC4V (4:4:4:4) or placebo on Day 1.
16579462|NCT02748967|Experimental|Group 5|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
16579811|NCT02746731|Experimental|Prehabilitation|'Cardiorespiratory and resistance training.
16579464|NCT02748954|Experimental|Thoughts.|"Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week"
16579465|NCT02748954|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
16579466|NCT02748954|Experimental|Assertiveness|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict
16579467|NCT02748954|Experimental|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
16579468|NCT02748954|Active Comparator|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
16579469|NCT02748941|Experimental|symptomatic and asymptomatic patients|
16579470|NCT02748928|Experimental|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.
~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
16579471|NCT02748915|Experimental|Patients using cochlear implants|All patients using cochlear implants included in the study will take electrophysiological and psychoacoustic tests to measure auditive parameters regarding the study objectives : ECAP, EABR, speech recognition and MCL.
16579472|NCT02748915|Experimental|Patients using EAS device|Patients using EAS device for more than 11 months will take electrophysiological and psychoacoustic tests with the implant functioning only with electrical pulses or in bimodal mode to measure ECAP, EABR, speech recognition and MCL ; this will allow to perform bimodal comparison.
16579473|NCT02748915|Experimental|Patients with bilateral cochlear implant|Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
16579474|NCT02748902|Experimental|ingenol mebutate 0.05% gel|Single group, open label. All subjects will receive active product.
16579475|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
16579476|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
16579477|NCT02748876|Experimental|His-Ventricular (HV)-optimised|His-Ventricular (HV) optimised atrioventricular delay
16579478|NCT02748876|No Intervention|Non-optimised|Standard atrioventricular delay
16579479|NCT02748863|Placebo Comparator|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
16579480|NCT02748863|Experimental|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
16579481|NCT02748863|Active Comparator|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
16579482|NCT02748850|Active Comparator|leukemia patients|Patients with acute leukemia and / or refractory anemia with excess blasts and comprising a number of blasts in the blood greater than 5% device.
16579483|NCT02748850|Placebo Comparator|apheresis patients|patients with non-myeloid hematological malignancy
16579484|NCT02748837|Experimental|Dose escalation cohort of ERY974|Dose escalation (DE) will proceed with the dose level increment and the dose cohort size being guided by a safety evaluations during and at the end of each cohort. DE initially utilizes an accelerated titration design (ATD) and once the first dose limiting toxicity (DLT) is observed, DE will continue using a modified continual reassessment method (mCRM) until MTD.
16579485|NCT02748837|Experimental|Cohort expansion in gastric cancer|Patients with GPC3 positive advanced gastric cancer or gastroesophageal junction cancer will receive ERY974 at recommended dose until disease progression.
16579486|NCT02748837|Experimental|Cohort expansion in esophageal carcinoma|Patients with GPC3 positive advanced squamous cell esophageal carcinoma will receive ERY974 at recommended dose until disease progression.
16579487|NCT02748837|Experimental|Cohort expansion in other solid tumors|Patients with other GPC3 positive advanced solid tumors will receive ERY974 at recommended dose until disease progression
16579488|NCT02748811|No Intervention|Control group|The control group receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change in treatment or progression. If the patient has other health problems, those issues will be assessed either by the oncologist or by the general practitioner. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
16579489|NCT02748811|Active Comparator|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. They will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
16579490|NCT02748798|Experimental|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
16579491|NCT02748798|Experimental|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
16579492|NCT02748785|Experimental|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
16579493|NCT02748785|Experimental|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
16579494|NCT02748785|Experimental|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
16579495|NCT02748785|Experimental|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
16579496|NCT02748772|Active Comparator|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
16579497|NCT02748772|Placebo Comparator|Pure chemotherapy（Xelox）|chemotherapy alone for the patients of Advanced Colorectal Cancer
16579498|NCT02748759|Active Comparator|EXP 1: Manual mobilization / CPM|Patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist. After a pause of 5 minutes, the patient was collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension.
16579499|NCT02748759|Active Comparator|EXP 2: CPM / Manual mobilization|Patients were collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension. After a pause of 5 minutes, patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist.
16579500|NCT02748746|Experimental|Surgery no Lymphedema|The inclusion criteria for involving the first group is surgery time. No one will be involved into the first group if surgery was applied 18 months ago before enrollment to this study. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum. Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
16579501|NCT02748746|Experimental|Surgery having Lymphedema|The second group will contain patients who had breast cancer surgery and having upper extremity lymphedema.Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
16579502|NCT02748746|Active Comparator|Healthy Women|The third group will contain healthy women. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
16579503|NCT02748733|Active Comparator|Adapted double mini PET|"PET = Peritoneal Equilibration Test, a test routinely performed to measure peritoneal transport rates of solutes and water in peritoneal dialysis patients. To this end the routinely administered dialysis fluid is infused into the peritoneal cavity. The test will be modified (adapted):
~A short, small cycle (0.6 mL/m² BSA, 30 min) followed by a long, large cycle (1.4 mL/m², 120 min) will be performed in each patient and compared to a standard double mini PET."
16579504|NCT02748733|Placebo Comparator|Standard double mini PET|The Standard double mini PET consists of two identical cycles (fill volume 1 L/m², 75 min of dwell time)
16579505|NCT02748720|Experimental|RFM Visible|Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
16579506|NCT02748720|No Intervention|RFM No Visible|Patients will be randomize in a Group 2, where the parameters of TVe and respiratory flow would not be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). Always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the Spanish Society of Neonatology, based on international recommendations (1-3.5) apply. In turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks
16579507|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
16579508|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
16579509|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
16579510|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
16579511|NCT02748694|Placebo Comparator|Part 1 (SRD): Placebo Cohorts 1-5|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
16579512|NCT02748694|Experimental|Part 1 (SRD): Cohort 1: TAK-041 5/20 mg|TAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period.
16579513|NCT02748694|Experimental|Part 1 (SRD): Cohort 2: TAK-041 10/40 mg|TAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period.
16579514|NCT02748694|Experimental|Part 1 (SRD): Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
16579515|NCT02748694|Experimental|Part 1 (SRD): Cohort 4: TAK-041 120 mg|TAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
16579516|NCT02748694|Experimental|Part 1 (SRD): Cohort 5: TAK-041 160 mg|TAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
16579517|NCT02748694|Placebo Comparator|Part 2 (MRD): Placebo Cohorts 1-4|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period.
16579518|NCT02748694|Experimental|Part 2 (MRD): Cohort 1: TAK-041 40/20 mg|TAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
16579519|NCT02748694|Experimental|Part 2 (MRD): Cohort 2: TAK-041 80/40 mg|TAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
16579520|NCT02748694|Experimental|Part 2 (MRD): Cohort 3: TAK-041 120/60 mg|TAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
16579521|NCT02748694|Experimental|Part 2 (MRD): Cohort 4: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
16579522|NCT02748694|Experimental|Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen A|TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.
16579523|NCT02748694|Experimental|Part 3: RBA/Food Effect: Regimen B|TAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2.
16579524|NCT02748694|Placebo Comparator|Part 4: MRD: Placebo|TAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia
16579525|NCT02748694|Experimental|Part 4: MRD: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia.
16579526|NCT02748681|Active Comparator|Telemedicine Group|Patient group with a telemedicine monitoring system
16579527|NCT02748681|Active Comparator|Standard Group|Patient Group without a telemedicine monitoring
16579528|NCT02748668||ECMO|No intervention. Blood specimen collection.
16579529|NCT02748668||Control|No intervention. Blood specimen collection.
16579530|NCT02748655|Placebo Comparator|Tap water|Oral consumption of tap water
16579531|NCT02748655|Active Comparator|Alkaline ionized water|Oral consumption of alkaline ionized water
16579532|NCT02748642|Experimental|Part A Cohort A: BITS7201A Dose Level 1 Subcutaneous (SC)|Healthy participants will receive a single SC dose of BITS7201A dose Level 1 on Day 1.
16579533|NCT02748642|Experimental|Part A Cohort B: BITS7201A Dose Level 2 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 2 on Day 1.
16579534|NCT02748642|Experimental|Part A Cohort C: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 on Day 1.
16579535|NCT02748642|Experimental|Part A Cohort D: BITS7201A Dose Level 4 Intravenous (IV)|Healthy participants will receive a single IV dose of BITS7201A dose Level 4 on Day 1.
16579536|NCT02748642|Experimental|Part A Cohort E: BITS7201A Dose Level 6 IV|Healthy participants will receive a single IV dose of BITS7201A dose Level 6 on Day 1.
16579537|NCT02748642|Placebo Comparator|Part A: Placebo|Healthy participants will receive a single SC or IV dose of placebo matched to BITS7201A on Day 1.
16579538|NCT02748642|Experimental|Part B Cohort F: BITS7201A Dose Level 3 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 3 every 4 weeks (Q4W) on Days 1, 29, and 57.
16579539|NCT02748642|Experimental|Part B Cohort G: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 Q4W on Days 1, 29, and 57.
16579540|NCT02748642|Experimental|Part B Cohort H: BITS7201A Dose Level 5 SC|Healthy participants will receive SC dose of BITS7201A dose Level 5 Q4W on Days 1, 29, and 57.
16579541|NCT02748642|Experimental|Part B Cohort I:BITS7201A Dose Level 5 SC (Mild Atopic Asthma)|Mild atopic asthma participants will receive SC dose of BITS7201 dose Level 5 Q4W on Days 1, 29, and 57.
16579542|NCT02748642|Placebo Comparator|Part B: Placebo|Healthy participants or mild atopic asthma participants will receive SC doses of placebo matched to BITS7201A Q4W on Days 1, 29, and 57.
16579543|NCT02748629|Active Comparator|ProGrip Mesh Repair|80 patients are randomized to inguinal hernia repair using selfgripping ProGrip Mesh (Covidien Parietex ProGrip Self-Fixating Mesh) - sutureless fixation.
16579544|NCT02748629|Active Comparator|Lichtenstein Operation|80 patients are randomized to inguinal hernia repair using lightweight polypropylene mesh (<40 g/m2) with standard Lichtenstein technique.
16579545|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
16579546|NCT02748603||Patient with non ST Elevation - Acute Coronary Syndrome|
16579547|NCT02748603||Patient with stable Coronary Artery Disease (CAD)|
16579548|NCT02748590|Experimental|Neuromodulation|
16579549|NCT02748577|Experimental|Migraine|Participants with migraines will complete one study visit where they will complete several questionnaires and will also complete Quantitative Sensory Testing (QST) Pain Measurements. They must be migraine-free during the visit and no migraine within 48 hrs of study visit
16579550|NCT02748577|Active Comparator|Healthy Controls|Healthy Controls will complete one study visit where they will complete several questionnaires and will complete Quantitative Sensory Testing (QST) Pain Measurements.
16579551|NCT02748564|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
16579552|NCT02748551|Experimental|Laparoscopic surgery|Traditional open procedure for patient with locally advanced gastric cancer
16579553|NCT02748551|Active Comparator|Open surgery|Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
16579554|NCT02748538||Face Down|To posture in the face down position for the first 24 hours following surgery.
16579812|NCT02746731|Active Comparator|Reference|Usual care.
16579555|NCT02748538||Position to Support the Break|The head is positioned so that the retinal breaks (which caused the retinal detachment) are positioned at the highest point of the eye and well supported by the intra-ocular gas bubble left within the eye at the completion of surgery.
16579556|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
16579557|NCT02748512|Experimental|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
16579558|NCT02748512|Active Comparator|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
16579559|NCT02748499|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
16579560|NCT02748499|Active Comparator|Control|The control group maintains daily activities.
16579561|NCT02748486|Experimental|Jumping To Conculsions|Metacognitive Training Jumping to conclusions module
16579562|NCT02748486|Experimental|Theory of Mind|Metacognitive Training To empathize... module
16579563|NCT02748486|Sham Comparator|Control|group discussion of current events
16579564|NCT02748473|Other|pelvic floor muscle strength|evaluated pelvic floor muscle strength before and after Pilates exercises program on sedentary nulliparous women
16579565|NCT02748473|Other|Device: 3D perineal ultrasound|evaluated the pubovisceral muscle thickness and the levator hiatus area before and after Pilates exercises program on sedentary nulliparous women
16579566|NCT02748460||Patients treated with Esmya|Any patient who was confirmed as receiving one dose of Esmya
16579567|NCT02748447|Experimental|A-FiO2|24 hours in automated FiO2 adjustment to maintain SpO2 within a target range
16579568|NCT02748447|No Intervention|M-FiO2|24 hours in manual adjustment of FiO2 to maintain SpO2 within a target range
16579569|NCT02748434|Other|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
16579570|NCT02748434|Other|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
16579571|NCT02748421|Other|Lumera Microscope with OCT RESCAN|in the group microscope coupled to OCT, patients will undergo retinal surgery using the Lumera microscope with Rescan OCT Zeiss
16579572|NCT02748421|Other|Conventional Microscope|control group without OCT RESCAN
16579573|NCT02748395|Placebo Comparator|Placebo|Injection of 3.5mL of normal saline into the point of maximal tenderness in the abdomen
16579574|NCT02748395|Experimental|Treatment|Injection of 20mg triamcinolone and 1% lidocaine into the point of maximal tenderness in the abdomen
16579575|NCT02748382|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
16579576|NCT02748382|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
16579577|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
16579578|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
16579579|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
16579580|NCT02748343|Active Comparator|allograft bone|traditional allograft bone
16579581|NCT02748343|Experimental|tissue-engineered bone|tissue-engineered bone
16579582|NCT02748330|Experimental|Ticagrelor|Oral ticagrelor 90 mg tablet, twice daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
16579583|NCT02748330|Active Comparator|Clopidogrel|Oral clopidogrel 75 mg tablet, once daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
16579584|NCT02748317|Experimental|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
16579585|NCT02748304|Placebo Comparator|control|just follow up after liver resection in HCC patients
16579586|NCT02748304|Active Comparator|sorafenib|use sorafenib after liver resection in HCC patients
16579587|NCT02748304|Active Comparator|sorafenib and aspirin|use sorafenib and aspirin after liver resection in HCC patients
16579588|NCT02748291|Experimental|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
16579589|NCT02748291|Active Comparator|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
16579590|NCT02748265|Other|Inhaled Epoprostenol, phenylephrine, sevoflurane|Inhaled Epoprostenol (Flolan), phenylephrine, volatile anesthesia maintenance (Sevoflurane)
16579591|NCT02748265|Other|Inhaled Epoprostenol phenylephrine & Propofol|Inhaled Epoprostenol (Flolan), phenylephrine and intravenous anesthesia maintenance (Propofol)
16579592|NCT02748252||HIV patients|HIV patients admitted in Stroke units for the first occurence of acute stroke
16579593|NCT02748252||non HIV patients|non HIV patients admitted in Stroke units for the first occurence of acute stroke
16579594|NCT02748239|Active Comparator|MEDIAS 2 CT|The MEDIAS CT is a newly developed education program for the initiation of a conventional insulin therapy in type 2 diabetic patients.
16579595|NCT02748239|Placebo Comparator|Current CT program|This program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients.
16579596|NCT02748226||Retrospective cohort|This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals.
16579597|NCT02748226||Prospective cohort|This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals.
16579598|NCT02748213|Experimental|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
16579599|NCT02748213|Experimental|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
16579600|NCT02748200|Experimental|external beam radiotherapy: Dose level 1|57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)
16579601|NCT02748200|Experimental|external beam radiotherapy: dose level 2|60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)
16579602|NCT02748200|Experimental|external beam radiotherapy: dose level 3|62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)
16579603|NCT02748187|Experimental|Intervention|Cognitive Behavioural Analysis System of Psychotherapy
16579604|NCT02748174|Experimental|Episodic Migraine group|100 patients with chronic or episodic migraine
16579605|NCT02748174|Experimental|Chronic Migraine Group|100 patients with chronic or episodic migraine
16579606|NCT02748174|Experimental|Post concussive Headache Group|75 patients
16579607|NCT02748161|Active Comparator|DEB-TACE: Standard Endhole Catheter|Subjects will undergo DEB-TACE using a standard endhole catheter.
16579608|NCT02748161|Active Comparator|DEB-TACE: Surefire Infusion System|Subjects will undergo DEB-TACE using the Surefire Infusion System.
16579609|NCT02748148|Experimental|Medication therapy management|Medication therapy management service that is enhanced by the incorporation of pharmacogenomics and medication risk mitigation factor technology
16579610|NCT02748135|Experimental|TB-403 20mg/kg|
16579611|NCT02748135|Experimental|TB-403 50mg/kg|
16579612|NCT02748135|Experimental|TB-403 100mg/kg|
16579613|NCT02748135|Experimental|TB-403 175mg/kg|
16579614|NCT02748122|Experimental|Adolescents with T2DM|
16579615|NCT02748109|Experimental|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback
16579616|NCT02748109|Active Comparator|Vestibular Rehabilitation|Vestibular rehabilitation
16579617|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
16579618|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
16579619|NCT02748083|Active Comparator|tDCS group|The active tDCS group will be stimulated with transcranial Direct Current Stimulation (tDCS).
16579620|NCT02748083|Sham Comparator|Sham tDCS group|The sham tDCS group will have stimulation with sham transcranial Direct Current Stimulation (tDCS).
16579621|NCT02748070|Experimental|Prednisone|Provided oral steroid and topical steroid
16579622|NCT02748070|Placebo Comparator|Placebo|Provided oral placebo and topical steroid
16579623|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
16579624|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
16579625|NCT02748044|Experimental|Eligible patients for CC-Cruiser test|
16579626|NCT02748031|Experimental|eligible patients group|
16579629|NCT02748005|Experimental|Fenugreek seeds extract 500 mg|Fenugreek seeds extract(Furosap) 500 mg
16579630|NCT02747992||PECS 0|receiving paravertebral block
16579631|NCT02747992||PECS 1|receiving paravertebral block and blocks targeting pectoral musculature
16579632|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA330)|Combination of hemodialysis and hemoperfusion (HA330) therapy All subjects in the study phase will receive hemodialysis plus hemoperfusion(HA330) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
16579633|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA130)|Combination of hemodialysis and hemoperfusion (HA130) treatment All subjects in the study phase will receive hemodialysis and hemoperfusion(HA130) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
16579634|NCT02747979|Active Comparator|hemodialysis only|hemodialysis only All subjects in the study phase will receive regular hemodialysis treatment three times per week.
16579635|NCT02747953|Experimental|afatinib|
16579636|NCT02747940|Experimental|patients with chronic migraine|flunarizine for patients with chronic migraine
16579637|NCT02747940|Experimental|patients with fibromyalgia|pregabalin for patients with fibromyalgia
16579638|NCT02747940|Experimental|patients with chronic migraine and fibromyalgia|flunarizine and pregabalin for patients with chronic migraine and myalgia
16579639|NCT02747927|Placebo Comparator|Placebo|Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).
16579640|NCT02747927|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0).
16579641|NCT02747914|Experimental|Transcranial magnetic stimulation therapy|Group of patients treated with rTMS low than 5Hz
16579642|NCT02747914|Active Comparator|Conventional exercise treatment|Group of patients treated with conventional exercise
16579643|NCT02747901|Experimental|Kinesiotaping Group|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
16579889|NCT02746133||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
16579644|NCT02747901|Active Comparator|Cold Therapy Group|Cold Therapy group received cold pack immediately after operation and following postoperative days.
16579645|NCT02747901|No Intervention|Control Group|Control group have no intervention.
16579646|NCT02747888|No Intervention|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition
~Screening and Enrollment:
~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
~- Sample stored in Biorepository"
16579647|NCT02747888|Experimental|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition
~Screening and Enrollment:
~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
~- Specimen Testing and Analysis
~•Referral to Genetic Counselor, if indicated"
16579648|NCT02747875|Active Comparator|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
16579649|NCT02747875|Active Comparator|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
16579650|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
16579651|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
16579652|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
16579653|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
16579654|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
16579655|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
16579656|NCT02747823|Experimental|CBT124|CBT124, single dose of 1 mg/kg, IV infusion
16579657|NCT02747823|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 1 mg/kg, IV infusion
16579658|NCT02747823|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 1 mg/kg, IV infusion
16579659|NCT02747810|Experimental|New TENS design|To determine the function and safety of the strap design by evaluating the electrical connection to electrode, 2) the security in the insole and the electronic unit, and 3) facilitating observation and hand access to the top panel for adjusting the stimulation strength. 4) to elicit toe twitching with stimulation of tribal nerve
16579660|NCT02747797|Experimental|Advanced cancer with lucitanib-targeting biomarker(s)|Lucitanib 10 mg orally daily
16579661|NCT02747784|Experimental|Study group experimental|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
16579662|NCT02747784|Active Comparator|Study group active comparator|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Working memory (WOME)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
16579663|NCT02747784|No Intervention|Control group|48 female control subjects aged 18 years or older (24 without surgery, 24 with urogynecological or breast cancer surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
16579664|NCT02747758|Sham Comparator|Control|sham transcranial direct current stimulation (tDCS)
16579665|NCT02747758|Experimental|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
16579666|NCT02747758|Experimental|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
16579667|NCT02747745|No Intervention|Control Group|Group receive no intervention
16579668|NCT02747745|Experimental|Interventional Group|Four risk areas reflecting the great needs of FCGs of PWDs: depressive symptoms, burden, distress to problematic behaviors of PWDs and healthy behaviors.
16579669|NCT02747732|Experimental|one arm|"Therapy initiation 30 days max from screening.
~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
16579670|NCT02747719|Experimental|Light and exercise|Exposure to light with exercise
16579671|NCT02747706|Experimental|Parent Mentoring|1-on-1, phone, SMS/text, and smartphone-based parent-to-parent mentoring.
16579672|NCT02747706|No Intervention|Usual Care|No intervention through study.
16579673|NCT02747680|Other|type 1 diabetes|type 1 diabetes >5 years duration Well controlled (a1c <7.5%)
16579674|NCT02747680|Other|healthy controls|healthy controls
16579972|NCT02745613|Experimental|Family history of T2D|The participants will undergo 8 weeks of combined exercise
16579675|NCT02747667||Eye with late IOL complication|Alle patients with IOL complication (subgroup: in-the-bag dislocation; out-of-the-bag dislocation; haptic dislocation)
16579676|NCT02747667||Eyes with no late IOl complication|
16579677|NCT02747654|No Intervention|standard dosing|a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight
16579678|NCT02747654|Experimental|Genotype-guided dosing|INH dose determined based on developed model
16579679|NCT02747641|Other|treatment|only one arm
16579680|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
16579681|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
16579682|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
16579683|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
16579684|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
16579685|NCT02747602|Experimental|Group ABC|AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
16579686|NCT02747602|Experimental|Group BCA|caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
16579687|NCT02747602|Experimental|Group CAB|caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
16579688|NCT02747589|Experimental|Treatment Group|Subjects will be implanted to assess the feasibility of stimulating visual cortex to restore vision in blind volunteers.
16579689|NCT02747576||Medulloblastoma Group|Medulloblastoma survivors, 30 between the ages of 12-20 years and 30 between 21-30 years.
16579690|NCT02747576||Control Group|Health comparison group frequency matched on age (30 between the ages of 12-20 years and 30 between 21-30 years), gender and race.
16579691|NCT02747563|Experimental|Active Surveillance|Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
16579692|NCT02747563|Active Comparator|Controls|Patients without known diagnosis of prostate cancer Intervention - PSA measurement
16579693|NCT02747550|Experimental|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
16579694|NCT02747550|Active Comparator|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy.
16579695|NCT02747537|Experimental|Arm 1: Sorafenib and Irinotecan|"Sorafenib is an oral drug which will be administered on an outpatient basis twice a day continuously (every day of a 21-day cycle) at approximately the same times each day. For patients unable to swallow whole pills, an oral suspension may be prepared with tablets.
~Irinotecan will be administered orally (mixed with cranberry type juice) on an outpatient basis once a day on Days 1-5 of a 21-day cycle. Irinotecan should be given at least 1 hour after sorafenib."
16579696|NCT02747524|Experimental|Vita Mamba|Nutrient fortified peanut butter paste for 26 weeks.
16579697|NCT02747524|No Intervention|Control|
16579698|NCT02747511|Active Comparator|Haloperidol|
16579699|NCT02747511|Placebo Comparator|Placebo|
16579700|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
16579701|NCT02747498|Experimental|Posterior box isolation in addiction to pulmonary vein isolation|Posterior box isolation in addiction to circumferential pulmonary vein isolation
16579702|NCT02747485|Experimental|organic left-sided regurgitant valve|
16579703|NCT02747472|Placebo Comparator|Placebo|Infusion of saline
16579704|NCT02747472|Active Comparator|GIP(1-42)|Infusion of agonist, GIP(1-42)
16579705|NCT02747472|Experimental|GIP-A|Infusion of GIP-A alone
16579706|NCT02747472|Experimental|GIP-A + GIP(1-42)|Infusion of GIP-A and GIP(1-42)
16579707|NCT02747459|Experimental|SSS Intervention|Sensory Supported Swimming-eight, 30 minute lessons
16579708|NCT02747446|Experimental|Honey|added sugar: diet with 25% acacia honey
16579709|NCT02747446|Experimental|Fructose:glucose mixture|added sugar: Diet with 25% energy as a fructose:glucose mixture
16579710|NCT02747446|No Intervention|control|no intervention: Diet with 45% starch and no honey or added sugars
16579711|NCT02747433|Active Comparator|ALPS + Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
16579712|NCT02747433|Active Comparator|ALPS + Robot + Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
16579713|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
16579714|NCT02747420|Sham Comparator|Sham Group|
16579717|NCT02747394|Experimental|Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of adaptive Cogmed
16579718|NCT02747394|Other|Non-Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of non-adaptive Cogmed
16579719|NCT02747381|Experimental|intervention|receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications
16579720|NCT02747381|No Intervention|control|Asthmatic patients receiving conventional asthma medications
16579721|NCT02747368|Other|Wet age related macular degeneration|Ocusweep system is compared to results of conventional devices.
16579722|NCT02747342|Experimental|SHR3680; SHR3680+SHR3162|In dose esclation and expansion phase, SHR3680 will be administered orally In combination phase, SHR3680 will be administered together with SHR3162
16579723|NCT02747329|Experimental|1st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
16579724|NCT02747329|Active Comparator|1st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
16579725|NCT02747329|Experimental|2st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
16579726|NCT02747329|Active Comparator|2st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
16579727|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 20|
16579728|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 30|
16579729|NCT02747303|Active Comparator|Stereotactic Radiosurgery to 2 mm GTV to PTV margins|
16579730|NCT02747303|Experimental|Stereotactic Radiosurgery to 0 mm GTV to PTV margins|
16579731|NCT02747290|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
16579732|NCT02747264|Experimental|eRAPID intervention|Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment online and weekly for 6 weeks post treatment (a total of 12 weeks) and then at 18 & 24 weeks. Hospital staff will be able to review eRAPID reports and use the information during the consultation in clinic, when attending radiotherapy or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.
16579733|NCT02747264|No Intervention|Usual care|The Usual care patients act as a comparison to the patients using eRAPID. They complete a paper-based quality of life questionnaire at baseline and then 6, 12 and 24 weeks after. The researchers will also collect clinical process measures for this group including number of hospital contacts and admissions.
16579734|NCT02747251|Experimental|Strengthen your Shoulder & Usual Care|"Instructions in a home-based intervention consisting of progressive high volume resistance training with an elastic band. Instructions provided 0, 2, 5, and 10 weeks after baseline. Usual care includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
16579735|NCT02747251|Active Comparator|Usual Care|"Includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
16579736|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
16579737|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
16579738|NCT02747199|Active Comparator|Coronary artery implanted with SYNERGY stent|One of the blocked coronary artery of a patient will received SYNERGY stent
16579739|NCT02747199|Active Comparator|Coronary artery implanted with ABSORB scaffold|Another blocked coronary artery of the same patient will received ABSORB scaffold
16579740|NCT02747186|Active Comparator|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.
~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
16579741|NCT02747186|Active Comparator|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.
~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
16579742|NCT02747173||RCC patients with bone metastases|Patients will receive the standard TKI treatment for first line treatment naive metastatic RCC. Sunitinib or pazopanib as decided by the investigator.
16579743|NCT02747160|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a six-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
16579744|NCT02747147|No Intervention|A- Control|Group A will have their PIVs assessed daily and record kept of PIV dislodgement or replacement
16579745|NCT02747147|Experimental|B - Device Intervention|patients will have their PIVs assessed daily and record kept of PIV displodgement or replacement. patients will additionally have a single blood collection attempted using the study device
16579746|NCT02747134|Experimental|Emotion Regulation and Mindfulness skills|A 10 week intervention including emotion regulation and mindfulness skills from dialectical behavioral therapy (DBT) was delivered.
16579747|NCT02747134|Active Comparator|Psychoeducation|Psychoeducation consisted of 5 session in which basic information about depressive symptoms and how to prevent depression relapse was given.
16579777|NCT02746965|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
16579778|NCT02746952|Experimental|UCART19|
16579748|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
16579749|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
16579750|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
16579751|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
16579752|NCT02747095|Experimental|Spectral CT image|Interventions: IQon Spectral CT
16579753|NCT02747082|Active Comparator|1% sodium hypochlorite (NaOCl)|"Retreatment of root-filled teeth with infection with 1% NaOCl as irrigation solution.
~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
16579754|NCT02747082|Active Comparator|2% chlorhexidine gluconate (CHX)|"Retreatment of root-filled teeth with infection with 2% CHX as irrigation solution.
~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
16579755|NCT02747069||NICU electronic stethoscope|Neonatal patients of any gestation admitted to the neonatal intensive care unit (NICU) and undergoing routine monitoring with ECG and pulse oximetry Heart rate will be evaluated using an electronic stethoscope
16579756|NCT02747069||Newborns <32 weeks and ECG|Neonatal patients <32 weeks gestation Heart rate will be assessed at the time of delivery with both an electronic stethoscope and ECG using a pre placed lead system
16579757|NCT02747056|Experimental|Autism spectrum disorder studyA part1|The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
16579758|NCT02747056|Experimental|Autism spectrum disorder studyA part2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
16579759|NCT02747056|Other|Control adults Study A, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
16579760|NCT02747056|Other|Control adults Study A, part 2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
16579761|NCT02747056|Experimental|Autism spectrum disorder Study B, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
16579762|NCT02747056|Experimental|Autism spectrum disorder Study B, part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements.
16579763|NCT02747056|Other|Control adults, Study B part 1|The subjects will perform clinical, psychological and neuropsychological assessment.The subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
16579764|NCT02747056|Other|Control adults, Study B part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements
16579765|NCT02747043|Experimental|ABP 798|ABP 798 was administered at a dose of 375 mg/m^2 as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
16579766|NCT02747043|Active Comparator|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
16579767|NCT02747030|Experimental|Ocriplasmin intravenously|All subjects included in this phase I study are in the experimental treatment arm and will undergo a vitrectomy augmented with retinal vein cannulation and intravenous Ocriplasmin infusion.
16579768|NCT02747017||CDI patients|Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
16579769|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
16579770|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
16579771|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
16579772|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
16579773|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
16579774|NCT02746978|Active Comparator|Peer directed education|A revised education approach that focuses on problem solving discussions delivered by peers and grounded clinical information is compared to traditional approach of didactic clinician-driven education lectures
16579775|NCT02746978|Other|Patient Engagement Portal|A patient-owned portal to manage injury information is maintained in real-time by patients and families and shared with other care providers after inpatient rehabilitation discharge.
16579776|NCT02746965|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
16579779|NCT02746939|No Intervention|Pre-curriculum assessment|Assessments will be administered to 3rd and 4th grade students prior to receiving curriculum training in fitness and nutrition.
16579780|NCT02746939|Experimental|Post-curriculum assessment|Assessments will be administered to 3rd and 4th grade students (matched from pre-curriculum assessment) after receiving 4-6 week InSciEd Out Fitness and Nutrition Curriculum.
16579781|NCT02746926|Experimental|4x20 mg tafamidis meglumine soft gel capsule|
16579782|NCT02746926|Experimental|48.8 mgA tafamidis free acid capsule|
16579783|NCT02746926|Experimental|61 mgA tafamidis free acid capsule|
16579784|NCT02746913|Experimental|Urodynamics, followed by Pessary|
16579785|NCT02746913|Experimental|Pessary, followed by Urodynamics|
16579786|NCT02746900|Experimental|Cervical cerclage|After the woman is placed in the dorsal lithotomy position and the bladder is emptied with a urinary catheter to reduce the chance of bladder injury, surgical preparation with Betadine will be performed. Breisky retractors and Sims retractors will be used to exposure the entire cervix. Sponge ring forceps will be used to optimized visualization of the cervix and provide the necessary countertraction at the suture entry and exit sites. McDonald technique will be performed placing 4-6 bites circumferentially around the cervix. Only one stitch will be used. The suture will be places as high as feasible
16579787|NCT02746900|No Intervention|No intervention|Bed rest will be not recommended.
16579788|NCT02746887||Preterm cohort|Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g
16579789|NCT02746887||Term control cohort|Healthy term infants
16579790|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
16579791|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
16579792|NCT02746861|Experimental|Diabetes Self-Management Support (DSMS)|Patient receives 6-months of DSMS while receiving support from a trained peer mentor (Peer-supported DSMS).
16579793|NCT02746861|No Intervention|Usual Care|Patient continues to receive usual care.
16579794|NCT02746848|Experimental|Patients with cornea injury|Patients with cornea injury who received healing Amniotic Membrane Extract Eye Drop.
16579795|NCT02746835|Experimental|Exercise Protocol|Set of exercises for balance, endurance, muscle strength and flexibility
16579796|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
16579797|NCT02746796|Experimental|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
16579798|NCT02746796|Experimental|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
16579799|NCT02746796|Experimental|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.
~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.
~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
16579800|NCT02746796|Placebo Comparator|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.
~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.
~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
16579801|NCT02746783|Active Comparator|Group 1|Single dose of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
16579802|NCT02746783|Experimental|Group 2|Double dose of MUTAGRIP® (one dose into the right deltoid area and the other one into the left deltoid area) containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
16579803|NCT02746770|Experimental|Cawthorne and Cooksey exercises group|Intervention: Participants allocated in both control and experimental groups were receiving treatment for their specific vestibular disorders. Patients assigned to the experimental group also performed the Cawthorne and Cooksey exercises for vestibular rehabilitation during a six week of treatment period.
16579804|NCT02746770|No Intervention|control group|intervention: The control group will not perform the active exercise that will be applied to intervention group.
16579805|NCT02746757|No Intervention|Ischemia-reperfusion no intervention|Ischemia-reperfusion without intervention
16579806|NCT02746757|Experimental|Ischemia-reperfusion with RIPC|Ischemia-reperfusion with intervention by RIPC
16579807|NCT02746757|Experimental|Ischemia-reperfusion with RIPC and Ex 9-39|Ischemia-reperfusion with RIPC and Ex 9-39
16579808|NCT02746744|Experimental|Rituximab|Infusion of Mabthera/Rituximab every 6 months
16579809|NCT02746744|Active Comparator|Dimethyl Fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
16579810|NCT02746744|Sham Comparator|Sodium Chloride solution|Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)
16579813|NCT02746718|Other|Restrictive Respiratory Failure|A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
16579814|NCT02746705|Active Comparator|Transcranial Direct Current Stimulation (tDCS)|
16579815|NCT02746705|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|
16579816|NCT02746692|Experimental|Intervention|
16579817|NCT02746692|Active Comparator|Comparison|
16579818|NCT02746679|Experimental|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
16579819|NCT02746679|No Intervention|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
16579820|NCT02746666|Experimental|Intervention|Under pharmacist's behavioral intervention
16579821|NCT02746666|No Intervention|Control|No pharmacist's behavioral intervention
16579822|NCT02746653|Experimental|Use of TroClose1200(TM) for access port and closure device|TroClose in 1 port
16579823|NCT02746627|Active Comparator|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
16579824|NCT02746627|Experimental|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
16579825|NCT02746627|Experimental|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
16579826|NCT02746614|Active Comparator|Psychomotor Therapy & Adaptive Behavior|After the initial assessment of adaptive behavior, i.e.., set of skills that each individual with intellectual disability should train to cope with environmental demands, a Psychomotor Intervention Program was designed specifically. The program integrated individual and group sessions during 3 months, and the main goals of the program were related to independent functioning, motor development, economic and professional activities, academic and verbal skills.
16579827|NCT02746614|Active Comparator|Psychomotor Therapy & Motor Proficiency|Motor Proficiency After the initial assessment, a Psychomotor Intervention Program was designed specifically for participants with IDD. This program integrated individual and group sessions during 3 months, and the main goals of the program were related to motor coordination (balance, manual dexterity and coordination, global and fine praxis).
16579828|NCT02746601|Experimental|Risk Assessment, Counselling & Resources|Patients complete an electronic preconception health risk assessment tool. Results from the tool are directly uploaded or scanned into the patients' electronic medical record. A healthcare provider provides behavioural counselling, based on results of the risk assessment. Patients are given a customized handout that includes health recommendations and resources based on the patient's identified risk factors.
16579829|NCT02746575|Experimental|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
16579830|NCT02746562|Experimental|Freeze all|Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle
16579831|NCT02746562|No Intervention|Fresh embryo transfer|Standard procedure
16579832|NCT02746549|Experimental|1.5 Tesla MRI|Measurement of renal perfusion by 1.5 Tesla MRI with arterial spin labelling
16579833|NCT02746549|Experimental|3.0 Tesla MRI|Measurement of renal perfusion by 3.0 Tesla MRI with arterial spin labelling
16579834|NCT02746536|Experimental|Slow chest compression|Patients will receive the slow chest compression for one minute, immediately after 6MST.
16579835|NCT02746536|Placebo Comparator|No slow chest compression|Immediately after 6MST, the patient will not receive the SCC and will remain seated at rest for one minute, without any intervention.
16579836|NCT02746523||Case / Retired NHL Players|"All interventions for this group are described below:
~Sensory Organization Test (SOT): Balance and proprioception test
~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.
~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression
~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders
~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment
~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
16579837|NCT02746523||Age Matched Controls|"All interventions for this group are described below:
~Sensory Organization Test (SOT): Balance and proprioception test
~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.
~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression
~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders
~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment
~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
16579838|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
16579839|NCT02746497|Active Comparator|Group E (early intervention)|One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
16579840|NCT02746497|Active Comparator|Group L (late intervention)|After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
16579841|NCT02746484|Experimental|Ability platform program|Multi-domain at home rehabilitation program delivered through the Ability platform.
16579842|NCT02746484|Active Comparator|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
16579843|NCT02746458|No Intervention|Standard of Care Physical Therapy|This group will receive the standard of care physical therapy program for 6 weeks.
16579844|NCT02746458|Experimental|Blood Flow Restriction Plus Standard of Care Physical Therapy|This group will receive the same standard of care physical therapy program for 6 weeks plus blood flow restriction.
16579845|NCT02746445||ASD Subjects|No interventions. This is an observation of subjects who received MeRT utilizing assessment documentation.
16579846|NCT02746432|No Intervention|Control group|Routine intra operative saline infusion to be administered.pre-operation and timed assessment lab set to be obtained.
16579847|NCT02746432|Experimental|Intervention group.Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin (Human regular insulin) ) infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
16579848|NCT02746419|Experimental|Experimental|Subjects will receive renal denervation.
16579849|NCT02746419|Sham Comparator|Control|Subjects will receive all procedures as experimental group but renal denervation system will not be turned on.
16579850|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
16579851|NCT02746393|Experimental|Intervention|Health Advocates Program
16579852|NCT02746393|Active Comparator|211 Arm|211 Information Sheet
16579853|NCT02746380|Experimental|LBAL|Adalimumab
16579854|NCT02746380|Active Comparator|Humira®|Adalimumab
16579855|NCT02746367||MDD|Patients diagnosed with Major Depressive Disorder
16579856|NCT02746367||BPI|Patients diagnosed with bipolar I
16579857|NCT02746367||BPII|Patients diagnosed with bipolar II
16579858|NCT02746354|Experimental|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
16579859|NCT02746354|No Intervention|Usual care|
16579860|NCT02746328|Experimental|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
16579861|NCT02746315|Experimental|Experimental 1|Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.
16579862|NCT02746315|Experimental|Experimental 2|Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.
16579863|NCT02746315|Experimental|Experimental 3|Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.
16579864|NCT02746315|Experimental|Experimental 4|Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.
16579865|NCT02746302|Experimental|HS-20004|One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
16579866|NCT02746302|Placebo Comparator|Placebo|Placebo Injected s.c. (under the skin) once for one subject.
16579867|NCT02746276|Other|Ceftriaxone and metronidazole|Pharmacokinetic study of ceftriaxone and metronidazole in malnourished children
16579868|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
16579869|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
16579870|NCT02746250|Active Comparator|Tension type headache|The investigator measures the muscle soreness and muscle stiffness before the patients starts their prescribed treatment with amitriptyline - and again after they have reached their optimal dosage of amitriptyline.
16579871|NCT02746250|No Intervention|Healthy controls|The investigator measures the muscle soreness and muscle stiffness once.
16579872|NCT02746237|Experimental|KAR5585|KAR5585 Capsules
16579873|NCT02746237|Placebo Comparator|Placebo|Placebo capsules
16579874|NCT02746224|Other|group 1A|the surgical technique initially dissects the inferior mesenteric vein (IMV).
16579875|NCT02746224|Other|group 1B|the surgical technique initially dissects the inferior mesenteric artery (IMA).
16579876|NCT02746224|Other|group 2A|the patients will have a latero-terminal colorectal anastomosis
16579877|NCT02746224|Other|group 2B|the patients will have a termino-terminal colorectal anastomosis.
16579878|NCT02746211|Experimental|High Titre Influenza virus|High Titre Influenza virus
16579879|NCT02746211|Experimental|Medium - High Influenza virus|Medium - High Influenza virus
16579880|NCT02746211|Experimental|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
16579881|NCT02746211|Experimental|Low titre Influenza Vaccine|Low titre Influenza Vaccine
16579882|NCT02746198|Experimental|Verum|2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
16579883|NCT02746198|Placebo Comparator|Placebo|2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
16579884|NCT02746185|Active Comparator|Low-molecular-weight heparin|dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
16579885|NCT02746185|Experimental|Rivaroxaban|rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
16579886|NCT02746172|Experimental|Cochlear Implant Recipients|cochlear implant recipients
16579887|NCT02746172|No Intervention|Normal Hearing Volunteers|Normal hearing volunteers
16579888|NCT02746146|Experimental|Chronic dialysis patients|"The study population consists of patients over 70 (≥) and under 85 years (<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (<) 7 points (Dusseux et al. 2015).
~Intervention: Systematic use of a prognostic score"
16579890|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
16579891|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
16579892|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
16579893|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
16579894|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
16579895|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
16579896|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
16579897|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
16579898|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
16579899|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
16579900|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
16579901|NCT02746094|Experimental|The study population|"The study population is comprised of adult men less than 80 years of age who are consulting for ED lasting for over 6 months following a prostatectomy that took place 18 to 60 months ago. The patients are currently in a stable relationship that has been going on for at least 3 months, have an IIEF-EF score between 6 and 25, and have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).
~Intervention: 8 bi-weekly LIESWT sessions"
16579903|NCT02746068|Experimental|AXS-02|Administered orally in the morning for 6 weeks
16579904|NCT02746068|Placebo Comparator|Placebo|Administered orally in the morning for 6 weeks
16579905|NCT02746042|Experimental|Sinupret extract coated tablets|"Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.
~There will be no dose change during the trial."
16579906|NCT02746042|Placebo Comparator|Placebo coated tablets|Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.
16579907|NCT02746029||Children with cardiac murmur|
16579908|NCT02746016|Experimental|Infant Formula supplemented with Oligosaccharides|Ready to feed infant formula ; Feed ad libitum.
16579909|NCT02746003|Other|Managed Aquifer Recharge water|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control at different times.
16579910|NCT02746003|Other|Control|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control arms at different times.
16579911|NCT02745990|Experimental|EPO group|In EPO group, The recombinant human erythropoietin (rhEPO) will be given by 500 U/kg/dose intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
16579912|NCT02745990|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
16579913|NCT02745977|Other|Dairy Free Diet- guaiac + on dairy free diet|Dairy Free Diet x 3 weeks then stool guaiac positive
16579914|NCT02745977|Other|Guaiac negative on dairy free diet|on dairy free diet x 3 weeks, then stool guaiac negative
16579915|NCT02745964|Experimental|LMA supreme|Anesthesia is maintained using LMA supreme during surgery.
16579916|NCT02745964|Active Comparator|I-gel|Anesthesia is maintained using I-gel during surgery.
16579917|NCT02745951|Experimental|Heliox|Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass
16579918|NCT02745951|Active Comparator|Standard of care|Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass
16579919|NCT02745938||Mitochondrial disease|Patients with mitochondrial disease, investigated by blood samples and exercise test.
16579920|NCT02745938||Metabolic myopathy|Patients with metabolic myopathy, investigated by blood samples and exercise test.
16579921|NCT02745938||Muscular dystrophy|Patients with muscular dystrophy, investigated by blood samples and exercise test.
16579922|NCT02745938||Healthy controls|Healthy controls, investigated by blood samples and exercise test.
16579923|NCT02745925|Experimental|normal-weight|normal-weight women
16579924|NCT02745925|Experimental|obesity|obese women
16579925|NCT02745912|Experimental|Metformin + Naltrexone/Bupropion|Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
16579926|NCT02745899|Active Comparator|Soy milk substitute Healthy|Healthy children aged 6-18 will drink 240 ml of soy milk substitute.
16579927|NCT02745899|Active Comparator|Soy milk substitute Asthma|Asthmatic children aged 6-18 will drink 240 ml of soy milk substitute.
16579928|NCT02745899|Experimental|Cow milk Healthy|Healthy children aged 6-18 will drink 240 ml of cow milk.
16579929|NCT02745899|Experimental|Cow milk Asthma|Asthmatic children aged 6-18 will drink 240 ml of cow milk.
16579930|NCT02745886|Experimental|Metformin group|Metformin 0.85 twice daily for 6 months
16579931|NCT02745886|No Intervention|Standard diet group|
16579932|NCT02745886|Other|CR group|Calorie restriction diet will be given to this group.
16579933|NCT02745873|Experimental|Arm A|Ascorbic Acid 250 mg in tablet form was used.
16579934|NCT02745873|Experimental|Arm B|Ascorbic Acid 500 mg in tablet form was used.
16579935|NCT02745860|Experimental|Sequence AB|Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
16579936|NCT02745860|Experimental|Sequence BA|Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
16579937|NCT02745847|Experimental|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
16579938|NCT02745834|Experimental|Chronic Ankle Instability|Soldiers who suffer from chronic ankle instability who had a first major ankle sprain one year or more ago, and did not sustained any major ankle sprain in the last two months, will go through Gait analysis intervention.
16579939|NCT02745834|Experimental|Healthy controls|Healthy soldiers who are not suffering from chronic ankle instability, will go through Gait analysis intervention.
16579940|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
16579941|NCT02745808|Experimental|HUC-MSCs|Intracavernous injection of 15 million HUC-MSCs.
16579942|NCT02745808|Experimental|Injectable Collagen Scaffold + HUC-MSCs|Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
16579943|NCT02745795|Experimental|MIG: Motivational Interview Group|Group submitted to three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
16579944|NCT02745795|Sham Comparator|CIG: Conventional Intervention Group|Group submitted to three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
16579945|NCT02745769|Experimental|Ramucirumab + Merestinib|Ramucirumab intravenously (IV) on day 1 and day 15 in combination with merestinib orally once a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
16579946|NCT02745769|Experimental|Ramucirumab + Abemaciclib|"Ramucirumab IV on day 1 and day 15 in combination with abemaciclib orally twice a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
~On June 21st 2017 the Ramucirumab + Abemaciclib arm was cancelled with no participants enrolled."
16579947|NCT02745756|Experimental|Combined Cell Therapy|Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
16579948|NCT02745743|Experimental|Arm 1|Biomarker-enriched advanced hematological neoplasms
16579949|NCT02745743|Experimental|Arm 2|Other selected advanced hematological neoplasms
16579950|NCT02745730|Active Comparator|Glucose|Shake sweetened with glucose
16579951|NCT02745730|Active Comparator|Fructose|Shake sweetened with fructose
16579952|NCT02745730|Experimental|Sucralose|Shake sweetened with sucralose
16579953|NCT02745730|Experimental|Allulose|Shake sweetened with allulose
16579954|NCT02745717|Experimental|cord blood and IST group|Administration of antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days, Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml, plus one unit of at least 4/6 HLA loci matched cord blood transfusion 24 hours after last dose of ATG.
16579955|NCT02745717|Active Comparator|IST group|Antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days , Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml.
16579956|NCT02745704|Experimental|PEG-IFN group|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.
16579957|NCT02745704|No Intervention|NAs group|Patients do not need to change their NAs treatment.
16579958|NCT02745691||A. Surgery|A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
16579959|NCT02745691||B. Radiochemotherapy|B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
16579960|NCT02745691||C. Targeted therapy|C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
16579961|NCT02745691||D. Immunotherapy|Any new immunotherapy for lung cancer
16579962|NCT02745678|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation.
16579963|NCT02745665||1-Elite Cyclist|"10 symptomatic cyclists with unilateral diagnosis of iliac EF,
~FLOW MEDIATED DILATION Ankle brachial pressure index (ABPI) PULSE WAVE VELOCITY AND AUGMENTATION INDEX Blood pressure RAMP Test"
16579964|NCT02745665||2-Amateur Cyclist|"10 asymptomatic cyclists with no evidence of EF
~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
16579965|NCT02745665||3-Control|"10 age-matched healthy male group
~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
16579966|NCT02745652|Experimental|pulsed electromagnetic field (PEMF)|patients in this group received the pulse electromagnetic field with frequency 50 Hz and intensity 80 gauss for 30 min.The patient was in sitting position, while the forearm was rested on the bed inside the solenoid in supination position
16579967|NCT02745652|Experimental|Therapeutic ultrasound (US)|Pulsed mode US was applied over the volar surface of the forearm (the carpal tunnel area) 15 min per session with a frequency of 1 MHz and intensity of 1.0 W/cm2
16579968|NCT02745639|Experimental|VMAT-SIB + XELOX|"A VMAT-SIB technique was used. Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and Organs at risks.
~The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment."
16579969|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
16579970|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
16579971|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
16579973|NCT02745613|Experimental|No Family history of T2D|The participants will undergo 8 weeks of combined exercise
16579974|NCT02745600|Other|Software assisted RFA treatment|Non-controlled, prospective, multicenter study arm, to evaluate RFA therapy simulation software.
16579975|NCT02745587|Experimental|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
16579976|NCT02745587|Active Comparator|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
16579977|NCT02745574|Experimental|Combined maneuver|Combined maneuver: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm dihydrogen monoxide (H2O). The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
16579978|NCT02745574|Experimental|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
16579979|NCT02745574|No Intervention|Control group|CO2 was removed by passive exsufflation through the port site.
16579980|NCT02745561|Experimental|Chemoradiotherapy Arm|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
16579981|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
16579982|NCT02745522|Experimental|Oxytocin|Oxytocin nasal spray
16579983|NCT02745522|Placebo Comparator|Placebo|Placebo nasal spray
16579984|NCT02745509|Experimental|Extensive Intraoperative Peritoneal Lavage|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles), followed by complete aspiration of the fluid . The abdomen will be closed as per standard.
16579985|NCT02745509|No Intervention|Standard Treatment|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal lavage will be done < 3 cycles with 3 liters or less of warmed normal saline. The abdomen will be closed as per standard.
16579986|NCT02745496|Other|TRUS Biopsy|Standard of Care Treatment
16579987|NCT02745496|Other|TRUS/FUSION Biopsy|Interventional Treatment
16579988|NCT02745483|Experimental|Separable clustered electrodes|Enrolled patients in the prospective study (RFA using separable clustered electrodes (Octopus®)) for treatment-naive HCC (n=79)
16579989|NCT02745483|No Intervention|Historical control group|Patients who received RFA according to routine protocol in our center (multiple internally-cooled electrodes) for treatment-naive HCC from Jan 2011 to July 2013 in our institution (n=74) .
16579990|NCT02745470|Experimental|Lixisenatide injection|intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI
16579991|NCT02745470|Placebo Comparator|Normal saline|control : normal saline 0.3 cc subcutaneous injection before functional MRI
16579992|NCT02745444|Other|low-calorie formula diet|Donor taking low-calorie formula diet, 50% of basal energy rate, individually calculated with Mifflin-St. Jeor formula.
16579993|NCT02745444|No Intervention|no diet|Donor ingesting food as usual.
16579994|NCT02745444|Other|protein-restricted diet|Donor taking protein-restricted diet according to diet plans of clinical dietetics of University Hospital of Cologne, with unchanged calorie supply, individually calculated with Mifflin-St. Jeor formula.
16579995|NCT02745444|No Intervention|Normal protein supply|Donor taking same dishes as protein-restricted diet group but with customary protein levels, with unchanged calorie supply.
16579996|NCT02745431|Experimental|Oxytocin nasal spray|Oxytocin nasal spray
16579997|NCT02745431|Placebo Comparator|Placebo nasal spray|Placebo nasal spray
16579998|NCT02745405|Experimental|Fat Suit Condition|Participants are randomly assigned to wear a fat suit and then walk across campus.
16579999|NCT02745405|Other|Control Condition|Participants are randomly assigned to wear the same clothing that is on the fat suit but in their own size and then walk across campus.
16580000|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
16580001|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
16580002|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
16580003|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
16580004|NCT02745379|Experimental|BFPSC+|The group receives a combination (DFDBA)+buccal fat pad derived stem cells BFPSC and PRF for sinus augmentation
16580005|NCT02745379|Active Comparator|BFPSC-|The group receives a combination of demineralized freeze-dried bone allografts DFDBA (lacking any cells) and PRF for sinus augmentation
16580006|NCT02745366|Experimental|BFPSC+|The combination of BFPSC+FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure.
16580007|NCT02745366|Active Comparator|BFPSC-|The combination of FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure
16580008|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
16580009|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
16580010|NCT02745340|Active Comparator|Acetate|
16580011|NCT02745340|Experimental|Citrate|
16580012|NCT02745314||>74 years|Older than 74 year-old patients
16580013|NCT02745288|Experimental|Nerve block|This arm will receive inferior alveolar nerve block
16580014|NCT02745288|No Intervention|control|Control arm will not receive inferior alveolar block
16580015|NCT02745275|Experimental|Peer-led Health Education|A single 60 minute interactive workshop led by the trained health coach followed by a series of three one hour discussion groups
16580016|NCT02745275|No Intervention|Control|No intervention
16580017|NCT02745262||Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
16580018|NCT02745262||Non Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
16580019|NCT02745249|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention which focus on improving dietary practices, specifically improved diversity of foods and energy intakes of pregnant women, and improved intake of calcium and iron/folic acid (IFA) supplements.
16580020|NCT02745249|No Intervention|A&T-non intensive|A&T-non intensive aim only receive MNCH services
16580021|NCT02745236|Experimental|Nurse Practitioner Led-Care|"Nurse Practitioner (NP) Intervention Initial Visit and Interventions: An experienced nurse practitioner with extra atrial fibrillation (AF) management training will complete the initial assessment to determine a treatment plan based on current AF Guidelines. The NP will provide patient education on AF management.
~Follow-up: Follow-up will occur at 3 and 6 months from baseline to evaluate the patient's response to treatment and will be modified as required based on AF symptoms, testing results and physical assessment.
~A physician will be consulted for advanced specialty AF management or if a patient requires admission to hospital."
16580022|NCT02745236|Active Comparator|Cardiologist Led-Care|"Standard Care Initial Visit and Intervention: A general cardiologist will manage patients as per their usual practice.
~Follow-up: As per the cardiologist's usual practice. The patient's care will remain with the family physician if no follow-up is required.
~Follow-up: Follow-up will be determined as per the cardiologist's usual practice. If a follow-up appointment is required it will done in the cardiologist's own independent clinic. The patient's care will be referred back to the family physician if no follow-up is required."
16580023|NCT02745223|Experimental|PresbiDrops (CSF-1)|Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.
16580024|NCT02745223|Placebo Comparator|Placebo|Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.
16580025|NCT02745210|Experimental|Experimental|13C Magnetic resonance (MR) spectroscopy.
16580026|NCT02745197|Experimental|Nutritional Supplement|2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
16580027|NCT02745197|Placebo Comparator|Placebo|2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
16580028|NCT02745184|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
16580029|NCT02745171|No Intervention|Control group|This group will be evaluated after three months there will be a reassessment, in this case the participating subjects do not perform any kind of therapy.
16580030|NCT02745171|Experimental|Experimental group|There will be an initial evaluation, after a month of physical therapy at the end of the protocol, and twice more after the protocol, both interval a month.
16580031|NCT02745158||FOP Patients|
16580032|NCT02745145|Experimental|Abituzumab 1500 milligram (mg)|
16580033|NCT02745145|Experimental|Abituzumab 500 mg|
16580034|NCT02745145|Placebo Comparator|Placebo|
16580035|NCT02745132|Other|Cognitive evaluation in HCV patients|"Neuropsychological evaluation and Brain MRI
~Intervention: The only intervention to be carried out along the study will consist of complete neuro-psychological tests and MRI studies performed at different times.
~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied: A neuro-psychological battery of tests and brain MRI studies will be performed at different times before and after the end of the treatment. The participation in the study will not influence neither the indication to treat nor the treatment used.
~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
16580036|NCT02745119|Experimental|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
16580037|NCT02745119|Experimental|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
16580038|NCT02745106|Experimental|PADN treatment|"Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:
~Ablation catheter
~Carto 3, Carto RMT, Stereotaxis
~Swan-Ganz catheter"
16580039|NCT02745106|Sham Comparator|Control (Sham)|"Procedure: Right heart catheterization
~Using following device:
~- Swan-Ganz catheter"
16580040|NCT02745093|Experimental|64-84 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-84 days will receive 200 µg mifepristone followed by misoprostol 24-48 hours later.
16580041|NCT02745093|No Intervention|57-63 days gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
16580042|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
16580043|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
16580044|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
16580045|NCT02745041|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]
16580046|NCT02745041|Active Comparator|Cryoprecipitate|Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]
16580157|NCT02744313||AP Naive|Group followed over 12 weeks to measure fat deposition, insulin resistance, and glucose tolerance.
16580047|NCT02745028|Other|With monosodium glutamate|Results of one time gastric emptying study with a single dose of monosodium glutamate; 1 g for weight greater than 45 kg, 700mg between 35 and 44,900 kg, 600mg between 25 and 34,900, 500mg between 15 and 25 kg and 250mg in less than 15 kg
16580048|NCT02745015|Experimental|treatment|immediate non-surgical periodontal treatment
16580049|NCT02745015|Other|control|non-surgical periodontal treatment scheduled for the following 3-monthly visit
16580050|NCT02745002|Experimental|navigated bronchoscopy|
16580051|NCT02744989|Experimental|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
16580052|NCT02744989|Sham Comparator|Sham tDCS|
16580053|NCT02744976|Experimental|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
16580054|NCT02744976|Active Comparator|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
16580055|NCT02744963|Experimental|Free and convenient medicine access|Free access to a list of essential medicines. Medicines are either mailed to the patient or dispensed at the point of care.
16580056|NCT02744963|No Intervention|Usual medicine access|Usual access to medicines.
16580057|NCT02744950|Active Comparator|Intermediate/complex repair|This arm will have closures of scalp defects with deep and superficial suture placement.
16580058|NCT02744950|Experimental|Pulley stitches|This arm of the study will have only pulley stitches to close the entire defect.
16580059|NCT02744937|Experimental|A|continuing LDA
16580060|NCT02744937|No Intervention|B|discontinuing LDA
16580061|NCT02744924|Experimental|Physical activity intervention|Participants undergo the community-based physical activity promotion (see Intervention)
16580062|NCT02744911|Experimental|Telemedicine group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device via the internet using the telemedicine application. Also includes speech-language pathologists providing treatment via the telemedicine application.
16580063|NCT02744911|Active Comparator|In person group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device in person. Also includes speech-language pathologists providing treatment in person.
16580064|NCT02744898|Experimental|Carboplatin AUC and Abraxane 100mg/m2|
16580065|NCT02744885|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
16580066|NCT02744885|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
16580067|NCT02744872|Active Comparator|Felodipine|Tablet Felodipin 10 mg x 1 daily
16580068|NCT02744872|Placebo Comparator|Placebo|Identical placebo once daily
16580069|NCT02744859|Experimental|Calorie Label|"Labels will read [lower calorie bound] - [upper calorie bound] calories per container. 2,000 calories a day is used for general nutrition advice but calorie needs vary."
16580070|NCT02744859|Experimental|Warning Label|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay."
16580071|NCT02744859|Experimental|Warning Label with Graphics|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. These labels will also have graphic depictions of each health condition above the corresponding text."
16580072|NCT02744859|No Intervention|No label|We will also have a condition where no labels are presented-- business as usual.
16580073|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:
~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and
~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
16580074|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:
~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and
~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
16580075|NCT02744833|Experimental|GMI-1271|
16580076|NCT02744833|Active Comparator|Enoxaparin Sodium (Lovenox®)|
16580077|NCT02744820|Placebo Comparator|Cohort 1 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
16580078|NCT02744820|Placebo Comparator|Cohort 2 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
16580079|NCT02744820|Placebo Comparator|Cohort 3 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
16580080|NCT02744820|Placebo Comparator|Cohort 4 (Part 2)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
16580081|NCT02744807||non-Chronic endometritis|patients with intrauterine adhesion only
16580082|NCT02744807||Chronic endometritis|patients with intrauterine adhesion as well as Chronic endometritis
16580083|NCT02744794|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
16580084|NCT02744781|Experimental|Lumbar disc degeneration; LDD|The LDD group included subjects with at least 1 abnormal disc from L1-2 to L5-S1 of grade III, IV, or V. The non-LDD group included subjects with 5 normal discs of grade I or II. For further assessment, the most damaged disc of the 5 constituted the highest grade of LDD.
16580213|NCT02743936|Active Comparator|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
16580085|NCT02744768|Experimental|Treatment|"Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.
~HLA typing will be performed immediately after the diagnosis for eligible patients.
~MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation."
16580086|NCT02744755|Experimental|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
16580087|NCT02744755|Active Comparator|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
16580088|NCT02744742|Experimental|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16580089|NCT02744742|Active Comparator|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
16580090|NCT02744729|Experimental|Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.
16580091|NCT02744716|Experimental|non-balloon group|with aspirin
16580092|NCT02744716|Experimental|balloon group|with aspirin and intrauterine balloon
16580093|NCT02744716|No Intervention|control group|without aspirin and intrauterine balloon
16580094|NCT02744703|Active Comparator|self-etch adhesive|application of self-etch adhesive on cavities.
16580095|NCT02744703|Experimental|CAPE-S|CAPE before self-etch adhesive
16580096|NCT02744703|Active Comparator|total-etch adhesive|total-etch adhesive on cavities.
16580097|NCT02744703|Experimental|CAPE-T|CAPE before total-etch adhesive application
16580098|NCT02744690|Experimental|MMC Injection|Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy
16580099|NCT02744690|Active Comparator|MMC Sponge Application|Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed
16580100|NCT02744677|Experimental|TPVR - Main Cohort|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
16580101|NCT02744677|Experimental|TPVR - THV Registry|Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
16580102|NCT02744664|Experimental|Experimental|The subject receive Cryotherapy and than receive Icotinib 125mg, 3 times a day, orally administered until disease progression or intolerable toxicity reaction.
16580103|NCT02744651|Active Comparator|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
16580104|NCT02744651|Active Comparator|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
16580105|NCT02744638|Experimental|probiotic yoghurt & Arilin|probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
16580106|NCT02744638|Placebo Comparator|chemically acidified milk & Arilin|chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
16580107|NCT02744625|Active Comparator|Shock lower Mean Arterial Pressure (MAP)|Vasopressor-dependent treated to lower MAP (65 mmHg)
16580108|NCT02744625|Experimental|Shock higher MAP|Vasopressor-dependent treated to higher MAP (75 mmHg)
16580109|NCT02744625|No Intervention|Healthy participant awake|Healthy participant awake
16580110|NCT02744625|Experimental|Healthy participant sedated|Healthy participant Under light sedation
16580111|NCT02744612|Experimental|Treatment (Ibrutinib and Brentuximab Vedotin)|Patients receive ibrutinib PO QD on days 1-21 and brentuximab vedotin IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16580112|NCT02744599|Experimental|Device prompting|
16580113|NCT02744599|No Intervention|Control|Patients receive standard of care
16580114|NCT02744586|Experimental|Strengthening our Vows (SOV) Group|"Participants in the SOV arm will participate in the Together HIV Free and Protecting My Spouse plans."
16580115|NCT02744586|Placebo Comparator|Good Health Package Plus (GHPP) Group|Participants in the GHPP arm will receive education on the prevention of helminths, schistosomiasis, hypertension, diabetes, and diarrheal diseases through participatory and interactive group sessions.
16580116|NCT02744573||General Anaesthesia|ANI and SPI values under general anaesthesia
16580117|NCT02744573||Spinal Anaesthesia|ANI and SPI values under spinal anaesthesia
16580118|NCT02744573||Spinal Anaesthesia + Sedation|ANI and SPI values under spinal anesthesia in combination with sedation
16580119|NCT02744573||Control|ANI and SPI values under no anaesthesia
16580120|NCT02744560|Experimental|patients|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
16580121|NCT02744547|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
16580122|NCT02744547|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
16580123|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
16580124|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
16580125|NCT02744521|Experimental|Symptom based screening intervention|
16580126|NCT02744521|No Intervention|control|
16580127|NCT02744508|Active Comparator|P group|Palonosetron group
16580128|NCT02744508|Experimental|PD group|Palonosetron and dexamethasone group
16580129|NCT02744495|Experimental|postoperative nausea and vomiting risk factors|Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.
16580130|NCT02744495|No Intervention|control|No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.
16580131|NCT02744482|Experimental|Risedronate|Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
16580132|NCT02744482|Placebo Comparator|Placebo|Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.
16580133|NCT02744469||New patients|''New tuberculosis patients'' are patients just diagnosed for tuberculosis, and who were never treated for tuberculosis or who are treated for less than 1 month. In total, 1192 new patients will be recruited.
16580134|NCT02744469||Retreatment patients|''Retreatment tuberculosis patients'' are patients just diagnosed for tuberculosis and who were previously treated for tuberculosis (for a duration of 1 month at least). This group includes: patients with treatment relapse, failure and patients who return after default. In total, 298 retreatment patients will be recruited.
16580135|NCT02744456|Other|N-of-1 trial|Patients with hypertension who are taking none or one BP medication will be will be provided with prescriptions for up to 3 BP medications representative of different BP medication classes (i.e., losartan, an angiotensin system blocking agent; amlodipine, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic). Patients will be asked to take each medication for 2 weeks at a low dose, 2 weeks at a medium dose, and then 2 weeks at a high dose; provide health information and identify which medication they prefer to remain on following the N-of-1 trial (i.e., for long-term use).
16580136|NCT02744443|Experimental|Leucine|Leucine supplementation (10 g/d)
16580137|NCT02744443|Placebo Comparator|Placebo|Placebo supplementation (alanine, 10 g/d)
16580138|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
16580139|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
16580140|NCT02744417|Experimental|Smoking cessation therapy|Non-surgical periodontal therapy and concurrent smoking cessation therapy, with Smoking cessation counseling, Nicotine replacement therapy, use of bupropion hydrochloride and varenicline
16580141|NCT02744404||POC EID|Point of Care Early Infant Diagnosis qualitative technologies (Alere q) will be implemented. Sample collection and testing will happen in the same location within the health care facility.
16580142|NCT02744404||Laboratory-based testing|Conventional laboratory-based testing using the Abbott m2000 technology will continue to be used per standard of care in Malawi. Dried blood spot samples will be collected at health care facilities and transported within the national network to centralized laboratories for testing.
16580143|NCT02744391|Experimental|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
16580144|NCT02744378|Active Comparator|Clobetasol Group|clobetasol propionate (0.05%) cream
16580145|NCT02744378|Active Comparator|Tacrolimus Group|tacrolimus (0.1%) cream
16580146|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
16580147|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :
~low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)
~pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
16580148|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
16580149|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
16580150|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
16580151|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
16580152|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
16580153|NCT02744339|Experimental|Riociguat|Riociguat up-titrated to a maximum of 1.5mg TID
16580154|NCT02744339|Placebo Comparator|Placebo|Placebo sham-titrated TID
16580155|NCT02744326|Experimental|Text message reminder group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive text message reminders to attend or schedule a follow-up outpatient referral.
16580156|NCT02744326|No Intervention|Usual Care group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive the usual standard of care.
16580158|NCT02744300|Experimental|BABI-2 Lifestyle Intervention|Participants in this group will take part in the web-based lifestyle intervention which includes access to the lifestyle intervention website and personalized coaching from a Lifestyle Coach.
16580159|NCT02744300|No Intervention|Post-GDM Follow-up Group|Participants in this group will have access to a separate website containing links to information about diabetes prevention.
16580160|NCT02744287|Experimental|Arm 1: Phase 1 Dose Escalation|Participants with advanced pancreatic or prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
16580161|NCT02744287|Experimental|Arm 2: Phase 2 Dose Expansion|Participants with advanced pancreatic or prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
16580162|NCT02744274|Experimental|Verum acupuncture|16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
16580163|NCT02744274|Placebo Comparator|Sham acupuncture|16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
16580164|NCT02744248|Active Comparator|IOP Injection|Participants will receive 1 injection of the IOP at Days 1,once time.
16580165|NCT02744248|Placebo Comparator|0.9% normal saline|Participants will receive 1 injection of 0.9% normal saline at Days 1,once time.
16580166|NCT02744235|Other|Patients undergoing Polysomnography|
16580167|NCT02744222|Experimental|BCD-054, 180 mcg, biweekly|Patients of Groups 1 will receive blinded BCD-054 180 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 1 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
16580168|NCT02744222|Experimental|BCD-054, 240 mcg, biweekly|Patients of Groups 2 will receive blinded BCD-054 240 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 2 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
16580169|NCT02744222|Active Comparator|Avonex®, 30 mcg, weekly|Patients of Group 3 (reference group) will receive blinded Avonex® 30 mcgintramuscularly once a week for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive).
16580170|NCT02744222|Placebo Comparator|Placebo, 0,5 ml, weekly|Patients of Group 4 (placebo) will receive blinded placebo once a week for the first 20 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive)
16580171|NCT02744196|Experimental|Acellbia + methotrexate|"106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15.
~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days."
16580172|NCT02744196|Placebo Comparator|Placebo + methotrexate|"53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15.
~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days."
16580173|NCT02744183|Active Comparator|Control Group|Maintain habitual habits
16580174|NCT02744183|Active Comparator|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
16580175|NCT02744183|Experimental|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
16580176|NCT02744170|Experimental|COPD patients with delivery order 1, 2, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
16580177|NCT02744170|Experimental|COPD patients with delivery order 2,3, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
16580178|NCT02744170|Experimental|COPD patients with delivery order 3, 2, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
16580179|NCT02744170|Experimental|COPD patients with delivery order 1, 3, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
16580180|NCT02744170|Experimental|COPD patients with delivery order 2, 1, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
16580181|NCT02744170|Experimental|COPD patients with delivery order 3, 1, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
16580182|NCT02744157|Other|structured lifestyle program|The program consisted of an individual visit to a nurse for a health check-up and lifestyle counseling at baseline, six month and one year. The program also consisted of five group educations which included lectures on nicotine, alcohol, physical inactivity, eating habits, stress, sleeping habits and behavior changes
16580183|NCT02744144||Non-infection|Patients without clinical infection or positive wound culture
16580184|NCT02744144||Infection|Patients with clinical infection and positive wound culture
16580185|NCT02744131|Active Comparator|OCP|Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.
16580186|NCT02744131|Active Comparator|Metformin|Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.
16580211|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
16580187|NCT02744118|Experimental|Marijuana Screening and Brief Counseling|The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
16580188|NCT02744118|Active Comparator|Healthy Internet Use Model|The media screening and brief counseling intervention is based on a media use screening and brief counseling intervention tested as the active comparator for a 5As tobacco cessation randomized control trial (NCT01312480) and the 2010 American Academy of Pediatrics policy statement on children and media.
16580189|NCT02744105|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
16580190|NCT02744105|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
16580191|NCT02744092|Experimental|Randomized Arm 1|Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
16580192|NCT02744092|Active Comparator|Randomized Arm 2|Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
16580193|NCT02744092|Experimental|Preference Cohort|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).
~Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC).
~Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin."
16580194|NCT02744079|Active Comparator|Low carbohydrate diet|45 subjects will receive a very low carbohydrate diet between a positive breast biopsy and surgical tumor removal
16580195|NCT02744079|Active Comparator|Low fat diet|20 subjects will receive a lo fat diet between a positive breast biopsy and surgical tumor removal
16580196|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
16580197|NCT02744053|Experimental|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
16580198|NCT02744040|Other|Early ART initiation|Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
16580199|NCT02744040|Other|Deferred ART initiation|ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)
16580200|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Contrast Imaging|Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
16580201|NCT02744014|Experimental|Early intervention group|The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
16580202|NCT02744014|Other|Late intervention group|This group will receive the same training with a delay of 60-90 days, serving initially as control.
16580203|NCT02744001|Experimental|Low Added Sugar Diet|Menu containing <10% of total daily energy intake from added sugars.
16580204|NCT02743988|Experimental|Low target range|Low oxygen saturation target range: SpO2 85-89%
16580205|NCT02743988|Active Comparator|High target range|High oxygen saturation target range: SpO2 91-95%
16580206|NCT02743975|Experimental|Treatment group|Bevacizumab-800CW
16580207|NCT02743962|Active Comparator|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
16580208|NCT02743962|Experimental|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
16580209|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
16580210|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
16580212|NCT02743936|Experimental|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
16580214|NCT02743923|Active Comparator|carboplatin-paclitaxel- bevacizumab|carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg all administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by bevacizumab maintenance every 3 weeks until progression
16580215|NCT02743923|Active Comparator|cisplatin-pemetrexed|pemetrexed 500 mg/m2 administered intravenously on day 1 and cisplatin 75 mg/m2 administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by maintenance pemetrexed every 3 weeks until progression.
16580216|NCT02743910||Stage II-III breast cancer|Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.
16580217|NCT02743897|Experimental|Direct-acting antiviral treatment for HCV|
16580218|NCT02743884|Experimental|Esophageal Cooling Device|Esophageal cooling
16580219|NCT02743884|Experimental|Esophageal Warming|Esophageal warming
16580220|NCT02743871|Experimental|Cohort 1|10 mg of PF-06817024 or placebo
16580221|NCT02743871|Experimental|Cohort 2|30 mg of PF-06817024 or placebo
16580222|NCT02743871|Experimental|Cohort 3|100 mg of PF-06817024 or placebo
16580223|NCT02743871|Experimental|Cohort 4|300 mg of PF-06817024 or placebo
16580224|NCT02743871|Experimental|Cohort 5|1000 mg of PF-06817024 or placebo
16580225|NCT02743871|Experimental|Cohort 6|2000 mg of PF-06817024 or placebo
16580226|NCT02743871|Experimental|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
16580227|NCT02743871|Experimental|Cohort 8|300 mg of PF-06817024 or placebo
16580228|NCT02743871|Experimental|Cohort 9|IV dose to be determined of PF-06817024 or placebo
16580229|NCT02743871|Experimental|Cohort 10|PF-06817024 or placebo
16580230|NCT02743871|Experimental|Cohort 11|PF-06817024 or placebo
16580231|NCT02743871|Experimental|Cohort 12|PF-06817024 or placebo
16580232|NCT02743871|Experimental|Cohort 13|PF-06817024 or placebo
16580233|NCT02743858||Breast Cancer-Related Lymphedema|Bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder and the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed at baseline (prior to surgery), post-operatively (after surgery) and at scheduled timepoints of 6 months, 12 months, 18 months, and 24 months after surgery for a total of 2 years. For a patient who is diagnosed with lymphedema at ≥ 13 months after surgery, surveillance will continue for an additional 12 months after [lymphedema] diagnosis, and total surveillance time may exceed 2 years. Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. All patients will complete the ULL-27 (upper limb lymphedema) quality-of-life questionnaire at baseline and at each scheduled visit.
16580234|NCT02743832|Experimental|High-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
16580235|NCT02743832|Active Comparator|High-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
16580236|NCT02743832|Experimental|Low-level group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
16580237|NCT02743832|Active Comparator|Low-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
16580238|NCT02743819|Experimental|Treatment|Treatment with the combination of pembrolizumab and ipilimumab.
16580239|NCT02743806|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once every 8 weeks until vedolizumab is commercially available. (Per MM approval, dosing regimen may be modified per physician's decision).
16580240|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:
~An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;
~No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and
~Normal and stable allograft function at screening visit defined as-
~For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)
~For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) > 45 ml/min/1.73 m^2."
16580241|NCT02743780|Experimental|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
16580242|NCT02743780|Placebo Comparator|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
16580243|NCT02743767|No Intervention|Before interventions|Only observational activity for this arm, to record the frequency and triggering factors of airway complications during general anaesthesia.
16580244|NCT02743767|Experimental|After interventions|After introducing five different treating adaptations in airway management we want to record the frequency of airway complications during general anaesthesia.
16580245|NCT02743754|Placebo Comparator|Standard Therapy|Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
16580246|NCT02743754|Active Comparator|Standard Therapy and hyperbaric oxygen|Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
16580247|NCT02743741|Experimental|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
16580248|NCT02743728||All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
16580249|NCT02743715|Active Comparator|Active tDCS|Electric current of 2mA delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
16580429|NCT02742532|Placebo Comparator|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
16580250|NCT02743715|Sham Comparator|Sham tDCS|In this group, the cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
16580251|NCT02743702|Experimental|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
16580252|NCT02743702|Experimental|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
16580253|NCT02743676||Avian influenza A|Natural history of Avian influenza A, particularly H5N1 strain which has a high potential of causing a global human pandemic, and real-world treatment practices will be observed in this study. This registry program will not require, recommend, or provide any specific treatment or medications.
16580254|NCT02743663||Wheezing subjects|Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
16580255|NCT02743663||Healthy cohort|One study visit will be completed with healthy participants. At this visit, three breathing tests will be performed: multiple-breath washout, forced oscillation technique, and spirometry. As well, an allergy skin test will be performed at the visit.
16580256|NCT02743650|Experimental|Sodium Bicarbonate|"All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).
~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening."
16580257|NCT02743637|Experimental|SDX-7320|Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
16580258|NCT02743624|Other|Pressure Support Titration|The analysis of the diagnostic accuracy of the breathing pattern variables, P 0.1 and the rate of tracheal muscle relaxation.
16580259|NCT02743611|Experimental|Arm 1 Does Escalation|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.
~Rimiducid may be administered in response to treatment-related toxicity."
16580260|NCT02743611|Experimental|Arm 2 Dose Escalation|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.
~Rimiducid may be administered in response to treatment-related toxicity."
16580261|NCT02743611|Experimental|Arm 1 Part 2 Dose Expansion|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701 at the recommended cell dose level.
~Rimiducid may be administered in response to treatment-related toxicity."
16580262|NCT02743611|Experimental|Arm 2 Part 2 Dose Expansion|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701 at the recommended cell dose level.
~Rimiducid may be administered in response to treatment-related toxicity."
16580263|NCT02743598|Experimental|Liraglutide|
16580264|NCT02743585|Experimental|Rapid diagnostic arm|"Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) AND FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen will be performed.
~The Interventions to be administered are the rapid diagnostic tests: FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen.
~Subjects will be recruited 8am-3pm daily, weekdays only. Results of the BCID and Rosco test will be communicated to the managing physicians by phone in real-time."
16580265|NCT02743585|No Intervention|Standard of care (control)|Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) will be used. FilmArray BCID and Rosco Diagnostica ESBL and carbapenemase screen will NOT be performed. Subjects will be recruited 8am-3pm daily, weekdays only.
16580266|NCT02743572|No Intervention|control group|preterm infants of this group with iron-free PN for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
16580267|NCT02743572|Experimental|iron sucrose-1|preterm infants of this group with iron supplementation of 100μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
16580268|NCT02743572|Experimental|iron sucrose-2|preterm infants of this group with iron supplementation of 200μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
16580269|NCT02743572|Experimental|iron sucrose-3|preterm infants of this group with iron supplementation of 300μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
16580270|NCT02743572|Experimental|iron sucrose-4|preterm infants of this group with iron supplementation of 400μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
16580271|NCT02743559|Active Comparator|Vitamin D group|Children born to mothers who received vitamin D during pregnancy will undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform(LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
16580272|NCT02743559|Placebo Comparator|Placebo group|Children born to mothers who received placebo during pregnancy will also undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform (LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
16580399|NCT02742740|Experimental|Chemo Buddy|Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
16580273|NCT02743546|Experimental|Dose Optimization:Participant with Certain B-Cell Malignancies|Participants with certain B-cell malignancies (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], or follicular lymphoma [FL]) will receive rising doses of intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met. Dose escalation will continue until the recommended phase 2 dose or maximum tolerated dose is reached.
16580274|NCT02743546|Experimental|Dose Expansion: Participants with DLBCL|Participants with DLBCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
16580275|NCT02743546|Experimental|Dose Expansion: Participants with FL|Participants with FL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
16580276|NCT02743546|Experimental|Dose Expansion: Participants with MCL|Participants with MCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
16580277|NCT02743546|Experimental|Dose Expansion: Participants with CLL|Participants with chronic lymphocytic leukemia (CLL) will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
16580278|NCT02743520|Experimental|Cardiac event monitor|Participants will under go evaluation with a two week cardiac event monitor.
16580279|NCT02743494|Experimental|Nivolumab|
16580280|NCT02743494|Placebo Comparator|Placebo|
16580281|NCT02743468||Healthy Volunteers|Healthy Volunteers
16580282|NCT02743455|Active Comparator|Group 1|Subjects will receive 1.0x10^8 TCID50 of MVA-BN as two doses subcutaneously on Day 1 and Day 29. N=15
16580283|NCT02743455|Experimental|Group 2|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
16580284|NCT02743455|Experimental|Group 3|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as two doses intramuscularly on Day 1 and Day 29. N=15
16580285|NCT02743455|Experimental|Group 4|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as a single dose intramuscularly on Day 1 and matching placebo on Day 29. N=15
16580286|NCT02743455|Active Comparator|Group 5|Subjects will receive = / > 4.74 log10 PFU of YF-Vax as a single dose subcutaneously on Day 1 and matching placebo on Day 29. N=15
16580287|NCT02743455|Experimental|Group 6|Subjects with prior receipt of MVA-BN will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
16580288|NCT02743442|Experimental|Transoral surgery|
16580289|NCT02743429|Experimental|Long term infusion of ch14.18/CHO|10 day continuous Infusion of ch14.18/CHO.
16580290|NCT02743416||ECG screening|Will be screened for AF using only one-stop protocol
16580291|NCT02743416||Control group|as per regular standard as of today
16580292|NCT02743403|Active Comparator|Neurodyn Portable TENS|"Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.
~The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.
~The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.
~Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.
~Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject."
16580293|NCT02743403|Placebo Comparator|Placebo TENS- Neurodyn Portable TENS|"Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.
~The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active."
16580294|NCT02743403|No Intervention|Control|"Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.
~The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS."
16580295|NCT02743390|Active Comparator|TNF-alpha inhibitor drug|Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
16580296|NCT02743390|Placebo Comparator|Placebo drug|Saline infusion (250mL)
16580297|NCT02743377|Experimental|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
16580298|NCT02743377|Experimental|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
16580299|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
16580300|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
16580301|NCT02743351|Experimental|ProTmune|
16580302|NCT02743351|Active Comparator|Control Arm|
16580303|NCT02743338|Experimental|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
16580304|NCT02743338|Active Comparator|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
16580400|NCT02742727|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
16580305|NCT02743338|Active Comparator|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
16580306|NCT02743338|Active Comparator|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
16580307|NCT02743325|Active Comparator|ALARA protocol|SVT ablation by ALARA protocol
16580308|NCT02743325|Active Comparator|current treatment|SVT ablation by conventional protocol
16580309|NCT02743312|Experimental|Torso Weights then Sham Weights|"No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks.
~Participants wear the Fitbit Flex throughout."
16580310|NCT02743312|Experimental|Sham Weights then Torso Weights|"No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks.
~Participants wear the Fitbit Flex throughout."
16580311|NCT02743299|Experimental|CPR simulation|CPR simulation with and without ventilator
16580312|NCT02743286|No Intervention|Control condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
16580313|NCT02743286|Experimental|Frequent sit-to-stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 15 2-minute standing interruptions, 3 per hour, and a mid-point bathroom break.
16580314|NCT02743286|Experimental|Walking breaks (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 2-minute walking interruptions, 3 per hour, and a mid-point bathroom break.
16580315|NCT02743286|Experimental|Stand More (Protocol D)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 10-minute standing breaks, 1 per hour, and a mid-point bathroom break.
16580316|NCT02743260|Experimental|pitavastatin (OATP1B1)|2 mg pitavastatin single dose
16580317|NCT02743260|Experimental|metformin (MATE1, MATE2K, OCT1, OCT2)|500 mg metformin single dose
16580318|NCT02743260|Experimental|digoxin (intestinal & renal P-glycoprotein)|0.5 mg digoxin single dose
16580319|NCT02743260|Experimental|adefovir dipivoxil (OAT1)|10 mg adefovir dipivoxil single dose
16580320|NCT02743260|Experimental|sitagliptin (OAT3)|100 mg sitagliptin single dose
16580321|NCT02743260|Experimental|cocktail (all substances)|combination of all individual drugs at respective single doses
16580322|NCT02743247|Experimental|Tacrolimus and Mycophenolate mofetil|Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
16580323|NCT02743234|Experimental|FMT|Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
16580324|NCT02743234|Active Comparator|Fidaxomicin|10 days fidaxomicin 200 mg x 2 daily
16580325|NCT02743234|Active Comparator|Vancomycin|10 days vancomycin 125 x 4 daily
16580326|NCT02743221|Experimental|Trifluridine/tipiracil + bevacizumab|"Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.
~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.
~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks."
16580327|NCT02743221|Active Comparator|Capecitabine + bevacizumab|Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks
16580328|NCT02743208|Experimental|Furlong Evolution femoral stem|Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.
16580329|NCT02743208|Active Comparator|Furlong H-A.C. femoral stem|Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.
16580330|NCT02743195|Other|Polyphenol/prebiotic blend|Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
16580331|NCT02743182|Active Comparator|Pegylated interferon alfa-2a|adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
16580332|NCT02743182|No Intervention|Control|HBeAg-negative patients receiving nucleos(t)ide analogues
16580333|NCT02743169||Standard Practice|This group will consist of ambulance calls under the standard practice of Aman Foundation for ambulance placement.
16580334|NCT02743169||Post-Intervention|This group will consist of ambulance calls after the spatially-optimized placement of ambulances.
16580335|NCT02743156|Active Comparator|angiography-guided PCI|angiography-guided percutaneous coronary intervention
16580336|NCT02743156|Experimental|IVUS-guided PCI|intravascular ultrasound guided percutaneous coronary intervention
16580337|NCT02743143|Experimental|Exercise therapy|High aerobic intensity training and maximal strength training 2 times per week in 1 year at the Hospital's Exercise Training Clinic. Patients receive comprehensive support from Trondheim municipal administration to facilitate adherence.
16580338|NCT02743143|Active Comparator|Follow-up care as usual|The usual care (UC) group will receive the usual physical activity offered by the primary health care system. UC includes the traditional physical activity advice from the Health Directorate. The UC group are invited to supervised exercise at the exercise training Clinic after 1 year.
16580339|NCT02743130|Experimental|Blackcurrant nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
16580340|NCT02743130|Experimental|Lingonberry nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
16580341|NCT02743130|Active Comparator|Reference|Sugar control, contains 17.5 g glucose and 17.5 g fructose in water
16580342|NCT02743117|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
16580343|NCT02743117|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
16580344|NCT02743104|Active Comparator|Ketamine for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.
~This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
16580345|NCT02743104|Active Comparator|Propofol for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.
~This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
16580346|NCT02743078|Experimental|Bevacizumab and TTFields Therapy|Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.
16580347|NCT02743065||Device: HepaSphere Microspheres|HepaSphere Microsphere
16580348|NCT02743039|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
16580349|NCT02743039|No Intervention|Control Standard of CAP|No assignment to participate in the CareerAdvance® program, but given community referrals and resources
16580350|NCT02743026|Experimental|Intervention|participants will complete the FOXY intervention
16580351|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI|with/without Charcoal Block
16580352|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI (replicate)|with/without Charcoal Block
16580353|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI VHC|with/without Charcoal Block with Valved Holding Chamber
16580354|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 1|with/without Charcoal Block
16580355|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 2|with/without Charcoal Block
16580356|NCT02743000||Women ages 18-35|Women ages 18-35 who do and do not engage in binge eating will be included in the study
16580357|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
16580358|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
16580359|NCT02742974|No Intervention|FloTrac™ and EV1000™ pre and post-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the pre and post-operative period in the control arm.
16580360|NCT02742974|Experimental|FloTrac™ and EV1000™ peri-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the perioperative period for the intervention arm
16580361|NCT02742961||Peripheral nerve block|Intervention arm. Participants who receive a peripheral nerve block identified through submission of an appropriate physician billing code
16580362|NCT02742961||No peripheral nerve block|Control arm. Participants who do not receive a peripheral nerve block identified through lack of a submission of an appropriate physician billing code
16580363|NCT02742948|Active Comparator|preoperative antibiotic group|200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
16580364|NCT02742948|Active Comparator|early intraoperative antibiotic group|200 women will receive IV ceftriaxone (2g) immediately with skin incision
16580365|NCT02742948|Active Comparator|post cord clamping antibiotic group|200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
16580366|NCT02742935|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes.
16580367|NCT02742922|Experimental|Culturally adapted therapy (C-MAP)|Culturally adapted manual assisted (C-MAP) brief problem solving therapy
16580368|NCT02742922|No Intervention|Treatment as usual|This arm will receive no intervention only TAٓU.
16580369|NCT02742909|Active Comparator|rhBNP|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received rhBNP.
16580370|NCT02742909|Placebo Comparator|Placebo|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received placebo.
16580371|NCT02742896||Restoration of Erectile dysfunction|The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
16580372|NCT02742883|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
16580373|NCT02742870||Patients with MRI pelvic imaging|Women over 18 years old, having undergone a magnetic resonance imaging of the pelvis within the CHU Brugmann Hospital
16580374|NCT02742857|Experimental|Treatment Group|
16580375|NCT02742844|Experimental|APZ2 application|Topical, single application of APZ2; 500000 cells per square cm;
16580427|NCT02742545|No Intervention|Usual Care|Clinicians in care teams assigned to the standard of care arm will continue to provide up-to-date, patient-specific guideline-based treatment recommendations as is the standard of care at Mayo Clinic.
16580428|NCT02742532|Experimental|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
16580376|NCT02742831|Experimental|Intervention|"The intervention group will receive a one-on-one in-person intervention of 6 sessions, each lasting approximately 60 minutes. The intervention is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. The overview of the 6 sessions is as follows:
~Behavioral chain analysis of episodes where parent felt stressed and episode where things went well. Identification of sources of interpersonal support.
~Stress relief. Development of a detailed crisis plan.
~Problem solving techniques.
~Emotional regulation exercises.
~Positive parenting, review of parenting challenges.
~Reflection, repeat behavioral chain analysis. Update crisis plan."
16580377|NCT02742831|Active Comparator|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
16580378|NCT02742818|Other|Upper body blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
16580379|NCT02742818|Other|Underbody blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
16580380|NCT02742805|Experimental|High Dose Vitamin D|Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
16580381|NCT02742805|Active Comparator|Low Dose Vitamin D|Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
16580382|NCT02742792|Experimental|Resistance training|Resistance training, twice a week during 12 weeks.
16580383|NCT02742792|Other|Advice on lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
16580384|NCT02742779|Experimental|High-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
16580385|NCT02742779|Experimental|High-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 3.
16580386|NCT02742779|Experimental|Low-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
16580387|NCT02742779|Experimental|Low-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
16580388|NCT02742779|Experimental|MD Cohort: PIC (Part 2)|Participants will receive multiple ascending dose administered orally using PIC from Day 1 to Day 13 twice daily (BID) or may even be thrice daily (TID) or four times a day (QD) depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
16580389|NCT02742779|Experimental|MD Cohort: Solution Formulation (Part 4)|Participants will receive multiple ascending dose in fed or fast condition, administered orally using solution from Day 1 to Day 13 BID or may even be TID or QD depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
16580390|NCT02742779|Placebo Comparator|Placebo PIC|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
16580391|NCT02742779|Placebo Comparator|Placebo Solution|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
16580392|NCT02742779|Experimental|SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using PIC on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 1.
16580393|NCT02742779|Experimental|SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using solution formulation on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 3.
16580394|NCT02742766|Experimental|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
16580395|NCT02742766|Experimental|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
16580396|NCT02742766|Experimental|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
16580397|NCT02742753||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
16580398|NCT02742740|No Intervention|Control|Standard of care for chemotherapy treatment.
16580401|NCT02742714|Experimental|PillCam SBC|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
16580402|NCT02742688|Experimental|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|
16580403|NCT02742688|Placebo Comparator|Placebo|
16580404|NCT02742675|Experimental|androgen deprivation therapy|Patients will receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide acetate, goserelin acetate, buserelin, or triptorelin) subcutaneously or as an injection AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily).
16580405|NCT02742675|Experimental|androgen deprivation therapy plus definitive treatment|Patients will receive androgen-deprivation therapy as in arm I in addition to definitive treatment including surgery to remove prostate or radiation therapy to the prostate.
16580406|NCT02742662|Experimental|Smart Technology Group|The Smart Technology Group will receive a technology-based lifestyle intervention program which uses wearable technology, smartscales and smartphone applications to track and deliver feedback on caloric expenditure, physical activity, caloric intake and body weight. Participants will receive information through smartphone applications on strategies to make changes to their diet, physical activity, and weight-related behaviors along with standard 3 monthly in-person weight management visits.
16580407|NCT02742662|Other|Standard Weight Management Group|The Standard Weight Management Group will receive 3 monthly in-person weight management visits during which they will receive standard of care lifestyle recommendations in accordance with the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline.
16580408|NCT02742649|Experimental|Fixed Combination (FC) Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one segment of timolol maleate combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
16580409|NCT02742649|Experimental|Bimatoprost Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
16580410|NCT02742649|Experimental|Timolol Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of timolol and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
16580411|NCT02742636|Experimental|Group A (treatment group)|The patients in this group will have their catheter directly removed in the OR after LH.
16580412|NCT02742636|Active Comparator|Group B (control group)|The patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).
16580413|NCT02742623||Rivaroxaban|Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
16580414|NCT02742610|Experimental|Mindfulness with Contingency Management|The intervention (MSI-CM) will involve two individual pre-quit in-person sessions and two post-quit phone counseling sessions, a series of brief mindfulness trainings that will be delivered via smartphone, that prompts participants to practice a mindfulness exercise five times a day while abstinent during the 2-week incentivized abstinence period (using CM) plus an additional 2 weeks (without CM) following the participant's target quit date. The MSI-CM participants will be asked to provide CO video via smartphone twice daily with monetary incentives provided (CM). Participants will receive monetary incentives contingent on each confirmed CO level (less than 7 ppm) for the CM period. We will use CM as an adjunct strategy to enhance the efficacy of mindfulness training.
16580415|NCT02742610|Active Comparator|Active Control|Participants assigned to the control group will receive two individual pre-quit in-person sessions and two post-quit phone counseling sessions, similar to the MSI-CM except for mindfulness introduction/discussion. Participants in the control group will receive the same monetary incentives on average as the participants in the MSI-CM for submitting CO videos, regardless of CO levels (non-abstinent contingent), during the 2-week post-TQD period. Each participant in the group (the non-contingent CO group) will be yoked to a single participant (selected randomly with stratification) in the MSI-CM. The yoked participant receives the same amount of monetary incentives as his or her matched participant in the contingent CO (MSI-CM) group.
16580416|NCT02742597|Active Comparator|Group A|Intervention group (n = 86) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting
16580417|NCT02742597|Active Comparator|Group B|Before/After Intervention group (n = 10) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting
16580418|NCT02742597|No Intervention|Group C|Control group (n = 77)
16580419|NCT02742597|No Intervention|Group D|Health Administrative Data Group (n = 430) Number of matched data controls. Not taking part in intervention.
16580420|NCT02742584|Experimental|Group A|Cough Stress Test with a comfortably full bladder.
16580421|NCT02742584|Experimental|Group B|Cough Stress Test with an empty bladder after straight catheterization.
16580422|NCT02742584|Experimental|Group C|Cough Stress Test with a bladder infused with 200 cc of saline.
16580423|NCT02742584|Experimental|Group D|Cough Stress Test with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary.
16580424|NCT02742558|Experimental|cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
16580425|NCT02742558|Active Comparator|shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
16580426|NCT02742545|Experimental|MayoExpertAdvisor|Clinicians in care teams assigned to the intervention arm will have access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
16580430|NCT02742519|Experimental|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
16580431|NCT02742519|Experimental|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
16580432|NCT02742519|Experimental|Part 2: ivacaftor|open label period
16580433|NCT02742506|Experimental|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
16580434|NCT02742506|Active Comparator|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
16580435|NCT02742493|Experimental|0.028 bonded to canines|lower fixed canine and canine retainer and upper removable Hawley (Intervention A)
16580436|NCT02742493|Experimental|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer and upper removable Hawley (Intervention B)
16580437|NCT02742493|Active Comparator|removable Hawley-type|lower hawley-type and upper hawley removable retainer (Control)
16580438|NCT02742480||Dabigatran|300 patients treated with dabigatran under the habitual clinical practice.
16580439|NCT02742480||Acenocoumarol|200 patients treated with acenocoumarol under the habitual clinical practice.
16580440|NCT02742467|Experimental|1|Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
16580441|NCT02742467|Active Comparator|2|Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
16580442|NCT02742467|Active Comparator|3|Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.
16580443|NCT02742454|Active Comparator|Standard 30-60 Seconds Cord Clamping|Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.
16580444|NCT02742454|Experimental|VentFirst 120 Seconds Cord Clamping|Assisted ventilation (face mask Continuous Positive Airway Pressure, CPAP, or Positive Pressure Ventilation, PPV) will be provided prior to cord clamping at 120 seconds.
16580445|NCT02742441|Experimental|122-0551 Foam|"122-0511 Foam, topically applied twice daily
~Intervention: Drug: 122-0551 Foam"
16580446|NCT02742441|Placebo Comparator|Vehicle Foam|"Vehicle Foam, topically applied twice daily
~Intervention: Drug: Vehicle Foam"
16580447|NCT02742428|Experimental|Ascites drainage before surgery.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. An indwelling catheter insertion into abdominal cavity and slow, systematic ascites evacuation for 7 or more days before surgery (if it cannot be scheduled immediately) will be performed. Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
16580448|NCT02742428|Other|Observation.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. A standard of care: observation or acute paracentesis (>5000ml) will be performed while waiting for the surgery (if it cannot be scheduled immediately). Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
16580449|NCT02742415|Experimental|Cancer patients receiving hand massage|Caring Hand massage will be provided to the outpatients undergoing chemotherapy
16580450|NCT02742402|Experimental|Observation|Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
16580451|NCT02742402|Active Comparator|Diagnostic imaging|Patients undergo abdominal ultrasound and if the result is inconclusive or negative for appendicitis patients will have abdominal computed tomography. Laparoscopic appendectomy is done for patients with appendicitis in diagnostic imaging.
16580452|NCT02742389|No Intervention|Standard counseling|This group will receive the standard counseling that all our patients would receive if they are scheduled to have urodynamic testing. This counseling will include a description of the procedure and a handout about urodynamic testing
16580453|NCT02742389|Other|Standard + Preprocedure Telephone Call|The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
16580454|NCT02742376|Other|Soft surface|A soft sponge used for physiotherapy is placed on the floor along a path,
16580455|NCT02742376|Other|Floor|The subject will walk on the floor.
16580456|NCT02742376|Other|Shoes|Special shoes (Kyboot) with air cushions that are meant to relieve pressure will be used.
16580457|NCT02742350|Experimental|IMT+Exercise|The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
16580458|NCT02742350|No Intervention|Exercise Control|Aerobic Exercise and Stretching
16580459|NCT02742337||Test|Newly diagnosed female patients with rheumatoid arthritis who have not previously used a disease modifying anti-rheumatic drug.
16580460|NCT02742337||Control|Female patients not having a diagnosis of rheumatoid arthritis and who have not previously used a disease modifying anti-rheumatic drug.
16580461|NCT02742324|Experimental|Ruxolotinib and peg-IFN alpha -2a|"Phase I
~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly
~Phase II
~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
16580462|NCT02742311|Active Comparator|transforaminal endoscopic discectomy|
16580463|NCT02742311|Active Comparator|interlaminar endoscopic discectomy|
16580464|NCT02742298|Other|QMUS|All patients will undergo serial quantitative muscle ultrasound.
16580465|NCT02742298|Other|EIM|All patients will undergo serial electrical impedance myography measures.
16580466|NCT02742285|Other|Artemether + lumefantrine|One single adult dose of artemether + lumefantrine 80 + 480 mg
16580467|NCT02742272||ED Headache or Migraine Patients|The investigators will perform a prospective cohort study of patients ages 6-18 years presenting to the ED with a complaint of headache or migraine over a 12 month period.
16580468|NCT02742259||Beta Cutoff|Assay
16580469|NCT02742259||Pivotal|Assay
16580470|NCT02742246|No Intervention|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
16580471|NCT02742246|Active Comparator|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
16580472|NCT02742246|Experimental|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
16580473|NCT02742233|Experimental|saxagliptin|"saxagliptin & Regular treatment:
~saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd"
16580474|NCT02742233|Placebo Comparator|placebo|"placebo & Regular treatment:
~placebo, dose: 5mg, po, qd"
16580475|NCT02742220|Experimental|Isometric Handgrip Training Group|Experimental group will perform home-based unilateral handgrip exercise and will be recommended to increase daily physical activity levels.
16580476|NCT02742220|Sham Comparator|Control Group|Control group will be recommended to increase daily physical activity levels.
16580477|NCT02742207||Observational|All comers with Atrial fibrillation
16580478|NCT02742194|Placebo Comparator|Placebo|Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
16580479|NCT02742194|Experimental|Ginger group|Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
16580480|NCT02742181|Experimental|Alvimopan group|In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
16580481|NCT02742181|Other|Control Group|Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.
16580482|NCT02742168|Experimental|Breast Cancer,99mTc-3PRGD2,SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of breast cancer
16580483|NCT02742155|Experimental|Play2Sleep|For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
16580484|NCT02742155|Active Comparator|Comparison|In the comparison group, only standard public health handouts on infant sleep will be reviewed with parents.
16580485|NCT02742142|Placebo Comparator|control|Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
16580486|NCT02742142|Experimental|silver diammine fluoride|the subjects received the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution was painted onto the exposed tooth root surfaces. This treatment was repeated after 12 and 24 months.
16580543|NCT02741726|Experimental|single acupoint stimulation|The acupoints of single point group is bilateral Neiguan points(PC6), Electric stimulation was given through electrode attached to the acupoints.
16580544|NCT02741726|Placebo Comparator|no stimulation|false stimulation group only attach electrodes without electric current.
16580700|NCT02740803|Experimental|NaF + NaMFP - R|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
16580487|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
16580488|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
16580489|NCT02742103|Experimental|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
16580490|NCT02742103|Placebo Comparator|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
16580491|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
16580492|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
16580493|NCT02742064||MDD-Single Episode|1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
16580494|NCT02742064||MDD-Recurrent|1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
16580495|NCT02742064||Bipolar Disorder|1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
16580496|NCT02742051|Experimental|Everolimus+Letrozole|everolimus 10mg/d,po + letrozole 2.5mg/d,po * 18 weeks
16580497|NCT02742051|Active Comparator|Fluorouracil+epirubicin+cyclophosphamide|Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 * 6 cycles (every 21 days per cycle)
16580498|NCT02742038|Experimental|Fluoride varnish plus education|Biannual fluoride varnish every 6 month/ 24 months plus educational component
16580499|NCT02742038|Placebo Comparator|Placebo varnish plus education|Biannual placebo varnish every 6 month/ 24 months plus educational component
16580500|NCT02742025|Other|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.
~Intervention: Inclusion visit
~Intervention: Coronarography on day 0"
16580501|NCT02742025|Experimental|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.
~Intervention: Inclusion visit
~Intervention: Nurse consultation
~Intervention: Telephone contact
~Intervention: Coronarography on day 0"
16580502|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.
~Intervention: Risk estimation prior to surgery and immediately after the surgery.
~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
16580503|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.
~Intervention: Risk estimation prior to surgery and immediately after the surgery.
~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
16580504|NCT02741973|Experimental|Yoga|Students have 10 weeks yoga instead of school sport.
16580505|NCT02741973|Active Comparator|School sport|Students have 10 weeks regular school sport.
16580506|NCT02741960|Experimental|metformin|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
16580507|NCT02741960|Placebo Comparator|placebo|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
16580508|NCT02741947|Active Comparator|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
16580509|NCT02741947|Experimental|Levodopa Benserazide Teva Italia|Levodopa Benserazide Teva Italia100+25mg and 200+50mg, tablet, tid e qid, for four weeks
16580510|NCT02741934||Preterm cohort|Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled.
16580511|NCT02741934||Term control cohort|The infants who were born from 2008 to 2009 with term gestational age will be enrolled.
16580512|NCT02741921|Experimental|Normal airway|intubation with normal airway Cormack-Lehane classivication I
16580513|NCT02741921|Experimental|difficult airway|intubation with difficult airway Cormack-Lehane classivication III
16580514|NCT02741908|Experimental|Fixed diet plan|Patients received a fixed diet plan to assist in the choice of foods aimed at changing eating behavior. Dietary intake was evaluated by using 3 nonconsecutive 24-hour dietary recalls collected at each visit. Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
16580568|NCT02741570|Active Comparator|Extreme Regimen|Specified dose on specified days
16580701|NCT02740803|Experimental|NaF + NaMFP - NR|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
16580515|NCT02741908|Experimental|Calorie counting diet|Patients underwent a calorie counting diet, in which each patient has received a table list with equivalent points for food and drinks, and was instructed to record all daily food or drink intake and calculate the total score of points consumed (1 point = 3.6 calories). They were allowed to eat any food but were limited to the recommended amount of points (or calories equivalents). Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
16580516|NCT02741895||Postoperative patients|The target populations for the study are patients undergoing robotic cystectomy, open colectomy, abdominal hysterectomy, esophagectomy, lung lobectomy, gastric bypass, and hip replacement at Cedars-Sinai Medical Center.
16580517|NCT02741882||Cases|Mothers who delivered a baby with microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
16580518|NCT02741882||Controls|Mothers who delivered a baby without microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
16580519|NCT02741869|Experimental|single arm|This is a single arm, open label study. Subjects who meet eligibility criteria will be treated with photodisinfection therapy (MRSAid™).
16580520|NCT02741856|Experimental|Arm 1 (carboplatin/paclitaxel+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1
~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (50Gy/25 fractions)"
16580521|NCT02741856|Experimental|Arm 2 (cisplatin/capecitabine+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14
~Cycles 3 and 4 are given concomitantly with radiotherapy (50Gy/25 fractions). Capecitabine stops on last day of RT."
16580522|NCT02741856|Experimental|Arm 3 (carboplatin/paclitaxel+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1
~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (60Gy/25 fractions)"
16580523|NCT02741856|Experimental|Arm 4 (Cisplatin+Capecitabine+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14 Cycles 3 and 4 are given concomitantly with radiotherapy (60Gy/25 fractions). Capecitabine stops on last day of RT."
16580524|NCT02741843|Experimental|Patient Education|
16580525|NCT02741843|No Intervention|Control|
16580526|NCT02741830||Uterosacral ligament suspension (USLS)|This group of patients underwent the procedure of native tissue vaginal reconstructive surgery using uterosacral ligament suspension for pelvic organ prolapse.
16580527|NCT02741830||Robotic sacrocolpopexy (RSC)|This group of patients underwent the reconstructive pelvic surgery of robotic sacrocolpopexy using synthetic mesh.
16580528|NCT02741817|Experimental|Aspirin 20mg|Supplied with sachets of 100mg soluble aspirin and training, instructions and equipment will be provided to prepare 20 mg dose twice daily x14 then aspirin 75mg once daily x14
16580529|NCT02741817|Experimental|Aspirin 75mg|This is the standard dose of aspirin the participant will already be taking. The study will require the participants to switch to soluble aspirin for two weeks to enable accurate comparison with the other dose and to take their aspirin dose in the morning. Participants will be provided with a supply of soluble aspirin, along with training, instructions and equipment to help prepare it. They should not take their usual aspirin tablets whilst receiving the study medication, but should continue all other usual medications.
16580530|NCT02741804|Active Comparator|BBH-1001 Brain Health Supplement|Patients will be given supplement containing ingredients all approved by the FDA: Turmeric (125mg), fisetin (16.65mg), green tea leaf extract (17.5mg), EPA (75mg), DHA (150mg) and Vitamin D3 (250IU). Patients will take 4 softgels once per day for entire study duration (18 months).
16580531|NCT02741804|Placebo Comparator|Brain Health Placebo|Patients will be given a pill resembling the study supplement, but instead consisting of Soybean oil (608mg). Patients will take 4 softgels once per day for the entire study duration (18 months).
16580532|NCT02741791|Experimental|AXS-05|
16580533|NCT02741791|Active Comparator|Bupropion|
16580534|NCT02741778|Other|Minimally invasive group|"In this group, all manipulations are finished by laparoscopy and thoracoscopy.
~Horizontal position, undergoing laparoscopy through 5-port method. The sequence: gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes ), gastric tube making, and jejunostomy.
~Left lateral position, undergoing thoracoscopy through 3-port method. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection, gastro-esophageal anastomosis by using CEEA."
16580535|NCT02741778|Other|Open group|"Right lateral position, Traditional thoracotomy through the 7th intercostal incision. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection.
~Then,oped the diaphragm,undergoing gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes), gastric tube making, gastro-esophageal anastomosis by using CEEA. Nasointestinal tube is placed for feeding."
16580536|NCT02741765|Active Comparator|Group 1: Sham Group|Sham group will receive Sham rTMS+Aerobic Exercise
16580537|NCT02741765|Experimental|Group 2: Real Group|rTMS+Aerobic Exercise
16580538|NCT02741752|Experimental|test group|decortication group
16580539|NCT02741752|No Intervention|control|without decortication
16580540|NCT02741739|Experimental|Reference Drug|REGN1033 Reference Formulation
16580541|NCT02741739|Experimental|Test Drug|REGN1033 Test Formulation
16580542|NCT02741726|Experimental|dual acupoint stimulation|The acupoints of dual point group are bilateral Neiguan points(PC6) combined with Danzhong point(RN17), electric stimulation was given through electrode attached to the acupoints.
16580545|NCT02741713|Sham Comparator|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
16580546|NCT02741713|Active Comparator|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
16580547|NCT02741700|Experimental|Gout storytelling video|Patients view a culturally relevant patient storytelling in African-American Veterans' own voices about gout and its treatment.
16580548|NCT02741700|Active Comparator|Video about management of another chronic condition|Patient narrated slide show of roughly the same duration as the experimental arm, summarizing management of a non-gout condition.
16580549|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).
~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.
~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
16580550|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).
~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.
~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
16580551|NCT02741674||Roux-en-y gastric bypass (RYGB)|"Adults and children age ≤79 years at time of surgery
~Had a primary (not revision) Roux-en-y gastric bypass from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)
~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
16580552|NCT02741674||Adjustable gastric banding (AGB)|"Adults and children age ≤79 years at time of surgery
~Had a primary (not revision) adjustable gastric banding procedure from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)
~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
16580553|NCT02741674||Sleeve gastrectomy (SG)|"Adults and children age ≤79 years at time of surgery
~Had a primary (not revision) sleeve gastrectomy from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)
~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
16580554|NCT02741661||Normal coronary arteries|Patients in whom coronary arteriography has demonstrated no significant tortuosity.
16580555|NCT02741661||Tortuous coronary arteries|Patients in whom coronary arteriography has demonstrated tortuous coronary arteries defined as >1 major bend of >45 degrees in a major coronary artery
16580556|NCT02741648||ELBW Infants with Prolonged Irradiation Storage Time|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
16580557|NCT02741648||ELBW Infants without Irradiation Storage|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
16580558|NCT02741648||ELBW Infants with NEC|"Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy."
16580559|NCT02741648||ELBW Infants without NEC|Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
16580560|NCT02741635|Experimental|New Nasal Pillows Mask|Participants to use nasal pillows mask one night in lab overnight polysomnography.
16580561|NCT02741622|Experimental|Exercise|Acute High aerobic intensity training (HIT) and long slow distance training (LSD)
16580562|NCT02741609|Experimental|Early/Late Stage Lyme disease|Have early Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with early stage Lyme disease. Subjects must have a physician-diagnosed erythema migrans (EM) rash and should have systemic symptoms indicative of disseminated infection. Symptoms may include fever, headache, fatigue, myalgias, arthralgias, and stiff neck. Paired acute and convalescent titers will be drawn (first draw at time of initial visit and second draw 4 weeks later). Have late Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with late stage Lyme disease, including but not limited to disseminated rash, arthritis, meningitis, facial palsy, or carditis. Qualified subjects will be administered the Borrelia Diagnostic Test.
16580563|NCT02741596|Experimental|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
16580564|NCT02741596|Experimental|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
16580565|NCT02741583|Experimental|altitude rehabilitation program|3 weeks rehabilitation program at high altitude (3200m)
16580566|NCT02741583|Active Comparator|rehabilitation program|3 weeks rehabilitation program at low altitude (760m)
16580567|NCT02741570|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
16580569|NCT02741557|Experimental|DTG/RPV FDC-DTG plus RPV|Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 2 under fed state.
16580570|NCT02741557|Experimental|DTG plus RPV-DTG/RPV FDC|Subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 2 under fed state.
16580571|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
16580572|NCT02741531|Experimental|Intervention|Patients in this group will have their bladder filled with 150 cubic centimeters (cc) of saline solution prior to being moved to the PACU.
16580573|NCT02741531|No Intervention|Control|patients in this group will have their bladders drained completely prior to being moved to the PACU as is the current standard of care.
16580574|NCT02741518|Active Comparator|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
16580575|NCT02741518|Placebo Comparator|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
16580576|NCT02741505|Experimental|Sleep Deprivation followed by Normal Sleep|Subjects will be sleep deprived at the sleep laboratory.
16580577|NCT02741492|Active Comparator|Block Group|Continuous Transversus Abdominis Plane Catheter
16580578|NCT02741492|Sham Comparator|Sham Group|Continuous Sham Catheter
16580579|NCT02741479|Experimental|K Tape Group|
16580580|NCT02741479|Active Comparator|Sham Group|
16580581|NCT02741479|Experimental|No Tape|
16580582|NCT02741466|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
16580583|NCT02741453|Active Comparator|Standard Practice|Placement of a CVC by standard practice
16580584|NCT02741453|Experimental|Bilateral IJ Ultrasound Scanning|Placement of a CVC after mandatory ultrasound scanning of both right and left internal jugular veins
16580585|NCT02741440||Affected Participants|Twenty-five (25) participants with molecularly confirmedSCA7
16580586|NCT02741427|Placebo Comparator|G1 (group 1) - Conventional toothpaste|G1 used a conventional toothpaste in daily oral regimen
16580587|NCT02741427|Experimental|G2 (group 2) - Whitening toothpaste|G2 used a whitening toothpaste containing blue pigment in daily oral regimen
16580588|NCT02741427|Active Comparator|G3 (group 3) - 10 % Carbamide peroxide|G3 made an at-home tooth bleaching with 10 % Carbamide peroxide
16580589|NCT02741414|Experimental|H pylori culture negative group|The patients who have the negative result of H pylori culture were classified into H pylori culture negative group.
16580590|NCT02741414|Experimental|The first successful eradication group|The patients with first eradication therapy of H. pylori infection have the first successful treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and proton pump inhibitors （PPIs) dose selection from CYP2C19 gene sequencing.
16580591|NCT02741414|Experimental|The refractory infection of H. pylori group|The patients with first eradication therapy of H. pylori infection have the two failure treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and PPIs dose selection from CYP2C19 gene sequencing.
16580592|NCT02741401|Active Comparator|Therapy standard|Patients receive usual postoperative care
16580593|NCT02741401|Experimental|Therapy standard + hand-foot massage|Patients receive usual postoperative care and hand-foot massage
16580594|NCT02741388|Experimental|Selinexor + immunochemotherapy|"Selinexor will be administered orally on Day1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy, R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine) or R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin) for 3 cycles (choice of the immunochemotherapy left at the investigator's decision before patient's inclusion).
~Different dose levels of selinexor will be examined sequentially in each group: 20 mg flat (DL-1), 40 mg flat (DL1), 60 mg flat (DL2), 80 mg flat (DL3)."
16580595|NCT02741375||Brain Death Group (BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
16580596|NCT02741375||Non-Brain Death Group (Non BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
16580597|NCT02741362|Experimental|ADSC arm|Single intravenous administration of Stromal Vacsular Fraction (SVF) cells soinating Adipose Derived Stem Cells (ADSC) 6 week baseline data prior to the injection of ADSC will be collected. 6 week, 3 months and 6 months follow up data will be compared against baseline.
16580598|NCT02741336|Experimental|CBT-I Intervention|For those randomized to the CBT-I group, the therapist will initiate telephone-delivered cognitive-behavioral therapy within 2 weeks of baseline assessment. Participants will complete 4 telephone sessions over a period of 8 weeks. Sessions last approximately 45 minutes. CBT-I is a short-term, focused psychotherapy that is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.
16580670|NCT02740985|Experimental|Arm KD|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy-naïve patients with colorectal carcinoma.
16580671|NCT02740985|Experimental|Arm L|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with other solid tumours.
16580599|NCT02741336|Active Comparator|Self-Monitoring Control Group|Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
16580600|NCT02741323|Experimental|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
16580601|NCT02741323|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
16580602|NCT02741310|Placebo Comparator|Placebo|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
16580603|NCT02741310|Experimental|Erenumab|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
16580604|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
16580605|NCT02741284|Experimental|No Oxygen|Room air
16580606|NCT02741284|Active Comparator|Oxygen|10L oxygen by nonrebreather mask
16580607|NCT02741271|Experimental|MF/F MDI 100/10 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.
16580608|NCT02741271|Active Comparator|MF MDI 100 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.
16580609|NCT02741258|Experimental|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
16580610|NCT02741258|Active Comparator|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
16580611|NCT02741245|Active Comparator|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
16580612|NCT02741245|Active Comparator|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
16580613|NCT02741245|Active Comparator|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
16580614|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
16580615|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
16580616|NCT02741232|Active Comparator|Pectoral nerve block|After induction of general anesthesia and under ultrasound visual guidance, pectoral block is performed with 30 mL total of local anesthetic (1% lidocaine + 1/400000 epinephrine). 10 mL of local anesthetic between pectoralis major muscle and pectoralis minor muscle and 20 mL between pectoralis minor muscle and serratus anterior muscle at the third rib.
16580617|NCT02741232|Sham Comparator|Sham block|No needle or injection will be used
16580618|NCT02741219|Placebo Comparator|Control Group|Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.
16580619|NCT02741219|Experimental|Dex Group|Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.
16580620|NCT02741206|Active Comparator|High Risk PTSD Group 1|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
16580621|NCT02741206|Active Comparator|High Risk PTSD Group 2|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
16580622|NCT02741206|Experimental|Low Risk PTSD Control|Twenty additional women, who are at lower risk and thus not eligible for randomization, will also receive one psycho-education session and usual care (control group 2).
16580623|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
16580624|NCT02741180|Other|Patients with Arrhythmias|
16580625|NCT02741180|Other|Healthy Control|
16580626|NCT02741167||CRS and HIPEC|Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy
16580627|NCT02741154|Experimental|aromataze group|patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
16580628|NCT02741154|Active Comparator|classic group|same protocol for induction without aromataze inhibitor
16580629|NCT02741141|Active Comparator|Classical partograph|Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
16580630|NCT02741141|Experimental|New partograph|The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
16580633|NCT02741115|Experimental|Drug|Udenafil. One tablet twice daily for 26 weeks
16580634|NCT02741115|Experimental|Placebo|Placebo. One tablet twice daily for 26 weeks
16580635|NCT02741102|Experimental|Women with AUFI|Women with AUFI must meet criteria for uterine transplant. In vitro fertilization to obtain 6 (screened) healthy embryos for cryo-preservation precedes uterine transplant from an appropriate donor The recipient will be required to take potent anti rejection medications including Thymoglobulin, Prednisone, Tacrolimus, Mycophenolate Mofetil (MMF) , later substituted with Azathioprine to avoid birth defects. One year later, up to 6 attempts using 1 screened embryo at a time will be tried to achieve pregnancy. During pregnancy, the high risk pregnancy and transplant teams will follow the recipient. The goal is a full term baby and delivery will be by Caesarian section. A second pregnancy may be attempted. Afterward, the uterus will be explanted.
16580636|NCT02741089||Indication for a flexible bronchoscopy|Patients representing to the hospital with the indication for a flexible bronchoscopy
16580637|NCT02741076|Experimental|Structured discontinuation opioid therapy Suboptimal Responder|
16580638|NCT02741076|Experimental|Structured discontinuation opioid therapy Optimal responders|
16580639|NCT02741076|Experimental|Continuation of opioid therapy Suboptimal responders|
16580640|NCT02741076|Experimental|Structured Continuation of opioid therapy Optimal responders|
16580641|NCT02741063|Experimental|high autistic and oxytocin group|subject with high ASQ scores will receive oxytocin treatment
16580642|NCT02741063|Experimental|low autistic and oxytocin group|subject with low ASQ scores will receive oxytocin treatment
16580643|NCT02741063|Placebo Comparator|high autistic and placebo group|subject with high ASQ scores will receive placebo treatment
16580644|NCT02741063|Placebo Comparator|low autistic and placebo group|subject with low ASQ scores will receive placebo treatment
16580645|NCT02741050|Experimental|Tailored Physical Activity Intervention|Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
16580646|NCT02741050|Active Comparator|Standard of Care Control Group|Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.
16580647|NCT02741037|Experimental|Dyadic lifestyle intervention|Mothers and daughters participate in the Unidas partner intervention together.
16580648|NCT02741037|Experimental|Individual lifestyle intervention|Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers.
16580649|NCT02741037|Other|Usual Care|Mothers and daughters receive usual care.
16580650|NCT02741024|Active Comparator|Amodiaquine-Artesunate (ASAQ)|Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
16580651|NCT02741024|Active Comparator|Artemether-Lumefantrine (AL)|Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).
16580652|NCT02741011|Other|Radiological imaging|Mentally handicapped patients underwent sedation anesthesia with IV Propofol and then tomographic images were obtained with NewTom 5G. Orthopantomographies (OPGs) were obtained by processing the raw images and radiological examination of the patients were performed on OPGs.
16580653|NCT02740998||Depo Provera|Ten women ages 18-40 who elect to start a using Depo Provera for contraception.
16580654|NCT02740998||Mirena IUD|Ten women ages 18-40 who elect to start a using a Mirena IUD for contraception.
16580655|NCT02740998||Nexplanon|Ten women ages 18-40 who elect to start a using Nexplanon for contraception.
16580656|NCT02740998||Control: Tubal Sterilization|Five women ages 18-40 who elect to have a tubal sterilization.
16580657|NCT02740985|Experimental|Arm A|AZD4635 monotherapy as nanoparticle suspension 125 mg BID
16580658|NCT02740985|Experimental|Arm B|AZD4635 monotherapy as nanoparticle suspension 75 mg QD
16580659|NCT02740985|Experimental|Arm C|AZD4635 monotherapy as nanoparticle suspension 100 mg QD
16580660|NCT02740985|Experimental|Arm D|AZD4635 as nanoparticle suspension 75 mg QD plus durvalumab
16580661|NCT02740985|Experimental|Arm E|AZD4635 as nanoparticle suspension 100 mg QD plus durvalumab
16580662|NCT02740985|Experimental|Arm EA|AZD4635 as nanoparticle suspension plus enzalutamide
16580663|NCT02740985|Experimental|Arm AA|AZD4635 as nanoparticle suspension plus abiraterone acetate
16580664|NCT02740985|Experimental|Arm F|AZD4635 as nanoparticle suspension plus durvaluamb in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
16580665|NCT02740985|Experimental|Arm G|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
16580666|NCT02740985|Experimental|Arm H|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with other solid tumours.
16580667|NCT02740985|Experimental|Arm I|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
16580668|NCT02740985|Experimental|Arm J|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
16580669|NCT02740985|Experimental|Arm K|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with colorectal carcinoma.
16580672|NCT02740985|Experimental|Arm CA|AZD4635 capsule formulation monotherapy 75 mg, 150 mg, and 200 mg QD. A lower dose of 125 mg or 100 mg may be given. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CA. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycle 1 and Cycle 2 will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
16580673|NCT02740985|Experimental|Arm CB|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
16580674|NCT02740985|Experimental|Arm CC|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus docetaxel. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CC. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycles will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
16580675|NCT02740972|Experimental|NS-065/NCNP-01 40mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
16580676|NCT02740972|Experimental|NS-065/NCNP-01 80mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
16580677|NCT02740972|Placebo Comparator|Placebo|Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment
16580678|NCT02740959|Experimental|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
16580679|NCT02740959|Experimental|Astragalus Polysaccharides 250 mg|PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
16580680|NCT02740946|Experimental|Exercise therapy|Exercise therapy 5 months
16580681|NCT02740933|Experimental|Demeclocycline|"All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.
~The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first."
16580682|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
16580683|NCT02740894||targeted therapy|according to national healthy policy, targeted therapy is the optional therapy
16580684|NCT02740894||traditional chemotherapy|according to national healthy policy, chemotherapy is the first line treatment.
16580685|NCT02740881|Experimental|Training Support System|Participants receive training in Contingency Management and immediately receive the full training support system and quality assurance feedback for 15 months while they provide the treatment.
16580686|NCT02740881|Active Comparator|CM-CAT then TSS|Participants are trained in Contingency Management and use the treatment without training support and quality assurance feedback for 9 months. After 9 months they continue using Contingency Management but now receive the full training support system and quality assurance feedback for 6 months.
16580687|NCT02740868|Active Comparator|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
16580688|NCT02740868|Active Comparator|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
16580689|NCT02740868|Active Comparator|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
16580690|NCT02740842|Active Comparator|Non-intensive group|Essential Health Care (EHC) only This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
16580691|NCT02740842|Experimental|Intensive group|"Interpersonal behavioral change communication This arm will have a behavior change communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
~In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm."
16580692|NCT02740829|Placebo Comparator|Intranasal placebo|placebo comparator
16580693|NCT02740829|Experimental|Intranasal glucagon|active intervention
16580694|NCT02740803|Experimental|NaF - R|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
16580695|NCT02740803|Experimental|NaF - NR|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
16580696|NCT02740803|Experimental|NaMFP- R|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
16580697|NCT02740803|Experimental|NaMFP- NR|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
16580698|NCT02740803|Experimental|SnF + NaF - R|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
16580699|NCT02740803|Experimental|SnF + NaF - NR|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
16580702|NCT02740803|Experimental|AmF - R|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes followed by rinsing with distilled water.
16580703|NCT02740803|Experimental|AmF - NR|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes not followed by rinsing with distilled water.
16580704|NCT02740803|Experimental|0 Fluoride - R|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes followed by rinsing with distilled water.
16580705|NCT02740803|Experimental|0 Fluoride - NR|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes not followed by rinsing with distilled water.
16580706|NCT02740790|Experimental|HPV vaccine 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
16580707|NCT02740790|Placebo Comparator|Placebo 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
16580708|NCT02740790|Experimental|HPV vaccine 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
16580709|NCT02740790|Experimental|HPV vaccine 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
16580710|NCT02740790|Placebo Comparator|Placebo 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
16580711|NCT02740790|Placebo Comparator|Placebo 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
16580712|NCT02740777|Experimental|2-dose adolescent|300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
16580713|NCT02740777|Experimental|3-dose adolescent|300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
16580714|NCT02740777|Experimental|3-dose adult|300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
16580715|NCT02740764|Experimental|Optimization of drug prescribing|The group with optimization program will have: (i) a medical history of the drug prescribing; (ii) analysis and pharmaceutical recommendations and (iii) preparation of a management plan. Notices will be sent only to referring physicians in this experimental group.
16580716|NCT02740764|No Intervention|No intervention|This group will receive the current management of patients in geriatric or memory consultation, during which the intervention of a clinician pharmacist is not provided. There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital, but the recommendations will not be transmitted to the referring physicians of patients.
16580717|NCT02740751|Active Comparator|Still-Tee|Generic name: galactogoe herbal tee, still-tee Dosage: Three cups (each 200 ml) of tea of Still-Tee galactogogue tea will be used Frequency: Three times in a day Duration: for 4 weeks after birth
16580718|NCT02740751|Placebo Comparator|Placebo|The mothers of the babies will receive placebo tea which does not contain galactogogue herbs
16580719|NCT02740751|No Intervention|Water|The mothers of the babies will receive water
16580720|NCT02740725|Active Comparator|Recommendation of Patching|Patients will receive two hours of patching in the case of one line difference of best corrected visual acuity(BCVA) between two eyes during one month.
16580721|NCT02740725|Active Comparator|Recommendation of Patching and interactive binocular treatment|Patients will receive interactive binocular treatment addition to patch therapy in the least of 4 to 5 days of a week within 20-30 minutes in each day during one month.
16580722|NCT02740712|Other|single arm probe drugs and rucaparib|Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib
16580724|NCT02740686||Frequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the frequent exacerbators group based on whether they have had 2 or more hospitalisations for exacerbations or have taken 2 or more courses on steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
16580725|NCT02740686||Infrequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the infrequent exacerbators group based on whether they have had no more than 1 hospitalisation for exacerbations or have not taken more than 1 course of steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
16580726|NCT02740686||Healthy smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and currently smoke.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. A resting blood sample will be taken from these patients and used to compare baseline measurements with the COPD groups.
16580727|NCT02740686||Healthy never smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and have never smoked.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. Resting blood samples will be taken from these patients and used to compare baseline measurements with the COPD groups.
16580728|NCT02740673|Other|Driving simulator|Using the driving simulator for 30 min.
16580729|NCT02740660|Experimental|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
16580730|NCT02740660|Placebo Comparator|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
16580731|NCT02740647|Experimental|Intervention group|Intervention group will be getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery.
16580732|NCT02740647|Placebo Comparator|Control group|the Control group will be getting intra-venous Placebo (0.9% 50 ml of sodium chloride) for 5 days.
16580733|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
16580734|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
16580735|NCT02740621||Patients with coronary heart disease|coronary angiography with finding coronary heart disease currently no cancer 40 years or older
16580736|NCT02740621||control patients|coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older
16580737|NCT02740608|Other|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
16580738|NCT02740595|Experimental|Nicotine|Use an e-cig filled with liquid with nicotine
16580739|NCT02740595|Experimental|no nicotine|Use an e-cig filled with liquid without nicotine
16580740|NCT02740595|Sham Comparator|sham comparator|Use an empty e-cigarette (sham control)
16580741|NCT02740582|Experimental|Tolcapone First, then Placebo|Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
16580742|NCT02740582|Placebo Comparator|Placebo First, then Tolcapone|Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
16580743|NCT02740556|Placebo Comparator|AdhereTech Passive Monitoring|Patients not using the HepCure patient app while AdhereTech passively monitors adherence (no chimes or reminders).
16580744|NCT02740556|Experimental|HepCure Toolkit|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard with AdhereTech passively monitoring adherence (no chimes or reminders).
16580745|NCT02740556|Experimental|HepCure Toolkit and AdhereTech Active Features|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard and with AdhereTech actively monitoring adherence (chimes and reminders enabled).
16580746|NCT02740543|Active Comparator|Allergic Asthma (AA)|
16580747|NCT02740543|No Intervention|Control|
16580748|NCT02740530|Experimental|rTMS Active|High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
16580749|NCT02740530|Placebo Comparator|rTMS Sham|Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex
16580750|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
16580751|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.
~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
16580752|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.
~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
16580753|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to less than 75) and BMI from 18.5 to 45
16580754|NCT02740491||The study population|The study population consists of adult patients diagnosed with localized breast cancer who have completed adjuvant treatment (chemotherapy, radiotherapy) and who are cared for in the Medical Oncology department of the Nîmes University Hospital.
16580755|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
16580756|NCT02740465|Experimental|COPD Patients|
16580757|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
16580758|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
16580759|NCT02740439|Experimental|Intervention Meal|Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
16580760|NCT02740439|Placebo Comparator|Control Meal|Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
16580761|NCT02740426|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
16580762|NCT02740426|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
16580763|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
16580764|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
16580765|NCT02740400|Experimental|CT-TTNB|patients receive CT-TTNB to diagnose PPLs.
16580766|NCT02740400|Experimental|EBUS-GS|patients receive EBUS-GS to diagnose PPLs.
16580767|NCT02740387|Experimental|OTO-104|12 mg dexamethasone
16580768|NCT02740374|Experimental|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.
~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
16580769|NCT02740374|Active Comparator|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.
~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
16580770|NCT02740361|Experimental|Deprexis|This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
16580771|NCT02740361|Experimental|DeprexisPlus|This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)
16580772|NCT02740361|No Intervention|Waitlist Control|Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.
16580773|NCT02740348|Experimental|ZocDoc Assistance|Research assistant sets up follow-up appointment for subject using ZocDoc.
16580774|NCT02740348|Active Comparator|ZocDoc Information|Research assistance provides subject with written information about ZocDoc.
16580775|NCT02740348|No Intervention|Usual Care|ED staff gives written and verbal discharge instructions to subject.
16580776|NCT02740335|Experimental|Octaplex|Participants to receive1 Octaplex infusion intravenously
16580777|NCT02740335|Active Comparator|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
16580778|NCT02740322|Other|Hum Test|To examine and compare the Hum Test, Weber Test, and audiogram in their ability to detect and identify hearing loss, hearing loss will be simulated with the use of ear plugs (mimicking conductive hearing loss). Subjects will serve as their own control as these tests will be conducted with and without ear plugs.
16580779|NCT02740309|Experimental|Integrated Brief Behavior Therapy (IBBT) Intervention|4-sessions of IBBT for youth anxiety and depression.
16580780|NCT02740309|Active Comparator|Treatment as usual|Treatment as usual
16580781|NCT02740296||Healthy controls|Healthy controls
16580782|NCT02740296||RRMS|Relapsing-Remitting Multiple Sclerosis
16580783|NCT02740296||RRMS+MDD|Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder
16580784|NCT02740296||MDD|Major Depressive Disorder
16580785|NCT02740283|Experimental|Pregnant women|As a diagnostic study, the cohort will recruit 300 pregnant women who meet inclusion and exclusion criteria outlined below. OGTTs will be performed between 18 and 20 gestational weeks (early-OGTT) and 24 to 28 gestational weeks (regular-OGTT). Clinical and laboratory information of the mother and their offspring will be collected for analysis.
16580786|NCT02740270|Experimental|Arm A|
16580787|NCT02740270|Experimental|Arm B|
16580788|NCT02740257||Group 1 Artificial Lesions|Photos will be taken of skin lesion markings using a smartphone
16580789|NCT02740257||Group 2 high risk|A convenience sample of patients will be recruited. This population will consist of patients with known high risk to have new/changing lesions, and who fall within the Fitzpatrick skin types I-IV. High risk patients include, but are not limited to, those with dysplastic nevus syndrome, previous history of melanoma/non-melanoma skin cancer, fair skin, >16 nevi, family history of melanoma, and/or immunosuppressed status. The first photography session will be taken by the research team in all 13 projections. After the first visit, the patient will be instructed to take photographs every month for 12 months using the TBDP app on their smart phone or tablet, and have follow-up research appointments every 6 months.
16580790|NCT02740244|Active Comparator|active iTBS|Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score < 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
16580791|NCT02740244|Sham Comparator|sham iTBS|The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.
16580792|NCT02740231|Active Comparator|Reference product|
16580793|NCT02740231|Experimental|JTA-004 50 (2 ml)|
16580794|NCT02740231|Experimental|JTA-004 50 (4 ml)|
16580795|NCT02740231|Experimental|JTA-004 100 (2 ml)|
16580796|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
16580797|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
16580798|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
16580799|NCT02740192|Experimental|Adductor Canal Block|Patients in this group received local infiltration of bupivacaine in the adductor canal after surgery, in addition to the periarticular injection intra-op.
16580800|NCT02740192|Sham Comparator|Periarticular Injection|Patients in this group received a bandaid at the presumed adductor canal injection site, in addition to the periarticular injection intra-op.
16580801|NCT02740179|Experimental|Eplerenone|Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
16580802|NCT02740179|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
16580803|NCT02740166|No Intervention|Banding ligation group|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
16580804|NCT02740166|Experimental|Propranolol group|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
16580805|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under
~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD
~History of liver transplant"
16580806|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under
~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD
~No history of liver transplant, managed medically"
16580807|NCT02740127|Experimental|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.
~Study staff calls participant about 3 days after surgery."
16580808|NCT02740127|Active Comparator|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.
~Study staff calls participant about 3 days after surgery."
16580811|NCT02740101|Experimental|oxytocin nasal spray|subjects administrating oxytocin were divided into experimental group
16580812|NCT02740101|Placebo Comparator|placebo nasal spray|subjects administrating placebo were divided into controlled group
16580813|NCT02740075||Hand-ventilated|This group will be transported from the operating room to the intensive care unit with the anesthesia provider ventilating the patient by hand via Mapleson circuit and supplemental oxygen. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators. The anesthesia provider will be blinded to the end-tidal carbon dioxide levels and respiratory rate.
16580814|NCT02740075||Mechanically ventilated|This group will be transported from the operating room to the intensive care unit with the patient being ventilated by a transport ventilator with controlled tidal volume, respiratory rate, and positive end-expiratory pressure. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators.
16580815|NCT02740062|Active Comparator|Active treatment|Active tDCS treatment
16580816|NCT02740062|Sham Comparator|Sham treatment|Sham tDCS treatment
16580817|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
16580818|NCT02740023|Active Comparator|Phonak Audéo V90-13|The Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
16580819|NCT02740023|Experimental|Successor of Phonak Audéo V90-13|The successor of Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
16580820|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
16580821|NCT02739984|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
16580822|NCT02739984|Experimental|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
16580823|NCT02739971|Active Comparator|Low AGEs diet|Participants randomized to this arm will receive active instruction on reducing dietary AGEs intake, in addition to standard of care dietary guidance for type 2 diabetes.
16580824|NCT02739971|Placebo Comparator|Standard of care dietary guidance|Participants randomized to this arm will only recieve standard of care dietary guidance for type 2 diabetes.
16580825|NCT02739958|Active Comparator|Propofol group|Patients receive only intravenous anesthetics
16580826|NCT02739958|Placebo Comparator|Isoflurane group|Patients receive isoflurane /fentanyl anesthesia
16580827|NCT02739945|Other|Open cubital tunnel release|In situ decompression (MacKinnon and Novak 2005) is made through a 6-10 cm longitudinal incision along the course of the ulnar nerve midway between the medial epicondyle and the olecranon.
16580828|NCT02739945|Other|Endoscopic cubital tunnel release|Endoscopic release follows Hoffmann's technique (Hoffmann 2006) that demonstrated the safety and efficacy of this technique in a cadaveric model and in a clinical study.
16580829|NCT02739906|Experimental|HinsBet®|
16580830|NCT02739906|Active Comparator|Humalog®|
16580831|NCT02739906|Active Comparator|Huminsulin® Normal|
16580832|NCT02739893|Experimental|Scope Guide Assisted|Scope Guide Assist to be utilized during colonoscopy
16580833|NCT02739893|Placebo Comparator|Standard|Colonoscopy completed using current SOC without scopeguide assist.
16580834|NCT02739880|Experimental|The study population|"The study population consists of postmenopausal patients (more than 2 years and less than 10 years) with a body mass index <35 with sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.
~Intervention: Intra-mucosal Injections of Cross-linked Hyaluronic Acid"
16580835|NCT02739867||Unprovoked VTE|Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism
16580836|NCT02739841|Experimental|Ventilator hyperinflation|For the ventilator hyperinflation techniques (VHI), the study consists of three consecutive periods 1) baseline period: 10 minutes rest in side lying by effected lung uppermost with head-up 30 degree 2) Intervention period: Patients were positioned as same as baseline period and 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial 3) recovery period: 10 minutes rest in the same position but reduce VT to initial.
16580837|NCT02739841|Experimental|Chest physical therapy|For the conventional chest physical therapy (CPT), the study will be performed in the similar procedure except the intervention period, the patient will be received vibration and passive of the both upper extremity.
16580838|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
16580839|NCT02739815|Placebo Comparator|Placebo|Will receive a placebo (10 ml of distilled water) in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
16580840|NCT02739815|Active Comparator|T1|Will receive Tranexamic acid 15 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
16580841|NCT02739815|Active Comparator|T2|Will receive Tranexamic acid 20 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
16580842|NCT02739815|Active Comparator|T3|Will receive Tranexamic acid 25 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
16580843|NCT02739802|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
16580844|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
16580845|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
16580846|NCT02739776||A|Pt receiving standard Epidural block care for vaginal delivery
16580847|NCT02739763|Experimental|Plasmodium falciparum sprozoite (PfSPZ) challenge|Challenge agent
16580848|NCT02739737|Experimental|Blinded Reviewers|Subjects receiving randomized sham manuscript for review
16580849|NCT02739737|Experimental|Unblinded Reviewers|Subjects receiving randomized sham manuscript for review
16580850|NCT02739724|Active Comparator|Classic laparoscopy|Patients will undergo laparoscopy surgery with classic laparoscopy technic.
16580851|NCT02739724|Experimental|Laparoscopy single port access|Patients will undergo laparoscopy surgery by single port access technic.
16580852|NCT02739711|Active Comparator|Glycoprotein IIb/IIIa inhibitor|Glycoprotein IIb/IIIa inhibitor administration
16580853|NCT02739711|No Intervention|Standard therapy|No glycoprotein IIb/IIIa inhibitors
16580854|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
16580855|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
16580856|NCT02739685|Experimental|Bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
16580857|NCT02739685|Active Comparator|Stent|Implantation everolimus-eluting stent in chronic total occlusion
16580858|NCT02739672|Experimental|TAH tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet
16580859|NCT02739672|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
16580860|NCT02739659|Experimental|carbon-ion radiotherapy|Four dose levels [59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 64 GyE/16Fx are safely delivered, the recommended dose (or 64 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.
16580861|NCT02739646|Experimental|Females|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
16580862|NCT02739646|Experimental|Males|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
16580863|NCT02739633|Experimental|Genexol-PM + Gemcitabine|Genexol-PM125 mg/m2 will be administered in combination with gemcitabine 1,000 mg/m2 weekly for 3 weeks followed by one week of rest. Each cycle is 28 days.
16580864|NCT02739620|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
16580865|NCT02739620|No Intervention|Control|Control group
16580866|NCT02739607|Experimental|Transdiagnostic program|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
16580867|NCT02739607|No Intervention|Wait list control group|This arm represents the wait-list comparison group.
16580868|NCT02739594|Experimental|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
16580869|NCT02739594|Active Comparator|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
16580870|NCT02739581|Experimental|Endoscopic variceal ligation with Non-selective B-blockers|
16580871|NCT02739581|Active Comparator|Endoscopic variceal ligation with Placebo|
16580872|NCT02739568|Experimental|Pitolisant (BF2.6449|Histamine H3 receptor H3R antagonist/ inverse agonist
16580873|NCT02739568|Placebo Comparator|Placebo|Placebo
16580874|NCT02739555|Active Comparator|1: Percutaneous treatment|Percutaneous treatment of OO is a thermal tumor destruction by radiofrequency or laser photocoagulation performed under CT control with strict aseptic approach and most often under general anesthesia. The introductive needle is inserted toward the nidus. Then the optic fiber or the radiofrequency probe is inserted in the nidus center and thermal destruction of the tumor is obtained.When the distance between the nidus and a nerve or the skin is less than 10 mm, infusion of normal saline or CO2 is introduced as spacing agent. When the nidus is in the subchondral bone, cold normal saline is introduced in the joint to protect the cartilage. In addition, a thermocouple is placed in the epidural or foraminal space to continuously monitor the temperature. A procedure typically required between 1 and 2 h from the time the patient entered the CT unit.
16580998|NCT02738710|Experimental|transumbilical wound|transumbilical incision
16580875|NCT02739555|Experimental|2: Bisphosphonate treatment|"The treatment consists of 3 infusions of zoledronic acid administered at a monthly interval. Bisphosphonate treatment is considered finished 1 month after the third bisphosphonate infusion (V4 visit). In few cases, the analgesic efficacy provided by 3 bisphosphonate infusions cannot be sufficient: 1 to 3 additional infusions could be proposed to the patient.
~Zoledronic acid is supplied as a 4 mg/100 ml solution for infusion. It will be administered as infusion over 30 minutes under the supervision of a nurse. Adults will receive intravenous infusion of 4 mg of zoledronic acid. Children will receive infusion of 0.025 mg/kg of zoledronic acid.
~The investigators propose abacus corresponding to zoledronic acid volume to infuse during 30 minutes for children."
16580876|NCT02739542|Active Comparator|Tecfidera|Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
16580877|NCT02739542|Placebo Comparator|Placebo|Placebo by mouth twice daily.
16580878|NCT02739529|Experimental|Cohort 1|Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
16580879|NCT02739529|Experimental|Cohort 2|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
16580880|NCT02739529|Experimental|Cohort 3|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
16580881|NCT02739516|Active Comparator|Control|In letrozole stimulated cycle: On the day of ovulation trigger the patient received standard dose of Human chorionic gonadotropin (10,000 IU).
16580882|NCT02739516|Experimental|Study|In letrozole stimulated cycle: On the day of ovulation trigger the patient received hCG 10000 IU plus FSH co-trigger (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once .
16580883|NCT02739490|No Intervention|Group control|It does not perform any kind of guided exercise.
16580884|NCT02739490|Experimental|Core Training Group|The training was distributed in four positions defined ventral plank, side plank left, right side board and bridge semiflexion knees, respectively. With time isometric contraction of 30 seconds repeated four times with rest 30 seconds between repetitions. During 10 sessions distributed twice weekly.
16580885|NCT02739477|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
16580886|NCT02739464|Experimental|Exercise + SOC PT/OT|SOC treatment plus a personalized, structured, and quantifiable exercise program (MP10) carried out soon after admission until hospital discharge (including during the BICU stay and time on ventilation.
16580887|NCT02739464|Active Comparator|SOC PT/OT|Only SOC for treating in-patient burn subjects
16580888|NCT02739451|Active Comparator|standard oxygen group|Oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system
16580889|NCT02739451|Experimental|High-flow nasal oxygen (HFNO) group|"Device that delivers humidified and warmed high-flow oxygen at flows greater than 15 L/min.
~HFNO will be initiated at a flow rate of 50 L/min and 100% FiO2. If the target SpO2 is not reached, the flow rate will be increased to 60 L/min. Then, FiO2 will be tapered to target an SpO2≥95. The minimal flow rate will be 45 L/min"
16580890|NCT02739438||E Cigarette users|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months. Total pack years of smoking should be less than 20 for their smoking history, with normal lung function (FEV1 and FEV1/FVC) and no clinical symptoms of airway obstruction/inflammation (cough, dyspnea, sputum and wheeze).
16580891|NCT02739438||Cigarette smokers|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
16580892|NCT02739438||Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
16580893|NCT02739425|Other|Standard Procedure plus use of sentimag|Detection of the nodes carried out using the gamma probe and also the sentimag - all patients receive both diagnostic interventions
16580894|NCT02739412|Experimental|Interleukin-2|IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
16580895|NCT02739399|Other|Patient receiving phenylephrine 2ug/kg|phenylephrine 2ug/kg in case of hypotension
16580896|NCT02739386||Cohort Population|Individuals included in a large US-based administrative medical claims database with underlying autoimmune disorder exposed to ipilimumab for the treatment of melanoma.
16580897|NCT02739373|Experimental|BMS-986189|Specified Dose on Specified Day
16580898|NCT02739373|Placebo Comparator|Placebo|Specified Dose on Specified Day
16580899|NCT02739360|Experimental|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
16580900|NCT02739347|Experimental|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
16580901|NCT02739347|Sham Comparator|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
16580902|NCT02739334|Experimental|ENRICH|The intervention will integrate the Play and Learning Strategies (PALS) program, a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler with Coordinated Approach To Child Health (CATCH), a behaviorally-based school health promotion program based on Social Cognitive Theory (SCT) to increase opportunities for healthy eating and activity.
16580903|NCT02739334|Active Comparator|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
16580904|NCT02739321|Experimental|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.
~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
16580999|NCT02738710|Active Comparator|infra umbilical wound|infra umbilical incision
16581000|NCT02738697|Experimental|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
16580905|NCT02739321|Experimental|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.
~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
16580906|NCT02739308|Experimental|Intervention: Proprioceptive Training|"The intervention will be the implementation of a proprioceptive training program for the fencing athletes in the intervention group.
~In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes, three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes, and preferably one of each category. The categories have exercises with different levels of difficulty and can change the exercises occur by different proposed levels or the complexity of the exercise by changing category. The training program will be implemented by the same evaluator over the 12 weeks."
16580907|NCT02739308|Placebo Comparator|Control|The control group will not make the intervention and will continue with the usual training fencing.
16580908|NCT02739295|Experimental|G-CSF|An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.
16580909|NCT02739295|Placebo Comparator|Placebo|An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.
16580910|NCT02739282|Active Comparator|Systematic therapeutic drug monitoring|"Systematic therapeutic drug monitoring performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring (rescue therapeutic drug monitoring, transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events."
16580911|NCT02739282|No Intervention|"Rescue therapeutic drug monitoring"|"In the rescue therapeutic drug monitoring arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached."
16580912|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
16580913|NCT02739269|Sham Comparator|AFC group|AFC measurement
16580914|NCT02739256|Experimental|voiding trial 4 hours post-op|
16580915|NCT02739256|Active Comparator|voiding trial post-op day 1|
16580916|NCT02739243|Experimental|Tailored group intervention|"Participants take part in the tailored group intervention which consists of five 90-minute group sessions over eight weeks. The sessions are in the form of structured group talk/discussions following specific themes:
~Session 1 - Coping and acceptance: identification of common themes from participants' feedback, provision of information about support services, mindfulness practices
~Session 2 - Distress: introduction of the distress model, identification of resources, breathing practices
~Session 3 - Handling of stressful situations: individual identification in tandems, discussion of common pitfalls in the group
~Session 4 - Self-care: inspection of individual daily routines, group collects positive experiences with windows for self-care
~Session 5 - Feedback and outlook: stabilisation, retrospective reflection on the group experience and its benefits and, if applicable, potential adverse events"
16580917|NCT02739243|Active Comparator|Treatment as usual|Participants are provided with brief information in a leaflet, about the possibilities for individual counselling including referral to the local outpatient cancer counselling centre providing client-centred counselling and financial social work.
16580918|NCT02739230|Active Comparator|Exparel Injection|
16580919|NCT02739230|Active Comparator|On-Q intraarthicual catheter placement|
16580920|NCT02739217|Experimental|PBI-4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
16580921|NCT02739204|Experimental|Celecoxib|Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
16580922|NCT02739191|Experimental|Intervention|Prophylactic negative pressure wound therapy
16580923|NCT02739178|Experimental|GSF Sanitation intervention|This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
16580924|NCT02739178|No Intervention|Comparator|This arm will receive the GSF intervention in 2017 or later.
16580925|NCT02739165|Experimental|ART-123|
16580926|NCT02739165|Placebo Comparator|Placebo|
16580927|NCT02739139|Placebo Comparator|Placebo|Placebo
16580928|NCT02739139|Experimental|AlphaBrain|AlphaBrain(TM)
16580929|NCT02739126|Active Comparator|Thick USS (1.7mm) with use of additional aspiration needle|
16580930|NCT02739126|Active Comparator|Thin USS (1.4mm)|
16580931|NCT02739100|Experimental|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
~Intervention Drug: Triferic"
16580932|NCT02739100|Experimental|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).
~Intervention: Drug: Triferic"
16580933|NCT02739100|Experimental|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).
~Intervention: Drug: Triferic"
16580934|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
16580935|NCT02739061|Active Comparator|cognitive behavioral group therapy|cognitive behavioral group therapy
16580936|NCT02739061|Active Comparator|drug therapy|drug therapy
16580937|NCT02739061|Active Comparator|The combination therapy|cognitive behavioral group therapy and drug therapy
16580938|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
16581179|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
16580939|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
16580940|NCT02739022|Experimental|Early Psychological Support for the Critically Ill (EPSCI)|patients will receive EPSCI in parallel with medical treatment
16580941|NCT02739009|Experimental|MOR106|Single intravenous administration of MOR106
16580942|NCT02739009|Placebo Comparator|Placebo|Single intravenous administration of Placebo
16580943|NCT02739009|Experimental|MOR106 MAD|Multiple intravenous administration of MOR106
16580944|NCT02739009|Placebo Comparator|Placebo MAD|Multiple intravenous adminstration of Placebo
16580945|NCT02738996|Experimental|60-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 30 min
16580946|NCT02738996|Experimental|30-15 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 15 min
16580947|NCT02738996|Experimental|15-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 60 min
16580948|NCT02738996|Experimental|60-15|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 15 min
16580949|NCT02738996|Experimental|30-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 60 min
16580950|NCT02738996|Experimental|15-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 30 min
16580951|NCT02738983|Experimental|Bioradiotherapy|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).
16580952|NCT02738970|Active Comparator|Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
16580953|NCT02738970|Experimental|Part 1-Cohort 2: Pertuzumab 400 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
16580954|NCT02738970|Experimental|Part 1-Cohort 3: Pertuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
16580955|NCT02738970|Experimental|Part 1-Cohort 4: Pertuzumab 1200 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
16580956|NCT02738970|Active Comparator|Part 1-Cohort 5: Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
16580957|NCT02738970|Experimental|Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
16580958|NCT02738970|Experimental|Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
16580959|NCT02738970|Experimental|Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
16580960|NCT02738970|Experimental|Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
16580961|NCT02738970|Experimental|Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
16580962|NCT02738970|Experimental|Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.
16580963|NCT02738957|Other|Prenatal Counseling Group|"Patients in the PCG will receive specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one two midwives involved in the study. The information will include: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models. During the counseling sessions patients will have the opportunity to discuss questions on breastfeeding."
16580964|NCT02738957|No Intervention|Control Group|No breastfeeding counseling during the antenatal period will be provided. The Control Group will receive non-specific counseling with standard orientation regarding breastfeeding after delivery and during their postpartum hospitalization period. This standard orientation will be provided by one of the midwives of the hospital during a single counseling session with brief guidance covering the following topics: starting breastfeeding, hygiene, infants' conditions, colostrum/breast milk, infants' positions, duration of breastfeeding, frequency of feeds, mammary milking, and stopping breastfeeding.
16580965|NCT02738944|Active Comparator|Integrated Care|Telepsychiatry Collaborative Care
16580966|NCT02738944|Active Comparator|Referral Care|Telepsychiatry Enhanced Referral
16580994|NCT02738736|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
16580967|NCT02738931|Experimental|Treatment Sequence ABC|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
16580968|NCT02738931|Experimental|Treatment Sequence BCA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
16580969|NCT02738931|Experimental|Treatment Sequence CAB|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
16580970|NCT02738931|Experimental|Treatment Sequence ACB|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
16580971|NCT02738931|Experimental|Treatment Sequence BAC|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
16580972|NCT02738931|Experimental|Treatment Sequence CBA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
16580973|NCT02738918|Experimental|Nulojix|
16580974|NCT02738905|Experimental|Rifaximin|Participants will receive study drug for a period of 7 days.
16580975|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
16580976|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
16580977|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
16580978|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
16580979|NCT02738840|Experimental|Prodigy MRI or Proclaim Elite MR|"The Prodigy MRI system is only MR conditional for scans of the head and extremities (upper except shoulder, lower except hip).
~The Proclaim Elite system is MR conditional for scans of the head, extremities or any other body part."
16580980|NCT02738827|Other|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
16580981|NCT02738814|Experimental|PAED > 13|When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
16580982|NCT02738814|No Intervention|PAED < 14|Caregivers must first try to reassure patients.
16580983|NCT02738801|Experimental|GLPG1690 600 mg once daily (QD)|
16580984|NCT02738801|Placebo Comparator|Placebo QD|
16580985|NCT02738775|Experimental|Cohort 1|Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.
16580986|NCT02738775|Experimental|Cohort 2|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.
16580987|NCT02738775|Experimental|Cohort 3|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
16580988|NCT02738775|Experimental|Cohort 4|Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
16580989|NCT02738775|Experimental|Cohort 5|Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
16580990|NCT02738775|Experimental|Cohort 6|Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
16580991|NCT02738762|Active Comparator|intervention group|enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU
16580992|NCT02738762|No Intervention|control group|patients receive normal treatment, no glutamine supplementation
16580993|NCT02738749|Other|ICD group|Adult patients with newly implanted ICD devices for primary prevention will be enrolled. At baseline, 3-, 6-, 9-, and 12-month followup visit, the medial information and blood samples will be collected.
16580995|NCT02738736|No Intervention|Usual Care|Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
16581001|NCT02738697|Other|Follow-up|Routine follow-up were performed instead of adjuvant chemotherapy
16581002|NCT02738684||lung cancer|A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
16581003|NCT02738671||Type 1 Diabetes Mellitus|These T1DM patients have late diabetes onset.(latent autoimmune diabetes in adult, LADA)
16581004|NCT02738671||Type 2 Diabetes Mellitus|A subgroup of these T2DM patients are obesity patients who will have the bariatric surgery. These obese T2DM subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain MRI at baseline and 6 months after their surgery.
16581005|NCT02738671||Control|A subgroup of these non-diabetic people are obesity patients who will have the bariatric surgery. These obese subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain fMRI at baseline and 6 months after their surgery.
16581006|NCT02738658|Experimental|Bioresorbable vascular scaffold (BVS)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
16581007|NCT02738658|Active Comparator|Everolimus-eluting stent (EES)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
16581008|NCT02738645||pneumonia in RICU|The patients admit in RICU because of pneumonia.
16581009|NCT02738632|Experimental|Telmisartan/Amlodipine+Hydrochlorothiazide|Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
16581010|NCT02738632|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
16581011|NCT02738619|Active Comparator|vitamin d3|1600 UI
16581012|NCT02738619|Placebo Comparator|placebo|placebo
16581013|NCT02738606|Experimental|Group I (surgery, chemotherapy)|Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
16581014|NCT02738606|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
16581015|NCT02738580|Active Comparator|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
16581016|NCT02738580|Active Comparator|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
16581017|NCT02738567||local anesthesia with adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia with adrenaline
16581018|NCT02738567||local anesthesia without adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia without adrenaline
16581019|NCT02738554|Other|Treatment cessation arm|Cessation of treatment as according to European Association for the Study of the Liver Guidelines for chronic hepatitis B
16581020|NCT02738541|Active Comparator|Group 1|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
16581021|NCT02738541|Placebo Comparator|Group 2|PLACEBO DENTRIFICE WITHOUT PYROPHOSPATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
16581022|NCT02738528|Experimental|Experimental Group|Mental practice and brushing guidance in patients with Parkinson Disease
16581023|NCT02738528|No Intervention|Control group|Brushing guidance in patients without Parkinson Disease
16581024|NCT02738515|Active Comparator|Group 1|Scaling and Root Planing (SRP) with 0.75% BORIC ACID GEL for treating furcation defect
16581025|NCT02738515|Placebo Comparator|Group 2|Scaling and Root Planing (SRP) with PLACEBO GEL for treating furcation defect.
16581026|NCT02738502|Experimental|Single Group|Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
16581027|NCT02738489|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes. Only one arm in this study
16581028|NCT02738463||Group 1 case|This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
16581029|NCT02738463||Group 2 control|This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
16581030|NCT02738450|Active Comparator|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
16581031|NCT02738450|Active Comparator|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
16581032|NCT02738450|Placebo Comparator|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
16581033|NCT02738437|No Intervention|control|Control Group receiving standard treatment
16581034|NCT02738437|Active Comparator|intervention group|Intervention Group receiving the standard treatment and the kryptonite-bone cement
16581035|NCT02738424||3T patients : Calculate the ADC scores|In this group all the patients perform a 3 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS (picture archiving and communication system) Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
16581036|NCT02738424||1.5T patients : Calculate the ADC scores|In this group all the patients perform a 1,5 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
16581037|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
16581039|NCT02738385|Experimental|High Intensity Interval Training|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
16581040|NCT02738385|Active Comparator|Moderate Intensity Interval Training|Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
16581041|NCT02738372||Chronic Shoulder Pain|"Men / women aged between 18 and 70 years.
~Patients suffering from shoulder pain, defined as pain presented or exacerbated by movements in the shoulder, pain intensity ≥ 2 measured by a numerical scale with values from 0 to 10, meaning 0= no pain and 10= the worst pain, will be included in this study, among all these following shoulder pain conditions: (i) Rotator Cuff tendinopathy; (ii) Adhesive Capsulitis; (iii) glenohumeral instability; (iv) SLAP lesion; (v) and/or acromioclavicular pathology. Subjects will not be required to undergo diagnostic imaging (i.e. Magnetic Resonance Imaging) to diagnosis the pathology because of the recruitment will be carried out by clinical findings.
~Duration of symptoms: greater than 3 months."
16581042|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
16581043|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
16581044|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:
~t0: FIT -> if positive : OC; t = 1 year: FIT -> if positive : OC; t = 2 years: FIT -> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
16581045|NCT02738346|Experimental|Arm A : Carboplatin-Etoposide|Intravenous administration of Carboplatin Auc 5 at Day 1 and Intravenous administration of 100 mg / m² / of Etoposide J Day 1 to Day 3 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
16581046|NCT02738346|Active Comparator|Arm B : Topotecan|Per os administration of 2.3 mg / m² of Topotecan Day 1 to Day 5 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
16581047|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
16581048|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
16581049|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
16581050|NCT02738320|Experimental|Intervention|Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected.
16581051|NCT02738320|No Intervention|Usual Care|Control patients will receive the usual care when discharge to a nursing home from the hospital is expected.
16581052|NCT02738307|Experimental|altitude exposure|Altitude Exposure Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
16581053|NCT02738294|Experimental|Suspected EGC group|Participants with suspected EGC from white light endoscopy were enrolled.The endoscopist first used white light endoscopy to identify suspected gastric lesions and assessed lesions carefully with magnifying view, non-magnifying NBI view and ME-NBI view in sequence. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
16581054|NCT02738281||Rett Syndrome|This is a prospective natural history study examining the phenotypic variations of individuals with mutations in MECP2 or meeting the diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome. The overwhelming majority will be female, but males meeting diagnostic criteria will be included. No interventions are planned.
16581055|NCT02738281||MECP2 Duplication|This is a prospective natural history study examining the phenotypic variations of individuals with MECP2 duplications. The majority are expected to be males, but females expressing a duplication will be included. No interventions are planned.
16581056|NCT02738281||RTT related disorders|This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
16581057|NCT02738268|Sham Comparator|Control group|Control group: receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
16581058|NCT02738268|Experimental|Treatment Group|Treatment Group: receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
16581059|NCT02738255|Active Comparator|Polysomnogram with Varnum Mouthpiece|Varnum mouthpiece, similar to a mouth tape with central opening
16581060|NCT02738255|No Intervention|Regular Polysomnogram|Overnight sleep study with no mouthpiece
16581061|NCT02738242|Experimental|Novus system users|Sixteen (16) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be recruit for this study and will receive the Novus system for daily use.
16581062|NCT02738229|Experimental|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:
~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
16581063|NCT02738229|Placebo Comparator|control|placebo pill
16581064|NCT02738216|Experimental|Prenatal Yoga|A 9-week prenatal yoga program
16581065|NCT02738216|Active Comparator|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
16581066|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):
~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
16581067|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):
~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
16581068|NCT02738190|Active Comparator|Albumin|5% Albumin to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and albumin to reach the standard volume administered to these patients (400 ml)
16581069|NCT02738190|Active Comparator|Fresh Frozen Plasma|Fresh Frozen Plasma to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and plasma to reach the standard volume administered to these patients (400 ml)
16581070|NCT02738177|Active Comparator|misoprostol group|30 candidates were receive 2 tablets of misoprostol (PGE1) 200ug (i.e. 400 ug) 4 hrs prior to surgical evacuation
16581071|NCT02738177|Active Comparator|Effox group|30 candidates were received 2 tablets of Effox (Isosorbide mononitrate) 20 mg (i.e 40 mg) 4 hrs prior to surgical evacuation
16581072|NCT02738177|Active Comparator|combination therapy group|30 candidates were received 1 tablets of misoprostol 200ug & 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation.
16581073|NCT02738151|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
16581074|NCT02738151|Active Comparator|Tresiba|Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
16581075|NCT02738138|Experimental|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
16581076|NCT02738138|Experimental|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
16581077|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
16581078|NCT02738099||Arrest from presume Cardiac etiology|Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
16581079|NCT02738086|Experimental|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
16581080|NCT02738086|Experimental|Wait-List Control Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
16581081|NCT02738073|Placebo Comparator|Control|
16581082|NCT02738073|Active Comparator|Interventional|
16581083|NCT02738060|Experimental|Case group|The patients in case group will be received baked milk daily in the form of muffin for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
16581084|NCT02738034|Experimental|Adaptive training group|The intervention group will be composed of hypertensive participants with cognitive decline that will be submitted to the training program (Cogmed) for approximately 10 weeks. Across training, task difficulty was adjusted as a function of individual performance.
16581085|NCT02738034|Active Comparator|Active control Group|In the control group, hypertensive patient will be submitted to a set of online games available on the internet and previously determined. In this way, the control group will receive the same motivation, as well as will be engaged in computerized activities, in the same way as the experimental group. The difference is that these varied games do not provide any type of intense and adaptive training, at the same time as they do not stimulate any specific cognitive function.
16581086|NCT02738021|Experimental|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
16581087|NCT02738008|Experimental|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
16581088|NCT02737995|Experimental|Iron Replacement|
16581089|NCT02737982||IHD Men|Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
16581090|NCT02737982||IHD Women|Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
16581091|NCT02737969||TEE/Angio fusion software|Patients planned to undergo a transcatheter-based structural heart disease procedure that utilizes TEE and fluoroscopic guidance
16581092|NCT02737943|Experimental|Arm1 Mebo|20 : receiving Moist Exposed Burn Ointment (MEBO) at sites of donor graft and recipient at time of operation and in dressing
16581093|NCT02737943|Placebo Comparator|Arm2 Placebo|20 : receiving Standard cream Zagazig University Hospital (Antibiotics & analgesics)
16581094|NCT02737930|Experimental|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
16581095|NCT02737930|Placebo Comparator|Placebo|Matching placebo
16581096|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
16581097|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
16581098|NCT02737904|Active Comparator|Control group|Usual care - conventional, personalised in-patient rehabilitation 4 weeks duration
16581099|NCT02737904|Experimental|Intervention group|Usual care - conventional, personalised in-patient rehabilitation - plus APT cycling programme 4 weeks duration
16581100|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
16581101|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
16581102|NCT02737878|Experimental|Aerobic Training and Resistance Training (A&RT)|The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
16581103|NCT02737878|Experimental|Aerobic Training (AT)|The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
16581180|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
16581181|NCT02737397|Placebo Comparator|placebo|placebo and placebo
16581104|NCT02737878|Experimental|Resistance Training (RT)|The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
16581105|NCT02737878|Active Comparator|Balance and Tone Program (CON)|The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
16581106|NCT02737865|Experimental|SMI and sonazoid (single arm)|Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line
16581107|NCT02737852|Experimental|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
16581108|NCT02737839|Experimental|Arm 1: STEPPING ON|"Adaptation Waves is to adapt Stepping On to the oncology setting/Pilot Waves is to determine the feasibility & acceptability of the program for older adults receiving cancer care/Gait & Balance Waves is to determine whether the participants experience changes in their gait & balance
~Complete baseline questionnaires about Instrumental Activities of Daily Living, Medical Outcome Study Activities, Karnofsky Performance Status, falls in past 3 months, medications, comorbidities, vision & hearing, The Falls Behavioral Scale, The Falls Efficacy Scale-International, Patient Reported Outcome pain, PRO neuropathy
~7 week STEPPING ON program is multi-component learning environment which has shown to help reduce falls
~A home visit to gather any feedback on the experience of the program
~Follow-up questionnaires up to 3 months after completion of the program
~Participants may elect to participate in a booster session to reinforce concepts 3-6 months after completion of the program"
16581109|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
16581110|NCT02737826|Active Comparator|Phase II - Gabapentin + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
16581111|NCT02737826|Placebo Comparator|Phase II - Placebo + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
16581112|NCT02737826|Experimental|Phase II - Buprenorphine taper|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
16581113|NCT02737813|Experimental|Isobaric Marcaine|Isobaric Marcaine 2.2 mL for spinal block
16581114|NCT02737813|Active Comparator|Hyperbaric Marcaine|Hyperbaric Marcaine 2.2 mL for spinal block
16581115|NCT02737800|Active Comparator|1A endometrioma more than 5cm|Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
16581116|NCT02737800|Sham Comparator|1B endometrioma more than 5cm control|Endometrioma aspiration Standard long stimulation protocol & ICSI
16581117|NCT02737800|Active Comparator|2A endometrioma less than 5cm|Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
16581118|NCT02737800|Sham Comparator|2B endometrioma less than 5cm control|Standard long stimulation protocol & ICSI
16581119|NCT02737787|Experimental|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab every two weeks over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.This cohort has completed recruitment.
16581120|NCT02737787|Experimental|ESO-1 Vaccine and Nivolumab|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
16581121|NCT02737774|Experimental|Icotinib and Pemetrexed/Carboplatin|"Icotinib: Icotinib for 18 weeks, 125mg Tid，PO. Chemotherapy: pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.
~Then continue with Icotinib, 125mg Tid，PO. until disease progression."
16581182|NCT02737384|Experimental|Treatment|
16581183|NCT02737371|Experimental|F901318 Dose level A oral|F901318 adverse events days 1-10
16581184|NCT02737371|Placebo Comparator|Placebo Dose level A oral|Placebo adverse events days 1-10
16581185|NCT02737371|Experimental|F901318 Dose level B oral|F901318 adverse events days 1-10
16581122|NCT02737761|Experimental|Optimal Adherence|"Participants will all undergo a qualitative interview and adherence measurements at baseline and 12 weeks after hospital discharge.
~In person the participants will receive a MEMSCaps device and an Actigraph accelerometer. They will be asked to begin wearing the accelerometer after their initial interview and to begin using the MEMSCaps device once they arrive at home. Participants will use the MEMSCap throughout the entire study and will wear the Actigraph for 2 weeks at baseline and again at 12 weeks."
16581123|NCT02737748|Experimental|Treatment Group|TWB-103 add-on Tegaderm
16581124|NCT02737748|Placebo Comparator|Control Group|Placebo+Tegaderm
16581125|NCT02737735|Experimental|Chemotherapy combined with compound herbal medicine|Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years，which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
16581126|NCT02737735|Active Comparator|Chemotherapy|The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
16581127|NCT02737722|Experimental|Bisphosphocin Nu-3|Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
16581128|NCT02737722|Placebo Comparator|Placebo|Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
16581129|NCT02737709|Experimental|Paclitaxel and Carboplatin regimen|Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.
16581130|NCT02737696|Active Comparator|Control|Participants in this group will have access to Drug Enforcement Administration's website (JustThinkTwice.gov). The JustThinkTwice website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz. Youth in this group will be informed that they will be prompted (by email and phone; described below) when the next online survey is available to complete. Youth will be asked to use this website for 30 minutes, twice per week (for a total of 60 minutes per week) for about 3-4 weeks.
16581131|NCT02737696|Experimental|Experimental|"Participants assigned to the Web-based prescription opioid prevention for adolescents will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks."
16581132|NCT02737670|Active Comparator|Sulodexide|Sulodexide 25 mg twice per day for 40 days
16581133|NCT02737670|Placebo Comparator|Placebo|1 tablet twice per day for 40 days
16581134|NCT02737657||Cohort 1|Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
16581135|NCT02737657||Cohort 2|Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
16581136|NCT02737644||CHD birth cohort|Cases are identified as those whose newborns screened and confirmed with CHD during the follow-up and four age- and delivery-hospital matched controls are selected for each case from the rest of the cohort.
16581137|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Chameleon personal lubricant via occlusive patch"
16581138|NCT02737618|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
16581139|NCT02737605|Experimental|Sequence 1|Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
16581140|NCT02737605|Experimental|Sequence 2|Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
16581141|NCT02737605|Experimental|Sequence 3|Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
16581142|NCT02737605|Experimental|Sequence 4|Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
16581143|NCT02737605|Experimental|Sequence 5|Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
16581144|NCT02737605|Experimental|Sequence 6|Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
16581145|NCT02737592|Experimental|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
16581146|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
16581186|NCT02737371|Placebo Comparator|Placebo Dose level B oral|Placebo adverse events days 1-10
16581187|NCT02737371|Experimental|F901318 Dose level C oral|F901318 adverse events days 1-10
16581188|NCT02737371|Placebo Comparator|Placebo Dose level C oral|Placebo adverse events days 1-10
16581147|NCT02737566|Experimental|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
16581148|NCT02737566|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
16581149|NCT02737553|Active Comparator|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.
~doi: 10.1097/AOG.0000000000000823.)."
16581150|NCT02737553|Active Comparator|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
16581151|NCT02737540||Major depressive episode|This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
16581152|NCT02737540||Healthy subjects|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
16581153|NCT02737527|Experimental|Ultrasound with Fluoroscope|"This group undergoes lumbar sympathetic block using ultrasound and fluoroscope.
~Preparation: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Ultrasound for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
16581154|NCT02737527|Active Comparator|Fluoroscope only|"This group undergoes lumbar sympathetic block using fluoroscope only.
~Device: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Fluoroscope for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
16581155|NCT02737514|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
16581156|NCT02737514|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
16581157|NCT02737514|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
16581158|NCT02737501|Experimental|Randomized Phase: Brigatinib 90 mg QD/180 QD|Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
16581159|NCT02737501|Active Comparator|Randomized Phase: Crizotinib 250 mg BID|Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
16581160|NCT02737501|Experimental|Crossover Phase: Brigatinib 90 mg QD/180 mg QD|Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
16581161|NCT02737488|Experimental|TST|
16581162|NCT02737488|Active Comparator|TAU Group|
16581163|NCT02737475|Experimental|Part 1: Dose Escalation|"BMS-986178 at specified doses at specified intervals
~Enrollment is closed for this arm"
16581164|NCT02737475|Experimental|Part 2: Dose Escalation and Expansion|"BMS-986178 in combination with Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
16581165|NCT02737475|Experimental|Part 3: Dose Escalation and Expansion|"BMS-986178 in combination with Ipilimumab at specified doses at specified intervals
~Enrollment is closed for this arm"
16581166|NCT02737475|Experimental|Part 4: Dose Schedule and Exploration|"BMS-986178/Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
16581167|NCT02737475|Experimental|Part 5: Dose Schedule and Exploration|"BMS-986178/Ipilimumab at specified doses at specified intervals
~Enrollment is closed for this arm"
16581168|NCT02737475|Experimental|Part 6: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
16581169|NCT02737475|Experimental|Part 7: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
16581170|NCT02737475|Experimental|Part 8: Dose Exploration|"BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval
~Enrollment is closed for this arm"
16581171|NCT02737475|Experimental|Part 9: Dose Exploration|"BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals
~Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]"
16581172|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
16581173|NCT02737436|Experimental|Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
16581174|NCT02737436|Experimental|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
16581175|NCT02737423|Experimental|vitamin D|single IM dose 600,000 IU of cholecalciferol
16581176|NCT02737410|Active Comparator|Treatment|Treatment group obtaining Gut-directed Hypnotherapy
16581177|NCT02737410|No Intervention|Control|Control group
16581178|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
16581189|NCT02737358|Placebo Comparator|Placebo|Matched placebo will be given to half of the study participants.
16581190|NCT02737358|Active Comparator|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
16581191|NCT02737345||Waiting list|Patients on the liver transplant waiting list
16581192|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
16581193|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
16581194|NCT02737319|Experimental|Rosuvastatin|40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.
16581195|NCT02737319|No Intervention|Control|Use of standard therapy in elective angioplasty.
16581196|NCT02737306|Experimental|PRO 140|up to 60 subjects will be enrolled. PRO 140 will be administered as a 525 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for up to 100±7 days. Subjects will return to the clinic for three Follow-up visits at 2 weeks after the last treatment visit, 30 days after the last treatment visit and one year after the first treatment visit.
16581197|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
16581198|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
16581199|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
16581200|NCT02737280|Active Comparator|Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
16581201|NCT02737280|Experimental|High flow oxygen therapy|High flow nasal cannula oxygen therapy with Airvo (TM, Fisher & Paykel Healthcare) device
16581202|NCT02737267|Experimental|Moderately high protein diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 40% of the energy derived from carbohydrates, 30% of the energy derived from protein and 30% of the energy derived from fat
16581203|NCT02737267|Placebo Comparator|Low fat diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 60% of the energy derived from carbohydrates, 18% of the energy derived from protein and 22% of the energy derived from fat
16581204|NCT02737254|Experimental|Oxytocin and Secure CBM training|
16581205|NCT02737254|Active Comparator|Placebo and Secure CBM training|
16581206|NCT02737254|Active Comparator|Oxytocin and Neutral CBM training|
16581207|NCT02737254|Placebo Comparator|Placebo and Neutral CBM training|
16581208|NCT02737241|Active Comparator|LP-HoLEP|Low power Holmium laser enucleation of the prostate
16581209|NCT02737241|Active Comparator|HP-HoLEP|High power Holmium laser enucleation of the prostate
16581210|NCT02737228|Experimental|CG200745 PPA|CG200745 PPA plus Gemcitabine and Erlotinib
16581211|NCT02737215|Active Comparator|CPAP group|patients will receive CPAP therapy for the first 7 days after extubation from CABG
16581212|NCT02737215|No Intervention|Control Group|Patients will receive usal care
16581213|NCT02737202|Experimental|Saracatinib|Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
16581214|NCT02737189|Experimental|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
~Best Medical Treatment and maximum supportive care"
16581215|NCT02737189|Other|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
16581216|NCT02737176|Experimental|Tobacco cessation intervention|Tobacco cessation intervention is implemented for 12 weeks. The nicotine dependence status is evaluated by the FTND (Fagerstrom Test for Nicotine Dependence) test. The point 3 or more is regarded as a moderate or high tobacco dependence and determining a cessation intervention. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Even if participants fail to abstain from smoking, the oral treatment is continued. In case of the use of the NRTs (nicotine patch and/or gum), the investigators supply it for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
16581217|NCT02737176|No Intervention|Non-tobacco cessation intervention|Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
16581218|NCT02737150|Active Comparator|Self-expandable valve under local anesthesia|CoreValve Evolut R valve under local anesthesia with conscious sedation
16581219|NCT02737150|Active Comparator|Self-expandable valve under general anesthesia|CoreValve Evolut R valve under general anesthesia
16581220|NCT02737150|Active Comparator|Balloon-expandable valve under local anesthesia|Edwards Sapien 3 valve under local anesthesia with conscious sedation
16581221|NCT02737150|Active Comparator|Balloon-expandable valve under general anesthesia|Edwards Sapien 3 valve under under general anesthesia
16581222|NCT02737137|Other|Manual measurement by the anesthetist|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic : Group 1
16581223|NCT02737137|Experimental|Measurement by a pressure gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the injection pressure of the local anesthetic : Group 2
16581224|NCT02737124|Experimental|1000 Mg Acetaminophen|Acetaminophen will be given 24 hours before surgery
16581225|NCT02737124|Active Comparator|Placebo|A sugar pill will be given 24 hours before the scheduled surgery.
16581226|NCT02737098|Active Comparator|Standard Implementation|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
16581256|NCT02736929|No Intervention|Waiting Period Control (WP-CON)|WP-CON group will receive minimal attention in the form of weekly telephone calls to assess current emotional state and to provide supportive, nondirective, brief counseling if participants report experiencing a crisis. Any participant assigned to the WP-CON group will be given the opportunity to receive CPT-C after the post-waiting period assessment.
16581257|NCT02736916|Experimental|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
16581227|NCT02737098|Active Comparator|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
16581228|NCT02737085|Experimental|Diffuse Large B Cell Lymphoma(DLBCL)|The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16581229|NCT02737072|Experimental|20 mg LY2510924 + 1500 mg Durvalumab|20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
16581230|NCT02737072|Experimental|30 mg LY2510924 + 1500 mg Durvalumab|30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
16581231|NCT02737072|Experimental|40 mg LY2510924 + 1500 mg Durvalumab|40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
16581232|NCT02737059|Placebo Comparator|Codeine/naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d."
16581233|NCT02737059|Placebo Comparator|Naloxegol/ codeine placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d."
16581234|NCT02737059|Active Comparator|Codeine/ naloxegol|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d."
16581235|NCT02737059|Active Comparator|codeine placebo/ naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d."
16581236|NCT02737046|Experimental|Belinostat + Zidovudine|Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
16581237|NCT02737033|Experimental|Rhodiola|Rhodiola rosea 800mg single dose
16581238|NCT02737033|Placebo Comparator|Placebo|placebo 800mg single dose
16581239|NCT02737020|Experimental|Rhodiola|Rhodiola rosea 200mg up to four times a day for 28 days
16581240|NCT02737020|Placebo Comparator|Placebo|Placebo pill manufactured to mimic Rhodiola rosea 200mg, up to four times a day for 28 days
16581241|NCT02737007|Experimental|[14C]-GSK3191607 IV Microdose|Subjects will receive a single microdose of 100 micrograms (mcg) of [14C]-GSK3191607 by intravenous infusion over 15 minutes on Day 1 of the study.
16581242|NCT02736994|Other|Immersion in water|water
16581243|NCT02736994|Active Comparator|Immersion in water + cleansing tablet|Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
16581244|NCT02736994|Experimental|Immersion in water with PIP|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium)
16581245|NCT02736981|Active Comparator|Behavioral Weight Loss (BWL)|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment.
16581246|NCT02736981|Active Comparator|BWL + Autonomous Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
16581247|NCT02736981|Active Comparator|BWL + Extrinsic Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
16581252|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
16581253|NCT02736942|Active Comparator|Laparoscopic|Laparoscopic TME
16581254|NCT02736942|Experimental|Transanal|TaTME
16581255|NCT02736929|Active Comparator|Cognitive Processing Therapy - Cognitive|Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
16581258|NCT02736916|Active Comparator|Conventional PCI|LD-SCLC patients with Conventional PCI
16581493|NCT02735434|Experimental|Internet-based ACT|Brief clinical psychiatric assessment to determine eligibility (video-based).
16581259|NCT02736903|Active Comparator|Individual intervention|Behavioral: PennFit mobile individual intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their own daily steps and the minutes for vigorous, moderate, and muscle-strengthening exercises that they completed for each day. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening.
16581260|NCT02736903|Experimental|Online network intervention|Behavioral: PennFit mobile online network intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their exercises. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening. Participants were randomly assigned to 4-person online networks in the PennFit app. Participants in the online networks could see both their own information and the profiles and activity logs of the three other people assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
16581261|NCT02736890|Active Comparator|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
16581262|NCT02736890|Placebo Comparator|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
16581263|NCT02736877|Experimental|Lumera Microscope with OCT RESCAN|In the group microscope coupled to OCT, patients will undergo corneal surgery using the Lumera Microscope WITH RESCAN OCT - ZEISS. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
16581264|NCT02736877|Active Comparator|Conventional Microscope|The control group will undergo corneal transplant with conventional microscope without coupled OCT. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
16581265|NCT02736851|No Intervention|Control group|Usual care
16581266|NCT02736851|Active Comparator|Home-based telemedicine group|Nurse-tutor support at home for 6 months
16581267|NCT02736838|Experimental|Phase I|Interventions: Different positions will be applied to subjects to measure preipheral tissue oxygenation, pressure, and changes in microvascular flow. Subjects will be placed up to 4 hours in each of the standard positions for the experiment: supine decubitus (SD) right lateral decubitus (RLD), left lateral decubitus (LLD). SD measurements will be made at 0, 30 and 45 degrees of inclination to bed. RLD and LLD positions will be evaluated with a body inclination of 30 and 90ª. The subjects will lie down on a memory foam mattress for an articulated bed, as are commonly used at home, residential or hospital care. Between the subject and the mattress will be inserted the pressure measuring surface. Measurements in each position will be made during intervals of 0-4 hours in the same position (SD-RLD-LLD) in each of the inclinations of the bed (0º, 30°, 45 °) or body (30º, 90º), respectively.
16581268|NCT02736825|Active Comparator|Group A, Ulthera System with standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using standard transducers. Energy levels for each transducer will be set to EL2:
~Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line
~DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
16581269|NCT02736825|Experimental|Group B, Ulthera System with prototype 2 simulines transducers|"Subjects randomized to Group B will receive a Ultherapy® treatment with a total minimum pulse count of 336 pulses (+5%) using the prototype 2 simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:
~Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line
~DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
16581270|NCT02736812|Experimental|French Lyophilized Plasma|receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice
16581271|NCT02736812|Active Comparator|Normal Saline Solution|receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice
16581272|NCT02736799|Sham Comparator|Sham vibrating capsule|Sham vibrating capsule
16581273|NCT02736799|Active Comparator|Vibrant Capsule (1 vibration)|1 vibration/min
16581274|NCT02736799|Active Comparator|Vibrant Capsule (3 vibration)|3 vibrations/min
16581275|NCT02736799|Active Comparator|Vibrant Capsule (5 vibration)|5 vibrations/min
16581276|NCT02736773|Experimental|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
16581277|NCT02736760|Experimental|Daylight photodynamic therapy (PDT)|"One intervention in the daylight photodynamic therapy arm:
~Daylight photodynamic therapy using Methylaminolevulinate (MAL) will be performed five times within 18 months (visits 1-5). In the PDT group the patients will apply a chemical sunscreen (SPF 50+) to the whole face and other light-exposed, unprotected areas of the skin. After at least 15 minutes a lesion preparation of AKs (removal of crusts) will be performed and methylaminolevulinate (MAL) will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours."
16581278|NCT02736760|Active Comparator|Cryosurgery|In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
16581279|NCT02736747|Active Comparator|Cryotherapy (ice pack)|A pack with 1000g of crushed ice without air will be placed for 20 consecutive minutes on a pre-delimited rectangular area with dimensions of 25 x 35 cm and will be fixed with a non-compressive elastic band. One strip of plastic paper will encompass the paretic leg of the subjects, avoiding direct contact from the skin with the ice pack.
16581436|NCT02735707|No Intervention|No simvastatin|Patients will not receive simvastatin for up to 28 days while the patient remains in hospital.
16581280|NCT02736747|Placebo Comparator|Placebo (sand pack)|"For placebo application, the pack will be filled with 1000g of thin sand, in environmental temperature, so that the pressure exerted will be the same as the ice pack. All other experimental procedures will follow the same protocol as cryotherapy application."
16581281|NCT02736734|Other|CRH condition|All HV first underwent a baseline manometry measurement. After 30 minutes, an intravenous CRH injection was done. The same measurement was repeated but now with CRH administered.
16581282|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
16581283|NCT02736708||PSC|Male or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not
16581284|NCT02736695|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
16581285|NCT02736682|Experimental|Single dose antibiotic|2g of intra venous Ceftriaxone and 500 mgs Intra venous metronidazole is administered to the mothers as a Single dose pre-operative30-60 minutes before surgery.
16581286|NCT02736682|Active Comparator|multiple dose antibiotic.|Multiple doses of IV Ceftriaxone 1g and metronidazole 500mgs given to the mother during surgery there after Ceftriaxone 1g every day for 3 days and IV metronidazole 500 mgs every 8 hours for 3 days.
16581287|NCT02736669|Active Comparator|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
16581288|NCT02736669|Experimental|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
16581289|NCT02736656|Experimental|Open-Label Treatment|"Subjects 6-11 yrs of age will be treated with 100 to 400 mg SPN-812 ER (100 mg capsule).
~Subjects 12-17 yrs of age will be treated with 100 to 600 mg SPN-812 ER (100, 200 mg capsule).
~Subjects are given a choice to extend their participation in the study every 6 months for up to 72 months."
16581290|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
16581291|NCT02736604|Experimental|Air anesthesia|air will be used as carrier agent for maintenance of anesthesia
16581292|NCT02736604|Active Comparator|Nitrous Oxide anesthesia|nitrous oxide will be used as carrier agent for maintenance of anesthesia
16581293|NCT02736591|Active Comparator|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI
16581294|NCT02736591|Active Comparator|Growth hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
16581295|NCT02736578|Experimental|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
16581296|NCT02736578|Experimental|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
16581298|NCT02736552|Experimental|S-1 for 6 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection
16581299|NCT02736552|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
16581300|NCT02736539|Experimental|Active|galacto-oligosaccharides
16581301|NCT02736539|Placebo Comparator|Placebo|Placebo
16581302|NCT02736526|Experimental|Surgical treatment|The recession or resection of the horizontal extraocular muscles will be processed in the beginning of the trial.
16581303|NCT02736526|No Intervention|Observation only|
16581304|NCT02736513|Experimental|AZD9291 80 mg - naive patients|naive patients with tumors harbouring either exon 19 deletion, L858R, T790M, or uncommon sensitizing EGFR mutations, will be treated with AZD9291 80 mg/day
16581305|NCT02736513|Experimental|AZD9291 80 mg - previously treated T790M was diagnosed|Patients previously treated with first and second generation EFGR TKIs (either Gefitinib, Erlotinib or Afatinib) in whom T790Mwas diagnosed either in the tumor specimen or in the ctDNA after testing it following the most recent disease progression, will be treated with AZD9291 80 mg/day
16581306|NCT02736513|Experimental|AZD9291 80 mg - previously treated unrelated to T790M|patients advanced NSCLC previously treated with 1st/2nd generation EGFR TKIs (either gefitinib. erlotinib or afatinib) who progressed unrelated to T790M (T790M-). No restriction regarding the number of prior EGFR TKIs or cytotoxic chemotherapy lines of treatment is applied.
16581307|NCT02736500|Experimental|28 GBq 177Lu-DOTATATE|5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) 177Lu-DOTATATE
16581308|NCT02736500|Experimental|22 GBq 177Lu-DOTATATE|6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi) 177Lu-DOTATATE
16581309|NCT02736487|Active Comparator|Group A: True-Washout-Sham|Subjects in group A receives true air filtration intervention, then at least two weeks of washout period, followed by sham air filtration intervention.
16581310|NCT02736487|Active Comparator|Group B: Sham-Washout-True|Subjects in group B receives sham air filtration intervention, then at least two weeks of washout period, followed by true air filtration intervention.
16581768|NCT02733640|Experimental|Ranitidine|Drug: Ranitidine 150 mg twice-daily
16581313|NCT02736461||Group 1- With strabismus|Study group with strabismus happening after floor fracture repair
16581314|NCT02736461||Group 2- Without strabismus|No strabismus happening after floor fracture repair
16581315|NCT02736448|Experimental|Arm Lu-PRRT-Cap|Arm Lu-PRRT-Cap: oral low dose of capecitabine in association with Lu-PRRT (at 3.7 Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
16581316|NCT02736448|Experimental|Arm Lu-PRRT|Arm Lu-PRRT: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
16581317|NCT02736435|Experimental|Fibroid dimension < 8 cm|"Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.
~Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound."
16581318|NCT02736435|Experimental|Fibroid dimension > 8 cm|"Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.
~Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.
~Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc."
16581319|NCT02736422|Other|hyperpolarised xenon|evaluating the sensitivity of pulse sequences for 129Xe magnetic resonance imaging in the lungs, heart and brain and monitoring the transient changes in vital signs during and following the gas inhalation
16581320|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
16581321|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
16581322|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
16581323|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
16581324|NCT02736396||Healthy Controls|Medical History, Neuropsychological tests, clinical assessments, fMRI
16581325|NCT02736396||Cognitive impairment|Medical History, Neuropsychological tests, clinical assessments, fMRI
16581326|NCT02736383||Tranexamic Acid|Patients that receive 2 gm TXA during surgery
16581327|NCT02736383||No Tranexamic Acid|Patients that receive no TXA during surgery
16581328|NCT02736344|Experimental|BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:
~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent
~Delivery System - Rapid Exchange (RX) Coronary System
~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®
~Ridaforolimus drug - CAS Registry Number: 572924-54-0
~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
16581329|NCT02736331|Experimental|Treatment 1 Beverage|Treatment 1
16581330|NCT02736331|Placebo Comparator|Treatment 2 Beverage|Treatment 2
16581331|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
16581332|NCT02736305|Experimental|Regorafenib|Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
16581333|NCT02736292|Experimental|participant|
16581334|NCT02736266|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.
16581335|NCT02736240|Active Comparator|Control Arm|7-valent pneumococcal conjugate vaccine
16581336|NCT02736240|Experimental|Test Arm|13-valent pneumococcal conjugate vaccine
16581337|NCT02736227|Experimental|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
16581338|NCT02736214|Experimental|Lifestyle counseling|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
16581339|NCT02736214|No Intervention|Control group|The control group answered a baseline questionnaire in the waiting room and received standard care.
16581340|NCT02736201|Experimental|IMT+ T-CaRe®on; n = 10|The instrumental manual therapy with the switched on capacitive diathermy electrode
16581341|NCT02736201|Sham Comparator|IMT+ T-CaRe® off; n = 10|The instrumental manual therapy with the switched off capacitive diathermy electrode
16581342|NCT02736188|Experimental|Drug: Aceneuramic Acid Extended-Release Tablets|Participants will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).
16581343|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
16581344|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
16581345|NCT02736162||Perampanel|Participants with a diagnosis of epilepsy who received perampanel as primary or secondary (conversion) monotherapy at any time between 1 Jan 2013 and 15 Oct 2015.
16581346|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.
~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
16581347|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
16581348|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
16581349|NCT02736123|Experimental|Arm A consists of 3 phases or steps|"Induction Phase Nivolumab 3 mg/kg IV infusion every 2 weeks for 3 doses
~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)
~Maintenance Phase (after recovery from surgery) Nivolumab 3 mg/kg IV infusion every 3 weeks"
16581769|NCT02733627|Experimental|BI 1467335 10 mg (low dose)|
16581350|NCT02736123|Experimental|Arm B consists of 3 phases or steps|"Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses
~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)
~Maintenance Phase (after recovery from surgery) Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses; then, Nivolumab 3 mg/kg IV infusion every 3 weeks"
16581351|NCT02736084|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
~Exercises:
~Gratitude for positive events Using personal strengths Gratitude letter Enjoyable and meaningful activities Recalling past success Performing acts of kindness Repeating one of the previous exercises."
16581352|NCT02736071|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
16581353|NCT02736071|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
16581354|NCT02736071|Placebo Comparator|Placebo|Women will receive an oral placebo similar to Tramadol and an oral placebo similar to Celecoxib 2 hours before the procedure
16581355|NCT02736058|Experimental|Participants|the included pregnant females will undergo trans-abdominal sonography as well as trans-vaginal sonography , to diagnose the abnormal placentation and the results will be compared to the intra- operative as well as the pathological examination of the specimen.
16581356|NCT02736045|No Intervention|Control|Sham control. Subjects will be asked to write a journal (per week).
16581357|NCT02736045|Experimental|emWave|Our approach will be to test the impact of a behavioral intervention through a smartphone application, emWave software, which will be provided to all our subjects. The intervention (emWave) is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention.
16581358|NCT02736032|Active Comparator|With GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
16581359|NCT02736032|Active Comparator|Without GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
16581360|NCT02736019|Active Comparator|Celecoxib|Women will receive oral celecoxib 200mg 2 hours before the procedure
16581361|NCT02736019|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
16581362|NCT02736019|Placebo Comparator|Placebo|Women will receive a placebo similar to celecoxib and a placebo similar to Tramadol
16581363|NCT02736006|Experimental|20 meters air dive|
16581364|NCT02735980|Experimental|Prexasertib (Platinum Sensitive Disease)|105 mg/m^2 Intravenous (IV) prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had platinum-sensitive disease (has prior platinum based therapy with subsequent progression greater or less than 90 days after last dose of platinum based therapy).
16581365|NCT02735980|Experimental|Prexasertib (Platinum Resistant Disease)|105 mg/m^2 IV prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had resistant/refractory disease (did not have an objective response to platinum-based therapy or had progression greater than 90 days after the last dose of platinum).
16581366|NCT02735980|Experimental|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|40 mg/m^2 IV prexasertib Day 1, 2, and Day 3 of a 14 day cycle in participants with ED-SCLC platinum sensitive disease.
16581367|NCT02735967|Experimental|Group manual therapy + diadynamic|"Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
~Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient."
16581368|NCT02735967|Active Comparator|Group manual therapy|Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
16581369|NCT02735967|Active Comparator|Group diadynamic|An electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF),4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
16581370|NCT02735954||Marijuana Users|Individuals who use marijuana
16581371|NCT02735954||Combined Marijuana and Tobacco Users|Individuals who use marijuana and also smoke cigarettes
16581372|NCT02735954||Non-Marijuana Users|Individuals who do not use marijuana
16581373|NCT02735941||UC group|Patients with ulcerative colitis (active or remission)
16581374|NCT02735941||CD group|Patients with Crohn's disease (active or remission)
16581375|NCT02735941||Colon cancer group|Patients with colon cancer or metastasis
16581376|NCT02735941||control group|healthy individuals
16581437|NCT02735707|Active Comparator|Simvastatin|Patients will receive simvastatin (80mg enterally once daily) for up to 28 days while the patient remains in hospital.
16581494|NCT02735434|Active Comparator|Internet-based discussion forum|Brief clinical psychiatric assessment to determine eligibility (video-based).
16581377|NCT02735928|Experimental|PIPAC|PIPAC stands for Pressurized IntraPeritoneal Aerosol Chemotherapies. Enrolled patients will undergo to explorative laparoscopy as usual and PC index will be determined according to Fagotti score (PIV). Pathological response will be determined by serial peritoneal biopsies. Then a pressurized aerosol containing cisplatin followed by doxorubicin will be applied via a nebulizer. The PIPAC procedure can be repeated after 4-6 weeks until progression or limiting toxicity
16581378|NCT02735915|Experimental|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
16581379|NCT02735902|Experimental|vitamin K antagonist or Direct oral anticoagulant treatment|"In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.
~Intervention: anticoagulant"
16581380|NCT02735902|Active Comparator|vitamin K antagonist or Direct oral anticoagulant + Aspirin|"In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.
~Intervention: anticoagulant Intervention: Aspirin"
16581381|NCT02735889|Other|No carbonation (control)|No carbonation (NC, control): Potable water + sugar
16581382|NCT02735889|Active Comparator|Low carbonation|Low carbonation (LC): Potable water + sugar + little CO2
16581383|NCT02735889|Active Comparator|High carbonation|High carbonation (HC): Potable water + sugar+ high CO2
16581384|NCT02735876|Experimental|acalabrutinib plus rituximab|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
16581385|NCT02735876|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 200 subjects).
16581386|NCT02735876|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 50 subjects).
16581387|NCT02735863|Experimental|ABX464|Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
16581388|NCT02735863|Placebo Comparator|ABX464 Matching placebo|Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
16581389|NCT02735850|Experimental|Ablative SBRT to all (max 3) sites followed by L19-IL2|Ablative cohort
16581390|NCT02735850|Active Comparator|Ablative SBRT to all (max 3) sites|Ablative cohort
16581391|NCT02735850|Experimental|SBRT 1 site, L19-IL2 and then standard of care|Non-ablative cohort
16581392|NCT02735850|Active Comparator|Standard of care|Non-ablative cohort
16581393|NCT02735837|Active Comparator|doxycycline gel|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
16581394|NCT02735837|Placebo Comparator|placebo gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
16581395|NCT02735824||patients with suspected PID|From included patients with suspected primary immunodeficiency (PID), i.e. patients with recurrent/unusual infection, immune dysregulation and/or susceptibility to malignancies from whom consent to participate was obtained, nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
16581396|NCT02735824||healthy relatives of patients with PID|From healthy relatives of patients with suspected PID from whom consent to participate was obtained, nucleated cells will be used for genetic testing in order to compare their genetic information with the one form their relatives with suspected PID.
16581397|NCT02735824||Healthy volunteers|From healthy volunteers from whom consent to participate was obtained, nucleated blood cells will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement. The data obtained will be compared to age matched patients with suspected PID.
16581398|NCT02735798|Experimental|Single Arm Study - Arm 1|10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
16581399|NCT02735785|Experimental|intervention|behavioral intervention
16581400|NCT02735785|No Intervention|control|control
16581401|NCT02735772|Other|cystocele|"Arm: Patients with paravaginal defect cystocele
~Intervention: transobturator approach for paravaginal repair"
16581402|NCT02735759|Other|Healthy Volunteers|This cohort will consist of ten healthy volunteers. The photoacoustic flow cytometry device will be used to establish device settings. The intervention with the subject will include the PAFC device to establish appropriate device settings.
16581403|NCT02735759|Other|Venous Thromboembolism|This cohort will consist of ten patients with newly diagnosed, non-life threatening acute venous thromboembolism. The intervention with the subjects is to perform the photoacoustic flow cytometry device to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.
16581438|NCT02735707|No Intervention|No immunoglobulin against SARS-CoV-2|Patients will not receive any preparation of immunoglobulin intended to neutralise SARS-CoV-2 during the index hospitalisation.
16581574|NCT02734966|Experimental|arm 1|lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
16581405|NCT02735733|Active Comparator|Room temperature arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at room temperature.
16581406|NCT02735733|Experimental|Cold arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at approximately 32 degrees F for the study group.
16581407|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.
~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
16581408|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.
~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
16581409|NCT02735707|Active Comparator|Corticosteroid Domain: fixed-duration Hydrocortisone|The patient will receive IV Hydrocortisone 50 mg every 6 hours for up to 7 days.
16581410|NCT02735707|No Intervention|Corticosteroid Domain:No systemic corticosteroid (no placebo)|The patient will receive no systemic corticosteroid for the treatment of CAP or its direct complications, up until study day 28.
16581411|NCT02735707|Active Comparator|Corticosteroid Domain: shock dependant Hydrocortisone|The patient will receive hydrocortisone (50mg IV every 6 hours) while the patient is in septic shock.
16581412|NCT02735707|Active Comparator|Antibiotic Domain: Ceftriaxone + Macrolide|Ceftriaxone and site preferred macrolide will be administered for empiric antibiotic therapy
16581413|NCT02735707|Active Comparator|Antibiotic Domain: Moxifloxacin or Levofloxacin|Moxifloxacin or levofloxacin will be administered for empiric antibiotic therapy
16581414|NCT02735707|Active Comparator|Antibiotic Domain: Piperacillin-tazobactam + Macrolide|Piperacillin-tazobactam and site preferred macrolide will be administered for empiric antibiotic therapy
16581415|NCT02735707|Active Comparator|Antibiotic Domain: Ceftaroline + Macrolide|Ceftaroline and site preferred macrolide will be administered for empiric antibiotic therapy
16581416|NCT02735707|Active Comparator|Antibiotic Domain: Amoxicillin-clavulanate + Macrolide|Amoxicillin-clavunate and site preferred macrolide will be administered for empiric antibiotic therapy
16581417|NCT02735707|Active Comparator|Macrolide Duration Domain: Standard course macrolide|The patient will receive macrolide therapy for 3-5 days. This arm is nested within the Antibiotic Domain.
16581418|NCT02735707|Active Comparator|Macrolide Duration Domain: Extended course macrolide|The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.
16581419|NCT02735707|No Intervention|No antiviral agent active against influenza (no placebo)|The patient will receive no antiviral agent active against influenza, including oseltamivir.
16581420|NCT02735707|Active Comparator|Five-day course of Oseltamivir|The patient will receive a five-day course of oseltamivir.
16581421|NCT02735707|Active Comparator|10-day course of oseltamivir|The patient will receive a ten-day course of oseltamivir.
16581422|NCT02735707|No Intervention|No antiviral for COVID-19|The patient will receive no antiviral agent intended to be active against SARS-CoV-2 infection.
16581423|NCT02735707|Active Comparator|Lopinavir/ritonavir for COVID-19|Patients will receive lopinavir/ritonavir (kaletra) 400/100mg enterally every 12 hours intended to be active against SARS-CoV-2 infection.
16581424|NCT02735707|Active Comparator|Hydroxychloroquine for COVID-19|Patients will receive hydroxychloroquine intended to be active against SARS-CoV-2 infection.
16581425|NCT02735707|Active Comparator|Hydroxychloroquine + lopinavir/ritonavir for COVID-19|Patients will receive both hydroxychloroquine and lopinavir/ritonavir intended to be active against SARS-CoV-2 infection.
16581426|NCT02735707|No Intervention|No immune modulation for COVID-19|Patients will not receive any immune modulating therapy intended to be active against COVID-19.
16581427|NCT02735707|Active Comparator|Interferon-β1a for COVID-19|Patients will receive Interferon-β1a intended to be active against COVID-19.
16581428|NCT02735707|Active Comparator|Anakinra (interleukin-1 receptor antagonist) for COVID-19|Patients will receive anakinra intended to be active against COVID-19.
16581429|NCT02735707|Active Comparator|Fixed-duration higher dose Hydrocortisone|The patient will receive IV Hydrocortisone 100mg every 6 hours for up to 7 days.
16581430|NCT02735707|Active Comparator|Tocilizumab|Patients will receive Tocilizumab intended to be active against COVID-19
16581431|NCT02735707|Active Comparator|Sarilumab|Patients will receive Sarilumab intended to be active against COVID-19
16581432|NCT02735707|No Intervention|No Vitamin C|Patients will not receive vitamin c (no placebo)
16581433|NCT02735707|Active Comparator|Vitamin C|Patients will receive IV Vitamin C (50mg/kg every 6 hours for 16 doses)
16581434|NCT02735707|No Intervention|Standard Care Thromboprophylaxis|Patients will receive local standard care thromboprophylaxis for 14 days.
16581435|NCT02735707|Active Comparator|Therapeutic Anticoagulation|Therapeutic anticoagulation with IV unfractionated heparin or subcutaneous low molecular weight heparin.
16581488|NCT02735486|Experimental|Ginger drink|Experimental: Ginger drink (300 ml) to be consumed during the study visit
16581439|NCT02735707|Active Comparator|Convalescent plasma|Patients will receive at least one, and not more than two, units of convalescent plasma within 48 hours of randomisation.
16581440|NCT02735707|No Intervention|Clinician-preferred invasive ventilation|Patients will receive invasive mechanical ventilation as determined by the treating clinician.
16581441|NCT02735707|Active Comparator|Protocolised invasive mechanical ventilation strategy|Patient will receive a protocolised invasive mechanical ventilation strategy
16581442|NCT02735707|Active Comparator|Eritoran|Patients will receive Eritoran intended to be active against COVID-19
16581443|NCT02735707|Active Comparator|Apremilast|Patients will receive Apremilast intended to be active against COVID-19
16581444|NCT02735707|No Intervention|No antiplatelet|Patients will not receive any antiplatelet agent or NSAID for 14 days while patient remains in hospital
16581445|NCT02735707|Active Comparator|Aspirin|Patients will receive aspirin for up to 14 days while the patient remains in hospital
16581446|NCT02735707|Active Comparator|P2Y12 inhibitor|Patients will receive either clopidogrel, prasugrel, or ticagrelor (as per site preference).
16581447|NCT02735694|Active Comparator|Cycloserine|Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
16581448|NCT02735694|Placebo Comparator|Placebo|Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose
16581449|NCT02735681|Active Comparator|Probing Treatment Right Eye|Meibomian gland will be performed on the right upper eye lid of each participant.
16581450|NCT02735681|Placebo Comparator|Fellow Eye (Left) Untreated|The fellow eye (left) will be used at the untreated control
16581451|NCT02735668|Active Comparator|Shoulder Conventional Exercises|"The protocol consists in:
~Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment.
~Therapeutic Education about chronic shoulder pain.
~The treatment duration is 1 day per week during 6 weeks."
16581452|NCT02735668|Experimental|Multimodal Physiotherapy|"The protocol consists in:
~Dry Needling in active myofascial trigger points.
~Neurodynamic techniques.
~Scapular exercises.
~Therapeutic Education about chronic shoulder pain.
~The treatment duration is 1 day per week during 6 weeks."
16581453|NCT02735668|Experimental|Scapular exercises|"The protocol consists in:
~Scapular exercises
~Therapeutic Education about chronic shoulder pain.
~The treatment duration is 1 day per week during 6 weeks."
16581454|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
16581455|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
16581456|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
16581457|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
16581458|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
16581459|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
16581460|NCT02735629|Experimental|CX1739 - 300 mg|Study Drug - low dose
16581461|NCT02735629|Placebo Comparator|Placebo|Placebo
16581462|NCT02735629|Experimental|CX1739 - 600 mg|Study drug - mid Dose
16581463|NCT02735629|Experimental|CX1739 - 900 mg|Study drug - high dose
16581464|NCT02735616||study|"15 CVA patients, 1-3 weeks after their first stroke. The patients will be hospitalized in the neurology department at the geriatric Beit-Rivka hospital at Petah-Tiva, Israel.
~patients with pacemaker or those who use Beta-Blocker drugs, as well as patients with cerebellar injury, will be excluded from the research"
16581465|NCT02735616||control|15 patients from the orthopedic department at the same hospital, matching by age and gender to the study group.
16581466|NCT02735603|Experimental|Nalterxone/Bupropion + Placebo + Moxifloxacin|Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
16581467|NCT02735603|Experimental|Placebo + Moxifloxacin + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
16581489|NCT02735486|Placebo Comparator|Placebo: Super pure water|Super Pure water low in nitrate content
16581490|NCT02735473|Experimental|Choline bitartrate|Powdered drink mix containing choline bitartrate 19 mg. per kg.
16581491|NCT02735473|Placebo Comparator|Placebo|Powdered drink mix containing matching placebo
16581492|NCT02735460|Experimental|Treatment arm|In this arm the Andago V2.0 is used.
16581770|NCT02733627|Experimental|BI 1467335 15 mg (medium dose)|
16581468|NCT02735603|Experimental|Moxifloxacin + Naltrexone/Bupropion + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.
16581469|NCT02735603|Experimental|Naltrexone/Bupropion + Moxifloxacin + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.
16581470|NCT02735603|Experimental|Placebo + Naltrexone/Bupropion + Moxifloxacin|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
16581471|NCT02735603|Experimental|Moxifloxacin + Placebo + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
16581472|NCT02735590|Experimental|Open-label 3HP|Participants in the Treatment Arm will receive high dose INH (15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg) with Pyridoxine supplementation (25mg), and Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months. Dispensing of IP and Directly Observed Treatment (DOT) field visits in Treatment Arm participants will be performed by staff members not involved in TB symptom screening or investigation. Participants receiving 3HP who develop symptoms of hepatotoxicity will be evaluated by an Investigator.
16581473|NCT02735590|No Intervention|Baseline Screening; Active Surveillance|Adult volunteers living in TB hyperendemic communities of South Africa will be consented and screened. Individuals with HIV infection and conditions likely to affect the performance of the COR assay, or the safety and/or efficacy of the 3HP investigational regimen, will not be enrolled. Active surveillance for TB disease (Observation Arm), including regular symptom screening and symptom-targeted TB investigation (all participants) will be conducted on this Arm.
16581474|NCT02735577|Experimental|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
16581475|NCT02735564|Experimental|RYGB|Bariatric Surgery:Roux-en-y
16581476|NCT02735564|Experimental|SG|Bariatric Surgery: Sleeve Gastrectomy
16581477|NCT02735564|Placebo Comparator|Control|BMI matched control
16581478|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
16581479|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
16581480|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
16581481|NCT02735538||osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
16581482|NCT02735538||osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
16581483|NCT02735525|Experimental|Smartphone monitoring|Intervention arm
16581484|NCT02735512||Group I|Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
16581485|NCT02735512||Group II|Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
16581486|NCT02735512||Group III|Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.
16581487|NCT02735499|Experimental|Treatment with Botox|Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.
16581771|NCT02733627|Experimental|BI 1467335 20 mg (high dose)|
16581495|NCT02735421|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening on half of the face (determined by randomization)
16581496|NCT02735421|Placebo Comparator|Vehicle gel|Vehicle gel, once daily in the evening on half of the face (determined by randomization)
16581497|NCT02735408|Experimental|100% KT Tension|100% KT Tension
16581498|NCT02735408|Experimental|50% KT Tension|50% KT Tension
16581499|NCT02735408|Experimental|0% KT Tension|0% KT Tension
16581500|NCT02735408|No Intervention|Control (Without KT)|Control (Without KT)
16581501|NCT02735395|Placebo Comparator|Control|Scaling and root planing (SRP) + two placebo pills thrice a day (TID) for 14 days (control group)
16581502|NCT02735395|Active Comparator|MTZ 250 (7 days)|SRP + MTZ (250mg/TID) + AMX, for 7 days and placebos for another 7 days
16581503|NCT02735395|Active Comparator|MTZ 400 (7 days)|SRP + MTZ (400mg/TID) + AMX, for 7 days and placebos for another 7 days
16581504|NCT02735395|Active Comparator|MTZ 250 (14 days)|SRP +MTZ (250mg/TID) + AMX for 14 days
16581505|NCT02735395|Active Comparator|MTZ 400 (14 days)|SRP +MTZ (400mg/TID) + AMX for 14 days
16581506|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.
~Intervention: Behavioral: Tobacco quitline EHR referral"
16581507|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.
~Intervention: Behavioral: Tobacco quitline Fax referral"
16581508|NCT02735382|Experimental|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
16581509|NCT02735382|Active Comparator|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
16581510|NCT02735369|Placebo Comparator|Placebo|Placebo Comparator
16581511|NCT02735369|Experimental|2% OC-10X|2% OC-10X
16581512|NCT02735356|Experimental|Treatment (itraconazole and placebo)|Patients apply itraconazole topically BID and placebo topically BID for 12 weeks.
16581513|NCT02735343|Active Comparator|Standard treatment arm|compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
16581514|NCT02735343|Experimental|Research arm|Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
16581515|NCT02735330|Active Comparator|GROUP 1|68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol
16581516|NCT02735330|Placebo Comparator|GROUP 2|68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
16581517|NCT02735317|Experimental|FORRAD group|"This group of patients will receive Oral Ulcer Gargle (FORRAD®) during study for prevention and treatment of acute radiation-induced oral mucositis (OM).
~This is the experimental group."
16581518|NCT02735317|Active Comparator|Quadruple mixture group|"This group of patients will receive quadruple mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, during study for prevention and treatment of acute radiation-induced oral mucositis (OM).
~This is the active comparator group."
16581519|NCT02735304|Other|Innovation treatment 3M ESPE materials|"The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment during the Impression intervention.
~Materials to be used all 3M ESPE - Astringent Retraction Paste, Imprint™ 4 Preliminary, Imprint™4 VPS, Imprint™ 4 Bite, Intra-oral syringes, Impression Tray,"
16581520|NCT02735304|Other|standard clinical practice treatment|"The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment during the Impression intervention
~Materials as per the operating dentist's choice to be recorded on CRF"
16581521|NCT02735291|Experimental|Single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
16581522|NCT02735265|Experimental|Virtual reality group|45 min standard treatment plus 45 min virtual reality balance training used by Kinect for Xbox game. Game choosed based on motor learning principle. Training task such as reach or stepping in various direction, squat, stand up, upper trunk forward or lateral bench.
16581523|NCT02735265|Active Comparator|Standard treatment only group|90 min standard treatment. Depended on patient's ability, principle used by motor learning, sensory process, motor control, task oriented training, symmetry w't bearing.
16581524|NCT02735252|Experimental|Group A: Androgen Signaling Inhibition|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving treatments that inhibit androgen signaling to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581525|NCT02735252|Experimental|Group B: Immunotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving immunotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581526|NCT02735252|Experimental|Group C: Radiotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving radiotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581527|NCT02735252|Experimental|Group D: Targeted Therapy Not Otherwise Specified|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving targeted therapy and investigational therapeutics to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581528|NCT02735252|Experimental|Group E: DNA Damage Response|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581529|NCT02735252|Experimental|Group F: Aggressive Variant Disease|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients with variants of disease that display aggressive behavior to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581530|NCT02735252|Experimental|Group G1: Castration Sensitive, ADT naïve and ADT < 3 months|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581531|NCT02735252|Experimental|Group G2:Castration Sensitive,Pre-treated w/ sub-optimal PSA|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581532|NCT02735252|Experimental|Group R: Advanced Renal Cell Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581533|NCT02735252|Experimental|Cohort U: Advanced Urothelial Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
16581534|NCT02735239|Experimental|Durvalumab and standard of care chemotherapy|Phase 1 will evaluate the safety of durvalumab alone (Cohort A1) administered before chemotherapy (oxaliplatin + capecitabine) in subjects with metastatic or locally advanced Oesophageal Cancer + Chemotherapy
16581535|NCT02735239|Experimental|Durvalumab + tremelimumab and standard of care chemotherapy|Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy (Cohort A2).
16581536|NCT02735239|Experimental|Recommended combination of doses from Cohort A1 or A2|Subjects in Cohort B are subjects with metastatic/locally advanced Oesophageal Cancer. Subjects in Cohort B will receive the recommended combination dose from Cohort A1 (durvalumab alone administered before chemotherapy (oxaliplatin + capecitabine)) or A2 (Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy) and Chemotherapy.
16581537|NCT02735239|Experimental|Durvalumab, surgery and standard of care chemotherapy|Durvalumab 750mg + Chemotherapy (Cohort C)
16581538|NCT02735239|Experimental|Durvalumab, surgery, standard of care chemo and radiotherapy|Durvalumab 750mg + Chemotherapy Radiotherapy (Cohort D)
16581539|NCT02735239|Experimental|Durvalumab, surgery, new standard of care chemotherapy C-FLOT|Durvalumab 750mg + Chemotherapy (Cohort C-FLOT)
16581540|NCT02735226||Acute Stroke patient|Patients who are presented to hospital within 7days from onset. The key measurement of clinical quality controlled in patients with acute stroke managment and inhouse stroke care were record automatically
16581541|NCT02735213|Experimental|577-MPL|"577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
16581542|NCT02735213|Active Comparator|TLT|"Traditional laser will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
16581543|NCT02735200|Experimental|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
16581544|NCT02735200|Active Comparator|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
16581545|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
16581546|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
16581547|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:
~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
16581548|NCT02735161|Experimental|Exercise training|"Four exercise training sessions. Two endurance training sessions, one with high intensity interval training and one session of moderate intensity of longer duration. Two strength training session; one with high load and few repetitions and one with low load and many repetitions.
~Fatigue and lactate will be measured before, after and 24 hours post-exercise. Trainings sessions will be randomized."
16581549|NCT02735148|No Intervention|Conventional Training|Conventional training sessions generally consisted of exercises which aimed to improve range of motion, strength, and movement quality in upper and lower extremity as an in-patient rehabilitation protocol. Also developing static and dynamic postural control and increasing walking distance were the other aims of training. Duration of the Conventional Training is 45 minute per session, 3 days a week for 6 weeks.
16581575|NCT02734966|Experimental|arm 2|higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
16581576|NCT02734966|Active Comparator|Tiopronin Injection|Tiopronin Injection 200mg OD for 4 weeks
16581772|NCT02733627|Placebo Comparator|Placebo|
16581550|NCT02735148|Experimental|Body Weight Supported Treadmill Training|"Body weight supported treadmill training (BWSTT) was composed of outpatients who were undertaken only BWST training with 45-minute sessions, 2 days a week during 6 weeks.
~BWST Training
~Locomat (Hocoma) was used in BWSTT group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait pattern."
16581551|NCT02735148|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
16581552|NCT02735135|Experimental|Airsoft Duo First|"Patients randomized to this arm will be placed on an AIRSOFT DUO mattress for day 0. They will then be switched to a SENTRY 1200 mattress until the end of month 1.
~Intervention: AIRSOFT DUO for 1 day Intervention: SENTRY 1200 for 1 month"
16581553|NCT02735135|Experimental|SENTRY 1200 First|"Patients randomized to this arm will be placed on a SENTRY 1200 mattress for day 0. They will then be switched to an AIRSOFT DUO mattress until the end of month 1.
~Intervention: SENTRY 1200 for 1 day Intervention: AIRSOFT DUO for 1 month"
16581554|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
16581555|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
16581556|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
16581557|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
16581558|NCT02735109|Other|description|photographies and biopsy on normal area
16581559|NCT02735096|Experimental|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
16581560|NCT02735083|Experimental|UCART19 follow-up|
16581561|NCT02735070|Experimental|Corisitina D|The patient will use the medication 4 times a day - orally The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine. Coristina® d is indicated as an analgesic, antipyretic, antiallergic, and nasal congestion for the treatment of the symptoms of influenza and common cold.
16581562|NCT02735070|Active Comparator|Resfenol|The patient will use the medication 4x / day - orally Resfenol® drug acts against the symptoms of colds and flu, such as nasal congestion, runny nose, fever, headache, muscle pain and other symptoms. The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.
16581563|NCT02735057|Experimental|Phase I|"for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)
~for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
16581564|NCT02735044|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter [U/mL]) Subcutaneous(SC) injection once daily for 12 months.
16581565|NCT02735044|Active Comparator|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
16581566|NCT02735031|Active Comparator|EXENATIDE|"Exenatide
~week 1-2: 5 µg twice daily
~week 3-6: 10 µg twice daily (if tolerated)"
16581567|NCT02735031|Placebo Comparator|PLACEBO|"Placebo matched to exenatide
~week 1-2: 5 µg twice daily
~week 3-6: 10 µg twice daily (if tolerated)"
16581568|NCT02735018|Experimental|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
16581569|NCT02735018|Experimental|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
16581570|NCT02735005|Experimental|SMAF assessment|"Face to face interview for the Functional Autonomy Measurement System (SMAF) tool questionnaire For disabled patients living at home, the Social SMAF questionnaire is used in addition.
~Data related to care consumption of each enrolled patients are collected too."
16581571|NCT02734992|Other|Acceptance and Commitment therapy + MTAU|"The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou & Karekla, 2015). The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness.
~Participants will be asked to remain stable on their pharmacotherapy during this study. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions.
~Participants will complete questionnaires at pre-, post-treatment, and at 3-month follow-up. The WL group will enter treatment at the 3-month follow-up of the ACT-group."
16581572|NCT02734992|Other|MTAU/ Wait-list Control Gr|"The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment. Participants will complete the same questionnaires at three different time points: pre-, post-treatment, and at 3-month follow-up.
~Participants will be asked to remain stable on their pharmacotherapy during this study and inform the researchers of any changes. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Excluded participants will be referred to appropriate services."
16581573|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
16581674|NCT02734290|Experimental|Arm A|pembrolizumab + weekly paclitaxel
16581577|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
16581578|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.
~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
16581579|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
16581580|NCT02734927|Active Comparator|schizophrenia group|Schizophrenia patients suffering
16581581|NCT02734927|Sham Comparator|control group|subjects showing no psychological or neurological disorder
16581582|NCT02734914|Experimental|SF-URS with automatic control of RPP|Participants in SF-URS with automatic control of renal pelvic pressure (RPP) group undergo ureteroscopy using the intelligent pressure control device (Medical irrigation and suctioning platform with pressure feedback function, and suctioning ureteral access sheath with function of pressure measuring).
16581583|NCT02734914|Active Comparator|conventional F-URS|Participants in conventional F-URS group undergo ureteroscopy using the classic flexible ureteroscope.
16581584|NCT02734901|Active Comparator|400 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
16581585|NCT02734901|Active Comparator|200 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
16581586|NCT02734901|Placebo Comparator|Placebo control|Raspberry deprived supplement Acute intake of 600 mL (1x daily)
16581587|NCT02734888|Other|Healthy control|"Will undergo PET scan as a negative control"
16581588|NCT02734888|Other|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
16581589|NCT02734888|Other|E-cigarette user|Will undergo PET scan
16581590|NCT02734875|Experimental|Intervention|Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy. Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
16581591|NCT02734875|No Intervention|Usual Care|Primary care providers will provide usual care.
16581592|NCT02734862|Experimental|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.
~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
16581593|NCT02734862|Active Comparator|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).
~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
16581594|NCT02734862|Experimental|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.
~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
16581595|NCT02734849|Experimental|25 mg AK001|25 mg AK001 will be administered as multiple doses
16581596|NCT02734849|Experimental|250 mg AK001|250 mg AK001 will be administered as multiple doses
16581597|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients will be administered as multiple doses
16581598|NCT02734836|Experimental|Zilver PTX Stent|Diagnostic assessment of the lesion after implantation of drug eluting stent with Balloon Angioplasty and placement of the Zilver PTX Stent with Optical Coherence Tomography (OCT)
16581599|NCT02734823||Ancillary-Correlative (ovary imaging, hormonal analysis)|Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.
16581600|NCT02734810|Experimental|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
16581601|NCT02734810|Experimental|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to <7 years
16581602|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
16581603|NCT02734784|Experimental|Photodynamic Therapy and SRP|
16581604|NCT02734784|Sham Comparator|SRP and Sham Photodynamic Therapy|
16581605|NCT02734771|Experimental|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
16581606|NCT02734758||Atrial fibrillation stroke|
16581607|NCT02734758||Non-atrial fibrillation Stroke|
16581608|NCT02734745|Experimental|flash glucose monitoring|Patients will use a device: Freestyle Libre for 14 days
16581609|NCT02734732|Active Comparator|Ciprofloxacin|T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy
16581675|NCT02734290|Experimental|Arm B|pembrolizumab + capecitabine
16581610|NCT02734732|Active Comparator|Trimethoprim/Sulfamethoxazole|Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy
16581611|NCT02734719|Experimental|the group treated with electrical stimulation|
16581612|NCT02734706|Experimental|LRC™ capsule|
16581613|NCT02734706|Placebo Comparator|Placebo capsule|
16581614|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
16581615|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
16581616|NCT02734680|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
16581617|NCT02734680|Experimental|Stereotactic Radiotherapy(SBRT) Group|Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
16581618|NCT02734667|Experimental|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
16581619|NCT02734667|No Intervention|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
16581620|NCT02734654|No Intervention|Control group|patients do not receive remote preconditioning prior to lung lobectomy
16581621|NCT02734654|Experimental|RIPC group|patients receive remote preconditioning prior to lung lobectomy
16581622|NCT02734641||intravenous (IV) iron therapy|"Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects.
~20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested."
16581623|NCT02734641||healthy volunteer|healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks.
16581624|NCT02734628|Experimental|Dexpanthenol|A squeeze of ointment, approximately 0.5 cm in length corresponding to an amount of about 0.3 g of ointment, which is equal to 15 mg dexpanthenol , twice daily (once in the morning and once in the evening) over a period of 14 days was applied topically under occluded conditions
16581625|NCT02734628|Placebo Comparator|Placebo|Subjects received applications of placebo corresponding to verum
16581626|NCT02734615|Experimental|Arm A|Patients will get LSZ102 single agent during dose escalation.
16581627|NCT02734615|Experimental|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
16581628|NCT02734615|Experimental|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
16581629|NCT02734615|Experimental|Arm 1|Patients will get LSZ102 single agent during dose expansion
16581630|NCT02734615|Experimental|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
16581631|NCT02734615|Experimental|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
16581632|NCT02734615|Experimental|Arm 4|Patient will get LSZ102 in combination with BYL719 during dose expansion
16581633|NCT02734602|Other|Cognitive Testing|Subjects will take part in verbal assessments as well as computer testing.
16581634|NCT02734602|Active Comparator|Magnetic Resonance Imaging|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. We will acquire the following: structural MRI, resting state MRI, diffusion tensor imaging data (DTI), and arterial spin labeling (ASL). We may also ask subjects to complete an emotional capture task.
16581635|NCT02734602|Active Comparator|Positron Emission Tomography|Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.
16581636|NCT02734589|Active Comparator|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
16581637|NCT02734589|Experimental|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
16581638|NCT02734589|Active Comparator|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
16581639|NCT02734576|Experimental|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
16581640|NCT02734563||Multiple hernia group|Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed.
16581641|NCT02734563||Control group|Males without any history or presence of hernias
16581642|NCT02734550|Active Comparator|Control|Diagnosis of invasive candida infection according to standard of care.
16581643|NCT02734550|Experimental|(1,3)-β-D-glucan guidance|Treatment according to BDG-result
16581644|NCT02734537|Experimental|Arm A (IMRT)|Patients undergo IMRT QD 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
16581645|NCT02734537|Experimental|Arm B (IMRT, cisplatin)|Patients undergo IMRT QD 5 days a week and receive cisplatin IV over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
16581646|NCT02734524|Experimental|NK infusion+chemotherapy|Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.
16581647|NCT02734524|Active Comparator|chemotherapy|Receive the same taxol and carboplatin in experimental arm without NK cell infusion.
16581648|NCT02734511|Experimental|Drug: sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
16581649|NCT02734498|Active Comparator|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
16581650|NCT02734498|Active Comparator|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
16581651|NCT02734498|No Intervention|Control group|No ECT treatment for control group.
16581652|NCT02734485|Active Comparator|active Deep Tms|Each DTMS session consisted in two consecutive stimulations: a first low-frequency (1 Hz) stimulation in the motor cortex (110% of the motor threshold, for 15 minutes)and a second high-frequency (10Hz) one in the prefrontal cortex (100% motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).The coil contains two symmetric devices, perfectly designed to rouse both hemispheres at the same time.
16581653|NCT02734485|Sham Comparator|sham deep tms|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an inactive DTMS coil.
16581654|NCT02734472||Hanzhong cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
16581655|NCT02734472||Mei county cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
16581656|NCT02734459|Experimental|tobramycin and dexamethasone ophthalmic test ointment|The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
16581657|NCT02734459|Active Comparator|TobraDex® ointment|The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
16581658|NCT02734446|Active Comparator|Reuterin D3 drops|Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)
16581659|NCT02734446|Placebo Comparator|Placebo|The patients will receive 5 drops/day of placebo for 3 months
16581660|NCT02734433|Experimental|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
16581661|NCT02734420|Experimental|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs; Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up: Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
16581662|NCT02734420|Experimental|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette; Follow up; Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
16581663|NCT02734407|Experimental|Open-Label Arm|"2mg Aflibercept, as needed, intravitreal administration.
~All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.
~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.
~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
16581664|NCT02734394|Experimental|Cardiovascular and strength training exercise|24 sessions (~12 weeks) exercise
16581665|NCT02734368||Healthy non-smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
16581666|NCT02734368||Asymptomatic smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
16581667|NCT02734368||COPD subjects|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
16581668|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
16581669|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
16581670|NCT02734342|Experimental|Exercise, Kinesiophobia and Knee Osteoarthritis|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. During the hour, participants will complete a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improve aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted.
16581671|NCT02734329|Experimental|Zero Ischemia group|Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
16581672|NCT02734329|Active Comparator|Conventional group|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
16581673|NCT02734303||Potentially Exposed NM Residents|residents of the state of New Mexico (NM) potentially exposed to radioactive fallout fromthe Trinity nuclear test conducted in 1945
16581676|NCT02734277||Group 1: Detectable C-peptide by MMTT|"Participants with detectable C-peptide at their:
~Last Immune Tolerance Network (ITN) T1DM week 104 study visit,
~Last AbATE (NCT00129259) follow-up visit, or
~Last ITN066AI T1DES visit
~Detectable C-peptide is defined as a value above the lower limit of detection."
16581677|NCT02734277||Group 2:Undetectable C-peptide by MMTT|"Participants without detectable C-peptide at their:
~Last ITN T1DM week 104 study visit,
~Last AbATE follow-up visit, or last
~ITN066AI T1DES visit
~Undetectable C-peptide is defined as a value below the lower limit of detection."
16581678|NCT02734251|Placebo Comparator|Placebo|Dietary Supplement: Placebo
16581679|NCT02734251|Experimental|Relora|Dietary Supplement: Relora, 750 mg/day
16581680|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
16581681|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
16581682|NCT02734225|Experimental|EXPERIMENTAL|Functional recovery Balance training
16581683|NCT02734225|Active Comparator|CONTROL|Functional recovery Balance training Dynamometric Platform training
16581684|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
16581685|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
16581686|NCT02734199||Enrollment Period 1 Cohort|Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
16581687|NCT02734199||Enrollment Period 2 Cohort|Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
16581688|NCT02734199||Enrollment Period 3 Cohort|Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
16581689|NCT02734186|Experimental|Sh|Mono infected with Schistosoma haematobium
16581690|NCT02734186|Experimental|ShMp|Coinfected with Schistosoma haematobium andMansonella perstans
16581691|NCT02734173|Active Comparator|Genotype 1a Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
16581692|NCT02734173|Active Comparator|Genotype 1b Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin
16581693|NCT02734173|Active Comparator|Genotype 1a/1b Compensated Cirrhotic Arm|• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
16581694|NCT02734160|Experimental|Galunisertib + Durvalumab|(Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).
16581695|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
16581696|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
16581697|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
16581698|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
16581699|NCT02734121|Experimental|Educational group intervention|The pre-consultation educational group intervention will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
16581700|NCT02734121|No Intervention|Standard Care|Routine pre-consultation education
16581701|NCT02734108|Experimental|Transcranial direct current stimulation|10 patients will be stimulated twice a day for two weeks or 20 sessions. 2 milli ampere stimulation will be applied for 25 min respecting a period of four hours between sessions.
16581702|NCT02734095|Experimental|Intravascular Ultrasound data|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
16581703|NCT02734082||Elevated Troponin and pathological EC|Patients with acute ischemic stroke with elevated Troponin
16581704|NCT02734082||No elevated Troponin or pathological EC|Patients with acute ischemic stroke without elevated Troponin
16581705|NCT02734082||Elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography
16581706|NCT02734082||No elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography
16581767|NCT02733640|Active Comparator|Pantoprazole|Drug: Pantoprazole 40 mg once-daily
16581707|NCT02734069||Sarcopenic|Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
16581708|NCT02734069||Non Sarcopenic|Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
16581709|NCT02734056|Experimental|Music|The intervention to be administered is music
16581710|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
16581711|NCT02734030||Control Group|"Knee pain-free females with no history of lower limb injuries serving as a control group.
~."
16581712|NCT02734030||Anterior Knee Pain Group|Females with anterior knee pain syndrome were enrolled in this group.
16581713|NCT02734017|Other|standard course|group not receiving medication review
16581714|NCT02734017|Other|pharmacist-led standardized medication review|"pharmacist-led standardized medication review including :
~Medical and pharmaceutical admission medication reconciliation and treatment review
~Medical and pharmaceutical medication reconciliation at discharge and treatment review
~Medication Liaison Service"
16581718|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
16581719|NCT02733991|Active Comparator|Control|MiniMed™640G alone
16581720|NCT02733978|Experimental|ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
16581721|NCT02733978|No Intervention|non-ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
16581722|NCT02733965|Other|standard course|"The patients in the control group will have a classic course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.
~Group workshops entitled Disease and drugs, Dietary and sports activity, Psychology Workshop during which the patient will be able to participate in order to get all the information he needs.
~Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.
~Moreover, in the control arm, a systematic short pharmaceutical interview with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):"
16581723|NCT02733965|Other|Long Pharmaceutical Consultations|The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
16581724|NCT02733952|Active Comparator|tranexamic acid|"bolus intravenous injection of tranexamic acid 10mg/kg (maximum1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1L of saline for 10 h (maximum
~1 g/10 h)"
16581725|NCT02733952|Active Comparator|Pericervical Tourniquet|The tourniquet method will be used where the urinary bladder will be dissected downwards from the lower uterine segment, and then a perforation will be made in the posterior leaflet of the broad ligament bilaterally at the level of uterine isthmus. A tourniquet (using 16- inch Foley catheter) will be passed through the perforation encircling the uterine arteries bilaterally. The Fallopian tubes and the ovaries will be carefully excluded from the line of the tourniquet to avoid direct compression and necrosis. The tourniquet will be released intermittently (at about 30 minutes interval) during the surgery and ﬁnally removed after the repair of the uterus
16581726|NCT02733939|Experimental|Technology intervention|Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
16581727|NCT02733939|No Intervention|Usual care|"Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality (Biståndshandläggaren) where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues."
16581728|NCT02733926|No Intervention|City kindergarten|Children living in a normal city kindergarten that hardly has vegetation in backyards
16581729|NCT02733926|Experimental|adding of vegetation into the backyards.|"Children living in a normal city kindergarten that has plenty of vegetation in backyards.
~Intervention: adding of vegetation into the backyards."
16581730|NCT02733926|No Intervention|Nature kindergarten|Children living in a city kindergarten where children go regularly into a natural forest
16581731|NCT02733900|Experimental|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
16581732|NCT02733900|Other|Control group|Patients with coxarthrosis
16581733|NCT02733887|Experimental|lymphoma|The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
16581734|NCT02733874|Experimental|test group|Compound Clobetasol Propionate Ointment
16581735|NCT02733874|Active Comparator|control group|Calcipotriol Betamethasone Ointment
16581736|NCT02733848|Experimental|DIET|A registered dietician (RD) will meet with and thoroughly review the patients diet. The patient will be counseled on a diet lower in refined carbohydrates and higher in protein.
16581737|NCT02733848|Active Comparator|Creon|Subjects will be provided Creon at a dose of 500 units/kg of lipase to be taken with meals and snacks to see if this decreases frequency and severity of hypoglycemia.
16581738|NCT02733848|Placebo Comparator|Placebo|Subjects will be provided placebo and advised to take it with meals and snacks to provide.
16581739|NCT02733835|Experimental|Remifentanil|Remifentanil Patient Controlled Analgesia
16581740|NCT02733822|Experimental|IMP: buccal naloxone (single dose)|0.8 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
16581741|NCT02733822|Experimental|IMP: buccal naloxone (double dose)|1.6 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
16581742|NCT02733822|Active Comparator|Intramuscular (IM) reference|0.8 mg IM injection of 1 mg/ml Naloxone Hydrochloride Injection
16581743|NCT02733822|Active Comparator|Intravenous (IV) reference|0.8 mg IV injection of 1 mg/ml Naloxone Hydrochloride Injection
16581744|NCT02733809|Experimental|Sorafenib|Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.
16581745|NCT02733783|Experimental|septorhinoplasty patients|Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
16581746|NCT02733770|Active Comparator|Sleeve gastrectomy|US DOopler for Patient with BMI of 40 or more than 35 with co-morbidities underwent Sleeve gastrectomy
16581747|NCT02733770|Active Comparator|Mini Gastric Bypass|US DOopler for Patient with BMI of 40 or more than 35 wtih co-morbidities underwent mini gastric bypass
16581748|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
16581749|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
16581750|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
16581751|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
16581752|NCT02733744|Experimental|Fecal Microbiota Transplant|"Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards.
~Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water."
16581753|NCT02733731|Experimental|Chinese Herbal Compound Ointment|This kind of CHCO composed of several chinese herbs,dong quai,angelica,resina draconis and lithospermum.The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks.
16581754|NCT02733731|Active Comparator|Estriol|The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks in two groups.
16581755|NCT02733718|Other|Group 1: no enteral feeding|intervention: NIRS (near-infrared spectroscopy)
16581756|NCT02733718|Other|Group 2: Feeding is reduced by %50|intervention: NIRS (near-infrared spectroscopy)
16581757|NCT02733718|Other|Group 3: Feeding will be continued|intervention: NIRS (near-infrared spectroscopy)
16581758|NCT02733705|Placebo Comparator|Control|normal saline IV plus propofol infusion
16581759|NCT02733705|Active Comparator|Fentanyl|0.5 mcg/kg ideal body weight IV plus propofol infusion
16581760|NCT02733692|Experimental|GURHL Code Smartphone application|Experimental arm will receive the 'Understanding Reproductive Health for Ladeez (GURHL) Code 'app' (application) for their smartphone with sexual health information. The intervention is embedded in the smart phone application. This includes sexual and reproductive health knowledge, plus access to a National Planned Parenthood health educator, and directions to other nearby clinics. Participants will be assessed using A-CASI at 3 months after enrollment.
16581761|NCT02733692|No Intervention|Control|"The control arm will receive usual care. That is, they will receive a web-based flyer. This flyer will include a list of clinics and other trusted available resources, but without hyperlinks.
~Participants will be assessed using A-CASI at 3 months after enrollment."
16581762|NCT02733679|Experimental|Ataxia Telangiectasia|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
16581763|NCT02733679|Active Comparator|Healthy controls|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
16581764|NCT02733666|Experimental|Absorbable screw group|One absorbable screw was used for fixation in the experimental group
16581765|NCT02733666|No Intervention|K-wires group|two 1.8-mm K-wires were used for the fixation in the control group. The K-wires were the most common used by the orthopaedic surgeon.
16581766|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
16581773|NCT02733614|Experimental|SRX246|SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks
16581774|NCT02733614|Placebo Comparator|Placebo|oral administration, capsules, daily for 8 weeks
16581775|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
16581776|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
16581777|NCT02733575|Other|Compassion Focused Therapy|Intervention
16581778|NCT02733562||Binge eaters|Classificated preoperatively
16581779|NCT02733562||Volume eaters|Classificated preoperatively
16581780|NCT02733562||sweet eaters|Classificated preoperatively
16581781|NCT02733562||snack eaters|Classificated preoperatively
16581782|NCT02733549||patient|Patients with sudden onset dizziness (SOD) analysed LFTs
16581783|NCT02733549||control|The control group with 98 healthy volunteer analysed LFTs
16581784|NCT02733536|Experimental|Scenario A|manikin with normal standard airway
16581785|NCT02733536|Experimental|Scenario B|Cervical immobilization using a standard Patriot cervical extraction collar (Oessur Americas, Foothill Ranch, CA, USA), applied to the manikin's neck by an instructor.
16581786|NCT02733536|Experimental|Scenario C|Cervical immobilization using a vacuum mattress (Ferno-Washington, Inc. Wilmington, OH, USA), applied to the manikin's neck by an instructor
16581787|NCT02733523|Experimental|"Program Sentirnos bien"|"The intervention Program Sentirnos bien is based around a group dynamic, held once a week during 3 months, aimed at:
~Promoting the uptake of self-care healthy habits
~Promoting social capital at individual level:
~Promoting health literacy"
16581788|NCT02733523|No Intervention|Control arm|The control arm will receive no intervention. Once the trial is finished, i.e. after the last follow-up evaluation, this arm will receive the intervention (waiting-list approach).
16581789|NCT02733510||subclinical rejection group|patients whose protocol biopsy outcome is subclinical rejection and treat with steroid pulse therapy (methylprednisolone)
16581790|NCT02733510||No rejection group|patients whose protocol biopsy outcome is normal
16581791|NCT02733497|Active Comparator|Sympathectomy Group|Excision of ganglia at T3 level
16581792|NCT02733497|Active Comparator|Sympathicotomy Group|Resection of sympathetic chain at T3 level
16581793|NCT02733484|Experimental|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
16581794|NCT02733484|Placebo Comparator|Placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
16581795|NCT02733471|Experimental|Lidocaine|Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.
16581796|NCT02733471|Placebo Comparator|Control|Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy
16581797|NCT02733458|Experimental|GELAD/Radiation|Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
16581798|NCT02733445||dasatinib cohort|Patients with CML receiving dasatinib
16581799|NCT02733445||nilotinib cohort|Patients with CML receiving nilotinib
16581800|NCT02733432|Experimental|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
16581801|NCT02733432|Experimental|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
16581802|NCT02733432|Active Comparator|Cohort 3|Oral fluconazole (150mg) administered on day 1.
16581803|NCT02733419|Experimental|Enfuvirtide + OB (Not Randomized)|Participants will receive enfuvirtide 90 milligram (mg) twice daily (b.i.d.) and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants not meeting the randomization criteria will receive enfuvirtide 90 mg b.i.d and OB for next 24 weeks (up to Week 52).
16581804|NCT02733419|Experimental|Enfuvirtide + OB (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive enfuvirtide 90 mg b.i.d. and OB for next 24 weeks (up to Week 52).
16581805|NCT02733419|Experimental|OB alone (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive OB alone for next 24 weeks (up to Week 52).
16581806|NCT02733406|Other|Target Controlled Infusion|This group of patients will have their anaesthesia induced with Target Controlled Infusion (TCI)
16581807|NCT02733406|Other|Velocity Controlled Infusion|This group of patients will have their anaesthesia induced with Velocity Controlled Infusion (VCI)
16581808|NCT02733393|Experimental|SPG Block|
16581809|NCT02733380|Experimental|Chidamide combined with VDDT regimen|Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles
16581810|NCT02733367|Experimental|Infacort|Infacort® granules
16581811|NCT02733354||Control Group|Control Group:perform routine oral education.Both groups were asked to complete kidney disease knowledge questionnaire before education.
16581812|NCT02733354||Intervention Group|Intervention Group ：On the basis of Control Group, watching video demonstration of each type of dialysis. The videos were based on real cases, showing patients with peritoneal and hemodialysis life modes, lasting for 20 minutes respectively for each type of dialysis. Both groups were asked to complete kidney disease knowledge questionnaire before education.
16581813|NCT02733341|Active Comparator|Oral Ticagrelor|Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
16581814|NCT02733341|Active Comparator|Intravenous Cangrelor|Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
16581815|NCT02733328||AKI Patients|Patients with AKI
16581816|NCT02733328||Non-AKI Patients|Patients without AKI
16581817|NCT02733315|Experimental|DCMP|
16581818|NCT02733302|Experimental|Hope theory|
16581819|NCT02733276|Experimental|Electroacupuncture|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: 6 needles in each lower limb, 8 abdominal, 3 in upper extremity and 3 on the front
16581820|NCT02733276|Sham Comparator|Electroacupuncture sham|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: needles on each forearm on nonselective points
16581821|NCT02733276|No Intervention|Control|Initially no intervention. In a second period in this group we will perform EAP
16581822|NCT02733263|Experimental|Group 1|Participants will first consume in the the order of 0 g RMD, 15 g RMD, 25 g RMD for 3 weeks each
16581823|NCT02733263|Experimental|Group 2|Participants will first consume RMD in the the order of 0 g RMD, 25 g RMD, 15 g RMD for 3 weeks each
16581824|NCT02733263|Experimental|Group 3|Participants will first consume RMD in the the order of 15 g RMD, 0 g RMD, 25 g RMD for 3 weeks each
16581825|NCT02733263|Experimental|Group 4|Participants will first consume RMD in the the order of 15 g RMD, 25 g RMD, 0 g RMD for 3 weeks each
16581826|NCT02733263|Experimental|Group 5|Participants will first consume RMD in the the order of 25 g RMD, 15 g RMD, 0 g RMD for 3 weeks each
16581827|NCT02733263|Experimental|Group 6|Participants will first consume RMD in the the order of 25 g RMD, 0 g RMD, 15 g RMD for 3 weeks each
16581828|NCT02733250|Other|Pembrolizumab + Nab-Paclitaxel|"Phase I will determine the recommended Phase II dose (RP2D) of nab-paclitaxel when given in combination with pembrolizumab. Escalation for nab-paclitaxel will be conducted following a 3+3 design. First cohort of 3 patients will receive nab-paclitaxel on Days 1 and 8 at a dose of 100 mg/m2 intravenous (IV) in combination with pembrolizumab at 200 mg IV every 3 weeks. If no dose limiting toxicities (DLT) occur, the dose of nab-paclitaxel will be escalated to 100 mg/m2 on Days 1, 8 and 15 every 3 weeks. The dose of pembrolizumab will remain the same. If no DLTs occur, dose level 2 will be defined as the RP2D. In the Phase II, pembrolizumab will be administered at 200 mg IV every 3 weeks and nab-paclitaxel will be administered at the RP2D."
16581829|NCT02733237|Experimental|male oxytocin group|male subjects with oxytocin treatment
16581830|NCT02733237|Experimental|female oxytocin group|female subjects with oxytocin treatment
16581831|NCT02733237|Placebo Comparator|male placebo group|male subjects with placebo treatment
16581832|NCT02733237|Placebo Comparator|female placebo group|female subjects with placebo treatment
16581833|NCT02733211|Experimental|Closed Loop System|MD-Logic automated insulin delivery system - all subjects wearing the study system during nights over 4 weeks
16581834|NCT02733211|Active Comparator|Sensor augmented pump therapy|Sensor augmented pump therapy - all subjects are using sensor augmented pump therapy over 4 weeks
16581835|NCT02733198|Experimental|Prognosis-guided|Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
16581836|NCT02733198|No Intervention|Standard medical therapy|Duration of bed rest and duration of length of stay will be decided by the attending physician.
16581837|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
16581838|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
16581839|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
16581840|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
16581841|NCT02733159|Experimental|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
16581842|NCT02733146||cardiac arrest patients|Patients who has suffered a cardiac arrest
16581843|NCT02733133|Experimental|Uncovered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and cover the area before engaging in contact with the female partner.
16581844|NCT02733133|Experimental|Covered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and will not cover the area before engaging in contact with the female partner.
16581845|NCT02733120|Experimental|Healthy matched controls|Study Day: The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
16581846|NCT02733120|Experimental|Adults with Autism Spectrum Disorder|The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
16581847|NCT02733107|Other|Apatinib+Etoposide|Apatinib combined with Etoposide
16581848|NCT02733094|Experimental|Open-label|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.
16581849|NCT02733081|No Intervention|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
16581850|NCT02733081|Experimental|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
16581851|NCT02733068|Experimental|HPV-16/18 vaccine|Including 6000 participants who received the HPV-16/18 vaccine 0.5ml.
16581852|NCT02733068|Placebo Comparator|HPV-16/18 placebo|Including 6000 participants who received the HPV-16/18 placebo 0.5ml.
16581853|NCT02733055|Experimental|subjects|participant undergoing posturographic evaluation
16581854|NCT02733042|Experimental|Arm A: Durvalumab + Lenalidomide ± Rituximab|"Participants assigned to Arm A will receive:
~Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and
~Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of:
~Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or
~All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL
~Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5.
~All treatment cycles were 28 days."
16581855|NCT02733042|Experimental|Arm B: Durvalumab + Ibrutinib|"Participants assigned to Arm B will receive:
~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13
~Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason.
~All treatment cycles were 28 days."
16581856|NCT02733042|Experimental|Arm C: Durvalumab + Rituximab ± Bendamustine|"Participants assigned to Arm C will receive:
~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13
~Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose)
~Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6.
~All treatment cycles were 28 days."
16581857|NCT02733042|Experimental|Arm D: Durvalumab Monotherapy|Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
16581858|NCT02733029|Experimental|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
16581859|NCT02733029|No Intervention|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
16581860|NCT02733003|Experimental|Women's Health CoOp (WHC)|This is an adapted behavioral intervention for women in South Africa, who use alcohol and other drugs and are living with HIV or at risk of acquiring HIV.
16581861|NCT02732990|Experimental|Exercise training - Whole body exercise|Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks
16581862|NCT02732990|Experimental|Exercise training - One-legged exercise|Control subjects will train high intense one-legged exercise for 6 weeks
16581863|NCT02732990|Experimental|Exercise training - 2-legged cycling CHF|CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks
16581864|NCT02732990|Experimental|Exercise training - CHF|CHF Patients will train high intense one-legged exercise for 6 weeks
16581865|NCT02732977|Other|expert system|System for predicting patients heart failure, that can predict response to a personalized treatment from the analysis of a set of data (images, physiological data , treatment outcomes ) .
16581866|NCT02732964|No Intervention|Control|baseline hemodynamics and anxiety screen; no music
16581867|NCT02732964|Experimental|Pandora Music|A study investigator will create a station in the Pandora® music application based on the patient's preferred music genre or artist.
16581868|NCT02732964|Experimental|Mozart Music|A study investigator will turn on a playlist of pre-selected Mozart music.
16581869|NCT02732951|Experimental|BI 1026706|
16581870|NCT02732951|Active Comparator|Placebo|
16581871|NCT02732938|Experimental|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing
~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
16581872|NCT02732925|Sham Comparator|Arm 1 - Sham Procedure|"Sham Procedure & Conservative Treatment
~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.
~Below is a list of the conservative management they will be managed by their Doctor:
~Bisphosphonates
~Pain relief
~Systemic chemotherapy for Myeloma disease
~Bed rest
~Radiotherapy
~Physiotherapy
~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used."
16581873|NCT02732925|Active Comparator|Arm 2 - Balloon Kyphoplasty|"Balloon Kyphoplasty & Conservative Treatment - Interventional Arm
~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.
~Below is a list of the conservative management they will be managed by their Doctor:
~Bisphosphonates
~Pain relief
~Systemic chemotherapy for Myeloma disease
~Bed rest
~Radiotherapy
~Physiotherapy
~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used."
16581874|NCT02732912|Active Comparator|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
16581875|NCT02732912|Experimental|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
16581876|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
16581877|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
16581878|NCT02732886|Experimental|Betafoam®|Brand name: Betafoam® Generic term: Wound dressing with 3% povidone iodine
16581879|NCT02732886|Active Comparator|Medifoam®|Brand name: Medifoam® Generic term: Wound dressing
16581880|NCT02732873|Experimental|FibroFix|
16581881|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
16581882|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
16581883|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
16581884|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 30)
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
16581885|NCT02732847|Other|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
16581886|NCT02732847|Other|Usual|usual date
16581887|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
16581888|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
16581889|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
16581890|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
16581891|NCT02732821||Gastric Per Oral Endoscopic Myotomy|All patients presenting with Gastroparesis will undergo Per oral endoscopic gastric myotomy
16581892|NCT02732808|Experimental|poor ovarian responder|The women with diagnose of poor ovarian responder after IVF/ICSI treatments underwent ovulation stimulation and egg collection in the same IVF/ ICSI cycle ( Shanghai protocol)
16581893|NCT02732795|Experimental|Morphine dosing|Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
16581894|NCT02732782|Experimental|Isometric exercise|Isometric exercise (90% maximum voluntary contraction (MVC), 12 weeks, 4 times a week, 5 sets of 4 repetitions a 3 seconds)
16581895|NCT02732782|Active Comparator|Eccentric exercise|"Eccentric training (Alfredson approach, 12 weeks, 2 sets per day with extended and two sets per day with bended knee, 15 repetitions per set)"
16581896|NCT02732782|No Intervention|Control|Control, no intervention
16581897|NCT02732769|Active Comparator|Group treated by radiosurgery with stereotaxic frame|Subjects will receive a radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)
16581898|NCT02732769|Experimental|Group treated by radiosurgery with the thermoformed mask|Subjects will receive a radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®
16581899|NCT02732756|Experimental|Sleep Restriction|The Sleep Restriction condition will allow 6.5 hours in bed, which in previous research results in an average of 6.1-6.3 hours of nightly sleep. This condition reflects a realistic dose of sleep restriction (similar to the school-night sleep of 15-20% of healthy adolescents) that has been shown to be feasible and to induce daytime sleepiness, inattention, and irritability/moodiness in typically developing adolescents.
16581900|NCT02732756|Experimental|Sleep Extension|The Sleep Extension condition will allow adolescents to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep), which (a) is how long adolescents sleep during controlled trials of sleep satiation and naturally on non-school nights, (b) has been shown to result in a well-rested state, and (c) matches clinical recommendations for adolescents.
16581901|NCT02732743|Other|Food Supplement Physiomanna® Baby|Dosage: 1g/kg body
16581902|NCT02732730|Experimental|PrEP Acceptor|"For those women who choose to accept PrEP (Truvada), the following adherence support package will be provided:
~Cognitive Behavioral Theory adherence support sessions
~Two-way SMS communications
~Optional monthly adherence support clubs Drug level counseling for those randomized to that extra intervention (1:1)"
16581903|NCT02732730|No Intervention|PrEP Decliner|Standard of care
16581904|NCT02732717||abnormal ultrasound index|twin pregnancy with abnormal ultrasound index
16581905|NCT02732717||normal ultrasound index|twin pregnancy with normal ultrasound index
16581906|NCT02732704|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System
16581907|NCT02732691|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
16581908|NCT02732678|Experimental|Cohort of a dose of Propranolol 80 mg/day|
16581909|NCT02732678|Experimental|Cohort of a dose of Propranolol 120 mg/day|
16581910|NCT02732678|Experimental|Cohort of a dose of Propranolol 160 mg/day|
16581911|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
16581912|NCT02732626|Active Comparator|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
16581913|NCT02732626|Experimental|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
16581914|NCT02732613|Experimental|Actual weight Group|Patients in Actual weight Group: The selection of Laryngeal Mask Airway classic will be based on actual body weight, followed the recommendations of manufacturer (size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
16581915|NCT02732613|Experimental|Ideal weight Group|Patients in Ideal weight Group: The selection of Laryngeal Mask Airway classic will be based on ideal body weight, followed the recommendations of manufacturer ( size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
16581916|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
16581917|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
16581918|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
16581919|NCT02732574|Experimental|OPEP Device Treatment|Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
16581920|NCT02732574|Sham Comparator|SHAM Device|Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
16581921|NCT02732561|Sham Comparator|Sham Device|Sham device
16581922|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
16581923|NCT02732548|Active Comparator|NPWT Only|Study subjects who are randomized to the control arm will be treated with Negative Pressure Wound Therapy (NPWT) and additional standard care treatments. No cellular or acellular biological tissue scaffold will be allowed for subjects in this study arm for the first 6 weeks of the study. Subjects who are randomized to this arm and who do not experience at least a 50% surface area reduction of the study wound by the 6 week study visit will have the option to cross over into the NPWT + MIRODERM treatment arm.
16581924|NCT02732548|Experimental|NPWT + MIRODERM|Subjects in this arm will receive NPWT and standard care, plus application(s) of the MIRODERM product.
16581925|NCT02732522|Experimental|Misoprostol sublingual|
16581926|NCT02732522|Active Comparator|Misoprostol vaginal|
16581927|NCT02732509||Lean|Body mass index less than 25 kg/m2
16581928|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
16581929|NCT02732496|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
16581930|NCT02732496|Placebo Comparator|Youth Appropriate Online Games|Engaging games not designed to improve cognition
16581931|NCT02732483|Experimental|Endo-Clot(TM)|
16581932|NCT02732470|Experimental|Qi Gong|The effect of Qi Gong training on quality of life in patients with systemic lupus erythematosus
16581933|NCT02732444||COPD and APD patients in LTOT|• COPD and APD patients in LTOT
16581934|NCT02732444||Healthy Control|• Patients without significant cardiorespiratory disease, matched for age and body mass index with the other group.
16581935|NCT02732431|Other|trisomy 21|Parents will complete two sleep symptom questionnaires (PSQ-SRBD and CSHQ) and children will be evaluated by a paediatric pulmonologist and allergist with skin allergy test. An Ear, Nose and Throat specialist will complete two questionnaires (CAS-15 and SCR) carrying a nasopharyngoscopy. Then, children will perform an overnight polysomnography in the Department of Paediatric Functional Investigations of University Hospital in Nice.
16581936|NCT02732418|Experimental|Depo-Provera CI 45 mg|a single subcutaneous (SC) injection of 45 mg/0.3 mL
16581937|NCT02732418|Experimental|Depo-Provera CI 75 mg|a single subcutaneous (SC) injection of 75 mg/0.5 mL
16581938|NCT02732418|Experimental|Depo-Provera CI 105 mg|a single subcutaneous (SC) injection of 105 mg/0.7 mL
16581939|NCT02732418|Active Comparator|Depo-subQ 104|a single subcutaneous (SC) injection of 104 mg/0.65 mL
16581940|NCT02732405|Experimental|MK5172 /MK8742|
16581941|NCT02732392|Experimental|lymphadenectomy|
16581942|NCT02732379|Experimental|Lavender Aromatherapy|Aromatherapy with lavender essential oil.
16581943|NCT02732379|Experimental|Rose Aromatherapy|Aromatherapy with rose essential oil
16581944|NCT02732379|Experimental|Ginger Aromatherapy|Aromatherapy with ginger essential oil
16581945|NCT02732379|Placebo Comparator|Placebo Aromatherapy|Aromatherapy with pure water
16581946|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
16581947|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
16581948|NCT02732353|Active Comparator|Minced beef|Minced beef
16581949|NCT02732353|Experimental|Hydrolyzed beef|Hydrolyzed beef
16581950|NCT02732340|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
16581951|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
16581952|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
16581953|NCT02732314|Experimental|Investigational OTC Cream|Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
16581954|NCT02732314|Placebo Comparator|Placebo Cream|Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
16581955|NCT02732314|Active Comparator|Cosmetic Eczema Cream|Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
16581956|NCT02732314|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor.
~Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions."
16581957|NCT02732288|Experimental|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
16581958|NCT02732288|Experimental|Healthy volunteers|Melatonin 3mg, orally, at 8pm
16581959|NCT02732275|Experimental|DS-3201b|
16581960|NCT02732262|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
16581961|NCT02732262|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
16581962|NCT02732262|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
16581963|NCT02732249|Active Comparator|Triple regimen group|Esomeprazole 20mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
16581964|NCT02732249|Experimental|Low metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg bid for 14 days
16581965|NCT02732249|Experimental|High metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
16581966|NCT02732223|Experimental|Functional treatment|Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.
16581967|NCT02732223|Placebo Comparator|Control treatment|Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets
16581968|NCT02732197||Sedation (S)|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
16581969|NCT02732197||No sedation (NS)|Parturients who did not receive any sedative agent after the spinal anesthesia performance.
16581970|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
16581971|NCT02732171|Other|Screening Bone Marrow Aspirate|All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs) by immunohistochemistry. The bone marrow sample is also used for other research tests.
16581972|NCT02732158|Experimental|Nutrition Products|Two servings per day of the sachet study product mixed with water; 1 carotenoid capsule per day
16581973|NCT02732145|Placebo Comparator|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
16581974|NCT02732145|Placebo Comparator|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
16581975|NCT02732145|Placebo Comparator|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
16581976|NCT02732145|Active Comparator|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
16581977|NCT02732132|Active Comparator|Ketamine and Midazolam|ketamine 1 mg/kg midazolam 0.1 mg/kg
16581978|NCT02732132|Experimental|Propofol and Fentanyl|propofol 1 mg/kg fentanyl 1 mcg/kg
16581979|NCT02732119|Experimental|Cohort A|Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
16581980|NCT02732119|Experimental|Cohort B|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
16581981|NCT02732119|Experimental|Cohort C|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
16581982|NCT02732119|Experimental|Group 1|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
16581983|NCT02732119|Experimental|Group 2|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
16581984|NCT02732093|Active Comparator|stellate block|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml of lidocaine 2% after routine induction of general anesthesia and before endotracheal intubation
16581985|NCT02732093|Placebo Comparator|control|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml normal saline (Na.Cl 0.9%) (control group) after routine induction of general anesthesia and before endotracheal intubation
16581986|NCT02732080|Experimental|Deferred coronary stenting|In this arm, after establishing TIMI -3 flow in infarct related artery with balloon angioplasty, patients will undergo stent implantation when coronary autoregulatory function was recovered (initial hyperemic flow was subsided and baseline resistance was increased). Recovery of the auto regulatory function will be determined by measuring microvascular flow and resistance. After stenting microvascular flow / resistance will continue to be monitored using pressure/flow sensor tipped guide wire until the completion of 1 hour follow up period.
16581987|NCT02732080|Active Comparator|Immediate stenting|In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
16581988|NCT02732054|Active Comparator|HIV-Group 1|Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, and 6
16581989|NCT02732054|Experimental|HIV-Group 2|Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, 2, and 6
16581990|NCT02732015|Experimental|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
16581991|NCT02732015|Active Comparator|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
16581992|NCT02732002|Experimental|OCBRA group.|This group of patients will follow the proposed methodological approach for work related injuries rehabilitation.
16581993|NCT02731989||study group|The surgeon will estimate the size difference between the undescended and the normally located testis. Independently the ultrasonographer will measure the true size of both testes in the study group.
16581994|NCT02731989||Control group|The same measurments will be done by the surgeon and the ultrasonographer on boys without cryptorchism.
16581995|NCT02731976|Experimental|GFD|After instruction of a dietician, participants adhered to a gluten-free diet for 4 weeks.
16581996|NCT02731963|Experimental|Mechanical bowel preparation|80 Patients who received mechanical bowel preparation with 4 packets of polyethylene glycol in 4 liters of water, 4 hours before intervention.
16581997|NCT02731963|No Intervention|No mechanical bowel preparation|81 Patients who received clear liquid diet 1 day before intervention.
16581998|NCT02731950|Active Comparator|A magnesium|"Consists of 20 patients:
~Each receive bupivacaine 0.125% with 5% magnesium sulfate by infusion through a small diameter multi-hole soft catheter generally used for epidural analgesia positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 hours postoperative. A bolus of 5 ml of the study solution will be injected in the catheter after aspiration test before connection to infusion pump that delivers continuous infusion pump that delivers continuous infusion at a fixed rate of 5 ml/h.
~postoperative : 25 µg fentanyl for breakthrough pain. placebo will be given in same intravenous instead of paracetamol and ketorolac of group B , to keep the investigator blinded"
16581999|NCT02731950|No Intervention|B control|"Consists of 20 patients:
~saline as placebo infusion through a small diameter multi-hole soft catheter positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 Postoperative pain control will be managed with 1gm paracetamol /6 hr, Ketorolac 30 mg every 8-12 hour .25 µg fentanyl for breakthrough pain."
16582000|NCT02731937|Other|GE Healthcare CT Revolution (CT scanner)|Each subject will be scanned twice: the first time will be the subjects' clinically indicated CT exam and the second scan will be performed on the GE Healthcare CT Revolution (CT scanner) both scans will will be obtained.
16582001|NCT02731924||Ultrasound for Appendicitis|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected appendicitis
16582002|NCT02731911||Ozurdex® (dexamethasone intravitreal implant)|Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
16582003|NCT02731885|Experimental|Fasted Conditions|50mg of ABX464 (two 25mg capsules) /Fasted
16582004|NCT02731885|Experimental|Fed Conditions|50mg of ABX464 (two 25mg capsules) /Fed
16582005|NCT02731872|Experimental|High Flow humidification system|In addition to their usual oxygen apparatuses, the treatment group will have an Airvo humidifier system installed in the home. The supplied oxygen flow will be entrained along with room air through the Airvo humidification system. this combined respiratory gas will then be warmed and humidified and delivered to the patient via a nasal cannula. The total respiratory gas flow rate will be between 20-25 l/min, depending on participant´s preference. Then the oxygen fraction is adjusted until the subjects target oxygen saturation levels are achieved.
16582006|NCT02731872|No Intervention|Standard oxygen therapy|The control group will continue receiving the standard oxygen therapy prescribed by the department
16582007|NCT02731859||EndoBarrier|All patients with EndoBarrier treatment
16582008|NCT02731846|Experimental|FF/UMEC/VI (100/62.5/25 mcg) + placebo|Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
16582009|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg|Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
16582010|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + placebo|Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
16582011|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
16582012|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
16582013|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
16582014|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
16582015|NCT02731807|Experimental|Dose A, B, C, D, E|All participants will receive all doses throughout the course of the study.
16582016|NCT02731807|Experimental|Dose D, E, C, B, A|All participants will receive all doses throughout the course of the study.
16582017|NCT02731807|Experimental|Dose C, D, E, A, B|All participants will receive all doses throughout the course of the study.
16582018|NCT02731807|Experimental|Dose E, D, C, B, A|All participants will receive all doses throughout the course of the study.
16582019|NCT02731794|Experimental|LVA group|LVA group: left ventricular assist group.
16582020|NCT02731794|Active Comparator|BiVA group|BiVA group: Biventricular assist group.
16582021|NCT02731768|Active Comparator|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively. They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
16582022|NCT02731768|Experimental|Social support-enhanced|Participants will receive the same intervention components as the Standard group, as well as two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
16582023|NCT02731755|Active Comparator|Oat intervention|67.7g oatflake and 22.5g oatbran concentrate - single intake (mixed with water)
16582024|NCT02731755|Placebo Comparator|Control|39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder, 6.5g cellulose and mixed with water
16582025|NCT02731742|Experimental|Dose A MK-1966 + Dose A SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
16582026|NCT02731742|Experimental|Dose A MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
16582027|NCT02731742|Experimental|Dose B MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
16582028|NCT02731742|Experimental|Dose C MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
16582029|NCT02731742|Experimental|Part B Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
16582030|NCT02731742|Experimental|Part C Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
16582031|NCT02731729|Experimental|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
16582032|NCT02731729|Experimental|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
16582033|NCT02731716|Experimental|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
16582034|NCT02731716|Experimental|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
16582035|NCT02731716|Experimental|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
16582036|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
16582037|NCT02731690|Experimental|Open Label UX001, 6g/day|
16582038|NCT02731677|Experimental|Experimental|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
16582039|NCT02731677|No Intervention|Control|The control group no suffered intervention.
16582040|NCT02731664|Experimental|GLP-1|Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
16582041|NCT02731664|Placebo Comparator|Control|Intravenous saline
16582042|NCT02731651|Active Comparator|Open Hysterectomy|Open hysterectomy was performed with taking one of the ovaries at the beginning and the other ovary was removed at the end of the surgery.
16582043|NCT02731651|Active Comparator|LaparoscopicAssistedVaginalHysterectomy|Surgery in Group 2 (LAVH): Laparoscopic Assisted Vaginal Hysterectomy was performed with taking one of the ovary at the beginning of the procedure and the other ovary was removed at the end of the surgery.
16582044|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
16582045|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
16582046|NCT02731625|Experimental|Kettlebell Training|Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
16582047|NCT02731625|Active Comparator|Army Physical Readiness Training|Army Physical Readiness Training (PRT) per Army Field Manual 7-22
16582048|NCT02731612|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
16582049|NCT02731612|Placebo Comparator|Placebo|Placebo added to current treatment for 6 weeks
16582050|NCT02731599|Experimental|treadmill training|20-minutes treadmill training per day, 6 times a week, for 4 weeks
16582051|NCT02731586|Experimental|osseointegration using Allogenic MSC's|Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA.
16582052|NCT02731573|Experimental|Treatment arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.
16582053|NCT02731573|Other|Control arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.
16582054|NCT02731560|Other|Single Arm|Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs
16582055|NCT02731547|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
16582056|NCT02731547|No Intervention|Control group|
16582057|NCT02731534|Experimental|Z-213|
16582058|NCT02731534|Active Comparator|Saccharated Ferric Oxide|
16582059|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
16582060|NCT02731508|Experimental|True stimulation|True repetitive bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, daily 20 minutes for 10 sessions
16582061|NCT02731508|Sham Comparator|Sham stimulation|Repetitive bihemispheric transcranial direct current stimulation, as the experimental stimulation condition but only for 30 seconds
16582102|NCT02731274|Experimental|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
16582103|NCT02731274|No Intervention|Control|
16582062|NCT02731495|Experimental|EGCG|Participants were randomly divided based on age, sex and severity of TBI in two groups. Randomization lists was computer-generated by a statistician and participants, project managers and employees at the clinic are completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients received EGCG supplement was in the form of 400 mg oral capsules with a purity of 80% catechin. EGCG powder of each capsule was dissolved in 10 ml deionized water and given to patients via gavage (1 capsule per day) for a week.
16582063|NCT02731495|Placebo Comparator|Placebo|Placebo group only received 10 ml of deionized water via gavage for a week.
16582064|NCT02731482|Experimental|Training Group|Patients with bronchiectasis in home-based pulmonary rehabilitation
16582065|NCT02731482|Active Comparator|Control Group|Patients with bronchiectasis in usual care and recommendations for performing exercises
16582066|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
16582067|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
16582068|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
16582069|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
16582070|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
16582071|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
16582072|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
16582073|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
16582074|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
16582075|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
16582076|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
16582077|NCT02731456|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude.
16582078|NCT02731443||ESx|Epilepsy patients undergoing elective surgical resection of brain tissue; study group: epilepsy surgery=ESx.
16582079|NCT02731443||DE|Epilepsy patients undergoing elective depth electrodes insertion in general anesthesia; control group: depth electrodes=DE.
16582080|NCT02731430|Active Comparator|group I: morphine group|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
16582081|NCT02731430|Placebo Comparator|group II: control group|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
16582082|NCT02731417|Experimental|Urinary retention-group 1|For women with post partum urinary retention designated for experimental treatment.
16582083|NCT02731417|Active Comparator|Urinary retention-group 2|For women with post partum urinary retention designated for current departmental protocol treatment.
16582084|NCT02731404|Other|IPPV ventilation|standard intermittent positive pressure ventilation in patients undergoing laparoscopic cholecystectomy
16582085|NCT02731404|Other|HFJV ventilation|high frequency jet ventilation in patients undergoing laparoscopic cholecystectomy
16582086|NCT02731391|Experimental|Mesh repairment|patients undergoing pelvic floor Reconstruction using mesh
16582087|NCT02731391|Active Comparator|Tradition Neoplasty|patients undergoing traditional surgical approaches
16582088|NCT02731378|Experimental|EPO plus sustained iron dextran|Group 1, EPO treatment at the original dose plus IV iron dextran 200 mg every three weeks (Q3W) for 15 weeks
16582089|NCT02731378|Experimental|EPO plus aggressive iron dextran|Group 2, EPO treatment at the original dose plus IV iron dextran 100 mg, twice a week (BIW) for five weeks
16582090|NCT02731378|Active Comparator|Double EPO|Group 3, the control group, doubling the EPO dose without preplanned iron supplementation
16582091|NCT02731365|Experimental|DBS LFP Activa PC+S|The study aims at testing a slightly modified device (battery) that is similar to the approved system that has the potential of offering future patients a closed loop system with automatic adjustments of stimulation. The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming.
16582092|NCT02731352|Experimental|iodine-131 Refractory/Resistant Differentiated Thyroid Cancer|iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer
16582093|NCT02731339|Experimental|Women with Urinary incontinence|
16582094|NCT02731339|Experimental|Women without Urinary incontinence|
16582095|NCT02731326|Experimental|iHEART|Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
16582096|NCT02731326|No Intervention|Usual Care|Participants will continue with usual care with their physician.
16582097|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
16582098|NCT02731300|Active Comparator|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
16582099|NCT02731300|Sham Comparator|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
16582100|NCT02731287|Experimental|Timolol|Timolol maleate 0.5% topical solution; 50% of the patients treated (randomized)
16582101|NCT02731287|Placebo Comparator|Placebo|Saline topical solution; 50% of the patients treated (randomized)
16582104|NCT02731261|Experimental|Experimental|
16582105|NCT02731261|No Intervention|Control|
16582106|NCT02731235|Other|Control|Prophylactic stroke medication and recommendations for lifestyle changes
16582107|NCT02731235|Active Comparator|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
16582108|NCT02731209|Experimental|catheter insertion for 2 weeks|50 randomized patients that will do urodynamic urinary examination and will be inserted urinary catheter for 2 weeks
16582109|NCT02731209|No Intervention|follow up|50 randomized patients that will do urodynamic urinary examination and will be regularly followed by nephrologist
16582110|NCT02731196|Experimental|Early exercise intervention group|Education, stabilization and neurodynamic level one exercises will be provided to the intervention group within one to two weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will be provided with education, stabilization and neurodynamic level two exercises and a pedometer to monitor step count between week 4 and week 10 following the surgery.
16582111|NCT02731196|Active Comparator|Late exercise intervention group|Education, stabilization and neurodynamic level one and two exercises will be provided to the active comparator group within 4-6 weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will also be given instructions and a pedometer to monitor step count between week 4 and week 10 following the surgery.
16582112|NCT02731183|Experimental|FMT|Patients included will receive standard FMT, and then will be followed up for 8 weeks.
16582113|NCT02731170|Experimental|rehabilitation treatment (MIRT)|MIRT consists of a 4-week physical therapy. daily sessions are subdivided in: motor treatment (2 hour), occupational therapy (1 hour) and speech Therapy (1 hour)
16582114|NCT02731157|Experimental|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
16582115|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
16582116|NCT02731144|Experimental|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
16582117|NCT02731144|Active Comparator|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
16582118|NCT02731131|Experimental|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
16582119|NCT02731131|Experimental|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
16582120|NCT02731118|Experimental|Placebo and Salovum|6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
16582121|NCT02731118|Experimental|Salovum and placebo|6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14
16582122|NCT02731105|Active Comparator|Arm 1|Acnatac® Gel on left face and Epiduo® Gel on right face once daily for three weeks
16582123|NCT02731105|Active Comparator|Arm 2|Epiduo® Gel on left face and Acnatac® Gel on right face once daily for three weeks
16582124|NCT02731092|Experimental|Lactoferrin 100 mg/kg|100 mg/kg enteral administration daily for 30 days
16582125|NCT02731092|Experimental|Lactoferrin 200 mg/kg|200 mg/kg enteral administration daily for 30 days
16582126|NCT02731092|Experimental|Lactoferrin 300 mg/kg|300 mg/kg enteral administration daily for 30 days
16582127|NCT02731079|Active Comparator|Covidien|Group that will have sleeve gastrectomy performed using the Covidien iDrive powered stapler with absorbable polymer membrane staple line reinforcement.
16582128|NCT02731079|Active Comparator|Ethicon|Group that will have sleeve gastrectomy performed using the Ethicon Echilon powered stapler with absorbable polymer membrane staple line reinforcement.
16582129|NCT02731066|Experimental|High pro, carbo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
16582130|NCT02731066|Experimental|Standard pro, carbo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
16582131|NCT02731066|Experimental|High pro, placebo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
16582132|NCT02731066|Experimental|Standard pro, placebo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
16582133|NCT02731053|Experimental|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
16582134|NCT02731053|No Intervention|Control|Participants will receive a brochure describing the nature, causes, and consequences of depression, as well as available prevention/treatment options
16582135|NCT02731040||Controls|Women who are/have been on bisphosphonate therapy for osteoporosis who have not suffered an atypical femoral fracture
16582136|NCT02731040||Fracture Group|Women who are/have been on bisphosphonate therapy for osteoporosis who have suffered an atypical femoral fracture
16582137|NCT02731027||Healthy Controls|
16582138|NCT02731027||Participants with Spinal Cord Injury|
16582139|NCT02731014|Experimental|Dry Needling Group|Dry Needling, Manual Therapy, and Exercise.
16582140|NCT02731014|Sham Comparator|Sham Dry Needling Group|Sham Dry Needling, Manual Therapy, and Exercise.
16582141|NCT02731001|Experimental|Proton therapy|Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.
16582142|NCT02731001|Active Comparator|Photon therapy|Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.
16582143|NCT02730988|Experimental|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 & 2 & 1 Plan™, a 1200 calorie, high protein diet targeting ~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
16582144|NCT02730988|Active Comparator|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
16582145|NCT02730975|Experimental|AA Reduced dose-normal diet (A)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a standard breakfast
16582146|NCT02730975|Experimental|AA reduced dose-fat diet (B)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a fat breakfast
16582147|NCT02730975|Active Comparator|AA normal dose-fasting conditions (C)|Abiraterone acetate at approved dose of 1000 mg po daily in cycles of 28 days administered in fasting conditions
16582148|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
16582149|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
16582150|NCT02730949|Experimental|1 g D-chiro-Inositol + 400 mcg Folic Acid|1 g D-chiro-Inositol + 400 mcg folic acid once daily
16582151|NCT02730949|Active Comparator|400 mcg folic|400 mcg folic acid only once daily
16582152|NCT02730936|Experimental|Antimicrobial Hernia Repair Device|Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields.
16582153|NCT02730923|Experimental|Arm A: AZD2014 plus anastrozole|
16582154|NCT02730923|Active Comparator|Arm B: anastrozole alone|
16582155|NCT02730910|Experimental|Purple Wheat Crackers|Bran-enriched purple wheat wholegrain crackers served in 120 g portion.
16582156|NCT02730910|Experimental|Purple Wheat Granola Bars|Bran-enriched purple wheat wholegrain granola bars served in 160 g portion.
16582157|NCT02730897||VATS|Patients operated by means of minimal invasive technique (VATS or roboticVATS)
16582158|NCT02730897||Open|Patients operated by means of open thoracotomy
16582159|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
16582160|NCT02730871|Experimental|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
16582161|NCT02730871|Placebo Comparator|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
16582162|NCT02730858|Experimental|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;
~-- Standard oncology care with palliative care."
16582163|NCT02730858|Active Comparator|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;
~-- Standard oncology care"
16582164|NCT02730845|Active Comparator|Intra-articular dexmedetomidine|Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
16582165|NCT02730845|Placebo Comparator|Intravenous dexmedetomidine|patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
16582166|NCT02730832|Experimental|Patients with schizophrenia|
16582167|NCT02730819|Experimental|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
16582168|NCT02730806|Experimental|NLP PTSD intervention protocol|Behavioral intervention (NLP) - intervention method will be 5 weekly personal therapy and counseling sessions with a certified therapist specializing in NLP, implementing the NLP PTSD protocol, such as Visual Kinesthetic Dissociation (VKD) behavioral technique for PPPTSD cases
16582169|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
16582170|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
16582171|NCT02730780|Other|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
16582172|NCT02730780|Other|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
16582173|NCT02730767|Experimental|Intervention Group|Partially supervised exercise intervention: Survivors in the intervention group will be asked to add at least 2.5 hours of intense physical activities per week. These should include at least 30 min of strength building exercises and 2 hours of aerobic exercises per week. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
16582174|NCT02730767|No Intervention|Control Group|The control group will keep their physical activity level constant over the 1 year of the study. Thereafter, they will have the opportunity to receive the same intervention than the intervention group had received (off-trial) to benefit in the same way from an active lifestyle.
16582175|NCT02730741|Experimental|Lcr restituo® sachet and placebo|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening) and the placebo at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening).
16582176|NCT02730741|Experimental|Lcr restituo® sachet|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
16582177|NCT02730741|Placebo Comparator|Placebo|The placebo at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
16582178|NCT02730728|Active Comparator|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
16582179|NCT02730728|Active Comparator|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
16582180|NCT02730728|Active Comparator|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
16582181|NCT02730715||Thymoglobulin|blood specimen collection
16582182|NCT02730715||Basiliximab|blood specimen collection
16582183|NCT02730689|Experimental|A group|DP-R207 >> rosuvastatin+ezetimibe
16582184|NCT02730689|Active Comparator|B group|rosuvastatin+ezetimibe >> DP-R207
16582185|NCT02730676||Electronic Cigarette #1|VUSE® Original Digital Vapor Cigarettes (29 mg nicotine)
16582186|NCT02730676||Electronic Cigarette #2|VUSE® Menthol Digital Vapor Cigarettes (29 mg nicotine)
16582187|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
16582188|NCT02730650|Experimental|Platelet Rich Therapy|Each subject will receive six injections of Platelet Rich Plasma (PRP) at designated points on each side of their face (twelve total). Injection points are spaced evenly across the inferior border of the cheek and mid-cheek, and are consistent on each patient. Patients will receive a post-injection phone call within 48 hours of the procedure. Photographs will be taken at two time points as part of the research to serve as a point of comparison before and after platelet rich plasma. Patients will receive the Global Aesthetic Improvement Scale amd tje Face-Q Questionnaire 1 month post-op
16582189|NCT02730637|No Intervention|Standard care|Patients with elevated biomarkers receive a standard treatment.
16582190|NCT02730637|Active Comparator|Interventional care|Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.
16582191|NCT02730624|Experimental|piperacillin/tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h
16582192|NCT02730611||Patients|Patients with morbid obesity and vertical sleeve gastrectomy
16582193|NCT02730598|Experimental|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
16582194|NCT02730598|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
16582195|NCT02730585||Acute appendicitis|all patients admitted to our hospital with a clinically suspected acute appendicitis.
16582196|NCT02730572||Concerta to authorized generic (AG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to AG formulation will be observed.
16582197|NCT02730572||Concerta to equivalent generic (EG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to EG formulation will be observed.
16582198|NCT02730559|Experimental|Intervention Group|Group A (Parent-adolescent dyads)
16582199|NCT02730559|Active Comparator|Control Group - Active Comparator|Group B (Adolescents only)
16582200|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
16582201|NCT02730533|Active Comparator|Control group|No PPI treatment should given after the initial allocation. Patient will be admitted, and ESD will be performed. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
16582202|NCT02730533|Experimental|Esomeprazole group|Esomeprazole should start as soon as possible after the initial allocation. During the 7 days of p.o. treatment, patient will be admitted, and ESD will be performed as soon as completing the p.o. treatment. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
16582203|NCT02730520||Immuno-allergology patients|Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.
16582204|NCT02730507|Experimental|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
16582205|NCT02730507|Active Comparator|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
16582206|NCT02730494|Active Comparator|Lcr Regenerans® vaginal capsule|Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
16582207|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 3 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
16582208|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 4 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
16582209|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 5 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
16582210|NCT02730481|Experimental|ORAXOL|"Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules
~Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
16582211|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
16582212|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
16582213|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
16582214|NCT02730442|Experimental|Single dose F901318 with fluconazole|AUC0-t for F901318 will be assessed before and after 5 days of treatment with fluconazole oral
16582215|NCT02730429|Placebo Comparator|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.
~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
16582216|NCT02730429|Experimental|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.
~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.
~Letrozole is administered as standard of care in both study arms."
16582217|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
16582218|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
16582219|NCT02730403||Opioid Use Disorder Patients|
16582220|NCT02730390||Probucol Tablets|Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).
16582221|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
16582222|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
16582223|NCT02730364|Experimental|Theraflu night powder|Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
16582224|NCT02730364|No Intervention|No Treatment|Participants in this arm will not receive any medication
16582225|NCT02730351|Experimental|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
16582226|NCT02730351|Experimental|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
16582227|NCT02730338|Active Comparator|Arm A: Supervised exercise group|Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support
16582228|NCT02730338|Other|Arm B: Self directed exercise group|Self directed exercise and psychosocial support group
16582229|NCT02730325|Active Comparator|SBI 10 g BID|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams twice per day
16582230|NCT02730325|Placebo Comparator|Placebo BID|Placebo
16582231|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
16582232|NCT02730299|Experimental|NiCord® (omidubicel)|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:
~ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))
~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.
~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
16582233|NCT02730299|Active Comparator|Unmanipulated CBU(s)|
16582234|NCT02730273|Experimental|Trial Nasal Mask|Participants to use nasal mask in-home for a week and one night in lab overnight polysomnography.
16582235|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
16582236|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
16582292|NCT02729857|Active Comparator|Healthy|Subjects with no chronic diseases receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
16582237|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
16582238|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
16582239|NCT02730221||Patients admitted during measurement 1|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period before the implementation of a new electronic patient data management system
16582240|NCT02730221||Patients admitted during measurement 2|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period after the implementation of a new electronic patient data management system
16582241|NCT02730208|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
16582242|NCT02730208|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
16582243|NCT02730195|Experimental|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
16582244|NCT02730182|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
16582245|NCT02730169|Experimental|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
16582246|NCT02730169|Experimental|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
16582247|NCT02730169|Experimental|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
16582248|NCT02730169|Placebo Comparator|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
16582249|NCT02730156|Experimental|Altitude exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
16582250|NCT02730143|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure after 6 days at low altitude
16582251|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
16582252|NCT02730117|Experimental|Early renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, starting within 12 hours after randomization
~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
16582253|NCT02730117|Placebo Comparator|Conventional renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, after the patients reached at least one of the following criteria;
~pH < 7.15 or serum HCO3 < 15 mEq/L
~serum K >= 6 mEq/L
~Signs of volume overload or P/F ratio < 200
~BUN > 60 mg/dL
~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
16582254|NCT02730104||Cohort A: Patients with small bowel NET|Patients with small bowel NET (including appendiceal NETs)
16582255|NCT02730104||Cohort B: Patients with gastric NET|Patients with gastric NET (gastroduodenal)
16582256|NCT02730104||Cohort C: Patients with pancreatic NET|
16582257|NCT02730104||Cohort D: Patients with colorectal NET|Patients with colorectal NET (this includes mid-gut)
16582258|NCT02730104||Cohort E: Unknown primary tumor|
16582259|NCT02730091|Active Comparator|Letrozole or anastrozole|Letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
16582260|NCT02730091|Experimental|Vinorelbine + Anastrozole or letrozole|Oral vinorelbine 50 mg (1 soft capsule of 30 mg and 1 soft capsule of 20 mg) three times a week every ( Monday, Wednesday and Friday) before lunch and letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
16582261|NCT02730078|Active Comparator|Attention-meetings (AG)|Attention-control
16582262|NCT02730078|Experimental|VEMOFIT (VG)|Personal value exploration, disease education, emotional skills and goal setting.
16582263|NCT02730065|Active Comparator|Structured Aerobic Dance Training Group|Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
16582264|NCT02730065|Placebo Comparator|Stretching plus education|Participants in the control group will receive a weekly 3-hour group-based (group of 5 participants) programme containing stretching exercise, stress reduction and health education on dementia and stroke prevention for 6 months. The programme consists of low-intensity seated stretching, psychoeducation on stress management, various relaxation methods with practice as well as education on the causes, identification, treatment and prevention of stroke and dementia. Benefits of physical exercise will also be discussed but will its weight will be evenly balanced with other forms of evidence-based preventive strategies.
16582265|NCT02730052|Active Comparator|Omron 9200T without Telemonitoring|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
16582266|NCT02730052|Experimental|Omron 9200T plus Telemonitoring|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
16582293|NCT02729844||Neolifes Heart|All premature infants, admitted at the neonatal intensive care unit (NICU) of the University Medical Centre Groningen, born <30 weeks or birth weight < 1000 gram, who participate in NeolifeS
16582267|NCT02730039||Cancer Care Providers|"Provider will attend a MCPT two-day intensive workshop that will include:
~Didactic Components
~Experiential Exercises
~Simulated patient role plays with actors
~Provider completes MCPT Workshop Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)
~MCP Core Competency Trainer rated Assessment
~MCP Pre & Post Workshop Knowledge Assessment
~MCPT Session Evaluation Assessment Provider will participate in training follow-up calls & webinars for approximately 6 -12 months following completion of MCPT workshop.
~Provider will have ongoing access to MCPT Website with a discussion board, training resources and materials for clinical care.
~Provider will complete follow-up assessment at 3, 6, 9, & 12 months post-training
~Training Update
~Goal Evaluation Form
~MCP Core Competency Self-Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)"
16582268|NCT02730026|Experimental|Surgery with Ketoprofen|Fifty healthy volunteers underwent removal one of lower third molar, will be treated to control pain, swelling and trismus with ketoprofen 100 mg
16582269|NCT02730026|Experimental|Surgery with Ketoprofen and Omeprazole|Fifty healthy volunteers underwent removal the other lower third molars, will be treated to control pain, swelling and trismus with ketoprofen 200 mg associated with Omeprazole 20 mg
16582270|NCT02730013|Experimental|Square Stepping Exercise|Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
16582271|NCT02730013|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
16582272|NCT02730000|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
16582273|NCT02730000|Experimental|ART with Riva Self Cure|Occlusal-proximal restoration in primary molars using Riva Self Cure from SDI, encapsulated, pre-dosed and mechanized handling.
16582274|NCT02729987|Experimental|Minimum Support Group (MSG)|Intervention group with 8 week access to the online stress management programme with minimal support from a coach (WorkGuru).
16582275|NCT02729987|Experimental|Discussion Group|Intervention group with 8 week access to the online stress management programme with minimal support from a coach, plus access to an online facilitated messaging board (WorkGuru).
16582276|NCT02729987|No Intervention|Waiting List Control (WLC)|Control group with access to the intervention after 16 weeks
16582277|NCT02729974|Experimental|ROTEM|Participants randomized to this arm will have rapid testing of hematocrit and clotting function every 30 minutes during the hysterectomy portion of their surgery for placenta accreta, with transfusion of blood products based on defined abnormalities in these tests.
16582278|NCT02729974|Active Comparator|Standard treatment|Participants randomized to this arm will have standard visual assessment of blood loss and standard laboratory studies to assess blood count and clotting function when indicated during the hysterectomy portion of their surgery for placenta accreta. Transfusion of blood products will be based on abnormalities of these test results.
16582279|NCT02729961|Experimental|Treatment (brentuximab vedotin, ceritinib)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive ceritinib PO QD on days 8-21 of course 1 and on days 1-21 for all subsequent courses. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
16582280|NCT02729948|Experimental|Screening (TCE)|Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
16582281|NCT02729935|Experimental|Parecoxib|40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
16582282|NCT02729935|Placebo Comparator|Placebo|An equal volume of saline
16582283|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
16582284|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
16582285|NCT02729896|Experimental|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
16582286|NCT02729896|Experimental|Expansion Phase|For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1 and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months (during maintenance treatment for FL participants).
16582287|NCT02729896|Experimental|Safety Run-In Phase|For DLBCL, during the induction treatment Cycles 1-6 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1.
16582288|NCT02729883|Experimental|Supportive care (Take the Fight)|Patients receive patient navigation via strategists from the Take the Fight for 8 weeks. Patients also complete interviews regarding perceived physical, logistical, psychosocial, and informational challenges experienced prior to meeting with strategists/navigators and how challenges were addressed by navigator or others, perceived benefits or limitations of navigator assistance. Strategists also complete interviews regarding their perceptions on how patients benefited from participation, challenges patients experienced that were directly or indirectly related to their cancer diagnosis and treatment, how these concerns were addressed, barriers to addressing these concerns, and patient health literacy.
16582289|NCT02729870||Oral Glucose Gel|This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
16582290|NCT02729870||Oral Placebo Gel|The group will consist of participants ages 1 - 7. The subjects who are less than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3- 7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
16582291|NCT02729857|Experimental|Familial hypercholesterolemia|Subjects diagnosed with familial hypercholesterolemia receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
16582294|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
16582295|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
16582296|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
16582297|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
16582298|NCT02729805|Placebo Comparator|Saline|A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
16582299|NCT02729805|Active Comparator|Ketamine 0.5mg/kg|A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
16582300|NCT02729805|Experimental|Ketamine 0.75mg/kg|A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
16582301|NCT02729792|Experimental|Single site rTMS|"Each treatment session will consist of:
~1200 pulses of iTBS over a posterior target location followed by a 60 minute interval, then 1200 pulses of iTBS over an anterior target location."
16582302|NCT02729792|Active Comparator|Dual site rTMS|"Each treatment session will consist of:
~600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location followed by a 60 minute interval, then 600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location."
16582303|NCT02729779|Experimental|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
16582304|NCT02729779|Active Comparator|Aerobic Group|The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
16582305|NCT02729766|Active Comparator|Empagliflozin 25mg Tbl|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
16582306|NCT02729766|Placebo Comparator|Placebo P-Tablet|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
16582307|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
16582308|NCT02729753|Other|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
16582309|NCT02729740|Other|Penumbra Smart System|
16582310|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
16582311|NCT02729714|Active Comparator|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
16582312|NCT02729714|Placebo Comparator|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
16582313|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
16582314|NCT02729688|Active Comparator|ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
16582315|NCT02729688|Active Comparator|customized pressure guide bandage|Bandaging was applied by spiral methods. Three customized pressure guide elastic bandage were applied by stretching until the elliptical shape marker in the bandage turned into circular shape with 50% overlapping from foot to just below knee level.
16582316|NCT02729675|Experimental|Access Intervention|Worksites in this condition received weekly Fruit and Vegetable markets
16582317|NCT02729675|Experimental|Enhanced Intervention|Worksites in this condition received weekly Fruit and Vegetable markets and Educational Interventions including Campaigns, Newsletters, DVDs, A Website, and Chef Demonstrations
16582318|NCT02729675|Active Comparator|Comparison Intervention|Worksites in this condition received Stress and Physical Activity Interventions
16582319|NCT02729662|Other|Patients with ADPKD|This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.
16582320|NCT02729649|Experimental|ArmAssist therapy|The group will be treated with ArmAssist robot therapy.
16582321|NCT02729649|Active Comparator|Conventional therapy|The group will be treated with conventional therapy.
16582322|NCT02729649|Active Comparator|Extended Conventional therapy|The group will be treated with extended conventional therapy.
16582323|NCT02729636|Experimental|FES:a|The group will be treated with multipad electrical stimulation device.
16582324|NCT02729636|Active Comparator|control|The group will be treated with conventional treatment.
16582325|NCT02729623|Experimental|Single CannaHALER dose 10 ± 0.1 mg|Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
16582326|NCT02729623|Experimental|Single CannaHALER dose 15 ± 0.1 mg|Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
16582327|NCT02729623|Experimental|Single CannaHALER dose 20 ± 0.1 mg|Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
16582328|NCT02729623|Experimental|Single CannaHALER dose 25 ± 0.1 mg|Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
16582329|NCT02729610|Active Comparator|DLT group|In this arm, patient will be intubated with a double lumen endotracheal tube
16582330|NCT02729610|Experimental|BB group|In this arm, patient will be intubated with an endobronchial blocker
16582331|NCT02729597||Myotonic dystrophy type 1 patients|"Patients with myotonic dystrophy type 1 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.
~To be assessed at baseline and follow-up:
~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
16582332|NCT02729597||Myotonic dystrophy type 2 patients|"Patients with myotonic dystrophy type 2 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.
~To be assessed at baseline and follow-up:
~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
16582333|NCT02729597||Controls|"Healthy control subjects who meet all inclusion and exclusion criteria for healthy controls.
~To be assessed at baseline and follow-up:
~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
16582334|NCT02729584||Normal weight|
16582335|NCT02729584||Obese|
16582336|NCT02729571|Experimental|MTBVAC Group 1|Intervention: MTBVAC live vaccine (low dose)
16582337|NCT02729571|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose)
16582338|NCT02729571|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose)
16582339|NCT02729571|Active Comparator|BCG Control Group|Intervention: commercially available BCG live vaccine
16582340|NCT02729558|No Intervention|observation|Watchful waiting
16582341|NCT02729558|Active Comparator|local stereotactic radiotherapy (SRT)|local SRT in three fractions of 8 Gy to the surgical cavity
16582342|NCT02729545|Experimental|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
16582343|NCT02729545|Active Comparator|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
16582344|NCT02729532||Xpert cohort|HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)
16582345|NCT02729532||Standard of Care cohort|HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)
16582346|NCT02729519|Other|Group A|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
16582347|NCT02729519|Experimental|Groupe B|standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
16582348|NCT02729506|Active Comparator|Arm A|"Intervention:
~Yttrium-90 Transarterial Radioembolization
~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).
~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.
~Patients must not be less than 18 and not more than 80 and can be either gender.
~Patients must have a performance status of ECOG score equal to or less than 2.
~Child-Pugh's A or Early B, score 8 and above"
16582349|NCT02729506|Active Comparator|Arm B|"Intervention:
~Trans-arterial chemo-embolization using Drug-eluting beads
~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).
~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.
~Patients must not be less than 18 and not more than 80 and can be either gender.
~Patients must have a performance status of ECOG score equal to or less than 2.
~Child-Pugh's A or Early B, score 8 and above"
16582350|NCT02729493|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
16582351|NCT02729480|Experimental|Continued Stimulation Group|Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
16582352|NCT02729480|Active Comparator|Delayed Continuation Group|Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
16582353|NCT02729467|Experimental|Panel 1|Participants will receive a single 250 milligram (mg) dose of JNJ-53718678 on Day 1 and 200 mg itraconazole once a day on Days 4 to 11 along with a single 250-mg dose of JNJ-53718678 on Day 9.
16582354|NCT02729467|Experimental|Panel 2|Participants will receive a single 500-mg dose of JNJ-53718678 on Day 1; a single 600-mg dose of rifampicin along with a single 500-mg dose of JNJ-53718678 on Day 4 and 600 mg rifampicin once daily on Days 5 to 11 along with a single 500-mg dose of JNJ-53718678 on Day 9.
16582355|NCT02729454|Active Comparator|Exclusively physical therapy|The patients will be submitted to 15 therapeutical sessions two times per week with length of 40 minutes for motor physiotherapy . Each session of the motor physiotherapy will be constituted of exercises that include stretching (emphasizing the front of the torso), reinforcement (with emphasis in inferior members extensores); active exercises as transference (for example, to put into motion it bed or uprising of a chair), to reach and to grasp and training of balance and march.
16582356|NCT02729454|Experimental|Mental Practice And Physical Therapy|In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
16582357|NCT02729441|Active Comparator|Ramipril|"Maximal recommended dose of ramipril Altace® (10 mg/d) given as an active comparator for 12 week."
16582358|NCT02729441|Experimental|Perindopril|"Perindopril Coversyl® at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks."
16582359|NCT02729428||Exercise trained young adults|Exercise trained young adults between the age of 18-35 years.
16582360|NCT02729428||Sedentary young adults|Sedentary young adults between the age of 18-35 years.
16582361|NCT02729428||Exercise trained older adults|Exercise trained older adults between the age of 55-75 years.
16582362|NCT02729428||Sedentary older adults|Sedentary older adults between the age of 55-75 years.
16582363|NCT02729415|Experimental|Stromal Vascular Fraction Cells (SVF Cells)|The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.
16582364|NCT02729402|Experimental|Older Cochlear Implant Subjects|We will assign the study participants to a diagnostic intervention (cognitive testing) before and after their cochlear implant.
16582365|NCT02729389|Experimental|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
16582366|NCT02729389|Experimental|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
16582367|NCT02729376|Experimental|Single dose of [14C]-galeterone|[14C]-galeterone will be supplied as 325 mg capsules (powder in capsule [PIC]). The treatment to be administered will be 2600 mg (~500 µCi) (8 x 325 mg capsules).
16582368|NCT02729363|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline visit to determine the immediate effects of guided relaxation intervention on stress and pain in outpatients with sickle cell disease.
16582369|NCT02729363|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients talk about their sickle cell disease experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
16582370|NCT02729350|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.
16582371|NCT02729350|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
16582372|NCT02729337|Experimental|ITG (In This Together)|This will be a multi-week behavioral intervention delivered daily via text messaging. Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
16582373|NCT02729337|No Intervention|Control Group|Given the preliminary nature of the intervention development, the control group will be inactive but blinded. They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk. Messages will be didactic and not driven by the IMB model.
16582374|NCT02729324|Experimental|FORRAD group|This group of patients will receive Medical Radiation Protectants (FORRAD®) during study for prevention and treatment of acute radiation-induced dermatitis. This is the experimental group.
16582375|NCT02729324|Active Comparator|Biafine group|This group of patients will receive Trolamine (Biafine) during study for prevention and treatment of acute radiation-induced dermatitis. This is the active comparator group.
16582376|NCT02729311|Experimental|Group 1|Paired PLIÉ Program, immediate start
16582377|NCT02729311|Other|Group 2|Paired PLIÉ Program, delayed start
16582378|NCT02729298|Experimental|Advanced Solid Tumors|"Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle
~AND
~Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle."
16582503|NCT02728557|Experimental|Supportive psychotherapy|Participants will receive supportive therapy.
16582379|NCT02729298|Experimental|EGFR+ NSCLC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
16582380|NCT02729298|Experimental|BRAF-, KRAS-, or NRAS-Mutated CRC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
16582381|NCT02729298|Experimental|Persistent/Recurrent Ovarian Cancer|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
16582382|NCT02729298|Experimental|BRAF-Mutated Melanoma|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
16582383|NCT02729285|Experimental|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
16582384|NCT02729285|Placebo Comparator|placebo|On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.
16582385|NCT02729272|Experimental|Ultrasonic ESD|Laparoscopic colpotomy by ultrasonic ESD (Harmonic Synergy Hook Blade; Ethicon Endo-Surgery) during total laparoscopic hysterectomy.
16582386|NCT02729272|Active Comparator|Monopolar ESD|Laparoscopic colpotomy by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany) during total laparoscopic hysterectomy.
16582387|NCT02729259|Other|Virtual Reality Snowworld|The subjects will receive Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
16582388|NCT02729259|Other|Virtual Reality slides of nature|The subjects will see several slides of the nature through virtual reality goggles during their wound care. The nurse will be doing the wound care.
16582389|NCT02729259|Other|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
16582390|NCT02729246|No Intervention|Control Group|
16582391|NCT02729246|Other|Surgery Group|The patients in this group will undergo Laparoscopic Gastric Bypass surgery
16582392|NCT02729233|Other|patients receiving biopsies|UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
16582393|NCT02729220|Other|Healthy controls|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
16582394|NCT02729220|Other|Smokers|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
16582395|NCT02729220|Other|COPD rapid decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
16582396|NCT02729220|Other|COPD slow decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
16582399|NCT02729194|Experimental|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
16582400|NCT02729168|Experimental|Human rabies vaccines|Five doses 0.5 mL vaccine INDIRAB® on D0, D3, D7, D14, D28 using administered intramuscularly.
16582401|NCT02729155|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
16582402|NCT02729155|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
16582403|NCT02729155|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
16582404|NCT02729155|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
16582405|NCT02729142|Experimental|Tibial cortical density evaluation|
16582406|NCT02729129|Experimental|Commercially available highly-efficient facemask|
16582407|NCT02729129|Sham Comparator|Sham facemask|
16582408|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
16582409|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
16582410|NCT02729103||Treatment patterns, healthcare resource utilization and costs|Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
16582411|NCT02729103||Mortality|Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
16582412|NCT02729090|Experimental|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks
16582413|NCT02729090|Active Comparator|Device: treadmill Train_Comb_aerobic|strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series.
16582414|NCT02729077||Increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry. Patients in this arm will be especially evaluated for hypoxemia and other complications.
16582415|NCT02729077||Not increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry.
16582416|NCT02729064|Experimental|Intranasal 40|Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
16582417|NCT02729064|Experimental|Intranasal 80|Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
16582418|NCT02729064|Placebo Comparator|Placebo|Patients will receive intranasal normal saline via a metered nasal dispenser
16582419|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16582420|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
16582421|NCT02729038|Experimental|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
16582422|NCT02729038|Experimental|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
16582423|NCT02729038|Experimental|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
16582424|NCT02729038|Experimental|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
16582425|NCT02729038|Experimental|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
16582426|NCT02729038|Experimental|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
16582427|NCT02729025|Placebo Comparator|Placebo|Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
16582428|NCT02729025|Experimental|Evolocumab 420 mg QM|Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
16582429|NCT02729012|Active Comparator|Case|Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
16582430|NCT02729012|Placebo Comparator|Control|Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
16582431|NCT02728999|Other|Group A|Steep Trendelenburg
16582432|NCT02728999|Experimental|Group B|Decreased Trendelenburg
16582433|NCT02728986|Active Comparator|Compression1|Multilayer compression bandage (Profore)
16582434|NCT02728986|Experimental|Compression2|Coban2 compression system
16582435|NCT02728973||ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
16582436|NCT02728973||conventional treatment program|conventional treatment
16582437|NCT02728960|Experimental|Traumatic Brain Injury|Documented history of Traumatic Brain Injury
16582438|NCT02728960|Active Comparator|Normal Controls|No prior history of concussion, TBI, blast exposure, stroke, or other major neurological disorder
16582439|NCT02728960|Active Comparator|Sequence Development Volunteers|
16582440|NCT02728947|Active Comparator|2mg|1 week on 2mg/24 hr patch
16582441|NCT02728947|Active Comparator|4mg|1 week on 4mg/24hr patch
16582442|NCT02728947|Active Comparator|6mg|1 week on 6mg/24hr patch
16582443|NCT02728947|Active Comparator|8mg|1 week on 8mg/24hr patch
16582444|NCT02728934||Golimumab Intravenous (IV)|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Golimumab IV.
16582445|NCT02728934||Infliximab|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Infliximab.
16582446|NCT02728921|Active Comparator|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
16582447|NCT02728921|Experimental|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
16582448|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
16582449|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
16582450|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
16582451|NCT02728882|Experimental|single arm|"Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days，the first day,the fourth day,the seventh day,28 days,31 days,34 days.
~Duration:Total seven times."
16582452|NCT02728869|Experimental|Heat Stable Rotavirus (HSRV) Vaccine|25 healthy adults who will be administered a single dose of test HSRV vaccine
16582453|NCT02728869|Placebo Comparator|Placebo for Heatstable Rotavirus vaccine|25 healthy adults who will be administered a single dose of placebo
16582454|NCT02728869|Experimental|Heat Stable Rotavirus Vaccine|25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
16582455|NCT02728869|Active Comparator|RotaTeq|25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals
16582456|NCT02728856|Experimental|Sun Protection Factor (SPF) 50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
16582457|NCT02728856|Experimental|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
16582458|NCT02728843|Experimental|Deferiprone 300 mg|One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg
16582459|NCT02728843|Experimental|Deferiprone 600 mg|One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg
16582460|NCT02728843|Experimental|Deferiprone 900 mg|One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg
16582461|NCT02728843|Experimental|Deferiprone 1200 mg|Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg
16582462|NCT02728843|Placebo Comparator|Placebo|Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day
16582463|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.
~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.
~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
16582464|NCT02728817|Active Comparator|arteriovenous fistula (AVF)|Patient receiving a traditional arteriovenous fistula at the wrist (end-cephalic vein to side-radial artery)
16582465|NCT02728817|Experimental|RADAR|Patient receiving an arteriovenous fistula at the wrist using the Radial Artery Deviation And Reimplantation technique (end-radial artery to side-cephalic vein)
16582466|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
16582467|NCT02728778|Active Comparator|Botulinum toxin A|Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.
16582468|NCT02728778|Other|Acupuncture|Patients will receive four facial acupuncture treatments every two weeks.
16582469|NCT02728765|Active Comparator|auto CPAP|Each patient will be interviewed by the physician on duty and invited to participate in the overnight hospital based auto continuous positive airway pressure (CPAP) titration study for 1 night and then commencement of auto CPAP treatment for 6 months.
16582470|NCT02728765|Placebo Comparator|Subtherapeutic CPAP|Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
16582471|NCT02728752|Placebo Comparator|Placebo|Subjects randomized to placebo will receive 4 infusions of placebo every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to Octagam 10%. After response assessment at Week 16, all subjects with no confirmed deterioration and subjects switched to Octagam 10% due to confirmed deterioration but without further confirmed deterioration during the First Period will continue to receive 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to placebo and switched to Octagam 10% due to confirmed deterioration, who deteriorate also during Octagam 10% treatment at 2 consecutive visits will drop-out after response assessment at Week 16 and will not enter the Extension Period.
16582472|NCT02728752|Experimental|Octagam10%|Subjects randomized to Octagam will receive 4 infusions of 2.0 g/kg Octagam 10% every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to the alternate treatment. After response assessment at Week 16, all subjects with no confirmed deterioration during the First Period will continue receiving 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to Octagam and switched to the alternate treatment due to confirmed deterioration will drop-out after response assessment at Week 16 and will not enter the Extension Period.
16582473|NCT02728739|Experimental|Acute Heart Failure Patients|Acute Heart Failure patients with elevated levels of BNP ( >30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.
16582474|NCT02728726|Experimental|Treatment group|study drug (sugammadex) administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and patient is extubated.
16582475|NCT02728726|Placebo Comparator|Control group|placebo administered intravenously after routine reversal of anesthesia is performed and patient is extubated.
16582476|NCT02728713|Experimental|Cranial manipulation|"Assessment for cranial strain patterns, followed by indirect cranial manipulation to treat dysfunctions found on assessment, followed by reassessment.
~Repeated for a total of eight visits no less than one week apart."
16582477|NCT02728713|Sham Comparator|Sham/placebo|Assessment for cranial strain patterns, followed a laying on of hands, followed by reassessment. Repeated for a total of eight visits no less than one week apart.
16582504|NCT02728557|Experimental|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
16582478|NCT02728700|Experimental|Treatment (sirolimus, HSCT, MMF)|Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.
16582479|NCT02728687|Experimental|Mannitol and menthol cream|Mannitol and menthol cream (Water, Mannitol, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the menthol cream will be applied to the participant's feet. Whether the mannitol and menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
16582480|NCT02728687|Active Comparator|Menthol cream|Cream containing menthol (Water, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the mannitol and menthol cream will applied to the participant's feet. Whether the menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
16582481|NCT02728674|Other|Man+Breathlessness|Person in the case is a male. Symptom in the case is breathlessness.
16582482|NCT02728674|Other|Man+Pain|Person in the case is a male. Symptom in the case is pain.
16582483|NCT02728674|Other|Woman+Breathlessness|Person in the case is a female. Symptom in the case is breathlessness.
16582484|NCT02728674|Other|Woman+Pain|Person in the case is a female.Symptom in the case is pain.
16582485|NCT02728661|Experimental|PACE|PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
16582486|NCT02728661|Experimental|Delayed PACE|After being notified of their randomized condition at baseline (up to 6 weeks prior to surgery), Delayed PACE participants will not have contact with coaches until 12 weeks after surgery. At 12 weeks after surgery, Delayed PACE participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks. Further, participants may opt to receive regular text messages or emails from coaches if they prefer.
16582487|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
16582488|NCT02728635|Active Comparator|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
16582489|NCT02728635|Active Comparator|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
16582490|NCT02728635|Active Comparator|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
16582491|NCT02728622|Experimental|Tamoxifen|Tamoxifen 40 mg is given orally once daily until progression
16582492|NCT02728622|Active Comparator|Chemotherapy|Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression
16582493|NCT02728609||Blue towel: vacuum pack device|Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
16582494|NCT02728609||ABThera abdominal closure|Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
16582495|NCT02728596|Experimental|Clinic group 1 (clinic with automated system)|Patients with a high risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSFs not be used for drugs that have a low risk of FN.
16582496|NCT02728596|Experimental|Clinic group 2 (clinic with no automated system)|Patients receive CSF based on clinical practice guidelines.
16582497|NCT02728596|Experimental|Clinic group 3 (clinic with automated system)|Patients with a high or moderate risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSFs not be used for drugs that have a low risk of FN.
16582498|NCT02728596|Active Comparator|Clinic group 4 (clinic with automated system)|Patients with a high risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSF not be used for drugs that have a moderate risk of FN.
16582499|NCT02728583|Active Comparator|Margarine enriched with plant sterols and fish oil|Low-fat margarine (25 g per day) with added plant sterols and Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) from fish oil
16582500|NCT02728583|Placebo Comparator|Placebo margarine|Low-fat margarine (25 g per day) without added plant sterols and EPA + DHA
16582501|NCT02728570|Experimental|Low Flavonoids then High Flavonoids|Participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks.
16582502|NCT02728570|Experimental|High Flavonoids then Low Flavonoids|Participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks.
16582505|NCT02728544|Experimental|Prader Willi syndrome|16 (8 males) PWS adolescents and young adults
16582506|NCT02728544|Active Comparator|Obese controls|16 - sex, age, and BMI-matched controls
16582507|NCT02728531|Experimental|Bendamustine, Rituximab, Cytarabine|"Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.
~In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.
~On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.
~Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.
~Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).
~Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
16582508|NCT02728518|Experimental|Nebulized Amikacin|patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam
16582509|NCT02728518|Active Comparator|Amikacin Intravenous|patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam
16582510|NCT02728505|Active Comparator|SinuSurf irrigation twice daily|This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
16582511|NCT02728505|Placebo Comparator|NeilMed Sinus rinse irrigation twice daily|This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
16582512|NCT02728492|Experimental|Quisinostat 8 mg & Paclitaxel & Carboplatin|Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
16582513|NCT02728492|Experimental|Quisinostat 10 mg & Paclitaxel & Carboplatin|Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
16582514|NCT02728492|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
16582515|NCT02728492|Experimental|Quisinostat 8 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
16582516|NCT02728492|Experimental|Quisinostat 10 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
16582517|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
16582518|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1250 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
16582519|NCT02728466|Active Comparator|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
16582520|NCT02728466|Active Comparator|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
16582521|NCT02728466|Placebo Comparator|Flavanols and procyanidins deprived supplement|Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
16582522|NCT02728453|Experimental|Empagliflozin|25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
16582523|NCT02728453|Active Comparator|Glimepiride|2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.
16582524|NCT02728440||Hypogonadotropic hypogonadism patients|30 patients with idiopathic hypogonadotrophic hypogonadism
16582525|NCT02728427|Experimental|Suprapubic Catheterization|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.
16582526|NCT02728427|Active Comparator|Transurethral Catheterization|Transurethral catheterization using Foley catheter will be performed for patients in this group.
16582527|NCT02728414|Experimental|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
16582528|NCT02728414|Other|placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
16582529|NCT02728401||INSI|Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
16582530|NCT02728401||CSSS|Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
16582531|NCT02728401||Viral|The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
16582532|NCT02728388|Experimental|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.
~16 to 24 hours post study drug treatment, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
16582533|NCT02728375|Experimental|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 45 minutes,three times per week for sixteen weeks
16582534|NCT02728375|Active Comparator|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength. The exercises will be performed 45 minutes, three times per week for sixteen weeks
16582535|NCT02728349|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
16582536|NCT02728336|Active Comparator|Heart Failure Patients|patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony
16582537|NCT02728336|Active Comparator|Control|20 matched control subjects
16582538|NCT02728323|Active Comparator|Levobupivacaine 100 mg, USG TAP Block|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
16582539|NCT02728323|Placebo Comparator|Placebo|20 ml of Saline (for 100 mg Levobupivacaine) intramuscularly, at the end of surgery
16582540|NCT02728310|Active Comparator|Levobupivacaine infusion|1500 mg of Levobupivacaine by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
16582541|NCT02728310|Placebo Comparator|Saline infusion|300 ml of Saline (for Levobupivacaine as placebo) by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
16582542|NCT02728297|Experimental|Staged ETS|Video-assisted endoscopic sympathicotomy from level of T3 to level of T12 on one side
16582543|NCT02728284|Active Comparator|Normal Cardiovascular System|70 with a history of heart or lung disease
16582544|NCT02728284|Active Comparator|Abnormal Cardiovascular System|30 without any history of heart or lung disease
16582545|NCT02728271|Experimental|HPC cell infusion|Autologous HPC will be infused within 24 hours of completing the chemotherapy. A total of 5 x 106/kg CD34+ HPC will be infused. The remaining HPC will be stored as back-up, to be used in case of graft failure.
16582546|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16582547|NCT02728245|Placebo Comparator|Control group|"Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.
~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
16582548|NCT02728245|Experimental|Case group|"Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.
~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
16582549|NCT02728232|Experimental|Internal Iliac artery ligation group|in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure
16582550|NCT02728232|Active Comparator|Hysterectomy only|in this group patients will undergo cesarean hysterectomy only
16582551|NCT02728219|Experimental|hepatectomy|Comparison of Treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion
16582552|NCT02728219|Active Comparator|TACE|
16582553|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
16582554|NCT02728193|Experimental|RFA|Radiofrequency ablation
16582555|NCT02728193|Experimental|MWV|Microwave ablation
16582556|NCT02728193|Experimental|PEI|Percutaneous ethanol injection
16582557|NCT02728180|Experimental|Xingnaojing and standard care|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
16582558|NCT02728180|Active Comparator|Standard care only|Subjects will receive guidelines-based standard care only.
16582559|NCT02728167|Experimental|Pre-coagulation by HIFU-AR|Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
16582560|NCT02728167|No Intervention|Standard liver resection|Standard liver resection
16582561|NCT02728154||Normal control|The subjects in the normal heart function group will provide a blood sample and stool sample.
16582562|NCT02728154||heart failure|The subjects in history of heart failure group will provide a blood sample and stool sample.
16582563|NCT02728154||pre-HFpEF|The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
16582564|NCT02728141|Placebo Comparator|Water|Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
16582565|NCT02728141|Active Comparator|Sucrose|Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
16582566|NCT02728128||Low cardiac output syndrome|Patients who experience low cardiac output syndrome
16582567|NCT02728128||No low cardiac output syndrome|Group that does not experience low cardiac output syndrome.
16582568|NCT02728115|Experimental|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells/weight range per administration of Cellavita HD (n= 3) .
16582569|NCT02728115|Experimental|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells/weight range per administration of Cellavita HD (n= 3).
16582573|NCT02728089|Experimental|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
16582574|NCT02728076|Experimental|Radiation Therapy followed by Lumpectom|Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
16582575|NCT02728063|Experimental|Single arm|Supplementation with Lactibiane Tolerance
16582576|NCT02728050|Experimental|Treatment (sorafenib, G-CLAM)|See Detailed Description.
16582577|NCT02728037|Experimental|Magnesium-Based Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
16582578|NCT02728037|Active Comparator|Lidocaine-Only Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
16582579|NCT02728037|No Intervention|Wait-Listed Patients|This arm is a non-randomized, no-treatment arm consisting of women who are on the waiting list for the chronic pain clinic.
16582580|NCT02728024||A|Complete the questionnaires with personal aid
16582581|NCT02728024||B|questionnaires are completed by patients alone
16582582|NCT02728011|Experimental|Intervention|Scientific Brain Training (SBT)
16582583|NCT02728011|Placebo Comparator|Controle|Tetris
16582584|NCT02727998|Experimental|Single infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
16582585|NCT02727998|Experimental|Two infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 4, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
16582586|NCT02727998|Active Comparator|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
16582587|NCT02727985|Experimental|Pharmacist weaning schedule|The Neuromodulation clinic pharmacist will develop a weaning schedule for these patients. Schedules will be individualized taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
16582588|NCT02727985|No Intervention|Self/Family Physician weaning schedule|Patients will wean off their opioids by themselves or with their family physician without the assistance of a prepared schedule.
16582589|NCT02727972|Other|Cognitive Testing|Cognitive assessments
16582590|NCT02727972|Active Comparator|Magnetic Resonance Imaging|All subjects will have one MRI with a possibility of one functional MRI (fmri).
16582591|NCT02727972|Active Comparator|Positron Emission Tomography|All subjects will have PET scan using FPEB or ABP688.
16582592|NCT02727959||Patients newly diagnosed with IBD|
16582593|NCT02727959||Symptomatic non IBD-controls|Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
16582594|NCT02727946|Other|optimal resuscitation|This group of multiple trauma patients will be resuscitated with crystalloids, analgesics, blood products as needed. Then follow up of the difference between arterial and venous CO2 to difference between arterial and venous oxygen tension, serum lactate, renal function, other organ affection along over the short hospital stay period
16582595|NCT02727920|Experimental|Experimental|drink containing pyridoxine, folate; B12); taurine, choline, glucuronic acid; tyrosine, phenylalanine*, malic acid, and caffeine administered one time.
16582596|NCT02727920|Placebo Comparator|Placebo drink|Placebo drink administered one time.
16582597|NCT02727907|Experimental|BCD-033|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
16582598|NCT02727907|Active Comparator|Rebif|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
16582599|NCT02727907|Placebo Comparator|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
16582600|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
16582601|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
16582602|NCT02727881|Experimental|Squalamine solution, 0.2% BID|Squalamine lactate ophthalmic solution, 0.2% bis in die (BID) + ranibizumab every 4 weeks
16582711|NCT02727127||Bipolar Patients|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
16582603|NCT02727881|Placebo Comparator|Placebo solution BID|Placebo ophthalmic solution BID + ranibizumab every 4 weeks
16582604|NCT02727868|Other|exclusive breast irradiation group|to assess the impact of irradiation areas
16582605|NCT02727868|Other|breast and sternal irradiation group|to assess the impact of irradiation areas
16582606|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
16582607|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
16582608|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
16582609|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
16582610|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
16582611|NCT02727803|Experimental|Myeloablative regimen 1|"Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3.
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.
~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
16582612|NCT02727803|Experimental|Non-myeloablative regimen 2|"Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s).
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.
~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
16582613|NCT02727803|Experimental|Reduced intensity regimen 3|"Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2.
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.
~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
16582614|NCT02727790|Experimental|PES Treatment|Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System
16582615|NCT02727790|No Intervention|Control|Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System
16582616|NCT02727777|Experimental|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group
~Participants take TAK-228 1 time every day of a 28 day cycle.
~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.
~Participant checks blood sugar every day before TAK-228 dose."
16582617|NCT02727777|Experimental|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group
~Participants take TAK-228 1 time every day of a 28 day cycle.
~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.
~Participant checks blood sugar every day before TAK-228 dose."
16582618|NCT02727777|Experimental|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group
~Participants take TAK-228 1 time every day of a 28 day cycle.
~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.
~Participant checks blood sugar every day before TAK-228 dose."
16582619|NCT02727764|Experimental|Cohort I|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e12 vg/ MCP joint, 0.6x10e12 vg/ PIP joint or 0.3x10e12 vg/ DIP joint single intra-articular injection
16582620|NCT02727764|Experimental|Cohort II|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint single intra-articular injection
16582621|NCT02727764|Experimental|Cohort III|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint ART-I02 or maximum Tolerated Dose (MTD) as assessed in cohorts I and II: single intra-articular injection
16582622|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
16582623|NCT02727738|Experimental|Methimazole plus selenium|Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days
16582624|NCT02727738|Active Comparator|Methimazole|Methimazole 5-30 mg daily for 90 days
16582625|NCT02727725|Experimental|Traminer MRI Sequence|The TRAMINER MRI sequence implementation to be tested allows the acquisition of high resolution MR images in the free-breathing patient, by combining multiple averages and motion correction with the TRAMINER preparation.
16582626|NCT02727712|Experimental|TPVB T2/3+T5/6+GA|the group A of patients has been received bilateral thoracic paravertebral block (TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4), before general anesthesia management
16582627|NCT02727712|Experimental|TPVB T3/4+GA|the group Bof patients has been received bilateral thoracic paravertebral block (TPVB 3/4) by ropivacaine(0.3%,10ml*4), before general anesthesia management Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
16582628|NCT02727712|Placebo Comparator|GA|group C under control (without TPVB)program Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
16582629|NCT02727699|Experimental|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
16582630|NCT02727699|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
16582631|NCT02727686|Experimental|Water Load (WL) Post-Operative Day 1|All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
16582632|NCT02727673||healthy volunteers|matched group
16582633|NCT02727673||hepatitis cirrhosis|negative group
16582634|NCT02727673||hepatocellular carcinoma|patients with primary HCC
16582744|NCT02726958||group T|other patients
16582635|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
16582636|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
16582637|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
16582638|NCT02727647|Experimental|Arm 1|FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
16582639|NCT02727647|Experimental|Arm 2|FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months
16582640|NCT02727634|Other|Postoperative elective CABG patients|Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.
16582641|NCT02727621|Active Comparator|Dexmedetomidine group|
16582642|NCT02727621|Active Comparator|Propofol group|
16582643|NCT02727608|Experimental|Eculizumab|Intravenous infusion
16582644|NCT02727595|Experimental|CyclaPlex Implant|Implant device for reduction of the inter metatarsal angle (IMA) without osteotomy.
16582645|NCT02727569||Feasibility Study|10 subjects. Subjects will performed two different versions of the new visual field algorithm with DLS (differential light sensitivity) strategies. Two repeats of each strategy will be performed.
16582646|NCT02727569||Clinical evaluation study|100 subjects. Subjects will performed a visual field assessment with the new visual field algorithm with MMDT (Moorfields Motion Displacement Test) and DLS -like stimuli and a commercial available SITA algorithm (DLS-like strategy). Two repeats of each strategy will be performed.
16582647|NCT02727556|Experimental|Functional dyspepsia patient|Visual stimuli of food and non-food images will be presented to patients. Non-food images include positive, neutral, negative emotional pictures.
16582648|NCT02727556|Experimental|Healthy|Visual stimuli of food and non-food images will be presented to participants. Non-food images include positive, neutral, negative emotional pictures.
16582649|NCT02727543|No Intervention|Control|Participants randomized to this arm will not receive the intervention.
16582650|NCT02727543|Experimental|Intervention|Participants randomized to this arm will receive the intervention, Medisafe, a smartphone application.
16582651|NCT02727530|Experimental|GROUP RECEIVING VISCERAL MANUAL THERAPY-ADVICES|Subjects will receive 2 manual therapy sessions and advices.
16582652|NCT02727530|Experimental|GROUP RECEIVING ADVICES|Subjects will receive advices.
16582653|NCT02727517|Active Comparator|Early (≤ 60 seconds) cord clamping|Early (≤ 60 seconds) cord clamping
16582654|NCT02727517|Active Comparator|Delayed cord clamping|Delayed (≥ 180 seconds) cord clamping
16582655|NCT02727504||Patient with aortic valve stenosis|"115 patients will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.
~Then will be performed :
~An electrocardiogram
~2D and 3D echocardiography
~Dobutamine stress echocardiography
~Blood tests : blood electrolytes, creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-ProBNP), C reactive protein (CRP), soluble suppression of tumorigenicity-2 (ST-2)
~A cardiac MRI
~A cardiac scanner
~A 6-minutes walking test
~An evolution of the Duke Activity Score"
16582656|NCT02727491|Experimental|dextromethorphan|1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy
16582657|NCT02727491|Placebo Comparator|Placebo|30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group
16582658|NCT02727478|Experimental|Balance training group|1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
16582659|NCT02727478|No Intervention|Control group|Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.
16582660|NCT02727465||meningitis cases|any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged <16 years) or next-of-kin (for non-survivors)
16582661|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
16582662|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
16582663|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
16582664|NCT02727439|Experimental|Sedentary Subjects|Healthy lean sedentary subjects.
16582665|NCT02727439|Experimental|Athletes|Active athletes.
16582666|NCT02727426|Experimental|low salt diet|All subjects will be instructed to maintain a low-sodium (LS) diet, with an intake of less than 2.3 g of salt per day (DASH eating plan; US Department of Health and Human Services, 2006) for 7 days (washout period).
16582667|NCT02727426|Experimental|high salt diet|After washout period, all subjects will be instructed to maintain a high-sodium (HS) diet, with an intake of 11.2 g of salt per day for 7 days.
16582668|NCT02727413||Infective endocarditis|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with infective endocarditis in accordance with Duke criteria and scheduled for valve surgery
16582669|NCT02727413||Valvular heart disease|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with valvular heart disease, with no signs of infection, scheduled for valve replacement surgery
16582670|NCT02727400||advanced maternal age|Infertile women due to advanced maternal age
16582671|NCT02727400||Young patients|women under 35 undergoing infertility treatments
16582672|NCT02727387|Experimental|TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL|2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for<14 years old ,800 mg/die for>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for<14 years old, 50 mg/m2 for>14 years old)
16582673|NCT02727374|Experimental|EXPERIMENTAL|Physiotherapy intervention, plus cognitive-behavioural intervention
16582674|NCT02727374|Active Comparator|CONTROL|Physiotherapy intervention
16582675|NCT02727361|Experimental|Cholinergic striatal imaging|Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer
16582676|NCT02727348|Experimental|Sciatic block with or without femoral block|Sciatic block with or without femoral block performed on the patient with 3mg/kg of ropivacaine
16582677|NCT02727348|Active Comparator|Spinal anaesthesia|Spinal anaesthesia will be performed on the patient with heavy marcaine 0.5% up to 3mls
16582678|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
16582679|NCT02727322|Active Comparator|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
16582680|NCT02727322|Placebo Comparator|Placebo|Receives matching placebo
16582681|NCT02727309|Experimental|apatinib|Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.
16582682|NCT02727296|Active Comparator|propofol|Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
16582683|NCT02727296|Active Comparator|sevoflurane|Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
16582684|NCT02727283|Experimental|Cohort 1|Subjects will receive 1 placebo and 3 escalating doses in one of the four treatment periods. The planned dose range is 10 mg to 200 mg. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
16582685|NCT02727283|Experimental|Cohort 2|Cohort 2 will proceed after completion of the treatment periods in Cohort 1. Subjects assigned to Cohort 2 will participate in up to 4 dosing periods which include up to 2 escalating doses and placebo in Periods 1 and 2, and a pilot food effect in Periods 3 and 4. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
16582686|NCT02727270||Parkinson's - High Stress|Parkinson's disease patients with self-reported high strain/stress.
16582687|NCT02727270||Parkinson's - Low Stress|Parkinson's disease patients with self-reported low strain/stress.
16582688|NCT02727270||Controls - High Stress|Healthy controls (no neurological disease) with self-reported high strain/stress.
16582689|NCT02727270||Controls - Low Stress|Healthy controls (no neurological disease) with self-reported low strain/stress.
16582690|NCT02727270||Huntington's - High Stress|Huntington's disease patients with self-reported high strain/stress.
16582691|NCT02727270||Huntington's - Low Stress|Huntington's disease patients with self-reported low strain/stress.
16582692|NCT02727257|Experimental|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. All the exercises are aerobic. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
16582693|NCT02727257|No Intervention|healthy controls|we assessed the attentive Reaction Times in healthy controls, that don't receive rehabilitative treatment
16582694|NCT02727231|Experimental|day and night closed loop control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
16582695|NCT02727231|Active Comparator|usual insulin pump therapy management|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (FreeStyle Navigator CGM)
16582696|NCT02727218|Experimental|chest tube removal after 3 hours|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal after 3 hours.
16582697|NCT02727218|Active Comparator|delayed chest tube removal|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal according to the department's protocol, most probably post operative day 1 (POD1)
16582698|NCT02727205|Experimental|Single Arm|One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.
16582699|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
16582700|NCT02727192|No Intervention|Control group|No sleep apnea treatment
16582701|NCT02727179|Experimental|Laparoscopic group|Liver resection performed by laparoscopic approach
16582702|NCT02727179|Active Comparator|Open group|Liver resection performed by open approach
16582703|NCT02727166|Experimental|Inulin 8 g/d|Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
16582704|NCT02727166|Placebo Comparator|maltodextrine 8 g/d|
16582705|NCT02727153|Experimental|"Ultra E.R.A.S."|Discharge patients on Post Operative Day 2
16582706|NCT02727153|Active Comparator|Classic E.R.A.S.|Discharge patients on Post Operative Day 4
16582707|NCT02727140|Experimental|Yoga with Asana (yoga postures)|
16582708|NCT02727140|Experimental|Yoga without Asana (yoga postures)|
16582709|NCT02727140|No Intervention|Wait-list control group|
16582710|NCT02727127||Healthy Volunteers|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
16582712|NCT02727114||participants aged 8 weeks to 3 years|"Echographic measurement of skin thickness at the proximal forearm, the deltoid region and medial thigh (till age of 2 years) in participants aged 8 weeks to 3 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
16582713|NCT02727114||participants aged 3 to 6 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 3 to 6 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
16582714|NCT02727114||participants aged 6 to 12 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 6 to 12 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
16582715|NCT02727114||participants aged 12 to 18 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 12 to 18 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
16582716|NCT02727101|Active Comparator|phenobarbital|"After 12 weeks of baseline observation on phenobarbital medication, the treatment with perampanel will introduced as add on medication."
16582717|NCT02727101|Active Comparator|valproate|"After 12 weeks of baseline observation on valproate medication, the treatment with perampanel will introduced as add on medication."
16582718|NCT02727101|Active Comparator|lamotrigine|"After 12 weeks of baseline observation on lamotrigine medication, the treatment with perampanel will introduced as add on medication."
16582719|NCT02727101|Active Comparator|levetiracetam|"After 12 weeks of baseline observation on levetiracetam medication, the treatment with perampanel will introduced as add on medication."
16582720|NCT02727101|Active Comparator|zonisamide|"After 12 weeks of baseline observation on zonisamide medication, the treatment with perampanel will introduced as add on medication."
16582721|NCT02727101|Active Comparator|pregabalin|"After 12 weeks of baseline observation on pregabaline medication, the treatment with perampanel will introduced as add on medication."
16582722|NCT02727101|Active Comparator|lacosamide|"After 12 weeks of baseline observation on lacosasmide medication, the treatment with perampanel will introduced as add on medication."
16582723|NCT02727101|Active Comparator|clobazam|"After 12 weeks of baseline observation on clobazam medication, the treatment with perampanel will introduced as add on medication."
16582724|NCT02727101|Active Comparator|ezogabine|"After 12 weeks of baseline observation on ezogabine medication, the treatment with perampanel will introduced as add on medication."
16582725|NCT02727101|Active Comparator|eslicarbazepine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
16582726|NCT02727101|Active Comparator|topiramate|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
16582727|NCT02727101|Active Comparator|tiagabine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
16582728|NCT02727088|Active Comparator|Pulpectomy : root canal treatment|Pulpectomy : ablation of the whole dental pulp, preparation and filling of the whole root canal system
16582729|NCT02727088|Experimental|Pulpotomy : Conservative pulp management|Pulpotomy : ablation of the coronal part of the pulp
16582730|NCT02727062||OM Pain Smartphone Application|This study examines whether the smartphone OM Pain App is a feasible and valid tool to assess pain from radiation-induced oral mucositis.
16582731|NCT02727049|Experimental|injured athlete for OMM|Participating athletes who sustain an injury will receive standard of care with the Intervention osteopathic manipulative medicine (OMM)
16582732|NCT02727049|No Intervention|injured athlete no OMM|Participating athletes who sustain an injury will receive standard of care withOUT osteopathic manipulative medicine (OMM)
16582733|NCT02727036|Experimental|Pumpkin seed oil|Pumpkin seed oil (1g) capsules - 2 capsules per day for 12 weeks
16582734|NCT02727036|Active Comparator|Pumpkin seeds|Packet of pumpkin seeds (4.1 grams /~0.15ounces) - 1 pack per day for 12 weeks
16582735|NCT02727023|Experimental|Osteopathic Manipulative Medicine|The thoracic inlet release, The Miller Thoracic Pump, Pedal Pump will be performed. These techniques are gentle and would be rhythmic in motion.
16582736|NCT02727010||mothers with motor impairment due to a rare disease|20 Women with motor impairment due to a rare disease
16582737|NCT02727010||mothers with motor impairment not related to a rare disease|controls, 20 women with motor impairment not related to a rare disease
16582738|NCT02726997|Experimental|Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)|"NEOADJUVANT CHEMOTHERAPY: Before debulking surgery, patients receive durvalumab and carboplatin IV over 1 hour on day 1, and paclitaxel IV over 3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo debulking surgery.
~SURGERY: After 3 courses of chemotherapy, patients undergo debulking laparoscopic surgery.
~ADJUVANT THERAPY: Beginning after debulking surgery, patients receive carboplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on days 1, 8, and 15, and durvalumab IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive durvalumab IV over 1 hour on day 1 and 15. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity."
16582739|NCT02726984|Experimental|case|Patients with carotid plaque ≥ 50% symptomatic (ischemic stroke on CT or MR) during the last 15 days
16582740|NCT02726984|Experimental|control|Patients with asymptomatic carotid plaque ≥ 50%
16582741|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.
~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
16582742|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.
~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
16582743|NCT02726958||group M|patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure
16582745|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
16582746|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
16582747|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
16582748|NCT02726919|Other|Clobazam treatment|This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
16582749|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
16582750|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
16582751|NCT02726893||patients undergoing colonoscopy|patients undergoing colonoscopy were observed in terms of the bowel preparation quality which is measured by Boston Bowel Preparation Scale (BBPS).
16582752|NCT02726880|Active Comparator|Referral for care|
16582753|NCT02726880|Experimental|Behavioral therapy|
16582754|NCT02726867|Active Comparator|levetiracetam|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 4000 mg levetiracetam.
16582755|NCT02726867|Active Comparator|lacosamide|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 600 mg lacosamide.
16582756|NCT02726867|Active Comparator|ketamine|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 2.5 mg/kg ketamine.
16582757|NCT02726867|Active Comparator|phenobarbital|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin (PHT) with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after PHT loading will receive intravenously (i.v.) phenobarbital 15 mg/kg.
16582758|NCT02726854|Experimental|Apatinib|Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
16582759|NCT02726841|Experimental|Hybrid TAAD repair|The group includes patients who underwent open thoracoabdominal aortic repair + abdominal stenting.
16582760|NCT02726841|Active Comparator|Conventional TAAD repair|The group includes patients who underwent classic thoracoabdominal aortic repair with dacron prosthesis.
16582761|NCT02726828|Active Comparator|group I: morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
16582762|NCT02726828|Active Comparator|group II: ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
16582763|NCT02726828|Active Comparator|group III: morphine + ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
16582764|NCT02726802|Experimental|Physical Therapy route of entry|The subject will see a physical therapist as their initial encounter into the healthcare system
16582765|NCT02726802|Active Comparator|Primary Care Provider rout of entry|The subject will see a primary care provider as their initial encounter into the healthcare system
16582766|NCT02726789|Experimental|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
16582767|NCT02726776|Experimental|Suspension without prior climbing|Free Suspension in a harness after baseline measurements and without prior climbing
16582768|NCT02726776|Experimental|Suspension with prior climbing|Free Suspension in a harness after baseline measurements and after climbing in moderate intensity for 10 minutes
16582769|NCT02726763|Experimental|tDCS with cognitive training|We will collect: 1) self-reported demographic information (~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (~10min) [60]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (~5 min)
16582770|NCT02726750||Observational (biospecimen collection)|Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
16582771|NCT02726737|Experimental|sodium bicarbonate|0.7 mL of 8.4% sodium bicarbonate & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
16582772|NCT02726737|Active Comparator|Non-sodium bicarbonate|Sterile distilled water & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
16582773|NCT02726724|Experimental|Condition B|An audience of 5 people with at least 2 neonatologists will be present with the operator during the intubation of the mannequin.
16582774|NCT02726724|Experimental|Condition A|Only the staff will be present with the operator during the intubation of the mannequin.
16582775|NCT02726711|Experimental|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.
~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.
~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
16582802|NCT02726516|Placebo Comparator|Placebo|Placebo volunteers will be administered one dose of placebo 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of placebo for 4 days for the chronic testing.
16582803|NCT02726503|Experimental|Treatment Arm|
16583646|NCT02720822|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on weeks two and three.
16582776|NCT02726711|Placebo Comparator|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.
~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.
~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
16582777|NCT02726685|Experimental|RT (respiratory training) group|Besides traditional rehabilitation therapy, subjects also receive 12-week respiratory training.
16582778|NCT02726685|Sham Comparator|Control group|Besides traditional rehabilitation therapy, subjects receive 12-week sham training unrelated to respiratory function.
16582779|NCT02726672|Experimental|Respiratory rehabilitation|Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
16582780|NCT02726672|No Intervention|control group|No respiratory rehabilitation
16582781|NCT02726659|Experimental|Celecoxib|Adjunct celecoxib in 6 week treatment
16582782|NCT02726659|Placebo Comparator|Placebo|Adjunct placebo in 6 week treatment
16582783|NCT02726646|Placebo Comparator|Debridement|mechanical debridement in one session and application of 1 mg placebo microspheres in two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
16582784|NCT02726646|Experimental|Debridement plus Doxycycline|mechanical debridement in one session associated with the application of 1 mg of microspheres loaded with doxycycline per periodontal pockts, two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
16582785|NCT02726620|Experimental|Hypotension decision support|"The intervention period. Several decision support elements are implemented to notify anesthesia providers: attending anesthesiologists and in-room anesthesia providers of intraoperative hypotension (threshold of a mean arterial pressure below 60 mmHg). Two types of decision support will be implemented: near real-time decision support and feedback emails.
~Near real-time decision support elements will notify the anesthesia providers of a blood pressure drop below the threshold and display the associated increased risk of acute kidney injury. The notification is presented through the pager system for attending anesthesiologists and through the anesthesia information management system for the in-room anesthesia provider.
~All providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension that is associated with an increased risk of organ injury due to organ ischemia."
16582786|NCT02726620|Active Comparator|Usual care group|The 'before' period - or historic control group - during which no decision support for intraoperative hypotension was being used, also known as 'usual care'. This is the three year period prior to the intervention period (the 'Intraoperative hypotension decision support' arm).
16582787|NCT02726607|Experimental|HITSystem 2.0|Pregnant women who are eligible for PMTCT services will be enrolled in the HIV Infant Tracking System 2.0 (HITSystem 2.0) intervention during their first PMTCT appointment and followed until 12 weeks postpartum.
16582788|NCT02726607|Active Comparator|Standard of PMTCT Care|Pregnant women who are eligible for PMTCT services will receive standard of care PMTCT services at the control hospital. The records of women enrolled during their first PMTCT appointment will be used to assess outcomes during the same follow-up period.
16582789|NCT02726594||Patients|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
16582790|NCT02726594||Subjects|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district ETH / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
16582791|NCT02726581|Experimental|Investigational Arm|"Nivolumab, Pomalidomide and Dexamethasone
~Enrollment is closed for this arm"
16582792|NCT02726581|Active Comparator|Control Arm|"Pomalidomide and Dexamethasone
~Enrollment is closed for this arm"
16582793|NCT02726581|Experimental|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone
~Enrollment is closed for this arm"
16582794|NCT02726568|Experimental|Icotinib 375mg Tid|The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.
16582795|NCT02726555|Experimental|Red yeast rice and atorvastatin|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
16582796|NCT02726555|Active Comparator|Atorvastatin alone|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
16582797|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
16582798|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
16582799|NCT02726529|Experimental|Brighter Bites|Children of families in the intervention group will also receive the Coordinated Approach to Child Health (CATCH) school-based curriculum in addition to families receiving fresh fruits and vegetables to take home from school once a week along with nutrition education for 8 weeks in Fall and 8 weeks in Spring semesters of the school year.
16582800|NCT02726529|Active Comparator|Comparison|
16582801|NCT02726516|Experimental|Treated|Treated volunteers will be administered one dose of PRJ-205 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of PRJ-205 for 4 days for the chronic testing.
16582928|NCT02725606|Active Comparator|Pegylated Recombinant Human G-CSF|100ug/kg 6 subjects (2 subjects per GW003 cohort)
16582804|NCT02726490|Active Comparator|Glyburide|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
~The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.
~The dose of glyburide will be increased as needed to a maximum of 20mg /day.
~Antenatal testing will be initiated at 28 weeks
~Patients will receive monthly growth scans"
16582805|NCT02726490|Active Comparator|Glucovance|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
~The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.
~Patients will receive monthly growth scans
~Antenatal testing will be initiated at 28 weeks."
16582806|NCT02726477|Experimental|Wuling San|"This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.
~A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry."
16582807|NCT02726477|Placebo Comparator|placebo|A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.
16582808|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
16582809|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
16582810|NCT02726438|Experimental|Debio 1450|"Participants will receive 3 oral administrations of Debio 1450 at a dose of 240 mg approximately 12 hours apart. The last dose should be given approximately 2, 4, 6 or 12 hours prior to surgery with 3 patients each to be dosed at each of these time points.
~If the surgery is delayed by more than 12 hours postdose, the patients could receive up to 2 additional administrations (approximately 12 hours apart) to ensure that the last dose is administered between 2 and 12 hours before the surgery."
16582811|NCT02726438|No Intervention|Calibration|A single participant will not receive the study drug, providing data to be used as calibration.
16582812|NCT02726425|Experimental|Second Life Participants|Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)
16582813|NCT02726425|Active Comparator|Face-to-Face Participants|The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.
16582814|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
16582815|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 1|Regimen 1 of ND0612 continuous SC infusion over 24 hrs
16582816|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 3|Regimen 3 of ND0612 continuous SC for over 16 hrs
16582817|NCT02726373|Experimental|Intermittent walking training|
16582818|NCT02726373|Active Comparator|Continuous Walking Training|
16582819|NCT02726360||Oncology physician|Physicians (MD or DO) in the oncology departments of participating hospitals will complete a survey. Non-English language proficiency will be assessed by self-assessment using Interagency Language Roundtable (ILR) scale, which the PI has previously used. The physician survey is collected among treating physicians of patients enrolled to MSK IRB approved protocols 12-099 and 12-223 at some of the participating hospitals. For physicians who already completed this survey as part of participation in protocol 12-099 or 12-223, data will be extracted from the respective study's REDCap database.
16582820|NCT02726360||patients|Audio record the initial visits between patients and their treating physician. Analyze 48 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
16582821|NCT02726347|Active Comparator|Smokers between the ages of 19-80|current smokers between the ages of 19 and 80
16582822|NCT02726347|Active Comparator|elderly individuals (over age 50)|elderly individuals, defined as subjects age 50 years or older, without a history of frequent infections, COPD, or asthma
16582823|NCT02726347|Active Comparator|COPD subjects|COPD subjects between the age of 19 and 80, without history of recurrent bacterial infections.
16582824|NCT02726347|Active Comparator|Asthmatics subjects|Asthmatics between the ages of 19 and 80
16582825|NCT02726347|Active Comparator|Subjects with recurrent bacterial infections|Individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
16582826|NCT02726334|Experimental|Group/Stream 1 - Monotherapy|"Patient group: Patients who have failed at least two lines of chemotherapy for metastatic disease.
~Treatment: BNC101 administered via intravenous infusion over 60 minutes weekly.
~Patients with stable disease or a response at or after day 56 (2 cycles) will be allowed to continue to receive weekly doses of BNC101 until disease progression."
16582827|NCT02726334|Experimental|Group/Stream 2 - Combination Chemo|"Patient Group: Patients who have failed at least one line of chemotherapy for metastatic disease.
~Treatment: BNC101 administered in combination with FOLFIRI
~Participants will be treated until disease progression, intolerable toxicity, withdrawal of consent, or study termination by the Sponsor, whichever occurs first."
16582828|NCT02726308|Active Comparator|Dexamethasone Group|I.V. Dexamethasone 5 mg just before induction plus intra-operative 10 ml/kg Ringer's lactate solution.
16582829|NCT02726308|Active Comparator|Dexamethasone and super-hydration Group|I.V. Dexamethasone 5 mg just before induction of anesthesia plus intraoperative 30 ml/kg Ringer's lactate solution
16582830|NCT02726295|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.
16582831|NCT02726295|Placebo Comparator|Matched placebo|Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).
16582832|NCT02726269|Active Comparator|CLA (Clarithro+Lanso+Amoxi)|Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
16582833|NCT02726269|Experimental|PLA (Panto+Levoflox+Azithro)|Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
16582834|NCT02726256||Diabetes and Impaired glucose Tolerance (G-CREDIT)|Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
16582835|NCT02726243||IBD without CRC|
16582836|NCT02726243||IBD with CRC|
16582837|NCT02726243||IBD with dysplasia|
16582838|NCT02726243||non IBD without CRC|
16582839|NCT02726243||non IBD with CRC|
16582840|NCT02726243||IBD-PSC without CRC|
16582841|NCT02726243||IBD-PSC with CRC|
16582842|NCT02726243||IBD-PSC with dysplasia or healthy subjects|IBD-PSC with dysplasia or healthy subjects for whom a colonoscopy is scheduled
16582843|NCT02726230|Experimental|Ananya Intervention|"Strengthen enumeration and mapping of areas to ensure reach of front line workers (FLWs: auxiliary nurse midwives- ANMs; community health workers- ASHAs; anganwadi workers- AWWs).
~Convene monthly FLW meetings to build skills and get trained in job kits to increase the quantity and quality of household visits.
~Train FLWs on communication skills and use of mobile kunji, a job-aid tool, to improve FLWs' communication with households.
~A mass media campaign inclusive of street theatre, tv and radio, and a mobile van.
~Community mobilization linking mass media efforts with self-help groups.
~Quality improvement activities at public health facilities.
~Facility-based skills training to staff delivering infants to improve quality of care"
16582844|NCT02726230|No Intervention|Control Condition|standard of care public health services in India
16582845|NCT02726217|Experimental|CareSmarts Intervention|Participants in the program receive text messages about diabetes self-care
16582846|NCT02726217|Active Comparator|Control|Standard of Care reminders and assessments for individuals with Diabetes
16582847|NCT02726204|Active Comparator|Healthy Subjects|Seven healthy patients will serve as controls based on preliminary data in healthy volunteers using CAREX with gravity elimination alone versus gravity elimination plus path assistance.
16582848|NCT02726204|Active Comparator|Chronic Post Stroke Right Side Hemiparesis|Radiologically verified unilateral stroke patients with at least 4 months previously.
16582849|NCT02726191|Experimental|Posit Science|
16582850|NCT02726191|Experimental|Lumosity|
16582851|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.
~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
16582852|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.
~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
16582853|NCT02726152|Experimental|Polymer clips|Patients will be randomised to polymer clips for closure of the appendiceal stump
16582854|NCT02726152|Active Comparator|Endoloops|Patients will be randomised to endoloops for closure of the appendiceal stump
16582855|NCT02726139||Emory University|Samples obtained at and shipped from Emory University
16582856|NCT02726139||University of Michigan|Samples obtained at and shipped from University of Michigan
16582857|NCT02726126||C group, (n=25)|C group, (n=25) each patient received transdermal placebo patch
16582858|NCT02726126||TDF group, (n=25)|TDF group, (n=25) each patient received transdermal therapeutic system-fentanyl 50μg/h
16582859|NCT02726126||TDM group, (n=25)|TDM group, (n=25) each patient received transdermal therapeutic system containing 7 mg of melatonin
16582860|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
16582861|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
16582862|NCT02726100|Experimental|Intervention arm|Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.
16582863|NCT02726100|No Intervention|Control arm|"Control group doesn't use SMARTHealth Diabetes.The usual-care in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance."
16582864|NCT02726087|Experimental|ministernotomy|"Minimally invasive aortic valve replacement with Partial J upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice."
16582865|NCT02726087|Active Comparator|full sternotomy|Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.
16582866|NCT02726074|Experimental|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
16582867|NCT02726061|Experimental|Internet Based psychological support|The internet-based psychological support intervention (PATH) is an internet based Problem Solving Therapy, stress management training and conflict management training program.
16582868|NCT02726048|Experimental|Full face/Nasal masks|Simplus/Eson
16582929|NCT02725606|Experimental|GW003 300ug/kg|6-8 subjects
16582930|NCT02725606|Experimental|GW003 650ug/kg|6-8 subjects
16582931|NCT02725606|Experimental|GW003 850ug/kg|6-8 subjects
16582932|NCT02725593|Experimental|Dapagliflozin|
16582869|NCT02726035|Experimental|Group 1 A-ABAB|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 1 will receive oral naltrexone 50 mg daily during weeks 5-7 (3 weeks). They will switch to placebo for weeks 8-10, then return to naltrexone for weeks 11-13, then placebo for weeks 14-16 (i.e., A-ABAB double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
16582870|NCT02726035|Experimental|Group 2 A-BABA|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 2 will receive oral placebo once daily during weeks 5-7. They will then be switched to oral naltrexone 50 mg daily for weeks 8-10, then return to placebo for weeks 11-13, then naltrexone for weeks 14-16 (i.e., A-BABA double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
16582871|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
16582872|NCT02726009|Experimental|Degarelix|
16582873|NCT02725996|Experimental|curative therapy+NK infusion|Adjuvant adoptive immune therapy using NK cell 4 times after curative therapy
16582874|NCT02725996|Other|curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation[RFA]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
16582875|NCT02725983|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015). Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
16582876|NCT02725983|Active Comparator|No Intra Oral camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015) and considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon was not used.
16582877|NCT02725970||Children's Nutrition Research Center|Survey, no intervention.
16582878|NCT02725970||Western Human Nutrition Research Center|Survey, no intervention.
16582879|NCT02725970||Human Nutrition Research Center On Aging|Survey, no intervention.
16582880|NCT02725970||Delta Obesity Prevention Research Center|Survey, no intervention.
16582881|NCT02725970||Beltsville Human Nutr Research Center|Survey, no intervention.
16582882|NCT02725970||Grand Forks Human Nutr Research Center|Survey, no intervention.
16582883|NCT02725957|Experimental|Trehalose 9%|Single dose administration of Trehalose 9% for IV infusion.
16582884|NCT02725957|Placebo Comparator|Saline 0.9%|Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)
16582885|NCT02725944||Patients with cryptogenic stroke and TIA|Implantation of ICRM in all participants.
16582886|NCT02725931|Experimental|Activity group|Pulmonary rehabilitation plus physical activity intervention
16582887|NCT02725918|Experimental|Pem mono|Patients in arm B will receive pemetrexed (500 mg/m2, d1) every 3 weeks until PD or intolerable toxicities.
16582888|NCT02725918|Active Comparator|Pem+Cis|Patients in arm A will receive 4 cycles of cisplatin (75 mg/m2, d1) and pemetrexed (500 mg/m2, d1) every 3 weeks, those without disease progression (PD) and being tolerable judged by investigator will continue single-agent pemetrexed (500 mg/m2, d1) every 3 weeks as maintenance until progression or intolerable toxicities.
16582889|NCT02725905|Experimental|Multi-Modal Education (MME)|1) The MME is a three year multi-modal educational intervention including a series of interactive learning components and interventions focused on integrated weight management counseling. Prior to its launch, each component of the curriculum will be refined using a school participatory approach to help ensure feasibility and acceptability.
16582890|NCT02725905|Active Comparator|Traditional Education (TE)|2) The TE arm of the study includes the school's current curriculum which may include topics related to the treatment of weight management and obesity.
16582891|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
16582892|NCT02725879||HASIMOTO's PATIENTS (HT)|Children and Adolescents diagnosed with Hashimoto's clinical hypothyroidism.
16582893|NCT02725879||CONTROL GROUP (C)|Healthy individuals matched for gender and age
16582894|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
16582895|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
16582896|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
16582897|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
16582898|NCT02725840||Proton beam radiation therapy|The participants in this group will be receiving proton therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
16582899|NCT02725840||X-ray based radiation therapy|The participants in this group will be receiving X-ray radiation therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
16582900|NCT02725827|Active Comparator|HA group|One the day of frozen-thawed embryo transfer, frozen embryos will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife), a hyaluronan-enriched embryo transfer medium, will be used as embryo transfer medium. EmbryoGlue contains a higher concentration of hyaluronan than the control medium.
16582901|NCT02725827|Active Comparator|Control group|For women allocated to the control group, the usual transfer medium used in the study centers will be used and will serve as control. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.
16582902|NCT02725814|Experimental|Sucrose|
16582903|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
16582904|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
16582905|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
16582906|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
16582907|NCT02725775|Active Comparator|100% OJ|240ml 100% Florida Orange Juice consumed on a daily basis for 10 weeks.
16582908|NCT02725775|Placebo Comparator|Equicaloric Orange Drink|An equicaloric placebo orange drink (containing equivalent dose of sucrose, glucose, fructose, vitamin C and citric acid for flavour) consumed daily for 10 weeks.
16582909|NCT02725762|Experimental|Photobiomodulation Treatment|Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
16582910|NCT02725762|Sham Comparator|Sham Treatment|Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
16582911|NCT02725749|Experimental|Laser|
16582912|NCT02725749|Experimental|Exercise|
16582913|NCT02725749|Experimental|Laser and Exercise|
16582914|NCT02725736|Experimental|Atosiban|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Atosiban group.
16582915|NCT02725736|Experimental|Nifedipine|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Nifedipine group.
16582916|NCT02725723|Experimental|Subject after epidural injection|Subjects are patients from the clinic who have been diagnosed with Lumbar spinal stenosis and determined eligible for receiving steroidal epidural injection for pain management
16582917|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
16582918|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
16582919|NCT02725697||TCM treatment|TCM treatment (e.g. acupuncture, Tuina massage, Chinese herbal medicine, moxibustion, electroacupuncture, ear acupuncture)
16582920|NCT02725684||Glioblastoma|Observational study, no intervention
16582921|NCT02725671|Other|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
16582922|NCT02725658|Other|DOSI|
16582923|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
16582924|NCT02725632|No Intervention|Control|"An age-matched control group will be enrolled and consented. A Data Collection Sheet will be used to document data from the subject's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.
~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. Another blood drawn will be collected after one month. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
16582925|NCT02725632|Active Comparator|OSA|"Newly diagnosed OSA patients will be enrolled and consented. A Data Collection Sheet will be used to document data from the patient's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.
~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. The patients on CPAP treatment will be followed-up for 1 month. Another blood drawn will be collected after one month of CPAP treatment. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
16582926|NCT02725619|Experimental|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
16582927|NCT02725619|Active Comparator|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
16582933|NCT02725593|Placebo Comparator|Dapagliflozin placebo|
16582934|NCT02725580|Experimental|Open Label|Subjects with diagnosis of vLINCL6 Batten disease will receive a single intrathecal injection into the lumbar spinal cord region of AT-GTX-501.
16582935|NCT02725567|Experimental|Part A|"Group 1: Participants 12 to < 24 months
~Group 2: Participants 6 to < 12 months (enrollment begins after an assessment of data from Group 1)
~Group 3: Participants 3 to < 6 months (enrollment begins after an assessment of data from Group 2)"
16582936|NCT02725567|Experimental|Part B|"Group 5: Participants 12 to < 24 months (enrollment begins after an assessment of data from Part A, Group 1)
~Group 6: Participants 6 to < 12 months (enrollment begins after an assessment of data from Part A, Group 2)
~Group 7: Participants 4 to < 6 months (enrollment begins after an assessment of data from Part A, Group 3)"
16582937|NCT02725567|Experimental|Part A/B|- Group 8: Participants 1 to < 4 months of age
16582938|NCT02725554|Active Comparator|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
16582939|NCT02725554|Experimental|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
16582940|NCT02725541|Experimental|Experimental|Trastuzumab emtansine at a dose of 3.6 mg/kg will be administered via intravenous infusion for 6 weeks (two 21-day cycles).
16582941|NCT02725528|Active Comparator|collagenase injection|This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.
16582942|NCT02725528|Active Comparator|limited palmar fasciectomy|The Dupuytren's cord will be excised under local anesthesia in a minor procedure room setting or main operating room under local or general anesthetic depending on the complexity of the disease and the surgeon's routine. As this is a pragmatic study comparison of collagenase injections (novel intervention) to limited palmar fasciectomy as it is actually presently performed in all settings academic or community (local in minor room or general/local anesthetic in the main operating room) will be examined. Surgery will be performed according to the operating surgeon's preferred technique i.e. zig-zag Brunner incision or straight incision with z-plasty closure of the skin.
16582943|NCT02725515|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
16582944|NCT02725515|Placebo Comparator|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
16582945|NCT02725502|Active Comparator|Linagliptin treatment group|Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin
16582946|NCT02725502|Placebo Comparator|Placebo group|Group will receive placebo for 3 months in addition to their insulin
16582947|NCT02725489|Experimental|Part 1 Cohort 1: 1x10^6 cells Vigil|The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
16582948|NCT02725489|Experimental|Part 1 Cohort 2: 1x10^7 cells Vigil|Cohort 2 will receive Vigil at 1x10^7 cells/ID injection and durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
16582949|NCT02725489|Experimental|Part 1 Cohort -1: 1x10^5 cells Vigil|If needed, Cohort -1 will be used which will receive Vigil at 1x10^5 cells/ID injection and Durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
16582950|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
16582951|NCT02725463|Experimental|vestibular implant|Up to 30 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
16582952|NCT02725450|Experimental|Motor Imagery + Psychomotor Battery of fine motor skills|Application of Motor Imagery together with normal practice improves fine motor skills in disabled individuals.
16582953|NCT02725437|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
16582954|NCT02725437|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
16582955|NCT02725437|Placebo Comparator|Placebo (accelerated schedule)|
16582956|NCT02725437|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
16582957|NCT02725437|Experimental|High-dose C. difficile Vaccine (non-accelerated schedule)|
16582958|NCT02725437|Placebo Comparator|Placebo (non-accelerated schedule)|
16582959|NCT02725424|Active Comparator|Her2 Positive with SOX|Her-2 Positive patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin 130 mg/m2, iv, d1 S-1 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), po,Bid， d1-14 Every 3weeks
16582960|NCT02725424|Experimental|Her2 Positive with SOXT|Her-2 positive patients treated with Oxaliplatin plus S-1 and Trastuzumab Oxaliplatin : As Above S-1: As Above Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks
16582961|NCT02725424|Active Comparator|Her2 Negative with SOX|Her2 Negative patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin As Above S-1 As Above Every 3 weeks
16582962|NCT02725424|Experimental|Her2 Negative with DOS|Her-2 Negative patients treated with Docetaxel plus Oxaliplatin and S-1（DOS） Docetaxel 60 mg/m2, iv, d1 Oxaliplatin 100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks
16582963|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
16582964|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
16582965|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
16582966|NCT02725398|Experimental|Buscopan group|First to use standard white light to observe, to record spasm score, to observe the lesion.Buscopan (BSP, 20mg) is administered by endoscopic nurse, recorded blindly.
16582967|NCT02725398|Active Comparator|Scopolamine group|First to use standard white light to observe, to record spasm score, to observe the lesion.Scopolamine is administered by endoscopic nurse, recorded blindly.
16582968|NCT02725398|Placebo Comparator|physiological saline group|First to use standard white light to observe, to record spasm score, to observe the lesion. Physiological saline is administered by endoscopic nurse, recorded blindly.
16582969|NCT02725385||Ancillary-Correlative (stress and coping)|"PART I:
~Participants complete a questionnaire that measures several psychological constructs including stress, anxiety, depression, coping mechanisms, uncertainty, positive and negative emotions, and life satisfaction over 15-30 minutes.
~PART II:
~Participants undergo a Trier Social Stress Test during a laboratory session over 1.5 hours."
16582970|NCT02725372|Experimental|Inhaled Nitric Oxide 75mcg/KgIBW/Hr|"Part 1:
~15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.
~Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment (Open Label Treatment - All Subjects)"
16582971|NCT02725372|Placebo Comparator|Placebo|"Part 1:
~Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period"
16582972|NCT02725359|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
16582973|NCT02725359|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
16582974|NCT02725359|Active Comparator|Bupivacaine|Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
16582975|NCT02725346|Experimental|Computer-assisted planning|Acromioplasty with planification
16582976|NCT02725346|Active Comparator|No planning|Acromioplasty without planification
16582977|NCT02725333|Other|Shoulder Stabilization|Anteroposterior and superoinferior translations were assessed in patients, before and after shoulder stabilization, through a dedicated patient-specific measurement technique based on optical motion capture and computed tomography.
16582978|NCT02725320||Female Rotator Cuff Surgical Group|Females, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
16582979|NCT02725320||Male Rotator Cuff Surgical Group|Males, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
16582980|NCT02725294||COPD patients|Veterans with COPD who are cared for at VA Puget Sound Health Care System (Seattle, WA) or VA Eastern Colorado (Denver, CO) who are at high risk for a COPD exacerbation based on an exacerbation treated with prednisone or antibiotics in the year preceding enrollment.
16582981|NCT02725294||Informal Caregiver for COPD patients|Informal caregiver (ie. family member, friend, etc.) for the patient with COPD who is participating in the COPD patients cohort.
16582982|NCT02725281|No Intervention|Control group|"The patients in Group-I were not interfered by researchers before and during lithotripsy."
16582983|NCT02725281|Active Comparator|Stress ball|"The patients in Group II were given stress ball into their both palms as a before the lithotripsy and told to squeeze the ball whenever they would like."
16582984|NCT02725281|Active Comparator|Music|"The patients in Group-III were listened to the music chosen by them with a headset as a nonpharmacological method during lithotripsy."
16582985|NCT02725268|Experimental|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligrams per square meter (mg/m^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
16582986|NCT02725268|Experimental|Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg|Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
16582987|NCT02725268|Experimental|Sapanisertib 30 mg|Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
16582988|NCT02725268|Experimental|Sapanisertib 4 mg + MLN1117 200 mg|Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
16582989|NCT02725255|Experimental|Papaya seed porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
16582990|NCT02725255|Active Comparator|Albendazole and Plain porridge|Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
16582991|NCT02725255|Placebo Comparator|Plain porridge|arm receiving 300ml plain porridge daily (without papaya seeds)
16582992|NCT02725242|Experimental|Once-daily budesonide/formoterol (160/4.5 μg/d)|once-daily budesonide/formoterol (160/4.5 μg/d)
16582993|NCT02725242|Active Comparator|Twice-daily Budesonide (200μg)|twice-daily Budesonide (400μg/d)
16582994|NCT02725229|Active Comparator|parasternal block group|Patients in this group will be randomized to receive an parasternal block and PCA.
16582995|NCT02725229|Active Comparator|TENS group|Patients in this group will be randomized to receive an TENS and PCA.
16582996|NCT02725229|Active Comparator|control group|Patients in this group will be randomized to receive an PCA.
16582997|NCT02725203|Experimental|Intervention: Activate intervention|Participants in the intervention arm will visit their primary care nurse four times in a three-month period for structured and comprehensive support in achieving an improved level of physical activity.
16582998|NCT02725203|No Intervention|Control|Patients in the control arm will receive care as usual.
16582999|NCT02725190|Other|Group 1|Normal sleep night.
16583000|NCT02725190|Other|Group 2|Sleepless night.
16583001|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
16583002|NCT02725164|Placebo Comparator|Uncuffed tracheal tubes|After tracheal intubation with an uncuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
16583003|NCT02725164|Active Comparator|Cuffed tracheal tubes|After tracheal intubation with a cuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
16583004|NCT02725138|Experimental|Probiotic|subjects will be treated with probiotic containing Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
16583005|NCT02725138|Placebo Comparator|Placebo|subjects will be treated with placebo without Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
16583006|NCT02725125|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0days,the first day,the second day,28 days,29 days Duration:total five times
16583007|NCT02725112|Experimental|Pregabalin ER- Target Release 330mg|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
16583008|NCT02725112|Experimental|Pregabalin ER - Slow Release 330mg|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
16583009|NCT02725112|Experimental|Pregabalin ER - Fast Release 330mg|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
16583010|NCT02725112|Experimental|Pregabalin IR - 300mg|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
16583011|NCT02725112|Experimental|Pregabalin ER - Target Release 82.5mg|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
16583012|NCT02725112|Experimental|Pregabalin ER - Aberrant Fast 330mg|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
16583013|NCT02725099|Active Comparator|Oral Ticagrelor|
16583014|NCT02725099|Experimental|Chewing Ticagrelor|
16583015|NCT02725086|Experimental|Part 1; Filgrastim 5 ㎍/kg|Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
16583016|NCT02725086|Experimental|Part 2; Filgrastim 10 ㎍/kg|Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
16583017|NCT02725073|Experimental|photodynamic therapy|Photodynamic therapy with a novel photosensitizer and flexible laser catheter
16583018|NCT02725060|Experimental|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:
~Posture study with blood samples for autoantibody testing
~24-hour heart rhythm and blood pressure monitoring
~autonomic function tests
~Quantitative Axonal Sudomotor Reflex Testing
~Total blood volume assessment
~Pharmacologic testing with phenylephrine
~Pharmacologic testing with isoproterenol
~Cardiac output with rebreathing
~Assessment of splanchnic capacitance
~Microneurography"
16583019|NCT02725047|Experimental|TREATMENT - CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
16583020|NCT02725047|Placebo Comparator|PLACEBO - SAND|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
16583021|NCT02725034|Active Comparator|Group 1|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
16583022|NCT02725034|Experimental|Group 2|High definition endoscopy with Optic Enhancement targeted biopsies for gastric intestinal metaplasia.
16583023|NCT02725021|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
16583024|NCT02725021|No Intervention|Control group|
16583025|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
16583026|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
16583027|NCT02724969|Experimental|MILK intervention group|Semi-automated text messages sent to participants' cellular phones 3-5 times per week beginning Week 25 of pregnancy, through 8 weeks postpartum, specific to breastfeeding support and prevention of perceived insufficient milk supply.
16583028|NCT02724969|Active Comparator|Text4Baby control intervention group|Text4Baby automated texts sent to participants' cellular phones 3-5 times per week from Week 25 of pregnancy through the postpartum period from the national Text4Baby system. Messages provide general prenatal and postpartum support, including breastfeeding.
16583029|NCT02724956|Experimental|Ambu AuraGain|"SGAD placement using Ambu AuraGain
~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.
~Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.
~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.
~Inflate cuff and remove aScope."
16583030|NCT02724956|Experimental|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector
~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.
~Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.
~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.
~Inflate cuff and remove aScope."
16583056|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
16583057|NCT02724774|Experimental|Promoting First Relationships® (PFR)|10 week home visiting program
16583058|NCT02724774|No Intervention|Parent Information Packet|A packet is mailed to the families, including handouts related to child development, health, and local resources.
16583059|NCT02724761|Experimental|Experimental: Racemic Epinephrine|Over the Counter (OTC) - 0.5 mL Nebulized Racemic Epinephrine
16583060|NCT02724761|Placebo Comparator|Placebo: 0.9% Normal Saline|0.5 mL 0.9% Normal Saline
16583031|NCT02724943|Experimental|TX CORD Intervention|TX CORD Intervention. The intervention entailed: (1) BMI screening, (2) Next Steps brief counseling materials for the healthcare provider, (3) a 3-month intensive Mind Exercise Nutrition Do It! and Coordinated Approach To Child Health (MEND/CATCH) phase, which included the Mind Exercise Nutrition Do it! ( MEND) programs for preschool (ages 2-5) and school-aged (ages 6-12) children coupled with adapted CATCH activities, and (5) a 9-month transition MEND/CATCH Transition phase, which offered monthly reinforcement sessions for parents and children, and twice weekly Young Men's Christian Association (YMCA) sports for children. Community Health Workers (CHWs) serve as program liaisons and assist in delivering all intervention group sessions as well as tracking families. Electronic Health Record (EHR) changes supported the screening and Next Steps delivery.
16583032|NCT02724943|Active Comparator|Brief Clinic Comparison|Next Steps brief clinical intervention. The comparison program was a 12-month clinic-based program conducted at twelve partner healthcare clinics and entailed (1) EHR changes to support childhood obesity clinical visits; (2) BMI screening, (3) Next Steps brief counseling materials for the healthcare provider, and (4) Next Steps self-paced booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity.
16583033|NCT02724930|No Intervention|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
16583034|NCT02724930|Experimental|Implementation Facilitation|"Enhanced facilitation of COPES implementation.
~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
16583035|NCT02724917|Experimental|APN1125, Low Dose|APN1125, Low Dose
16583036|NCT02724917|Experimental|APN1125, Mid Dose|APN1125, Mid Dose
16583037|NCT02724917|Experimental|APN1125, High Dose|APN1125, High Dose
16583038|NCT02724917|Placebo Comparator|Placebo|Placebo to match
16583039|NCT02724904|Experimental|Allogeneic Stem Cell Transplantation|Patients will undergo reduced intensity conditioning (fludarabine and thiotepa) followed by fully matched related or unrelated allogeneic stem cell transplantation. Afterwards, patients will receive standard post-transplant care (Methotrexate).
16583040|NCT02724891||Arm 1 paper form first|paper questionnaires first then web/smart phone questionnaires after a 2-week washout period
16583041|NCT02724891||Arm 2 web/smartphone form first|web/smart phone questionnaires first then paper questionnaires after a 2-week washout period
16583042|NCT02724878|Experimental|Bevacizumab And Atezolizumab Combination|"1200 mg of Atezolizumab intravenously x 3 weeks
~15 mg/kg of Bevacizumab intravenously x 3 weeks.
~One cycle will be 3 weeks in duration."
16583043|NCT02724865|Active Comparator|Oral appliance therapy; Somnodent®|Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
16583044|NCT02724865|Active Comparator|Oral appliance therapy; Herbst®|Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
16583045|NCT02724852|Active Comparator|HIV-infected adults|"Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.
~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
16583046|NCT02724852|Experimental|HIV-uninfected adults|"Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.
~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
16583047|NCT02724839|Experimental|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
16583048|NCT02724839|Experimental|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
16583049|NCT02724839|Experimental|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
16583050|NCT02724826|Experimental|Qigong therapy|The qigong treatment was done according to medical qigong, and is a way of affecting and directing qi (energy) for medical benefit. Each qigong practice included body posture adjustment, gentle movement, meditation, relaxation, breathing regulation practices and massage. The qigong was practiced in groups of ten to 15 participants. Each qigong session started with information about the philosophy and a general warm-up with soft movements and 14 selected qigong exercises according to the Biyun method.
16583051|NCT02724826|Active Comparator|Exercise therapy|Exercise therapy was carried out individually, adjusted for each participant. A physiotherapist instructed the participant with focused on the cervical and shoulder/thoracic regions. Each training session included stationary bicycle for ten minutes, 40 minutes of dynamic exercises. These exercises consisted of active movements in all neck directions and muscle exercises aimed to maintain/increase circulation, endurance and strength. The load at the muscle exercises was to achieve between 30 and 70% of maximum muscle capacity and was gradually increased as endurance and strength were gained.
16583052|NCT02724813|Experimental|Intervention arm|Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
16583053|NCT02724813|Active Comparator|Wait-list arm|Participant in this arm will receive therapy 8 weeks after initial assessment. Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
16583054|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
16583055|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
16584256|NCT02716935|Active Comparator|lipid based nutrient supplement|lipid based nutrient supplement (Nutributter)
16583061|NCT02724748|Experimental|Educational intervention|Beside usual care the intervention will encourage collaborative practices between staff, patients and family members to adopt more human patient-centred approach on the unit. The intervention is designed to impact on treatment culture and thereby treatment practices on the study wards.
16583062|NCT02724748|No Intervention|Treatment as usual|Wards allocated to comparison wards continue with their usual care. No restrictions on how nursing staff works in these wards, although participation in corresponding projects is not supported.
16583063|NCT02724735||Longitudinal Observational Cohort|Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189.
16583064|NCT02724722|Experimental|Intervention|a simple flyer in one empty bag with face-to-face health education
16583065|NCT02724722|Placebo Comparator|No Intervention|a simple flyer in one empty bag with no face-to-face health education
16583066|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
16583067|NCT02724670|Other|Radiation|IGRT 5x 2Gy/week, total dose: 78 Gy
16583068|NCT02724657|Experimental|Buteyko Method|Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
16583069|NCT02724657|No Intervention|Control|Asthma education.
16583070|NCT02724644|Experimental|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
16583071|NCT02724644|Placebo Comparator|EN3835 Placebo|Placebo
16583072|NCT02724631|Experimental|TubeClear® (Phase I)|To determine feasibility and tolerability, 15 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
16583073|NCT02724618|Experimental|Curcumin plus RT|120mg/day nanocurcumin during RT course
16583074|NCT02724618|Placebo Comparator|Placebo plus RT|120mg/day placebo of nanocurcumin during RT course
16583075|NCT02724605|Other|Group A|Red blood cells unit age 14 days or less
16583076|NCT02724605|Other|Group B|Red blood cells unit age more than 14 days
16583077|NCT02724592|Experimental|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
16583078|NCT02724592|Active Comparator|control|control group, only Fluoride varnish (Duraphat®)
16583080|NCT02724566|Other|Apelin then Placebo|First clamp during which an apelin infusion will be administered followed by a wash-out period and then, a second clamp in which a placebo infusion will be administered
16583081|NCT02724566|Other|Placebo then Apelin|First clamp during which a placebo infusion will be administered followed by a wash-out period and then, a second clamp in which an apelin infusion will be administered
16583082|NCT02724553|Other|Vertical orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the vertical position during routine cataract surgery
16583083|NCT02724553|Other|Horizontal orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the horizontal position during routine cataract surgery
16583084|NCT02724540|Experimental|Arm 1 - BE|Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.
16583085|NCT02724540|Experimental|Arm 2 - TACE|Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
16583086|NCT02724540|Experimental|Arm 3 - DEB - CLOSED|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.
16583087|NCT02724527|Placebo Comparator|Placebo|Matching capsule (BID administration Q12H)
16583088|NCT02724527|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) at 400 mg dose (100 mg x 4 capsules) (BID administration Q12H)
16583089|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
16583090|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
16583091|NCT02724475|Experimental|LA group|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated.
16583092|NCT02724475|Experimental|3D-CRT group|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times.
16583093|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
16583094|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
16583095|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
16583096|NCT02724436|Experimental|TACE|transcatheter arterial chemoembolization
16583097|NCT02724436|Experimental|TACE+radioembolization|TACE plus radioembolization with Y-90: 100
16583098|NCT02724423|Experimental|NRL-1 Ictal|During the ictal or peri-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
16583099|NCT02724423|Experimental|NRL-1 Inter-Ictal|During the inter-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
16583100|NCT02724410|Active Comparator|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages <13; age 13 or greater, then 1 gm daily)
16583101|NCT02724410|Experimental|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
16583102|NCT02724397|Experimental|Experimental group|(White endoscopy and then LCI/BLI) The patients will be evaluated by Standard White Light and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI).
16583103|NCT02724397|Active Comparator|Control group|(LCI/BLI then white endoscopy) The patients will be evaluated by Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy.
16583104|NCT02724384|Experimental|Group 1|Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly
16583105|NCT02724384|Experimental|Group 2|Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly
16583106|NCT02724384|Experimental|Group 3|Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly
16583107|NCT02724371|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
16583108|NCT02724371|Experimental|Revision Breast Reconstruction|participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
16583109|NCT02724358|Experimental|TACE|iodized oil (5ml) + Pirarubicin (20mg)
16583110|NCT02724358|Experimental|Rg3|20mg, BID, maintained though Month 12
16583111|NCT02724358|Experimental|TACE + Rg3|the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
16583112|NCT02724358|Experimental|Control|standard liver protective therapy
16583113|NCT02724345||CK18 positive|HCC patients with CK18 high expression levels in tumor tissue.
16583114|NCT02724345||CK18 negative|HCC patients with CK18 high expression levels in tumor tissue.
16583115|NCT02724332|No Intervention|control group|Patients will be treated with radical hepatectomy only.
16583116|NCT02724332|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE
16583117|NCT02724319||Left heart catheterization patients|Patients presenting to the UF Health Jacksonville cardiac catheterization laboratory for left heart catheterization for suspected coronary artery disease and intent to undergo percutaneous coronary intervention will be targeted for enrollment and will be genotyped by SpartanRX
16583118|NCT02724306|Experimental|Active Lifestyle Programme|ALP will receive supervised exercise sessions twice per week for three months and once per week for the following three months. Participants will also take part in biweekly physical activity workshops for the period of the intervention. Each session consists of a warm-up (5-10min), aerobic (20-30min) and resistance exercises (15-20), and cool-down (5-10)stretches lasting in total 60min. The intensity of exercises will be at 65-85% of maximum heart rate as determined by maximal fitness test. Exercise will take place in small groups of two to five people. Behaviour change workshops to aid the uptake and maintenance of physical activity will be delivered every fortnight throughout the whole intervention period totalling 12 workshops. Workshops will also take place in small groups.
16583119|NCT02724306|No Intervention|Standard Care|The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
16583120|NCT02724293|Placebo Comparator|Group I (placebo)|patients received placebo.
16583121|NCT02724293|Active Comparator|Group II (pregabaline 300 once)|patients received pregabalin 300 mg 2 hours preoperatively.
16583122|NCT02724293|Active Comparator|Group III (pregabaline 300 twice)|patients received pregabalin 300 mg 2 hours preoperatively and 12 hours after the preoperative dose.
16583123|NCT02724293|Active Comparator|Group IV (pregabaline 600)|patients received pregabalin 600 mg 2 hours preoperatively
16583124|NCT02724280|Active Comparator|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
16583125|NCT02724280|Placebo Comparator|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
16583126|NCT02724267|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE only.
16583127|NCT02724267|Experimental|internal radiation group|Patients will be treated with TACE combined with internal radiation.
16583128|NCT02724254|Experimental|AP611074 5% gel|100 mg twice daily doses of AP611074 5% gel
16583129|NCT02724254|Placebo Comparator|Placebo|AP611074 matching placebo gel
16583130|NCT02724241|Experimental|nicotine|use of an e-cigarette filled with liquid with nicotine
16583131|NCT02724241|Experimental|no nicotine|Use of an e-cigarette filled with liquid without nicotine
16583132|NCT02724241|Sham Comparator|sham comparator|Use of empty e-cigarette (sham control)
16583133|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study, initially up to 30 μg/kg. BMN 111 will be administered in the daily dosing regimen: 15 μg/kg per day.
16583134|NCT02724215||Patients with Sleep Apnea|Patients with increased apnea-hypopnea-index (>5/h)
16583135|NCT02724215||Patients without Sleep Apnea|Patients with normal apnea-hypopnea-index (5/h and below)
16583136|NCT02724202|Experimental|Open Label|All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
16583137|NCT02724189||Patients attending the preoperative assessment clinic|Patients in preoperative assessment clinic
16583138|NCT02724176|Experimental|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
16583139|NCT02724163|Active Comparator|Mitoxantrone|"Course 1
~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).
~Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).
~Course 2
~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).
~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
16583140|NCT02724163|Experimental|Liposomal daunorubicin|"Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.
~Course 1
~Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).
~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).
~Course 2
~Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).
~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
16583141|NCT02724163|Experimental|Gemtuzumab Ozogamicin Dose Finding Study|"Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.
~Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.
~Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10."
16583142|NCT02724163|Active Comparator|High dose cytarabine|Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
16583143|NCT02724163|Experimental|Fludarabine & cytarabine|"Two courses of:
~Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).
~Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion"
16583144|NCT02724163|Active Comparator|Myeloablative conditioning|"Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).
~Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses)."
16583145|NCT02724163|Experimental|Reduced intensity conditioning|"Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).
~Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses)."
16583146|NCT02724150|Active Comparator|Omeprazole High dose|Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
16583147|NCT02724150|Experimental|Omeprazole Low Dose|Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
16583148|NCT02724137|Experimental|Physical Therapy Rehab and Fitbit®|Standard outpatient physical therapy rehabilitation after total knee replacement with the addition of a Fitbit® to promote physical activity.
16583149|NCT02724137|Active Comparator|Physical Therapy Rehab|Standard outpatient physical therapy rehabilitation after total knee replacement.
16583150|NCT02724124|Experimental|static stretching|group of 11 volunteers (gSS)
16583151|NCT02724124|Experimental|warm up -|group of 11 volunteers (gWU)
16583152|NCT02724124|Experimental|static stretching + warm up|(group of 11 volunteers - SS+WU)
16583153|NCT02724124|Experimental|warm up+static stretching|(group of 11 volunteers - WU+SS)
16583154|NCT02724124|Other|Control Group|No intervention - athletes rested
16583155|NCT02724111|Experimental|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade [NMB] (train-of-four [TOF] count 0, post-tetanic count [PTC] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
16583156|NCT02724111|Active Comparator|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade [NMB] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change [a prone position]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
16583157|NCT02724098|Active Comparator|intravenous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
16583158|NCT02724098|Active Comparator|subcutaneous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.
16583159|NCT02724085|Active Comparator|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16583160|NCT02724085|Active Comparator|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16583161|NCT02724085|Active Comparator|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16583162|NCT02724085|Active Comparator|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16584257|NCT02716935|No Intervention|non intervention group|This group will not be supplemented
16583163|NCT02724085|Active Comparator|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16583164|NCT02724085|Active Comparator|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16583165|NCT02724085|Active Comparator|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
16583166|NCT02724072|Experimental|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
16583167|NCT02724059|Experimental|Patients with mediastinal lesions|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA
16583168|NCT02724046|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
16583169|NCT02724046|Active Comparator|Household prophylaxis|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
16583170|NCT02724046|Active Comparator|Village prophylaxis|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
16583171|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
16583172|NCT02724033|Active Comparator|Group B|Group B - antiemetic
16583173|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
16583174|NCT02724020|Active Comparator|Arm A: Single-agent Everolimus 10 mg QD|Everolimus 10 mg capsules, orally, once daily (QD) in a 28-day treatment cycle until disease progression, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program (Median duration of treatment was 15.43 weeks up to data cut-off: 6 March 2020).
16583175|NCT02724020|Experimental|Arm B: Single-agent MLN0128 30 mg QW|MLN0128 30 mg capsules, orally, once weekly (QW) on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.64 weeks up to data cut-off: 6 March 2020).
16583176|NCT02724020|Experimental|Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD|MLN0128 4 mg and MLN1117 200 mg capsules, orally, both once daily for 3 days per week (QD X 3) on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.43 weeks up to data cut-off: 6 March 2020).
16583177|NCT02724007||All participants|
16583178|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
16583179|NCT02723981|Experimental|COMBO-Stent|Implantation of COMBO-Stent and medication with (N)OAC and clopidogrel for 3 months followed by (N)OAC alone
16583180|NCT02723981|Active Comparator|Any Drug eluting or bare metal stent|Implantation of any drug eluting oder bare metal stent combined with anticoagulant medication according to ESC guidelines
16583181|NCT02723968|Other|Continuous glucose monitoring system|OGTT followed by continuous glucose monitoring system and finally IGTT and HbA1C dosage
16583182|NCT02723955|Experimental|Part 1A: Dose escalation feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
16583183|NCT02723955|Experimental|Part 1B: Expansion feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
16583184|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
16583185|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
16583186|NCT02723955|Experimental|Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)|Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
16583187|NCT02723955|Experimental|Part 2B: Expansion-feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
16583188|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
16583189|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
16583190|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
16583191|NCT02723942|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
16583192|NCT02723942|No Intervention|no intervention|no intervention
16583193|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
16583194|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
16583195|NCT02723916|Experimental|Intervention: ezParent Program|
16583196|NCT02723916|Active Comparator|Control: Health-e Kids App|
16583197|NCT02723903|Other|with CAD and somatic symptom|Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
16583198|NCT02723903|Other|without CAD, with somatic symptom|Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
16583199|NCT02723903|No Intervention|without CAD, without somatic symptom|Have neither coronary artery disease nor somatic symptom, continue follow-up.
16583200|NCT02723903|Other|with CAD, without somatic symptom|Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
16583201|NCT02723890|Experimental|Tyto Device|examination with Tyto device carried out by a nurse and sent online to the principle and co-investigators for remote analysis.
16583202|NCT02723877|Experimental|Eribulin and PQR309|PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing.
16583203|NCT02723864|Experimental|1|VX-970 will be administered IV on Days 2 and 9 of each 21-day cycle; Veliparib will be administered orally twice a day (BID) Days 1-3 and 8-10 of each cycle; Cisplatin will be administered at 40 mg/m2 IV Day 1 (and Day 8 from DL3 onwards) of each cycle
16583204|NCT02723851||Acute MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
16583205|NCT02723851||Non-MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
16583206|NCT02723825|Placebo Comparator|Less or equal to 2mm|the residual displacement is less than or equal to 2mm
16583207|NCT02723825|Placebo Comparator|Between 2-4mm|the residual shift is between 2-4mm, manual reset once again, as still between 2-4mm
16583208|NCT02723825|Active Comparator|Greater than 4mm|the residual displacement is greater than 4mm
16583209|NCT02723812|Experimental|GCFLU® Influenza vaccine (Split virion, Inactivated)|One dose 0.5 mL vaccine GCFLU® administered intramuscularly.
16583210|NCT02723799|Experimental|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
16583211|NCT02723799|Other|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
16583212|NCT02723786|Experimental|GSK1070806 3 mg/kg IV|Subjects received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Subjects also received a combination immunosuppression comprized of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.
16583213|NCT02723773|Experimental|LTFU Group|Long-Term Follow-Up of the subjects who received at least one dose of the HZ/su vaccine in the primary studies ZOSTER-006/022
16583214|NCT02723773|Experimental|Additional Dose Group (1AdD Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 1 additional dose of the HZ/su vaccine in the current study.
16583215|NCT02723773|Experimental|Revaccination Group (Rev Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 2 additional doses of the HZ/su vaccine in the current study on a 0, 2 Month schedule (N=60).
16583216|NCT02723773|Sham Comparator|Control Group (Ctrl Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive no additional doses of the HZ/su vaccine in the current study and will control for the 1-Additional and Revaccination groups
16583217|NCT02723760|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of rheumatoid arthritis
16583218|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
16583219|NCT02723734||African-American Men (AAM)|AAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
16583220|NCT02723734||Non-African American Men (NAAM)|NAAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
16583221|NCT02723721|Experimental|Picato gel|application on1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
16583222|NCT02723708|Experimental|Self activation of VTA bold signal|Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
16583223|NCT02723695|Experimental|Patients|Surgery (cochlear implantation)
16583224|NCT02723695|Active Comparator|Controls|Asymptomatic subjects
16583225|NCT02723669|Experimental|AR10|AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g)
16583226|NCT02723669|Active Comparator|acetylcysteine|acetylcysteine solution; oral 20% (200 mg/mL)
16583227|NCT02723656|Active Comparator|Proactive mailed care coordination|
16583228|NCT02723656|Active Comparator|Proactive telephone care coordination.|
16583229|NCT02723630|Experimental|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
16583230|NCT02723630|Experimental|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
16583231|NCT02723630|Experimental|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
16583232|NCT02723630|Experimental|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
16583233|NCT02723630|Experimental|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
16585708|NCT02707744||atrial fibrillation|patients with heart failure and atrial fibrillation
16583234|NCT02723630|Experimental|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
16583235|NCT02723617|Other|MED 0.5|
16583236|NCT02723617|Other|MED 2.5|
16583237|NCT02723617|Other|MED 5.5|
16583238|NCT02723617|Other|AAD 2.5|
16583239|NCT02723604|Experimental|Experimental: Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
16583240|NCT02723591|Active Comparator|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
16583241|NCT02723591|Active Comparator|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
16583242|NCT02723578|Experimental|Pemetrexed and Erlotinib|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and Erlotinib 150 mg PO once daily on days 1-21 every 21 days
16583243|NCT02723552|No Intervention|Control|Control participants undergo no intervention.
16583244|NCT02723552|Experimental|Exercise|Exercise group participants will undergo 16 weeks of 3x/week supervised aerobic exercise of at least 40 minutes per session. After the supervised exercise phase, they will be monitored and supported to maintain an increased physical activity level for eight months.
16583245|NCT02723539|Experimental|MBN-101|MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
16583246|NCT02723539|Placebo Comparator|Vehicle|MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate
16583247|NCT02723526||Single arm|
16583248|NCT02723513|Experimental|Preterm Adults|All enrolled preterm adults will undergo non-contrast enhanced MRI (using ultra-short echo time methods), hyperpolarized noble gas MRI (using hyperpolarized xenon-129), x-ray computed tomography (CT), pulmonary function tests, and questionnaires in a single visit.
16583249|NCT02723500|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
16583250|NCT02723487|No Intervention|Group A|Control
16583251|NCT02723487|Active Comparator|Group B|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.125%), 0.5 ml/kg on each side.
16583252|NCT02723487|Active Comparator|Group C|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.25%), 0.5 ml/kg on each side.
16583253|NCT02723474|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.
16583254|NCT02723461|Active Comparator|pulsatile oxytocin|Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
16583255|NCT02723461|Active Comparator|continuous oxytocin|Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
16583256|NCT02723448|Other|Single Arm Study|Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant [Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients]. There is no maximum number of cycles.
16583257|NCT02723435|Experimental|Midostaurin|Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16583258|NCT02723422|Experimental|Prehabilitation Visit/Increased Physical Therapy post-TAVR|
16583259|NCT02723422|Active Comparator|Control|Standard of care physical therapy post-TAVR
16583260|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
16583261|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
16583262|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
16583263|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
16583264|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
16583265|NCT02723396||Parkinson|Prospective observation of a cohort of consecutive patients with idiopathic PD in an ecological setting.
16583266|NCT02723396||Healthy|The same assessments will be performed in a subgroup of age- and sex-matched healthy volunteers.
16583267|NCT02723383|Experimental|BACLOFEN|patient will receive baclofen caps
16583268|NCT02723383|Placebo Comparator|PLACEBO|patient will receive placebo caps (lactose)
16583269|NCT02723370|Experimental|Initial Intervention|Staff will receive the intervention during the initial intervention period.
16583270|NCT02723370|Experimental|Delayed Intervention|Staff will receive the intervention during the replication study.
16583271|NCT02723357|Experimental|Financial Coaching & Access to Services|Participants in this arm will receive monthly financial coaching and access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
16583272|NCT02723357|Active Comparator|Access to Services|Participants in this arm will receive access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
16585712|NCT02707705|No Intervention|No intervention: group C|Patients without any device or intervention.
16583273|NCT02723344|Experimental|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
16583274|NCT02723344|Placebo Comparator|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
16583275|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
16583276|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
16583277|NCT02723318|Experimental|Financia Coaching & Social Services Referrals|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
16583278|NCT02723318|Active Comparator|Social Services|Enrollment in the control arm offers access to social services referrals.
16583279|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
16583280|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.
~+topical testosterone treatment for >1 year"
16583281|NCT02723292|Experimental|Experimental group services|This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
16583282|NCT02723292|Active Comparator|Control group services|Youth in the control arm will receive a work readiness training curriculum focused on competencies to secure employment. This will include such topics as building customer service skills, clear and direct communication, and creating a work portfolio.
16583283|NCT02723279|Experimental|EPNS group|
16583284|NCT02723279|Active Comparator|TT group|
16583285|NCT02723266|Experimental|Intervention|Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
16583286|NCT02723266|No Intervention|Control|Control does not receive the intervention.
16583287|NCT02723253|Experimental|Radiotherapy plus Tom-Ox|Patients received concomitant boost RT (55 Gy/5 weeks) with concurrent Tom-Ox chemotherapy. The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
16583288|NCT02723240|Other|Part 1|"NUC-3373 IV Infusion on Day 1, Day 8, Day 15, Day 22, (28 day cycle)
~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
16583289|NCT02723240|Other|Part 2|"NUC-3373 IV Infusion on Day 1, Day 15 (28 day cycle)
~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
16583290|NCT02723227|Experimental|Financial Coaching & Social Service Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
16583291|NCT02723227|Active Comparator|Social Services Referral|Enrollment provides for access to referrals to social services.
16583292|NCT02723214|Active Comparator|Frame-based stereotactic brain biopsy|Brain biopsy
16583293|NCT02723214|Active Comparator|Frameless fiducial-less brain biopsy|Brain biopsy
16583294|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
16583295|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
16583296|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
16583297|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
16583298|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
16583299|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
16583300|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
16583301|NCT02723188|Sham Comparator|Sham|Sham electrical stimulation
16583302|NCT02723188|Experimental|DC: Direct current|Direct current electrical stimulation
16583303|NCT02723188|Experimental|AC: Alternating current|Alternating current electrical stimulation
16583304|NCT02723175|Experimental|Sham tDCS Stimulation|"30 minutes of the sham transcranial Direct Current Stimulation
~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
16584321|NCT02716493|Experimental|Telerehabilitation group|Patients with unresectable thoracic neoplasia receiving chemotherapy treatment
16583305|NCT02723175|Experimental|Anodal tDCS Stimulation of DLPFC|"30 minutes of the active transcranial Direct Current Stimulation (tDCS)
~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
16583306|NCT02723162|Experimental|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
16583307|NCT02723162|Active Comparator|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
16583308|NCT02723162|Active Comparator|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
16583309|NCT02723162|Placebo Comparator|PBO+PBO|Double placebo taken for 28 days
16583310|NCT02723149|Experimental|Approach Avoidance Training Condition|The AAT group will push away the joystick from marijuana pictures 90% of the trials and pull towards the marijuana pictures 10% of the trials.
16583311|NCT02723149|Sham Comparator|Sham Condition|The sham group will undergo the same procedures, except the ratio for marijuana pictures will be 50% push and 50% pull.
16583312|NCT02723136|Experimental|Smartphone application|Participants allocated to this arm will receive a smartphone application developed to assist and guide the study of internal medicine and its subspecialties. The application will provide feedback to participants regarding their overall performance in terms of correct answers and the overall time required to solve a clinical vignette.
16583313|NCT02723136|No Intervention|Usual care|Students allocated to this arm will not receive any further assistance in studying for this trial's tests.
16583314|NCT02723123|Experimental|CPAP|CPAP will be provided for a approximately 45 minutes.
16583315|NCT02723123|Experimental|NIPPV|NIPPV will be provided for a approximately 45 minutes.
16583316|NCT02723123|Experimental|NIV-NAVA|NIV-NAVA will be provided for a approximately 45 minutes.
16583317|NCT02723110||rs78408340 heterozygous carriers|
16583318|NCT02723110||homozygous non-risk allele carriers|
16583319|NCT02723097|Experimental|Relaxation Response Resiliency Program (3RP)|
16583320|NCT02723084|Experimental|Arm A|Co-formulated ABT-493/ABT-530 (300 mg/120 mg) administered once daily (QD) for 8 weeks in HCV genotype (GT) 2 -infected, DAA treatment-naïve participants without cirrhosis.
16583321|NCT02723084|Active Comparator|Arm B|sofosbuvir (400 mg) QD co-administered with weight based ribavirin (RBV) 600-1000 mg divided twice daily (BID) for 12 weeks in HCV GT2 -infected, DAA treatment-naïve participants without cirrhosis.
16583322|NCT02723071|Experimental|Cohort A: Ocrelizumab 200 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
16583323|NCT02723071|Experimental|Cohort B: Ocrelizumab 375 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
16583324|NCT02723071|Experimental|Cohort C: Ocrelizumab 375/750 mg/m^2|Participants will receive first infusion of ocrelizumab 375 mg/m^2 followed by 7 infusions of 750 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
16583325|NCT02723058|Experimental|ICMHM|ICMHM mothers receive services of a primary care clinician (PCP) and a care manager both trained in depression care management in a shelter-based primary care clinic.
16583326|NCT02723058|No Intervention|Treatment as Usual|Treatment as Usual mothers receive usual services of a PCP and case manager from a shelter-based primary care clinic. .
16583327|NCT02723045|Active Comparator|Open modified Lichtenstein repair|Patients will undergo open repair of their inguinal hernias
16583328|NCT02723045|Active Comparator|Laparoscopic TEP inguinal hernia repair|Patients will undergo laparoscopic repair of their inguinal hernias
16583329|NCT02723032|Other|Healthy Subjects and patients|Validation of SpO2 sensor in healthy subjects as a first step. Validation of SpO2 sensor in patients as a second step.
16583330|NCT02723019|Experimental|Intervention Group|Volunteer Peer Mentor + Behavioral Health Nurse
16583331|NCT02723019|No Intervention|Control|Care as Usual
16583332|NCT02723006|Experimental|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
16583333|NCT02723006|Experimental|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
16583334|NCT02723006|Experimental|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
16583335|NCT02722993|Active Comparator|Probiotics|
16583336|NCT02722993|Placebo Comparator|Placebo|
16583337|NCT02722980|Placebo Comparator|Placebo|Capsules
16583338|NCT02722980|Active Comparator|Active|Capsules.
16583339|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
16583340|NCT02722954|Experimental|Demcizumab and Pembrolizumab|Demcizumab will be administered prior to pembrolizumab
16583341|NCT02722941|Active Comparator|Cohort A: Maintenance Therapy|Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
16583342|NCT02722941|Active Comparator|Cohort B: Maintenance Therapy|Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.
16583343|NCT02722928|No Intervention|Conventional 1:1 oxygen/air gas mixture|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
16583344|NCT02722928|Experimental|Pure oxygen ventilation|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture (60% oxygen concentration) during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with 100% (pure) oxygen concentration
16583345|NCT02722915|Experimental|fMRI Neurofeedback up-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
16583346|NCT02722915|Experimental|fMRI Neurofeedback down-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
16583347|NCT02722902|Experimental|LIPID + Carnitor|"intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion
~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.
~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
16583348|NCT02722902|Placebo Comparator|LIPID + PLAC|"Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)
~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
16583349|NCT02722902|Placebo Comparator|PLAC|"Infusion of saline (no IntraLipid and no carnitor)
~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h."
16583350|NCT02722889||Healthy controls|Healthy control patients
16583351|NCT02722889||Type A dissection|Patients with proven type A dissection,
16583352|NCT02722876|Experimental|Contralateral rehabilitation|8-weeks of resistance training of the non-operative limb following ACL reconstruction
16583353|NCT02722876|Placebo Comparator|Placebo flexibility exercise|8-weeks of 'placebo' flexibility training of the upper limb
16583354|NCT02722850|Experimental|ALIVE - Physical Activity|PA CONDITION: The goal of the PA condition is to encourage participants to gradually increase moderate to vigorous PA to 150 minutes per week and to increase resistance training to a total of 15 minutes per day twice per week.
16583355|NCT02722850|Experimental|ALIVE - Dietary Modification|DIET CONDITION: The goal of the dietary condition includes increasing intake of fruit and vegetable to 5-servings per day. The program also encourages participants to increase the consumption of colorful fruits and vegetables. The fat goals consist of reducing saturated fats to <10% of total kilocalories per day, trans fats to <3 grams per day, and added sugar to <50 grams per day.
16583356|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16583357|NCT02722824|Placebo Comparator|Placebo|Wearable stimulators will be placed on the patients and controls without stimulation for 20 minutes
16583358|NCT02722824|Experimental|Active Stimulation|Instrinsic auricular muscles will be stimulated for 20 minutes
16583359|NCT02722824|Sham Comparator|Sham|An area out of the instrinsic auricular muscles region will be stimulated with the same parameters of the active group for 20 minutes
16583360|NCT02722824|No Intervention|Passive Control|Only the electrodes of the wearable stimulators will be inserted but there will not be electrostimulation for 20 minutes
16583361|NCT02722811|Experimental|Etanercept treatment group|Subcutaneous injection etanercept of 50 mg/w and Health education, exercise and diet guidance; treatment: 8 weeks
16583362|NCT02722811|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 8 weeks
16583363|NCT02722798|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 44
16583364|NCT02722785|No Intervention|Usual Care Observation Group|Patients allocated to usual care control will receive the standard patient care program as provided by the department of surgical gastroenterology, Rigshospitalet
16583365|NCT02722785|Experimental|Aerobic and Resistance Exercise Training|Patients allocated to this group will receive usual care plus a supervised aerobic and resistance exercise program at CFAS' facilities consisting of 2 weekly sessions of approximately 60 minutes.
16583366|NCT02722772|Experimental|Etanercept treatment group|Intra-articular injection of etanercept of 25 mg/w/joint and Health education, exercise and diet guidance; treatment: 5 weeks (If both knees are involved, the more significant symptomatic side is chosen for injection by etanercept)
16583367|NCT02722772|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 5 weeks
16583368|NCT02722759|Other|hemoglobin measurement arm|"In this arm hemoglobin measurement is done by four different devices
~device Radical-7 for non-invasive measurement of SpHb
~device HemoCue for taking capillary and venous blood for measurement of HcHb
~device ABL 800 for measurement of BGAHb
~device Siemens ADVIA for measurement of labHb
~For measurement of haemoglobin by the devices the following interventions have to be done:
~venous or arterial puncture (routine)
~capillary puncture
~placing of the Radical 7 sensor"
16583369|NCT02722746|Placebo Comparator|Ropivacaine only Control group|The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.
16583370|NCT02722746|Active Comparator|Ropivacaine + 2 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.
16583371|NCT02722746|Active Comparator|Ropivacaine + 5 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.
16583372|NCT02722733|Active Comparator|G-CSF (filgrastim)|1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.
16583373|NCT02722733|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|"Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).
~G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis."
16583374|NCT02722720|Experimental|Carotid stenting, Transradial approach|Internal carotid artery stenting using transradial arterial approach
16583375|NCT02722720|Active Comparator|Carotid stenting, Transfemoral approach|Internal carotid artery stenting using transfemoral arterial approach
16583376|NCT02722694|Experimental|Subcutaneous(SC) Abatacept|
16583377|NCT02722694|Placebo Comparator|Placebo|
16583378|NCT02722681||Symptomatic spinal lipoma patients|Spinal lipoma patients undergoing surgery due to symptomatic lipoma. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intraoperatively and usually discarded, some will be kept for research.
16583379|NCT02722681||Asymptomatic spinal lipoma patients|Spinal lipoma patients who remain asymptomatic. Routine blood and urine samples will be taken as part of routine clinical care, some will be kept for research.
16583647|NCT02720822|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on week two. Morphine 24 mg/day on week three.
16583380|NCT02722681||Non-lipoma spinal conditions|Patients undergoing spinal surgery for a non-lipoma related condition. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intra-operatively and usually discarded, some will be kept for research.
16583381|NCT02722668|Experimental|No ATG|Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
16583382|NCT02722668|Experimental|ATG|Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
16583383|NCT02722655||Type 1 diabetes mellitus|Sudden onset of symptoms and non-overweight/obese
16583384|NCT02722655||Type 2 diabetes mellitus|Insidious onset of symptoms and overweight/obese
16583385|NCT02722655||Type 1.5 diabetes mellitus|Overlap of type 1 and type2 diabetes mellitus clinical characteristics
16583386|NCT02722655||Other types of diabetes mellitus|According American Diabetes Association criteria
16583387|NCT02722642|Experimental|Bronchial basal cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
16583388|NCT02722629|Experimental|Aspiration in COPD patients|All COPD patient will be evaluated systematically by FEESST (Flexible Endoscopic Evaluation of Swallowing with Sensory Testing) with direct evaluation of aspiration by direct observation.
16583389|NCT02722616|Active Comparator|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
16583390|NCT02722616|Active Comparator|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.
~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
16583391|NCT02722616|Other|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
16583392|NCT02722603|Experimental|gabapentin / placebo tramadol|gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
16583393|NCT02722603|Active Comparator|tramadol / placebo gabapentin|tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.
16583394|NCT02722590||All Participants|Participants who are prescribed Fycompa (Perampanel) film-coated tablets and oral suspension per approved prescribing information in a normal clinical practice setting will be enrolled and observed prospectively for up to 24 Weeks.
16583395|NCT02722564|Experimental|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
16583396|NCT02722551|Experimental|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
16583397|NCT02722538|Experimental|Residual Tumor following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
16583398|NCT02722538|Experimental|No Residual Tumor Following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
16583431|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
16583432|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
16583433|NCT02722265|Experimental|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
16583434|NCT02722252||Embryoscope group|
16583400|NCT02722512|Experimental|Newly Diagnosed High Grade Glioma (HGG)|Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
16583401|NCT02722512|Experimental|Recurrent HGG and Ependymoma|On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.
16583402|NCT02722499|Experimental|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
16583403|NCT02722499|Experimental|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
16583404|NCT02722499|Experimental|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
16583405|NCT02722486|Active Comparator|Standard Vestibular Rehabilitation|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions of an hour each). During these sessions, standard balance training exercises will be done at the discretion of the physical therapists.
16583406|NCT02722486|Experimental|Vestibular Rehabilitation/Balance Belt|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions). They will undergo standard balance training exercises with the physical therapists like the control group, but will also undergo an additional 15 minutes of Balance Belt exercises during each session.
16583407|NCT02722473|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5°C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5°C for 24 hours.
16583408|NCT02722473|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5°C for 48 hours
16583409|NCT02722447|Active Comparator|Rivaroxaban|Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)
16583410|NCT02722447|Experimental|Placebo|Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)
16583411|NCT02722434|Experimental|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
16583412|NCT02722434|Active Comparator|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
16583413|NCT02722421|Experimental|Efavirenz group|HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.
16583414|NCT02722408|Experimental|Gemcabene|Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84. Participants were followed until Day 112.
16583415|NCT02722395||Single arm cohort study|
16583416|NCT02722382|No Intervention|Usual Nephrology Care|Nephrology care at Geisinger Health System.
16583417|NCT02722382|Active Comparator|Patient-Centered Kidney Transitions Care|Health system intervention which will implement informatics tools (including a disease registry, predictive modeling, and advance directives) and a disease specific care manager who will provide services and navigate patients through kidney disease transitions.
16583418|NCT02722369|Active Comparator|Control Arm|"IV carboplatin AUC5 (area under curve) on Day1
~IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3"
16583419|NCT02722369|Experimental|Investigational Arm|"IV gemcitabine 1200mg/m2 on Day 1 and Day 8
~IV carboplatin AUC5 on Day 1
~Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)"
16583420|NCT02722356|Experimental|Oxytocin|Oxytocin administered according to proposed protocol
16583421|NCT02722356|Active Comparator|Standard Practice|Oxytocin administered according to standard practice at facility
16583422|NCT02722343|Experimental|Tenofovir intravaginal ring|The tenofovir intravaginal ring (TFV IVR) is 55.0 mm in diameter, consisting of a single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. The IVR delivers 8-10mg/day of TFV.
16583423|NCT02722343|Active Comparator|Truvada oral tablets|"The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg). The tablets are commercially available as Truvada. The tablets are blue, capsule-shaped, film-coated, debossed with GILEAD on one side and with 701 on the other side"
16583424|NCT02722330|Experimental|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:
~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
16583425|NCT02722304|Experimental|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
16583426|NCT02722304|Experimental|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
16583427|NCT02722304|Experimental|GLASSIA 60 mg/kg|60 mg/kg body weight/week
16583428|NCT02722304|Experimental|GLASSIA 120 mg/kg|120 mg/kg body weight/week
16583429|NCT02722304|Placebo Comparator|Placebo|Human Albumin 2%
16583430|NCT02722291|Experimental|presbyopia|All participants perform all exams under 3 conditions, that is baseline, with out pinhole glasses, and with multiple pinhole glasses
16583436|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
16583437|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
16583438|NCT02722226|Experimental|Simulation based sedation learning (Intervention Group)|The program includes online learning. It is followed by development of interactive presentations, based on simulated cases or simulated patients (actors), low fidelity simulation for specific technical skills as well as high fidelity scenarios of complications related to sedation.
16583439|NCT02722226|No Intervention|Control Group|
16583440|NCT02722213|Experimental|Mindfulness-Based Stress Reduction|"The intervention is an 8-week Mindfulness-Based Stress Reduction (MBSR) course, with 8 weekly 2.5-hour group sessions, and 1 all-day (6.5 hours) retreat, taught per standard protocol in a group setting. The course includes instruction and practice of meditation, breathing techniques, gentle yoga and Tai Chi poses, with shared discussion, brief readings and home practice between sessions. Participants will continue with usual care and receive standard educational materials on healthy lifestyles and stress management.
~Note: This study will recruit patients eligible for exercise-based cardiac rehabilitation (CR). Randomization to either MBSR or control (no MBSR) condition will occur within two strata (CR; no CR) will occur based on current enrollment in CR at time of study enrollment."
16583441|NCT02722213|No Intervention|Control (No MBSR)|"Those randomized to the control condition will continue with usual care and receive standard educational materials on healthy lifestyles and stress management. At the end of the study control participants will receive a compact disc and workbook on MBSR.
~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
16583442|NCT02722200|Experimental|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
16583443|NCT02722200|Placebo Comparator|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
16583444|NCT02722187|Experimental|microsurgery|40 patients will undergo subinguinal microscopic varicocelectomy
16583445|NCT02722187|Active Comparator|laparoscopy|20 patients will undergo laparoscopic varicocelectomy
16583446|NCT02722174||BED|Binge Eating Disorder
16583447|NCT02722174||ADHD|Attention Deficit Hyperactivity Disorder
16583448|NCT02722174||SUD, cocaine subtype|Stimulant Use Disorder, cocaine subtype
16583449|NCT02722174||BPD|Borderline Personality Disorder
16583450|NCT02722174||BPD, Cohort 2|Borderline Personality Disorder, Cohort 2
16583451|NCT02722174||HC|Healthy Controls
16583452|NCT02722161|Experimental|[14C]BI 1482694|
16583453|NCT02722148|Experimental|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
16583454|NCT02722135|Experimental|Volasertib|
16583455|NCT02722122|Experimental|AIR DNase™ 2.5 mg|2.5 mg of AIR DNase™ administered once daily via inhalation for 28 days
16583456|NCT02722096|Experimental|Axillary block anesthesia|Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery
16583457|NCT02722096|Active Comparator|Local anesthesia|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
16583458|NCT02722083|Experimental|BAY X002134|Subjects will be given BAY X002134
16583459|NCT02722083|Placebo Comparator|Placebo|Subjects will be given a placebo
16583460|NCT02722070||Healthy Controls|Age matched control for the various clinical groups
16583461|NCT02722070||Neurodegenerative patients|
16583462|NCT02722070||Stroke patients|
16583463|NCT02722070||Neuropsychiatric patients|
16583464|NCT02722057||Cohort 1 - Interventional|The Interventional cohort will not be utilized.
16583465|NCT02722057||Cohort 2 - Non Interventional|A Non-Interventional Cohort comprising pediatric (<18 years of age) and adult R117H-CFTR patients treated with commercially-available Kalydeco.
16583466|NCT02722057||Cohort 3 - Historical|A Historical Cohort comprising data from an earlier time period for pediatric (<18 years of age) and adult patients with the R117H-CFTR mutation who have never been exposed to Kalydeco and matched on age, gender, and lung function to patients in the Non-Interventional Cohort.
16583467|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
16583468|NCT02722018|Experimental|Part 1: GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
16583469|NCT02722018|Experimental|Part 2 (Optional): GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of two Phase III prototype tablets (Prototype 4 or 5) in a crossover fashion.
16583470|NCT02722018|Experimental|Part 3: GDC-0810 dose level B - Low Fat Meal/Fasted|Participants will receive a single dose of GDC-0810 dose level B on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal or under fasted condition either as Phase II tablet (with low fat meal) or as the Phase III prototype tablet selected from Parts 1 or 2 (with low fat meal or under fasted conditions), in a crossover fashion.
16583648|NCT02720822|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg/day on weeks one, two and three.
16583471|NCT02722005|Experimental|Financial Coaching & Access to Services|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
16583472|NCT02722005|Active Comparator|Access to Services|Participants will have access to a host of referrals to social services (this is the intervention for this group)
16583473|NCT02721992||Graves' Disease|Patients with Graves' disease, without Graves' Orbitopathy
16583474|NCT02721992||Graves' Orbitopathy|Patients with Graves' disease, with Graves' Orbitopathy
16583475|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
16583476|NCT02721966|Experimental|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
16583477|NCT02721966|Experimental|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
16583478|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
16583479|NCT02721953|Experimental|Hypocaloric diet plus butyrate|Hypocaloric diet plus butyrate
16583480|NCT02721953|Placebo Comparator|Hypocaloric diet plus placebo|Hypocaloric diet plus placebo
16583481|NCT02721940|Experimental|Treatment group|In the treatment group, patients will be given local injection of enriched autologous mononuclear cells and zoledronic acid into the necrotic area following core decompression by drilling.
16583482|NCT02721940|Experimental|Control group|In the control group, core decompression will be performed, but no treatment will be given.
16583483|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Subjects will receive 4 massotherapy sessions and 4 of HYPOPRESSIVE ABDOMINAL GYMNASTIC (HAG).
16583484|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
16583485|NCT02721914|Experimental|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
16583486|NCT02721901|Experimental|iEAT Manual Intervention|Caretakers of 10 children will be randomized to participate in the integrated Eating Aversion Treatment (iEAT) intervention. iEAT is a technology-based manual which aims to increase the child's food consumption.
16583487|NCT02721901|Active Comparator|Control group|Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
16583488|NCT02721888|Experimental|Main study|
16583489|NCT02721875|Experimental|Volasertib monotherapy|
16583490|NCT02721875|Experimental|Volasertib + azacitidine combination|
16583491|NCT02721862|Experimental|Experimental|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
16583492|NCT02721862|Placebo Comparator|Control|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
16583493|NCT02721849|Experimental|adolescent yoga / parent control|The adolescent will receive an 12 week yoga course, while one parent will only answer the questionnaires.
16583494|NCT02721849|Experimental|adolescent waitlist / parent yoga|One parent will participate in an 12 week yoga course, while the adolescent will receive the intervention after the follow-up period.
16583495|NCT02721849|Experimental|adolescent yoga / parent yoga|Both adolescent and parent will participate in an 12 week yoga course at the same time.
16583496|NCT02721849|No Intervention|adolescent waitlist / parent control|The adolescent will receive the intervention after the follow-up period, while one parent will only answer the questionnaires.
16583497|NCT02721836|Experimental|Yoga|12 week yoga course, two times a week 75 minutes each time
16583498|NCT02721836|Active Comparator|Nutrition|3 counselling sessions within 12 weeks
16583499|NCT02721823|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
16583500|NCT02721823|Active Comparator|control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
16583501|NCT02721810|No Intervention|Control|Prompts standard to rounds or electronic medical records.
16583502|NCT02721810|Experimental|Prompting Intervention|Prompting consideration of 3-month functional outcome.
16583503|NCT02721797||Skin|Patients with EDS diagnosis having surgery, have debrided skin retained for this research
16583504|NCT02721797||Tendon|Patients with EDS diagnosis having surgery, have debrided tendon retained for this research
16583505|NCT02721797||Uterine tissue|Patients with EDS diagnosis having surgery, have debrided uterine tissue retained for this research
16583506|NCT02721797||Vaginal tissue|Patients with EDS diagnosis having surgery, have debrided vaginal tissues retained for this research
16583507|NCT02721797||Ligaments|Patients with EDS diagnosis having surgery, have debrided ligaments retained for this research
16583508|NCT02721784|Other|Pre- and Post- Radiotherapy MRI|"mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:
~Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy
~External Beam Radiotherapy to be given after 3 months of androgen deprivation"
16583509|NCT02721758|Experimental|Brief Motivational Intervention|Single, 60-minute, manualized behavioural intervention designed to support cardiac rehabilitation enrollment, informed by principles of motivational interviewing
16583510|NCT02721758|No Intervention|Usual Care|Standard encouragement to enroll in cardiac rehabilitation, and meeting with a researcher to complete study questionnaires
16583511|NCT02721745|Experimental|Natural Fatigue|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
16583512|NCT02721745|Experimental|tDCS anodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
16583513|NCT02721745|Experimental|tDCS cathodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
16583514|NCT02721745|Experimental|tDCS sham|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
16583515|NCT02721745|Experimental|inhibitory TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
16583516|NCT02721745|Experimental|Sham TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
16583517|NCT02721732|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
16583518|NCT02721719||Healthy Adults|[Not receiving Vedolizumab] Healthy adults who have not donated blood within the past two months and who have no history of blood-borne diseases.
16583519|NCT02721719||Adults with no Inflammatory Bowl Disease|[Not receiving Vedolizumab] Adult patients undergoing endoscopy for indications other than Inflammatory Bowel Disease or other inflammatory conditions of the bowel (such as colon cancer screening or polypectomy)
16583520|NCT02721719||Donors with Ulcerative Colitis|[Set to receive Vedolizumab] Adults with an established diagnosis of UC (≥ 6 months preceding involvement in study) who are both scheduled for an endoscopy and are about to receive Vedolizumab treatment (standard of care).
16583521|NCT02721706|Experimental|CIPA screening tool|Patients are evaluated by CIPA nutritional screening tool
16583522|NCT02721706|No Intervention|usual hospital clinical care|Patients are not subject of CIPA screening tool, and continue the usual hospital clinical care
16583523|NCT02721693|Experimental|Treadmill exercise test|Patients are subjected to an incremental Cardiopulmonary Exercise Test to exhaustion
16583524|NCT02721680|Experimental|Healthy Subjects- Awareness Training Group 1|Subjects in this arm will undergo an internal awareness training program.
16583525|NCT02721680|Experimental|Healthy Subjects - Awareness Training Group 2|Subjects in this arm will undergo an external awareness training program.
16583526|NCT02721667|No Intervention|Enhanced Usual Care|"Participants receive a home BP monitor, are taught how to measure home BP and are encouraged to take BP readings to appointments with their providers. In addition, they will be reminded to perform a home BP series each quarter for study outcome purposes, which will encourage self-monitoring.
~Home BP readings will be teletransmitted for data collection purposes but neither participants nor providers will have access to the these readings. High BP levels that trigger safety alerts to research personnel are the only exception - participants and their primary care providers will be made aware of these."
16583527|NCT02721667|Active Comparator|Telemonitoring and Case Management|"Home BP series mean, trends and individual readings will be generated for use by the case manager. Participants in this arm will each be assigned a pharmacist case manager who holds full prescribing privileges and who will:
~Administer health behaviour modification counselling, teach BP self-monitoring, and monitor medication adherence;
~Review telemonitored health portal BP summaries and make medication regimen adjustments according to guideline-concordant study protocol;
~Fax a summary of these adjustments to the participant's primary care provider (to make them aware of treatment changes); and
~Facilitate communication between participants and providers."
16583530|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
16583531|NCT02721628|Experimental|Epi-keratoplasty Group|Epi-keratoplasty Group: Reversible keratoplasty performed with only the removal of corneal epithelium of the host cornea. A donor graft is transplanted on the recipients' eye locating on the Bowman's layer.
16583532|NCT02721628|Active Comparator|Collagen Cross-Linking Group|Collagen Cross-Linking: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
16583533|NCT02721615|Active Comparator|Laminectomy|Comparison of bone decompression versus no decompression for reducing intra spinal pressure
16583534|NCT02721615|Active Comparator|Duraplasty|Expansion duraplasty versus no duraplasty for reducing intraspinal pressure
16583535|NCT02721615|Active Comparator|Hypothermia|Localised hypothermia for reducing intra spinal pressure and improving spinal cord metabolism
16583536|NCT02721602|Experimental|Intervention Group|Families in the Families Preventing Diabetes Together intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
16583537|NCT02721602|No Intervention|Measurement Only|No intervention only measurements
16583538|NCT02721589|Experimental|Injection SHR-1210|200mg/vial
16583539|NCT02721576|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T>40Gy/20f,week 1->5"
16583540|NCT02721563|Active Comparator|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
16583541|NCT02721563|Placebo Comparator|Control Group|"Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
16583542|NCT02721550|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4"
16583543|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
16583544|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
16583545|NCT02721524|Active Comparator|Group R (ring)|Patients in Group R will undergo tricuspid ring annuloplasty
16583546|NCT02721524|Active Comparator|Group S (suture)|Patients in Group S will undergo De Vega's suture annuloplasty
16583547|NCT02721511|Experimental|Furosemide injection solution 8mg/mL|8mg/mL (total dose=80mg) of furosemide injection solution administered subcutaneously as 30mg over the first hour and then as 12.5 mg per hours over the subsequent 4 hours.
16583548|NCT02721498|Active Comparator|Visit A|Rest period for 30-60 minutes
16583549|NCT02721498|Active Comparator|Visit B|Airway clearance session utilising the Active Cycle of Breathing techniques (ACBT) supervised by a specialist physiotherapist for 30-60 minutes.
16583550|NCT02721485|Other|Normal Saline|Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Ringer's Lactate following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
16583551|NCT02721485|Other|Ringer's Lactate|Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Normal Saline following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians in for the final 90-day test period.
16583552|NCT02721472|Other|sickle cell disease patients|Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) < 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).
16583553|NCT02721459|Experimental|Dose Escalation|Escalating Doses of XL888 with Vemurafenib plus Cobimetinib.
16583554|NCT02721446|Other|VHA Cohort|Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if > 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
16583555|NCT02721446|Other|Eskenazi Health System Cohort|Investigators will use EHR data from Indiana Network for Patient Care (INPC) to identify a cohort of live patients with at least one primary care visit in the prior 12 months. Investigators will use identical methods to construct Framingham risk score variables from the EHR data.
16583556|NCT02721433|Active Comparator|4 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
16583557|NCT02721433|Active Comparator|12 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
16583558|NCT02721420|Other|Drug + short message(SMS) reminder|dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course
16583559|NCT02721420|Other|Drug + no short message(SMS) reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.
16583560|NCT02721420|Other|Drug+ Health worker reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.
16583561|NCT02721420|Other|Drug at hospital + SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.
16583562|NCT02721420|Other|Drug at Hospital+no SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course
16583563|NCT02721407|Experimental|Anti-CD22 CAR-T|Administrated with CD22.CAR-T cells on day 0,1,2 in the lympho-depleted patients
16583564|NCT02721394|Experimental|Researcher Implemented FCT|Children receive functional communication training. Assessment and initial intervention sessions are completed by the researcher and family carers are trained to continue the intervention at home.
16583565|NCT02721394|Experimental|Family Carer Implemented FCT 1|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher in person.
16583566|NCT02721394|Experimental|Family Carer Implemented FCT 2|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher via videoconferencing and support from a family carer assistant in person.
16583567|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
16583568|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
16583569|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
16583570|NCT02721368|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
16583571|NCT02721368|Active Comparator|Comparator medical device|Juvederm® Voluma® with Lidocaine
16583572|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
16583573|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
16583574|NCT02721342||Ramipril, Irbesartan and Atorvastin treatment|A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.
16583575|NCT02721329|Active Comparator|APAP without SensAwake|Auto CPAP delivered from the ICON+ CPAP device.
16583576|NCT02721329|Experimental|APAP with SensAwake|Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
16583577|NCT02721316|Experimental|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
16583578|NCT02721316|No Intervention|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
16583579|NCT02721303|Active Comparator|obese older aged, aged 65-85, BMI 30-40|Older aged patients who are obese and between the ages of 65-85 with a BMI between 30-40.
16583580|NCT02721303|Active Comparator|normal weight older aged, aged 65-85, BMI 18-25|Older aged patients who are of normal weight and between the ages of 65-85 with a BMI between 18-25.
16583581|NCT02721303|Active Comparator|obese younger aged, aged 21-45, BMI 30-40|Younger aged patients who are obese and between the ages of 21-45 with a BMI between 30-40 .
16583582|NCT02721290|Active Comparator|Femoral nerve block using Ultrasound and neurostimulator|Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.
16583583|NCT02721290|Experimental|Femoral nerve block using femoral artery target|Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.
16583613|NCT02721082|Experimental|Opt Out|"Participants in this arm will be first enrolled to receive cessation treatment and will only not receive it by opting out. Participant will receive a Opt Out treatment program. Participants will receive counseling and nicotine replacement therapy."
16583649|NCT02720822|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg/day on weeks one and two. Morphine 24 mg/day on week three.
16583584|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
16583585|NCT02721264|Experimental|Fecal Microbiota Transplantation (FMT)|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.
16583586|NCT02721264|Active Comparator|Standard Treatment Care|
16583587|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
16583588|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
16583589|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
16583590|NCT02721238|Active Comparator|Resuscitation with 30ml/kg plasmalyte|
16583591|NCT02721238|Experimental|Resuscitation with 20% Albumin|
16583592|NCT02721225|Active Comparator|Fructooligosaccharide|"One kind of prebiotics agent defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
16583593|NCT02721225|Placebo Comparator|Pocari-Sweat|Commercially produced isotonic solution by Otsuka Pharmaceutical Co., Ltd., Tokyo,Japan
16583594|NCT02721212|Experimental|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.
~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
16583595|NCT02721212|Active Comparator|Control Group|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).
~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.
~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
16583596|NCT02721199||Prospective Cohort|Neural Respiratory Drive Automated EMGpara assessment
16583597|NCT02721186|Experimental|MDA with DHAp and SLD Primaquine|MDA will be conducted at two time points with an approximate four-week interval. All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
16583598|NCT02721186|No Intervention|Control|The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms. This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
16583599|NCT02721173|Experimental|Tazarotene group|This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
16583600|NCT02721173|Active Comparator|Adapalene group|This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.
16583601|NCT02721160|Experimental|Nutrition PBF|45 health centres are assigned to this group. The intervention consists in a performance based financing scheme applied to nutrition services.
16583602|NCT02721160|No Intervention|Control|45 health centres are in the control group. Health centres in this group are not incentivized, but they receive an equivalent funding to the one received by the intervention group. The main difference is that this payment is not based on their own performance.
16583603|NCT02721147|Experimental|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
16583604|NCT02721147|Active Comparator|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
16583605|NCT02721134|Other|additional blood tubes|
16583606|NCT02721121|Active Comparator|circumferential pulmonary vein isolation|circumferential pulmonary vein isolation
16583607|NCT02721121|Experimental|Linear ablation in addiction to pulmonary vein isolation|Linear ablation in addiction to pulmonary vein isolation
16583608|NCT02721108|Experimental|Mindfulness: Group A|Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
16583609|NCT02721108|Active Comparator|Relaxation: Group B|Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
16583610|NCT02721108|No Intervention|Treatment as usual: Group C|No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.
16583611|NCT02721095|Experimental|0.9%NaCl|KCl plus 0.9%NaCl
16583612|NCT02721095|Active Comparator|0.45%NaCl|KCl plus 0.45%NaCl
16583645|NCT02720822|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
16583614|NCT02721082|Active Comparator|Opt In|"Traditional approach to tobacco treatment program. Participants must first indicate they are ready to quit smoking by opting in to receive Opt In treatment program."
16583615|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
16583616|NCT02721056|Experimental|NBTXR3, IL or IA injection +SBRT|"Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 42% of the baseline tumor volume, activated by SBRT.
~Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT."
16583617|NCT02721043|Experimental|Personalized Genome Vaccine 001|"PGV-001 (peptides + Poly-ICLC)
~Peptides: 100mcg per peptide per dose.
~Poly-ICLC (Hiltonol®, Oncovir): 1.4mg (0.7mL, 2mg/mL)"
16583618|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
16583619|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
16583620|NCT02721004||Rheumatoid arthritis participants|Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
16583621|NCT02720991|Experimental|Mifepristone and sublingual misoprostol|200 mg mifepristone and 400 ug sublingual misoprostol
16583622|NCT02720978|Experimental|Intravenous oxytocin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.
~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:
~Verification rupture of membranes and gestational age.
~Choosing the treatment group Intravenous oxytocin from red envelope, randomly.
~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
~Induction according to departmental protocol of each delivery way.
~Data collecting after the delivery."
16583623|NCT02720978|Experimental|vaginal prostaglandin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.
~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:
~Verification rupture of membranes and gestational age.
~Choosing the treatment group vaginal prostaglandin from red envelope, randomly.
~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
~Induction according to departmental protocol of each delivery way.
~Data collecting after the delivery."
16583624|NCT02720965|Experimental|Electronic pump|Continuous nerve blocks Remote-controlled perineural local anesthetics delivery
16583625|NCT02720965|No Intervention|single injection|single injection
16583626|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).
~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
16583627|NCT02720939||ASD group|ASD patients who met the diagnostic criteria of either autistic disorder or Asperger's disorder defined by the DSM-IV criteria
16583628|NCT02720939||TD group|Typically development controls without lifetime diagnosis with ASD or any psychiatric disorders
16583629|NCT02720926|Experimental|TKI258 combined with Xeloda/Oxaliplatin|TKI258 200 mg once a day (OD) 5 days on/2 days off Capecitabine (Xeloda) 2000 mg/m2 bid d1-14 Oxaliplatin 130mg/m2 d1 q21days
16583630|NCT02720913|Experimental|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
16583631|NCT02720913|Active Comparator|Standard Suture Tying|Standard Suture Tying
16583632|NCT02720900|Placebo Comparator|Maltodextrin|powder, 1.8g/day
16583633|NCT02720900|Active Comparator|B-GOS|powder, 1.8g/day
16583634|NCT02720887||pregnant woman|Patient to receive an amniocentesis for medical reasons other than study and who will have a measure of nanoparticles load
16583635|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
16583636|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
16583637|NCT02720861||non embolic ischemic stroke|acute ischemic stroke from atherosclerosis or lacunar stroke
16583638|NCT02720848|Experimental|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
16583639|NCT02720848|Active Comparator|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
16583640|NCT02720822|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
16583641|NCT02720822|Experimental|Morphine Sulfate (0, 0, 8 mg)|Placebo on weeks one and two. Morphine 8 mg/day on week three.
16583642|NCT02720822|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo on week one. Morphine 8 mg/day on weeks two and three.
16583643|NCT02720822|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo on week one. Morphine 8 mg/day on week two. Morphine 16 mg/day on week three.
16583644|NCT02720822|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg/day on weeks one, two and three.
16583650|NCT02720822|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on weeks two and three.
16583651|NCT02720822|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on week two. Morphine 32 mg/day on week three.
16583652|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
16583653|NCT02720783|Experimental|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg|One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
16583654|NCT02720783|Active Comparator|Placebo plus Econazole nitrate 150 mg|One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days
16583655|NCT02720783|Active Comparator|Placebo plus Benzydamine HCl 6 mg|One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
16583656|NCT02720783|Placebo Comparator|Placebo|One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days
16583657|NCT02720770|Experimental|norditropine simplex|
16583658|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
16583659|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
16583660|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
16583661|NCT02720731||children|aged from 1 to 18 years with motor disorder
16583662|NCT02720731||adults|aged from 18 to 80 years with motor disorder
16583663|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
16583664|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
16583665|NCT02720705|Active Comparator|DEX I|active comparator receive 0.5µg/kg dexmedetomidine orally half an hour before operation
16583666|NCT02720705|Placebo Comparator|Saline Control|2ml oral 0.9%saline half an hour before operation
16583667|NCT02720705|Active Comparator|DEX II|active comparator receive,1µg/kg dexmedetomidine orally half an hour before operation
16583668|NCT02720692|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
16583669|NCT02720692|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 7 doses.
16583670|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
16583671|NCT02720666|Experimental|Group A:K-001 2700mg/d (1350mg BID)|K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
16583672|NCT02720666|Experimental|Group B: K-001 3240mg/d (1620mg BID)|K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
16583673|NCT02720666|Experimental|Group C: K-001 3780mg/d (1890mg BID)|K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
16583674|NCT02720666|Experimental|Group D: K-001 4320mg/d (2160mg BID)|K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
16583675|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
16583676|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
16583677|NCT02720640|Experimental|Implant 'on' vs implant 'off'|Intra-individual comparison of implant 'on' vs implant 'off'
16583678|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
16583679|NCT02720614|Experimental|Hypofractionated radiation/chemotherapy|"Hypofractionated radiation：Patients receive accelerated hypofractionated radiation: three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks.
~Chemotherapy: Regimen 1 is as follows: vinorelbine (NVB) was administered by intravenous infusion at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and carboplatin (CBP) is administered at a concentration-time curve (AUC) of 5 mg/ml on d8. This treatment was repeated every 28 days. One cycle of chemotherapy is performed concurrently with the radiotherapy.
~Chemotherapy: Regimen 2 is as follows: paclitaxel at 30 mg/m2 and cisplatin at 20 mg/m2 (TP) are administrated every week for 5 weeks continuously."
16583680|NCT02720601|Experimental|Irinotecan & Capecitabine|"Irinotecan at 120 mg/m2 intravenously every three weeks + Capecitabine at 1500 mg/m2/day orally twice per day for a total of 14 days.
~The treatment cycle is once every 21 days."
16583681|NCT02720588||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
16583682|NCT02720588||Sibling group|Sex-matched unaffected siblings of ASD probands
16583683|NCT02720588||TD group|Typically developing controls without lifetime ASD or a family history of ASD
16583684|NCT02720575|Active Comparator|A|50,000 IU of crystalline D2 in 5 capsules.. Vitamin D2 in its natural state consumed orally via capsule
16583685|NCT02720575|Active Comparator|B|50,000 IU of crystalline D3 in 5 capsules.. Vitamin D3 in its natural state consumed orally via capsule
16583686|NCT02720575|Active Comparator|C|50,000 IU of vitamin D2 from vitamin D2 yeast in 5 capsules. Vitamin D generated in yeast. Acts as a comparator to the yeast in bread.
16583687|NCT02720575|Active Comparator|D|50,000 IU of vitamin D2 from yeast cell walls in 5 capsules. Yeast cell walls rich in Vitamin D. Acts as a comparator to the yeast in bread.
16583763|NCT02720120|Experimental|Part 2: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
16583688|NCT02720575|Experimental|E|50,000 IU of vitamin D2 from 2 slices of bread made from bread. Bread raised with yeast rich in vitamin D. Main experimental arm.
16583689|NCT02720575|Experimental|F|50,000 IU of vitamin D2 from 2 slices of bread. Bread raised with yeast and yeast cell walls rich in vitamin D.
16583690|NCT02720562||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
16583691|NCT02720562||TD group|Typically development controls without lifetime diagnosis with ADHD
16583692|NCT02720549|Experimental|post-ischemic conditioning group|
16583693|NCT02720549|Placebo Comparator|valvular surgery with bypass group|
16583694|NCT02720536|Experimental|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
16583695|NCT02720523|Experimental|Placebo / Upadacitinib 7.5 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.
~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks."
16583696|NCT02720523|Experimental|Placebo / Upadacitinib 15 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
16583697|NCT02720523|Experimental|Placebo / Upadacitinib 30 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
16583698|NCT02720523|Experimental|Upadacitinib 7.5 mg / Upadacitinib 7.5 mg|"Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks."
16583699|NCT02720523|Experimental|Upadacitinib 15 mg / Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
16583700|NCT02720523|Experimental|Upadacitinib 30 mg / Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
16583701|NCT02720510|Active Comparator|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
16583702|NCT02720510|Active Comparator|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
16583703|NCT02720497|Experimental|60-minute Prolonged Exposure|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
16583704|NCT02720497|Active Comparator|90-minute Prolonged Exposure|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
16583705|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
16583706|NCT02720471|Active Comparator|Locoregional anesthesia|Classical locoregional analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh will be performed in patients of this arm
16583707|NCT02720471|Experimental|Peroperative infiltration|Peroperative infiltration of local anesthetics (IAL) will be performed in patients of this arm
16583708|NCT02720458|Experimental|Standardized hypnotic taper and self-help program|
16583709|NCT02720458|Active Comparator|Standardized hypnotic taper only|
16583712|NCT02720432|Experimental|CIMT|"A soft splint or restraint will be posed to best functioning hand of the infant only during the therapy session. Parents will be educated to perform the therapy, which consists of stimulation of reaching and grasping with the hemiplegic arm.
~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform CIMTfor 30 minutes, 6 days a week."
16583713|NCT02720432|Experimental|HABIT|"No restraint will be implemented and instead of promoting unilateral grasping, bimanual grasping will be stimulated. Toys will be precisely selected to stimulate progressed bimanual grasping. The approach of the therapist and parents remain equal.
~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform HABIT for 30 minutes, 6 days a week."
16583714|NCT02720432|Sham Comparator|Baby-massage|3 sessions of baby-massage will be given by a qualified instructor
16583715|NCT02720419||Synergy stent|
16583716|NCT02720406|Active Comparator|Intravenous ketamine0.5mg/kg|intravenous ketamine 0.5 mg/kg given after induction of anesthesia and before surgery.
16583717|NCT02720406|Active Comparator|Nebulized ketamine 1mg/kg|nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.
16583718|NCT02720406|Active Comparator|Nebulized ketamine 2mg/kg|nebulized ketamine group received 2mg/kg ketamine by nebulzation before induction of anesthesia.
16583719|NCT02720406|Placebo Comparator|control group|control group received placebo nebulization
16583720|NCT02720393|Placebo Comparator|Regular diet|Meals and snacks will contain carrageenan in the amount consumed in the typical daily diet and will be selected by the study dietician and distributed to study subjects randomized to the regular diet study arm.
16583721|NCT02720393|Experimental|No-carrageenan diet|No-carrageenan diet will be composed of meals and snacks selected by the study dietician and distributed to study participants who are randomized to the no-carrageenan diet study arm.
16583722|NCT02720380|Experimental|Buteyko|Children in the intervention group will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
16583723|NCT02720380|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
16583764|NCT02720120|Experimental|Part 2: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 mg.
16586232|NCT02704234|Placebo Comparator|Placebo|Placebo Acupuncture 2 times per week for 5 weeks
16583724|NCT02720367|Experimental|7-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
16583725|NCT02720367|Experimental|21-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.
16583726|NCT02720354|Experimental|A single Intravenous bolus injection|A single Intravenous bolus injection of 11C[DMDPA]
16583727|NCT02720341|Experimental|ARMin|Therapy on ARMin robotic device
16583728|NCT02720328|Other|DOAC-treated patients|Concerning patients taking DOACs, blood samples are drawn to evaluate DOAC plasma concentration. One EDTA tube is also drawn to extract DNA and determine the genetic profile of genes involved in the metabolism of DOACs. The aim will be to assess if genetic determinants can explain the observed interindividual variability in plasma concentrations.
16583729|NCT02720315|Experimental|Intensive cryotherapy|Application of ice in a plastic bag wrapped to the patient's site of pain, and kept in place for 20min.
16583730|NCT02720315|No Intervention|Control|Existing pain control practice of physicians and nurses, which includes application of a chemical cold pack.
16583731|NCT02720302|Experimental|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.
~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.
~At each consultation with the overweight child and his/her biological parents there are two therapists present."
16583732|NCT02720302|Experimental|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3)."
16583733|NCT02720289|Experimental|Video-based social learning|Video-based social learning class
16583734|NCT02720289|Active Comparator|Traditional didactic|Traditional didactic class
16583735|NCT02720276|Experimental|Training after acute stroke|Intervention: Outdoor walking and strength training.
16583736|NCT02720263|Experimental|Double-Blind ASP4345 Multiple Dose Levels|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered under fasting conditions. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions.
16583737|NCT02720263|Placebo Comparator|Double-Blind Placebo Multiple Dose|Matching placebo capsules will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, matching placebo capsules will be administered with food. On days 2-6 and 8-13, matching placebo will be administered under fed conditions.
16583738|NCT02720263|Experimental|Open-Label ASP4345|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered with food. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions. This is an optional cohort where subjects will be enrolled to further characterize pharmacodynamics in the event a higher sample size is necessary to determine changes in electrophysiological biomarkers.
16583739|NCT02720250|Experimental|Omega-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
16583740|NCT02720250|Experimental|Regular|Intake of 3 regular chicken eggs per day for three weeks.
16583741|NCT02720237|Experimental|Brief Intervention|Brief Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the ART clinic
16583742|NCT02720237|Experimental|MET+CBT Intervention|MET+CBT Intervention (6 in-person sessions and 3 optional group sessions), study assessment visits, and standard of care from providers at the ART clinic
16583743|NCT02720237|No Intervention|Assessment-Only Control|Study assessment visits and standard of care from providers at the ART clinic
16583744|NCT02720224|Experimental|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol ([14C]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
16583745|NCT02720211|Active Comparator|Gray tinted spectacle lenses|Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
16583746|NCT02720211|Experimental|Thin-Film spectacle lenses|Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength
16583747|NCT02720198|Active Comparator|Levomilnacipran|Levomilnacipran ER is switched from SSRI.
16583748|NCT02720198|Active Comparator|Quetiapine|Quetiapine XR is added in addition to current SSRI.
16583750|NCT02720172|Experimental|Early Home Exercise Program|The early home exercise program is an exercise-based self-management program for patients immediately after cervical spine surgery.
16583751|NCT02720172|Other|Usual Care|Usual postoperative care.
16583752|NCT02720159|Experimental|TREATMENT|
16583753|NCT02720146||Artificital tear|The epitheliotrophic ability in cell and animal model
16583754|NCT02720146||Human peripheral serum|The epitheliotrophic ability in cell and animal model
16583755|NCT02720146||Human platelet lysate|The epitheliotrophic ability in cell and animal model
16583756|NCT02720133||Patients with cardiovascular risk factors who fast Ramadan|Stable clinical and biochemical parameters before Ramadan fasting
16583757|NCT02720120|Experimental|Part 1: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
16583758|NCT02720120|Experimental|Part 1: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
16583759|NCT02720120|Experimental|Part 1: Ocrelizumab 2000 mg|Participants will receive single IV infusion of ocrelizumab 2000 mg.
16583760|NCT02720120|Experimental|Part 1: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
16583761|NCT02720120|Placebo Comparator|Part 1: Placebo|Participants will receive single IV infusion of placebo matched to ocrelizumab.
16583762|NCT02720120|Experimental|Part 2: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
16583765|NCT02720107|Experimental|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
16583766|NCT02720094|Experimental|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
16583767|NCT02720094|Experimental|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
16583768|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
16583769|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
16583788|NCT02720055|Experimental|Psychological Workbook|Psychological work book containing information and activities aimed at improving outcomes.
16583789|NCT02720055|Active Comparator|Basic information workbook|Basic information which represents current practice
16583790|NCT02720042|Experimental|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
16583791|NCT02720029|Experimental|pH/impedance monitor|
16583792|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
16583793|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
16586418|NCT02703051|Experimental|GMI-1271 with Filgrastim|GMI-1271 with Filgrastim
16583794|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
16583795|NCT02720003|Experimental|LTX DCB|Patients treated with Bard Lutonix DCB
16583796|NCT02719990|Experimental|Somavaratan in adults with GHD|Cohort 1: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult subjects with GHD irrespective of age and gender
16583797|NCT02719990|Experimental|Somavaratan in women on estrogen|Cohort 2: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult female subjects with GHD on oral estrogen (regardless of age)
16583798|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
16583799|NCT02719964|Experimental|A: UCR Games→SP-Directed Therapy|Participants in Arm A will first participate in Visual Attention Program (UCR Games) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
16583800|NCT02719964|Experimental|B: Lumosity→SP-Directed Therapy|Participants in Arm B will first participate in General Cognitive Rehabilitation Games (Lumosity) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
16583801|NCT02719964|Experimental|C: SP-Directed Therapy→UCR Games|Participants in Arm C will first participate in Speech Pathologist-Directed Therapy followed by Visual Attention Program (UCR Games) with assessment sessions prior to and following each treatment intervention.
16583802|NCT02719964|Experimental|D: SP-Directed Therapy→Lumosity|Participants in Arm D will first participate in Speech Pathologist-Directed Therapy followed by General Cognitive Rehabilitation Games (Lumosity) with assessment sessions prior to and following each treatment intervention.
16583803|NCT02719951|Experimental|autistic patients|[18F]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
16583804|NCT02719951|Experimental|FXS patients|[18F]FPEB PET imaging MRI Biological samples
16583805|NCT02719951|Experimental|Healthy subjects|[18F]FPEB PET imaging MRI Biological samples
16583806|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
16583807|NCT02719938|No Intervention|Control|Usual care.
16583808|NCT02719925|Experimental|Mineral water rich in magnesium|- 1,5 L per day of mineral water containing 160 mg/L of magnesium
16583809|NCT02719925|Active Comparator|Water low in magnesium|- 1,5 L per day of mineral water containing 50 mg/L of magnesium
16583810|NCT02719912|Experimental|Valve Replacement|Mitral valve replacement
16583811|NCT02719899||1|Healthy Volunteers
16583812|NCT02719886|Experimental|Fetal growth ultrasound every 2 weeks|Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
16583813|NCT02719886|Active Comparator|Fetal growth ultrasound every 4 weeks|Ultrasound to measure fetal growth every 4 weeks (i.e. 28, 32 and 36 weeks gestation). Usual Care.
16583814|NCT02719873||control group|the group with normal BMI
16583815|NCT02719873||study group|The group with the BMI more than 24.9 kg per meter square to study the impact of maternal obesity in pregnancy outcome
16583816|NCT02719860|Experimental|Green tea|
16583817|NCT02719860|Experimental|Black tea|
16583818|NCT02719860|Placebo Comparator|Placebo tea|
16583819|NCT02719847|Experimental|EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
16583820|NCT02719834||Acetaminophen, then placebo|Participants in this group will receive acetaminophen for the first four weeks, then placebo for the next four weeks.
16583821|NCT02719834||Placebo, then acetaminophen|Participants in this group will receive placebo for the first four weeks, then acetaminophen for the next four weeks.
16583822|NCT02719821|Experimental|Intervention|Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
16583823|NCT02719808||Tenofovir1|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.
16583824|NCT02719808||Tenofovir2|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.
16583825|NCT02719808||Tenofovir3|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one week after delivery.
16583826|NCT02719808||Tenofovir4|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one month after delivery.
16583827|NCT02719808||Group without any treatment|100 patients don't receive any blockade therapies
16583828|NCT02719795|Experimental|Ropivacaine|Ropivacaine hydrochloride injection； Generic name：Naropin； Dosage form：Liquid、Injectable formulation； Dosage：105mg；30ml； Frequency：Once.
16583829|NCT02719795|Placebo Comparator|Normal saline|Medical Normal saline Generic name：Normal saline； Dosage form：Liquid、Injectable formulation； Dosage：30ml； Frequency：Once.
16583861|NCT02719574|Experimental|PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent|Relapsed or Refractory (R/R) AML
16583830|NCT02719782|Experimental|HBV/TCR T cell Infusion|"This is a single-arm study.
~Patients will receive a total of 2 cycles, in which first 28-day treatment cycle consists of escalating doses of TCR-T on Day 1, Day 8, Day 15 and Day 22, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of second (final) cycle. A one month treatment break will be given between the cycles."
16583831|NCT02719756|Experimental|Metformin & Dapagliflozin|Metformin stable dose tablets and Dapagliflozin 10 mg tablets by mouths, once daily in morning for 3 months
16583832|NCT02719756|Active Comparator|Metformin up-titration|Metformin tablets up-titration by mouths, for 3 months
16583833|NCT02719743|Active Comparator|H5N1 Formulation 1 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.
16583834|NCT02719743|Experimental|H5N1 Formulation 2 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
16583835|NCT02719743|Experimental|H5N1 Formulation 3 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
16583836|NCT02719743|Experimental|H5N1 Formulation 4 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
16583837|NCT02719743|Experimental|H5N1 Formulation 5 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
16583838|NCT02719730|Experimental|Reimbursement arm|Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
16583839|NCT02719730|No Intervention|Control arm|Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.
16583840|NCT02719717|Experimental|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
16583841|NCT02719704|Experimental|"MEXA-SE"|Intervention on physical fitness, eating habits and body image
16583842|NCT02719704|No Intervention|Control|School of the control group carried out one semester with the regular and traditional activities. The control school had three physical educations lessons per week, similar of experimental schools.
16583843|NCT02719704|Experimental|"Espelho, espelho meu"|School-based intervention on body image
16583844|NCT02719691|Experimental|Dose-Escalation of Alisertib and MLN0128|This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.
16583845|NCT02719691|Experimental|Dose-Expansion of Alisertib and MLN0128|"Group 1:
~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.
~Group 2:
~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.
~Pancreatic Cancer Cohort:
~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
16583846|NCT02719678|Experimental|Intervention group|Invitation to up to three general health checks over a 10-year period
16583847|NCT02719678|No Intervention|Control group|Control group
16583848|NCT02719665|Experimental|Phase 1a (OMEGA-SPM-DOSE)|PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
16583849|NCT02719665|Active Comparator|SPM - Phase 1b (OMEGA-SPM-DOSE)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
16583850|NCT02719665|Placebo Comparator|Placebo - Phase 1b (OMEGA-SPM-PLACEBO)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
16583851|NCT02719652||symptomatic ICAD|symptomatic intracranial atherosclerosis diseases
16583852|NCT02719652||asymptomatic ICAD|asymptomatic intracranial atherosclerosis diseases
16583853|NCT02719613|Experimental|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
16583854|NCT02719600|Experimental|Down Syndrome Group|Group with Down Syndrome
16583855|NCT02719600|Active Comparator|Typical Development Group|Control group with typical development
16583856|NCT02719587|Placebo Comparator|control group|Control group (8 males, 7 females; 42.54±5.82 years) (SRP): SRP followed by administration of a placebo. The placebo was identical except for the fish oil.
16583857|NCT02719587|Active Comparator|test group|Test group (8 males, 7 females; 40.87±9.7 years) (SRP+omega-3 PUFAs): SRP followed by omega-3 PUFAs supplementation. The test drug contained omega-3 PUFAs including 6.25 mg EPA and 19.19 mg DHA obtained from the Atlantic salmon Salmo salar.Both test and placebo drugs were taken twice a day by the patients for six months. Subjects came to the clinic every 4 weeks during the 6 month course of the experiment to replenish their medication. Remaining medications were checked for compliance. At each evaluation visit (1, 3 and 6 months), oral soft and hard tissue examinations and adverse-event evaluations were performed.
16583858|NCT02719574|Experimental|PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)|
16583859|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine|
16583860|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine|
16583862|NCT02719574|Experimental|PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent|AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
16583863|NCT02719574|Experimental|PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent|R/R AML/MDS, previously treated with FT-2102
16583864|NCT02719574|Experimental|PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
16583865|NCT02719574|Experimental|PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
16583866|NCT02719574|Experimental|PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment
16583867|NCT02719574|Experimental|PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent|Treatment naïve AML for whom standard treatments are contraindicated
16583868|NCT02719574|Experimental|PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine|Treatment naïve AML who are candidates for azacitidine first line treatment
16583869|NCT02719561|Experimental|Fatigue intervention|Fatigue Intervention is to be co-designed by participants, and likely to include education, energy conservation and activity promotion. Participants will also decide the name of the Fatigue Intervention
16583870|NCT02719548|Experimental|Breastshield treatment group A|"Participants will be treated with the following three breast shields:
~Soft edge oval - Hard oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
16583871|NCT02719548|Experimental|Breastshield treatment group B|"Participants will be treated with the following three breast shields:
~Modified PF breast shield - Soft edge oval - Hard oval Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
16583872|NCT02719548|Experimental|Breastshield treatment group C|"Participants will be treated with the following three breast shields:
~Hard oval - Soft edge oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
16583873|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
16583874|NCT02719509||Observational Cohort|All emergency department patients who had a cardiac ultrasound performed as part of their diagnostic workup
16583875|NCT02719496|Experimental|IBEROGAST|Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.
16583876|NCT02719483|Active Comparator|rESWT + traditional conservative therapy|Radial extracorporeal shock wave therapy (rESWT) performed with the Swiss DolorClast device (EMS Electro Medical Systems, Nyon, Switzerland) plus traditional conservative therapy.
16583877|NCT02719483|Other|Traditional conservative therapy|Traditional conservative therapy alone.
16583878|NCT02719470|Experimental|normal cognition|Group 1: patients with normal cognitive profile, assessed with MMSE (27 ≤ correct score ≤ 30) undergoing MIRT
16583879|NCT02719470|Experimental|mildly impaired cognition|Group 3: patients with middle cognitive decline, assessed with MMSE (20 ≤ correct score < 27) undergoing MIRT
16583880|NCT02719470|Experimental|moderately-severely impaired cognition|Group 2: patients cognitive decline, assessed with MMSE (correct score < 20) undergoing MIRT
16583881|NCT02719470|Experimental|patients with normal executive functions|Group 4: patients with pathological executive functions, assessed with FAB (FAB ≥ 13.8) undergoing MIRT
16583882|NCT02719470|Experimental|pathological executive functions|Group 5: patients with pathological executive functions, assessed with FAB (FAB < 13.8) undergoing MIRT
16583883|NCT02719457|Other|6 minute walk test (6 MWT)|patients will be perform the six minute walk test (6 mwt) to evaluate their exercise capacity.
16583884|NCT02719457|Other|spot marching test (SMT)|patients will be perform the spot marching test (SMT) to evaluate their exercise capacity.
16583885|NCT02719431|Other|Warfarin/Warfarin + K-877|
16583886|NCT02719418||Tinzaparin|Hospitalized patients with chronic renal insufficiency (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin 3500 or 4500 unit sub-cutaneous once daily.
16583887|NCT02719405|Placebo Comparator|Amino Acid Formula|
16583888|NCT02719405|Active Comparator|EHCF|Extensively Hydrolyzed Casein Formula
16583889|NCT02719405|Active Comparator|EHCF + LGG|Extensively Hydrolyzed Casein Formula + Lactobacillus GG
16583890|NCT02719392|Active Comparator|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
16583891|NCT02719392|Active Comparator|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
16583892|NCT02719392|Active Comparator|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
16583893|NCT02719392|Placebo Comparator|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
16583894|NCT02719379|Experimental|Asthmatics|19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response
16583940|NCT02719132|Active Comparator|Arm 2|Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)
16583895|NCT02719379|Active Comparator|Non-asthmatics|19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers)
16583896|NCT02719379|Other|Asthmatics - Serum Stored|Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community.
16583897|NCT02719366|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
16583898|NCT02719366|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
16583899|NCT02719353|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
16583900|NCT02719353|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
16583901|NCT02719327|Experimental|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
16583902|NCT02719327|Placebo Comparator|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
16583903|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
16583904|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
16583905|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
16583906|NCT02719301||Men/Women between 18 & 85|Accepting both healthy and non-healthy subjects. A portion of the subjects will have a fluid management issue or heart failure.
16583907|NCT02719288|Experimental|CLARIX® CORD 1K|Applied in addition to standard of care tendon repair surgery.
16583908|NCT02719288|No Intervention|Standard of care tendon repair surgery only|
16583909|NCT02719275||Suicidal Behaviour|
16583910|NCT02719275||Suicidal Ideation|
16583911|NCT02719275||Other Mental Health|
16583912|NCT02719275||Other Health|
16583913|NCT02719262|Experimental|Intervention|installing ventilation in the workplace
16583914|NCT02719249||Men with ESRD on dialysis or transplant|
16583915|NCT02719236|Active Comparator|Direct anterior approach|Primary total hip arthroplasty using a direct anterior approach
16583916|NCT02719236|Active Comparator|Direct lateral approach|Primary total hip arthroplasty using a direct lateral approach
16583917|NCT02719223|Experimental|High Flux Hemodialysis|
16583918|NCT02719223|Experimental|OL-HDF|
16583919|NCT02719210|Experimental|High Volume Plasma Exchange with Standard Treatment|
16583920|NCT02719210|Active Comparator|Standard Treatment|"Standard Treatment is defined as anti raised Intra-cranial pressure
~Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).
~Mannitol
~Hypertonic 3% Saline"
16583921|NCT02719197|Experimental|AC-083, Single Ascending Dose|AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
16583922|NCT02719197|Placebo Comparator|Placebo, Single Ascending Dose|Matched placebo administered as single ascending doses in parallel to AC-083
16583923|NCT02719184||Healthy volunteers|
16583924|NCT02719184||COPD GOLD I|Chronic obstructive pulmonary disease
16583925|NCT02719184||COPD GOLD II|Chronic obstructive pulmonary disease
16583926|NCT02719184||COPD GOLD III|Chronic obstructive pulmonary disease
16583927|NCT02719184||A1AT Deficiency|Alpha one anti-trypsin deficiency
16583928|NCT02719171|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
16583929|NCT02719171|Experimental|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
16583930|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
16583931|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
16583932|NCT02719171|Experimental|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
16583933|NCT02719158|Experimental|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
16583934|NCT02719158|Experimental|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
16583935|NCT02719158|Sham Comparator|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
16583936|NCT02719145||Control group (group 1)|10 healthy volunteer subjects.
16583937|NCT02719145||Asthma group (group 2)|10 asthmatic patients.
16583938|NCT02719145||COPD group (group 3)|10 COPD patients.
16583939|NCT02719132|Experimental|Arm 1|Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)
16584136|NCT02717715|No Intervention|Control group|The participants in the control group will only receive usual care.
16583941|NCT02719119|Experimental|monthly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation monthly.
16583942|NCT02719119|Experimental|bi-weekly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation bi-weekly.
16583943|NCT02719106||Ultimaster stent|
16583944|NCT02719093|Experimental|recombinant FSH|recombinant FSH 150UI daily
16583945|NCT02719067||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV and ICD-10 criteria
16583946|NCT02719067||TD group|Typically developing controls without lifetime ASD or a family history of ASD
16583947|NCT02719054|Experimental|stimulation|Cognitive behavioral therapy for mother and play stimulation for children aged 6 to 12 months
16583948|NCT02719054|No Intervention|Mother child dyad|
16583949|NCT02719041||Tissue samples|Tissue samples taken from women treated for ovarian cancer will be stained.
16583950|NCT02719028|Placebo Comparator|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
16583951|NCT02719028|Experimental|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
16583952|NCT02719028|Experimental|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
16583953|NCT02719028|Experimental|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
16583954|NCT02719015|Experimental|rAd.CD40L + Pembrolizumab|"The dose escalation phase will include rAd.CD40L dose escalation and increase in the number of injected sites/lesions. Once patients tolerate dose level 1 (1 injection site and 1x1011vp-MTD) in Dose Escalation cohort, Expansion cohort will open with same maximum number of injection sites at maximum tolerated dose from Dose Escalation cohort.
~All participants receive same dosage of Pembrolizumab in both phases."
16583955|NCT02719002|Experimental|OCT C-scan|
16583956|NCT02718989|Experimental|10 Kilohertz (KHz)|"Transcutaneous application of 10 Kilohertz (KHz) current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16583957|NCT02718989|Experimental|Transcutaneous Electrical Stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 100 Hz and pulse width 100 microseconds"
16583958|NCT02718989|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
16583959|NCT02718976|Experimental|Shamrock guided by US/MR image fusion|Use of US/MR image fusion guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
16583960|NCT02718976|Other|Shamrock guided by US|Use of US guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
16583961|NCT02718963|Experimental|Control group|"control group(N=10): who does not have dysphagia symptom
~apply Synchronized Electrical Stimulation Device
~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function
~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
16583962|NCT02718963|Experimental|Experimental group|"experimental group(N=10): who have dysphagia symptoms
~apply Synchronized Electrical Stimulation Device
~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function
~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
16583963|NCT02718950|Experimental|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks.
16583964|NCT02718937|Experimental|BTA-C585|BTA-C585 100 mg oral capsule
16583965|NCT02718937|Placebo Comparator|Placebo|Matching placebo capsule
16583966|NCT02718924||morbidly obese pregnant|Term pregnant women with BMI more than 40
16583967|NCT02718924||non obese pregnant|Term pregnant women with BMI less than 30
16583968|NCT02718911|Experimental|LY3022855 + Durvalumab (Dose Escalation)|LY3022855 given intravenously (IV) in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
16583969|NCT02718911|Experimental|LY3022855 + Tremelimumab (Dose Escalation)|LY3022855 given IV in combination with tremelimumab given IV. Treatment may continue until disease progression or discontinuation.
16583970|NCT02718911|Experimental|LY3022855 + Durvalumab (Expansion)|LY3022855 given IV in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
16583971|NCT02718898|Experimental|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.
~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
16583972|NCT02718898|Placebo Comparator|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.
~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
16583973|NCT02718885|Sham Comparator|Maltodextrin|Maltodextrin
16583974|NCT02718885|Active Comparator|Inulin|Inulin-type fructans
16583975|NCT02718872|Experimental|Tobacco cessation online training|Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
16583976|NCT02718859|Active Comparator|irreversible electroporation (IRE)|Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
16583977|NCT02718859|Experimental|IRE & NK cells|Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
16583978|NCT02718846|Experimental|Meniace and Isobide|co-administration Isobide solution and Meniace tablets
16583979|NCT02718846|Active Comparator|Meniace|single administration Meniace tablets
16583981|NCT02718820|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression.
16583982|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
16583983|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
16583984|NCT02718794|Experimental|Simulation training first|A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment.
16583985|NCT02718794|Experimental|Problem-based learning first|Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
16583986|NCT02718781|Experimental|Talk and leaders|This group will comprise of health talk and regular contact with community leaders.
16583987|NCT02718781|Experimental|Talk, leaders and equipment|This group will comprise of health talk and regular contact with community leaders. Moreover, a home-based equipment (handgrip) will be delivered to them
16583988|NCT02718781|Active Comparator|Talk|This group will comprise of a health talk only.
16583989|NCT02718755|Experimental|Fludarabine + Cytarabine + Erwinase|"Induction Phase: Participants receive 1-2 cycles during the Induction phase.
~Participants receive 1-2 cycles during the Induction phase.
~Participants receive Fludarabine by vein on Days 1-5 and Cytarabine by vein.
~Participants receive Erwinase by vein or as an injection into the muscle on Days 1-7.
~Consolidation Phase: Participants receive up to 3 cycles during the Consolidation phase.
~Participants receive Fludarabine by vein on Days 1-4 and Cytarabine by vein.
~On Day 1 and then every other day for 15 days (3, 5, 7 and so on), participant receives Erwinase by vein or as an injection into the muscle."
16583990|NCT02718742|Experimental|Treatment (nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16583991|NCT02718729|Other|Rectal cancer patients|All patients who will fulfill the inclusions criteria. Patients will undergo formal curative radical Laparoscopic resection for rectal cancer
16583992|NCT02718716|Experimental|UCB7665 dose 1|Subjects in this Arm will receive 5 subcutaneous (sc) doses of UCB7665 at 1-week intervals
16583993|NCT02718716|Experimental|UCB7665 dose 2|Subjects in this Arm will receive 3 subcutaneous (sc) doses of UCB7665 dose 2 at 1-week intervals
16583994|NCT02718716|Experimental|UCB7665 dose 3|Subjects in this Arm will receive 2 subcutaneous (sc) doses of UCB7665 dose 3 at 1-week intervals
16583995|NCT02718716|Experimental|UCB7665 dose 4|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 4
16583996|NCT02718716|Experimental|UCB7665 dose 5|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 5
16583997|NCT02718703|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
16583998|NCT02718690|Experimental|Transcutaneous nerve stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16583999|NCT02718690|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
16584000|NCT02718677||1. Refacto AF (NIS)|Non-Interventional Study
16584001|NCT02718664|No Intervention|A (fasting)|Fasting condition
16584002|NCT02718664|Experimental|B (fed)|Fed condition (test meal)
16584003|NCT02718638|Other|physical exercises group|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.
16584004|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
16584005|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
16584006|NCT02718599|Active Comparator|Terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
16584007|NCT02718599|Placebo Comparator|CONTROL|Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).
16584008|NCT02718573||Non-liver transplants with HCV|
16584009|NCT02718573||Liver transplants with HCV|
16584010|NCT02718560|Experimental|Group 1 - Writing with 1 cm cue|This group uses to write space of 1 cm size
16584011|NCT02718560|Experimental|Group 2 - Writing with 1.5 cm cue|This group uses to write space of 1.5 cm size
16584012|NCT02718560|Experimental|Group 3 - Writing without cue|This group writes without using cues
16584013|NCT02718560|No Intervention|Group 4 - no writing|This group do not write. Only wrist mobilization is performed.
16584014|NCT02718547|Experimental|Participants receiving Combigan drops in order to reduce IOP|All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
16584015|NCT02718534|Experimental|ERTAS-1|first limb rehabilitation therapy took place within 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
16584016|NCT02718534|Active Comparator|ERTAS-2|first limb rehabilitation therapy took place after 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
16584017|NCT02718521|Experimental|Hydration Therapy Combined With Isosorbide Dinitrate|Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography
16584018|NCT02718521|Active Comparator|Conventional hydration group|normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography
16584019|NCT02718508|No Intervention|Standard Care|All enrolled adolescents will continue to receive standard trauma center care, a brief intervention during their hospitalization by a trauma center social worker which is required by institutional policy.
16584020|NCT02718508|Experimental|Standard Care plus e-Parenting Group|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
16584021|NCT02718495|Placebo Comparator|Part A|Part A consists of two treatment groups, SAD and MAD. Both treatment groups will consist of 3 cohorts. In SAD, subjects will receive a single dose of PTI-428 or placebo. In MAD, subjects will receive once daily dosing of PTI-428 or placebo for 7 days.
16584022|NCT02718495|Placebo Comparator|Part B|Part B will consist of 2 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
16584023|NCT02718495|Placebo Comparator|Part C|Part C will consist of 3 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
16584024|NCT02718482|Experimental|Gemcitabine and Docetaxel|Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
16584025|NCT02718482|Experimental|Ifosfamide|Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks
16584026|NCT02718469|Experimental|Ebola Vaccine - low dose|Low Dose Zaire Ebola Vaccine
16584027|NCT02718469|Experimental|Ebola Vaccine - mid dose|Mid Dose Zaire Ebola Vaccine
16584028|NCT02718469|Experimental|Ebola Vaccine - high dose|High Dose Zaire Ebola Vaccine
16584029|NCT02718469|Placebo Comparator|Placebo|Placebo
16584030|NCT02718456|No Intervention|Standard of care|Standard HIV counseling and referral to care
16584031|NCT02718456|Experimental|CD4 testing|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week.
16584032|NCT02718456|Experimental|CD4 testing plus peer counseling|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
16584033|NCT02718443|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
16584034|NCT02718430|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
16584035|NCT02718417|Active Comparator|Arm A|Chemotherapy followed by observation
16584036|NCT02718417|Experimental|Arm B|Chemotherapy followed by avelumab in maintenance
16584037|NCT02718417|Experimental|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
16584038|NCT02718404|Experimental|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.
~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.
~During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
~Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI."
16584137|NCT02717702||ACS Patients|Subjects will be patients presenting to the Emergency Department for evaluation of ACS.
16584138|NCT02717689|Experimental|Biomarker arm|Biomarker based adjustment of corticosteroid dose.
16584039|NCT02718391|Experimental|Arm A: Autologous Dendritic Cell vaccine|Daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days starting from the second day after each vaccine dose. Vaccine doses will be given intradermally in two sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis.The first dose (WK1) will consist of freshly prepared vaccine, whereas for all the further doses cryopreserved aliquots will be utilized. The remaining 5 doses will be administered every 4 weeks to complete six months of therapy (six vaccines).
16584040|NCT02718391|No Intervention|Arm B: follow up|Arm B: Patients will undergo laboratory and clinical assessment, tumor re-staging, blood collection for immunological biomarkers every 12 weeks until relapse.
16584041|NCT02718378|Placebo Comparator|No added active|placebo without estetrol
16584042|NCT02718378|Active Comparator|estetrol dose level 1|estetrol given in dose level 1
16584043|NCT02718378|Active Comparator|estetrol dose level 2|estetrol given in dose level 2
16584044|NCT02718378|Active Comparator|estetrol dose level 3|estetrol given in dose level 3
16584045|NCT02718365|Experimental|Group A|Wedge resection
16584046|NCT02718365|Active Comparator|Group B|Segmentectomy
16584047|NCT02718339|Experimental|Intensive counseling by a pulmonologist|Counselor visit during hospitalization, telephone follow up for 4 weeks and a follow up visits.
16584048|NCT02718339|No Intervention|Usual care|
16584049|NCT02718326|Experimental|Dosing regimen 1|Participants will receive IVT aflibercept dosing regimen 1
16584050|NCT02718326|Experimental|Dosing regimen 2|Participants will receive IVT aflibercept dosing regimen 2
16584051|NCT02718326|Sham Comparator|Dosing regimen 3|Participants will receive matching sham injections
16584052|NCT02718313||Intraventricular conduction delay|Transthoracic echocardiography will be performed to investigate whether the patients have the cardiac disease or not. The transthoracic echocardiography will be performed after the induction of general anesthesia and before the start of surgery.
16584053|NCT02718300|Experimental|Part 1: Ruxolitinib + Parsaclisib|Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
16584054|NCT02718300|Experimental|Part 2: Ruxolitinib + Parsaclisib|Part 2 will compare 2 doses of parsaclisib .
16584055|NCT02718300|Experimental|Part 3: Ruxolitinib + Parsaclisib|Part 3 will compare 2 different long term dosing strategies.
16584056|NCT02718300|Experimental|Part 4: Ruxolitinib + Parsaclisib|Part 4 will compare 2 different daily dosing strategies.
16584057|NCT02718287|Experimental|Treatment:|Home visiting with PCCSF
16584058|NCT02718287|Experimental|Control|Home visiting no PCCSF
16584059|NCT02718274|No Intervention|Control|Standard of care.
16584060|NCT02718274|Active Comparator|Self-testing|Community-Based Distribution Agents (CBDAs) in the HIV Self-Testing (HIVST) Arm villages will be trained to provide HIVST services as well as reproductive health services.
16584061|NCT02718274|Active Comparator|Self-testing + home HIV care home initiation|CBDAs will be trained to provide HIV Self-Testing plus offer home assessment and HIV care initiation (first assessment and first 14 days of HIV care medications), with this additional intervention aimed at facilitating linkage into care.
16584062|NCT02718261|Experimental|Verum (pantoprazole)|
16584063|NCT02718261|Placebo Comparator|Placebo|0.9% saline
16584064|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
16584065|NCT02718235||Overall survival HCCIS low risk|HCCIS 2 points
16584066|NCT02718235||Overall survival HCCIS medium risk|HCCIS 1 point
16584067|NCT02718235||Overall survival HCCIS high risk|HCCIS 0 point
16584068|NCT02718222|Experimental|3-9 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 3 months.
~Nepal and Sri Lanka: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 9 months."
16584069|NCT02718222|Experimental|9-15 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 9 months.
~Nepal and Sri Lanka: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 15 months."
16584070|NCT02718209|Experimental|Frozen section|Frozen sections taken from women operated on for possible gynecologic malignancies.
16584071|NCT02718196|Experimental|Application Users|English-speaking parents of children ages 6-24 months who are interested in starting sleep training within the next month.
16584072|NCT02718183|Experimental|PH|Hydrogen peroxide 35% to intracoronal bleaching in discoloration teeth eith endodontic treatment
16584073|NCT02718183|Experimental|PC|Carbamide peroxide 37% to intracoronal bleaching in discoloration teeth eith endodontic treatment
16584074|NCT02718170|Experimental|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
16584075|NCT02718170|Active Comparator|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
16584076|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
16584077|NCT02718144|Experimental|estetrol|3 + 3 design with inter-patient dose escalation
16584139|NCT02717689|No Intervention|Standard care|The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function
16584080|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
16584081|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
16584082|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
16584083|NCT02718092|Active Comparator|Plastic Stent|Three 7 Fr OR two 10 Fr Plastic Stents will be used
16584084|NCT02718092|Active Comparator|Axios FCSEMS|15 mm Axios Fully Covered Self Expanding Metal Stent
16584085|NCT02718079|Experimental|Standard medical therapy with Plasma Exchange|Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
16584086|NCT02718079|Active Comparator|Standard medical therapy alone|Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
16584087|NCT02718066|Experimental|HBI-8000 in combination with nivolumab|HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
16584088|NCT02718053||spasticity|patients affected by spasticity of the lower limbs
16584089|NCT02718053||controls|healthy subjects
16584090|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
16584091|NCT02718027||Participants with Alport Syndrome|Participants diagnosed with Alport syndrome aged between 2 months and 50 years
16584092|NCT02718014|Other|pre menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
16584093|NCT02718014|Other|post menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
16584095|NCT02717988|Experimental|SKI-O-703 50 mg|SKI-O-703 capsule (2x25 mg)
16584096|NCT02717988|Experimental|SKI-O-703 100 mg|SKI-O-703 capsule (4x25 mg)
16584097|NCT02717988|Experimental|SKI-O-703 200 mg|SKI-O-703 capsule (1x200 mg)
16584098|NCT02717988|Experimental|SKI-O-703 400 mg|SKI-O-703 capsule (2x200 mg)
16584099|NCT02717988|Experimental|SKI-O-703 600 mg|SKI-O-703 capsule (3x200 mg)
16584100|NCT02717988|Experimental|SKI-O-703 800 mg|SKI-O-703 capsule (4x200 mg)
16584101|NCT02717988|Placebo Comparator|Placebo|Placebo capsule
16584102|NCT02717975|Active Comparator|Without valve|"Trial removal of catheter without catheter valve in patients with urinary retention. These are those patients who have catheter on free drainage, attend the clinic for catheter removal and bladder to be filled naturally ( which may take upto 4-5 hours). After removal of catheter they will be asked to drink plenty of fluids while waiting for the bladder to fill up.
~This is the traditional method of catheter removal."
16584103|NCT02717975|Experimental|With valve|"Trial removal of catheter in patients with urinary retention with closed catheter valve. These patients will be asked to close the valve 3-4 hours before attending the clinic prior to catheter removal. Here the intervention is catheter valve that allows bladder to be comfortably full by the time patient arrives in the clinic. By this intervention the investigators hypothesise that the investigators can save the clinic time as the patient will not need to wait for natural bladder filling which generally takes 4-5 hours.
~Intervention: Urinary catheter valve"
16584104|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
16584105|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
16584106|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
16584107|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
16584108|NCT02717936|Other|Immunohistochemistry|Patients are investigated using immunohistochemistry with Pancytokeratin
16584109|NCT02717923|Experimental|Maintenance Treatment|A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.
16584110|NCT02717910|Experimental|Health game group|Participants in this arm will receive the health game intervention including both 20 minutes guided training session at school and 2 weeks free usage of the health game during free time.
16584111|NCT02717910|Sham Comparator|Web page group|Participants in this arm will receive the web page intervention including both 20 minutes guided training session at school and 2 weeks free usage of the web page during free time.
16584112|NCT02717910|No Intervention|Group with no intervention|The participants in this arm will receive no intervention.
16584140|NCT02717676|Experimental|Group A|Episiotomy
16584141|NCT02717676|No Intervention|Group B|no episiotomy
16584536|NCT02715193|Experimental|REMD-477 Treatment A|Administered as a single SC dose in subjects with Type 1 Diabetes
16584113|NCT02717884|Experimental|TCP, ATRA, Cytarabine|"Phase I part:
~The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.
~Intervention: Four dose levels of TCP (20 mg, 40 mg**, 60 mg**, 80 mg** on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.
~**TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment"
16584114|NCT02717871|Experimental|Treatment (PACK-CXL)|Photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL)
16584115|NCT02717871|Active Comparator|Antimicrobial therapy|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.
~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):
~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).
~OR
~1b. a Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
~2. Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
~3. Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium"
16584116|NCT02717858|Experimental|Liraglutide|
16584117|NCT02717858|Placebo Comparator|Placebo|
16584118|NCT02717845|Experimental|CT scan Ellipse|New medical device for high tibial osteotomy
16584119|NCT02717845|Active Comparator|CT scan Tomofix|Established medical device for high tibial osteotomy
16584120|NCT02717832|Experimental|Insulin Sensitivity|
16584121|NCT02717819|Experimental|Resistance training and protein|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
16584122|NCT02717819|Placebo Comparator|Resistance training and placebo|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
16584123|NCT02717806|Experimental|PATHway|"Patients allocated to the PATHway intervention will be given a 4 week run-in period as an outpatient to get acquainted with the system. During this run-in period, the PATHway system will also be installed in each participant's home. They will be provided with a training manual and a quick set up guide for getting started with PATHway in the home.
~After this 4 week run-in period, the PATHway system will be set up for each individual patient including a patient specific exercise prescription. The patient will then exercise with the PATHway platform for 6 months."
16584124|NCT02717806|No Intervention|Usual care|Patients randomized to the control group will receive usual care.
16584125|NCT02717793|Experimental|isometric muscle strength|"isometric muscle strength was measured with a digital hand-held dynamometer. The digital hand-held dynamometer was held by the therapist against the flexor aspect of the distal forearm of the subject, on the wrist joint. Subject was asked to maintain the position and a break test was done with progressive loading of 5 seconds given by the tester. The peak isometric strength was recorded by a second tester at the end of 5 seconds. A standardised instructions and verbal encouragement was given to the subject for motivation. Subject as well as the tester was blinded to the values recorded on the digital hand-held dynamometer. An average of three measurements (with a rest period of 4 minutes in between each trial session) was recorded for the analysis. After each trial session, the rate of perceived exertion (RPE) was asked to the subject using the 1-10 Borg rating of perceived exertion scale"
16584126|NCT02717793|Experimental|1RM measurement of muscle strength|1RM measurement was done using the Brzycki 1RM prediction equation. In first testing session, subject was instructed to perform a general warm up for 5 minutes. Thereafter, the subject was asked to perform 10 repetitions of the movement using the amount of resistance that the subject felt she will be able to lift for only less than 10 times. The selection of the weight is made based on a list of weights provided (1kg to 10kg). When the subject performed the movement for 10 times or more, then the resistance was increased 1kg at a time, until the subject can perform only 9 or fewer repetitions of the movement correctly throughout the range of motion. A 3 minutes rest period was given to the subject before the new attempt was done with the increased weight. A standardized verbal encouragement was provided for motivation
16584127|NCT02717780|Active Comparator|SEVO-FENTA|Patients scheduled for lower limb surgery will receive a balanced anesthesia with fentanyl and sevoflurane.
16584128|NCT02717780|Experimental|DES-REMI|Patients scheduled for lower limb surgery will receive a balanced anesthesia with remifentanil and desflurane.
16584129|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
16584130|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
16584131|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
16584132|NCT02717741|Experimental|tafetinib|tafetinib administered daily for 2 weeks, followed by a 1-week off period
16584133|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses
~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter
~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
16584134|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)
~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter
~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
16584135|NCT02717715|Experimental|Intervention group|Stroke patients from the intervention group will be, on top of usual care, offered a holistic home based and semi-supervised stroke rehabilitation program followed by a period of tele-supervision.
16586495|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
16584146|NCT02717650|Experimental|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
16584147|NCT02717650|Experimental|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
16584148|NCT02717650|Active Comparator|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
16584149|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
16584150|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
16584151|NCT02717624|Experimental|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
16584152|NCT02717611|Experimental|ACP-196 (acalabrutinib)|ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID
16584153|NCT02717598|Experimental|CSP|Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
16584154|NCT02717598|Experimental|HSP|Hot snare polypectomy, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp,then use Electrocoagulation until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
16584155|NCT02717585|No Intervention|Control Group|For the no intervention group (Control), patients will only receive standardized treatment for FM at the Pain Clinic. All patients will receive a multifaceted tailored regimen that incorporates one or more lines of pharmacological and/or non-pharmacological therapy. All assessment and management will be performed according to evidence-based therapeutic recommendations put forward by the Canadian Rheumatology Association and Canadian Pain Society.
16584156|NCT02717585|Active Comparator|Treatment Group (CPAP)|In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
16584157|NCT02717572|Experimental|FDG-PET/CT and FDG-PET/MR|"10 mCI fludeoxyglucose IV bolus approximately 60 minutes before first PET/CT
~Immediately following PET/CT scan, the participant will be moved to PET/MR scanner
~The scans will take place at baseline and also one more time point between Day 1 and Day 7. There needs to be at least 24 hours between the baseline and repeat imaging"
16584158|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
16584159|NCT02717533||blood volume|dry weight adjusted according to ideal blood volume obtained from absolute blood volume measurement (Daxor)
16584160|NCT02717520|Experimental|All study participants|One permanent molar with an approximal and occlusal carious lesion restored with EQUIA Forte, and one permanent molar with an approximal and occlusal carious lesion restored with Tetric EvoCeram
16584161|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
16584162|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
16584163|NCT02717494|Experimental|Arm 1A (PPV-23)|In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
16584164|NCT02717494|Experimental|Arm 1B (PCV-10)|In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
16584165|NCT02717494|Placebo Comparator|Arm 1C (placebo)|In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
16584166|NCT02717494|Experimental|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
16584167|NCT02717494|Experimental|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
16584168|NCT02717494|Experimental|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.
16584169|NCT02717481||Patients with known aortic aneurysm|"Patients with known abdominal aortic aneurysm diagnosed in clinical follow-up or after an invasive procedure to repair it.
~US-CT Fusion examination"
16584170|NCT02717455|Experimental|Treatment (STRATUM 1)|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
16584171|NCT02717455|Experimental|Treatment (STRATUM 2)|Patients with non-progressed DIPG will be enrolled. All patients will take the study drug panobinostat (LBH589).
16584172|NCT02717442|Experimental|OTO-104|12 mg dexamethasone
16584173|NCT02717442|Placebo Comparator|Placebo|
16584174|NCT02717429|Experimental|Mindfulness Meditation Training (MMT)|Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration. The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness. In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
16584227|NCT02717117|Experimental|Feeding|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
16584175|NCT02717429|Active Comparator|Computerized Cognitive Training|The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group. Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
16584176|NCT02717429|No Intervention|Wait-List Control Group|This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
16584177|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
16584178|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) or electrical coagulation group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip or electrical coagulation therapy.
16584179|NCT02717403|Experimental|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
16584180|NCT02717403|Experimental|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
16584181|NCT02717403|Experimental|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
16584182|NCT02717390|Experimental|Bright By Three (BB3) Intervention|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years
16584183|NCT02717390|Active Comparator|Texts for Child Safety (TCS) Intervention|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
16584184|NCT02717377|No Intervention|Uninterrupted sitting|Subjects remained seated all day except to rise from the chair to void.
16584185|NCT02717377|Active Comparator|Sitting + one bout of activity|Subjects remained seated all day, except to rise from the chair to void, and to perform one bout of 30-minutes moderate-intensity walking. Physical activity was performed at 0800, after measures of vitals and basal questionnaire assessments, but before breakfast.
16584186|NCT02717377|Experimental|Sitting + microbursts of activity|Subjects rose from the seated position every hour for 6-hours from 0910 to 1430 to complete 5-minute bouts of moderate-intensity walking, yielding a total activity time of 30-minutes.
16584187|NCT02717364||Population With Yervoy Exposure|Population With Yervoy Exposure
16584188|NCT02717351|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16584189|NCT02717338|Experimental|Competence|Participants will be assigned to review our donor coping website.
16584190|NCT02717338|Experimental|Autonomy|Participants will be assigned to receive a brief telephone interview.
16584191|NCT02717338|Experimental|Relatedness|Participants will be asked to join a closed Facebook group for one month.
16584192|NCT02717338|Experimental|Competence + Autonomy|Participants will be assigned to the web site review, followed by the brief telephone interview.
16584193|NCT02717338|Experimental|Competence + Relatedness|Participants will be assigned to the web site review, followed by the one-month Facebook group membership.
16584194|NCT02717338|Experimental|Autonomy + Relatedness|Participants will be assigned to the brief telephone interview, followed by the one-month Facebook group membership.
16584195|NCT02717338|Experimental|Competence + Autonomy + Relatedness|Participants will be assigned to the web site review, brief telephone interview, and one-month Facebook group membership.
16584196|NCT02717338|No Intervention|Treatment-as-Usual Control|Participants will receive the standard communications that New York Blood Center has with all first-time donors.
16584197|NCT02717325|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
16584198|NCT02717299|Experimental|Sensor Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The surgeon will use this data to intraoperatively align the knee according to the indications of the data.
16584199|NCT02717299|Placebo Comparator|Surgeon Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The computer displaying the data will be turned away from the surgeon, so that he is not able to use the sensor data, and must balance the knee with feel and visual estimation of balance.
16584200|NCT02717286|Sham Comparator|Control|"20 first permanent molars from children aged between 6 to 12 years old presenting MIH will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the European Academy of Pediatric Dentistry (EADP) criteria.
~Intervention of Control: The restorative treatment using a total-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
16584228|NCT02717091|Experimental|FOLFIRINOX|4 course of FILFIRINOX before surgery
16584201|NCT02717286|Experimental|Test|"20 first permanent molars from children aged between 6 to 12 years old presenting Molar Incisor Hypomineralization will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the EAPD criteria.
~Intervention of test: the restorative treatment using a self-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), air jet (5 s), adhesive application (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
16584202|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
16584203|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.
~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
16584204|NCT02717260|Sham Comparator|Sham transcranial noise stimulation|subjects are stimulated 3 times with sham transcranial random noise stimulation (tRNS) (Starstim) with a 30 seconds offset
16584205|NCT02717260|Active Comparator|1 Active transcranial random noise stimulation|subjects are stimulated 1 time with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes and 2 times with sham tRNS
16584206|NCT02717260|Active Comparator|3 Active transcranial random noise stimulation|subjects are stimulated 3 times with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes
16584207|NCT02717247|Experimental|Active tRNS treatment|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).
~100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days"
16584208|NCT02717247|Sham Comparator|Placebo tRNS treatment|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
16584209|NCT02717234|Active Comparator|Impact Advanced Recovery|Oral nutrition supplement intended for consumption at 3 servings per day
16584210|NCT02717234|Experimental|Impact Advanced Recovery-R|Oral nutrition supplement intended for consumption at 3 servings per day
16584211|NCT02717221|Experimental|18F-MPG:EGFR+|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
16584212|NCT02717221|Experimental|18F-MPG:post-TKI EGFR+|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.
16584213|NCT02717221|Experimental|18F-MPG:post-chemo EGFR+|Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
16584214|NCT02717221|Experimental|18F-MPG:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
16584215|NCT02717221|Experimental|18F-MPG:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
16584216|NCT02717221|Experimental|18F-MPG:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
16584217|NCT02717208|Active Comparator|HL036 0.5mg/ml|Administration : 2 times per day for one day
16584218|NCT02717208|Active Comparator|HL036 5mg/ml|Administration : 2 times per day for one day
16584219|NCT02717195|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
16584220|NCT02717195|Experimental|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
16584221|NCT02717195|Experimental|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
16584222|NCT02717195|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
16584223|NCT02717169|Other|Biometrical Tracker|The participants are equipped with an wrist watch. The activity tracker measures biometrical information like, steps, sleep duration and heart rate.
16584224|NCT02717156|Experimental|Treatment (EphB4-HSA and pembrolizumab)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, and 15 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16584225|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:
~prolonged chest pain > 10 minutes,
~recent infectious context <7 days
~young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion
~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.
~This is an observational study that does not affect the management of patients."
16584226|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
16584229|NCT02717091|Experimental|GEM + nab-PTX|2 course of GEM + nab-PTX before surgery
16584230|NCT02717078|Experimental|LoBAG Diet|Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks.
16584231|NCT02717078|Active Comparator|Control Diet|Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks.
16584232|NCT02717065|Experimental|Characterization, Audiovisual|"Characterization: Tinnitus characterization tools (Minimal Masking Level, Tinnitus Functional Index, Tinnitus Handicap Inventory, and Subjective rating scale) are assessed in an individual over time to determine baseline variability.
~Audiovisual: The individual will watch a series of silent videos of a person speaking, both with and without a tone matched to their tinnitus as well as videos of a still face with and without the matched tone."
16584233|NCT02717052|Experimental|(S)-ketamine|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)
~all patients and 10 HC (randomized, double blind)
~Interventions:
~Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2"
16584234|NCT02717052|Placebo Comparator|Placebo|"0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
~10 HC (randomized, double blind)
~Interventions:
~Drug: Placebo Other: Main study: PET1 Other: Main study: PET2"
16584235|NCT02717052|Experimental|(S)-ketamine (Pilot Study II, 5 subj.)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
~Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.
~Pilot-study II is cross-over design!
~Interventions:
~Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
16584236|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study II, 5 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
~Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.
~Pilot-study II is cross-over design!
~Interventions:
~Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
16584237|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study I, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)
~Interventions:
~Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2"
16584238|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study III, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
~Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes
~Interventions:
~Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2"
16584239|NCT02717039||Blood Draw|A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
16584240|NCT02717013|Placebo Comparator|Placebo Diet Restriction|
16584241|NCT02717013|Placebo Comparator|Placebo No Diet Restriction|
16584242|NCT02717013|Active Comparator|HMB Diet Restriction|
16584243|NCT02717013|Active Comparator|HMB No Diet Restriction|
16584244|NCT02717000||NASH|
16584245|NCT02717000||No NASH|
16584246|NCT02716987|Experimental|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with [18F] ([18F]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
16584247|NCT02716987|Experimental|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
16584248|NCT02716987|Experimental|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
16584249|NCT02716987|Experimental|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
16584250|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
16584251|NCT02716974|Experimental|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
16584252|NCT02716961|No Intervention|Monotherapy|Barely epirubicin was instilled after TURBT. Epirubicin was immediately instilled in 24h after TURBT. Instillation was conducted regularly for a year: once in a week for 8 times, once in two weeks for 8 times, once in a month for 6 times.
16584253|NCT02716961|Experimental|Combination|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. Intervention: GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
16584254|NCT02716948|Experimental|Treatment (nivolumab, stereotactic radiosurgery)|Patients receive nivolumab IV over 60 minutes on day 1. Patients then undergo stereotactic radiosurgery on day 8 per standard of care. Courses with nivolumab repeats every 14 days in the absence of disease progression or unacceptable toxicity.
16584255|NCT02716935|Experimental|Fortified lipid based nutrient supplement|lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin
16584258|NCT02716922|Experimental|Cervical cerclage|Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
16584259|NCT02716922|No Intervention|No intervention|No cerclage Women randomized to not receive cerclage represent the control arm
16584260|NCT02716909|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
16584261|NCT02716909|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
16584262|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
16584263|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
16584264|NCT02716883|No Intervention|Non AMT|"Freshly prepared fortified eye drops (cefazolin 50 mg/mL and amikacin 14 mg/mL) were applied as starting treatment. In the first 3 days, eye drops are applied round the clock followed by drops every 2 h during waking hours until results of laboratory investigation were available.
~After preparation of the culture results, the antimicrobial treatment was narrowed according to bacterial sensitivity. Also topical betamethasone 0.1% four times a day on a tapering weekly dosage until 3-4 weeks is used for all patients. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented"
16584265|NCT02716883|Active Comparator|AMT|"This group (case group) received above mentioned routine antibiotic therapy followed by double-layer amniotic membrane transplantation 2-5 days after the start of medications and the second group (control group) only received routine antibacterial therapy.
~The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented."
16584266|NCT02716857|Experimental|Oxycodone extended-release|Egalet ADER oxycodone tablet
16584267|NCT02716857|Placebo Comparator|Placebo of Oxycodone extended-release|Egalet ADER oxycodone placebo tablet
16584268|NCT02716844|Experimental|Exercise Group,|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
16584269|NCT02716844|No Intervention|Control Group|Nothing given to control group, told to continue their normal life for 6 weeks.
16584270|NCT02716831|Experimental|Counseling & Acceptance-based Therapy|Nutritional Counseling & Acceptance-based Therapy (N-CAAT) incorporates acceptance-based behavioral strategies and nutritional counseling designed to encourage willingness to tolerate distress and the ability to pursue chosen values in an adaptive manner despite distressing internal experiences. In addition to these skills, a principal focus of the treatment will be on identifying, practicing, and achieving behavioral goals, such as normalization of eating, reduction of maladaptive dietary restraint and restriction, and elimination of compensatory behaviors.
16584271|NCT02716831|Active Comparator|Cognitive Therapy for Eating Disorders|Participants in the Cognitive Behavioral Therapy for Eating Disorders (CBT) condition will receive 20-sessions of standard CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn and published in his book Cognitive Behavioral Therapy and Eating Disorders.
16584272|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
16584273|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
16584274|NCT02716805|Experimental|Cohort 1|"Subjects received Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
16584275|NCT02716805|Experimental|Cohort 2|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
16584276|NCT02716805|Experimental|Cohort 3|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
16584277|NCT02716805|Experimental|Cohort 4|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
16584537|NCT02715193|Placebo Comparator|Matching placebo|Administered as a single SC dose in subjects with Type 1 Diabetes
16584278|NCT02716792|Experimental|Ibandronate 15-Minute Infusion|Participants will receive ibandronate IV infusions over a 15-minute interval.
16584279|NCT02716792|Active Comparator|Ibandronate 60-Minute Infusion|Participants will receive ibandronate IV infusions over a 60-minute interval.
16584280|NCT02716779|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
16584281|NCT02716779|Placebo Comparator|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
16584282|NCT02716779|Experimental|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
16584283|NCT02716766|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
16584284|NCT02716766|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily from Day 1 to 14
16584285|NCT02716753|Experimental|Seminal plasma|Half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
16584286|NCT02716753|Placebo Comparator|Physiological NaCL solution|An amount of physiological NaCL solution equal to half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
16584287|NCT02716740|Experimental|Leucine-enriched amino acid : 2.16g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
16584288|NCT02716740|Experimental|Leucine-enriched amino acid : 4g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
16584289|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
16584290|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
16584291|NCT02716714|Active Comparator|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
16584292|NCT02716714|Active Comparator|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
16584293|NCT02716701|Experimental|Exercise Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will be asked to increase their activity level, with a goal of at least doubling their average daily activity (steps)
16584294|NCT02716701|Active Comparator|Control Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will not be encouraged to increase their activity level
16584295|NCT02716688|Experimental|Radiotherapy and S-1 arm|Radiotherapy will be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy. Preplanned concurrent S-1 (70mg/m²/day) will be administered on Day 1 for 14 days, every 3 weeks. After dCRT, maintenance S-1 will be given up to two cycles.
16584296|NCT02716675|Experimental|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
16584297|NCT02716675|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
16584298|NCT02716675|Placebo Comparator|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
16584299|NCT02716662|Experimental|Open Label|Axona
16584300|NCT02716649||All participants|No intervention
16584301|NCT02716636|No Intervention|Fast placement|Placement of the tenaculum quickly and without avoiding ratchet
16584302|NCT02716636|Experimental|Slow placement of the tenaculum|Placement of the tenaculum over a 7-10 second time frame and not allowing the tenaculum to ratchet audibly.
16584303|NCT02716623|Experimental|CR Diet and Exercise|Participants will be asked to follow specific diet intervention and exercise regimen.
16584304|NCT02716610|Experimental|INH 69 U (low)|single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
16584305|NCT02716610|Experimental|INH 69 U (high)|single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
16584306|NCT02716610|Experimental|INH 139 U|single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
16584307|NCT02716610|Experimental|INH 208 U|single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
16584308|NCT02716610|Active Comparator|LIS 18 U|single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
16584309|NCT02716597|Experimental|25% Albumin|25% albumin 75 grams IV over 1 hour once.
16584310|NCT02716597|Placebo Comparator|Placebo|0.9% normal saline 200mL IV over 1 hour once.
16584311|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
16584312|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
16584313|NCT02716571|Other|Healthy Donors|Healthy Donors will given white blood cell and plasma
16584314|NCT02716558|Experimental|Moisture tolerant resin sealant|Moisture resistant sealant (wet bond sealant)
16584315|NCT02716558|Active Comparator|ART sealant|Glass inomer based sealant
16584316|NCT02716545|Experimental|Endoscopic Intervention Group|Endoscopic therapy
16584317|NCT02716532|Other|Peptamen AF|over 7 days
16584318|NCT02716519|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks
16584319|NCT02716519|Active Comparator|Standard Card|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
16584320|NCT02716506||Symptomatic POP|POP surgery in year 2015
16584322|NCT02716480|Experimental|Mobility Coaching|"45 patients undergoing bariatric surgery received a monthly mobility coaching session of 20 to 30 min by phone during 6 months."
16584323|NCT02716480|Experimental|Diet Coaching|"45 patients undergoing bariatric surgery received a monthly diet coaching session of 20 to 30 min by phone during 6 months."
16584324|NCT02716467|Experimental|intercessory prayer group|Patients in the experimental group receive prayer of intercession during radiotherapy treatment.
16584325|NCT02716467|Active Comparator|Radiotherapy Treatment|Patients in the radiotherapy group not receive prayer of intercession during radiotherapy treatment.
16584326|NCT02716454|Experimental|Early Surgery - ES|Early laparoscopic ileocaecal resection
16584327|NCT02716454|No Intervention|Step-up therapy - STUP|Treatment with step-up conservative approach according to good clinical practice.
16584328|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
16584329|NCT02716428|Experimental|Cohort 1|12 weeks of Faldaprevir plus TD-6450 plus Ribavirin
16584330|NCT02716428|Experimental|Cohort 2|12 weeks of Faldaprevir plus TD-6450
16584331|NCT02716415|Active Comparator|Calmoseptine Ointment|Calmoseptine Ointment as part of a structured skin care regimen.
16584332|NCT02716415|Active Comparator|Destin Maximum Strength 40% Zinc|Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
16584333|NCT02716402|Other|Cyanotic congenital heart disease|Patients who previously have been examined with cerebral MRI and V/Q SPECT/CT will be re-examined with cerebral MRI and V/Q SPECT/CT
16584334|NCT02716389|Other|Mask on|
16584335|NCT02716389|Other|Mask off|
16584336|NCT02716376|Experimental|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
16584337|NCT02716376|No Intervention|No treatment|Observation: No treatment.
16584338|NCT02716363|Experimental|Device : Rotablator|We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
16584339|NCT02716350|Experimental|B-GOS|powder, 3.5g/day
16584340|NCT02716350|Placebo Comparator|Maltodextrin|powder, 3.5g/day
16584341|NCT02716337|Other|Intervention group|In the intervention group VLBW infants were fed target fortified human milk Growth and safety were compared to a historical group of VLBW infants fed with standard fortified human milk
16584342|NCT02716324|Active Comparator|ADHD Portal|In this arm, the ADHD Portal was used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
16584343|NCT02716324|Experimental|ADHD Portal plus Care Manager (CM)|In this arm, the ADHD Portal was combined with the CM. Clinicians, teachers, and parents used the ADHD Portal as standard of care. In addition, clinicians, teachers, parents, and any external mental health providers interacted with a CM, who had access to information contained in the ADHD Portal.
16584344|NCT02716311|Other|Afatinib|Afatinib 40 mg/d until progression
16584345|NCT02716311|Experimental|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
16584346|NCT02716298|Active Comparator|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
16584347|NCT02716298|Active Comparator|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
16584348|NCT02716285|Experimental|Ileocolonic release peppermint oil|Colon-targeted-delivery capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
16584349|NCT02716285|Experimental|Small intestinal release peppermint oil (Tempocol®)|Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
16584350|NCT02716285|Placebo Comparator|Placebo|Capsule containing microcrystalline cellulose, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
16584351|NCT02716272|Experimental|MONOTHERAPY ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
16584352|NCT02716272|Experimental|COMBINATION ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
16584353|NCT02716259|Experimental|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and oral antiseptics (clorhexidine 0.12% rinse),
16584354|NCT02716259|Placebo Comparator|Supragingival prophylaxis|Two sessions of supragingival prophylaxis under local anesthesia and an oral rinse with no antiseptic properties.
16584355|NCT02716246|Experimental|Cohort 1 Low Dose|Dose of 0.5 X 10^13 vg/kg
16584356|NCT02716246|Experimental|Cohort 2 Mid Dose|Dose of 1 X 10^13 vg/kg
16584357|NCT02716246|Experimental|Cohort 3 High Dose|Dose of 3 X 10^13 vg/kg
16584358|NCT02716233|Active Comparator|Arm 1|pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
16584359|NCT02716233|Experimental|Arm 2|pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
16584360|NCT02716220|Experimental|'Percutaneous Coronary Intervention' /Scaffold Implantation|PCI for enrolled subjects: implantation of the DREAMS 2G Drug-Eluting Coronary Scaffold System
16584361|NCT02716207|Experimental|Maximal tolerated dose with CyberKnife|SBRT will be delivered in 5 fractions within 1 to 2 weeks by the following schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5 with BED10 in correspondence to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy respectively while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is four weeks between each dose level. In case patient presents III/IV GI toxicity, three additional patients will be included at the same dose level. The Maximal Tolerated Dose will be defined as the dose for which at least 2 patients in 3, or at least 3 patients in 9, will present with a limiting toxicity.
16584390|NCT02716090|Active Comparator|Epiduo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.
16584391|NCT02716077|Experimental|Single arm|FDG PET/CT scan pre-therapy
16584362|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
16584363|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
16584364|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
16584365|NCT02716181|Active Comparator|"Атопик phase 1"|"For the first phase of the study, subjects will be randomized to receive treatment with Атопик Soothing Cream."
16584366|NCT02716181|Placebo Comparator|Placebo - phase 1|For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.
16584367|NCT02716181|Active Comparator|"Атопик phase 2"|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
16584368|NCT02716181|Placebo Comparator|Placebo - phase 2|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
16584369|NCT02716168|Experimental|Video consultation|Video consultation between cancer patient, general practitioner and oncologist at the start of chemotherapy treatment
16584370|NCT02716168|No Intervention|usual care|Usual care. The patients General Practitioner will receive standard discharge summary and ambulant notes from the oncologist specialist
16584371|NCT02716142|Experimental|Group A|rectal misoprostol 400 microgram
16584372|NCT02716142|Active Comparator|Group B|sublingual misoprostol 400 microgram
16584373|NCT02716129|Active Comparator|Group 1|Morphine group
16584374|NCT02716129|Active Comparator|Group 2|Morphine plus Nalbuphine group
16584375|NCT02716116|Experimental|Part 1: Dose Escalation Component|TAK-788 treatment for participants with advanced NSCLC.
16584376|NCT02716116|Experimental|Part 2: Expansion Cohort 1|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI), and who have no active, measurable central nervous system (CNS) metastases.
16584377|NCT02716116|Experimental|Part 2: Expansion Cohort 2|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
16584378|NCT02716116|Experimental|Part 2: Expansion Cohort 3|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
16584379|NCT02716116|Experimental|Part 2: Expansion Cohort 4|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations), without active CNS metastases.
16584380|NCT02716116|Experimental|Part 2: Expansion Cohort 5|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.
16584381|NCT02716116|Experimental|Part 2: Expansion Cohort 6|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions, who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases
16584382|NCT02716116|Experimental|Part 2: Expansion Cohort 7|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.
16584383|NCT02716116|Experimental|Part 3: Extension Cohort|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.
16584384|NCT02716116|Experimental|Part 1A: Dose Escalation Combination Component|TAK-788 treatment in combination with pemetrexed/carboplatin for participants with NSCLC harboring EGFR exon 20 insertion mutation in approximately 3 dose levels. This cohort is only for participants at selected sites in the United States.
16584385|NCT02716116|Experimental|Part 1B, Cohort 1: TAK 788 Antidiarrhea Prophylaxis, Monotherapy|TAK-788 monotherapy with primary antidiarrhea prophylaxis for participants with NSCLC with EGFR exon 20 activating insertions and who have no active, measurable CNS metastases. This cohort is only for participants at selected sites in the United States.
16584386|NCT02716116|Experimental|Part 1B, Cohort 2: TAK 788 Antidiarrhea Prophylaxis, Combination Therapy|TAK-788 in combination with pemetrexed/carboplatin treatment with primary antidiarrhea prophylaxis for participants with NSCLC with EGFR exon 20 activating insertions and who have no active, measurable CNS metastases. This cohort is only for participants at selected sites in the United States.
16584387|NCT02716103||Initial Cohort: feasibility|Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
16584388|NCT02716103||2nd Cohort - pre-treatment|If feasibility is determined with initial cohort, bone marrow collection and peripheral blood collection from 20 patients with untreated AL amyloidosis who are scheduled to undergo antineoplastic therapy will be evaluated to isolate a plasma cell clone. An additional 3 teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving therapy. For those who complete therapy and achieve complete response or very good partial response, subsequent samples of bone marrow and peripheral blood will be sent for minimal residual disease detection (based on the previously identified cancer clone) at 6 to 12 months post treatment.
16584389|NCT02716090|Experimental|Dalap Duo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.
16584392|NCT02716064|Experimental|TAP-CM Intervention|Patients in this arm will be encouraged to complete the Healthy Lifestyle App modules and use McMaster PHR to self manage their chronic disease. Participants will also be completing the health and life goals using the App. The TAPESTRY-CM reports generated will then be reviewed by the clinic huddle teams
16584393|NCT02716051|Experimental|MRI|Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
16584394|NCT02716051|Active Comparator|PET|At day 1 , in the morning, patient will undergo an PET analysis
16584395|NCT02716038|Experimental|MPDL3280A, Carboplatin, Nab-paclitaxel|"Subjects with advanced or recurrent cancers receiving:
~MPDL3280A every 21 days for up to 84 days
~Carboplatin every 21 days for up to 84 days
~Nab-paclitaxel every 7 days for up to 84 days"
16584396|NCT02716025||Case Group|
16584397|NCT02716025||Control Group|
16584398|NCT02716012|Experimental|MTL-CEBPA Monotherapy|MTL-CEBPA administered weekly, twice weekly or thrice weekly over 3 weeks followed by 1 week of rest defining a 28-day cycle.
16584399|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (combination)|MTL-CEBPA is administered weekly or twice weekly in combination with sorafenib over 3 weeks followed by 1 week of rest defining a 28-day cycle.
16584400|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (sequential)|MTL-CEBPA is administered weekly or twice weekly for 2 cycles (28-day cycle) followed by 2 cycles of sorafenib
16584401|NCT02715999|Active Comparator|Quadratus Lumborum Block|Quadratus Lumborum block group (QL) patients will receive unilaterally Quadratus Lumborum block using Bupivacaine 0.2 %
16584402|NCT02715999|Active Comparator|Transversus abdominis plane block|Transversus abdominis plane block (TAP) patients will receive unilaterally TAP block using Bupivacaine 0.2 %
16584403|NCT02715986|Experimental|Severly depressed patients|Recruitment of twenty depressive subjects will be conducted within the hospital service adult psychiatry.These patients are referred for indication of ECT sessions for severe resistant depression. Four MRI evaluations (3T MRI examination) are programmed in such patients to analyze structural changes in the hippocampus.
16584404|NCT02715973|Experimental|Nutritional Supplement|"Diet Counseling (Energy=200 kcal/kg/day, (present weight) protein =3-4 gm/kg/day)
~Nutritional supplement (Providing extra 40 kcal/kg/day)"
16584405|NCT02715973|Active Comparator|Standard nutritional treatment|"Diet counselling only (Energy=200 kcal/kg/day (present weight) protein =3-4 gm/kg/day).
~Standard nutritional treatment"
16584406|NCT02715960|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
16584407|NCT02715947|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
16584408|NCT02715934|Experimental|Glucose to Goal|Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
16584409|NCT02715934|Other|Control Group|Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
16584410|NCT02715921|Experimental|Cystic fibrosis patients|Receive tele-exercise training and undergo pulmonary function testing and exercise testing
16584411|NCT02715908|Experimental|LBEC0101|Etanercept 50mg
16584412|NCT02715895|Experimental|Friso|Friso formula feeding
16584413|NCT02715895|Experimental|Wyeth|Wyeth formula feeding
16584414|NCT02715895|Active Comparator|Breast milk|Breast milk feeding
16584415|NCT02715882|Experimental|1 injection of CBLB502 0.35 μg/kg|One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
16584416|NCT02715882|Experimental|1 injection of CBLB502 0.45 μg/kg|One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
16584417|NCT02715882|Experimental|2 injections of CBLB502 0.35 μg/kg|Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
16584418|NCT02715882|Experimental|2 injections of CBLB502 0.45 μg/kg|Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
16584419|NCT02715869|Active Comparator|A pharmacologic cardiac preconditioning|Sevoflurane as a pharmacologic preconditioner for the heart
16584420|NCT02715869|Active Comparator|B ischeamic preconditioning|ischemic preconditioning by inflation the cuff of blood pressure
16584421|NCT02715856|Active Comparator|Group I (standard follow up, physical activity measurement)|Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.
16584422|NCT02715856|Experimental|Group II (mobile surveillance)|Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.
16584423|NCT02715830|Experimental|One Artery|In this arm after obtain the good result after the angioplasty of one artery the procedure stops
16584424|NCT02715830|Experimental|More than one artery|In this arm, after obtain a good result of the angioplasty of one artery, we continue trying one or two more arteries
16584500|NCT02715388|Experimental|Silicon oil removal 3D visualization|
16584501|NCT02715375|Experimental|Device: CREON2000A|Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
16587245|NCT02697266||Post-call anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
16584425|NCT02715817|Active Comparator|Virtual Rehabilitation - VR|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.
~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
16584426|NCT02715817|Active Comparator|Conventional Therapeutic Exercises - CTE|A program of conventional therapeutic exercises (G1) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1: 30 minutes of upper limb PNF diagonal exercise (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes of scapula PNF diagonal exercise (anterior and posterior elevation); b) protocol 2: 20 minutes of lower limb PNF diagonal exercise (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes of pelvis PNF diagonal exercise (anterior and posterior depression), and 10 minutes gait cycle training;
16584427|NCT02715817|Experimental|VR and CTE|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
16584428|NCT02715804|Experimental|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
16584429|NCT02715804|Placebo Comparator|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
16584430|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of study will receive access to the Healthy Lifestyle App and the McMaster PHR
16584431|NCT02715791|Other|TAP-HC-DM|Patients randomized to the intervention group will get TAP-HC-DM intervention from time zero
16584432|NCT02715778||Adult Participants|
16584433|NCT02715778||Child Participants|
16584434|NCT02715765|Sham Comparator|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
16584435|NCT02715765|Experimental|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
16584436|NCT02715765|Experimental|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
16584437|NCT02715752||Herpes Simplex Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
16584438|NCT02715752||Human Papillomavirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
16584439|NCT02715752||Epstein-Barr Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
16584440|NCT02715752||Cytomegalovirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
16584441|NCT02715752||Varicella Zoster Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
16584442|NCT02715739||All participants|
16584443|NCT02715726|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
16584444|NCT02715726|Experimental|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was >=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter [mmol/L]) at Week 8.
16584445|NCT02715713||testosterone deficiency group|Men between the ages of 40 to 80-years-old with testosterone deficiency
16584446|NCT02715713||prostate cancer group|Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
16584447|NCT02715700|Experimental|Maintenance Methadone and MK-1439|Participants maintained on a stable methadone regimen (20 to 200 mg once daily) for ≥14 days prior to Day 1 will continue to receive methadone maintenance once per day on Days 1 to 7. From Day 2 to 6, participants will also receive doravirine 100 mg once daily.
16584448|NCT02715687|Placebo Comparator|Placebo|Will receive 30 days treatment with oral placebo of 200mg
16584449|NCT02715687|Active Comparator|Interventional|Will receive 30 days treatment with oral Amiodarone of 200mg
16584450|NCT02715674|Placebo Comparator|control group|take 4lt/min oxygen with Plasti-med oxygen therapy mask
16584451|NCT02715674|Active Comparator|IS group|in postoperatively, patients will carry out Plasti-med TRIFLO 5 min per hour for 6 hours.
16584452|NCT02715674|Active Comparator|CPAP group|in postoperatively, patients will carry out 10 cmH2O noninvasive continuous positive airway pressure with BIPAP VISION 5 min per hour for 6 hours.
16584453|NCT02715661|Active Comparator|Coronary artery disease|those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .
16584502|NCT02715375|Sham Comparator|Device: Sham Comparator|Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
16584454|NCT02715661|Active Comparator|Metabolic Syndrome|Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)>130 and/or Diastolic Blood Pressure (DBP)>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference >102cm in males;>88cm in females), Fasting triglycerides > 1.695 mmol/L, Low HDL cholesterol: Males < 1.04 mmol/L; Females < 1.29 mmol/L, Fasting glucose >5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
16584455|NCT02715661|Active Comparator|Health Control|Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
16584456|NCT02715648|No Intervention|No Phenazopyridine before cystoscopy|This group will not receive phenazopyridine prior to cystoscopy
16584457|NCT02715648|Experimental|Phenazopyridine before cystoscopy|This group will receive 200mg of phenazopyridine prior to cystoscopy
16584458|NCT02715635|Active Comparator|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®
~Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate"
16584459|NCT02715635|Placebo Comparator|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®
~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
16584460|NCT02715622||Open Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia open repair surgical procedure
16584461|NCT02715622||Laparoscopic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia laparoscopic repair surgical procedure
16584462|NCT02715622||Robotic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia robotic-assisted laparoscopic repair surgical procedure
16584465|NCT02715596|Experimental|Intervention A|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
16584466|NCT02715596|Placebo Comparator|Intervention B|Placebo supplementation in a 15 cc emulsion stick-pack
16584467|NCT02715570|Experimental|Single dose - healthy volunteers|
16584468|NCT02715570|Experimental|Repeat dose - healthy volunteers|
16584469|NCT02715570|Experimental|Single dose - asthmatic patients|
16584470|NCT02715557|Experimental|Full Access to the relapse prevention program|The participants will receive access to the relapse prevention program throughout the entire 6-week trial period.
16584471|NCT02715557|Experimental|TAU|The participants will receive treatment as usual (TAU) for 6-weeks, and will receive access to the relapse prevention program after the completion of the 6 month follow-up.
16584472|NCT02715544|Experimental|Intervention group|The group will receive healthy lifestyle intervention
16584473|NCT02715544|Active Comparator|control group|Other: physical activity and dietary guidelines
16584474|NCT02715531|Experimental|Arm A (Hepatocellular Carcinoma [HCC], All subtypes)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior treatment are non-randomized and will receive atezolizumab and bevacizumab, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.
16584475|NCT02715531|Experimental|Arm B (Gastric Cancer)|Participants with previously untreated human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) are non-randomized and will receive atezolizumab, bevacizumab, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil [FU]), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered as maintenance therapy without oxaliplatin instead of infusional 5-FU and leucovorin, and biologic therapy may be given every 3 weeks (q3w). In the event that a patient experiences unacceptable toxicity after replacement of infusional 5-FU and leucovorin with capecitabine, the patient may be allowed to switch back to 5-FU and leucovorin following investigator discussion with the Medical Monitor.
16584476|NCT02715531|Experimental|Arm C (Metastatic Pancreatic Cancer)|Participants with previously untreated metastatic pancreatic cancer are non-randomized and will receive atezolizumab q2w starting on Day 1, Cycle 1 (each cycle of 28 days). Administration of nab-paclitaxel followed by gemcitabine will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.
16584534|NCT02715206|Experimental|keepin' it REAL classic|middle schools will implement keepin' it REAL classic drug prevention curriculum
16584535|NCT02715206|Experimental|keepin' it REAL rural|middle schools will implement the keepin' it REAL rural curriculum
16584477|NCT02715531|Experimental|Arm E (Randomized Metastatic Esophageal Cancer)|Participants with squamous metastatic esophageal cancer (mEC) will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab and FOLFOX, q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab followed by cisplatin and 5-FU q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.
16584478|NCT02715531|Experimental|Arm F (Randomized HCC)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior systemic treatment will be randomized (1:1) into Group F1 and Group F2. Participants will receive atezolizumab alone (Group F2) or combined with bevacizumab (Group F1) on a q3w schedule, with dosing on Day 1 of each 21 day Cycle. Treatment with atezolizumab with or without bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator. Participants who are randomly assigned to Group F2 (atezolizumab monotherapy) and experience investigator-assessed unequivocal radiographic progression as per RECIST v1.1 will also be given the option to cross over to atezolizumab and bevacizumab combination therapy, provided they meet the criteria for crossover and Medical Monitor approval is obtained.
16584479|NCT02715518|Active Comparator|FFR-guided strategy arm|FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis > 90%, we will judge FFR value of ≤ 0.80.
16584480|NCT02715518|Active Comparator|Angiography-guided strategy arm|"Non-IRA stenosis with > 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.
~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
16584481|NCT02715505|Experimental|HSC835|HSC835 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation
16584482|NCT02715492|Active Comparator|Transarterial Chemoembolization|1st group: included 20 patients with HCC treated by TACE only.
16584483|NCT02715492|Experimental|TACE and LMWH|2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).
16584484|NCT02715479|Experimental|Treatment A|Single DTG tablet under fed conditions for a specified period
16584485|NCT02715479|Experimental|Treatment B|Two BMS955176 tablets under fed conditions for a specified period
16584486|NCT02715479|Experimental|Treatment C|Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period
16584487|NCT02715466|Experimental|Gelatine|Balanced gelatine solution
16584488|NCT02715466|Active Comparator|Electrolyte|Balanced electrolyte solution
16584489|NCT02715453|Experimental|Intervention on frailty|Intervention on frailty in addition to the usual care by the cardiologist. A multidisciplinary team (physicians, nurses and physiotherapists and nutritionists) will carry out the intervention on frailty
16584490|NCT02715453|No Intervention|Control|Conventional strategy consisting only of the usual care by the cardiologist
16584491|NCT02715440|Experimental|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs : 25% reduction of the benzodiazepines dose or related drugs every 2 weeks during nine weeks in order to stop the treatment .
16584492|NCT02715440|No Intervention|Delayed intervention|usual care without intervention
16584493|NCT02715427|Active Comparator|Conventional care|"Preoperative consultation Information support conventional perioperative No bowel preparation
~Day before surgery Normal diet until midnight No carbohydrate loading Premedication with anxiolytic
~Operative day Conventional general anaesthesia Classic management perfused volumes Conventional use of drains at the operative site Standard nasogastric drainage Conventional analgesia protocol
~Postoperative time Mobilization from J1 Progressive refeeding Progressive removal of venous, arterial and urinary catheters. Gradual recovery of the usual treatment from J1 Breathe physiotherapy depending on the clinical course No stimulation of intestinal transit"
16584494|NCT02715427|Experimental|Enhanced recovery|"Preoperative consultation Specific information about the enhanced rehabilitation No bowel preparation Immunonutrition for the 7 preoperative days
~Day before surgery Minimal preoperative fasting No premedication Carbohydrate loading
~Operative day Optimized general anesthesia Reduced volumes perfused Limiting use of drains at the operative site Reduced doses of morphine Local anesthetic usage No standard use of nasogastric drainage
~Postoperative time Stimulation mobilization from D0 Refeeding on demand  from D0 Early removal of venous, arterial and urinary catheters. J1 recovery from the majority of the usual treatment Breathe physiotherapy from D0 to D5 Ileus prevention by chewing gum"
16584495|NCT02715414|Active Comparator|Multiple Family Group (MFG)|A multiple family group (MFG) is a 12-week, family-centered, group delivered intervention consists of six to eight families (caregiver/child dyads). Groups meet for approximately two hours per week, and sessions focus on targeting family-level factors that are associated with child problem behaviors. Specifically, eight of the 12 sessions are devoted to establishing rules (family organization, consistent discipline), responsibilities (inter-connectedness, expectancies), relationships (family warmth, within family support), respectful communication (family communication and conflict). An additional four sessions are focused on factors that impact the ability of families to incorporate new behaviors (family stress and social support).
16584496|NCT02715414|Experimental|MFG + Clinic Implementation Team|This condition consists of service providers, directors, and clinic staff who will create site-specific plans to enhance uptake and implementation of MFG. CITs address potential barriers to implementation and adjust the format and structure of MFG as needed in order to be implemented as part of clinic care.
16584497|NCT02715414|No Intervention|Standard Care|Standard Care consists of services including outpatient individual and family therapy, which are offered as part of clinic care.
16584498|NCT02715401|Experimental|Sequence 1|"T → R
~T : HCP1303 R : HGP1201 + HIP1402"
16584499|NCT02715401|Experimental|Sequence 2|"R → T
~T : HCP1303 R : HGP1201 + HIP1402"
16584503|NCT02715362|Experimental|TAI-GPC3-CART cells|A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
16584504|NCT02715349|Experimental|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
16584505|NCT02715349|No Intervention|Control|Family and patient do not receive psychoeducation, but still receive standard hospital services for schizophrenia.
16584506|NCT02715336|Experimental|Study group: High Responders|1000 units hCG
16584507|NCT02715336|No Intervention|Control group: High Responders|1000 units hCG
16584508|NCT02715336|Experimental|Study group: Normal Responders|5000 units hCG
16584509|NCT02715336|No Intervention|Control group: Normal Responders|5000 units hCG
16584510|NCT02715336|Experimental|Study group: Low Responders|10000 units hCG
16584511|NCT02715336|No Intervention|Control group: Low Responders|10000 units hCG
16584512|NCT02715297|Experimental|Arm A: SRT to the resection cavity|Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
16584513|NCT02715297|No Intervention|Arm B: Observation|Observation without adjuvant radiotherapy.
16584514|NCT02715284|Experimental|Part 1: Participants receiving dostarlimab|Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
16584515|NCT02715284|Experimental|Part 2A: Participants receiving dostarlimab|In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.
16584516|NCT02715284|Experimental|Part 2B: Cohort A1 dMMR/MSI-H|Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >= IIIB) disease.
16584517|NCT02715284|Experimental|Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer|Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >=IIIB) disease.
16584518|NCT02715284|Experimental|Part 2B: Cohort E NSCLC|Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
16584519|NCT02715284|Experimental|Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers|Participants with recurrent or advanced dMMR/MSI-H solid tumors or polymerase ɛ mutated (POLE -mut) solid tumors , except endometrial cancers, that have progressed following up to 2 prior lines of systemic therapy for recurrent or advanced (>=Stage IIIB) disease and who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
16584520|NCT02715284|Experimental|Part 2B: Cohort G PROC without known BRCA|Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
16584521|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
16584522|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
16584523|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will self-administer bexagliflozin tablets once daily for 24 weeks.
16584524|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will self-administer placebo (inactive tablet) once daily for 24 weeks.
16584525|NCT02715245|Experimental|Experimental Group|Patients with multiple chronic disease referred to Mobile Rehabilitation and Physical therapy team (MRPTT) and Nurse-led case Management in the province of Almeria that comply the inclusion criteria; as well as their caregivers.
16584526|NCT02715245|No Intervention|Control Group|Patients with multiple chronic disease and their caregivers belonging to health centers or areas where there is no figure MRPTT or Nurse-led case Management to reach this population
16584527|NCT02715232|Experimental|Female-to-Males|Female-to-Male Transsexuals receiving Testosterone treatment
16584528|NCT02715232|Experimental|Male-to-Females|Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment
16584529|NCT02715232|No Intervention|Female Controls|Female Controls receiving no intervention
16584530|NCT02715232|No Intervention|Male Controls|Male controls receiving no intervention
16584531|NCT02715219|Experimental|intervention group|Subjects in intervention group will be given an appointment date to attend the an Asthma Education Programme.
16584532|NCT02715219|No Intervention|control group|Subjects in control group will routinely go for the normal follow up in Respiratory Clinic without receive any intervention.
16584533|NCT02715206|Experimental|Control|middle schools not receiving keepin' it REAL; continue their own programs if any.
16584538|NCT02715180|Other|Chest computed tomography|Low dose chest computed tomography during expiration and inspiration
16584539|NCT02715167|Active Comparator|Group Budesonide|Inhaled corticoids
16584540|NCT02715167|Placebo Comparator|Group Placebo|Placebo by inhalation
16584541|NCT02715154|Active Comparator|Dexmedetomidine 0.5 µg/kg/h|Solution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
16584542|NCT02715154|Placebo Comparator|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
16584543|NCT02715128|Active Comparator|real tDCS|anode over electrode position F3, cathode over F4, 20 min, 2mA intensity
16584544|NCT02715128|Sham Comparator|sham tDCS|frequency and duration correspondent active tDCS, ramp in and ramp out periods only without intermittent stimulation
16584545|NCT02715115|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
16584546|NCT02715115|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
16584547|NCT02715089||Precise treatment|All patients should accept next-generation sequencing (NGS) test before treatment.
16584548|NCT02715076|Experimental|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
16584549|NCT02715076|Experimental|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
16584550|NCT02715076|Experimental|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
16584551|NCT02715076|Experimental|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
16584552|NCT02715076|Experimental|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
16584553|NCT02715076|Experimental|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
16584554|NCT02715063|Experimental|High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
16584555|NCT02715063|Active Comparator|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
16584556|NCT02715063|Active Comparator|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
16584557|NCT02715063|Placebo Comparator|Usual clinical care|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
16584558|NCT02715050|Experimental|Group A - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
16584559|NCT02715050|Experimental|Group B - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
16584560|NCT02715050|Experimental|Group C - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
16584561|NCT02715050|Experimental|Group D - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group D, received program 2 before strength training, and program 2 after training."
16584562|NCT02715037||Acute tonsillitis|Patients referred to the tertiary care center with severe acute tonsillitis but without peritonsillar cellulitis, infectious mononucleosis, or abscess formation.
16584563|NCT02715037||Peritonsillar cellulitis|Patients referred to the tertiary care center with severe acute tonsillitis and peritonsillar cellulitis but without abscess formation.
16584564|NCT02715037||Infectious mononucleosis|Patients referred to the tertiary care center with acute tonsillitis and biochemical or serological signs of infectious mononucleosis but without abscess formation.
16584565|NCT02715037||Controls|Patients treated for conditions not related to the throat and without signs or symptoms of recent throat disease.
16584566|NCT02715024|Experimental|Tamsulosin alone|
16584567|NCT02715024|Experimental|Tamsulosin + solifenacin|
16588533|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
16584568|NCT02715011|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-63709178 in Part 1 (in different cohorts). Each subsequent cohort will receive JNJ-63709178 at an increased dose level. Ascending doses may be given initially to minimize or prevent cytokine release syndrome. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
16584569|NCT02715011|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-63709178 at the recommended Phase 2 dose(s) (RP2D) determined in dose expansion phase.
16584570|NCT02714998|Active Comparator|Methotrexate only|Single dose of systemic Methotrexate administered to 55 patients.
16584571|NCT02714998|Active Comparator|Salpingectomy only group|Laparoscopic unilateral salpingectomy performed to 61 patients.
16584572|NCT02714998|Active Comparator|Salpingectomy following Methotrexate|15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
16584573|NCT02714985||confirmed chikungunya cases|cases with confirmed chikungunya fever and included for follow-up as per protocol
16584574|NCT02714972|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
16584575|NCT02714972|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
16584576|NCT02714959|Experimental|Proleukin|Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9
16584577|NCT02714946|Active Comparator|LA Arm|Percutaneous Laser Ablation
16584578|NCT02714946|Active Comparator|RFA Arm|Percutaneous Radiofrequency Ablation
16584579|NCT02714933|Experimental|MRI sequence Advanced ZTE|
16584580|NCT02714920|Other|DNA Repair enzyme signature|Tumor biopsies and blood samples performed specifically to determine DNA Repair enzyme signature biomarkers profiles (CHEMRAD assay)
16584581|NCT02714907|Experimental|AF assessed from Cortrium C3 data|Atrial fibrillation assessed from Cortrium C3 device data
16584582|NCT02714907|Experimental|AF assessed from Holter data|Atrial fibrillation assessed from Holter data
16584583|NCT02714894||Clozapine Responders (Non-URS)|"Definition of non-URS
~(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment."
16584584|NCT02714894||Clozapine Non-Responders (URS)|"Definition of URS
~Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.
~CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items."
16584585|NCT02714894||Healthy Controls|Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.
16584586|NCT02714881|Other|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
16584587|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
16584588|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
16584589|NCT02714842|Experimental|Radiolabelled Diclofenac tablet A|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
16584590|NCT02714842|Experimental|Radiolabelled diclofenac tablet B|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
16584591|NCT02714842|Active Comparator|Voltaren|Single dose of enteric coated diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
16584592|NCT02714842|Experimental|Radiolabelled diclofenac tablet C|Single dose of delayed release diclofenac sodium (25 mg) tablet radiolabelled with 4 MBq 99mTc
16584593|NCT02714829|Experimental|Inject BMP|ExcelOS-inject containing rhBMP-2
16584594|NCT02714829|Active Comparator|ExcelOS-inject|ExcelOS-inject without rhBMP-2
16584595|NCT02714803|Experimental|Connective tissue massage group|Connective tissue massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
16584596|NCT02714803|Active Comparator|Classic massage group|Classic massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
16584597|NCT02714803|Sham Comparator|Sham massage group|Sham massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
16584598|NCT02714777||Pediatric population from 4 to 8 years-old|Description of the Autonomic nervous system activity (parasympathetic activity)
16584599|NCT02714751|No Intervention|Observational group|
16584600|NCT02714751|Other|Group after information intervention|Control group after daily information to healthcare team
16584601|NCT02714738|Experimental|Infraclavicular Block|The patient will be positioned supine. The operating limb may be positioned abducted or adducted by side depending on operator preference and patient factors. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. Local anaesthetic (lidocaine 2% with epinephrine 1:200.000) will be injected posterior to the artery with the intention achieving the U shape, cranio-postero-caudal spread. Local anaesthetic will be deposited to the lateral and medial cords as well, if required. The total dose of the local anaesthetic will be 20-30 ml, as clinically indicated.
16584632|NCT02714543|Experimental|aloevera group|aloevera juice twice daily for 3 months. aloevera gel one scoop to be applied 3-4 times daily for 3 months
16588534|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
16584602|NCT02714738|Experimental|Axillary Brachial Plexus Block|The patient will be positioned supine with the operative upper limb extended, flexed at the elbow, rested on a pillow to expose the axilla. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. All four nerves in the axillary region are being blocked. The local anesthetic (lidocaine 2% with epinephrine 1:200.000, 15-25 ml) will be divided among the four nerves as clinically indicated by the spread, but at least 3 ml applied to each nerve.
16584603|NCT02714725|Placebo Comparator|Control group (Group C)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
16584604|NCT02714725|Active Comparator|Group Dexmedetomidine (Group DEX)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
16584605|NCT02714712||HCV group (Peginterferon alfa-2a)|A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
16584606|NCT02714712||Control Group|There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.
16584607|NCT02714699|Experimental|diclofenac potassium|oral diclofenac potassium
16584608|NCT02714699|Active Comparator|hyoscine butyl bromide|oral hyoscine butyl bromide
16584609|NCT02714699|Placebo Comparator|placebo|oral placebo
16584610|NCT02714686|Experimental|Radio Mass Media Family Planning Campaign|Clusters receive a three-year mass media campaign on family planning in an attempt to reduce cognitive barriers to contraception
16584611|NCT02714686|No Intervention|Control group|
16584612|NCT02714673||ADELC|Cohort of patients on long term anticoagulation and undergoing a primary hip or knee replacement.
16584613|NCT02714673||CONTROL|Cohort of patients not on long term anticoagulation and undergoing a primary hip or knee replacement.
16584614|NCT02714660||Participants with Type 2 Diabetes|Adults with type 2 diabetes will be enrolled in this mixed methods observational study.
16584615|NCT02714647|Experimental|Experimental|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on accuracy over speed prior to practicing the motor task. Participants will also have extended deadlines (750 ms) throughout the task to ensure an accuracy preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
16584616|NCT02714647|Sham Comparator|Control|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on speed over accuracy prior to practicing the motor task. Participants will also have short deadlines (250 ms) throughout the task to ensure a speed preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
16584617|NCT02714634|Experimental|methotrexate + biologic group|"Methotrexate +
~biologic chosen by investigator"
16584618|NCT02714634|Active Comparator|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
16584619|NCT02714621|No Intervention|Feasibility of MR-HIFU for painful gynaecological metastases|Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.
16584620|NCT02714621|Experimental|Treatment using MR-HIFU of painful gynaecological metastases|Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)
16584621|NCT02714608|Experimental|Ginsenoside H dripping pills|Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
16584622|NCT02714608|Experimental|Ginsenoside H dripping pills+Placebo|Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
16584623|NCT02714608|Placebo Comparator|Placebo|Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
16584624|NCT02714595|Experimental|Cefiderocol|Participants will receive cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
16584625|NCT02714595|Active Comparator|Best Available Therapy (BAT)|Best available therapy (BAT) will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
16584626|NCT02714582|Experimental|Bedside shift report|"The experimental group (nurses and patients) will:
~develop a tailored BSR-intervention by use of co-design, diagnostic interviews, and pilot testing
~use the tailored BSR-intervention, with participation of the patient, instead of the regular nurse shift report"
16584627|NCT02714582|No Intervention|No bedside shift report|The control group will not use bedside shift report, but will use the regular nurse shift report without participation of the patient
16584628|NCT02714569|Experimental|Part A: LY3202328 (LY)|Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
16584629|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
16584630|NCT02714569|Experimental|Part B: LY3202328 (LY)|A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
16584631|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
16584633|NCT02714543|Active Comparator|steroid group|intralesional injection of hydrocortisone 100mg and injection hyaluronic acid 1500IU once a week for 6 weeks with Capsules SM Fibro once daily for 3 months.
16584634|NCT02714530|Experimental|Radiotherapy combined with erlotinib|Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
16584635|NCT02714530|Active Comparator|Radiotherapy alone|Radiotherapy 3 Gy x 10 alone
16584636|NCT02714517|Experimental|hydrotherapy|patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks
16584637|NCT02714517|Active Comparator|controls|patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks
16584638|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
16584639|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
16584640|NCT02714491|Active Comparator|Music|Erigo + Music: During each stepping verticalization session the patient receives auditory stimulation (earphones) with previously preferred music
16584641|NCT02714491|Active Comparator|Metronome|Erigo + Metronome: During each stepping verticalization session the patient receives auditory stimulation (earphones) with a metronome (rhythmic with the stepping movement)
16584642|NCT02714491|Active Comparator|Silence|Erigo + Silence: During each stepping verticalization session the patient does note receive any auditory stimulation.
16584643|NCT02714478|Experimental|treatment|"3 Equistasi devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
16584644|NCT02714478|Placebo Comparator|controls|"3 placebo devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
16584645|NCT02714465|Experimental|Hyperbaric oxygen therapy|All patients underwent radiosurgery with clinical and instrumental signs of cerebral radionecrosis
16584646|NCT02714452|Other|Intervention|Person-centred care
16584647|NCT02714452|No Intervention|Control|Conventional care
16584648|NCT02714439|Experimental|High-Resolution Microendoscopy (HRME)|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
16584649|NCT02714426|Active Comparator|Brain Health|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
16584650|NCT02714426|Experimental|Mindfulness-inspired Treatment/Testing|"Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
16584651|NCT02714413|Placebo Comparator|Sucrose 50g + placebo|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
16584652|NCT02714413|Experimental|Sucrose 50g + D-allulose 2.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
16584653|NCT02714413|Experimental|Sucrose 50g + D-allulose 5.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
16584654|NCT02714413|Experimental|Sucrose 50g + D-allulose 7.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
16584655|NCT02714413|Experimental|Sucrose 50g + D-allulose10.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
16584656|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
16584657|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
16584658|NCT02714387||ICU patients|Patients with Non Traumatic Neuro-Vascular Diseases. Medical data concerning ICU stay will be collected.
16584659|NCT02714374|Experimental|GL-ONC1|Cohort 3, 5, 7, 8, 9
16584660|NCT02714361|Active Comparator|Vitamin D3 supplement|Participants will be asked to take 1 capsule of vitamin D3 supplement (1500 IU) (37.5ug) daily for a total duration of 8 weeks.
16584661|NCT02714361|Placebo Comparator|Placebo|Participants will be asked to take 1 capsule of placebo (65% olive oil) daily for a total duration of 8 weeks.
16584662|NCT02714322|Experimental|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
16584663|NCT02714322|Active Comparator|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
16584664|NCT02714309|Experimental|Control Trial|A mixed macronutrient breakfast meal is consumed without additional protein, following a period of rest. An ad libitum lunch meal is subsequently consumed.
16584665|NCT02714309|Experimental|Exercise No Preload Trial|Following an exercise bout a mixed macronutrient breakfast meal is consumed without additional protein. An ad libitum lunch meal is subsequently consumed.
16584666|NCT02714309|Experimental|Exercise With Preload Trial|Following low/moderate intensity exercise bout, whey protein (20g) administered prior to consumption of mixed macronutrient breakfast meal. An ad libitum lunch meal is subsequently consumed.
16584667|NCT02714296|Active Comparator|Group Nutridrink 200ml|50 patients: two days before the investigation is assigned to a diet with the use of specialized clinical nutrition Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
16584668|NCT02714296|Active Comparator|Group Nutridrink compact protein|two days before the study is assigned diet with the addition of specialized clinical nutrition Nutridrinc compact protein 125 ml 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
16584669|NCT02714296|No Intervention|Group control|only diet without receiving specialized nutrition
16584670|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
16584671|NCT02714270|Active Comparator|modified partograph|routine modified partograph
16584672|NCT02714270|Active Comparator|paperless partograph|paperless partograph with no graph paper
16584673|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
16584674|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
16584675|NCT02714231|Experimental|diclofenac|oral diclofuhenac sodium
16584676|NCT02714231|Active Comparator|hyoscine|oral hyoscine butyl bromide
16584677|NCT02714218|Experimental|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV|Specified dose on specified days
16584678|NCT02714218|Experimental|Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV|Specified dose on specified days
16584679|NCT02714218|Experimental|Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg|Specified dose on specified days
16584680|NCT02714205|Experimental|Transdermal Nitroglycerin|Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr. Dose escalation up to 0.6 mg/hr.
16584681|NCT02714205|Placebo Comparator|Placebo|Daily transdermal placebo patch.
16584682|NCT02714192|Experimental|BCTT|Participants received an standardized exercise stress test within 7 days of concussive injury. Stress test is stopped when participant experiences any exacerbation of symptoms. Heart rate at time of symptom exacerbation is referred to as the threshold heart rate (THR). Stress test is known as the Buffalo Concussion Treadmill Test.
16584683|NCT02714192|No Intervention|No BCTT|All participants in the no intervention arm did not get assessed using the BCTT until they had fully recovered or when they had their second clinic visit fourteen days after their first visit.
16584684|NCT02714179|Active Comparator|Group Preemptive (Group PE),|Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
16584685|NCT02714179|Active Comparator|Group Preventive (Group PV),|Group II: i.V. paracetamol 1 g (100 ml) was given before the end of surgery.
16584686|NCT02714166|Experimental|Sunscreen lotion Sun Protection Factor 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
16584687|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
16584688|NCT02714153|Experimental|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
16584689|NCT02714140|Experimental|Group A: More preferred Existing + Common|Group A participants will be offered the common option and 3 currently available testing options that are targeted at the distribution of preferences among participants.
16584690|NCT02714140|Experimental|Group B: More preferred Enhanced + Common|"Group B participants will be offered the common option and 3 preference-informed enhanced testing options, which include combinations of features that may not yet be available in the study area."
16584691|NCT02714140|Active Comparator|Group C: Less preferred + Common|Group C participants will be offered the common option and 3 predicted less-preferred options. With the common option being the best option in Group C, this group is effectively a non-PB-HCT comparison group.
16584692|NCT02714127||Cases|"Women (25-64 years old) with abnormal cytology results and/or (high risk) HPV infection refered for colposcopy, and hence possibly diagnosed with an (high risk) HPV infection and/or cervical (pre)cancerous lesions.
~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
16584693|NCT02714127||Controls|"Healthy women (25-64 years old), falsely diagnosed with abnormal cytology and/or (high risk) HPV infection, but referred for colposcopy, are included as negative controls. Based on a specificity of 76.14% of the HPV type-specific PCR (polymerase chain reaction) used, an estimated 24 out of these 100 participants will be incorrectly scheduled for colposcopy and serve as the control group.
~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
16584694|NCT02714114||Cases: HPV vaccinated group|"Women (18-26 years old) whom are previously vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.
~No clinical evaluations will be performed."
16584695|NCT02714114||Controls: HPV unvaccinated group|"Women (18-26 years old) whom are not vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.
~No clinical evaluations will be performed."
16584696|NCT02714101|Experimental|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
16584697|NCT02714088|Experimental|Intervention|Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach >90% of their maximal heart rate.
16585117|NCT02711462|Other|Cohort 6|Subjects receive a single dose of PF 06687234 or placebo via the IV route
16584698|NCT02714088|No Intervention|Control|Participants will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
16584699|NCT02714075|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
16584700|NCT02714062|Placebo Comparator|Placebo|Days 1-56: Placebo
16584701|NCT02714062|Experimental|VI-0521 Mid Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
~Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
16584702|NCT02714062|Experimental|VI-0521 Top Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
~Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
~Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
~Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
16584703|NCT02714049|Experimental|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
16584704|NCT02714049|Experimental|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
16584705|NCT02714036|Experimental|MN-166 (ibudilast)|MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.
16584706|NCT02714023|Active Comparator|Normal Saline|Patients were randomized to receive normal saline as an irrigation solution during appendectomy.
16584707|NCT02714023|Active Comparator|Sterile Water|Patients were randomized to receive sterile water as an irrigation solution during appendectomy.
16584708|NCT02714023|No Intervention|No irrigation used|Patients who do not receive any irrigation at time of operation.
16584709|NCT02714010|Experimental|Arm 1|Patients take EGFR-TKI alone till tumor progression
16584710|NCT02714010|Active Comparator|Arm 2|Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI
16584711|NCT02713997|No Intervention|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
16584712|NCT02713997|Experimental|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
16584713|NCT02713997|Experimental|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
16584714|NCT02713984|Experimental|HER2 positive cancers|Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells
16584715|NCT02713971|Experimental|Gamepad|Biofeedback rehabilitation with Gamepad system.
16584716|NCT02713971|Active Comparator|Control|Conventional physiotherapy.
16584717|NCT02713958|Experimental|Tele rehabilitation|Telerehabilitation:The subjects in the study group will receive two treatments in Telerehabilitation and one treatment in the clinic weekly . At home they will be asked practice daily active exercises with the Meditouch Ltd. system.
16584718|NCT02713958|Active Comparator|rehabilitation|Traditional Occupational Therapy:The subjects in this group will receive three treatments in the clinic every week. At home they will be asked to practice daily active exercises in the same level of difficulty and duration as the study group but without the Meditouch Ltd. system
16584719|NCT02713945|Experimental|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
16584720|NCT02713945|Placebo Comparator|Control|Placebo administrated orally once daily in the morning
16584721|NCT02713932||Transcatheter aortic valve implantation|
16584722|NCT02713919|Experimental|Intervention Group|Adapted German PRO-SELF© Plus Pain Control Program
16584723|NCT02713919|No Intervention|Control Group|No intervention
16584724|NCT02713906|Experimental|X-Ray Knee Guide group|Total knee arthroplasy using Materialise X-Ray Knee Guides
16584725|NCT02713893|Experimental|Econazole nitrate 1% plus Benzydamine HCl 0.12%|5 grams of Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days
16584726|NCT02713893|Active Comparator|Placebo plus Econazole nitrate 1%|5 grams of Placebo plus Econazole nitrate 1% intravaginal cream, once daily for 15 consecutive days
16584727|NCT02713893|Active Comparator|Placebo plus Benzydamine HCl 0.12%|5 grams of Placebo plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days.
16584728|NCT02713893|Placebo Comparator|Placebo|5 grams of Placebo intravaginal cream, once daily for 15 consecutive days.
16584729|NCT02713880||Patients with Transthyretin-Related Familial|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
16584730|NCT02713867|Active Comparator|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
16584731|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
16584732|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
16584733|NCT02713841|Experimental|Inhaled insulin (LOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)
16584734|NCT02713841|Experimental|Inhaled insulin (MOM1)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
16584735|NCT02713841|Experimental|Inhaled insulin (MOM2)|repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
16584736|NCT02713841|Experimental|Inhaled insulin (HOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)
16584737|NCT02713841|Active Comparator|subcutaneous insulin lispro (LIS)|single 6 unit dose of insulin lispro administered subcutaneously
16584879|NCT02712970||Stage-R|Recurrent PSD following any type of treatment. Other flap techniques such as V-Y advancement flap, Z-Plasty will be performed.
16584738|NCT02713828|Experimental|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
16584739|NCT02713828|Experimental|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
16584740|NCT02713815|Sham Comparator|control group|sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
16584741|NCT02713815|Active Comparator|rTMS group|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
16584742|NCT02713802|Experimental|Test product|Propofol solution (1% [10 mg/mL]), via intravenous injection
16584743|NCT02713802|Active Comparator|Reference product|Propofol emulsion (1% [10 mg/mL]), via intravenous injection
16584744|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
16584745|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
16584746|NCT02713776|Experimental|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
16584747|NCT02713776|Placebo Comparator|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
16584748|NCT02713763|Experimental|Sunitinib|Sunitinib 37.5 mg/day
16584749|NCT02713750||HIV female adolescents|sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status
16584750|NCT02713737|Experimental|HFNC group|HFNC: Heated humidified high-flow nasal cannula.
16584751|NCT02713737|Active Comparator|NIV group|NIV: Noninvasive ventilation.
16584752|NCT02713724|Active Comparator|DAPS-group|Physical exercise
16584753|NCT02713724|Active Comparator|Standard-group|Limited physical exercise
16584754|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
16584755|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
16584756|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
16584757|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
16584758|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
16584759|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
16584760|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
16584761|NCT02713685|Experimental|Subarachnoid block|Subarachnoid block will be given in lateral position
16584762|NCT02713685|Active Comparator|Peripheral nerve block|Combined Femoral and Sciatic nerve block will be given using nerve stimulation technique
16584763|NCT02713672|Experimental|Intervention group|Psychiatric patients with a CYP2D6 or CYP2C19 PM or IM genotype, using antidepressants or antipsychotics metabolized by CYP2D6 or CYP2C19
16584764|NCT02713672|No Intervention|Control group|Psychiatric patients with a CYP2D6 or CYP2C19 EM genotype using antidepressants or antipsychotics
16584765|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
16584766|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
16584767|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
16584768|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
16584769|NCT02713620|Placebo Comparator|Healthy|"the Healthy group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
16584770|NCT02713620|Active Comparator|HIV-Group1|"the Standard doses group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
16584771|NCT02713620|Active Comparator|HIV-Group 2|"the Four doses group receiving four intramuscular doses of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
16584772|NCT02713620|Active Comparator|HIV-Group 3|"the Four double doses group receiving four intramuscular double doses (40 μg) of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
16584773|NCT02713607|Experimental|doxycycline|Given doxycycline and assessment of gut, blood and skin
16584774|NCT02713607|No Intervention|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
16584775|NCT02713594|Placebo Comparator|Control|Counseling from WTQL
16584776|NCT02713594|Experimental|Incentive|Counseling from WTQL; Financial incentive to participate
16584777|NCT02713581||Women with proximal VTE|"Patients will correspond to cases of proximal venous thromboembolism. They will be recruited during consultations conducted for the chronic management of a history of proximal venous thromboembolism or thrombophilia following a recent history of proximal venous thromboembolism. Venous thromboembolism, outside of acute phase episodes, has good symptom stability over time; no difference is to be expected between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease.
~Intervention: Blood sampling"
16584778|NCT02713581||Women with >1 healthy pregnancy|"This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy.
~Intervention: Blood sampling"
16584779|NCT02713568|Active Comparator|Ultrasound|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.
~An Ultrasound scan to estimate the fetal weigth will be carried out during the 36th week of gestation."
16584780|NCT02713568|Experimental|Magnetic Resonance|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.
~A Magnetic Resonance examination to estimate the fetal weigth will be carried out during the 36th week of gestation."
16584781|NCT02713555|Experimental|Roux-en-Y Gastric Bypass group|Morbidly obese patients with type 2 diabetes mellitus will be examined before and after the Roux-en-Y Gastric Bypass procedure
16584782|NCT02713555|Experimental|Gastric sleeve group|Morbidly obese patient with type 2 diabetes Mellitus will be examined before and after the Gastric Sleeve procedure
16584783|NCT02713555|No Intervention|Method /control group|Healthy normal weight participants matched by age and gender to the intervention study will be examined with the same methods as the intervention groups and serve as participants in a method study and as a metabolic normal reference group.
16584784|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
16584785|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
16584786|NCT02713529|Experimental|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
16584787|NCT02713516|Experimental|Single Arm|The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.
16584788|NCT02713503||Healthy Drivers|Driving Observation and VisionCoach
16584789|NCT02713490|Active Comparator|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
16584790|NCT02713490|Active Comparator|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
16584791|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 1 Test 1|Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
16584792|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 2 Test 2|Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
16584793|NCT02713477|Placebo Comparator|Placebo - Reference 1|Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
16584794|NCT02713477|Other|Insulin glargine (Lantus) - Reference 2|Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition
16584795|NCT02713464|Active Comparator|maternal education|Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.
16584796|NCT02713464|No Intervention|Historic control|Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.
16584797|NCT02713464|No Intervention|No intervention|Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.
16584798|NCT02713451|Active Comparator|Liberal Oxygenation (LO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
16584799|NCT02713451|Experimental|Conservative Oxygenation (CO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
16584800|NCT02713438|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.
~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
16584801|NCT02713438|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the child. The parent is actively participating in forming plans by the child.
~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
16584802|NCT02713438|Experimental|Collaborative Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (child and parent). Physical activity may be performed jointly by both persons in the dyad.
~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
16585118|NCT02711462|Other|Cohort 7|This is an optional cohort where Japanese subjects will receive PF 06687234 or placebo via the SC route
16584803|NCT02713438|Active Comparator|Education|The education group received extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
16584804|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
16584805|NCT02713412|Experimental|Glucose|75g glucose and 150mg C13-acetate in 300ml water
16584806|NCT02713412|Placebo Comparator|Control|300ml water
16584807|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
16584808|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
16584811|NCT02713373|Experimental|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
16584812|NCT02713360|Experimental|Cognitive therapy|The intervention consists of 3 steps. 1: Consultation with a nurse that aims of identifying what the anxiety consist of and how the patient experiences his or her life situation with an ICD. A plan is made to structure the treatment. 2: Participation in an individualized intervention based on anxiety type specific protocols. 3. The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
16584813|NCT02713360|No Intervention|Usual care|The control group will receive usual care which consists of control of ICD, disease control and treatment, and at one of the sites an offer of a group information meeting where experiences and events with ICD are discussed. The meeting takes place at Rigshospitalet every other month.
16584814|NCT02713347|Experimental|ADAPT Intervention|"The intervention includes 3 components:
~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.
~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.
~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.
~The nurse and social worker visits are in-person or by phone."
16584815|NCT02713347|No Intervention|Enhanced usual care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referrals to and ongoing care from cardiology, pulmonary, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of baseline depression surveys if they screen positive for depression, and patients will be given an information sheet that outlines self-care for CHF or COPD.
16584816|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
16584817|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
16584818|NCT02713308||Group1-CRT|Patients with RV-to-LV delay≥80ms, CRT standard programming (single-point)
16584819|NCT02713308||Group2-MPP|Patients with RV-to-LV delay<80ms, CRT programming with MPP (multi-point)
16584820|NCT02713295||Subjects with Moderate to Severe Plaque Psoriasis|Subjects with Moderate to Severe Plaque Psoriasis in Greece
16584821|NCT02713282|Experimental|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
16584822|NCT02713269|Experimental|Treatment (thermal ablation, SSRS)|Patients undergo thermal ablation and CT-guided SSRS via intensity-modulated radiation therapy on different dates within a 1-14 day window. The order of treatment is at the doctor's discretion.
16584823|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
16584824|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
16584825|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
16584826|NCT02713230|Active Comparator|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
16584827|NCT02713230|Active Comparator|EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
16584828|NCT02713230|Placebo Comparator|Placebo|20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
16584829|NCT02713217||Pre-Implementation Cohort|Eligible patients will be recruited and enrolled prior to implementation of the blended integrated care model in each study site. They will be exposed to care as usual in the CBOCs.
16584830|NCT02713217||Post-Implementation Cohort|"Eligible patients will be recruited and enrolled following implementation of the blended integrated care model in each study site. These participants are thus exposed to the intervention model."
16584831|NCT02713204|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
16584832|NCT02713204|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
16584833|NCT02713204|Experimental|Aflibercept (IAI) 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
16584834|NCT02713191|Experimental|Dexmedetomidine|Dexmedetomidine + fentanyl before, and dexmedetomidine infusion during, procedure
16584835|NCT02713191|Active Comparator|Midazolam|Midazolam + fentanyl before, and matching saline infusion during, procedure
16584836|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
16584837|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
16584838|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
16584839|NCT02713165|Experimental|Raisins Enhanced Diet|Participants will be provide with a Raisin Enhanced Diet over a short term period of time.
16584840|NCT02713152||Patients with OAG|Patients with a diagnosis of Open Angle Glaucoma
16584841|NCT02713152||Controls|Controls without a diagnosis of Open Angle Glaucoma
16584842|NCT02713139|Experimental|Colpistatin 5DT|
16584843|NCT02713139|Active Comparator|Gynecological Flagyl|
16584844|NCT02713139|Active Comparator|Gino-Canesten 3|
16584845|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer
16584846|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer
16584847|NCT02713113|Active Comparator|group 1|patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
16584848|NCT02713113|Active Comparator|group II|patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
16584849|NCT02713113|Active Comparator|group III|patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
16584850|NCT02713087|Active Comparator|Ephedrine|
16584851|NCT02713087|Active Comparator|Phenylephrine|
16584852|NCT02713074|Active Comparator|Group A|povidone-iodine group
16584853|NCT02713074|Active Comparator|Group B|Normal saline group
16584854|NCT02713061|Experimental|TAK-850 0.5 mL|TAK-850 0.5 mL (15 µg of hemagglutinin [HA] antigen per strain), subcutaneous injection, once on Day 1.
16584855|NCT02713048||Acute coronary syndrome culprit coronary lesion|
16584856|NCT02713048||Stable obstructive coronary artery disease|
16584857|NCT02713048||Non-obstructive coronary artery disease|
16584858|NCT02713035|No Intervention|Usual|Receive standard medical therapy for eczema
16584859|NCT02713035|Experimental|Treatment|Receive standard medical therapy for eczema plus behavioral self help intervention
16584860|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
16584861|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
16584862|NCT02713009|Experimental|Treatment 1|Pregnancy multivitamin + vitamin D daily from ~Week 12 gestation until delivery
16584863|NCT02713009|Placebo Comparator|Treatment 2|Pregnancy multivitamin + placebo daily from ~Week 12 gestation until delivery
16584864|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
16584865|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
16584866|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)
16584867|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP/PBO|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
16584868|NCT02712983|Placebo Comparator|Cohort A (3 capsules o.d.): PBO|Cohort A (3 capsules o.d.): Inhaled placebo (PBO)
16584869|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)
16584870|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP/PBO|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
16584871|NCT02712983|Placebo Comparator|Cohort B (5 capsules o.d.): PBO|Cohort B (5 capsules o.d.): inhaled placebo (PBO)
16584872|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)
16584873|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP/PBO|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
16584874|NCT02712983|Placebo Comparator|Cohort C (4 capsules b.i.d.): PBO|Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)
16584875|NCT02712970||stage-I|Single pit in the midline, no lateral extension. Pit-picking technique will be performed.
16584876|NCT02712970||Stage-II|>1 pits in the midline, no lateral extension. Pit-picking and Bascom cleft lift techniques will be performed.
16584877|NCT02712970||Stage-III|Midline pit/pits plus lateral extension in one direction. Bascom cleft lift technique will be performed.
16584878|NCT02712970||Stage-IV|Midline pit/pits plus lateral extension in both directions. Rhomboid excision with the Limberg Flap will be performed.
16584880|NCT02712957|Experimental|NEO6860|NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
16584881|NCT02712957|Placebo Comparator|Placebo|In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).
16584882|NCT02712957|Active Comparator|Naproxen|Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.
16584883|NCT02712944|Active Comparator|Testosterone|Testosterone intramuscular every 2 weeks
16584884|NCT02712944|Placebo Comparator|Saline|Saline intramuscular every 2 weeks
16584885|NCT02712918|Experimental|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.
16584886|NCT02712918|Placebo Comparator|Standard care|Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.
16584887|NCT02712905|Experimental|INCB059872|
16584888|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:
~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.
~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML
~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.
~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
16584889|NCT02712866||Patients treated with vedolizumab|
16584890|NCT02712853||Autism Spectrum Disorder (ASD)|"Age at enrollment: 18 months to 6 years with established DSM-5 diagnosis of autism spectrum disorder. Exclusion criteria include:
~wards of the state syndromic autism (attributed to a known genetic mutation) active periodontal infection active upper respiratory infection"
16584891|NCT02712853||Control|"Age 18 months to 6 years without autism spectrum disorder (may have typical development or developmental delay without autism - as defined by negative MCHAT-R or negative ADOS-II evaluation)
~Exclusion criteria include:
~wards of the state active periodontal infection active upper respiratory infection"
16584892|NCT02712840|Experimental|Freeze-All Protocol|Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
16584893|NCT02712840|Active Comparator|Fresh Protocol|Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.
16584894|NCT02712827|Experimental|Progrip|The Progrip group is the intervention group. Patients will undergo laparoscopic total extraperitoneal repair of inguinal hernia. The surgeon will use a self-gripping mesh to repair the hernia. No fixation is required for the mesh.
16584895|NCT02712827|Active Comparator|Non-Progrip|"The Non-Progrip group is the control group.
~Operation is performed under general anesthesia. A standard three-trocar technique is used: one infra-umbilical camera trocar (1cm) and two 5mm trocars placed at midline between the umbilicus and pubic bone (or one at the side of inguinal hernia). A laparoscope is inserted to the preperitoneal space through the incision. The space is insufflated with carbon dioxide. Dissection is performed, hernia content (if any) is reduced.
~A non self-gripping synthetic mesh is placed. Fibrin glue is used for fixation."
16584896|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender
~The pain began while taking hormonal contraceptive
~Secondary PVD
~On exam, atrophic vestibular tissue (dry and thin)"
16584897|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender
~Primary PVD
~There may be sensitivity to palpation of the umbilicus
~Normal appearing vestibule"
16584898|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender
~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.
~Normal appearing vestibule"
16584899|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule
~Pelvic floor muscles are tight and tender
~Primary or Secondary PVD"
16584900|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule
~Primary PVD
~There may be sensitivity to palpation of the umbilicus
~Normal appearing vestibule
~Pelvic floor muscles are tight and tender"
16584901|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule
~The pain began while taking hormonal contraceptive
~Secondary PVD
~On exam, atrophic vestibular tissue (dry and thin)
~Pelvic floor muscles are tight and tender"
16584902|NCT02712801|Experimental|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
16584903|NCT02712801|Active Comparator|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
16584904|NCT02712788|Active Comparator|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
16584905|NCT02712788|Placebo Comparator|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
16585001|NCT02712177||Coadministration B_RV234|Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
16584906|NCT02712775|Experimental|Minocycline|Experimental group will receive an infusion of minocycline, the investigational drug, through a needle in a vein in the arm at the dose of 200 mg at 1 h prior to transplantation and 100 mg 12 h and 24 h after transplantation. In addition, the donated liver will be flushed with 200 mg minocycline 1 h prior to transplantation.
16584907|NCT02712775|Placebo Comparator|Saline|Placebo group will receive an infusion of saline, a placebo, through a needle in a vein in the arm according to the same schedule. In addition, the donated liver will be flushed with saline 1 h prior to transplantation.
16584908|NCT02712749|Experimental|Group A : Sound with Binaural Beats|"Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz through generated by the software Gnaural in stereo option"
16584909|NCT02712749|Active Comparator|Group B : Sound without Binaural Beats|"Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the software Gnaural in mono option"
16584910|NCT02712736|Other|Survey respondents|The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.
16584911|NCT02712723|Active Comparator|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
16584912|NCT02712723|Experimental|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
16584913|NCT02712723|Experimental|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
16584914|NCT02712710|Experimental|wear a functional knee brace|20 subjects with symptomatic medial compartment knee OA, with grade 2 to 4 on Kellgren and Lawrence scale, and showing willing to wear a functional knee brace. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
16584915|NCT02712710|No Intervention|no wear a functional knee brace|Another 20 subjects with comparable body height, weight, and sex. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
16584916|NCT02712697|Experimental|WM Group|Shentong Granules, two packs, bid, P.O., 48weeks; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
16584917|NCT02712697|Placebo Comparator|Hormone Group|Placebo ; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
16584918|NCT02712671||Enrolled subjects|Subjects attending the Ian Charleson Centre and agreeing to be tested for latent, subclinical and active tuberculosis using Chest radiograph, Blood interferon gamma release assay, Tuberculin skin testing, Sputum induction for mycobacterial microscopy and culture with spirometry, and Mycobacterium tuberculosis polymerase chain reaction testing.
16584919|NCT02712658|Active Comparator|terbutaline|terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
16584920|NCT02712658|Placebo Comparator|Placebo|placebo is administered as isotonic saline (10 ml)
16584921|NCT02712619|Experimental|metformin 250mg|metformin 375/250 mg
16584922|NCT02712619|Experimental|metformin 1000mg|metformin 1000/1000 mg
16584923|NCT02712593|Experimental|Niagen™ 100|
16584924|NCT02712593|Experimental|Niagen™ 300|
16584925|NCT02712593|Experimental|Niagen™ 1000|
16584926|NCT02712593|Experimental|Placebo|
16584927|NCT02712580|Active Comparator|First investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light."
16584928|NCT02712580|Active Comparator|Second investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light."
16584929|NCT02712580|Placebo Comparator|ES Wetling W200 with white light|Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
16584930|NCT02712580|Placebo Comparator|ES Wetling W200 with red light|Placebo device - 'ES Wetling W200 Placebo with red light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
16584931|NCT02712554|Experimental|Treatment A:CL-108 22.5mg/975mg/37.5mg|CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
16584932|NCT02712554|Experimental|Treatment B:CL-108 37.5mg/1625mg/62.5mg|CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
16584933|NCT02712554|Active Comparator|Treatment C:M366 22.5mg/975mg|M366 22.5 mg/975 mg tablet by mouth
16584934|NCT02712554|Active Comparator|Treatment D: M366 37.5mg/1625mg|M366 37.5 mg/1625 mg tablet by mouth
16584935|NCT02712554|Placebo Comparator|Treatment E: Placebo|Placebo 0 mg tablet by mouth
16584936|NCT02712528|Active Comparator|remifentanil-based|remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
16584937|NCT02712528|Placebo Comparator|sevoflurane-sufentanil balanced|balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen
16584938|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
16584939|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
16584940|NCT02712502||Study group (OG).|"50 patients c and acute exacerbation of chronic bacterial rhinosinusitis in the study group (OG).
~The treatment regimen in the study group.
~Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.
~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
16584941|NCT02712502||Control group (CG).|"50 patients c and acute exacerbation of chronic rhinosinusitis in the control group (CG).
~The treatment regimen of the control group. Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.
~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
16584942|NCT02712489||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-003"
16584943|NCT02712476|Active Comparator|Mannitol,furosemide|Mannitol 0.5mg/kg and furosemide 0.5mg/kg IV is compared with mannitol 1mg/kg and furosemide 0.5mg/kg
16584944|NCT02712476|Placebo Comparator|Mannitol, placebo|Mannitol 0.5mg/kg and placebo is compared with mannitol+forosemide
16584945|NCT02712463||Participants with Schizophrenia|This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
16584946|NCT02712450||Control group|"Patients included from January 2016 to August 2016
~Before regulating doctors training course"
16584947|NCT02712450||Experimental group|"Patients included from January 2017 to August 2017
~After regulating doctors training course"
16584948|NCT02712437|Experimental|PROSPECT|Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for >30 days with an insomnia severity index score of >14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.
16584949|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
16584950|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
16584951|NCT02712411|Experimental|Sequence 1|"T → R
~T : HCP1303 R : HGP1201 + HIP1402"
16584952|NCT02712411|Experimental|Sequence 2|"R → T
~T : HCP1303 R : HGP1201 + HIP1402"
16584953|NCT02712398|Experimental|Phasix™ ST|Subjects treated with Phasix™ ST mesh
16584954|NCT02712385|No Intervention|Control - usual care|Usual post-TIA/minor stroke care as per current healthcare system protocol will be given to patients in control group and details will be recorded.
16584955|NCT02712385|Active Comparator|Manual|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual'.
16584956|NCT02712385|Active Comparator|Manual + pedometer, 1|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a General Practitioner.
16584957|NCT02712385|Active Comparator|Manual + pedometer, 2|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a Stroke nurse.
16584958|NCT02712372|Experimental|Part 1, Dose Level 1|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
16584959|NCT02712372|Experimental|Part 1, Dose Level 2|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
16584960|NCT02712372|Experimental|Part 1, Dose Level 3|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
16584961|NCT02712372|Experimental|Part 1, Dose Level 4|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
16584962|NCT02712372|Experimental|Part 1, Dose Level 5|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
16584963|NCT02712372|Experimental|Part 1, Dose Level 6|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
16584964|NCT02712372|Experimental|Part 2, Dose Level 1|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
16584965|NCT02712372|Experimental|Part 2, Dose Level 2|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
16584966|NCT02712372|Experimental|Part 2, Dose Level 3|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
16584967|NCT02712372|Placebo Comparator|AZD4831 Placebo|"Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
~Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12"
16584968|NCT02712359|Other|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
16584969|NCT02712359|Other|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
16584970|NCT02712359|Other|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
16585002|NCT02712177||Coadministration B_MMRV12|Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
16584971|NCT02712359|Other|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
16584972|NCT02712346|Experimental|Treatment|Ambrisentan 5 mg PO daily
16584973|NCT02712346|Placebo Comparator|Placebo|One inactive pill PO daily
16584974|NCT02712333|Experimental|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
16584975|NCT02712333|Sham Comparator|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
16584976|NCT02712320|Experimental|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
16584977|NCT02712307|Experimental|5 days|Phenoxymethylpenicillin 800 mg x 4 for 5 days
16584978|NCT02712307|Active Comparator|10 days|Phenoxymethylpenicillin 1000 mg x 3 for 10 days
16584979|NCT02712294|No Intervention|Control Group (GC)|The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
16584980|NCT02712294|Experimental|NMES Group (GE)|Receiving the usual care and guidance on their illness, underwent 30 minute NMES sessions twice a week for two months using an electrostimulator. Specifically, 5 cm adhesive surface electrodes in four alternate channels on the Rectus Femoris (two channels the right and two on the left) were used to deliver two-phase symmetrical currents, with a rectangular pulse wave at a frequency of 35 Hz and pulse duration of 250 μ. The time of ascent and descent was one second, contraction time was four seconds and relaxation was eight seconds.
16584981|NCT02712281|Experimental|Autism MEAL Plan|Parents of eligible children who are randomized to the Autism Managing Eating Aversions and Limited variety (MEAL) Plan will participate in group-based parent training sessions (4 parents per group).
16584982|NCT02712281|Active Comparator|Parent Education|Parents of eligible children who are randomized to the Parent Education Arm will receive group-based parent education (PE). Each group includes 4 parents.
16584983|NCT02712268|Other|After introduction of the checklist|Review of medications of all consecutive admitted patients during the study period using a checklist
16584984|NCT02712255|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.
~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
16584985|NCT02712255|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the patient. The partner is actively participating in forming plans by the patient.
~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning"
16584986|NCT02712255|Experimental|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (the patient and the partner). Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
16584987|NCT02712255|Active Comparator|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
16584988|NCT02712242|Experimental|Platelet Rich Fibrin|PRF was laid directly on the palatal wound immediately after harvesting the tissue graft and stabilized
16584989|NCT02712242|Active Comparator|Butyl cyanoacrylate|Butyl cyanoacrylate was directly applied on the palatal wound after harvesting the tissue graft
16584990|NCT02712242|Placebo Comparator|Wet Gauze|Wet Gauze was placed for 1 minute on the palatal wound after harvesting the tissue graft
16584991|NCT02712229|Experimental|CONNECT Intervention|At clinics randomized to the CONNECT intervention, oncology nurses will be selected by a nurse advisory panel to receive standardized primary palliative care training. A multi-step deployment strategy will be employed to orient oncologists and implement CONNECT processes. CONNECT nurses will administer CONNECT to enrolled patients and caregivers. An intervention fidelity monitoring and maintenance plan will be implemented to ensure high quality and consistent delivery of the intervention.
16584992|NCT02712229|No Intervention|Usual Care Control|At clinics randomized to Usual Care, enrolled patients and caregivers will continue to receive supportive oncology care according to usual practice.
16584993|NCT02712216|Other|Trocar Insertion Sites|Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
16584994|NCT02712203||12 months|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age
16584995|NCT02712203||13 months|MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age
16584996|NCT02712203||14 months|MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age
16584997|NCT02712203||15 months or more|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older
16584998|NCT02712190|Experimental|Low - High frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 250/min and respiratory rate 500/min
16584999|NCT02712190|Experimental|High - Low frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 500/min and respiratory rate 250/min
16585000|NCT02712177||Coadministration B_RV246|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
16585003|NCT02712177||Separate administration B246_RV357|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
16585004|NCT02712177||Separate administration B12_MMRV13|Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
16585005|NCT02712177||Routine vaccines only at 2, 3 and 4 months of age (RV234)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
16585006|NCT02712177||Routine vaccines only at 2, 4 and 6 months of age.(RV246)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
16585007|NCT02712164|Experimental|Experimental: Modified NPWT dressing|In the experimental group, a microporous silver-impregnated foam with a thin silicone contact layer (Mepilex Ag) will be applied. A macroporous foam layer (V.A.C. GranuFoam) and an occlusive dressing (V.A.C. Drape) will then be applied to cover the foam, plus 3-5cm border of intact skin. The occlusive dressing will then be pinched and a 2cm hole will be cut to apply the SensaT.R.A.C. Pad that supplies pressure from the NPWT unit. NPWT will be applied at 125mmHg throughout treatment using KCI's InfoV.A.C. Therapy Unit. The donor site dressing will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
16585008|NCT02712164|Active Comparator|Control: Tegaderm|In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
16585009|NCT02712151|Active Comparator|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
16585010|NCT02712151|Active Comparator|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
16585011|NCT02712125|Active Comparator|isosorbide mononitrate|Received 20 mg isosorbid mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily until delivery
16585012|NCT02712125|Placebo Comparator|Control|Received placebo vaginal tablets once daily until delivery
16585015|NCT02712086|No Intervention|usual dietary management|Control group: usual dietary management Following the intervention, the stomach of patients underwent many changes
16585016|NCT02712086|Experimental|care of with usual dietary protein supplementation|Intervention group: Usual dietary management with protein supplementation (30g) in addition to the usual inputs
16585017|NCT02712073||patients undergoing colonoscopy|
16585018|NCT02712060||EDS patients|Patients with the diagnosis of Ehlers-Danlos syndrome
16585019|NCT02712060||controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
16585020|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
16585021|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
16585022|NCT02712034|Placebo Comparator|Medication-assisted treatment (MAT)|Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.
16585023|NCT02712034|Experimental|MAT + A-CHESS|Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.
16585024|NCT02712021|Experimental|Cerebral Palsy-Study group|The intervention consisted of wearing a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.
16585025|NCT02712021|Active Comparator|Cerebral Palsy-Control Group|Children with clinical characteristics similar to the study group; they will be assessed using the same protocol but with no use of lycra garments
16585026|NCT02712008|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
16585027|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
16585028|NCT02712008|Active Comparator|Aflibercept 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
16585029|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
16585030|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
16585031|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
16585082|NCT02711683||DL-3-n-butylphthalide group|using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
16585032|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
16585033|NCT02712008|Experimental|Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
16585034|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
16585035|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
16585036|NCT02711982|Active Comparator|Optic nerve decompression|Optic canal and optic nerve sheath decompression within 5 days from trauma occur.
16585037|NCT02711982|Active Comparator|methylprednisolone|a maximum daily dose of 1 g of methylprednisolone
16585038|NCT02711969|Experimental|Apatinib mesylate|
16585039|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.
~Two patient populations will be enrolled in DE and DC. Cohort A: Patients with prior progression on enzalutamide or apalutamide by PCWG2 criteria who were receiving a stable dose of enzalutamide at the time of study entry. Cohort B: Patients who were enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria."
16585040|NCT02711917|Experimental|SP1- sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
16585041|NCT02711917|Experimental|SP2- Sevoflurane MAC 0.75|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
16585042|NCT02711917|Experimental|SP3 -Sevoflurane MAC 1.0|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.
16585043|NCT02711917|Experimental|SP4- Sevoflurane MAC 0.5|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
16585044|NCT02711917|Experimental|SP5- Sevoflurane MAC 0.75|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
16585045|NCT02711917|Experimental|SE1- Sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
16585046|NCT02711917|Experimental|SE2- Sevoflurane 0.75|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
16585047|NCT02711917|Experimental|SE3- Sevoflurane MAC 1.0|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
16585048|NCT02711904|Active Comparator|Extubation U|Remifentanil concentration between 2 - 3 ng/ml.
16585049|NCT02711904|Experimental|Extubation T|Remifentanil concentration between 3 - 4 ng/ml
16585050|NCT02711891|Experimental|5% Loperamide gel|Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
16585083|NCT02711683||donepezil group|only using donepezil treatment in patients with mild to moderate AD
16585084|NCT02711670|Experimental|thiazide|Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating
16585297|NCT02710344|No Intervention|Usual Care|Usual care at community mental health care provider
16585051|NCT02711891|Placebo Comparator|Placebo gel|Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
16585052|NCT02711878|Experimental|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
16585053|NCT02711878|Active Comparator|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
16585054|NCT02711865||MK-0646|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
16585055|NCT02711865||Control|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
16585056|NCT02711852|Experimental|Drug: Duvelisib (IPI-145)|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg.
16585057|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
16585058|NCT02711839|Experimental|Treatment Group|White sweet potato formula
16585059|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|"Standard of care
~(N=15 participants in this group)"
16585060|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10^6). After receiving at least 300X10^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.
~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.
~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.
~(N=15 participants in this group)"
16585061|NCT02711813|Placebo Comparator|Placebo|Placebo to TAB08
16585062|NCT02711813|Experimental|TAB08 Dose 1|
16585063|NCT02711813|Experimental|TAB08 Dose 2|
16585064|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
16585065|NCT02711787|Experimental|Experimental group|Robotic device Gloreha (Gloreha, Idrogenet, Italy) and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
16585066|NCT02711787|Active Comparator|Control group|Physiotherapy, occupational therapy and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
16585067|NCT02711761|Experimental|15 cm|The depth of guide wire will be 15 cm from puncture site of skin prior to tissue dilation during central venous catheterization
16585068|NCT02711761|Experimental|17.5 cm|The depth of guide wire will be 17.5 cm from puncture site of skin prior to tissue dilation during central venous catheterization
16585069|NCT02711761|Active Comparator|20 cm|The depth of guide wire will be 20 cm from puncture site of skin prior to tissue dilation during central venous catheterization
16585070|NCT02711748|Experimental|Bradycardia|Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
16585071|NCT02711748|Experimental|PEA|In case of bradycardia. The patient unconscious, not breathing, the ECG - bradycardia 30 / min - no pulse. Pulseless electrical activity
16585072|NCT02711735|Active Comparator|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
16585073|NCT02711735|Placebo Comparator|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
16585074|NCT02711722|Active Comparator|PScli1|Patients are ventilated in Pressure support (PS) according to the Clinical settings for 30min.
16585075|NCT02711722|Active Comparator|NAVAcli|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to match to respiratory muscle unloading reached with PScli1. Patients are ventilated in NAVAcli for 30min.
16585076|NCT02711722|Active Comparator|NAVA40%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 40% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA40% for 30min.
16585077|NCT02711722|Active Comparator|NAVA60%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 60% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA60% for 30min.
16585078|NCT02711722|Active Comparator|PScli2|Patients return to PS ventilation, according to the Clinical settings as in PScli1 for 30min.
16585079|NCT02711709|Other|Intra-abdominal sepsis|Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
16585080|NCT02711696|Active Comparator|A, GCED cohort|GCED, Gluten Contamination Elimination Diet
16585081|NCT02711696|No Intervention|B, time cohort|Cohort B consisted of patients on long term follow-up that accepted a repeated biopsies 60 or more months later the first control biopsy.
16585085|NCT02711657|Experimental|Fibrocyte measurement and lung function test|All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.
16585086|NCT02711644|Experimental|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
16585087|NCT02711644|Active Comparator|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
16585088|NCT02711631|No Intervention|Control: Standard therapy|Participants in this arm of the study will receive standard therapy.
16585089|NCT02711631|Experimental|MedBIKE|Participants in this arm will be using the new MedBIKE system as their method of rehabilitation.
16585090|NCT02711618|Experimental|UltraShape Contour I V3 treatment|Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28
16585091|NCT02711605|Experimental|Unilateral UltraShape treatment|One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
16585092|NCT02711605|Experimental|Bilateral UltraShape treatment|Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
16585093|NCT02711592|Other|Genetic Panel for Analgesics|Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.
16585094|NCT02711579|Experimental|Celecoxib for electroencephalography|Electroencephalography will be performed before and after celecoxib administration
16585095|NCT02711579|Placebo Comparator|Placebo for electroencephalography|Electroencephalography will be performed before and after placebo administration
16585096|NCT02711579|Experimental|Celecoxib for motor evoked potential|Motor evoked potential will be measured before and after celecoxib administration
16585097|NCT02711579|Placebo Comparator|Placebo for motor evoked potential|Motor evoked potential will be measured before and after placebo administration
16585098|NCT02711566|Active Comparator|Sensorimotor training|"Patients in this arm were assigned to the 'Physioassistant: Haptic training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation.
~All participating centers used the exact same apparatus and experimental set-up."
16585099|NCT02711566|Experimental|Haptic training|Patients in this arm were assigned to the 'Physioassistant: Sensorimotor training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation. All participating centers used the exact same apparatus and experimental set-up.
16585100|NCT02711553|Experimental|8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
16585101|NCT02711553|Placebo Comparator|Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
16585102|NCT02711553|Experimental|80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).
16585103|NCT02711553|Placebo Comparator|Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
16585104|NCT02711540||Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
16585105|NCT02711540||No Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did not receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
16585106|NCT02711527|Active Comparator|Acupunture group A|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total) Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation , all needles will be retained for 30 minutes."
16585107|NCT02711527|Active Comparator|Acupunture group B|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total). Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes."
16585108|NCT02711501|Experimental|Laser irradiation|laser-assisted surgery with the following parameters: Wavelength:810 nanometer, power: 3 W, pulse mode,pulse length 100 µs, pulse interval 200 µs
16585109|NCT02711501|Experimental|blade|conventional surgery by blade
16585110|NCT02711488|Experimental|Intervention group|Combine primary prevention activities at the school level with secondary prevention at the household level
16585111|NCT02711488|No Intervention|Control group|No intervention
16585112|NCT02711462|Other|Cohort 1|Subjects will receive 2mg of PF 06687234 or placebo via the SC route
16585113|NCT02711462|Other|Cohort 2|Subjects will receive 20mg PF 06687234 or placebo via the SC route
16585114|NCT02711462|Other|Cohort 3|This is an optional cohort that may be added anytime during the study. In this cohort, subjects will receive PF 06687234 or placebo via the SC route
16585115|NCT02711462|Other|Cohort 4|Subjects will receive 40mg of PF 06687234 or placebo via the SC route
16585116|NCT02711462|Other|Cohort 5|Subjects will receive 80mg of PF 06687234 or placebo via the SC route
16585119|NCT02711462|Other|Cohort 8|Subjects in this cohort may receive 20 mg of PF 06687234 or placebo via the SC route every week with a total of 5 doses
16585120|NCT02711462|Other|Cohort 9|Subjects in this cohort may receive 40 mg of PF 06687234 or placebo via the SC route every two weeks with a total of 3 doses
16585121|NCT02711462|Other|Cohort 10|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
16585122|NCT02711462|Other|Cohort 11|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
16585123|NCT02711449|Experimental|Methylprednisolone|125 mg Methylprednisolone intravenously approximately 30 minutes prior to skin incision
16585124|NCT02711449|Placebo Comparator|Placebo|0.9% Saline intravenously approximately 30 minutes prior to skin incision
16585125|NCT02711436|Active Comparator|Computed Tomography Scan|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with Computed Tomography scan.
16585126|NCT02711436|Active Comparator|Fast Magnetic Resonance Imaging|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with T1/T2-weighted MRI.
16585127|NCT02711423|Experimental|Part I (Dose Escalation): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1.
16585128|NCT02711423|Placebo Comparator|Part I (Dose Escalation): Placebo|Participants will receive a single SC dose of matching placebo on Day 1.
16585129|NCT02711423|Experimental|Part II (PK Extension): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.
16585130|NCT02711397||Celiac patients|Celiac patients following a GFD for at least one year prior to the inclusion in the study.
16585131|NCT02711397||Positive controls|Healthy children and adults on an unrestricted gluten containing diet.
16585132|NCT02711397||Negative controls|Healthy infants who were exclusively fed with infant formula specifically labelled as gluten-free.
16585133|NCT02711371||Cannabis Dependence|Cannabis dependent individuals according to DSM 4 criteria, aged 18-40 years
16585134|NCT02711371||Healthy|Healthy controls, socio-demographically matched
16585135|NCT02711358|Experimental|indomethacin|indomethacin suppositories
16585136|NCT02711358|Placebo Comparator|placebo|placebo suppositories
16585137|NCT02711345|Experimental|Escalation|
16585138|NCT02711345|Experimental|Expansion Group 1|
16585139|NCT02711345|Experimental|Expansion Group 2|
16585140|NCT02711345|Experimental|Expansion Group 3|
16585141|NCT02711345|Experimental|Expansion Group 4|
16585142|NCT02711332||Degree of Haemolysis|Each subject will have four capillary blood sampling on different fingers. A reference venous blood sampling will be conducted.
16585143|NCT02711319|Active Comparator|active (real) rTMS (ACTIVE GROUP)|"The patients were randomly distributed in two study groups: real or sham rTMS group.
~For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes."
16585144|NCT02711319|Sham Comparator|sham rTMS (SHAM GROUP)|For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
16585145|NCT02711306|Experimental|GMN Diet|In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.
16585146|NCT02711306|Placebo Comparator|PN Diet|In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.
16585147|NCT02711293|Experimental|ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard plus enhanced nutrition counseling.
16585148|NCT02711293|Experimental|ART home delivery + no enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard counseling.
16585149|NCT02711293|Experimental|No ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home to provide enhanced nutrition counseling. Participants will not receive ART home delivery.
16585150|NCT02711293|No Intervention|Standard of care|Participants in this arm receive facility-based ART care and no enhanced nutrition counseling. They receive community health worker visits as per the standard of care in Dar es Salaam.
16585151|NCT02711280|Experimental|Sevoflurane General anesthesia|Anesthesia was induced with 8% sevoflurane with 8L/min oxygen. Anesthesia was maintained with 1-3% sevoflurane in oxygen/air mixture.
16585152|NCT02711280|Experimental|Propofol General anesthesia|Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
16585153|NCT02711267|Experimental|Phase 1: Optimization Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump). On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream. The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other. Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
16585154|NCT02711267|Experimental|Phase 2: Formulation Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. Different topical 5% acyclovir formulations currently available on the market will be tested. One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application. The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
16585331|NCT02710097|Experimental|Active THC and Active Ethanol|
16585332|NCT02710097|Experimental|Placebo THC and Active Ethanol|
16585155|NCT02711267|Experimental|Phase 3: Pilot BE study|4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
16585156|NCT02711267|Experimental|Phase 4: Main BE Study|20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
16585157|NCT02711241|Active Comparator|Dipyrone|
16585158|NCT02711241|Active Comparator|Papaverine|
16585159|NCT02711228|Experimental|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
16585160|NCT02711202|Active Comparator|Sirolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at post-operative day (POD) 14, they were randomized to sirolimus monotherapy.
16585161|NCT02711202|Active Comparator|Tacrolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at POD 14, they were randomized to tacrolimus monotherapy.
16585162|NCT02711189|Active Comparator|Oxytocin|Intranasal oxytocin will be delivered on twice daily basis in this crossover trial.
16585163|NCT02711189|Placebo Comparator|Placebo|Within Subject Design
16585164|NCT02711176|Experimental|Tavanex & Nexium & Tinafas|"Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days"
16585165|NCT02711176|Active Comparator|Lanzol & Klacid &Iramox|Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days
16585166|NCT02711163|Experimental|Extensively hydrolyzed formula|Feeding extensively hydrolyzed formula
16585167|NCT02711163|Placebo Comparator|Amino acid formula|Feeding amino acid formula
16585168|NCT02711150|Experimental|EPD Measurements|"Intervention:
~PLL Length Measured through US will be done with the subject placed on the Epidural Positioning Device."
16585169|NCT02711150|Active Comparator|Flexed Position Measurements|"Intervention:
~PLL Length Measured through US will be done with the subject placed in a flexed lumbar spine position."
16585170|NCT02711137|Experimental|INCB057643|
16585171|NCT02711137|Experimental|INCB057643 + Standard of Care (SOC) agents|
16585172|NCT02711124||Group with hemoglobin A1c < 7|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
16585173|NCT02711124||Group with hemoglobin A1c ≥ 7%|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
16585174|NCT02711111|Experimental|orthodontic bone anchor|new bone anchor device, which creates anterior traction on the upper jaw. Placed on the chin-region intra-orally.
16585175|NCT02711111|Active Comparator|face mask protraction|control group, conventional treatment method. Face mask creates anterior traction on the upper jaw
16585176|NCT02711098|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
16585177|NCT02711098|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
16585178|NCT02711085||Acute trauma|Those within the first 3 weeks of a non-catastrophic injury affecting the musculoskeletal system, including but not limited to whiplash or other road-traffic collisions, sports injuries, work-related injuries, sprains, strains, slips and falls and non-displaced fractures that don't require surgical correction.
16585179|NCT02711072|Placebo Comparator|control group|
16585180|NCT02711072|Active Comparator|infiltration group|
16585181|NCT02711059|Active Comparator|parathyroidectomy|change in insulin resistance
16585182|NCT02711059|No Intervention|control|the study participant will be examined parallel with the active comparator
16585183|NCT02711046|Experimental|single stage nasolabial flap|single staged nasolabial flap as an interpositional material after surgical resection of fibrous band in oral submucous fibrosis
16585184|NCT02711033|Experimental|Laparoscopic-assisted total gastrectomy|Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.
16585185|NCT02711033|Active Comparator|Open total gastrectomy|Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
16585186|NCT02711020|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy delivered in individual format.
16585187|NCT02711020|Experimental|Personal Construct Therapy|Personal Constructs Therapy delivered in individual format.
16585188|NCT02711007|Experimental|apatinib|apatinib 750mg tablet or 500mg tablet by mouth, Qd half an hour after dinner
16585189|NCT02710994|Experimental|CDFR0209, Then Losec|Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
16585190|NCT02710994|Experimental|Losec, Then CDFR0209|Subjects first received Losec 40 mg each morning in a fasting state for 7 days. After a washout period of 14 days, they then received CDFR0209 in a fasting state each morning for 7 days.
16585191|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
16585333|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
16585192|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
16585193|NCT02710968|Experimental|11540KE and Balt Goldbal 2 balloon|"Patients meeting inclusion criteria will receive fetoscopic tracheal occlusion using the fetoscopy sheath 11540 KE and the Balt Goldbal2 detachable balloon.
~Participants with an O/E LHR 25% (severe group) will have FETO completed at 27 weeks + 0 days to 29 weeks + 6 days gestation. Balloon removal is 4-5 weeks after that.
~Participants with an O/E LHR 25 - <30% (less severe group) will have FETO completed at 30 weeks + 0 days to 31 weeks + 6 days gestation. Balloon removal is 3 - 4 weeks after that."
16585194|NCT02710955|Experimental|Thickened infant formula|
16585195|NCT02710942|Experimental|SPHERE intervention|It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
16585196|NCT02710942|Experimental|PRISM intervention|It is a targeted self-guided Internet-based CBT intervention. PRISM was built upon the myWHI diary, an electronic headache diary. PRISM helps users discover their headache triggers by analyzing the inputted diary data using association rule mining. Once one or multiple headache triggers are identified the application uses an algorithm to provide the user with a few personalized recommendations to help them to cope with these triggers. The algorithm is based on the opinion of clinical experts (e.g., medical health professionals, psychologists). The user chooses recommendations to follow and sets goals in the application to follow them. To support the process, the application checks in with users about their goals and tracks goal completion.
16585197|NCT02710942|No Intervention|Usual care|Participants can continue doing what they usually do to deal with their migraines.
16585198|NCT02710929||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
16585199|NCT02710929||TD group|Typically development controls without lifetime diagnosis with ADHD
16585200|NCT02710916|Sham Comparator|perimetric glaucoma patients|
16585201|NCT02710916|Active Comparator|preperimetric glaucoma patients|
16585202|NCT02710916|Sham Comparator|perimetric glaucoma control patients|
16585203|NCT02710903|Experimental|Healthy with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with probing depths (PD) ≤4mm, no evidence of inter proximal clinical attachment loss (CAL), and <20% of sites with bleeding on probing (BOP).
16585204|NCT02710903|Experimental|Periodontal Disease with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
16585205|NCT02710903|Experimental|Healthy with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with PD ≤4mm, no evidence of interproximal CAL, and <20% of sites with BOP.
16585206|NCT02710903|Experimental|Periodontal Disease with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
16585207|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years. For Cohort 2 every attempt will be made to enroll 20 subjects >= 4 to < 8 years of age, 12 subjects >= 2 to < 4 years of age and 12 subjects >= 1 month to < 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
16585208|NCT02710877|Experimental|Programmed Intermittent bolus (PIEB)|Intervention: epidural analgesia through administration of a mixture of levobupivacaine 0,0625% and sufentanil 4 mcg. Intermittent bolus of 10 ml mixture every 75 minutes. Patient controlled bolus of 5 ml same mixture, lock-out 15 minutes.
16585209|NCT02710877|Active Comparator|Manuale epidural bolus (TOP-UP)|Intervention: manual epidural bolus of 15 ml levobupivacaine 0,0625% and sufentanil 5 mcg on maternal request.
16585210|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
16585211|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
16585212|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
16585213|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
16585214|NCT02710838|Experimental|Cancer group|All patients receive the infrared endoscopy after injecting indocyanine green（ICG） intravenously.
16585215|NCT02710838|Other|Non-cancer group|All patients receive the infrared endoscopy after injecting ICG intravenously.
16585216|NCT02710825|Experimental|Osteopathic treatment|
16585217|NCT02710825|Placebo Comparator|Simulated osteopathic treatment|
16585218|NCT02710812||Rectum sparing group|"Patients who have all of the following requirements:
~Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy);
~Written informed consent (after 2nd restaging).
~Note: They will be subject to wait-and-see approach only patients with cCR."
16585219|NCT02710799|Active Comparator|Control|Referrals will be evaluated through the state's protocols
16585220|NCT02710799|Experimental|Intervention|Referrals will be evaluated through the state's protocols associated with telephone-based teleconsultations.
16585221|NCT02710786||Gastric bypass|Patients undergoing gastric bypass
16585222|NCT02710773|Experimental|Backward Walking Treadmill Training|The subjects will perform a backward walking training on treadmill device
16585223|NCT02710773|Active Comparator|Treadmill training|The subjects will perform a walking training on treadmill device
16585224|NCT02710760|No Intervention|Control|Households in the control group receive no special treatment.
16585225|NCT02710760|Experimental|Adoption Encouragement Treatment|"Households in the Adoption Encouragement Treatment group were visited between March and April 2015 and offered child nutrition focused adoption encouragement. Both the male household head and the primary female caregiver were invited to attend these meetings (though the household head is the primary target), where the nutritional benefits of Quality Protein Maize (QPM) adoption for children were emphasized along with the agronomic properties. In addition, the fact that only small amounts of QPM are necessary to nourish children was highlighted and small seed bag sizes were offered. During the adoption encouragement visit, we offered the option to order up to three 2 kg bags of QPM for free."
16585226|NCT02710760|Experimental|Consumption Encouragement Treatment|In addition to receiving the Adoption Encouragement Treatment, households in the Consumption Encouragement Treatment group received additional information, targeted to the caregiver, and tools for separating Quality Protein Maize and targeting it to young children in the household in August 2015. They will additionally receive further guidance in February 2016.
16585227|NCT02710747|Experimental|Genetic Group|Dose (mg/week) = [5.6044 - 0.02614 × Age [in years] + 0.0087 × Height [cm] + 0.0128 × Weight [kg] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 *1/*2 - 0.9357 × CYP2C9 *1/*3 - 1.0616 × CYP2C9 *2/*2 - 1.9206 × CYP2C9*2/*3 - 2.3312 × CYP2C9 *3/*3 - 0.1092 × Asian race - 0.5503 × amiodarone ]2
16585228|NCT02710747|No Intervention|Control Group|Dose for the first three days after operation will be 4.5mg/d.
16585229|NCT02710734|Experimental|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
16585230|NCT02710734|Experimental|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
16585231|NCT02710734|Experimental|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
16585232|NCT02710734|Experimental|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
16585233|NCT02710721|Experimental|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
16585234|NCT02710721|Active Comparator|Control|mediterranean diet
16585235|NCT02710708|Experimental|Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)|Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
16585236|NCT02710695|Active Comparator|Control|This group will receive a 10 minute discussion
16585237|NCT02710695|Active Comparator|Intervention|This group will receive a 10 minute standardized discussion
16585238|NCT02710682|Active Comparator|Mini-open surgery|Surgery
16585239|NCT02710682|Experimental|Ultrasound-guided Tendon fenestration|Tendon fenestration
16585240|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
16585241|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
16585242|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
16585243|NCT02710656|Experimental|Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
16585244|NCT02710656|Active Comparator|Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
16585245|NCT02710643|No Intervention|MRD - BEFORE RT|Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
16585246|NCT02710643|No Intervention|MRD + BEFORE RT AND MRD - AFTER RT|Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
16585247|NCT02710643|Experimental|MRD + BEFORE RT AND MRD + AFTER RT|"Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).
~Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated."
16585248|NCT02710630|Active Comparator|Dabigatran etexilate capsule|
16585249|NCT02710630|Experimental|Dabigatran etexilate tablet A1|
16585250|NCT02710630|Experimental|Dabigatran etexilate tablet B1|
16585251|NCT02710630|Experimental|Dabigatran etexilate tablet C1|
16585252|NCT02710630|Experimental|Dabigatran etexilate tablet D1|
16585253|NCT02710630|Experimental|Dabigatran etexilate tablet E1|
16585254|NCT02710604|Active Comparator|CMX157 5mg versus TDF|CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days
16585255|NCT02710604|Active Comparator|CMX157 10mg versus TDF|CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days
16585256|NCT02710604|Active Comparator|CMX157 25mg versus TDF|CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days
16585257|NCT02710604|Active Comparator|CMX157 50mg versus TDF|CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days
16585258|NCT02710604|Active Comparator|CMX157 100mg versus TDF|CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days
16585259|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.
~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
16585260|NCT02710578|Active Comparator|Alcohol|Alcohol
16585261|NCT02710578|Placebo Comparator|Placebo|Tonic water
16585262|NCT02710565|Other|Cohort|"Participants who are scheduled to have an endo bronchial ultrasound (EBUS) trans bronchial needle aspiration (TBNA) will provide additional samples. These samples will then be sent to Imperial College London to see whether a cell line can be grown.
~If growth is successful then the samples will be returned to our pathology department to see if grading is possible and then to compare these results with the previous diagnostic samples.
~The cell line samples will not be used for patient diagnosis."
16585263|NCT02710552|Active Comparator|Three antihypertensive Drugs|Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
16585264|NCT02710552|Active Comparator|Two antihypertensive drugs|Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
16585265|NCT02710539|Active Comparator|Free combination|Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy
16585266|NCT02710539|Active Comparator|Tripliam|fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily
16585267|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
16585268|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
16585269|NCT02710526|Experimental|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
16585270|NCT02710513|Experimental|Beta-glucans|2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)
16585271|NCT02710500|Experimental|Cohort 1 (Low Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10^12 in one muscle.
~Intervention Drug: rAAVrh.MHCK7.DYSF.DV"
16585272|NCT02710500|Experimental|Cohort 2 (High Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10^12 vg in one muscle.
~Intervention Drug: rAAVrh74.MHCK7.DYSF.DV"
16585273|NCT02710487|Experimental|REM Sleep Awakening (REMSA)|The investigators will actively awaken each subject from nocturnal REM sleep in a sleep laboratory setting, in the hour preceding her/his habitual wake time.
16585274|NCT02710487|Experimental|NREM Sleep Awakening (NREMSA)|Awakening from the NREM sleep stage N2 will be the control intervention.
16585275|NCT02710474|Active Comparator|Standard Care|Preterm infants will receive current Standard Care (SC) in the NICU.
16585276|NCT02710474|Experimental|Intervention|Preterm infants will receive Family Nurture Intervention (FNI) in addition to current Standard Care (SC) in the NICU. Specifically, staff will support the parents and facilitate contact between mother and infant during the NICU stay.
16585277|NCT02710474|Active Comparator|Term Controls|Full term infants will receive current Standard Care (SC) in the NICU. Term Controls (TC)
16585278|NCT02710474|Active Comparator|Chart Review|Chart review will be conducted to acquire a comparison group to determine if our study participants differ from the non-study population.
16585279|NCT02710461|Experimental|Subjects with abdominal obesity|Intervention with grape pomace and pomegranate pomace
16585280|NCT02710448|Experimental|Metformin|Metformin in patients with renal failure
16585281|NCT02710435||Arm 1 - Prospective|Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Neovasc Reducer System implant procedure
16585282|NCT02710435||Arm 2 - COSIRA|Includes subjects who were previously enrolled and treated with the Neovasc Reducer System during the COSIRA study and agree to participate in this long term follow up study
16585283|NCT02710435||Arm 3 - CE Mark|"Includes subjects who received a Neovasc Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study
~Arm 3 has been closed to enrollment-June 2017"
16585284|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
16585285|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
16585286|NCT02710409|Experimental|Quadrivalent influenza vaccine|
16585287|NCT02710409|Active Comparator|Trivalent influenza vaccine A|Active Comparator A
16585288|NCT02710409|Active Comparator|Trivalent influenza vaccine B|Active Comparator B
16585289|NCT02710396|Experimental|Cohort 1|Subjects will receive single agent pembrolizumab 200 mg IV will be administered every 3 weeks for up to 2 years.
16585290|NCT02710396|Experimental|Cohort 2|Subjects will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of nab-paclitaxel and carboplatin administered with cycles 1 and 2.
16585291|NCT02710396|Experimental|Cohort 3|Subject will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of pemetrexed and carboplatin administered with cycles 1 and 2.
16585292|NCT02710383||Participants genetically diagnosed with Cystic fibrosis|Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years
16585293|NCT02710370||Controls|Patients who meet criteria for gastric bypass surgery, and do not have a documented history of Type 1 or Type 2 Diabetes.
16585294|NCT02710370||Participants with Type 2 Diabetes|Patients who meet criteria for gastric bypass surgery, and have a documented history of Type 2 Diabetes.
16585295|NCT02710357|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
16585296|NCT02710357|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 4 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
16585298|NCT02710344|Experimental|Telehealth|Usual care at community mental health care provider PLUS psychiatric telehealth program with remote monitoring.
16585299|NCT02710331|Experimental|Active THC and Placebo Ethanol|
16585300|NCT02710331|Experimental|Active THC and Active Ethanol|
16585301|NCT02710331|Experimental|Placebo THC and Active Ethanol|
16585302|NCT02710331|Placebo Comparator|Placebo THC and Placebo Ethanol|
16585303|NCT02710318|Experimental|Immunization Alert on|Children with visits seen when the immunization alert is on
16585304|NCT02710318|No Intervention|Immunization Alert off|Children with visits seen when the alert is off
16585305|NCT02710305|Active Comparator|Group A|oral hyoscine butyl bromide tablets plus lidocaine cream
16585306|NCT02710305|Placebo Comparator|Group B|oral placebo tablets plus placebo cream
16585307|NCT02710292|Other|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
16585308|NCT02710292|Other|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
16585309|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
16585310|NCT02710266|Placebo Comparator|Placebo group|hepatectomy without Gabexate Mesilate
16585311|NCT02710266|Experimental|Preoperative Gabexate Mesilate group|Gabexate Mesilate administered from the preoperative day
16585312|NCT02710266|Experimental|Intraoperative Gabexate Mesilate group|Gabexate Mesilate administered from the operative day
16585313|NCT02710253|Experimental|Treatment (SBRT or EBRT)|Patients undergo either 4, 5, or 10 fractions of SBRT, or 5-15 fractions of EBRT to any site of metastatic disease daily for any time between 4 days and 3 weeks as determined by the treating radiation oncologist. Patients with at least SD after the second imaging evaluation may undergo additional SBRT in 4 fractions or EBRT in 3 fractions.
16585314|NCT02710227||liver cirrhosis|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
16585315|NCT02710227||control|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
16585316|NCT02710214|Experimental|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
16585317|NCT02710214|Placebo Comparator|Placebo|Placebo pill daily for 8 weeks.
16585318|NCT02710201|No Intervention|Control|No feedback on progress of other participants.
16585319|NCT02710201|Experimental|Descriptive Social Norm|Average physical activity of other participants in study conveyed to this group.
16585320|NCT02710201|Experimental|Descriptive-plus-Injunctive Social Norm|Average physical activity of other participants in study and message of approval or disapproval (depending on how one is faring compared to others) conveyed to this group.
16585321|NCT02710188|Experimental|HTL0009936 modified release (MR) Formulation|Intervention: 5 different modified release formulations of HTL0009936, as a single dose
16585322|NCT02710188|Active Comparator|HTL00009936 immediate release (IR) fasted|Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state
16585323|NCT02710162|Experimental|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
16585324|NCT02710149|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD20-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
16585325|NCT02710136|Experimental|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.
~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
16585326|NCT02710123|Experimental|Aerobic Exercise|Participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during the Buffalo Concussion Treadmill Test (BCTT). The script will ask the participant to exercise one a day for 20 minutes at 80% of HRT. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Sub-Threshold exercise prescription
16585327|NCT02710123|Placebo Comparator|Stretching Exercise|Participants will receive a prescription for stretching exercises that they will be asked to do daily. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Structured stretching exercise prescription.
16585328|NCT02710110|Experimental|Active Respiratory Trainer|Participants enrolled in this arm will be given the PowerLung trainer. The adjustable spring allows for discrete and calibrated changes to the valve, which in turn blocks air until sufficient inspiratory or expiratory pressure is applied by an individual. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
16585329|NCT02710110|Sham Comparator|Sham Trainer|Participants enrolled in this arm will be given the PowerLung trainer; however, the adjustable spring allows for discrete and calibrated changes to the valve and these will not have any resistance. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
16585330|NCT02710097|Experimental|Active THC and Placebo Ethanol|
16585334|NCT02710084|Experimental|Oxytocin|The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
16585335|NCT02710084|Placebo Comparator|Saline|During the first phase, patients randomized to the placebo group will receive intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants will receive oxytocin, in identical doses.
16585336|NCT02710071|Experimental|Placebo, Nebivolol, Hydrochlorothyazide|Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
16585337|NCT02710071|Experimental|Placebo, Hydrochlorothyazide, Nebivolol|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
16585338|NCT02710058||Arab American Women with Breast Cancer|We conducted a study using an evaluation assessment survey to assess the impact of the AMBER support groups on quality of life parameters, compliance with treatment appointments, and patient/family support. After reviewing preliminary results, we identified several recurrent themes, such as the need for health information, discrepancies around the extent of family support and disease disclosure, and an overall satisfaction with the support groups. To further examine these themes, we are initiating a qualitative research study using an in-depth interview guide. A trained interviewer bilingual in Arabic and English will conduct 10-15 in-depth interviews, to saturation, with AMBER's support group participants over a 6 month period.
16585339|NCT02710045|Active Comparator|MV at 9 months|"Measles Vaccine at 9 months of age. Measles Vaccine at 18 months of age. All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.
~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
16585340|NCT02710045|Active Comparator|DTP + MV at 9 months|Measles Vaccine at 9 months of age. DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
16585341|NCT02710045|Active Comparator|DTP at 9 months|DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
16585342|NCT02710032|Experimental|Intervention|Social Network-Based Adherence Intervention
16585343|NCT02710032|No Intervention|Control|Control
16585344|NCT02710019|Experimental|Psychoeducational video games|Participants in this group will play the Back to Reality Series video games: (1) Harry's Journey which delivers experiential knowledge about psychosis and marijuana use; (2) Harry's Journal which challenges their understanding of 12 psychiatric symptoms associated with psychosis and (3) the PathwaysToCare Map which uses colourful 3D images and voice-overs to depict actual mental health and addictions services for youth available in Hamilton. These in
16585345|NCT02710019|Other|Control video game|The control video game is a spelling/memory quiz involving with themes from pop culture. The control game will not provide any education about mental health and addictions issues It should be noted that all participants will play both sets of games during their initial and only visit. Participants are randomized to determine which game they will play first during this visit. This is not an RCT or a crossover design. There is no follow up or clinical assessments.
16585346|NCT02710006|Experimental|SonoHysteroAVC|Three-dimensional sonohysterography is the first point for uterine cavity volume estimation, and it is going to be performed in all participants. The investigators are going to fill the uterine cavity twice by saline solution during single sonohysterography procedure, and acquise the volumetric datasets of uterus for offline analysis. The 3D dataset containing the entire uterine cavity will by analyzed using a personal computer and/or the ultrasound machine with specific softwere.
16585347|NCT02709993|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
16585348|NCT02709980|Placebo Comparator|Sleep Education|6 sessions of sleep education.
16585349|NCT02709980|Active Comparator|Cognitive Behavior Therapy for Insomnia|6 sessions of cognitive behavioral therapy for insomnia (CBT-I).
16585350|NCT02709967|Active Comparator|Material support|Writing materials
16585351|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
16585352|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
16585353|NCT02709954|Experimental|Active THC and Placebo Ethanol|
16585354|NCT02709954|Experimental|Active THC and Active Ethanol|
16585355|NCT02709954|Experimental|Placebo THC and Active Ethanol|
16585356|NCT02709954|Placebo Comparator|Placebo THC and Placebo Ethanol|
16585357|NCT02709941|Active Comparator|IMST Training Group|Subjects in inspiratory muscle strength training group will complete 30 breaths against a resistance set at 75% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
16585358|NCT02709941|Placebo Comparator|Placebo Training Group|Subjects in placebo training group will complete 30 breaths against a resistance set at 15% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
16585359|NCT02709928|Experimental|TD-0714|Capsule formulation
16585361|NCT02709915|Experimental|Breakfast Diet (Bdiet)|The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
16585362|NCT02709915|Active Comparator|6 small meals diet (6Mdiet)|The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
16585363|NCT02709902|Experimental|Adapalene/BP gel, 0.3%/2.5%|Topical, once daily, for 84 days.
16585364|NCT02709902|Active Comparator|EPIDUO® FORTE|Topical, once daily, for 84 days.
16585365|NCT02709902|Placebo Comparator|Placebo|Topical, once daily, for 84 days.
16585366|NCT02709889|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
16585367|NCT02709876|Experimental|Stem Cells|Intravitreal Injection of bone marrow derived CD34+, CD133+, CD271+ stem cells.
16585368|NCT02709863|Active Comparator|Sevoflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
16585369|NCT02709863|Active Comparator|Desflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
16585370|NCT02709863|Active Comparator|Propofol|6-10 mg/kg/h, iv infusion, during operation
16585371|NCT02709850|Placebo Comparator|Cohorts A, D: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
16585372|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 20 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 20 milligrams (mg) subcutaneously on Day 1.
16585373|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 120 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 120 mg subcutaneously on Day 1.
16585374|NCT02709850|Placebo Comparator|Cohorts B, C: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
16585375|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 40 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 40 mg subcutaneously on Day 1.
16585376|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 80 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 80 mg subcutaneously on Day 1.
16585377|NCT02709850|Placebo Comparator|Cohorts AA-DD: Placebo|Participants received IONIS ANGPTL3-LRx-matching placebo subcutaneously once per week for 6 weeks.
16585378|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 10 mg|Participants received IONIS ANGPTL3-LRx 10 mg subcutaneously once per week for 6 weeks.
16585379|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 20 mg|Participants received IONIS ANGPTL3-LRx 20 mg subcutaneously once per week for 6 weeks.
16585380|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 40 mg|Participants received IONIS ANGPTL3-LRx 40 mg subcutaneously once per week for 6 weeks.
16585381|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 60 mg|Participants received IONIS ANGPTL3-LRx 60 mg subcutaneously once per week for 6 weeks.
16585382|NCT02709837|Active Comparator|Poorly cooked meat-Good chewing|Meat cooked 10min at 75°C, chewing without appliance
16585383|NCT02709837|Active Comparator|Highly cooked meat-Good chewing|Meat cooked 45min at 90°C, chewing without appliance
16585384|NCT02709837|Active Comparator|Poorly cooked meat-Bad chewing|Meat cooked 10min at 75°C, chewing with appliance
16585385|NCT02709837|Active Comparator|Highly cooked meat-Bad chewing|Meat cooked 45min at 90°C, chewing with appliance
16585386|NCT02709824|Active Comparator|Chlorhexidine gluconate with ADS|Chlorhexidine 0.12% plus Anti-Discoloration System Mouthwash
16585387|NCT02709824|Active Comparator|Chlorhexidine gluconate without ADS|Chlorhexidine 0.12% Mouthwash
16585388|NCT02709811|Experimental|electrochemotherapy|
16585389|NCT02709798|Experimental|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
16585390|NCT02709798|Placebo Comparator|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
16585391|NCT02709785|Experimental|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
16585392|NCT02709785|Experimental|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
16585393|NCT02709785|Placebo Comparator|Group 3 Placebo|28 subjects with plaque and gingival inflammation
16585394|NCT02709772|Active Comparator|Provider Alert|This arm is the intervention arm. This arm will receive the Electronic Record Alert.
16585395|NCT02709772|No Intervention|No Provider Alert|This arm is the control arm.
16585396|NCT02709759|Active Comparator|MI|Motivational interviewing focused on reducing alcohol use, delivered by videoconferencing.
16585397|NCT02709759|Active Comparator|BA|Brief Advice to reduce drinking delivered by videoconferencing
16585398|NCT02709759|Active Comparator|MI + ITM|Motivational intervention to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
16585399|NCT02709759|Active Comparator|BA + ITM|Brief Advice to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
16585400|NCT02709759|Active Comparator|MI + ITM + EI|Participants in this arm receive MI delivered by videoconferencing and ITM over 9 months rather than 1
16585401|NCT02709759|Active Comparator|BA + ITM + EI|Participants in this arm receive BA delivered by videoconferencing and ITM over 9 months rather than 1
16585402|NCT02709759|Active Comparator|BA + EI|Participants in this arm receive BA delivered by videoconferencing over 9 months rather than 1
16585403|NCT02709759|Active Comparator|MI + EI|Participants in this arm receive MI delivered by videoconferencing over 9 months rather than 1
16585404|NCT02709746|Experimental|Vortioxetine 10 mg/day|
16585405|NCT02709746|Experimental|Vortioxetine 20 mg/day|
16585406|NCT02709746|Active Comparator|Fluoxetine 20 mg/day,|
16585407|NCT02709746|Placebo Comparator|Placebo|
16585408|NCT02709733|Experimental|VR Motivation Training|Weekly training sessions with a VR motivation treatment 1 hour per week for 8 weeks.
16585409|NCT02709720|Experimental|1|2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy
16585410|NCT02709707||Patients with diabetes|
16585416|NCT02709655|Active Comparator|Fluoxetine 20 mg/day,|A decision has been taken to stop recruitment into this treatment arm.
16585417|NCT02709655|Placebo Comparator|Placebo|
16585418|NCT02709642|No Intervention|Control|Control Participants will complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight.
16585419|NCT02709642|Experimental|Deposit Contract|The deposit contract group will also complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight. In addition, the deposit contract group will be asked to make a deposit of at least $100 each 10-week period over the course of one year (50 weeks). Each week, they will recoup 1/10 of their 10-week deposit if they are within two pounds of their baseline weight or lower. If they are more than two pounds above their baseline weight, they will forfeit 1/10 of their 10-week deposit. The money they forfeited for that week will go into a collective pool to be divided up at the end of each 10-week period by all deposit contract participants who successfully maintained their weight loss at the end of the 10-week period.
16585420|NCT02709629|Experimental|Individualized and adaptive computerised cognitive training|Training in this group is individualized using a computer algorithm which assigns tasks (from a pool of 33 training tasks) on the basis of cognitive strengths and weaknesses as determined by the training program. In addition, task difficulty is adaptive and responsive to performance level. Participants are able to see feedback on their progress each training session in the form of a session-score. A range of behavior change techniques are used throughout the training period (delivered via scheduled monitoring phone calls, and email contact with participants) to support the compliance and adherence of participants. These include a range of motivation and confidence building strategies, based on a theoretical framework. Participants are required to train for approx. 30 min., 3 times per week, for 8 weeks.
16585421|NCT02709629|Active Comparator|Active control|"Training in this group is generic, and tasks (from the same pool of 33 training tasks) are randomly selected by the training program. In addition, task difficulty is fixed, such that irrespective of performance, each time a participant is presented with a given task, the level of difficulty returns to the basic level. Participants in this arm do not receive feedback on their progress at the end of each training session. The same protocol of behavior change techniques is used in this intervention arm.
~Participants are also required to train for approx. 30 min., 3 times per week, for 8 weeks."
16585422|NCT02709616|Experimental|Personalized cellular vaccine|DC based cellular vaccine
16585423|NCT02709603|Experimental|Group A|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
16585424|NCT02709603|Placebo Comparator|Group B|oral 2 tablets (PLACEBO) 30 minutes before the procedure
16585425|NCT02709590|Experimental|Group A|oral diclofenac potassium plus lidocaine anesthetic cream placed into their cervix immediately before HSG
16585426|NCT02709590|Placebo Comparator|Group B|oral placebo tablets plus placebo cream placed into their cervix immediately before HSG
16585427|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
16585428|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
16585429|NCT02709564|Placebo Comparator|Group A|400 mg placebo
16585430|NCT02709564|Active Comparator|Group B|400 microgram misoprostol
16585431|NCT02709551|Experimental|HRV-Bfb|HRV biofeedback, training about 30 minutes/day
16585432|NCT02709551|Experimental|MBI|Mindfulness based intervention, training about 30 minutes/day
16585433|NCT02709551|Other|MBI_HRV-Bfb|Mindfulness based HRV biofeedback. Wait list control group for the interventions HRV-Bfb and MBI, after the main phase intervention with combined method.
16585434|NCT02709538|Experimental|GSP 301 NS|
16585435|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
16585436|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7.0|
16585437|NCT02709525|Experimental|hyaluronic acid|Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
16585438|NCT02709525|Placebo Comparator|Blood clot|Immediately after the extractions, the other side socket was naturally filled with blood clot.
16585439|NCT02709512|Experimental|Drug: ADI-PEG 20 plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
~In Combination With:
~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
16585440|NCT02709512|Placebo Comparator|Drug: Placebo plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
~In Combination With:
~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
16585441|NCT02709499|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
16585442|NCT02709499|Experimental|6J LLLT|The Laser radiation will be made with 4J by spot
16585443|NCT02709486|Experimental|Low dose|Investigational product
16585444|NCT02709486|Experimental|High dose|Investigational product
16585445|NCT02709486|Placebo Comparator|Placebo|Investigational product
16585446|NCT02709473|Active Comparator|propofol|Propofol arm includes patients that induction of general anesthesia started with propofol and followed by remifentanil and rocuronium administration
16585447|NCT02709473|Active Comparator|remifentanil|Remifentanil arm include patients that induction of general anesthesia started with remifentanil and followed by propofol and rocuronium administration
16585448|NCT02709460|Experimental|Lateral occlusion|Women included in this arm is randomized to lateral occlusion of the uterine artery
16585449|NCT02709460|Active Comparator|cervical occlusion|Women included in this arm is randomized to occlusion of the uterine artery at cervical entry
16585450|NCT02709447|Experimental|Date SMART|Group based prevention
16585451|NCT02709447|Active Comparator|Health Promotion|Group based prevention
16585452|NCT02709434|Active Comparator|Intervention group|Patients with quiescent IBD who are randomized to receive the active intervention of the psychoeducational programme
16585453|NCT02709434|Placebo Comparator|Control group|Randomized to standard care
16585609|NCT02708446|Active Comparator|Sublingual misoprostol|200mg mifepristone + 400mcg sublingual misoprostol q3h
16585454|NCT02709421||Indomethacin Group|"All the patients with high risks of PEP received administration of one single dose of 100mg rectal indomethacin after ERCP.
~Patients were considered high risk of PEP if they met one of the following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, cannulation time≥10 minutes; pneumatic dilatation of an intact biliary sphincter, ≥3 inadvertent pancreatic duct cannulation, opacification of pancreatic acini, or the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush or forceps."
16585455|NCT02709408||Carbapenem-resistant Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-resistant Enterobacteriaceae
16585456|NCT02709408||Carbapenem-resistant A. baumannii|Patients with bloodstream infections due to carbapenem-resistant Acinetobacter baumannii
16585457|NCT02709408||Susceptible Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-susceptible Enterobacteriaceae matched to carbapenem-resistant ones by centre, type of ward, infection type, acquisition and previous duration of hospitalisation.
16585458|NCT02709408||Admitted control patients|Patients without infection due to Enterobacteriaceae matched to carbapenem-resistant Enterobacteriaceae cases according to centre, ward and previous length of hospitalisation.
16585459|NCT02709395|Experimental|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
16585460|NCT02709382|Experimental|FEP-TAZ|Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)
16585461|NCT02709369|Experimental|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
16585462|NCT02709356|Experimental|Alzheimer's disease|"Patients with mild Alzheimer's disease.
~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
16585463|NCT02709356|Experimental|Controls|"Healthy elderly people
~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
16585464|NCT02709343|Experimental|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
16585465|NCT02709343|Placebo Comparator|Placebo|Placebo product manufactured to look like MSCs
16585466|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:
~LunaRich X Capsules (12 capsules per day)
~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)
~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)
~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
16585467|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
16585468|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
16585469|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
16585470|NCT02709304|Placebo Comparator|Standard Gel|Standard gel not containing local anesthetic used to insert urinary catheters.
16585471|NCT02709304|Experimental|Lidocaine Gel|lidocaine containing gel uses to insert urinary catheters
16585472|NCT02709291|Other|Community Health Workers|Community health workers will complete a 5-day interventionist training to deliver a behavioral parent training intervention.
16585473|NCT02709291|Other|Parent-Child Dyads|Parents and children will receive a behavioral parent training intervention delivered by community health workers.
16585474|NCT02709278|Other|Group 1A: low dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^3 cfu by the aerosol inhaled route, followed by bronchoscopy.
16585475|NCT02709278|Other|Group 1B: medium dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
16585476|NCT02709278|Experimental|Group 1C: standard dose aerosol BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
16585477|NCT02709278|Experimental|Group 1D: standard dose intradermal BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
16585478|NCT02709278|Other|Group 2A: lower than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
16585479|NCT02709278|Other|Group 2B: close to the standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^5 cfu by the aerosol route, followed by bronchoscopy.
16585480|NCT02709278|Other|Group 2C: higher than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^6 cfu by the aerosol inhaled route, followed by bronchoscopy.
16585610|NCT02708446|Active Comparator|Buccal misoprostol|200mg mifepristone + 400mcg buccal misoprostol q3h
16585481|NCT02709278|Experimental|Group 2D: close to or higher than standard aerosol BCG|9 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
16585482|NCT02709278|Experimental|Group 2E: close to or higher than standard intradermal BCG|12 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
16585483|NCT02709265|Experimental|Cohort 1|amikacin/fosfomycin (30/12 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
16585484|NCT02709265|Experimental|Cohort 2|amikacin/fosfomycin (60/24 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
16585485|NCT02709265|Experimental|Cohort 3|amikacin/fosfomycin (90/36 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
16585486|NCT02709265|Experimental|Cohort 4|amikacin/fosfomycin (90/36 mg) delivered via the PARI LC Sprint Nebulizer (single dose)
16585487|NCT02709265|Experimental|Cohort 5|amikacin/fosfomycin (Dose and Nebulizer to be chosen based on results from Cohorts 1 - 4)
16585488|NCT02709252|Experimental|Cohort|Only one cohort is included with comparisons of two different hemodynamic parameters
16585492|NCT02709213||Patients with CT-diagnosed acute colitis|Patients with symptomatic colitis (fever and/or pain and/or diarrhea) proven by computed tomography
16585493|NCT02709200||Dexmedetomidine|Patients that received dexmedetomidine during open heart surgery.
16585494|NCT02709200||No dexmedetomidine|Patients that didn't receive dexmedetomidine during open heart surgery.
16585495|NCT02709187|Experimental|RT group|combination dose of Candesartan and Rosuvastatin and DP-R208 in order
16585496|NCT02709187|Experimental|TR group|DP-R208 and combination dose of Candesartan and Rosuvastatin in order
16585497|NCT02709174||pregnant with pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
16585498|NCT02709174||pregnant without pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
16585499|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
16585500|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
16585501|NCT02709148|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
16585502|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
16585503|NCT02709122|Experimental|With Tension pneumothorax|evaluation of the patient with the existing tension pneumothorax during a simulated CPR - breathing
16585504|NCT02709122|Experimental|Without Tension pneumothorax|evaluation of the patient without the existing tension pneumothorax during a simulated CPR - breathing
16585505|NCT02709109|Experimental|Sequence 1: VX-371 + Hypertonic Saline (HS), then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 milligram (mg)/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their cystic fibrosis (CF) standard of care.
16585506|NCT02709109|Experimental|Sequence 2: HS, then VX-371 + HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
16585507|NCT02709109|Experimental|Sequence 3: VX-371 + Placebo, then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
16585508|NCT02709109|Experimental|Sequence 4: Placebo, then VX-371 + Placebo|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
16585509|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
16585510|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
16585511|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
16585512|NCT02709070|Active Comparator|resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
16585513|NCT02709070|Experimental|highly-purified CTL|Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective participants who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Participants in the immunotherapy group received a number up to 5×10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. Participants were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving resection, followed by 6-9 treatments during 6 months to 2 years after receiving resection.
16585514|NCT02709057|Active Comparator|Life-style intervention 1|Life-style intervention in participants with low genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
16585515|NCT02709057|Active Comparator|Life-style intervention 2|Life-style intervention in participants with high genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
16585516|NCT02709057|No Intervention|Control 1|No intervention in participants with low genetic risk score
16585517|NCT02709057|No Intervention|Control 2|No intervention in participants with high genetic risk score
16585518|NCT02709044|Experimental|Ringer lactate 20 mL/kg|This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
16585519|NCT02709044|Experimental|Ringer lactate 40 ml/kg|This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
16585520|NCT02709031|Active Comparator|Cicletanine|Patients will take escalating doses of cicletanine
16585521|NCT02709031|Experimental|Cicletanine + magnesium|Patients will take escalating doses of cicletanine; patients will in addition take magnesium
16585522|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
16585523|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
16585524|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
16585525|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
16585526|NCT02708992|Experimental|Cefixime/Azithromycin|Eight participants will receive three oral doses of 800 mg cefixime (q 8 hours) on Day 1, followed by three oral doses of 800 mg cefixime (q 8 hours)+ one oral dose of 1000 mg azithromycin (with first dose of cefixime) on day 10
16585527|NCT02708979|Active Comparator|University Exam Period|This visit takes place the week before an exam at the university assuming that this will induce a stress response. Measurements (see description elsewhere) are being taken within 1-2 weeks prior to an university exam.
16585528|NCT02708979|Placebo Comparator|University Non-exam Period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period. Measurements (see description elsewhere) are being taken in a control-period without exams (at least 4 weeks after and 4 weeks prior to an exam)
16585529|NCT02708966|Experimental|Gymnema Sylvestre|Patients with IGT
16585530|NCT02708966|Placebo Comparator|Placebo|Patients with IGT
16585531|NCT02708953|Experimental|Treatment (thoracic manipulation)|Patients in the initial manipulation group will attend physical therapy two sessions per week for 3 weeks for a total of 6 sessions. Each treatment session will last for a total of 15 minutes. After the initial manipulation group receives 3 weeks of treatment they will wait for 1-week, be retested, and then crossover into the other group.
16585709|NCT02707731|Experimental|Hydrokinesiotherapy in preterm|Salivary cortisol samples, pain applying the Neonatal Infant Pain Scale Scale, heart rate, respiratory rate and oxygen saturation were collected before and after hydrokinesiotherapy
16585532|NCT02708953|Active Comparator|Wait-list (thoracic manipulation)|When individuals are assigned to the wait-list control group they will serve as the control for 3 weeks while the initial manipulation group receives treatment. After serving as the wait-list control condition for 3 weeks, this group will then return for testing and will receive the manipulation package as described below at 4 weeks.
16585533|NCT02708940|Active Comparator|Usual care|Control arm - these patients will get usual care as part of the PHP and IOP programs at UCLA. They will not receive mobile support messages.
16585534|NCT02708940|Active Comparator|Participatory technology development|Intervention - Patients will have access to a website that allows them to co-create mobile support messages with their therapist to support their care as part of the PHP and IOP programs at UCLA.
16585535|NCT02708927|Experimental|patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
16585536|NCT02708927|Experimental|Control|healthy subject
16585537|NCT02708914|Other|UB-851|
16585538|NCT02708914|Other|Eprex then UB-851|
16585539|NCT02708901|Active Comparator|GI Vivomixx®|25 children with GI symptoms
16585540|NCT02708901|Placebo Comparator|GI Placebo|25 children with GI symptoms
16585541|NCT02708901|Active Comparator|NGI Vivomixx®|25 children without GI symptoms
16585542|NCT02708901|Placebo Comparator|NGI placebo|25 children without GI symptoms
16585543|NCT02708888|Experimental|Trunk training|Exercises: Core stability training
16585544|NCT02708888|Sham Comparator|Cognitive exercises|Exercises: The RevArte Visual Search Test (RVST) of Lafosse et al (2013) and the Visuospatial Neglect Test Battery (VNTB) of Vaes et al. (2015)
16585545|NCT02708875|Experimental|Mixed Meal Challenge|Participants will consume a liquid mixed meal (~300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
16585546|NCT02708875|Active Comparator|Glucose Challenge|Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
16585547|NCT02708862|Experimental|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
16585548|NCT02708849|Experimental|Ketamine plus lamotrigine|
16585549|NCT02708849|Placebo Comparator|ketamine plus placebo|
16585550|NCT02708836|Active Comparator|ETT only|Endotracheal tube intubation after induction of anesthesia. Ventilation with ETT until emergence.
16585551|NCT02708836|Experimental|Combined ETT/LMA technique|Placement of LMA after induction of anesthesia. Intubation of trachea with ETT via LMA with fiberoptic bronchoscope. Ventilation with ETT throughout case. Removal of ETT while deeply anesthetized. Ventilation with LMA until emergence.
16585552|NCT02708810|Other|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
16585553|NCT02708797|Other|Migraine with aura Patients|Patients with migraine with aura will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
16585554|NCT02708797|Other|Controls|Control group with healthy volunteers will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
16585555|NCT02708784||Pompe disease|Patients will perform muscle strength measurement with dynamometer and MR-imaging. After 8 months the investigations will be repeated.
16585556|NCT02708784||Myotonic Dystrophy|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
16585557|NCT02708784||Healthy controls|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
16585558|NCT02708771|Experimental|Intervention|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
16585559|NCT02708771|Placebo Comparator|Control|Capsules of similar appearance and flavor without active drug
16585560|NCT02708758|Active Comparator|Treatment group|Medical nutrition therapy plus self monitoring capillary glucose levels and if necessary drug therapy (metformin or insulin) when goals are not met.
16585561|NCT02708758|No Intervention|Routine care group|Prenatal routine care without medical nutrition therapy and without self monitoring capillary glucose levels and drug therapy specific for GDM.
16585562|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
16585563|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
16585564|NCT02708732||DLBCL Participants|A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
16585565|NCT02708719|Other|Pulmonary rehabilitation|multimodal pulmonary Rehabilitation program (3 weeks Duration)
16585566|NCT02708706|Experimental|physical therapy and hyaluronic acid|patient received ultrasound-guided steroid injection via rotator interval
16585567|NCT02708706|Active Comparator|physical therapy only|patient received ultrasound-guided steroid injection via posterior recess
16585568|NCT02708693|Experimental|experimental: steroid injection and splinting|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine) and a customized volar thermoplastic wrist splint
16585569|NCT02708693|Active Comparator|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
16585570|NCT02708680|Active Comparator|Entinostat plus Atezolizumab|Patients in this arm will receive entinostat at the RP2D in combination with atezolizumab
16585571|NCT02708680|Placebo Comparator|Placebo plus Atezolizumab|Patients in this arm will receive placebo in combination with atezolizumab
16585710|NCT02707705|Experimental|: Auricular Acupuncture (needle patch) group A|Needle patch: Patients receiving the auricular acupuncture protocol with needles inserted on adhesive tape.
16585572|NCT02708654|Experimental|Intervention|Participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.(5) Research coordinators to remotely monitor weight gain thresholds and add alert into the participant's electronic health record for verified weight gain
16585573|NCT02708654|No Intervention|Control|Participants will receive usual care.
16585574|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
16585575|NCT02708628|Active Comparator|Patients using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin two times in a day.
16585576|NCT02708628|Active Comparator|Patients not using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will not use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin.
16585577|NCT02708615|Other|Vertical rotation|Vertical insertion and 90 degree rotation of speculum in vagina
16585578|NCT02708615|Other|Straight horizontal insertion|Straight horizontal insertion of speculum with no rotation in vagina
16585579|NCT02708602||β2AR Arg16Arg (AA group)|People with β2AR Arg16Arg genotype.
16585580|NCT02708602||β2AR Arg16Gly (AG group)|People with β2AR Arg16Gly genotype.
16585581|NCT02708602||β2AR Gly16Gly (GG group)|People with β2AR Gly16Gly genotype.
16585582|NCT02708602||β2AR Gln27Gln (CC group)|People with β2AR Gln16Gln genotype.
16585583|NCT02708602||β2AR Gln27Glu (CG group)|People with β2AR Gln27Glu genotype.
16585584|NCT02708602||β2AR Glu27Glu (GG group)|People with β2AR Glu27Glu genotype.
16585585|NCT02708589|Active Comparator|probiotic|the probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic (fructooligosaccharide).
16585586|NCT02708589|Placebo Comparator|Placebo|Placebo capsules have identical appearance to probiotic capsules and contain Maltodextrin.
16585587|NCT02708576|Experimental|NGM313|Administration of active NGM313
16585588|NCT02708576|Placebo Comparator|Placebo|Administration of placebo comparator
16585589|NCT02708563|Experimental|Immediate intubation|These infants will have immediate endotracheal suctioning after delivery. They will then have resuscitation per Neonatal Resuscitation Program guidelines.
16585590|NCT02708563|Experimental|Immediate resuscitation|These infants will have immediate resuscitation per the Neonatal Resuscitation Program guidelines without endotracheal suctioning.
16585591|NCT02708550|Experimental|Participatory Organizational Intervention|Participatory intervention (workshops) with workers, consultants and leaders. The workshops will find solutions for increased use of assistive devices
16585592|NCT02708550|No Intervention|Control|This group will go through the same baseline and follow-up tests as the intervention group, but will not receive any intervention.
16585593|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
16585594|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
16585595|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
16585596|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
16585597|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
16585598|NCT02708511|Experimental|Diagnostic (Cu 64 DOTA-B-Fab)|Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT 60 minutes post-injection and 24 hours post-injection
16585599|NCT02708498|Experimental|Kronoberg Educational Intervention|The educational intervention is provided to ten nursing homes.
16585600|NCT02708498|No Intervention|Skåne Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
16585601|NCT02708498|Experimental|Skåne Educational Intervention|The educational intervention is provided to ten nursing homes.
16585602|NCT02708498|No Intervention|Kronoberg Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
16585603|NCT02708485|No Intervention|Control group|No intervention
16585604|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
16585605|NCT02708472|Experimental|Open-label|"Subjects who qualify will receive daily active synchronized Transcranial Magnetic Stimulation (sTMS) treatments. Treatment will be initiated on Day 1 of the study. Subjects will come to the clinic for 5 daily treatment sessions for a total of 4 treatment weeks (20 treatment sessions). Treatment will be discontinued at the end of Week 4. Subjects will be clinically evaluated for safety and efficacy at the end of each of the four weekly treatment courses.
~At the end of Week 4, subjects who have not met the endpoint of 50% reduction in Hamilton Anxiety Rating Scale (HAM-A) score will be eligible to be considered for 2 additional weeks of daily treatment in an extended phase (for a total of 30 treatment sessions)."
16585606|NCT02708459|Active Comparator|Control|Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
16585607|NCT02708459|Active Comparator|Bupevecaine group|Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
16585608|NCT02708459|Active Comparator|Dex group|catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
16585611|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.
~In week two the alternate anesthetic would be administered.
~Mandibular molar and canine tested for pulpal anesthesia"
16585612|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.
~Mandibular molar and canine tested for pulpal anesthesia"
16585613|NCT02708420|Other|Glidescope intubation|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
16585614|NCT02708420|Other|Macintosh Laryngoscope|This standard technique involves laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
16585615|NCT02708407|Experimental|Peritoneal Dialysis Group|These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
16585616|NCT02708407|No Intervention|Control Group|These participants will continue to receive standard HF care.
16585617|NCT02708394|Experimental|olanzapine|Atypical antipsychotic
16585618|NCT02708394|Placebo Comparator|placebo|Placebo comparator
16585619|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
16585620|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
16585621|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
16585622|NCT02708355|Experimental|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
16585623|NCT02708355|Experimental|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
16585624|NCT02708355|Placebo Comparator|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
16585625|NCT02708329|Active Comparator|CTO coronary angioplasty +T-provisional stenting|Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.
16585626|NCT02708329|Experimental|CTO coronary angioplasty + Mini-crush stenting|Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.
16585627|NCT02708316||schizophrenia group|schizophrenia patients in the group
16585628|NCT02708316||control group|healthy population
16585629|NCT02708303||Foregut Surgery|Foregut surgery includes conditions of the esophagus, stomach and proximal small intestine. More specifically foregut surgery includes surgery for gastroesophageal reflux disease, hiatal hernias, and paraesophageal hernias.
16585630|NCT02708290||Test arm|The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
16585631|NCT02708290||Control arm|The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.
16585632|NCT02708277|Experimental|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
16585633|NCT02708277|Experimental|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
16585634|NCT02708264|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
16585635|NCT02708264|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
16585636|NCT02708251|Experimental|glyceryl trinitrate cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
16585637|NCT02708251|Experimental|lidocaine cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
16585638|NCT02708251|Placebo Comparator|placebo cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
16585639|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
16585640|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
16585641|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
16585642|NCT02708225|Experimental|interventional - with a medical clown|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test with a medical clown present
16585643|NCT02708225|No Intervention|non interventional|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test without a medical clown present
16585677|NCT02707965|Active Comparator|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
16585711|NCT02707705|Placebo Comparator|Needle-free patch: group P.|Patients who received the auricular acupuncture protocol with adhesive tape without needles.
16585644|NCT02708212|Active Comparator|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
16585645|NCT02708212|Active Comparator|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
16585646|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
16585647|NCT02708186|Placebo Comparator|Placebo|Placebo
16585648|NCT02708173|Experimental|One dose Vaccine in aged 18-60 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.
16585649|NCT02708173|Experimental|One dose Vaccine in aged 3-17 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.
16585650|NCT02708160|Placebo Comparator|Fluoride Free toothpaste|Fluoride free (0%), silica based toothpaste
16585651|NCT02708160|Experimental|1.1% Fluoride toothpaste|Prevident 5000 Plus, silica based toothpaste
16585652|NCT02708160|Active Comparator|0.243% Fluoride Toothpaste|silica based fluoride toothpaste
16585653|NCT02708147|Sham Comparator|Conventional treatment|"Conventional treatment means that there will be only contact with physician/paediatrician and maybe drugs prescription.
~Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after."
16585654|NCT02708147|Experimental|Physiotheraphy + Conventional treatment|Apart Conventional treatment a Physiotherapy protocol (techniques and education) will be performed on 5 sessions and evaluations will be made after each session as well as on baseline and on the 3th, 5th and 21st days and an interview 30 days after.
16585655|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
16585656|NCT02708121|Experimental|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
16585657|NCT02708121|Active Comparator|Comparator Arm|Participant receives access to weight loss treatment alone.
16585658|NCT02708108|Experimental|Obesity Intervention|Personalized 28-day Dietary Intervention and Activity and Exercise Intervention with the goal to reduce fat gain and lean muscle loss while inducing an overall negative energy balance.
16585659|NCT02708095|Experimental|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
16585660|NCT02708095|Experimental|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
16585661|NCT02708095|Placebo Comparator|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
16585662|NCT02708082||Glaucoma|Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry
16585663|NCT02708069|Other|e-Unstuck condition|Parents in the e-Unstuck condition will be asked to complete each of the e-Unstuck modules (one per week) over the course of the nine-week intervention, in addition to reading the UOT manual.
16585664|NCT02708069|Other|In-Person condition|Parents participating in the in-person condition will be asked to attend two in-person trainings (approximately 125 and 100 minutes respectively) on the Unstuck and On Target (UOT) curriculum, in addition to reading the UOT manual.
16585665|NCT02708056|Other|Sugammadex, Bridion|Drug were given intravenously by a anesthesiologist at the end of surgery
16585666|NCT02708043|Other|F-LMA group|LMA were placed to 814 patients for adenoidectomy surgery. Researchers evaluated flexible laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.
16585667|NCT02708030|Active Comparator|Ketogenic Diet|Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
16585668|NCT02708030|Experimental|Modified Atkins Diet|Modified Atkins Diet (MAD) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
16585669|NCT02708030|Experimental|Low Glycemic Index Therapy|Low Glycemic Index Therapy (LGIT) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
16585670|NCT02708017|Active Comparator|S-TAP block|ultrasound guided bilateral subcostal TAP block
16585671|NCT02708017|Active Comparator|P-TAP block|ultrasound guided bilateral Posterior TAP block
16585672|NCT02708004|Experimental|ACT-132577|3 different dose levels
16585673|NCT02708004|Placebo Comparator|Placebo|Matching active drug
16585674|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
16585675|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
16585676|NCT02707978|Experimental|Experimental F 18 T807|
16585706|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
16585707|NCT02707744||sinus rhythm|patients with heart failure and sinus rhythm
16585678|NCT02707965|Active Comparator|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
16585679|NCT02707952|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
16585680|NCT02707952|Active Comparator|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
16585681|NCT02707952|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
16585682|NCT02707952|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
16585683|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
16585684|NCT02707939||Controls|Patients with no developmental diagnoses
16585685|NCT02707913|Experimental|BF-Amlodipine Tablet 10mg|During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours
16585686|NCT02707913|Active Comparator|Norvasc Tablet 10mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours
16585687|NCT02707900|Experimental|Vorinostat + AGS-004|"Vorinostat (VOR) 400 mg PO - two paired doses at Step 2 (Enrollment) - Only participants demonstrating an in vivo response to the 2nd of the paired VOR doses will proceed to the AGS-004 manufacturing and treatment in Steps 3 through 7.
~Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal (ID) injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses."
16585688|NCT02707887|Placebo Comparator|Treatment as Usual|Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.
16585689|NCT02707887|Active Comparator|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.
16585690|NCT02707887|Active Comparator|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
16585691|NCT02707874|Active Comparator|CI 0.2% ropivacaine|"Patients in Group Continuous Infusion (CI) will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.
~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.
~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.
~3) Oral acetaminophen 1,000 mg 6 hourly."
16585692|NCT02707874|Active Comparator|PIB 0.2% ropivacaine|"Patients in Group programmed intermittent boluses (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.
~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.
~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.
~3) Oral acetaminophen 1,000 mg 6 hourly."
16585693|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):
~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial
~OR
~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial
~Administered for 48 weeks, or until ibalizumab becomes commercially available"
16585694|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):
~800 mg once every two weeks for qualifying patients who have never received ibalizumab
~Administered for 48 weeks, or until ibalizumab becomes commercially available"
16585695|NCT02707835|Active Comparator|control group|self massage, skin care education, manual lymph drainage exercise, compression garment
16585696|NCT02707835|Active Comparator|manual lymph drainage group|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
16585697|NCT02707835|Experimental|experimental group|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
16585698|NCT02707822||kidney or liver transplantation|Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.
16585699|NCT02707809|No Intervention|Control|Routine anesthesia care for kidney transplant
16585700|NCT02707809|Experimental|Dexmedetomidine|Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine
16585701|NCT02707796|Experimental|Hemicolectomy|Oxygen reserve index and partial oxygen pressure will be noted for patients undergoing hemicolectomy
16585702|NCT02707783||Bioresorbable vascular scaffold (BVS) implantation|Patients with un/stable angina that require coronary revascularization undergoing the BVS implantation
16585703|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
16585704|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
16585705|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
16585713|NCT02707692|Other|Placebo, Flu, Pneumovax|"Each subject will take Influenza (Fluarix®, GSK), Pneumococcal (Pneumovax®23, Merck), and placebo. Randomization will determine the order in which the subjects receive the injections. There are six potential study arms, one for each order in which someone could receive the injections:
~Arm 1: Placebo, Flu, Pneumovax"
16585714|NCT02707692|Other|Arm 2: Placebo, Pneumovax, Flu|Arm 2: Placebo, Pneumovax, Flu
16585715|NCT02707692|Other|Arm 3: Flu, Placebo, Pneumovax|Arm 3: Flu, Placebo, Pneumovax
16585716|NCT02707692|Other|Arm 4: Pneumovax, Placebo, Flu|Arm 4: Pneumovax, Placebo, Flu
16585717|NCT02707692|Other|Arm 5: Pneumovax, Flu, Placebo|Arm 5: Pneumovax, Flu, Placebo
16585718|NCT02707692|Other|Arm 6: Flu, Pneumovax, Placebo|Arm 6: Flu, Pneumovax, Placebo
16585719|NCT02707679|Other|Effects of Mulligan's Mobilization|The patients in this arm (n=18) received two techniques pertaining to Mulligan's Mobilization with movement approach (Mulligan's Straight Leg-Raise with Traction and Tibial Gliding) along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed before the treatment, 45 minutes after the initial treatment, at the end of the 4-session-treatment during 2-week period and 6 weeks later.
16585720|NCT02707679|Other|Effects of Kinesiotaping|Patients in this arm were applied kinesiotaping on quadriceps and hamstring muscle along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. The same assessment parameters was conducted on this arm too.
16585721|NCT02707666|Experimental|Pembrolizumab+Surgery+Chemotherapy|Neoadjuvant pembrolizumab, followed by surgery, followed by adjuvant pemetrexed and cisplatin
16585722|NCT02707653|Other|Miso|Misoprostol 400 s/l
16585723|NCT02707640|Placebo Comparator|Matching Placebo|
16585724|NCT02707640|Experimental|N-Acetylcysteine|
16585725|NCT02707640|Other|Pirfenidone|Background therapy
16585726|NCT02707627||Laser Therapy|Participants will receive laser therapy for the treatment of their hypertrophic burn scars. Laser treatment decisions will be tailored to meet the needs of the patient.
16585727|NCT02707614||Robotic vs open prostastectomy|One group is operated by open prostatectomy the other by robotic assistance
16585728|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.
~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
16585729|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.
~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
16585730|NCT02707588|Experimental|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
16585731|NCT02707588|Active Comparator|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
16585732|NCT02707575||Ranibizumab|Intravitreal Ranibizumab
16585733|NCT02707562|Experimental|GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
16585734|NCT02707549|Active Comparator|Normal Saline Group|the patients included in this group will receive normal saline solution (0.9% sodium chloride) during surgery and in the first 24 hours after ICU admission.
16585735|NCT02707549|Experimental|Balanced Crystalloid Solution Group|the patients included in this group will receive balanced crystalloid solution during surgery and in the first 24 hours after ICU admission.
16585736|NCT02707536|No Intervention|No socket grafting|Extraction with normal socket healing
16585737|NCT02707536|Active Comparator|Socket grafting with platelet rich fibrin (PRF) alone|Extraction with socket grafting with platelet rich fibrin (PRF) alone.
16585738|NCT02707536|Active Comparator|Socket grafting with bone grafting alone|Extraction with socket grafting using bone graft (xenograft).
16585739|NCT02707536|Active Comparator|Socket grafting with PRF and bone grafting|Extraction with socket grafting using PRF combined with bone graft (xenograft).
16585740|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
16585741|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
16585742|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
16585743|NCT02707510|Experimental|Intervention Arm|Patients in the intervention group will be provided with all programmatic materials (including copies of power point presentations, copies of reading texts, and audio CDs) and classes will be held in group format, with a maximum of 9 participants per group. Classes will meet weekly, in a group, and at a set time. All classes will be facilitated jointly by the two Co-PIs. All participants will complete surveys before class, during class, at the end of class, 1 month after the end of class, 6 months after the end of class and 1 year after the end of the class. Additionally, those randomized to the intervention group will be asked to attend a 1 time focus group 1 week after the end of the class.
16585744|NCT02707510|No Intervention|Control Arm|Patients in the control group will be asked to complete surveys at: baseline, 6 weeks after baseline (T1), and 1 month after T1. After T1, the control group will off study and will be permitted to attend the next available GRACE course.
16585745|NCT02707497|Experimental|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
16585746|NCT02707497|Placebo Comparator|placebo|The control group will not use any platelet-increased drugs.
16585747|NCT02707484|Experimental|Thalidomide Group（100mg）|
16585748|NCT02707484|Experimental|Thalidomide Group（50mg）|
16585749|NCT02707484|Placebo Comparator|placebo -controlled Group|
16585750|NCT02707471|Experimental|SM-AET|a self-management intervention for enhancing skills to improve adherence and reduce symptom interference (SM-AET) (active intervention group)
16585751|NCT02707471|Other|general health education Intervention|general health education Intervention (control group)
16585752|NCT02707458|Experimental|Single arm|All subjects will receive probucol, starting with a fixed dose of 600 mg daily following the evening meal. The variable plasma concentrations achieved and the resulting modification in concentration of CSF apoE will suggest an ideal range of plasma concentrations for use of the drug as an inducer of increased availability of apoE in the CSF. The known dose-proportionality of the drug in plasma will then be used to estimate an ideal individualized dose for each participant. The effects of such individualized dosage will be tested over 1 year of follow-up observations, searching for treatment effects on CSF apoE and for evidence of other treatment effects, particularly including adverse effects.
16585753|NCT02707445|Experimental|GENIUS|All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months
16585754|NCT02707432|Experimental|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
16585755|NCT02707432|Experimental|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
16585756|NCT02707419|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
16585757|NCT02707419|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
16585758|NCT02707406|Experimental|NEOX®CORD 1K|Intervention Other: hct/p human cell or tissue product: NEOX®CORD 1K Intervention other: human tissue application of of NEOX®CORD 1K on subject wound
16585759|NCT02707406|Active Comparator|Standard of Care|Intervention Other: standard of care alone Other intervention of Standard dressing with a non-adherent wound contact layer, a classic foam pad or gauze for moderately draining wounds, a secondary bandage, and institution of an investigator-approved off-loading device
16585760|NCT02707393|Experimental|single arm|Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A
16585761|NCT02707380|Active Comparator|Group 1 Resistance Training Group|Participants will perform 3 exercises, one of which will be a series of 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
16585762|NCT02707380|Active Comparator|Group 2 Standard of Care|Participants will perform 3 exercises that do not include the 7 muscle-strengthening exercises + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
16585763|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 1|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include two pre-tests and two post-tests, building in an observation period that is not present in Wave 2.
16585764|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 2|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include one pre-test and three post-tests.
16585765|NCT02707354|Experimental|Probe based confocal laser endomicroscopy (Cellvizio)|intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console.
16585766|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
16585767|NCT02707328|Experimental|A|"Chemotherapy:
~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle
~Radiation:
~20-55 GY over 5 fractions
~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy."
16585768|NCT02707315|Experimental|A|"Chemotherapy:
~Gemcitabine 1000 mg/m2 weekly x 3 on 28 day cycle
~Radiation:
~25 Gy over 5 fractions
~Surgery:
~surgical resection of pancreas
~treatment plan:
~1 cycle of chemotherapy, followed by stereotactic radiosurgery, followed by an additional 6 cycles of chemotherapy or surgical resection"
16585769|NCT02707302|Experimental|Iodophor-impregnated adhesive drapes|"In the iodophor-impregnated adhesive drapes group, routine disinfection will be carried out and bacteria samples will be harvested 1 cm from the wound site using sterilized swabs prior to use of the surgical adhesive drapes, and again at the end of surgery before skin suturing, for preoperative bacterial culture. The packaging of the 3M™ iodophor-impregnated adhesive drapes will be opened and the aseptic adhesive drapes unfolded until the stop instruction. The adhesive drapes will then be pasted to the surgical wound and smoothed using an aseptic cloth, taking care to avoid air bubbles."
16585770|NCT02707302|Experimental|Iodophor-free adhesive drapes|Patients in the iodophor-free adhesive drapes group will undergo the same procedures, but with iodophor-free drapes.
16585771|NCT02707276|Experimental|Active LFMS|Active Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
16585772|NCT02707276|Sham Comparator|Sham LFMS|Sham Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
16585773|NCT02707263|Active Comparator|Intravenous continuous infusion of heparin (IV UFH)|Heparin will be administered intravenously.
16585774|NCT02707263|Active Comparator|Subcutaneous heparin|Heparin will be subcutaneously administered.
16585775|NCT02707250|Placebo Comparator|Placebo|Oblique subcostal tap block with normal sterile saline ,20 ml, bilateral, single shot,24h
16585776|NCT02707250|Active Comparator|Bupivacaine|Oblique subcostal tap block with bupivacaine 0,25% ,20 ml, bilateral, single shot,24h
16585777|NCT02707250|Active Comparator|Pethidine|Oblique subcostal tap block with pethidine 1% ,10 ml,bilateral,single shot,24h
16585778|NCT02707250|Active Comparator|Pethidine Local Infiltration (L.I.)|Local infiltration of pethidine 1% at trocar insertion sites, 5ml /site, 24h compared with Tap Block with pethidine 1%
16585779|NCT02707237|Other|Verbal counseling|Parents with threatened delivery will receive verbal counseling only
16585780|NCT02707237|Other|Verbal, pictorial, written counseling|Parents with threatened delivery will receive verbal counseling supplemented with pictorial and written information
16585781|NCT02707224|Experimental|Group A|combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
16585782|NCT02707224|Experimental|Group B|DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
16585783|NCT02707211|Experimental|Anti-oxLDL IgM antibodies|administration Anti-oxLDL IgM antibodies
16585784|NCT02707198|No Intervention|Group A|Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
16585785|NCT02707198|Active Comparator|Group B|Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
16585786|NCT02707198|Active Comparator|Group C|Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
16585787|NCT02707185|Other|Physicians|"Physician in training:
~All internal medicine (IM), emergency medicine (EM), anesthesia (A), surgery (S) residents and all hospital ICU nurses."
16585788|NCT02707185|Other|Nurses|Nurses in Training
16585789|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.
~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
16585790|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.
~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
16585791|NCT02707159|Experimental|Nab paclitaxel / gemcitabine|Patients will receive 125 mg per m2 nab-paclitaxel and 1000 mg per m2 on days 1, 8 and 15 followed by one week of rest before new treatment cycle.
16585792|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
16585793|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
16585794|NCT02707120|Experimental|PRGF-Endoret eye-drops|
16585795|NCT02707120|Active Comparator|Artificial tears eye-drops|
16585796|NCT02707107|Active Comparator|3 g of zidebactam (1 g q8h) and 6 g of cefepime (2 g q8h) or 6|administered as IV infusions every q8h, over a period of 60 minutes.
16585797|NCT02707107|Placebo Comparator|Placebo|administered as IV infusions every q8h, over a period of 60 minutes.
16585798|NCT02707094|Other|Usual Care (Medication + Exercise)|Usual Care: Participants will receive guidance on over-the-counter and prescribed pain medications to use to treat their chronic low back pain symptoms. The Research Coordinator (RC) will provide instructions for low back pain stretching and strengthening exercises. The Licensed Provider (LP) will determine if any exercises should be excluded based on their physical limitations. Participants enrolled in the usual care treatment arm will track the frequency of their back stretching and strengthening exercise sessions on the Pain Medication & Exercise Diary. For the purpose of this study, treatment compliance will be met if participants complete the exercises a minimum of three times per week.
16585799|NCT02707094|Experimental|Biomodulator + Usual Care|Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).
16585800|NCT02707081|Placebo Comparator|Placebo control group|Saline was given both intraperitoneally and intravenously during caesarean section
16585801|NCT02707081|Active Comparator|Intraperitoneal instillation group|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.
16585802|NCT02707081|Active Comparator|Intravenous injection group|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding
16585803|NCT02707068|Experimental|QOLITI|"Intervention group receives the QOLITI (Quality Of LIfe Tool for IBD) manual immediately to work with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.
~Participants will be invited to discuss their experiences after the end of the actual study. These interviews are no obligatory part of the QOLITI study."
16585804|NCT02707068|No Intervention|Waitlist Control group (WLC)|Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions.
16585805|NCT02707055|Experimental|Active Drug|Ghrelin Receptor Inverse Agonist
16585806|NCT02707055|Other|Counseling Support|Counseling support
16585807|NCT02707055|Other|MI-VF|Motivational Interviewing with Video Feedback
16585808|NCT02707055|Placebo Comparator|Placebo|Placebo
16585809|NCT02707042|Other|Group A|Control
16585810|NCT02707042|Other|Group B|Amoxicillin
16585811|NCT02707042|Other|Group C|
16585842|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
16585813|NCT02707016|Other|High dose sevoflurane|"Inhaled sevoflurane 8% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).
~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.
~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
16585814|NCT02707016|Other|Low dose sevoflurane|"Inhaled sevoflurane 5% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).
~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.
~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
16585815|NCT02707003||AZ PACU|Observation of standard of care with capnography blinded
16585816|NCT02707003||TWH PACU|Observation of standard of care with capnography blinded
16585817|NCT02706990|Other|Physica KR|Patients who have received a Physica KR total knee implant.
16585818|NCT02706990|Other|Physica PS|Patients who have received a Physica PS total knee implant.
16585819|NCT02706977|Experimental|Diabetes Group - Low Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
16585820|NCT02706977|Experimental|Diabetes Group - High Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
16585821|NCT02706977|Other|Diabetes Group - No Electroretinogram (ERG) Delays|Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
16585822|NCT02706977|Other|Age-Matched Controls|Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.
16585823|NCT02706964|Experimental|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
16585824|NCT02706951|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.
~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
16585825|NCT02706951|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.
~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
16585826|NCT02706951|Experimental|Methotrexate / Upadacitinib 30 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.
~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
16585827|NCT02706951|Experimental|Methotrexate / Upadacitinib 15 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.
~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
16585828|NCT02706938|Other|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
16585829|NCT02706938|Other|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
16585830|NCT02706925|Experimental|BI 443651|
16585831|NCT02706925|Placebo Comparator|Placebo|
16585832|NCT02706912|Experimental|VOTA Group|All enrolled subjects are in this arm. After pre-assessment subjects have an 8-week waiting period, after which a mid-assessment takes place. Subject then participate in VOTA therapy for 8 weeks, followed by a post-assessment . The pre-/mid-assessment difference is used to control for spontaneous recovery. The mid-/post-assessment difference is used to ascertain efficacy.
16585833|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
16585834|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
16585835|NCT02706886|Placebo Comparator|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
16585836|NCT02706886|Experimental|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
16585837|NCT02706886|Experimental|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
16585838|NCT02706886|Experimental|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
16585839|NCT02706886|Experimental|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
16585840|NCT02706886|Placebo Comparator|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
16585841|NCT02706886|Experimental|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
16585843|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
16585844|NCT02706873|Active Comparator|Methotrexate|"Period 1: Participants will receive placebo to upadacitinib once daily and methotrexate once weekly for 48 weeks.
~Period 2: Participants will continue on placebo to upadacitinib once daily and methotrexate once weekly until the study is unblinded, after which participants will receive open-label methotrexate up to Week 260."
16585845|NCT02706873|Experimental|Upadacitinib 7.5 mg (Japan-only)|"Period 1: Participants will receive upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly for 48 weeks.
~Period 2: Participants will continue on upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 7.5 mg up to Week 260."
16585846|NCT02706873|Experimental|Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily and placebo to methotrexate once weekly for 48 weeks.
~Period 2: Participants will continue on upadacitinib 15 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 15 mg up to Week 260."
16585847|NCT02706873|Experimental|Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily and placebo to methotrexate once weekly for 48 weeks.
~Period 2: Participants will continue on upadacitinib 30 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 30 mg once daily. After implementation of Protocol Amendment 6 participants will receive upadacitinib 15 mg once daily up to Week 260."
16585848|NCT02706860|Experimental|"80 mg atorvastatin for 2 days regimen"|80 mg atorvastatin/ day for 2 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
16585849|NCT02706860|Experimental|"40 mg atorvastatin for 5-9 days preoperative regime"|40 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
16585850|NCT02706860|Experimental|"80 mg atorvastatin for 5-9 days preoperative regime"|80 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
16585851|NCT02706847|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks.
~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
16585852|NCT02706847|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks.
~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
16585853|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks.
~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
16585854|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks.
~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
16585855|NCT02706834|Experimental|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585856|NCT02706834|Experimental|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585857|NCT02706834|Experimental|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585858|NCT02706834|Experimental|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585859|NCT02706834|Experimental|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585884|NCT02706652||all patients|all eligible patients
16585885|NCT02706639||SVAS group|Children or adults must:be between the ages of 0-85; have clinical features of SVAS; SVAS-like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
16585959|NCT02706158|Experimental|supplement and balanced diet|"Woman at high risk of pre-eclampsia:
~supplements. 1500 mg Calcium and 1200 IU Vitamin D for 2 months. balanced diet."
16585860|NCT02706834|Experimental|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585861|NCT02706834|Experimental|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
16585862|NCT02706834|Experimental|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
16585863|NCT02706834|Experimental|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
16585864|NCT02706834|Experimental|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
16585865|NCT02706834|Experimental|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
16585866|NCT02706821|Active Comparator|Treatment sequence 1|PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
16585867|NCT02706821|Active Comparator|Treatment sequence 2|Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
16585868|NCT02706808|Experimental|resistance starch for CKD|- Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
16585869|NCT02706808|Experimental|cross-over period|intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
16585870|NCT02706795|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
16585871|NCT02706782|Experimental|TAI-meso-CART|A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions. The dose is 1-10x106/kg meso-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. Patients will undergo cannula--DSA radiography--CAR-T cells perfusion. The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
16585872|NCT02706769|Active Comparator|Paracetamol|Participants will take blinded Paracetamol (as they were taking before entering the study)
16585873|NCT02706769|Placebo Comparator|Placebo|Participants will take blinded Paracetamol
16585874|NCT02706756|Experimental|Education, exercise and manual therapy|"One group will receive education and advice, manual therapy that is applied toward the impairments of the subject, a prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Subjects will be seen twice weekly for 4 to 6 weeks, depending on the progression.
~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
16585875|NCT02706756|Active Comparator|Education and exercise|"Group will receive a prescriptive intervention designed to strengthen the hip and surrounding regions as well as improve flexibility of the lower extremity. This group will not receive additional physiotherapy management but will be schedule bi-weekly to review the home exercises and to receive appropriate educational support.
~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
16585876|NCT02706756|Placebo Comparator|Supervised neglect|"Group will receive supervised neglect. We will monitor this group for changes or emergent situations but no formal care will be provided.
~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
16585877|NCT02706730|Experimental|OTO-104|12 mg dexamethasone
16585878|NCT02706717|Active Comparator|Visbiome Extra Strength|
16585879|NCT02706717|Placebo Comparator|Placebo for Visbiome Extra Strength|
16585880|NCT02706704|Active Comparator|Intravitreal|Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
16585881|NCT02706704|Active Comparator|Systemic|Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
16585882|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
16585883|NCT02706678|Experimental|Tacrolimus sustained-release capsule group|Oral
16585886|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85 have a presumed or confirmed diagnosis of WS; have a parent/guardian available to provide consent and assist in answering medical questions
16585887|NCT02706626|Experimental|Brigatinib|Experimental: Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent
16585888|NCT02706613|Other|Face to Face Pulmonary Rehabilitaton|6 week incremental pulmonary rehabilitation (PR) programme. Participants will attend 12 sessions over the 6 week period. The components of the PR programme will include an exercise programme. Education sessions will also be provided and include anatomy of the lungs and what is COPD, anxiety and depression, self management, managing breathlessness, medications and treatments, managing exacerbations of COPD and chest infections, clearing sputum and the Active Cycle of Breathing Technique, nutrition, pacing, smoking cessation. Participants on the face to face arm will also be instructed to carry out the pulmonary rehabilitation exercises an additional three times a week at home.
16585889|NCT02706613|Active Comparator|Online Pulmonary Rehabilitation|Those randomised to receive the online programme will be given log-in details and a password, and instructions to begin the 6 week programme at home. The online programme mirrors the conventional face-to-face PR programme and the exercise and educational components are given by means of instructional videos. Participants will be instructed to exercise five times a week. Participants in the online arm will receive during the PR course telephone contact to record any adverse or serious adverse events.
16585890|NCT02706600|Other|Written Self Management|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
16585891|NCT02706600|Active Comparator|Online Self Management|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.
~Medication and symptom diaries. Appointment diary, pulmonary rehabilitation videos to promote and support exercises that can be done in the home.
~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.
~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
16585892|NCT02706587|Experimental|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
16585893|NCT02706587|Sham Comparator|Sham Control|No electrostimulation
16585894|NCT02706574||Isolated Traumatic Brain Injury|This group will present to our Level 1 Trauma Center with a Traumatic Brain Injury and no other associated injuries. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
16585895|NCT02706574||Isolated Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient with no injury to their head. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
16585896|NCT02706574||Combined Traumatic Brain Injury and Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient that had injuries to both their head and body. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
16585897|NCT02706574||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
16585898|NCT02706561|Experimental|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
16585899|NCT02706561|Experimental|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
16585900|NCT02706548|Experimental|Occupational Therapy Intervention Group|Thirty-minute intervention in which the participant and interventionist discuss past medication taking performance, medication-related goals, and strategies to meet goals. Intervention is enhanced with motivational interviewing and therapeutic use of self.
16585901|NCT02706548|Active Comparator|Standard Care Intervention Group|Thirty-minute educational intervention in which the participant and interventionist review a pamphlet on adherence to medication.
16585954|NCT02706184|Experimental|Intervention|Patients receive E. coli Nissle suspension
16585955|NCT02706184|Placebo Comparator|Control|Patients receive placebo
16586022|NCT02705729|Active Comparator|Ketac Universal|Simplified glass ionomer tooth filling
16585902|NCT02706535|Experimental|Part 1 Cohort 1|Subjects will receive a single dose of GSK525762 10 mg on Day 1 followed by 200 mg Itraconazole two times a day (BID) on Day 3. On Day 4 to Day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On Day 7 subjects will receive a single dose of GSK525762 5 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
16585903|NCT02706535|Experimental|Part 1 Cohort 2|Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
16585904|NCT02706535|Experimental|Part 2|Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
16585905|NCT02706522|Experimental|Allocated to Carbohydrated group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Carbohydrated group
~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
16585906|NCT02706522|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Placebo group
~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
16585907|NCT02706509|Active Comparator|oral tramadol|Patients will receive oral Tramadol 50 mg capsules (n=50)' . After an hour, Jaydess intrauterine device will be inserted.
16585908|NCT02706509|Sham Comparator|verbal anesthesia|'verbal anesthesia' (n=50) After an hour, Jaydess intrauterine device will be inserted
16585909|NCT02706496||young adults (20-35yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
16585910|NCT02706496||middle age(45-60yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
16585911|NCT02706496||elderly(65-74yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
16585912|NCT02706483|Experimental|Plecanatide|Plecanatide 6.0 mg tablets
16585913|NCT02706470|Experimental|Cyclosporin A|Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.
16585914|NCT02706470|Active Comparator|Dydrogesterone|Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.
16585915|NCT02706457||cohort 2012 - 2014|all patients admitted for > 48 hours on the Intensive Care Unit in 2012, 2013 and 2014
16585916|NCT02706444|Active Comparator|Conventional Balloon Angioplasty|Conventional balloon angioplasty. After fistulogram, full expansion of conventional balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
16585917|NCT02706444|Active Comparator|Drug-Coated Balloon Angioplasty|Drug-coated balloon angioplasty. After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
16585918|NCT02706431|No Intervention|Normoventilation|The patients will be normoventilated before anesthesia
16585919|NCT02706431|Experimental|Hyperventilation|Prior to anesthesia, the patients will hyperventilate during 2 mins or until symptoms from the central nervous system (e.g. dizziness).
16585920|NCT02706418|Other|Clinical Massage Therapy|
16585921|NCT02706405|Experimental|Group I (JCAR014, durvalumab)|Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
16585922|NCT02706405|Experimental|Group II (durvalumab, JCAR014)|Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
16585924|NCT02706379|Experimental|Local cerebral oxygen saturation|use NIRS technical to detect local cerebral oxygen saturation of both sides of brain
16585956|NCT02706171|Experimental|A: pre-operative|"Radiation- CyberKnife:
~35-40 Gy over 5 fractions
~Surgery:
~Surgical resection of sarcoma"
16585957|NCT02706171|Experimental|B: Post-operative|"Radiation- CyberKnife:
~40 Gy over 5 fractions"
16585958|NCT02706171|Experimental|C: Non-resectable|"Radiation- CyberKnife:
~50 Gy over 5 fractions"
16585925|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:
~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.
~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
~Dose Expansion Phase:
~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.
~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
16585926|NCT02706340||Vaginal delivery|Women who have had a copper IUD placed within 10 minutes of a vaginal delivery of at least 34 weeks 0 days gestation.
16585927|NCT02706340||Cesarean delivery|Women who have had a copper IUD placed within 10 minutes of a cesarean delivery of at least 34 weeks 0 days gestation.
16585928|NCT02706327|Experimental|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
16585929|NCT02706327|Experimental|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
16585930|NCT02706327|Placebo Comparator|Control|8-week follow-up with placebo insole and home based exercise program
16585931|NCT02706314||Critically ill patients with CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 with CIP
16585932|NCT02706314||Critically ill patients without CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 without CIP
16585933|NCT02706314||Healthy volunteers|Healthy volunteers with neither critical illness nor CIP
16585934|NCT02706301|Experimental|Telephone-Based Coping Skills Training (CST)|The CST condition will receive 5 sessions of a cognitive behavior theory-based protocol that teaches coping skills (e.g., relaxation, activity pacing/planning, cognitive restructuring) relevant to managing pain as well as psychological distress.
16585935|NCT02706301|No Intervention|Standard care control|The standard care control condition will receive resources and referrals related to survivorship health. This information will be provided to the participant during their initial survivorship care consult.
16585936|NCT02706288|Experimental|Weight loss with diet with exercise|Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after 7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until 7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
16585937|NCT02706275|Experimental|Warming Group|External warming via forced air warming
16585938|NCT02706275|No Intervention|Control Group|Standard of care body temperature management
16585939|NCT02706262|No Intervention|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
~Dietary intervention - None."
16585940|NCT02706262|No Intervention|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
~Dietary intervention - None."
16585941|NCT02706262|Experimental|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.
~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
16585942|NCT02706262|Experimental|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.
~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
16585943|NCT02706262|Experimental|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.
~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
16585944|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.
~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
16585945|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.
~On study Enoxaparin will be administered for up 14 days during hospitalization."
16585946|NCT02706236|Active Comparator|Intervention Arm|Pancreatic enzyme replacement (Pancrelipase) with meals and snacks daily, for 4 weeks.
16585947|NCT02706236|Placebo Comparator|Placebo Arm|Lactose placebo tablets with meals and snacks, for 4 weeks.
16585948|NCT02706223|Experimental|Pharmacist Led|This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
16585949|NCT02706223|Experimental|Nurse Led|This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
16585950|NCT02706210||vascular cognitive disorders pre-dementia (VCD-P)|
16585951|NCT02706210||amnestic mild cognitive impairment (aMCI)|
16585952|NCT02706197|Experimental|IA No treatment except standard-of-care (SOC) surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
16585953|NCT02706197|Experimental|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
16585960|NCT02706158|No Intervention|women without nutrition or supplement intervention|usual follow-up in the gynecology out patient clinic, without nutrition or supplement intervention.
16585961|NCT02706145|Experimental|Intervention Group (West Louisville)|This group will be exposed to the social norming campaign via traditional, mass, and social media over the three-year intervention period.
16585962|NCT02706145|No Intervention|Control Group (East Nashville)|This group will serve as the control group, and measures of social norms and attitudes toward violence will be compared between this group and the intervention group.
16585963|NCT02706132|Experimental|The MSCs group|The group of patients receive allogeneic MSCs therapies.
16585964|NCT02706119|Experimental|Glargine insulin|Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
16585965|NCT02706119|Active Comparator|Regular insulin|Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
16585966|NCT02706106|Experimental|Knee brace with a hole|Patients will be prepared to receive the device of knee brace with a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
16585967|NCT02706106|Placebo Comparator|Knee brace without a hole|Patients will be prepared to receive the device of knee brace without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
16585968|NCT02706093|Other|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
16585969|NCT02706093|Other|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
16585970|NCT02706093|Other|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
16585971|NCT02706093|Other|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
16585972|NCT02706080||Antithrombotic agents|We propose to realize a single-center prospective registry of patient under Antithrombotic agent who came to the emergency unit for any reason.
16585973|NCT02706067|Experimental|Orlistat|Participants will receive intermittent orlistat for up to 4 years, with the dose determined according to body weight changes.
16585974|NCT02706054|Placebo Comparator|C-group|patients receiving an IM saline injection near the nerve root (periradicular)
16585975|NCT02706054|Experimental|M-group|patients receiving an IM Meloxicam injection near the nerve root (periradicular)
16585976|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
16585977|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
16585978|NCT02706028|Active Comparator|ultrasound group|Patients in the ultrasound group received underwater US therapy to both hands and wrists for 7 minutes with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
16585979|NCT02706028|Sham Comparator|control group|The control group received sham treatment (the ULTRON home OE-302® device was not turned on) during 10 sessions for 7 minutes per session.
16585980|NCT02706015|Experimental|Cefaliv® & Placebo|Dihydroergotamine mesylate+ dipyrone sodium + caffeine
16585981|NCT02706015|Active Comparator|Neosaldina® & Placebo|Isometheptene mucate + dipyrone sodium + anhydrous caffeine
16585982|NCT02706002|Active Comparator|hip prosthesis under fluoroscopy|implantation of femoral stem of hip prosthesis in this group of patients are under fluoroscopic guidance for stem size and stem alignment and last rap before original stem implantation will be checked for alignment , lateral and vertical offsets parameters.
16585983|NCT02706002|Sham Comparator|hip prosthesis without fluoroscopy|in this group of patients rasping of femoral canal during hip prosthesis is made via anatomic landmarks which confirmed by to senior surgeons and than original stem implanted.
16585984|NCT02705989|Placebo Comparator|Single Ascending Dose (SAD)|Single ascending dose of BMS-986195 or Placebo matching BMS-986195
16585985|NCT02705989|Placebo Comparator|Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
16585986|NCT02705989|Placebo Comparator|Japanese-Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
16585987|NCT02705989|Experimental|Relative Bioavailability with Food Effects (Open Label)|
16585988|NCT02705976|Active Comparator|self-managing warfarin|self-managing warfarin patients who are educated in dosing warfarin to achieve target INR value
16585989|NCT02705976|Experimental|algorithm-suggested warfarin dosing|algorithm-suggested warfarin dosing, where the participants are provided with a dosage suggestion of their warfarin dosage (calculated dose) to achieve target INR
16586023|NCT02705729|Active Comparator|Ketac Molar Quick|Glass ionomer tooth filling
16586055|NCT02705469|Experimental|Dose Escalation and Dose Confirmation - ZEN003694 Single Agent|ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
16585990|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
16585991|NCT02705950|Active Comparator|intrathecal baclofen bolus|In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
16585992|NCT02705950|Placebo Comparator|placebo|In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
16585993|NCT02705937|Experimental|Dairy product|The product will be taken for 14 days
16585994|NCT02705937|Active Comparator|Aequasyal mouth spray medical device|The spray will be taken for 14 days
16585995|NCT02705924|Experimental|Psychoeducational intervention|group participating to the first psychoeducational intervention: it consists in a week-end session in a SPA center including several conferences about HBOC familial risk, cancer prevention, prophylactic possibilities (surgery), recommendations about nutrition and physical activity a risk modulators, assisted medical procreation and embryo selection, social support...). Besides conferences, Moreno role games and group sharing are organized under the supervision of a psychotherapist.
16585996|NCT02705924|Other|Waiting list|delayed intervention: group participating to the second psychoeducational intervention (6 months later). Intervention is same as in the intervention arm but it is delayed. Because questionnaires are completed before this second intervention in both arms and allocation to arms are randomized, it represents an adequate control group.
16585997|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
16585998|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
16585999|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
16586000|NCT02705898|Experimental|LPA+Fitbit|A 12-week LPA+Fitbit intervention for depressed women in intensive alcohol treatment. This will include: 1) a single in-person physical activity (PA) counseling orientation session; 2) 6 brief, phone-based PA counseling sessions focused on increasing PA and strategically using bouts of PA to cope with affect and alcohol cravings; 3) use of the Fitbit fitness tracker for physical activity goal-setting and daily self-monitoring; and 4) weekly supportive messages delivered by email.
16586001|NCT02705898|Active Comparator|Health Education Contact Control (HEC)|The HEC condition will include: 1) an in-person orientation session, 2) 6 telephone-delivered health education sessions, and 3) weekly health-related e-mails. A variety of health and lifestyle topics will be addressed including the following: Session 1 (week 1) - Nutrition-What to Eat and What Not to Eat; Session 2 (week 2) - Sleep Problems and Sleep Hygiene; Session 3 (week 4) - Alcohol Use among Women; Session 4 (week 6) - Relaxation training; Session 5 (week 8) - Time Management and Assertiveness; and Session 6 (week 10) - Being a Smart Patient when Coordinating your Healthcare.
16586002|NCT02705885|Experimental|Gingipain IgY|Participants consume lozenges containing IgY against gingipains of Porphyromonas gingivalis
16586003|NCT02705885|Placebo Comparator|Placebo IgY|Participants consume lozenges containing placebo IgY
16586004|NCT02705872|Experimental|Programmed intermittent boluses|Epidural analgesia performed with programmed intermittent boluses.
16586005|NCT02705872|Active Comparator|Continuous perfusion|Epidural analgesia performed with a continuous perfusion.
16586006|NCT02705859|Other|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.
~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
16586007|NCT02705846||BRCA1 mutation carriers|Men with a known pathogenic germline BRCA1 mutation
16586008|NCT02705846||BRCA2 mutation carriers|Men with a known pathogenic germline BRCA2 mutation
16586009|NCT02705846||BRCA1 controls|Men known not to carry a pathogenic germline BRCA1 mutation
16586010|NCT02705846||BRCA2 controls|Men known not to carry a pathogenic germline BRCA2 mutation
16586011|NCT02705833||Population with R/M SCCHN|Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection
16586012|NCT02705820|Experimental|single arm study|experimental treatment with maintenance pembrolizumab
16586013|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
16586014|NCT02705781|Experimental|General|One arm study: smARTrack Feeding Tube System.
16586015|NCT02705768|No Intervention|Healthy control|Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
16586016|NCT02705768|Experimental|Carbamazepine group|Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
16586017|NCT02705768|Experimental|Oxcarbazepine group|Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
16586018|NCT02705755|Experimental|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
16586019|NCT02705755|Experimental|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
16586020|NCT02705755|Experimental|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
16586021|NCT02705742|Other|stem cells group|mesenchymal stem cells only
16586024|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
16586025|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
16586026|NCT02705703|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
16586027|NCT02705677||Rett syndrome|This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.
16586028|NCT02705677||MECP2 Duplication disorder|This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.
16586029|NCT02705677||Rett-related disorders: CDKL5, FOXG1|This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
16586030|NCT02705664|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 7 weeks on all affected toenails of one foot
16586031|NCT02705664|Active Comparator|Urea Ointment + Bifonazole Cream|"On the opposite foot:
~Urea 40% ointment to be applied once a day under occlusion for 2-3 weeks depending on the achievement of optimal diseased toenail plates removal)
~Bifonazole 1% cream to be applied for 4 weeks on affected toenails (after the maximum 3-week treatment period with Urea ointment)"
16586032|NCT02705651|Experimental|Somatostatin-Analog|A long acting somatostatin analog will be applied.
16586033|NCT02705651|No Intervention|No treatment|This arm will be be the observational control according to the endpoints of the study. No intervention will be made.
16586034|NCT02705638|Experimental|Rituximab and Lenalidomide|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
16586035|NCT02705625|Experimental|MIV-711:1|MIV-711 for a total of 26 w
16586036|NCT02705625|Experimental|MIV-711:2|MIV-711 for a total of 26 w
16586037|NCT02705625|Placebo Comparator|Placebo|Placebo for a total of 26 w
16586038|NCT02705612|Other|control group|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
16586039|NCT02705612|Experimental|experimental group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group. Patients also receive nimotuzumab during the external radiotherapy.
16586040|NCT02705586|Experimental|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
16586041|NCT02705573|Experimental|Mannitol 20%|Mannitol 1g/ kg BW
16586042|NCT02705573|Placebo Comparator|Nacl 0.9%|NaCl 0.9% 5ml/ kg BW
16586043|NCT02705560|Experimental|Cow´s milk (3.9% fat, pasteurized)|Cow´s milk (3.9% fat, pasteurized) Single dose, 600 ml milk
16586044|NCT02705560|Experimental|Hard, yellow cheese|"Hard, yellow cheese Single dose, 100 g cheese
~+ 500 ml water"
16586045|NCT02705560|Active Comparator|Soy based drink|Soy based drink Single dose, 600 ml soy drink (soy drink + plant based cream)
16586046|NCT02705547|Experimental|Rosuvastatin (Crestor)|This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
16586047|NCT02705534|Experimental|Treatment|Subjects will receive sofosbuvir, ledipasvir and ribavirin
16586048|NCT02705521|No Intervention|Treatment as usual group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). They will be assessed for progression and be provided with a home exercise program. Range of motion in their shoulder will be collected on a weekly basis using the MIRA technology. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
16586049|NCT02705521|Experimental|Treatment as usual plus Exergames group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). Rather than use a home exercise program patients will be provided with a laptop computer and kinect sensor. they will use the new technology to play 'Exergames' each program will be tailored to the patients progress and patients can play the system as often as they wish. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
16586050|NCT02705508|Experimental|PEG group|Treatment PEG dosages were as follows: days 1 and 8,30min intravenous infusion of 1000mg/m2 gemcitabine;day1,4h intravenous infusion of 100mg/m2 etoposide,day1-3,deep intramuscular injection of 2500U/m2 Pegaspargase at three different sites.The regimen was repeated every 3 weeks.Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved-field radiation (IFRT) dose was 50-56 Gy.Stage IIIE/IVE patients were given for a maximum of six cycles.
16586051|NCT02705495|Active Comparator|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
16586052|NCT02705495|Other|Control|Recommendation for use of cranberry products only
16586053|NCT02705482|Experimental|Arm A: MEDI0562 and durvalumab|MEDI0562 and durvalumab
16586054|NCT02705482|Experimental|Arm B: MEDI0562 and tremelimumab|MEDI0562 and tremelimumab
16586056|NCT02705456|Experimental|HA-Tooth Paste|"Tooth Brushing HA
~Cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite twice daily over the duration of the study (24 weeks).
~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
16586057|NCT02705456|Active Comparator|FL-Tooth Paste|"Tooth Brushing FL
~Cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste twice daily over the duration of the study (24 weeks).
~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
16586058|NCT02705443||Tissue w/ Thermographic Anomaly|"Visibly undamaged tissue with anomaly identified by the thermographic image
~No intervention
~Standard of care"
16586059|NCT02705443||Tissue w/o Thermographic Anomaly|"Visibly undamaged tissue with no anomaly identified by the thermographic image
~No intervention
~Standard of care"
16586060|NCT02705443||Tissue w/ Visible Anomaly|"Visibly damaged tissue
~No intervention
~Standard of care"
16586061|NCT02705430|No Intervention|A|Group A will continue their actual therapy (control).
16586062|NCT02705430|Experimental|B|Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study
16586063|NCT02705430|Experimental|C|Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study
16586064|NCT02705430|Experimental|D|Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study
16586065|NCT02705417||Group A|Patients in whom selection of vascular access relied upon physical examination and medical history, during pre-operative surgical assessment
16586066|NCT02705417||Group B|Patients who underwent vascular mapping using color Doppler Ultrasonography in addition to physical examination and history during pre-operative evaluation.
16586067|NCT02705378|Active Comparator|Polyethylene glycol|17g power qday; reconstituted in water for naso/orogastric tube administration
16586068|NCT02705378|Experimental|naloxegol|25mg qday; crushed pill reconstituted in water for naso/orogastric tube administration
16586069|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
16586070|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
16586071|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
16586072|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
16586073|NCT02705339|Experimental|Arm 1: Rociletinib|"Rociletinib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg twice per day during each 28-day cycle.
~After completion of cycle 1, patients who tolerate the 500 mg twice per day dose without significant adverse effect may increase dosing to 625 mg twice per day at the discretion of the investigator"
16586074|NCT02705326|Experimental|Opti-Speech|Speech treatment will be guided by Opti-Speech's visual feedback of tongue movement during speech
16586075|NCT02705300|Experimental|Chemotherapy plus tocotrienol|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.
~Daily: Tocotrienol 300 mg x 3 daily"
16586076|NCT02705300|Placebo Comparator|Chemotherapy plus placebo|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.
~Daily: Placebo x 3 daily"
16586077|NCT02705287||Vitamin D dynamics-pregnant|Pregnant women recruited to measure Vitamin D dynamics during pregnancy.
16586078|NCT02705287||Vitamin D dynamics-nonpregnant|Non-pregnant women recruited to measure Vitamin D dynamics.
16586079|NCT02705287||Delivery-placental transfer|Pregnant women planning to deliver by scheduled c-section who will be dosed with vitamin D3 in late gestation (week 36-38).
16586080|NCT02705287||Delivery-Vitamin D|Pregnant women will be dosed with vitamin D3 at term when they come in for their pre-surgical appointments prior to their scheduled c-section
16586081|NCT02705287||Delivery-25(OH) Vitamin D|Pregnant women will be dosed with 25(OH)D3 when they come in for their pre-surgical appointments
16586082|NCT02705274|Active Comparator|Prompt Panretinal Photocoagulation|PRP= Panretinal Photocoagulation. PRP alone.
16586083|NCT02705274|Experimental|Bevacizumab with deferred PRP|Bevacizumab = Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
16586084|NCT02705261|Experimental|Cognitive-behavior therapy|Cognitive-behavior therapy to teach parents the skills to help their children. Participants will have access to the program as often as they wish and have the post assessment at week 12.
16586085|NCT02705248||Group A|(Group A) case group: 40 pregnant females at 6- 13wks presenting with a history of recurrent pregnancy loss (two or more failed clinical pregnancies as documented by ultrasonography or histopathology examination according to the American Society of Reproductive Medicine) (ASRM, 2008).
16586086|NCT02705248||Group B|control group: 40 pregnant females at 6- 13wks with no history of abortion.
16586087|NCT02705222|Active Comparator|D&C group|Women will undergo D&C
16586088|NCT02705222|Active Comparator|Hysteroscopy group|Women will undergo hysteroscopy
16586089|NCT02705209|Active Comparator|Treatment|
16586091|NCT02705196|Experimental|Arm 1 Intratumoral LOAd703|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment.
~The following LOAd703 doses will be evaluated:
~Dose level 1: 5 X 10^10 viral particles per treatment Dose level 2: 1 X 10^11 viral particles per treatment Dose level 3: 5 X 10^11 viral particles per treatment"
16586092|NCT02705196|Experimental|Arm 2: Intratumoral LOAd703 + atezolizumab|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment. A fixed dose of atezolizumab 1680 mg will be given every 4 weeks on day 1 of each chemotherapy cycle.
~Patients will be assigned to the following LOAd703 doses:
~Dose level 1: 1 X 10^11 viral particles per treatment Dose level 2: 5 X 10^11 viral particles per treatment"
16586093|NCT02705183|Active Comparator|A: Surgery & Post-operative radiotherapy|Surgery & Post-operative radiotherapy
16586094|NCT02705183|No Intervention|B: Surgery only|Surgery only
16586095|NCT02705170||left ventricle dilatation|The subjects of the investigation will be patients with recent diagnosis of unknown left ventricle dilatation. These subjects received coronary artery angiography as exam suggested by guidelines to discriminate the cause of left ventricle dilatation. In subjects without documentation of coronary artery lesions, the Authors will assess the index of microvascular resistance.
16586096|NCT02705157||Bone metastasis of the long bone|Patients with bone metastases of the long bone(s) receiving surgical stabilisation of a pathologic or impending fracture or receiving radiotherapy for a painful metastasis.
16586097|NCT02705144||biopsies from lung tissue affected by emphysema|analysis of the number of stem cell niches
16586098|NCT02705144||biopsies from lung tissue affected by interstitial fibrosis|analysis of the number of stem cell niches
16586099|NCT02705144||biopsies from normal appearance lung tissue|analysis of the number of stem cell niches
16586100|NCT02705131|Experimental|Balance Chiropractic Therapy(BCT)|patients are in the sitting position and receive the Balance Chiropractic Therapy(BCT) .1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.The patients will received BCT 1 time every other day, 20min each time. a total of 10 times in 20 days.
16586101|NCT02705131|Active Comparator|Traction Therapy(TT)|patients will receive the Traction Therapy(TT):The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
16586102|NCT02705118|Experimental|Automatic registration arm|"Automatic registration for fusion imaging of US and MRI will be performed.
~Automatic Imaging fusion of ultrasonography and MRI"
16586103|NCT02705118|Active Comparator|Manual registration arm|"Manual registration for fusion imaging of US and MRI will be performed.
~Manual Imaging fusion of ultrasonography and MRI"
16586104|NCT02705105|Experimental|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab
~If >1 patient has a DLT at first dose level, then the following cohort will be enrolled:
~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
16586105|NCT02705105|Experimental|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab
~Subjects will be separated further into cohorts by tumor type"
16586106|NCT02705092|Experimental|Subliminal priming with subliminal reward stimuli|"This intervention consisted of five presentations [three cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal priming (displayed for 17 ms), and positive words as subliminal reward (displayed for 17 ms)].
~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
16586107|NCT02705092|Experimental|Subliminal priming with supraliminal reward stimuli|"This intervention consisted of four presentations [two cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal prime (displayed for 17 ms), and positive words as supraliminal reward (displayed for 150 ms)].
~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
16586108|NCT02705066|Placebo Comparator|Placebo (Cellulose)|
16586109|NCT02705066|Experimental|Cognizin 250 mg/day|
16586110|NCT02705066|Experimental|Cognizin 500 mg/day|
16586111|NCT02705053|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 2)|The subjects' Sensor-Augmented Pump Open-Loop Care for the second week of the study before any adjustments to pump settings, using a CGM and Insulin Pump.
16586112|NCT02705053|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on CGM glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device. Algorithmic adjustment of carbohydrate ratios prior to closed-loop initiation, and continued basal rate and carbohydrate ratio algorithmic optimization during closed-loop use will occur.
16586113|NCT02705040||Normal|bone mineral density T>=-1.0
16586114|NCT02705040||Osteopenia|bone mineral density -1.0>T>=-2.5
16586115|NCT02705040||Osteoporosis|bone mineral density T<-2.5
16586116|NCT02705027|Active Comparator|Standard|"After randomization one half of the patients receive a Freka®-Trilumina probe, which is inserted in nasogastric route an then pushed  using a small forceps which is inserted through the endoscope into the small intestine."
16586181|NCT02704585|Other|Masimo|Connection to Masimo pulse oximeter for measuring oxygen saturation after birth
16588535|NCT02688543|Experimental|RF treatment|Patients treated with radio frequency of the genicular nerves
16586117|NCT02705027|Experimental|Freka®-EasyIn|The other half of the patients will receive a Freka®-EasyIn probe which is directly placed in the small intestine inserted over the endoscope, after endoscopy was initially pushed - as far as possible - into the small intestine.
16586118|NCT02705014|Experimental|treatment group|patients were administered with pulsatile gonadotropin-releasing hormone (GnRH )therapy for 12 months at an interval of 90 minutes.The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L.
16586119|NCT02704988|Active Comparator|Colon Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
16586120|NCT02704988|Active Comparator|Colon Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
16586121|NCT02704988|Active Comparator|Rectal Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
16586122|NCT02704988|Active Comparator|Rectal Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
16586123|NCT02704975|Experimental|Rehabilitation and Dry Needling|Standard Rehabilitation Protocol following shoulder stabilization surgery and Dry Needling to the Shoulder girdle 1 time a week for 4 weeks between weeks 4 and 8 post operatively
16586124|NCT02704975|Active Comparator|Rehabilitation|Standard Rehabilitation Protocol following shoulder stabilization surgery alone
16586125|NCT02704962|Experimental|trifluoperazine plus olanzapine|trifluoperazine 5mg/day + olanzapine 5mg/day
16586126|NCT02704962|Active Comparator|full-dose olanzapine|olanzapine 10mg/day
16586127|NCT02704949|Experimental|Low-dose|The intervention is to use 1/4 fluoroscopy dose while the ureteroscopy is being performed
16586128|NCT02704949|Active Comparator|Full-dose|The intervention is to use full fluoroscopy dose while the ureteroscopy is being performed
16586129|NCT02704936||Male donor|42 samples of semen from male donor attached to a donation program Normal sperm count as WHO 2010.
16586130|NCT02704936||IUI positive pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and have obtained positive pregnancy in any of the first 4 treatments IUI
16586131|NCT02704936||IUI unsuccessful pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and after undergoing maximum 4 cycles have unsuccessfully IUI indication of IVF / ICSI.
16586132|NCT02704923|Active Comparator|Atropine|
16586133|NCT02704923|Placebo Comparator|Placebo|
16586134|NCT02704910|Placebo Comparator|Voluntary subject|Patient without parkinson disease, without deep brain stimulation
16586135|NCT02704910|Active Comparator|Patients|Subthalamic stimulation
16586136|NCT02704897|Experimental|Intervention Arm|"Wound assessment tool - delivered via a smartphone. A link will be sent to participants on discharge, which can be accessed at any point should they have concerns about their wound.
~They will also be sent the tool at 3 additional time-points."
16586137|NCT02704897|No Intervention|Control Arm|Normal Post-operative Care
16586138|NCT02704884|Experimental|probiotic soy milk|consume a diet containing 200 ml/day probiotic soy milk in intervention group
16586139|NCT02704884|Active Comparator|soy milk|200 ml/day soy milk in the control condition
16586141|NCT02704845||Ankylosing Spondylitis|
16586142|NCT02704845||Chronic non-specific low back pain|
16586143|NCT02704832|No Intervention|Arm A|"Arm A Standard oncological care: patients will be treated according to daily oncological practices as defined for each type of cancer, in the Management protocol of Oncology written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months."
16586144|NCT02704832|Experimental|Arm B|"Arm B Geriatrician Intervention: patients will be treated according to the same Management protocol of Oncology than patients in the arm Standard oncological care.
~Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the Management protocol of Geriatrics.
~The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months."
16586230|NCT02704247|Experimental|Testing CARDIOSPACE System|Healthy volunteers have to test CARDIOSPACE System
16586145|NCT02704819|Experimental|Non-specialist doctor +DSS|"Patients allocated to +DSS group will receive the following intervention:
~V1: appointment with a non-specialist doctor with the support of the DSS
~V2: appointment with an overseeing expert
~V3: DSS Customised Vestibular Physiotherapy
~V4: follow-up visit with the overseeing expert"
16586146|NCT02704819|Active Comparator|Non-specialist doctor -DSS|"Patients allocated to -DSS group will receive the following intervention:
~V1: appointment with a non-specialist doctor without the support of the DSS
~V2: appointment with an overseeing expert
~V3: Standard Physiotherapy Practice
~V4: follow-up visit with the overseeing expert"
16586147|NCT02704793|Experimental|Bilateral 1 Hz Cerebellar rTMS|Patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days.
16586148|NCT02704793|Sham Comparator|Sham (electrical stimulation)|Sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS.
16586149|NCT02704780|Active Comparator|400 Microgram Misoprostol|Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group
16586150|NCT02704780|Active Comparator|800 Microgram Misoprostol|Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group
16586151|NCT02704767|Placebo Comparator|TarceP|Tarceva with Placebo
16586152|NCT02704767|Experimental|TarceA|Tarceva with Apatinib
16586153|NCT02704754|Experimental|suvorexant|10 to 20 mg to be administered before bedtime
16586154|NCT02704754|Placebo Comparator|Placebo pill|A pill without active ingredients
16586155|NCT02704741|Experimental|all subjects|"Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.
~Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).
~Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic."
16586156|NCT02704728|Experimental|Thetanix|In Part A, 8 subjects will receive a single dose and in Part B, 8 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules
16586157|NCT02704728|Placebo Comparator|Placebo|In Part A, 2 subjects will receive a single dose and in Part B, 2 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules.
16586158|NCT02704715|Other|general anesthesia,orbital operation|"diagnosed as orbital disease and ocular tumor
~over 16 years old
~orbital operation under general anesthesia"
16586159|NCT02704702|Other|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)
~There will be a washout of at least 7 days between the each period."
16586160|NCT02704702|Other|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)
~There will be a washout of at least 7 days between the each period."
16586161|NCT02704702|Other|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)
~There will be a washout of at least 7 days between the each period."
16586162|NCT02704702|Other|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)
~There will be a washout of at least 7 days between the each period."
16586163|NCT02704702|Other|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)
~There will be a washout of at least 7 days between the each period."
16586164|NCT02704702|Other|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)
~There will be a washout of at least 7 days between the each period."
16586165|NCT02704689|Experimental|AccuLIF|
16586166|NCT02704676||control patients|normal pregnant women, 3rd trimester
16586167|NCT02704676||mild pre-eclampsia|patients with albuminuria +1 and blood pressure >140/90 and <160/110
16586168|NCT02704676||sever pre-eclampsia|patients diagnosed as sever pre-eclampsia according to criteria done by ACOG
16586169|NCT02704663|Experimental|Transumbilical route|Transumbilical removal of benign adnexal masses via laparoscopy.
16586170|NCT02704663|Active Comparator|Lateral abdominal route|Lateral transabdominal removal of benign adnexal masses via laparoscopy.
16586171|NCT02704650|Experimental|Vaginal fluid of healthy patient|vaginal fluid sample from healthy patients
16586172|NCT02704650|Experimental|Vaginal fluid of ovary cancer patients|vaginal fluid sample from patients with ovary cancer
16586173|NCT02704637|Experimental|HS-1000 recording|Each non-invasive recording session with the HS-1000 device will be done for 10 consecutive uninterrupted minutes. Patients will be recorded once daily for the duration of their time in ICU or for up to 14 days total. In the case the PI or a member of the study team positively confirms vasospasm based on clinical assessment or follow-up care during the monitoring period, the patient will be recorded twice daily for up to 14 consecutive days or for their duration in the ICU.
16586174|NCT02704624|Active Comparator|Vitamin D|Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
16586175|NCT02704624|Placebo Comparator|Placebo|The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
16586176|NCT02704611|Active Comparator|Group I|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week).
16586177|NCT02704611|Sham Comparator|Group II|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
16586178|NCT02704598|Active Comparator|Rivaroxaban|Patients with deep venous thrombosis using Rivaroxaban for 6 months, and then will be evaluated with DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
16586179|NCT02704598|Active Comparator|Warfarin|Patients with deep venous thrombosis using Warfarin for 6 months, and then will be evaluated wiht DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
16586180|NCT02704585|Other|Nellcor|Connection to Nellcor pulse oximeter for measuring oxygen saturation after birth
16586182|NCT02704572|Experimental|6months to 2years after shingles|Patients will be vaccinated with Zostavax from 6 months to 2 years after zoster illness.
16586183|NCT02704572|Active Comparator|2years to 5years after shingles|Patients will be vaccinated with Zostavax from 2 years to 5 years after zoster illness.
16586184|NCT02704559|Experimental|Study effect of DWC20156 on DWC20155 PK|To study effect of DWC20156 on DWC20155 PK
16586185|NCT02704559|Experimental|Study effect of DWC20155 on DWC20156 PK|To study effect of DWC20155 on DWC20156 PK
16586186|NCT02704546|Experimental|Methylphenidate|In experimental days taking MPH, subjects will take 20mg Ritalin® (Novartis AG) in two tablets of 10mg, by swallow 1 hour prior to performing the physical test.
16586187|NCT02704546|Placebo Comparator|Placebo|In experimental days with placebo subjects will be asked to ingest 2 capsules identical to Ritalin® capsules, by swallow 1 hour prior to performing the physical test.
16586188|NCT02704533|Experimental|Optimization Phase - Group A|"n=6; three times 9x10^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.
~If >75% efficacious, the treatment will be simplified to two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 (Group B1).
~If <75% efficacious, the treatment will be increased to three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)"
16586189|NCT02704533|Experimental|Optimization Phase - Group B1|"n=6; two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.
~If >75% efficacious, the treatment will be simplified to one injection 2.7x10^6 PfSPZ Vaccine (Group C1).
~If <75% efficacious, the treatment will be increased to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2)."
16586190|NCT02704533|Experimental|Optimization Phase - Group B2|"n=6; three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.
~If >75% efficacious, the treatment will be simplified to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).
~If <75% efficacious, the treatment will be increased to three times 2.7x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3)."
16586191|NCT02704533|Experimental|Optimization Phase - Group C1|"n=6; one time 2.7x10^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.
~If Group C1 gets vaccinated, study will proceed to verification phase after completion."
16586192|NCT02704533|Experimental|Optimization Phase - Group C2|"n=6; two times 2.7x10^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.
~If Group C2 gets vaccinated, study will proceed to verification phase after completion."
16586193|NCT02704533|Experimental|Optimization Phase - Group C3|"n=6; three times 2.7x10^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.
~In case C3 shows <75% efficacy, verification phase will not be done."
16586194|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D1|"n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI.
~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
16586195|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D2|"n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI.
~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
16586196|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D3|"n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI.
~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
16586197|NCT02704533|Experimental|Verification Phase - Group V1|"n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides >75% protection (5/6) against homologous CHMI (V1).
~Optimal & maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2).
~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8."
16586198|NCT02704533|Experimental|Verification Phase - Group V2|"n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2).
~Optimal & maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides >75% protection (5/6) against homologous CHMI (V1).
~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.
~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
16586199|NCT02704533|Placebo Comparator|Verification Phase - Group P1|"n=6; normal saline as placebo. This group will follow the regimen selected for Group V1.
~Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
16586231|NCT02704234|Experimental|Active Acupuncture|Active Acupuncture 2 times per week for 5 weeks
16586200|NCT02704533|Placebo Comparator|Verification Phase - Group P2|"n=6; NS as placebo. This group will follow the regimen selected for Group V2.
~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.
~Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
16586201|NCT02704520|Other|Control arm|Patients in the control arm will undergo surgery and then receive a course of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil) and follow-up assessments as standard i.e. standard clinical practice
16586202|NCT02704520|Experimental|Intervention arm|Patients in the intervention arm will be split into one of two groups according to their response to chemoradiotherapy. Patients who show a good response (mrTRG I&II) will be offered deferral of surgery and receive the standard course of chemotherapy. Patients who show a poor response (mrTRG III-V) will receive 12 weeks of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil), undergo repeat restaging, and then continue to surgery or defer surgery. Depending on chemotherapy regimen received patients may then receive a further 12 weeks of chemotherapy.
16586203|NCT02704507|Experimental|Topical steroid|Topical retinoid plus topical steroid applied daily to half of the face for 4 weeks, followed by 4 weeks of topical tretinoin. Patients will be randomized to which side receives the topical steroid.
16586204|NCT02704507|Placebo Comparator|Topical emollient|Topical retinoid plus topical emollient applied daily to the opposite half of the face for 4 weeks, followed by 4 weeks of topical tretinoin.
16586205|NCT02704494|Experimental|Resveratrol|Resveratrol + Losartan
16586206|NCT02704494|Placebo Comparator|Placebo|Placebo + Losartan
16586207|NCT02704481|Experimental|Mifepristone-misoprostol|Women randomized to receive 200 mg mifepristone to take on Day 1, 800 mcg buccal misoprostol to take 24-48 hours after later, and four placebo misoprostol pills to take a further 3-12 hours later.
16586208|NCT02704481|Experimental|Misoprostol-misoprostol|Women randomized to receive a placebo mifepristone pill to take on Day 1 and two doses of 800 mcg buccal misoprostol, the first of which should be taken 24-48 hours after the placebo and the second of which should be taken 3-12 hours after the first misoprostol dose.
16586209|NCT02704468||CAVI and FGF-21|renal transplant patients for more than 1 month measured FGF-21 and CAVI
16586210|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up
16586211|NCT02704416|No Intervention|Control arm|Control arm - continued implanted cardioverter defibrillator therapy
16586212|NCT02704416|Active Comparator|Intervention Arm|ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy
16586213|NCT02704416|Other|Single Cross Over Arm|these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine
16586214|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
16586215|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
16586216|NCT02704390|Experimental|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
16586217|NCT02704377|Experimental|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
16586218|NCT02704364|Experimental|NGM282 Dose 1|NGM282 Dose 1
16586219|NCT02704364|Experimental|NGM282 Dose 2|NGM282 Dose 2
16586220|NCT02704364|Active Comparator|Placebo|Placebo
16586221|NCT02704351||Sugammadex group|sugammadex to reverse neuromuscular blockade following cardiac surgery
16586222|NCT02704338|Experimental|Regulatory T cells|CD4(cluster of differentiation)+CD25+CD127- T cells isolated from peripheral blood mononuclear cells were be expanded with GMP(Good Manufacturing Practice) anti-CD3/CD28 coated beads in the presence of IL-2 and all-trans retinoid acid.
16586223|NCT02704325|Experimental|GALGT2 Viral Vector|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
16586224|NCT02704325|Experimental|Saline|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
16586225|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
16586226|NCT02704299|Experimental|Autologous T cells-Based Immunotherapy|Surgery Chemotherapy Autologous T cells-Based Immunotherapy
16586227|NCT02704286|Sham Comparator|Generic Osteoarthritis Risk Information|Participants in this arm received generic osteoarthritis information that was not personalized.
16586228|NCT02704286|Experimental|Personalized Osteoarthritis Risk|Participants in this arm obtained their personalized osteoarthritis risk from the internet-based Osteoarthritis Risk Calculator.
16586229|NCT02704260|Experimental|GENETIC ANALISYS|GENETIC ANALYSIS AND RESEARCH OF GENETIC BLOOD SAMPLE
16586233|NCT02704221|Active Comparator|Behavioral Parent Training (BPT)|The control group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks and 2) attend 12 weekly BPT training sessions.
16586234|NCT02704221|Experimental|BPT + Contingency Management (BPT+CM)|The experimental group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks, 2) attend 12 weekly BPT training sessions, and 3) receive monetary rewards for achieving weekly step-count goals.
16586235|NCT02704208|Experimental|Behavioral: Thrive With Me Intervention|Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
16586236|NCT02704208|Placebo Comparator|Behavioral: Thrive With Me Control|Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
16586237|NCT02704195|Active Comparator|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
16586238|NCT02704195|Experimental|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
16586239|NCT02704182|Active Comparator|Real tDCS|Direct current stimulation using anodal electrode, 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
16586240|NCT02704182|Sham Comparator|Sham tDCS|Sham direct current stimulation, 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
16586241|NCT02704169|Experimental|Spatially registered endoscopy for H&N cancer|
16586242|NCT02704156|Experimental|SBRT plus Pembrolizumab and Trametinib|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
16586243|NCT02704156|Active Comparator|SBRT plus Gemcitabine|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
16586244|NCT02704143|Experimental|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
16586245|NCT02704130|Experimental|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
16586246|NCT02704130|Active Comparator|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
16586247|NCT02704117|Experimental|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
16586248|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
16586249|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
16586250|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
16586251|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
16586252|NCT02704078|Active Comparator|EBUS-TBNA|Mediastinal lymph node aspiration shall be performed transtracheally.
16586253|NCT02704078|Experimental|EUS-B-FNA|Mediastinal lymph node aspiration shall be performed transesophageally
16586254|NCT02704065||Recurrent AA amyloidosis|Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
16586255|NCT02704065||Control group 1|Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
16586256|NCT02704065||Control group 2|Renal transplant recipients whose primary diseases are other than amyloidosis
16586257|NCT02704052|Active Comparator|Standard enoxaparin dose|We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion-the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
16586258|NCT02704052|Experimental|Real time enoxaparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time enoxaparin dose adjustment and will receive followup steady state peak and trough aFXa levels. aFXa monitoring will be discontinued when in range peak levels are obtained, when enoxaparin prophylaxis is discontinued at surgeon discretion, or when the patient is discharged. Patients may be continued on enoxaparin prophylaxis after discharge per attending surgeon discretion but aFXa levels will not be followed in the outpatient environment.
16586259|NCT02704026||Inflammatory Bowel Disease|Patients 6-18 of age at the time of enrolment who have IBD at any stage of disease activity, on any or no treatment
16586260|NCT02704026||Control|Age- and sex-matched healthy controls
16586261|NCT02704013|Other|Intervention|Patients with overactive bladder will receive anticholinergic therapy: oral oxybutynin in daily dose 0.2-0.5 mg/kg divided in two daily doses for 3 to 6 months depending on treatment outcome assessed 3 months after start of intervention.
16586262|NCT02704000|No Intervention|Control|No interventions - only baseline and endline assessments to be conducted at children's home.
16586263|NCT02704000|Experimental|Home visits by CDAs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained child development agents (CDAs). CDAs will implement the Jamaica curriculum intervention during the home visits..
16586264|NCT02704000|Experimental|Home visits by CHWs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained community health workers (CHWs) trained on delivering the intervention. CHWs will implement the Jamaica curriculum intervention during the home visits..
16586265|NCT02703987|Experimental|Group I|Fermented infant milk formula
16586266|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
16586267|NCT02703974|Experimental|Early handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and nudges built after Phase II data collection.
16586268|NCT02703974|Experimental|Late handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations and nudges built at the same time, after Phase II data collection.
16586269|NCT02703974|Active Comparator|Early handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and will receive a Hand hygiene education-based program, after Phase II data collection is complete.
16586270|NCT02703974|Active Comparator|Late handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after Phase II data collection is complete, when the Hand hygiene education-based program will commence.
16586271|NCT02703961|Experimental|experimental|"concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.
~During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.
~After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;
~The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
~docetaxel 75mg/m2, d43,d64."
16586272|NCT02703961|Other|control|"standard chemoradiotherapy with weekly cisplatin.
~Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.
~Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy."
16586273|NCT02703948|Other|Restylane Silk with Lidocaine|
16586274|NCT02703935|Experimental|health talk and adventure-based training|Participate will join a four-day adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 12 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
16586275|NCT02703935|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
16586276|NCT02703922|Other|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
16586277|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
16586278|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
16586279|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
16586280|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
16586281|NCT02703896|Placebo Comparator|Group C (placebo)|"Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)"
16586282|NCT02703896|Active Comparator|Either PPIs or H2RAs|"Drug Intervention Two doses at 8.00 pm and then at 6.00 am
~Group L (lansoprazole 15 mg)
~Group E(esomeprazole 20 mg)
~Group P (pantoprazole 20 mg)
~Group R (rabeprazole 10 mg)
~Group O (omeprazole 20 mg)
~Group T (cimetidine 200 mg)
~Group F (famotidine 20 mg)
~Group N (nizatidine 150 mg)
~Group Z (ranitidine 150 mg)
~Group S (lafutidine 10 mg)"
16586283|NCT02703896|Active Comparator|Either PPIs or H2RAs+prokinetics|"Drug intervention Two doses at 8.00 pm and then at 6.00 am
~Group L D (lansoprazole 15 mg+ domperidone 10 mg)
~Group EM (esomeprazole 20 mg+metoclopramide 10 mg)
~Group PD (pantoprazole 20 mg+domperidone 10)
~Group RM (rabeprazole 10 mg+metoclopramide 10 mg)
~Group OD (omeprazole 20 mg+domperidone 10)
~Group TD (cimetidine 200 mg+domperidone 10)
~Group FM (famotidine 20 mg+metoclopramide 10 mg)
~Group NM (nizatidine 150 mg+metoclopramide 10 mg)
~Group ZD (ranitidine 150 mg+ domperidone 10 mg)
~Group SD (lafutidine 10 mg+domperidone 10 mg)"
16586284|NCT02703896|Active Comparator|Either PPIs or H2RAs+Prokinetic|Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
16586285|NCT02703896|Other|Intervention Orogastric intubation|After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
16586286|NCT02703883|Experimental|Body Weight Support|Treatment protocol consisted of 18 training sessions on the BWST, three times a week, every session included three sets of six minutes of locomotion with rest intervals of 2 min of rest.
16586287|NCT02703870|Active Comparator|Verum tDCS|Verum group receiving complete treatment of tDCS
16586288|NCT02703870|Sham Comparator|sham tDCS|Sham group receiving sham tDCS
16586289|NCT02703870|Active Comparator|real VRT|Real Vision Restoration Training
16586290|NCT02703844|Active Comparator|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 12 weeks, 7 days a week, twice daily for 20 minutes.
16586291|NCT02703844|Sham Comparator|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 12 weeks in the same manner as the active arm: 7 days a week, twice daily for 20 minutes.
~Individuals allocated to this arm will be later crossed over, in unblinded fashion. to the active arm if the treatment shows evidence of efficacy and safety."
16586292|NCT02703831|Active Comparator|Dual attending|Two attending spine surgeons during the critical portions of the surgery
16586293|NCT02703831|Placebo Comparator|Single attending|One spine attending and an assistant during the critical portions of the surgery, The assistant can be a spine fellow, a resident or a physician's assistant.
16586294|NCT02703818|Experimental|Senza|Spinal Cord Stimulation for UEP
16586295|NCT02703805|Experimental|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors.
16586296|NCT02703805|Active Comparator|Standard YMCA membership|A 12 week standard YMCA membership.
16586297|NCT02703792||Care home staff|Care home staff working in the homes in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
16586298|NCT02703792||NHS staff|GPs supporting residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
16586299|NCT02703792||Service user representatives|Service or carers of an older person with dementia attending and Age UK carers group
16586300|NCT02703792||Relatives of residents|Relatives of residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
16586301|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).
~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
16586302|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.
~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
16586303|NCT02703766|Active Comparator|Lean|"Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.
~Overfeeding induced weight gain and subsequent weight loss"
16586304|NCT02703766|Experimental|Obese|"obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.
~Overfeeding induced weight gain and subsequent weight loss"
16586305|NCT02703753|Experimental|Intervention group|The intervention is an integral and multidisciplinary lifestyle intervention consisting of a healthy diet, appropriate physical activity and, if applicable, smoking cessation, customised to the needs of the women.
16586306|NCT02703753|No Intervention|Control group|The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
16586307|NCT02703740|Experimental|HA 20 mg/mL|
16586308|NCT02703740|Experimental|HA 24 mg/mL|
16586309|NCT02703727||OAC|Patients on oral anticoagulation therapy (OAC) will receive a pharmacists led medication review with a focus on anticoagulation therapy (extended polymedication check)
16586310|NCT02703714|Experimental|Treatment|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
16586311|NCT02703701||Usual Care|Group enrolled during normal emergency department operating procedures (without a physician present at triage).
16586312|NCT02703701||Physician at Triage|Group enrolled while a physician is present at triage.
16586313|NCT02703688|Experimental|Healthy Homes|Behavioral Intervention
16586314|NCT02703688|Active Comparator|Usual Care|Counseling session delivered by pediatrician
16586315|NCT02703675|Experimental|adult healthy volunteer|Adult healthy volunteers will be recruited from staff in Dept. Neurology, medical students. They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
16586316|NCT02703675|Experimental|adult normothermic patient|"Adult normothermic patients will be recruited from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.
~They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours."
16586317|NCT02703675|Experimental|adult sick febrile patient|"Adult sick febrile patients will be enrolled from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.
~Five of the patients will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
~Other five patients will received 2 rounds of cooling process each 2 hours long"
16586318|NCT02703662|Active Comparator|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
16586319|NCT02703662|Experimental|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
16586320|NCT02703649|Experimental|Single dose|Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.
16586321|NCT02703649|Active Comparator|Daily dose|Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
16586322|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
16586323|NCT02703623|Experimental|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
16586324|NCT02703623|Experimental|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
16586325|NCT02703623|Active Comparator|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
16586326|NCT02703610|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
16586327|NCT02703610|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
16586328|NCT02703597|Experimental|ASPIRE Group|"ASPIRE Group contains participants with and without intent to use tobacco. Participants engage in five 70-minute sessions of ASPIRE spread over a period of 4 weeks (2 sessions in the last week). During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco. During each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute breaks.
~At baseline, after 2 sessions, following the last session of the intervention, and one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Also, baseline survey again completed."
16586329|NCT02703597|Experimental|GSA-ASPIRE-Network Group|"GSA-ASPIRE-Network Group contains participants with and without intent to use tobacco. In groups, participants engage in five 70-minute sessions of ASPIRE conducted over a period of 4 weeks (2 sessions in the last week). However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. During each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute GSAs. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
~At baseline, after 2 sessions, following the last session of the intervention, and one month after the intervention has ended, participants complete psychosocial surveys and social network surveys."
16586330|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
16586331|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
16586332|NCT02703571|Experimental|Advanced or metastatic solid tumors|Patients in the Phase I portion of the study who have advanced or metastatic solid tumors
16586333|NCT02703558|No Intervention|No dye|Participants will not receive a preoperative or intraoperative dye prior to their intraoperative concomitant cystoscopy.
16586334|NCT02703558|Active Comparator|Phenazopyridine|Participants will receive a single 200mg oral dose of phenazopyridine with a sip of water 30 minutes prior to their surgery which involves an intraoperative concomitant cystoscopy.
16586335|NCT02703558|Active Comparator|Fluorescein|Participants will receive 0.25cc of 10% intravenous sodium fluorescein administered by anesthesia during their surgery, immediately prior to their intraoperative concomitant cystoscopy.
16586336|NCT02703545||Peutz-Jeghers syndrome|
16586337|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family
~first degree relative and 1 second degree relative(1st degree link) or
~first degree relatives or
~1 first degree relative and 2 or more second degree relatives"
16586338|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
16586339|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
16586340|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
16586341|NCT02703532|Experimental|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
16586342|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
16586343|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
16586344|NCT02703532|Active Comparator|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
16586345|NCT02703519|No Intervention|1 cesarean section|control group
16586346|NCT02703519|No Intervention|2 cesarean sections|control group
16586347|NCT02703519|Experimental|resection of uterine scar tissue|2 cesarean sections with resection of uterine scar tissue from first cesarean section
16586348|NCT02703506|Experimental|Experimental. Pain Education Program|Ten group sessions of treatment with a patient education pain for chronic neck pain (biopsychosocial approach). The group sessions of 60-120 minutes twice a week with a maximum of 10 participants.
16586349|NCT02703506|Active Comparator|Control|"The control group: individualized session of physical therapy (TENS and exercise).
~Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises ."
16586582|NCT02701920||Newborns and surgical delivery|Well term newborn infants following birth by cesarean section.
16586350|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
16586351|NCT02703480|Experimental|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
16586352|NCT02703480|Experimental|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
16586353|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
16586354|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
16586355|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
16586356|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
16586357|NCT02703441|Experimental|Intervention: Tablet computer|Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
16586358|NCT02703441|No Intervention|Control group|Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
16586359|NCT02703415|Active Comparator|Bupivacaine|caudal Bupivacaine
16586360|NCT02703415|Active Comparator|Tramadol|caudal Tramadol
16586361|NCT02703402|Experimental|Exercise protocol|Will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA
16586362|NCT02703402|Experimental|Manual of exercises|Treatment Group: will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises.
16586363|NCT02703389|Experimental|Video|An innovative video will be developed to explain the nature of non-severe acute otitis media and the rationale for watchful waiting and antimicrobial stewardship. This video will be viewed at recruitment and will be available online for further viewing later.
16586364|NCT02703389|Active Comparator|Pamphlet|Informative pamphlet containing the same information as the video.
16586365|NCT02703389|No Intervention|No intervention|This is the reference standard currently.
16586366|NCT02703376|Other|Patients after esophageal surgery|Oral Prednisone for 12 weeks
16586367|NCT02703363|Experimental|Minocycline with TAU|
16586368|NCT02703363|Experimental|Celecoxib with TAU|
16586369|NCT02703363|Experimental|Minocycline and celecoxib with TAU|
16586370|NCT02703363|Active Comparator|Placebo with TAU|
16586371|NCT02703350|Experimental|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
16586372|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
16586373|NCT02703350|Experimental|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
16586374|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
16586375|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
16586376|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
16586377|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
16586378|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
16586379|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
16586380|NCT02703324|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
16586381|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
16586382|NCT02703298|Experimental|TRX-818|
16586383|NCT02703285|Experimental|questionnaire|task of the participants in the study to determine the chest sound based on specific sounds
16586414|NCT02703077|Active Comparator|2: ERCP + Balloon Dilation|This group after the diagnosis of difficult bile duct stones, will be submitted to Balloon dilation of the papilla
16586384|NCT02703272|Experimental|Part 1: Ibrutinib|The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
16586385|NCT02703272|Experimental|Part 2: Ibrutinib|Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
16586386|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:
~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
16586387|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:
~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
16586388|NCT02703246|Active Comparator|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
16586389|NCT02703246|Active Comparator|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
16586390|NCT02703233|Active Comparator|Nitrous Oxide|Patients receive nitrous oxide via mask.
16586391|NCT02703233|Placebo Comparator|Placebo (Oxygen)|Patients receive oxygen via mask.
16586392|NCT02703220|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.
16586393|NCT02703220|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
16586394|NCT02703220|Experimental|Finasteride|Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.
16586395|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
16586396|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
16586397|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
16586398|NCT02703194|Experimental|Prednisone|Prednisone mono-therapy
16586399|NCT02703194|Experimental|Prednisone and Leflunomide|Prednisone and Leflunomide combination therapy
16586400|NCT02703181|Experimental|Cohort 1(600 mg Epelsiban or placebo[every 8 hours])|Each subject will receive 200 mg of epelsiban administered TID (every 8 hours) (total daily dose of 600 mg) or a matching placebo administered every 8 hours.
16586401|NCT02703168||Immediate loading|Patients were allocated to treatment group in the core study. Immediate loading was defined as follows: Implant(s) will be restored with a temporary restoration on the day of surgery
16586402|NCT02703168||Early loading|Patients were allocated to treatment group in the core study. Early loading was defined as follows: Healing caps will be placed on the implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
16586403|NCT02703155|Other|Home Oral Glucose tolerance test kit|Providing children with Cystic Fibrosis between 10 and 17 years of age with Home Oral glucose tolerance test kit to screen Cystic fibrosis related Diabetes.
16586404|NCT02703142||Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
16586405|NCT02703129|Experimental|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
16586406|NCT02703116|Experimental|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
16586407|NCT02703116|Active Comparator|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
16586408|NCT02703103|Experimental|Standard cardiopulmonary resuscitation|standard CPR (30:2) according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
16586409|NCT02703103|Experimental|asynchronous cardiopulmonary resuscitation|asynchronuos CPR according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
16586410|NCT02703090|Placebo Comparator|Placebo|Normal saline infusion
16586411|NCT02703090|Active Comparator|Drug lower dose|Remifentanil infusion
16586412|NCT02703090|Active Comparator|Drug higher dose|Remifentanil infusion
16586413|NCT02703077|Active Comparator|1: ERCP + Spyglass + EHL|This group after the diagnosis of difficult bile duct stones, will be submitted to spyglass cholangioscopy + EHL (electrohydraulic lithotripsy)
16586419|NCT02703038||Cardiogenic shock|Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
16586420|NCT02703025|Experimental|GCB 70 administered group|Green coffee bean extract capsule 500mg, BD
16586421|NCT02703012|Experimental|Adjustment of ventilator settings by EIT|Individual Adjustment of Ventilator settings using an algorithm based on electrical impedance tomography.
16586422|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
16586423|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
16586424|NCT02702986|Experimental|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
16586425|NCT02702973||Observe the fundus characteristics|Observe the fundus characteristics after high doses of interferonα-2b therapy in patients with melanomas of the skin.
16586426|NCT02702960|Experimental|part. liver transplant and BMT|"Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.
~Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).
~If eligible, patients will begin:
~Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.
~Patients followed up through post transplant day 60, then weekly following discharge."
16586427|NCT02702947|Experimental|Prunus Domestica|Prunus domestica extract capsules, 100mg, BD
16586428|NCT02702934|Experimental|High-amylose rusks|Test meal with 100g of carbohydrates coming from high-amylose rusks
16586429|NCT02702934|Active Comparator|Control rusks|Test meal with 100g of carbohydrates coming from regular rusks used as control
16586430|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
16586431|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
16586432|NCT02702908||mPC|Prostate cancer patients with bone metastases (mPC)
16586433|NCT02702908||mCRPC|Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
16586434|NCT02702895||Phase 1|Former ASPIRE participants
16586435|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
16586436|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
16586437|NCT02702882|Other|Fenugreek seeds extract 500 mg|Fenugreek seeds extract ( Furosap) one caps once a day
16586438|NCT02702869||uCL(A)|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
16586439|NCT02702869||uCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, or Veau-III).
16586440|NCT02702869||bCL(A)|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
16586441|NCT02702869||bCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
16586442|NCT02702869||CP|Children with cleft secondary palate only, but intact lip and alveolus. Subgroup analysis by severity (submucous, Veau-I, or Veau-II).
16586443|NCT02702856||Men screened for prostate cancer|
16586444|NCT02702843|Active Comparator|Xenon Light|Laparoscopic cholecystectomy with Xenon Light
16586445|NCT02702843|Experimental|Near infrared light|Laparoscopic cholecystectomy with Near infrared light
16586446|NCT02702830||Diagnostic (MRI and CPET)|Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart. Patients also undergo MRI before and within 60 seconds after exercising.
16586447|NCT02702817|Active Comparator|naproxen|naproxen sodium tablets 220 mg twice daily for two years
16586448|NCT02702817|Placebo Comparator|placebo|tablets identical in appearance to naproxen tablets twice daily for two years
16586449|NCT02702804|Experimental|High Intensity Interval Training|Participants will attend two sessions per week for the 6 week intervention. Each session will consist of 6-10 sets of 60 second high intensity intervals interspersed with 60 seconds recovery. The workload during each interval will be set at 80-90% of peak power achieved during the VO2peak test. This is predicted to elicit 85-95% heart rate reserve in the participants. After each interval the participant's heart rate and rate of perceived exertion (RPE) will be collected. After each session a researcher will complete an Adverse Event form to record if an event occurred or not. Additionally the participant will complete a physical activity enjoyment (Perceived activity enjoyment scale) after one session per week.
16586450|NCT02702791|Experimental|Intervention|Telecoaching - feasible goal setting and feedback to enhance patient's motivation and commitment - in addition to pulmonary rehabilitation.
16586451|NCT02702791|Other|Usual care|includes only general advices regarding physical activity.
16586452|NCT02702778|Active Comparator|4mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 4mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
16586453|NCT02702778|Active Comparator|7mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 7mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
16586454|NCT02702778|Active Comparator|10mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 10mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
16586519|NCT02702297||Single arm|daily multimodal monitoring during pregnancy after PPROM, Analysis of neonatal routine parameters and histologic examination of placenta
16586455|NCT02702765|Experimental|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
16586456|NCT02702752|Other|DYNASDY|The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
16586457|NCT02702752|Active Comparator|Control group|A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
16586458|NCT02702739|Active Comparator|Group I (<65 years)|Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
16586459|NCT02702739|Active Comparator|Group II (>65 years)|Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
16586460|NCT02702726|No Intervention|Congee and juice only|Control breakfast providing 50g carbohydrate
16586461|NCT02702726|Active Comparator|Congee and juice with coconut gel|Control breakfast, plus 25g coconut oleogel (solid)
16586462|NCT02702726|Active Comparator|Congee and juice with coconut oil|Control breakfast, plus 25g coconut oil (liquid)
16586463|NCT02702726|Active Comparator|Congee and juice with sunflower gel|Control breakfast, plus 25g sunflower oleogel (solid)
16586464|NCT02702726|Active Comparator|Congee and juice with sunflower oil|Control breakfast, plus 25g sunflower oil (liquid)
16586465|NCT02702713|Active Comparator|Dairy BEF + egg placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo
16586466|NCT02702713|Active Comparator|Egg BEF + dairy placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo
16586467|NCT02702713|Active Comparator|Bakery BEF + dairy placebo + egg placebo|200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo
16586468|NCT02702713|Placebo Comparator|All placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo
16586469|NCT02702700|Experimental|Lipoplatin/Visudyne-mediated photodynamic therapy|200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
16586472|NCT02702674|Active Comparator|propranolol plus oxytocin|121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.
16586473|NCT02702674|Placebo Comparator|placebo plus oxytocin|121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.
16586474|NCT02702661|Experimental|Procedure - FICB|Fascia Iliaca Block following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
16586475|NCT02702661|Active Comparator|Procedure - LAI|Local Anaesthetic Infiltration following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
16586476|NCT02702648|Experimental|AC-082, Single Ascending Dose|Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level
16586477|NCT02702648|Placebo Comparator|Placebo, Single Ascending Dose|Subjects receive a single dose of the matched placebo
16586478|NCT02702648|Experimental|AC-082, Multiple Ascending Dose|Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level
16586479|NCT02702648|Placebo Comparator|Placebo, Multiple Ascending Dose|Subjects receive the matched placebo for 4 days
16586480|NCT02702635|Experimental|All Subjects|All recruited subjects
16586481|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
16586482|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
16586483|NCT02702596|Experimental|MBIC + DEF|Measurement-Based Integrated Care with Depression Education Fotonovela
16586484|NCT02702596|Experimental|MBIC + SE|Measurement-Based Integrated Care + Standard Education
16586485|NCT02702570|Other|CASA intervention|Each participant serves as his/her own control. Measures administered before and after an intervention.
16586486|NCT02702557|Other|Elastic Band Exercises|Unsupervised Elastic band exercises performed once a day until the patient is discharged from the hospital. One exercise for the upper extremity (row exercise level 1-3) and one exercise for the lower extremity (knee extension level 1-3). The two exercises are both performed as 3 sets of 10 repetitions.
16586487|NCT02702544|Experimental|neutral position|the patient is in the neutral position, located on his back on a flat surface
16586488|NCT02702544|Experimental|legs raised for 20 degrees|patient is placed on a flat surface, legs raised for 20 degrees, supported around ankles
16586489|NCT02702544|Experimental|legs raised for 30 degrees|patient is placed on a flat surface, legs raised for 30 degrees, supported around ankles
16586490|NCT02702544|Experimental|legs raised for 45 degrees|patient is placed on a flat surface, legs raised for 45 degrees, supported around ankles
16586491|NCT02702544|Experimental|legs raised for 60 degrees|patient is placed on a flat surface, legs raised for 60 degrees, supported around ankles
16586492|NCT02702531|Experimental|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
16586493|NCT02702531|Experimental|Water + Povidone-iodine Solution|Clearify Visualization with Water + Povidone-iodine Solutionused during laparoscopic surgery
16586494|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
16586496|NCT02702505|Experimental|NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time. The new formulation has received the Food and Drug Administrations 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).19
16586497|NCT02702505|Other|ProRoot MTA|Control group. This group will receive the old formulation of MTA in the pulpotomy and the tooth will receive a full coverage stainless steel crown restoration.
16586498|NCT02702492|Experimental|KPT-9274|"Part A: [CLOSED TO ENROLLMENT]
~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
16586499|NCT02702492|Experimental|KPT-9274 & Niacin Extended Release (ER)|"Part B:[CLOSED TO ENROLLMENT]
~500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
16586500|NCT02702492|Experimental|KPT-9274 + Nivolumab|"Part C:
~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.
~Nivolumab 480 mg IV administered Day 1 during each 28 day cycle."
16586501|NCT02702466|Experimental|Immediate SPA Therapy|6 day immediate SPA treatment (soon after randomization) and written information with physical exercises adapted to their pathology and also a program of healthcare at the USB key
16586502|NCT02702466|Active Comparator|Late SPA Therapy|Written information with physical exercises adapted to their pathology and a program of healthcare at the USB key and late 6 day SPA treatment
16586503|NCT02702453|Experimental|Development and Testing|Develop an online interactive, tailored intervention to address the needs of men and partners interested in sexual recovery after treatment for localized prostate cancer during the first 6 months after treatment. The intervention will undergo content testing through 4 focus groups with prostate cancer survivors and partners and usability testing with 5 survivors and partners
16586504|NCT02702427|Experimental|ARM 1|Patients with Adenovirus or CMV infection after HSCT and no reduction of viral disease or stable disease with 10E6 viral copies within 2 weeks of antiviral treatment will receive a single infusion of virus-specific T-Cells
16586505|NCT02702414|Experimental|Prior Systemic Therapy|Participants with previously systemically treated HCC receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
16586506|NCT02702414|Experimental|Systemic Therapy Naive|Participants with HCC who had not received treatment for systemic disease receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
16586507|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
16586508|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
16586509|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
16586510|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
16586511|NCT02702362|Active Comparator|anodal stimulation|"Patients received anodal tDCS (on the precuneus ) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS.
~A final CRS-R is performed 5 days after the end of the session to assess the potential long term effects of the tDCS."
16586512|NCT02702362|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed 5 days after the end of the session.
16586513|NCT02702349|Other|1|penicillin test and challenge
16586514|NCT02702336|Experimental|EYTO-Kids Intervention Group|Adolescents will receive 16h of training (2h healthy lifestyle training, social marketing and communication, 6h to design activities, 2h session together with all intervention high-schools, 6h to practice and standardize activities) and 4h (1h/activity) to implement 4 activities in schools. The scholars will receive 4 activities designed by adolescents, focusing on: 1) increasing fruit consumption, 2) increasing vegetable consumption, 3) increasing physical activity practice and to reduce sedentary lifestyles and, 4) decreasing sugary drinks and fast-food consumption.
16586515|NCT02702336|No Intervention|Control Group|The control group will not receive any kind of intervention (only the assessment).
16586516|NCT02702323|Experimental|Apatinib & TACE|Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
16586517|NCT02702323|Active Comparator|TACE|TACE therapy one times every 4-6 weeks.
16586518|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
16586520|NCT02702284|Other|Adequate health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
16586521|NCT02702284|Experimental|Adequate health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
16586522|NCT02702284|Other|Limited health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
16586523|NCT02702284|Experimental|Limited health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
16586524|NCT02702271|Experimental|WATCHMAN FLX|WATCHMAN FLX implant: This is a single arm study
16586525|NCT02702258|Experimental|MB-BP|This is the primary intervention tested in this single arm trial.
16586526|NCT02702245|Placebo Comparator|Placebo comparator: Control|OGTT without thylakoids.
16586527|NCT02702245|Experimental|Experimental: Thylakoids 5 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 5 g. Intervention: OGTT at one occasion.
16586528|NCT02702245|Experimental|Experimental: Thylakoids 10 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 10 g. Intervention: OGTT at one occasion.
16586529|NCT02702232||Parkinson's disease|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex- and age-matched normal subjects with be recruited from the public. These patients will be evaluated by ultrasonography for shoulder.
16586530|NCT02702232||Normal|Normal controls who will be evaluated by ultrasonography for shoulder
16586531|NCT02702219|Experimental|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
16586532|NCT02702219|Active Comparator|Static stretching|Static stretching of the hamstrings muscles to be performed every day
16586533|NCT02702206|Experimental|corticosteroids SASD injection|under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
16586534|NCT02702206|Experimental|hyaluronic acid (ARTZ) SASD injection|under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
16586535|NCT02702206|Placebo Comparator|normal saline SASD injection|under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine
16586536|NCT02702193|Experimental|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
16586537|NCT02702193|No Intervention|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
16586538|NCT02702180|Experimental|molgramostim continuously|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg once daily for 24 weeks
16586539|NCT02702180|Experimental|molgramostim intermittently|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg for seven days and placebo nebuliser solution for seven days for 24 weeks (12 cycles)
16586540|NCT02702180|Placebo Comparator|placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
16586541|NCT02702167|Experimental|High-frequency rTMS|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
16586542|NCT02702167|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
16586543|NCT02702167|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
16586544|NCT02702154|Experimental|High-frequency rTMS|20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
16586545|NCT02702154|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
16586546|NCT02702154|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
16586547|NCT02702141|Experimental|SGN-CD19B|
16586548|NCT02702128|Active Comparator|Tranexamic acid|1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
16586549|NCT02702128|Placebo Comparator|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
16586553|NCT02702102|Experimental|11C-PBR28 PET scans|Participants will receive one IV injection of up to 20 millicuries of 11C-PBR28.
16586554|NCT02702089||IAPE|Intersphincteric AP excision
16586555|NCT02702089||HP|Hartmann's procedure
16586556|NCT02702076|Experimental|Apomorphine|This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
16586557|NCT02702076|Placebo Comparator|Placebo|This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
16586558|NCT02702063|Other|TTE vs. EC + calibration group|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.
~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial."
16586559|NCT02702063|Other|Right heart catheterisation|Twenty five patients undergoing routine right heart catheterization (RHC) at the department of cardiology for the evaluation of suspected pulmonary hypertension or heart failure will be included in this trial. EC measurements will be obtained during RHC, and a TTE (for measuring LVOT-area) will be performed immediately before undergoing RHC. Inclusion and exclusion criteria are similar as described above.
16586560|NCT02702063|Other|Passive leg raising test|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.
~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial.
~SV and CO will be measured using TTE and EC. Patient's legs will then be raised by 45degree, and SV and CO measurements will be repeated after 1 minute. Changes in SV and CO observed with both methods will be compared."
16586561|NCT02702050|Active Comparator|Conventional treatment group|Conventional treatment group will receive an educational session before commencement of the program. Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises will be provided within a 6-week period (i.e., two sessions per week) to all subjects. No mechanical stimulation will be given.
16586562|NCT02702050|Experimental|Mechanical stimulation group|A 10 minute mechanical stimulation program - 'Mechanical stimulation (LPG system; Cellu M6 Integral I), will be provided after each of the twelve sessions of conventional treatment.
16586563|NCT02702037|Experimental|Intervention|"The participants will be supported to perform the sit-to-stand exercise at least four times per day during 12 weeks (7 days/week).
~The participants will also be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week)."
16586564|NCT02702037|No Intervention|Control|Standard care
16586565|NCT02702011|Experimental|empagliflozin low dose|
16586566|NCT02702011|Experimental|empagliflozin medium dose|
16586567|NCT02702011|Experimental|empagliflozin high dose|
16586568|NCT02702011|Placebo Comparator|placebo|
16586569|NCT02701998|Experimental|mHealth-Enhance Physical Activity Intervention|Tech-PAI participants will be given 3 goals: 1) to increase their average baseline daily walking exercise by 30 minutes at week 12; 2) to increase their average baseline daily steps by 4,000 at week 12; and 3) to get up and walk for at least 2 minutes after every 60 minutes of sitting. Participants will receive instruction on how to gradually and safely increase their bout-related walking exercise and steps over the 12 week period. In addition to goal setting, Tech-PAI participants will receive a commercially available activity tracker and accompanying that provides real-time monitoring of steps, activity minutes, and issues a text-based prompt after 60 minutes of sitting to get up and move. Also, participants will receive a weekly e-mail feedback message from research staff on goal progress and will be asked to view weekly Internet-based video lessons that will provide behavioral strategies to increase MPA and steps and decrease SB during the first 6 weeks of the intervention period.
16586570|NCT02701998|Active Comparator|Physical Activity Intervention|PAI participants will be given the same goals as Tech-PAI intervention participants and receive a pedometer and related print materials to assist them in recording and increasing daily steps and bout-related MPA (but no activity tracker, access to video-based skills training lessons, or weekly feedback).
16586571|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
16586572|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
16586573|NCT02701972|Experimental|Control and Test|Pre-implantation and Post-implantation of BACE device
16586574|NCT02701959|Placebo Comparator|Low nitrate lettuce|50g of low nitrate lettuce (placebo) on single occasions
16586575|NCT02701959|Active Comparator|High nitrate lettuce|50g of high nitrate lettuce (intervention) on single occasions
16586576|NCT02701946|Experimental|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US).
16586577|NCT02701946|Placebo Comparator|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
16586578|NCT02701933|Other|Ketamine-Saline|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, ketamine is administered on the first assessment and placebo (saline) is administered on the second assessment.
16586579|NCT02701933|Other|Saline-Ketamine|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, placebo (saline) is administered on the first assessment and ketamine is administered on the second assessment.
16586580|NCT02701920||NICU infants and hat|Newborn infants of any gestation on the neonatal intensive care unit (NICU).
16586581|NCT02701920||NICU infants and sensor|Newborn infants of any gestation requiring heart rate monitoring on the neonatal intensive care unit.
16586583|NCT02701920||Newborns needing stabilisation|Newborn infants requiring resuscitation or stabilisation following birth.
16586584|NCT02701920||Parental feedback|Parental feedback of babies recruited into HeartLight will be sought.
16586585|NCT02701920||Healthcare provider feedback|Healthcare professionals caring for babies recruited into HeartLight will have their feedback on the device sought.
16586586|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
16586587|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.
~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
16586588|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
16586589|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
16586590|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
16586591|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
16586592|NCT02701881|Experimental|Long stenting group|
16586593|NCT02701881|Active Comparator|Short stenting group|
16586594|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
16586595|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
16586596|NCT02701855||Hypertension and progressive MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
16586597|NCT02701855||Hypertension and stable MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
16586598|NCT02701855||Hypertension, without MCI|60 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
16586599|NCT02701842|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
16586600|NCT02701842|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points.
16586601|NCT02701829|Experimental|Health Fairs (HF)|Drivers will undergo U&C Health Fair follow-up either Regular or Urgent Follow-up: Timeline is determined by health status, with regular follow-up continuing for at least two weeks and urgent follow-up continuing for at least a month
16586602|NCT02701829|Experimental|HF + text messaging + home BP monitoring|Drivers will receive: U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months A home BP monitoring equipment with instructions to self-monitor BP for nine months
16586603|NCT02701829|Experimental|HF +Tech + social network support (SNS).|"Drivers will receive:
~U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months and home BP monitoring equipment with instructions to self-monitor BP for nine months A social network support intervention in which selected family/peers encourage drivers to maintain healthy behaviors for nine months"
16586604|NCT02701816||K-INNOVA|Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).
16586605|NCT02701777|Active Comparator|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
16586606|NCT02701777|Active Comparator|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
16586607|NCT02701777|Active Comparator|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
16586608|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
16586609|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
16586610|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
16586611|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
16586612|NCT02701712|Experimental|Magnetic resonance - guided radiation therapy (MRgRT)|Magnetic resonance (MR) - guided radiation therapy
16586613|NCT02701699|Experimental|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
16586614|NCT02701686|Experimental|quit immediately (QI)|Subjects in the QI group will receive a smoking cessation booklet plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit now, as quitting can greatly reduce risks, (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention during each telephone follow-up. The whole intervention will be limited to less than 1 min or slightly longer if necessary. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the counsellor will congratulate to the subjects who successfully quit smoking, while deliver the same brief intervention as a booster for those who continue to smoke.
16586615|NCT02701686|Experimental|cut down to quit (CDTQ)|Subjects in the CDTQ group will also receive the smoking cessation booklet plus a brief intervention using the AWARD model. Instead of asking them to quit immediately, they will be advised gradually cutting down on their cigarette consumption. Also, the subjects will be provided with an education card that contains reduction strategies and a suggested plan to reduce smoking. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the nurse counsellor will repeat the warning message that one out of two smokers will be killed by smoking, and remind the subjects of their next reduction target. The counsellor will congratulate subjects who quit or reduce smoking on their success. When subjects fail to quit or reduce their cigarette consumption, the counsellor will reinforce the health hazards of continued smoking and the benefits of quitting, and encourage them to try again immediately or in the near future.
16586616|NCT02701673|Experimental|Belinostat/Gem/Bu/Mel + AutoSCT|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1.
~Caphosol oral rinses 30 mL four times a day used from Day -8. Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
~Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1. Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2. Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2. Participants with cluster of differentiation antigen 20 (CD20+) tumors receive Rituximab 375 mg/m2 by vein on Day -9.
~Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
~Melphalan 60 mg/m2/d by vein on Day -2. Stem cell transplant by vein given on Day 0."
16586617|NCT02701660|Experimental|electronic medication dispenser|An Automatic Tablet Dispensing and Packaging System is used to repack all solid oral prescription medications for each participant into unit-of-dose pouches. Every participant receives a roll with pouches for 14-28 days loaded into a dispenser installed at their homes. The electronic medication dispenser is a remote controlled, electronic medication management aid reminding the patients with acoustic alerts to take their medication.
16586618|NCT02701647|Experimental|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
16586619|NCT02701647|Experimental|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
16586620|NCT02701647|Sham Comparator|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
16586621|NCT02701634|Experimental|ENTO|ENTO 400 mg or 200 mg tablet twice daily for 48 weeks
16586622|NCT02701634|Placebo Comparator|Placebo|Placebo to match tablet twice daily for 48 weeks
16586623|NCT02701621|Active Comparator|MIRT Group|Individuals underwent Multidisciplinary Intensive Rehabilitation Treatment. It consists of 4 weeks of physical therapy in a hospital setting with four daily sessions for five days and one hour of physical exercise on the sixth day.The duration of each session is about one hour. The first session comprises cardiovascular warm-up activities, relaxation and muscle-stretching. The second session includes aerobic exercises and the use of different devices: a stabilometric platform, treadmill plus, crossover, cycloergometer. The third is a session of occupational therapy. The last session includes one hour of speech therapy. The rehabilitation program can also include: robotic-assisted walking training, virtual reality training and meetings with a Psychologist.
16586624|NCT02701621|Experimental|MIRT-AT|"Patients underwent land-based therapy in association with aquatic therapy, three times per week for four weeks.
~The land-based activities included the second and the third session of MIRT.
~The water sessions were divided in 3 phases:
~i) Warm Up Exercises. This phase lasted 10 minutes and comprised walking performances.
~ii) Central session Training. This phase lasted 30-45 minutes and comprised trunk mobility exercises in standing position and sitting on a floating device, static and dynamic exercises. The successive balance training exercises comprised: maintaining balance with closed eyes; balance control with one leg resting on a step; postural control changing the support base.
~iii) Cool-down. This phase lasted 5 minutes and comprised general stretching exercises and gentle walking."
16586625|NCT02701608|Experimental|Oral switch treatment|Oral switch to the combination of levofloxacin and rifampicin
16586626|NCT02701608|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of staphylococci IE (European guidelines 2015)
16586627|NCT02701595|Experimental|Oral switch treatment|Oral switch to amoxicillin
16586628|NCT02701595|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)
16586629|NCT02701582|Experimental|Goal Directed Therapy|Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
16586630|NCT02701582|Active Comparator|Control Group|FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
16586701|NCT02701127|Placebo Comparator|Placebo|Oral placebo pill
16586631|NCT02701569|Experimental|Rebound exercise|Repeated jumping on a mini trampoline was performed with feet slightly apart
16586632|NCT02701569|No Intervention|Control|No exercise was administered but participants continued with routine medical care
16586633|NCT02701556|Experimental|Bausch & Lomb (B&L) NNR06 Multi-Purpose Solution (MPS)|B & L investigational NNR06 used as a rub care regimen (Test)
16586634|NCT02701556|Active Comparator|COMPLETE MPS|B&L Multi-Purpose Solution as a rub care regimen (Control)
16586635|NCT02701543|Active Comparator|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
16586636|NCT02701543|Active Comparator|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
16586637|NCT02701530|Experimental|Targeted smoking cessation|"Smoking cessation program tailored in cooperation with the target group; smokers with low education.
~Peer-based anti-relapse strategy. Recruitment strategy: peer-driven, written invitations and posters."
16586638|NCT02701530|No Intervention|Control|No smoking cessation program.
16586639|NCT02701517|Active Comparator|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
16586640|NCT02701517|Experimental|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
16586641|NCT02701504||Sleep apnea group|The patients who are found to have sleep apnea based on the results of the portable sleep study
16586642|NCT02701504||Non sleep apnea group|The patients who are found to have no sleep apnea based on the results of the portable sleep study
16586643|NCT02701491|Experimental|Ginger|Ginger
16586644|NCT02701491|Placebo Comparator|Placebo|Placebo-no intervention
16586645|NCT02701478|Other|N2O exposure|"There is only one arm in this study. All patients under General Anesthesia are exposed to 4 different doses or concentrations of inhaled N2O that is combined with the anesthetic desflurane. Each patient will be submitted to the standard nociceptive stimulus when inhaled N2O is at 0, 50, 25, and finally back to 0%. ANI and NoL Indices variations between before stimulus and after stimulus at each N2O concentration will be assessed and compared. This will allow to demonstrate an analgesic effect (less variations of ANI and NoL) when inhaled N2O is high (50%) testifying for the analgesic effect of this gas N2O."
16586646|NCT02701465|Experimental|Intervention group|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
16586647|NCT02701465|Active Comparator|Control group|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
16586648|NCT02701452|Experimental|COAGO|All patients undergoing antagonist protocol and at high risk of OHSS (estradiol level ≥ 3000 pg/mL and/or more than 20 follicles ≥ 11mm on the day of triggering) were triggered by GnRH agonist.
16586649|NCT02701439||HIV-infected|"Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.
~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
~Abbreviated demographic and clinical evaluation
~TB history and evaluation
~Obtain three sputum samples - one early morning sample and two spot samples
~HIV testing (and CD4 if positive)
~Chest radiograph
~Small membrane filtration intervention"
16586650|NCT02701439||HIV negative|"Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.
~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
~Abbreviated demographic and clinical evaluation
~TB history and evaluation
~Obtain three sputum samples - one early morning sample and two spot samples
~HIV testing (and CD4 if positive)
~Chest radiograph
~Small membrane filtration intervention"
16586651|NCT02701426|Experimental|participant|agree to participate to the program combining physical activity and nutritional counseling
16586652|NCT02701426|No Intervention|no participant|disagree to participate to the program
16586653|NCT02701413|Experimental|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
16586654|NCT02701413|Sham Comparator|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
16586655|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
16586656|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
16586657|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
16586658|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
16586659|NCT02701374|Experimental|1:TRK-700|high dose
16586660|NCT02701374|Experimental|2:TRK-700|low dose
16586661|NCT02701374|Placebo Comparator|3:Placebo|Placebo
16586702|NCT02701114|Active Comparator|Proximal|Proximal Adductor Canal Block
16586703|NCT02701114|Active Comparator|Distal|Distal Adductor Canal Block
16586662|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
16586663|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
16586664|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
16586665|NCT02701335|Experimental|Experimental group|Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
16586666|NCT02701335|Active Comparator|Control group|Gloreha device and standardized exercise. 12 sessions over 4 weeks (3 sessions per week).
16586667|NCT02701322|Experimental|Medical Clown|the study group will be accompanied by a medical clown from the arrival to the premise, through the actual examination and after exiting the exam room. The medical clown will explain about the upcoming examination and will induce a less stressed atmosphere. After the examination the clown will close the session for the patient.
16586668|NCT02701322|No Intervention|Control|The control group will do the same videofluoroscopic procedure but without a medical clown.
16586669|NCT02701309||Non-invasive Iron detection|Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.
16586670|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
16586671|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
16586674|NCT02701270|Experimental|Experimental Dietary Fibre 1|
16586675|NCT02701270|Experimental|Experimental Dietary Fibre 2|
16586676|NCT02701270|Active Comparator|Polydextrose|
16586677|NCT02701270|Active Comparator|Dextrose control|
16586678|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
16586679|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
16586680|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
16586681|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
16586682|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
16586683|NCT02701244||Permanent Breast Seed Implant (PBSI)|Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
16586684|NCT02701231|Sham Comparator|Sham control|Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
16586685|NCT02701231|Experimental|Low-frequency Rotating Magnetic Therapy|Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
16586686|NCT02701218|Experimental|Single cycle|single cycle of canalith repositioning procedure
16586687|NCT02701218|Experimental|multiple cycles of CRP|multiple cycles of canalith repositioning procedure CRP will be stopped if 1) no nystagmus and vertigo in all positions 2) complications exited 3) stable nystagmus in the 2 last cycles
16586688|NCT02701205|Experimental|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
16586689|NCT02701205|Experimental|etanercept (half dose)|One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
16586690|NCT02701205|Placebo Comparator|Placebo|Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24
16586691|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
16586692|NCT02701179|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
16586693|NCT02701179|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
16586694|NCT02701166|Experimental|Bezafibrate|Bezalip retard 400mg tablet
16586695|NCT02701166|Placebo Comparator|Placebo|Placebo 400mg tablet
16586696|NCT02701153|Experimental|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
16586697|NCT02701140|Active Comparator|Ticagrelor|Ticagrelor will be given in a loading dose of 180 mg followed by a dose of 90 mg twice daily.
16586698|NCT02701140|Active Comparator|Clopidogrel|Clopidogrel will be given in a loading dose of 600 mg followed by a dose of 75 mg once a day.
16586699|NCT02701127|Active Comparator|Niacinamide 1 gram|Oral niacinamide, 1 gram daily
16586700|NCT02701127|Active Comparator|Niacinamide 3 grams|Oral niacinamide, 3 grams daily
16586704|NCT02701101|Other|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:
~Risk Assessment (standard of care; Braden, Waterlow, or Norton)
~Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)
~SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
16586706|NCT02701075|Experimental|MC5-A Scrambler Therapy|MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
16586707|NCT02701075|Sham Comparator|MC5-A Scrambler Therapy Sham Device|The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
16586708|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
16586709|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
16586710|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
16586711|NCT02701036||sporadic adult onset ataxia|SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
16586712|NCT02701036||cerebellar multiple system atrophy|Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.
16586713|NCT02701010|Active Comparator|Group 1|Structured training and leaflet
16586714|NCT02701010|Active Comparator|Group 2|Structured training
16586715|NCT02701010|Active Comparator|Group 3|Leaflet
16586716|NCT02701010|Sham Comparator|Group 4|Control group
16586717|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
16586718|NCT02700984|Experimental|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
16586719|NCT02700984|Active Comparator|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
16586720|NCT02700971|Experimental|Cutaneous Biopsy for microarray analysis|To determine whether outcomes improve as a function of anti-tumor immunity which may enable the use of this technique as a predictive biomarker of treatment response.
16586721|NCT02700958|Experimental|Remote ischemic preconditioning|Remote Ischemic Preconditioning (RIPC) is performed by inflating blood pressure cuff for 5-minutes at 200 mmHg, or if patients systolic blood pressure is higher than 200 mmHg 20 mmHg above systolic pressure, alternated with 5-minute deflation for 4 times.
16586722|NCT02700958|Sham Comparator|SHAM remote ischemic preconditioning|SHAM Remote Ischemic Preconditioning (RIPC-SHAM) is accomplished by alternating 4 cycles of 5-minute inflation with 5-minute deflation. Blood pressure cuff will be inflated to 10-20 mmHg. RIPC-SHAM is performed with standard blood pressure cuff on upper-arm.
16586723|NCT02700945|Active Comparator|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
16586724|NCT02700945|No Intervention|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
16586725|NCT02700932|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
16586726|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
16586727|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
16586728|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
16586729|NCT02700906|Active Comparator|Corticosteroid injection|For corticosteroid injection, triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
16586730|NCT02700906|Active Comparator|Lidocaine injection|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
16586731|NCT02700893|Experimental|Atropine + propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
16586732|NCT02700893|Active Comparator|Atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
16586733|NCT02700880||Heart failure patients with LifeVest|Subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator
16586734|NCT02700867|Experimental|Proximal tibia|Assumption of intraosseous access into the proximal tibia. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
16586735|NCT02700867|Experimental|Proximal humerus|Assumption of intraosseous access into the proximal humerus. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
16586736|NCT02700854|Experimental|5% carbon-dioxide inhalation|5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
16586739|NCT02700828|Active Comparator|Hydrocortisone|Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
16586740|NCT02700828|Placebo Comparator|Placebo|Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
16586741|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
16586742|NCT02700815|Active Comparator|Diclofenac|
16586743|NCT02700815|Active Comparator|Capsaicin|
16586744|NCT02700815|Placebo Comparator|Placebo|
16586745|NCT02700802|Experimental|Feed1st: Face-to-face provider delivered referral|In this arm of the study, caregivers will receive usual care and a brief face-to-face referral to the Feed1st program delivered by the provider.
16586746|NCT02700802|Experimental|Feed1st: Text message delivered referral|In this arm of the study, caregivers will receive usual care and an automated brief text message referral to the Feed1st program from the health care provider. The text message referral will align as closely as possible with the face-to-face referral.
16586747|NCT02700802|No Intervention|Standard of Care|Usual care includes passive delivery of information from nursing staff about all available food options in the hospital including the self-serve food pantries in the standard Caregiver FYI Admissions Packet.
16586748|NCT02700789||Pregnant women|Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures.
16586749|NCT02700776||COHORT I-BIRADS 1 or 2,|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0 and 6-12.
16586750|NCT02700776||COHORT II -BIRADS 3|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0, 3-6, and 6-12.
16586751|NCT02700776||COHORT III-BIRADS 4-6|SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
16586752|NCT02700763|Experimental|[18F]dabrafenib molecular imaging|A [18F]dabrafenib PET scan will be performed at baseline (7 days or less before the start of treatment with oral dabrafenib).
16586753|NCT02700750|Other|OCT exam|OCT exam No Arm No Intervention
16586754|NCT02700737|Active Comparator|Group A|"Interventional cardiologists presented with limited dataset including only information that is available from imaging parameters currently recommended by clinical practice guidelines."
16586755|NCT02700737|Experimental|Group B|Interventional cardiologists presented with the full dataset, including imaging parameters currently recommended by clinical practice guidelines and image-based simulation modelling.
16586756|NCT02700724|Other|Observation|Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
16586757|NCT02700724|Other|Immediate Surgery|Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
16586758|NCT02700711|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance.
16586759|NCT02700711|Experimental|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance.
16586760|NCT02700698||Healthy lean|Healthy lean women, 25-35 years
16586761|NCT02700698||Obese IR|Obese, insulin resistant women, 25-35 years
16586762|NCT02700685|Experimental|Pycnogenol|"Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
~Subjects < 30 kg body weight: 20 mg Pycnogenol/day Subjects >= 30 kg body weight: 40 mg Pycnogenol/day"
16586763|NCT02700685|Placebo Comparator|Placebo|Placebo treatment (identical capsules containing excipients only)
16586764|NCT02700685|Active Comparator|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release. Subjects < 30 kg body weight: 20 mg methylphenidate once per day Subjects >= 30 kg body weight: 30 mg methylphenidate once per day
16586765|NCT02700672||Institutionalized older adults|Observational study
16586766|NCT02700672||Non-institutionalized older adults|Observational study
16586767|NCT02700659||UC monitoring patients|"Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations.
~All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder.
~No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes."
16586768|NCT02700646|No Intervention|standard care|Standard care comparison
16586769|NCT02700646|Experimental|inpatient|Inpatient recommendations to parents regarding infant motor activities
16586770|NCT02700646|Experimental|inpatient/outpatient|Inpatient and outpatient recommendations to parents regarding infant motor activities
16586771|NCT02700633||Those with pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
16586772|NCT02700633||Those without pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
16586773|NCT02700620|Experimental|Treatment group|Internet-delivered CBT
16586774|NCT02700620|No Intervention|Control group|Waitlist control
16586775|NCT02700607|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16586776|NCT02700607|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
16586830|NCT02700243|Experimental|Fitbit|Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
16586831|NCT02700243|No Intervention|Usual Care|Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
16586777|NCT02700594|Active Comparator|Hip mobilization|Prone posterior-to-anterior Grade IV hip joint mobilization: The subject will be placed in prone on a treatment table. The intervening physical therapist will place the heel of his hand on the greater trochanter of the femur on the involved side provide rhythmic anterior-directed force. The subject will receive 3 bouts of 30 seconds of continuous mobilizations with 10 seconds rest in between bouts. For the prone posterior-to-anterior Grade IV hip joint mobilization, the intervening therapist will perform all 3 bouts in the same position.
16586778|NCT02700594|Active Comparator|Spine mobilization|Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization: The subject will be placed in prone on the treatment table. The intervening physical therapist will place his thumbs on the transverse process, on the affected side, of the L3, L4 or L5 vertebrae and provide a rhythmic anterior-directed force. Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization, the intervening therapist will perform 1 bout on each of L3, L4 and L5 for a total of 3 bouts
16586779|NCT02700581|Active Comparator|low PEEP conventional ventilation|PEEP 2 mmHg tidal volume 10ml/kg
16586780|NCT02700581|Experimental|moderate PEEP conventional ventilation|PEEP 7 mmHg tidal volume 10ml/kg
16586781|NCT02700581|Experimental|low PEEP protective ventilation|PEEP 2 mmHg with tidal volume 6 ml/kg
16586782|NCT02700581|Experimental|moderate PEEP protective ventilation|PEEP 7 mmHg tidal volume 6ml/kg
16586783|NCT02700568|Experimental|axitinib|Patients will receive axitinib.
16586784|NCT02700542|Active Comparator|Intervention|"Participants randomly assigned to the intervention group will receive the Integrated Pest Management (IPM) treatment 2-4 weeks of completion of the baseline assessment.The IPM protocol for this research will focus on pest control in the bathrooms and kitchen and will include an assessment of the pest problem, thorough cleaning, patching of small holes, identification and referral of any necessary large repairs, and targeted application of safe pesticides as needed. In cases of severe infestation, a second treatment visit might be required in the home.
~In addition to the intervention, the family will be provided with basic information about good pest-control practices, such as appropriate food storage, and be given a set of food storage containers."
16586785|NCT02700542|Placebo Comparator|Control|Participants randomly assigned to the control group will be offered the equivalent intervention, information, and food storage containers after completion of their 12-month assessment.
16586786|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
16586787|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
16586788|NCT02700516||Recurrent GN|Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
16586789|NCT02700516||Non-recurrent GN|Renal transplant recipients with non-recurrent primary glomerulonephritis.
16586790|NCT02700516||Non-GN|Renal transplant recipients with etiologies other than primary glomerulonephritis.
16586791|NCT02700503|Experimental|Intervention|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
16586792|NCT02700490|Active Comparator|Specialist|Assessment and treatment of common mental disorders by a clinical psychologist in primary care facilities.
16586793|NCT02700490|Experimental|Enhanced Usual Care|Assessment and treatment of common mental disorders by a general practitioner and nurse practitioner, who have been trained in the WHO mhGap manual, in primary care facilities.
16586794|NCT02700477|Active Comparator|Fenugreek seed extract|Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks
16586795|NCT02700477|Placebo Comparator|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
16586796|NCT02700464|Experimental|Bladder EpiCheck Urine Test|Bladder EpiCheck Urine Test
16586797|NCT02700464|Active Comparator|Gold Standard|Cystoscopy and pathology
16586798|NCT02700451|Placebo Comparator|Intravenous (IV) Placebo|IV Placebo arm
16586799|NCT02700451|Experimental|IV Ketorolac|IV Ketorolac arm
16586800|NCT02700451|Experimental|IV Acetaminophen|IV Acetaminophen arm
16586801|NCT02700438|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
16586802|NCT02700438|Experimental|Urgent PC Neuromodulation System®|The Urgent PC Neuromodulation System® (Uroplasty, Minnetonka, MN, USA) was used for percutaneous posterior tibial nerve stimulation. Subjects underwent one 30-min session 2 days per week for 8 consecutive weeks in an outpatient clinic. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion. PPTNS was undertaken at the highest amplification (0-20 mA) at a frequency of 20 Hz, causing neither a motor response nor pain.
16586803|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
16586804|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
16586832|NCT02700230|Experimental|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies.
16588536|NCT02688530|Placebo Comparator|0mg IV Dexamethasone|0mg IV Dexamethasone
16586805|NCT02700412|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).
~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
16586806|NCT02700399|Other|Erigo® First|"Erigo® 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Traditional Tilt table 0 - 60 degrees
~Step frequency on Erigo® = 48"
16586807|NCT02700399|Other|Traditional first|"Traditional Tilt table 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Erigo® 0 - 60 degrees
~Step frequency on Erigo® = 48"
16586808|NCT02700386|Experimental|Adjuvant Hypofractionated Radiation|"Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a boost or conedown) to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions."
16586809|NCT02700373|Experimental|PDC-APB|"PDC-APB Intra-Muscular (IM)
~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
16586810|NCT02700373|Placebo Comparator|Placebo|"Placebo
~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
16586811|NCT02700360|Experimental|Part 1(1,000mg dose): group 1|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; cross-over period: 7 days
16586812|NCT02700360|Experimental|Part 1(1,000mg dose): group 2|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; cross-over period: 7 days
16586813|NCT02700360|Experimental|Part 2(500mg dose): group 3|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; cross-over period: 7 days
16586814|NCT02700360|Experimental|Part 2(500mg dose): group 4|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
16586815|NCT02700360|Experimental|Part 2(2,000mg dose): group 5|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, after high-fat diet intake; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; cross-over period: 7 days
16586816|NCT02700360|Experimental|Part 2(2,000mg dose): group 6|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
16586817|NCT02700347|Experimental|Low dose pyrazinamide|Day 0: Pyrazinamide 10mg/kg, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 10mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
16586818|NCT02700347|Experimental|Standard dose pyrazinamide|Day 0: Pyrazinamide 25mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 25mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
16586819|NCT02700347|Experimental|High dose pyrazinamide|Day 0: Pyrazinamide 35mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 35mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
16586820|NCT02700334|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
16586821|NCT02700334|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
16586822|NCT02700321|Experimental|High Flow nasal cannula oxygen (HFNC)|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/Airvo® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
16586823|NCT02700321|Active Comparator|STANDARD high flow Face Mask (HFFM)|"Patients randomized in Standard face mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
16586824|NCT02700308|Active Comparator|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
16586825|NCT02700308|Experimental|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
16586826|NCT02700295||Orthokeratology contact lens group|
16586827|NCT02700282|Experimental|Cystic Fibrosis children|"Children with Cystic Fibrosis will experience lung function measurement while backpack carrying.
~Aerobic Capacities will also be assessed during treadmill gait."
16586828|NCT02700282|Active Comparator|Healthy Children|"Healthy Children will experience lung function measurement while backpack carrying.
~Aerobic Capacities will also be assessed during treadmill gait."
16586829|NCT02700256||Patients undergoing a procedure|Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third & final call for that day will be placed at 11:00am.
16586833|NCT02700217|Experimental|Spinal Anaesthesia|2.5ml of heavy 0.5% Bupivacaine, 400mg of Diamorphine (Spinal Anaesthesia) & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
16586834|NCT02700217|Active Comparator|Rectus Sheath Injection|50ml of 0.25% I-Bupivacaine max 2mg/kg (IV block Anaesthesia) injected into rectus sheath bilaterally & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
16586835|NCT02700204|Experimental|PicoWay 532nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 532nm hand-piece
16586836|NCT02700204|Experimental|PicoWay 1064nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 1064nm hand-piece
16586837|NCT02700191|No Intervention|Control|For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.
16586838|NCT02700191|Experimental|uCor|For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.
16586839|NCT02700178|Experimental|Biofeedback|Participants will be asked to participate in all or a subset of daily activities for wheelchair users. The intervention will consist of visual and/or auditory cues to guide their movement while performing the tasks during one to two sessions.
16586840|NCT02700165|Experimental|CoolSculpting with CoolMini|The treatments are designed to see if fat in the submandibular/submental area (chin), can be reduced using cryolipolysis.
16586841|NCT02700152|Experimental|all subjects|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape device according to the study protocol and user manual.
~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
16586842|NCT02700139|Experimental|Aspheric lens|An aspheric lens which is supposed to slow myopic progression in children by unique asphericity (proprietary information)
16586843|NCT02700139|No Intervention|Single vision spheric/toric lenses|Control: single vision spheric/toric lenses
16586844|NCT02700126||undergoing propofol based TIVA for clip|This study is an observational study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm. We will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
16586845|NCT02700113||ASD|There is only one group; minimally verbal individuals with Autism Spectrum Disorder aged 4 to 17 years.
16586846|NCT02700100|Experimental|Pulmonary Valved Conduit (PV-001)|Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.
16586847|NCT02700087|Placebo Comparator|H2 blocker versus placebo|"The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily).
~Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo."
16586848|NCT02700087|Active Comparator|Treatment arm|Patients who develop severe airway symptoms while they are in the H2 blocker versus placebo arm will then cross over to the treatment arm of the study. These patients will exit randomization and be unblinded. These patients will all be given H2 blockers, and the effects of the H2 blockers will be monitored and studied. Alternatively, patients' families may also elect to undergo surgery to treat laryngomalacia.
16586849|NCT02700074||Minimally Verbal|Minimally verbal adolescents with Autism Spectrum Disorder
16586850|NCT02700074||Verbal Impaired|Language impaired adolescents with ASD
16586851|NCT02700074||Verbal Normal|Language normal adolescents with ASD
16586852|NCT02700074||Typically Developing|Typically developing adolescent controls
16586853|NCT02700061|Experimental|Induced Constraint Therapy - ICT|Physical rehabilitation with Induced Constraint Therapy as part of the occupational therapy. Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
16586854|NCT02700061|Experimental|Robotic occupational therapy|Physical rehabilitation with Robotic occupational therapy. Robotic Occupational Therapy three times a week for twelve weeks.
16586855|NCT02700048|Placebo Comparator|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
16586856|NCT02700048|Experimental|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
16586857|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
16586858|NCT02700035|No Intervention|BZDDD Prevention Program Control|We employed a randomized block (RB) design; blocked on reservation, 147 families were randomly assigned to the control condition. We completed a post-test and a 6-month youth follow-up.
16586890|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.
~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.
~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
16586859|NCT02700022|Experimental|Alisertib combined with R-EPOCH|Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
16586860|NCT02700009|Experimental|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
16586861|NCT02700009|Active Comparator|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
16586862|NCT02699996|Experimental|self-management + peer mentoring|Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
16586863|NCT02699983|Experimental|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.
~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.
~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.
~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
16586864|NCT02699983|Active Comparator|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
16586865|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.
~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
16586866|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
16586867|NCT02699944|Experimental|CRT sub-optimal responder|Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still <50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.
16586868|NCT02699931|Experimental|Electric3D|3D electric toothbrush (Oral-B) with orthodontic head.
16586869|NCT02699931|Active Comparator|Manual|Manual orthodontic toothbrush (Oral-B).
16586870|NCT02699918|Experimental|screening oxymetry|nocturnal oxymetry to screen for sleep apnea
16586871|NCT02699905||Sepsis|Patients with the diagnosis of sepsis or septic shock
16586872|NCT02699905||Control|Healthy control with no evidence of active infection, or recent infection in the past 4 weeks.
16586873|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
16586874|NCT02699879||Pirfenidone|Participants will receive pirfenidone orally according to the physician discretion.
16586875|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
16586876|NCT02699853|Experimental|Arm I (RRC)|Patients undergo RRC at day 0.
16586877|NCT02699853|Experimental|Arm II (ORC)|Patients undergo ORC at day 0.
16586878|NCT02699840||Menactra Study Group 1|Participant aged 2 through 11 years at vaccination
16586879|NCT02699840||Menactra Study Group 2|Participant aged 12 through 17 years at vaccination
16586880|NCT02699840||Menactra Study Group 3|Participant aged 18 through 55 years at vaccination
16586881|NCT02699827|Active Comparator|Magnesium sulphate group|Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate
16586882|NCT02699827|Placebo Comparator|Placebo group|Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%
16586883|NCT02699814|Experimental|H3 Parent/Child Dyads|A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99 years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem. For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
16586884|NCT02699801|Active Comparator|Propofol|Patients received propofol for post-operative sedation
16586885|NCT02699801|Active Comparator|Dexmedetomidine|Patients received dexmedetomidine for post-operative sedation
16586886|NCT02699788|Experimental|Multifunction Cardiogram|non-invasive computerized, multiphase, resting electrocardiogram analysis device
16586887|NCT02699775||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
16586888|NCT02699762|Experimental|experimental group|self rehabilitation of upper limb in experimental group + BTI + usual physiotherapy
16586889|NCT02699762|No Intervention|control group|BTI + usual physiotherapy
16586903|NCT02699710|Experimental|Part 1: GDC-0853, Rabeprazole (Fasting State)|Participants will receive single dose of GDC-0853 (200 milligrams [mg]) in a crossover design as either the capsule or tablet formulation in the fasted state with the final fixed treatment consisting of the tablet formulation administered in the fasted state after prior administration of rabeprazole (20 mg twice daily [BID]) for 3 days.
16587058|NCT02698605|Experimental|Usability test study of the MirrorPath|This study was a one-arm study and all subjects used the device and received usability test.
16586891|NCT02699736||Cohort I|Enrolled from August 1994. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586892|NCT02699736||Cohort II|Enrolled from January 1996. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586893|NCT02699736||Cohort III|Enrolled from February 1997. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586894|NCT02699736||Cohort IV|Enrolled from March 1999. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). The eligibility criteria of a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion has been removed for patients joining the study in 1999 and beyond, since the intention of the study is to include most patients eligible for antiretroviral therapy. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586895|NCT02699736||Cohort V|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586896|NCT02699736||Cohort VI|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586897|NCT02699736||Cohort VII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586898|NCT02699736||Cohort VIII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586899|NCT02699736||Cohort IX|Enrolled from December 2011. Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586900|NCT02699736||Cohort X|All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment >2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
16586901|NCT02699736||Cohort XI|"HIV-1 positive persons ≥18 years of age, not already enrolled in EuroSIDA, are eligible for inclusion. Participants should be enrolled consecutively in one of the following two groups:
~Participants who have started integrase inhibitor (INSTI) based antiretroviral therapy (ART) after 1/1/2012 and have a CD4 cell count and HIV-RNA available in the 12 months prior to starting INSTI or within 3 months after starting INSTI
~If participants have not started INSTI, they should be included providing they have a CD4/HIV-RNA in the 12 months prior to baseline or within 3 months after baseline.
~For all patients enrolled and under follow up, laboratory, therapeutic, clinical and demographic data, date on pregnancy and data on hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually."
16586902|NCT02699723|Experimental|Treatment (arsenic trioxide, itraconazole)|Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
16587059|NCT02698592|Active Comparator|CelsiusTMDS® 8 mm catheter|50 patients underwent ablation with CelsiusTMDS® 8 mm catheter.
16586904|NCT02699710|Experimental|Part 2: GDC-0853, Rabeprazole (Fasting or Fed State)|Participants will receive single dose of GDC-0853 (200 mg) tablet formulation in the fasted or fed state in a crossover design with the final fixed treatment consisting of the tablet formulation administered in the fed state after prior administration of rabeprazole (20 mg BID) for 3 days.
16586905|NCT02699710|Experimental|Part 3: GDC-0853, Methotrexate|Participants will receive single dose of methotrexate (7.5 mg) under fasting conditions on Day 1 (5 mg folic acid will be administered the following day [Day 2]) and then GDC-0853 (200 mg) tablet formulation twice daily (BID) under fasting conditions (an overnight fast for the morning dose and a 2 hour fast for the evening dose) from Days 15 to 20 after washout period from Days 2 to 14. On Day 21, participants will receive single dose of methotrexate (7.5 mg) with single dose of GDC-0853 (200 mg) tablet formulation under fasting conditions, and folic acid (5 mg) will be administered on Day 22.
16586906|NCT02699697|Experimental|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
16586907|NCT02699697|Experimental|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
16586908|NCT02699684|Other|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
16586909|NCT02699684|Other|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
16586910|NCT02699671||acute myocardial infarction|
16586911|NCT02699658|Experimental|levofloxacin in healthy|
16586912|NCT02699645|Experimental|Triple Pill (active treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
16586913|NCT02699645|Placebo Comparator|Placebo|received via blinded study capsules
16586914|NCT02699619|Active Comparator|2 Hansson pins without plate|Patients with undisplaced femoral neck fractures operated with 2 isolated Hansson pins.
16586915|NCT02699619|Active Comparator|3 Hansson pins interlocked in a plate|Patients with undisplaced femoral neck fractures operated with 3 Hansson pins interlocked in plate (Pinloc).
16586916|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
16586917|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
16586918|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
16586919|NCT02699580|Experimental|Biodegradable collagen implant|Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.
16586920|NCT02699580|Active Comparator|Without biodegradable collagen implant|Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.
16586921|NCT02699567||Lean AA|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
16586922|NCT02699567||Obese AA|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
16586923|NCT02699567||Lean GG|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
16586924|NCT02699567||Obese GG|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
16586925|NCT02699554||Orthopaedic surgery|
16586926|NCT02699541|Experimental|Intervention group|Intervention group participants will receive the educational intervention based on the Information, Motivational, Behavioral change model.
16586927|NCT02699541|No Intervention|Control group|Control group participants will receive usual care treatment and referral to diabetes educational consultation if required.
16586928|NCT02699515|Experimental|MSB0011359C (M7824)|
16586929|NCT02699502|Experimental|patients with osteoporotic hip fractures|The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.
16586930|NCT02699489|Experimental|Laparoscopic donor nephrectomy arm|This group will undergo laparoscopic donor nephrectomy
16586931|NCT02699489|Active Comparator|Open donor nephrectomy arm|This group will undergo open donor nephrectomy
16586932|NCT02699476|Active Comparator|Individual + Computer A|Daily activities involve playing one hour of computer games (e.g., hangman, boggle, word scramble, chess; computer cognitive training A (CCA)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
16586933|NCT02699476|Experimental|Individual + Computer B|Daily activities involve playing an alternative set of computer games (computer cognitive training B (CCB)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
16586934|NCT02699476|Active Comparator|Group + Computer B|Daily activities involve group and individual cognitive therapy discussions on health, nutrition, and other topics and computer cognitive training B (CCB).
16586935|NCT02699463|Active Comparator|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
16586936|NCT02699463|Placebo Comparator|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
16586972|NCT02699216|Experimental|Phase 1 Active Treatment|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
16586937|NCT02699450|Active Comparator|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
16586938|NCT02699450|Experimental|Arm B: 1.5 mg Faricimab|Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
16586939|NCT02699450|Experimental|Arm C: 6 mg Faricimab|Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
16586940|NCT02699437||Pregnant women with preeclampsia|Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.
16586941|NCT02699424|Other|Radiotherapy|
16586942|NCT02699411|Active Comparator|dry needling|Dry needling on the vastus is performed in patients undergoing ACL fortnight after the intervention and then evaluated. REL dry needling while supplies last twenty insertions before treatment, at midnight, a week and five weeks.
16586943|NCT02699411|Active Comparator|Stability and propioception|Proprioception and stability exercises in patients undergoing ACL fortnight after the intervention and then evaluates performed before treatment, at midnight, a week and five weeks.
16586944|NCT02699398|Experimental|VR-based therapy|3 weeks of home-based treatment for motor training using a virtual reality rehabilitation setup.
16586945|NCT02699398|Active Comparator|Control|3 weeks of home-based occupational therapy for motor training.
16586946|NCT02699385|Experimental|Oral Rehydration Therapy (ORT) + Domperidone|Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
16586947|NCT02699385|Experimental|Oral Rehydration Therapy + Placebo|Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.
16586948|NCT02699372|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.
16586949|NCT02699372|Experimental|RO6889450: Part 1 Single Ascending Dose (SAD)|Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram [mg] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.
16586950|NCT02699372|Experimental|RO6889450: Part 2 Multiple Ascending Dose (MAD)|The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
16586951|NCT02699359|Experimental|HS-1000 recording|Study participants will receive HS-1000 ICP readings for a continuous 16 minute interval in a 30 degree supine position. Recordings will be obtained in one session. When possible, these recordings will be obtained at their initial examination and all follow-up visits. Sports Medicine staff will coordinate the HS-1000 device earplug insertion and recordings so as not to interfere with, nor marginally delay the patient's normal, routine clinical evaluation.
16586952|NCT02699346|Experimental|HS-1000 recording|Eligible patients and healthy subjects will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears. HS-1000 monitoring intervals will last from 20 minutes continuously. Following completion of data collection, HS-1000 will be removed.
16586953|NCT02699333||Microscopic colitis cases|Patients found to have microscopic colitis based on colonic biopsies.
16586954|NCT02699333||Controls|Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.
16586955|NCT02699320||"Asymptomatic"|"Asymptomatic meaning patients showed well tolerance to parenteral nutrient (PN) administration and there were no complications occurred within two months (n=7);"
16586956|NCT02699320||CLABSI|with central catheter-related blood stream infections (CLABSI) meaning patients had fever, increased neutrophils, documented positive catheter blood culture but exclude other source of infection (n=5)
16586957|NCT02699320||PNALD|with parenteral nutrient associated liver disease (PNALD), meaning SBS patients showed elevated liver enzymes and bilirubin (n=14).
16586958|NCT02699320||healthy controls|Seven healthy infants who had added complementary were served as controls (n=7).
16586959|NCT02699307|Experimental|Intervention|OT-led counseling based on home activity pattern
16586960|NCT02699294|Experimental|Contract-relax PNF stretch|A contract-relax PNF stretching techniques of the pectoralis minor muscle including latent trigger points will be applied by Group 1 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
16586961|NCT02699294|Experimental|Z-stretch|The Z- stretch of the pectoralis minor muscle including latent trigger points will be applied by Group 2 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
16586962|NCT02699294|Experimental|Manual pressure release|The single intervention of manual pressure release will be only applied to Group 3 according to the techniques describe by Simons et al. (1999).
16586963|NCT02699294|No Intervention|Control|This is a control group.
16586964|NCT02699281|Experimental|Ultra-micronized Palmitoylethanolamide|Ultra-micronized Palmitoylethanolamide 600 mg twice a day
16586965|NCT02699281|Placebo Comparator|Placebo|Placebo tab twice a day
16586966|NCT02699268||Infants (term borns and preterm borns)|Intervention: simultaneous lung function measurement using VoluSense Pediatrics and a mask-based method with an ultrasonic flowmeter (EcoMedics Exhalyzer)
16586967|NCT02699242|Experimental|Simulator arm|In the Simulation arm group the subjects will be trained on the virtual reality bronchoscopic simulator (ORSIM simulator) for up to 60 minutes as active intervention, before they undertake the 2nd Fiber optic intubations.
16586968|NCT02699242|No Intervention|Control arms|The control arm will be exposed only to the didactic teaching. The subjects will not undergo simulator training before undergoing 2nd fiber optic intubations.
16586969|NCT02699229||Malignant|Tissue sample
16586970|NCT02699229||Benign|Tissue sample
16586971|NCT02699229||Normal|Tissue Sample
16586973|NCT02699216|Placebo Comparator|Phase 1 Sham Treatment|Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
16586974|NCT02699216|Experimental|Phase 2 Open Label|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
16586975|NCT02699203|Experimental|High-carbohydrate meal|High carbohydrate breakfast meal consisting of oatmeal and berries.
16586976|NCT02699203|Experimental|Low-carbohydrate meal|Low carbohydrate breakfast meal consisting of eggs and avocado.
16586977|NCT02699190||Prospective Study Cohort|This cohort comprises recently identified individuals for whom a clinical decision has been made to pursue whole genome sequencing (WGS) as a first-line diagnostic test. The cohort also includes each subject's biological parents.
16586978|NCT02699190||Historical Study Cohort|This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
16586979|NCT02699177||Suspected PCD but negative|"CBF measurements:
~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.
~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.
~The two methods will be compared."
16586980|NCT02699177||Suspected PCD but positive|"CBF measurements:
~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.
~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.
~The two methods will be compared."
16586981|NCT02699164|Experimental|combine group|"Conventional physiotherapy applied 15 sessions of treatment. In addition to conventional physiotherapy non-surgical spinal decompression therapy applied.
~First 10 sessions of treatment non-surgical decompression therapy applied and last 5 sessions spinal stabilization exercise applied."
16586982|NCT02699164|Experimental|conventional physiotherapy|conventional physiotherapy applied 15 sessions of treatment. Conventional physiotherapy consisted hotpack, Transcutaneal Electric Nerve Stimulation(TENS) and Ultrasound Currents. Spinal stabilization exercises applied last five sessions of therapy.
16586983|NCT02699138|Experimental|Trazodone|To determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
16586984|NCT02699138|Placebo Comparator|Placebo|To compare placebo outcomes against administration of trazodone
16586985|NCT02699125|Experimental|Placebo, Guanfacine, Hydrochlorothyazide|Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
16586986|NCT02699125|Experimental|Placebo, Hydrochlorothyazide, Guanfacine|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.
16586987|NCT02699099|Experimental|Coad group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
16586988|NCT02699099|Experimental|RTS,S group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
16586989|NCT02699099|Experimental|Control group|Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
16586990|NCT02699086|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
16586991|NCT02699086|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsules, trice daily, p.o. after meal for 28 days
16586992|NCT02699073|Experimental|Regorafenib|dose of regorafenib : 160mg once daily
16586993|NCT02699047|Experimental|Fish oil|3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
16586994|NCT02699047|Placebo Comparator|Control group|3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
16586995|NCT02699034|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
16586996|NCT02699008|Active Comparator|HPR-Ticagrelor row|ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
16586997|NCT02699008|Active Comparator|HPR-Clopidogrel row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
16586998|NCT02699008|Active Comparator|unHPR row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
16586999|NCT02698995|Placebo Comparator|Group A|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+1 ml saline=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
16587000|NCT02698995|Active Comparator|Group B|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+2 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
16587001|NCT02698995|Active Comparator|Group C|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+4 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
16587002|NCT02698982|Experimental|Monitoring|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring accessible to the anesthesia provider.
16587003|NCT02698982|Sham Comparator|Sham|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring blinded to the anesthesia provider
16587004|NCT02698982|No Intervention|Control|elderly non scheduled for surgery
16587005|NCT02698969|Experimental|Sugammadex|patients enrolled who will receive sugammadex 2 mg*kg-1 at the end of surgery
16587006|NCT02698969|Active Comparator|Nestigmine, Atropine|patients enrolled who will receive neostigmine 50 mcg*kg-1 and atropine 15 mcg*kg-1 at the end of surgery
16587007|NCT02698943||Study Group|Participants who underwent phacoemulsification surgery and implantation of the Envista MX-60 IOL
16587008|NCT02698930|Experimental|dexmedetomidine group|
16587009|NCT02698930|Placebo Comparator|Control group|
16587010|NCT02698917|Active Comparator|Group 1|Low normal PaCO2, low normal PaO2, low normal MAP
16587011|NCT02698917|Active Comparator|Group 2|High normal PaCO2, low normal PaO2, low normal MAP
16587012|NCT02698917|Active Comparator|Group 3|Low normal PaCO2, high normal PaO2, low normal MAP
16587013|NCT02698917|Active Comparator|Group 4|High normal PaCO2, high normal PaO2, low normal MAP
16587014|NCT02698917|Active Comparator|Group 5|Low normal PaCO2, low normal PaO2, high normal MAP
16587015|NCT02698917|Active Comparator|Group 6|High normal PaCO2, low normal PaO2, high normal MAP
16587016|NCT02698917|Active Comparator|Group 7|Low normal PaCO2, high normal PaO2, high normal MAP
16587017|NCT02698917|Active Comparator|Group 8|High normal PaCO2, high normal PaO2, high normal MAP
16587018|NCT02698904|Experimental|Guided Relaxation Technique|Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.
16587019|NCT02698904|Sham Comparator|Documentary movie|"Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes documentary movie.
~Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes documentary movie (listening via headphone. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes."
16587020|NCT02698891|Experimental|Neulasta|"After the screening procedures confirm participation in the research study:
~Completion of 4 cycles of dose dense Adjuvant Doxorubicin Cyclophosphamide (AC)
~Paclitaxel via IV, once every 2 week x 4 cycles
~Neulasta™ (Pegfilgrastim) will be administered in Paclitaxel cycles, if:
~The patient experiences a prior episode of fever and neutropenia.
~If the patient has an active infection this decision will be at provider discretion.
~If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
16587021|NCT02698878|Active Comparator|Control Group|Control Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
16587022|NCT02698878|Experimental|Intervention Group|Intervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
16587023|NCT02698865|Experimental|MONOVISC|MONOVISC High Molecular Weight Hyaluronan
16587024|NCT02698865|Placebo Comparator|Saline|Physiologic saline
16587025|NCT02698852|Experimental|BuMA Supreme group|Totally 1000 subjects combined the 220 subjects from randomized controlled trial(RCT) group
16587026|NCT02698839|Experimental|BuMA Supreme group|This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
16587027|NCT02698839|Active Comparator|BuMA™ group|This group contains 220 subjects.
16587028|NCT02698826|Experimental|Adult patients resuscitated from cardiac arrest|Rapid FiO2 optimization protocol
16587029|NCT02698813|Experimental|UCMSCs-HA|Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).
16587030|NCT02698813|Active Comparator|Control|Procedure: Transdermal injection of hyaluronic acid only.
16587031|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
16587032|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
16587057|NCT02698618|Active Comparator|Clopidogrel|A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg
16587033|NCT02698787|Experimental|Group 1|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 1 will be receiving the FAST (experimental) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 1 will be switched to the commercially available ACE (control) sound coding strategy.
16587034|NCT02698787|Experimental|Group 2|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.
16587035|NCT02698761|No Intervention|Standard of Care|Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
16587036|NCT02698761|Experimental|Comprehensive Care Plan|Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.
16587037|NCT02698748|Experimental|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
16587038|NCT02698748|Placebo Comparator|Placebo|Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.
16587039|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
16587040|NCT02698735|Placebo Comparator|Placebo|Vehicle control
16587041|NCT02698722|No Intervention|Control|This group will receive verbal education about dialytic and non-dialytic therapies via a standardized script.
16587042|NCT02698722|Experimental|Intervention|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
16587043|NCT02698709||Healthy corneas (C)|Corneas of normal candidates to refractive surgery who did not develop any sign of corneal ectasia after laser in situ keratomileusis during a two year follow-up period were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
16587044|NCT02698709||Overt keratoconus (Kc)|Whether both eyes manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers. Such eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
16587045|NCT02698709||Forme fruste keratoconus (FFKc)|Whether only one eye manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers, and the fellow eye seemed unaffected. Such unaffected eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
16587046|NCT02698696|Experimental|ECo program|Objective: to inform the patient about cognitive impairments and their repercussions; to train the patient in problem-solving skills through exercises; to implement strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises, tools (tokens, cards, maps, chessboard) Modules: Psychoeducation, Attention, Memory, Executive Functions, Functional Impairments
16587047|NCT02698696|Experimental|CRT program|Objective: problem-solving skills training through exercises, in order to use strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises Modules: Cognitive Flexibility, Working Memory, Planning
16587048|NCT02698696|Active Comparator|Supportive psychotherapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' cognitive and functional impact, social skills, and the regulation of sleep and daily activities.
16587049|NCT02698683||malnourished|low zinc, low albumin, anthropometric measures lower than percentile 5 lymphocyte count
16587050|NCT02698683||well nourished|normal zinc, normal albumin, anthropometric measures higher than percentile 5 lymphocyte count
16587051|NCT02698657|Experimental|ASP5094 Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
16587052|NCT02698657|Placebo Comparator|Placebo Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
16587053|NCT02698644|Experimental|isoamyl2cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
16587054|NCT02698631|Active Comparator|Conventional AF ablation.|A standard radiofrequency AF ablation procedure will be carried out without LGE information.
16587055|NCT02698631|Experimental|LGE-MRI guided AF ablation.|Fibrosis information obtained from post-processed LGE-MRI will be used to guide AF ablation procedures.
16587056|NCT02698618|Experimental|Ticagrelor|A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)
16588537|NCT02688530|Experimental|4mg IV Dexamethasone|4mg IV Dexamethasone
16587060|NCT02698592|Active Comparator|Thermocool® 3.5 mm irrigated catheter|50 patients underwent ablation with Thermocool® 3.5 mm catheter of irrigated tip.
16587061|NCT02698592|Experimental|Thermocool® SF catheter|50 patients underwent ablation with Thermocool® SF catheter.
16587062|NCT02698579||Participants treated with Lenti-D|Partcipants who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304.
16587063|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
16587064|NCT02698553|Experimental|Bupropion XL once daily|Healthy subjects will receive Bupropion XL 150milligram (mg) once daily for 5 days (Day 1 to Day 5) and then Bupropion XL 300 mg once daily from Day 6 to Day 14.
16587065|NCT02698527|Active Comparator|Non-Buffered Lidocaine|Vulvar biopsy conducted using non-buffered lidocaine as anesthesia
16587066|NCT02698527|Experimental|Buffered Lidocaine|Vulvar biopsy conducted using buffered lidocaine as anesthesia
16587067|NCT02698514|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
16587068|NCT02698514|Experimental|Desflurane|Anesthesia was maintained with desflurane.
16587069|NCT02698501|Experimental|MEDI9929|MEDI9929 is a human monoclonal antibody immunoglobulin IgG2λ directed against TSLP. MEDI9929 binds with human TSLP and prevents its interaction with thymic stromal lymphopoietin receptor (TSLPR).
16587070|NCT02698501|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP.
16587071|NCT02698488|Active Comparator|Embryo Selection by Morphology|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study
16587072|NCT02698488|Active Comparator|Embryo Selection by Morphology and Mass Spectroscopy|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study. After dilution, embryo culture media will be analyzed by electrospray ionization quadrupole time-of-flight (ESI-QTOF) MS. The spectra will be collected in the negative ion mode. Abundance of ions in each spectrum will be further analyzed.
16587073|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
16587074|NCT02698462|Other|FIT and Questionnaire|Six thousand persons eligible for the national CRC screening program will be selected. They will be selected from four areas that are considered representative of the Netherlands. All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
16587075|NCT02698449|Experimental|cognitive rehabilitation + transcranial stimulation|specific cognitive rehabilitation combined to transcranial direct current stimulation
16587076|NCT02698449|Experimental|cognitive rehabilitation + stimulation sham|specific cognitive rehabilitation combined to transcranial direct current stimulation sham
16587077|NCT02698449|Experimental|placebo rehab + transcranial stimulation|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation
16587078|NCT02698449|Experimental|placebo rehab + stimulation sham|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation sham
16587079|NCT02698436|Experimental|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
~Other Names: Cleanser is marketed while the device is not marketed"
16587080|NCT02698436|Active Comparator|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.
~Other names: Both products are marketed"
16587081|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
16587082|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
16587083|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.
~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
16587084|NCT02698371|Active Comparator|FBDC-SE (G1; Control)|Futurabond DC (single dose blister) will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; FBDC drying layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20s.
16587085|NCT02698371|Active Comparator|FBDC-SE-EE (G2; Control )|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute. The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of Futurabond DC (FBDC) as self-etch mode simultaneously in dentin and enamel, and the light-cured (LED light; 1000mW/cm2), during 20s.
16587108|NCT02698228|Active Comparator|Ultra-sound guided femoral nerve block|Intravenous injection of 0.1mg/kg of morphine.Injection of 20cc of 0.5% bupivacaine around their femoral nerve under direct ultrasound guidance
16587109|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
16587110|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
16587086|NCT02698371|Other|FBU-ER (G3)|FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
16587087|NCT02698371|Other|FBU-SE (G4)|FuturabondU® (FBU) apply in enamel and dentin as SE mode. Activating FBU SingleDose. FBU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20 seconds.
16587088|NCT02698371|Other|ADU-ER (G5)|Adhese®Universal (ADU) apply by etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15 seconds in dentin and 30 seconds in enamel); Etch agent rinse with water for 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Adhesive ADU will be scrubbed into the tooth surface (enamel and dentin) for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2 for 20s.
16587089|NCT02698371|Other|ADU-SE (G6)|Adhese®Universal (ADU)apply by self-etch (SE) mode. Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with ADU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 20 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2.
16587090|NCT02698358||K-EPIC|Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
16587091|NCT02698345||K-POP|Patients with isolated popliteal artery disease undergoing endovascular therapy using drug-eluting balloon (In.PACT Admiral, Medtronic)
16587092|NCT02698332|Active Comparator|Algorithm for UTI|Practices in this groups receives a diagnostic algorithm for UTI by post
16587093|NCT02698332|No Intervention|Control|Practices in this group does not receive anything in addition to instructions in the observational registration.
16587094|NCT02698319|No Intervention|Conventional Triage|Conventional triage using Danish Emergency Process Triage (DEPT).
16587095|NCT02698319|Experimental|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is used as triage form in the ED. The Copenhagen Triage Algorithm consists of a few vital parameters and a clinical assessment from the ED nurse.
16587096|NCT02698306|Experimental|Dexamethasone|Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days
16587097|NCT02698306|Active Comparator|Diclofenac Sodium|Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days
16587101|NCT02698280|Experimental|Treatment|Patients are treated with bevacizumab and nimustine. Every 6 weeks is defined as one therapeutic cycle. Adverse effect is evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Hematologic toxicity is evaluated every 2 weeks. Liver function, renal function, and electrolytes are assessed every 4-6 weeks. Platelet should be no less than 100*10^9/L and neutrophil count should be no less than 1.5*10^9/L.
16587102|NCT02698267|Experimental|BIIB074|Administered orally on Day 1 and Day 11
16587103|NCT02698254|Experimental|Arm I (conventional fractionation)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
16587104|NCT02698254|Active Comparator|Arm II (conventional fractionation, bevacizumab)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
16587105|NCT02698241|Other|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
16587106|NCT02698228|Sham Comparator|Standard of Care|Intravenous injection of 0.1mg/kg of morphine. Injection of 5cc of 0.9% normal saline into the subcutaneous tissue of the thigh.
16587107|NCT02698228|Active Comparator|Femoral nerve block|Intravenous injection of 0.1mg/kg of morphine. Injection of 20cc of 0.5% bupivacaine into the fascia iliaca space using standard anatomic landmarks.
16587111|NCT02698202|Experimental|Digital Breast Tomosynthesis|to the experimental arm will be offered twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
16587112|NCT02698202|No Intervention|standard mammography|to the control arm the usual 2D standard mammography exam will be offered
16587115|NCT02698176|Experimental|Birabresib 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received birabresib 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
16587116|NCT02698176|Experimental|Birabresib 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
16587117|NCT02698176|Experimental|Birabresib 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
16587118|NCT02698176|Experimental|NMC Cohort-Part B|Participants (up to 30) in Part B will receive birabresib at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive birabresib at the RP2D. Participants will continue receiving birabresib at an assigned/adjusted dose level for continuous cycles up to 24 months.
16587119|NCT02698163|Active Comparator|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
16587120|NCT02698163|Experimental|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
16587121|NCT02698150||Remote monitoring|Active group of patients undergoing daily remote monitoring using sensors and wearables
16587122|NCT02698150||Control|Control group of patients undergoing standard follow up wth no remote monitoring
16587123|NCT02698124||Decitabine|"Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.
~Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression."
16587124|NCT02698111|Experimental|Donafeinib|donafenib 200mg,bid
16587125|NCT02698098||Compulsory Drug Detention Center|Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
16587126|NCT02698098||Voluntary Treatment Center|Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.
16587127|NCT02698085|Experimental|Intervention Goup|Actual Diacutaneous Fibrolysis
16587128|NCT02698085|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis
16587129|NCT02698072|Experimental|Exercise and dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).
~6 dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using Hong's fast-in and fast-out technique with multiple rapid needle insertion."
16587130|NCT02698072|Active Comparator|Exercise and sham dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).
~6 sham dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using a park sham device consists of a base with a hole in the centre and sticky tape on the bottom. From the top of the base extends a double tube, continuing the central hole in the base."
16587131|NCT02698059|Experimental|Treated|iNAP® Sleep Therapy System Treatment
16587132|NCT02698059|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline
16587133|NCT02698046|Experimental|Ferrous sulfate|
16587134|NCT02698046|Placebo Comparator|Placebo|
16587135|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
16587136|NCT02698020|No Intervention|Control|High level of supplemental inspired oxygen
16587137|NCT02698020|Experimental|Room-air|Supplemental oxygen only provided if oxygen saturation below target
16587138|NCT02698007|No Intervention|without lma|standard fiberoptic bronchoscopy without lma
16587139|NCT02698007|Experimental|with lma|fiberoptic bronchoscopy with the use of lma
16587140|NCT02697994|Experimental|Sterile Water Injection|Participants randomised to the intervention group received 4 intracutaneous injections of 0.1 ml sterile water into the skin surrounding the Michaelis rhomboid over the sacral area.
16587141|NCT02697994|Placebo Comparator|Dry Injection|Participants in the control group received 4 dry injections in the same region using an insulin needle .
16587174|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
16588538|NCT02688530|Experimental|6mg IV Dexamethasone|6mg IV Dexamethasone
16587142|NCT02697981|Experimental|intervention group|Pregnant post bariatric surgery women will receive nutritional counseling from a specialist dietitian, to ensure a healthy balanced diet including adequate daily servings from all food groups, intake of essential nutrient during pregnancy such as iron and folic acid and limitation of high-sugar and fatty foods. Patients will also be advised concerning eating at scheduled times (e.g., 4-6 times daily), supplements, preference of water. Advice concerning healthy cooking methods will also be given, as well as advised to avoid soft drinks, drinking during meals, grazing and emotional eating, and fast foods. Subject of lifestyle in general - encouraged to incorporate suitable physical activity on most days, refraining from alcohol, and smoking. intervention: nutrition counseling
16587143|NCT02697981|No Intervention|control group|The control group is comprised of healthy pregnant women, of similar age, smoking behavior and background. No treatment will be given, just follow-up data collection.
16587144|NCT02697968|Experimental|Electroacupuncture|
16587145|NCT02697955|Experimental|Bupivacaine-epinephrine|10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
16587146|NCT02697955|Placebo Comparator|Placebo|10 ml normal saline water (sodium chloride solution, 0,9%)
16587147|NCT02697942|No Intervention|Standard of care|Participants randomized to the standard of care arm will not receive any intervention.
16587148|NCT02697942|Experimental|Cognitive training (CT)|"Participants randomized to the CT arm will be given a tablet with connection to Lumosity®, which is a web-based brain game. Participants will use the tablets to play brain games at each dialysis session."
16587149|NCT02697942|Active Comparator|Exercise training (ET)|Participants randomized to ET arm will be given a stationary foot peddler. This foot peddler will be situated at a comfortable distance from the dialysis chair so that the patient can comfortably reach the peddler. Participants will use the foot peddlers at each dialysis session.
16587150|NCT02697929|Active Comparator|sugammadex|at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
16587151|NCT02697929|Active Comparator|neostigmine|at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation
16587152|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
16587153|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
16587154|NCT02697903|Experimental|9 elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Natural Pomegranate Juice supplementation during and 48h following the first weightlifting training session."
16587155|NCT02697903|Placebo Comparator|9elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Placebo Juice supplementation during and 48h following the second weightlifting training session."
16587156|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:
~Procedure: Ridge preservation procedure"
16587157|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:
~Device: Mucograft® seal Procedure: Ridge preservation procedure"
16587158|NCT02697877||Patients with known or suspected coronary artery disease.|Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.
16587159|NCT02697864|Experimental|48.8 mgA tafamidis free acid tablet|
16587160|NCT02697864|Experimental|58 mgA tafamidis free acid tablet|
16587161|NCT02697864|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
16587162|NCT02697851|Experimental|Group 1|Microgynon 30® for 21 days, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Evotaz® for 14 days
16587163|NCT02697851|Experimental|Group 2|Evotaz® for 14 days followed by 7 days wash-out, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Microgynon 30® for 14 days (participants may chose to complete a 21 day pack). The total duration of the study is 57 days (+screening and follow up visits) and patients will have 3 intensive pharmacokinetic days on days 14, 35 and 56
16587164|NCT02697838|Experimental|Experimental: Apatinib plus chemotherapy|
16587165|NCT02697825|Other|changes in eye|Changes in both intraocular pressure and optic nerve sheath diameter will be correlated in robotic surgeries to find out any statistical relation existing between two.
16587166|NCT02697812|Experimental|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
16587167|NCT02697812|No Intervention|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
16587168|NCT02697799|Experimental|High-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
16587169|NCT02697799|Experimental|Mid-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
16587170|NCT02697799|No Intervention|No modified recruitment strategy|Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
16587171|NCT02697786|Active Comparator|AVR preformed with full sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.
~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
16587172|NCT02697786|Experimental|AVR preformed with minimal invasive sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.
~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
16587173|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
16587175|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
16587176|NCT02697747||Ultrasound education|Training in the use of ultrasound to identify the L3-L4 interspace
16587179|NCT02697721|Experimental|Powerful Tools for Caregivers|A 6-week psycho-educational program
16587180|NCT02697721|Other|Control group, delayed intervention|Control group with delayed intervention
16587181|NCT02697708|Placebo Comparator|Control Diet|Control (no additional potassium added to diet): Arm will consist of a 16 day balance period with a basal diet set at ~2340mg K/day; based on average American intake.
16587182|NCT02697708|Active Comparator|Potassium Supplement Diet|Potassium gluconate: Arm will consist of a 16 day balance period with the basal (control) diet plus the addition of 1000mg of K/day from potassium gluconate (12 tablets).
16587183|NCT02697708|Experimental|Potato Diet|Potato diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg of K/day from white potatoes.
16587184|NCT02697708|Experimental|French fries Diet|French fry diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg K/day from French fries.
16587185|NCT02697695||laparoscopic sleeve gastrectomy|patients who underwent laparoscopic sleeve gastrectomy (LSG) due to obesity and/or metabolic syndrome
16587186|NCT02697695||laparoscopic Roux-en-Y- gastric bypass|patients who underwent laparoscopic Roux-en-Y- gastric bypass (LRYGB) due to obesity and/or metabolic syndrome
16587187|NCT02697695||laparoscopic omega-loop gastric bypass|patients who underwent laparoscopic omega-loop gastric bypass (LOLGB) due to obesity and/or metabolic syndrome
16587188|NCT02697682|Experimental|Intervention|All patients are recieving the treatment.
16587189|NCT02697656|Active Comparator|Treatment as usual + self-help|Interdisciplinary treatment as usual at the outpatient pain clinic + an additional self-help binder with resources about pain management and employment advice.
16587190|NCT02697656|Experimental|Treatment as usual + IPS|Individual job support (IPS) as an integrated part of the interdisciplinary treatment at the outpatient pain clinic.
16587191|NCT02697643|Experimental|BHCDS-based recommendations|The Experimental condition will use the BH-CDS tool and receive tailored recommendations in addition to treatment as usual.
16587192|NCT02697643|Placebo Comparator|Non-tailored recommendations|The Control condition will use the BH-CDS tool and receive non-tailored recommendations in addition to treatment as usual.
16587193|NCT02697630|Experimental|Pembrolizumab and Entinostat|
16587194|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
16587195|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
16587196|NCT02697591|Experimental|Phase 1: 20.0 Milligram Per Kilograms (mg/kg) Every 2 Weeks (Q2W)|Participants received IV infusion of study drug at a dose of 20.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587197|NCT02697591|Experimental|Phase 1: 0.03 mg/kg Q2W|Participants received intravenous (IV) infusion of study drug at a dose of 0.03 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587198|NCT02697591|Experimental|Phase 1: 0.1 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.1 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587199|NCT02697591|Experimental|Phase 1: 0.3 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.3 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587200|NCT02697591|Experimental|Phase 1: 1.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 1.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587201|NCT02697591|Experimental|Phase 1: 3.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 3.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587202|NCT02697591|Experimental|Phase 1: 5.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 5.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587203|NCT02697591|Experimental|Phase 1: 10.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 10.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587204|NCT02697591|Experimental|Phase 1: 400 mg/kg Every 4 Weeks (Q4W)|Participants received IV infusion of study drug at a dose of 400 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587205|NCT02697591|Experimental|Phase 2: 300 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 300 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
16587206|NCT02697565|Experimental|Train-the-Trainers Arm|Intervention Arm receives the Healthy Caregivers- Healthy Children Toolkit (healthy lifestyle role modeling intervention) via a nutritional gate keeper. The toolkit reinforces center health and activity policy standards.
16587207|NCT02697565|Other|Attention Control Arm|Control Arm that receives an attention control safety curriculum.
16587208|NCT02697552|Experimental|HBI-8000|HBI-8000 at the assigned dose twice weekly.
16587209|NCT02697539|Placebo Comparator|AmF/SnF2 group|Patients in this arm were adviced to use a standart dentifrice over the course of the study (AmF/SnF2, Meridol®, GABA, Lörrach, Germany).
16587210|NCT02697539|Active Comparator|mHA group|Patients in this arm were adviced to use the new dentifrice over the course of the study (mHA, BioRepair®, Wolff, Bielefeld, Germany).
16587211|NCT02697526|Other|Terumo|Patients in this arm will receive Terumo after catheterization
16587212|NCT02697526|Other|Tensoplast|Patients in this arm will receive Tensoplast after catheterization
16587213|NCT02697513|No Intervention|Before Period|Collection of patient-related data without interventions being made
16587214|NCT02697513|Active Comparator|After Period|Implementation of a simple infection management protocol as well as a 'Sepsis First Aid' kit to assist in the management of patients with acute infection
16587243|NCT02697279|Active Comparator|Traditional Incision and Drainage|Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
16587216|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
16587217|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
16587218|NCT02697461|Experimental|Intrinsic Foot Arm|In arm 1, a randomized control trial will be used in the investigation of validity and reliability comparing multisegmented foot motion, clinical joint physiological and accessory motion, and morphologic foot measurements, and the effect of intrinsic foot strengthening on multisegmented foot function.
16587219|NCT02697461|Experimental|Joint Mobilization Arm|In arm 2, the investigation of group differences in clinical and laboratory measures of multisegmented foot motion and kinetics will use a case control design. A randomized controlled trial will be conducted in the study investigating joint mobilization, with the researcher performing the assessments and the provider performing the treatments blinded to group allocation
16587220|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
16587221|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
16587222|NCT02697435|Experimental|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
16587223|NCT02697435|Placebo Comparator|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
16587224|NCT02697422|Experimental|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
16587225|NCT02697422|No Intervention|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
16587226|NCT02697409|Experimental|Intervention group|The intervention group receives two school-based modules taking less than two hours each delivered by medical students in the schools.
16587227|NCT02697409|No Intervention|Control group|
16587228|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
16587229|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
16587230|NCT02697383|Experimental|Ixazomib (MLN9708) and Dexamethasone|Patients with high risk SMM will be enrolled on the pilot study and treated with 2 drug combination (Cycles 1-12 Ixazomib at 4 mg weekly on days 1, 8 and 15, and dexamethasone on days 1, 8, 15 and 22 of 28 day cycle); the dexamethasone dose will be 40 mg/week the first 4 cycles, thereafter 20 mg/week.
16587231|NCT02697370|Other|Pharmacokinetic based factor VIII dosage|Patient's routine prophylactic factor VIII concentrate infusion will be given in the morning and the exact time (hours and minutes) and dose recorded. There is no wash out so the date, time and dose of the previous 2 prophylactic doses must be accurately known. Samples will be collected that afternoon, the following morning and the following afternoon. Samples can be taken at any convenient time but the exact time must be recorded. Factor VIII levels will be measured and this pharmacokinetic data will be used to calculate the dose of factor VIII (to be infused on alternate days) required to maintain a predicted factor VIII ≥1.5 IU/dL at all times(this will be rounded up to the nearest full 250 IU vial)
16587232|NCT02697357||Caregivers|This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
16587233|NCT02697344|Experimental|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
16587234|NCT02697331|Active Comparator|progesterone|74 patients will receive progesterone pessary 200mg twice daily
16587235|NCT02697331|Placebo Comparator|Placebo|74 patients will receive placebo
16587236|NCT02697318|Other|Professional Administration|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
16587237|NCT02697318|Other|Self-Administration (new method)|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
16587238|NCT02697305|Experimental|IV BCAA test|IV application of BCAA solution
16587239|NCT02697305|Experimental|ORAL BCAA test|At once oral ingestion of BCAA capsules
16587240|NCT02697305|Placebo Comparator|ORAL PLACEBO test|At once oral ingestion of placebo capsules
16587241|NCT02697292|Placebo Comparator|Placebo/Normal Saline Group|Subjects will receive placebo for 4 infusions. After completion of the blinded phase, subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
16587242|NCT02697292|Active Comparator|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
16587244|NCT02697279|Experimental|Loop drainage|Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.
16587246|NCT02697266||Regular-shift anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
16587247|NCT02697253|Experimental|Successful drug|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.
~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
16587248|NCT02697253|Experimental|Unsuccessful drug|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered Sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.
~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
16587249|NCT02697253|Placebo Comparator|Success placebo|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.
~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
16587250|NCT02697253|Placebo Comparator|Unsuccess placebo|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.
~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
16587251|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
16587252|NCT02697227|Active Comparator|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
16587253|NCT02697227|Active Comparator|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
16587254|NCT02697214|Active Comparator|Apple Watch|Apple Watch heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device .
16587255|NCT02697214|Active Comparator|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
16587256|NCT02697214|Active Comparator|Mio Fuse|Mio Fuse heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
16587257|NCT02697214|Active Comparator|Basis Peak|Basis Peak heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
16587258|NCT02697201|Experimental|Intralipid Infusion, then Saline|Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
16587259|NCT02697201|Sham Comparator|Saline Infusion, then Intralipid|Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
16587260|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
16587261|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
16587262|NCT02697175|Experimental|Live Video-Colposcopy|Women are able to observe their colposcopic examination in real-time watching a flat screen in front of them
16587263|NCT02697175|Active Comparator|No Live Video-Colposcopy|Women are not able to observe their colposcopic examination in real-time
16587264|NCT02697162|Experimental|Antiseptic-coated catheter|Hydrophilic intermittent urinary catheter coated with octenidine chloride
16587265|NCT02697162|Placebo Comparator|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
16587266|NCT02697149||intervention|patients undergoing nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
16587267|NCT02697149||control|patients undergoing standard endoscopic retrograde cholangiopancreatography
16587268|NCT02697136|Experimental|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
16587269|NCT02697136|Placebo Comparator|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
16587270|NCT02697123||antepartum and postpartum|This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
16587271|NCT02697110|Experimental|A: Edutainment based intervention|This group receives the usual routine immunization at 6, 10, 14 weeks and 9 months and an Edutainment intervention package of limited group (i.e., 3-5 women) drama based video session (Edutainment) followed by a Question and Answer session with mothers on early brain development, parenting skills, communication and negotiating skills at 6 weeks. Mothers will be encouraged to train fathers and other caregivers at home with reinforcement of key messages at subsequent clinic visits. Key messages will be delivered through the use of flip charts at 14 weeks and given to mothers as take home for use in engaging the fathers partners and other caregivers for their child. Reinforcement of key messages at subsequent visits will be through the use of videos and flip chart.
16587272|NCT02697110|No Intervention|B|This group receives routine immunization care (usually includes group health talk) at 6, 10, 14 weeks and 9 months.
16587273|NCT02697097||Control Arm Group|Participants aged 18-30, Male and Female (10 participants each). Control group must have normal range of movement and no evidence of femoro-acetabular impingement (FAI) on clinical examination (negative impingement test, no symptoms). Other exclusions for Control Group include previous surgery to hip joint/s, history of arthritis, family history of FAI, patients who have had symptoms of hip pain in the preceding 1 year or may have other conditions which may affect the hip joint or hip muscle strength including neurological conditions or muscular dystrophy.
16587274|NCT02697097||FAI Arm Comparison Group|Participants aged 18-30, Male and Female (10 participants each). Participants with femoro-acetabular impingement as diagnosed clinically and on radiological imaging for the comparison group (MRI).
16587275|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
16587276|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
16587277|NCT02697058|Experimental|Part 1: Safety and PK|BAX2398 in combination with 5-FU/calcium levofolinate
16587278|NCT02697058|Experimental|Part 2: Safety, PK, Efficacy|BAX2398 in combination with 5-FU/calcium levofolinate
16587279|NCT02697058|Active Comparator|Part 2: 5-FU/calcium levofolinate alone|5-FU/calcium levofolinate
16587280|NCT02697045|Other|ARIPIPRAZOLE|ABILIFY MAINTENA 400 MG LAI Aripiprazole 400mg, IM, Once a month
16587281|NCT02697032|Experimental|Patients|At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.
16587282|NCT02697019|Experimental|Internet-delivered ERITA|
16587283|NCT02696993|Experimental|Group A (nivolumab, SRS)|Patients receive nivolumab IV over 90 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
16587284|NCT02696993|Experimental|Group B (nivolumab, WBRT)|Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
16587285|NCT02696993|Experimental|Group C (nivolumab, ipilimumab, SRS)|Patients receive nivolumab as in Group A and ipilimumab IV over 90 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
16587286|NCT02696993|Experimental|Group D (nivolumab, ipilimumab, WBRT)|GROUP D: Patients receive nivolumab as in Group A and ipilimumab as in Group C. Patients undergo WBRT once daily for 10 days.
16587287|NCT02696980|Experimental|Rescue|Intervention: Positive expiratory pressure (PEEP) 10 will be applied after the administration of methacholine
16587288|NCT02696980|Experimental|Prophylaxis|Intervention: Positive expiratory pressure (PEEP) 10 will be applied during the administration of methacholine
16587289|NCT02696980|Placebo Comparator|No PEEP|Intervention: Positive expiratory pressure (PEEP) 0 will be applied during the administration of methacholine
16587290|NCT02696967|Experimental|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
16587291|NCT02696967|Placebo Comparator|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
16587292|NCT02696954|Experimental|Group A|
16587293|NCT02696954|Experimental|Group B|
16587294|NCT02696941|Experimental|Metformin|Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.
16587295|NCT02696941|Experimental|SGLT2|Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.
16587296|NCT02696928|Other|Artemeter-Lumefantrine (combination therapy)|"33 patients
~(standard of care)"
16587297|NCT02696928|Active Comparator|Artemeter-Lumefantrine and Primaquine (combination therapy)|33 patients
16587298|NCT02696928|Experimental|Artemeter-Lumefantrine and MB (combination therapy)|33 patients
16587299|NCT02696915|Placebo Comparator|Placebo|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.
16587300|NCT02696915|Active Comparator|Bupivacaine|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.
16587301|NCT02696902|Experimental|MEDI3902 500 mg|Participants will receive a single intravenous (IV) dose of 500 mg MEDI3902.
16587302|NCT02696902|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
16587303|NCT02696902|Experimental|MEDI3902 1500 mg|Participants will receive a single IV dose of 1500 mg MEDI3902.
16587304|NCT02696889|Experimental|ROSE-1 Protocol|Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
16587305|NCT02696876|Active Comparator|Control group|Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.
16587306|NCT02696876|Experimental|Intervention group|Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space.
16587307|NCT02696863||filling a questionnaire and interview|"The questionnaire is tracking occupational carcinogens. It consists of 30 questions , fills an average of 3 minutes and includes three response categories: yes, no and do not know. A questionnaire will be added social and professional issues.
~Interviews will be conducted with the patient to identify obstacles and facilitating elements"
16587308|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
16587341|NCT02696642|Experimental|mild HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with mild hepatic impairment (HI).
16587435|NCT02696057|Active Comparator|Manual technics|Manual technics was consisted of soft tissue technics, muscle energy technics, joint mobilization.
16587309|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
16587310|NCT02696837|Active Comparator|ETT & Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and Muscle Relaxant
16587311|NCT02696837|Active Comparator|ETT & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and No Muscle Relaxant
16587312|NCT02696837|Active Comparator|Proseal LMA & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and NO Muscle Relaxant
16587313|NCT02696837|Active Comparator|Proseal LMA & Subparalytic Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and subparalytic dose Muscle Relaxant
16587314|NCT02696824|Experimental|CBT-AD|Those assigned to the CBT-AD [cognitive behavioral therapy for adherence and depression) condition, will have up to 8 additional sessions delivered by the study clinic nurse. Additionally, those assigned to CBT-AD will have the procedures available to those assigned to ETAU.
16587315|NCT02696824|No Intervention|ETAU|"Participants in both conditions receive usual care plus the following procedures below.
~All participant will have the benefit of the psychosocial assessment, and the clinic nurse will provide feedback to the participant and to their clinic doctor about their depression. Additionally, all participants will undergo standard of care second line treatment adherence counseling in the clinic . The clinic doctor will not be restricted in terms of referral or treatment of depression for their patient with respect to antidepressant medications or other interventions available."
16587316|NCT02696811|Placebo Comparator|Oat biscuits|Participants will eat 3 oat biscuits per day for 6 weeks
16587317|NCT02696811|Experimental|White Carrots|Participants will eat 100g (cooked weight) of white carrots per day for 6 weeks
16587318|NCT02696798|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
16587319|NCT02696798|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
16587320|NCT02696798|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.
~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
16587321|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
16587322|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
16587323|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
16587324|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
16587325|NCT02696772|Experimental|Energy balance|Intervention day diet containing 100% of estimated energy requirements
16587326|NCT02696772|Experimental|Energy restriction|Intervention day diet containing 25% of estimated energy requirements
16587327|NCT02696759|Other|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
16587328|NCT02696746||Pain related conditions|Subjects with painful or painless conditions (observational study, no interventions)
16587329|NCT02696733|Experimental|UG - ONB|Patients with the bladder tumor located on the lateral wall, with the high risk of adductor muscles contraction during TURBT under spinal anesthesia.
16587330|NCT02696720|Experimental|Lidocaine|During a period of six weeks, a lidocaine patch will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
16587331|NCT02696720|Sham Comparator|Sham|During a period of six weeks, a visually identical patch (sham) will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
16587332|NCT02696707|Active Comparator|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
16587333|NCT02696707|Active Comparator|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
16587334|NCT02696694||P25-P75|serum progesterone between 25 and 75 percentile
16587335|NCT02696694||<P25 ó >P75|serum progesterone <25 or >75 percentile
16587336|NCT02696681|Experimental|Cognitive Behavioral Therapy|Integrating CBT for any substance use or mental health problems with CBT for adherence/self-care
16587337|NCT02696668|Active Comparator|modified FaME|Participants in the modified FaME group will receive a 16 weeks falls rehabilitation programme which will be tailored and progressed according to their abilities and their needs by the physiotherapist / instructor providing the rehabilitation at the hospital.
16587338|NCT02696668|Experimental|Multisensory|Participants in the multisensory group will receive balance exercises training which will be tailored and progressed to their abilities and needs.
16587339|NCT02696655|Experimental|liver transplant patients|Patients will use a behavioural intervention to assess its usability
16587340|NCT02696642|Experimental|Control group|Anetumab ravtansine was given at 6.5 mg/kg body weight (BW) as a 1 hour intravenous (IV) infusion once every 3 weeks (Q3W) for subjects with adequate hepatic and renal function.
16587342|NCT02696642|Experimental|moderate HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate hepatic impairment (HI).
16587343|NCT02696642|Experimental|moderate RI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate renal impairment (RI).
16587344|NCT02696629||Education and follow up|Participants who refuse or fail to have PAP treatment or Oral appliance or other treatments for sleep apnea. They also refuse or have counter-indication for surgical treatment. The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
16587345|NCT02696629||Upper airway surgery|Participants who undergo uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery.
16587346|NCT02696629||Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
16587347|NCT02696616|Experimental|BI 655088|
16587348|NCT02696616|Placebo Comparator|Placebo|
16587349|NCT02696603|Experimental|Participants with Parkinson disease|People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
16587350|NCT02696603|Experimental|Participants without Parkinson disease|People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
16587351|NCT02696590|Experimental|MS patients injectable Vitamin D3|MS patients who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
16587352|NCT02696590|Experimental|MS patients orally Vitamin D3|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
16587353|NCT02696590|Active Comparator|Healthy groups Injectable Vitamin D3|who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
16587354|NCT02696590|Active Comparator|Healthy groups Vitamin D3 orally|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
16587355|NCT02696577|Active Comparator|Low dose aspirin|Received aspirin 81mg once daily for 6 weeks
16587356|NCT02696577|Active Comparator|Low dose aspirin plus omega 3 group|Received aspirin 81mg and omega 3 once daily for 6 weeks.
16587357|NCT02696564|Active Comparator|Losartan|At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
16587358|NCT02696564|Placebo Comparator|placebo|At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.
16587359|NCT02696551|Experimental|Interventional hospital|Interventional hospital, which will receive 3-month medical education
16587360|NCT02696551|No Intervention|Non-interventional hospital|Non-interventional hospital, which will not receive 3-month medical education.
16587361|NCT02696538|Experimental|Experimental|All participants included in this group and will complete all three outcomes assessment
16587362|NCT02696512|Experimental|IBRF ACP/MCP Group 1|The Treatment group will be receiving a combination of pharmaceuticals (polypharmacy using FDA-approved products) and nutraceuticals (Nutraceutical supplementation) and median nerve stimulation (MNS)
16587363|NCT02696512|Other|Standard of Care Group 2|Standard of Care only
16587364|NCT02696499|Experimental|PA101B|
16587365|NCT02696499|Placebo Comparator|Placebo|
16587366|NCT02696486|Experimental|Exercise Training|
16587367|NCT02696473|Experimental|High Carrot Dose|The volunteer will eat 250g carrot for breakfast with 2 slices of bread and 10g butter
16587368|NCT02696473|Experimental|Low Carrot Dose|The volunteer will eat 100g of carrot for breakfast with 2 slices of bread and 10g butter
16587369|NCT02696460|Active Comparator|N2O/O2 analgesia|Wound debridement under analgesia with N2O/O2 premix.
16587370|NCT02696460|Active Comparator|Lidocaine/Prilocaine analgesia|Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
16587371|NCT02696447||Cancer treated by radiotherapy|Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
16587372|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
16587373|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
16587374|NCT02696421||Non diabetic, non obese|
16587375|NCT02696421||Non diabetic obese|
16587376|NCT02696421||Diabetic|
16587377|NCT02696408|Experimental|Laser treatment|preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)
16587378|NCT02696408|Placebo Comparator|laser-off|daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)
16587379|NCT02696395|Active Comparator|DePuy Tri-Lock®|Total hip replacement with DePuy Tri-Lock® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
16587380|NCT02696395|Active Comparator|DePuy Corail®|Total hip replacement with DePuy Corail® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
16587383|NCT02696369|Experimental|2% Lidocaine HCL:Epinephrine inj.|2% Lidocaine HCL with epinephrine 1:200,000
16587384|NCT02696369|Active Comparator|2% Lidocaine HCL:Epinephrine inj. (3M)|2% Lidocaine HCl with epinephrine 1:80,000
16587385|NCT02696356|Experimental|Cohort 1|0.1mg GRN-1201
16587386|NCT02696356|Active Comparator|Cohort 2|1.0mg GRN-1201
16587387|NCT02696356|Experimental|Cohort 3|3.0mg GRN-1201
16587388|NCT02696343|Experimental|EPI experimental|Preterm infants randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
16587389|NCT02696343|Sham Comparator|EPI control|Preterm infants randomized to receive the Sham (blind pacifier) during tube feedings.
16587390|NCT02696330|Active Comparator|clopidogrel|50 patients undergoing ICSI
16587391|NCT02696330|Active Comparator|enoxaparin|50 patients undergoing ICSI
16587392|NCT02696330|Placebo Comparator|placebo|50 patients undergoing ICSI
16587393|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
16587394|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
16587395|NCT02696304|Other|TBI for childhood leukemia|Patients with a metabolic syndrom who received TBI.
16587396|NCT02696304|Other|No TBI for childhood leukemia|Patients with a metabolic syndrom without previousTBI
16587397|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
16587398|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
16587399|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
16587400|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
16587401|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
16587402|NCT02696278|Experimental|Hummus and vegetables|Children will receive a lesson about vegetables and hummus and vegetables as part of their daily snack.
16587403|NCT02696278|Experimental|Vegetables only|Children will receive a lesson about vegetables and vegetables as part of their daily snack.
16587404|NCT02696265|Active Comparator|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
16587405|NCT02696265|Active Comparator|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
16587406|NCT02696252||CGM Users|
16587407|NCT02696239|Active Comparator|V-lock suture|V-lock absorbable Wound Closure Device, by Covidien
16587408|NCT02696239|Active Comparator|Vicryl suture|Vicryl suture by Ethicon
16587409|NCT02696239|Active Comparator|Lapra-Ty II|Lapra-Ty II, Absorbable Suture Clip, by Ethicon
16587410|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
16587411|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
16587412|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
16587413|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
16587414|NCT02696213|Experimental|SCOOT Immediate|This group will receive SCOOT immediately
16587415|NCT02696213|Other|SCOOT Delayed|This group will receive SCOOT after 6 weeks
16587416|NCT02696200|Experimental|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
16587417|NCT02696200|No Intervention|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
16587418|NCT02696187|Experimental|KOLwebben|Patients in the experimental group will be introduced to KOL-webben during their ordinary visits to the primary care center. All patients will receive a pedometer
16587419|NCT02696187|No Intervention|Control group|Other than receiving a pedometer the patients in the control group will not receive any intervention.
16587420|NCT02696174|Experimental|Health Microinsurance Scheme|Households owning the HMI package, entitling them to visit and receive treatment from the selected primary care clinic
16587421|NCT02696174|No Intervention|Out-Of-Pocket|Households who visit the selected primary care clinic, but pay by Out-Of-Pocket
16587422|NCT02696161|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
16587423|NCT02696161|Placebo Comparator|5% dextrose|5% dextrose for hydrodissection
16587424|NCT02696148|Experimental|Liraglutide|
16587425|NCT02696148|Placebo Comparator|Placebo|
16587426|NCT02696135||Hypertrophic cardiomyopathy|Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
16587427|NCT02696122|Experimental|Local Group|Local infiltration under general anesthesia via laryngeal mask
16587428|NCT02696122|Experimental|Spinal Group|Spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine
16587429|NCT02696109|Experimental|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
16587430|NCT02696109|Active Comparator|Treatment as Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
16587431|NCT02696096|Other|All Participants|FMRI Suboxone
16587432|NCT02696083|Experimental|Active Treatment|
16587436|NCT02696057|Active Comparator|Exercise|Spinal stabilization exercises were applied all the patients in this group accompanied by physiotherapist.
16587437|NCT02696044|Experimental|Participants aged 0 months to 3 years|Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.
16587438|NCT02696044|Experimental|Participants aged 4 to 6 years|Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.
16587439|NCT02696044|Experimental|Participants aged 7 to 9 years|Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.
16587440|NCT02696044|Experimental|Participants aged 10 to 14 years|Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.
16587441|NCT02696044|Experimental|Participants aged 15 to 20 years|Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.
16587442|NCT02696044|Experimental|Participants aged 21 years and older|Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.
16587446|NCT02696018||Critically ill patients|Ultrasonography in critically ill patients in weaning from mechanical ventilation
16587447|NCT02696005||Group I|15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
16587448|NCT02696005||Group II|15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
16587449|NCT02695992|Active Comparator|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
16587450|NCT02695992|Active Comparator|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
16587451|NCT02695979||Patients undergoing OLT|Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).
16587452|NCT02695940|Active Comparator|LEO 124249 ointment 30 mg/g|Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day
16587453|NCT02695940|Placebo Comparator|LEO 124249 ointment vehicle|LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day
16587454|NCT02695927|Experimental|Chronic|Crossover study on the benefits of computer rehabilitation glasses on chronic sufferers of hemispatial neglect
16587455|NCT02695927|Experimental|Acute|Randomized, controlled study on the benefits of computer rehabilitation glasses on acute sufferers of hemispatial neglect
16587456|NCT02695927|Experimental|Optimization|Study to identify optimal operating parameters of computer rehabilitation glasses
16587457|NCT02695927|Active Comparator|Duration|Study to determine duration of effect of computer rehabilitation glasses
16587458|NCT02695914||Control group|Conventional treatment methods will be given to cases in control group.
16587459|NCT02695914||Experiment group|On the base of control group, Compound Qingre Granule will be added to in experiment group.
16587460|NCT02695901|Experimental|Chlorhexidine gluconate (0,12%)|Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).
16587461|NCT02695901|Experimental|M. alternifolia oil (Nanoparticle solution)|Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).
16587462|NCT02695888|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
16587463|NCT02695888|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
16587464|NCT02695875|Experimental|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
16587465|NCT02695875|Other|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
16587466|NCT02695862|Experimental|Bolus Terlipressin|Injection terlipressin after 2 mg bolus it will be given 2 mg QID
16587467|NCT02695862|Active Comparator|Terlipressin continuous(4mg/24hours)|Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)
16587468|NCT02695849||NSCLC Participants|Participants with non-squamous NSCLC will be enrolled in this study.
16587469|NCT02695836|Active Comparator|Standard feedback|Facilities in this arm will receive an initial face-to-face dissemination workshop that includes feedback of research data on modifiable aspects of their microsystem context but no goal setting.
16587470|NCT02695836|Experimental|Basic assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive a face-to-face goal setting workshop focused on modifiable areas of their microsystem context and two virtual support workshops at six month intervals.
16587471|NCT02695836|Experimental|Enhanced assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive an additional face-to-face goal setting workshop focused on modifiable areas of their microsystem context, two additional face-to-face support workshops at six month intervals plus on-demand email and telephone support.
16587472|NCT02695823|Experimental|Patients undergoing liver transplantation|
16587473|NCT02695810|Experimental|Dapagliflozin|Dapagliflozin, 10 mg per day
16587474|NCT02695810|Active Comparator|Metformin|Metformin, 2 x 850 mg per day
16587475|NCT02695810|Active Comparator|Exercise|Exercise, interval training
16587476|NCT02695810|No Intervention|Control|No intervention
16587477|NCT02695797|Experimental|Immunotherapy|Intravenous immunoglobulin (IVIG) and oral prednisolone. IVIG and oral prednisolone are administered simultaneously: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day).
16587478|NCT02695797|No Intervention|Control|No immunotherapy.
16588539|NCT02688530|Experimental|8mg IV Dexamethasone|8mg IV Dexamethasone
16587479|NCT02695784|Experimental|Probiotic continuation|This Group will Continue probiotics Beyond 34 weeks corrected Gestational agent standard practice
16587480|NCT02695784|No Intervention|Standard treatment Group|This group will continue current standard practice of stopping probiotics at 34 weeks corrected gestational age
16587481|NCT02695771|Experimental|Mitomycin C|Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
16587482|NCT02695771|Active Comparator|Gemcitabine|Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
16587483|NCT02695771|No Intervention|No intervention|Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.
16587484|NCT02695758|Active Comparator|interscalene brachial plexus block|Direct interscalene nerve block injection via brachial plexus
16587485|NCT02695758|Active Comparator|Bupivacaine extended-release liposome injection|Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
16587486|NCT02695745|Experimental|V116517|V116517 aqueous suspension; 300 mg
16587487|NCT02695745|Active Comparator|Celecoxib|Celecoxib capsules; 400 mg (2 capsules of 200 mg each)
16587488|NCT02695745|Placebo Comparator|Placebo|Placebo
16587489|NCT02695732|Experimental|Carvedilol|Carvedilol，6.25mg-12.5mg/d,oral,6-36 months
16587490|NCT02695732|Active Comparator|endoscopy|endoscopy，every 4 weeks until eradication of varices
16587491|NCT02695719|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
16587492|NCT02695719|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
16587493|NCT02695706|Experimental|Laboratoires Mercurochrome Reparador|A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.
16587494|NCT02695693|Experimental|TeachTown|Students in kindergarten-through-second-grade autism support classrooms in this arm receive access to TeachTown, an online academic and pre-academic intervention designed for students with autism. Their teachers also receive coaching in the use of TeachTown, as well as coaching in other evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
16587495|NCT02695693|Active Comparator|Control|Teachers in kindergarten-through-second-grade autism support classrooms in this arm receive coaching in evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
16587496|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
16587497|NCT02695667||OSAS subjects|CPAP Referral OSAS
16587498|NCT02695667||Risk-Free subjects|paired normal control subjects
16587499|NCT02695654||Chronic pain in knee osteoarthritis|Ultrasound guided single shot Adductor canal block with 0,25% Levobupivacaine 14 ml and 100 mcg Clonidine
16587500|NCT02695641|Experimental|Stage 1 - Low dose administration|Ten hemodialysis patients will receive IV infusion treatment with 1.25mg bevacizumab and undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and pharmacokinetic/dynamic (PK/PD) data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcomes are met in stage 1, the study will be terminated, otherwise the study will progress to stage 2.
16587501|NCT02695641|Experimental|Stage 2 - Dose escalation|If outcomes are not met in stage 1, Ten additional hemodialysis patients will receive IV infusion treatment with 2.50mg bevacizumab treatment. They will undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and PK/PD data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcome is not met, the study will be terminated.
16587502|NCT02695628|Experimental|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
16587503|NCT02695602|Experimental|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
16587504|NCT02695602|Experimental|Submucous Resection (SMR)|Turbinoplasty using non-powered instruments
16587505|NCT02695576|Experimental|Surgery|Lumbar fusion surgery Physiotherapy Cognitive behavioral therapy
16587506|NCT02695576|Active Comparator|Non-surgery|Physiotherapy Cognitive behavioral therapy
16587507|NCT02695563|No Intervention|controls|The patients will be not treated with vaginal lactoferrin
16587508|NCT02695563|Active Comparator|Lactoferrin|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
16587509|NCT02695550|Experimental|CT-707|ALK-positive non-small cell lung cancer resistant to Crizotinib treatment
16587510|NCT02695537|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).
~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
16587511|NCT02695524|Active Comparator|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
16587512|NCT02695524|Experimental|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
16587513|NCT02695511|Experimental|25% CR|25% caloric restriction
16587514|NCT02695511|No Intervention|CO (control)|healthy lifestyle recommendation
16587515|NCT02695498|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a standardized course in mindfulness mediation and yoga.
16587516|NCT02695498|Experimental|Migraine/stress Education|This course will educate participants about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
16587517|NCT02695485|Other|sensate flap|the donor nerve harvested with the flap
16587518|NCT02695472|Placebo Comparator|Placebo Arm|One Placebo tablet, twice daily
16587519|NCT02695472|Experimental|40 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet and 1 placebo tablet per day
16587520|NCT02695472|Experimental|80 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet twice per day
16587521|NCT02695459|Experimental|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
16587522|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
16587523|NCT02695433|Experimental|Active treatment (AT) diet plan|1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period
16587524|NCT02695433|Placebo Comparator|Control (CT) diet plan|at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period
16587525|NCT02695420|Placebo Comparator|Placebo BID|Participants will receive placebo BID.
16587526|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
16587527|NCT02695420|Experimental|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
16587528|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
16587529|NCT02695407|Experimental|3 days cannulation|radial artery cannula removed after 3 days
16587530|NCT02695407|Experimental|5 days cannulation|radial artery cannula removed after 5 days
16587531|NCT02695394||MS / CIS|
16587532|NCT02695394||Healthy controls|
16587533|NCT02695381|Experimental|Etodolac-lidocaine Topical Patch|Therapy with experimental drug
16587534|NCT02695381|Placebo Comparator|Placebo|Therapy with placebo
16587535|NCT02695368|Experimental|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:
~regular operating theater
~ultra-Clean operating theaters"
16587536|NCT02695368|Experimental|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
16587537|NCT02695368|Experimental|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
16587538|NCT02695355|Experimental|ADHD medication effects|Single dose methylphenidate (Ritalin tablets); 10 mg for ages 8-13; 15 mg for ages 13-17
16587539|NCT02695342|Experimental|Home balance exercise program|The home-based exercise program will be tailored to address the underlying balance deficits in COPD and individualized according to each participant's ability. Physiotherapists will teach the program in four home visits over the first 6 weeks of the study; in the event of an exacerbation, a fifth visit will be provided to modify the program. Participants will be given an exercise DVD (with portable player), and will be instructed to perform the program 3 times/week for 6 months. Therapists will provide bi-monthly telephone support.
16587540|NCT02695329|Active Comparator|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
16587541|NCT02695329|No Intervention|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
16587542|NCT02695316|Other|Migrant Women|Focus Group Discussion in native Language with n=20
16587543|NCT02695316|Other|Health Care Professionals|Focus Group Discussion with n=20 Health Care Professionals
16587544|NCT02695316|Other|Interpreters|One-to-one Interviews with n=4 intercultural Interpreters
16587545|NCT02695316|Other|Telephone Interpreting Protocols|Retrospective quantitative analysis of n=50 Telephone Interpreting Protocols (questionnairs)
16587546|NCT02695303|Experimental|BAY 987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16587547|NCT02695290|Experimental|Afatinib|
16587548|NCT02695277|Experimental|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
16587549|NCT02695277|Active Comparator|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
16587550|NCT02695264|Experimental|HS-1000 recording|ICP readings will be recorded from both the invasive and HeadSense non-invasive ICP monitor for an aggregate of 30 minutes. During the recording sessions, a webcam will take periodic snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other clinical parameters that are displayed on screen, with a focus on blood pressure and heart rate (HR). Recording sessions will be done until an aggregate of at least 30 minutes of data are collected, depending on the patient's clinical condition. Recording sessions may be repeated over several days until the 30 minute target is reached.
16587551|NCT02695251|Experimental|Low AGE meal|Renal functional parameters are measured at baseline and after a low AGE (eggs) meal
16587552|NCT02695251|Experimental|High AGE meal|Renal functional parameters are measured at baseline and after a high (mixed nuggets) AGE (eggs) meal
16587553|NCT02695238|Experimental|prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, prophylactic manual rotation will be performed.
16587554|NCT02695238|No Intervention|No prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, expectant management for delevery will be performed
16587555|NCT02695225|Other|Lay-led tobacco abstinence|Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
16587556|NCT02695225|Other|Lay-led promotion of Ohio Quit Line|Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
16587557|NCT02695212|Experimental|Apremilast ( open label)|"Investigational Product: Apremilast
~Doses: Period A:
~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6
~Period B:
~30mg Twice per day, day #7 through week #24
~Period C:
~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
16587558|NCT02695199|Experimental|laparoscopic varicocelectomy|laparoscopic Doppler ultrasound assisted laparoscopic varicocelectomy group
16587559|NCT02695199|Sham Comparator|microscopic varicocelectomy|conventional Microscopic Subinguinal varicocelectomy group
16587560|NCT02695186||A/IM alone|Patients with intestinal metaplasia who undergo gastroscopy and blood sample analysis
16587561|NCT02695186||B/IM and MS|Patients with intestinal metaplasia and metabolic syndrome who undergo gastroscopy and blood sample analysis
16587562|NCT02695186||C/Healthy controls|Healthy controls without intestinal metaplasia or metabolic syndrome who undergo gastroscopy and blood sample analysis
16587563|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
16587564|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
16587565|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
16587566|NCT02695147||TAVI via Subclavian approach|Any TAVI procedure using any valve type performed via the subclavian approach
16587567|NCT02695147||TAVI via Direct Aortic approach|Any TAVI procedure using any valve type performed via the direct aortic approach
16587568|NCT02695134|Other|Intervention Group|This group will receive 6 Healing Touch treatments over 3 weeks
16587569|NCT02695134|No Intervention|Control Group[|This group will continue with their usual medical treatments but receive NO Healing Touch
16587570|NCT02695108|Experimental|classical approach for neck pain|patients in this arm received classical approaches for neck pain. Cervical manual therapy was performed on patients in this arm and they were also instructed to to perform cervical endurance, strength and stretching exercises. Rehabilitation period was lasted for 6 weeks. Pain, quality of life and scapular kinematics were assessed before and after rehabilitation program.
16587571|NCT02695108|Experimental|scapular exercise on neck pain|patients in this arm received cervical manual therapy and cervical exercises too. Apart from cervical manual therapy and cervical exercises,patients also performed scapular stabilization exercise targeting trapezius, serratus anterior and rhomboid muscles. Rehabilitation period was lasted for 6 weeks. The same assessment parameters was conducted on this arm too.
16587572|NCT02695069|Experimental|All Participants|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
16587573|NCT02695043|Experimental|MMPET Group|This group of subjects will be comprised of a subset of culturally diverse patients admitted to the Bellevue the Traumatic Brain Injury Unit at Bellevue. Treatment will focus on improving awareness and comprehension of TBI and its long-term consequences, fostering increased trust in the TBI rehabilitation team, and conveying the importance of continued TBI follow up to maximize recovery.
16587574|NCT02695043|Active Comparator|Control Group|The Control Group will be comprised of equally diverse subset of patients who will receive Standard of Care Treatment.
16587575|NCT02695017|Experimental|Iso inertial|Subjects should do 12 exercise repetition with Iso inertial machine
16587576|NCT02695017|Experimental|Conventional machine|Subjects should do 12 exercise repetition with conventional machine
16587577|NCT02695004|Experimental|Donepezil 35 mg|Donepezil 35 mg or placebo
16587578|NCT02695004|Experimental|Donepezil 70 mg|Donepezil 70 mg or placebo
16587579|NCT02695004|Experimental|Donepezil140 mg|Donepezil 140 mg or placebo
16587580|NCT02695004|Experimental|Donepezil 210 mg|Donepezil 210 mg or placebo
16587581|NCT02695004|Experimental|Donepezil 280 mg|Donepezil 280 mg or placebo
16587582|NCT02694991|Experimental|OMT Group|Osteopathic Manipulative Treatment 15 minutes once a day for 8 days
16587583|NCT02694991|No Intervention|Control Group|No intervention, only usual care
16587584|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
16587585|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
16587586|NCT02694965||Stage IV/Unresectable Stage III Melanoma|Observational - Eligible patients with stage IV/unresectable stage III melanoma selected to undergo treatment with an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a combination of an anti-CTLA-4 antibody/anti-PD-1 antibody will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.
16589661|NCT02681198|Experimental|Lofexidine and paroxetine|Lofexidine in the presence of paroxetine
16587587|NCT02694965||Stage III/IV Adjuvant Melanoma|Observational - 1) Patients either undergoing resection of stage III or stage IV melanoma or have previously undergone resection and who are considered candidates for adjuvant anti-PD-1 antibody immunotherapy. 2) Patients who previously underwent resection of stage III or stage IV melanoma and received prior adjuvant anti-PD-1 antibody immunotherapy and have subsequently developed recurrent melanoma.
16587588|NCT02694952|Active Comparator|FAV-Africa|FAV-Africa infusion at enrollment, and then at two and six hours after enrollment, if necessary. To be given as unblinded rescue dose at twelve hours if fourth dose of antivenom necessary.
16587589|NCT02694952|Experimental|EchiTabPlus-ICP|EchiTabPlus-ICP infusion at enrollment, and then at two and six hours after enrollment, if necessary.
16587590|NCT02694939|Experimental|STAND|Receives STAND intervention delivered in community mental health setting.
16587591|NCT02694939|Active Comparator|Usual Care|Receives usual care from community therapists.
16587592|NCT02694926|Other|adrenal insufficiency|
16587593|NCT02694900|Experimental|Resuscitation on the flor|2 min asynchronous cardiopulmonary resuscitation. The patient lies on the floor
16587594|NCT02694900|Experimental|Resuscitation on the stretcher|2 min asynchronous cardiopulmonary resuscitation. The patient lies on a stretcher
16587595|NCT02694874|Experimental|Rosiglitazone|Participants will receive rosiglitazone 0.045mg/kg/dose twice daily dosing, for 4 days
16587596|NCT02694874|Placebo Comparator|Placebo|Participants will receive placebo (grounded placebo powder) at a dose of 0.045mg/kg/dose twice daily for 4 days
16587597|NCT02694861||Registry Group|Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
16587598|NCT02694861||Prospective Group|A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
16587599|NCT02694848|Other|Salvianolate injection group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
16587600|NCT02694848|Active Comparator|Aspirin group|Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
16587601|NCT02694848|Experimental|Salvianolate injection and aspirin group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
16587602|NCT02694835|Experimental|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
16587603|NCT02694835|Active Comparator|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
16587604|NCT02694822|Experimental|AGEN1884|anti-CTLA-4 antibody
16587605|NCT02694809|Experimental|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
16587606|NCT02694809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
16587607|NCT02694796|Experimental|Intervention|The 'Physical activity program after a balneotherapy' intervention involves providing a workshop during a balneotherapy about physical activity and use of automated physical activity program including website, mobile app and connected devices, and after the balneotherapy, the access to the automated program during 12 months.
16587608|NCT02694796|No Intervention|Control|Patients included in the control arm will receive a booklet including informations about physical activity recommendations and practice.
16587609|NCT02694783|Experimental|Treatment Arm|ex vivo generated polyomavirus-specific T cells from HLAmatched donor
16587610|NCT02694770|Experimental|Neihulizumab|Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.
16587611|NCT02694770|Active Comparator|"Conventional Treatment"|Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.
16587612|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
16587613|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
16587614|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
16587615|NCT02694731|Experimental|Mobile application intervention|Participants receive a mobile app with a 5-week mindful eating program and ongoing tools for coping with cravings
16587616|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
16587617|NCT02694705|Experimental|CPAP|3 minutes of preoxygenation with a portable ventilator providing Continuous Positive Airway Pressure (CPAP) at 5 cmH20 and an FiO2 of 100%.
16587618|NCT02694705|Experimental|BVM|3 minutes of preoxygenation with a bag-valve-mask (BVM) device and oxygen flow rate of 15 litres / minute.
16587619|NCT02694705|Experimental|NRM|3 minutes of preoxygenation with a non-rebreather mask (NRM) device and oxygen flow rate of 15 litres / minute.
16587620|NCT02694692||Follow-up|No further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care & Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
16587621|NCT02694679|No Intervention|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
16587622|NCT02694679|Active Comparator|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
16587623|NCT02694679|Active Comparator|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
16587624|NCT02694679|Active Comparator|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
16587625|NCT02694679|Active Comparator|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
16587626|NCT02694679|Active Comparator|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
16587627|NCT02694679|Active Comparator|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
16587628|NCT02694679|Active Comparator|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
16587629|NCT02694679|No Intervention|Friendship 0|CBNH 0% of population targeted
16587630|NCT02694679|Experimental|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
16587631|NCT02694679|Experimental|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
16587632|NCT02694679|Experimental|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
16587633|NCT02694679|Experimental|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
16587634|NCT02694679|Experimental|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
16587635|NCT02694679|Experimental|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
16587636|NCT02694679|Experimental|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
16587637|NCT02694666|Experimental|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
16587638|NCT02694666|Placebo Comparator|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
16587639|NCT02694653|Active Comparator|Drug Arm|Acetaminophen 1000 mg in 100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
16587640|NCT02694653|Placebo Comparator|Placebo Arm|100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
16587641|NCT02694640|Experimental|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
16587642|NCT02694640|Experimental|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
16587643|NCT02694640|Experimental|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
16587644|NCT02694627|Experimental|Intervention|See intervention description
16587645|NCT02694627|No Intervention|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but do not receive any intervention.
16587646|NCT02694614|Experimental|smartphone-assisted dietary coaching|
16587647|NCT02694601|Experimental|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
16587648|NCT02694588|Active Comparator|Infliximab|5 mg/kg body weight, week 0/2/6, then every 8 weeks
16587649|NCT02694588|Active Comparator|Vedolizumab|300 mg, week 0/2/6, then every 8 weeks
16587650|NCT02694575||Other|Other - currently on other treatment (i.e., non-incretin based therapies)
16587651|NCT02694575||GLP-1|Currently on GLP-1 analogue therapy
16587652|NCT02694575||DPP-4|Currently on DPP-4 inhibitor therapy
16587653|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
16587654|NCT02694549|Experimental|CaveoVasc|
16587655|NCT02694536|Experimental|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
16587656|NCT02694523|Active Comparator|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
16587657|NCT02694523|Experimental|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
16587658|NCT02694510|Active Comparator|Light-protection|Light-protection of TPN solutions. TPN bags and infusion sets will be protected from light by aluminum foils throughout the study period.
16587659|NCT02694510|Active Comparator|Light-exposure|TPN bags and infusion sets will be exposed to light throughout the study period.
16587660|NCT02694484|Other|Healthy volunteers|For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit
16587661|NCT02694471|Experimental|Old group|16 old participants (55-65 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
16587662|NCT02694471|Active Comparator|Young group|7 young participants (18-30 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
16587663|NCT02694458|Experimental|Modeling arm|Early vancomycin monitoring and bayesian dosage adjustment
16587664|NCT02694458|Sham Comparator|Control arm|Usual vancomycin dose and monitoring strategy
16587665|NCT02694432|Active Comparator|GOALS|Participants will use for approximately four months an online platform, GOALS, consisting of weekly lessons designed to enhance blood pressure control. Recommended lifestyle changes for hypertension, including a low-sodium diet, physical activity, weight loss (if appropriate) and behavioral self-management skills will be offered. Attention to medication adherence and pharmacist support as well as that of a dedicated online health coach and ongoing collaboration with the primary care physician are also provided.
16587666|NCT02694432|Experimental|Minding GOALS|Participants in this arm will also use the GOALS standard tools for blood pressure control. To further maximize success, they will receive additional online behavioral training throughout the 4-month intervention that focuses on mind-body approaches. Weekly topics, for example, will include meditation lessons, mindfulness-based stress reduction and mindfulness-based eating awareness.
16587667|NCT02694419||obese/PCO|Women with PCOS who are overweight\obese with BMI ≥ 25 kg/m2.
16587668|NCT02694419||normal weight/PCO|Women with PCOS who are normal weight with BMI < 25 kg/m2.
16587669|NCT02694419||Obese/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are overweight\obese with BMI ≥ 25 kg/m2.
16587670|NCT02694419||normal weight/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are normal weight with BMI < 25 kg/m2.
16587671|NCT02694393|Experimental|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
16587672|NCT02694380||Head and Neck|Subjects with head and neck cancer receiving radiation therapy.
16587673|NCT02694380||Prostate|Subjects with prostate cancer receiving radiation therapy.
16587674|NCT02694380||Breast|Subjects with breast cancer receiving radiation therapy.
16587675|NCT02694380||Lung|Subjects with lung cancer receiving radiation therapy.
16587676|NCT02694367||Recurrent miscarriage group|Women with previous history of RM, defined as two or more consecutive miscarriages
16587677|NCT02694367||Control group|Women with no history of RM
16587678|NCT02694354|Experimental|BI 685509|
16587679|NCT02694354|Placebo Comparator|Placebo|matching placebo
16587680|NCT02694341|Active Comparator|Bakri Balloon with abdominal traction stitch|bakri balloon will be inserted with abdominal traction stitch
16587681|NCT02694341|Experimental|Bakri Balloon without abdominal traction stitch|bakri balloon will be inserted with no performance of abdominal traction stitch
16587682|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
16587683|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
16587684|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
16587685|NCT02694302|Experimental|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
16587686|NCT02694302|Active Comparator|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
16587687|NCT02694289|Other|Metformin|Continue Metformin while admitted to hospital
16587688|NCT02694289|Other|Subcutaneous (sliding scale) Insulin|Discontinue Metformin upon admission and be placed on sliding scale subcutaneous insulin treatment while admitted to hospital
16587689|NCT02694276|Experimental|Internet-based cognitive behavior therapy|10 sessions of ICBT during 10 weeks.
16587690|NCT02694263|Experimental|Canagliflozin + Metformin|Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
16587691|NCT02694263|Active Comparator|Repaglinide + Metformin|Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
16587692|NCT02694263|Active Comparator|Pioglitazone + Metformin|Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
16587727|NCT02694029|Active Comparator|VisionRT (VRT), Then ABC|VisionRT-based deep inspiration breath-hold to assist radiation therapy. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH
16587693|NCT02694263|Active Comparator|Gliclazide + Metformin|Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
16587694|NCT02694263|Active Comparator|Glimepiride + Metformin|Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.
16587695|NCT02694250|Other|DTRAX Cervical Cervical Cage with DTRAX Bone Screw|
16587696|NCT02694237|Active Comparator|Verbal|This group will only receive a verbal discussion based on the same script used for all three groups. This is the control group.
16587697|NCT02694237|Active Comparator|Verbal + Model|This group will receive a verbal discussion aided with an anatomic model intervention that group participants will be able to touch throughout the discussion.
16587698|NCT02694237|Active Comparator|Verbal + Video|This group will receive a verbal discussion aided with a knee anatomy video intervention that will be played on silent an orated by an interviewer.
16587699|NCT02694224|Experimental|vismodegib plus chemotherapy|Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)
16587700|NCT02694224|Active Comparator|chemotherapy|Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses
16587701|NCT02694211|Experimental|Intervention group ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
16587702|NCT02694211|No Intervention|Control group|No intervention, business as usual
16587703|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
16587704|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
16587705|NCT02694172|No Intervention|Lean non diabetic|Lean and healthy subjects receiving no intervention
16587706|NCT02694172|Experimental|Overweight non diabetic|fiber rich cereal bars, two bars a day for 4 weeks
16587707|NCT02694172|Experimental|Overweight diabetic|fiber rich cereal bars, two bars a day for 4 weeks
16587708|NCT02694146|Experimental|PRP (platelet rich plasma)|"37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.
~For PRP administration:
~The injection should be performed at room temperature.
~The administration should be carried out under aseptic conditions.
~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
~The PRP is injected into the synovial space."
16587709|NCT02694146|Active Comparator|Hylan G-F 20 (Synvisc-One ®)|"37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).
~It is necessary to remove synovial fluid before injecting Hylan G-F 20.
~The injection should be performed at room temperature.
~The administration should be carried out under aseptic conditions.
~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
~The Hylan G-F 20 is injected into the synovial space.
~After injecting Hylan G-F 20 the patient should stand 5 minutes."
16587710|NCT02694133|Experimental|Aphasia group|Aphasia
16587711|NCT02694120||colonoscopy population|
16587712|NCT02694107|Experimental|Proprioceptive exercises|Proprioceptive exercises performed 3 sessions per week for 4weeks
16587713|NCT02694107|No Intervention|Control|Without any exercises
16587714|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
16587715|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
16587716|NCT02694081|Experimental|Uncut Roux-en-Y Reconstruction|Uncut Roux-en-Y Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
16587717|NCT02694081|Active Comparator|Billroth II Reconstruction|Billroth II Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
16587718|NCT02694068||Discovery for Aim One|2173 subjects will be involved in the discovery cohort.
16587719|NCT02694068||Replication for Aim One|1673 subjects will comprise the replication cohort.
16587720|NCT02694068||Discovery for Aim Two|824 subjects will be involved in the discovery cohort.
16587721|NCT02694068||Replication for Aim Two|538 subjects will comprise the replication cohort.
16587722|NCT02694055|Experimental|Proactive Community Case Management (ProCCM)|Villages assigned to the experimental arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing proactive case detection in addition to integrated Community Case Management (ProCCM).
16587723|NCT02694055|Active Comparator|integrated Community Case Management (iCCM)|Villages assigned to the active comparator arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing passive integrated Community Case Management (iCCM) exclusively at a fixed health post to patients who initiate their own care-seeking.
16587724|NCT02694042|Experimental|Mission is Remission® Group|Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
16587725|NCT02694042|No Intervention|Control Group|Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
16587726|NCT02694029|Active Comparator|ABC (Active Breathing Coordinator ), Then VRT|Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
16587728|NCT02694016|Experimental|Remote ischemic preconditioning|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
16587729|NCT02694016|No Intervention|Control group|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis
16587730|NCT02694003|Experimental|Intervention|The intervention arm will receive access to the BNBD-NDD Intervention.
16587731|NCT02694003|No Intervention|Usual Care|The usual care arm does not receive the BNBD-NDD intervention. This arm is free to access other resources while enrolled in the study. After the 8-month follow up time point, the usual care arm will be able to access the intervention.
16587732|NCT02693990|Experimental|Grade II (Atypical) Meningiomas, STR|Patient will be treated at the starting dose of Intensity Modulated Proton Therapy (IMPT) which is pre-determined.
16587733|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, GTR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
16587734|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, STR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
16587735|NCT02693964||Postmenopausal women with T1D|Postmenopausal between 45-70 years of age and having T1D for at least 10 years
16587736|NCT02693964||Postmenopausal women without diabetes|Postmenopausal between 45-70 years of age without diabetes
16587737|NCT02693951|Experimental|the prophylactic use of antibiotics group|Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
16587738|NCT02693951|No Intervention|Control|Routine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment
16587739|NCT02693938|Experimental|luteal phase clamp|Luteal euglycemic clamp administered during luteal phase of menstrual cycle.
16587740|NCT02693938|Active Comparator|follicular phase clamp|Follicular euglycemic clamp administered during follicular phase of menstrual cycle.
16587741|NCT02693912||acute lung injury|Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
16587742|NCT02693912||control|Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
16587743|NCT02693886||A group|Experience of endoscopist: >2000 cases
16587744|NCT02693886||B group|Experience of endoscopist:between 1000 and 2000 cases
16587745|NCT02693886||C group|Experience of endoscopist:between 500 and 1000 cases
16587746|NCT02693886||D group|Experience of endoscopist:<500 cases
16587747|NCT02693873|Other|Single Arm Study:|All participants will receive GLA:D Canada, an education and neuromuscular exercise program
16587748|NCT02693860|Experimental|huJ591 followed by 89Zr-J591|Subjects will receive two infusions of unlabeled huJ591 on days 1 and 15 (+/- 1 day). 89Zr-J591 will be administered on day 22 (+/- 1 day) and 5-8 days later. PET/CT will be performed followed by repeat imaging of the prostate. Radical prostatectomy with or without lymph node dissection is performed 2 to 4 weeks after the second dose of J591.
16587749|NCT02693834|Experimental|PLS AFO first then DA AFO|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
16587750|NCT02693834|Experimental|DA AFO first then PLS AFO|Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week
16587751|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
16587752|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
16587753|NCT02693808|Active Comparator|Autologous fat injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
16587754|NCT02693808|Active Comparator|Hyaluronic acid injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
16587755|NCT02693795|Experimental|Baduanjin exercise group|"The participants randomized to Baduanjin exercise will collectively practice at cardiac rehabilitation centre in Guangdong Provincial Hospital of Chinese Medicine. A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
16587756|NCT02693795|Active Comparator|usual exercise control group|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
16587757|NCT02693782|Placebo Comparator|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
16587758|NCT02693782|Active Comparator|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
16587759|NCT02693769|Experimental|fluticasone/formoterol BAI|To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
16587760|NCT02693769|Active Comparator|Ultibro Breezhaler|Ultibro Breezhaler 85/43 µg (1 puff o.d.)
16587761|NCT02693756|No Intervention|Control|Participants will be allowed to perform all usual activities but should refrain from performing the motor imagery exercises.
16587762|NCT02693756|Experimental|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:
~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
16592701|NCT02660905|Experimental|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
16587763|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
16587764|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
16587765|NCT02693730||Healthy Control|Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
16587766|NCT02693730||Irritable Bowel Syndrome (IBS)|Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
16587767|NCT02693730||Ulcerative Colitis (UC)|Clinically and histologically confirmed diagnosis of ulcerative colitis
16587768|NCT02693717|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16587769|NCT02693704|Experimental|Normal hearing|People showing no hearing loss (< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
16587770|NCT02693704|Experimental|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).
~Introduction of speech signal via the DAI of two hearing aids among:
~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
16587771|NCT02693704|Experimental|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).
~Introduction of speech signal via the DAI of two hearing aids among:
~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
16587772|NCT02693704|Experimental|Profound hearing impaired|"Patients showing profound hearing loss (> 80 dB HL).
~Introduction of speech signal via the DAI of two hearing aids among:
~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
16587773|NCT02693691|Experimental|CardioMEMS HF System|Subjects will collect pulmonary artery pressure measurements daily which will be used by health care professionals to adjust cardiac medications.
16587774|NCT02693678|Experimental|Massage|10 min massage therapy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
16587775|NCT02693678|Experimental|Diathermy|10 min diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
16587776|NCT02693678|Sham Comparator|Sham diathermy|10 min sham diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
16587777|NCT02693665|Experimental|FACE-TC Intervention|Adolescent/family dyads randomized to the experimental condition receive Family Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention - 3 sessions scheduled one week apart of approximately 60 minutes duration each. Session 1 - Lyon Advance Care Planning Survey-Adolescent & Surrogate versions. Session 2 - Respecting Choices Interview facilitated by trained/certified facilitator with adolescent and family. Focuses on patient's understanding of their illness, possible complications, goals of care and treatment preferences in 3 bad outcome situations; and the Session 3 - Five Wishes an advance directive.
16587778|NCT02693665|No Intervention|Treatment As Usual (TAU)|Adolescent/family dyads randomized to the treatment as usual (TAU) condition receive written information on advance care planning, but no active intervention.
16587779|NCT02693652|Experimental|CVI-HBV-002 (20ug, 3 shots)|"HBV surface antigen 20ug/dose
~Intramuscular injection at 0, 1, 2 month"
16587780|NCT02693652|Experimental|CVI-HBV-002 (20ug, 6 shots)|"HBV surface antigen 20ug/dose
~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
16587781|NCT02693652|Experimental|CVI-HBV-002 (40ug, 3 shots)|"HBV surface antigen 40ug/dose
~Intramuscular injection at 0, 1, 2 month"
16587782|NCT02693652|Experimental|CVI-HBV-002 (40ug, 6 shots)|"HBV surface antigen 40ug/dose
~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
16587783|NCT02693639||liver transplantation grafts|
16587784|NCT02693626|Experimental|intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per day for the time leading up to the quit day and the following 12 weeks.
~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
16587916|NCT02692833||Non-AKI patients|Patients who do not develop acute kidney injury within the first 5 days following their cardiac surgical operation.
16587785|NCT02693626|No Intervention|No cessation message intervention|Control group participants only will receive one text message every week, thanking them for being in the study, providing study center contact details, and reminding them of the time until their free month at the end of follow up. Another one to two messages will be sent per week until the end of the 24 week. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points.
16587786|NCT02693626|Experimental|Not intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per week for the time leading up to the quit day and the following 12 weeks.
~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
16587787|NCT02693613|Experimental|Group 1|Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
16587788|NCT02693613|Experimental|Group 2|Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
16587789|NCT02693600|Active Comparator|Partial Trapeziectomy (PT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with with ligamentoplasty and partial trapeziectomy.
16587790|NCT02693600|Active Comparator|Total Trapeziectomy (TT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with ligamentoplasty and total trapeziectomy.
16587791|NCT02693587||Misodel group in Holbæk|Misodel for induction of labour in Holbæk
16587792|NCT02693587||Angusta group in Roskilde and Næstved|Angusta for induction of labour in Roskilde and Næstved
16587793|NCT02693574|Active Comparator|Clarithromycin|Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days
16587794|NCT02693574|Experimental|Levofloxacin|Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days
16587795|NCT02693561|Active Comparator|Deep Breathing Exercises|Technical Deep Breathing.
16587796|NCT02693561|Active Comparator|Self-Help Book|Reading the self-help book.
16587797|NCT02693561|Active Comparator|Deep Breathing Exercises and Book|"Technical Deep Breathing and Reading the self-help book.
~Reading the self-help book and will be trained by the physical therapist to perform deep breathing."
16587798|NCT02693561|No Intervention|Control|Not suffer any intervention
16587799|NCT02693548||Familial hypercholesterolaemia patients|Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH.
16587800|NCT02693548||Unaffected relatives|Relatives of FH patients without FH (genetically defined)
16588053|NCT02691988|Experimental|ICS withdrawal|Guided ICS withdrawal combined with optimization of bronchodilator treatment
16587819|NCT02693522|Experimental|somatropin|Subcutaneous injection
16587820|NCT02693522|Active Comparator|Eutropin|Subcutaneous injection
16587821|NCT02693483|Active Comparator|povidone iodine|153 cases undergoing cesarean sections will have preoperative vaginal cleansing with 10% povidone iodine
16587822|NCT02693483|No Intervention|no vaginal cleansing|153 cases undergoing cesarean sections
16587823|NCT02693470|Other|single-arm study|"50 patients with severe psoriasis who received Stelara(ustekinumab) at 0 and 1 month. The investigators check microparticles level at baseline and 4 months later.
~50 patients without psoriasis: the microparticles are checked at baseline."
16587824|NCT02693457|Active Comparator|Drain|Intra-articular drain will be placed at closure of randomized knee for 24 hours
16587825|NCT02693457|Experimental|No Drain|No intra-articular will be placed in the contralateral knee of the same patient. A placebo drain will be placed so patient is unaware of which knee contains working drain.
16587826|NCT02693444|Active Comparator|Subacromial Lidocaine Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of lidocaine, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
16587827|NCT02693444|Placebo Comparator|Subacromial Saline Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of saline, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
16587828|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
16587829|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
16587830|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
16587831|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
16587832|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
16587833|NCT02693405|Experimental|child and adult survivors of brain tumor|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.
~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
16587834|NCT02693405|Experimental|healthy controls|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.
~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
16587835|NCT02693392|Active Comparator|Control|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.
16587836|NCT02693392|Experimental|Fenugreek|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.
16587837|NCT02693379|Experimental|D-VIA|HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
16587838|NCT02693366|Experimental|Autologous Cell Therapy|We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
16587839|NCT02693353||Study Group|Patients with diagnosed epiretinal membrane undergoing cataract surgery.
16587840|NCT02693353||Control Group|Patients without epiretinal membrane undergoing cataract surgery.
16587841|NCT02693327||Mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
16587842|NCT02693327||Non-mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
16587843|NCT02693314|Experimental|Jarro-Dophilus EPS® Group|Jarro-Dophilus EPS® (5 billion CFU/capsule) probiotic formulation capsule for 28 days
16587844|NCT02693314|Experimental|Jarro-Dophilus EPS® High Potency Group|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule) probiotic formulation capsule for 28 days
16587845|NCT02693314|Placebo Comparator|Placebo Group|Placebo capsule for 28 days
16587846|NCT02693301|No Intervention|Control|Children who follow the recommendations of their pneumologist
16587847|NCT02693301|Experimental|Experimental|A two month intervention program 3 days/week will be carried out. The session will last ~60 minutes, and will consist of a combined training (aerobic training ~30 min, and strength ~30 min of 7 whole body exercises (3 sets x 10 repetitions).The load was gradually increased as the strength of each child improved, i.e., from 40% of five-repetition maximum (5RM) lifting ability at the start of the program to 60% of 5RM at the end of the program. All sessions were individually supervised by trained professionals.
16587848|NCT02693288|No Intervention|Ultrasound-guided nerve block|
16587849|NCT02693288|Experimental|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaine 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
16587850|NCT02693275|Other|Quotient® System iPad Test|The Quotient® System iPad Test is a test specifically designed to provide clinicians with objective measures in ability to maintain seated stillness, sustained attention to a monotonous task and inhibiting incorrect impulsive responses. The attention task with motion analyses provides a number of objective measures for detailed assessment of the subject's movements and attentiveness.
16587851|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
16587852|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
16587853|NCT02693236|Experimental|adenovirus-transfected autologous DC vaccine plus CIK cells|
16587854|NCT02693210|Active Comparator|Group A: Methotrexate|Participants will receive methotrexate at dosage >=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.
16587855|NCT02693210|Experimental|Group B: Rituximab Monotherapy|Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
16587856|NCT02693210|Experimental|Group C: Rituximab and Cyclophosphamide|Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.
16587857|NCT02693210|Experimental|Group D: Methotrexate and Rituximab|Participants will receive >=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.
16587858|NCT02693197|Experimental|Cohort 1:T-817MA|Mild hepatic impairment subjects
16587859|NCT02693197|Experimental|Cohort 2:T-817MA|Healthy subjects matched to subjects in Cohort 1
16587860|NCT02693197|Experimental|Cohort 3:T-817MA|Moderate hepatic impairment subjects
16587861|NCT02693197|Experimental|Cohort 4:T-817MA|Healthy subjects matched to subjects in Cohort 3
16587862|NCT02693197|Experimental|Cohort 5 :T-817MA|Severe hepatic impairment subjects
16587863|NCT02693197|Experimental|Cohort 6:T-817MA|Healthy subjects matched to subjects in Cohort 5
16587864|NCT02693184||Fragility Fracture Case|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
16587865|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
16587866|NCT02693145|No Intervention|standard of care (SOC) arm|Individuals found to be out of HIV medical care will receive standard of care to re-engage. This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
16587867|NCT02693145|Experimental|Intervention arm|Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
16587868|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
16587869|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
16587870|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
16587871|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
16587872|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
16587873|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
16587874|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
16587875|NCT02693106|Experimental|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.
~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
16587876|NCT02693093|Placebo Comparator|placebo|TID Day for 28 Days
16587877|NCT02693093|Experimental|100 mg NI-03|TID Day for 28 Days
16587878|NCT02693093|Experimental|200 mg NI-03|TID Day for 28 Days
16587879|NCT02693093|Experimental|300 mg NI-03|TID Day for 28 Days
16587880|NCT02693080|Experimental|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent
16587881|NCT02693067|Experimental|PV-10|Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
16587882|NCT02693054|Experimental|Hybrid Fractional Laser Treatment|Halo (1470nm and 2940 nm) laser
16587883|NCT02693041|Active Comparator|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
16587884|NCT02693041|Placebo Comparator|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
16587885|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
16587886|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
16587887|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
16587888|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
16587889|NCT02693028|Active Comparator|probiotic lozenge|Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
16587890|NCT02693028|Active Comparator|Probiotic capsule|Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
16587891|NCT02693028|Active Comparator|Probiotic chewing gum|The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
16587892|NCT02693028|Placebo Comparator|Placebo lozenge|Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
16587893|NCT02693028|Placebo Comparator|Placebo capsule|Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
16587894|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
16587895|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
16587896|NCT02692976|Experimental|Myeloid dendritic cells (mDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
16587897|NCT02692976|Experimental|Plasmacytoid dendritic cells (pDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
16587898|NCT02692976|Experimental|mDC and pDC vaccinations|Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.
16587899|NCT02692963|Experimental|BCG vaccination|
16587900|NCT02692963|No Intervention|Control|
16587901|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
16587902|NCT02692937|Experimental|Surgery and exercise|Neurolysis of peripheral nerves in the back of the head and/or neck. Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
16587903|NCT02692937|Active Comparator|Exercise, Active Comparator|Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
16587905|NCT02692911||Women with gallstones|Women aged 50-74 with gallstones
16587906|NCT02692898||1|Archived CNS neoplasm specimens, in which primary diagnostic studies are complete, and for which there is excess tissue for analysis in the form of unstained slides or paraffin blocks
16587907|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
16587908|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically-indicated surgeries
16587910|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
16587911|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
16587915|NCT02692833||AKI Patients|Patients who develop acute kidney injury within the first 5 days following their cardiac surgical operation.
16588054|NCT02691988|Active Comparator|Usual care|Optimization of bronchodilator treatment
16587917|NCT02692820|Experimental|Probiotic|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of probiotics (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (each at 2.5 x 109 colony forming units (CFUs)). The product contains freeze-dried bacteria and excipients in a gelatin capsule.
16587918|NCT02692820|Placebo Comparator|Placebo|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of the placebo containing excipients alone in a gelatin capsule
16587919|NCT02692807|Active Comparator|Hip arthroscopy surgical procedures (HIPARTI Study)|Surgery is performed under general anaesthesia. Traction and joint access is controlled by fluoroscopy. A diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented. Any labral, chondral and bony pathology (cam or pincer) is treated. Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum is secured with suture anchors. Pincer and cam resection is performed using an arthroscopic burr. Cartilage lesions maybe left untreated or treated with debridement or microfracture.
16587920|NCT02692807|Placebo Comparator|Sham surgery (HIPARTI Study)|The same arthroscopic procedures as stated above are preformed, but no surgical interventions related to Cam, Pincer, or labral tear are performed, only diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented.
16587921|NCT02692807|Active Comparator|Prospective Cohort (HARP Study)|Those that are not willing to be included in the RCT (HIPARTI Study), will be asked if they are willing to be included in the prospective cohort, or ongoing in countries were ONLY the surgery is performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).
16587922|NCT02692781|Experimental|Dose Cohort 1|20mg MOD-6031 / Placebo
16587923|NCT02692781|Experimental|Dose Cohort 2|50mg MOD-6031 / Placebo
16587924|NCT02692781|Experimental|Dose Cohort 3|100mg MOD-6031 / Placebo
16587925|NCT02692781|Experimental|Dose Cohort 4|150mg MOD-6031 / Placebo
16587926|NCT02692781|Experimental|Dose Cohort 5|200mg MOD-6031 / Placebo
16587927|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
16587928|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
16587929|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
16587930|NCT02692755|Experimental|Palbociclib + Letrozole or Fulvestrant|
16587931|NCT02692742|Experimental|Myelo001|Myelo001 100 mg QD
16587932|NCT02692742|Placebo Comparator|Placebo|Matching Placebo QD
16587933|NCT02692729|Experimental|supraumbilical transverse|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis. Above the panniculus, the fatty tissues are not particularly thick. A transverse opening of the aponeurosis and of the parietal peritoneum was done. Then the approach to the lower uterine segment was easy. A Ricard retractor was put in place.
16587934|NCT02692729|Active Comparator|pfannenstiel|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
16587935|NCT02692716|Experimental|Oral semaglutide|
16587936|NCT02692716|Placebo Comparator|Placebo|
16587937|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
16587938|NCT02692690|Experimental|before-after|TENS stimulation neck and thigh
16587939|NCT02692677|Experimental|JNJ-42756493|Each participant will receive a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493 at Pre-dose,0.5,1,2,3,4,8,12 hour post-dose(pd) on Day 1;24,36 h pd on Day 2;48 h pd on Day 3,72 h pd on Day 4; 96 h pd on Day 5;192 h pd on Day 9,216 h pd on Day 10,240 h pd on Day 11,264 h pd on Day 12,288 h pd on Day 13 and 312 h pd on Day 14
16587940|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
16587941|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
16587942|NCT02692638|Experimental|Early laparoscopic enterolysis|Patient randomized to the early laparoscopy arm will undergo diagnostic laparoscopy within 24 hours of admission (depending on surgeon and operating room availability). Standard laparoscopy will be performed including supine positioning, sequential compression devices, and appropriate pre-incision antibiotics. Trocar placement will be at the surgeon's discretion and as appropriate for the patient's previous incisions. The necessity for conversion will be left to the discretion of the attending surgeon. Post operative management will conform to the standards of care. Nasogastric tubes will not be routinely placed.
16587943|NCT02692638|Active Comparator|trial of nonoperative management|Patients randomized to the trial of nonoperative management arm will undergo standard therapy including nil per os (NPO), nasogastric decompression only if actively vomiting, intravenous fluids while awaiting return of bowel function. Patients who do not achieve return of bowel function within 72 hours of admission will undergo attempted laparoscopic enterolysis with the understanding that conversion to open procedure may be necessary.
16588055|NCT02691975|Experimental|SHR3680|Tablet
16587944|NCT02692625|Experimental|Group A|"Group A (test group): This group consist of 80 children receiving the probiotic lozenges.
~The Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). The probiotic lozenge is used twice daily for two months."
16587945|NCT02692625|Placebo Comparator|Group B|"Group B (control group): This group consist of 80 children receiving the placebo lozenges.
~The placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.The placebo lozenges is used twice daily for two months."
16587946|NCT02692612||Young|
16587947|NCT02692612||Middle-Aged|
16587948|NCT02692612||Old|
16587949|NCT02692599|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated mumps vaccine;"
16587950|NCT02692599|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;
~Intervention: control live attenuated mumps vaccine;"
16587951|NCT02692586|Experimental|FlowTriever System|
16587952|NCT02692573|Experimental|prone|Prone positioned after delivery
16587953|NCT02692573|Active Comparator|supine|Supine positioned after delivery
16587954|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
16587955|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
16587956|NCT02692547|Other|Hybrid-logic closed loop system|All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.
16587957|NCT02692534||Cocaine negative|Patients with preoperative urine cocaine negative results
16587958|NCT02692534||Cocaine positive|Patients with preoperative urine cocaine positive results
16587959|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
16587960|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
16587961|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
16587962|NCT02692482|Active Comparator|standard care|
16587963|NCT02692469|Active Comparator|Duodenal Switch Surgical Intervention|a DS procedure involves creating a sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel
16587964|NCT02692469|Experimental|Single Anastomosis Duodenal-Ileal Bypass|The SADI defers from the DS in that after the duodenum is separated from the stomach, preserving the pylorus, a loop of bowel 200 cm from the ileo-cecal valve is anastomosed with the pylorus, thus requiring only one anastomosis
16587965|NCT02692456|Active Comparator|Double needle celiac neurolysis (DNCN)|Patients were subjected to CT guided celiac neurolysis using 2 needle antero-crural technique on each side with patient in prone position and both needles will be lateral to the aorta
16587966|NCT02692456|Placebo Comparator|Single needle celiac neurolysis (SNCN)|Patients were subjected to CT guided celiac neurolysis using a single needle antero-crural approach from left side to be just in the front of the aorta near the origin of celiac trunk with patient in lateral position with his left side up then after the injection the patient were kept to his right side up for more homogenous spread of the dye.
16587967|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
16587968|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
16587969|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
16587970|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
16587971|NCT02692404||Hospital Birth|Healthy nulliparous participants, planning spontaneous vaginal or induced vaginal delivery, and planning delivery at a hospital woman-care birth center (Magee-Womens Hospital of UPMC) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to utilize labor epidural analgesia for pain control during labor.
16587972|NCT02692404||Midwife Center Birth|Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
16587973|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
16587974|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
16587975|NCT02692378|Active Comparator|Treatment|"Standard haemodialysis treatment thrice weekly (using a standard dialysate containing bicarbonate at a concentration of 35mmols/L) with the addition of oral sodium bicarbonate 500mg capsules for 12 weeks (weeks 5-16 of the study).
~The dosage will be titrated to individual blood levels. Starting dose will be 1g twice daily and if predialysis bicarbonate levels remain <22mmols/L the dose will be increased by 0.5g twice daily each week. The maximum dose would be 3g twice daily.
~The oral sodium bicarbonate may be withheld on dialysis days, when bicarbonate will be supplemented through the dialysate. This will be assessed on a case by case basis."
16587976|NCT02692378|No Intervention|Control|Standard haemodialysis treatment thrice weekly using a standard dialysate containing bicarbonate at a concentration of 35mmols/L.
16587977|NCT02692365|Experimental|Calcium channels|Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
16587978|NCT02692365|Experimental|Tumor perfusion|Magnetic Resonance + hemodynamic + infusion of gadolinium
16587979|NCT02692352|Experimental|Experimental|8 sessions of Goal Management Training
16587980|NCT02692352|Active Comparator|Active control group|8 sessions of Brain Health Workshop
16587981|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
16587982|NCT02692326|Experimental|Intervention: Cyclic parenteral nutrition Cohort|All newborn who were included in the study to receive cyclic parenteral nutrition (within 24 hours). The parenteral nutrition was stopped for one hour the first day until 4 hours in preterm infants and 6 hours in term neonates.
16587983|NCT02692326|No Intervention|Control: Continuous parenteral nutrition|All newborn who were included in the study to receive continuous parenteral nutrition (24 hours). The parenteral nutrition was given by a central line in 24 hours with a basal flow
16587984|NCT02692313|Placebo Comparator|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
16587985|NCT02692313|Experimental|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
16587986|NCT02692313|Experimental|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
16587987|NCT02692313|Experimental|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
16587988|NCT02692300|No Intervention|Control Group|Patients will undergo standard anesthesia and will be blinded to EEG-based data, as per standard of care in this patient population.
16587989|NCT02692300|Experimental|EEG-Guided Group|Practitioners will follow the EEG-Guided protocol to limit the incidence of EEG burst suppression by decreasing administration of anesthesia. The EEG-guided protocol is suggestive rather than prescriptive, and practitioners will exercise judgment depending on the clinical situation.
16587990|NCT02692287|Other|Use of the PPH Butterfly|The PPH Butterfly will be inserted into the vagina of a healthy postnatal woman
16587991|NCT02692274||Primary Health care clinics|A survey of 100 primary Health care clinics was carried out
16587992|NCT02692274||Pregnant and breast feeding women|208 patients were recruited from nine clinics that participated in the survey for evaluation of the accuracy of results produced by the HIV rapid test.
16587993|NCT02692261|Active Comparator|Hyalossᵀᴹ matrix|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation
16587994|NCT02692261|Active Comparator|Apatos alone xenograft|Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation
16587995|NCT02692248|Experimental|Ibrutinib -R-GEMOX-Dexa|"Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:
~Induction phase:
~Rituximab 375 mg/m2 IV day 1
~Gemcitabine 1000 mg/msq IV on day 1 or 2 (at investigator discretion).
~Oxaliplatine 100 mg/msq on day 1 or 2 (after Gemcitabine administration);
~Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.
~Ibrutinib 560 mg daily for 14 days.
~Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.
~Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity."
16587996|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
16587997|NCT02692235|Placebo Comparator|placebo|24 weeks isonitrogenous supplementation
16587998|NCT02692222||PPV|This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output.
16587999|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
16588000|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
16588001|NCT02692196|Experimental|Neurofeedback Training|Neurofeedback training - neurofeedback of fronto-limbic functional connectivity.
16588002|NCT02692196|Sham Comparator|Sham Control|Sham training - feedback that is not related with fronts-limbic connectivity (motor connectivity)
16588003|NCT02692183||Parkinson Disease (PD) tremor patients|Patients with PD before and after MRI guided Focused ultrasound thalamotomy
16588004|NCT02692183||Essential tremor (ET) patients|Patients with ET before and after MRIFocused ultrasound guided thalamotomy
16588005|NCT02692170|Experimental|CVI-HBV-001 (5 μg)|"HBV surface antigen 5 μg/dose
~Intramuscular injection at 0, 1, 6th month"
16588006|NCT02692170|Experimental|CVI-HBV-001 (10 μg)|"HBV surface antigen 10 μg/dose
~Intramuscular injection at 0, 1, 6th month"
16588007|NCT02692170|Experimental|CVI-HBV-001 (20 μg)|"HBV surface antigen 20 μg/dose
~Intramuscular injection at 0, 1, 6th month"
16588008|NCT02692170|Experimental|CVI-HBV-001 (40 μg)|"HBV surface antigen 40 μg/dose
~Intramuscular injection at 0, 1, 6th month"
16588009|NCT02692170|Active Comparator|Conventional Hepatitis B vaccine (20 μg)|"HBV surface antigen 20 μg/dose
~Intramuscular injection at 0, 1, 6th month"
16588010|NCT02692157|Placebo Comparator|Placebo|Placebo Comparator: Placebo - During this arm, Placebo medication will be administered orally each evening at 8pm.
16588011|NCT02692157|Active Comparator|NT-814 50 mg|Active Comparator: NT-814 50 mg - During this arm, 50 mg NT-814 will be administered orally each evening at 8pm.
16588012|NCT02692157|Active Comparator|NT-814 100 mg|Active Comparator: NT-814 100 mg - During this arm, 100 mg NT-814 will be administered orally each evening at 8pm.
16588013|NCT02692157|Active Comparator|NT-814 200 mg|Active Comparator: NT-814 200 mg - During this arm, 200 mg NT-814 will be administered orally each evening at 8pm.
16588014|NCT02692144|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
16588015|NCT02692144|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
16588016|NCT02692144|Placebo Comparator|White-bread|47g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
16588017|NCT02692131||Speckle strain|All adult patients undergoing on pump CABG Surgery.
16588018|NCT02692131||Tissue doppler strain|All adult patients undergoing on pump CABG Surgery
16588019|NCT02692118||sepsis|Patients with septic shock admitted to ICU
16588020|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
16588021|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.
~HDR brachytherapy is also accomplished as an out-patient."
16588022|NCT02692092||Total Arthroplasty Patients|Any patient who has received a total hip or total knee arthroplasty at a healtheast acute care hospital.
16588023|NCT02692079|Experimental|T-PRF+Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Test group sites were treated with T-PRF+allograft
16588024|NCT02692079|Experimental|Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Control group sites were treated with only allograft
16588025|NCT02692066||Healthy Controls|Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
16588026|NCT02692066||Children with Chronic Liver Disease|Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
16588027|NCT02692053|Experimental|Patients with septic shock|
16588028|NCT02692053|Other|Blood samples from a historical cohort of healthy volunteers|
16588029|NCT02692040|Experimental|12-24 mg (B1) dose of G3215|"G3215 multiple dose, subcutaneous injection:
~5 doses over a 4 week treatment period at escalating doses to a max of 24 mg."
16588030|NCT02692040|Experimental|6-10 mg (B2) dose of G3215|"G3215 multiple dose, subcutaneous injection:
~5 doses over a 4 week treatment period at escalating doses to a max of 10 mg."
16588031|NCT02692040|Experimental|5-16 mg (B3) dose of G3215|"G3215 multiple dose, subcutaneous injection:
~5 doses over a 4 week treatment period at escalating doses to a max of 16 mg."
16588032|NCT02692040|Experimental|3.2mg (C) infusion pump dose of G3215|G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo [saline]).
16588033|NCT02692040|Placebo Comparator|Placebo (B) - saline|5 subcutaneous injections of 0.9% saline, over a 4 week treatment period
16588034|NCT02692040|Placebo Comparator|Placebo (A) - saline|Single subcutaneous injection of 0.9% saline
16588035|NCT02692040|Experimental|0.1 mg dose G3215 (A1)|0.1 mg G3215 single dose, subcutaneous injection
16588036|NCT02692040|Experimental|0.5 mg dose G3215 (A1)|0.5 mg G3215 single dose, subcutaneous injection
16588037|NCT02692040|Experimental|1.5 mg dose G3215 (A1)|1.5 mg G3215 single dose, subcutaneous injection
16588038|NCT02692040|Experimental|4 mg dose G3215 (A2) with varied formulation|4 mg G3215 single dose, subcutaneous injection
16588039|NCT02692040|Experimental|4 mg dose G3215 (A3) with varied formulation|4 mg G3215 single dose, subcutaneous injection
16588040|NCT02692040|Experimental|4 mg dose G3215 (A4) with varied formulation|4 mg G3215 single dose, subcutaneous injection
16588041|NCT02692040|Experimental|4 mg dose G3215 (A5) with varied formulation|4 mg G3215 single dose, subcutaneous injection
16588042|NCT02692040|Experimental|8 mg dose G3215 (A7)|8 mg G3215 single dose, subcutaneous injection
16588043|NCT02692040|Experimental|10 mg dose G3215 (A6)|10 mg G3215 single dose, subcutaneous injection
16588044|NCT02692040|Experimental|12 mg dose G3215 (A8)|12 mg G3215 single dose, subcutaneous injection
16588045|NCT02692040|Experimental|16 mg dose G3215 (A9)|16 mg G3215 single dose, subcutaneous injection
16588046|NCT02692040|Experimental|32 mg dose G3215 (A10)|32 mg G3215 single dose, subcutaneous injection
16588047|NCT02692040|Experimental|48 mg dose G3215 (A11)|48 mg G3215 single dose, subcutaneous injection
16588048|NCT02692027|Active Comparator|Standard of care|Standard of care in Lesotho. ART-initiation after at least two clinic visits for pre-ART counseling and monthly follow-up visits at the clinic thereafter.
16588049|NCT02692027|Experimental|Same-day ART initiation with less frequent follow-up visits|Proposition of same-day ART initiation with less frequent follow-up visits thereafter.
16588050|NCT02692014||coronary heart disease|2,400 patients who are diagnosed with CHD and have received more than 2 times of coronary angiography within 12-24 months.
16588051|NCT02692001|No Intervention|Current MealTrain menu|This is the current menu being employed for food ordering in the pediatric inpatient wards.
16588052|NCT02692001|Experimental|Intervention MealTrain menu|The intervention menu included child-friendly labeling (attractive characters, fun food names and traffic light system) to encourage healthier choices.
16592702|NCT02660892|Experimental|Protein Intake|Threonine intake - Dietary supplement
16588057|NCT02691949|Experimental|Mycophenolate mofetil standard|mycophenolate mofetil 250mg 2# twice per day (BID)
16588058|NCT02691949|Experimental|Mycophenolate sodium low|mycophenolate mofetil 250mg 1# twice per day (BID)
16588059|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
16588060|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
16588061|NCT02691923|Active Comparator|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
16588062|NCT02691923|Experimental|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
16588063|NCT02691910|Active Comparator|CONCURRENT CHLOROQUINE+PRIMAQUINE|"The infected individuals were treated with the standard chloroquine (CQ)+primaquine(PQ) regimen to malaria caused by Plasmodium vivax.
~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.
~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
16588064|NCT02691910|Experimental|CHLOROQUINE|"The infected individuals were initially treated with chloroquine (CQ) alone and the primaquine(PQ) was introduced on day 28.
~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.
~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 28 of CQ treatment. Total dose, 3.5mg/kg.
~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
16588065|NCT02691897|Experimental|Melatonin|Melatonin 3mg once daily at bedtime
16588066|NCT02691897|Placebo Comparator|Placebo|Placebo 1 tablet once daily at bedtime
16588067|NCT02691884||Patients before/after Pressure Exertion|100 pregnant patients at term in low risk pregnancies, undergoing a routine cardiotocography, will experience different amounts of manual pressure on their abdomen. The amount of pressure applied will be recorded and the fetal heart rate will be compared before and at the time of maternal abdominal pressure.
16588068|NCT02691871|Experimental|Apatinib + Docetaxel|Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
16588069|NCT02691858|Experimental|Hydrocortisone|Hydrocortisone IV 10 mg/kg with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
16588070|NCT02691858|Placebo Comparator|Saline|Saline IV 100 ml with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
16588071|NCT02691845|Other|BA|Brief advice to exercise. This serves as a control condition.
16588072|NCT02691845|Active Comparator|BA + SHE + HE|Brief advice to exercise + supervised & home-based exercise + health education
16588073|NCT02691845|Experimental|BA + SHE + CBEX|Brief advice to exercise + supervised & home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
16588074|NCT02691832|Experimental|research arm|"the trial contains one group which will undergo the described protocol three times:
~connected to rectal thermistor and to the double sensor
~connected to rectal thermistor, double sensor and cooling system of Icetron Technologies Ltd.
~connected to rectal thermistor and to the double sensor integrated into a helmet."
16588075|NCT02691806|Experimental|research arm|Each of the 14 participants will undergo the same 2 days experimental protocol, separated by at least 2 days rest.
16588076|NCT02691793|Experimental|sunitinib|sunitinib 50 mg will be administered orally daily
16588077|NCT02691780|Experimental|Sorafenib|Sorafenib 200mg bid will be administered orally daily every 3weeks
16588078|NCT02691767|Experimental|pazopanib|pazopanib 800 mg will be administered orally daily every 3weeks
16588079|NCT02691754|Experimental|free paracetamol|the General Practitioners can prescribe paracetamol for free (covered by NHS). Patients can receive monthly dose at the local hospital
16588080|NCT02691754|No Intervention|standard drug prescription|"Paracetamol is not included in the list of drugs than can be prescribed in charge of National Health System by General Practitioners.
~The General Practitioners can prescribe other drugs or recommend paracetamol payed by the patient (out of pocket) at the chemistry."
16588081|NCT02691741|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
16588082|NCT02691741|Active Comparator|839MP|AT LISA® tri IOL, bilateral implantation
16588083|NCT02691728|Experimental|Treatment Arm|12 Week treatment with LDV/SOF FDC
16588084|NCT02691715|Experimental|Endometrial saline plus curettage|5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant.
16588085|NCT02691715|Active Comparator|Endometrial curettage|Only routine endometrial curettage performed
16588086|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
16588087|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
16588088|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
16588089|NCT02691689|Other|Patients with ASD or VSD and PAH|
16588090|NCT02691676|Experimental|Plasmalyte|Arm 1: Plasmalyte in 5% glucose infusion solution (PL), manufactured by Baxter Healthcare as slightly alkalizing (Na+ 140; K+ 5.0; Mg2+ 1.5; Cl- 98; acetate 27; gluconate 23)
16588091|NCT02691676|Active Comparator|Ringerfundin|Arm 2: Ringerfundin infusion solution (RF), manufactured by B. Braun as acid-base neutral (Na+ 145; K+ 4.0; Mg2+ 1.0; Ca2+ 2.5; Cl- 127; acetate 24; malate 5.0).
16588092|NCT02691663|Active Comparator|Oral bicarbonate supplementation group|0.3 meq/kg/day NaHCO3 capsules
16588093|NCT02691663|Placebo Comparator|Placebo group|Methylcellulose capsules
16588094|NCT02691650||polytrauma patients|Patients with severe traumatic injury, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
16588095|NCT02691650||burns patients|Patients with burns trauma, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
16588096|NCT02691637||H. pylori eradication group|Patients who have had H. pylori infection. After diagnosis of H. pylori infection, the patients who subsequently received successful H. pylori eradication treatment according to appropriate indication.
16588097|NCT02691637||Control Group|Patients who still have H. pylori infection. The patients of control group do not have successful H. pylori eradication result or do not received eradication treatment for any reason.
16588098|NCT02691624||sentinel lymph node biopsy|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive sentinel lymph node biopsy
16588099|NCT02691624||axillary lymph node dissection|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive axillary lymph node dissection
16588100|NCT02691611||Alpha-1 Antitrypsin|All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy
16588101|NCT02691611||Healthy Control|Healthy controls with no lung diseases
16588102|NCT02691598|Experimental|Group A|Dexmedetomidine Hydrochloride 4ug/ml；0.05ml/kg.h infusion for 24hours
16588103|NCT02691598|Placebo Comparator|Group B|Normal Saline 0.05ml/kg.h infusion for 24hours
16588104|NCT02691585|Experimental|Music intervention group 1|Raga 1 will be given
16588105|NCT02691585|Experimental|Music intervention group 2|Raga 2 will be given
16588106|NCT02691585|Experimental|Music intervention group 3|Raga 3 will be given
16588107|NCT02691585|No Intervention|Control Group 4|No raga. Just collection of electrophysiological parameters will be done.
16588108|NCT02691572|Active Comparator|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
16588109|NCT02691572|Experimental|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
16588110|NCT02691559|Active Comparator|maternal inflammation group|Amniotic fluid analysis by blood gas device: evaluate the possible association between maternal inflammation and amniotic fluid pH two groups will be designed. One group will consist of infants born to mothers with infection/inflammation whereas the control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
16588111|NCT02691559|Active Comparator|normal pregnancy group|Amniotic fluid analysis by blood gas device: The control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
16588112|NCT02691546||Subjects aged 75 years or older|
16588113|NCT02691533|Experimental|ω3 PUFA(10% Omegavan 100 ml)|
16588114|NCT02691533|Experimental|ω6 PUFA (20% Intralipid 50 ml)|
16588115|NCT02691533|Placebo Comparator|Placebo Arm|No Lipid Emulsion will be given in this arm
16588116|NCT02691520||Taiwan Participants with Treatment Resistant Depression|Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.
16588117|NCT02691507|Active Comparator|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
16588118|NCT02691507|Experimental|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
16588119|NCT02691494|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
16588120|NCT02691494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
16588121|NCT02691494|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
16588122|NCT02691481|Active Comparator|Oatmeal breakfast|consuming 200 kcal of plain cooked oatmeal for breakfast
16588123|NCT02691481|Active Comparator|Glucerna formula|consuming 200 kcal of Glucerna shake for breakfast
16588124|NCT02691481|Active Comparator|Ultra Glucose Control formula|consuming 200 kcal of Ultra Glucose Control shake for breakfast
16588125|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.
~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .
~The second set of measurements is taken in lateral position after position change.
~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
16588126|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.
~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .
~The second set of measurements is taken in lateral position after position change.
~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
16588127|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt
~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
16588128|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
16588129|NCT02691442|Active Comparator|Ropivacaine 0.75%|The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space
16588130|NCT02691442|Active Comparator|Levobupivacaine 0.5%|The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space
16588131|NCT02691442|Active Comparator|Levobupivacaine 0.5% + epinephrin|The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space
16588132|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 10%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
16588133|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 25%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
16588134|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
16588135|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
16588136|NCT02691403|Sham Comparator|Placebo QL block|30 ml single shot QL block with saline 0.9%
16588137|NCT02691403|Active Comparator|Active QL block|30 ml single shot QL block with 0.25% levo-bupivacaine
16588138|NCT02691390|Experimental|study group|alcoholics - dTMS group
16588139|NCT02691390|Sham Comparator|control group|alcoholics - sham group
16588140|NCT02691377|Experimental|Acupuncture group|Participants will receive acupuncture for 8 weeks. In particular, acupuncture will be performed three times a week in earlier 4 weeks and twice a week in later 4 weeks.
16588141|NCT02691377|Sham Comparator|Sham Acupuncture group|Participants will receive sham acupuncture for 8 weeks. The procedure is the same as the acupuncture arm.
16588142|NCT02691364||Healthy|Healthy women
16588143|NCT02691364||Preeclamptic|Pregnant women with preeclampsia
16588144|NCT02691351||non-Hodgkin T-cell Lymphoma|
16588145|NCT02691338||patients undergoing thrombectomy|20 anesthetized patients undergoing intra-arterial catheterization for thrombectomy after CVA. The patients will be recruited at the Rambam Health Center, Haifa, Israel. The patients will undergo EEG recording for 5 minutes at the begining of the procedure, after initiating the anesthesia (general or sedation - according to the patient's clinical status). At the end of the procedure, while the patient is still anesthetized, he will undergo another EEG recording for 5 minutes.
16588146|NCT02691338||Control - healthy individuals|15 health individuals under sedation for other procedures. They will undergo EEG recording for 5 minutes during the procedure, while they are under sedation, to validate the sensitivity of the EEG to the effect of the anaesthetic medications.
16588147|NCT02691325|Experimental|Part A (Sequence 1) - Placebo, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 matching placebo (one inhalation) in treatment period 1, and single dose of GSK2269557 200 microgram (mcg) (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
16588148|NCT02691325|Experimental|Part A (Sequence 2) - GSK2269557 100 mcg, Placebo|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 matching placebo (two inhalations) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
16588149|NCT02691325|Experimental|Part A (Sequence 3) - GSK2269557 100 mcg, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
16588150|NCT02691325|Experimental|Part B- GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) once daily via the ELLIPTA DPI for 10 days. Doses of GSK2269557 may be modified based on emerging data from Part A.
16588151|NCT02691325|Experimental|Part B- GSK2269557 matching Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo (2 inhalations) once daily via the ELLIPTA DPI for 10 days.
16588152|NCT02691325|Experimental|Part C- GSK2269557 200 mcg with and without activated charcoal|Subjects will receive a single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) via the ELLIPTA DPI with activated charcoal in one treatment period and without ingestion of activated charcoal in another treatment period. The washout period between each dosing day will be at least 14 days. Dose of GSK2269557 may be modified based on emerging data from Part A.
16588153|NCT02691312||Type 1 diabetes (T1D)|Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
16588154|NCT02691299|Active Comparator|Treatment Arm|All subjects will receive study treatment in 4-week cycles: Fruquintinib, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.
16588155|NCT02691299|Placebo Comparator|Control Arm|All subjects will receive study treatment in 4-week cycles: Placebo, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease
16588156|NCT02691286||Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
16593183|NCT02657798||Healthy controls|Healthy participants with no history of depression
16588157|NCT02691286||No Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock
16588158|NCT02691273|Experimental|breathing technique|this arm includes learning breathing technique using the patient's smartphone.
16588159|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
16588160|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
16588161|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
16588162|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
16588163|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
16588164|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
16588165|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
16588166|NCT02691234|Experimental|Extracorporeal Shockwave Therapy and debridement|The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
16588167|NCT02691234|Active Comparator|debridement and cleansing.|The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
16588168|NCT02691221|Other|Participants with previous suicide attempt or ideation|Participants will complete daily tasks assigned for completion through a downloaded application on their mobile device and completing six 2-hour long outcome assessment sessions including rater-lead scales over the course of six months.
16588169|NCT02691208|Experimental|Group I Kinesiotherapy|women with pain treated with a predefinided exercises protocol of 30 minutes.
16588170|NCT02691208|Experimental|Group II Acupuncture|women with pain treated with a predefinided exercises protocol of 30 minutes followed by 30 minutes of acupuncture, used in predefined points
16588171|NCT02691195|Placebo Comparator|group control|group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
16588172|NCT02691195|Experimental|group SPB|group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
16588173|NCT02691182|Experimental|Open-label treatment with SPN-810|Subjects aged 6-12 years will be treated with SPN-810 starting day 1 of Visit 1 of the study. The subjects will be given a choice of extending their participation in the study every 6-month period for up to 36 months. The clinician will be able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability.
16588174|NCT02691169|Experimental|18F-DCFPyL Injection|The subjects will receive the 18F-DCFPyL Injection (less than or equal to 9 mCi (333 MBq)) at visits 2 and 3.
16588175|NCT02691156||Premature Infants|Premature infants GA 24 to ≤34 wks at risk for hyperbilirubinemia will have BBC, ETCOc, and COHbc measured during 0-7 days of life.
16588176|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
16588177|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
16588178|NCT02691130|Experimental|A: M-001 0.5mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine
~Two administrations of non adjuvanted M-001, 0.5mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
16588179|NCT02691130|Experimental|B: M-001 1.0mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine
~Two administrations of non adjuvanted M-001, 1.0mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
16588180|NCT02691130|Placebo Comparator|C: Saline & H5N1 influenza vaccine|"Biological/Vaccine: Two saline administrations followed by H5N1 influenza vaccine
~Two administrations of saline followed by 3mcg Alum/H5N1 influenza vaccinated intervals of 19-23 days"
16588181|NCT02691117|Experimental|Garlic concentrate|Garlic gel concentrate- once a day topical application
16588182|NCT02691104|Experimental|Intervention|"Use of the app and Fitbit alongside 5-7 week pulmonary rehabilitation programme (plus goal-setting help from physiotherapist), and then app and Fitbit plus intermittent contact with physiotherapist for 8 weeks after pulmonary rehabilitation
~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
16588183|NCT02691104|Other|Control|"Attend 5-7 week pulmonary rehabilitation programme (usual care) and wear blinded Fitbit during pulmonary rehabilitation and for 8 weeks afterwards
~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
16588184|NCT02691078|Experimental|Adult patients with neuroendocrine tumors|
16588185|NCT02691065|Experimental|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
16588186|NCT02691065|No Intervention|Protease inhibitor|Continuation of protease-inhibitor based regimen
16588187|NCT02691052||Pts receiving nab-paclitaxel/gemcitabine|Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.
16593866|NCT02653274|Active Comparator|FINGER (RAGI) MILLET PORRIDGE|Finger (ragi) millet breakfast porridge
16588188|NCT02691026|Experimental|Pembrolizumab|200 mg pembrolizumab, i.v. infusion every 3 weeks for up to 10 cycles
16588189|NCT02691013|Placebo Comparator|Placebo|Patients will receive a Placebo tablet every evening.
16588190|NCT02691013|Active Comparator|Ramelteon|Patients will receive Ramelteon 8mg every evening.
16588191|NCT02691000|Experimental|Bright White Light (BWL) Litebook|Participants will be instructed to use the BWL Litebook for an hour every day for 8 weeks.
16588192|NCT02691000|Placebo Comparator|Dim Red Light (DRL) Litebook|Participants will be instructed to use the DRL (comparison condition) Litebook for an hour every day for 8 weeks.
16588193|NCT02690987|Experimental|Overweight/obese subjects|Overweight/obese volunteers with BMI 28.0-50.0 kg/m2, otherwise healthy. This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design.
16588194|NCT02690987|Experimental|Ex-smokers|"Abstinent tobacco dependent individuals who score at least moderately on tobacco dependence as measured retrospectively using the Fagerström Test for Nicotine Dependence (FTND), and who have been in stable tobacco abstinence for at least 6 weeks.
~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
16588195|NCT02690987|Experimental|Ex-alcohol dependent subjects|"Abstinent alcohol dependent individuals who score at least moderately alcohol dependent as measured retrospectively using the Severity of Alcohol Dependence Questionnaire (SADQ), and who have been abstinent for at least 6 weeks.
~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
16588196|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
16588197|NCT02690961|Experimental|Kukoamine B Mesilate 0.06mg/kg|Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16588198|NCT02690961|Experimental|Kukoamine B Mesilate 0.12mg/kg|Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16588199|NCT02690961|Experimental|Kukoamine B Mesilate 0.24mg/kg|Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16588200|NCT02690961|Experimental|Placebo 0.06mg/kg|Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16588201|NCT02690961|Experimental|Placebo 0.12mg/kg|Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16588202|NCT02690961|Experimental|Placebo 0.24mg/kg|Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16588203|NCT02690948|Experimental|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16588204|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16588205|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH
~Impregnated on lactose saccharose globules (380 mg/capsule)"
16588206|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
16588207|NCT02690922|Experimental|ph+ ALL with dasatinib|patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.
16588208|NCT02690909|Experimental|Redy™ Renal Denervation System|Renal Denervation System
16588209|NCT02690896|Experimental|UCF Behavioral Intervention Group|The intervention group will be the UCF Caregiver Support. Participants will receive a 90 minute group session, once a week, for a period of 6 consecutive weeks.
16588210|NCT02690896|Active Comparator|Community Comparison Group|Comparison group members will come from potential local support groups include, but are not limited to, the support group at the Faith Assembly of God church, the caregiver support group at the First Baptist Church of Orlando, and the caregiver support group at the Alzheimer's and Dementia Resource Center.
16588211|NCT02690883|Active Comparator|Lispro|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
16588212|NCT02690883|Experimental|Exenatide|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
16588213|NCT02690870|Experimental|tamoxifen|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
16588233|NCT02690740|Experimental|open label|"test/retest of a titrated quantitative CPT (TqCPT) with outcomes: CPT-scoring system and correlation with digital photo analysis.
~in all patients: 1 Arm = CPT test/re-test, no comparator
~No intervention of a new drug (CPT-solution registered (ALK- Abelló, Hørsholm, Denmark));"
16588234|NCT02690727|Experimental|RP6530 in fast condition|A single dose of RP6530 following fast condition
16588235|NCT02690727|Experimental|RP6530 in fed condition|A single dose of RP6530 following fed condition
16588214|NCT02690870|Active Comparator|clomiphene|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
16588215|NCT02690857|Experimental|Docosahexaenoic acid|"Each capsule of DHA contains 100 mg DHA in triglycerides from algal oil, 0.125 mg alpha-tocopherol and 0.125 mg ascorbic acid.
~Subjects receive an orally and daily ingestion of DHA capsules (5mg/kg for 15 days followed by 10 mg/kg for another 15 days without interruption between the 2 periods)."
16588216|NCT02690857|Placebo Comparator|Sunflower oil|Placebo capsules contain the same quantities of antioxidants and triglycerides of sunflower oil. Subjects receive an orally and daily ingestion of placebo capsules for 28 days.
16588217|NCT02690844|Active Comparator|Clonazepam|Clonazepam (Klonopin®) treatment arm - 1 mg clonazepam (Klonopin® tablet) TID, dissolved in mouth for 3 minutes then expectorated
16588218|NCT02690844|Placebo Comparator|Mucolox® alone|Mucolox® only - 5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated
16588219|NCT02690844|Experimental|Mucolox® and clonazepam|Mucolox® and clonazepam - 1mg Clonazepam/5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated.
16588220|NCT02690831|Active Comparator|Inspiratory Muscle training (IMT)|"The IMT program consisted of supervised and domiciliary exercises:
~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 6 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:
~First week: 30% Maximum Inspiratory Pressure (MIP)
~Second week: 40% MIP
~Third week: 50% MIP
~Fourth week: 50% MIP
~Fifth week: 60% MIP
~Sixth week: 60% MIP
~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen."
16588221|NCT02690831|Experimental|IMT + Manual Therapy and Motor Control Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:
~- MT:
~Upper cervical region mobilization in flexion
~Lower cervical postero-anterior mobilization + maintained traction
~Costovertebral joint postero-anterior mobilization
~Thrust dorsal
~Cervical postero-anterior mobilization
~- MCE:
~Isometric contraction of the deep neck flexors.
~Isometric contraction of the neck extensors.
~Neural self-mobilization.
~Cervical retraction with theraband.
~Sphinx.
~Scapular adduction exercises in prone.
~Scapular adduction exercises in sitting position with theraband."
16588222|NCT02690818|Experimental|Behavioral intervention arm|"Regularly scheduled medication reminder text messages
~Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.
~Standard of care: Monthly reminder call and clinic visit"
16588223|NCT02690818|No Intervention|Control group receiving standard care|Standard of care: Monthly reminder call and clinic visit
16588224|NCT02690805||Breast cancer patients receiving neoadjuvant chemotherapy|One arm: Combined MRI-SMM Imaging
16588225|NCT02690792|Placebo Comparator|NAFLD/NASH - Placebo|"In NAFLD/NASH Group: Identically appearing Placebo capsules given as double-blinded, randomized intervention as a comparator to Vitamin E intervention.
~Dosage: Placebo capsules. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
16588226|NCT02690792|Active Comparator|NAFLD/NASH - Vitamin E|"In NAFLD/NASH Group: Vitamin E capsules given as double-blinded, randomized intervention as a comparator to Placebo capsules intervention.
~Dosage: Vitamin E 200 IU/capsule. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
16588227|NCT02690779|Experimental|Patients watching educational video|The educational intervention will consist of a 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration. This video will be posted on YouTube. Group 1 will consist of 30 subjects who will be instructed to view this video prior to beginning their colonoscopy preparation. Information to access the YouTube video will be provided to the patients by endoscopy nurse assessment staff when contacting the patients as per standard practice to review appointment scheduling and procedure-day logistics.
16588228|NCT02690779|Sham Comparator|Patients not watching educational video|Group 2 will consist of 30 subjects who will not receive instructions to view the video. They will be given routine care instructions for bowel prep.
16588229|NCT02690766|Other|Physical Activity Group|The Success Study's Standard Behavioral Weight Change Intervention consists of 75 minute group sessions held monthly which include 30 minutes of physical activity with a licensed Physical Activity Instructor. Web Lessons that include information on Physical Activity, Nutrition and Healthy Behaviors will also be provided to participants on the study's website.
16588230|NCT02690753|Experimental|Tailored repositioning + Standardised incontinence care + TAP|A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
16588231|NCT02690753|Experimental|Standard repositioning + Standardised incontinence care + TAP|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
16588232|NCT02690753|No Intervention|Usual care|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care. Instead of using comfort Shield® barrier cream cloths, incontinence care will be given to patients using the standard procedure on the ward. Instead of using the turn and position system, patients will be turned according to the standard procedure on the ward.
16588361|NCT02689843|Active Comparator|Metformin|Metformin 1500 mg daily
16588236|NCT02690714|Experimental|6.6 mg/kg Plasminogen (Human) Intravenous|6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion
16588237|NCT02690701|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
16588238|NCT02690701|Placebo Comparator|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.
~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
16588239|NCT02690688||Pneumoperitoneum|Patients scheduled for laparoscopic (minimal invasive) abdominal surgery supported by pneumoperitoneum. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
16588240|NCT02690688||Open Surgery|Patients scheduled for conventional (open) abdominal surgery. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
16588241|NCT02690675|Experimental|Intervention high-iron fortified milk|This group received a high dose of iron by formula milk (1.2mg/100mL) between 6 and 12 months of age.
16588242|NCT02690675|Experimental|Intervention low-iron fortified milk|This group received a low dose of iron by formula milk (0.4mg/100mL) between 6 and 12 months of age.
16588243|NCT02690662|Experimental|Obese with kidney stones|Hypocaloric diet for 3 months
16588246|NCT02690636|Active Comparator|Conventional|The patients will receive adjuvant radiotherapy conventionally fractionated 5000 cgy fractionated by 200cgy daily fractions, five fractions per week over 5 weeks with an additional 200cgy daily for five days as boost for patients with breast conservative surgery.
16588247|NCT02690636|Experimental|Hypofractionated|The patients will receive adjuvant radiotherapy hypofractionated 266cgy daily fractions, five fractions per week for total 16 fractions and an additional five daily fractions will be added as boost for patients with breast conservative surgery.
16588248|NCT02690623|Experimental|Pediatric hospitalist program|As currently planned, hospitalist services will involve an in-house hospitalist at all hours. The attending hospitalist on each hospitalist service will make morning rounds on weekdays and be present supervising the residents or providing care throughout the day. A different hospitalist will cover at night. On weekends, one hospitalist will cover up to 2 services each day. None will work for more than 25 hours at a stretch.
16588249|NCT02690623|Active Comparator|General Pediatric Inpatient Services|The attending pediatrician on each service conducts daily morning rounds on weekdays, supervises the students and house staff and is available to the residents by phone or in person during the day. On some afternoons the attending physician may be responsible for supervising care in a pediatric clinic. On weeknights, an on-call pediatrician is available to the residents by phone. On weekends two on-call pediatricians make rounds, supervise the residents, and take call from home for the 4 services. Each service usually maintains 10-20 patients at a time and generally accepts 8-12 new admissions per admitting day. This approach on the General Pediatric Services will not be changed materially as hospitalists assume responsibility for one or more of the 4 services.
16588250|NCT02690610|Experimental|Patients with mediastinal lesions|EBUS TBNA of mediastinal lesions or lymph nodes
16588251|NCT02690597|Other|Patient|"State-trait anxiety inventory Y-A form (STAI Y-A form)
~Anxiety visual analog scale evaluation(A-AVS)."
16588252|NCT02690584|Experimental|Metacognitive therapy|Metacognitive therapy, one 45-60 min session weekly during 10 weeks.
16588253|NCT02690571|Sham Comparator|Filtered air exposure|One hour exposure to filtered air during intermittent exercise in controlled chamber, 6 hours after exposure bronchoscopy is performed.
16588254|NCT02690571|Experimental|Biodiesel exhaust exposure|One hour exposure to biodiesel exhaust (generated at same running conditions as earlier studies with diesel exhaust at approximate particle matter concentration 300 mcg/m3) during intermittent exercise in controlled chamber. Six hours after exposure bronchoscopy is performed.
16588256|NCT02690545|Experimental|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10^8 cells/m2 and 2x10^8 cells/m^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10^8 cells/m^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10^8 cells/m^.
~Phase II: The study team planning to enroll 31 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
16588257|NCT02690532||High risk group|Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
16588258|NCT02690532||Non-celiac group|Children who are self-diagnosed with non-celiac gluten sensitivity.
16588259|NCT02690532||Control Group|Healthy control group (matched for age and gender).
16588260|NCT02690519|Experimental|GLPG1837 dose 1 and GLPG1837 dose 2|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
16588261|NCT02690506|Placebo Comparator|Group C|Oral placebo pill was administered 2 hours before anesthesia
16588262|NCT02690506|Active Comparator|Group P|Oral pregabalin 150 mg was administered 2 hours before anesthesia
16588263|NCT02690493|Active Comparator|Acupuncture Only|Patients will be treated with acupuncture only.
16588264|NCT02690493|Active Comparator|Functional Taping Only|Patients will be treated with taping only.
16588265|NCT02690493|Experimental|Acupuncture and Functional Taping|Patients will be treated with both acupuncture and taping at the same session.
16588362|NCT02689843|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily
16588363|NCT02689830|Experimental|Bead Block microspheres|Prostate embolization
16588266|NCT02690480|Experimental|PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)|Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
16588267|NCT02690480|Active Comparator|Placebo+fulvestrant(FaslodexTM)|Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
16588268|NCT02690467|Experimental|Insupen G34x3,5mm|Needle for insulin pen 3,5 mm long and with a diameter of 34 gauge
16588269|NCT02690467|Active Comparator|Insupen G32x4mm|Needle for insulin pen 4 mm long and with a diameter of 32 gauge
16588270|NCT02690441|Experimental|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
16588271|NCT02690441|Active Comparator|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
16588272|NCT02690428|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
16588273|NCT02690415||Antibiotics Given|Patients who's treating physician prescribed antibiotics following incision and drainage of their abscess.
16588274|NCT02690415||Antibiotics Not Given|Patients who's treating physician did not prescribed antibiotics following incision and drainage of their abscess.
16588275|NCT02690402|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
16588276|NCT02690389|No Intervention|Control|standard procedure is used
16588277|NCT02690389|Sham Comparator|Flumazenil only group|flumazenil is given
16588278|NCT02690389|Active Comparator|control with acupuncture|control with acupuncture
16588279|NCT02690389|Active Comparator|control with acupuncture and flumazenil|control with acupuncture and flumazenil
16588280|NCT02690376|Other|Magnetic Assisted Capsule Endoscopy|There is only one arm and its does not reach criteria for other options
16588281|NCT02690350|Experimental|Cohort 1 U3-1784 2.5 mg/kg|U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
16588282|NCT02690350|Experimental|Cohort 2 U3-1784 3.75 mg/kg|U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
16588283|NCT02690350|Experimental|Cohort 3 U3-1784 5.6 mg/kg|U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
16588284|NCT02690337|Experimental|DS-1123|This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.
16588285|NCT02690324|Experimental|Major depressive disorder|DSM-5 major depressive disorder HAMD-17 > 16
16588286|NCT02690324|Active Comparator|panic disorder|DSM-5 panic disorder PDSS>7
16588287|NCT02690324|Active Comparator|normal control|age >20, healthy adults HAMD-17<17 PDSS<7
16588288|NCT02690311|Sham Comparator|LED with bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
16588289|NCT02690311|Experimental|LED without bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
16588290|NCT02690285|Other|Part 1: glutathione transferase zeta 1 (GSTZ1) haplotyping|The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
16588291|NCT02690285|Experimental|Part 2: Dichloroacetate (DCA) Kinetics|Eight study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will complete a DCA kinetic study on day 5, at the Clinical Research Clinic (CRC).
16588292|NCT02690272|Experimental|Psychic processes|Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant
16588293|NCT02690259|Experimental|Sentinel node procedure|Enrolling all eligible endometrial cancer patient to the Sentinel node concept using indocyanine green.
16588294|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
16588295|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
16588296|NCT02690220|Other|surgical mesh implantation|Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.
16588297|NCT02690207|Experimental|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
16588298|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PLACEBO THERAPY SESSION
~Post-Placebo therapy/Pre-procedure
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PROCEDURE
~Post-procedure -Rate pain level of procedure"
16588299|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~BUDDHIFY THERAPY SESSION
~Post-Buddhify therapy/Pre-procedure
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PROCEDURE
~Post-procedure -Rate pain level of procedure"
16588300|NCT02690194|No Intervention|Control Group|"Pre-Procedure
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PROCEDURE
~Post-procedure -Rate pain level of procedure"
16588301|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
16588302|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
16588303|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
16588304|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
16588305|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
16588306|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
16588307|NCT02690168||Healthy Men|
16588308|NCT02690155||Rivaroxaban|NVAF patients who were initiated on rivaroxaban for stroke prevention
16588309|NCT02690155||VKA (Vitamin K antagonist)|NVAF patients who were initiated on VKA for stroke prevention
16588310|NCT02690142|Experimental|ABY-035 i.v.|Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
16588311|NCT02690142|Experimental|ABY-035 s.c.|Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
16588312|NCT02690142|Experimental|ABY-035 i.v. in psoriasis patients|Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
16588313|NCT02690142|Experimental|ABY-035 s.c. in psoriasis patients|Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
16588314|NCT02690129|Active Comparator|Group I (Progesterone Group)|"Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.
~Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.
~If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .
~Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation."
16588315|NCT02690129|Placebo Comparator|Group II ( Control group)|Will follow the same plan of management without progesterone support.
16588316|NCT02690116|Experimental|Qigong/Tai Chi Easy|The Qigong/Tai Chi Easy (QG/TCE) intervention has been standardized, manualized, and has a formal training program for instructors from the Institute of Integral Qigong and Tai Chi (IIQTC).
16588317|NCT02690116|Sham Comparator|Sham Qigong|This active control group uses a gentle movement intervention, with similar types of movements with the same energy expenditure, but without the meditative states and breath focus as QG/TCE (validated in the pilot study using the Meditative Movement Inventory).
16588318|NCT02690116|Active Comparator|Educational Support|The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
16588319|NCT02690103|Active Comparator|Group 1|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
16588320|NCT02690103|Experimental|Group 2|Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.
16588321|NCT02690090||enoxaparin|enoxaparin prophylaxis as directed by treating Intensivist
16588322|NCT02690077|Active Comparator|Method 1 by Preference 1|Delivery through the Family-Centered Cesarean for patients with known Family-Centered preference.
16588323|NCT02690077|Active Comparator|Method 1 by Preference 2|Delivery through the Family-Centered Cesarean for patients with known Traditional Cesarean preference.
16588324|NCT02690077|Active Comparator|Method 2 by Preference 1|Delivery through the Traditional Cesarean for patients with known Family-Centered preference.
16588325|NCT02690077|Active Comparator|Method 2 by Preference 2|Delivery through the Traditional Cesarean for patients with known Traditional Cesarean preference.
16588326|NCT02690064|Experimental|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral 1) antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) 2) Resveratrol (1500 mg) 3) Mitoquinol (10 mg) or placebo on two days separated by at least 72 hours.
16588327|NCT02690064|Experimental|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following one of the following: 1) an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day, 2) 1500 mg Resveratrol once a day or 3) 10 mg Mitoquinol once a day.
16588328|NCT02690051|Experimental|BeSmooth Peripheral Stent system|Patients treated with the BeSmooth Peripheral Stent System
16588329|NCT02690038|Experimental|Intervention Arm 1: Treatment|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).
~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
16588330|NCT02690038|Active Comparator|Intervention Arm 2: Control|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).
~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
16588331|NCT02690025|Experimental|ZP1848 High dose|s.c. administration of high dose
16588332|NCT02690025|Experimental|ZP1848 Medium dose|s.c. administration of medium dose
16588333|NCT02690025|Experimental|ZP1848 Low dose|s.c. administration of low dose
16588334|NCT02690012|Active Comparator|Drug Magnesium oxide|Participants will be given standard dose levels of Magnesium oxide according to the level of magnesium in blood.
16588335|NCT02690012|Active Comparator|Drug Magnesium citrate|Participants will be given standard dose levels of Magnesium citrate according to the level of magnesium in blood.
16588336|NCT02689999|Experimental|Dexrabeprazole 10 mg Enteric-Coated Tablets|Dexrabeprazole 10 mg Enteric-Coated Tablets / once daily
16588337|NCT02689986|Experimental|Treatment arm|Bendamustine, Rituximab
16588338|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
16588339|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.
~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
16588340|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
16588341|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
16588342|NCT02689960|Other|vaginal administration first|Intervention first visit: vaginal administration of 100mg prednisone suppository, Intervention second visit: rectal administration of 100mg prednisone suppository
16588343|NCT02689960|Other|rectal administration first|Intervention first visit: rectal administration of 100mg prednisone suppository, Intervention second visit: vaginal administration 100mg prednisone suppository
16588344|NCT02689947|Experimental|Restylane Silk|open label no placebo control
16588345|NCT02689934|Experimental|Lactoflorene colesterolo|Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day
16588346|NCT02689934|Placebo Comparator|Placebo Lactoflorene colesterolo|placebo, powder form, 1 packet per day
16588347|NCT02689921|Experimental|Neoadjuvant Biological Therapy|"Subjects will receive an aromatase inhibitor for the duration of the study [exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).
~Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).
~Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)"
16588348|NCT02689908|Other|The patients underwent thorax CT|The patients refered to radiology service underwent thorax computed tomography without contrast material for the evaluation of various complaints such as dyspnea, hemoptysis and pulmonary infections.
16588349|NCT02689895|Other|Intervention|Research assistants visit participants at home, and send SMS texts on scheduled days for 3 months to encourage adherence to ART. Pill charts, visit charts and text charts are completed. this is called modified directly administered anti-retroviral therapy (mDAART). In addition to the intervention, participants receive standard care at their usual clinic which comprises 3 monthly doctor reviews and adherence counseling at each review visit.
16588350|NCT02689895|No Intervention|Control|Participants get usual care at their clinic, which comprises 3 monthly doctor review visits and adherence counseling at each visit.
16588351|NCT02689882|Experimental|pharmacokinetic study|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
16588352|NCT02689869|Experimental|Ibrutinib and GA 101|"Initial therapy 6 cycles of Ibrutinib:
~Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.
~1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).
~Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:
~Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.
~In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months."
16588353|NCT02689856|Placebo Comparator|Vehicle cream|Placebo control base cream
16588354|NCT02689856|Experimental|3% hydrocortisone|3% Hydrocortisone acetate cream
16588355|NCT02689856|Experimental|0.5% hydrocortisone|0.5% Hydrocortisone acetate cream
16588356|NCT02689856|Experimental|5% lidocaine|5% Lidocaine hydrochloride cream
16588357|NCT02689856|Experimental|1% lidocaine|1% Lidocaine hydrochloride cream
16588358|NCT02689856|Experimental|3% Hydro 5% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 3% and 5% cream
16588359|NCT02689856|Experimental|0.5% Hydro 1% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 0.5% and 1% cream
16588360|NCT02689843|Active Comparator|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily
16588364|NCT02689817|Experimental|Monitoring patch, no display|Participants in this condition will receive a padded bandage that monitors pressure over time. In this arm, healthcare providers will not be able to view the pressure data collected.
16588365|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
16588366|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
16588367|NCT02689791|No Intervention|Control (SWF)|Standard Wheat Flour (SWF) Muffins
16588368|NCT02689791|Experimental|Resistant Starch Type 4|Resistant Wheat Starch Muffins
16588369|NCT02689778|Experimental|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
16588370|NCT02689778|Placebo Comparator|Placebo|Oral placebo with breakfast and with dinner for 12 months.
16588371|NCT02689765|Experimental|Anthocyanins|Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
16588372|NCT02689765|Placebo Comparator|Control|A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
16588373|NCT02689752|Experimental|fruquintinib|fruquintinib suspension, 5 mg （100 mCi）oral taken once
16588374|NCT02689739||Obese Pregnant cohort|Women will be consented to participate and then separated into a study group of obese women (BMI >/= 30).
16588375|NCT02689739||Non-obese Pregnant cohort|This will be the control group of non-obese women (BMI <30).
16588376|NCT02689726|Experimental|GTL001 + Aldara, 5% imiquimod cream|2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
16588377|NCT02689713|Experimental|Topical Voriconazole Study Drug Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Voriconazole study drug placed on graft site.
16588378|NCT02689713|Placebo Comparator|Topical Sterile Water Placebo Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Sterile Water Placebo placed on graft site.
16588379|NCT02689700||HCMV antibody-transfer|Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
16588380|NCT02689700||VZV antibody-transfer|Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation
16588381|NCT02689687|Experimental|Intervention|All participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.
16588382|NCT02689661||Obese participants|Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.
16588383|NCT02689661||Lean participants|Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.
16588384|NCT02689635|Active Comparator|Sodium Restricted Diet|Low Salt (cardiac) diet
16588385|NCT02689635|Active Comparator|Regular Diet|Non-Cardiac diet
16588386|NCT02689622|Experimental|Evaluation of disease prognostic factors|Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
16588387|NCT02689609||Single arm|All patients will receive intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy as standard of care. They will have baseline pre-treatment and post-IMRT serum thyroid function test at least yearly after IMRT.
16588388|NCT02689596|Active Comparator|OT|Oxytocin
16588389|NCT02689596|Placebo Comparator|Placebo|Placebo
16588390|NCT02689583|Experimental|Successful treatment|The patients with H. pylori infection have successful treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
16588391|NCT02689583|Experimental|refractory infection|The patients with H. pylori infection have failed treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
16588392|NCT02689570||type 1 diabetic patients|Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
16588393|NCT02689557|Other|measures of the volumes|Measures of the volumes of the lower limbs. A measure to rest, a measure of effort (walk) and a measure recovery. Intervention.
16588394|NCT02689544|Experimental|static stretching|Group of 15 volunteers (gSS)
16588395|NCT02689544|Experimental|dynamic stretching|Group of 15 volunteers (gDS)
16588396|NCT02689544|Other|control|Group of 15 volunteers (gC)
16588397|NCT02689531||High-Risk (Adult =>18 years old)|"Treated with one or more of the following respiratory modalities for at least 12 continuous hours, either currently or within the prior 7 days:
~Invasive mechanical ventilation
~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)
~High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.
~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.
~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
16588398|NCT02689531||Other-ICU/Standard Risk|Patients do not fulfill high-risk criteria, but, are receiving an antibiotic for treatment of lower respiratory tract infection or undifferentiated sepsis.
16588399|NCT02689531||High-Risk (Pediatric ≥120 days old and <18 years old)|"Currently treated with one or more of the following respiratory modalities for at least 24 hours:
~Invasive mechanical ventilation via endotracheal intubation
~New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy
~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)
~High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM
~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM
~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
16588400|NCT02689531||High-Risk (Pediatric <120 days old)|Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days
16588401|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
16588402|NCT02689505|Experimental|BI 836880|
16588403|NCT02689466||cervical dystonia|clinically documented cervical dystonia (focal cervical or segmental with neck involvement)established by history and physical/neurological examination, at least 18 years old.
16588404|NCT02689466||healthy volunteers|age and sex matched healthy volunteers, atleast 18 years old.
16588405|NCT02689453|Experimental|1A|IL-15 for 10 doses over two weeks followed byalemtuzumab for 4 weeks per dosing schema to determine the maximum tolerated dose (MTD)
16588406|NCT02689453|Experimental|1B|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks at the maximum tolerateddose (MTD)
16588407|NCT02689440|Experimental|Treatment (dasatinib, venetoclax)|Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
16588408|NCT02689427|Experimental|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Cycles repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
16588409|NCT02689414|Experimental|Remote ischaemic preconditioning|Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
16588410|NCT02689414|Sham Comparator|Control to RIPC|Four episodes of 5 minutes during which the pressure in the cuff is equal to venous pressure are performed. Between all the episodes there is a 5-minute pause.
16588411|NCT02689401|Experimental|Ferumoxtyol (Feraheme) with MRI|Patients will undergo a pre-contrast MRI followed by a pre determined dose of of IV Ferumoxyto. Post-contrast MRI imaging will be performed immediately following Ferumoxytol infusion and 48 hours after Ferumoxytol administration with subsequent image analysis.
16588412|NCT02689388|Active Comparator|General Anesthesia with nerve block|Femoral Nerve Block
16588413|NCT02689388|No Intervention|General Anesthesia no nerve block|No femoral Nerve Block
16588414|NCT02689375|Experimental|Patients to receive spinal cord stimulator|
16588415|NCT02689362|Experimental|Evogliptin 2.5mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
16588416|NCT02689362|Experimental|Evogliptin 5.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
16588417|NCT02689362|Experimental|Evogliptin 10.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
16588418|NCT02689362|Active Comparator|Sitagliptin 100mg+Placebo Evogliptin|SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
16588419|NCT02689349|Experimental|Esteem Implant|Implantation of Esteem
16588420|NCT02689336|Experimental|Erlotinib and Temozolomide|"Erlotinib is an oral drug that will be administered on an outpatient basis at a dose of 85 mg/m^2/dose once a day continuously (every day of a 28-day cycle)
~Temozolomide is an oral drug that will be administered on an outpatient basis at a dose of 180mg/m2/dose once a day on Days 1-5 of a 28-day cycle."
16588421|NCT02689323|Experimental|Open label|Participants will undergo 5 sessions of active rTMS
16588422|NCT02689310|Other|Standard Care - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
16588423|NCT02689310|Experimental|Honey Treatment - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
16588424|NCT02689310|Other|Standard Care - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
16588425|NCT02689310|Experimental|Honey Treatment - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
16588426|NCT02689297|Other|group A|Mouthwash (chlorine dioxide 12ml two times per day, for three weeks)
16588427|NCT02689297|Other|group B|Small toothbrush for tongue cleaning two times per day for three weeks
16588428|NCT02689284|Experimental|Margetuximab plus pembrolizumab|margetuximab administered in combination with pembrolizumab
16588429|NCT02689258|Experimental|Part A Cohort A|200 mg of HTX-011A by infiltration
16588430|NCT02689258|Placebo Comparator|Part A Cohort B|Saline Solution by infiltration
16588431|NCT02689258|Experimental|Part A Cohort C|200 mg of HTX-011B by infiltration
16588432|NCT02689258|Experimental|Part A Cohort D|400 mg of HTX-011B by infiltration
16588433|NCT02689258|Experimental|Part A Cohort E|600 mg of HTX-011B by infiltration
16588434|NCT02689258|Experimental|Part B Cohort A|Subjects will be enrolled in Part B following completion of enrollment in Part A to evaluate HTX-011 and HTX-002, with or without saline solution.
16588435|NCT02689258|Experimental|Part C Cohort A|Subjects will be enrolled in Part C following completion of Part B to evaluate 400 mg HTX-011B via instillation, bupivacaine HCl 100 mg via injection and saline placebo via injection
16588436|NCT02689258|Experimental|Part D Cohort A|Up to 300 mg of HTX-011B
16588437|NCT02689258|Placebo Comparator|Part D Cohort B|Saline Solution
16588438|NCT02689245|Experimental|Tenofovir + Fecal Microbiota Transplantation (FMT)|
16588439|NCT02689245|Active Comparator|Tenofovir|
16588440|NCT02689232|Experimental|Thromboelastography (TEG) level|
16588441|NCT02689232|Active Comparator|Coagulation Profile|
16588442|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
16588443|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
16588444|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
16588445|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
16588446|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
16588447|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
16588448|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
16588449|NCT02689193||Salmonella|Patients for whom blood cultures grew Salmonella species.
16588450|NCT02689193||No pathogen|Patients for whom blood cultures did not grow a pathogen and no pathogen was detected using other routine care diagnostics (e.g. malaria with the use of a malaria rapid test).
16588451|NCT02689193||Another pathogen|Patients for whom blood cultures grew with another pathogen or a pathogen was detected using other routine care diagnostics (e.g. malaria with the use of malaria rapid test).
16588452|NCT02689193||Healthy controls|Healthy controls. Patients without fever but from whom blood is drawn for another reason (e.g. check of cholesterol).
16588453|NCT02689180|Placebo Comparator|Withdraw of furosemide|Withdraw of of 40 or 80 mg of furosemide per day
16588454|NCT02689180|Active Comparator|Maintenance of furosemide|Maintenance of 40 or 80 mg of furosemide per day
16588455|NCT02689167|Active Comparator|Arm A 4/6|"Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks on  alternating with 2 weeks off "
16588456|NCT02689167|Experimental|Arm B 2/3|"Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks on  alternating with 1 week off "
16588457|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
16588458|NCT02689141|Experimental|Bendamustine + Ofatumumab + Ibrutinib|Bendamustine: 70mg/m² i.v. Ofatumumab: 1000 mg i.v. Ibrutinib: 420 mg po
16588459|NCT02689115||Clinical activity|Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) > 3.6.
16588460|NCT02689115||Clinical remission|Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) < 2.4.
16588461|NCT02689102||ILD patients|ILD patients scheduled for diagnostic bronchoscopy with biopsy and/or broncho-alveolar lavage will undergo additional imagaing with probe based optical techniques.
16588462|NCT02689089|Other|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
16588463|NCT02689076|Experimental|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
16588464|NCT02689076|Active Comparator|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
16588465|NCT02689076|No Intervention|Usual Care (No HIE Notification and No Care Coordination)|Absence of VA provider notification of non-VA hospitalization via HIE plus Absence of post-hospital geriatric care transitions intervention [Usual Care]
16588466|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
16588467|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
16588468|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
16588469|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
16588497|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
16588498|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
16588470|NCT02689050||Patients with lymphadenopathy|Patients ≥ 18 years of age, with (suspected) NSCLC or suspected sarcoidosis, and at least one suspected mediastinal/hilar lesion that are scheduled for standard diagnostic endosonographic workup will undergo additional needle based confocal laser endomicroscopy (nCLE) measurements of suspected lesions.
16588471|NCT02689037|Experimental|stenting+medical treatment|Patients in PTAS+MT group will receive Percutaneous transluminal angioplasty and stenting and medical treatment (aspirin 100mg daily and clopidogrel 75mg daily)
16588472|NCT02689037|Active Comparator|Aspirin plus clopidogrel|Patients in aspirin plus clopidogrel group will receive aspirin 100mg daily and clopidogrel 75mg daily for 90 days.
16588473|NCT02689024|Experimental|Continuous FICB with local anesthetics|"With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.
~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores."
16588474|NCT02689024|Active Comparator|Traditional care with systemic analgesia|"Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.
~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required."
16588475|NCT02689011|Experimental|Group F|Femoral nerve Block Group
16588476|NCT02689011|Active Comparator|Group E|Epidural Group
16588477|NCT02688998|Active Comparator|Venous access PORT or PICC|Participants will receive a central line placement either a PORT or a PICC prior to the initiation of chemotherapy.
16588478|NCT02688998|No Intervention|No intervention|Participants will only receive a central line if required once chemotherapy has been initiated.
16588479|NCT02688985|Experimental|RMS Cohort Arm 1: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
16588480|NCT02688985|Experimental|RMS Cohort Arm 2: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
16588481|NCT02688985|Experimental|RMS Cohort Arm 3: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
16588482|NCT02688985|Experimental|RMS Cohort Arm 4: Ocrelizumab + LP|Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
16588483|NCT02688985|Experimental|PPMS Cohort: Ocrelizumab + LP|For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.
16588484|NCT02688972|Experimental|cold water immersion|
16588485|NCT02688972|Other|control|13 volunteers
16588486|NCT02688959|Experimental|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
16588487|NCT02688959|Active Comparator|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
16588488|NCT02688959|No Intervention|Control|Participants in the control arm will not attend a class and not be given a video.
16588489|NCT02688933|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
16588490|NCT02688933|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
16588491|NCT02688920||With T2DM|Subjects with type 2 diabetes.
16588492|NCT02688920||Without T2DM|Subjects without type 2 diabetes
16588493|NCT02688907|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
16588494|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
16588495|NCT02688881|Experimental|sirolimus|sirolimus 1mg will be administered orally daily
16588496|NCT02688868|Experimental|new specifications (Diameter 2.25mm)of Firehawk stent|Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
16588499|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
16588500|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
16588501|NCT02688816||Women undergoing cervical cancer screening|"HIV-infected women will undergo a cervical cancer screening examination using the VIA method. A digital photograph of the cervix will also be taken to aide visual screening. This is known as digital cervicography, and it is currently standard of care within cervical cancer screening clinics in Zambia.
~Cervical samples will be collected for molecular testing using Xpert HPV, and OncoE6. Cervical biopsy samples will also be obtained for confirmatory histopathologic diagnosis."
16588502|NCT02688803|Active Comparator|Dose dense AC-P|Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
16588503|NCT02688803|Active Comparator|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
16588504|NCT02688803|Active Comparator|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
16588505|NCT02688790|Experimental|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
16588506|NCT02688790|Experimental|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
16588507|NCT02688790|Experimental|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
16588510|NCT02688764|Experimental|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron
~PA21 (Velphoro®), chewable tablets 250 mg iron
~PA21 (Velphoro®), powder for oral suspension 500 mg iron
~PA21 (Velphoro®), powder for oral suspension 250 mg iron
~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
16588511|NCT02688764|Active Comparator|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
16588512|NCT02688738|No Intervention|Control|Standard of care
16588513|NCT02688738|Active Comparator|Treatment|Oral doxycycline
16588514|NCT02688725|Experimental|Ultrasound|post mastectomy ultrasound
16588515|NCT02688712|Experimental|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
16588516|NCT02688699|Experimental|EndoClot|spraying of Endoclot powder after EMR or ESD
16588517|NCT02688699|No Intervention|control|
16588518|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
16588519|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
16588520|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
16588521|NCT02688647|Experimental|KD025 400 mg Daily|Two 200 mg tablets (400 mg) KD025 QD. Subjects will take 2 tablets with their morning meal or within 5 minutes of completing a meal.
16588522|NCT02688647|Other|Best Supportive Care (BSC)|Best supportive care is treatment and/or drug determined by each subject's prescribing physician.
16588523|NCT02688634||Treatment|Participants in this group are randomize to receive post-operative antibiotic of Amoxicillin x7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
16588524|NCT02688634||Non-Treatment|Participants in this group will be randomize to no post-operative antibiotic. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
16588527|NCT02688608|Experimental|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
16588528|NCT02688595|Experimental|Seldinger|Use a 23 gauge introducer needle for ultrasound-guided central venous catheterization
16588529|NCT02688595|Experimental|Modified Seldinger|Use a 22 gauge Angiocath Plus catheter for ultrasound-guided central venous catheterization
16588530|NCT02688582|Experimental|TCI group|Patients who receive cefepime based on TCI for a maximum of 5 days with a target concentration of cefepime of 16 mg/L.
16588531|NCT02688569|Experimental|CBT-CWP|Participants in this condition will receive Cognitive Behavioral Therapy for Chronic Widespread Pain (CBT-CWP)
16588532|NCT02688569|No Intervention|Control|Participants in the Control condition will not receive CBT-CWP. They will however, continue completing the weekly assessments.
16588540|NCT02688517|Other|Ancillary-Correlative (genomic analysis)|Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.
16588541|NCT02688504||serious road accidents|Drivers involved in serious road accidents (hospitalization > 24 hours)
16588542|NCT02688504||non-serious road accidents|drivers involved in non-serious road accidents (hospitalization < 24 hours).
16588543|NCT02688491|Experimental|A (Intervention group,sunitinib)|Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks
16588544|NCT02688491|No Intervention|B(observation group)|Patients with radical nephrectomy are observed without intervention
16588545|NCT02688478|Active Comparator|Filtered air|Exposure for 3 hours to filtered air followed by subject specific inhaled allergen challenge
16588546|NCT02688478|Experimental|Phthalate|Exposure for 3 hours to dibutyl phthalate followed by subject specific inhaled allergen challenge
16588547|NCT02688465|Experimental|Apomorphine pump|
16588548|NCT02688452|Active Comparator|Group 1|Young Healthy Adults
16588549|NCT02688452|Active Comparator|Group 2|Young Healthy Adults
16588550|NCT02688439|Active Comparator|Leg in a neutral position|Sciatic nerve block, with leg kept in a neutral position after anesthesia (control group)
16588551|NCT02688439|Experimental|Leg raised 30°|Sciatic nerve block, with leg raised 30° by placing the back of the foot over a support placed on the OR table and maintained in that position for 15 min
16588552|NCT02688439|Experimental|Distal tourniquet placed on the lower part of the leg|Sciatic nerve block, and distal tourniquet placed on the lower part of the leg (upper part of the tourniquet being about 4-6 inches from the ankle) with the leg in a neutral position.
16588553|NCT02688426|Sham Comparator|0J LLLT|The sham treatment is performed in the same way as treatment with LBP, however, with the apparatus switched off
16588554|NCT02688426|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
16588555|NCT02688413|Experimental|MindMotionPRO|MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
16588556|NCT02688413|Active Comparator|Self-Directed Prescribed Exercises|Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
16588557|NCT02688400|Experimental|Diacerein|One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
16588558|NCT02688400|Active Comparator|Celecoxib|One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
16588559|NCT02688387|Experimental|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
16588560|NCT02688387|Experimental|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
16588561|NCT02688387|Experimental|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
16588562|NCT02688374|Other|Treatment A:Treatment B:Treatment C|Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
16588563|NCT02688374|Other|Treatment B:Treatment C:Treatment A|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
16588564|NCT02688374|Other|Treatment C:Treatment A:Treatment B|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
16588565|NCT02688374|Other|Treatment A: Treatment C:Treatment B|Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
16588566|NCT02688374|Other|Treatment B:Treatment A: Treatment C|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
16588567|NCT02688374|Other|Treatment C:Treatment B:Treatment A|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
16588568|NCT02688361|Experimental|Fluimucil® (reference) then Acetylcysteine (test) 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Acetylcysteine (test).
16588569|NCT02688361|Experimental|Acetylcysteine (test) 2% solution then Fluimucil® (reference)|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Fluimucil® (reference).
16588629|NCT02687945|Active Comparator|No outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of self-guided physiotherapy exercises
16588570|NCT02688348|Other|Ancillary-Correlative (late toxicity and QOL)|Patients complete the EORTC QLQ-BLM-C30 at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
16588571|NCT02688335|Experimental|Cloud9 Snoring Treatment|Snoring participants will be instructed to use the device as much as possible for 2 weeks.
16588572|NCT02688322|Experimental|2 g q12 of sulbactam, 1 h infusion|2 g of sulbactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 1 h every 12 h.
16588573|NCT02688309|Experimental|Clinic Patients|"Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis.
~Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an anterior chamber (AC) tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection."
16588574|NCT02688309|Placebo Comparator|OR Patients|Patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macular hole. Surgical patients who agree to participate will have an anterior chamber (AC) tap at the beginning of surgery.
16588575|NCT02688296||Pilon Fractures|Patients who are implanted with Fibulock and have a Pilon fracture
16588576|NCT02688296||High Risk Patients|Patients who are implanted with Fibulock and are at high risk of complications from ankle surgery due to conditions such as diabetes, advanced age or osteoporosis
16588577|NCT02688296||Otherwise Healthy Patients|Patients implanted with Fibulock who are healthy other than their ankle fracture
16588578|NCT02688283|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
16588579|NCT02688283|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
16588580|NCT02688283|Placebo Comparator|White-bread|45g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
16588581|NCT02688270|Experimental|Vascana® (0.9% nitroglycerin cream)|
16588582|NCT02688270|Placebo Comparator|Vehicle cream|
16588583|NCT02688244|Active Comparator|Irrigation|Irrigation of the area with at least 300ml normal saline using the power suction/irrigator
16588584|NCT02688244|Active Comparator|No irrigation|Only suction with the power suction/irrigator without saline attached
16588585|NCT02688231|Experimental|High intensity group|
16588586|NCT02688231|Experimental|Low intensity group|
16588587|NCT02688231|Active Comparator|Control group - conventional treatment|
16588588|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
16588589|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
16588590|NCT02688205||Shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
16588591|NCT02688205||Without shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
16588592|NCT02688192|Active Comparator|Arm I (Intervention)|"Assessment including
~Wear an electronic accelerometer
~Quality of life assessment
~Physical fitness evaluation
~Participate in a fitness program which includes:
~8 group meetings of 90 minutes weekly
~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
16588593|NCT02688192|Active Comparator|Arm II (Waitlist Control [WLC])|"Assessment including
~Wear an electronic accelerometer
~Quality of life assessment
~Physical fitness evaluation
~After waiting 6 months they will begin the fitness program as described in Arm I"
16588594|NCT02688179||Cardiac surgery patients|
16588595|NCT02688166||Breast Cancer|Breast cancer patients who are undergoing internal mammary lymph node radiation
16588596|NCT02688166||Lung Cancer, thymic cancer or mesothelioma|"Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy
~Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure"
16588597|NCT02688153|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
16588598|NCT02688153|Active Comparator|Stented aortic bioprostheses|Stented aortic bioprostheses
16588599|NCT02688140|Experimental|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).
~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.
~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
16588630|NCT02687932|Experimental|LCZ696|LCZ696 for 12 months
16588631|NCT02687932|Active Comparator|Valsartan|Valsartan for 12 months
16588632|NCT02687919|Experimental|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
16588633|NCT02687919|No Intervention|Usual Care|Typical physician recommendations for MS.
16588662|NCT02687659|Experimental|Study group using TEMIS system|using TEMIS system during physical exercises: walking, biking, running
16588922|NCT02686021|Active Comparator|Ibuprofen and Placebo|"This is the second of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
16588600|NCT02688140|Active Comparator|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7, oral tretinoin twice daily on day 1-28 (max. up to day 60).
~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.
~Consolidation I:
~IDA 5 mg/m2 i.v. day 1-4 Ara-C 1000 mg/m2/3h i.v. day 1-4 ATRA 45 mg/m2 p.o. day 1-15
~Consolidation II:
~MTZ 10 mg/m2 i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15
~Consolidation III:
~IDA 12 mg/m2 i.v. day 1 Ara-C 150 mg/m2 every 8h i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15
~Maintenance (duration 7 cycles = 2 years; one cycle lasts 106 days):
~6-MP 50 mg/m2 p.o. Cycle 1-7: day 1-91 (followed by 15 days of ATRA on days 92-106)
~MTX 15mg/m2 i.m./p.o. Cycle 1-7: once weekly for 91 days (followed by 15 days of ATRA on days 92-106)
~ATRA 45 mg/m2 p.o. Cycle 1-6: day 92-106 Cycle 7: without ATRA Administration
~(treatment break of 6-MP and MTX during ATRA administration)"
16588601|NCT02688127|Experimental|tranexamic acid group|tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section
16588602|NCT02688127|Placebo Comparator|placebo group|the control group will receive 500 cc of ringer lactate 20 minute before cesarean section
16588603|NCT02688114|Experimental|Barrett's Esophagus Treatment|All participants are in the treatment arm. Patients with Barrett's esophagus will undergo baseline surveillance endoscopy, be treated with radiofrequency ablation, and undergo follow up endoscopy 1, follow up endoscopy 2, and follow up endoscopy 3.
16588604|NCT02688101|Experimental|DpC|DpC capsules, administered orally
16588605|NCT02688088|Active Comparator|Drug Cocktail|Single dose of drug cocktail (caffeine, warfarin, dextromethorphan, and midazolam) administered orally on Day 1 of Period 1.
16588606|NCT02688088|Experimental|Abemaciclib + Drug Cocktail|Abemaciclib administered orally every 12 hours on Days 1 - 12 of Period 2 with a single dose of drug cocktail administered orally on Day 8 of Period 2.
16588607|NCT02688088|Experimental|Abemaciclib - Period 3|Abemaciclib administered orally every 12 hours on Days 13 to 28 of Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
16588608|NCT02688088|Experimental|Abemaciclib - Period 4|Abemaciclib administered orally every 12 hours on Days 1 to 28 of Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
16588609|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
16588610|NCT02688062|Experimental|NeuroRegen Scaffold with BMMCs transplantation|
16588611|NCT02688062|Experimental|Surgical intradural decompression and adhesiolysis|
16588612|NCT02688049|Experimental|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.
16588613|NCT02688049|Experimental|NeuroRegen scaffold/neural stem cells transplantation|Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury.
16588614|NCT02688036|Experimental|hypofractionated CRT|hypofractionated concurrent chemoradiotherapy
16588615|NCT02688036|Active Comparator|conventionally fractionated CRT|conventionally fractionated concurrent chemoradiotherapy
16588616|NCT02688023|Experimental|single-arm Irinotecan-Oxaliplatin-5-Fluorouracil/leucovorin|Irinotecan,oxaliplatin and 5-fluorouracil/leucovorin(5-fluorouracil/leucovorin can be substituted with Capecitabine or S-1)
16588617|NCT02688010|No Intervention|Control|No specific noise reduction strategies to restrict noise exposure less than 45 dB combined with either continuous bright light or continuous near darkness or unstructured combination of the two during the hospitalization.
16588618|NCT02688010|Experimental|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
16588619|NCT02687997|Experimental|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
16588620|NCT02687997|No Intervention|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
16588621|NCT02687984|Experimental|RBP-7000 PLGH A|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
16588622|NCT02687984|Experimental|RBP-7000 PLGH B|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
16588623|NCT02687984|Active Comparator|RBP-7000 PLGH C|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
16588624|NCT02687971|Active Comparator|Thermotherapy alone|"Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30 applications will be used. Depending on the size of the lesion, more than one application may be administered."
16588625|NCT02687971|Experimental|Thermotherapy plus Miltefosine|"In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.
~The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day)."
16588626|NCT02687958|Experimental|A Everolimus 10mg (every cycle) until PD|Patients with stable disease, partial response or complete response after 4- 6 cycles of induction chemotherapy with Cisplatin or Carboplatin plus Etoposide or alternative first line chemotherapy according with local practice will receive maintenance therapy with Everolimus 10mg every cycle (28days) until PD or unacceptable toxicity.
16588627|NCT02687958|No Intervention|B Observational|Patients in this arm will meet observation criteria
16588628|NCT02687945|Active Comparator|Outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of outpatient physiotherapy with 2-3 weekly sessions
16588634|NCT02687906|Experimental|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours
~The starting dose for Cohort 1 (ages 12 to <18 years) was 40 mg/kg meropenem and 40 mg/kg vaborbactam, or 2 g meropenem 2 g vaborbactam for subjects ≥50kg in weight. Following completion of Cohorts 1 and 2 an independent DSMB assessed the PK, safety and tolerability data and determined that the new starting dose for Cohort 3 (ages 2 to < 6 years) would be 60 mg/kg or 2 g meropenem 2 g vaborbactam for subjects >33 kg in weight."
16588635|NCT02687893|Experimental|Aerobic Exercise Week|Subjects will complete 45 minutes of aerobic exercise twice during a 7 day period. Exercise will be graded based on the participant's relative capacity determined at the screening visit. Each exercise session will be followed by 60 minutes of monitored resting recovery.
16588636|NCT02687893|Experimental|Resistance Exercise Week|Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
16588637|NCT02687893|No Intervention|No Exercise Week|Subjects will perform no exercise during this week.
16588638|NCT02687880||All Subjects|"All subjects will undergo a surgical procedure (Testicular biopsy) to harvest their testicular tissue. In most cases, this will be done as part of their routine care but it is possible the subject may elect to have the procedure as part of a research only biopsy."
16588639|NCT02687867||Dabigatran|Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.
16588640|NCT02687867||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
16588641|NCT02687854||Apixaban|Non-valvular atrial fibrillation patients who were initiated on apixaban for stroke prevention
16588642|NCT02687854||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on Vitamin K antagonist for stroke prevention
16588643|NCT02687841|Experimental|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
16588644|NCT02687841|Active Comparator|PTX|Pentapentoxifylline 400mg QD for 10 days
16588645|NCT02687828||Subjects receiving adalimumab|The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.
16588646|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
16588647|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
16588648|NCT02687802||Mechanical ventilation|Patients under mechanical ventilation for more than 24h
16588649|NCT02687789|Experimental|Medical Device: WO3191|The vaginal suppository is used for the reduction and/or inhibition of vaginal biofilms that were shown to be related to recurrent bacterial vaginosis.
16588650|NCT02687789|Active Comparator|Medical Device: Vagisan® Lactic Acid|It is used for the maintenance and restoration of a natural pH level in the vagina. The acidification of the vaginal milieu with lactic acid promotes the growth of typical vaginal flora (lactic acid bacteria) and is unfavourable for the growth of pathogens in the vagina. Vagisan® Lactic Acid is used in the post-treatment of bacterial vaginosis.
16588651|NCT02687763|Experimental|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
16588652|NCT02687750|Experimental|MRI|"Eppendorf tubes containing 10% fluorine-19 diluted in agar were taped to the upper thigh of participants. Investigational device was used to image the phantom with Magnetic resonance imaging (MRI). Imaging was performed for anatomical (proton) and fluorine (agent detection). Total scan time was under 1 hour.
~Objectives:
~Verify RF coil functionality
~Obtain preliminary detection threshold limits using a human coil loading"
16588653|NCT02687737|Experimental|Exercise|The participants will have the following tests performed: Maximum Expiratory Pressure (MEP), insertion of a fine-wire electromyography (EMG) electrode into the mid-line base of the tongue, will complete swallowing tasks and breathing tasks under Videofluoroscopy (fluoroscopy on only during the actual task)
16588654|NCT02687724|Active Comparator|Standard treatment as per SmPC|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
16588655|NCT02687724|Experimental|Intervention Arm|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
16588656|NCT02687698|Experimental|Ketogenic diet|Patients will be suggested to follow a ketogenic diet for 8 weeks.
16588657|NCT02687698|No Intervention|Control|Usual diet.
16588658|NCT02687685|Experimental|Skin to skin contact immediate|At birth, the baby will be placed and dried on the breast of his mother where thermoregulation manoeuvres will be applied and once the cord clamping procedure has taken place; the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least one hour or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, it will be allowed again after these interventions. During immediate SSC, mother and baby receive continuous monitoring by the health staff
16588659|NCT02687685|Active Comparator|skin to skin contact early|At birth, the baby will be dried and placed on the abdomen and chest of his mother where thermoregulation manoeuvres are applied once there is an indication that the cord clamp procedure has been completed. At this time the baby will go to the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby who has 60 minutes of life, will proceed with the initiation of SSC for at least one hour or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC the mother and baby will receive monitoring by health personnel
16588660|NCT02687672|Experimental|Stem Cell Transplantation|Injection of leukapheresis-derived, purified, autologous CD34+and CD133+ stem cells
16588661|NCT02687672|Experimental|Stem Cells|Injection of bone marrow-derived, purified, autologous CD34+and CD133+ stem cells.
16588663|NCT02687646|Experimental|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
16588664|NCT02687633|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
16588665|NCT02687633|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
16588666|NCT02687620||AS patients receiving Anti-TNF treatment|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
16588667|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
16588668|NCT02687594||single group|sucroferric oxyhydroxide
16588669|NCT02687581|Experimental|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
16588670|NCT02687581|Active Comparator|6-hour patching|wear the eye patch for 6-hour
16588671|NCT02687555|Experimental|Intervention|Computerized Cognitive Bias Modification of Appraisals (CBM-App), developed from that used by Woud et al. (2012,2013). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
16588672|NCT02687555|Sham Comparator|Control|Computerized Peripheral Vision Task (PVT), developed from that used by Calkins et al. (2015). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
16588673|NCT02687542|Placebo Comparator|Placebo|Placebo
16588674|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
16588675|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
16588676|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
16588677|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
16588678|NCT02687529||Low Risk|Tested with CST001
16588679|NCT02687529||Known Risk|Tested with CST001
16588680|NCT02687516|Experimental|Family-based behavioral social facilitation therapy.|The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
16588681|NCT02687516|Active Comparator|Treatment as usual|The TAU condition involves an assessment day with the multidisciplinary team (pediatrician, dietician, physical therapist and psychologist) at the hospital obesity clinic. Further a session with the nurse at the hospital clinic making a plan for behavioral lifestyle changes followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital clinic every third month for 12 months. After 12 months they will be offered treatment by family-based behavioral social facilitation therapy (as in the other treatment arm).
16588682|NCT02687503|Other|Daily dose of probiotic|All children enrolled into the study will receive a daily dose of probiotic
16588683|NCT02687490|Experimental|Abraxane|Abraxane: 125 mg/m2, D1, D8, D15 every 28 days
16588684|NCT02687477|Sham Comparator|Sham procedure|Patients in the sham group will take sham procedure like PADN.
16588685|NCT02687477|Experimental|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
16588691|NCT02687438|Experimental|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
16588692|NCT02687425|Experimental|pioglitazone|The patients under the long-term treatment of imatinib mesylate acquire pioglitazone additionally.
16588693|NCT02687412|Experimental|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
16588694|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.
~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
16588695|NCT02687399|Experimental|TT-173|It will be sprayed using this syringe and a nozzle tip couplet to it one time over the surgical lesion surfaces on the exposed tissues of the knee
16588696|NCT02687399|Placebo Comparator|placebo|It will be sprayed over the surgical lesion surfaces on the exposed tissues of the knee
16588697|NCT02687386|Experimental|Mitoxantrone packaged EDV|Mitoxantrone packaged EDV (EnGeneIC Dream Vector)
16588698|NCT02687373|Experimental|Part 1: Grp 1A - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination."
16588699|NCT02687373|Placebo Comparator|Part 1: Grp 1A - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination."
16588700|NCT02687373|Experimental|Part 1: Grp 1B - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588701|NCT02687373|Placebo Comparator|Part 1: Grp 1B - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588702|NCT02687373|Experimental|Part 1: Grp 1C - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588703|NCT02687373|Placebo Comparator|Part 1: Grp 1C - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588704|NCT02687373|Experimental|Part 1: Grp 2A - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
16588705|NCT02687373|Placebo Comparator|Part 1: Grp 2A - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
16588706|NCT02687373|Experimental|Part 1: Grp 2B - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
16588707|NCT02687373|Placebo Comparator|Part 1: Grp 2B - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
16588708|NCT02687373|Experimental|Part 1: Grp 2C - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
16588709|NCT02687373|Placebo Comparator|Part 1: Grp 2C - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
16588710|NCT02687373|Experimental|Part 1: Grp 2D - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588711|NCT02687373|Placebo Comparator|Part 1: Grp 2D - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588771|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
16588772|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
16589395|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
16588712|NCT02687373|Experimental|Part 1: Grp 2E - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588713|NCT02687373|Placebo Comparator|Part 1: Grp 2E - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588714|NCT02687373|Experimental|Part 1: Grp 3A - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
16588715|NCT02687373|Placebo Comparator|Part 1: Grp 3A - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
16588716|NCT02687373|Experimental|Part 1: Grp 3B - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
16588717|NCT02687373|Placebo Comparator|Part 1: Grp 3B - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
16588718|NCT02687373|Experimental|Part 1: Grp 3C - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
16588719|NCT02687373|Placebo Comparator|Part 1: Grp 3C - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
16588720|NCT02687373|Experimental|Part 1: Grp 3D - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588721|NCT02687373|Placebo Comparator|Part 1: Grp 3D - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588722|NCT02687373|Experimental|Part 1: Grp 3E - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588723|NCT02687373|Placebo Comparator|Part 1: Grp 3E - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
16588724|NCT02687373|Experimental|Part 2: Group 1 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose."
16588725|NCT02687373|Experimental|Part 2: Group 2 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose."
16588726|NCT02687373|Experimental|Part 2: Group 3 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose."
16588727|NCT02687373|Placebo Comparator|Part 2: Group 4 - Normal Saline|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals."
16588730|NCT02687347|Experimental|study arm|low dose methadone (1-10mg daily)
16588731|NCT02687347|Active Comparator|control arm|low dose morphine (1-10 mg/day)
16588732|NCT02687334||Standard general anesthesia induction|Patients scheduled for elective surgery at the First Hospital of China Medical University will be recruited for the study beginning in February 2016.We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia
16588733|NCT02687321||Advanced ovarian cancer patients|Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study. The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence. In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
16588734|NCT02687308|Active Comparator|1Retrograde radical prostatectomy RRP|This opem surgical prostatectomy techniques described by Patrick Walsh is made through prostatic dissection, from apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
16588735|NCT02687308|Experimental|2Anterograde radical prostatectomy RRP2A|This opem surgical prostatectomy techniques dissect the prostate, bladder neck and the neurovascular bundle, in an antegrade way, from bladder neck to the apex. With careful bladder neck dissection and preservation, careful nervesparing procedures with meticulous retroprostatic dissection of the posterior layer of Denonvilliers' fascia, and urethrovesical anastomosis performed through a monofilament running suture.
16588736|NCT02687295|Placebo Comparator|Control group|Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
16588737|NCT02687295|Active Comparator|Thylakoid group|Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.
16588738|NCT02687269|Experimental|Ranolazine|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, Ranolazine at a dose of 375 mg twice daily.
16588739|NCT02687269|Placebo Comparator|Placebo|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, placebo twice daily.
16588740|NCT02687256|Experimental|Protocol 1: Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
16588741|NCT02687256|Experimental|Protocol 1: Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
16588742|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 1|Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
16588743|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 2|Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
16588744|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 3|Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
16588745|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 4|Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
16588746|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 5|Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
16588747|NCT02687256|Experimental|Protocol 2 (Part 2): Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
16588748|NCT02687256|Experimental|Protocol 2 (Part 1): Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
16588749|NCT02687243|Experimental|Interactive Virtual Application|Online application
16588750|NCT02687243|No Intervention|Standard of Care|No intervention and Hospital Standard of Care
16588751|NCT02687230|Experimental|Cohort 1|Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
16588752|NCT02687230|Experimental|Cohort 2|Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
16588753|NCT02687230|Experimental|Cohort 3|Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
16588754|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
16588755|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
16588756|NCT02687204|Active Comparator|Enoxaparin prophylaxis|All enrolled patients will receive twice daily enoxaparin prophylaxis. Patients with identified out of range peak anti-Xa levels will receive real time dose adjustment and will be considered as the experimental arm.
16588757|NCT02687204|Experimental|Real time dose adjustment|Patients with identified out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment
16588758|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
16588759|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
16588760|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
16588761|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
16588762|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
16588763|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
16588764|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
16588765|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
16588766|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
16588767|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
16588768|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
16588769|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
16588770|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
16588773|NCT02687178|Active Comparator|Canrenone 50 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
16588774|NCT02687178|Active Comparator|Canrenone 100 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
16588775|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
16588776|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
16588777|NCT02687152|Experimental|Arginase inhibition|N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min
16588778|NCT02687139|Experimental|18F-DCFPyL PET/CT|
16588779|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
16588780|NCT02687113|Other|CT/US fusion|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.
~Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
16588781|NCT02687100|Experimental|Beclomethasone|Patients will receive beclomethasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning. The solution will be aspirated 15 minutes after the instillation.
16588782|NCT02687100|Placebo Comparator|Placebo|Patients will receive 8 mL of saline without any drug.
16588783|NCT02687087|Experimental|Visco-ease|Visco-ease is a suspension of multilamellar vesicles comprising lipids in ratios which mimic the lipidic composition of endogenous extra-alveolar lamellar bodies. Visco-ease is suspended in physiological saline (0.9% NaCl) to provide a final dose concentration of 19.6 mg/mL. Visco-ease is a white to off-white turbid suspension. The device under evaluation in this clinical investigation is Visco-ease at a concentration of 19.6 mg/mL.
16588784|NCT02687087|Placebo Comparator|RIX-Placebo|Physiological Saline (sodium chloride 0.9% (w/v)
16588785|NCT02687074|Experimental|Intubation rate on 28 days|patients with respiratory failure treat with HFNC or NIV and intubation rate on 28 days
16588786|NCT02687061||Chronic hepatitis B|Patients diagnosed with chronic hepatitis B
16588787|NCT02687061||Chronic hepatitis C|Patients diagnosed with chronic hepatitis C
16588788|NCT02687048|Active Comparator|EX protocol|Participants will receive a revised version of the Otago exercise program (OEP) - an individualized home-based exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week. The exercises are for strength and balance and are gradually progressed over the course of the study to meet the individual's abilities.
16588789|NCT02687048|Experimental|EX Plus protocol|"These participants will receive mindful meditation coaching via 6 one-hour small group sessions with an experienced meditation instructor. They will also be expected to practice mindful meditation at home following online audio recordings (free of charge from University of California, Los Angeles; http://marc.ucla.edu/body.cfm?id=22) and written instructions a minimum of five times per week for 30 minutes. Participants will complete a meditation log to record their practice.
~These participants will also receive the same revised version of the Otago exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week."
16588790|NCT02687035|Experimental|TAVR|Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
16588791|NCT02687022|Experimental|Myopia (Peramis)|Peramis aberrometry: 30 consecutive LASIK candidates with myopia and regular astigmatism who agree to participate in the study will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer.
16588792|NCT02687022|Active Comparator|Myopia (iDesign)|iDesign aberrometry: The same 30 consecutive LASIK candidates scanned in the Myopia (Peramis) arm will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
16588793|NCT02687022|Experimental|Irregular astigmatism (Peramis)|Peramis aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer
16588794|NCT02687022|Active Comparator|Irregular astigmatism (iDesign)|iDesign aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
16588795|NCT02687009|Experimental|Niclosamide|
16588796|NCT02686996|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (2 tablets twice daily) for 14 weeks
16588797|NCT02686996|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of identical placebo tablets ( 2 tablets twice daily) for 14 weeks
16588798|NCT02686983|Experimental|Active|Betamethasone and local anesthetic.
16588799|NCT02686983|Placebo Comparator|Placebo|Saline with local anesthetic.
16588800|NCT02686957||women closed|"This cohort will include women who underwent repair for obstetric fistula at three fistula repair hospitals in Guinea and who had a closed fistula at hospital discharge.
~no intervention will be done."
16588801|NCT02686944|Experimental|Intuvax (ilixadencel)|"Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12).
~Max 10 000 000 allogeneic dendritic cells/ml per injection."
16588802|NCT02686931||Control|Control: Normal developmental children with orthopedic disease
16588803|NCT02686931||Experimental|Experimental: Developmental delayed children
16588804|NCT02686918|Experimental|consultation by Advanced Practice Nurse.|During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
16593867|NCT02653274|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge
16588805|NCT02686905|Experimental|Topical vitamin patch|Dietary Supplement: PatchMD Vitamin D3/Calcium Patch Dietary Supplement: PatchMD Multivitamin Patch Dietary Supplement: PatchMD B12 Energy Plus Patch
16588806|NCT02686905|Experimental|Oral vitamins|Dietary Supplement: Chewable Multivitamin with Iron Dietary Supplement: Chewable Calcium Dietary Supplement: Quick Dissolve B12
16588807|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
16588808|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
16588809|NCT02686879|No Intervention|Natural progession|Following the natural progression of axial growth and refractive error.
16588810|NCT02686879|Experimental|Anisohyperopes - intervention eye|The more hyperopic eye will be fitted with a centre-near multifocal contact lens
16588811|NCT02686879|Experimental|Hyperopes|Both eyes will be fitted with centre-near multifocal contact lenses.
16588812|NCT02686879|Experimental|Anisohyperopes - fellow eye|The less hyperopic eye will be fitted with a single vision contact lens if required.
16588813|NCT02686866|Experimental|Body composition measurement|All patients will undergo body composition measurement with dual-energy X-ray absorptiometry and bioelectrical impedance analysis methods. Hand grip strength will also be performed.
16588814|NCT02686853|Experimental|Intrathecal administration group|
16588815|NCT02686840|Experimental|sublingual misoprostol|Group A (100 patients): will be treated with sublingual misoprostol
16588816|NCT02686840|Active Comparator|vaginal misoprostol|Group B (100 patients): will be treated with vaginal misoprostol
16588817|NCT02686827|Experimental|Paricalcitol (Vitamin D3)|paricalcitol, (Zemplar® 5 μg/ml Abbvie), will be administered via the subcutaneous route 4 times at 0.5 ml (registered dose of 5 μg/ml, thus 2.5 μg per sub-cutaneous injection). The minimum time interval between two injections is 4 days, which is a significantly lower frequency than the prescribed maximum of 3 times a week or every other day.
16588818|NCT02686827|Active Comparator|Placebo|Placebo, the same constituents as Zemplar (propylene glycol 30% (v/v) alcohol 20% (v/v)) but no paricalcitol, same dosage as verum-arm.
16588820|NCT02686788|Experimental|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
16588821|NCT02686775|Experimental|Patient coach|Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
16588822|NCT02686775|Active Comparator|Standard treatment|Standard care.
16588823|NCT02686762|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
16588824|NCT02686762|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
16588825|NCT02686762|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
16588826|NCT02686749|Active Comparator|AF catheter Ablation|Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
16588827|NCT02686749|Active Comparator|FDA approved anti arrhythmic drug|FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.
16588828|NCT02686736|Other|Internet-based educational intervention|The Internet-based educational intervention will include four educational sessions that will be provided during a four-week period. The follow up will last three-months.
16588829|NCT02686736|No Intervention|Control group|In the control group, teens will continue the usual school provided sexual education and will be invited to answer the internet-based self-applied questionnaire at the same time as the intervention group.
16588830|NCT02686723|Experimental|ACL injury|Subjects who has ACL injury repaired and who were allowed to return to sport
16588831|NCT02686723|Active Comparator|Healthy subjects|Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)
16588832|NCT02686710|Active Comparator|VIMA|Patiens receiving volatile induction and maitenance of anesthesia
16588833|NCT02686710|Active Comparator|TIVA|Patiens receiving total intravenous anesthesia based on propofol
16588834|NCT02686710|Active Comparator|Combi|Patiens receiving total intravenous induction and volatile anesthesia
16588835|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
16588836|NCT02686697|Placebo Comparator|Placebo|matching placebo
16588837|NCT02686684||Dimethyl Fumarate|MS patients who started treatment with dimethyl fumarate
16588838|NCT02686684||Healthy Control|
16588839|NCT02686658|Experimental|Dose Group 1|Zimura Dose Administration 1
16588840|NCT02686658|Experimental|Dose Group 2|Zimura Dose Administration 2
16588841|NCT02686658|Sham Comparator|Dose Group 3|Sham Administration 1
16588842|NCT02686658|Experimental|Dose Group 4|Zimura Dose Administration 3
16588843|NCT02686658|Experimental|Dose Group 5|Zimura Dose Administration 4
16588844|NCT02686658|Sham Comparator|Dose Group 6|Sham Administration 2
16588845|NCT02686645|Experimental|Fecal Microbiota Therapy|Vancomycin 125 mg po qid for 7 days or metronidazole 500 mg po tid for 7 days pre-treatment. Loperamide 4 mg po after morning prep and 2 mg post treatment. The route of administration fecal microbiota will be by retention enema via a rectal tube.
16588846|NCT02686632|Experimental|Palate Brushing|"In this group the intervention is palatal brushing, performed by the participants following each meal for a period of 6 months. This will be performed using the provided toothbrush (device). The results will determine if brushing the palate in an efficient intervention for reducing the microbial count and inflammation associated with denture stomatitis."
16588847|NCT02686632|No Intervention|Regular Oral Hygiene|The participants in this study arm will not be prescribed or allocated any intervention. The participants will be asked to continue with the regular hygiene and denture maintenance practices for the duration of the trial.
16594241|NCT02650570||Healthy Control|Healthy controls age matched to the Head/Neck cancer group.
16588848|NCT02686619|Active Comparator|Mycophenolate Mofetil + Cyclosporine|Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.
16588849|NCT02686619|Experimental|Mycophenolate Mofetil + Sirolimus|Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
16588850|NCT02686606|Experimental|Vital 1.5|200ml orally over 30 minutes
16588851|NCT02686606|Active Comparator|Ensure Plus|200ml orally over 30 minutes
16588852|NCT02686593|Other|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
16588853|NCT02686580|Experimental|Collagen paste|Injection of Permacol Collagen paste into the fistula tract.
16588854|NCT02686567|Active Comparator|with TDT|with TDT
16588855|NCT02686567|Active Comparator|without TDT|without TDT
16588856|NCT02686554||AD patients|
16588857|NCT02686554||AD patients immunized|
16588858|NCT02686528|Experimental|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
16588859|NCT02686528|Active Comparator|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
16588860|NCT02686515|Active Comparator|Single-task balance training group|Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
16588861|NCT02686515|Experimental|Dual-task balance training group|Participants in the dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks. They will perform a cognitive task or motor task concurrently with the balance/gait task. The framework of progressive balance exercises in the dual-task training group will be progressed from simple to more complex tasks as outlined for the single-task training group. In addition, a variety of added tasks will be progressively integrated into the dual-task balance training program.
16588862|NCT02686502|No Intervention|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
16588863|NCT02686502|Active Comparator|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
16588864|NCT02686502|Active Comparator|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
16588865|NCT02686489|Experimental|Heated humidification (HH)|Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
16588866|NCT02686489|Active Comparator|Cool bland aerosol (LVN)|Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.
16588867|NCT02686476|Active Comparator|Empagliflozin dose group|Patient Receive Standard of Care with Empagliflozen
16588868|NCT02686476|No Intervention|Standard dose group|Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin
16588869|NCT02686463|Experimental|the laparoscopy group|Patients who are randomized to the laparoscopy group.
16588870|NCT02686463|Experimental|the laparotomy group|Patients who are randomized to the laparotomy group.
16588871|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:
~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
16588872|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
16588873|NCT02686411||Participant in Palliative Care Unit (PCU)|"Participants complete 2 questionnaires after being transferred to the PCU.
~Two (2) weekdays after completion of first set of questionnaires, 2 more questionnaires completed."
16588874|NCT02686411||Caregiver of Participant in Palliative Care Unit (PCU)|"Caregiver of participant complete 2 questionnaires after participant transferred to the PCU.
~Two (2) weekdays after completion of first set of questionnaires, 2 questionnaires completed."
16588875|NCT02686398|Active Comparator|Fluad|88 CKD patients were vaccinated with Fluad.
16588876|NCT02686398|Active Comparator|Agrippal|86 CKD patients were vaccinated with Agrippal.
16588877|NCT02686385|Experimental|Prednisolone + N-Acetylcysteine|Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
16588878|NCT02686385|Active Comparator|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
16588879|NCT02686372|Experimental|HBV/TCR-T cell|Biological: HBV antigen specific TCR redirected T cell infusion.
16588880|NCT02686359|Experimental|Burning Mouth Syndrome Patients|saliva, blood and urinary samples
16588881|NCT02686359|Active Comparator|controls|saliva, blood and urinary samples
16588921|NCT02686021|Active Comparator|Metamizole and Placebo|"This is one of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
16588882|NCT02686346|Experimental|BV-ICE|"Phase I:
~4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;
~Phase II:
~4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4"
16588883|NCT02686333|Experimental|Meditation Intervention Arm|10-15 minute meditation practices (brief silent meditations, guided meditations, body scans, gentle arm movement exercises). Before each session, the interventionist will perform a brief check in, and may discuss the patient's experience with them for 1-2 minutes after the intervention. Patients will be encouraged to practice the techniques at home between sessions. Patients will also be offered literature on mental health promotion.
16588884|NCT02686333|No Intervention|Control Group (No Meditation Exposure)|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as Usual in the dialysis setting.
16588885|NCT02686320||Rheumatoid arthritis >65 years old|
16588886|NCT02686320||Rheumatoid arthritis <50 years old|
16588887|NCT02686307||ICD Implant|All patients receiving a dual chamber ICD
16588888|NCT02686294|Experimental|T-R|First period : administration of test drug Second period : administration of reference drug
16588889|NCT02686294|Experimental|R-T|First period : administration of reference drug Second period : administration of test drug
16588890|NCT02686281|Experimental|Cohort A (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Other: Placebo"
16588891|NCT02686281|Experimental|Cohort B (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Other: Placebo
~The dose administered in Part A (fed) was based on the outcome of Part A (fasted)."
16588892|NCT02686268||Individuals diagnosed with known positive C9ORF72 ALS|Individuals diagnosed with known positive C9ORF72 ALS
16588893|NCT02686255||Children 0-18 months post heart surgery|complete blood count for all children 0-18 months going through cardiac surgery
16588894|NCT02686242||spinal anesthesia|patients receive spinal anesthesia before general anesthesia
16588895|NCT02686242||general anesthesia|patients receive general anesthesia
16588896|NCT02686216|Experimental|F-18 THK-5351|F-18 THK-5351 imaging
16588897|NCT02686203|Experimental|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).
~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment."
16588898|NCT02686190|Experimental|Luxtherapy|Luxtherapy exposition
16588899|NCT02686190|No Intervention|Not luxtherapy|Not luxtherapy exposition
16588900|NCT02686177|Experimental|1: Liraglutide|Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
16588901|NCT02686177|Active Comparator|2: Add on oral antidiabetic medication|Metformin or sulfonylurea depending on monotherapy
16588902|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
16588903|NCT02686151|Active Comparator|letrozole|2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
16588904|NCT02686151|Other|Polygeline Injection|500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days
16588905|NCT02686138|Experimental|50mg BID|Tenapanor, 50mg BID (100mg total)
16588906|NCT02686138|Placebo Comparator|Placebo|Placebo
16588907|NCT02686099|Experimental|SternaLock 360|Sternal closure performed with SternaLock 360 as a primary closure system
16588908|NCT02686099|Active Comparator|Wire Cerclage|Sternal closure performed with standard wire cerclage as a primary closure system
16588909|NCT02686086|Placebo Comparator|Standard hospital jet nebuliser|"Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser.
~Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation."
16588910|NCT02686086|Active Comparator|Vibrating mesh nebuliser|Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
16588911|NCT02686073||Group A|Underweight participants whose body mass index is less than 18.5 kg/m2
16588912|NCT02686073||Group B|Control group, in which the participants belong to the normal body mass index range , from 18.5 to 29.9 kg/m2
16588913|NCT02686073||Group C|Obese participants whose body mass index is more than or equal to 30 kg/m2.
16588914|NCT02686060|Experimental|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
16588915|NCT02686060|No Intervention|without in-line filters.|
16588916|NCT02686047|Experimental|the HYAJOINT Plus group|the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
16588917|NCT02686047|Active Comparator|The Synvisc-One group|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
16588918|NCT02686034|Active Comparator|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
16588919|NCT02686034|Sham Comparator|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
16588920|NCT02686021|Experimental|Metamizole and Ibuprofen|all patients (n=42) will receive metamizol and ibuprofen in one session. In the other session half will receive metamizol and placebo (n=21) and the other half will receive ibuprofen and placebo. The order will be randomized (balanced).
16594242|NCT02650557||CSF group|consecutive patients with angiographically documented CSF
16588923|NCT02686008|Experimental|HPV negative tumors|10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
16588924|NCT02686008|Experimental|HPV positive tumors|10 patients with HPV positive tumors: p16 positive and HPV positive tumors
16588925|NCT02685995|Active Comparator|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
16588926|NCT02685995|Active Comparator|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
16588927|NCT02685982|Experimental|Rhythmic Sensory Stimulation|Participants in this group will undertake 30 minutes of daily Rhythmic Sensory Stimulation, for 5 day per week, for a total of 5 weeks. The stimulation consists of specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range. The intervention is conducted at the participant's home using a portable device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit. This device is a low-voltage consumer product device that has built in low frequency (subwoofer-type) speakers. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration that is synchronized with the relaxing musical track.
16588928|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol & 18F-FDG PET scans.
16588929|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
16588930|NCT02685943|Experimental|CAMS treatment|Psychotherapy using the Collaborative Assessment and Management of Suicidality framework
16588931|NCT02685943|Active Comparator|Treatment as usual|Ordinary treatment for suicidal patients
16588932|NCT02685930||Pneumonia without ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Antibiotic choice and duration of therapy will not be influenced by the dedicated ICU stewardship team.
16588933|NCT02685930||Pneumonia with ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Recommendations for antibiotic choice and duration of therapy will be provided by the dedicated ICU stewardship team (consisting of pulmonary fellows and ICU pharmacists)
16588934|NCT02685917|Experimental|Microfracture with Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
16588935|NCT02685917|Active Comparator|Microfracture without Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
16588936|NCT02685904|Experimental|ENIA11|25 mg of ENIA11 subcutaneously administered twice weekly
16588937|NCT02685904|Placebo Comparator|Placebo|25 mg of Placebo subcutaneously administered twice weekly
16588938|NCT02685891|Active Comparator|playing tones|During slow-wave sleep short tones (50ms, 50dB) will be played
16588939|NCT02685891|Sham Comparator|Playing no tones|During slow-wave sleep no tones will be played
16588940|NCT02685865|Active Comparator|FCSEM Stent|WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
16588941|NCT02685865|Active Comparator|Plastic Stents|WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
16588942|NCT02685852|Active Comparator|Arm 1: Exenatide (5mcg) + Acarbose Placebo|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose placebo immediately prior to the high-carb meal
16588943|NCT02685852|Active Comparator|Arm 2: Exenatide (5mcg) + Acarbose (25mg)|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
16588944|NCT02685852|Placebo Comparator|Arm 3: Exenatide Placebo + Acarbose (25mg)|Exenatide placebo 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
16588945|NCT02685839|Active Comparator|Traditional rehabilitation|"Each subject will do traditional rehabilitation work two times per week and one hour at a time
~, lasting 24 weeks."
16588946|NCT02685839|Experimental|Power rehabilitation|Each subject will do Power rehabilitation work with motion tracking and biofeedback recording two times per week and one hour at a time, lasting 24 weeks.
16594243|NCT02650557||control group|age- and gender-matched control subjects
16588947|NCT02685826|Experimental|Cohort A: High risk, TNE|"High risk, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were administered
~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle
~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle
~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
16588948|NCT02685826|Experimental|Cohort B: >=65 years old, TNE|">= 65 years old, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered
~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle
~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle
~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
16588949|NCT02685826|Experimental|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:
~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle
~Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
16588950|NCT02685813||Pregnant women in Denmark|Pregnant women in Denmark participating in prenatal screening. This counts for approximately 50000 pregnancies/year and covers >95% of all pregnancies nationally.
16588951|NCT02685787|Experimental|Psychosocial Intervention|Every caregiver in this arm will be assigned to a permanent counselor.
16588952|NCT02685787|Active Comparator|Educational Intervention on AD|The caregiver enrolled in this arm will not be assigned to a counselor but will participate to group sessions on AD education.
16588953|NCT02685774|Other|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
16588954|NCT02685774|Other|TR group|T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
16588955|NCT02685761|No Intervention|Low Transverse|Patients in this arm will undergo their cesarean section using the standard low transverse skin incision location
16588956|NCT02685761|Experimental|Midline Vertical|Patients in this arm will undergo their cesarean section using a midline vertical skin incision
16588957|NCT02685761|Experimental|High Transverse|Patients in this arm will undergo their cesarean section using a high transverse skin incision, above the pannus
16588958|NCT02685748|Experimental|Aspirin & pantoprazole|"Aspirin 1000 mg/pd per os in two doses
~Pantoprazole 40 mg/pd per os in two doses for gastric protection"
16588959|NCT02685748|Placebo Comparator|Placebo|"Two pills in the morning and two in the evening
~All pills (aspirin, pantoprazole an placebo) will be the same looking- in the same capsules."
16588960|NCT02685735|Active Comparator|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
16588961|NCT02685735|Placebo Comparator|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
16588962|NCT02685722|Experimental|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
16588963|NCT02685722|Experimental|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
16588964|NCT02685709|Experimental|Run-in phase|Oral octreotide capsules
16588965|NCT02685709|Experimental|RCT phase - Oral|Oral octreotide capsules
16588966|NCT02685709|Active Comparator|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
16588967|NCT02685709|Experimental|Combination phase (sub-study)|Octreotide capsules plus cabergoline
16588968|NCT02685696|Experimental|Alexis O Retractor|Group 1 received the Alexis-O-Retractor at thet time of first Caesarean Section
16588969|NCT02685696|Active Comparator|Metal Retractor|Group 2 received the traditional self retaining metal Retractor at thet time of first Caesarean Section
16588970|NCT02685683|Experimental|GED-0301 Induction (160mg) followed by intermittent 160 mg|"GED-0301 160 mg by mouth (PO) daily (QD) for 12 weeks, followed by alternating GED 0301 160 mg QD for 4 weeks and no IP for 4 week, up to Week 100"
16588971|NCT02685670|Experimental|Mixed CD19CAR transfer|All subjects will be infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number
16588972|NCT02685657|Experimental|AC followed by Docetaxel with Selumetinib|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle, 75 mg of SELUMETINIB twice a day PO on days 1-21 of every 3 week cycle
16588973|NCT02685657|Active Comparator|AC followed by Docetaxel|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle
16588974|NCT02685644||Laparoscopic removal|Patients with endometrioma who will undergo laparoscopic removal of cysts.
16588975|NCT02685631||Observational/data registry collection|Patients receiving Yttrium-90 resin microspheres as part of care
16588976|NCT02685618|Experimental|Iloprost + M1006B offset by -10 mmHg|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg
~Intervention: Drug: Iloprost + M1006B offset -10mmHg"
16589431|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency.
16588977|NCT02685618|Experimental|Iloprost + M1006B, No offset|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset
~Intervention: Drug: Iloprost + M1006B, No offset"
16588978|NCT02685618|Placebo Comparator|Placebo + M1006B offset by -10 mmHg|"Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg
~Intervention: Drug: Placebo + M1006B offset -10mmHg"
16588979|NCT02685618|Placebo Comparator|Placebo + M1006B, No offset|"Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset
~Intervention: Drug: Placebo + M1006B, No offset"
16588980|NCT02685605|Experimental|Experimental Arm (A)|Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
16588981|NCT02685605|Active Comparator|Control Arm (B)|Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
16588982|NCT02685592|Experimental|Lentigo maligna patients|All the participants with histologically confirmed lentigo maligna will receive photodynamic therapy three times with 2 weeks' intervals. The borderline of treatment area is delineated with Wood's lamp and hyperspectral imaging system using 5 millimeter margins. Before applying the 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) light sensitizing gel the skin of treatment area is prepared with fractional ablative CO2-laser to enhance absorption. Ameluz® is spread as a 1 millimeter thick layer on the skin. After light sensitizer absorption the treatment area is illuminated with artificial red light (Aktilite CL128 lamp) using a light dose of 90 J/cm2. Finally 4 weeks after the last PDT treatment LM is excised surgically using 5 mm margins.
16588983|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
16588984|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
16588985|NCT02685553|Experimental|1|Use of NIR
16588986|NCT02685514|Experimental|HIFU Graves|Applying the High intensity Focused Ultrasound treatment to the relapsed Graves' disease Patients.
16588987|NCT02685501||Combat women soldiers|Women soldiers in combat units
16588988|NCT02685501||Non combat women soldiers|Women soldiers in non-combat units
16588989|NCT02685488|Active Comparator|Transcranial Ultrasound Power|Transcranial Ultrasound Power
16588990|NCT02685488|Sham Comparator|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
16588991|NCT02685475||Diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
16588992|NCT02685475||Non-diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
16588993|NCT02685462|Active Comparator|Group 1 (Rosuvastatin)|Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.
16588994|NCT02685462|Active Comparator|Group 1 (Digoxin)|Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.
16588995|NCT02685462|Active Comparator|Group 1 (Caffeine)|Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.
16588996|NCT02685462|Active Comparator|Group 2 (Atorvastatin)|Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.
16588997|NCT02685462|Experimental|Cenicriviroc|"Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12.
~Subjects in Group 3 will receive Cenicriviroc on Days 2-12."
16588998|NCT02685462|Active Comparator|Group 3 (Simvastatin)|Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.
16588999|NCT02685449|Placebo Comparator|group A|"On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal.
~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
16589000|NCT02685449|Active Comparator|group B|"On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal.
~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
16589001|NCT02685436|Other|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
16589002|NCT02685423|Experimental|Visual Deprivation - 10 days|10 days of visual deprivation followed by vision training
16589003|NCT02685423|Active Comparator|Vision Training Only|Vision training without visual deprivation
16589004|NCT02685410|Experimental|One Night Stan Pilot Testing Group|The pilot testing of the One Nigh Stan prototype intervention will utilize 20 young black women aged 18-24 as participants.
16589005|NCT02685397|Active Comparator|LHRH agonist + Enzalutamide|Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)
16589006|NCT02685397|Experimental|LHRH agonist + Enzalutamide + SBRT|Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment
16589007|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
16589008|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
16589009|NCT02685371||Breathing effort type|Current known criteria for constrictive pericarditis will be test under: 1- spontaneous breathing 2- Breathing with a negative pressure of -15 to - 30 cm of water 3- Breathing with a negative pressure of more than - 30 cm of water.
16589010|NCT02685358|Experimental|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consisted of 4 brief sessions over 8 weeks.
16589011|NCT02685358|Active Comparator|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
16589012|NCT02685345|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days
16589013|NCT02685345|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days
16589014|NCT02685345|Placebo Comparator|placebo|placebo tablets, orally, once daily for up to 28 days
16589015|NCT02685332|Experimental|Stereotactic Radiation|"Single Fraction Stereotactic Radiation. Step No. Fractions Dose per fraction
~-1 1 20 0 (starting) 1 22.5
~1 26.5
~1 30"
16589016|NCT02685319|Experimental|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
16589017|NCT02685306|Active Comparator|Taxane|Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
16589018|NCT02685306|Experimental|Bavituximab plus Taxane|Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
16589019|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
16589020|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
16589021|NCT02685280|Experimental|DBS for psychiatric disorders patients|Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention
16589022|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
16589023|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
16589024|NCT02685254|Experimental|Initial group therapy|'Structural skills training group' - Start up with weekly structured skills training group for 14 weeks supplemented by homework training
16589025|NCT02685254|Other|Initial control condition|Treatment as usual/clinical management the first 15 weeks pending deferred start of group therapy (partially cross-over)
16589026|NCT02685241||General population|General population
16589027|NCT02685228|Experimental|decitabine & gemcitabine|"This group was treated by low dose decitabine combinated with gemcitabine regimen. decitabine: 5mg/m2 d1-d5; gemcitabine: 1.0g/m2,d8,d15,d22. 28days for one cycle.
~every 28days for one cycle"
16589028|NCT02685228|Active Comparator|gemcitabine|This group was treated by gemcitabine only. Gemcitabine: 1.0g/m2, d8,d15,d22; 28 days for one cycle. every 28days for one cycle
16589029|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
16589030|NCT02685189||0.75 mg/kg Previous exposure to stannsoporfin|Previous exposure 0.75 mg/kg
16589031|NCT02685189||1.5 mg/kg Previous exposure to stannsoporfin|Previous exposure 1.5 mg/kg
16589032|NCT02685176|Experimental|No Heat|No active heating will be provided post cooling
16589033|NCT02685176|Experimental|Head|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the head following cooling
16589034|NCT02685176|Experimental|Torso|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the torso following cooling
16589035|NCT02685163|Experimental|Antioxidant Ice-cream|Natural antioxidant Ice-cream
16589036|NCT02685163|Placebo Comparator|Control Ice-cream|Natural control ice-cream
16589037|NCT02685150|Experimental|Functional dyspepsia|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice and those who fulfill with Rome III criteria for functional dyspepsia are to be classified into this group.
16589038|NCT02685150|Experimental|Acid reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice. Participants with acid reflux are to confirmed by Omeprazole test, one kind of proton-pump inhibitor (PPI) tests.
16589039|NCT02685150|Experimental|Bile reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging and Analysis of gastric juice. Participants with bile reflux are to be confirmed by Analysis of gastric juice.
16589040|NCT02685150|Experimental|Health volunteers|Health volunteers for routine checkup. Participants are to undergo Endoscopic Tri-Modal Imaging as well as Analysis of gastric juice and those who show no abnormal findings are to be classified into this group.
16589041|NCT02685137|Experimental|Active drug-Stannsoporfin|"Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice
~20 mg/mL 1.5 mL/vial"
16589042|NCT02685137|Sham Comparator|Reference Therapy-Sham|Sham Injection, no injection followed by a Band-Aid to thigh
16589043|NCT02685124|Experimental|Bahia orange juice|250 ml twice daily for 7 days
16589044|NCT02685124|Experimental|Cara Cara orange juice|250 ml twice daily for 7 days
16589045|NCT02685124|Placebo Comparator|Isocaloric control drink|250 ml twice daily for 7 days
16589046|NCT02685111|Active Comparator|A. Pegfilgrastim|D2 once a cycle pegfilgrastim arm
16589047|NCT02685111|Experimental|B. Filgrastim|Intermittent Every Other Days of 5 Shot (D3-11) filgrastim arm
16589048|NCT02685098|Experimental|Active/Treatment Group|Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.
16589049|NCT02685098|No Intervention|Observation Group 1|Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.
16589050|NCT02685098|No Intervention|Observation Group 2|"Tissue Collection Group:
~Amputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation."
16589051|NCT02685098|No Intervention|Observation Group 3|Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.
16589144|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
16589052|NCT02685098|No Intervention|Control Group 4|Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur.
16589053|NCT02685085|Experimental|Misoprostol|in this group misoprostol 25 ug will be administrated for induction of labor every 6 hours
16589054|NCT02685085|Experimental|Foley's catheter|In this group foley's catheter 30 cc will be used for induction of labor
16589055|NCT02685085|Experimental|Combined|Both misoprostol 25 ug and foley's catheter will be used for induction
16589056|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
16589057|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
16589058|NCT02685059|Experimental|MEDI4736|part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks
16589059|NCT02685059|Placebo Comparator|Placebo|part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks
16589060|NCT02685059|Active Comparator|Taxane|Nab-Paclitaxel 125 mg/m² weekly for 12 weeks
16589061|NCT02685059|Active Comparator|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
16589062|NCT02685059|Active Comparator|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
16589063|NCT02685046|Experimental|Intervention|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
16589064|NCT02685033|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was < 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
16589065|NCT02685033|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
16589066|NCT02685020|Experimental|Group 1A|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
16589067|NCT02685020|Placebo Comparator|Group 1B|Participants will receive placebo at weeks 0, 12, 24 and 48.
16589068|NCT02685020|Experimental|Group 2A|Participants will receive Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 0, 12 and 24.
16589069|NCT02685020|Placebo Comparator|Group 2B|Participants will receive placebo at weeks 0, 12 and 24.
16589070|NCT02685020|Experimental|Group 3A|Participants will receive Ad26.Mos.HIV vaccine at Week 0; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 8 and 24.
16589071|NCT02685020|Placebo Comparator|Group 3B|Participants will receive placebo at weeks 0, 8 and 24.
16589072|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
16589073|NCT02684994|Other|Cognitive Processing Therapy|Cognitive Processing Therapy
16589074|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
16589075|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
16589076|NCT02684968|Experimental|Colorectal Surgery with QL block having anesthetic|Bilateral QL catheter with local anesthetic infusion + intravenous patient controlled narcotic medication
16589077|NCT02684968|Placebo Comparator|Colorectal Surgery with QL block having saline|Bilateral QL catheter with normal saline infusion + intravenous patient controlled narcotic medication
16589078|NCT02684955||Cerebral spectroscopy + pupillometry|During CPR, rSO2 will be monitored continuously as well as quantitative measurements of the pupillary light reaction every 5 minutes.
16589079|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
16589080|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
16589081|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
16589082|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
16589083|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
16589179|NCT02684357|Placebo Comparator|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16589432|NCT02682654|Experimental|Ankle/Knee brace|Dr. Scholl's Prototype Ankle or Knee Brace
16589084|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
16589085|NCT02684929|Experimental|vegan|Vegan subjects interveinted with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
16589086|NCT02684929|Active Comparator|omnivor|Omnivorous subjects iterveined with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
16589087|NCT02684916|Experimental|Chiropractic treatment|Visit with active treatment.
16589088|NCT02684916|Placebo Comparator|Placebo|Visit without active treatment.
16589089|NCT02684903|No Intervention|Services As Usual (SAU)|Participants receive all the usual services provided by DHS- Children's Services.
16589090|NCT02684903|Experimental|Parent Child Interaction Therapy (PCIT)|"Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.
~."
16589091|NCT02684890||Tinnitus patients|Patients with tinnitus lasting over 3 months
16589092|NCT02684890||Non-tinnitus patients|Patients without tinnitus
16589093|NCT02684877||Intensive care survivors|Observational study
16589094|NCT02684851|Placebo Comparator|Placebo|Inactive
16589095|NCT02684851|Active Comparator|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
16589096|NCT02684825|Experimental|Continuous plus standard cardiac monitoring|Continuous cardiac monitoring by Reveal LINQTM- LNQ11 Internal Loop Recorder (ILR) plus standard cardiac monitoring
16589097|NCT02684825|No Intervention|Standard cardiac monitoring|Routine cardiac monitoring with follow-up at the same frequency, but with no Implantable Loop Recorder
16589098|NCT02684812|Active Comparator|Tranexamic Acid|Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.
16589099|NCT02684812|No Intervention|Control|Standard care
16589100|NCT02684799|Experimental|Part 1 Group 1 (Cenicriviroc)|Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
16589101|NCT02684799|Active Comparator|Part 1 Group 1 (Omeprazole)|Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
16589102|NCT02684799|Experimental|Part 1 Group 2 (Cenicriviroc)|Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
16589103|NCT02684799|Active Comparator|Part 1 Group 2 (Famotidine)|Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
16589104|NCT02684799|Experimental|Part 2 (Cenicriviroc)|Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
16589105|NCT02684799|Active Comparator|Part 2 (Omeprazole)|Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
16589106|NCT02684786|Experimental|Prior right heart catheterization|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status.
16589107|NCT02684786|Experimental|Scheduled for right heart catheterization|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
16589108|NCT02684773||Incentre Nocturnal Hemodialysis|These are patients who converted to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week) from conventional hemodialysis (4 hours/session, 3 sessions/week) at the inception of this study and are eligible for the long-term follow-up phase of the study.
16589109|NCT02684773||Conventional Hemodialysis|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elected to remain on this dialysis schedule at the inception of this study and are eligible for the long term follow-up phase of the study.
16589110|NCT02684760|Experimental|Cohort 1: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
16589111|NCT02684760|Experimental|Cohort 2: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
16589112|NCT02684760|Experimental|Cohort 3: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
16589113|NCT02684760|Experimental|Cohort 4: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
16589114|NCT02684760|Experimental|Cohort 5: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
16589115|NCT02684760|Experimental|Cohort 6: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
16589116|NCT02684747|Experimental|Treatment - Autologous Transfusion|Participants will be randomized to the treatment group (autologous transfusion)
16589117|NCT02684747|Placebo Comparator|Control - Normal Saline (Placebo)|Participants will either be randomized to the control group (saline transfusion)
16589118|NCT02684734||Patients on no immunosuppressant|This includes patients on no medication or mesalamine.
16589180|NCT02684357|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16589119|NCT02684734||Patients on immunosuppressants|This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.
16589120|NCT02684721|No Intervention|Control group|Patients in the control group receive usual care as a minimum. This includes 3-5 days of hospitalisation where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
16589121|NCT02684721|Experimental|Exercise group|8-week home-base exercise programme: Patients in the intervention group receive the same usual care as patients in the control group. In addition the patients participate in an 8 week home-based exercise programme, including follow-up telephone calls with the physiotherapist after 1 week, 2 weeks and 4 weeks. Briefly put, the patients are required to exercise for a minimum of 3 times per week for 30-60 minutes, and with 3-4 intervals of approximately 1 minute at a high intensity level. Total exercise time and intervals increase during the 8 week programme. The patients can choose whatever type of exercise they prefer, and they are generally encouraged to choose something they already do, or something that they have previously had positive experiences doing.
16589122|NCT02684708|Active Comparator|COPDAC-28|cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3
16589123|NCT02684708|Experimental|DECOPDAC-21|patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
16589124|NCT02684695||Group A|Patients with enthesitis-related arthritis
16589125|NCT02684695||Group B|Patients with other forms of juvenile idiopathic arthritis (extended oligoarticular JIA and polyarticular JIA)
16589126|NCT02684682|Other|12h Group|Intervention 'Frequency of mechanical control of plaque (12h)'
16589127|NCT02684682|Other|24h Group|Intervention 'Frequency of mechanical control of plaque (24h)'
16589128|NCT02684682|Other|48h Group|Intervention 'Frequency of mechanical control of plaque (48h)'
16589129|NCT02684669|Experimental|High-dose naloxone|naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration.
16589130|NCT02684669|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
16589131|NCT02684656|Active Comparator|Hemodialysis|Intervention: Patients will be switch to hemodialysis and basal plasma oxalate levels as well as oxalate removal by hemodialysis will be determined after two weeks of treatment.
16589132|NCT02684656|Active Comparator|Hemodiafiltration|Intervention: Patients will be switch back to hemodiafiltration and basal plasma oxalate levels as well as oxalate removal by hemodiafiltration will be determined after two weeks of treatment.
16589133|NCT02684643|Experimental|enhanced individualised therapy|Patients' dialysis dosage, medication as well as dietary plan will be modified.
16589134|NCT02684643|Experimental|non-enhanced individualised therapy|Patients' medication as well as dietary plan will be modified without alteration of dialysis dosage.
16589135|NCT02684643|Experimental|regular intervention|Phosphate binders and calcitriol will be prescribed and adjusted without altering patients' diet habit.
16589136|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
16589137|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
16589138|NCT02684617|Experimental|rrCLL Cohort|Participants with refractory chronic lymphocytic leukemia (rrCLL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
16589139|NCT02684617|Experimental|rrMM Cohort|Participants with relapsed or refractory multiple myeloma (rrMM) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
16589140|NCT02684617|Experimental|rrDLBCL Cohort|Participants with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
16589141|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
16589142|NCT02684604||Fertile women|44 fertile women
16589143|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.
~Intervention: Aramchol"
16589322|NCT02683382|No Intervention|No treatment|Part 3 of the study: other eye is a control eye with no treatment for 45 days.
16589145|NCT02684578|Experimental|Metformin|This arm will be receiving the study drug, Metformin, for the duration of the 18 month study. They will begin this drug on a low dose of Metformin, increasing the dosage in a step-wise fashion to avoid unwanted gastrointestinal discomfort, a common side effect when patients begin taking Metformin. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
16589146|NCT02684578|No Intervention|Observe|This arm will maintain standard of care for dry AMD, which is observation. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
16589147|NCT02684565|Active Comparator|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
16589148|NCT02684565|Active Comparator|BCAA Low Protein Supplement|Subjects will be randomly assigned to take low BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
16589149|NCT02684552|Experimental|Non invasive ventilation|Patients perform physical test with non invasive ventilation
16589150|NCT02684552|Active Comparator|Oxygen|Patients perform physical test with oxygen with mask
16589151|NCT02684539|Experimental|tilt table Erigo®|observation of physiological parameters, tilting table with onset of syncope
16589152|NCT02684526|Active Comparator|Eovist Contrast agent|To determine if Eovist contrast agent induces a transient abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans.
16589153|NCT02684526|Active Comparator|Non Eovist Contrast agents|To determine if using non-Eovist contrast agents produce the same abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans. Determine if this event is exclusive to Eovist contrast.
16589154|NCT02684513|Active Comparator|Oral Carbohydrate Beverage Group|Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
16589155|NCT02684513|Active Comparator|Rehydration Beverage Group|Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
16589156|NCT02684513|No Intervention|Fasted Controls|Subjects assigned to this group will fast for ≥8 hours prior to surgery.
16589157|NCT02684500||aneurysmal subarachnoid hemorrhage|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) for a aneurysmal subarachnoid hemorrhage in subjects undergoing hypertensive therapy for cerebral vasospasm in SAH, to justify the withholding of enteral nutrition.
16589158|NCT02684487|Active Comparator|vitamin D3|Patients will be given single dose of vitamin D3 within 24 hours of new-onset severe sepsis, followed by weekly doses of vitD3 (25,000 IU) up to 90 days to assess clinical outcomes and key biomarkers.
16589159|NCT02684487|Sham Comparator|Placebo|Patients will be given placebo intervention within 24 hours of new onset severe sepsis followed by or placebo for up to 90 days to assess clinical outcomes and key biomarkers.
16589160|NCT02684461|Active Comparator|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
16589161|NCT02684461|Active Comparator|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
16589162|NCT02684461|Active Comparator|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
16589163|NCT02684448||Robotic-Assisted Inguinal Hernia Repair|Subjects who have undergone robotic-assisted (da Vinci) inguinal hernia repair from the initiation of robotic-assisted hernia repair at site through December 2015.
16589164|NCT02684448||Open Inguinal Hernia Repair|Subjects who have undergone open inguinal hernia repair from the day prior to initiation of robotic-assisted hernia repair through 5 years prior to initiation.
16589165|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
16589166|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.
~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
16589167|NCT02684409|Experimental|PROT-CL-NP101-015.01|
16589168|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
16589169|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
16589170|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
16589171|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
16589172|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
16589173|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
16589174|NCT02684383|Experimental|rDEN3∆30 vaccine|Participants will receive the rDEN3∆30 vaccine at Day 0.
16589175|NCT02684383|Placebo Comparator|Placebo|Participants will receive placebo at Day 0.
16589176|NCT02684370|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16589177|NCT02684370|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16589178|NCT02684370|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16589181|NCT02684357|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
16589182|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:
~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery
~education about signs and symptoms of urinary retention"
16589183|NCT02684344|Active Comparator|Education Group|"Subjects will receive:
~1) education about signs and symptoms of urinary retention"
16589184|NCT02684331||T2DM|
16589185|NCT02684318|Experimental|Dose Level 1|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 100 mg BID
16589186|NCT02684318|Experimental|Dose Level 2|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 150 mg BID
16589187|NCT02684318|Experimental|Dose Level 3|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 200 mg BID
16589188|NCT02684318|Experimental|Dose Level 4|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 250 mg BID
16589189|NCT02684318|Experimental|Dose Level 5|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 250 mg BID
16589190|NCT02684318|Experimental|Dose Level 6|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 300 mg BID
16589191|NCT02684318|Experimental|Dose Level 7|PM01183 + olaparib PM01183 3 mg/m² IV olaparib 300 mg BID
16589192|NCT02684305|Experimental|Administration of Propess|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:
~1.Administration of Propess for additional 24 hours."
16589193|NCT02684305|Experimental|Intravenous oxytocin infusion + balloon|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:
~2. Intravenous oxytocin infusion combined with intracervical balloon administration, inflated with 60cc of saline."
16589194|NCT02684292|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
16589195|NCT02684292|Active Comparator|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
16589196|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
16589197|NCT02684266|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen
16589198|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
16589199|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).
~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
16589200|NCT02684240|Experimental|Nitazoxanide|Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.
16589201|NCT02684240|Other|Control|Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.
16589202|NCT02684227|Experimental|Treatment (enzalutamide, paclitaxel, carboplatin)|Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
16589203|NCT02684214|Experimental|Food secure families|high and marginal household food security
16589204|NCT02684214|Experimental|Food insecure families|low and very low household food security
16589205|NCT02684201|Experimental|Boston Scientific cord stimulator lead|"A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance."
16589206|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
16589207|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
16589208|NCT02684175|Active Comparator|In-Person CI Counseling Session|Participants (n=6) randomized to receive an in-person CI counseling session will receive what normally occurs with patients pursuing cochlear implantation. The counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, an explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
16589209|NCT02684175|Experimental|Remote CI Counseling Session|Participants (n=6) randomized to receive a remote CI counseling session will be receiving the counseling session remotely. The participants will be counseled remotely by the audiologist located in Lexington, KY via the telemedicine system (intervention). This counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
16594559|NCT02648334|Active Comparator|IN.PACT drug coated balloon|IN.PACT drug coated balloon
16589210|NCT02684162|Experimental|Treatment (guadecitabine, DLI)|Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
16589211|NCT02684149|Experimental|A|Relational touch before the first arterial puncture and the second arterial puncture without relational touch
16589212|NCT02684149|Experimental|B|First arterial puncture without relational touch and relational touch before the second arterial puncture
16589213|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
16589214|NCT02684136|Placebo Comparator|placebo|9 nights placebo
16589215|NCT02684123|Active Comparator|Apremilast|Apremilast 30mg twice daily
16589216|NCT02684123|Placebo Comparator|Placebo|Placebo pills twice daily
16589217|NCT02684097|Active Comparator|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
16589218|NCT02684097|Placebo Comparator|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
16589219|NCT02684084|Active Comparator|Combination group (RBZ+DEX)|30 eyes will receive an intravitreal Lucentis (0.5 mg) injection followed by Ozurdex implant (0.7 mg) injection within 0 to 8 days.
16589220|NCT02684084|Active Comparator|Monotherapy group (DEX only)|30 eyes will receive Ozurdex implant (0.7 mg) injection only
16589221|NCT02684071|Experimental|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
16589222|NCT02684058|Experimental|HGG cohort: Dabrafenib and trametinib|HGG cohort: All patients in the HGG cohort will receive DRB+TMT
16589223|NCT02684058|Active Comparator|LGG cohort: Carboplatin with vincristine|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
16589224|NCT02684058|Experimental|LGG cohort: Dabrafenib and trametinib|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
16589225|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
16589226|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
16589227|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
16589228|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
16589229|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
16589230|NCT02684032|Experimental|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
16589231|NCT02684019|Active Comparator|Dexmedetomidine|1microgram/kilogram loading dose followed by 0.5 microgram/kilogram/hour IV
16589232|NCT02684019|Active Comparator|Magnesium sulphate|40milligram/kilogram loading dose followed by 10milligram/kilogram/hour IV
16589233|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
16589234|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
16589235|NCT02683993|Experimental|Stone breaking|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with low frequency parameters.
16589236|NCT02683993|Experimental|Stone dusting|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with high frequency parameters.
16589237|NCT02683980|Experimental|Ablation of the prostate|ablation of the prostate will be performed using the study device: Lumenis Pulse P120H Holmium Laser
16589238|NCT02683967|Active Comparator|Acupuncture|These patients received acupuncture during the follicular development phase and on the day of egg collection.
16589239|NCT02683967|No Intervention|Control|Patients received standard care, no acupuncture.
16589240|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
16589241|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
16589244|NCT02683928|Experimental|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
16589245|NCT02683928|Placebo Comparator|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
16589246|NCT02683915||Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
16589247|NCT02683915||Non-cooled group|Infants in the non-cooled group received the current standard of care and will be placed under radiant heaters or in incubators, which are servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.
16589248|NCT02683902|Active Comparator|Active tDCS + Diet|The participants will receive active tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
16589249|NCT02683902|Sham Comparator|Sham tDCS + Diet|The participants will receive sham tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
16589250|NCT02683889|Experimental|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
16589323|NCT02683369|Experimental|Iron Supplement|Participants will consume one tablet of Blood Builder®/Iron Response®, once per day, every day, for 8 weeks.
16589251|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
16589252|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
16589253|NCT02683863|Other|Group 1|"There will be 4 CSF sampling groups at the Week 6 visit for PK assessment:
~1. Four subject for CSF samples 3 hours after dosing"
16589254|NCT02683863|Other|Group 2|2. Four subjects for CSF samples 5 hours after dosing
16589255|NCT02683863|Other|Group 3|3. Four subjects for CSF samples 7 hours after dosing
16589256|NCT02683863|Other|Group 4|4. Four subjects for predose CSF samples
16589257|NCT02683850|Experimental|Omega-3 SPM|"Intervention: Study participants will be instructed to take 3 Omega-3 SPM™ softgel supplements in the morning and 3 Omega-3 SPM™ soft gel supplements in the evening for two weeks.
~At weeks two participants whose PROMIS-43 Pain Intensity score indicates a reduction in pain levels weeks, will take 2 Omega-3 SPM™ soft gel supplements in the morning and 2 in the evening for the remaining 2 weeks of the study.
~Participants whose PROMIS-43 Pain Intensity score remained the same after two weeks, or increased will take 4 Omega-3 SPM™ soft gel supplements in the morning and 4 SPM™ softgels in the evening for the remaining two weeks of the study."
16589258|NCT02683837|Active Comparator|Standard practice|"Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure).
~Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane."
16589259|NCT02683837|Experimental|Pupillometry|Remifentanil infusion guided by changes in pupillary diameter. Anesthesia maintenance with sevoflurane.
16589260|NCT02683824|Experimental|pancreatic cancer patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
16589261|NCT02683824|Experimental|healthy patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
16589262|NCT02683811|Experimental|Intervention group|Diario della Salute (DDS-2), a school-based program aimed to promote psychological well-being and to prevent cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity in preadolescents aged 11-13 years. The program is composed by 5 highly standardised interactive units led by previously trained teachers during school hours (15 hours total). Units focus on emotional and social issues related to adolescent developmental tasks. The goal is to promote the adolescent emotional and social skills.
16589263|NCT02683811|No Intervention|Control group|No intervention aimed at preventing cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity and promoting emotional and social well-being is administered at school by teachers.
16589264|NCT02683798|Active Comparator|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
16589265|NCT02683798|Experimental|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
16589266|NCT02683785|Experimental|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
16589267|NCT02683785|Placebo Comparator|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
16589268|NCT02683772|Experimental|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
16589269|NCT02683772|Active Comparator|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
16589270|NCT02683759|Active Comparator|Treatment Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
16589271|NCT02683759|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
16589272|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
16589273|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
16589274|NCT02683733|Active Comparator|Treatment Arm|"Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
~Starting dose: 50 mg BID of Bio-enhanced Curcumin Soft Gelatin Capsule Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
16589275|NCT02683733|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
16589276|NCT02683720|Experimental|ONS1|new product
16589277|NCT02683720|Active Comparator|ONS2|usual care
16589278|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
16589279|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
16589280|NCT02683694|Other|study arm|iOCT is performed
16589281|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
16589324|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
16589325|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
16589326|NCT02683343||carpal tunnel syndrome|No intervention
16589282|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
16589283|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
16589284|NCT02683655|Experimental|Apatinib 500mg qd p.o.|Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
16589285|NCT02683655|Experimental|Apatinib 750mg qd p.o.|Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
16589286|NCT02683629|Experimental|NTCELL|NTCELL Implantation
16589287|NCT02683629|Sham Comparator|Sham Surgery|Sham Surgery
16589288|NCT02683616|Experimental|OSA + T2DM|CPAP treatment
16589289|NCT02683616|Experimental|OSA no T2DM|CPAP treatment
16589290|NCT02683616|No Intervention|T2DM no OSA|Standard care
16589291|NCT02683616|No Intervention|Healthy controls no ÓSA|no intervention
16589292|NCT02683603|Active Comparator|aerosolised (AS) colistin group|"the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume <8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break > 20%."
16589293|NCT02683603|Active Comparator|intravenous (IV) colistin goup|"the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day."
16589294|NCT02683590|Experimental|sternum by a ceramic implant|The replacement of the sternum by a ceramic implant
16589295|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
16589296|NCT02683564|Experimental|BOW015|Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
16589297|NCT02683564|Active Comparator|Remicade|Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
16589298|NCT02683551||Ligasure|Patients underwent to Sutureless Thyroidectomy with Ligasure SmallJaw
16589299|NCT02683551||Harmonic|Patients underwent to Sutureless Thyroidectomy with Harmonic FOCUS
16589300|NCT02683538|Experimental|Separable cluster electrode|radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
16589301|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
16589302|NCT02683499|Experimental|Ultrasonic tips|Prepared surfaces will be finished with ultrasonic tips
16589303|NCT02683499|No Intervention|Conventional|Prepared surfaces will be finished with ordinary burs
16589304|NCT02683486|Experimental|Activities of daily living on iO2t|Patients will complete simulated activities of daily living on intelligent oxygen therapy (an auto-titrating oxygen system)
16589305|NCT02683486|Active Comparator|Activities of daily living on LTOT|Patients will complete activities of daily living on their usual long-term oxygen therapy.
16589306|NCT02683473||Infants|Infants aged 1-3 months
16589307|NCT02683460|Experimental|patella resurfacing group|Procedure: Patellar component Resurfacing with onlay technique
16589308|NCT02683460|Active Comparator|patella retention|Procedure: patellar retention Trimming of osteophytes when appropriate
16589309|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
16589310|NCT02683434|Experimental|KT|Kinesio Taping Application
16589311|NCT02683434|No Intervention|CONTROL|
16589312|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
16589313|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
16589314|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
16589315|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
16589316|NCT02683408|Experimental|diosmiplex|diosmiplex 630 mg BID administered orally
16589317|NCT02683408|Placebo Comparator|placebo|placebo BID administrered orally
16589318|NCT02683395|Experimental|Treatment Group A|Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
16589319|NCT02683395|Experimental|Treatment Group B|Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
16589320|NCT02683382|Experimental|Moisturizing Eye Product (product in development)|Moisturizing eye product in liquid form (medical device product in development). Part 1 of the study: Administered to both eyes 4 times/day for 1 day. Part 2: to one eye 4 times/day for 9 days. Part 3: to one eye 4 times/day for 45 days. Parts 2 & 3: treatment eyes randomized.
16589321|NCT02683382|Active Comparator|Moisturizing Eye Product, Comparison|Moisturizing eye product in liquid form (medical device CE-marked). Part 2 of the study: Administered to one eye 4 times/day for 9 days. Treatment eyes randomized.
16589328|NCT02683330|Experimental|Mindfulness-based intervention (MBI)|Participants randomly assigned to the MBI group will receive 8 sessions over an 8-week period. The sessions will last 1 hour and will be held via video-conference through Skype, an online application.
16589329|NCT02683330|No Intervention|Wait-list control (WLC)|Participants randomly assigned to the WLC group will be discouraged from any new mindfulness related activities during the trial. The WLC group will be offered the opportunity to take part in the MBI at the end of the 20-week follow-up.
16589330|NCT02683317|Experimental|DHA group|Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.
16589331|NCT02683317|Sham Comparator|Control group|"Control group will receive sunflower oil, the excipient of the DHA in our intervention.
~They will receive it once a day, administered by enteral feeding throughout 14 days."
16589332|NCT02683304|Experimental|The study population|The study population consists of consecutive headache patients (visual analogue scale > 3) presenting at the emergency department of the Nîmes University Hospital
16589333|NCT02683291|Active Comparator|Tacrolimus + Mycophenolate|"The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.
~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
16589334|NCT02683291|Experimental|Tacrolimus + Sirolimus|"The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).
~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
16589335|NCT02683278|Experimental|Cognitive-Behavioral Therapy|Group-based cognitive-behavioral manualized treatment
16589336|NCT02683278|Experimental|Mindfulness-acceptance Therapy|Group-based mindfulness-acceptance manualized treatment
16589337|NCT02683278|Active Comparator|Education|Group-based manualized pain education
16589338|NCT02683265|Experimental|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg Aptensio XR)
16589339|NCT02683265|Placebo Comparator|Placebo comparator|Placebo capsules
16589340|NCT02683252|Experimental|Normal patients|Patients with normal bone appearance on conventional MR images
16589341|NCT02683252|Experimental|Carpal osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the carpal bones on conventional MR images (hypointensity on T1 weighted sequences, no contrast enhancement).
16589342|NCT02683252|Experimental|Femoral head osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the femoral head on conventional MR images (fat containing signal anomalies with geographic contours in the femoral epiphysis).
16589343|NCT02683252|Experimental|Pseudarthrosis|Patients presenting a non consolidated macroscopic bone fracture for over 6 months (clinical history and imaging findings).
16589344|NCT02683252|Experimental|Compartment syndrome|Patients with a confirmed compartment syndrome on intra-compartment pressure assessement
16589345|NCT02683239|Experimental|Fasinumab dosing regimen 1|
16589346|NCT02683239|Experimental|Fasinumab dosing regimen 2|
16589347|NCT02683239|Experimental|Placebo|
16589348|NCT02683226|Experimental|metformin and alogliptin|Vipdomet 12.5 mg/1000 mg tablets
16589349|NCT02683226|Experimental|pioglitasone and alogliptin|Incresync 12,5 mg/30 mg tablets
16589350|NCT02683213|Active Comparator|Fluoxetine|One capsule Fluoxetine 20mg once daily for 6 months.
16589351|NCT02683213|Placebo Comparator|Placebo|One matching capsule placebo once daily for 6 months.
16589352|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
16589353|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
16589354|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
16589355|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
16589356|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
16589357|NCT02683148|Experimental|Arm 1: DHEA Dose Level 1|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
16589358|NCT02683148|Experimental|Arm 2: DHEA Dose Level 2|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
16589359|NCT02683148|Experimental|Arm 3: DHEA Dose Level 3|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
16589360|NCT02683148|Experimental|Arm 4: DHEA Phase II|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
16589361|NCT02683135|Active Comparator|High-carbohydrate diet|
16589362|NCT02683135|Experimental|Low-carbohydrate diet|
16589363|NCT02683135|Experimental|Low-carbohydrate diet with post-meal walking|
16589364|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
16589365|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
16589366|NCT02683096||SGA Infants|
16589369|NCT02683070|Experimental|The PNB group|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) will be performed after the completion of surgery before extubation.
16589370|NCT02683070|Active Comparator|The TRAM group|Intravenous tramadol of 1.5mg/kg will be administrated after the completion of surgery before extubation.
16589371|NCT02683057||IPAQ HIgh|Excessive physical activity:IPAQ quantifying the activity physical according vigorous intensity activities at least 3 days per week adding a minimum total physical activity of at least 1500MET-minutes / week or 7 or more days any combination of walking, moderate intensity or vigorous intensity activities a total minimum of physical activity of at least 3,000 MET-minutes / week
16589372|NCT02683057||IPAQ Moderate|Ideal Physical activity: IPAQ quantifying the activity physical according 3 days or more of vigorous intensity physical activity at least 20 minutes per day or 5 or more days of moderate intensity and / or walk at least 30 minutes per day or 5 or more days of any combination of walking, moderate-intensity activity and activity vigorous intensity for a total minimum of physical activity of at least 600 MET-minutes / week.
16589373|NCT02683057||IPAQ Low|IPAQ quantifying the activity physical according Insufficient physical activity: Individuals who can not put on the criteria of the above categories.
16589374|NCT02683044|Experimental|Li-ESWT 5 weeks|Consists of five sessions of Low-Intensity Extracorporeal Shock Wave Therapy , one per week, with 3000 pulses at 0,15 mg/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 2000 pulses to the body of the penis and 1000 pulses at its base. Total duration: 5 weeks.
16589375|NCT02683044|Active Comparator|Li-ESWT 3 weeks|Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
16589376|NCT02683031|No Intervention|Without Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
16589377|NCT02683031|Experimental|With Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
16589378|NCT02683018|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 Smoked Cannabis High CBD/low THC cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
16589379|NCT02683018|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
16589380|NCT02683005|Experimental|Ledipasvir/Sofosbuvir|Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.
16589381|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
16589382|NCT02682979||Geriatric patients|100 consecutive geriatric patients admitted in the Emergency Department of the Brugmann Hospital, Horta site, from 01/04/2015.
16589383|NCT02682966||PMI|Postoperative Myocardial injury, postoperative troponin levels ≥ 60 ng/L
16589384|NCT02682966||Control|postoperative troponin levels < 60 ng/L
16589385|NCT02682953|Experimental|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
16589386|NCT02682940|Other|Usual Care Patients on MDI or CSII|Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
16589387|NCT02682927|Experimental|ZX008 - 0.8 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
16589388|NCT02682927|Experimental|ZX008 - 0.2 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
16589389|NCT02682927|Placebo Comparator|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
16589390|NCT02682901|Active Comparator|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
16589391|NCT02682901|Placebo Comparator|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
16589392|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
16589393|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
16589394|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
16589396|NCT02682862|Experimental|Spiolto Respimat|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
16589397|NCT02682862|Active Comparator|Striverdi Respimat|olodaterol 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
16589398|NCT02682849||Retrospective cohort|
16589399|NCT02682849||Prospective PleuralFlow cohort|
16589400|NCT02682836|Experimental|single arm|Walk with Ease physical activity intervention
16589401|NCT02682823|Experimental|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
16589402|NCT02682823|Experimental|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
16589403|NCT02682823|Experimental|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
16589404|NCT02682823|Other|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
16589405|NCT02682823|Other|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
16589406|NCT02682810|Active Comparator|DNA PCR HIV diagnostic test|SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.
16589407|NCT02682810|Experimental|Alere Q POC nucleic acid-based platform|POC test to provide same-day diagnosis
16589408|NCT02682797||1|At all study visits a complete ophthalmic examination, visual acuity and refractive error, Spectralis OCT, Cirrus OCT, Topcon OCT, PS-OCT, Optomap Fundus photography will be performed.
16589413|NCT02682771|Active Comparator|Control|Individuals were treated with Conventional Respiratory Physiotherapy (CRP), twice in immediate postoperative day and three times in first postoperative day.
16589414|NCT02682771|Experimental|Bilevel positive airway pressure|Individuals were treated with positive pressure, in the BIPAP mode (bilevel positive airway pressure, with inspiratory pressure:12 cmH20 and expiratory pressure: 8 cmH20) twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each
16589415|NCT02682771|Experimental|Load inspiratory breathing exercises|Individuals were treat with PowerBreathe, a device for inspiratory muscle, with 40% maximal inspiratory pressure, measured at preoperative, twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each.
16589416|NCT02682758|Other|Patients of normal weight|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index of less than 30.
16589417|NCT02682758|Other|Obese patients|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index equal to or more than 30.
16589418|NCT02682745|Experimental|R-T1-T2|First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll
16589419|NCT02682745|Experimental|R-T2-T1|First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l
16589420|NCT02682745|Experimental|T1-T2-R|First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug
16589421|NCT02682745|Experimental|T1-R-T2|First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll
16589422|NCT02682745|Experimental|T2-R-T1|First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l
16589423|NCT02682745|Experimental|T2-T1-R|First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug
16589424|NCT02682732|Experimental|FDG-PET/CT|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be performed at diagnosis and at the end of induction chemotherapy (like cytarabine and daunorubicin). Then, patients will be followed to assess their response, and imaging-guided bone marrow sampling will be repeated in the likely event of disease relapse.
16589425|NCT02682693|Experimental|Denosumab|Denosumab every 4 weeks for 6 cycles.
16589426|NCT02682693|Experimental|nab-Paclitaxel weekly|nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.
16589427|NCT02682693|Experimental|nab-paclitaxel 2 of 3 weeks|nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.
16589428|NCT02682693|Experimental|EC every two weeks or every three weeks|Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
16589429|NCT02682680|Experimental|Colesevelam|Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks
16589430|NCT02682680|Active Comparator|Ezetimibe|Ezetimibe 10 mg once daily for 24 weeks
16589433|NCT02682641|Experimental|IBRUTINIB + RITUXIMAB|"Subjects will receive the ibrutinib in combination with rituximab according to the following schedule:
~Ibrutinib 560 mg daily po until disease progression or unacceptable toxicity. In case of sustained negative MRD (at least for 6 months) after 2 years of continuous therapy, ibrutinib will be discontinued.
~Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1). Rituximab 375 mg/m2 iv, day one of every cycle 3, 5, 7 and 9."
16589434|NCT02682628|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
16589435|NCT02682615||requirement of norepinephrine|requirement of norepinephrine <0,1 µg/kgKG/min versus ≥0,1 µg/kgKG/min
16589436|NCT02682602||Diseased Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
16589437|NCT02682602||Normal Hip|Subjects will have a normal hip.
16589438|NCT02682602||Implanted Group|All subjects from the Diseased Hip group were implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA
16589439|NCT02682589|Active Comparator|Open surgery|Patients undergo open CME. A standard midline incision carefully protected is made through the abdominal wall and the abdominal cavity is explored. A colectomy with CME is performed with the removal of the afflicted colon and its accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia.
16589440|NCT02682589|Experimental|Laparoscopic surgery|Patients undergo laparoscopic CME. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with carbon dioxide to allow access and visualization. The abdominal cavity is explored. A colectomy with CME is performed using laparoscopic-assisted techniques. A 6-8cm midline auxiliary incision is made for specimen extraction and anastomosis.
16589441|NCT02682576|Experimental|Brachial artery ultrasound imaging|Brachial artery ultrasound imaging is a non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery using high resolution continuous electrocardiogram-gated B-mode (2D) ultrasound imaging during reactive hyperemia.
16589442|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
16589443|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
16589444|NCT02682550||Ctrl|healthy volunteers, sex- and age matched Blood drawing at one time point: 20 ml
16589445|NCT02682550||PT|"polytrauma patients fulfilling the following criteria:
~injury severity score ≥25
~age ≥ 18 Blood drawing at admission to the emergency room, 8 h, 24h, 48 h, 120 h and 240 h post trauma: 20 ml"
16589446|NCT02682537||Female, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 Years
16589447|NCT02682537||Female, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
16589448|NCT02682537||Female, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
16589449|NCT02682537||Female, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
16589450|NCT02682537||Female, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
16589451|NCT02682537||Female, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
16589452|NCT02682537||Female, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
16589453|NCT02682537||Female, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
16589454|NCT02682537||Female, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
16589455|NCT02682537||Male, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 years
16589456|NCT02682537||Male, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
16589457|NCT02682537||Male, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
16589458|NCT02682537||Male, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
16589459|NCT02682537||Male, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
16589460|NCT02682537||Male, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
16589461|NCT02682537||Male, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
16589462|NCT02682537||Male, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
16589463|NCT02682537||Male, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
16589464|NCT02682524|Active Comparator|test|
16589465|NCT02682524|Active Comparator|reference|
16589466|NCT02682511|Experimental|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
16589467|NCT02682511|Experimental|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
16589468|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
16589469|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
16589470|NCT02682485|Experimental|Cipro, metronidazole, neomycin combo|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
16589471|NCT02682485|Placebo Comparator|Saline|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
16589472|NCT02682472|Experimental|SettleIN|SettleIN - Adjustment to care programme intervention
16589473|NCT02682459|Experimental|Lisinopril|Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.
16589474|NCT02682459|No Intervention|No intervention|Patients will receive only the standard immunosuppressive therapy.
16589475|NCT02682446||Negative H. pylori group|The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
16589476|NCT02682446||Previous H. pylori infection group|The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
16589477|NCT02682446||Eradicated H. pylori group|The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
16589478|NCT02682446||Persistent H. pylori group|The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
16589479|NCT02682433|Experimental|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same position, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
16589480|NCT02682433|Experimental|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same positionabdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
16589481|NCT02682420|Other|endoAVF|
16589482|NCT02682407|Experimental|OMS721 (narsoplimab)|Administration of OMS721 (narsoplimab)
16589483|NCT02682381|Experimental|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
16589484|NCT02682381|Experimental|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
16589485|NCT02682381|Active Comparator|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
16589486|NCT02682368||POCUSS Trial-1 Acute Biliary Disease|Patients with suspected biliary pathology which will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
16589487|NCT02682368||POCUSS Trial-2 Acute Diverticulitis|Patients with suspected diverticulitis will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
16589488|NCT02682368||Radiology Report|Departmental imaging and reports.
16589489|NCT02682368||Surgical diagnostic|Intraoperative findings of patients that undergo emergency surgery.
16589490|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of bacteremia and/or urinary tract infection and/or respiratory tract infection (including tracheobronchitis) or sepsis
16589491|NCT02682342||Healthy Subjects|Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine > 1.5 men, > 1.5 women), liver enzymes > 2.5x normal, pregnant at the time of screening will be excluded
16589492|NCT02682329|Active Comparator|CP 10% + HP 40%|Carbamide Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. CP at home and HP at office
16589493|NCT02682329|Active Comparator|CP 15% + HP 40%|Carbamide Peroxide 15% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
16589494|NCT02682329|Active Comparator|CP 20% + HP 40%|Carbamide Peroxide 20% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
16589495|NCT02682329|Active Comparator|HP 10% + HP 40%|Hydrogen Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. HP at Home and HP at office
16589496|NCT02682316|Active Comparator|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
16589497|NCT02682316|Experimental|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
16589498|NCT02682303|Experimental|elastic bandage|In this study, Idealplast C® (6cm*2.5m) was used.
16589499|NCT02682303|Placebo Comparator|Non-standardized tape (NST)|In the NST group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used.
16589500|NCT02682290|Other|rheological measurement of sputum|"patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.
~Then all participants will have an induced expectoration with hypertonic salin solution."
16589501|NCT02682277|Active Comparator|Medical device polyglucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
16589502|NCT02682277|Placebo Comparator|Placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
16589532|NCT02682095||Individual interviews|Hypertensive patients who have considered changing lifestyle regarding one or more of the areas of tobacco, alcohol, diet, physical activity or stress.
16589503|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
16589504|NCT02682251|Experimental|Heart Failure Patients with CRT-CIED|PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
16589505|NCT02682238|Experimental|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
16589506|NCT02682238|Placebo Comparator|Vehicle|Vehicle (placebo) gel
16589507|NCT02682225|Experimental|Sequence 1: Qualification Session|Participants will receive Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 1 and Treatment B (0.5 milligram per kilogram (mg/kg) of intravenous racemic ketamine and intranasal placebo concurrently) on Day 2.
16589508|NCT02682225|Experimental|Sequence 2: Qualification Session|Participants will receive Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo concurrently) on Day 1 and Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 2.
16589509|NCT02682225|Experimental|Sequence 3: Treatment Phase|Participants in Sequence 3 will receive Treatment A (intravenous placebo and intranasal placebo) on Day 1 of period 1, Treatment D (intravenous placebo and intranasal 112 milligram (mg) of esketamine as 4 devices, each with 28 mg esketamine) on Day 1 of period 2, Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo) on Day 1 of period 3, Treatment C (intravenous placebo and intranasal 84 mg esketamine as 3 devices, each with 28 mg esketamine followed by 1 device with placebo) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
16589510|NCT02682225|Experimental|Sequence 4: Treatment Phase|Participants in Sequence 4 will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
16589511|NCT02682225|Experimental|Sequence 5: Treatment Phase|Participants in Sequence 5 will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment D on Day 1 of period 3, Treatment A on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
16589512|NCT02682225|Experimental|Sequence 6: Treatment Phase|Participants in Sequence 6 will receive Treatment D on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment B on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
16589513|NCT02682212|Experimental|Physiotherapy intervention|Intensive pelvic floor muscle training (PFMT) given by a physiotherapist with vaginal/rectal pressure feedback once a week for 12 weeks.
16589514|NCT02682212|No Intervention|No intervention|Standard care
16589515|NCT02682199||Whole Brain Radiation|Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy.
16589516|NCT02682186|No Intervention|Control group (1)|The PECS Blocks are not (1) performed.
16589517|NCT02682186|Experimental|PECS group (2)|The PECS Blocks are performed (2): A single injection of Ropivacaine after dilution with sodium chloride 0.9% per fascial plane and per side.
16589518|NCT02682173|Active Comparator|Laparoscopic gastric bypass|MR Abdomen in morbidly obese patients receiving gastric bypass
16589519|NCT02682173|Active Comparator|Laparoscopic sleeve gastrectomy|MR Abdomen morbidly obese patients receiving sleeve gastrectomy
16589520|NCT02682160|Other|Use of Protein Assistant|patients can use the Protein Assistant during 2 months to evaluate the quantity of protein's intake.
16589521|NCT02682147|Experimental|Hypoxia Administration study group|40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
16589522|NCT02682147|Experimental|Hyperoxia Administration study group|40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
16589523|NCT02682147|Experimental|Sildenafil|40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
16589524|NCT02682134|Experimental|"Xylocaine X"|Patients received xylocaine gel as lubricant on endotracheal tube
16589525|NCT02682134|Experimental|"Dexamethasone D"|Patients were given dexamethasone 8 mg intravenously
16589526|NCT02682134|Experimental|"xylocaine and dexamethasone XD"|Patients were given both xylocaine gel and dexamethasone 8 mg intravenously
16589527|NCT02682121|Placebo Comparator|Placebo|Patients on placebo.
16589528|NCT02682121|Active Comparator|Active drug|Patients on Metformin, 850mg twice daily for 6mos.
16589529|NCT02682108|Other|Diffusion-weighted imaging|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
16589530|NCT02682095||Patients: achieved BP control|Patients who have achieved blood pressure control (≤140/90 mmHg)
16589531|NCT02682095||Patients: not achieved BP control|Patients who have not achieved blood pressure control (>140/90 mmHg)
16589534|NCT02682082|Experimental|Neurolysis without Bupivacaine|Experimental Group: Endoscopic ultrasound guided celiac plexus Neurolysis without Bupivacaine so only with Absolute Alcohol 20 mL
16589535|NCT02682082|Active Comparator|Neurolysis with Bupivacaine|Endoscopic ultrasound guided celiac plexus Neurolysis with Bupivacaine (0.5% Bupivicaine 20mL + Absolute Alcohol 20 mL)
16589536|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
16589537|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
16589538|NCT02682043|Experimental|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
16589539|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
16589540|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
16589541|NCT02682017|Placebo Comparator|Treatment 1|Pork meat from pigs feed with a standard feed
16589542|NCT02682017|Experimental|Treatment 2|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
16589543|NCT02682004||Women with postpartum depression|
16589544|NCT02682004||Women without postpartum depression|
16589545|NCT02681991|Experimental|test|Renamezin capsule 2g, tid, PO
16589546|NCT02681978|Active Comparator|Ivabradine group|Ivabradine 5 mg twice daily + standard medical therapy
16589547|NCT02681978|Other|Control group|Standard medical therapy
16589548|NCT02681965|Experimental|LEAN|Participants randomized to the weight loss program will initially receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity. Written instructions in the LEAN book will include recording daily diet and exercise in the logs. At the end of the study, participants will return, via a stamped addressed envelope, the logs to the study office so compliance can be assessed.
16589549|NCT02681965|No Intervention|Waitlist Control|Participants randomized to the waitlist control study arm will be mailed the six-month questionnaires, which will include reporting of weight. On return of the 6-month questionnaires each woman will be provided with the entire weight loss program packet.
16589550|NCT02681952|Active Comparator|Renamezin->Kremezin|
16589551|NCT02681952|Active Comparator|Kremezin->Renamezin|
16589552|NCT02681939|Experimental|Tulsi|One capsule of Tulsi (Ocimum sanctum) orally, every morning and evening in empty stomach for 60 days regularly.
16589553|NCT02681939|No Intervention|No Tulsi|No intervention
16589554|NCT02681926||Average force group|A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. In the Average Force group, the operators decided to use the mean contact force as target parameter indicating a good lesion.
16589555|NCT02681926||Force Time Integral group|In the Force Time Integral (FTI) group, the operators decided to use the FTI as target parameter indicating a good lesion.
16589556|NCT02681913|No Intervention|standard cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.
~The cardioplegic maintenance solution consists of a 500 ml normal saline (0.9% NaCl) infusion bag. Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.
~This arms receives standard intermittent 20:1 diluted warm blood cardioplegic solution.
~Intervention: n/a"
16589557|NCT02681913|Experimental|adenosine enriched cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.
~The cardioplegic maintenance solution consists of a 1000 mg = 500 ml adenosine infusion bag (2 mg/ml). Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.
~This arms receives adenosine enriched, intermittent 20:1 diluted warm blood cardioplegic solution.
~Intervention: Drug: Adenosine"
16589558|NCT02681900|Experimental|Self-affirmation|Participants in the self-affirmation arm write about their most important value, reasons why is important and an example of when they enacted that value. This is the Self-affirmation manipulation task as described in the intervention.
16589559|NCT02681900|Active Comparator|Control|Participants in this arm complete a control equivalent of the self-affirmation task, where they write about their least important value, reasons why is may be important to someone else and an example of when another person may have enacted that value. This is the Control task as described in the intervention.
16589560|NCT02681887|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 12 weeks
16589561|NCT02681887|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
16589616|NCT02681471|Active Comparator|Bipolar TURP|Patients in Group B (Bipolar) were used bipolar resectoscope TURis (OLYMPUS, Tokyo, Japan) and 0,9% Sodium chloride as an irrigation fluid.
16589617|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
16589562|NCT02681874|Experimental|Group A (Treatment Arm)|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Sessions are 90 minutes. Groups consist of a maximum of five parents. Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions. Parent Leaders receive a week-long leadership training to deliver the program and will be supervised by the PI who is a licensed clinical psychologist.
16589563|NCT02681874|Active Comparator|Group B (Control Arm)|Parents in the control condition will receive the Smart and Secure Children (SSC) program's written handouts. Handouts include didactic curriculum content and instruct parents to write goals and document goal progress.
16589564|NCT02681861|Experimental|Part 1: ASP6294 Single Ascending Intravenous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo intravenously. If no dose limiting toxicities are observed escalation to the next higher dose is planned approximately every 3 weeks. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
16589565|NCT02681861|Experimental|Part 2: ASP6294 Single Ascending Subcutaneous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
16589566|NCT02681835|Experimental|Position 1|Standard position during intubation. Intubator is behind head of the victim, propped up on both elbows
16589567|NCT02681835|Experimental|Position 2|Intubator is behind head of the victim, lies on the left side
16589568|NCT02681835|Experimental|Position 3|Intubator stands astride the victims, intubated using the face-to-face
16589569|NCT02681822||Healthy young subjects|Healthy young Chinese Han subjects aged 18-30
16589570|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
16589571|NCT02681809|Experimental|Ocriplasmin 0.125mg|
16589572|NCT02681809|Sham Comparator|Sham injection|
16589573|NCT02681796|Experimental|Study: Bupivacaine Epidural + standard of care pain regimen|-The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
16589574|NCT02681796|No Intervention|Control: Standard of care pain regimen|-The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
16589575|NCT02681783|Active Comparator|neovascular AMD group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
16589576|NCT02681783|Experimental|CSR group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
16589577|NCT02681783|Experimental|iPCV group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
16589578|NCT02681783|No Intervention|cataract patients|Patients diagnosed with cataracts requiring cataract surgery will serve as study controls. No intervention will be applied to these patients.
16589579|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
16589580|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
16589581|NCT02681744|No Intervention|Control Group|These participants will be instructed to maintain their habits during 24 weeks. Before and after the aforementioned period, they will be asked to perform body composition and strength assessments, using DXA and isokinetic dynamometer, respectively.
16589582|NCT02681744|Experimental|Experimental group|Participants from the experimental group will assign to the resistance training program undergo physician screening at rest and under cardiopulmonary exercise test conditions before starting the program. Following a three-week familiarization process, participants undergo one repetition maximum (1-RM) testing for each of the exercises of the training program. This procedure intended to determine exercise load and will be systematically repeated in four-week intervals. Volunteers will train thrice per week during 24 weeks. The training program will involve the following exercises: chest press, lat pulldown, knee extension, hamstrings curl, leg press, hip abduction.
16589583|NCT02681718|Experimental|Community Health Worker education|During a six-month intervention period, the CHWs will conduct six home-based visitations and provide individualized diabetes education using an intensive diabetes lifestyle curriculum called Diabetes Learning Circle (DLC), developed and used by the Sinai Diabetes Education Program. At each visit, lasting for approximately one hour, the participants will be motivated to set SMART behavioral goals for diabetes self-management. At each visit after the initial visit, CHWs will follow-up with each participant to check their progress on their behavioral SMART goals. In addition, the CHWs will conduct intermittent phone calls (at least one monthly) and home visits as needed.
16589584|NCT02681718|Experimental|Cell phone text messaging|The participants in the text messaging group will receive weekly text messages through CareMessage. Each participant will receive 3-4 text messages per week for 6 months.
16589585|NCT02681718|No Intervention|Control|The participants in the control group will receive education as determined by the hospital's diabetes educator, dietitian, physician, or the participant's managed care provider. No additional education will be provided by the research team.
16589618|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
16589586|NCT02681705|Experimental|Study Treatment|All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with Temozolomide. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as Temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
16589587|NCT02681692|Active Comparator|MEI colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system
16589588|NCT02681692|No Intervention|Standard colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) without the assistance of magnetic scope navigation system
16589589|NCT02681692|Active Comparator|MEI colon model Group|"Colonoscopist would be randomized to perform colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part.
~All force variation data would be recorded by a image storage device."
16589590|NCT02681692|No Intervention|Standard colon model Group|Colonoscopist would be randomized to perform conventional colonoscopy on a colon model without an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
16589591|NCT02681679|Experimental|0.1% bromfenac ophthalmic solution|Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.
16589592|NCT02681679|Placebo Comparator|control physiological normal saline|Patients received control physiological normal saline twice a day for 3 days before surgery.
16589593|NCT02681666|Active Comparator|FODMAPs CONTROL arm|Dietary intervention in this cohort with irritable bowel syndrome will be administered a low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet by a dietician.
16589594|NCT02681666|Experimental|MB-IBS-EAT INTERVENTION STUDY arm|Irritable Bowel Syndrome eating awareness training intervention will be started in a comprehensive 8 weekly sessions of Mindfulness eating training.
16589595|NCT02681653|Active Comparator|Statin|Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
16589596|NCT02681653|Placebo Comparator|Placebo|Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
16589597|NCT02681640|Experimental|uPAR PET|One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions
16589598|NCT02681627|Active Comparator|endometrial scratch|Patient will be randomised to the intervention arm which is the luteal phase endometrial scratch
16589599|NCT02681627|Sham Comparator|touching cervix|Patient will have a speculum examination and cleaning of the cervix with cotton tip with saline but no scratch
16589600|NCT02681614|Experimental|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation.
~All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
16589601|NCT02681601|Active Comparator|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
16589602|NCT02681601|Active Comparator|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
16589603|NCT02681588|Experimental|Obese group|
16589604|NCT02681588|Active Comparator|Normal Weight group|
16589605|NCT02681575|Experimental|Cog-Fun A|Metacognitive-Functional occupational therapy intervention (Cog-Fun - A) includes enhancing self awareness in occupational context, acquiring executive strategies and skills and implementation across multiple occupational domains.
16589606|NCT02681562|Experimental|Olaparib triple negative|Olaparib short administration in triple negative breast cancer
16589607|NCT02681562|Experimental|Olaparib BRCA mutated|Olaparib short administration in BRCA mutated patients
16589608|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
16589609|NCT02681536|Experimental|Minidose long protocol|Down-regulation started on day 20 of the previous cycle by GnRH agonist triptorelin (0.5 µg Decapeptyl; Ferring). On the second day of menstruation, when down regulation was confirmed (as evidenced by endometrial thickness <5 mm and/or E2 levels <50 pg/mL) using transvaginal sonography (TVS) by Voluson 730 Pro (GE, Fairfield, CT) apparatus, gonadotropin (Merional; IBSA) was commenced at an initial dose of 300-450 IU/day for the first 5 days followed by individual adjustment in Gn dose according to ovarian response and the dose of Decapeptyl 50µg/day was continued until day of HCG administration.
16589610|NCT02681536|Experimental|microdose flare protocol|OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.
16589611|NCT02681523|Experimental|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
16589612|NCT02681510|Experimental|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
16589613|NCT02681484|Experimental|Hypertensive|Patients diagnosed with hypertension (I10, either on drug therapy or verified by 24h blood pressure measurements) administered to anthroposophic speech therapy (intervention).
16589614|NCT02681484|Active Comparator|Normotensive|Patients diagnosed with tension headache (G 44.2) or anxiety disorders (F41) administered to anthroposophic speech therapy (intervention).
16589615|NCT02681471|Active Comparator|Monopolar TURP|Patients in Group M (Monopolar) were used monopolar resectoscope (Karl Storz, Tottling, Germany) and 5% Mannitol as an irrigation fluid.
16589619|NCT02681445||Group 1 Healthy Non Smokers|No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray Non-Smoker
16589620|NCT02681445||Group-2 Smokers|No TB History No TB Symptoms No TB History Negative Mantoux test Smoker 10 + Cigarettes/day
16589621|NCT02681445||HIV Positive|"No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray HIV Positive
~CD4 count >200"
16589622|NCT02681445||TB Suspect Group|WHO Screening Recommendation Protocls Unexplained Cough Sputum production Fever Weight Loss or loss of appetite Night Sweats
16589623|NCT02681445||Lower Respiratory Track Infection|TB Lab test Negative Ab Normal Chest X-ray HIV Negative
16589624|NCT02681432|Experimental|HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
16589625|NCT02681432|Active Comparator|No HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
16589626|NCT02681419|Active Comparator|Needle fenestration|Needle fenestration
16589627|NCT02681419|Active Comparator|Suture wick|suture wick using 10-0 vicryl
16589628|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
16589629|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
16589630|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
16589631|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
16589632|NCT02681393|Experimental|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
16589633|NCT02681393|Active Comparator|Brochure Only|Participants will receive the Aerobic Exercise After Stroke educational brochure only.
16589634|NCT02681380|Experimental|Relation learning|Participants of this group will benefit form a specific learning on relation, Balint like. They will have 7 sessions during 3 months.
16589635|NCT02681380|Placebo Comparator|Control group|Participants of this group will have no learning related to relation with patient.
16589636|NCT02681367|No Intervention|fresh embryo transfer|Patient with RIF underwent ICSI cycle followed by Day 5 fresh embryo transfer.
16589637|NCT02681367|Experimental|Freeze all|Patient with RIF. All of them underwent ICSI cycle, all their embryos were cryopreserved at Day 5 and transferred in a consecutive natural cycle.
16589638|NCT02681354|Experimental|A additional BioRescue training|Using a playful rehabilitation, BioRescue
16589639|NCT02681354|No Intervention|Regular training|
16589640|NCT02681328||Afirma GEC|single molecular test GEC of collected tissue
16589641|NCT02681328||ThyroSeq v.2|single molecular test ThyroSeq v.2 of collected tissue
16589642|NCT02681328||Afirma GSC|single molecular test GSC of collected tissue
16589643|NCT02681328||ThyroSeq v.3|single molecular test ThyroSeq v.3 of collected tissue
16589644|NCT02681315|Experimental|6 liter/min group|Infants will be extubated to a HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) at ﬂow rate of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
16589645|NCT02681315|Active Comparator|3 liter/min group|Infants will be extubated to HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) a ﬂow rate of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
16589646|NCT02681302|Experimental|All Participants|"Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
~Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
16589647|NCT02681289|Experimental|physiotherapy group|Early goal directed neuromotor therapy applied by physiotherapist
16589648|NCT02681289|Experimental|family group|Early goal directed neuromotor therapy applied by family
16589649|NCT02681276|Experimental|Irrigation with 3% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 3 % NaOCl irrigation during instrumentation. If the patient's first visit was on an uneven date the concentration of the irrigant was 3 %.
16589650|NCT02681276|Active Comparator|Irrigation with 0.5% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 0.5 % NaOCl irrigation during instrumentation. If the patient's first visit was on an even date the concentration of the irrigant was 0.5 %.
16589651|NCT02681263|Experimental|Temocillin|"Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
~Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients)."
16589652|NCT02681250|Experimental|Titanium-zirconium|Patients receiving titanium-zirconium implants
16589653|NCT02681250|Active Comparator|Titanium|Patients receiving titanium implants
16589654|NCT02681237|Experimental|Cediranib and Olaparib|"Cediranib will be given by mouth, at a dose of 20 mg, once a day, everyday.
~Olaparib will given by mouth, at a dose of 300 mg, twice a day, every day."
16589655|NCT02681224|Active Comparator|Active Product with Occlusion|TR987 Gel with Silon Bandage
16589656|NCT02681224|Active Comparator|Active Product without Occlusion|TR987 without Silon Bandage
16589657|NCT02681224|Placebo Comparator|Placebo Gel with Occlusion|Placebo Gel with Silon Bandage
16589658|NCT02681224|Placebo Comparator|Placebo Gel without Occlusion|Placebo Gel without Silon Bandage
16589659|NCT02681211|Experimental|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
16589660|NCT02681211|Active Comparator|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
~Ketorolac 0.5mg/kg, max 30mg
~Metoclopramide 0.1 mg/kg, max 10mg
~Diphenhydramine 1mg/kg, max 50mg
~Normal saline fluid bolus 20mL/kg, max 1000mL"
16589662|NCT02681185|Experimental|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
16589663|NCT02681185|Active Comparator|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
16589664|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.
~The applied florbetaben radioactive dose will be ± 20%."
16589665|NCT02681146|Experimental|Group1|Educational advice + physiotherapist treatment
16589666|NCT02681146|Experimental|Group2|Educational advice + physiotherapist treatment
16589667|NCT02681146|Experimental|Group3|Educational advice + physiotherapist treatment
16589668|NCT02681146|Experimental|Group4|Educational advice + physiotherapist treatment
16589669|NCT02681146|Experimental|Group5|Educational advice + physiotherapist treatment
16589670|NCT02681146|Experimental|Group6|Educational advice + physiotherapist treatment
16589671|NCT02681146|Experimental|Group7|Educational advice + physiotherapist treatment
16589672|NCT02681146|Experimental|Group8|Educational advice + physiotherapist treatment
16589673|NCT02681133||patients with knee pain|
16589674|NCT02681120||High risk/BMI > 30|Women at elevated risk for breast cancer will have imaging (MRI and mammogram) pre-bariatric surgery and 1 year post-bariatric surgery, and blood and tissue collection (blood draw and biopsy) pre-bariatric surgery, 2 weeks post-bariatric surgery, and 1 year post-bariatric surgery.
16589675|NCT02681120||Women with normal BMI|Deidentified samples that were donated to the IU Komen Tissue Bank will be used for comparison to the high risk/BMI > 30 cohort.
16589676|NCT02681107|Experimental|Single Arm|Single cohort to receive Accelerated Partial Breast Irradiation (APBI) 27Gy in 5 fractions
16589677|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
16589678|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
16589679|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
16589680|NCT02681081|Other|Control|For sessions 2 through 4, maintain normal eating patterns.
16589681|NCT02681081|Active Comparator|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
16589682|NCT02681081|Active Comparator|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
16589683|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
16589684|NCT02681042|Experimental|SentreHeart Lariat|Left atrial appendage closure with SentreHeart Lariat device
16589685|NCT02681029|Experimental|Blastocyst transplantation|The infertile women who underwent intra- uterus transferring of blastocyst from thawed cleavage embryo
16589686|NCT02681029|Placebo Comparator|Control|The infertile women who underwent intra- uterus transferring of thawed cleavage embryo.
16589687|NCT02681016|Experimental|"Sirolimus-eluting stent Calypso"|"Commercially approved coronary stent system Calypso (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm."
16589688|NCT02681016|Active Comparator|"Everolimus-eluting stent Xience Prime"|Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.
16589689|NCT02680990|Active Comparator|Exercise Education|Distribution of exercise education materials
16589690|NCT02680990|Experimental|Band Together|A strength-training and walking program with or without an exercise partner throughout neoadjuvant therapy.
16589691|NCT02680977|Experimental|MP-Equivalent; MP-Low; MP+DDCI|"MP-Equivalent: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI (for example 100mg of Madopar corresponds to 500mg of Levodopa in MP).
~MP-Low: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 350mg of Levodopa in MP) MP+DDCI: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 100mg of Levodopa in MP plus 25mg of Benserazide)"
16589692|NCT02680977|Active Comparator|LD+DDCI; LD-DDCI|"LD+DDCI: Levodopa plus Benserazide (dispersible formulation). The dose is calculated as 3.5mg per kg of body weight.
~LD-DDCI: Levodopa without any dopa decarboxylase inhibitor (galenic formulation). The dose is 5-fold than LD+DDCI."
16589693|NCT02680977|Placebo Comparator|Placebo|Powder of groundnuts
16589694|NCT02680951|Experimental|Dose Level 1|"Study participants #1 - #6 receive dose level 1 of dasatinib (60/mg/m2/day) in addition to the standard treatment, for up to 2 courses. Each treatment course is 29 days.
~Treatment course 1 consists of:
~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5
~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5
~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5
~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines
~Dasatinib orally, once daily on days 6-29
~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
16589695|NCT02680951|Experimental|Dose Level 2|"Study participants # 7 - # 12 receive dose level 2 of dasatinib (80/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 1 did not experience intolerable side effects. Each treatment course is 29 days.
~Treatment course 1 consists of:
~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5
~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5
~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5
~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines
~Dasatinib orally, once daily on days 6-29
~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
16589696|NCT02680951|Experimental|Dose Level 3|"Study participants # 13 - # 18 receive dose level 3 of dasatinib (100/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 2 did not experience intolerable side effects. Each treatment course is 29 days.
~Treatment course 1 consists of:
~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5
~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5
~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5
~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines
~Dasatinib orally, once daily on days 6-29
~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
16589697|NCT02680938|Active Comparator|oxytocin group|10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
16589698|NCT02680938|Placebo Comparator|control group|1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
16589699|NCT02680925|Placebo Comparator|Conventional ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
16589700|NCT02680925|Active Comparator|Lung protective ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 6 ml/kg with PEEP 6 cmH2O during two-lung ventilation and TV of 4 ml/kg PEEP 6 cmH2O during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
16589701|NCT02680912|Experimental|Warm needle acupuncture|"Warm needle acupuncture (wenzhen; 温针) is where moxa cones are placed on the handle of the needle, after the needle has been inserted. Once lit, heat transmits along the shaft of the needle to the acupuncture point.
~Moxa refers to the herb mugwort (Artemisia vulgaris) that is burnt to warm specific parts of the body, including acupuncture points."
16589702|NCT02680912|Active Comparator|Basic needle acupuncture|Basic needle acupuncture is the use of acupuncture needles alone, without other methods of stimulation.
16589703|NCT02680899|Experimental|Curricular Intervention|The intervention is a novel science education curriculum in mental health and addiction called My Mind, My Body.
16589704|NCT02680886||Novosyn® Quick|Skin closure using rapid absorbable suture material
16589705|NCT02680873|Other|SASI bypass|sleeve gastrectomy done and gastro-ileum anastomosis 2.5 meter from the ileocecal valve . the anastomosis is less than 3cmm in diameter . the concept to push undigested food early to the ileum to stimulate intestinal hormones secretion to control diabetes .
16589706|NCT02680847|Experimental|ALO-02|One arm, open label, active
16589707|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
16589708|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
16589709|NCT02680821|Other|Isolated ACL-revision|The standard operation with an isolated Anterior cruciate ligament.
16589710|NCT02680821|Other|Combined ACL and ALL surgery|An operation with an Anterior cruciate ligament combined with an anterolateral ligament.
16589711|NCT02680808|Experimental|midazolam with F901318|Pharmacokinetic profile of midazolam 2 mg orally when given after dosing with F901318 to steady state.
16589712|NCT02680795|Experimental|Wild Type UGT1A1|Cohort A: Open for Enrollment Wild Type UGT1A1, Belinostat IV
16589713|NCT02680795|Experimental|Heterozygous UGT1A1*28|Cohort B: Closed For Enrollment Heterozygous UGT1A1, Belinostat IV
16589714|NCT02680795|Experimental|Homozygous UGT1A1*28|Cohort C: Open For Enrollment Homozygous UGT1A1, Belinostat IV
16589715|NCT02680782|Experimental|X4P-001 QD|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
16589716|NCT02680782|Experimental|X4P-001 BID|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
16589717|NCT02680769|Experimental|Magnesium|300 mg of citrate Mg/daily
16589718|NCT02680769|Placebo Comparator|Placebo|placebo group
16589719|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
16589720|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
16589721|NCT02680743|Experimental|Intervention Group|"Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.
~They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.
~Intervention:Education of parents to pursue prompt hearing screening."
16589722|NCT02680730|Experimental|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
16589723|NCT02680730|Experimental|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
16589724|NCT02680717|Active Comparator|Treatment 1|Calcipotriene 0.005% ointment
16589725|NCT02680717|Active Comparator|Treatment 2|Clobetasol 0.05% ointment
16589726|NCT02680717|Active Comparator|Treatment 3|Tacrolimus 0.1% ointment
16589727|NCT02680704|Other|PEEP Titration Arm|PEEP titrated mechanical ventilation
16589728|NCT02680691|Experimental|Robot, then conventional training|Robot assisted gait training 4 weeks after conventional gait training
16589729|NCT02680691|Active Comparator|Conventional, then robot training|Conventional gait training 4 weeks after robot assisted gait training
16589730|NCT02680678|Active Comparator|Colloid preload|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) 15 minutes before spinal anesthesia.
16590640|NCT02674880|Experimental|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
16589731|NCT02680678|Active Comparator|Colloid Co-load|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) beginning with spinal anesthesia.
16589732|NCT02680678|Active Comparator|Crystalloid Preload|20 patients each patient receives 20 ml/kg of Ringer's lactate solution 15 minutes before spinal anesthesia.
16589733|NCT02680678|Active Comparator|Crystalloid Co-load|20 patients each patient receives 20 ml/kg of Ringer's lactate solution beginning with spinal anesthesia.
16589734|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
16589735|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
16589736|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
16589737|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
16589738|NCT02680626|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
16589739|NCT02680626|Active Comparator|Non-magnesium|Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks
16589740|NCT02680613|Experimental|Motivational SMS|This arm will receive 15 motivational SMS about cervical cancer and screening.
16589741|NCT02680613|Experimental|Travel Voucher|This arm will receive a voucher covering return transport from the screening clinic. This arm will also receive identical 15 motivational SMS about cervical cancer and screening as the Motivational SMS arm.
16589742|NCT02680613|No Intervention|Control|This arm will receive standard sensitization during study period (church announcements, screening promotion by key community leaders and posters in community, as well as sensitization by the research assistants conducting the door-to-door household recruitment) during the study and follow-up period. They will also receive one SMS message with the location of screening services during the study period. At the conclusion of the study, participants in the arm will receive identical motivational SMS as the other two arms.
16589743|NCT02680600|Experimental|Study arm|"Cefepime dosing
~Blood sampling
~Urine sampling
~Determination of renal markers
~Population pharmacokinetic modeling
~Covariate screening
~Monte Carlo simulations"
16589744|NCT02680587|Placebo Comparator|Observational (no SBRT)|Evaluating men with oligometastatic prostate cancer lesions randomized to observation
16589745|NCT02680587|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
16589746|NCT02680587|Experimental|DCFPyL-PET/MRI|DCFPyL-PET/MRI or -PT/CT Estimate the proportion of DCFPyL-PET/MRI or -PET/CT positive sites that are positive for new or progressive metastatic disease by bone scan at 6-months from SBRT and vice versa
16589747|NCT02680574|Experimental|vadadustat|
16589748|NCT02680574|Active Comparator|darbepoetin alfa|
16589749|NCT02680561|Experimental|Treatment A: Fp MDPI|Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
16589750|NCT02680561|Experimental|Treatment B: FS MDPI|Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
16589751|NCT02680561|Active Comparator|Treatment C: Comparator|Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
16589752|NCT02680548|Active Comparator|0.9% saline (salt water)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
16589753|NCT02680548|Active Comparator|local anesthetic (freezing)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
16589754|NCT02680548|Active Comparator|local anesthetic (freezing) and steroid|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
16589755|NCT02680535|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to ultrasound-guided laser irradiation using a FDA cleared laser and an interstitial optical fiber.
16589756|NCT02680522|Active Comparator|Control Group|composed of healthy volunteers who underwent training with virtual reality. Exercises with game through virtual reality
16589757|NCT02680522|Experimental|Parkinson's Group|composed of patients with Parkinson's disease and who underwent training with virtual reality. exercises with game through virtual reality
16589758|NCT02680509|Experimental|All|All patient will undergo a unilateral sympathicotomy R3. After this left and right will be compared
16589759|NCT02680496|Experimental|Lokomat - Treadmill - Overground|Walking order: lokomat walking, treadmill walking, overground walking
16589760|NCT02680496|Experimental|Lokomat - Overground - Treadmill|Walking order: lokomat walking, overground walking, treadmill walking
16589761|NCT02680496|Experimental|Treadmill - Lokomat - Overground|Walking order: treadmill walking, lokomat walking, overground walking
16589762|NCT02680496|Experimental|Treadmill - Overground - Lokomat|Walking order: treadmill walking, overground walking, lokomat walking
16589763|NCT02680496|Experimental|Overground - Lokomat - Treadmill|Walking order: overground walking, lokomat walking, treadmill walking
16589764|NCT02680496|Experimental|Overground - Treadmill - Lokomat|Walking order: overground walking, treadmill walking, lokomat walking
16589765|NCT02680483||AF cohort|AF consecutive patients
16589766|NCT02680470|Experimental|Virtual Observed Therapy|Intervention = Virtual observed therapy of participants taking TB therapy
16589767|NCT02680457|Active Comparator|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
16589768|NCT02680457|Active Comparator|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
16589769|NCT02680444|Experimental|Reappraisal-Only Intervention|Participants were instructed to independently practice the Self-Administered Reappraisal-Only Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the positive reappraisal instructions available online. This involved thinking about how one could grow, learn or benefit from the negative event in any way possible.
16589770|NCT02680444|Experimental|Mindful-Reappraisal Intervention|Participants were instructed to independently practice the Self-Administered Mindful-Reappraisal Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the Mindful-Reappraisal instructions available online. This involved thinking about the negative event in an objective, non-judgmental way, then following the Reappraisal-Only instructions, and closing off with a brief mindfulness breathing technique.
16589771|NCT02680444|Active Comparator|Event Recall Active Control|Participants were instructed to independently practice the Self-Administered Event Recall Exercise in the evening for five days. In this condition, participants were only instructed to recall a negative event from that day with no reappraisal exercise.
16589772|NCT02680431||Neurofibromatosis 1|10 mL venous blood sample taken from patients with type 1 neurofibromatosis
16589773|NCT02680431||Control|10 mL venous blood sample taken from age- and gender-matched healthy controls
16589774|NCT02680418|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
16589775|NCT02680418|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
16589776|NCT02680418|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
16589777|NCT02680418|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
16589778|NCT02680418|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
16589779|NCT02680418|Experimental|Multiple dose|Repeat doses of FDL169 to be administered at a dose level to be determined
16589780|NCT02680405||Atopic Dermatitis|Subjects with Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
16589781|NCT02680405||Non Atopic Dermatitis|Subjects with no Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
16589782|NCT02680392|Experimental|Pulsed and Continuous Radiofrequency|In this group of patients undergoing total knee arthroplasty (allocation of patients is randomized), Pulsed radiofrequency (PRF) is applied to the saphenous nerve of the knee, associated to Continuous Radiofrequency (TRF) applied to the genicular nerves of the knee . A sham catheter is inserted in the mid-tigh to simulate a continuous adductor canal block, and connected to an infusion of normal saline (assessor and patient blinded to the treatment)
16589783|NCT02680392|Active Comparator|Continuous adductor canal block|"Continuous Adductor Canal Block
~Continuous adductor canal block is performed in this group of patients, with a catheter infusing ropivacaine 0.2% in the first 48 hours after surgery.
~The solutions bags are labelled in order to make assessor and patients, blinded to the treatment (Ropivacaine vs Normal Saline)"
16589784|NCT02680379|Experimental|Minocycline, then Minocycline/Lovastatin|Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
16589785|NCT02680379|Experimental|Lovastatin, then Minocycline/Lovastatin|Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months
16589786|NCT02680366|Experimental|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
16589787|NCT02680366|Active Comparator|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
16589788|NCT02680353|Active Comparator|Study group|Patients received bilateral superficial cervical plexus block before operation
16589789|NCT02680353|No Intervention|Control group|Patients received no intervention before operation
16589790|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
16589791|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
16589792|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
16589793|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
16589794|NCT02680288|Placebo Comparator|Oral Placebo|Oral inert treatment
16589795|NCT02680288|Experimental|Active Treatment, Low-Dose|Lorcaserin 10 mg, single dose
16589796|NCT02680288|Experimental|Active Treatment, High-Dose|Lorcaserin 20 mg, single dose
16589797|NCT02680275|Experimental|Doxycycline,Dead Sea Peloid Gel,placebo|"Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally
~Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally"
16589798|NCT02680262|Experimental|Intervention group 1|HPV self-sampling kit mailed directly
16589799|NCT02680262|Experimental|Intervention group 2|HPV self-sampling kit on demand
16589800|NCT02680262|Experimental|Intervention group 3|second reminder
16589801|NCT02680249|Experimental|CTP-656 Fed, low fat|Single dose of CTP-656 150 mg administered after a low-fat breakfast
16589802|NCT02680249|Experimental|CTP-656 Fasted|Single dose of CTP-656 150 mg administered fasted
16589803|NCT02680249|Experimental|CTP-656 Fed, high fat|Single dose of CTP-656 150 mg administered after a moderate-fat breakfast
16589804|NCT02680236||Breast Cancer Patients|"This pilot study proposes to explore the effect of art therapy on breast cancer patients' perception of pain, and its impact on daily functioning by offering four sessions of individual art therapy, spaced between one to three weeks apart.
~The study will be open to breast cancer patients over the age of 18, who have been assessed by the Royal Marsden (RM) Pain Team, and who report having persistent post treatment pain of at least moderate intensity for the preceding two weeks despite having been optimally treated for their pain already, and who fulfil the inclusion criteria."
16589805|NCT02680223|Active Comparator|Precision tinted lenses|Precision tinted lenses will be provided for one month.
16589806|NCT02680223|Sham Comparator|Non-beneficial tinted lenses|Tinted lenses at a colour different from but not easily distinguishable from the precision tinted will be provided for one month.
16589807|NCT02680210|Other|cognitive measures and questionnaires|the material of the study will consist of cognitive measures and questionnaires in order to (1) compare the cognitive performances and behavioral manifestations between patients with TBI and volunteers without neurological disorders and (2) to analyze the links between cognitive and behavioural measures in the TBI population
16589808|NCT02680197|Experimental|CHF5259 12.5 μg total daily dose|"CHF5259 or Placebo administration:
~Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
16589809|NCT02680197|Experimental|CHF5259 25 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
16589810|NCT02680197|Experimental|CHF5259 50 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
16589811|NCT02680197|Experimental|CHF5259 100μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day
~Interventions :
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
16589812|NCT02680197|Placebo Comparator|CHF5259 matched Placebo BID|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day
~Interventions :
~Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
16589813|NCT02680184|Experimental|Part 1: Dose-Escalation - CMP-001 and Pembrolizumab|Participants will receive up to 5 escalating dose levels (1 milligram [mg], 3 mg, 5 mg, 7.5 mg and 10 mg) of CMP-001 via intratumoral injection according to one of 2 schedules (Schedule A: once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued; Schedule B: once weekly for 2 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule.
16589814|NCT02680184|Experimental|Part 1: Dose-Expansion - CMP-001 and Pembrolizumab|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
16589815|NCT02680184|Experimental|Part 2: CMP-001 Monotherapy and Crossover to Combination|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses <10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
16589816|NCT02680171|Experimental|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
16589817|NCT02680171|Sham Comparator|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
16589818|NCT02680158|Experimental|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
16589819|NCT02680158|Experimental|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
16589820|NCT02680158|Experimental|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
16589821|NCT02680158|Experimental|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
16589892|NCT02679729|Experimental|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589822|NCT02680158|Experimental|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
16589823|NCT02680158|Experimental|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
16589824|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
16589825|NCT02680132|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
16589826|NCT02680132|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
16589827|NCT02680119|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
16589828|NCT02680119|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
16589829|NCT02680106|Experimental|SPINNER|All patients in this arm will be treated with the SPINNER dressing.
16589830|NCT02680106|Active Comparator|JELONET|All patients in this arm will be treated with JELONET dressing, regarded as the standard of current care for split-skin donor-site wounds.
16589831|NCT02680093||Cervical length in pregnant women.|"Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up. will be followed while coming to routine monitoring.
~physiological parameter of cervical length will be measured as the differential predictor to determine their due date."
16589832|NCT02680080|Active Comparator|Positive control group|"subjects will receive a single 400 mg tablet of Moxifloxacin - the most commonly used positive control in thorough QTc (TQT) studies. Subjects will be continuously recorded by a Holter monitor for 24 hours"
16589833|NCT02680080|Active Comparator|Grapefruit group|subjects will drink one liter of fresh pink-grapefruit juice as fast as possible. The pink-grapefruit juice will be squeezed in the morning of the experiment in the cardiology department. ECG will be performed immediately pre dose and at 1, 2, 3, 4, 6, 8, 12, 24 after fresh pink-grapefruit juice administration. In addition, subjects will be continuously recorded by a Holter monitor for 24 hours
16589834|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
16589835|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
16589836|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
16589837|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
16589838|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
16589839|NCT02680041|Experimental|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
16589840|NCT02680028|Active Comparator|Standard length intramedullary nail|220mm intramedullary nail
16589841|NCT02680028|Experimental|Short length intramedullary nail|175mm intramedullary nail
16589842|NCT02680015|Experimental|Experimental Group|Immediate enrollment in the PEERS group.
16589843|NCT02680015|No Intervention|Waitlist Group|Research measures while waiting for PEERS; will receive PEERS within one year.
16589844|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
16589845|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
16589846|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
16589847|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
16589848|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
16589849|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
16589850|NCT02679989|Experimental|Intermittent Energy Restriction|Weight loss intervention: Intermittent Energy Restriction
16589851|NCT02679989|Active Comparator|Continuous Energy Restriction|Weight loss intervention: Continuous Energy Restriction
16589852|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
16589853|NCT02679963|Experimental|Maintenance Olaparib|Olaparib (experimental arm): 600 mg daily (2 doses of 300 mg (2*2 tablets of 150 mg) taken approximately 12 hours apart) po, administered until disease progression or toxicity requiring its interruption. Olaparib has to be started no later than 6 weeks after the last administration of induction chemotherapy, and no later than 3 weeks after the CT scan confirming response to induction chemotherapy
16589854|NCT02679963|Placebo Comparator|Placebo|Placebo (control arm): 2 doses of 300 mg per day (2*2 tablets of 150 mg) taken approximately 12 hours apart
16589855|NCT02679950||Initial diagnosis|The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
16589856|NCT02679950||Late relapse|"The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse.
~Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department."
16589857|NCT02679937|Experimental|Fit4Duty|6-week weight gain prevention group
16589858|NCT02679937|Active Comparator|Nutrition Education|Two, 50 minute educational videos.
16589859|NCT02679924|Experimental|Restylane Silk|Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
16589860|NCT02679924|Sham Comparator|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
16589861|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
16589862|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
16589863|NCT02679898|No Intervention|Lean Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
16589864|NCT02679898|No Intervention|Overweight/Obese Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
16589865|NCT02679898|Experimental|Unloaded-Whole Body Vibration (WBVT)|Lower-body exercise training on a vibration platform
16589866|NCT02679898|Experimental|Loaded-Whole Body Vibration (WBVT)|Externally loaded lower-body exercise training on a vibration platform
16589867|NCT02679872||VATS team 1|Video-assisted thoracoscopic surgery team, from institution/hospital 1.
16589868|NCT02679872||VATS team 2|Video-assisted thoracoscopic surgery team, from institution/hospital 2.
16589869|NCT02679872||VATS team 3|Video-assisted thoracoscopic surgery team, from institution/hospital 3.
16589870|NCT02679872||VATS team 4|Video-assisted thoracoscopic surgery team, from institution/hospital 4.
16589871|NCT02679859|Experimental|B-type natriuretic guided medical therapy optimisation|B-type natriuretic guided medical therapy optimisation
16589872|NCT02679859|No Intervention|Normal medical management|
16589873|NCT02679846|Experimental|Standardized protocol of AEDs withdrawal|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
16589874|NCT02679846|No Intervention|Current practice|Centers will continue their current practice
16589875|NCT02679833|Placebo Comparator|Placebo|A toothpaste, with the same matrix, all components, and appearance like the active arm but not containing vitamin B12.
16589876|NCT02679833|Active Comparator|Cyanocobalamin|A toothpaste with cyanocobalamin 100 µg cyanocobalamin per 1 g.
16589877|NCT02679820|Experimental|PostPlacental IUD insertion|Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries.
16589878|NCT02679820|No Intervention|Control|IUD will be offered as a method of contraception after puerperium
16589879|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
16589880|NCT02679807|Placebo Comparator|Placebo|sucrose
16589881|NCT02679794|Experimental|Egg consumption|Consuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
16589882|NCT02679794|Placebo Comparator|Control|Consuming sautéed vegetables and 3g canola oil without eggs
16589883|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
16589884|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
16589885|NCT02679768|Active Comparator|Circadian Reinforcement Therapy|Circadian reinforcement therapy
16589886|NCT02679768|Placebo Comparator|Standard treatment|Standard treatment
16589887|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
16589888|NCT02679742|Experimental|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program
16589889|NCT02679742|Placebo Comparator|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program
16589890|NCT02679729|Experimental|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589891|NCT02679729|Experimental|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589893|NCT02679729|Experimental|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589894|NCT02679729|Experimental|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589895|NCT02679729|Experimental|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589896|NCT02679729|Experimental|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
16589897|NCT02679729|Experimental|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
16589898|NCT02679716|Other|study group|MRI of the cerebral arteries ist performed
16589899|NCT02679703|Experimental|High voltage|The applied parameters of high voltage electrical stimulation are medium voltage of 100 volts, an increase in the course of the session, frequency of 10 Hz, with application in the donor areas of thigh or scalp for 40 minutes, 25% above of level engine daily until complete epithelialization, and removal of the dressing type rayon.
16589900|NCT02679703|Experimental|Neuromuscular transcutaneous electrical stimulation (TENS)|10 Hz, 40 min, 200 μs and 25% above of motor level
16589901|NCT02679703|Experimental|Control Group|There will be no intervention
16589902|NCT02679690|Experimental|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
16589903|NCT02679690|Experimental|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
16589904|NCT02679677|Sham Comparator|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
16589905|NCT02679677|Experimental|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
16589906|NCT02679664|Experimental|Treatment group|20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
16589907|NCT02679664|No Intervention|Control group|Standard medical care only. No rosuvastatin group.
16589908|NCT02679651||Control group|Healthy Adults without foot pain
16589909|NCT02679651||DIsease group|Adults diagnosed with fat pat atrophy and report symptoms of foot pain and have participated in clinical trial to treat fat pad atrophy.
16589910|NCT02679638||Kaplan Hospital|Breast cancer survivors recruited at the Kaplan Medical Center
16589911|NCT02679638||Rambam Hospital|Breast cancer survivors recruited at the Rambam Medical Center
16589912|NCT02679638||Sheba|Breast cancer survivors recruited at the Sheba Medical Center
16589913|NCT02679638||Barzilai|Breast cancer survivors recruited at the Barzilai Medical Center
16589914|NCT02679599|Other|Cardiac rehabilitation as usual|Participants will receive cardiac rehabilitation as usual (i.e., as offered in the clinical setting).
16589915|NCT02679599|Experimental|Cardiac rehabilitation plus B-MOBILE-CARDIAC smartphone app|Participants will receive cardiac rehabilitation as usual, plus access to the B-MOBILE-CARDIAC smartphone application through 4 weeks post-rehabilitation.
16589916|NCT02679586|Experimental|Diffusion weighted MRI Group|"All patients will receive a double baseline diffusion weighted MRI (performed on the same day as the Baseline MRI).
~Patients participating in Part I will receive another MRI approximately 1 week (day 8-11) after the first dose of Chemotherapy (chemotherapy will be determined by the treating physician and is not assigned as part of this trial).
~Patients participating in Part II will receive a single MRI 1-2 weeks after the first dose of Chemotherapy A (chemotherapy will be determined by the treating physician and is not assigned as part of this trial). A second MRI will be repeated within 2 weeks prior to the start of Chemotherapy B."
16589917|NCT02679573|Experimental|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
16589918|NCT02679573|Active Comparator|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
16589919|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
16589920|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
16589921|NCT02679547||Appendicitis|The patients with appendicitis
16589922|NCT02679547||Control|The participants without appendicitis
16589923|NCT02679534|Experimental|hand massage|"Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice do not disturb, and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand."
16589924|NCT02679534|Active Comparator|hand holding|The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
16589955|NCT02679300|Experimental|Virtual reality group|During a single intervention session, participants will perform 2 sets of 2 minutes of pelvic tilt exercises using serious games. These serious games have to be controlled by pelvic tilts. Patients will perform the exercises in a standing position in front a TV-screen, on which the games will be displayed. Wireless motion sensors will be mounted to the patient's spine and pelvis to track the movements of the pelvis.
16589925|NCT02679534|Other|rest group|The passive control group will have a 20 minutes rest period including the same environmental adjustments as the massage and hand holding groups in addition to the standard care administered in the ICU. The standard care includes the pharmacological and non-pharmacological treatments used to promote recovery and symptom relief. In the study ICU, cardiac surgery patients are automatically prescribed a pain management protocol that includes the regular administration of morphine, unless extraordinary patient circumstances require different prescriptions. Patients might equally receive breakthrough doses of analgesia in addition to regular opioids. Of the existing non-pharmacological interventions, repositioning and back rubs are commonly employed in the study ICU to provide patient comfort.
16589926|NCT02679521|Active Comparator|rESWT|Radial extracorporeal shock wave therapy (rESWT).
16589927|NCT02679521|Placebo Comparator|Placebo|Placebo treatment.
16589928|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
16589929|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
16589930|NCT02679495|Active Comparator|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
16589931|NCT02679495|No Intervention|No intervention|No meassures are taken to change life style of enrolled patients.
16589932|NCT02679482||Selective laser trabeculoplasty (SLT)|Patients who underwent to Selective laser trabeculoplasty
16589933|NCT02679482||Pattern laser trabeculoplasty (PLT)|Patients who underwent to Pattern laser trabeculoplasty
16589934|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
16589935|NCT02679456|Active Comparator|Treatment Group 1 (Fluconazole)|Fluconazole
16589936|NCT02679456|Experimental|Treatment Group 2: (SCY-078)|Dose regimen 1
16589937|NCT02679456|Experimental|Treatment Group 3 (SCY-078)|Dose regimen 2
16589938|NCT02679443|No Intervention|Delayed Arm|Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
16589939|NCT02679443|Experimental|Immediate Arm|Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
16589940|NCT02679430|Other|Prostate Arterial Embolization|"Intervention: Patients will undergo prostatic artery embolization.
~The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms."
16589941|NCT02679417|Active Comparator|aerobic exercise|Each participant reach a minimum of 50 minutes of some form of aerobic exercise including running on a treadmill 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
16589942|NCT02679417|Active Comparator|resistant exercise|Each participant reach a minimum of 50 minutes of some form of strength training involving repetitions of a resistance training exercise for each major muscle group at an intensity for at least 60% of a one-repetition max, 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
16589943|NCT02679391||A|69 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2011. All post weight loss. , 96% female, BMI by the time of operation 26, mean age 41 (SD 9.5). Their mean weight loss in BMI units: 17.8 (SD 5.12).
16589944|NCT02679391||B|70 consecutive operated patients by plastic surgeons at Karolinska University Hospital 2010-2012. All post weight loss. 86% female, BMI by the time of oepration 26, mean age 38.6 (SD 11.4). Their mean weight loss in BMI units: 17.4 (SD 4.8).
16589945|NCT02679391||C|70 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2013-2014. All post weight loss. 90% female, BMI by the time of operation 26, mean age 46.8 (SD 10.1). Their mean weight loss in BMI units: 16.3 (SD 5.11)
16589946|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
16589947|NCT02679365|Experimental|group a|This arm will have lower segment cesarean section done with double locking technique for closure of Rectus Sheath.
16589948|NCT02679365|Active Comparator|group b|This arm will have lower segment cesarean section done with continuous non-locking technique for closure of rectus sheath.
16589949|NCT02679352|Experimental|SMR stemless|Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
16589950|NCT02679339|Experimental|CNTX-2022 (lidocaine gel, 40%)|Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
16589951|NCT02679339|Placebo Comparator|Placebo|Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
16589952|NCT02679326|Experimental|study group|will receive stretching guidance and high level active Ultrasound
16589953|NCT02679326|Placebo Comparator|control group|will receive stretching guidance and very low level of Ultrasound
16589954|NCT02679313|Experimental|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit).
16589956|NCT02679300|Active Comparator|Control group|During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
16589957|NCT02679287|Experimental|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
~SAP=sensor-augmented pump only
~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
16589958|NCT02679287|Experimental|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
~SAP=sensor-augmented pump only
~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
16589959|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
16589960|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
16589961|NCT02679261|Experimental|Atorvastatin|Oral administration Atorvastatin 20 mg per day
16589962|NCT02679261|Placebo Comparator|Control|Oral administration of Placebo
16589963|NCT02679248|Experimental|Neo40 Daily®|
16589964|NCT02679248|Experimental|Placebo|
16589965|NCT02679235|Experimental|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
16589966|NCT02679222|Experimental|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
16589967|NCT02679209|Experimental|Bone allograft|commercially available demineralized bone matrix putty allograft will be used to fill in the defect after opening a periodontal flap
16589968|NCT02679209|Experimental|Amnion chorion membrane|Amnion chorion commercially available allograft bioresorbable membrane as a guided tissue regeneration technique will be used to in the defect after opening a periodontal flap
16589969|NCT02679196|Experimental|KA2237|Open label treatment with KA2237
16589970|NCT02679183|Placebo Comparator|Control 0|No Intervention. This group received Premature Milk Formula. This group did not receive any Medically-Graded Honey.
16589971|NCT02679183|Experimental|Group 1|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 5 gram/day) for 2 weeks
16589972|NCT02679183|Experimental|Group 2|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 10 gram/day) for 2 weeks
16589973|NCT02679183|Experimental|Group 3|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 15 gram/day) for 2 weeks
16589974|NCT02679170||Routine clinical practice group (NSCLC ALK+, ROS1)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1
16589975|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
16589976|NCT02679131|Experimental|Cohort A|Normal Renal function, Belinostat IV, Dose A
16589977|NCT02679131|Experimental|Cohort B|Mild Impairment, Belinostat IV, Dose A
16589978|NCT02679131|Experimental|Cohort C|Moderate Impairment, Belinostat IV, Dose B
16589979|NCT02679131|Experimental|Cohort D|Severe Impairment, Belinostat IV, Dose B
16589980|NCT02679118|Experimental|Sentire|The patients will undergo their laparoscopic gastric bypass, during the operative period at pre-defined time points, a small amount of gas from the abdomen will be withdrawn and analyzed for the device. The laparoscopic gastric bypass will proceed without interference or effect from the device.
16589981|NCT02679105|Placebo Comparator|ALK diluent|Human albumin
16589982|NCT02679105|Active Comparator|ALK Alutard birch or 5-grasses|Grass pollen suspension or birch pollen suspension
16589983|NCT02679092|Active Comparator|Dilapan (14wks 0days-15wks, 6days)|The clinician will place 1 to 2 osmotic cervical dilators (Dilapan-S) (4mm x 65mm) the day before the participant's procedure.
16589984|NCT02679092|Active Comparator|Dilapan (16wks 0days-18wks, 6days)|The clinician will place 3 to 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
16589985|NCT02679092|Experimental|Mifepristone (14wks 0days-15wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
16589986|NCT02679092|Experimental|Mifepristone (16wks 0days-18wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
16589987|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
16589988|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
16589989|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
16589990|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
16589991|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
16589992|NCT02679053|Experimental|Exercise (IG)|Aerobic exercise three times per week on indoor bicycles at 60 to 75% of maximal heartrate aiming at a weekly total of 17.5kcal/kg bodyweight for 6 consecutive weeks. The exercise will take place under supervision. At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
16589993|NCT02679053|Placebo Comparator|Control (CG)|Basic stretching and mobilisation program 3 times per week each for approx. 40 minutes, also under supervision for 6 consecutive weeks. At the end of every week physical fitness is evaluated by the queens step test.At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
16590641|NCT02674880|Placebo Comparator|Placebo|5 ml of saline via nebulizer b.i.d.
16589994|NCT02679040|Experimental|Immediate Mammary Reconstruction|Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction
16589995|NCT02679027|Active Comparator|Easy intubation|Intubation difficulty score <5
16589996|NCT02679027|Active Comparator|Difficult intubation|Intubation difficulty score >5
16589997|NCT02679014|Placebo Comparator|Placebo|Participants will receive placebo capsules (2 capsules) twice daily for 28 days.
16589998|NCT02679014|Experimental|RO5459072|Participants will receive RO5459072 100 milligrams (mg) capsules (2*50 mg capsules) twice daily for 28 days.
16589999|NCT02679001||RA participants treated with a TNF inhibitor or TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.
16590000|NCT02678988|Experimental|A1: Tocilizumab AI followed by PFS-NSD in abdomen|Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
16590001|NCT02678988|Experimental|A2: Tocilizumab AI followed by PFS-NSD in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
16590002|NCT02678988|Experimental|A3: Tocilizumab AI followed by PFS-NSD in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
16590003|NCT02678988|Experimental|B1: Tocilizumab PFS-NSD followed by AI in abdomen|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
16590004|NCT02678988|Experimental|B2: Tocilizumab PFS-NSD followed by AI in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
16590005|NCT02678988|Experimental|B3: Tocilizumab PFS-NSD followed by AI in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
16590006|NCT02678975|Active Comparator|Control|Alkylating chemotherapy
16590007|NCT02678975|Experimental|Experimental|Alkylating chemotherapy + disulfiram + copper
16590008|NCT02678962|Active Comparator|SN6AD1 group|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
16590009|NCT02678962|Active Comparator|SBL-3 group|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
16590010|NCT02678962|Active Comparator|LS-313 MF30 group|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
16590011|NCT02678962|Active Comparator|AT LISA tri 839 MP group|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
16590012|NCT02678962|Active Comparator|ART group|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
16590013|NCT02678962|Active Comparator|LS-313 MF30T group|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
16590014|NCT02678949|Experimental|Inhaled Fluticasone 50 mcg/twice day|Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
16590015|NCT02678949|Experimental|Inhaled Fluticasone 100 mcg/twice day|Group 3;Inhaled fluticasone. 100 mcg/twice day for a period of 4 weeks
16590016|NCT02678949|Experimental|Inhaled Albuterol|Group 2 and group 3, inhaled albuterol one dose of 400 mcg.
16590017|NCT02678936|Experimental|PRP|The operation will be performed with application of platelet rich plasma
16590018|NCT02678936|No Intervention|non-PRP|The operation will be performed without addition of platelet-rich plasma
16590019|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
16590020|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
16590021|NCT02678910|Experimental|Ovarian Cryopreservation|Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use.
16590022|NCT02678897|No Intervention|Pain management in early pregnancy MTOP|Patients in early pregnancy (pregnancy weeks <9weeks) undergoing medical termination of pregnancy gets Ibuprofen (tbl 600mg 3 times a day) and Paracetamol (tbl 1000mg 3 times a day).
16590023|NCT02678897|Experimental|Patient controlled analgesia (PCA)|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.
~Patients get pain medication (Oxynorm) via PCA"
16590024|NCT02678897|Active Comparator|Oxynorm on-demand|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.
~Patients get extra pain medication (Oxynorm) on-demad from the nurse."
16590025|NCT02678884|Experimental|HNSCC Patients receiving RT|
16590026|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
16590027|NCT02678858|Experimental|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) shall target expressive and interactional behavior skills together with those social cognitive domains (facial and prosodic affect recognition, social perception, theory-of-mind) known to be most impaired (Savla, 2012) and most closely associated with functional outcome (Fett, 2012) in schizophrenia.
16590028|NCT02678858|Active Comparator|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Therapy (NCRT) shall target impairments in attention, memory, and executive functions as an active comparator to the ISST.
16590029|NCT02678845|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
16590030|NCT02678845|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
16590031|NCT02678832||Cancer patients|
16590032|NCT02678832||Physicians|
16590033|NCT02678832||Oncology nurses|
16590034|NCT02678819|Experimental|Digital Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid during anesthesia and intensive care crises management.
16590035|NCT02678819|No Intervention|No digital aid|Anesthesia and intensive care crises managed without any cognitive aid.
16590036|NCT02678806|Experimental|Postoperative radiotherapy group|Patients hospitalized in Affiliated Tumor Hospital of Guangxi Medical University from 1st November 2017, who were diagnosed as BCLC-A stage hepatocellular carcinoma, accepted hepatocellular carcinoma resection, pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule < 1cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction were selected and received margin postoperative radiotherapy.
16590037|NCT02678806|Active Comparator|Postoperative TACE group|
16590038|NCT02678793|Other|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
16590039|NCT02678780|Experimental|Cohort A|"Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.
~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)"
16590040|NCT02678780|Experimental|Cohort B|Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
16590041|NCT02678767|Experimental|HIV+ with neurocognitive disorder|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
16590042|NCT02678767|Active Comparator|HIV+ without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
16590043|NCT02678767|Active Comparator|HIV- without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
16590044|NCT02678741|Active Comparator|No clinical response|No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy
16590045|NCT02678741|Active Comparator|Develop PD|Develop PD after initial clinical response to CPI monotherapy
16590046|NCT02678741|Active Comparator|Stable Disease|Stable disease for at least 6 months on CPI monotherapy
16590047|NCT02678728|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12hr of aortic cross clamp off
16590048|NCT02678728|Placebo Comparator|Normal saline|IV loading and infusion of same volume of normal saline after induction until 12hr of aortic cross clamp off
16590049|NCT02678715|Experimental|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
16590050|NCT02678715|Experimental|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
16590051|NCT02678715|Experimental|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
16590052|NCT02678715|Experimental|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
16590053|NCT02678715|Experimental|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
16590054|NCT02678715|Experimental|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
16590055|NCT02678702|Experimental|CBT-I|Behavioral intervention: CBT-I
16590056|NCT02678702|Active Comparator|Treatment as usual|Intervention: Control group receiving treatment as usual
16590058|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
16590059|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
16590060|NCT02678663|Experimental|Injection-assisted cold snare polypectomy (I-CSP)|Polyps in this group will be resected with the cold snare technique after pre-lift of the lesion with a submucosal injection of methylene blue-tinted normal saline solution. The polyp and a small rim of normal tissue will be then snared closely and removed in a single piece without the use of electrocautery.
16590061|NCT02678663|Active Comparator|Endoscopic mucosal resection (EMR).|"Polyps in this group will be removed in a single piece by using an inject-and-cut EMR technique. Methylene blue-tinted normal saline solution will be injected into the submucosal space followed by the application of snare cautery for lesion resection."
16590062|NCT02678650|Experimental|volatile anesthetics group|10min after intubation, begin to sevoflurane wash-in / wash-out operation: sevoflurane administration was interrupted for at least 10 min, by washout with a high fresh gas flow (10 l/min) to achieve a MAC value below 0.2. Following the interruption, sevoflurane was again washed in with a high fresh gas flow (6 l/min) to achieve 1 MAC end-tidal concentration as soon as possible, and repeated twice periods of 10 minutes. Discontinuation of the halogenated agent for at 15 minutes during the last wash out time.
16590063|NCT02678650|Placebo Comparator|propofol intravenous anesthesia group|propofol infusion 3-5μg / kg / h
16590064|NCT02678624|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
16590065|NCT02678624|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
16590066|NCT02678611|Experimental|Basis 250|
16590067|NCT02678611|Experimental|Basis 500|
16590068|NCT02678611|Placebo Comparator|Placebo|
16590069|NCT02678598||Micafungin group|
16590070|NCT02678585|Active Comparator|Nalbuphine|53 patients received intravenous regional lidocaine plus Nalbuphine
16590071|NCT02678585|Other|Control group|53 patients received intravenous regional lidocaine
16590072|NCT02678572|Experimental|Melphalan/HDS|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
16590073|NCT02678559|Experimental|TEE monitory system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
16590074|NCT02678559|Experimental|mini-invasive monitoring system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
16590075|NCT02678546||patients in outpatients departments|patients from outpatients departments in teaching hospital
16590076|NCT02678546||General|participants from center of continuing education in China Medical University
16590077|NCT02678533|Experimental|Fanconi anemia|G-CSF and Plerixafor
16590078|NCT02678520|Experimental|3-D conformal radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using a 3-D conformal radiation technique (3-D CRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
16590079|NCT02678520|Active Comparator|Intensity modulated radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using intensity modulated radiation therapy (IMRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
16590080|NCT02678507||Patients with chronic pain on opioids|
16590081|NCT02678494|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
16590082|NCT02678481|Experimental|MR-targeted biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.
16590083|NCT02678481|Experimental|TRUS-guided biopsy|Patients of arm B receive a saturation TRUS-guided prostate biopsy.
16590084|NCT02678468||high-risk group|children with birth history of pre-term, low birth weight children with develop delay
16590085|NCT02678468||normal group|children with normal birth history and normal development
16590086|NCT02678455|Experimental|TV005 vaccine|Participants will receive one dose of TV005 vaccine at study entry (Day 0).
16590087|NCT02678455|Placebo Comparator|Placebo|Participants will receive one dose of placebo at study entry (Day 0).
16590088|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
16590089|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
16590090|NCT02678429|Active Comparator|DBS programming, standard of care|DBS settings determined from the standard Neurologist symptomatic response, first
16590091|NCT02678429|Experimental|DBS progamming from Atlas|DBS settings determined from the a functional atlas only,first
16590092|NCT02678416|Experimental|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
16590093|NCT02678416|Experimental|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
16590094|NCT02678416|Experimental|Placebo|All participants receive placebo as one of 4 interventions in random sequence
16590095|NCT02678416|Experimental|Morphine|All participants receive morphine as one of 4 interventions in random sequence
16590096|NCT02678403|Experimental|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
16590097|NCT02678403|Sham Comparator|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
16590164|NCT02677922|Experimental|Subcutaneous (SC) azacitidine|Subjects with either an IDH1 or IDH2 mutation will receive azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
16590189|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
16590098|NCT02678390|Experimental|Healthy women|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.
~Interventions:
~A control day with no MCT and no aerobic exercise.
~A 5 day consecutive MCT intake of 30 g/day.
~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.
~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
16590099|NCT02678390|Experimental|Women with prediabetes|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.
~Interventions:
~A control day with no MCT and no aerobic exercise.
~A 5 day consecutive MCT intake of 30 g/day.
~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.
~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
16590100|NCT02678377|Active Comparator|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
16590101|NCT02678377|Sham Comparator|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
16590102|NCT02678364|Placebo Comparator|Control egg group|Two or less control (non-biofortified) eggs per week
16590103|NCT02678364|Active Comparator|Vitamin D3-eggs group|Seven vitamin D3-biofortified eggs per week
16590104|NCT02678364|Active Comparator|25-Hydroxyvitamin D-eggs group|7 25-hydroxyvitamin D-biofortified eggs per week
16590105|NCT02678351|Experimental|Diagnostic (68Ga-PSMA PET/MRI)|Patients receive 68Ga-PSMA IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
16590106|NCT02678338|Experimental|Hu5F9-G4|Dose Escalation: CD47 blocking antibody Hu5F9-G4
16590107|NCT02678325|Active Comparator|Standardized normal protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 20% of the total caloric intake
16590108|NCT02678325|Experimental|Standardized high protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 33% of the total caloric intake
16590112|NCT02678299|Experimental|Treatment|
16590113|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
16590114|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
16590115|NCT02678273|Experimental|Intervention group|Intervention
16590116|NCT02678273|No Intervention|Control group|Standard care when patient is in the hospital. At discharge, patients may be referred to community services as deemed necessary by the hospital team. This is not restricted.
16590117|NCT02678260|Experimental|PDR001|PDR001 will be administered i.v. every two weeks until a patient experiences unacceptable toxicity, progressive disease as per irRC and/or treatment is discontinued at the discretion of the investigator or the patient. The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and evaluations, a treatment cycle will consist of 28 days. During the study, cohorts of patients will be treated with PDR001 until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
16590118|NCT02678247|Active Comparator|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
16590119|NCT02678247|Active Comparator|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
16590120|NCT02678234|Experimental|Theraflu Aktiv powder for oral solution|Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
16590121|NCT02678234|No Intervention|No Treatment|Participants in this arm will not receive any medication
16590122|NCT02678221|Active Comparator|Sildenafil citrate with Aspirin|will receive sildenafil citrate 20mg ̸ 8hours plus low dose aspirin 150mg/day
16590123|NCT02678221|Other|placebo with Aspirin|will receive placebo plus low dose aspirin 150mg/day
16590124|NCT02678208|Active Comparator|Tranexamic acid|received tranexamic acid containing 1 g/10mL tranexamic acid diluted with 20 mL of 5% glucose over a 5 minute period
16590125|NCT02678208|Other|placebo|received 30 mL of 5% glucose over the same period of time.
16590126|NCT02678195|Experimental|3 days amoxicillin + 2 days placebo|3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
16590127|NCT02678195|Active Comparator|5 days amoxicillin|5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
16590128|NCT02678182|No Intervention|A1: Surveillance|Patients in this Arm will follow current UK standard of care for this setting and will be reviewed every 4 weeks
16590129|NCT02678182|Experimental|Arm A2: Capecitabine Maintenance|1250 mg/M2/DAY on days 1-21
16590130|NCT02678182|Experimental|Arm A3: MEDI4736 (Durvalumab)|IV treatment on day 1 +15, on a 28 day cycle.
16590131|NCT02678182|Active Comparator|Arm B1: Trastuzumab Maintenance|6mg/kg on day 1 every 21 days
16590132|NCT02678182|Experimental|Arm A4: Rucaparib|600mg PO twice daily
16590133|NCT02678182|Experimental|Arm A5: Capecitabine and Ramucirumab|capecitabine 1250 mg/m2/day PO in two divided doses continuously from days 1-21 of each 21 day cycle (see section 12) and ramucirumab 8mg/kg IV day 1 and day 8
16590134|NCT02678169||Penumbra Aspiration System|Penumbra Aspiration System with the ADAPT technique
16590135|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
16590137|NCT02678130|Active Comparator|InterFuse Group|Patients are randomized based on last digit (odd) of social security number to be treated with an InterFuse T device
16590138|NCT02678130|Active Comparator|Control Group: Standard of care TLIF|treated with a standard of care TLIF (Transforaminal Lumbar Interbody Fusion) device (e.g. Stryker's AVS Unilif)
16590139|NCT02678117|Active Comparator|Pregabalin & placebo|: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
16590140|NCT02678117|Active Comparator|Magnesium sulphate & Placebo|will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
16590141|NCT02678117|Active Comparator|Pregabalin & Magnesium sulphate|: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
16590142|NCT02678117|Placebo Comparator|Placebo|will receive placebo medications at the same time and route of administration of other groups.
16590143|NCT02678104|Experimental|Chlorhexidine mouth wash|Tooth extraction. The patients will start using Chlorhexidine mouthwash on 2nd day of extraction twice daily for 7 days.
16590144|NCT02678104|Experimental|Manuka Honey|intra-alveolar application of Manuka Honey after tooth extraction.
16590145|NCT02678091|Experimental|Patients|Patients with an orbital mass
16590146|NCT02678065|Experimental|InPact Admiral|Patients treated with the InPact Admiral balloon for popliteal lesions
16590147|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
16590148|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
16590149|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.
~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
16590150|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.
~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
16590151|NCT02678026|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early).
~Women will receive pessary soon after UIC"
16590152|NCT02678026|No Intervention|No intervention|No treatment
16590153|NCT02678013|Experimental|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
16590154|NCT02678013|Active Comparator|RFA+CTL|RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
16590155|NCT02678000|Experimental|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.
~For Part 2, patients will receive LHW090 once daily for 4 weeks."
16590156|NCT02678000|Placebo Comparator|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
16590157|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
16590158|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
16590159|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
16590160|NCT02677948|Experimental|Pacritinib and Ibrutinib|"Phase I: Patients will receive Pacritinib 100-200 mg twice daily along with Ibrutinib 420mg/day.
~Phase II Lead-In: Pacritinib at MTD daily continuous x 2 months followed by Pacritinib at MTD twice daily along with Ibrutinib 420mg/day."
16590161|NCT02677935|Experimental|Intervention|community support program
16590162|NCT02677922|Experimental|Oral AG-120 + Subcutaneous (SC) azacitidine|Subjects with an IDH1 mutation will receive AG-120 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
16590163|NCT02677922|Experimental|Oral AG-221 + Subcutaneous (SC) azacitidine|Subjects with an IDH2 mutation will receive AG-221 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
16590165|NCT02677896|Experimental|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received enzalutamide orally once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
16590166|NCT02677896|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
16590167|NCT02677883|Experimental|Arm I: Manometry-guided thoracentesis|Intervention Group - Patients undergo fine needle- aspiration, called therapeutic thoracentesis, to drain fluid accumulated around the lung. Unlike Arm II, the intervention group will have their pleural pressure monitored during the procedure.
16590168|NCT02677883|Active Comparator|Arm II: Symptom-guided thoracentesis|Comparison Group - Patients undergo symptom-guided thoracentesis, the current standard-of-care is to drain fluid until 1) it is all gone or 2) a symptom occurs that indicates the lung may take longer to fully re-expand and drainage should be stopped.
16590169|NCT02677870|Other|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
16590170|NCT02677870|Active Comparator|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
16590171|NCT02677870|Experimental|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
16590172|NCT02677857|Active Comparator|Lifestyle|Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship. The goal will be to increase MVPA to > 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals. Initially, participants will be encouraged to complete MVPA > 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention). Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., > 10 min in length). Any MVPA in bouts of > 10 min in length will be counted towards the MVPA goal. Participants will self-monitor their MVPA using the Polar® Loop tracking system.
16590173|NCT02677857|Active Comparator|Lifestyle + SB|Participants will receive everything that is described in Lifestyle. Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk. The goal will be to reduce sedentary time by > 2 hrs/day or > 14 hrs/wk. Participants will shape towards the goal. Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day. For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day. To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention. Participants will self-monitor their SB using the Polar® Loop tracking system.
16590174|NCT02677857|No Intervention|Newsletter|Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors. This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
16590175|NCT02677844|Experimental|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
16590176|NCT02677844|Placebo Comparator|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
16590177|NCT02677844|Active Comparator|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
16590178|NCT02677844|Experimental|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
16590179|NCT02677844|Active Comparator|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
16590180|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
16590181|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
16590182|NCT02677805|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
16590183|NCT02677805|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
16590184|NCT02677792|Experimental|Behavioral Family Intervention (BFI)|
16590185|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
16590186|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
16590187|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
16590188|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
16590190|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
16590191|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
16590192|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
16590193|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|After reconstitution and radiolabeling, 99mTc-rhAnnexin V-128 was administered as a single intravenous bolus of 350 MBq +/- 10% at baseline, after the 2nd cycle, after the 4th cycle and 12 weeks after AC chemotherapy.
16590194|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
16590195|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
16590196|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
16590197|NCT02677675|Experimental|Intervention (reminder module)|"A reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants)"
16590198|NCT02677675|No Intervention|Control (standard care)|Control group received standard care only (routine adherence counselling and paper-based appointment scheduling)
16590199|NCT02677662|Sham Comparator|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise or rest.
16590200|NCT02677662|Experimental|Diesel exhaust exposure|2 hour exposure to dilute diesel exhaust (approximate PM10 (particulate matter<10um) concentration 300 mcg/m3) during intermittent exercise or rest.
16590201|NCT02677649|Active Comparator|cranberry|30 grams/day freeze dried whole cranberry powder added to a basal diet comprising meats, dairy products, simple sugars, and stevia
16590202|NCT02677649|Placebo Comparator|placebo|30 grams/day placebo powder [made with maltodextrin (CPC Maltrin M-180), citric acid, artificial cranberry flavor (Lorann oils), fructose, red color (Lorann oils), and grape shade] added to a basal diet comprising meats, dairy products, simple sugars, and stevia
16590203|NCT02677636|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
16590204|NCT02677636|Placebo Comparator|Placebo Comparator|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
16590205|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral
~Dose: 200 mg PO with small sip of water
~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps
~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
16590206|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous
~Dose: 25 mg
~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,
~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
16590207|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy
~Dose: 300cc during cystoscopy to visualize the ureters
~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection
~Contraindications when used as a genitourinary irrigation solution: anuria"
16590208|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy
~Dose: 300cc
~Known adverse events: no known significant adverse events
~Contraindications: none"
16590209|NCT02677610|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
16590210|NCT02677610|Placebo Comparator|Vehicle|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
16590211|NCT02677597|Experimental|Cisplatin Combined With S-1|Cisplatin 75mg/m2 ivgtt d1 S-1 BSA<1.5 50mg bid，BSA≥1.5 60mg bid po d1-14
16590212|NCT02677597|Experimental|Cisplatin Combined With Paclitaxel|Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h
16590213|NCT02677584|Active Comparator|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
16590214|NCT02677584|Active Comparator|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
16590215|NCT02677571|Experimental|PVB|51 patients receiving US guided homolateral paravertebral thoracic block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
16590216|NCT02677571|Experimental|PECS|51 patients receiving US guided pectorals nerve block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
16590217|NCT02677558||CFOP obese|"Transthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study.
~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia."
16590218|NCT02677558||CFOP control|"Transthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study.
~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia"
16590219|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
16590220|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
16590221|NCT02677532|Active Comparator|Epidural infusion|Thoracic epidural bolus of 10 ml levobupivacaine 0.25% plus sufentanil 0.15 mcg/kg before end of surgery, followed by continuous epidural infusion of 0.12% levobupivacaine plus 0.4 mcg/ml at 5 ml/h infusion rate for 48 hours.
16590222|NCT02677532|Experimental|Wound infusion plus morphine bolus|Intravenous slow bolus of 10 mg morphine, wound infiltration with 10 ml levobupivacaine 0.5%, followed by pre-peritoneal continuous wound infusion of levobupivacaine 0.25% at 4 ml/h infusion rate for 48 hours.
16590223|NCT02677519|Experimental|10 mg Aptensio XR|10 mg methylphenidate, extended release
16590224|NCT02677519|Experimental|15 mg Aptensio XR|15 mg methylphenidate, extended release
16590225|NCT02677519|Experimental|20 mg Aptensio XR|20 mg methylphenidate, extended release once daily
16590226|NCT02677519|Experimental|30 mg Aptensio XR|30 mg methylphenidate, extended release
16590227|NCT02677519|Experimental|40 mg Aptensio XR|40 mg methylphenidate, extended release
16590228|NCT02677519|Experimental|50 mg Aptensio XR|50 mg methylphenidate, extended release
16590229|NCT02677519|Experimental|60 mg Aptensio XR|60 mg methylphenidate, extended release
16590230|NCT02677506|Experimental|Supraclavicular|Supraclavicular brachial plexus block will be done.
16590231|NCT02677506|Active Comparator|Infraclavicular|Infraclavicular brachial plexus block block will be done.
16590232|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
16590233|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
16590234|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
16590235|NCT02677480|Active Comparator|Test group, probiotic tablets and gel|Test group, probiotic tablets and gel: tablets with probiotic bacteria (10exp8/tablet) and pH-rising components and gel (with probiotic bacteria and pH-rising components) in trays on the teeth once a week.
16590236|NCT02677480|Placebo Comparator|Placebo group, placebo tablets and gel|Placebo group, placebo tablets and gel: placebo tablets without probiotic bacteria and pH-rising components and gel (with no probiotic bacteria but with pH-rising components) in trays on the teeth once a week.
16590237|NCT02677467||Spontaneous epistaxis|A participant enroll if their age is over 18 with spontaneous epistaxis and their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs immediately treatment for hypertensive urgency. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
16590238|NCT02677467||Bleeding of wound|A participant enroll if their age is over 18 with bleeding of wound and their cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds' condition is serious or their pain is much severe. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
16590239|NCT02677454|Experimental|Flash Glucose Monitor|"Each patient with Type 1 diabetes will have a subcutaneous tissue FGM sensor inserted. The sensor will produce a maximum of 1440 tissue fluid glucose measurements per 24 hours and 20160 measurements during the 14 day study. The FGM data (Abbott Freestyle Libre) will be compared to the time-matched reference blood glucose measurements.
~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose 6 to 10 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study."
16590240|NCT02677441|Experimental|Conservative management|Conservative management includes a sling for 10 days, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
16590241|NCT02677441|Active Comparator|Surgery|Surgical fixation of ACJD with coracoclavicular and acromioclavicular fixation, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
16590242|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
16590325|NCT02676869|Experimental|IMP321 dose escalation|IMP321 administered fortnightly in addition to SOC pembrolizumab.
16590243|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
16590244|NCT02677415|Other|Local anesthesia|local anesthesia and spontaneous breathing will be maintained.
16590245|NCT02677415|Other|General anesthesia|Intravenous anesthetics and controlled ventilation will be used .
16590246|NCT02677402|Experimental|cold water immersion|Participants immersed their lower limbs in water of ~12°C
16590247|NCT02677402|Experimental|contrast water therapy|Participants immersed their lower limbs in water : alternated every 2 min between ~12°C and ~35°C for CWT
16590248|NCT02677402|Experimental|thermo neutral immersion|Participants immersed their lower limbs in water of ~35°C
16590249|NCT02677389|Experimental|Arm I (Enhanced SCP)|See Detailed Description
16590250|NCT02677389|Active Comparator|Arm II (SCP)|"Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on Healthy Habits at 1, 2, 4, and 8 weeks. Specific topics in emails include positive self-talk, daily relaxation breathing techniques, better sleep, and ways to find pleasure."
16590251|NCT02677363|Experimental|Older adults|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
16590252|NCT02677350|Experimental|Pilot|Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.
16590253|NCT02677337|No Intervention|No intervention|
16590254|NCT02677337|Other|Educational Program|chart abstraction will be conducted post education intervention component.
16590255|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
16590256|NCT02677311|Other|Cases|Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
16590257|NCT02677311|Other|Controls|Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
16590258|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
16590259|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
16590260|NCT02677285||Skin graft|The bioimpedance measurement is done with a purpose built patch that has electrodes in contact with the wound and reference electrodes.
16590261|NCT02677285||Operation wound|The bioimpedance measurement is done with commercial electrodes places in healthy skin surrounding the wound.
16590262|NCT02677259|Experimental|Estradiol + Standard Luteal Phase Support|"17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation
~Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation"
16590263|NCT02677259|Active Comparator|Standard Luteal Phase Support|1. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
16590264|NCT02677246|Experimental|Denosumab|Phase 1, 3+3 design with inter-patient dose escalation from 1mg/kg/dose to 2mg/kg/dose, and possibility of a dose de-escalation of 0.5mg/kg/dose, A modification of 3+3 design is implemented to take into account the achievement of bone resorption blockade by Denosumab. CTX is a biologic marker of bone resorption. Provided a decrease of CTX blood level will be observed under the lower limit (2,5th percentile) for age and sex, or under 20% of the pre-treatment level, there will be no reason to continue escalating the dose. This modified 3+3 design prevents exposure of children to dose escalations that would not be needed regarding the medical and biological aims of this trial.
16590265|NCT02677233||preeclamptic group|"Blood pressure: greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after 20 weeks of gestation (Roberts et al., 2013).
~Proteinuria: protein/creatinine ratio greater than or equal to 0.3
~In the absence of proteinuria, a new-onset hypertension with new onset of the following:
~thrombocytopenia: platelet count less than 100.000/microliter
~renal insufficiency: serum creatinine greater than 1.1 mg/dl
~impaired liver function: elevated concentration of liver transaminases
~pulmonary edema
~cerebral or visual symptoms
~Severe right upper quadrant or epigastric pain unresponsive to medication."
16590266|NCT02677233||non preeclamptic group|All are normotensive with blood pressure <140/90 with no proteinuria.
16590267|NCT02677220|Experimental|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
16590268|NCT02677207|Experimental|JNJ-39393406|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
16590269|NCT02677207|Placebo Comparator|Placebo|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
16590415|NCT02676336|Placebo Comparator|Placebo|3mg placebo daily
16594560|NCT02648334|Experimental|Lutonix drug coated balloon|Lutonix drug coated balloon
16590270|NCT02677194|Experimental|Exposition LED|The patient is his own witness. This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm. Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act : exposition to LED 590nm (4 or 12sec) or 630nm(4min30 or 15 min) or 830 nm (6 or 12 min).
16590271|NCT02677194|Other|Control|Device without any LED exposition : This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm or control (1 mini-zone)
16590272|NCT02677181|Experimental|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).
~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
16590273|NCT02677181|Active Comparator|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
16590274|NCT02677168|Experimental|cNEP|Subjects with OSA will be treated with cNEP (continuous negative external pressure) at home for three weeks
16590275|NCT02677155|Experimental|Intranodal immunotherapy and anti-PD1|"Induction phase: 3 cycles of sequential intranodal immunotherapy (SIIT), every second week:
~Radiotherapy 8 Gy single dose day 2, Rituximab 5 mg intranodal day 1 and 3, Autologous dendritic cells 1x 10 e8 intranodal day 4 and 5, GM-CSF 50 ug subcutaneously day 4 and 5, Pembrolizumab 200 mg intravenous day 5,
~Consolidation phase:
~Pembrolizumab 200 mg intravenous every third week for 8 cycles"
16590276|NCT02677142|Active Comparator|Attention Control Group (CG)|Behavioural: CG: Social Skills Activities: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific social skill and activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
16590277|NCT02677142|Experimental|Experimental Group (EG)|Behavioral: Structured social skills training program, SSIP. Participants in this arm will experience an 8-week manualized intervention program that addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion). Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
16590278|NCT02677129|Experimental|home-based exercise intervention|"home-based exercise intervention:
~Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems."
16590279|NCT02677129|No Intervention|Waiting control group|The wait list control group receives usual care over the study period. Usual care depends on the hospital guidelines as well as oncologists' and physicians' consideration.
16590280|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590281|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590282|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590283|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590284|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590285|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590286|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590287|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590288|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
16590416|NCT02676336|Active Comparator|Cross-over|Subjects on placebo will be offered 3 months of active post-treatment
16590289|NCT02677103|Experimental|RSWT group|The RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder. RSWT will be performed once per week, and will be continued for 3 weeks.
16590290|NCT02677103|Experimental|USNP group|All needle punctures will be guided by ultrasound (US). The puncture needle is a 3.8cm 22# needle attached on a 5ml syringe. Before puncture, the skin of the puncture site will be sterilized with better iodine, and the transducer will be covered with a sterilized plastic bag. After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by ultrasound to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff.
16590291|NCT02677103|Experimental|RSWT plus USNP|In this group, each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs
16590292|NCT02677090|Placebo Comparator|Placebo|Placebo
16590293|NCT02677090|Active Comparator|Dose 1 - Promitor®|Investigational product Dose 1
16590294|NCT02677090|Active Comparator|Dose 2 - Promitor®|Investigational product Dose 2
16590295|NCT02677090|Active Comparator|Dose 3 - Promitor®|Investigational product Dose 3
16590296|NCT02677077||Czech Republic|Approximately 230 participants with RRMS receiving commercial natalizumab in Czech Republic
16590297|NCT02677077||Belgium|Approximately 70 participants with RRMS receiving commercial natalizumab in Belgium
16590298|NCT02677064||patients with acute leukemia (AML or ALL)|
16590299|NCT02677051|Placebo Comparator|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
16590300|NCT02677051|Experimental|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in ~ 50 µmol sulforaphane.
~Body weight Dose of sulforaphane 34 kg ~ 50 µmol 68 kg ~ 100 µmol 102 kg ~ 150 µmol"
16590301|NCT02677038|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16590302|NCT02677025|Experimental|Young Women's Health CoOp (YWHC)|This is an adapted behavioral intervention for young women in Cape Town South Africa who dropped out of school, who use alcohol and other drugs and are at risk for HIV.
16590303|NCT02677025|Active Comparator|HIV Counseling/Testing|Provide age and gender appropriate standard HIV counseling and testing.
16590304|NCT02677012||Arm I (RESOLVE TM)|Patients undergo AFG reconstructive surgery comprising washing and low velocity spinning using a commercially available system that washes the lipoaspirate with lactated Ringer's solution separates non-fat material from the fat with gentle centrifugal force and suction.
16590305|NCT02677012||Arm II (Cytori PureGraft TM)|Patients undergo AFG reconstructive surgery comprising gravity filtration using a commercially available system in which the lipoaspirate is rinsed with lactated RL and the non-fat material is filtered through mesh.
16590306|NCT02677012||Arm III (Coleman technique)|Patients undergo AFG reconstructive surgery comprising standard centrifugation at 3200 rpm for 3 minutes with the resulting oil and aqueous layers discarded.
16590307|NCT02676986|Active Comparator|Cohort I (ER positive cohort)|Approximately 180 patients with ER positive breast cancer will be randomised 2:1 in favour of enzalutamide to receive enzalutamide plus exemestane or exemestane alone.
16590308|NCT02676986|Active Comparator|Cohort II (AR positive, TNBC cohort)|55 patients with AR positive, TNBC will receive single agent treatment with enzalutamide.
16590309|NCT02676973|Active Comparator|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
16590310|NCT02676973|Active Comparator|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
16590311|NCT02676973|Active Comparator|Apical Transvaginal Mesh Repair|Uphold™ LITE
16590312|NCT02676947|Experimental|Open Label|Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months
16590313|NCT02676934|Experimental|Et group|applying end tidal concentration as a control target for delivery of sevoflurane
16590314|NCT02676934|No Intervention|FGF group|using Fresh gas control for sevoflurane delivery
16590315|NCT02676921||GROUP 1|Ten samples of sinus membrane where harvested from fifteen patients during a surgical nasal approach for treatment of chronic rhinosinusitis.
16590316|NCT02676908|No Intervention|4 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for four weeks (usual care)
16590317|NCT02676908|No Intervention|4 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for four weeks (usual care)
16590318|NCT02676908|Experimental|2 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for two weeks (trial group)
16590319|NCT02676908|Experimental|2 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for two weeks (trial group)
16590320|NCT02676895|Experimental|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
16590321|NCT02676895|Experimental|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
16590322|NCT02676895|Active Comparator|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
16590323|NCT02676882|Other|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score </= 10.
16590324|NCT02676882|Other|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score >/= 15.
16590326|NCT02676856|Experimental|CR group|For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
16590327|NCT02676856|Experimental|Non-CR group|For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
16590328|NCT02676843|Experimental|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
16590329|NCT02676830|Experimental|K-312|
16590330|NCT02676817||Group 1|Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
16590331|NCT02676817||Group 2|Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.
16590332|NCT02676804|Experimental|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
16590333|NCT02676791|Experimental|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
16590334|NCT02676791|No Intervention|B (Control)|Esophageal resection will be performed without esophageal washout.
16590335|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
16590336|NCT02676765|Experimental|Allergen|Subjects will be administered either Timothy Grass or Short Ragweed sublingual allergen tablets, depending on their individual allergic sensitization.
16590337|NCT02676765|Placebo Comparator|Placebo|Subjects will be administered placebo sublingual tablets
16590338|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
16590339|NCT02676739|Placebo Comparator|Placebo|Capsule with no active medical ingredients to be taken orally once a day for 12 weeks.
16590340|NCT02676739|Active Comparator|Adderall XR 10mg|10mg Adderall XR capsule to be taken orally once a day for 12 weeks.
16590341|NCT02676739|Active Comparator|Adderall XR 20mg|20mg Adderall XR capsule to be taken orally once a day for 12 weeks.
16590342|NCT02676726|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
16590343|NCT02676726|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
16590344|NCT02676713|Experimental|TCM Sequential Treatment|"After conservative surgery, patients start to take pre-ovulation decoction for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found LUFS or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles.
~Pre-ovulation decoction is HuoXueXiaoYi decoction, and post-ovulation decoction is BuShenZhuYun decoction. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.
~All drugs are tcm formula granules, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
16590345|NCT02676713|Placebo Comparator|Placebo|"After conservative surgery, patients start to take pre-ovulation decoction(placebo) for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found luteinized unruptured follicle syndrome (LUFS) or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction(placebo) for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.
~Pre-ovulation decoction and post-ovulation decoction is placebo, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
16590346|NCT02676700|Active Comparator|Pelvic floor muscle training and Kaatsu|"Participants are instructed in the PFMT program by primary investigator and instructed in Kaatsu training by a research nurse. The Kaatsu training is performed 4 times a week before PFMT. The program includes 2 x 15 knee extensions with partly occlusion of the blood supply to the thigh. Training level is >12 RM. Training is performed sitting on a chair and rubber bands are used to increase resistance. Training adherence and bother with the training is reported in a training diary. At week 6 the research nurse adjusts the training program.
~The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.
~Training adherence and any bother with the training is reported in a training diary."
16590347|NCT02676700|Active Comparator|pelvic floor muscle training|"Participants perform the same PFMT program as the intervention group. The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.
~Training adherence and any bother with the training is reported in a training diary."
16590348|NCT02676687|Active Comparator|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
16590349|NCT02676687|Experimental|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
16590796|NCT02673827|No Intervention|Group control|Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
16590350|NCT02676674|Experimental|Dose 1|Three topical applications of 100,000 units for a total of 300,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
16590351|NCT02676674|Experimental|Dose 2|Three topical applications of 300,000 units for a total of 900,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
16590352|NCT02676661||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
16590353|NCT02676661||peri-implant disease|The subjects who suffered from peri-implant disease.
16590354|NCT02676648|Experimental|Experimental: Condition 1|1) core program; 2) breath meter; 3) text messages; 4) diet-appropriate food and cookbooks
16590355|NCT02676648|Experimental|Experimental: Condition 2|1) core program
16590356|NCT02676648|Experimental|Experimental: Condition 3|1) core program; 2) breath meter
16590357|NCT02676648|Experimental|Experimental: Condition 4|1) core program; 2) text messages
16590358|NCT02676648|Experimental|Experimental: Condition 5|1) core program; 2) diet-appropriate food and cookbooks
16590359|NCT02676648|Experimental|Experimental: Condition 6|1) core program; 2) breath meter; 3) text messages
16590360|NCT02676648|Experimental|Experimental: Condition 7|1) core program; 2) breath meter; 3) diet-appropriate food and cookbooks
16590361|NCT02676648|Experimental|Experimental: Condition 8|1) core program; 3) text messages; 4) diet-appropriate food and cookbooks
16590362|NCT02676635|Experimental|Ergonomics Training Only|Participants in this arm receive Ergonomics training only
16590363|NCT02676635|Experimental|Ergonomics and Safety Voice Training|Participants in this arm receive training on both Ergonomic principles and Safety Voice training
16590364|NCT02676635|No Intervention|Control Group|Participants in this arm will receive no additional Ergonomics or Safety Voice training
16590365|NCT02676622|Experimental|Stem-cell mobilization and Leukapheresis|"Stem-cell mobilisation will be achieved using Cyclophosphamide (CY) 4g/m² (2g/m2 on 2 consecutive days) followed 5 days later by filgrastim (G-CSF) 10 mg/kg injection. This will be done daily until the day before the last day of leukapheresis. The PBSCs will be harvested usually between day +9 and +11 of completing CY.
~Leukapheresis will be performed to a target cell dose of 3-8 x106 CD34+ cells/kg Approximately 1 month later patients will undergo HSCT"
16590366|NCT02676609|Active Comparator|Use of smart phone application (device glucal)|"Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio.
~During the first month, then during the second month they'll use as usual their traintement and meal without the apllication"
16590367|NCT02676609|Active Comparator|Use of smart phone application (second month)|"During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin.
~Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio."
16590368|NCT02676596|Other|Cohort 1|Japanese and Non-Japanese subjects receiving K-312 50 mg QD
16590369|NCT02676596|Other|Cohort 2|Japanese and Non-Japanese subjects receiving K-312 100 mg QD
16590370|NCT02676596|Other|Cohort 3|Japanese and Non-Japanese subjects receiving K-312 200 mg QD
16590371|NCT02676596|Other|Cohort 4|Japanese and Non-Japanese subjects receiving K-312 400 mg QD
16590372|NCT02676596|Other|Cohort 5|Japanese and Non-Japanese subjects receiving K-312 25 mg QD
16590373|NCT02676596|Other|Cohort 6|Japanese and Non-Japanese subjects receiving K-312 10 mg QD
16590374|NCT02676583|Active Comparator|Billateral tonsil fossa closure|tonsillectomy
16590375|NCT02676583|Active Comparator|No closure of tonsil fossa|tonsillectomy
16590376|NCT02676583|Active Comparator|Unilateral tonsil fossa closure|tonsillectomy
16590377|NCT02676557||LASIK|
16590378|NCT02676544|Experimental|Embosphere microspheres|Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.
16590379|NCT02676531|Experimental|Walking Meditation|"Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound Budd and Dha and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week."
16590380|NCT02676531|No Intervention|No Walking meditation|keep regular activities, sedentary life style.
16590381|NCT02676518||polycystic ovary syndrome women|PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
16590382|NCT02676505||1|"Group (I)(Coached group):
~It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds."
16590383|NCT02676505||2|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth.
16590384|NCT02676492||Tic Disorder|Boys with a diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD) aged 11-14 years
16590385|NCT02676492||Control|Boys aged 11-14 years without a diagnosis of TS/CTD (i.e. typically developing)
16590417|NCT02676323|Experimental|Treatment|Participants will be given panobinostat in combination with fludarabine and cytarabine. Treatment consists of one course of therapy given over 12 days. Participants will also receive intrathecal triples and leucovorin
16590386|NCT02676479|Experimental|Uterine Lavage Group|"The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene.
~The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure (Previvo Uterine Lavage System™, CA, U.S.A.) to recover preimplantation embryos."
16590387|NCT02676466|Experimental|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
16590388|NCT02676466|Placebo Comparator|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
16590389|NCT02676466|Active Comparator|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
16590390|NCT02676466|Placebo Comparator|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
16590391|NCT02676466|Active Comparator|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
16590392|NCT02676466|Other|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
16590393|NCT02676466|Other|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
16590394|NCT02676466|Other|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
16590395|NCT02676453|Experimental|Intervention|Dental hygienist support
16590396|NCT02676453|No Intervention|control|Care as usal
16590397|NCT02676440|Other|Treatment|Toothpaste containing 1.11% Fluoride as Sodium Monofluorophosphate and Zinc Citrate Trihydrate Serum containing 0.17% Fluoride as Sodium Monofluorophosphate and Zinc Sulphate Heptahydrate
16590398|NCT02676440|Other|Comparator|Silica toothpaste 1350ppm F as Sodium Fluoride
16590399|NCT02676414|Other|Education program|"Group of patients participating in the interactive hypertension education program of the DHL© My blood pressure - OK!"
16590400|NCT02676414|No Intervention|Controls|"Group of patients not participating in the interactive hypertension education program of the DHL© My blood pressure - OK! (usual care)"
16590401|NCT02676401|Experimental|MT-3995 Low|
16590402|NCT02676401|Experimental|MT-3995 Middle|
16590403|NCT02676401|Experimental|MT-3995 High|
16590404|NCT02676388|Experimental|Freeze-dried, Capsulized FMT|Patients included will receive bowel lavage and subsequent Freeze-dried, Capsulized FMT, and then will be followed up for 3 months.
16590405|NCT02676388|Experimental|Fresh FMT|Patients included will receive bowel lavage and subsequent Fresh FMT, and then will be followed up for 3 months.
16590406|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
16590407|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
16590408|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
16590409|NCT02676362|Experimental|the first day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 5., 10., 30.
16590410|NCT02676362|Experimental|the 2nd day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 10., 30., 5.
16590411|NCT02676362|Experimental|the 3rd day|Gingival crevicular fluid collection with filter paper the length of sampling time in second: 30., 5., 10.
16590412|NCT02676349|Experimental|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
16590413|NCT02676349|Active Comparator|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
16590414|NCT02676336|Active Comparator|Violet™ Iodine|3mg molecular iodine (I2) daily
16590418|NCT02676310|Experimental|Cohort 1: Bimatoprost 0.3% (Formulation B)|0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
16590419|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation A)|0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.
16590420|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation B)|0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
16590421|NCT02676310|Experimental|Cohort 3: Bimatoprost 1% (Formulation B)|1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
16590422|NCT02676310|Experimental|Cohort 4: Bimatoprost 3% (Formulation B)|1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
16590423|NCT02676297|Experimental|Test product A|tiotropium
16590424|NCT02676297|Experimental|Test product B|tiotropium
16590425|NCT02676297|Active Comparator|reference product|tiotropium
16590426|NCT02676284|Experimental|Durolane SJ|single dose injection
16590427|NCT02676258|Experimental|Si-Hy soft contact lens|olifilon B daily disposable soft contact lens
16590428|NCT02676258|Active Comparator|Vistakon soft contact lens|narafilcon A daily disposable soft contact lens
16590429|NCT02676245|Experimental|Viewing NBS + DBS Educational Movies|Group A: pregnant women who will view the NBS and residual specimen movies and printed materials during one visit between 30 and 40 weeks gestation.
16590430|NCT02676245|Experimental|Viewing NBS Educational Movie only|Group B: pregnant women who will view the NBS movie only and printed materials at one visit between 30 and 40 weeks. The movies will be presented on a tablet PC.
16590431|NCT02676245|No Intervention|No Educational Interventions|Control Group: pregnant women who will receive no experimental intervention during pregnancy or the postpartum period but will receive whatever information is routinely provided by their OB clinic and/or delivery center.
16590432|NCT02676232|Experimental|Intervention|Participants in this arm will follow DARWeb: an online psychosocial intervention for children with recurrent abdominal pain and their parents. This is composed by 7 units for parents and 7 units for children, that have been developed from the cognitive-behavioral model, including setting goals, relaxation and distraction techniques, changing maladaptive thoughts and assertive communication training. The team under the program only contact with families for sending reminders and to answer potential technical problems or doubts
16590433|NCT02676232|No Intervention|Control|Participants allocated in this arm will not receive intervention. However, they will be invited to participate once the families allocated to the experimental group complete the program.
16590434|NCT02676219|Experimental|RS01|oral care product containing containing sodium monofluorophosphate and sodium fluoride
16590435|NCT02676219|Placebo Comparator|Water|Water
16590436|NCT02676206|Experimental|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
16590437|NCT02676206|No Intervention|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
16590438|NCT02676193|Experimental|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
16590439|NCT02676193|Experimental|Blank Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using blank packaging for three months. Blank packaging will indicate participants brand and will not have any brand-related images or labels.
16590440|NCT02676193|No Intervention|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
16590441|NCT02676167|Other|Intervention|
16590442|NCT02676154|Other|Fesoterodine|Open-Label
16590443|NCT02676128|Experimental|Mobile Health ART Adherence Application (mARTAA)|mARTAA will use a smartphone-delivered application developed by Twine Health, Inc.
16590444|NCT02676128|Active Comparator|Face-to-Face ART Adherence Intervention|A single face-to-face ART adherence intervention will be administered.
16590445|NCT02676115|Active Comparator|Control Group|Standard Post Operative Skin Care
16590446|NCT02676115|Experimental|Treatment Group|Medipore Tape will be applied to ACL reconstruction Incision
16590447|NCT02676102|Active Comparator|Control Group|Participant will watch an educational video produced in partnership with the community of black men including customers, employers and owners of BOBs.
16590448|NCT02676102|Active Comparator|Targeted Intervention|Participants will watch an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
16590449|NCT02676102|Active Comparator|Tailored Intervention|Participants will watch videos with content individualized to participant's pre-intervention ODBI scores representing their organ donation beliefs
16590450|NCT02676089|Experimental|CHF 5993 200/6/12.5 µg|"Treatment A:
~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB"
16590451|NCT02676089|Active Comparator|CHF 1535 200/6 µg|"Treatment B:
~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF"
16590452|NCT02676089|Active Comparator|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|"Treatment C (open-label arm):
~CHF 1535 200/6 µg: 2 inhalations bid
~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio"
16590453|NCT02676076|Experimental|CHF 5993 100/6/12.5 µg|"Treatment A:
~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB"
16590454|NCT02676076|Active Comparator|CHF 1535 100/6 µg|"Treatment B :
~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF"
16590455|NCT02676063||neonatal Hypoxic Ischemic encephalopathy|moderate or severe HIE among term and late preterm newborn
16590456|NCT02676050|Experimental|Imaging agents and imaging devices|All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be <100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
16590457|NCT02676024|No Intervention|Control|Resuscitation teams will participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR without being provided cognitive aids. Participants in this group will be allowed to use any cognitive aid that they happen to keep with them and would normally use in their practice, for example, flash cards or smart phone apps.
16590458|NCT02676024|Experimental|Knowledge-based cognitive aid|"Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. However, they will be trained in using a knowledge-based cognitive aid, which will be used by a dedicated team member (the cognitive aid reader)."
16590459|NCT02676024|Experimental|Cognitive aids with roles defined (CARD)|Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. Participants will be trained to use the cognitive aids with roles defined (CARD) system. However, they will not be given knowledge-based cognitive aids and there will be no dedicated cognitive aid reader in the team.
16590460|NCT02676024|Experimental|Integrated cognitive aids|Participants will be trained to use the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid, which will be used by a dedicated cognitive aid reader.
16590461|NCT02676011|Active Comparator|Group A|Intramuscular (IM) atropine (0.01 mg/kg) (1 ml) 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
16590462|NCT02676011|Active Comparator|Group B|1 ml normal saline IM 30 minutes before induction of anesthesia, intravenously (IV) atropine (0.01 mg/kg) in 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
16590463|NCT02676011|Active Comparator|Group C|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and 1mg/kg atropine mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
16590464|NCT02676011|Placebo Comparator|Group D|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
16590465|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
16590466|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
16590467|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
16590468|NCT02675998|Placebo Comparator|Placebo|Placebo
16590469|NCT02675985|Experimental|Intervention arm|Early intensive physical therapy will be the intervention arm. There is not a control group.
16590470|NCT02675972||patient with poor outcome|modified Rankin scale≥3
16590471|NCT02675972||patients with favorable outcome|modified Rankin scale<3
16590472|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
16590473|NCT02675946|Experimental|CGX1321 alone and with pembrolizumab|"Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle
~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle.
~Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).
~Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
16590474|NCT02675933|No Intervention|Standard of Care|"The control arm participants will receive only a satisfaction survey once disposition is determined by the physician provider. The satisfaction survey will be collected by the research associated and kept in a protected location, along with all other study materials.
~All patients will receive standard of care, which at this institution is the help of Child Life Specialists, when they are available and requested by the physician. Physicians will be instructed to request Child Life Specialists with the same discretion as with all patients."
16590475|NCT02675933|Active Comparator|Questionnaire|"Participants who are randomized to the questionnaire arm will receive a patient-centered questionnaire at the beginning of their visit. This single page document will ask questions about their child including, but not limited to, diagnoses, suggestions for distraction, sensory issues that may affect their visit, and method to best administer medications. The research associate will ask them to fill it out to the best of their ability and will collect the questionnaire prior to a physician provider seeing the patient. At least one physician provider must review the questionnaire prior to seeing the patient.
~Once disposition is determined, the satisfaction survey will be distributed by the research associate along with an envelope for the parent to seal their survey within."
16590476|NCT02675920||High risk group of HCC|"known high risk group of HCC according to AASLD guideline. And patients whose risk index is equal to or higher than 2.33.
~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive).
~Patients undergo ultrasonography and LDCT using non-ionic monomer iodinated CT contrast media biannually and the interval between ultrasound and LDCT is within 30 days."
16590477|NCT02675907|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
16590478|NCT02675907|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
16590479|NCT02675894|Active Comparator|RFA with cooled-wet electrode|RFA is performed using three cool-wet electrodes in switching bipolar mode under the fused US guidance.
16590480|NCT02675894|Active Comparator|RFA with separable clustered electrode|RFA using separable clustered electrode in switching monopolar mode under the fused US guidance
16590481|NCT02675881|Active Comparator|RFA DSM|Eligible patients who undergo RFA using DSM and separable clustered electrodes.
16590940|NCT02672800|Experimental|Writing intervention|
16590941|NCT02672800|No Intervention|Control|
16590482|NCT02675881|No Intervention|RFA SSM|Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
16590483|NCT02675868|Experimental|Norepinephrine|The noradrenaline group: a group of 10 subjects that will receive noradrenaline 0.05 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
16590484|NCT02675868|Active Comparator|Vasopressins|The vasopressin group: a group of 10 subjects that will receive vasopressin 0.04 IU/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
16590485|NCT02675868|Active Comparator|Phenylephrine|The phenylephrine group: a group of 10 subjects that will receive phenylephrine 0.5 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
16590486|NCT02675868|Placebo Comparator|Placebo|The placebo group: a group of 10 subjects that will receive NaCl 0.9% infusion for 5 hours, starting 60 minutes before endotoxin administration.
16590487|NCT02675855|Experimental|GrafixPRIME®|GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices
16590488|NCT02675855|Active Comparator|Active Comparator|Wound cover, Dressing Application Patients will be fitted with off-loading devices
16590489|NCT02675842|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
16590490|NCT02675842|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
16590491|NCT02675829|Experimental|Cohort 1: Lung cancers, HER2 mutant|
16590492|NCT02675829|Experimental|Cohort 2: Lung cancers, HER2 amplified|
16590493|NCT02675829|Experimental|Cohort 3: Colorectal cancers|
16590494|NCT02675829|Experimental|Cohort 4: Endometrial cancers|
16590495|NCT02675829|Experimental|Cohort 5: Salivary gland cancers|
16590496|NCT02675829|Experimental|Cohort 6: Other solid cancers|
16590497|NCT02675816|Other|Inspire® (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
16590498|NCT02675803|Experimental|VAY736|VAY736 active
16590499|NCT02675803|Placebo Comparator|Placebo|VAY736 placebo
16590500|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
16590501|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
16590502|NCT02675777|Experimental|Quality Improvement Intervention|"Quality improvement intervention: 4 months during which a practice facilitator supports the clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs (see Intervention) as part of behavioral health integration."
16590503|NCT02675777|No Intervention|Usual Care|Care received after 2/2016 but before active implementation begins, which includes passive access to tools in the EHR and 2 months of preparation in each clinic (team building and local pretesting by a local implementation team supported by the external practice facilitator).
16590504|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
16590505|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.
~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.
~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
16590506|NCT02675751|Experimental|wavefront-guided PRK with iDesign|wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser
16590507|NCT02675725||Post cardiac surgery|Patients after cardiac surgery with signs of decreased organ perfusion and the need of fluid therapy.
16590508|NCT02675712||Adults with acute mood disorders|Adults aged over 18 diagnosed with an acute episode of a mood disorder using DSM-V criteria
16590509|NCT02675699|Experimental|Optimisation + HENRY|
16590510|NCT02675699|Active Comparator|HENRY as standard|
16590511|NCT02675673|Active Comparator|GJ-Tube arm|Patients randomized to his arm would usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made into the stomach through the frozen skin. The feeding tube is placed through this puncture into the stomach and the tube tip is placed in the small bowel. Once the GJ-tube has been inserted, the tube in the nose is removed.
16590512|NCT02675673|Active Comparator|G-Tube arm|Patients who are randomized to this arm will usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made through the frozen skin. A small guiding tube or catheter is placed through this puncture into the stomach, and is advanced up the esophagus and out of the mouth. The feeding tube is then pulled into the mouth, down the esophagus, and positioned through the abdomen with its inside tip in the stomach.
16590513|NCT02675660|Experimental|L-Homoarginine|125 mg of L-homoarginine
16590514|NCT02675660|Placebo Comparator|Placebo|placebo capsules
16590515|NCT02675647|Experimental|Intervention group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients.
~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB."
16590676|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
16590516|NCT02675647|Active Comparator|Control group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients.
~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB."
16590517|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
16590518|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
16590519|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
16590520|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
16590521|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
16590522|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
16590523|NCT02675621|Placebo Comparator|Control|Mix 1 flavored still beverage
16590524|NCT02675621|Active Comparator|Phenolic beverage 1|Mix 2 flavored still beverage with a high dose phenolic extract
16590525|NCT02675621|Active Comparator|Phenolic beverage 2|Mix 3 flavored still beverage with a high dose phenolic extract1 and a fruit extract
16590526|NCT02675621|Active Comparator|Phenolic beverage 3|Mix 4 flavored still beverage with a low dose phenolic extract3 and a fruit extract
16590527|NCT02675608||Year 1 Group 1|They are between 18-65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
16590528|NCT02675608||Year 1 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
16590529|NCT02675608||Year 1 Group 3|They are between 18-65 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
16590530|NCT02675608||Year 1 Group 4|They are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
16590531|NCT02675608||Year 1 Group 5|They are between 35-50 years of age, meet the criteria listed above for non-diabetic subjects in Group 1, with the exception of chronic HIV with or without hepatitis B or C infection, and have current medical history of CD4 T-cell counts 300-800.
16590532|NCT02675608||Year 2 Group 1|They are between 18-64 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
16590533|NCT02675608||Year 2 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
16590534|NCT02675608||Year 2 Group 3|If they are between 18-64 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
16590535|NCT02675608||Year 2 Group 4|If they are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
16590536|NCT02675582|Placebo Comparator|Control|Mix 1 flavored still beverage
16590537|NCT02675582|Experimental|Herbal beverage 1|Mix 2 flavored still beverage with a botanical extract(1)
16590538|NCT02675582|Experimental|Herbal Beverage 2|Mix 3 flavored still beverage with a botanical extract(2)
16590539|NCT02675582|Experimental|Combined Herbal Beverage|Mix 4 flavored still beverage with 2 botanical extracts (1,2)
16590540|NCT02675569|Active Comparator|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
16590541|NCT02675569|Experimental|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
16590542|NCT02675556|Experimental|Allogeneic hMSCs|Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
16590543|NCT02675556|Placebo Comparator|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
16590544|NCT02675556|Experimental|Pilot - Allogeneic hMSCs|Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
16590545|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
16590546|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
16590547|NCT02675530|Experimental|healthy control|Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.
16590548|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines
16590549|NCT02675491|Experimental|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
16590550|NCT02675478|Experimental|AC220|This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.
16590553|NCT02675452|Experimental|AMG 176 - Part 1a|Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.
16590554|NCT02675452|Experimental|AMG 176 - Part 1b|Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
16590555|NCT02675452|Experimental|AMG 176 - Part 3a|Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.
16590556|NCT02675452|Experimental|AMG 176 - Part 3b|Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
16590557|NCT02675452|Experimental|AMG 176 - Part 3c|Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
16590558|NCT02675452|Experimental|AMG 176 - Part 3d|Part 3d - Participants in the United States with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW), for 3 weeks, in combination with itraconazole.
16590559|NCT02675452|Experimental|AMG 176 - Part 4|Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break, in combination with azacitidine.
16590560|NCT02675439|Experimental|Dose escalation monotherapy|ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
16590561|NCT02675439|Experimental|Dose escalation combination|ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued
16590562|NCT02675426|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive Upadacitinib 15 mg once daily for 12 weeks.
~Period 2: Participants will continue on Upadacitinib 15 mg once daily."
16590563|NCT02675426|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive Upadacitinib 30 mg once daily for 12 weeks.
~Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
16590564|NCT02675426|Experimental|Placebo and Upadacitinib 15 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.
~Period 2: Participants will receive Upadacitinib 15 mg once daily."
16590565|NCT02675426|Experimental|Placebo and Upadacitinib 30 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.
~Period 2: Participants will receive Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
16590566|NCT02675413|Experimental|Dimethyl Fumarate|Open label dimethyl fumarate (Tecfidera) at the US approved dose of 120mg BID for 7 days and then 240mg BID thereafter for 12 months.
16590567|NCT02675400|Active Comparator|Medication Arm|Vyvanse Arm: 3-week open-label titration beginning at 20 mg Vyvanse (a class II drug), and be increased weekly during the titration period until an optimal response is obtained and then continue for 5 weeks. Optimal response is defined as a clinician Clinical Global Impression-Improvement score (CGI-I) ≤ 2 with minimal associated adverse events. Fathers will remain on optimal dose through the course of the study. In cases of poor tolerability or loss of efficacy the dose can be changed. If an optimal response is not achieved a trial with a long acting methylphenidate will be initiated based upon the Texas algorithm for stimulant medication. The study physician will be available by phone 24 hours/day; participants will be instructed to call with any safety concerns.
16590568|NCT02675400|Active Comparator|Behavioral Parent Training Arm|"Behavioral Parent Training (BPT) Arm: Fathers in the BPT group will receive weekly parent training sessions based on the Barkley manual, Defiant Children, Third Edition. The child participants will also come to several sessions at the clinician's and supervisor's discretion."
16590569|NCT02675387|Active Comparator|Traditional Group|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine
16590570|NCT02675387|Experimental|Buzzy|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine after sensitizing the area with a vibrating device
16590571|NCT02675374|Experimental|Treatment group|24 patients
16590572|NCT02675374|Placebo Comparator|Control group|24 patients
16590573|NCT02675361|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
16590574|NCT02675361|No Intervention|Comparison group|"Participants allocated to this group will receive usual care, which includes follow-up visits according to the complexity of the congenital heart disease. Usual care can vary across clinics, however, they all include meeting with a nurse and a physician.
~This is established as a comparison group since there is the risk of contamination in this group."
16590575|NCT02675361|No Intervention|Control group|"Participants in this group will receive usual care. Follow-up visits will depend on the complexity of the disease.
~Five clinis comprise this section of the study and will be part of an longitudinal, observational study, which investigators will use as a control group."
16590576|NCT02675348|Experimental|Dietary Supplement: Beef Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.
~Intervention will last for 10 weeks. Participants will ingest 20g of beef protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
16590636|NCT02674906|Active Comparator|heparin|A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
16590637|NCT02674893|Experimental|type 2 diabetics treated with GLP1 analogue|
16590577|NCT02675348|Experimental|Dietary Supplement: Whey Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.
~Intervention will last for 10 weeks. Participants will ingest 20g of whey protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
16590578|NCT02675348|Active Comparator|Dietary Supplement: CHO|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.
~Intervention will last for 10 weeks. Participants will ingest 20g of maltodextrin powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
16590579|NCT02675335|Active Comparator|Sitagliptin|Sitagliptin tablets, 100mg per day, 12 weeks treatment
16590580|NCT02675335|Placebo Comparator|Placebo|Placebo tablets, 1 tablet per day, 12 weeks treatment
16590581|NCT02675322|Experimental|Danlou Tablets|Danlou tablets (4.5 g oral dose taken once daily) for 90 days
16590582|NCT02675322|Placebo Comparator|placebo|matching placebo for 90 days
16590583|NCT02675309|Experimental|MT-8554, rosuvastatin and simvastatin|Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
16590584|NCT02675283|Other|coeliac disease point of care test|Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
16590585|NCT02675270|Experimental|Phonological, Orthographic, Untrained|
16590586|NCT02675270|Experimental|Semantic, Lexical, Untrained|
16590587|NCT02675257|Experimental|Cognitive-behavioural group treatment|"Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control.
~Interventions:
~Diabetes-related affective problems analysis
~Goal setting towards improvement of glycaemic control
~Diabetes-specific problem-solving therapy
~Interventions to increase diabetes treatment motivation
~Activation of personal and social resources
~Reduction of barriers to self-care/glycaemic control
~Cognitive restructuring of diabetes-related problems
~Goal definition regarding self-care/glycaemia/well-being"
16590588|NCT02675257|Active Comparator|Treatment-as-usual|"Standard diabetes education.
~Interventions:
~Health care and specific topics (e. g. blood pressure)
~Healthy foods, cooking recommendations, recipes
~Sports, activities and exercise
~Foot care: exercises, care & control, injuries, neuropathy
~Diabetes complications
~Social aspects of living with diabetes"
16590591|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
16590592|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
16590593|NCT02675231|Active Comparator|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
16590594|NCT02675218||Patients with rheumatoid arthritis.|Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.
16590595|NCT02675205|Active Comparator|clopidogrel-aspirin|clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.
16590596|NCT02675205|Experimental|ticagrelor-aspirin|Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery
16590597|NCT02675192||Proof cohort : muscular assessment|"Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...
~Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...
~Urinary collection : metabolome tests
~Maximal voluntary quadriceps strength (MVC)
~Checking muscle functional skills
~Muscular biopsy"
16590598|NCT02675179|Experimental|EOS + Spiral CT pelvimetry|Women with an indication of pelvimetry will be included in this study. They will be their own control because they will benefit from the two methods of diagnosis : EOS new technique, and spiral CT (usual technique).
16590599|NCT02675166||Pediatric cancer young adult survivors|544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
16590600|NCT02675153|Experimental|Upper gastrointestinal strictures|Patients with upper gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
16590601|NCT02675153|Experimental|Lower gastrointestinal strictures|Patients with lower gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
16590602|NCT02675140|Experimental|ZENTEL|Children in intervention group 1 was received 400 mg single-dose albendazole administration, by mouth, for once.
16590603|NCT02675140|Experimental|ZENTEL and Vitamin A Soft Capsules|Children in intervention group 2 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially, by mouth.
16590604|NCT02675140|No Intervention|No drug adminitrated|Children in this Group were received no intervention as control group
16590605|NCT02675127|Experimental|A Test|Test drug (Daktavira, European Egyptian Pharmaceutical Industries)1 tablet contains 60 mg Daclatasvir
16590606|NCT02675127|Active Comparator|B Reference|Reference drug (Daklinza, (Bristol-Myers Squibb Pharma, UK)) 1 tablet contains 60 mg Daclatasvir
16590607|NCT02675114|Active Comparator|Surgical aortic valve replacement (SAVR)|
16590608|NCT02675114|Experimental|Transcatheter aortic valve replacement (TAVR)|
16590609|NCT02675101|Active Comparator|Whole nuts|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
16590610|NCT02675101|Experimental|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 18 g olestra/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Fat free Pringles will be provided to participants for the duration of the study.
16590611|NCT02675101|Placebo Comparator|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
16590612|NCT02675088|Experimental|high-dose TRT|high-dose thoracic radiotherapy X-ray RT
16590613|NCT02675088|Active Comparator|standard-dose TRT|standard-dose thoracic radiotherapy XRT
16590614|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
16590615|NCT02675049|Placebo Comparator|0.9% saline|Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
16590616|NCT02675049|Experimental|dexmedetomidine 1 µg.kg-1|Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
16590617|NCT02675049|Experimental|dexmedetomidine 1.5 µg.kg-1|Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
16590618|NCT02675049|Experimental|dexmedetomidine 2 µg.kg-1|Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
16590619|NCT02675036|Experimental|Primary canine tooth|Extraction of primary canine tooth
16590620|NCT02675036|Experimental|Primary canine and primary molar teeth|Extraction of primary canine and primary first molar teeth
16590621|NCT02675023|Experimental|Auto-injector (AI)|M923 administered via AI
16590622|NCT02675023|Experimental|Prefilled syringe (PFS)|M923 administered via PFS
16590623|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES|ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
16590624|NCT02674997||Study participants|Participants with Hemophila A
16590625|NCT02674971|Active Comparator|INCREASE|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) per day.
16590626|NCT02674971|Active Comparator|COMBINATION|This condition will be identical to the INCREASE condition, except it will also have a goal regarding the number of high-ED foods to consume and substituting low-ED foods for high-ED foods. Thus, this condition will have ED goals to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day. Foods with an ED >1.0 kcal/g but < 3.0 kcal/g will be unlimited; however, lower ED foods will be strongly encouraged. Furthermore, additions to beverages (i.e., sugar, cream) will count toward the > 3.0 kcal/g goal if the additions meet that ED criteria.
16590627|NCT02674958|Active Comparator|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
16590628|NCT02674958|No Intervention|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
16590629|NCT02674945||Wireless Activity tracker: Fitbit|Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.
16590630|NCT02674932|Experimental|Signature Strengths|"Patients will complete the Values in Action Youth Survey (VIA-Youth) and will receive a list of his/her top character strengths (signature strengths). The patient will then participate in the Identifying and Using Signature Strengths Intervention."
16590631|NCT02674932|Active Comparator|Coping Skills + Memory Aid|Patients will complete the VIA-Youth but will not receive any results. The patient will then participate in the Identifying and Writing Down Coping Skills Intervention.
16590632|NCT02674932|Other|Coping Skills (Treatment as Usual)|Patients will complete the VIA-Youth but will not receive any results. After completing the VIA-Youth, the study team member and patient will have a treatment-as-usual discussion about coping skills. (This is equivalent to treatment as usual that is already provided on the psychiatric unit-doctors and nurses on the unit already have this a discussion about coping skills with patients).
16590633|NCT02674919|Experimental|Nordic Hamstring|The Nordic Hamstring group performs a progressive strengthening program (Mjolsnes et al., 2004) comprising of the Nordic Hamstring exercise during a period of 10 weeks. The training load increases from one session per week in week 1 to 3 sessions per week in week 3-10. Number of sets and repetitions progressively increase from 2 to 3 and 5 to 12, respectively. The exercise program is performed in the end of a regular football training session.
16590634|NCT02674919|Other|Control|The control group are asked not to perform the exercise or any other specific strength training for the hamstring muscles and to continue to play football as usual.
16590635|NCT02674906|Active Comparator|citrate|A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
16590638|NCT02674893|Active Comparator|Type 2 diabetics not treated with incretins|
16590639|NCT02674893|Other|Healthy subjects|
16590642|NCT02674867|Experimental|Early treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART before 6 months-of-age (early treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
16590643|NCT02674867|Other|Late treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART after 24 months-of-age (late treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
16590644|NCT02674854|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
16590645|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
16590646|NCT02674854|Active Comparator|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
16590647|NCT02674841|Experimental|Feedback group|Receives live feedback on TUT and pulling force during exercises.
16590648|NCT02674841|Active Comparator|Control group|Receives no feedback on TUT but on pulling force during exercises.
16590649|NCT02674828|Experimental|Reinforcement treatment|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
16590650|NCT02674828|Active Comparator|Standard Treatment|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
16590651|NCT02674815|Experimental|Intervention|Patients within this arm will perform two weeks of high intensity interval training prior to colorectal/thoracic surgery. Exercise intensity will be 100% of the peak power output (PPO) during maximal cardiopulmonary exercise testing. Patients will exercise for 15 seconds at 100% PPO and rest for 15 seconds (passive) for 30 minutes or until exhaustion. This will be performed 5 days a week for 2 weeks.
16590652|NCT02674802||Retrospective study|People who has successfully eradicated helicobacter pylori more than six months detected helicobacter pylori by the C-urea breath test in order to evaluate the reinfection.
16590653|NCT02674802||Prospective study|People who has infected helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6 months detected helicobacter pylori by the C-urea breath test in order to prospect the reinfection .
16590654|NCT02674789|Experimental|Exercise day|Behavioral intervention: 90min bike ergometer test at 70% of VO2max. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
16590655|NCT02674789|No Intervention|Non exercise day (Rest day)|No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
16590656|NCT02674776|Experimental|HuZhen Capsule|The main elements of HuZhen Capsule include Polygonum cuspidatum, Ligustrum lucidum etc.
16590657|NCT02674776|Placebo Comparator|Placebo Capsule|Placebo appearance, content color and taste should be consistent with HuZhen Capsule.
16590658|NCT02674763|Experimental|Dose Escalation Schedule A|IMGN779 administered on days 1 and 15 of a 28-day cycle
16590659|NCT02674763|Experimental|Dose Escalation Schedule B|IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle
16590660|NCT02674763|Experimental|Dose Escalation Schedule C|IMGN779 administered on days 1 and 8 of a 21-day cycle
16590661|NCT02674763|Experimental|Dose Expansion Cohort|Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.
16590662|NCT02674750|Experimental|CUDC-907|RR-DLBCL, including with MYC alterations detected by FISH or by >=40% MYC by IHC
16590663|NCT02674737|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both sedative and analgesic(dexmedetomidine, tramadol and flurbiprofen) are applied to this group of patients.
16590664|NCT02674737|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(tramadol and flurbiprofen) are applied to this group of patients.
16590665|NCT02674724|Experimental|Gym Group|With gym equipments, twice per week for 12 weeks.
16590666|NCT02674724|Active Comparator|Free Weights Group|With dumbbells, elastics, twice per week for 12 weeks.
16590667|NCT02674724|Placebo Comparator|Control Group|The control group will be instructed to perform stretching exercises at home in the same 12-week period, according to an illustrated booklet.
16590668|NCT02674711|Experimental|Educational Video|Evidence-based video: Best Advice for People Taking Opioid Medication
16590669|NCT02674711|No Intervention|Usual Care|Usual care education provided at time of pre-operative appointment.
16590670|NCT02674698|Other|VA Integrated Service Networks Group 1|Access to the CNH Dashboard Step 1
16590671|NCT02674698|Other|VA Integrated Service Networks Group 2|Access to the CNH Dashboard Step 2
16590672|NCT02674698|Other|VA Integrated Service Networks Group 3|Access to the CNH Dashboard Step 3
16590673|NCT02674698|Other|VA Integrated Service Networks Group 4|Access to the CNH Dashboard Step 4
16590674|NCT02674672|Experimental|VenaTech Retrievable arm|VenaTech Retrievable arm
16590675|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
16590677|NCT02674646|Experimental|Group A: Verum Acupuncture|Group A: Verum Acupuncture (Needle Acupuncture) Needlepoints Bilateral PC 6, S 36, L 8, L 9 Unilateral R4, R 6 Acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
16590678|NCT02674646|Sham Comparator|Group B: Sham Acupuncture|Group B: Sham Acupuncture (Needle Acupuncture) Needlepoints 8 needles in the medioaxillary line below the 6th rib, bilateral 2 needles unilateral Sham-acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
16590679|NCT02674633|Active Comparator|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
16590680|NCT02674633|Active Comparator|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
16590681|NCT02674620|No Intervention|Conservative|Standard conservative care of concussion
16590682|NCT02674620|Experimental|Treadmill|Aerobic exercise treatment for concussion
16590683|NCT02674607|Experimental|patients|thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
16590684|NCT02674607|No Intervention|controls|thirty healthy children of matched age and sex
16590685|NCT02674594||Patient treated with Dabigatran|
16590686|NCT02674594||Patient treated with Rivaroxaban|
16590687|NCT02674594||Patient treated with Apixaban|
16590688|NCT02674594||Patient treated with Warfarin|
16590689|NCT02674581|Experimental|Healthy Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
16590690|NCT02674581|Experimental|Mild Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
16590691|NCT02674581|Experimental|Moderate Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
16590692|NCT02674581|Experimental|Severe Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
16590693|NCT02674581|Experimental|End Stage Renal Disease Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
16590694|NCT02674568|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine administered intravenously on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for 2 cycles. An additional 2 cycles of rovalpituzumab tesirine (retreatment) was permitted for eligible participants.
16590695|NCT02674555|Experimental|ASP8273|Two Parts - Part A: 14C-radio labeled; Part B: non radio labeled (optional)
16590696|NCT02674529|Active Comparator|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
16590697|NCT02674529|Placebo Comparator|Placebo|A placebo pill will be taken over an 8-week period.
16590698|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
16590699|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
16590700|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
16590701|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
16590702|NCT02674490|Experimental|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
16590703|NCT02674490|Sham Comparator|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
16590704|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
16590705|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
16590737|NCT02674269|Placebo Comparator|TC-3 Gel|One intravesical instillation of 60 ml TC-3 gel
16590942|NCT02672787|Active Comparator|ED usual care plus education|ED usual care plus education
16590708|NCT02674451|Active Comparator|RIPC|Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
16590709|NCT02674451|Sham Comparator|Controls|Participants will have routine blood pressure measurements will be obtained.
16590710|NCT02674438|Experimental|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic
~Intervention #1 - Clinical algorithm: the EHMRG 7-day and EHMRG30-ST risk scores, which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation, or emergency department discharge.
~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
16590711|NCT02674438|No Intervention|Control|Usual care without access to the EHMRG/EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
16590712|NCT02674425||Young adults (18-40)|Healthy adult volunteers, aged between 18 and 40, with no prior/current eye problems or family history of genetic eye diseases and good general health.
16590713|NCT02674425||Older adults (50-70)|Healthy adult volunteers, aged between 50 and 70, with no prior/current eye problems or family history of genetic eye diseases and good general health.
16590714|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
16590715|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
16590716|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
16590717|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
16590718|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
16590719|NCT02674373||Localized gastric cancer|resectable tumor receiving a curative intent treatment.
16590720|NCT02674373||advanced gastric cancer|unresectable tumor treated with palliative chemotherapy
16590721|NCT02674360|Active Comparator|SDM Online Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of a web-based SDM online Training (intervention group I). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The SDM online training works on the modeling principle.
16590722|NCT02674360|Active Comparator|Face-to-Face SDM Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of an individualized, context-based SDM individual face-to-face training at the workplace of the participants (intervention group II). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The individual training works on the coaching principle.
16590723|NCT02674360|No Intervention|Control Group|The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
16590724|NCT02674347|Experimental|Cohort 1: 3 g or 6 g of Zidebactam|"Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours [q8h]) (n=8) IV infusions administered over 60 minutes.
~Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes."
16590725|NCT02674347|Placebo Comparator|Placebo|"Cohort 1: Placebo every 8 hours [q8h] (n=2) IV infusions administered over 60 minutes.
~Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes."
16590726|NCT02674334|Active Comparator|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
16590727|NCT02674334|Active Comparator|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
16590728|NCT02674321|Experimental|SD-809|• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.
16590729|NCT02674308||Vedolizumab|
16590730|NCT02674308||Other Biologic Agents|
16590731|NCT02674295|Experimental|Cohort 1|50 milligram (mg) of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration.
16590732|NCT02674295|Experimental|Cohort 2|20 mg of intravenous esketamine in 30 milliliter (mL), fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
16590733|NCT02674282|Experimental|ACL-injured|ACL injured professional soccer players submitted to ACL reconstruction.
16590734|NCT02674282|No Intervention|Control|Healthy professional soccer players
16590735|NCT02674269|Experimental|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
16590736|NCT02674269|Experimental|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
16590738|NCT02674256|Active Comparator|CRH injection|Intervention: intravenous injection of CRH 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together then the solution will be injected IV over the course of 1 minute
16590739|NCT02674256|Placebo Comparator|placebo injection|"Intervention: intravenous saline injection
~1mL of saline will be injected intravenously over the course of 1 minute"
16590740|NCT02674243|Experimental|Iodopovidone group|Patients who will be randomized for using iodopovidone solution for pleurodesis.
16590741|NCT02674243|Active Comparator|Talc group|Patients who will be randomized for using Talc for pleurodesis.
16590742|NCT02674230||Extreme obesity|BMI ≥35kg/m2
16590743|NCT02674230||Obesity|BMI 24-34.9kg/m2
16590744|NCT02674230||Normal subjects|BMI <24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
16590745|NCT02674217|Experimental|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS) or primary progressive (PPMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
16590746|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
16590747|NCT02674204|Placebo Comparator|Control|One matching placebo daily
16590748|NCT02674191|Experimental|Group 1|Device: mini-plates supported molar intrusion (Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence Procedure/Surgery: Application of ULTRACARE benzocaine 20%, topical anesthesia (Ultradent Products, Inc) Procedure/Surgery: Administration of , Mepivacaine-l local anesthesia Procedure/Surgery: BETADINE povidone-iodine 10% a local disinfectant Drug: (150g Clindamycin/tds) for 1 week Postoperative antibiotic Drug: (Cataflam 25mg), are prescribed post-operatively an analgesic
16590749|NCT02674191|No Intervention|Group 2|hyperdivergent adolescence with no intervention
16590750|NCT02674178|Active Comparator|Age <35|< 35 years old included 201 women who are further subdivided according o FSH/LH ratio into G1A (201 patients) with FSH/LH ratio <2 and G1B (37 patients) with FSH/LH ratio ≥2.
16590751|NCT02674178|Active Comparator|Age ≥ 35|. Group 2 ≥ 35 years old included 34 women who are further subdivided according o FSH/LH ratio into G2A (25 patients) with FSH/LH ratio <2 and G2B (9 patients) with FSH/LH ratio ≥2
16590752|NCT02674165|Experimental|Intervention|"The pregnancy prevention intervention to be tested is an adaptation of Becoming a Responsible Teen (BART), an evidence-based (proven to work by research) HIV prevention curriculum designed primarily for African American adolescents, ages 14-18, in community-based settings.
~The culturally-adapted version HART consists of nine sessions, lasting about 2 hours each, and includes interactive group discussions and role plays that are -performed by adolescents. Unlike BART, one PTSD awareness session has been added to address what happens to people who have been exposed to mental trauma and natural disasters."
16590753|NCT02674165|No Intervention|Control or nutrition|Nutrition/fitness curriculum will teach students about ingredients in food that are good for the body and will keep it in good health
16590754|NCT02674152|Experimental|BI 836880|
16590755|NCT02674139|Active Comparator|IUD insertion 6 Weeks after delivery|Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
16590756|NCT02674139|Experimental|Immediate Post-placental insertion|Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
16590757|NCT02674126|Placebo Comparator|Control group|Control group
16590758|NCT02674126|Active Comparator|Maternal sound group|Maternal sound
16590759|NCT02674113|Active Comparator|regional anesthesia bupivacaine|regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy
16590760|NCT02674113|Placebo Comparator|regional anesthesia placebo|subcutaneous injection procedure placebo (0.9% sodium chloride in water)
16590761|NCT02674087||Expectant women|
16590762|NCT02674074|Experimental|measurement of corneal temperature by infrared thermography|
16590763|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year).
16590764|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year)
16590765|NCT02674035|Active Comparator|Device: 2-0 monofilament nylon suture|Plication of the anterior rectus sheath (correction of diastasis of the rectus abdominis muscles) was performed in two layers with Device 2-0 monofilament nylon suture (control group). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
16590766|NCT02674035|Active Comparator|Device: Single layer 2-0 monofilament|Single layer with a Device 2-0 monofilament nylon suture (correction of diastasis of the rectus abdominis muscles) (group I). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
16590792|NCT02673866|Placebo Comparator|Placebo|Placebo
16590793|NCT02673866|Active Comparator|Pregabalin|Pregabalin
16590794|NCT02673840|Experimental|Ketotifen|
16590795|NCT02673840|Placebo Comparator|Placebo|
16590943|NCT02672787|Experimental|Intervention|Subjects will receive the ED-based behavioral intervention
16590767|NCT02674035|Active Comparator|Device: Barbed suture Quill Nylon 1|Using a continuous Device Barbed suture Quill Nylon 1 (correction of diastasis of the rectus abdominis muscles) (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
16590768|NCT02674022|Active Comparator|Mothers of Children with ASD|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
16590769|NCT02674022|Active Comparator|Mothers of Typically Developing Children|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
16590770|NCT02674009||laBCC Participants|Participants with laBCC who received at least one dose of Vismodegib in routine clinical practice for 32 months (between 02 Aug 2013 and 31 Mar 2016).
16590771|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
16590772|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
16590773|NCT02673983|Experimental|Patients undergoing endoscopic full-thickness biopsy|
16590774|NCT02673970||observational arm|From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab
16590775|NCT02673957||Blood pressure cuff protocol|All participants receive a baseline control blood test, and all participants receive the blood pressure cuff inflation protocol and blood sampling following the cuff protocol.
16590776|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
16590777|NCT02673931|Experimental|GLP-1|"700 patients will be randomized to GLP-1, that will be administered as follows:
~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin added 25 microg Byetta (Lilly, Exenatide).
~The study drug infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes. A set dose of 17.4 microg will be given."
16590778|NCT02673931|Placebo Comparator|Placebo|"20% Human Albumin is given as placebo. 700 patients will be randomized to placebo, that will be administered as follows:
~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin.
~The placebo infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes at the same rate as the study drug."
16590779|NCT02673931|Experimental|Restrictive Oxygenation|"The intervention is FiO2 of 50%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 50% as long as the arterial O2 saturation (Sa02) remains above 91% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after
~a maximum of 1 hours of intervention or
~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
16590780|NCT02673931|Active Comparator|Liberal Oxygenation|"The intervention is a FiO2 of 100%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 100% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after
~a maximum of 1 hours of intervention or
~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
16590781|NCT02673918|Experimental|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
16590782|NCT02673918|Experimental|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
16590783|NCT02673905|Experimental|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
16590784|NCT02673905|Experimental|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
16590785|NCT02673892|Experimental|PODS intervention|The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
16590786|NCT02673892|No Intervention|Usual Care|Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.
16590787|NCT02673879|Active Comparator|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
16590788|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated.
16590789|NCT02673866|Experimental|DS-1971a 400 mg TID|DS-1971a 400 mg three times per day (TID)
16590790|NCT02673866|Experimental|DS1971a 400 mg BID|DS1971a 400 mg twice per day (BID)
16590791|NCT02673866|Experimental|DS1971a 100 mg BID|DS1971a 100 mg BID
16590797|NCT02673827|Experimental|experimental group|"Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation.
~They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation."
16590798|NCT02673814|Experimental|Arm A (durvalumab)|10 mg/kg durvalumab alone every two weeks
16590799|NCT02673814|Experimental|Arm B (bavituximab + durvalumab)|3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks
16590800|NCT02673814|Experimental|Arm C (bavituximab + durvalumab)|3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks
16590801|NCT02673801||Patient referred to orthopedic clinic|Orthopedic assessment in the outpatient clinic as well as a new algorithm (using patient-reported symptoms and radiographic evaluation) will be applied
16590802|NCT02673775|Placebo Comparator|Clean Air|Subjects will be exposed to clean air for 3 hours.
16590803|NCT02673775|Experimental|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
16590804|NCT02673762||Normal glucose metabolism|Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
16590805|NCT02673762||Pre-diabetes|Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
16590806|NCT02673762||Type II diabetes|Hemoglobin A1c 6.5% or greater, fasting blood glucose >125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
16590807|NCT02673749|Experimental|RP-G28 Dose 1|
16590808|NCT02673749|Experimental|RP-G28 Dose 2|
16590809|NCT02673749|Placebo Comparator|Placebo|
16590810|NCT02673736|Experimental|PLX73086|"Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.
~Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease)."
16590811|NCT02673723|Experimental|Dezocine|Dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
16590812|NCT02673723|Placebo Comparator|Controlled|The same amount of saline is given for 10 seconds after surface anesthesia
16590813|NCT02673710||Participants with metastatic colorectal cancer|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
16590814|NCT02673697|Experimental|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
16590815|NCT02673697|Active Comparator|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
16590816|NCT02673684|Sham Comparator|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
16590817|NCT02673684|Experimental|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
16590818|NCT02673671||Subjects with unknown POI status consented pre-surgery|Up to 100 subjects may be consented prior to surgery who are planned to undergo gastrointestinal surgery or a planned surgery that does not involve the abdominal cavity. The investigator does not change the routine medical care of study participants.
16590819|NCT02673671||Subjects with known/unknown POI status consented post-surgery|Up to 50 subjects who have undergone gastrointestinal surgery or surgery not involving the abdominal cavity may be consented post- operatively during their hospital stay for this study.The investigator does not change the routine medical care of study participants.
16590820|NCT02673658|Active Comparator|Motor + problem solving|This method focuses on spontaneous movement (rather than facilitated movement). Self-initiated, functionally directed movement is emphasized. Intervention includes guidance and cues, which gently call the child's attention to the support surface, and a set-up of the environment for small increments of movement so that the child can solve a movement problem. Passive movements are not used. Each small increment of movement to advance sitting skill or other motor skills is paired with a specific object or toy that challenges a cognitive concept for spatial problem solving. In this approach, the parent will adjust toys and supports to encourage changes of position from sitting, to transitions in and out of sitting to crawling or standing, but will not assist the child physically.
16590821|NCT02673658|Active Comparator|Body weight support training|In this approach, infants will be supported physically by their parents to take steps, sit, crawl, or reach, in practice sessions focused simply on the motor skill. Toys or problem solving will not be part of this intervention, but the child will be assisted (lifted by the parent) through movement to improve strength and learn specific movements and new positions. The child will be able to perform as much of the movement as possible, but the parents will initiate the activity if the child does not initiate, and the parent will lift the child passively through the task if the child is unable to move.
16590822|NCT02673645|No Intervention|Control group|These youth will receive standard mathematics instruction and support, but not the intensive tutoring offered through the intervention.
16591175|NCT02671162|Active Comparator|Fumaria|Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.
16590823|NCT02673645|Experimental|SAGA Innovations|These youth will receive the intensive mathematics tutoring by SAGA Innovations, with students randomized to tutors.
16590824|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
16590825|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
16590826|NCT02673606|Experimental|Estradiol 2mg Dose|2mg dose of estradiol (oral administration)
16590827|NCT02673606|Experimental|Estradiol 4mg Dose|4mg dose of estradiol (oral administration)
16590828|NCT02673606|Placebo Comparator|Placebo|placebo (oral administration)
16590829|NCT02673593|Placebo Comparator|Placebo|Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
16590830|NCT02673593|Experimental|DS102 100mg Single Dose|Taken orally once by Cohort 1
16590831|NCT02673593|Experimental|DS102 500mg Single Dose|Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
16590832|NCT02673593|Experimental|DS102 1000mg Single Dose|Taken orally once by Cohort 3
16590833|NCT02673593|Experimental|DS102 2000mg Single Dose|Taken orally once by Cohort 4
16590834|NCT02673593|Experimental|DS102 500mg Multiple Dose|Taken orally once a day for 28 days by Cohort 5
16590835|NCT02673593|Experimental|DS102 1000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 6
16590836|NCT02673593|Experimental|DS102 2000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 7
16590837|NCT02673580|Other|Open Access telePRO|Intervention: In open access, contact to the outpatient clinic is initiated by the patient by filling in a PRO questionnaire.
16590838|NCT02673580|Other|Standard telePRO|No intervention: In standard telePRO, outpatient follow-up activity is determined by a clinician and patients receive a questionnaire at fixed intervals.
16590839|NCT02673567|Experimental|TEV-48125 - 1|Dose Regimen 1
16590840|NCT02673567|Experimental|TEV-48125 - 2|Dose Regimen 2
16590841|NCT02673567|Experimental|TEV-48125 - 3|Dose Regimen 3
16590842|NCT02673567|Placebo Comparator|Placebo|Matching Placebo
16590843|NCT02673554|Experimental|Oral glucose tolerance test|An oral glucose challenge (75 g)
16590844|NCT02673554|Active Comparator|GIP Bolus|Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
16590845|NCT02673554|Active Comparator|GIP Infusion|Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
16590846|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
16590847|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
16590848|NCT02673528||Directly underwent TLA|Patients with the diagnosis who underwent directly total laparoscopic appendectomy
16590849|NCT02673528||Lap Assisted App|Patients with the diagnosis of acute appendicitis who underwent a successful laparoscopic assisted appendectomy
16590850|NCT02673528||Advanced to TLA|Patients with the diagnosis of acute appendicitis in whom laparoscopic assisted appendectomy attempted; however, because it fail advanced to total laparoscopic appendectomy.
16590851|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
16590852|NCT02673515|No Intervention|control group|control group
16590853|NCT02673502|Experimental|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
16590854|NCT02673502|Experimental|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery.
16590855|NCT02673489|Experimental|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
16590856|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
16590857|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
16590858|NCT02673463|Experimental|Spironolactone|Spironolactone 25 mg once daily for 2 years
16590859|NCT02673463|Placebo Comparator|Placebo|Matched placebo once daily for 2 years
16590860|NCT02673437||Rivaroxaban group|Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
16590861|NCT02673437||Alternative dual antiplatelet therapy|Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
16590862|NCT02673424|Active Comparator|FFR-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by FFR-guided strategy.
16590863|NCT02673424|Active Comparator|IVUS-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by IVUS-guided strategy.
16590864|NCT02673398|Experimental|Treatment (neratinib)|Patients receive neratinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16590865|NCT02673385||Brazelton scale|Procurement across Brazelton scale
16590866|NCT02673385||No test|usual care
16590867|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
16590868|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
16590869|NCT02673359|Active Comparator|Progesterone group|Vaginal progesterone suppositories will be given
16590870|NCT02673359|Active Comparator|Cerclage group|Cervical cerclage will be performed.
16590871|NCT02673346||employees|YKHC employees
16590872|NCT02673333|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
16590875|NCT02673307|No Intervention|Controle|The volunteer does not chew gum during the study period
16590876|NCT02673307|Experimental|Chewing gum|The volunteer chews gum during the first 45 min after ingestion of 250 ml water
16590877|NCT02673294|Experimental|intervention (6-12 months)|Participants with a chronicity between 6-12 months
16590878|NCT02673294|Experimental|Intervention (12-24 months)|Participants with a chronicity between 12-24 months
16590879|NCT02673294|Experimental|Intervention (>24 months)|Participants with a chronicity >24 months
16590880|NCT02673281|Experimental|Walnut shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
16590881|NCT02673281|Placebo Comparator|Placebo shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
16590882|NCT02673268|Experimental|Patients with breast cancer|
16590883|NCT02673255|Experimental|Sanofi Pasteur (Tenivac)|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
16590884|NCT02673255|Experimental|MassBiologics|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: MassBiologics, Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
16590885|NCT02673242|No Intervention|Control|No treatment other than medical
16590886|NCT02673242|Experimental|Intervention|Inspiratory muscle training
16590887|NCT02673229|Active Comparator|Collagenase Santyl|Applied topically (2 mm thickness once daily)
16590888|NCT02673229|Sham Comparator|Bacitracin|Applied topically (2 mm thickness) once daily
16590889|NCT02673216||Spontaneous abortion|Women attending for suspected spontaneous abortion
16590890|NCT02673216||Normal pregnant women|Normal pregnant women attending for nuchal translucency scan
16590891|NCT02673203|Active Comparator|Lean Healthy Control|(BMI <25 kg/m2)
16590892|NCT02673203|Active Comparator|Obese non-diabetic subject|BMI > 30 kg/m2
16590893|NCT02673177|Experimental|Robot-assisted total mesorectal excision|Robot-assisted total mesorectal excision (RTME) for rectal cancer. Two different RTME procedures were chose to personalized patients. Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
16590894|NCT02673177|Active Comparator|Laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed. The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
16590895|NCT02673164|Active Comparator|CSCC_ASC|Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)
16590896|NCT02673164|Placebo Comparator|Placebo|Saline
16590897|NCT02673151|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11. Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA 11 Beginning 50-100 minutes later, a low dose CT will be obtained from vertex to mid thighs; followed by a static PET emission scan over the same .
16590898|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
16590899|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
16590900|NCT02673125|Experimental|Double embryo transfer|Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
16590901|NCT02673112|Experimental|STEP-mhc + LS|Subjects will be asked to perform exercise at 80% of the heart rate threshold determined using the Balke protocol for 5 minutes greater than their measured minutes of MVPA/day at baseline (Subthreshold exercise program). They will also be given a light stretching protocol (5 stretches). The exercise intervention will last for 6 weeks and will be supported by weekly health coaching.
16590902|NCT02673112|Active Comparator|LS alone|Subjects will be given a light stretching program alone (5 stretches). The exercise program will last for 6 weeks.
16590903|NCT02673099|Other|HDF online|All patients were started on HF (high-flux) hemodialysis. After 6 months they were then treated by HDF online.
16590904|NCT02673086|Active Comparator|coracoid approach|Patients in this group will be randomized to receive an coracoid approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
16590905|NCT02673086|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
16590906|NCT02673073|Placebo Comparator|Control_Education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
16590907|NCT02673073|Experimental|Intervention_Diary|All patients will receive patient's information/education booklet on the heart failure including life style modification. In addition, patients also receive a patient's diary for self-recording of 6 parameters: body weight, blood pressure, heart rate, number of remaining pills, degree of pitting edema, and degree of dyspnea.
16590908|NCT02673060|Experimental|dose escalation of MBC-11|MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
16590909|NCT02673047||Botox®|Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
16590910|NCT02673021|Experimental|Microwave Ablation|Microwave Ablation
16590911|NCT02673008|Experimental|MRD-directed DLI|For patients with MRD+ and without grade II/>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.
16590912|NCT02672995|Experimental|Single arm dose-escalation|"Fractionated stereotactic radiosurgery:
~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.
~Concurrent bevacizumab:
~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
16590913|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
16590914|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
16590915|NCT02672969|Experimental|Smoke evacuation uses|Smoke evacuation uses means using RapidVac Smoke Evacuator with electrosurgical unit during coagulation and cutting surgery. (Experimental group)
16590916|NCT02672969|No Intervention|no smoke evacuation uses|No smoke evacuation uses means using only the regular electrosurgical unit during coagulation and cutting surgery. (Control group)
16590917|NCT02672956|Experimental|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
16590918|NCT02672956|Experimental|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
16590919|NCT02672956|Experimental|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
16590920|NCT02672943|No Intervention|Normal|30 normal volunteers with age, sex and BMI-match as control group
16590921|NCT02672943|Active Comparator|treatment group|The Rehabilitation treatment group will receive rehabilitation training once per day, 3 days per week, for 12 weeks. The duration of each session is about 1 hour. Participants will first receive relaxation exercises, positioning and self-stretch exercises (emphasizing on spinal mobility and flexor muscle groups of limbs and trunk) for 15 minutes. Then they will have balance training for 20 minutes. The investigators will use goal-directed tasks, such as different types of ball games, for balance training. At the end, participants will receive walking exercise for 20 minutes, and cool down exercises for 5 minutes.
16590922|NCT02672943|Sham Comparator|non-treatment group|The group will not receive non-rehabilitation treatment, before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
16590923|NCT02672917|Experimental|Group C|MVT-5873 is administered in Group C every 4 weeks by intravenous infusion. Each cycle is 28 days. During dose escalation, doses of MVT-5873 will be increased to define the MTD. Up to 30 patients will be treated at the RP2D.
16590924|NCT02672917|Experimental|Group D|MVT-5873 is administered in Group D every 2 weeks by intravenous infusion. During dose escalation, doses of MVT-5873 will be increased to defined he MTD. Up to 30 patients will be treated at the RP2D.
16590925|NCT02672917|Experimental|Group E|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
16590926|NCT02672904|Active Comparator|CO2 laser|Patients undergoing endoscopic treatment with CO2 laser
16590927|NCT02672904|Active Comparator|KTP laser|Patients undergoing endoscopic treatment with KTP laser
16590928|NCT02672891|Experimental|Device|condom balloon catheter which is composed of a latex condom (SURE natural latex condom, Shanghai) and a 16-20 F, 2 ways silicon coated Foley catheter (Egypt). The catheter was introduced inside the condom and tied over tightly several times with a silk suture, to prevent air escape.
16590929|NCT02672878|Experimental|BVS implantation in patients with ISR|
16590930|NCT02672865|Experimental|HIPEC|The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.
16590931|NCT02672852|Experimental|Risankizumab|Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).
16590932|NCT02672852|Placebo Comparator|Placebo|Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).
16590933|NCT02672839|Experimental|Period 1 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
16590934|NCT02672839|Experimental|Period 1 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
16590935|NCT02672839|Experimental|Period 2 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
16590936|NCT02672839|Experimental|Period 2 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
16590937|NCT02672826|Experimental|adipose tissue surgery|The adipose tissue surgery (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated.
16590938|NCT02672813|Experimental|Pectoral Nerve I and II block|Under Ultrasound guidance, Pectoral nerve I block is given for every breast surgery using 10ml of 0.25 % Ropivacaine ( without added preservatives). Similarly Pectoral nerve II block is also given using 20 ml of 0.25% Ropivacaine ( without added preservative) in same group of patient.
16590939|NCT02672813|No Intervention|No block|Pectoral nerve block is not given in this group of patients undergoing breast surgery
16590944|NCT02672774|Other|Gastric cancer|Consecutive patients with gastric cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
16590945|NCT02672774|Other|Colorectal cancer|Consecutive patients with colorectal cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
16590946|NCT02672761|Experimental|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
16590947|NCT02672761|Experimental|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
16590948|NCT02672761|Active Comparator|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
16590949|NCT02672761|Placebo Comparator|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
16590950|NCT02672748|Experimental|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
16590951|NCT02672748|No Intervention|Control|The control families receive a garden as a delayed intervention after two years.
16590952|NCT02672735|Experimental|Corrective Exercise Program|Participants in the Corrective Exercise Program (CEP) group (n = 28) will be given a four-week corrective exercise programming intervention.
16590953|NCT02672735|No Intervention|Control|The participants in the Control (CON) group (n = 28) will have their four-week corrective exercise programming intervention deferred for 4 weeks, and as such, will serve as the comparative group for the CEP group.
16590954|NCT02672722|Experimental|Healthy Test Subjects|We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
16590955|NCT02672709|Experimental|Anticoagulation|Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.
16590956|NCT02672696|Experimental|FluoroMap group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).
~In this group, the surgeon will use the FluoroMap 3D reconstruction system (Stryker Inc) with the standard fluoroscopy to help him place the cephalic screw in the femoral head."
16590957|NCT02672696|No Intervention|Test group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).
~In this group, the surgeon will use only the standard fluoroscopy to help him visualize the position of the cephalic screw in the femoral head."
16590958|NCT02672670|Experimental|Coping-oriented supportive programme|Coping-oriented supportive programme: education of the SCI disease information, learning from role model by watching a well-established DVD, discussion about how to break down stressors and used appropriate coping strategies (problem-solving training, cognitive re-constructing, relaxation exercises, and activity scheduling) to manage the stressors relating to SCI. Social skills training and ways of maintaining and improving social support will also be discussed and practiced in the COSP.
16590959|NCT02672670|Active Comparator|A didactic group|Usual rehabilitation care--routine inpatient rehabilitation care and brief education in groups (structured by both the rehabilitation nurses and the researcher), which will consist of similar professional contacts as the intervention (COSP) group, and thus can balance between the two study groups for the effect of social contacts and attention to SCI patients during group sessions. The intervention in the comparison group will be conducted by a rehabilitation nurse in the SCI wards. The knowledge/didactic education presented to the patients in the comparison group will be the basic health education and relevant information provided by the rehabilitation nurses in their routine care (mainly including knowledge of SCI, nutritional needs, skin care, bowel and bladder training, and other physical and psychological care of patients with SCI provided by the inpatient rehabilitation wards).
16590960|NCT02672644|Experimental|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
16590961|NCT02672644|Experimental|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
16590962|NCT02672631||Median Nerve injury hand|Participants will be randomly called; and that 10 participants which had unilateral median nerve transection totally and repaired primely in our clinic at 2014. In the sample, correlations between physical examination (Tinnel Test, motor strength assessment (Medical Research Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW) monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test), ENMG with the DTI results will be assessed.
16590963|NCT02672631||Healthy Hand|Control group will be taken from patients other hand which had not injured before. And we will compare with first group's results.
16590964|NCT02672618||chronic heart failure|18-85years old,having symptoms of heart failure,New York Heart Association（NYHA） class II or above American College of Cardiology/American Heart Association（ACC/AHA） class B, C, including hypertensive heart disease, rheumatic heart disease, ischemic cardiomyopathy and idiopathic cardiomyopathy
16590965|NCT02672618||normalCardiac function|18-85years old,no symptoms of heart failure,NYHA class I or above ACC/AHA class A, including controled hypertension,stability coronary heart disease and rheumatic heart disease
16590966|NCT02672618||healthy volunteers|18-85years old,Without basic cardiovascular diseases
16590967|NCT02672605|No Intervention|Control|Participant completes a survey measuring abortion stigma prior to receiving the mandatory Pennsylvania State consent for their abortion.
16590968|NCT02672605|Experimental|Investigational|Participant completes a survey measuring abortion stigma after receiving the mandatory Pennsylvania State consent for their abortion.
16590969|NCT02672592|Active Comparator|Anakinra|Anakinra//Kineret® 100mg s.c. bid
16590970|NCT02672592|Placebo Comparator|Placebo|Sodium Chloride 0.9% s.c. bid
16590971|NCT02672579||Children 4-7 years|Pediatric subjects between the ages of 4 and 7 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
16590972|NCT02672579||Children 8-17 years|Pediatric subjects between the ages of 8 and 17 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
16590973|NCT02672579||Parents|Parents of pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of their child's severity of pruritus.
16590974|NCT02672579||Clinicians|Clinicians treating pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of the child's severity of pruritus.
16590975|NCT02672566|Experimental|Experimental group : enoxaparin|Experimental group will take enoxaparin (4000 Ui / Day) and will benefit from the usual care.
16590976|NCT02672566|Active Comparator|Control group|The control group will only benefit from the usual care.
16590977|NCT02672553|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
16590978|NCT02672553|Active Comparator|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
16590979|NCT02672540|Experimental|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
16590980|NCT02672540|Placebo Comparator|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
16590981|NCT02672527|Experimental|TRA|"At Day 1 (D1), premedication with dexamethasone (20 mg) and a 5-HT3 receptor antagonist anti-emetic agent will be intravenously administered 30 minutes prior to trabectedin administration. Trabectedin will be administered through a central venous catheter at a starting dose of 1.5 mg/m² over 24 hours, diluted in at least 500 mL of normal saline solution or of glucose 5% injectable solution.
~Each treatment cycle will last 21 days. Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal, or toxicities.
~In case of disease progression, the further treatments will be based on investigator's judgement."
16590982|NCT02672527|No Intervention|BSC|"Treatment:
~Patients will receive the best supportive care (BSC) in order to alleviate their symptoms and improve their Quality of Life (QoL).
~Antineoplastic agents (including surgery, radiotherapy, thermotherapy, chemotherapy, immunotherapy, hormonal treatment or antibodies-based treatments) are prohibited.
~Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal.
~In case of disease progression, a treatment with trabectedin will be proposed (cross-over). In case of patient refusal, the further treatments will be based on investigator's judgement."
16590983|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.
~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
16590984|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.
~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
16590985|NCT02672501|Experimental|anti-CD19-CAR-T cells|patients receive chemotherapy(CF, cyclophosphamide and Fludarabine) on day -6 to day -1, then infusied with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity.
16590986|NCT02672488|Experimental|Sorafenib and Metformin|Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day
16590987|NCT02672488|Active Comparator|Sorafenib Alone|Sorafenib 400μg tablet by mouth, twice per day
16590988|NCT02672475|Experimental|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16590989|NCT02672462|Experimental|Renal denervation|
16590990|NCT02672449|Experimental|External beam radiotherapy|A total of 65 consecutive newly diagnosed prostate cancer patients with 2013 NCCN high risk category will be consecutively enrolled in a prospective phase II trial on Carbon Ions Boost Followed by Pelvic Photon Radiotherapy .
16590991|NCT02672436|Experimental|ENERGI-F703|ENERGI-F703, topical application, 2 times daily for 12 weeks
16590992|NCT02672436|Placebo Comparator|Placebo|ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
16590993|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
16590994|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
16590995|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
16590996|NCT02672397|Experimental|Hispanic Intervention|Hispanic subjects that receive additional epidural education [44 patients]
16590997|NCT02672397|No Intervention|Hispanic Control|Hispanic subjects that receive standard of care [44 patients]
16590998|NCT02672397|Experimental|Non-Hispanic Intervention|Non-Hispanic subjects that receive additional epidural education [44 patients]
16590999|NCT02672397|No Intervention|Non-Hispanic Control|Non-Hispanic subjects that receive standard of care [44 patients].
16591030|NCT02672189|Experimental|EVA-Online self-management group|The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.
16591000|NCT02672384|Experimental|patients in ICU|"Dental examination will be performed to diagnose CP based on the Centre for Diseases Control definition.
~A point of care P. gingivalis test (Denka Seiken Co (Japan) ) on saliva and detection of antibodies against P. gingivalis in sera will be performed.
~In case of discrepancies between both diagnoses methods, RT-PCR for identification of P. gingivalis and other pathogens will be performed on samples of periodontal pocket performed in routine."
16591001|NCT02672371|Experimental|active eMNS|Subjects with receive active eMNS for 20 minutes.
16591002|NCT02672371|Sham Comparator|sham eMNS|Subjects with receive sham eMNS for 20 minutes.
16591003|NCT02672358|Experimental|Dabrafenib +Trametinib|Oral Dabrafenib plus Oral Trametinib
16591004|NCT02672345||Sevoflurane Group|Group of patients receiving sevorane during extracorporeal circulation period.
16591005|NCT02672345||Not Sevoflurane Group|Group of patients who did not receive the sevorane during extracorporeal circulation period.
16591006|NCT02672332|Experimental|SB204 4%|SB204 4% topically once daily
16591007|NCT02672332|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
16591008|NCT02672319|Experimental|EUS-guided glue injection|Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
16591009|NCT02672319|No Intervention|Historical control|A historical control group of HCC patients with gastroesophageal variceal bleeding who underwent conventional cyanoacrylate injection by OGD for index variceal bleeding based on de-identified data from an existing prospective GI bleed database from 2009-2013 would also be included to allow a more meaningful interpretation of the rebleeding rate from gastroesophageal varices from this study.
16591010|NCT02672306|Experimental|UCMSCs|Subjects with Alzheimer's Disease Intervention: UCMSCs
16591011|NCT02672306|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
16591012|NCT02672293|Experimental|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
16591013|NCT02672280|Experimental|Medical Collagen Membrane with MSC|Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).
16591014|NCT02672280|Active Comparator|Medical Collagen Membrane|Application of medical collagen membrane only.
16591015|NCT02672267|Experimental|Stem Cells|Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells
16591016|NCT02672267|Placebo Comparator|Placebo|Lactated Ringer's Solution
16591017|NCT02672254||Shams|Samples without any type of treatment
16591018|NCT02672254||Samples with 1 treatment|These samples will be treated with only one therapy: chemical agents such as cisplatin or other metallic compounds, or with superficial radiotherapy. These results will help us understand the effectiveness of each treatment by itself on cSCC cells.
16591019|NCT02672254||Samples with 2 treatments|These samples will be treated with both, chemical agents followed by superficial radiotherapy. These results will provide us information concerning the effectiveness of both treatments, wich is expected to be enhanced by the concomitant effects.
16591020|NCT02672241|Experimental|radio-chemotherapy plus nimotuzumab|Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
16591021|NCT02672228|Experimental|MalariaSense device|This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR
16591022|NCT02672215|Experimental|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
16591023|NCT02672215|Active Comparator|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
16591024|NCT02672215|No Intervention|control group|A waitlist control condition and received the generic intervention after completing all measurements
16591025|NCT02672202|Active Comparator|Duloxetine|Treatment
16591026|NCT02672202|Active Comparator|Pregabalin|Treatment
16591027|NCT02672202|Placebo Comparator|Placebo|
16591028|NCT02672189|No Intervention|Waiting list control group|Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.
16591029|NCT02672189|Experimental|EVA-Online guided group|"The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).
~Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support."
16591060|NCT02671942|Active Comparator|roflumilast:250μg|Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
16591031|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
16591032|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
16591033|NCT02672163|Experimental|AACD-Therapy group|6 patients are recruited to the AADC-therapy group. Autologous atrial appendage derived cells (AADCs) are harvested from the appendage tissue removed during the venal cannulation of bypass. The cells and their extracellular matrix are placed with tissue clue to Cormatrix-sheet and further on top of the myocardium in the area of infarction scar. The procedure is done simultaneously with CABG surgery. The patients will be carefully monitored after the operations and cardiac MRI and echocardiogram will be performed previously to surgery as well as during the follow ups.
16591034|NCT02672163|Active Comparator|Control group|20 patients are recruited to form the control group. They are patients scheduled for elective CABG surgery and they meet the same inclusion and exclusion criteria as the therapy group. There patients are followed as the hospital protocol with out any additional imagination or blood tests.
16591035|NCT02672150|No Intervention|Control|During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 & 3 to document what practice was before the study.
16591036|NCT02672150|Active Comparator|Core|"In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.
~these principles to their improvement efforts during the implementation phase."
16591037|NCT02672150|Experimental|Enhanced|While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
16591038|NCT02672137|Experimental|knowledge translation|knowledge translation 12-month multi-facet intensive knowledge translation measures that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
16591039|NCT02672137|No Intervention|Usual care|no intervention
16591040|NCT02672111|Experimental|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)
~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
16591041|NCT02672111|Experimental|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
16591042|NCT02672098|Experimental|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
16591043|NCT02672085|Experimental|PRP infiltration|Supraspinatus interstitial lesion needling and infiltration with PRP
16591044|NCT02672085|Active Comparator|Needling|Supraspinatus interstitial lesion needling and infiltration with NaCl
16591045|NCT02672072||Control group|5-day specific training with dedicated scenario done by an ICU expert simulation team after the period of the study
16591046|NCT02672072||Simulation group|5-day specific training with dedicated scenario done by an ICU expert simulation team
16591047|NCT02672059||Peripheral Neuropathy|Patients with peripheral neuropathy (observational study, no interventions)
16591048|NCT02672046||Patients with knee injuries|Patients referred to assessment at the Clinic of Sports Injuries
16591049|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
16591050|NCT02672020|Experimental|patients with adrenal tumor|
16591051|NCT02672007|Other|Included patients|All included patients will have respiratory rates measured by a research assistant using a criterion standard approach, by the SensiumVitals device and by the ward staff.
16591052|NCT02671994|Experimental|A (experimental group)|Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
16591053|NCT02671994|No Intervention|B (control group)|Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
16591054|NCT02671968|Experimental|CGM group|
16591055|NCT02671968|No Intervention|Control group|
16591056|NCT02671955|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
16591057|NCT02671955|Experimental|Part 2: Biomarker Evaluation|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
16591058|NCT02671955|Experimental|Part 3: Dose Expansion|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
16591059|NCT02671955|Experimental|Part 4: Dose Expansion|Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
16591061|NCT02671942|Active Comparator|roflumilast:375μg|Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
16591062|NCT02671942|Active Comparator|roflumilast:500μg|Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
16591063|NCT02671942|Placebo Comparator|placebo|Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
16591064|NCT02671929|Experimental|self-help program + feedback|Patients in this arm receive access to the internet-based self-help program and get feedback on their progress in the program.
16591065|NCT02671929|Active Comparator|self-help program|Patients in this arm receive access to the internet-based self-help program and don't get any therapeutic feedback
16591066|NCT02671916||all patients|questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU
16591067|NCT02671903|Active Comparator|Pacemaker: AV optimised, His pacing|Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.
16591068|NCT02671903|No Intervention|No pacing|Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.
16591069|NCT02671890|Experimental|Arm I (chemotherapy and disulfiram)|Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
16591070|NCT02671890|Active Comparator|Arm II (chemotherapy and placebo)|Patients receive chemotherapy at the discretion of the treating oncologist and placebo PO on days 1-28 or days 1-35.
16591071|NCT02671890|Experimental|Cohort I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
16591072|NCT02671864|Other|1: incretin-based therapy|Patients with incretin-based therapy
16591073|NCT02671864|Other|2: other antidiabetic|Patients with other antidiabetic
16591074|NCT02671851||Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs at the level of T3-T4 with 20 mL bupivacaine 0.375% as an adjunct to general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
16591075|NCT02671851||IV metamizole sodium, paracetamol|Patients received only standardized general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
16591076|NCT02671838|Other|Musculoskeletal ultrasound program|Participants will receive the musculoskeletal ultrasound program
16591077|NCT02671838|No Intervention|Control|Participants will not be receiving the musculoskeletal ultrasound program.
16591078|NCT02671825|Experimental|PUR0217a|PUR0200 formulation 1
16591079|NCT02671825|Experimental|PUR0228a|PUR0200 formulation 2
16591080|NCT02671825|Experimental|PUR0228b|PUR0200 formulation 3
16591081|NCT02671825|Experimental|PUR0228c|PUR0200 formulation 4
16591082|NCT02671825|Experimental|PUR0230c|PUR0200 formulation 5
16591083|NCT02671825|Active Comparator|Reference Product 1|Reference Product formulation with active charcoal
16591084|NCT02671825|Active Comparator|Reference Product 2|Reference Product without active charcoal
16591085|NCT02671799|Experimental|VenTouch System Implant|The VenTouch System is indicated for patients who have moderately severe or severe functional mitral regurgitation (grade 3 or 4 MR).
16591086|NCT02671786|Experimental|Intervention Arm|"Intervention area: Provision of community based health care to severely malnourished children 6 months age in 16 tribal villages by trained semi-literate village health workers.
~Treatment of severely malnourished children through MAHAN RUTF & MAHAN Vit-Min mix
~Growth monitoring of all children below the age of 5 years
~Treatment of associated diseases like Diarrhea, Pneumonia, Malaria, etc.
~Management of resistant or relapsed severely malnourished cases by pediatrician.
~Intensive behavior change communication of parents of children below the age of 5 years for proper nutrition.
~Dose: 46 gms of proteins/kg/day & 100170 calories/kg/day with gradual escalation with micro nutrient supplementation Route: Oral Frequency: 4 times a day Duration: 12 weeks"
16591087|NCT02671786|No Intervention|Control Arm|Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
16591088|NCT02671773||BTS Step 2 Asthmatic patients|Group of 20 asthmatic patients on British Thoracic Society (BTS) treatment step 2 - regular low dose inhaled corticosteroids (dose of <400 micrograms/day BDP equivalent)
16591089|NCT02671773||BTS Step 4 Asthmatic patients on treatment with fluticasone|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled fluticasone (dose of >500 micrograms/day)
16591090|NCT02671773||BTS Step 4 Asthmatic patients on treatment with budesonide|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled budesonide (dose of >800 micrograms/day)
16591091|NCT02671760|Experimental|Treatment|SM-1
16591092|NCT02671760|Active Comparator|Comparator|2-drug combination
16591093|NCT02671760|Placebo Comparator|Placebo|Placebo
16591094|NCT02671747|Experimental|Pilot workshop|Participants attend intervention. No control arm
16591095|NCT02671734|No Intervention|control|Subjects in this arm received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
16591096|NCT02671734|Active Comparator|intervention|Subjects in this arm viewed a video detailing key elements of informed consent. Subjects in this arm also received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
16591097|NCT02671721|No Intervention|Conventional Strategy|Patients will receive usual and prudent PEEP and tidal volume settings.
16591098|NCT02671721|Experimental|Maximal Compliance Strategy|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
16591099|NCT02671721|Experimental|Transpulmonary Pressure Strategy|Personal PEEP titration using transpulmonary pressures obtained from a naso/orogastric tube containing an esophageal balloon port
16591100|NCT02671708|Experimental|IDA+BUCY|For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
16591101|NCT02671708|Active Comparator|BUCY|"For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days
~-3 and -2."
16591102|NCT02671695|Experimental|Group 1|chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
16591103|NCT02671695|Experimental|Group 2|chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months
16591104|NCT02671682|Experimental|Immunoadsorption|Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume
16591105|NCT02671682|Active Comparator|Plasmapheresis|Plasmapheresis on 5 consecutive days with 2l plasma exchange
16591106|NCT02671669|Active Comparator|Usual Care (UC)|
16591107|NCT02671669|Active Comparator|Movn application (MVN)|
16591108|NCT02671630|No Intervention|Control group|Patients receive only usual hospital care
16591109|NCT02671630|Experimental|Experimental group|Patients receive only usual hospital care and community-based computerized cognitive training program
16591110|NCT02671617|No Intervention|Control|Control: This group of patients will receive 'current best practice' as per UK NHS recommendations for their specific cancer management prior to surgery.
16591111|NCT02671617|Experimental|High intensity interval training|"Exercise: Participants in this group will attend 3-4 times per week to complete HIIT training during the period from diagnosis to surgery.
~High intensity interval training (HIIT)"
16591112|NCT02671591|Experimental|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP. The control condition is a one-hour, theory-based, one-to-one session that will help YBMSM think more about using condoms consistently and correctly with every sex partner.
16591113|NCT02671591|Active Comparator|control|"This condition will include the provision of free condoms and lubricants - selected from a buffet of condoms and lubricants designed to offer men a broad selection of high quality products that can optimize the fit and feel of condoms during sex."
16591114|NCT02671578|Experimental|Nitrous oxide|Nitrous oxide sedation
16591115|NCT02671565||Hyaluronic acid (HA) injection users|Patients with at least one procedure claim for intra-articular administration of hyaluronic acid (procedure codes: J7320, J7322, J7325, Q4084, J7317, Q4083, J7321, Q4085, J7323, Q4086, J7324, J7327, J7326) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as HA users.
16591116|NCT02671565||Corticosteroids (CS) injections users|Patients with at least one procedure claim for intra-articular administration of corticosteroids (procedure codes: J1020, J1030, J1040, J1094, J1100, J2920, J2930, J0702, J0704, J3300, J3301, J3302, J3303, J1700, J1710, J1720, J2650, J2920, J2930) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as CS users.
16591117|NCT02671565||HA non-users|Patients who do not have any claims for procedural or surgical intervention including HA and CS injections in first 90 days after their first specialist visit will be considered as HA non-users
16591118|NCT02671552|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren protein-type A microspheres IV and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during Magnetic Resonance Imaging (MRI) or computed tomography (CT) follow up.
16591119|NCT02671539|Experimental|open label injection of rAAV2.REP1|This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison
16591120|NCT02671526|Experimental|Computerized Plasticity-based Adaptive Cognitive Training|
16591121|NCT02671513|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.
16591122|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
16591123|NCT02671487|Experimental|Mind-Body Skills Groups|Mind-body skills groups will be administered for 2 hours once a week for 10 weeks and then once a month for 10 months.
16591124|NCT02671487|No Intervention|Wait List Control|No intervention will be administered. Students will have the opportunity to receive the intervention at the end of the study.
16591125|NCT02671461|Experimental|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
16591126|NCT02671461|Experimental|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
16591127|NCT02671461|Placebo Comparator|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
16591128|NCT02671448||Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care.
16591129|NCT02671435|Experimental|Part 1 -Dose escalation with 5 dose escalation cohorts|Durvalumab and monalizumab
16591130|NCT02671435|Experimental|Part 2 - Dose expansion with 4 dose expansion cohorts|Durvalumab with monalizumab
16591131|NCT02671435|Experimental|Part 3 -Dose Exploration with 10 dose exploration cohorts.|Durvalumab and monalizumab and standard of standard of care systemic therapy with or without a biologic agent and monalizumab in combination with biologic agent in CRC.
16591132|NCT02671409|Placebo Comparator|Control group|The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
16591171|NCT02671188|Placebo Comparator|Placebo|Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.
16591172|NCT02671175|Active Comparator|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
16591173|NCT02671175|Placebo Comparator|dihydroartemisinin-piperaquine Placebo|Placebo comparator (matching tablets containing no active ingredients)
16591133|NCT02671409|Experimental|MOB Group|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
16591134|NCT02671396|Experimental|Virtual reality based intervention|Virtual reality based balance training
16591135|NCT02671396|Active Comparator|Conventional intervention|Conventional balance training
16591136|NCT02671383|Active Comparator|Darunavir|Darunavir/Ritonavir 400/100mg once daily
16591137|NCT02671383|Active Comparator|Lopinavir|Lopinavir/Ritonavir 400/100mg twice daily
16591138|NCT02671357||ERAMIP with EEN|Minimally invasive pancreaticoduodenectomy (MIPD) with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory with EEN
16591139|NCT02671344||IAD group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
16591140|NCT02671344||FIV group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
16591141|NCT02671344||ICSI group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
16591142|NCT02671318|Active Comparator|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
16591143|NCT02671318|Active Comparator|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
16591144|NCT02671305|Experimental|placental circulation intact|preterm newborns assisted bedside with placental circulation intact
16591145|NCT02671305|Active Comparator|cord milking|preterm newborns who receive cord milking before assistance performed in a routine setting
16591146|NCT02671292|Experimental|Interpersonal Psychotherapy (IPT-WG)|IPT-WG targets the difficult social functioning and stressful events that are associated with loss of control eating and that are highly relevant to the adolescent children of military personnel.
16591147|NCT02671292|Active Comparator|Health Education (HE)|HE improves knowledge on various health topics including, alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
16591148|NCT02671279|Other|Low calorie diet|Dietary intervention group
16591149|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
16591150|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
16591151|NCT02671240||- Patients with behavioral addiction|
16591152|NCT02671240||- Patients with no behavioral addiction|
16591153|NCT02671227|Active Comparator|intrathecal bupivacaine + Mg sulfate|intrathecal bupivacaine 15 mg + intrathecal Mg sulfate 50 mg. in gynecologic laparoscopic surgeries.
16591154|NCT02671227|Active Comparator|intrathecal bupivacaine|intrathecal bupivacaine 15 mg in gynecologic laparoscopic surgeries.
16591155|NCT02671214|Placebo Comparator|Control|100 g high fibre flour
16591156|NCT02671214|Active Comparator|Active 1|85 g high fibre flour + 15 g legume flour
16591157|NCT02671214|Active Comparator|Active 2|98 g high fibre flour + 2 g guar gum
16591158|NCT02671214|Active Comparator|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
16591159|NCT02671214|Active Comparator|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
16591160|NCT02671214|Active Comparator|Active 5|96 g high fibre flour + 4 g guar gum
16591161|NCT02671214|Active Comparator|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
16591162|NCT02671214|Active Comparator|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
16591163|NCT02671214|Active Comparator|Active 8|94 g high fibre flour + 6 g guar gum
16591164|NCT02671214|Active Comparator|Active 9|98 g high fibre flour + 2 g konjac mannan
16591165|NCT02671214|Active Comparator|Active 10|96 g high fibre flour + 4 g konjac mannan
16591166|NCT02671214|Active Comparator|Active 11|100 g low fibre flour
16591167|NCT02671201||Group A|Theoretical training will be scheduled for 2 hours with lectures in basics of emergency ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 4 hours.
16591168|NCT02671201||Group B|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
16591169|NCT02671201||Group C|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound.
16591170|NCT02671188|Experimental|GSK3050002 100 mg/mL|Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
16591174|NCT02671162|Placebo Comparator|Wheat|Placebo capsule/ 2 capsule 3 times per day
16591176|NCT02671149|Experimental|Drink water|Participants will receive two 150ml drinks of water during the dehydration protocol
16591177|NCT02671149|No Intervention|Drink nothing|Participants will drink nothing during the dehydration protocol
16591178|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
16591179|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
16591180|NCT02671123|Active Comparator|Coronary PCI with OCT with Co-Registration|Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
16591181|NCT02671123|Placebo Comparator|Coronary PCI with OCT without Co-Registration|"Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted.
~I"
16591182|NCT02671110|Experimental|Transforming Your Life|The TYL program emphasized: 1) helping participants develop and maintain healthy habits and disrupt unhealthy habits, 2) enabling participants to create a personal food and exercise environment that increases exposure to healthy eating and physical activity and encourages automatic responding to goal-related cues, and 3) facilitating participants' weight loss motivation.
16591183|NCT02671110|Active Comparator|Diabetes Prevention program|The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
16591184|NCT02671097|Experimental|BAY1841788 (ODM-201) + Rosuvastatin|All subjects will receive a single dose BAY1841788 (ODM-201) (600 mg) followed by multiple doses BAY1841788 (ODM-201) (600 mg BID) as well as 2 times a single dose rosuvastatin (5 mg), once alone and once in combination with BAY1841788 (ODM-201).
16591185|NCT02671084|Experimental|Sevoflurane Group|Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
16591186|NCT02671084|Placebo Comparator|Control Group|Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
16591187|NCT02671058|Active Comparator|Cortenema|Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
16591188|NCT02671058|Experimental|Hydrocortisone acetate|Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
16591189|NCT02671045||A - Genomic profile by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
16591190|NCT02671045||B - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
16591191|NCT02671045||C - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
16591192|NCT02671045||D - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
16591193|NCT02671045||E - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
16591194|NCT02671045||F - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
16591195|NCT02671045||G - No genomic profiling|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.
16591196|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
16591197|NCT02671019|Experimental|Internet-based treatment|A five-module Internet-based treatment program for harmful alcohol use (including therapist support) based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
16591198|NCT02671019|Active Comparator|Face-to-face treatment|Same treatment content as in the Internet-based treatment delivered via face-to-face treatment sessions in specialized addiction treatment.
16591199|NCT02671006||Patients|Patients with an active Chronic Urticaria according to the EAACI criteria will be included. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
16591460|NCT02669420|Experimental|extra amniotic misoprostol|misoprostol dissolved in warm saline , become dissolute misoprostol saline solution(200 microgram every 4 hours)
16591200|NCT02671006||Volunteers|Volunteers must no have history of immediate allergy (patients under medical follow up for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched). Controls should have no history of atopy, urticaria or immediate allergy declared (rhinitis, urticaria, asthma) at the time of the test. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
16591201|NCT02670993|Experimental|Control group : Singing sessions.|Patients will participate to singing working sessions. They will continue to take their usual treatments during the study period.
16591202|NCT02670993|Active Comparator|Control group : Painting sessions.|Patients will continue to participate to painting work sessions, and to take their usual treatments during the study.
16591203|NCT02670980|Experimental|Retina Implant|Intelligent Retinal Implant System
16591204|NCT02670954|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both routine analgesic and sedation(dexmedetomidine,tramadol and flurbiprofen) are applied for this group of patients.
16591205|NCT02670954|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(Tramadol and flurbiprofen) is applied for this group of patients.
16591206|NCT02670941|Experimental|Ginger|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
16591207|NCT02670941|Experimental|Lavender|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
16591208|NCT02670941|Experimental|Orange|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
16591209|NCT02670941|Placebo Comparator|Jojoba|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
16591210|NCT02670928|Active Comparator|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
16591211|NCT02670928|Experimental|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
16591212|NCT02670915|Experimental|Meal-time faster-acting insulin aspart and insulin degludec|
16591213|NCT02670915|Active Comparator|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
16591214|NCT02670915|Experimental|Post-meal faster-acting insulin aspart and insulin degludec|
16591215|NCT02670902|Experimental|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
16591216|NCT02670902|Active Comparator|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus three telephone recovery check-up calls post-discharge.
16591217|NCT02670876|Experimental|Anti-bullying intervention|An anti-bullying intervention target to perpetrators of school bullying was conducted. The program consisted of 8 sessions over 4 weeks and was conducted by a board-certified psychiatrist and a therapist with previous training in psychosocial treatments. The intervention was based on cognitive-behavioral therapy (CBT) principles and addressed various factors that have been associated with perpetrators of school bullying, including impulse control, perspective taking (empathy), and the enhancement of communication skills.
16591218|NCT02670863|Experimental|Experimental Infant Formula|Experimental Infant Formula containing a prebiotic
16591219|NCT02670863|Active Comparator|Standard Infant Formula|Standard bovine milk-based term infant formula
16591220|NCT02670850|No Intervention|Control group|Patients received only routine hospital care
16591221|NCT02670850|Experimental|Intervention group|Patients received regular hospital routine care and model-based intervention program
16591222|NCT02670837|Experimental|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
16591223|NCT02670837|Experimental|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
16591630|NCT02668211|Other|PROFEMUR Preserve RSA|Single cohort of subjects prospectively implanted with PROFEMUR® Preserve Classic femoral components
16591224|NCT02670824|Experimental|CN-105 Active Drug|"The CN-105 drug administered via IV at an escalating scale of mg/kg.
~A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg"
16591225|NCT02670824|Placebo Comparator|Placebo|Normal Saline
16591226|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
16591227|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
16591228|NCT02670798|No Intervention|Control|Standard of care hematologic management in the operating room
16591229|NCT02670798|Experimental|Study|Standard of care hematologic management plus additional monitoring with the intervention of Thromboelastography laboratory testing and use of a thromboelastography-guided transfusion protocol.
16591230|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.003 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
16591231|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.01 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
16591232|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.02 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
16591233|NCT02670785|Placebo Comparator|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
16591234|NCT02670772|Active Comparator|Stavudine|Stavudine 20mg twice daily for 96 weeks
16591235|NCT02670772|Active Comparator|Tenofovir Disoproxil Fumarate|Tenofovir 300mg once daily for 96 weeks
16591236|NCT02670759|Experimental|Paravertebral analgesia|A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
16591237|NCT02670759|Active Comparator|Intercostal analgesia|An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.
16591238|NCT02670746||Nab-paclitaxel in combination with gemcitabine (AG)|The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).
16591239|NCT02670733||high responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, intracranial pressure (ICP) increases above the median for the study population.
16591240|NCT02670733||low responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, the level of intracranial pressure (ICP) increases below the median for the study population.
16591241|NCT02670720|Experimental|avoralstat|Five avoralstat capsules (100 mg) to be taken three times daily by mouth
16591242|NCT02670707|Experimental|"Cytarabine (experimental) arm"|On this arm, patients will receive single therapy with cytarabine.
16591243|NCT02670707|Active Comparator|"Vinblastine/prednisone (standard) arm"|On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.
16591244|NCT02670694||Rett Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
16591245|NCT02670694||Angelman's Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Angelman's Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
16591246|NCT02670694||Prader-Willi Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Prader-Willi Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
16591247|NCT02670694||Control|Siblings of RTT, AS and PW subjects will serve as control subjects.
16591248|NCT02670681|Active Comparator|Aerobic Exercise Mild Intensity|The subjects engage in aerobic exercise training (8 weeks) of mild intensity (continuous). The intensity is controlled by a corresponding heart rate at anaerobic threshold.
16591249|NCT02670681|Active Comparator|Aerobic Exercise Moderate Intensity|The subjects engage in aerobic exercise training (8 weeks) of moderate intensity (continuous). The intensity is controlled by a corresponding heart rate between anaerobic threshold and respiratory compensation point.
16591250|NCT02670681|Active Comparator|Aerobic Exercise High Intensity|The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
16591251|NCT02670668|Experimental|Mutation analysis- NACwith PCR|consisting of 50 patients undergoing NACwith pathological compete response
16591252|NCT02670668|Experimental|Mutation analysis-NAC with SD/PD.|consisting of 50 patients undergoing NAC with SD/PD
16591253|NCT02670655|Experimental|Group A (short-time iontophoresis group)|Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h)
16591254|NCT02670655|Active Comparator|Group B (short-time conventional group)|Group B was treated with conventional AFL-PDT with a short incubation time (2 h)
16591255|NCT02670655|Active Comparator|Group C (long-time conventional group)|Group C was treated with conventional AFL-PDT with a standard incubation time (3 h)
16591256|NCT02670642|Experimental|On demand 20 mg esomeprazole|On demand treatment with 20-mg esomeprazole once daily when needed
16591257|NCT02670642|Active Comparator|Continuous 20 mg esomeprazole|Continuous treatment with 20 mg esomeprazole once daily
16591258|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.
~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
16591259|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.
~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
16591811|NCT02667041|Active Comparator|Blood biomarkers|Investigation of pre- and post-treatment protein biomarkers
16591260|NCT02670616|Experimental|ibrutinib in combination with r-CHOP|Ibrutinib560 mg daily on day 1-21 per each cycle ,Rituximab375 mg/m2, Cyclophosphamide750 mg/m2, doxorubicin 50 mg/m2, vincristine1.4 mg/m2 on day 1; Prednisolone 100mg per day on day 1-5 ,cycle length: 21 days ,Six cycles of treatment
16591261|NCT02670603|Experimental|Experimental arm|In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
16591262|NCT02670603|Other|Control arm|"In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.
~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm."
16591263|NCT02670590|Experimental|NAFLD|diet
16591264|NCT02670577||stage I or II HR-positive, HER2-negative|"Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive & HER2 negative
~& Axillary lymph node status: 0-3 involved"
16591265|NCT02670577||HER2+|"Histologically proven invasive T1a or T1b breast cancer
~& Hormone receptor negative or positive
~& HER2 positive
~& Axillary lymph node status: 0-1 involved"
16591266|NCT02670577||Triple Negative|"Histologically proven invasive T1a or T1b breast cancer
~& Hormone receptor negative
~& HER2 negative
~& Axillary lymph node status: 0-1 involved"
16591267|NCT02670577||Neoadjuvant|Stage I or II patients receiving neoadjuvant therapy.
16591268|NCT02670564|Experimental|Total body irradiation (TBI)|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.
~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
16591269|NCT02670564|Experimental|Busulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.
~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
16591270|NCT02670564|Experimental|Treosulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.
~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
16591271|NCT02670551|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
16591272|NCT02670551|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
16591273|NCT02670551|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
16591274|NCT02670538|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
16591275|NCT02670538|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
16591276|NCT02670538|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
16591277|NCT02670525|Experimental|Relapsed/Refractory leukemia|"Cohort 1: Relapsed/refractory leukemia
~Acute lymphoblastic leukemia, first or greater relapse
~Acute myeloid leukemia, first or greater relapse
~Leukemia refractory to induction chemotherapy
~Other recurrent leukemia
~Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy
~After the screening procedures confirms patient eligibility:
~Leukemia Profiling will be performed
~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
16591278|NCT02670525|Experimental|New diagnosis|"Cohort 2: New diagnosis
~Acute myeloid leukemia, new diagnosis (excluding acute promyelocytic leukemia (APL))
~New diagnosis infant MLL-rearranged ALL or low hypodiploid (<40 chromosomes) ALL
~Rare leukemia- e.g., JMML, leukemia of ambiguous lineage
~Secondary leukemia
~Myelodysplastic syndrome (MDS) not eligible for stem cell transplant
~After the screening procedures confirms eligibility:
~Leukemia Profiling will be performed
~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
16591279|NCT02670512|Experimental|Telehome Monitoring|Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment reminders, educational content).
16591280|NCT02670512|No Intervention|Standard of Care|Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone communication and using pen and paper log to track their treatments and supplies.
16591281|NCT02670499|Experimental|GAP-FLEX|Study Device will be used up to 6 times per day for up to 6 minutes to aid in the recovery and improve the degree of flexion from TKR
16591282|NCT02670499|Active Comparator|CPM|Control Device will be used up to 2 hours per day for up to 3 times per day to aid in the recovery and improve the degree of flexion from TKR and be compared to the Study Device
16591283|NCT02670486|No Intervention|standard of care|Usual urodynamics with no intervention.
16591284|NCT02670486|Active Comparator|Audiovisual intervention|Audiovisual stimulus during urodynamic testing.
16591285|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
16591286|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
16591287|NCT02670460|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left subclavian vein.
16591288|NCT02670447||First episode of psychosis patients|Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.
16591289|NCT02670434|Experimental|NK-104-CR|Controlled release NK-104
16591290|NCT02670434|Placebo Comparator|Placebo|Livalo Placebo
16591291|NCT02670434|Active Comparator|Livalo® Immediate Release IR|Immediate Release Livalo®
16591292|NCT02670421|Active Comparator|Face to face Heart SMART program|Stress management program presented in a face to face meeting of 90-100 minutes with daily printed program instructions to follow over the next 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
16591293|NCT02670421|Active Comparator|Online Heart SMART program|Stress management program in the form of 10- minute videos completed weekly by participant on-line for 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
16591294|NCT02670395|Experimental|JNJ-54416076|Participants will receive single dose of JNJ-54416076 (in ascending dose) in Part 1 and 2 doses of JNJ-54416076 (one dose in the fasted state and an identical dose in the fed state) in Part 2. The dose selected for Part 2 will be selected based on the preliminary safety and PK data in Part 1.
16591295|NCT02670395|Experimental|Placebo|Participants will receive single dose of placebo in Part 1.
16591296|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
16591297|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
16591298|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.
16591299|NCT02670369|Experimental|Sitting time prompt|All participants will receive a prompting device (one-arm intervention).
16591300|NCT02670356|Experimental|Fish oil|fish oil, 1500 mg/day, EPA:DHA ratio of 4:1, each capsule containing 750 mg total EPA+DHA, 2 capsules/day for 10 weeks
16591301|NCT02670356|Experimental|krill oil|krill oil, 300 mg/day, each capsule containing 74 mg total EPA+DHA , 1 capsule/day for 10 weeks
16591302|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
16591303|NCT02670330|Experimental|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
16591304|NCT02670317|Experimental|G CHOP 21 + Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
16591305|NCT02670304|Experimental|letrozole|letrozole for the first day after ovum picked up at least for 5 days.
16591306|NCT02670304|Active Comparator|aspirin|asprin for the first day after ovum picked up at least for 5 days.
16591307|NCT02670291|Active Comparator|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
16591308|NCT02670291|Sham Comparator|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
16591309|NCT02670278||US-Washington, Idaho|healthy breastfeeding women and their infants
16591310|NCT02670278||US-California|healthy breastfeeding women and their infants
16591311|NCT02670278||Sweden|healthy breastfeeding women and their infants
16591312|NCT02670278||Spain|healthy breastfeeding women and their infants
16591313|NCT02670278||Peru|healthy breastfeeding women and their infants
16591314|NCT02670278||Kenya|healthy breastfeeding women and their infants
16591315|NCT02670278||Ethiopia-rural|healthy breastfeeding women and their infants
16591316|NCT02670278||Ethiopia-urban|healthy breastfeeding women and their infants
16591317|NCT02670278||The Gambia-rural|healthy breastfeeding women and their infants
16591318|NCT02670278||The Gambia-urban|healthy breastfeeding women and their infants
16591319|NCT02670278||Ghana|healthy breastfeeding women and their infants
16591320|NCT02670265|Active Comparator|Parenteral nutrition|Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
16591321|NCT02670265|Placebo Comparator|Isotonic fluid|Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
16591322|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
16591323|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
16591324|NCT02670239||EVLP group|All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
16591325|NCT02670226|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
16591326|NCT02670226|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
16591327|NCT02670213||NovoThirteen®|
16591328|NCT02670200|Experimental|intervention arm / verum arm|Participants can work on ten modules specialized cognitive behavior treatments to learn and deal with mindfulness, acceptance and commitment. They should learn to handle their emotions, to accept the situation and to get in an active future. The participants can direct contact a psychotherapist via email, Chat or Skype/tokbox. The modules based on Cognitive Behavior Therapy.
16591329|NCT02670200|Active Comparator|non-intervention arm / control group|Participants can work on six modules with information und education goals for learning something about their possibilities to become a better mood, better psychovegetative or psychosocial situation as cancer patient. This modules are based on Cognitive Behavior Therapy. The non-intervention arm will only allow contact to the platform, no direct contact to a psychotherapist (in opposite to the intervention arm) is available.
16591330|NCT02670187|Experimental|GLS-5300|GLS-5300 at 0.67 mg DNA/dose
16591331|NCT02670187|Experimental|GLS-5300 at 2 mg DNA/dose|GLS-5300 at 2 mg DNA/dose
16591332|NCT02670187|Experimental|GLS-5300 at 6 mg DNA/dose|GLS-5300 at 6 mg DNA/dose
16591333|NCT02670174|Active Comparator|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
16591461|NCT02669420|Experimental|vaginal misoprostol|misoprostol tablet soaked with distilled water and inserted in the posterior fornix of the vagina( 200 microgram every 4 hours)
16591334|NCT02670174|Experimental|Separate kinetic chain training|A home exercise program consisting of traditional training exercises as well as separate exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
16591335|NCT02670174|Experimental|Integrated kinetic chain training|A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
16591336|NCT02670161|Active Comparator|Treatment A (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
16591337|NCT02670161|Active Comparator|Treatment B (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
16591338|NCT02670161|Active Comparator|Treatment C (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
16591339|NCT02670148|Experimental|Chiropractic Care (CC)|Participants in the CC group will receive evaluation and treatment (chiropractic manipulative therapy) from a doctor of chiropractic over a 4 week period.
16591340|NCT02670148|No Intervention|Waitlist control group (WC)|Participants allocated to the waitlist control group will not receive any chiropractic treatment during the active study period. These individuals will be scheduled for one additional study visit following allocation. This final study visit will be scheduled 4 weeks after allocation (± 7 days). WC participants are not restricted from receiving any other healthcare during study participation. However, participants in the WC group will be asked not to receive any chiropractic care or spinal manipulation by any other provider during the 4 week intervention period. After WC participants complete the final study visit, they will be offered chiropractic care. This treatment will not be part of the study and no data will be collected at these visits.
16591341|NCT02670135|Placebo Comparator|triclosan free toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
16591342|NCT02670135|Active Comparator|Triclosan containing toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
16591343|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
16591344|NCT02670109|Experimental|Unique|"Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.
~Then they will undergo an Autologous Hematopoietic Stem Cell Transplantation."
16591345|NCT02670096|Experimental|Reference therapy|"Baseline evaluation of subjects without acetazolamide administration
~Follow up evaluation of subjects one hour after acetazolamide administration"
16591346|NCT02670083|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
16591347|NCT02670083|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
16591348|NCT02670070|Active Comparator|Coadministration of G+R|Coadministration of gemigliptin 50mg and rosuvastatin 20mg
16591349|NCT02670070|Experimental|Combination G/R|Combination of gemigliptin 50mg / rosuvastatin 20mg
16591350|NCT02670057|Experimental|Transnasal SPG block|
16591351|NCT02670044|Experimental|Dose-Escalation, Arm A (Venetoclax + Cobimetinib)|Participants will receive Venetoclax daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib daily on Days 1-21 of each 28-day treatment cycle.
16591352|NCT02670044|Experimental|Dose-Escalation, Arm B (Venetoclax + Idasanutlin)|Participants will receive Venetoclax on Days 1-28 of each 28 day treatment cycle and Idasanutlin daily or twice daily on Days 1-5 of each 28 day treatment cycle.
16591353|NCT02670044|Experimental|Dosing Schedule Optimization, Arm B (Venetoclax+Idasanutlin)|Participants will receive Venetoclax on Days 1-21 or Days 1-14 of each 28-day treatment cycle and Idasanutlin daily on Days 1-5 of each 28 day treatment cycle.
16591354|NCT02670031||Newly Diagnosed Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
16591462|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
16591355|NCT02670031||Well-Controlled Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
16591356|NCT02670031||Resistant Essential Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
16591357|NCT02670018|Active Comparator|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets
16591358|NCT02670018|Experimental|C|Combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets
16591359|NCT02670005||FFR-PCI group|patients with ST-segment elevation myocardial infarction (STEMI) who received fractional flow reserve (FFR)-guided selective percutaneous coronary intervention (PCI)
16591360|NCT02670005||angiography-PCI group|patients with STEMI who received angiography-guided selective PCI
16591361|NCT02669992|Experimental|Stapled anastomosis|Stapled anastomosis by the use of commercially available linear stapler device
16591362|NCT02669992|Active Comparator|Hand-sewn anastomosis|Hand-sewn by the use of a resorbable monofilament suture
16591363|NCT02669992|Experimental|Abdominal wall mesh closure|Closure by the use of a mesh low-weight net device
16591364|NCT02669992|Active Comparator|Abdominal wall suture closure|Closure by the use of slowly absorbing monofilament suture
16591365|NCT02669979|Experimental|Intervention|"Intervention in the research groups is professional oral care with tooth brush, ordinary fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month."
16591366|NCT02669979|No Intervention|Control|Care as usual. Common oral hygiene help administered by nursing staff.
16591367|NCT02669966|Experimental|Study Arm|Donor candidates with their intended recipients who meet criteria will be enrolled into this, the sole arm of our study. Donor-recipient pairs will be screened to meet criteria, and will proceed to kidney transplantation and post-transplant monitoring
16591368|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;
~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
16591369|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
16591370|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
16591371|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
16591372|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
16591373|NCT02669914|Experimental|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
16591374|NCT02669914|Experimental|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
16591375|NCT02669914|Experimental|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
16591376|NCT02669901|Other|Patients with opioid substance abuse disorders|All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
16591377|NCT02669888|Experimental|Indigo naturalis ointment|"Form: ointment
~Dose: each gram of ointment contains 200µg of indirubin
~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
16591378|NCT02669888|Placebo Comparator|Placebo|"Form: ointment
~Dose: vehicle
~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
16591379|NCT02669875|Active Comparator|Serelaxin|IV infusion of serelaxin (RLX030) for 2 hours
16591380|NCT02669875|Placebo Comparator|Placebo|IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours
16591381|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
16591382|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
16591383|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
16591384|NCT02669849|Placebo Comparator|Placebo|
16591385|NCT02669849|Experimental|VX-210|
16591386|NCT02669836|Experimental|Posterior fossa decompression surgery|The bone is surgically removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected
16591387|NCT02669836|Experimental|Dural augmentation surgery|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
16591388|NCT02669823||Children <15y|no intervention
16591389|NCT02669823||Adults >=15y|no intervention
16591390|NCT02669810|Experimental|PROTHERACYTES|The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia) or a catheter introduced via the femoral / radial route up to coronary arteries for epicardiac injections (BullFrog/Mercator).
16591391|NCT02669810|Active Comparator|Standard of Care|Patients will be treated as standard treatment for CHF post - AMI.
16591392|NCT02669797|Experimental|EMI|EMI (Arm 1): (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; and (2) a 8-week maintenance phase with EMI tips delivered on high stress days.
16591393|NCT02669797|Experimental|EMI + HV|"EMI + HV (Arm 2) includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) a 8-week maintenance phase with EMI tips delivered on high stress days."
16591394|NCT02669797|Experimental|EMI + HV + Video feedback|"EMI + HV + Video Feedback (Arm 3) includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
16591395|NCT02669784|Active Comparator|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
16591396|NCT02669784|Active Comparator|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
16591397|NCT02669771||Enzalutamide group|oral
16591398|NCT02669758|Experimental|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
16591399|NCT02669745||Women of Chinese Descent|Females of Chinese descent, aged 18 year to 70 year, diagnosed with Stage 1 or Stage 2 (excluding those involving more than 3 lymph nodes) breast cancer.
16591400|NCT02669732|Experimental|DS-8500a 75 mg once daily (QD)|tablets, orally, once daily for up to 28 days
16591401|NCT02669732|Placebo Comparator|Placebo|tablets, orally, once daily for up to 28 days
16591402|NCT02669719|Experimental|chemotherapy followed dendritic cells|pemetrexed and carboplatin chemotherapy followed dendritic cells infusion from Cycle 3
16591403|NCT02669719|Active Comparator|chemotherapy|pemetrexed and carboplatin chemotherapy only
16591404|NCT02669706||IV pentamidine|Pentamidine 4mg/kg IV every month (maximum 300mg)
16591405|NCT02669693|Placebo Comparator|bread without olives|Intervention (no olives): Subjects will consume a meal of 109 g white bread and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
16591406|NCT02669693|Active Comparator|bread with olives|Intervention (olives 100 g): Subjects will consume a meal of 109 g white bread, 100 g of olives and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
16591407|NCT02669680|Experimental|G-CSF + Standard therapy|Standard care of acute-on-chronic liver failure and application of G-CSF
16591408|NCT02669680|Active Comparator|Standard therapy|Standard care of acute-on-chronic liver failure
16591409|NCT02669667|Experimental|Cohort 1|single dose of MEDI9314 or placebo
16591410|NCT02669667|Experimental|Cohort 2|single dose of MEDI9314 or placebo
16591411|NCT02669667|Experimental|Cohort 3|single dose of MEDI9314 or placebo
16591412|NCT02669667|Experimental|Cohort 4|single dose of MEDI9314 or placebo
16591413|NCT02669667|Experimental|Japanese Cohort|single dose of MEDI9314 or placebo
16591414|NCT02669667|Experimental|Cohort 5|single dose of MEDI9314 or placebo
16591415|NCT02669654|Experimental|Day-care management of Severe Pneumonia|management in Day-care clinic
16591416|NCT02669654|No Intervention|Existing Treatment Centre (ETC)|Severe Pneumonia management in Existing Treatment Centre
16591417|NCT02669641|Experimental|Steatosis|Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline
16591418|NCT02669628||Surgical technique|Laparoscopic ovarian cystectomy
16591419|NCT02669628||Alcohol sclerotherapy|US-aspiration and alcohol sclerosis
16591420|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
16591421|NCT02669602||No intervention|No Intervention
16591422|NCT02669589|Active Comparator|heparin anticoagulation|"Systemic anticoagulation of the continuous renal replacement therapy with heparin.
~Dose will be titrated to maintain aPTT (activated partial thromboplastin time) between 45-60s)"
16591423|NCT02669589|Experimental|citrate anticoagulation|"Regional anticoagulation of the continuous renal replacement therapy with citrate.
~Target posthemofilter ionized calcium level: 0.25-0.35 mmol/l"
16591424|NCT02669576|Experimental|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
16591425|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
16591497|NCT02669121|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.
16591631|NCT02668198|Experimental|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
16591426|NCT02669563|Experimental|Stage 1|"Subjects (n = 4 to 10) will be injected once with 20 mCi of [13N]ammonia and receive a 20 minute PET scan. They will then be injected once with 6.5 mCi of one of the two new drugs under study, [18F]4F-MHPG or [18F]3F-PHPG, and receive a 60 minute PET scan.
~On a second visit to the clinic, subjects will be injected once with 6.5 mCi of [18F]3F-PHPG or [18F]4F-MHPG (whichever was not used for the first visit) and receive a 60 minute PET scan."
16591427|NCT02669563|Experimental|Stage 2|"Subjects (n = 20 to 26) will be injected with 20 mCi of [13N]ammonia and receive a 20 minute PET scan.
~They will then be injected once with 6.5 mCi of [18F]4F-MHPG or [18F]3F-PHPG (whichever was chosen based on Stage 1 of the study) and receive a 60 minute PET scan. On a second visit to the clinic, subjects will be injected once with 20 mCi of [11C]HED and receive a 40 minute scan."
16591428|NCT02669550|Experimental|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
16591429|NCT02669550|Experimental|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
16591430|NCT02669537|Experimental|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
16591431|NCT02669537|No Intervention|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
16591432|NCT02669537|Experimental|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
16591433|NCT02669537|No Intervention|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
16591434|NCT02669524|Active Comparator|T2D + OGTT + LY2409021|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
16591435|NCT02669524|Placebo Comparator|T2D + OGTT + placebo|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.
16591436|NCT02669524|Active Comparator|T2D + IIGI + LY2409021|Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
16591437|NCT02669524|Placebo Comparator|T2D + IIGI + placebo|Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.
16591438|NCT02669524|Active Comparator|T2D + MEAL + LY2409021|Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.
16591439|NCT02669524|Placebo Comparator|T2D + MEAL + placebo|Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.
16591440|NCT02669524|Active Comparator|CTRL + OGTT + LY2409021|Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
16591441|NCT02669524|Placebo Comparator|CTRL + OGTT + placebo|Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.
16591442|NCT02669524|Active Comparator|CTRL + IIGI + LY2409021|Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
16591443|NCT02669524|Placebo Comparator|CTRL + IIGI + placebo|Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.
16591444|NCT02669524|Active Comparator|CTRL + MEAL + LY2409021|Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.
16591445|NCT02669524|Placebo Comparator|CTRL + MEAL + placebo|Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.
16591446|NCT02669511|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
16591447|NCT02669498|Active Comparator|Surgery with fallopian tube removal|Patients receiving routine fallopian tube removal during pelvic surgery after randomization.
16591448|NCT02669498|No Intervention|Surgery without fallopian tube removal|Fallopian tubes are not removed during pelvic surgery after randomization.
16591449|NCT02669485|Experimental|ICG|Administering indocyanine green during surgery and the use of ICG fluorescence imaging to assess bowel perfusion during surgery
16591450|NCT02669472|Experimental|F&V Intervention|Housing complexes randomized to the intervention arm received a multicomponent intervention comprised of a year-round, discount, mobile fresh fruit and vegetable market ('Fresh To You') that was paired with nutrition education interventions including educational newsletters, recipe cards, campaigns, taste-testings and videos in both English and Spanish.
16591451|NCT02669472|Experimental|Control Intervention|Housing complexes randomized to the comparison arm received a year-long intervention on physical activity and stress reduction including educational campaigns and materials in both English and Spanish.and a YMCA membership for those who joined the campaigns.
16591452|NCT02669459|Active Comparator|LLETZ|LLETZ (Large Loop excision of the transformation zone) treatment conform current guidelines, which is also the current gold standard in the Netherlands
16591453|NCT02669459|Other|Imiquimod 5% cream|intervention group
16591454|NCT02669446||Ectoin containing Lozenges|treatment with Ectoin containing lozenges
16591455|NCT02669446||Hyaluronic acid containing lozenges|treatment with hyaluronic acid containing lozenges
16591456|NCT02669446||Saline solution for gargling|Subjects in were requested to gargle with salt water
16591457|NCT02669433|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
16591458|NCT02669433|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
16591459|NCT02669433|Placebo Comparator|Placebo|Placebo
16591463|NCT02669394|Experimental|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.
~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
16591464|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
16591465|NCT02669381|Other|Experimental: phenylalanine intake|Dietary supplement: phenylalanine intake
16591466|NCT02669368|Active Comparator|Standard dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
16591467|NCT02669368|Active Comparator|Low dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
16591468|NCT02669368|Active Comparator|Low dose Rocuronium + Magnesium Sulfate|Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
16591469|NCT02669342|Active Comparator|Group A: Sharklet Catheter for 2 weeks first|"Arm A will have catheters inserted according to the schedule below:
~Sharklet catheter inserted for 2 weeks
~Standard catheter inserted for 2 weeks
~Sharklet catheter inserted for 4 weeks
~Standard catheter inserted for 4 weeks"
16591470|NCT02669342|Active Comparator|Group B: Sharklet Catheter for 4 weeks first|"Arm B will have catheters inserted according to the schedule below:
~Sharklet catheter inserted for 4 weeks
~Standard catheter inserted for 4 weeks
~Sharklet catheter inserted for 2 weeks
~Standard catheter inserted for 2 weeks"
16591471|NCT02669329|Experimental|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
16591472|NCT02669303|Experimental|platelet-rich plasma group|Autologous platelet-rich plasma subacromial injection
16591473|NCT02669303|Active Comparator|Methylprednisolone group|Methylprednisolone subacromial injection
16591474|NCT02669290|Experimental|Guided|Guided LV lead placement for CRT.
16591475|NCT02669290|Active Comparator|Non-Guided|Non-guided LV lead placement for CRT.
16591476|NCT02669277|No Intervention|group A|no platelet enhancing therapy
16591477|NCT02669277|Active Comparator|group B|Standard IVIG single dose 1.0 gm /kg/dose
16591478|NCT02669277|Experimental|group C|minipool IVIG product single dose 1.0 gm /kg/dose
16591479|NCT02669264|Experimental|Part 1: ADCT-402 dose escalation|"Weekly administration - Participants will receive an intravenous (IV) infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.
~3-week administration - Participants will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.
~The dose escalation will be conducted according to a 3+3 design."
16591480|NCT02669264|Experimental|Part 2: ADCT-402 expansion|All participants will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee
16591483|NCT02669238|Experimental|Implant|Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
16591484|NCT02669238|Active Comparator|Oral treatment|Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)
16591488|NCT02669199|Experimental|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
16591489|NCT02669186|Experimental|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
16591490|NCT02669186|Active Comparator|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
16591491|NCT02669173|Experimental|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
16591492|NCT02669160|Experimental|Experimental|Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
16591493|NCT02669160|Other|Control|Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.
16591494|NCT02669134|Active Comparator|SonR optimization|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
16591495|NCT02669134|Placebo Comparator|Fixed settings|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed Off)."
16591496|NCT02669121|Placebo Comparator|Placebo|NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.
16591498|NCT02669108|Other|PET/MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
16591499|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
16591500|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
16591501|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
16591502|NCT02669069|Active Comparator|PS1|
16591503|NCT02669069|Active Comparator|PS2|
16591504|NCT02669069|Active Comparator|PS3|
16591505|NCT02669056|Experimental|preterm babies|preterm babies (less than 28 weeks)
16591506|NCT02669056|Other|term babies|term babies with blood test prescription
16591507|NCT02669043|Experimental|Ketamine|All participants receive open-label ketamine
16591508|NCT02669030|Experimental|Suvorexant|suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
16591509|NCT02669030|Placebo Comparator|Placebo|no augmentation of FDA-approved antidepressant treatment
16591510|NCT02669017|Experimental|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
16591511|NCT02669017|Experimental|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.
~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
16591512|NCT02669004|Active Comparator|Intermittent bolus epidural morphine|"Patients who received epidural morphine with patient- controlled intermittent bolus epidural analgesia (PCIEA) represented Group 1. Epidural catheter was inserted by surgeon under direct visualization at the midpoint of the incision and advanced 5-6 cm cephalad to thoracic 4-5 before surgical closure.
~Patients received morphine 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion."
16591513|NCT02669004|Active Comparator|Continuous epidural morphine|epidural morphine with patient- controlled continuous epidural analgesia (PCCEA) represented Group 2. Infusion the following initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
16591514|NCT02668991||Cohort 1|It will consist of planned 100 children and adults with Autism Spectrum Disorder (ASD) aged 6 years and older with no requirements regarding concurrent therapies or treatments.
16591515|NCT02668991||Cohort 2|It will consist of planned 50 children and adults aged 6 and older who, as part of their standard care, happen to be beginning a behavioral intervention within 2 weeks after the baseline visit of the study. This intervention can be an applied behavior analysis (ABA) program or similar or a social skills program or a school-based autism program and must be intended to last at least throughout the duration of the study.
16591516|NCT02668991||Cohort 3|It will consist of planned 30 normally developing children and adults. These participants will only have a single visit wherein they will undergo a single session with the task battery and biosensors. There should be 5 participants aged 6-9 years, 5 aged 10-12 years, 5 aged 13-17 years, and 5 aged 18 years and older. This cohort should approximate the male:female ratio in Cohorts 1 & 2, with approximately 1 female for every 5 males.
16591517|NCT02668978|Experimental|Hemopatch™|Hemopatch™ sealing hemostat
16591518|NCT02668978|Active Comparator|Control|Standard surgical technique
16591519|NCT02668965|No Intervention|control|intrauterine infusion with standard embryo culture media 10 microliters before embryo transfer
16591520|NCT02668965|Experimental|intrauterine hCG|intrauterine infusion with hCG (500 IU) 10 microliters before embryo transfer
16591521|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
16591522|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
16591523|NCT02668926|Experimental|Lisdexamfetamine, d-amphetamine, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
16591524|NCT02668926|Experimental|d-amphetamine, Placebo, Lisdexamfetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
16591525|NCT02668926|Experimental|Placebo, Lisdexamfetamine, d-amphetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
16591526|NCT02668913|Experimental|Diagnostic Analysis|This arm will be subject to Caris Molecular profiling.
16591527|NCT02668900|Experimental|Decision support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
16591528|NCT02668900|No Intervention|Usual care|The control group will not receive the decision support intervention prior to consultation with the physician.
16591529|NCT02668874|Active Comparator|Isolite® technique Device|The Isolite® technique differs in that it utilizes a flexible plastic dental adapter to separate the teeth from the cheek and tongue. The resident dentist will show the child the Isolite® before it is placed in the mouth. The resident with whom the child is scheduled will then apply the sealants.
16591530|NCT02668874|Active Comparator|cotton roll technique Device|The resident dentist with whom the child is scheduled with apply the sealants after the cotton roll technique has been placed.
16591531|NCT02668861|Experimental|Vitamin D+Budesonide Nasal Spray|Vitamin D 4000IU/day for 8 weeks + Budesonide Nasal Spray 128ug/d for 8 week
16591532|NCT02668861|Placebo Comparator|placebo+Budesonide Nasal Spray|Placebo for 8 weeks + Budesonide Nasal Spray128ug/d for 8 week
16591533|NCT02668848|Experimental|urine monitoring group|Patients of urine monitoring group will be checked for urine specific gravity (USG) once between 6a.m. to 12 m.d. in the first 5 days after admission. Patients will be advised to have water according to the level of USG.
16591534|NCT02668835||Cohort 1|Idiopathic Parkinson's Disease as defined by the UK brain bank criteria and history of resting tremor.
16591535|NCT02668835||Cohort 2|Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist
16591536|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
16591537|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
16591538|NCT02668809|Experimental|Experimental Group 1|consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence.
16591539|NCT02668809|Experimental|Experimental group 2|Consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence, varnish application
16591540|NCT02668809|Placebo Comparator|Control Group|Consent,clinical exam, microbiological sampling, questionnaires
16591541|NCT02668796|Experimental|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
16591542|NCT02668796|Active Comparator|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
16591543|NCT02668796|Placebo Comparator|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
16591544|NCT02668783|Experimental|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
16591545|NCT02668783|Placebo Comparator|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
16591546|NCT02668770|Experimental|Dose Escalation Group: MGN1703 + Ipilimumab|"Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment."
16591547|NCT02668770|Experimental|MTD Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.
~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long."
16591548|NCT02668770|Experimental|MTD Group: MGN1703 (intratumoral injection) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.
~MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long."
16591549|NCT02668770|Experimental|MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.
~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long."
16591550|NCT02668757|Other|HeartHab application arm|Patients in the HeartHab application arm will receive the mobile application during study period.
16591551|NCT02668744|Experimental|Intervention|TX Sprouts
16591552|NCT02668744|Placebo Comparator|Control|Delayed Intervention
16591553|NCT02668718|Other|Adjuvant radiotherapy|Patients who were randomized to adjuvant radiotherapy following radical prostatectomy
16591554|NCT02668718|No Intervention|Watchful waiting|Patients who were randomized to watchful waiting following radical prostatectomy
16591555|NCT02668705|No Intervention|Human RA|A sham research informed consent form will be explained by a research assistant
16591556|NCT02668705|Experimental|ECA|A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
16591557|NCT02668705|Experimental|ECA + Human RA|A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant
16591558|NCT02668692|Experimental|LEO 80185 gel|
16591559|NCT02668692|Active Comparator|Dovobet ® ointment|
16591560|NCT02668679|Active Comparator|Children and their parents with the presence of Dream Doctors|The DD will use various methods for entertaining the child and alleviate stress . The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
16591561|NCT02668679|Placebo Comparator|Children and their parents without the presence of DD|No DD during the gastroscopy. The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
16591562|NCT02668666|Experimental|Investigational Treatment|"71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.
~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
16591563|NCT02668653|Experimental|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib
~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant
~Continuation: up to 36 cycles with the experimental drug quizartinib"
16591564|NCT02668653|Active Comparator|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo
~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant
~Continuation: up to 36 cycles with placebo"
16591565|NCT02668640||Participants with RA receiving adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks
16591566|NCT02668614|Experimental|WR-22 model microwave sensor|
16591567|NCT02668601||GDM Exposed|Children exposed to gestational diabetes in utero
16591568|NCT02668601||Non-GDM Exposed|Children not exposed to gestational diabetes in utero
16591569|NCT02668588|Experimental|LF-PB 30 mg|extended release of octreotide
16591570|NCT02668588|Placebo Comparator|Placebo|extended release of placebo
16591571|NCT02668575|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality CF care provided to all patients at the UPMC CF Center.
16591572|NCT02668575|Experimental|Supportive Care Intervention|Patients randomized to the intervention arm will receive a protocolized supportive care intervention from a palliative care nurse practitioner.
16591573|NCT02668562|Experimental|Early CABG|Patients to undergo early CABG
16591574|NCT02668562|Active Comparator|Delayed CABG|Patients to undergo delayed CABG
16591575|NCT02668549||Patients with Opioid dispensings|Patients receiving two or more opioid dispensings within 18 months
16591576|NCT02668549||Patients with Diuretic dispensings (neg control)|Patients receiving two or more Diuretics dispensings within 18 months will serve as negative control
16591577|NCT02668536|Experimental|UV Filter + BNP|A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
16591578|NCT02668536|Sham Comparator|BNP only|A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
16591579|NCT02668536|Active Comparator|Standard|As the active comparator, participants will have 5 sites on their torso where they will have standard sunscreen applied.
16591580|NCT02668536|No Intervention|Control|Participants will have 5 sites on their torso where no agent will be applied.
16591581|NCT02668523|Experimental|Raindrop|A single arm study to evaluate the effectiveness of a 2mm Raindrop Near Vision Inlay for the treatment of presbyopia in pseudophakic subjects. This corneal inlay is placed under a LASIK flap or in a corneal pocket, and is designed to change the anterior curvature of the cornea, resulting in the ability to reduce spectacle dependency for near and intermediate tasks.
16591582|NCT02668510|Experimental|Platelet Rich Plasma Injection Group|shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin
16591583|NCT02668510|Placebo Comparator|Placebo injection group|shockwave therapy with placebo normal saline injection
16591584|NCT02668497|Experimental|De-novo PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
16591585|NCT02668497|Experimental|L-dopa PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
16591586|NCT02668484|Experimental|repositionable valve prosthesis|Lotus
16591587|NCT02668484|Active Comparator|balloon-expandable valve prosthesis|Sapien
16591588|NCT02668471|Experimental|Ultrasound guided|Radial artery catheters will be placed with the assistance of bedside ultrasound.
16591589|NCT02668471|Active Comparator|traditional method|Radial artery catheters will be placed by the palpation technique only.
16591590|NCT02668458|Experimental|NIV|NIV group, preoxygenation by NIV: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, PEEP of 5 cm H2O and FiO2 at 100%.
16591591|NCT02668458|Active Comparator|HFNC|High-flow nasal canula oxygen therapy. NHFC group, preoxygenation by NHFC: oxygen flow rate of 60 L / min and 100% FiO2
16591592|NCT02668445|Experimental|Low carbohydrate|Subjects will eat a low carbohydrate diet
16591593|NCT02668445|Experimental|High carbohydrate|Subjects will eat a high carbohydrate diet
16591594|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
16591629|NCT02668224|Active Comparator|Control group|Control: Usual activities from day 1 to Day 75.
16591812|NCT02667028||patients receiving PCI|patients receiving percutaneous coronary intervention(PCI)
16591595|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
16591596|NCT02668419|Active Comparator|Usual Care|Patients in this group were subject to regular Physical Therapy Sessions in the hospital and each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise.
16591597|NCT02668419|Experimental|Neuromuscular Electrical Stimulator|Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
16591598|NCT02668406||Burkholderia pseudomallei|Patients for whom blood cultures grew Burkholderia pseudomallei
16591599|NCT02668406||No pathogen|Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis
16591600|NCT02668406||Another pathogen|Patients for whom blood cultures grew another pathogen
16591601|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
16591602|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
16591603|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
16591604|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
16591605|NCT02668380||Apatinib|Apatinib Tablets: 850 mg,po, once daily , 28 days for a cycle
16591606|NCT02668367|Active Comparator|BTA-C585 oral capsules|100 mg capsules; Multiple ascending doses (MAD) from 100 mg to 600 mg
16591607|NCT02668367|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
16591608|NCT02668341||psoriasis patients in Denmark|non-interventional survey study in psoriasis patients in daily practice care
16591609|NCT02668341||psoriasis patients in Spain|non-interventional survey study in psoriasis patients in daily practice care
16591610|NCT02668341||psoriasis patients in Poland|non-interventional survey study in psoriasis patients in daily practice care
16591611|NCT02668341||psoriasis patients in Germany|non-interventional survey study in psoriasis patients in daily practice care
16591612|NCT02668328|Experimental|Behavioral Intervention|The proposed study involves a 2-phase randomized clinical trial in adults with recently diagnosed T2D. Participants will be randomized to a wait-list Control group, BI, or Tailored-BI. In Phase 1, wait-list Control participants will receive 6 months of standard care; BI and Tailored-BI participants will receive 6 months of Active Intervention. In Phase 2, wait-list Control group participants will cross-over to the delayed Tailored-BI, and the BI and Tailored-BI participants will enter a 6-month observation phase to examine maintenance effects of the intervention.
16591613|NCT02668315|Experimental|Cohort 1|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9 x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
16591614|NCT02668315|Experimental|Cohort 2|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9 x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
16591615|NCT02668315|Experimental|Cohort 3|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9 x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
16591616|NCT02668302|Experimental|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
16591617|NCT02668302|Active Comparator|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
16591618|NCT02668289|Other|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
16591619|NCT02668276|Placebo Comparator|Standard NCCN counseling|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
16591620|NCT02668276|Experimental|Standard NCCN counseling and Oncotype DX results|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.
16591621|NCT02668263|Active Comparator|Surgery and Drain|Group 1 will be allocated to receive a drain intra-operatively.
16591622|NCT02668263|Other|Surgery alone|Group 2 will not receive a drain and no further intervention.
16591623|NCT02668263|Experimental|Surgery and quilting sutures|Group 3 will not receive a drain but will receive quilting sutures
16591624|NCT02668250|Experimental|Experimental group : OPTI-AGED|The OPTI-AGED group will receive a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia.
16591625|NCT02668250|Active Comparator|Control Group :|The control group will not benefit from the OPTI-AGED intervention but patients will receive the usual care.
16591626|NCT02668237|Experimental|Experimental group|The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.
16591627|NCT02668237|Active Comparator|Control Group|The children will benefit from the usual care : an antibiotic prevention treatment.
16591628|NCT02668224|Experimental|Vibrasens : Test group|Training programme: vibration training 3/week from Day 1 to Day 60 + Usual activities from day 60 to Day 75.
16591632|NCT02668185|Experimental|Active drug first|Baseline period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Washout period - 2 weeks Matched placebo orally bd - 2 weeks Monitoring period - 2 weeks
16591633|NCT02668185|Placebo Comparator|Placebo|Baseline period - 2 weeks Matched placebo orally bd - 2 weeks Washout period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Monitoring period - 2 weeks
16591634|NCT02668172|Experimental|Pasireotide LAR 60 mg monotherapy week 12|"After enrollment, acromegaly patients on combination treatment will half their regular weekly dose of pegvisomant (PEGV) for 12 weeks (run-in period).
~When insuline-like growth factor 1 (IGF-I) remains within the age adjusted normal limits after 12 weeks, PEGV and the LA-SSA (Octreotide Long Acting Release (LAR) or Lanreotide Autogel) with Pegvisomant (PEGV) are discontinued and patients are switched to pasireotide LAR 60 mg for 12 weeks."
16591635|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 12|When IGF-I rises above the adjusted normal limits after 12 weeks (run-in period), these subjects will switch their LA-SSA to Pasireotide LAR 60 mg every 4 weeks and continue with the reduced PEGV dose of the run-in period, for the remaining 12 weeks.
16591636|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 24|"Between week 12 and 24 dose adaptations of PEGV are not permitted unless IGF-I drops below the age adjusted normal limits, then the dose of PEGV will be decreased stepwise with 20 mg weekly until IGF-I is within the age adjusted normal limits.
~At week 24, efficacy will be assessed, as the number of patients with a normal IGF-I in the two different groups; the combination Pasireotide LAR 60 mg / PEG V dose and monotherapy Pasireotide LAR 60 mg.
~From week 24 patients will continue with Pasireotide LAR 60 mg monotherapy, or Pasireotide LAR will be combined with 50% of the original dose of PEGV, or with an increasing dose of PEGV every 8 weeks depending on the treatment arm."
16591637|NCT02668159|Experimental|Fish peptide|
16591638|NCT02668159|Experimental|Vitamin D|
16591639|NCT02668159|Experimental|Fish peptide + Vitamin D|
16591640|NCT02668159|Placebo Comparator|Control|
16591641|NCT02668146|Experimental|perampanel|Perampanel administration
16591642|NCT02668146|Placebo Comparator|placebo|Placebo administered to subjects.
16591643|NCT02668133|Active Comparator|lipid-based nutrient supplement SQ-LNS|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution
~1 mg isotopically enriched 68Zn intravenously"
16591644|NCT02668133|Experimental|lipid-based nutrient supplement SQ-LNS with phytase|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution
~1 mg isotopically enriched 68Zn intravenously"
16591645|NCT02668120||Cases|Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
16591646|NCT02668120||Low-risk pregnancy|Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
16591647|NCT02668120||High-risk pregnancy|Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.
16591648|NCT02668107|Active Comparator|Intervention Group (Hammock positioning)|Babies in the intervention group (IG), will be positioned supine in a hammock in the incubator, with the appropriate postural adjustments.
16591649|NCT02668107|No Intervention|Control Group|Those selected for the control group (CG) will be placed in the incubator following the service routine.
16591650|NCT02668094|Active Comparator|Group L|Lidocaine 40mg was given intravenously before injection of propofol
16591651|NCT02668094|Active Comparator|Group LP|Pregabalin 75 mg was given orally 2 hour before surgery
16591652|NCT02668094|Active Comparator|Group HP|Pregabalin 150 mg was given orally 2 hour before surgery
16591653|NCT02668081|Experimental|Endoscopic papillary balloon dilation|For EPBD group, after selective cannulation of the common bile duct by the catheter, cholangiography will be performed to confirm the diagnosis of bile duct pathology. A 0.025-0.035-inch guidewire will then be inserted into the bile duct through the catheter. A dilating balloon (The controlled radial expansion (CRE) balloon dilation catheter, CRE balloon 5.5 cm (centimeter) in length, 1-1.2 cm/1.2-1.5 cm/1.5-2.0 cm in diameter) will be passed via the pre-positioned guidewire into the bile duct. Using fluoroscopic and endoscopic guidance, the balloon will be inflated with contrast medium up to the optimal size and duration (normally 5min (minutes)) after the waist on the balloon disappeared according to the patients' condition and tolerance.
16591654|NCT02668081|Active Comparator|Endoscopic sphincterotomy|"For EST group,endoscopic sphincterotomy(EST) will be done as large as possible with a pull type sphincterotome (The TRUEtome, Biliary sphincterotomy sphincterotome, Single-use sphincterotome CleverCut2V)
~Other interventions: surgical intervention, endoscopic stenting, percutaneous transhepatic cholangiogram with balloon dilation"
16591655|NCT02668068|Active Comparator|Control Group|Large volume whole-lung lavage (WLL) only
16591656|NCT02668068|Experimental|Experimental Group|Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
16591657|NCT02668055|Experimental|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells in wound, stick with wound edge skin suture, with vaseline gauze bandaging, controlled side not adding slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes
16591658|NCT02668042|Experimental|liveness tissue skin|
16591659|NCT02668029|Experimental|oxygen|oxygen administered through a nasal cannula at a personalized, fixed flow
16591660|NCT02668029|Placebo Comparator|medical air|Medical air administered through a nasal cannula at the same flow
16591661|NCT02668016|Experimental|Atorvastatin 20mg Daily|Atorvastatin 20mg daily for 1 month
16591662|NCT02668016|Placebo Comparator|Placebo|Placebo daily for 1 month
16591663|NCT02668016|No Intervention|No Treatment|No Atorvastatin or placebo for 1 month
16591664|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
16591665|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
16591666|NCT02667990|Experimental|orthopaedic stilettoe|orthopaedic stilettoe will be compared to standard stilettoe and comfy trainer
16591667|NCT02667977|Active Comparator|Group 1|These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids
16591668|NCT02667977|Active Comparator|Group 2|These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids
16591669|NCT02667964|Other|Healthy controls|Spiroergometry
16591670|NCT02667964|Other|Patients with T2DM|Spiroergometry
16591671|NCT02667964|Other|Patients with T1DM|Spiroergometry
16591672|NCT02667951|No Intervention|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
16591673|NCT02667951|Experimental|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
16591674|NCT02667938|Experimental|Treatment 1|HCP1303 capsule 5/0.2mg + HCP1303 capsule 5/0.4mg placebo+ HGP1201 placebo
16591675|NCT02667938|Experimental|Treatment 2|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg + HGP1201 placebo
16591676|NCT02667938|Active Comparator|Active Comparator|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg placebo+ HGP1201
16591677|NCT02667925|Experimental|Intervention arm|Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
16591680|NCT02667899|Active Comparator|DBS group|Besides routine treatment, Doc patients in this group will accepted deep brain stimulation treatment.
16591681|NCT02667899|Active Comparator|TMS group|Besides routine treatment, Doc patients in this group will accepted transcranial magnetic stimulation treatment.
16591682|NCT02667899|Placebo Comparator|Control group|This Doc patients will accepted routine treatment.
16591683|NCT02667886|Experimental|Part A|X4P-001 + axitinib dose escalation
16591684|NCT02667886|Experimental|Part B|"Randomized assignment to one of two regimens:
~X4P-001 at the Part A maximum tolerated dose (MTD), in combination with axitinib
~X4P-001 at 0.5x Part A MTD, in combination with axitinib"
16591685|NCT02667886|Experimental|Part C|X4P-001 monotherapy
16591686|NCT02667873|Experimental|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
16591687|NCT02667860|Experimental|Intracorporeal anastomosis|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
16591688|NCT02667860|Active Comparator|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
16591689|NCT02667847||Preoperative patients|Preoperative patients were asked to verbally rate their anxiety 1=on a scale from 0-10 and 2=using the new smiley scale
16591690|NCT02667834|Experimental|Social Cognition and Interaction Training (SCIT)|SCIT Social cognition and interaction training program.
16591691|NCT02667834|Active Comparator|Therapeutic education program (ETP)|Therapeutic education program
16591692|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
16591693|NCT02667808||Focus Group|Participants with HIV and receiving antiretroviral therapy (ART) will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
16591694|NCT02667808||Questionnaire|Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
16591695|NCT02667795|Experimental|Monitored walking based exercise|Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
16591696|NCT02667795|No Intervention|Control|No intervention
16591760|NCT02667327|Active Comparator|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
16591761|NCT02667327|Placebo Comparator|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
16591941|NCT02666105|Experimental|Exemestane Therapy|
16591697|NCT02667782|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is developed by Jon Kabat-Zinn in 1979 (Kabat-Zinn, 1990). It is an eight-week Program that includes practices such as gentle mindful movement (awareness of the body), a body scan (to systematically nurture awareness of the body region by region), and sitting meditation (awareness of the breath to include the four foundations of mindfulness, namely, body, feeling tone, mental state, and mental content) (Cullen, 2011).
16591698|NCT02667782|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, & Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
16591699|NCT02667769|Other|Fasting day without any food|Complete fasting: On a fast day under this Protocol no solid food may be eaten unless it is solid, medically prescribed part of a bedtime snack just before falling asleep (which must sometimes be to prevent nocturnal hypoglycaemia with injection of basal insulin before going to sleep) , Otherwise, the patient have ad libitum access to mineral water and unsweetened tea (possibly a fluid intake restriction should be considered for other diseases).
16591700|NCT02667769|Other|Fasting day with calorie- & carbohydrate-free food|During a fasting day for this protocol, patients may calories in unlimited quantity and (with calorie-free dressing) Take carb food like tomatoes, cucumbers, lettuce to be, both during meal periods and in between, if desired.
16591701|NCT02667743|Experimental|Paclitaxel Micelles for Injection + Cisplatin|"In the First Period, 230 mg/m2 of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
~In the Second Period, 300 mg/㎡ of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device to patients whose minimum neutrophil ≥1.0 × 109 /L and minimum platelet count ≥80 × 109 /L and with no hematologic toxicity of grade II to IV occurred in the First Period. Then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment."
16591702|NCT02667743|Active Comparator|Paclitaxel Injection + Cisplatin|175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
16591703|NCT02667730|Placebo Comparator|Physiotherapy only|This group will receive non-pharmacological advice and physiotherapy only
16591704|NCT02667730|Experimental|Acetaminophen + physiotherapy|This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy
16591705|NCT02667730|Experimental|Naproxen + physiotherapy|This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy
16591706|NCT02667730|Experimental|Celecoxib + physiotherapy|This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy
16591707|NCT02667717|Experimental|Experimental group : Mirror Therapy|Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
16591708|NCT02667717|Active Comparator|Control group : Usual care|The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.
16591709|NCT02667704|Experimental|Nintedanib|
16591710|NCT02667704|Experimental|Bosentan|
16591711|NCT02667691|Experimental|SODB Dimpless-caloric restriction|This arm receives daily two capsules of SODB Dimpless 40mg containing 480 UI of superoxide dismutase (SOD), associated with a moderate caloric restriction.
16591712|NCT02667691|Placebo Comparator|Placebo-caloric restriction|This arm receives daily two capsules Placebo containing excipients only, associated with a moderate caloric restriction.
16591713|NCT02667678|Experimental|Cohort HIVOL, patients infected by HIV|Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
16591714|NCT02667665||Alzheimer's Disease Dementia|
16591715|NCT02667665||non-Dementia|
16591716|NCT02667652|Active Comparator|short biliarypancreatic limb|short biliarypancreatic limb
16591717|NCT02667652|Active Comparator|long biliarypancreatic limb|long biliarypancreatic limb
16591718|NCT02667639|Active Comparator|Treatment|A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
16591719|NCT02667639|Placebo Comparator|Placebo|A single 0.9% sodium chloride injection will be administered subcutaneously.
16591720|NCT02667626|Experimental|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.
~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
16591721|NCT02667626|Active Comparator|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.
~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
16591722|NCT02667613|Experimental|HABIT-ILE|HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
16591723|NCT02667613|Active Comparator|Control|A two weeks period of usual customary care.
16591724|NCT02667600||Cesarean Section Group|Patients undergoing cesarean section
16591762|NCT02667327|No Intervention|Standard of Care|Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.
16591763|NCT02667314|Experimental|Jigsaw Puzzle Group|Jigsaw puzzles & Cognitive health counseling
16591764|NCT02667314|Active Comparator|Cognitive Health Counseling Group|Cognitive health counseling only
16591727|NCT02667574|Other|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
16591728|NCT02667561|Experimental|Testosterone gel 1% 2.2 mg|Testosterone gel 1% Topical use 2.2 mg (220 mg of gel) once daily duration of treatment: 28 days
16591729|NCT02667561|Experimental|Testosterone gel 1% 4.4 mg|Testosterone gel 1% Topical use 4.4 mg (440 mg of gel) once daily duration of treatment: 28 days
16591730|NCT02667561|Experimental|Testosterone gel 1% 8.8 mg|Testosterone gel 1% Topical use 8.8 mg (880 mg of gel) once daily duration of treatment: 28 days
16591731|NCT02667561|Placebo Comparator|Placebo of Testosterone Gel 1%|Placebo of Testosterone Gel 1% Topical use Approximately 550 mg of gel Once daily duration of treatment: 28 days
16591732|NCT02667548||patients receiving PCI|patients receiving PCI
16591733|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% healthy|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
16591734|NCT02667535|Experimental|Isosorbide Mononitrate 0.5% anal fissure|Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
16591735|NCT02667535|Experimental|Isosorbide Mononitrate 1.0% anal fissure|Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
16591736|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% anal fissure|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
16591737|NCT02667522|Experimental|Parenting Intervention|Parenting Intervention: Parent-Child Interaction Therapy (PCIT)
16591738|NCT02667522|No Intervention|Waitlist Control|Waitlist Control Condition
16591739|NCT02667496|Experimental|Leukine|"Administered SC in treatment cycles up to 24 weeks
~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
16591740|NCT02667496|Placebo Comparator|Placebo|"Administered SC in treatment cycles up to 24 weeks
~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
16591741|NCT02667483|Experimental|DS-5141b|"DS-5141b, Subcutaneous injection
~Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.
~Level 1: 0.1 mg/kg
~Level 2: 0.5 mg/kg
~Level 3: 2.0 mg/kg
~Level 4: 6.0 mg/kg
~Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.
~Part 2-Extension: Two doses, 2.0 mg/kg or 6.0 mg/kg, of DS-5141b will be administered subcutaneously once a week for 48 weeks."
16591742|NCT02667470|Experimental|Solifenacin|
16591743|NCT02667457|Experimental|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
16591744|NCT02667457|Experimental|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
16591745|NCT02667444|Experimental|SB204 4%|SB204 4% topically once daily
16591746|NCT02667444|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
16591747|NCT02667418|Other|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
16591748|NCT02667418|Other|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
16591749|NCT02667418|Other|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
16591750|NCT02667405|Experimental|Whirlpool|Immersion in Whirlpool during therapy
16591751|NCT02667405|Active Comparator|Hot Pack|Hot Pack Application during therapy.
16591752|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
16591753|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
16591754|NCT02667379|Other|Diagnostic skin testing|Diagnostic skin testing with cat dander samples on volar forearms.
16591755|NCT02667366|Experimental|Tel-PT|Tel-PT receives a manualized short-term CBT. Treatment consists of one initial face-to-face appointment and 8-12 subsequent telephone sessions between patient and licensed therapist. Each telephone contact lasts between 20 and 30 minutes and take place on a weekly and later biweekly basis.
16591756|NCT02667366|Active Comparator|TAU and text messages|Control Group receives treatment as usual and additionally weekly text messages containing general information about depression.
16591757|NCT02667353|Other|electroconvulsive therapy|only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
16591758|NCT02667340|Experimental|Superstarch|Supplementation with Superstarch before a simulated soccer game
16591759|NCT02667340|Placebo Comparator|Placebo|Supplementation with placebo before simulated soccer game.
16591765|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:
~The patient is subjected to tympanometry test on the specific ear,
~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,
~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
16591766|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
16591767|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
16591768|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
16591769|NCT02667262||Extended Release and/or Long-Acting Opioids|
16591770|NCT02667249||check list|clinical pathway using a paper based check-list
16591771|NCT02667249||integrated clinical pathway|clinical pathway in form of a clinical pathway integrated into the paper based medical treatment and nursing documentation
16591772|NCT02667236|Active Comparator|A-101 Solution|A-101 Solution 40% administered once
16591773|NCT02667236|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
16591774|NCT02667223|Experimental|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
16591775|NCT02667223|Active Comparator|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered subcutaneously to healthy volunteers
16591776|NCT02667223|Experimental|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
16591777|NCT02667223|Experimental|Cohort 5: bococizumab 450 mg + rHUPH20|bococizumab 450 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
16591778|NCT02667223|Experimental|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to subjects with hypercholesterolemia receiving a statin
16591779|NCT02667210||No shopping behavior|
16591780|NCT02667210||Minimal shopping behavior|
16591781|NCT02667210||Marked shopping behavior|
16591782|NCT02667210||Extensive shopping behavior|
16591783|NCT02667197||Opioid overdose and poisoning|
16591784|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 1|Low FODMAP Oral Nutrition Supplement
16591785|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 2|Low FODMAP Oral Nutrition Supplement
16591786|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 3|Low FODMAP Oral Nutrition Supplement
16591787|NCT02667184|Experimental|FOS Supplement|Supplement containing fructooligosaccharides
16591788|NCT02667171|Active Comparator|Control group|The control group will receive standardized conventional supervised COPD rehabilitation, delivered in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks.
16591789|NCT02667171|Experimental|Online COPD rehabilitation|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
16591790|NCT02667158||No shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
16591791|NCT02667158||Minimal shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
16591792|NCT02667158||Marked shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
16591793|NCT02667158||Extensive shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
16591794|NCT02667145|Experimental|Intervention|Self care program focusing on the assistive device, For 4 weeks (1 to week lasting 90 minutes).
16591795|NCT02667145|No Intervention|Control group|receive only a brochure with orientations of joint protection.
16591796|NCT02667132||medical treatment|In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate
16591797|NCT02667132||surgical treatment|lumpectomy, mastectomy, abscess drainage
16591798|NCT02667132||surgical+medical treatment|first medical, after surgical treatment or first surgical, after medical treatment
16591799|NCT02667119|Experimental|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
16591800|NCT02667119|Active Comparator|Standard Care|Standard substance abuse treatment services
16591801|NCT02667106|Experimental|Single-dose, open label RX0041-2|Active Drug
16591802|NCT02667080|Active Comparator|Ejaculate 1|Semen sample after 2-7 days of sexual abstinence
16591803|NCT02667080|Active Comparator|Ejaculate 2|Semen sample after 2 hours of sexual abstinence
16591804|NCT02667067|Other|Ant cervical discectomy & fusion (ACDF)|
16591805|NCT02667067|Experimental|Simplify Disc|Simplify Disc
16591806|NCT02667054|Active Comparator|Active 4%|One dose of 4mL of RX0041 4% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
16591807|NCT02667054|Placebo Comparator|Placebo|One dose of 4mL of RX0041 placebo for one day in the mucous membrane prior to a diagnostic or surgical procedure.
16591808|NCT02667054|Active Comparator|Active 8%|One dose of 4mL of RX0041 8% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
16591809|NCT02667041|Experimental|rTMS treatment (Monophasic vs. biphasic)|Safety and efficacy
16591810|NCT02667041|Active Comparator|EEG/ERP biomarkers|Investigation of pre- and post-treatment cognitive biomarkers
16591813|NCT02667015|Experimental|Anxiety Sensitivity Intervention|Group receives the 3-week, 6-session Anxiety Sensitivity Intervention. This is a 6-session psychotherapy occurring twice weekly (60-90 minutes) for three weeks. This psychotherapeutic treatment is focused on reducing anxiety sensitivity and includes many components, but primarily consists of psychoeducation about the relationship between anxiety and substance use disorders, interoceptive exposures, in vivo exposures, and cognitive challenging.
16591814|NCT02667015|No Intervention|Control Group|Receives only treatment as usual
16591815|NCT02667002|Experimental|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
16591816|NCT02667002|Experimental|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
16591817|NCT02667002|Active Comparator|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
16591818|NCT02666989|Active Comparator|open placebo|8 weeks of open placebo treatment
16591819|NCT02666989|No Intervention|waitlist group|4 weeks of waiting list followed by 4 weeks of open placebo treatment
16591820|NCT02666976|Experimental|ilaprazole group|ilaprazole 20mg once daily for 4 weeks.
16591821|NCT02666963|Experimental|RTA 901 10 mg or 40 mg or Placebo|RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose. Group 1: RTA 901 10 mg or matching placebo Group 2: RTA 901 20 mg or matching placebo Group 3: RTA 901 ≤ 40 mg or matching placebo Group 4: RTA 901 ≤ 80 mg or matching placebo Group 5: RTA 901 ≤ 160 mg or matching placebo Group 6: RTA 901 ≤ 320 mg or matching placebo Group 7: RTA 901 ≤ 640 mg or matching placebo Dose selection will be based on the safety, tolerability and available pharmacokinetics observed in prior study groups.
16591822|NCT02666963|Experimental|RTA 901 Dose TBD or Placebo|RTA 901 capsules, Dose TBD mg or placebo taken orally once daily for 14 days. Group 8: RTA 901 X mg or matching placebo Group 9: RTA 901 ≤Y mg or matching placebo Group 10: RTA 901 ≤Z mg or matching placebo The actual doses for Arm 2 will be selected based on the safety and available pharmacokinetic data obtained from Arm 1.
16591823|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
16591824|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
16591825|NCT02666937||ICU-patients (prospective)|Critically ill patients (18 years and older) on mechanically ventilation who have an arterial line and require bloodgasanalysis for medical reasons
16591826|NCT02666937||Emergency Department (prospective)|Patients (18 years and older), who are presented to the Emergency Department, and require bloodgasanalysis for medical reasons
16591827|NCT02666937||Pulmonary department (prospective)|Patients (18 years and older) who visit the outpatient clinic of the pulmonary department for different pulmonary functional test and require bloodgasanalysis for medical reasons
16591828|NCT02666937||Pulmonary department (retrospective)|Patients (18 years and older) who visited the outpatient clinic of the pulmonary department in the past of the VU medical centre in Amsterdam or the Medical Centre Alkmaar for different pulmonary functional test and required bloodgasanalysis for medical reasons
16591829|NCT02666924|Experimental|Cooking class|The addition of diabetes cooking educational classes to standard diabetes education classes. Cooking classes are a series of four, four-hour sessions. These cooking classes will be led by a registered dietitian, a registered nurse and a chinese chef. Conducted in Mandarin or Cantonese. The cooking education focus is culturally specific teaching for Chinese-Canadian persons living with diabetes.
16591830|NCT02666924|Active Comparator|Control|Type 2 diabetes educational classes, consisting of two sessions, one week apart, four-hour classes. These classes are taught by a registered dietitian and nurse, in Mandarin or Cantonese.
16591831|NCT02666911|Experimental|4D Ultrasound|4D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. The same patients will be imaged with both 2D and 4D transducers.
16591832|NCT02666911|Active Comparator|2D ultrasound|2D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury.The same patients will be imaged with both 2D and 4D transducers.
16591833|NCT02666898|Experimental|Obinutuzumab and Ibrutinib CLL treatment|"3 parts
~PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:
~GA101:
~C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v
~Ibrutinib:
~D3 Month 1 to Day 30 Month 15: 420mg daily PO
~PART 2: 4 cycles / 28 days
~After evaluation at D1 month 9:
~patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
~patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
~Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
~Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
~Ibrutinib 420mg/day PO
~PART 3 (only in GAI-FC+Ibru arm) :
~After evaluation at D1 of M16:
~patients CR with BM MRD< 10-4, treatment stopped
~patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative."
16591834|NCT02666885|Experimental|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
16591835|NCT02666872|Experimental|Motivational interviewing on vaccination|An educational strategy based on motivational interviewing of approximately 15 minutes to promote vaccination, in maternity ward.
16591836|NCT02666872|No Intervention|Brochure about vaccines for infants|Parents in the control group only received a brochure about vaccines for infants. This brochure is given to all fathers and mothers giving birth to the CHUS, participating or not at our study.
16591837|NCT02666859|Experimental|Unilateral Transradial Amputation|This group includes people with a unilateral transradial amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
16591838|NCT02666859|Experimental|Unilateral Transhumeral Amputation|This group includes people with a unilateral transhumeral amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
16591839|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
16591840|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
16591841|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
16591842|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
16591843|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
16591844|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
16591845|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
16591846|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
16591847|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
16591848|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
16591849|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
16591850|NCT02666820|Active Comparator|Large balloon dilatation|Patients underwent clearance of common bile duct stones using a papillary large balloon dilatation.
16591851|NCT02666820|Active Comparator|Mechanical lithotripsy|Patients underwent clearance of common bile duct stones using a mechanical lithotripsy.
16591852|NCT02666807|Experimental|Ginger|Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
16591853|NCT02666807|Placebo Comparator|Placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily
16591854|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 20 micrograms sufentanil, followed by the placement of the epidural catheter
16591855|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
16591856|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
16591857|NCT02666768|Experimental|gamma interferon-1b|Gamma interferon-1b 100 mcg SC 3 times weekly for 12 months
16591858|NCT02666742|Experimental|DOAC (Direct Oral Anticoagulant)|Participants will be asked to take standard dose approved for stroke prophylaxis
16591859|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
16591860|NCT02666729||AF Ablation Procedure|Patients with AF who are schedule for a first time pulmonary vein isolation (PVI) for AF using the TactiCath catheter. Patients will have four pulmonary veins ablated during procedure. The researcher will perform AF Ablation with contact force information on two veins. The research will perform AF Ablation without contact force information on the other two veins.
16591861|NCT02666703|Experimental|Study (CytoSorb)|In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
16591862|NCT02666703|No Intervention|Control|In the control group (20 patients) no filter will be installed on the CPB.
16591863|NCT02666703|Active Comparator|Corticosteroid|In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
16591864|NCT02666690|Experimental|Patients with metastatic cancer treated with anti angiogenics|
16591865|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
16591866|NCT02666664|Placebo Comparator|Placebo|Placebo control
16591867|NCT02666651|Experimental|Test group|Administration of oral tolvaptan (15-60mg PO titration) during admission for decompensated heart failure
16591868|NCT02666651|Other|Control group|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority
16591869|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
16591870|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
16591871|NCT02666625||Patients treated for cancer in childhood|
16591872|NCT02666612|Other|Patients with metastatic cancer|
16591873|NCT02666599|Experimental|18F-FDG PET/CT|18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''
16591874|NCT02666586|Placebo Comparator|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
16591875|NCT02666586|Experimental|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
16591876|NCT02666586|Experimental|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
16591877|NCT02666586|Experimental|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
16591878|NCT02666586|Experimental|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
16591879|NCT02666573|Experimental|Photodynamic therapy protocol|In addition to scaling and root debridement, test sites received PDT according to manufacturer's instructions.
16591880|NCT02666573|Other|SRP|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
16591881|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
16591882|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
16591883|NCT02666547|Other|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
16594561|NCT02648321|Experimental|Motivational Interviewing|Motivational Interviewing
16591884|NCT02666534|Experimental|AFL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
16591885|NCT02666534|Active Comparator|MAL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
16591886|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
16591887|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
16591888|NCT02666482|Experimental|Stop Smoking SF Web App - baseline|"Online Study 1 will test the data gathering aspects of the proposed web app using a baseline, usual care intervention consisting of a static smoking cessation guide, the Guía para Dejar de Fumar, tested in printed form in the Muñoz et al. (1997) study. The print version of the guide yielded an 11% quit rate at 3 months. The investigators will utilize the content of the guide as the main element of the baseline app, so it will serve to estimate baseline utilization and quit rates when this already tested intervention is provided in a web app format. Participants can join the study online by going to: https://stopsmokingsf.org"
16591889|NCT02666469|Active Comparator|Group A Hyperbaric Oxygen Therapy and Exercise Program|Group A: Hyperbaric Oxygen Therapy (HBOT) and Exercise with HBOT sessions for 90 minutes, once daily, 5 times a week for 8 consecutive weeks. HBOT will be provided with 100% oxygen at 2.0 ATA. Patients will exercise in the multiplace hyperbaric chamber while receiving hyperbaric oxygen.
16591890|NCT02666469|Active Comparator|Group B Exercise Program|Group B: Exercise Program in the hyperbaric medical unit without exposure to HBOT
16591891|NCT02666456||Cross-sectional cohort|Patients with chronic peripheral neuropathic pain
16591892|NCT02666456||Longitudinal cohort|Painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, Operation)
16591893|NCT02666443|Placebo Comparator|Control (C)|Control intervention (no dexamethasone)
16591894|NCT02666443|Experimental|Peri-neural (N)|Peri-neural Dexamethasone 1 mg
16591895|NCT02666443|Experimental|Intravenous|Intravenous Dexamethasone 1 mg
16591896|NCT02666430|Experimental|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
16591897|NCT02666430|Active Comparator|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
16591898|NCT02666417|Active Comparator|MNP+iron and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as FeFum and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
16591899|NCT02666417|Active Comparator|MNP+iron+GOS and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
16591900|NCT02666404|Experimental|Volume Resuscitation|We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
16591901|NCT02666391|Experimental|UCMSCs|Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)
16591902|NCT02666391|No Intervention|controls|Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion
16591903|NCT02666378|Experimental|CMR/ECHO|"Prior to starting chemotherapy treatment, the participant will undergo the following procedures:
~Cardiac Magnetic Resonance Imaging (CMR)
~Echocardiogram (ECHO) in patients with no clinically indicated scans
~Each imaging procedure will be repeated at predetermined times during the protocol
~Simple blood collection for plasma biomarker analysis"
16591904|NCT02666365|Active Comparator|Bolus infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion
16591905|NCT02666365|Active Comparator|Continuous Infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion
16591906|NCT02666352|Experimental|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
16591907|NCT02666352|Experimental|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
16591908|NCT02666352|Experimental|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
16591909|NCT02666339|Experimental|Hortitherapy group|Hortitherapy + Usual care
16591910|NCT02666339|Active Comparator|Control group|Usual care
16591911|NCT02666326|No Intervention|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.
~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
16591912|NCT02666326|Experimental|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
16591913|NCT02666300|Experimental|TaperGuard ETT|tracheal intubation with the TaperGuard ETT，the ETT cuff is Taper-shangped.
16591914|NCT02666287|Experimental|Sequence 1|"Each subject will receive all the 9 treatment regimens in the following order: A,G/B/F/C,H/E/D,I with a washout period of 7 days between each treatment period administered via the ELLIPTA inhaler. Where Treatment A= BAT/FF 900/300 microgram (mcg) (3 inhalations of 300/100 mcg).
~Treatment B= BAT 900 mcg (3 inhalations of 300 mcg) concurrently with FF (lactose) 300 mcg (3 inhalations of 100 mcg) from separate inhalers.
~Treatment C= BAT 900 mcg (3 inhalations of 300 mcg). Treatment D= FF (lactose) 300 mcg (3 inhalations of 100 mcg). Treatment E= FF (magnesium stearate [MgSt]) 300 mcg (3 inhalations of 100 mcg). Treatment F= FF/VI 300/75 mcg (3 inhalations of 100 mcg/25 mcg). Treatment G= 7-day repeat doses: BAT/FF 300/100 mcg (1 inhalation). Treatment H= 7-day repeat doses: BAT 300 mcg (1 inhalation). Treatment I= 7-day repeat doses: FF (lactose) 100 mcg (1 inhalation)."
16591915|NCT02666287|Experimental|Sequence 2|Each subject will receive all the 9 treatment regimens in the following order: B/C,H/A,G/D,I/F/E with a washout period of 7 days between each treatment period.
16591916|NCT02666287|Experimental|Sequence 3|Each subject will receive all the 9 treatment regimens in the following order: C,H/D,I/B/E/A,G/F with a washout period of 7 days between each treatment period.
16591917|NCT02666287|Experimental|Sequence 4|Each subject will receive all the 9 treatment regimens in the following order: D,I/E/C,H/F/B/A,G with a washout period of 7 days between each treatment period.
16591918|NCT02666287|Experimental|Sequence 5|Each subject will receive all the 9 treatment regimens in the following order: E/F/D,I/A,G/C,H/B with a washout period of 7 days between each treatment period.
16591919|NCT02666287|Experimental|Sequence 6|Each subject will receive all the 9 treatment regimens in the following order: F/A,G/E/B/D,I/C,H with a washout period of 7 days between each treatment period.
16591920|NCT02666274||RK Group|participants colonised with Klebsiella spp. resistant to either 3GC or carbapenems (RK cohort of index carriers of Resistant Klebsiella)
16591921|NCT02666261||Breast Cancer Pathology Samples|Data on the epidemiology and HER2 testing of breast cancer will be collected from pathology routine diagnostics.
16591922|NCT02666235|Active Comparator|Remote ischaemic conditioning|Intermittent inflation of a forearm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a curtain.
16591923|NCT02666235|Sham Comparator|Control group|Sham intervention: Arm cuff placement but without inflation during a 40 minute period. A curtain will obscure the patient from the clinical team during this time. Arm cuff placement, no inflation.
16591924|NCT02666196|Experimental|DAA-I 6mg|Subjects given solid compound in vials containing 6mg per vial
16591925|NCT02666196|Experimental|DAA-I 50mg|Subjects given solid compound in vials containing 50mg per vial
16591926|NCT02666196|Experimental|DAA-I 110mg|Subjects given solid compound in vials containing 110mg per vial
16591927|NCT02666196|Placebo Comparator|Placebo|Subjects given 25ml placebo dissolved in 200ml water
16591928|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
16591929|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
16591930|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
16591931|NCT02666170|Experimental|therapy with alpha-lipoic acid daily for six months|
16591932|NCT02666157|Active Comparator|Dabigatran|oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
16591933|NCT02666157|Active Comparator|Rivaroxaban|oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
16591934|NCT02666157|Active Comparator|Apixaban|oral apixaban 5 mg (2.5 mg in specific population) bid for entire study period
16591935|NCT02666144||Glaucoma|
16591936|NCT02666144||Normal|
16591942|NCT02666092||Fish allergy|"51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited.
~Interventions will include:
~A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations
~A detection of anti-Anisakis and anti-fish antibodies"
16591943|NCT02666092||Control|"51 subjects presenting no allergic manifestations after contact with fish.
~Interventions will include:
~A questionnaire on domestic exposure to fish
~A detection of anti-Anisakis and anti-fish antibodies"
16591944|NCT02666079|Experimental|Treatment arm|Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.
16591945|NCT02666053|Experimental|Treatment A|Single BMS-663068 tablet under fasted conditions
16591946|NCT02666053|Experimental|Treatment B|Single BMS-663068 tablet with a high fat meal
16591947|NCT02666053|Experimental|Treatment C|Single BMS-663068 tablet after a single famotidine tablet under fasted conditions
16591948|NCT02666040|Experimental|U - ULTRAPRO|Inguinal Hernia Surgery with ULTRAPRO® meshes, a new ULTRAPRO® mesh will be implanted in patients in the group (AG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment.
16591949|NCT02666040|Active Comparator|P - Prolene|"Inguinal Hernia Surgery with Prolene® meshes, the conventional mesh in polypropylene Prolene® will be implanted in patients in the control group (CG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment."
16591950|NCT02666027|Experimental|FIVA ON|The FIVA will be turned on for cases randomized to an even number. The ON light will be covered by tape. Routine induction and maintenance of anesthesia and rate and manner of delivery of IV fluid will be administered at the discretion by the anesthesiologist. The FIVA monitor will only monitor the first IV fluid bag since the study will be unblinded once the FIVA monitor alarm is triggered. When the IV bag is empty and the FIVA alarm is triggered, the anesthesiologist will turn off the FIVA and change the IV bag. The following will be recorded by the anesthesiologist: Type of surgical procedure; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA during the procedure; VAS assessment of ease of use of the FIVA; Loudness of audial alarm of the FIVA.
16591951|NCT02666027|Placebo Comparator|FIVA OFF|The FIVA will be off for cases randomized to odd numbers. The indicator lights will be covered by tape. Routine induction and maintenance of anesthesia and rate/manner of delivery of IV fluid will be administered at the discretion of the anesthesiologist. The IV bag may run dry with or without being noticed by the anesthesiologist. When they detect the empty bag, it will be changed after the removal of the FIVA. The anesthesiologist will record the presence or absence of air in the IV tubing following the termination of the study. The following will be recorded by the anesthesiologist: Type of surgery; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA device; VAS assessment of ease of use of the FIVA; Assessment of audial alarm of the FIVA.
16591952|NCT02666014|Active Comparator|Sugammadex group|"Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.
~The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding."
16591953|NCT02666014|Active Comparator|Neostigmine group|"Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.
~Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.
~Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered."
16591954|NCT02666001|Experimental|Part 1 (BMS-663068+methadone)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone
16591955|NCT02666001|Experimental|Part 2 (BMS-663068+buprenorphine and norbuprene)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine
16591956|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
16591957|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
16591958|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
16591959|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
16591960|NCT02665962|Other|Calorie Restricted (CR) program|The intervention will provide individualized CR program, meal replacement products and nutritional counseling sessions.
16591961|NCT02665936|Active Comparator|group L|Epidural levobupivacaine 0.125% (Chirocaine) in normal saline in a total volume of 10 ml will be administered epidurally in active stage of labor
16591962|NCT02665936|Active Comparator|group LD4|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 4 mg in a total volume 10 ml
16591963|NCT02665936|Active Comparator|group LD8|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 8 mg in a total volume 10 ml
16591964|NCT02665923||Newborn (gastric emptying)|A total of 50 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
16591965|NCT02665923||Infants (4-6mons)|Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
16591966|NCT02665923||Infants (9-12 months)|Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
16591967|NCT02665910|Experimental|SHR0302|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets
16591968|NCT02665910|Placebo Comparator|SHR0302 placebo comparator|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)
16591969|NCT02665897||Eclampsia|pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
16591970|NCT02665897||severe preeclampsia|pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
16591971|NCT02665897||healthy|matched normotensive pregnant women.
16591972|NCT02665884||Glaucoma EX-PRESS|Glaucoma patients who underwent glaucoma surgery between the years 2014-2015 and had diurnal intraocular pressure measurements over 24 hours.
16591973|NCT02665884||Control Group|Glaucoma patients who had been treated with anti-glaucoma drops and had diurnal intraocular pressure measurements over 24 hours.
16591974|NCT02665871|Experimental|one dose of Influenza Vaccine in aged 18 years and older|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
16591975|NCT02665871|Experimental|One dose of Influenza Vaccine in aged 3-17 year|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
16591976|NCT02665871|Placebo Comparator|placebo in aged 18 years and older|placebo in 10 subjects aged 18 years and older on day 0
16591977|NCT02665871|Placebo Comparator|placebo in aged 3-17 years|placebo in 10 subjects aged 3-17 years on day 0
16591978|NCT02665858|Active Comparator|IIH Patients|Patients diagnosed with Idiopathic Intracranial Hypertension who undergo OCT imaging
16591979|NCT02665858|Active Comparator|Control Group|Patients diagnosed with headache with ruled out Idiopathic Intracranial Hypertension who undergo OCT imaging
16591980|NCT02665845|Experimental|5-ASA group|Patients will receive corticosteroids with optimized 5-ASA.
16591981|NCT02665845|Active Comparator|Control group|Patients will receive corticosteroids alone.
16591982|NCT02665832|Experimental|AB|Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
16591983|NCT02665832|Experimental|BA|DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
16591984|NCT02665819||Pediatric cancer women survivors|Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
16591985|NCT02665806|Experimental|Ciclesonide|
16591986|NCT02665806|Active Comparator|Fluticasone|
16591987|NCT02665793|Experimental|DBPCFC to peanut cookie, then single-dose DBPCFC x 2|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):
~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit
~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions"
16591988|NCT02665793|Experimental|Single dose DBPCFC x 2, then DBPCFC to peanut cookie|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):
~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions
~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit"
16591989|NCT02665780|Experimental|Treatment|Periodontal debridement, tongue cleaning, mouth rinsing with 20ml Cetylpyridium Chloride daily for 24 weeks
16591990|NCT02665767|No Intervention|On-site sonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert.
16591991|NCT02665767|Active Comparator|Smartphone-based Telesonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an offsite expert.
16591992|NCT02665754|Experimental|Active group|In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
16591993|NCT02665754|Placebo Comparator|Placebo group|In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
16591994|NCT02665741|Other|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
16591995|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
16591996|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
16591997|NCT02665728|Experimental|BLI400|BLI400 Laxative
16591998|NCT02665715|Experimental|Low carbohydrate/Standard carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
16591999|NCT02665715|Experimental|Standard carbohydrate/Low carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
16592000|NCT02665702|Experimental|Endostar Combined With NVB and DDP|Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
16592001|NCT02665689|Active Comparator|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
16592002|NCT02665689|Experimental|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.
~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
16592003|NCT02665663|Other|healthy volunteers|"Constitution of a control group consisting of 20 healthy volunteers, matched for age and sex to establish a normal pressure force of the language depending on the age and sex value"
16592004|NCT02665663|Other|Patients with Amyotrophic Lateral Sclerosis|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis (ALS), included at diagnosis of the disease on clinical and electromyographic arguments addressed in speech pathology consultation without a complaint swallowing.
16592005|NCT02665663|Other|patients with Amyotrophic Lateral Sclerosis and swallowi|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis ( ALS) and swallowing disorders clinically objectified in the ENT consultation.
16592006|NCT02665650|Experimental|AFM13 + Pembrolizumab|Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.
16592007|NCT02665637|Active Comparator|CT-P6|Trastuzumab
16592008|NCT02665637|Active Comparator|US-licensed Herceptin|Trastuzumab
16592009|NCT02665624|Active Comparator|Stewed apricot juice + senna group|68 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. Additional one liter of stewed apricot juice (made with dried apricot) were told to be drunken until 2 h before colonoscopy.
16592010|NCT02665624|Active Comparator|senna alone group|60 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. 1 patient was dropped out due to obstructive sigmoid colon cancer.
16592011|NCT02665611|Experimental|intervention group|"intervention for improvement of treatment adherence Intervention group- This group will be followed by the MOMA call center (By the MOMA nures every couple weeks and by the study coordinatore and the treating Doctor at special visits as the study required.) The group will be monitored according to number of parameters, including treatment Adherence."
16592012|NCT02665611|Experimental|control group|"treatment as usual Control group- Treatment will continue as usual by the Doctor.(This group will allso be followed by the Study Coordinator at the same visits as the Intervention group.The group will be monitored according to number of parameters, including treatment Adherence."
16592013|NCT02665585|Experimental|C-Guard carotid stent|Carotid stenting procedure by C-Guard stent implantation (InspireMD, Boston, MA, USA)
16592014|NCT02665585|Active Comparator|Wallstent carotid stent|Carotid stenting procedure by Wallstent implantation (BostonScientific, Marlborough, MA, USA)
16592015|NCT02665572|No Intervention|renal transplant without bladder recycling|the patients allocated to this arm and met inclusion criteria will undergo renal transplant without prior recycling of the bladder
16592016|NCT02665572|Active Comparator|renal transplantation with bladder recycling|the patients allocated in this arm will undergo bladder recycling prior to renal transplantation
16592017|NCT02665559||Hypogonadism group|a cross-sectional and prospective study, in HIV-infected men less than 50 years old, with HIV-RNA ≤ 50 cop/mL under ART who had never presented AIDS
16592018|NCT02665546||Case|Patients with diagnosis of LCH based on histopathological or clinical and radiological findings.
16592019|NCT02665546||Controls|Current or ex smokers matched with cases for age, gender and smoking history.
16592020|NCT02665533|Active Comparator|Dexamethasone|Dexamethasone 8 mg, one capsule single preoperative dose.
16592021|NCT02665533|Experimental|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg, one capsule single preoperative dose.
16592022|NCT02665520|Active Comparator|stem cells injection in penis|Treatment Injection of adipose derived cells into penis experimental;randomised
16592023|NCT02665520|No Intervention|controled arm|
16592024|NCT02665507|Active Comparator|LLLI|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition LLLI (low level laser irradiation) treatment performed with Gallium-Aluminium-Arsenide 808 nm laser ( GaAlAs 808nm laser ).
16592025|NCT02665507|Sham Comparator|Sham|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition sham LLLI treatment
16592026|NCT02665481|Experimental|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
16592027|NCT02665481|Experimental|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
16592028|NCT02665481|Experimental|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.
~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
16592029|NCT02665481|Active Comparator|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
16592030|NCT02665468|Other|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
16592031|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
16592032|NCT02665455|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
16592033|NCT02665442|Experimental|Stylet|This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
16592034|NCT02665442|No Intervention|Non-Stylet|This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
16592035|NCT02665429|No Intervention|Control|Providers who are subject only to the routine implementation of clinical practice guidelines without additional experimental intervention
16592036|NCT02665429|Experimental|Intervention|"Providers who are subject to routine clinical practice guideline implementation AND receive provider's own individual prescribing data profile intervention (Individual prescribing data profile and self-assessment)"
16592037|NCT02665416|Experimental|Part I: Selicrelumab, Vanucizumab/Bevacizumab|Participants will receive a fixed dose of vanucizumab, 2 grams via IV infusion on Days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC in ascending dose levels on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (expected 24 months). Due to the discontinuation of Vanucizumab development, Participants ongoing in Part I will switch from Vanucizumab to Bevacizumab. All the dose escalation has been performed using Vanucizumab.
16592038|NCT02665416|Experimental|Part II: Selicrelumab, Bevacizumab|Bevacizumab will be administered via IV infusion on days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC after the Bevacizumab infusion at the dose determined in the Part I of the study on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (expected 18 months).
16592039|NCT02665403|Experimental|play intervention|30 minutes of hospital play interventions
16592040|NCT02665403|Placebo Comparator|control|usual care
16592041|NCT02665390|Experimental|treatment|Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.
16592042|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
16592043|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
16592044|NCT02665364|Experimental|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
16592045|NCT02665364|Placebo Comparator|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
16592046|NCT02665351|Active Comparator|Peramivir 300mg Q12H|Peramivir 300 mg, administered intravenously, twice daily (every 12 hours)
16592047|NCT02665351|Active Comparator|Peramivir 600mg Q24H|Peramivir 600 mg, administered intravenously, once daily (every 24 hrs)
16592048|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
16592049|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
16592050|NCT02665325||TSHsuppressive therapy group|TSH-suppressive therapy group: newly diagnosed differentiated thyroid carcinoma and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
16592051|NCT02665325||Negative control group|Healthy volunteers (normal T3,T4,FT3,FT4,TSH, TG-ab,TPO-ab,TG) are recruited to match the patients with age, gender, education level, ect.
16592052|NCT02665325||Positive control group|Newly diagnosed nodular goiter and undergone thyroidectomy according to the China thyroid association guidelines for the management of thyroid nodule and thyroid cnacer; followed by L-T4 replacement therapy 6/12 months.
16592053|NCT02665286|Placebo Comparator|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
16592054|NCT02665286|Active Comparator|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
16592055|NCT02665286|Active Comparator|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
16592056|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
16592057|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
16592058|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
16592059|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
16592060|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
16592061|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
16592062|NCT02665247|Experimental|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
16592063|NCT02665247|Other|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
16592064|NCT02665234|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
16592065|NCT02665234|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
16592066|NCT02665221|Placebo Comparator|Control group|
16592067|NCT02665221|Experimental|Treatment group|
16592068|NCT02665208|Active Comparator|Treatment As Usual (TAU)|Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
16592069|NCT02665208|Active Comparator|Nicotine Replacement Therapies|Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
16592332|NCT02663518|Experimental|Nivolumab Combination|Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma
16592070|NCT02665208|Active Comparator|Text Message Intervention|Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
16592071|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
16592072|NCT02665182|Experimental|Up-positioning of the testes|Patients receive standard medical therapy and supportive therapy
16592073|NCT02665182|No Intervention|Medical therapy only|Patients receive standard medical therapy only
16592074|NCT02665169|Experimental|Exercise intervention group|Supervised exercise intervention of 12 months. One Taiji and one gym training per week for first six months followed by 6 months free independent use of municipal facilities, including gym, swimming hall and weight room. Written and oral health counselling provided.
16592075|NCT02665169|Active Comparator|Control group|Control group, without any induced exercise intervention. Written and oral health counselling provided.
16592076|NCT02665156|Experimental|Robotic Stapled orthotopic neobladder|Intracorporeal stapled neobladder using robotic staplers: Partly stapled orthotopic neobladder: robotic staplers applied to create the neobladder neck and to suture the left side of the posterior aspect of neobladder. Right side of the posterior aspect of neobladder and the anterior aspect of the neobladder hand sewn.
16592077|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
16592078|NCT02665130|Active Comparator|Tai-Chi group|Tai-Chi exercise plus Indacaterol 150ug/day
16592079|NCT02665130|Placebo Comparator|Pulmonary rehabilitation group|Conventional exercise plus Indacaterol 150ug/day
16592080|NCT02665117|Active Comparator|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
16592081|NCT02665117|Active Comparator|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
16592082|NCT02665104||patients without neurological symptoms|carotid endarterectomy patients who dont'have any neurological symptoms after carotid clamping
16592083|NCT02665104||patients with neurological symptoms|carotid endarterectomy patients who have new neurological symptoms after carotid clamping
16592084|NCT02665091|Experimental|Peer Education Group|Group was self compared after the intervention
16592085|NCT02665078||Thoracoscopic Ultrasound|Patients who undergo lobectomy or an anatomical segmental resection for malignant lung tumors will be enrolled in the study. After lung resection, the lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross section with maximum diameter. The ultrasound image with size measurement of the tumor will be recorded using an ultrasound scanner (EU-Y0008, OLYMPUS MEDICALSYSTEMS CORP., Tokyo, Japan). After ultrasound evaluation, the specimen will be delivered directory to the pathology laboratory and the actual tumor size and histological diagnosis will be determined. In addition, we will evaluate the differences between US image and pathological morphology using HE slides of lung tumor.
16592086|NCT02665065|Experimental|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
16592087|NCT02665065|Active Comparator|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
16592088|NCT02665052|Experimental|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
16592089|NCT02665052|Experimental|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
16592090|NCT02665052|Placebo Comparator|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
16592091|NCT02665039|Experimental|Vinflunine + gemcitabine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:
~280 mg/m2 in patients with GFR 40-60 ml/min
~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min
~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
16592333|NCT02663518|Experimental|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with TTI-621
16592092|NCT02665039|Active Comparator|Carboplatin + gemcitabine|"Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
16592093|NCT02665026|Experimental|stoma closure at different times|choose different times to do stoma closure after surgery for rectal cancer
16592094|NCT02665013|Experimental|Tailored|Participants will complete surveys at each intervention time point. Based on survey responses, they will receive vaccine information on the study website tailored to their vaccine concerns and values
16592095|NCT02665013|Placebo Comparator|Untailored|Participants will complete surveys at each intervention time point and receive vaccine information on the study website. The vaccine information will NOT be tailored to their concerns and values.
16592096|NCT02665013|No Intervention|Usual Care|Participants will complete surveys at each intervention time point. They will receive vaccine information sheets that are provided in the well child visits at enrollment in the study.
16592097|NCT02665000|Experimental|Study arm: Structured training programme|"The participants in study arm will undergo 5 days training program in laparoscopic appendectomy using the Box and Wet Trainer as intervention. Each training session will take up to 2 hours. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.
~After the above training, they will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and graded based on a validated GOALS scoring system 6. The Primary Outcome will be the difference of the GOALS results between the 2 groups. Secondary outcomes will include OSAT score, patient outcome, residents' feedback score as well as conversion rates to open surgery."
16592098|NCT02665000|No Intervention|Control arm: non-training|"Participant in study arm will not receive any additional training during the training week. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.
~They will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and then graded based on a validated GOALS scoring system 6"
16592099|NCT02664987||Patients receiving cancer pain treatment|
16592100|NCT02664974|Experimental|HEN group|Home Enteral Nutrition
16592101|NCT02664974|Active Comparator|Control group|Dietary Counseling
16592102|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
16592103|NCT02664948|Experimental|Intervention group|Early geriatric follow-up after discharge from hospital in the patient's home
16592104|NCT02664948|No Intervention|Control group|Usual care with follow-up home-visits conducted by home care and the GP after discharge, if they consider it as necessary
16592105|NCT02664935|Experimental|Arm A: AZD4547|"AZD4547 - FGFR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20 & 80mg Trial Dose & Schedule: 80 mg BD, Continuous dosing, 21 day cycle
~Closed to recruitment."
16592106|NCT02664935|Experimental|Arm B: Vistusertib (AZD2014)|"Vistusertib (AZD2014) - MTORC1/2 Inhibitor Route & Formulation: Oral, Tablets Strengths: 25mg Trial Dose & Schedule: 125 mg BD, Intermittent dosing (2 continuous days in 7), 28 day cycle.
~Closed to recruitment."
16592107|NCT02664935|Experimental|Arm C: Palbociclib|Palbociclib - CDK4/6 Inhibitor Route & Formulation: Oral, Capsules Strengths: 75, 100 & 125mg Trial Dose & Schedule: 125 mg OD, Intermittent dosing (21 days on, 7 days off), 28 day cycle.
16592108|NCT02664935|Experimental|Arm D: Crizotinib|Crizotinib - ALK Inhibitor Route & Formulation: Oral, Capsules Strengths: 200 & 250mg Trial Dose & Schedule: 250 mg BD, Continuous dosing, 21 day cycle.
16592109|NCT02664935|Experimental|Arm E: Selumetinib & Docetaxel|"AZD6244 (Selumetinib) - MEK Inhibitor Route & Formulation: Oral, Capsules Strengths: 25mg Trial Dose & Schedule: 75 mg BD, Continuous dosing, 21 day cycle.
~Docetaxel - Chemotherapy Route & Formulation: IV infusion over 30-60 minutes, concentrate for solution for infusion.
~Trial Dose & Schedule: 75 mg/m2, 3-weekly, 21 day cycle."
16592110|NCT02664935|Experimental|Arm F: AZD5363|"AZD5363 - AKT Inhibitor Route & Formulation: Oral, Tablets Strengths: 80 & 200mg Trial Dose & Schedule: 480 mg BD, Intermittent dosing (4 days on, 3 days off), 28 day cycles.
~Closed to recruitment."
16592111|NCT02664935|Experimental|Arm G: Osimertinib (AZD9291)|"Osimertinib (AZD9291) - EGFRM+ and T790M+ Inhibitor Route & Formulation: Oral, Tablets Strengths: 80mg Trial Dose & Schedule: 80 mg OD, Continuous dosing, 21 day cycles
~Closed to recruitment."
16592112|NCT02664935|Experimental|Arm NA: Durvalumab (MEDI4736)|"Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 200mg Trial Dose & Schedule: 10 mg/kg IV, 2-weekly.
~Closed to recruitment."
16592113|NCT02664935|Experimental|Arm H: Sitravatinib|"Sitravatinib - VEGFR Inhibitor Route & Formulation: Oral, Capsules Strengths: 10 & 40mg Trial Dose & Schedule: 120 mg OD, Continuous dosing, 21 day cycles
~Closed to recruitment."
16592114|NCT02664935|Experimental|Arm J: AZ6738 & Durvalumab|"AZD6738 - ATR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20mg, 80mg, 100mg Trial Dose & Schedule: 240 mg twice daily (BD) on days 15-28 of 28 day cycle.
~Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 500mg Trial Dose & Schedule: 1500mg on day 1 of each 28 day cycle"
16592115|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
16592116|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
16592117|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
16592118|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
16592141|NCT02664753|Experimental|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.
~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
16592119|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
16592120|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
16592121|NCT02664896||Knee Osteoarthritis Cohort|Subjects with knee osteoarthritis will be asked to participate in the knee osteoarthritis testing session. This group will participate in 1 three hour testing session.
16592122|NCT02664896||Healthy Subject Cohort|Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
16592123|NCT02664883||Group I (no cancer or hematuria)|Patients with no evidence of cancer and no hematuria undergo collection of blood and urine samples at baseline and 2 months for analysis via the Flow Cytometry MDSC Clinical Assay
16592124|NCT02664883||Group II (localized RCC)|Patients diagnosed with localized renal cell carcinoma undergo collection of blood and urine samples at baseline and after nephrectomy for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI within 30 days after nephrectomy.
16592125|NCT02664883||Group III (metastatic RCC)|Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
16592126|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
16592127|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
16592128|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
16592129|NCT02664857|Active Comparator|vitamin D|After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
16592130|NCT02664857|Sham Comparator|Placebo|Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
16592131|NCT02664844|Experimental|Obese adolescent|
16592132|NCT02664818||Heart failure|Hospitalized patients with primary discharge diagnosis of heart failure and who were aged 18 years or older.
16592133|NCT02664805|Active Comparator|LEO 124249 ointment|Twice daily cutaneous application for 8 weeks
16592134|NCT02664805|Placebo Comparator|LEO 124249 ointment vehicle|Twice daily cutaneous application for 8 weeks
16592135|NCT02664792|Experimental|Diagnosis or suspicion of non-small cell lung carcinoma|SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
16592136|NCT02664779|Experimental|Arrhythmia diagnosis with the 10 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias.
16592137|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 6 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
16592138|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 4 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
16592139|NCT02664766|No Intervention|Control condition|Control condition with no intervention. Participants will be recording their daily alcohol consumption. No lifestyle modification during this period.
16592140|NCT02664766|Experimental|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
16594562|NCT02648321|Active Comparator|Health Education|Health Education
16592142|NCT02664753|Placebo Comparator|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).
~Intervention: 10 days of intravenous placebo (isotonic saline)"
16592143|NCT02664740|Experimental|Phage therapy|"Patients randomized to this arm will have phage therapy.
~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
16592144|NCT02664740|Placebo Comparator|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.
~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
16592145|NCT02664727|Experimental|Heavy drinkers|The effects of acute exercise in heavy drinkers. Participants will cycle on ergometer for 30 min at 50-60% of Heart Rate Reserve (HRR).
16592146|NCT02664727|Experimental|Alcoholic patients|The effects of acute exercise in alcoholic patients. Participants will cycle on ergometer for 30 min at 55-60% of Heart Rate maximal (HRmax).
16592147|NCT02664714|Active Comparator|PFMT Individualized|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s) 4(5s/10s), 5(5s/5s), 6(5s/5s), 7(6s/6s),8(6s/6s), 9(8s/8s) 10(8s/8s), 11(10s/10s),12(10s/10s)
16592148|NCT02664714|Experimental|PFMT individualized with group|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
16592149|NCT02664714|Active Comparator|12 group PFMT|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
16592150|NCT02664701|Active Comparator|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.
~Intervention: Baseline evaluation with a psychiatrist
~Intervention: Individual supportive therapy
~Intervention: Evaluations with a psychiatrist"
16592151|NCT02664701|Experimental|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.
~Intervention: Baseline evaluation with a psychiatrist
~Intervention: Cognitive behavioural group therapy
~Intervention: Evaluations with a psychiatrist"
16592152|NCT02664688|Experimental|Lumbar stabilization exercises|Home exercise program to perform daily for 6 months
16592153|NCT02664688|Active Comparator|Flexor Exercises|Home exercise program to perform daily for 6 months
16592154|NCT02664675||Periimplantitis|"patients formerly treated with a non surgical procedure without antibiotics with at least one functional dental implant with at least on pocket deeper than 5 mm with bleeding on probing and radiographical alveolar bone loss.
~These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis."
16592155|NCT02664675||Periodontitis|patients formerly treated with a non surgical procedure without antibiotics for a generalized severe chronic periodontitis (in accord to Armitage 2009) and needing a resective surgical procedure (periodontal pockets deeper than 5 mm with bleeding on probing) These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis.
16592156|NCT02664675||Healthy patient|healthy patients needing crown lengthening allowing collection of gingival explants
16592157|NCT02664662|Experimental|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
16592158|NCT02664662|No Intervention|standard education|Only provide one paper of post operation and give education of rehabilitated exercise
16592159|NCT02664649|Experimental|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].
~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
16592160|NCT02664649|Active Comparator|Standard of care|VKA or Antiplatelet therapy
16592161|NCT02664636|Experimental|The study population|"The study population consists of patients 20 and 75 years of age who have had a supra-tentorial ischemic or hemorrhagic stroke. The study covers consulting or hospitalized patients at the neurological rehabilitation service (NHS) of Grau du Roi Medical Center, part of the Nîmes University Hospital. Most patients originate from a 2-4 week stay in the neurological acute care, cardiac or polyvalent departments of the University Hospitals of Montpellier or Nîmes.
~Intervention: Physiotherapy
~Intervention: Occupational therapy
~Intervention: Functional near-infrared spectroscopy"
16592162|NCT02664623|Experimental|Dietary advice sheet|"Patients in this arm will receive a dietary advice sheet at the beginning of the study.
~Intervention: Dietary advice sheet"
16592163|NCT02664623|Experimental|Dietary advice sheet + consults with dietician|"In addition to receiving a dietary advice sheet at the beginning of the study, patients randomized to this arm will have individual consultations with a dietician at inclusion, month 1 and month 3.
~Intervention: Dietary advice sheet Intervention: Individual dietary consultations"
16592164|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
16592165|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
16592198|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
16592168|NCT02664584||Cross-sectional cohort|Cohort who took part in the cross-sectional study (n=5186)
16592169|NCT02664584||Cross-sectional cohort + follow-up|Cohort who took part in both the cross-sectional and follow-up study (planned n=500 (on-going))
16592170|NCT02664571|Other|ACA with isolated hemosiderosis|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis.
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
16592171|NCT02664571|Other|ACA with lobar hematoma(s)|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s).
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
16592172|NCT02664571|Other|Alzheimer's without ACA|"This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA).
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
16592173|NCT02664571|Other|Healthy volunteers|"This group is composed of healthy volunteers.
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
16592174|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
16592175|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
16592176|NCT02664545|Experimental|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into.
16592177|NCT02664545|Active Comparator|Tendon Graft|ACL reconstruction is when a tendon graft (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee) is taken and used to replace the torn ACL.
16592178|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
16592179|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
16592180|NCT02664519|Experimental|Exercise training followed by no exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
16592181|NCT02664519|Experimental|No exercise training followed by exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
16592182|NCT02664519|No Intervention|Normal Control|Control subjects without CKD will undergo baseline assessment as above.
16592183|NCT02664506|Experimental|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
16592184|NCT02664493|Experimental|SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.
~Methylprednisolone 0.5 g daily for 3 days will be administered in (Steroid pulse therapy) SPT group."
16592185|NCT02664493|No Intervention|non-SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.
~Steroid pulse therapy (SPT) will not be applied and no additional treatment will be added in non-SPT group"
16592186|NCT02664480||study group|Reproductive age women with polycystic ovary syndrome and irregular menses (Salivary Alpha-amylase Levels of 3rd and 24th day of menstrual cyclus)
16592187|NCT02664480||control group|Reproductive age women with regular menses (Salivary Alpha-amylase level of 3rd and 24th day of menstrual cyclus)
16592188|NCT02664467|Experimental|Bright light therapy (BLT)|Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
16592189|NCT02664467|Placebo Comparator|Placebo dim light|Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
16592190|NCT02664454|Experimental|Systematic nurse-led GA|Interactive educational seminar for GPs and nurses, and focused on geriatric assessment in primary care combined with Systematic nurse-led GA and dedicated hotline for GPs seeking geriatric advice
16592191|NCT02664454|Experimental|GP-led GA on a case-by-case basis, as decided by the GP|Interactive educational seminar for GPs, and focused on Geriatric assessment in primary care combined with a GP-led GA on a case-by-case basis, as decided by the GP, and a dedicated hotline for GPs seeking geriatric advice
16592192|NCT02664454|No Intervention|No intervention|No educational seminar Usual care
16592193|NCT02664441|Active Comparator|Exenatide once weekly extended-release|Injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (Bydureon®) for 36 weeks in randomized intervention followed by 18 weeks open label exenatide once weekly extended-release.
16592194|NCT02664441|Placebo Comparator|Matching placebo|Weekly injections of placebo for 36 weeks followed by 18 weeks open label exenatide once weekly extended-release.
16592195|NCT02664428|Active Comparator|PREBIOIL TEST|Product tests prepared with olives flour, buckwheat flour, pea flour, chestnut flour, oil chemical leavening agents, salt, sucrose. Baked
16592196|NCT02664428|Placebo Comparator|CONTROL|Product control prepared with wheat flour, oil, chemical leavening agents, salt, sucrose. Baked
16592197|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
16592199|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
16592200|NCT02664389|Experimental|Genetic analysis of patient with early-onset breast cancer|Sequencing of 200 selected genes in patient with early-onset breast cancer without genomic alterations of BRCA1, BRCA2 or TP53
16592201|NCT02664389|Experimental|Genetic analysis of patient with early-onset ovarian cancer|Sequencing of 200 selected genes in patient with early-onset ovarian cancer without genomic alterations of BRCA1, BRCA2
16592202|NCT02664389|Experimental|Genetic analysis of patient with pediatric cancer|Sequencing of 200 selected genes in patient with pediatric cancer without genomic alteration of TP53
16592203|NCT02664389|Experimental|Genetic analysis of patient with early-onset colorectal cancer|Sequencing of 200 selected genes in patient with early-onset colorectal cancer without genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation or without genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
16592204|NCT02664389|Experimental|Genetic analysis of patient with multiple primary tumors|Sequencing of 200 selected genes in patient with Multiple primary malignant tumors without syndromic presentation
16592205|NCT02664376||Geriatric ward population|Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
16592206|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
16592207|NCT02664350|Experimental|Genotype Arm|Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
16592208|NCT02664350|Active Comparator|Traditional Arm|Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
16592209|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
16592210|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
16592211|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
16592212|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
16592213|NCT02664285|Other|closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section.
16592214|NCT02664285|Other|No closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will not sutured after cesarean section.
16592215|NCT02664259|Experimental|UTB-VBN-EBUS group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
16592216|NCT02664259|Active Comparator|UTB-VBN-EBUS-X-ray group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
16592217|NCT02664233|Experimental|Connected group|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
16592218|NCT02664233|No Intervention|Usual diabetes education and care|Participants will receive standard diabetes education and care; each of the recruiting clinics offers diabetes self-management education programs.
16592219|NCT02664220|Experimental|Povidone-iodine irrigation|
16592220|NCT02664220|Active Comparator|No irrigation|
16592221|NCT02664207|Experimental|Fetal Surgery in Women with ex|"Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:
~a BMI greater than 35 (but less than or equal to 40 kg/m2)
~(minor) Fetal structural abnormality
~(well-controlled) Diabetes
~Previous preterm delivery (followed by a full term delivery)
~Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).
~Intervention: Open Fetal Repair of Myelomeningocele"
16592222|NCT02664194|Active Comparator|Control Group|Primary percutaneous coronary intervention only
16592223|NCT02664194|Experimental|03 Hours Hypothermia Group - Proteus® Cooling System|03 hours of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
16592224|NCT02664194|Experimental|01 Hour Hypothermia Group - Proteus® Cooling System|01 hour of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
16594563|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX, SBRT|
16592225|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
16592226|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
16592227|NCT02664168|Active Comparator|Aquacel Ag Surgical Dressing|
16592228|NCT02664168|Active Comparator|Single-Use Negative Pressure Wound Therapy (PICO)|
16592229|NCT02664155|Experimental|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:
~Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months
~Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
16592230|NCT02664155|Active Comparator|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
16592231|NCT02664142|Experimental|BIS Group|"BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)
~GA induction (Phase 1):
~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
~anaesthesia (Phase 2, Phase 3):
~hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
16592232|NCT02664142|Experimental|Non-BIS Group|"BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)
~GA induction (Phase 1):
~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
~anaesthesia (Phase 2, Phase 3):
~hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
16592233|NCT02664129|Experimental|Experimental group with video|30 patients will watch the video of them in acute decompensation phase
16592234|NCT02664129|Sham Comparator|Control group without video|30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales
16592235|NCT02664116|Experimental|Cambia|Diclofenac postassium powder for oral solution and placebo injection
16592236|NCT02664116|Active Comparator|ketorolac|ketorolac intramuscular injection and placebo oral solution
16592237|NCT02664103|Experimental|SAR439281(Cohort 1)|Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
16592238|NCT02664103|Experimental|SAR439281(Cohort 2)|Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
16592239|NCT02664103|Experimental|SAR439281(Cohort 3)|Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
16592240|NCT02664077|Experimental|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
16592241|NCT02664077|Placebo Comparator|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
16592242|NCT02664064|Experimental|online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants receive online curriculum, access to a live health coach, interactive group message forums, and connected weight and activity monitoring devices.
16592243|NCT02664064|No Intervention|Matched Control|A de-identified dataset of control subjects matched on age, gender, prediabetes diagnosis, body mass index, comorbidities and socioeconomic status will be cultivated for comparison to the active intervention arm.
16592244|NCT02664051|Placebo Comparator|placebo|mannitol
16592245|NCT02664051|Active Comparator|disodium cromoglycate|disodium cromoglycate
16592246|NCT02664038|Experimental|CRT+IDC|Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling
16592247|NCT02664038|Active Comparator|Computer Game Play+IDC|Computer arcade games for 13 weeks plus Individual Drug Counseling
16592248|NCT02664025|Active Comparator|simulation group|Interns will carry out 10 VE on a simulator
16592249|NCT02664025|No Intervention|Control group|Interns who will not perform any simulated VE
16592250|NCT02664012|Active Comparator|Own Brand Menthol Cigarette|Own Brand Menthol Cigarette
16592251|NCT02664012|Experimental|Electronic Menthol Cigarette #1|VUSE® (menthol flavor, 14 mg nicotine)
16592252|NCT02664012|Experimental|Electronic Menthol Cigarette #2|VUSE® (menthol flavor, 29 mg nicotine)
16592253|NCT02664012|Experimental|Electronic Menthol Cigarette #3|VUSE® (menthol flavor, 36 mg nicotine)
16592254|NCT02664012|Active Comparator|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
16592255|NCT02663999|Experimental|diazepam nasal spray (AB)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
16592256|NCT02663999|Experimental|diazepam nasal spray (BA)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
16592257|NCT02663986|Experimental|Organizational Skills Training (OST) Intervention|"To improve children's organizational functioning, OST focuses on four key skills.
~Tracking Assignments
~Managing Materials
~Time Management
~Task Planning"
16592258|NCT02663960|Experimental|fixed citrate doses protocol|Fixed citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which was set to meet a circuit citrate concentration of 4 mmol/l (duration: the maximum time is 72 hrs).
16592259|NCT02663960|Active Comparator|adjusted citrate doses protocol|Adjusted citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which the starting infusion rate be set 2.5 % of blood flow ( dosage range: 160-250ml/h) and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l (duration: the maximum time is 72 hrs. )
16592260|NCT02663947||ultrasound group|ultrasonographic measure for optic nerve sheath diameter
16592261|NCT02663934|Experimental|Exercise (EXS)|All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity & duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.
16592262|NCT02663934|Active Comparator|Social Interaction Stretching (SIS)|This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.
16592263|NCT02663921|Experimental|Healthy volunteers|Healthy volunteers without cutaneous disorders associated with pigmentary changes
16592266|NCT02663895|Experimental|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
16592267|NCT02663882|Experimental|smoking-related self control task|self control practice - smoking related task
16592268|NCT02663882|Active Comparator|Non-smoking-related self control task|self control practice - non-smoking related task
16592269|NCT02663869||HIV Aging-Young|200 patients
16592270|NCT02663869||HIV Aging-Old|200 patients
16592271|NCT02663869||controls|1200 patients
16592272|NCT02663843|Experimental|i-gel airway|I-gel inserted for the low skill fibreoptic intubation technique
16592273|NCT02663843|Experimental|air-Q airway|Air-Q inserted for the low skill fibreoptic intubation technique
16592274|NCT02663830|Experimental|(Sildenafil & clomiphene citrate group)|105 Patients will receive 25 mg sildenafil citrate 6 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
16592275|NCT02663830|Active Comparator|clomiphene only|105 patients will receive only clomiphene citrate 100mg/day (day 2 to 6) orally (2 tablets at same time daily).
16592276|NCT02663817|Experimental|IMRT|Study participants being treated according to the standard of care with intensity modulated radiotherapy (IMRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
16592277|NCT02663804|Active Comparator|Implant design 1|Journey II, BCS, Smith&Nephew
16592278|NCT02663804|Active Comparator|Implant design 2|Persona, Zimmer
16592279|NCT02663804|Active Comparator|Implant design 3|Unity, Corin
16592280|NCT02663778|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
16592281|NCT02663778|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
16592282|NCT02663752|Other|Deferasirox|All patients are already on commercial deferasirox before entering the study.
16592283|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
16592284|NCT02663726|Experimental|Yoga intervention group|10 weekly 75-min sessions of specialised yoga plus written advice about physical activity for older adults
16592285|NCT02663726|Active Comparator|Waiting list control group|Usual care plus written advice about physical activity for older adults
16592286|NCT02663713|Experimental|Ticagrelor|Ticagrelor 60 mg twice daily
16592287|NCT02663713|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily
16592288|NCT02663700|Experimental|1.8x10^6 sporozoites 2 doses|To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 3 and 11. n=8
16592289|NCT02663700|Experimental|2.7x10^6 sporozoites 2 doses|To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 5 and 13. n=8
16592290|NCT02663700|Experimental|2.7x10^6 sporozoites 3 doses|Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80
16592291|NCT02663700|Experimental|4.5x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 4.5x10^5 sporozoites on study weeks 1 and 9. n=8
16592292|NCT02663700|Experimental|9x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 9x10^5 sporozoites on study weeks 1 and 9. n=8
16592331|NCT02663518|Experimental|Rituximab Combination|Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies
16592293|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
16592294|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
16592295|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
16592296|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
16592297|NCT02663661|Other|Autoantibody negative subjects|Subjects who are relatives of persons with T1DM and have tested negative for autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test.
16592298|NCT02663661|Other|One autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for one autoantibody will have a Metabolic Challenge Admission followed by a CGM home test..
16592299|NCT02663661|Other|Two or more autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for two or more autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test..
16592300|NCT02663635|Other|Single Arm|
16592301|NCT02663622|Experimental|CD24Fc 240 mg|CD24Fc in 240 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
16592302|NCT02663622|Experimental|CD24Fc 480 mg|CD24Fc in 480 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
16592303|NCT02663622|Experimental|CD24Fc 960 mg|CD24Fc (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
16592304|NCT02663622|Placebo Comparator|Placebo|Placebo to CD24Fc (saline IV injection solution) on day -1 or days -1, 14, and 28 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
16592305|NCT02663596|Experimental|Vancomycin|Patients with vancomycin mixed in the CRRT solution(s)
16592306|NCT02663583||Intensity-Modulated Proton Therapy or( IMPT) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.
~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.
~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
16592307|NCT02663583||TransOral Robotic Surgery (TORS) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.
~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.
~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
16592308|NCT02663570|Experimental|open|therapy with melatonin 2 mg daily for six months
16592309|NCT02663557||non-hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP<140 mmHg; 2. Systolic blood pressure-coefficient variation (SBP-CV) < Median SBP-CV
16592310|NCT02663557||non-hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP< 140 mmHg; 2. SBP-CV > Median SBP-CV
16592311|NCT02663557||hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV < Median SBP-CV
16592312|NCT02663557||hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV > Median SBP-CV
16592313|NCT02663544|Active Comparator|Limited dairy diet|Three 8 oz. servings per week of non-fat milk. Participants will otherwise eat their usual diet, but will be asked not to consume any dairy products not provided by the study.
16592314|NCT02663544|Experimental|Low-fat dairy diet|3.3 daily servings of non-fat and low-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
16592315|NCT02663544|Experimental|Full-fat dairy diet|3.3 daily servings of full-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
16592316|NCT02663531|Experimental|Mild cognitive impairment|Patients with mild cognitive impairment
16592317|NCT02663531|Experimental|Alzheimer Disease|Patients with Alzheimer Disease
16592318|NCT02663531|Experimental|Healthy|Healthy volunteers
16592319|NCT02663518|Experimental|TTI-621 Escalation Phase|The Escalation Phase will include multiple doses of TTI-621
16592320|NCT02663518|Experimental|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
16592321|NCT02663518|Experimental|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
16592322|NCT02663518|Experimental|T-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
16592323|NCT02663518|Experimental|Hodgkin Lymphoma|Monotherapy expansion cohort with TTI-621
16592324|NCT02663518|Experimental|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with TTI-621
16592325|NCT02663518|Experimental|Acute Lymphoblastic Leukemia|Monotherapy expansion cohort with TTI-621
16592326|NCT02663518|Experimental|Multiple Myeloma|Monotherapy expansion cohort with TTI-621
16592327|NCT02663518|Experimental|Acute Myeloid Leukemia|Monotherapy expansion cohort with TTI-621
16592328|NCT02663518|Experimental|Myelodysplastic Syndrome|Monotherapy expansion cohort with TTI-621
16592329|NCT02663518|Experimental|Myeloproliferative Neoplasms|Monotherapy expansion cohort with TTI-621
16592330|NCT02663518|Experimental|Small Cell Lung Cancer|Monotherapy expansion cohort with TTI-621
16594564|NCT02648269|Experimental|SEL-110|Single intravenous dose of SEL-110
16592334|NCT02663518|Experimental|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with TTI-621
16592335|NCT02663518|Experimental|Part 4: Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621
16592336|NCT02663505||Group 1|Patients receiving either elective or emergency surgery.
16592337|NCT02663492|Experimental|TEAS group|Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
16592338|NCT02663492|Active Comparator|Medication group|On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
16592339|NCT02663492|No Intervention|Control group|The patients of control group receive routine nursing care, including (1) to be observed the changes in patient condition, (2) to eat high-calories, high-protein, high-vitamin, easy-to-digest foods during chemotherapy, (3) to be treated by psychological care, (4) to be prevented against the occurrence of phlebiti, and (5) to use Ondansetron and Omeprazole as direction.
16592340|NCT02663479|Experimental|Cardiopressin|A 5 capsule proprietary blend of herbal extracts and nutrients
16592341|NCT02663479|Placebo Comparator|Placebo|A 5 capsule placebo matched in color and size to the Experimental supplement
16592342|NCT02663466||Recurrent Group|Patients with clinically confirmed recurrence of sacrococcygeal pilonidal sinus following Limberg flap surgery were eligible (recurrent group, RG). They were evaluated for erroneous off-midline closures as an exposure variable.
16592343|NCT02663466||Nonrecurrent Group|Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
16592344|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
16592345|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
16592346|NCT02663440|Experimental|IMRT|Hypofractionated IMRT With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor
16592347|NCT02663427|Experimental|PG(-) and Hp(-) Group|PG negative （pepsinogen（PG）Ⅰ > 70ng/ml or PGⅠ/PGⅡ >7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
16592348|NCT02663427|Experimental|PG(-) and Hp(+) Group|PG negative and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
16592349|NCT02663427|Experimental|PG(+) and Hp(-) Group|PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0) and Hp negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
16592350|NCT02663427|Experimental|PG(+) and Hp(+) Group|PG positive and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
16592351|NCT02663414|Experimental|Atlas device|Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
16592352|NCT02663401|No Intervention|Control|Control situation in campus cafeterias where no labelling of food is proposed
16592353|NCT02663401|Experimental|Front-of-pack labelling (5-CNL)|Introduction of the 5-CNL front-of-pack nutrition label on shelf display tags for every food and beverage sold in the campus cafeteria. Communication campaigns accompanying the introduction of the label
16592354|NCT02663375||ACURATE TA™ Transapical Aortic Biorposthesis|Patients implanted with ACURATE TA™ Transapical Aortic Biorposthesis and Delivery System
16592355|NCT02663349|Experimental|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One hour group sessions will be offered twice a week for 12 weeks. In addition, one hour of individual training will be provided weekly by an instructor.
16592357|NCT02663323|Experimental|MeRes100 - BRS|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
16592358|NCT02663310|Experimental|Surgery with Rehabilitation|Surgically removed cysts, and collected intracystic fluids and cerebrospinal fluid for histological and molecular analyses. Samples will be collected during the surgery and will be cryo-protected for further analyses. All subjects will enroll for intensive rehabilitation 60 days after surgery.
16592359|NCT02663310|Active Comparator|Rehabilitation|All subjects will enroll for intensive rehabilitation everyday as instruction.
16592360|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.
~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
16592361|NCT02663284|Experimental|Perineural block|Perineural block with Ropivacaine 0.5%
16592362|NCT02663271|Experimental|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
16592363|NCT02663271|Other|Historical Controls|Historical controls treated with continuous bevacizumab alone or in combination with standard chemotherapy will be compared with the Optune arm. Information will be collected: Bevacizumab or additional chemotherapy, physical examination and quality of life questionnaires performed and brain MRI.
16592364|NCT02663258|Experimental|Pembrolizumab arm|All participants treated with Pembrolizumab, 200mg iv, 3weekly
16592365|NCT02663245|Experimental|Intervention 1|Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
16592366|NCT02663245|Experimental|Intervention 2|Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
16592367|NCT02663245|No Intervention|Control group|No intervention. Data of the control groups will be retrieved from the SIDIAP.
16592368|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
16592369|NCT02663219|Experimental|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
16592370|NCT02663219|No Intervention|Control|Standard of care
16592371|NCT02663206|Other|Botulinum toxin injection|"Drug/Device: Botulinum toxin injection; Endoscopic Botulinum toxin (BTX) injection at lower esophagus; Upper endoscopy with Botulinum toxin injection.
~The procedure will be performed as an outpatient basis by an endoscopist. Sedation can be in form of conscious sedation, monitored anesthesia care or general anesthesia. An upper endoscope will be inserted into the patient's mouth and advanced into lower esophagus. Botulinum toxin (Botox@) 100 units 8-10 (25 units/mL) will be injected in 1-ml portion in each of four quadrants about 1 cm above the Z-line (the LES region).
~At 1 month follow-up, patients who do not response to the first botox injection (Eckardt score > 3) will receive the second botox injection.
~At 3-month follow-up, POEM will be offered as a rescue therapy to both non-responders (Eckardt score > 3 at 3-month follow-up after the procedure) and relapsers (Eckardt score ≤ 3 at 3-month follow-up but becomes > 3 during the follow-up)"
16592372|NCT02663206|Other|peroral endoscopic myotomy|"Procedure/Surgery: peroral endoscopic myotomy.
~The procedure will be performed by an endoscopist (gastroenterologist or surgeon). General anesthesia will be started and upper endoscope will be inserted into the patient's mouth and advanced into the stomach. Endoscopic myotomy will be performed. Mucosal entry will then be closed using endoscopic clips or endoscopic suturing.
~All patients will recover from their procedures according to standard practice. They will remain nothing per oral (NPO) the night after the procedure and started on intravenous proton pump inhibitors. A gastrografin esophagram will be obtained the next day and if no evidence of leak, the diet will be advanced to a soft diet for two weeks. The patients will be evaluated by study coordinator/PI on a daily basis during their hospitalization."
16592373|NCT02663193||Enzalutamide Group|Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
16592374|NCT02663193||Abiraterone Acetate plus Prednisone group|Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
16592375|NCT02663180|Experimental|Intervention group|they will be enrolled in an educational program and video contact.
16592376|NCT02663180|No Intervention|Control group|No intervention
16592377|NCT02663167|Experimental|Internet-delivered Cognitive-Behavioral Therapy|
16592378|NCT02663154|Experimental|Aromatherapy|Aromatherapy inhaler (QueaseEASE, Soothing Scents Inc, Enterprise, AL) applied to nauseous post surgical paediatric patients in the postanesthetic care unit
16592379|NCT02663154|Placebo Comparator|Placebo|Saline inhaler applied to nauseous post surgical paediatric patients in the postanesthetic care unit
16592380|NCT02663141|Experimental|Losartan|Oral losartan 50 mg daily for 6 months
16592381|NCT02663141|Placebo Comparator|Placebo|Oral placebo daily for 6 months
16592382|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
16592383|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
16592384|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
16592385|NCT02663115||Arm 1|Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy
16592386|NCT02663115||Arm 2|Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF>50%)
16592387|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
16592388|NCT02663089|Experimental|[14C]-GSK961081 IV+GSK961081 inhalation; [14C]-GSK961081 oral|On Day 1 of Treatment Period 1, after an overnight fast of at least 8 hours, each subject will receive [14C] GSK961081 4 micrograms (mcg) by IV infusion over 1 hour. Within 5 minutes after the start of infusion, subjects will take 1200 mcg non-radiolabelled GSK961081 by inhalation. After Treatment Period 1, there will be a washout of at least 2 weeks. On Day 1 of Treatment Period 2, after an overnight fast of at least 8 hours, each subject will take 200 mcg [14C]-GSK961081 as an oral solution.
16592389|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
16592390|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
16592391|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
16592392|NCT02663063|Experimental|SSP treatment group|Case on SSP treatment
16592393|NCT02663063|Sham Comparator|Non-SSP treatment group|Sham SSP treatment
16592394|NCT02663050|Experimental|Kinesio taping group|only Kinesio taping treatment group
16592395|NCT02663050|Active Comparator|NSAID treatment group|only NSAIDs taking group
16592396|NCT02663050|Active Comparator|Combination treatment group|NSAIDs plus Kinesio taping group
16592397|NCT02663037||1|"Subjects will be recruited from a pool of elderly patients who present to the Emergency Department.
~To be eligible for participation in the study, patients must meet ALL of the following criteria:
~Age ≥ 55 years old
~Triaged as P2 or P3 in the Emergency Department
~Singapore citizen or Permanent Resident
~Provision of Informed consent
~Not previously already enrolled in this study"
16592398|NCT02663024|Experimental|Arm 1|0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
16592399|NCT02663024|Experimental|Arm 2|1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
16592400|NCT02663024|Experimental|Arm 3|1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
16592401|NCT02663024|Active Comparator|Arm 4|0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
16592402|NCT02663011||5YR boy|
16592403|NCT02663011||5YR girl|
16592404|NCT02663011||4YR boy|
16592405|NCT02663011||4YR girl|
16592406|NCT02663011||3YR boy|
16592407|NCT02662985|Active Comparator|Group 1|"In Treatment Period-1:
~Patients in this group will be administered secukinumab with 12 weeks of treatment from baseline.
~In Treatment Period-2:
~Patients will continue to receive the same active dose of secukinumab every 4 weeks until Week 24
~In Treatment Period 3 (extension period):
~the extension period is to allow responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
16592408|NCT02662985|Placebo Comparator|Group 2|"In Treatment Period-1:
~Patients will receive placebo at baseline and same time points as secukinumab until Week 8.
~In Treatment Period-2:
~Patients will commence open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12
~In Treatment Period-3:
~Open-label secukinumab will continue to be assigned to patients"
16592409|NCT02662972|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards the sphenopalatine ganglion in the affected side (ipsilateral to the pain)
16592410|NCT02662959|Experimental|Irinotecan|In the experimental arm, patients receive single agent of irinotecan as third line treatment in metastatic gastric cancer.
16592411|NCT02662946|Experimental|ICG- angiography|"Colonic resection margins and colo-rectal anastomosis are intraoperatively assessed using fluorescence angiography to evaluate colonic perfusion. If perfusion at the resection margin is judged insufficient the colon is re-resected to obtain a satisfactory perfusion"
16592412|NCT02662946|Active Comparator|No angiography|Subjective measures are employed to determine anastomotic perfusion
16592413|NCT02662933|Experimental|Bedside Assessment Measures|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.
~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
16592414|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
16592415|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
16592416|NCT02662894|Experimental|Valsartan 160mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.
16592417|NCT02662894|Experimental|Valsartan 320mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.
16592418|NCT02662894|Active Comparator|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
16592419|NCT02662894|Active Comparator|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
16592420|NCT02662855|Active Comparator|Control|WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
16592421|NCT02662855|Experimental|Treatment|WHO-recommended therapies plus oral administration of Favipiravir
16592422|NCT02662842||FlowSmart Infusion set, then current set|Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
16592469|NCT02662491|Experimental|vitamin D and calcium|daily oral vitamin D(3) (2000 IU) and calcium (600 mg) for 6 months
16592470|NCT02662491|Experimental|Calcium supplement|daily oral calcium (600 mg) for 6 months
16592423|NCT02662829|Experimental|Community-based intervention (CBI)|"Nurse training and mentorship in TB prevention using clinical algorithm based on national guidelines.
~Health education using a treatment literacy curriculum for parents and guardians.
~Community outreach by trained village health workers."
16592424|NCT02662829|Active Comparator|Standard of Care (SOC)|At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
16592425|NCT02662816|Experimental|glutathion|The study will validate the detection and the quantification of glutathione in muscle and liver using 1H MRS
16592426|NCT02662803|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
16592427|NCT02662803|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
16592428|NCT02662790|Experimental|Preterm|
16592429|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
16592430|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
16592431|NCT02662751|Active Comparator|Routine Imaging|"Patients randomized to this arm will have routine post-stroke/TIA imaging assessments.
~Intervention: Routine Imaging Assessment"
16592432|NCT02662751|Experimental|LDWBA first|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.
~Intervention: LDWBA first followed by Routine Imaging Assessment if required."
16592433|NCT02662738|Active Comparator|A wheat product|A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
16592434|NCT02662738|Placebo Comparator|Control|A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
16592435|NCT02662738|Other|Glucose solution|A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
16592436|NCT02662725|Experimental|ipilimumab + Stereotactic Radiosurgery|ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
16592437|NCT02662712|Experimental|Part 1: Single Dose Escalation|The single dose escalation phase of the study will consist of 6 dosing sessions (Sessions I to VI) evaluated in 2 panels (Panels 1 and 2). The dose of JNJ-56136379 will be consecutively escalated over 5 levels, alternating between the 2 panels. Panel 1 will receive 3 single doses (SD1, SD3 and SD3fed) in Sessions I, III and V, respectively. Panel 2 will receive 3 single doses (SD2, SD4 and SD5) in Sessions II, IV and VI, respectively. There will be a washout period of at least 14 days between consecutive JNJ-56136379/placebo dosing in each individual participant.
16592438|NCT02662712|Experimental|Part 1: Multiple dose session|After completion of the fifth single dose session another panel of healthy participant (panel 3) receive multiple doses of JNJ-56136379 at one dose level (MDx) or placebo for 12 or 19 consecutive days (Session VII) in fed or fasted conditions.
16592439|NCT02662712|Experimental|Part 2: Multiple dose escalation|Multiple dose levels will be given in Panel 4 in Session VIII (European sites), Sessions IX and X (European and/or Asian sites) Session XI (Asian sites) for 28 consecutive days in fed conditions. Optional Sessions A-B-C (Panel 4) used for further dose evaluations at European and/or Asian sites. Per session, participants will receive JNJ 56136379 or placebo. Dose progression to the next multiple dose level may be adapted based on the emerging safety and PK outcome of the previous dosing levels.
16592440|NCT02662686|Active Comparator|Control|Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).
16592441|NCT02662686|Experimental|MitoScore|Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.
16592442|NCT02662673|Other|Localized prostate cancer, Focal treatment.|
16592443|NCT02662660|Experimental|Port-sites infiltration:Bupivacaine0,25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
16592444|NCT02662660|Experimental|Epidural analgesia:Levobupivacaine0.125%|"Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.
~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours."
16592445|NCT02662660|Active Comparator|Metamizole and Acetaminophen iv|Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
16592446|NCT02662647|Experimental|DCAG plus HLI|Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion.
16592447|NCT02662647|Experimental|DCAG|Patient will be treated with decitabine combining modified CAG regimen without other treatments.
16592471|NCT02662491|Experimental|vitamin D supplement|daily oral vitamin D(3) (2000 IU) for 6 months
16592472|NCT02662491|Placebo Comparator|Placebo|daily placebo tablet for 6 months
16592473|NCT02662478||primary gastric GIST|Consisted of all consecutive cases of primary gastric stromal tumors (PGST) that underwent laparoscopic surgery (LS).
16592474|NCT02662465|Experimental|mucositis grade 1, laser 660|Group 1 will include patients with oral mucositis grade 1. Sera used wavelength of 660nm, power 100mW and lluencia of 4 J / cm².
16592448|NCT02662634|Experimental|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
16592449|NCT02662634|Experimental|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.
~Platinum-doublet chemotherapy can be any of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
16592450|NCT02662634|Experimental|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).
~Radiation therapy per PI"
16592451|NCT02662634|Experimental|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.
~Platinum-doublet chemotherapy choice of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).
~Radiation therapy per PI."
16592452|NCT02662621|Other|ill patient|Patient with a cancer disease
16592453|NCT02662621|Other|Healthy volunter|Subject without any cancer pathology
16592454|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
16592455|NCT02662595|No Intervention|Control|
16592456|NCT02662595|Active Comparator|Text message|Subjects in this arm will receive a text message reminder in due time for measles vaccination.
16592457|NCT02662595|Active Comparator|Text message and voice call|Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
16592458|NCT02662582|Experimental|CK-2127107 1000 mg, then placebo|Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
16592459|NCT02662582|Experimental|Placebo, then CK-212710 1000 mg|Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
16592460|NCT02662569|Active Comparator|Atorvastatin (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
16592461|NCT02662569|Active Comparator|Atorvastatin (QM)|Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
16592462|NCT02662569|Experimental|Evolocumab Q2W + Atorvastatin|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
16592463|NCT02662569|Experimental|Evolocumab QM + Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
16592464|NCT02662556|Experimental|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
16592465|NCT02662543||Hospitalized AGE patients|Children less than 18-years-old hospitalized due to acute gastroenteritis to seven Estonian hospitals participating in this study
16592466|NCT02662530|Active Comparator|Botulinum toxin type A clinical|Initial and optimization of BoNT-A injection parameters will be conducted by clinical visual assessment
16592467|NCT02662530|Active Comparator|Botulinum toxin type A kinematic|Initial and optimization of BoNT-A injection parameters will be conducted by kinematic assessment
16592468|NCT02662504|Experimental|multimodal treatment + intrapleural PDT|"surgery of the MPM: extended pleurectomy/decortication (eP/D)
~intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.
~then:
~prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray)
~adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation"
16592475|NCT02662465|Experimental|mucositis grade 2, laser 660|Group 2 included patients with oral mucositis grade 2. Sera used with a wavelength of 660nm, power 100mW and lluencia of 8 J / cm².
16592476|NCT02662465|Experimental|mucositis grade 3, laser 790|Group 3 included patients with oral mucositis grade 3 Sera used laser diode AsGaAl operating in continuous mode, with a wavelength of 790 nm, power of 100mW and fluency of 8 J / cm².
16592477|NCT02662452|Experimental|GLPG2222 single dose|Single dose of GLPG2222 oral suspension
16592478|NCT02662452|Placebo Comparator|Placebo single dose|Single dose of placebo oral suspension
16592479|NCT02662452|Experimental|GLPG2222 multiple doses|Multiple doses of GLPG2222 oral suspension
16592480|NCT02662452|Placebo Comparator|Placebo multiple doses|Multiple doses of placebo oral suspension
16592481|NCT02662439|Experimental|BCM group|The patients are measured by Body Composition Monitor (BCM) and both the patient and the physician know the results and adjust the diuretic therapy accordingly.
16592482|NCT02662439|Placebo Comparator|Control group|The patients are measured by Body Composition Monitor (BCM) but neither the patient nor the physician know the results, the physician adjusts the diuretic therapy as usual, according to the protocols.
16592483|NCT02662426|Experimental|Drugs for experimental group|Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
16592484|NCT02662426|Active Comparator|Drugs for positive control group|Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day.Drugs must be used on the day of fever and last for five days continuously.
16592485|NCT02662426|Placebo Comparator|Drugs for placebo control group|Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
16592486|NCT02662400|Experimental|MNCs GROUP|Patients with Type 2 Diabetes mellitus
16592487|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
16592488|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
16592489|NCT02662374|Active Comparator|Control|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid
16592490|NCT02662374|Experimental|Group 1|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Extra soft toothbrush, brushing with saline bd
16592491|NCT02662374|Experimental|Group 2|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Supersaturated Calcium Phosphate Spray, 5ml qid
16592492|NCT02662361||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
16592493|NCT02662361||peri-implant disease|The subjects who suffered from peri-implant disease.
16592494|NCT02662348|Experimental|Interleukin-2 Transfusion|Patients receive low-dose Recombinant Human Interleukin-2 SC daily beginning 3 days before the first HER2Bi armed T cell infusions infusion.
16592495|NCT02662348|Experimental|T Cells Transfusion|Patients receive HER2Bi-Armed T Cells IV weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
16592496|NCT02662335|Experimental|Arm I (computer-assisted cognitive training)|Patients complete a computerized working memory training program (Cogmed) over 35 minutes a day, 5 times a week for 6 weeks.
16592497|NCT02662335|Active Comparator|Arm II (wait-list)|Patients undergo standard follow-up care for 6 weeks. Following standard follow-up care, patients may complete Cogmed as in the Intervention Group in weeks 7-13.
16592498|NCT02662322|Experimental|HYPNOSIS|hypnotic communication, confusion procedure during peripheral intravenous catheterization
16592499|NCT02662322|Active Comparator|NOCEBO|negative connotation communication during peripheral intravenous catheterization
16592500|NCT02662322|Placebo Comparator|NEUTRAL|neutral connotation communication during peripheral intravenous catheterization
16592501|NCT02662309|Experimental|MPDL3280A|Patients receive 2x 3-weekly cycles of MPDL3280A (one infusion on the first day of each cycle) prior to cystectomy surgery.
16592502|NCT02662296|Experimental|Treatment (ibrutinib or idelalisib)|Patients receive ibrutinib PO QD on days 1-28 or idelalisib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16592503|NCT02662283|Active Comparator|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
16592504|NCT02662283|Experimental|Reh-acteoside|Oral take reh-acteoside (0.4g bid) for 8 weeks
16592505|NCT02662283|Experimental|Reh-acteoside+Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) and reh-acteoside (0.4g bid) for 8 weeks
16592506|NCT02662270||Cases|Patients with a fibromyalgia diagnosis established according to the American College of Rheumatology current criteria by a trained physician.
16592507|NCT02662270||Controls|Healthy subjects paired by age and gender to the subjects in the cases group.
16592508|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
16592509|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
16592576|NCT02661750||Step 1|Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
16592510|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
16592511|NCT02662218||Patients with superficial wounds|A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible.
16592512|NCT02662205|Active Comparator|Traditional Group|Traditional process psychotherapy group
16592513|NCT02662205|Experimental|Yoga Therapy Group|Psychotherapy group integrating yoga and process dialogue
16592514|NCT02662205|Active Comparator|Yoga Class|Yin yoga class
16592515|NCT02662192|Experimental|Intervention|Exercise + health education + auditory rehabilitation 10 weeks of exercise, interactive health education, socialization and auditory rehabilitation program
16592516|NCT02662192|Active Comparator|Auditory rehabilitation alone|"auditory rehabilitation alone
~1 hour of group auditory rehabilitation once a week for 10 weeks"
16592517|NCT02662179||Elderly patients with solid tumors|The group will include elderly patients with a malignant solid tumor: ovary cancer, breast cancer, digestive cancer (colo-rectal, pancreas), lung cancer or urinary tract cancer (including bladder cancer).
16592518|NCT02662166|Experimental|MRI and biomarkers in bladder cancer|Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity
16592519|NCT02662153||Long-term opioid-use cohort|Persons who have received 70 or more days of Schedule II opioid dispensed in a 90-day period, after at least 183 days with no opioid dispensing.
16592520|NCT02662153||IR/SA to ER/LA Switchers|Persons who have switched to or added on an ER/LA product after stable use of an IR/SA opioid regimen.
16592521|NCT02662153||IR/SA to IR/SA Switchers|Persons who have switched to or added on a new IR/SA opioid after stable use of a different IR/SA opioid regimen.
16592522|NCT02662140|Experimental|Mobile Health Application Group|"emobile health application will enhance the existing evidence informed curriculum of a Multiple Family Group model (called 4 Rs and 2 Ss for Strengthening Families Model) for families with children who have disruptive behavior disorders. This mobile application consists of two primary components that will support engagement and integration of the model's core concepts in family life. The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
16592523|NCT02662127|Experimental|SIGVARIS®. Class 2 - RAL: 23-32|Graduated elastic compression stockings
16592524|NCT02662114||Tresiba®|
16592525|NCT02662101|Experimental|Single arm, exsalt application|
16592526|NCT02662088||Laparoscopic-lavage|Patients with colonic diverticulitis submitted to laparoscopic lavage
16592527|NCT02662075|Experimental|E-cigarette/tobacco Smoking Exposure|
16592528|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
16592529|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
16592530|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
16592531|NCT02662023|Experimental|RIGHT side BOLUS and left side basal|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours
16592532|NCT02662023|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later
16592533|NCT02661997|Experimental|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
16592534|NCT02661997|Active Comparator|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
16592535|NCT02661984||Healthy (no pulmonary disease)|Healthy children 4 - 6 years old with no pulmonary disease and not exhibiting respiratory illness or sinusitis.
16592536|NCT02661984||Asthmatic (physician diagnosed)|Asthmatic children 4 - 6 years old not exhibiting acute asthma symptoms, respiratory illness or sinusitis.
16592537|NCT02661971|Active Comparator|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
~Docetaxel 50 mg/m², d1
~Oxaliplatin 85 mg/m², d1
~Calciumfolinat 200 mg/m², d1
~5-Fluorouracil 2600 mg/m², d1"
16592538|NCT02661971|Experimental|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab
~Ramucirumab 8mg/kg, d1
~Docetaxel 50 mg/m², d1
~Oxaliplatin 85 mg/m², d1
~Calciumfolinat 200 mg/m², d1
~5-Fluorouracil 2600 mg/m², d1"
16592539|NCT02661958|Experimental|S6G5T-3|topical cream
16592540|NCT02661958|Experimental|S6G5T-1|topical cream
16592541|NCT02661958|Active Comparator|S6G5T-5|topical cream
16592542|NCT02661958|Active Comparator|S6G5T-7|topical cream
16592543|NCT02661958|Active Comparator|S6G5T-6|topical cream
16592544|NCT02661958|Placebo Comparator|S6G5T-8|topical cream
16592545|NCT02661945|Experimental|Near focus with narrow band imaging|Near focus with narrow band imaging is used for marking the tumor margin.
16592546|NCT02661945|No Intervention|Indigo carmin|After indigo carmine was sprayed over the lesion, marking is performed.
16592547|NCT02661932|Experimental|Letrozole associated COS|"Breast cancer patients undergo fertility preservation with letrozole associated COS for oocyte collection.
~Letrozole is administered orally (5mg/day) during the entire stimulation protocol until ovulation triggering."
16592548|NCT02661919|Experimental|Emfit mattress sensor|
16592549|NCT02661906|Experimental|SKY Pre|Sudarshan Kriya Yoga is provided to all the enrolled participants. The baseline characteristics of patient is compared with that of their characteristics after yoga intervention. All the participants were provided with yoga training for 6 days and then asked to perform the SKY at home daily till 12 week. The questionnaire on anxiety, depression and quality of life were administered at the baseline and at the end of 6 days of yoga. Biochemical parameters such as HbA1c, lipid profile, fasting glucose and post meal glucose were measured at baseline and after 12 week of intervention.
16592550|NCT02661906|Active Comparator|SKY post|The enrolled participants were provided with SKY intervention and their pre and post data were recorded.
16592551|NCT02661893|Experimental|JNJ-42847922 and Rifampin|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ-42847922 on Day 1; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed with one oral dose of rifampin 600 mg (2*300 mg) on Day 5; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed on Day 12, following once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5-12.
16592552|NCT02661880|Experimental|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
16592553|NCT02661867||VD|Vaginal delivery group - women who gave birth of offspring through the vagina without the use of special instruments such as forceps or a vacuum extractor (instrumental vaginal delivery)
16592554|NCT02661867||CS|Cesarean section group - women delivered by surgical procedure in which one or more incisions are made through a mother's abdomen and uterus to deliver a baby. Cesarean section is performed when a vaginal delivery would put the baby's or mother's life or health at risk.
16592555|NCT02661854|Experimental|MM09 Mannosylated 5.000 subcutaneous|5.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16592556|NCT02661854|Experimental|MM09 Mannosylated 10.000 subcutaneous|10.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16592557|NCT02661854|Experimental|MM09 Mannosylated 30.000 subcutaneous|30.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16592558|NCT02661854|Experimental|MM09 Mannosylated 50.000 subcutaneous|50.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16592559|NCT02661854|Experimental|MM09 Mannosylated 5.000 sublingual|5.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16592560|NCT02661854|Experimental|MM09 Mannosylated 10.000 sublingual|10.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16592561|NCT02661854|Experimental|MM09 Mannosylated 30.000 sublingual|30.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16592562|NCT02661854|Experimental|MM09 Mannosylated 50.000 sublingual|50.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16592563|NCT02661854|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
16592564|NCT02661841|Experimental|LI-Guided Therapy|One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.
16592565|NCT02661841|Active Comparator|Control|One hundred and fifty chronic heart failure patients treated based on guidelines only.
16592566|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
16592567|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
16592568|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
16592569|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
16592570|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
16592571|NCT02661815|Experimental|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
16592572|NCT02661802|Experimental|Oxygen Supplementation|Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source.
16592573|NCT02661789|Active Comparator|GnRHa|Goserelin 3.6 mg implant
16592574|NCT02661789|Placebo Comparator|Placebo|Injection of saline
16592575|NCT02661763||Schoolchildren in Zambia|Schoolchildren in grades 7-12 in fifteen randomly selected schools in Lusaka area
16592577|NCT02661750||Step 2|Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
16592578|NCT02661750||Step 3|Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
16592579|NCT02661750||Step 4|Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
16592580|NCT02661750||Step 5|Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.
16592581|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
16592582|NCT02661724|Experimental|Take Charge Burn - Pain (TCBR-Pain)|The TCBR-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress.
16592583|NCT02661724|No Intervention|Education attention control|The attention group receives an educational materials that is matched to the TCBR-Pain intervention in terms of session length and time on the web-based program. The web-based Education attention condition includes 7 sessions delivered over 7 weeks. The Education Attention Control is education materials commonly employed in rehabilitation centers and has been successfully used in several studies as a comparison to active rehabilitation interventions
16592584|NCT02661711|Experimental|Aflibercept (Eylea)|All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
16592585|NCT02661698|Placebo Comparator|Placebo 1|"Placebo
~All participants will be given a placebo for the first visit. The other 3 arms will be randomised in a counterbalanced order."
16592586|NCT02661698|Placebo Comparator|Placebo 2|Placebo
16592587|NCT02661698|Active Comparator|DHA rich oil|Omega-3 oil: DHA enriched
16592588|NCT02661698|Active Comparator|EPA rich oil|Omega-3 oil: EPA enriched
16592589|NCT02661685|Experimental|autologous IKDC-like cell|Received autologous IKDC-like cells
16592591|NCT02661659|Other|Weekly Vaccination|Maintenance multipeptide vaccine (S-588210) administered every week
16592592|NCT02661659|Other|Every other Week Vaccination|Maintenance multipeptide vaccine (S-588210) administered every other week
16592593|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
16592594|NCT02661633||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
16592595|NCT02661633||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
16592596|NCT02661607|Other|Point of care echocardiography after central venous catheter|Point of care echocardiography plus chest radiography
16592597|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
16592598|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
16592599|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
16592600|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
16592601|NCT02661581|Experimental|Peer Support|Peer support intervention group: During the first 3 months of DSME, participants in the DSMS intervention group will be invited to attend 6 lifestyle change sessions delivered a 2-person peer leader team and conducted bi-weekly. Immediately following the 3 months of DSME, participants are invited to attend 9 months of weekly DSMS sessions (60-minutes per session) delivered by a Peer Leader. These sessions are designed to sustain the self-management gains achieved in the 3 months of DSME.
16592602|NCT02661581|No Intervention|Wait-list Control|Immediately following the 6 bi-weekly DSME sessions, participants randomized to the Wait-list control group will have completed their participation in the study.
16592603|NCT02661568||Population with condition and with exposure|
16592604|NCT02661555|Experimental|Aerobic exercise|Aerobic exercise two times per week for 24 weeks.
16592605|NCT02661555|No Intervention|Habitual lifestyle|Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.
16592606|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592607|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592608|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592631|NCT02661451|Active Comparator|OHFT|Optimal Heart Failure Therapy
16592667|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
16592609|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592610|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592611|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592612|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592613|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592614|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592615|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592616|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
16592617|NCT02661529|Active Comparator|Transesophageal Echocardiogram|Patients undergoing an Transesophageal Echocardiogram (TEE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
16592618|NCT02661529|Active Comparator|Transthoracic Echocardiogram|Patients undergoing an Transthoracic Echocardiogram (TTE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
16592619|NCT02661516||Vitamin K Antagonists|Vitamin K Antagonists dose as specified
16592620|NCT02661503|Active Comparator|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
16592621|NCT02661503|Experimental|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
16592622|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
16592623|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
16592624|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
16592625|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
16592626|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
16592627|NCT02661477|Other|pegylated interferon + placebo|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.
16592628|NCT02661477|Other|placebo + pegylated interferon|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).
16592630|NCT02661451|Experimental|TAVR (with SAPIEN 3 THV) and OHFT|Transcatheter heart valve and Optimal Heart Failure Therapy
16592632|NCT02661438|Other|Placebo to Ciprofloxacin DPI|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
16592633|NCT02661425||Standard of Care|
16592634|NCT02661425||EnteraGam|
16592635|NCT02661386|Other|Manometry Device|"During the last 10 minutes of subjects waking up from anesthesia, the motility procedure will be performed."
16592636|NCT02661373|Experimental|Treatment Arm|Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
16592637|NCT02661360|Experimental|Starting condition of swaddled|
16592638|NCT02661360|Experimental|Starting Condition of Unswaddled|
16592639|NCT02661347|Active Comparator|Active comparator: tDCS & Risperidone|In the active arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2 milliampere (mA) for 20 minutes, twice a day for five consecutive days, for a total of 10 sessions.
16592640|NCT02661347|Sham Comparator|Sham comparator: tDCS & Risperidone|In the sham arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2mA for 1 minute, twice a day for five consecutive days, for a total of 10 sessions.
16592641|NCT02661334|Placebo Comparator|Placebo|30g white rice flour
16592642|NCT02661334|Experimental|Low dose|5g/day Creatine Monohydrate (25g white rice flour) for 28 days
16592643|NCT02661334|Experimental|Loading dose|Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
16592644|NCT02661334|Experimental|High dose|High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period
16592645|NCT02661308|Experimental|Systematic bright light exposure|Systematic bright light exposure for 30 min. for 4 weeks
16592646|NCT02661308|Active Comparator|Systematic dim light exposure|Systematic dim light exposure for 30 min. for 4 weeks
16592647|NCT02661295|Other|Ferric Citrate|Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.
16592648|NCT02661282|Experimental|Arm I (temozolomide, CMV-specific T cells, surgery)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer IV over 1-5 minutes on day 22. Patients undergo surgery on day 30 of cycle 1. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-21. Treatment repeats every 42 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16592649|NCT02661282|Active Comparator|Arm II (temozolomide, CMV-specific T cells)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16592650|NCT02661269||Septic patients|Septic patients with fluid overload (fluid balance + 4 L)
16592651|NCT02661269||Post-cardiac surgery patients|Patients after cardiac surgery, at arrival on ICU.
16592652|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
16592653|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
16592654|NCT02661243|Other|Dentate Sjogren's syndrome arm|30 human adults affected by SS with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
16592655|NCT02661243|Other|Dentate healthy controls arm|30 healthy human adults with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
16592656|NCT02661243|Other|Edentulous Sjogren's syndrome arm|30 human edentulous adults affected by SS with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
16592657|NCT02661243|Other|Edentulous healthy controls arm|30 healthy human edentulous adults with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
16592658|NCT02661230|Experimental|COGNIPLUS|Exercise-Gaming
16592659|NCT02661217|Other|Pre-discharge treatment initiation|Patients received first dose at any point after Randomization but no later than 12 h before discharge.
16592660|NCT02661217|Other|Post-discharge treatment initiation|Patients received first dose after discharge and up to 14 days thereafter.
16592661|NCT02661204||Population A|Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
16592662|NCT02661204||Population B|Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
16592663|NCT02661204||Population C|Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
16592664|NCT02661204||Population D|Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
16592665|NCT02661191|Other|asthma severity and disease exacerbation|intramuscular cholecalciferol 100,000 IU, followed by oral cholecalciferol 5000 IU weekly plus 400 IU daily for one year
16592666|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
16592668|NCT02661152|Experimental|Radio-/Chemoradiotherapy + nimorazole|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole but receiving the drug, which is normal standard radiotherapy of HNSCC in Denmark.
16592669|NCT02661152|No Intervention|Radio-/Chemoradiotherapy|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole and not receiving the drug, that is normally part of standard radiotherapy of HNSCC in Denmark.
16592670|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to <60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
16592671|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m^2 to <30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
16592672|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
16592673|NCT02661100|Experimental|CDX-1401 + Poly-ICLC + Pembrolizumab followed by Pembrolizumab|Patients receive CDX-1401, Poly-ICLC and Pembrolizumab for 4 cycles (Q 3 weeks) followed by Pembrolizumab alone (Q 3 weeks) until disease progression.
16592674|NCT02661087|Experimental|Bipolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy
16592675|NCT02661087|Active Comparator|Monopolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy
16592676|NCT02661074||Fishermen|"Fisherman followed by the Service de Santé des Gens de Mer of Boulogne-sur-Mer, France (occupational exposure to fish).
~A questionnaire will be completed."
16592677|NCT02661074||Fish processing factories|"Workers of fish processing factories who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France (occupational exposure to fish).
~A questionnaire will be completed."
16592678|NCT02661074||Control|"Workers who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France, but do not work in fish processing factories.
~A questionnaire will be completed."
16592679|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
16592680|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
16592681|NCT02661048|Experimental|Open label|Non-randomized, open label clinical trial that intends to treat 10 subjects with refractory ventricular tachycardia with the CyberHeart system using standard radiosurgical techniques.
16592682|NCT02661035|Experimental|Reduced Intensity Conditioning|Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
16592683|NCT02661022|Experimental|SL-401/Pomalidomide/ Dexamethasone|SL-401 in combination with Pomalidomide and Dexamethasone
16592684|NCT02661009||Plasma and tissue matching|
16592685|NCT02661009||predicting clinical efficacy|
16592686|NCT02660983|Placebo Comparator|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
16592687|NCT02660983|Experimental|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
16592688|NCT02660983|Experimental|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
16592689|NCT02660970|Active Comparator|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
16592690|NCT02660970|Placebo Comparator|Placebo-band|Children will have to wear a 'placebo-wristband'
16592691|NCT02660970|Active Comparator|Iberogast|Children will have to take Iberogast drops
16592692|NCT02660970|Placebo Comparator|Placebo-drops|Children will have to take placebo-drops
16592693|NCT02660957|Experimental|self-determination smoking cessation|Subjects in the intervention group will be allowed to select their own schedules of quitting after discussing their situation with the counsellor (quit immediately (QI), or quit progressively (QP) with the ultimate goal of completing cessation over an acceptable period). Subjects in the intervention group will receive a self-help quitting leaflet published by the Hong Kong Council on Smoking and Health plus a series of brief interventions using the AWARD model.
16592694|NCT02660957|Placebo Comparator|health life|Subjects in the placebo control group will receive a smoking cessation leaflet published by the Hong Kong Council on Smoking and Health (COSH), as will the intervention group. Moreover, subjects in the placebo control group will undergo a similar schedule of telephone follow-up as those in the intervention group. They will receive a 'placebo' intervention with a 'placebo booster' of the same duration on increasing physical activity and fruit and vegetable intake.
16592695|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
16592696|NCT02660944|Placebo Comparator|Placebo|Saline placebo
16592697|NCT02660931|Experimental|AKI Risk Notification|Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.
16592698|NCT02660931|No Intervention|Usual Care|These patients will receive usual clinical care, with no acute kidney injury risk notification.
16592699|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
16592700|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
16592703|NCT02660879|Placebo Comparator|Written Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given written educational materials, and given 5 minutes to read these materials. They were then re-taped for their inhaler technique.
16592704|NCT02660879|Experimental|Online Video Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.
16592705|NCT02660866|Placebo Comparator|SMT+APT+Placebo|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min
~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy."
16592706|NCT02660866|Active Comparator|SMT+APT+Vorapaxar|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min
~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy.
~Vorapaxar: Vorapaxar 2.08mg/day"
16592707|NCT02660853|Other|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
16592708|NCT02660840|Experimental|0.5 mg Test, then 0.5 mg reference|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)
16592709|NCT02660840|Experimental|0.5 mg reference, then 0.5 mg Test|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)
16592710|NCT02660840|Experimental|1 mg Test, then 1 mg reference|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)
16592711|NCT02660840|Experimental|1 mg reference, then 1 mg Test|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)
16592712|NCT02660840|Experimental|5 mg Test, then 5 mg reference|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)
16592713|NCT02660840|Experimental|5 mg reference, then 5 mg Test|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)
16592715|NCT02660814|Placebo Comparator|Healthy periodontium without obesity|"GCF samples were taken at baseline
~Intervention: Gingival crevicular fluid collection"
16592716|NCT02660814|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
16592717|NCT02660814|Placebo Comparator|Healthy periodontium with obesity|"GCF samples were taken at baseline
~Intervention: Gingival crevicular fluid collection"
16592718|NCT02660814|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
16592719|NCT02660801|Experimental|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
16592720|NCT02660801|Experimental|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
16592721|NCT02660788|Active Comparator|Control Arm|Mail
16592722|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
16592723|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
16592724|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
16592725|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
16592726|NCT02660762|Experimental|Modified MRCUKALLⅫ/ECOGE2993 Regimen|"All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate
~,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis."
16592727|NCT02660736|Experimental|Regimen AB|"Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.
~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.
~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.
~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
16592728|NCT02660736|Experimental|Regimen BA|"Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.
~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.
~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.
~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
16592729|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
16592731|NCT02660697|Active Comparator|Test - Extraction site development group|In the test group 29 healthy patients presenting 33 single rooted teeth scheduled for extraction with Extraction Defect Sounding (EDS) Class 3-4 type buccal bony dehiscences were included. 29 maxillary single rooted teeth and 4 single rooted teeth in the mandible (27 incisors, 2 canines and 4 premolars) were removed and treated by the novel extraction site development method. Pre- and postoperative ConeBeam Computer Tomography (CBCT) data were collected for further analysis.
16592732|NCT02660697|No Intervention|Control - Spontaneous healing group|In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
16592733|NCT02660684|Experimental|Prograf + MTX|
16592734|NCT02660684|Active Comparator|Cyclosporine + MTX (historical control)|
16592735|NCT02660671|Active Comparator|Usual care|Email outreach
16592736|NCT02660671|Experimental|Active choice|Email outreach + active choice
16592737|NCT02660671|Experimental|Financial incentive + Active choice|Email outreach + active choice + financial incentive
16592738|NCT02660658|Other|Intrathecal dexmedetomidine|"Up-down sequential allocation
~The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance"
16592740|NCT02660632|Placebo Comparator|Thoracic epidural analgesia (TEA)|Patients who will be subjected for midline laparotomy, will receive epidural analgesia through an inserted thoracic epidural catheter before induction of general anesthesia
16592741|NCT02660632|Active Comparator|Rectus sheath catheter block|After insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected on each side, then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
16592742|NCT02660619||Low-risk patients|These will be patients with a prescription for opioids for chronic pain for at least 30 days, recruited from university-affiliated pain and rehabilitation medicine clinics that routinely employ precautions to avoid prescribing such medication to individuals seeking it for non-therapeutic reasons
16592743|NCT02660619||High-risk patients|These patients will be in treatment for addiction to opioids and have (or have had) a prescription of opioids to treat pain.
16592744|NCT02660606||Group 1: Opioid abusers|
16592745|NCT02660606||Group 2: Abusers of other substances|
16592746|NCT02660606||Group 3: Non-opioid abusers|
16592747|NCT02660606||Group 4: Non-opioid users|
16592748|NCT02660593|Experimental|SanGrow|Patients will be given SanGrow Decoction 150 ml per day for 3 months.
16592749|NCT02660580|Experimental|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
16592750|NCT02660580|Active Comparator|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
16592751|NCT02660580|Experimental|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
16592752|NCT02660580|Active Comparator|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
16592753|NCT02660580|Experimental|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
16592754|NCT02660567|Experimental|Amr Maneuver|Active management of third stage plus Amr's maneuver
16592755|NCT02660567|No Intervention|Active management alone|Active management of third stage alone
16592756|NCT02660554|No Intervention|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
16592810|NCT02660242|Active Comparator|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
16592811|NCT02660242|Experimental|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
16592757|NCT02660554|Experimental|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
16592758|NCT02660541|Active Comparator|Betafoam|Brand name: Betafoam® This is a medicated device (dressing) consisting of 3% povidone iodine.
16592759|NCT02660541|Active Comparator|Allevyn Silver dressing|Brand name: Allevyn® Silver
16592760|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
16592761|NCT02660515|Active Comparator|ORIF|The operation has to be performed within 3 weeks after the initial trauma. According to the current standard, antibiotic prophylaxis (Cefazoline, 1000 milligram intravenous) will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis and the arteria radialis. After the fracture site is exposed, the fracture will be reduced and an appropriate volar locking plate will be positioned. The type and brand of the plate are at discretion of the treating surgeon. When a dorsal approach is deemed necessary the distal radius will be approached between the third and fourth dorsal extensor tendon compartments. To evaluate the quality of articular reduction, fluoroscopic images will be obtained. Wound closure will be performed using standard techniques.
16592762|NCT02660515|Active Comparator|ORIF with additional wrist arthroscopy|Surgery will be performed by a certified trauma surgeon, with experience in wrist arthroscopy. A delay of minimal 5 days before performing arthroscopy is mandatory to enable visualisation due to the organisation of the hematoma. During wrist arthroscopy, the forearm will be positioned upright and in neutral position, the elbow flexed by 90° and axial traction of 4-6 kg will be performed. Four portal entrees are created by superficial stab incisions and blunt preparation through the joint capsule; one midcarpal radiair and one midcarpal ulnar portal and the 3-4 and 6-R portal. A shaver is used for removal of fracture haematoma and osteocartilaginous debris. Cartilage damage will be graded using the Outerbridge classification system. With the 1 mm hook probe assessment of the quality of reduction and ligamentous injuries (TFCC, scapholunate and lunotriquetral) will be performed. Wound closure will be performed using standard techniques.
16592763|NCT02660502|Experimental|BioChaperone insulin lispro 0.1 U/kg|
16592764|NCT02660502|Experimental|BioChaperone insulin lispro 0.2 U/kg|
16592765|NCT02660502|Experimental|BioChaperone insulin lispro 0.4 U/kg|
16592766|NCT02660502|Active Comparator|Humalog®|
16592767|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
16592768|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
16592769|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
16592770|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
16592771|NCT02660450|Experimental|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
16592772|NCT02660450|Experimental|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
16592773|NCT02660450|Experimental|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
16592774|NCT02660437|Active Comparator|Effect of PR in MCI-group|Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of MCI-Group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR). Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques.
16592775|NCT02660437|Placebo Comparator|Effect of PR in control-group|"Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of control-group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR).
~Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques."
16592776|NCT02660424|Experimental|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
16592777|NCT02660424|Experimental|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
16592778|NCT02660411|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.
~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
16592779|NCT02660411|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.
~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
16592780|NCT02660398|No Intervention|Controls|Our control group will consist of an observational cohort of 40 patients in whom we will make quantitative assessments of the Train-of-four ratio (TOF ratio). This is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
16592781|NCT02660398|Other|Intervention|The intervention consists of a protocol for intraoperative management of neuromuscular blockade with rocuronium and reversal with neostigmine. A train-of-four count of 4 at the thumb will be confirmed prior to administration of an adjusted dose of neostigmine. TOF ratio is measured in the same manner as for the Control group, it is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
16592782|NCT02660385|Experimental|Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
16592783|NCT02660385|Active Comparator|Heart Failure Self-Management Education|Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
16592784|NCT02660372|Experimental|Imonogas|Imonogas 120 mg, 1 capsule three times daily for 8 weeks
16592785|NCT02660372|Active Comparator|Espumisan|Espumisan 40 mg, 2 capsules four times daily for 8 weeks
16592786|NCT02660359|Experimental|600 U Dysport® Group|
16592787|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
16592788|NCT02660359|Experimental|800 U Dysport® Group|
16592789|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
16592790|NCT02660346|Active Comparator|Group A - Daptomycin or Vancomycin|Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.
16592791|NCT02660346|Experimental|Group B - Daptomycin with Ceftaroline|Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.
16592792|NCT02660333|Placebo Comparator|Placebo|Maltodextrin
16592793|NCT02660333|Active Comparator|Prebiotic|Fructooligosaccharide
16592794|NCT02660333|Active Comparator|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
16592795|NCT02660320|Active Comparator|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
16592796|NCT02660320|Placebo Comparator|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
16592797|NCT02660307|Experimental|PROGRESS group|this group received the intervention based in meditation in the first 8 weeks. They were instructed to practice at least 5 times a week for up to half an hour a day. During the second 8 week period this group were left to manage their practice on their own.
16592798|NCT02660307|Other|control group|this group received no intervention in the first 8 weeks. During the second 8 week period, this group received the same intervention based in meditation that received PROGRESS group.
16592799|NCT02660294|Experimental|Platlet rich plasma|For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity
16592800|NCT02660294|No Intervention|Hormone replacement therapy|Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity
16592801|NCT02660281|Other|Full Intensity TBI-based Conditioning|Total Body Irradiation 1200 cGy of 150 cGy over 4 or 5 days, days -5 or -4 to -1 Fludarabine 30 mg/m2/day x 3 days, days -6, -5, -4 Stem Cell Infusion, day 0 Post- Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Mesna 50 mg/kg/day x 2 days, days +3 and +4
16592802|NCT02660281|Other|Full Intensity Chemo-Only Conditioning|Fludarabine 25 mg/m2/day x 5 days, days -6, -5, -4, -3, -2 Busulfan 130 mg/m2/day x 4 days, days -6, -5, -4, -3 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell Infusion Mesna 14.5 mg/kg/day x 2 days, days -3 and -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, days +3 and +4
16592803|NCT02660281|Other|Reduced Intensity Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
16592804|NCT02660281|Other|Non-Myeloablative Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell InfusionMesna 14.5 mg/kg/day x 2 days, days -3 and -2 Total Body Irradiation 200 cGy, day -1 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, day +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, day +3 and +4
16592805|NCT02660281|Other|Reduced Intensity Conditioning with Addition of Thiotepa|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Thiotepa 8 mg/kg, day -3 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
16592806|NCT02660268|Experimental|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
16592807|NCT02660268|No Intervention|Control|Patients in the control group will receive standard care
16592808|NCT02660242|No Intervention|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
16592809|NCT02660242|Active Comparator|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
16592812|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
16592813|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
16592814|NCT02660203|Experimental|forced expiration|2 daily sessions of forced expiration on ipsilateral decubitus from day 1 after surgery until chest tube removal
16592815|NCT02660203|No Intervention|control|No session of forced expiration
16592816|NCT02660190|Experimental|PDD|PDD at flexible cystoscopy
16592817|NCT02660190|Experimental|WL|WL only at flexible cystoscopy
16592818|NCT02660177|Experimental|metamizole|single IV metamizole (10mg/kg) administration
16592819|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
16592820|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
16592821|NCT02660151|Experimental|Treatment A-B|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
16592822|NCT02660151|Experimental|Treatment B-A|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
16592823|NCT02660138|Experimental|600 U Dysport® Group|
16592824|NCT02660138|Placebo Comparator|600 U Dysport® Placebo Group|
16592825|NCT02660138|Experimental|800 U Dysport® Group|
16592826|NCT02660138|Placebo Comparator|800 U Dysport® Placebo Group|
16592827|NCT02660125|Active Comparator|endometrial scratch injury|endometrial scratch done before ICSI cycle
16592828|NCT02660125|No Intervention|control|IcSI cycle without prior endometrial injury
16592829|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
16592830|NCT02660099|Experimental|Internet-delivered CBT|12 weeks of internet-delivered cognitive behavior therapy provided through a secure internet platform and online clinician contact
16592831|NCT02660086|Experimental|Personalized feedback|Emails and letters providing personalized nutrition feedback about food choices and health, social norms, and financial incentives for healthy food choices
16592832|NCT02660086|No Intervention|Control|Monthly letters with general nutrition information
16592833|NCT02660073|Experimental|NMES+FES group|NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
16592834|NCT02660073|Experimental|Control+FES group|Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
16592835|NCT02660060|Experimental|Pramipexole Dexa Medica|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
16592836|NCT02660060|Active Comparator|Pramipexole Boehringer Ingelheim Pharma|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
16592837|NCT02660047|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.
~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.
~Duration: 26 weeks"
16592838|NCT02660047|Placebo Comparator|Liraglutide - Placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.
~Dose: same as Liraglutide
~Duration: 26 weeks"
16592839|NCT02660034|Experimental|Phase 1A|Approximately 50 participants for the dose escalation until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
16592840|NCT02660034|Experimental|Phase 1B|Approximately 180 participants for expansion in eight selected arms with nine cohorts.
16592841|NCT02660008|Experimental|ZP4207|ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.
16592842|NCT02660008|Active Comparator|GlucaGen|GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.
16592843|NCT02659956||Individuals without known CNS disease|Family members of patient participants
16592844|NCT02659956||Patient Controls|a target population of 20 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
16592845|NCT02659956||Patients with multiple sclerosis|Up to 100 adults (age greater than or equal to 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
16592846|NCT02659943|Experimental|LEVEL 1 - Participants Who Received 0.66x10^6 CAR T Cells Only|LEVEL 1 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells only
16592847|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 2-Participants Who Received - 0.66x10^6 CAR T Cells Foll/by 2x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 2 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 2x10^6 CAR T cells
16592848|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 3 - Participants Who Received 0.66x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 3 - participant who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
16592849|NCT02659943|Experimental|LEVEL 2 - Participants Who Received 2x10^6 CAR T Cells Only|LEVEL 2 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells only
16592930|NCT02659436|Active Comparator|Verbal-linguistic CBT|Participants will receive 4 sessions of verbal cognitive restructuring and exposure therapy delivered in an individual therapy format.
16592850|NCT02659943|Experimental|LEVEL 2 Followed by LEVEL 3-Participants Who Received 2x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 2 followed by LEVEL 3 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
16592851|NCT02659943|Experimental|LEVEL 3 - Participants Who Received 6x10^6 CAR T Cells Only|LEVEL 3 - participants who received - 6x10^6 Chimeric Antigen Receptor (CAR) T cells only
16592852|NCT02659930|Experimental|1/Group 1|Pomalidomide and liposomal doxorubicin given at escalating doses to patients with KS requiring systemic therapy
16592853|NCT02659930|Experimental|2/ Group I; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
16592854|NCT02659930|Experimental|3/Group II|Pomalidomide with liposomal doxorubicin given at escalating doses in to patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS requiring systemic therapy
16592855|NCT02659930|Experimental|4/Group II; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS or KS with concurrent KSHVassociated MCD or KICS requiring systemic therapy
16592856|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer|Pit and fissure sealing using conventional glass-ionomer cement
16592857|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement|Pit and fissure sealing using conventional glass-ionomer cement
16592858|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer -|Restoration using conventional glass-ionomer cement
16592859|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement -|Restoration using conventional glass-ionomer cement
16592860|NCT02659904|Active Comparator|Less than 2 mm|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: Less than 2 mm remaining palatal tissue thickness
16592861|NCT02659904|Active Comparator|2 mm or more|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: 2 mm or more remaining palatal tissue thickness
16592862|NCT02659891|Active Comparator|Group 1 (Treatment)|Intravenous immune globulin (IVIg; Privigen®) 1g/kg monthly for 2 months with immunosuppression reduction.
16592863|NCT02659891|Placebo Comparator|Group 2 (Control)|Placebo infusion monthly for 2 months with immunosuppression reduction
16592864|NCT02659865|Placebo Comparator|Part A: Placebo|Single oral dose of placebo administered in one of three study periods
16592865|NCT02659865|Experimental|Part A: LY3039478 new formulation|Escalating single oral dose of LY3039478 administered in two of three study periods
16592866|NCT02659865|Experimental|Part B: LY3039478 original formulation|Single oral dose of LY3039478 administered in one of two study periods
16592867|NCT02659865|Experimental|Part B: LY3039478 new formulation|Single oral dose of LY3039478 administered in one of two study periods
16592868|NCT02659852|Experimental|Side by side group|
16592869|NCT02659852|Active Comparator|Stent in stent group|
16592870|NCT02659839||Cancer patients admitted to the ICU|Patients with cancer admitted to the ICU. No intervention will be administered.
16592871|NCT02659826|Experimental|anodal tsDCS and gait training|Volunteers will be submitted to anodal transcutaneous spinal cord stimulation and gait training
16592872|NCT02659826|Experimental|cathodal tsDCS and gait training|Volunteers will be submitted to cathodal transcutaneous spinal cord stimulation and gait training
16592873|NCT02659826|Sham Comparator|sham tsDCS and gait training|Volunteers will be submitted to sham transcutaneous spinal cord stimulation and gait training
16592874|NCT02659826|Experimental|High frequency rTMS and gait training|Volunteers will be submitted to high frequency transcranial magnetic stimulation and gait training
16592875|NCT02659826|Experimental|Low frequency rTMS and gait training|Volunteers will be submitted to low frequency transcranial magnetic stimulation and gait training
16592876|NCT02659826|Sham Comparator|sham rTMS and gait training|Volunteers will be submitted to sham transcranial magnetic stimulation and gait training
16592879|NCT02659800|Experimental|Arm A - Low Dexamethasone (LD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation
~Laboratory Biomarker Analysis Correlative Studies"
16592880|NCT02659800|Experimental|Arm B High Dexamethasone (HD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation
~Laboratory Biomarker Analysis Correlative Studies"
16592881|NCT02659800|Experimental|Arm A1 (LD) Control - Placebo|"Patients receive single dose Placebo IM (blinded). Patients also on Dexamethasone </=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot
~Laboratory Biomarker Analysis Correlative Studies"
16592882|NCT02659800|Experimental|Arm A2 (LD) MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm A (Blinded) . Patients also on Dexamethasone <=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot
~Laboratory Biomarker Analysis Correlative Studies"
16592883|NCT02659800|Experimental|Arm B1 HD MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm B (Blinded) . Patients also on Dexamethasone >= 4mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot
~Laboratory Biomarker Analysis Correlative Studies"
16592884|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
16592885|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
16592886|NCT02659774|Experimental|Group A|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
16592887|NCT02659774|Placebo Comparator|Group B|Face to Face counseling (Motivational intervention) + Booklet + SMS
16592888|NCT02659774|Placebo Comparator|Group C|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
16592889|NCT02659774|Placebo Comparator|Group D|Phone counseling (Motivational intervention) + booklet + SMS
16592890|NCT02659761|Experimental|dolutegravir/abacavir/lamivudine|All study subjects will receive triumeq (600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine) single tablet that will be taken orally, once daily, during 96 weeks
16594565|NCT02648269|Experimental|SEL-212|Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
16592891|NCT02659748|Experimental|Milk fat|A 21-day low-fat (E%) experimental diet including milk fat with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single (bioactive) fatty acids.
16592892|NCT02659748|Experimental|Control Fat|A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
16592893|NCT02659735|Experimental|Panel 1: Treatment ADBC|Participants will receive Treatment A (600 milligram [mg] JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 1; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 2; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 3; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
16592894|NCT02659735|Experimental|Panel 1: Treatment BACD|Participants will receive Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 1; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 2; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 3; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
16592895|NCT02659735|Experimental|Panel I: Treatment CBDA|Participants will receive Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 1; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 2; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 3; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
16592896|NCT02659735|Experimental|Panel I: Treatment DCAB|Participants will receive Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 1; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 2; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 3; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
16592897|NCT02659735|Experimental|Panel 2: Treatment EFG|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
16592898|NCT02659735|Experimental|Panel 2: Treatment FGE|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
16592899|NCT02659735|Experimental|Panel 2: Treatment GEF|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
16592900|NCT02659735|Experimental|Panel 2: Treatment GFE|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
16592901|NCT02659735|Experimental|Panel 2: Treatment FEG|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
16592902|NCT02659735|Experimental|Panel 2: Treatment EGF|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
16592903|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
16592904|NCT02659683|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
16592905|NCT02659683|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
16592931|NCT02659436|Experimental|Imagery-based CBT|Participants will receive 4 sessions of imagery-based cognitive work and behavioural experiments delivered in an individual therapy format.
16592906|NCT02659657|Experimental|Interleukin-2 interventions|Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).
16592907|NCT02659644|Experimental|Oral citrulline|
16592908|NCT02659631|Experimental|PF-06671008|
16592909|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
16592910|NCT02659605|Experimental|Delayed cord clamping above the perineum|
16592911|NCT02659605|Active Comparator|Delayed cord clamping below the perineum|
16592912|NCT02659592|Experimental|infertile cancer survivors|infertile cancer survivors who seek to conceive and had frozen ovarian tissue when diagnosed years before
16592913|NCT02659579|Experimental|The Reader Organisation's Shared Reading Programme|In the Reader Organisation's Shared Reading Programme, parents and children will attend The Reader Organisation's weekly shared reading programme for 8 weeks. The programme consists of two different modules. Parents will attend 'Magical Storytimes' with their children, in which a collection of shared book reading sessions are led by a project worker. Parents will also attend sessions on their own ('Stories for you and Yours') in which they will be informed how to choose books and read interactively with their child.
16592914|NCT02659579|Active Comparator|Shared Reading control|In the Shared Reading control parents and children will attend a weekly shared reading group at a library for 8 weeks where parents/children will read in a shared reading group which will be coordinated by a group facilitator.
16592915|NCT02659553||mild steatosis|5% - 30% of hepatocytes have fatty infiltration
16592916|NCT02659553||moderate steatosis|30% - 60% of hepatocytes have fatty infiltration
16592917|NCT02659553||No steatosis|No or less than 5% of hepatocytes have fatty infiltration
16592918|NCT02659540|Experimental|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
16592919|NCT02659540|Experimental|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
16592920|NCT02659527|Active Comparator|standardized needle biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.
~According to the randomization, the standardized 12 core TRUS (TransRectal UltraSound)-guided biopsy is performed without knowledge of imaging findings by the urologist. If the biopsy is negative patients will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
16592921|NCT02659527|Experimental|image-guided biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.
~Patients will have a standardized 12 core TRUS-guided biopsy without knowledge of imaging findings by the urologist. Patients randomized in this arm will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
16592922|NCT02659514|Experimental|Poziotinib, oral tablets|
16592923|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
16592924|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
16592925|NCT02659488|Other|Lisdexamfetamine|During the Treatment Phase, subjects will be evaluated after 1, 2, 3, 4, 6, 8, 10, and 12 weeks (see Figure 2). The morning after completing the first fMRI scan, LDX will be started at 30 mg q AM (Baseline). After 1 week, LDX will then be increased to 50 mg q AM (Visit 1); after another week, LDX will be increased to 70 mg q AM (Visit 2). A single downward dose titration to 50 mg is allowed during week 3 if 70 mg/d is not tolerated. LDX dose at week 4 (50 or 70 mg/d) will be maintained for the next 8 weeks. Patients who do not tolerate 50 or 70 mg/day will be terminated. For patients who complete the 12-week treatment phase, LDX will be stopped at week 12 visit.
16592926|NCT02659475|Experimental|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
16592927|NCT02659462||patients post Fontan palliation for single ventricular hear|Cardio Pulmonary Exercise Testing
16592928|NCT02659462||Subjects post surgical correction of congenital heart disease|Cardio Pulmonary Exercise Testing
16592929|NCT02659462||Healthy patients|Cardio Pulmonary Exercise Testing
16593717|NCT02654223|Experimental|MG56 Mannosylated 300 sublingual|300 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16592932|NCT02659423||Green Dot BIC 1|"Bystander Intervention Components Clusters will include at least a component of Green Dot.
~E.g. Comparisons will be made across schools that have Green Dot versus those that don't have Green Dot. (BIC 1)"
16592933|NCT02659423||Online BIC 2|"Bystander Intervention Components Clusters will include at least a component of online bystander training.
~E.g. Comparisons will be made across schools that have online bystander training versus those that do not. (BIC 2)"
16592934|NCT02659423||Alternative programs BIC 3|"Bystander Intervention Components Clusters will include at least a component of Green Dot.
~E.g. Comparisons will be made across schools that have alternative program versus those that do not. (BIC 3)"
16592935|NCT02659410|Experimental|Heat stress|4h exposure to heat stress alone or in combination with different solvents. Solvent concentrations are equal to their TLV. Heat conditions are 21, 25 and 30°C (WBGT). Inhalation exposure for all solvents and demal exposure for toluene.
16592936|NCT02659397|Experimental|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
16592937|NCT02659397|Placebo Comparator|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
16592938|NCT02659384|Experimental|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
16592939|NCT02659384|Experimental|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
16592940|NCT02659384|Experimental|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
16592941|NCT02659371|Experimental|Low energy diet|Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d.
16592942|NCT02659358||Biosensor + Patient Reported Outcomes (PRO)|Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
16592943|NCT02659345|Experimental|Art Therapy|The art therapy intervention will be executed by an art therapist at the Cancer Center. The same art therapy practices that are utilized in daily practice will be employed in this study. The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities. Sessions will conclude with processing of the art and supportive counseling as appropriate. Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist. Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
16592944|NCT02659332|Experimental|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
16592945|NCT02659319|Experimental|Family Lifestyle (FL; n = 117)|This arm includes the Family Food & Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
16592946|NCT02659319|Experimental|FL + Family Dynamics (FL+FD; n = 88)|This arm includes the Family Food & Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food & Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
16592947|NCT02659319|Experimental|FL + Peer Group (FL+PG; n = 124)|This arm includes the Family Food & Lifestyle intervention plus the 12-session, Peer Group intervention.
16592948|NCT02659319|Experimental|FL + FD + Peer Group (FL+FD+PG; n = 130)|This arm includes the Family Food & Lifestyle intervention plus the Family Dynamics Intervention plus the Peer Group intervention.
16592949|NCT02659319|No Intervention|Control (n = 82)|Non-intervention control group
16592950|NCT02659306|Experimental|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
16592951|NCT02659293|Active Comparator|Lenalidomide (Control)|Treatment with lenalidomide only
16592952|NCT02659293|Experimental|Experimental Combination Regimen|Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
16592953|NCT02659280|Active Comparator|Standard of Care Therapy|Home Health or Outpatient Physical therapy services (a minimum of 1x/week).
16592954|NCT02659280|Experimental|Adjunct Therapy|"Home Health or Outpatient Physical therapy services (a minimum of 1x/week) with an adjunct Home Exercise Program given up to 1x/wk via Store and Forward tele-health through the Hudl Technique app."
16592955|NCT02659267|Experimental|Interventions Group=|Group of change behavior including physical activity and healthy eating habits promotion.
16592956|NCT02659267|No Intervention|Control Group=|Group that will not receive the VAMOS program as intervention, only participate in the Health Academy Program Activities.
16592957|NCT02659254|Experimental|Firesorb Implantation|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）in patients with coronary artery lesions.
16592958|NCT02659241|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5. Patients then undergo standard of care laparoscopy. Patients may also receive adavosertib PO QD on days 8-12, 15-19, and 22-26 for up to 28 days based on surgery schedule.
16592959|NCT02659228|Placebo Comparator|Control 1 (negative control)|Individuals with a diagnosis of UWS without neural markers of consciousness
16592960|NCT02659228|Active Comparator|Control 2 (positive control)|Individuals with a diagnosis of MCS, who are behaviourally responsive and who present neural markers of consciousness
16592961|NCT02659228|Experimental|Target Population|Individuals with a clinical diagnosis of UWS, but who possess some neurophysiological signatures of conscious awareness
16592962|NCT02659215|Experimental|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
16593184|NCT02657785|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
16592963|NCT02659215|Active Comparator|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
16592964|NCT02659202|Experimental|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
16592965|NCT02659176|Active Comparator|Transperineal repair with PIS|transperineal repair of anterior rectocele with limited internal sphincterotomy
16592966|NCT02659176|Active Comparator|Transperineal repair without PIS|transperineal repair of anterior rectocele only
16592967|NCT02659163|Experimental|intervention|Intervention subjects will receive feedback on their health behaviors along with clinical recommendations.
16592968|NCT02659163|Active Comparator|control|Control subjects will receive feedback on their health behaviors for self-guided care.
16592969|NCT02659150|Other|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
16592970|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
16592971|NCT02659111|Experimental|High-intensity physical exercise, HIFE|
16592972|NCT02659111|Active Comparator|Physical training advice|
16592973|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
16592974|NCT02659085|Active Comparator|Electroconvulsive Therapy (ECT)|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly. Each participating clinic decides for each patient whether the treatment is given uni- or bilateral, as well as the exact stimulation parameters. Choice of anesthetic drug (e.g. thiopental of propofol) and muscle relaxant is done by local anesthesiologist. The procedure differs in no way from how a given patient would have been treated if he or she were not included in the study.
16592975|NCT02659085|Experimental|Ketamine IV Infusion|Ketamin intra venous infusions of racemic ketamine (0.5mg/kg), delivered over a period of 40 minutes thrice weekly, as ECT (Monday, Wednesday and Friday).
16592976|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1
~Specified Dose on Specified Days"
16592977|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2
~Specified Dose on Specified Days"
16592978|NCT02659046||FH30|Patients treated by Pirkanmaa physician-staffed emergency medical service (EMS) unit
16592979|NCT02659046||FH10|Patients treated by Helsinki and Uusimaa physician-staffed emergency medical service (EMS) unit
16592980|NCT02659033|Active Comparator|ceftriaxone|healthy volunteer who receive ceftriaxone
16592981|NCT02659033|Active Comparator|cefotaxime|healthy volunteer who receive cefotaxime
16592986|NCT02659007|Experimental|yoga|yoga, 2 times a week for 8 weeks
16592987|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
16592988|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
16592989|NCT02658981|Experimental|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study
~Laboratory Biomarker Analysis"
16592990|NCT02658981|Experimental|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity
~Pharmacological Study
~Laboratory Biomarker Analysis"
16593413|NCT02656082|Experimental|Etanercept|Intradermal injection of etanercept. The dosage is determined based on discoid lesion radius. Weekly injection up to 12 weeks.
16592991|NCT02658981|Experimental|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study
~Laboratory Biomarker Analysis"
16592992|NCT02658981|Experimental|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)
~Pharmacological Study
~Laboratory Biomarker Analysis"
16592993|NCT02658981|Experimental|Intratumoral Studies|"Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.
~(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)"
16592994|NCT02658968|Experimental|Betalutin|10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
16592995|NCT02658955|Experimental|Short stitch|Patients in which abdominal wall is closed by short stitch technique
16592996|NCT02658955|No Intervention|Large stitch|Patients who didn't receive properly closure according with the protocol
16592997|NCT02658942|Active Comparator|Ureteroscopy|Intervention: Flexible ureteroscopy for removal of lower calyceal stones using holmium:YAG laser lithotripsy
16592998|NCT02658942|Active Comparator|Shockwave lithotripsy|Intervention: Shockwave lithotripsy for lithotripsy of lower calyceal stones using Siemens Lithostar Lithotriptor
16592999|NCT02658929|Experimental|bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
16593000|NCT02658916|Experimental|Panel 1: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
16593001|NCT02658916|Experimental|Panel 2: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
16593002|NCT02658916|Experimental|Panel 3: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
16593003|NCT02658916|Experimental|Panel 4: BIIB092 (Expansion Panel)|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
16593004|NCT02658903|Experimental|Study arm with Oxys-Cathter|The study group is treated with a modified urinary catheter, which delivers electromagnetic therapy to prevent and treat bacterial colonization during the study period. The intervention is the insertion of the study urinary catheter (foley) into the bladder.
16593005|NCT02658903|Other|Control-arm with commercial catheter|The control group is treated with a commercial urinary catheter. The intervention is the insertion of the control urinary catheter (foley) into the bladder,
16593009|NCT02658877|Experimental|Omalizumab|
16593010|NCT02658877|Placebo Comparator|Placebo|
16593011|NCT02658864|Experimental|10-mg group|Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state.
16593012|NCT02658864|Experimental|20-mg group|Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state.
16593013|NCT02658864|Experimental|40-mg group|Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state.
16593014|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
16593015|NCT02658838|Experimental|full amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with full amount low molecular weight heparin until they leave hospital.
16593016|NCT02658838|Experimental|half amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with half amount low molecular weight heparin until they leave hospital.
16593017|NCT02658838|Experimental|No low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with no low molecular weight heparin.
16593018|NCT02658825|Experimental|Panel 1: Dose level 1|Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B [(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1].
16593019|NCT02658825|Experimental|Panel 1: Dose level 2|Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D [placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1].
16593020|NCT02658825|Experimental|Panel 2: Treatment EFG|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
16593021|NCT02658825|Experimental|Panel 2: Treatment FGE|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
16593022|NCT02658825|Experimental|Panel 2: Treatment GEF|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
16593023|NCT02658825|Experimental|Panel 2: Treatment GFE|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
16593024|NCT02658825|Experimental|Panel 2: Treatment FEG|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
16593025|NCT02658825|Experimental|Panel 2: Treatment EGF|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
16593026|NCT02658812|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
16593027|NCT02658799|Experimental|diclofenac potassium|"Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen.
~Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.
~To promote compliance, each patient was recalled monthly."
16593028|NCT02658799|Active Comparator|placebo|"or placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.
~Administration of placebo was undertaken from baseline to 2 months, no drug (placebo) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.
~To promote compliance, each patient was recalled monthly."
16593029|NCT02658786||Hepatitis B patients|Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years
16593030|NCT02658786||Hepatitis C patients|Biopsy proven Hepatitis C virus infected cases will be followed for the period of 5 years
16593031|NCT02658786||Non Alcoholic Fatty liver Disease patients|Biopsy proven Non Alcoholic Fatty liver Disease patients cases will be followed for the period of 5 years
16593032|NCT02658773|Active Comparator|lidocaine-Prilocaine cream|lidocaine-Prilocaine anesthetic cream placed into their cervix prior to having the IUD inserted
16593033|NCT02658773|Placebo Comparator|placebo cream|an inert placebo cream placed into their cervix
16593034|NCT02658760|Experimental|Bupivacaine|30cc of 0.25% bupivacaine
16593035|NCT02658760|Active Comparator|Dexmedetomidine and bupivacaine|30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
16593036|NCT02658747||Cohort Docetaxel|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)
16593037|NCT02658734|Experimental|Trastuzumab emtansine|
16593038|NCT02658721|Experimental|lidocaine+adjunct tramadol|In the first group (LDC+TRA group), IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation.
16593039|NCT02658721|Experimental|lidocaine+systemic tramadol|In the second group (LDC+SysTRA group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation.
16593040|NCT02658721|Active Comparator|lidocaine|In the third group (LDC group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL.
16593041|NCT02658708|Experimental|Arm 1: Bright blue-green light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, -21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
16593042|NCT02658708|Active Comparator|Arm 2: Dim red light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, 21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 days randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
16593043|NCT02658695||Group 1|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) <10 mm.
16593044|NCT02658695||Group 2|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) >10 mm.
16593045|NCT02658682|Experimental|ABM +|Attention Bias Modification
16593046|NCT02658682|Sham Comparator|ABM -|Sham Attention Bias Modification
16593047|NCT02658669|Experimental|Cognitive-Behavioral Therapy for Insomnia|6-week manualized treatment designed to improve symptoms of chronic insomnia.
16593143|NCT02658058|Experimental|Ultrasound-guided paramedian technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided paramedian technique using parasagittal oblique view
16593048|NCT02658669|Active Comparator|Sleep Education|6-week manualized treatment designed to provide information regarding traumatic brain injury and its relationship to sleep disturbance, which incorporates training in sleep hygiene to help improve nighttime sleep and daytime functioning.
16593051|NCT02658643|Experimental|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
16593052|NCT02658643|Active Comparator|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
16593053|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
16593054|NCT02658617||patients|20 patients were enrolled. Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire). 1-2 days after the imaging patients started the treatment with duloxetine: 30mg for the first three days, then 60-90mg.
16593055|NCT02658617||healthy controls|Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire).
16593056|NCT02658604||Home visit by pharmacist|Patients of participating pharmacies age 65 or older, who are on 5 or more chronic prescription medications, and who have a need for, and agree to, a home visit by a pharmacist for a medication review.
16593057|NCT02658591|Active Comparator|Control|Crackers/pasta with no faba bean fraction
16593058|NCT02658591|Experimental|Faba bean protein concentrate|Crackers/pasta with added faba bean protein concentrate
16593059|NCT02658591|Experimental|Faba bean protein isolate|Crackers/pasta with added faba bean protein isolate
16593060|NCT02658591|Experimental|Faba bean flour|Crackers/pasta with added faba bean flour
16593061|NCT02658591|Experimental|Faba bean starch|Crackers/pasta with added faba bean starch
16593062|NCT02658578|Active Comparator|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
16593063|NCT02658578|Placebo Comparator|Sham PNS|In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
16593064|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
16593065|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
16593066|NCT02658552|Experimental|HIFU treatment|To collect the data after HIFU treatment
16593067|NCT02658526||control|children without anesthesia / surgery
16593068|NCT02658526||anesthesia|children with anesthesia for diagnostic reason
16593069|NCT02658526||surgery|children with anesthesia / surgery
16593070|NCT02658513||All Patients|"All patients will undergo both of the following interventions:
~Lancet blood sampling Standard intravenous blood sampling"
16593071|NCT02658500|Experimental|Infant Formula|200 newborns just consume the infant formula from 0-42 days to six months age.
16593072|NCT02658500|Other|Breast Milk|100 newborns were just fed with breast milk from after birth to six months age.
16593073|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
16593074|NCT02658474|Experimental|ACT-group|Group based Acceptance and Commitment Therapy. The patients will attend to three sessions which last for three days. Between the sessions the patients will train at home on ACT related topics. The whole intervention will last for three months.
16593075|NCT02658474|No Intervention|Primary care|Treatment in a primary care setting.
16593076|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
16593077|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
16593078|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
16593079|NCT02658448|Experimental|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
16593080|NCT02658435|Experimental|Tafenoquine 300 milligram (mg) single dose|Participants will receive single dose of TQ (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
16593081|NCT02658435|Placebo Comparator|Matched Placebo 300mg single dose|Participants will receive single dose of matched placebo (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
16593082|NCT02658422|Experimental|Sequence A-B (Test Montelukast then Reference Montelukast)|Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
16593181|NCT02657798||Depressed patients taking sertraline|Patients with depression who have been randomised to the sertraline arm in the PANDA trial
16593083|NCT02658422|Experimental|Sequence B-A (Reference Montelukast then Test Montelukast)|Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
16593084|NCT02658409|Experimental|GC3106(quadrivalent)|0.5ml, intramuscular, a single dosing
16593085|NCT02658409|Active Comparator|Fluarix™tetra Syringe Inj.(Quadrivalent)|0.5ml,intramuscular,a single dosing
16593086|NCT02658396|Experimental|GO-203-2C|"Patients who fulfill eligibility criteria will be entered into the trial to receive Bortezomib and GO-203-2C.
~After the screening procedures confirm participation in the research study:
~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
~Bortezomib
~GO-203-2C"
16593087|NCT02658383|Experimental|Cleaner cookstove received after visit 2|This arm receives the cleaner cookstove earlier in the study (after visit 2 which is approximately after 6 months)
16593088|NCT02658383|Experimental|Cleaner cookstove received after visit 4|This arm receives the cleaner cookstove later in the study (thus acting as a control arm until after visit 4 which is after approximately 1 yr and 6 months)
16593089|NCT02658370|Experimental|animated home-based exercises (Wii-fit)|using the Wii game console by Nintendo
16593090|NCT02658370|Active Comparator|conventional home-based exercise program|by using a compilation with 31 exercises especially for rheumatoid arthritis patients
16593091|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
16593092|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
16593093|NCT02658344|Experimental|Jointstem|Autologous Adipose Tissue derived MSCs
16593094|NCT02658344|Placebo Comparator|Saline solution|Sodium chloride
16593095|NCT02658318||Pierre Robin Syndrome (PRS)|Cleft palate patients with the Pierre Robin Syndrome.
16593096|NCT02658318||non-PRS|Cleft palate patients without the Pierre Robin Syndrome.
16593097|NCT02658305||transoral group|orthognathic patients that were treated with a transoral surgical approach
16593098|NCT02658305||transbuccal group|orthognathic patients that were treated with a transbuccal surgical approach
16593099|NCT02658292|Active Comparator|NAFT900|NAFT900 (Naftifine hydrochloride foam, 3%)
16593100|NCT02658292|Placebo Comparator|Vehicle|Vehicle Foam
16593101|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
16593102|NCT02658266|Experimental|Resistance training|Home based resistance training 12 weeks home based resistance training 3 times per week, 10-12 reps, 2 sets
16593103|NCT02658266|No Intervention|Control group|No instructed exercise training. Continue with habitual physical activity.
16593104|NCT02658253|Experimental|Group A1:Primvac 20 µg +alhydrogel|"Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
16593105|NCT02658253|Experimental|Group A2:Primvac 20 µg +GLA-SE|Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
16593106|NCT02658253|Experimental|Group B1:Primvac 50 µg +alhydrogel|"Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
16593107|NCT02658253|Experimental|Group B2:Primvac 50 µg +GLA-SE|Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
16593108|NCT02658253|Experimental|Group C1:Primvac 50 µg +alhydrogel|"Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
16593109|NCT02658253|Experimental|Group C2: Primvac 50 µg +GLA-SE|"Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE
~Vaccination schedule: D0, D28 and D56"
16593110|NCT02658253|Placebo Comparator|Group C3: Placebo|"Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)
~Vaccination schedule: D0, D28 and D56"
16593111|NCT02658253|Experimental|Group D1:Primvac 100 µg +alhydrogel|"Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
16593112|NCT02658253|Experimental|Group D2: Primvac 100 µg +GLA-SE|"Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE
~Vaccination schedule: D0, D28 and D56"
16593113|NCT02658253|Placebo Comparator|Group D3: placebo|"Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)
~Vaccination schedule: D0, D28 and D56"
16593114|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
16593115|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
16593116|NCT02658214|Experimental|Cohort 1|ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
16593117|NCT02658214|Experimental|Cohort 2|Small-cell lung cancer (SCLC)
16593118|NCT02658214|Experimental|Cohort 3|Triple-negative breast cancer (TNBC)
16593119|NCT02658214|Experimental|Cohort 4|Triple-negative breast cancer (TNBC)
16593120|NCT02658214|Experimental|Cohort 5|Gastric/gastro-esophageal junction (GEJ)
16593121|NCT02658214|Experimental|Cohort 6|Pancreatic ductal adenocarcinoma (PDAC)
16593122|NCT02658214|Experimental|Cohort 7|Esophageal squamous cell carcinoma (ESCC)
16593123|NCT02658201|Other|MRI group|Ultrafast MRI
16593124|NCT02658188|Experimental|ASP8825 group|
16593125|NCT02658175|Experimental|Treatment-naïve Group|Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 [NCT02211209] and ISIS 304801-CS16 [NCT02300233]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period.
16593126|NCT02658175|Experimental|CS6-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
16593127|NCT02658175|Experimental|CS16-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
16593128|NCT02658162|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
16593129|NCT02658162|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
16593130|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
16593131|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
16593132|NCT02658136|Other|1 arm study: CCT estimated right ventricular function.|
16593133|NCT02658123|Active Comparator|Group A: Standard of care|"Standard of care pre-operative education
~Standard of care home health visits
~Standard of care follow-up post-operative visits with surgeon and CWOCN
~At 30-days post hospital discharge, the participant will:
~See the physician
~Turn in Patient Data Collection Form
~Turn in Healthcare Utilization Form
~Complete The City of Hope QOL Survey for Ostomy Patients
~Ostomy assessment with a CWOCN, including photo of ostomy site"
16593134|NCT02658123|Experimental|Group B: Phone call|"Standard of care pre-operative education
~Standard of care home health visits
~Standard of care follow-up post-operative visits with surgeon and CWOCN
~Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.
~At 30-days post hospital discharge, the participant will:
~See the physician
~Turn in Patient Data Collection Form
~Turn in Healthcare Utilization Form
~Complete The City of Hope QOL Survey for Ostomy Patients
~Ostomy assessment with a CWOCN, including photo of ostomy site"
16593135|NCT02658110|Sham Comparator|Non Protein Trial|Mixed Macronutrient Breakfast Meal and Mixed Macronutrient Lunch Meal served without additional whey protein
16593136|NCT02658110|Experimental|Preload Trial|Whey protein (20g) administered 15 minutes prior to Mixed Macronutrient Breakfast Meal
16593137|NCT02658110|Experimental|With Meal Trial|Whey protein (20g) administered alongside Mixed Macronutrient Breakfast Meal
16593138|NCT02658110|Experimental|Post Meal Trial|Whey protein (20g) administered 15 minutes after Mixed Macronutrient Breakfast Meal
16593139|NCT02658097|Experimental|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
16593140|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
16593141|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
16593142|NCT02658058|Active Comparator|Landmark technique|As intervention, patients in this group are administered landmark guided midline spinal anesthesia.
16593182|NCT02657798||Depressed patients taking placebo|Patients with depression who have been randomised to the placebo arm in the PANDA trial
16593144|NCT02658058|Experimental|Ultrasound-guided midline technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided midline technique using transverse median view
16593145|NCT02658045||Normal healthy volunteers|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in healthy volunteers during 6 min walking test
16593146|NCT02658045||COPD patients|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in COPD patients during 6 min walking test
16593147|NCT02658032|Other|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
16593148|NCT02658032|Other|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
16593149|NCT02658032|Other|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
16593150|NCT02658032|Experimental|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
16593151|NCT02658019|Experimental|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
16593152|NCT02658006||Cardiac surgical patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
16593153|NCT02657993|Experimental|Hypnosis|The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
16593154|NCT02657993|Active Comparator|Attention Control (Non-Hypnosis)|The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
16593155|NCT02657980|Experimental|YBand(YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (total of 10 applications)
16593156|NCT02657980|Sham Comparator|Sham-Yband(YDT-201N)|sham-tDCS application 5 days a week for 2 weeks (total of 10 applications)
16593157|NCT02657954|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training
16593158|NCT02657954|Active Comparator|Holistic Cognitive Education (HCE)|Holistic Cognitive Education
16593159|NCT02657941|Experimental|Motivational group|psycho-education program inspired by motivational interviewing and behavioral psychotherapy
16593160|NCT02657941|Active Comparator|educational group|exclusively informative psycho-education program
16593162|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
16593163|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
16593164|NCT02657902||Gamma 3 Nail|Fractures that were treated with a Gamma 3 nail
16593165|NCT02657902||Gamma 3 Nail + U-Blade|Fractures that were treated with a Gamma 3 nail and additional with antirotation U-blade lag screws.
16593167|NCT02657876|Experimental|ExpressGraft-C9T1 Skin Tissue|Enrolled participants receive one application of ExpressGraft-C9T1 skin tissue
16593168|NCT02657863||Healthy volunteer|Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
16593169|NCT02657863||Prostate cancer patients being treat with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
16593170|NCT02657863||Prostate cancer patients being treated with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
16593171|NCT02657850||control cohort - study subject self-reporting|Participants who have another cancer (not head and neck cancer) and undergoing treatment will self-report their dysphagia symptoms.
16593172|NCT02657850||study cohort - study subject self-reporting|Participants who have head and neck cancer and undergoing treatment will self-report their dysphagia symptoms.
16593173|NCT02657850||study cohort - provider reporting|Participants who have head and neck cancer and undergoing treatment will have their dysphagia symptoms reported by the provider.
16593174|NCT02657837||Cystic Fibrosis|Children 2.5 to 18 years old with confirmed diagnosis of cystic fibrosis
16593175|NCT02657837||Children with other respiratory disease|Children 2.5 to 18 years old with confirmed diagnosis of respiratory disease including but not limited to asthma, transplant, and sickle cell anemia.
16593176|NCT02657837||Healthy Children|Children and adults 2.5 to 30 years old with no history of chronic disease
16593177|NCT02657824||measuring ejection fraction|ejection fraction in an acute dyspneic patients
16593178|NCT02657811|Active Comparator|Bench Incubation|These embryos will be randomized to the bench incubator.
16593179|NCT02657811|Active Comparator|Time Lapse Incubation|These embryos will be randomized to the Time Lapse Incubator.
16593180|NCT02657811|Active Comparator|Time Lapse Incubation - Modified|These embryos will be randomized to the bench incubator.
16593544|NCT02655263|Experimental|GH infusion|12 hours of fasting
16593185|NCT02657759|Experimental|CARDICHOL|Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.
16593186|NCT02657759|Placebo Comparator|Placebo|"placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.
~2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch."
16593187|NCT02657746|No Intervention|usual care|Usual care comprises existing services for hypertension control in the community without any additional training
16593188|NCT02657746|Experimental|multi-component interventions|: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
16593189|NCT02657733|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and Nellcor Bedside Respiratory Patient Monitoring System
16593190|NCT02657720|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and PTAF2 (flow meter)
16593191|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
16593192|NCT02657694||Sofosbuvir+Ledipasvir|Following patients treating with Sofosbuvir+Ledipasvir
16593193|NCT02657694||Sofosbuvir+Daclatasvir|Following patients treating with Sofosbuvir+Daclatasvir
16593194|NCT02657694||Sofosbuvir+Velpatasvir|Following patients treating with Sofosbuvir+Velpatasvir
16593195|NCT02657681|Experimental|tSMS|30 min of tSMS, one session per day, for 9 days over 2 weeks
16593196|NCT02657681|Placebo Comparator|sham|30 min of sham, one session per day, for 9 days over 2 weeks
16593197|NCT02657668|Experimental|Treatment Group|Emotion focused therapy: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
16593198|NCT02657668|No Intervention|Control Group|Control group: For control group interactions to be effective in therapeutic outcomes, the psycho-educational group was assigned as control group. The Psycho-educational group was conducted in four sessions (without pretest and posttest sessions). They became familiar with etiology and role of psychological factors in IBS, without any psychotherapy. Eight members were removed (because of being absent more than three sessions).
16593199|NCT02657655|Experimental|Kinesia 360 Users|Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
16593200|NCT02657642||Cohort 1 (exposed)|cohort 1: patients who will receive the OMAGE-P transitional care in geriatric or internal medicine departement of the Eaubonne Hospital
16593201|NCT02657642||Cohort 2 (non exposed)|Cohort 2: : patients included in the usual care arm of the OMAGE RCT study in 2007-2008
16593202|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
16593203|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
16593204|NCT02657616||No anticoagulation with VKA/NOAC|No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
16593205|NCT02657616||Anticoagulation with vitamin-k-antagonists|The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
16593206|NCT02657616||Anticoagulation with novel oral anticoagulants|The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
16593207|NCT02657603|Active Comparator|LAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the adductor canal
16593208|NCT02657603|Active Comparator|SAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the contralateral adductor canal
16593209|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
16593210|NCT02657551|Experimental|Regorafenib|Regorafenib tablets orally, once daily at predetermined dosage for 21 days per cycle
16593211|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
16593212|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
16593213|NCT02657512|Experimental|Arm A|"Period  rivaroxaban alone
~Washout period (at least 6 days)
~Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration"
16593214|NCT02657512|Experimental|Arm B|". Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period  rivaroxaban alone
~Washout period (at least 6 days)
~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration"
16593545|NCT02655263|Experimental|GH and ketone bodies infusion|12 hours of fasting
16593215|NCT02657512|Experimental|Arm C|". Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period  rivaroxaban alone"
16593216|NCT02657499||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
16593217|NCT02657499||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
16593218|NCT02657486|Experimental|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
16593219|NCT02657473|Active Comparator|TIS 300mg once daily|Tobramycin inhalation solution (TIS) 300mg once daily for at least 9 months and up to 12 months
16593220|NCT02657473|Placebo Comparator|Placebo once daily|Saline 0.9% inhalation solution 300mg once daily for at least 9 months and up to 12 months
16593221|NCT02657460|Experimental|MTX-ATMPs|methotrexate-autologous tumor derived microparticles
16593222|NCT02657460|Sham Comparator|cisplatin|Cisplatin is a traditional treatment for lung cancer
16593223|NCT02657447|Experimental|Arm 1: Betalutin with lilotomab dose 1|Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
16593224|NCT02657447|Experimental|Arm 2: Betalutin with lilotomab dose 2|Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
16593225|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
16593226|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
16593227|NCT02657408|Experimental|BI 1026706|
16593228|NCT02657408|Experimental|Placebo|
16593229|NCT02657395|Experimental|PriMatrix|Use of PriMatrix as a substitute for a subepithelial connective tissue graft under a coronal positioned flap for root coverage.
16593230|NCT02657382|Experimental|Heart Rate Variability (HRV) Biofeedback (BF)|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests. Participants in this group will also participate in heart rate variability (HRV) biofeedback (BF) during the first six weeks of the study.
16593231|NCT02657382|Experimental|Waitlist Control|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests.Participants in this group will receive the heart rate variability (HRV) biofeedback (BF) intervention between the week 6 and week 12 study visits.
16593232|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
16593233|NCT02657356|Placebo Comparator|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
16593234|NCT02657356|Experimental|Bardoxolone methyl capsules|Each patient will receive bardoxolone methyl capsules administered orally once a day for 24 weeks. Starting dosage for each patient is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
16593235|NCT02657343|Experimental|Cohort A|Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time.
16593236|NCT02657343|Experimental|Cohort B|Ribociclib will be given orally once day continuously for a 21-day cycle of treatment (except at Dose Level -2, when Ribociclib is given Days 1-14 of a 21 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose.
16593237|NCT02657343|Experimental|Cohort C|Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care.
16593238|NCT02657330|Experimental|SBP-101|SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
16593239|NCT02657317|Experimental|FORT-A|"has been labeled FORT-A. FORT-A is provided on an outpatient basis and includes 12 daily group pain management and physical therapy sessions spanning three weeks. Group interventions are supplemented by individual psychotherapy, biofeedback, and case staffings. CBT sessions were decreased in favor of CAM components. FORT-A participants will receive 270 minutes (4½ hours) of intervention a day for 12 days over 3 weeks."
16593240|NCT02657317|Active Comparator|VA Treatment As Usual|"Treatment As Usual (TAU) represents usual VA Care based on as usual appointments and referrals from VA providers. TAU can include active medical interventions, psychosocial intervention, and other rehabilitation strategies."
16593241|NCT02657304|Experimental|Coaching group|PPC + Coaching
16593242|NCT02657304|Active Comparator|Control group|PPC
16593243|NCT02657291|Experimental|Costoclavicular|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the costoclavicular approach
16593244|NCT02657291|Active Comparator|Paracoracoid|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the paracoracoid or standard approach
16593245|NCT02657278|Other|Symptomatic Peripheral arterial disease|Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication.
16593246|NCT02657265|Experimental|SpineJack® system|Spine fracture management
16593247|NCT02657265|Active Comparator|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
16593248|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
16593249|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
16593250|NCT02657239|Experimental|MOVE UP Intervention|Subjects will participate in a healthy lifestyle weight management intervention focused on healthy eating and increasing physical activity
16593251|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
16593252|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
16593253|NCT02657213|Experimental|Minimed 640G with smartguard activated|"Group SmartGuard On: Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640G insulin pump with SmartGuard activation"
16593254|NCT02657213|Active Comparator|Minimed 640G with smartguard off|"Group SmartGuard Off Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640 insulin pump without SmartGuard activation"
16593255|NCT02657187|Experimental|rocuronium 1|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
16593256|NCT02657187|Experimental|rocuronium 2|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
16593257|NCT02657187|Experimental|rocuronium 3|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
16593258|NCT02657187|Experimental|rocuronium 4|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
16593259|NCT02657174|Experimental|G1- experimental active comparator group|G1 - (Experimental) 40 third molars surgeries will be performed in a conventional manner. At the end of surgery low level laser in auricular acupuncture points will be applied for prevention of inflammation and pain in a split-mouth design.
16593260|NCT02657174|Placebo Comparator|G2- control group|G2 - (Control) 40 third molars surgeries will be performed in the conventional manner, identically to the G1. At the end of surgery low level laser device off in auricular acupuncture points will be applied. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1, with split-mouth design.
16593261|NCT02657161|Active Comparator|Group A|"Comparator vaccine RABIPUR®
~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
16593262|NCT02657161|Experimental|Group B|"PIKA Rabies vaccine
~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
16593263|NCT02657161|Experimental|Group C|"PIKA Rabies vaccine with an accelerated regimen
~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)"
16593264|NCT02657148||Immediate postpartum Nexplanon|Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.
16593265|NCT02657148||Control|Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
16593266|NCT02657135|Experimental|History of Traumatic Brain Injury|All participants have a history of TBI. At study outcome participants are provided treatment recommendations that are the result of a consensus meeting of all physician investigators. Follow up care is not provided by this clinical trial.
16593267|NCT02657122|Experimental|TD-1473 for SAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
16593268|NCT02657122|Placebo Comparator|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
16593269|NCT02657122|Experimental|TD-1473 for MAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
16593270|NCT02657122|Placebo Comparator|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
16593271|NCT02657109|Active Comparator|Control|Participants are submitted to cardiac rehabilitation protocol of the hospital where it will be conducted the study, which consists in respiratory exercises of 3 series Inspirations Maximum Sustained for 10 reps, 3 sets of 20 repetitions metabolic exercises with dorsiflexion and plantar flexion and ankle and wrist extension and fingers of the upper limbs. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of postoperative and on the fifth postoperative day
16593272|NCT02657109|Active Comparator|Early mobilization|Participants performed exercise in cycle ergometer of lower Limbs, pedaling for 20 consecutive minutes at a moderate level with Heart Rate Assessment and the Borg scale to evaluate the Voluntary Comfort. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of oepratório post and on the fifth postoperative day
16593297|NCT02656940|Experimental|Group 2 - diet rich in MUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.
~Group 2 received diet rich in monounsaturated fatty acids (MUFA). The volunteers were asked to consume daily virgin olive oil, totaling 35.2g to 50.6g, and 1 capsule of 1g of soybean oil."
16593273|NCT02657096|Experimental|Hybenx treatment|Both quadrants included maxillary teeth 11-16 and 21-26. Each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional SRP + desiccant (Hybenx). In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the marginal gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
16593274|NCT02657096|Sham Comparator|Scaling and Root Planing|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
16593275|NCT02657083|Experimental|Glucose control using DreaMed MD-AID|In this group the subjects use a closed loop system (DreaMed Substance Administration Device) that combines glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™), which provides real-time interstitial glucose values, with a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) and computer algorithm, which directs insulin delivery in response to glucose sensor data.
16593276|NCT02657083|Active Comparator|Glucose control using SAP|In this group the subjects use a standard treatment (Sensor Augmented Pump), characterised by glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™) which provides real-time interstitial glucose values and a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) without computer algorithm decisions.
16593277|NCT02657070|Experimental|Experimental Group|Virtual reality based therapy with augmented visuomotor feedback.
16593278|NCT02657070|Active Comparator|Control Group|Virtual reality based therapy without augmentation.
16593279|NCT02657057|Experimental|Transcutaneous Tibial Nerve Stimulation|TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
16593280|NCT02657057|Active Comparator|Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
16593281|NCT02657044|Active Comparator|EMR|In the EMR-arm, endoscopic resection will be performed using the (p)EMR technique.
16593282|NCT02657044|Active Comparator|ESD|In the ESD-arm, endoscopic resection will be performed using the (h)ESD technique.
16593283|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
16593284|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
16593285|NCT02657018|Experimental|Intervention|MOBIGAME group
16593286|NCT02657018|Active Comparator|Control|Lifestyle counseling group
16593287|NCT02657005|Experimental|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
16593288|NCT02656992|Experimental|High-IMT group|Intervention group receive supervised training sessions three times per week for 8 weeks. Each sessions lasted 21 minutes and comprised seven cycles of 2 minutes of breathing on an inspiratory threshold device followed by 1 minute of rest. High-IMT was performed at the maximal load tolerable for each 2-minute work interval and was progressively increased over the training period.
16593289|NCT02656992|Sham Comparator|Control group|Control group was prescribed at 10% of baseline maximal inspiratory pressure, and remained at this level during all training sessions for 8 weeks.
16593290|NCT02656979|Other|Blood flow pre&post IOP lowering|After measurement of blood flow with MRI and measurements of ocular parameters the patient receives the IOP lowering eye drop latanoprost once daily in one eye for approximately one week and then the measurements are are repeated in the same manner.
16593291|NCT02656979|No Intervention|Blood flow|The subjects will do blood flow measurements with MRI and measurements of ocular parameters only once. No intervention with IOP lowering drops.
16593292|NCT02656966|Active Comparator|Auricular acupuncture + standard therapy|Patients, who will wish acupuncture, will receive this intervention, in addition to standard therapy
16593293|NCT02656966|No Intervention|Standard therapy alone|Patients who do not wish acupuncture will be asked if they will fill in the study questionnaire
16593294|NCT02656953|Experimental|VDU lenses|VDU lenses provide a clear vision of the intermediate zone at a distance of approximately 70 centimeters, which is closer than distant vision at a distance of more than 2 meters (e.g. driving), but further than near vision at a distance of 40 centimeters (e.g. reading), so the computer screen is seen clear without the need for excessive focusing effort or bad postures. In this study Zeiss® Officelens Plus lenses with a Silhouette® frame were used.
16593295|NCT02656953|Active Comparator|Progressive lenses|Progressive lenses or multifocal lenses provide a continuous range of focal power between near and far distances.Progressive lenses have some lens power for the intermediate zone as well, but this zone might not be large enough for comfortable and ergonomic computer work. In this study Zeiss® Multifocal Precision Plus lenses with a Silhouette® frame were used.
16593296|NCT02656940|Experimental|Group 1 - diet rich in n-3 and n-6 PUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.
~Group 1 received diet rich in n-3 and n-6 polyunsaturated fatty acids (PUFA). The volunteers were asked to consume daily a mixture of virgin olive oil and soybean oil, totaling 35.2g to 52.8g, and 2 g of fish oil."
16593298|NCT02656940|Experimental|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming 1 sachet of 2g of soybean oil and 1 capsule of 1g of soybean oil by day.
16593299|NCT02656927|Experimental|Yoga Condition|
16593300|NCT02656927|Placebo Comparator|Wait-list Control Condition|
16593301|NCT02656914|Experimental|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
16593302|NCT02656914|Placebo Comparator|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
16593303|NCT02656901|Active Comparator|Auto Total endovenous anesthesia|The closed loop delivering as already approved by ClinicalTrials.gov Identifier: NCT00392158
16593304|NCT02656901|Sham Comparator|Manual Desflurane anesthesia|The anesthesia will be maintained with desflurane to target the BIS of 50.
16593305|NCT02656901|Sham Comparator|Manual sevoflurane anesthesia|The anesthesia will be maintained with sevoflurane to target the BIS of 50.
16593306|NCT02656901|Sham Comparator|Manual total endovenous anestesia|In ManualTIVA group, the anesthesia will be maintained with propofol to target the BIS of 50
16593307|NCT02656888|Experimental|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
16593308|NCT02656888|Placebo Comparator|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
16593309|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.
~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
16593310|NCT02656849|Experimental|BAY 1000394|"After the screening procedures confirm eligibility to participate in the research study:
~Each treatment cycle lasts 4 weeks.
~Participants will take the study drug orally at predetermined times and dosage per cycle."
16593311|NCT02656823|Other|ANKYLOS C/X 6.6 mm implants|ANKYLOS C/X 6.6 mm implants
16593312|NCT02656810|Experimental|Sequence A|Single subcutaneous injection of two teriparatide products (PF708 and Forteo)
16593313|NCT02656810|Experimental|Sequence B|Single subcutaneous injection of two teriparatide products (Forteo and PF708)
16593314|NCT02656797|Experimental|AM-B|Topical Amphotericin-B 0.4% liposomal gel
16593315|NCT02656797|Placebo Comparator|Placebo|Placebo gel preparation
16593316|NCT02656784|Experimental|Trial-Based Cognitive Therapy (TBCT)|"Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach, based on the work of Franz Kafka The Trial and developed by Professor Irismar Reis de Oliveira at Federal University of Bahia, Brazil. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All individuals in the group will be submitted to MRI"
16593317|NCT02656784|Experimental|Behavioral Therapy (ERP)|The Behavioral Therapy is an intervention of first choice for treatment of OCD , which employs the technique of Exposure and Response Prevention (ERP) , considered the gold standard to the disorder. The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All individuals in the group will be submitted to MRI
16593318|NCT02656784|No Intervention|Control Group|The control group consisted of individuals without OCD, matched with the experimental group in terms of gender,age and education. In this group are not included in individuals in psychotherapeutic care and with a history of neurological or psychiatric disorder; however, all them will be submitted to MRI .
16593319|NCT02656771|Active Comparator|Echo Bi-Metric THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.
~It is a relatively new implant that is now in routine clinical use. The stem uses many of the features of the known and used Integral® and Bi-Metric® hip stems while integrating new design features to further enhance clinical performance such as a reduced neck geometry to allow for increased ROM and decreased risk of neck impingement, a polished neck designed to reduce debris should impingement occur and a polished bullet-shape distal tip to reduce distal stresses."
16593320|NCT02656771|No Intervention|Bi-Metric Porous Primary THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.
~It was introduced in 1984 and have shown good clinical results and excellent stem survival in register studies"
16593321|NCT02656758|Experimental|Executive function training|the experimental group will receive 12 sessions of intensive Executive function training weekly immediately
16593322|NCT02656758|Other|the waitlist group|the waitlist group will wait 12 weeks before receiving intensive executive function training for comparison.
16593323|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
16593324|NCT02656732|Experimental|coronally advanced flap with amnion chorion membrane|coronally advanced flap was reflected and amnion chorion allograft membrane was placed under the flap as a guided tissue regeneration barrier.
16593325|NCT02656732|Active Comparator|subepithelial connective tissue graft|coronally advanced flap was reflected and subepithelial connective tissue graft was harvested from the palate and placed under the flap.
16593326|NCT02656719|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
16593327|NCT02656719|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
16593328|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
16593329|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
16593330|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
16593331|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
16593332|NCT02656680|Experimental|FB+Friends|FB+Friends is a Facebook-delivered weight loss intervention. For this group, the study team continued to enroll participants through week 8.
16593333|NCT02656680|Active Comparator|FB Only|FB Only Facebook-delivered weight loss intervention including only study participants.
16593334|NCT02656667|Experimental|neuromuscular electrical stimulation|conventional pulmonary rehabilitation including exercise training on treadmill and neuromuscular electrical stimulation with a medical device for quadriceps muscle strengthening
16593335|NCT02656667|Experimental|cycle ergometer training|conventional pulmonary rehabilitation including exercise training on treadmill and quadriceps strenghthening on cycle-ergometer
16593336|NCT02656641|No Intervention|Control|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will not complete any scales during other sessions.
16593337|NCT02656641|Experimental|Continuous Client Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will review and discuss their results and at the beginning of each session.
16593338|NCT02656641|Experimental|Continuous Self Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will not have access to these results.
16593339|NCT02656628||Fractures of humerus femur tibia|Dynamic Locking Screw 3.7mm and 5.0mm
16593340|NCT02656615|Experimental|Abiraterone|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
16593341|NCT02656602|No Intervention|Nurse Counseling|A trained endoscopy nurse provided patients with all information on their scheduled colonoscopy.
16593342|NCT02656602|Experimental|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI.All elements of informed consent for colonoscopy (risks, alternatives) were included.
16593343|NCT02656589||Herceptin probable sensitive group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable sensitive group
16593344|NCT02656589||Herceptin probable resistant group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable resistant group
16593345|NCT02656576|Other|patient with suspected lesions of the tonsillar region|patients will have a tonsil biopsy and a smear
16593346|NCT02656563|Experimental|Radium 223 Arm|Radium 223 Dichloride (Xofigo®)
16593347|NCT02656563|No Intervention|Non Treatment Arm|Control Arm
16593348|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
16593349|NCT02656537|Experimental|EnSite™ HD Grid Catheter AF/AT Mapping|
16593350|NCT02656524||Cohort1/Regorafenib|All patients with at least 1 treatment with regorafenib
16593351|NCT02656511|Experimental|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
16593352|NCT02656498|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
16593353|NCT02656498|Experimental|MCI Subjects|MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
16593354|NCT02656498|Experimental|AD Subjects|AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
16593355|NCT02656498|Experimental|Subjects with other neurodegenerative disease|Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
16593356|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
16593357|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
16593358|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
16593359|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
16593360|NCT02656472|Active Comparator|Tranexamic Acid Arm|TXA arm will include 10 subjects who will receive TXA for duration of surgery.
16593361|NCT02656472|Active Comparator|Epsilon Aminocaproic Acid Arm|EACA arm will include 10 subjects who will receive EACA for the duration of surgery.
16593362|NCT02656433|Placebo Comparator|Placebo Group|Receive treatment with physiotherapy
16593363|NCT02656433|Experimental|Experimental or tRNS Group|Receive treatment with physiotherapy plus Transcranial Random Noise Stimulation (tRNS)
16593364|NCT02656420|Placebo Comparator|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
16593365|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
16593366|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
16593412|NCT02656108|Active Comparator|controlled cord traction|the cord will be held in one hand and the other hand will be placed just above the woman's pubic boneto stabilize the uterus during cord traction
16593367|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
16593368|NCT02656407|Experimental|Ultrasensitive Doppler|Intraoperative ultrasensitive Doppler acquisitions by using an ultrasound device for functional area detection
16593369|NCT02656394|Active Comparator|GL101|GL101 topical gel
16593370|NCT02656394|Placebo Comparator|Placebo|Placebo topical gel
16593375|NCT02656368|Experimental|Interventional, open label, Safety/Efficacy Study|SEBORRHEAMEDIS Face Cream Interventional 30
16593376|NCT02656355|No Intervention|Stage 1:Healthy people|To establish baseline and reliability.
16593377|NCT02656355|No Intervention|Stage 2:Healthy people|To establish stage 3 training protocol.
16593378|NCT02656355|No Intervention|Stage 2:PD people|To establish stage 3 training protocol.
16593379|NCT02656355|Experimental|Stage 3:PD APA training group|Weight shift training and APA feedback.
16593380|NCT02656355|Experimental|Stage 3:PD Balance training group|Weight shift training without APA feedback.
16593381|NCT02656355|No Intervention|Stage 3:PD Control group|Control group
16593382|NCT02656342|Experimental|250 mg DCS|64 patients receive 250 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
16593383|NCT02656342|Experimental|100 mg D-Cycloserine|64 patients receive 100 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
16593384|NCT02656342|Active Comparator|Placebo|32 patients receive placebo two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
16593385|NCT02656329|Experimental|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
16593386|NCT02656329|Experimental|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
16593387|NCT02656316|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
16593388|NCT02656316|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
16593389|NCT02656303|Experimental|Ublituximab + TGR-1202|Ublituximab IV treatment + TGR-1202 oral daily dose
16593390|NCT02656290|Experimental|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
16593391|NCT02656277|Experimental|Decision tool|The decision tool includes a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention.
16593392|NCT02656277|Active Comparator|Information on Shoulder Dislocation|Subjects in this arm will receive the standard of care information available to patients to make this treatment decision.
16593393|NCT02656251|Active Comparator|0.12% Clorhexidine with alcohol|0.12% Clorhexidine with alcohol, 15ml every 12 hour for 4 days
16593394|NCT02656251|Experimental|0.12% Clorhexidine without alcohol|0.12% Clorhexidine without alcohol, 15ml every 12 hour for 4 days
16593395|NCT02656251|Placebo Comparator|control|placebo 15ml every 12 hour for 4 days
16593396|NCT02656225|Experimental|Ejiao compound|The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
16593397|NCT02656225|Active Comparator|Niferex|The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
16593398|NCT02656212|Experimental|(+)-epicatechin 30mg|10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin
16593399|NCT02656212|Placebo Comparator|placebo|5 subjects will be randomized to a placebo
16593400|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
16593401|NCT02656186|Experimental|Single-arm pretest-posttest|In this study, the subjects served as their own controls. Subjects who were eligible based on inclusion criteria first entered into a 2-week pre-intervention period, during which they received nutrition counseling to keep their routine dietary habits. This was followed by an intervention period, during which an oral nutritional supplement was used over a period of 2 weeks.
16593402|NCT02656173|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
16593403|NCT02656173|Experimental|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
16593404|NCT02656160|Placebo Comparator|Placebo|
16593405|NCT02656160|Active Comparator|Dalfampridine|
16593406|NCT02656147|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
16593407|NCT02656147|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
16593408|NCT02656147|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
16593409|NCT02656121|Experimental|Vitamin D|1st subgroup will be tested and treated with vitamin D together with Clomiphene Citrate for induction of ovulation
16593410|NCT02656121|Active Comparator|control|2nd subgroup will be treated with Clomophene Citrate only
16593411|NCT02656108|Experimental|omiited controlled cord traction|neither controlled cord traction nor fundal pressure will be applied. The placenta will be delivered physiologically and signs of placental separation will be awaited
16593414|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
16593415|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
16593416|NCT02656056|Experimental|Lean Adults|Adults with a BMI between 21-25 will consume 8 oz of the fermented soybean beverage, twice daily.
16593417|NCT02656056|Experimental|Obese Adults|Adults with a BMI between 32-37 will consume 8 oz of the fermented soybean beverage, twice daily.
16593418|NCT02656043|Active Comparator|XPF-005|Active treatment: XPF-005 Gel
16593419|NCT02656043|Placebo Comparator|Vehicle gel|Placebo: XPF-005 Vehicle Gel
16593420|NCT02656030|Experimental|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise 2 times/week, 6 weeks duration
16593421|NCT02656030|Experimental|cranio-cervical flexion exercise|cranio-cervical flexion exercise 2 times/week, 6 weeks duration
16593422|NCT02656030|Active Comparator|usual care|Usual care 2 times/week, 6 weeks duration
16593423|NCT02656017|Experimental|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:
~Increase to 500mg twice daily at week 2
~Increase to 1000mg qAM, 500mg qPM at week 4
~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).
~Increased titrations based on tolerability"
16593424|NCT02656017|Placebo Comparator|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:
~Increase to 500mg twice daily at week 2
~Increase to 1000mg qAM, 500mg qPM at week 4
~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).
~Increased titrations based on tolerability"
16593425|NCT02656004|Experimental|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
16593426|NCT02656004|Experimental|Control|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
16593427|NCT02655991|Experimental|Telephone Case Monitoring|Telephone care management augmenting treatment as usual
16593428|NCT02655991|Active Comparator|Treatment as Usual|Case management, psychotherapy, and pharmacotherapy as usual
16593429|NCT02655978||Healthy Volunteers|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
16593430|NCT02655978||Medically Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
16593431|NCT02655978||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).
16593432|NCT02655965|Experimental|Ropivacaine + Clonidine|"A pecs block of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior.
~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
16593433|NCT02655965|Placebo Comparator|Sodium Chloride|"A pecs block of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior).
~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
16593434|NCT02655952|Experimental|Foxy-5|"Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.
~There will be a maximum of 8 dose cohorts. Cohorts 1-4 will be conducted in the United Kingdom and Denmark whereas cohorts 5-8 will only be conducted in Denmark. As doses in cohort 1 and 2 have been investigated in the previous phase I study, cohorts 1+2 and 3 can be run in parallel with dose escalation approved by the DSMB at all times.
~DK+UK: Cohort 1: 0.8 mg/kg DK+UK: Cohort 2: 1.3 mg/kg DK+UK: Cohort 3: 1.8 mg/kg DK+UK: Cohort 4: 2.3 mg/kg DK only: Cohort 5: 3.0 mg/kg DK only: Cohort 6: 4.0 mg/kg DK only: Cohort 7: 5.3 mg/kg DK only: Cohort 8: 7.0 mg/kg"
16593435|NCT02655939|Active Comparator|Reflex Plus|Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
16593436|NCT02655939|Placebo Comparator|Placebo|Placebo Sachets to be taken once in a day Before breakfast for the study duration
16593437|NCT02655926|Active Comparator|STN Arm|Participants would only have STN deep brain stimulation switched at optimal settings for that participant on for 12 weeks.
16593438|NCT02655926|Active Comparator|VC/VS Arm|Participants would only have VC/VS deep brain stimulation switched on at optimal settings for that participant for 12 weeks.
16593439|NCT02655913|Experimental|vitamin C+ mEHT+ supportive care|"Patients will be allocated into 3 Vitamin C infusion dosage groups:
~1g/kg.d,1.2g/kg.d,1.5g/kg.d;3 times a week for 8 weeks(25 infusions);concurrent with Modulated Electro-Hyperthermia (mEHT): 150W x 60 min/session,3 times a week for 8 weeks (25 sessions);together with supportive care."
16593440|NCT02655913|Placebo Comparator|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
16593441|NCT02655887|Experimental|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
16593442|NCT02655874|Experimental|Six-monthly influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
16593443|NCT02655874|Active Comparator|Annual influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
16593444|NCT02655861||Ichthyosis|
16593445|NCT02655848|Active Comparator|@ Cuff repair with LHB tenodesis|In case of pathologic changes of the long Head Biceps tendon, a tenodesis is performed in adjunct to performing an arthroscopic rotator cuff repair.
16593446|NCT02655848|Active Comparator|@ cuff repair with LHB tenotomy|In case of pathologic changes of the long Head Biceps tendon, a tenotomy is performed in adjunct to performing an arthroscopic rotator cuff repair.
16593447|NCT02655835|Experimental|Internet Mindfulness Meditation Intervention|Six-week internet mindfulness meditation training program including handouts and daily guided meditations
16593448|NCT02655835|Experimental|Access|Written information handouts on mindfulness meditation and access to guided daily meditations
16593449|NCT02655822|Experimental|Cohort 1 - Closed|Ciforadenant
16593450|NCT02655822|Experimental|Cohort 2 - Closed|Ciforadenant
16593451|NCT02655822|Experimental|Cohort 3 - Closed|Ciforadenant
16593452|NCT02655822|Experimental|Cohort 4|Ciforadenant + atezolizumab
16593453|NCT02655822|Experimental|Cohort 5 - Closed|Ciforadenant
16593454|NCT02655809|Other|Physica KR|Patients who have received a Physica KR total knee implant.
16593455|NCT02655796|Experimental|Moderate/High Risk|Participants assessed as moderate/high risk of falling according to the CDC Algorithm for Fall Risk Assessment
16593456|NCT02655796|Experimental|Low Risk|Participants assessed as low risk of falling according to the CDC Algorithm for Fall Risk Assessment
16593457|NCT02655783|Active Comparator|control|normal saline, 250 ml/h, until expulsion of placental
16593458|NCT02655783|Experimental|intervention|normal saline + 5% dextrose, 250 ml/h, until expulsion of placental
16593459|NCT02655770|Active Comparator|Liraglutide arm|Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
16593460|NCT02655770|Placebo Comparator|Placebo arm|Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
16593461|NCT02655757|Active Comparator|Sitagliptin|Sitagliptin 100mg QD
16593462|NCT02655757|Placebo Comparator|Placebo|Placebo
16593463|NCT02655744||newly-diagnosed patients with primary CNS lymphoma|
16593464|NCT02655731|Other|Treatment|PVI with HeartLight
16593465|NCT02655718|Other|Patients with ACS|Patients with ACS who underwent coronary angiography within 72 hours from the onset of disease. In identifying nonobstructive coronary atherosclerosis , patients underwent cardiac contrast MRI.
16593466|NCT02655705|Active Comparator|Cyclosporine A|Cyclosporine 200 mg/day (male) and 150 mg/day (female) orally, divided twice daily for 16 weeks
16593467|NCT02655705|Active Comparator|Methotrexate|Methotrexate was started with 10 mg/week orally as a single dose, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
16593468|NCT02655692|Placebo Comparator|Placebo|Saline dose
16593469|NCT02655692|Experimental|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
16593470|NCT02655692|Experimental|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
16593471|NCT02655679|Experimental|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
16593472|NCT02655679|Experimental|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
16593473|NCT02655679|Placebo Comparator|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
16593474|NCT02655679|Experimental|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
16593475|NCT02655679|Placebo Comparator|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
16593476|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
16593477|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
16593478|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
16593479|NCT02655640||Lupus|Characteristics of patients with Systemic Lupus Erythematosus. No interventions will be administered. Patients will be asked to complete questionnaires.
16593480|NCT02655640||Scleroderma|Characteristics of patients with Systemic Sclerosis. No interventions will be administered. Patients will be asked to complete questionnaires.
16593481|NCT02655627|Experimental|Group A|Usual Care Group: A brochure which emphasis the importance of physical activity and exercise in Type 2 DM will be given to the patients in this group after the evaluation.
16593482|NCT02655627|Experimental|Group B|Supervised Clinical Exercise Training Group: Patients in this group will continue group exercise training includes aerobic and resistance training, 1 hour in a day, 3 times in a week for 8 weeks with the supervision of a researcher physiotherapist.
16593483|NCT02655627|Experimental|Group C|Internet Based Exercise Training Group. the patients to this group will be a member of the web site named www.diyabetvehareket.com. The participation of the patients will be provided with the videos directing them to 1 hour in a day, 3 times in a week for 8 week both aerobic and resistance exercise training from the researcher physiotherapist.
16593484|NCT02655614|Experimental|SAD Stage: GDC-0134|Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).
16593485|NCT02655614|Placebo Comparator|SAD Stage: Placebo|Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.
16593486|NCT02655614|Experimental|MAD Stage: GDC-0134|Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
16593487|NCT02655614|Placebo Comparator|MAD Stage: Placebo|Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
16593488|NCT02655614|Other|Open-Label Safety Expansion (OSE)|Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.
16593489|NCT02655601|Experimental|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
16593490|NCT02655601|Active Comparator|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide [TMZ]). A total of 80 subjects will be in this study arm.
16593491|NCT02655588|Experimental|ImbPST|"ImbPST Arm: Participants in this arm will interact with imbPST program which provides a simulated therapy session based on the Problem Solving Treatment-Primary Care (PST-PC) treatment manual used in depression clinical trials . imbPST via a virtual therapist (presented via audio and video) provides programmed instructions on the steps and skills of problem solving, emotional support, and tailored feedback to the user's input."
16593492|NCT02655588|No Intervention|Control Group|Control Arm: Participants in this group will not receive any treatment for their depression and their depressive symptoms will be monitored for 6 to 9 weeks
16593493|NCT02655575|Experimental|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.
~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
16593494|NCT02655575|Active Comparator|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
16593495|NCT02655562|Experimental|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
16593496|NCT02655562|Placebo Comparator|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
16593497|NCT02655549|Experimental|Cohort 1 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
16593498|NCT02655549|Experimental|Cohort 2 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
16593499|NCT02655549|Experimental|Cohort 3 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
16593500|NCT02655536|Experimental|bevacizumab plus erlotinib|bevacizumab 15mg/kg every 3 weeks plus erlotinib 150mg per day
16593501|NCT02655536|Active Comparator|erlotinib|erlotinib 150mg per day
16593502|NCT02655523|Active Comparator|Bupivacaine+Triamcinolone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 40 mg of triamcinolone.
16593503|NCT02655523|Active Comparator|Bupivacaine+Dexamethasone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 4 mg of dexamethasone.
16593504|NCT02655523|Placebo Comparator|Bupivacaine+Saline|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL of preservative free normal saline.
16593505|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
16593506|NCT02655497|Experimental|Cognitive Training|Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
16593507|NCT02655497|Active Comparator|Psychosocial education|The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The control group will receive brain-health education.
16593508|NCT02655484|Other|COPD patients|Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.
16593509|NCT02655471|Experimental|HTLV-1 plus Tropical Spastic paraparesis|"Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of Raltegravir and Zidovudine during 48 weeks"
16593510|NCT02655458|Experimental|autologous PBMC reconstitution, Elotuzumab, Lenalidomide|Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
16593612|NCT02654847|Active Comparator|Norepinephrine 3 micrograms/mL|1mL of a solution of norepinephrine, containing 3 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
16593511|NCT02655445|Active Comparator|Mini-craniotomy|"Intervention: Bone flap > 30mm and replaced, placement of Jackson-Pratt drain
~A linear incision located over the biggest bulk of the hematoma is made. Dura is opened and a wide opening of the pseudomembrane is done. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
16593512|NCT02655445|Active Comparator|Twist Drill Craniostomy|"Intervention: twist drill burr hole <5mm, placement of Integra basket-type drain
~A stab incision to the scalp is made, at the approximate location of the thickest diameter of hematoma. The twist-drill hole <5mm is placed obliquely to the surface of the skull, at an angle of about 45° until perforation of the dura. No irrigation is performed. A basket-type drain (Integra) is placed in the subdural space and tunneled underneath the skin"
16593513|NCT02655445|Active Comparator|Burr Hole Craniostomy|"Intervention: 2 Burr Holes >5mm and <30mm, placement of Jackson-Pratt drain
~First burr hole at the site of maximal diameter, second anterior and superior to that point. The scalp incisions are so planned that they can be incorporated into a craniotomy if necessary. Visible membranes are opened with a sharp hook until the pia is visualized. Gentle irrigation is performed and continued until the returning liquid is clear. Two burr holes are placed to facilitate drainage. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
16593514|NCT02655432||Spot photoscreener|Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.
16593515|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
16593516|NCT02655406|Active Comparator|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
16593517|NCT02655406|No Intervention|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
16593527|NCT02655380|Experimental|ketamine 1|Anesthesia induction with ketamine 1 mg followed by remifentanil.
16593528|NCT02655380|Experimental|ketamine 2|Anesthesia induction with ketamine 2 mg followed by remifentanil.
16593529|NCT02655367|Experimental|Milled followed by flaked oats|Participant consumes test meal consisting of porridge made from milled oats on study day 1, followed by porridge made from flaked oats on study day 2
16593530|NCT02655367|Experimental|Flaked followed by milled oats|Participant consumes test meal consisting of porridge made from flaked oats on study day 1, followed by porridge made from milled oats on study day 2
16593531|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
16593532|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
16593533|NCT02655341||Consecutive STEMI Patients|All patients with AMI referred for primary PCI in a single centre
16593534|NCT02655328|Experimental|athlete under asthma treatment|athlete suffering from asthma blood sample urine sample
16593535|NCT02655315|Active Comparator|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
16593536|NCT02655315|Placebo Comparator|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
16593537|NCT02655302|Other|Bacterial exacerbations|Patients with at least 10^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.
16593538|NCT02655302|Other|Non-bacterial exacerbations|Patients without detected bacteria or below 10^7 UFC/ml in sputum during their first COPD exacerbation.
16593539|NCT02655289|Experimental|Modulated TENS|
16593540|NCT02655289|Placebo Comparator|Placebo TENS|
16593541|NCT02655276|Experimental|100 mg microencapsulated Glycine and then Placebo tablets|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.
16593542|NCT02655276|Experimental|Placebo tablets and then 100 mg microencapsulated Glycine|Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.
16593543|NCT02655263|No Intervention|Control|12 hours of fasting
16593546|NCT02655237|Experimental|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
16593547|NCT02655237|Active Comparator|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
16593548|NCT02655224|Experimental|Relugolix 40 mg|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix 40 mg, tablet, orally once daily before breakfast for 12 weeks.
16593549|NCT02655224|Placebo Comparator|Placebo|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix placebo-matching tablet, orally once daily before breakfast for 12 weeks.
16593550|NCT02655211|Active Comparator|CO2-CO2-Med|Participants will receive two blocks of CO2 laser treatment, followed by one block of usual care.
16593551|NCT02655211|Active Comparator|Med-CO2-CO2|Participants will receive one block of usual care, followed by two blocks of CO2 laser therapy.
16593552|NCT02655211|Active Comparator|CO2-Med-CO2|Participants will receive one block of CO2 laser therapy, one block of usual care, and finally one more block of CO2 laser therapy.
16593553|NCT02655211|Active Comparator|PDL-PDL-MED|Participants will receive two blocks of PDL laser therapy, followed by one block of usual care.
16593554|NCT02655211|Active Comparator|Med-PDL-PDL|Participants will receive one block of usual care, followed by two blocks of PDL laser therapy.
16593555|NCT02655211|Active Comparator|PDL-Med-PDL|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
16593556|NCT02655211|Active Comparator|PDL-CO2-Med|Participants will receive one block of PDL laser therapy, followed by one block of CO2 laser therapy, followed by one block of usual care.
16593557|NCT02655211|Active Comparator|CO2-PDL-Med|Participants will receive one block of CO2 laser therapy, followed by one block of PDL laser therapy, followed by one block of usual care.
16593558|NCT02655211|Active Comparator|Med-PDL-CO2|Participants will receive one block of usual care, followed by one block of PDL laser therapy, followed by one block of CO2 laser therapy.
16593559|NCT02655211|Active Comparator|Med-CO2-PDL|Participants will receive one block of usual care, followed by one block of CO2 laser therapy, followed by one block of PDL laser therapy.
16593560|NCT02655211|Active Comparator|PDL-Med-CO2|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of CO2 laser therapy.
16593561|NCT02655211|Active Comparator|CO2-Med-PDL|Participants will receive one block of CO2 laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
16593562|NCT02655198|Experimental|fenfluramine|"Experimental : one armed open label study :
~Add-on fenfluramine in refractory Lennox Gastaut patients. Starting dose 0.2mg/kg/day. In non-responders (<50% seizure frequency decrease), dose will be uptitrated every 4 weeks from 0,2 to 0,4 and max 0,8 mg/kg/day (max 30 mg). Total duration study and max exposure to the drug 20 weeks"
16593563|NCT02655185||Heart failure|
16593564|NCT02655172|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
16593565|NCT02655172|Active Comparator|Control group|healthy patients who will perform cognitive tasks
16593566|NCT02655159||Abraxane® treatment in patients with metastatic breast cancer|Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
16593567|NCT02655146|Experimental|GnRHa protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 (Progynova) 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2.In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .A single dose of Triptorelin 0.1mg is administrated on the 3rd day after embryo implanted with routine luteal phase support.
16593568|NCT02655146|Other|routine luteal phase protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
16593569|NCT02655133|Active Comparator|Pentaglobin®|Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).
16593570|NCT02655133|Placebo Comparator|Physiologic Solution|Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)
16593571|NCT02655120|Experimental|Bone Marrow +BMP7|The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
16593572|NCT02655120|Placebo Comparator|Drilling|Group I: a simple drill is practiced
16593573|NCT02655081|Experimental|Dietary supplement|Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
16593574|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.
~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
16593575|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.
~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
16593576|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
16593577|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
16593578|NCT02655042||RCT-01|Participants in previous clinical trial that received blinded injection of RCT-01
16593579|NCT02655042||Placebo|Participants in previous clinical trial that received blinded injection of placebo
16593582|NCT02655003|Experimental|INH (Intervention Nursing Homes)|TIME consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of NPS. The staff, physicians and nursing home managers in the intervention nursing homes will receive a one-day education program. Three nurses from each unit will receive further education including practical and theoretical training for three hours.
16593583|NCT02655003|Active Comparator|CNH (Control Nursing Homes)|A brief two hours education-only intervention about dementia and NPS will be given to the staff in for the control nursing homes (CNH). The staff and physicians in the control nursing homes continue practice as usual.
16593584|NCT02654990|Experimental|Arm A - 20mg PAN TIW|20mg panobinostat three times a week, 2 weeks on/1week of in combination with s.c. bortezomib and p.o. dexamethasone
16593585|NCT02654990|Experimental|Arm B - 20mg PAN BIW|20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
16593586|NCT02654990|Experimental|Arm C - 10mg PAN TIW|10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
16593587|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
16593588|NCT02654964|Experimental|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:
~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
16593589|NCT02654951|Experimental|Visual + Force Feedback|Participants will complete a set of trials while receiving visual feedback only. After finishing, participants will continue to a new set of trials while receiving force feedback only.
16593590|NCT02654951|Experimental|Force + Visual Feedback|Participants will complete a set of trials while receiving force feedback only. After finishing, participants will continue to a new set of trials while receiving visual feedback only.
16593591|NCT02654938|Experimental|Mobilan (M-VM3)|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Investigational Drug Product
16593592|NCT02654938|Placebo Comparator|Placebo|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Placebo (Glucose 5%)
16593593|NCT02654925||Young Men|men 21-40 years of age
16593594|NCT02654925||Young Women|women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.
16593595|NCT02654925||Older Men|men 55-100 years of age
16593596|NCT02654925||Older Women|women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).
16593597|NCT02654912|Experimental|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
16593598|NCT02654912|No Intervention|Reactive Focal Test and Treat|This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).
16593599|NCT02654899|Experimental|Part 1_Cohort 1_Active;|Single ascending dose of PF-06815345
16593600|NCT02654899|Placebo Comparator|Part 1_Cohort 1_Placebo;|Single dose of placebo
16593601|NCT02654899|Experimental|Part 1_Cohort 2_Active|Single ascending dose of PF-06815345
16593602|NCT02654899|Placebo Comparator|Part 1_Cohort 2_Placebo|Single dose of placebo
16593603|NCT02654899|Experimental|Part 2|Single dose of solid dosage formulation (test) versus liquid dosage formulation (reference) of PF-06815345
16593604|NCT02654886|Experimental|Resistance Exercise Training|Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
16593605|NCT02654873||Benign|Benign pathology specimens with macroscopically
16593606|NCT02654873||Suspicious|Suspicious group includes the conditions such as increasing of the gallbladder wall thickness, having calcifications or polyps in the gallbladder.
16593607|NCT02654873||Malign|Malign group includes the conditions such as detecting mass or irregularities in the gallbladder wall.
16594566|NCT02648269|Experimental|SEL-037|Single intravenous dose of SEL-037 (pegsiticase)
16593613|NCT02654847|Active Comparator|Norepinephrine 4 micrograms/mL|1mL of a solution of norepinephrine, containing 4 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
16593614|NCT02654847|Active Comparator|Norepinephrine 5 micrograms/mL|1mL of a solution of norepinephrine, containing 5 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
16593615|NCT02654847|Active Comparator|Norepinephrine 6 micrograms/mL|1mL of a solution of norepinephrine, containing 6 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
16593616|NCT02654847|Active Comparator|Norepinephrine 7 micrograms/mL|1mL of a solution of norepinephrine, containing 7 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
16593617|NCT02654847|Active Comparator|Norepinephrine 8 micrograms/mL|1mL of a solution of norepinephrine, containing 8 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
16593618|NCT02654834||Pediatric Operating Room (OR) Staff|OR Staff exposed to nitrous oxide, and other volatile anesthetics
16593619|NCT02654834||Pediatric Intensive Care Unit (ICU) Staff|ICU Staff unexposed to any volatile anesthetics
16593620|NCT02654821|Experimental|TCR treatment|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
16593621|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
16593622|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
16593623|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
16593624|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
16593625|NCT02654795|Placebo Comparator|Patients without stroke|This group will consists of patients scheduled for atrial fibrillation ablation without history of stroke.
16593626|NCT02654795|Experimental|Patients with history of stroke|This group will consists of patients after ischemic stroke and history of atrial fibrillation.
16593627|NCT02654782|Active Comparator|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
16593628|NCT02654782|Active Comparator|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
16593629|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
16593630|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
16593631|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
16593632|NCT02654743|Experimental|SF|"Sulforaphane (SF) will be administered in an approximate dosage of 1 µmol SF/lb (2.2 kg µmol/kg) body weight. This dosage roughly approximates the dosage that was used in the Singh et al, (2014; PNAS) clinical trial of sulforaphane in male adolescents and adults with autism. The sulforaphane will be supplied as glucoraphanin (GR)-enriched broccoli seed extract tablets (manufacturing details follow). Each active tablet will contain 125 mg broccoli seed extract (containing 37 µmol GR, which is equivalent to about 15 µmol SF), 50 mg dried broccoli sprouts (a source of myrosinase, the enzyme that converts GR to SF), 15 mg ascorbic acid, 55.90 mg microcrystalline cellulose, and other minor GRAS excipients used for tablet forming.
~The total dose per day will depend of study participants' body weight."
16593633|NCT02654730|Experimental|G6PD deficient 0.25 mg/kg PQ + DHAP|
16593634|NCT02654730|Experimental|G6PD deficient 0.4 mg/kg PQ + DHAP|
16593635|NCT02654730|Active Comparator|G6PD deficient DHAP only|
16593636|NCT02654730|Active Comparator|G6PD normal 0.25 mg/kg PQ + DHAP|
16593637|NCT02654730|Active Comparator|G6PD normal 0.4 mg/kg PQ + DHAP|
16593638|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
16593639|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
16593640|NCT02654704||Healthy Young Adults|Healthy young adults aged 18-25. Vaccination in all cohorts/groups.
16593641|NCT02654704||Asthma Young Adults|Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
16593642|NCT02654704||Immunocompromised Young Adults|"Young adults aged 18-25 that are immunocompromised (e.g. following treatment for leukemia).
~Vaccination in all cohorts/groups."
16593643|NCT02654704||Healthy Older Adults|Healthy older adults aged 55+ Vaccination in all cohorts/groups.
16593644|NCT02654704||Asthma Older Adults|Older adults 55+ with asthma. Vaccination in all cohorts/groups.
16593645|NCT02654704||Immunocompromised Older Adults|"Older adults aged 55+ that are immunocompromised (e.g. following treatment for leukemia).
~Vaccination in all cohorts/groups."
16593646|NCT02654678|Experimental|Enalapril Orodispersible Minitablets|Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure.
16593647|NCT02654665|Experimental|Liraglutide|Liraglutide will be administered once daily by subcutaneous injection at a starting dose of 0.6 mg, increasing at 0.6 mg/week increments to a maximum of 3.0 mg over the next 6 weeks, as tolerated.
16593648|NCT02654665|Active Comparator|Bariatric Surgery|Subjects will have outcomes measured within 28 days before surgery. Post-operative management and frequency of follow-up visits will be decided by the bariatric surgeon. Study visits for biochemical and endothelial function testing; MRI and liver biopsy and / or fibroscan will follow the same schedule as that of the lifestyle and liraglutide arms. Target weight loss for the first 26 weeks post-surgery is at least 30% of excess body weight.
16593649|NCT02654665|Active Comparator|Diet modification and exercise|Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
16593650|NCT02654652|Experimental|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
16593651|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
16593652|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
16593653|NCT02654626|Experimental|KBP-7072: Cohort 1|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
16593654|NCT02654626|Experimental|KBP-7072: Cohort 2|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
16593655|NCT02654626|Experimental|KBP-7072: Cohort 3|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
16593656|NCT02654626|Experimental|KBP-7072: Cohort 4|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
16593657|NCT02654613|Active Comparator|Quality Improvement Intervention|In intervention clinics, staff will follow QI methodology to undertake a detailed assessment of their HIV-TB care and to prioritize the steps to improve treatment outcomes. A senior nurse will be identified to be the QI champion and will be trained by the study team to fulfil this role. The QI champion in the clinic then provides peer-leadership, mentorship and support for the implementation of the prioritized changes until the checklist is complete and all integrated HIV-TB service components meet the required standard.
16593658|NCT02654613|No Intervention|Control Standard of Care|The control arm will continue with the usual support that is received for HIV-TB service integration
16593659|NCT02654587|Experimental|OSE2101|OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).
16593660|NCT02654587|Active Comparator|Docetaxel or Pemetrexed|"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.
~Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.
~Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal."
16593661|NCT02654574|Experimental|Face-to-face collection followed by collection by phone|Reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, followed by the collection of IADL by phone, one month later.
16593662|NCT02654574|Experimental|Collection by phone followed by face-to-face collection|Collection of IADL by phone, followed by the collection of the IADL questionnaire using the reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, one month later.
16593663|NCT02654561|Placebo Comparator|Saline|
16593664|NCT02654561|Experimental|Heparin|If severe sepsis with suspected DIC is diagnosed, the Heparin sodium(2ml:12500 units) will be administered intravenously continuously for 24 hours. The course of treatment will last 7 days or until the death or discharge.
16593665|NCT02654548|Experimental|PCOS women and babies|Sebum output using Sebutape on post-partum PCOS women and new born babies.
16593666|NCT02654548|Active Comparator|Non-PCOS women and babies|Sebum output using Sebutape on post-partum non-PCOS women and new born babies.
16593667|NCT02654522|Experimental|Filler|Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
16593668|NCT02654522|No Intervention|Scale Validation|"One forearm of one of three subjects will be randomized to the scale control forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale control forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining randomized forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the control forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study."
16593669|NCT02654509|Experimental|EEE vaccine|Eastern Equine Encephalitis Vaccine will be administered as primary doses of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area and booster doses of 0.1 mL given intradermally in the volar aspect of the forearm. The primary series will be administered on Days 0 and 26-35 with a booster at 6 months. Titers will be collected 28-35 days after the second primary vaccine is < 1:40, the subject will receive a booster dose 28- 90 days of obtaining the titer result.
16593670|NCT02654496||Group 1 (Successful weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had successful weight loss
16593671|NCT02654496||Group 2 (Suboptimal weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had suboptimal weight loss
16593672|NCT02654496||Group 3 (Control group)|A control group who has not had Roux-en-Y gastric bypass surgery and are of similar age, gender, body mass index as the gastric bypass groups.
16593673|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
16593674|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
16593675|NCT02654457||Women with Breast Cancer #1|IVD Study
16593676|NCT02654457||Women with Breast Cancer #2|IVD Study
16593677|NCT02654457||Women with Breast Cancer #3|IVD Study
16593678|NCT02654444||GenASIs HiPath IHC #1|Expression of HER2 antibody. Semi-Quantitative value
16593679|NCT02654444||GenASIs HiPath IHC #2|Expression of HER2 antibody. Semi-Quantitative value
16593680|NCT02654444||GenASIs HiPath IHC #3|Expression of HER2 antibody. Semi-Quantitative value
16593681|NCT02654431||Breast Cancer patients|Breast cancer patients
16593682|NCT02654431||women with breast cancer|women with breast cancer
16593683|NCT02654431||Cancer patients|Cancer patients
16593684|NCT02654418|Experimental|SIC 8000, 10 mL ampoules|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with SIC 8000 injectate solution.
16593685|NCT02654418|Active Comparator|reference comparator|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with Reference Comparator Injectate solution (site standard of care injectate solution).
16593686|NCT02654405|Experimental|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
16593687|NCT02654405|Placebo Comparator|Placebo|Placebo capsule with 2 mg of sodium butyrate for making taste or odor, (9 mg/day)
16593688|NCT02654392|Placebo Comparator|placebo|This group will receive isoenergetic carbohydrate (corn syrup) supplement daily for 5 weeks
16593689|NCT02654392|Other|Polyunsaturated fatty acid group|This group will receive a plant essential fatty acid food supplement, Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils, containing a 2.5:1 omega-6 to omega-3 ratio (1.5 g per 70kg body mass plus an additional 0.5 g on exercise days)
16593690|NCT02654379||Cohort|Cohort consisting of participants who are in the center to receive an infusion for rituximab for a non-oncology indication.
16593691|NCT02654366|Experimental|Community Supported Risk Reduction Group|Six weekly sessions will be scheduled during daytime and evening hours to accommodate the daily schedules of BNEP registrants and their CSPs. Each session meets for 60 minutes. Groups will consist of 5-6 BNEP registrant-CSP dyads (10-12 individuals). While BNEP registrants and CSPs attending the group together will receive an attendance incentive, BNEP registrants attending without a CSP will not earn one. The group leader will follow a manual that includes a structured outline. The group manual content combines risk reduction / treatment readiness and community outreach approaches. Following the introduction, each group session is divided into two components: 1) Risk Reduction and Treatment Readiness (30 min) and 2) Community Outreach skills (20 min).
16593692|NCT02654353|Other|Group A: stepwise ablation|Stepwise ablation of persistent atrial fibrillation (conventional treatment arm) In this arm, patients will be treated with the conventional stepwiese ablation approach
16593693|NCT02654353|Active Comparator|Group B: sequential substrate ablation|Sequential substrate ablation of persistent atrial fibrillation (novel procedure) In this arm, patients will undergo an ablation procedure that consist of PVI, cardioversion, linear ablation and atrial fibrillation re-induction after blocked lines, followed by electrogram-guided ablation
16593694|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
16593695|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
16593696|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
16593697|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
16593698|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
16593699|NCT02654301|Placebo Comparator|Control group|sucrose drink (Control, sucrose 50g + deionized water 100g)
16593700|NCT02654301|Active Comparator|5 g xylose group|5 g xylose (Test 1, sucrose : xylose = 10:1),
16593701|NCT02654301|Active Comparator|3.33 g xylose group|3.33 g xylose (Test 2, sucrose : xylose = 15:1)
16593702|NCT02654301|Active Comparator|2.5 g xylose group|2.5 g xylose (Test 3, sucrose : xylose = 20:1)
16593703|NCT02654288||single arm|The pancreatic cancer patients without history of chemotherapy who will receive gemcitabine-based chemotherapy will be recruited and the sera IgG4 and IL-10 will be detected before and after chemotherapy.
16593704|NCT02654275|Active Comparator|Proprioceptive Intervention|Strength training on a non-stable surface
16593705|NCT02654275|No Intervention|No Proprioceptive Intervention|Conventional strength training
16593706|NCT02654249|Other|THD and mucopexy|Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.
16593707|NCT02654249|Active Comparator|Ligasure hemorroidectomy|Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.
16593708|NCT02654236|Placebo Comparator|Placebo|Heavy Drinkers on placebo
16593709|NCT02654236|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
16593710|NCT02654236|No Intervention|Non-drinking Controls|Non-drinking healthy controls
16593711|NCT02654223|Experimental|MG56 Mannosylated 60 subcutaneous|60 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16593712|NCT02654223|Experimental|MG56 Mannosylated 100 subcutaneous|100 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16593713|NCT02654223|Experimental|MG56 Mannosylated 300 subcutaneous|300 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16593714|NCT02654223|Experimental|MG56 Mannosylated 500 subcutaneous|500 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
16593715|NCT02654223|Experimental|MG56 Mannosylated 60 sublingual|60 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16593716|NCT02654223|Experimental|MG56 Mannosylated 100 sublingual|100 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16593718|NCT02654223|Experimental|MG56 Mannosylated 500 sublingual|500 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
16593719|NCT02654223|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
16593720|NCT02654197||H.pylori positive children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
16593721|NCT02654197||H.Pylori negative children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
16593722|NCT02654184|Active Comparator|Supine group|Anesthesia induction with sevoflurane for the patient while he is in supine position.
16593723|NCT02654184|Active Comparator|Right lateral group|Anesthesia induction with sevoflurane for the patient while he is in right lateral position position.
16593724|NCT02654171|Experimental|AK0529|Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.
16593725|NCT02654171|Placebo Comparator|Placebo|Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.
16593726|NCT02654158||Low-dose of Fuganlin Oral Liquid|"oral
~less than 1 years old: 5mL each time and three times a day
~1~3 years old: 10mL each time and three times a day
~4~6 years old: 10mL each time and four times a day
~7~12 years old: 10mL each time and five times a day"
16593727|NCT02654158||High-dose of Fuganlin Oral Liquid|"oral
~less than 1 years old: 10mL each time and three times a day
~1~3 years old: 20mL each time and three times a day
~4~6 years old: 20mL each time and four times a day
~7~12 years old: 20mL each time and five times a day"
16593728|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
16593729|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)
~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)
~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)
~Drug: Pomalidomide
~•Capsules,Oral,4 mg,once daily, on Days 1-21
~Other Name: Pomalyst
~Drug: Dexamethasone
~Subjects ≤ 75 years old:
~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)
~Subjects > 75 years old:
~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)
~Other Names:
~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
16593730|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide
~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst
~Drug: Dexamethasone
~Subjects ≤ 75 years old:
~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22
~Subjects > 75 years old:
~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,
~Other Names:
~Decadron
~Dexamethasone Intensol
~Dexpak
~Taperpak"
16593731|NCT02654119|Experimental|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
16593732|NCT02654106|Experimental|Refractory Brain Metastases|Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases
16593733|NCT02654093|Experimental|Group A|A → B → C / A: Cholecalciferol, B: Raloxifene, C: Cholecalciferol+Raloxifene
16593734|NCT02654093|Experimental|Group B|A → C → B
16593735|NCT02654093|Experimental|Group C|B → A → C
16593736|NCT02654093|Experimental|Group D|B → C → A
16593737|NCT02654093|Experimental|Group E|C → A → B
16593738|NCT02654093|Experimental|Group F|C → B → A
16593739|NCT02654080|Experimental|Group 1: Vaccine|Participants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
16593740|NCT02654080|Placebo Comparator|Group 2: Placebo|Participants will receive placebo vaccine at Day 0 and Months 1, 3, 6, and 9.
16593741|NCT02654054|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
16593742|NCT02654054|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
16593743|NCT02654054|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
16593744|NCT02654041|Experimental|Hypothyroxinemia induced patients|Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.
16593745|NCT02654028|Experimental|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
16593746|NCT02654028|Active Comparator|Control group|These group of patients will not receive autotransfusion before or after liver resection.
16593748|NCT02654002|Experimental|Cohort 1: Cilofexor 10 mg|Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
16593749|NCT02654002|Experimental|Cohort 2: Cilofexor 30 mg|Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
16593750|NCT02654002|Experimental|Cohort 3: Cilofexor 100 mg|Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
16593751|NCT02654002|Experimental|Cohort 4: Cilofexor 300 mg|Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
16593752|NCT02654002|Experimental|Cohort 5: Cilofexor 100 mg|Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
16593753|NCT02654002|Experimental|Cohort 6: Cilofexor 50 mg|Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
16593754|NCT02654002|Experimental|Cohort 7: Cilofexor 15 mg|Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
16593755|NCT02654002|Experimental|Cohort 8: Cilofexor 10 mg|Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
16593756|NCT02654002|Experimental|Cohort 9: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
16593757|NCT02654002|Experimental|Cohort 10: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
16593758|NCT02653989|Experimental|MDV9300|
16593759|NCT02653976|Experimental|SP-02L (darinaparsin for injection)|
16593760|NCT02653963|No Intervention|Conventional AGV|A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
16593761|NCT02653963|Experimental|Triamcinolone adjuctival AGV|Subtenon Periplate 10 mg triamcinolone acetonide around the AGV plate after fixation of AGV Plate to the sclera
16593762|NCT02653950|Active Comparator|Traditional|a control arm of patients undergoing traditional septoplasty for DNS
16593763|NCT02653950|Experimental|Endoscopic|patients undergoing endoscopic septoplasty.
16593764|NCT02653937|Experimental|Kampo medicine|7.5g per day of Tsumura's shigyakusan ( Tsumura & Co ) was administered to each of 110 cases.
16593765|NCT02653924|Active Comparator|silk suture|silk suture
16593766|NCT02653924|Active Comparator|vicryl suture|vicryl suture
16593767|NCT02653924|Active Comparator|nylon suture|nylon suture
16593768|NCT02653924|Active Comparator|polypropylene suture|polypropylene suture
16593769|NCT02653911|Experimental|acupuncture group|"Bilateral ST25, EX-CA1, CV4 and SP6 will be selected for treatment. After routine sterilization of the local skin, bilateral ST25, EX-CA1, CV4 and SP 6 will be inserted by the needles (0.30 mm in diameter, 40 mm in length) to a depth of 25-30 mm to the abdominal muscle layer with the manipulation of lifting, thrusting and rotating until de qi. Each session will last for 30 minutes, and the manipulation of lifting, thrusting and rotating evenly three times will be used for CV 4 and SP 6 every 10 minutes. If the date of treatment is during the menstrual circle, the treatment will be continued as usual. Participants will be treated three times a week for 12 weeks with 36 sessions."
16593770|NCT02653911|Sham Comparator|Sham-acupuncture group|The sham ST25, EX-CA1, CV4 and SP 6, which are 1 cun (25 mm) outward to ST25, EX-CA1, CV4 and SP 6, will be inserted to 2-3 mm with needles with a diameter of 0.30 mm and a length of 13 mm. The needles will be inserted without de qi or any manipulation. The treatment sessions will be the same as those in the acupuncture group.
16593771|NCT02653898|Active Comparator|Focused Screening and Treatment + ITU|Approved antimalarial based on the malaria species identified on the monthly follow ups, following national treatment guidelines in Cambodia AND Insecticide Treated Uniform with 40% Permethrin; DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
16593772|NCT02653898|Active Comparator|Focused Screening and Treatment + sITU|Approved antimalarial based on the malaria species identified at the monthly follow up and following national treatment guidelines in Cambodia AND sham treated uniform. DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
16593773|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + ITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive insecticide treated uniforms with 40% Permethrin
16593774|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + sITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive sham treated uniforms
16593775|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
16594828|NCT02646722||mild pain|patients move a hand only on rocuronium injection
16593776|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
16593777|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
16593778|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
16593779|NCT02653833|Experimental|Healthy Controls (HC)|Healthy men currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. This is repeated at baseline and shortly after taking beetroot juice extract.
16593780|NCT02653833|Experimental|Becker Muscular Dystrophy (BMD)|"currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. Using a lower body negative pressure (LBNP) chamber, the subjects are tested for impaired exercise induced vasodilation to the skeletal muscle or functional sympatholysis. This is repeated at baseline and shortly after taking beetroot juice extract."
16593781|NCT02653820|Experimental|Chemotherapy patients|Chemotherapy patients will receive reflexology treatment
16593782|NCT02653807|Experimental|mobilization with movement|MWM at the talocrural joint during active weight bearing ankle dorsiflexion with the belt
16593783|NCT02653807|Active Comparator|osteopathic mobilization|passive mobilization of the talo-crural joint
16593784|NCT02653781|Experimental|Realistic simulation; Performance|Student participation in the study will happen on demand by enrollment in activities of dialogue-exhibition (workshop) on realistic simulation in the context of patient safety. Check the performance of students in face of simulation workshop for test realistic simulation.
16593785|NCT02653781|Other|theoretical-practical classes|Will be to give a theoretical-practical classes for students of control group the provision of similar opportunities
16593786|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
16593787|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
16593788|NCT02653755|Active Comparator|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
16593789|NCT02653755|Active Comparator|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
16593790|NCT02653742|Experimental|Ketorolac|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use.
16593791|NCT02653742|Experimental|Fentanyl|Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
16593792|NCT02653742|Experimental|Ketorolac and Fentanyl|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use and Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
16593793|NCT02653729|Experimental|Espidone, Olepra, Donu & C.B.T|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days
16593794|NCT02653729|Active Comparator|Espidone, Olepra & Donu|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night
16593795|NCT02653716|Active Comparator|Case Management|CM
16593796|NCT02653716|Experimental|New Orleans Intervention Model|NIM
16593797|NCT02653703|Placebo Comparator|Vehicle, topical ethanol 96%|Exposure: 10 % topical trans-cinnamaldehyde [CAS Number: 14371-10-9] Vehicle: 96% ethanol
16593798|NCT02653703|Experimental|Topical L-menthol 40%|Exposure: 10 % trans-cinnamaldehyde [CAS Number: 14371-10-9] Intervention: 40% l-menthol [CAS Number: 2216-51-5] Vehicle: 96% ethanol
16593799|NCT02653677|Active Comparator|commercial bread, wheat flour|Intake of the specific kind of bread
16593800|NCT02653677|Experimental|wheat, organic flour|Intake of the specific kind of bread
16593801|NCT02653677|Experimental|wheat, supermarket flour|Intake of the specific kind of bread
16593802|NCT02653677|Experimental|einkorn, organic flour|intake of the specific kind of bread
16593832|NCT02653508|No Intervention|Control|61 overweight and obese adolescents aged 13-15 years old were the control group of the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
16593806|NCT02653651|Active Comparator|Ketamine|Ketamine infused at 0.1 mg/kg/hour
16593807|NCT02653651|Experimental|Lidocaine|Lidocaine infused at 1 mg/kg/hour
16593808|NCT02653651|Placebo Comparator|Placebo|An equal volume of saline
16593809|NCT02653638|Experimental|Drug|"Control-Hypercapnic Trials: Three stepwise CO2 elevations will be applied to the patient by adding fractional concentration of inspired CO2 (FICO2) at 2%, 4%, and 6% each time, balanced with room air. The end tidal CO2 (PetCO2) will be elevated and maintained constant for three minutes at each target level. Breath-by-breath changes in minute ventilation (VE) and PetCO2 will be measured.
~Drug-Indomethacin: Healthy volunteers, indomethacin suspension will be orally administered at 1.2 mg/kg. After drug administration, the patient will rest quietly for 90 minutes."
16593810|NCT02653625|Experimental|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
16593811|NCT02653612|Experimental|Experimental Arm|This cohort will receive the contrast agent
16593812|NCT02653599|Experimental|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
16593813|NCT02653599|Experimental|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
16593814|NCT02653599|Placebo Comparator|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
16593815|NCT02653586|Experimental|"program In Favor of Resilience Self"|"The program In Favor of Resilience Self was delivered to adolescence aged 15-17, over 2 months. The program contained nine weekly, 90-min lessons that focus on enhancing self- resilience, self-esteem, self-image, body image. All students completed a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
16593816|NCT02653586|No Intervention|control group|The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
16593817|NCT02653573|Experimental|Intervention|Telephone health coaching over 3 months with supporting education materials.
16593818|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
16593819|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
16593820|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
16593821|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
16593822|NCT02653547|Experimental|standard multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
16593823|NCT02653547|Experimental|high-frequency multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
16593824|NCT02653547|Experimental|standard multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
16593825|NCT02653547|Experimental|high-frequency multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
16593826|NCT02653534|Experimental|Intervention Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
16593827|NCT02653534|No Intervention|Control|Routine visits by government health workers
16593828|NCT02653521|Experimental|adaptive radiation therapy (ART)|40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.
16593829|NCT02653521|No Intervention|the control group|40 patients treated with original plan for full treatment course.
16593830|NCT02653508|Experimental|Diet and Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, while the nutritional education comprised of a supplementary 15 minutes of group-based sessions that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
16593831|NCT02653508|Experimental|Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
16593833|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
16593834|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
16593835|NCT02653482|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg daily
16593836|NCT02653482|Placebo Comparator|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
16593837|NCT02653469||Augmented ventilation with fluid loading|This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
16593838|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
16593839|NCT02653443|Experimental|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
16593840|NCT02653443|Experimental|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
16593841|NCT02653430|Experimental|Bariatric Surgery|Sleeve Gastrectomy
16593842|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg/day
16593843|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg/day
16593844|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg/day
16593845|NCT02653417|Placebo Comparator|Regimen 4|Placebo
16593846|NCT02653404||Cases|"A blood sample necessary to perform QFT-GIT will be taken, together with other routine blood samples, from children with following diagnosis:
~latent tuberculous infection: active TB contact, TST positive, lack of clinical and RX signs of active-TB
~active TB: clinical and radiologic evidences of active-TB, positivity to microbial tests to BK
~not infected: patients evaluated as TB contacts, with negative TST and negative clinical/radiological/microbial results for TB."
16593847|NCT02653391|Experimental|Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
16593848|NCT02653391|Experimental|Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
16593849|NCT02653391|Placebo Comparator|Placebo A|Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
16593850|NCT02653391|Placebo Comparator|Part B Placebo|Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
16593851|NCT02653378|Active Comparator|DIET ARM|A 25% energy depletion (daily for 3 days) induced by reducing the amount of energy intake that would otherwise keep the individual in energy balance.
16593852|NCT02653378|Active Comparator|EX ARM|A 25% energy depletion (daily for 3 days) induced by performing aerobic exercise at 50% of V02max.
16593853|NCT02653365||Non-invasive ventilation|All patients eligible for inclusion in the study were treated with Non-invasive ventilation.
16593854|NCT02653352|No Intervention|Control|The control group received two one-hour general sessions on health issues and printed general advices regarding healthy diets.
16593855|NCT02653352|Experimental|Lifestyle modification|Intervention was focused on the reduction in consumption of sugar-sweetened carbonated beverages by students. During seven months of one school year, a healthy lifestyle education programme was implemented using simple messages encouraging water consumption instead of sugar-sweetened carbonated beverages. Education was delivered via classroom activities; banners were hung promoting water consumption, and water bottles with the logo of the campaign were given to children and schoolteachers.
16593856|NCT02653339|Experimental|Qufeng Shengshi Fang and Loratadine|Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
16593857|NCT02653339|Active Comparator|Loratadine|Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough[needs update] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
16593858|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
16593859|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
16593860|NCT02653313|Experimental|ParvOryx|ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).
16593861|NCT02653300|Experimental|Oral Insulin|treatment
16593862|NCT02653287|Experimental|Intervention|The experimental intervention is a unique combination of four individual counseling sessions based in motivational interviewing focusing on physical activity, dietary behavior and behavioral strategies. The individual sessions will provide a tailored personalized intervention including problem-solving and goal setting for increasing physical activity, and following a healthy diet. Healthy Lifestyle Coaches (RN or MPH) will be responsible for conducting the individual for a caseload of participants. There are no drugs involved in the intervention.
16593863|NCT02653287|Active Comparator|Control|The control group intervention will receive four individual phone calls checking in with participants regarding questions about the study or from the group sessions, and educational sessions focusing on SLE disease management, each lasting approximately 10-15 minutes.
16593864|NCT02653274|Active Comparator|OATS PORRIDGE|Oats breakfast porridge
16593868|NCT02653261|Experimental|Tranexamic Acid|Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
16593869|NCT02653261|Placebo Comparator|Placebo|An equal volume of saline
16593870|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
16593871|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
16593872|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
16593873|NCT02653235|Active Comparator|Typhoid vaccination|Salmonella typhi vaccination
16593874|NCT02653235|Placebo Comparator|Placebo|0.9% sodium chloride
16593875|NCT02653222|Experimental|Renal sympathicolysis|"The patient will have:
~Ambulatory Blood Pressure Monitoring
~Magnetic Resonance Angiography
~Blood test
~Renal sympathicolysis
~Ambulatory Blood Pressure Monitoring
~Magnetic Resonance Angiography"
16593876|NCT02653209|Experimental|Sitagliptin - DPP4i|
16593877|NCT02653209|Experimental|Canagliflozin - SGLT2i|
16593878|NCT02653209|Experimental|Pioglitazone - TZD|
16593879|NCT02653196|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|"Matched Unrelated Donor HSCT (minimum 9/10 human leukocyte antigen [HLA] match) OR Matched Related Donor HSCT (10/10 HLA match). Conditioning regimen begins 12 days prior to stem cell infusion and includes the following drugs:
~Keratinocyte Growth Factor Alemtuzumab Thiotepa Etoposide Melphalan Fludarabine Tacrolimus (Cyclosporine A may be substituted for Tacrolimus) Mycophenolate mofetil"
16593880|NCT02653183|Active Comparator|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.
~Duration of treatment:
~Total 5 days included the day of surgery and 4 post-operative days."
16593881|NCT02653183|Experimental|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.
~Duration of treatment:
~Total 5 days included the day of surgery and 4 post-operative days."
16593882|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
16593883|NCT02653170|Experimental|SCM|"One intervention is provided:
~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
16593884|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:
~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:
~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
16593885|NCT02653157||Burn patients with VAT or VAP with MDR-GNB|Adult patients with burn and/or inhalation injury requiring intubation
16593886|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
16593887|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
16593888|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
16593889|NCT02653131|Experimental|DPP-4|The administration of the DPP-4 inhibitor in the form of a pill once per day
16593890|NCT02653131|No Intervention|NO DPP|no therapy
16593891|NCT02653118||Cohort 1: V503 in the Base Study|Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
16593892|NCT02653118||Cohort 2: GARDASIL in the Base Study|Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
16593893|NCT02653105|Experimental|OLFM4|Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.
16593896|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia, Arthrosis (finger- and Rhizarthrosis, Gonarthrosis, Anklearthrosis), and Arthritis with an planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
16593897|NCT02653066|No Intervention|Control|Participant is recruited via usual avenues including flyers and physician referral. This includes participants who received a HealtheRx with advertisement for phone survey but did not call in based on advertisement.
16593898|NCT02653066|Experimental|Intervention with consent form|After completing survey, participant in HealtheRx+ group receives $5 bill with their survey check and blank registry consent form.
16593899|NCT02653066|Experimental|Intervention with return of consent form|After returning signed consent form, participant in HealtheRx++ group is mailed $5 bill.
16593900|NCT02653040|Experimental|Dynamic lighting|Indoor lighting with low-lux no-blue wavelengths at night.
16593901|NCT02653040|No Intervention|Treatment as usual|Characterized by full white light with little variation through a day cyclus.
16593902|NCT02653027|Experimental|Lumacaftor Ivacaftor|Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
16593903|NCT02653014|Experimental|Cohort 1|Healthy Volunteers will receive multiple dose of KBP-5074
16593904|NCT02653014|Experimental|Cohort 2|Healthy Volunteers will receive multiple dose of KBP-5074
16593905|NCT02653014|Experimental|Cohort 3|Healthy Volunteers will receive multiple dose of KBP-5074
16593906|NCT02653014|Experimental|Cohort 4|Healthy Volunteers will receive multiple dose of KBP-5074
16593907|NCT02653014|Experimental|Cohort 5|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
16593908|NCT02653014|Experimental|Cohort 6|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
16593909|NCT02653001|Experimental|Experimental arm|Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components
16593910|NCT02652988|Active Comparator|Active-tDCs|17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
16593911|NCT02652988|Sham Comparator|Sham-tDCS|17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
16593912|NCT02652975|Experimental|Category 1|Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
16593913|NCT02652975|Experimental|Category 2|Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
16593914|NCT02652975|Experimental|Category 3|Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
16593915|NCT02652962|Experimental|Gelesis200 x 2, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
16593916|NCT02652962|Experimental|Gelesis200 x 2, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
16593917|NCT02652962|Placebo Comparator|Placebo x 2, 10 min|3 x Placebo capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
16593918|NCT02652962|Placebo Comparator|Placebo x 2, 30 min|3 x Placebo capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
16593919|NCT02652962|Experimental|Gelesis200 x 3, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
16593920|NCT02652962|Experimental|Gelesis200 x 3, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
16593921|NCT02652962|Placebo Comparator|Placebo x 3, 10 min|3 x Placebo capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
16593922|NCT02652962|Placebo Comparator|Placebo x 3, 30 min|3 x Placebo capsules administered 30 minutes before each of 3 meals (breakfast, lunch, dinner).
16593923|NCT02652949|Experimental|Endovascular Repair|Valiant Evo Thoracic Stent Graft System
16593924|NCT02652936|Experimental|AF-130 capsule|AF-130 oral capsules administered as a single dose or once daily for 7 days
16593925|NCT02652936|Placebo Comparator|AF-130 matching placebo capsule|Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
16593926|NCT02652923|Experimental|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
16593927|NCT02652923|Experimental|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
16593928|NCT02652910|Experimental|IL-2 programmed CD19.CAR-T cells|Administrated with IL-2 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
16593929|NCT02652910|Experimental|IL-7/IL-15 programmed CD19.CAR-T cells|Administrated with IL-7/IL-15 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
16593930|NCT02652897||Exposure to glioma resection surgery|Patients undergoing elective glioma resection
16593931|NCT02652897||Exposure to colon resection surgery|Patients undergoing elective colon cancer resection
16593932|NCT02652884|Experimental|Group 1|will receive single dose intramuscular corticosteroid deltoid deposit (as phosphate and betamethasone acetate, 2 mL) for immediate postintubation.
16593933|NCT02652884|Placebo Comparator|Group 2|will receive 2 ml saline 0.9% NaCl in deltoid immediately postintubation.
16593934|NCT02652871|Experimental|LY2510924 + Idarubicin + Cytarabine|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients. On Day 8, LY2510924 administered after bone marrow aspiration and/or biopsy is performed.
~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.
~Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.
~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.
~Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.
~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
16593935|NCT02652858|Experimental|Pulse wave's speed observational arm|Whole patients for who the pulse wave's speed are measured during a cardiopulmonary bypass during cardiac surgery
16594829|NCT02646722||moderate pain|patients move a arm on rocuronium injection
16593936|NCT02652845|Experimental|Intervention-Wellness Engagement Program|"The group assigned to the intervention arm will receive treatment as described below for a twelve week period:
~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events"
16593937|NCT02652845|No Intervention|Delayed treatment control group|The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.
16593938|NCT02652832|Active Comparator|Depression Electroconvulsive therapy|40 patients with major depression receiving a mean of 12 sessions of Electroconvulsive therapy
16593939|NCT02652832|Active Comparator|Depression active repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
16593940|NCT02652832|Sham Comparator|Depression sham repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of sham 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
16593941|NCT02652832|Active Comparator|Schizophrenia active transcranial magnetic stimulati|40 patients with schizophrenia and predominant negative symptoms receiving 20 sessions of intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
16593942|NCT02652832|Sham Comparator|Schizophrenia sham transcranial magnetic stimulation|patients with schizophrenia and predominant negative symptoms receiving 20 sessions of sham intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
16593943|NCT02652832|Active Comparator|Schizophrenia active transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
16593944|NCT02652832|Sham Comparator|Schizophrenia sham transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of sham transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
16593945|NCT02652832|No Intervention|Healthy volunteers|80 healthy volunteers receiving no stimulation
16593946|NCT02652819|Experimental|FG-4592|Intervention is investigational treatment FG-4592
16593947|NCT02652819|Placebo Comparator|Placebo|Double blinded placebo control
16593948|NCT02652806|Experimental|FG-4592|Intervention is investigational treatment FG-4592
16593949|NCT02652806|Active Comparator|EPO|Intervention is subject's current dose of Li Xue Bao (epoetin alfa)
16593950|NCT02652793|Experimental|Experimental|All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.
16593951|NCT02652780|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
16593952|NCT02652780|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
16593953|NCT02652767|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
16593954|NCT02652767|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
16593955|NCT02652754|Other|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
16593956|NCT02652741|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
16593957|NCT02652728|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
16593958|NCT02652715|Experimental|Basic science (Salvia hispanica seed)|Patients receive Salvia hispanica seed PO QD for 12 weeks.
16593959|NCT02652702|Experimental|Circular Stapler-assisted Colostomy|Using Circular Stapler-assisted Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
16593960|NCT02652702|Experimental|Hand-stitching Colostomy|Using Conventional Hand-stitching Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
16593961|NCT02652689|Experimental|Diagnostic ultrasound|Recording Doppler ultrasound signals noninvasively from the right chest wall
16594051|NCT02652013|Experimental|40 patients with multiple sclerosis|The study sample will consist of 40 patients with multiple sclerosis. MS patients and control subjects will be recruited on the Rennes (Centre Hospitalier Universitaire and Pôle de Médecine Physique et de Réadaptation Saint-Hélier) and Angers sites (Centre Hospitalier Universitaire) participating in COGNISEP project
16593962|NCT02652676|Experimental|Reversible Pulmonary Artery Banding|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
16593963|NCT02652663||ECA-MRI group|ECA-MRI group (patients who underwent conventional MRI using extracellular contrast agent [ECA])
16593964|NCT02652663||Gd-EOB-MRI group|Gd-EOB-MRI group (patients who underwent gadoxetic acid-enhanced MRI)
16593965|NCT02652650|Experimental|Ethinylestradiol/Norethindrone|During the first oral contraceptive (OC) cycle participants will receive ethinylestradiol/norethindrone 35 microgram (mcg)/1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in). During the second OC cycle (from Day 29 to Day 56), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg alone qd for 21 days on Days 29 to 49 (Cycle II: OC alone, reference). During the third OC cycle (from Day 57 to Day 84), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg qd for 21 days on Days 57 to 77 and in addition JNJ-63623872, 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test).
16593966|NCT02652637|Experimental|Mechanical and oral antibiotic bowel preparation|Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.
16593967|NCT02652637|No Intervention|No bowel preparation|No mechanical bowel preparation or oral antibiotics.
16593968|NCT02652624|Experimental|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
16593969|NCT02652624|Active Comparator|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
16593970|NCT02652624|Experimental|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
16593971|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
16593972|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
16593973|NCT02652598|Experimental|Open-Label|Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
16593974|NCT02652585|Active Comparator|Naltrexone|"1 capsule naltrexone 25 mg per day, oral use, day 1 to day 3;
~1 capsule naltrexone 50 mg per day, oral use, day 4 to day 28"
16593975|NCT02652585|Placebo Comparator|Placebo|1 capsule placebo, oral use, day 1 to day 28
16593976|NCT02652572|Experimental|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
16593977|NCT02652559|Experimental|Home initiation|Home initiation of long-term NIV will be compared with standard in-hospital initiation. NIV at home will be titrated by a specialised nurse of our home mechanical ventilation centre (HMV) on transcutaneously measured gas exchange and respiratory electromyography and will be adjusted with the use of telemedicine.
16593978|NCT02652559|Active Comparator|Inhospital initiation|Inhospital initiation of NIV is standard care and in the study will be set as the control arm.
16593979|NCT02652546|Active Comparator|A|CC-11050 200mg (2 capsules) BID with food
16593980|NCT02652546|Placebo Comparator|B|Placebo (2 capsules) BID with food
16593981|NCT02652520|Experimental|Kidney transplantation|HEMO2Life® use in organ preservation solution. Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
16593982|NCT02652507|Other|Anesthesia for MRI|"All patients will receive the same drugs.
~A loading dose of dexmedetomidine of 2 mcg/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h. Bolus dose 2 mg/kg of ketamine will be given after the initial set of research images have been taken."
16593983|NCT02652494||Patients receiving Apremilast per daily clinical practice|Dutch patients receiving Apremilast according to daily clinical practice
16593984|NCT02652481|Other|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).
~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
16594052|NCT02652013|Other|40 healthy subjects|All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
16593985|NCT02652468|Experimental|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Participants receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Participants also undergo total nodal irradiation on day -1.
~TRANSPLANT: Participants undergo TCR alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg participant body weight (BW), patients may receive a second graft on day 1.
~GVHD PROPHYLAXIS: Participants receive mycophenolate mofetil orally twice a day (PO BID) on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the participant)."
16593986|NCT02652455|Experimental|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.
~Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
~Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
16593987|NCT02652442|Experimental|centrifugation|"Participants will be rotated in a darkened rotary chair booth with 1 ear positioned 7-8 cm off-axis and the other ear positioned on-axis. Following a 5-minute rest period, the procedure will be repeated with the opposite ear positioned off-axis. Participants will receive 10 sessions in a 4-week period.
~In addition, participants will perform balance and gait exercises to improve postural stability and mobility and will be provided a written home exercise program."
16593988|NCT02652429|Experimental|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
16593989|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
16593990|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
16593991|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
16593992|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
16593993|NCT02652416|Experimental|Placebo (SRD part)|placebo
16593994|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
16593995|NCT02652403|Active Comparator|Complete conventional dentures|Complete dentures fabricated by conventional technique.
16593996|NCT02652403|Active Comparator|Complete simplified dentures|Complete dentures fabricated by simplified technique
16593997|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
16593998|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
16593999|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
16594000|NCT02652377|Experimental|EDP-494 SAD Cohorts|EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration
16594001|NCT02652377|Experimental|EDP-494 MAD/POC Cohorts|EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days
16594002|NCT02652377|Placebo Comparator|EDP-494 SAD Placebo Cohort|
16594003|NCT02652377|Placebo Comparator|EDP-494 MAD/POC Placebo Cohort|
16594004|NCT02652351|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
16594005|NCT02652338|Active Comparator|MNC-01|potassium, magnesium, and vitamins (MNC-01)
16594006|NCT02652338|Placebo Comparator|Placebo|cellulose, microcrystalline [NF], HPMC E15,
16594007|NCT02652325|Active Comparator|povidone-iodine|
16594008|NCT02652325|Active Comparator|3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP swabs|
16594009|NCT02652325|Placebo Comparator|Saline|
16594010|NCT02652312|Active Comparator|Group 'D'|"Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.
~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.
~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
16594011|NCT02652312|Placebo Comparator|Group 'P'|"Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.
~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.
~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
16594012|NCT02652299||Early Rheumatoid Arthritis group|Following informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
16594013|NCT02652299||Longstanding Rheumatoid Arthritis group|Following informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
16594014|NCT02652299||Control group: Synovial tissue and peripheral blood|20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
16594015|NCT02652286|Other|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
16594016|NCT02652273|Experimental|Abatacept|Abatacept 125mg administered via subcutaneous injection once a week for 24 weeks
16594053|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
16594054|NCT02651974|Active Comparator|Control condition|A control invitation letter similar to the previous standard (non-incentive) invitation with slight wording and grammatical improvements will be mailed to patients randomly assigned to this group.
16594274|NCT02650310|Experimental|Thermostable device transfer|This arm is the study group: embryo transfer protocol using a new thermostable device.
16594017|NCT02652260|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.
16594018|NCT02652260|Experimental|Deferred Switch to Doravirine, Tenofovir, Lamivudine|Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.
16594019|NCT02652247|Experimental|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
16594020|NCT02652247|Experimental|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
16594021|NCT02652247|Experimental|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
16594022|NCT02652247|Experimental|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
16594023|NCT02652234|Experimental|Endostar-subcutaneous injection/Chemotherapy|
16594024|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
16594025|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
16594026|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
16594027|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
16594028|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
16594029|NCT02652182||1|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Huai'an first people's hospital
16594030|NCT02652182||2|patients with acute ST(S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Nanjing Drum Tower hospital
16594031|NCT02652169|Experimental|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
16594032|NCT02652169|Experimental|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
16594033|NCT02652169|Experimental|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
16594034|NCT02652169|Active Comparator|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
16594035|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
16594036|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
16594037|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
16594038|NCT02652143|Experimental|sibling oocytes in vivo|randomized oocytes assigned to in vivo culture
16594039|NCT02652143|Active Comparator|sibling oocyte in vitro|randomized oocytes assigned to in vitro culture
16594040|NCT02652130|Experimental|Safety population|All subjects who participated in Protocol MSB-GVHD001 and received at least one remestemcel-L infusion in that protocol.
16594041|NCT02652091||Interferon beta-1b|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are injecting Betaseron via the Betaconnect device.
16594042|NCT02652078|Sham Comparator|Control|Sham treatment in identical format to treatment arm but without shockwave production
16594043|NCT02652078|Experimental|Shockwave|Active shockwave treatment to calf muscle bulk
16594044|NCT02652065|Active Comparator|Healthy skin|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.
~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
16594045|NCT02652065|Experimental|Psoriasis plaque|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).
~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
16594046|NCT02652052|Other|Group 1: Observational|Observational only
16594047|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
16594048|NCT02652039||cancer patients|
16594049|NCT02652026|Experimental|Treatment Group|The Treatment Group (TG) received full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron, Acteon, Merignac, France) and Gracey curettes (Hu- Friedy, Chicago, USA).Also received Oral Hygienic Instructions
16594050|NCT02652026|Active Comparator|Control Group|The Control Group (CG) received periodontal prophylaxis at baseline, by removal of supragingival deposits (plaque and calculus) with ultrasonic scaler. Also received Oral Hygienic Instructions
16594182|NCT02651025|No Intervention|Passive Stretching Program|Patients included in control group will submit to passive stretching program of lower limbs, during hemodialysis, three times a week, for twelve weeks.
16594055|NCT02651974|Active Comparator|Cost condition|A control invitation letter with the addition of one line informing participants of the average value of the KIT procedure will be mailed to patients randomly assigned to this group.
16594056|NCT02651974|Active Comparator|Cost/Future condition|An invitation letter with the average value of the KIT procedure and a sentence assuring participants that should a follow-up test be requested, it will also be provided free of charge will be mailed to patients randomly assigned to this group.
16594057|NCT02651961|Active Comparator|One stage exchange|One stage exchange of the chronically infected implant
16594058|NCT02651961|Active Comparator|Two stage exchange|Two stage exchange of the chronically infected implant
16594059|NCT02651948|Experimental|Transperineal prostate biopsy (TPB)|Transperineal prostate biopsy MRI-guided
16594060|NCT02651948|Active Comparator|Transrectal prostate biopsy (TRB)|Transrectal prostate biopsy echo-guided
16594061|NCT02651935|Experimental|Intellivent ASV|Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
16594062|NCT02651935|No Intervention|PCV+PSV|PCV+PSV is a conventional ventilation strategy of pressure controlled ventilation PCV) and pressure support ventilation (PSV).In this arm, FiO2, pressure control levels, respiratory frequency and all the ventilator settings will be manually adjusted by the physicians in charge.
16594063|NCT02651909||Rivaroxaban Cohort|Evidence of Rivaroxaban use with-in the last 48hours Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
16594064|NCT02651909||Control cohort not taking Rivaroxaban|Not taking Rivaroxaban - matched to Rivaroxaban group by age gender, type of injury or illness requiring urgent surgery Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
16594065|NCT02651896||HypoIGRT|"Low Risk (T1-T2a, Gleason score 6, and PSA < 10 ng/mL)
~Intermediate Risk (T1-T2c, Gleason 7, and PSA 10-20 ng/mL)
~High Risk (T3 - 4 , Gleason 8-10, and/or PSA > 20 ng/mL) Neoadjuvant hormone therapy is allowed on groups 2 and 3"
16594066|NCT02651883|Active Comparator|Screening invitation (with education)|Participants will receive a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic.
16594067|NCT02651883|Experimental|Self-collection for HPV testing|Participants in the intervention arm will receive a kit to self-collect a sample and return it for HPV testing. Participants will then receive a phone call providing their HPV results plus (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic, if desired.
16594068|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
16594069|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
16594070|NCT02651870|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
16594071|NCT02651857|Experimental|Endoscopy exploratory single arm|
16594072|NCT02651844|Experimental|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
16594073|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.
~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
16594074|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
16594075|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
16594076|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
16594077|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.
~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
16594078|NCT02651805|Experimental|Mechanical Insufflation-Exsufflation Group|Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation
16594079|NCT02651805|Active Comparator|Usual Care Group|Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart
16594080|NCT02651792|Active Comparator|ketamine- propofol|IV Ketamine 1mg/kg + Propofol 1.2 mg/kg will be given for sedation.
16594081|NCT02651792|Active Comparator|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
16594082|NCT02651779|Active Comparator|Closed reduction and plasterimmobilisation|The control group will be treated with closed reduction and cast immobilization. This will take place under local anaesthesia by means of a haematoma block with 20 cc Lidocaine 1%. Closed reduction will be preferably performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilizing wrist and hand in the reduced position. Additional radiographs will be performed to verify the success of the reduction. After this has been confirmed, the wrist will be immobilized initially in a split plaster and later changed into a circular cast for five to six weeks immobilization in total.
16594183|NCT02650999|Experimental|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
16594083|NCT02651779|Other|Open reduction and internal plate fixation|The surgery will be performed by a certified trauma surgeon. According to the current standard treatment protocol, antibiotic prophylaxis will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis muscle and the radial artery. After the fracture site is exposed, the fracture will be reduced and provisionally fixed under fluoroscopy with K-Wires/reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Fracture reduction and screw placement will be confirmed by radiographic images. Additionally, fixation can be supported by a dorsal plate or radial column plate. This will be at discretion of the surgeon and depends on the fracture configuration and the position of the fragments. Wound closure will be performed at the discretion of the surgeon using standard techniques.
16594084|NCT02651766|No Intervention|Waiting List control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
16594085|NCT02651766|Experimental|Cupping massage treatment|Received the 5 cupping treatments, application twice a week on the upper back and neck
16594086|NCT02651753|Experimental|A|"Period 1: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
~Period 2: Test drug(CKD-337), 1 capsule administered under fed conditions."
16594087|NCT02651753|Experimental|B|Period 1: Test drug(CKD-337), 1 capsule administered under fed conditions. Period 2: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
16594088|NCT02651740|Experimental|Combining therapy|taking rifaximin for 3 days and then receiving fecal microbiota transplantation with donor stool through enteral nutrition tube
16594089|NCT02651727|Experimental|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
16594090|NCT02651727|Experimental|Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
16594091|NCT02651727|Experimental|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
16594092|NCT02651714|Placebo Comparator|Placebo|Oral
16594093|NCT02651714|Experimental|Tradipitant|Oral
16594094|NCT02651688|Experimental|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
16594095|NCT02651688|Experimental|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
16594096|NCT02651688|Placebo Comparator|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
16594097|NCT02651675|Experimental|AAV directed hLDLR gene therapy|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
16594098|NCT02651662|Experimental|Open label (cemiplimab)|Experimental cohorts will consist of multiple dose levels of cemiplimab administered intravenously (IV) every 2 weeks (Q2W)
16594099|NCT02651662|Experimental|Open label (cemiplimab and REGN1979)|Experimental cohorts will consist of a single dose level of cemiplimab administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)
16594100|NCT02651649|Experimental|Parturients with FGR/OSA who use CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for Continuous Positive Airway Pressure (CPAP). Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
16594101|NCT02651649|No Intervention|Parturients with FGR/OSA and no CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for CPAP. Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
16594102|NCT02651636|Experimental|Open label|Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
16594103|NCT02651623|Experimental|Sertraline|Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
16594104|NCT02651623|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
16594105|NCT02651623|Placebo Comparator|Drug - Placebo|placebo - placebo administered on Days 1 through 14
16594106|NCT02651610|Active Comparator|Taxane|Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
16594107|NCT02651610|Experimental|Bavituximab plus taxane|Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
16594108|NCT02651597|Experimental|Low Viscous|Low Viscous Beta Glucan Oatmeal
16594109|NCT02651597|Experimental|Medium Viscous|Medium Viscous Beta Glucan Oatmeal
16594110|NCT02651597|Experimental|High Viscous|High Viscous Beta Glucan Oatmeal
16594111|NCT02651584|Experimental|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
16594141|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer Plus|Therapists implement aFRIENDS in the school setting while supported by their supervisor assigned to the Train-the-Trainer Plus (TT+) implementation strategy (supervisors participate in training workshops and receive further/on-going consultation on conducting supervision with active therapists).
16594112|NCT02651584|Experimental|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
16594113|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the chest
16594114|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST & FINGER|Cohort of 10 patients undergoing general anesthesia, monitored by optical signals at the chest and at the fingertip
16594115|NCT02651558|Experimental|OBPM 2015-MD-0022 - FINGER|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the fingertip
16594116|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
16594117|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
16594118|NCT02651532||IBS + Confocal Laser Endomicroscopy|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
16594119|NCT02651532||Control + Confocal Laser Endomicroscopy|Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening
16594120|NCT02651519|Sham Comparator|Control|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
16594121|NCT02651519|Experimental|stellate-ganglion block|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.
16594122|NCT02651506|Experimental|Electromagnetic Navigation Bronchoscopy|
16594123|NCT02651506|Active Comparator|Transthoracic Needle Biopsy|
16594124|NCT02651493|Active Comparator|Down syndrome|photographs of individuals less than 18 yo with Down syndrome
16594125|NCT02651493|Active Comparator|Control group|photographs of individuals less than 18 yo with a genetic referral (not Down syndrome) or a healthy sibling to a child with Down syndrome
16594126|NCT02651480|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, plant-based diet for 14 weeks, and will attend nutrition classes in the form of a weekly support group.
16594127|NCT02651480|Active Comparator|Control Group|The control group will follow an unrestricted diet with no instruction.
16594128|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
16594129|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
16594130|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
16594131|NCT02651454|Experimental|Daesiho-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
16594132|NCT02651454|Experimental|Jowiseungcheung-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
16594133|NCT02651454|Placebo Comparator|Placebo|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
16594134|NCT02651441|Experimental|D-CIK|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.
16594135|NCT02651441|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
16594136|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
16594137|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
16594138|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
16594139|NCT02651402|Active Comparator|FRIENDS for Life Train-the-Trainer|Therapists implement FRIENDS (a CBT protocol for students with anxiety) in the school setting, while supported by their supervisor assigned to the Train-the-Trainer (TT) implementation strategy (supervisors participate in training workshops on conducting supervision with active therapists).
16594140|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer|Therapists implement an adapted version of FRIENDS (aFRIENDS) in the school setting while supported by their supervisor assigned to the TT strategy.
16594142|NCT02651376|Experimental|Conventional plus AAIT|Participants received conventional treatment (anti-opportunistic infections and ART) plus a dose (3 times of MNCs) of AAIT.
16594143|NCT02651363||Patients treated with Dolocordralan|
16594144|NCT02651350|Experimental|Methylprednisolone|Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
16594145|NCT02651350|Active Comparator|Standard Treatment|Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.
16594146|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
16594147|NCT02651324|Experimental|Treatment Group|A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
16594148|NCT02651324|Placebo Comparator|Placebo|A placebo (saline) will be given in place of ketamine
16594149|NCT02651311|Experimental|Block|"ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.
~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4."
16594150|NCT02651311|Placebo Comparator|No block|Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
16594151|NCT02651298|Experimental|Fractional CO2-laser|3 treatments with fractional co2-laser
16594152|NCT02651298|No Intervention|Untreated control|untreated control side of caesarean section scar
16594153|NCT02651285|Experimental|G-CSF|The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF
16594154|NCT02651285|Placebo Comparator|CONTROL|The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.
16594155|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
16594156|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
16594157|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
16594158|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
16594159|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
16594160|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
16594161|NCT02651207||local anaesthetic spray group|women will either chose the above, ethyl chloride spray prior to having their contraceptive implant fitted or the below injection. This comes in a canister and a maximum of 5 spray for 5 seconds will be applied topically to the skin at the site of the contraceptive implant insertion
16594162|NCT02651207||local anaesthetic injection group|women will either chose ethyl chloride spray prior to having their contraceptive implant fitted or the injection, subcutaneous 1% lidocaine, usually a dose of about 1-2 mls to the area skin where the contraceptive implant is to be inserted.
16594163|NCT02651194|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
16594164|NCT02651181|Experimental|Closed Loop System|
16594165|NCT02651168|Other|aflibercept|aflibercept treatment aflibercept, 40 mg/mL Solution for Intravitreal Injection
16594166|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
16594167|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
16594168|NCT02651142|Experimental|SLNB with para-SLN dissection|patients receive sentinel lymph node biopsy patients receive para-sentinel lymph node dissection
16594169|NCT02651142|Experimental|SLNB without para-SLN dissection|patients received sentinel lymph node biopsy
16594170|NCT02651116|Experimental|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
16594171|NCT02651116|Placebo Comparator|Placebo|10 mL of Placebo
16594172|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
16594173|NCT02651090|Experimental|sonazoid|treatment arm with sonazoid
16594174|NCT02651077||Case Group|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at Nantes University Hospital for surgical indication of endometriosis lesions ablation.
16594175|NCT02651077||Control Group|38 women aged 18 to 45 years old without suggestive signs of endometriosis
16594176|NCT02651064|Experimental|HIP|Received a 30% rebate on targeted fruits and vegetables (TFV) purchased using SNAP benefits in participating retailers. TFV earning the rebate included fresh, canned, frozen, and dried fruits and vegetables without added sugars, fats, oils, or salt, excluding white potatoes, mature legumes (dried beans and peas), and 100% juice.
16594177|NCT02651064|No Intervention|Non-HIP|Received SNAP benefits as usual.
16594178|NCT02651051|Sham Comparator|High Fat Breakfast Meal|High fat breakfast meal served without addition of whey protein isolate
16594179|NCT02651051|Experimental|High Fat Breakfast Meal + Whey Protein|High fat breakfast meal served with addition of whey protein isolate
16594180|NCT02651038|Experimental|Micafungin|Micafungin is administered per clinical need and the pharmacokinetic parameters are analyzed
16594181|NCT02651025|Experimental|Resistance Exercise Program|Patients included in intervention group will submit to resistance exercise training during hemodialysis, three times a week, for twelve weeks. This program includes exercises for the upper and lower limbs.
16594184|NCT02650986|Experimental|Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
16594185|NCT02650986|Experimental|Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
16594186|NCT02650973|Experimental|Sequence A|3 doses of CHS-1701 or Neulasta, random order
16594187|NCT02650973|Experimental|Sequence B|3 doses of CHS-1701 or Neulasta, random order
16594188|NCT02650973|Experimental|Sequence C|3 doses of CHS-1701 or Neulasta, random order
16594189|NCT02650947|Experimental|Sucralose|Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
16594190|NCT02650947|Placebo Comparator|Placebo|Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
16594191|NCT02650934||Adverse remodelling|EF below 40% following MI and remain below 40% after reperfusion
16594192|NCT02650934||not adverse remodelling|EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
16594193|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
16594194|NCT02650921|No Intervention|No Intervention|
16594195|NCT02650895|Experimental|CD24Fc|Single dose of CD24Fc is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in CD24Fc and 2 subject in placebo.
16594196|NCT02650895|Placebo Comparator|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
16594197|NCT02650882|Placebo Comparator|placebo|Placebo group (PG) Nine athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a fixed load at 15% MIP, placebo protocol.
16594198|NCT02650882|Experimental|Experimental|Experimental group (EG) Ten athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a progressive load at 60%, 70% and 80 % of MIP.
16594199|NCT02650869|Experimental|Standard care + Breast milk+ Probiotics|The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.
16594200|NCT02650869|Active Comparator|Standard care|The control group will be given standard care without the addition of probiotics
16594201|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.
~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.
~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
16594202|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.
~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.
~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
16594203|NCT02650843||Patients with parkinsonism|Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
16594204|NCT02650830||1) Normal control|metabolically healthy with no obesity
16594205|NCT02650830||2) prediabetes|defined in 'inclusion criteria'
16594206|NCT02650830||3) type 2 diabetes|defined in 'inclusion criteria'
16594207|NCT02650817|Experimental|Elacestrant (formerly RAD1901)|To receive daily oral elacestrant
16594208|NCT02650804|Experimental|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.
~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
16594209|NCT02650791|No Intervention|Prophylactic Platelet Transfusions|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 10^9/L.
16594210|NCT02650791|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 10^9/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions
16594238|NCT02650596|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.
16594239|NCT02650583|Experimental|Supportive care (Enhancing Connections Program)|Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
16594211|NCT02650752|Experimental|Lapatinib in Tandem With Capecitabine|A minimum of one patient at each dose level will be enrolled. Patients will receive a 4 week treatment cycle consisting of lapatinib 3 day on/11 day off in tandem with capecitabine 7 day on/7 day off with lapatinib. Both drugs will be administered orally as outpatient. Safety, toxicity, and DLT will be assessed weekly during the cycle 1 (first 4 weeks). Each patient will be monitored during cycle 1 prior to enrolling the next patient to the next higher dose level. Dose escalation will take place if no DLT or less than two occurrences of grade 2 toxicity (except those listed below) is observed within a given patient. In the event that a second instance of separate grade 2 toxicity (except those listed below) is noted, the cohort will be expanded to 3 patients at the same dose level and the study will revert to the standard 3+3 design with 3 patients per cohort. There will be no intra-patient dose escalation.
16594212|NCT02650739||SS-OCTdetermined group|Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT
16594213|NCT02650739||Control group|Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon
16594214|NCT02650726|Placebo Comparator|control group|The participants in this group are instructed to consume placebo capsules every day during the trial period.
16594215|NCT02650726|Experimental|treatment group|The participants in this group are instructed to consume anthocyanin capsules every day during the trial period.
16594216|NCT02650713|Experimental|Dose-Escalation (Part IA): RO6958688 + Atezolizumab|Participants will receive RO6958688 weekly (QW) at escalating doses starting at 5 mg, in combination with a fixed dose (1200 mg) of atezolizumab every 3 weeks (Q3W). RO6958688 dosage will not exceed the MTD if defined in the BP29541 study.
16594217|NCT02650713|Experimental|Dose/Schedule Finding (Part IB): RO6958688 + Atezolizumab|"Part IB will explore different RO6958688 administration schedules in combination with atezolizumab, consisting of:
~Cohort A: will compare the QW vs Q3W dosing schedules at a flat dose of RO6958688.
~Step Up dosing schedules: RO6958688 dose will start at 40 mg and increase with each administration up to the MTD or 1200 mg, whichever occurs first."
16594218|NCT02650700|Experimental|Chemotherapy plus spleen radiotherapy|Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). The intervention is spleen radiotherapy.
16594219|NCT02650700|Other|Chemotherapy alone|Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy. The intervention is spleen radiotherapy.
16594220|NCT02650687||Elective Non Cardiac Surgical Patients|65 years of age and older
16594221|NCT02650674|Experimental|Product A: NP-0148|Cereal product belVita Milk & Cereals - High in SDS
16594222|NCT02650674|Experimental|Product B: NP-0149|Cereal product belVita Honey & Nuts - High in SDS
16594223|NCT02650674|Experimental|Product C: NP-0150|Cereal product belVita Mixed Berry - High in SDS
16594224|NCT02650674|Experimental|Product D: NP-0151|Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
16594225|NCT02650674|Experimental|Product E: NP-0152|Cereal product Kellogg's Trésor Duo Choco - Low in SDS
16594226|NCT02650674|Experimental|Glucose reference|Glucose solution performed on three occasions
16594227|NCT02650661|Experimental|Online program & Health coaching|"This group is provided with Online health management program, Health coaching and Workshop."
16594228|NCT02650661|Experimental|Online program|"This group is provided with Online health management program."
16594229|NCT02650661|Active Comparator|Enhanced Usual Care|"This group is provided with Standard health educational booklet."
16594230|NCT02650648|Experimental|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10^6/kg in level 1; 14.9x10^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
16594231|NCT02650635|Experimental|Treatment (CTX, pegfilgrastim, TLR8 agonist VTX-2337)|Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
16594232|NCT02650622||Cohort 1-Newborns aged 1-2 days|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
16594233|NCT02650622||Cohort 2-Children aged 0-18 years|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
16594234|NCT02650622||Cohort 3-Diseased childrens and families|Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
16594235|NCT02650609|Experimental|Methylprednisolone|"Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.
~Capsules will be administered orally in the morning, during breakfast with a glass of water.
~Dose is adapted according to the weight of the patient (1mg/kg):
~<60 kg: 3 pills of 16 mg/day
~60-80kg: 4 pills of 16 mg/day
~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
16594236|NCT02650609|Placebo Comparator|Placebo|"Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.
~Dose is adapted according to the weight of the patient (1mg/kg):
~<60 kg: 3 pills of 16 mg/day
~60-80kg: 4 pills of 16 mg/day
~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
16594237|NCT02650596|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.
16594240|NCT02650570||Head/Neck Cancer|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC)
16594244|NCT02650544|Experimental|mirtazapine|Mirtazapine arm will be orally administered with mirtazapine 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
16594245|NCT02650544|Placebo Comparator|Placebo|Placebo arm will be orally administered with placebo 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
16594246|NCT02650518|No Intervention|Control|Subject receives the standard of care that is provided by the primary team taking up his/her case.
16594247|NCT02650518|Experimental|Catheter change+Short-course Antibiotics|
16594248|NCT02650505|Experimental|LEO 43204|LEO 43204 will be applied topically to the skin under open conditions 10 times
16594249|NCT02650505|Placebo Comparator|LEO 43204 vehicle|LEO 43204 vehicle will be applied topically to the skin under open conditions 10 times
16594250|NCT02650492|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
16594251|NCT02650479|Other|IV exenatide - pilot study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
16594252|NCT02650479|Experimental|Treatment Group A - core study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
16594253|NCT02650479|Experimental|Treatment Group B - core study|IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
16594254|NCT02650479|Experimental|Treatment Group C - core study|IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
16594255|NCT02650466|Experimental|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
16594256|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
16594257|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
16594258|NCT02650427|Experimental|DPPIV Inhibition|The study will include 3 weeks administration (± 7 days) of sitagliptin as monotherapy (taken orally). The study will use 3 doses: the first five patients will receive 100 mg/day, the next five 200 mg/day and the last five patients 600 mg/day. During this time, arrangements will be made for surgical resection, as per the standard of care treatment of patients. Blood samples will be obtained for immunology studies. The study will end one week after surgery. Patients will continue their treatment for HCC as prescribed by the clinician.
16594259|NCT02650414|Experimental|CART22 cells|"Subjects <50kg will receive 0.2-1 x 107 CART22 cells/kg as a split dose over three days as follows:
~Day 1, 10% fraction: 0.2-1x106 CART22 cells/kg
~Day 2, 30% fraction: 0.6-3x106 CART22 cells/kg
~Day 3, 60% fraction: 1.2-6x106 CART22 cells/kg
~Subjects ≥50kg will receive 1-5x108 CART22 cells as a split dose over three days as follows:
~Day 1, 10% fraction: 1-5x107
~Day 2, 30% fraction: 0.3-1.5x108
~Day 3, 60% fraction: 0.6-3x108"
16594260|NCT02650401|Active Comparator|Extracranial solid tumors harboring NTRK1/2/3,|"Arm closed for further enrollment
~ROS1, ALK non-gene fusion molecular alterations
~Oral entrectinib (RXDX-101)"
16594261|NCT02650401|Active Comparator|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"Arm closed for further enrollment
~molecular alterations, including gene fusions
~Oral entrectinib (RXDX-101)"
16594262|NCT02650401|Active Comparator|Neuroblastoma|"Arm closed for further enrollment
~Oral entrectinib (RXDX-101)"
16594263|NCT02650401|Active Comparator|Non-neuroblastoma, extracranial solid tumors|"Arm closed for further enrollment
~harboring - NTRK1/2/3, ROS1, ALK gene fusions
~Oral entrectinib (RXDX-101)"
16594264|NCT02650401|Active Comparator|Any participant unable to swallow capsules|"Arm closed for further enrollment
~Any participant who otherwise meet all other eligibility criteria
~Oral entrectinib (RXDX-101)"
16594265|NCT02650401|Active Comparator|Expansion: CNS tumors harboring NTRK1/2/3, ROS1|"gene fusions
~Oral entrectinib (RXDX-101)"
16594266|NCT02650401|Active Comparator|Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1|"NTRK 1,2,3 and ROS1 fusions
~Oral entrectinib (RXDX-101)"
16594267|NCT02650388|Other|Post TAVI neurocognitive outcome|"TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective Eyeball test, Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced."
16594268|NCT02650375|Experimental|Metatinib Tromethamine|
16594269|NCT02650362|Experimental|spinal cord stimulation|
16594270|NCT02650349|Experimental|spinal cord stimulation|The Vectris® SureScan® MRI lead will be connected to a RestoreSensor® SureScan® MRI neurostimulator.
16594271|NCT02650336||CIN proup|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
16594272|NCT02650336||control group|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
16594273|NCT02650310|No Intervention|Conventional transfer|This arm is the control group (conventional embryo transfer protocol) where there is no intervention.
16594830|NCT02646722||severe pain|patients show generalized movement because of pain
16594275|NCT02650297|Experimental|CDT and pneumatic compression pump|combined decongestive therapy consists of the pressure of bandage, manual lymphatic drainage, and exercises that increase the flow of lymph and skin care are used. Intermittent pneumatic pump is not as a part of CDT, but it can be used as an adjunct method. This device according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk.
16594276|NCT02650297|No Intervention|not CDT and pneumatic compression pump|Patients in the control group received no treatment for lymphedema but were placed on the waiting list for CDT as soon as possible after the 8 weeks follow-up period.
16594277|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
16594278|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using Stryker's robotic-arm assisted surgery system Mako
16594279|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
16594280|NCT02650271|Active Comparator|Tenofovir|Patients will be received tenofovir (1#/d) after 3 days of liver resection.
16594281|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
16594282|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
16594283|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 66-69, 70-75, 76-80, 81-85).
16594284|NCT02650245|Experimental|Moderate protein and 10gm lactulose|40% of daily recommended intake of protein based on weight
16594285|NCT02650232|Other|Young Healthy Volunteers|We will evaluate in this group (18 - 40 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
16594286|NCT02650232|Other|Old Healthy Volunteers|We will evaluate in this group (50 - 80 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
16594287|NCT02650232|Other|Patients with heart failure|We will evaluate in this group (50 - 80 y + Heart failure) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
16594288|NCT02650219||gaucher disease type 1|"Inclusion criteria:
~Adult patients >= 18 years old
~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
16594289|NCT02650219||Control|healthy subjects intervention: genetic analyses
16594290|NCT02650206|Experimental|Liraglutide group|"Drug with diet control intervention: Subjects assigned to this group receive blinded pens containing liraglutide (commonly known as Victoza), manufactured by Novo Nordisk. Subjects will inject 0.6 mg daily into abdomen during the first week of the study, and if tolerated, will increase dose to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.
~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
16594291|NCT02650206|Placebo Comparator|Placebo group|"Diet control-only intervention: Subjects assigned to this group receive blinded pens containing placebo (normal saline) instead of liraglutide (commonly known as Victoza). Subjects will inject 0.6 mg of placebo daily during the first week of the study, will increase to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.
~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
16594292|NCT02650193|Experimental|HSP-130|"Cycle 0:
~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)
~Cycles 1-4:
~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.
~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.
~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
16594293|NCT02650180|Other|Soberlink Cellular Device|Soberlink Cellular Device: a Breath Alcohol Analyzer
16594294|NCT02650167|Experimental|Colostrum|
16594295|NCT02650167|Experimental|Witness|
16594296|NCT02650154||Pre-ketamine group|Blood samples are taken prior to the administration of ketamine.
16594297|NCT02650154||Post-ketamine group|Blood samples are taken several hours after the administration of ketamine.
16594298|NCT02650141|Experimental|ziyinxiehuo Granules|Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.
16594299|NCT02650141|Active Comparator|zishenqinggan Granules|Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.
16594300|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
16594301|NCT02650102|Experimental|antipsychotics|This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
16594302|NCT02650102|No Intervention|health control|This group was treated with no invention
16594303|NCT02650089|Experimental|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
16594304|NCT02650089|Experimental|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 8 repetitions were performed for each exercise, with an interval of 90 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
16594305|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
16594306|NCT02650076|Experimental|Healthy|
16594307|NCT02650063|Experimental|DE-117 ophthalmic solution|
16594308|NCT02650050|Experimental|Micropulsed laser photocoagulation|
16594309|NCT02650050|Sham Comparator|Sham micropulsed laser photocoagulation|
16594310|NCT02650011||ACLF cohort|Patients who have chronic liver disease and admitted for acute deterioration of liver function
16594311|NCT02649998|Active Comparator|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
16594312|NCT02649998|Active Comparator|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
16594313|NCT02649998|Active Comparator|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
16594314|NCT02649985|Experimental|Relapsing-Remitting Multiple Sclerosis|"Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, at least one gadolinium enhancing lesion on a MRI within 12 months of enrollment, or at least one new FLAIR bright lesion on MRI within 6 months of enrollment.
~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
16594315|NCT02649985|Experimental|Progressive Multiple Sclerosis|Subjects meeting the definition for SPMS/PPMS (Primary Progressive Multiple Sclerosis) by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year.
16594316|NCT02649985|Active Comparator|Alzheimer's Disease|Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26.
16594317|NCT02649985|Other|Healthy Control|This group will serve as non disease population.
16594318|NCT02649985|Experimental|Multiple Sclerosis Ocrelizumab|"Subjects who have been prescribed Ocrelizumab by their treating MS neurologist but have not yet started the first Ocrelizumab infusion.
~Subjects will undergo two separate visits for [F-18]PBR06 PET scans, once before starting Ocrelizumab and the second visit 3 months after completion of the initial Ocrelizumab doses."
16594319|NCT02649972|Experimental|Cobimetinib|This is an open-label, multicenter, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors. Visits during the treatment period are to be completed on Day 1, Day 15 (this visit can be by telephone), Day 29, and every 28 days thereafter. For patients treated on the study for six months, at the discretion of the Principal Investigator, visits can be spaced out to every 56 days (every 2 cycles instead of every cycle). After 24 cycles of treatment, if imaging demonstrates sustained stability in the opinion of the principal investigator, tumor assessments can be performed ever 1 year.
16594320|NCT02649959|Experimental|Open Label|CM-AT
16594323|NCT02649933||Watch PAt 200|obese pregnant women, pregnancy between 12 and 15 weeks
16594324|NCT02649920|Experimental|Cervical ripening balloon|Prospective
16594325|NCT02649920|Active Comparator|Dinoprostone|Retrospective
16594326|NCT02649907|Experimental|Weight loss|3 months weight loss intervention by behavioral intervention
16594327|NCT02649894|Experimental|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
16594328|NCT02649894|Active Comparator|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
16594329|NCT02649881||isolated heart from heart transplantation|
16594330|NCT02649868|Experimental|1|Treatment of hepatic tumors using bead embolization.
16594331|NCT02649855|Experimental|A/Sequential docetaxel followed by PROSTVAC|Standard ADT followed by sequential docetaxel + prostvac
16594332|NCT02649855|Experimental|B/ Combined docetaxel with PROSTVAC|Standard ADT followed by combined docetaxel + prostvac
16594333|NCT02649855|Experimental|C/ PROSTVAC prior to docetaxel|Standard ADT followed by prostvac, then docetaxel
16594334|NCT02649842|Experimental|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
16594335|NCT02649829|Experimental|Single Arm|dendritic cell vaccination plus chemotherapy
16594336|NCT02649803|Other|community hospital|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the nearest community hospital or Shanghai Children's Medical Center, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to install asthma APP at their smart phone to follow up."
16595168|NCT02644395|Experimental|Chlorthalidone|Testing new indication for approved drug
16594347|NCT02649764|Experimental|Treatment (fludarabine phosphate, cytarabine, prexasertib)|Patients =/< 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients > 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
16594348|NCT02649751|Experimental|Group 1|"200 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
16594349|NCT02649751|Experimental|Group 2|"400 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
16594350|NCT02649751|Experimental|Group 3|"400 mg roscovitine (8) or (4) placebo twice daily for cycles of 7 days (4 days on and 3 days off)"
16594351|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
16594352|NCT02649712|Active Comparator|Unilateral stent|Patients undergo placement of unilateral biliary stent on day 1.
16594353|NCT02649712|Active Comparator|Bilateral stents|Patients undergo placement of bilateral biliary stents on day 1.
16594354|NCT02649699|Other|Additional 3D MRI scans|Participating patients will receive additional 3D MRI scans during pre and post RT planning for their primary brain tumors.
16594355|NCT02649686|Experimental|Durvalumab plus Trastuzumab|Durvalumab q3w until PD Trastuzumab q3w x 6
16594356|NCT02649673|Experimental|LCL161+topotecan+Pegylated GCSF (PEG-GCSF)|"Dose Escalation: Groups of 3-6 patients per dose level (DL) will initiate treatment in escalating doses until the maximum tolerated dose (MTD) is reached. MTD is defined as the highest combination of doses that results in dose-limiting toxicities for 2 of 6 patients per dosing group.
~LCL161: orally, on Days 1, 8, 15 of each 21-day cycle. Maximum dose not to exceed 1200 mg/week.
~topotecan: orally, for first 5 days of each 21-day cycle. Maximum dose not to exceed 2.3 mg/m2 per day.
~Pegylated GCSF (PEG-GCSF) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
~Dose Expansion: 24 additional patients will be treated at the MTD in 2 cohorts (SCLC-12 patients; ovarian cancer-12 patients)"
16594357|NCT02649647|Active Comparator|Conventional Resection|Patients receive conventional resection with standard proximal excision margin. The sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
16594358|NCT02649647|Experimental|Proximally Extended Resection|Patients receive proximally extended resection. The whole sigmoid colon and rectum proximal to the tumor is removed, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
16594359|NCT02649634|Experimental|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
16594360|NCT02649634|Active Comparator|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
16594361|NCT02649621|Experimental|Amniotic Membrane Extract Eye Drop recipient|patients with limbal stem cell Deficiency who receive amniotic membrane transplantation and amniotic membrane extract eye drop as eye drop.
16594362|NCT02649608|Experimental|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
16594363|NCT02649608|Experimental|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
16594364|NCT02649608|Experimental|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
16594365|NCT02649608|Experimental|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
16594366|NCT02649608|Experimental|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
16594367|NCT02649608|Experimental|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
16594368|NCT02649608|Experimental|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
16594369|NCT02649608|Experimental|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
16594370|NCT02649595|Other|Red Cross respite care|A 2 week free stay at a Red Cross respite center after hospitalization.
16594371|NCT02649595|No Intervention|Streets/communal programmes|Homeless being discharged from hospital to the streets and communal programmes.
16594372|NCT02649582|Experimental|Single Arm|Dendritic cell vaccine plus temozolomide chemotherapy
16594373|NCT02649569||Observational (continuous activity monitoring, questionnaires)|Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
16594374|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
16594375|NCT02649556|Active Comparator|CC|Ad libitum use of CC
16594376|NCT02649543|Active Comparator|Primary Closure|Primary Closure is made after surgery.
16594377|NCT02649543|Active Comparator|Delayed Primary Closure|Delayed Primary Closure is made after at least 7 days.
16594378|NCT02649543|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Device is used in the wound.
16594379|NCT02649530|Experimental|WNT974|Patients will receive 10 mg of WNT974 daily by mouth.
16594380|NCT02649517|Other|chronic inflammation|All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
16594381|NCT02649504|Active Comparator|R+3D, MMF|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
16594382|NCT02649504|Placebo Comparator|R+3D, Placebo|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Placebo will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
16594383|NCT02649478|Experimental|Fluticasone / Salmeterol|"fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (LOMI) inhaler device twice a day by inhalation throughout the study"
16594384|NCT02649478|Active Comparator|Advair Diskus 100/50|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
16594385|NCT02649478|Placebo Comparator|placebo inhaler|placebo inhaled powder twice a day by inhalation throughout the study
16594386|NCT02649465|Active Comparator|SGLT2 inhibitor|N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
16594387|NCT02649465|Active Comparator|Sulfonylurea|N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.
16594388|NCT02649452|Experimental|vibration|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
16594389|NCT02649452|Active Comparator|Exercises|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between
16594390|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
16594391|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 months followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
16594392|NCT02649426|Experimental|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
16594393|NCT02649426|Sham Comparator|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
16594394|NCT02649413|Experimental|Early response to prednisone treatment|intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.
16594395|NCT02649400||Diastolic Heart Failure|Women with diastolic heart failure and previous coronary artery disease
16594396|NCT02649387|Experimental|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks* for up to 36 courses in the absence of disease progression or unacceptable toxicity.
~Note: *The last course may last up to 56 days to accommodate the study drug discontinuation visit."
16594397|NCT02649374|No Intervention|Gestational diabetes mellitus|women diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
16594398|NCT02649374|Active Comparator|No GDM, Dietary Modifications|Women without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
16594399|NCT02649374|No Intervention|No GDM, free diet|Women without GDM, for whom diet. exercise are continued regulary without any modifications
16594400|NCT02649361|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16594401|NCT02649361|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16594402|NCT02649348|Other|pre-operative prehabilitation|Patients in the pre-operative prehabilitation group required the exercise intervention protocol, which included climbing six flights of stairs at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction following abdominal surgery by using a full elastic breathable abdominal bandage.
16594403|NCT02649348|No Intervention|Comparator|Patients in the control group did not need to undergo this pre-rehabilitation protocol and prepared conventionally.
16594404|NCT02649335|Active Comparator|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study.
16594405|NCT02649335|Active Comparator|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
16594406|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
16594407|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
16594408|NCT02649309|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
16594409|NCT02649309|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
16594410|NCT02649309|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
16594411|NCT02649309|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
16594412|NCT02649296|Other|Treatment with Skanlab Bodywave|Treatment with Skanlab Bodywave twice a week for four weeks at the affected knee.
16594413|NCT02649296|No Intervention|No treatment|Treatment with Skanlab Bodywave without function twice a week for four weeks.
16594414|NCT02649283|Other|Breast symmetrisation with OrbiSymm|Standard surgical intervention of up to 30 patients including placement of the OrbiSymm device
16594415|NCT02649283|Other|Breast symmetrisation without device|Standard surgical intervention of up to 30 patients without the Orbix device; only routine reduction/symmetrisation intervention
16594416|NCT02649270|Experimental|Group1|10 Psoriasis patients,T1h 0.2mg/kg,only single dose administration at week 1.
16594417|NCT02649270|Experimental|Group2|10 Psoriasis patients,T1h 0.4mg/kg ,first administration at week 1 and continous administration from fifth week for 9 weeks.
16594418|NCT02649270|Experimental|Group3|10 Psoriasis patients,T1h 0.8mg/kg,first administration at week 1 and continous administration from fifth week for 9 weeks.
16594419|NCT02649270|Experimental|Group4|"10 Psoriasis patients,T1h 1.6mg/kg,first administration at week 1 and biweekly from fifth week for 9 weeks.
~."
16594420|NCT02649257|Experimental|MC 6125 AS IOL + CTR|All patients received the same procedure: cataract surgery with phakoemulsification, implantation of a capsular tension ring (CTR13/11) and implantation of an intraocular lens (MC 6125 AS).
16594421|NCT02649244|Experimental|The Family Caregiver Training Program|The experimental group received a 2 hour intervention training on activities of daily throughout the early, middle, and late stages of dementia including communication, eating/feeding, nutrition, bathing, grooming, dressing, toileting, and transferring.
16594422|NCT02649244|No Intervention|Standard Care|The control group received a 1 1/2 hour training, however the information was based on what has been deemed standard care by the Alzheimer's Association.
16594423|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
16594424|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
16594425|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
16594426|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
16594427|NCT02649218|Experimental|Ligelizumab|QGE031 240 mg s.c. q4w x 13 treatments
16594428|NCT02649205||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
16594429|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
16594430|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
16594431|NCT02649179|Experimental|local infiltration with ropivacaine|patients were to receive 0.75% ropivacaine
16594432|NCT02649179|Placebo Comparator|local infiltration with 0.9% saline|patients were to receive placebo
16594433|NCT02649166|Experimental|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Summit RC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
16594434|NCT02649153|Experimental|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus.
16594435|NCT02649153|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
16594436|NCT02649153|No Intervention|empty control|This group patients will not receive gum chewing or smoked plum.
16594437|NCT02649140|No Intervention|Group 1|Group1 is control group and participants do not need intervention.
16594438|NCT02649140|Experimental|Group 2|Group 2 is vinegar Group and participants in this group are asked to drink 15ml vinegar(Ninghuafu, Sanxi, China)after dinner at noon and evening respectively for a period of four weeks.
16594439|NCT02649127|Experimental|Imaginal Therapy Only|The imaginal exercise of exposure therapy will be manualized (Rothbaum, Foa & Hembree, 2007) and adapted with the permission of Dr. Foa for combat-related stress disorders (Peterson, Cigrang & Riggs, 2008). While traditional exposure therapy includes both imaginal exposure and in vivo exposure, this study will use only the imaginal exposure components. Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes.
16594467|NCT02648958|Experimental|Dexmedetomidine group|The dexmedetomidine group received the dexmedetomidine.
16594440|NCT02649127|Experimental|Exercise Only|The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity [>60% of oxygen uptake reserve (VO2R)], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate >60% of their individually-determined heart rate reserve.
16594441|NCT02649127|Experimental|Imaginal Therapy & Exercise Combined|Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes. Participants will exercise listening to their tape at least 5-times/week outside of scheduled unit Physical Training. Participants will wear the heart rate monitor to record their exercise activity.
16594442|NCT02649127|Active Comparator|Nurse-led Self-Care|The Self-Care Group will use written materials that outline the benefits of thinking about problems the individual is facing as well as the benefits of exercise, however doing the two activities together will not be advocated as part of the material. A fact sheet prepared by the National Center for PTSD, Returning from the War Zone: A Guide for Military Personnel as well as a list of coping strategies and self-care behaviors adapted from the National Center for PTSD guide, Self-Care and Self-Help Following Disasters, will be used to guide the discussion. The research nurse will meet with the participant five times over 8-weeks at weeks 1, 2, 4, 6, and 8 to encourage use of the self-care fact sheet and assess the participant for safety.
16594443|NCT02649114|Active Comparator|Cognitive-Behavioural Therapy|This version of CBT is based on techniques employed in evidence-based approaches to a transdiagnostic sample. The programme includes; individualized formulation, taking into account different maintaining factors across cases (e.g., nutritional and/or emotional drivers for binging); agenda setting; homework; change in diet (particularly to improve carbohydrate intake); diary-keeping; exposure; behavioral experiments; cognitive restructuring; and surveys. The behavioral change is maintained as a focus, along with changes in mood and cognitions.
16594444|NCT02649114|Experimental|Compassion-Focused Therapy|There are four main treatment elements to the program. Two of these are linked to the experience of being a therapy group. This involves patients providing compassionate support to other group members.The third treatment element involves compassionate mind training which mainly focuses on activating the soothing system via imagery and related practical exercises.The final element of the program aims to help patients improve their ability to use their wider social network to access support.
16594445|NCT02649101|Experimental|thalidomide plus chemotherapy|thalidomide tablet 100mg qn po
16594446|NCT02649101|Active Comparator|chemotherapy|Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.
16594447|NCT02649075|Active Comparator|SBI 10 g BID|Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
16594448|NCT02649075|Placebo Comparator|Placebo BID|Placebo w/control protein
16594449|NCT02649062|Experimental|NGM282 Dose 1|NGM282
16594450|NCT02649062|Experimental|NGM282 Dose 2|NGM282
16594451|NCT02649062|Placebo Comparator|Placebo|Placebo
16594452|NCT02649049||Patients with NAFLD|Patients with NAFLD are the cases.
16594453|NCT02649049||control group|Healthy people without NAFLD are controls.
16594454|NCT02649036||Emergency call population|Citizens over 18 years old from the Capital Region of Denmark with a first time emergency call within a two-year study period (1/12-2011-30/11-2013)
16594455|NCT02649036||Background population|Citizens over 18 years old from the Capital Region of Denmark with no emergency call within a two-year study period (1/12-2011-30/11-2013)
16594456|NCT02649023||A: Patients with deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A"
16594457|NCT02649023||B: Patients without deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B"
16594458|NCT02649010|Active Comparator|Group A|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
16594459|NCT02649010|Active Comparator|Group B|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
16594460|NCT02648997|Experimental|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
16594461|NCT02648997|Experimental|Cohort 2: Nivolumab in Combination with Ipilimumab|"External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)
~Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks)
~Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
16594462|NCT02648984|Other|Patient group|Patients with ventricular septal defect
16594463|NCT02648984|Other|Control group|Healthy control subjects
16594464|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
16594465|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
16594466|NCT02648958|Placebo Comparator|Control group|The control group received saline instead of dexmedetomidine.
16594468|NCT02648945|Active Comparator|high intensity exercise|"high intensity exercise on a treadmill according to Balke's Protocol.
~high intensity of exercises for each group of 15 participants were set at 80-85% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax
~After rearrangement, it will be:
~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
16594469|NCT02648945|Active Comparator|low intensity exercise|"low intensity exercise on a treadmill according to Balke's Protocol. low intensity of exercises for each group of 15 participants were set at 50-55% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax
~After rearrangement, it will be:
~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
16594470|NCT02648932|Other|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
16594471|NCT02648932|Other|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
16594472|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules, 3 times per day)
16594473|NCT02648906|Experimental|Choline alfoscerate|"Drug: Choline alfoscerate and Donepezil
~concomitant administration"
16594474|NCT02648906|Placebo Comparator|Placebo|Drug: Donepezil only
16594475|NCT02648893|Experimental|MBFC-Exp|The MBFC-Exp (Multiple biofortified food crops - Experimental) arm will consume meals based on biofortified food crops.
16594476|NCT02648893|Active Comparator|MBFC-C|The MBFC-C (Multiple biofortified food crops - Control) arm will consume the same meals based on non-biofortified (commercially available) food crops.
16594477|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
16594478|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
16594479|NCT02648867|Experimental|Patients receiving PushCoach feedback|Patients will receive continuous maternal feedback from the PushCoach device, which includes both audio and visual feedback of fetal head movement during the second stage of labor
16594480|NCT02648867|Active Comparator|Patients blinded to PushCoach feedback|Patients will not receive continuous maternal feedback from the PushCoach device (it will be in place and collect data), but will receive normal feedback from the clinician during the second stage of labor.
16594481|NCT02648854|Other|Group 1|<Group 1> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition)
16594482|NCT02648854|Other|Group 2|<Group 2> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition)
16594483|NCT02648841|Active Comparator|Adjuvant Chemotherapy|The interventions of adjuvant chemotherapy group is 8 cycles of SOX(S-1+Oxaliplatin) chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
16594484|NCT02648841|Experimental|Adjuvant Chemo-radiotherapy|The interventions of adjuvant chemo-radiotherapy group is concurrent chemo-radiotherapy to be give after 4-6 cycles of chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral. Six cycles of SOX chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
16594485|NCT02648828||Intern|Interns are in their first year of residency.
16594486|NCT02648828||Residents|Residents are in their 2nd or 3rd year of residency.
16594487|NCT02648828||Attendings|Attendings are physicians who have completed their residency.
16594488|NCT02648815|Active Comparator|Percutaneous catheter drainage group|Percutaneous catheter drainage (PCD) of necrotic tissue and pathological collections formed during acute pancreatitis
16594489|NCT02648815|Active Comparator|Abdominal paracentesis evacuation group|Abdominal paracentesis drainage (APD) of peritoneal fluid during acute pancreatitis
16594490|NCT02648802|Experimental|Cavity shaving and CM assessment|Standardized BCS with additional cavity shaving before CM assessment.
16594491|NCT02648802|Placebo Comparator|CM assessment|Standardized BCS with CM assessment.
16594492|NCT02648776||Estazolam|Exposure to sedative-hypnotic drugs; Patients who have taken estazolam for at least one week before the first date of enrollment
16594493|NCT02648776||Lorazepam|Exposure to sedative-hypnotic drugs; Patients who have taken lorazepam for at least one week before the first date of enrollment
16594494|NCT02648776||Diazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Diazepam for at least one week before the first date of enrollment
16594495|NCT02648776||Alprazolam|Exposure to sedative-hypnotic drugs; Patients who have taken Alprazolam for at least one week before the first date of enrollment
16594496|NCT02648776||Flunitrazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Flunitrazepam for at least one week before the first date of enrollment
16594497|NCT02648776||Zolpidem|Exposure to sedative-hypnotic drugs; Patients who have taken Zolpidem for at least one week before the first date of enrollment
16594498|NCT02648776||Zopiclone|Exposure to sedative-hypnotic drugs; Patients who have taken Zopiclone for at least one week before the first date of enrollment
16594499|NCT02648776||Control Group|Patients not taking any of the included or any other anxiety-hypnotic agents
16594500|NCT02648750|Experimental|Rehabilitation Assistant|Bridges stroke self-management programme. Delivered by rehabilitation assistants. Participants will receive a minimum of 4 sessions over a 4-6 week period.
16594501|NCT02648750|Active Comparator|Therapist|"Bridges stroke self-management programme. Delivered by registered stroke therapists (Occupational therapists or physiotherapists).
~Participants will receive a minimum of 4 sessions over a 4-6 week period."
16594502|NCT02648737|Experimental|Cognitive Behavioural Therapy (CBT)|Patients who will receive CBT plus clinical monitoring will receive 10 weekly individual sessions (60-75 minutes), tailored to the preferences and needs of each patient. In each session, a registered psychologist will address specified aspects of (coping with) anxiety and related concerns with a specific focus on behaviour and thoughts associated with anxiety.
16594503|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status. Patients who receive clinical monitoring only will be given the option to receive CBT once the trial is completed.
16594504|NCT02648724|Experimental|Part 1: Dose-Escalation|Sym015 will be tested in four dose titration cohorts. A substitute or an additional dose level could potentially be evaluated.
16594505|NCT02648724|Experimental|Part 2: Basket Cohort|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification will receive Sym015 at the RP2D. Included in this group will be a subset of patients who have received prior therapy with a MET-targeting TKI.
16594506|NCT02648724|Experimental|Part 2: NSCLC MET-Amplified Cohort|Patients with advanced NSCLC with MET-amplification will receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
16594507|NCT02648724|Experimental|Part 2: NSCLC METex14del Cohort|Patients with advanced NSCLC with METex14del will receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
16594508|NCT02648711|Experimental|CRLX101 alone|Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2 (or 10 mg/m^2 if 12 mg/m^2 is not well tolerated. No other dose levels will be explored.
16594509|NCT02648711|Experimental|CRLX101 in combination with bevacizumab|Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2. No other dose levels will be explored.
16594510|NCT02648711|Experimental|CRLX101 in combination with mFOLFOX6|Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 and 5FU 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous infusion). The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2.
16594511|NCT02648698|Experimental|Antibiotic group|This group received antibiotic therapy
16594512|NCT02648698|No Intervention|Control group|This group did not receive antibiotic therapy
16594513|NCT02648685||normal glycaemic metabolism|100 subjects
16594514|NCT02648685||Type 2 Diabetes|300 subjects
16594515|NCT02648672|Experimental|BPN14770|A single oral dose of BPN14770.
16594516|NCT02648672|Placebo Comparator|Placebo|A single oral dose of placebo matching BPN14770
16594517|NCT02648659|Experimental|triple with clarithromycin|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks
16594518|NCT02648659|Experimental|triple with metronidazole|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks
16594519|NCT02648659|Experimental|quadruple|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks
16594520|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
16594521|NCT02648633|Experimental|Nivolumab & Valproate Following G.K.|Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
16594522|NCT02648620|Experimental|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
16594523|NCT02648607|Experimental|Customised Orthosis|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
16594524|NCT02648594|Experimental|Intervention: Hook wire CT guided|"There is only one arm. When patient undergo surgery , the radiologist will place a CT-guided Hook wire in order to localize it in patient lung. The intervention consists to place a CT-guided hook wire in contact with the pulmonary nodule under local anesthesia.
~Then, the thoracoscopy will be realised. Then, the surgery piece will be examined to confirm if the node is in the surgery piece"
16594525|NCT02648581|Experimental|Subcutaneous Ustekinumab|
16594526|NCT02648568|Active Comparator|Hypnosis plus relaxation|Ericksonian hypnosis, based on sensations when awakening partially during N3 ; Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
16594527|NCT02648568|Active Comparator|Relaxation|Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
16594528|NCT02648555|No Intervention|Standard follow-up (controls)|Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine.
16594529|NCT02648555|Experimental|W+D protocol (lifestyle intervention)|Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine
16594530|NCT02648542|Active Comparator|CAS vs. tDCS|Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)
16594531|NCT02648542|Sham Comparator|Combined CAS+tDCS vs. Sham|Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation
16594532|NCT02648529|Experimental|Patients with BCECTS|Patients with BCECTS on which MRI, fMRI and neuropsychological assessment will be performed
16594533|NCT02648529|Other|Healthy volunteers|Healthy volunteers on which MRI, fMRI and neuropsychological assessment will be performed
16594534|NCT02648516|Experimental|Conventional plus AAIT|Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 2 study visit.
16594535|NCT02648503|Experimental|Deep neuromuscular block|PTC=1-2
16594536|NCT02648503|Active Comparator|Moderate neuromuscular block|TOF=1-2
16594537|NCT02648490|Experimental|HLX07, in patients with solid cancers.|"Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive weekly infusion of assigned dose of HLX07. No intra-patient dose escalation is allowed.The proposed dose escalation sequence is 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg.
~Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07, followed by dexamethasone 10 mg intravenous infusion for 10 minutes, and followed by diphenhydramine 30 mg intravenous infusion for 10 minutes. If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions."
16594538|NCT02648477|Experimental|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.
~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
16594539|NCT02648477|Experimental|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
16594540|NCT02648464|Experimental|Hydroxychloroquine|Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.
16594541|NCT02648464|Placebo Comparator|Placebo|Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.
16594542|NCT02648451|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES Rome for a period of 9 days
16594543|NCT02648438|Experimental|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
16594544|NCT02648438|Experimental|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
16594545|NCT02648425|Experimental|Regimen A / Amended Regimen A|"Regimen A: Cisplatin + 5-fluorouracil
~ASLAN001 daily in combination with:
~Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles.
~Or
~Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin
~ASLAN001 daily in combination with:
~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles."
16594546|NCT02648425|Experimental|Regimen B|"Regimen B: Cisplatin + capecitabine
~ASLAN001 daily in combination with:
~Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles."
16594547|NCT02648412|Experimental|Ketamine sedation|"Procedure scheduled under ketamine sedation. Baseline pupillary diameter measurement in alert subjects. Injection of a bolus of 1 mg/kg of ketamine. Every minute, tetanic stimulations of incremental intensities (10-20-30-40-60 milliamps), during 5 seconds.
~Pupillary diameter measurement before and after each stimulation. End of study period, beginning of procedure."
16594548|NCT02648399|Placebo Comparator|control group|only unilateral center lymph node dissection
16594549|NCT02648399|Experimental|experimental group|bilateral center lymph node dissection
16594550|NCT02648386|Sham Comparator|Laparoscopic surgery|Patients receive no interventions after rectal cancer treatment.
16594551|NCT02648386|Experimental|NeuroRegen scaffold transplantation|Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.
16594552|NCT02648386|Experimental|NeuroRegen scaffold/BMMCs transplantation|Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
16594553|NCT02648386|Experimental|NeuroRegen scaffold/HUC-MSCs transplantation|Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
16594554|NCT02648373|Experimental|Education|Patients receive an educational video about low back pain based on the Consumer Reports Choosing Wisely recommendation for patients with back pain to avoid early imaging and remain as active as possible. After the video the evaluator and patient discussed key themes from the video and the patient was able to ask any questions. Previously scheduled physical therapy then began with treatment at the therapist's discretion.
16594555|NCT02648373|Active Comparator|Control|Previously scheduled physical therapy was provided with treatment at the therapist's discretion. No educational intervention was provided before beginning physical therapy
16594556|NCT02648360|Experimental|Text Messaging Intervention Arm|Participants will be enrolled in either a dietary or physical activity text messaging program. The dietary program will include nutritional education, reading nutrition labels, portion control, making lifestyle changes, finding social support, and identifying triggers. The physical activity program will provide information on the benefits of physical activity, exercise tips, and encouragement to live more active lifestyles. The programs have limited interactive capability; patients will be asked to respond to specific questions, but questions asked by the participants will be answered with an automated message asking them to contact their health care provider.
16594557|NCT02648347|Experimental|vadadustat|
16594558|NCT02648347|Active Comparator|darbepoetin alfa|
16594567|NCT02648256|Experimental|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:
~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.
~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
16594568|NCT02648243|No Intervention|Control|Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
16594569|NCT02648243|No Intervention|Pharmacist delivered usual care at discharge|Patients will receive the usual counseling at discharge by the clinical pharmacists.
16594570|NCT02648243|Experimental|structured intervention at discharge and tailored follow up|The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
16594571|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
16594572|NCT02648217|Experimental|IDegAsp U100 BID|
16594573|NCT02648217|Active Comparator|BIAsp U100 BID|
16594574|NCT02648204|Experimental|Semaglutide 0.5 mg/Week|
16594575|NCT02648204|Experimental|Semaglutide 1.0 mg/Week|
16594576|NCT02648204|Active Comparator|Dulaglutide 0.75 mg/Week|
16594577|NCT02648204|Active Comparator|Dulaglutide 1.5 mg/Week|
16594578|NCT02648191|Experimental|Active stimulation|
16594579|NCT02648191|Sham Comparator|Inactive stimulation|
16594580|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
16594581|NCT02648178|Active Comparator|HALO Triton|HALO tank model
16594582|NCT02648165|Experimental|ABM +|Attention Bias Modification
16594583|NCT02648165|Sham Comparator|ABM -|Sham Attention Bias Modification
16594584|NCT02648165|Experimental|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
16594585|NCT02648165|Sham Comparator|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
16594586|NCT02648139|Experimental|Experimental dentifrice|Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
16594587|NCT02648139|Active Comparator|Control Dentifrice|"Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%)
~Intervention protocol: three times per day (pea-like amount), for seven consecutive days."
16594588|NCT02648126|Other|Pure red cell aplasia participants|Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.
16594589|NCT02648113|Experimental|Restrictive transfusion strategy|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
16594590|NCT02648113|Experimental|Liberal transfusion strategy|Transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL.
16594591|NCT02648100||A|120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
16594592|NCT02648100||B|510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
16594593|NCT02648100||C|188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
16594594|NCT02648100||D|93 patients from the clinical trial GETUG 19 (UNICANCER)
16594595|NCT02648087|Other|With and without SDB|comparison of patients with and without sleep-disordered breathing
16594596|NCT02648074|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation.
16594597|NCT02648074|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).
~Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation."
16594598|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
16594599|NCT02648048|Experimental|Vismodegib and Pirfenidone|Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
16594600|NCT02648035||Subcutaneous Tocilizumab|Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
16594601|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
16594602|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
16594603|NCT02648009|Other|Healthy Volunteers|"Arm 1
~Group 1A: control male volunteers between 19 and 50 years of age.
~Group 1B: control female volunteers between 19 and 50 years of age.
~Group 1C: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice
~Group 1D: control male volunteers between 19 and 50 years of age.
~Group 1E: control female volunteers between 19 and 50 years of age.
~Group 1F: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice"
16594639|NCT02647814|No Intervention|Usual Care|The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
16594831|NCT02646709|Experimental|Ketamine 1|Ketamine 1 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
16594604|NCT02648009|Other|Hypertension Hypertrophy Volunteers|"Arm 2
~Group 2A: patients aged 30 to 75 with hypertension and hypertrophy
~Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM).
~Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.
~Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.
~Group 2E: patients aged 30 to 75 with hypertrophy
~Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM).
~Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.
~Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents."
16594605|NCT02647996||Conscious patients|"group: TBI patients awoken from comatose state with normal level of consciousness.
~intervention: fMRI (resting state) and structural (DTI)"
16594606|NCT02647996||DOC patients|"group: TBI patients awoken from comatose state with abnormal level of consciousness
~intervention: fMRI (resting state) and structural (DTI)"
16594607|NCT02647983|Experimental|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection to be used a MRI contrast agent.
16594608|NCT02647970|Experimental|Group A|Dietary intervention
16594609|NCT02647970|Active Comparator|Group B|Dietary intervention
16594610|NCT02647957|Experimental|Group A|Hospital using Code Stroke
16594611|NCT02647957|No Intervention|Group B|Hospital not using Code Stroke
16594612|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
16594613|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
16594614|NCT02647931|Experimental|Voice Therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia patients.
16594615|NCT02647918|Experimental|Group 1|Subjects with normal renal function
16594616|NCT02647918|Experimental|Group 2|Subjects with mild renal impairment
16594617|NCT02647918|Experimental|Group 3|Subjects with moderate renal impairment
16594618|NCT02647918|Experimental|Group 4|Subjects with severe renal impairment
16594619|NCT02647918|Experimental|Group 5|Subjects with ESRD requiring HD
16594620|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
16594621|NCT02647892|Active Comparator|Arm A|10 mg/mL lidocaine; Frequency: 1
16594622|NCT02647892|Active Comparator|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
16594623|NCT02647892|Active Comparator|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
16594624|NCT02647892|Active Comparator|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
16594625|NCT02647879||Hepatitis C infected|All patients diagnosed with hepatitis C in Iceland
16594626|NCT02647866|Experimental|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
16594627|NCT02647866|Experimental|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
16594628|NCT02647866|Experimental|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
16594629|NCT02647866|Experimental|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
16594630|NCT02647866|Placebo Comparator|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
16594631|NCT02647853|Experimental|TAT4 Gel concentration A|TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
16594632|NCT02647853|Experimental|TAT4 Gel concentration B|TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
16594633|NCT02647853|Placebo Comparator|Placebo|Placebo product once daily to 50 cm2 for 14 days.
16594634|NCT02647840|Other|Voice therapy|All participants will receive voice therapy based on the Estill model. This is very similar to our usual intervention.
16594635|NCT02647827|Active Comparator|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
16594636|NCT02647827|Active Comparator|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
16594637|NCT02647827|Active Comparator|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
16594638|NCT02647814|Experimental|Salud al Día|The participants in the intervention group will receive interactive text-messages with a link to support if needed for: clinic appointment reminders, follow-up on medicine and referral adherence, and illness care needs and use. Participants will additionally receive reminders for insurance renewal, food stamp applications, and health-promoting community events. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
16594640|NCT02647801|Experimental|Mindfulness intervention|The experimental group comes to weekly laboratory meetings and practices mindfulness. Participants also fill out self-report questionnaires which assess self-control and mindfulness.
16594641|NCT02647801|No Intervention|Control group|The control group comes to weekly laboratory meetings and fills out self-report questionnaires which assess self-control and mindfulness. No mindfulness training is carried out.
16594642|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
16594643|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
16594644|NCT02647775|Other|multi-port VATS|Multi-port VATS is an operative method
16594645|NCT02647775|Other|single-port VATS|Single-port VATS is an operative method
16594646|NCT02647762|Experimental|CF101 1mg|CF101 1mg, orally q12 hours
16594647|NCT02647762|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
16594648|NCT02647762|Active Comparator|MTX once weekly|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.
16594649|NCT02647762|Placebo Comparator|Placebo|Placebo control , orally q12 hours
16594650|NCT02647749|Experimental|Group 1 : Cardiac rythm radiofrequency ablation|Prospective recruitment
16594651|NCT02647749|Experimental|Group 1: Implantation or programming of a pacemaker|Prospective recruitment
16594652|NCT02647749|Experimental|Group 1: Risk of serious arrhythmias or sudden death|Prospective recruitment
16594653|NCT02647749|Active Comparator|Group 2: Cardiac rythm radiofrequency ablation|Retrospective recruitment
16594654|NCT02647749|Active Comparator|Group 2 : Implantation or programming of a pacemaker|Retrospective recruitment
16594655|NCT02647749|Active Comparator|Group 2 : Risk of serious arrhythmias or sudden death|Retrospective recruitment
16594656|NCT02647736|Experimental|Copeptin values in normo- to hyperosmolar states|
16594657|NCT02647723|Experimental|Oral supplement for pregnant women|450 mg/daily of DHA beginning at 10-16 weeks of gestation through the end of pregnancy
16594658|NCT02647723|Placebo Comparator|Sugar pill|450 mg/daily of sugar pill beginning at 10-16 weeks of gestation through the end of pregnancy
16594659|NCT02647710|Experimental|PHAT Life Intervention|PHAT Life: Preventing HIV/AIDS Among Teens, is a uniquely-tailored intervention designed for recently-arrested juvenile offenders on probation. The program will teach teens about HIV/AIDS, sexually transmitted infections, and safer decision-making. PHAT Life draws on social learning theory and a Social-Personal Framework to address individual and social mechanisms related to HIV-risk, including emotion regulation, peer norms, partner communication, relationship characteristics, and HIV/AIDS/STI and substance use knowledge, attitudes, and beliefs.
16594660|NCT02647710|Active Comparator|Health Promotion Control|A health promotion program focusing on nutrition, physical activity, substance use, and sexual health.
16594661|NCT02647697|Experimental|Radiprodil|Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.
16594662|NCT02647684|Experimental|Self- Direced Triple P|Self-directed Triple P workbook to be completed over 10 weeks. Over the course of the workbook parents will think about the changes they would like to make to their child's behaviour. They are taught strategies to enhance their relationship with their child, and promote desirable behaviours. They learn about options for managing problem behaviours and have the opportunity to decide if they would like to use any of these approaches with their child in a clear and consistent way. Parents have practice period to use the approaches they have learnt in weeks 1-3. By the end of week 6 they will have had practice in using their chosen positive parenting approaches, learnt to set goals and monitor their own behaviour when using these strategies. The final weeks aim to help parents identify times when the strategies may not be working and provide survival tips on what to do at these times.
16594663|NCT02647671|Experimental|Aquamin®|Experimental: Aquamin® (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
16594664|NCT02647671|Active Comparator|Calcium Carbonate|Active Comparator: Calcium Carbonate (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
16594665|NCT02647671|Placebo Comparator|Placebo|Placebo (Maltodextrin) - 4 capsules; 2 to be taken in the morning and 2 in the evening
16594666|NCT02647658|Experimental|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy (GBC+PIPT)
16594667|NCT02647658|Active Comparator|GBC|Guideline Based Care (GBC)
16594668|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
16594669|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
16594670|NCT02647632|Experimental|16 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 16 weeks
16594671|NCT02647632|Experimental|24 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 24 weeks
16594672|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
16594673|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
16594674|NCT02647606|Experimental|McGrath Group|MgGrath videolaryngoscope will be used for nasotracheal intubation with MILS
16594675|NCT02647606|Experimental|Pentax-AWS Group|Pentax-AWS videolaryngoscope will be used for nasotracheal intubation with MILS
16594676|NCT02647606|Experimental|Macintosh Laryngoscope Group|Macintosh Laryngoscope will be used for nasotracheal intubation with MILS
16594677|NCT02647593||gallstone hepatitis group,|gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),
16594678|NCT02647593||control group|control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)
16594679|NCT02647567|Experimental|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
16594680|NCT02647567|Placebo Comparator|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
16594681|NCT02647554|Experimental|Ulinastatin group|Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.
16594682|NCT02647554|Placebo Comparator|Placebo group|Placebo control group：Matching with medication
16594683|NCT02647541|Experimental|Nutritional intervention|Consultation with a dietitian, including nutritional recommendations and supplementation.
16594684|NCT02647541|No Intervention|Standard therapy|No specific nutritional recommendations.
16594685|NCT02647528|Experimental|Treatment|Patients in this arm receive treatment
16594686|NCT02647528|Placebo Comparator|Placebo|Patients in this arm do not receive treatment
16594687|NCT02647515|Experimental|ranibizumab|
16594688|NCT02647502|Active Comparator|Continuous calorie restriction|Participants will be provided with a diet that includes approximately 78% of calories each day that would be needed to maintain current BMI.
16594689|NCT02647502|Experimental|Intermittent calorie restriction|Participants will be provided a diet that with a daily calorie intake required to maintain current BMI, except only 25% of this calorie intake will be provided for 2 days a week.
16594690|NCT02647502|Placebo Comparator|Control calorie intake|Participants will be assigned to consume enough calories each day required to maintain current BMI
16594691|NCT02647489|Experimental|1A - 20 µg PAMVAC + Alhydrogel|The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
16594692|NCT02647489|Experimental|2A - 20 µg PAMVAC + GLA-SE|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
16594693|NCT02647489|Experimental|3A - 20 µg PAMVAC + GLA-LSQ|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
16594694|NCT02647489|Experimental|4A - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
16594695|NCT02647489|Experimental|5A - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
16594696|NCT02647489|Experimental|6A - 50 µg PAMVAC + GLA-LSQ|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
16594697|NCT02647489|Experimental|1B - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
16594698|NCT02647489|Experimental|2B - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
16594699|NCT02647489|Experimental|3B - 100 µg PAMVAC + Alhydrogel|The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
16594700|NCT02647489|Experimental|4B - 100 µg PAMVAC + GLA-SE|The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
16594701|NCT02647489|Placebo Comparator|5B - Placebo|The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)
16594702|NCT02647476|Experimental|Study group|Immunomodulating nutrition (Reconvan)
16594703|NCT02647476|Active Comparator|Control group|Standard nutrition (Peptisorb)
16594704|NCT02647463|Experimental|Attachment and Biobehavioral Catch-up|10-session intervention for parents and infants aimed at increasing parents' nurturance and following the lead, and reducing frightening behavior
16594705|NCT02647463|No Intervention|Waitlist Control|Waitlist Control
16594706|NCT02647450||GIANT Clinic Group|Patients are required to have been refereed to the GI and Nutrition team Clinic at the Royal Marsden Hospital. In the clinic they will be assessed for their symptoms using the Gastrointestinal Symptom Rating Scale (GSRS).
16594707|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
16594708|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
16594709|NCT02647424|Other|PCOS group|PCOS women with anovulation
16594710|NCT02647424|Other|Ovulatory group|Ovulatory group planned for intra-uterine insemination
16594711|NCT02647411||Projeto Boa Visão|Review of records between 1995 and 2000, in totality of 16.806 patients between 2 and 40 years old
16594712|NCT02647411||Projeto Olhar Brasil|Review of records between March and September 2014, in totality of 163 patients between 6 and 18 years old
16594713|NCT02647398|Experimental|A: Supervised combined training|INTERVENTION: Two supervised 75 min-vigorous aerobic training & strength training
16594714|NCT02647398|Active Comparator|B: Supervised strength training|ACTIVE COMPARATOR: Two supervised 45-minute sessions of strength training & Participants will be advised to comply with international recommendations of physical activity (150 min pf MVPA)
16594715|NCT02647385|Experimental|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
16594716|NCT02647385|Experimental|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
16594717|NCT02647372|Experimental|Endocrinological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be endocrinological evaluation including metabolic measures, calorimetric parameters.
16594718|NCT02647372|Experimental|Neurological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be neurological evaluation including UPDRS scale.
16594752|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
16594832|NCT02646709|Experimental|Ketamine 1.5|Ketamine 1.5 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
16594719|NCT02647359|Experimental|Ataluren|Participants will receive ataluren orally 3 times a day (TID) at a dose of 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 48 weeks in Stage 1 (double-masked period) and for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
16594720|NCT02647359|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren TID orally in the morning, at midday, and in the evening for 48 weeks in Stage 1 (double-masked period) and ataluren orally TID at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
16594721|NCT02647346|Experimental|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
16594722|NCT02647333|Experimental|Omega-3 fatty acid|Omega-3 fatty acids for 8 weeks, dosage are 3 and 4 g/day for women and men, respectively.
16594723|NCT02647333|Experimental|Omega-6 fatty acid|Omega-6 fatty acids for 8 weeks, dosage are 20 and 27 g/day for women and men, respectively.
16594724|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
16594725|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
16594726|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
16594727|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
16594728|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
16594729|NCT02647307|Experimental|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg).
16594730|NCT02647294|Experimental|Polyunsaturated omega-3 fatty acids|Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.
16594731|NCT02647294|Placebo Comparator|Placebo|Patients will receive placebo (soya oil)
16594732|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
16594733|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
16594734|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
16594735|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
16594736|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
16594737|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
16594738|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
16594739|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
16594740|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
16594741|NCT02647268|No Intervention|Control (no oxytocin) pretreatment|The myometrial samples are bathed in physiological saline solution (PSS).
16594742|NCT02647268|Active Comparator|Magnesium Sulphate|The myometrial samples are bathed in a 3.5mM magnesium sulphate solution.
16594743|NCT02647268|Active Comparator|Magnesium Sulphate + oxytocin|The myometrial samples are bathed in a 3.5mM magnesium sulphate plus 10-5M oxytocin solution.
16594744|NCT02647255|Experimental|PE and methylprednisolone pulse|Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange >7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
16594745|NCT02647255|Active Comparator|Methylprednisolone pulse|Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
16594746|NCT02647242|Experimental|Patients with parkinson's disease|Patients with parkinson's disease
16594747|NCT02647229|Active Comparator|Isosmotic bowel cleansing preparation|Isosmotic solution ingested prior to colonoscopy
16594748|NCT02647229|Active Comparator|Colonic Hyrdrotherapy|Colonic hydrotherapy is an FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician.2 There
16594749|NCT02647216|Active Comparator|Mindfulness Based Cognitive Therapy (MBCT)|MBCT is a structured 8-week group intervention which integrates aspects of cognitive behavioral therapy (CBT) with components of the Mindfulness Based Stress Reduction (MBSR) program.
16594750|NCT02647216|Active Comparator|Treatment as Usual (TAU)|Subjects randomized to TAU will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study (for the TAU group) and outside of the study (for the MBCT group) will be assessed at the 3-month follow up (Visit 3).
16594751|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
16594753|NCT02647190|Experimental|Erwinia Chrysanthemi asparaginase|This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.
16594754|NCT02647177||Pancreatic Cyst Group|Only the eligible participant in the study are considered for inclusion in this group.
16594755|NCT02647151|Active Comparator|METHYLAMINOLEVULINATE HYDROCHLORIDE|METHYLAMINOLEVULINATE HYDROCHLORIDE (MAL)cream 160mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
16594756|NCT02647151|Experimental|AMINOLEVULINIC ACID HYDROCHLORIDE|AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
16594757|NCT02647138|Experimental|White Noise|Subject will have white noise machine placed in room.
16594758|NCT02647125|Experimental|Huachansu Arm|Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.
16594759|NCT02647125|Active Comparator|Control Arm|Patients in this arm will receive thoracic radiotherapy alone.
16594760|NCT02647112|Experimental|Bladder EpiCheck|Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology
16594761|NCT02647112|No Intervention|Practice of medicine|Practice of medicine including cystoscopy and cytology
16594762|NCT02647099|Active Comparator|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
16594763|NCT02647099|Placebo Comparator|Placebo|One tablet placebo orally once daily for three years
16594764|NCT02647086|Experimental|Period 1|Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)
16594765|NCT02647086|Experimental|Period 2|Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).
16594766|NCT02647073|Experimental|Mobile monitoring device arm|Canary 01 Mobile Vital Signs Monitoring Device
16594767|NCT02647060||idiopathic pulmonary hypertension|"diagnose as idiopathic pulmonary arterial hypertension
~clinical stable over 3 months
~able to walk and can do bicycle cardiopulmonary exercise testing"
16594768|NCT02647060||secondary pulmonary hypertension|"diagnose as pulmonary hypertension
~clinical stable over 3 months
~able to walk and can do bicycle cardiopulmonary exercise testing"
16594769|NCT02647047|Experimental|Spinal|Patients will receive spinal analgesia (morphine 0.2 mg) before general anesthesia for minor laparotomic liver resection.
16594770|NCT02647047|Active Comparator|Epidural|Patients will receive epidural analgesia (bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL) before general anesthesia for minor laparotomic liver resection.
16594771|NCT02647034||pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
16594772|NCT02647034||non-pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
16594773|NCT02647021|Active Comparator|Therapeutic Exercise|"Therapeutic Exercise Program (standard care) will include:
~Neck range of motion and strengthening, and posture retraining.
~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function."
16594774|NCT02647021|Experimental|Therapeutic + Lower Body Exercise|"The Therapeutic Exercise Program (standard care) will include:
~Neck range of motion and strengthening, and posture retraining.
~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function.
~The Resistance Exercise component will target 6-8 muscle groups of the lower extremities and core including gluteal, quadriceps, hamstrings, abdominals, and gastrocnemius muscles. A progressive introduction of exercises will occur over the first 3 weeks.
~a personalized program of lower extremity resistance exercises
~core strengthening exercises"
16594775|NCT02647008|Experimental|ACTIVE TENS|ACTIVE TENS
16594776|NCT02647008|Placebo Comparator|PLACEBO|INACTIVE TENS
16594777|NCT02647008|No Intervention|CONTROL|NO TENS
16594778|NCT02646995|Experimental|Active|modified lipid formulation
16594779|NCT02646995|Active Comparator|Control|fish oil
16594780|NCT02646982|Experimental|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) >100 mm Hg, diastolic blood pressure (DBP) >40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
16594781|NCT02646982|Placebo Comparator|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
16594782|NCT02646969|Active Comparator|Formula regimen 1|"Product Control from enrollment to transition phase 1 (blinded administration), followed by open label administration for 2 months.
~Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old"
16594783|NCT02646969|Active Comparator|Formula regimen 2|Product Test 1 from enrollment to transition phase 1 (blinded administration) Product Control for 2 months(open label) Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old
16594784|NCT02646969|No Intervention|Reference group|Infants fed HM exclusively through at least 4 months of age. Once breastfeeding is over and if wished Infant will receive Product test 2 until 1 year old followed by the commercial follow-up formula
16594785|NCT02646956||Age Group-Children|Children between ages of 7 and 14
16594786|NCT02646956||Age Group-Adults|Healthy adults who are the parent of the children
16594824|NCT02646748|Experimental|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.
~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
16594825|NCT02646735|Experimental|Fulvestrant|Fulvestrant 500 mg
16594787|NCT02646943||Cohort of patients with chronic chagas cardiomyopathy|"We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice.
~The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG."
16594788|NCT02646930|Experimental|Incidence of CE|To determine rates of CE in women undergoing initial IVF and outcomes
16594789|NCT02646917|Active Comparator|SkinPen II|Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.
16594790|NCT02646917|Active Comparator|SkinPen Precision|Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.
16594791|NCT02646904|Experimental|Beclometasone Dipropionate (BDP)|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.
16594792|NCT02646904|Active Comparator|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
16594793|NCT02646891|Placebo Comparator|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
16594794|NCT02646891|Experimental|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
16594795|NCT02646891|Experimental|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
16594796|NCT02646891|Placebo Comparator|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
16594797|NCT02646891|Experimental|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
16594798|NCT02646891|Experimental|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
16594799|NCT02646891|Placebo Comparator|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
16594800|NCT02646891|Experimental|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
16594801|NCT02646891|Experimental|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
16594802|NCT02646891|Experimental|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
16594803|NCT02646878|Other|Harmony 1 Sensor Group A|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 90 minutes after sensor insertion.
16594804|NCT02646878|Other|Harmony 1 Sensor Group B|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 12 hours after sensor insertion.
16594805|NCT02646865|Experimental|Self-Compassion Enhanced Cognitive-Behavioral Therapy|Group Cognitive-Behavioral Therapy for social anxiety enhanced with exercises targeting self-compassion
16594806|NCT02646865|Active Comparator|Cognitive-Behavioral Therapy|Standard Group Cognitive-Behavioral Therapy for social anxiety
16594807|NCT02646852|Experimental|PLX038 Q3W|intravenous infusion once every 3 weeks
16594808|NCT02646852|Experimental|PLX038 QW ×2|intravenous infusion once weekly for 2 consecutive weeks of a 4-week cycle
16594809|NCT02646839|Experimental|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
16594810|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
16594811|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
16594812|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
16594813|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
16594814|NCT02646813|Active Comparator|Intraluminal Placement|These patients will have the Arndt endobronchial blocker placed within the endotracheal tube for lung isolation during their thoracic surgery. The observer will measure time required to place blocker correctly prior to surgery.
16594815|NCT02646813|Experimental|Extraluminal Placement|These patients will have the Arndt endobronchial blocker placed outside of the endotracheal tube for lung isolation during their thoracic surgery. The investigator will measure the time required for placement.
16594816|NCT02646800|Experimental|Micafungin group|Intravenous (IV)
16594817|NCT02646787|Experimental|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
16594818|NCT02646787|Experimental|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
16594819|NCT02646787|No Intervention|Control|No intervention during the subject's standard wound care session
16594820|NCT02646774|Experimental|Micafungin group|Injection
16594821|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
16594822|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
16594823|NCT02646748|Experimental|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
16594833|NCT02646709|Experimental|Ketamine 2|Ketamine 2 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
16594834|NCT02646696||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
16594835|NCT02646696||Typically Developing Children|typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
16594836|NCT02646683|Other|Early Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)
~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
16594837|NCT02646683|Other|Late Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)
~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
16594838|NCT02646670|Active Comparator|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml . This group will be five about patients about any age, with diabetic macular edema randomly chosen
16594839|NCT02646670|Active Comparator|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml. This group will be about five patients about any age, with diabetic macular edema randomly chosen
16594840|NCT02646670|Active Comparator|Ranibizumab and Aflibercept|- In this group will be held two applications of 0.1 ml Aflibercept(the first and the third doses) interspersed with one application of Ranibizumab 0.1 ml(the second dose). This group will be about five patients about any age, with diabetic macular edema randomly chosen
16594841|NCT02646670|Active Comparator|Aflibercept and Ranibizumab|- This group will be held two applications of Ranibizumab 0.1 ml(the first and the third doses) interspersed with one application of Aflibercept 0.1 ml(the second dose). This group will be five about patients about any age, with diabetic macular edema randomly chosen
16594842|NCT02646657|Other|Early UC|Patients with 'early UC' defined as disease duration < 4 years and no other treatments than aminosalicylates and/or corticosteroids
16594843|NCT02646657|Other|Late UC|Patients with 'late UC' defined as active disease despite treatment with immunosuppressives (IS) and/or anti-TNF. Patients wih intolerance to IS AND anti-TNF will also be allowed in the latter group.
16594844|NCT02646644||Metastasized intestinal NET|We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
16594845|NCT02646631|Experimental|Usual Treatment|
16594846|NCT02646631|Experimental|MORE|
16594847|NCT02646631|Active Comparator|MORE + MI|
16594848|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
16594849|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
16594850|NCT02646605||patients initiating ART|HIV positive men and women initiating ART
16594851|NCT02646605||patients on established ART|HIV positive men and women on established ART
16594852|NCT02646592|Experimental|alfentanil|"Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.
~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery."
16594853|NCT02646579|Experimental|Spinal and Peripheral Dry Needling|Participants will receive dry needling to the low back and painful areas in the leg.
16594854|NCT02646579|Active Comparator|Peripheral Dry Needling|Participants will receive dry needling to painful areas in the leg.
16594855|NCT02646566|Experimental|APD421 standard|Single (standard) dose IV APD421
16594856|NCT02646566|Experimental|APD421 high|Single (high) dose IV APD421
16594857|NCT02646566|Placebo Comparator|Placebo|Single IV placebo
16594858|NCT02646553||Children refered to the obesity clinic.|All children refered to the obesity clinic for examination and optionally treatment are invited.
16594859|NCT02646540|Experimental|Tolvaptan 30 mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 30 mg of tolvaptan concomitantly with their standard dose of diuretics.
16594860|NCT02646540|Active Comparator|Metolazone 5mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 5mg metolazone concomitantly with their standard dose of diuretics.
16594861|NCT02646540|Active Comparator|IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive two and a half (2.5) times their standard dose of diuretics.
16594862|NCT02646527|Experimental|DT+|Dignity Therapy is conducted with patients and partners
16594863|NCT02646527|Experimental|DT|Dignity Therapy is conducted only with patients
16594864|NCT02646527|No Intervention|SPC|standard palliative care
16594865|NCT02646514|Experimental|RFA with RF catheter (ELRA®) with stenting|
16594866|NCT02646514|Active Comparator|stenting|
16594867|NCT02646501|Experimental|group A+PSGB|(Antiarrhythmic drug + percutaneous stellate ganglion block) group
16594869|NCT02646488|Active Comparator|Cluster 1|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
16594870|NCT02646488|Active Comparator|Cluster 2|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
16594871|NCT02646488|Active Comparator|Cluster 3|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
16594872|NCT02646488|Active Comparator|Cluster 4|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
16594873|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
16594874|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
16594875|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
16594876|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
16594877|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method - presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in EKG; and acute pulmonary edema - will be treated with HD.
16594878|NCT02646436|Other|PD treatment|Patients stage 5 (creatinine clearance < 15 ml/min) requiring dialysis treatment immediately without absolute contraindication to the PD method will receive unplanned PD treatment. High volume PD (HVPD) will be used during the first 7 days of PD in order to achieve metabolic and fluid control. The procedure for acute PD has been published recently by our team . At this point, patients will be discharged from hospital and they will be treated by intermitent PD at the dialysis unit of the University Hospital.until their family be trained and home be prepared for the implementation of technique.
16594879|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
16594880|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
16594881|NCT02646410|Other|FPD+NDOT|Fixed-point delivery (FPD) combined with non directly observed treatment (NDOT)
16594882|NCT02646410|Other|FPD+DOT|Fixed-point delivery (FPD) combined with directly observed treatment (DOT)
16594883|NCT02646410|Other|DDD+NDOT|door-to-door delivery (DDD) combined with non directly observed treatment (NDOT)
16594884|NCT02646410|Other|DDD+DOT|door-to-door delivery (DDD) combined with directly observed treatment (NDOT)
16594885|NCT02646397|Experimental|Fosinopril,benidipine combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.
16594886|NCT02646397|Experimental|Fosinopril,hydrochlorothiazide combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.
16594887|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
16594888|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
16594889|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
16594890|NCT02646358|Experimental|Cohort 1: Normal Renal Function|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
16594891|NCT02646358|Experimental|Cohort 2: Mild Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
16594892|NCT02646358|Experimental|Cohort 3: Moderate Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
16594893|NCT02646358|Experimental|Cohort 4: Severe Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
16594894|NCT02646358|Experimental|Cohort 5: End Stage Renal Disease|Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours
16594895|NCT02646345||Pre Checklist|All surgical encounters before surgical checklist implementation
16594896|NCT02646345||Post Checklist|All surgical encounters after surgical checklist implementation
16594897|NCT02646332|Experimental|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
16594898|NCT02646332|Active Comparator|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
16594899|NCT02646319|Experimental|Treatment (nanoparticle albumin-bound rapamycin)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
16594937|NCT02646059|Experimental|Telephone group|Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
16594938|NCT02646059|No Intervention|Control group|No intervention will be giving to this group.
16594939|NCT02646046|Experimental|Combi lone-CPR|"Intervention group
~: Newly developed method"
16594900|NCT02646306||Shoulder Impingement Syndrome|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
16594901|NCT02646306||Healthy Subjects|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
16594902|NCT02646280|Experimental|Massage therapy and contact experience|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading associated with a preparation to the contact phase of the massage using the typical elements of neurocognitive rehabilitation such as motor imagery, dynamic state during which a person mentally simulates an action, and language, necessary to understand the way of perceiving and organizing sensory, cognitive and phenomenological informations by the patients and so to interpretate pain in a more articulate way.
16594903|NCT02646280|Active Comparator|Massage therapy|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading.
16594904|NCT02646267|Experimental|standard intensity warfarin group|standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)
16594905|NCT02646267|Experimental|low intensity warfarin group|low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)
16594906|NCT02646267|Active Comparator|dabigatran etexilate group|110mg dabigatran etexilate was administrated twice a day
16594907|NCT02646254|Active Comparator|blood cardioplegia|these patients received blood cardioplegia
16594908|NCT02646254|Active Comparator|del nido cardioplegia|these patients received del nido cardioplegia
16594909|NCT02646241|Experimental|unroofing biopsy|
16594910|NCT02646241|Active Comparator|EUS-FNB|
16594911|NCT02646228||molecular profiling, patient derived cells|
16594912|NCT02646215|Active Comparator|Inspiratory muscle training group|Threshold inspiratory muscle training
16594913|NCT02646215|No Intervention|Control group|No training
16594914|NCT02646202|Active Comparator|Sclerotherapy group|thirty patients treated by sclerotherapy for OV using ethanolamine oleate 5%.
16594915|NCT02646202|Active Comparator|Endoscopic band ligation group|thirty patients treated by endoscopic banding using the Euro-Ligator system.
16594916|NCT02646202|Experimental|Sclero-ligation (SL) group|thirty patients treated by intra variceal endoscopic sclerotherapy combined with band ligation.
16594917|NCT02646189|Experimental|REP 2139-Ca + immunotherapy|"REP 2139-Ca is the calcium chelate complex formulation of REP 2139.
~Zadaxin is thymosin alpha 1
~Pegasys is pegylated interferon alpha 2a
~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is > 2000 copies / ml.
~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys."
16594918|NCT02646163|Experimental|REP 2055|Treatment with REP 2055
16594919|NCT02646150||critical limb ischemia|
16594920|NCT02646137|Active Comparator|Transarterial chemoembolization (TACE)|treated by transarterial chemoembolization
16594921|NCT02646137|Experimental|Radiofrequency ablation with TACE|Radiofrequency ablation combined with TACE
16594922|NCT02646137|Experimental|Microwave ablation combined with TACE|Microwave ablation combined with TACE.
16594923|NCT02646124|Experimental|Diazepam|Naproxen +Diazepam
16594924|NCT02646124|Active Comparator|Placebo|Naproxen + Placebo
16594925|NCT02646111|Experimental|Genotype 1b without cirrhosis|12 weeks without Ribavirin
16594926|NCT02646111|Experimental|Genotype 1b with cirrhosis|12 weeks with Ribavirin
16594927|NCT02646111|Experimental|Genotype 1a without cirrhosis|12 weeks with Ribavirin
16594928|NCT02646111|Experimental|Genotype 1a with cirrhosis|24 weeks with Ribavirin
16594929|NCT02646098|Active Comparator|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
16594930|NCT02646098|No Intervention|No CD34+ cell selection|No CD34+ cell selection
16594931|NCT02646085|Experimental|Intervention|C11 Methionine positron emission tomography (PET/CT) studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 10 millicuries of C11 Methionine will be injected intravenously. Approximately 60 minutes following tracer injection, the patient will be positioned on a Siemens Biograph PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first with while the patient is free breathing. PET will be acquired at 3 minutes per bed position using the 3D mode, approximately 6-7 bed positions. C11 Methionine PET/CT imaging will take less than 60 minutes.
16594932|NCT02646072|Active Comparator|Diabetes mellitus patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
16594933|NCT02646072|No Intervention|Diabetes mellitus control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
16594934|NCT02646072|Active Comparator|Non diabetic patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
16594935|NCT02646072|No Intervention|Non diabetic control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
16594936|NCT02646059|Experimental|Text group|Text messages containing reminds of blood donation information would be sent to donors in this group.
16594940|NCT02646046|Active Comparator|Conventional lone-CPR|Conventional CPR group
16594941|NCT02646033||robotic surgery|all those patients aged 40 - 60 years undergoing robotic surgeries, who does not have any ophthalmic complains.
16594942|NCT02646020|Experimental|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
16594943|NCT02646020|Active Comparator|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28
16594944|NCT02646007|Experimental|BM-MSC|Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienböck's disease.
16594945|NCT02645994|Experimental|Target Controlled Infusion|Propofol is administered through a target controlled infusion pump based on Marsh model to achieve a BIS of 50 and manually adjusted to maintain BIS between 40 and 60
16594946|NCT02645994|Active Comparator|Closed Loop Anesthesia Delivery System|Propofol is administered through Closed Loop Anesthesia Delivery System which is titrated automatically to achieve a target BIS of 50 and maintain it between 40 and 60.
16594947|NCT02645981|Experimental|Donafenib|Drug:Donafenib; Dose:200mg,bid,po.
16594948|NCT02645981|Active Comparator|Sorafenib(Nexavar)|Drug:Sorafenib; Dose:400mg,bid,po.
16594949|NCT02645955||Control group, disease history|people who didn't have disease history of Maintenance Hemodialysis
16594950|NCT02645955||The MHD patient group, diseases history|Maintenance Hemodialysis Patients
16594951|NCT02645942|Experimental|Intervention group|L-carnitine 1400 mg daily for 8 weeks
16594952|NCT02645942|Placebo Comparator|Placebo group|Placebo
16594953|NCT02645916|Experimental|DSGOST|admission to Danggui-Sayuk-Ga-Osuyu-Saenggang-tang granule
16594954|NCT02645916|Placebo Comparator|Placebo|admission to placebo
16594955|NCT02645903|Active Comparator|transversus abdominis plane block|"Patients who received a tranversus abdominis plane block with ultrasound after standard general anesthesia represented Group 1.
~The tranversus abdominis plane block was performed bilaterally by obtaining an image with real time ultrasound guidance with a 6-13 MHz linear probe.
~The block was placed with a 22 G 80 mm needle while obtaining real-time images via an in-plane technique.
~Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline. These were administered to the left and right abdominal walls.
~Postoperative analgesia was administered through a morphine the patient-controlled analgesia device."
16594956|NCT02645903|Placebo Comparator|nonblocked|Patients who received standard general anesthesia alone made up Group 2. Postoperative analgesia was administered through a morphine the patient-controlled analgesia device.
16594957|NCT02645890|Active Comparator|CKD-397|Tadalafil/ Tamsulosin Fixed dose combination
16594958|NCT02645890|Experimental|TD+TM|Tadalafil/ Tamsulosin Coadministration
16594959|NCT02645877||Prehospital care|All pre-hospital service data were collected from January 2005 to December 2014 from the Beijing Emergency Center and Beijing Red Cross Emergency Center, which oversee all pre-hospital care in Beijing. The major illnesses were classified into 34 disease spectrum categories according to the Medical Priority Dispatch System (MPDS) which total includes 34 diseases. Data on pre-hospital emergency demand and first aid-related time intervals were analyzed to determine trends over the period.
16594960|NCT02645864|Experimental|Apatinib and Irinotecan|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and irinotecan 150mg q2w. Cohort 2: apatinib 500 mg per day and irinotecan 150mg q2w. Cohort 3: apatinib 750 mg per day and irinotecan 150mg q2w.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event
~Grade 3 non-hematologic toxicity including fever, nausea, vomiting, and diarrhea that continues despite optimal medical management) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will stop and the dose of combination treatment in this cohort will be documented."
16594961|NCT02645851|Experimental|"PLR-induced SV changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
16594962|NCT02645851|Experimental|"PLR-induced PP changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
16594963|NCT02645851|Other|Usual Care|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
16594964|NCT02645838|Experimental|Motivational interviewing group|"Structural motivational interviewing for one section (about 20 mins)，provided by family physician
~Follow-up telephone call，provided by family physician"
16594965|NCT02645838|No Intervention|Brief advice group|Brief advice without motivational interviewing (about 5 mins), provided by family physician
16594966|NCT02645799|Active Comparator|LABR-312|"LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.
~Three (3) doses will be tested:
~Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.
~OCT follow-up will be performed at 9 months."
16594998|NCT02645591|Experimental|Nerve Sparing RARP + AmnioFix®|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
16594967|NCT02645799|Placebo Comparator|saline|"Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.
~Three (3) doses will be tested:
~Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.
~OCT follow-up will be performed at 9 months."
16594968|NCT02645786||Case|"Differentiated thyroid cancer group:
~who received total- or near-total thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD) of Chuncheon Sacred Heart Hospital.
~1) age less than 45 years old when receiving total or near-total thyroidectomy, 2) serum level of TSH<0.1 mU/L in the intermediate recurrence-risk or TSH<0.3 mU/L in the low recurrence-risk group13, 14 over 2 years before study entry, 3) receiving TSH suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and 4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea and chest discomfort) during therapy."
16594969|NCT02645786||Control|"Control group As each DTC patient was enrolled, control subjects were selected from patients who visited endocrinology department for thyroid nodule work-up. The control group had to meet the following criteria
~1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), 2) within the reference range of serum TSH (0.3-4.6 mU/L), 3) no history of structural heart disease, arrhythmia, or cardiac symptoms, 4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension."
16594970|NCT02645773|Experimental|Pre-laser|non-ablative laser Laser Pre-wounding low dose laser Pre-wounding medium dose laser Pre-wounding high dose
16594971|NCT02645773|Experimental|Immediate-laser|non-ablative laser Laser low dose - immediate after wounding Laser medium dose - immediate after wounding Laser high dose - immediate after wounding
16594972|NCT02645773|Experimental|Post-laser|non-ablative laser Laser low dose - post wounding Laser medium dose - post wounding Laser medium dose - post wounding
16594973|NCT02645773|No Intervention|Control|Untreated control wound
16594974|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
16594975|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
16594976|NCT02645747||Group 1|The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
16594977|NCT02645734|Active Comparator|Injection intravitreous bevacizumab|Injection intravitreous bevacizumab at a dose 1.25mg
16594978|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 1.25 mg|Injection ziv-aflibercept at dose of 1.25 mg
16594979|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 2.5 mg|Injection ziv-aflibercept at dose of 2.5 mg
16594980|NCT02645721|Experimental|Extended self-help program with guidance|The program is a comprehensive CBT program lasting 12 weeks, with as many modules. The modules are quite extensive. A guide with basic education in psychotherapy assists and counsels participants online.
16594981|NCT02645721|Active Comparator|Briefer Self-help program, no guidance|This self-help program also lasts 12 weeks but contains only 9 modules; a pause occurs during the final weeks of the program for self-testing of acquired skills. The modules are quite brief. Participants receive no guidance.
16594982|NCT02645721|Other|WL: Extended self-help program, choice of guidance intensity|Participants will be put on a waiting list. After 12 weeks on the waiting list, participants will receive access the the extended self-help program used in the experimental arm. However, participants will be offered a choice between three guidance options of varying intensity: proactive guidance, reactive guidance (only at participant request) or no guidance.
16594983|NCT02645708|Other|Retrograde Intrarenal Surgery (RIRS)|Patients in Group 1 undergo Retrograde Intrarenal Surgery
16594984|NCT02645708|Other|EPVL after RIRS|"Patients in Group 2 undergo external physical vibration lithecbole after Retrograde Intrarenal Surgery.
~with the help of changing the position and direction of the extracorporeally physical vibration machine, the urinary stone was discharged from the urinary collecting system"
16594985|NCT02645695|Active Comparator|routine pulmonary rehabilitation|routine pulmonary rehabilitation consisted of position giving technique
16594986|NCT02645695|Active Comparator|chest wall vibration technique|chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours.
16594987|NCT02645682|Experimental|anti-infection CVC (Certofix®protect)|intervention group
16594988|NCT02645682|Active Comparator|normal CVC (Certofix®)|control group
16594989|NCT02645669|Experimental|Study site|Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture
16594990|NCT02645669|Placebo Comparator|Control site|Only Scaling and Root planing (SRP) was performed
16594991|NCT02645656|Experimental|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals.
16594992|NCT02645643|Experimental|intervention group|Medical students rolled into this group would accept education of medical humanities.
16594993|NCT02645643|No Intervention|control group|Medical students rolled into this group would not gain education of medical humanities.
16594994|NCT02645630|Experimental|Right Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the right side.
16594995|NCT02645630|Experimental|Left Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the left side.
16594996|NCT02645630|Active Comparator|Sham Cervical Manipulation|Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
16594997|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
16594999|NCT02645591|Active Comparator|Nerve Sparing RARP|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
16595000|NCT02645578|Experimental|RMNS group|Focus intervention: right median nerve stimulation plus standard management
16595001|NCT02645578|No Intervention|Control group|Standard management
16595002|NCT02645565|Active Comparator|Low dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
16595003|NCT02645565|Active Comparator|High Dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
16595004|NCT02645552|Experimental|Tranexamic acid|Focused intervention
16595005|NCT02645552|Placebo Comparator|Sodium chloride|Placebo control
16595006|NCT02645539|Experimental|Single Arm|All patients are treated with the intravascular ventricular assist system (iVAS).
16595007|NCT02645526|Experimental|KMC with woolen cap|In this group, the head of the patients will be covered with a woolen cap during KMC.
16595008|NCT02645526|No Intervention|KMC without woolen cap|In this group, the head of the patients will be uncovered during KMC.
16595009|NCT02645513|Experimental|Malaria-only text messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to malaria diagnosis and treatment.
16595010|NCT02645513|Experimental|Malaria, pneumonia, and diarrhea messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to diagnosis and treatment of malaria, pneumonia, and diarrhea
16595011|NCT02645513|Placebo Comparator|Control|No text message reminders to health workers, just the usual health system supports.
16595012|NCT02645500|Experimental|Physical activity message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to physical activity.
~The training workshop include one core session and one booster session at one month.
~Daily messages in relation to physical activity will be sent to the participants."
16595013|NCT02645500|Active Comparator|Healthy diet message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to healthy diet .
~The training workshop include one core session and one booster session at one month.
~Daily messages in relation to healthy diet will be sent to the participants."
16595014|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
16595015|NCT02645474|Active Comparator|Paravertebral block with ropivacaine|Patients are treated with an older technique (paravertebral block with ropivacaine), somehow established in treating pain after breast surgery. This technique has been shown to be effective but has an intrinsic risk of iatrogenic pneumothorax and is considered technically demanding.
16595016|NCT02645474|Experimental|PECS block with ropivacaine|Patients are treated with PECS block, which has been already adopted in common clinical practice as an alternative to paravertebral block for postoperative pain treatment after breast surgery. This technique is thought to be somehow simpler to perform and safer with regard to pneumothorax, however no studies have been done yet to statistically compare the two blocks with regard to safety and effectiveness.
16595017|NCT02645461|Active Comparator|Riluzole|Riluzole 50 mg twice daily in ALS patients
16595018|NCT02645461|Experimental|PEA plus Riluzole|Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
16595019|NCT02645448|Other|Resistance Exercise Low intensity|"Day 1 (Control Session)
~Day 2 (Resistance Exercise)
~Day 3 (Duration of effect)"
16595020|NCT02645448|Other|Resistance Exercise High intensity|"Day 1 (Control Session)
~Day 2 (Resistance Exercise)
~Day 3 (Duration of effect)"
16595021|NCT02645435|Active Comparator|Hip direct anterior approach|Patients with hip arthritis
16595022|NCT02645435|Active Comparator|Lateral hip approach|Patients with hip arthritis
16595023|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
16595024|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
16595025|NCT02645383|Active Comparator|PASCAL group|Patients undergone PASCAL laser photocoagulation
16595026|NCT02645383|Active Comparator|Conventional group|Patients undergone conventional laser photocoagulation
16595027|NCT02645370|Active Comparator|Active Comparator:Topiramate|The treatment with TPM is initiated at a 50 mg daily dose and sequentially increase every 7 days, as tolerated, in 25 mg increments up to a target dose of 150 mg total/day.
16595028|NCT02645370|Experimental|Experimental:Danzhen|The treatment with Danzhen is 3 tablets triple daily.
16595029|NCT02645357|Experimental|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
16595030|NCT02645357|Other|Control group|No on-screen, point-of-care computer reminders on clinical practice.
16595031|NCT02645344|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Low frequency rTMS at 1 Hz was applied over P5 of the contralesional hemisphere in addition to conventional rehabilitation
16595032|NCT02645344|Experimental|rTMS combined with sensory cueing (SC)|Vibration cueing was emitted using a wristwatch device on the hemiplegic arm combined with low frequency rTMS in addition to conventional rehabilitation
16595033|NCT02645344|Active Comparator|Conventional rehabilitation|Physical therapy and occupational therapy
16595034|NCT02645331|Experimental|Remind-to-move|RTM involved a wristwatch device worn on more-affected arm which emitted sensory cueing continuously to remind the children to use the more-affected hand to engage in daily activities or complete bimanual tasks intensively, 5 hour per day, 5 days every week, for 3 consecutive weeks.
16595169|NCT02644382||Key Informant interviews|20 in-person or phone qualitative interviews with patients.
16595035|NCT02645331|Active Comparator|Modified constraint induced movement therapy (mCIMT)|children were encouraged to wear a customer-made volar resting splint that extended from below the elbow to the fingertips on their noninvolved hands for 5 hour daily except for toileting, writing and specific physical sports, for 3 weeks. Each child was supervised by one therapist to complete structured unimanual practice with the affected hand during the supervised session, 5 days every week, for 3 consecutive weeks.
16595036|NCT02645331|Placebo Comparator|Conventional rehabilitation|Conventional splinting, muscle strengthening, stretching, and neurodevelopmental facilitation techniques for 1hr daily, 2 day per week for 3 weeks.
16595037|NCT02645305|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.
16595038|NCT02645292|Experimental|1 mile Walk using treadmill|Walking for 1 mile on treadmill (American Motion Fitness, 8800D) as fast as participant can, without any inclination
16595039|NCT02645292|Experimental|Stair Climbing|30 meters of vertical distance to be covered (14 flights of stairs with a total of 154 steps)
16595040|NCT02645279|Active Comparator|oral 30% glucose|oral 30% glucose total 200 mg/kg with 0.5-1 mL increments
16595041|NCT02645279|Active Comparator|IV midazolam|intravenous administration of midazolam 0.1 mg/kg
16595042|NCT02645266|Experimental|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
16595043|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
16595044|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
16595045|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
16595046|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
16595047|NCT02645240|Experimental|Heparin injection|Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
16595048|NCT02645227|Active Comparator|Group 1|Open flap debridement (OFD)
16595049|NCT02645227|Active Comparator|Group 2|OFD with Platelet rich fibrin (PRF)
16595050|NCT02645227|Active Comparator|Group 3|OFD with PRF and 1.2% Rosuvastatin
16595051|NCT02645214|Placebo Comparator|Control scrubs (non-antiseptic)|subject will wear control scrubs for the duration of a 12-hour ICU shift
16595052|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 1|subject will wear antiseptic impregnated scrubs-type 1 for the duration of a 12-hour ICU shift
16595053|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 2|subject will wear antiseptic impregnated scrubs-type 2 for the duration of a 12-hour ICU shift
16595054|NCT02645201|Active Comparator|Probiotic|Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days
16595055|NCT02645201|Placebo Comparator|Placebo|Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days
16595056|NCT02645188|Experimental|Experimental|Cueing
16595057|NCT02645188|No Intervention|Control|
16595058|NCT02645175|Experimental|TW1025|TW1025 oral solution, 20ml, 3 times per day (daily dose: 60 ml)
16595059|NCT02645175|Placebo Comparator|Placebo|TW1025 oral solution matched placebo, 20ml, 3 times per day
16595060|NCT02645162|Experimental|Preschool|"This arm will receive the community-based preschool intervention.
~The preschool sessions will include 2 groups per day (3 years 6months to 4 years 6 months in the morning session and 4 years 7 months to 5 year 6 months in the afternoon session at the time of enrolment)
~Each session will last 3 hours for 5 days per week.
~The expected CYL-to-child ratio will be 1:15; however, given the expected high level of local demand it may exceed to a maximum of 1:20 ratio."
16595061|NCT02645162|No Intervention|Control|The control group will receive standard services available in the community.
16595062|NCT02645149|Experimental|No actionable genetic aberration/available targeted therapy|Patients with BRAF and NRAS wild type tumour for whom there is no actionable genetic aberration in tumour tissue or no available matched targeted theray. These patients will receive trametinib based upon the known MAPK excess activity in the majority of melanomas that may be inhibited by a MEK inhibitor.
16595063|NCT02645149|Experimental|Matched targeted therapy|Patients with BRAF and NRAS wild type tumour for whom there is a targeted therapy available, will receive targeted drug matched to gene defect in tumour. If a patient cannot receive the matched targeted therapy because of the existence of one or more drug specific exclusion criteria, an alternative matched therapy may be assigned, or trametinin, or clinical trials if available.
16595064|NCT02645149|Experimental|Mucosal melanoma|Patients with mucosal melanoma and BRAF V600 and NRAS wild type tumour will receive trametinib with ribociclib. A large proportion of mucosal melanomas (47/67, 70%) harbour alterations (CDK4 and CCND1 amplifications, as well as CDKN2A deletions) potentially responsive to CDK4/6 and MEK inhibitors. In addition, although not identified as a significantly mutated driver, a number of samples also had CDK6 amplifications (9/67, 13%) that indicates potential sensitivity to CDK4/6 inhibitors.
16595065|NCT02645149|Other|BRAF / NRAS mutant melanoma|Patients with BRAF / NRAS mutations in tumour tissue will be treated with standard approved targeted therapies (dabrafenib and trametinib) or on clinical trials, and will be followed for clinical response and survival outcomes.
16595066|NCT02645136|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
16595067|NCT02645136|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation (AES) associated with Pelvic Floor Muscle Training (PFMT), supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
16595068|NCT02645136|Placebo Comparator|Control|Control Group
16595128|NCT02644668|Experimental|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
16595069|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
16595070|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
16595071|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
16595072|NCT02645110|Experimental|MC Hand soap|For bacterial removal trial: Hand washing with the tested soap following bacterial application
16595073|NCT02645110|Sham Comparator|Water|For bacterial removal trial: Hand washing with tap water alone following bacterial application
16595074|NCT02645097|Active Comparator|Proximal saphenous nerve block|The anesthesiologist will administer a saphenous proximal nerve block if specified in the randomization envelope.
16595075|NCT02645097|Active Comparator|Distal saphenous nerve block|The anesthesiologist will administer a saphenous distal nerve block if specified in the randomization envelope.
16595076|NCT02645084|Active Comparator|Intervention|Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
16595077|NCT02645084|No Intervention|Control|Control: Hospital-based standard practice for the detection of colorectal cancer patients with hereditary or familial colorectal cancer, informed by the referral criteria that are being used in the intervention group
16595078|NCT02645071|Experimental|Physical activity|The experimental arm is a 15-20 min interactive session, which aims to reduce participants' sedentary behavior and increase physical activity by increasing their motivation, self-efficacy, and knowledge of different types of easy exercises.
16595079|NCT02645058|Experimental|RIRS (retrograde intrarenal surgery)|In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones > 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
16595080|NCT02645058|Experimental|ESWL (extracorporeal shockwaves lithotripsy)|In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
16595081|NCT02645045||Dry eye|Patients with dry eye syndrome
16595082|NCT02645045||normal|Patients without dry eye
16595083|NCT02645032|Experimental|Test group|Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
16595084|NCT02645032|Active Comparator|Comparator group|"Biological/Vaccine:
~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).
~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28)."
16595085|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
16595086|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
16595087|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
16595088|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
16595089|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
16595090|NCT02645006|Experimental|Intervention arm- 3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
16595091|NCT02645006|Other|Control arm- 1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention
16595092|NCT02644993|Experimental|Proton beam therapy|
16595093|NCT02644980|Experimental|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
16595094|NCT02644980|Experimental|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
16595095|NCT02644967|Experimental|Arm 1|IMO-2125 intratumoral injection plus ipilimumab
16595096|NCT02644967|Experimental|Arm 2|IMO-2125 intratumoral injection plus pembrolizumab
16595097|NCT02644954|Active Comparator|Metformin|Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily
16595098|NCT02644954|Placebo Comparator|Placebo|Topical coal tar and topical calcipotriol
16595099|NCT02644941|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
16595100|NCT02644941|Active Comparator|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
16595167|NCT02644395|Active Comparator|Amlodipine|Current treatment of choice
16595101|NCT02644915|Experimental|study group|"Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.
~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
16595102|NCT02644915|Placebo Comparator|control group|"100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.
~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
16595103|NCT02644902|Experimental|Technology Arm|5 days training of health workers in THP through avatar assisted cascade training and supervision
16595104|NCT02644902|Active Comparator|Specialist Arm|5 days training and supervision of health workers in THP by specialists
16595105|NCT02644889||Patients advanced NSCLC EGFR mutated|This is an observational study, there is no intervention.
16595106|NCT02644876|Experimental|Penehyclidine group|Penehyclidine inhalation will be administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
16595107|NCT02644876|Placebo Comparator|Control group|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
16595108|NCT02644863|Experimental|DC-CIK|After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.
16595109|NCT02644863|Sham Comparator|Chemotherapy|After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.
16595110|NCT02644837|Active Comparator|i-Gel and AuraGain|"In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.
~Interventions with both devices will be
~Insertion of the laryngeal mask airway
~Assessment of ease of insertion
~Ability to perform positive pressure ventilation
~Measurement of OLP
~Fibreoptic assessment with Ambu A-scope
~Ability to insert nasogastric tube
~Record number of manipulations
~An assessment of device related trauma"
16595111|NCT02644837|Active Comparator|AuraGain and i-Gel|"In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.
~Interventions with both devices will be
~Insertion of the laryngeal mask airway
~Assessment of ease of insertion
~Ability to perform positive pressure ventilation
~Measurement of OLP
~Fibreoptic assessment with Ambu A-scope
~Ability to insert nasogastric tube
~Record number of manipulations
~An assessment of device related trauma"
16595112|NCT02644824|Experimental|Biventricular Pacing (BiVp)|Consented infants with wide QRS randomized to receive standard of care and BiVp.
16595113|NCT02644824|No Intervention|Control (wide QRS)|Consented infants with wide QRS randomized to receive standard of care alone.
16595114|NCT02644824|No Intervention|Control (narrow QRS)|This is an observation control group. Consented infants with narrow QRS will enter control group 2 without randomization.
16595115|NCT02644811|Experimental|Group A - Miniscrews|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.
~Fixed appliance in the maxilla or maxilla and mandible.
~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs."
16595116|NCT02644811|Active Comparator|Group B - Molarblock|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.
~Fixed appliance in the maxilla or maxilla and mandible.
~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs."
16595117|NCT02644798||ARDS patients|ARDS patients in Han nationality
16595118|NCT02644759|Experimental|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
16595119|NCT02644746|Experimental|Acupuncture group|Acupuncture has a long time used for chronic pain including low back pain, sciatica, and other pain related to spina via stimulating specific acupuncture points.
16595120|NCT02644746|Placebo Comparator|Placebo needle group|The placebo needle using in this trial will be unpenetrated needles. Based on our previous research, the placebo needle is a valid control for acupuncture research and may eliminate the placebo effect of acupuncture.
16595121|NCT02644720|Experimental|multifocal intraocular lens group|
16595122|NCT02644720|Active Comparator|monofocal intraocular lens group|
16595123|NCT02644707|Experimental|L-selenomethionine|A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
16595124|NCT02644707|Placebo Comparator|Placebo|A group randomized to receive placebo (control group) for 6 months
16595125|NCT02644694|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
16595126|NCT02644668|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
16595127|NCT02644668|Experimental|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
16595129|NCT02644655|Experimental|CD19-specific chimeric antigen receptor|After pretreatment, cluster of differentiation antigen 19 (CD19)-specific chimeric antigen receptor will be transfused.
16595130|NCT02644642|Experimental|DLT(Double Lumen Tube) group|disconnection technique will be applied
16595131|NCT02644642|Experimental|BB(Bronchial Blocker) group|disconnection technique will be applied
16595132|NCT02644629|Active Comparator|Active IV|Will receive IV Ketamine, along with IN placebo.
16595133|NCT02644629|Active Comparator|Active IN|Will receive IN Ketamine, along with IV placebo.
16595134|NCT02644616|Active Comparator|trial group(tolvaptan group)|trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
16595135|NCT02644616|Placebo Comparator|control group|control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)
16595136|NCT02644603|Experimental|Enhanced Recovery After Surgery|Patients underwent ERAS protocol
16595137|NCT02644603|No Intervention|Conventional Treatment|Patients underwent conventional treatment
16595138|NCT02644590|Experimental|Melatonin treatment|Adolescents with Type 1 Diabetes will undergo baseline 24 hour ambulatory blood pressure monitoring, followed by treatment with Melatonin for 3 weeks, using a single tablet at bed time, and repeat of the 24-hour blood pressure test following treatment period.
16595139|NCT02644577|Experimental|metformin group|Metformin 1000mg/day
16595140|NCT02644577|Placebo Comparator|placebo group|starch
16595141|NCT02644564||Ultrasonography|Patients will undergo structured clinical examination and ultrasonography of both shoulders on the day of inclusion. They also fill out an injury registration form, Oxford Shoulder Score and QuickDASH. Follow-up at 3, 6 and 12 months will be identical, but without ultrasonography and injury registration form.
16595142|NCT02644551|Experimental|CELEXT07|suspension that is applied topically to the infected nail(s) daily.
16595143|NCT02644551|Placebo Comparator|placebo|placebo is a suspension that simulates the physical properties of the experimental agent CELEXT07. It is applied topically to the infected nail(s) daily.
16595144|NCT02644551|Active Comparator|Penlac|Is a standard of care for the condition and is applied topically to the infected nail(s) daily.
16595145|NCT02644538|No Intervention|nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks
16595146|NCT02644538|Active Comparator|PegIFN alfa-2a + nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks
16595147|NCT02644525|Placebo Comparator|2|Subjects given vitamin placebo
16595148|NCT02644525|Experimental|imatinib|Subjects given drug (200 mg, 400 mg, or 600 mg)
16595149|NCT02644499|Active Comparator|Combination therapy|Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
16595150|NCT02644499|Active Comparator|Monotherapy|Methotrexate (up to 25 mg once a week) for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
16595151|NCT02644486|Experimental|A Group|
16595152|NCT02644486|Experimental|B Group|
16595153|NCT02644486|Active Comparator|C Group|
16595154|NCT02644473|Experimental|Tranexamic acid|Investigators will administer topical (1.5g) TXA during total knee arthroplasty and total hip arthroplasty
16595155|NCT02644473|Placebo Comparator|Control|
16595156|NCT02644460|Experimental|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
16595157|NCT02644460|Experimental|Stratum B|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
16595158|NCT02644447|Experimental|HUC-MSCs Transplantation|
16595159|NCT02644447|Experimental|HUC-MSCs with Injectable Collagen Scaffold Transplantation|
16595160|NCT02644434|Active Comparator|Conventional Strategy|Patients randomized to the conventional strategy group would undergo either jailed wire technique (diameter of side branch<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of side branch≥2.5mm).
16595161|NCT02644434|Experimental|Intentional Strategy|Patients randomized to the intentional strategy group would undergo either jailed balloon technique (diameter of side branch<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of side branch≥2.5mm).
16595162|NCT02644421|Experimental|VVZ-149|"The following doses will be administered intravenously:
~Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours
~Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours"
16595163|NCT02644421|Active Comparator|Lidocaine|"The following doses will be administered intravenously:
~Lidocaine 4mg/kg LBM over 0.5 hours
~Normal saline over 7.5 hours"
16595164|NCT02644421|Placebo Comparator|Placebo|Normal saline administered intravenously over 8 hours
16595165|NCT02644408|Experimental|Megestrol and chemoradiotherapy|"Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.
~chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w."
16595166|NCT02644408|Active Comparator|chemoradiotherapy|chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.
16595170|NCT02644382||Focus Groups|four qualitative focus groups of 6-10 women each.
16595171|NCT02644382||Physician Interviews|physician qualitative interviews over the telephone.
16595172|NCT02644382||Usual care cohort (pilot)|50 women who will be surveyed before and after their surgical consult
16595173|NCT02644382||Decision aid cohort (pilot)|50 women who will be surveyed before and after their surgical consult and will also be sent a web-based decision aid
16595174|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
16595175|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
16595176|NCT02644343|Experimental|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.
~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
16595177|NCT02644330|Active Comparator|surgical group|The patients in Group A (surgical group) underwent surgical repair with cardiopulmonary bypass
16595178|NCT02644330|Experimental|closure group|The patients in Group B (closure group) underwent minimally invasive transthoracic device closure.
16595179|NCT02644317|Experimental|with modified shoe inserts|wear the modified shoe inserts and shoes for balance test.
16595180|NCT02644317|No Intervention|without modified shoe inserts|only wear the shoes for balance test.
16595181|NCT02644304|Active Comparator|Clomiphene citrate plus cabergoline|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)
16595182|NCT02644304|Active Comparator|Clomiphene citrate plus placebo|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)
16595183|NCT02644291|Experimental|mebendazole|oral mebendazole as dose escalation (three groups), or l oral mebendazole at maximum dose for extended cohort. Given in 3 divided doses with meals as chewable 500 mg tablets based on calculated patient surface area.
16595184|NCT02644278|Experimental|VX-984 120 mg + PLD 40 mg/m^2|
16595185|NCT02644278|Experimental|VX-984 240 mg + PLD 40 mg/m^2|
16595186|NCT02644278|Experimental|VX-984 480 mg + PLD 40 mg/m^2|
16595187|NCT02644278|Experimental|VX-984 720 mg + PLD 40 mg/m^2|
16595188|NCT02644252|Experimental|Performance status 0-1, Arm A|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
16595189|NCT02644252|Experimental|Performance status 0-1, Arm B|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
16595190|NCT02644252|Experimental|Performance status 2, Arm A|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
16595191|NCT02644252|Experimental|Performance status 2, Arm B|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression
16595192|NCT02644239|Active Comparator|Group control|classical ketogenic diet
16595193|NCT02644239|Active Comparator|Group case|Group case: modified ketogenic diet to reduce at least 20% saturated fat, up> 50% of the acid supply monounsaturated, increasing> 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group
16595194|NCT02644226||Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
16595195|NCT02644226||Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
16595196|NCT02644213|Experimental|research arm|"12 young, healthy civilian volunteers will participate in this study. The experiment will take place in a dome room.
~The experiment will be performed according to the protocol of using CAREN and MOTEK systems:
~CAREN high (Computer Assisted Rehabilitation Environment) which screens virtual scene in the dome.
~MOTEK (Motek Medical©, the Netherlands) which is a two track treadmill (for each leg) placed on a rotatable platform.
~each subject will undergo the same experiment protocol."
16595197|NCT02644200|No Intervention|ORS|Controls treated with oral rehydration solution (standard therapy)
16595198|NCT02644200|Active Comparator|ORS+GT|Group treated with oral rehydration solution plus gelatin tannate
16595199|NCT02644187|Other|Left side first -Aktilite CL128|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
16595200|NCT02644187|Other|Right side first -Aktilite CL128|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
16595201|NCT02644187|Other|Left side first -BF-RhodoLED|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
16595202|NCT02644187|Other|Right side first -BF-RhodoLED|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
16595203|NCT02644161|Active Comparator|Combination acupuncture treatment (CAI)|Post stroke depression patients will receive Dense Cranial Electroacupuncture Stimulation (DCEAS) and body acupuncture. Patients will continue their existing antidepressant and rehabilitation therapy as usual.
16595204|NCT02644161|Sham Comparator|Least acupuncture stimulation (LAS)|Post stroke depression patients will receive Least acupuncture stimulation (LAS). Patients will continue their existing antidepressant and rehabilitation therapy as usual.
16595205|NCT02644148|Other|Conventional Roux-en-Y anastomosis|Conventional Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
16595206|NCT02644148|Experimental|Uncut Roux-en-Y anastomosis|Uncut Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
16595239|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
16596136|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
16595207|NCT02644135|Experimental|Halo Oral Spray|Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
16595208|NCT02644135|Placebo Comparator|Halo Placebo|The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
16595209|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
16595210|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.
~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
16595211|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.
~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
16595212|NCT02644096|No Intervention|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
16595213|NCT02644096|Other|Intervention|counselling and support after discharge from hospital
16595214|NCT02644070|Experimental|alveolar bone preservation with mp3|Extraction sockets grafted with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy) with graft particle size between 600 and 1000 µm and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
16595215|NCT02644070|Experimental|alveolar bone preservation with apatos|Extraction sockets grafted with cortical porcine bone with particle size between 600 and 1000 µm (Apatos, Osteobiol, Coazze, Italy ) and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
16595216|NCT02644070|No Intervention|NO_graft|extraction sockets with spontaneous healing
16595217|NCT02644057|Active Comparator|M-group|Will be given milrinone as an intravenous infusion at 0.2-0.6 mcg/kg/min for a maximum period of 72 hours and adjusted based on creatinine clearance measured by cockcroft-gault equation. It would be titrated based on hemodynamic response , urine output and at the discretion of the treating physician
16595218|NCT02644057|Active Comparator|D-group|Will be given dobutamine as an intravenous infusion at a maximum rate of 20 mcg/kg/min depending on patient tolerance and would adjusted based on hemodynamic response, urine output and at the discretion of treating physician
16595219|NCT02644044|Experimental|Treatment|Treatment with IT methotrexate
16595220|NCT02644031|Experimental|Mtwo rotary system|( continuous rotation system)
16595221|NCT02644031|Experimental|safe-sider rotary system|(reciprocating system)
16595222|NCT02644031|Experimental|hand files|k-files
16595223|NCT02644018|Experimental|Ingavirin|Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
16595224|NCT02644018|Placebo Comparator|Placebo|Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
16595225|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
16595226|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
16595227|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
16595228|NCT02643953|No Intervention|Control Group|This arm includes women who are eligible and give birth (including cases of fetal or infant death) in the intervention period in comparative health wards, who will not receive the interventions and who will continue to receive their usual pattern of utilization of maternity care.
16595229|NCT02643953|Experimental|Other|The intervention will need to be multi-faceted, and will consist of provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; conditional cash transfers to promote uptake of services and targeted community health education and advocacy activities
16595230|NCT02643927|Experimental|standard 8-weeks MBSR|8-week program
16595231|NCT02643927|Experimental|4-week shortened MBSR|Short 4 sessions intervention
16595232|NCT02643927|No Intervention|Control Group|control group: No intervention
16595233|NCT02643914|Experimental|Nicotine Cravings|
16595234|NCT02643901|Experimental|Ic-GW003 150ug/kg 4-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
16595235|NCT02643901|Experimental|Ic-GW003 300ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
16595236|NCT02643901|Experimental|Ic-GW003 500ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
16595237|NCT02643901|Experimental|Ic-GW003 650ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
16595238|NCT02643901|Experimental|Ic-GW003 850ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
16595240|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
16595241|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
16595242|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
16595243|NCT02643849|Experimental|Spanner|
16595244|NCT02643836|Experimental|Treatment PEMF|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
16595245|NCT02643836|Sham Comparator|Sham Treatment|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The sham group will contain 38 subjects. Each study subject will receive two hats, which contain a de-activated PEMF device, the device will still be blinking to show sham treatment activity. The sham subjects will receive the sham treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
16595246|NCT02643823|Experimental|hUC-MSC + DMARDs|Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.
16595247|NCT02643823|Active Comparator|DMARDs|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.
16595248|NCT02643810|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak heart rate) and low-intensity intervals (50-70% of peak heart rate).
16595249|NCT02643810|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 70-75% of peak heart rate.
16595250|NCT02643810|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
16595251|NCT02643797|Experimental|Intervention Group: MA Health Coaching|"Patients in the intervention group will receive the MA Health Coaching intervention during their primary care visits, as well a follow-up calls to encourage/monitor progress and offer support."
16595252|NCT02643797|No Intervention|Usual Care|"Patients in this group will receive treatment as usual during their primary care visits."
16595253|NCT02643784|Experimental|Rosuvastatin|Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
16595254|NCT02643784|No Intervention|Control|Control group(don't take rosuvastatin until 14th day), as directed by the study physician.
16595255|NCT02643771|Experimental|Diabetic group|Subjects with Chronic Periodontitis and Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
16595256|NCT02643771|Experimental|Nondiabetic group|Subjects with Chronic Periodontitis and without Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
16595257|NCT02643758|Experimental|Bifocal soft contact lenses|Device: Bifocal soft contact lenses Use of bifocal contact lenses with nasally decentered optical zone to control the progression of myopia
16595258|NCT02643758|No Intervention|Single vision spectacles|Control: Single vision spectacles
16595259|NCT02643745|Experimental|Nephrology Intervention|Nephrology intervention before surgery:
16595260|NCT02643745|No Intervention|Standard of Care|No nephrology intervention before surgery (standard of care)
16595261|NCT02643732|Experimental|Methylphenidate|"Methylphenidate 10mg (one tablet) twice daily, increasing to 20mg (two tablets) twice daily following assessment 2 weeks into trial.
~24 weeks duration"
16595262|NCT02643732|Placebo Comparator|Placebo|"Identical, over-encapsulated placebo tablets manufactured to be identical to the experimental tablets. One tablet twice daily, increased to two tablets twice daily following assessment 2 weeks into trial.
~24 weeks duration."
16595263|NCT02643719|Active Comparator|Topiramate|
16595264|NCT02643719|Active Comparator|Behavioral intervention|
16595265|NCT02643719|Active Comparator|topiramate and behavioral intervention|
16595266|NCT02643719|Active Comparator|Standard of Care|
16595267|NCT02643706||CIN|CIN was defined as an absolute increase in serum creatinine concentration of at least 0.5 mg/dL (44.2umol/l) or a relative rise of at least 25% from baseline on the follow-up blood sample drawn 24 to 72 hours after the operation.
16595268|NCT02643706||Control|The enrolled patients without CIN.
16595269|NCT02643693|Experimental|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
16595270|NCT02643693|Experimental|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
16595271|NCT02643693|Experimental|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
16595272|NCT02643680|Experimental|The novel biocellulose wound dressing|
16595273|NCT02643680|Active Comparator|Bactigras|
16595334|NCT02643368|Active Comparator|mOPV2 at 6 and 7 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
16595274|NCT02643667|Experimental|Phase I: Ibrutinib|"Ibrutinib: will be given by mouth daily
~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP
~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
16595275|NCT02643667|Experimental|Phase II: Ibrutinib|"Ibrutinib: will be given by mouth daily
~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP
~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
16595276|NCT02643654|Placebo Comparator|Placebo|The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
16595277|NCT02643654|Active Comparator|MABp1|MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α (IL-1α). The entire MABp1 heavy and light chain sequences are identical to those found in naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual. It is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
16595278|NCT02643641|Experimental|BM32-3|2 placebo injections will be given followed by 3 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
16595279|NCT02643641|Experimental|BM32-4|1 placebo injections will be given followed by 4 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
16595280|NCT02643641|Experimental|BM32-5|5 injections with 20 micrograms each of BM321, BM322, BM325 and BM326 will be given
16595281|NCT02643641|Placebo Comparator|Placebo|5 placebo injections (alhydrogel only) will be given
16595282|NCT02643628|Experimental|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
16595283|NCT02643628|Experimental|Microneedling followed by Bellafill treatment|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
16595284|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
16595285|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
16595286|NCT02643602|Experimental|Bicarbonate and theophylline|Hydration with bicarbonate in addition to theophylline
16595287|NCT02643602|Active Comparator|Sodium and theophylline|Hydration with sodium chloride in addition to theophylline
16595288|NCT02643589|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
16595289|NCT02643589|Active Comparator|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
16595290|NCT02643576|No Intervention|Control|Usual SNAP-like food benefits
16595291|NCT02643576|Experimental|Rewards|Usual SNAP-like food benefits, plus a modification to this food benefit program that entails a 30% bonus on eligible fruit and vegetable purchases (i.e. F&V bonus)
16595292|NCT02643576|Experimental|Restrictions|Usual SNAP-like food benefits, plus a modification that requires no sugar-sweetened beverages, candy, or sweet baked goods be purchased
16595293|NCT02643576|Experimental|Rewards plus restrictions|Usual SNAP-like food benefits, plus two modifications to this food benefit program: one modification includes a 30% bonus on eligible fruit and vegetable purchases and the other modification is that sugar-sweetened beverages, candy, or sweet baked goods are not allowed to be purchased (i.e. Bonus & Restriction)
16595294|NCT02643563|Experimental|Ropivacaine 0.5%|Low volume (5 ml) Interscalene Block with Ropivacaine 0.5%
16595295|NCT02643563|Active Comparator|Ropivacaine 1%|Low volume (5 ml) Interscalene Block with Ropivacaine 1%
16595296|NCT02643563|Active Comparator|Bupivacaine 0.5% + epinephrine 1:200,000|Low volume (5 ml) Interscalene Block with Bupivacaine 0.5% + epinephrine 1:200,000
16595297|NCT02643550|Experimental|Dose escalation|Dose escalation of monalizumab in combination with cetuximab
16595298|NCT02643550|Experimental|Expansion cohort 1|monalizumab + cetuximab expansion cohort
16595299|NCT02643550|Experimental|Expansion cohort 2|monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
16595300|NCT02643550|Experimental|Expansion cohort 3|monalizumab + cetuximab + anti-PD(L)1
16595301|NCT02643537||Luxation erecta|All patients with Inferior shoulder dislocation in fixed abduction, also known as luxatio erecta humeri (LEH)
16595302|NCT02643524|Active Comparator|Nutrition and Exercise Counseling|CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
16595303|NCT02643524|Active Comparator|Control|CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit
16595304|NCT02643511|Experimental|Prostate biopsy,Hemiablative focal Brachytherapy|This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
16595335|NCT02643368|Active Comparator|mOPV2 at 6 and 8 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
16595305|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
16595306|NCT02643485||Study group|Patients undergoing forefoot reconstruction of hallux valgus or hallux rigidus
16595307|NCT02643485||Control group|Healthy volunteers (Students)
16595308|NCT02643472|Other|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
16595309|NCT02643472|Experimental|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
16595310|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
16595311|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
16595312|NCT02643446||G1: IPV+OPV, 1 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV.
16595313|NCT02643446||G2: IPV+OPV, 1 m+7d followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV.
16595314|NCT02643446||G3: IPV+OPV, 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
16595315|NCT02643446||G4: IPV+OPV, 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 5 months of age, that is one month after the second dose of OPV.
16595316|NCT02643446||G5: OPV, 3 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 5 months of age, that is one month after the third dose of OPV.
16595317|NCT02643446||G6: OPV, 1 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
16595318|NCT02643446||G7: OPV, 1 m+7d followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of OPV.
16595319|NCT02643446||G8: IPV+IPV, 1 m+7d followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV.
16595320|NCT02643446||G9: IPV+IPV, 2 m followup|Using 2 doses of IPV and 1 doses of OPV at 2, 3,4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the second dose of IPV and just before the first dose of OPV.
16595321|NCT02643446||G10: IPV+OPV, 1 m and 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV;the third sample at 5 months of age, that is one month after the second dose of OPV.
16595322|NCT02643446||G11: IPV+OPV, 1 m+7d and 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV,the third sample at 4 months of age, that is one month after the first dose of OPV.
16595323|NCT02643446||G12: IPV+IPV,1 m+7d and 2 m followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV,the third sample at 4 months of age, that is one month after the second dose of IPV.
16595324|NCT02643433|Experimental|MR and JE coadministration group|Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
16595325|NCT02643433|Active Comparator|MR administration alone group|Infants aged 8 months are vaccinated measles-rubella combined vaccine alone
16595326|NCT02643420|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)
~Supplied in prefilled single-use syringes for subcutaneous injection
~Administered on Day 2 of each cycle"
16595327|NCT02643420|Active Comparator|Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta® [NDC 55513-190-01] manufactured by Amgen)
~Single-dose subcutaneous injection administered on Day 2 of each cycle"
16595328|NCT02643407|Experimental|Docetaxel plus Nedaplatin|docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
16595329|NCT02643407|Active Comparator|Docetaxel plus Cisplatin|docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
16595330|NCT02643394|Active Comparator|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
16595331|NCT02643394|Active Comparator|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
16595332|NCT02643381|Experimental|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
16595333|NCT02643381|Experimental|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
16595336|NCT02643368|Active Comparator|mOPV2 at 6 and 10 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
16595337|NCT02643368|Active Comparator|mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age|Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age
16595338|NCT02643355|Experimental|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
16595339|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
16595340|NCT02643342|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39 of refractive index 1.56.
16595341|NCT02643342|Sham Comparator|Orthokeratology with normal compression factor|Subjects wearing orthokeratology lenses of normal compression factor about 0.50-0.75D.
16595342|NCT02643342|Active Comparator|Orthokeratology with increased compression factor|Subjects wearing orthokeratology lenses of increased compression factor about 1.50-1.75D.
16595343|NCT02643329|Experimental|BF-Gliclazide Tablet 80mg|During the study session, healthy male subjects will be administered a single oral dose of BF-Gliclazide Tablet 80 mg after an overnight fast of approximately 10 hours.
16595344|NCT02643329|Active Comparator|Diamicron 80mg Tablet|During the study session, healthy male subjects will be administered a single oral dose of Diamicron 80 mg Tablet after an overnight fast of approximately 10 hours.
16595345|NCT02643316|Active Comparator|Same day 4 L preparation of PEG|Receive 1 gallon (4 L) of Polyethylene Glycol (PEG) preparation on the morning of the colonoscopy.
16595346|NCT02643316|Active Comparator|Split dose 4 L preparation of of the PEG|Receive the split-dose regimen. Will take half (2 L) of the PEG preparation the evening before colonoscopy and half (2 L) of the PEG preparation on the morning of the procedure.
16595347|NCT02643303|Experimental|Phase 1, Cohort 1A|IV Durvalumab + IT/IM polyICLC
16595348|NCT02643303|Experimental|Phase 1, Cohort 1B|IV Durvalumab + IV Tremelimumab + IT/IM polyICLC
16595349|NCT02643303|Experimental|Phase 1, Cohort 1C|IV Durvalumab + IT Tremelimumab + IT/IM polyICLC
16595350|NCT02643303|Experimental|Phase 2 Cohort|Once the recommended combination doses of the triplet dosing regimen has been determined in Cohort 1C, subsequent subjects will be enrolled into Cohort 2 to receive the recommended combination doses of both checkpoint antibodies in combination with polyICLC.
16595351|NCT02643290|Other|Patients|Adult patients with low back pain secondary to an high degree scolisis are treated by fiting with a brace 2-4 hours a day and tracked for 6 months.
16595352|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
16595353|NCT02643277|Experimental|Mobile phone text messaging|The intervention will receive text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring. The messages provide tips and suggestions, and positive reinforcement or encouragement, for improving lifestyle behaviors and compliance with therapy.
16595354|NCT02643264|Experimental|rTMS 10 Hz|Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).
16595355|NCT02643264|Sham Comparator|rTMS Sham|Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).
16595356|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
16595357|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
16595358|NCT02643238|Experimental|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
16595359|NCT02643238|Active Comparator|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
16595360|NCT02643225||pregnant women with gestational diabetes|case group
16595361|NCT02643225||non diabetic pregnant women|control group
16595362|NCT02643212|Placebo Comparator|Placebo|
16595363|NCT02643212|Experimental|Rivaroxaban|Rivaroxaban 10mg, 1 once a day
16595364|NCT02643186|Active Comparator|misoprostol group|preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy
16595365|NCT02643186|Active Comparator|uterine artery ligation group|bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy
16595366|NCT02643173||Volatile|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents.
16595367|NCT02643173||Intravenous|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents.
16595368|NCT02643160|Experimental|Functional Trunk Training Group|Functional Trunk Training which includes strengthening of trunk muscle and functional activities including trunk region.
16595369|NCT02643160|No Intervention|Control Group|No intervention, the continued their regular physical therapy
16595370|NCT02643147|Experimental|CA125 guided strategy|In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels
16595371|NCT02643147|Active Comparator|Conventional strategy|Standard treatment strategy Therapy is based on established european guidelines
16595372|NCT02643134|Other|Group 1|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
16595373|NCT02643134|Other|Group 2|Patients in Group 2 undergo external physical vibration lithecbole for the treatment after extracorporeal shockwave lithotripsy(ESWL).A multi-dimensional physical harmonic vibration inertial guidance technology
16595374|NCT02643121||children with sepsis, SIRS|Data will be collected and analyzed from childrens with SIRS or septic state who will be admitted to the Department of Anesthesia and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections, sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be defined according to commonly used criteria - by International pediatric sepsis consensus conference.
16595375|NCT02643121||control group, healthy children|The samples children undergoing elective surgery will be used as a controls, i.e. samples from patients without signs of infection.
16595376|NCT02643108|Experimental|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
16595377|NCT02643108|No Intervention|No episiotomy|No episiotomy is performed during operative vaginal delivery, unless vitally indicated (for example severe fetal distress). The woman may tear spontaneously. Regular manual perineal support is applied.
16595378|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
16595379|NCT02643082|Experimental|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
16595380|NCT02643082|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
16595381|NCT02643069|Experimental|Intervention Geriatric Program|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, according to the treating physicians (s) surgeon and the performance of a geriatrician . This management will consist of the therapeutic plan, access to geriatric levels of care, coordination with primary and social care, rehabilitation, and discharge plan.
16595382|NCT02643069|No Intervention|Usual clinical practice|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, agreed with the treating physicians (s) surgeon.
16595384|NCT02643043|Other|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
16595385|NCT02643030|Experimental|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
16595386|NCT02643030|Active Comparator|hypercapnia|Tidal volume (6ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
16595387|NCT02643017|Placebo Comparator|normal saline|
16595388|NCT02643017|Experimental|Dex|
16595389|NCT02643004|Active Comparator|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
16595390|NCT02643004|Active Comparator|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
16595391|NCT02642991|Experimental|Phenacite Test lens then comfilcon A control lens|Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
16595392|NCT02642991|Active Comparator|Comfilcon A control lens then Phenacite test Lens|Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
16595393|NCT02642978|Experimental|RSRCLM|robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.
16595394|NCT02642978|Active Comparator|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.
16595395|NCT02642965|Experimental|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.
~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
16595396|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
16595397|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
16595398|NCT02642939|Experimental|mifepristone|mifepristone 300 mg capsule per day, orally in 28-day cycles
16595399|NCT02642926|Active Comparator|Monopolar endoscopic endometrial ablation|
16595400|NCT02642926|Experimental|Bipolar endoscopic endometrial ablation|
16595401|NCT02642913|Experimental|Enzalutamide without Sorafenib|Will get enzalutamide, at the dose approved by the FDA for prostate cancer. If this dose has serious side effects, a lower dose will be given to new patients as they take part in the study. At the end of this part of the study, the recommended dose of enzalutamide will be set for all patients on this study. More patients will then be treated with this dose.
16595402|NCT02642913|Experimental|Enzalutamide with Sorafenib|Will get enzalutamide and sorafenib. The first group of patients will get the recommended dose of enzalutamide with sorafenib by mouth either once or twice daily. The dose of sorafenib you receive will depend on when the patient starts the study. At the beginning of the study, patients will be treated with a lower dose of sorafenib. If this dose does not have serious side effects, a higher dose will be given to new patients as they take part in the study.
16595403|NCT02642900|Experimental|Nystatin 100.000 units|Patients were treated with a topical antifungal nystatin oral suspension(1000.000 units) 5mL every six hours/14 days. Patients were instructed to rinse the solution for 5 minutes and then to spit the solution out. Samples were collected on days 7, 14 and 30 after the end of treatment (follow-up).
16595404|NCT02642900|Active Comparator|Photodynamic Therapy|Patients used mouthwash with methylene blue 0.005% for 20 minutes (pre-irradiation time). The palatal mucosa was irradiated using a low level laser with the following settings: wavelength of 660 nm, energy density of 120 J/cm ², output power of 40 milliwatt, 2 minutes per point. PDT was performed in two sessions (one session per week). Samples were collected immediately after each clinical procedure and 30 days after the second procedure (follow-up).
16595405|NCT02642887|Experimental|The test group|This group included 30 recession defects treated with mTA + SCTG
16595406|NCT02642887|No Intervention|The control group|This group included 30 recession defects treated with cTT + SCTG
16595407|NCT02642874|Experimental|Methocarbamol|Methocarbamol twice daily
16595408|NCT02642874|Placebo Comparator|placebo|Calcium carbonate twice daily
16595409|NCT02642861|Active Comparator|Cyclobenzaprine|Cyclobenzaprine administration for 2 weeks
16595410|NCT02642861|Placebo Comparator|PLacebo|Calcium carbonate for 2 weeks
16595411|NCT02642848|Active Comparator|HTO with micro fracture|High tibial osteotomy(HTO) with micro fracture is an common treatment for the correction of malalignment of the knee treating osteoarthritis.
16595412|NCT02642848|Experimental|HTO with bone marrow stem cell|High tibial osteotomy(HTO) with transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone.
16595413|NCT02642848|Experimental|HTO with adipose derived stem cell|High tibial osteotomy(HTO) with autologous adipose-derived stromal vascular fraction transplantation using LipoSculptor collecting from abdominal fat tissue.
16595414|NCT02642809|Experimental|Arm 1: Pembrolizumab and Brachytherapy|"Brachytherapy dose=16 Gy delivered in 2 fractions of 8 Gy per fraction, separated by 7-10 days between fractions.
~Pembrolizumab started within 1 week after completion of brachytherapy administered as an intravenous infusion over 30 minutes. It will be given every 3 weeks.
~Standard of care endoscopic biopsy will take place at time of enrollment and 2-6 months (optional) after pembrolizumab initiation.
~Research endoscopic biopsy for 8 consented patients will take place 1-2 weeks after initiation of brachytherapy.
~Peripheral blood will be collected: Pre-brachytherapy, Post-brachytherapy but pre-pembrolizumab (on day 1), Day 22 after the start of pembrolizumab, 3, 6, and 12 months (+/- 2 weeks) after the start of pembrolizumab, and time of progression"
16595415|NCT02642796|No Intervention|Group I (control)|Patient controlled analgesia (epidural fentanyl): PCA only
16595416|NCT02642796|Experimental|group II|PCA plus lumbar plexus & sciatic nerve transcutaneous electric nerve stimulation (LS-TENS)
16595417|NCT02642796|Experimental|group III|PCA plus surgical wound transcutaneous electric nerve stimulation ( SW-TENS)
16595418|NCT02642783|Other|Descriptive analysis|panelists were asked to rate different sensory attributes for different laxative bowel cleansing solutions on a 15 cm line scale.
16595419|NCT02642783|Other|Acceptability test|panelists were asked to rate the acceptability of different laxative bowel cleansing solutions using the 9-point hedonic scale.
16595420|NCT02642757|Experimental|Brief intervention|AUDIT brief intervention
16595421|NCT02642757|Sham Comparator|Control group|Pamphlet on alcohol use
16595422|NCT02642744|Other|Attending nurse model|The attending nurse model of in-hospital care delivery aims to improve patient understanding, shared decision making, medication adherence, and reduce early readmissions after discharge to improve quality of life. On the inpatient stroke unit, the attending nurse will take ownership of essential aspects of an individual stroke patient's care, education, and transition out of the hospital. To further contribute to the patient's plan of care, the attending nurse will be present on daily teaching rounds.
16595423|NCT02642744|No Intervention|Conventional inpatient nursing care|Standard of care nursing care patients receive while inpatient
16595424|NCT02642731||Patients for elective TKA|patients with normal or near normal plasma creatinine who come for elective total knee arthroplasty
16595425|NCT02642718|Placebo Comparator|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
16595426|NCT02642718|Experimental|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision. (a single dose).
16595427|NCT02642705|Experimental|High intensity interval training N|High intensity interval training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing ambient air (normoxia)
16595428|NCT02642705|Experimental|High intensity interval training H|High intensity interval training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing hypoxic air (about 3 500 m of altitude)
16595429|NCT02642705|Active Comparator|Constant load exercise training N|Constant load exercise training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing ambient air (normoxia)
16595430|NCT02642705|Experimental|Constant load exercise training H|Constant load exercise training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing hypoxic air (about 3 500 m of altitude)
16595431|NCT02642705|Experimental|Hypoxic conditioning at rest|Hypoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, hypoxic breathing for one hour (about 4500 m of altitude) while seating quietly
16595432|NCT02642705|Sham Comparator|Normoxic conditioning at rest|Normoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, normoxic breathing for one hour (ambient air) while seating quietly
16595433|NCT02642692|Experimental|Patellar Tendon Graft|Kind of graft that will be used for acl reconstruction
16595434|NCT02642692|Experimental|Hamstring Graft|Kind of graft that will be used for acl reconstruction
16597019|NCT02632214|Experimental|Deaf|Group of early profound deaf participants fMRI measure
16595435|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
16595436|NCT02642666|Experimental|Yoga intervention|While in the yoga intervention arm of the study participants will practice yoga at home and at school for six weeks with the goal of practicing yoga daily during that time period. Yoga classes will be held twice a week at school. On the days that the children do not practice yoga at school, they will practice yoga at home with the use of a children's yoga video that mirrors the yoga class that they attend at school.
16595437|NCT02642666|No Intervention|Normal school and home activities|While in the wait-list group the children will continue with their regular activities both at home and at school.
16595438|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
16595439|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
16595440|NCT02642640|Other|melatonin-placebo|subjects will receive melatonin first and placebo second
16595441|NCT02642640|Other|placebo-melatonin|subjects will receive placebo first and melatonin second
16595442|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
16595443|NCT02642614|Experimental|BI 1026706 low dose|
16595444|NCT02642614|Experimental|BI 1026706 medium|
16595445|NCT02642614|Experimental|BI 1026706 high dose|
16595446|NCT02642614|Placebo Comparator|Placebo|
16595447|NCT02642601|Experimental|indomethacin|one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer
16595448|NCT02642601|No Intervention|no medication|no indomethacine before embryo transfer
16595449|NCT02642588|Experimental|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
16595450|NCT02642588|No Intervention|control|women will be given only clear liquids during labor
16595451|NCT02642562|No Intervention|Standard care|Participants in this arm will receive their usual care
16595452|NCT02642562|Experimental|Standard care plus IV iron infusion|"Iron to be administered as iron (III) isomaltoside 1000 / ferric derisomaltose.
~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg Body weight <50 kg: 20 mg/kg Hb ≥10 g/dL and body weight 50 to <70 kg: 1000 mg Hb ≥10 g/dL and body weight ≥70 kg: 20 mg/kg up to a max of 1500 mg Hb < 10 g/dL and body weight 50 to <70 kg: 20 mg/kg Hb < 10 g/dL and body weight ≥70 kg: 20 mg/kg up to a max of 2000 mg"
16595453|NCT02642549|Experimental|Girls for Health Intervention (G4H)|G4H will integrate proven girls' education strategies with innovative vocational interventions to build 1350 girls' career aspirations and academic achievement
16595454|NCT02642549|No Intervention|Control Condition|standard of care to support school attendance among girls (i.e., school tracking of attendance and reaching out to truant girls).
16595455|NCT02642536|Active Comparator|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
16595456|NCT02642536|Active Comparator|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
16595457|NCT02642523|Placebo Comparator|Saline Infusion|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
16595458|NCT02642523|Experimental|Insulin Clamp|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
16595459|NCT02642523|Experimental|BNP Infusion (Nesiritide)|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
16595460|NCT02642510|Experimental|DVD Structured Education|Participants in this group will watch an educational DVD in addition to standard teaching by nursing staff.
16595461|NCT02642510|Active Comparator|Standard Educational Teaching|Participants in this group will receive educational teaching by their assigned nursing staff.
16595462|NCT02642497|Active Comparator|local ketamine group|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
16595463|NCT02642497|Placebo Comparator|control group|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
16595464|NCT02642497|Active Comparator|systemic ketamine group|Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
16595465|NCT02642484|Active Comparator|Gabapentin|Gabapentin twice daily
16595466|NCT02642484|Placebo Comparator|PLacebo|Calcium carbonate twice daily
16595467|NCT02642471|Experimental|Arm 1|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
16595500|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
16595893|NCT02639572|Experimental|Siloss® bone graft|Based on the sequence, in the test site,Siloss® was placed.
16595468|NCT02642471|No Intervention|Arm 2|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
16595469|NCT02642471|Experimental|Arm 3|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
16595470|NCT02642471|No Intervention|Arm 4|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
16595471|NCT02642458||trastuzumab plus chemotherapy|Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
16595472|NCT02642458||pertuzumab plus trastuzumab plus chemotherapy|Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
16595473|NCT02642445|Experimental|Renal Sympathetic Denervation|Renal sympathetic Denervation are conducted from the adventitia of renal artery
16595474|NCT02642445|No Intervention|Control Group|Renal Sympathetic Denervation are not conducted in control group.
16595475|NCT02642432|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
16595476|NCT02642419|Experimental|Rivaroxaban|
16595477|NCT02642419|Experimental|Rivaroxaban and single antiplatelet drug|
16595478|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
16595479|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
16595480|NCT02642380|Experimental|4 cycles|Oral administration of dexamethasone 40 mg for four consecutive days every 14 days for 4 courses
16595481|NCT02642380|Active Comparator|1 cycle|Oral administration of dexamethasone 40 mg for four consecutive days
16595482|NCT02642367|Experimental|no use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection without use of stylet with McGrath videolaryngoscope after endotracheal tube was rolled up circularly for 3 min
16595483|NCT02642367|Active Comparator|use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection using a styletted endotracheal tube with McGrath videolaryngoscope
16595484|NCT02642328|Experimental|HIIT Training|Circuit training with strength and power. The chosen exercises were (random order): Sit-Ups, Mountain Climbers, Plank, Side Skater, Push Ups, Ground Support with Vertical Jump, Overhead Squat, Box Jump.Time total = 4 minutes
16595485|NCT02642328|Active Comparator|Control|Running aerobic exercise at 65% of VO2Max
16595486|NCT02642315|Other|open-label|"open-label single arm study
~Horizant, 600 mg oral once daily at 5 pm for 360 days."
16595487|NCT02642302|Experimental|HIIT With 60 sec Rest|The experimental (1) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 60 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
16595488|NCT02642302|Experimental|HIIT With 120 sec Rest|The experimental (2) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 120 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
16595489|NCT02642302|Active Comparator|Control|Continuous exercise at 50-55% of VO2max with similar total work
16595490|NCT02642289|Experimental|Probiotic1: Lactobacillus acidophilus|Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)
16595491|NCT02642289|Placebo Comparator|Placebo|Inactivate substance
16595492|NCT02642289|Experimental|Probiotic2: Lactobacillus Rhamnosus GG ®|Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)
16595493|NCT02642276|Active Comparator|Maximal walking group|Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
16595494|NCT02642276|Active Comparator|Submaximal walking group|Patients to be randomized to the 'submaximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to 2/3 of pain-free walking distance.
16595495|NCT02642276|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
16595496|NCT02642263|No Intervention|Oxytocin|Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
16595497|NCT02642263|Experimental|Carbetocin|100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby. For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
16595498|NCT02642250|Experimental|Entoban Capsules|Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
16595499|NCT02642250|Experimental|Metronidazole DS|Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.
16595501|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
16595502|NCT02642224|Experimental|Social work intervention|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
16595503|NCT02642211|Active Comparator|phako|eyes receiving phakoemulsification for cataract surgery
16595504|NCT02642211|Active Comparator|MSICS|Eyes undergoing manual small incision cataract surgery
16595505|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
16595506|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
16595507|NCT02642172|Experimental|ITF (Inulin/OFS 75/25)|16 gram/day of ITF (Inulin/OFS 75/25)
16595508|NCT02642172|Placebo Comparator|placebo|16 gram/day of maltodextrin (placebo)
16595509|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
16595510|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
16595511|NCT02642133|Other|Intervention|All patients were in the same arm - this is a cohort study where the group serves as their own control. Patients who did not undergo the procedure were not included in this outcomes study.
16595512|NCT02642120|Experimental|Receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
16595513|NCT02642120|No Intervention|Do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
16595514|NCT02642107|Experimental|Elective neck irradiation|Whole neck irradiation is given in the positive neck. Elective neck irradiation of Level II,III,Va lymph node area is given in negative neck, and Level IV,Vb and Supraclavicular fossa lymph node area were not irradiated in negative neck.
16595515|NCT02642107|Active Comparator|Whole neck irradiation|Whole neck irradiation is given regardless of the positive or negative neck.
16595516|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
16595517|NCT02642068||ADHD group|Drug-naïve adult ADHD Probands
16595518|NCT02642068||Sibling group|Unaffected Siblings of Drug-naïve Adult ADHD
16595519|NCT02642068||Control group|Age-, sex-, handedness-, and IQ-matched controls without lifetime ADHD or a family history of ADHD
16595520|NCT02642055|Experimental|Neuro+ Intervention|30 sessions (900 minutes) of Neuro+ Attention Training administered over 10 weeks.
16595521|NCT02642055|Active Comparator|Treatment as Usual|Continuation of current treatment for ADHD
16595522|NCT02642042|Experimental|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16595523|NCT02642029|Experimental|Intermittent TBS (iTBS)|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
16595524|NCT02642029|Active Comparator|Continuous TBS (cTBS)|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
16595525|NCT02642029|Sham Comparator|Sham TBS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
16595526|NCT02642016|Experimental|CDX-0158|
16595527|NCT02642003|Experimental|GCSF+SMT|5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
16595528|NCT02642003|No Intervention|SMT|
16595529|NCT02641990|Experimental|Group 1|ITCA 650 20/60 mcg/day, ITCA placebo
16595530|NCT02641990|Experimental|Group 2|ITCA placebo, ITCA 650 20/60 mcg/day
16595531|NCT02641964||ARDS group|patients with acute necrotizing pancreatitis complicated by ARDS
16595532|NCT02641964||non-ARDS group|acute necrotizing pancreatitis patients without ARDS
16595533|NCT02641951|Placebo Comparator|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
16595534|NCT02641951|Active Comparator|Pecs II block|Ultrasound guided Pecs II block
16595535|NCT02641938|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
16595536|NCT02641938|Placebo Comparator|Normal Saline|IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
16595537|NCT02641925|Active Comparator|Omentum preserving|Omentum preserving: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed.
16595538|NCT02641925|Experimental|Total omentectomy|Total omentectomy: Whole omentum will be removed.
16595786|NCT02640222||AC-experienced treated with VKA|AC-experienced treated with VKA
16595539|NCT02641912|Experimental|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
16595540|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.
~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
16595541|NCT02641899|Experimental|Experimental Treatment|ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg
16595542|NCT02641886|Experimental|Jian Pi Yi Shen Hua Tan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
16595543|NCT02641886|Placebo Comparator|the Placebo Group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
16595544|NCT02641873|Experimental|BBI608 + FOLFIRI +Bevacizumab|
16595545|NCT02641860|Other|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
16595546|NCT02641860|Other|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells mid-dose group
16595547|NCT02641860|Other|Mesenchymal progenitor cells Dosage 3|Mesenchymal progenitor cells high-dose group
16595548|NCT02641847|Experimental|High risk group A|TA(E)C x 4 cycles to GP x 4 cycles (docetaxel + doxorubicin (epirubicin) + cyclophosphamide to gemcitabine + cisplatin), docetaxel: 75 mg/m2 IV on day 1; doxorubicin: 50 mg/m2 IV on day 1 or epirubicin 75 mg/m2 IV on day 1; cyclophosphamide: 500 mg/m2 IV on day 1; gemcitabine: 1250 mg/m2 IV on day 1 and 8; cisplatin: 75 mg/m2 IV on day 1, dosing interval is 21 days.
16595549|NCT02641847|Active Comparator|High risk group B|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
16595550|NCT02641847|Other|Low risk group C|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
16595551|NCT02641834|Experimental|Veg Group|Group that starts with the Vegetarian diet
16595552|NCT02641834|Active Comparator|Med group|Group that starts with the Mediterranean diet
16595553|NCT02641821|Experimental|Nifedipine GITS|
16595554|NCT02641808|Experimental|follicular flushing group|Monofollicular IVF therapy with follicular flushing up to five times after aspiration of the follicule at the time to the oocyte pick-up
16595555|NCT02641808|Active Comparator|aspiration group|Monofollicular IVF therapy with aspiration only at the time of the oozyte pick-up
16595556|NCT02641795|Experimental|Experimental|Minimally invasive robotic cochlear implantation with custom device
16595557|NCT02641782|Active Comparator|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
16595558|NCT02641782|Experimental|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
16595559|NCT02641769|Other|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
16595560|NCT02641756|Experimental|Study Population|"This is a single arm study. The investigators will include 10 HIV positive patients under chronic CART (combined antiretroviral therapy).
~The intervention will consist on treatment interruption after in depth sampling under CART"
16595561|NCT02641743|Experimental|Inslow|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) Inslow at 7:00 AM.
16595562|NCT02641743|Placebo Comparator|standard balanced formula|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) standard balanced formula at 7:00 AM.
16595563|NCT02641730|Experimental|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
16595564|NCT02641730|Experimental|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
16595565|NCT02641730|Experimental|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
16595566|NCT02641717|Experimental|All subjects|All patients enrolled in this study will self-collect a vaginal swab (experimental) then have a physician collected vaginal swab (gold standard)
16595567|NCT02641704||Multidisciplinary program|Multidisciplinary program designed and administered by the Competence- and Integration Center in Sonderborg Municipality
16595568|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.
~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.
~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.
~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.
~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.
~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.
~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles
~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
16595569|NCT02641652|Active Comparator|Sertraline|sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
16595570|NCT02641652|Placebo Comparator|Placebo|placebo
16595571|NCT02641639|Active Comparator|Fosbretabulin tromethamine|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P
16595572|NCT02641639|Placebo Comparator|Placebo|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo
16595573|NCT02641626|Experimental|Urgent Coronary Angiography|Urgent Coronary Angiography: as soon as possible, when the patient is randomized.
16595574|NCT02641626|Active Comparator|Deferred coronariography|Deferred coronary angiography: after extubation if the patient has a good neurologic prognosis.
16595575|NCT02641613|Active Comparator|supraclavicular|patients receive a supraclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
16595576|NCT02641613|Experimental|retroclavicular block|patients receive a retroclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
16595577|NCT02641600|Active Comparator|Elastic stockings|Class 1 elastic stockings (18-21 mmHg)
16595578|NCT02641600|Placebo Comparator|Placebo stockings|Placebo stockings (0 mmHg)
16595579|NCT02641587|Experimental|CHTP 1.2|Ad libitum use of the CHTP 1.2
16595580|NCT02641587|Active Comparator|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
16595581|NCT02641574||previous 1|women who have had in their past one cesarean section
16595582|NCT02641574||previous 2|women who have had in their past 2 cesarean sections
16595583|NCT02641574||previous 3|women who have had in their past 3 cesarean sections
16595584|NCT02641574||previous 4|women who have had in their past 4 cesarean sections
16595585|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
16595586|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
16595587|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
16595588|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
16595589|NCT02641548|Experimental|Silicone sock+heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet and a sock of silicone is used every night.
16595590|NCT02641548|Active Comparator|Heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet
16595591|NCT02641535|Experimental|research arm|"12 healthy volunteers from the border guard of the police forces will participate in this study. The subjects will undergo 4 experiment days:
~Recruitment , medical examination and VO2max test.
~Acclimatization day by performing moderate exercise protocol under hot and humid climate.
~3.2 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:
~Protective garment in current use + NBC mask.
~The new BC membrane protective garment + NBC mask"
16595592|NCT02641522|Experimental|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
16595593|NCT02641509|Experimental|NBI to perform the polipectomy|this arm will undergo polypectomy with the use of NBI to define the margins of the lesion
16595594|NCT02641509|Experimental|no NBI to perform the polypectomy|this arm will undergo polipectomy without the use of NBI to define the margins of the lesion
16595595|NCT02641496|Experimental|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
16595596|NCT02641496|Active Comparator|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
16595597|NCT02641483|Experimental|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
16595598|NCT02641470|Experimental|DA9301|Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
16595599|NCT02641470|Placebo Comparator|Placebo|Orally administration of placebo pills (1000 mg/day) for 4 weeks.
16595600|NCT02641457|Experimental|Aflibercept x Ranibizumab|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab
16595601|NCT02641444||Efavirenz|Receiving efavirenz as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
16595602|NCT02641444||Atazanavir|Receiving atazanavir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
16595603|NCT02641444||Raltegravir|Receiving raltegravir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
16595604|NCT02641444||Maraviroc|Receiving maraviroc as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
16595605|NCT02641431|Experimental|mapping/ablation|Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.
16595606|NCT02641418|Other|Exercise|only 1 arm to trial
16595607|NCT02641405|Experimental|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
16595608|NCT02641405|Placebo Comparator|Placebo|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
16595787|NCT02640222||AC-experienced treated with apixaban|AC-experienced treated with apixaban
16595788|NCT02640222||AC-experienced treated with dabigatran|AC-experienced treated with dabigatran
16595609|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
16595610|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
16595611|NCT02641392|Experimental|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
16595612|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
16595613|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
16595614|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
16595615|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
16595616|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
16595617|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
16595618|NCT02641366||Tremor kinetics after DBS|This group have already undergone Deep Brain Stimulation (DBS) placement and will have measurements of tremor kinetics by using the electromagnetic tracking. The electromagnetic sensors will be placed on the arm and hand while the routine outpatient neurologic examinations are being performed. The testing will be performed with the DBS system in both the on and off settings.
16595619|NCT02641366||Tremor kinetics before and after DBS|This group will have measurements of tremor kinetics by using electromagnetic tracking prior to being scheduled to undergo Deep Brain Stimulation (DBS) placement. A total of two testing sessions will be performed: the first session will be performed during the routine preoperative visit, the second session will be performed during the routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
16595620|NCT02641353|Experimental|Treatment A: Apremilast 30 mg Tablet - Fasted|A single oral dose of 30 mg apremilast tablet after an overnight fast.
16595621|NCT02641353|Experimental|Treatment B: Apremilast 30 mg Oral Suspension - Fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
16595622|NCT02641353|Experimental|Treatment C - Apremilast 30 mg Oral Suspension - Fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
16595623|NCT02641340|Experimental|Cycle 1, Cohort 1|Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
16595624|NCT02641340|Experimental|Cycle 1, Cohort 2|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
16595625|NCT02641340|Experimental|Cycle 1, Cohort 3|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
16595626|NCT02641340|Experimental|Cycle 1, Cohort 4|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
16595627|NCT02641340|Experimental|Cycle 2, Cohort 1|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
16595628|NCT02641340|Experimental|Cycle 2, Cohort 2|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
16595629|NCT02641340|Experimental|Cycle 2, Cohort 3|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
16595630|NCT02641340|Experimental|Cycle 2, Cohort 4|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
16595631|NCT02641340|Experimental|Cycle 3, Cohort 1|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
16595632|NCT02641340|Experimental|Cycle 3, Cohort 2|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
16595633|NCT02641340|Experimental|Cycle 3, Cohort 3|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
16595634|NCT02641340|Experimental|Cycle 3, Cohort 4|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
16595635|NCT02641327||Internal ward|Patients hospitalized in Internal Medicine unit with unstable blood pressure that need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical, hypotension or Hypertension patients, patients with kidney failure, heart disease, stroke)
16595636|NCT02641327||ICU|Patients hospitalized in intensive care with arterial line that allow continuous blood pressure measurement
16595637|NCT02641314|Experimental|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
16595638|NCT02641301|Experimental|Subjects Roux-en-Y-gastric bypass (RYGB)|Sustained release morphine sulfate, 30 mg
16595639|NCT02641301|Active Comparator|Control volunteers matched with RYGB|Sustained release morphine sulfate, 30 mg
16595640|NCT02641288|Experimental|Ropivacaine irrigation|Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
16595789|NCT02640222||AC-experienced treated with rivaroxaban|AC-experienced treated with rivaroxaban
16595641|NCT02641288|Placebo Comparator|Normal saline irrigation|Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
16595642|NCT02641275|Experimental|Intervention|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions.
16595643|NCT02641275|No Intervention|Control group|no intervention other than existing support (see exclusion criteria). However, intervention will be offered and studied secondary as well (after 1 1/2 year of no intervention).
16595644|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
16595645|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
16595646|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.
~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
16595647|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.
~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
16595648|NCT02641210|Experimental|Periodontal Treatment|The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration.
16595649|NCT02641210|No Intervention|No Periodontal Treatment|Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline.
16595650|NCT02641197|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after brachial artery occlusion by a standard upper arm pneumatic blood pressure cuff. The procedure is non-invasive and does not employ ultrasound.
16595651|NCT02641171||Entire Cohort|This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.
16595652|NCT02641158|Other|Control Group|
16595653|NCT02641158|Experimental|Care Facilitation Group|
16595654|NCT02641145|Experimental|Active AL cardiac amyloidosis|75 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of blood of the heart, as well as the heavy metal analysis of the blood at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
16595655|NCT02641145|Active Comparator|Remission AL cardiac amyloidosis|25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)<40 mg/dL for > 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart as well as a heavy metal analysis of the blood at baseline.
16595656|NCT02641145|Experimental|Active AL Pre-CMP|36 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up. Subjects with contraindications to Cardiac MRI or gadolinium contrast may still be eligible for study participation.
16595657|NCT02641145|No Intervention|Multiple Myeloma Controls|25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
16595658|NCT02641145|Experimental|Heart Failure|10 individuals with diagnosis of heart failure without amyloidosis by standard criteria will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline..
16595659|NCT02641132|Experimental|Pterygium surgery: Head and body.|Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.
16595660|NCT02641132|Active Comparator|Pterygium surgery: Body.|Application of Mitomycin C 0.02% after excision of the body only of the pterygium.
16595661|NCT02641119||Albumin|Patients receiving any amount of 5% albumin during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician.
16595662|NCT02641119||Saline-only|Patients receiving only saline during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician
16595663|NCT02641106|Experimental|Video Directly Observed Therapy|VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
16595790|NCT02640209|Experimental|Arm 1|
16595791|NCT02640196|Placebo Comparator|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
16595664|NCT02641106|Active Comparator|In-Person DOT|In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
16595665|NCT02641093|Experimental|Pembrolizumab|Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin
16595666|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
16595667|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
16595668|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
16595669|NCT02641067|Experimental|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
16595670|NCT02641054|Experimental|CVXL-0107 then cross-over to placebo|"Study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa.
~Cross-over to placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa"
16595671|NCT02641054|Placebo Comparator|Placebo then cross-over to CVXL-0107|"Placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa.
~Cross-over to study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa"
16595672|NCT02641041|Experimental|Cohort 1|A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1
16595673|NCT02641041|Experimental|Cohort 2|A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1
16595674|NCT02641041|Experimental|Cohort 3|One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15
16595675|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
16595676|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
16595677|NCT02641002|Experimental|Dose escalation of CC-90002|CC-90002 by intravenous (IV) infusion on a 28 day cycle
16595678|NCT02640989|Experimental|Group 1|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Seasonal trivalent influenza vaccine, Anflu®"
16595679|NCT02640989|Experimental|Group 2|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Seasonal trivalent influenza vaccine, VAXIGRIP"
16595680|NCT02640989|Active Comparator|Group 3|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Seasonal trivalent influenza vaccine, Fluarix"
16595681|NCT02640976|Active Comparator|Poor responders|"This group will include women who underwent IVF/ICSI cycle and produced 4 oocytes or less.
~intervention:
~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (300 IU).
~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.
~Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
16595682|NCT02640976|Active Comparator|Good responders|"This group will include women who produced (5 or more oocytes) after COH.
~Intervention:
~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml
~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.
~When at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
16595683|NCT02640963|Experimental|Intervention: the GrACE programme|The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
16595684|NCT02640963|Placebo Comparator|Control Group|All subjects assigned to the control group were given the option to engage in other activities that were offered by the facility during the 12-week intervention period. Activities were facility specific, and included Zumba aerobic exercise and walking, however no specific resistance exercises were offered.
16595685|NCT02640950|Experimental|Open-Label TMS|Active Transcranial Magnetic Stimulation
16595686|NCT02640937||Orthopaedic device related infections|"Inclusion Criteria:
~infections after fracture fixation or prosthetic joint surgery
~Affected bone or joint: Long bones of the lower extremity; hip joint, knee joint;
~Bacterial growth of S. epidermidis at the site of interest
~Written consent
~Age: 18 and older"
16595687|NCT02640924|Experimental|Proton radiotherapy|Proton radiotherapy will be totally 66 cobalt gray equivalent (CGE) in 10 fractions and delivered once daily, 5 fractions per week, over 2 weeks for HCC more than 1 cm away from the alimentary tract.
16595792|NCT02640196|Placebo Comparator|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope laryngoscope followed with intubating the difficult airway simulator
16595793|NCT02640196|Active Comparator|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq laryngoscope followed with intubating the difficult airway simulator
16597020|NCT02632214|Experimental|Hearing signers|Group of hearing signer controls fMRI measure
16595688|NCT02640924|Experimental|Radiofrequency Ablation|Multiple-electrode radiofrequency with switch-controller system (ME-SWC RFA) can create a large coagulation necrosis volume and successful treat HCC sized more than 3 cm, extending to 8.5 cm. ME-SWC RFA system uses up to 3 electrodes parallel insertion to inside of the tumors with an equilateral triangular confirmation before initiation of ablation. The distances between electrodes are about 1.5-2 cm, estimated by ultrasound measuring. The switching machine is set on the auto-mode, and all electrodes work alternately and switching each other automatically after impendence surge.
16595689|NCT02640898|Active Comparator|FU-based chemoradiotherapy|patients will be treated with the INT0116 regimen.
16595690|NCT02640898|Experimental|docetaxel-based chemoradiotherapy|patients will be treated with modified DCF chemotherapy in combination with docetaxel-based chemoradiotherapy.
16595691|NCT02640885|Experimental|Foley's cather tamponade|Balloon tamponade with 2-way Foley's Cather was successfully used during cesarean section due to sever postpartum haemorrhage after failure of medical treatment.
16595692|NCT02640872||HAPPY Cohort|A elderly cohort for chronic diseases
16595693|NCT02640859||Normal cohort|Normal cohort for biobank
16595694|NCT02640846|Active Comparator|Norepinephrine|Doser
16595695|NCT02640846|Active Comparator|Milrinone|Doser
16595696|NCT02640846|Active Comparator|Levosimendan|Doser
16595697|NCT02640833|Experimental|Duvelisib+Venetoclax|
16595698|NCT02640820|Experimental|Sensitization Phase|Up to two doses of Sensitizing DPCP Ointment will be applied and subjects who exhibit a sensitization response will enter the Treatment Phase. Pharmacokinetics (PK) of Sensitizing DPCP Ointment will be measured in a subset of subjects. For PK, blood will be collected prior to application of the Sensitizing DPCP Ointment and again at 1, 2, and 24 hours after application.
16595699|NCT02640820|Experimental|Treatment Phase|In the Treatment Phase, subjects will receive doses of Treatment DPCP Ointment weekly for 10 weeks. Subjects who at the end of the Treatment Phase have exhibited partial clearance of warts may be given the option to continue with an additional 10 weekly treatments.
16595700|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
16595701|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
16595702|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
16595703|NCT02640794|Active Comparator|Aspirin +clopidogrel|Patients would be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d)
16595704|NCT02640794|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d)
16595705|NCT02640781|Experimental|covered stent|newly designed covered stent group
16595706|NCT02640781|Active Comparator|uncovered stent|currently used uncovered stent group
16595707|NCT02640768|Experimental|educational training|educational training
16595708|NCT02640768|No Intervention|no educational training|no educational training wards
16595709|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
16595710|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
16595711|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
16595712|NCT02640729|Experimental|Nelotanserin|Nelotanserin 40mg then nelotanserin 80 mg
16595713|NCT02640729|Placebo Comparator|Placebo|Placebo
16595714|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
16595715|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
16595716|NCT02640703|Active Comparator|morning vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 am
16595717|NCT02640703|Active Comparator|evening vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 pm
16595720|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
16595724|NCT02640651|Experimental|DC-Stimulator (PLUS version)|For tDCS stimulation, anodal stimulation of the right dorsolateral prefrontal cortex will be performed for twenty minutes at 2mA. The current will be applied by a battery-driven tDCS stimulator via a pair of saline-soaked sponge electrodes (25 cm2 surface). The anodal electrode will be placed on the scalp at the F4 position according to the international 10-20 EEG coordinate system. 20 minute tDCS sessions will be conducted ten times over a two week period
16595725|NCT02640638|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care
16595726|NCT02640638|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care
16595727|NCT02640625|Experimental|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
16595728|NCT02640612|Experimental|BI 695501|
16595729|NCT02640599|Experimental|Vestibular Rehabilitation + Areobic Exercise|
16595730|NCT02640599|Active Comparator|Vestibular Rehabilitation|
16595794|NCT02640196|Active Comparator|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
16595731|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).
~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
16595732|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
16595733|NCT02640560||Children with food allergy|"Children with food allergy to nuts, hazelnuts, walnuts, shellfish and mollusks (1-14 years old).
~The Parents of the cases children will compile a Food allergy questionnaire"
16595734|NCT02640560||Healthy Children|Healthy Children (1-14 years old) The Parents of the control children will compile a Control questionnaire
16595735|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
16595736|NCT02640534|Experimental|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
16595737|NCT02640534|Active Comparator|Enzalutamide|Enzalutamide 160 mg od until disease progression
16595738|NCT02640521|No Intervention|Control Parents|
16595739|NCT02640521|Active Comparator|Treatment Parents|Chart reminders (paper or electronic medical records, depending on clinic wishes) to prompt providers to ask about in home smoking at every medical visit; establishing a New York State Quit line referral system in the pediatric practice; and amending the training curriculum for providers and the patient education materials that are part of a provider toolkit, to focus on the negative impact of second hand smoke (SHS) on their children,and specifically, asthma outcomes.
16595740|NCT02640508|Experimental|Combination Eribulin and lenvatinib|Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.
16595741|NCT02640495||Study subjects|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
16595742|NCT02640482|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind [DB] treatment period)
16595743|NCT02640482|Experimental|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
16595744|NCT02640482|Experimental|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label [OL] treatment period)
16595745|NCT02640469|Active Comparator|Chlorhexidine with water rinse|This is a traditional method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
16595746|NCT02640469|Experimental|Chlorhexidine without water rinse|This is an experimental method of disinfection. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
16595747|NCT02640469|Active Comparator|Chlorhexidine + sterillium hand rub|This is a standard method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
16595748|NCT02640456||Para- or retropharyngeal abscess|Patients with para- or retropharyngeal abscess.
16595749|NCT02640456||Neck abscess|Patients with neck abscess without relation to the pharynx or salivary glands.
16595750|NCT02640443|Experimental|Treatment|Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.
16595751|NCT02640430|Active Comparator|standard treatment|"Control group will be made of 20 COPD patients with severe and very severe airflow obstruction, mucus hypersecretion and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.
~Control group will b treated with PEP-bottle over 10 daily sessions (20 minutes twice a day). Patients are asked to breath against a positive expiratory pressure determined by a column of water in a bottle (PEP Bolltle). PEP is one of the validated treatment used in the clearance of bronchial secretions in COPD patients.
~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
16595752|NCT02640430|Experimental|Free Aspire|"Experimental group will be made of 20 COPD patients with severe and very severe airflow obstruction , mucus hypersecretion , and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.
~Patients are asked to use FREE ASPIRE Free Aspire is an electro-medical device which removes bronchopulmonary secretions noninvasively, without using a suction catheter and without generating airway pressure, positive or negative.
~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
16595753|NCT02640417|Experimental|Nucleotides + B12|Nucleotides + Vitamin B12 Dose: two capsules, three times per day + placebo corresponding to Group B treatment
16595754|NCT02640417|Active Comparator|B vitamins|Vitamin B1 + Vitamin B6 + Vitamin B12 Dose: one tablet, three times daily + placebo corresponding to Group A treatment
16595755|NCT02640404|Experimental|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
16595756|NCT02640404|Experimental|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
16595757|NCT02640391||Quiescent UC|Patients with quiscent UC who will undergo colonoscopy for surveillance or mucosal healing check up
16595825|NCT02639975|Experimental|600 mg PBF-677|
16595826|NCT02639975|Placebo Comparator|Placebo 100 mg|
16595827|NCT02639975|Placebo Comparator|Placebo 200 mg|
16595758|NCT02640365|Experimental|GROUP A / GROUP B (two differents cohorts)|"GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)
~Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)
~MM-398 : 60mg/m²
~Irinotecan (CPT-11) : 90mg/m²
~Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)
~MM-398 : 80mg/m²
~CPT-11: 90mg/m²
~Level 3A: DOUBLIRI dose 60/120 (12-18 patients)
~MM-398 : 60mg/m²
~CPT-11: 120mg/m²
~Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)
~MM-398 : 80mg/m²
~CPT-11 : 120 mg/m²
~GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)
~same level as group A + LV/5FU - bevacizumab regimen :
~Bevacizumab : 5mg/kg(day (d) 1)
~Leucovorin (LV) : 400mg/m² (d1)
~5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)"
16595759|NCT02640352|Active Comparator|Probi Defendum|Dietary supplement (tablet) with probiotics
16595760|NCT02640352|Placebo Comparator|Placebo|Dietary supplement (tablet) without probiotics
16595761|NCT02640339||Parkinson Disease|Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, with alpha-synuclein deposits in neurons which aggregate into Lewy bodies.
16595762|NCT02640339||Mutiple system atrophy|is a degenerative neurological disorder. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance, and autonomic functions of the body such as bladder control or blood-pressure regulation. Neuronal death probably occurs as a consequence of alpha-synuclein aggregation in oligodendroglia.
16595763|NCT02640339||REM sleep behavior disorder|a sleep disorder in which you physically act out vivid, often unpleasant dreams with vocal sounds and sudden, often violent arm and leg movements
16595764|NCT02640339||dementia with Lewy bodies|"causes a progressive decline in mental abilities.
~It may also cause visual hallucinations, which generally take the form of objects, people or animals that aren't there. This can lead to unusual behavior such as having conversations with deceased loved ones.
~Another indicator of Lewy body dementia may be significant fluctuations in alertness and attention, which may include daytime drowsiness or periods of staring into space. And, like Parkinson's disease, Lewy body dementia can result in rigid muscles, slowed movement and tremors."
16595765|NCT02640339||Pure autonomic failure|Pure autonomic failure is dysfunction of many of the processes controlled by the autonomic nervous system, such as control of blood pressure•Blood pressure may decrease when people stand, and they may sweat less and may have eye problems, retain urine, become constipated, or lose control of bowel movements
16595766|NCT02640339||Healthy controls|Healthy normals with no neurological involvement
16595767|NCT02640326|Active Comparator|Active Comparator|The catheterized arm will have Standard of care Foley urinary catheter insertion according to usual institutional care pathways in the operating room prior to surgery initiation. The urinary catheter will be assessed for removal on the morning of post-operative day 1, and patients will be monitored for urinary complications once catheter is removed until patient has successfully voided spontaneously within 8 +/- 2 hours.
16595768|NCT02640326|Experimental|Experimental Arm|The non-catheterized arm will have standard of care Foley urinary catheter insertion, with no Foley Urinary Catheter inserted prior to, during, or after surgery unless the patient is showing signs of urinary retention after surgery. Patient will be monitored for urinary complications starting in the recovery room until patient has successfully voided spontaneously within 8 +/- 2 hours
16595769|NCT02640313|Experimental|18F-choline PET-MR imaging|"Intervention: 18F-choline PET-MR imaging.
~Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.
~Procedure: dynamic and static 18F-choline PET-MR."
16595770|NCT02640300|Experimental|Immediate discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules at week 3. All capsules contained placebo (i.e., the antipsychotic drugs were abruptly discontinued). Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
16595771|NCT02640300|Experimental|Gradual discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
16595772|NCT02640287|Experimental|Waldenström macroglobulinemia|Patients with diagnosis of Waldenström macroglobulinemia
16595773|NCT02640287|Experimental|Others B-cell malignancies|Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma
16595774|NCT02640287|Other|Healthy subjects|Control healthy subjects without B-cell malignancy
16595775|NCT02640274|Experimental|Intervention group|The intervention is an individual nurse-led counselling programme in addition to usual care.
16595776|NCT02640274|Other|Control group|usual care
16595777|NCT02640261||Group 1|Single embryo transfer on day 5, according to standard embryo morphological criteria
16595778|NCT02640261||Group 2|Single embryo transfer on day 5, chosen on the basis of both embryo morphological criteria and levels of cytokines measured in the individual FF.
16595780|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
16595781|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
16595782|NCT02640222||AC-naive treated with VKA|AC-naive treated with VKA
16595783|NCT02640222||AC-naive treated with apixaban|AC-naive treated with apixaban
16595784|NCT02640222||AC-naive treated with dabigatran|AC-naive treated with dabigatran
16595785|NCT02640222||AC-naive treated with rivaroxaban|AC-naive treated with rivaroxaban
16595795|NCT02640183|Experimental|Group A (EMLA)|3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
16595796|NCT02640183|Placebo Comparator|Group B (Placebo)|3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
16595797|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
16595798|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
16595799|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
16595800|NCT02640144|Active Comparator|Treatment group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of Sodium Hyaluronate 1% - ARTHREASE TM
16595801|NCT02640144|Placebo Comparator|Control group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of BPS - Buffer Phosphate Solution - as a placebo
16595802|NCT02640131|Experimental|BSHR Intervention|"Couples will attend 30-minute clinic consultations with an Urologist and a Sexual Health Counsellor and receive session-specific chapters of the Kindness, Intimacy, Sexuality and Satisfaction manual over the course of the intervention.
~The BSHR Intervention involves two complementary components; the bio-medical, and the psychosocial. The bio-medical component for both arms intervention includes an urologist consultation at a pre-operative appointment and 5 f/u appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
~The psychosocial component aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive sexual health counseling and manualized support."
16595803|NCT02640131|Active Comparator|Attention Control|"Survivorship Counseling: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) and receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You Manual. The bio-medical component is the same in both arms.
~The core topics discussed during over 7 counseling sessions include: preparation for immediate post-surgery recovery, Kegel exercises, nutrition and prostate cancer, exercise and prostate cancer, and maintaining healthy lifestyle change."
16595804|NCT02640118|Active Comparator|Pancreatectomised + Lixisenatide|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a Lixisenatide-injection will be given subcutaneously"
16595805|NCT02640118|Placebo Comparator|Pancreatectomized + lixisenatide-placebo|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a placebo-injection will be given subcutaneously."
16595806|NCT02640118|Active Comparator|Healthy + Lixisenatide|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a Lixisenatide-injection will be given subcutaneously"
16595807|NCT02640118|Placebo Comparator|Healthy + lixisenatide-placebo|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a placebo-injection will be given subcutaneously"
16595808|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
16595809|NCT02640092|Experimental|[18F]GTP1|Participants will complete [18F]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each [18F]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of [18F]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]GTP1.
16595810|NCT02640079|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy aimed at reducing pain catastrophizing.
16595811|NCT02640066|Experimental|acupuncture|acupuncture treatment with Supportive care
16595812|NCT02640066|No Intervention|standard treatment|Supportive care measures only
16595813|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
16595814|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
16595815|NCT02640040|Experimental|combined surgery|combined surgery for enrolled patients with CPT(Congenital Pseudarthrosis of Tibia): sleeve resection of the pathological soft tissues, intramedullary rod fixation, packaged lilac bone autograft,and llizarov external fixation device installation.
16595816|NCT02640027|No Intervention|Treatment in the Clinic Only|Patients in Group A will receive their follow-up care entirely at the investigators institution
16595817|NCT02640027|Experimental|Treatment in the Clinic and at Home|Cast removal at home using a telemedicine tool
16595818|NCT02640014|Experimental|Study 1: Milk OIT follow up|Follow up on patient with severe milk allergy how have participated to milk OIT.
16595819|NCT02640014|No Intervention|Study 1: Follow up|Follow up on patient with severe milk allergy how have not participated to milk OIT.
16595820|NCT02639988||rheumatoid arthritis and type 2 diabetes|
16595821|NCT02639988||osteoarthritis and type 2 diabetes|
16595822|NCT02639975|Experimental|100 mg PBF-677|
16595823|NCT02639975|Experimental|200 mg PBF-677|
16595824|NCT02639975|Experimental|400 mg PBF-677|
16595830|NCT02639962||NSTEMI|patients hospitalized with NSTEMI diagnosed according to the national Danish guidelines, and are scheduled to coronary angiography.
16595831|NCT02639962||patients with stable angina pectoris|Patients in this group have stable angina symptoms and had verified plaques by earlier CAG or Cardiac CT
16595832|NCT02639949|Experimental|Group CBT|
16595833|NCT02639949|Active Comparator|Standard Care|
16595834|NCT02639936||Immunocompetent controls|Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
16595835|NCT02639936||Solid organ transplant recipients|Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
16595836|NCT02639936||Stem cell transplant recipients|Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
16595837|NCT02639936||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
16595838|NCT02639936||Patients with chronic renal failure|Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
16595839|NCT02639936||Individuals with HIV infection|Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
16595840|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
16595841|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
16595842|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
16595843|NCT02639910|Experimental|Cohort A|tafasitamab (MOR208) in combination with idelalisib
16595844|NCT02639910|Experimental|Cohort B|tafasitamab (MOR208) in combination with venetoclax
16595845|NCT02639884|Experimental|Evaluation Group|All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring
16595846|NCT02639871||healthy volunteers|31P-MR Spectroscopy and CEST for Validation of MRI/MRS methods
16595847|NCT02639871||HD presymptomatic individuals|General medical exam Clinical assessment with illness rating scales: Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS) and Total Functional Capacity (TFC), 31P-MR Spectroscopy and CEST
16595848|NCT02639871||early affected HD patients|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
16595849|NCT02639871||Controls|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
16595850|NCT02639858|Experimental|Docetaxel-PM|Docetaxel-PM 75mg/m2 IV infusion
16595851|NCT02639845||Patients Prescribed Eye Drops|Patients who are scheduled to receive prescription eye drops due to complications such as cataract surgery, glaucoma, retina surgery, or eye-related condition.
16595852|NCT02639819|Experimental|Treatment|Study drug
16595853|NCT02639806||Prospective - General Anesthetic|The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
16595854|NCT02639806||Retrospective - Local Anesthetic with Sedation|The retrospective group will have received local anesthetic from the surgeon using lidocaine injected subcutaneously and received sedation using fentanyl and midazolam as needed to achieve the desired level of sedation.
16595855|NCT02639793|Active Comparator|manual radiofrequency ablation|Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
16595856|NCT02639793|Active Comparator|magnet navigation ablation|Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
16595857|NCT02639793|Active Comparator|cryoablation|Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
16595858|NCT02639780||healthy young female|
16595859|NCT02639780||healthy young male|
16595860|NCT02639780||healthy older female|
16595861|NCT02639780||healthy older male|
16595862|NCT02639780||obese older female|
16595863|NCT02639780||obese older male|
16595864|NCT02639767|Experimental|pemetrexed/cisplatin with pleural IMRT|This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.
16595865|NCT02639754|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
16595866|NCT02639754|Active Comparator|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
16595867|NCT02639741|Active Comparator|Oral Melatonin Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of melatonin (6 mg) or placebo tablet will be given one hour before the start of anesthesia.
16595868|NCT02639741|Active Comparator|Oral Vitamin C Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of vitamin C (2 gr) or placebo tablet will be given one hour before the start of anesthesia.
16595869|NCT02639741|Placebo Comparator|Oral Placebo Tablet|Preoperative single oral dose of placebo tablet will be given one hour before the start of anesthesia.
16595894|NCT02639572|Placebo Comparator|Hydroxyapatitie Bone graf|Based on the sequence, the control site which was treated by Hydroxyapatite graft only.
16596522|NCT02635451||study group|Study group included 20 pregnant women with PPROM and fulfilled the inclusion and exclusion criteria.
16595870|NCT02639728|Experimental|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
16595871|NCT02639728|Experimental|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
16595872|NCT02639728|Experimental|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
16595873|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
16595874|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
16595875|NCT02639689|Experimental|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.
~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
16595876|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
16595877|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
16595878|NCT02639663|Experimental|women whom are interested in breastfeeding and have not begun.|"Post-partum primi and multiparous women Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
~Control group: participants will not receive any device for breastfeeding pain control"
16595879|NCT02639663|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
16595880|NCT02639650|Active Comparator|control group|etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle
16595881|NCT02639650|Experimental|study group|paclitaxel + cisplatin or carboplatin，two weeks a cycle
16595882|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
16595883|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
16595884|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
16595885|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
16595886|NCT02639624|Experimental|Low bicarbonate dialysate First|Dialysis with low bicarbonate dialysate (expected normal for an adult ~24 mEq) for the first half of dialysis then switched over to normal bicarbonate dialysate for the second half.
16595887|NCT02639624|Active Comparator|Normal bicarbonate dialysate First|Dialysis with normal (37 mEq) for the first half of dialysis then switched over to low bicarbonate dialysate
16595888|NCT02639611|Active Comparator|Immediate Post Operative Acupuncture Treatment|
16595889|NCT02639611|Active Comparator|Acupuncture Treatment After 6 Weeks of Recovery|
16595890|NCT02639598|Experimental|flunarizine|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).
~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 5 mg/day flunarizine once daily in the first week, followed by 10 mg/day flunarizine in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
16595891|NCT02639598|Active Comparator|topiramate|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).
~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 25 mg/day topiramate once daily in the first week, followed by 50 mg/day topiramate in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
16595892|NCT02639585|Experimental|Treatment arm|Daclinza and Sunvepra
16595895|NCT02639559|Experimental|Arm 1: Donors|-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10^6 CD34+ cells/kg and at least ≥ 2 x 10^6 CD34+ cells/kg from the combined collections.
16595896|NCT02639559|Experimental|Arm 2: Recipients|-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0
16595897|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595898|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595899|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595900|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595901|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595902|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595903|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1.33 mg/kg)|Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595904|NCT02639546|Experimental|Phase II (Suspension) Cobimetinib (1 mg/kg)|Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
16595905|NCT02639533|Experimental|Pregabalin|Pregabalin 150 mg PO single dose
16595906|NCT02639533|Placebo Comparator|Placebo|Placebo (a pill of same physical characteristics as the one used for the experimental arm, containing starch) PO single dose
16595907|NCT02639520|Active Comparator|Group Canephron® N|Canephron® N & fosfomycin trometamol-placebo
16595908|NCT02639520|Active Comparator|Group Fosfomycin Trometamol|Canephron® N-placebo & fosfomycin trometamol
16595909|NCT02639494|Experimental|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
16595910|NCT02639481|Active Comparator|Control group standard physiotherapy|Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
16595911|NCT02639481|Active Comparator|Erigo®Pro group without FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
16595912|NCT02639481|Active Comparator|Erigo®Pro group with FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
16595913|NCT02639468|Experimental|Tomographie par impédance électrique|Tomographie par impédance électrique
16595914|NCT02639455|No Intervention|Athlete group|Participants wo regularly exercise and are student athletes.
16595915|NCT02639455|No Intervention|Non-exercise group|Participants who are not student athletes.
16595916|NCT02639455|Experimental|Exercise group|Participants are not student athletes but commit to modest exercise for 5 weeks as part of this study.
16595917|NCT02639442|Experimental|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
16595918|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
16595919|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
16595920|NCT02639416|Active Comparator|Standard management|Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days
16595921|NCT02639416|Experimental|Polymeric formula|Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
16595922|NCT02639416|Experimental|Elemental formula|Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
16595923|NCT02639403|Experimental|RT for Obstructing Rectal Cancer|Conformal three-dimensional RT was planned (3D-RT) in patients with obstructing rectal cancer not amenable for curative resection
16595924|NCT02639390|Experimental|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
16595925|NCT02639390|Active Comparator|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
16595926|NCT02639377|Experimental|Chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
16595927|NCT02639377|Placebo Comparator|Placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
16595928|NCT02639364|Active Comparator|conventional ventilation strategy|The conventional ventilation strategy use volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, combination with low tidal volume and adequate PEEP level.
16595929|NCT02639364|Experimental|BILEVEL-APRV protocol|According to our BILEVEL-APRV protocol, BILEVEL-APRV APRV mode with specific settings,combination with spontaneous breathing.
16595930|NCT02639351|Experimental|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
16595931|NCT02639351|Experimental|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
16595932|NCT02639351|Experimental|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
16595933|NCT02639351|Experimental|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
16595934|NCT02639351|Active Comparator|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
16595935|NCT02639338|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
16595936|NCT02639338|Experimental|SOF/VEL|SOF/VEL tablet for 12 weeks
16595938|NCT02639312||1|hemifacial microsomia
16595939|NCT02639312||2|mandibular prognathism
16595941|NCT02639286|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC)
16595942|NCT02639286|Experimental|ISIS 304801|300 mg of study drug administered via SC
16595945|NCT02639260|Experimental|Cohort A|3,000 mg/day
16595946|NCT02639260|Experimental|Cohort B|10000 mg/day
16595947|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
16595948|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16595949|NCT02639234|Experimental|Vigil™ + Nivolumab|Patients meeting study eligibility criteria will receive doublet therapy comprising of (i) Vigil™ 1 x 10^7 cells by intradermal injection every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and (ii) nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks.
16595950|NCT02639221|Experimental|PXT002331|
16595951|NCT02639221|Placebo Comparator|Placebo|
16595952|NCT02639208|Experimental|PatientsLikeMe (PLM)|"After the screening procedures confirm eligibility.
~Baseline Survey Assessment and PatientsLikeMe Introduction
~Treatment Evaluation on PLM website at predetermined times per protocol
~Final Survey"
16595953|NCT02639195||Treatment, retrospective|Retrospective analysis on patients treated with manual physical therapy in quality of life outcomes as measured by pre and post treatment questionnaires. Chart review.
16595954|NCT02639195||Untreated control|Prospective data collection via questionnaire of subjects with a history of small bowel obstruction in an observational manner. No treatment is performed.
16595955|NCT02639182|Experimental|AGS-16C3F|Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
16595956|NCT02639182|Active Comparator|Axitinib|Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
16595957|NCT02639169|Experimental|music|Apply live music through techniques music therapy in group experimental and evaluation through the visual analog scale (VAS) and numeric.
16595958|NCT02639169|No Intervention|Comparative|Apply the visual analog scale (VAS) and numeric.
16595959|NCT02639156|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day will be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days.
16595960|NCT02639143|Experimental|ticagrelor|Ticagrelor, 180 mg, oral administration. followed by 90 mg bid
16595961|NCT02639143|Active Comparator|Clopidogrel|Clopidogrel 600 mg loading dose taken orally, followed by 75 mg qd.
16595962|NCT02639130|Active Comparator|Vildagliptin|"After a screening examination, patients were treated with vildagliptin and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.
~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.
~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
16595963|NCT02639130|Placebo Comparator|Placebo|"After a screening examination, patients were treated with placebo, and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.
~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.
~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
16595964|NCT02639117|Other|Vismodegib|Vismodegib 150 mgs po qd. Open label.
16596003|NCT02638831|Experimental|Ketorolac Tromethamine|Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
16595965|NCT02639104|Experimental|Cervical postural related neck pain|Patients recruit in this group who has a neck pain without radiculopathy. If the patient examination shows neurologic deficits, this patient will exclude in this study. All patients will undergo lateral cervical spine spot radiography and serratus anterior needle electromyography. Cervical segmental angle measurements will be done in all patients.
16595966|NCT02639104|Sham Comparator|Control group|The healthy volunteers recruit in this group. All inviduals will undergo lateral cervical spot radiography and serratus anterior needle electromypography
16595967|NCT02639091|Experimental|BAY 94-9343 + Pemetrexed + Cisplatin|Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
16595968|NCT02639078|Experimental|TD-0714|One time dosing in capsule formulation
16595969|NCT02639078|Placebo Comparator|Placebo|Placebo comparator one time dosing in capsule formulation
16595970|NCT02639065|Experimental|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
16595971|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
16595972|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
16595973|NCT02639039|Active Comparator|Cortisone Injection|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
16595974|NCT02639039|Active Comparator|Trigger Point Dry Needling|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
16595975|NCT02639026|Experimental|Cohort 1|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 1 tests 8 Gy x 3 fractions
16595976|NCT02639026|Experimental|Cohort 2|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 2 tests 17 Gy x 1 fraction.
16595977|NCT02639013|Experimental|ttransducer technique|the nurses will measure intraabdominal pressure at each shift during the day by using transducer technique
16595978|NCT02639000|Experimental|Blastocyst|Embryo transfer of at maximum 2 embryos at blastocyst stage
16595979|NCT02639000|Active Comparator|Cleavage|Embryo transfer of at maximum 2 embryos at cleavage stage
16595980|NCT02638987|Experimental|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
16595981|NCT02638987|No Intervention|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
16595982|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
16595983|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
16595984|NCT02638961|Placebo Comparator|Standard treatment|Only standard medical treatment
16595985|NCT02638961|Active Comparator|IMT group|Standard medical treatment associated to Inspiratory muscle training
16595986|NCT02638961|Active Comparator|FES group|Standard medical treatment associated to functional electrostimulation of both legs for 45 minutes a day, 2 days per week for a total of 12 weeks.
16595987|NCT02638961|Active Comparator|IMT+FES group|Standard medical treatment associated to combination of inspiratory muscle training and functional electrostimulation of both legs
16595988|NCT02638948|Placebo Comparator|Placebo|Placebo + Methotrexate dose as specified
16595989|NCT02638948|Experimental|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
16595990|NCT02638948|Experimental|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
16595991|NCT02638935|Other|BI-RADS 3|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
16595992|NCT02638935|Other|BI-RADS 4a|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
16595993|NCT02638935|Other|BI-RADS 4b|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
16595994|NCT02638935|Other|BI-RADS 4c|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
16595995|NCT02638922||no treatment|girls who never received estradiol treatment
16595996|NCT02638922||Estradiol treatment|girls who received estradiol treatment
16595997|NCT02638909|Experimental|ceritinib|Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
16595998|NCT02638896|Experimental|Dose reduction arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
16595999|NCT02638896|Active Comparator|Dose maintenance arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
16596000|NCT02638896|Other|Etanercept discontinuation arm|AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.
16596001|NCT02638857|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.
16596002|NCT02638857|Experimental|DC-PMAT cells|After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.
16596075|NCT02638285|Experimental|LH group|LH group
16596076|NCT02638285|Experimental|clomiphene citrate|clomiphene citrate
16596004|NCT02638831|Active Comparator|Ketoprofen|Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
16596005|NCT02638818||minimally invasive whipple|Surgical technique (minimally invasive vs open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
16596006|NCT02638818||traditional whipple|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
16596007|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
16596008|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
16596009|NCT02638792|Experimental|Internet-based exposure therapy|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
16596010|NCT02638792|Active Comparator|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
16596011|NCT02638792|No Intervention|Waitlist|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, and 4, 12 months later using the same questionnaires as the treatment group. The participants will be able to choose which treatment they receive i.e. no randomization.
16596012|NCT02638779|Experimental|Blood sampling|Blood sampling will be performed in all patients and healthy volunteers
16596013|NCT02638766|Other|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
16596014|NCT02638753|Active Comparator|Education|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology.
16596015|NCT02638753|Experimental|Education combined with hypnosis|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology combined with hypnosis.
16596016|NCT02638740|Active Comparator|SCALING AND ROOT PLANING (SRP)|Scaling and root planning with ultrasonic scalar
16596017|NCT02638740|Experimental|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
16596018|NCT02638727|Active Comparator|Drug Arm|This group treat with L-Citrulline (3 grams per day)
16596019|NCT02638727|Placebo Comparator|Placebo Arm|this group treat with placebi every day
16596020|NCT02638714|Experimental|Stem Cells|Intervention: Transplantation of autologous purified stem cells
16596021|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
16596022|NCT02638688||2D ultrasound|2D-US measurements are the most accurate method for measuring fibroid volumes
16596023|NCT02638688||3D ultrasound|3D-US measurements are the most accurate method for measuring fibroid volumes
16596024|NCT02638688||postoperative|actual volume using change in water path measurements are the most accurate method for measuring fibroid volumes
16596025|NCT02638675|Experimental|Wellness program, accelerometer, incentives|During the intervention period (weeks 1 to 12), intervention participants will be eligible to earn daily reward points contingent on step count goal achievement. Intervention participants will earn 100 reward points (i.e. $1) for each day that specific step count goals are reached. During weeks 13 to 24, participants will no longer receive daily reward points for completing specific step count goals.
16596026|NCT02638675|Active Comparator|Wellness program and accelerometer|During the 24 week trial, control participants will receive no additional incentives when step count goals are reached.
16596027|NCT02638662||First time IVF patients. Observational|Those who are doing IVF for the first time.
16596028|NCT02638662||Donors Observational|Those who are doing IVF for the sole purpose of donating their eggs.
16596029|NCT02638662||2 or more IVF cycles Obervational|Those who have done IVF 2 or more times with no success.
16596030|NCT02638649||subjects who call 911 for dyspnea|All subjects who call 9-1-1 for difficulty breathing will have the potential to be enrolled in the study.
16596031|NCT02638636|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
16596032|NCT02638636|No Intervention|Waitlist|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment when the first group has finished (i.e. week 10).
16596033|NCT02638623|Active Comparator|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
16596034|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
16596035|NCT02638610|Experimental|Sensation measurement|patients with eyelid pathology going through eyelid surgery.
16596036|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
16596037|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
16596038|NCT02638584|Experimental|Ilaprazole|Ilaprazole tab 10mg, 2 tablets once daily for 8 weeks.
16596039|NCT02638584|Active Comparator|Rabeprazole|Rabeprazole tab 20mg, 1 tablet once daily for 8 weeks.
16596132|NCT02637921|Experimental|Hypoxic Bed rest|Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
16596040|NCT02638571|Sham Comparator|Usual education|Households in the control clusters (kebeles) will receive usual nutrition education from Health extension workers, about complementary foods, over 9 months.
16596041|NCT02638571|Experimental|Enhanced Education|Additional education sessions from Health extension workers (HEWs) trained on use of pulses for complementary foods (CF). HEWs provide nutrition education programs and counseling about pulse-cereal mix complementary foods, over 9 months.
16596042|NCT02638558|Experimental|written + oral explanation|patients will undergo both written and oral explanation for preparation with split dose
16596043|NCT02638558|Experimental|written explanation|patients will receive only a written explanation for preparation with split dose
16596044|NCT02638545|Experimental|dexmedetomidine|
16596045|NCT02638532|Other|Foot Fat Pad Grafting|All subject who enter into the study will undergo the fat pad grafting procedure to either the Heel or Forefoot based on the discretion of the PI, Co-investigator and the study subject.
16596046|NCT02638519|Other|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
16596047|NCT02638519|Other|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
16596048|NCT02638506|Experimental|Intranasal Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
16596049|NCT02638506|Placebo Comparator|Salinex|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
16596050|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
16596051|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
16596052|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
16596053|NCT02638480|No Intervention|Control|The control subjects will be treated with only the current SOC including NSAIDs and physical therapy.
16596054|NCT02638480|Experimental|Experimental|The experimental subjects will be treated with current SOC and will also use a kneeMD splint 3 times a day for 20 minutes per session
16596055|NCT02638467|Experimental|Bosutinib and Bone Marrow Transplant|Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI. Patients will be transplanted with the aim to transplant > 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow. Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
16596056|NCT02638454|Active Comparator|HL-YNG|"Healthy young sedentary males and females 20-30 yrs old
~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
16596057|NCT02638454|Experimental|FL-OLD|"Functionally-limited older sedentary males and females without sarcopenia (70-85 yrs old)
~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
16596058|NCT02638454|Experimental|SR-OLD|"Functionally-limited older sedentary males and females with clinically defined sarcopenia (70-85 yrs old)
~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
16596059|NCT02638428|Experimental|Refractory/relapsed solid tumor or AML|Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
16596060|NCT02638415|Experimental|HVPG group|HVPG-guided therapy
16596061|NCT02638415|Other|non-HVPG group|routine therapy
16596062|NCT02638402||Stage I, II, III, IV ovarian cancer|Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
16596063|NCT02638402||Stage I, II, III, IV endometrial cancer|Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital
16596064|NCT02638389|Experimental|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
16596065|NCT02638376|Active Comparator|KXL treatment only|
16596066|NCT02638376|Active Comparator|KXL and topography-guided PRK|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
16596067|NCT02638350|Experimental|Intervention lung ultrasound|All patients will have strategy with lung ultrasoundlung ultrasound
16596068|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
16596069|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
16596070|NCT02638324|Active Comparator|Renal nervous denervation.|Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
16596071|NCT02638324|Active Comparator|Renal nervous denervation (delayed)|Renal nervous denervation is performed after six months on the waiting list
16596072|NCT02638298|Experimental|NPWT dressing|
16596073|NCT02638298|Placebo Comparator|Standard dry gauze dressing|
16596074|NCT02638285|Experimental|HCG group|HCG group
16596077|NCT02638272|Other|spine surgery|The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.
16596078|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
16596079|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
16596080|NCT02638246|Experimental|Contingent|Participants in this group received incentives contingent on meeting pre-specified daily blood-glucose testing adherence goals.
16596081|NCT02638246|Active Comparator|Noncontingent|Participants in this group received incentives independent of meeting pre-specified daily blood glucose testing adherence goals.
16596082|NCT02638233|Other|Sofosbuvir 400mg/Ledipasvir 90 mg|Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC) for 8 weeks
16596083|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
16596084|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
16596085|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
16596086|NCT02638194|Active Comparator|Hookah Smoking Group|10 participants will smoke tobacco hookah for 2 hours
16596087|NCT02638194|Active Comparator|Hookah Secondhand Smoke Group|10 individuals will be exposed to secondhand hookah tobacco smoke for 2 hours
16596088|NCT02638181|Experimental|trabeculectomy|
16596089|NCT02638168|Active Comparator|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
16596090|NCT02638168|Placebo Comparator|Placebo|inert placebo ingredient
16596091|NCT02638155||Food Addiction Group|Those participants identified as having food addiction by the Yale Food Addiction Scale.
16596092|NCT02638155||No Food Addiction Group|Those participants with no identified food addiction
16596093|NCT02638142||Continuous Furosemide Infusion|continuous intravenous furosemide infusion
16596094|NCT02638142||Intermittent Furosemide Infusion|bolus intermittent intravenous furosemide infusion
16596095|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
16596096|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
16596097|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
16596098|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
16596099|NCT02638116|Experimental|Ibrutinib + Omeprazole|Participants will receive a dose of Ibrutinib 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7 and Omeprazole at a dose of 40 mg tablets orally once on Days 3 through 7.
16596100|NCT02638103|Experimental|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
16596133|NCT02637921|Active Comparator|Normoxic bed rest|Participants are on bed rest in normobaric normoxia with standardised nutritional intake
16596134|NCT02637908|Experimental|Mindfulness training|The mindfulness training (experimental condition) will receive 6-weeks of mindfulness training for parents provided in a group setting.
16596135|NCT02637908|No Intervention|Wait-list control|The wait-list control group will receive no intervention during the course of the study. The control group will be offered training following the completion of the study.
16596101|NCT02638103|Experimental|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
16596102|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
16596103|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
16596104|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.
~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
16596105|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.
~Level 1: Maximum Tolerated Dose (MTD)"
16596106|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.
~Level 1: Pembrolizumab 200 mg Q3 wks"
16596107|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.
~Level 1: MTD"
16596108|NCT02638077||Group 1|2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
16596109|NCT02638064|Experimental|Surgiflo injection|Injection of surgiflo in the pilonidal sinus cavity after curettage of its content
16596110|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
16596111|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
16596112|NCT02638038|Experimental|Oral INT 131 3 mg|Oral INT-131 Double blind study
16596113|NCT02638038|Experimental|Oral INT-131 1 mg|Oral INT-131 Double blind
16596114|NCT02638038|Placebo Comparator|Placebo|Oral placebo Double blind
16596115|NCT02638012|Experimental|HHT - Floseal|"Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.
~If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care)."
16596116|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
16596117|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
16596118|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
16596119|NCT02637986|Experimental|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
16596120|NCT02637986|Placebo Comparator|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
16596121|NCT02637986|Experimental|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
16596122|NCT02637986|Placebo Comparator|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
16596123|NCT02637973|Experimental|Empagliflozin|Empagliflozin, film-tablet, 25mg once daily
16596124|NCT02637973|Placebo Comparator|Placebo|Placebo, once daily
16596125|NCT02637960|Experimental|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
16596126|NCT02637960|Experimental|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
16596127|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
16596128|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
16596131|NCT02637921|Active Comparator|Hypoxic ambulatory|Participants ambulatory in normobaric hypoxia with standardised nutritional intake
16596137|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
16596138|NCT02637882|Experimental|First intervention (ear plug)|"Other: ear plug
~Other Name: eastnova ear plug"
16596139|NCT02637882|Other|Second intervention (eye mask)|"Other: eye mask
~The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
~Other Name: Sleeping mask"
16596140|NCT02637882|Other|Ear plug and eye mask|The patients will receive the mixed intervention (eye mask) and (ear plug ) in the first night (N1) from 9 pm to 6 am.
16596141|NCT02637869||Control Group - non-intervention|Clinics that did not participate in the APM project
16596142|NCT02637869||Alternative Payment Model -intervention|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
16596143|NCT02637856|Experimental|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
16596144|NCT02637856|Experimental|Ocrelizumab (substudy)|Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
16596145|NCT02637843|Active Comparator|Slender arm|Uses the terumo slender sheath for radial angiography or angioplasty
16596146|NCT02637843|No Intervention|Standard arm|Uses the terumo standard sheath (Routine) for radial angiography or angioplasty
16596147|NCT02637830|Experimental|Fluoride varnish and fluoride toothpaste|Application of fluoride varnish (Duraphat) at the begining of the study. Application of fluoride toothpaste (Crest) twice a day for 3 days.
16596148|NCT02637830|Placebo Comparator|placebo toothpaste|Application of placebo toothpaste twice a day for 3 days
16596149|NCT02637830|Active Comparator|Fluoride toothpaste|Application of fluoride toothpaste (Crest) twice a day for 3 days
16596150|NCT02637817||Control Group|Neonates with no evidence of brain lesions on conventional MRI.
16596151|NCT02637817||Patients Group|Neonates with PWML diagnosed by conventional MRI.
16596152|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
16596153|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
16596154|NCT02637791|Experimental|Intervention|The virtual glove in their homes for a period of 8 weeks and advised to try to build up to using the system for a maximum of 20 minutes 3 times a day for 8 weeks.
16596155|NCT02637791|No Intervention|Control|Usual care
16596156|NCT02637778|Experimental|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
16596157|NCT02637778|Experimental|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
16596158|NCT02637765|No Intervention|Control Group|Usual Physical Activity
16596159|NCT02637765|Experimental|Intervention Group|8-week increased physical activity program
16596160|NCT02637752|Active Comparator|Lifestyle counseling|Intervention: Lifestyle counseling or nutrition/physical counselling
16596161|NCT02637752|No Intervention|No Intervention|To ensure that both groups benefited equally from the study, the control group received the counselling and the handouts at the end of the study.
16596162|NCT02637739|Experimental|Pregnancy of unknown location|pregnant women of at least 5 weeks by last menstrual period and transvaginal ultrasound did not revealed intra-uterine pregnancy or ectopic pregnancy Intervention: hysteroscope
16596163|NCT02637726|Experimental|TIVA0|Propofol : TIVA guided by clinical signs. Remifentanil
16596164|NCT02637726|Experimental|TIVA BIS|propofol : TIVA guided by EEG Monitoring. Remifentanil
16596165|NCT02637726|Experimental|TCI KBIS|Propofol : TCI Kataria guided by EEG Monitoring. Remifentanil.
16596166|NCT02637726|Experimental|TCI SBIS|Propofol : TCI Schnider guided by EEG Monitoring. Remifentanil.
16596167|NCT02637713|Experimental|Radiofrequency Energy to the Lower Esophageal Sphincter (LES)|All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.
16596168|NCT02637700|Experimental|Intravenous Immunoglobulin|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.
16596169|NCT02637700|Placebo Comparator|Placebo (Saline 0.9%)|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).
16596170|NCT02637687|Experimental|Phase 1 dose escalation: Dose level 1_Cohort 1|
16596171|NCT02637687|Experimental|Phase 1 dose escalation: Dose level 2_Cohort 2|
16596172|NCT02637687|Experimental|Phase 1 dose escalation: Dose level 3_Cohort 3|
16596173|NCT02637687|Experimental|Phase 2 expansion: Patients with tumors bearing NTRK fusions (IFS)_Cohort 1|
16596174|NCT02637687|Experimental|Phase 2 expansion: Other extra-cranial solid tumors_Cohort 2|
16596175|NCT02637687|Experimental|Phase 2 expansion: Primary CNS tumors_Cohort 3|
16596176|NCT02637674|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF
16596177|NCT02637661||Initial AMI|To study the sensitivity, specificity, positive predictive value, and negative predictive value of different earlobe crease as risk factors of AMI
16596178|NCT02637661||No coronary heart disease|To study the characteristics of earlobe crease
16596179|NCT02637648|Experimental|Sodium oxbate|oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
16596180|NCT02637648|Placebo Comparator|Placebo|oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
16596181|NCT02637635|Experimental|Breast reconstruction with implant|The patients will undergo breast reconstruction with an expander prosthesis.
16596182|NCT02637635|Experimental|Autologous fat transplantation|The patients will undergo lipofilling as a pre-treatment before they will undergo breast reconstruction with an expander prosthesis.
16596183|NCT02637622||Best-Worst Scaling (Case 2)|Preference elicitation survey using a best-worst scaling method.
16596184|NCT02637622||Discrete Choice Experiment|Preference elicitation survey using a discrete choice experiment method.
16596185|NCT02637609||Likert Scale|Priority elicitation survey using a Likert scale method.
16596186|NCT02637609||Best-Worst Scaling (Case 1)|Priority elicitation survey using a best-worst scaling method.
16596187|NCT02637596|Experimental|RFA group|Twenty-fourth consecutive patients with histologically proved pancreatic cancer [stage IIb (n=4), III (n=15), IV (n=5) ]underwent intraoperative RFA of primary tumor.
16596188|NCT02637583|Active Comparator|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
16596189|NCT02637583|Experimental|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
16596190|NCT02637583|Active Comparator|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
16596191|NCT02637570|Experimental|Hibiscus tea|420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day
16596192|NCT02637570|Experimental|green tea|450 mg green tea 2 hour after dinner with 1 glass of cool water every day
16596193|NCT02637570|Placebo Comparator|control group|450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day
16596194|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
16596195|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
16596196|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
16596197|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
16596198|NCT02637544|Active Comparator|Verum|"Acupuncture therapy.
~For this study arm following acupuncture points suitable for facial pain, according to traditional chinese medicine, were chosen:
~F2, F3, F34, IT3, IT19, S7, T21 and temporomandibular joint ear acupuncture points. Only intervention is the acupuncture therapy."
16596199|NCT02637544|Placebo Comparator|Placebo|Placebo acupuncture therapy. For this study arm points outside of the meridians according to traditional chinese medicine, were chosen. Only intervention is the acupuncture therapy.
16596200|NCT02637531|Experimental|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
16596201|NCT02637531|Experimental|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596202|NCT02637531|Experimental|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
16596203|NCT02637531|Experimental|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596204|NCT02637531|Experimental|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596205|NCT02637531|Experimental|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596206|NCT02637531|Experimental|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596207|NCT02637531|Experimental|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596208|NCT02637531|Experimental|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596209|NCT02637531|Experimental|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596210|NCT02637531|Experimental|Part H: High-circulating MDSCs: IPI-549 and nivolumab|Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
16596211|NCT02637518||Hospital Universitario de Getafe|"Assessment of frailty tools in elderly people
~The Geriatric Department attends patients:
~1800/year - acute unit. 800/year - Orthogeriatrics and Interconsultation Unit. 300/year - Day Hospital. 4000/year - Outpatient office. 1200/year - Domiciliary Care."
16596212|NCT02637518||Diabetes Frail Ltd.|Assessment of frailty tools in elderly people Has significant experience in managing research studies in older people.
16596213|NCT02637518||Università Cattólica del Sacro Cuore|"Assessment of frailty tools in elderly people
~The Geriatric Unit is compounded by:
~24 beds of Acute Care Ward 46 beds of Intensive Rehabilitation Unit 20 beds of Day Hospital Outpatient clinic"
16596214|NCT02637518||Gérontopole de Toulouse|"Assessment of frailty tools in elderly people
~The Geriatric Unit is compounded by:
~5 Acute Care Units - 100 beds. 3 Rehabilitation Unit - 75 beds. Long term care Unit - 140 beds. 2 Day Hospitals Outpatient Clinic"
16596215|NCT02637518||Jagiellonian University Medical College|Assessment of frailty tools in elderly people The Department of Internal Medicine and Gerontology is the largest centre in Poland limited to the Geriatric market.
16596342|NCT02636764|Experimental|exercise group + short-wave diathermy|Besides the intervention of the exercise group after the exercises will be applied diathermies short wave in continuous mode. For that will be used apparatus, 27.12 megahertz, by means of vulcanized rubber electrodes (12x17 cm) with gentle warming for 30 minutes.
16596216|NCT02637505|Active Comparator|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
16596217|NCT02637505|Sham Comparator|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
16596218|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
16596219|NCT02637479|Experimental|Pituitary radiosurgery group|Subjects will receive a pituitary radiosurgery by GammaKnife® during a brief hospitalization associated with standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
16596220|NCT02637479|Active Comparator|Control group|Subject will receive standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
16596221|NCT02637466|Experimental|Vortioxetine|In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
16596222|NCT02637466|Placebo Comparator|Placebo|"In cycle I of the study, 80 eligible depressed women with breast cancer will be randomized into an 8-week, double-blind, placebo-controlled, flexible-dose vortioxetine (10-20 mg) treatment arm versus placebo arm.
~Responders to placebo treatment will complete their study participation at the end of Cycle I, and will not proceed to Cycle II."
16596223|NCT02637453|Active Comparator|PVI|Pulmonary vein isolation (PVI)
16596224|NCT02637453|Experimental|PVI+6L|PVI plus 6 additional lines at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
16596225|NCT02637440|No Intervention|Conservative|After the index primary PCI. The control group will receive best medical therapy and regular follow up and only PCI for recurrent angina with evidence of inducible ischaemia.
16596226|NCT02637440|Active Comparator|FFR guided|FFR group will undergo FFR at 4 weeks of the index primary PCI as OPD. If FFR is less than 0.8, then PCI will be performed
16596227|NCT02637440|Active Comparator|angiogram guided|The group will undergo PCI for all significant lesions more than 50
16596228|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
16596229|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
16596230|NCT02637414|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
16596231|NCT02637414|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
16596232|NCT02637401||Therapy group|Dialectical behaviour therapy: a psychological therpay involving 16 group sessions plus approximately 5 individual meetings over 4 months.
16596233|NCT02637388|Placebo Comparator|Placebo Comparator: Control Breakfast|Breakfast cereal and yoghurt only (placebo, negative control)
16596234|NCT02637388|Experimental|Experimental: beta-Glucan Breakfast|Breakfast cereal and yoghurt with the addition of 4g beta-glucan (14.7g Oatwell28 powder)
16596235|NCT02637375|Experimental|Therapy|Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.
16596236|NCT02637362|Active Comparator|Ankle + Sham metatarsal|Ankle block + sham metatarsal block
16596237|NCT02637362|Active Comparator|Ankle + Metatarsal|Ankle block + metatarsal block
16596238|NCT02637362|Active Comparator|Metatarsal + sham ankle|Metatarsal block + sham ankle block
16596239|NCT02637349|Experimental|POST SCP|Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
16596240|NCT02637349|Active Comparator|POST TAU|Patient receives treatment as usual (TAU) after active treatment ends.
16596241|NCT02637336|Experimental|Acupuncture|acupuncture session were inserted, and maintained for 20 minutes in paragraph 6 of the channel the pericardium (Neiguan).
16596242|NCT02637336|Experimental|Aerobic Exercise|The aerobic exercise session was conducted through 20 minutes.
16596243|NCT02637336|Experimental|Aromatherapy|Eucalyptus essential oil was inhaled by volunteers for 20 minutes
16596244|NCT02637336|No Intervention|Control|In the control session the volunteers remained seated at rest for 20 minutes without performing therapy.
16596245|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
16596246|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
16596247|NCT02637310|Experimental|N02RS1 1200mg|Combination of Broussonetia spp and Lonicera spp
16596248|NCT02637310|Placebo Comparator|Placebo|sugar pill
16596343|NCT02636764|Experimental|exercise group + Low level laser therapy|Apart from intervening in the exercise group, will be applied to Low level laser therapy, through the laser unit, Class 3b, gallium-aluminum-arsenide, continuous mode, wavelength: 830 nanometer, power: 30 watts.
16596249|NCT02637297|Experimental|Group I (immediate intervention group)|Participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
16596250|NCT02637297|Active Comparator|Group II (wait-list control group)|At week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
16596251|NCT02637284|Experimental|Intervention 1a (cohort 1)|Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin (12 subjects)
16596252|NCT02637284|Experimental|Intervention 1a (cohort 2)|Single dose of 3 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
16596253|NCT02637284|Experimental|Intervention 1a (cohort 3)|Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
16596254|NCT02637284|Placebo Comparator|Control group 1a (cohort 1)|Single dose of 1 oral tablet of PCO-03 as placebo (2 subjects)
16596255|NCT02637284|Placebo Comparator|Control group 1a (cohort 2)|Single dose of 3 oral tablets of PCO-03 as placebo (2 subjects)
16596256|NCT02637284|Placebo Comparator|Control group 1 a (cohort 3)|Single dose of 6 oral tablets of PCO-03 as placebo by mouth (2 subjects)
16596257|NCT02637284|Experimental|Intervention 1b|Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks (36 subjects)
16596258|NCT02637284|Placebo Comparator|Control group 1b|Multiple dose regime of 3 oral tablets of PCO-03 as placebo every 8 hours during 2 weeks (6 subjects)
16596259|NCT02637271|Experimental|Total Meal Replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
16596260|NCT02637271|Active Comparator|Typical Diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
16596261|NCT02637245||Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema. There will be no intervention in this cohort, only observation of standard of care.
16596262|NCT02637232||Mirvaso® / Onreltea TM|
16596263|NCT02637206|Experimental|Part 1 (Single Application)|All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).
16596264|NCT02637206|Experimental|Part 2 (Repeat Application)|All subjects will have repeat applications of GSK2894512 0.5%, 1% cream and placebo twice a day for 7 days on both side (left and right, 3 in total) of their upper back (approximately 5 centimeter (cm) in diameter >10 cm away from another application area) under non-occlusive conditions and covered with gauze using adhesive. GSK2894512 0.5% and 1% cream and placebo will be randomized according to the randomization code in the same manner as Part 1.
16596265|NCT02637193|Experimental|Venlafaxine|Maximum dose of 450 mg/day (225 mg BID given at approximately 12 hours apart) Venlafaxine, dose titrated from a starting single dose (QD) of 75 mg venlafaxine in the morning of Days 1 and 2, followed by BID escalating doses administered on Days 3 through 10, followed by 450 mg/day (BID) on Days 11 through 13, and on Day 14 only the morning dose of 225 mg will be administered, then 3 days (Days 15, 16 and 17) of down titration
16596266|NCT02637193|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
16596267|NCT02637193|Placebo Comparator|Drug -- placebo|Placebo administered on Days 1 through 13 and on Days 15 to 17
16596268|NCT02637180||patients with low-energy fracture(s)|"The study will include patients from pre-defined groups of individuals (postmenopausal, perimenopausal, male, and steroid induced osteoporosis) who would be anyway eligible to receive treatment for their condition according to standard medical practice and Greek treatment guidelines.
~Drug: anti-osteoporotic medication (bisphosphonates, denosumab, strontium ranelate, teriparatide, SERMs)"
16596269|NCT02637167|Active Comparator|Rifaximin|Rifaximin: one tablet (550 mg) morning and evening for three months
16596270|NCT02637167|Active Comparator|Saccharomyces boulardii|S. boulardii: two capsules (500 mg) morning and evening for three months
16596271|NCT02637167|No Intervention|Control group|The third group receives no intervention
16596272|NCT02637154|Active Comparator|Motivational Interviewing|With 30 patients Motivational Interviewing method will be used during each visit
16596273|NCT02637154|Active Comparator|Standard Education|With 30 patients Standard Education material will be used during each visit
16596274|NCT02637141|Experimental|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
16596275|NCT02637141|Experimental|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
16596276|NCT02637141|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
16596277|NCT02637128|Experimental|artemether-lumefantrine (AL)|"20mg artemether/120 mg lumefantrine per tablet, Coartem-D™; Novartis, Basel, Switzerland administered following manufacturer's prescribed weight-based dosing, twice daily for 3 days.
~5-14 kg: 1 tablet; 15-24: 2 tablets; 25-34 kg: 3 tablets; >34 kg: 4 tablets per dose"
16596278|NCT02637128|Experimental|artesunate-amodiaquine (ASAQ)|25mg artesunate/67.5 mg amodiaquine or 50 mg artesunate/135mg amodiaquine per tablet, Coarsucam™; Sanofi-Aventis, Paris, France administered following manufacturer's prescribed weight-based dosing, once daily for 3 days 4.5-8.9 kg: 1 25mg/67.5 mg tablet; 9-17.9 kg: 1 50mg/135 mg tablet; 18-35.9 kg 2 50mg/135 tablets; >36 kg: 4 50mg/135mg tablets per dose
16596279|NCT02637115|Placebo Comparator|Placebo|Placebo corresponds to a solution of Phosphate buffer saline (PBS) and glycerol, that is the carrier used in the 3 other groups receiving the bacteria (active arms)
16596280|NCT02637115|Experimental|Live Akk 9|Live Akkermansia muciniphila (Akk) at the dose of 10exp9 live bacteria (one billion of live bacteria) per day
16596281|NCT02637115|Experimental|Live Akk 10|Live Akkermansia muciniphila (Akk) at the dose of 10exp10 live bacteria (ten billion of live bacteria) per day
16596282|NCT02637115|Experimental|Killed Akk|This group corresponds to Akkermansia muciniphila that have been heat-killed. The initial quantity of bacteria before the heating procedure was of 10exp10 bacteria.
16596283|NCT02637102||Patients undergoing cardiac or vascular surgery|
16596284|NCT02637089||PD-non-MCI|Patients with Parkinson's disease, no mild cognitive impairment
16596285|NCT02637089||PD-MCI|Patients with Parkinson's disease with mild cognitive impairment
16596286|NCT02637089||MCI (non-PD-MCI)|Patients with mild cognitive impairment, no Parkinson's disease
16596287|NCT02637089||HC (non-PD-non-MCI)|Healthy Controls (age-matched to patients)
16596288|NCT02637076|Experimental|narcolepsy with cataplexy|patients given single dose of Xyrem
16596289|NCT02637076|Experimental|healthy controls|healthy controls given a single dose of Xyrem
16596290|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
16596291|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
16596292|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
16596293|NCT02637050||CTEPH Patients|Patients with confirmed diagnosis of CTEPH
16596294|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
16596295|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
16596296|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
16596297|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
16596298|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
16596299|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
16596300|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
16596301|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
16596302|NCT02637024|Experimental|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
16596303|NCT02637024|Experimental|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
16596304|NCT02636998||Normal weight|BMI <85th percentile
16596305|NCT02636998||Obese|BMI > 95th percentile
16596306|NCT02636972||Group 1|Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.
16596307|NCT02636972||Group 2A|History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
16596308|NCT02636972||Group 2B|History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
16596309|NCT02636972||Group 3|Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.
16596310|NCT02636972||Group 4|Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).
16596311|NCT02636972||Group 5|Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use
16596312|NCT02636972||Group 6|Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).
16596313|NCT02636959|Active Comparator|high volume saline irrigation (HVSI)|High volume nasal spray, NeilMed® Sinus Rinse, is a high saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
16596314|NCT02636959|Active Comparator|low volume saline irrigation (LVSI)|Low volume nasal spray, Salinex Rinse, is a low saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
16596344|NCT02636751|Experimental|In-person prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment. General information about pain control, such as ice application and medication usage will also be provided
16596315|NCT02636946|Experimental|Bimatoprost Sustained-Release (SR)|"Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2).
~Contralateral Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2)."
16596316|NCT02636946|Active Comparator|Selective Laser Trabeculoplasty (SLT)|"Assigned Primary Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
~Contralateral Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2)."
16596317|NCT02636933||59 prematurely born children|Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
16596318|NCT02636933||93 full-term born children|Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
16596319|NCT02636920|Other|TEP-CASES|"25 Case Patients will follow the Therapeutic Education to the Patient (TEP).
~In addition the following procedures will be performed:
~Pediatric Asthma Quality of Life Questionnaire (PAQLQ);
~Children Asthma Control Test (C-ACT);
~Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);
~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
16596320|NCT02636920|No Intervention|TEP-CONTROLS|"25 Control Patients will follow the usual care program:
~The Pediatric Asthma Quality of Life Questionnaire (PAQLQ);
~The Children Asthma Control Test (C-ACT);
~the Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);
~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
16596321|NCT02636907|Experimental|BI 695501|
16596322|NCT02636894|Other|Restylane Silk|Restylane Silk
16596323|NCT02636881|Active Comparator|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
16596324|NCT02636881|Sham Comparator|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.
~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage [41-43].
~All the operating surgeons will receive proper training in the operative procedure before study start."
16596325|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
16596326|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
16596327|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
16596328|NCT02636842|Other|Location|Deltoid or Gluteal Muscle
16596329|NCT02636829|Experimental|Multiple Sclerosis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.
~Intervention: QALCIMUM questionnaire
~Intervention: Determination of calcium intake by a dietician interview"
16596330|NCT02636829|Experimental|Rheumatoid Arthritis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.
~Intervention: QALCIMUM questionnaire
~Intervention: Determination of calcium intake by a dietician interview"
16596331|NCT02636816|Experimental|Infusion|carbetocin is given slowly
16596332|NCT02636816|Active Comparator|Bolus|carbetocin is given quickly
16596333|NCT02636803|Experimental|oxfendazole 6 mg/kg|patients receive 6 mg/kg oxfendazole once
16596334|NCT02636803|Experimental|oxfendazole 30 mg/kg|patients receive 30 mg/kg oxfendazole once
16596335|NCT02636803|Experimental|oxfendazole 6 mg/kg 3 times|patients receive 6 mg/kg oxfendazole three times
16596336|NCT02636803|Active Comparator|albendazole 400 mg|patients receive 400 mg albendazole once
16596337|NCT02636790|Active Comparator|Surgery wait time (< 8 weeks)|Outcomes of patients with sinus surgery of less than 8 weeks.
16596338|NCT02636790|Active Comparator|Surgery wait time (> 1 year)|Outcomes of patients with sinus surgery of more than 1 year.
16596339|NCT02636764|Active Comparator|exercise group|An exercise protocol drawn up with the objective will be held to strengthen the musculature: flexor and extensor of the knee; extension, abduction, hip side rotator, using the weight and the elastic band.
16596340|NCT02636764|Placebo Comparator|exercise group + Ultrasound therapy|Apart from intervening in the exercise group, an ultrasound device is used .
16596341|NCT02636764|Experimental|exercise group + interferential current|Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
16596345|NCT02636751|Experimental|Tele-prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
16596346|NCT02636751|Active Comparator|Usual care group|The participants in this group will be provided with the hospital's usual documentation before total joint arthroplasties, consisting of information regarding the pre- and post-surgery course and medication.
16596347|NCT02636738|Experimental|experiment|Vela XL thulium laser, laser fiber and accessories
16596348|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Group|Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
16596349|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Expansion Cohort|Expansion cohort for up to 10 additional patients with alveolar soft part sarcoma. Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
16596350|NCT02636712||ImageReady™ MR Conditional Pacing System|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant
~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
16596351|NCT02636699|Experimental|Viaskin Peanut 250mcg|
16596352|NCT02636699|Placebo Comparator|Placebo|
16596353|NCT02636673||Robotic-assisted sigmoid resection|Patient that have undergone robotic-assisted sigmoid resection for benign or malignant disease between 2010 and 2015
16596354|NCT02636673||Laparoscopic sigmoid resection|Patient that have undergone laparoscopic sigmoid resection for benign or malignant disease between 2010 and 2015
16596355|NCT02636647|Active Comparator|FMT|Fecal transplant via enema once
16596356|NCT02636647|No Intervention|No treatment|No transplant performed
16596357|NCT02636634|Other|diagnostic imaging strategy|PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy
16596358|NCT02636621|Active Comparator|Brazilian Dental Appliance|The device increases the volume of the airway by mandibular traction.
16596359|NCT02636621|Placebo Comparator|Placebo|Oral device that does not change the volume of the airway
16596360|NCT02636608||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
16596361|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
16596362|NCT02636582|Experimental|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
16596363|NCT02636582|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
16596364|NCT02636569|Active Comparator|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
16596365|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
16596366|NCT02636556|Experimental|chemoradiation|concurrent chemoradiation.
16596367|NCT02636543||Group 2a-patient|75 patients who attended a genetic counselling consultation.
16596368|NCT02636543||Group 2a-public|75 persons belonging to general population.
16596369|NCT02636543||Group 2b-patient|75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).
16596370|NCT02636543||Group 2b-public|75 persons belonging to general population (those persons are different than patients from group 2a).
16596371|NCT02636543||Group 2b-professional|75 genetic professionals.
16596372|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
16596373|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
16596374|NCT02636517|Other|C. Difficile without IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
16596375|NCT02636517|Other|C. Difficile with IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
16596376|NCT02636491|Experimental|investigational device|"MD-Logic-Automated Insulin Delivery System, Version 01.05.02
~The device is being used continuously over 60 hours for insulin therapy"
16596377|NCT02636491|Placebo Comparator|MiniMed Paradigm® Veo™ System|"sensor augmented insulin pump
~The device is being used continuously over 60 hours for insulin therapy"
16596378|NCT02636478||reference group|therapy naive patients with a sleep related breathing disorder
16596379|NCT02636478||therapy group|patients with devices treating their sleep related breathing disorder
16596380|NCT02636465||obese healthy adults|persons with BMI> 30 kg/m2
16596381|NCT02636465||obese COPD patients|COPD-patients (GOLD I-IV Group A-D) with BMI> 30 kg/m2
16596382|NCT02636465||OHS-patients|patients with defined OHS: BMI>30 kg/m2 and sleep related breathing disease, no COPD
16596383|NCT02636439|Active Comparator|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.
~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
16596384|NCT02636439|Active Comparator|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.
~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.
~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
16596385|NCT02636426|Experimental|sorafenib|In this phase I study patients are treated with high-dose, pulsatile sorafenib in escalating AUC0-12h cohorts.
16596386|NCT02636413|Experimental|LacTEST|0,45 g of gaxilose po, once, per diagnostic test performed.
16596387|NCT02636413|Active Comparator|Hydrogen Breath Test|25 to 50 g of lactose po, once, per diagnostic test performed.
16596388|NCT02636400|No Intervention|expectant|7 menstrual cycles of expectant management
16596389|NCT02636400|Experimental|postop IUI|4 IUI cycles within 7 menstrual cycles
16596390|NCT02636387||Desmopressin|0.2mg tablets, dose titrated to effect
16596391|NCT02636387||Placebo|Placebo Comparator
16596392|NCT02636374|Experimental|Guided Imagery|Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
16596393|NCT02636361|Experimental|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
16596394|NCT02636361|Experimental|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
16596395|NCT02636361|Experimental|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
16596396|NCT02636361|Experimental|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
16596397|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
16596398|NCT02636348|Experimental|Calcium/Vitamin D Bar|Dietary supplement consumed as 2 calcium and vitamin D fortified snack bars per day
16596399|NCT02636348|Experimental|Calcium/Vitamin D Pill|Dietary supplement consumed as several capsules per day
16596400|NCT02636348|Placebo Comparator|Placebo Bar|Placebo consumed as 2 isocaloric, unfortified snack bars per day
16596401|NCT02636348|Placebo Comparator|Placebo Pill|Placebo consumed as several capsules per day
16596402|NCT02636335|Experimental|Bright Light|"8 a.m. study participants will be exposed to Bright Light (4500 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.
~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
16596403|NCT02636335|Experimental|Control|"8 a.m. study participants will be exposed to a Control Light Condition (230 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.
~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
16596404|NCT02636322|Experimental|Arm I (RLI WITH EPOCH)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
16596405|NCT02636322|Experimental|Arm II (RLI WITH R-CHOP)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
16596406|NCT02636309|No Intervention|control group|control group only filled up the questionnaires. They didn't receive intervention
16596407|NCT02636309|Experimental|intervention group|physical therapy at work
16596408|NCT02636296|Experimental|Pilates|Group received 12 week of inspired-Pilates intervention (2 days/week, 60 minutes duration).
16596409|NCT02636296|Other|Control|Control group was oriented to maintain the habitual activities during 12 weeks
16596410|NCT02636283|Active Comparator|Entresto|oral route
16596411|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
16596412|NCT02636270|Experimental|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
16596413|NCT02636257|Experimental|Recessive Spherical Headed Silicone Intubation|The silicone nasolacrimal intubation under nasal endoscopy can restore natural drainage pathway in tears and as an out-patient surgery, it is more simple,cheap and mini-invasive.Recessive Spherical Headed Silicone Intubation is safe,convenient and almost unpainful for no trauma.It has no facial scar and no damage for structure and function of lacrimal duct.Besides,silica gel is non-toxic and nonirritating.Nasal endoscopy handed by otorhinolaryngologist helps intraoperative visualization about anatomy of the nasal cavity,understanding and management of congenital nasolacrimal duct obstruction and is the only method that confirms the correct anatomic position of the catheterization and in real time,avoiding traditionally the blind raking-out wire by the ophthalmologist alone.Compare to the classic DCR,its short therapeutic effects are equal but more convenient and fewer time and money-cost.
16596520|NCT02635464|Active Comparator|hUC-MSCs+CABG|
16596521|NCT02635464|Active Comparator|CABG|
16596414|NCT02636257|Other|Dacryocystorhinostomy|Nasolacrimal duct obstruction is common among patients with epiphora,which is seriously affect the quality of life. The treatment principle is to restore or rebuild the lacrimal duct drainage channel. The classic operation type is dacryocystorhinostomy(DCR), which is complex for face-section particularly.After surgery the lacrimal passage can't siphon the tear out physically any more so that it will effect the patients' life.Besides,the operating time,bleeding volume,hospitalization time and total cost for the surgery is higher.
16596415|NCT02636244|Experimental|SHAPE Gel|1% SHAPE Gel applied twice daily for 12 weeks.
16596416|NCT02636231|Active Comparator|IMRT and concurrent Endostar|"IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
~IMRT is to give GTV 60Gy in 27 fractions."
16596417|NCT02636231|Experimental|IMRT alone|IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.
16596418|NCT02636218|Active Comparator|0.9% NaCl control|Normal saline
16596419|NCT02636218|Experimental|Ketamine|Anesthetic
16596420|NCT02636205|Experimental|Armeo|Group receiving Armeo therapy
16596421|NCT02636192||Cohort 1|Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).
16596422|NCT02636192||Cohort 2|Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).
16596423|NCT02636179||448 children|Children aged 11-15 years from a historical cohort born after In Vitro Fertilization or Intracytoplasmic Sperm Injection at Hospital Saint Joseph of Marseille
16596424|NCT02636179||1344 children|Children aged 11-15 years born spontaneously schooling in the same geographic area as case
16596425|NCT02636166|Other|Pregnancy test|"Clearblue investigational Pregnancy test
~Clearblue Marketed pregnancy test
~Professional pregnancy test"
16596426|NCT02636153|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
16596427|NCT02636153|Experimental|Restricted Phosphorus Diet|Diet containing 500mg of phosphorus per day
16596428|NCT02636140|Experimental|Light|Randomized amount and color of light
16596429|NCT02636127|Experimental|Systemic Sclerosis (SSc) patient|15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
16596430|NCT02636127|Other|healthy patient|15 healthy patients will be recruited and blood samples will be obtained
16596431|NCT02636114|Active Comparator|scaling and root planing|this was an international study in which scaling and root planing was done in systemically healthy patients patients with chronic periodontitis
16596432|NCT02636114|No Intervention|control group|Scaling and planing was not done that no intervention is carried out in this group
16596433|NCT02636088|Experimental|Cetuximab|Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
16596434|NCT02636075||Upper 1/3 of thyroid tissue|
16596435|NCT02636075||Middle 1/3 of thyroid tissue|
16596436|NCT02636075||Lower 1/3 of thyroid tissue|
16596437|NCT02636075||Below thyroid tissue|
16596438|NCT02636062||Follow-up CAC > 0|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.
16596439|NCT02636062||Follow-up CAC zero|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.
16596440|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
16596441|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
16596442|NCT02636036|Experimental|enadenotucirev and nivolumab|
16596443|NCT02636023|Experimental|SPhENo-Cardiograph / ECG|SPhENo-Cardiograph and ECG
16596444|NCT02636010|Experimental|MK-3475 Pembrolizumab|MK-3475 at a dose of 200 mg every three weeks for 1 year with a potential expansion of 1 additional year of treatment in case of clinical benefit and patient agreement
16596445|NCT02635997||patients on antiresorptive therapy|Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day
16596446|NCT02635984|Placebo Comparator|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
16596447|NCT02635984|Active Comparator|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
16596448|NCT02635971|Experimental|TAI chemotherapy|Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
16596449|NCT02635971|Active Comparator|Chemotherapy|Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
16596450|NCT02635958||Group 1|BMI 18.5 to 24.9
16596451|NCT02635958||Group 2|BMI 25 to 29.9
16596452|NCT02635958||Group 3|BMI 30 to 34.9
16596453|NCT02635958||Group 4|BMI ≥ 35
16596454|NCT02635945|Experimental|PBF-680 10 mg|2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
16596455|NCT02635945|Placebo Comparator|Placebo|2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
16596456|NCT02635932|Experimental|Functional Splint group|Patient will be using the functional splint during their activity daily life
16596457|NCT02635932|Active Comparator|Night Splint group|Patients will use the night splint during the sleep time
16596458|NCT02635919|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
16596459|NCT02635919|No Intervention|Control|Smokers in this group will not be given the mSMART application.
16596460|NCT02635906|Experimental|2 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for two hours
16596461|NCT02635906|Active Comparator|4 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for four hours
16596462|NCT02635893|Active Comparator|D-Cycloserine/Placebo + Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
16596463|NCT02635893|Active Comparator|Training+Med/Placebo+Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
16596464|NCT02635893|Active Comparator|Training+Med+Stimulation/Placebo Stim|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.
16596465|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
16596466|NCT02635867|Active Comparator|Indirect pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal Resin-based dentin bonding agent
16596467|NCT02635867|Active Comparator|Direct pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal
16596468|NCT02635854|Experimental|Test group|The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.
16596469|NCT02635854|Other|Control group|The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.
16596470|NCT02635828|Experimental|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
16596471|NCT02635815||Group I|twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up. All underwent upper gastrointestinal endoscopy.
16596472|NCT02635815||Group II|thirty four patients without bleeding. All underwent upper gastrointestinal endoscopy.
16596473|NCT02635802|Experimental|Remifentanil|injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished.
16596474|NCT02635802|Experimental|Lidocaine|injection form concentration 10mg/ml loading dose 100-400mg local anesthesia
16596475|NCT02635802|Experimental|Remifentanil+Lidocaine|"injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished
~+ injection form concentration 10mg/ml loading dose 100-400mg local anesthesia"
16596476|NCT02635789|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
16596477|NCT02635789|Placebo Comparator|Placebo gel|Placebo gel is matched ingredient with NPC-12G gel
16596478|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided in pull-apart peanut protein capsules or sachets
16596479|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
16596480|NCT02635763|Other|PNBs1|Femoral nerve and the lateral cutaneous nerve block combined with general anesthesia
16596481|NCT02635763|Other|PNBs2|Lumbar plexus and sacral plexus nerve block combined with general anesthesia
16596482|NCT02635750|Experimental|BI 409306|
16596483|NCT02635750|Experimental|Donepezil low dose|
16596484|NCT02635750|Experimental|Donepezil high dose|
16596485|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
16596486|NCT02635724|Experimental|Peramivir|Single dose 600 mg IV injection
16596487|NCT02635711|Experimental|Adapted Taekwondo training|An adapted TKD training regime which was developed by our research team [16] will be used in this study. This training programme is designed to train balance control, eye-hand coordination and facilitate skeletal development for children with DCD. The high-impact striking techniques (e.g., punching and blocking) incorporated in the programme may stimulate bone growth [15]. Subjects who are assigned to the TKD training group will attend a weekly 1-h session of TKD training that will be held at the University of Hong Kong for 12 weeks. All TKD training sessions will be conducted by a qualified World Taekwondo Federation black belt coach.
16596488|NCT02635711|Active Comparator|Control|Subjects who are assigned to the DCD-control group will receive no TKD training during the study period. Instead, they will participate in jogging exercise daily (one hour per day) for 12 weeks. Participants will be encouraged to jog to school or other places every day, as appropriate. Pedometers will be used to monitor their exercise level and enhance habitual physical activity. The pedometer count (steps per day) will be documented in a log book by the parents. Signed log books will be returned to our research personnel after the intervention period. In addition, children with DCD in this group will receive an adapted TKD training menu and 12 training/demonstration sessions immediately after the follow-up testing is completed.
16596489|NCT02635698|Experimental|Intervention group, Optifast|OPTIFAST, medically supervised weight-management program
16596490|NCT02635698|Active Comparator|Control group, Low-energy, low-fat|Food-based program, current standard of care for weight management
16596491|NCT02635685|Experimental|Intervention group|Intervention with Clinical Decision Support tool installed on units.
16596492|NCT02635685|No Intervention|Control group|Control group without intervention with Clinical Decision Support tool installed on units.
16596495|NCT02635659|Experimental|Encapsulated nutrients|The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
16596496|NCT02635659|Placebo Comparator|Placebo|The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
16596497|NCT02635646|Experimental|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
16596498|NCT02635646|Active Comparator|individual approach|individual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
16596499|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
16596500|NCT02635620||e-cigarette group|Probands are smokers who intend to start vaping for the first time. The probands are recruited in e-cigarette shops. It is aimed to include 60 persons who start vaping. A baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking/vaping behaviour and health status at the beginning and after 1, 2 and 3 months.
16596501|NCT02635620||smoking cessation group|Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
16596502|NCT02635607|Other|Fixed Protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
16596503|NCT02635607|Other|Flexible protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
16596504|NCT02635594|Experimental|Carnipure® tartrate|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
16596505|NCT02635594|Placebo Comparator|Placebo|1000mg cellulose + 475mg L-tartaric acid
16596506|NCT02635581|Experimental|DELTA TT|
16596507|NCT02635555|Experimental|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.
~Episodes of hypotension will be treated with these vasopressors ."
16596508|NCT02635555|Active Comparator|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.
~Episodes of hypotension will be treated with these vasopressors ."
16596509|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
16596510|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
16596511|NCT02635529|Active Comparator|OFD + DFDBA|Intrabony defects treatment was carried out with OFD + DFDBA
16596512|NCT02635529|Active Comparator|OFD+DFDBA+AM|Intrabony defects treatment was carried out with OFD + DFDBA+ AM
16596513|NCT02635516|Experimental|Treatment|Only one arm was used and this arm received Near-Infrared Phototherapy.
16596514|NCT02635503|Experimental|transrectal specimen extraction|Laparoscopic colorectal resection with natural orifice specimen extraction will be performed for patients in this group.
16596515|NCT02635503|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
16596516|NCT02635490||prophylactic antibiotics|
16596517|NCT02635477|Experimental|Intervention Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with an actigraphy device that displays an adaptive personalized daily step count goal and audible alerts to increase physical activity
16596518|NCT02635477|Experimental|Control Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with a matching actigraphy device that has a blacked-out screen and does not display step count goals or provide audible alerts (functions in silent monitoring mode only)
16596519|NCT02635464|Experimental|hUC-MSCs+Injectable collagen scaffold+CABG|
16596523|NCT02635451||control group|Control group also included 20 pregnant women without PPROM following every recorded case of PPROM and matched for gestational age.
16596524|NCT02635438|Experimental|Arm A|Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days
16596525|NCT02635438|Active Comparator|Arm B|Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days
16596526|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
16596527|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
16596528|NCT02635412|Placebo Comparator|Scheduled delivery at 34 weeks|Scheduled delivery at 34 weeks (range 33 weeks 5 days to 34 weeks 3 days)
16596529|NCT02635412|Active Comparator|Scheduled delivery at 36 weeks|Scheduled delivery at 36 weeks (range 35 weeks 5 days to 36 weeks 3 days)
16596530|NCT02635399|Placebo Comparator|conventional group|Conventional PPPD
16596531|NCT02635399|Experimental|DJ-pexy group|PPPD with additional DJ-pexy to anchor DJ to transverse colon
16596532|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
16596533|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
16596534|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
16596535|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
16596536|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TPM) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
16596537|NCT02635360|Experimental|Following chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
16596538|NCT02635360|Experimental|Concurrent to chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.
16596539|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
16596540|NCT02635334|Experimental|Montelukast 10 mg daily for 8 weeks|Study subjects will take montelukast 10 mg orally daily for 8 weeks
16596541|NCT02635334|Placebo Comparator|Placebo daily for 8 weeks|Study subjects will take placebo orally daily for 8 weeks
16596542|NCT02635321||Patients with LGMD 2T|Four patients over 18 years old with genetically verified LGMD 2T.
16596543|NCT02635308|Experimental|Experimental|"High-Intensity, Unilaterally-Biased Resistance training 3x/wk x 12wk MOVE"
16596544|NCT02635295|Experimental|Mobile cooperation|Nursing student - nurse teacher mobile cooperation during the clinical practicum.
16596545|NCT02635295|No Intervention|Standard cooperation|Nursing student - nurse teacher standard cooperation during the clinical practicum.
16596546|NCT02635282|Active Comparator|IN fentanyl and midazolam|group of patients who are randomized to receive intranasal fentanyl and midazolam
16596547|NCT02635282|Experimental|IN ketamine|group of patients who are randomized to receive intranasal ketamine
16596548|NCT02635269|Experimental|Sugar|The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
16596549|NCT02635256|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
16596550|NCT02635243|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
16596551|NCT02635243|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
16596552|NCT02635243|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
16596553|NCT02635230||Patients with chronic oral anticoagulation and P2Y12 inhibitor|Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
16596554|NCT02635217|Experimental|Group A1|EGD performed before the Colonoscopy with Carbon Dioxide insufflation.
16596555|NCT02635217|Experimental|Group A2|EGD performed before the Colonoscopy with room air insufflation.
16596556|NCT02635217|Experimental|Group B1|Colonoscopy performed before the EGD with Carbon Dioxide insufflation.
16596557|NCT02635217|Experimental|Group B2|Colonoscopy performed before the EGD with room air insufflation.
16596558|NCT02635204|Experimental|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
16596559|NCT02635204|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
16596560|NCT02635191|Experimental|Tailored Group|In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
16596561|NCT02635191|Active Comparator|Standard group|In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.
16596589|NCT02634944|Sham Comparator|Healthy Control|Healthy controls will be administered the VOMS tool. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
16596616|NCT02634788|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
16596562|NCT02635178|Experimental|Active|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
16596563|NCT02635178|Placebo Comparator|Control|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
16596564|NCT02635165|Active Comparator|Surgical treatment with Stracos|The patient was placed in the lateral decubitus position. The procedure involved a curvilinear thoracic incision overlying the center of the fractured segments. The intercostal muscles were dissected off the rib on its superior aspect away from the fracture site, and the fracture was then reduced. The investigators then chose the most suitable Stracos, which is to be found in two available sizes, 6 or 9 claws, according to the length of the fracture. The clip chosen was molded according to the shape of the corresponding rib and the claws were crimped using special pliers on and around the fractured rib.The investigators treated only one rib out of two with Stracos, and as for displaced or comminuted fractures, the adjacent rib was wrapped using vicryl suture on the osteosynthesis rib.
16596565|NCT02635165|No Intervention|Medical treatment|
16596566|NCT02635152|Experimental|Interpretation Bias Modification (IBM)|"Treatment consists of eight brief sessions. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response."
16596567|NCT02635152|Active Comparator|Progressive Muscle Relaxation (PMR)|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
16596568|NCT02635139|Experimental|Breakfast Skipping|Effect of breakfast skipping on metabolism
16596569|NCT02635139|Experimental|Dinner Skipping|Effect of dinner skipping on metabolism
16596570|NCT02635113|Experimental|PD Shoe|40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.
16596571|NCT02635100|Experimental|MNT Algorithm|All participants will be monitored using an existing (FDA approved) CPAP machine that has been modified to be externally controlled by a computer with the MNT algorithm, for titration.
16596572|NCT02635087||high risk group|"the miRNA tool predict this group of patients as high risk"
16596573|NCT02635074|Experimental|Treatment (ibrutinib, idarubicin, cytarabine)|"INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.
~CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16596574|NCT02635061|Experimental|ACY-241 in combination with nivolumab|
16596575|NCT02635048|Other|Group 1|Patients in Group 1 undergo mini percutaneous nephrolithotomy
16596576|NCT02635048|Other|Group 2|Patients in Group 2 undergo percutaneous nephrolithotomy
16596577|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
16596578|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
16596579|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
16596580|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
16596581|NCT02635009|Active Comparator|Arm I (PCI using 3DCRT)|Patients undergo PCI using 3DCRT daily for 2 weeks.
16596582|NCT02635009|Experimental|Arm II (PCI with HA using IMRT)|Patients undergo PCI with HA using IMRT daily for 2 weeks.
16596583|NCT02634983|Experimental|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
16596584|NCT02634983|Placebo Comparator|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
16596585|NCT02634970|Experimental|Ranibizumab at 0.5 mg|Single arm, intravitreal injection
16596586|NCT02634957|Experimental|3 day absolute voice rest|participants would begin initiation of voice/speaking 3 days post phonomicrosurgery for benign vocal fold lesions
16596587|NCT02634957|Experimental|7 day absolute voice rest|participants would begin initiation of voice/speaking 7 days post phonomicrosurgery for benign vocal fold lesions
16596588|NCT02634944|Experimental|mTBI|mTBI (concussed) participants will be administered the VOMS after concussive event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
16596590|NCT02634944|Experimental|BLAST mTBI|Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
16596591|NCT02634944|Experimental|BLUNT mTBI|Blunt mTBI (concussed) participants will be administered the VOMS after concussive blunt event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
16596592|NCT02634931|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
16596593|NCT02634918||Ultrasound|3 groups of hemophilia patients - Those with > 20 bleeds into a joint, those with < 2 bleeds into a joint and those with no bleeds into a joint will be enrolled into the study
16596594|NCT02634918||those with < 2 bleeds into a joint and|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
16596595|NCT02634918||those with no bleeds into a joint will be enrolled into the st|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
16596596|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
16596597|NCT02634905|No Intervention|Control|
16596598|NCT02634892|No Intervention|Standard of Care (SOC)|Patients receive usual or standard of care regarding management of early stage pressure ulcers
16596599|NCT02634892|Experimental|SOC plus PRO-TECT|Patients receive usual or standard of care plus the addition of PRO-TECT.
16596600|NCT02634879|No Intervention|Control|Control Group
16596601|NCT02634879|Active Comparator|Loss Aversion|Each physician in this arm will have access to funds prior to earning them.
16596602|NCT02634879|Active Comparator|Group Incentive|Each physician will receive 50% of their potential incentive based on group performance. Physicians will also receive information on the performance of physicians on key CI measures in their group.
16596603|NCT02634866||Group N|The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
16596604|NCT02634866||Group D|The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
16596605|NCT02634866||Group D_HF|The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
16596606|NCT02634853|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
16596607|NCT02634853|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
16596608|NCT02634840|Experimental|Surgical intervention|"Patients receiving our modified bilateral sagittal split osteotomy procedure during orthognathic surgery, intervention arm in prospective cohort study"
16596609|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
16596610|NCT02634814|Experimental|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-perceived strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
16596611|NCT02634814|Sham Comparator|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
16596612|NCT02634814|Active Comparator|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
16596613|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.
~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
16596614|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.
~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
16596615|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.
~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
16596617|NCT02634788|Experimental|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
16596618|NCT02634788|Experimental|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
16596619|NCT02634788|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
16596620|NCT02634775|Experimental|CKD - no dialysis|Change in treatment strategy: Start on dialysis, transplantation
16596621|NCT02634775|Experimental|Patients on PD|Change in treatment strategy: Change of PD prescription, start on HD, transplantation
16596622|NCT02634775|Experimental|Patients on HD|Change in treatment strategy: Change of HD prescription, transplantation
16596623|NCT02634749|Experimental|Nordic diet|The participant in the Nordic diet group will experience three interventions: a) a systematic introduction of taste portions, b) Protein reduced complementary foods (milk cereal drinks, porridge and baby milk with reduced protein content), and c) homemade and industry manufactured main meals with a predominance of Nordic ingredients.
16596624|NCT02634749|No Intervention|Regular diet|The participants will be given the current advice on infant feeding issued by the Swedish National Food Agency. They will also be given regular, commercially available milk cereal drinks, porridge, baby milk and industry manufactured main meals. No advice or recipes on meals will be given apart from the current recommendations.
16596625|NCT02634736|Experimental|Exergame plus usual treatment|Exergame programme plus usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
16596626|NCT02634736|No Intervention|Usual treatment|No exergame programme, just usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
16596627|NCT02634723||Previously Untreated Patients (PUPs)|PUPs in China with Moderate to Severe Hemophilia A
16596628|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
16596629|NCT02634697|Experimental|3RP Intervention Group|"AF Patients will undergo the 3RP intervention which will comprise of the following:
~i. One-one-one session: each subject will spend an hour with a clinician to set specific goals for the intervention. They will also answer questionnaires.
~ii. ECG monitoring: Enrolled subjects may be monitored with an ECG at some point after the time of consent up to the day of the one-on-one session, and again after completing the 8 weeks.
~iii. Weeks 1 - 8: subjects will meet with the clinician/staff member as a group once a week for 1.5 hours each where they will be taught a variety of techniques to elicit the relaxation response as well as other cognitive skills.
~At the end of the 4th (mid-point) and 8th (last) weekly session, subjects will answer questionnaires.
~iv. 6 month follow up: 3 months after the final 3RP session to answer questionnaires.
~v. Subjects will be asked to keep track of their AF episodes during the course of the study."
16596630|NCT02634697|Active Comparator|3RP Waitlist Control Group|The Control Group will wait for 6 months (from the time the Intervention group starts the 3RP intervention) and then will undergo the same study procedures as the intervention group - except for the 6 month follow up.
16596631|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
16596632|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
16596633|NCT02634671|Other|22Q11|24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
16596634|NCT02634671|Other|SCHIZOPHRENIA|24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
16596635|NCT02634658|Experimental|Medical ICU Subjects|All Medical ICU subjects that meet eligibility criteria and are enrolled in the study will receive muscle Ultrasounds, Nerve Conduction Studies and Electromyography (EMG).
16596636|NCT02634658|Experimental|Neuro ICU Subjects|All Neuro ICU subjects that meet eligibility criteria and are enrolled in the study will receive Nerve Conduction Studies and Electromyography (EMG).
16596637|NCT02634645||Patients with Barrett's Esophagus|Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).
16596638|NCT02634645||Patients with invasive esophageal cancer|Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.
16596639|NCT02634632|Experimental|Subjects with cancer|choose to write advance directives
16596640|NCT02634619|Active Comparator|Ventral Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
16596641|NCT02634619|Active Comparator|Dorsal Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
16596674|NCT02634385|No Intervention|Small Renal Mass|Patient's with a small renal mass will be undergoing embolization prior to laparoscopic partial nephrectomy.
16596675|NCT02634372|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
16597021|NCT02632214|Sham Comparator|Hearing non signers|Group of hearing non signer controls fMRI measure
16596642|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
16596643|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
16596644|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
16596645|NCT02634593|No Intervention|Control|Control
16596646|NCT02634593|Active Comparator|Low glycemin load snacks|Low glycemic load snacks, consumed during specific times
16596647|NCT02634580|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
16596648|NCT02634580|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
16596649|NCT02634580|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
16596650|NCT02634580|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
16596651|NCT02634567|No Intervention|Treatment as Usual|This group will not any training with the Cogmed training program.
16596652|NCT02634567|Experimental|Training Group|This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
16596653|NCT02634541|Active Comparator|DMARD-naive|Sulfasalazine will be given as the initial therapy.
16596654|NCT02634541|Experimental|Post-sulfasalazine|Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.
16596655|NCT02634528|Experimental|Julphar Insulin N|Julphar Insulin N, human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
16596656|NCT02634528|Active Comparator|Huminsulin® Basal|Huminsulin® Basal, neutral protamine hagedorn (NPH), human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
16596657|NCT02634515|Experimental|Julphar Insulin R|Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
16596658|NCT02634515|Active Comparator|Huminsulin® Normal|Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
16596659|NCT02634502|Experimental|Treatment|Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
16596660|NCT02634489|Active Comparator|Tamsulosin HCl and Solifenacin Succinate|Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.
16596661|NCT02634489|Active Comparator|EC905 (tamsulosin HCI and solifenacin succinate)|Participants will receive a fixed combination tablet (3 dose strengths).
16596662|NCT02634476|Experimental|cognitive bias modification training|Participants complete four sessions of the alcohol approach/avoidance task.
16596663|NCT02634476|Sham Comparator|sham training|Participants complete four sessions of the sham approach/avoidance task.
16596664|NCT02634463|Other|Antipsychotic Immunoassay Development Participants|No study agent will be administered as a part of this study. Participants must be on Aripiprazole or Olanzapine, or Paliperidone or Risperidone, orally, daily or long-acting injectable versions, as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for use in the development of antipsychotic immunoassays. Participants may also be on long acting injectable versions of the medication.
16596665|NCT02634450|No Intervention|Control|Current practice of Early Infant Diagnosis in Mozambique: using conventional system of collecting blood on Dried Blood Spot and sending it to central laboratory for PCR processing and receiving result by SMS printer.
16596666|NCT02634450|Active Comparator|Intervention|Point Of Care Device (Alere q) is used for Early Infant Diagnosis, with the sample collected and processed in the consultation room with the device
16596667|NCT02634437|Experimental|Normal Renal Function|Ulipristal acetate, 10 mg, oral administration
16596668|NCT02634437|Experimental|Moderate Renal Impairment|Ulipristal acetate, 10 mg, oral administration
16596669|NCT02634437|Experimental|Severe Renal Impairment|Ulipristal acetate, 10 mg, oral administration
16596670|NCT02634424|Experimental|MyPKFiT|Personalized prophylaxis : Treatment is adjustment according to PK modeling
16596673|NCT02634398||Treated subjects|All subjects recruited and treated wiht the Axium neurostimulator
16596676|NCT02634372|Active Comparator|Supportive therapy|Supportive therapy: 20 individual sessions 60 minutes each for 6 months.
16596677|NCT02634359|Other|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
16596678|NCT02634359|Other|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).
~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
16596679|NCT02634359|Other|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
16596680|NCT02634346|Experimental|ALKS 3831|Administered as a coated bilayer tablet
16596681|NCT02634346|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
16596682|NCT02634346|Placebo Comparator|Placebo|Administered as a coated bilayer tablet
16596683|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
16596684|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
16596685|NCT02634320|Other|Aripiprazole Lauroxil|Intramuscular (IM) injection
16596687|NCT02634294|Experimental|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
16596688|NCT02634281|Experimental|group A|Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
16596689|NCT02634281|Active Comparator|group B|group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
16596690|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
16596691|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
16596692|NCT02634255|Active Comparator|Rocuronium elective surgery|patients undergoing inguinal herniorrhaphy
16596693|NCT02634255|Experimental|Rocuronium emergency surgery|patients undergoing appendectomy
16596694|NCT02634242|Experimental|Si-Wu-Tang (SWT)|Subjects are recommended to drink 125 mL of SWT (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
16596695|NCT02634242|Placebo Comparator|placebo|Subjects are recommended to drink 125 mL of Placebo (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
16596696|NCT02634229||Diabetic family members|(i) probands negative for GCK/MODY2 , HNF1A/MODY3 genes and HNF4A/MODY1; (ii) dominant inheritance of diabetes (three consecutive affected generations, or two generations with at least 2 diabetic patients in a generation); (iii) Diagnosis of diabetes before age 40 years in at least 3 diabetic family members; (iv) negative testing for anti-GAD and IA2-antibodies; and (v) body mass index < 30 kg/m2 (to avoid inclusion of patients with insulin-resistant type 2 diabetes).
16596697|NCT02634229||Healthy relatives|Healthy subjects whose relationship is relevant for genetic analysis and necessary for the validation step (family cosegregation study)
16596698|NCT02634216|Experimental|Type 1 Diabetics using CGM|Type 1 diabetics using Continuous Glucose MonitoringCGM to take 500 mg daily of Capros supplement (250 mg twice a day) at lunch and dinner.
16596699|NCT02634203|Experimental|Balloon Pulmonary Angioplasty (BPA)|Non-operable patients with CTEPH allocated to BPA arm
16596700|NCT02634203|Active Comparator|Riociguat|Non-operable patients with CTEPH allocated to Riociguat arm
16596701|NCT02634190||Triple negative women|Women 30 years of age or older coming for routine cervical screening who tested triple negative at baseline with the interventions: Thinprep® LBC, HR HC2® HPV DNA and APTIMA® HPV Assay
16596702|NCT02634190||Women tested positive|Women who tested positive in any of the tests Thinprep® LBC, HR HC2® HPV DNA or APTIMA® HPV Assay will undergo colposcopy and be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a 5 year period on a yearly basis
16596703|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
16596704|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
16596705|NCT02634164|No Intervention|control|"Control Treatment with Oral Glucose Tolerance Test:
~Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken."
16596706|NCT02634164|Experimental|Leucine Supplement|Control Treatment with Oral Glucose Tolerance Test:
16596707|NCT02634164|Experimental|Isoleucine Supplement|Isoleucine Combined with Oral Glucose Tolerance Test:
16596708|NCT02634164|Experimental|Leucine and Isoleucine Supplement|Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:
16596709|NCT02634151|Placebo Comparator|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
16596780|NCT02633683|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
16596710|NCT02634151|Experimental|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
16596711|NCT02634138|Experimental|Intervention|Revitive IX Neuromuscular Electrical Stimulation Device
16596712|NCT02634099|Other|hemoglobine monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
16596713|NCT02634086||Percutaneous coronary intervention|Patients with triple-vessel coronary artery disease underwent percutaneous coronary intervention.
16596714|NCT02634086||Coronary artery bypass graft|Patients with triple-vessel coronary artery disease underwent coronary artery bypass graft.
16596715|NCT02634086||Optimal medication therapy|Patients with triple-vessel coronary artery disease underwent optimal medication therapy only.
16596716|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
16596717|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
16596718|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
16596719|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
16596720|NCT02634060|Experimental|Home Based Fecal Calprotectin|"IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients.
~IBDoc® results will be forwarded to the patient and the health care professional."
16596721|NCT02634047|Active Comparator|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
16596722|NCT02634047|Experimental|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
16596723|NCT02634034|Experimental|NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)|
16596724|NCT02634034|Experimental|Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)|
16596725|NCT02634034|Experimental|Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)|
16596726|NCT02634021|Active Comparator|dexmedetomidine group|dexmedetomidine 1 mcg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
16596727|NCT02634021|Experimental|midazolam group|midazolam 0.1 mg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
16596728|NCT02634008|Experimental|Cohort 1|Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.
16596729|NCT02634008|Experimental|Cohort 2|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks
16596730|NCT02634008|Experimental|Cohort 3|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks
16596731|NCT02633995||preeclampsia|spinal anaesthesia will be given for cesarean section
16596732|NCT02633995||normotensive|spinal anaesthesia will be given for cesarean section
16596733|NCT02633969|Experimental|Indomethacin Capsules low dose|Indomethacin Capsules low dose twice daily for up to three days
16596734|NCT02633969|Experimental|Indomethacin Capsules high dose|Indomethacin Capsules high dose twice daily for up to three days
16596735|NCT02633956|Experimental|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
16596736|NCT02633956|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
16596737|NCT02633956|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
16596738|NCT02633956|Placebo Comparator|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
16596739|NCT02633943||Subjects with hemoglobinopathies|Subjects treated with ex vivo gene therapy product in a bluebird bio-sponsored clinical trial who agree to participate in this study
16596740|NCT02633930|Experimental|berberine quadruple therapy|Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.
16596741|NCT02633930|Active Comparator|clarithromycin quadruple therapy|Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16596742|NCT02633917|Experimental|Motor control exercises|One group should perform motor control exercises
16596743|NCT02633917|Active Comparator|Standard exercises|the other group should perform standard physiotherapy exercises
16596744|NCT02633904|Active Comparator|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
16596745|NCT02633904|Experimental|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
16596746|NCT02633891|Experimental|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
16596747|NCT02633891|Active Comparator|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
16596748|NCT02633878|Experimental|CHM+MP|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
16596945|NCT02632565|Active Comparator|intra-articular saline|intra-articular 7 mL saline injection for 3 times with one week intervals
16596749|NCT02633878|Placebo Comparator|CHM Placebo+MP Placebo|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
16596750|NCT02633878|Experimental|CHM+MP Placebo|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
16596751|NCT02633878|Experimental|CHM Placebo+MP|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
16596752|NCT02633852|Experimental|Aflibercept (EYLEA) 2mg /0.05 ml|Aflibercept (EYLEA) 2mg /0.05 ml
16596753|NCT02633839|Experimental|Adults who smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.
~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
16596754|NCT02633839|Experimental|Adults who don't smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.
~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
16596755|NCT02633826||kidney transplant recipients|kidney transplant recipients of an allograft from a living donor, no intervention
16596756|NCT02633813|Experimental|Naftifine hydrochloride 2%|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
16596757|NCT02633813|Active Comparator|Naftin® 2% (Naftifine hydrochloride 2%)|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
16596758|NCT02633813|Placebo Comparator|Placebo vehicle cream.|A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
16596759|NCT02633800|Experimental|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
16596760|NCT02633800|Placebo Comparator|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
16596761|NCT02633787|Experimental|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
16596762|NCT02633774|Active Comparator|Rhythm control group|1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation 2. check the echo, brain perfusion CT and K-MOCA on baseline 3. confirm a thrombus through the TEE 4. Cardioversion after 1 month 5. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines) 6. If AF recur, RFCA 7. check the brain perfusion CT, K-MOCA after 3M and 12M
16596763|NCT02633774|Active Comparator|Rate control group|1. No AAD, just anticoagulation 2. HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin) 3. check the echo, brain perfusion CT and K-MOCA on baseline 4. check the brain perfusion CT and K-MOCA after 3M and 12M 5. Without the treatment about antiarrythmia and rhythm control, diffication of rate control, the subject will be drop out for study.
16596764|NCT02633761|Active Comparator|Group 1|200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours
16596765|NCT02633761|Placebo Comparator|Group 2|placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.
16596766|NCT02633748|Other|Intervention|The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
16596767|NCT02633748|No Intervention|Control|The twenty participants in the control arm will undergo the same pre assessment as the intervention arm, receive a presentation on breathing exercises, and undergo the same post and three-month follow-up assessments. The control arm will also be offered the same Mindfulness-Based Cancer Survivorship program given to the intervention arm following the three month follow-up.
16596768|NCT02633735|Experimental|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
16596769|NCT02633735|No Intervention|Usual Care|
16596770|NCT02633722|Experimental|TRF-b|Participants are instructed to eat between 8am-5pm
16596771|NCT02633722|Experimental|TRF-d|Participants are instructed to eat only between 12-9pm
16596772|NCT02633722|No Intervention|Baseline|No lifestyle instruction given
16596773|NCT02633709|Placebo Comparator|Part 1: Single Ascending Dose: Placebo|Participants will receive a single dose of matching placebo orally on Day 1 of Part 1.
16596774|NCT02633709|Experimental|Part 1: Single Ascending Dose: Risdiplam|Participants will receive a single ascending dose (SAD) of Risdiplam orally on Day 1 of Part 1.
16596775|NCT02633709|Experimental|Part 2: Food Effect: Fasted-Fed|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fasted state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fed state on Day 1.
16596776|NCT02633709|Experimental|Part 2: Food Effect: Fed-Fasted|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fed state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fasted state on Day 1.
16596777|NCT02633709|Experimental|Part 3: Itraconazole Interaction|In Period 1 a single oral dose of Risdiplam will be administered. After a wash-out period in Period 2 participants will be administered oral doses of itraconazole twice daily from Day 1 to Day 8. On Day 4 participants will receive a single oral dose of Risdiplam in the fed state in combination with itraconazole.
16596778|NCT02633696|Active Comparator|Legalón Sil i.v 350 mg|8 healthy volunteers received 1 vial of 350 mg iv of sylibin lyophilisate for solution for infusion (legalon sil) in two hours (single dose).
16596779|NCT02633696|Experimental|Silybin-phosphatidylcholine oral 360 mg|8 healthy volunteers received 9 capsules of 40 mg of sylibin each one (360 mg in total) orally.
16596781|NCT02633670|Experimental|Hemopatch|The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion.
16596782|NCT02633670|Active Comparator|Standard technique|Standard hemostatic agents (floseal, tisseal).
16596783|NCT02633657|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
16596784|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
16596785|NCT02633631||Women seeking family planning services|Women seeking family planning and gynecological services will be enrolled in our study.
16596786|NCT02633618|Experimental|Analgecine|3ml, 2 times per day, continuous infusion for two weeks.
16596787|NCT02633618|Active Comparator|Neurotropin|3ml, 2 times per day, continuous infusion for two weeks.
16596788|NCT02633605||First Sense Breast Exam|
16596789|NCT02633592|Active Comparator|HRARM|Patients and healthy volunteers are subjected to position change ( LLP to SP) during pressure measurements with HR-ARM.
16596790|NCT02633592|Active Comparator|MRI Defecography|Patients and healthy volunteers are subjected to position change during MRI Defecography
16596791|NCT02633579|Active Comparator|Erythromycin lactobionate|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
16596792|NCT02633579|Active Comparator|Erythromycin lactobionate with atropine|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
16596793|NCT02633579|Placebo Comparator|Atropine|"Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.
~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %"
16596794|NCT02633579|Placebo Comparator|Placebo|Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
16596795|NCT02633566|Active Comparator|Functional plantar orthoses|Functional plantar orthoses in polypropylene with Medial Heel Skive technique
16596796|NCT02633566|Placebo Comparator|Placebo plantar orthoses|Plantar orthoses made in Ethil Vinyl Acetate (22º Shore) without correction of the pronation
16596797|NCT02633553|Experimental|radiotherapy group|complete resection and adjuvant radiotherapy
16596798|NCT02633553|No Intervention|observation group|complete resection
16596799|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
16596805|NCT02633514|Experimental|Radiochemotherapy|adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
16596806|NCT02633514|Sham Comparator|radiotherapy|adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
16596811|NCT02633488|Placebo Comparator|Placebo|12 weeks of Placebo tablet 3 x daily
16596812|NCT02633488|Experimental|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
16596813|NCT02633475||CONTROL: women no miscarriage|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
16596814|NCT02633475||CASE: patients with IRM|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
16596815|NCT02633462|Active Comparator|Test Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis and treated with scaling and root planing(SRP) along with Myo-inositol supplementation
16596816|NCT02633462|Active Comparator|Control Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis treated with Myo-inositol along with oral hygiene instructions.
16596817|NCT02633449|Experimental|cognitive behavioral therapy + tDCS|Group cognitive behavioral therapy combined with tDCS
16596818|NCT02633449|Active Comparator|cognitive behavioral therapy + sham-tDCS|Group cognitive behavioral therapy combined with sham-tDCS
16596819|NCT02633449|Placebo Comparator|cognitive behavioral therapy|Group cognitive behavioral therapy only
16596820|NCT02633436||cancer tissues|SLC1A5 expression of esophageal cancer tissues from patients
16596821|NCT02633436||paired adjacent tissues|SLC1A5 expression of paired adjacent esophageal tissues from patients
16596822|NCT02633423|Experimental|PEEP and CPAP|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
16596823|NCT02633423|Experimental|ZEEP and CPAP|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
16596824|NCT02633423|Experimental|PEEP and NO VM|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
16596825|NCT02633423|Placebo Comparator|ZEEP and NO VM|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
16596826|NCT02633410|Active Comparator|Transtibial|Transtibial technique used to create femoral tunnel
16596827|NCT02633410|Active Comparator|Anteromedial|Anteromedial technique used to create femoral tunnel
16596828|NCT02633397|Experimental|Riociguat|Treatment Arm
16596829|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
16596830|NCT02633384|Experimental|SMOFlipid|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion
16596831|NCT02633384|Other|Lipofundin|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion
16596832|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
16596833|NCT02633358|Experimental|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
16596834|NCT02633358|No Intervention|Control group|No therapeutic hypothermia for controlled data.
16596835|NCT02633345|Experimental|Probiotic|The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 * 109 CFU/tablet. The participants will take two tablets a day for four weeks.
16596836|NCT02633345|Placebo Comparator|Control|Placebo tablets. The participants will take two tablets a day for four weeks.
16596837|NCT02633319|Experimental|Parenting Training|Skilful Parenting: 12-week group-based parent intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages.
16596838|NCT02633319|Experimental|Agricultural Training|Agrics: Initial 3-month agricultural training intervention with ongoing support afterwards.
16596839|NCT02633319|Experimental|Parenting and Agricultural Training|Village farmer groups receiving both Skilful Parenting and Agrics interventions.
16596840|NCT02633319|No Intervention|Control|6-month wait-list control group
16596841|NCT02633306|Experimental|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
16596842|NCT02633293|Experimental|Inhaled Treprostinil|Open-label access
16596843|NCT02633280||COPD-Untreated (Group 1)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that did not receive COPD treatment in the last 6 months (beta 2 agonists, corticosteroids, anticholinergics).
16596844|NCT02633280||COPD-uncontrolled (Group 2)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that receive a COPD treatment (e.g. beta 2 agonists, corticosteroids, anticholinergics) but with a post-bronchodilator FEV1< 80% and an FEV1/FVC < 0.7 or with 1-2 exacerbation/year
16596845|NCT02633280||Control subjects (Group 3)|In this Group will be enrolled patients of both sex and older than 40 years; (2) will be free from lung disease as determined by a physician; (3) will have a normal spirometry (FEV1> 85% and FEV1/FVC > 0.7)
16596846|NCT02633267|Experimental|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
16596847|NCT02633267|Active Comparator|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
16596848|NCT02633254|Experimental|Single arm|Treatment group Magentic Resonance guided High Intensity Focused Ultrasound will be employed on uterine fibroids
16596850|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
16596851|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
16596852|NCT02633202|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone: Patients receive intensity modulated-radiotherapy (IMRT) alone
16596853|NCT02633202|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
16596854|NCT02633189|Experimental|erlotinib and bevacizumab|
16596855|NCT02633189|Active Comparator|erlotinib|
16596856|NCT02633176|Active Comparator|cisplatin and docetaxel|"Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles.
~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m^2 intravenously every week.
~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
16596882|NCT02632942|Experimental|HAQ Criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:
~60% or greater diameter of the main AVF
~50% diameter of AVF with at least one more av>40% in diameter.
~50% in diameter and divides into branches of same size.
~av likely to interfere with cannulation on physical examination.
~>30% in diameter and associated with stenosis at site of origin."
16596883|NCT02632942|Active Comparator|Current Recommendation|Obliteration of accessory vein which satisfy the current recommendations only defined as accessory vein with a diameter greater than 25% of the AVF diameter.
16596857|NCT02633176|Experimental|cetuximab, cisplatin, and docetaxel|"Induction chemotherapy: Patients receive cetuximab 400mg/m^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles.
~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m^2 intravenously followed by cisplatin 30mg/m^2 intravenously every week.
~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
16596858|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
16596859|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
16596860|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
16596861|NCT02633150|Experimental|Polyphenol|red grapes polyphenol supplementation on metabolic parameters in obese insulinoresistant subjects
16596862|NCT02633150|Placebo Comparator|Placebo|Placebo supplementation on metabolic parameters in obese insulinoresistant subjects
16596863|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months
16596864|NCT02633124|Experimental|Edelvaiss Multiline NEO|The Edelvaiss Multiline NEO design allows to position the access to the infusion line outside of the incubator, without increasing the residual volume and this device has been validated by the manufacturer as part of CE marking for a period of 21 days.
16596865|NCT02633124|Other|Standard Infusion Set|The infusion set used for the standard group is the infusion set usually used.
16596866|NCT02633111||Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
16596867|NCT02633098|Experimental|Artesunate|Artesunate 200mg oral tablets once daily for 14 days.
16596868|NCT02633098|Placebo Comparator|Matching placebo|Matching placebo oral tablets once daily for 14 days.
16596870|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
16596871|NCT02633046|Other|Acthar Gel|Acthar Gel, 1 mL (80 U) by subcutaneous injection (SC) 3x/week will be administered to all participants from Week 0 to 50. Tapering of dose to 1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 2x/week it must remain at this level. Participants unable to tolerate 1 mL SC 2x/week will be discontinued. All participants will have an End of Study/Early Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP).
16596872|NCT02633020|Experimental|AMG 714|Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
16596873|NCT02633020|Placebo Comparator|Placebo|Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
16596874|NCT02633007|Experimental|CVT-301 then Placebo (AB)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
16596875|NCT02633007|Experimental|Placebo then CVT-301 (BA)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
16596876|NCT02632981|Active Comparator|chronic periodontitis patients|gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
16596877|NCT02632981|Placebo Comparator|periodontally healthy controls|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
16596878|NCT02632968|Active Comparator|Pinhole surgery with orthodontic buttons|Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
16596879|NCT02632968|Active Comparator|Pinhole surgery without buttons|Pinhole surgery without orthodontic buttons The selected participants were assigned in test and control. In the control group, after administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions till the recession defects were covered. No sutures or orthodontic buttons were used in the control site.
16596880|NCT02632955|Experimental|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
16596881|NCT02632955|Sham Comparator|Regular Angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
16596944|NCT02632565|Active Comparator|intra-articular 0.5% lidocaine|intra-articular 7 mL 0.5% lidocaine injection for 3 times with one week intervals
16596884|NCT02632929||Diabetic Foot Ulcers at Amputation Risk|Patients at high risk for limb amputation from a diabetic foot ulcer will be treated with comprehensive, interdisciplinary approach (usual care) in combination with early application of advanced therapy; dehydrated human amniotic membrane allografts (AMNIOEXCEL®, Derma Science, Princeton, New Jersey).
16596885|NCT02632916|Active Comparator|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg
16596886|NCT02632916|Experimental|Denosumab|Subcutaneous denosumab 1.0mg/kg
16596887|NCT02632903|Experimental|Intravenous Zoledronic Acid|Intravenous Zoledronic Acid 0.025mg/kg at baseline and 6 months
16596888|NCT02632890||Patients survey|Adult patients treated with abatacept for rheumatoid arthritis
16596889|NCT02632890||HCP survey|HCP with at least 1 patient taking abatacept
16596890|NCT02632890||Retrospective chart review study|Adult patients treated with abatacept for rheumatoid arthritis
16596891|NCT02632877|Experimental|Pirfenidone with MODD|"Active ingredients: Pirfenidone 8% with modified oxide diallyl disulfide (MODD) 0.016%.
~Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency and duration: topically applied every eight hours for 6 months."
16596892|NCT02632877|Active Comparator|Ketanserin|"Active ingredients: Ketanserin 2%. Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency and duration: topically applied every 12 hours for 6 months."
16596893|NCT02632864|Experimental|Proton arm|Proton beam therapy
16596894|NCT02632851||Ectoin inhalation solution|treatment according to instructions for use
16596895|NCT02632851||Pari NaCl inhalation solution (0.9%)|treatment according to instructions for use
16596896|NCT02632838|Experimental|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
16596897|NCT02632838|No Intervention|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
16596898|NCT02632825|Experimental|Nasal High Flow|NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen
16596899|NCT02632825|No Intervention|Control|Control is no NHF intervention
16596900|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
16596901|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
16596902|NCT02632799|Experimental|NHF small cannula|NHF 8 L/min (Airvo2) , Smaller cannula (neonatal, yellow)
16596903|NCT02632799|Experimental|NHF big cannula|NHF 8 L/min (Airvo2) , Bigger cannula (neonatal, purple)
16596904|NCT02632799|Experimental|Mask CPAP|CPAP 5cm H2O
16596905|NCT02632799|No Intervention|no intervention|control
16596906|NCT02632786|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
16596907|NCT02632786|Placebo Comparator|Placebo|Placebo
16596908|NCT02632773|Experimental|Parent Learning Style 1|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
16596909|NCT02632773|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
16596910|NCT02632773|Other|Learning Style 1 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
16596911|NCT02632773|Other|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
16596912|NCT02632760|Active Comparator|ferric carboxymaltose|ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
16596913|NCT02632760|Placebo Comparator|Placebo|Placebo intravenous infusion
16596914|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
16596915|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
16596916|NCT02632734|Experimental|CoreBone Cone device|Experimental: CoreBone Cone device After extraction intervention will include the placement of CoreBone Cone device derived from coral that its dimensions is 4-5mm width and 8-10mm height. One cone for each extraction socket.Its advantage is that it fits well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month. We predict that CoreBone Cones are more effective than particulate device.
16596917|NCT02632734|Experimental|CoreBone 500 device|After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
16596918|NCT02632721|Experimental|Dose Escalation Cohorts (Phase I)|Combination treatment of decitabine with escalating doses of BI 836858
16596919|NCT02632721|Experimental|Extension Cohorts (Phase I)|Combination treatment of decitabine with BI 836858 at MDT (Maximum Tolerated Dose)
16596920|NCT02632721|Experimental|Arm 1 (Phase II)|Combination treatment of decitabine with BI 836858 at R2PD (Recommended Phase II dose)
16596921|NCT02632721|Other|Arm 2 (Phase II)|Monotherapy treatment with decitabine (standard of care treatment)
16596922|NCT02632708|Experimental|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]) may continue on maintenance therapy and receive daily treatment with AG-120.
16596923|NCT02632708|Experimental|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
16596924|NCT02632708|Experimental|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
16596925|NCT02632708|Experimental|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
16596926|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
16596927|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
16596928|NCT02632695|Experimental|FOOTFIT Plus|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports and allows regular communication with the wound care provider on progress.
16596929|NCT02632695|Experimental|FOOTFIT|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports. There is not regular communication with the wound care provider on progress.
16596930|NCT02632669|Experimental|Hemigland focal LDR brachytherapy|Hemigland focal LDR brachytherapy using permanent iodine 125 seed implantation
16596931|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
16596932|NCT02632643|Experimental|lifestyle counseling|
16596933|NCT02632630|Active Comparator|Amino Acids w/Electrolytes in Dextrose|Peripheral parenteral nutrition (PPN)
16596934|NCT02632630|Active Comparator|Ensure product|Calorie and protein dense oral nutritional supplement for patients with elevated nutritional needs.
16596935|NCT02632630|Active Comparator|Crystalloid solutions|Standard care intravenous maintenance fluids.
16596936|NCT02632630|Active Comparator|Oral nutritional supplementation|Nutrient-enhanced drink products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake.
16596937|NCT02632617||CTA Group|Participants in CTA group will primarily receive computed tomographic angiography examination before surgery. Those with positive findings in CTA (≥50% diameter stenosis in main coronary artery) or uncertain diagnosis caused by motion artifact or calcium artifact are required to undergo ICA, and coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis according to the ICA result. Participants with negative findings in CTA do not need further coronary artery evaluation, and CABG won't be performed during the surgery.
16596938|NCT02632617||ICA Group|Participants in ICA group will undergo ICA as guideline recommend before surgery, coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis
16596939|NCT02632604|Active Comparator|Bottom-up to top-down cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes
16596940|NCT02632604|Active Comparator|Top-down to bottom-up cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes
16596941|NCT02632604|Placebo Comparator|Computer games|Participants are given 40 hours of computer games commonly found on the internet and which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc).
16596942|NCT02632578||HIV-positive|
16596943|NCT02632578||HIV-negative|
16596946|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
16596947|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
16596948|NCT02632539|Active Comparator|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
16596949|NCT02632539|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
16596950|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
16596951|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
16596952|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
16596953|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
16596954|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
16596955|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
16596956|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
16596957|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
16596958|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
16596959|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
16596960|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
16596961|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
16596962|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
16596963|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
16596964|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
16596965|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
16596966|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
16596967|NCT02632513|Experimental|continuous ultrasonic irrigation|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
16596968|NCT02632513|No Intervention|Syringe irrigation|In the syringe irrigation group, irrigation was done using 27 gauge syringe.
16596969|NCT02632500|Experimental|30 compressions and 2 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 30 compressions and 2 seconds of pause protocol (30 chest compressions followed by 2 seconds of pause) on a manikin connected to the Personal Computer."
16596970|NCT02632500|Experimental|50 compressions and 5 seconds of pauses|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 50 compressions and 5 seconds of pause protocol (50 chest compressions followed by 5 seconds of pause) on a manikin connected to the Personal Computer."
16596971|NCT02632500|Experimental|100 compressions and 10 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 100 compressions and 10 seconds of pause protocol (100 chest compressions followed by 10 seconds of pause) on a manikin connected to the Personal Computer."
16596972|NCT02632500|Experimental|hands-only|"After the randomization the participant will be asked to perform 8 minutes of CPR following the hands-only protocol (continuous chest compressions without any pauses) on a manikin connected to the Personal Computer."
16596973|NCT02632487|Active Comparator|Exercise|This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.
16596974|NCT02632487|Experimental|Exercise + Non-Exercise Physical Activity (NEPA)|This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).
16596975|NCT02632474|Experimental|Low-dose|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
16596976|NCT02632461|Experimental|Podcast (+Bite Counter)|Participants in this group will receive podcasts twice weekly in conjunction with using a wearable wrist device called a Bite Counter. The Bite Counter tracks the number of bites/calories per bite. (Podcasts plus Bite Counter)
16596977|NCT02632461|Active Comparator|Podcast (+Mobile App)|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile application to track their diet. (Podcasts plus Mobile Diet Application)
16596978|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
16596979|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
16596980|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
16596981|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
16596982|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
16596983|NCT02632448|Experimental|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
16596984|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
16596985|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
16596986|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
16596987|NCT02632435|Other|Peripherally inserted central catheter|PICC line will be inserted for the delivery and duration of chemotherapy.
16596988|NCT02632435|Other|portacath|PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.
16596989|NCT02632422|Experimental|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
16596990|NCT02632422|Sham Comparator|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
16596991|NCT02632422|Experimental|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
16596992|NCT02632422|Sham Comparator|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
16596993|NCT02632422|Other|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
16596994|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
16596995|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
16596997|NCT02632383|Experimental|Test Group|"Intervention: Young with Diabetes - app The test group receives standard care and the mHealth app Young with Diabetes - app to support young people to self-manage their diabetes.
~The young people's parents are also invited to download the app. The diabetes team (doctors, nurses and dieticians) also have the app and uses the app in their consultations with the young people."
16596998|NCT02632383|No Intervention|Control Group|The control group receives standard care
16596999|NCT02632370||Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
16597000|NCT02632357|Experimental|AS group|Subjects with ULNTT asymmetry > 10°
16597001|NCT02632357|No Intervention|S group|Subjects with ULNTT symmetry
16597002|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
16597003|NCT02632331|Experimental|Fasted dosing preceding group|
16597004|NCT02632331|Experimental|Fed dosing preceding group|
16597005|NCT02632318|Experimental|Light|Dawn simulation for 30 minutes prior to habitual wake time
16597006|NCT02632318|No Intervention|No light|Darkness for 30 minutes prior to habitual wake time
16597007|NCT02632305|Experimental|Treatment|"Eligible patients will receive nab-paclitaxel in combination with gemcitabine + cisplatin at the recommended phase II dose based on the phase I study completed in metastatic pancreas cancer patients.
~The doses of study drugs will be as follows:
~nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days
~Cisplatin 25 mg/m2 day 1 and 8 every 21 days
~Gemcitabine 800 mg/m2 day 1 and 8 every 21 days
~Nab-paclitaxel will be administered first followed by cisplatin and then gemcitabine on day 1 and 8 of each treatment cycle. Cycles will be 3 weeks in length (21 days)."
16597008|NCT02632292|Experimental|Absorb GT1|Bioresorbable everolimus-eluting scaffolds
16597009|NCT02632292|Active Comparator|Promus|Everolimus-eluting stents
16597010|NCT02632279|Experimental|TRP depleted|TRP depleted protein drink
16597011|NCT02632279|Placebo Comparator|Placebo|Balanced protein drink (+1.21g of TRP)
16597012|NCT02632266|Active Comparator|Powder HMF|Once patient has reached 80ml/kg/day of enteral feedings, 1 pack of powder HMF will be added to 50 ml of human or donor breast milk, then increased to a maximum of 2 packs for 50 ml following the unit feeding advancement protocol and this will be continued up until 48 hours prior to discharge.
16597013|NCT02632266|Active Comparator|Liquid HMF|Once patient has reached 80ml/kg/day of enteral feedings, researchers will add 1 packet (5 ml) of liquid HMF to 50 ml of human or donor breast milk, then increase to 2 packs to 50 ml following the unit feeding protocol and this will be continued up until 48 hours prior to discharge.
16597014|NCT02632253|Active Comparator|Moderate intensity continuous exercise|"Patients perform two weekly supervised MICE session on a cycling ergometer per week plus one self monitored 30-60 min MICE training of choice at home.
~MICE is performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down)."
16597015|NCT02632253|Experimental|High intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min.
~Additionally patients perform one self monitored 30-60 min MICE training of choice per week at home."
16597016|NCT02632240|Active Comparator|Control group|Surgery:The tunnel technique for covering gingival recession. Graft: connective tissue.
16597017|NCT02632240|Active Comparator|Study group|Surgery:The tunnel technique for covering gingival recession.Graft: xenogenic collagen matrix (Mucoderm).
16597018|NCT02632227||Hypovolemia|patients with hypovolemic signs including hypotension, decreased central venous pressure (less than 5mmHg), and decreased urine output
16597022|NCT02632201|Experimental|PIK-HER2 cells|PIK-HER2 cells treatment will be performed every 3 weeks with a total of three periods.
16597023|NCT02632201|Active Comparator|DC-PMAT|DC-PMAT treatment will be performed every 3 weeks with a total of three periods.
16597024|NCT02632188|Active Comparator|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
16597025|NCT02632188|Experimental|DC-PMAT treatment|On the basis of postoperative routine treatment, patients will receive 3 cycles of dendritic cell-precision multiple antigen T (DC-PMAT) cells treatment.
16597026|NCT02632175|Experimental|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
16597027|NCT02632162||cardiac surgery|active Group screening
16597028|NCT02632162||orthopedic surgery|control Group screening
16597029|NCT02632149|Experimental|Vagus nerve Stimulation is on|
16597030|NCT02632136|Active Comparator|TAP block group|"This group will receive 30 ml of 0.25% Bupivacine given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine.
~They will also receive normal saline injections at port sites, which will be injected before the ports are inserted. 15 ml of normal saline will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports."
16597031|NCT02632136|Placebo Comparator|Peri-Portal block Group|"They will receive 0.5% Bupivacaine injections at port sites, which will be injected before the ports are inserted. 15 ml of 0.5% Bupivacaine will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports.
~This group will also receive 30 ml of Normal Saline Injection given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine."
16597032|NCT02632123||Idiopathic pulmonary fibrosis|Patients newly diagnosed with idiopathic pulmonary fibrosis
16597033|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
16597034|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
16597035|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
16597036|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
16597037|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
16597038|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
16597039|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
16597040|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
16597041|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
16597042|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
16597043|NCT02632097|Experimental|Histoacryl|Intervention: Lichtenstein Hernioplasty with Histoacryl™(cyanoacrylate glue 0.5 ml) for mesh fixation (Optilene™ mesh 60 g/m2 (B. Braun))
16597044|NCT02632097|Experimental|Suture|Intervention: Lichtenstein Hernioplasty with Sutures (polypropylene 2/0) to fix the Optilene™ mesh 60 g/m2 (B. Braun)
16597045|NCT02632071|Active Comparator|80 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
16597046|NCT02632071|Active Comparator|120 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
16597047|NCT02632071|Active Comparator|180 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
16597048|NCT02632071|Active Comparator|240 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
16597049|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
16597050|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
16597051|NCT02632032|Other|Insulin therapy and diabetes education|Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.
16597052|NCT02632019|Active Comparator|gemcitabine|Gemcitabine treatments will be performed once a week with a total of six times
16597053|NCT02632019|Experimental|Dendritic cell-precision T cell for neo-antigen|Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.
16597054|NCT02632006|Experimental|PIK-PD-1 cells|PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.
16597055|NCT02632006|Active Comparator|DC-PMAT|DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.
16597056|NCT02631980|Experimental|IV iron|Postoperative iv iron administration (Ferinject) upon arrival in after surgery recovery room
16598791|NCT02620618|Experimental|Intravitreal Infliximab|Patients with refractory behcets uveitis.
16597057|NCT02631980|Placebo Comparator|IV placebo|Postoperative iv placebo administration upon arrival in after surgery recovery room
16597058|NCT02631967|Experimental|Kono anastomosis|Patients receiving Kono anastomosis
16597059|NCT02631967|Experimental|Stapled side-to-side anastomosis|Patients receiving stapled side-to-side anastomosis
16597060|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
16597061|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
16597062|NCT02631941|Experimental|Z7200|single dose (two inhalations)
16597063|NCT02631941|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
16597064|NCT02631941|Experimental|Z7200 with charcoal|single dose (two inhalations)
16597065|NCT02631941|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
16597066|NCT02631941|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
16597067|NCT02631928|Experimental|Julphar Insulin 30/70|human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
16597068|NCT02631928|Active Comparator|Huminsulin® Profil III|human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
16597069|NCT02631902|Experimental|Exercise|Community-based exercise program
16597070|NCT02631902|Experimental|Exercise plus dietary intervention|Community-based exercise and dietary intervention program
16597071|NCT02631902|No Intervention|Control|Habitual physical activity and habitual dietary pattern
16597072|NCT02631889|Experimental|Transcollation technology|the use of transcollation technology for hilium dissection during Lung surgery
16597073|NCT02631889|Active Comparator|Traditional Electrocautery|The use of electrocautery for hilium dissection during lung surgery
16597074|NCT02631876|Experimental|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee [BIRC]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
16597075|NCT02631876|Experimental|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
16597076|NCT02631863|Experimental|ALA|Patients will receive 3 topical treatments of aminolaevulinic acid 500mg
16597077|NCT02631863|Placebo Comparator|Placebo|Patients will receive 3 topical treatments of placebo 500mg
16597078|NCT02631850|Active Comparator|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
16597079|NCT02631850|Active Comparator|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
16597080|NCT02631850|Active Comparator|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 2.6 hours video conference consultation throughout the treatment period.
16597081|NCT02631850|Active Comparator|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on activities of daily living (ADLs) with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of strengthening exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
16597082|NCT02631837|Experimental|vNOTES hysterectomy|vaginal Natural Orifice Transluminal Endoscopic Surgery
16597083|NCT02631837|Active Comparator|LSC hysterectomy|Laparoscopic hysterectomy
16597084|NCT02631824|Active Comparator|Standard treatment|open reduction and internal fixation TFNA
16597085|NCT02631824|Experimental|Augmentation|open reduction and internal fixation TFNA Augmentation (Cement)
16597086|NCT02631811|Experimental|Supportive /palliative care intervention|patients will be supported by a multidisciplinary palliative specialist team
16597087|NCT02631811|No Intervention|usual medical follow up|patients will be supported by the support care team if asked by the oncologist
16597088|NCT02631798|Experimental|Dye staining|Food grade dye mucosal staining
16597089|NCT02631785|Experimental|Anxious group|Youth diagnosed with anxiety disorder will receive Cognitive Behavioral Therapy for reducing anxiety symptoms.
16597090|NCT02631785|No Intervention|Control group|Healthy youth will be recruited for comparison but their participant in the study will not include intervention.
16597091|NCT02631772|Experimental|Late Cohort, Arm 1|Ledispasvir (LDV) and Sofosbuvir (SOF) monotherapy x 12 weeks
16597092|NCT02631772|Active Comparator|Late Cohort, Arm 2|Ledispasvir (LDV) and Sofosbuvir (SOF) +ribavirin x 12 weeks
16597093|NCT02631759|Experimental|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
16597094|NCT02631759|Placebo Comparator|Placebo|52 patients will be recruited over 2 years in the control group
16597095|NCT02631746|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
16597097|NCT02631720||Adult Lung Transplant Recipients|Adult lung transplant recipients undergoing lung transplant at each of the participating centers.
16597098|NCT02631707|No Intervention|Control Standard Protein Diet|Control Arm Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%).
16597099|NCT02631707|Experimental|Intervention High Protein Diet|Intervention Arm Percentage energy from carbohydrate (40%), protein (30%) and fat (30%).
16597100|NCT02631694|Experimental|Fear reactivation with propranolol|
16597101|NCT02631694|Placebo Comparator|Fear reactivation with placebo|
16597102|NCT02631694|Placebo Comparator|No fear reactivation with propranolol|
16597103|NCT02631681|Experimental|Men with prostate cancer on androgen deprivation therapy|Group based supervised combined aerobic and resistance training for 12 weeks.
16597104|NCT02631668|Experimental|ferrous succinate and vitamin C|In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
16597105|NCT02631668|Active Comparator|ferrous succinate with normal dosage|In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
16597106|NCT02631668|Active Comparator|ferrous succinate with double dosage|In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
16597107|NCT02631655|Other|device 18FDOPA|impact of device 18F-FDOPA PET on treatment decisions
16597108|NCT02631642|Experimental|HMPL-689|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
16597109|NCT02631642|Placebo Comparator|HMPL-689 placebo|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
16597110|NCT02631629|Placebo Comparator|Non-fortified foods SA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of South Asian (SA) origin
16597111|NCT02631629|Placebo Comparator|Non-fortified foods CA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of Caucasian (CA) origin
16597112|NCT02631629|Active Comparator|Vitamin D fortified foods SA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of South Asian (SA) origin
16597113|NCT02631629|Active Comparator|Vitamin D fortified foods CA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of Caucasian (CA) origin
16597114|NCT02631616|Experimental|Treatment arm|Monthly injections of Somatostatin (Sandoatatin LAR - 30mg)
16597115|NCT02631603|Experimental|Placebo|Capsules of placebo will be taken for 3 months.
16597116|NCT02631603|Active Comparator|Prednisolone|"Oral prednisolone, anticipated dose:
~first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.
~Individual capsules will be prepared using rounded dose."
16597117|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
16597120|NCT02631551|Experimental|GSP 301 NS|
16597121|NCT02631551|Active Comparator|Olopatadine HCl NS|
16597122|NCT02631551|Active Comparator|Mometasone furoate NS|
16597123|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
16597124|NCT02631538|Placebo Comparator|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
16597125|NCT02631538|Experimental|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
16597126|NCT02631538|Experimental|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
16597127|NCT02631538|Active Comparator|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
16597128|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
16597637|NCT02628249|Experimental|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.
16597129|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
16597130|NCT02631512|Other|Woulgan Gel|Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)
16597131|NCT02631512|Other|Intrasite Hydrogel|Primary dressing with Intrasite Hydrogel
16597132|NCT02631499|Experimental|Adjuvant TACE|TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.
16597133|NCT02631499|No Intervention|Control|no interventions were assigned after hepatectomy
16597134|NCT02631486|Experimental|Early|"The first group will use sling for comfort only. Active assisted exercises in closed chain and in safe zone are allowed in the first 4 weeks.
~The rehabilitation stages will start from active assisted progressing to more active stages phases until full recovery. The whole program will last about 3 months."
16597135|NCT02631486|Active Comparator|Conservative|The second group will use a sling for 6 weeks. The rehabilitation stages will start with active assisted/closed chain movements with short levers, it will progress to more active stages phases until full recovery. The whole program will last about 3 months.
16597136|NCT02631473|Active Comparator|1st Stage-Group A|"Day 1: 50 mg NANO-efavirenz single dose
~Days 4-21: 50 mg NANO-efavirenz OD (once daily)"
16597137|NCT02631473|Active Comparator|1st Stage-Group B|"Days 1-7: 400mg NANO-lopinavir BID (twice daily)
~Days 8-21: Wash-out period
~Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID"
16597138|NCT02631473|Active Comparator|2nd Stage-Group A-Group 1-Dose level 1|"21 Days: 300mg NANO-efavirenz OD
~4 weeks: Wash-out period
~21 days: 600mg Sustiva OD"
16597139|NCT02631473|Active Comparator|2nd Stage-Group A-Group 2-Dose level 2|"21 Days: 200mg NANO-efavirenz OD
~4 weeks: Wash-out period
~21 days: 400mg Sustiva OD"
16597140|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 1|"7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD
~2 weeks: Wash-out period
~7 days: NANO-lopinavir (200mg +/- ritonavir®)"
16597141|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 2|"7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)
~2 weeks: Wash-out period
~7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD"
16597142|NCT02631460|Experimental|S1 and Carboplatin|S1 80-120 mg/d+Carboplatin AUC=5 Patients without progression received maintenance until disease progression with S1
16597143|NCT02631460|Active Comparator|pemetrexed and Carboplatin|pemetrexed 500 mg/m2+ Carboplatin AUC=5 Patients without progression received maintenance until disease progression with pemetrexed
16597144|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
16597145|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
16597146|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
16597147|NCT02631434|Experimental|sit-to-stand|To perform a sit-to-stand test
16597148|NCT02631434|Active Comparator|six minute walking test|To perform a six minutes walking test
16597149|NCT02631421||Pulmonary Arterial Hypertension|Clinical diagnosis of pulmonary arterial hypertension
16597150|NCT02631421||Healthy subjects and patients with other causes of PH|Patients referred for right heart catheterization who do not have PAH
16597151|NCT02631408|No Intervention|Control Group|No additional treatment. Routine iv. antibiotic prophylaxis only.
16597152|NCT02631408|Experimental|Vancomycin Group|Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
16597153|NCT02631395|Other|Training group|Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition season; the training Group (intervention Group) and the Control Group.The intervention group completed strength training exercises Three times a week the Whole competition season.
16597154|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
16597155|NCT02631382|Experimental|wet cupping : double cupping|wet cupping: (traditional cupping technique): cupping (suction) - Scarification - cupping (suction)
16597156|NCT02631382|Experimental|wet cupping: single cupping|wet cupping:(Asian cupping): Puncture by needles then cupping (suction):
16597157|NCT02631369|Experimental|inter- & intrarater reliability study|pre-study: inter- and intrarater reliability study in 30 healthy subjects, interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
16597158|NCT02631369|Experimental|cyclotorsion in forth nerve palsy|measurement of cyclotorsion on SLO-fundusphoto in 20 patients forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
16597159|NCT02631369|Experimental|cyclotorsion in healthy subjects|measurement of cyclotorsion on SLO-fundusphoto in 30 healthy subjects to be compared to patients with forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
16597160|NCT02631356|Placebo Comparator|Ringer's lactate solution|Infusion of Ringer's lactate solution (10ml/kg) in the control group
16597161|NCT02631356|Active Comparator|Succinylated gelatin|Infusion of Succinylated gelatin (10ml/kg) in the test group
16597162|NCT02631343|Experimental|Intervention KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
16597163|NCT02631343|Other|Control|Routine visits by government health workers
16597193|NCT02631122|Active Comparator|Supraclavicular BPNB|Patients in this group will be randomized to receive an Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
16597164|NCT02631330|Experimental|Falls prevention group|"Intervention group that will receive a monthly talk (individual or collective) of 30 minutes on the advantages of having a free fall hazards environment and multiple physical exercise component: balance,muscle strength and aerobic capacity and risk polypharmacy and abuse of drugs, especially benzodiazepines). In the same monthly meeting, subjects will be train Multicomponent physical activity program during 60 minutes. 15 minutes of gait and balance training; 15 minutes of endurance training; 30 minutes of aerobic training according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459"
16597165|NCT02631330|No Intervention|Control group|Subjects will receive the same information provided at the beginning to Falls prevention group. They will not receive further information during the follow-up period.
16597166|NCT02631317||rt-PA|patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.
16597167|NCT02631304||Patients undergoing cardiac surgery|Elderly patients scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of cardiopulmonary bypass.
16597168|NCT02631291|Experimental|Lifestyle|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet.
16597169|NCT02631291|No Intervention|Usual Care|Participants randomized to this condition will receive the written education provided to all participants.
16597170|NCT02631291|Experimental|LIfestyle + coaching|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet; and behavioral self-monitoring + motivational interviewing lifestyle coaching.
16597171|NCT02631278|Other|single arm|Intraoperative radiofrequency ablation
16597172|NCT02631265|Active Comparator|Reduction of insulin basal rate at the time of exercise|
16597173|NCT02631265|Active Comparator|Reduction of insulin basal rate 20 minutes prior to exercise|
16597174|NCT02631265|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
16597175|NCT02631252|Experimental|Open-label, Single-arm|"Hydroxychloroquine + Mitoxantrone + Etoposide
~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days"
16597176|NCT02631239|Active Comparator|MESA|Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
16597177|NCT02631239|Experimental|ESA|Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
16597178|NCT02631226||Pregnant women colonized by resistant enterobacteria|
16597179|NCT02631200|Experimental|Advance care plan|Participants will be offered the opportunity to complete an advance care plan.
16597180|NCT02631200|No Intervention|Usual care|Participants will be offered usual care for 12 weeks (and only then be offered the opportunity to complete an advance care plan).
16597181|NCT02631187|Experimental|Balloon Eustachian Tuboplasty|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
16597182|NCT02631174|No Intervention|cohort 1|Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
16597183|NCT02631174|Active Comparator|cohort 2.1|"• Cohort 2.1 - 6 neonates undergoing ECMO.
~Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume
~Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume"
16597184|NCT02631174|Active Comparator|cohort 2.2|"• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB
~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.
~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
16597185|NCT02631174|Active Comparator|cohort 2.3|"• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB
~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.
~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
16597186|NCT02631174|Active Comparator|cohort 3|Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is < 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
16597187|NCT02631161|Experimental|EQUIA forte|Dental non-carious cervical restorations are being restored with a glass hybrid restorative system (Medical product: EQUIA forte).
16597188|NCT02631161|Active Comparator|Filtek Supreme XT/Clearfil SE Bond|Dental non-carious cervical restorations are being restored with a composite resin based material/Adhesive combination (Medical product: Filtek Supreme XT/Clearfil SE Bond).
16597189|NCT02631148|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
16597190|NCT02631148|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
16597191|NCT02631135|Placebo Comparator|Group 1 (TIVA)|Only propofol (started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1)
16597192|NCT02631135|Active Comparator|Group 2 (TIVA+D)|Propofol started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1),and also dexmedetomidine infusion (started as 0.5 μg.kg-1 without making the loading dose and the dose change was not made during the operation)
16597194|NCT02631122|Active Comparator|Retroclavicular BNPB|Patients in this group will be randomized to receive an Ultrasound Guided Retroclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
16597195|NCT02631109|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
16597196|NCT02631096|Experimental|0.2 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
16597197|NCT02631096|Experimental|0.4 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
16597198|NCT02631096|Experimental|ARB-001467 or Placebo|HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
16597199|NCT02631096|Experimental|0.4 mg/kg ARB-001467|HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
16597200|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (high GI)|Subjects will consume meals which are high glycemic index for breakfast (Honey stars cereal), lunch (glutinous rice meal) and snack (white bread and jam) in the whole body calorimeter. A take-away high glycemic index dinner will be provided.
16597201|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (low GI)|Subjects will consume meals which are low glycemic index for breakfast (All bran cereal), lunch (basmati rice meal) and snack (multigrain bread and sugar-free jam) in the whole body calorimeter. A take-away low glycemic index dinner will be provided.
16597202|NCT02631070|Experimental|Experimental Arm - Luspatercept (ACE-536)|Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
16597203|NCT02631070|Placebo Comparator|Control Arm: Placebo|Subcutaneous injection every 3 weeks
16597204|NCT02631057||Non-Valvular Atrial Fibrillation|
16597205|NCT02631057||acute ischemic stroke|
16597206|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
16597207|NCT02631044|Experimental|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
16597208|NCT02631031|Other|morning administration|administration of single oral dose valsartan (160 mg) in the morning
16597209|NCT02631031|Other|evening administration|administration of single oral dose valsartan (160 mg) in the evening
16597210|NCT02631018|Experimental|Physical Activity Enhanced Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations. This arm, uniquely, will receive a culturally based physical activity component.
16597211|NCT02631018|Active Comparator|Standard Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
16597212|NCT02631005|Experimental|Walk With Ease Participants|"Participants will receive a copy of the Walk With Ease workbook. This workbook provides guidance on walking safety and on how to start and maintain a regular walking program. It is designed to help participants increase their physical activity over a six-week period. Participants will complete self-reported outcomes questionnaires before and after completion of the program."
16597213|NCT02630992|Experimental|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
16597214|NCT02630979||No treatment|Clinical and medical oncology physicians.
16597215|NCT02630966|Experimental|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
16597216|NCT02630966|Experimental|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
16597217|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
16597218|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
16597219|NCT02630940||Idiopathic pulmonary fibrosis sufferers|Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
16597220|NCT02630927|Placebo Comparator|Part 1 Single-Ascending (SAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
16597221|NCT02630927|Placebo Comparator|Part 2 Multiple-Ascending (MAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
16597222|NCT02630927|Experimental|Part 3 Bioavailability & Food Effect|The dose to be assessed in Part 3 will be selected based on emerging safety, tolerability and PK/PD data from preceding cohorts in Part 1 and Part 2, which will be reviewed during a dose decision meeting.
16597223|NCT02630927|Experimental|Experimental Part 4 (Subjects of Japanese Origin)|Two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3
16597224|NCT02630927|Experimental|Experimental Part 5 Open-label Multiple-Ascending (MAD)|Up to two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
16597225|NCT02630914|Experimental|Intervention|All patients will have the hybrid procedure of ablation of atrial fibrillation.
16597226|NCT02630901|Experimental|PRX003|
16597227|NCT02630901|Placebo Comparator|Placebo|
16597228|NCT02630888|Active Comparator|Memantine|Patients randomized to this group will receive a dose of 15 mg / day of memantine during the first week (V0); all have the dose of memantine increased on the second week (V1) at the dose of 30 mg / day (in two divided doses of 15 mg).
16597229|NCT02630888|Placebo Comparator|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine.
16597230|NCT02630875|Active Comparator|A4250 1|Dose I
16597231|NCT02630875|Active Comparator|A4250 2|Dose 2
16597232|NCT02630875|Active Comparator|A4250 3|Dose 3
16597233|NCT02630875|Active Comparator|A4250 4|Dose 4
16597234|NCT02630875|Active Comparator|A4250 5|Dose 5
16597235|NCT02630875|Active Comparator|A4250 6|Dose 6
16597236|NCT02630862|Active Comparator|aspirin|acetylsalcylic acid 100 mg per day give orally for six months, starting the day of carotid endoartherectomy
16597237|NCT02630862|Active Comparator|aspirin plus dipyridamole|acetylsalicylic acid 25 mg plus dipyridamole extended release 200 mg, combined in a capsule, per day starting the day of carotid endoartherectomy
16597238|NCT02630849|Experimental|IMF group|intercostal muscle flap and pericostal no-compression suture of the intercostal space
16597239|NCT02630849|Active Comparator|IINB group|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
16597240|NCT02630836|Experimental|XCEL-MT-OSTEO-BETA|Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing
16597241|NCT02630836|Other|Standard treatment|Standard surgical treatment with isolated endomedullary nailing
16597242|NCT02630823|Experimental|Arm 1: MK-3475|"Patients will undergo endometrial biopsy followed by 2 doses of MK-3475 3 weeks apart. 3-4 weeks after the second dose of MK-3475, the standard of care surgical resection will take place, followed by standard of care adjuvant therapy. Tissue and blood will be collected at the time of surgical resection for immune analysis. For patients whose pathology confirms high-risk features and advanced stage, MK-3475 will be given every 3 weeks starting 4 -6 weeks after completion of adjuvant therapy for a maximum of 4 doses post-surgery.
~MK-3475 will be given intravenously at a dose of 200 mg over the course of 30 minutes.
~The standard of care chemotherapy will consist of 6 cycles of paclitaxel and carboplatin AUC 5 every 3 weeks for 6 cycles.
~The decision to administer radiation therapy will be per the treating physician. If the patient does not receive radiation therapy, then the patient will start MK-3475 every 3 weeks x 4 doses after the completion of chemotherapy."
16597243|NCT02630810|Experimental|Early oral hydration|Early oral intake of 100 ml clear unsweetened water 1 hour following the Cesarean Section, then upon patient's desire, then starting semisolid, solid food when participant passed flatus.
16597244|NCT02630810|Active Comparator|Delayed oral hydration|Oral intake of 100 ml clear unsweetened water after 6 hours from the end of CS then upon patient's request,then starting semisolid, solid food when participant passed flatus.
16597245|NCT02630797|Placebo Comparator|Blueberry baseline|No blueberry products provided as part of the usual dietary intake
16597246|NCT02630797|Active Comparator|Blueberry Low|One blueberry product per day containing an equivalent of 0.75 cups of fresh blueberries provided as part of usual dietary intake for 42 days
16597247|NCT02630797|Active Comparator|Blueberry Medium|Two blueberry products per day containing an equivalent of 1.5 cups of fresh blueberries provided as part of usual dietary intake for 42 days
16597248|NCT02630797|Active Comparator|Blueberry High|Four blueberry products per day containing an equivalent of 3 cups of fresh blueberries provided as part of usual dietary intake for 42 days
16597249|NCT02630784|Experimental|Homecare ventilator|NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
16597250|NCT02630784|Active Comparator|ICU ventilator|NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.
16597251|NCT02630771||PDAP only|Persistent dentoalveolar pain disorder patients who do not fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
16597252|NCT02630771||PDAP + TMD|Persistent dentoalveolar pain disorder patients who also fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
16597253|NCT02630771||Painfree controls|Painfree subjects. Pressure pain threshold before/during conditioned pain modulation.
16597254|NCT02630758|Experimental|Mindfulness-based Yoga|"Participants in the 12-week mindfulness-based yoga condition were guided by a gentle yoga DVD that included postures (asanas), pranayama (breathing exercises), and relaxation (meditation). Participants were asked to complete 60-75 minutes of the DVD twice per week and were encouraged to do more if they were interested.
~Following the initial baseline assessment and randomization telephone interview, participants in the yoga group completed weekly 15-minute telephone sessions for the first month and bi-weekly telephone sessions for the second and third for a total of eight sessions over the 12 weeks. The mindfulness telephone sessions were modified from the Mindfulness-Based Stress Reduction."
16597255|NCT02630758|Active Comparator|Walking Control Group|"The 12-week walking control condition included twice-weekly home practice with a 65-minute walking DVD (Sansone, 2008) and eight telephone sessions with the telephone counselor.
~Participants were asked to complete 60 minutes of the DVD (or other walking) twice weekly and encouraged to do more if they were interested.
~Participants received telephone sessions on the same schedule as the yoga condition. The education sessions covered a variety of health and wellness related topics."
16597679|NCT02628015||youths full-term|born 2001 or 2002 born after 38 weeks
16597256|NCT02630745|Active Comparator|Immediate periodontal surgery (Group 1)|periodontal surgical procedure in the form of open flap debridement will be performed immediately( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) after obturation of the root canal system( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
16597257|NCT02630745|Active Comparator|Delayed periodontal surgery (Group 2)|periodontal surgical procedure in the form of open flap debridement( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) will be performed 3 months after obturation of the root canal system ( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
16597258|NCT02630732|Active Comparator|Brain School|Pain Neuroscience Education Program
16597259|NCT02630732|Active Comparator|Back School|Classical Back School
16597260|NCT02630719|Active Comparator|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
16597261|NCT02630719|Placebo Comparator|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
16597262|NCT02630706|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
16597263|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
16597264|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
16597265|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
16597266|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
16597267|NCT02630680||Colorectal diseases patients|
16597268|NCT02630667|Experimental|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response.
16597269|NCT02630667|Experimental|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response.
16597270|NCT02630667|Experimental|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response.
16597271|NCT02630667|Placebo Comparator|Non-Caloric Placebo|Non-caloric placebo consisting of artificial sweeteners
16597272|NCT02630654||GEP NETs|Patients with a suspected diagnosis of metastatic GEP NETs
16597273|NCT02630654||Healthy controls|Healthy controls matched by age and gender.
16597274|NCT02630641||Prostate cancer patients|
16597275|NCT02630628|Experimental|Tacrolimus|route: oral duration: 96 weeks
16597276|NCT02630628|Active Comparator|Mycophenolate Mofetil|route: oral duration: 96 weeks
16597277|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.
~For Cohorts A & B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
16597278|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
16597279|NCT02630615||Cohort C (healthy volunteers)|Blood samples will be collected from eligible health volunteers only once. These samples will be used to test the CTC chip system. Two tubes of peripheral blood will be collected and taken to the PI's lab for processing.
16597280|NCT02630602|Active Comparator|Functional goat cheese|The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks
16597281|NCT02630602|Placebo Comparator|Control cheese|Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks
16597282|NCT02630589|Experimental|ABI implantation|All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
16597283|NCT02630576|Experimental|Men - Left Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
16597284|NCT02630576|Experimental|Men - Right Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
16597285|NCT02630576|Experimental|Women - Left Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
16597286|NCT02630576|Experimental|Women - Right Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
16597357|NCT02630160|Active Comparator|Intraarticular Catheter with anesthesic|Intraarticular infusion with Bupivacaine Hydrochloride
16597287|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
16597288|NCT02630550||Aortic Aneurysm Repair|The impact of large abdominal retractors and an abdominal aortic cross-clamp on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
16597289|NCT02630550||Femoral Endarterectomy|The impact of the clamping of a large peripheral arterial vessel on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
16597290|NCT02630524|Experimental|Low Carbohydrate Diet|
16597291|NCT02630524|Active Comparator|Standard Diet|
16597292|NCT02630511|Experimental|Asthma Group|Asthma group to receive mannitol, methacholine or placebo challenge tests
16597293|NCT02630511|Experimental|Control Group|Control group to receive mannitol, methacholine or placebo challenge tests
16597294|NCT02630498|Experimental|study (first group)|The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
16597295|NCT02630498|No Intervention|Controlled (second group)|The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.
16597296|NCT02630485|Experimental|Graceful Lifestyle Changes & MYO|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.
~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
16597297|NCT02630485|Experimental|Graceful Lifestyle Changes|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.
~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
16597298|NCT02630485|Placebo Comparator|Letrozole & MYO|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
16597299|NCT02630485|Placebo Comparator|Letrozole|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
16597300|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.
~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
16597301|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.
~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.
~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
16597302|NCT02630459|Placebo Comparator|Double Blind Treatment Phase (DBTP): Placebo|Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
16597303|NCT02630459|Experimental|DBTP: Erenumab 28 mg QM|Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
16597304|NCT02630459|Experimental|DBTP: Erenumab 70 mg QM|Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
16597305|NCT02630459|Experimental|DBTP: Erenumab 140 mg QM|Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
16597306|NCT02630459|Experimental|Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM|Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.
16597307|NCT02630459|Experimental|CHU Sub-Study: Two 70 mg/mL AI/pens|A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study
16597308|NCT02630459|Experimental|CHU Sub-Study: One 140 mg/mL AI/pen|A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study
16597309|NCT02630446|Experimental|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
16597310|NCT02630446|No Intervention|standard dementia care|Control group receiving all types of standard dementia care except in-home respite care of the Baluchon type.
16597311|NCT02630433|Experimental|Index cholecystectomy|Cholecystectomy within 48 hours after inclusion.
16597312|NCT02630433|Active Comparator|Scheduled cholecystectomy|Cholecystectomy 6 weeks after inclusion.
16597313|NCT02630420|Experimental|cetuximab and savolitinib|Following assessment in Part 1 of dose-limiting toxicity and maximum tolerated dose, this drug combination will be administered in Part 2 of the study to assess safety, tolerability, response rate, and progression-free survival.
16597314|NCT02630407|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (product name: Hymovis, Fidia Spa, Padova, Italy) the day after ACL reconstruction (after drainage removal)
16597315|NCT02630407|Placebo Comparator|Placebo group|Single injection of 3 ml saline solution the day after ACL reconstruction (after drainage removal)
16597316|NCT02630394|Experimental|Azithromycin prophylaxis|Azithromycin will be supplied as a 250-mg tablet. Participants weighing less than 40 mg will be instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday), and participants who weigh more than 40 kg will be instructed to take 2 tablets on the same 3 days per week.
16597317|NCT02630381|Experimental|Shock wave arm|Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
16597318|NCT02630381|No Intervention|Contra-lateral arm|The distal radius and/or wrist that did not receive UESWT will not be treated
16597319|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.
~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
~Number of subjects : 14"
16597320|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.
~Experimental phase II soft-tissue sarcoma :
~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
~Number of subjects : 48"
16597321|NCT02630368|Experimental|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.
~Control-arm phase II soft-tissue sarcoma :
~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.
~Number of subjects : 24"
16597322|NCT02630368|Experimental|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.
~Experimental phase II Group breast cancer :
~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
~Number of subjects : 32"
16597323|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :
~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.
~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.
~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).
~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.
~Number of subjects : 47"
16597324|NCT02630368|Experimental|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :
~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.
~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.
~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).
~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.
~Number of subjects : 32"
16597325|NCT02630355|Sham Comparator|Control|Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation
16597326|NCT02630355|Active Comparator|Low Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.
16597327|NCT02630355|Active Comparator|Standard Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.
16597328|NCT02630355|Active Comparator|High Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.
16597329|NCT02630342|Experimental|Group 1: preparation materials only|This group will receive preparation materials for a clinical MRI scan. These include links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur only at home.
16597330|NCT02630342|Experimental|Group 2: Materials with review|This group will receive in preparation for a clinical MRI scan links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur at home and include a visit with research team to review preparation materials with the research team
16597331|NCT02630342|Experimental|Group 3: Mock MRI scanner|This group will receive the same materials as training group 1. In addition they will attend the mock scanner where the research team will utilise a mock MRI scanner to practice lying down in a scanner, staying still , wearing headphones and watching a movie/video on the mirror system.
16597332|NCT02630342|No Intervention|Neuro-oncology retrospective controls|A retrospective control group of neuro-oncology patients from the 3 years prior to the study initiation. This group will be used to determine the age at which patients were able to complete a diagnostic MRI without GA
16597333|NCT02630342|Experimental|Neuro-oncology prospective|Child life specialist preparation will be provided to these patients. This preparation for Diagnostic MRI scanning in which utilise the Mock MRI scanner as preparation for the scan.
16597334|NCT02630329|Experimental|vNOTES adnexectomy|Vaginal Natural Orifice Transluminal Endoscopic Surgery
16597335|NCT02630329|Active Comparator|LSC adnexectomy|Laparoscopic adnexectomy
16597338|NCT02630303|Experimental|LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
16597339|NCT02630303|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
16597340|NCT02630290|Placebo Comparator|Ropivacaine|After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
16597341|NCT02630290|Experimental|Ropivacaine + Dexmedetomidine|After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
16597342|NCT02630277|Experimental|Arm 1|1:1 Intravitreal Aflibercept Injection once every 4 weeks
16597343|NCT02630277|Experimental|Arm 2|Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)
16597344|NCT02630264|Experimental|Combination therapy|"E10A+chemotherapy group (360 subjects):
~E10A (Endostatins) of 1.0×1012VP on day 1 and 6
~Paclitaxel Injection 160mg/m2 on day 3
~Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days."
16597345|NCT02630264|Experimental|Chemotherapy|"Chemotherapy-alone group (180 subjects):
~Paclitaxel Injection 160mg/m2 on day 1
~Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days"
16597346|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
16597347|NCT02630238|Experimental|Branched-Chain Amino Acid group|The branched-chain amino acid group will be on a hypocaloric diet, exercise and receive 0.342g/kg of BCAA per day, partially accounted for through their diet with the rest provided by a BCAA supplement
16597348|NCT02630238|Placebo Comparator|Placebo Group|The placebo will be on a hypocaloric diet, exercise and receive isoenergetic beverage with carbohydrate instead of branched-chain amino acids
16597349|NCT02630225|Experimental|Intervention|"Participants in this arm will receive three intervention services in addition to treatment as usual services:
~A brief intervention including a feedback session utilizing principles of Motivational Interviewing (MI).
~Extended outreach services (6 months) using the Critical Time Intervention (CTI) approach.
~Multi-agency attention."
16597350|NCT02630225|Other|Treatment as Usual|Participants in this arm will receive the usual care offered to victims of gun shot wounds.
16597351|NCT02630212||Control|Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
16597352|NCT02630212||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Qilu Hospital
16597353|NCT02630199|Experimental|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
16597354|NCT02630186|Experimental|Single Arm Rociletinib and MPDL3280A|Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.
16597355|NCT02630173|Experimental|Non vital teeth with apical radiolucency|Endodontic treatment was performed in non vital teeth with periapical radiolucency. Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 3 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 or #15K-files. Coronal flaring with # 2 and #3 Gates-Glidden drills was done.Calcium hydroxide was filled in the canals with the help of a lentulo spiral.At the second appointment,calcium hydroxide paste was removed and copious irrigation with 3% sodium hypochlorite was followed by 5.0 mL 17% ethylenediaminetetraacetic acid with a final rinse of 5.0 mL of 3% sodium hypochlorite. The canals were obturated with gutta-percha and ZOE sealer.
16597356|NCT02630173|Active Comparator|Vital teeth|Only scaling and root planing will be done in contralateral vital tooth with pocket depth >5mm .Non surgical periodontal treatment in the form of scaling and root planing was provided in minimum of two sessions using ultrasonic scaler (Satelec P5 Booster Suprasson) and hand instruments (Hu-friedy scalers and curettes).
16597680|NCT02628015||adults preterm|Birthweight <1500g
16597358|NCT02630160|Placebo Comparator|Intraarticular Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by intraarticular catheter
16597359|NCT02630160|Active Comparator|Perifascial Catheter with anesthesic|Perifascial infusion with Bupivacaine Hydrochloride
16597360|NCT02630160|Placebo Comparator|Perifascial Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by Perifascial catheter
16597361|NCT02630147|Experimental|Night-vanilla|Intervention = exposition to vanilla scent A quantity of 2 ml of a saturated vanilla solution (2% vanillin) will be applied on premature pyjamas infant's, close to his face (on each shoulder and on the upper chest).
16597362|NCT02630147|No Intervention|Night-no vanilla|The only difference with the experimental arm is the absence of vanilla (usual, standard care)
16597363|NCT02630134|Experimental|Baeta|These patients receive the Baeta device and take it home.
16597364|NCT02630121|Placebo Comparator|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
16597365|NCT02630121|Active Comparator|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
16597366|NCT02630108|Experimental|Thermal Ablation & TACE|"Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.
~EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
16597367|NCT02630108|Active Comparator|TACE alone|Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
16597368|NCT02630095|Other|Control.|No anticoagulation，just routine follow up.
16597369|NCT02630095|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
16597370|NCT02630082|Other|Intervention|Circumcision and flexible sigmoidoscopy
16597371|NCT02630069|Experimental|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
16597372|NCT02630069|Placebo Comparator|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
16597373|NCT02630069|No Intervention|Healthy control|No intervention
16597374|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.
~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
16597375|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
16597376|NCT02630017|Experimental|ADHD group|Adults with ADHD
16597377|NCT02630017|Experimental|non-ADHD group|Adults without ADHD
16597378|NCT02630004|Experimental|Melatonin|Melatonin oral gel 3%
16597379|NCT02630004|Placebo Comparator|Placebo|Placebo oral gel
16597380|NCT02629991|Experimental|Intranasal Oxytocin|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
16597381|NCT02629991|Placebo Comparator|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
16597382|NCT02629978|Experimental|radiofrequency ablation|In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
16597383|NCT02629965|Experimental|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
16597384|NCT02629965|Active Comparator|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
16597385|NCT02629952|Experimental|Blueberry Tea|3 cups of blueberry tea per day x 4 weeks
16597386|NCT02629952|No Intervention|No Treatment|No Treatment
16597387|NCT02629939|No Intervention|questionnaires|"Questionnaires will be distributed to families of heart patients to test the theoretical knowledge to perform CPR The questionnaires were distributed to internal, cardiology clinics and clinic T by a doctor, Paramedic or medical student. The family will be asked to fill out the questionnaire independently.
~The questionnaires will be distributed in Hebrew, Arabic, Russian and English The research questionnaire will include questions about able to perform basic CPR"
16597388|NCT02629939|Experimental|to participate in a short course for learning CPR|": The investigators will offer patients and their relatives to participate in a short course for learning CPR.
~Relatives will receive a prescription Containing a proposal for participation in the course
~Prescription will be awarded in four places:
~-.Family physicians as a suggestion during a routine visit / presentation of cardiac problem
~Heart Rehabilitation Institute - cardionegev
~Doctors internal medicine department as part of a patient's discharge letter with heart disease
~Doctors in cardiology clinic The prescription will be accompanied by several minutes of explanation about the program and its importance The investigators consider the level of responsiveness and participation, find out which arm yielded the highest number of participants (actual turnout of the total prescriptions distributed) And how to expand their activities"
16597389|NCT02629926||Patients to receive GH replacement|30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
16597390|NCT02629926||Patients who will not receive GH replacement|An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
16597391|NCT02629913|Experimental|Intervention|mementor somnium
16597392|NCT02629913|Other|Waitlist|
16597393|NCT02629900|Experimental|Intermittent fasting group|Participants will restrict their daily food intake (time restricted feeding) to an 8-hour time period between 1200 to 2000 hours. During the remaining 16-hour intermittent fasting period (2000 to 1200 hours) participants will be allowed to drink zero calorie beverages (diet soda pop, black coffee, tea, water, etc) in order to maintain normal hydration. There will be no attempt to restrict food intake. Rather simply to restrict the time period each day when food is consumed.
16597394|NCT02629887|Active Comparator|Face Mask|Standard Face Mask with T piece resuscitator for neonatal resuscitation. Face mask placement per Neonatal Resuscitation Program resuscitation guideline.
16597681|NCT02628015||adults full-term|born after 38 weeks
16597395|NCT02629887|Active Comparator|Non-inflatable supraglottic airway|Use of non-inflating supraglottic airway with T-piece resuscitator instead of Standard Face Mask with T piece resuscitator for neonatal resuscitation, replacing standard of care face mask in Neonatal Resuscitation Program guideline.
16597396|NCT02629874|Active Comparator|EA-230 (30mg/kg)|Subjects will receive EA-230, 30 mg/kg
16597397|NCT02629874|Active Comparator|EA-230 (90mg/kg)|Subjects will receive EA-230, 90 mg/kg
16597398|NCT02629874|Active Comparator|EA-230 (180mg/kg)|Subjects will receive EA-230, 180 mg/kg
16597399|NCT02629874|Placebo Comparator|Placebo|subjects receive placebo
16597400|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
16597401|NCT02629861|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
16597402|NCT02629861|Experimental|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
16597403|NCT02629848|Experimental|Motesanib + Paclitaxel + Carboplatin|Motesanib 125 mg, (5 x 25 mg) tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target Area Under the Curve (AUC) of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib 125 mg, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
16597404|NCT02629848|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
16597405|NCT02629835|Active Comparator|Intravenous dexamethasone 8 mg|patients receiving intravenous 8 mg of dexamethasone in parallel to ultrasound guided axillary nerve block with a standardized local anesthetic solution
16597406|NCT02629835|Active Comparator|Perineural dexamethasone 8 mg|patient receiving perineural 8 mg of dexamethasone in a mixture with a standardized local anesthetic solution for ultrasound guided axillary block
16597408|NCT02629809|Experimental|Treatment (iFCG)|See Detailed Description.
16597409|NCT02629796||CIDP treated (IVIG)|patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment
16597410|NCT02629796||control|healthy subjects
16597411|NCT02629783|Experimental|Physiotherapy + Corticosteroid injection + Psychomotor therapy|Usual care + intervention
16597412|NCT02629783|Active Comparator|Physiotherapy + Corticosteroid injection|Usual care
16597413|NCT02629757|Experimental|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.
16597414|NCT02629744|Experimental|Etrolizumab|Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.
16597415|NCT02629731|Experimental|ankle OA|inclusion criteria: 1) diagnosis of ankle OA or PTTD [non-control subjects only], 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m) with the primary impediment to pain-free ambulation being ankle OA or PTTD
16597416|NCT02629731|Experimental|flat foot|inclusion criteria: 1) diagnosis of flat foot, 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m)
16597417|NCT02629731|No Intervention|control|inclusion criteria: 1) between 18 and 80 years of age, and 2) ambulatory (able to walk at least 15 m)
16597418|NCT02629718|Experimental|A(NACT)|Neoadjuvant Chemotherapy followed by Radical Surgery
16597419|NCT02629718|Active Comparator|B(RS)|Radical Surgery alone
16597420|NCT02629705|Other|Group A|"Placebo intervention
~Assessment block (3 days)
~Washout-phase of 21-35 days
~Carrageenan intervention
~Assessment block (3 days)"
16597421|NCT02629705|Other|Group B|"Carrageenan intervention
~Assessment block (3 days)
~Washout-phase of 21-35 days
~Placebo intervention
~Assessment block (3 days)"
16597422|NCT02629692|Experimental|Vodobatinib (K0706) capsules|
16597423|NCT02629679||Males nonathletes|Boys non-involved in organized sport and exercising
16597424|NCT02629679||Females nonathletes|Girls non-involved in organized sport and exercising
16597425|NCT02629679||Males athletes|Athletic boys (involved in sports)
16597426|NCT02629679||Females athletes|Athletic girls (involved in sports)
16597427|NCT02629666|Active Comparator|Exercise Referral Scheme (ERS)|In the Exercise Referral Scheme (ERS) intervention participants will undergo a physical activity program of 16 weeks, with two sessions per week (60 minutes each session). Participants will be asked to perform the activity in a moderate to vigorous intensity (according to each individual's progression) during the central part of each session. Intensity will be estimated using the modified Borg Scale of Perceived Exertion (e.g. moderate intensity activity will be considered as a 4 to 6 and vigorous-intensity activity as a 7 to 9) or with training loads (i.e. ankle weights and dumbbells) corresponding to 70-80% of maximum, adjusted progressively during the training period. ERS programs will be based on a combination of aerobic, strength-based, balance and flexibility activities, with a specially trained PA specialist. These sessions will be always performed under the supervision of the same trainer. The PA intervention is adapted to the participants' functional status.
16597458|NCT02629471|Experimental|response time due to light flashs pulses|light flashing effects on response time to random target appearance
16597459|NCT02629458|Experimental|Patients requiring surgery|
16597460|NCT02629432||Cosyconet COPD Cohort|MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort.
16597428|NCT02629666|Experimental|ERS + Self-management Strategies|"Participants will undergo the aforementioned Physical Activity program plus 11 sessions of Self-Management Strategies (SMS).
~SMS start with a face-to-face session in an indoor primary-care facility. The next 6 sessions are further implemented in a group format. SMS are aimed at increasing self-efficacy in reducing sedentary behaviour and at adopting/maintaining an active behaviour as complement to a standard physical activity program (ERS). SMS group sessions will be conducted during week 3 to 11 of the ERS, after the PA sessions (6 sessions: 3 once a week, 3 once every second week). There will be 4 telephone contacts during the adherence phase, at week 15, 20, 25 and 30."
16597429|NCT02629666|No Intervention|Control group|Researchers will give to all participants during the first informative meeting (prior assessment) a written general booklet standardized across sites with WHO recommendation regarding PA regular practice for health. During the intervention, a health advice meeting with standardized topics about healthy lifestyle and feedback on some outcomes regarding their results will be held twice in the Primary Health Centre (at week 5, and at week 11). Researchers will send a letter or phone call prior to each follow up reminding the next assessment.
16597430|NCT02629653|Other|Single arm|The endovascular cooling system will be Zoll IVTM. This system consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585)
16597431|NCT02629640||Research Participants|Medical history questionnaire; clinical assessment and review; participant follow-up; blood or buccal sample; post mortem examination.
16597432|NCT02629627|Experimental|cojugated ALC/Leucine+Metformin|Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
16597433|NCT02629627|Active Comparator|Metformin+placebo conjugatedALC/leucine|active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
16597434|NCT02629627|Placebo Comparator|Placebo of Metformin|Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
16597435|NCT02629627|Placebo Comparator|ACL/Leu placebo|Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
16597436|NCT02629614|Experimental|TAPS Stimulation|Temporal Afferent Patterned Stimulation (TAPS) is alternating bursts of TENS stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
16597437|NCT02629614|Sham Comparator|Sham Stimulation|0 amplitude stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
16597438|NCT02629601|Experimental|Active Rewards|Participant will receive the standard active rewards incentives.
16597439|NCT02629601|Active Comparator|Active Rewards Doubled|Participant will receive the standard active rewards doubled in magnitude.
16597440|NCT02629601|Active Comparator|Active Rewards & Lottery 1|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward.
16597441|NCT02629601|Active Comparator|Active Rewards & Lottery 1 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward. Includes broadcasting winners (number) each week.
16597442|NCT02629601|Active Comparator|Active Rewards & Lottery 2 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 2 with a 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward. Includes broadcasting winners (number) each week.
16597443|NCT02629588||Persons in coma or vegetative state|People who survived TBI have a period of complete unconsciousness or coma with no awareness of themselves or their surroundings received multimodal or unimodal sensory stimulation.People in a coma are unaware and unresponsive, but not asleep as there is no sleep-wake cycle. While in a coma, people are unable to speak, follow commands or open their eyes. The person in coma may have a simple reflex in response to touch or pain, but essentially there is no meaningful response to external stimuli. There is an absence of awareness of self and the environment, even under conditions of vigorous external stimulation. Coma can last from hours to days, depending on the severity of the brain damage, and sometimes a person can remain in a comatose state for months and even years.
16597444|NCT02629562|Experimental|Arm 1|first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously
16597445|NCT02629562|Experimental|Arm 2|first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously
16597446|NCT02629549|Experimental|OTL38|Dosage calculated by weight of individual
16597447|NCT02629536|Experimental|Active-verum-NAC tablet|Intervention: Twice-daily administration of N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablets
16597448|NCT02629536|Placebo Comparator|Sham-placebo tablet|Intervention: Twice daily administration of sham/placebo tablet
16597449|NCT02629523|Experimental|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
16597450|NCT02629510|Experimental|Tachosil|The group composed of patients whose surgical margin of cervix will be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
16597451|NCT02629510|No Intervention|No Tachosil|The group composed of patients whose surgical margin of cervix will NOT be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
16597452|NCT02629497|Experimental|Healthy subjects for Omega-6 protection|Platelets from healthy donors will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
16597453|NCT02629497|Experimental|T2DM patients for Omega-6 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
16597454|NCT02629497|Active Comparator|Healthy control for Omega-3 protection|Platelets from healthy donors will be assessed for regulation by Fish Oil (omega-3 fatty acid).
16597455|NCT02629497|Active Comparator|T2DM for Omega-3 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Fish Oil (omega-3 fatty acid).
16597456|NCT02629484|Active Comparator|Focused Cardiac Ultrasound|participants randomised to receive focused cardiac ultrasound prior to surgery for hip fracture
16597457|NCT02629484|No Intervention|Standard care (clinical assessment)|Participants randomised to standard care receive clinical assessment of the patient
16597461|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
16597462|NCT02629406||Diabetes typ 1|Patients with typ 1diabetes with a duration of the disease between 10-20 years (HbA1C >65 mmol/l) and age 20-50 will be exposed to intermittent hypoxia.
16597463|NCT02629406||Healthy controls|Healthy controls, age 20-50 will be exposed to intermittent hypoxia.
16597464|NCT02629393|Experimental|ORGN001 (formerly ALXN1101)|
16597465|NCT02629380|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (Hymovis, Fidia Farmaceutici SpA, Padova, Italy) at the end of the arthroscopic meniscectomy
16597466|NCT02629380|Other|meniscectomy alone|Arthroscopic meniscectomy alone
16597467|NCT02629354|Experimental|Ibuprofen and Caffeine|
16597468|NCT02629354|Active Comparator|Ibuprofen|
16597469|NCT02629341|Active Comparator|Functional yogurt powder|This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic
16597470|NCT02629341|Placebo Comparator|Control yogurt powder|This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched
16597471|NCT02629328|Other|CardioCel|Treatment with CardioCel implant
16597472|NCT02629315|Active Comparator|10% neutral buffered formaldehyde|Specimens will be fixed for 24-48hours in 10% neutral buffered formaldehyde and then dissected for lymph nodes.
16597473|NCT02629315|Experimental|Carnoy's solution|Specimens will be fixed for 24-48hours in Carno'ys solution and then dissected for lymph nodes.
16597474|NCT02629302|Experimental|animal assisted therapy|"Standard therapy (speech therapy, occupational therapy and physiotherapy) that is done in the presence and with Integration of an animal."
16597475|NCT02629302|Active Comparator|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
16597476|NCT02629289|Other|Treatment A|HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region
16597477|NCT02629289|Other|Treatment B|US-approved Neulasta, 6 mg, single SC injection in the deltoid region
16597478|NCT02629289|Other|Treatment C|EU-approved Neulasta, 6 mg, single SC injection in the deltoid region
16597479|NCT02629250|Placebo Comparator|SV maximization|Goal-directed fluid therapy with stroke volume maximization. Device: The Volume-View system from Edwards Co.
16597480|NCT02629250|Experimental|supernormal DO2|"Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery.
~Device: The Volume-View system from Edwards Co."
16597481|NCT02629237|Experimental|Multifaceted education group|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
16597482|NCT02629237|No Intervention|control group|Subjects will not be asked to watch education film and not participate in counseling session before and after surgery.
16597483|NCT02629224|Experimental|Renal impairment|
16597484|NCT02629224|Experimental|Haemodialysis|
16597485|NCT02629211|Experimental|NaviAid™ AB|NaviAid™ AB device procedure
16597486|NCT02629198||normal weight|Healthy men and women ages 25-40 and 55-75. BMI 18.5 to 25.0
16597487|NCT02629198||overweight|Healthy men and women ages 25-40 and 55-75. BMI 25.0 to 30.0
16597488|NCT02629198||obese|Healthy men and women ages 25-40 and 55-75. BMI over 30
16597489|NCT02629185||normal weight|BMI 18.5 to 25.0 Healthy men and women ages 25-40 and 55-75
16597490|NCT02629185||overweight|BMI 25.0 to 30.0 Healthy men and women ages 25-40 and 55-75
16597491|NCT02629185||obese|BMI over 30.0 Healthy men and women ages 25-40 and 55-75
16597492|NCT02629172||Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)|Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label
16597493|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).
~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
16597494|NCT02629159|Active Comparator|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.
~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
16597495|NCT02629159|Experimental|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.
~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
16597496|NCT02629146|Experimental|Midazolam|Drug: Midazolam (experimental)
16597497|NCT02629146|Placebo Comparator|Isotonic saline|Drug: Isotonic saline (placebo)
16597498|NCT02629146|Active Comparator|Fentanyl|Drug: Fentanyl (active comparator)
16597499|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
16597536|NCT02628886|Experimental|maternal group|13-valent pneumococcal conjugate vaccine [Prevenar13®] (PCV13) vaccine, 0.5ml, once, stat, plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
16597714|NCT02627755|Active Comparator|Glide group|Device: Glidescope® use
16597500|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
16597502|NCT02629107||Healthy Volunteers|Healthy volunteers, age 18-34.
16597503|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
16597504|NCT02629081||Controls & Cases|Controls (participants without heartburn or other GERD symptoms undergoing standard upper endoscopy for the following: anemia, weight loss, diarrhea, and screening for esophageal varices) and Cases (participants with heartburn or other GERD symptoms undergoing standard endoscopy for heartburn or other GERD symptoms.)
16597505|NCT02629068|Experimental|PURPOSE|"Parents in the PURPOSE group will join a secret Facebook group for 2 months. Groups will be lead by 2 peer leaders and include 20 parent participants."
16597506|NCT02629068|No Intervention|Treatment as Usual (TAU)|Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
16597507|NCT02629055|Experimental|Respiratory EMG|Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
16597508|NCT02629055|No Intervention|Care as usual|NIV will be initiated according to standard care protocol.
16597509|NCT02629042|Active Comparator|Control|
16597510|NCT02629042|Experimental|Experimental|
16597511|NCT02629029|Other|Surgical - therapeutic free flap|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will be imaged using two systems: (i) pre-operative CTA with IV contrast; (ii) intra-operative fluorescence endoscopy with ICG.
16597512|NCT02629016|Experimental|Mindfulness|Education and experiential exercises for mindfulness including movement, thoughts and meditation
16597513|NCT02629016|Active Comparator|Wellness|Education and experiential exercises for general wellness including sleep hygiene, goal setting and power poses.
16597514|NCT02629016|No Intervention|Waitlist|Students receive regular health class instruction without intervention.
16597515|NCT02629003|Active Comparator|[11C]Cimbi-36|"[11C]Cimbi-36
~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
16597516|NCT02629003|Active Comparator|[11C]Cimbi-36-5|"[11C]Cimbi-36-5
~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
16597517|NCT02628990|Experimental|1.6 g plant stanols|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols), consumed with a meal daily for 4 weeks
16597518|NCT02628990|Experimental|2 g plant stanols|A yoghurt drink containing plant stanol ester (2 grams plant stanols), consumed with a meal daily for 4 weeks
16597519|NCT02628990|Experimental|1.6 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
16597520|NCT02628990|Experimental|2 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (2 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
16597521|NCT02628990|Placebo Comparator|Placebo|A placebo yoghurt drink, consumed with a meal daily for 4 weeks
16597522|NCT02628977|Experimental|OSA Health Education & Support Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer educator.
16597523|NCT02628977|Active Comparator|Attention Control Group|Participants in the attention control group will receive standard sleep literature, providing information about Obstructive Sleep Apnea and access to available sleep services.
16597524|NCT02628964|Active Comparator|4.5% e-cig|e-cigarettes with nicotine cartridges
16597525|NCT02628964|Placebo Comparator|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
16597526|NCT02628951|Experimental|Ramucirumab + Paclitaxel|"Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
~Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason."
16597527|NCT02628938|Experimental|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
16597528|NCT02628938|Experimental|Miswak sticks|Sticks twice a day for 7 days
16597529|NCT02628938|Active Comparator|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
16597530|NCT02628925||Recovery room|10 medical staff working in the recovery room
16597531|NCT02628925||Orthopedic ward|10 medical staff working on the orthopedic ward
16597532|NCT02628912||long-term survivors of HPV-related oropharyngeal cancer|This is a cross-sectional pilot study of long-term survivors of HPV-related oropharyngeal cancer treated with CTRT who are at least three years from treatment completion. This study consists of a onetime assessment of cardiopulmonary fitness, physical function status, measurement of lean body mass, endothelial function quality of life assessment, medical history and blood laboratory evaluation for traditional cardiac risk factors, endocrine derangement and inflammation.
16597533|NCT02628899|Other|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
16597534|NCT02628899|Other|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
16597535|NCT02628899|Other|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
16597636|NCT02628275|Active Comparator|Light physical activity|LPA (40-55% of maximum heart rate) for 150 min/week
16597537|NCT02628886|Placebo Comparator|control group|placebo sterile 0.9% sodium chloride, 0.5ml, once, stat plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
16597538|NCT02628886|Experimental|neonatal group|tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV 13 0.5ml at birth, 8 weeks and 16 weeks
16597539|NCT02628873|Experimental|Arm 1 (HyCoSy followed by HSG)|HyCoSy procedure followed by HSG procedure
16597540|NCT02628873|Experimental|Arm 2 (HSG followed by HyCoSy)|HSG procedure followed by HyCoSy procedure
16597541|NCT02628860|Experimental|Ferinject|"Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .
~Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.
~Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial."
16597542|NCT02628847|Experimental|Drug|Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
16597543|NCT02628847|Placebo Comparator|control|placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
16597544|NCT02628834|Experimental|Fascial mobilization|First day intervention: Patients will take fascial mobilization techniques to management of plantar flexor spasticity
16597545|NCT02628834|Experimental|Stretching exercise|Second day intervention:Patients will take fascial mobilization techniques to management of plantar flexor spasticity
16597546|NCT02628834|No Intervention|Healthy Volunteers|Healthy individuals will only be evaluated with no intervention
16597547|NCT02628821||Preterm Infants treated with non-invasive ventilation|"Preterm Infants of less than 32 weeks of Gestational age treated with synchronized non-invasive ventilation (SNIPPV) to prevent intubation or extubation failure based in a prospective protocol:
~nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria if they are in a stable situation.
~Electively For extubation:
~Preterm infants in which nCPAP extubation has previously failed or Prolonged mechanical ventilation (more than 15 days) with high respiratory parameters (PMAP > 10 cmH2O and FiO2>35%)."
16597548|NCT02628808||Autism Spectrum Disorder|For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
16597549|NCT02628808||controls|Age 6 to 40 Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
16597550|NCT02628795|Experimental|PRT + FM|Progressive resistance training + functional mobility training 3 d/wk x 16 wk
16597551|NCT02628795|Active Comparator|Usual Care|Post-surgical usual care including physical therapy
16597552|NCT02628782|Experimental|InSeal VCD|InSeal's Vascular Closure Device Use of the experimental VCD to close the access site of the artery
16597553|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
16597554|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
16597555|NCT02628756|Experimental|Endometrial injury|Hysteroscopic-guided endometrial injury (Karl Storz, Tuttlingen, Germany).
16597556|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.
~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
16597557|NCT02628730|Active Comparator|Ablation Index Group|PVI using radiofrequency ablation (RFA) guided by Ablation Index.
16597558|NCT02628730|Other|Reference Group (Contact Force Group)|That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
16597559|NCT02628717||SOF/SMV|SOF/SMV 400mg/150mg QD 12-24 weeks
16597560|NCT02628717||SOF/DCV|SOF/DCV 400mg/60mg QD 12-24 weeks
16597561|NCT02628717||SOF/LDV|SOF/LDV 400mg/90mg QD 12-24 weeks
16597562|NCT02628717||treatment duration|12 - 24 weeks
16597563|NCT02628704|Experimental|Selinexor, carfilzomib and dexamethasone|60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
16597564|NCT02628704|Placebo Comparator|Placebo, carfilzomib and dexamethasone|Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
16597565|NCT02628691||HCV coinfection with no-to-moderate fibrosis|
16597566|NCT02628678|Other|Fructooligosaccharide (FOS)|Subjects will be required to take 8 grams of FOS per day for a total of 10 days.
16597567|NCT02628665|Experimental|24 to 48 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power.
~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
16597568|NCT02628665|Active Comparator|48 to 72 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power.
~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
16597569|NCT02628652|Experimental|Gluco-Galacto-Oligosaccharide (GOS)|Subjects randomized to this treatment arm will ingest GOS once per day for a total of 14 days. One level of GOS will be taken during Phase I and 2 levels of GOS will be taken during Phase II.
16597570|NCT02628652|Experimental|Gluco-Oligosaccharide (GLOS)|Subjects randomized to this treatment arm will ingest GLOS once per day for a total of 14 days. One level of GLOS will be taken during Phase I and 2 levels of GLOS will be taken during Phase II.
16597571|NCT02628652|Active Comparator|FructoOligosaccharide (FOS)|Subjects randomized to this treatment arm will ingest FOS once per day for a total of 14 days. One level of FOS will be taken during Phase I and 2 levels of FOS will be taken during Phase II.
16597572|NCT02628639|Experimental|electroencephalography recording|Cerebral measurements from high-density electroencephalography after the presentation of personalized stimulations
16597573|NCT02628626|Placebo Comparator|Placebo|Patients in this arm will receive placebo for 4 weeks.
16597574|NCT02628626|Active Comparator|Colesevelam and Clonidine|Patients in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks.
16597575|NCT02628613|Active Comparator|Paclitaxel plus Epirubicin|Paclitaxel plus Epirubicin for 4 cycles, paclitaxel 80 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
16597576|NCT02628613|Experimental|Vinorelbine plus Epirubicin|Vinorelbine plus Epirubicin for 4 cycles, vinorelbine 25 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
16597577|NCT02628600|Experimental|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
16597578|NCT02628600|Experimental|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
16597579|NCT02628587|Experimental|Generic clopidogrel|Patients are assigned to take generic clopidogrel
16597580|NCT02628587|Active Comparator|Patent clopidogrel|Patients are assigned to take patent clopidogrel (Plavix)
16597581|NCT02628574|Experimental|TRX518 monotherapy (Parts A and B)|Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
16597582|NCT02628574|Experimental|TRX518 with gemcitabine (Part C)|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
16597583|NCT02628574|Experimental|TRX518 with pembrolizumab (Part D|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
16597584|NCT02628574|Experimental|TRX518 with nivolumab (Part E)|Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
16597585|NCT02628561|Active Comparator|Active tdcs/M1|Anodal tDCS on primary motor cortex and CIMT (constraint induced movement therapy)
16597586|NCT02628561|Experimental|Active tdcs/Premotor|Anodal tDCS on premotor cortex and CIMT (constraint induced movement therapy)
16597587|NCT02628561|Sham Comparator|Sham tdcs|Sham tDCS and CIMT (constraint induced movement therapy)
16597588|NCT02628548|Experimental|Cognitive training program 1|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
16597589|NCT02628548|Experimental|Cognitive training program 2|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
16597590|NCT02628535|Experimental|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
16597591|NCT02628522|Experimental|ADRCs therapy|"Infiltration with 20mL Lidocaine 2% and Epinephrine 1:100 000. Liposuction will be done from the abdomen using Tulip cannulas. Fat will be processed with Celution system.
~Isolated ADRCs will be administered in chronic anal fissures."
16597592|NCT02628509||cardiac devices|patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
16597593|NCT02628496|Experimental|Arm 1: CLM|"On the day of surgery, participants will have placement of laser-safe endotracheal tube and a rigid laryngoscope will be introduced into the oral cavity to gain access to the laryngeal introitus and then placed into suspension (standard of care)
~Fluorescein dye will be administered intravenously
~Confocal laser probe will be introduced through the rigid laryngoscope and touched first on the lesion of concern and put into scanning mode in order to obtain photos and video footage of the lesions. The probe will then be placed on normal appearing vocal fold tissue to obtain a control sample.
~The remainder of the procedure is standard excisional biopsy and KTP laser photoablation"
16597594|NCT02628483|Experimental|Ultimate Omega|5 capsules of Ultimate Omega fish oil daily in the morning with food
16597595|NCT02628483|Active Comparator|Meg-3|5 capsules of Meg-3 fish oil daily in the morning with food
16597596|NCT02628470|Experimental|group cervical manipulation|The patient is supine without a pillow and physiotherapist standing in the ipsilateral corner of the hand of the thrust.
16597597|NCT02628470|Placebo Comparator|Placebo group|Participants will receive a protocol of domiciliary cervical control exercises.
16597598|NCT02628470|Active Comparator|Group cervical mobilization|Oscillatory mobilization technique. With the patient in prone, the investigator applies an oscillatory motion in the most painful cervical segment for three minutes
16597599|NCT02628457||Mild Subgroup|patients with supraspinatus tendon retracted upto medial 1/3rd of humerus head and arthroscopic rotator cuff repair done by single row.
16597600|NCT02628457||Moderate Subgroup|patients with supraspinatus tendon retracted between medial 1/3rd of humerus head and glenoid,and arthroscopic rotator cuff repair done by single row.
16597601|NCT02628457||Severe subgroup|patients with supraspinatus tendon retracted beyond glenoid and arthroscopic rotator cuff repair done by single row
16597602|NCT02628444|Experimental|STAGE-I Group 1: CYD Dengue Vaccine|Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).
16597603|NCT02628444|Experimental|STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)|Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).
16597604|NCT02628444|Experimental|STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)|Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).
16597605|NCT02628444|Experimental|STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)|Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
16597606|NCT02628444|Experimental|STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
16597607|NCT02628444|Experimental|STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
16597608|NCT02628444|Experimental|STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)|Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
16597609|NCT02628444|Experimental|STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
16597610|NCT02628444|Experimental|STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
16597611|NCT02628431||General anesthesia|Patients that will recieve general anesthesia for elective surgery
16597612|NCT02628431||Regional or neuraxial anesthesia|Patients that will revieve regional or neuraxial anesthesia for elective surgery
16597613|NCT02628418|Experimental|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:
~General Rehabilitation
~Specific hand rehabilitation by Gloreha device"
16597614|NCT02628418|Other|Control Group|"The patients in the Control Group underwent to following interventions:
~General Rehabilitation
~Specific hand rehabilitation performed by physiotherapist"
16597615|NCT02628405|Experimental|Treatment (R2-ICE)|Patients receive lenalidomide PO daily on days 1-14, rituximab IV on day 1, ifosfamide IV over 24 hours on day 2, carboplatin IV over 1-2 hours on day 2, and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CMR, PMR, or NMR may receive 2 more cycles per physician discretion. After completion of 2 cycles of R2ICE treatment, patients achieving objective status of CMR, PMR or NMR may proceed to SCT during the event monitoring phase.
16597616|NCT02628392|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
16597617|NCT02628392|Experimental|DS-8500a 50 mg QD|DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
16597618|NCT02628392|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
16597619|NCT02628392|Placebo Comparator|placebo|placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
16597620|NCT02628392|Active Comparator|Sitagliptin|capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet
16597621|NCT02628379||Class 1, 2, or 3 alterations, with targeted therapy|Patients put on targeted therapies matched to specific genomic alterations.
16597622|NCT02628379||Site-specific therapy determined by tissue of origin testing|Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)
16597623|NCT02628379||Empiric CUP therapy|Patients put on empiric treatment at physician discretion
16597624|NCT02628366|Experimental|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
16597625|NCT02628366|No Intervention|Fixed Dialysate Temperature at 36.5°C|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
16597626|NCT02628353|Placebo Comparator|Placebo|control group
16597627|NCT02628353|Experimental|Phenolic compound|treated group
16597628|NCT02628327||Glaucoma subjects|Survey given to all glaucoma subjects agreening to study.
16597629|NCT02628314||Osteoarthritis|Study population to include adult men and women with osteoarthritis.
16597630|NCT02628301|Active Comparator|Hypercaloric diet|Hypercaloric diet (1.6x REE) for 30 days
16597631|NCT02628301|Placebo Comparator|Normal diet|Normocaloric diet (1.0xREE)
16597632|NCT02628288|Active Comparator|PCI with Axxess device + AbsorB BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with AXXESS device and additional Absorb BVS.
16597633|NCT02628288|Active Comparator|PCI with Modified T with Absorb BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with a modified T stenting technique using Absorb BVS.
16597634|NCT02628275|No Intervention|Control|Continued inactivity
16597635|NCT02628275|Active Comparator|Moderate to vigorous physical activity|MVPA (55-90% of maximum heart rate) for 150 min/week (current recommendations)
16597638|NCT02628249|Experimental|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.
16597639|NCT02628249|Experimental|Base + BCAA|Base protein intake + Branched chain amino acids
16597640|NCT02628249|Experimental|Base + EAA|Base protein intake + essential amino acids.
16597641|NCT02628249|Experimental|Base + NEAA|Base protein intake + non essential amino acids
16597642|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
16597643|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
16597644|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
16597645|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
16597646|NCT02628197|Active Comparator|CONTROL GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.Scaling and root planing was not done in this group.
16597647|NCT02628197|Active Comparator|TEST GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received scaling and root planing along with calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.
16597648|NCT02628171|Other|Control|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of cashew nuts (control).
16597649|NCT02628171|Active Comparator|Cashew|Participants will receive a controlled diet, typical of an American diet, with 42 g/day of cashew nuts (base diet with cashew nuts).
16597650|NCT02628145|Experimental|Resistance Training Intervention|The RT intervention will take place three times per week for approximately 12 weeks on non-consecutive days using 8-10 exercises for major muscle groups utilizing free weights and machines follow American College of Sports Medicine and National Strength and Conditioning Association guidelines for RT in older adults.
16597651|NCT02628145|Active Comparator|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
16597652|NCT02628132|Experimental|Durvalumab and Paclitaxel|After one cycle of paclitaxel, durvalumab will be given concurrently with paclitaxel. Once paclitaxel cycles are completed, durvalumab will be continued alone until disease progression or unacceptable toxicity.
16597653|NCT02628119|Experimental|Intra-procedural access flow|"Management of access dysfunction based on intra-procedure access flow monitoring.
~Criteria for target access flow:
~Within 90% of baseline access flow if known 180% increase from pre-intervention flow if access flow not known 600ml/min for thrombosed grafts and 500 ml/min for thrombosed arteriovenous fistula in case baseline access flow not known"
16597654|NCT02628119|Active Comparator|Standard Angioplasty|Intervention based on current standards of care i.e. 2 dimensional angiographic views.
16597655|NCT02628106|Experimental|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
16597656|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
16597657|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
16597658|NCT02628080|Experimental|Cohort 1|Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
16597659|NCT02628080|No Intervention|Cohort 2|Device: PET-CT, Device: DWI-MRI
16597662|NCT02628054|Active Comparator|Typhoid Vaccine|Typhoid vaccination in single 0.5mL injections into the non-dominant deltoid muscle in the arm
16597663|NCT02628054|Placebo Comparator|Placebo|A single 0.5mL injection of 0.9% sodium chloride saline solution into the non-dominant deltoid muscle in the arm
16597664|NCT02628041|Active Comparator|Permanent Iodine-125 seed implant|Prostate brachytherapy using Iodine-125 seed implant to a prescription dose of 144 Gy delivered to the Target volume defined as Clinical Target volume (CTV)+ 0-3 mm margin.
16597665|NCT02628041|Experimental|High-dose-Rate Prostate brachytherapy|"Prostate brachytherapy implant using Iridium-192 to a prescription dose of 19 Gy delivered to the CTV in one fraction. Greater than 95% coverage of the CTV with the prescription dose is considered per protocol, 90-95% coverage is considered a minor deviation and, < 90% coverage is considered a major deviation.
~Attempts should be made to achieve these other dosimetric values:
~D90: 105-115%
~V150 ≤ 35%
~V200 ≤ 12%"
16597666|NCT02628028|Experimental|Part A 5 mg LY3337641|Given once a day for 4 weeks.
16597667|NCT02628028|Experimental|Part A 10 mg LY3337641|Given once a day for 4 weeks.
16597668|NCT02628028|Experimental|Part A 30 mg LY3337641|Given once a day for 4 weeks.
16597669|NCT02628028|Placebo Comparator|Part A Placebo|Given once a day for 4 weeks.
16597670|NCT02628028|Experimental|Part B 5 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
16597671|NCT02628028|Experimental|Part B 10 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
16597672|NCT02628028|Experimental|Part B 30 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
16597673|NCT02628028|Placebo Comparator|Part B Placebo|Given once a day for 12 weeks.
16597674|NCT02628015||preschool children preterm|born 2010 or 2011 Birthweight <1500g
16597675|NCT02628015||preschool children full-term|born 2010 or 2011 born after 38 weeks
16597676|NCT02628015||school children preterm|same children from the preschool group will be tested 2 years later again
16597677|NCT02628015||school children full-term|same children from the preschool group will be tested 2 years later again
16597678|NCT02628015||youths preterm|born 2001 or 2002 Birthweight <1500g
16597682|NCT02628002|Experimental|Test arm|The subjects randomized to the anti-gravity treadmill arm will be instructed on the safe use of the Alter-G treadmill by the study staff. After this instruction, subjects will be exercised on the Alter-G anti-gravity treadmill using the conventional Bruce protocol with unweighting to 75% of their body weight to reach target heart rate. If the subject is unable to reach the target heart rate, they will be further unweighted to 50% of their body weight to enable the subject to reach target heart rate on the Bruce protocol. If the subject is still unable to reach target heart rate with 50% unweighting, the patient's subsequent SPECT images will be excluded from use in the research comparison to control subject images.
16597683|NCT02628002|Active Comparator|Control arm|The control arm subjects will undergo the conventional treadmill/regadenoson pharmacological stress SPECT. Consistent with standard practice, these patients will perform adjunctive low-intensity walk on a conventional treadmill prior to regadenoson and Tc-99m injection if tolerated.
16597684|NCT02627989||Diflucortolone valerate (Nerisona/Texmeten)|Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
16597685|NCT02627976|Active Comparator|breast edema vest|
16597686|NCT02627963|Experimental|Tivozanib hydrochloride|Patients randomized to this arm will receive the study drug, tivozanib hydrochloride.
16597687|NCT02627963|Active Comparator|Sorafenib|Patients randomized to this arm will receive the comparator drug, sorafenib.
16597688|NCT02627950|Active Comparator|Isotonic sodium chloride + Ticagrelor|46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy
16597689|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor|46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
16597690|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor + Metoclopramide|46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
16597691|NCT02627937||pediatric sleep apnea|The children were confirmed to have OSAHS by comprehensive polysomnography (PSG).
16597692|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
16597693|NCT02627911|Other|Usual System (open-loop)|"In open loop, the patient will be provided with its usual pump and a CGM. To estimate rest and physical activity in patients being sedentary situation ( Centers : Caen, Nancy & Strasbourg) or in situations of physical activity ( Centers : CHSF Marseille and Besancon ) , the usual system will be complemented by an accelerometer  ActiGraph  and a  ActiHeart  heart rate monitor."
16597694|NCT02627911|Experimental|DIABELOOP System (closed-loop)|In the closed loop, the patient's pump will be replaced by the Diabeloop system consisting of insulin pump Cellnovo driven by remote control augmented by Diabeloop software and connected to the CGM.
16597695|NCT02627898|Experimental|Green tea extract|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
16597696|NCT02627898|Placebo Comparator|Placebo|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
16597697|NCT02627885|Active Comparator|ICBT|Internet-based CBT for Parkinsons Disease with therapist contact added to standard medical treatment
16597698|NCT02627885|Other|SMT|Standard Medical Treatment for Parkinsons Disease only
16597699|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
16597700|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
16597701|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
16597702|NCT02627859|Experimental|Durolane SJ|Durolane SJ intra-articular injection; device
16597703|NCT02627846|Active Comparator|EndoVenous Laser Ablation|EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
16597704|NCT02627846|Active Comparator|MechanoChemical Ablation (ClariVein®)|Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.
16597705|NCT02627833||Subject Group|Patients suffering from Bronchiolitis Obliterans
16597706|NCT02627833||Control Group|Age and sex matched control group
16597707|NCT02627820|Experimental|Experimental Drug|Isis 420915/GSK 299872, an antisense oligonucleotide. Administered subcutaneously three times per week for the first week, and then weekly for 18 months. Each dose shall contain 300 mg of active drug.
16597708|NCT02627807|Experimental|Individualized CTV|Patients receive IMRT using individualized CTV based on disease extension risk atlas and computer-aided delineation. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
16597709|NCT02627807|Active Comparator|Traditional CTV|Patients receive IMRT using traditional CTV. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
16597710|NCT02627794|Experimental|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.
~Restora™ Steroid eluting spacer (experimental).
~Each nostril will receive one each of above spacers."
16597711|NCT02627781||suspected appendicitis|This group includes all patients with suspected appendicitis, who are admitted to our University Hospital.
16597712|NCT02627768||Cohort 1: Ustekinumab Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
16597713|NCT02627768||Cohort 2: TNFi Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
16597715|NCT02627755|Experimental|Glide+aScope group|Device: combined use of two airway devices Glidescope® + aScope®
16597716|NCT02627742|Experimental|METANEB|Patients will receive standard care with the addition of therapy with The MetaNeb® System.
16597717|NCT02627729|Active Comparator|Linear cutter-Circular stapler J pouch|J pouch anal anastomosis after laparoscopic low anterior resection
16597718|NCT02627729|Active Comparator|Circular stapler Side-to-end anastomosis|side to end coloanal anastomosis after laparoscopic low anterior resection
16597719|NCT02627716|Experimental|SOS Intervention Group|Subjects benefit from the SOS Plan in addition to the usual follow-ups
16597720|NCT02627716|No Intervention|Control Group|Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)
16597721|NCT02627690||Islet transplanted|patients who underwent islet transplantation
16597722|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
16597723|NCT02627677|Experimental|Cohort A: ponatinib 30 mg QD|ponatinib 30 mg, taken orally once daily
16597724|NCT02627677|Experimental|Cohort B: ponatinib 15 mg QD|ponatinib 15 mg, taken orally once daily
16597725|NCT02627677|Active Comparator|Cohort C: nilotinib 400 mg BID|nilotinib 400 mg, taken orally twice daily
16597726|NCT02627664||observational study|natural history of non dopaminergic signs
16597727|NCT02627651|Experimental|brain injury|children post brain injury
16597728|NCT02627651|Active Comparator|controls|children typically developed age matched
16597729|NCT02627638|Other|Osteopathic treatment|
16597730|NCT02627625|Experimental|test product A|tiotropium
16597731|NCT02627625|Experimental|test product B|tiotropium
16597732|NCT02627625|Experimental|test product C|tiotropium
16597733|NCT02627625|Active Comparator|Commercial product D|tiotropium
16597734|NCT02627625|Active Comparator|commercial product E|tiotropium
16597735|NCT02627612|Experimental|TM RWB PLUS Pro Vetus|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this group and request that they voluntarily join TM RWB and receive mentorship from their matched and assigned mentor. In addition to TM RWB membership, research participants will also receive approximately four months of mentorship from a ProVetus mentor to assist them in further transitioning within the five domains.
16597736|NCT02627612|Active Comparator|TM RWB ONLY|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this arm and request that they voluntarily join TM RWB. Weekly emails will provide lists of voluntary physical/social activities available to all Chapter members. No participation is required in these activities.
16597737|NCT02627612|No Intervention|Control Group (Waitlist)|Research participants (recent Veterans) will be placed on a waitlist for approximately sixteen months. Based on their desires, the research participants in this group will have opportunity to belong to TM RWB plus receive approximately four months of mentorship from trained, peer-mentors (who are TM RWB volunteers).
16597738|NCT02627599||Chronic Obstructive Pulmonary Disease|"More than 12 million adults are diagnosed with COPD
~COPD is the 3rd leading cause of death in the U.S.
~Breathing difficulty is the major reason patients seek medical attention
~COPD patients requiring hospitalization are associated with higher costs
~Oximetry is an important tool for assessing need for Long-Term Oxygen Therapy
~LTOT has been proven to improve survival and quality of life
~Patients provided with a breath responsive variable bolus oxygen conserving device:
~support increased activity
~improve quality of life
~increase functional capability
~reduce portable oxygen source utilization
~maintain and/or improve oxygen saturation"
16597739|NCT02627586|Active Comparator|Moderate intensity continuous exercise|Moderate intensity continuous exercise (MICE) is performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group will perform MICE training three times per week. Cycling resistance will be adjusted weekly according to heart rate and Borg scale.
16597740|NCT02627586|Experimental|High-intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. Moderate intensity continuous exercise (MICE) is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group performs two HIIT sessions and one MICE session per week.
~In both training forms cycling resistance will be adjusted weekly according to heart rate and Borg scale."
16597741|NCT02627573|Experimental|Thymoglobulin|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
16597742|NCT02627573|Experimental|PTCy|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
16597743|NCT02627560|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
16597744|NCT02627560|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
16597745|NCT02627547|Experimental|Experimental tests|2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training
16597746|NCT02627534|Active Comparator|Ultrasonic Debridement (UD)|Ultrasonic Debridement (UD) (n=20)
16597747|NCT02627534|Experimental|UD + Antimicrobial Photodynamic Therapy|Ultrasonic Debridement + aPDT (UD+aPDT) (n=20)
16597748|NCT02627521|Experimental|PRU Guided CABG|Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value >235 or a PRU value between >170 and <235 for two consecutive days as documented by VerifyNow assay.
16597749|NCT02627521|Active Comparator|CABG per standard of care|Timing of CABG per standard of care
16599255|NCT02617459|Active Comparator|Betaxolol eye drops|Betaxolol eye drops 5ml/12.5mg per bottle
16597750|NCT02627508|Experimental|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.
~Weeks 1 and 2: 30mg twice daily (total 60mg per day)
~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)
~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)
~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)
~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)
~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
16597751|NCT02627508|Placebo Comparator|Placebo|Placebo
16597752|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
16597753|NCT02627469|No Intervention|Control|Common oral hygiene help administered by nursing staff
16597754|NCT02627469|Experimental|Intervention|Extended professional oral hygiene care Electric toothbrush (Oral-B Professional Care 7000) 1100 ppm sodium fluoride dentifrice (Zendium Classic, Opus Health Care AB/Zendium)
16597755|NCT02627456|Experimental|1A|(n=5), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (4.5x105) via DVI. All 5 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination.
16597756|NCT02627456|Experimental|1B|(n=S), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (9.0x10S) via DVI. All S subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination
16597757|NCT02627456|Experimental|1C|(n=30), will be the targeted dose for the Pilot Safety Group. Subjects will receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. 15 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to each administration of PfSPZ Vaccine, while 15 will not, except prior to PfSPZ Vaccine #3 when all 30 subjects will receive antimalarial treatment with ASAQ.
16597758|NCT02627456|Experimental|1D|(n=15), will be the CHMI control group. Subjects will not receive any PfSPZ vaccinations but will serve as infectivity controls for CHMI. All 15 subjects will receive antimalarial treatment with ASAQ prior to PfSPZ Challenge.
16597759|NCT02627456|Experimental|2|(n=60), will be the targeted vaccine dose arm and receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the pilot study indicate otherwise.
16597760|NCT02627456|Placebo Comparator|3|(n=60), will be the placebo arm and receive vaccinations with normal saline via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the Pilot Study indicate otherwise.
16597761|NCT02627456|Active Comparator|4|(n=SS), will be group- matched (age, sex, village) controls for Arm 2 for the duration study. Subjects previously enrolled in Arm 3 may re-enroll in Arm 4. All subjects will receive antimalaria treatment at enrollment
16597762|NCT02627443|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16597763|NCT02627430|Experimental|Treatment (talazoparib and Hsp90 inhibitor AT13387)|Patients receive talazoparib PO QD on days 1-7 (course 0). Beginning in course 1, patients receive talazoparib PO QD on days 1-28 and HSP90 inhibitor AT13387 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16597764|NCT02627417|Experimental|Dapsone: (Disulone®)|Dapsone: Disulone® given orally at 100 mg per day
16597765|NCT02627417|Active Comparator|"Prednisone (Cortancyl®) alone and standard of care"|"Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and standard of care (control arm)"
16597766|NCT02627404|Other|Main module|Blood sample
16597767|NCT02627391|Experimental|Early surgery|Surgical aortic valve replacement
16597768|NCT02627391|Active Comparator|Delayed surgery according to guidelines|Surgical aortic valve replacement
16597769|NCT02627378|Active Comparator|Extracorporeal Membrane Oxygenation|Patients received Extracorporeal Membrane Oxygenation (ECMO) support
16597770|NCT02627378|Placebo Comparator|Non Extracorporeal Membrane Oxygenation|Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
16597771|NCT02627365|Experimental|Individualized, interactive SMS|Individualized, interactive SMS intervention plus Standard care. Messages sent automatically using the Text-IT system.
16597772|NCT02627365|No Intervention|Standard care|Standard care according to Kenyan guidelines, including clinic-based adherence education and counseling.
16597773|NCT02627352|Experimental|Transscleral Cyclophotocoagulation|Subjects undergo a Micropulse Transscleral Cyclophotocoagulation(TSCPC) laser surgery, where a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
16597774|NCT02627339||Healthy controls|Healthy controls age 10 to 90 years
16597775|NCT02627326|Active Comparator|Group 1|Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
16597776|NCT02627326|Active Comparator|Group 2 Chlorhexidine|Interventions done in 30 patients and included intracanal medicament . After biomechanical preparation of root canal, 2%Chlorhexidine gluconate gel as an intracanal medicament was placed in root canal from pulp chamber to apex for 3 months (replacing every month). After 3 months,periodontal surgery in the form of open flap debridement (OFD) was performed in the respective tooth and medicament was changed and placed further for 3 months (replacing every month). Obturation was done after 3 months of OFD.
16597777|NCT02627313|Experimental|GammaPod|GammaPod tumour bed boost
16597778|NCT02627287|Experimental|DV3316 pen-injector|
16597779|NCT02627287|Active Comparator|FlexPen®|
16597780|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
16597781|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
16597782|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.
~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
16597783|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
16597784|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide (TEC)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
16597785|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
16597786|NCT02627248|Experimental|Epirubicin and Docetaxel (ET)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
16597787|NCT02627248|Experimental|Epirubicin and Docetaxel+Huaier (ET+HE)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
16597788|NCT02627235|Experimental|DIAL Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
16597789|NCT02627235|Active Comparator|Wait List Control|Access to the intervention 12 weeks following baseline assessment.
16597790|NCT02627222|Active Comparator|Treatment|Daily consumption of two cassava-based meals prepared with pro-vitamin A rich biofortified cassava
16597791|NCT02627222|Placebo Comparator|Control|Daily consumption of two cassava-based meals prepared with common white cassava
16597792|NCT02627209|Active Comparator|serum angiotensin converting enzyme|spectrophotometric assay
16597793|NCT02627209|Active Comparator|serum lysozyme|radial immunodiffusion
16597794|NCT02627196|Experimental|Device and Medical Management|Subjects will be implanted with the BAROSTIM NEO System and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
16597795|NCT02627196|Active Comparator|Medical Management|Subjects will receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
16597796|NCT02627183||Paroxysmal AF + catheter ablation|Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
16597797|NCT02627183||Permanent/persistent AF + exercise|Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
16597798|NCT02627170||Healthy adults group|Age 20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
16597799|NCT02627157||myopia patients|20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
16597800|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
16597801|NCT02627131|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
16597802|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
16597803|NCT02627105|Experimental|Beef group|Subjects in this group are asked to consume 4 or more servings of beef per week and to exclude all other red meats from their diet for the 6 month study.
16597804|NCT02627105|Other|Non-beef group|Subjects in this group are asked to avoid all red meats from their diet for the 6 month study.
16599256|NCT02617446|Placebo Comparator|Placebo|i.v. infusion for 24 hours
16597805|NCT02627092|Experimental|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.
~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
16597806|NCT02627092|No Intervention|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.
~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
16597807|NCT02627079|Active Comparator|Cohort 1|"Cohort 1 will include 15 sedentary participants who have completed all cancer therapy except adjuvant hormonal therapy.
~All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity level for 12 weeks.."
16597808|NCT02627079|Active Comparator|Cohort 2|Cohort 2 will include 15 sedentary participants in active treatment. All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity levels for 12 weeks.
16597809|NCT02627066|Active Comparator|Volume Control|This group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
16597810|NCT02627066|Active Comparator|Volume Control + Exercise|This group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
16597811|NCT02627053|Experimental|rivaroxaban|
16597812|NCT02627040|Active Comparator|InterTan Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
16597813|NCT02627040|Active Comparator|Gamma 3 Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
16597814|NCT02627027|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
16597815|NCT02627027|Experimental|TR group|T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
16597816|NCT02627014|Experimental|INTERVENTION|Manual Therapy in temporomandibular joint and cervical region. Home physical therapy in temporomandibular joint and cervical region.
16597817|NCT02627014|Active Comparator|CONTROL|Manual therapy in cervical region Home physical therapy in cervical region
16597818|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
16597819|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
16597820|NCT02626988|Experimental|Intervention|The intervention group will receive capacity building sessions on the 'Promotion of a biodiverse diet' and will include both Agriculture and Nutrition topics, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal. 5 Sessions will be held in each village over 12 months.
16597821|NCT02626988|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
16597822|NCT02626975||ACL reconstruction ballooning|"ACL reconstruction with short hamstring tendon autograft
~arm ballooning
~arm no ballooning"
16597823|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
16597824|NCT02626949|Experimental|MBSR Course|Mindfulness-Based Stress Reduction Course (MBSR) consisting of 8 weekly sessions, 2.5 hours each, and a 5 hour silent retreat during the 6th week of the program.
16597825|NCT02626949|Experimental|HEP Course|Health Enhancement Program (HEP) consisting of 8 weekly sessions, 2.5 hours each, and 1.5 hour monthly educational sessions after the 8 week intervention.
16597826|NCT02626936|Active Comparator|Dual-hormone CL with overestimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 95g of carbohydrates.
16597827|NCT02626936|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
16597828|NCT02626923||Patients on once daily Maraviroc|Maraviroc tablet 600 mg once daily 48 weeks
16597829|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
16597830|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
16597831|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
16597832|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
16597833|NCT02626897|Other|Sarcoidosis - GENEActiv device first|Six patients start with the GENEActiv wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the ActiGraph GT3X device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
16597834|NCT02626897|Other|Sarcoidosis - ActiGraph device first|Six patients start with the ActiGraph GT3X wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the GENEActiv device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
16597835|NCT02626884|Experimental|Ibrutinib|All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
16597836|NCT02626858|Other|extra treatment planning CT-scan|Extra pre-operative CT-scan for treatment planning in RT
16597837|NCT02626845|Active Comparator|Rituximab Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
16597838|NCT02626845|Placebo Comparator|Placebo Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
16597839|NCT02626832|Experimental|Healthy Control|This group is represented by healthy controls
16597840|NCT02626832|Experimental|Depression|This experimental group is represented by subjects with depression
16597841|NCT02626832|Experimental|Schizophrenia|This experimental group is represented by subjects with schizophrenia
16597842|NCT02626832|Experimental|Prodromal subjects|This experimental group is represented by subjects with prodromal symptoms for schizophrenia
16597843|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
16597844|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
16597845|NCT02626806||patients with hemodynamic significant CAD;|
16597846|NCT02626806||patients without hemodynamic significant CAD|
16597847|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
16597848|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for > 1 conventional, systemic pre-treatment
16597849|NCT02626780|Experimental|SVF Injection|Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
16597850|NCT02626767|Experimental|Intervention|Participants were required to complete a high-intensity interval exercise training intervention, which took place three time per week for 10 weeks. The exercise sessions comprised of 4 to 7 repetitions of 45 s maximal effort exercise, based on boxing, dance, soccer and basketball drills), interspersed with 90-s rest. During each repetitions participants were encouraged to reach >90% of their individual maximal heart rate. Participants were asked to maintain their dietary habits throughout the intervention period.
16597851|NCT02626767|No Intervention|Control|Participants were asked to maintain their usual diet, physical education and physical activity habits during the intervention period and were not aware that an exercise intervention was taking place at other study sites.
16597852|NCT02626754|Experimental|Sunitinib|Sunitinib malate, 12.5mg/capsule, 50mg/day
16597853|NCT02626741|Experimental|meal replacement group|the participants receive a meal replacement plus life style modification
16597854|NCT02626741|Experimental|control group|the participants receive life style modification only.
16597855|NCT02626715|Active Comparator|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)
~Trade Name (generic name)"
16597856|NCT02626715|Active Comparator|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)
~Trade Name (generic name)"
16597857|NCT02626689||β-thalassemia transfusion dependent subjects|Participants will complete 3 quality of life instruments (i.e. FACT-AN, the SF-36v2, and the TranQol) once every 3 weeks, in addition to a TranQol instrument on the day of a RBC transfusion. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
16597858|NCT02626689||β-thalassemia Non Transfusion Dependent (NTD) subjects|Participants will complete 2 quality of life instruments (i.e. FACT-An and the the SF-36v2l) once every 3 weeks, in addition to completing the non-transfusion dependent Patient Recorded Outcome (PRO) tool on a daily basis. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
16597859|NCT02626676|Experimental|Educational Programme Group|Stage 5D Chronic Kidney Disease Patients on high-efficiency hemodialysis programme - 4-hour sessions, 3 times a week will be followed up
16597860|NCT02626663||aHUS|atypical Hemolytic Uremic Syndrome
16597861|NCT02626663||TTP|Thrombotic thrombocytopenic purpura
16597862|NCT02626663||MAHA|other microangiopathic hemolytic anemias
16597863|NCT02626650|Active Comparator|Check symptoms one has experienced|This is the baseline condition. When asked to indicate concussion symptoms (or most other kinds of symptoms for medical conditions), people usually place a check mark next to each symptom they have experienced.
16597864|NCT02626650|Experimental|Check symptoms one has not experienced|Participants place a check mark next to each symptom they have NOT experienced in the most recent sports season.
16597865|NCT02626650|Experimental|Uncheck symptoms one has experienced|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have experienced in the most recent sports season.
16597866|NCT02626650|Experimental|Uncheck symptoms one has not experienced.|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have NOT experienced in the most recent sports season.
16597867|NCT02626637|Experimental|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
16597868|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
16597935|NCT02626117|Active Comparator|CAF+ SCTG+ laser depithelialisation|CAF + SCTG and Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium.
16597869|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
16597870|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
16597871|NCT02626598||Treated patients|Patients treated with blended Belotero for etched-in fine lines of the cutaneous lip, and/or radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area will be evaluated with photographs, physician ratings, and patient improvement assessments.
16597872|NCT02626585|No Intervention|Control|Control group (n=20): Following removal of nasal cast on postoperative first week, no additional taping was applied to this group.
16597873|NCT02626585|Experimental|2-weeks of PRT|2-weeks of PRT (n=17): Following removal of nasal cast on postoperative first week, 2 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 3rd week).
16597874|NCT02626585|Experimental|4-weeks of PRT|4-weeks of PRT (n=20): Following removal of nasal cast on postoperative first week, 4 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 5th week).
16597875|NCT02626572|Experimental|S47445 5mg|
16597876|NCT02626572|Experimental|S47445 15mg|
16597877|NCT02626572|Experimental|S47445 50mg|
16597878|NCT02626572|Placebo Comparator|Placebo|
16597879|NCT02626546||Major surgical procedures|All patients selected to follow up
16597880|NCT02626533||Total knee arthroplasty patients|Patients undergoing total knee arthroplasty for osteoarthritis are enrolled in the study. Blood and joint fluid samples will be obtained from patients, and questionnaires will be administered to assess pain and stiffness.
16597881|NCT02626520|Experimental|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
16597882|NCT02626520|Experimental|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
16597883|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.
~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.
~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles
~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
16597884|NCT02626494|Experimental|Cocaine Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
16597885|NCT02626494|Active Comparator|Healthy Control Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
16597886|NCT02626481|Experimental|Daratumumab + Dexamethasone|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
16597887|NCT02626468||Normal|Participants with no diagnosis of respiratory disease between the ages of 0 and 80
16597888|NCT02626468||COPD|Patients from different diagnostic groups between the ages of 0 and 80
16597889|NCT02626455|Experimental|Copanlisib + R-B or R-CHOP / Arm 1|Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) [R-B] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP] (safety run-in and phase III)
16597890|NCT02626455|Placebo Comparator|Placebo + R-B or R-CHOP / Arm 2|Combination of placebo and R-B or R-CHOP (phase III only)
16597891|NCT02626442|Experimental|Group Exercise Class|6 month group balance/exercise class, three days a week - up to one hour. Exercise program includes walking around a track, bodyweight/balance exercises, and an obstacle course.
16597892|NCT02626442|No Intervention|Testing|Subjects enrolled in other MERCE exercise and robotics interventions will receive balance/walking tests, MRI with famous name recognition task, and cognitive testing pre and post their intervention.
16597893|NCT02626429|Experimental|Active, Young Adult Famale|Participants will complete a bout of exercise and then consume a randomly assigned amino acid intake prior to measuring whole body 13CO2 excretion and phenylalanine oxidation.
16597894|NCT02626416|Experimental|telemedicine group|Congenital cataract patients use telemedicine to pursue and adjust the time of follow-up under non-clinical settings
16597895|NCT02626416|No Intervention|non-telemedicine group|Congenital cataract patients pursue and adjust the time of follow-up through outpatient visit in the hospital
16597896|NCT02626403|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (bilateral fronto-parietal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
16597972|NCT02625831||healthy patients|48 healthy patients. Biological analysis were performed.
16597897|NCT02626403|Sham Comparator|sham tDCS|Patients will receive sham tDCS (15 second of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
16597898|NCT02626390|Experimental|Implicit Learning|Physiotherapy delivered based on implicit treatment guidance - achieved primarily by reducing the frequency of verbal coaching statements and promoting an external focus of attention.
16597899|NCT02626390|Active Comparator|Explicit Learning|Physiotherapy delivered based on explicit treatment guidance - achieved primarily by giving frequent verbal coaching statements and promoting an internal focus of attention.
16597900|NCT02626377|Experimental|Interventional arm|'Support provided by social worker'
16597901|NCT02626377|Other|Non-interventional arm|'Information booklet receipt'
16597902|NCT02626364|Experimental|Treatment|crenolanib 100mg PO TID
16597903|NCT02626351|Experimental|Receiving/ received QI intervention|A clinic which is presently receiving the Intensive Phase of the QI intervention, or is in the Maintenance Phase
16597904|NCT02626351|Active Comparator|Not yet received QI intervention|A clinic which has not yet received the QI intervention
16597905|NCT02626338|Experimental|Arm A|"Mitoxantrone
~Cytarabine
~Crenolanib"
16597906|NCT02626338|Experimental|Arm B|"Mitoxantrone
~Etoposide
~Cytarabine
~Crenolanib"
16597907|NCT02626338|Experimental|Arm C|"Fludarabine
~Cytarabine
~G-CSF
~Idarubicin
~Crenolanib"
16597908|NCT02626312|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy 5 days a week for a total of 15 or 25 fractions in the absence of disease progression or unacceptable toxicity.
16597909|NCT02626299|Placebo Comparator|200 mg/day DHA|Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
16597910|NCT02626299|Experimental|1000 mg/day DHA|The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
16597911|NCT02626286|Other|HIV quarterly global care|HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.
16597912|NCT02626273|Experimental|intervention group|an intervention group who will undergo the management program combining physical activity and restrictive diet at Tza Nou Medical House for 10 months
16597913|NCT02626273|Other|a control group|a control group who will not undergo any intervention
16597914|NCT02626260|Experimental|Cohort 1b|The subject test one adhesive strip on the peristomal area
16597915|NCT02626247|Active Comparator|Vitamin A + Long chain PUFA|The test product is a food supplement containing Vitamin A + Long chain Poly Unsaturated Fatty Acids (PUFA). It is presented as a hard shell capsule containing lipophylic nutrients.
16597916|NCT02626247|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
16597917|NCT02626234|Experimental|INC280|
16597918|NCT02626221||Single|Single Cohort Study
16597919|NCT02626208|Experimental|Nestorone®/ Estradiol 75|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 75 ug/day of estradiol
16597920|NCT02626208|Experimental|Nestorone®/Estradiol 100|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 100 ug/day of estradiol
16597921|NCT02626208|Experimental|Nestorone®/ Estradiol 200|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 200 ug/day of estradiol
16597922|NCT02626195|Experimental|nutritional support program apply|Preoperative nutritional support program is given for 5 or more days preoperatively by nutritional support program.
16597923|NCT02626195|No Intervention|historical control group|Historical control group is that did not receiving
16597924|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
16597925|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
16597926|NCT02626169|Active Comparator|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
16597927|NCT02626169|Active Comparator|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
16597928|NCT02626156|Experimental|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
16597929|NCT02626156|Active Comparator|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
16597930|NCT02626143|Experimental|Investigational nutrient-rich whey protein formula|
16597931|NCT02626143|Active Comparator|Cow's milk based formula|
16597932|NCT02626143|No Intervention|Breast milk|
16597933|NCT02626130|Experimental|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
16597934|NCT02626130|Experimental|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
16597936|NCT02626117|Sham Comparator|CAF+SCTG+ sham laser depithelialisation|CAF+ SCTG+ sham LASER deepithelialisation was applied to remove the sulcular epithelium.
16597937|NCT02626104|Experimental|A - Lactoferrin|Bovine lactoferrin orally - 100 mg twice a day, for whole antibiotic treatment period.
16597938|NCT02626104|Placebo Comparator|B - Maltodextrin|Maltodextrin orally - 100 mg twice a day, for whole antibiotic treatment period.
16597939|NCT02626091|Experimental|Perfusion evaluation of anastomosis|During left-sided colonic resections, anastomosis perfusion will be estimated by the visual appreciation of the surgeon and the ICG fluorescence-based enhanced reality. These two approaches will be compared.
16597940|NCT02626078||observation and interview of residents|residents will be observed over lunch and an interview will be held with each resident after lunch
16597941|NCT02626065|Experimental|Nivolumab, patients with BRAF mutation|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
~Blood sampling at different time"
16597942|NCT02626065|Experimental|Nivolumab, patients with BRAF wild type|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
~Blood sampling at different time"
16597943|NCT02626026|Experimental|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
16597944|NCT02626026|Placebo Comparator|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
16597945|NCT02626026|Experimental|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
16597946|NCT02626026|Placebo Comparator|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
16597947|NCT02626026|Experimental|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
16597948|NCT02626026|Placebo Comparator|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
16597949|NCT02626000|Experimental|Talimogene Laherparepvec + Pembrolizumab|Talimogene laherparepvec is administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 3 weeks after the initial dose and every 3 weeks (Q3W) thereafter. Pembrolizumab is administered by intravenous infusion at a dose of 200 mg Q3W after the initial dose. Participants are treated until complete response, no injectable lesions, confirmed disease progression, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first.
16597950|NCT02625987|Experimental|Continuous intradermic stitch|Closure was did with a continuous intradermic stitch.
16597951|NCT02625987|Sham Comparator|Separated stitches|Like comparator was used a closure with separated stitches.
16597952|NCT02625974|Experimental|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
16597953|NCT02625974|Other|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
16597954|NCT02625961|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
16597955|NCT02625948|Active Comparator|tranexamic acid|tranexamic acid
16597956|NCT02625948|Placebo Comparator|Placebo|0.9% NaCl
16597957|NCT02625948|No Intervention|observation(spot sign -)|regular clinical treatment
16597958|NCT02625922|Experimental|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
16597959|NCT02625922|Experimental|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
16597960|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
16597961|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
16597962|NCT02625896|Experimental|Intervention|A sequence of free fall manoeuvres performed using the human body: A free fall velocity reduction prior to main parachute deployment followed by a head high body attitude prior to main parachute extraction.
16597963|NCT02625896|No Intervention|Control|Normal main parachute extraction performed in a manner that is typical for the study participant.
16597964|NCT02625883||Survivors|Patients with out-of-Hospital resuscitation and return of spontaneous circulation. Structured interview for quality of life (questionnaire) one year after resuscitation.
16597965|NCT02625870|Experimental|Omega-3-Acid Ethyl Esters 90 Soft Capsules|
16597966|NCT02625870|Placebo Comparator|Corn Oil|
16597967|NCT02625857|Experimental|Dose Cohort 1A and 1B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
16597968|NCT02625857|Experimental|Dose Cohort 2A and 2B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
16597969|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
16597970|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
16597971|NCT02625831||SLE patients|"165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without.
~Biological analysis were performed."
16597974|NCT02625805|Experimental|Participants diagnosed with ADD/ADHD|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
16597975|NCT02625805|Experimental|Healthy participants|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
16597976|NCT02625792|Experimental|Endo-Clot(TM)|The intervention group
16597977|NCT02625779|Active Comparator|Valproate and Placebo|Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks
16597978|NCT02625779|Experimental|Valproate and Cytidine-containing Drug|Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks
16597979|NCT02625779|Experimental|Valproate and Creatine-containing Drug|Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8
16597980|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
16597981|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
16597982|NCT02625753|Active Comparator|Codeine plus paracetamol|Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
16597983|NCT02625753|Placebo Comparator|placebo|Placebo every 6 hours for 72 hours after photorefractive keratectomy.
16597984|NCT02625740|Experimental|Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm
16597985|NCT02625740|Active Comparator|Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic)
16597986|NCT02625727|Experimental|hyaluronic acid group|hyaluronic acid injection
16597987|NCT02625727|Active Comparator|hyaluronic acid and corticosteroid group|hyaluronic acid combined corticosteroid injection
16597988|NCT02625714|Other|A group|Renexin® → SID142
16597989|NCT02625714|Other|B group|SID142 → Renexin®
16597990|NCT02625701|Experimental|Goal-Directed-Therapy (GDT)|"Besides the basal infusion of crystalloids at 3-6 ml/kg/h, colloids (200 ml) or crystalloids (200 ml) are given over 10 min in the presence of signs of absolute/relative hypovolemia as detected by a fall in cardiac output/stroke volume (CO/SV) or if Pressure Pulse Variation (PVV) or Stroke Volume Variation (SVV) exceeds 10-12%, particularly in the presence. Fluid filling is interrupted when SV fail to increase > 10% (or PVV/SVV =< 10%) Otherwise, vasopressors can be used to achieve appropriate mean arterial pressure (MAP>70 mmHg, within ±20% of baseline).
~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
16597991|NCT02625701|Active Comparator|Restrictive strategy|"Crystalloids are given at a fixed rate of 3-6 ml/kg/h. Otherwise, vasopressors can be used to achieve appropriate MAP (>70 mmHg, within ±20% of baseline).
~Blood losses are replaced with colloids (1:1) or crystalloids (2:1). Clinicians in charge of the patients are free to use hemodynamic parameters such as PVV or SVV, always attempting to limit the amount of fluid infusion and to maintain normovolemia"
16597992|NCT02625688|Placebo Comparator|Early cord clamping|Cord clamping will be applied after 30 seconds post delivery.
16597993|NCT02625688|Active Comparator|Delayed cord clamping|Cord clamping will be applied after 3 minutes post delivery.
16597994|NCT02625688|Active Comparator|Cord milking|The baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
16597995|NCT02625662||iFSHD group|First recruitment group
16597996|NCT02625649||RYGB|RYGB-operated type 2 diabetic patients
16597997|NCT02625649||non-RYGB|non-RYGB-operated type 2 diabetic controls
16597998|NCT02625636|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions
16597999|NCT02625636|Experimental|SAR438544 dose 2|Single dose of SAR438544 given SC under fasting conditions
16598000|NCT02625636|Experimental|SAR438544 dose 3|Single dose of SAR438544 given SC under fasting conditions
16598001|NCT02625636|Placebo Comparator|Placebo|Single dose of placebo given SC under fasting conditions
16598002|NCT02625636|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions
16598003|NCT02625636|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions
16598004|NCT02625623|Experimental|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
16598005|NCT02625623|Active Comparator|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
16598041|NCT02625363|Experimental|Glucose Ref and 450 ml water|250 ml glucose solution with 50 gram available carbohydrate per serving. Sample was consumed with additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
16599637|NCT02614976|Experimental|Padding|Padding before application of blood pressure cuff
16598006|NCT02625610|Experimental|Avelumab|"Induction Phase: Subjects will be administered with oxaliplatin and either 5-Fluorouracil (5-FU) or capecitabine for 12 weeks.
~Maintenance Phase: Subjects will be administered with intravenous (IV) infusion of avelumab once every 2 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
16598007|NCT02625610|Active Comparator|Oxaliplatin-fluoropyrimidine doublet|"Induction Phase: Subjects will be administered with oxaliplatin and either 5-FU or capecitabine for 12 weeks.
~Maintenance Phase: Subjects will continue the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5-FU/Leucovorin (LV) or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Subjects who are not deemed eligible to receive further chemotherapy will receive best supportive care (BSC) alone with no active therapy."
16598008|NCT02625597|Experimental|Dental Materials|
16598009|NCT02625584|Other|Shared Reading Control|Reading Together - Shared Reading Control. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will not be trained to read with their child. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
16598010|NCT02625584|Experimental|Dialogic Reading|Reading Together - Dialogic Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a dialogic reading style. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
16598011|NCT02625584|Experimental|Pausing for Reading|Reading Together - Pausing for Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a style which involves pausing, recasting and open questioning. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
16598012|NCT02625571|Experimental|Intervention|
16598013|NCT02625558|Active Comparator|Riociguat|Active drug
16598014|NCT02625558|Placebo Comparator|Placebo|placebo
16598015|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
16598016|NCT02625532|Active Comparator|Follicular phase|Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
16598017|NCT02625532|Experimental|Luteal phase|Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
16598018|NCT02625519|Experimental|Urinary follicle-stimulating hormone|Controled Ovarian stimulation with urinary follicle-stimulating hormone
16598019|NCT02625519|Experimental|Recombinant follicle-stimulating hormone|Ovarian stimulation with recombinant follicle-stimulating hormone
16598020|NCT02625506|Placebo Comparator|Levobupivacaine|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
16598021|NCT02625506|Active Comparator|Levobupivacaine and Tramadol|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
16598022|NCT02625493||study population|All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
16598024|NCT02625467|Experimental|Penetrating keratoplasty|Conventional penetrating keratoplasty technique
16598025|NCT02625467|Experimental|PALK|Pachymetry and Excimer laser assisted lamellar keratoplasty
16598026|NCT02625454|Experimental|Intravenous Acetaminophen|Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen
16598027|NCT02625454|Active Comparator|Oral Acetaminophen|Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen
16598028|NCT02625441|Experimental|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
16598029|NCT02625441|Active Comparator|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
16598030|NCT02625428|Experimental|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
16598031|NCT02625428|Experimental|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
16598032|NCT02625415|Experimental|Vitamin B6|Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
16598033|NCT02625415|Placebo Comparator|Placebo|Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
16598034|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
16598035|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
16598036|NCT02625389|Experimental|Embolization with Lipiodol Ultra Fluid and glue|
16598037|NCT02625376|Experimental|Trans-Resveratrol|capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
16598038|NCT02625376|Active Comparator|Resvega|"capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.
~two capsules daily : one in the morning and evening for 24 months"
16598039|NCT02625376|Placebo Comparator|Placebo|capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
16598040|NCT02625363|Experimental|Glucose Ref - Std|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
16598042|NCT02625363|Experimental|White Bread with 250 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption
16598043|NCT02625363|Experimental|White Bread and 700 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption. Moreover, subjects given additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
16598044|NCT02625363|Experimental|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
16598045|NCT02625350|Experimental|Instant noodle without soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes and drained
16598046|NCT02625350|Experimental|Instant noodle with soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes, drained, and given additional 250 ml of water as soup
16598047|NCT02625350|Experimental|Glucose reference|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
16598048|NCT02625337|Active Comparator|Pembrolizumab mono|Pembrolizumab monotherapy
16598049|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib short|Pembrolizumab combined with a short scheme of dabrafenib+trametinib
16598050|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib intermediate|Pembrolizumab combined with an intermediate scheme of dabrafenib+trametinib
16598051|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib long|Pembrolizumab combined with a long scheme of dabrafenib+trametinib
16598052|NCT02625324|Experimental|Endovascular repair|Valiant Evo Thoracic Stent Graft System
16598053|NCT02625311|Experimental|MIS|Minimal invasive surgery for placement total knee prosthesis
16598054|NCT02625311|Active Comparator|conventional approach|"conventional open surgery for placement total knee prosthesis."
16598055|NCT02625298|Experimental|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
16598056|NCT02625298|Experimental|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
16598057|NCT02625285||G6PD Deficient Volunteers|"Subjects with age ≥ 18 years
~Male and female
~Previously tested G6PD deficient at SMRU clinic"
16598058|NCT02625285||G6PD Intermediate or Heterozygous Volunteers|"Subjects with age ≥ 18 years
~Female
~Previously tested G6PD intermediate or heterozygous for G6PD variants at SMRU clinic"
16598059|NCT02625285||G6PD-Normal Volunteers|"Subjects with age ≥ 18 years
~Male and female
~Previously tested G6PD normal at SMRU clinic"
16598060|NCT02625272|Experimental|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
16598061|NCT02625272|No Intervention|Group B|novel laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were divided at the beginning of the operation intracorporeally.
16598062|NCT02625272|No Intervention|Group C|the traditional laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer.
16598063|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
16598064|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
16598065|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
16598066|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
16598067|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
16598068|NCT02625246|Experimental|Group 1|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
16598069|NCT02625246|Experimental|Group 2|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
16598070|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
16598071|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
16598072|NCT02625220|Experimental|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
16598073|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
16598074|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
16598075|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
16598076|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
16598077|NCT02625194|Experimental|Oxygen|Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
16598078|NCT02625194|No Intervention|Control|Bronchoscope-guided intubation is performed without oxygen supply.
16598079|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
16598080|NCT02625168|Experimental|Afatinib|Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
16598153|NCT02624778|Placebo Comparator|Placebo x 72 weeks|Placebo administered IV for 72 wks
16598081|NCT02625168|Experimental|Erlotinib|Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
16598082|NCT02625155|Other|Standard of Care (SOC Arm)|Standard of Care UDT
16598083|NCT02625155|Other|Selective PGx Testing (Test Arm)|Standard of Care UDT with selective PGx testing
16598084|NCT02625142|Experimental|Family-centered rounds checklist|"During the post-intervention period, health care team members on two pediatric inpatient services received the Family-centered Rounds Checklist tool, as well as training in how to use the checklist in the delivery of effective family-centered rounds"
16598085|NCT02625142|No Intervention|Usual care|Two pediatric inpatient services were not provided the Family-centered rounds checklist tool, and delivered morning rounds in their usual manner. These services served as a control.
16598086|NCT02625129||Pharmacist-provided travel care|
16598087|NCT02625103|Experimental|Clozapine|treatment as usual: administration of clozapine between 9 and 12 pm. Blood sampling 10 -14 hours post drug administration
16598088|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.
~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
16598089|NCT02625077|Experimental|Laparoscopic valvuloplasty|Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
16598090|NCT02625077|Active Comparator|Laparoscopic Toupet fundoplication|Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
16598091|NCT02625064||1: patient at High risk for ARDSp|Severe pneumonia and（PaO2/FIO2）>300mmHg
16598092|NCT02625064||2: patient at High risk for ARDSexp|Severe sepsis and without ARDS
16598093|NCT02625064||3: mild ARDS|PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
16598094|NCT02625064||4: moderate ARDS|PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O
16598095|NCT02625064||5: severe ARDS|PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O
16598096|NCT02625051|Active Comparator|Ureteroscopy|Kidney stone of participants in this arm will be treated with ureteroscopy (URS). A ureteral stent will be inserted at the end of the procedure.
16598097|NCT02625051|Active Comparator|Percutaneous nephrolithotomy|Kidney stone of participants in this arm will be treated with percutaneous nephrolithotomy (PNL). A percutaneous nephrostomy tube will be inserted at the end of the procedure.
16598098|NCT02625038|Experimental|Interventional|3D-planned osteotomies with patient-specific guides
16598099|NCT02625025|Experimental|Low pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Low Pression Pneumoperitoneum (8 mm Hg)
16598100|NCT02625025|Experimental|Standard pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Standard Pression Pneumoperitoneum (12 mm Hg)
16598101|NCT02625012||Vitiligo|A serial of vitiligo patients under treatment with UVB-NB
16598102|NCT02624999|Experimental|Immunotherapy|Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
16598103|NCT02624999|Active Comparator|Standard chemotherapy|Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
16598104|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
16598105|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
16598106|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
16598107|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).
16598108|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).
16598109|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
16598110|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
16598111|NCT02624986|Experimental|FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
16598112|NCT02624973|Experimental|A|ER/PGR>50% TP53 wt
16598113|NCT02624973|Experimental|B|ER/PGR>50% TP53 mutated
16598114|NCT02624973|Experimental|C|ER/PGR<50% TP53 wt
16598115|NCT02624973|Experimental|D|ER/PGR<50% TP53 mutated
16598116|NCT02624973|Experimental|E|HER2+ TP53 wt
16598117|NCT02624973|Experimental|F|HER2+ TP53 mutated
16598118|NCT02624973|Experimental|G|Triple negative breast cancer TP53 wt
16598119|NCT02624973|Experimental|H|Triple negative breast cancer TP53 mutated
16598120|NCT02624960|Experimental|Accucinch Implant|Accucinch Implant procedure is completed
16598121|NCT02624947|Placebo Comparator|Treatment Group A|Formulation buffer (0.5mL injection)
16598122|NCT02624947|Active Comparator|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
16598123|NCT02624908|Active Comparator|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
16598124|NCT02624908|Placebo Comparator|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
16598125|NCT02624895||mCRC: Anti-EGFR MAbs + FOLFOX 1st line|• Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per clinical practice.
16598126|NCT02624895||mCRC: Anti EGFR MAbs + FOLFIRI 1st line|Adults (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFIRI plus panitumumab or FOLFIRI plus cetuximab as upfront treatment as per clinical practice
16598127|NCT02624882|Experimental|Positive rapid Group A Streptococcus (GAS) test|In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy
16598128|NCT02624882|Active Comparator|Negative rapid GAS test|If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
16598129|NCT02624869|Experimental|evolocumab (AMG 145)|Single arm all subjects receive evolocumab (AMG 145) every 4 weeks (QM)
16598130|NCT02624856|Experimental|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
16598131|NCT02624856|Active Comparator|Standard bupivacaine plus dexamethasone|Bupivacaine 0.5% 10 mL plus 2 mg dexamethasone for quadriceps sparing femoral nerve block and bupivacaine 0.25% 20 mL plus 2 mg of dexamethasone for posterior knee compartment periarticular injection.
16598132|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
16598133|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
16598134|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
16598135|NCT02624830|Experimental|Drug, Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to intravenous glucagon have been tested.
16598136|NCT02624817|Experimental|Drug: Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.
16598137|NCT02624804|Experimental|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated lymphocytes"
16598138|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;
~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
16598139|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;
~1-DAY ACUVUE® MOIST contact lenses"
16598140|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;
~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
16598141|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;
~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
16598142|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;
~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
16598143|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;
~1-DAY ACUVUE® MOIST contact lenses"
16598144|NCT02624778|Experimental|LY3002813 Single dose 1|LY3002813 administered intravenously (IV) once
16598145|NCT02624778|Experimental|LY3002813 Single dose 2|LY3002813 administered IV once
16598146|NCT02624778|Experimental|LY3002813 Single dose 3|LY3002813 administered IV once
16598147|NCT02624778|Experimental|LY3002813 Multiple dose 1 x 24 wks|LY3002813 administered IV for 24 wks
16598148|NCT02624778|Experimental|LY3002813 Multiple dose 2 x 24 wks|LY3002813 administered IV for 24 weeks
16598149|NCT02624778|Experimental|LY3002813 Multiple dose 3 x 72 wks|LY3002813 administered IV for 72 wks
16598150|NCT02624778|Experimental|LY3002813 Multiple dose 4 x 72 weeks|LY3002813 administered IV for 72 wks
16598151|NCT02624778|Placebo Comparator|Placebo given once|Placebo administered IV once
16598152|NCT02624778|Placebo Comparator|Placebo x 24 weeks|Placebo administered IV for 24 wks
16598160|NCT02624752|No Intervention|Standard of Care|"Standard of care could include liberalized diet consisting of 3 meals and snacks served daily or the standard oral nutrition supplementation (ONS) routinely used in the hospital, as prescribed by the medical team.These routine meals and snacks are the standard of care."
16598161|NCT02624752|Experimental|Ensure|Patients randomized to Enhanced Oral Nutritional Supplementation (ONS) will receive the standard of care hospital menu (3 meals and snacks per day) plus 2 cans of Ensure (or similar product) per day while in hospital and will continue 2 cans per day of Ensure when discharged home until they have been receiving the enhanced ONS for a total of 90 days.
16598162|NCT02624739|Experimental|Intervention|Reassure Non-Contact Respiration Monitor: Respiration parameters transmitted by the Reassure device will be evaluated daily by the study team and participants will be contacted for further evaluation if a change in respiration patterns is noted. Participants will continue with standard of care heart failure treatment.
16598163|NCT02624739|Active Comparator|Control|Reassure Non-Contact Respiration Monitor: Respiration parameters will be transmitted and stored, but there will be no active evaluation of respiration patterns. Participants will continue with standard of care heart failure treatment.
16598164|NCT02624726|Experimental|FOLFIRI/Aflibercept|5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
16598165|NCT02624713|Other|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
16598166|NCT02624713|Other|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
16598167|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
16598168|NCT02624700|Experimental|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
16598169|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
16598170|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
16598171|NCT02624674|Experimental|Multi-spectral Imaging Group|All subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
16598172|NCT02624661|Experimental|Glycerol injection|The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
16598173|NCT02624648|Placebo Comparator|Placebo Group|"The effects of Placebo on sexual function, desire and depression in postmenopausal women.
~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).
~The Beck Depression Inventory II will be used to ward off depression"
16598174|NCT02624648|Experimental|Maca (Lepidium Meyenii Walp) Group|"The effects of Lepidium Meyenii Walp on sexual function, desire and depression in postmenopausal women.
~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).
~The Beck Depression Inventory II will be used to ward off depression"
16598175|NCT02624635|Active Comparator|Manual Therapy|The treatment for this group will be manual therapy.
16598176|NCT02624635|Experimental|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip.
16598177|NCT02624622|Active Comparator|CHW applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
16598178|NCT02624622|Experimental|Mother applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. Mother is given the chlorhexidine during the first prenatal care visit to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
16598179|NCT02624609|Placebo Comparator|Control without pomegranate juice|Control meal will be white bread and a glass of water containing the same amounts of sugars naturally present in the pomegranate juice.
16598180|NCT02624609|Experimental|Test with pomegranate juice|Test meal will be white bread with a glass of pomegranate juice
16598181|NCT02624596|Experimental|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
16598182|NCT02624596|Active Comparator|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
16598183|NCT02624557|Experimental|Moderate hepatic impairment group|Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9
16598184|NCT02624557|Experimental|Severe hepatic impairment group|Subjects with severe hepatic impairment with Child-Pugh score 10 - 15
16598185|NCT02624557|Experimental|Matching healthy control group|Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.
16598186|NCT02624544|Experimental|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
16598187|NCT02624544|Active Comparator|Group B|desonide
16598188|NCT02624531|Other|fertility-sparing surgery|NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy
16598189|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
16598190|NCT02624505|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
16598191|NCT02624505|Active Comparator|90 mcg Reference Product|Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
16598192|NCT02624505|Active Comparator|180 mcg Reference Product|Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
16598193|NCT02624505|Experimental|90 mcg Test Product|Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
16598194|NCT02624492|Experimental|BI 836826-GemOx|
16598195|NCT02624492|Active Comparator|R-GemOx|
16598196|NCT02624479|Experimental|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
16598197|NCT02624479|Experimental|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
16598198|NCT02624479|Experimental|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
16598199|NCT02624466||CKD - no dialysis|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
16598200|NCT02624466||Patients on PD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and PD fluid, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
16598201|NCT02624466||Patients on HD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and spent dialysate, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
16598202|NCT02624453|Experimental|IMMY LFA positive patients|HIV positive patients who will be positive for cryptococcal antigen (by the IMMY LFA test) would be consented for lumbar puncture in search of cryptococcal meningitis (CM). If CM is not confirmed, they would be prescribed pre-emptive fluconazole based therapy at 800mg/day for two weeks (placed on antiretroviral therapy two weeks after screening for cryptococcal antigen), then 400mg/day for 8 weeks and thereafter 200mg/day until CD4 counts increases beyond 200cells/ml. (CM confirmed cases will be referred to the ACTA trial ISRCTN45035509)
16598203|NCT02624453|Active Comparator|IMMY LFA negative patients|HIV positive patient who will be negative for cryptococcal antigen (by the IMMY LFA test) would not be consented for lumbar puncture, will be placed immediately on antiretroviral therapy immediately after screening for cryptococcal antigen and would not be placed on fluconazole pre-emptive therapy.
16598204|NCT02624440|Experimental|Clarithromycin|p.o. clarithromycin 250 mg twice daily for 180 days
16598205|NCT02624440|Experimental|Sulfamethoxazole/trimethoprim|p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days
16598206|NCT02624440|Experimental|Observation|Observation without prophylactic antibiotic treatment
16598207|NCT02624427|Experimental|Glaucoma Eyes|Measurement of intraocular pressure (IOP)
16598208|NCT02624427|Active Comparator|Healthy Eyes|age-matched healthy eyes as controls will undergo Measurement of intraocular pressure (IOP)
16598209|NCT02624414|Other|Anti TNF induction therapy 6-12 months|All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.
16598210|NCT02624401|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion.
16598211|NCT02624401|Experimental|Propofol|Intravenous propofol using target controlled infusion.
16598212|NCT02624401|Experimental|S-ketamine|Intravenous S-ketamine using target controlled infusion.
16598213|NCT02624401|Experimental|Sevoflurane|Inhalational sevoflurane using target controlled inhalation.
16598214|NCT02624401|Placebo Comparator|Placebo|Intravenous saline.
16598215|NCT02624388|Experimental|Arm A: Genistein followed by Placebo|Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
16598216|NCT02624388|Experimental|Arm B: Placebo followed by Genistein|Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
16598217|NCT02624375|Experimental|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
16598281|NCT02623933|Experimental|MRI assisted HDR monotherapy|HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy
16598218|NCT02624362|Experimental|Odor+ Positive belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor improves asthma symptoms (therapeutic suggestion)
16598219|NCT02624362|Experimental|Odor + Negative belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor worsens asthma symptoms (asthmogenic suggestion)
16598220|NCT02624349|Active Comparator|Transplant|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
16598221|NCT02624349|Active Comparator|Control|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
16598222|NCT02624336|Active Comparator|DTC1 mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
16598223|NCT02624336|Placebo Comparator|Oradex mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
16598224|NCT02624336|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
16598225|NCT02624323|Experimental|Axillary catheterization|Real-time ultrasound-guided axillary vein catheterization, in plain technique.
16598226|NCT02624323|Experimental|Jugular catheterization|Real-time ultrasound-guided jugular vein catheterization, out of plain technique.
16598227|NCT02624310|Experimental|Droxidopa First, Placebo Second|Participants in this arm will receive droxidopa first, then cross over and receive placebo
16598228|NCT02624310|Experimental|Placebo First, Droxidopa Second|Participants in this arm will receive placebo first, then cross over and receive droxidopa
16598229|NCT02624297|No Intervention|Control Group|Healthy control group for comparisons with coronary artery disease groups.
16598230|NCT02624297|No Intervention|CAD without OSA - Control|Clinical follow-up.
16598231|NCT02624297|Experimental|CAD without OSA - Intervention|Aerobic exercise training.
16598232|NCT02624297|No Intervention|CAD with OSA - Control|Clinical follow-up.
16598233|NCT02624297|Experimental|CAD with OSA - Intervention|Aerobic exercise training.
16598234|NCT02624284|Sham Comparator|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
16598235|NCT02624284|Experimental|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
16598236|NCT02624284|Experimental|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
16598237|NCT02624271|Experimental|GastroPanel|GastroPanel test on blood samples
16598238|NCT02624258|Experimental|RNA CART19 cells|CD19 RNA redirected autologous T-cells (RNA CART19 cells)
16598239|NCT02624245|Experimental|Experimental: Conventional Physical Therapy|Strength, this arm will receive hip and knee muscle strengthening with and without weight bearing.
16598240|NCT02624245|Active Comparator|Movement control training|Movement control training, this arm will receive movement control training associated to muscle strengthening.
16598241|NCT02624232||Patients with anorectal malformations|"Participants are identified through relevant diagnostic codes in ICD-10(Q 42) and ICD-9(75.120, 75.121) in patients which underwent surgery for ARM in the years 1985-2005 are included if informed consent is obtained.
~Relevant questionnaires regarding symptoms and QoL are completed before the following examinations:anorectal manometry, endoanal ultrasonography, pudendal nerve conduction velocity, colon transit time, Magnetic resonans(MR)-scan of the pelvis and uroflowmetry."
16598242|NCT02624219|Experimental|Group 1|N = 55 receive 7.5 mcg A/H5N8 + AS03 on Day 1, 22
16598243|NCT02624219|Experimental|Group 2|N = 55 receive 7.5 mcg A/H5N8 + MF59 on Day 1, 22
16598244|NCT02624219|Experimental|Group 3|N = 55 receive 15 mcg A/H5N8 unadjuvanted on Day 1, 22
16598245|NCT02624219|Experimental|Group 4|N = 55 receive 15 mcg A/H5N8 + AS03 on Day 1, 22
16598246|NCT02624219|Experimental|Group 5|N = 55 receive 15 mcg A/H5N8 + MF59 on Day 1, 22
16598247|NCT02624206|Active Comparator|Juice A|Half of the group to receive Juice A, a novel juice flavor.
16598248|NCT02624206|Active Comparator|Juice B|Half of the group to receive Juice B, a novel juice flavor different from Juice A.
16598249|NCT02624193|Experimental|MBSR Program|"MBSR Program:
~The MBSR intervention is a nine-week program designed to cultivate mindfulness, a focused non-judgmental awareness of the present moment. It consists of eight 2-hour weekly sessions and one 3-hour retreat and the content includes three main components: 1) material related to mindfulness, meditation, yoga, and the mind-body connection; 2) experiential practice of mindful meditation (sitting, lying down, walking), gentle mindful yoga, and body scan during group meetings and encouragement of home practice; and 3) group discussion focused on problem-solving related to barriers to effective practice. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
16598282|NCT02623920|Experimental|Brentuximab, Bendamustine, Rituximab|Brentuximab Vedotin in Combination with Bendamustine and Rituximab
16598283|NCT02623907||AS group|Severe AS patients, without severe AR
16598284|NCT02623907||AR|Severe AR patients, without severe AS
16598285|NCT02623881|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
16599639|NCT02614963|Placebo Comparator|Placebo group|Irritable bowel syndrome patients treated with placebo
16598250|NCT02624193|Placebo Comparator|HT Program|"Healthy Topics Program:
~The health education program Healthy Topics (HT) will serve as an attention control group. The HT program is focused on providing age-appropriate health information and education. There is minimal content overlap in the MBSR and HT programs regarding self-care and healthy eating; however, the style, structure, and content of the MBSR and HT programs are distinct. HT participants will receive no training in MBSR or meditation. Topics covered include physical activity, nutrition, managing weight, building health, personal care, understanding adolescence, tobacco, alcohol, and other drugs. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
16598253|NCT02624167|Active Comparator|NW-3509A|Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
16598254|NCT02624167|Placebo Comparator|Placebo|Patients will receive matching placebo BID
16598255|NCT02624141|Experimental|Epoetin Beta 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.
16598256|NCT02624128|Experimental|valproic acid plus cisplatin and cetuximab|
16598257|NCT02624102|Experimental|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
16598258|NCT02624102|Experimental|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
16598259|NCT02624102|Other|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
16598260|NCT02624089|Experimental|Ropivacaine Group|This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
16598261|NCT02624089|Placebo Comparator|Placebo group|This group will receive placebo (normal saline) based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered at the onset of pneuomoperitoneum during appendectomy.
16598262|NCT02624089|No Intervention|Non-enrolled group|This group will not receive either intervention (ropivicaine) or placebo (normal saline), but will have primary and secondary endpoints evaluated.
16598263|NCT02624076|Experimental|Acupuncture plus expectant management|
16598264|NCT02624076|Active Comparator|expectant management|
16598265|NCT02624063|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
16598266|NCT02624063|Experimental|Simeprevir + Sofosbuvir|Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
16598267|NCT02624050|Active Comparator|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
16598268|NCT02624050|Active Comparator|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
16598269|NCT02624037|Experimental|Individualized Dosage Precision IFX Dashboard|A clinician will select a dose and dosing frequency that is populated by a pharmacokinetic dashboard system that monitors and aims to dose patients to maintain a target trough infliximab concentration. Dosage and dosing frequency may vary from each patient.
16598270|NCT02624024||Acute chest pain or equivalent ischemic symptoms|acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI)
16598271|NCT02624011|Experimental|Physical inactivity|Study arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
16598272|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
16598273|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
16598274|NCT02623985|Experimental|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
16598275|NCT02623985|Experimental|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
16598276|NCT02623985|Experimental|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
16598277|NCT02623972|Experimental|Arm A: Eribulin > AC|"Eribulin-Administered via iv, at predetermined dosage and schedule per cycle
~Two research breast biopsies
~Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle
~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle
~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection
~Radiation Therapy
~Endocrine Therapy (if applicable)
~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
16598278|NCT02623972|Experimental|Arm B: AC > Eribulin|"Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle
~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle
~Two research breast biopsies
~Eribulin-Administered via iv, at predetermined dosage and schedule per cycle
~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection
~Radiation Therapy
~Endocrine Therapy (if applicable)
~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
16598279|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.
~After the IPC is removed, participant is called one time each month by study staff to check on their status."
16598280|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.
~After the IPC is removed, participant is called one time each month by study staff to check on their status"
16598321|NCT02623699|Experimental|Multiple Ascending Dose|Part B: Randomized multiple ascending dose
16598286|NCT02623881|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
16598287|NCT02623868|Experimental|Group 1|A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
16598288|NCT02623868|Experimental|Group 2|B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
16598289|NCT02623868|Experimental|Group 3|C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
16598290|NCT02623868|Experimental|Group 4|A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
16598291|NCT02623868|Experimental|Group 5|B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
16598292|NCT02623868|Experimental|Group 6|C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
16598293|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
16598294|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
16598295|NCT02623842|Experimental|Radiofrequency|
16598296|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
16598297|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
16598298|NCT02623816|Experimental|Sub-optimal/optimal dosing|Patients will not change sub-optimal dosing regimen of omeprazole 20 mg for 6 weeks after which they will receive optimal dosing of omeprazole for 4 weeks. Rescue antacid use is permitted. Total duration of 10 weeks.
16598299|NCT02623816|No Intervention|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 10 weeks.
16598300|NCT02623816|Experimental|Optimal dosing|Patients will be administered optimal dosing of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
16598301|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
16598302|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
16598303|NCT02623790|Experimental|Test meal (butter)|Subjects will eat one test meal containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
16598304|NCT02623790|Experimental|Test meal (cheddar cheese)|Subjects will eat one test meal containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
16598305|NCT02623790|Experimental|Test meal (cream cheese)|Subjects will eat one test meal containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
16598306|NCT02623777|Experimental|AXOS as first intervention|AXOS as first intervention
16598307|NCT02623777|Experimental|SCFA as first intervention|SCFA as first intervention
16598308|NCT02623764||MCI due to Alzheimer´s disease|Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
16598309|NCT02623764||Mild dementia due to Alzheimer´s disease|Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
16598310|NCT02623764||Mild dementia due to Lewy body disease|Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
16598311|NCT02623751|Experimental|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
16598312|NCT02623738|Placebo Comparator|Placebo ophthalmic solution|Eyedrop
16598313|NCT02623738|Experimental|DE-117 ophthalmic solution low|Eyedrop
16598314|NCT02623738|Experimental|DE-117 ophthalmic solution high|Eyedrop
16598315|NCT02623738|Active Comparator|Latanoprost ophthalmic solution 0.005%|Eyedrop
16598316|NCT02623725|Experimental|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
16598317|NCT02623725|Experimental|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
16598318|NCT02623712|Active Comparator|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
16598319|NCT02623712|Active Comparator|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
16598320|NCT02623699|Experimental|Single Ascending Dose|Part A: Randomized single ascending dose
16598323|NCT02623686|Experimental|Aroma group|"two massages delivered within a two day period
~the patient will choose the essential oils used from blend A and blend B (if no choice is made, therapist will choose blend A and B alternately). One drop of the essential oil blend will be added to 5 mls of grapeseed base oil.
~an Inhalation Patch with the same blend of oils as used in the massage will be left by the therapist for use on each of the two nights following the aromatherapy massage intervention. Its use will be explained to the patient and to the member of nursing staff. The Inhalation Patch will be applied to the patient's upper chest when it is time to sleep at approximately 11 pm and will be removed the following morning at approximately 6 am."
16598324|NCT02623686|No Intervention|Control Group|Normal Care
16598325|NCT02623673||bevacizumab plus dexamethasone 0.7mg|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
16598326|NCT02623660|Experimental|Experimental|This group will receive treatment from the ODIN1 device in conjunction with standard care and diagnostic device testing.
16598327|NCT02623660|Active Comparator|Control|This group will receive the standard care and the diagnostic device testing.
16598328|NCT02623647|Other|A single-arm, nonrandomized|stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions
16598329|NCT02623634||observation|this study measure the cuff leak volume and cuff leak ratio according to the cuff leak test with different positions and waveform,, at the same time observe the patient general condition, vital signs, oxygen saturation, cuff leak test results under different conditions and the breathing machine parameters, the diameter of the airway, the use of sedatives and hormones, after extubation stridor and intubation is happening again, the use of NPPV after extubation, patient outcomes
16598330|NCT02623608|Experimental|High fat meal|Subjects eat a high fat breakfast (reference breakfast) at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h.
16598331|NCT02623608|Experimental|High fat meal + Active Ingredient 1|"Subjects eat the same high fat breakfast with the active ingredient 1 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
16598332|NCT02623608|Experimental|High fat meal + Active Ingredient 2|"Subjects eat the same high fat breakfast with the active ingredient 2 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
16598333|NCT02623608|Experimental|High fat meal + Active Ingredient 3|"Subjects eat the same high fat breakfast with the active ingredient 3 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
16598334|NCT02623608|Experimental|High fat meal + Active Ingredient 4|"Subjects eat the same high fat breakfast with the active ingredient 4 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
16598335|NCT02623595|Experimental|SBRT+GM-CSF|Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
16598336|NCT02623582|Experimental|Cohort 1|The first 3 subjects to receive RNA CART123 cells will receive up to 3 doses of RNA CART123 cells, with no lymphodepleting chemotherapy prior to infusion.
16598337|NCT02623582|Experimental|Cohort 2|"The remaining 12 subjects of the study will receive up to six IV doses of RNA CART123 cells.
~Subjects in Cohort 2 may be given lymphodepleting chemotherapy 4 days (+/- 1 day) prior to the first CART123 cell infusion (if ALC> 500/uL).
~Lymphodepleting chemotherapy may be repeated before the fourth dose of RNA CART123 cells (if ALC> 500/uL).
~Lymphodepleting chemotherapy includes a single dose of cyclophosphamide (1g/m2) Weight used for dosing will be the weight obtained prior to the apheresis procedure Cell numbers are based on CAR+ cells with CAR expression determined by flow cytometry Based on the product release criteria, at least 20% of the total cells will be RNA CART123 cells.
~Dosing will not be changed for changes in subject weight The indicated doses are +/- 20% to account for manufacturing variability."
16598338|NCT02623569|Experimental|Ivabradine|Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR（heard rate）>80times/min of subjects.
16598339|NCT02623569|Active Comparator|Atenolol|Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR （heard rate）>80times/min of subjects.
16598340|NCT02623556|Experimental|TB subjects|"720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method.
~360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h."
16598341|NCT02623556|Experimental|non-TB subjects with lung disease and suspected TB subjects|360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
16598342|NCT02623543|Experimental|OrthoK|OrthoK lenses will be prescribed for subjects randomly and followed for 2yrs throughout wearing the lenses. There will be an enrollment appointment, dispense appointment, 1-day, 1-week, 1-month, 6-month, 12-month, and 24-month follow-ups.
16598343|NCT02623543|Placebo Comparator|Control|Subjects in the randomly assigned control will continue to wear their glasses throughout the 2yr follow-up period. There will be an enrollment appointment, 6-month, 12-month, and 24-month follow-ups.
16598559|NCT02622165|Experimental|The REWARD serious game intervention|A mobile 4-week serious game intervention will be administered.
16598344|NCT02623530|Active Comparator|Control group|Control group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), not based on the Active Learning Model for Critical Thinking (MEAPC).
16598345|NCT02623530|Experimental|Experimental group|Experimental group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), based on the Active Learning Model for Critical Thinking (MEAPC).
16598346|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
16598347|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
16598348|NCT02623504|Experimental|Equetro|200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.
16598349|NCT02623504|Placebo Comparator|Placebo|Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.
16598350|NCT02623491|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
16598351|NCT02623491|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10.
16598352|NCT02623478|Experimental|Insulin Lispro - Test Formulation|Novel formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
16598353|NCT02623478|Active Comparator|Insulin Lispro - Reference Formulation|Marketed formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
16598354|NCT02623465|Experimental|Part A:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin once in each of 3 periods
16598355|NCT02623465|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
16598356|NCT02623465|Experimental|Part B:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin with each meal for 14 days
16598357|NCT02623465|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
16598358|NCT02623452|Experimental|Part A:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin once in each of 3 periods
16598359|NCT02623452|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin once in each of 3 periods
16598360|NCT02623452|Experimental|Part B:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin with each meal for 14 days
16598361|NCT02623452|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin with each meal for 14 days
16598362|NCT02623439|Experimental|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
16598363|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Eligible eye(s) treated at study visit M01 (week 0).
~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.
~Retreatment permitted at later time points if retreatment criteria met.
~Re-treatment criteria:
~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.
~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)
~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
16598364|NCT02623426|Active Comparator|Intravitreal methotrexate 400µg in 0.1mL|"Eligible eye(s) treated at study visit M01 (week 0).
~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.
~Retreatment permitted at later time points if retreatment criteria met.
~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
16598365|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5mg in 0.05mL|"Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).
~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.
~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.
~Re-treatment permitted at later time points if re-treatment criteria met."
16598366|NCT02623413||Sites implementing contact precautions|"Centers isolating for VRE may only participate if complying with the following standards:
~Contact precautions triggered by the initial detection of VRE
~Patients discharged as a VRE-carrier must be placed in contact isolation upon readmission
~Termination of contact precautions after at least two consecutive VRE-negative consecutive fecal screening cultures
~Resumption of contact isolation on first subsequent VRE-positive culture
~Contact precautions must encompass the following measures:
~Patients: Placement in single rooms. Cohorting is only permitted, in case of unavailability of single rooms
~Staff and visitors: Wearing of gloves and gowns when entering the room.
~Patients: Wearing of gloves and gowns when leaving the room."
16598367|NCT02623413||Sites not implementing contact precautions|Only VRE colonized or infected patients with urinary or fecal incontinence or diarrhea (defined as > 3 loose bowel movements/day), must be isolated in single rooms at any time during the study.
16598368|NCT02623400||Preterm infants and their parents|Preterm infants born before 34 weeks gestational age and/or with a birth weight lower than 1500g and their parents.
16598369|NCT02623387|Active Comparator|Standard Paravertebral Block|Patients receiving a conventional paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered using anatomical landmarks
16598370|NCT02623387|Active Comparator|Ultrasound Guided Paravertebral Block|Patients receiving paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered under ultrasound guidance
16598371|NCT02623374|Experimental|SH-CBT|This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
16598372|NCT02623374|No Intervention|No Treatment-Wait Control (NTWC)|Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e. baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation). They will be offered the SHCBT intervention off trial following the final assessment (i.e. A2).
16598373|NCT02623361|Placebo Comparator|Sham|
16598374|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
16598375|NCT02623348|Experimental|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
16598376|NCT02623348|No Intervention|usual care|No intervention
16598377|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
16598378|NCT02623335|No Intervention|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
16598379|NCT02623322|Experimental|MHAA4549A 3600 milligrams (mg)|Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
16598380|NCT02623322|Experimental|MHAA4549A 8400 mg|Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
16598381|NCT02623322|Placebo Comparator|Placebo|Participants will receive single-dose placebo by IV administration.
16598382|NCT02623309|Experimental|HAPLO graft|"Conditioning regimen
~Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.
~Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.
~Prophylaxis regimen for GVHD
~F CSA and MMF (starting day +5)
~Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4
~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d."
16598383|NCT02623309|Active Comparator|MUD graft|"Conditioning regimen
~Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.
~Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.
~Prophylaxis regimen for GVHD
~CSA and MMF will be used from day -1 after UD
~Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2
~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg"
16598384|NCT02623296|Experimental|GLPG1205 and single CYP450 substrate cocktail dose|Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
16598385|NCT02623296|Placebo Comparator|Placebo and single CYP450 substrate cocktail dose|Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail
16598386|NCT02623270|Experimental|Noninvasive Ventilation|After induction of anesthesia, checking of ability to bag mask ventilating the patient, the manual bag ventilation will be replaced by a Noninvasive Ventilator, V60 (Philips)
16598387|NCT02623244||ovarian endometrioma|Women with ovarian endometrioma noted by ultrasonography.
16598388|NCT02623244||The control group|Women with age and body mass index matched and without ovarian endometrioma in ultrasonography
16598389|NCT02623231|Experimental|escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
16598390|NCT02623231|Placebo Comparator|placebo|Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
16598391|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
16598392|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
16598393|NCT02623218|Active Comparator|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
16598394|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
16598395|NCT02623218|Active Comparator|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
16598396|NCT02623205|Active Comparator|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
16598397|NCT02623205|Placebo Comparator|Placebo|Lactose pill manufactured to mimic Escitalopram pill
16598398|NCT02623192||ARDS|
16598399|NCT02623179|Active Comparator|A-Culture and Sensitivity group|Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
16598400|NCT02623179|Active Comparator|B-Diagnosis by Molecular Testing|Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
16598401|NCT02623153|Active Comparator|capecitabine and oxaliplatin|capecitabine of 1000 mg/m2, orally administered twice a day on days 1-14 and oxaliplatin at 130 mg/m2on day 1, as intravenous 2 h infusion
16598402|NCT02623153|Experimental|S1, oxaliplatin and docetaxel|S1 of 40 mg/m2, orally administered twice a day on days 1-14,oxaliplatin 130 mg/m2 and docetaxel 40 mg/m2on day 1 as intravenous
16598403|NCT02623140|Experimental|Biofreedom|Biofreedom stent treatment at index procedure
16598404|NCT02623140|Active Comparator|Orsiro|Orsiro stent treatment at index procedure
16598405|NCT02623127|Experimental|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
16598560|NCT02622165|No Intervention|Control group|School curriculum as usual
16598406|NCT02623114|Experimental|Methylphenidate|ADHD patients with methylphenidate administration Generic names include concerta, metadata and penid. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
16598407|NCT02623114|Experimental|Atomoxetine|ADHD patients with atomoxetine administration Generic names include strattera. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
16598408|NCT02623101|Active Comparator|Standard of care procedure|"Clinical suspected basal cell carcinomas, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most clinical suspicious part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. Hematoxylin/eosin stained sections of the punch biopsies will be evaluated by an experienced pathologist. Subjects will receive surgical excision according to subtype.
~When there is any doubt by reflectance confocal microscopic diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma."
16598409|NCT02623101|Experimental|Reflectance confocal microscopy (RCM)|The Vivascope 1500 and Vivascope 3000 (handheld divice) will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed on clinical suspected basal cell carcinomas, of all subtypes. When there are signs of a basal cell carcinoma imaged by RCM, subjects will receive surgical excision according to subtype. When there is any doubt by RCM diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma.
16598410|NCT02623088||PAP therapies|Patients with sleep apnea syndrome treated by CPAP after respiratory and vascular assessment and followed 5-7 years, as part of a clinical research.
16598411|NCT02623075|Experimental|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
16598412|NCT02623075|Experimental|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
16598413|NCT02623075|Active Comparator|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
16598414|NCT02623062|Active Comparator|Compound Sodium Alginate Oral Suspension sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
16598415|NCT02623062|Placebo Comparator|Matching placebo sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
16598416|NCT02623049||octogenarians patients - Apixaban|octogenarians patients who will be treated with Apixaban
16598417|NCT02623049||younger than 70 years patients - Apixaba|younger than 70 years patients who will be treated with Apixaba
16598418|NCT02623049||octogenarians patients - Rivaroxaban|octogenarians patients who will be treated with Rivaroxaban
16598419|NCT02623049||younger than 70 years patients - Rivaroxaban|younger than 70 years patients who will be treated with Rivaroxaban
16598420|NCT02623049||octogenarians patients - Dabigatran|octogenarians patients who will be treated with Dabigatran
16598421|NCT02623049||younger than 70 years patients - Dabigatran|younger than 70 years patients who will be treated with Dabigatran
16598422|NCT02623036|Active Comparator|Enalapril arm|Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.
16598423|NCT02623036|Active Comparator|Lisinopril arm|Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.
16598424|NCT02623023|Experimental|Combigan group|Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
16598425|NCT02623023|Placebo Comparator|Refresh tears|Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
16598426|NCT02623010|Experimental|Single arm|Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment
16598427|NCT02622997|Active Comparator|Refrigerated|Sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
16598428|NCT02622997|Experimental|Incubated at 25oC for 1 week|Sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
16598429|NCT02622997|Experimental|Incubated at 25oC for 2 weeks|Sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
16598430|NCT02622984|Experimental|RBIRT|Telehealth model or the remote administration of SBIRT, a short term, brief intervention and referral to treatment for alcohol abuse.
16598431|NCT02622984|Active Comparator|SBIRT|Face-to-face intervention and referral to treatment for alcohol abuse.
16598432|NCT02622971|Active Comparator|PBMT and Cryotherapy|Volunteers allocated in this group received phototherapy (PBMT - applied in six points of quadriceps) and cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
16598433|NCT02622971|Active Comparator|Cryotherapy and PBMT|Volunteers allocated in this group received cryotherapy (20 minutes in PRICE protocol) and phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
16598434|NCT02622971|Active Comparator|PBMT (active phototherapy)|Volunteers allocated in this group received active phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
16598435|NCT02622971|Placebo Comparator|PBMT (placebo phototherapy)|Volunteers allocated in this group received placebo phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. The placebo PBMT device was identical to the active devices and displayed the same settings and emitted the same sound regardless of the comparator.
16598436|NCT02622971|Active Comparator|Cryotherapy|Volunteers allocated in this group cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. Two flexible ice packs filled with ice cubes and water (with a volume of 1.15 liters each) were used in order to cover the entire quadriceps. Rubber belts were used to apply compression and to affix the packs tightly to the volunteers' quadriceps.
16598437|NCT02622958|Experimental|PH94B Nasal Spray|Water based solution of 16 ppm PH94B. Each nasal spray delivers .8 micrograms PH94B in 50 microliters
16598438|NCT02622958|Placebo Comparator|Placebo Nasal Spray|Water based solution, each nasal spray delivers 50 microliters of droplets.
16598439|NCT02622945|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
16598440|NCT02622945|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
16598441|NCT02622932|Experimental|Anlotinib and 14C-labeled Anlotinib|each participant will be given a single dose of 14C-labeled gilteritinib.
16598442|NCT02622906|Placebo Comparator|Placebo|1 injection per month during 6 months of the placebo product
16598443|NCT02622906|Active Comparator|Pasireotide|1 injection per month during 6 months of the Pasireotide LP (60mg/injection)
16598444|NCT02622893|Active Comparator|Transperitoneal laparoscopic nephrectomy|Patients in this group underwent transperitoneal laparoscopic nephrectomy in 45-60º modified flank position after receiving epidural catheter in the sitting position before the surgery.
16598445|NCT02622893|Active Comparator|Retroperitoneal laparoscopic nephrectomy|Patients in this group underwent retroperitoneal laparoscopic nephrectomy in lateral decubitis position after receiving epidural catheter in the sitting position before the surgery.
16598446|NCT02622880|Active Comparator|: IMPACT|along 10 days before surgery
16598447|NCT02622880|Experimental|immunomodulatory supplement|along 10 days before surgery
16598448|NCT02622867|Experimental|Lactobacillus plantarum 3547|1 capsule/daily during 12 weeks with Lactobacillus plantarum 3547 (10x109 cfu/d). The capsule contains 77 mg probiotic Lp3547 and 390 mg maltodextrin
16598449|NCT02622867|Placebo Comparator|Maltodextrin|1 daily capsule of maltodextrin (425 mg) during 12 weeks
16598450|NCT02622854|Experimental|plasma exchange|plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides <=10 mmol/l
16598451|NCT02622854|Active Comparator|conservative treatment|infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
16598452|NCT02622841|Experimental|BLEND|Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.
16598453|NCT02622828|Other|Behavioural|Participant-identified community based activity
16598454|NCT02622815||Healthy blood donors|10,000 highly controlled blood donors in the age range 30-70 years
16598455|NCT02622815||Moli-sani subjects|A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).
16598456|NCT02622815||Cancer patients|4,000 Patients with breast, lung, and gastrointestinal tumors.
16598457|NCT02622802|Experimental|ex-vivo placenta perfusion|ex vivo placenta perfusion study with exposure to paracetamol, erythromycin and azithromycin
16598458|NCT02622789||Controls|Age-matched Healthy Controls
16598459|NCT02622789||General Exercises|Low Back Pain Participants Receiving General Exercises
16598460|NCT02622789||Pilates Exercises|Low Back Pain Participants Receiving Pilates Exercises
16598461|NCT02622776|Other|Vaginal DNA Collection|Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.
16598462|NCT02622763|Experimental|10 millions dose|a total of 10 millions tolerogenic dendritic cells
16598463|NCT02622763|Experimental|100 millions dose|a total of 100 millions tolerogenic dendritic cells
16598464|NCT02622750|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
16598465|NCT02622750|Active Comparator|four-branched Dacron graft|"A four-branched Dacron graft (Boston Scientific Inc, Boston, MA) and a stent graft (MicroPort Medical Co Ltd, Shanghai, China) were used in total arch replacement combined with stented elephant trunk (SET) implantation.The SET was inserted into the true lumen of the descending aorta.The proximal edge of the residual aorta was trimmed to match the proximal end of the stent graft.The anastomosis between the four-branched prosthetic graft and the distal aorta containing the intraluminal stented graft was carried out using open aortic technique."
16598466|NCT02622737|Experimental|Functional Training|Functional exercise training program
16598467|NCT02622737|Experimental|Stationary Bike|Stationary bike training program
16598468|NCT02622737|Experimental|Exergaming|Virtual Reality Exposure Therapy
16598469|NCT02622724|Experimental|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
16598470|NCT02622724|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
16598471|NCT02622711|Experimental|DI Dietary Intervention|Individualized dietary counselling to reduce body weight
16598472|NCT02622711|Experimental|PAI Physical Activity Intervention|Individualized physical activity counseling to reduce body weight
16598473|NCT02622711|Experimental|PADI Physical Activity+Diet Intervention|Individualized dietary and physical activity counseling to reduce body weight
16598474|NCT02622711|Experimental|LII Less Intensive Intervention|Materials and guidelines available to general public
16598475|NCT02622698|Placebo Comparator|Control|The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
16598476|NCT02622698|Experimental|Treatment|Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily. No other modifications were made to the patient's diet. Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
16598477|NCT02622685|Experimental|DWP10292|"Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration
~Arms: DWP10292"
16598478|NCT02622685|Placebo Comparator|DWP10292 Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations
~Arms: Placebo"
16598479|NCT02622685|Experimental|Ursodeoxycholic acid (UDCA)|"Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations
~Arms: Ursodeoxycholic acid (UDCA)"
16598480|NCT02622685|Placebo Comparator|Ursodeoxycholic acid (UDCA) Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations
~Arms: Placebo"
16598481|NCT02622672|Experimental|Placebo|glycerin.soy-lecithin, and water
16598482|NCT02622672|Experimental|Supplement|water-soluble Ubiquinol 100 mg/d
16598483|NCT02622659|Experimental|Fuganlin Oral Liquid|"Fuganlin Oral Liquid:oral
~less than 1 years old: 5mL each time and three times a day
~1~3 years old: 10mL each time and three times a day
~4~6 years old: 10mL each time and four times a day
~7~12 years old: 10mL each time and five times a day
~Xiaoer Jiebiao Oral Liquid placebo:oral
~1~2 years old: 5mL each time and twice a day
~3~5 years old: 5mL each time and three times a day
~6~14 years old: 10mL each time and twice a day"
16598484|NCT02622659|Active Comparator|Xiaoer Jiebiao Oral Liquid|"Xiaoer Jiebiao Oral Liquid:oral
~1~2 years old: 5mL each time and twice a day
~3~5 years old: 5mL each time and three times a day
~6~14 years old: 10mL each time and twice a day
~Fuganlin Oral Liquid placebo:oral
~less than 1 years old: 5mL each time and three times a day
~1~3 years old: 10mL each time and three times a day
~4~6 years old: 10mL each time and four times a day
~7~12 years old: 10mL each time and five times a day"
16598485|NCT02622646||Well controlled patients|Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
16598486|NCT02622646||Poor controlled patients|Patients with poor disease control, based on the international guidelines: AJBR>2, ABR>2 for severe BE or ABR >5 for non-severe BE
16598487|NCT02622633|Experimental|Stimulation|One week after implantation of the device, participants randomized in this arm will receive continuous magnetic stimulation of high frequency (50Hz) with epidural electrode for 12 weeks. And then, the epidural electrode will be turned off for more 12 weeks in a crossover fashion.
16598488|NCT02622633|Sham Comparator|Sham Stimulation|One week after implantation of the device, participants randomized in this arm will receive sham stimulation for 12 weeks and then continuous magnetic stimulation with epidural electrode of high frequency (50Hz) stimulation for more 12 weeks.
16598489|NCT02622620||Patients with glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
16598490|NCT02622607|Experimental|ZOL|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 months for 12 months.
16598491|NCT02622607|No Intervention|Control|No investigational treatment
16598492|NCT02622594|Active Comparator|1|Treatment 1 will include microneedling performed prior to ALA application to their right face and ALA application only to the left face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
16598493|NCT02622594|Active Comparator|2|Treatment 2 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
16598494|NCT02622594|Active Comparator|3|Treatment 3 will include microneedling performed prior to ALA application to their right face and ALA application only to the left side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
16598495|NCT02622594|Active Comparator|4|Treatment 4 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
16598496|NCT02622581||NSCLC, Non-squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.
~3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)"
16598497|NCT02622581||NSCLC, Squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.
~1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)"
16598498|NCT02622581||NSCLC, Non-squamous cell carcinoma (not tested)|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.
~Not tested for molecular alterations (CRISP satellite untested patients stage IIIB/IIIC/IV).)."
16598499|NCT02622581||NSCLC, Stage II/III|800 patients with NSCLC stage II, or stage IIIA, or with NSCLC stage IIIB/C if they are eligible for curative surgery and/or radiochemotherapy
16598500|NCT02622581||Small cell lung cancer (SCLC)|Up to 1200 patients with SCLC (limited stage (LD) or extensive stage (ED)) if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, or are receiving best supportive care
16598581|NCT02622035|Experimental|1b|high visual perception load high interactive
16598582|NCT02622035|Experimental|2|Gain frame; Fear
16598583|NCT02622035|Experimental|2b|high visual perceptual load
16598584|NCT02622035|Experimental|3|Loss frame; Anger
16598501|NCT02622568|Active Comparator|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
16598502|NCT02622568|Experimental|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
16598503|NCT02622555||Mirabegron treatment|Women with overactive bladder syndrome eligible for Mirabegron treatment
16598504|NCT02622542|Active Comparator|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
16598505|NCT02622542|Experimental|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
16598506|NCT02622529||Screening through Questionnaires|All of the patients within this single existent Arm will receive the questionnaires.
16598507|NCT02622516|Active Comparator|Intervention Group (IG)|Participants in the intervention group subjects (IG) will receive physiotherapy treatment in vestibular rehabilitation based on multisensory exercises consisting of the group of therapeutic proposals that stimulation of the vestibular, proprioceptive and visual associated with manual therapy treatment proposed by the techniques cervical global pompage and classic massage therapy on neck and shoulder girdle .
16598508|NCT02622516|Experimental|Control Group (CG)|Participants in the control group subjects (CG) will receive physiotherapy treatment in vestibular rehabilitation based on Cawthorne and Cooksey Exercises, consisting of eye movements in different directions, slowly and quickly; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
16598509|NCT02622503||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.
16598510|NCT02622490|Active Comparator|Low carb. one meal|Intervention: One meal of 750 kcal with 20 % of energy content from carbohydrates
16598511|NCT02622490|Active Comparator|Low Carb. 5 small meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 20 % of energy content from carbohydrates.
16598512|NCT02622490|Active Comparator|High carb. one meal|Intervention: One meal of 750 kcal with 50 % of energy content from carbohydrates
16598513|NCT02622490|Experimental|High carb. 5 meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 50 % of energy content from carbohydrates.
16598514|NCT02622477||Participants with idiopathic pulmonary fibrosis|Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.
16598515|NCT02622464|Experimental|micro injection of SVF in vocal cords|micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords
16598516|NCT02622451|Other|Youth Behavioral Intervention|Teen Intervene
16598517|NCT02622451|Other|Parent Education|Everyday Parenting
16598518|NCT02622438|Other|Course and follow up of patients affected by FSHD|
16598519|NCT02622425|Active Comparator|PD01|Carotenoid-producing Bacillus strain PD01
16598520|NCT02622425|Placebo Comparator|Placebo|Maltodextrin
16598521|NCT02622412|Experimental|Intervention Group|Patients randomised to the intervention group will get immediate access to the Multi-professional breathlessness service (MBS).
16598522|NCT02622412|Other|Control Group|Patients randomised to the control group will get delayed MBS intervention. They will receive standard care and get access to the service after a waiting time of eight weeks.
16598523|NCT02622399|Experimental|Project NOW|Participants in the intervention arm receive access to free mobile communications and a web-based informational platform supported by txtwire.
16598524|NCT02622399|No Intervention|Control|Participants in the control arm do not receive access to the txtwire platform.
16598525|NCT02622386|Experimental|Riboflavin|Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
16598526|NCT02622386|Placebo Comparator|Placebo|Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
16598527|NCT02622373||Birth Between 23-32 Weeks Gestation|Babies born between 23-32 weeks of gestational age will have their body composition determined using PEA POD Infant Body Composition System at 34 weeks, 36 weeks and 40 weeks of corrected age.
16598528|NCT02622373||Birth Between 34-36 Weeks Gestation|Babies born at 34 weeks and 36 weeks of gestational age will have their body composition measured using PEA POD Infant Body Composition System as soon as they are off parenteral nutrition and receiving full enteral nutrition.
16598529|NCT02622373||Birth at Term|Body composition will be measured using PEA POD Infant Body Composition System in this group will be obtained prior to discharge.
16598530|NCT02622360||Dyslexia|Individuals with confirmed dyslexia.
16598531|NCT02622360||Control|Healthy control subjects.
16598532|NCT02622334|Experimental|Part A|Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days.
16598533|NCT02622334|Experimental|Part B|Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days.
16598585|NCT02622035|Experimental|3b|low visual preceptual load
16598586|NCT02622035|Experimental|4|Loss frame; Fear
16599640|NCT02614950|Experimental|Treatment interuption|
16598534|NCT02622321|Experimental|Arm A: 1.5 mg/kg Emicizumab QW|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
16598535|NCT02622321|Active Comparator|Arm B (Control): No Prophylaxis, Then Emicizumab|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
16598536|NCT02622321|Experimental|Arm C: 1.5 mg/kg Emicizumab QW|Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
16598537|NCT02622321|Experimental|Arm D: 1.5 mg/kg Emicizumab QW|Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
16598538|NCT02622308|Experimental|single-case design|"The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:
~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design)."
16598539|NCT02622295|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session high-frequency active-resisted stance or single-session low-frequency active-resisted stance
16598540|NCT02622295|Experimental|3 year Training Study|Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to 3 years of high-frequency active-resisted stance training or 3 years of low-frequency active-resisted stance training
16598541|NCT02622282|Experimental|Experimental Group|Participants will receive text messages and telephone calls during the length of their participation. Participants will receive a handout with information on PAD and physical activity.
16598542|NCT02622282|Active Comparator|Control Group|Participants will receive a handout with information on PAD and physical activity.
16598543|NCT02622269|Experimental|Patient-regulated compression|Patient-regulated compression device
16598544|NCT02622269|Active Comparator|Standard compression|Standard compression device
16598545|NCT02622256|Experimental|Health System: HTN Intervention|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys.
16598546|NCT02622256|No Intervention|Health System: HTN Control, survey only|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys. Participants in this arm will be exposed to daily messages about heart health and asked to tweet about health.
16598547|NCT02622243|Experimental|tiotropium|2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
16598548|NCT02622243|Experimental|glycopyrronium|1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge
16598549|NCT02622230|Experimental|Mianhuahua Flavonoids Tablets|Mianhuahua Flavonoids Tablets, oral administration
16598550|NCT02622230|Placebo Comparator|Placebo|Placebo, oral administration
16598551|NCT02622217|Experimental|Sleep deprived|Participants undergo a simulation session after an on call night
16598552|NCT02622217|No Intervention|Rested|Participants undergo a simulation session after a night of normal sleep at home
16598553|NCT02622204||Corrective osteotomy|patients with knee osteoarthritis undergoing corrective osteotomy
16598554|NCT02622191|Experimental|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
16598555|NCT02622191|Experimental|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
16598556|NCT02622178|Experimental|Healthy Subjects|42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
16598557|NCT02622178|Experimental|Glaucoma Suspects|45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
16598558|NCT02622178|Experimental|Glaucoma Patients|49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
16599694|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
16598561|NCT02622152|Active Comparator|Right lateral position group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for 30 minutes period on the supine position Repositioning the patients for 30 minutes period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
16598562|NCT02622152|Active Comparator|Routine hospital care group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for two-hours period on supine position Repositioning the patients for two-hours period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
16598563|NCT02622139|Experimental|Multispectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography (MSOT) for the evaluation of disease activity in inflammatory bowel diseases (IBD)
16598564|NCT02622126|Active Comparator|Normotensive pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).
~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
16598565|NCT02622126|Active Comparator|Mild preeclampsia pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).
~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
16598566|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
16598567|NCT02622100||Bioresorbable Vascular Scaffold|
16598568|NCT02622087|Experimental|Hormonal contraceptive|Women who receive one-session-treatment while they are on the hormonal contraceptive pill
16598569|NCT02622087|Experimental|Naturally cycling- high estradiol|Naturally cycling women who receive one-session-treatment during a period of high estradiol
16598570|NCT02622087|Experimental|Naturally cycling-low estradiol|Naturally cycling women who receive one-session-treatment during a period of low estradiol
16598571|NCT02622074|Experimental|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via intravenous (IV) infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
16598572|NCT02622074|Experimental|Cohort B: KNpCb (Regimen 1) / KAC|Participants first receive KNpCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
16598573|NCT02622074|Experimental|Cohort C: KNpCb (Regimen 2) / KAC|Participants first receive KNpCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
16598574|NCT02622074|Experimental|Cohort D: KNpCb (Regimen 3) / KAC|Participants first receive KNpCb Regimen 3 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
16598575|NCT02622074|Experimental|Cohort E: KTCb (Regimen 1) / KAC|Participants first receive KTCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
16598576|NCT02622074|Experimental|Cohort F: KTCb (Regimen 2) / KAC|Participants first receive KTCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
16598577|NCT02622061||PCD Subjects|Participants 5 and older with PCD.
16598578|NCT02622061||Healthy Subjects|Participants 5 and older without any pulmonary disease.
16598579|NCT02622048|Experimental|Stage 2 Parents experiencing psychosis|Parents all receive the self-directed Triple P Positive Parenting Programme
16598580|NCT02622035|Experimental|1|Gain frame; Anger
16598587|NCT02622022|Active Comparator|Morphine|18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily
16598588|NCT02622022|Placebo Comparator|Placebo|18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily
16598589|NCT02622009||COPD I|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE I
16598590|NCT02622009||COPD II|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE II
16598591|NCT02622009||COPD III|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE III
16598592|NCT02622009||NONSMOKERS|BRONCHOSCOPIC PROCEDURE IN NONSMOKERS
16598593|NCT02622009||CURRENT OR EXSMOKERS|BRONCHOSCOPIC PROCEDURE IN CURRENT OR EXSMOKERS
16598594|NCT02621996|Experimental|Hammock group|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
16598595|NCT02621996|Active Comparator|control group|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
16598596|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
16598597|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
16598598|NCT02621970|Experimental|IC plus CC plus IMRT plus AC|Induction chemotherapy: TP -- Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 2 cycles; Concurrent chemotherapy: PX -- Cisplatin 25 mg/m2, D1-3 and Xeloda 2000mg/m2, D1-14, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy; Adjuvant chemotherapy: Xeloda 2500mg/m2, D1-14, every 3 weeks for 2 cycles
16598599|NCT02621970|Active Comparator|CC plus IMRT|Concurrent chemotherapy: Cisplatin 100 mg/m2, D1, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
16598600|NCT02621957|Experimental|Female Healthy Volunteers|Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4). During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8. Pravastatin will be co-administered on Day 7.
16598601|NCT02621944|Experimental|Participants 1-10|"This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.
~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.
~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
16598602|NCT02621944|Experimental|Participants 11-20|"This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.
~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.
~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
16598603|NCT02621944|Experimental|Participants 21-30|"This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.
~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.
~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
16598604|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
16598605|NCT02621931|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
16598606|NCT02621931|Experimental|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
16598607|NCT02621918|Experimental|Progressive Resistance Training (PRT)|For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
16598737|NCT02620956|Active Comparator|obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
16598608|NCT02621918|Experimental|Aerobic Exercise (AER)|Aerobic exercise was conducted with a mini ergometer cycling (Mini Bike E5 Acte Sports) attached to the patient chair. Patients exercised 50-60 minutes of continuous workout with increased load. The workload was adjusted when necessary, according to the perceived effort made by the patient. The scale of perceived exertion, Borg scale (Borg and Noble , 1974), was used in accordance with the proposed By The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995), which defines the values of perceived exertion between 12 and 16.
16598609|NCT02621918|Placebo Comparator|NEPLA|The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
16598610|NCT02621905|Active Comparator|Sporanox|100 mg
16598611|NCT02621905|Experimental|Lozanoc|50 mg
16598612|NCT02621892|Experimental|50mg BID|Tenapanor
16598613|NCT02621892|Placebo Comparator|Placebo|Placebo
16598614|NCT02621879|Experimental|Bilateral Gluteal Advancement Flap|Advancement of both gluteal muscles to the midline after release incisions in their fascia.
16598615|NCT02621866|Experimental|Active|UVA irradiation.
16598616|NCT02621866|Sham Comparator|Sham UVA irradiation|
16598617|NCT02621853|Other|MRI+RAMAN|Patients will undergo an MRI for assessment of the fat content of the liver. Then during surgery, their livers will be illuminated (for a few seconds) by Raman spectroscope (the device in question) to see if MRI findings correlate well with Raman spectroscopy findings.
16598618|NCT02621840|Experimental|Intervention|Patients in the intervention group will be mandated to complete the PAT with Dr. Koka. After scheduling the surgery with the surgical coordinator, intervention patients will be required to go directly to Dr. Koka's office, to complete all necessary pre-operative steps.
16598619|NCT02621840|No Intervention|Usual Care|Patients in the usual care group will be treated with the standard protocol that is currently utilized in the Wills Eye Hospital Cataract and Primary Eye Care (CPEC) Service. After scheduling the surgery with the surgical coordinator, the patient will be given pre-admission testing (PAT) paperwork to be completed. The patient schedules the PAT on his or her own with the primary care physician.The patient will be given the information for Dr. Koka's cardiology office if he or she has any problem getting the PAT done.
16598620|NCT02621827|Experimental|Non-pregnant, non-lactating (NPNL)|"NPNL women are age and parity matched to pregnant women. Each NPNL women is studied twice, approximately 3 months apart.
~At each study period the participant receives (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3."
16598621|NCT02621827|Experimental|Pregnant/Lactating|Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
16598622|NCT02621814|Experimental|Experimental 1|Formula feeding
16598623|NCT02621814|Experimental|Experimental 2|Formula feeding
16598624|NCT02621801|Experimental|Intervention|Stress Management and Resiliency Training for Residents (SMART-R)
16598625|NCT02621801|Active Comparator|Waitlist Control|The control group will receive the same intervention (SMART-R) after the experimental group.
16598626|NCT02621788|Experimental|First Year Residents|Stress Management and Resiliency Training for Residents (SMART-R) delivered to first year residents in the departments of medicine and psychiatry at Massachusetts General Hospital
16598627|NCT02621775|Experimental|Computer-based stress management program|Immediate e-learning condition with minimal contact (n =40),
16598628|NCT02621775|Experimental|Stress management in face-to-face|Immediate treatment in face - to- face (n = 40)
16598629|NCT02621775|Other|Waiting list|Waiting list (n=40)
16598630|NCT02621762|Experimental|Mg first|Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
16598631|NCT02621762|Experimental|Bicarbonate first|Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
16598632|NCT02621749|Active Comparator|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
16598633|NCT02621749|Active Comparator|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
16598634|NCT02621710||Minimally invasive hysterectomy|Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition
16598635|NCT02621710||Abdominal hysterectomy|Patients undergoing scheduled abdominal hysterectomy for benign condition
16598636|NCT02621697|Experimental|Cognitive motor training|Evaluate the effectiveness of a 12-week training based on dual-task (motor and cognitive) in institutionalized elderly.
16598637|NCT02621697|Active Comparator|Control Group|kinesiotherapeutic conventional treatment
16598638|NCT02621684|Experimental|Arm 1: Aerobics|"Complete baseline questionnaires either online or on paper
~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline
~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.
~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.
~Require physical evaluation and orientation to the WellAware gym
~12 week walking program at the WellAware Center
~required to check in with gym staff to check attendance
~advised to walk at own pace for 3 days per week
~15 minutes per day for the first 2 weeks
~30 minutes per day for the next 2 weeks
~50 minutes or more for remaining weeks"
16598639|NCT02621684|Experimental|Arm 2: Resistance training|"Complete baseline questionnaires either online or on paper
~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline
~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.
~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.
~Require physical evaluation and orientation to the WellAware gym
~12 week weight lifting program at WellAware Center
~exercise physiologists will work with each patient to develop a custom routine
~exercise load will start at 60% of one-repetition maximum and progress from 8 to 12 repetitions
~2-4 sets of repetition exercises will be performed to target upper & lower muscle groups
~resistance load will be added by 5 pounds when patients can complete more than 12 repetitions"
16598738|NCT02620956|Experimental|asthmatic obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
16598640|NCT02621684|Active Comparator|Arm 3: Usual care|"Complete baseline questionnaires either online or on paper
~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline
~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.
~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations."
16598641|NCT02621671|Experimental|Arm 1: Cognitive Interviews|"Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions.
~Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease.
~The entire visit will take no more than 90 minutes with no follow-up.
~The first 10-20 participants will be randomized to this arm."
16598642|NCT02621671|Experimental|Arm 2: Experimental survey|"Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions.
~After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool.
~Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned.
~The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity."
16598643|NCT02621658|Active Comparator|Clear Liquid Diet|Clear Liquid Diet the day before colonoscopy.
16598644|NCT02621658|Experimental|Full Liquid Diet|Full Liquid Diet the day before colonoscopy.
16598645|NCT02621645|Experimental|Early intervention|Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
16598646|NCT02621645|Active Comparator|Late intervention|Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
16598647|NCT02621632|Other|Healthy subjects and patients|To done a novel compression system. 20 healthy subjects and 20 patients done a novel compression system termed Socknleg and a compression class III stocking as a comparator.The Socknleg compression system was developed by the investigator and produced by Sigvaris AG, St. Gallen, Switzerland.
16598648|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
16598649|NCT02621619|Placebo Comparator|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
16598650|NCT02621606|Experimental|Part 1, Healthy Participants|Healthy participants receive a single intravenous (IV) dose of ~370 megabecquerel (MBq) [11C]MK-6884 in Part 1 of the study.
16598651|NCT02621606|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants receive two separate IV doses of ~370 MBq [11C]MK-6884 in Part 2 of the study. Administration of the two doses is separated by at least 3 hours.
16598652|NCT02621606|Experimental|Part 3, Participants with AD|Participants with AD receive a single IV dose of ~370 MBq [11C]MK-6884 in Part 3 of the study.
16598653|NCT02621593|Experimental|Treatment of dry eye secondary to MGD|Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
16598654|NCT02621580|No Intervention|Control|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and do not require laser or anti-VEGF treatment in at least one eye.
16598655|NCT02621580|Experimental|Treatment: Pan-Retinal Photocoagulation|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and require PRP laser in at least one eye.
16598656|NCT02621567|Experimental|Bright Light Therapy Group|Participants in this group will receive bright light therapy lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
16598657|NCT02621567|Placebo Comparator|Dim Light Group|Participants in this group will receive modified dim lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
16598658|NCT02621554|Experimental|resveratrol supplementation|Dietary Supplement: Resveratrol
16598659|NCT02621554|Placebo Comparator|placebo supplementation|Dietary Supplement: Placebo
16598660|NCT02621541|Experimental|Preoperative diagnosis|Preoperative diagnosis
16598661|NCT02621528|Other|CeraFlex occluder|The Lifetech CeraFlex™ study is a triple-arm study.
16598662|NCT02621515|Experimental|Nivolumab|All patients in this trial will receive treatment with nivolumab for 24 months. Treatment will be discontinued if confirmed disease progression has been demonstrated, if unacceptable toxicity or intercurrent illness prevents further treatment, and when informed consent is withdrawn. After discontinuation of treatment, follow-up will start. Duration of follow-up depends on survival of patients, with a maximum of 24 months. Therefore the end of this study is determined as 24 months after the last patient in this trial has started follow-up, has died, withdraws consent or is lost to follow-up for a different reason
16598663|NCT02621502|Experimental|Quinoa variety 1|1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
16598664|NCT02621502|Experimental|Quinoa variety 2|1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
16598665|NCT02621502|Experimental|Quinoa variety 3|1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
16598698|NCT02621255|Active Comparator|General anesthesia|General Anesthesia: Effect of general anesthesia will compare with regional anesthesia without use of nonsteroid antiinflammatory drug usage. Propofol 2mg/kg and rocuronium will be administered to patients for anesthesia induction. Anesthesia maintenance will ensure with sevoflurane %2 and N2O/O2 %50/50 mixture.
16598666|NCT02621502|Experimental|Quinoa variety 4|1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
16598667|NCT02621502|Active Comparator|Anhydrous Glucose|1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
16598668|NCT02621489|Experimental|Bydureon 2 mg Once Weekly|Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.
16598669|NCT02621489|Active Comparator|Humulin kwickpen|Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
16598670|NCT02621476|Experimental|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
16598671|NCT02621476|Experimental|Usual care|Usual care
16598672|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
16598673|NCT02621450|Placebo Comparator|standart dialysate|dialysate sodium 140 mEq/L
16598674|NCT02621450|Other|low sodium dialysate|dialysate sodium will be reduced from 140 mEq/L to 137 mEq/L
16598675|NCT02621437|Experimental|Intervention group (osteopathy)|Patients will have three sessions of osteopathy and 6 phone questionnaires.
16598676|NCT02621437|Other|control group|Patients will have 6 phone questionnaires.
16598677|NCT02621424|Experimental|RTMS|repetitive transcranial magnetic stimulation
16598678|NCT02621424|Sham Comparator|sham|sham noise to block the sound of treatment
16598679|NCT02621411||Substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are found current use of the certain substance(s).
16598680|NCT02621411||Non-substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are not found use of any substance.
16598681|NCT02621398|Experimental|Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients undergo 3D CRT or IMRT QD 5 days a week for 6 weeks. Beginning 2-6 weeks after, 2 weeks before the end, or at the start of chemotherapy and radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
16598682|NCT02621385|Experimental|Tradipitant|One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16
16598683|NCT02621359|Experimental|Quadruple therapy|Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
16598684|NCT02621346|Experimental|Imagery Group|The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
16598685|NCT02621346|Active Comparator|Maintenance Group|The maintenance group will continue to perform the leg press three times per week at 1/3rd of final strength assessment. This is the percentage of intensity recommended to maintain muscle mass and strength gains by the American College of Sports Medicine.
16598686|NCT02621346|Active Comparator|Control Group|Control group will come in 3 times per week for 20 minutes and complete 3 sets of 8-12 of a bicep curl 1/3 of predicted 1 RM
16598687|NCT02621333|Experimental|CIK combined chemotherapy group|autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.
16598688|NCT02621333|Active Comparator|chemotherapy group|platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.
16598689|NCT02621320|Experimental|Vitamin D|alcohol-based (Ethanol 65%) Vitamin D3 (Vi-De 3®. WILD) solution 6000IU per day.
16598690|NCT02621320|Placebo Comparator|Placebo|Same alcohol-based solution (Ethanol 65%) as intervention product but without cholecalciferol
16598691|NCT02621307|Experimental|Salba|50g glucose 25g ground Salba (Salba Corporation Ltd, Buenos Aires, Argentina) 200ml water
16598692|NCT02621307|Experimental|Flax|50g glucose 31g ground Flax (Bob's Red Mill Natural Raw Whole Flaxseed) 200ml water
16598693|NCT02621307|Placebo Comparator|Control|50g glucose 200ml water
16598694|NCT02621294|Experimental|Measuring protein requirement|Measuring protein requirement of athletes by feeding different amount of protein in the form of amino acid mixture and measuring their oxidation through expired CO2
16598695|NCT02621281|Active Comparator|cold storage|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
16598696|NCT02621281|Active Comparator|Kidney Transporter machines|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
16598697|NCT02621268|Experimental|Indocyanine Green|Dosage calculated by weight of individual, 5mg/kg.
16598739|NCT02620943||Exposed Group|Pregnant mothers reporting inadequate (<4) dietary diversity during pregnancy
16598699|NCT02621255|Active Comparator|bupivacaine|Regional Anesthesia: Effect of regional anesthesia will compare with general anesthesia without use of nonsteroid antiinflammatory drug usage. Combined epidural-spinal anesthesia will be performed to patients. %5 bupivacain and 20µg fentanyl will apply for spinal anesthesia. Anesthesia maintenance will ensure with bupivacain.
16598700|NCT02621242|Other|Cohort|All subjects will undergo all procedures
16598701|NCT02621190|No Intervention|A|patients without CTCs or AR-V7 negative CTCs are treated according to their physician's discretion
16598702|NCT02621190|Experimental|B|patients with AR-V7 positive CTCs are treated with cabazitaxel 25mg/m2 q3w
16598703|NCT02621177|Experimental|NBP607|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
16598704|NCT02621177|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
16598705|NCT02621164|Experimental|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
16598706|NCT02621164|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
16598707|NCT02621151|Experimental|Pembrolizumab, Gemcitabine, and RT|"Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)
~Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)
~External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)
~Gemcitabine 27 mg/m^2 IV twice weekly for 4 weeks concurrent with EBRT
~Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
16598708|NCT02621138||cerebral palsy|Age 6-12 years Gross Motor Function Classification System I-II
16598709|NCT02621138||control|Age 6-12 years
16598710|NCT02621125|Experimental|Fertilix|Fertilix supplementation
16598711|NCT02621125|Placebo Comparator|Placebo|Placebo
16598712|NCT02621112|Experimental|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
16598713|NCT02621112|Active Comparator|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
16598714|NCT02621112|Active Comparator|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
16598715|NCT02621086|Experimental|Level 1|10g of Cellodextrin
16598716|NCT02621086|Experimental|Level 2|20g of Cellodextrin
16598717|NCT02621086|Experimental|Level 3|30g of Cellodextrin
16598718|NCT02621086|Experimental|Level 4|50g of Cellodextrin
16598719|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
16598720|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
16598721|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
16598722|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
16598723|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
16598724|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
16598725|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
16598726|NCT02621034|Experimental|Control|K-file hand instrumentation
16598727|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
16598728|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
16598732|NCT02621008|Experimental|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
16598733|NCT02620995|Experimental|hypertensive patients|Hypertensive patients will receive a single oral dose of sildenafil citrate (100 mg) - acute protocol - and a chronic 30-day treatment with sildenafil citrate (50 mg twice daily) - chronic protocol. Penile and systemic microvascular function will be evaluated before and one hour after acute sildenafil administration and in the end of each treatment period.
16598734|NCT02620995|Sham Comparator|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
16598735|NCT02620982|Experimental|ARIES Application|Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
16598736|NCT02620969||Patients on haemodialysis|During a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
16598740|NCT02620943||Unexposed group|Pregnant mothers reporting adequate (>=4) dietary diversity during pregnancy
16598916|NCT02619734|Experimental|Stem Cell Injection|Intramuscular implantation of Autologous bone marrow-derived mononuclear cells
16598741|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
16598742|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
16598743|NCT02620891|Active Comparator|experimental group|Using helium oxygen mixture
16598744|NCT02620891|No Intervention|matched group|Using air oxygen mixture
16598745|NCT02620878|Experimental|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.
~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
16598746|NCT02620878|Active Comparator|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).
~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
16598747|NCT02620865|Experimental|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
16598748|NCT02620852|Active Comparator|Annual Arm|Women in this arm will receive Athena standard of care mammography screening, including annual mammograms. They will complete a health questionnaire and receive screening advice based on a basic risk assessment.
16598749|NCT02620852|Experimental|Risk-Based Arm|Women in this arm will receive risk-based screening, where risk is calculated based on a model including personal history, family history, and genetic testing. All women in the risk-based arm complete a health questionnaire, provide a saliva sample for genetic testing, and receive screening advice based on a comprehensive risk assessment. Women in this arm will be tested for a panel of 9 genes related to breast cancer risk as well as a panel of SNPs, which can further modify risk. Women will be assigned a screening start date, screening stop date, and screening frequency.
16598750|NCT02620839|Experimental|Cohort 1A|Alpelisib: 200 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
16598751|NCT02620839|Experimental|Cohort 2A|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
16598752|NCT02620839|Experimental|Cohort 2B|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
16598753|NCT02620839|Experimental|Cohort 3A|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
16598754|NCT02620839|Experimental|Cohort 3B|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
16598755|NCT02620839|Experimental|Cohort 4A|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
16598756|NCT02620839|Experimental|Cohort 4B|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
16598757|NCT02620826|Experimental|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
16598758|NCT02620826|Active Comparator|Pulpotomy|Primary molars treated with MTA pulpotomy.
16598759|NCT02620813|No Intervention|No Acne|Healthy subjects without acne between the ages of 15-45
16598760|NCT02620813|Experimental|Acne Subjects on Topical Tretinoin Treatment|Subjects with acne before and after topical retinoid therapy
16598761|NCT02620813|Experimental|Acne Subjects on Systemic Isotretinoin Treatment|Subjects with acne before and after isotretinoin therapy
16598762|NCT02620800|Experimental|FABLOx|5 fluorouracil (5-FU ) (180 mg/m^2/day for 14 days), by continuous intravenous infusion (CIVI) via ambulatory pump, nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15, bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15, calcium leucovorin (20 mg/m^2) IV bolus on Days 1, 8, 15, and oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15. First bevacizumab infusion is given over 90 minutes.
16598763|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
16598764|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
16598765|NCT02620774|Experimental|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
16598789|NCT02620631|Placebo Comparator|Placebo|Subjects receive intrathecal injection of saline at time of spinal anesthesia
16598790|NCT02620631|Experimental|Morphine|Subjects receive intrathecal injection of morphine sulfate 0.2mg at time of spinal anesthesia
16598766|NCT02620774|Active Comparator|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
16598767|NCT02620761|Placebo Comparator|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
16598768|NCT02620761|Experimental|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
16598769|NCT02620748|Experimental|Tranexamic Acid|This arm will receive an injection of Tranexamic Acid
16598770|NCT02620748|Placebo Comparator|Saline|This arm will receive an injection of Saline Solution
16598771|NCT02620735|Active Comparator|Exercise Only|Participants receive 12-weeks PA training (1x/week - 60 min) group sessions with a CEP/RKin, and a progressively structured home-based exercise program based on the American College of Sports Medicine (ACSM) guidelines.It combines aerobic-resistance exercise with flexibility training, and progresses towards increased in intensity and improved fitness. The goal is at least 150 min/week of moderate-intensity aerobic activity. Participants are also asked to complete 3-5 additional home-based sessions of aerobic, and resistance activities each week. Initial intensity is based on the performance of the exercises during a group session and is self-monitored via the 10-point rating of perceived exertion, with a prescribed training zone of 4-7.
16598772|NCT02620735|Experimental|Exercise + iMOVE|Participants will receive the same exercise program at the Exercise Only group + 1) one-on-one telephone-based counselling (10 x 30-minute telephone: weeks 1, 2, 3, 4, 5, 6, 8, and 12 (during the exercise program) and at weeks 20,28 (post-exercise program booster sessions)); 2) supportive software on smart-phone devices (the HealthCoach program), 3) use of Fit-bit and corresponding software. The iMOVE intervention was designed to enhance sustained behavior change. The theoretical constructs employed are based on promoting motivation and establishing: a) exercise self-efficacy, b) social support for exercise and c) positive exercise-induced feelings during the acute intervention (12 weeks) and post-exercise program period (6 months).
16598773|NCT02620722|Experimental|LOP Measurement|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument and the gold-standard technique with the handheld Doppler ultrasound.
16598774|NCT02620709|Experimental|Hula intervention|"Participants randomized to the intervention arm will receive the 6-month KaHOLO Program within 1 week of baseline data collection. The first 3 months of the KaHOLO was designed and standardized as a culturally-based PA, which includes 12 weeks of hula lessons. These hula lessons consist of two 60 minute classes per week over 12 weeks. Each hula lesson will consist of 15 participants, providing with the opportunity to engage in social support network.
~The last three months of the program will be reduced to once a week sessions. One week will consist of hula lessons for 60 minutes. The remaining 3 weeks will consist of the intervention group meeting for 45 minutes with the community-peer educator."
16598775|NCT02620709|No Intervention|Wait-List Control|After baseline data collection and education, participants randomized to the wait-list control arm will not receive the KaHOLO Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not receive the intervention for 6 months until after the intervention arm is completed and their 6 month follow-up data collection is completed. They will not receive any other intervention from us during the 6 month period but they will be instructed to continue with their routine medical care as usual.
16598776|NCT02620696|Experimental|Treatment 1|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide placebo daily from Days 1-42"
16598777|NCT02620696|Experimental|Treatment 2|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 25 mg daily for 14 days (Days 15-28)
~netazepide placebo daily from Days 1-14, and from Days 29-42"
16598778|NCT02620696|Experimental|Treatment 3|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 25 mg daily for 14 days (Days 29-42)
~netazepide placebo daily from Days 1-28"
16598779|NCT02620696|Experimental|Treatment 4|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide placebo daily from Days 1-28"
16598780|NCT02620696|Experimental|Treatment 5|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 1 mg daily for 14 days (Days 15-28)
~netazepide placebo daily from Days 1-14"
16598781|NCT02620696|Experimental|Treatment 6|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 5 mg daily for 14 days (Days 15-28)
~netazepide placebo daily from Days 1-14"
16598782|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.
~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
16598783|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.
~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
16598784|NCT02620670|Active Comparator|Individuals with obesity|Body mass index (BMI) is 30.0 to 39.9 kg / m2 and a waist circumference greater than 80 cm in women and 90 cm for men Physical activity of moderate intensity for 3 days
16598785|NCT02620670|Active Comparator|Individuals with normal weight|Body mass index BMI is 18.5 to 24.9 kg / m2 with lower waist circumference of 80 cm for women and 90 cm for men Physical activity of moderate intensity for 3 days
16598786|NCT02620657||Non interventional study|The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
16598787|NCT02620644|Other|G1 Diabetics with no retinpathy|Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
16598788|NCT02620644|Other|G2 Non diabetics|Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
16598792|NCT02620605|Active Comparator|Late administration of Cabirgoline 0.5 mg|Cabergoline 0.5mg (Dostinex®, Pfizer Australia Pty Ltd ) administrated once daily started on day of HCG triggering and continued for 8 days.
16598793|NCT02620605|Experimental|Early administration of Cabirgoline 0.5mg|Cabergoline 0.5mg(Dostinex®, Pfizer Australia Pty Ltd ) once daily stared once patients fulfilling the inclusion criteria at any day of cycle and continued for 8 days post HCG trigger.
16598794|NCT02620592|Active Comparator|ZYDPLA1 tablet|ZYDPLA1 tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
16598795|NCT02620592|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
16598796|NCT02620579|Experimental|Personalized Pharmaceutical and Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive the pain processing education modules as the combined intervention for this arm.
16598797|NCT02620579|Placebo Comparator|Placebo Pharmaceutical, General Education|This group will have the placebo pharmaceutical administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
16598798|NCT02620579|Active Comparator|Placebo Pharmaceutical, Personalized Education|This group will have the placebo pharmaceutical administered orally and receive the pain processing education modules as the combined intervention for this arm.
16598799|NCT02620579|Active Comparator|Personalized Pharmaceutical, General Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
16598800|NCT02620566|Active Comparator|Bupivacain -Caudal|Single shot Caudal Block will receive Group C with 1ml per kg Bupivacain 0,25%.
16598801|NCT02620566|Active Comparator|Bupivacain- Local|Single shot Local Infiltration will receive Group L with 0,2ml per kg Bupivacain 0,25%.
16598802|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
16598803|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
16598804|NCT02620514|No Intervention|Health-literacy Assessment|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with low adherence will continue to one or more intervention groups that address needs based on the results of the survey.
16598805|NCT02620514|Experimental|Health-literacy Assessment + Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
16598806|NCT02620514|Experimental|Health-literacy Assessment + Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education about IBD.
16598807|NCT02620514|Experimental|Health-literacy Assessment + Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education regarding their medications.
16598808|NCT02620514|Experimental|Health-literacy Assessment + Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive financial support for medications.
16598809|NCT02620501|Placebo Comparator|Placebo|Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
16598810|NCT02620501|Experimental|Experimental|Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
16598811|NCT02620488|Active Comparator|Healthy Control|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
16598812|NCT02620488|Experimental|Sickle Cell Disease|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
16598813|NCT02620475|Active Comparator|Gold standard of care|The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.
16598814|NCT02620475|Experimental|SutureSafe dressings|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
16598815|NCT02620462|Experimental|Wearable sensor-based exercise training|The intervention group in addition to standard of care, will receive 6 weeks of sensor-based balance training that provides real-time visual feedback of lower extremities during exercise. The visual feedback is provided on computer screen.
16598816|NCT02620462|No Intervention|Control Group|The control group only receives standard of care.
16598817|NCT02620449|Experimental|single arm study|
16598818|NCT02620436|Experimental|Core Mother Shelter Model|Existing mother shelters will be renovated, and mother shelters will be built at intervention sites, to meet the Core Mother Shelter Model. This model includes ensuring a safe infrastructure with four walls, a roof, doors and windows that lock, a toilet, running water, and beds.
16598819|NCT02620436|No Intervention|Standard of Care|Existing mother shelters with no changes made, except to ensure that they can provide standard of care.
16598820|NCT02620410|Other|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
16598821|NCT02620384|Placebo Comparator|Experimental: Placebo|This group will receive all standard heart failure therapy and placebo pill.
16598822|NCT02620384|Active Comparator|Experimental: Metolazone|This group will receive all standard heart failure therapy with addition of metolazone.
16598823|NCT02620371|Placebo Comparator|(bupivacaine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine)
16598824|NCT02620371|Active Comparator|(bupivacaine, ketamine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine plus ketamine 1 mg/kg) .
16598915|NCT02619734|No Intervention|Control|Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers
16598825|NCT02620358|Experimental|High Work of Breathing|"If patient has weaning criteria, a Spontaneous Breathing Trial (SBT) with T Tube for 2 hours will be done.
~The patient will be extubated after the SBT if he has no criteria of SBT failure."
16598826|NCT02620358|Experimental|Low Work of Breathing|"If patient has weaning criteria a Spontaneous Breathing Trial (SBT) with Pressure Support Ventilation of 8 cmH2O for 30 minutes will be done.
~The patient will be extubated after the SBT if he has no criteria of SBT failure."
16598827|NCT02620345|Experimental|Dydrogesterone M/ Women Pregnancy|"Reducing the size of fibroids with medication
~Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy
~Dosage:
~1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day
~The lost in size of fibroids throughout pregnancy after 48 weeks."
16598828|NCT02620345|Experimental|Dydrogesterone M/ Reproductive Age|"Reducing the size of fibroids with medication
~Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age
~Dosage:
~1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day
~The lost in size of fibroids after 24 weeks."
16598829|NCT02620332|Placebo Comparator|Placebo injection|Water for injection
16598830|NCT02620332|Experimental|MultiPepT1De injection low dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
16598831|NCT02620332|Experimental|MultiPepT1De injection medium dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
16598832|NCT02620332|Experimental|MultiPepT1De injection high dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
16598833|NCT02620319|Experimental|biodegradable stent|endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
16598834|NCT02620306|Experimental|Fimasartan(A)|
16598835|NCT02620306|Experimental|Fimasartan(B)|
16598836|NCT02620306|Active Comparator|Losartan(A)|
16598837|NCT02620306|Active Comparator|Losartan(B)|
16598838|NCT02620293|Experimental|Eczema Emollient|Eczema Repair Emollient
16598839|NCT02620280|Active Comparator|Carbo-abrax, surgery, anthra|Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
16598840|NCT02620280|Experimental|Carbo-abrax-MPDL3280A, surgery, anthra|Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
16598841|NCT02620267|Experimental|tDCS Stimulation|Each subject will receive all three types of stimulation on separate days- anodal, cathodal, and sham stimulation
16598842|NCT02620241|Other|sitting position|infants are in a sitting position for 20 minutes
16598843|NCT02620228|Experimental|BIP Biopsy System|Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
16598844|NCT02620215|Experimental|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
16598845|NCT02620215|Active Comparator|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
16598846|NCT02620176|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
16598847|NCT02620176|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
16598848|NCT02620163|Experimental|YH22162|YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
16598849|NCT02620163|Active Comparator|telmisartan/amlodipine|Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
16598850|NCT02620150|Experimental|Experimental|CCBT plus Escitalopram, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
16598851|NCT02620150|Placebo Comparator|Placebo|CCBT plus Placebo, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
16598852|NCT02620137|Experimental|Multicentrum® 3 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 3 months
16598853|NCT02620137|Active Comparator|Multicentrum® 12 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 12 months
16598854|NCT02620124|No Intervention|Natural cycle, control|Treatment cycles with normal luteal support with progesteron
16598855|NCT02620124|Experimental|Natural cycle, intervention|Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
16598856|NCT02620124|No Intervention|Hormone replacement cycle, control|Standard hormone replacement cycle with estrogen and progesteron
16598857|NCT02620124|Experimental|Hormone replacement cycle, intervention|Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
16598858|NCT02620111|Experimental|Whey protein high leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
16598859|NCT02620111|Active Comparator|Whey protein normal leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein normal in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
16598860|NCT02620098|Experimental|Size Matters Handwriting Program|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The intervention group consisted of 23 kindergarten students comprising all students in two kindergarten support classrooms, one in each of two neighboring schools. All students in the group received the Size Matters Handwriting Program.
16598861|NCT02620098|No Intervention|Control|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The control group consisted of 12 kindergarteners comprising all students in a kindergarten support classroom at a third school. They received no additional interventions.
16598862|NCT02620085||Graves' disease|Patient had been diagnosed of Graves' disease and now under euthyroid status
16598863|NCT02620072|Experimental|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
16598864|NCT02620072|Placebo Comparator|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
16598865|NCT02620059|Experimental|Lifestyle Intervention|"Behavioral: Lifestyle Intervention These women will receive the Healthy Lifestyle Intervention. This intervention will have been delivered during 12 weeks, which will be Distance learning program (multimedia or internet). During the intervention (12 weeks) and follow up period, women will receive not only motivational messages through the Short Message System (SMS) but also a pedometer to record their steps.The intervention will focus on women increasing physical activity (walking) to 10'000 steps per day and receiving healthy eating guidelines.
~This intervention curriculum will cover topics related to healthy eating, physical activity, and stress management during postpartum. General information about postpartum period will also be provided."
16598866|NCT02620059|No Intervention|Control|These women will receive general information via pamphlet about postpartum period and tips for stress management.
16598867|NCT02620046|Experimental|Group A: Vedolizumab SC 108 mg Q2W|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:
~Completed the Maintenance Period (Week 52), or
~Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6."
16598868|NCT02620046|Experimental|Group B: Vedolizumab SC 108 mg QW|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.
~•Participants from current study who experience treatment failure while on study."
16598869|NCT02620033|No Intervention|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
16598870|NCT02620033|Active Comparator|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
16598871|NCT02620020|Experimental|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
16598872|NCT02620020|Experimental|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
16598873|NCT02620020|Experimental|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
16598874|NCT02620020|Experimental|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
16598875|NCT02620007|Experimental|Experimental arm|oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
16598876|NCT02620007|Placebo Comparator|Control arm|a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks
16598877|NCT02619994|Active Comparator|Control Arm|"Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.
~Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.
~Treatment duration: for at least 20 months"
16598878|NCT02619994|Experimental|Experimental Arm|"Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.
~Delamanid (100 mg bid for the entire treatment period)
~Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)
~Levofloxacin (750 ~1000 mg/day)
~Pyrazinamide (1000~ 2000 mg/day)"
16598879|NCT02619981|Active Comparator|Father present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Father present
16598880|NCT02619981|Active Comparator|Mother Present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Mother present
16598881|NCT02619981|Active Comparator|Both parents present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , both parents present
16598882|NCT02619968|Experimental|Experimental group|"Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application.
~Application of the tourniquet Will be held in conjunction with exercises for the experimental group.
~Tennis ball: will initially be 3 sets, where one series with 10 grips, increasing 5 grips every week, 60 seconds rest every series.
~Halter: are performed with load of 1 kg, 2 kg and 3 kg. Handgrip: they will be performed 3 sets of dynamic manual hold exercises in the intensity of 40% of MVC.
~Home program: at home will be performed isometric exercises with tennis ball on the same frequency as in performing ambulatory without applying the tensiometer."
16598883|NCT02619968|Sham Comparator|Group control|Will be held the same isometric and isotonic concentric ambulatory and home with the same duration, frequency and intensity, except is not to apply the tourniquet.
16598884|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
16598885|NCT02619942|Active Comparator|D2 radical operation group|In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.
16598886|NCT02619942|Experimental|CME group|In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.
16598887|NCT02619916|Experimental|MBCT|Mindfulness-Based Cognitive Therapy
16598888|NCT02619916|Experimental|CBT|Cognitive Behavioral Therapy
16598889|NCT02619916|No Intervention|TAU|Treatment as usual
16598890|NCT02619903|No Intervention|COPD Control|Subjects with COPD recieve no treatment. When exiting the trial after 12 months, they do however receive the intervention.
16598891|NCT02619903|Active Comparator|COPD Test|Subjects with COPD that do get the additional dental cleaning, as well as dental examination.
16598892|NCT02619890||Patients with glioma requiring treatment|Patients with glioma requiring treatment, who undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent
16598893|NCT02619877|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
16598894|NCT02619877|Active Comparator|Standard therapy|Standard therapy for patients with diabetic foot ulcer
16598895|NCT02619864|Experimental|AZD2014 plus temozolomide|Patients will receive single agent AZD2014 for 2 days immediately prior to surgery at a fixed dose of 125 mg bid po (i.e. on days -2, -1, and on morning of day 0 [day of surgery]). After recovery from surgery, patients will start the dose escalation (within 7-21 days after tumour resection).
16598896|NCT02619851|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
16598897|NCT02619851|Active Comparator|Conventional Therapy|Typical therapy conducted for burn injury patients
16598898|NCT02619838||Aptus CCS 5.0 or/and 7.0 screws|Procedure/Surgery: Subtalar, Double or Triple Arthrodesis of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint of the foot with the Aptus CCS 5.0 or/and 7.0 screws
16598899|NCT02619825|Other|"Group 1 healthy volunteers"|Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness [VD] and left ventricular [LV]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups [0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years]).
16598900|NCT02619825|Other|Group 2 Patients CMH primitive|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Hypertrophic Cardiomyopathy (HCM) non obstructive primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
16598901|NCT02619825|Other|Group 3 Patients primitive CMD:|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Dilated Cardiomyopathy primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
16598902|NCT02619812|Active Comparator|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
16598903|NCT02619812|Active Comparator|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
16598904|NCT02619812|Active Comparator|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
16598905|NCT02619812|Placebo Comparator|Group D: Double Placebo|Double placebo twice per day
16598906|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
16598907|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
16598908|NCT02619786|Experimental|inhaled colistin|Inhaled colistin 75 mg mixed with normal saline up to 4 ml every 12 hours at least 5 days
16598909|NCT02619773|Experimental|Mupirocin dressing|"Mupirocin + island dressing applied to surgical incision until postoperative day 5.
~Intervention: mupirocin ointment applied to extrication incision."
16598910|NCT02619773|No Intervention|Island dressing|Island dressing applied to surgical incision until postoperative day 2. This arm will not undergo any intervention.
16598911|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
16598912|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
16598913|NCT02619747|Active Comparator|Compound Sodium Alginate Oral Suspension sachet|Single dose of contents of two 10 ml sachets of Compound Sodium Alginate Oral Suspension
16598914|NCT02619747|Placebo Comparator|Matched placebo|Single dose of contents of two 10 ml sachets of matched placebo
16599007|NCT02619149|Placebo Comparator|Control|Saline solution
16598917|NCT02619721|Experimental|Sacral Neuromodulation is on|Sacral Neuromodulation is on as soon as implantation
16598918|NCT02619721|Placebo Comparator|Sacral Neuromodulation is off|Sacral Neuromodulation is off after implantation
16598919|NCT02619708|No Intervention|Standard Preoperative Experience|The preoperative visit will be performed, as it would be normally. Patients will be given a description of the preoperative experience, they will be told what to expect, they will be given brochures detailing what will happen on the day of the surgery, and will be given the opportunity to ask questions. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
16598920|NCT02619708|Experimental|Immersive Preoperative Experience|The preoperative visit will be performed, as it would be normally, with the only addition of a 5-minute video for the patients randomized to the intervention group. Patients will be given a few minutes to watch the video, and will have the chance to ask questions. The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
16598921|NCT02619695|Experimental|Ketoprofen|Interventional arm: ketoprofen gel 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
16598922|NCT02619695|Placebo Comparator|Placebo|Placebo arm: placebo gel form of ketoprofen
16598923|NCT02619682|Experimental|Treatment (ixazomib citrate and lenalidomide)|Within 30-120 days after finishing autologous transplant, patients receive ixazomib citrate PO on days 1, 8 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-28. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients will continue to alternate between ixazomib citrate and lenalidomide every 2 courses for up to 24 months in the absence of disease progression or unacceptable toxicity.
16598924|NCT02619669|Experimental|TAK-228 followed by TAK-228 plus Letrozole|"Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.
~The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects."
16598925|NCT02619656|Experimental|Treatment|"Patients randomized to insufflation with CO2.
~Intervention: CO2 Insufflation with CO2Efficient Endoscopic Insufflator on managed flow setting at 3.4 L/min"
16598926|NCT02619656|Active Comparator|Control|"Patients randomized to insufflation with ambient air.
~Intervention: Ambient air insufflation with Evis Exera 111 CLV-190 on medium air flow setting 0.68 L/min"
16598927|NCT02619643|Experimental|Primed PAS 1A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
16598928|NCT02619643|Experimental|Unprimed PAS 1B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
16598929|NCT02619643|Sham Comparator|Sham PAS|A single session of sham paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied
16598930|NCT02619643|Experimental|Primed PAS 2A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
16598931|NCT02619643|Experimental|Unprimed PAS 2B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
16598932|NCT02619643|Experimental|Primed PAS 1C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
16598933|NCT02619643|Experimental|Primed PAS 2C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
16598934|NCT02619630|Experimental|High-Risk (HR) patients|Nelarabine during consolidation and maintenance
16598935|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
16598936|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
16598937|NCT02619604|Other|Clinician education|
16598938|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
16598939|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
16598940|NCT02619578|Other|TEAS Group|TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
16598941|NCT02619578|Other|Con Group|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
16598942|NCT02619565|Other|Blood samples if evolution of the disease|blood samples at Day 0 and also if there is an evolution of the disease
16598943|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
16599008|NCT02619136|Experimental|Restrictive Transfusion Strategy|We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
16598944|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
16598945|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
16598946|NCT02619539||Trauma patients|All patients having / suspected to have severe trauma injuries admitted to participating centers.
16598947|NCT02619526|Experimental|Nebivolol|Nebivolol 10mg, once a day
16598948|NCT02619526|Active Comparator|Carvedilol|Carvedilol 25mg, twice a day
16598949|NCT02619513|No Intervention|General anesthesia group(Group GA)|Group GA received general anesthesia only and intravenous analgesia pump.
16598950|NCT02619513|Experimental|TEB group(Group GE)|Group GE received continuous thoracic epidural block(TEB) combined with general anesthesia and postoperative continuous thoracic epidural analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
16598951|NCT02619513|Experimental|PVB without DEX group (Group GT)|Group GT received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block(PVB) combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
16598952|NCT02619513|Experimental|PVB with DEX group(Group GTD)|Group GTD received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia,but with dexmedetomidine 0.5μg/kg added to ropivacaine in PVB as an adjuvant.
16598953|NCT02619500|Experimental|Thrust Manipulation|Subjects in this arm will receive spinal thrust manipulation to both the cervical and thoracic spines.
16598954|NCT02619500|Active Comparator|Non-thrust Mobilizations|Subjects in this arm will receive spinal non-thrust mobilizations to both the cervical and thoracic spines
16598955|NCT02619487|Experimental|8-12 years old, parent receiving text|text message to parent only
16598956|NCT02619487|Active Comparator|13-18 years old, parent receiving text|text message to parent only
16598957|NCT02619487|Active Comparator|13-18 years, both receiving text|Text message to parent and adolescent
16598958|NCT02619487|No Intervention|No text|No text will be sent
16598959|NCT02619474|Experimental|Experimental|Patients who have been admitted to the 3F or 3M wards under the care of the clinical teaching unit (CTU) after the introduction of the new, labelled whiteboard.
16598960|NCT02619474|No Intervention|Control|Patients who have been admitted to the 3R surgical ward under the care of any of the nursing groups without the introduction of the new labelled whiteboard.
16598961|NCT02619461|Experimental|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes.
16598962|NCT02619461|No Intervention|Control|Resting
16598963|NCT02619448|Experimental|Chemotherapy with hypofractionated RT|Carboplatin AUC 2 + Paclitaxel 50 mg/m2 given weekly x 4 concurrently with radiation therapy (70 Gy in 20 fractions) over 4 weeks
16598964|NCT02619435|Experimental|regorafenib|
16598965|NCT02619422|Other|Intensivo|intensive cardiac rehabilitation program in less time
16598966|NCT02619422|No Intervention|Convencional|standard cardiac rehabilitation program
16598967|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
16598968|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
16598969|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
16598970|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
16598971|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
16598972|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
16598973|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
16598974|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
16598975|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
16598976|NCT02619383|Experimental|HBOT|All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
16598977|NCT02619370|Experimental|Intervention|Play 'My Gift of Grace,' a conversation card game for 4-6 players (the game consists of 20 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues); all game sessions will be audio recorded and transcribed.
16598978|NCT02619370|Active Comparator|Control|"Review and discuss a brochure on ACP called Advance Care Planning: Tips from the National Institute of Aging. Discussion will be prompted by the researcher asking participants to discuss the information they've just read with the group. However, there will not be a formal structure to this discussion."
16598979|NCT02619357|Experimental|Cohort 1|10 subjects diagnosed with COPD (GOLD stages 2 and 3). Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
16600038|NCT02612441|Experimental|1 real Acupuncture group-intervention|real Acupuncture Needles
16598980|NCT02619357|Experimental|Cohort 2|10 subjects diagnosed with asthma. Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
16598981|NCT02619331|Experimental|Atopic volunteers|Allergy tests will be performed in allergic patients with rhinoconjunctivitis and allergy test reading measured following two different methodologies. 1) test reading based on conventional wheal and flare measurement (wheal diameter in mm, CWFM), 2) test reading based on high speed laser doppler imaging (HS-LDI). Both type of tests reading will be compared.
16598982|NCT02619318|Experimental|The Balancing Everyday Life (BEL) intervention|The BEL was developed on the basis of previous research on lifestyle interventions made by our own group and other researchers [1, 2]. It is a group-based programme (5-8 participants) with 12 sessions, one session a week, and 2 booster sessions with two-week intervals. The themes for the group sessions are, e.g., activity balance, healthy living, work-related activities, and social activities. Each session contains a main group activity and a home assignment to be completed between sessions. The main group activity starts with analysing the present situation and proceeds with identifying desired goals and finding strategies for how to reach them. The home assignment is aimed at testing one of the proposed strategies. Self-analysis, setting goals, finding strategies and evaluating the outcome of tested strategies form a process for each session, but also for the BEL intervention as a whole.
16598983|NCT02619318|Active Comparator|Care as usual (standard occupational therapy)|Standard occupational therapy involves support to open-market employment and support in managing everyday life in general.
16598984|NCT02619305|Experimental|Immediate treatment|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
16598985|NCT02619305|No Intervention|Delayed treatment|Participants will be social network ties of women receiving no intervention but who will be placed on a waitlist to receive the intervention after a 12-month delay.
16598986|NCT02619292|Experimental|Mindful Movement Program|"Mindfulness is moment-to-moment, present-centered, purposive non-judgmental awareness; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals"
16598987|NCT02619279|Experimental|Immediate treatment|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
16598988|NCT02619279|No Intervention|Delayed treatment|Participants' mothers will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
16598989|NCT02619266|Experimental|Acupuncture+Placebo|Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
16598990|NCT02619266|Active Comparator|Megestrol Acetate+Sham acupuncture|Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
16598991|NCT02619266|Placebo Comparator|Placebo+Sham acupuncture|Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
16598994|NCT02619240||patients suspected of TB|patients suspected of TB requiring to undergo bronchoscopy as part of the investigation
16598995|NCT02619227|Experimental|Immediate treatment|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
16598996|NCT02619227|No Intervention|Delayed treatment|Participants will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
16598997|NCT02619214|Experimental|Oxygen 30%|Patient receives 1 hour of general anesthesia with a 30% oxygen concentration.
16598998|NCT02619214|Experimental|Oxygen 60%|Patient receives 1 hour of general anesthesia with a 60% oxygen concentration.
16598999|NCT02619201|Experimental|ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
16599000|NCT02619201|Active Comparator|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
16599001|NCT02619188||Hyperemesis gravidarum|Hyperemesis gravidarum patients admitted to hospital PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis), Intervention at discharge : PUQE-form, Nutritional form and Blood sampling
16599002|NCT02619188||Control: Healthy pregnant women|Outpatients NOT subjected to severe nausea and emesis (PUQE-score <13). PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis).
16599003|NCT02619175|Experimental|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).
~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
16599004|NCT02619175|Active Comparator|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.
~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
16599005|NCT02619162|Experimental|Letrozole+Nintedanib|Letrozole+Nintedanib
16599006|NCT02619149|Active Comparator|Intervention|Piperacillin-tazobactam combination product
16599009|NCT02619136|Active Comparator|Liberal Transfusion Strategy|We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
16599010|NCT02619123|Active Comparator|invitation to mammography screening|44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.
16599011|NCT02619123|Experimental|invitation to tailored screening|44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.
16599012|NCT02619110|Other|backward walking treadmill training|The intervention group not only received four weeks of conventional physical therapy but also accepted additional four weeks of backward walking treadmill training at the same time
16599013|NCT02619110|Other|conventional physical therapy|The conventional physical therapy training focused on strengthening, postural control, functional mobility and forward gait training program but excluded backward walking training
16599014|NCT02619097|Experimental|0.08mg/kg|Pegol-sihematide injection, 0.08mg/kg, single-dose
16599015|NCT02619097|Experimental|0.2mg/kg|Pegol-sihematide injection, 0.2mg/kg, single-dose
16599016|NCT02619097|Experimental|0.33mg/kg|Pegol-sihematide injection, 0.33mg/kg, single-dose
16599017|NCT02619097|Experimental|0.5mg/kg|Pegol-sihematide injection, 0.5mg/kg, single-dose
16599018|NCT02619097|Experimental|0.7mg/kg|Pegol-sihematide injection, 0.7mg/kg, single-dose
16599019|NCT02619084|Experimental|STN DBS ON First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
16599020|NCT02619084|Experimental|STN DBS OFF First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
16599021|NCT02619071|Experimental|Refractory or relapsed acute myeloid leukemia|
16599022|NCT02619058|Experimental|Arm 1（NKT cells single low dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 1×10^9 on d1, 2×10^9 on d3, 4×10^9 on d29, 8×10^9 on d31.
16599023|NCT02619058|Experimental|Arm 2（NKT cells single high dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3, 5×10^9 on d29, 5×10^9 on d31.
16599024|NCT02619058|Experimental|Arm 3（NKT cells multiple dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3 of each 28 days-cycle, the dosing will be ended after 8 cycles.
16599025|NCT02619045|Other|Solid tumors|Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.
16599026|NCT02619032|Active Comparator|Remifentanil|Drug: Remifentanil (Ultiva). Intraoperative intravenous infusion of remifentanil 0.5-1 μg/kg/min for up to 1 h.
16599027|NCT02619032|Active Comparator|Fentanyl|Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.
16599028|NCT02619019|Active Comparator|Dexamethasone group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
16599029|NCT02619019|Active Comparator|Pethidine group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
16599030|NCT02619019|Placebo Comparator|Control group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
16599031|NCT02619006||Immediate Cord Clamping|Healthy term infants who were previously randomized or assigned at birth to the control group known as immediate cord clamping. The cord was clamped and cut within10 seconds after birth.
16599032|NCT02619006||Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
16599033|NCT02618993|Placebo Comparator|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
16599034|NCT02618993|Experimental|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
16599037|NCT02618967|Experimental|AMG 570 - 7 mg|Participants will receive a single dose 7 mg dose of AMG 570 administered subcutaneously.
16599038|NCT02618967|Experimental|AMG 570 - 21 mg|Participants will receive a single 21 mg dose of AMG 570 administered subcutaneously.
16599039|NCT02618967|Experimental|AMG 570 - 70 mg|Participants will receive a single 70 mg dose of AMG 570 administered subcutaneously.
16599040|NCT02618967|Experimental|AMG 570 - 140 mg|Participants will receive a single 140 mg dose of AMG 570 administered subcutaneously.
16599041|NCT02618967|Experimental|AMG 570 - 210 mg|Participants will receive a single 210 mg dose of AMG 570 administered subcutaneously.
16599042|NCT02618967|Experimental|AMG 570 - 420 mg|Participants will receive a single 420 mg dose of AMG 570 administered subcutaneously.
16599043|NCT02618967|Experimental|AMG 570 - 700 mg|Participants will receive a single 700 mg dose of AMG 570 administered subcutaneously.
16599044|NCT02618967|Placebo Comparator|Placebo|Participants will receive a single dose of the matching AMG 570 placebo administered subcutaneously.
16599045|NCT02618954|Other|Study patient|Articular ultrasound at each study follow-up
16599046|NCT02618941|Experimental|AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/adjuvanted
16599047|NCT02618941|No Intervention|Control|Untreated control group
16599048|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
16599049|NCT02618915|Experimental|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10^12 genome copies (GC)/kg DTX101
16599050|NCT02618915|Experimental|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10^12 GC/kg DTX101
16599051|NCT02618902|Experimental|tolerogenic dendritic cells (tolDC)|Each vaccine (5x106, 10x106 , or 15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the subclavicular region (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides.
16599052|NCT02618889|Active Comparator|CBT plus botox|Participants will be randomized to receive BoNT (onabotulinumtoxinA). Patients will undergo study assessments four weeks later. We will inject a total of 250 units of onabotulinumtoxinA, as the average optimal dose in cervical dystonia,11 using a 100:1 dilution with normal saline. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
16599053|NCT02618889|Placebo Comparator|CBT plus placebo|Participants will be randomized to receive normal saline (placebo). We will inject a total of 250 units of normal saline, as this is the average optimal dose of onabotulinumtoxinA in cervical dystonia. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
16599054|NCT02618876|Active Comparator|Nalbuphine group|30 children will be given Caudal Bupivacaine plus Nalbuphine.
16599055|NCT02618876|Other|Control group|30 children will be given Caudal Bupivacaine.
16599056|NCT02618863|Active Comparator|1 , cricoid pressure|30 male
16599057|NCT02618863|Active Comparator|2,cricoid pressure|30 female
16599058|NCT02618850|Other|Advanced CRC patients undergoing first-line chemotherapy|single cohort
16599059|NCT02618837|Active Comparator|Downstream strategy arm|downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
16599060|NCT02618837|Active Comparator|Upstream strategy arm|upstream administration strategy (ticagrelor only)
16599061|NCT02618824|Active Comparator|HTK Solution|Hearts will be arrested with HTK solution during cardiac operation
16599062|NCT02618824|Active Comparator|HTK Solution + TWBC|Hearts will be arrested with HTK solution during cardiac operation and received terminal warm blood cardioplegia before aortic cross clamp removal.
16599063|NCT02618811||Group 1|not sarcopenic
16599064|NCT02618811||Group 2|sarcopenic
16599065|NCT02618811||Group 3|not myosteatotic
16599066|NCT02618811||Group 4|myosteatotic
16599067|NCT02618785|Experimental|Hyoscine|The experiment group receive Hyoscine 10 mg 2 tablets by mouth before hysterosalpingography procedure
16599068|NCT02618785|Placebo Comparator|Placebo|The control group receive placebo by mouth before hysterosalpingography procedure
16599069|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
16599070|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
16599071|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
16599072|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
16599073|NCT02618746|Experimental|Group A, Telerehabilitation|The 12-month home care/rehabilitative program will include the following components: a) individualized action plan; b) educational session on self management; c) physical exercise sessions to remote monitoring; d) access to the call centre; e) professional weekly calls by physiotherapists, dietician and physician with remote connection as a response to possible incidents; f) remote monitoring selectively and temporarily.
16599074|NCT02618746|Active Comparator|Group B, Hospital based Rehabilitation|Patients assigned to the hospital based program will visit the hospital twice weekly for 12 months in order to participate in a multidisciplinary rehabilitation program including exercise, physiotherapy dietary and psychological advice by the staff of the rehabilitation centre based at the University clinic.
16599075|NCT02618746|No Intervention|Group C, Usual care Group|The control group will follow the usual care not involving the initial 8-week rehabilitation program neither maintenance hospital rehabilitation sessions or home telemonitoring of vital signs.
16599076|NCT02618733|Experimental|Ticagrelor|Ticagrelor 90mg, twice a day
16599077|NCT02618733|Active Comparator|Clopidogrel|Clopidogrel 75mg, once a day
16599078|NCT02618720|Experimental|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
16599150|NCT02618200|Experimental|3D prostate ultrasound|3D prostate ultrasound will be performed in patients the day before radical prostatectomy
16599151|NCT02618187|Experimental|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
16600039|NCT02612441|Sham Comparator|2 sham Acupuncture group|sham Acupuncture Needles
16599079|NCT02618720|Placebo Comparator|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
16599080|NCT02618707||Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
16599081|NCT02618694|Experimental|Group 1|patient had posterior retroperitoneoscopic adrenalectomy
16599082|NCT02618694|Active Comparator|Group 2|patient had Transperitoneal laparoscopic adrenalectomy
16599083|NCT02618681||AMI with earlobe crease|To observe the prognosis for AMI with earlobe crease
16599084|NCT02618681||AMI without earlobe crease|To observe the prognosis for AMI without earlobe crease
16599085|NCT02618668|Experimental|Ketamine / Propofol Admixture|Ketamine / Propofol Admixture: I.V propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+ 4 ml saline in a 20-ml syringe which resulted in 0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol.
16599086|NCT02618668|Active Comparator|Propofol|I.V propofol 2 mg/kg
16599087|NCT02618655||Fever，none definite diagnosis|Those who have fever，but the doctor can not make definite diagnoses with the diagnostic methods available.
16599088|NCT02618642|Active Comparator|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
16599089|NCT02618642|Active Comparator|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
16599090|NCT02618642|Active Comparator|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
16599091|NCT02618642|Placebo Comparator|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
16599092|NCT02618629|Experimental|14C-Z-215|
16599093|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
16599094|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
16599095|NCT02618603|Experimental|BoNT-A treatment group|Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);
16599096|NCT02618603|Active Comparator|Triamcinolone acetonide treatment group|Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;
16599097|NCT02618577|Experimental|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:
~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
16599098|NCT02618577|Active Comparator|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
16599099|NCT02618564|Active Comparator|2 TABS QHS|Sennosides 2 tabs, taken two nights before the colonoscopy
16599100|NCT02618564|Active Comparator|3 TABS QHS|Sennosides 3 tabs, taken two nights before the colonoscopy
16599101|NCT02618564|Active Comparator|2 TABS AM|Sennosides 2 tabs, taken the morning before the colonoscopy
16599102|NCT02618564|Active Comparator|3 TABS AM|Sennosides 3 tabs, taken the morning before the colonoscopy
16599103|NCT02618564|Active Comparator|2 TABS AM & QHS|Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.
16599104|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
16599105|NCT02618525|Active Comparator|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
16599106|NCT02618525|Active Comparator|Jaw thrust maneuver|Jaw thrust maneuver is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
16599107|NCT02618512|Experimental|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
16599108|NCT02618499|Active Comparator|oxytocin inmediately at birth|Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
16599109|NCT02618499|Experimental|oxytocin at 3 minutes|Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped
16599110|NCT02618486|Experimental|Obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
16599111|NCT02618486|Active Comparator|Non obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
16599112|NCT02618473|No Intervention|seloken|"In seloken arm, patients performs the cardiac CT procedure regarding the national scan guidelines, ande receive 5-10 intravenous seloken, until heart rate below 60 beats pr minit is achieved."
16599113|NCT02618473|Experimental|non-seloken|"Patients randomized to non-seloken, do not receive any medication."
16599114|NCT02618460|Experimental|Whole Group|
16599115|NCT02618447|Experimental|Arm 1: 4D phase contrast MR scan|"Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes):
~Scan 1: Baseline (pre-portal vein embolization (PRE))
~Scan 2: Early after PVE (within 48 hours)
~Scan 3: Late after PVE (at 3-8 weeks).
~Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan.
~Scan 2: 4D phase contrast sequences and imaging for localization."
16599116|NCT02618434|Experimental|Low dose SPN-810|Subjects will be treated with low dose of SPN-810
16599117|NCT02618434|Experimental|High dose SPN-810|Subjects will be treated with high dose of SPN-810
16599118|NCT02618434|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
16599119|NCT02618421||Participants Aged 40 Years or Over|Cross-section of general population of males and females in China, Taiwan, and South Korea
16599120|NCT02618408|Experimental|Low dose SPN-810|Subjects will be treated with low dose SPN-810
16599121|NCT02618408|Experimental|High dose SPN-810|Subjects will be treated with high dose SPN-810
16599122|NCT02618408|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
16599123|NCT02618395|Experimental|Treatment A|
16599124|NCT02618395|Experimental|Treatment B|
16599125|NCT02618395|Experimental|Treatment C|
16599126|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
16599127|NCT02618369|Other|MR-HIFU treatment|"The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.
~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan."
16599128|NCT02618356|Experimental|combined use Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.
~BSA(body surface area) S-1 dosage <1.25 m2 80 mg/d
~1.25m2 - <1.5 m2 100 mg/d
~1.5 m2 120 mg/d"
16599129|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
16599130|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
16599131|NCT02618330|Experimental|retainer: 0.75-mm-thick film|
16599132|NCT02618330|Experimental|retainer: 1.00-mm-thick film|
16599133|NCT02618317|Active Comparator|Heparin Lock Solution|Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .
16599134|NCT02618317|Experimental|Trissodium Citrate 30%|Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .
16599135|NCT02618317|Experimental|Minocycline-EDTA 30 mg/ml - 3 mg/ml|Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.
16599136|NCT02618304|Experimental|moderate to severe meibomian gland dysfunction|
16599137|NCT02618291|Experimental|Active Geriatric Evaluation (AGE tool)|The Active Geriatric Evaluation is a comprehensive assessment and management tool consisting of a 20-minute clinical screening instrument (Brief Assessment Tool, BAT) to identify 8 geriatric syndromes, and complementary diagnostic evaluations and propositions of management & treatment for each syndrome.
16599138|NCT02618291|Active Comparator|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
16599139|NCT02618278|Experimental|Intervention|Patients randomised to the intervention arm will receive a individual, goal -orientated physiotherapy management package within 2 weeks G.P referral for physiotherapy.
16599140|NCT02618278|Active Comparator|Usual care|Patients randomised to usual care will receive the same individual, goal-orientated physiotherapy management as the intervention arm but at 6 weeks post G.P referral, as is usual care.
16599141|NCT02618265|Experimental|Mobile terminal|Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
16599142|NCT02618265|Active Comparator|traditional management|Stroke received traditional management for secondary prevention administration
16599143|NCT02618265|Active Comparator|website platform management|Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
16599144|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
16599145|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
16599146|NCT02618239|Experimental|Healthy subjects|Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
16599147|NCT02618226||Optic nerve ultrasound|Optic nerve sheath diameter (ONSD) measurement will be performed in subjects with concomitant measurement of Intracranial Pressure (ICP) from an invasive ICP monitor. The operator measuring ONSD will be blinded to concomitant ICP.
16599148|NCT02618213|Active Comparator|Continous Positive Airway Pressure|CPAP is administered through a binasal tube fitted with a Benveniste gas jet administered with humified airflow. Start flow is 12-14 l/min and can be changed to maximum 15 or minimum 12 l/min. Oxygen can be supplied as needed to keep SpO2 (peripheral capillary Oxygen saturation) within acceptable limits.
16599149|NCT02618213|Active Comparator|High Flow Oxygenation Therapy|HFOT is administered by optiflow Junior ( Fisher&Paykal Healthcare® Auckland, New Zealand) Start flow 12-14 l/min. Oxygen can be supplied as needed to keep Sp02 within acceptable limits
16599152|NCT02618187|Placebo Comparator|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
16599153|NCT02618187|Experimental|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
16599154|NCT02618187|Experimental|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
16599155|NCT02618174|Placebo Comparator|Neutral Control Condition|Message about age of University of Birmingham
16599156|NCT02618174|Placebo Comparator|Food-based Control Condition|Message about variety of vegetables in the world
16599157|NCT02618174|Active Comparator|Health Condition|Message about the health benefits of eating vegetables
16599158|NCT02618174|Active Comparator|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
16599159|NCT02618174|Experimental|Liking Social Norm|Message suggesting most people like eating vegetables
16599160|NCT02618161|Experimental|Arm A|HDR Brachytherapy single dose of 15 Gy followed by EBRT of 46 Gy in 23 fractions and Androgen deprivation therapy 6 months to 3 years, (sequencing of HDR followed by EBRT)
16599161|NCT02618161|Active Comparator|ARM B|External Beam Radiotherapy (EBRT) of 46 Gy in 23 fractions, followed by single dose of HDR brachytherapy of 15 Gy boost and Androgen deprivation therapy 6 months to 3 years (timing of HDR Brachytherapy Treatment is changed compared to ARM A)
16599162|NCT02618148|Experimental|ESTROGEN HERBALS 21|"Used for women who wish to monthly menstruation
~Applies to the following strengths:
~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
16599163|NCT02618148|Experimental|ESTROGEN HERBALS 28|"Used for women who do not wish to monthly menstruation
~Applies to the following strengths:
~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
16599164|NCT02618135|Experimental|Intervention Group|10 child participants in the intervention group will take part in a total of 24 sessions spread over an 8-week period, and a final follow-up review 1 month after the completion of the training session. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy.
16599165|NCT02618135|Other|Control Group|10 child participants in the control group will not receive BCI training during the first 8 weeks of their study participation; they will act as controls. At week 9, subjects in this group will go through the BCI training similar to the intervention group. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy. They will take part in a total of 24 sessions spread over an 8-week period, followed by a final follow-up review 1 month after the completion of the training sessions.
16599166|NCT02618109|Other|Relapse Group|"Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.
~Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis."
16599167|NCT02618109|Other|Control Group|"Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.
~Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.
~These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients."
16599168|NCT02618096|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
16599169|NCT02618096|Active Comparator|Oxytocin & Dinoprostone|"Women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
16599170|NCT02618083|Experimental|retinal detachment|color Doppler ultrasound of the eye
16599171|NCT02618070|Experimental|Functional dyspepsia patient|Yogurt ingestion
16599172|NCT02618070|Experimental|Healthy|Yogurt ingestion
16599173|NCT02618057|Experimental|Steroid|Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days
16599174|NCT02618057|Active Comparator|Control|Levofloxacin, 10mg/kg/day, IV, for 5days
16599175|NCT02618044||Obese patients without preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass without preoperative GER at 24h-impedance pH monitoring (Group G-)
16599176|NCT02618044||Obese patients with preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass with preoperative GER at 24h-impedance pH monitoring (Group G+)
16599177|NCT02618031|Other|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
16599178|NCT02618031|Experimental|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
16599179|NCT02618018|Experimental|intraocular lens|AT TORBI 709M toric intraocular lens
16599180|NCT02618005|Experimental|LcS group|Consuming probiotic capsule
16599181|NCT02618005|No Intervention|Control group|
16599182|NCT02617992||EMR Surveillance|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions undertaking a surveillance visit will be included in this cohort.
16599211|NCT02617758|Experimental|Treatment AB|Participants will receive Treatment A (single application of DURAGESIC fentanyl transdermal system 100 microgram per hour (µg/h) dose) as Reference in Period 1; followed by Treatment B (single application of Fentanyl transdermal system [JNJ-35685-AAA-G021] 100 µg/h dose) as test in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
16599257|NCT02617446|Active Comparator|treatment|The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.
16599183|NCT02617979|Experimental|Arm 1: SAFECARE at Home|"Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.
~The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.
~All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients."
16599184|NCT02617979|No Intervention|Arm 2: Standard of Care|-All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
16599185|NCT02617966|Other|single study arm|all participants
16599186|NCT02617953|Experimental|Active rTMS(A)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
16599187|NCT02617953|Experimental|Active rTMS(B)|Temporal low frequency repetitive transcranial magnetic stimulation
16599188|NCT02617953|Sham Comparator|Sham condition(C)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
16599189|NCT02617940|Experimental|fissure sealant|single placement of resin-based sealant on occlusal surface and oral hygiene orientation
16599190|NCT02617940|Placebo Comparator|oral hygiene orientation|single application of water on occlusal surface and oral hygiene orientation
16599191|NCT02617927||Vedolizumab Cohort|"Group 1a Mothers exposed to Vedolizumab at any time during pregnancy (and up to 3 months prior to last menstrual period [LMP], if this information is available).
~Group 1b Infants born to Group 1a patients."
16599192|NCT02617927||Anti-TNF Agents Cohort|"Group 2a Patients with IBD who were exposed to anti-TNFs at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
~Group 2b Infants born to Group 2a patients."
16599193|NCT02617927||Conventional therapy only Cohort|"Patients with IBD who were exposed to conventional therapy only any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
~• Group 3b Infants born to Group 3a patients."
16599194|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).
~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.
~Radiographs and DXA will be read in random and varied order."
16599195|NCT02617888|Active Comparator|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
16599196|NCT02617888|No Intervention|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
16599197|NCT02617888|No Intervention|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
16599198|NCT02617875|Active Comparator|Conventional EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a conventional EMS physician, if this is the result of the randomization software.
16599199|NCT02617875|Other|Tele-EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a tele-EMS physician, if this is the result of the randomization software.
16599200|NCT02617862|Experimental|PCI imaging system|
16599201|NCT02617849|Experimental|Pembrolizumab, Carboplatin, Paclitaxel|Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
16599202|NCT02617823|No Intervention|semi-recumbent|rutine positioning at the hospital today
16599203|NCT02617823|Experimental|lateral position|experimental position to be evaluated against rutine
16599204|NCT02617810|Experimental|JNJ-42847922 Plus Midazolam Plus Warfarin|Participants will receive Treatment A (midazolam 4 milligram [mg] syrup once on Day 1 and warfarin 25 mg tablet once on Day 3) followed by Treatment B (JNJ-42847922 20 mg once daily from Day 1 to Day 9, midazolam 4 mg syrup once on Day 7 and warfarin 25 mg tablet once on Day 9). A washout period of 14 to 21 days will be maintained between each treatment period.
16599205|NCT02617797|Experimental|Radiofrequency|Experimental group: women with urinary incontinence are subjected to standard treatment cinesiotherapy perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic in beyond the RF application in the genital area once a week to total 5 sessions.
16599206|NCT02617797|Sham Comparator|Radiofrenquency Off|Control group: women with stress urinary incontinence will be submitted to the treatment of cinesioterapia standard perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic beyond the application of radiofrequency off in genital area once a week with the total of 5 sessions.
16599207|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
16599208|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
16599209|NCT02617771|Active Comparator|Vit D|Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
16599210|NCT02617771|No Intervention|Control|
16599316|NCT02617017|Placebo Comparator|Placebo|
16599212|NCT02617758|Experimental|Treatment BA|Participants will receive Treatment B [single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose] as test in Period 1; followed by Treatment A (single application of DURAGESIC fentanyl transdermal system 100 µg/h dose) as Reference in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
16599213|NCT02617745|Experimental|Stupp protocol|Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
16599214|NCT02617732|Experimental|Tianqi capsule|a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
16599215|NCT02617732|Placebo Comparator|placebo|a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
16599216|NCT02617719||Primary care|Staff, patients aged 75 years and older and their carers associated with a single, participating United Kingdom primary care practice.
16599217|NCT02617706|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 - 4 weeks + standard wound care
16599218|NCT02617706|No Intervention|Standard of care|standard wound care for 4 weeks
16599219|NCT02617693|Other|Standard of care|
16599220|NCT02617693|Experimental|Life style intervention|
16599221|NCT02617680|Experimental|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Concentration of oxygen should be 50%.
16599222|NCT02617680|Experimental|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially.Concentration of oxygen should be 50%.
16599223|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
16599224|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
16599225|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
16599226|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
16599227|NCT02617654|Active Comparator|Liraglutide treatment|Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
16599228|NCT02617654|Placebo Comparator|Placebo treatment|Treatment with placebo once daily for 52 weeks
16599229|NCT02617641|Experimental|TAVIEenM@RCHE intervention|The experimental group will receive a web-based tailored nursing intervention. Between 3 and 4 sessions of 15 to 25 minutes each are completed within 4 weeks. A booster session is delivered at 8 weeks post randomization.
16599230|NCT02617641|Active Comparator|Publicly available websites|The control group will receive hyperlinks to four publicly available websites and one online booklet on the topic of walking.
16599231|NCT02617628|Active Comparator|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
16599232|NCT02617628|Active Comparator|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
16599233|NCT02617615|Experimental|MB-110|oral hard-gel capsule formulation. One dose strength, 25 mg of MB-110, will be filled into the #00 hard-gel capsule.
16599234|NCT02617615|Placebo Comparator|Placebo|in the same #00 hard-gel capsules.
16599235|NCT02617602|Experimental|Goal directed therapy|Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals
16599236|NCT02617602|Active Comparator|Control|Conventional therapy
16599237|NCT02617589|Experimental|Nivolumab + Radiotherapy Arm|Nivolumab IV infusion + Radiotherapy dose as specified
16599238|NCT02617589|Active Comparator|Temozolomide + Radiotherapy Arm|Temozolomide + Radiotherapy dose as specified
16599239|NCT02617576||Flavored contrast|This group of patients will have the choice to flavor their contrast.
16599240|NCT02617576||Unflavored contrast|This group of patients will drink the contrast without flavoring.
16599241|NCT02617563||Minimally invasive lumbar fusion|A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.
16599242|NCT02617550|Experimental|Vericiguat + Nitroglycerin|Co-administration of vericiguat and nitroglycerin
16599243|NCT02617550|Placebo Comparator|Placebo + Nitroglycerin|Aministration of matching placebo and nitroglycerin.
16599244|NCT02617537|Experimental|BAY86-5300|Patients suffering from dysmenorrhea, treated with Yaz
16599245|NCT02617537|Placebo Comparator|Placebo|Patients suffering from dysmenorrhea,treated with placebo
16599246|NCT02617524|Experimental|Valve Medical Dedicated Sheath|Valve Medical Dedicated Sheath version 00
16599247|NCT02617511|Experimental|Omega-3 Supplementation|This groups will supplement their regular diet with 2.97 grams of combined omega-3 fatty acid (EPA/DHA) supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
16599248|NCT02617511|Placebo Comparator|Placebo|This group will supplement their regular diet with 3.0 grams of a combined omega-3-6-9 supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
16599249|NCT02617498|Active Comparator|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
16599250|NCT02617498|Active Comparator|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
16599251|NCT02617485|Experimental|MabionCD20®|"A course of MabionCD20® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.
~Intervention: Drug: Rituximab"
16599252|NCT02617485|Active Comparator|MabThera®|"A course of MabThera® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.
~Intervention: Drug: Rituximab"
16599253|NCT02617472|Experimental|Pelvic floor exercise|Pelvic floor exerciser, daily use
16599254|NCT02617459|Experimental|Levobetaxolol eye drops|Levobetaxolol eye drops 5ml/25mg per bottle
16599258|NCT02617433|Experimental|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.
16599259|NCT02617420||Intervention|All patients will be enrolled in one arm. These patients will have monitoring devices placed on their asthma controller and rescue medication, with data transmitted both to their smartphones and a dashboard accessed by their primary pediatric pulmonary provider.
16599260|NCT02617407|Experimental|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
16599261|NCT02617407|Active Comparator|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
16599262|NCT02617394|Active Comparator|Control group|
16599263|NCT02617394|Experimental|Study group|
16599264|NCT02617381|Experimental|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
16599265|NCT02617368||KC group|KC group included patients those were diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system
16599266|NCT02617368||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
16599267|NCT02617368||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
16599268|NCT02617355|Other|Prototype vs Covidien magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs Covidien magnetic drape
16599269|NCT02617355|Other|Prototype vs 4 commercial drapes|"New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs 4 commercially available magnetic drapes:
~Green Covidien Magnetic Drape Jac-Cell Medic Reusable Magnetic Pad DeRoyal Magnetic Pad size 10 x 16 DeRoyal Magnetic Pad size 20 x 16"
16599270|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
16599271|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
16599272|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
16599273|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group.
16599274|NCT02617316|Other|barefoot first|Ten runners carried on barefoot test first and then in-shoes.
16599275|NCT02617316|Other|in shoes first|Ten runners carried on in-shoes test first and then barefoot.
16599276|NCT02617303|Experimental|OTAGO'S program arm|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive OTAGO'S exercise program during three months, followed by adherence phase. Falls and fractures will be quarterly followed during 15 months.
16599277|NCT02617303|Active Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. Normal medical treatment will be provided by family physicians and nurses. Falls and fractures will be quarterly followed during 15 months.
16599278|NCT02617290|Experimental|Ticagrelor Arm|Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
16599279|NCT02617290|Active Comparator|Clopidogrel Arm|Clopidoprel is an oral antiplatelet agent which was approved for use in the European Union by the European Commission in 1997 and available as generic since 2007. The standard dose of clopidogrel is one 75 mg tablet once a day. The dosage for the loading dose is normally 300 mg but 600 mg is also used. Clopidogrel is the standard of care for PCI at the moment.
16599280|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
16599281|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
16599282|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
16599283|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
16599284|NCT02617264|Experimental|Axillary lymph node FNA Biopsy|A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
16599285|NCT02617251||neonatology patients|neonatology patients
16599286|NCT02617251||paediatric patients|paediatric patients
16599287|NCT02617238|Active Comparator|PWV group|"Cardiovascular risk management based on PWV will include altogether
~the implementation of international guidelines,
~the normalisation of blood pressure, and
~the normalisation of arterial stiffness"
16599288|NCT02617238|No Intervention|Conventional group|These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension
16599289|NCT02617225||DHaAL Intervention|The group receives standard Ailment-free Life (DHaAL) DHaAL intervention
16599290|NCT02617225||DHaAL +CFSS Intervention|This group received the standard DHaAL intervention and additional support under another UNICEF program named Child Friendly School System (CFSS).
16599291|NCT02617225||Control|This group receive the standard / business-as-usual support from the Education Department, but does not receive DHaAL or CFSS Interventions.
16599292|NCT02617212|Experimental|Definitive abutment|Implant surgery. No abutment dis-/reconnections.
16599293|NCT02617212|Active Comparator|Conventional treatment|Implant surgery. Three abutment dis-/reconnections.
16599294|NCT02617199|Experimental|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
16599295|NCT02617199|Active Comparator|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
16599296|NCT02617186|Active Comparator|Thoracoscopic Lobectomy|
16599297|NCT02617186|Active Comparator|Robotic Lobectomy|
16599298|NCT02617173|Experimental|Transcutaneous electrical nerve stimulation|Low current electrical stimulator
16599299|NCT02617160|Experimental|MD Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
16599300|NCT02617160|Active Comparator|Control Group-Medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
16599301|NCT02617134|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
16599302|NCT02617121|Active Comparator|Gabapentin|oral gabapentin 300 mg 1 hours before induction of anesthesia
16599303|NCT02617121|Active Comparator|ramosetron|ramosetron 0.3 mg iv at end of surgery
16599304|NCT02617121|Active Comparator|Gabapentin and ramosetron|oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery
16599305|NCT02617108|Experimental|Foley balloon|Foley balloon following TCRS: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
16599306|NCT02617108|No Intervention|control groups|control groups: women will not receive any therapy of the treatment (comparison group).
16599307|NCT02617108|Experimental|postoperative estrogen therapy groups|Subjects received postoperative hormone therapy as per the protocol in use in our center for Asherman Syndrome. Immediately after the operation, the subjects were started on a 3- month course of cyclical hormonal therapy, consisting of orally administrated oestradiol valerate 2-4mg/day for 21 days, orally administrated medroxyprogesterone acetate 8mg /day from day 12 to 21 of the oestradiol valerate therapy. The second treatment cycle started one week after the completion of the first cycle, and the third treatment cycle started one week after the second cycle.
16599308|NCT02617095|Experimental|T2762|One drop of T2762 in each eye 3 to 6 times daily
16599309|NCT02617095|Active Comparator|Optive|One drop of Optive in each eye 3 to 6 times daily
16599310|NCT02617082||partial breast irradiation|
16599311|NCT02617069|Experimental|Group 1 (Cardiac surgery+botulinum toxin)|All patients underwent conventional cardiac surgery. After the main stage of the surgery botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
16599312|NCT02617069|Active Comparator|Group 2 (Cardiac surgery+placebo)|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
16599313|NCT02617056||Observational group|Subjects with dementia
16599314|NCT02617043|Experimental|HF-WBI|Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.
16599315|NCT02617017|Experimental|Buspirone|
16599318|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
16599319|NCT02616952|Experimental|Chinese herbal therapy group|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks.
16599320|NCT02616952|Other|Pelvic floor muscle training group|Pelvic floor muscle training includes intensive exercises and home exercises. Intensive exercises are conducted in hospital once a week while home exercises are performed three times daily for 12 weeks.
16599321|NCT02616939||Patients with suspected cardiac disease|"Patients eligible for cardiac CT will be included with a focus on symptomatic patients with low-intermediate risk for obstructive coronary artery disease.
~Patients will undergo Cardiac CT scanning (with the SpotLight CT)."
16599322|NCT02616926|Experimental|Hepatic resection|"Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
~Intervention: Hepatic resection"
16599323|NCT02616926|Active Comparator|TACE + RFA|"TACE is performed as a primary treatment for hepatocellular carcinoma. RFA will be performed two weeks later if necessary.
~Intervention: TACE; RFA"
16599324|NCT02616913|Experimental|R,R-monatin|150 mg single dose
16599325|NCT02616913|Active Comparator|Moxifloxacin|400 mg tablet single dose
16599326|NCT02616913|Placebo Comparator|Placebo|placebo single dose
16599327|NCT02616900|Experimental|eSight Eyewear|Main arm
16599328|NCT02616887||Vertebral metastases|Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .
16599329|NCT02616874|Experimental|MVA.HIVconsv plus romidepsin|MVA.HIVconsv plus romidepsin
16599330|NCT02616861|Experimental|IW-1973|1973 Escalating Doses
16599331|NCT02616861|Placebo Comparator|Placebo|Matching Placebo
16599332|NCT02616848|Experimental|Everolimus, Eribulin|
16599333|NCT02616835|Experimental|theta-burst TMS|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
16599334|NCT02616835|Sham Comparator|sham theta-burst TMS|Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
16599335|NCT02616822|Experimental|trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
16599336|NCT02616822|Placebo Comparator|Placebo|Used for placebo substance single dose
16599337|NCT02616809|Experimental|Sitting|Participants will sit continuously for 8 hours in a simulated office environment
16599338|NCT02616809|Experimental|slow cycling|Participants will cycle at regular hourly intervals during an 8-hr simulated office environment
16599339|NCT02616809|Experimental|standing|Participants will change posture (from sitting to standing) during hourly intervals for an 8-hr period in a simulated office environment
16599340|NCT02616809|Experimental|slow walking|Participants will transition from sitting to slow walking on a treadmill desk at regular hourly intervals during an 8-hr period in a simulated office environment
16599341|NCT02616796|Experimental|Social gaze training|Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
16599342|NCT02616796|No Intervention|No Training|Appropriate social gaze behavior will not be reinforced.
16599343|NCT02616783|Experimental|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
16599344|NCT02616783|Active Comparator|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
16599345|NCT02616770|Experimental|S1226 (4%)|S1226 (4%) dosed as single dose for 2 minutes
16599346|NCT02616770|Placebo Comparator|Saline (for 4%)|3 mL saline and medical air as single dose for 2 minutes
16599347|NCT02616770|Experimental|S1226 (8%)|S1226 (8%) dosed as single dose for 2 minutes
16599348|NCT02616770|Placebo Comparator|Saline (for 8 %)|3 mL saline and medical air as single dose for 2 minutes
16599349|NCT02616770|Experimental|S1226 (12%)|S1226 (12%) dosed as single dose for 2 minutes
16599350|NCT02616770|Placebo Comparator|Saline (for 12%)|3 mL saline and medical air as single dose
16599351|NCT02616757|Active Comparator|Simple Bone Cyst Patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.
~There will also be optional blood samples taken o measure bone alkaline phosphatase."
16599352|NCT02616757|Active Comparator|Fracture patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.
~There will also be optional blood samples taken to measure bone alkaline phosphatase."
16599353|NCT02616757|Placebo Comparator|Health volunteers|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.
~There will also be optional blood samples taken to measure bone alkaline phosphatase."
16599354|NCT02616744|Experimental|Arm A: Ibandronic acid|Ibandronic acid 150 mg per os per month for two years
16599355|NCT02616744|Placebo Comparator|Arm B: Placebo|Placebo per os per month for two years
16599356|NCT02616731|Active Comparator|Tranexamic acid|
16599357|NCT02616731|Active Comparator|Diosmin|
16599358|NCT02616718|Experimental|Ventral incisional hernia|Repeated computed tomography scan of abdomen
16599359|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
16599360|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
16599361|NCT02616692||HCC patients / Cohort 1|Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics
16599638|NCT02614963|Experimental|Clostridium Butyricum group|Irritable bowel syndrome patients treated with Clostridium Butyricum
16599362|NCT02616679||Cognitively Normal|Participants will be deemed cognitively normal based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
16599363|NCT02616679||Amnestic Mild Cognitive Impairment (aMCI)|Participants will be deemed aMCI based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
16599364|NCT02616666|Experimental|Dapagliflozin 10 mg|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
16599365|NCT02616666|Active Comparator|Standard of Care (SOC)|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
16599366|NCT02616653|Active Comparator|Sitting followed by lateral position|First half of participants will be assigned to have their L3-L4 intervertebral space located first in the sitting position followed by the lateral position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
16599367|NCT02616653|Active Comparator|Lateral followed by sitting position|Second half of participants will be assigned to have their L3-L4 intervertebral space located first in the lateral position followed by the sitting position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
16599368|NCT02616640|Experimental|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
16599369|NCT02616640|Experimental|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
16599370|NCT02616640|Experimental|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
16599371|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
16599372|NCT02616614|Active Comparator|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
16599373|NCT02616614|Experimental|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
16599374|NCT02616614|Placebo Comparator|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
16599375|NCT02616601|Experimental|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
16599376|NCT02616601|Active Comparator|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
16599377|NCT02616601|Placebo Comparator|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
16599378|NCT02616588|Experimental|Intervention Arm|All participants are enrolled into the intervention arm and receive the Veteran Patient Navigator and Social Work Intervention.
16599379|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
16599380|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
16599381|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
16599382|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.
16599383|NCT02616562|Active Comparator|Open labelled daily Norditropin® (0.034 mg/kg/day)|Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.
16599384|NCT02616549|Experimental|Sudarshan Kriya Yoga|
16599385|NCT02616549|No Intervention|Waitlist Control|
16599386|NCT02616536|Active Comparator|Flipped classroom|The flipped classroom is new pedagogical method, which employs asynchronous video lectures and practice problems as homework and active, group-based problem solving activities in the classroom.
16599387|NCT02616536|Active Comparator|traditional classroom|The classroom lecture is a special form of communication in which voive, gesture. Movements, facial expression and eye contact can either complement or detract from the content. No matter what your topic, your delivery and manner of speaking immeasurably influence your student's' attentiveness and learning.
16599388|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
16599389|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
16599390|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
16599391|NCT02616510||PCOS|Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism
16599392|NCT02616510||POI|amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L
16599393|NCT02616497|Active Comparator|Aspirin|100mg/day
16599394|NCT02616497|Active Comparator|Triflusal|300mg twice or 600mg once daily
16599395|NCT02616484|Active Comparator|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.
~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
16599396|NCT02616484|Placebo Comparator|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.
~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
16599397|NCT02616471|Experimental|High-fat cheese (HFC) group|"The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).
~No further dairy and cheese consumption is allowed"
16599398|NCT02616471|Experimental|Low-fat cheese (LFC) group|The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
16599399|NCT02616471|Active Comparator|No-cheese/carbohydrate group (CTR)|For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
16599400|NCT02616458|Experimental|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours. The research assistant provided and reviewed proper dosing instructions for acetaminophen and ibuprofen, and provided a prescription for antipyrine/benzocaine analgesic ear drops to each family to use as pain relief if their child did develop ear pain in the subsequent 12 months.
16599401|NCT02616458|Active Comparator|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
16599402|NCT02616445|Placebo Comparator|MAD Study|
16599403|NCT02616445|Placebo Comparator|Fed-Fasted|
16599404|NCT02616445|Experimental|CSF|
16599405|NCT02616432|Experimental|Tomosynthesis + FFDM|Women enrolled to DBT Arm will undergo manufacturer-defined DBT
16599406|NCT02616432|No Intervention|FFDM - Standard of Care for Screening|Women enrolled to the FFDM Arm will undergo bilateral digital mammogram with standard CC and MLO views acquired
16599407|NCT02616419|Experimental|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
16599408|NCT02616419|Active Comparator|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
16599409|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
16599410|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
16599411|NCT02616393|Experimental|Cohort A - Brain Metastases|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with BM
16599412|NCT02616393|Experimental|Cohort B - Leptomeningeal Metastases|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with LM
16599413|NCT02616393|Experimental|Cohort C - Brain Metastases at initial presentation|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC with BM at initial presentation
16599414|NCT02616380||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
16599415|NCT02616367|Experimental|liposomal bupivacaine Periarticular injection|Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).
16599416|NCT02616367|Active Comparator|Ropivacaine Periarticular Injection|Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine
16599417|NCT02616354|Active Comparator|Group I|"Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
16599418|NCT02616354|Placebo Comparator|Group II|"group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).
~Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
16599419|NCT02616341|Experimental|Team ERP (T-ERP) Intervention|The ERP team intervention (T-ERP) consists of 25 sessions over 20 weeks with four components: (a) 3-4 pretherapy individual session with therapist, (b) 12 weekly group sessions (90-mins) led by a therapist and, (c) 10 individual coaching sessions with a case manager during weeks 2-11 of the group, and (d) 2 booster group sessions to reinforce relapse prevention
16599420|NCT02616341|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes standard community treatment consisting of a personalized treatment plan and assistance with treatment referrals to available community resources
16599421|NCT02616328||Participants with confirmed rheumatoid arthritis|
16599422|NCT02616315|Placebo Comparator|Group A: Placebo|Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
16599423|NCT02616315|Experimental|Group B: Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
16599424|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
16599425|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
16599426|NCT02616302|Experimental|>30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
16599427|NCT02616302|Experimental|>30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
16599428|NCT02616289|Experimental|Emollient|Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.
16599429|NCT02616289|No Intervention|Control|Routine Standard of care only for severe acute malnutrition.
16599430|NCT02616276|Active Comparator|Control|Control breakfast
16599431|NCT02616276|Experimental|Intervention 1|High glycemic index breakfast
16599432|NCT02616276|Experimental|Intervention 2|Low glycemic index breakfast
16599433|NCT02616263|Experimental|Foot Intervention|The intervention is a progressive, home based exercise program aimed to increase ankle and foot plantarflexion muscle strength, increase ankle dorsiflexion and toe flexion range of motion, and to retrain individuals to dorsiflex the ankle while keeping the toes in a neutral position. A trained physical therapist with experience working with older adults with diabetes and foot specific complications will monitor and progress the exercise program assuring participant safety and maximizing exercise benefit.
16599434|NCT02616263|Active Comparator|Shoulder Intervention|Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation and a tailored dose of active shoulder motion.
16599435|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.
~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
16599436|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
16599437|NCT02616237|Experimental|Intervention Group|"Lifestyle Intervention: The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.
~Besides the Facebook contents, the participants will also receive government printed health information on healthy eating, physical activity, obesity and cancers."
16599438|NCT02616237|No Intervention|Control Group|The participants randomized into the Control Group will only receive government printed health information on healthy eating, physical activity, obesity and cancers.
16599439|NCT02616224||Participants with unresectable LA/mBC|
16599440|NCT02616198|Active Comparator|EquiaFil G-coat|EquiaFil G-coat combination was applied on one randomly selected cavity to be restored
16599441|NCT02616198|Active Comparator|EquiaFil Fuji Varnish|EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored
16599442|NCT02616198|Active Comparator|Riva SC G-coat|River SC G-coat combination was applied on one randomly selected cavity to be restored
16599443|NCT02616198|Active Comparator|Riva SC Fuji Varnish|River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored
16599444|NCT02616185|Experimental|Dose Escalation|PF-06753512
16599445|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
16599446|NCT02616159|Experimental|Oatmeal 1|40 g cereal
16599447|NCT02616159|Experimental|Oatmeal2|40 g cereal
16599448|NCT02616159|Experimental|Oatmeal 3|40 g cereal
16599451|NCT02616146|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
16599452|NCT02616146|Active Comparator|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
16599453|NCT02616120|Placebo Comparator|Placebo|placebo identified to SQJZ herbal mixtures, 29.375g, 2 times per day.for 12 weeks.
16599454|NCT02616120|Active Comparator|SQJZ herbal mixtures|SQJZ herbal mixtures 29.375g, 2 times per day.for 12 weeks.
16599455|NCT02616107|Experimental|Intervention|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the intervention group and will receive the booklet, Managing Cancer Care: A Caregiver's Guide (MCC-CG) (N=18)
16599456|NCT02616107|Active Comparator|Control|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the control group and will receive the Symptom Management Toolkit (N=17)
16599457|NCT02616094|Experimental|Treatment Seeking Alcohol Dependent Adults|Group consists of 100 treatment seeking alcohol dependent (AD) men and women (ages 18-60). AD subjects will complete either 8 weeks of outpatient treatment at the Yale Stress Center, or the first 4 weeks as inpatient treatment at the CNRU, followed by 4 weeks of outpatient treatment at the Yale Stress Center. While in outpatient treatment, AD subjects may be admitted to the CNRU or HRU for the 1-5 days prior to one or both of their scans, to ensure abstinence for their scans.
16599458|NCT02616094|Active Comparator|Social Drinking Controls|Group consists of demographically and handedness matched 50 socially drinking controls. Healthy controls will be moderate and binge/heavy social drinkers who will participate in a single MRI session after baseline assessments. Healthy controls may be admitted to the HRU overnight prior to their scan.
16599459|NCT02616094|Active Comparator|Prazosin/Placebo Group|This is a separate group of 60 treatment seeking AD subjects in a NIAAA-funded RCT of Prazosin vs placebo for alcohol dependence ( PI: Sinha, Hic protocol 0705002691, NCT00585780) to assess target primary and secondary predictors of alcohol treatment outcomes in the context of a currently ongoing RCT. AD subjects enrolled in the PZ/PL RCT will NOT be given drugs as part of this study. That study and intervention is listed elsewhere (NCT00585780). Subjects will participate in a baseline scan and a second scan between weeks 10-12 of the 12-week RCT with follow-ups. PZ/PL is only given to subjects enrolled in 0705002691, not the current protocol.
16599460|NCT02616081||Clean Intermittent Catheterization|
16599461|NCT02616081||Indwelling Catheter|
16599462|NCT02616081||Bladder Surgery|
16599463|NCT02616068|Experimental|transdermal patch & placebo|transdermal patch 100 mg once a day for 7 days and placebo (for loxoprofen sodium 60 mg tablet) by mouth, every 8 hours for 7 days
16599464|NCT02616068|Active Comparator|loxoprofen sodium & placebo|loxoprofen sodium 60 mg by mouth, every 8 hours for 7 days and placebo (for transdermal patch 100 mg) once a day for 7 days
16599465|NCT02616055|Experimental|50mg Daily|One 50mg tesevatinib tablet per day
16599466|NCT02616055|Experimental|100mg Daily|Two 50mg tesevatinib tablets per day
16599467|NCT02616055|Experimental|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
16599468|NCT02616055|Experimental|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
16599469|NCT02616042|Experimental|Centella asiatica and bamboo salt|Participants received a dentifrice which contains Centella asiatica, bamboo salt, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime). All participants used the assigned dentifrices for 4 days in each trial cycle.
16599470|NCT02616042|Experimental|Centella asiatica|Participants received a dentifrice which contains Centella asiatica, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
16599471|NCT02616042|Placebo Comparator|Control dentifrice|Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
16599472|NCT02616029|Experimental|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.
~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
16599473|NCT02616029|Experimental|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.
~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
16599474|NCT02616016|Other|MRI guided High Intensity Focused Ultrasound Treatment|"Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images.
~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.
~An individual treatment sonication will last approximately 30 seconds."
16599475|NCT02616003|Other|Super-super Obese Patients|Multimorbid, super-super obese patients that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 1000 kcal) for weight loss surgery to achieve technical operability.
16599476|NCT02615990|Experimental|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
16599477|NCT02615990|Active Comparator|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
16599478|NCT02615977|Experimental|Intervention|"In the verum treatment condition, i.e. Zooming Joystick Task, 90% of all alcohol-related pictures appear in the landscape format and hence are trained to be pushed away."
16599479|NCT02615977|Placebo Comparator|Placebo Intervention|In the placebo condition, i.e. Zooming Joystick Task (Placebo), alcohol picture are as often pushed away as pulled towards the subject.
16599480|NCT02615951|Other|Nutrient transporters study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression
16599481|NCT02615951|Other|Chemokine receptors study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression
16599482|NCT02615951|Other|Genes study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression
16599483|NCT02615951|Other|Protein surface study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression
16599484|NCT02615951|Other|Protein surface & genes data validation|"Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from protein surface study and genes study arms analysis."
16599485|NCT02615938|Experimental|Start HCQ block Verum|During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
16599486|NCT02615938|Placebo Comparator|Start HCQ block Placebo|At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
16599487|NCT02615938|Experimental|Stop HCQ block Verum|Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
16599488|NCT02615938|Placebo Comparator|Stop HCQ block Placebo|Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
16599489|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation, it is proposed by one of the investigators, patients that clinical data from this psychiatric examination, conducted as part of their usual care, are recorded as part of the research that their is proposed and explained. An information note is then distributed and not collected their opposition
16599490|NCT02615912|Other|Surfactant Exposure|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5% Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5% Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% Silwet* DA-63 (Momentive) 1.5% Sodium lauryl sulfate (Sigma Aldrich) 1.0% Water
16599491|NCT02615899|Active Comparator|Matched|Administer Targeted (specific) balance exercise interventions
16599492|NCT02615899|Active Comparator|Mismatched|Administer Untargeted (non-specific) balance exercise interventions
16599493|NCT02615886|Experimental|Observational Control|Randomized participants will be observed for diarrhea incidences throughout the 6 month trial with no intervention.
16599494|NCT02615886|Experimental|Rice Bran|Randomized participants will consume a measured dose of rice bran daily throughout the 6 month trial.
16599495|NCT02615873|Experimental|AP CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
16599496|NCT02615860|Experimental|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
16599497|NCT02615860|Active Comparator|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
16599498|NCT02615847|Experimental|Memantin arm|Memantinhydrochlorid, administered once per day during 12 month. Dosage is from 0-20 mg.
16599499|NCT02615834|No Intervention|Control group|
16599500|NCT02615834|Active Comparator|Study group|
16599501|NCT02615821|Experimental|Affective Mental Contrasting|"Before the goal formation or mental contrasting activities, participants will receive information about the affective benefits of exercising (e.g. regular physical activity has been shown to reduce stress, physical activity is enjoyable), and related research support including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit affective judgements. Specifically, the affective condition will include the additional prompts Why might you find exercise to be enjoyable, pleasant, exciting, or fun? for eliciting outcomes, and Why might you find exercise to be unenjoyable, unpleasant, boring, or miserable? for eliciting obstacles."
16599502|NCT02615821|Active Comparator|Instrumental Mental Contrasting|"Before the goal formation or mental contrasting activities,participants will receive information about the instrumental benefits of exercising (e.g., regular physical activity reduces the risk of developing cancer) and related research support, again including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit either instrumental judgements. Specifically, the instrumental conditions will include the prompts Why might you find exercise to be useful, advantageous, beneficial, or important? for eliciting outcomes, and Why might you find exercise to be unimportant, useless, inconvenient, or detrimental? for eliciting obstacles."
16599503|NCT02615821|Active Comparator|Standard Mental Contrasting|In the standard condition, the space where the affective and instrumental benefits of physical activity were listed in the instrumental and affective conditions, will be left blank in the standard condition, and no additional prompting questions will be given, allowing for the idiosyncratic identification of obstacles and outcome.
16599504|NCT02615808|Experimental|Oxygen saturation data visualization|During intervention periods staff in both units will have access to the data visualization tool in the electronic health record.
16599505|NCT02615808|No Intervention|Control|During control periods, the staff will not have access to the data visualization and will continue to use standard of care electronic health record and monitor data to understand oxygen status and trends.
16599506|NCT02615795|No Intervention|Control|Best practice
16599507|NCT02615795|Experimental|Intervention|Best practice + Tele Monitoring of physiological parameters (heart frequence, oxygen saturation, weight, FEV1), and answers to disease specific questions, using Tunstall monitoring device.
16599508|NCT02615782|Experimental|A group|"Period 1: CKD-397 1T single oral administration under fasting condition
~Period 2: CKD-397 1T single oral administration under fed condition (high fat meals)"
16599509|NCT02615782|Experimental|B group|"Period 1: CKD-397 1T single oral administration under fed condition (high fat meals)
~Period 2: CKD-397 1T single oral administration under fasting condition"
16599510|NCT02615769|Experimental|Invitation with focused information of spirometry|
16599511|NCT02615769|Active Comparator|Standard invitition|
16599512|NCT02615756|Experimental|Physical exercise|
16599513|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
16599514|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
16599515|NCT02615730|Experimental|Paclitaxel & GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
16599516|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
16599517|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
16599518|NCT02615704||Active APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP with MEMS
16599519|NCT02615704||Active APP without MEMs|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP without MEMS
16599520|NCT02615704||Control APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP with MEMS
16599521|NCT02615704||Control APP without MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP without MEMS
16599522|NCT02615691|Experimental|Previously untreated patients (PUPs)|"Part A (Main Study): Participants age <3 years and not experienced two joint bleeds will receive on- demand treatment of 10-80 international unit per kilogram (IU/kg) of BAX 855 intravenously depending on the severity of the bleeding episode and age <3 years or after a maximum of two joint bleeds will receive prophylaxis treatment with dose of 25-80 IU/kg of BAX855 IV (based on investigator discretion) once weekly for up to 100 EDs.
~Part A (Surgery): In participants, the administration of BAX 855 will be individualized based on the participants IR and half-life. For major surgery to achieve the target level of 80-100% FVIII in plasma of normal FVIII level and for minor surgery >=30-60% FVIII levels for dental or other invasive surgery.
~Part B (Immune tolerance induction [ITI]): Participants will receive prophylaxis treatment of 100-200 IU/kg BAX 855 IV daily or 50 IU/kg three time in a week and will be reduced to twice weekly to maintain FVIII trough level of 1% for further 3 months."
16599523|NCT02615678|Experimental|Acupuncture|Acupuncture including scalp needling will be applied to selected points based on literature
16599524|NCT02615639|Experimental|HPDC-T cells & entecavir|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.
16599525|NCT02615639|Active Comparator|entecavir|entecavir 0.5mg tablet by mouth, every night.
16599526|NCT02615639|Experimental|HPDC-T cells & IFN-a-2a|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
16599527|NCT02615639|Active Comparator|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
16599528|NCT02615639|Experimental|HPDC-T cells & Telbivudine|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.
16599529|NCT02615639|Active Comparator|Telbivudine|Telbivudine 600mg tablet by mouth, every night.
16599530|NCT02615626||Group 1|Periodontal healthy
16599531|NCT02615626||Group 2|Gingivitis, Non-surgical Periodontal Treatment
16599532|NCT02615626||Group 3|Chronic Periodontitis, Non-surgical Periodontal Treatment
16599533|NCT02615613|Experimental|High acceptability meal|A custard recipe was used as the high acceptability meal
16599534|NCT02615613|Experimental|Low acceptability meal|The regular custard recipe was reformulated to yield a low acceptability version
16599535|NCT02615600|Experimental|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
16599536|NCT02615587||AF patients in Denmark / Cohort 1|"The base population of AF patients for diagnosis and health care utilization / resource use will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code will be identified.
~Further Data sources used:
~Registry of Medicinal Product Statistics: for determining the individuals' use of prescription medicine DREAM database: for investigation of sickness benefit and productivity loss Statistics Denmark's databases: on social services from municipalities Cause of Death Registry: AF-patients or controls who died during the study period (2000-2013) Danish Civil Registry: used for identification of controls, holds information about age, gender"
16599537|NCT02615574|Experimental|αDC1 vaccine + CKM|all subjects enrolled in study
16599538|NCT02615561|Experimental|Phase 1 (Cure phase)|Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)
16599539|NCT02615561|Experimental|Phase 2 (Care phase) / Arm 1|Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD
16599540|NCT02615561|Active Comparator|Phase 2 (Care phase) / Arm 2|Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD
16599541|NCT02615548|Experimental|Community exercise class|Regular community exercise class is the intervention. It is an exercise class that incorporate PWR moves( UP,ROCK,STEP,TWIST) and cardiovascular training.
16599542|NCT02615548|Active Comparator|self-directed exercise activity|Self-directed exercise.
16599543|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
16599544|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
16599545|NCT02615509|Other|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.
~After collecting the cases together with ground truth a readers study will be performed."
16599546|NCT02615496||Educational materials: Physicians|
16599547|NCT02615496||Educational materials: Patients|
16599548|NCT02615483|Experimental|Web-based platform|Access to a web-based platform
16599549|NCT02615483|No Intervention|Control|Conventional
16599550|NCT02615470|Experimental|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
16599551|NCT02615470|Active Comparator|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
16599552|NCT02615457|Experimental|Arm I|Patients taking Huaier Granule for adjuvant treatment after the triple negative breast cancer has been surgically removed. The Huaier Granule (Qidong Gaitianli Medicines Co., Ltd.) should be given orally from the 3rd day after surgery up to 5 years after surgery or until study termination.
16599553|NCT02615457|No Intervention|Arm II|Patients not taking Huaier Granule after the triple negative breast cancer has been surgically removed.
16599554|NCT02615444|Experimental|Beta-glucan enriched oatcake|Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
16599555|NCT02615444|Placebo Comparator|Isocaloric control|Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.
16599556|NCT02615431||MitraClip Intervention|the influence of MitraClip on Apnoea Asleep
16599557|NCT02615418|Active Comparator|Fully active treatement|
16599558|NCT02615418|Sham Comparator|partially active|first 2.5 weeks will receive sham treatment followed by active
16599559|NCT02615405|Experimental|EPA|3.5 g/day in Studies 1 & 2
16599560|NCT02615405|Active Comparator|DHA|1.75 g/day in Studies 1 & 2
16599561|NCT02615405|Placebo Comparator|Placebo capsules|oleic oil in Study 1
16599562|NCT02615392|Experimental|Park prescription|The participants in this group will receive a brief counseling on physical activity together with a park prescription that highlights the importance of engaging in at least 150 minutes of physical activity per week and the possibility of engaging in physical activity in the park. In addition, they are invited to join in a structured and supervised physical activity program in the park. The structured physical activity program will take place in public parks located in the participants' neighbourhood. Participants will receive text messages for reminder and registration purposes approximately once a week. Also, participants will receive a sheet to monitor their weekly physical activity, information about parks in their neighborhood, and a counseling phone call half-way through the study.
16599563|NCT02615392|No Intervention|Control|The participants in this group will not be given any park prescription or be invited to participate in the weekly program in the park. However, they will receive all the information materials provided to the experimental group after the study has ended.
16599564|NCT02615379|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care
16599565|NCT02615379|No Intervention|Standard of care|standard wound care for 2 weeks
16599601|NCT02615184|Placebo Comparator|Maintenance: Placebo|Participants who are eligible to enter the Maintenance of Healing period as confirmed by endoscopy will be re-randomized to receive placebo-matching capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
16599635|NCT02614989|Experimental|MRI guided Focused Ultrasound treatment|"MRI guided focused ultrasound thalamotomy
~Patients will undergo unilateral thalmotomy using MRI guided Focused Ultrasound intervention for the treatment of the tremor"
16599566|NCT02615366|Active Comparator|Tranexamic Acid|Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution [1% TXA] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
16599567|NCT02615366|Placebo Comparator|Placebo Control|Placebo control will be either 100 ml of 0.9% NaCl solution or tablets of similar appearance containing no medicinal ingredients; placebo will be administered according to the same regimen as the intervention group.
16599568|NCT02615353|Experimental|Lifestyle Intervention|6 months of a bi-weekly Nutrition Education, Physical Activity, and Behavioral Modification program
16599569|NCT02615353|Placebo Comparator|Usual Care Control|Medical screening and dietary counseling with a Endocrinologist and Registered Dietitian
16599570|NCT02615340|Active Comparator|Enteral melatonin 0.5 mg|Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
16599571|NCT02615340|Active Comparator|Enteral melatonin 2 mg|Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
16599572|NCT02615340|Placebo Comparator|Enteral matched placebo|Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
16599573|NCT02615327|Experimental|Active Treatment 1|8g Polydextrose
16599574|NCT02615327|Experimental|Active Treatment 2|12 g Polydextrose
16599575|NCT02615327|Experimental|Active Treatment 3|16 g Polydextrose
16599576|NCT02615327|Placebo Comparator|Placebo|0 g Polydextrose
16599577|NCT02615314||BPPV without migraine|Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
16599578|NCT02615314||BPPV with migraine|Thirty-two patients (11.4%) with migraine were identified. Diagnosis and classification of migraine and its differentiation from other type of headaches was based on third edition of International classification of headache disorders (ICHD-III beta) by international headache society (IHS). All patients with migraine had migrainous headache with or without aura and they all were diagnosed in our institution and followed by our neurology staff.
16599579|NCT02615301|Experimental|Salmon (HD+HK)|Tailor-made salmon with high levels of vitamin D3 and K1
16599580|NCT02615301|Experimental|Salmon (LD+HK)|Tailor-made salmon with low levels of vitamin D3 and high K1
16599581|NCT02615301|Experimental|Salmon (HD+LK)|Tailor-made salmon with high levels of vitamin D3 and low K1
16599582|NCT02615301|Experimental|Supplement (vitamin D + Calcium)|Supplement with vitamin D and Calcium
16599583|NCT02615288|Active Comparator|High Dose Vitamin D3 (10,000 IU daily)|
16599584|NCT02615288|Placebo Comparator|Low Dose Vitamin D3 (1000 IU daily)|
16599585|NCT02615275|Experimental|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
16599586|NCT02615262|Experimental|Experimental|Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia
16599587|NCT02615262|Placebo Comparator|Control|0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia
16599588|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
16599589|NCT02615236|Experimental|PERINEAL ULTRASOUND|Perineal ultrasound with a bedside scanner by inserting a the probe into the perineum and reviewed in real-time
16599590|NCT02615236|Active Comparator|Clinical diagnosis|Diagnosis of OASIS will be clinically
16599591|NCT02615223|Experimental|Arm1|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
~Patients receive cryoablation therapy."
16599592|NCT02615223|Experimental|Arm2|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
16599593|NCT02615210|No Intervention|Standard|Standard of care biopsies with optional SOC-directed biopsy afterwards
16599594|NCT02615210|Experimental|Study|SOC-directed biopsies using the SpyGlass System plus standard of care biopsies
16599595|NCT02615197|Active Comparator|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014).
16599596|NCT02615197|Experimental|Dialectical Behavior Therapy + DBT Prolonged Exposure protocol|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014) plus an adapted version of Prolonged Exposure therapy for PTSD.
16599597|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of erosive esophagitis [EE] confirmed by endoscopy).
16599598|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of EE confirmed by endoscopy).
16599599|NCT02615184|Experimental|Maintenance: Dexlansoprazole 30 mg|Participants in the Healing Period: Dexlansoprazole 60 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
16599600|NCT02615184|Experimental|Maintenance: Dexlansoprazole 15 mg|Participants in the Healing Period: Dexlansoprazole 30 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
16599602|NCT02615171|Active Comparator|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
16599603|NCT02615171|Active Comparator|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
16599604|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
16599605|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
16599606|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
16599607|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
16599608|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
16599609|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
16599610|NCT02615132|Experimental|Treatment Group|The study SLP will instruct the patient to use the ipad apps as intervention for at least one-hour per day, until they are admitted to outpatient SLP services or for a maximum of 8 weeks, whichever comes first. Throughout the telemedicine treatment phase, patients' progress will be monitored remotely by a study SLP through Apps/Skype/Facetime/Telephone consultation on a weekly basis.
16599611|NCT02615132|No Intervention|Control|Patients will be sent home with standard of care.
16599612|NCT02615119|Experimental|Anorexia nervosa|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
16599613|NCT02615119|Experimental|Generalized anxiety disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
16599614|NCT02615119|Experimental|Panic disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
16599615|NCT02615119|Experimental|Major depressive disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
16599616|NCT02615119|Experimental|Brain injury|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
16599617|NCT02615119|Active Comparator|Healthy comparison|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
16599618|NCT02615106|Experimental|Endostar Combined With Radiotherapy|Drug: Endostar Endostar 7.5 mg/m2/day, day 1-14 Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
16599619|NCT02615080|Active Comparator|CRD007|CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks
16599620|NCT02615080|Placebo Comparator|Placebo|Matching placebo tablets given given twice daily for 14 weeks
16599621|NCT02615067|Experimental|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
16599622|NCT02615054||treated with trastuzmab no cardiac effects|
16599623|NCT02615054||treated with trastuzmab with cardiac effects|
16599624|NCT02615054||healthy volunteers no cancer treatment|
16599625|NCT02615041|Experimental|1 g by bolus injection|1 g of meropenem with bolus injection every 8 h regimen
16599626|NCT02615041|Experimental|1 g by 3 h infusion|1 g of meropenem with 3 h infusion every 8 h regimen
16599627|NCT02615041|Experimental|2 g by 3 hinfusion|2 g of meropenem with 3 h infusion every 8 h regimen
16599628|NCT02615028|Other|Closed eyes double-leg stance|Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
16599629|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
16599630|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
16599631|NCT02615002|Experimental|piromelatine 5 mg|5 mg tablets once daily
16599632|NCT02615002|Experimental|piromelatine 20 mg|20 mg tablets once daily
16599633|NCT02615002|Experimental|piromelatine 50 mg|50 mg tablets once daily
16599634|NCT02615002|Placebo Comparator|Placebo|Placebo tablet once daily
16599636|NCT02614976|No Intervention|Control|No padding before application of blood pressure cuff
16599641|NCT02614937|Experimental|Squalamine and ranibizumab to Week 10|"All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy.
~All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6.
~Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups"
16599642|NCT02614937|Experimental|Continue Squalamine, ranibizumab PRN|Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
16599643|NCT02614937|Experimental|Stop Squalamine, ranibizumab PRN|Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
16599644|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
16599645|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
16599646|NCT02614911||Sick patients|Biological sampling of blood for all patients. Biological sampling of saliva, biopsies (skin and endoscopic), feces, for some patients
16599647|NCT02614911||Healthy relatives|Biological sampling of blood for all healthy relatives
16599648|NCT02614898||Eculizumab|The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.
16599649|NCT02614885||Prophylactic Mastectomy|Females undergoing prophylactic mastectomy with RFA performed on the excised tissue.
16599650|NCT02614872|Experimental|GLASSIA®|Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
16599651|NCT02614872|No Intervention|Institution standard of care (SOC)|Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
16599652|NCT02614859|Active Comparator|A|
16599653|NCT02614859|Experimental|B|
16599654|NCT02614846|Experimental|Hetrombopag Olamine|All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
16599655|NCT02614833|Experimental|Paclitaxel + IMP321 at the RPTD|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
16599656|NCT02614833|Active Comparator|Comparator: Paclitaxel + Placebo|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
16599657|NCT02614820|Experimental|treatment group|inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals
16599658|NCT02614820|Other|control group|inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals
16599659|NCT02614807|Experimental|Intervention|All recruited patients will receive a standard endorsement of lower fluid intake (<1.5 Litres/day) by a hypertension nurse and physician and an additional treatment consisting of a bottle (237 ml) of Nepro (a low sodium, low potassium content protein supplement) a day (supply for 4 weeks will be provided).
16599660|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
16599661|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
16599662|NCT02614768|Experimental|Glucose Sensor|Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
16599663|NCT02614742|Active Comparator|SFX-01|300mg bid for up to 28 days.
16599664|NCT02614742|Placebo Comparator|Placebo|300mg placebo bid for up to 28 days
16599665|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.
~Interventions:
~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
16599666|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.
~Interventions:
~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
16599667|NCT02614716|Experimental|LY3090106|LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
16599668|NCT02614716|Placebo Comparator|Placebo|Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
16599669|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
16599670|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
16599671|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
16599693|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
16599672|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
16599673|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
16599674|NCT02614664||Single ventricle|Patients with single ventricle physiology presenting for laparoscopic procedures.
16599675|NCT02614651|Experimental|The study population|"The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute.
~Intervention: Find visual comfort threshold related to light intensity
~Intervention: Find the size of the visual field
~Intervention: Effectiveness of brightness control
~Intervention: Performance of color correction
~Intervention: Vuzix Wrap 1200DX virtural reality glasses"
16599676|NCT02614638|Active Comparator|1st observational period (before experimental intervention)|"Patients in this arm are included during a first month of observation before the intervention is implemented.
~Intervention: One month of department-wide observation"
16599677|NCT02614638|Experimental|2nd obs. period (during experimental intervention)|"Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented.
~Intervention: Pharm Tech participates in department"
16599678|NCT02614625||Normal subjects|Patient with healthy, normal eyes
16599679|NCT02614625||Eyes with corneal disease|"Subjects that have any of the following conditions
~Corneal dystrophy or degeneration
~Corneal scarring
~Corneal ulcer
~Corneal injury
~Keratoconus
~Patients who had undergone corneal surgery
~Patients with other corneal disease"
16599680|NCT02614625||Eyes with retinal disease|"Subjects that have any of the following conditions:
~Diabetic macular edema
~Cystoid macular edema
~Age related macular degeneration
~Retinal vascular disorders (e.g. retinal artery occlusion)
~Epiretinal membrane
~Choroidal nevus
~Macular hole
~Patients who had undergone retinal surgery
~Patients with other retinal disease"
16599681|NCT02614625||Eyes with glaucoma|Eyes diagnosed with glaucoma of any type and any stage
16599682|NCT02614612|Experimental|Itacitinib (200 mg)|Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
16599683|NCT02614612|Experimental|Itacitinib (300 mg)|Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
16599684|NCT02614599|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
16599685|NCT02614599|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
16599686|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
16599687|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
16599688|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
16599689|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
16599690|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
16599691|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
16599692|NCT02614573|Experimental|The study population|The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.
16599695|NCT02614547|Placebo Comparator|Placebo|Participants received infusion rates of placebo matched to SAGE-547.
16599696|NCT02614547|Experimental|SAGE-547|Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).
16599697|NCT02614534|Experimental|Proactive cytoreductive surgery + HIPEC|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).
16599698|NCT02614534|Active Comparator|Proactive cytoreductive surgery|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).
16599699|NCT02614508|Experimental|Cohort A (buparlisib, ofatumumab)|Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16599700|NCT02614508|Experimental|Cohort B (buparlisib, ibrutinib)|Patients receive buparlisib as in Cohort A and ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16599701|NCT02614495|Experimental|Surufatinib|300mg once-daily
16599702|NCT02614482|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 1 month and 4 months.
16599703|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
16599704|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
16599705|NCT02614456|Experimental|Interferon-gamma and nivolumab|"Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously Nivolumab: 3 mg/kg intravenously
~Induction phase: IFN-γ every other day alone for 1 week Combination phase: IFN-γ every other day & Nivolumab every 2 weeks for 3 months Single agent phase: Nivolumab every 3 weeks up to 1 year"
16599706|NCT02614443|Experimental|Depression Condition|Participants in this group will be offered the Space from Depression programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
16599707|NCT02614443|Experimental|Anxiety Condition|Participants in this group will be offered the Space from Anxiety programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
16599708|NCT02614443|Experimental|Stress Condition|Participants in this group will be offered the Space from Stress programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
16599709|NCT02614430|Active Comparator|Vocational training|Participants are randomized into the intervention group (training) where they are offered a training course of 4-9 weeks of physical training three times a week with a physiotherapist.
16599710|NCT02614430|No Intervention|Control|Participants are randomized into the control group where they are offered the standard treatment.
16599711|NCT02614417||Polysomnography|Patients undergo an one-night in-hospital polysomnography to diagnose sleep-disordered breathing
16599712|NCT02614404|Experimental|Imatinib combination therapy|Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
16599713|NCT02614404|Active Comparator|dihydroartemisinin plus piperaquine|Administration of dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
16599714|NCT02614391|Experimental|Active distraction using a tablet|Children were admitted in a comfortable room with a parent and started to play with a videogame suitable for their age three minutes before procedure. They continued to play the videogame during venipuncture. The use of a computer tablet permitted to play with one hand only.
16599715|NCT02614391|Active Comparator|Passive distracion|Children were admitted in a comfortable room with a parent and received various kinds of passive distractions: nurses singing a song, reading a book, blowing bubbles and playing a puppet show. The technique that most engaged the child, was continued during procedure.
16599716|NCT02614378|Active Comparator|Subject receiving treatment|participant receiving air insufflation
16599717|NCT02614378|Placebo Comparator|Subject receiving placebo|participant not receiving air insufflation
16599718|NCT02614365|Experimental|Aerobic Exercise|6-month 3-time/week aerobic exercise, and a 12-month passive follow-up.
16599719|NCT02614365|Active Comparator|Stretch Exercise|6-month 3-time/week stretch exercise, and a 12-month passive follow-up.
16599720|NCT02614352|Experimental|AG1502|
16599721|NCT02614352|Active Comparator|Candesartan + Atorvastatin|
16599722|NCT02614339|Experimental|metformin|
16599723|NCT02614339|Active Comparator|control|
16599724|NCT02614326|Experimental|Memory Flexibility (MemFlex) Training|MemFlex training draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014). MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks used throughout the workbook, and guides the participant in completion of the tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive a phone call at the beginning of week three to check progress, and clarify any difficulties.
16599747|NCT02614196|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
16599748|NCT02614196|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
16599749|NCT02614196|Experimental|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
16599725|NCT02614326|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. The workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The participant will receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties.
16599726|NCT02614313|Active Comparator|Fructose double-blind|Fructose during breath test, double-blind 35g
16599727|NCT02614313|Active Comparator|Fructose open|Fructose during breath test, open 35g
16599728|NCT02614313|Placebo Comparator|Sweet placebo double-blind|Assugrin during breath test double-blind
16599729|NCT02614313|Placebo Comparator|Neutral placebo double-blind|Water during breath test double-blind
16599730|NCT02614300|Active Comparator|Pulmonary Rehabilitation|These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
16599731|NCT02614300|Active Comparator|Chest Physiotherapy|"The ELTGOL technique (total slow expiration with glottis open in lateral decubitus) for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary."
16599732|NCT02614300|Active Comparator|Pulmonary Rehabilitation and Chest Physiotherapy|"This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.
~Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs."
16599733|NCT02614300|No Intervention|Control Group|"For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.
~The physiotherapist will also do monthly telephone calls for patient's monitoring."
16599734|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
16599735|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
16599736|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
16599737|NCT02614261|Experimental|Galcanezumab 120 mg|"Galcanezumab 240 mg given as loading dose at first dosing visit followed by 120 mg once a month for 2 months by subcutaneous (SC) injection.
~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
16599738|NCT02614261|Experimental|Galcanezumab 240 mg|"Galcanezumab 240 mg given by SC injection once a month for 3 months.
~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
16599739|NCT02614261|Placebo Comparator|Placebo|"Placebo given by SC injection once a month for 3 months.
~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
16599740|NCT02614248|Experimental|Coconut Oil|Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
16599741|NCT02614248|Active Comparator|Standard of Care|Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
16599742|NCT02614235|Experimental|Pocket-ECG III System|After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
16599743|NCT02614235|Active Comparator|Conventional Holter|Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
16599744|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
16599745|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
16599746|NCT02614196|Experimental|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
16599750|NCT02614196|Experimental|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
16599751|NCT02614196|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
16599752|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
16599753|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
16599754|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
16599755|NCT02614157|Experimental|LLND+TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
16599756|NCT02614157|No Intervention|TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND
16599757|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
16599758|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
16599759|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
16599760|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
16599761|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
16599762|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
16599763|NCT02614118|Active Comparator|Ketorolac tromethanine|10 mg oral Ketorolac tromethanine 45 minutes before root canal treatment
16599764|NCT02614118|Active Comparator|Acetaminphen & Ketorolac tromethamine|1000 mg Acetaminophen and 10 mg Ketorolac tromethamine oral 45 minutes before root canal treatment
16599765|NCT02614118|Placebo Comparator|Placebo|placebo 45 minutes before root canal treatment
16599766|NCT02614105|Experimental|Pelvic floor muscle training|Participants in the pelvic floor muscle training group will receive group exercise sessions (1 hour) at the physiotherapy out-patient department of the hospital once a week for 16 weeks with guidance from an experienced pelvic floor physiotherapist. The group exercise sessions will focus on pelvic floor muscle training, relaxation and breathing techniques. Participants in the pelvic floor muscle training group will also receive an individually adapted pelvic floor muscle training program for daily home use.
16599767|NCT02614105|Experimental|Cough-suppression|Participants in the cough-suppression group will receive a group education session with general information about cough-suppression therapy and advice about how to distinguish between unproductive and productive cough to enable them to perform airway clearance techniques when required. In addition, participants will receive one to two individual sessions (30-60 minutes) of cough-suppression therapy tailored to the individual needs based on symptoms and underlying disease activity
16599768|NCT02614105|Experimental|Control group|Participants in the group will receive guidance and instruction in terms of correct contraction of the pelvic floor muscles at clinical assessment. Control group participants will receive brief written information about pelvic floor muscle training and cough-suppression therapy, but no other form of regular follow-up or intervention throughout the intervention period.
16599769|NCT02614092|Experimental|Water based Activity+ Cognitive Training|water-based physical activity + classroom based cognitive training
16599770|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
16599771|NCT02614066|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
16599772|NCT02614040|Active Comparator|0.9% Saline|Patients in a month randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
16599773|NCT02614040|Active Comparator|Physiologically-balanced|Patients in a month randomized to physiologically-balanced isotonic fluid will receive physiologically-balanced isotonic crystalloid (Plasma-Lyte© A or Lactated Ringer's) whenever isotonic intravenous fluid administration is ordered by the treating provider.
16599774|NCT02614014|Experimental|Psychological intervention|Cognitive-behavior interventional program
16599775|NCT02614014|No Intervention|Control|No intervention
16599776|NCT02614001|Experimental|inspiratory muscle training, stroke rehabilitation|Inspiratory muscle training with a pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) will be start at a resistance equal to 30% of their MIP or at a load which patient can tolerate, and then the loading will be gradually increased 2cm H2O per week or as symptom tolerated and according to the RPE scale. Each patient will receive regular post-stroke rehabilitation program.
16599777|NCT02614001|Other|control group|stroke rehabilitation.
16599778|NCT02613988|Other|MR imaging and standard treatment|Patients with glioblastoma undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) at pre-CCRT; 4 weeks after completion of the CCRT; and every 2 or 3 months during the adjuvant temozolomide therapy.
16599779|NCT02613975|Experimental|on positional device|patients who could not tolerate cpap will be provided with positional device for treatment of OSA which will vibrate when patients lie in prone position
16599780|NCT02613975|Experimental|patients on dental device|patients on dental devices but not optimally treated for OSA will be provided positional device for optimization of treatment for OSA, which will vibrate when patients lie in prone position
16599781|NCT02613962|Experimental|relapsed or refractory pediatric tumor|This is a prospective, international, multicentric clinical proof-of-concept study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory pediatric tumors. The molecular screening will be done on a newly biopsied or resected tumor sample obtained at the time of relapse/progression, using high-throughput technologies, primarily WES and RNA Sequencing, and bioinformatics analysis.
16599782|NCT02613949|Active Comparator|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
16599783|NCT02613949|Active Comparator|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
16599784|NCT02613949|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
16599785|NCT02613936|Experimental|Active anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
16599786|NCT02613936|Sham Comparator|Placebo anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
16599787|NCT02613923|Experimental|GO! To Sleep|Participants in the intervention group will be provided with a code and website address to participate in this program. This program includes reminder emails and is 6 weeks in duration. Participants will be given a blood draw to measure biomarkers.
16599788|NCT02613923|Active Comparator|informational control|Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
16599789|NCT02613910|Experimental|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to <= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if <LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
16599790|NCT02613897|Active Comparator|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
16599791|NCT02613897|Active Comparator|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
16599792|NCT02613897|Placebo Comparator|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
16599793|NCT02613884|Experimental|Treatment|All patients with a 25OHD level <30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
16599794|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
16599795|NCT02613845||Cardiac surgery|Study subjects are all patients who underwent cardiac surgery with cardiopulmonary bypass at the University Hospital Basel during the year 2013.
16599796|NCT02613832|Experimental|EPAP Group|The EPAP devices increase the alveolar pressure. This effect is obtained through valves that generate a resistance to airflow during expiration.
16599797|NCT02613832|Experimental|Breath Stacking Group|The Breath Stacking consists on the implementation of subsequent inspiratory efforts through a one way valve, which allows stacked volume of gas during each inspiration, until it reaches a maximum lung volume.
16599798|NCT02613819|Experimental|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)
~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.
~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
16599799|NCT02613806|Experimental|D group (dexmedetomidine)|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion with microperfusion pump at the beginning of the surgery,and continued till end of surgery.
16599800|NCT02613806|Active Comparator|C group (saline)|The patients received equal volume normal saline by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
16599801|NCT02613793||Preterm pre-eclampsia (cases)|Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
16599802|NCT02613793||Pregnant patients (controls)|Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition
16599803|NCT02613780|Active Comparator|Sequential group|Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking
16599804|NCT02613780|Active Comparator|Simultaneous group|Photorefractive keratectomy and crosslinking will be performed on the same day
16599805|NCT02613767||Obese|"BMI >30 kg/m2, Protein meal,
~L-[ring 13C6]Phenylalanine infusion"
16599806|NCT02613767||Overweight|"BMI >25 and < 30 kg/m2, Protein meal,
~L-[ring 13C6]Phenylalanine infusion"
16599807|NCT02613767||Healthy-Weight|"BMI >18 and < 25 kg/m2, Protein meal,
~L-[ring 13C6]Phenylalanine infusion"
16599808|NCT02613754|Experimental|Contingency Management|Contingency Management (CM+): This procedure is designed to reinforce treatment attendance, non-gambling behaviour, and study completion. Participants will earn points that will be recorded on vouchers that could be subsequently redeemed for gift cards at a variety of local businesses. Submission of evidence of gambling behaviour or non-attendance re-sets the point value for future vouchers to the starting level. This intervention is in addition to Treatment as Usual.
16599809|NCT02613754|Active Comparator|Treatment as Usual|Treatment as Usual (TAU): This is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling.
16599810|NCT02613741|Experimental|Intervention|12 weeks of lifestyle-based physical activity intervention
16599811|NCT02613741|No Intervention|Control|12 weeks of no intervention
16599812|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
16599813|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
16599814|NCT02613715|Experimental|Blackberry juice with 12% ethanol|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml alcohol beverage (38%) and 17 g sugar.
16599815|NCT02613715|Experimental|Blackberry juice|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml water and 17 g sugar.
16599816|NCT02613702|Experimental|Modified Free Gingival Graft|Twenty patients will receive the modified free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap, similarly to what is done in a connective tissue graft surgery.
16599817|NCT02613702|Active Comparator|Original Free Gingival Graft technique|Twenty patients will receive the original technique of free gingival graft at the inferior incisors area.
16599818|NCT02613689|Experimental|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
16599819|NCT02613689|Active Comparator|Control Group|Subjects will receive SMS support text messages
16599820|NCT02613676|Experimental|TcB screening before discharge|Participants in this group will be screened for jaundice using the JM 105 transcutaneous device. The TcB value will be plotted on the Bhutani nomogram to assess the risk category. Infants who are categorised as high risk according to the nomogram will require blood sampling for TsB and assessment for need for phototherapy.
16599821|NCT02613676|Other|Standard care (visual inspection)|Participants in this group will be managed routinely according to the current standard of care where babies are assessed for jaundice by visual inspection. Babies in this group will require blood draw for TsB if there are visibly jaundiced
16599822|NCT02613663|Experimental|immediate implants with nanobone graft|Nano-hydroxyapatite bone graft fill the gap between immediate implant and labial bone wall.
16599823|NCT02613663|Active Comparator|immediate implants with autogenous bone graft|Autogenous graft fill the gap between immediate implant and labial bone wall.
16599824|NCT02613650|Experimental|MEK162 and mFOLFIRI, all patients|
16599825|NCT02613598|Experimental|Bortezomib and Ruxolitinib|Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.
16599826|NCT02613585|Experimental|Permethrin Impregnated Clothing|Uniforms and work clothing (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin by Insect Shield.
16599827|NCT02613585|No Intervention|Untreated Clothing|Uniforms and work clothing sent to Insect Shield, washed and refolded (no permethrin applied).
16599828|NCT02613572|Experimental|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
16599829|NCT02613572|Experimental|alpha lipoic acid 800mg|once daily with meal x 5 days
16599830|NCT02613572|Experimental|alpha lipoic acid 1200mg|once daily x 5 days
16599831|NCT02613572|Placebo Comparator|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
16599832|NCT02613572|Experimental|ALA 600 mg|once daily with a meal for 2 weeks
16599833|NCT02613572|Placebo Comparator|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
16599834|NCT02613572|Experimental|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
16599835|NCT02613559|Experimental|TK001 0.1mg|Injection:single Intravitreal Injection
16599836|NCT02613559|Experimental|TK001 0.5mg|Injection:single Intravitreal Injection
16599837|NCT02613559|Experimental|TK001 1.0mg|Injection:single Intravitreal Injection
16599838|NCT02613559|Experimental|TK001 2.0mg|Biological: TK001 Injection:single Intravitreal Injection
16599839|NCT02613559|Experimental|TK001 2.5mg|Biological: TK001 Injection:single Intravitreal Injection
16599840|NCT02613559|Experimental|TK001 3.0mg|Injection:single Intravitreal Injection
16599841|NCT02613546|Experimental|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:
~evaluation session;
~sessions of psychoeducation about the CBT model
~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
16599842|NCT02613546|Other|Control|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
16599843|NCT02613533|Experimental|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
16599844|NCT02613520|Experimental|Group 1a (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
16599845|NCT02613520|Placebo Comparator|Group 1a (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
16599846|NCT02613520|Other|Group 1a (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
16599847|NCT02613520|Experimental|Group 1b (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
16599848|NCT02613520|Placebo Comparator|Group 1b (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
16599849|NCT02613520|Other|Group 1b (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
16599850|NCT02613520|Experimental|Group 2a (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
16599851|NCT02613520|Placebo Comparator|Group 2a (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
16599852|NCT02613520|Experimental|Group 2b (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
16599853|NCT02613520|Placebo Comparator|Group 2b (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
16599854|NCT02613520|Experimental|Group 3a (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
16599855|NCT02613520|Placebo Comparator|Group 3a (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
16599856|NCT02613520|Experimental|Group 3b (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
16599857|NCT02613520|Placebo Comparator|Group 3b (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
16599858|NCT02613520|Experimental|Group 4a (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
16599859|NCT02613520|Placebo Comparator|Group 4a (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
16599860|NCT02613520|Experimental|Group 4b (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
16599861|NCT02613520|Placebo Comparator|Group 4b (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
16599862|NCT02613520|Experimental|Group 5a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.
16599863|NCT02613520|Experimental|Group 5b (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
16599864|NCT02613520|Placebo Comparator|Group 5b (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
16599865|NCT02613520|Experimental|Group 5c (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
16599866|NCT02613520|Placebo Comparator|Group 5c (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
16599867|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
16599868|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
16599869|NCT02613494|Active Comparator|Hyoscine|Hyoscine hydrobromide
16599870|NCT02613494|Active Comparator|Glycopyrrolate|Glycopyrronium bromide
16599871|NCT02613494|Placebo Comparator|Placebo|Placebo
16599872|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
16599873|NCT02613468|Placebo Comparator|Periodontally healthy|"Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.
~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
~Intervation: Collection of periodontal records and pregnancy parameters."
16599874|NCT02613468|Placebo Comparator|Periodontally diseased, untreated|"This group is comprised of individuals who do not accept treatment Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.
~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.
~Birth weight was recorded at the end of pregnancy."
16599875|NCT02613468|Active Comparator|Periodontally diseased, treated|"This group is comprised of individuals who agree to treatment. Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.
~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.
~Initial Periodontal Therapy is completed (calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
~Birth weight was recorded at the end of pregnancy. Intervation: Collection of periodontal records and pregnancy parameters."
16599876|NCT02613455|Active Comparator|Kenalog (triamcinolone )|Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
16599877|NCT02613455|Active Comparator|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
16599878|NCT02613429|Active Comparator|Cranial horizontal|identification of the airway by from the cranial end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination from the cranial end at the level of the thyroid catilage , horizontally and thereafter moving caudally
16599879|NCT02613429|Active Comparator|caudal longitudinal|identification of the airway from the distal end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination caudally, and then moving cranially
16599880|NCT02613416|Experimental|Denosumab|6 monthly subcutaneous injections of denosumab
16599881|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
16599882|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
16599883|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
16599914|NCT02613156||control group|patients in the control group underwent conventional open surgery
16599915|NCT02613143||Surgery|
16599884|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
16599885|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
16599886|NCT02613390|Experimental|MRI-Based Image Guidance|"MRI images of the spine taken of anesthetized participant in the operative prone position. These images are exported into a computer navigation program, and used to help the doctor perform surgery.
~Pain and symptom questionnaires completed at baseline and at follow up."
16599887|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
16599888|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
16599889|NCT02613364|Experimental|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
16599890|NCT02613364|Experimental|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
16599891|NCT02613364|Active Comparator|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
16599892|NCT02613351|Experimental|scooting|incremental test to establish the relationship between leg and breathing heaviness with increasing demand (speed) during scooting
16599893|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
16599894|NCT02613325|Experimental|Arm 1: fPAM imaging & Single cell PAM imaging|"fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.
~When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.
~Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.
~To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged"
16599895|NCT02613286|Experimental|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
16599896|NCT02613286|Active Comparator|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
16599897|NCT02613273|Experimental|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
16599898|NCT02613273|Experimental|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
16599899|NCT02613273|No Intervention|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
16599900|NCT02613260|No Intervention|Usual Care|Patients in this study arm will receive usual care from their primary care clinic.
16599901|NCT02613260|Experimental|FIT Outreach + Usual Care|Patients in this study arm will receive usual care at their primary care clinic and the intervention.
16599902|NCT02613247|Experimental|Immediate-start group|Hylan G-F 20 6 mL intra-articular knee injection
16599903|NCT02613247|Other|Delayed-start group|Washout control group which then becomes an experimental group (Hylan G-F 20 6 mL intra-articular knee injection) at 6 weeks post-enrolment
16599904|NCT02613234|Experimental|Experimental Group|Active Intervention on brain waves by cathode tDCS
16599905|NCT02613234|Sham Comparator|Control Group|Sham Intervention on brain waves by cathode tDCS
16599906|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
16599907|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
16599908|NCT02613195|Experimental|Hydrogen-rich Celsior solution|Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.
16599909|NCT02613195|No Intervention|Celsior solution|Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.
16599910|NCT02613182|Experimental|Open Label|Open Label Study Drug NEOD001
16599911|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
16599912|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
16599913|NCT02613156||laparoscopic group|patients in the laparoscopic group underwent laparoscopic resection of recurrent HCC
16599916|NCT02613130|Experimental|Two-Step stannous fluoride toothpaste|Two-Step stannous fluoride toothpaste
16599917|NCT02613130|Active Comparator|Potassium nitrate toothpaste|Potassium nitrate toothpaste
16599918|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
16599919|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
16599920|NCT02613104|Experimental|Sad to Happy|emotion recognition modification - sad>happy
16599921|NCT02613104|Placebo Comparator|Sad control|emotion recognition modification - sad>happy control
16599922|NCT02613104|Experimental|Angry to Happy|emotion recognition modification - angry>happy
16599923|NCT02613104|Placebo Comparator|Angry control|emotion recognition modification - angry>happy control
16599924|NCT02613091|Experimental|Clemastine|This group will receive 8mg of clemastine daily.
16599925|NCT02613078|Experimental|Gut-Directed Hypnotherapy (GDH)|Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week)
16599926|NCT02613078|Experimental|Probiotic (NS)|Nutritional supplement SymbioLact B once a day diluted in water or tea
16599927|NCT02613078|Active Comparator|Active Controls (AC)|AC group keeps a symptom dairy (self-monitoring)
16599928|NCT02613065|Experimental|Eggwhite protein shake|Participants drink a NOW Foods protein shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
16599929|NCT02613065|Active Comparator|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
16599930|NCT02613052|Placebo Comparator|Agitated Normal Saline|Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.
16599931|NCT02613052|Active Comparator|Albumin only|10 mL of agitated 5% albumin will be used for the bubbly study.
16599932|NCT02613052|Experimental|Albumin and Propofol|7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.
16599933|NCT02613039|Other|female outpatient subjects|Patients requiring combined Oral Contraceptives therapy.
16599934|NCT02613026|Experimental|Combined therapy group|pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.
16599935|NCT02613026|Experimental|Sequential therapy group|cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.
16599936|NCT02613013|Active Comparator|single LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
16599937|NCT02613013|Experimental|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure
16599938|NCT02613000||All enrolled patients/Group A|500 consecutive adult patients will be enrolled in Part A (clinical data)
16599939|NCT02613000||Patients with blood and urine sampling/Group B|Patients with informed consent signed (anticipated 200 out of 500 patients) will participate in Part A (clinical data) and B (intestinal-specific biomarkers from blood and urine)
16599940|NCT02612987|Experimental|iCBT|
16599941|NCT02612974|Experimental|Group A|Hirudinaria granulosa and Qurse mafasil are given
16599942|NCT02612974|Active Comparator|Group B|Qurse mafasil only given
16599943|NCT02612961|Experimental|Saline Instillation|3mL normal saline from pink sodium chloride bullet instilled into tracheostomy immediately prior to suctioning.
16599944|NCT02612961|Sham Comparator|Placebo|Pretend to instill 3mL of normal saline using empty pink sodium chloride bullet immediately prior to suctioning.
16599945|NCT02612948|No Intervention|Standard Care|Standard care for delerium
16599946|NCT02612948|Active Comparator|Quetiapine|Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
16599947|NCT02612922|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
16599948|NCT02612922|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
16599949|NCT02612909|Placebo Comparator|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
16599950|NCT02612909|Active Comparator|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
16599951|NCT02612909|Active Comparator|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
16600035|NCT02612454|Experimental|Body weight 30 kg to <60 kg|Administered Q2W
16599952|NCT02612909|Placebo Comparator|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
16599953|NCT02612909|Experimental|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
16599954|NCT02612896|Experimental|Elimination arm|"Both human and porcine interventions at four-monthly intervals in the first two study years, for a total of six iterations (only human interventions will be detailed here):
~Human: Mass drug administration, praziquantel 10mg/kg, according to the list of WHO recommended anthelmintic drugs for use in preventive chemotherapy for taeniasis. And Health Education"
16599955|NCT02612896|Experimental|Control intervention arm|Human: yearly health education, for a total of five iterations. The intervention on the pig host will not be detailed here)
16599956|NCT02612883||Esophagus|Measuring of tissue perfusion of the esophagus
16599957|NCT02612883||Liver|Measuring of tissue perfusion of the liver
16599958|NCT02612883||Stomach|Measuring of tissue perfusion of the stomach
16599959|NCT02612883||Pancreas|Measuring of tissue perfusion of the pancreas
16599960|NCT02612883||Colon|Measuring of tissue perfusion of the colon
16599961|NCT02612870|Active Comparator|Sienna+ retro and Technetium 1|"Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
16599962|NCT02612870|Active Comparator|Sienna+ peri and Technetium 1|"Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
16599963|NCT02612870|Active Comparator|Sienna+ retro 4-6 and Technetium 1|"Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
16599964|NCT02612870|Active Comparator|Sienna+ peri 4-6 and Technetium 1|"Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
16599965|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
16599966|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
16599967|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
16599968|NCT02612844|Experimental|NNC0143-0406|
16599969|NCT02612844|Active Comparator|Insulin Aspart|
16599970|NCT02612831|Other|Early bariatric surgery|patient receive their procedure early (within 3 months)
16599971|NCT02612831|Other|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
16599972|NCT02612805|Experimental|Aerobic training group|This group perform aerobic hydrogymnastics.
16599973|NCT02612805|Active Comparator|Combined training group|This group perform combined hydrogymnastics.
16599974|NCT02612805|Placebo Comparator|Training placebo|This group perform stretching and relaxation in aquatic environment.
16599975|NCT02612792|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
16599976|NCT02612792|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
16599977|NCT02612792|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin for treating furcation defect
16599978|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
16599979|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
16599980|NCT02612766|Other|Single Arm|This is a single-arm interventional study, in which each patient gets 50 grams/day of pure, uncontaminated oats
16599981|NCT02612753|Experimental|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
16599982|NCT02612753|Sham Comparator|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
16599983|NCT02612740|Experimental|Test Group|The bone defect was filled with granules of deproteinized bovine bone (Bio-Oss, Geistlich Pharm, AG Wolhausen, Switzerland)
16599984|NCT02612740|No Intervention|Control Group|No filling material was used in the bone healing
16599985|NCT02612727|Experimental|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
16599986|NCT02612727|Active Comparator|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
16599987|NCT02612714|Other|medication status|Rosuvastatin 5 mg qd for 6 months, Quitted rosuvastatin for 6 months, Re-administrated rosuvastatin for 6 months
16599988|NCT02612701|Experimental|Cigarettes|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
16599989|NCT02612701|Experimental|E-cigarettes (nicotine free e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
16599990|NCT02612701|Experimental|E-cigarettes (low nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
16600036|NCT02612454|Experimental|Body weight 15 kg to <30 kg|Administered every 4 weeks (Q4W)
16600037|NCT02612454|Experimental|Body weight 5 kg to <15 kg|Administered Q4W
16599991|NCT02612701|Experimental|E-cigarettes (high nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
16599992|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
16599993|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
16599994|NCT02612675|Active Comparator|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
16599995|NCT02612675|Experimental|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
16599996|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
16599997|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
16599998|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
16599999|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
16600000|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
16600001|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
16600002|NCT02612649||Ramosetron group|Female patients with diarrhea-predominant irritable bowel syndrome
16600003|NCT02612636|Active Comparator|ear plug and eye mask|"The patients will not receive the intervention in the first night (N1) from 9 pm to 6 am
~The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
~The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
~The patients will receive the intervention (eye mask and ear plug) in the fourth night (N4) from 9 pm to 6 am."
16600004|NCT02612636|No Intervention|control|The researcher will assess and observe the patients who are receiving the routine hospital nursing care during the four nights.
16600005|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
16600006|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
16600007|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
16600008|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
16600009|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
16600010|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
16600011|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
16600012|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
16600013|NCT02612597|Experimental|Bedrest|4 days of bedrest
16600014|NCT02612597|Experimental|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
16600015|NCT02612584|Experimental|Pinhole soft contact lens|
16600016|NCT02612571||Wind instrument players|A wind instrument is defined as any instrument that contains a resonator, in which a column of air is set into resonation by the player blowing into a mouthpiece at one end of the resonator.
16600017|NCT02612571||Non-wind instrument players|A non-wind instrument is defined as any instrument that does not contain a resonator.
16600018|NCT02612558|Experimental|Fostamatinib 150 mg|Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks
16600019|NCT02612545|Active Comparator|ACT|Patients randomized to ACT will receive DHA-PPQ only
16600020|NCT02612545|Experimental|TACT|Patients randomized to TACT will receive DHA-PPQ plus MQ
16600021|NCT02612532|Experimental|LuCID|"Standardised exhaled volatile organic compound collection by ReCIVA breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)"
16600022|NCT02612519|Experimental|Alfapump - Substudy 1|Alfapump implantation
16600023|NCT02612519|Active Comparator|TIPS - Substudy 1|TIPS implantation
16600024|NCT02612519|Experimental|Alfapump - Substudy 2|Alfapump implantation
16600025|NCT02612519|No Intervention|Standard - Substudy 2|Standard treatment
16600026|NCT02612506|Experimental|Hepalatide|Hepalatide 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
16600027|NCT02612506|Placebo Comparator|Placebo|Placebo 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
16600028|NCT02612480|Experimental|Ticagrelor and acetylsalicylic acid|7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
16600029|NCT02612480|Active Comparator|Clopidogrel and acetylsalicylic acid|7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
16600030|NCT02612480|Placebo Comparator|Placebo and acetylsalicylic acid|7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
16600031|NCT02612480|Placebo Comparator|Placebo|7 day treatment with 2 placebos
16600032|NCT02612467|Experimental|Stratified care|Patients are stratified into low, medium, high risk of poor outcome. Stratified care are delivered by special trained physiotherapists according to risk group
16600033|NCT02612467|Active Comparator|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
16600034|NCT02612454|Experimental|Body weight ≥60 kg|Administered every two weeks (Q2W)
16600040|NCT02612428|Experimental|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
16600041|NCT02612428|Other|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
16600042|NCT02612415|Experimental|High flow nasal cannula (HFNC)|Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC
16600043|NCT02612415|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure delivered using any interface (hood, mask or prongs)
16600044|NCT02612402|Experimental|Learning algorithm|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT the Patients will receive daily messages, a learning algorithm will study the exercise response to each type of message and personalize the best message sequence for each patient.
16600045|NCT02612402|Active Comparator|control|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT THE Patients will receive a weekly reminder to exercise.
16600046|NCT02612389|Experimental|MM Intervention taught via DVD|Receive Meditative Movement training via DVD with pre and post interventional testing.
16600047|NCT02612389|No Intervention|MM Intervention Waitlist Control|Testing at same frequency as Meditative Movement interventional subjects.
16600048|NCT02612376||AD, DS, Mild Cognitive Impairment|Persons with age-related Mild Cognitive Impairment (MCI) or Alzheimer Disease (AD) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria. Individuals with Down Syndrome (DS) according to clinical diagnosis, with cognitive ability sufficient to follow directions.
16600049|NCT02612376||Healthy Controls|"Non-DS community-dwelling controls
~Non-pregnant mothers and fathers of DS individuals (controls)
~An Informant (study partner) available to complete functional interviews/survey measures annually."
16600050|NCT02612363|Experimental|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group
~Analgesia
~Dexmedetomidine start at 0.7ug/kg/hour
~Dose range: 0.2- 0.7 u/kg/hour
~Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
16600051|NCT02612363|Placebo Comparator|Standard sedation|"Control drug for sedation in early goal directed sedation group
~Analgesia
~Control drug
~Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
16600052|NCT02612350||Increased Risk for Cancer Development|The group is to include at least 1000 individuals who are at high risk for the development of cancer. Risk is assessed through the completion of a clinical history questionnaire. Examples of such subjects include those with known hereditary cancer syndrome pathogenic variants without a diagnosis of cancer, with significant family history of breast, ovarian, colon, or lung cancer or melanoma, or another strong history of cancer but no prior molecular diagnosis, heavy smokers or those exposed to carcinogens and mutagens. The individuals who meet criteria for inclusion will undergo cell-free DNA isolation and circulating-tumor DNA (ctDNA) analysis for the detection of genetic mutations associated with the possible development of a malignancy.
16600053|NCT02612337|Experimental|OTO-104|12 mg dexamethasone
16600054|NCT02612337|Placebo Comparator|Placebo|
16600055|NCT02612324|Experimental|Pono Choices|Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program for Middle School Youth in Hawaii. The program includes 9.5 hours of scripted lessons or modules.
16600056|NCT02612324|Active Comparator|Business as Usual|Middle school sexual health content or programs chosen by control group schools.
16600057|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
~TGR-1202: Fixed oral daily dose"
16600058|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6
~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
16600059|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
16600060|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
16600061|NCT02612298|Experimental|arotinolol|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks
16600062|NCT02612298|Active Comparator|Metoprolol|Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
16600063|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
16600064|NCT02612272|Active Comparator|Corticosteroid|"This arm will receive intra-articular betamethasone.
~4cc of 1% lidocaine, 1cc of 0.9% normal saline and 1cc (6 mg) of betamethasone.
~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site
~Please see detailed description of study for further information."
16600065|NCT02612272|Experimental|Ketorolac|"This arm will receive intra articular ketorolac.
~2cc (60 mg) of ketorolac and 4cc of 1% lidocaine
~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site
~Please see detailed description of study for further information."
16600066|NCT02612259|Experimental|TRYPTOPHAN|"tryptophan 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.
~Total treatment duration for each patient is 6 months."
16600067|NCT02612259|Placebo Comparator|PLACEBO|"lactose capsules 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.
~Total treatment duration for each patient is 6 months."
16600068|NCT02612246|Experimental|GLPG1972 single dose|Single oral dose of GLPG1972 solution - ascending doses
16600069|NCT02612246|Placebo Comparator|Placebo single dose|Single oral dose of placebo solution
16600070|NCT02612246|Experimental|GLPG1972 multiple doses|Multiple oral doses of GLPG1972 solution - ascending doses
16600071|NCT02612246|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo solution
16600072|NCT02612233|Active Comparator|Pregabalin|Pregabalin 150mg ON week 1 increased to Pregabalin 300mg ON weeks 2-11 then decrease to Pregabalin 150mg ON week 12 then STOP
16600073|NCT02612233|Active Comparator|Duloxetine|Duloxetine 30mg ON week 1 increase to Duloxetine 60mg weeks 2-11 then decrease to Duloxetine 30mg ON week 12 then STOP
16600074|NCT02612233|Placebo Comparator|Placebo|1 capsule ON week 1- increase to 2 capsules ON week 2-11 then decrease to 1 capsule ON week 12 then STOP.
16600075|NCT02612220|Experimental|Experimental Group|Complete hemostasis will be achieved using BioFoam® Surgical Matrix
16600076|NCT02612220|Active Comparator|Control Group|Complete hemostasis will be achieved without the use of topical agents, using conservative hemostasis
16600077|NCT02612194|Experimental|Cohort 1|c-MET high (> 50%), RON null (0-9%)
16600078|NCT02612194|Experimental|Cohort 2|c-MET + (10-100%), RON + (10-100%)
16600079|NCT02612194|Experimental|Cohort 3|c-MET null (0-9%), RON + (10-100%)
16600080|NCT02612181|Experimental|Dexmedetomidine group|Dexmedetomidine group: Dexmedetomidine infusion for dexmedetomidine group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Dexmedetomidine doses 0-0.7 mcg/kg/h
16600081|NCT02612181|Placebo Comparator|Control group|Control group: Placebo infusion for control group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Control drug doses 0-0.7 mcg/kg/h
16600082|NCT02612168|Experimental|All patients|Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
16600083|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
16600084|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
16600085|NCT02612142|Experimental|aerobic exercise (AE)|Intervention type: Behavioral. Intervention name: Aerobic exercise Intervention description: 10 days of daily aerobic exercise (brisk walking, jogging); duration: 30 minutes per session; intensity: 65%-75% of age-predicted maximal heart rate. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
16600086|NCT02612142|Sham Comparator|stretching exercise (ST)|Intervention type: Behavioral. Intervention name: Stretching exercise Intervention description: 10 days of daily stretching exercise; duration: 30 minutes per session. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
16600087|NCT02612142|No Intervention|no intervention (NI)|No behavioral intervention. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
16600088|NCT02612129|Experimental|arimoclomol|arimoclomol capsules for oral administration (3 times daily). Doses:150-600 mg/day (based on weight)
16600089|NCT02612129|Placebo Comparator|Placebo|Matching placebo capsules
16600090|NCT02612116|Active Comparator|pulverized ticagrelor sublingually|Pulverized ticagrelor 180 mg (Brilique) administered sublingually
16600091|NCT02612116|Active Comparator|pulverized ticagrelor orally|Pulverized ticagrelor 180 mg (Brilique) administered orally
16600092|NCT02612116|Active Comparator|Integral ticagrelor orally|Ticagrelor 180 mg (Brilique) administered orally in integral tablets
16600093|NCT02612103||Active Crohns disease|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index > 4.
16600094|NCT02612103||Crohns disease in remission|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4.
16600095|NCT02612103||Active ulcerative colitis|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index > 3.
16600096|NCT02612103||Ulcerative colitis in remission|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index ≤ 3.
16600097|NCT02612103||Irritable bowel syndrome|Verified irritable bowel syndrome according to standard criteria.
16600098|NCT02612103||Healthy controls|No known chronic diseases which needs continuously medication.
16600099|NCT02612090|Active Comparator|Active Treatment Beverage|Strawberry
16600100|NCT02612090|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
16600101|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
16600102|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
16600103|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
16600104|NCT02612051|Experimental|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
16600105|NCT02612051|Experimental|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
16600106|NCT02612051|Experimental|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
16600107|NCT02612051|Experimental|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16600108|NCT02612051|Experimental|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16600109|NCT02612051|Experimental|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16600110|NCT02612051|Experimental|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
16600111|NCT02612051|Experimental|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.
16600112|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
16600113|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
16600114|NCT02612025|Experimental|Exercise group|Exercise training during intensive medical treatment
16600115|NCT02612025|No Intervention|Control group|Usual Care
16600116|NCT02612012||Axillary radiotherapy|
16600117|NCT02611999|No Intervention|Control|Physicians in this Arm received only a paper memo with a list of common imaging tests and procedures.
16600118|NCT02611999|Experimental|Single Price|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
16600119|NCT02611999|Experimental|Paired Inside/Outside Prices|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
16600120|NCT02611986|Experimental|McGrath MAC|tracheal intubation using the McGrath MAC
16600121|NCT02611986|Experimental|Macintosh Laryngoscope|tracheal intubation using the Macintosh Laryngoscope
16600122|NCT02611973|Experimental|HU without aspirin|
16600123|NCT02611973|Active Comparator|HU + aspirin maintenance|
16600124|NCT02611973|Other|HU + AAG|Observational arm
16600125|NCT02611960|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle until progressive disease (PD) or unacceptable toxicity or a maximum of up to 35 cycles.
16600126|NCT02611960|Active Comparator|Standard of Care Chemotherapy|Participants receive capecitabine 1000 mg/m^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle OR gemcitabine 1250 mg/m^2 IV Days 1 and 8 of each 3-week cycle OR docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.
16600127|NCT02611947||Healthy Volunteers|"Inclusion criteria:
~Aged 18 or more.
~Never smoked.
~No respiratory infection in the 4 weeks before the begin of the study.
~No history of pulmonary resection.
~No active malignancy or malignancy of any organ system within the past 5 years."
16600128|NCT02611934|Experimental|Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
16600129|NCT02611934|No Intervention|no-Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
16600130|NCT02611921|Experimental|Crossover Group: Ketamine verses Placebo|"Phase 1: Two ascending doses of intranasal ketamine
~Two week washout
~Phase 2: Two doses of placebo"
16600131|NCT02611921|Experimental|Crossover Group: Placebo verses Ketamine|"Phase 1: Two doses of placebo
~Two week washout
~Phase 2: Two ascending doses of intranasal ketamine"
16600132|NCT02611908|Experimental|ibrutinib +obinutuzumab|
16600133|NCT02611895|Experimental|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
16600134|NCT02611882|Experimental|High-risk prostate cancer pre-prostatectomy (preRP) population|"Patients with high-risk prostate cancer pre-prostatectomy.
~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
16600135|NCT02611882|Experimental|Biochemical Recurrence (BCR)|"Patients with prostate cancer with biochemical recurrence
~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
16600136|NCT02611882|Experimental|Castrate Resistant Prostate cancer (CRCP) population|"Patients with castrate resistant prostate cancer.
~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
16600137|NCT02611869|Experimental|Cryoballoon|
16600138|NCT02611869|Active Comparator|RF ablation|
16600139|NCT02611856||monochorial-biamniotic pregnancies|
16600163|NCT02611713||Arm B: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device
16600164|NCT02611700|Experimental|experimental group|Nimotuzumab+TP(paclitaxel+cisplatin)
16600165|NCT02611700|Placebo Comparator|control group|Placebo + TP(paclitaxel+cisplatin)
16600140|NCT02611843|Experimental|Peer-Supported Web CBT|Semi-structured brief sessions conducted weekly for the 12 weeks of study treatment by a certified peer support specialist. Sessions focus on helping participants use the skills they are learning in the Web CBT treatment in their daily lives. Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
16600141|NCT02611843|Experimental|Self-Managed Web CBT|Self-managed Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
16600142|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
16600143|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
16600144|NCT02611830|Experimental|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
16600145|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)
~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
16600146|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)
~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
16600147|NCT02611804|Experimental|Diclofenac Sodium Gel, 3%|Diclofenac Sodium Gel, 3%, applied twice daily for 60 days
16600148|NCT02611804|Active Comparator|Solaraze®|Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days
16600149|NCT02611804|Placebo Comparator|Vehicle of Test Product|Vehicle of Test Product, Gel, applied twice daily for 60 days
16600150|NCT02611791|Experimental|Radiofrequency|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genitalia.
16600151|NCT02611791|Sham Comparator|Radiofrenquency Off|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genital which was turned off, but a water-soluble gel was used
16600152|NCT02611778|Experimental|FYB201|FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
16600153|NCT02611778|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
16600154|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
16600155|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
16600156|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
16600157|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
16600158|NCT02611739|Experimental|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
16600159|NCT02611739|Active Comparator|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
16600160|NCT02611726|Active Comparator|Acupuncture treatment|Individualized acupuncture needle insertion according to traditional Chinese and Japanese medicine on top of standard medical care during In-Vitro-Fertilization. Acupuncture needles will be inserted to body surface points following traditional diagnosis (anamnesis, tongue, pulse and abdomen inspection) according to practitioner discretion.
16600161|NCT02611726|No Intervention|Control|Standard medical care during In-Vitro-Fertilization.
16600162|NCT02611713||Arm A: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
16600168|NCT02611661|Other|Stratum 1: Observe|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~No further treatment just observation"
16600169|NCT02611661|Experimental|Stratum 2: Percutaneous ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
16600170|NCT02611661|Experimental|Stratum 3: SBRT|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
16600171|NCT02611661|Experimental|Stratum 4: SBRT + Percutaneous Ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation
~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
16600172|NCT02611661|No Intervention|Stratum 5: Referral for systemic therapy|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
16600173|NCT02611648|No Intervention|standard HLD|Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)
16600174|NCT02611648|Experimental|double HLD|Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)
16600175|NCT02611648|Experimental|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
16600176|NCT02611635||VKA treatment of AF / Cohort 1|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
16600177|NCT02611635||NOAC treatment of AF / Cohort 2|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
16600178|NCT02611622|Active Comparator|Arm 1: Control|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one
~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.
~Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey
~Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
16600179|NCT02611622|Experimental|Arm 2: LUMA ENT™|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one
~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.
~Participants in the intervention group will proceed to viewing the LUMA ENT™ videos pertinent to their thyroid condition using either of the two iPADS (the videos should not last longer than 10 minutes)
~Once video viewing is complete, participants will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist, especially as relates to questions that arise as a result of viewing the video
~Subsequently, the participants will proceed to filling out Demographic Survey and Patient Satisfaction Survey"
16600180|NCT02611609|Experimental|Cohort 1|Low dose MultiStem
16600181|NCT02611609|Experimental|Cohort 2|High dose MultiStem
16600182|NCT02611609|Experimental|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
16600183|NCT02611596|Experimental|Ranolazine|Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
16600184|NCT02611596|Placebo Comparator|Placebo|Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
16600185|NCT02611583|Active Comparator|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
16600186|NCT02611583|Placebo Comparator|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
16600187|NCT02611570||LDCT and follow-up|LDCT(1.5 mSV) at enrollment. If subjects with positive result of LDCT, then subjects will be under surgery, resection or followed by every 3-12 months for their possible occurrence of lung cancer.The frequency of follow-up depends on their pathological status and changes of nodules.
16600188|NCT02611557|Other|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
16600189|NCT02611544|Active Comparator|Acceptance and Commitment Therapy|6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
16600190|NCT02611544|Active Comparator|Survivorship Education|6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
16600191|NCT02611544|Active Comparator|Enhanced Usual Care|"Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled Facing Forward: Life After Cancer Treatment."
16600238|NCT02611206|Experimental|Open Label rTMS|All participants who qualify will undergo 6 weeks of open-label rTMS.
16600239|NCT02611193|Experimental|Manipulative treatment|Manipulative Treatment
16600240|NCT02611193|Sham Comparator|Simulated manipulative treatment|Simulated manipulative treatment
16600266|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
16600192|NCT02611531|Experimental|Video Module Education (VME)|The RE will provide participants with a tablet device and will demonstrate how to access VME and complete the pre/post e-learning assessments. The RE will provide technical support but will neither participate directly in the education nor help with the self-assessments. The participants will first complete the pre-assessment e-learning tool on the tablet. They will then watch the video instruction that will provide a complete demonstration with verbal instructions on correct inhaler technique. Next the participants will complete the post-assessment e-learning tool. Based on participants' performance, they will be directed to further tailored video-instruction. The cycle of self-assessment and video instruction will continue until sufficient mastery has been achieved.
16600193|NCT02611531|Active Comparator|Teach-To-Goal (TTG)|Participants assigned to the TTG condition will be provided with an intensive, iterative education and evaluation strategy that consists of the following steps.
16600194|NCT02611518|Experimental|Panel 1|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 17.
16600195|NCT02611518|Experimental|Panel 2|Participant will be administered a single oral dose of metformin 500-mg on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 16.
16600196|NCT02611505|Experimental|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram [mg] of esketamine base per 100 microliter [mcl]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
16600197|NCT02611505|Experimental|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
16600198|NCT02611505|Experimental|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
16600199|NCT02611492|Active Comparator|Intensive Arm (A)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
~+ Post-SCT Maintenance"
16600200|NCT02611492|Experimental|Light Arm (B)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
~+ Post-SCT Maintenance"
16600201|NCT02611466|Experimental|ASP7962|Participants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
16600202|NCT02611466|Active Comparator|Naproxen|Participants receive 500 mg of naproxen orally twice daily for 4 weeks.
16600203|NCT02611466|Placebo Comparator|Placebo|Participants receive placebo orally twice daily for a period of 4 weeks.
16600204|NCT02611453|Experimental|Single arm|"All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. Air contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium."
16600205|NCT02611440|Experimental|Pharmacist Intervention|It will be a semi -structured interviews with patient and pharmacist over various time after the stroke (at Month0, M3, M6, M9) combined with patient's therapeutic follow-up from various healthcare professionals.
16600206|NCT02611440|No Intervention|Control|No pharmacist intervention planned.
16600207|NCT02611427|Active Comparator|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
16600208|NCT02611427|Active Comparator|Education|Booklet about physical activity
16600209|NCT02611414|Experimental|anodal tDCS|TDCS will be delivered with two saline-soaked sponge electrodes. The main electrode to anodal stimulation will be placed over the motor cortex, M1. The second electrode is neutral and will be placed on the skin overlying the supraorbital region The current will be delivered at the intensity of 2mA for 20 minutes. The procedure will be repeated at five consecutive days.
16600210|NCT02611414|Sham Comparator|Sham tDCS|Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
16600211|NCT02611401|Experimental|Mindulness Based Intervention|intervention with group-based Mindfulness Based Intervention
16600212|NCT02611401|Active Comparator|Active Control|intervention with group-based Psychoeducation and Relaxation
16600213|NCT02611388|Experimental|2/10HZ TEAS pretreatment|Patients were given 30min of 2/10HZ TEAS before anesthesia
16600214|NCT02611388|Experimental|10/50HZ TEAS pretreatment|Patients were given 30min of 10/50HZ TEAS before anesthesia
16600215|NCT02611388|Sham Comparator|fake stimulation|Patients were only attached electrodes without electric current
16600216|NCT02611375|Experimental|tDCS + FTP group|This group of individuals with tetraplegia will receive transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1). Stimulation at 2mA will be applied for 20 minutes while subjects complete a total of 1 hour of functional task practice (FTP) per session. (Only 20 minutes of functional task practice be be performed with stimulation on). 3 sessions will be completed per week for 4 weeks.
16600217|NCT02611375|Active Comparator|PNSS + FTP group|This group of individuals with tetraplegia will receive peripheral nerve somatosensory stimulation (PNSS) to the median nerve of the primary hand being trained. Stimulation will be set to elicit a sensory - not motor - response. Stimulation will be performed concurrently with the entire functional task practice (FTP) session. 3 sessions will be completed per week for 4 weeks.
16600218|NCT02611375|Active Comparator|sham tDCS + FTP group|This group of individuals with tetraplegia will receive sham transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1) alongside functional task practice. Stimulation will be briefly turned on at the beginning of FTP and again after 20 minutes of practice in order to create a sham effect and maintain blinding of the participants. 3 sessions will be completed per week for 4 weeks.
16600263|NCT02611011||Women|Women seeking health services will perform the Congo Red Dot test (GV-005) individually by following the the test instructions
16600264|NCT02610985|Active Comparator|2-Dimensional laparoscopic hysterectomy|traditional 2-D laparoscopy
16600219|NCT02611362|Experimental|Intervention|"Subjects in the intervention group will each receive a smartphone with a data service plan as the active arm. The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
16600220|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
16600221|NCT02611336|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
16600222|NCT02611323|Experimental|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
16600223|NCT02611323|Experimental|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
16600224|NCT02611323|Experimental|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
16600225|NCT02611323|Experimental|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
16600226|NCT02611310||Participants with HER2-positive unresectable LA/mBC|
16600227|NCT02611297|Other|Transbronchial lung biopsy with cryoprobe|
16600228|NCT02611284|Experimental|Treatment Cohort (LISA)|All preterm infants born at < 32 WG between October 2013 and November 2014 who met inclusion criteria were managed by the new LISA technique.
16600229|NCT02611284|Other|Historical Cohort (INSURE)|The control group was collected from the period immediately before the study's initiation (from Jun 2012 to September 2013). This cohort was comprised of preterm infants of less than 32 WG who met the inclusion criteria.
16600230|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
16600231|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
16600232|NCT02611258|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
16600233|NCT02611245|Experimental|Indocyanine green|This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.
16600234|NCT02611232|Active Comparator|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
16600235|NCT02611232|Placebo Comparator|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
16600236|NCT02611219|Experimental|Arm 1: Pediatric patients|"Patients will wear a Fitbit Flex during hospitalization
~Completion of Demographic Data Form at baseline, discharge from hospital, and at the six week clinic visit
~Assist in recording time out of bed using the SCT Daily Activity Log
~Fill out (some with help of parents) applicable questionnaires: Child Health Ratings Inventories-General Health Module (5-12 years), General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years) at baseline, discharge from hospital, and at six week clinic visit
~Patients will be assessed using standard physical therapy assessment tools to determine functioning, muscle strength, endurance, and mobility: The Functional Independence Measure for Children and Manual Muscle Testing is done weekly, discharge from hospital, and at six week clinic visit. The 3-Minute Step Test is done at admission, discharge from hospital, and at six week clinic visit."
16600237|NCT02611219|Experimental|Arm 2: Parents of pediatric patients|"Parents will be considered participants as they will be completing study questionnaires.
~Completion of Demographic Data Form at baseline
~Assist in recording time out of bed using the SCT Daily Activity Log
~Fill out applicable questionnaires: General Health Module-Baseline Parent Report -Adolescent (13-18 Years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), and General Health Module Follow Up Parent Report-School Age (5-12 years), HSCT Module-Follow UP Parent Report School Age (5-12 years), HSCT Module-Follow Up Parent Report Adolescent (13-18 years), HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years) at baseline, discharge from hospital, and at six week clinic visit.
~Assist child with Child Health Ratings Inventories-General Health Module (5-12 years) at baseline, discharge at hospital, and at six week clinic visit"
16600241|NCT02611180||Arm 1: Acute skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).
~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.
~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
16600242|NCT02611180||Arm 2: Chronic skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).
~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.
~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
16600243|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
16600244|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
16600245|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
16600246|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
16600247|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
16600248|NCT02611141|Other|Patient with Retromolar Gap|20 patients with a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
16600249|NCT02611141|Other|Patient without a Retromolar Gap|20 patients without a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
16600250|NCT02611128||Peripubertal girls|Peripubertal girls with varying androgen concentrations will have careful phenotype/genotype assessment, primarily to assess the relationship between urinary exosomal DENND1A.V2 and serum free testosterone concentrations.
16600251|NCT02611102|Experimental|MCT oil + Butter in Coffee|This group will be provided with MCT oil and butter to add to their daily coffee intake.
16600252|NCT02611102|Placebo Comparator|Low calorie coffee|This group will continue to drink their normal daily coffee with < 50kcal of creamer and/or sweetener.
16600253|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
16600254|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
16600255|NCT02611076|Experimental|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
16600256|NCT02611076|Active Comparator|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
16600258|NCT02611050|Experimental|Option Grid|Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
16600259|NCT02611050|Other|Usual Care|Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.
16600260|NCT02611037|Experimental|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2), methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).
~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.
~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
16600261|NCT02611024|Experimental|PM01183 Escalation Group|"PM01183 1.0 mg/m^2 D1 60 min (-5/+20 min) i.v. infusion q3wk
~Irinotecan 75 mg/m^2 D1-8 90 min (-5/+30 min) i.v. infusion q3wk"
16600262|NCT02611024|Experimental|Irinotecan Escalation Group|"PM01183 3.0 mg/m^2 D1 60 min (-5/+20 min) i.v. infusion q3wk
~Irinotecan 15 mg/m^2 D1-8 90 min (-5/+30 min) i.v. infusion q3wk"
16600265|NCT02610985|Experimental|3-Dimensional laparoscopic hysterectomy|experimental 3-D laparoscopy
16600267|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
16600268|NCT02610959|Experimental|Intervention group|Intervention with cod 200 grams two times the week for four months.
16600269|NCT02610959|Experimental|Control group|Control group which will continue to eat their habitual diet.
16600270|NCT02610946|Placebo Comparator|Paper-based|Use of paper-based calenders, reminders, medication list, and blood pressure, fluid intake tracking methods in adolescent renal transplant care
16600271|NCT02610946|Experimental|Electronic application|Use of electronic apps (iphone or i-Pad mini) to determine whether it can improve compliance with transplant care and readiness to transition to adult care.
16600272|NCT02610933|No Intervention|Vitamin K antagonist|Vitamin K antagonist treatment targeting an international normalized ratio of 2 to 3 for 18 months
16600273|NCT02610933|Active Comparator|rivaroxaban|Rivaroxaban 10 mg tablet by mouth once daily for 18 months
16600274|NCT02610933|Active Comparator|rivaroxaban and vitamin K2|Rivaroxaban 10 mg tablet by mouth once daily and MK-7 2000 microgram tablet by mouth thrice weekly for 18 months
16600275|NCT02610920|Experimental|Iron-tracer Injection and Biopsy|Single injection of 30mg of iron sucrose followed by axillary ultrasound-guided biopsy of lymph node within 2 hours.
16600276|NCT02610907|Experimental|Cohort 01a|"This is a sub-study testing three patches consisting of an adhesive patch and a sleeve. The sleeve can contain one of three solutions:
~Buffer Own output Simulated output (digestive enzymes)
~All subjects will test the three solutions at the same time, hence the three patches with different solutions will be placed on the peristomal skin simultanously."
16600277|NCT02610894|Experimental|mHealth application|Participants will be provided an iPad Mini tablet computer loaded with an mHealth application (PoCAH) to provide enhanced post-operative pain care management. The app will utilize algorithms tailored to the patient's needs and symptoms in an attempt to reduce poor outcomes related to post-operative pain management.
16600278|NCT02610894|Active Comparator|Control Group|Participants will be provided an iPad Mini tablet computer loaded with a PDF of the As usual standard discharge and care instructions for post-operative pain care management.
16600279|NCT02610881|Experimental|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
16600280|NCT02610881|Experimental|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
16600281|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
16600282|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
16600283|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
16600284|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
16600285|NCT02610842|Experimental|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
16600286|NCT02610829|Experimental|Gamma Tocopherol|Subjects will ingest 1400 mg gamma tocopherol, orally administered in 3 doses separated by 12 hours.
16600287|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
16600288|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
16600289|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
16600290|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
16600291|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
16600292|NCT02610790||Connected bracelet|Patients with a colorectal surgery planned will be included. Fifteen days before surgery, patients will have a connected bracelet permitting to quantify the number of steps and distance achieved each day before surgery.
16600293|NCT02610777|Active Comparator|Azacitidine|Azacitidine 75 milligram per square meter (mg/m^2), intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles.
16600294|NCT02610777|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 mg/m^2, intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+ or - 10) infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles.
16600295|NCT02610764|Experimental|Experimental diagnostic test|"Evaluation and enumeration of circulating Tumor cells from the blood with two different CTC-detection platforms: one established test (CellSearch) and one experimental test (ScreenCell).
~Control diagnostic test: CT-Scan of the Chest and the Abdomen, Endoscopy and Endosonography, Clinical response and histo pathologic response. (% Of vital tumor Cells in the histologic specimen)."
16600296|NCT02610751||Smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
16600297|NCT02610751||Non-smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
16600298|NCT02610738|Experimental|Junior KICk-OFF education programme|Participants will attend an age appropriate self management programme (Junior KICk-OFF) designed to improve their knowledge and understanding of type 1 diabetes
16600299|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
16600300|NCT02610712|Experimental|TRD patients|Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
16600301|NCT02610699|Active Comparator|Smartphone otoscope/Conventional otoscope|Participating clinicians will use a smartphone otoscope for one month followed by a conventional otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
16600302|NCT02610699|Active Comparator|Conventional otoscope/Smartphone otoscope|Participating clinicians will use a conventional otoscope for one month followed by a smartphone otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
16600303|NCT02610686|Other|Chloroquine|Single treatment arm
16600304|NCT02610647|Other|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.
~Intervention: Tapping test"
16600305|NCT02610647|Experimental|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Tapping test"
16600306|NCT02610647|Experimental|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Blinding mask
~Intervention: Tapping test"
16600307|NCT02610647|Experimental|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Anti-noise helmet
~Intervention: Tapping test"
16600308|NCT02610647|Experimental|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Blinding mask
~Intervention: Anti-noise helmet
~Intervention: Tapping test"
16600309|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
16600310|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
16600311|NCT02610621|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and chemotherapy.
16600312|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
16600313|NCT02610595|Experimental|experimental group|Jianpixiaozhong particles and Wuse Dietotherapy
16600314|NCT02610582|Other|Treatment arm|single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points
16600315|NCT02610582|Other|Waiting group Arm|Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
16600316|NCT02610569|Active Comparator|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
16600317|NCT02610569|Experimental|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
16600318|NCT02610556|Experimental|TP plus IMRT|Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
16600319|NCT02610556|Active Comparator|DDP plus IMRT|Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
16600320|NCT02610543|Experimental|UCB5857|UCB5857 once daily for 12 weeks
16600321|NCT02610543|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
16600322|NCT02610530||Non-Surgery|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
16600323|NCT02610530||Surgery-A|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
16600324|NCT02610530||Surgery-B|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
16600325|NCT02610517|Other|Provider Training|Training providers to offer alcohol pharmacotherapy to at-risk drinkers interested in quitting or reducing their drinking as part of overall HIV care could be an important strategy to reduce hazardous alcohol use in this medically-ill population.
16600326|NCT02610517|Other|Patient Intervention|Determine the effectiveness of a computer-delivered brief intervention (CBI) for reducing hazardous drinking in the HIV clinical care setting at two intervention clinics: University of Alabama at Birmingham (UAB) and the University of Washington (UW).
16600327|NCT02610504|Experimental|Durolane 3ml|Single intra-articular injection into shoulder
16600328|NCT02610491|Placebo Comparator|Placebo|Cellulose
16600329|NCT02610491|Active Comparator|Hesperidin|Citrus peel extract
16600330|NCT02610465||1|Computed Tomography (CT) images
16600331|NCT02610452|Experimental|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.
~Intervention: Clown therapy"
16600332|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
16600333|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
16600334|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
16600335|NCT02610400|Experimental|RACD without RAVC|In this arm, subjects will receive RACD without the addition of RAVC.
16600336|NCT02610400|Experimental|RACD+RAVC|"In this arm, subjects will receive both:
~(i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)"
16600337|NCT02610400|Experimental|rfMDA without RAVC|In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.
16600338|NCT02610400|Experimental|rfMDA+RAVC|"In this arm, subjects will receive both:
~(i) reactive focal mass drug administration (rfMDA) and (ii) RAVC."
16600339|NCT02610387|Active Comparator|Arm 1:tDCS|Transcranial direct current stimulation (tDCS) Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days
16600340|NCT02610387|Sham Comparator|Arm 2: Sham tDCS|Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days
16600341|NCT02610374|Other|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
16600342|NCT02610374|Other|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
16600343|NCT02610374|Other|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
16600344|NCT02610361|Experimental|BGB-283|
16600345|NCT02610348|Experimental|Group A|Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
16600346|NCT02610348|Experimental|Group B|Toddlers vaccinated with Infanrix hexa® in study A3L12
16600347|NCT02610335|Active Comparator|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
16600348|NCT02610335|Other|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
16600349|NCT02610322|Experimental|Whole soy group|Whole soy replacement diet: to incorporate 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods.
16600350|NCT02610322|Placebo Comparator|Control group|Usual diet: to receive a conventional lifestyle education on MetS.
16600351|NCT02610309|Experimental|Family-Based Crisis Intervention|The Family-Based Crisis Intervention (FBCI) is a single-session intervention that takes place in the Emergency Department. Adolescents randomized to the experimental condition received a standard psychiatric evaluation followed by the experimental intervention. FBCI was administered by licensed psychiatric social workers who were trained in the intervention. The research clinician provided FBCI to the suicidal adolescent and his/her parent(s)/guardian(s) in a 60-90 minute session in which she helped the adolescent and family develop a joint crisis narrative of the problem and taught them cognitive-behavioral skill-building, therapeutic readiness, psycho-education about depression, and safety planning.
16600352|NCT02610309|No Intervention|Treatment As Usual|Treatment as usual included an emergency psychiatry evaluation (standard care).
16600353|NCT02610296|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
16600354|NCT02610296|Placebo Comparator|Placebo|isotonic saline
16600355|NCT02610283|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
16600356|NCT02610283|Placebo Comparator|Placebo|isotonic saline
16600357|NCT02610270|Experimental|2 Gums|Athletes that continued their usual training and diet, who took 2 gums of omega 3 (DHA 760 mg) during the experimental period.
16600358|NCT02610270|Experimental|3 Gums|Athletes that continued their usual training and diet, who took 3 gums of omega 3 (DHA 1140 mg) during the experimental period.
16600359|NCT02610270|No Intervention|Control|Athletes and coaches that continued their usual training and diet, but did not take any supplements during the experimental period.
16600360|NCT02610257|Active Comparator|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
16600361|NCT02610257|Active Comparator|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
16600362|NCT02610257|Active Comparator|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
16600363|NCT02610257|Active Comparator|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
16600364|NCT02610257|No Intervention|No Vibration|
16600365|NCT02610244|No Intervention|Treatment As Usual|Standard treatment as usual as directed by the physician.
16600366|NCT02610244|Experimental|Modified Cogmed Training|10 weeks of computerized training (3x weekly for 35-minutes each session) that targets thinking skills that are often impaired in individuals diagnosed with ADHD.
16600367|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
16600368|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
16600369|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
16600370|NCT02610205||Caring touch interventions|The study was conducted as a mixed-methods design. A recruitment of potential study participants was made up from a list of incoming patients arriving at the emergency department following an MVA, and who upon medical examinations were given an injury severity score between 0-3 and subsequently discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating of 0 indicates no physical injury; 1-3 represents minor physical injuries. The patients were informed about the study by mail during the week after the MVA, and those interested in participating in the caring touch intervention were asked to contact the investigator and subsequently completed a written informed consent form during the first encounter with the therapist.
16600371|NCT02610179|Active Comparator|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
16600372|NCT02610179|Experimental|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
16600373|NCT02610166|Experimental|Game|Access to the game.
16600374|NCT02610166|Active Comparator|Usual Care|Control group.
16600375|NCT02610153||Cohort 1|Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units
16600376|NCT02610140|Experimental|BAY94-9343|Drug Anetumab ravtansine given Intravenously (IV)
16600377|NCT02610140|Active Comparator|Vinorelbine|Drug Vinorelbine given Intravenously
16600378|NCT02610127||OBIZUR - Prospective Participants|Participants enrolled and treated with Obizur after the prospective study start date
16600379|NCT02610127||OBIZUR - Retrospective Participants|Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
16600380|NCT02610114|Experimental|Z-Score and computer algorithm|
16600381|NCT02610114|Active Comparator|Z-Score|
16600382|NCT02610101|Active Comparator|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
16600383|NCT02610101|Active Comparator|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
16600384|NCT02610101|Active Comparator|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
16600385|NCT02610088|Active Comparator|Dapagliflozin|Dapagliflozin will be started in patient with type 2 diabetes mellitus
16600386|NCT02610088|Active Comparator|Gliclazide|Gliclazide will be started in patient with type 2 diabetes mellitus
16600387|NCT02610075|Experimental|AZD1775|This is a single-arm study in which all patients will receive AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
16600388|NCT02610062|Experimental|AGS67E 1.2 mg/kg Schedule 1|Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
16600389|NCT02610062|Experimental|AGS67E 1.8 mg/kg Schedule 1|Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
16600390|NCT02610062|Experimental|AGS67E 2.4 mg/kg Schedule 1|Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
16600391|NCT02610062|Experimental|AGS67E 0.6 mg/kg Schedule 2|Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
16600392|NCT02610062|Experimental|AGS67E 0.9 mg/kg Schedule 2|Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
16600393|NCT02610049|Active Comparator|Control|Subjects will receive 8 sessions of Cognitive Processing Therapy.
16600394|NCT02610049|Experimental|Experimental|Subjects will receive 8 sessions of CPT + Art Therapy 8 sessions of individual therapy.
16600395|NCT02610049|Experimental|Experimental 2|Subject to receive 8 sessions of individual therapy for Art + CPT Cognitive Processing Therapy intervention pre-specified to be administered separately.
16600396|NCT02610036||neuropathic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
16600397|NCT02610036||neuroischemic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
16600399|NCT02610010|Experimental|IMRT alone|Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy
16600400|NCT02610010|Active Comparator|IMRT plus concurrent chemotherapy|Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy
16600401|NCT02609997|Experimental|Single-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
16600402|NCT02609997|Experimental|Three-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a three-piece IOL
16600403|NCT02609984|Experimental|CMB305 (sequentially administered LV305 and G305)+Atezolizumab|Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
16600404|NCT02609984|Active Comparator|Atezolizumab|Participants received 1200 mg/day atezolizumab by IV infusion Q3W for up to approximately 2 years.
16600405|NCT02609971|Experimental|Vibration group|The vibration group (Vibration at 50 Hz) will hold an exercise protocol on the vibration platform (model Power Plate® pro5 ™), which is to stay on on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
16600406|NCT02609971|No Intervention|Control group|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
16600407|NCT02609958|Experimental|Treatment Arm A|Varlitinib (ASLAN001) tablets
16600507|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
16600408|NCT02609945|Experimental|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.
~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
16600409|NCT02609932|Other|SD or SS|In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
16600410|NCT02609906|Other|PhilosTM with augmentation (Depuy-Synthes)|The intervention group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)
16600411|NCT02609906|Other|MultiLoc®-Nail (Depuy-Synthes)|The comparison group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
16600412|NCT02609893|Active Comparator|Modified Directly Observed Therapy|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks
16600413|NCT02609893|Active Comparator|Unobserved Dosing|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks
16600414|NCT02609880|Experimental|Cognitive Behavioral Therapy|This group will receive Cognitive Behavioral Therapy to optimize sleep, pain, and mood in women with gynecologic cancers. The therapy will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
16600415|NCT02609880|Placebo Comparator|Psychoeducation|This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
16600416|NCT02609867|Experimental|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
16600417|NCT02609854|Experimental|Sham Sustained Acoustic Medicine Device|Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
16600418|NCT02609854|Experimental|3 MHz Sustained Acoustic Medicine Device|3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
16600419|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
16600422|NCT02609815|Experimental|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
16600423|NCT02609815|Active Comparator|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
16600424|NCT02609802|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
16600425|NCT02609802|Experimental|Desflurane|Anesthesia was maintained with desflurane.
16600426|NCT02609789|Experimental|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
16600427|NCT02609789|Experimental|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
16600428|NCT02609789|Experimental|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
16600429|NCT02609789|Experimental|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
16600430|NCT02609789|Experimental|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
16600431|NCT02609789|Experimental|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
16600432|NCT02609789|Experimental|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
16600433|NCT02609776|Experimental|Part 1:Amivantamab Monotherapy+Combination Dose Escalations|The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
16600434|NCT02609776|Experimental|Part 2:Amivantamab Monotherapy+Combination Dose Expansion|Participants will receive IV infusion of Amivantamab as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety, tolerability, pharmacokinetic, and to assess preliminary efficacy in monotherapy and combination therapy cohorts.
16600435|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
16600436|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
16600437|NCT02609737|Experimental|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging & therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
16600438|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
16600439|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
16600440|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
16600441|NCT02609698|Experimental|Coroflex ISAR 3 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 3 months
16600442|NCT02609698|Active Comparator|Coroflex ISAR 6 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 6 months
16600443|NCT02609685|Other|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
16600444|NCT02609685|No Intervention|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
16600445|NCT02609672|Experimental|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
16600446|NCT02609672|Other|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
16600447|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
16600448|NCT02609646||linezolid|patients treated with linezolid
16600449|NCT02609646||meropenem|patients treated with meropenem
16600450|NCT02609646||piperacillin/tazobactam|patients treated with piperacillin/tazobactam
16600451|NCT02609646||vancomycin|patients treated with vancomycin
16600452|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
16600453|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
16600454|NCT02609620|Experimental|Treatment|In the treatment group: The LunGuard Peristaltic Feeding Tube (PFT) will be positioned in the ICU and positioning will be verified by X-ray. Nutritional formula will be fed into the stomach via the feeding lumen of the PFT
16600455|NCT02609620|Active Comparator|Control|Patients in the control group will have a Convatec Levin Duodenal Tube inserted according to standard procedure, which is considered the gold standard.
16600456|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
16600457|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
16600458|NCT02609594|Active Comparator|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
16600459|NCT02609594|Experimental|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
16600460|NCT02609594|Experimental|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
16600461|NCT02609568||Control Group 1|Children with non-trauma complaints
16600462|NCT02609568||Control Group 2|Children with non TBI and musculoskeletal trauma
16600463|NCT02609568||Cases|Children admitted to hospital with moderate/severe isolatedTBI
16600464|NCT02609555|Experimental|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
16600508|NCT02609295|Placebo Comparator|Placebo|Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily
16600509|NCT02609295|Experimental|ALA group|Individuals who consumed 1.2 g (two capsules) of perilla oil daily
16600465|NCT02609542||STOL group|"STOL children will be recruited in the neuropediatric unit at the GHICL in Lille. Children will be followed and we will determine if capacities of verbal memory of the children presenting STOL diagnosed at an early stage of their development (before 6 years) are predictive of the evolution of the disorder according to their cognitive profile and more specifically, their language profile as well as their tests performances. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
~Patients with a persistent STOL will be identified at the end of the follow up."
16600466|NCT02609542||Control group|Children with no language development disorder willing to participate in the study will be recruited at school. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
16600467|NCT02609529|Experimental|SBI|Entergam 10 g/day PO
16600468|NCT02609529|Placebo Comparator|Placebo|Placebo 10 g/day PO
16600469|NCT02609516||Healthy|Patients without any of the pre-specified chronic diseases
16600470|NCT02609516||Multimorbid|Patients having any two or more of the pre-specified chronic diseases
16600471|NCT02609503|Experimental|Open label|Pembrolizumab
16600472|NCT02609503|Other|Radiation|Intensity Modulated Radiation Therapy (IMRT)
16600473|NCT02609490|Experimental|Treatment-Azilsartan|Azilsartan tabelts
16600474|NCT02609490|Active Comparator|Positive Control-olmesartan medoxomil|olmesartan medoxomil tablets
16600475|NCT02609477|Experimental|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
16600476|NCT02609477|Experimental|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
16600477|NCT02609477|Experimental|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
16600478|NCT02609477|Active Comparator|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
16600479|NCT02609477|Active Comparator|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
16600480|NCT02609477|Placebo Comparator|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
16600481|NCT02609464|Active Comparator|Inturrupted Knotte Sutures|
16600482|NCT02609464|Active Comparator|Barbed Sutures|
16600483|NCT02609451|Experimental|2 weeks|Ileostomy closure after 2 weeks
16600484|NCT02609451|Experimental|12 weeks|Ileostomy closure after 12 weeks
16600485|NCT02609438|Active Comparator|Short breaks|Participants instructed to stand/move for 1-2 minutes every half hour throughout the workday
16600486|NCT02609438|Active Comparator|Long breaks|Participants instructed to take two 15-minute activity breaks during each workday
16600487|NCT02609425|Other|STRATAFIX|Anastomosis of esophagus to stomach
16600488|NCT02609412|Experimental|Static compression of LMTRP|static compression of most sensitive LMTRP with the foam roll for 90 seconds
16600489|NCT02609412|Experimental|Dynamic self-myofascial release of calf|dynamic self-myofascial release rolling back and forth on the entire calf for 90 seconds with the foam roll
16600490|NCT02609412|Placebo Comparator|Placebo laser acupuncture of LMTRP|placebo laser acupuncture applied on most sensitive LMTRP of the calf, light and acoustic sounds provided, but laser remains switched off, 90 seconds
16600491|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
16600492|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
16600493|NCT02609386|Experimental|Regimen 1|IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.
16600494|NCT02609386|Active Comparator|Regimen 2|Regimen 1 but without IRX-2
16600495|NCT02609373|Other|Sleep intervention|Sleep intervention
16600496|NCT02609360|Active Comparator|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
16600497|NCT02609360|Active Comparator|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
16600498|NCT02609360|Experimental|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
16600499|NCT02609347|Experimental|Manual Therapy Group|Participants in the manual therapy group will receive 3 treatment sessions of joint mobilization based on the physical therapist's clinical decision making.
16600500|NCT02609347|Sham Comparator|Control Group|Participants in the control group will receive a sham manual therapy treatment consisting of soft tissue mobilization and Grade I mobilizations at the proximal tib/fib joint.
16600501|NCT02609334|Placebo Comparator|Placebo|Matching placebo tables are given as a single dose
16600502|NCT02609334|Active Comparator|CRD007 Low dose|"Low dose of CRD007 (pemirolast sodium) given as a single dose"
16600503|NCT02609334|Active Comparator|CRD007 High dose|"High dose CRD007 (pemirolast sodium) given as a single dose"
16600504|NCT02609321|Experimental|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
16600505|NCT02609321|Active Comparator|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
16600506|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
16600510|NCT02609282|Experimental|Prompt group|Following an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered by Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing.
16600511|NCT02609282|No Intervention|Control group|The control group will receive the same education session as the prompt group, but will receive no prompts on their PC.
16600512|NCT02609269||Decipher GRID Patients|Patients who have been tested with any of the Decipher suite of genomic solutions.
16600513|NCT02609256|Experimental|Stereotactic infarct tissue aspiration|Patients receive the stereotactic infarct tissue aspiration 24-48 hours after cerebral infarction beside medical therapy.
16600514|NCT02609256|Sham Comparator|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc;
16600515|NCT02609243|Active Comparator|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
16600516|NCT02609243|Active Comparator|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
16600517|NCT02609243|Active Comparator|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
16600518|NCT02609243|Active Comparator|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
16600519|NCT02609230|Experimental|A|For the first arm (A), dose escalation will use the following single patient dose-escalation cohorts based on 'Design 4' proposed by Simon and colleagues: 125, 250, and 500 mg. every 3 weeks.
16600520|NCT02609230|Experimental|B|Following completion of Arm A dose escalation, subsequent cohorts will be tested in a minimum of 3 patients, the Arm B dose cohort will consist of dose levels administered every week (planned dosing of 250, 375, 500 and 625 mg).
16600521|NCT02609217||Multiparous|12 multiparous women and their partners, planned to undergo elective term cesarean section.
16600522|NCT02609217||Nulliparous|12 nulliparous women and their partners, planned to undergo elective term cesarean section.
16600523|NCT02609204|Experimental|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
16600524|NCT02609191|Experimental|The study population: first 30 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body exam using the Discovery A
~Intervention: First whole body exam using the Stratos DR
~Intervention: Second whole body exam using the Stratos DR"
16600525|NCT02609191|Experimental|The study population: last 20 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body exam using the Discovery A
~Intervention: First whole body exam using the Stratos DR"
16600526|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
16600527|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
16600528|NCT02609165|Active Comparator|study group|rhNGF 180 µg/ml eye drops solution
16600529|NCT02609165|Placebo Comparator|control group|vehicle eye drops solution
16600530|NCT02609152|Experimental|Continuous perfusion of esmolol|Intervention: Drug: Continuous perfusion of esmolol
16600531|NCT02609152|Placebo Comparator|Continuous perfusion of saline|Intervention: Continuous perfusion of saline
16600532|NCT02609139|Experimental|<=400mg Modified Release Tablets, Fasted|Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
16600533|NCT02609139|Experimental|100mg Modified Release Tablets, Fasted|100 mg PF-06650833 modified release tablets administered under fasted conditions
16600534|NCT02609139|Experimental|20mg Modified Release Tablets, Fasted|20 mg PF-06650833 modified release tablets administered under fasted conditions
16600535|NCT02609139|Experimental|<= 400mg Modified Release Tablets, Fed|Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
16600536|NCT02609139|Experimental|100mg Modifed Release Tablets, Fed|100 mg PF-06650833 modified release tablets administered with high fat meal food intake
16600537|NCT02609139|Experimental|20mg Modified Release Tablets, Fed|20 mg PF-06650833 modified release tablets administered with high fat meal food intake
16600538|NCT02609126|Experimental|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
16600539|NCT02609126|Placebo Comparator|Vehicle|4 mL carrier fluid
16600540|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
16600541|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
16600577|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
16600578|NCT02608866|Experimental|SF-SSRS|Single-Fraction (SF) Stereotactic Spine Radiosurgery
16600579|NCT02608866|Experimental|MF-SSRS|Multiple-Fraction (MF) Stereotactic Spine Radiosurgery
16600542|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
16600543|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
16600544|NCT02609087|Experimental|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
16600545|NCT02609087|Experimental|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
16600546|NCT02609074|Experimental|CPC/rhBMP-2|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.
~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC/rhBMP-2 microffolds (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
16600547|NCT02609074|Active Comparator|CPC|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.
~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC paste (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
16600548|NCT02609061|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
16600549|NCT02609061|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
16600550|NCT02609061|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating furcation defect
16600551|NCT02609048|Placebo Comparator|Placebo Dose|Placebo Capsule Two Capsules Daily
16600552|NCT02609048|Experimental|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
16600553|NCT02609048|Experimental|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
16600554|NCT02609035|Experimental|Intervention|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.
16600555|NCT02609035|No Intervention|Control|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.
16600556|NCT02609022|Experimental|CV-MG01|The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
16600557|NCT02609022|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
16600558|NCT02609009|Experimental|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
16600559|NCT02609009|Other|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
16600560|NCT02608996|Active Comparator|Subcutaneous BNP|Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
16600561|NCT02608996|Placebo Comparator|Subcutaneous placebo|Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
16600562|NCT02608983|Experimental|Treatment 1|
16600563|NCT02608983|Experimental|Treatment 2|
16600564|NCT02608983|Placebo Comparator|Treatment 3|
16600565|NCT02608970|Experimental|BMS-986177|BMS-986177 specified dose on specified days
16600566|NCT02608970|Other|Placebo|Placebo specified dose on specified days
16600567|NCT02608957|Experimental|Latella Knee Implant System|
16600568|NCT02608944|Experimental|MRI perfusion vs. PET Imaging perfusion|Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging
16600569|NCT02608931|Experimental|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
16600570|NCT02608931|Placebo Comparator|Placebo Capsules|placebo
16600571|NCT02608918|Experimental|BMS-955176|BMS-955176 specified dose on specified days
16600572|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
16600573|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
16600574|NCT02608892|Experimental|Intervention|BSweet2Babies video
16600575|NCT02608892|No Intervention|Control|Usual care
16600576|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
16600580|NCT02608853||Liraglutide-like Cohort|
16600581|NCT02608853||LEADER™-like Cohort|
16600582|NCT02608840|Experimental|MCI auditory stimulation|MCI patients receiving auditory stimulation during sleep (crossover arm 1)
16600583|NCT02608840|Sham Comparator|MCI sham stimulation|Sham intervention: MCI patients sleeping with headphones but sounds not played (crossover arm 2)
16600584|NCT02608840|Experimental|Older adult auditory stimulation|healthy older adults receiving auditory stimulation during sleep (crossover arm 1)
16600585|NCT02608840|Sham Comparator|older adult sham stimulation|Sham intervention: healthy older adults sleeping with headphones but sounds not played (crossover arm 2)
16600586|NCT02608827|Active Comparator|Slow breathing group (GRL)|After randomization and have done aerobic exercise, patients allocated in this arm of the study, using the device-guided breathing - Slow breathing group (GRL), for 15 minutes during the experimental session.
16600587|NCT02608827|Placebo Comparator|Music group (GC)|After randomization and have done aerobic exercise, patients allocated in this study arm will hear slow music - Music group (GC), for 15 minutes during the experimental session.
16600588|NCT02608801||Patients from NoFRACT|Patients from NoFRACT who consent to participate in this sub-study, will be offered examination and treatment with anti-osteoporotic drugs cf. treatment algorithm in the main-study. I.e. if osteoporosis is present clinically or at DXA scan, treatment is started.
16600589|NCT02608788|Active Comparator|S.L.® & Difflam Forte ®|"1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg and 3.0 mg/ml Benzydamine ,Difflam Forte ® 5.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
16600590|NCT02608788|Placebo Comparator|placebo ( for Acular® )|placebo(distilled water)spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
16600591|NCT02608788|Active Comparator|Acular® & S.L.®|"5％ Ketorolac Tromethamine , Acular® 8.0 mg and 1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
16600592|NCT02608788|Experimental|Difflam Forte ® & Acular®|"3.0 mg/ml Benzydamine , Difflam Forte ® 5.0 mg and 5％ Ketorolac Tromethamine Acular® 8.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
16600593|NCT02608775|Experimental|Metrodoloris Medical System|Application of a skin electrode
16600594|NCT02608775|Active Comparator|Aisys® care station, Acertys|SPI calculated from photoplethysmography
16600595|NCT02608762||pediatric/adolescent patients with brain tumors|A prospectively recruited of newly-diagnosed pediatric/adolescent patients with brain tumors or head/neck cancers
16600596|NCT02608749|Experimental|IC|Integrated care (IC)
16600597|NCT02608749|Experimental|LEE|Lower extremity exercise (LEE)
16600598|NCT02608749|Experimental|HC|Home care (HC)
16600599|NCT02608736|Experimental|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
16600600|NCT02608736|Placebo Comparator|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
16600601|NCT02608723|Active Comparator|Standard shock waves device|3 sessions were applied: one per week.
16600602|NCT02608723|Active Comparator|Austere shock waves device|3 sessions were applied: one per week.
16600603|NCT02608723|Active Comparator|Sophisticated shock waves device|3 sessions were applied: one per week.
16600604|NCT02608710|Experimental|Single Dose|Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9.
16600605|NCT02608710|Experimental|Multiple Dose|RDEA3170 12 mg once daily (qd)
16600606|NCT02608710|Experimental|Single Dose Food Effect|Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8.
16600607|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
16600608|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
16600609|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
16600610|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
16600612|NCT02608671|No Intervention|Continuous skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
16600613|NCT02608671|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
16600614|NCT02608658|Experimental|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
16600708|NCT02608151|Active Comparator|Touch massage without oil|massage without oil
16600615|NCT02608632|Experimental|Group 1 (RDN guided by HFS)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access. After that high-frequency stimulation (HFS) was used before the initial and after each radiofrequency (RF) delivery within the renal artery. RDN was considered to have been achieved when the sudden increase of blood pressure (> 15 mm Hg from invasive arterial monitoring) was eliminated in response to HFS.
~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery."
16600616|NCT02608632|Active Comparator|Group 2 (RDN as standard procedure)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access.
~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery. High-frequency stimulation (HFS) was performed before and after RDN to just to verify the response of BP"
16600617|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
16600618|NCT02608606|No Intervention|oral administration of tacrolimus|Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.
16600619|NCT02608606|Active Comparator|sublingual administration of tacrolimus|sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.
16600620|NCT02608593||Implant reconstruction with Strattice|Women having immediate breast reconstruction with partial or total Strattice cover
16600621|NCT02608593||Implant reconstruction without Strattice|Women having immediate implant based breast reconstruction where no Strattice has been used
16600622|NCT02608580|Other|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.
~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
16600623|NCT02608567||Preserved LV GLS|"Patients will be compared according to the level of LV global longitudinal strain (GLS) as derived from transthoracic echocardiography and speckle tracking analysis.
~Two groups will be compared regarding outcome: preserved LV GLS vs. reduced LV GLS. The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data."
16600624|NCT02608567||Reduced LV GLS|The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data.
16600625|NCT02608554|Experimental|Taichi|The 24 forms of simplified TCC recommended as the popular health sport by the General Administration of Sport of China were applied.
16600626|NCT02608554|Active Comparator|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise.
16600627|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
16600628|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
16600629|NCT02608502|Experimental|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
16600630|NCT02608502|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
16600631|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
16600632|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
16600633|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
16600634|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
16600635|NCT02608463|Other|Part A - Neuropathic Pain|Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
16600636|NCT02608463|Other|Part A - Non-Neuropathic Pain|Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
16600637|NCT02608463|Other|Part A - Control|Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
16600638|NCT02608463|Experimental|Part B - rTMS|Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
16600639|NCT02608450|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
16600640|NCT02608450|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
16600641|NCT02608437|Experimental|SGI-110 and Ipilimumab|SGI-110 in combination with Ipilimumab
16600642|NCT02608424|Experimental|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .
~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
16600643|NCT02608411|Experimental|ARQ-197|ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.
16600644|NCT02608398||overweight children at weight-loss camp|This is an observational study there is no intervention. The investigators will carry out metabolic profiling on a cohort of overweight or obese children who are attending a commercial weight loss camp for 2-5 weeks.
16600645|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
16600646|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
16600647|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
16600648|NCT02608372|Experimental|Sequence A|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-UP-CTR
16600649|NCT02608372|Experimental|Sequence B|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-CTR-UP
16600650|NCT02608372|Experimental|Sequence C|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-LD-CTR
16600651|NCT02608372|Experimental|Sequence D|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-CTR-LD
16600652|NCT02608372|Experimental|Sequence E|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-LD-UP
16600653|NCT02608372|Experimental|Sequence F|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-UP-LD
16600654|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
16600655|NCT02608346|Other|Blood sampling|
16600656|NCT02608333|Experimental|ESDM-12|ESDM -12 : 60 children will receive 12 hours a week of ESDM ( Early Start Denver Model)intervention delivered by trained therapists during 2 years.ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
16600657|NCT02608333|Active Comparator|Control group|control group: 120 children will receive heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period
16600658|NCT02608320|Experimental|Treatment Sequence (ACB) Position (RLR)|Participants will receive treatment A (Duragesic 12.5 microgram per hour [mcg/h]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
16600659|NCT02608320|Experimental|Treatment Sequence (BAC) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
16600660|NCT02608320|Experimental|Treatment Sequence (CBA) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
16600661|NCT02608320|Experimental|Treatment Sequence (BCA) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
16600662|NCT02608320|Experimental|Treatment Sequence (CAB) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
16600663|NCT02608320|Experimental|Treatment Sequence (ABC) Position (RLR)|Participants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
16600664|NCT02608320|Experimental|Treatment Sequence (ACB) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
16600665|NCT02608320|Experimental|Treatment Sequence (BAC) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
16600666|NCT02608320|Experimental|Treatment Sequence (CBA) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
16600667|NCT02608320|Experimental|Treatment Sequence (BCA) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
16600668|NCT02608320|Experimental|Treatment Sequence (CAB) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
16600669|NCT02608320|Experimental|Treatment Sequence (ABC) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
16600670|NCT02608320|Experimental|Treatment Sequence (DFE) Position (RLR)|Participants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
16600936|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
16600671|NCT02608320|Experimental|Treatment Sequence (EDF) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
16600672|NCT02608320|Experimental|Treatment Sequence (FED) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
16600673|NCT02608320|Experimental|Treatment Sequence (EFD) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
16600674|NCT02608320|Experimental|Treatment Sequence (FDE) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
16600675|NCT02608320|Experimental|Treatment Sequence (DEF) Position (RLR)|Participants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
16600676|NCT02608320|Experimental|Treatment Sequence (DFE) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
16600677|NCT02608320|Experimental|Treatment Sequence (EDF) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
16600678|NCT02608320|Experimental|Treatment Sequence (FED) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
16600679|NCT02608320|Experimental|Treatment Sequence (EFD) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
16600680|NCT02608320|Experimental|Treatment Sequence (FDE) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
16600681|NCT02608320|Experimental|Treatment Sequence (DEF) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
16600682|NCT02608307||AYA patients|Adolescence and young adults (AYA) who meet eligibility criteria and consent to participate in the study.
16600683|NCT02608307||Parents of AYA patients|Parents of AYA patients who meet eligibility criteria and consent to participate in the study.
16600684|NCT02608307||Health Care Providers (HCPs)|Health care providers who meet eligibility criteria and consent to participate in the study.
16600685|NCT02608294|Experimental|Experimental Group|Kinesio Taping Procedure application with 35% strain.
16600686|NCT02608294|Sham Comparator|Sham Group|Kinesio Taping Sham procedure application without strain.
16600687|NCT02608281|Other|CEDEM|diagnostic contrast enhanced Dual Energy mammograms after Iodine based contrast media administration compared to CE MRI
16600688|NCT02608268|Experimental|Dose escalation MBG453 alone|
16600689|NCT02608268|Experimental|Dose escalation MBG453 in combination with PDR001|
16600690|NCT02608268|Experimental|Dose Ranging group|
16600691|NCT02608268|Experimental|Dose Expansion of MBG453 alone|
16600692|NCT02608268|Experimental|Dose Expansion of MBG453 in combination with PDR001|
16600693|NCT02608268|Experimental|Safety run in for MBG453 in combination with decitabine|
16600694|NCT02608255|Experimental|acute coronary syndromes|
16600695|NCT02608242|Experimental|YH22189|YH22189 FDC tablet of Yuhan Corporation
16600696|NCT02608242|Active Comparator|Twynsta 80/10mg|Telmisartan/Amlodipine 80/10mg (FDC)
16600697|NCT02608242|Active Comparator|Crestor 20mg|Rosuvastatin 20mg
16600698|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.
~BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).
~BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.
~Nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.
~Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.
~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
16600699|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.
~First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes
~Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes
~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
16600700|NCT02608216|Experimental|FLT PET/CT|All subjects will receive an [18F]FLT PET/CT scan.
16600701|NCT02608203|Experimental|patients with gastroenteropancreatic neuroendocrine tumors|
16600702|NCT02608190|Experimental|Active training|Patients will undergo active working memory training (see description of protocol).
16600703|NCT02608190|Active Comparator|Passive training|Patients will undergo passive working memory training (see description of protocol).
16600704|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
16600705|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
16600706|NCT02608164|Active Comparator|Vitamin D oral spray solution|An oral spray solution containing 3000IU (75micrograms) vitamin D3 per spray
16600707|NCT02608164|Active Comparator|Vitamin D capsules|A capsule containing 3000IU (75micrograms) vitamin D3 per capsule
16600709|NCT02608151|Experimental|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
16600710|NCT02608138||1|Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
16600711|NCT02608125|Experimental|PRN1371|Drug: PRN1371
16600712|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
16600713|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
16600714|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
16600715|NCT02608086|Other|Control|"Flyer What can I do facing a crisis?"
16600716|NCT02608086|Experimental|Psychological First Aid|"Psychological First Aid according to an adapted protocol based on the WHO PFA Operation Guide 2012 Brochure Network and Services Flyer What can I do facing a crisis?."
16600717|NCT02608073|Experimental|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
16600718|NCT02608060|Experimental|Epoetin Beta - 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
16600719|NCT02608047||dengue patients|Dengue patients confirmed by Non-structural protein and RNA
16600720|NCT02608047||Healthy controls|Healthy population without any diseases
16600721|NCT02608034|Experimental|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
16600722|NCT02608021||Amnestic mild cognitive impairment|
16600723|NCT02608021||Cognitively normal|
16600724|NCT02608008||Data analysis transfemoral aortic valve implantation|Periinterventional data analysis during structural heart procedures like transfemoral aortic valve implantation with and without the use of EchoNavigator System Release II.
16600725|NCT02608008||Data analysis MitraClip|Periinterventional data analysis during structural heart procedures like MitraClip Implantations with and without the use of EchoNavigator System Release II.
16600726|NCT02608008||Data analysis PFO|Periinterventional data analysis during structural heart procedures like PFO implantations with and without the use of EchoNavigator System Release II.
16600727|NCT02608008||Data analysis ASD|Periinterventional data analysis during structural heart procedures like ASD implantations with and without the use of EchoNavigator System Release II.
16600728|NCT02607995||low key intervention|for the whole group
16600729|NCT02607982|Experimental|Concurrent Chemoradiotherapy Arm|Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
16600730|NCT02607969|Experimental|seen once every six weeks|Parents will be educated about home program and they will be asked to control once every six weeks.
16600731|NCT02607969|Experimental|seen once a week.|Parents will be educated about home program and they will be asked to control once a week.
16600732|NCT02607956|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for at least 144 weeks
16600733|NCT02607956|Active Comparator|Blinded Phase: DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for at least 144 weeks
16600734|NCT02607956|Experimental|Open-Label (OL) Phase|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
16600735|NCT02607943|Experimental|Insulin Glargine|subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events
16600736|NCT02607943|Active Comparator|Regular Insulin|short acting regular insulin pre-meal with added NPH at bed time if start eating
16600737|NCT02607930|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 144 weeks
16600738|NCT02607930|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 144 weeks
16600739|NCT02607930|Experimental|Open-Label (OL) Phase|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
16600740|NCT02607917|Experimental|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
16600741|NCT02607917|Experimental|Media|These geographic areas will receive the media intervention over a two year period.
16600742|NCT02607917|No Intervention|No Intervention|Adjacent states will receive no intervention.
16600743|NCT02607904|Experimental|GWP42003-P|"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).
~Participants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.
~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
16600744|NCT02607891|Experimental|STP + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early.
~STP Arm: Last patient completion October 2018"
16600745|NCT02607891|Placebo Comparator|STP + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.
~STP Arm: Last patient completion February 2018"
16600746|NCT02607891|Experimental|VPA + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.
~VPA Arm: Last patient completion February 2018"
16600747|NCT02607891|Placebo Comparator|VPA + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.
~VPA Arm: Last patient completion January 2018"
16600748|NCT02607865|Experimental|Semaglutide 3 mg|
16600749|NCT02607865|Experimental|Semaglutide 7 mg|
16600750|NCT02607865|Experimental|Semaglutide 14 mg|
16600751|NCT02607865|Active Comparator|Sitagliptin 100 mg|
16600752|NCT02607852|Other|Arm A|Patients between the ages of 5-18 years. They will complete the 5-18 version of the BOQ on iPads or through the HTTPS Tonic link.
16600753|NCT02607852|Other|Arm B|Patients between the ages of 0-4 years. They will complete the 0-4 version of the BOQ and appropriate Pediatric Symptom Checklists (i.e. baby or preschool) on iPads or through the HTTPS Tonic link.
16600754|NCT02607839|Placebo Comparator|normal saline|normal saline intravenous infusion
16600755|NCT02607839|Active Comparator|glucose|glucose intravenous infusion
16600756|NCT02607826|Experimental|Intervention arm|
16600757|NCT02607826|No Intervention|Standard of Care|
16600758|NCT02607813|Experimental|Dose escalation LXH254|
16600759|NCT02607813|Experimental|Dose expansion LXH254: Group 1|
16600760|NCT02607813|Experimental|Dose expansion LXH254: Group 2|
16600761|NCT02607813|Experimental|Dose expansion LXH254: Group 3|
16600762|NCT02607813|Experimental|Dose expansion: LXH254 + PDR001|
16600763|NCT02607813|Experimental|Dose escalation LXH254 + PDR001|
16600764|NCT02607800|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
16600765|NCT02607800|Active Comparator|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
16600766|NCT02607787|Experimental|Exercise Group|As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme. The home-based walking and strengthening intervention is individually tailored for each participant. They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
16600767|NCT02607787|Other|Control Group|This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study. However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24. They are aware of their group allocation throughout the duration of the study.
16600768|NCT02607774|Experimental|Secukinumab|Secukinumab over 24 weeks
16600769|NCT02607761|Experimental|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
16600770|NCT02607761|No Intervention|Control|No intervention
16600771|NCT02607761|Active Comparator|Control 1|2 minutes video with same images but information on work-family balance.
16600772|NCT02607748|Experimental|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
16600773|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
16600774|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
16600775|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
16600776|NCT02607722||Nintedanib|Patients with IPF
16600777|NCT02607709|Placebo Comparator|Nephroureterektomy|scheduled to receive routine standard open or robot assisted nephroureterectomy without lymphadenectomy
16600778|NCT02607709|Experimental|Nephroureterektomy + Lymphadenectomy|scheduled to received mapped lymphadenectomy in conjugation with nephroureterectomy
16600779|NCT02607696|Experimental|Zolpidem 1.75 mg|Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily
16600780|NCT02607696|Experimental|Zolpidem 3.50 mg|Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily
16600781|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
16600782|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
16600783|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
16600784|NCT02607670|Experimental|TAT4 Gel|The participant will apply TAT4 Gel to the nasolabial fold area once daily.
16600785|NCT02607670|Placebo Comparator|Placebo|The participant will apply Placebo Gel to the nasolabial fold area once daily.
16600786|NCT02607657|Experimental|Eplerenone 25 mg|Eplerenone 25 mg Tablet Oral Once daily
16600787|NCT02607657|Experimental|Eplerenone 50 mg|Eplerenone 50 mg Tablet Oral Once daily
16600788|NCT02607657|Experimental|Eplerenone 100 mg|Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily
16600789|NCT02607657|Experimental|Eplerenone 50 mg x 2|Eplerenone 50 mg Tablet Oral Twice daily
16600790|NCT02607657|Experimental|Eplerenone 25 mg x 2|Eplerenone 25 mg Tablet Oral Twice daily
16600791|NCT02607644|Experimental|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
16600792|NCT02607644|Active Comparator|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
16600793|NCT02607631|Experimental|Single arm|Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity
16600794|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
16600795|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
16600796|NCT02607592|Experimental|Nadaplatin and Pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
16600797|NCT02607592|Active Comparator|Cisplatin/Pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
16600798|NCT02607579|Active Comparator|Ropivacaine|This group is given an adductor canal block with Ropivacaine which is the previous gold standard medication.
16600799|NCT02607579|Experimental|Exparel|This group is given an adductor canal block with Exparel which is believed to last longer and provide a better pain relief post-operatively.
16600800|NCT02607566|Experimental|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
16600801|NCT02607566|Active Comparator|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
16600802|NCT02607553|Experimental|Experimental: G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
16600803|NCT02607540|Experimental|Two cycles PF-radiotherapy|"2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
~radiotherapy： 50Gy，2 Gy/d，5d/w."
16600804|NCT02607540|Active Comparator|Four cycles PF-radiotherapy|"4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
~radiotherapy： 50Gy，2 Gy/d，5d/w."
16600805|NCT02607527|Other|Device Implantation|Transcatheter IRIS placement
16600806|NCT02607514|Experimental|immediate yoga arm|participants will immediately start the 8-week hyperthermic yoga intervention
16600807|NCT02607514|Other|delayed yoga arm|participants will wait 8-weeks to start the 8-week hyperthermic yoga intervention
16600808|NCT02607501|Other|eCLIPs BRS|Implant eCLIPs BRS at target aneurysm
16600809|NCT02607488|Placebo Comparator|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
16600810|NCT02607488|Active Comparator|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.
~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
16600811|NCT02607488|Active Comparator|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
16600812|NCT02607488|Active Comparator|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
16600813|NCT02607475|Experimental|Robotic telesonography compared to conventional sonography|All participants will receive two imaging studies: (1) Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix), and (2) conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare).
16600814|NCT02607462|Experimental|PRP|Platelet-rich plasma taken made from centrifuged venous blood.
16600815|NCT02607462|Placebo Comparator|Saline|Sodium chloride 0.9% used as placebo.
16600816|NCT02607449|Experimental|A|Standard TB treatment+ treatment regiment with FS-1 drug. Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.
16600817|NCT02607449|Placebo Comparator|B|Standard TB treatment + treatment regiment with a placebo. Instead of study drug the placebo was given to the patients orally once per day along with other prescribed TB drugs (in quntity equal to study drug).
16600818|NCT02607436|Experimental|Sarpogrelate + Aspirin|Sarpogrelate as an active drug
16600819|NCT02607436|Active Comparator|Aspirin alone|Aspirin as an active comparator
16600820|NCT02607423|Experimental|Diagnostic (18F-FDG PET/CT)|"Patients undergo fludeoxyglucose F-18 PET/CT at baseline and after course 1 of chemotherapy. Patients undergo 1 of 3 chemotherapy regimens at the discretion of the investigator.
~CHEMOTHERAPY REGIMEN 1: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, and 8. Patients also receive cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY REGIMEN 2: Patients receive docetaxel IV over 60 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY REGIMEN 3: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
16600821|NCT02607410|Active Comparator|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
16600822|NCT02607410|Active Comparator|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
16600823|NCT02607384|Experimental|Vision problems|Children with refractive error will be prescribed eyeglass wearing, and children with convergence insufficiency will be given orthoptic exercises. Children with any other vision problem will be given a specialist referral to a pediatric eye specialist.
16600824|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
16600825|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
16600826|NCT02607358||Clopidogrel|Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing
16600827|NCT02607358||Acetacylicacid|Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing
16600828|NCT02607345|Active Comparator|Glucomedics®|25gr Glucomedics®
16600829|NCT02607345|Experimental|Zusto®|25gr Zusto®
16600830|NCT02607332|Experimental|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
16600831|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
16600832|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
16600833|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
16600834|NCT02607306|Active Comparator|Insulin degludec OD|
16600835|NCT02607306|Active Comparator|Liraglutide OD|
16600836|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
16600837|NCT02607280|Experimental|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
16600838|NCT02607267||laparoscopic Roux en Y Gastric Bypass|patients undergoing LRYGB, being the first surgical treatment for severe obesity
16600839|NCT02607267||laparoscopic Sleeve Gastrectomy|patients undergoing LSG, being the first surgical treatment for severe obesity
16600840|NCT02607254|Experimental|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
16600841|NCT02607254|Experimental|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
16600842|NCT02607241|Active Comparator|BRS|"OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.
~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval."
16600843|NCT02607241|Experimental|DCB-only|FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance
16600844|NCT02607228|Experimental|Alobresib Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of alobresib up to 9 mg to determine the MTD.
16600845|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
16600846|NCT02607228|Experimental|Alobresib Dose Expansion (Group 1)|Participants will receive a dose less than or equal to MTD of alobresib (based on safety, pharmacodynamics (PD), and tolerability).
16600847|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 2)|Participants will receive a dose less than or equal to MTD of alobresib plus enzalutamide (based on safety, PD, and tolerability).
16600848|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 3)|Participants will receive alobresib plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
16600849|NCT02607215|Experimental|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days
~DDP:75 mg/m2, D1 every 21 days"
16600850|NCT02607215|Active Comparator|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
16600851|NCT02607202|Experimental|Arm A|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes. Treatment to be repeated Q21 days.
16600852|NCT02607202|Experimental|Arm B|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by carboplatin AUC 2 on Day 1 and 8 by IV administration over 60 minutes. Treatment to be repeated Q21 days.
16600853|NCT02607176|Experimental|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
16600854|NCT02607163|Experimental|dexmedetomidine|dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
16600855|NCT02607163|Placebo Comparator|control|saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
16600856|NCT02607137|Experimental|Health Education|Health information related to physical activity
16600857|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
16600858|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
16600859|NCT02607111|Experimental|open label|Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks
16600860|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
16600937|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
16600861|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
16600862|NCT02607072|Experimental|Aspirin 200 mg daily|Aspirin 200 mg daily
16600863|NCT02607072|Experimental|Aspirin 100 mg daily|Aspirin 100 mg daily
16600864|NCT02607072|Placebo Comparator|Placebo control|Placebo control
16600865|NCT02607046|Experimental|Exercise|Exercise Training
16600866|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
16600867|NCT02607033|Experimental|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
16600868|NCT02607033|Active Comparator|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
16600869|NCT02607020|Experimental|Physical exercise|
16600870|NCT02607020|Active Comparator|Relaxation|
16600871|NCT02607007|Experimental|2% M.F. Milk|Breakfast meal: 250 mL 2% M.F. milk, 75 g white toast, 23.2 g strawberry jam, 100 mL water
16600872|NCT02607007|Experimental|2% M.F. Plain Greek Yogurt|Breakfast meal: 175 g 2% plain Greek yogurt, 75 g white toast, 23.2 g strawberry jam, 100 mL + 75 mL water
16600873|NCT02607007|Experimental|31% M.F. Cheddar Cheese|Breakfast meal: 30 g 31% M.F. cheddar cheese, 75 g white toast, 27.0 g strawberry jam, 100 mL + 220 mL water
16600874|NCT02607007|Experimental|Soy Beverage|Breakfast meal: 250 mL soy beverage, 75 g white toast, 19.3 g strawberry jam, 100 mL water
16600875|NCT02607007|Experimental|Water (control)|Breakfast meal: 250 mL + 100 mL water
16600876|NCT02606994|Experimental|Oral Defense Toothpaste|The experimental group will brush with Oral Defense Toothpaste three times per day during the study
16600877|NCT02606994|Placebo Comparator|Crest Toothpaste/Magic Mouth Rinse|The placebo group will brush with Crest Toothpaste three times per day during the study. Participants in the placebo comparator group who require additional management of their oral mucositis pain will be provided Magic Mouth Rinse.
16600878|NCT02606981|Experimental|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
16600879|NCT02606981|Placebo Comparator|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
16600880|NCT02606955|Experimental|BIA REST|BIA DW assessment
16600881|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
16600882|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
16600883|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
16600884|NCT02606916|Experimental|SMART & S-1/DDP|Patients in experimental group receive daily simultaneous modulated accelerated radiotherapy combined with DDP and S-1.
16600885|NCT02606903|Experimental|BI 695501 prefilled syringe|
16600886|NCT02606903|Experimental|BI 695501 autoinjector|
16600887|NCT02606877|Experimental|Treatment naïve|Treatment naïve to pirfenidone
16600888|NCT02606877|Experimental|Pirfenidone-treated|Treatment before with pirfenidone
16600889|NCT02606864|Experimental|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
16600890|NCT02606864|Experimental|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
16600891|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
16600892|NCT02606812|Experimental|Traditional-food|During the 3 months, a dish containing traditional food will be provided 5 days per week. The food will contain an average of 600 Kcal, ≤ 50 mg of cholesterol, ≥ 10 g of fiber, ≥ 130 g of vegetables, and ≤ de 200 mg of sodium. Each dish will be accompanied with 3 standard-sized corn tortillas.
16600893|NCT02606812|No Intervention|Control|Is the group who will intake the cafeteria fast food. The control group will receive habitually consumed fast food provided by the cafeteria of the campus at a similar caloric proportion.
16600894|NCT02606799|No Intervention|Standard Care|intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
16600895|NCT02606799|Experimental|CytoSorb|all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
16600896|NCT02606786|Experimental|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
16600897|NCT02606773|Experimental|600 mg Novo C plus|Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)
16600898|NCT02606773|Experimental|900 mg Novo C Plus|Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)
16600899|NCT02606773|Active Comparator|500 mg intravenous vitamin C|Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)
16600900|NCT02606773|Active Comparator|500 mg oral vitamin C|Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)
16600901|NCT02606760|Experimental|P-3073|P-3073
16600902|NCT02606760|Placebo Comparator|vehicle of P-3073|vehicle of P-3073
16600903|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
16600904|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
16600905|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
16600906|NCT02606721||Challenge Subjects|Male or female subjects aged 5 - 35 with suspected food allergy and an upcoming scheduled clinical food challenge
16600907|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
16600908|NCT02606695||NuvaMap and NuvaMap OR in Thoracolumbar Spinal Fusion|
16600909|NCT02606682|Experimental|NPT200-11 - Cohort 1, Dose 1|Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600910|NCT02606682|Experimental|NPT200-11 - Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600911|NCT02606682|Experimental|NPT200-11 - Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600912|NCT02606682|Experimental|NPT200-11 - Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600913|NCT02606682|Experimental|NPT200-11 - Cohort 5 ,Dose 5|Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600914|NCT02606682|Experimental|NPT200-11 -Cohort 6, Dose 6|Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600915|NCT02606682|Experimental|NPT200-11 - Cohort 7, Dose 7|Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
16600916|NCT02606669|Experimental|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
16600917|NCT02606669|No Intervention|Control|Diet and Physical Activity advice only. No treatment plan.
16600918|NCT02606643|Active Comparator|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.
~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
16600919|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
16600920|NCT02606630|Experimental|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
16600921|NCT02606617|Active Comparator|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
16600922|NCT02606617|Placebo Comparator|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
16600923|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
16600924|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
16600925|NCT02606591|Experimental|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
16600926|NCT02606565|Experimental|Intervention arm: 4% chlorhexidine|Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
16600927|NCT02606565|No Intervention|Control arm: Dry cord care|Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
16600928|NCT02606552|Active Comparator|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
16600929|NCT02606552|Experimental|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
16600930|NCT02606552|Other|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
16600931|NCT02606539|Active Comparator|surgery and methotrxate|The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG
16600932|NCT02606539|Active Comparator|methotrxate|The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG
16600933|NCT02606526|Experimental|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
16600934|NCT02606526|Active Comparator|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
16600935|NCT02606513|Experimental|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
16600938|NCT02606487||CF pulmonary exacerbation group|Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
16600939|NCT02606461|Experimental|Selinexor 60mg|"Phase 2: 57 patients were randomized to selinexor or placebo in a 1:1allocation.
~Phase 3: Approximately 277 patients will be randomized to selinexor (~185 patients) or placebo (~92 patients) in a 2:1 allocation."
16600940|NCT02606461|Placebo Comparator|Placebo|"Phase 2: Approximately 57 patients were randomized to selinexor or placebo in a 1:1 allocation.
~Phase 3: Approximately 277 patients will be randomized to selinexor (~185 patients) or placebo (~92 patients) in a 2:1 allocation."
16600941|NCT02606448|Active Comparator|Femoral Nerve Block|Patients in this group received preoperative ultrasound guided femoral nerve blocks by senior anesthesiologist using ropivicaine.
16600942|NCT02606448|Experimental|Liposomal Bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
16600943|NCT02606435|Experimental|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
16600944|NCT02606435|Active Comparator|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
16600945|NCT02606422|Experimental|Active HD-tDCS plus Speech-Language Therapy|Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
16600946|NCT02606422|Sham Comparator|Sham plus Speech-Language Therapy|Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.
16600947|NCT02606409|Active Comparator|Dexmedetomidine|Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for >24h.
16600948|NCT02606409|Active Comparator|Propofol|Propofol sedation at 10-70µg/kg/h for >24h.
16600949|NCT02606383|Experimental|Dapaconazole|Dapaconazole 2% Cream Topical
16600950|NCT02606383|Active Comparator|Ketoconazole|Ketoconazole 2% Cream Topical
16600951|NCT02606370|Experimental|Unstable shoes|Wearing unstable shoes during 1 month
16600952|NCT02606370|No Intervention|Control Group|Not Wearing unstable shoes
16600953|NCT02606357|Experimental|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
16600954|NCT02606344|Experimental|Intervention Group (IG)|Loans were provided to poor women who enrolled in the intervention group. A participatory learning and action curriculum was integrated into loan meetings, which took place every 2 weeks.
16600955|NCT02606344|No Intervention|Control Group (CG)|
16600956|NCT02606331|Experimental|Piezosurgery|In one half of the dental arch, piezosurgery will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
16600957|NCT02606331|Experimental|ER:YAG Laser|In one half of the dental arch, ER:YAG laser irradiation will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
16600958|NCT02606318|Experimental|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
16600959|NCT02606318|Other|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
16600960|NCT02606305|Experimental|Regimen A (Mirvetuximab soravtansine + Bevacizumab)|Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
16600961|NCT02606305|Experimental|Regimen B (Mirvetuximab soravtansine + Carboplatin)|Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.
16600962|NCT02606305|Experimental|Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)|Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.
16600963|NCT02606305|Experimental|Regimen D (Mirvetuximab soravtansine + Pembrolizumab)|Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
16600964|NCT02606305|Experimental|Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)|Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.
16600965|NCT02606292|Experimental|Arm 1: PAE assessment|-The PAE-EUS assessment will be performed in the operating room by the after induction of general anesthesia and following strict sterile technique while the patient is being positioned and prepped for esophageal surgery.
16600966|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
16600967|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
16600968|NCT02606266|Experimental|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
16600969|NCT02606266|No Intervention|Control group|Control group with standard care who do not receive the investigational medicinal product
16600970|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
16600971|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
16600972|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
16600973|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
16600974|NCT02606227|Experimental|Experimental group:financial incentives|Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
16600975|NCT02606227|Other|Control group:no financial intervention|Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
16600976|NCT02606214|Experimental|Dose Level 1: 50 mg TBA-354|50 mg TBA-354 for 14 days (two 25 mg once daily)
16600977|NCT02606214|Placebo Comparator|Dose Level 1: Placebo|Placebo cohort for Dose Level 1
16600978|NCT02606214|Experimental|Dose Level 2: 100 mg TBA-354|100 mg TBA-354 for 14 days (one 100 mg tablet once daily)
16600979|NCT02606214|Placebo Comparator|Dose Level 2: Placebo|Placebo cohort for Dose Level 2
16600980|NCT02606214|Experimental|Dose Level 3: 200 mg TBA-354|200 mg TBA-354 for 14 days (two 100 mg once daily)
16600981|NCT02606214|Placebo Comparator|Dose Level 3: Placebo|Placebo cohort for Dose Level 3
16600982|NCT02606214|Experimental|Dose Formulation Comparison Cohort|"All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.
~Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose."
16600983|NCT02606201|Experimental|IPSMA|Injection Peri Sphincter Myofibers Autologous
16600984|NCT02606188|Active Comparator|Modified High-flow nasal cannula therapy|Patients undergoing bronchoscopy are given Modified High-flow nasal cannula oxygen therapy all the time.
16600985|NCT02606188|Active Comparator|Nasal cnnnula therapy|Patients undergoing bronchoscopy are given nasal cannula oxygen therapy all the time.
16600986|NCT02606175|Other|Admitted for renal transplantation|"Patients who are hospitalised on the abdominal transplantation surgery ward at the University Hospitals of Leuven (UZLeuven) and undergo a kidney transplantation during this hospitalisation.
~Intervention: taking questionnaires and tests at predefined timepoints:
~at discharge: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire
~1 month after kidney transplantation: BAASIS, medication knowledge test
~3 months after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test
~1 year after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire
~2 years after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire"
16600987|NCT02606149|Active Comparator|Standard of information|Information on chemotherapy as done in routine practice following national and international guidelines
16600988|NCT02606149|Experimental|Truthful information on chemotherapy risks|Information on the potential role of anticancer chemotherapy in worsening life-threatening conditions
16600989|NCT02606136|Experimental|pamrevlumab (FG-3019)|Each subject will receive pamrevlumab (FG-3019) (35 mg/kg, every 2 weeks) for up to 156 weeks.
16600990|NCT02606123|Experimental|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
16600991|NCT02606097|Experimental|regorafenib|regorafenib 160 mg daily, 3 weeks on/1 week off
16600992|NCT02606084|Experimental|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance [CLCR,m] greater than or equal to >= 50 to 79 milliliter/minute [mL/min]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
16600993|NCT02606084|Experimental|Cohort 2|Participants with moderate renal impairment (CLCR,m >=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
16600994|NCT02606084|Experimental|Cohort 3|Participants with severe renal impairment (CLCR,m less than [<] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
16600995|NCT02606084|Experimental|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m >= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
16600996|NCT02606058|No Intervention|Early cord clamping (Control Arm)|Immediate cord clamping (< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.
16600997|NCT02606058|Experimental|Deferred cord clamping|Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.
16600998|NCT02606045|Active Comparator|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
16600999|NCT02606045|Active Comparator|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
16601000|NCT02606032|Active Comparator|Metronidazole+doxycylcine+terbinafine|Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days
16601001|NCT02606032|Placebo Comparator|Placebo|Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days
16601002|NCT02606006|Active Comparator|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
16601003|NCT02606006|Experimental|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
16601004|NCT02605993|Experimental|Cohort 1|"During the Treatment Period, participants were administered ravulizumab 1400 milligram (mg) on Day 1, ravulizumab 1000 mg on Day 15 and Day 29, and then ravulizumab 1000 mg every 4 weeks for 7 doses.
~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kilograms (kg), 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
16601034|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
16601065|NCT02605629|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
16601066|NCT02605629|Placebo Comparator|Placebo|Patients will self-administer the study placebo twice per day (morning, evening) for 6 months, for the efficacy assessment
16601005|NCT02605993|Experimental|Cohort 2|"During the Treatment Period, participants were administered ravulizumab 2000 mg on Day 1, ravulizumab 1600 mg on Day 22 and Day 43, and then ravulizumab 1600 mg every 6 weeks for 4 doses.
~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
16601006|NCT02605993|Experimental|Cohort 3|"During the Treatment Period, participants were administered ravulizumab 1600 mg on Day 1 and Day 15, ravulizumab 2400 mg on Day 29, and then ravulizumab 2400 mg every 8 weeks for 3 doses.
~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
16601007|NCT02605993|Experimental|Cohort 4|"During the Treatment Period, participants were administered ravulizumab 3000 mg on Day 1, ravulizumab 5400 mg on Day 29, and then ravulizumab 5400 mg every 12 weeks for 2 doses.
~During the Extension Period, participants were administered ravulizumab 5400 mg every 12 weeks for up to 5 years."
16601008|NCT02605980||Male|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
16601009|NCT02605980||Female|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
16601010|NCT02605967|Experimental|PDR001 - Investigational drug|anti-PD1 humanized monoclonal antibody
16601011|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
16601012|NCT02605954|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
16601013|NCT02605954|Active Comparator|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.
~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
16601014|NCT02605928|Experimental|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
16601015|NCT02605915|Experimental|Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.
16601016|NCT02605915|Experimental|Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg|Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
16601017|NCT02605915|Experimental|Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.
16601018|NCT02605915|Experimental|Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.
16601019|NCT02605915|Experimental|Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide|Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.
16601020|NCT02605915|Experimental|Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel|Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.
16601021|NCT02605915|Experimental|Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
16601022|NCT02605915|Experimental|Cohort 2B: Atezolizumab/Trastuzumab emtansine|Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
16601023|NCT02605915|Experimental|Cohort 2C: Safety Expansion|Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
16601024|NCT02605915|Experimental|Cohort 2D: Safety Expansion|Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
16601025|NCT02605902|Active Comparator|iCBIT|internet-delivered Comprehensive Behavioral Intervention for Tics (iCBIT) consisting of psychoeducation, habit reversal training (HRT), function-based assessment and intervention, and relaxation training
16601026|NCT02605902|Placebo Comparator|Control intervention/reference test|internet-delivered psychoeducation and relaxation training.
16601027|NCT02605902|Active Comparator|face-to-face CBIT-treatment|face-to-face CBIT-treatment
16601028|NCT02605889|Experimental|Group A|Laser acupuncture
16601029|NCT02605889|Sham Comparator|Group B|Simulation Laser acupuncture
16601030|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
16601031|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
16601032|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
16601033|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
16601035|NCT02605850|Placebo Comparator|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
16601036|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
16601037|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
16601038|NCT02605837|Experimental|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
16601039|NCT02605837|Placebo Comparator|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
16601040|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
16601041|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
16601042|NCT02605811|Experimental|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
16601043|NCT02605811|Active Comparator|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
16601044|NCT02605798|Experimental|T test|Test drug (Elbanovir)1 tablet contains 400 mg Sofosbuvir
16601045|NCT02605798|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16601046|NCT02605798|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16601047|NCT02605785|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will received a Tau PET scan.
16601048|NCT02605772|Experimental|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
16601049|NCT02605772|Experimental|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
16601050|NCT02605759|Experimental|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
16601051|NCT02605746|Experimental|2-4 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.
16601052|NCT02605746|Experimental|4-8 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.
16601053|NCT02605746|Experimental|22-26 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.
16601054|NCT02605720|Experimental|Dihydroartemisinin-piperaquine|
16601055|NCT02605707|Experimental|Intravenous stem cell transplantation|Intravenous transplantation of autologous endothelial progenitor cells plus conventional treatment include rehabilitation
16601056|NCT02605707|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
16601057|NCT02605694|Experimental|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
16601058|NCT02605694|Active Comparator|Arm 2|"R-CHOP will be administered as follows:
~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)
~Cyclophosphamide (750 mg/m2)
~Doxorubicin hydrochloride (50 mg/m2)
~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)
~Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)
~Prednisone (100 mg) will be administered."
16601059|NCT02605681||septic patients|We recruited the patients admitted to the Department of Critical Care Medicine, Zhongda Hospital, a tertiary hospital, from November 2017 to March 2018. The inclusive criteria were adult patients (age > 18 years-old and < 80 years-old) diagnosed with sepsis, according the definition of the Surviving Sepsis Campaign (2016). Exclusive criteria included: 1. age < 18 years-old or > 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dL), autoimmune diseases and Alzheimer syndrome; 5. patients deceased or discharge from ICU within 24 hours; or, 6. written consents could not be obtained.
16601060|NCT02605668|Experimental|Intensified Psychological Intervention|Intensified psychological intervention (Cognitive Behavioral Therapy), based on optimized extinction learning
16601061|NCT02605668|Active Comparator|Treatment As Usual|Standard intervention (Cognitive Behavioral Therapy) without optimized extinction learning
16601062|NCT02605655|Experimental|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
16601063|NCT02605655|Placebo Comparator|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
16601064|NCT02605642||CT-P13|biosimilar infliximab
16601067|NCT02605616|Experimental|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
16601068|NCT02605616|Placebo Comparator|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
16601069|NCT02605590|Experimental|1.25 mg|Part 1: single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.
16601070|NCT02605590|Experimental|2.5 mg|Part 1: single inhaled dose of 2.5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 2.5 mg AIR DNase for 5 consecutive days.
16601071|NCT02605590|Experimental|5 mg|Part 1: single inhaled dose of 5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 5 mg AIR DNase for 5 consecutive days.
16601072|NCT02605590|Placebo Comparator|Placebo|Placebo comparator for each of the dose levels, administered accordingly as single inhaled dose in Part 1 followed by once daily inhaled dose for 5 consecutive days in Part 2.
16601073|NCT02605577|Experimental|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
16601074|NCT02605577|No Intervention|control group|group of late preterm infants using current nutritional management protocol during hospital stay
16601077|NCT02605551|Active Comparator|OMT Group|During the initial visit, the subject will have his BP recorded manually by the osteopathic physician in a standardized fashion. The subject will then undergo the OMT protocol and have his BP recorded again immediately afterwards. This will represent the conclusion of the initial visit. There will be 2 subsequent visits about 2-3 weeks apart that will be identical to this visit. Following the third visit, the next follow-up will be 2 months afterwards. However, the patient will only have his BP checked, and will not undergo an OMT treatment. The final visit will be another 2 months afterwards and will also be a simple BP check with no OMT treatment. The principles of lifestyle modification (diet/exercise/weight loss) will also be discussed at each visit.
16601078|NCT02605551|Placebo Comparator|Control Group|Patients in this arm will only receive lifestyle modification recommendations at each visit, along with a BP check. No antihypertensive medication changes will be made unless indicated by the guidelines.
16601079|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
16601080|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
16601081|NCT02605525|Experimental|SM101 12 mg/kg|Human soluble recombinant Fcγ Receptor IIB
16601082|NCT02605525|Experimental|SM101 24 mg/kg|Human soluble recombinant Fcγ Receptor IIB
16601083|NCT02605525|Placebo Comparator|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
16601084|NCT02605512|Other|Breast cancer patients with 3DCRT|Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
16601085|NCT02605499|Experimental|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
16601086|NCT02605499|No Intervention|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
16601087|NCT02605486|Experimental|Palbociclib in Combination with Bicalutamide|This is a non-randomized, open-label, phase I/II trial for patients with AR(+) MBC . There will be a dose finding phase I portion of the study to establish the recommended phase II dose (R2PD). This will be followed by a phase II where efficacy is evaluated. Patients with AR(+)ER(-) breast cancer treated on the phase I at the recommended phase II dose will be counted towards the primary endpoint analysis for the phase II study.
16601088|NCT02605460|Other|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY) 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
16601089|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
16601090|NCT02605434|Experimental|AP-CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
16601091|NCT02605434|Active Comparator|SINEMET®|IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
16601092|NCT02605421|Experimental|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
16601093|NCT02605408||Cataract surgery|Phacoemulsification and artificial IOL implantation with and without LenSx® laser system
16601094|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
16601095|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
16601096|NCT02605382|Experimental|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
16601097|NCT02605382|Placebo Comparator|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
16601098|NCT02605369|Experimental|Intervention arm: An integrated package|Pregnant women in the intervention clusters will receive an integrated package consisting of peer support for facility based births by pregnancy buddies, mama kits and mobile phone messages. These components will all aim at mitigating the three delays and increasing the proportion of facility based births.
16601099|NCT02605369|No Intervention|Control arm: Standard of care|Pregnant women in the control clusters will continue to receive the standard of care for pregnant women according to Ugandan Ministry of Health guidelines
16601100|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 1]|Phase 1: Radium-223 dichloride; 30 kiloBecquerel (kBq)/kg body weight (33 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
16601101|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 2]|Phase 1: Radium-223 dichloride; 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
16601102|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 3]|Phase 1: Radium-223 dichloride; 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
16601103|NCT02605356|Placebo Comparator|Placebo +SoC [Phase 2]|Phase 2: Matching placebo (isotonic saline) every 4 weeks for a total of 6 doses plus SoC (Standard of care) bortezomib/dexamethasone.
16601104|NCT02605356|Experimental|Radium-223 dichloride + SoC [Phase 2]|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 4 weeks for 6 doses plus SOC bortezomib/dexamethasone
16601105|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
16601106|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
16601107|NCT02605330||Fibrinogen plasma level in CABG|In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
16601108|NCT02605330||Fibrinogen plasma level in AVR|In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
16601109|NCT02605330||Fibrinogen plasma level in AAR|In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
16601110|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
16601111|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
16601112|NCT02605291|Experimental|Experimental arm 1|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
16601113|NCT02605291|Experimental|Experimental arm 2|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
16601114|NCT02605291|Experimental|Experimental arm 3|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
16601115|NCT02605278|Experimental|Clinical program for pain and depression|Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.
16601116|NCT02605278|Active Comparator|Control|Care as usual
16601117|NCT02605265|Active Comparator|Capecitabine Alone|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT
~Adjuvant Chemotherapy:
~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
16601118|NCT02605265|Experimental|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT
~Adjuvant Chemotherapy:
~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
16601119|NCT02605252|Experimental|CHB patients|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.
16601120|NCT02605239|Experimental|bleaching teeth|Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception
16601121|NCT02605226|Experimental|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
~Patients receive cryoablation therapy."
16601122|NCT02605226|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
16601123|NCT02605213|Experimental|Vancomycin|Vancomyicn 250 mg every 6 hours for 12 weeks
16601124|NCT02605213|Placebo Comparator|Placebo|placebo every 6 hours for 12 weeks
16601125|NCT02605200|Other|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
16601126|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
16601127|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
16601128|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
16601129|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
16601130|NCT02605174|Experimental|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
16601131|NCT02605174|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
16601132|NCT02605174|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
16601133|NCT02605174|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
16601134|NCT02605161||Parkinson's disease group|"patients diagnosed with Parkinson's disease by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus
~to undergo pre-operative MRI with contrast"
16601135|NCT02605161||Control group|"patients diagnosed with either essential tremor or cervical dystonia by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus
~to undergo pre-operative MRI with contrast"
16601138|NCT02605135||Continued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab and 10 mL of vaginal lavage at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months
16601139|NCT02605135||Discontinued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage (Aim 2) at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months. Should the participant discontinue pessary use, we will additionally culture the microbes that are present on the pessary and compare those to the vaginal microbiota.
16601140|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
16601141|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
16601142|NCT02605109||RiskMERS|Exposed to case-patients
16601143|NCT02605096|Experimental|MRI group|"This arm assess the use of MRI as the first line examination of suspected scaphoid fracture (replacing conventional plain x-ray).
~Patients with negative findings will receive a splint and contact card to a specialist wrist clinic if the pain persists for ten to fourteen days after initial presentation.
~Patients with positive findings will receive a plaster cast and undergo a CT scan (to evaluate displacement) and will be referred to the fracture clinic. Furthermore, if the CT scan confirms a displaced fracture, that might require surgery, the patient should be seen by a Hand Specialist at fracture clinic.
~All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
16601144|NCT02605096|Active Comparator|X-ray group|"This arm is the current standard of care pathway for the diagnosis of patients with suspected scaphoid fracture. This includes an initial clinical assessment on arrival to the Emergency Department of Urgent Care Centre followed by a plain x-ray (using a 4-view scaphoid protocol).
~Patients with negative/positive findings for scaphoid fracture in the initial X-ray will be immobilised with a splint/plaster cast.
~All patients will be referred to an initial fracture clinic and a proportion of patients are likely to require additional imaging scans (usually CT but also MRI) and follow-up appointments in the fracture clinic. All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
16601145|NCT02605083|Experimental|eFT508|Escalation cohort
16601146|NCT02605070|Experimental|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
16601147|NCT02605070|No Intervention|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.
~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.
~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
16601148|NCT02605057|Experimental|LEO 80185 gel|LEO 80185 gel will be allocated to 7 different test sites on each subject
16601149|NCT02605057|Experimental|Dovobet Ointment|Dovobet Ointment will be allocated to 7 different test sites on each subject
16601150|NCT02605044|Experimental|Masitinib + FOLFIRI|masitinib + FOLFIRI
16601151|NCT02605044|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
16601152|NCT02605005||GA|general anesthesia
16601153|NCT02605005||ISB|interscalene block
16601154|NCT02604992|Experimental|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
16601155|NCT02604992|Experimental|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
16601156|NCT02604992|Experimental|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
16601157|NCT02604992|Experimental|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
16601158|NCT02604992|Experimental|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
16601159|NCT02604992|Experimental|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
16601160|NCT02604966|Experimental|Artesunate (AS) group|P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
16601161|NCT02604966|Active Comparator|DHA - PPQ group|P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
16601162|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
16601163|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
16601164|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
16601165|NCT02604940|Experimental|dexmedetomidine|Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
16601166|NCT02604940|Active Comparator|Normal Saline|Control group will receive Normal saline over 15 minutes at the beginning of surgical closure
16601167|NCT02604927|Placebo Comparator|Placebo|800 mg of dextrose, four times per day, during 28 days.
16601168|NCT02604927|Experimental|Beta-alanine|800 mg of beta-alanine, four times per day, during 28 days.
16601169|NCT02604914|Experimental|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
16601170|NCT02604914|Experimental|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
16601171|NCT02604914|Active Comparator|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
16601172|NCT02604901|Experimental|Screening and Brief Intervention (BI)|Screening and Brief Intervention (BI) at initial prescription fill and at each additional refill.
16601173|NCT02604901|Experimental|Pill Box (PB)|Pill Box (PB) and information about their medications at the initial fill and at each additional refill.
16601174|NCT02604901|Experimental|Brief Intervention + Pill Box (BI+PB)|Screening and Brief Intervention (BI) and Pill Box (PB) at initial prescription fill and at each additional refill.
16601175|NCT02604901|No Intervention|Standard Care (SC)|The Standard Care (SC) arm administered traditional dispensing and counseling by Rite Aid® pharmacists.
16601176|NCT02604888|Other|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Alopecia Areata in several types apply on the scalp drops of the MEXIS/M6S PATENT - lotion against Alopecia
16601177|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
16601178|NCT02604862|Experimental|FIB ONE administration|All participants in this clinical study will be dosed on one occasion with FIB ONE. The final dosage will be less than 100 µg.
16601179|NCT02604862|Experimental|AZD1236 administration|To quantify the change in mean FIB ONE fluorescence amplification gradient in the presence of AZD1236 in the fibroproliferative lung
16601180|NCT02604849||Received therapy desconolizacion against Klebsiella pneumoniae|
16601181|NCT02604849||Patients who do not receive the therapy|
16601182|NCT02604836|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
16601183|NCT02604823|Experimental|Group A (Naïve Participants)|Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms [mcg]) subcutaneously once weekly for 48 weeks.
16601184|NCT02604823|Experimental|Group B (Conventional Interferon Pretreated Participants)|Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
16601185|NCT02604823|Experimental|Group C (Lamivudine Pretreated Participants)|Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
16601186|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
16601187|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
16601188|NCT02604797|Experimental|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
16601189|NCT02604797|Experimental|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
16601226|NCT02604576|Experimental|Group 1|FDC Bromopride 10 mg and Simethicone 80 mg
16601190|NCT02604784|Experimental|cohort A|Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.
16601191|NCT02604784|Experimental|cohort B|Cohort B: For patients that have not indication for systemic therapy with standard chemotherapy. This cohort has a phase I design; with a dose-escalation design the maximum tolerated doses and recommended doses of Cisplatin + Doxorubicin and Oxaliplatin (according to the pathology) administered through PIPAC in patients with peritoneal carcinomatosis will be evaluated.
16601192|NCT02604758|Experimental|Tidal Model|the psychiatric nursing approach based on the Tidal Model
16601193|NCT02604758|No Intervention|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
16601194|NCT02604745||Degenerative Mitral Regurgitation|This cohort includes patients that have had mitral valve surgery for Degenerative Mitral Regurgitation (Type II)
16601195|NCT02604732|Active Comparator|Patients who stop Aspirin|Patients need to stop Aspirin 1 week before the surgery
16601196|NCT02604732|Experimental|Patients who continue Aspirin|Patients will continue Aspirin
16601197|NCT02604719|Experimental|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
16601198|NCT02604719|Placebo Comparator|placebo|10 ml normal saline will be administered intravenously just after birth
16601199|NCT02604706|Experimental|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
16601200|NCT02604706|Experimental|LP Acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. BC-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
16601201|NCT02604706|Active Comparator|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
16601202|NCT02604693||Chronic Beryllium Disease|Those that have been diagnosed with the disease. No interventions will be administered.
16601203|NCT02604693||Beryllium Sensitization|Those that have been diagnosed with beryllium sensitization and do not have chronic beryllium disease. No interventions will be administered.
16601204|NCT02604693||normal controls|Those that do not have chronic beryllium disease or beryllium sensitization. No interventions will be administered
16601205|NCT02604680|Experimental|BLI1100-1|Topical gel
16601206|NCT02604680|Experimental|BLI1100-2|Topical gel
16601207|NCT02604680|Experimental|BLI1100-3|Topical gel
16601208|NCT02604680|Experimental|BLI1100-4|Topical gel
16601209|NCT02604680|Placebo Comparator|Placebo|Topical gel
16601210|NCT02604667||Group 1: Cancer and Stroke|Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
16601211|NCT02604667||Group 2: Stroke and No Cancer|Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
16601212|NCT02604667||Group 3: Cancer and No Stroke|Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
16601213|NCT02604654|Experimental|Yiqitongluo group|Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.
16601214|NCT02604641|Placebo Comparator|Placebo group|0 mg CoQ10 daily
16601215|NCT02604641|Active Comparator|Quvital LD group|50 mg CoQ10 daily
16601216|NCT02604641|Active Comparator|Quvital HD group|150 mg CoQ10 daily
16601217|NCT02604628|No Intervention|Control|Patients will be treated as standard of care.
16601218|NCT02604628|Experimental|Antibiotic Stewardship Intervention|Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.
16601219|NCT02604615|Experimental|Capecitabine-oxaliplatin 2 cycles|oxaliplatin：65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
16601220|NCT02604615|Active Comparator|Capecitabine-oxaliplatin 4 cycles|oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
16601221|NCT02604602||PPH|
16601222|NCT02604602||non-PPH|
16601223|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
16601224|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
16601225|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
16601227|NCT02604576|Active Comparator|Group 2|Bromopride 10 mg (Digesan ® - Sanofi Aventis)
16601228|NCT02604563||Arm A: Clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
~Peripheral blood draw will occur at baseline and no more than every 6 months until death.
~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
~May be approached about optional bone marrow biopsy"
16601229|NCT02604563||Arm B: No clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
~Peripheral blood draw will occur at baseline and no more than every 6 months until death.
~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
~May be approached about optional bone marrow biopsy"
16601230|NCT02604563||Arm C: No clonal hematopoiesis & no follow-up|"Complete several self-administered health assessments at baseline with no further follow-up
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up
~Peripheral blood draw will occur at baseline with no further follow-up
~Buccal swabs will occur at baseline with no further follow-up"
16601231|NCT02604563||Arm D: Hip replacement|"Complete several self-administered health assessments at baseline and every 6 months until death.
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
~Participants with or without clonal hematopoiesis who are undergoing hip replacement
~Peripheral blood draw will occur at baseline and no more than every 6 months until death.
~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
~May be approached about optional bone marrow biopsy"
16601232|NCT02604563||Arm E: Trauma|-Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge.
16601233|NCT02604550|Active Comparator|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
16601234|NCT02604550|Active Comparator|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
16601235|NCT02604537|Active Comparator|Betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone (Celestone)
16601236|NCT02604537|Experimental|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac (Toradol)
16601237|NCT02604524|Experimental|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
16601238|NCT02604524|Placebo Comparator|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
16601239|NCT02604511|Experimental|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
16601240|NCT02604498|Experimental|Liver function impaired|Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
16601241|NCT02604498|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
16601242|NCT02604485|Other|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
16601243|NCT02604472||CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
16601244|NCT02604472||IC+CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
16601245|NCT02604459|Active Comparator|Usual general anesthesia care|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.
~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
16601246|NCT02604459|Experimental|Optimized general anesthesia care|The subjects will have general anesthesia with propofol, fentanyl, sevoflurane. In addition the subjects will be monitored with a depth of anesthesia monitor (BIS) and a cerebral oximeter (Foresight). These additional monitors will be used to direct care. BP management: Systolic BP will be maintained within 20% of baseline systolic BP variables.
16601247|NCT02604446|Experimental|Tapentadol|depot Tapentadol in addition to usual pain treatment
16601248|NCT02604446|Active Comparator|Oxycodone|depot Oxycodone in addition to usual pain treatment
16601249|NCT02604446|Placebo Comparator|Placebo|depot glucose placebo in addition to usual pain treatment.
16601250|NCT02604433|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
16601251|NCT02604433|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
16601252|NCT02604420||Transplant, no TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
16601253|NCT02604420||Transplant, +TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
16601254|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
16601255|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
16601256|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
16601257|NCT02604394|Active Comparator|Rheolytic Thrombectomy with PCI|"Rheolytic Thrombectomy (RT) will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).
~The single-pass antrograde thrombectomy technique will be used."
16601258|NCT02604394|Sham Comparator|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
16601259|NCT02604381|Experimental|Glucosamine Sulfate Potassium Chloride/Ginkgo Biloba Extract|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
16601260|NCT02604381|Placebo Comparator|Placebo|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
16601261|NCT02604368|Experimental|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, administered once a day on a per weight basis.
16601262|NCT02604368|Placebo Comparator|Placebo|Soybean oil, soft gelatin capsule, administered once a day on a per weight basis.
16601263|NCT02604355|Experimental|Healthy Participants (Multiple-Ascending Dosing)|
16601264|NCT02604355|Experimental|Healthy Participants (Single-Ascending Dosing)|
16601265|NCT02604355|Experimental|Healthy Participants (Study of Food Effect)|
16601266|NCT02604355|Experimental|Participants with Chronic Hepatitis B (Proof of mechanism)|
16601267|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
16601268|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
16601269|NCT02604329|Experimental|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
16601270|NCT02604316|Experimental|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate
16601271|NCT02604316|No Intervention|Control- Non Arabinoxylan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
16601272|NCT02604316|Experimental|Beta-Glucan|10 days of weight loss diet calculated as 100% RMR AND 6g Beta-Glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
16601273|NCT02604316|No Intervention|Control Non Beta glucan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
16601274|NCT02604290|Experimental|Kinesio Taping method|"The tape is applied depending on the physical examination:
~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.
~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.
~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
16601275|NCT02604290|Sham Comparator|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
16601276|NCT02604277|Experimental|Group Intervention Program|Patients diagnosed with Bipolar Disorder will receive therapy in a group setting of 4 to 12 male and female participants.
16601277|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
16601278|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
16601279|NCT02604251|Experimental|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
16601280|NCT02604251|Active Comparator|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
16601281|NCT02604238|Experimental|Group A|"Administered a safe dose of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a safe dose of Alteplase."
16601282|NCT02604238|No Intervention|Group B|All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.
16601283|NCT02604225|Experimental|Penthrox|Methoxyflurane
16601284|NCT02604225|Placebo Comparator|Placebo|Saline 0.9%
16601285|NCT02604212|Placebo Comparator|Placebo Low Dose Comparator|Placebo (low dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
16601286|NCT02604212|Placebo Comparator|Placebo High Dose Comparator|Placebo (high dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
16601287|NCT02604212|Experimental|ARC-520 1.0 mg/kg|Low dose (1.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
16601288|NCT02604212|Experimental|ARC-520 2.0 mg/kg|High dose (2.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
16601289|NCT02604199|Placebo Comparator|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
16601290|NCT02604199|Placebo Comparator|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
16601291|NCT02604199|Experimental|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
16601292|NCT02604199|Experimental|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
16601293|NCT02604186|Experimental|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
16601294|NCT02604186|Placebo Comparator|Placebo Injections|Placebo injections at adductors and triceps surae
16601295|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
16601296|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
16601297|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
16601298|NCT02604160|Experimental|LY3113593|Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A.
16601299|NCT02604160|Placebo Comparator|Placebo|0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.
16601300|NCT02604147|Sham Comparator|Simulated inspiratory muscle training|Inspiratory muscle training with load of 15% of maximal inspiratory pressure.
16601301|NCT02604147|Experimental|Inspiratory muscle training group|Inspiratory muscle training with initial load of 50% of maximal inspiratory pressure.
16601302|NCT02604134|Other|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
16601303|NCT02604134|Other|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
16601304|NCT02604121|Experimental|transepithelial brushing|transepithelial brushing in liquid-based technology + biopsy
16601305|NCT02604108|Experimental|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
16601306|NCT02604108|Experimental|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
16601307|NCT02604095|Experimental|Melatonin|Take one table at bedtime.
16601308|NCT02604082|Active Comparator|Vibocompression (VB)|Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration
16601309|NCT02604082|Active Comparator|Hyperinflation (HMV)|Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
16601310|NCT02604082|Experimental|HMV+VB|Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
16601311|NCT02604069|Experimental|Continuous Glucose Monitor|Application of CGM for 6 days following free flap reconstruction in conjunction with clinical monitoring
16601312|NCT02604056|Active Comparator|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
16601313|NCT02604056|Experimental|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
16601314|NCT02604043|Experimental|supraglottic impendence/pH probe|
16601315|NCT02604030|Experimental|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
16601316|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
16601317|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
16601318|NCT02604004|Active Comparator|Period 1|Epivir ® tablet 150-mg single dose (drug reference)
16601319|NCT02604004|Experimental|Period 2|Lamivudine 150-mg tablet single dose (drug test)
16601320|NCT02603978|No Intervention|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
16601321|NCT02603978|Active Comparator|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
16601322|NCT02603978|Active Comparator|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
16601323|NCT02603978|Active Comparator|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
16601324|NCT02603965|Experimental|Diagnostic (Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
16601325|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
16601326|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
16601327|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
16601328|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
16601329|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
16601330|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
16601331|NCT02603926|Experimental|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
16601332|NCT02603913||Normal pregnancy|Normal uncomplicated pregnancy
16601333|NCT02603913||Pre-eclampsia|"Hypertension (>140 mmHg systolic or >90 mmHg diastolic) developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:
~Proteinuria (>300 mg/day)
~Other maternal organ dysfunction
~renal insufficiency (creatinine >90 μmol/L)
~liver involvement (elevated transaminases - and/or severe right upper quadrant or epigastric pain)
~neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)
~hematological complications (thrombocytopenia, disseminated intravascular coagulation, hemolysis)
~Uteroplacental dysfunction"
16601334|NCT02603913||Pregnancy induced hypertension|New onset of hypertension (>140 mmHg systolic or >90 mmHg diastolic) after 20 weeks gestation, without proteinuria, in a previously normotensive woman.
16601335|NCT02603913||Preterm birth|Babies born alive before 37 weeks of pregnancy are completed.
16601336|NCT02603913||Intra-uterine growth restriction|Moderate IUGR is an estimated fetal weight and / or abdominal circumference < 10th percentile for its gestational age Severe IUGR is an EFW (estimated fetal weight) and/ or AC (abdominal circumference) < 5th percentile for its gestational age
16601337|NCT02603900|Experimental|Adductor Canal Catheter|This group will receive ropivacaine 0.5% 15 ml for the adductor canal block under ultrasound guided nerve block. A multi-orifice catheter will be placed in the adductor canal and an infusion of ropivacaine 0.2% at 10 ml/hr will be continued for 72 hours.
16601338|NCT02603900|Experimental|Local Infiltration of Analgesia|Local infiltration using 20 ml of free bupivacaine solution (Marcaine 0.25% with epinephrine 1:200000, ) diluted with 40 ml of normal saline following implantation of the knee prosthesis, the solution will be injected into the vastus medialis (5 ml), medial retinaculum (5 ml), origin of MCL (5 ml) and LCL (5 ml), lateral portion of quadriceps tendon (5 ml), vastus lateralis (5 ml), and subcutaneous tissues especially along saphenous nerve distribution (30 ml). Postoperatively, a sham adductor canal catheter will be placed as in the ACC arm following stabilization in the PACU to infuse only normal saline with an initial bolus of 15 ml saline and infusion of saline at 10ml/hr for 72 hours.
16601339|NCT02603887|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16601340|NCT02603874|Experimental|Target Tape|Including target tape in the procedure
16601341|NCT02603874|No Intervention|Control|Without target tape in the procedure
16601342|NCT02603861|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
16601343|NCT02603861|Experimental|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
16601344|NCT02603861|Experimental|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
16601345|NCT02603861|Experimental|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
16601346|NCT02603861|Active Comparator|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
16601347|NCT02603848|Experimental|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
16601348|NCT02603848|Active Comparator|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
16601349|NCT02603835|Experimental|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
16601350|NCT02603822|Experimental|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
16601351|NCT02603809|Placebo Comparator|Placebo|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
16601352|NCT02603809|Experimental|Aprocitentan 5 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
16601353|NCT02603809|Experimental|Aprocitentan 10 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
16601354|NCT02603809|Experimental|Aprocitentan 25 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
16601355|NCT02603809|Experimental|Aprocitentan 50 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
16601356|NCT02603809|Active Comparator|Lisinopril 20 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
16601357|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
16601358|NCT02603783|Active Comparator|Capsaicin|1,5 mg capsaicin in 30 minutes
16601359|NCT02603783|Placebo Comparator|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
16601360|NCT02603770|Experimental|XueZhiKang (XZK)|XueZhiKang (XZK) 1200 mg
16601361|NCT02603770|Active Comparator|Lovastatin|Lovastatin 20 mg
16601362|NCT02603757|Active Comparator|Group A|Standard-dose of 2,000 IU Vitamin D3, daily
16601363|NCT02603757|Experimental|Group B|Higher-dose of 50,000 IU of Vitamin D3, weekly
16601364|NCT02603744|Experimental|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
16601365|NCT02603744|Experimental|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
16601366|NCT02603744|Experimental|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
16601367|NCT02603718|Experimental|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
16601368|NCT02603718|Experimental|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
16601369|NCT02603705|Experimental|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
16601370|NCT02603692||Pediatric group (ages 8-17)|PROMIS pediatric domains for emotional distress (anxiety and depression), physical function (fatigue, pain interference, mobility and upper extremity), and peer relations
16601371|NCT02603692||Adult group (ages 18-35)|PROMIS adult domains. To reduce respondent burden, the multi-form design will be used which includes the short form of physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity.
16601372|NCT02603692||Parent/guardian proxy|Parent/guardian will complete the parental proxy PROMIS instruments based on corresponding child age (ages 5 to 17 years)
16601373|NCT02603679|Active Comparator|A: Weekly Paclitaxel|Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period. Thereafter, treatment is switched to endocrine treatment in combination with palbociclib. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
16601374|NCT02603679|Experimental|B: Tamoxifen + Palbociclib|Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
16601375|NCT02603679|Experimental|B: Aromatase Inhibitor + Palbociclib|Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
16601376|NCT02603679|Experimental|B: Goserelin + Aromatase Inhibitor + Palbociclib|Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
16601377|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
16601378|NCT02603653|Experimental|Patients|Virtual radial task in 3D
16601379|NCT02603653|Experimental|Controls|Virtual radial task in 3D
16601380|NCT02603640|Experimental|epileptic patient|
16601381|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
16601382|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
16601383|NCT02603614|Experimental|Cenderitide-Placebo|"Infusion Period A: Cenderitide Infusion Period B: Placebo
~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
16601384|NCT02603614|Experimental|Placebo-Cenderitide|"Infusion Period A: Placebo Infusion Period B: Cenderitide
~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
16601385|NCT02603601|Active Comparator|Standard lifestyle intervention|The standard lifestyle intervention is a 1-hour individual nutritional counseling session with a registered dietician at BIDMC.
16601386|NCT02603601|Experimental|Mind-body lifestyle intervention|The mind-body lifestyle intervention is a 10-week mindfulness-based intervention that integrates mindfulness with traditional behavioral strategies to improve long-term weight maintenance.
16601387|NCT02603588|Experimental|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
16601388|NCT02603588|Sham Comparator|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
16601389|NCT02603575|Experimental|Caspofungin and corticosteroids|patients treat with caspofungin and corticosteroids on the base of sulfanilamide
16601390|NCT02603575|Active Comparator|Caspofungin and no corticosteroids|patients treat with caspofungin on the base of sulfanilamide
16601391|NCT02603575|Active Comparator|corticosteroids and no caspofungin|patients treat with corticosteroids on the base of sulfanilamide
16601392|NCT02603575|Active Comparator|no corticosteroids and no caspofungin|patients treat with sulfanilamide only
16601393|NCT02603562|Experimental|ATYR1940|Intrapatient dose escalation ATYR1940: ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg for up to 12 Weeks. The dose level in this study will not exceed 3.0 mg/kg.
16601394|NCT02603562|Placebo Comparator|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
16601395|NCT02603549||Surgery or Blood Patch|
16601436|NCT02603276|Active Comparator|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
16601396|NCT02603536|Experimental|Vulnerable or pilot participant|"In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period. Participants will be requested to respond to the outgoing message How are you? within 48 hours; they may respond that they are doing well or that they have a problem. A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
16601397|NCT02603523|Experimental|Senior Dance|The intervention group will attend a single educational class on fall risk factors and prevention, and will participate in a 12-week, twice-weekly group-based program of Senior Dance. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. Senior Dance-certified instructors will lead the classes. The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups.
16601398|NCT02603523|No Intervention|Control group|Participants in the control group will attend the same educational class on fall risk factors and prevention that intervention group participants will receive, and will be instructed not to take part in any regular exercise programs such as supervised group exercise, Tai Chi, Yoga, or any dance activity during the study period. At the end of the study, they will be offered Senior Dance classes, twice a week, during 12 weeks.
16601399|NCT02603510|Experimental|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
16601400|NCT02603510|Experimental|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
16601401|NCT02603497|Experimental|Control (Subjects with normal renal function)|Oral
16601402|NCT02603497|Experimental|Mild renal impairment|Oral
16601403|NCT02603497|Experimental|Moderate renal impairment|Oral
16601404|NCT02603497|Experimental|Severe renal impairment|Oral
16601405|NCT02603471|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
16601406|NCT02603471|Active Comparator|Informational group|A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
16601407|NCT02603458|Placebo Comparator|Placebo|Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
16601408|NCT02603458|Experimental|NRX-1074 Dose Group|Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
16601409|NCT02603445|Experimental|Follicular lymphoma (FL)|
16601410|NCT02603445|Experimental|Mantle cell lymphoma (MCL)|
16601411|NCT02603432|Experimental|Arm A|Avelumab plus Best Supportive Care (BSC)
16601412|NCT02603432|Other|Arm B|"Best Supportive Care (BSC) alone
~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued."
16601413|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
16601414|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
16601415|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
16601416|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
16601417|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
16601418|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
16601419|NCT02603406|Experimental|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
16601420|NCT02603406|No Intervention|Group B|mechanical barrier disruption procedure Drug: no-specific intervention
16601421|NCT02603393|Experimental|QVA149|
16601422|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
16601423|NCT02603380||Clinical staff|Clinicians in the Royal Infirmary of Edinburgh.
16601424|NCT02603380||Patients|Patients in intensive care units and general wards in the Royal Infirmary of Edinburgh.
16601425|NCT02603367|Experimental|Supportive care (COMFORT communication intervention)|"Participants receive the printed communication tool A Communication Guide for Caregivers, a guide developed from the COMFORT communication curriculum, a national training program for palliative care communication. After a 1 week period to review the material, participants undergo communication coaching with a research nurse by phone over approximately 1 hour."
16601426|NCT02603354|Active Comparator|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
16601427|NCT02603354|Experimental|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
16601428|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
16601429|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
16601432|NCT02603302|Experimental|Locally advanced rectal cancer|"RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU
~Surgery 8 weeks after the neoadjvuant treatment."
16601433|NCT02603289||Teen|< 17 years of age
16601434|NCT02603289||Adult|17 years of age or older
16601435|NCT02603289||Adult with Primer Aligners|17 years of age or older This group will get Primer Aligners
16601437|NCT02603276|Active Comparator|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
16601438|NCT02603276|Experimental|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
16601439|NCT02603263||Workplace Restaurant Customers|"1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study)
~Study consists of three phases:
~Pre Intervention
~Intervention
~Post Intervention
~All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster."
16601440|NCT02603250||Wicking|50% of the 132 children enrolled in the study will have their Hb measured using the wicking method of HemoCue® 201+ blood collection.
16601441|NCT02603250||Gravity|50% of the 132 children enrolled in the study will have their Hb measured using the gravity method of HemoCue® 201+ blood collection.
16601442|NCT02603237|Other|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
16601443|NCT02603237|Other|Fat tolerance test|The same participants will receive an oral standardized fat load test
16601444|NCT02603224|Experimental|MRG-201|
16601445|NCT02603224|Placebo Comparator|Placebo|
16601446|NCT02603211||Women with Breast Tumors|Women with breast tumors.
16601447|NCT02603198|Active Comparator|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
16601448|NCT02603198|Active Comparator|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
16601449|NCT02603185|Experimental|Hemay007|"Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.
~Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.
~Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses"
16601450|NCT02603185|Placebo Comparator|Placebo|"Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.
~Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses"
16601451|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
16601452|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
16601453|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
16601454|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
16601455|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
16601456|NCT02603159|Experimental|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
16601457|NCT02603159|Active Comparator|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
16601458|NCT02603146|Experimental|Hydroxychloroquine Group|Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
16601459|NCT02603146|Placebo Comparator|Placebo Group|Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
16601460|NCT02603133|Other|Cohort 1|The intervention will begin for all NICUs, with baseline surveys as necessary pre-work. For those unable to attend, a link to the baseline survey will be emailed with site champion instructions to complete in groups at staff meetings and during shift change. Two weeks later, three randomly (random number generator) assigned NICUs (block 1) included in the first block webinar will then receive Module 1 of the intervention with Modules 2-6 being rolled out monthly. The second block of three NICUs starts approximately six-month later.
16601461|NCT02603133|Other|Cohort 2|This second block of 3 NICUs will start approximately six-months after roll-out of group 1. At time point 0 this NICUs in this group will receive a lecture on safety culture, unrelated to the burnout intervention.
16601462|NCT02603133|Experimental|Cohort 3 (July cohort) WISER 2.0|"Individually randomized to one of two cohorts. Cohort 1 to start will serve as the waitlist control 1 before starting their version of the intervention. Each cohort will experience modified versions of WISER, which only differ by the spacing of intervention. Participants will receive 10-day sequential or 10-day non-sequential rollout of the resilience tools. Seq will receive the tools on ten consecutive days. NSeq will receive messages daily noThursdays, Fridays and Saturdays.
~Days 1 through 3 will be offered 3GT. Day 4 will continue with 3GT but add a single day activity for Gratitude. Day 5 adds a single activity for Awe. Day 6 adds a single day activity for RAK. Days 7 -10 the participant is offered the choice of Gratitude, Awe or RAK to accompany their daily 3GT. At 1 month follow-up time point, participants will receive 8 days of the 1 Good Chat tool, as a booster. At 6 month follow-up, participants will receive a gratitude exercise."
16601463|NCT02603120|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
16601464|NCT02603120|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
16601465|NCT02603120|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
16601466|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.
~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
16601467|NCT02603107|Experimental|Stay on Baseline Regimen (SBR)|"Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.
~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
16601468|NCT02603094|Experimental|clear fluids until premedication|allowed to drink until premedication, aprox 30 minutes before anaesthesia induction. Fasting for solids and non-clear fluids is six hours.
16601469|NCT02603094|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction clear fluid Ingestion. Fasting for solids and non-clear fluids is six hours.
16601470|NCT02603081|Placebo Comparator|Placebo|0 mg SPI-1005 bid po x 21d
16601471|NCT02603081|Active Comparator|Low dose|200 mg SPI-1005 bid po x 21d
16601472|NCT02603081|Active Comparator|Mid dose|400 mg SPI-1005 bid po x 21d
16601473|NCT02603081|Active Comparator|High dose|600 mg SPI-1005 bid po x 21d
16601474|NCT02603068|Experimental|Individual Maximum Tolerated Dose (iMTD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.
16601475|NCT02603068|Experimental|Fixed Dose (FD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.
16601476|NCT02603055|Experimental|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
16601477|NCT02603055|Active Comparator|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co., Ltd. three doses, 30μg/0.5ml per dose
16601478|NCT02603042||Observation|Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease
16601479|NCT02603029|Placebo Comparator|Placebo cream|Cream with 0% Silver fir wood extract (Belinal)
16601480|NCT02603029|Active Comparator|Belinal cream|Cream with 2% Silver fir wood extract (Belinal)
16601481|NCT02603016|Experimental|GLSE compound group|GLSE compound 2g each time by mouth,twice a day for 42 days.
16601482|NCT02603016|Experimental|Maitake mushroom extract compound group|Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
16601483|NCT02603016|Experimental|Ginseng compound group|Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
16601484|NCT02603016|No Intervention|blank control group|Take nothing.
16601485|NCT02603003|Placebo Comparator|Cisplatin|Cisplatin
16601486|NCT02603003|Placebo Comparator|Pemetrexed|Pemetrexed
16601487|NCT02603003|Experimental|Jinfukang|Jinfukang
16601488|NCT02602990||Cerebral AVM treated with SQUID™|
16601489|NCT02602977|Experimental|multiple-dose RIPC|Multiple-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive 4 cycles of remote ischemic preconditioning of the upper limb per day in the 7 consecutive days before the endotoxemia experiment. The last dose will be applied 40 minutes before LPS administration.
16601490|NCT02602977|Experimental|single-dose RIPC|Single-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive a single RIPC dose, starting 40 minutes before LPS administration.
16601491|NCT02602977|Active Comparator|control group|Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
16601492|NCT02602964|Experimental|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
16601493|NCT02602964|No Intervention|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
16601494|NCT02602951|Experimental|Control|Pilot subjects
16601495|NCT02602951|Experimental|Patients|Patients with an intracranial disorder or needing a supraaortic trunk MRA
16601496|NCT02602938|Experimental|aspirin|"The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles.
~The CTC was evaluated at baseline, and every 28 days for 2 months."
16601497|NCT02602925|Experimental|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
16601498|NCT02602925|Other|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
16601499|NCT02602912|Experimental|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability.
16601500|NCT02602899|Experimental|PINS Deep Brain Stimulator|Deep Brain Stimulator is on,continuous stimulation to the brain,
16601501|NCT02602886|Experimental|Exposure and Response Prevention Therapy|
16601502|NCT02602873||good efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can reach effective outcome.
16601503|NCT02602873||poor efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can not reach effective outcome.
16601504|NCT02602860|Experimental|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.
~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
16601505|NCT02602860|Experimental|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.
~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.
~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg."
16601506|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
16601507|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
16601508|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
16601509|NCT02602834|Experimental|HTx|Heart transplant recipients n=15
16601510|NCT02602834|Active Comparator|Control|Healthy controls n=5
16601511|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
16601512|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
16601513|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
16601514|NCT02602808||post-ERCP pancreatitis|Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.
16601515|NCT02602795|Experimental|Distress Tolerance (DT)|Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
16601516|NCT02602795|Active Comparator|HIV/STI Intervention|Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
16601517|NCT02602795|No Intervention|Treatment As Usual (TAU)|Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.
16601518|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.
~The investigators will perform transcriptome profiling in this group."
16601519|NCT02602769||Control cohort|Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
16601520|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
16601521|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
16601522|NCT02602743|Experimental|remifentanyl, ketamine|Experimental:Remifentanyl and ketamine Remifentanyl vial 2 mg, Ketamine vial 500mg/10 mlt by intravenous. 2 mg/kg ketamine and 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
16601523|NCT02602743|Active Comparator|propofol, ketamine|"Active comparator:Propofol and ketamine Propofol injectable emulsion vial 200 mg/20 mlt, Ketamine vial 500mg/10 mlt by intravenous.
~2 mg/kg ketamine and 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started."
16601524|NCT02602730|Experimental|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
16601525|NCT02602730|Active Comparator|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
16601526|NCT02602717|Experimental|thyroid cancer|
16601527|NCT02602704|Active Comparator|Bazedoxifene & Calcium/Vit D|"Enrollment: 57
~Drug: Bazedoxifene 20 mg/day (Viviant)
~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
16601528|NCT02602704|Active Comparator|Calcium/Vit D|"Enrollment: 57
~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
16601529|NCT02602691|Active Comparator|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
16601530|NCT02602691|Experimental|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
16601531|NCT02602678|Experimental|PRONE-Supine|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
16601532|NCT02602678|Experimental|SUPINE - Prone|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
16601533|NCT02602665|Experimental|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
16601534|NCT02602665|Experimental|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
16601535|NCT02602652|Experimental|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
16601536|NCT02602639|Experimental|Functional electrical stimulation rowing|Using an Odstock 4 channel neuromuscular stimulator with Concept 2 Rower
16601537|NCT02602613|Experimental|AMEND|
16601538|NCT02602600|Experimental|Liraglutide|Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.
16601539|NCT02602587|Experimental|blood samples and bone marrow samples|The patients included in this study will be processed according to the standard treatment in force for their disease. This study does not in any way interfere with this treatment regimen, and is only based on additional samples of blood and bone marrow in acts planned in the prognostic or follow-up protocols. Treatment shall start within the 15 days following inclusion and first sampling.
16601540|NCT02602574||ERCP- induced acute pancreatitis|"All patients with indication for ERCP will be prepared for ERCP. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.
~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample.
~Upon clinical and laboratory confirmation of acute pancreatitis according to ESGE guidelines for post-ERCP pancreatitis, will be further monitored during hospitalization for evaluation of the severity of the disease."
16601541|NCT02602574||non -ERCP acute pancreatitis|"All patients with acute pancreatitis according to Atlanta criteria admitted through Emergency Department will be taken 30 ml of heparinized peripheral venous blood and urine sample upon 24 hours after the clinical symptoms have started. 10 mL of collected blood samples will be examined in the Department of Laboratory Medicine. Other 20 mL of blood samples will be sent to Department of Physiology and Immunology, School of Medicine where immunologic analysis will be performed.
~This group of patients will be further monitored during hospitalization for evaluation of the severity of the disease. Severity of the disease will be assessed according to the Atlanta criteria."
16601542|NCT02602574||Control group|"Control group will consist of patients who underwent ERCP but didn't develop acute pancreatitis. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.
~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample."
16601543|NCT02602561|Active Comparator|HMB|3 g HMB/day
16601544|NCT02602561|Placebo Comparator|Placebo|Placebo administered similar to the active comparator
16601545|NCT02602548||Open Shoulder Surgery|Culture
16601546|NCT02602548||Arthroscopic Shoulder Surgery|Culture
16601547|NCT02602535|Experimental|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
16601548|NCT02602535|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
16601549|NCT02602522|Experimental|Experimental|The patients in this arm will be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
16601550|NCT02602522|Active Comparator|controlled|The patients in this arm will be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule prepared, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
16601551|NCT02602509|Experimental|Celecoxib plus rifampicin group|Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg
16601552|NCT02602509|Experimental|Celecoxib plus pyrazinamide group|Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg
16601553|NCT02602496|Experimental|Control|3 servings of refined grains per day.
16601554|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
16601555|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
16601556|NCT02602483|Experimental|Triple combination|Powder for oral administration
16601557|NCT02602483|Active Comparator|Ibuprofen|Powder for oral administration
16601558|NCT02602483|Active Comparator|Magnesium + ascorbic acid|Powder for oral administration
16601559|NCT02602483|Placebo Comparator|Placebo|Powder for oral administration
16601560|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
16601561|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
16601562|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
16601563|NCT02602444||STEMI|ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
16601564|NCT02602444||NSTEMI|non-ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
16601565|NCT02602431|Active Comparator|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
16601566|NCT02602431|Placebo Comparator|Extra-oral placebo|Laser point will be placed in region without irradiation on.
16601567|NCT02602431|Active Comparator|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
16601568|NCT02602431|Placebo Comparator|intra-oral placebo|Laser point will be placed in region without irradiation on.
16601569|NCT02602418|Experimental|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
16601570|NCT02602418|Other|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
16601571|NCT02602392|Experimental|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
16601572|NCT02602392|Active Comparator|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
16601573|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
16601574|NCT02602366|Other|Month 1|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
16601575|NCT02602366|Other|Month 2|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
16601576|NCT02602366|Other|Month 3|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
16601577|NCT02602366|Other|Month 4|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
16601578|NCT02602353|Experimental|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
16601579|NCT02602353|Placebo Comparator|Placebo Patch|One Placebo Patch applied once daily for 3 days
16601580|NCT02602353|Other|No Treatment|No Treatment for 3 days
16601581|NCT02602340|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
16601582|NCT02602327|Experimental|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
16601583|NCT02602314|Experimental|Imatinib + Nilotinib|
16601584|NCT02602314|Experimental|Nilotinib|
16601585|NCT02602301|Active Comparator|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
16601586|NCT02602301|Active Comparator|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
16601587|NCT02602301|Placebo Comparator|3|Group C in which 109 women continued their labour course without any further augmentation.
16601588|NCT02602288|Experimental|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
16601589|NCT02602288|Active Comparator|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
16601590|NCT02602275|Experimental|Neurexan®|0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
16601591|NCT02602275|Placebo Comparator|Placebo|3 tablets, 40-60 minutes before the second MRI
16601592|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
16601593|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
16601594|NCT02602249|No Intervention|Experimental Group A(control group)|saline infusion and follow up
16601595|NCT02602249|Experimental|Experimental Group B|MUC1-gene-DC-CTL will be used against tumor cells.
16601596|NCT02602249|Experimental|Experimental Group C|MUC1-peptide-DC-CTL will be used against tumor cells.
16601597|NCT02602236|Experimental|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
16601598|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
16601599|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
16601600|NCT02602210|Active Comparator|group A|Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
16601601|NCT02602210|Placebo Comparator|group B|Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)
16601602|NCT02602197|Active Comparator|Paracetamol|1 gr paracetamol received intravenously bolus 15 minutes after anesthetic induction and at the postoperative 6 th,12 th, 18 th and 24 th hours
16601603|NCT02602197|Active Comparator|Dexketoprofen|50 mg dexketoprofen received intravenous bolus 15 minutes after anesthetic induction and at the postoperative 8 th,16 th and 24 th hours.
16601604|NCT02602184|Experimental|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
16601605|NCT02602184|Placebo Comparator|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
16601606|NCT02602171|Experimental|dereverberation condition|Oldenburger Sentence test, localization test
16601607|NCT02602171|Experimental|reverberation condition|Oldenburger Sentence test, localization test
16601608|NCT02602158|Active Comparator|Octanoic acid (1-13C, 99%)|100 µL 13C Octanoic acid (Cambridge isotope laboratories)
16601609|NCT02602158|Active Comparator|TRIOCTANOIN (1,1,1-13C3, 99%)|100 µL 13C Trioctanoin (Cambridge isotope laboratories)
16601610|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease that were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have an SFA stent) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for six months. At six months a standard post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
16601611|NCT02602132|Experimental|Clamping group|Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
16601612|NCT02602132|No Intervention|Free drainage group|The urinary catheter will be removed without prior clamping.
16601613|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
16601614|NCT02602106|Experimental|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.
~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
16601615|NCT02602106|No Intervention|Control group|Sedentary healthy pregnant women
16601616|NCT02602093|Active Comparator|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
16601617|NCT02602093|Active Comparator|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
16601618|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
16601619|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
16601620|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
16601621|NCT02602067|Experimental|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).
~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
16601622|NCT02602054|Experimental|Surgical treatment|Implement surgical treatment for closure of patent ductus arteriosus
16601623|NCT02602054|Active Comparator|Control group|"- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg
~- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg
~- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg"
16601624|NCT02602041||Patients with breast cancer and partners|We will invite 10 women with early stage breast cancer (BC) and their partners for a semi-structured interview.
16601625|NCT02602041||Patients with testicular cancer and partners|We will invite 10 men with disseminated testicular cancer (TC) and their partners for a semi-structured interview.
16601626|NCT02602028|Experimental|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
16601627|NCT02602028|Experimental|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
16601628|NCT02602002|Experimental|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
16601629|NCT02602002|Placebo Comparator|Placebo|Saline (0.9%)
16601630|NCT02601989|Experimental|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
16601631|NCT02601989|Placebo Comparator|Placebo|Per oral intake of placebo
16601632|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
16601633|NCT02601963|Experimental|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
16601634|NCT02601963|Experimental|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
16601635|NCT02601963|Placebo Comparator|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
16601636|NCT02601950|Experimental|Open-label Tazemetostat|All Cohorts [Cohort 1 - MRT, RTK, ATRT, or tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] Cohort 2 - Relapsed/refractory synovial sarcoma (SS18-SSX rea), Cohort 3 - Other INI1-negative tumors or any solid tumor with an EZH2 GOF mutation, Cohort 4 - Renal medullary carcinoma, Cohort 5 - Epithelioid sarcoma, Cohort 6 - Epithelioid sarcoma undergoing mandatory tumor biopsy and Cohort 7 - Poorly differentiated chordoma (or other chordoma with Sponsor approval)] will receive 800 mg oral Tazemetostat BID x 28 days
16601637|NCT02601937|Experimental|Open-label Tazemetostat|"Dose Escalation: Level 1 (Starting Dose) Oral Tazemetostat 240 mg/m^2 BID; Level 2 Oral Tazemetostat 300 mg/m^2 BID; Level 3 Oral Tazemetostat 400 mg/m^2 BID; Level 4 Oral Tazemetostat 520 mg/m^2 BID; Level 5 Oral Tazemetostat 700 mg/m^2 BID; Level 6 Oral Tazemetostat 900 mg/m^2 BID; Level 7 Oral Tazemetostat 1200 mg/m^2 BID
~Dose Expansion:
~Cohort 1: Oral tazemetostat 1200mg/m2 BID Cohort 2: Oral tazemetostat 520mg/m2 BID Cohort 3: Oral tazemetostat 520mg/m2 BID Cohort 4: Oral tazemetostat 800mg/m2 TID (2400mg/m2/day)"
16601638|NCT02601924|Active Comparator|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
16601639|NCT02601924|Active Comparator|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
16601746|NCT02601235|Experimental|Naridrin|Naridrin: 2 drops in each nostril once daily as prescription
16601640|NCT02601924|Active Comparator|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
16601641|NCT02601924|Active Comparator|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
16601642|NCT02601911|Active Comparator|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
16601643|NCT02601911|Active Comparator|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
16601644|NCT02601911|Placebo Comparator|Placebo|This group receive a caplet including placebo, before applying the injection.
16601645|NCT02601898|Experimental|Lipoic acid|vaginal capsules of lipoic acid (10 mg, one capsule per day)
16601646|NCT02601898|Active Comparator|Progesterone|Vaginal soft gel of progesterone (200 mg, two capsules per day)
16601647|NCT02601885|Experimental|Group 2|Participants will receive multiple doses of ABT-555 or placebo
16601648|NCT02601885|Experimental|Group 3|Participants will receive multiple doses of ABT-555 or placebo
16601649|NCT02601885|Experimental|Group 1|Participants will receive multiple doses of ABT-555 or placebo
16601650|NCT02601859|Experimental|Phase 3|Administration of Lithium to 11 individuals with MCI (non-randomised) for 9 weeks. Lithium dose escalates from 100mg to 200mg to 400mg, then a 3 week wash out period, total study duration 12 weeks. Blood samples taken at regular intervals throughout trial and analysed for GSK-3 enzyme activity in blood.
16601651|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
16601652|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
16601653|NCT02601807|Active Comparator|Active|Subjects given active ActiPatch device before or after crossover (randomised)
16601654|NCT02601807|Placebo Comparator|Placebo|Subjects given placebo ActiPatch device before or after crossover (randomised)
16601655|NCT02601794|Experimental|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
16601656|NCT02601794|No Intervention|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
16601657|NCT02601781|Experimental|Primary PCI (PPCI) with BVS|Primary percutaneous coronary intervention (PPCI) with bioresorbable vascular scaffold (BVS) implantation in STEMI patients. Following the arterial route, PPCI (performed according to the international guidelines) aims to recanalize an occluded coronary artery that is then maintained patent inserting an endovascular permanent prosthesis (stent). In this study we aim to assess the results following the use of a fully bioresorbable prosthesis (BVS) during PPCI using a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation). BVS has the theoretical advantage, as compared with a permanent stent, to disappear within 24-36 months from implantation restoring the native pristine vessel state.
16601658|NCT02601768||ASD II|Transcatheter closure of ASD II
16601659|NCT02601755|Experimental|iCanCope app and website|Intervention: Behavioral: iCanCope app and website
16601660|NCT02601755|Active Comparator|Attention control group|Intervention: Behavioral: Attention control group
16601661|NCT02601742|Active Comparator|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
16601662|NCT02601742|Placebo Comparator|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
16601663|NCT02601729||RT-CGM population|Prospective data collection during standardized clinical follow-up and from filled out questionnaires.
16601664|NCT02601729||Pump only population|Retrospective data collection on demographic and clinical characteristics.
16601665|NCT02601716|Experimental|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.
~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
16601666|NCT02601716|Experimental|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.
~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
16601667|NCT02601716|Experimental|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.
~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
16601747|NCT02601235|Active Comparator|0.05 % Oxymetazoline Hydrochloride|2 pumps in each nostril every 12 hours
16601668|NCT02601716|Experimental|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10^5 PfSPZ) 21 days prior to the second CHMI.
~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
16601669|NCT02601716|Other|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
16601670|NCT02601716|Other|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
16601671|NCT02601703|Experimental|Tacrolimus Ointment 0.1%|
16601672|NCT02601703|Active Comparator|Protopic® ointment, 0.1%|
16601673|NCT02601703|Placebo Comparator|Placebo of Tacrolimus Ointment|
16601674|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
16601675|NCT02601677|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
16601676|NCT02601677|Active Comparator|Standard Control|Fluoxetine
16601677|NCT02601664|Active Comparator|Combined Intervention|Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
16601678|NCT02601664|Active Comparator|Conventional PCI|Conventional PCI
16601679|NCT02601651|Experimental|Lidocaine|Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
16601680|NCT02601651|Placebo Comparator|Normal saline|Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
16601681|NCT02601638|Experimental|Arm 1|"Demographics and Health History Questionnaire (5-10 minutes to complete)
~Pre-Class Laryngectomy Survey (5-10 minutes to complete)
~Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes
~Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.
~Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)
~Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.
~Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
16601682|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
16601683|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
16601684|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
16601685|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
16601686|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
16601687|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
16601688|NCT02601612|Experimental|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
16601689|NCT02601612|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
16601690|NCT02601612|Experimental|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
16601691|NCT02601612|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
16601692|NCT02601599|Experimental|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
16601693|NCT02601599|No Intervention|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
16601694|NCT02601586|Experimental|PR oxycodone|"A titration phase of two weeks, in three steps:
~Level 1 (from D1 to D5):
~Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)
~Levodopa placebo 100 mg/day bid (50 mg/50 mg)
~Level 2 (from D6 to D10):
~Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)
~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)
~Level 3 (from D11to D15):
~Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)
~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)
~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
~A withdrawal period:"
16601748|NCT02601222|Experimental|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
16601695|NCT02601586|Active Comparator|levodopa|"A titration phase of two weeks, in three steps:
~Level 1 (from D1 to D5):
~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)
~Levodopa 100 mg/day bid (50 mg/50 mg)
~Level 2 (from D6 to D10):
~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)
~Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)
~Level 3 (from D11to D15):
~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)
~Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)
~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
~A withdrawal period:"
16601696|NCT02601586|Placebo Comparator|Placebo|"A titration phase of two weeks, in three steps:
~Level 1 (from D1 to D5):
~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)
~Levodopa placebo 100 mg/day bid (50 mg/50 mg)
~Level 2 (from D6 to D10):
~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)
~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)
~Level 3 (from D11to D15):
~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)
~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)
~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
~A withdrawal period:"
16601697|NCT02601573|Experimental|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
16601698|NCT02601573|Experimental|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
16601699|NCT02601573|Experimental|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
16601700|NCT02601573|Experimental|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
16601701|NCT02601573|Experimental|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
16601702|NCT02601560|Experimental|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
16601703|NCT02601560|Experimental|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
16601704|NCT02601560|Experimental|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
16601705|NCT02601560|Experimental|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
16601706|NCT02601560|Experimental|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
16601707|NCT02601560|Placebo Comparator|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
16601708|NCT02601560|Experimental|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
16601709|NCT02601560|Placebo Comparator|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
16601710|NCT02601547|Experimental|intervention|"PET-FDG brain imaging and NPT should be performed at T0 (within the 15 days before chemotherapy), at Tf (within 1 month after chemotherapy termination), T+12 (Tf+12 months: within the first month after one year of achievement of chemotherapy). Several PET parameters should be calculated: minimal Standard Uptake Value (SUV), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
~NPT scores (3 values) should be correlated with the five better values on PET-FDG.
~Each patient will be monitored along a time period of 18 months.
~Duration of the study: one year to include the 15 patients with all the exams; 18 months follow-up for each; total of 30 months."
16601711|NCT02601534|Experimental|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.
~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
16601712|NCT02601534|Placebo Comparator|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.
~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
16601713|NCT02601521|Experimental|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response [automated phone calls] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
16601714|NCT02601521|Active Comparator|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
16601715|NCT02601508|Active Comparator|Modarate Blockade Group|Neuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine & glycopyrrolate will be given for the recovery.
16601716|NCT02601508|Experimental|Deep Blockade Group|Neuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
16601749|NCT02601222|Placebo Comparator|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
16601717|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score > 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
16601718|NCT02601482|Experimental|Control (CON)|No exercise intervention.
16601719|NCT02601482|Experimental|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
16601720|NCT02601482|Experimental|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
16601721|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
16601722|NCT02601443|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
16601723|NCT02601443|No Intervention|Routine care (watch and wait)|
16601724|NCT02601430|Experimental|BOLD-MRI|Blood Oxygen Level Dependent (BOLD)-MRI assessment of limb perfusion before and after standard of care endovascular therapy.
16601725|NCT02601417|No Intervention|Control|Group which considers both blood culture and bile culture for antibiotics choice
16601726|NCT02601417|Experimental|Trial|Group which considers only blood culture and ignore bile culture for antibiotics choice. Patients in this arm would undergo bile culture but ignore the result when choosing antibiotics
16601727|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
16601728|NCT02601391|Other|STEPPS within forensic services.|"Forensic inpatients attend the STEPPS-HI group. Consent will be obtained. Pre and post group psychometric questionnaires will be completed as well as each service user attending a short semi-structured interview following the conclusion of the group .
~Primary nurse will fill in pre and post group questionnaires. Facilitators will complete short feedback forms each session and attend a focus group upon completion.
~Psychology Assistants/Interns will collect records of self harm and violence/aggressive incidents for each service user as well as records of nursing observation level and leave status taken."
16601729|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
16601730|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
16601731|NCT02601365|Experimental|Aerosolized Sargramostim|A self-controlled, open-label study to evaluate safety of Sargramostim administered by nebulization
16601732|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
16601733|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.
~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
16601734|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
16601735|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.
~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
16601736|NCT02601326|Active Comparator|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
16601737|NCT02601326|Active Comparator|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
16601738|NCT02601313|Experimental|Axicabtagene ciloleucel/brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma (MCL) will receive conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0 or brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 CAR T cells/kg, with a maximum dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 1 or brexucabtagene autoleucel at a targeted dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 2.
16601739|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
16601740|NCT02601287|Experimental|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
16601741|NCT02601287|Experimental|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
16601742|NCT02601274|Experimental|Single Group Assignment|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .
16601743|NCT02601261||Patients with some access to internet during stay|
16601744|NCT02601261||Patients without access to internet during stay|
16601745|NCT02601248|Experimental|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
16601831|NCT02600702|No Intervention|usual care|quadricep exercise
16601750|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16601751|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
16601752|NCT02601196|Other|Ulipristal acetate treatment|Women who receive UPA treatment before another IVF cycle.
16601753|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
16601754|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
16601755|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
16601756|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
16601757|NCT02601157|Experimental|Orsiro SES/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
16601758|NCT02601157|Active Comparator|Orsiro SES/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
16601759|NCT02601157|Experimental|CX-ISAR/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
16601760|NCT02601157|Active Comparator|CX-ISAR/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
16601761|NCT02601144|Experimental|VFS|variable frequency deep brain stimulation (VFS)
16601762|NCT02601144|Active Comparator|HFS|high frequency deep brain stimulation (HFS)
16601763|NCT02601144|Active Comparator|LFS|low frequency deep brain stimulation (LFS)
16601764|NCT02601144|No Intervention|DBS off|deep brain stimulation off
16601765|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
16601766|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
16601767|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
16601768|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
16601769|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
16601770|NCT02601118|Experimental|training group|41 training students were pre-tested before education with Micro Expression Training Tool (METT) and Subtle Expression Training Tool (SETT) at baseline and then, took second METT and SETT tests after a 1-hour class about interpreting micro and subtle expressions.
16601771|NCT02601118|No Intervention|control group|41 control students were pre-tested before education with METT and SETT at baseline and then, took the second tests without attend the training class.
16601772|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
16601773|NCT02601105|Experimental|Centella Asiatica Cream|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
16601774|NCT02601092|Experimental|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.
~No drugs or devices will be used."
16601775|NCT02601092|Active Comparator|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.
~No drugs or devices will be used."
16601776|NCT02601079|Active Comparator|Conventional biopsy|"4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
16601777|NCT02601079|Active Comparator|Endodrill biopsy|"4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
16601778|NCT02601066|Experimental|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
16601779|NCT02601053|Active Comparator|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
16601780|NCT02601053|Experimental|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
16601781|NCT02601040|Experimental|Attenuated Hepatitis A Vaccine, H2 Strain|Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.
16601782|NCT02601040|Experimental|Inactivated Hepatitis A Vaccine, Lu8 Strain|Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.
16601783|NCT02601040|Placebo Comparator|Group A Meningococcal Polysaccharide vaccine|Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.
16601784|NCT02601027|Experimental|0.125% Bupivacaine|0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter
16601785|NCT02601027|Placebo Comparator|Placebo|Saline infusion (sham) via transversus abdominis plane (TAP) catheter.
16601786|NCT02601014|Experimental|Treatment (nivolumab and ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
16601787|NCT02601001|Placebo Comparator|Placebo|Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
16601788|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 37.5 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
16601789|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 50 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
16601790|NCT02600988|No Intervention|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
16601791|NCT02600988|Experimental|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
16601792|NCT02600988|Experimental|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
16601793|NCT02600975|Active Comparator|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
16601794|NCT02600975|Active Comparator|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
16601795|NCT02600962||STEMI|Patients discharged with STEMI
16601796|NCT02600962||NSTEMI|Patients discharged with NSTEMI
16601797|NCT02600949|Experimental|Treatment (synthetic tumor-associated peptide vaccine therapy)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4 and 6, then every 3 weeks until week 30, then at weeks 39 and 51. Beginning 30 minutes after each vaccine is administered, patients then receive imiquimod cream topically after 30 minutes. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 3 weeks until week 51 in the absence of disease progression or unacceptable toxicity.
16601798|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
16601799|NCT02600923|Experimental|Palbociclib + Letrozole|palbociclib and letrozole combination
16601800|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.
~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.
~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.
~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
16601801|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.
~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.
~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.
~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
16601802|NCT02600897|Experimental|Dose-escalation Cohort: FL|Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
16601803|NCT02600897|Experimental|Dose-escalation Cohort: DLBCL|Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
16601804|NCT02600897|Experimental|Expansion Cohort: FL|Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
16601805|NCT02600897|Experimental|Expansion Cohort: DLBCL|Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
16601806|NCT02600884|Experimental|Families Talking Together Plus (FTT+HPV)|Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
16601807|NCT02600884|Active Comparator|Brief motivational interviewing (BMI)|Parents in the brief motivational interviewing (BMI) group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
16601808|NCT02600871|Experimental|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.
~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.
~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
16601809|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.
~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.
~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
16601810|NCT02600858|Experimental|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
16601811|NCT02600858|Other|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
16601812|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
16601813|NCT02600832|Experimental|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
16601814|NCT02600832|Sham Comparator|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
16601815|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
16601816|NCT02600819|Experimental|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
16601817|NCT02600806|Other|Azithromycin/levofloxacin|Azithromycin or levofloxacin are given according to serum procalcitonin levels
16601818|NCT02600793|Experimental|Arm 1|Single dose IV ceftaroline will be administered
16601819|NCT02600780|Active Comparator|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
16601820|NCT02600780|Experimental|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
16601821|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
16601822|NCT02600754|Experimental|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
16601823|NCT02600754|Experimental|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
16601824|NCT02600754|No Intervention|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
16601825|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
16601826|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
16601827|NCT02600728|Experimental|experimental group (EG)|The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS).
16601828|NCT02600728|Active Comparator|control group (CG)|The control training (CT) consisted of a similar gait training without DMCS.
16601829|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
16601830|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
16601832|NCT02600702|Experimental|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
16601833|NCT02600702|Active Comparator|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
16601834|NCT02600689|Experimental|Physical exercise training|Combined aerobic and resistance exercise for 30 or more minutes at least 3 times per week for 12 weeks using the Wii Fit Plus
16601835|NCT02600689|Active Comparator|Cognitive exercise training|Cognitive, brain-training, video gaming ~30 minutes per session, 3 times per week for 12 weeks
16601836|NCT02600676|Active Comparator|TENS, 10 weeks (active) 2 hours a day.|26 children.
16601837|NCT02600676|Placebo Comparator|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
16601838|NCT02600663||acute back pain|
16601839|NCT02600650|Experimental|Experimental|Receive daily authentic Testosterone boosting supplement
16601840|NCT02600650|Placebo Comparator|Placebo|Receive daily placebo supplementation
16601841|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
16601842|NCT02600637|Active Comparator|Education|Educational group program
16601843|NCT02600624||Participants|Women who are in active labor and their newborn infants.
16601844|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
16601845|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
16601846|NCT02600598|Experimental|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
16601847|NCT02600598|Experimental|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
16601848|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
16601849|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
16601850|NCT02600572|Experimental|Isometric exercise|Subjects performing the isometric exercises intervention
16601851|NCT02600572|Experimental|Eccentric exercise|Subjects performing the eccentric exercises intervention
16601852|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
16601853|NCT02600533|No Intervention|Standard care/control group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the standard of care group will be provided standard educational resources (booklet and DVD), with no additional instructions. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
16601854|NCT02600533|Experimental|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
16601855|NCT02600520|Active Comparator|Rosuvastatin Group|SRP followed by RSV gel LDD
16601856|NCT02600520|Active Comparator|Atorvastatin Group|SRP followed by ATV gel LDD
16601857|NCT02600520|Placebo Comparator|Placebo group|SRP followed by placebo gel LDD
16601858|NCT02600507|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as capsules once daily for 6 weeks
16601859|NCT02600507|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as capsules once daily for 6 weeks
16601860|NCT02600507|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
16601861|NCT02600494|Experimental|40 mg ITI-007 (Lumateperone)|40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
16601862|NCT02600494|Experimental|60 mg ITI-007 (Lumateperone)|60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
16601863|NCT02600494|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
16601864|NCT02600481|Experimental|low-pressure pneumoperitoneum group|Subjects assigned to the low-pressure pneumoperitoneum group will receive 7-10 mm Hg carbon dioxide pneumoperitoneum, and the expected duration is longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
16601865|NCT02600481|Active Comparator|standard-pressure pneumoperitoneum group|Subjects assigned to the standard-pressure pneumoperitoneum group will receive 12-16 mm Hg carbon dioxide pneumoperitoneum, which is expected lasted longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
16601866|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
16601867|NCT02600455||Patients who are treated with ORENCIA|Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
16601868|NCT02600442||main and unique cohort|
16601869|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
16601870|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
16601871|NCT02600416|Other|AV port reversal|Patients undergoing citrate CVVH.
16601872|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
16601873|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
16601874|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
16601875|NCT02600390|Experimental|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
16601876|NCT02600390|Experimental|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
16601877|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
16601878|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
16601879|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
16601880|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
16601881|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
16601882|NCT02600312|Active Comparator|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
16601883|NCT02600312|No Intervention|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
16601884|NCT02600299|Experimental|Intervention Arm|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship. This program is designed to take place on three individual days on a weekend. For each session, three major topics will be covered, with lectures and interactive workshop integrated. Sessions will be conducted by healthcare professionals who are experts/well-versed in their respective domains.
16601885|NCT02600299|Placebo Comparator|Usual Care|No active intervention provided.
16601886|NCT02600286|Experimental|1|"Arm (1) will be randomised to receive either :
~5 mg/per os of EllaOne every day through 12 months.
~10 mg/per os of EllaOne every day through 12 months.
~EllaOne placebo/per os every day through 12 months."
16601887|NCT02600286|Experimental|2|"Arm (2) will be randomised to receive either :
~5 mg/per os of EllaOne every day through 12 months.
~10 mg/per os of EllaOne every day through 12 months.
~EllaOne placebo/per os every day through 12 months."
16601888|NCT02600286|Experimental|3|"Arm (3) will be randomised to receive either :
~5 mg/per os of EllaOne every day through 12 months.
~10 mg/per os of EllaOne every day through 12 months.
~EllaOne placebo/per os every day through 12 months."
16601889|NCT02600273|Active Comparator|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
16601890|NCT02600273|Experimental|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
16601891|NCT02600273|Experimental|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
16601892|NCT02600273|Experimental|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
16601893|NCT02600260|Other|enoxaparin|A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
16601894|NCT02600260|Other|no intervention|Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
16601895|NCT02600247|Experimental|Duloxetine group|"Experimental: Duloxetine group
~Phase I (preemptive): 1day before operation (30mg for 1 day)
~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon"
16601896|NCT02600247|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
16601897|NCT02600234|Experimental|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
16601898|NCT02600234|Placebo Comparator|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
16601900|NCT02600195|Experimental|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
16601901|NCT02600195|No Intervention|Control sites|Continue current practices
16601902|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
16601903|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
16601904|NCT02600169||Patients treated with pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.
16601905|NCT02600156|Experimental|Single arm study|MR guided focal laser ablation of prostate cancer using the Visualase Thermal Therapy System.
16603303|NCT02591069|Experimental|All patients will undergo the same procedure|
16601906|NCT02600130|Experimental|Cohort 1|Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.
16601907|NCT02600130|Experimental|Cohort 2|Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.
16601908|NCT02600130|Placebo Comparator|Cohort 3|Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion.
16601909|NCT02600117|Other|Tenofovir disoproxil fumarate|300 mg, orally, once a day for 3 years or when sAg+ve seroconverts to sAb+ve whichever comes earlier
16601910|NCT02600104|Experimental|all subjects|will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
16601911|NCT02600091|Experimental|MBCT Intervention|Participants in the Mindfulness-based Cognitive Therapy Intervention arm will receive an 8-week programme in mindfulness-based cognitive therapy
16601912|NCT02600091|No Intervention|Waiting List Control|The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
16601913|NCT02600078|Active Comparator|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
16601914|NCT02600078|Sham Comparator|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
16601915|NCT02600078|Active Comparator|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
16601916|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.
~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
16601917|NCT02600052|Experimental|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
16601918|NCT02600052|Active Comparator|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
16601919|NCT02600039|Experimental|ELTGOL|
16601920|NCT02600039|Active Comparator|Acapella|
16601921|NCT02600026|Experimental|Video Camera: Intervention|DriveCam video event recorder with feedback
16601922|NCT02600026|Placebo Comparator|Video Camera: Monitoring|DriveCam video event recorder with no feedback
16601923|NCT02600000|Experimental|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
16601924|NCT02600000|Experimental|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
16601925|NCT02600000|Experimental|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
16601926|NCT02600000|Experimental|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
16601927|NCT02599987|Experimental|Inspiratory Muscle Training Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The training group will carry with IMT load of 50% of MIP. Weekly, patients attend the Cardiopulmonary Physical Therapy Laboratory for evaluation of MIP and load adjustment, performing a training session in the presence of the therapist, while other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
16601928|NCT02599987|Sham Comparator|Sham Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The sham group will carry without load, but will be subjected to the same procedures in the experimental group (simulation of load adjustment in the Cardiopulmonary Physical Therapy Laboratory) to ensure blinding of the study, other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
16601929|NCT02599961|Experimental|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
16601930|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
16601931|NCT02599935|Experimental|educational intervention and supplements|structured educational intervention and dietary supplements
16601932|NCT02599935|Active Comparator|usual interventions|Usual treatment without nutritional supplements or structured assessment
16601933|NCT02599922|Experimental|Group 1: 2.0 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601934|NCT02599922|Experimental|Group 2: 4.0 x 10^10 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601935|NCT02599922|Experimental|Group 3: 1.2 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601936|NCT02599922|Experimental|Group 4: 3.6 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601937|NCT02599922|Experimental|Group 4a: 3.6 x 10^11 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601938|NCT02599922|Experimental|Group 5: 1.1 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601939|NCT02599922|Experimental|Group 5a: 1.1 x 10^12 vg/mL of AGTC-401|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601940|NCT02599922|Experimental|Group 6: 3.2 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
16601941|NCT02599922|Experimental|Group 7: MTD of AGTC-401|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
16601942|NCT02599909||1/ Cohort 1|Subjects with hepatocellular carcinoma
16601943|NCT02599896|Experimental|Group 1|5 mg/kg/IV on Day 0
16601944|NCT02599896|Experimental|Group 2|5 mg/kg SC on Day 0
16601945|NCT02599896|Experimental|Group 3|20 mg/kg IV on Day 0
16601946|NCT02599896|Experimental|Group 4|40 mg/kg IV on Day 0
16601947|NCT02599896|Experimental|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
16601948|NCT02599896|Experimental|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
16601949|NCT02599896|Experimental|Group 7|5 mg/kg SC on Day 0, Week 4
16601950|NCT02599896|Experimental|Group 8|20 mg/kg IV on Day 0, Week 4
16601951|NCT02599883|Experimental|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
16601952|NCT02599870|Experimental|NeuroIDgenetix Test Panel Intervention|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
16601953|NCT02599870|No Intervention|Control|The medical provider for the control group will not receive the NeuroIDgenetix Test Panel results and will make post-operative pain management recommendations based as usual. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
16601954|NCT02599857|Experimental|CONCOR smartphone application|Use of CONCOR smartphone application
16601955|NCT02599857|No Intervention|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
16601956|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
16601957|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
16601958|NCT02599831|Experimental|Electrical pudendal nerve stimulation|"Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum).
~Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 times per week for 8 weeks."
16601959|NCT02599831|Active Comparator|PFM training with Transanal ES|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of < 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
16601960|NCT02599818|Experimental|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
16601961|NCT02599818|No Intervention|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
16601995|NCT02599610|Experimental|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
16601996|NCT02599597|Experimental|Therapist-assisted iCBT|Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse. Monthly depression screening with therapist feedback.
16601962|NCT02599805|Experimental|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
16601963|NCT02599805|No Intervention|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:
~Full medical assessment in all cases.
~Surgical operation/Intervention where indicated.
~Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
16601964|NCT02599792|Experimental|CTP-656, 150 mg|Single Oral Dose
16601965|NCT02599792|Active Comparator|Kalydeco, 150 mg|Single oral dose
16601966|NCT02599792|Experimental|CTP-656, 75 mg or matching placebo|Subjects will be administered 75 mg CTP-656 for 7 days.
16601967|NCT02599792|Experimental|CTP-656, 150 mg or matching placebo|Subjects will be administered 150 mg CTP-656 for 7 days.
16601968|NCT02599792|Experimental|CTP-656, high dose or matching placebo|Subjects will be administered up to 300 mg CTP-656 for 7 days.
16601969|NCT02599779|Experimental|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.
~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
16601970|NCT02599779|Experimental|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.
~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
16601971|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
16601972|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
16601973|NCT02599753|Experimental|18F-DTBZ for Parkinson's Disease|The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
16601974|NCT02599740|Placebo Comparator|Placebo|Rice only
16601975|NCT02599740|Active Comparator|Assumed active|Assumed key active consumed with rice
16601976|NCT02599740|Active Comparator|Natural fruit extract|Natural fruit extract consumed with rice
16601977|NCT02599727|Experimental|Active Isometric exercise|Subjects performing the isometric exercises intervention
16601978|NCT02599727|Active Comparator|No exercise|Subjects not performing the isometric exercises intervention
16601979|NCT02599714|Experimental|Triplet Combination (Dose Finding)|Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
16601980|NCT02599714|Experimental|Triplet Combination (Dose Expansion)|Additional patients will be enrolled at the dose determined in Part A.
16601981|NCT02599701|Placebo Comparator|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
16601982|NCT02599701|Experimental|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
16601983|NCT02599675|Experimental|Vitamin D3|Vitamin D3 capsules for 12 weeks (2000 IU daily, equivalent to 50 ug)
16601984|NCT02599675|Placebo Comparator|Placebo|Placebo capsules for 12 weeks (the number of daily capsules will match that of the vitamin D-group)
16601985|NCT02599662|Other|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
16601986|NCT02599662|Other|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
16601987|NCT02599662|Other|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
16601988|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
16601989|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
16601990|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
16601991|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
16601992|NCT02599623|Experimental|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
16601993|NCT02599623|Active Comparator|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
16601994|NCT02599610|Active Comparator|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
16601997|NCT02599597|Active Comparator|Monthly screening with feedback|Monthly depression screening with therapist feedback.
16601998|NCT02599597|No Intervention|Control|No intervention, follow-up along with all participants at 6 and 12-months.
16601999|NCT02599584|Experimental|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
16602000|NCT02599584|No Intervention|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
16602001|NCT02599571|Other|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
16602002|NCT02599571|Other|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
16602003|NCT02599558|Experimental|Cytosponge,Diet,EEsAI Pro,Phone call|Patients going through the six food elimination diet (clinically)for EoE, will be asked to participate. We will introduce 1 of the 6 foods previously eliminated for two weeks, than another for two weeks, at the end of 4 weeks the participant will return to swallow the cytosponge to monitor them through the diet, rather than multiple repeat Upper Endoscopies. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the diet, which foods to add or take out of the diet.
16602004|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
16602005|NCT02599532|Other|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
16602006|NCT02599532|Other|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
16602007|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
16602008|NCT02599493|Experimental|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
16602009|NCT02599493|Active Comparator|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
16602010|NCT02599480|Active Comparator|mirabegron|Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
16602011|NCT02599480|Placebo Comparator|Placebo|Patients will be orally administererd with a placebo once a day during 12 months.
16602012|NCT02599467|Experimental|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.
~Procedure: ULNT 1 and EMG recording."
16602013|NCT02599467|Experimental|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.
~Procedure: ULNT 1 and EMG recording"
16602014|NCT02599467|Active Comparator|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.
~Procedure: ULNT 1 and EMG recording."
16602015|NCT02599454|Experimental|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.
~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
16602016|NCT02599441||Ankle fracture cases|
16602017|NCT02599415|Other|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
16602018|NCT02599402|Experimental|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
16602019|NCT02599402|Experimental|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
16602020|NCT02599389|No Intervention|Standard balloon|Angioplasty with use of standard balloons
16602021|NCT02599389|Experimental|Drug-coated balloons|Angioplasty with use of drug-coated balloons
16602022|NCT02599389|Experimental|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
16602023|NCT02599376|Active Comparator|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
16602024|NCT02599376|Experimental|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
16602025|NCT02599363|Experimental|Dose Escalation Treatment Arm|
16602026|NCT02599350||1|Patients receiving mechanical ventilation
16602027|NCT02599337|Experimental|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
16602028|NCT02599337|Active Comparator|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
16602029|NCT02599324|Experimental|Renal Cell Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.
~Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus."
16602030|NCT02599324|Experimental|Urothelial Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.
~Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel."
16602031|NCT02599324|Experimental|Gastric Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.
~Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
16602032|NCT02599324|Experimental|Colorectal Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.
~Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
16602033|NCT02599324|Experimental|Urothelial Carcinoma Ibrutinib- Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b.
16602034|NCT02599324|Experimental|Urothelial Carcinoma with Pembrolizumab - Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels in combination with pembrolizumab to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.
16602035|NCT02599311|Other|the efficacy|transvaginal synthetic mesh
16602036|NCT02599311|No Intervention|the recurrence rate|transvaginal synthetic mesh
16602037|NCT02599311|No Intervention|the quality of life|transvaginal synthetic mesh
16602038|NCT02599311|Other|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
16602039|NCT02599298|Active Comparator|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
16602040|NCT02599298|No Intervention|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
16602041|NCT02599285||Fixation|Patients with a trimalleolar AO Weber C fracture with open reduction and fixation of the posterior malleolar fragment.
16602042|NCT02599285||No Fixation|Patients with a trimalleolar AO Weber C fracture without open reduction and fixation of the posterior malleolar fragment.
16602043|NCT02599272|Other|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
16602044|NCT02599272|Active Comparator|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
16602045|NCT02599272|Active Comparator|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
16602046|NCT02599259|Experimental|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
16602047|NCT02599259|No Intervention|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
16602048|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.
~Interventions:
~In hospital pain evaluation
~In hospital questionnaires
~Telephone conctact at 3 months"
16602049|NCT02599207|Experimental|Matched related umbilical cord blood|Six subjects will receive an infusion of HLA matched sibling umbilical cord blood cells.
16602050|NCT02599207|Experimental|Mismatched related umbilical cord blood|Nine subjects will receive an infusion of HLA-mismatched (≥3/6 match) or matched sibling umbilical cord blood cells.
16602051|NCT02599194|Experimental|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
16602052|NCT02599181|Experimental|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland prior to perineural catheter removal.
16602053|NCT02599181|No Intervention|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
16602054|NCT02599168|Active Comparator|Dexmedetomidine group|Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
16602055|NCT02599168|Placebo Comparator|Non-Dexmedetomidine group|Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
16602056|NCT02599155|Placebo Comparator|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
16602057|NCT02599155|Active Comparator|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
16602058|NCT02599142|Active Comparator|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
16602059|NCT02599142|Experimental|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
16602060|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
16602061|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
16602062|NCT02599116|Other|Microbiome cohort|"Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.
~Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires
~Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
16602063|NCT02599103|Placebo Comparator|fat-free milkshake|
16602064|NCT02599103|Active Comparator|Olive oil|
16602065|NCT02599103|Experimental|soybean oil|
16602066|NCT02599103|Experimental|fried soybean oil|
16602067|NCT02599103|Experimental|palm oil|
16602068|NCT02599103|Experimental|fried palm oil|
16602069|NCT02599103|Experimental|camellia oil|
16602070|NCT02599103|Experimental|fried camellia oil|
16602071|NCT02599103|Experimental|tallow|
16602072|NCT02599103|Experimental|fried tallow|
16602073|NCT02599090|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle
~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
16602074|NCT02599090|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
16602075|NCT02599090|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
16602076|NCT02599090|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
16602077|NCT02599077|Experimental|Dienogest|the patient handling with 2 mg dienogest / day.
16602078|NCT02599077|Active Comparator|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
16602079|NCT02599064|Experimental|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
16602080|NCT02599051|Active Comparator|Monarc|Placement of a transobturator monarc sling for stress urinary incontinence
16602081|NCT02599051|Experimental|Mini-arc|Placement of a single incision mini-arc sling for stress urinary incontinence
16602082|NCT02599038|Experimental|Serine supplementation|Serine oral administration 20mg/kg/day
16602083|NCT02599025|No Intervention|Supine position|Children tested while lying down
16602084|NCT02599025|No Intervention|Standing position|Children tested while standing
16602085|NCT02599025|Experimental|Cycling supine postion|Children lying down with APT cycling system
16602086|NCT02599025|Experimental|Cycling standing postion|Children standing with Innowalk cycling system
16602087|NCT02599012|Experimental|Subjects|
16602088|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
16602089|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
16602090|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
16602091|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
16602092|NCT02598986|Placebo Comparator|white pita bread|Pita bread made of white wheat flour
16602093|NCT02598986|No Intervention|Whole grain pita bread|no macronutrient supplementation
16602094|NCT02598986|Experimental|Restored white pita bread|macronutrient supplementation
16602095|NCT02598986|Experimental|Fortified white pita bread|macronutrient supplementation 2
16602096|NCT02598973|Active Comparator|Exercise|aerobic walking
16602097|NCT02598973|No Intervention|No exercise|normal activity
16602098|NCT02598960|Experimental|BMS-986156: Dose Escalation|
16602099|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Escalation|
16602100|NCT02598960|Experimental|BMS-986156: Dose Expansion|
16602101|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Expansion|
16602102|NCT02598960|Experimental|BMS986156 + Nivo: Cohort Expansion|
16602103|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
16602104|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
16602105|NCT02598934|Experimental|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
16602106|NCT02598934|Experimental|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
16602107|NCT02598921|Other|Three dimensional ultrasound|Three dimensional ultrasound evaluated the uterine cavity for cavitary lesions
16602108|NCT02598921|Other|Office hysteroscopy|Office hystrescopy evaluated the uterine cavity for cavitary lesions
16602109|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
16602183|NCT02598453|Experimental|Ibandronate IV|Participants will receive ibandronate 3 mg IV once every 3 months
16602110|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
16602111|NCT02598895|Experimental|Treatment (docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
16602112|NCT02598882|Active Comparator|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
16602113|NCT02598882|Active Comparator|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
16602114|NCT02598869|Active Comparator|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
16602115|NCT02598869|Active Comparator|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
16602116|NCT02598856|Experimental|Intranasal naloxone 1x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
16602117|NCT02598856|Active Comparator|Intranasal naloxone 2x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
16602118|NCT02598856|Active Comparator|Intravenous naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
16602119|NCT02598856|Active Comparator|Intramuscular naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
16602120|NCT02598843|Active Comparator|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is removed and patients mobilise fully weightbearing for a further 2 weeks out of cast, with internal shoe insert heel raise. Commence physiotherapy at 10 weeks, when cast removed.
16602121|NCT02598843|Experimental|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossur rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 8 weeks.
16602122|NCT02598830|Experimental|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:
~weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+
~weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+
~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:
~weeks 15-17, familiarization period
~week 18, test period
~weeks 19-28, intervention period
~weeks 29-30, test period"
16602123|NCT02598830|Placebo Comparator|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)
~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:
~weeks 15-17, familiarization period
~week 18, test period
~weeks 19-28, intervention period
~weeks 29-30, test period"
16602124|NCT02598817||Standard Infant Formula|Standard Infant Formula containing High Sn-2
16602125|NCT02598804|Experimental|Intervention group|"No single group but 2 groups :
~Intervention group (5 educational workshop in addition to spa therapy)
~Control group (Written information booklet in addition to spa therapy)"
16602126|NCT02598804|Other|control group|"No single group but 2 groups :
~Intervention group (5 educational workshop in addition to spa therapy)
~Control group (Written information booklet in addition to spa therapy)"
16602127|NCT02598791|Active Comparator|IIGI+GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
16602128|NCT02598791|Active Comparator|IIGI+GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
16602129|NCT02598791|Placebo Comparator|IIGI+NaCl (placebo)|4 hour i.v. NaCl (placebo) during isoglycemic conditions
16602130|NCT02598791|Active Comparator|IIGI+GIP+GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
16602131|NCT02598791|Other|50 g OGTT|50 g oral glucose tolerance test (OGTT)
16602132|NCT02598778|Active Comparator|Chlorhexidine gluconate (.12%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
16602133|NCT02598778|Active Comparator|Sodium fluoride oral rinse (.05%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
16602134|NCT02598778|Active Comparator|Coconut oil|A food product. In previous studies it has shown positive effects on the reduction of oral plaque and gingivitis as an oral rinse.
16602135|NCT02598778|Placebo Comparator|Deionized water|Water that has had the majority of its ions removed.
16602136|NCT02598765|Active Comparator|Standard Trabeculectomy|Patients in the Standard Trabeculectomy arm will undergo regular trabeculectomy
16602137|NCT02598765|Experimental|Microtrabeculectomy|Patients in the Microtrabeculectomy arm will undergo microtrabeculectomy
16602184|NCT02598453|Experimental|Ibandronate Oral|Participants will receive ibandronate 150 milligrams (mg) tablet once monthly
16602138|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
16602139|NCT02598739|Experimental|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.
~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).
~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
16602140|NCT02598739|Other|Control group|Waiting list for the exercises.
16602141|NCT02598726|Experimental|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
16602142|NCT02598713|Experimental|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
16602143|NCT02598687|Other|treatment|treatment arm: TH-302 pre-treatment day 4 and weekly during treatment. 5 x carboplatin and paclitaxel, radiotherapy: 23 x 1.8Gy HX4 scans day 1 and day 8,surgery 6-10 weeks after chemo-radiotherapy
16602144|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
16602145|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
16602146|NCT02598661|Experimental|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
16602147|NCT02598661|Experimental|Part 2: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
16602148|NCT02598661|Placebo Comparator|Part 2: Placebo|Matching Placebo to Imetelstat will be administered.
16602149|NCT02598648|Other|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
16602150|NCT02598648|Other|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.
~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
16602151|NCT02598648|Other|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2< 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
16602152|NCT02598635|Experimental|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
16602153|NCT02598635|Placebo Comparator|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
16602154|NCT02598622|Experimental|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
16602155|NCT02598622|Experimental|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
16602156|NCT02598609|Other|Cluster A|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
16602157|NCT02598609|Other|Cluster B|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.
16602236|NCT02598024|No Intervention|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
16602158|NCT02598609|Other|Cluster C|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.
16602159|NCT02598596|Experimental|Pegloticase regimen <120 kg - Main Study|Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
16602160|NCT02598596|Experimental|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
16602161|NCT02598596|Experimental|Pegloticase PK Sub-Study|Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
16602162|NCT02598596|Experimental|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
16602163|NCT02598596|Experimental|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
16602164|NCT02598596|Experimental|Pegloticase and Azathioprine|Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
16602165|NCT02598583|Experimental|Cohort 1|"Intravenous infusion of ALXN1210 as follows:
~Induction phase: a) 400 milligrams (mg) on Day 1 and Day 8, 600 mg on Day 15; or b) 600 mg on Day 1, 600 mg on Day 15
~Maintenance phase: the first 5 doses of 900 mg on Day 29 and every 4 weeks thereafter
~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:
~≥40 to <60 kilograms (kg): 3000 mg every 8 weeks
~≥60 to <100 kg: 3300 mg every 8 weeks
~≥100 kg: 3600 mg every 8 weeks"
16602166|NCT02598583|Experimental|Cohort 2|"Intravenous infusion of ALXN1210 as follows:
~Induction phase: 600 mg on Day 1, 900 mg on Day 15
~Maintenance phase: the first of 5 doses of 1800 mg on Day 29 and every 4 weeks thereafter
~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:
~≥40 to <60 kg: 3000 mg every 8 weeks
~≥60 to <100 kg: 3300 mg every 8 weeks
~≥100 kg: 3600 mg every 8 weeks"
16602167|NCT02598570|Experimental|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
16602168|NCT02598557|Experimental|Arm I (exemestane)|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
16602169|NCT02598557|Experimental|Arm II (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
16602170|NCT02598557|Experimental|Arm III (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
16602171|NCT02598544|Other|lean men|
16602172|NCT02598544|Other|Obese men without type 2 diabetes|
16602173|NCT02598544|Other|Obese men with type 2 diabetes|
16602174|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
16602175|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
16602176|NCT02598518|Experimental|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
16602177|NCT02598518|Active Comparator|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
16602178|NCT02598505|Experimental|Indacaterol|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
16602179|NCT02598505|Placebo Comparator|Placebo|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
16602180|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
16602181|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
16602182|NCT02598466||Abatacept|
16602185|NCT02598440|Experimental|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
16602186|NCT02598440|Experimental|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
16602187|NCT02598427|Experimental|Intrathecal Pertuzumab and Trastuzumab|"Four cohorts will enroll in a dose escalation of pertuzumab and a consistent dose of trastuzumab. The cohorts will be assigned as follows:
~Cohort: Intrathecal Dose:
~10mg pertuzumab, 80mg trastuzumab
~20mg pertuzumab, 80mg trastuzumab
~40mg pertuzumab, 80mg trastuzumab
~80mg pertuzumab, 80mg trastuzumab"
16602188|NCT02598414|Experimental|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
16602189|NCT02598414|Active Comparator|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
16602190|NCT02598388|Experimental|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
16602191|NCT02598388|Experimental|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
16602192|NCT02598388|Experimental|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
16602193|NCT02598375||Children with feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have the feeding intolerance at least for12 hours or more.
16602194|NCT02598375||Children without feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have not the feeding intolerance signs at least for 12 hours or less
16602195|NCT02598362|Other|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
16602196|NCT02598362|Other|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
16602197|NCT02598349|Experimental|Proton Radiation with capecitabine|"The following will be performed in this group: Proton Radiation Therapy with concomitant oral chemotherapy, capecitabine taken on radiation treatment days for 6 weeks. A surgical resection will be performed between 8 and 16 weeks if radiographic studies suggest operability.
~Additionally, a Functional Assessment of Cancer Therapy (FACT-Hep) questionnaire is to be filled out by participants at baseline, at week 4 and week 6, then 1 month after completion of treatment, then every 3 months for 1 year, and then every 6 months for 3 years. The FACT-Hep questionnaire is specific to those with gastrointestinal cancers focusing on hepatobiliary and pancreatic cancer."
16602198|NCT02598336|Other|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
16602199|NCT02598336|Other|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
16602200|NCT02598323|Experimental|patients with active singleton pregnancy between 16 and 26 SA|
16602201|NCT02598310|Experimental|nab-paclitaxel plus trastuzumab|Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
16602202|NCT02598297|Active Comparator|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
16602203|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
16602204|NCT02598284|Experimental|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
16602205|NCT02598284|Experimental|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
16602206|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
16602207|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
16602208|NCT02598258|Experimental|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
16602209|NCT02598245|Active Comparator|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
16602210|NCT02598245|Experimental|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
16602211|NCT02598232|Experimental|1,414nm Nd:YAG laser|It has high absorption coefficient in water and a short pulse width.
16602289|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
16602212|NCT02598219|Experimental|Pre-operative SN mapping with radionucleide|"1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA
~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye
~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.
~If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).
~If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology"
16602213|NCT02598219|Other|B : Current initial staging protocols|Current initial staging protocols
16602214|NCT02598206|Experimental|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:
~A - B B - A"
16602215|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
16602216|NCT02598180|Experimental|VergenixTM Flowable Gel|VergenixTM Flowable Gel
16602217|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
16602218|NCT02598154||Study population|The study population consists of patients whose age is between 20 and 75 years and who experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients or patients consultating in the neurological rehabilitation service (NHS) at the Grau du Roi Medical Center, Nîmes University Hospital.
16602219|NCT02598141|Other|Per-op biopsy around material|"Patients included in this study require biopsies for suspicion of infected osteo-articular materials (implants, protheses, nails, screw, plates).
~Interventions:
~Biological sampling grinding
~Biological sampling with standard procedures"
16602220|NCT02598128|Experimental|RELiZORB|Treatment (RELiZORB)
16602221|NCT02598128|Placebo Comparator|Control|Placebo control
16602222|NCT02598115|No Intervention|Before collarborative pharmaceutical care|"All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.
~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
16602223|NCT02598115|Experimental|After collarborative pharmaceutical care|"All clusters start in the No Intervention arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.
~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
16602224|NCT02598102|Experimental|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
16602225|NCT02598102|Placebo Comparator|Placebo|Placebo one hour prior to stent removal
16602226|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:
~NYMC BX-51B reassortant of B/Massachusetts/2/2012
~NYMC X-179A reassortant of A/California/7/2009 (H1N1)
~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
16602227|NCT02598089|Placebo Comparator|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
16602228|NCT02598076|Active Comparator|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
16602229|NCT02598076|Experimental|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
16602230|NCT02598063|Active Comparator|ADV + Lamivudine|Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
16602231|NCT02598063|Experimental|Peginterferon alfa-2a + Lamivudine|Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
16602232|NCT02598050||older surgical patients|Patients 65 years of age and older having lower extremity joint replacement surgery.
16602233|NCT02598037|Other|FTO gene polymorphism|test meal after fasting for 12 hours
16602234|NCT02598024|Experimental|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
16602235|NCT02598024|Experimental|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
16602237|NCT02598011|Experimental|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.
~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
16602238|NCT02598011|Experimental|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.
~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
16602239|NCT02597998|Experimental|14C-BI 409306|14C-BI 409306 oral solution
16602240|NCT02597985|Active Comparator|Prehabilitation|Will receive 4 weeks of supervised exercised prescription before they undergo TAVR and will monitor and record, improvement if any, in the short-term physical performance battery score
16602241|NCT02597985|Placebo Comparator|Usual care|Will receive usual care
16602242|NCT02597972|Active Comparator|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
16602243|NCT02597972|Active Comparator|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
16602244|NCT02597959||risk factors of musculoskeletal injuries|trainees for surgical assistants - determining the level of risk
16602245|NCT02597959||design wearable devices|Creating feedback mechanism to reduce surgical assistant musculoskeletal risk
16602246|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
16602247|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
16602248|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
16602249|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
16602250|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
16602251|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
16602252|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
16602253|NCT02597894|Other|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
16602254|NCT02597868|Active Comparator|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
16602255|NCT02597868|Experimental|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
16602256|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
16602257|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
16602258|NCT02597842|Experimental|shuangxuezu|Patients were given 30min of TEAS before induction until the end of the operation at two acupoints.
16602259|NCT02597842|Experimental|neiguanxuezu|Patients were given TEAS at neiguan acupoint.
16602260|NCT02597842|Experimental|zusanlixuezu|Patients were given TEAS at Zusanli acupoint.
16602261|NCT02597842|Sham Comparator|duizhaozu|Patients were not given TEAS at two acupoints.
16602262|NCT02597829|Other|Open Label Certolizumab Pegol|Active Treatment
16602263|NCT02597816|Other|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
16602264|NCT02597803|Experimental|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
16602265|NCT02597803|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
16602266|NCT02597803|Experimental|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
16602267|NCT02597790||Group A (HIV/HCV coinfected)|
16602268|NCT02597790||Group B (HIV monoinfected)|
16602269|NCT02597777|Placebo Comparator|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
16602270|NCT02597777|Experimental|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
16602316|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
16602965|NCT02593318|Experimental|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
16602271|NCT02597764|Active Comparator|Standard Urotherapy (SU)|Standard Urotherapy (SU): A non-invasive therapy combining cognitive, behavioral and physical therapy. The study team will explain the problem to the children and their parents and educate them on the following: proper voiding mechanics, sitting, standing positions, how and when to void, techniques on relaxing pelvic floor muscles, and avoiding straining. An assessment of bowel habits will be done and their diet and drinking/voiding habits will be modified to maintain proper hydration with timed voiding. Voiding diaries will be provided for the assessment of the bladder and bowel habits.
16602272|NCT02597764|Experimental|Standard Urotherapy (SU) + Diaphragmatic Beathing (DB)|"Standard Urotherapy (SU) with the addition of Diaphragmatic Breathing (DB):
~A non-invasive breathing technique that is performed by a marked expansion of the abdomen (contracting diaphragm) rather than chest cavity during inspiration and tightening of the stomach muscles during expiration. Participants will lie on their back on a flat surface. Head is supported with a pillow and knees are bent forward supported by another pillow. Participants will place one hand on chest and the other on the abdomen, then start inhalation by moving their abdomen out against their hand, breathing in through their nose while keeping their chest and the other hand as still as possible. During expiration, the participants will tighten their abdominal muscles by forcing them inward and breathe out through pursed lips while keeping the hand on the chest as still as possible. Participants will be asked to perform this exercise for 10 minutes 3 times daily for 3 months."
16602273|NCT02597751|Experimental|Treatment Arm|Participants are randomized to treatment group. After the first MRI scan, participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a second MRI scan. Twelve weeks later, participants have a third, follow-up scan.
16602274|NCT02597751|No Intervention|Waitlist control|"Participants are randomized to the waitlist control group. After the first MRI scan, participants wait for 12 weeks and then have a 2nd MRI scan. Participants then have 10 treatment sessions with an occupational therapist and are assessed by an independent occupational therapist before and after treatment. Participants then have a third MRI scan to examine brain changes associated with intervention."
16602275|NCT02597738|Experimental|Lung/ Head and Neck Cancer Group|Blood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five.
16602276|NCT02597738|Experimental|Chronic inflammatory disease|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
16602277|NCT02597738|Experimental|At risk for lung cancer|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
16602278|NCT02597738|Experimental|Healthy people who exercise|Blood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise.
16602279|NCT02597738|Experimental|Lung cancer with planned resection|"Blood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits.
~Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded."
16602280|NCT02597738|Experimental|Solid tumor cancer w/ radiation therapy|Blood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years.
16602281|NCT02597725||Urodynamics|There is no intervention in this study.
16602282|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
16602283|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
16602284|NCT02597699|Active Comparator|Arm 1: Sufentanil + Lidocaïne|"For patients randomized to arm 1, as in the current practice, we will inject Sufentanil intra-cordially at the dose of 1.5 μg / kg of the estimated fetal weight, then the Lidocaïne 1% bolus of 10 ml (10 mg / ml).
~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of fetal asystole, we will inject 100mg of Lidocaïne 1% in bolus of 10 ml. In the event of failure of the procedure, we will inject 10ml of KCL 10% intra-cordial if the cord is always accessible, if not intra-cardiac."
16602285|NCT02597699|Experimental|Arm 2: Remifentanil + Lidocaïne|"For patients randomized to arm 2, we will inject 30 μg of intravenous Remifentanil (Ultiva®) followed by Xylocaine 1% in a 10 ml bolus (10 mg / ml).
~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of asystole, we will inject 100 mg of Lidocaïne 1% in bolus of 10 ml. In case of failure of the procedure, we will inject 10 ml of KCL 10% intra-cordial if the cord is still accessible, if not intra-cardiac."
16602286|NCT02597686|Experimental|SD-PB training|
16602287|NCT02597673|Active Comparator|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
16602288|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
16602347|NCT02597348|No Intervention|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
16602348|NCT02597335|Experimental|IDH1/IDH2|
16602349|NCT02597322|Experimental|AXITINIB|
16602290|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
16602291|NCT02597660|Active Comparator|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
16602292|NCT02597660|Placebo Comparator|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
16602293|NCT02597647|Experimental|Live attenuated influenza vaccine|Healthy adult volunteers given intranasal FluMist (Live Attenuated Influenza vaccine). Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after LAIV.
16602294|NCT02597647|Placebo Comparator|Saline nasal spray|Healthy adult volunteers given intranasal saline nasal spray. Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after saline administration.
16602295|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
16602296|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
16602297|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
16602298|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
16602299|NCT02597621||Healthy Controls|Healthy controls.
16602300|NCT02597608|Experimental|UPPR: Control|No interventions are provided.
16602301|NCT02597608|Experimental|UPPR: Livelihoods only|Livelihoods programmes offered by UPPR.
16602302|NCT02597608|Experimental|UPPR: Livelihoods plus nutrition|Livelihoods programmes offered by UPPR, plus nutrition programmes offered by UPPR.
16602303|NCT02597608|Experimental|CLP: Livelihoods only|Livelihoods programmes offered by CLP.
16602304|NCT02597608|Experimental|CLP: Livelihoods plus nutrition|Livelihoods programmes offered by CLP, plus nutrition programmes offered by CLP.
16602305|NCT02597608|Experimental|Shiree: Livelihoods only|Livelihoods programmes offered by Shiree.
16602306|NCT02597608|Experimental|Shiree: Livelihoods plus nutrition|Livelihoods programmes offered by Shiree, plus nutrition programmes offered by Shiree.
16602307|NCT02597595|Experimental|patients|thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
16602308|NCT02597595|No Intervention|controls|thirty healthy children of matched age and sex
16602309|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.
~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
16602310|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.
~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
16602311|NCT02597569||Historical Control|Patient participants will be recruited from an inpatient rehabilitation stroke unit prior to introducing CO-OP KT training to the stroke team. Patient participants will receive Usual Care from their stroke team.
16602312|NCT02597569||CO-OP KT Exposure group|Patient participants will be recruited from an inpatient rehabilitation stroke unit after the stroke team has been exposed to CO-OP KT training. Patient participants will receive Usual Care, augmented by CO-OP KT, from their stroke team.
16602313|NCT02597556|Active Comparator|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
16602314|NCT02597556|Placebo Comparator|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
16602315|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
16602317|NCT02597530|Experimental|Long-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.Patients in Long-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and continued until the end of the surgery with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
16602318|NCT02597530|Other|Short-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.The patients in Short-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
16602319|NCT02597530|Placebo Comparator|Sham group|Patients in sham group will be pasted electrodes 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
16602320|NCT02597517||Intervention group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and positive stool antigen test for H pylori in whom gastric body mucosal will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
16602321|NCT02597517||Control group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and negative stool antigen test for H pylori in whom gastric mucosal body will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
16602322|NCT02597504|Active Comparator|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
16602323|NCT02597504|Experimental|Validity and Reliability|"Reliability:
~Test-Retest
~Validity:
~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
16602324|NCT02597491|Active Comparator|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
16602325|NCT02597491|Active Comparator|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
16602326|NCT02597491|Active Comparator|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
16602327|NCT02597491|Active Comparator|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
16602328|NCT02597491|Active Comparator|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
16602329|NCT02597491|Active Comparator|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
16602330|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
16602331|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
16602332|NCT02597465|Experimental|SPARC1507|SPARC1507
16602333|NCT02597465|Experimental|Chemotherapy|Chemotherapy
16602334|NCT02597452|Other|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
16602335|NCT02597439|Active Comparator|Omega-3 fatty acids|Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
16602336|NCT02597439|Placebo Comparator|Placebo|Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
16602339|NCT02597413||Before group|Women in this group are included before the implementation of a strategy of systematic catheterization (they will not be catheterized).
16602340|NCT02597413||After group|"Women in this group are included after the implementation of a department-wide strategy of systematic catheterization.
~Intervention: catheterization"
16602341|NCT02597400|Experimental|HMS5552 and Metformin|"All subjects will receive the following:
~Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;
~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;
~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
16602342|NCT02597387|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
16602343|NCT02597374|Experimental|Experimental|A 45 mn EEG for all the participants.
16602344|NCT02597361|Active Comparator|Irbesartan|Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.
16602345|NCT02597361|Placebo Comparator|Placebo|Placebo once or twice per day for 2 years.
16602346|NCT02597348|Experimental|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
16602350|NCT02597309|Active Comparator|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
16602351|NCT02597309|Placebo Comparator|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
16602352|NCT02597283|Experimental|Biguard stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
16602353|NCT02597283|Active Comparator|Sirolimus-eluting stent system|PCI with regular sirolimus-eluting stent system
16602354|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
16602355|NCT02597257|Placebo Comparator|Normal Saline|"normal saline
~total 250 ml
~once a week
~4 times"
16602356|NCT02597257|Active Comparator|Lidocaine HCl|"lidocaine 3 mg/kg mixed in normal saline
~total 250 ml
~once a week
~4 times"
16602357|NCT02597244|Experimental|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
16602358|NCT02597231|Experimental|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
16602359|NCT02597231|Placebo Comparator|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
16602360|NCT02597218||Patients following hepatectomy|"Patients following hepatectomy of any type, any gender. Roughly, we will describe: type of resection, presence of cancer,use of mechanical/pharmacological prophylaxis, major/minor bleedings ocurring during observation period.
~Outcomes: Venous thromboembolism (VTE)[deep vein thrombosis (DVT) and pulmonary embolism (PE)] and portal thrombosis (PT)."
16602361|NCT02597205|Experimental|Mobile app|Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages
16602362|NCT02597192|Active Comparator|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
16602363|NCT02597192|Placebo Comparator|Placebo group|oral hygiene products without Bacillus
16602364|NCT02597179||Metastatic Breast Cancer, Young Breast Cancer|Patients with feasible biopsy site.
16602365|NCT02597166|Other|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
16602366|NCT02597153|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
16602367|NCT02597140|Experimental|Lidocaine group|Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
16602368|NCT02597140|Placebo Comparator|Control group|Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.
16602369|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
16602370|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
16602371|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
16602372|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
16602373|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
16602374|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
16602375|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
16602376|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
16602377|NCT02597114|Experimental|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
16602378|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
16602379|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
16602380|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
16602381|NCT02597075|Active Comparator|Arm B:|Standard therapy
16602382|NCT02597062|Experimental|Carfilzomib plus cyclophosphamide plus dexamethasone|20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg
16602383|NCT02597049|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
16602384|NCT02597049|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
16602385|NCT02597049|Placebo Comparator|Placebo|Placebo given SC once a week for 24 weeks.
16602386|NCT02597036|Experimental|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
16602387|NCT02597036|Experimental|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
16602388|NCT02597036|Experimental|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
16602389|NCT02597036|Experimental|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
16602390|NCT02597036|Experimental|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
16602391|NCT02597023|Experimental|MitoQ|MitoQ, 20 mg per day for six weeks
16602392|NCT02597023|Placebo Comparator|Placebo|Placebo, inert excipient, one time per day for six weeks
16602393|NCT02597010|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
16604165|NCT02585362|No Intervention|Control group|Participants will receive standard care
16602394|NCT02597010|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
16602395|NCT02596984|Experimental|caspofungin|Caspofungin will be administered according to the international recommendation.
16602396|NCT02596971|Experimental|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
16602397|NCT02596971|Experimental|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
16602398|NCT02596971|Experimental|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
16602399|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
16602400|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
16602401|NCT02596932|Other|Tight control|"Intervention Standard Care:
~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60 mg/dL"
16602402|NCT02596932|Experimental|Less tight control|"Intervention:
~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60mg/dL"
16602403|NCT02596919|Other|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
16602404|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
16602405|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
16602406|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
16602407|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
16602408|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
16602409|NCT02596893|Placebo Comparator|Placebo|Placebo once daily (QD) until the Week 52 Visit
16602410|NCT02596880|Experimental|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
16602411|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
16602412|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
16602413|NCT02596828|Experimental|RIST|
16602414|NCT02596815|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 3 times a week during 6 continuous weeks.The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
16602415|NCT02596815|Active Comparator|Waiting list control group|Patients assigned to a 6 week waiting list to receive treatment
16602416|NCT02596802|Experimental|FETO therapy|Intervention name: FETO therapy
16602417|NCT02596789|Other|state dependency TMS|TMS performed at rest and during a cognitive/emotional task
16602418|NCT02596776|Active Comparator|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
16602419|NCT02596776|Experimental|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
16602420|NCT02596776|Active Comparator|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
16602421|NCT02596763|Other|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
16602422|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
16602451|NCT02596568|Sham Comparator|Sham tDCS stimulation|tDCS electrodes will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor, however stimulation will never be turned on.
16602423|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
16602424|NCT02596737|Other|workers|"Workers will fulfil a visual analog scale of Well-being regarding 3 main categories: Physically, Mentally, At Work."
16602425|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
16602426|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
16602427|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
16602428|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
16602429|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
16602430|NCT02596685|Experimental|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.
~Patients undergo a second bronchoscopy during week 5."
16602431|NCT02596685|Experimental|Arm B (control)|"Patients receive no intervention.
~Patients undergo a second bronchoscopy during week 5."
16602432|NCT02596685|Experimental|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
16602433|NCT02596685|Experimental|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
16602434|NCT02596672|Experimental|Intervention|They will complete a 12-week peer-led walking programme. Participants will be paired together as walking partners and will be given a pedometer and step count logs for self-monitoring. The walking co-ordinators will facilitate walking groups two times a week in the local areas, lasting for 30 minutes. The nature of the walks will be tailored to the participants stated preferences of types of activity. Participants will also receive local walking route maps. After 12 weeks, the formal peer-led component will finish and participants will be encouraged to continue walking with their walking partners other activity programmes organised in the fold in order to maintain activity levels.
16602435|NCT02596672|No Intervention|Control|"Folds assigned to the control group will not receive any additional support to change their physical activity behaviour over the course of the intervention period.
~At the six-month data collection point they will be offered a referral to a local walking group in their area or advice on beginning a self-directed walking programme (similar to Public Health Agency www.choosetolivebetter.com/content/getting-active). They will be asked to complete outcome measures at baseline and follow up time-points. Post-study a sample of control participants will be asked to attend a focus group, exploring their views on social activity as form of physical activity for older adults in folds."
16602436|NCT02596659|Experimental|The experimental group|Participants in the experimental group received radial extracorporeal shock wave therapy (rESWT) plus physical therapy for 3 weeks.
16602437|NCT02596659|Sham Comparator|The control group|Participants in the control group received sham shockwave therapy plus physical therapy for 3 weeks.
16602438|NCT02596646|Active Comparator|Group A|Early Precut
16602439|NCT02596646|Active Comparator|Group B|Prolonged cannulation attempts
16602440|NCT02596633|No Intervention|Treatment as Usual|Participants carry on with their usual care
16602441|NCT02596633|Active Comparator|Intervention|ACT self help book with telephone support calls; Telephone-support Acceptance and Commitment therapy (ACT)
16602442|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
16602443|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
16602444|NCT02596594|Experimental|Port intervention|"The subcutaneous intraumbilical port-system will be implanted in IUGR patients with the cerebroplacental ratio less than 1 (cerebroplacental ratio= PI in the middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.
~The fetuses will receive AAs and glucose supplementation via a subcutaneously implanted intraumbilical perinatal port system till the delivery. Control by doppler and cardiotocogram"
16602445|NCT02596594|No Intervention|control|"IUGR patients with the cerebroplacental ratio less than 1 (CPR= PI middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.
~Control by doppler and cardiotocogram"
16602446|NCT02596581|No Intervention|diabetics with periodontally healthy group|Control group
16602447|NCT02596581|No Intervention|systemically and periodontally healthy group|Control group
16602448|NCT02596581|Active Comparator|diabetics with chronic periodontitis group|non-surgical periodontal treatment was performed
16602449|NCT02596581|Active Comparator|chronic periodontitis group|non-surgical periodontal treatment was performed
16602450|NCT02596568|Experimental|Active tDCS stimulation|Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
16602452|NCT02596555|Experimental|Dabigatran treatment|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
16602453|NCT02596542|Experimental|Water temperature|
16602454|NCT02596529|Experimental|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
16602455|NCT02596529|Active Comparator|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
16602456|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.
~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
16602457|NCT02596490|Experimental|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:
~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
16602458|NCT02596490|Experimental|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:
~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.
~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.
~Participants continue daily meditation practice and some other short exercises at home."
16602459|NCT02596490|Experimental|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
16602460|NCT02596490|Experimental|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
16602461|NCT02596490|Other|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
16602462|NCT02596477|Experimental|Vepoloxamer - Low dose|Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
16602463|NCT02596477|Experimental|Vepoloxamer - High dose|Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
16602464|NCT02596477|Placebo Comparator|5% dextrose in water (D5W)|D5W administered intravenously over 3 hours
16602465|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
16602466|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
16602467|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
16602468|NCT02596438||Asian Americans|Foreign born or children of foreign born Asian American from Hepatitis B endemic areas residing in Sacramento, CA.
16602469|NCT02596425|Experimental|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
16602470|NCT02596425|Experimental|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
16602471|NCT02596425|Experimental|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
16602474|NCT02596399|Experimental|DSTA4637S|
16602475|NCT02596399|Placebo Comparator|Placebo|
16602476|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
16602477|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
16602478|NCT02596373|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
16602479|NCT02596373|Active Comparator|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
16602480|NCT02596360|Experimental|Dextromethorphan|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
16602481|NCT02596360|Placebo Comparator|Placebo|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
16602484|NCT02596334|Active Comparator|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
16602485|NCT02596334|Experimental|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
16602486|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
16602487|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
16602488|NCT02596308|Experimental|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
16602489|NCT02596308|Experimental|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
16602490|NCT02596295||Mothers for term infants|Lactating mothers
16602491|NCT02596295||Mothers for preterm infants|Lactating mothers
16602492|NCT02596282|Active Comparator|Clinical Officer (CO),|COs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
16602493|NCT02596282|Experimental|Nurse Midwife (NMW)|NMWs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
16602494|NCT02596269|Experimental|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
16602495|NCT02596269|Placebo Comparator|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
16602496|NCT02596256|Experimental|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
16602497|NCT02596256|Active Comparator|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
16602498|NCT02596243|Experimental|GX-188E|GX-188E + EP
16602499|NCT02596243|Placebo Comparator|placebo|Placebo + EP
16602500|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
16602501|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
16602502|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
16602503|NCT02596217|Experimental|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
16602504|NCT02596217|Experimental|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
16602505|NCT02596217|Experimental|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
16602506|NCT02596217|Experimental|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
16602507|NCT02596217|Experimental|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
16602508|NCT02596217|Experimental|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
16602509|NCT02596217|Placebo Comparator|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
16602510|NCT02596217|Placebo Comparator|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
16602511|NCT02596204|Active Comparator|Data Upload|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. Subjects will continue to receive usual diabetes care. Phone calls and emails to the diabetes clinic will be initiated by the family.
16602512|NCT02596204|Experimental|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (diabetes educator, nurse practitioner and/or physician) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
16602513|NCT02596191|Experimental|patients with mild CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 1 and 10
16602514|NCT02596191|Experimental|patients with moderate CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 11 and 20
16602515|NCT02596191|Experimental|patients with severe CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score ≥21
16602516|NCT02596191|Other|control group|Healthy volunteers
16602517|NCT02596178|Experimental|EIT Guided PEEP Therapy|
16602518|NCT02596165|Experimental|Pulse wave analysis measurement|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
16602519|NCT02596152|Experimental|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
16602520|NCT02596152|Active Comparator|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
16602521|NCT02596139||Healthy people|
16602522|NCT02596126|Active Comparator|Treatment Prevention for Secondary CV|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
16602523|NCT02596126|Experimental|Cardiovascular Polypill|Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
16602524|NCT02596113||No pathological findings|blood and biopsy samples from normal colon mucosa
16602525|NCT02596113||>1 cm adenomatous polys|blood and biopsy samples from the polyp
16602526|NCT02596113||Colorectal cancer|blood (plasma) and biopsy samples from colorectal cancer
16602527|NCT02596100|Experimental|Tablet|80mg immediate release tablet
16602528|NCT02596100|Experimental|Capsule|80mg immediate release capsule
16602529|NCT02596087|No Intervention|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
16602586|NCT02595671|Active Comparator|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
16602530|NCT02596087|Experimental|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
16602531|NCT02596074|Experimental|Omiganan (CLS001)|CLS001 topical gel, 2.5%
16602532|NCT02596074|Placebo Comparator|Vehicle|Vehicle topical gel
16602533|NCT02596061|No Intervention|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
16602534|NCT02596061|Experimental|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
16602535|NCT02596061|Experimental|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
16602536|NCT02596061|Experimental|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
16602537|NCT02596048|Other|Iomeron|Patients will undergo a injection of Iomeron if they are scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral MDCTA examination
16602538|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
16602539|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
16602540|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
16602541|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
16602542|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
16602543|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
16602545|NCT02595983|Experimental|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
16602546|NCT02595970|Experimental|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
16602551|NCT02595931|Experimental|Treatment (irinotecan, M6620)|Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
16602552|NCT02595918|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
16602553|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16602554|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16602555|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
16602556|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16602557|NCT02595879|Experimental|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy.
16602559|NCT02595840|Experimental|Arm A: Afatinib|Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
16602560|NCT02595840|Experimental|Arm B: Pemetrexed|Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle
16602561|NCT02595827|No Intervention|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
16602562|NCT02595827|Active Comparator|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
16602563|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
16602564|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
16602565|NCT02595788||Supine position|Examination in the supine position
16602566|NCT02595788||Prone position|Change from supine to prone position
16602567|NCT02595775|Experimental|Round 1: Intervention arm|"Half of the endoscopists in Ontario will receive an individualized audit & feedback report.
~Individualized A/F report."
16602568|NCT02595775|No Intervention|Round 1: Control|Half of the endoscopists in Ontario will NOT receive an individualized audit & feedback report.
16602569|NCT02595775|Other|Round 2: Month 12|"All endoscopists in Ontario will receive an individualized audit & feedback report at month 12.
~Individualized A/F report"
16602570|NCT02595775|Other|Round 2: Poor performers|"In Round 2, selected 60 poorer performers will be randomly assigned to receive one of the following interventions at month 12:
~A/F report plus a high intensity intervention
~A/F report plus a low intensity intervention
~A/F report alone"
16602571|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
16602572|NCT02595749|Experimental|Intranasal Oxytocin (40 IU)|Two 20 IU doses of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be administered to each participant. Doses will be separated by 2 hours. Each 20 IU dose transferred into two, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 10 minutes.
16602573|NCT02595749|Placebo Comparator|Saline Nasal Spray|Two doses of placebo (consisting of 2ml sterile saline [Ocean Nasal Spray Solution]) will be administered to each participant. Doses will be separated by 2 hours. Each placebo dose transferred into two, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 10 minutes.
16602574|NCT02595736|Placebo Comparator|Placebo (SC)|Single subcutaneous (SC) dose of placebo
16602575|NCT02595736|Experimental|LY3200327 (SC)|Single escalating subcutaneous (SC) dose of LY3200327
16602576|NCT02595736|Experimental|LY3200327 (IV)|Single intravenous (IV) dose of LY3200327
16602577|NCT02595736|Placebo Comparator|Placebo (IV)|Single intravenous (IV) dose of placebo
16602578|NCT02595723|Experimental|Phenytoin, Then Megestrol|Participants first received pretreatment with Phenytoin 200 mg capsule twice/day for one day. Participants then received both Phenytoin (200 mg capsule twice/day) and liquid Megestrol (800 mg/day) for three consecutive days.
16602579|NCT02595723|Experimental|Placebo, Then Megestrol|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Megestrol (800 mg/day) for three consecutive days.
16602580|NCT02595723|Experimental|Placebo, Then Placebo|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Placebo (matching liquid Megestrol 800 mg/day) for three consecutive days.
16602581|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
16602582|NCT02595697|Experimental|J-EMT for Toddlers with Autism|The J-EMT intervention:(a) teach foundational social communicative behaviors, (b) teach related skills that predict long term language outcomes, (c) teach a range of communicative functions, (d) target specific spoken language skills as well as foundational skills, (e) incorporate instructional methods, contexts, and partners that increase social use of language in natural contexts, and (f) promote generalization and maintenance of newly learned skills to everyday activities and routines. In addition, because parents are essential partners for young children with ASD who are learning to communicate, studies are needed that (g) include parents and (h) specify the method and fidelity of parent instruction and fidelity and dosage with which parents use the trained strategies
16602583|NCT02595697|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
16602584|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
16602585|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
16602681|NCT02595047|Experimental|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
16602587|NCT02595671|Active Comparator|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
16602588|NCT02595671|Active Comparator|Digital Super Coach|Only receive coaching via digital super coach.
16602589|NCT02595671|Active Comparator|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
16602590|NCT02595658|Experimental|1|Carbohydrate only meal: Participants will consume a standardised carbohydrate meal (80 g of carbohydrates, 25 g protein, 0 g fat: meal composition, white rice, chicken, curry sauce; 420 kcal) and will self-administer (into the subcutaneous tissue of the abdomen, as per their regular routine) a rapid-acting insulin dose calculated as per the carbohydrate-counting ratio (e.g. 1 IU of insulin per 10 g of carbohydrates).
16602591|NCT02595658|Experimental|2|Participants will replicate Trial 1, but on this occasion the meal consumed will have an additional 50 g of fat (via addition of Ghee). This fat will be added to the sauce within the meal (80 g of carbohydrates, 25 g of protein, 50 g of fat; 735 Kcal). Participants will administer their rapid-acting insulin as per the carbohydrate counting method (i.e. the same IU of insulin as per Trial 1).
16602592|NCT02595658|Experimental|3|Trial 3) Participants will replicate Trial 2, but will administer a rapid-acting insulin dose that has been increased by 30%.
16602593|NCT02595658|Experimental|4|Participants will replicate Trial 2, but will administer an additional rapid-acting insulin dose of 30% 3 hrs post-meal.
16602594|NCT02595645|Experimental|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
16602595|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
16602596|NCT02595619|Experimental|RRT plus ECCO2R|
16602597|NCT02595606|Experimental|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
16602598|NCT02595606|No Intervention|control group|without treatment
16602601|NCT02595580|Experimental|GlucoPred|
16602602|NCT02595567|Other|ITPC|
16602603|NCT02595554|Active Comparator|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
16602604|NCT02595554|Experimental|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
16602605|NCT02595541|Active Comparator|milrinone group|milrinone
16602606|NCT02595541|Active Comparator|sildenafil and milrinone group|milrinone and sildenafil
16602607|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
16602608|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
16602609|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
16602610|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
16602611|NCT02595515|Experimental|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
16602612|NCT02595515|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
16602682|NCT02595034|Experimental|Clindamycin/BP Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
16602683|NCT02595034|Active Comparator|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
16602613|NCT02595502|Active Comparator|Sequence 1: Test Control Test|Test/control/test using the Johnson & Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
16602614|NCT02595502|Active Comparator|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
16602615|NCT02595489|Experimental|Vitamin D3|Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
16602616|NCT02595476|Experimental|BIS 55|"Induction:
~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)
~Orotracheal Intubation
~Remifentanil target decreased to 1 ng/ml
~Propofol target adjustment to reach BIS 55
~10 minutes steady state
~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds
~Pupillary dilation recording (videopupillometer Algiscan)"
16602617|NCT02595476|Active Comparator|BIS 25|"Induction:
~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)
~Orotracheal Intubation
~Remifentanil target decreased to 1 ng/ml
~Propofol target adjustment to reach BIS 25
~10 minutes steady state
~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds
~Pupillary dilation recording (videopupillometer Algiscan)"
16602618|NCT02595463|Experimental|Lidocaine|Following intraoperative IV placement, a 1.5 mg/kg bolus does of lidocaine hydrochloride is given and is followed by a continuous infusion of 2 mg/kg/hr until discharge from the Phase 1 recovery period.
16602619|NCT02595463|Placebo Comparator|Placebo|Following intraoperative IV placement, a bolus of saline is given and is followed by a continuous infusion until discharge from the Phase 1 recovery period. The volume of the bolus and rate of infusion are equivalent to that which would have been given in the experimental arm.
16602620|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
16602621|NCT02595437|Experimental|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
16602622|NCT02595424|Experimental|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16602623|NCT02595424|Active Comparator|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16602624|NCT02595398|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
16602625|NCT02595398|Sham Comparator|Sham Procedure|Matching suprachoroidal syringe with sham procedure
16602626|NCT02595385|Active Comparator|RAP|Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
16602627|NCT02595385|Active Comparator|CS|Reinfusion of shed blood during the operation
16602628|NCT02595385|Active Comparator|RAP and CS|RAP and CS used in combination
16602629|NCT02595385|No Intervention|Control|No intervention
16602630|NCT02595372|Experimental|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
16602631|NCT02595359|Experimental|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
16602632|NCT02595346|Experimental|hydroxychlorquine|hydroxychloroquine 200 mg twice a day for 6 months
16602633|NCT02595346|Placebo Comparator|control|placebo 2 pills a day for 6 months
16602634|NCT02595333|Experimental|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
16602635|NCT02595333|Experimental|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
16602636|NCT02595333|Experimental|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
16602637|NCT02595333|Experimental|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
16602638|NCT02595320|Experimental|Group A|capecitabine, 1500 mg, twice a day for 7 days on then 7 days off
16602639|NCT02595320|Active Comparator|Group B|capecitabine, 1250 mg/m2 OR 1000 mg/m2, twice a day for 14 days on then 7 days off
16602640|NCT02595307|Experimental|Pamphlet|Participant group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
16602641|NCT02595307|No Intervention|No Pamphlet|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
16602642|NCT02595294|Experimental|Cervical Lateral Glide|"15 minutes Cervical Lateral Glide neural mobilization
~5 times a week
~During 6 weeks
~Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
16602643|NCT02595294|No Intervention|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
16602644|NCT02595281|Experimental|Study arm|
16602684|NCT02595034|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
16602966|NCT02593318|Experimental|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
16602645|NCT02595268|Experimental|Pitavastatin Then JNJ-63623872|Participants will sequentially receive single oral dose of pitavastatin 1 milligram (mg) on Day 1, followed by JNJ-63623872 600 mg twice daily on Days 4 through 12 with a single oral dose of pitavastatin 1 mg administered in the morning of Day 9. All study drug intakes will be taken orally, under fed conditions (within approximately 10 minutes after completion of a meal).
16602646|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
16602647|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.
~This is the study group we will compare with high risk and no risk patients. No intervention"
16602648|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.
~No intervention"
16602649|NCT02595242|Experimental|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
16602650|NCT02595242|Experimental|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
16602651|NCT02595242|Experimental|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
16602652|NCT02595229|Active Comparator|PQ (Pronator quadraus) repair|Following volar plate osteosynthesis the pronator quadratus muscle is sutured with 3 to 5 U-shaped stitches using a polyfilament absorbable synthetic suture.
16602653|NCT02595229|No Intervention|No PQ repair|Following volar plate osteosynthesis the pronator quadratus muscle is placed in its anatomical position without suture repair.
16602654|NCT02595216|Experimental|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.
~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
16602655|NCT02595203|Experimental|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of [14C-pos 1]-Debio 1450 BES solution.
16602656|NCT02595203|Experimental|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of [14C-pos 1]-Debio 1450 BES solution.
16602657|NCT02595203|Experimental|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of [14C-pos 25]-Debio 1450 BES solution.
16602658|NCT02595190|Experimental|surgery group|sacral canal cyst microscopic tamponade treatment; resting state functional magnetic resonance imaging (rfMRI)
16602659|NCT02595190|Experimental|drug group|gabapentin + tramadol tablets; resting state functional magnetic resonance imaging (rfMRI)
16602660|NCT02595190|Placebo Comparator|control group|resting state functional magnetic resonance imaging (rfMRI)
16602661|NCT02595177|Experimental|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
16602662|NCT02595177|Experimental|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
16602663|NCT02595177|Experimental|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
16602664|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
16602665|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
16602666|NCT02595151||gastric intestinal metaplasia|Those fulfilling the criteria of GIM by CLE according to the study by Yuting Guo et al were included.
16602667|NCT02595151||normal gastric|diagnosed during routine colonoscopy procedures.
16602668|NCT02595138|Experimental|A|zoledronic acid received
16602669|NCT02595138|No Intervention|B|observation
16602670|NCT02595125|Sham Comparator|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
16602671|NCT02595125|Experimental|Direct technique|Intrauterine device (IUD) insertion by the direct technique
16602672|NCT02595112|Experimental|Patient undergoing otorhinolaryngologic surgery|Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure.
16602673|NCT02595099|Experimental|Mindfulness training|8 week programme of Mindfulness training
16602674|NCT02595086|Experimental|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
16602675|NCT02595086|Active Comparator|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
16602676|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
16602677|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
16602685|NCT02595021|Experimental|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
16602686|NCT02595021|Active Comparator|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
16602687|NCT02595008|Experimental|DSXS topical product|treatment with DSXS twice daily for 28 days
16602688|NCT02594995|Experimental|NBP in thrombolysis group|NBP 25mg bid for 2 weeks administered after 24 hours after receiving recombinant plasminogenactivator(rt-PA) thrombolysis
16602689|NCT02594995|Experimental|NBP group|NBP 25mg bid for 2 weeks administered for the patients who do not receive rt-PA
16602690|NCT02594995|No Intervention|Control group|Control group not receiving rt-PA thrombolysis, receiving basic therapy for acute stroke, e.g. aspirin/clopidogrel and lipid-lowering therapy
16602691|NCT02594995|No Intervention|Control in thrombolysis group|Control group receiving rt-PA thrombolysis
16602692|NCT02594982|Other|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
16602693|NCT02594969|Active Comparator|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
16602694|NCT02594969|Experimental|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
16602695|NCT02594956|Active Comparator|With Nasogastric Decompression|This group will receive conventional care according to the protocol of the service in place with removal of the nasogastric tube the 3rd postoperative day if the flow is < 500ml / 24h, if not removal will take place on the 5th postoperative day.
16602696|NCT02594956|Experimental|Without Nasogastric decompression|The nasogastric tube will be take off at the end of the surgery, just after the extubation.
16602697|NCT02594943|Active Comparator|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
16602698|NCT02594943|Active Comparator|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
16602699|NCT02594930|Experimental|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
16602700|NCT02594917||Test Group|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart failure, or exercise intolerance.
16602701|NCT02594917||Control Group|It will also include ten additional patients (ages 18-60 yrs) who are unaffected first-degree family members of the above subjects.
16602702|NCT02594904|Experimental|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
16602703|NCT02594904|Experimental|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
16602704|NCT02594904|Experimental|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
16602705|NCT02594904|Experimental|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
16602706|NCT02594891|Experimental|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
16602707|NCT02594891|Placebo Comparator|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
16602708|NCT02594878|Experimental|Pamidronatdinatrium 3mg/ml|Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
16602709|NCT02594878|Placebo Comparator|Natrium chloride 9 mg/ml|Natrium chloride 9 mg/ml volume equals experimental drug
16602710|NCT02594865|Active Comparator|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
16602711|NCT02594865|Active Comparator|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
16602712|NCT02594852|Experimental|Intervention (+ laser)|+ laser therapy
16602713|NCT02594852|Placebo Comparator|Non-intervention (- laser)|- laser
16602714|NCT02594839|Experimental|MSCs|2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
16602715|NCT02594839|Placebo Comparator|placebo|2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
16602716|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
16602717|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
16602718|NCT02594800|Active Comparator|standard dose|Drug: Rosuvastatin rosuvastatin 10 mg daily for 52 weeks.
16602719|NCT02594800|Experimental|intensive dose|Drug: Rosuvastatin rosuvastatin 20 mg daily for 52 weeks.
16602720|NCT02594787|Active Comparator|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
16602794|NCT02594293|No Intervention|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
16602721|NCT02594787|Placebo Comparator|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
16602722|NCT02594774|Experimental|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
16602723|NCT02594774|No Intervention|Standard medical treatment|Standard medical treatment
16602724|NCT02594761|Experimental|Treatment A|Hercules: 8 mg/kg i.v. infusion over 90 minutes
16602725|NCT02594761|Active Comparator|Treatment B|Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
16602726|NCT02594761|Active Comparator|Treatment C|Herceptin US: 8 mg/kg i.v. infusion over 90 minutes
16602727|NCT02594748|Experimental|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
16602728|NCT02594748|Active Comparator|Comparison group|The comparison group will receive routine care
16602729|NCT02594735|Other|open label|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
16602730|NCT02594722|Experimental|One single arm group|"COPD included in a pulmonary rehabilitation program
~Intervention:
~Investigators used a bedside cycloergometer with electrical stimulation. COPD perform 2 measure of oxygen uptake during exercise for compare aerobic capacities:
~Functional Electrical Stimulation Cycling (FES-cycling)
~Classic Cycloergometer endurance training with a sham electrical stimulation"
16602731|NCT02594709|Experimental|ONSM Multisession Radiosurgery|Multisession Radiosurgery
16602732|NCT02594696|Experimental|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.
~Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)
~Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
16602736|NCT02594670|Experimental|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
16602737|NCT02594670|Other|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
16602738|NCT02594670|Sham Comparator|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
16602739|NCT02594657|Experimental|pedal rate ON 50 RPM|
16602740|NCT02594657|Experimental|pedal rate on 80 RPM|
16602741|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
16602742|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
16602743|NCT02594631|Active Comparator|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
16602744|NCT02594631|Active Comparator|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
16602745|NCT02594605|Experimental|Platelet Rich Fibrin|Platelet Rich Fibrin was applied with conventional flap surgery for treatment of periodontal bone loss in test group.
16602746|NCT02594605|Active Comparator|Conventional Flap Surgery|Platelet Rich Fibrin was not applied to control groups. Only conventional flap surgery was applied to control groups.
16602747|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
16602748|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
16602749|NCT02594592||Older Men|Older Men (age > 55 years). complete questionaire
16602750|NCT02594592||Older Women|Older Women (age > 55 years),complete questionaire
16602751|NCT02594579|Active Comparator|Vitamin D|Dietary Supplement: Vitamin D3
16602752|NCT02594579|Placebo Comparator|Placebo|Dietary Supplement: Placebo
16602753|NCT02594566|Experimental|Research Subjects|A total of 3 injections of the vaccine (CyMVectin) will be given at Days 0, 28 (+4 days), and 56 (+4 days).
16602754|NCT02594553|Experimental|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
16602755|NCT02594553|No Intervention|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
16602756|NCT02594540|Experimental|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
16602757|NCT02594540|Sham Comparator|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
16603112|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
16602758|NCT02594527|Experimental|Volunteer-led physical activity sessions|Patient will receive volunteer-led physical activity sessions twice a day during admission.
16602759|NCT02594501|Experimental|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
16602760|NCT02594501|Active Comparator|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
16602761|NCT02594488|Active Comparator|Remote monitoring|Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
16602762|NCT02594488|No Intervention|Control arm|Follow-up at the same frequency, but with no implantable cardiac monitor
16602763|NCT02594475|Experimental|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
16602764|NCT02594475|Active Comparator|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
16602765|NCT02594462|Other|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.
~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
16602766|NCT02594449|Active Comparator|low concentration Benzalkonium Chloride|To use low concentration Benzalkonium Chloride Solution to gargle
16602767|NCT02594449|Active Comparator|high concentration Benzalkonium Chloride|To use high concentration Benzalkonium Chloride Solution to gargle
16602768|NCT02594449|Placebo Comparator|Normal Saline|To use Normal Saline to gargle
16602769|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
16602770|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
16602771|NCT02594423|Active Comparator|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
16602772|NCT02594423|Active Comparator|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
16602773|NCT02594410|Experimental|Treatment|patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
16602774|NCT02594397|Experimental|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
16602775|NCT02594397|Active Comparator|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
16602776|NCT02594397|Sham Comparator|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
16602777|NCT02594384|Experimental|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
16602778|NCT02594384|Experimental|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
16602779|NCT02594384|Experimental|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
16602780|NCT02594384|Experimental|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
16602781|NCT02594371|Experimental|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules
~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
16602782|NCT02594371|Active Comparator|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
16602783|NCT02594358|Active Comparator|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
16602784|NCT02594358|Active Comparator|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
16602785|NCT02594345|Experimental|Intervention group|
16602786|NCT02594332|Experimental|Mepolizumab|100 mg SC every 4 weeks for 13 injections
16602787|NCT02594332|Experimental|Placebo|Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
16602788|NCT02594319|Active Comparator|Control|Daily reporting of fruit and vegetable consumption
16602789|NCT02594319|Experimental|Daily reward|Incentives for fruit and vegetable consumption delivered daily
16602790|NCT02594319|Experimental|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
16602791|NCT02594306|Experimental|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
16602792|NCT02594306|Experimental|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
16602793|NCT02594306|Active Comparator|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
16602795|NCT02594293|Experimental|Pegasys 24 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks
16602796|NCT02594293|Experimental|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
16602797|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
16602798|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
16602799|NCT02594267|Experimental|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.
~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.
~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.
~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.
~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.
~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
16602800|NCT02594254|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
16602801|NCT02594254|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
16602802|NCT02594254|Experimental|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
16602803|NCT02594254|Experimental|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
16602804|NCT02594254|Experimental|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
16602805|NCT02594254|Experimental|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
16602806|NCT02594254|Experimental|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
16602807|NCT02594241|Active Comparator|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
16602808|NCT02594241|Placebo Comparator|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
16602809|NCT02594228|Experimental|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
16602810|NCT02594228|Experimental|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
16602811|NCT02594215|Experimental|Experimental|Experimental
16602813|NCT02594189|Other|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
16602814|NCT02594176|Experimental|Test Product|2.2 g FLEXISEQ® twice daily
16602815|NCT02594176|Placebo Comparator|Placebo|2.2 g placebo twice daily
16602816|NCT02594163|Experimental|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
16602817|NCT02594163|Active Comparator|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
16602818|NCT02594150|No Intervention|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
16602819|NCT02594150|Experimental|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
16602820|NCT02594150|Experimental|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
16602855|NCT02593968|Experimental|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
16602821|NCT02594150|Experimental|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
16602822|NCT02594137|Experimental|Without Watertight Duraplasty|"After standard craniectomy (12x15cm) and dural opening, the intervention, which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed."
16602823|NCT02594137|No Intervention|With Watertight Duraplasty|After standard craniectomy (12x15cm) and dural opening, watertight duraplasty with pericranium or an artificial graft is performed. Usual closure is then performed. This kind of duraplasty is performed by most neurosurgeons and this group will be used as a control.
16602831|NCT02594098|Experimental|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
16602832|NCT02594098|Placebo Comparator|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
16602833|NCT02594085|Experimental|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
16602834|NCT02594085|Experimental|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
16602835|NCT02594085|Experimental|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
16602836|NCT02594085|Experimental|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
16602837|NCT02594085|Experimental|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
16602838|NCT02594085|Experimental|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
16602839|NCT02594072|Experimental|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
16602840|NCT02594072|Active Comparator|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
16602841|NCT02594059|Experimental|Pulmonary idiopathic fibrosis|Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
16602842|NCT02594046|Experimental|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
16602843|NCT02594046|Placebo Comparator|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
16602844|NCT02594033|Experimental|3 mm needle|
16602845|NCT02594033|Experimental|3.5 mm needle|
16602846|NCT02594033|Active Comparator|4 mm needle|
16602847|NCT02594020|Other|dental bur versus air abrasion|1 tooth prepared with air abrasion versus one prepared tooth with dental bur
16602848|NCT02594020|Other|sono abrasion versus dental bur|1 tooth prepared with sono abrasion ans 1 tooth prepared with dental bur
16602849|NCT02594020|Other|air abrasion versus sono abrasion|1 tooth prepared with air abrasion versus 1 tooth prepared with sono abrasion
16602850|NCT02594007|Experimental|discharge home|SEEQ for 28 days. Cardiocom for 30 days
16602851|NCT02594007|Experimental|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
16602852|NCT02593994||Onyx Drug Eluting Stent|
16602853|NCT02593981|Active Comparator|Fruit/Honey Drink|Fruit/Honey Drink (2 canisters) will be taken orally twice a day. Subjects will consume the drink on days 1 through 28.
16602854|NCT02593981|Placebo Comparator|Placebo|Placebo (2 canisters) will be taken orally twice a day. Subjects will consume the placebo drink on days 1 through 28.
16602856|NCT02593968|Placebo Comparator|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
16602857|NCT02593955|Active Comparator|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
16602858|NCT02593955|Active Comparator|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
16602859|NCT02593955|No Intervention|Healthy control|MRI sub-study only
16602860|NCT02593942|Experimental|group I|remifentanil
16602861|NCT02593942|Experimental|group II|remifentanil, propofol
16602862|NCT02593929|Experimental|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
16602863|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
16602864|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
16602865|NCT02593890|Active Comparator|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
16602866|NCT02593890|No Intervention|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
16602867|NCT02593877|Experimental|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
16602868|NCT02593877|No Intervention|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
16602869|NCT02593864|Experimental|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
16602870|NCT02593851|Experimental|Part 1: Cohort 1a|Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
16602871|NCT02593851|Experimental|Part 1: Cohort 1b|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.
16602872|NCT02593851|Experimental|Part 1: Cohort 1c|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
16602873|NCT02593851|Experimental|Part 1: Cohort 1d|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
16602874|NCT02593851|Experimental|Part 1: Cohort 1e|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
16602875|NCT02593851|Experimental|Part 1: Cohort 2a|Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
16602876|NCT02593851|Experimental|Part 1: Cohort 2b|Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
16602877|NCT02593851|Experimental|Part 1: Cohort 2c|Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7
16602878|NCT02593851|Experimental|Part 1: Cohort 2d|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
16602879|NCT02593851|Experimental|Part 1: Cohort 2e|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
16602880|NCT02593851|Experimental|Part 1: Cohort 3a|Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
16602881|NCT02593851|Experimental|Part 1: Cohort 3b|Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
16602882|NCT02593851|Experimental|Part 1: Cohort 3c|Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
16602883|NCT02593851|Experimental|Part 1: Cohort 3d|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
16602884|NCT02593851|Experimental|Part 1: Cohort 3e|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
16602885|NCT02593851|Experimental|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
16602886|NCT02593838|Other|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
16602887|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
16606165|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
16602888|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
16602889|NCT02593812|Experimental|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
16602890|NCT02593812|Other|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
16602891|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
16602892|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
16602893|NCT02593786|Experimental|Nivolumab monotherapy|Nivolumab specified dose on specified days
16602894|NCT02593786|Experimental|Cohort Expansion|Nivolumab specified dose on specified days
16602895|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
16602896|NCT02593760|Active Comparator|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
16602897|NCT02593760|Experimental|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
16602898|NCT02593747|Experimental|Loratadine oral solution/syrup then Claritin peach syrup|Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
16602899|NCT02593747|Experimental|Claritin peach syrup then Loratadine oral solution/syrup|Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
16602900|NCT02593734|No Intervention|Control|No intervention
16602901|NCT02593734|Experimental|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
16602902|NCT02593721|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
16602903|NCT02593721|Active Comparator|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
16602904|NCT02593708|Experimental|Cohort 0|"Neratinib: 80 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
16602905|NCT02593708|Experimental|Cohort 1|"Neratinib: 120 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
16602906|NCT02593708|Experimental|Cohort 2|"Neratinib: 160 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
16602907|NCT02593708|Experimental|Cohort 3|"Neratinib: 200 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
16602908|NCT02593695|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
16602909|NCT02593695|Active Comparator|Standard Control|Fluoxetine
16602910|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
16602911|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
16602912|NCT02593669|Experimental|Neutral IOL|Phacoemulsification cataract surgery is performed with neutral IOL implantation.
16602913|NCT02593669|Experimental|Blue-blocking IOL|Phacoemulsification cataract surgery is performed with blue-blocking IOL implantation.
16602914|NCT02593656|Experimental|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
16602915|NCT02593656|Active Comparator|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
16602916|NCT02593643|Experimental|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
16602917|NCT02593643|Active Comparator|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
16602918|NCT02593643|Experimental|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
16602919|NCT02593643|Active Comparator|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
16602920|NCT02593630|Experimental|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
16602921|NCT02593617|Other|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
16602922|NCT02593617|Other|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
16602923|NCT02593617|Other|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
16602924|NCT02593617|Other|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
16602925|NCT02593617|Other|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
16602926|NCT02593617|Other|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
16602927|NCT02593591||Biomarker group|Advanced cancer undergoing genomic profiling
16602928|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
16602929|NCT02593565||Intervention|Woman, 18 years of age or older, currently pregnant, and have a diagnosis of vasculitis.
16602930|NCT02593552|Experimental|Video camera|DriveCam video event recorder with counseling feedback
16602931|NCT02593539|Experimental|Participants recieving nemiralisib|
16602932|NCT02593526|No Intervention|No Diuretic and 37°C dialysate|Standard of care, no diuretic
16602933|NCT02593526|Experimental|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
16602934|NCT02593526|Experimental|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
16602935|NCT02593526|Experimental|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
16602936|NCT02593513|Experimental|Daifert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
16602937|NCT02593513|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
16602938|NCT02593500|Experimental|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:
~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.
~Treatment period 2:
~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
16602939|NCT02593500|Experimental|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:
~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.
~Treatment period 2:
~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
16602940|NCT02593487|Experimental|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
16602941|NCT02593487|Active Comparator|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
16602942|NCT02593474|Other|Detoxification / induction|The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
16602943|NCT02593461|Experimental|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
16602944|NCT02593461|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
16602945|NCT02593448|Active Comparator|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.
~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.
~Intervention: NIRS during VOT on several timepoints."
16602946|NCT02593448|Experimental|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.
~Intervention: NIRS during VOT on several timepoints."
16602947|NCT02593435||No treatment|There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.
16602948|NCT02593422|Experimental|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
16602949|NCT02593422|Active Comparator|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
16602950|NCT02593409|Other|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
16602951|NCT02593396|Placebo Comparator|placebo|Placebo BD
16602952|NCT02593396|Experimental|Active|Bupropion hydrochloride sustained-release 150mg BD
16602953|NCT02593383|Experimental|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
16602954|NCT02593383|Experimental|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
16602955|NCT02593383|Experimental|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
16602956|NCT02593383|Experimental|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
16602957|NCT02593383|Placebo Comparator|Placebo group|Placebo Group: Blank Gel
16602958|NCT02593370|Experimental|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
16602959|NCT02593370|Active Comparator|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
16602960|NCT02593357|Experimental|COPD patients|measure of endothelial function with EndoPAT® in COPD patients
16602961|NCT02593344|Experimental|endopat|measure of endothelial function with endopat
16602962|NCT02593331|Placebo Comparator|Placebo|Participants will receive placebo matching to BFKB8488A.
16602963|NCT02593331|Experimental|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
16602964|NCT02593331|Experimental|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
16602967|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
16602968|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
16602969|NCT02593305|No Intervention|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
16602970|NCT02593292|Active Comparator|PROSPERO group (intervention group)|
16602971|NCT02593292|Placebo Comparator|control group|
16602972|NCT02593279|Active Comparator|asthma with proximal or diffuse lung damage|
16602973|NCT02593279|Experimental|asthma with small airway prevailing damage|
16602974|NCT02593266|Experimental|Intervention Group|weekly sessions of PIP for depression.
16602975|NCT02593266|No Intervention|Waiting list control group|This is treatment as usual.
16602976|NCT02593253|Experimental|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
16602977|NCT02593253|Active Comparator|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
16602978|NCT02593240|Experimental|Human Performance Institute©|These participants will be part of the intervention sites and will receive the Human Performance Institute© intervention for the duration of the study (18 months).
16602979|NCT02593240|Experimental|The iDiet® with Voucher|These participants will be part of the intervention sites and will receive the iDiet® with Voucher for the duration of the study (18 months).
16602980|NCT02593240|Experimental|The iDiet® with Food|These participants will be part of the intervention sites and will receive the iDiet® with Food for the duration of the study (18 months).
16602981|NCT02593240|No Intervention|Wait-listed control|These participants will be part of the control sites and will participate in outcome assessments for a 6-month period only.
16602982|NCT02593227|Experimental|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
16602983|NCT02593227|Experimental|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
16602984|NCT02593227|Experimental|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
16602985|NCT02593227|Experimental|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
16602986|NCT02593214|Experimental|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
16602987|NCT02593201|Experimental|Treatment|One extra week of antibiotic therapy
16602988|NCT02593201|Sham Comparator|Control|No extra antibiotics
16602989|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
16602990|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
16602991|NCT02593175|Experimental|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
16602992|NCT02593162|Experimental|Group 1|12 weeks of Faldaprevir plus low dose TD-6450 plus Ribavirin
16602993|NCT02593162|Experimental|Group 2|12 weeks of Faldaprevir plus high dose TD-6450 plus Ribavirin
16602994|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
16602995|NCT02593149|No Intervention|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
16602996|NCT02593136|Experimental|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
16602997|NCT02593136|Experimental|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
16603000|NCT02593110|Active Comparator|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
16603001|NCT02593110|Active Comparator|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
16603002|NCT02593110|Active Comparator|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
16603003|NCT02593110|Placebo Comparator|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
16603004|NCT02593097|Experimental|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
16603005|NCT02593097|Experimental|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
16603006|NCT02593084|Experimental|Higher Intensity Resistance Training|Participants will take part in a 12-week higher-intensity resistance training protocol.
16603007|NCT02593084|Active Comparator|Lower Intensity Resistance Training|Participants will take part in a 12-week lower-intensity resistance training protocol that will serve as the active comparator.
16603008|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
16603009|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
16603010|NCT02593058|Experimental|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
16603011|NCT02593058|Active Comparator|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
16603012|NCT02593045|Experimental|IPH4102|
16603013|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
16603014|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
16603015|NCT02593019|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
16603016|NCT02592993|Experimental|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
16603017|NCT02592980|Experimental|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
16603018|NCT02592980|Experimental|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
16603019|NCT02592967|Experimental|Cohort 1A and 1B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
16603020|NCT02592967|Experimental|Cohort 2A and 2B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
16603021|NCT02592954|Experimental|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
16603022|NCT02592954|Placebo Comparator|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
16603023|NCT02592928||Lleida Health Sector|"Lleida (168k inhabitants and 21 Primary Care centers). Primary Care centers from this health sector
~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
16603024|NCT02592928||Vic Health Sector|"Vic (49k inhabitants and 11 Primary Care Centers). Primary Care centers from this health sector
~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
16603025|NCT02592928||AISBE Health Sector|"Atenció Integral en Salut Barcelona Esquerra (AISBE) (540k inhabitants and 19 Primary Care centers). Primary Care centers from this health sector
~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
16603026|NCT02592915|Experimental|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
16603027|NCT02592915|Placebo Comparator|Control Group|Patients randomized in the Control Group will receive the Placebo
16603028|NCT02592902|Active Comparator|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
16603029|NCT02592902|Active Comparator|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
16603030|NCT02592889|No Intervention|CONTROL|OPTIMIZED MEDICAL TREATMENT
16603031|NCT02592889|Active Comparator|DEVICE|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM + OPTIMIZED MEDICAL TREATMENT
16603032|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
16603033|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
16603034|NCT02592863|Experimental|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
16603035|NCT02592863|Placebo Comparator|Placebo|Patients will take placebo 3 times per day for 12 weeks
16603036|NCT02592850|Experimental|Osteopathic Manipulative Treatment|Active manipulative treatment.
16603037|NCT02592850|Sham Comparator|Sham Osteopathic Manipulative Treatment|Sham manipulative treatment.
16603038|NCT02592837|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
16603039|NCT02592837|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
16603040|NCT02592824|Active Comparator|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
16603041|NCT02592824|Placebo Comparator|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
16603113|NCT02592408|Active Comparator|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
16606205|NCT02572193|Experimental|Active case|POEM procedure
16603042|NCT02592811|Active Comparator|ESLBD|"Endoscopic Sphincterotomy plus Large Balloon Dilatation +/- lithotripsy
~ERCP with deep cancellation of BDS
~Endoscopic large sphincterotomy
~Large Balloon Dilatation of Oddi Sphincter: with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
~Stone extraction with dormia basket or extraction balloon
~Mechanical Lithotripsy if needed"
16603043|NCT02592811|Active Comparator|CONV|"Conventional treatment associating Endoscopic Sphincterotomy +/- Mechanical Lithotripsy (ES+/-LM)
~ERCP with deep cancellation of BDS
~Endoscopic large sphincterotomy
~Stone extraction with dormia basket or extraction balloon
~Mechanical Lithotripsy if needed"
16603044|NCT02592798|Experimental|Abatacept|"Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.
~Open Label Period (OLE): Abatacept IV administered every 28 days"
16603045|NCT02592798|Placebo Comparator|Placebo|"Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.
~Open Label Period (OLE): Abatacept IV administered every 28 days"
16603046|NCT02592785|Experimental|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
16603047|NCT02592772|Experimental|Reduced Nicotine Non-Menthol (RNC)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine non menthol cigarettes (RNC: NRC 200; 0.07 mg nicotine yield cigarettes without menthol) during the 6 week experimental phase.
16603048|NCT02592772|Experimental|Reduced Nicotine Menthol (RNC-Men)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine menthol cigarettes (RNC-Men: NRC 201; 0.07 mg reduced nicotine content menthol cigarettes) during the 6 week experimental phase.
16603049|NCT02592772|Experimental|Conventional Nicotine Non-Menthol (CN)|Study participants will be randomized from their own brand of menthol cigarettes to the regular/conventional nicotine non menthol cigarettes (CN: NRC 600; 0.8 mg nicotine content) during the 6 week experimental phase.
16603050|NCT02592759|Experimental|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
16603051|NCT02592759|No Intervention|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
16603052|NCT02592746|Experimental|Palbociclib + Exemestane + GnRH agonist|
16603053|NCT02592746|Active Comparator|Capecitabine|
16603054|NCT02592733||Historical Cohort|Patients who have undergone infrarenal endovascular repair at each centre in the past.
16603055|NCT02592733||Prospective Cohort|Patients undergoing infrarenal endovascular repair in the study using CYDAR in addition to the local angiography equipment.
16603056|NCT02592720|Experimental|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
16603057|NCT02592720|Placebo Comparator|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
16603058|NCT02592707|Experimental|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
16603059|NCT02592694|Experimental|Cocktail with thrombus aspiration|Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration
16603060|NCT02592694|Active Comparator|Thrombus aspiration|Thrombus aspiration alone
16603061|NCT02592681|Experimental|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
16603062|NCT02592681|Active Comparator|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
16603063|NCT02592681|Sham Comparator|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
16603064|NCT02592668|Experimental|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
16603065|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
16603066|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
16603067|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
16603114|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
16603501|NCT02589756|Placebo Comparator|The control group|Participants who will avoid both fatty fish and nuts
16603068|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
16603069|NCT02592642|Experimental|Group 1|Self-management Program, Workbook, Video, Pedometer
16603070|NCT02592642|Active Comparator|Group 2|Instructional Workbook, Video, and Pedometer
16603071|NCT02592642|Experimental|Group a|Para-spinal TENS
16603072|NCT02592642|Placebo Comparator|Group b|Para-spinal Placebo TENS
16603073|NCT02592642|Experimental|Group c|Prototype Spinal Stenosis Belt
16603074|NCT02592642|Sham Comparator|Group d|Sham spinal stenosis belt
16603075|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
16603076|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
16603077|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
16603078|NCT02592616|Experimental|CON|Control (CON).
16603079|NCT02592616|Experimental|CW|Continuous Walking (CW).
16603080|NCT02592616|Experimental|IW|Interval Walking (IW).
16603081|NCT02592603|Active Comparator|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
16603082|NCT02592603|No Intervention|Standard Colonoscopy|Standard Colonoscopy without any additional device
16603083|NCT02592590|Experimental|Group A|
16603084|NCT02592590|Experimental|Group B|
16603085|NCT02592590|Experimental|Group C|
16603086|NCT02592590|Active Comparator|Group D|
16603087|NCT02592577|Experimental|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
16603088|NCT02592564|Experimental|Psychological treatment|Psychological treatment during 9 weeks.
16603089|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
16603090|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
16603091|NCT02592551|Placebo Comparator|Untreated arm (control)|4 patients will not receive MEDI4736 or Tremelimumab.
16603092|NCT02592538|Experimental|RFA+stent+S-1|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
16603093|NCT02592538|Placebo Comparator|RFA+stent|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
16603094|NCT02592525|Experimental|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
16603095|NCT02592525|Experimental|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
16603096|NCT02592525|Experimental|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
16603097|NCT02592525|Experimental|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
16603098|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
16603099|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
16603100|NCT02592499|Experimental|HM III|Patients randomized to mechanical circulatory support will be treated with the HeartMate III (HM III) left ventricular assist device system.
16603101|NCT02592499|Active Comparator|OMM, Optimal Medical Management|"Patients randomized to OMM will be treated according to international guidelines.
~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012 Jul;33(14):1787-84"
16603102|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
16603103|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
16603104|NCT02592473|Experimental|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
16603105|NCT02592460|Experimental|poor-polyamines diet|
16603106|NCT02592460|Active Comparator|high-polyamines diet|
16603107|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
16603108|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
16603109|NCT02592434|Experimental|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
16603110|NCT02592434|Placebo Comparator|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
16603111|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
16603115|NCT02592408|Active Comparator|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
16603116|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
16603117|NCT02592395|Experimental|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
16603118|NCT02592382|Placebo Comparator|Isotonic saline spray|Isotonic saline (0.9% of NACL) given as nasal spray 3 times a day ( one puff for each nostril) for a two months period
16603119|NCT02592382|Experimental|Xylitol spray|Solid Xylitol diluted in normal saline(0.9% NACL) to a concentration of 5%. given as a nasal spray 3 times a day(one puff for each nostril) for two months period
16603120|NCT02592356|Experimental|Cabozantinib or Lenvatinib|Patients treated with cabozantinib s-malate or lenvatinib mesylate are observed for body weight, skeletal muscle and adipose tissue changes. Patients complete 3 to 4 questionnaires every 2 weeks for 6 months and then monthly up to 12 months. Patients also undergo physical assessments and body composition measurements by DXA and CT scans at baseline, months 3, 6, and 12.
16603121|NCT02592330|Experimental|Cultivated Autologous Limbal Epithelial Cell (CALEC) graft|Participants will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
16603122|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
16603123|NCT02592304|Other|dual energy ct|
16603124|NCT02592291|Experimental|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
16603125|NCT02592291|No Intervention|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
16603126|NCT02592278|Experimental|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
16603127|NCT02592278|Experimental|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
16603128|NCT02592278|Active Comparator|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
16603129|NCT02592252|Experimental|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
16603130|NCT02592252|Experimental|Microfinance only|Receive microfinance only
16603131|NCT02592252|Experimental|Gender training only|10 sessions of participatory gender training for women and their male partners
16603132|NCT02592252|No Intervention|No intervention|No microfinance or participatory gender training
16603133|NCT02592239|Experimental|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
16603134|NCT02592239|Experimental|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
16603135|NCT02592226|Active Comparator|Control group|
16603136|NCT02592226|Experimental|Protocol Group|
16603137|NCT02592213|Experimental|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
16603138|NCT02592200|Experimental|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
16603139|NCT02592200|Placebo Comparator|Placebo|Placebo capsules (two doses)
16603140|NCT02592187|Experimental|Experimental intervention|ReMemory-MCI training
16603141|NCT02592187|Active Comparator|Control intervention|Control intervention
16603142|NCT02592174|Other|HIV subjects|"Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.
~Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.
~Two substudies will be proposed:
~cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)
~sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
16603143|NCT02592161|Experimental|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
16603144|NCT02592161|Placebo Comparator|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
16603145|NCT02592148||Health subjects|Male and female
16603146|NCT02592122|Active Comparator|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
16603147|NCT02592122|Active Comparator|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
16603207|NCT02591758||Stable Angina with coronary angiogram|This study aims to correlate the biometric data collected and derived from the Hexoskin with the standard physiological assessment, in patients referred for coronary angiography for limiting angina. Afterwards, the clinician will decide of the best treatment strategy for the patient: coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) or no revascularization.
16603208|NCT02591732||Patient treated with Apixaban|
16603148|NCT02592109|Experimental|Enhanced Counseling using CFR based on LP|"The counseling will be done by individual face-to-face communications. The intervention's arm will get a counseling with an additional of 7-day cycle with adequate n-3 and optimal n-3/6 ratio for complementary feeding menu obtained from linear programming formulation.
~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet; definition, function, and source of omega-3; example of menu that contains adequate omega-3. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
16603149|NCT02592109|Active Comparator|General CFR Counseling|"The control's arm will get general counseling combining balance diet and IYCF principal, which already been used by Ministry of Health, with additional of 7-day cycle menu guidance modified from existing or available menu which can be downloaded for public on Ministry of Health official website.
~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet based on Ministry of Health's Recommendation, and example of balanced diet menu. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
16603150|NCT02592096|Experimental|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
16603151|NCT02592096|Experimental|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
16603152|NCT02592096|Experimental|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
16603153|NCT02592096|Active Comparator|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
16603154|NCT02592083|Active Comparator|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
16603155|NCT02592083|Experimental|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
16603156|NCT02592083|Experimental|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
16603157|NCT02592070|Experimental|30 minute treadmill walking|All participants will walk on the treadmill for 30 minutes and perform a battery of cognitive tasks immediately prior, immediately after, and one hour after completion of the 30 minute walking period.
16603158|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
16603159|NCT02592044|Experimental|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
16603160|NCT02592044|Placebo Comparator|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
16603161|NCT02592031|Experimental|XM17|XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
16603162|NCT02592031|Experimental|Gonal-f®|Gonal-f® will be provided in pens with integrated vials of 0.5 mL
16603163|NCT02592031|Active Comparator|Zoladex®|Zoladex® 3.6 mg will be administered by subcutaneous injection
16603164|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
16603165|NCT02591992|Active Comparator|Cardiac CT|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo computed tomography angiography (cardiac CT) as the first-choice imaging diagnostics
16603166|NCT02591992|Active Comparator|Invasive coronary angiography|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo invasive coronary angiography
16603167|NCT02591966||Biomarker group|"The patients who receive neoadjuvant systemic treatments:
~The patients who have distant metastatic sites at first and recur from surgery:
~The patients who are going to receive first-line chemotherapy:"
16603168|NCT02591953|Experimental|Ultrasound-guided Injection|Injection performed with ultrasound-guidance
16603169|NCT02591953|Active Comparator|Landmark-guided Injection|Injection performed at point of maximal tenderness along biceps tendon
16603170|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
16603171|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
16603172|NCT02591927|Active Comparator|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
16603173|NCT02591927|Placebo Comparator|Glucose 5%|Glucose 5%
16603209|NCT02591732||Patient treated with Rivaroxaban|
16603210|NCT02591732||Patient treated with Dabigatran|
16603211|NCT02591732||Patient treated with vitamin K antagonists|
16603212|NCT02591719|Experimental|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
16603213|NCT02591719|Sham Comparator|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
16603214|NCT02591719|Active Comparator|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
16603502|NCT02589743|Active Comparator|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
16603174|NCT02591914|Experimental|Altering regimens of Fovista™and Anti-VEGF Therapy|"All subjects will be treated with Fovista™ 1.5 mg/eye in combination with anti-VEGF therapy.
~The following doses of Anti-VEGF therapy will be delivered based on the Investigator's discretion:
~Lucentis® 0.5 mg/eye
~Avastin® 1.25 mg/eye
~Eylea® 2 mg/eye
~Subjects will be treated with Fovista™ and Anti-VEGF therapy every month for the first three months.
~The regimen for administration of each intravitreal agent will be as follows:
~Injection Day #1-Administration of Fovista™ 1.5mg/eye
~Injection Day #2-Administration of Fovista™ 1.5mg/eye followed by anti-VEGF therapy after Fovista™ injection
~The same regimen will be delivered monthly until the subject reaches maximum visual acuity benefit. Maximum visual acuity is defined as no increase in ETDRS visual acuity at two consecutive visits.
~Subsequent re-treatment with the Anti-VEGF therapy will use a PRN (as-needed) regimen based on protocol specified retreatment criteria."
16603175|NCT02591901|Experimental|Uro Vaxom|Uro Vaxom, Once daily for 3 months
16603176|NCT02591901|Placebo Comparator|Placebo|Placebo identical to main drug in shape and form
16603177|NCT02591888|Active Comparator|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
16603178|NCT02591888|Placebo Comparator|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
16603179|NCT02591862|Other|Coversin|"This is an open label, non-comparator study.
~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given."
16603180|NCT02591849|Active Comparator|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
16603181|NCT02591849|Placebo Comparator|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
16603182|NCT02591836|Experimental|Gemcabene 300 mg|Gemcabene 300 mg QD
16603183|NCT02591836|Experimental|Gemcabene 600 mg|Gemcabene 600 mg QD
16603184|NCT02591836|Experimental|Gemcabene 900 mg|Gemcabene 900 mg QD
16603185|NCT02591836|Placebo Comparator|Placebo|
16603186|NCT02591836|Active Comparator|Atorvastatin 10 mg|
16603187|NCT02591836|Active Comparator|Atorvastatin 40 mg|
16603188|NCT02591836|Active Comparator|Atorvastatin 80 mg|
16603189|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 10 mg|
16603190|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 40 mg|
16603191|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 80 mg|
16603192|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 10 mg|
16603193|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 40 mg|
16603194|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 80 mg|
16603195|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 10 mg|
16603196|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 40 mg|
16603197|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 80 mg|
16603198|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
16603199|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
16603200|NCT02591810|Active Comparator|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
16603201|NCT02591810|Active Comparator|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
16603202|NCT02591810|Active Comparator|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
16603203|NCT02591797|Experimental|"hand-eye-mouth technique"|"hand-eye-mouth (MOB) seeks to focus the patient in performing a sequence of movements in a fun way so that your attention is diverted from the puncture dental needle, also it seeks to the patient does not see the needle. The operator prior to infiltrate local anesthetic teaches the child a game to put the sleepy little water.After explain a first time, the sequence once or twice is repeated until the patient has mastered. We call this test. When we apply the anesthetic, the entire sequence must be repeated as in trials with the same tranquility and in the same tone of the game. The operator will use this technique during the inferior alveolar and lingual nerve block procedure"
16603204|NCT02591797|Active Comparator|Conventional technique|the operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child´s field of view by hand during the inferior alveolar and lingual nerve block
16603205|NCT02591784|Experimental|Nimotuzumab group|Nimotuzumab+radiotherapy
16603206|NCT02591771|Experimental|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
16603238|NCT02591550||healty controls|
16603239|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
16603240|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
16603215|NCT02591706|Active Comparator|Dental implant (C1)|"Internal Conical Connection: The C1 has a six-position cone index, except for the C1 narrow platform that has a four-position cone index. The conical connection is 2.00mm in depth, with a 12° cone. As a result of our meticulous manufacturing process a perfect fit between the implant and the abutment is achieved, eliminating micro-movements and minimizing bone resorption.
~Patient will be randomly assigned to one of the two groups after flap opening."
16603216|NCT02591706|Experimental|Dental implant (V3)|"The unique triangular shape of the coronal portion of the V3 implant results in less titanium and more bone and soft tissue visible in the esthetic zone, for a restorative-driven approach and easier soft tissue management. The V3 provides doctors with a more advantageous starting point; where greater volume of bone and soft tissue is achieved at the onset of implant placement.
~Patient will be randomly assigned to one of the two groups after flap opening."
16603217|NCT02591693|Experimental|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.
~On-going usual care from multi-professional team at hospice."
16603218|NCT02591693|No Intervention|Usual Care|On-going usual care from multi-professional team at hospice.
16603219|NCT02591680|Experimental|Neuromuscular training|Neuromuscular, this arm will receive neuromuscular training and muscle strengthening.
16603220|NCT02591680|Active Comparator|Strength|Strength, this arm will receive only muscle strengthening.
16603221|NCT02591667|Experimental|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.
~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.
~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
16603222|NCT02591654|Experimental|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
16603223|NCT02591641|Experimental|Standard of Care First, then Liquicell|Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
16603224|NCT02591641|Experimental|Liquicell First, then Standard of Care|Subjects were secured on a standard ambulance stretcher with an anti-shear mattress overlay placed on top of the stretcher, with a shear and pressure sensor attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken throughout the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated without the LiquiCell ASMO.
16603225|NCT02591628|Active Comparator|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
16603226|NCT02591628|No Intervention|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
16603227|NCT02591615|Active Comparator|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles
~OR
~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
16603228|NCT02591615|Active Comparator|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles
~Patients with CR, PR, or SD by irRC will then be treated with:
~For Squamous Carcinoma:
~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles
~OR
~For Non-squamous Carcinoma
~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
16603229|NCT02591602|Experimental|CASI|Teleradiology service for patients residing at home or in nursing homes
16603230|NCT02591602|No Intervention|CONTROLLI|X-ray hospital department
16603231|NCT02591589|Experimental|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
16603232|NCT02591589|Active Comparator|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
16603233|NCT02591576||ST-elevation myocardial infarction (STEMI)|
16603234|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
16603235|NCT02591563||Healthy children|6-36 months of age who will have the following study procedures: Venipuncture, Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis
16603236|NCT02591550||patients with normal cough sensitivity|
16603237|NCT02591550||patients with high cough sensitivity|
16603241|NCT02591524|Experimental|Cystic fibrosis airway colonization|Flexible bronchoscopy via the nasal route on the date of baseline visit, nasal lavage at baseline and after 6 month
16603242|NCT02591511|Experimental|health-education app|Smart phone and pad is a stroke-related health education app intervention group
16603243|NCT02591511|Active Comparator|health education manuals|stroke-related health education manual control group
16603244|NCT02591498|Active Comparator|Auditory|Administration of 40 hours of auditory training exercises
16603245|NCT02591498|Active Comparator|Visual|Administration of 40 hours of visual training exercises
16603246|NCT02591498|Placebo Comparator|Video Games|Administration of 40 hours of commercial video games
16603247|NCT02591485|Experimental|Attention Control Training|Computerized attention modification training, comprised of six sessions that delivered by internet, in purpose of modulate biases in attention for threat stimuli.
16603248|NCT02591485|No Intervention|Follow-up only|In this condition, a follow-up interviews will be conducted 3 months since the traumatic event had occurred.
16603249|NCT02591472|Active Comparator|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
16603250|NCT02591472|Experimental|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
16603251|NCT02591459|Other|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
16603252|NCT02591433|Experimental|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
16603253|NCT02591420|Experimental|Group 1: immediate ART and placebo infusion|Participants will start ART and will receive a single infusion of placebo at Day 0.
16603254|NCT02591420|Experimental|Group 2: immediate ART and VRC01 infusion|Participants will start ART and receive a single infusion of VRC01 at Day 0.
16603255|NCT02591420|Experimental|Group 3: immediate VRC01 infusion and subsequent ART|Participants will receive a single infusion of VRC01 on Day 0 followed by ART initiation on Day 7.
16603256|NCT02591407|Active Comparator|TAP Block- Exparel|Transversus abdominis plane block utilizing the medication Exparel®
16603257|NCT02591407|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia
16603258|NCT02591394|Experimental|STEP Clinic|
16603259|NCT02591394|Active Comparator|Usual Care|
16603260|NCT02591381|Experimental|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
16603261|NCT02591381|Experimental|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
16603262|NCT02591368|Active Comparator|Ligament reconstr. tendon interposition|Ligament reconstruction, tendon interposition.
16603263|NCT02591368|Active Comparator|Mini Tight rope with one-suture|Mini Tight rope with one suture
16603264|NCT02591368|Active Comparator|Mini Tight rope with two-suture|Mini Tight rope with two sutures
16603265|NCT02591355|Experimental|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
16603266|NCT02591355|Placebo Comparator|Saline|Saline solution injection
16603267|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
16603268|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
16603269|NCT02591329|Experimental|Experimental|The experimental condition (EXP) will receive the targeted intervention material developed and designed by the researchers using focus group discussions with parents. This information will include salient benefits of the consumption of calcium-rich products. In addition, self-regulatory strategies will be provided to encourage purchasing and consumption of calcium-rich products and address any potential barriers to purchase and consumption. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a grocery pad and a recipe book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
16603270|NCT02591329|Active Comparator|Standard Care|Individuals in the Control condition (CON) will receive general healthy eating materials including Canada's Food Guide, Healthier Grocery Shopping Guide and Cooking with Kids. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a note pad and an activity book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
16603271|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
16603272|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
16603273|NCT02591303|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency <85%) with 10 days actigraphy
16603274|NCT02591303|Experimental|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency >85%)
16603275|NCT02591290|Experimental|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
16603276|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
16603277|NCT02591251|Active Comparator|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
16603278|NCT02591251|Active Comparator|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
16603279|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
16603280|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
16603281|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
16603282|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
16603283|NCT02591225|Experimental|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
16603284|NCT02591225|Active Comparator|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
16603285|NCT02591212|Active Comparator|#ConnectDots|"Green Dot Intensive Bystander Training (INT Condition) (Randomized):
~Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
~Administered by: UK VIP Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training."
16603286|NCT02591212|Placebo Comparator|#ConnectWell|"Wellness Initiatives for Student Empowerment delivered by UK's Student Wellness Office Programming: Addresses elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
~Administered by: UK VIP/Student Wellness Ambassadors Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training"
16603287|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
16603288|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
16603289|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
16603290|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
16603291|NCT02591186|Experimental|Acupuncture arm|Participants receiving acupuncture during IVF process
16603292|NCT02591186|No Intervention|Control|Control arm not receiving acupuncture during IVF process
16603293|NCT02591173|Experimental|Angiotensin-(1-7)|Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
16603294|NCT02591173|Placebo Comparator|Saline|Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
16603295|NCT02591160|Other|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
16603296|NCT02591147|Active Comparator|Silver Diamine Fluoride 38%|Group 1 (SDF 38%) will receive the application of silver diammine fluoride (38% SDF solution) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
16603297|NCT02591147|Placebo Comparator|Placebo (Sterile water)|Group 2 Placebo (control) will receive the application of sterile water (placebo) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
16603298|NCT02591134|Experimental|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
16603299|NCT02591134|Placebo Comparator|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
16603300|NCT02591108|Experimental|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
16603301|NCT02591108|Active Comparator|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
16603302|NCT02591095|Experimental|ABT-263|oral Navitoclax (ABT-263) daily
16603304|NCT02591056|Experimental|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
16603305|NCT02591043|Other|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
16603306|NCT02591030|Placebo Comparator|GEMCIS|
16603307|NCT02591030|Experimental|mFOLFIRINOX|
16603308|NCT02591017|Other|morphine drops solo and placebo spray|"morphine 2% drops
~daily fixed dose of morphine equivalents < 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards
~daily fixed dose of morphine equivalents =/> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards"
16603309|NCT02591017|Other|ketamine/chitosan spray nasal and placebo drops|5 mg ketamine all 5 minutes, maximal 4 times an hour
16603310|NCT02591017|Other|morphine drops and ketamine/chitosan spray nasal|see above
16603311|NCT02591004|Experimental|Magesium sulphate|"Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).
~Doppler on fetal middle cerebral artery"
16603312|NCT02591004|Active Comparator|Nifedipine|"Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.
~Doppler on fetal middle cerebral artery"
16603313|NCT02590991||Prebiotics group|No intervention since is a follow-up study
16603314|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
16603315|NCT02590991||Control group|No intervention since is a follow-up study
16603316|NCT02590978|Experimental|Early cholecystectomy|Cholecystectomy within the first 72 hours of admission.
16603317|NCT02590978|Other|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
16603318|NCT02590965|Placebo Comparator|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
16603319|NCT02590965|Experimental|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
16603320|NCT02590952|Experimental|Epitinib|Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily)
16603321|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
16603322|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
16603323|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:
~An angiographic stenosis of more than 50% and less than 90% of the left main
~Any proximal descending anterior with a stenosis of more than 50% and less than 90%
~Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%
~Single remaining patent coronary artery with stenosis >50% and less than 90%"
16603324|NCT02590913|Experimental|group fructose|Volunteer was randomized into either group fructose or glucose
16603325|NCT02590913|Experimental|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
16603326|NCT02590900||at delivery|women who underwent cesarean at delivery, and needed iv paracetamol as part of multimodal analgesia. In these cases, paracetamol was administered q6h (2g loading dose, 1g q6h for 24 h), and blood and urine samples were collected to describe paracetamol disposition at delivery.
16603327|NCT02590900||postpartum|a subgroup of 8 women initially included in at delivery, underwent a second PK study 2-3 months postpartum and another PK study about 1 year after delivery. This PK study was based on a single iv paracetamol administration (2 g), and blood and urine samples were collected to describe paracetamol disposition in postpartum
16603328|NCT02590900||healthy female volunteers|"a group of 8 young healthy women not on oral contraceptives underwent a single PK study (2 g intravenous paracetamol) and blood and urine samples were collected to described paracetamol disposition in healthy female volunteers, not on oral contraceptives.
~Raw data as published by Gregoire et al (Clin Pharm Ther 2007) were available in 14 young women, all on contraceptives."
16603329|NCT02590887|Experimental|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010).
~The final beverage shall consist of:
~Oily phase: refined sunflower oil 5% w/w of the emulsion
~Aqueous phase (water) 95% w/w of the emulsion, containing equal volumes of solution A and B:
~Solution A:
~Hydrolyzed Lupine (1.17% w/w)
~Sucrose (14.03% w/w)
~Vanilla flavor (0.42% w/w)
~Drinking water (84.38% w/v)
~Solution B:
~Xanthan gum (0.28% w/w)
~Drinking water (99.72% w/v)
~The samples will guard and kept by the investigator until the day of delivery to the volunteers.
~The duration of treatment 4 weeks, during which the volunteers daily consume the contents of a tetra brik."
16603330|NCT02590874|Experimental|Duloxetine group|Active drug group
16603331|NCT02590874|Placebo Comparator|Placebo group|Inactive drug group
16603332|NCT02590861|Experimental|Dental implant|All participants will receive the same intervention, this is a single group study.
16603333|NCT02590848|No Intervention|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
16603334|NCT02590848|Experimental|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
16603335|NCT02590835|Active Comparator|Control group|Treated with conventional orthodontics
16603336|NCT02590835|Experimental|Test group|subjected to piezo-assisted orthodontics
16603503|NCT02589743|Experimental|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
16606278|NCT02571699|Experimental|Subgluteal block|Subgluteal block with decreasing volume
16603337|NCT02590822|No Intervention|Standard Care|The Standard Care group will be contacted weekly (where possible) to reinforce cognitive behavioural adaptations and encourage compliance to diet and exercise. They will be provided with standard lifestyle advice according to NICE guidance.
16603338|NCT02590822|Experimental|Total Dietary Replacement|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
~The TDR will be undertaken alongside health behaviour coaching and relapse prevention contact & current medications will need to be adjusted initially and throughout the study."
16603339|NCT02590822|Experimental|Supervised Exercise|"The exercise group will attend thrice weekly 60minute supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. An initial assessment of cardiorespiratory fitness will be performed (VO2 max) to allow design of a tailored exercise programme.
~Current medication will need to be adjusted initially and throughout the study."
16603340|NCT02590809|Experimental|Treatment group|20 patients
16603341|NCT02590809|Placebo Comparator|Placebo group|20 patients
16603342|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
16603343|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
16603344|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
16603345|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
16603346|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
16603347|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
16603348|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
16603349|NCT02590783|Experimental|experimental intervention surgery|screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
16603350|NCT02590783|Active Comparator|control intervention conservative|analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
16603351|NCT02590770|Active Comparator|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
16603352|NCT02590770|Placebo Comparator|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
16603353|NCT02590757|Active Comparator|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
16603354|NCT02590757|Active Comparator|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
16603355|NCT02590744|Experimental|eye patch|cover the sick eye with eye patch for 3 hours preoperatively.
16603356|NCT02590744|Placebo Comparator|non-eye patch|do not cover the sick eye before surgery.
16603357|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
16603358|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
16603359|NCT02590718|Experimental|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
16603360|NCT02590718|No Intervention|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
16603361|NCT02590705|Experimental|Group 1|surface anesthesia with lidocaine
16603362|NCT02590705|No Intervention|Group 2|no anesthesia
16603363|NCT02590692|Experimental|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
16603364|NCT02590679|Experimental|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
16603365|NCT02590666|Experimental|Bipolar electrode|Polyps resection with bipolar electrode
16603366|NCT02590666|Active Comparator|Microscissors or graspers|Polyps resection with microscissors or graspers
16603367|NCT02590653|Experimental|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
16603368|NCT02590653|Active Comparator|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
16603369|NCT02590640|Active Comparator|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
16603370|NCT02590640|Sham Comparator|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
16603371|NCT02590627|Active Comparator|A|Artemether-lumefantrine
16603372|NCT02590627|Experimental|B|Dihydroartemisinin-piperaquine
16603373|NCT02590614|Experimental|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
16603374|NCT02590614|Placebo Comparator|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
16603375|NCT02590601|Active Comparator|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.
~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
16603376|NCT02590601|Other|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
16603377|NCT02590588|Experimental|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
16603378|NCT02590575|Other|CO2 removal|
16603504|NCT02589743|Active Comparator|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
16603379|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
16603380|NCT02590549|Experimental|MyoRing Implantation combined with corneal cross linking|Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)
16603381|NCT02590536|Experimental|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
16603382|NCT02590536|Placebo Comparator|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
16603383|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
16603384|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
16603385|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
16603386|NCT02590510|Experimental|The small dose of group|The dose of methotrexate is 10 mg
16603387|NCT02590510|Active Comparator|The high dose of group|The dose of methotrexate is 15 mg
16603388|NCT02590497|Experimental|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
16603389|NCT02590471|Active Comparator|Stenting of the femoral artery.|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted.
16603390|NCT02590471|Experimental|Stenting of the femoral artery and fasciotomy.|Under local anesthesia standard endovascular exposure is made and lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
16603391|NCT02590458|Experimental|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
16603392|NCT02590445|Active Comparator|Active stimulation|Stimulator on followed by off
16603393|NCT02590445|Sham Comparator|Sham stimulation|Stimulator off followed by on
16603394|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Open Label)|LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
16603395|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Open Label)|LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
16603396|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 290 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
16603397|NCT02590432|Experimental|LINZESS® 145 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
16603398|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
16603399|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was reduced to 72 μg, if applicable.
16603400|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
16603401|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with CIC.
16603402|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with IBS-C.
16603434|NCT02590198||ANAES algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
16603505|NCT02589743|Experimental|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
16606411|NCT02570815|Experimental|indocyanine green|Non-toxic, fluorescent dye
16603403|NCT02590419|No Intervention|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
16603404|NCT02590419|Experimental|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
16603405|NCT02590406|Active Comparator|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
16603406|NCT02590406|Experimental|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.
~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
16603407|NCT02590393|Experimental|Nicotine + NNTAs|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain tobacco extract with nicotine + NNTAs in a vehicle of propylene glycol and vegtable glycerin, with tobacco or menthol flavor matched to each participant's preference. The yields of nicotine and NNTAs will be in the range of typical commercial cigarettes.
16603410|NCT02590367|Experimental|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
16603411|NCT02590367|Placebo Comparator|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
16603412|NCT02590354|Experimental|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
16603413|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
16603414|NCT02590315|Experimental|Digital Breast Tomosynthesis - DBT|Invitation for breast screening and random allocation. Participants randomised to DBT will be screened with bilateral, two-view combo mode (DBT images are obtained with DM images). DBT participants will have an additional radiation exposure for the combined DM and DBT examinations.
16603415|NCT02590315|Active Comparator|Conventional digital mammography - DM|Invitation for breast screening and random allocation. Participants randomised to DM will be screened with bilateral, two-view DM.
16603416|NCT02590302|Other|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
16603417|NCT02590289|Experimental|BBI-5000 Dose 1|Low dose of BBI-5000
16603418|NCT02590289|Experimental|BBI-5000 Dose 2|Middle dose of BBI-5000
16603419|NCT02590289|Experimental|BBI-5000 Dose 3|High dose of BBI-5000
16603420|NCT02590289|Experimental|BBI-5000 Dose 4|High dose of BBI-5000
16603421|NCT02590276|Experimental|Evaluation|Characterization
16603422|NCT02590263|Experimental|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
16603423|NCT02590263|Experimental|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
16603424|NCT02590263|Experimental|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
16603425|NCT02590263|Experimental|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
16603426|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
16603427|NCT02590237|Active Comparator|Direct Laryngoscopy|The trachea will be intubated via direct laryngoscopy using a traditional straight blade (Miller) laryngoscope.
16603428|NCT02590237|Experimental|KingVision Video Laryngoscope|The trachea will be intubated using the Ambu KingVision Video Laryngoscope size 1 pediatric blade.
16603429|NCT02590224|Active Comparator|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
16603430|NCT02590224|Active Comparator|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
16603431|NCT02590211|Other|non-poker players|(control group)
16603432|NCT02590211|Other|expert unproblematic poker players|(comparator)
16603433|NCT02590211|Other|pathological poker players|(comparator)
16603497|NCT02589769|Experimental|unsaturated fat|an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods
16603435|NCT02590198||PCT algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
16603436|NCT02590185|Experimental|cocktail probe drugs|"A capsule of omeprazole ABBOTT® 10mg
~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)
~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)
~A tablet of fexofenadine Zentiva® 120mg"
16603437|NCT02590146|Experimental|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
16603438|NCT02590146|No Intervention|Control group|Patients in this group will receive standard of care pain management offered in the office.
16603439|NCT02590133|Experimental|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
16603440|NCT02590133|Active Comparator|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
16603441|NCT02590120|Active Comparator|Enteral nutrition product : product A|Administration during 16 hours.
16603442|NCT02590120|Active Comparator|Enteral nutrition product : product B|Administration during 16 hours.
16603443|NCT02590107|Experimental|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
16603444|NCT02590094|Active Comparator|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
16603445|NCT02590094|Active Comparator|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
16603446|NCT02590094|Active Comparator|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
16603447|NCT02590094|Active Comparator|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
16603448|NCT02590094|Active Comparator|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
16603449|NCT02590094|Active Comparator|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
16603450|NCT02590094|Active Comparator|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
16603451|NCT02590094|Active Comparator|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
16603452|NCT02590094|Active Comparator|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
16603453|NCT02590081|Active Comparator|Normal saline|Normal saline will be used for wash back procedure at the end of hemodiaysis.
16603454|NCT02590081|Experimental|dextrose 5%|Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.
16603455|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
16603456|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
16603457|NCT02590055|Experimental|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
16603458|NCT02590042|Experimental|ADSC-SVF-002|Cells will be administered at 1x10^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10^6 cells/mL of defect.
16603459|NCT02590029|Experimental|Mindfulness|15 minute mindfulness session
16603460|NCT02590029|Experimental|Suggestion|15 minute therapeutic suggestion session
16603461|NCT02590029|Active Comparator|Psychoeducation|15 minute psychoeducation session
16603462|NCT02590016|Experimental|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
16603463|NCT02590016|Active Comparator|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
16603464|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1
~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
16603465|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
16603466|NCT02589990|Experimental|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
16603467|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.
~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
16603468|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.
~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
16603498|NCT02589769|Active Comparator|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced.
16603499|NCT02589756|Experimental|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
16603469|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.
~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
16603470|NCT02589964|Active Comparator|Probiotic|"Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:
~Lactobacillus acidophilus-over 7.5 billion Bifidobacterium lactis-over 6.0 billion Bifidobacterium longum-over 1.5 billion"
16603471|NCT02589964|Placebo Comparator|Placebo|"Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:
~Rice maltodextrin"
16603472|NCT02589938|Active Comparator|Standard Oral Hygiene|All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
16603473|NCT02589938|Experimental|Standard Oral Hygiene + True Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
~The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes."
16603474|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
~The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points."
16603475|NCT02589925|Sham Comparator|sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
16603476|NCT02589925|Active Comparator|NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
16603477|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
16603478|NCT02589886|Active Comparator|intervention|This arm will receive the education and self-help internet intervention added to usual care
16603479|NCT02589886|No Intervention|control|This arm will receive usual care only
16603480|NCT02589873|Active Comparator|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
16603481|NCT02589873|Active Comparator|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
16603482|NCT02589847|Experimental|RBX2660 Open-label|RBX2660 (microbiota suspension)
16603483|NCT02589847|Other|Historical control antibiotics|Retrospective Historical Control with standard of care
16603484|NCT02589834|Active Comparator|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
16603485|NCT02589834|No Intervention|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
16603486|NCT02589821|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
16603487|NCT02589821|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
16603488|NCT02589808|Experimental|Full TTE|Full echocardiogram.
16603489|NCT02589808|Experimental|VScan|Handheld echocardiogram.
16603490|NCT02589795|Experimental|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.
~50 µg CN54gp140, intradermally without electroporation, at Week 20."
16603491|NCT02589795|Experimental|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.
~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
16603492|NCT02589795|Experimental|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
16603493|NCT02589782|Experimental|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
16603494|NCT02589782|Experimental|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
16603495|NCT02589782|Experimental|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
16603496|NCT02589782|Active Comparator|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
16603500|NCT02589756|Experimental|The nut group|Participants who will avoid fatty fish
16603506|NCT02589730|Experimental|online mutual management|The patients received the online coaching of a doctor and diabetes educator via smart phone based welltang app.
16603507|NCT02589730|Experimental|online self-management|The patients received the online coaching of a doctor alone via smart phone based welltang app.
16603508|NCT02589730|No Intervention|hospital regular management|The patients received usual care and did not use smart phone.
16603509|NCT02589691|Experimental|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
16603510|NCT02589691|Placebo Comparator|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
16603511|NCT02589678|Other|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
16603512|NCT02589678|Other|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
16603513|NCT02589665|Experimental|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
16603514|NCT02589665|Experimental|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
16603515|NCT02589665|Experimental|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
16603516|NCT02589665|Placebo Comparator|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
16603517|NCT02589665|Experimental|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
16603518|NCT02589665|Experimental|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
16603519|NCT02589665|Placebo Comparator|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
16603520|NCT02589665|Experimental|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
16603521|NCT02589665|Experimental|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
16603522|NCT02589665|Experimental|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
16603523|NCT02589652||Switch group|Patients who have been assigned to pegylated interferon alfa-2a.
16603524|NCT02589652||Sequential combination group (S-C group)|Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.
16603525|NCT02589652||ETV group|Patients who have been assigned to entecavir monotherapy.
16603526|NCT02589639|Experimental|empagliflozin 10 mg|
16603527|NCT02589639|Experimental|empagliflozin 25 mg|
16603528|NCT02589639|Placebo Comparator|placebo|
16603529|NCT02589626|Experimental|empagliflozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
16603530|NCT02589626|Experimental|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
16603531|NCT02589613|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
16603532|NCT02589613|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
16603533|NCT02589613|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
16603534|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
16603535|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
16603536|NCT02589587|Active Comparator|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
16603537|NCT02589587|Other|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
16603538|NCT02589574|No Intervention|Control|Subjects of the control group will receive the usual announcement on the dates and times of offering free influenza vaccination, and reminder from hospital, and access to informational flyers posted at the hospital
16603539|NCT02589574|Experimental|Intervention|Subjects of the intervention group besides the usual information same as those stated in the control group, will receive four reminders on dates and details for free influenza vaccine. Together with the reminder, electronic text messages of educational information will be received
16603540|NCT02589561|Active Comparator|face to face fitting|face to face fitting of hearing aids
16603541|NCT02589561|Experimental|remote fitting|remote fitting of hearing aids
16603542|NCT02589535||septic|Group Gb: postoperative septic patients in intensive care unit (ICU)] Gb1: the group of septic patients treated with extracorporeal hemoperfusion therapy and conventional therapy according to the Surviving Sepsis Campaign guidelines Gb2 group treated with conventional therapy according to the Surviving Sepsis Campaign guidelines
16603543|NCT02589535||no septic|Ga: postoperative patients in emergency surgical ward (ES)
16603544|NCT02589535||healthy|Healthy people
16603545|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
16603546|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
16603547|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
16603548|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
16603549|NCT02589496|Experimental|pembrolizumab|"Cohort A :gastric cancer patients Cohort B : MSI-H gastric cancer patients All Chort receive the following treatment.
~Pembrolizumab 200 mg every 3 weeks"
16603550|NCT02589483|Experimental|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
16603551|NCT02589470|Experimental|COMETE|patients will attend a specific rehabilitation programme of memory
16603552|NCT02589470|No Intervention|CONTROL|the control group where patients will benefit from a standard treatment
16603553|NCT02589457|Active Comparator|Viread® tablet|Tenofovir Disoproxil Fumarate
16603554|NCT02589457|Experimental|CKD-390|Tenofovir Disoproxil Fumarate
16603555|NCT02589444|Experimental|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
16603556|NCT02589444|Sham Comparator|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
16603557|NCT02589444|Other|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations > 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
16603558|NCT02589431||Patients with severe sepsis|
16603559|NCT02589431||Controls|Healthy subjects
16603560|NCT02589418|Experimental|Healthy subjects|All subjects participate at 3 experimental conditions (Acupuncture, Sham-Acupuncture and No Acupuncture) at 3 different days in a randomized order.
16603561|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
16603562|NCT02589392|Experimental|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
16603563|NCT02589392|Active Comparator|Body wash|Cetaphil® Restoraderm® body wash (1/day)
16603564|NCT02589379||Pancreatic Resection|All consecutive patients undergoing pancreatic resection for benign or malignant disease and meet inclusion criteria.
16603565|NCT02589366|Experimental|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
16603566|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
16603567|NCT02589340|Experimental|Buspirone|Two week titration up to 10 mg tablet/3 times a day for 7 days
16603568|NCT02589340|Placebo Comparator|Placebo|Two week titration up to 3 tablets/3 times a day for 7 days
16603569|NCT02589327|Experimental|Exercise Intervention|Hight intensity resistance training group
16603570|NCT02589327|No Intervention|Control|No-exercise control group
16603571|NCT02589314||root planning|
16603572|NCT02589301|Experimental|Pegfilgrastim|Pegfilgrastim (Hematopoietic Growth Factor) injectable solution 6 mg / 0,6mL in a single subcutaneous application.
16603573|NCT02589301|Active Comparator|Neulastim (pegfilgrastim)|Neulastim injectable solution 6 mg / 0,6mL in a single subcutaneous application.
16603574|NCT02589288|Active Comparator|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
16603575|NCT02589288|Experimental|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
16603576|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
16603577|NCT02589249|Placebo Comparator|Placebo|placebo
16603578|NCT02589249|Active Comparator|AyuFlex1|AyuFlex1 (500 mg/d)
16603579|NCT02589249|Active Comparator|AyuFlex2|AyuFlex2 (1000 mg/d)
16603580|NCT02589236|Placebo Comparator|Placebo|Placebo Capsule
16603581|NCT02589236|Experimental|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
16603582|NCT02589236|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
16603583|NCT02589223|Active Comparator|Multisensory Stimulation Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
16603584|NCT02589223|Placebo Comparator|Control Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
16603585|NCT02589210|Experimental|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
16603586|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
16603587|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
16603588|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
16603589|NCT02589184|Experimental|hypergravity WITH isometric load|Patient performing rehabilitation exercises under hypergravity as well as loaded isometric squats
16603590|NCT02589184|Experimental|hypergravity WITHOUT isometric load|Patient performing rehabilitation exercises under hypergravity
16603591|NCT02589184|Experimental|normal gravity WITH isometric load|Patient performing rehabilitation exercises under normal gravity as well as loaded isometric squats
16603592|NCT02589184|Active Comparator|normal gravity WITHOUT isometric load|Patient performing rehabilitation exercises under normal gravity
16603593|NCT02589171|Experimental|Neo Close Abdominal Closure|
16603594|NCT02589171|Active Comparator|Carter Thomason Device|
16603595|NCT02589158|Experimental|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
16603596|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.
~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.
~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
~Melphalan administered at 60 mg/m2 on days -3 and -2.
~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.
~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.
~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
16603597|NCT02589132|No Intervention|Standard of Care|Families receiving Standard of Care
16603598|NCT02589132|Experimental|Mobile-Thrive application|Standard care plus Mobile-Thrive app
16603599|NCT02589119|Other|MSC-AFP|Single Treatment Group
16603600|NCT02589106|Experimental|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
16603601|NCT02589093|Experimental|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
16603602|NCT02589080|Experimental|Non-invasive sensory feedback|
16603603|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
16603604|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
16603605|NCT02589054||Patients|
16603606|NCT02589041|Experimental|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
16603607|NCT02589028|Experimental|premeal protein bar first|"intervention: premeal protein-enriched bar intake
~protein enriched bar(total serving: 30g, 43.28% carbohydrate; 1.29% fat; 40.39% protein; 42.63% fiber) will be given 30 minutes before breakfast
~protein enriched bar is provided with 150 ml of water
~amount of protein bar : 30g
~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
16603608|NCT02589028|Other|breakfast first|"intervention: breakfast follows by protein bar
~protein enriched bar is provided with 150 ml of water shortly after breakfast
~amount of protein bar : 30g
~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
16603609|NCT02589002|Experimental|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
16603610|NCT02589002|No Intervention|Control|Absence of sucralose ingestion
16603611|NCT02588989||transposition of the great arteries|Patients with a TGA
16603612|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
16603613|NCT02588963|Experimental|Experimental Group 1|Children whose caregivers were subjected to a health education session
16603614|NCT02588963|Experimental|Experimental Group 2|Children who were subjected to nasal clearance protocol
16603615|NCT02588963|Experimental|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
16603616|NCT02588963|Placebo Comparator|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
16603617|NCT02588950|Experimental|Part A: U-500R Single Injection|Bolus of U-500R administered via single subcutaneous (SC) injection in one of the two periods
16603618|NCT02588950|Experimental|Part A: U-500R CSII|Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII) in one of the two periods
16603619|NCT02588950|Experimental|Part B: U-500R TID|U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
16603620|NCT02588950|Experimental|Part B: U-500R BID|U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
16603621|NCT02588937|Experimental|EntecaBell ODT.|
16603622|NCT02588937|Active Comparator|Baraclude Tab.|
16603623|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
16603660|NCT02588638||Adult patients|Unclear movement disorder, unclear cognitive decline
16603624|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
16603625|NCT02588911|Active Comparator|Conventional Surgery|Limb with GSV insufficiency in the same patient, randomised to conventional surgery
16603626|NCT02588911|Active Comparator|Radiofrequency Ablation|Limb with GSV insufficiency in the same patient, randomised to radiofrequency ablation
16603627|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
16603628|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
16603629|NCT02588885|Experimental|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
16603630|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
16603631|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
16603632|NCT02588846|Experimental|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
16603633|NCT02588846|Experimental|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
16603634|NCT02588833|Experimental|Cohort 1|180 mg pegcetacoplan/day
16603635|NCT02588833|Experimental|Cohort 2|270 mg pegcetacoplan/day
16603636|NCT02588820|Experimental|Antiretroviral treatment|
16603637|NCT02588807|Experimental|Spirit1|Patients will take a daily nutritional supplement for 8 months
16603638|NCT02588794|Active Comparator|intervention|Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
16603639|NCT02588794|No Intervention|control|Standart CVVHD
16603640|NCT02588781|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
16603641|NCT02588768|Active Comparator|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
16603642|NCT02588768|Placebo Comparator|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
16603643|NCT02588755|Active Comparator|TACE+ Tegafur|Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
16603644|NCT02588755|Experimental|TACE|Patients will be treated with TACE alone in 4 or 8 weeks after resection.
16603645|NCT02588742|Experimental|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
16603646|NCT02588742|Placebo Comparator|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
16603647|NCT02588729|Experimental|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women's smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
16603648|NCT02588729|No Intervention|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
16603649|NCT02588716|Active Comparator|Terlipressin|Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
16603650|NCT02588716|Placebo Comparator|Control|same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
16603651|NCT02588703|Experimental|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
16603652|NCT02588703|Active Comparator|Usual Care|9-session 2-hour group counseling
16603653|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
16603654|NCT02588677|Experimental|Masitinib (3.0) & Riluzole|masitinib 3 mg/kg/day + riluzole
16603655|NCT02588677|Experimental|Masitinib (4.5) & Riluzole|masitinib 4.5 mg/kg/day (2) + riluzole
16603656|NCT02588677|Placebo Comparator|Placebo & Riluzole|Matched placebo
16603657|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
16603658|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
16603659|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
16603661|NCT02588638||Patients < 18 years|Patients with (penetrating) suspected cerebral neurogenetic diseases
16603662|NCT02588625|Experimental|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
16603663|NCT02588625|Experimental|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
16603664|NCT02588612|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
16603665|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
16603666|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
16603667|NCT02588573|Active Comparator|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
16603668|NCT02588573|Active Comparator|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
16603669|NCT02588560||HCV lymphoma patients with chemotherapy|Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
16603670|NCT02588547|Active Comparator|Granisetron 1|Intravenous granisetron 1 mg
16603671|NCT02588547|Active Comparator|Granisetron 0.7|Intravenous granisetron 0.7 mg
16603672|NCT02588547|Placebo Comparator|Placebo|intravenous 0.9% Sodium chloride (2 ml)
16603673|NCT02588534|Active Comparator|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
16603674|NCT02588534|Other|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
16603675|NCT02588521|Experimental|AL-794|AL-794 administered orally in a suspension
16603676|NCT02588521|Placebo Comparator|Vehicle|Suspension vehicle alone
16603677|NCT02588508|Experimental|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
16603678|NCT02588508|Experimental|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
16603679|NCT02588508|No Intervention|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
16603680|NCT02588495|No Intervention|Fasting|Participant will remain fasted following initial gastric ultrasound
16603681|NCT02588495|Experimental|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
16603682|NCT02588482|Experimental|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
16603683|NCT02588469|Experimental|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
16603684|NCT02588469|Active Comparator|control group|Physical activity program without compression socks during 3 months.
16603685|NCT02588456|Experimental|Single Arm|
16603686|NCT02588443|Experimental|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
16603687|NCT02588443|Experimental|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
16603688|NCT02588417|Active Comparator|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
16603689|NCT02588417|Active Comparator|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
16603690|NCT02588391|Experimental|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
16603691|NCT02588391|Experimental|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
16603692|NCT02588391|Other|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
16603693|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
16603694|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
16603695|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
16603696|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
16603697|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
16603698|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
16603699|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
16603700|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
16603701|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
16603702|NCT02588365|Experimental|Brain Training (Active)|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
16603767|NCT02587832|Active Comparator|NCPAP|Randomized to NCPAP
16603703|NCT02588365|Experimental|Brain Training (Passive)|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent level."
16603704|NCT02588365|Experimental|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
16603705|NCT02588352|Experimental|Healthy volunteers|Open label administration of salt tablets for one week
16603706|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
16603707|NCT02588326|Active Comparator|MFF 1, then MFF 2|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
16603708|NCT02588326|Active Comparator|MFF 2, then MFF 1|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
16603709|NCT02588313|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
16603710|NCT02588313|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
16603711|NCT02588313|Placebo Comparator|Placebo formulation|Placebo formulation
16603712|NCT02588300|Experimental|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
16603713|NCT02588287|Experimental|Tenofovir PK before and after SOF/LDV|
16603714|NCT02588274|Experimental|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm*40mm/0.3mm*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
16603715|NCT02588274|Placebo Comparator|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
16603716|NCT02588261|Experimental|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
16603717|NCT02588261|Active Comparator|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
16603718|NCT02588248|Experimental|Peppermint Oil|"Solution A) Peppermint oil solution (1.6% peppermint oil, which is 0.8% L-menthol)
~Ingredients:
~16mL of peppermint oil (provided by the NowFoods® company)
~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution
~1L prepackage sterile water
~2.6mL of undyed simethicone"
16603719|NCT02588248|Placebo Comparator|Placebo|"Solution B) Placebo solution
~Ingredients:
~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution
~1L prepackage sterile water
~2.6mL of undyed simethicone
~Instructions to prepare:
~Add tween and simethicone to sterile water. Then, shake vigorously.
~Once solution has settled, and patient has been randomized, draw 20mL of solution into a plastic syringe"
16603720|NCT02588235|Experimental|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
16603721|NCT02588235|Active Comparator|Atorvastatin Therapy|Atorvastatin (20 mg/day）
16603722|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
16603723|NCT02588209|Experimental|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
16603724|NCT02588209|Active Comparator|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
16603725|NCT02588196|Experimental|treatment of dexamethasone group|
16603726|NCT02588183|Experimental|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
16603727|NCT02588170|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
16603728|NCT02588170|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
16603729|NCT02588157|Active Comparator|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
16603730|NCT02588157|Active Comparator|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
16603731|NCT02588144|Active Comparator|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
16603732|NCT02588144|Experimental|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
16603733|NCT02588131|Experimental|tremelimumab plus MEDI4736|Tremelimumab in combination with MEDI4736
16603768|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
16606412|NCT02570802|Other|ultrasound of peripheral nerves|Ultrasonographic examination
16603734|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
16603735|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
16603736|NCT02588105|Experimental|Safety and Tolerability|All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability
16603737|NCT02588092|Experimental|Part 1: ADCT-301 (dose escalation)|"Weekly administration - Participants will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.
~3-week administration - Participants will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.
~The dose escalation will be conducted according to a 3+3 design."
16603738|NCT02588092|Experimental|Part 2: ADCT-301 (dose expansion)|Participants will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee.
16603739|NCT02588079|Experimental|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
16603740|NCT02588079|No Intervention|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
16603741|NCT02588066|Experimental|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
16603742|NCT02588066|No Intervention|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
16603743|NCT02588027|Active Comparator|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
16603744|NCT02588027|Placebo Comparator|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
16603745|NCT02588014||Schizophrenia|Individuals with schizophrenia
16603746|NCT02588014||Control|Neurotypical individuals
16603747|NCT02588001|Experimental|Enzalutamide Group|
16603748|NCT02587988|Experimental|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
16603749|NCT02587988|Active Comparator|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
16603750|NCT02587975|Experimental|Evogliptin 10 mg|Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL
16603751|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
16603752|NCT02587936|Experimental|Collaborative model|Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator
16603753|NCT02587936|No Intervention|Standard Care|Group to receive regular care
16603754|NCT02587910|Placebo Comparator|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
16603755|NCT02587910|Placebo Comparator|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
16603756|NCT02587897||Dental Hygiene Students|Students enrolled in the 2-year dental hygiene academic coursework programs at the University of Southern California and Loma Linda University who are exposed to high-intensity work-related hand activities as part of their training program.
16603757|NCT02587897||Occupational Therapy Students|Students enrolled in the 2-year occupational therapy academic coursework program at the University of Southern California.
16603758|NCT02587884|Active Comparator|Group TACE|Patients will treated with TACE after resection.
16603759|NCT02587884|No Intervention|Group Control|Patients will treated without TACE after resection.
16603760|NCT02587871|Experimental|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
16603761|NCT02587858||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI, other clinical findings, and PANK2 gene sequencing.
16603762|NCT02587858||PLAN|This group consists of individuals diagnosed with PLAN using a combination of MRI, other clinical findings and PLA2G6 gene sequencing.
16603763|NCT02587858||BPAN|This group consists of individuals diagnosed with BPAN using a combinatino of MRI, other clinical findings, and WDR45 gene sequencing.
16603764|NCT02587845|Active Comparator|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
16603765|NCT02587845|Experimental|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
16603766|NCT02587832|Active Comparator|HHHFNC|Randomized to HHHFNC
16603769|NCT02587806|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
16603770|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
16603771|NCT02587780||Inactive|people who perform < 30mins.day physical activity at a 'moderate' level of intensity.
16603772|NCT02587780||Active|people who perform 30mins-60 mins.day of physical activity at a 'moderate' level of intensity.
16603773|NCT02587780||Very active|People who perform > 60 mins.day of physical activity at a >moderate level of intensity.
16603774|NCT02587767|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
16603775|NCT02587767|Active Comparator|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
16603776|NCT02587754|Active Comparator|Verum acupuncture|10 sessions of verum acupuncture
16603777|NCT02587754|Placebo Comparator|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
16603778|NCT02587741|Experimental|oral drugs|oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid
16603779|NCT02587741|Experimental|lantus|basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.
16603780|NCT02587741|Experimental|Novomix30|premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .
16603781|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
16603782|NCT02587715|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
16603783|NCT02587702|Experimental|Improved Infant Formula Group|Containing β-Palmitate Content
16603784|NCT02587702|Placebo Comparator|General Infant Formula Group|Excluding β-Palmitate Content
16603785|NCT02587702|Active Comparator|Human Milk Group|Containing β-Palmitate Content Naturely in Human Milk
16603786|NCT02587689|Experimental|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
16603787|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH & Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
16603788|NCT02587663|Active Comparator|Group 1 (standard of care)|Patients undergo standard of care diagnostic imaging comprising bilateral mammography and targeted breast ultrasound.
16603789|NCT02587663|Experimental|Group 2 (bilateral whole-breast ultrasound)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
16603790|NCT02587663|Experimental|Group 3 (bilateral breast contrast-enhanced MRI)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral breast contrast-enhanced MRI.
16603791|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16603792|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16603793|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16603794|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
16603795|NCT02587624||RMN AF ablation|Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.
16603796|NCT02587611|Experimental|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.
~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
16603797|NCT02587611|Active Comparator|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.
~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
16603798|NCT02587598|Experimental|INCB053914|Monotherapy
16603799|NCT02587598|Experimental|INCB053914 + Azacitidine|
16603800|NCT02587598|Experimental|INCB053914 + I-DAC|
16603801|NCT02587598|Experimental|INCB053914 + Ruxolitinib|
16603802|NCT02587585|Experimental|Feedback against tailored target|For each two hour epoch, the watch calculate the level of activity for the same epoch the day before, and adds 5% as the new target to be achieved.
16603803|NCT02587585|Sham Comparator|No Feedback|For participants assigned to the control group, the smart watch will not provide any activity feedback against a target; it simply shows which two hour epoch a person is in.
16603804|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
16603805|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
16603806|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
16603807|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
16603808|NCT02587559|No Intervention|Control|usual medical advice regarding symptomatic control and activity modification
16603809|NCT02587559|Experimental|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
16603810|NCT02587546|Experimental|laryngeal carcinoma|patients with T1-T2 (some T3) laryngeal carcinoma will undergo treatment using thulium contact laser surgery - tumour resection
16603811|NCT02587546|Experimental|bilateral vocal cord paralysis|patients with bilateral vocal cord paralysis treated with partial arytenoidectomy will be treated using thulium laser surgery and laterofixation
16603812|NCT02587546|Experimental|subglottic stenosis|patients with subglottic stenosis treated endoscopically (incisions and dilatation) will be treated with thulium laser surgery
16603813|NCT02587533|Active Comparator|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
16603814|NCT02587533|Active Comparator|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
16603815|NCT02587533|Active Comparator|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
16603816|NCT02587533|Active Comparator|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
16603817|NCT02587520|Experimental|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
16603818|NCT02587520|Experimental|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
16603819|NCT02587520|Experimental|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
16603820|NCT02587520|Experimental|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
16603821|NCT02587520|Active Comparator|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
16603822|NCT02587520|Active Comparator|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
16603823|NCT02587520|Experimental|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
16603824|NCT02587520|Experimental|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
16603825|NCT02587520|Experimental|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
16603826|NCT02587520|Experimental|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
16603827|NCT02587520|Active Comparator|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
16603828|NCT02587520|Active Comparator|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
16603829|NCT02587520|Experimental|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (>=65) years received a single dose of the SP0173 Tdap vaccine.
16603830|NCT02587520|Experimental|Older Adults: SP0173 Formulation 2|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
16603831|NCT02587520|Experimental|Older Adults: SP0173 Formulation 3|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
16603832|NCT02587520|Experimental|Older Adults: SP0173 Formulation 4|Healthy participants aged >= 65 years received a single dose of the SP0173 Tdap vaccine.
16603833|NCT02587520|Active Comparator|Older Adults: Adacel®|Healthy participants aged >=65 years received Adacel®.
16603834|NCT02587520|Active Comparator|Older Adults: Boostrix®|Healthy participants aged >=65 years received Boostrix®.
16603835|NCT02587507|Placebo Comparator|Water|The subjects will ingest the HFHC meal with 500mL of water.
16603836|NCT02587507|Experimental|Orange juice|The subjects will ingest the HFHC meal with 500mL of orange juice.
16603837|NCT02587507|Active Comparator|Water with glucose|The subjects will ingest the HFHC meal with 500mL of water with glucose (isocaloric control of the orange juice).
16603838|NCT02587494|Active Comparator|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
16603839|NCT02587494|No Intervention|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for >24h post ROSC.
16603840|NCT02587468|Experimental|Juice Plus+(R)|Check of phenolic absorption between baseline and after 8wks of intake before-after comparison
16603841|NCT02587455|Experimental|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
16603842|NCT02587455|Experimental|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
16603843|NCT02587442|Experimental|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
16603890|NCT02587130|Experimental|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
16603844|NCT02587429|Experimental|Patienteducation|(Patients with PCS>22). An education in pain coping delivered by physiotherapists. The education consist of seven sessions over a four months period. Each session is individual and will last 30 minutes. Focus will be on pain behaviour and pain coping based on Cognitive Behavioral Therapy.
16603845|NCT02587429|No Intervention|Control group 1|(Patients with PCS>22). Patients randomly assigned to this arm will undergo usual treatment for total knee arthroplasty.
16603846|NCT02587429|No Intervention|Control group 2|(Patients with PCS<12). Patients in this arm will undergo usual treatment for total knee arthroplasty. Patients in this arm are not randomized but matched by age, gender and BMI with patients in control group 1.
16603847|NCT02587416|Experimental|Gemcabene 300 mg|Gemcabene 300 mg
16603848|NCT02587416|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
16603849|NCT02587416|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg
16603850|NCT02587403|Active Comparator|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
16603851|NCT02587403|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
16603852|NCT02587390|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
16603853|NCT02587390|Active Comparator|Simvastatin 80 mg|Simvastatin 80 mg
16603854|NCT02587377|Other|Cohort 1|single cohort of patient
16603855|NCT02587364|Experimental|Gemcabene 50 mg|Gemcabene 50 mg
16603856|NCT02587364|Experimental|Gemcabene 150 mg|Gemcabene 150 mg
16603857|NCT02587364|Experimental|Gemcabene 450 mg|Gemcabene 450 mg
16603858|NCT02587364|Experimental|Gemcabene 750/600 mg|Gemcabene 750/600 mg
16603859|NCT02587364|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
16603860|NCT02587364|Placebo Comparator|Placebo|Placebo
16603861|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
16603862|NCT02587351|Placebo Comparator|Placebo|Matched placebo
16603863|NCT02587338|Experimental|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
16603864|NCT02587338|Experimental|Sham tDCS|sham stimulation, same electrode positions
16603865|NCT02587325|Experimental|ABI-009|
16603866|NCT02587312|Active Comparator|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
16603867|NCT02587312|Experimental|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
16603868|NCT02587286|Experimental|Gather app|Use of the Gather mHealth diabetes management system
16603869|NCT02587286|No Intervention|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
16603870|NCT02587273|Other|Fentanyl|This is a pharmacokinetics study with a single arm. All participants will will undergo the intervention described under the intervention section
16603871|NCT02587260|Active Comparator|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
16603872|NCT02587260|Active Comparator|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
16603873|NCT02587260|Active Comparator|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
16603874|NCT02587260|Active Comparator|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
16603875|NCT02587260|Active Comparator|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
16603876|NCT02587260|Active Comparator|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
16603877|NCT02587234|Experimental|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
16603878|NCT02587234|Sham Comparator|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
16603879|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
16603880|NCT02587221|Placebo Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
16603881|NCT02587208|Active Comparator|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
16603882|NCT02587208|Active Comparator|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
16603883|NCT02587195|Experimental|Teriflunomide|Teriflunomide 14 mg Once Daily
16603884|NCT02587182|Experimental|Dry needling|Dry needling in the masseter and temporalis muscles
16603885|NCT02587169|Experimental|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
16603886|NCT02587156|Experimental|Meal serving at high dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount above 1.5 g protein/kg/day
16603887|NCT02587156|Active Comparator|Meal serving at low dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount below 0.8 g protein/kg/day
16603888|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
16603889|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
16603891|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
16603892|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
16603893|NCT02587104|Experimental|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
16603894|NCT02587091|No Intervention|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
16603895|NCT02587091|Experimental|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
16603896|NCT02587078|Active Comparator|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
16603897|NCT02587078|Active Comparator|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
16603898|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
16603899|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
16603900|NCT02587052||Prograf|100 patients treated with Prograf
16603901|NCT02587039|Placebo Comparator|Control: Usual care|This group will receive usual care and delirium assessments.
16603902|NCT02587039|Experimental|Treatment: Ischemic Pre-conditioning|Remote Ischemic pre-conditioning before cardiac surgery and delirium assessments.
16603903|NCT02587013|Experimental|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
16603904|NCT02587013|Active Comparator|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
16603905|NCT02587000|Active Comparator|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
16603906|NCT02587000|Placebo Comparator|Placebo|2 tablets of 5mg per day during 3 months, per os
16603907|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).
~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
16603908|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
16603909|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.
~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
16603910|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
16603911|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
16603912|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
16603913|NCT02586961|Placebo Comparator|0.9% saline solution - oral betamethasone placebo|Control arm: 0.9% saline solution - oral betamethasone placebo
16603914|NCT02586961|Experimental|adrenaline - oral betamethasone|Experimental arm : adrenaline and betamethasone
16603915|NCT02586948|Experimental|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
16603916|NCT02586935|Active Comparator|Tideglusib|
16603917|NCT02586935|Placebo Comparator|Placebo|
16603918|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
16603919|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
16603920|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
16603921|NCT02586883|Experimental|Patients with multiple bronchi dilations|
16603922|NCT02586883|Active Comparator|Control patients without transport abnormality|
16603923|NCT02586883|Active Comparator|Patients with typical cystic fibrosis|
16603926|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
16604084|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
16603927|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
16603928|NCT02586831|Experimental|Arm A|"Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.
~Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2
~Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year
~Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), & then every 2 weeks, for 52 weeks
~Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks."
16603929|NCT02586831|Placebo Comparator|Arm B|Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.
16603930|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
16603931|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
16603932|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
16603933|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
16603934|NCT02586792|Experimental|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
16603935|NCT02586792|Experimental|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
16603936|NCT02586779|Experimental|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
16603937|NCT02586779|Other|control group|consultations in the control group will be generated without whatsApp.
16603938|NCT02586766|Experimental|Behavioral: Project Sync|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care
16603939|NCT02586766|No Intervention|Comparison Group|This group did not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
16603940|NCT02586753|Experimental|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
16603941|NCT02586753|Experimental|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
16603942|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
16603943|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
16603944|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
16603945|NCT02586714||Normal weight|
16603946|NCT02586714||Overweight|
16603947|NCT02586714||Obese|
16603948|NCT02586701|Active Comparator|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
16603949|NCT02586701|No Intervention|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
16603950|NCT02586688|Active Comparator|Phase I TMS Active|Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
16603951|NCT02586688|Sham Comparator|Phase I TMS Sham|Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
16603952|NCT02586688|Other|Phase II Open Label Active TMS|Open label active TMS coil. Open label active NeuroStar® TMS.
16603953|NCT02586688|Other|Phase III Long-Term Follow up TMS Active|Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
16603954|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
16603955|NCT02586649|Experimental|Tiotropium Bromide group|The study participants will be randomly assigned to receive Tiotropium bromide,single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Tiotropium bromide capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
16603980|NCT02586467|Experimental|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
16603956|NCT02586649|Placebo Comparator|Placebo|The study participants will be randomly assigned to receive placebo , single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Placebo capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
16603957|NCT02586636|Other|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
16603958|NCT02586636|Other|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
16603959|NCT02586623|Experimental|Open Label Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally. During the Open Label Titration Period, patients will first receive 100 mg TID and their dose will be raised (in 100 mg increments) at subsequent visits until optimal dose is determined. During the Open Label Treatment Period, patients will receive active droxidopa100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to the patient's individual dose at the end of the Open-Label Titration Period).
16603960|NCT02586623|Placebo Comparator|Randomized Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period) or matching placebo.
16603961|NCT02586610|Experimental|Neoadjuvant Treatment|"All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:
~Pembrolizumab 200 mg IV Days 1, 22 and 43
~Capecitabine 825 mg/m2 PO in twice daily doses (total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
~Radiation therapy 50.4 GY. Daily fractions of 1.8 Gy over a 6 week interval, excludes weekends"
16603962|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
16603963|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
16603964|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
16603965|NCT02586571||Exclusive Breastfeeding A|Mother/infant pairs with exclusive breastfeeding up to 6 months of age. Secondary outcome measure 2 (Metabolisable energy content of breast milk) measured in this group only.
16603966|NCT02586571||Exclusive Breastfeeding B|Mother/infant pairs with exclusive breastfeeding up to 6 months of age.
16603967|NCT02586571||Partial Breastfeeding|Mother/infant pairs with partial breastfeeding along with complementary foods at 6 months of age.
16603968|NCT02586558|Active Comparator|Experimental Infant Formula|Milk-based infant formula with prebiotics
16603969|NCT02586558|Placebo Comparator|Reference group|Milk-based infant formula without prebiotics
16603970|NCT02586545|Experimental|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
16603971|NCT02586545|No Intervention|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
16603972|NCT02586532||1|Residents of towns participating in China Demonstration Project.
16603973|NCT02586519|Experimental|Active SurroSense Rx System + RCW|Patients randomized to the experimental group will be fitted with an active (alerting) version of the SurroSense R® smart insole System. This device will be placed in the RCW, underneath the liner. The device tab will be fed up the instep, through a hole in the liner, and affixed to the dorsum of the RCW by way of a tie.
16603974|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + RCW|Patients randomized to this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion.
16603975|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + iTCC|Patients in this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion. The RCW will be further secured using a device specific tie such that it acts as an iTCC.
16603976|NCT02586506|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
16603977|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
16603978|NCT02586467|Experimental|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
16603979|NCT02586467|Experimental|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
16604081|NCT02585869|Placebo Comparator|Placebo|Placebo once daily (QD)
16603981|NCT02586467|Experimental|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
16603982|NCT02586467|Experimental|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
16603983|NCT02586454|Experimental|Transmuscular quadratus lumborum (QL) block|Bilateral QL block using 20 ml 0.375% ropivacaine in each side (to a maximum dose 3 mg/kg) plus patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
16603984|NCT02586454|Active Comparator|Control|Patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
16603985|NCT02586441|Experimental|Electroencephalography|"Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.
~Raw EEG in a steady state was collected for 5 minutes.
~Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)
~Mechanical ventilation was initiated
~Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).
~On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.
~After extubation, BIS-VISTA TM monitoring was stopped."
16603986|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.
~Devices approved for use in DEFUSE 3:
~Trevo Retriever
~Solitaire™ FR Revascularization Device
~Penumbra thrombectomy system
~Covidien MindFrame Capture Revascularization Device"
16603987|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
16603988|NCT02586402|Experimental|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
16603989|NCT02586402|Active Comparator|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
16603990|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
16603991|NCT02586376|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
16603992|NCT02586376|Experimental|4J LLLT|The Laser radiation will be made with 4J by spot.
16603993|NCT02586376|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
16603994|NCT02586376|Experimental|8J LLLT|The Laser radiation will be made with 8J by spot.
16603995|NCT02586363|Active Comparator|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
16603996|NCT02586363|Experimental|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
16603997|NCT02586363|Experimental|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
16603998|NCT02586350|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
16603999|NCT02586350|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
16604000|NCT02586337|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
16604001|NCT02586337|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
16604002|NCT02586324|Other|global medium|
16604003|NCT02586324|Experimental|SSM|
16604004|NCT02586311|Experimental|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
16604005|NCT02586311|Active Comparator|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
16604006|NCT02586298|Experimental|ICSI with mitochondria|Half of the Metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and autologous mitochondria from the patient's ovarian cortex will be introduced into the oocyte during the intracytoplasmic sperm injection in the vitro fertilization treatment.
16604082|NCT02585856|Experimental|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
16604007|NCT02586298|Active Comparator|Control ICSI without mitochondria|The other half of the metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and will not receive autologous mitochondria during the intracytoplasmic sperm injection (ICSI) in the vitro fertilization treatment. Control Group
16604008|NCT02586285|Active Comparator|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
16604009|NCT02586285|No Intervention|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
16604010|NCT02586272|Experimental|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
16604011|NCT02586272|Other|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
16604012|NCT02586259||Cortiment®|Treatment according to routine clinical practice.
16604013|NCT02586246|Experimental|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
16604014|NCT02586246|Experimental|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
16604015|NCT02586233|Experimental|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
16604016|NCT02586233|Placebo Comparator|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
16604017|NCT02586220||normal pregnant women|150 normal pregnant women (28-32 weeks' gestation)
16604018|NCT02586220||pregnant women with gestational|100 pregnant women with gestational diabetes (28-32 weeks' gestation)
16604019|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
16604020|NCT02586194|Experimental|Control (Subjects with normal hepatic function)|Oral
16604021|NCT02586194|Experimental|Mild hepatic impairment|Oral
16604022|NCT02586194|Experimental|Moderate hepatic impairment|Oral
16604023|NCT02586181|Placebo Comparator|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate"
16604024|NCT02586181|Experimental|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
16604025|NCT02586168|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
16604026|NCT02586168|Placebo Comparator|Placebo|Placebo
16604027|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
16604028|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
16604029|NCT02586142|Experimental|Botulinum toxin type A(BTX-A) injection|To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.
16604030|NCT02586142|Active Comparator|BTX-A injection plus stretching exercise|Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.
16604031|NCT02586129|Experimental|YH14755|PO, Once Daily, 16 weeks
16604032|NCT02586129|Active Comparator|Metformin|PO, Once Daily, 16 weeks
16604033|NCT02586129|Active Comparator|Rosuvastatin|PO, Once Daily, 16 weeks
16604034|NCT02586116|Active Comparator|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
16604035|NCT02586116|Active Comparator|C-Plus|C-Plus PEEK IBF Device with autograft
16604036|NCT02586103||MRI|Patients who undergo simulated practice MRI on the day of or prior to their scheduled MRI.
16604037|NCT02586090|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
16604038|NCT02586090|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
16604039|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
16604040|NCT02586064|Experimental|Interpersonal Psychotherapy for PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
16604041|NCT02586064|Active Comparator|Prolonged Exposure|Exposure based intervention including exposure to memories and avoided places and activities
16604042|NCT02586051|Experimental|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.
~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
16604043|NCT02586051|Experimental|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.
~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
16604083|NCT02585856|Placebo Comparator|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
16604044|NCT02586038|Experimental|MLN-DEX-CYCLO arm|"Patients will receive nine 28-days induction cycles.
~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Cyclophosphamide: 300 mg/sqm orally on days 1, 8, 15"
16604045|NCT02586038|Experimental|MLN-DEX-THAL arm|"Patients will receive nine 28-days induction cycles.
~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Thalidomide: 100 mg/day orally"
16604046|NCT02586025|Experimental|Trastuzumab, Pertuzumab, Docetaxel|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
16604047|NCT02586025|Experimental|Trastuzumab, Placebo, Docetaxel|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
16604048|NCT02586012|Experimental|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
16604049|NCT02586012|Experimental|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
16604050|NCT02586012|Experimental|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
16604051|NCT02586012|Experimental|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
16604052|NCT02586012|Experimental|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
16604053|NCT02586012|Experimental|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
16604054|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
16604055|NCT02585986|Active Comparator|Probiotic|daily intake of 1 capsule containing probiotic.
16604056|NCT02585986|Placebo Comparator|Placebo|daily intake of 1 capsule containing placebo
16604057|NCT02585973|Other|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
16604058|NCT02585960|Experimental|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
16604059|NCT02585960|Experimental|FVIII trough target 1-3%|Standard treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 1-3%
16604060|NCT02585960|Experimental|FVIII trough target 8-12%|Intensified treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 8-12%
16604061|NCT02585947|Experimental|tenofovir for 24 weeks|"prophylactic (preemptive) treatment
~300mg for 24 weeks
~once daily"
16604062|NCT02585947|Experimental|tenofovir for 48 weeks|"prophylactic (preemptive) treatment
~300mg for 48 weeks
~once daily"
16604063|NCT02585934|Experimental|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
16604064|NCT02585934|Placebo Comparator|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
16604065|NCT02585921|No Intervention|Health & Wellness|Following enrollment, participants will learn about health and wellness.
16604066|NCT02585921|Experimental|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
16604067|NCT02585921|Experimental|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
16604068|NCT02585921|Experimental|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
16604069|NCT02585908|No Intervention|Experimental Group A(control group)|regular treatment and follow up
16604070|NCT02585908|Experimental|Experimental Group B|CIK will be used against tumor cells.
16604071|NCT02585908|Experimental|Experimental Group C|γδ T will be used against tumor cells.
16604072|NCT02585908|Experimental|Experimental Group D|CIK and γδ T will be used against tumor cells.
16604073|NCT02585895|Experimental|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
16604074|NCT02585895|Active Comparator|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
16604075|NCT02585882|Experimental|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
16604076|NCT02585882|No Intervention|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
16604077|NCT02585869|Experimental|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
16604078|NCT02585869|Experimental|Gemcabene 300 mg|Gemcabene 300 mg once daily (QD)
16604079|NCT02585869|Experimental|Gemcabene 600 mg|Gemcabene 600 mg once daily (QD)
16604080|NCT02585869|Experimental|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
16604085|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
16604086|NCT02585817|Experimental|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
16604087|NCT02585804|Experimental|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
16604088|NCT02585791|Experimental|vape NFEC containing 100% PG|Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
16604089|NCT02585791|Experimental|vape 100% vegetable glycerin -VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
16604090|NCT02585791|Experimental|vape PG+VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
16604091|NCT02585778|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
16604092|NCT02585778|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
16604093|NCT02585765|Experimental|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
16604094|NCT02585765|Placebo Comparator|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
16604095|NCT02585752|Experimental|Single centre, single arm|Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.
16604096|NCT02585739|Experimental|patient|patient with Cluster headache
16604097|NCT02585739|Other|healthy subject|patient without Cluster headache
16604098|NCT02585726|Active Comparator|Historical Control with Propensity Analysis|
16604099|NCT02585726|Experimental|VenaSeal Treatment Arm|
16604100|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
16604101|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
16604102|NCT02585700|Experimental|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:
~NYMC BX-51B reassortant of B/Massachusetts/2/2012
~X-181 reassortant of H1/A/California/7/2009
~X-223A reassortant of H3/A/Texas/50/2012."
16604103|NCT02585700|Placebo Comparator|Placebo|0.5 mL of phosphate buffered saline
16604104|NCT02585687|Experimental|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
16604105|NCT02585674|Experimental|MyStar DoseCoach|MyStar DoseCoach - Device-supported treat-to-target regimen. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
16604106|NCT02585674|Active Comparator|Routine Titration|Routine Titration - Routine titration defined by the Investigator. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
16604107|NCT02585661|Active Comparator|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
16604108|NCT02585661|Experimental|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
16604109|NCT02585648|Experimental|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
16604110|NCT02585648|Experimental|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
16604111|NCT02585635||Families|Families of children with haemophilia
16604112|NCT02585635||Clinicians|Haemophilia physicians
16604113|NCT02585622|Experimental|Bone marrow-derived Mesenchymal Stromal Cells|
16604114|NCT02585622|Placebo Comparator|Cryostor CS10|
16604115|NCT02585596|Experimental|YH23537 1000mg/day|YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks
16604116|NCT02585596|Experimental|YH23537 2000mg/day|YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks
16604117|NCT02585596|Experimental|YH23537 3000mg/day|YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks
16604118|NCT02585596|Experimental|YH23537 3000mg/day loading 1000mg/day|YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks
16604119|NCT02585596|Placebo Comparator|Placebo|YH23537 500mg placebo 3tab twice a day
16604120|NCT02585583|Other|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
16604121|NCT02585570|Experimental|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
16604122|NCT02585570|Experimental|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
16604123|NCT02585570|No Intervention|Normal saline|normal saline for 5minutes
16604124|NCT02585557|Experimental|Cluster A|50 practices randomly assigned to start intervention at month 9. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
16604125|NCT02585557|Experimental|Cluster B|50 practices randomly assigned to start intervention at month 11. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
16604126|NCT02585557|Experimental|Cluster C|50 practices randomly assigned to start intervention at month 12. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
16604127|NCT02585557|Experimental|Cluster D|50 practices randomly assigned to start intervention at month 14. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
16604128|NCT02585557|Experimental|Cluster E|50 practices randomly assigned to start intervention at month 16. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
16604129|NCT02585544|Other|Genital prolapse|Single arm: i.e., all patients
16604130|NCT02585531|Experimental|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
16604131|NCT02585531|Active Comparator|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
16604132|NCT02585518||Obese|Children and adolescents with a BMI at or above the 85th percentile for age and sex
16604133|NCT02585518||Healthy control|Children and adolescents with a BMI below the 85th percentile for age and sex
16604134|NCT02585505|Active Comparator|Intravenous|stem cells will be injected through intravenously in the subjects
16604135|NCT02585505|Active Comparator|superior pancreaticoduodenal|stem cells
16604136|NCT02585505|Active Comparator|splenic artery|stem cells will be injected through splenic in the subjects
16604137|NCT02585492|Active Comparator|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
16604138|NCT02585492|Experimental|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
16604139|NCT02585479|Experimental|systemic chemotherapy|Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.
16604140|NCT02585479|Active Comparator|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.
16604141|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
16604142|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
16604143|NCT02585453|Experimental|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
16604144|NCT02585453|Active Comparator|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
16604145|NCT02585453|Active Comparator|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
16604146|NCT02585440|Experimental|Group A|CMX157, tablet, 5 mg, QD, 14 days versus CMX157 placebo, 5 mg, tablet, QD, 14 days
16604147|NCT02585440|Experimental|Group B|CMX157, tablet, 10 mg, QD, 14 days versus CMX157, placebo tablet, 10 mg, QD, 14 days
16604148|NCT02585440|Experimental|Group C|CMX157, tablet, 25 mg, QD, 14 days versus placebo CMX157, placebo tablet, 25 mg, QD, 14 days
16604149|NCT02585440|Experimental|Group D|CMX157, tablet, 50 mg, QD, 14 days versus CMX157, placebo tablet, 50 mg, QD, 14 days
16604150|NCT02585440|Experimental|Group E|CMX157, tablet, 100 mg, QD, 14 days versus CMX157, placebo tablet, 100 mg, QD, 14 days
16604151|NCT02585427|Experimental|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
16604152|NCT02585427|Experimental|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
16604153|NCT02585427|Experimental|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
16604154|NCT02585427|Experimental|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
16604155|NCT02585427|Experimental|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
16604156|NCT02585427|Experimental|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
16604157|NCT02585414||85 healthy subjects with no history of DES|
16604158|NCT02585414||255 subjects with DES|
16604159|NCT02585401||Eylea product and application information / Cohort 1|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.
16604160|NCT02585388|Active Comparator|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
16604161|NCT02585388|Experimental|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
~And:
~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
16604162|NCT02585375|Experimental|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
16604163|NCT02585375|Active Comparator|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
16604164|NCT02585362|Active Comparator|Intervention group|Participants will receive physical exercise, nutrition counseling and a whey protein Supplement over 12 weeks
16604166|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
16604167|NCT02585336|No Intervention|Observation|
16604168|NCT02585336|Experimental|Brief intervention|
16604169|NCT02585323|Active Comparator|Immediate Intervention Group|Education session, Fitbit/FitViz, PT counselling: Participants receive this intervention in Months 1-3. The session will include a presentation on physical activity, an individual goal-setting session with a registered physiotherapist, and an orientation to the Fitbit Flex and the FitViz app. In Months 1 and 2, participants will use the Fitbit/FitViz. The PT will review the progress with participants via 20-minute bi-weekly phone calls, and progressively modify their activities. In Month 3, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls. In Months 4-9, participants may continue using the Fitbit/FitViz without access to a PT.
16604170|NCT02585323|Placebo Comparator|Delayed Intervention Group|Same intervention with a 3 month delay: The full intervention will be initiated in Month 4 and with a brief education session, use of a Fitbit Flex paired with the FitViz app, and counseling by a physiotherapist. In Months 6-9, participants will continue using Fitbit/FitViz without the PT phone calls.
16604171|NCT02585297||Control- semen|Semen of fertile men
16604172|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
16604173|NCT02585297||Case-semen|Semen of infertile men
16604174|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
16604175|NCT02585284||vicenarian|20 to 29 years. Five males and five females
16604176|NCT02585284||tricenarian|30 to 39 years. Five males and five females
16604177|NCT02585284||quadragenarian|40 to 49 years. Five males and five females
16604178|NCT02585284||quinquagenarian|50 to 59 years. Five males and five females
16604179|NCT02585284||sexagenarian|60 to 69 years. Five males and five females
16604180|NCT02585284||septuagenarian|70 to 79 years. Five males and five females
16604181|NCT02585284||octogenarian|80 to 89 years. Five males and five females
16604182|NCT02585284||nonagenarian|90-99 years. Five males and five females
16604183|NCT02585271|Other|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
16604184|NCT02585271|Other|Stent|Patients undergo placement of the stent as a bridge to surgery
16604185|NCT02585258|Experimental|arm A|prednisolone 5 mg per day
16604186|NCT02585258|Placebo Comparator|arm B|placebo capsules once per day
16604187|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
16604188|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
16604189|NCT02585232|Active Comparator|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
16604190|NCT02585232|Experimental|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
16604191|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).
~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.
~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
16604192|NCT02585206|No Intervention|Arm 1|"All 4 factors off - standard text message program
~Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity OFF"
16604193|NCT02585206|Active Comparator|Arm 2|Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity ON
16604194|NCT02585206|Active Comparator|Arm 3|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity OFF
16604195|NCT02585206|Active Comparator|Arm 4|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity ON
16604196|NCT02585206|Active Comparator|Arm 5|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity OFF
16604197|NCT02585206|Active Comparator|Arm 6|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity ON
16604198|NCT02585206|Active Comparator|Arm 7|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity OFF
16604199|NCT02585206|Active Comparator|Arm 8|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity ON
16604200|NCT02585206|Active Comparator|Arm 9|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity OFF
16604201|NCT02585206|Active Comparator|Arm 10|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity ON
16604202|NCT02585206|Active Comparator|Arm 11|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity OFF
16604203|NCT02585206|Active Comparator|Arm 12|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity ON
16604204|NCT02585206|Active Comparator|Arm 13|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity OFF
16604205|NCT02585206|Active Comparator|Arm 14|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity ON
16604206|NCT02585206|Active Comparator|Arm 15|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity OFF
16604207|NCT02585206|Active Comparator|Arm 16|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity ON
16604208|NCT02585206|No Intervention|WEB|"Phase II arm.
~Full access to standard BecomeAnEX.org web-based smoking cessation program."
16604209|NCT02585206|Active Comparator|WEB+OA_TXT|"Phase II arm.
~Full access to standard BecomeAnEX.org web-based smoking cessation program PLUS optimal-adherence text message program from Phase I."
16604210|NCT02585193|Other|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
16604211|NCT02585180|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
16604212|NCT02585180|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
16604213|NCT02585167|Active Comparator|Operation|"the fistula will be excised after dividing the sphincter and primary reconstruction
~."
16604214|NCT02585167|Experimental|VAAFT|the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.
16604215|NCT02585154|Experimental|Closed-loop Deep Brain Stimulation|Closed-loop Deep Brain Stimulation
16604216|NCT02585154|Active Comparator|Open loop Deep Brain stimulation|Open loop Deep Brain stimulation
16604217|NCT02585154|Other|No Deep Brain Stimulation|No Deep Brain Stimulation
16604218|NCT02585141|Experimental|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
16604219|NCT02585141|Active Comparator|incision|Surgical incision of perianal abscess under general anesthesia.
16604220|NCT02585128|Other|Patients following TAVI|
16604221|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
16604222|NCT02585102|Other|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
16604223|NCT02585102|Other|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
16604224|NCT02585089|Active Comparator|Spanish cured-pork ham|"One group will receive dry-cured pork ham of >10 months proteolysis (intervention product).
~Intervention: Dietary intake Dry-cured pork ham contains high doses of bioactive peptides produced during more than 10 months of proteolysis."
16604225|NCT02585089|Placebo Comparator|Cooked pork ham|The other group will receive cooked, uncured ham (placebo product). Intervention: Dietary intake. Cooked ham does not display bioactive peptides as they are produced during proteolysis of pork ham.
16604226|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
16604227|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
16604228|NCT02585050||patients alive discharged from hospital|patients alive discharged from hospital following CPR
16604229|NCT02585037|Experimental|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
16604230|NCT02585037|Experimental|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
16604231|NCT02585037|Placebo Comparator|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
16604232|NCT02585024|Experimental|1.5 mg cytisine|1.5 mg cytisine given as a single dose
16604233|NCT02585024|Experimental|3 mg cytisine|3 mg cytisine given as a single dose
16604234|NCT02585024|Experimental|4.5 mg cytisine|4.5 mg cytisine given as a single dose
16604235|NCT02585024|Experimental|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
16604236|NCT02585024|Experimental|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
16604237|NCT02585024|Experimental|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
16604238|NCT02585011|Experimental|Ropivacaine|Local infiltration anesthesia, single shot during surgery. 150 ml Ropivacaine (2mg/ml), added 0.5 ml Epinephrine (1mg/ml)
16604239|NCT02585011|Placebo Comparator|Placebo|Single shot during surgery.150 ml saline
16604240|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
16604241|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
16604242|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
16604243|NCT02584985|Other|ETAP : Endoscopic Transanal Proctectomy|"Primary transanal approach :
~Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).
~Secondary transabdominal approach :
~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
16604244|NCT02584985|Other|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
16604245|NCT02584972||children with Autism Spectrum Disorder|no intervention required
16604246|NCT02584972||heathy children|no intervention required
16604247|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
16604248|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
16604249|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
16604250|NCT02584946|Placebo Comparator|Low-AVA oat flour cookies|
16604251|NCT02584946|Experimental|High-AVA oat flour cookies|
16604253|NCT02584920|Experimental|HLX01|375mg/m2 iv single dose
16604254|NCT02584920|Active Comparator|Rituximab|375mg/m2 iv single dose
16604255|NCT02584907|Experimental|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
16604256|NCT02584907|No Intervention|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
16604257|NCT02584894|Placebo Comparator|rTMS 1Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 1Hz on dorsolateral prefrontal cortex (1Hz rTMS is describe in the literature to have no effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter . Heart rate measure With electrocardiogram
16604258|NCT02584894|Experimental|rTMS 10Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 10Hz on dorsolateral prefrontal cortex (10Hz rTMS is describe in the literature to have effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter. Heart rate measure with electrocardiogram
16604259|NCT02584881|Experimental|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
16604260|NCT02584881|No Intervention|Control|Standard care at discharge will be implemented with these trauma patients
16604261|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
16604262|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
16604263|NCT02584855|Experimental|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
16604264|NCT02584855|Experimental|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.
~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
16604265|NCT02584855|Placebo Comparator|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.
~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
16604323|NCT02584465|Experimental|B-Regorafenib|Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression
16604266|NCT02584855|Experimental|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.
~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
16604267|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
16604268|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
16604269|NCT02584816|Experimental|Group 1 - BRV-PV Lot A|BRV-PV Lot A + DPT- HepB-Hib + OPV
16604270|NCT02584816|Experimental|Group 2 - BRV-PV Lot B|BRV-PV Lot B+ DPT- HepB-Hib + OPV
16604271|NCT02584816|Experimental|Group 3 - BRV-PV Lot C|BRV-PV Lot C + DPT- HepB-Hib + OPV
16604272|NCT02584816|Active Comparator|Group 4 - ROTARIX|ROTARIX + DPT-HepB-Hib + OPV
16604273|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
16604274|NCT02584777|Experimental|Pacritinib|Oral administration
16604275|NCT02584764|Experimental|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
16604276|NCT02584751|Active Comparator|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
16604277|NCT02584751|Active Comparator|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
16604278|NCT02584751|Experimental|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
16604279|NCT02584751|Active Comparator|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
16604280|NCT02584738|Experimental|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.
~Intravenous methylprednisolone or oral prednisolone"
16604281|NCT02584738|Placebo Comparator|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone
16604282|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
16604283|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
16604284|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
16604285|NCT02584712|No Intervention|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
16604286|NCT02584712|Active Comparator|Exercise Training|This group undergone exercise training intervention during 4 weeks.
16604287|NCT02584699|Experimental|SABR|SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)
16604288|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
16604289|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
16604290|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
16604291|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
16604292|NCT02584660|Experimental|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
16604293|NCT02584660|Experimental|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
16604294|NCT02584647|Experimental|Phase 1: PLX3397 and Sirolimus|Cohort 1 (Phase 1): Subjects with unresectable or metastatic sarcoma will take orally PLX3397 (600 - 1000mg) in combination with Sirolimus (2-6mg) daily .
16604295|NCT02584647|Experimental|Phase 2: PLX3397 and Sirolimus|Cohort 2 (Phase 2): Subjects with unresectable or metastatic Malignant Peripheral Nerve Sheath Tumors (MPNSTs) will take PLX3397 and Sirolimus at the recommended Phase 2 dose (RP2D).
16604296|NCT02584634|Experimental|Group A|ALK negative Non-Small Cell Lung Cancer
16604297|NCT02584634|Experimental|Group B|ALK positive Non-Small Cell Lung Cancer
16604298|NCT02584621|Experimental|Check Yourself App With Feedback|Participants complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their visit with their health provider. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Health providers receive a summary report of health risk behaviors from Check Yourself prior to the visit.
16606708|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
16604299|NCT02584621|No Intervention|Usual Care|Participants are asked to complete health risk screening questions on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
16604300|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
16604301|NCT02584582|Experimental|Liraglutide + Liquid meal test|Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
16604302|NCT02584582|Experimental|Exenatide + Liquid meal test|Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
16604303|NCT02584582|Other|Baseline + Liquid meal test|Baseline day with no additional medication
16604304|NCT02584569|Experimental|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
16604305|NCT02584556|Experimental|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
16604306|NCT02584556|Active Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
16604307|NCT02584543|Experimental|HEV vaccine and HBV vaccine Co-administration group|
16604308|NCT02584543|Active Comparator|HEV vaccine control group|
16604309|NCT02584543|Active Comparator|HBV vaccine control group|
16604310|NCT02584530|No Intervention|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
16604311|NCT02584530|Experimental|Interventional group|Ultrasound guidance for PICC line placement and X-ray
16604312|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
16604313|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
16604314|NCT02584504|Experimental|Alirocumab 150 mg Q4W|Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
16604315|NCT02584504|Experimental|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
16604316|NCT02584504|Placebo Comparator|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
16604317|NCT02584491|Experimental|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
16604318|NCT02584478|Experimental|Phase 3 -Active Treatment Arm|"Phase 3: AL3818 8 mg once daily in combination with one background chemotherapy in 21-day cycles. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:
~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)
~Pegylated liposomal doxorubicin (PLD)
~Topotecan"
16604319|NCT02584478|Other|Phase 3-Control Treatment Arm|"Control Treatment Arm: Background chemotherapy treatment alone. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:
~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)
~Pegylated liposomal doxorubicin (PLD)
~Topotecan"
16604320|NCT02584478|Experimental|Phase 1b: AL3818 plus carboplatin and paclitaxel|Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
16604321|NCT02584478|Experimental|Phase 2a: AL3818 plus carboplatin and paclitaxel|Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b.
16604322|NCT02584465|Active Comparator|A-Tamoxifen|Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression
16606814|NCT02568163|Other|questionary|
16604324|NCT02584452|Active Comparator|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
16604325|NCT02584452|Active Comparator|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
16604326|NCT02584439|Other|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
16604327|NCT02584439|Other|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
16604328|NCT02584426|Experimental|Cefazolin Treatment|Subjects will receive antibiotic treatment with phonophoresis (i.e., hypodermoclysis) during test 1, and will be given standard of care for 8 weeks.
16604329|NCT02584426|No Intervention|Standard of Care Control|Subjects will not receive intervention and will receive standard of care for 8 weeks.
16604330|NCT02584413|Experimental|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
16604331|NCT02584400|Experimental|[18F]HX4 PET imaging|Injection with the hypoxia tracer [18F]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
16604332|NCT02584387|Experimental|3D VVRET|"Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)
~1 30 minute 3D VRET treatment session for arachnophobia."
16604333|NCT02584387|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
16604334|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
16604335|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age
~Venography with balloon occlusion test will be performed."
16604336|NCT02584361|Active Comparator|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
16604337|NCT02584361|Active Comparator|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
16604338|NCT02584348|Experimental|Gastric Ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed
16604339|NCT02584335|Active Comparator|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
16604340|NCT02584335|Placebo Comparator|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
16604341|NCT02584322|Experimental|ERAS patients|Enhanced recovery pathway
16604342|NCT02584309|Experimental|Arm 1: dexrazoxane & standard of care doxorubicin|"Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.
~Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.
~Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.
~In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
16604343|NCT02584309|Active Comparator|Arm 2: control (standard of care doxorubicin)|"Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.
~The last 10 patients enrolled after completion of enrollment to Arm 1 (dexrazoxane & standard of care doxorubicin) will be enrolled to Arm 2 (control arm - standard of care doxorubicin only)"
16604344|NCT02584296|No Intervention|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
16604345|NCT02584296|Experimental|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
16604346|NCT02584283|Experimental|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
16604347|NCT02584283|No Intervention|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
16604348|NCT02584270|Experimental|Prosthesis + Articulation Therapy|This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
16604349|NCT02584270|Other|No Prosthesis; Articulation Therapy Only|This arm will not receive a palatal augmentation prosthesis, but will receive standard articulation therapy, and is the control arm.
16604350|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
16604351|NCT02584257|Active Comparator|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
16604352|NCT02584257|Active Comparator|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
16604353|NCT02584257|Experimental|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
16604354|NCT02584257|Experimental|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
16604355|NCT02584244|Experimental|Patients with colorectal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
16604356|NCT02584244|Experimental|Patients with esophageal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
16604357|NCT02584244|Experimental|Pancreatic cancer patients receiving neoadjuvant chemotherapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
16604358|NCT02584244|Experimental|Pancreatic cancer patients not receiving neoadjuvant chemo|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
16604359|NCT02584244|Experimental|Gastric cancer patients who have received neoadjuvant therapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
16604360|NCT02584244|Experimental|Patients with early stage gastric cancer or precancerous lesions|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
16604361|NCT02584231|Experimental|Patients needing an urinary concentration test|Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)
16604362|NCT02584231|Experimental|Patients suffering from treatment resistant nocturnal enuresis|Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)
16604363|NCT02584218|Experimental|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
16604364|NCT02584218|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
16604365|NCT02584205|Experimental|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
16604366|NCT02584205|Placebo Comparator|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
16604367|NCT02584192|Experimental|the rehabilitation group|entailing an early home-based CR program
16604368|NCT02584192|Other|the control group|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
16604369|NCT02584179|Experimental|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.
~All men will have standard transrectal ultrasound guided biopsies"
16604370|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
16604371|NCT02584166||Control group|No intervention in 57 maternity units
16604372|NCT02584153|Experimental|Myoseal|The fibrin sealant and silver microparticles are sprayed onto the surface of the sutured myofascial incision following abdominal surgery.
16604373|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
16604374|NCT02584127|Experimental|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
16604375|NCT02584127|Experimental|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
16604376|NCT02584114|Experimental|Memory training group|The intervention is self-administration of 4 hours of memory training over 4 days per week, for 3 weeks (12 hours total). Memory training will be done with the Peak app for memory training http://www.peak.net.
16604377|NCT02584114|Active Comparator|Non-memory training group|The intervention is self-administration of 4 hours of training of games that do not involve memory such as language and card games over 4 days per week, for 3 weeks (12 hours total).
16604378|NCT02584101|Experimental|ACT|ACT therapy
16604379|NCT02584101|Active Comparator|Enhanced Treatment as Usual|Group support
16604380|NCT02584075|Experimental|Lifestyle intervention|
16604381|NCT02584062|Experimental|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
16604382|NCT02584062|Experimental|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
16604383|NCT02584049|Active Comparator|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
16604384|NCT02584049|Sham Comparator|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
16604385|NCT02584036||Receiving Influenza Vaccine|Patients who receive an influenza vaccine at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
16604386|NCT02584023|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
16604387|NCT02584023|Active Comparator|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
16604388|NCT02584010|Experimental|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
16604389|NCT02584010|Experimental|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
16604390|NCT02584010|No Intervention|Control|This group will not receive any intervention as a control group.
16604391|NCT02583997|Active Comparator|Routine third molar extraction|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care (i.e. with suturing of the lower alveoli).
~Intervention: Suturing of lower alveoli"
16604419|NCT02583802|Experimental|Ear pills and Shengmai capsule|On regular hemodialysis based on given auricular Ear pills and Shengmai capsule
16604392|NCT02583997|Experimental|Third molar extraction without suturing|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care, except that the resulting alveoli will not be sutured.
~Intervention: Non suturing of lower alveoli"
16604393|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
16604394|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
16604395|NCT02583971||Patients with AF|"Split into 3:
~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.
~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.
~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
16604396|NCT02583958|Experimental|Device Urgo 3103166|Soft-adherent hydro-desloughing dressing
16604397|NCT02583958|Active Comparator|Device Aquacel Extra|Hydrofibre dressing
16604398|NCT02583945|Experimental|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
16604399|NCT02583932|Experimental|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
16604400|NCT02583932|Placebo Comparator|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
16604401|NCT02583932|No Intervention|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
16604402|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
16604403|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
16604404|NCT02583919|Placebo Comparator|Placebo|Placebo
16604405|NCT02583906|Other|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
16604406|NCT02583906|No Intervention|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
16604407|NCT02583893|Experimental|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
16604408|NCT02583867|Experimental|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
16604409|NCT02583854|Active Comparator|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
16604410|NCT02583854|Experimental|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
16604411|NCT02583841|Active Comparator|Scaling and Root Planing( SRP)|This was an interventional study in which scaling and root planing was done in systemically healthy patients with chronic periodontitis
16604412|NCT02583841|No Intervention|Control Group|Scaling and root planing was not done , that is no intervention is carried out in the patients of this group.
16604413|NCT02583828|Active Comparator|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
16604414|NCT02583828|Experimental|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
16604415|NCT02583828|Experimental|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
16604416|NCT02583828|Active Comparator|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
16604417|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
16604418|NCT02583802|No Intervention|Control group|Control group received regular hemodialysis treatment, no given Ear pills and Shengmai capsule completed in the treatment of the first stage. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
16604420|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
16604421|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
16604422|NCT02583776|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
16604423|NCT02583776|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
16604424|NCT02583763||Fetuses/Children with IUGR|"The moving sequences of the heart movement are collected at the regular ultrasound examinations during pregnancy. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.
~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
16604425|NCT02583763||Healthy Controls|"The moving sequences of the heart movement are collected at two occasions approximately 4 weeks apart. This takes place during gestational weeks 28-36. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.
~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyze the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
16604426|NCT02583750|Experimental|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
16604427|NCT02583750|Experimental|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
16604428|NCT02583737|Active Comparator|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
16604429|NCT02583737|Active Comparator|group freeze bone allograft|sinus lifting with freeze bone bank filling
16604430|NCT02583698|Experimental|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP > 90 mmHg and HR >55/min
16604431|NCT02583698|Placebo Comparator|placebo|
16604432|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
16604433|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
16604434|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
16604435|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
16604436|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
16604437|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
16604438|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
16604439|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
16604440|NCT02583672|Experimental|N-acetylcysteine|The first 10 GD1 subjects will take 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. An interim analysis will be performed to determine if this dose produces changes in systemic redox status and brain glutathione (GSH) levels. If no signal of a significant change is observed, the remaining 20 subjects will receive up to 3600 mg NAC orally twice a day (7200 mg/day).
16604441|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
16604442|NCT02583646||normal weight|Girls age 8-14 below 85% in respect to weight for their age group
16604443|NCT02583646||overweight|Girls age 8-14 at or above 85% in respect to weight for their age group
16604444|NCT02583633|Active Comparator|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
16604445|NCT02583633|Active Comparator|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;
~One softgel every 20 min (4 doses)
~Two softgel every 6 hr (4 doses)
~One softgel every 6 hr (4 doses)
~One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
16604446|NCT02583620|Other|Emmetropic volunteers|Blood sample
16604447|NCT02583620|Other|High myopic volunteers|Blood sample
16604448|NCT02583607|Experimental|Brava and fat transfer|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.
~Woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
16604689|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
16604449|NCT02583594|Experimental|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
16604450|NCT02583594|Experimental|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
16604451|NCT02583581|Experimental|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
16604452|NCT02583568|Experimental|Part 1|In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
16604453|NCT02583568|Experimental|Part 2|In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
16604454|NCT02583555|Active Comparator|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
16604455|NCT02583555|No Intervention|Controls|Questionnaire every 3 months
16604456|NCT02583542|Experimental|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
16604457|NCT02583542|Experimental|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:
~Triple-negative breast cancer (TNBC)
~Squamous cell lung cancers
~Non-squamous cell lung cancers with KRAS mutations
~Non-squamous cell lung cancers with wild-type KRAS"
16604458|NCT02583529|Experimental|Back Tibial Nerve Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
16604459|NCT02583529|Placebo Comparator|Placebo Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
16604460|NCT02583516|Experimental|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
16604461|NCT02583516|Experimental|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
16604462|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
16604463|NCT02583490|Experimental|Low Pulse Amplitude ECT (LAP)|Right Unilateral LAP ECT
16604464|NCT02583490|Active Comparator|standard Right Unilateral ECT|standard Right Unilateral ECT
16604465|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
16604466|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
16604467|NCT02583464|Experimental|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
16604468|NCT02583464|Experimental|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
16604469|NCT02583451|Experimental|Treatment A|Treatment A is a placebo tablet matching lemborexant and placebo tablet matching zopiclone on nights in the clinic; placebo tablet matching lemborexant on nights at home.
16604470|NCT02583451|Experimental|Treatment B|Treatment B is zopiclone 7.5 mg tablet and placebo tablet matching lemborexant on nights in the clinic; placebo tablet matching lemborexant on nights at home.
16604471|NCT02583451|Experimental|Treatment C|Treatment C is lemborexant 2.5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 2.5 mg tablet on nights at home.
16604472|NCT02583451|Experimental|Treatment D|Treatment D is lemborexant 5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 5 mg tablet on nights at home.
16604473|NCT02583451|Experimental|Treatment E|Treatment E is lemborexant 10 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 10 mg tablet on nights at home.
16604474|NCT02583438|Experimental|Lifestyle intervention|
16604475|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
16604476|NCT02583412|Active Comparator|Group 1: Accelerated Schedule|
16604477|NCT02583412|Active Comparator|Group 2: Standard Schedule|
16604478|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
16604510|NCT02583204|No Intervention|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
16604479|NCT02583386|Active Comparator|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
16604480|NCT02583386|No Intervention|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
16604481|NCT02583386|Active Comparator|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
16604482|NCT02583386|Other|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
16604483|NCT02583373|Active Comparator|CAL02 Low-dose|Liposomal formulation
16604484|NCT02583373|Active Comparator|CAL02 High-dose|Liposomal formulation
16604485|NCT02583373|Placebo Comparator|Placebo|Saline
16604486|NCT02583360|Active Comparator|Study|Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
16604487|NCT02583360|No Intervention|Control|Eligible subjects who had VFSS alone with provider recommendations from the same single center.
16604488|NCT02583334|Experimental|Verum Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
16604489|NCT02583334|Sham Comparator|Sham Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).
16604490|NCT02583321|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
16604491|NCT02583321|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
16604492|NCT02583308|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
16604493|NCT02583308|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
16604494|NCT02583295|Active Comparator|Music group|Music sound
16604495|NCT02583295|Active Comparator|Maternal sound group|Maternal sound
16604496|NCT02583282|Experimental|Doxycycline|Intrapleural doxycycline
16604497|NCT02583282|Active Comparator|Iodopovidine|Intrapleural iodopovidine
16604498|NCT02583269|Experimental|Arm 1 (muscadine grape skin extract) 1 pill 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
16604499|NCT02583269|Experimental|Arm 2 (muscadine grape skin extract) 2 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
16604500|NCT02583269|Experimental|Arm 3 (muscadine grape skin extract) 3 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
16604501|NCT02583269|Experimental|Arm 4 (muscadine grape skin extract) 4 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
16604502|NCT02583269|Experimental|Arm 5 muscadine grape skin extract) 5 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
16604503|NCT02583256|Experimental|aQIV/aQIV|Subjects previously vaccinated with aQIV followed one year later by aQIV
16604504|NCT02583256|Experimental|aQIV/QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
16604505|NCT02583256|Experimental|QIV/aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
16604506|NCT02583256|Experimental|QIV/QIV|Subjects previously vaccinated with QIV followed one year later by QIV
16604507|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
16604508|NCT02583217||Ketamine|Ketamine+propofol
16604509|NCT02583217||Remifentanyl|Remifentanyl+propofol
16604511|NCT02583204|Experimental|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
16604512|NCT02583204|Experimental|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
16604513|NCT02583191|Experimental|Rivaroxaban|Arm A: Rivaroxaban
16604514|NCT02583191|Active Comparator|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
16604515|NCT02583178|Experimental|Aegis Sierra Ligation System|The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
16604516|NCT02583165|Experimental|Monotherapy arm|MEDI1873
16604517|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
16604518|NCT02583139|Experimental|Music Narrative Group|Prescribed medical/chemotherapy treatment plus standard care + Designed Music Narratives
16604519|NCT02583139|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
16604520|NCT02583126|Experimental|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
16604521|NCT02583126|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
16604523|NCT02583100|Experimental|Intensive Feedback|Participants in this arm will receive intensive feedback on their complication rates, surgical technique, and peri-operative surgical management from peer surgeons participating in the study.
16604524|NCT02583100|Active Comparator|Routine Feedback|Participants in this arm will receive routine feedback on their complication rates.
16604525|NCT02583074|Experimental|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
16604526|NCT02583074|Sham Comparator|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
16604527|NCT02583048|Experimental|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.
~Participants also received Multidrug Background Treatment (MBT) for TB.
~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
16604528|NCT02583048|Experimental|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.
~Participants also received Multidrug Background Treatment (MBT) for TB.
~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
16604529|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.
~Participants also received Multidrug Background Treatment (MBT) for TB.
~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
16604530|NCT02583035|Other|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
16604531|NCT02583022|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
16604532|NCT02583022|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
16604533|NCT02583022|Active Comparator|Elidel cream 1%|Elidel cream 1%, Twice daily for 4 weeks
16604534|NCT02583009|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
16604535|NCT02583009|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
16604536|NCT02583009|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
16604537|NCT02583009|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
16604538|NCT02582996|Experimental|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
16604539|NCT02582996|Active Comparator|Tylenol®|Acetaminophen
16604540|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
16604541|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
16604542|NCT02582957|Experimental|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
16604543|NCT02582957|No Intervention|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
16604544|NCT02582944|Experimental|Arm 1: Electromagnetic navigation|"The bronchoscope will be inserted transorally into the tracheobronchial tree and a standard airway inspection will be performed.
~Following airway inspection, the bronchoscope will be removed and the tip tracked steerable catheter with optical system will be advanced transorally through the vocal cords and into the tracheobronchial tree.
~Once the tip tracked catheter has been advanced to the peripheral pulmonary target lesion, the optical SpinView system will be removed from the tip tracked catheter and the 1.4mm radial endobronchial ultrasound mini-probe will be inserted through the tip-tracked catheter into the lung periphery to confirm the presence of a peripheral pulmonary lesion and accurate navigation.
~Once target confirmation has been performed using radial probe endobronchial ultrasound, biopsy of the peripheral lesion will be performed using biopsy forceps, brushes and aspiration needles."
16604649|NCT02582255|Experimental|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
16604650|NCT02582242|Experimental|BIAsp 30 TID|
16604651|NCT02582242|Active Comparator|BIAsp 30 BID|
16604545|NCT02582931|Experimental|Arm 1: MRI-guided SBRT|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
~Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.
~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
16604546|NCT02582918|No Intervention|Group 1: Usual Care|Usual care with opportunistic visit-based HCC surveillance.
16604547|NCT02582918|Experimental|Group 2: Patient Education and Patient Navigation Services|Mailed HCC surveillance outreach with patient education and patient navigation services.
16604548|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
16604549|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
16604550|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
16604551|NCT02582892|Other|Vit D|Vit D 20 mg/day
16604552|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
16604553|NCT02582866|Experimental|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.
~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
16604554|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.
~Lumbar puncture Blood sample"
16604555|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
16604556|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
16604557|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
16604558|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
16604559|NCT02582827|Experimental|ABI-011|IDN 5404 protein-bound particles for injectable suspension
16604560|NCT02582814|Experimental|dapagliflozin 5mg + insulin|dapagliflozin tablet 5mg + adjustable insulin
16604561|NCT02582814|Experimental|dapagliflozin 10mg + insulin|dapagliflozin tablet 10mg + adjustable insulin
16604562|NCT02582801|Experimental|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
16604563|NCT02582801|Active Comparator|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
16604564|NCT02582788|Active Comparator|Bleach|Patients will use bleach added to their baths twice a week.
16604565|NCT02582788|Active Comparator|Vinegar|Patients will use vinegar (dilute acetic acid) added to their baths twice a week.
16604566|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
16604567|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
16604568|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGy of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
16604569|NCT02582775|Experimental|Arm D: HCT with 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
16604570|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
16604571|NCT02582775|Experimental|Arm F: HCT Alone, 200 cGy BID of TBI|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
16604572|NCT02582775|Experimental|Arm G: HCT plus MSC, 200 cGy|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
16604573|NCT02582762|Experimental|Nail gel|apply nail gel twice daily
16604574|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
16604575|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
16604576|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
16604577|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
16607246|NCT02565134|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
16604578|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
16604579|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
16604580|NCT02582723|Active Comparator|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
16604581|NCT02582723|Active Comparator|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
16604582|NCT02582723|Experimental|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
16604583|NCT02582710|Experimental|VASCAZEN|Patients treated with Vascazen
16604584|NCT02582710|Placebo Comparator|Placebo|Patients treated with a placebo
16604585|NCT02582697|Active Comparator|Standard Arm - Standard BEP|"Participants 16 years or older will receive 4 cycles of Standard BEP as follows:
~Bleomycin 30,000 IU IV weekly for 3 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients < 16 years old and weighs ≥ 45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients <16 years old and weighs < 45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count ≥1 x10^9/ L
~The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.
~Each cycle is 3 weeks (21 days).
~The planned total duration of treatment is 12 weeks."
16604586|NCT02582697|Experimental|Experimental Arm - Accelerated BEP|"Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:
~Bleomycin 30,000 IU IV wkly for 2 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1- 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients <16years and weighs ≥45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients <16years and weighs <45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Filgrastim 10mcg/kg/day on day 6, until ANC ≥1 x10^9/ L
~Each cycle is 2 weeks (14days)
~Following 4xBEP cycles, patients will receive additional bleomycin as follows:
~- Bleomycin *15,000 - 30,000 IU IV wkly for 4 doses
~* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.
~The planned total duration is 12 weeks."
16604587|NCT02582684|Experimental|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
16604588|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
16604589|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) ± Ribavirin (RBV) according to standard of care and in line with the current local label
16604590|NCT02582645|Experimental|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
16604591|NCT02582645|Active Comparator|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
16604592|NCT02582632|Experimental|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
16604597|NCT02582606|Experimental|Regular|Regular meal pattern
16604598|NCT02582606|Experimental|Irregular|Irregular meal pattern
16604599|NCT02582593|Active Comparator|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
16604600|NCT02582593|Sham Comparator|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
16604654|NCT02582203|Active Comparator|Ceftaroline|600 mg IV (over 1 hour) every 12 hours for renal function > 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
16604601|NCT02582593|Active Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
16604602|NCT02582593|Sham Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
16604603|NCT02582593|Active Comparator|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
16604604|NCT02582593|Sham Comparator|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
16604605|NCT02582580|Active Comparator|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
16604606|NCT02582580|Active Comparator|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
16604607|NCT02582580|Active Comparator|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
16604608|NCT02582567|Experimental|Exercise intervention|3 times per week from the 17th week of gestation until delivery
16604609|NCT02582567|No Intervention|Control group|Usual care (control) group
16604610|NCT02582554|Experimental|Intervention|Intervention: NutriSTEP The intervention will be the administration of NutriSTEP, a nutrition risk screening questionnaire for preschoolers along with a nutrition education brochure called How to Build a Healthy Preschooler
16604611|NCT02582554|No Intervention|Control|Control: Wait-list control The wait-list control group will complete the NutriSTEP and receive the nutrition education information at the end of the 3 month study period
16604612|NCT02582541|Active Comparator|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
16604613|NCT02582541|Experimental|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
16604614|NCT02582528|Experimental|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
16604615|NCT02582528|Active Comparator|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
16604616|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
16604617|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
16604618|NCT02582502|Experimental|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
16604619|NCT02582502|Other|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
16604652|NCT02582229|Experimental|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
16604620|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
16604621|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
16604622|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
16604623|NCT02582437|Experimental|Chronic Opioid User|"The patients (ASA class I-III) who receive elective surgery s aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.
~The Patients who use opioid medication daily and regularly immediately before the day of surgery for more than four weeks. The minimum criteria for opioid dose in the intervention goup is oral morphine 20mg per day: Morphine Equivalent Daily Dose(MEDD)"
16604624|NCT02582437|No Intervention|Opioid Naive patient|"The patients (ASA class I-III) who receive elective surgery aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.
~The patients who do not use opioid medications immediately before the day of surgery for four weeks."
16604625|NCT02582424|Experimental|PDL-0101|EPA +astaxanthin
16604626|NCT02582424|Placebo Comparator|placebo|olive oil
16604627|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
16604628|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
16604629|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
16604630|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
16604631|NCT02582398|Experimental|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
16604632|NCT02582398|Placebo Comparator|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
16604633|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
16604634|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
16604635|NCT02582372|Experimental|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
16604636|NCT02582372|Active Comparator|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
16604637|NCT02582359|Experimental|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy
~MLN9708 -oral on predetermined days per cycle
~Cytarabine, continuous infusion for predetermined duration and dosage
~Daunorubicin short IV infusion or rapid injection for predetermined
~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
16604638|NCT02582346|Experimental|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
16604639|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
16604640|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
16604641|NCT02582320||Study patients|Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.
16604642|NCT02582307|Experimental|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
16604643|NCT02582307|Active Comparator|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
16604644|NCT02582281|Experimental|Non touch technique|"the intrauterine device TCu 380A will be inserted in the conventional method as follows: First, insert the speculum and view the cervix. The position of the cervix will very often confirm if the uterus is anteverted or retroverted. Second, using the Allis forceps hold the back of a cotton-ball swab and dip it into a povidine-iodine disinfectant solution, or equivalent. Swab the cervix. Then cut the threads to the appropriate length and remove the speculum.
~This technique omits the sounding of the uterus which is considered a quintessential procedure before IUD insertion for which there is no one established piece of evidence.The IUD is checked afterwards by transvaginal ultrasound."
16604645|NCT02582281|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
16604646|NCT02582268|Experimental|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
16604647|NCT02582268|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
16604648|NCT02582255|Experimental|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
16604655|NCT02582203|Active Comparator|Vancomycin|Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.
16604656|NCT02582190|Other|Colchicine group|Colchicine add on therapy in atrial fibrillation
16604657|NCT02582177|Experimental|Candicort®/ Nizoral®|Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
16604658|NCT02582177|Experimental|Baycuten N®/ Canesten®|Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
16604659|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
16604660|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
16604661|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
16604662|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
16604663|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
16604664|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
16604665|NCT02582138|Experimental|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
16604666|NCT02582138|Active Comparator|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
16604667|NCT02582125|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
16604668|NCT02582112|Active Comparator|Warming group|Active Comparator: Warming group
16604669|NCT02582112|Placebo Comparator|Control group|Control group
16604670|NCT02582099|Active Comparator|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
16604671|NCT02582099|Placebo Comparator|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
16604672|NCT02582086|Experimental|BOR15001L7 Cream|BOR15001L7 Cream with 5% 15019L0
16604673|NCT02582086|Placebo Comparator|Placebo Cream|Placebo Cream
16604674|NCT02582073|Placebo Comparator|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
16604675|NCT02582073|Placebo Comparator|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
16604676|NCT02582073|Experimental|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
16604677|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
16604678|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
16604679|NCT02582073|Active Comparator|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
16604680|NCT02582060|Other|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
16604681|NCT02582047|Active Comparator|Influenza vaccination with PPV23|concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine
16604682|NCT02582047|Active Comparator|Influenza vaccination with PCV13|concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine
16604683|NCT02582034|Active Comparator|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
16604684|NCT02582034|Experimental|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is > 205 GY, if possible 250 or 300 Gy.
16604685|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
16604686|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
16604687|NCT02582008|Experimental|Arm A (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
16604688|NCT02582008|Active Comparator|Arm B (varenicline, NRT)|Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.
16604690|NCT02581982|Experimental|Treatment (pembrolizumab, paclitaxel)|Patients receive pembrolizumab IV over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
16604691|NCT02581969||Prophylaxis|Prophylaxis group: treatment is based on regularly repeated infusions of clotting factor, 20-30 IU/kg -3 times a week
16604692|NCT02581969||On-demand|On-demand group: treatment administered when bleeding episode occur
16604693|NCT02581956|Experimental|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
16604694|NCT02581956|Placebo Comparator|No Intervention|No exercise required
16604695|NCT02581943|Experimental|Arm I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
16604696|NCT02581943|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
16604697|NCT02581930|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16604698|NCT02581917||Ancillary-Correlative (metabolic changes)|Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
16604699|NCT02581904|Experimental|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
16604700|NCT02581904|Active Comparator|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
16604701|NCT02581904|Active Comparator|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
16604702|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
16604703|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
16604704|NCT02581878|Experimental|Cohort 1a|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).
16604705|NCT02581878|Experimental|Cohort 1b|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
16604706|NCT02581878|Experimental|Cohort 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
16604707|NCT02581878|Experimental|Cohort 3|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
16604708|NCT02581878|Experimental|Cohort 4|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
16604709|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
16604710|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
16604711|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
16604712|NCT02581852|Other|Single arm assessment|Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
16604713|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
16604714|NCT02581826|Active Comparator|Silodosin|"Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.
~This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).
~The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
16604715|NCT02581826|Placebo Comparator|Placebo|"Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.
~This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).
~The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
16604716|NCT02581813|Experimental|RDa (Recommended dairy group)|4 servings of dairy per day + exercise (3 times per week with combination of aerobic and resistance exercise).
16604717|NCT02581813|Experimental|LDa (Low dairy group)|0-1 serving of dairy per day + exercise (the same as the RDa group)
16604718|NCT02581813|No Intervention|GCon (growth controls)|This no-intervention group will serve as the control to account for growth during the study.
16604719|NCT02581800|No Intervention|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
16604720|NCT02581800|Experimental|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
16604759|NCT02581540||Suspected Cardiac Chest Pain|This cohort is observed for the incidence of MACE (death, non-fatal myocardial infarction and emergency revascularisation)
16604721|NCT02581787|Experimental|Treatment (fresolimumab, SABR)|In Phase 1: Patients receive fresolimumab IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12 in total of 5 subjects. In Phase 2: . Fresolimumab will be administered IV at the dose selected in the preceding Phase 1 on Days 1, 15 and 36 and SABR will be administered in 4 fractions between Days 8 and 12.
16604722|NCT02581774||term isolated oligohydramnios|Labor Monitoring and normal delivery tracking
16604723|NCT02581774||prolonged pregnancies|Labor Monitoring and normal delivery tracking
16604724|NCT02581761|Experimental|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
16604725|NCT02581761|Placebo Comparator|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
16604726|NCT02581748|Experimental|safety|Assessment of safety of HLX02 at different doses
16604727|NCT02581748|Active Comparator|PK comparative|Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin®(U.S. and German)
16604728|NCT02581735||Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.
~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
16604729|NCT02581722|Experimental|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
16604730|NCT02581709|Experimental|Countering cognitive impairment|Each participant will complete neuropsychological assessments at baseline (prior to chemotherapy) and after chemotherapy. Patients identified as experiencing cognitive decline measured using Reliable Change Index on at least one cognitive function measure from before until after chemotherapy will be offered the intervention. Participants in the interventions will complete a neuropsychological assessment after completion of the intervention. Questionnaires to assess other non-cognitive factors e.g. quality-of-life will be administered at the end of chemotherapy to all participants and after the intervention to participants in the intervention.
16604731|NCT02581696|Other|Single arm|This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers. Subjects judged to be appropriate to this study by screening.
16604732|NCT02581683|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
16604733|NCT02581683|Active Comparator|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
16604734|NCT02581683|Sham Comparator|Sham|Participants in this arm will receive a sham adductor canal block
16604735|NCT02581670|Experimental|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
16604736|NCT02581657|Experimental|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
16604737|NCT02581657|Placebo Comparator|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
16604738|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
16604739|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
16604740|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
16604741|NCT02581631|Experimental|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
16604742|NCT02581618|Experimental|Study group|"Remote ischemic preconditioning arm
~Blood pressure cuff will be inflated up to 200 mmHg in the non-dominant arm for 5 minutes before guiding catheter engagement."
16604743|NCT02581618|No Intervention|Control group|No intervention will be performed. Percutaneous coronary intervention will be performed without ischemic preconditioning.
16604744|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
16604745|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
16604746|NCT02581592|Experimental|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
16604747|NCT02581592|Experimental|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
16604748|NCT02581579|Active Comparator|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
16604749|NCT02581579|Placebo Comparator|Placebo|MANITOL CAPSULES
16604750|NCT02581566|Active Comparator|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
16604751|NCT02581566|Active Comparator|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
16604752|NCT02581566|Other|control Group|30 patients will be given Intrathecal Bupivacaine
16604753|NCT02581553|Experimental|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
16604754|NCT02581553|Experimental|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
16604755|NCT02581553|Experimental|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).
16604756|NCT02581553|Experimental|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).
16604757|NCT02581553|Experimental|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
16604758|NCT02581553|Experimental|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
16604760|NCT02581527|Active Comparator|Rifampicin 150mg (Control)|2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)
16604761|NCT02581527|Experimental|Rifampicin 1200mg (Regimen 1)|2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)
16604762|NCT02581527|Experimental|Rifampicin 1800mg (Regimen 2)|2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)
16604763|NCT02581514|Experimental|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
16604764|NCT02581501|Experimental|Gemcitabine, ABRAXANE®, and Xeloda|"Level-1
~ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12.
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day
~Level 1
~ABRAXANE® 100 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day
~Level 2
~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 600 mg/m2 over 75 min Days 5 and 12
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day
~Level 3
~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 750 mg/m2 over 75 min Days 5 and 12
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day"
16604765|NCT02581488|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
16604766|NCT02581488|Active Comparator|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
16604767|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.
~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
16604768|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
16604769|NCT02581462|Experimental|FLOT alone|Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
16604770|NCT02581462|Experimental|FLOT + Herceptin/Pertuzumab|Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
16604771|NCT02581449|Experimental|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
16604772|NCT02581449|Placebo Comparator|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
16604773|NCT02581436|Experimental|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
16604774|NCT02581436|Active Comparator|Standard follow-up|Post Transplant surveillance based on standard of care.
16604775|NCT02581423|Experimental|Capecitabine|Participants will receive capecitabine for up to approximately 6 months.
16604776|NCT02581410|Experimental|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
16604777|NCT02581410|Active Comparator|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
16604778|NCT02581397|Experimental|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.
~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.
~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).
~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
16604779|NCT02581397|Experimental|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.
~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.
~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).
~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
16604780|NCT02581397|Active Comparator|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.
~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.
~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
16604781|NCT02581384|Experimental|Cohort 1 Dose Level 1 [Phase I]|Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
16604782|NCT02581384|Experimental|Cohort 1 Dose Level 2 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
16604783|NCT02581384|Experimental|Cohort 1 Dose Level 3 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
16604784|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
16604785|NCT02581384|Experimental|Cohort 2 Dose Level 3 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
16604786|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase II]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
16604787|NCT02581371|Experimental|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
16604788|NCT02581371|Placebo Comparator|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
16604789|NCT02581358|Experimental|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
16604790|NCT02581345|Experimental|M923|Participants assigned to receive M923
16604791|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
16604792|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
16604793|NCT02581332|Other|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
16604794|NCT02581319|Other|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
16604795|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
16604796|NCT02581293|Experimental|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
16604797|NCT02581293|Experimental|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
16604798|NCT02581293|Experimental|Both of them will be closed|Group 3: Both of them will be closed
16604799|NCT02581293|Experimental|None of them will be closed|Group 4: None of them will be closed
16604800|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel during ECMO
16604801|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel after removing ECMO
16604802|NCT02581254|Experimental|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp <10mm
16604803|NCT02581254|Experimental|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp <10mm
16604804|NCT02581241|Experimental|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.
~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.
~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
16604805|NCT02581241|Active Comparator|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.
~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.
~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
16604806|NCT02581228||Training Set|The objective of the Training stage is to assess the predictive potential of ML-PrediCare for melanoma patients' response to Ipilimumab, Pembrolizumab and Nivolumab.
16604807|NCT02581228||Validation Set|The objective of the Validation stage is to test the predictive power of ML -PrediCare in an independent set of patients diagnosed with melanoma.
16604808|NCT02581215|Experimental|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:
~Oxaliplatin 85 mg/m2 over 2-4 hours
~Irinotecan 165 mg/m2 over 90 minutes
~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
~Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
16604809|NCT02581215|Placebo Comparator|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:
~Oxaliplatin 85 mg/m2 over 2-4 hours
~Irinotecan 165 mg/m2 over 90 minutes
~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
~Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
16604810|NCT02581202||HIV-1 infected participants|HIV-1-infected participants on any triple highly active antiretroviral therapy (HAART) with plasma HIV-1 ribonucleic acid (RNA) level < 50 copies/mL for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically appropriate to lopinavir with ritonavir plus lamivudine (LPV/r+3TC) as decided by the physician in the routine clinical settings. Or HIV-1 infected participants who were switched on the dual therapy (LPV/r+3TC) no more than 60 days prior to enrollment.
16604811|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
16604812|NCT02581176|Experimental|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
16604813|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
16604814|NCT02581150|Other|Outpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during an ambulatory hospitalisation, with the use of an arterial closure device (ACD).
~The patients treated for PAD (Peripheral Arterial Disease) are informed and prepared in the morning of D0. The surgical endovascular procedure is performed at D0 before 1:00 p.m. The patients leave the hospital in the evening at D0 after a systematic visit."
16604815|NCT02581150|Other|Conventional inpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during a conventional hospitalisation, with or without ACD (ACD will be used at the discretion of the interventionalist).
~The patients treated for PAD arrive at the hospital the day before surgery (D-1). The surgical endovascular procedure takes place the next day (D0). The day after (D1), the patients leave the hospital after a systematic visit."
16604816|NCT02581137|Experimental|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
16604817|NCT02581124|Experimental|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
16604818|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
16604819|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
16604820|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
16604821|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
16604822|NCT02581072|Experimental|SB204 4%|SB204 4% once
16604823|NCT02581072|Experimental|SB204 8% or 12 %|SB204 8 or 12 % (supratherapeutic) once
16604824|NCT02581072|No Intervention|Moxifloxacillin|Moxifloxacillin 400 mg orally
16604825|NCT02581072|Placebo Comparator|Vehicle Gel|Placebo
16604826|NCT02581059|Experimental|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
16604827|NCT02581059|Active Comparator|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
16604828|NCT02581046|Experimental|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
16604829|NCT02581046|Experimental|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
16604830|NCT02581033|Experimental|Nucleoside analogue therapy cessation|To determine if a sustained virological response can be achieved after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
16604831|NCT02581020||1|Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.
16604832|NCT02581007|Experimental|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan & Post-transplant cyclophosphamide
16604833|NCT02580994|Experimental|Pembrolizumab + chemotherapy|Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease
16604834|NCT02580994|Active Comparator|Chemotherapy|4 cycles of cis/carboplatin and etoposide
16604835|NCT02580981|Experimental|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).
~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
16604836|NCT02580968|Experimental|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
16604837|NCT02580968|Active Comparator|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
16604838|NCT02580955|Experimental|LEGFLOW DCB|patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
16604839|NCT02580942|Experimental|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
16604840|NCT02580942|Sham Comparator|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
16604841|NCT02580929|Experimental|radiation|
16604842|NCT02580929|No Intervention|no radiation|
16604843|NCT02580916|Experimental|Group 1 (Postal)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team and deemed 'low risk'; SCQOLIT questionnaires will be administered by post.
16604844|NCT02580916|Experimental|Group 2 (Clinic-based)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team, for whom all aspects of the study will be conducted in the Dermatology clinic. SCQOLIT questionnaires will be administered according to the protocol.
16604845|NCT02580916|No Intervention|Group 3 (Interviews)|A Qualitative Researcher (Co-Investigator) will undertake structured interviews with approximately 20 patients from both Group 1 and 2. Potential participants will be invited to volunteer their contact details at the time of consent to the Questionnaire study. This is optional; they may refuse to do so and still take part in the main questionnaire study. The patient will then be contacted by the Qualitative Researcher (Co-Investigator) at a later date and subsequently consented for the interview.
16604846|NCT02580916|No Intervention|Group 4 (Clinician focus group)|We aim to discuss the project at the end of the study period in the same setting, to establish staff perspectives on the study, to establish usefulness of the SCQOLIT tool and to identify any barriers to implementation.
16604943|NCT02580227|Placebo Comparator|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
16605041|NCT02579590||Implanon group|"This group are using Implanon  (etonogestrel implant) 68 mg implant for 6-12 month"
16604847|NCT02580890|Experimental|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
16604848|NCT02580890|Sham Comparator|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
16604849|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
16604850|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
16604851|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
16604852|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
16604853|NCT02580851|Other|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
16604854|NCT02580851|Other|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol [21-23]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
16604855|NCT02580838|Experimental|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
16604856|NCT02580838|Active Comparator|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
16604857|NCT02580838|No Intervention|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
16604858|NCT02580825|Active Comparator|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
16604859|NCT02580825|Active Comparator|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
16604860|NCT02580812|Experimental|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
16604861|NCT02580812|Active Comparator|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
16604862|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
16604863|NCT02580786|Experimental|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
16604864|NCT02580786|No Intervention|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
16604865|NCT02580773|Other|Prophylactic anticoagulation|
16604866|NCT02580773|Experimental|Curative anticoagulation|
16604867|NCT02580760||Cosmetic silicone injection|People responding to inclusion criteria with a history of cosmetic silicone injection
16604868|NCT02580747|Experimental|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
16604869|NCT02580734|Placebo Comparator|placebo|tablet without melatonin
16604870|NCT02580734|Experimental|melatonin|tablet with melatonin
16604871|NCT02580721|Active Comparator|Thick mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
16604872|NCT02580721|Experimental|Thin mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
16604873|NCT02580721|Experimental|Thickened mucosa with connective tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Soft tissue augmentation will be performed with sub epithelial connective tissue graft.
16604874|NCT02580721|Experimental|Thickened mucosa with ADM|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Acellular dermal matrix, thick 1 x 4 cm will be used for vertical soft tissue augmentation.
16604875|NCT02580708|Experimental|Rociletinib and Trametinib|
16604876|NCT02580695|Experimental|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)
~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB
~Arm 2a: single infusion group. UC-MSCs at 0 month
~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
16604877|NCT02580695|Active Comparator|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
16605039|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
16604878|NCT02580682|Experimental|Sanfu herbal patch|one kind of acupoint application which used in hot dog days of summer,The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba asarum), Bai Jie Zi (Semen Sinapis Albae), and Rou Gui (Cortex Cinnamomi) at a ratio of 2:2:1:1:2:1.The bilateral Feishu (BL13), Pishu (BL20), Shenshu (BL23), Neiguan (PC6), and Guanyuan (CV4) acupoints were selected for treatment
16604879|NCT02580682|Experimental|Sanfu moxibustion|use moxibustion in hot dog days of summer,and adopting the indirect moxibustion box method at the bilateral BL13, BL20, and BL23 acupoints
16604880|NCT02580682|Experimental|Sanfu herbal patch and Sanfu moxibustion|use herbal patch and moxibustion together in hot dog days
16604881|NCT02580682|No Intervention|controlled|patients in this group will not accept herbal patch or moxibustion therapy in these 3 years. After the 3-year experimental period they will be offered corresponding treatments for free as well, so they are in our wait list.
16604882|NCT02580669|Experimental|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
16604883|NCT02580669|Experimental|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
16604884|NCT02580669|Experimental|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
16604885|NCT02580656|Experimental|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
16604886|NCT02580643||APS Injection|Autologous Protein Solution
16604887|NCT02580630|Active Comparator|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.
~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.
~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
16604888|NCT02580630|Active Comparator|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.
~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.
~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
16604889|NCT02580617|Experimental|ALLO-ASC|Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells
16604890|NCT02580604|Experimental|Calcium Infusion|Continuous calcium infusion during exercise
16604891|NCT02580604|Placebo Comparator|Saline Infusion|Continuous saline infusion during exercise
16604892|NCT02580591|Experimental|Empagliflozin low dose|
16604893|NCT02580591|Experimental|Empagliflozin high dose|
16604894|NCT02580591|Experimental|Empagliflozin medium dose|
16604895|NCT02580591|Placebo Comparator|Placebo|
16604896|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
16604897|NCT02580552|Experimental|Part A, MF|Intratumoral Injection of cobomarsen
16604898|NCT02580552|Experimental|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
16604899|NCT02580552|Experimental|Part C, MF|Subcutaneous or intravenous administration of cobomarsen as monotherapy
16604900|NCT02580552|Experimental|Part D, CLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
16604901|NCT02580552|Experimental|Part E, DLBCL, activated B-cell (ABC) subtype|Subcutaneous or intravenous administration of cobomarsen as monotherapy
16604902|NCT02580552|Experimental|Part F, ATLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
16604903|NCT02580539|Experimental|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
16604904|NCT02580539|Experimental|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
16604905|NCT02580526|Active Comparator|V-E mask ventilation technique crossover C-E mask ventilation|
16604906|NCT02580526|Active Comparator|C-E mask ventilation technique crossover V-E mask ventilation|
16604907|NCT02580513|No Intervention|Control|3 days with normal circadian alignment.
16604908|NCT02580513|Experimental|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
16604909|NCT02580500|Active Comparator|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
16604910|NCT02580500|Active Comparator|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
16604911|NCT02580487||retrospective group|Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files
16604912|NCT02580487||Prospective group|Patients who were interviewed before and after surgery when they were at the hospital
16604913|NCT02580474|Experimental|Daclatasvir plus Asunaprevir|
16604914|NCT02580461|Experimental|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
16607650|NCT02562534|Other|Patients with rhythm troubles|Patients with rhythm troubles
16604915|NCT02580461|No Intervention|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
16604916|NCT02580448|Experimental|Female Triple Negative Breast Cancer Patients|TNBC Patients - Enrollment is complete in this cohort
16604917|NCT02580448|Experimental|Female Estrogen Receptor (+) Breast Cancer Patients|Female ER(+) BC Patients - Enrollment is complete in this cohort
16604918|NCT02580448|Experimental|Male Breast Cancer Patients|Locally advanced or metastatic males with BC
16604919|NCT02580409|Other|Single-arm studies|Behavioral Intervention
16604920|NCT02580396|Other|Patients eligible for CanADVICE+® (smart phone app)|
16604921|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.
~When both needles were positioned inadequately for a facet joint."
16604922|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.
~when one of the needles for a facet joint medial branch was placed inadequately."
16604923|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.
~When all needles were placed adequately.'"
16604924|NCT02580370|Experimental|Dose A|Botulinum toxin type A
16604925|NCT02580370|Placebo Comparator|Dose B|Placebo comparator
16604926|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
16604927|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
16604928|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
16604929|NCT02580344|Other|Ibuprofen|
16604930|NCT02580331|Placebo Comparator|SRP and placebo|Oral prophylaxis followed by placement of placebo gel
16604931|NCT02580331|Active Comparator|SRP and 1% metformin|Oral prophylaxis followed by placement of 1% metformin gel
16604932|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
16604933|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
16604934|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
16604935|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
16604936|NCT02580279|Experimental|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
16604937|NCT02580279|Placebo Comparator|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
16604938|NCT02580253|Experimental|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
16604939|NCT02580253|Active Comparator|mFOLFOX6|Oxaliplatin (85 mg/m2 )+Fluorouracil (2800 mg/m2 ) q2w
16604940|NCT02580240|Placebo Comparator|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
16604941|NCT02580240|Experimental|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
16604942|NCT02580227|Active Comparator|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
16607651|NCT02562534|Other|Volunteers|Volunteers with normal ECG
16604944|NCT02580214|Experimental|Acerto|Preoperative immune nutrition for 5 days (Impact, Nestle) Preoperative fasting of 2h with a drink containing 12% maltodextrine No intravenous fluids postoperatively
16604945|NCT02580214|No Intervention|Control|No immune nutrition Preoperative fasting of 6-8 h Crystalloid intravenous fluids until PO day 1
16604946|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.
~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
16604947|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
16604948|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
16604949|NCT02580175|Active Comparator|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation
16604950|NCT02580175|Active Comparator|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
16604951|NCT02580162|Active Comparator|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
16604952|NCT02580162|Experimental|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
16604953|NCT02580162|Experimental|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
16604954|NCT02580162|Experimental|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
16604955|NCT02580149|Active Comparator|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
16604956|NCT02580149|Active Comparator|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
16604957|NCT02580123|Experimental|Experimental group|Received the intervention program.
16604958|NCT02580123|No Intervention|Control group|received the standard care
16604959|NCT02580110|Experimental|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
16604960|NCT02580110|Experimental|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
16604961|NCT02580110|Experimental|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
16604962|NCT02580097||Stroke|Ischemic stroke patients with sympton onset in 24 hours and no contradiction to MRI scan
16604963|NCT02580084|Active Comparator|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
16604964|NCT02580084|Experimental|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
16604965|NCT02580071|Experimental|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:
~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
16604966|NCT02580071|No Intervention|Control|Control group will receive standard of care
16604967|NCT02580058|Experimental|avelumab|Arm A: avelumab alone
16604968|NCT02580058|Experimental|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
16604969|NCT02580058|Active Comparator|PLD|Arm C: PLD alone
16604970|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
16604971|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
16604972|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
16604973|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
16604974|NCT02580019|No Intervention|conventional stroke treatment|Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation
16604975|NCT02580019|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation
16607803|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
16604976|NCT02580006|Experimental|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.
~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
16604977|NCT02580006|Experimental|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.
~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
16604978|NCT02579993|Experimental|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
16604979|NCT02579980|Experimental|DCE and DWI MRI group|Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.
16604980|NCT02579967|Experimental|1/ IOC Arm-Closed with amendment L (07/05/2019)|Immunosuppression Only Conditioning Arm
16604981|NCT02579967|Experimental|2/ RIC Arm - Closed with Amendment L (07/05/2019)|Reduced Intensity Conditioning Arm
16604982|NCT02579967|Experimental|3/ MAC Arm-Closed with amendment L (07/05/2019)|Myeloablative Conditioning Arm
16604983|NCT02579967|Experimental|4/RIC-MMF Arm|Reduced Intensity Conditioning with MMF duration de-escalation design
16604984|NCT02579967|No Intervention|5/Donor Arm|Donor
16604985|NCT02579954|No Intervention|control group|
16604986|NCT02579954|Experimental|intervention|Rehabilitation
16604987|NCT02579941|Experimental|Pregnant women at term, vaginal childbirth|
16604988|NCT02579941|Experimental|Pregnant women at term, cesarean delivery|
16604989|NCT02579941|Experimental|Female volunteers, age 18 to 40|
16604990|NCT02579928|Experimental|Ketamine|Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
16604991|NCT02579928|Experimental|Midazolam|Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),
16604992|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
16604993|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
16604994|NCT02579902|Active Comparator|Vitamin D3|50000 IU vitamin D3 capsule, one capsule every 2 weeks for 6 months.
16604995|NCT02579902|Placebo Comparator|placebo|Placebo capsule, one capsule every 2 weeks for 6 months.
16604996|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
16604997|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
16604998|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
16604999|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
16605000|NCT02579863|Experimental|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
16605001|NCT02579863|Active Comparator|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
16605004|NCT02579837|No Intervention|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
16605005|NCT02579837|Experimental|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.
~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
16605040|NCT02579590||DEMPA group|This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
16605006|NCT02579824|Experimental|DS-3032b|"Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.
~Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase."
16605007|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
16605008|NCT02579798|Experimental|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
16605009|NCT02579798|Active Comparator|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
16605010|NCT02579785|Experimental|mhealth intervention|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number. Also receives Mobile phone based intervention for post-abortion contraceptive uptake.
16605011|NCT02579785|No Intervention|Standard Care|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number.
16605012|NCT02579772|Active Comparator|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
16605013|NCT02579772|Placebo Comparator|Placebo|Treatment with placebo pills
16605014|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
16605015|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
16605016|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
16605017|NCT02579746|Experimental|intervention|The intervention group received usual care plus the DASHNa-CC intervention.
16605018|NCT02579746|Active Comparator|control|The control group received usual care.
16605019|NCT02579733|Active Comparator|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
16605020|NCT02579733|Placebo Comparator|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
16605021|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
16605022|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
16605023|NCT02579707|Active Comparator|Treatment A: Unfed|Treatment A: Single oral dose of AG-120 at Hour 0 on Day 1, following a 10-hour overnight fast.
16605024|NCT02579707|Active Comparator|Treatment B: Fed|Treatment B: Single oral dose of AG-120 at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
16605025|NCT02579707|Experimental|Part 2 Single Dose|PART 2 is an open-label study to determine the safety and PK parameters of a single 1000-mg oral dose of AG-120.
16605026|NCT02579681|Experimental|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
16605027|NCT02579668|Experimental|Language therapy in BSL|Working with Deaf practitioners to provide language activities in British Sign Language aimed at developing children's language skills.
16605028|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
16605029|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
16605030|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
16605031|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
16605032|NCT02579642|Placebo Comparator|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
16605033|NCT02579642|Experimental|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
16605034|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
16605035|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
16605036|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
16605037|NCT02579616|Experimental|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
16605038|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
16605042|NCT02579590||Cerazette group|This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
16605043|NCT02579590||Normal healthy group|Those women not using any method of contraception
16605044|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
16605045|NCT02579564|Experimental|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
16605046|NCT02579564|Active Comparator|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
16605047|NCT02579551|Experimental|Treatment (surgical excision)|Patients undergo surgical excision of the skin lesion consisting of 1 and 2 mm circumferential margins during visit 1.
16605048|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
16605049|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
16605050|NCT02579525|Experimental|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
16605051|NCT02579525|Active Comparator|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
16605052|NCT02579512||Extra-corporeal ECG Signal Analysis|
16605053|NCT02579499|Active Comparator|Fixed high-potent statin group|According to 2013 ACC/AHA guideline, patients will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels.
16605054|NCT02579499|Experimental|Targeted LDL-C goal statin group|Patients will be tiltrated statin intensity guided by follow-up LDL-C level
16605055|NCT02579473|Experimental|Cohort 0|"Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
16605056|NCT02579473|Experimental|Cohort 1|"Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
16605057|NCT02579473|Experimental|Cohort 2|"Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
16605058|NCT02579473|Experimental|Cohort 3|"Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal wash-out PK of rotigotine and pro-drug SER-214."
16605059|NCT02579460|Experimental|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
16605060|NCT02579434|Experimental|Male young adults|Arm 1: Male healthy volunteers aged from 20 to 45 years Midazolam (IV) on day 1
16605061|NCT02579434|Experimental|Male elderly adults|Arm 2: Male healthy volunteers aged over 45 years Midazolam (IV) on day 1
16605062|NCT02579434|Experimental|Female elderly adults|Arm 3: Female healthy volunteers aged over 45 years Midazolam (IV) on day 1
16605063|NCT02579434|Experimental|Female young adults|Arm 4: Female healthy volunteers aged 20 to 45 years Midazolam (IV) on day 1, Day 15
16605064|NCT02579421|Active Comparator|Males - Progesterone|200 mg progesterone BID
16605065|NCT02579421|Placebo Comparator|Males - Placebo|placebo BID
16605066|NCT02579421|Active Comparator|Females - Progesterone|200 mg progesterone BID
16605067|NCT02579421|Placebo Comparator|Females - Placebo|placebo BID
16605068|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
16605069|NCT02579395|Experimental|With spouse/romantic partner|
16605070|NCT02579395|Experimental|Without spouse/romantic partner|
16605071|NCT02579395|Other|Control|No Intervention
16605072|NCT02579382|Placebo Comparator|TDF + placebo|"Main Study Phase: Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily for up to 48 weeks + placebo administered orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
16605073|NCT02579382|Experimental|TDF + Vesatolimod 1 mg|"Main Study Phase:TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 1 mg tablet orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
16605074|NCT02579382|Experimental|TDF + Vesatolimod 2 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 2 mg tablet orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
16605075|NCT02579382|Experimental|TDF + Vesatolimod 4 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 4 mg tablet orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
16605076|NCT02579369|Experimental|ALLO-ASC-DFU|
16605077|NCT02579369|Active Comparator|Conventional Therapy|
16605078|NCT02579356|Experimental|Part1-A|The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
16605079|NCT02579356|Experimental|Part1-B|The Part1-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan once a day for 6 days in period 2.
16605137|NCT02578992|No Intervention|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
16605080|NCT02579356|Experimental|Part2-A|The Part2-A of groups take Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
16605081|NCT02579356|Experimental|Part2-B|The Part2-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Atorvastatin once a day for 6 days in period 2.
16605082|NCT02579343|Experimental|Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
16605083|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
16605084|NCT02579330|Experimental|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
16605085|NCT02579330|Sham Comparator|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
16605086|NCT02579317|Experimental|Resonance Breathing|Breathing is paced to the cardiovascular resonance frequency where heart, respiratory, and brain signals become aligned. This can potentially positively impact cognitive-emotional functioning.
16605087|NCT02579317|Placebo Comparator|Non-Resonance Breathing|Breathing is paced at a non-resonance frequency. It does not align heart, respiratory, and brain signals, and thus does not impact cognitive-emotional functioning.
16605088|NCT02579291|Experimental|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
16605089|NCT02579291|Active Comparator|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
16605090|NCT02579278||mrEMVI positive rectal tumours|20 patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).
16605091|NCT02579278||mrEMVI negative rectal tumours|20 patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.
16605092|NCT02579265|Experimental|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
16605093|NCT02579265|Active Comparator|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
16605094|NCT02579252|Experimental|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.
~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
16605095|NCT02579252|Placebo Comparator|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
16605096|NCT02579239|Experimental|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
16605097|NCT02579239|Placebo Comparator|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
16605098|NCT02579226|Experimental|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
16605099|NCT02579226|Experimental|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
16605100|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
16605101|NCT02579200|Active Comparator|Inspiratory Muscle Training (IMT)|POWERbreathe®KHA (IMT group)
16605102|NCT02579200|Sham Comparator|Sham Training|POWERbreathe®KH2 (sham group)
16605103|NCT02579187|Placebo Comparator|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
16605104|NCT02579187|Active Comparator|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
16605138|NCT02578979|Experimental|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
16605139|NCT02578979|Active Comparator|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
16605105|NCT02579187|Active Comparator|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
16605106|NCT02579187|Active Comparator|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
16605107|NCT02579174|Other|Manual (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for both the tibia component and the femur component
16605108|NCT02579174|Other|Manual (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for the tibia component and custom instrumentation for the femur component
16605109|NCT02579174|Other|Custom (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for both the tibia component and the femur component
16605110|NCT02579174|Other|Custom (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for the tibia component and manual instrumentation for the femur component
16605111|NCT02579161|Active Comparator|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period
~Intervention drug to be determined based on patient history etc."
16605112|NCT02579161|Active Comparator|Continued antibiotics|"Continued antibiotics until the removal of any external catheters
~Intervention drug to be determined based on patient history etc."
16605113|NCT02579148|Experimental|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
16605114|NCT02579148|Experimental|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
16605115|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
16605116|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
16605117|NCT02579109|Other|autistic patient|patient with autistic trouble
16605118|NCT02579109|Other|healthy volunteers|healthy volunteers
16605119|NCT02579096|Active Comparator|Allopurinol / Sham Comparator (Febuxostat)|Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol
16605120|NCT02579096|Active Comparator|Febuxostat / Sham Comparator (Allopurinol)|Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat
16605121|NCT02579083|Experimental|Segment A: Single MB66 Administration|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
16605122|NCT02579083|Placebo Comparator|Segment B: Repeated Administrations Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
16605123|NCT02579083|Experimental|Segment B: Repeated Administrations MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
16605124|NCT02579070|Experimental|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
16605125|NCT02579070|Placebo Comparator|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
16605126|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
16605127|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
16605128|NCT02579044|Other|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
16605129|NCT02579031|Active Comparator|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
16605130|NCT02579031|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
16605131|NCT02579018|Experimental|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
16605132|NCT02579018|Experimental|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
16605133|NCT02579018|Experimental|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
16605134|NCT02579005|Experimental|Patients with a living donor|Radiation + PBMC
16605135|NCT02579005|Experimental|Patients with a UCB donor|Radiation + UCB
16605136|NCT02578992|Experimental|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
16605140|NCT02578966|Experimental|Motivational Interview|INTERVENTION GROUP: in this group, composed of 6 UBS, the children and their respective mothers/fathers/responsible adults will be attended by the dentists at least once a year with an approach based on the Motivational Interview.
16605141|NCT02578966|Active Comparator|Traditional health education|CONTROL GROUP: in this group, composed of 6 UBS, the children and their respective mother/fathers/responsible adults will be attended by the dentists at least once a year based on the recommendations by the Brazilian Ministry of Health (BRASIL,2008-a) and on SSC-GHC's protocol (BRASIL, 2008-b). Additionally, the professional guidance script and the parents' booklet of SSC-GHC's oral health Program may be used.
16605142|NCT02578953|Experimental|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
16605143|NCT02578953|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
16605144|NCT02578940|Experimental|Single arm|Single intravenous administration of 18F-Fluciclovine for PET Scan
16605145|NCT02578927|Experimental|GT+Ex|Ingestion of one dose of 2 g of green tea (GT) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
16605146|NCT02578927|Placebo Comparator|PL+Ex|Ingestion of one dose 2 g of placebo (PL) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
16605147|NCT02578927|Active Comparator|Green Tea|Ingestion of one dose 2g of green tea (GT) at 10 minutes after the period of rest. In this section the volunteers does not practice aerobic exercise.
16605148|NCT02578914|Experimental|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
16605149|NCT02578914|Sham Comparator|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
16605150|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
16605151|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
16605152|NCT02578888|Active Comparator|Palliative Therapy|EORTCQLQ-30 and FAMCARE questionnaire every 6 weeks for 3 visits.
16605153|NCT02578888|Experimental|Palliative Therapy+ idiographic|EORTC QLQ-30, and FAMCARE questionnaire every 6 weeks for 3 visits plus patients undergo idiographic assessment.
16605155|NCT02578862|Experimental|Total Intravenous|Intravenous propofol for maintenance of anesthesia
16605156|NCT02578862|Active Comparator|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
16605157|NCT02578849||PD_no_LID|Patients with Parkinson´s disease without dyskinesia
16605158|NCT02578849||PD_LID|Patients with Parkinson´s disease with L-DOPA induced dyskinesia
16605159|NCT02578849||HC|Health controls, age-mathced.
16605160|NCT02578836|Experimental|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
16605161|NCT02578823|Experimental|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.
~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).
~A total of 40 participants will be enrolled."
16605162|NCT02578823|Active Comparator|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).
~A total of 20 participants will be enrolled."
16605163|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
16605164|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
16605165|NCT02578797|Experimental|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
16605166|NCT02578784|Placebo Comparator|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
16605167|NCT02578784|Active Comparator|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
16605168|NCT02578771|Experimental|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
16605169|NCT02578771|Experimental|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
16605170|NCT02578771|Active Comparator|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep [Chlorhexidine gluconate(CHG)/IPA] Teal Tint
16605171|NCT02578771|Placebo Comparator|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
16605172|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
16605173|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
16605174|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
16605175|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
16605176|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
16605177|NCT02578732|Experimental|FOLFOXA|"Schema:
~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**
~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment
~Antiemetics will be administered as per standard institutional policy."
16605178|NCT02578719|Placebo Comparator|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
16605179|NCT02578719|Placebo Comparator|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
16605180|NCT02578706|Active Comparator|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
16605181|NCT02578706|Active Comparator|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
16605182|NCT02578706|Placebo Comparator|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
16605183|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
16605184|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.
16605185|NCT02578667|No Intervention|Gorbly Compression not needed|
16605186|NCT02578667|Experimental|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
16605187|NCT02578654|Experimental|Interventions|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
16605188|NCT02578641|Experimental|Arm A|"4 cycles* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.
~*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion.
~As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days"
16605189|NCT02578641|Active Comparator|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
16605190|NCT02578628|Active Comparator|Active|These subjects will continue to receive Patient Engagement services.
16605191|NCT02578628|No Intervention|Control|These patients will have all Patient Engagement services discontinued.
16605192|NCT02578602|Experimental|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
16605193|NCT02578589|Active Comparator|surgery|
16605194|NCT02578589|Active Comparator|Conservative treatment|
16605195|NCT02578576||patients with flare-up|Disease flare-up is demonstrated by coloscopy at one month after resection.
16605196|NCT02578576||patients without flare-up|No flare-up is found by coloscopy at one month after resection.
16605197|NCT02578550|Experimental|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
16605198|NCT02578550|Experimental|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
16605199|NCT02578537|Experimental|Ticagrelor group|ticagrelor 180mg loading, followed by 90mg bid for 30 days
16605200|NCT02578537|Active Comparator|Clopidogrel group|clopidogrel 600mg loading, followed by 75mg/d for 30 days
16605201|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
16605202|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
16605203|NCT02578511|Experimental|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.
~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
16605204|NCT02578498|Placebo Comparator|High carbohydrate diet|high carbohydrate intake
16605205|NCT02578498|Active Comparator|Low carbohydrate diet|low carbohydrate intake
16605206|NCT02578485|Experimental|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
16605207|NCT02578485|Active Comparator|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
16605208|NCT02578485|Placebo Comparator|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
16605209|NCT02578485|Placebo Comparator|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
16605210|NCT02578485|Sham Comparator|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
16605211|NCT02578472|Experimental|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
16605212|NCT02578472|Experimental|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
16605213|NCT02578472|Experimental|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
16605214|NCT02578472|Experimental|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
16605215|NCT02578472|Experimental|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
16605216|NCT02578472|Experimental|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
16605217|NCT02578459|Experimental|Intrathecal Drug Delivery (ITDD)|These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain.
16605218|NCT02578459|Active Comparator|Conventional Medical Management (CMM)|These subjects will be treated with conventional medical management to treat their pain.
16605219|NCT02578446|Experimental|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
16605220|NCT02578446|Active Comparator|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
16605221|NCT02578433|Experimental|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
16605222|NCT02578433|Other|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
16605223|NCT02578420|Placebo Comparator|open-label placebo|"Participants (N=40) will have the information that they are receiving an inert cream (i.e. placebo). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes. The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary."
16605224|NCT02578420|Sham Comparator|deceptive placebo|"Participants (N=40) will have the information that they are receiving an analgesic cream (Antidolor, containing Lidocain), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream."
16605225|NCT02578420|Placebo Comparator|control group|Participants (N=40) will have the information that they are receiving an inert control cream.
16605226|NCT02578420|No Intervention|no treatment group|"Participants (N=40) will be told that they are in the no treatment group and that they will not receive an analgesic cream."
16605227|NCT02578407|Experimental|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
16605228|NCT02578394|Active Comparator|Group A|Anakinra 100mg and Placebo Depo-Medrone
16605229|NCT02578394|Active Comparator|Group B|Depo-Medrone 120mg and Placebo (Anakinra)
16605230|NCT02578381|Experimental|Boston Scientific PW versus St Jude PW|Performance of Boston Scientific PW vs St Jude PW
16605231|NCT02578381|Experimental|Boston Sci PW vs Boston Sci PW|Boston Sci PW vs Boston Sci PW
16605232|NCT02578381|Active Comparator|St Jude PW versus St Jude PW|Performance of St Jude PW vs St Jude PW
16605233|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP
~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).
~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.
~For HER-2 positive disease, trastuzumab should be added:
~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
16605234|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)
~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).
~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.
~For HER-2 positive disease, trastuzumab should be added:
~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
16605235|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
16605236|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
16605237|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
16605238|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
16605239|NCT02578329|Experimental|Med Diet|Intensively advised Mediterranean diet
16605240|NCT02578329|Active Comparator|Low Fat diet|usual low-fat dietary advice
16605241|NCT02578316|Experimental|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
16605242|NCT02578303|Experimental|Dementia group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).
~ROC method will be used to find a threshold value of IAH that separates the two groups.
~Interventions:
~Vascular flow measurement by PC-MRI
~Neuropsychological assessment
~Registration of sleep apnea
~Registration of blood pressure
~ECG holters
~Blood test
~Geriatric standard evaluation"
16605243|NCT02578303|Other|control group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).
~ROC method will be used to find a threshold value of IAH that separates the two groups.
~Interventions:
~Vascular flow measurement by PC-MRI
~Neuropsychological assessment
~Registration of sleep apnea
~Registration of blood pressure
~ECG holters
~Blood test
~Geriatric standard evaluation"
16605244|NCT02578290|Experimental|Treatment|Clinical Decision Support (CDS)
16605245|NCT02578290|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
16605246|NCT02578277|Experimental|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
16605247|NCT02578264||All participants|All subjects enrolled in the study will provide tumor and normal tissue and blood samples.
16605248|NCT02578251|Experimental|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
16605249|NCT02578251|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
16605250|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
16605251|NCT02578212|Placebo Comparator|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
16605252|NCT02578212|Sham Comparator|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
16605253|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
16605254|NCT02578186|Experimental|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
16605255|NCT02578186|Placebo Comparator|Placebo|Placebo elixir taken when subjects had trouble falling asleep
16605256|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
16605257|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
16605285|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
16605286|NCT02577991|No Intervention|Control group|No steroid
16605258|NCT02578160|Experimental|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
16605259|NCT02578160|Active Comparator|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
16605260|NCT02578147|Experimental|Mighty Girls|Girls in this group complete 3 different activities after school: 6 classroom sessions, 4 DRAMA-RAMA game play sessions, and 4 short game experience surveys. Classroom sessions are 1 hour long, 3 days a week for 2 weeks. Topics include: goal setting, choices and their effects; defining what makes a behavior risky; learning how to not get talked into doing risky things by friends (e.g., going to a party at a house where parents are not home); and learning to be critical of TV shows and other media that make it seem like lots of teens are having sex. These sessions teach girls skills and strategies that help them score game points in DRAMA-RAMA. These are important skills and strategies that they can use in everyday life to make wise choices. Classroom sessions are designed to be fun.
16605261|NCT02578147|Active Comparator|Game Girls|Girls in this group take part in activities that can be done from home or anywhere they have Wi-Fi access: 4 Science Valley game play sessions and 4 short game experience surveys. Science Valley is a web based game in which girls explore a virtual world and experiment with objects in this world using a computer, tablet or cell phone. Girls will play this game for about 20-30 minutes. There are no classroom sessions required to be able to play Science Valley. Science Valley is designed to be fun and to give girls a chance to build skills important to doing well in school: her problem solving and critical thinking skills. Girls will be given a link to use to access Science Valley on the internet. At the end of the game, they do a short game experience survey that asks questions about how easy, how hard, how fun etc. it was to play Science Valley. This survey will appear on the screen at the end of the Science Valley game play session.
16605262|NCT02578134|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
16605263|NCT02578134|Sham Comparator|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
16605264|NCT02578121|Experimental|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
16605265|NCT02578108|Active Comparator|no diagnostic genicular nerve blocks|no diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
16605266|NCT02578108|Active Comparator|diagnostic genicular nerve blocks|Set of diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
16605267|NCT02578095|Placebo Comparator|Placebo|Placebo QD
16605268|NCT02578095|Experimental|VK5211- 0.5mg|0.5mgQD
16605269|NCT02578095|Experimental|VK5211- 1.0mg|1.0mg QD
16605270|NCT02578095|Experimental|VK5211- 2.0mg|2.0mg QD
16605271|NCT02578082|Experimental|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR <30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
16605272|NCT02578082|Experimental|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.
~Intervention is TD-4208, 175mcg, inhaled, single dose."
16605273|NCT02578069|Experimental|Experimental|NOVA Intracranial sirolimus eluting stent system
16605274|NCT02578069|Active Comparator|Control|Apollo Intracranial stent system
16605275|NCT02578056|Experimental|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
16605276|NCT02578056|Sham Comparator|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
16605277|NCT02578043|Experimental|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
16605278|NCT02578043|Active Comparator|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
16605279|NCT02578043|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
16605280|NCT02578030|Experimental|SHP465 12.5 mg|A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
16605281|NCT02578030|Experimental|SHP465 25 mg|A single dose of SHP465 25 mg for Subjects aged 13-17 years
16605282|NCT02578017|Experimental|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
16605283|NCT02578017|No Intervention|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
16605284|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
16607804|NCT02561572|Experimental|Intervention|Acupuncture at the Yintang point for 30 minutes.
16605287|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
16605288|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
16605289|NCT02577978|Other|Medacta Sphere|Ball-and-socket
16605290|NCT02577978|Other|Medacta PS|Cam-and-post
16605291|NCT02577965|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
16605292|NCT02577965|Active Comparator|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
16605293|NCT02577952||People with Lipodystrophy & family|People currently living with lipodystrophy and their family members.
16605294|NCT02577939|Experimental|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
16605295|NCT02577926|Experimental|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
16605296|NCT02577926|Active Comparator|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
16605297|NCT02577913||FC patch low|Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
16605298|NCT02577913||LNG-COC|Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol
16605299|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
16605300|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
16605301|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
16605302|NCT02577874||Chinese Subjects|7 blood glucose tests taken over a two hour period
16605303|NCT02577874||European Subjects|7 blood glucose tests taken over a two hour period
16605304|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
16605305|NCT02577848|Experimental|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
16605306|NCT02577848|Placebo Comparator|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
16605307|NCT02577835||Hypertensive patients|No intervention. Patients will be sumbitted to standard tests required for hypertension management, including ambulatory blood pressure monitoring, and pharmacologically treated according to recommendations of international guidelines. The registry will include data from subjects fulfilling the inclusion criteria and whose data are contained in existing databases collected by the participating centers and who are regularly followed-up at the center. New subjects can be enrolled for this project, but they must be submitted to ambualtory blood pressure monitoring because it is required for evaluating their hypertension status, according to current recommendations.
16605308|NCT02577822|Other|Short Stem Group|Short femoral stem
16605309|NCT02577822|Other|Long Stem Group|standard-length stem
16605310|NCT02577809|Active Comparator|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
16605311|NCT02577809|Active Comparator|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
16605312|NCT02577809|Active Comparator|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
16605313|NCT02577783|Experimental|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
16605314|NCT02577783|Active Comparator|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
16605315|NCT02577770|Experimental|200mg caffeine plus acupuncture|In healthy subjects
16605316|NCT02577770|Experimental|400mg caffeine plus acupuncture|In healthy subjects
16605317|NCT02577770|Placebo Comparator|Decaffeinated plus acupuncture|In healthy subjects
16605318|NCT02577757|Other|healthy volunteers|achieving functional MRI
16605319|NCT02577757|Experimental|Eligible patients with awakened surgery|achieving functional MRI
16605320|NCT02577744|Active Comparator|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
16605321|NCT02577744|Active Comparator|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
16605322|NCT02577731|Other|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
16605323|NCT02577731|Other|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
16605324|NCT02577731|Other|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
16605325|NCT02577718|Experimental|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
16605386|NCT02577289|Experimental|Test group (PRF)|Patients will undergo open sinus lift using PRF as sole augmentation material and placing implants simultaneously then Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
16605326|NCT02577705|Experimental|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
16605327|NCT02577705|Experimental|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
16605328|NCT02577705|No Intervention|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
16605329|NCT02577692|Experimental|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
16605330|NCT02577692|Experimental|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
16605331|NCT02577666|Experimental|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
16605332|NCT02577666|Experimental|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
16605333|NCT02577666|Other|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
16605334|NCT02577653|Other|subjects|participant undergoing posturographic evaluation
16605335|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
16605336|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
16605337|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
16605338|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
16605339|NCT02577614|Experimental|FEIBA|Single dose of commercially available FEIBA
16605340|NCT02577614|Placebo Comparator|Normal Saline|Single dose of NaCl 0.9%
16605341|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
16605342|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
16605343|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
16605344|NCT02577588|Experimental|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
16605345|NCT02577575|Experimental|Oxytocin|40 IU Oxytocin
16605346|NCT02577575|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
16605347|NCT02577549|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
16605348|NCT02577549|Active Comparator|Attention Control|The attention control intervention will cover an 18-month period. There will be four total face to face group meetings over the 18 months, with one meeting each at months 1, 6, 12, and 18; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
16605349|NCT02577536||1 All Subjects|No interventions
16605350|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours
16605351|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours
16605352|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
16605718|NCT02575248|Experimental|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
16605353|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
16605354|NCT02577497|Experimental|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
16605355|NCT02577497|Experimental|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
16605356|NCT02577484||Participants|Subjects who satisfy both general and angiographic inclusion/exclusion criteria, and who have the pressure measurement taken with the Navvus catheter.
16605357|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
16605358|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
16605359|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
16605360|NCT02577458|Experimental|CM082 plus everolimus|CM082 plus everolimus
16605361|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
16605362|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.
~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.
~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.
~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
16605363|NCT02577432|Active Comparator|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
16605364|NCT02577432|Active Comparator|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
16605365|NCT02577419|Experimental|Target Fortification|
16605366|NCT02577419|Experimental|Higher Initial Concentration|
16605367|NCT02577419|Active Comparator|Portagen Growth Reference|
16605368|NCT02577406|Experimental|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
16605369|NCT02577406|Active Comparator|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
16605370|NCT02577393|Experimental|prophylactic EGCG group|
16605371|NCT02577393|Experimental|therapeutic EGCG group|
16605372|NCT02577393|Placebo Comparator|conventional therapy group|
16605373|NCT02577380|Experimental|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
16605374|NCT02577380|No Intervention|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
16605375|NCT02577367|Experimental|Levothyroxine on empty stomach|Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
16605376|NCT02577367|Active Comparator|Levothyroxine during feeding|Levothyroxine will be given while the enteral feeding is running
16605377|NCT02577354|Experimental|Treatment|
16605378|NCT02577354|Experimental|Control|
16605379|NCT02577341|Experimental|Nimotuzumab|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.
16605380|NCT02577341|Active Comparator|Control|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.
16605381|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
16605382|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
16605383|NCT02577302|Experimental|CAN-Stim Group - CAN-Stim System|"Intervention: tibial medical device
~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
16605384|NCT02577302|Active Comparator|SNS Group - Interstim® System|"Intervention: SNS Medical device
~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
16605385|NCT02577289|Active Comparator|Control group ( Hydroxyappetite)|Patients will undergo open sinus lift using nano crystalline hydroxyapatite as augmentation material and placing implants simultaneously then evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
16605719|NCT02575248|Active Comparator|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
16605387|NCT02577276|Experimental|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
16605388|NCT02577250|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
16605389|NCT02577237|Experimental|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
16605390|NCT02577237|Active Comparator|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
16605391|NCT02577224|Experimental|Intervention|Participants randomized to the intervention group (patient-initiated treatment) will be asked to initiate their own treatment during the nine months they are taking part in the trial. Intervention group participants will receive information about when and how to initiate an appointment. Contact details for the service will be provided along with information on how quickly an appointment will be made, with whom and the procedure in the case of an emergency. All patients requesting an appointment will be booked in to the next available slot within the twice weekly ring-fenced nurse-led clinics. Any subsequent scheduled appointments will be cancelled and all future treatment will be initiated by the patient.
16605392|NCT02577224|No Intervention|Control|Participants in the control group will receive treatment as usual. This consists of scheduled appointments in the hospital-based nurse-led botulinum toxin clinic. The frequency with which these appointments takes place are based on clinical judgement, but tend to range between every 6 weeks to every 4 months.
16605393|NCT02577211|Experimental|Hipocaloric enteral nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
16605394|NCT02577211|Active Comparator|Normocaloric enteral nutrition|25 kcal per kg of body weight and 1.7 grams of protein per kg.
16605395|NCT02577198|Experimental|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
16605396|NCT02577198|Other|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
16605397|NCT02577185|Experimental|botulinum toxin type A|Experimental drug
16605398|NCT02577185|Placebo Comparator|sodium chloride 9 mg/ml|Vehicle drug
16605399|NCT02577172|Experimental|Exercise group|Aerobic- and Strength Training program
16605400|NCT02577172|Active Comparator|Control group|One lifestyle counseling session
16605401|NCT02577159|Experimental|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
16605402|NCT02577146|Experimental|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
16605403|NCT02577133|Active Comparator|Lactobacillus reuteri group|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
16605404|NCT02577133|Placebo Comparator|Placebo group|Placebo (5 drops) for 28 days
16605405|NCT02577120||Low TEWL|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.
16605406|NCT02577120||High TEWL - No treatment|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
16605407|NCT02577120||High TEWL - Epiceram skin barrier function|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
16605408|NCT02577120||High TEWL - Ceramiseal|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site
16605409|NCT02577120||High TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
16605410|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
16605411|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
16605412|NCT02577081|Experimental|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
16605413|NCT02577068|Active Comparator|nefopam group|
16605414|NCT02577068|Active Comparator|propacetamol group|
16605415|NCT02577068|Experimental|nefopam and propacetamol group|
16605416|NCT02577055|Active Comparator|myomectomy|Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
16605417|NCT02577055|Experimental|embolisation|Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)
16605418|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
16605419|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
16605420|NCT02577029|Experimental|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous [IV]) every 4 weeks for 48 weeks (13 doses)."
16607805|NCT02561572|No Intervention|Control|No intervention for 30 minutes.
16605421|NCT02577029|Experimental|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
16605422|NCT02577029|Experimental|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
16605423|NCT02577029|Experimental|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
16605424|NCT02577029|Experimental|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
16605425|NCT02577029|Experimental|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
16605426|NCT02577029|Experimental|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
16605427|NCT02577029|Experimental|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
16605428|NCT02577016|Experimental|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
16605429|NCT02577016|Active Comparator|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
16605430|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
16605431|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
16605434|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
16605435|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
16605436|NCT02576964|Experimental|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared [mg/m^2] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous [SC] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
16605437|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
16605438|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
16605439|NCT02576951|Experimental|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
16605440|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
16605441|NCT02576938|Experimental|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks
~(Triamcinolone 0.1% topical also permitted)"
16605442|NCT02576938|Placebo Comparator|Placebo|"Administered orally once daily, for 16 weeks
~(Triamcinolone 0.1% topical also permitted)"
16605443|NCT02576925||Eligible patients|Adults having had a transient diplopia during the last 8 days.
16605444|NCT02576912|Experimental|Active Delta-9-THC and Placebo Pregnenolone|
16605445|NCT02576912|Experimental|Active Delta-9-THC and Active Pregnenolone|
16605446|NCT02576912|Experimental|Placebo Delta-9-THC and Active Pregnenolone|
16605447|NCT02576912|Placebo Comparator|Placebo Delta-9-THC and Placebo Pregnenolone|
16605448|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
16605449|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
16605450|NCT02576886|Experimental|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
16605836|NCT02574520|Active Comparator|Part 2|SABER-Bupivacaine and Bupivacaine HCl
16605451|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
16605452|NCT02576860|Experimental|Treatment|CLS001 (Omignan) gel applied once daily
16605453|NCT02576860|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
16605454|NCT02576847|Experimental|Treatment|Omiganan gel applied once daily
16605455|NCT02576834|Experimental|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
16605456|NCT02576834|Other|Services as Usual (SAU)|client receives services they would normally receive within the community
16605457|NCT02576821|Other|Patients with Hippocampal sclerosis non AD|Patients with Hippocampal sclerosis non AD (n=40)
16605458|NCT02576821|Other|Patients with Alhzeimer's Disase|Patients with Alhzeimer's Disase (n=40)
16605459|NCT02576821|Other|Patients with DLFT|Patients with DLFT (n=20)
16605460|NCT02576821|Other|Patients with CBD/PSP|Patients with CBD/PSP (n=20)
16605461|NCT02576821|Other|Normal controls|Normal controls (n=20)
16605462|NCT02576808|Experimental|Ginger extract|Drug
16605463|NCT02576808|Active Comparator|Loratadine|Drug
16605464|NCT02576795|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at escalating doses.
16605465|NCT02576782|Active Comparator|perineural dexamethasone group|21 patients received perineural dexamethasone plus bupivacaine 0.5%
16605466|NCT02576782|Active Comparator|systemic dexamethasone group|21 patients received systemic (intravenous) dexamethasone plus perineural bupivacaine 0.5%
16605467|NCT02576782|Sham Comparator|control group|21 patients received only perineural bupivacaine 0.5% plus intravenous saline
16605468|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
16605469|NCT02576756||with difficult intubation|Control population
16605470|NCT02576756||without difficult intubation|Control population
16605471|NCT02576743||Healthy subjects|Subjects with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning. 7 Tesla MRI
16605472|NCT02576743||Patients|Patients with an unruptured brain aneurysm or an unruptured arteriovenous malformation (AVM) with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning 7 Tesla MRI
16605473|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
16605474|NCT02576730||healthy subjects|patients without foot and ankle fracture s
16605475|NCT02576717|Experimental|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
16605476|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
16605477|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
16605478|NCT02576678|Experimental|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).
~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.
~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
16605479|NCT02576665|Experimental|Toca 511/Toca FC|"Toca 511: 14 mL intravenously daily for 3 days followed by up to 4 mL intratumorally or into resection cavity walls following biopsy or resection. Cutaneous melanoma patients may receive intralesional injections (up to 4 mL) daily for 5 days.
~Toca FC: 220 mg/kg/day orally starting at Week 5-6. Cycles are 5- to 7- day courses of treatment every 4 to 6 weeks."
16605480|NCT02576652|Other|Osteoarthritis Participants|Participants previously treated with denosumab and planning to undergo total hip replacement (THR) received one cycle of tetracycline administered at either 250 mg four times a day or 500 mg twice a day for 3 days and one cycle of demeclocycline administered at either 150 mg four times a day or 300 mg twice a day for 3 days, ten days after last dose of tetracycline in cycle 1. THR surgery was performed 5 to 42 days after the last dose of demeclocycline.
16605481|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
16605482|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
16605483|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
16605484|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
16605485|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
16605486|NCT02576626|Other|A|Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation
16605487|NCT02576626|Other|B|"Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.
~Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation"
16605488|NCT02576613|Experimental|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
16605489|NCT02576613|Experimental|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
16605490|NCT02576600|Experimental|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
16605491|NCT02576600|Sham Comparator|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
16605561|NCT02576353|Experimental|Cohort 5|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 800 mcg (n=8), or FCIV 50 mcg (n=2).
16605492|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
16605493|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
16605494|NCT02576574|Experimental|Arm A: Avelumab|
16605495|NCT02576574|Active Comparator|Arm B: Platinum-containing chemotherapy regimen|"Platinum-containing chemotherapy regimen: Investigator's choice platinum containing chemotherapy regimen to be administered consisting of one of the following:
~Non-squamous tumor histology
~Pemetrexed (500 milligram per meter square [mg/m^2]) +cisplatin (75 mg/m^2) or Pemetrexed (500 mg/m^2) + carboplatin (AUC 6 mg/mL*min)
~Squamous tumor histology
~Paclitaxel (200 mg/m^2) +carboplatin (AUC 6 mg/mL*min)
~Gemcitabine (1250 mg/m^2)+ cisplatin (75 mg/m^2)
~Gemcitabine (1000 mg/m^2 )+carboplatin (AUC 5 mg/mL*min)"
16605496|NCT02576574|Experimental|Arm C: Avelumab|
16605497|NCT02576561|Experimental|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml* GPI- 0100 (1:1 ratio)
16605498|NCT02576561|Active Comparator|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml* GPI- 0100 (1:1 ratio)
16605499|NCT02576561|Placebo Comparator|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
16605500|NCT02576561|Experimental|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml* GPI- 0100 (1:1 ratio)
16605501|NCT02576561|Active Comparator|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml* GPI- 0100 (1:1 ratio)
16605502|NCT02576561|Placebo Comparator|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
16605503|NCT02576561|Experimental|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml* GPI- 0100 (1:1 ratio)
16605504|NCT02576561|Active Comparator|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml* GPI- 0100 (1:1 ratio)
16605505|NCT02576561|Placebo Comparator|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
16605506|NCT02576548|Experimental|MEDI4276 0.05 mg/kg|Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605507|NCT02576548|Experimental|MEDI4276 0.1 mg/kg|Participants received IV dose of 0.1 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605508|NCT02576548|Experimental|MEDI4276 0.2 mg/kg|Participants received IV dose of 0.2 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605509|NCT02576548|Experimental|MEDI4276 0.3 mg/kg|Participants received IV dose of 0.3 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605510|NCT02576548|Experimental|MEDI4276 0.4 mg/kg|Participants received IV dose of 0.4 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605511|NCT02576548|Experimental|MEDI4276 0.5 mg/kg|Participants received IV dose of 0.5 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605512|NCT02576548|Experimental|MEDI4276 0.6 mg/kg|Participants received IV dose of 0.6 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605513|NCT02576548|Experimental|MEDI4276 0.75 mg/kg|Participants received IV dose of 0.75 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605514|NCT02576548|Experimental|MEDI4276 0.9 mg/kg|Participants received IV dose of 0.9 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
16605515|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
16605516|NCT02576522|Experimental|brain metastatic patients|Patients with single, large brain metastases from solid tumors
16605519|NCT02576496|Experimental|Tinostamustine (EDO-S101)|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
16605520|NCT02576470|Experimental|Videofluoroscopy (VF) and Barium|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium to provide biofeedback for targeted dysphagia swallowing maneuver.
16605521|NCT02576470|Active Comparator|Surface Electromyography (sEMG)|This group will receive the following types of procedures during visits. sEMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
16605522|NCT02576470|Active Comparator|Mixed VF and sEMG|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium, and EMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
16605523|NCT02576470|Experimental|VF with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
16605524|NCT02576470|Experimental|sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with anodal transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
16605525|NCT02576470|Experimental|Mixed VF, sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
16605562|NCT02576340|Active Comparator|study|drug was administered
16605526|NCT02576470|Sham Comparator|VF with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images without the transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
16605527|NCT02576470|Sham Comparator|sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images without the transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
16605528|NCT02576470|Sham Comparator|Mixed VF, sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images without transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
16605529|NCT02576470|Experimental|VF with reward|This group will receive the following the procedure outlined below for biofeedback. The biofeedback is based on the videofluoroscopy (VF) and Barium with financial reward.
16605530|NCT02576470|Experimental|sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3-days.
16605531|NCT02576470|Experimental|Mixed VF, sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3 days.
16605532|NCT02576457|Experimental|BMS-936559|BMS-936559 Intravenous infusion on specified days
16605533|NCT02576457|Other|Placebo|Placebo on specified days
16605534|NCT02576444|Experimental|Group 1|Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
16605535|NCT02576444|Experimental|Group 2|Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
16605536|NCT02576444|Experimental|Group 3|Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
16605537|NCT02576444|Experimental|Group 4|Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
16605550|NCT02576418|Experimental|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
16605551|NCT02576392|Experimental|Intervention|Informational letter mailed approximately 2 weeks prior to surgery, informational letter mailed approximately 2 weeks post surgery, pharmacist call if refill opioid medicine more than 28 days after surgery
16605552|NCT02576392|No Intervention|Control|Usual Care
16605553|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
16605554|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
16605555|NCT02576366|Experimental|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
16605556|NCT02576366|Experimental|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
16605557|NCT02576353|Experimental|Cohort 1|After a 10-hour fast, the 10 participants in this cohort are randomized to receive Fentanyl Sublingual (under the tongue) Spray (FSS) 100 mcg (n=8), or Fentanyl Citrate Intravenously (FCIV) 50 mcg (n=2).
16605558|NCT02576353|Experimental|Cohort 2|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 200 mcg (n=8), or FCIV 50 mcg (n=2).
16605559|NCT02576353|Experimental|Cohort 3|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 400 mcg (n=8), or FCIV 50 mcg (n=2).
16605560|NCT02576353|Experimental|Cohort 4|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 600 mcg (n=8), or FCIV 50 mcg (n=2).
16605564|NCT02576327|Experimental|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
16605565|NCT02576327|Active Comparator|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
16605566|NCT02576314|Active Comparator|Sofosbuvir and Daclatasvir|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
16605567|NCT02576314|Active Comparator|Ledipasvir/sofosbuvir|Participants will receive Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet daily for 12 weeks.
16605568|NCT02576301|Experimental|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
16605569|NCT02576301|Experimental|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
16605570|NCT02576301|Experimental|OXi4503 dose escalation|MTD for OXi4503 will be determined
16605571|NCT02576301|Experimental|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
16605572|NCT02576288|Experimental|Sitagliptin|100mg will be administered by mouth daily for 28days
16605573|NCT02576288|Placebo Comparator|Matching Placebo|One placebo will be administered by mouth daily for 28days
16605574|NCT02576275|Experimental|Duvelisib + Rituximab + Bendamustine|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
~Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.
~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
16605575|NCT02576275|Placebo Comparator|Placebo + Rituximab + Bendamustine|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib.
~Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.
~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
16605576|NCT02576262||HPV-positive women，30-65 years of age|
16605577|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
16605578|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
16605579|NCT02576236|Experimental|Triple therapy guided by result of the molecular resistance|"If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.
~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
16605580|NCT02576236|Active Comparator|Quadruple concomitant therapy|high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
16605581|NCT02576223|Active Comparator|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
16605582|NCT02576223|Placebo Comparator|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
16605583|NCT02576197|Active Comparator|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
16605584|NCT02576197|Placebo Comparator|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
16605585|NCT02576184|Experimental|Biologic Mesh|Biologic mesh placed in retromuscular position
16605586|NCT02576184|Experimental|Synthetic Mesh|Synthetic mesh placed in retromuscular position
16605587|NCT02576184|No Intervention|No Mesh|No mesh
16605588|NCT02576171|Experimental|Group-therapy + ICBT|This is an open trial with only one study arm
16605589|NCT02576158||Subjects will be women, 30-65 years of age|Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment.
16605590|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
16605591|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
16605592|NCT02576119|Experimental|Part 1: Sentinal Cohorts|Study is in 2 sequential cohorts (BMS-955176 or placebo) each to evaluate the safety, tolerability, and PK following multiple-dose administration of BMS-955176.
16605593|NCT02576119|Experimental|Part 2: Main QTc Study|3 period nested crossover study.
16605594|NCT02576106|Experimental|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
16605595|NCT02576093|Experimental|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
16605596|NCT02576093|Experimental|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
16605597|NCT02576093|Experimental|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
16605598|NCT02576093|Placebo Comparator|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
16605599|NCT02576080|Active Comparator|Standard Group|The Standard Group will receive adjuvant imatinib at a dose of 400 mg per day for a period of 3 years. Patients will be assessed for metastases every three months for three years with thoraco-abdominal and pelvic CT scan.
16605600|NCT02576080|Other|Experimental Group|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan. Surveillance
16605601|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
16605602|NCT02576067|Placebo Comparator|Placebo|matching placebo
16605603|NCT02576054|Experimental|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
16605604|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
16605605|NCT02576028|Other|standard treathment|two sessions of 45 minutes of active exercises for 10 days
16605606|NCT02576028|Experimental|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
16605607|NCT02576015|Experimental|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
16605608|NCT02576015|Sham Comparator|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
16605609|NCT02576002||Pediatric PAH patients|US pediatric population with PAH in MarketScan database during the period 2010-2013
16605610|NCT02575989|Active Comparator|1: control group|Classic - current management of trauma patients by French medical teams
16605611|NCT02575989|Experimental|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia
~Continuous monitoring of body temperature
~Ambulance warming (target : 30°C)
~Patient warming with dedicated blanket
~Infusion fluid warming (and temperature control)"
16605612|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
16605613|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
16605614|NCT02575976|Other|wait list control|no cardiac rehabilitation
16605615|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.
~Experimental: Phase 2
~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
16605616|NCT02575950|Experimental|LEO43204 0,018%|Experimental drug
16605617|NCT02575950|Placebo Comparator|Vehicle|Placebo
16605618|NCT02575937|Experimental|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
16605619|NCT02575937|Experimental|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
16605620|NCT02575937|Experimental|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
16605621|NCT02575924|Active Comparator|sequential medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3
~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5
~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
16605622|NCT02575924|Active Comparator|sequential medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3
~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5
~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
16605623|NCT02575924|Active Comparator|sequential medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3
~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5
~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
16605624|NCT02575924|Active Comparator|one step medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
16605625|NCT02575924|Active Comparator|one step medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
16605626|NCT02575924|Active Comparator|one step medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
16605627|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
16605628|NCT02575898|Other|One|"Creative writing and questionnaires interventions:
~First Session, Second Session, Third through Sixth Sessions"
16605629|NCT02575885|Experimental|Arm I (different type of ENDS product at each visit)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
16605630|NCT02575885|Experimental|Arm II (BLU e-cigarette ENDS product with different flavors)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
16605631|NCT02575872|Experimental|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
16605632|NCT02575872|No Intervention|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
16605633|NCT02575859|Experimental|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
16605634|NCT02575859|No Intervention|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.
~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor [pT] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
16605635|NCT02575846|Active Comparator|Human Milk|Neonates fed human milk
16605636|NCT02575846|Placebo Comparator|Formula|Neonates fed formula
16605637|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
16605638|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
16605639|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
16605640|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
16605641|NCT02575807|Experimental|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.
~* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
16605642|NCT02575807|Experimental|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).
~IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
16605643|NCT02575807|Experimental|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).
~IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
16605644|NCT02575807|Experimental|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).
~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.
~IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
16605645|NCT02575807|Experimental|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).
~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
16605646|NCT02575794|Experimental|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study"
16605647|NCT02575781|Experimental|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
16605648|NCT02575781|Experimental|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
16605649|NCT02575781|Experimental|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
16605650|NCT02575768||Severe AS: asymptomatic|Asymptomatic
16605651|NCT02575768||Severe AS: pure angina|Presence of exertional chest pain
16605652|NCT02575768||Normal controls|Healthy controls
16605653|NCT02575755|Experimental|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
16605654|NCT02575755|Active Comparator|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
16605655|NCT02575755|Experimental|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
16605656|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
16605657|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
16605658|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
16605659|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
16605660|NCT02575729|Experimental|Inject betamethasone by sonography|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
16605661|NCT02575729|Active Comparator|Inject betamethasone directly|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease directly. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
16605662|NCT02575716|Experimental|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
16605663|NCT02575716|Placebo Comparator|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
16605664|NCT02575703|Experimental|[¹⁴C]-LY3023414|Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
16605665|NCT02575690|Placebo Comparator|Placebo group|Obese patients with well-treated hypertension that receive placebo (pure microcrystalline cellulose)
16605666|NCT02575690|Experimental|Spirulina group|Obese patients with well-treated hypertension that receive Hawaiian spirulina (Cyanotech Corporation, Hawaii, US)
16605667|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
16605668|NCT02575664|Experimental|Buprenorphine|Buprenorphine 5 microg/h/7days patch
16605669|NCT02575664|Placebo Comparator|Placebo|Placebo patch
16605670|NCT02575651|Experimental|Fluzoparib|Each subject will receive a single dose of fluzoparib on day 1, and then subject will receive fluzoparib twice daily for 28 days during cycle 1.
16605671|NCT02575638|Experimental|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
16605672|NCT02575625|Experimental|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).
~Experimental procedures consist in:
~Fibroscan measure, preceded by tracking sonography.
~liver MRI (for substudy about MRI comparison, in step 2)
~a blood test for biological assessment of liver functions"
16605673|NCT02575612|Experimental|vacuum-assisted biopy|All patients enrolled in this study received a vacuum-assisted biopsy before surgery.
16605674|NCT02575599|Active Comparator|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
16605675|NCT02575599|No Intervention|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
16605676|NCT02575586|Experimental|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
16605677|NCT02575586|Active Comparator|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
16605678|NCT02575573||Admitted patients at the ED|
16605679|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
16605680|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
16605681|NCT02575534|Experimental|observational|"All patients will undergo 12-lead ECG and transthoracic echocardiography on the day of the study. These studies will be performed on patients as their previously implanted device is reprogrammed to pace in different modes. Patients will then receive an infusion of procainamide (12 mg/kg up to a maximum of 1 g) at a rate of 20 mg/min. Repeat ECG and echocardiograms will then be performed.
~The patient's device will be programmed to a specific setting before and after the procainamide infusion."
16605682|NCT02575521|Placebo Comparator|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
16605683|NCT02575521|Active Comparator|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
16605684|NCT02575508|Experimental|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16605685|NCT02575495|Experimental|7 days course of antibiotic treatment|To assign the 7 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
16605686|NCT02575495|Active Comparator|14 days course of antibiotic treatment|To assign the 14 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
16605687|NCT02575482|Experimental|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
16605688|NCT02575482|Placebo Comparator|Placebo|Placebo in healthy male subjects
16605716|NCT02575261|Experimental|Experimental:CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.
16605717|NCT02575261|No Intervention|No Intervention|
16605689|NCT02575456|Experimental|Group A|(4×10^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10^10 vp/vial), one shot in each arm, total dose of 1.6×10^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
16605690|NCT02575456|Experimental|Group B|(4×10^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10^10vp/vial), total dose of 8×10^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
16605691|NCT02575456|Placebo Comparator|Group C|(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
16605692|NCT02575443|Experimental|Moderate block (MB) group|
16605693|NCT02575443|Experimental|Deep block (DB) group|
16605694|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
16605695|NCT02575417|Experimental|Patient Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.
~Eligibility Criteria for Patient Only Groups:
~are 18 years or older
~speak and read English
~have at least one chronic illness (cancer, chronic pulmonary disease, coronary artery disease, congestive heart failure, peripheral vascular disease, severe chronic liver disease, diabetes with end organ damage, renal failure)
~have not completed an advance directive within the past 18 months
~are able to sit for about 2.5-3 hours
~are able to focus on the game for about 1.5-2 hours
~can complete required surveys"
16605696|NCT02575417|Experimental|Caregiver Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.
~Eligibility Criteria for Caregiver Only Groups:
~are 18 years or older
~speak and read English
~have been an unpaid caregiver for an adult over the age of 18 in the last 12 months. Being an unpaid caregiver may include helping with personal needs or household chores, managing a person's finances, arranging for outside services, or visiting regularly to see how they are doing. This person need not live with participants in order for them to identify as caregivers;
~are able to sit for about 2.5-3 hours
~are able to focus on the game for about 1.5-2 hours
~can complete required survey
~care recipient is capable of discussing medical issues
~care recipient has not completed an AD in past 18 months"
16605697|NCT02575417|Experimental|Surrogate Decision Maker with Patient|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.
~Eligibility Criteria for Surrogate Decision Maker and Patient Group:
~considers themselves a surrogate decision maker for an adult with a chronic illness (defined in Patient Only Group)
~are 18 years or older
~speak and read English
~are able to sit for about 2.5-3 hours
~are able to focus on the game for about 1.5-2 hours
~can complete required surveys
~both patient and surrogate decision maker are able to attend study session together
~patient must meet eligibility criteria defined in Patient Only group"
16605698|NCT02575404|Experimental|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
16605699|NCT02575404|Experimental|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
16605700|NCT02575404|Experimental|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
16605701|NCT02575391|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
16605702|NCT02575378|Other|Metronomic chemotherapy|Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
16605703|NCT02575378|Experimental|Metronimic chemotherapy plus Chinese Traditional Medicine|"Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
~Chinese Traditional Medicine"
16605704|NCT02575365|Experimental|Fingolimod arm|0.5 mg p.o fingolimod daily
16605705|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.
~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
16605706|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
16605707|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
16605708|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
16605709|NCT02575326|Other|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
16605710|NCT02575313|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
16605711|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
16605712|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
16605713|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
16605714|NCT02575274|Experimental|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
16605715|NCT02575274|Other|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
16605720|NCT02575235|Experimental|1.5mg Cetylpyridinium Chloride (CPC)|1.5mg CPC will be taken daily for four weeks.
16605721|NCT02575235|Experimental|4.5mg Cetylpyridinium Chloride (CPC)|4.5mg CPC will be taken daily for four weeks.
16605722|NCT02575235|Placebo Comparator|Control|Placebo will be taken daily for four weeks
16605723|NCT02575222|Experimental|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
16605724|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
16605725|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
16605726|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
16605727|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
16605728|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
16605729|NCT02575183|Experimental|Varenicline (Chantix)|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: 0.5 mg orally once a day Days 4 to 7: 0.5 mg orally twice a day Days 8 to end of treatment: 1 mg orally twice a day. Intervention 'Varinecline (Chantix)' and Intervention 'Behavioral Therapy'"
16605730|NCT02575183|Placebo Comparator|Placebo|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive a Placebo for Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: a placebo (matched to 0.5 mg of Varenicline) orally once a day Days 4 to 7: a placebo (matched to 0.5 mg of Varenicline) orally twice a day Days 8 to end of treatment: a placebo (matched to 1 mg of Varenicline) orally twice a day.
~Intervention 'Placebo (for Varenicline)' and Intervention 'Behavioral Therapy'"
16605731|NCT02575170|Experimental|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
16605732|NCT02575170|Placebo Comparator|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
16605733|NCT02575157|No Intervention|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
16605734|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:
~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.
~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
16605735|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:
~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.
~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
16605736|NCT02575131|Experimental|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
16605737|NCT02575131|Active Comparator|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
16605738|NCT02575131|Experimental|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
16605739|NCT02575131|Active Comparator|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
16605740|NCT02575131|Experimental|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).
~The breakfast is consumed at TNO"
16605741|NCT02575131|Experimental|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
16605742|NCT02575131|Active Comparator|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
16605743|NCT02575131|Experimental|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams* of water and consumed with 307 grams of skimmed milk at home
16605744|NCT02575131|Active Comparator|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
16605745|NCT02575131|Experimental|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).
~The breakfast is consumed at home"
16605746|NCT02575105||Pediatric Hydrocephalus|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
16605747|NCT02575105||Pediatric Control|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
16605748|NCT02575105||Adult Hydrocephalus|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
16605749|NCT02575105||Adult Control|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
16605750|NCT02575092|Active Comparator|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
16605751|NCT02575092|Experimental|Group B, hypertension|The hypertensive patients with their plasma Hcy levels <10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
16605752|NCT02575092|Experimental|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
16605753|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
16605754|NCT02575079|No Intervention|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
16605755|NCT02575066|Other|radiotherapy combined with pazopanib|patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
16605756|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
16605757|NCT02575040|Other|Fecal microbiota transplantation|Fecal microbiota transplantation only
16605758|NCT02575027|Experimental|Treatment (4pi radiotherapy)|Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation.
16605759|NCT02575014|Experimental|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
16605760|NCT02575014|No Intervention|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
16605761|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.
~The following interventions/exposures will be administered:
~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
16605762|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.
~The following interventions/exposures will be administered:
~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
16605763|NCT02574988||SCAR Patients|Patients diagnosed with severe cutaneous adverse reactions with be recruited
16605764|NCT02574975|Active Comparator|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
16605765|NCT02574975|Experimental|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
16605766|NCT02574975|Experimental|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
16605767|NCT02574975|Experimental|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
16605768|NCT02574975|Experimental|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
16605769|NCT02574962|Experimental|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
16605770|NCT02574949|Active Comparator|Conventional rate fluoroscopy|Radiation: 15 FPS Cine 15 PPS
16605771|NCT02574949|Experimental|Intermediate frame rate 7.5 fps|Radiation: 7.5 low Frame rate
16605772|NCT02574949|Experimental|Low frame rate|Low Cine 10 PPS
16605773|NCT02574936|Other|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
16605774|NCT02574923|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
16605775|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
16605776|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
16605777|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
16605837|NCT02574507|Experimental|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
16605778|NCT02574897|Experimental|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
16605779|NCT02574897|Active Comparator|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
16605780|NCT02574884|Other|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
16605781|NCT02574884|No Intervention|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
16605782|NCT02574884|Other|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
16605783|NCT02574871||Single Group|Psychological and biological data collection
16605784|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
16605785|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
16605786|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
16605787|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
16605788|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
16605789|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
16605790|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
16605791|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.
~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
16605792|NCT02574819|Experimental|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
16605793|NCT02574819|Placebo Comparator|Placebo|Placebo administered every other day for 2 weeks.
16605794|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
16605795|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
16605796|NCT02574780|Experimental|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
16605797|NCT02574780|Experimental|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
16605798|NCT02574767|Experimental|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
16605799|NCT02574767|Experimental|Routine diet & PA + PUFA Supplementation|Routine Diet & Physical Activity counseling care plus n3LC-PUFAs supplementation.
16605800|NCT02574767|Experimental|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
16605801|NCT02574767|Placebo Comparator|Routine diet & PA + PUFA placebo|Routine Diet & Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
16605802|NCT02574754|Experimental|warfarin|Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
16605803|NCT02574741|Active Comparator|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
16605804|NCT02574741|Active Comparator|Placebo|50% will be randomized to placebo.
16605805|NCT02574741|Active Comparator|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
16605806|NCT02574728|Experimental|Oral sirolimus, celecoxib, etoposide, and cyclophosphamide|Participants in this group will receive oral sirolimus and celecoxib in addition to cycles of oral etoposide and cyclophosphamide for up to two years.
16605807|NCT02574715||Levonorgestrel (Jaydess, BAY86-5028)|women aged 18 to 29 years following 6 (±1) months of Jaydess® use as their contraceptive method.
16605808|NCT02574702|No Intervention|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
16605809|NCT02574702|Experimental|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.
~Intervention: application of a contralateral drainage in surgical wound closure."
16607806|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
16605810|NCT02574689|Experimental|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
16605811|NCT02574689|Active Comparator|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
16605812|NCT02574663|Experimental|TGR-1202|TGR-1202 daily dose
16605813|NCT02574663|Experimental|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
16605814|NCT02574663|Experimental|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
16605815|NCT02574663|Experimental|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
16605816|NCT02574650|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
16605817|NCT02574637|Placebo Comparator|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
16605818|NCT02574637|Experimental|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
16605819|NCT02574637|Experimental|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
16605820|NCT02574637|Experimental|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
16605821|NCT02574637|Experimental|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
16605822|NCT02574624|Experimental|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
16605823|NCT02574611|Experimental|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
16605824|NCT02574611|Experimental|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
16605825|NCT02574611|Active Comparator|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
16605826|NCT02574611|Placebo Comparator|SCI placebo group|Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
16605827|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease
~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
16605828|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
16605829|NCT02574585|Experimental|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
16605830|NCT02574585|No Intervention|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
16605831|NCT02574572|Experimental|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
16605832|NCT02574559|Experimental|Caregiver of Child With Autism Spectrum Disorder|Caregivers attending eight weekly sessions of Cognitive Based Compassion Training Sessions and Meditation.
16605833|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
16605834|NCT02574533|Experimental|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.
~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
16605835|NCT02574520|Placebo Comparator|Part 1|SABER-Bupivacaine and Saline Placebo
16605840|NCT02574468|Active Comparator|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
16605841|NCT02574468|Active Comparator|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
16605842|NCT02574455|Experimental|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan on Days 1 and 8 of a 21-day treatment cycle. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable adverse events (AEs).
16605843|NCT02574455|Active Comparator|Treatment of Physician's Choice (TPC)|Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.
16605844|NCT02574442||Initial Colposcopy Visit|Women with a scheduled colposcopy and biopsy appointment at the Women's Clinic at Vancouver General Hospital
16605845|NCT02574429|Experimental|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
16605846|NCT02574403|Experimental|without eculizumab|
16605847|NCT02574377|Experimental|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
16605848|NCT02574377|Experimental|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
16605849|NCT02574377|Experimental|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
16605850|NCT02574364|Active Comparator|traditional incision|traditional incision : McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
16605851|NCT02574364|Experimental|modified incision|modified incision :The application of abdomen CT before surgery provides a new approach to the incision and new perception.
16605852|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
16605853|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
16605854|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
16605855|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
16605856|NCT02574338|Active Comparator|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
16605857|NCT02574338|Active Comparator|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
16605858|NCT02574325|Placebo Comparator|Placebo|Placebo
16605859|NCT02574325|Experimental|ARI-3037MO|ARI-3037MO
16605860|NCT02574312|Active Comparator|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
16605861|NCT02574312|Experimental|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
16605862|NCT02574299|No Intervention|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
16605863|NCT02574299|No Intervention|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
16605864|NCT02574299|Other|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
16605865|NCT02574299|No Intervention|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
16605866|NCT02574299|No Intervention|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
16605867|NCT02574299|Other|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
16605868|NCT02574286|Experimental|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
16605869|NCT02574273|Active Comparator|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
16605870|NCT02574273|Other|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
16605871|NCT02574260|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
16605872|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
16605873|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
16605874|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
16605875|NCT02574234|Experimental|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).
~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).
~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
16605876|NCT02574221|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
16605877|NCT02574221|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
16605878|NCT02574208|Active Comparator|"HIV testing by ELISA"|Patients enrolled in this arm will be tested by usual HIV Elisa
16605879|NCT02574208|Experimental|"HIV testing by rapid test"|Patients enrolled in this arm will be tested by the new rapid HIV test
16605880|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
16605881|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
16605882|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
16605883|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 1|alveolar recruitment maneuvers by CPAP then alveolar recruitment maneuvers by eSigh
16605884|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 2|alveolar recruitment maneuvers by eSigh then alveolar recruitment maneuvers by CPAP
16605885|NCT02574156|Experimental|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
16605886|NCT02574156|Experimental|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
16605887|NCT02574130|Experimental|Nebulized amikacin|Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
16605888|NCT02574130|Placebo Comparator|placebo|nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.
16605889|NCT02574117|Experimental|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
16605890|NCT02574104||Institution 1|"McGill University Health Center NICU staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Complete"
16605891|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Complete"
16605892|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Complete"
16605893|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Active"
16605894|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Active"
16605895|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Active"
16605896|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Preparing"
16605897|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Preparing"
16605898|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Pending"
16605899|NCT02574104||Institution 10|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
16607841|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
16605900|NCT02574104||Institution 11|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
16605901|NCT02574104||Institution 12|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
16605902|NCT02574104||Institution 13|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
16605903|NCT02574104||Institution 14|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
16605904|NCT02574104||Institution 15|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
16605905|NCT02574091|Experimental|Cohort 1-Experimental|"4 healthy adult participants will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
16605906|NCT02574091|Placebo Comparator|Cohort 1-Placebo|"2 healthy adult participants will be randomized to receive placebo (blank cream), applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
16605907|NCT02574091|Experimental|Cohort 2-Experimental|"4 healthy adult participants will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
16605908|NCT02574091|Placebo Comparator|Cohort 2-Placebo|"2 healthy adult participants will be randomized to receive matching placebo, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
16605909|NCT02574091|Experimental|Cohort 3-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
16605910|NCT02574091|Placebo Comparator|Cohort 3-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
16605911|NCT02574091|Experimental|Cohort 4-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
16605912|NCT02574091|Placebo Comparator|Cohort 4-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
16605913|NCT02574078|Experimental|Group A Nivolumab|Opdivo specified dose on specified days
16605914|NCT02574078|Experimental|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days
~Opdivo/Pemetrexed specified dose on specified days"
16605915|NCT02574078|Active Comparator|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days
~Pemetrexed specified dose on specified days"
16605916|NCT02574078|Experimental|Group B Nivolumab|Opdivo specified dose on specified days
16605917|NCT02574078|Other|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
16605918|NCT02574078|Active Comparator|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days
~Carboplatin/paclitaxel specified dose on specified days
~Carboplatin/pemetrexed specified dose on specified days
~Carboplatin/docetaxel specified dose on specified days
~Carboplatin/gemcitabine specified dose on specified days
~Paclitaxel specified dose on specified days
~Docetaxel specified dose on specified days
~Gemcitabine specified dose on specified days
~Pemetrexed specified dose on specified days"
16605919|NCT02574078|Experimental|Group C Nivolumb|Opdivo specified dose on specified days
16605920|NCT02574078|Active Comparator|Group D Erlotinib|Erlotinib specified dose on specified days
16605921|NCT02574078|Experimental|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
16605922|NCT02574078|Experimental|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
16605923|NCT02574065|Experimental|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
16605924|NCT02574065|Placebo Comparator|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
16605925|NCT02574052|Other|Behavioral|"The whole experiment was divided into three phases with each phase lasting two weeks.
~First Stage-Behavioral: just record participants' food choices Second Stage-Behavioral: menu labelling without nutrition education Third Stage- Behavioral; menu labelling with nutrition education"
16605926|NCT02574039|Experimental|Oat bran|66g oat bran made up in 350ml skimmed milk
16605927|NCT02574039|Placebo Comparator|Control|Refined grain product and 350ml skimmed milk
16605928|NCT02574026|Experimental|Psychomotor tasks|20 healthy subjects and 10 tetraplegic patients will participate to acquisition of MEG, EEG, MRI data during a motor tasks
16605929|NCT02574013|Experimental|sponge-assisted surgery group|Patients offered surgery with use of the retractor sponge
16605930|NCT02574013|No Intervention|Control group|Patients receiving standard care, i.e. surgery in Trendelenburg position
16605931|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:
~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
16607948|NCT02560740|Experimental|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
16605932|NCT02573987|Active Comparator|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
16605933|NCT02573987|Active Comparator|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
16605934|NCT02573974|Other|Case group|the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer
16605935|NCT02573974|Other|Control group|the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer
16605936|NCT02573961|Active Comparator|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
16605937|NCT02573961|Active Comparator|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
16605938|NCT02573961|Sham Comparator|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
16605939|NCT02573935|Experimental|Clarithromycin|Clarithromycin combined with VCD induction therapy
16605940|NCT02573935|Placebo Comparator|Placebo|Placebo combined with VCD induction therapy
16605941|NCT02573922|Experimental|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
16605942|NCT02573922|Active Comparator|Oxycodone|Oxycodone prolonged release tablet twice a day
16605943|NCT02573909|Experimental|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
16605944|NCT02573909|Experimental|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
16605945|NCT02573896|Experimental|NK cells with Ch14.18 & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of Ch14.18 on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
16605946|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
16605947|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
16605948|NCT02573870|Experimental|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
16605949|NCT02573870|Placebo Comparator|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
16605950|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
16605951|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
16605952|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
16605953|NCT02573844|Active Comparator|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.
~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
16605954|NCT02573844|Placebo Comparator|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.
~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
16605955|NCT02573831|Placebo Comparator|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
16605956|NCT02573831|Experimental|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
16605957|NCT02573818||SEDASYS System|
16605958|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
16605959|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire<22 Rigiscan test are performed for two nights
16605960|NCT02573779||Infants fed mother's own milk|Infants fed >50% mother's own milk with enteral feeding.
16605961|NCT02573779||Donor milk fed infants|Infants fed <50% mother's own milk (and thus >50% donor human milk) with enteral feeding.
16605962|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
16605963|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
16606163|NCT02572531|Active Comparator|L. reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 2 weeks
16605964|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
16605965|NCT02573753|Experimental|sleep restriction|Sleep restriction
16605966|NCT02573753|No Intervention|normal sleep|Normal sleep
16605967|NCT02573753|Experimental|weight gain|Weight gain
16605968|NCT02573740|Experimental|ABT-957|ABT-957 given twice a day for 84 days
16605969|NCT02573740|Placebo Comparator|Placebo|Placebo given twice a day for 84 days
16605970|NCT02573727|Experimental|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.
~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.
~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
16605971|NCT02573727|Active Comparator|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.
~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
16605972|NCT02573714|Experimental|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
16605973|NCT02573714|Placebo Comparator|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
16605974|NCT02573701|Experimental|1 Guideline treatment|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
16605975|NCT02573701|Active Comparator|2 Treatment as Usual|Participants will receive the Treatment as Usual (atypical antipsychotic) plus psychosocial treatment decided by clinician
16605976|NCT02573688|Experimental|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
16605977|NCT02573662||Case subjects|Physical active non-diabetic individuals of age 18 to 50 years, who are undergoing knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are recruited as cases for this case-control study. OGTT, blood- and urine sampling and DXA scans will be performed 3 times throughout the study period.
16605978|NCT02573662||Control group|Non-diabetic individuals matched for age, gender and physical activity are recruited as control subjects to establish a reference level likely to image the cases before they experienced their knee injury. Blood- and urine sampling, OGTT and DXA scans will be carried out 1-3 times for each control subject. No lifestyle intervention is implemented.
16605979|NCT02573649|Active Comparator|CLS-ON first|Closed-loop Stimulation on first
16605980|NCT02573649|Active Comparator|CLS-OFF first|Closed-loop Stimulation off first
16605981|NCT02573623||HIV-infected children with confirmed TB|Hospitalized children with TB confirmed by culture or GeneXpert
16605982|NCT02573623||HIV-uninfected children aged<5 years with confirmed TB|Hospitalized children aged<5 years with TB confirmed by culture or GeneXpert
16605983|NCT02573623||HIV-uninfected children aged>4 years with confirmed TB|Hospitalized children aged>4 years with TB confirmed by culture or GeneXpert
16605984|NCT02573623||HIV-infected control children|Children hospitalized in the surgery ward without any evidence of tuberculosis infection
16605985|NCT02573623||HIV-uninfected controls aged <5 years|Children <5 years hospitalized in the surgery ward without any evidence of tuberculosis infection
16605986|NCT02573623||HIV-uninfected controls aged >4 years|Children >4 years hospitalized in the surgery ward without any evidence of tuberculosis infection
16605987|NCT02573610|Experimental|DE-108|High concentration / Antibacterial Ophthalmic Solution
16605988|NCT02573610|Active Comparator|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
16605989|NCT02573597|Active Comparator|Part A Group 1|CEI bupivacaine and CEI sufentanil
16605990|NCT02573597|Active Comparator|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
16605991|NCT02573597|Active Comparator|Part B Group 3|CEI bupivacaine and PIEB sufentanil
16605992|NCT02573597|Active Comparator|Part B Group 4|PIEB bupivacaine and CEI sufentanil
16605993|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
16605994|NCT02573558||DEX|patients who received dexmedetomidine during the operation
16605995|NCT02573558||PPF|patients who received propofol during the operation
16605996|NCT02573545|Experimental|Test group: with IFE|Patients treated with IFE software
16605997|NCT02573545|Active Comparator|Test group: without IFE|Patients treated with Numaris 4 software
16605998|NCT02573519|Active Comparator|Diabetic patient|"The study consists of four different parts:
~11C Donepezil PET/CT scan
~3D-Transit
~3D-Transit during treatment with pyridostigmine
~3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
16605999|NCT02573519|Active Comparator|Healthy subjects|"The study consists of two different parts:
~11C Donepezil PET/CT scan
~3D-Transit"
16606000|NCT02573506|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
16606159|NCT02572583|Active Comparator|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
16606001|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment
~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)
~If <PR, move directly to CRT if not surgical candidates.
~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.
~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
16606002|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment
~If CR/PR, three more weeks of nab-paclitaxel followed by CRT
~If <PR, move directly to CRT if not surgical candidates.
~CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.
~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
16606003|NCT02573493|Experimental|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"6 weeks of nab-paclitaxel and cisplatin (days 1 & 22) followed by primary tumor site assessment
~If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab
~If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab
~CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy
~Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
16606004|NCT02573480|Experimental|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
16606005|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
16606006|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
16606007|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
16606008|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
16606009|NCT02573454|Experimental|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
16606010|NCT02573454|Active Comparator|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
16606011|NCT02573441|Experimental|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
16606012|NCT02573441|Experimental|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
16606013|NCT02573441|Other|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
16606014|NCT02573428||Autism Spectrum Disorder|Individuals who receive a clinical diagnosis of Autism Spectrum Disorder
16606015|NCT02573428||Developmental/Psychiatric Controls|Individuals who receive a clinical diagnosis of another developmental or psychiatric disorder
16606016|NCT02573428||Healthy Controls|Individuals who have no specific developmental or psychiatric diagnosis
16606017|NCT02573415|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
16606018|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
16606019|NCT02573402|Sham Comparator|Control|Sham stimulation.
16606020|NCT02573389|No Intervention|"Retrospective and prospective non-stented"|Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
16606021|NCT02573389|Experimental|"Prospective stented"|Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
16606022|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
16606023|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
16606160|NCT02572570|Experimental|Posterior Composite Resin Restoration|Participants will receive two commercially available tooth-colored restorative materials used for direct restoration as per manufacturer's instructions.
16606024|NCT02573363|Experimental|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.
~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
16606025|NCT02573350|Experimental|Delamanid|All patients received an initial dose of 100 mg BID (200 mg total daily dose), with an option to titrate to 200 mg BID (400 mg total daily dose) after an initial 2-week hospitalization at the investigator's discretion.
16606026|NCT02573337|Experimental|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
16606027|NCT02573324|Experimental|ABT-414, Radiation and Radiation/Temozolomide (TMZ)|ABT-414 is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. ABT-414 is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
16606028|NCT02573324|Placebo Comparator|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
16606029|NCT02573311|Experimental|men|
16606030|NCT02573298|Active Comparator|Ice|patients randomized to receive local ice on inflamed joint
16606031|NCT02573298|Active Comparator|Cold gas|patients randomized to receive cold gas on inflamed joint
16606032|NCT02573285|Active Comparator|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
16606033|NCT02573285|Active Comparator|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
16606034|NCT02573272||Epileptic patients with AEDs and eslicarbacepine|
16606035|NCT02573259|Experimental|Arm 1 PF-06801591|0.5 mg/kg IV every 21 days (Part 1)
16606036|NCT02573259|Experimental|Arm 2 PF-06801591|1.0 mg/kg IV every 21 days (Part 1)
16606037|NCT02573259|Experimental|Arm 3 PF-06801591|3.0 mg/kg IV every 21 days (Part 1)
16606038|NCT02573259|Experimental|Arm 4 PF-06801591|10 mg/kg IV every 21 days (Part 1)
16606039|NCT02573259|Experimental|Arm 5 PF-06801591|300 mg SC every 28 days (Part 1 and 2)
16606040|NCT02573246|Experimental|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
16606041|NCT02573246|Sham Comparator|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
16606042|NCT02573246|Experimental|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
16606043|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16606044|NCT02573233|Experimental|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16606045|NCT02573220|Experimental|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16606046|NCT02573194|Experimental|Animal source of proteins|Breakfast based on animal proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
16606047|NCT02573194|Experimental|Plant source of proteins|Breakfast based on plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
16606048|NCT02573194|Experimental|Animal and plant source of proteins|Breakfast based on both animal and plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
16606049|NCT02573194|Experimental|Low protein|Breakfast very low in protein: 1700 kJ, 5 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
16606050|NCT02573181|Experimental|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
16606051|NCT02573181|Active Comparator|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
16606052|NCT02573168|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
16606161|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
16606053|NCT02573168|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
16606054|NCT02573168|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.
~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
16606055|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
16606056|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
16606057|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
16606058|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
16606059|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
16606060|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
16606061|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
16606062|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
16606063|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
16606064|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
16606065|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
16606066|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
16606067|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
16606068|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
16606069|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
16606070|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
16606071|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
16606072|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
16606073|NCT02573142|Active Comparator|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
16606074|NCT02573142|Experimental|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
16606075|NCT02573129|Experimental|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
16606076|NCT02573129|Experimental|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
16606077|NCT02573116|Experimental|Obstructive sleep apnea with chronic parodontis|patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
16606078|NCT02573116|No Intervention|Obstructive sleep apnea without chronic parodontis|patients with severe OSA treated by CPAP
16606079|NCT02573090|Experimental|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
16606080|NCT02573090|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
16606081|NCT02573051|Active Comparator|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
16606082|NCT02573051|Active Comparator|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
16606083|NCT02573038|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
16606084|NCT02573025|Experimental|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
16606085|NCT02573025|Experimental|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
16606086|NCT02573012|Experimental|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
16606164|NCT02572531|Placebo Comparator|Placebo|Placebo lozenges three times daily for 2 weeks
16606087|NCT02573012|Experimental|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
16606088|NCT02572999||Valvular heart disease|All patients aged 70 years or older, consecutively admitted for elective heart valve surgery or if admitted for elective transcatheter aortic valve implantation, or if a patient presents with symptomatic moderate to severe valvular heart disease on hospital admission as evidenced by moderate to severe valve regurgitation or stenosis will be included in this cohort. Participants will be observed up to 30 days post-hospital discharge
16606089|NCT02572986|Experimental|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
16606090|NCT02572986|Active Comparator|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
16606091|NCT02572973|Active Comparator|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
16606092|NCT02572973|Placebo Comparator|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
16606093|NCT02572960|Placebo Comparator|Cholecalciferol|Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks
16606094|NCT02572960|Active Comparator|Valsartan|Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks
16606095|NCT02572960|Placebo Comparator|Placebo|Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks
16606096|NCT02572960|Active Comparator|Cholecalciferol and Valsartan|Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks
16606097|NCT02572947|Experimental|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
16606098|NCT02572934||Chemotherapy group (CT-group)|Patients treated with chemotherapy >20 years ago
16606099|NCT02572934||Radiotherapy group (RT-group)|Patients treated with radiotherapy >20 years ago
16606100|NCT02572934||Surgery-only group (SU-group)|Patients treated with only orchidectomy >20 years ago
16606101|NCT02572934||Control-group|Healthy controls
16606102|NCT02572921|Experimental|Positive Psychotherapy|Experimental Group (Positive Psychotherapy)
16606103|NCT02572921|Active Comparator|Cognitive Behavioral Therapy|Active Control Group (Cognitive Behavioral Therapy)
16606104|NCT02572908|Active Comparator|Fermented wheat bread for 7 days|Long sourdough fermentation
16606105|NCT02572908|Placebo Comparator|Yeast baked wheat bread for 7 days|Regular toast bread
16606106|NCT02572908|Other|Run-in|Gluten-free diet for 7 days before entering either bread period
16606107|NCT02572895|Active Comparator|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
16606108|NCT02572895|Placebo Comparator|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
16606109|NCT02572882|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
16606110|NCT02572882|Experimental|p-inulin|This arm is the 12 week p-inulin treatment phase (8 grams twice daily, oral).
16606111|NCT02572882|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
16606112|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
16606113|NCT02572856|Experimental|CGM patients|Apply continuous glucose monitor, calibrate and make glucose measurements. Measurements are blinded to the care provider
16606114|NCT02572843|Experimental|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
16606115|NCT02572830|Experimental|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
16606116|NCT02572830|Active Comparator|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
16606117|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
16606118|NCT02572817|Active Comparator|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
16606119|NCT02572804|Active Comparator|Rectus Sheath Catheter Group|Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
16606120|NCT02572804|Active Comparator|Epidural Group|Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
16606162|NCT02572544|Experimental|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
16606121|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
16606122|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
16606123|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
16606124|NCT02572765||Normotensive|Normotensive subjects
16606125|NCT02572765||Hypertensive|Hypertensive subjects
16606126|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
16606127|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
16606128|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
16606129|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
16606130|NCT02572726|Active Comparator|active rTMS|active repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
16606131|NCT02572726|Sham Comparator|'sham' rTMS|'sham' repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
16606132|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
16606133|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
16606134|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
16606135|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
16606136|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
16606137|NCT02572700||Patients with skin psoriasis without arthrits|20 patients with skin psoriasis without arthrits will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
16606138|NCT02572700||Healthy controls|20 healthy controls will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
16606139|NCT02572687|Experimental|Ramucirumab + MEDI4736 (NSCLC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given intravenously (IV) every 3 weeks (q3w) of a 21 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.
~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q3w. Participants may continue to receive study treatment until discontinuation criteria are met."
16606140|NCT02572687|Experimental|Ramucirumab + MEDI4736 (Gastric/GEJ)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV every 2 weeks (q2w) of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.
~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
16606141|NCT02572687|Experimental|Ramucirumab + MEDI4736 (HCC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV q2w of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.
~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
16606142|NCT02572674|Other|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
16606143|NCT02572661|Other|Squamous Head and Neck Cancer|radiation
16606144|NCT02572648||Participants with Heart Failure|Participants with heart failure will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
16606145|NCT02572648||Healthy Controls|Healthy controls will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
16606146|NCT02572635|Experimental|Cohort 1|50 µg of PnuBioVax
16606147|NCT02572635|Experimental|Cohort 2|200 µg of PnuBioVax
16606148|NCT02572635|Experimental|Cohort 3|500 µg of PnuBioVax
16606149|NCT02572635|Placebo Comparator|Placebo|Placebo
16606150|NCT02572622|Experimental|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
16606151|NCT02572622|Experimental|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
16606152|NCT02572622|Experimental|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
16606153|NCT02572609|Experimental|Mucosolvan ® adult syrup|
16606154|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
16606155|NCT02572596|Experimental|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
16606156|NCT02572596|Active Comparator|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
16606157|NCT02572583|Experimental|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
16606158|NCT02572583|Active Comparator|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
16606166|NCT02572505|Experimental|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
16606167|NCT02572492|Experimental|Carfilzomib/dexamethasone maintenance|Carfilzomib/dexamethasone maintenance after salvage HDT
16606168|NCT02572492|Sham Comparator|Observation without maintenance|Observation without maintenance after salvage HDT
16606169|NCT02572466||ESRD group|"Aged 18 years or older.
~was diagnosed as End-stage renal disease for more than one year.
~Attend hemodialysis 3 times a week consistently for more than 6 months.
~Hemodialysis with Kt/V > 1.2
~No urine output or is less than 500 ml per day.
~No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
16606170|NCT02572466||Control group|"Aged 18 years or older.
~without kidney disease (eGFR > 60 ml/min/1.73m2)"
16606171|NCT02572453|Experimental|Treatment (onalespib)|Patients receive onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16606172|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
16606173|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
16606174|NCT02572414|Experimental|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention consisted of three, 3-hour weekly small-group intervention sessions led by a trained facilitator using a detailed, scripted manual designed to increase adherence to guidelines for physical activity, 5-a-Day diet, and colon cancer screening.
16606175|NCT02572414|Active Comparator|Health Awareness Control|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
16606176|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
16606177|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
16606178|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
16606179|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
16606180|NCT02572388|Active Comparator|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
16606181|NCT02572388|Active Comparator|Group 2|50µg of R21 on days 0, 28, and 56.
16606182|NCT02572388|Active Comparator|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
16606183|NCT02572388|Active Comparator|Group 4|2µg of R21 mixed with 50µg of Matrix-M
16606184|NCT02572375|Experimental|Codeine Phosphate/Guaifenesin ER Tablet|Patients receiving an extended release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin twice a day for 6 and a half days total. Total dosage [2 tablets] is 60 mg Codeine Phosphate and 1200 mg Guaifenesin twice a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
16606185|NCT02572375|Active Comparator|Codeine Phosphate/Guaifenesin IR Tablet|Patients receiving an immediate release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin six times a day for 6 and a half days total. Dosage is 20 mg Codeine Phosphate and 400 mg Guaifenesin six times a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
16606186|NCT02572349|Experimental|IW-1701|Single Dose
16606187|NCT02572349|Placebo Comparator|Matching Placebo for IW-1701|Single Dose
16606188|NCT02572336|Active Comparator|THR-18|Single administration of intravenous THR-18 solution
16606189|NCT02572336|Placebo Comparator|Placebo|Single administration of intravenous THR-18 lookalike solution
16606190|NCT02572323|Active Comparator|Immediate group|1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
16606191|NCT02572323|Placebo Comparator|Deferred group|No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months
16606192|NCT02572310|Experimental|HV Cement|Simplex High Viscosity Bone Cement
16606193|NCT02572297||video-EEG|Patients suffering from drug-resistant partial epilepsy for whom a video-EEG monitoring of their seizures was scheduled as part of pre-surgical assessment
16606194|NCT02572284|Experimental|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
16606195|NCT02572271|Active Comparator|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
16606196|NCT02572271|Active Comparator|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
16606197|NCT02572258|Experimental|Nutritional oats cookie and educational session|Nutritional cookie with oats and nuts
16606198|NCT02572258|No Intervention|Educational session only|
16606199|NCT02572245|Active Comparator|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
16606200|NCT02572245|Active Comparator|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
16606201|NCT02572232|Experimental|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
16606202|NCT02572219|Active Comparator|Nutraceutical|Treated with nutraceutical compound
16606203|NCT02572219|Placebo Comparator|Placebo|Treated with placebo
16606204|NCT02572206|Other|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.
~30 minute structural MRI will be obtained to permit co-registration of PET images."
16606206|NCT02572180|Active Comparator|NIRS-based NF in 3D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 3D virtual reality classroom environment.
16606207|NCT02572180|Active Comparator|NIRS-based NF in 2D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 2D (normal computer screen) classroom environment.
16606208|NCT02572180|Active Comparator|EMG-based BF in 3D|An electromyogram (EMG)-based biofeedback training in which participants learn to self-regulate activity of the musculi supraspinatus will take place in a 3D virtual reality classroom environment.
16606209|NCT02572167|Experimental|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
16606210|NCT02572154|Other|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
16606211|NCT02572154|Other|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
16606212|NCT02572141|Experimental|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
16606213|NCT02572141|Active Comparator|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
16606214|NCT02572128|Experimental|Study 1|Iron fortified rice hot or cold extruded.
16606215|NCT02572128|Experimental|Study 2|Iron and zinc fortified rice hot extruded or coated.
16606216|NCT02572115|Active Comparator|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
16606217|NCT02572115|Active Comparator|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
16606218|NCT02572115|No Intervention|Control|This arm does not get the intervention.
16606219|NCT02572102|Experimental|Energy Drink|Two 16 ounce containers of an Energy Drink
16606220|NCT02572102|Active Comparator|Panax Ginseng|800 mg of Panax Ginseng in 70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
16606221|NCT02572102|Placebo Comparator|Placebo|70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
16606222|NCT02572089|Experimental|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
16606223|NCT02572089|Experimental|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
16606224|NCT02572089|Experimental|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
16606225|NCT02572089|Experimental|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
16606226|NCT02572089|Experimental|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
16606227|NCT02572076|Experimental|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
16606228|NCT02572050|Experimental|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
16606229|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
16606230|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
16606231|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
16606232|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
16606233|NCT02572024|Active Comparator|Baroreflex activation therapy|BAT ON
16606234|NCT02572024|Placebo Comparator|Placebo|BAT OFF
16606235|NCT02572011|No Intervention|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
16606236|NCT02572011|Experimental|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
16606237|NCT02571998|Experimental|Treatment|Omiganan (CLS001) Topical Gel applied once daily
16606238|NCT02571998|Placebo Comparator|Vehicle Gel|Vehicle Topical Gel applied once daily
16606239|NCT02571972|Experimental|Dorzolamide-timolol|"On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.
~Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.
~Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits
~At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
16606240|NCT02571959|Experimental|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
16606241|NCT02571946|Experimental|Proton beam therapy|
16606242|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
16606243|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
16606244|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
16606245|NCT02571907|Experimental|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
16606246|NCT02571894|No Intervention|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
16606247|NCT02571894|Experimental|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
16606248|NCT02571881|Active Comparator|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
16606249|NCT02571881|Experimental|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
16606250|NCT02571855|Experimental|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
16606251|NCT02571855|Placebo Comparator|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
16606252|NCT02571855|Experimental|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
16606253|NCT02571855|Placebo Comparator|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
16606254|NCT02571855|Experimental|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
16606255|NCT02571855|Placebo Comparator|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
16606256|NCT02571842|Experimental|Rituximab|"Drug: Rituximab
~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4
~Other Name: Mabthera"
16606257|NCT02571842|Active Comparator|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB
~An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of <130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB
~Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily
~Other Name: Enalapril, Lorsartan, Prednisolone"
16606258|NCT02571829|Experimental|ribociclib|single arm ribociclib Oral 600 mg x 1 a day duration according to response.
16606259|NCT02571816|Experimental|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
16606260|NCT02571816|Experimental|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
16606261|NCT02571816|Experimental|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
16606262|NCT02571803|Experimental|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
16606263|NCT02571803|Active Comparator|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
16606264|NCT02571790|Experimental|Relaxation optimized virtual reality|six relaxation sessions with virtual reality
16606265|NCT02571790|Experimental|Classical relaxation (without Virtual Reality).|six relaxation sessions without virtual reality
16606266|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
16606267|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
16606268|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
16606269|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
16606270|NCT02571777|Active Comparator|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
16606271|NCT02571764|Experimental|Nutritional Oats Cookie|
16606272|NCT02571751|Experimental|Breast Augmentation|
16606273|NCT02571738|Active Comparator|CHAM|Cryopreserved Human Amniotic Membrane
16606274|NCT02571738|Placebo Comparator|Control|Standard of Care
16606275|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:
~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.
~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested
~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab
~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes
~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
16606276|NCT02571712|Other|GANFORT®|One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.
16606277|NCT02571699|Active Comparator|Subgluteal sciatic block|Subgluteal block with similar volume
16606279|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
16606280|NCT02571660|Active Comparator|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
16606281|NCT02571660|Experimental|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
16606282|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
16606283|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
16606284|NCT02571608|Active Comparator|Metformin|Metformin, dosage same as the patient's regular dosage
16606285|NCT02571608|Placebo Comparator|Placebo|Placebo
16606286|NCT02571595|Experimental|Immediate dCBT-I group|Digital cognitive behavioural therapy for insomnia (dCBT-I) is a 6 session training program (spanning 6 to 12 weeks) designed to improve sleep. Participants in the immediate dCBT-I group will receive the Sleepio intervention shortly after enrollment.
16606287|NCT02571595|Experimental|Waitlist control group|Participants in the waitlist control group will receive sleep hygiene recommendations from validated online resources for HIV patients (http://www.catie.ca/en/positiveside/winter-2013/sleep-tight) around the time of enrollment. They will start the digital cognitive behavioural therapy for insomnia (dCBT-I) intervention 12-14 weeks after the initial enrollment.
16606288|NCT02571582||Patients died|"All patients underwent extensive evaluation:
~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
16606289|NCT02571582||living patients|"All patients underwent extensive evaluation:
~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
16606290|NCT02571569|Experimental|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
16606291|NCT02571569|Experimental|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
16606292|NCT02571569|Experimental|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
16606293|NCT02571556|Experimental|Dexamethasone Phosphate Ophthalmic Solution|
16606294|NCT02571543|Experimental|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.
~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
16606295|NCT02571543|No Intervention|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
16606296|NCT02571530|Experimental|Intra-arterial Cerebral Infusion of Trastuzumab|Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption
16606297|NCT02571517|Experimental|Glucocorticoids|"methylprednisolone intravenous administration of 2mg/kg/day (divided in two doses) and/or oral prednisolone 2,5 mg/kg/day (in two divided doses) during 7 days.
~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis"
16606298|NCT02571517|Placebo Comparator|Placebo|"will receive iv/oral glucose 5% solution as placebo of 2mg/kg/day and/or 2,5 mg/kg/day (divided in two doses) during 7 days.
~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis."
16606299|NCT02571504|Experimental|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
16606300|NCT02571504|Experimental|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
16606301|NCT02571491|Experimental|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:
~KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation
~during surgery remifentanil 0,3 mcg / kg / min.
~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
16606302|NCT02571491|Placebo Comparator|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:
~0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation
~during surgery remifentanil 0.3 mcg / kg / min.
~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
16606303|NCT02571478|Experimental|7-Month Wait List Group|Couples will be randomly assigned to a wait list group. This group will wait seven months before starting The Marriage Checkup.
16606304|NCT02571478|Experimental|MC Right Away|Couples will be randomly assigned to receive The Marriage Checkup right away.
16606333|NCT02571296|Placebo Comparator|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.
~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
16606372|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
16606305|NCT02571452|Experimental|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
16606306|NCT02571452|Active Comparator|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
16606307|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
16606308|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
16606309|NCT02571426|Active Comparator|Propofol|Continuous infusion during surgery. Individual dosage.
16606310|NCT02571426|Active Comparator|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
16606311|NCT02571413|Other|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
16606312|NCT02571413|Other|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
16606313|NCT02571400||Patients scheduled to undergo surgery|Patients scheduled to undergo surgery at St Vincent's Private Hospital Sydney
16606314|NCT02571387|Experimental|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
16606315|NCT02571387|Sham Comparator|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
16606316|NCT02571387|No Intervention|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
16606317|NCT02571374|Experimental|symbiotic group|Symbiotic group
16606318|NCT02571374|Placebo Comparator|placebo group|placebo group
16606319|NCT02571361|Active Comparator|Treatment A:|Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
16606320|NCT02571361|Active Comparator|Treatment B:|Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
16606321|NCT02571361|Active Comparator|Treatment C:|Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
16606322|NCT02571361|Active Comparator|Treatment D:|Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
16606323|NCT02571348|Active Comparator|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
16606324|NCT02571348|Active Comparator|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
16606325|NCT02571348|Active Comparator|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
16606326|NCT02571335|Experimental|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
16606327|NCT02571335|Active Comparator|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
16606328|NCT02571322|Experimental|Whole Body Vibration training|Use of the HyperVibe Whole Body Vibration training device for 12 weeks 3 times per week crossover to aerobic exercise
16606329|NCT02571322|Placebo Comparator|Aerobic Exercise|Aerobic exercise training for 12 weeks 3 times per week crossover to use of the HyperVibe Whole Body Vibration training device
16606330|NCT02571309|Other|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;
~Lung function testing with Bluetooth connection of external spirometry
~Symptom evaluation
~Actual treatment plan, based om lung function and symptoms
~Trend views of lung function, symptoms and asthma control"
16606331|NCT02571309|Other|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
16606332|NCT02571296|Active Comparator|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.
~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
16606369|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
16606370|NCT02571062|Experimental|experimental formulation|crossover design
16606334|NCT02571283|Experimental|Randomized Group A [Cocktail Injection]|"COCKTAIL INJECTION:
~Cocktail Injection Consists of:
~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose"
16606335|NCT02571283|Experimental|Randomized Group B [Cocktail Injection Plus Exparel]|"COCKTAIL INJECTION PLUS EXPAREL:
~Cocktail Injection Consists of:
~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose
~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
16606336|NCT02571283|Experimental|Randomized Group C [Marcaine Plus Exparel]|"MARCAINE PLUS EXPAREL:
~Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose
~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
16606337|NCT02571270|Active Comparator|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
16606338|NCT02571270|Active Comparator|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
16606339|NCT02571270|Active Comparator|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
16606340|NCT02571270|Active Comparator|survival|The survival of patients with heart failure may increase with exercise training.
16606341|NCT02571257|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
16606342|NCT02571257|Experimental|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
16606343|NCT02571257|Experimental|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
16606344|NCT02571244|Experimental|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
16606345|NCT02571244|No Intervention|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
16606346|NCT02571231|Experimental|HFV+vg|volume guarantee given
16606347|NCT02571231|Experimental|HFV-VG|Volume guarantee not given
16606348|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
16606349|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
16606350|NCT02571192|Experimental|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
16606351|NCT02571179|Experimental|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
16606352|NCT02571166|Experimental|HSV529|
16606353|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
16606354|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
16606355|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
16606356|NCT02571140|Active Comparator|Active Comparator|Subcutaneous injection of Teriparatide
16606357|NCT02571140|Experimental|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
16606358|NCT02571127|Experimental|Only treatment|two weekly applications (monday and thursday or tuesday and friday) for 12 weeks
16606359|NCT02571114|Active Comparator|Control 1|white bread - 25 g available carbohydrate
16606360|NCT02571114|Active Comparator|Control 2|white bread - 25 g available carbohydrate
16606361|NCT02571114|Sham Comparator|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
16606362|NCT02571114|Experimental|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
16606363|NCT02571101|Experimental|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
16606364|NCT02571101|Experimental|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
16606365|NCT02571101|Placebo Comparator|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
16606366|NCT02571088|Experimental|Training Program|The treatment will consist in an endurance training program. Only patients of the trained group will be subjected to this training program which will typically consist in 3 training sessions per week during 8 weeks i.e., 24 training sessions. Each training session will last 45 min. All training sessions will take place at the hospital and will be under medical supervision.
16606367|NCT02571088|No Intervention|No Training Program|It will be asked to the control patients to not change their habitual physical activity during the entire period of observation
16606368|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
16606371|NCT02571062|Experimental|final formulation|crossover design
16606373|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
16606374|NCT02571036|Experimental|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]
16606375|NCT02571036|Experimental|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]
16606376|NCT02571036|Experimental|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]
16606377|NCT02571036|Experimental|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]
16606378|NCT02571036|Experimental|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]
16606379|NCT02571036|Experimental|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]
16606380|NCT02571036|Experimental|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]
16606381|NCT02571036|Experimental|Expansion Cohort 7|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. [Closed for Enrollment]
16606382|NCT02571036|Experimental|Expansion Cohort 8|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]
16606383|NCT02571036|Experimental|Expansion Cohort 9|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]
16606384|NCT02571036|Experimental|Expansion Cohort 10|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]
16606385|NCT02571036|Experimental|Extension Cohort|150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.
16606386|NCT02571010|Experimental|Vibrotactile stimulation|"Patients in this arm will have
~treatment by medications and rehabilitation
~treatment by vibrotactile at medical center
~stimulation at home by soft tissue
~non stimulation on allodynia area"
16606387|NCT02571010|Sham Comparator|Sham Stimulation with Vibradol device switched off|"Patients in this arm will have
~treatment by medications and rehabilitation
~Sham vibrotactile treatment at medical center but with Vibradol device switched off
~abdominal breath exercises at home
~non stimulation on allodynia area"
16606388|NCT02571010|Other|Standard Medical treatment|Observational group, treated as usually by medications and rehabilitation.
16606389|NCT02570997|Active Comparator|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
16606390|NCT02570997|Placebo Comparator|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
16606393|NCT02570971|No Intervention|Control|Patients will receive supportive care measures.
16606394|NCT02570971|Experimental|Investigational|Patients will receive 500mL of 20% mannitol
16606395|NCT02570958|Experimental|Indocyanine green|
16606396|NCT02570945|Experimental|Intervention|Pharmacist-physician medication review
16606397|NCT02570945|No Intervention|Control|
16606398|NCT02570932|Experimental|Autologous Mesenchymal Bone Marrow Cell|"All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)
~Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
16606399|NCT02570919|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
16606400|NCT02570919|Experimental|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
16606401|NCT02570893|Experimental|adjuvant chemoradiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
16606402|NCT02570893|Experimental|adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
16606403|NCT02570880|Experimental|Bread sample vs. glucose solution|glycemic index
16606404|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
16606405|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
16606406|NCT02570854|Experimental|CSJ137|In Part 1 up to 48 subjects will receive a single dose of CSJ137. In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
16606407|NCT02570854|Placebo Comparator|Placebo|In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
16606408|NCT02570841|Active Comparator|Capsaicin|Treatment with Topical High dose Capsaicin
16606409|NCT02570841|Placebo Comparator|Placebo|Treatment with Topical Placebo
16606410|NCT02570828|Experimental|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
16606413|NCT02570789|Experimental|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
16606414|NCT02570776||observation|Cohort of patients for Endoscopy & they are assessed for Helicobacter pylori through the histopathology & also throgh C14 C UBT.
16606415|NCT02570763|Experimental|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
16606416|NCT02570763|Sham Comparator|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
16606417|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
16606418|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
16606419|NCT02570737||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
16606420|NCT02570737||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
16606421|NCT02570724|Active Comparator|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
16606422|NCT02570724|Active Comparator|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
16606423|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
16606424|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
16606425|NCT02570685|Experimental|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
16606426|NCT02570685|Experimental|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
16606427|NCT02570685|Active Comparator|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
16606428|NCT02570672|Experimental|Metformin|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated)
16606429|NCT02570672|Placebo Comparator|Placebo|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated) vs. placebo.
16606430|NCT02570659|No Intervention|Information Folder|A folder with advise and exercises used by physiotherapeutic clinic of Södersjukhuset Hospital (Treatment as usual)
16606431|NCT02570659|Experimental|Information Video|A multiprofessional information video
16606432|NCT02570646|Experimental|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
16606433|NCT02570633|Experimental|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
16606434|NCT02570633|Placebo Comparator|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
16606435|NCT02570620|Experimental|Observational cohort of patients|Patients will benefit from an ultrasonography of the cervix through endovaginal before induction of prostaglandins
16606436|NCT02570594|Other|healthy volunteers|
16606437|NCT02570581|Placebo Comparator|Plain jelly control|Plain jelly control
16606438|NCT02570581|Active Comparator|Jelly with: Paracetamol|"Jelly with:
~Paracetamol"
16606439|NCT02570581|Active Comparator|Jelly with Furosemide|Jelly with Furosemide
16606440|NCT02570581|Active Comparator|Jelly with Levothyroxine sodium salt|Jelly with Levothyroxine sodium salt
16606441|NCT02570581|Active Comparator|Jelly with memantine|Jelly with memantine
16606442|NCT02570581|Active Comparator|jelly with zopiclone|Jelly with zopiclone
16606443|NCT02570581|Active Comparator|jelly with alprazolam|elly with alprazolam
16606444|NCT02570581|Active Comparator|jelly with Oxazepam|Jelly with Oxazepam
16606445|NCT02570581|Active Comparator|jelly with donepezil|jelly with donepezil
16606446|NCT02570581|Active Comparator|Jelly with clopidogrel|jelly with clopidogrel
16606447|NCT02570581|Active Comparator|jelly with ramipril|jelly with ramipril
16606448|NCT02570581|Active Comparator|jelly with Paracetamol + Furosemide + Levothyroxine sodium sa|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
16606449|NCT02570581|Placebo Comparator|Plain apple compote control|Plain apple compote control
16606450|NCT02570581|Active Comparator|Apple compote Paracetamol|Apple compote Paracetamol
16606451|NCT02570581|Active Comparator|Apple compote Furosemide|Apple compote Furosemide
16606452|NCT02570581|Active Comparator|Apple compote Levothyroxine sodium salt|Apple compote Levothyroxine sodium salt
16606453|NCT02570581|Active Comparator|Apple compote Memantine|Apple compote Memantine
16606454|NCT02570581|Active Comparator|Apple compote Zopiclone|Apple compote Zopiclone
16606455|NCT02570581|Active Comparator|Apple compote Alprazolam|Apple compote Alprazolam
16606456|NCT02570581|Active Comparator|Apple compote Oxazepam|Apple compote Oxazepam
16606457|NCT02570581|Active Comparator|Apple compote Donepezil|Apple compote Donepezil
16606458|NCT02570581|Active Comparator|Apple compote Clopidogrel|Apple compote Clopidogrel
16606459|NCT02570581|Active Comparator|Apple compote Ramipril|Apple compote Ramipril
16606460|NCT02570581|Active Comparator|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopi|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopiclone Alprazolam
16606488|NCT02570360|Placebo Comparator|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
16607951|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
16606461|NCT02570568|Active Comparator|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
16606462|NCT02570568|Experimental|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
16606463|NCT02570568|Experimental|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
16606464|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
16606465|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
16606466|NCT02570529|Experimental|Albis®|The intervention group
16606467|NCT02570529|Placebo Comparator|Placebo|The placebo comparator group
16606468|NCT02570516|Active Comparator|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
16606469|NCT02570516|Experimental|NBI colonoscopy|Colonoscopy using NBI is performed in first place
16606470|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
16606471|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
16606472|NCT02570490|Experimental|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
16606473|NCT02570490|Active Comparator|Linezolid|600 mg by mouth every 12 hours for 10 days
16606474|NCT02570477|Active Comparator|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
16606475|NCT02570477|Active Comparator|Standard Therapy|125mg Vancomycin four times per day
16606476|NCT02570464|Experimental|Patients undergoing aortic aneurysm surgery with RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery with Remote ischemic preconditioning (RIPC)
16606477|NCT02570464|Sham Comparator|Patients undergoing aortic aneurysm surgery without RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery without Remote ischemic preconditioning (RIPC)
16606478|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
16606479|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
16606480|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
16606481|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
16606482|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
16606483|NCT02570399|Experimental|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
16606484|NCT02570386|Active Comparator|Control arm|Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
16606485|NCT02570386|Active Comparator|Intervention arm|Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
16606486|NCT02570373|Experimental|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
16606487|NCT02570360|Active Comparator|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
16606489|NCT02570347|Active Comparator|Routine use arm|"All participants allocated to this arm will be given
~Injection Tetanus toxoid 0.5 ml intramuscularly Stat
~Antibiotic (Co-amoxiclav) will be given to all patients for a minimum duration of 5 days.
~Daily clinical assessment would be done. Change of antibiotics is allowed if clinical failure occurs.
~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
16606490|NCT02570347|Experimental|Clinically-directed use arm|"Participants allocated to this arm will be given
~Injection Tetanus toxoid 0.5 ml intramuscularly Stat
~Daily clinical assessment would be done. Antibiotic (Co-amoxiclav) will be started only if clinical failure occurs.
~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
16606491|NCT02570334|Experimental|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
16606492|NCT02570334|Experimental|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
16606493|NCT02570334|Experimental|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
16606494|NCT02570321|Experimental|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
16606495|NCT02570321|Active Comparator|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
16606496|NCT02570321|Experimental|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
16606497|NCT02570321|Active Comparator|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
16606498|NCT02570321|Experimental|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
16606499|NCT02570321|Active Comparator|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
16606500|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen.
16606501|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
16606502|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
16606503|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
16606504|NCT02570282|Experimental|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
16606505|NCT02570282|Placebo Comparator|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
16606506|NCT02570269|Active Comparator|AuraGain|The patient will get a fiberoptic Intubation via the AuraGain larynxmask
16606507|NCT02570269|Placebo Comparator|Slotted Guedeltubus|The patient will get a fiberoptic intubation via the slotted Guedeltubus
16606508|NCT02570256|Experimental|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
16606509|NCT02570256|Experimental|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
16606510|NCT02570256|Experimental|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
16606511|NCT02570243|Active Comparator|Standard dose of Heparin|50IU/Kg heparin intravenously
16606512|NCT02570243|Experimental|High dose of Heparin|100IU/Kg heparin intravenously
16606513|NCT02570230|Placebo Comparator|Control|NSS infusion
16606514|NCT02570230|Experimental|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
16606515|NCT02570217|Experimental|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
16606516|NCT02570217|Active Comparator|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
16606517|NCT02570204|Experimental|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
16606518|NCT02570191|Experimental|Peginterferon alfa-2a|Participants received 180 micrograms (uG) of Pegasys (0.5 milliliter [mL] solution) once a week subcutaneously for 48 weeks.
16606519|NCT02570178|No Intervention|standard practice advice|standard practice advice
16606520|NCT02570178|Other|balance training|balance training using the Nintendo™ Wii console and its balance board.
16606521|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606522|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606523|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606524|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606525|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606526|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606527|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
16606528|NCT02570152|Experimental|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
16606529|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
16606530|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
16606531|NCT02570126|Experimental|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
16606532|NCT02570126|Active Comparator|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
16606533|NCT02570113|Experimental|Renal Denervation by Neurolysis|Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
16606535|NCT02570087|Active Comparator|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
16606536|NCT02570087|No Intervention|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
16606537|NCT02570074|Experimental|Fosfomycin - 3 doses QoD/7 doses QD|Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
16606538|NCT02570074|Experimental|Fosfomycin - 7 doses QD/3 doses QoD|Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
16606539|NCT02570061|Experimental|telephone|Information about the Calmette study was given by telephone
16606540|NCT02570061|Active Comparator|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
16606541|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
16606542|NCT02570035||Mirabegron group|Subjects with overactive bladder and cardiovascular disease prescribed mirabegron
16606543|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
16606544|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
16606545|NCT02570009|Active Comparator|TEAMS|
16606546|NCT02570009|Active Comparator|TEAMS+|
16606547|NCT02569996|Experimental|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
16606548|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
16606549|NCT02569970|Active Comparator|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
16606550|NCT02569970|Placebo Comparator|PLACEBO|1 month of treatment before EEG video.
16606551|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16606552|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16606553|NCT02569944|Active Comparator|perineal bag|Perineal bag was placed in infants to collect an urine sample.
16606554|NCT02569944|Experimental|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
16606555|NCT02569931|Experimental|study group|"36 participants recruited aged between 18 to 50 years of age
~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:
~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.
~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.
~During surgery the study group will undergo intra-operative tracking and pressure measurements."
16606556|NCT02569931|Other|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.
~The control group will undergo gait analysis and electromyography."
16606557|NCT02569918|Experimental|Surface electrical stimulation|Operation of hand prosthesis with surface electrical sensory feedback
16606558|NCT02569905|Active Comparator|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
16606559|NCT02569905|Active Comparator|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
16606560|NCT02569905|Placebo Comparator|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
16606563|NCT02569879||Infants Group|"All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.
~All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.
~All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.
~All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014."
16606564|NCT02569879||Pregnant women Group|• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014
16606565|NCT02569866|Active Comparator|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
16606566|NCT02569866|Placebo Comparator|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
16606567|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
16606568|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
16606569|NCT02569840|Other|Amino Acid Feed|An amino acid based multi-nutrient powdered feed
16606570|NCT02569827|Placebo Comparator|Cohort 1|"Placebo Q6H for 5 days
~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
16606571|NCT02569827|Active Comparator|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
16606572|NCT02569827|Active Comparator|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
16606573|NCT02569827|Active Comparator|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
16606574|NCT02569814|Other|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
16606575|NCT02569814|Other|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
16606576|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
16606577|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
16606578|NCT02569788|Experimental|CIRT Arm|Patients included in this arm were treated with carbon ion radiotherapy (CIRT).
16606579|NCT02569775|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
16606580|NCT02569762|Experimental|Sucralose-Aspartame|Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
16606581|NCT02569762|Experimental|Aspartame-Sucralose|Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
16606582|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
16606583|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
16606584|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
16606585|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (<40%)
16606586|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
16606587|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
16606588|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus…). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis…
16606589|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
16606590|NCT02569710|Experimental|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
16606591|NCT02569710|Experimental|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
16606592|NCT02569710|Experimental|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
16606593|NCT02569710|Experimental|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
16606594|NCT02569710|Experimental|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
16606595|NCT02569710|Experimental|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
16606627|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
16606596|NCT02569710|Experimental|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
16606597|NCT02569710|Experimental|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram [mg], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
16606598|NCT02569697|Other|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
16606599|NCT02569697|Other|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
16606600|NCT02569697|Other|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
16606601|NCT02569697|Other|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
16606602|NCT02569684|Active Comparator|Arm A|Prebiotic fibers: Oligofructose and inulin
16606603|NCT02569684|Placebo Comparator|Arm B|Maltodextrin
16606604|NCT02569671|Other|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
16606605|NCT02569671|Other|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
16606606|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
16606607|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
16606608|NCT02569645|Experimental|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
16606609|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
16606610|NCT02569619|Experimental|Activity Intervention|The activity intervention is MoVo-LISA (Göhner & Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
16606611|NCT02569619|Active Comparator|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
16606612|NCT02569606||Timeframe 2005 - 2007|Data of timeframe 2005 up to 2007 will be included
16606613|NCT02569606||Timeframe 2012 - 2014|Data of timeframe 2012 up to 2014 will be included
16606614|NCT02569593|Other|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
16606615|NCT02569567||US elastography|"Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic.
~Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis."
16606616|NCT02569554|Experimental|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
16606617|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:
~6 months of treatment; or
~24 months of treatment (if continued on chronic suppressive therapy)"
16606618|NCT02569528||Patients|Patients of consenting providers will complete a short survey and interview.
16606619|NCT02569528||Providers|Physicians treating patients with atrial fibrillation will complete a short survey and interview.
16606620|NCT02569515|Experimental|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
16606621|NCT02569502|Experimental|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
16606622|NCT02569489|Experimental|HBI-8000, Paclitaxel, Trastuzumab|HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
16606623|NCT02569476|Experimental|BGB-3111 and obinutuzumab|In the dose-escalation part, the dose levels and regimens will be evaluated. In the indication-specific expansion cohorts, patients will be assigned to different cohorts based on histology type.
16606624|NCT02569463|Experimental|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
16606625|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
16606626|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
16606628|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
16606629|NCT02569424|Experimental|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
16606630|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
16606631|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
16606632|NCT02569398|Experimental|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
16606633|NCT02569398|Experimental|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
16606634|NCT02569398|Experimental|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
16606635|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
16606636|NCT02569372|Experimental|GC1102 80,000 IU(Single does)|GC1102 80,000 IU(Single does) I.V.
16606637|NCT02569372|Experimental|GC1102 120,000 IU(Single does)|GC1102 120,000 IU(Single does) I.V.
16606638|NCT02569372|Experimental|GC1102 180,000 IU(Single does)|GC1102 180,000 IU(Single does) I.V.
16606639|NCT02569372|Experimental|GC1102 240,000 IU(Single does)|GC1102 240,000 IU(Single does) I.V.
16606640|NCT02569372|Experimental|GC1102 80,000 IU(Multiple does)|GC1102 80,000 IU(Multiple does) I.V.
16606641|NCT02569372|Experimental|GC1102 120,000 IU(Multiple does)|GC1102 120,000 IU(Multiple does) I.V.
16606642|NCT02569372|Experimental|GC1102 180,000 IU(Multiple does)|GC1102 180,000 IU(Multiple does) I.V.
16606643|NCT02569372|Experimental|GC1102 240,000 IU(Multiple does)|GC1102 240,000 IU(Multiple does) I.V.
16606644|NCT02569359|Experimental|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
16606645|NCT02569359|Placebo Comparator|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
16606646|NCT02569346|Active Comparator|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
16606647|NCT02569346|Experimental|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
16606648|NCT02569346|Experimental|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
16606649|NCT02569333|Experimental|Educational Video|Subjects to have access to educational video during hospital stay
16606650|NCT02569333|No Intervention|Usual Care|Patients to receive usual care and will not have access to educational video.
16606651|NCT02569320|Experimental|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16606652|NCT02569307|Active Comparator|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
16606653|NCT02569307|Active Comparator|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
16606654|NCT02569307|Active Comparator|Placebo|Placebo added to TAU
16606655|NCT02569307|Active Comparator|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
16606656|NCT02569294|Experimental|Choice 1: Yoga intervention|See intervention description
16606657|NCT02569294|Experimental|Choice 2: Hypnosis intervention|See intervention description
16606658|NCT02569294|Experimental|Choice 3: CBT intervention|See intervention description
16606659|NCT02569294|No Intervention|Control group|Participants who agreed not to participate in any of the interventions proposed.
16606660|NCT02569281|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
16606661|NCT02569281|Active Comparator|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
16606662|NCT02569268||exposure population|No special intervention(s) .
16606663|NCT02569242|Experimental|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
16606664|NCT02569242|Active Comparator|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
~OR
~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
16606665|NCT02569229||Patients with Cystic Fibrosis|Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children's hospital Basel and university children's hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
16606666|NCT02569216|Experimental|Electrical Inhibition (EI) intervention|Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
16606667|NCT02569203|Placebo Comparator|control group|standard enteral nutrition
16606668|NCT02569203|Experimental|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
16606669|NCT02569203|Experimental|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
16606670|NCT02569190|Experimental|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
16606671|NCT02569138|Experimental|Insole (Experimental)|specially designed insole, featuring hard and thin design, modified insole
16606672|NCT02569138|Experimental|Insole (Control)|usual insole found in footwear, non-modified insole
16606673|NCT02569125|Experimental|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
16606674|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
16606675|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
16606676|NCT02569099|Experimental|Intervention using standardised care|"Caregiver training /standardised care: where the participants (caregivers)s are trained on caring for relative who has survived a stroke once only for one hour using a developed curriculum.
~Plus Conventional care: where the participants continue to receive the usual care as offered in protocols for treatment of stroke in Zimbabwe."
16606677|NCT02569099|No Intervention|Control|No training offered to caregivers but conventional care only where the people who have survived a stroke receive the usual care as offered in protocols for treatment of stroke in Zimbabwe.
16606678|NCT02569073|Experimental|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
16606679|NCT02569073|Placebo Comparator|Placebo|Patients who receive Placebo every other night, orally
16606680|NCT02569060|Experimental|Immediate Intervention|"Participants randomized to the Intervention Arm will immediately begin a four-component intervention.
~Testing and monitoring of blood glucose levels
~Referral to and/or coordination with primary care provider
~Diabetes-appropriate food packages
~Diabetes self-management education and support"
16606681|NCT02569060|Active Comparator|Waitlist Control|"Participants randomized to the Waitlist Control arm will receive no intervention for six months, after which time they will begin a modified, four-component intervention.
~Testing and monitoring of blood glucose levels
~Referral to and/or coordination with primary care provider
~Diabetes-appropriate food packages
~Limited diabetes self-management education and support"
16606682|NCT02569047|Active Comparator|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
16606683|NCT02569047|Experimental|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
16606684|NCT02569034|Active Comparator|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
16606685|NCT02569034|Experimental|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
16606686|NCT02569021||Biphasic DBS stimulations|Subjects in this group will have Biphasic DBS stimulation setting performed, Unified Parkinson's Disease Rating Scale (UPDRS), Tremor Rating Scale (TRS), kinesia accelerometer assessment, Trigno wireless system (EMG) assessment and GaitRite walking assessment performed.
16606687|NCT02569008|Experimental|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
16606688|NCT02569008|Experimental|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
16606689|NCT02569008|Experimental|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
16606690|NCT02569008|Experimental|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
16606691|NCT02568995|Experimental|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
16606692|NCT02568995|Active Comparator|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
16606693|NCT02568982||patient with Cushing's disease|
16606694|NCT02568969|Experimental|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
16606695|NCT02568930||Heart Transplantation (HT)|The cohort includes advanced heart failure patients (60-80 years of age) listed for HT and their caregivers.
16606696|NCT02568930||Mechanical Circulatory Support (MCS)|The cohort includes advanced heart failure patients (60-80 years of age) scheduled for DT MCS and their caregivers.
16606697|NCT02568917|Active Comparator|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
16606698|NCT02568917|Experimental|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
16606699|NCT02568904||Alcohol binge|Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge
16606700|NCT02568904||Fructose|75 g Fructose orally
16606701|NCT02568904||Glucose|75 g Glucose orally
16606702|NCT02568904||Vehicle|2ml tap water per kg body weight
16606703|NCT02568891|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
16606704|NCT02568891|Placebo Comparator|Placebo|similar looking and tasting placebo without bacteria
16606705|NCT02568878|Experimental|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
16606709|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
16606710|NCT02568839|Active Comparator|A standard treatment|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.
~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
16606711|NCT02568839|Experimental|B experimental treatment|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.
~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
16606712|NCT02568826|Experimental|IDN 5243|IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities for intramuscular administration in 4 mg/mL vials. It will be administered twice daily for 5 consecutive days with the first administration in the morning (8.00-10.00 AM) and the second in the evening (6.00-8.00 PM).
16606713|NCT02568813|Experimental|Scales passation|
16606714|NCT02568800|Experimental|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
16606715|NCT02568800|Active Comparator|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
16606716|NCT02568787|Experimental|Rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
16606717|NCT02568787|Placebo Comparator|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
16606718|NCT02568774|Experimental|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
16606719|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
16606720|NCT02568761|Active Comparator|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
16606721|NCT02568761|Active Comparator|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
16606722|NCT02568748|Experimental|CIK with TACE for HCC stage B|HCC patients stage B treated with TACE and CIK as adjuvant therapy.
16606723|NCT02568748|Experimental|TACE only for HCC stage B|HCC patients stage B treated with TACE without receiving CIK cells infusion
16606724|NCT02568748|Experimental|CIK in HCC stage C or D|HCC stage C or D will receive supportive treatment in addition to CIK cells infusion
16606725|NCT02568748|No Intervention|Supportive treatment in HCC stage C or D|HCC stage C or D will receive supportive treatment only .
16606726|NCT02568735|Experimental|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight> 90kg by mouth
16606727|NCT02568735|Active Comparator|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
16606728|NCT02568722|Active Comparator|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
16606729|NCT02568722|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
16606730|NCT02568709|Active Comparator|Interventional|40 IU Oxytocin
16606731|NCT02568709|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
16606732|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
16606733|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
16606734|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
16606735|NCT02568670|Experimental|according to clinical signs|removal the peripheral catheter according to clinical signs
16606736|NCT02568670|No Intervention|sistematically every 96 hours|removal the peripheral catheter every 96 hours
16606737|NCT02568657|Active Comparator|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
16606738|NCT02568657|Active Comparator|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
16608224|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
16606739|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
16606740|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
16606741|NCT02568631|Experimental|serious game JeStiMulE|"Evaluation of the social cognition for adults with autism.
~The objective of the players of JeStiMulE (Educational Game for Multisensory Stimulation of Children with developmental disorders) will be to end the game after a period of learning and two periods of game (with emotional words and with idiomatic expressions understanding each three modules). The session ends when the module is carried out, what corresponds approximately at 1 am by module, that is 6 sessions of game.
~Evaluation of the social cognition for adults with autism."
16606742|NCT02568631|Placebo Comparator|control video game|"Evaluation of the social cognition for adults with autism.
~The objective of the players of the control video game will be to play 6 sessions of one hour.
~Evaluation of the social cognition for adults with autism."
16606743|NCT02568618|Other|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
16606744|NCT02568618|Other|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
16606745|NCT02568605|Experimental|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
16606746|NCT02568605|Placebo Comparator|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
16606747|NCT02568605|Other|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
16606748|NCT02568592|Experimental|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
16606749|NCT02568592|Experimental|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
16606750|NCT02568592|Experimental|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
16606751|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
16606752|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
16606753|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
16606755|NCT02568527|Experimental|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
16606756|NCT02568514|No Intervention|Usual care|Patients admitted to hospital floors without any other intervention.
16606757|NCT02568514|Experimental|Secure text messaging|Patients admitted to hospital floors on which physicians and other staff are able to communicate with each other (not to the patient) using mobile secure text messaging.
16606758|NCT02568501|Experimental|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
16606759|NCT02568501|Experimental|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
16606760|NCT02568488|Experimental|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
16606761|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
16606762|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
16606763|NCT02568462|Experimental|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
16606764|NCT02568449|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16606765|NCT02568436|No Intervention|Conventional Decrowding|Crowded upper incisors will be treated in the conventional manner with a fake irradiation without using low level laser therapy.
16606766|NCT02568436|Experimental|Low Level Laser Therapy|Each maxillary incisor will be subjected to low level laser therapy at specific times in order to accelerate tooth movement
16606767|NCT02568423|Experimental|Mirikizumab IV|Mirikizumab given by intravenous (IV) infusion once.
16606768|NCT02568423|Experimental|Mirikizumab SC|Mirikizumab given by subcutaneous (SC) injection once.
16606769|NCT02568423|Placebo Comparator|Placebo IV|Placebo given by IV infusion once.
16606770|NCT02568423|Placebo Comparator|Placebo SC|Placebo given by SC injection once.
16606771|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
16606772|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
16606773|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
16608225|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
16606774|NCT02568384|Experimental|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:
~40 to 70% of subjects will have type 1 diabetes
~Not more than 30% of subjects will use an insulin pump"
16606775|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
16606776|NCT02568332|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.
~Subjects: 20 HIV seropositive individuals"
16606777|NCT02568319|Experimental|LIPO-202|Experimental arm
16606778|NCT02568319|Placebo Comparator|Placebo|Placebo comparator
16606779|NCT02568306|Experimental|NNC0165-1562|
16606780|NCT02568306|Placebo Comparator|Placebo|
16606781|NCT02568293|Experimental|SBCV|SBCV is administered to the site immediately post balloon dilation.
16606782|NCT02568293|Placebo Comparator|Control|Saline is used as a control and is delivered immediately post balloon dilation.
16606783|NCT02568280|Experimental|Faster aspart|
16606784|NCT02568280|Active Comparator|Insulin aspart|
16606794|NCT02568254|Active Comparator|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
16606795|NCT02568254|Active Comparator|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
16606796|NCT02568254|Active Comparator|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
16606797|NCT02568254|Active Comparator|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
16606798|NCT02568254|Active Comparator|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
16606799|NCT02568254|Active Comparator|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
16606800|NCT02568241|Experimental|interferon Alfa-2b|High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI
16606801|NCT02568228|Experimental|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to ~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
16606802|NCT02568228|Experimental|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to ~900 mg/day EPA + DHA + DPA.
16606803|NCT02568228|Placebo Comparator|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
16606804|NCT02568215|Experimental|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
16606805|NCT02568215|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
16606806|NCT02568215|Placebo Comparator|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
16606807|NCT02568202||Survey|
16606808|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
16606809|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
16606810|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
16606811|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
16606812|NCT02568176|Experimental|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
16606813|NCT02568176|Experimental|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
16606815|NCT02568150|Other|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
16606816|NCT02568137|Experimental|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
16606817|NCT02568137|No Intervention|Usual background care|Standard care
16606818|NCT02568124|Experimental|Tranexamic acid|Tranexamic acid 750 mg daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
16606819|NCT02568124|Placebo Comparator|Placebo|Placebo tablet daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
16606820|NCT02568111|Experimental|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
16606821|NCT02568111|Placebo Comparator|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
16606822|NCT02568098|Experimental|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
16606823|NCT02568098|Experimental|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
16606824|NCT02568098|Experimental|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
16606825|NCT02568085|Experimental|1|thyroidectomy + Arista
16606826|NCT02568085|No Intervention|2|Thyroidectomy
16606827|NCT02568085|Experimental|3|Thyroidectomy with neck + Arista
16606828|NCT02568085|No Intervention|4|Thyroidectomy with neck
16606829|NCT02568059|Experimental|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
16606830|NCT02568059|Experimental|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
16606831|NCT02568046|Experimental|Sym004 12 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level 1
16606832|NCT02568046|Experimental|Sym004 9 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level -1
16606833|NCT02568046|Experimental|Sym004 (RP2D) + FOLFIRI|Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI
16606834|NCT02568033|Experimental|A|"Chemotherapy:
~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle
~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle
~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions
~Schedule is:
~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
16606835|NCT02568020|No Intervention|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
16606836|NCT02568020|Experimental|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
16606837|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
16606838|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
16606839|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
16606840|NCT02567994|Experimental|Teneligliptin|20mg qd
16606841|NCT02567994|Active Comparator|Sitagliptin|100mg qd
16606842|NCT02567981|Experimental|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
16606843|NCT02567981|Active Comparator|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
16606844|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
16606845|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
16606846|NCT02567955|Active Comparator|Immunogenicity two doses of Gardasil-9|Subjects will receive two doses of Gardasil-9
16606847|NCT02567955|Experimental|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a dose Cervarix and a dose Gardasil-9
16606848|NCT02567942|Other|propofol group|The patient who anesthetized by using propofol.
16606849|NCT02567942|Other|sevoflurane group|The patient who anesthetized by using propofol.
16606850|NCT02567929|Active Comparator|propofol group|The patient who anesthetized by using propofol.
16606851|NCT02567929|Active Comparator|sevoflurane group|The patient who anesthetized by using propofol
16606852|NCT02567916|Experimental|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
16606853|NCT02567916|Active Comparator|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
16606854|NCT02567903|Active Comparator|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
16606855|NCT02567903|Experimental|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
16606856|NCT02567890|Experimental|Internet-based DBI|Internet-based DBI, which consists of four interactive occasions, some homework assignments, and monitoring
16606857|NCT02567890|Placebo Comparator|Expressive writing|Expressive Writing (placebo/attention control) where participants write texts. This is the active control condition.
16606919|NCT02567409|Experimental|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
16606858|NCT02567890|No Intervention|Waiting list|A wait-list control condition.Those in the wait-list condition will not receive any treatment until they have done the 6-month follow-up assessment.
16606859|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
16606860|NCT02567864|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
16606861|NCT02567864|Active Comparator|control|The control group maintains daily activities.
16606862|NCT02567851|Experimental|Brentuximab Vedotin|brentuximab vedotin will be administered at an initial dose of 1.8 mg/kg every 3 weeks as a 30-minute outpatient i.v. infusion. A maximum of 16 cycles
16606863|NCT02567838|Experimental|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
16606864|NCT02567838|Placebo Comparator|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
16606865|NCT02567825|Active Comparator|Surgical Management|Tympanostomy Tube Placement Topical antimicrobial treatment of acute otitis media episodes with ofloxacin drops
16606866|NCT02567825|Other|Non-Surgical Management|Antimicrobial treatment of acute otitis media episodes with amoxicillin-clavulanate and/or ceftriaxone
16606867|NCT02567812||In-patient with PID|In-patient with PID who diagnosed at Kangbuk Samsung Hospital
16606868|NCT02567799|Experimental|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
16606869|NCT02567786|Active Comparator|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
16606870|NCT02567786|Active Comparator|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
16606871|NCT02567773|Experimental|Part A: GSK2881078|The first cohort subjects will receive GSK2881078 1.5 mg (for males) or 0.75 mg (for females) twice daily for 3 days followed by once daily for 25 days. The subsequent cohort subjects will receive GSK2881078 doses selected after reviewing the unblinded data from at least 2 weeks of dosing of at least 6 subjects in the first cohort. Each cohort subjects will receive GSK2881078 dose twice daily for the first 3 days followed by 25 days of once daily.
16606872|NCT02567773|Placebo Comparator|Part A: Placebo|Subjects will receive placebo twice daily for 3 days followed by once daily for 25 days.
16606873|NCT02567773|Experimental|Part B: GSK2881078-Itraconazole|Subjects will receive GSK2881078 (dose level will be determined based on the results from Part A) on Day 1 of Period-1 and Day 6 of Period-2. Subjects will also receive itraconazole 200 mg twice daily on Day1 of Period-2 and 200 mg once daily on Days 2-34 of Period-2.
16606874|NCT02567760|Active Comparator|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
16606875|NCT02567760|Placebo Comparator|Placebo group|Subject receive the Placebo product for 8 weeks.
16606876|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
16606877|NCT02567734|Experimental|Irreversible electroporation|In this group，eligible patients were selected to receive the CT-guided percutaneous irreversible electroporation ablation.
16606878|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
16606879|NCT02567708|Experimental|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
16606880|NCT02567695|Experimental|Treatment Sequence 1|Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.
16606881|NCT02567695|Experimental|Treatment Sequence 2|Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.
16606882|NCT02567682|Experimental|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
16606883|NCT02567656|Experimental|Single arm|RP6530 administered orally twice a day.
16606884|NCT02567643|Experimental|Stereotactic Radiosurgery|
16606885|NCT02567617|Active Comparator|Intervention group|Group receiving capsules with polyphenols.
16606886|NCT02567617|Placebo Comparator|Placebo controlled group|Group receiving capsules with starch.
16606887|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
16606888|NCT02567591|Experimental|A: physical activity program|at home physical activity program (during 12 weeks)
16606889|NCT02567591|No Intervention|B: conventional management|conventional management
16606890|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
16606891|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
16606892|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
16606893|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
16606894|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
16606895|NCT02567552|Experimental|Prolutex|Subcutaneous progesterone
16606896|NCT02567552|Active Comparator|Prontogest|Intramuscular progesterone
16606897|NCT02567539|Experimental|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
16607123|NCT02565914|Experimental|Part A: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
16606898|NCT02567526|No Intervention|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
16606899|NCT02567526|Experimental|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
16606900|NCT02567513|No Intervention|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
16606901|NCT02567513|Experimental|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
16606902|NCT02567513|Experimental|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
16606903|NCT02567500|Experimental|Patients with auditory hallucination|"Patients with auditory hallucination:
~Evaluation at time 0 and 6 month after of:
~The social cognitive marker (NeuroPsychologic assessment (NEPSY) II) : theory of mind and affect recognition
~The emotional marker:
~Differential Emotion Scale IV (DES IV): emotional individual stability
~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:
~Mini International Neuropsychiatric Interview (MINI) -Kids
~Psychosis section of Kiddie-SADS"
16606904|NCT02567500|Placebo Comparator|Patients without auditory hallucination|"Patients without auditory hallucination:
~Evaluation at time 0 and 6 month after of:
~The social cognitive marker (NEPSY II) : theory of mind and affect recognition
~The emotional marker:
~Differential emotion scale IV (DES IV): emotional individual stability
~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:
~Mini International Neuropsychiatric Interview (MINI) -Kids
~Psychosis section of Kiddie-SADS (Schedule for Affective Disorders and Schizophrenia )"
16606905|NCT02567487|Active Comparator|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
16606906|NCT02567487|Active Comparator|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
16606907|NCT02567474|No Intervention|control|no intervention
16606908|NCT02567474|Experimental|intervention|self management intervention based on 5A model
16606909|NCT02567461|Experimental|DAPT plus high-dose edoxaban|High-dose edoxaban will be represented by edoxaban 60mg od, which will be reduced to 30mg od in patients with ClCr ≤50mL/min.
16606910|NCT02567461|Experimental|DAPT plus low-dose edoxaban|Low-dose edoxaban will be defined as edoxaban 30mg od, which will be reduced to 15mg od in patients with ClCr ≤50mL/min.
16606911|NCT02567461|Active Comparator|DAPT|Aspirin 81 mg od plus clopidogrel 75 mg od
16606912|NCT02567448|Active Comparator|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
16606913|NCT02567448|Active Comparator|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
16606914|NCT02567435|Experimental|Regimen A (VAC/VI)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
16606915|NCT02567435|Experimental|Regimen B (VAC/VI/temsirolimus)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
16606916|NCT02567435|Experimental|Regimen C (FOXO1 fusion negative, VAC/VA)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
16606918|NCT02567409|Experimental|Arm A (berzosertib, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
16608377|NCT02557802|Experimental|Group B|Intramuscular injection at day 0, nasal spray at day 28
16606920|NCT02567396|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16606921|NCT02567383|Experimental|Hyperthermia|Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
16606922|NCT02567370|Placebo Comparator|Placebo|
16606923|NCT02567370|Active Comparator|AMG 581|
16606924|NCT02567357|Active Comparator|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
16606925|NCT02567357|Experimental|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
16606926|NCT02567344|Experimental|Active rTMS|Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
16606927|NCT02567344|Sham Comparator|Sham rTMS|Sham rTMS will be delivered to the Left DLPFC at 10 Hz using an electronic sham system used in multiple other investigations. A total of 4000 pulses of sham rTMS will be delivered.
16606928|NCT02567331|Experimental|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
16606929|NCT02567318|Experimental|MRI-scan|All study participants will complete a MRI-scan of the brain
16606930|NCT02567305||Actual Sepsis|"For infants below 44 weeks inclusive of corrected age clinical sepsis is defined, according to the Expert Meeting on Neonatal and Pediatric Sepsis (Report on the Expert Meeting on Neonatal and Pediatric Sepsis - 8 June 2010, EMA London). Confirmed sepsis is defined as positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)
~For children above 44 weeks corrected age clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005). Confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)"
16606931|NCT02567305||Suspected Sepsis|None of the above.
16606932|NCT02567292|No Intervention|Retrospective Control Group|Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
16606933|NCT02567292|Experimental|Exclusive Human Milk Diet Group|A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or <2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants >37 weeks and/or >2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
16606934|NCT02567279|Active Comparator|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
16606935|NCT02567279|Placebo Comparator|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
16606936|NCT02567266|Experimental|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
16606937|NCT02567266|Experimental|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
16606938|NCT02567266|Active Comparator|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
16606939|NCT02567253|Experimental|low dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
16606940|NCT02567253|Experimental|high dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
16606941|NCT02567253|Experimental|low dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
16606942|NCT02567253|Experimental|high dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
16606943|NCT02567240|Experimental|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
16606944|NCT02567240|No Intervention|Normal mediums|Islets will be harvested with regular mediums
16606945|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
16606946|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
16606947|NCT02567214|Experimental|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled
~1 time per day 21 days"
16606948|NCT02567214|Experimental|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled
~1 time per day 21 days"
16606949|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
16606950|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
16607124|NCT02565914|Experimental|Part B: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
16606951|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
16606952|NCT02567149|Experimental|Cidofovir|Cidofovir clinical resolution of treated warts as evaluated by the investigators
16606953|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
16606954|NCT02567136||Healthy Controls|Healthy control volunteers
16606955|NCT02567123|Experimental|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
16606956|NCT02567123|No Intervention|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
16606957|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
16606958|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
16606959|NCT02567097|Active Comparator|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
16606960|NCT02567097|Active Comparator|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
16606961|NCT02567097|Experimental|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
16606962|NCT02567097|Experimental|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
16606963|NCT02567084|Other|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc"
16606964|NCT02567071|Experimental|Intervention Group|75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
16606965|NCT02567071|Placebo Comparator|Placebo Group|75 children born by planned C-section will be exposed to clean swab.
16606966|NCT02567071|No Intervention|Control Group|75 children born vaginally.
16606967|NCT02567058|Experimental|3 groups of subjects|"3 groups:
~group I : healthy volunters
~group II : patient with an immobilisation (between 1 and 2 months)
~group III : patient with an antecedent of Achilles tendon breakage during the 10 past years
~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
16606968|NCT02567045|Experimental|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.
~Colonoscopy will be performed in case of a positive FIT."
16606969|NCT02567045|Active Comparator|one-time Colonoscopy|One-time Colonoscopy with sedation
16606970|NCT02567032|Experimental|Oxytocin|40 IU Oxytocin
16606971|NCT02567032|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
16606972|NCT02567019|Experimental|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
16606973|NCT02567019|Active Comparator|healthy volunteers|blood samples will be done for healthy volunteers
16606974|NCT02567006|Active Comparator|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
16606975|NCT02567006|Placebo Comparator|Usual care|Not receiving SMS messages
16606979|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
16606980|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
16606981|NCT02566967|Other|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
16606982|NCT02566954|Experimental|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.
~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
16606983|NCT02566941|Experimental|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
16606984|NCT02566941|No Intervention|Control|
16607001|NCT02566824|Active Comparator|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
16607125|NCT02565914|Experimental|Part C: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
16606985|NCT02566928|Experimental|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
16606986|NCT02566928|No Intervention|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
16606987|NCT02566915|No Intervention|CPET submaximal without EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.
16606988|NCT02566915|Experimental|CPET submaximal with EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.
16606989|NCT02566902|Active Comparator|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
16606990|NCT02566902|Experimental|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
16606991|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
16606992|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
16606993|NCT02566876|Active Comparator|Mixture of three Bifidobacteria|Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
16606994|NCT02566876|Placebo Comparator|Placebo|Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
16606996|NCT02566850|Experimental|Ekso Users|SCI subjects using Ekso
16606997|NCT02566837|Active Comparator|ELEC|electrical stimulation guidance
16606998|NCT02566837|Experimental|ECHO|ultrasound guidance
16606999|NCT02566824|Experimental|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
16607000|NCT02566824|Active Comparator|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
16607122|NCT02565927|Active Comparator|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
16607002|NCT02566811|Experimental|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)* with lymph node dissection to determine whether lymph nodes are positive or negative:
~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only
~Patients will then be followed up, to include assessment of adverse events and quality of life.
~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
16607003|NCT02566811|Active Comparator|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)*. Patients will receive systemic adjuvant treatment to include chemotherapy.
~Patients will then be followed up, to include assessment of adverse events and quality of life.
~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
16607004|NCT02566798|Experimental|Oleogrape|Patients are taking capsules of OleograpeSEED (Extract of grape and olive) 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days
16607005|NCT02566798|Placebo Comparator|Placebo|Patients are taking capsules of placebo (lactose) 3 times a day in the morning, at noon and in the evening during 7 days
16607006|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
16607007|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
16607008|NCT02566772|Experimental|TAS3681|All participants will receive TAS3681 in 28-day cycles. The Escalation phase includes participants who have progressed after abiraterone, enzalutamide and chemotherapy. Eleven dose escalation cohorts are planned, one of which includes a preliminary assessment of food effect. The MTD/recommended dose for further development will be used for participants in the Expansion Phase. The Expansion Phase will enroll participants who have progressed after abiraterone or enzalutamide with chemotherapy consisting of no more than 2 prior taxane-based therapies (Group A) or without any chemotherapy (Group B). Participants receive TAS3681 until discontinuation criteria are met.
16607009|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
16607010|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
16607011|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
16607012|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
16607013|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
16607014|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
16607015|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
16607016|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
16607017|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
16607018|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
16607019|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
16607020|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
16607021|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
16607022|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
16607023|NCT02566746|Experimental|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
16607024|NCT02566746|Active Comparator|Continuation of optimal medical therapy|"Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde during 12 months.
~At 12 months : patients will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter during 12 months."
16607025|NCT02566733|Experimental|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
16607026|NCT02566733|Active Comparator|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
16607203|NCT02565394|No Intervention|Comparator|A baseline survey will be completed following a surgical day with no dynamic activities
16607027|NCT02566720|Other|Treatment and MRI scanning|After informed consent has been obtained, the subjects will be examined by a physician and assigned a Disability Ratings Scale (DRS) score. Subjects will undergo MRI tractography study, which does not require the administration of contrast. All participants will receive oral amantadine at escalating doses to ensure tolerance (50mg twice daily for 7 days, then 100mg twice daily for 1 week, then 150mg twice daily, then 200mg twice daily). The usual length of stay on the inpatient brain injury program is ninety days. The MRI tractography study and DRS score will be repeated near the time of discharge or ninety days from enrollment.
16607028|NCT02566707|Experimental|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
16607029|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
16607030|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
16607031|NCT02566681|Experimental|MSC construct for Osteonecrosis|Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
16607032|NCT02566668||Asthmatic|1 year observational follow-up
16607033|NCT02566668||Non-Asthmatic|1 year observational follow-up
16607034|NCT02566655|Experimental|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
16607035|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
16607036|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
16607037|NCT02566629||healthy controls|collect faeces from healthy controls
16607038|NCT02566616|Experimental|Intervention|"Cubital Tunnel Release with stimulator for nerve location
~1 hour of Ulnar nerve stimulation"
16607039|NCT02566616|Active Comparator|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
16607040|NCT02566603|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
16607041|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
16607042|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
16607043|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
16607044|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
16607045|NCT02566564|Experimental|open label, single arm|Open label, single arm, dose escalating
16607046|NCT02566551|Experimental|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
16607047|NCT02566551|Active Comparator|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
16607048|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
16607049|NCT02566525|No Intervention|Control|Standard of care
16607050|NCT02566512|Other|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
16607051|NCT02566512|Other|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
16607052|NCT02566499|Experimental|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
16607053|NCT02566486|Other|Reciprocating system|Waveone root canal instrumentation file
16607054|NCT02566486|Other|Rotational system|ProTaper Next root canal instrumentation file
16607055|NCT02566460|Experimental|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
16607056|NCT02566460|Sham Comparator|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
16607057|NCT02566447||Symptomatic|Subjects will be categorized by the clinician as symptomatic for Trichomonas vaginalis infection.
16607058|NCT02566434|Experimental|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
16607059|NCT02566421|Experimental|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
16607060|NCT02566408|Experimental|Supportive Care (interview about KAPs towards PA)|"Participants undergo a 2-hour one-on-one interview and answer survey questions about their beliefs, attitudes, and preferences (KAPs) towards physical activity (PA). Ten topics will be used to explore older women's attitudes toward PA. Six topics will also be used to explore ethnic-specific and culture-specific contexts that surround older women's participation in PA.
~REFINEMENT OF THE PA INTERVENTION: Approximately 1-2 months after the conclusion of interviews, participants are invited to a joint session and presented with results of analyzed data. Participants are asked to review results and themes identified from interviews, and to concur whether conclusions capture their KAPs. Through this process a set of preferences that is agreed upon by all as most critical for enhancing PA participation, adherence, and retention will be identified."
16607061|NCT02566395|Experimental|Haploidentical Stem Cell Transplantation|Subjects will receive pretransplantation conditioning of total-body irradiation (1,200 cGy delivered in 8 fractions over 4 days [Days -9 through -6] and cyclophosphamide (60 mg/kg IV daily x 2 on Days -3 and -2). Donor lymphocyte infusion will occur on day -6; donor CD34+ cells will be infused on Day 0.
16607062|NCT02566382|Experimental|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
16607063|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
16607064|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
16607065|NCT02566356|Experimental|Oxytocin|40 IU Oxytocin
16607066|NCT02566356|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
16607067|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
16607068|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
16607069|NCT02566330||EndoBarrier|Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
16607070|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
16607071|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
16607072|NCT02566304|Experimental|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -7.
~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
16607073|NCT02566291||Supreme Group|Measuring Success rate and Insertion Time
16607074|NCT02566291||Gain Group|Measuring Success rate and Insertion Time
16607075|NCT02566278|Experimental|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) > 3 months to verify the Pcrit measurement obtained by the clinical equipment.
16607076|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
16607077|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
16607078|NCT02566252|Experimental|PUL-042|PUL-042 Inhalation Solution
16607079|NCT02566252|Experimental|Cromolyn sodium|Pre-Treatment with cromolyn sodium followed by PUL-042 Inhalation Solution Administration
16607080|NCT02566252|Experimental|Albuterol sulfate|Pre-Treatment with albuterol sulfate followed by PUL-042 Inhalation Solution Administration
16607081|NCT02566239|Experimental|Shared Data|"Share activity data with care team.
~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.
~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
16607082|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.
~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
16607083|NCT02566226|Placebo Comparator|Bupivacaine with normal saline|
16607084|NCT02566226|Active Comparator|Bupivacaine with intrathecal morphine|
16607085|NCT02566213|Other|Motor skills measurements|
16607086|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
16607087|NCT02566187|Other|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
16607088|NCT02566187|Other|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
16607089|NCT02566161||Trio Cohort|families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).
16607090|NCT02566148||HIV group|group living with HIV
16607091|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
16607092|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
16607093|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
16607094|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
16607095|NCT02566122||muscle strength ,muscle mass|
16607096|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
16607204|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch
~In-person smoking cessation counseling"
16607097|NCT02566096|Placebo Comparator|TAP with bupivicaine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
16607098|NCT02566096|Active Comparator|TAP with bupivicaine with morphine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
16607099|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
16607100|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
16607101|NCT02566070|Active Comparator|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
16607102|NCT02566070|Experimental|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
16607103|NCT02566057|Experimental|PGx testing guided treatment (PGT)|Results of the GeneceptTM Assay will be provided to their prescribers who may use the knowledge to guide medication management.
16607104|NCT02566057|No Intervention|Treatment as usual condition (TAU)|Patients will also utilize the GeneceptTM Assay but the results will not be provided back to their prescribers, who will treat the patients without the knowledge of pharmacogenetic testing results.
16607105|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).
~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.
~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
16607106|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).
~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.
~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
16607107|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
16607108|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
16607109|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
16607110|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.
~In general all proximal humerus fractures were operated except minimally or undisplaced."
16607111|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
16607112|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
16607113|NCT02565992|Experimental|CAVATAK and pembrolizumab|Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
16607114|NCT02565979|Active Comparator|Resveratrol|resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
16607115|NCT02565979|Placebo Comparator|Placebo|placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
16607116|NCT02565966|Experimental|Modified Atkins Diet (MAD)|
16607117|NCT02565966|No Intervention|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
16607118|NCT02565953|Experimental|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
16607119|NCT02565953|Active Comparator|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
16607120|NCT02565940||diabetic patient with foot infection|
16607121|NCT02565927|Experimental|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
16607126|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
16607127|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
16607128|NCT02565888|Active Comparator|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
16607129|NCT02565888|Experimental|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
16607130|NCT02565875|Experimental|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator
~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
16607131|NCT02565875|Placebo Comparator|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator
~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
16607132|NCT02565862|Active Comparator|Treatment A|"Day 1-2: 500mg twice daily (BID) metformin film-coated tablets
~Day 3-8: 1000mg BID metformin film-coated tablets"
16607133|NCT02565862|Experimental|Treatment B|"Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets
~Day 17-22: 1000mg BID metformin film-coated tablets
~+ 60mg QD daclatasvir film-coated tablets"
16607134|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
16607135|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
16607136|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
16607137|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
16607138|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
16607139|NCT02565823|Experimental|Exercise intervention|Subjects will undergo an acute bout of exercise for 45 mins at 75% of peak aerobic capacity
16607140|NCT02565810|Experimental|SB5 40mg|
16607141|NCT02565797|Experimental|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
16607142|NCT02565797|Experimental|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
16607143|NCT02565797|No Intervention|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
16607144|NCT02565784|Experimental|Intradermal injection|Restylane and/or Perlane
16607145|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
16607146|NCT02565758|Experimental|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
16607147|NCT02565758|Experimental|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
16607148|NCT02565745|Experimental|Skin Dressing|Hydrocolloid dressings applied during hospitalization
16607149|NCT02565745|Active Comparator|Moisturizing cream|Use of moisturizing cream, as part of conventional skin care
16607150|NCT02565732|Experimental|Dose A|Botulinum toxin type A
16607151|NCT02565732|Experimental|Dose B|Botulinum toxin type A
16607152|NCT02565732|Placebo Comparator|Dose C|Placebo comparator
16607153|NCT02565719|Experimental|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
16607154|NCT02565719|Experimental|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
16607155|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
16607156|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
16607157|NCT02565706|Active Comparator|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
16607158|NCT02565706|Active Comparator|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
16607159|NCT02565706|Experimental|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
16607160|NCT02565706|Active Comparator|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
16607161|NCT02565693|Experimental|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:
~Age ≥ 80 years
~Body weight ≤ 60 kg
~Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
16607162|NCT02565693|Other|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:
~- No antithrombotic treatment
~or:
~Acetylsalicylic acid 80 mg once daily
~Carbasalate calcium 100 mg once daily
~Clopidogrel 75 mg once daily
~Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily
~Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
16607163|NCT02565680|Placebo Comparator|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
16607164|NCT02565680|Experimental|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
16607165|NCT02565667|Experimental|KOL group|KOL stapler was used for rectal anastomosis
16607166|NCT02565667|Active Comparator|traditional stapler group|traditional stapler was used for rectal anastomosis
16607167|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
16607168|NCT02565641|Experimental|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
16607169|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
16607170|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
16607171|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
16607172|NCT02565602|Other|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
16607173|NCT02565589||ICU patient|Critically ill patients who were enrolled less than 24 hours after ICU admission.
16607174|NCT02565589||Control|Age-, sex-, and BMI-matched healthy subjects.
16607175|NCT02565576|Active Comparator|CFZ533|CFZ533
16607176|NCT02565576|Placebo Comparator|Placebo|Placebo
16607177|NCT02565563|Active Comparator|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
16607178|NCT02565563|Active Comparator|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
16607179|NCT02565550|Experimental|IBS patients|eat the low FODMAPs diet for one week
16607180|NCT02565550|Active Comparator|healthy controls|eat the low FODMAPs diet for one week
16607181|NCT02565537|Active Comparator|iDesign WFG LASIK|Wavefront-guided LASIK
16607182|NCT02565537|Active Comparator|Wavelight WFO LASIK|Wavefront-optimized LASIK
16607183|NCT02565524|Experimental|genetic and phenotypic profile|blood sample, clinical and neurocognitive assessment
16607184|NCT02565511|Experimental|Cohort I (CAD106)|CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
16607185|NCT02565511|Placebo Comparator|Cohort I (CAD106 Placebo)|Placebo to CAD106 + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
16607186|NCT02565511|Experimental|Cohort II (CNP520)|CNP520 (50 mg) capsules taken orally once daily
16607187|NCT02565511|Placebo Comparator|Cohort II (CNP520 Placebo)|Matching Placebo to CNP520 capsules taken orally once daily
16607188|NCT02565498|Other|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
16607189|NCT02565498|Experimental|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
16607190|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
16607191|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
16607192|NCT02565472|Experimental|Apple Juice|12 oz apple juice
16607193|NCT02565472|Experimental|Grape Juice|12 oz grape juice
16607194|NCT02565459|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
16607195|NCT02565459|No Intervention|No intervention|
16607196|NCT02565446|Other|MRE|Clinical Cohort: NAFLD COHORT RECRUITED FROM THE LIVER CLINIC: 120 adult subjects evaluated at Mayo Clinic with a diagnosis of NAFLD who are at risk to have NASH will be recruited from our outpatient Liver Disease Clinic. Metabolic syndrome is a strong predictor of NASH and will be used to best identify subjects with a clinical indication for liver biopsy according to AASLD guidelines. The proposed sample size for this experiment will be calculated based on sensitivity and specificity of MRE for differentiating various stages of fibrosis.
16607197|NCT02565433|Experimental|questionnaire administration|Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)
16607198|NCT02565420|Active Comparator|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
16607199|NCT02565420|Placebo Comparator|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
16607200|NCT02565407|Experimental|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
16607201|NCT02565407|Active Comparator|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
16607202|NCT02565394|Experimental|Micro-Break with Dynamic Activity|Micro Break with web based application of a video to lead surgeons through dynamic exercise activities
16607205|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch
~In-person smoking cessation counseling
~Contingent financial rewards for smoking abstinence"
16607206|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch
~In-person smoking cessation counseling
~Text messages to support smoking abstinence"
16607207|NCT02565368|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
16607208|NCT02565368|Experimental|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
16607209|NCT02565355|Other|Lifestyle Modification/Dietary Exclusion|In the lifestyle modification group, where specific IgG antibodies to foods are identified, the intervention is appropriate dietary elimination. The IgG antibody results will be disclosed and specific dietary elimination advice will be provided by an experienced dietician; provide diet alternatives to prevent nutritional deficiencies and improve adherence to diet. To improve compliance, a maximum of 2 high IgG positive foods will be eliminated at any one time in each 4 week period. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
16607210|NCT02565355|Other|The Standard Treatment Group|The standard therapy group will not receive results of IgG antibody testing. The patients will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relief as appropriate. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
16607211|NCT02565342|Experimental|Interscalene brachial plexus block|
16607212|NCT02565316|Active Comparator|Nepeta menthoides Boiss & Bohse freeze dried extract capsule|
16607213|NCT02565316|Active Comparator|Sertraline capsule|
16607214|NCT02565303|Experimental|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
16607215|NCT02565303|Experimental|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
16607216|NCT02565290|Active Comparator|Omega-3|2 capsules of omega 3 - 2 times a day
16607217|NCT02565290|Placebo Comparator|Soy oil|2 capsules of soy oil - 2 times a day
16607218|NCT02565277|Active Comparator|Influenza Vaccine|Fluzone injection once IM
16607219|NCT02565277|Placebo Comparator|Placebo|Saline Injection once IM
16607220|NCT02565264|Experimental|plasma-derived exosomes|plasma-derived exosomes
16607221|NCT02565251|Experimental|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
16607222|NCT02565251|Experimental|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
16607223|NCT02565251|Experimental|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
16607224|NCT02565251|Experimental|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
16607225|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
16607226|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
16607227|NCT02565212|Experimental|GROUP 1|montelukast sodium and mometasone
16607228|NCT02565212|Active Comparator|Group 2|montelukast
16607229|NCT02565212|Active Comparator|Group 3|mometasone furoate
16607230|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
16607231|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
16607232|NCT02565186|Experimental|Lasmiditan 100mg|Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
16607233|NCT02565186|Experimental|Lasmiditan 200mg|Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
16607234|NCT02565173|Experimental|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
16607235|NCT02565173|Experimental|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
16607236|NCT02565173|Experimental|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
16607237|NCT02565173|Active Comparator|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
16607238|NCT02565173|Placebo Comparator|placebo BID|placebo Ophthalmic Formulation
16607239|NCT02565160||Septic Arthritis|Patients suspected of having septic arthritis
16607240|NCT02565160||Osteoarthritis|Patients suffering with osteoarthritis undergoing an intervention
16607241|NCT02565160||Joint Revision|Patients who has a prosthetic joint in situ
16607242|NCT02565147|Experimental|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
16607243|NCT02565147|Active Comparator|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
16607244|NCT02565134|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
16607245|NCT02565134|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
16607247|NCT02565134|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
16607248|NCT02565121|Experimental|Olfactory disorder after brain trauma|Recruited from 250 patients with moderate to severe traumatic brain injury in the Hodeskadeprosjektet (TBI) cohort. Treatment with (first) corticosteroids and (second) olfactory stimulation.
16607249|NCT02565108|Experimental|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.
~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
16607250|NCT02565108|Placebo Comparator|Placebo|"Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.
~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
16607251|NCT02565095|Other|Carotid Baroreflex measurements|
16607252|NCT02565082|Experimental|Sickle cell disease|This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
16607253|NCT02565082|Other|Control|This arm will include an approximate number of 30 healthy volunteers.
16607254|NCT02565069|Experimental|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
16607255|NCT02565056|Active Comparator|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
16607256|NCT02565056|No Intervention|Treatment as usual|Treatment as usual.
16607257|NCT02565043|Experimental|RENASYS TOUCH Negative Pressure Wound Therapy Device|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the intermittent/variable therapy mode, for up to 28 days of therapy."
16607258|NCT02565043|Active Comparator|RENASYS TOUCH Negative Pressure Wound Therapy System|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the continuous therapy mode for up to 28 days of therapy."
16607259|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
16607260|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease& have not undergone PEA surgery due to the following reasons:
~Multiple co-morbidities
~Patients choice
~Mild disease /symptoms
~Awaiting Surgery"
16607261|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
16607262|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
16607263|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
16607264|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
16607265|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
16607270|NCT02564978|Experimental|Minocycline|Oral administration of minocycline.
16607271|NCT02564965|Other|Greater than 50% Necrosis|Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
16607272|NCT02564965|Other|Less than 50% Necrosis|Subjects who have less than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
16607273|NCT02564952|Experimental|GWP42003-P|"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.
~Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant."
16607274|NCT02564939|Active Comparator|ramelteon|receive ramelteon
16607275|NCT02564939|Placebo Comparator|placebo|receive placebo
16607276|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
16607277|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
16607278|NCT02564913||control group|
16607279|NCT02564913||pre-DM group|
16607280|NCT02564913||DM group|
16607283|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
16607284|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
16607285|NCT02564874|Experimental|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
16607286|NCT02564874|Experimental|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
16607287|NCT02564861|Experimental|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
16607288|NCT02564861|Experimental|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
16607289|NCT02564861|Experimental|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
16607290|NCT02564861|Experimental|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
16607291|NCT02564848|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
16607292|NCT02564835|Experimental|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
16607293|NCT02564835|Active Comparator|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
16607294|NCT02564835|No Intervention|Usual Care|Participants randomized to this arm will receive standard care only.
16607295|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
16607296|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
16607297|NCT02564809|Experimental|Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a cognitive training program (Fit Brains training) 6 hours a week for 8 weeks.
16607298|NCT02564809|Experimental|Exercise + Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a combination of aerobic exercise and a cognitive training program (Fit Brains training) for 6 hours a week over 8 weeks.
16607299|NCT02564809|Sham Comparator|Balanced And Tone|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will complete 3 weekly training sessions of 1 hour for 8 weeks.
16607300|NCT02564796|Placebo Comparator|Control|Group II (non-treatment group): Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
16607301|NCT02564796|Experimental|Epoetin alfa and iron supplements|Group I (treatment group): Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
16607302|NCT02564770||Rheumatoid arthritis (RA) participants|Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
16607304|NCT02564718|Experimental|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
16607305|NCT02564705||anterior cohort|Anterior Lumbar Interbody Fusion (ALIF)
16607306|NCT02564705||posterior cohort|"Posterolateral Fusion (PLF)
~Posterior Lumbar Interbody Fusion (PLIF)
~Transforaminal Lumbar Interbody Fusion (TLIF)"
16607307|NCT02564679|Experimental|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
16607308|NCT02564679|Experimental|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
16607309|NCT02564666|Active Comparator|Telephone counseling|regular telephone counseling per week
16607310|NCT02564666|No Intervention|No telephone counseling|no regular telephone counseling
16607311|NCT02564653|Other|Technical Assistance, training,clinical reminders|provider adherence to tobacco use treatment guidelines
16608378|NCT02557789|Experimental|Treatment A|Lefamulin as a 600 mg IR tablet in the fasted state
16607312|NCT02564653|Other|TTC + help of community health workers|We will assess this secondary aim by comparing smoking cessation outcomes among smokers who receive brief provider counseling alone only vs. smokers who receive provider counseling + community health worker counseling. The purpose of this assessment is to specifically analyze the impact of the community health worker counseling component of the intervention using a quasiexperimental design that leverages the larger RCT.
16607313|NCT02564640|Active Comparator|videolaryngoscope|patients intubated by using the videolaryngoscopy
16607314|NCT02564640|Active Comparator|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
16607315|NCT02564627|Experimental|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
16607316|NCT02564627|Active Comparator|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
16607317|NCT02564627|Other|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
16607318|NCT02564614|Experimental|RO7070179|Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
16607319|NCT02564601|Experimental|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
16607320|NCT02564601|Experimental|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
16607321|NCT02564601|No Intervention|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
16607322|NCT02564588|Experimental|Dasotraline|Dasotraline 4, 6, 8 mg
16607323|NCT02564588|Placebo Comparator|Placebo|Placebo Comparator
16607324|NCT02564575|Experimental|Cohort 1|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^6 PFU/mL of the HPIV3-EbovZ GP vaccine.
16607325|NCT02564575|Experimental|Cohort 2|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^7 PFU/mL of the HPIV3-EbovZ GP vaccine.
16607326|NCT02564562|Experimental|Treatment|Radiolabeled PF-06463922 in healthy volunteers
16607327|NCT02564549|Active Comparator|Group 1 (TRUS-guided biopsy)|"Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.
~mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.
~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).
~Patients will be followed, as per standard of care, for any potential infections from biopsies.
~Annual PSA tests performed as per routine standard of care."
16607328|NCT02564549|Experimental|Group 2 (mpMRI with targeted biopsy)|"Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.
~Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.
~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).
~Patients will be followed, as per standard of care, for any potential infections from biopsies.
~Annual PSA tests performed as per routine standard of care."
16607329|NCT02564536|Experimental|Arm 1: Pacritinib and Decitabine|"Patients will receive one cycle of single agent pacritinib.
~Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.
~Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.
~Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.
~Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.
~Patients may continue treatment for up to 12 cycles."
16607330|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
16607331|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
16607332|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
16607333|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
16607334|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
16607335|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
16607336|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
16607337|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
16607393|NCT02564081|Active Comparator|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
16607338|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.
~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
16607339|NCT02564471|Experimental|Doxycycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.
~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
16607340|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
16607341|NCT02564458|Experimental|Interval Exercise Training/Motivational Accelerometry (IET/MA)|All patients on the experimental arm receive the intervention of 5-12 weeks of pre-transplant IET, motivational accelerometry via the FitBit Surge, pre- and post-fitness assessments, and periodic quality of life and symptom surveys.
16607342|NCT02564458|No Intervention|Normal Standard of Care (control)|All patients on the control arm participate in the pre- and post-fitness assessment, are given the FitBit Surge without the motivational component, and are also given periodic quality of life and symptom surveys.
16607343|NCT02564445|Experimental|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.
~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
16607344|NCT02564445|Experimental|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.
~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
16607345|NCT02564445|Experimental|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.
~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).
~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
16607346|NCT02564432||POP 10 patient cohort|This is an observational study
16607347|NCT02564419|Experimental|Medtronic Activa PC+S|"Objective of this pilot phase early feasibility study is to assess the safety and feasibility of Medtronic Activa PC+S implant (device) by;
~Evaluating the ability of the Activa PC+S system to sense ECoG signals in subjects living with quadriplegia (C5 or C6 level).
~Assessing the feasibility of activating fundamental upper extremity muscles to reproduce hand grasp.
~These are important first steps towards creating and designing a device that can enhance or assist in performing activities of daily living (ADL) in the life of these subjects. Attachment 15.3"
16607348|NCT02564406|Experimental|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
16607349|NCT02564393||T|Control
16607350|NCT02564393||A|Adult with cystic fibrosis
16607351|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
16607352|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
16607353|NCT02564367|Experimental|Treatment|"First Cohort 1:
~(n = 30 patients) 18 cycles S-1"
16607354|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
16607355|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
16607356|NCT02564341|Experimental|TEACH Collaborative Care Intervention|Physicians randomized to the intervention will receive: 1) collaboration with an IT enabled nurse care manager; 2) physician education and academic detailing; and 3) facilitated access to a specialist in addictions to help manage the most challenging HIV-infected patients on COT.
16607357|NCT02564341|No Intervention|Standard of Care Control|Physicians in the control group will receive information summarizing guidelines for COT but will not have access to the support of the TEACH intervention.
16607358|NCT02564328|Active Comparator|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
16607359|NCT02564328|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
16607360|NCT02564315|Active Comparator|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607361|NCT02564315|Active Comparator|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607362|NCT02564315|Active Comparator|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607394|NCT02564081|No Intervention|Ctrl|No intervention
16607395|NCT02564068|Experimental|Oxytocin Only|Subjects will come in for one visit, and will receive only oxytocin
16607363|NCT02564315|Active Comparator|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607364|NCT02564315|Active Comparator|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607365|NCT02564315|Active Comparator|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607366|NCT02564315|Active Comparator|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607367|NCT02564315|Active Comparator|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
16607368|NCT02564315|Placebo Comparator|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:
~Phase 2: Preparation Phase Control Treatment
~Phase 3: No Treatment"
16607369|NCT02564302|No Intervention|Control|These patients will not receive a device, but have to fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
16607370|NCT02564302|Experimental|Treatment Group|These patients will receive the device. they are expected to use it for at least 5 minutes per day. Patients in this arm will fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
16607371|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
16607372|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
16607373|NCT02564276|Experimental|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
16607374|NCT02564276|Experimental|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
16607375|NCT02564263|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).
16607376|NCT02564263|Active Comparator|Chemotherapy|Participants received Investigator's choice of paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).
16607377|NCT02564237|Experimental|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
16607378|NCT02564237|Active Comparator|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
16607379|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
16607380|NCT02564198|Experimental|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.
~(Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle."
16607381|NCT02564185|Active Comparator|Control|"The control group will follow usual practice."
16607382|NCT02564185|Experimental|Education program|"The Education program group benefit in addition of a therapeutic education program including nursing follow-up at 1, 3 and 6 months."
16607383|NCT02564172|Experimental|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
16607384|NCT02564172|Active Comparator|OMM group|Optimal medical management alone.
16607385|NCT02564159|Experimental|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
16607386|NCT02564159|Other|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)
~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay < 48 hours"
16607387|NCT02564146|Active Comparator|nab-paclitaxel and gemcitabine (A)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine
~Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles"
16607388|NCT02564146|Experimental|gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine
~Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles"
16607389|NCT02564133|Experimental|detection of a patent foramen ovale|
16607390|NCT02564107|Experimental|Ibandronate|Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
16607391|NCT02564094|Experimental|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
16607392|NCT02564081|Experimental|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
16607396|NCT02564068|Experimental|Oxytocin & Placebo Crossover|Subjects will come in for two visit: They will receive either placebo or oxytocin on visit 1 and the other intervention of visit 2. Subjects will be blinded as to which drug they are receiving on which visit.
16607397|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
16607398|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
16607399|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
16607400|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
16607401|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
16607402|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
16607403|NCT02564042|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
16607404|NCT02564042|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
16607405|NCT02564042|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
16607406|NCT02564042|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
16607407|NCT02564042|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
16607408|NCT02564042|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
16607409|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
16607410|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
16607411|NCT02564029|Placebo Comparator|Placebo|Single dose
16607412|NCT02564029|Active Comparator|Lorazepam|2mg single dose
16607413|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
16607414|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
16607415|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
16607416|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
16607417|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
16607418|NCT02563977||DIEP flap breast reconstruction|14 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
16607419|NCT02563951|Experimental|GNS Spray 0.5mg|One spray of GNS 0.5mg/spray into right nostril.
16607420|NCT02563951|Experimental|GNS Spray 1.0mg|One spray of GNS 0.5mg/spray into both left and right nostril.
16607421|NCT02563951|Experimental|GNS Spray 2.0mg|One spray of GNS 1.0mg/spray into both left and right nostril.
16607422|NCT02563951|Active Comparator|Kytril 1mg (IV injection)|A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)
16607423|NCT02563951|Active Comparator|Kytril 1mg (Tablet)|a single dose (kytril 1mg, one tablet) orally administered with 240mL of water
16607424|NCT02563938|Experimental|AK001|Up to six single ascending doses of AK001.
16607425|NCT02563938|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion.
16607426|NCT02563925|Experimental|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab & durvalumab (75 mg & 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior & 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number & size of their brain metastases. Following the 1st dose, tremelimumab & duvralumab will be administered q28 days from the date of 1st tremelimumab & durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
16607427|NCT02563912|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
16607428|NCT02563912|Active Comparator|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
16607429|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
16607430|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
16607431|NCT02563886|Experimental|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
16607432|NCT02563886|Active Comparator|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
16607433|NCT02563873|No Intervention|Standard pacemaker settings|Standard pacemaker settings will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange
16607434|NCT02563873|Experimental|Tailored pacemaker settings|The pacemaker settings will be altered to match optimal heart rate range with respect to cardiac contractility, as determined by echocardiography. This will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange.
16607435|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:
~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
16607436|NCT02563847|Active Comparator|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607437|NCT02563847|Active Comparator|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607438|NCT02563847|Active Comparator|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607439|NCT02563847|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607440|NCT02563847|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607441|NCT02563847|Placebo Comparator|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607442|NCT02563847|Placebo Comparator|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
16607443|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
16607444|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
16607445|NCT02563821|Active Comparator|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.
~Injection of the rest of the loading dose (8mL).
~In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.
~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10."
16607446|NCT02563821|Active Comparator|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.
~Injection of the rest of the loadind dose (8 mL)
~In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.
~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10 (0 = no pain and 10 = insufferable pain)."
16607447|NCT02563808|Active Comparator|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
16607448|NCT02563808|Experimental|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
16607449|NCT02563795||Group I|Pregnant with BMI<30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
16607450|NCT02563795||Group II|Pregnant with BMI<30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
16607451|NCT02563795||Group III|Pregnant with BMI>30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
16607452|NCT02563795||Group IV|Pregnant with BMI>30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
16607453|NCT02563782|Sham Comparator|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
16607454|NCT02563782|Active Comparator|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
16607455|NCT02563769|Experimental|Treatment Arm 1|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
16607456|NCT02563769|Experimental|Treatment Arm 2|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
16607457|NCT02563769|Experimental|Treatment Arm 3|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
16607458|NCT02563756|Experimental|UKA, unicompartmental knee replacement|Procedure: Participants are operated with a mobile bearing medial unicompartmental knee arthroplasty (Oxford). They are followed with CT, functional tests and PROM, compared with those operated with TKA.
16607459|NCT02563756|Experimental|TKA, total knee replacement|Procedure: Participants are operated with a cruciate retaining conventional tricompartmental prosthesis (PFC). They are followed with CT, functional tests and PROM, compared with those operated with UKA.
16607460|NCT02563743|Experimental|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
16607619|NCT02562781|Active Comparator|Supplemental Oxygen|Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
16607461|NCT02563743|Active Comparator|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
16607462|NCT02563730|Experimental|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
16607463|NCT02563717|Active Comparator|Reference Device: T-piece System|
16607464|NCT02563717|Active Comparator|Investigational Device: The New System|
16607465|NCT02563704|Active Comparator|ARTES|"Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.
~Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.
~Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
16607466|NCT02563704|Active Comparator|QLD|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.
~Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.
~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
16607467|NCT02563704|Active Comparator|QNLD3|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.
~Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.
~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
16607468|NCT02563704|Active Comparator|QNLD2|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.
~Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.
~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
16607469|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
16607470|NCT02563678|Active Comparator|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
16607471|NCT02563678|Active Comparator|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
16607472|NCT02563678|Active Comparator|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
16607473|NCT02563678|Active Comparator|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
16607474|NCT02563678|Active Comparator|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
16607475|NCT02563678|Experimental|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
16607476|NCT02563678|Experimental|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
16607477|NCT02563678|Active Comparator|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
16607478|NCT02563678|Experimental|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
16607479|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) > 30
16607480|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) < 15
16607481|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
16607482|NCT02563613|Experimental|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
16607483|NCT02563613|Experimental|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
16607484|NCT02563613|Placebo Comparator|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
16607485|NCT02563600|Experimental|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
16607486|NCT02563600|Experimental|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
16607487|NCT02563600|No Intervention|No telephone call|No telephone call made to patient.
16607488|NCT02563587|Experimental|Group LT-CT|Laughter therapy with conventional treatment
16607489|NCT02563587|Placebo Comparator|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
16607490|NCT02563587|Sham Comparator|Group CT|Conventional treatment only
16607491|NCT02563574|Experimental|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
16607492|NCT02563574|Active Comparator|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
16607496|NCT02563548|Experimental|GAC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks).
16607497|NCT02563548|Experimental|NSCLC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
16607498|NCT02563535|Experimental|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
16607499|NCT02563535|Active Comparator|conventional PTA|angioplasty with conventional balloon
16607500|NCT02563522|Active Comparator|Active|VM202 + standard of care
16607501|NCT02563522|Placebo Comparator|Control|Placebo (VM202 Vehicle) + standard of care
16607502|NCT02563509|Experimental|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
16607503|NCT02563509|No Intervention|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
16607504|NCT02563496|Experimental|Tafenoquine 50 mg|Subjects with weight band of >=5 to <=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
16607505|NCT02563496|Experimental|Tafenoquine 100 mg|Subjects with weight band of >10 to <=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
16607506|NCT02563496|Experimental|Tafenoquine 150 mg|Subjects with weight band of >10 to <=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
16607507|NCT02563496|Experimental|Tafenoquine 200 mg|Subjects with weight band of >20 to <=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
16607508|NCT02563496|Experimental|Tafenoquine 300 mg|Subjects with weight band of >35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
16607509|NCT02563483|Experimental|Yoga and compassion meditation program|"The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of asana (poses), pranayama (breathing exercise) and meditation."
16607510|NCT02563483|No Intervention|control|this group was a non treatment group.
16607511|NCT02563457|Experimental|case|diabetic patients who will receive periodontal treatment blood sampling
16607512|NCT02563457|Experimental|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
16607513|NCT02563444|Experimental|Ultrasound fusion guiding system|
16607514|NCT02563431|Active Comparator|SP-ED|Classic use
16607515|NCT02563431|Experimental|4P-ED|Literature update
16607516|NCT02563418|Experimental|Patient with Huntington's disease|
16607517|NCT02563405|Active Comparator|doxazosin|To observe the effects of doxazosin (4 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
16607518|NCT02563405|Active Comparator|nifedipine|To observe the effects of nifedipine (30 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
16607519|NCT02563392|Experimental|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
16607520|NCT02563392|Active Comparator|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
16607521|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.
~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.
~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
16607522|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.
~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
16607523|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.
~Patients in this group will have morning hypertension that is classified into two types:
~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.
~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
16607524|NCT02563366|Experimental|MSCs group|Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.
16607525|NCT02563366|Placebo Comparator|Control group|Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.
16607526|NCT02563353|Active Comparator|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
16607527|NCT02563353|Experimental|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.
~12 months of Whole-body vibration on vibration platforms."
16607528|NCT02563353|Experimental|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.
~24 months of Whole-body vibration on vibration platforms"
16607529|NCT02563340|Experimental|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
16607530|NCT02563340|Active Comparator|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
16607531|NCT02563327|Active Comparator|Standard Therapy|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~Study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
16607532|NCT02563327|Experimental|Rifapentine-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
16607533|NCT02563327|Experimental|Rifapentine- and Moxifloxacin-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg."
16607534|NCT02563314|Experimental|intervention|
16607535|NCT02563314|Other|control|
16607536|NCT02563301|Active Comparator|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
16607537|NCT02563301|Active Comparator|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
16607538|NCT02563288|Active Comparator|Esmolol|Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
16607539|NCT02563288|Active Comparator|Dexmedetomidine|Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
16607540|NCT02563275|Other|Human fine motor skills measurements during weightlessness|
16607541|NCT02563262|Other|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
16607542|NCT02563249|Other|Dexterity, Coordination,Perception measurements|Dexterity, Hand-eye Coordination and Perception of Orientation and Distances
16607543|NCT02563236|Experimental|Parabolic flight and Augmented Reality interface alignments|
16607544|NCT02563223|Other|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
16607545|NCT02563210|Experimental|airway resistance measurement|interruption and plethysmography techniques airway resistance measurement at each routine visit
16607546|NCT02563197|Experimental|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
16607547|NCT02563184|Active Comparator|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
16607548|NCT02563184|Active Comparator|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
16607549|NCT02563171|Placebo Comparator|Healthy periodontium without obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
16607550|NCT02563171|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
16607551|NCT02563171|Placebo Comparator|Healthy periodontium with obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
16607552|NCT02563171|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
16607553|NCT02563158|No Intervention|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
16607554|NCT02563158|Experimental|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
16607555|NCT02563145|Experimental|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.
~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
16607556|NCT02563145|Active Comparator|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.
~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
16607557|NCT02563145|No Intervention|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
16607558|NCT02563132|Experimental|Carbon dioxide insufflation colonoscopy (CO2)|Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
16607559|NCT02563132|No Intervention|Air insufflation colonoscopy (AI)|Air insufflation during both insertion and withdrawal phase of the colonoscopy.
16607560|NCT02563119|Active Comparator|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
16607561|NCT02563119|Active Comparator|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
16607562|NCT02563119|No Intervention|Healthy controls|Thirty healthy, lean controls
16607563|NCT02563106|Experimental|SYN-004|SYN-004 150 mg
16607564|NCT02563106|Placebo Comparator|Placebo|Matching placebo
16607565|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
16607566|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
16607567|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
16607568|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
16607569|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
16607570|NCT02563067|Experimental|QAW039 150 mg|QAW039 150 mg once daily
16607571|NCT02563067|Experimental|QAW039 450 mg|QAW039 450 mg once daily
16607572|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
16607573|NCT02563054|Active Comparator|5-Fluorouracil + Cisplatin|Participants will receive 5-FU in combination with cisplatin upto disease progression.
16607574|NCT02563054|Experimental|Capecitabine + Cisplatin|Participants will receive capecitabine in combination with cisplatin upto disease progression.
16607575|NCT02563041|Experimental|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
16607576|NCT02563041|Active Comparator|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
16607577|NCT02563028|Experimental|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
16607581|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
16607582|NCT02563002|Active Comparator|Standard of Care|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
16607583|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
16607584|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
16607585|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
16607620|NCT02562781|Experimental|Air or supplemental oxygen|Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
16607586|NCT02562976||early gastric cancer group|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia in patients with early gastric cancer or high-grade neoplasia(HGN)
16607587|NCT02562976||non-early gastric cancer group|patients diagnosed as non- gastritis, gastritis or low-grade neoplasia (LGN) by pathology were defined as non-EGC group
16607588|NCT02562963|Experimental|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
16607589|NCT02562950|Experimental|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
16607590|NCT02562950|Experimental|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
16607591|NCT02562937|Experimental|Intervention|text messages related to sedentary behaviour
16607592|NCT02562937|No Intervention|Control|text messages unrelated to sedentary behaviour.
16607593|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
~Reevaluate at day 119:
~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
16607594|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;
~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.
~After day 91:
~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:
~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
16607595|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;
~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.
~After day 91:
~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
~Reevaluate at day 119:
~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
16607596|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
16607597|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
16607598|NCT02562885|Experimental|Acoustic pulses|"During NREM sleep:
~15 minutes without acoustic pulses
~15 minutes with acoustic pulses
~15 minutes without acoustic pulses
~Two different protocols are applied:
~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.
~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.
~Participants with ESES/CSWS: only Protocol A."
16607599|NCT02562872|Experimental|Cohort 1 Active DSM265|
16607600|NCT02562872|Placebo Comparator|Cohort 1 Placebo|
16607601|NCT02562872|Experimental|Cohort 2a Active DSM265|
16607602|NCT02562872|Placebo Comparator|Cohort 2a Placebo|
16607603|NCT02562872|Experimental|Cohort 2b Active DSM265|
16607604|NCT02562872|Placebo Comparator|Cohort 2b Placebo|
16607605|NCT02562859|Experimental|GLPG1837 as oral suspension fasted|Single dose of 500 mg GLPG1837 as oral suspension after an overnight fast
16607606|NCT02562859|Experimental|GLPG1837 as oral tablet fasted|Single dose of 500 mg GLPG1837 as oral tablet after an overnight fast
16607607|NCT02562859|Experimental|GLPG1837 as oral tablet fed|Single dose of 500 mg GLPG1837 as oral tablet after a high-fat high-calorie breakfast
16607608|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
16607609|NCT02562833|Experimental|Self-Management and exercise|
16607610|NCT02562833|Active Comparator|Educational|
16607611|NCT02562820|Experimental|Ketamine|Subjects will receive intravenous infusion of a 0.1, 0.5, 1.0, 2.0 or 4.5 mg/kg dose over the course of 40 minutes
16607612|NCT02562820|Placebo Comparator|Placebo|Subjects will receive an intravenous infusion of normal saline over the course of 40 minutes
16607613|NCT02562807|Active Comparator|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
16607614|NCT02562807|Placebo Comparator|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
16607615|NCT02562807|Active Comparator|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
16607616|NCT02562807|Placebo Comparator|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
16607617|NCT02562794|Experimental|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
16607618|NCT02562794|No Intervention|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
16607621|NCT02562768|Experimental|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
16607622|NCT02562768|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
16607623|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
16607624|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
16607625|NCT02562742||SOF+REB|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating clinical site.
16607626|NCT02562729|Experimental|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
16607627|NCT02562716|Experimental|Arm I (mFOLFIRINOX, surgery)|Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive 5-fluorouracil IV over 46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin, irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or unacceptable toxicity.
16607628|NCT02562716|Experimental|Arm II (gemcitabine, nab-paclitaxel, and surgery)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride treatment in the absence of disease progression or unacceptable toxicity.
16607629|NCT02562703|Active Comparator|ACTIVE tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
16607630|NCT02562703|Sham Comparator|SHAM tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.
16607631|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).
~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.
~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
16607632|NCT02562677|Experimental|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
16607633|NCT02562664|Active Comparator|CC with placebo|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with placebo tablets taken twice daily continuously for three cycles.
16607634|NCT02562664|Active Comparator|CC plus Metformin|received t100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with plus Metformin 500 mg twice daily continuously for three cycles.
16607635|NCT02562651|Experimental|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
16607636|NCT02562651|Active Comparator|Active comparator|Standard care for STEMI
16607637|NCT02562638|No Intervention|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
16607638|NCT02562638|Experimental|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
16607639|NCT02562625|Experimental|Pembrolizumab Alone|If the patient is randomised to the Pembrolizumab Arm Only then they will receive 200mg of pembrolizumab every 3 weeks.
16607640|NCT02562625|Experimental|Pembrolizumab plus Radiotherapy|If The patient is randomised to this arm they will receive 200mg of pembrolizumab every 3 weeks in combination with a radiotherapy dosage of 24Gy in 3 fractions to be given over 3 consecutive days (only).
16607641|NCT02562612|Experimental|SM-88|SM-88 multiple ascending doses
16607642|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin
~Interventions:
~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).
~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .
~Radiation: Intensity-modulated radiotherapy (IMRT)"
16607643|NCT02562586|Active Comparator|Closed Suction Drainage System|Group 1: patients undergoing total hip replacement received a Closed Suction Drainage System for 24 hours after the surgical procedure
16607644|NCT02562586|No Intervention|No Closed Suction Drainage System|Group 2: patients undergoing total hip replacement have not received a Closed Suction Drainage System after the surgical procedure
16607645|NCT02562573|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
16607646|NCT02562560|Experimental|TGA|
16607647|NCT02562560|Experimental|Controls|
16607648|NCT02562547||All Vaginal Births|The application of the Hem-Avert Perianal Stabilizer
16607649|NCT02562534|Other|Patients with conductive troubles|Patients with conductive troubles
16607652|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
16607653|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
16607654|NCT02562508|Experimental|9-17y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
16607655|NCT02562508|Experimental|9-14y (0,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
16607656|NCT02562508|Experimental|18-26y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
16607657|NCT02562495|Experimental|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
16607658|NCT02562482|Experimental|Group 1: VRC-CHKVLP059-00-VP 20 mcg|Group 1 subjects were randomized to receive two intramuscular (IM) injections of CHIKV VLP vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days) at a dose of 20 micrograms (mcg).
16607659|NCT02562482|Placebo Comparator|Group 2: Placebo (VRC-PBSPLA043-00-VP)|Group 2 subjects were randomized to receive two intramuscular (IM) injections of Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) placebo at Day 0 and Day 28 (+14 days).
16607660|NCT02562469|Experimental|ACTIVATE|ACTIVATE is a computerized neurocognitive training program (ACTIVATE; see: www.c8sciences.com) that simultaneously targets eight core neurocognitive factors (i.e., sustained attention, working memory (WM), response inhibition, speed of information processing, cognitive flexibility and control, multiple simultaneous attention, category formation, and pattern recognition and inductive thinking). ACTIVATE Is completed at home via computer with parent support. ACTIVATE intervention is conducted 3-5 times per week for between 20-30 minutes over the course or 3-4 months.
16607661|NCT02562456|Active Comparator|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars (rubber dam isolation + Adhesive system + composite resin Filtek z350)
16607662|NCT02562456|Experimental|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars with GIC Fuji IX
16607663|NCT02562443|Experimental|rigosertib + best supportive care (BSC)|
16607664|NCT02562443|Active Comparator|Physician's Choice (PC) + best supportive care (BSC)|
16607665|NCT02562430|Experimental|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
16607666|NCT02562430|Active Comparator|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
16607667|NCT02562417|Placebo Comparator|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
16607668|NCT02562417|Experimental|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
16607669|NCT02562391|Active Comparator|PVI+Box lesions|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.
16607670|NCT02562391|Experimental|PVI+Box lesions+LAA cutting|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.The left atrial appendage was removed by stapling and then cutting.
16607671|NCT02562378|Experimental|Trastuzumab + doxorubicin|Trastuzumab and non-pegylated liposomal doxorubicin: Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
16607672|NCT02562365|Experimental|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
16607673|NCT02562365|No Intervention|B: Follow-up|No interevention
16607674|NCT02562352|Experimental|TAPER program|"The intervention arm is comprised of:
~Identification of medications that are appropriate for discontinuation/dose reduction.
~Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction."
16607675|NCT02562352|No Intervention|Control|Standard of Care as wait list control
16607676|NCT02562339|Experimental|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
16607677|NCT02562339|Experimental|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
16607678|NCT02562326|Experimental|BioChaperone insulin lispro|
16607679|NCT02562326|Active Comparator|Humalog®|
16607680|NCT02562313|Experimental|BioChaperone insulin lispro|
16607681|NCT02562313|Active Comparator|Humalog®|Insulin lispro
16607682|NCT02562300|Active Comparator|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
16607683|NCT02562300|Active Comparator|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
16607684|NCT02562287|Experimental|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
16607685|NCT02562287|Active Comparator|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
16607686|NCT02562274|Placebo Comparator|Placebo group|Subjects are received the placebo product which has same color and smell look like the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) treatments once daily for 8 weeks
16607687|NCT02562274|Active Comparator|MP 50 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 50 mg/day treatments once daily for 8 weeks
16607688|NCT02562274|Active Comparator|MP 1500 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 1500 mg/day treatments once daily for 8 weeks
16607689|NCT02562261||Healthy|
16607690|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
16607691|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following
~Temperature of <36 °C (96.8 °F) or >38 °C (100.4 °F)
~Heart rate >90bpm
~Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)
~WBC <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³), or 10% bands in response to an infectious process.."
16607692|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output < 0.5 ml/kg/hr)] Septic shock is defined as severe sepsis plus persistently low blood pressure (< 5th percentile for age or systolic blood pressure < 2 standard deviations below normal for age) following the administration of intravenous fluids.
16607693|NCT02562248|Active Comparator|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
16607694|NCT02562248|Active Comparator|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
16607696|NCT02562222|Experimental|anodal tDCS on M1|anodal tDCS on left primary motor cortex
16607697|NCT02562222|Experimental|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
16607698|NCT02562222|Experimental|anodal tDCS on V1|anodal tDCS on visual cortex
16607699|NCT02562222|Experimental|cathodal tDCS on V1|cathodal tDCS on visual cortex
16607700|NCT02562222|Experimental|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
16607701|NCT02562222|Experimental|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
16607702|NCT02562222|Sham Comparator|sham tDCS|sham tDCS
16607703|NCT02562209|Experimental|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
16607704|NCT02562209|Active Comparator|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
16607705|NCT02562196|Experimental|optimized protocol chosen|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
16607706|NCT02562196|Sham Comparator|sham tDCS|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
16607707|NCT02562183|Experimental|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
16607708|NCT02562170|Active Comparator|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
16607709|NCT02562170|Active Comparator|Protexa|immediate breast reconstruction with an implant and Protexa
16607710|NCT02562157|Experimental|Patients with antro duodenal obstructions|NOTES gastroenteric anastomosis
16607711|NCT02562144|Experimental|Xylocaine spray|
16607712|NCT02562144|Placebo Comparator|Placebo|
16607713|NCT02562118|Experimental|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by Letrozole 2.5mg daily + lenvatinib x 12 weeks (for Part A) or continuous till progression or intolerability (Part B)
16607714|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
16607715|NCT02562092|No Intervention|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
16607716|NCT02562092|Other|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
16607717|NCT02562092|Other|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
16607718|NCT02562079|Experimental|subjects SSc diagnosed|
16607719|NCT02562079|Experimental|subjects Localised sclerosis diagnosed|
16607720|NCT02562079|Experimental|subjects Sc|
16607800|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
16607721|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
16607722|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
16607723|NCT02562053|Active Comparator|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
16607724|NCT02562053|Active Comparator|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
16607725|NCT02562053|Placebo Comparator|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
16607726|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
16607727|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
16607728|NCT02562027|Experimental|High-risk NSCLC participants|"Baseline assessment of demographics and comorbidities
~Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.
~Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living
~HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.
~All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
16607729|NCT02562014|Other|Lean|Participants with body mass index <=25
16607730|NCT02562014|Other|Overweight|Participants with body mass index >25
16607731|NCT02562001|Experimental|Outpatient active group|This group will receive active tDCS, combined with Lokomat gait training
16607732|NCT02562001|Experimental|Inpatient active group|This group will receive active tDCS, combined with Lokomat gait training
16607733|NCT02562001|Experimental|Outpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
16607734|NCT02562001|Experimental|Inpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
16607735|NCT02561988|Experimental|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
16607736|NCT02561975|Experimental|Patient suffering from complex congenital heart disease|
16607737|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose A|Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
16607738|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose B|Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607739|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose C|Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607740|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose D|Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607741|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose E|Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607742|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose F|Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607743|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose G|Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607744|NCT02561962|Experimental|Dose Expansion: AMG 224 Dose H + prior CD38 targeting antibody treatment|Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose [MTD] based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607745|NCT02561962|Experimental|Dose Expansion: AMG 224 Dose H + no prior CD38 targeting antibody treatment|Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
16607746|NCT02561949|Experimental|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
16607747|NCT02561949|Experimental|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
16607801|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
16607802|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
16607748|NCT02561936|Experimental|Panel 1: Group 1|Participants will receive Treatment A (25 milligram [mg] rilpivirine [RPV] formulated as the oral tablet under fed condition [standardized breakfast]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 [10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 [10*2.5 mg tablets, dispersed in water] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 [10*2.5 mg tablets, dispersed in water] under fed condition).
16607749|NCT02561936|Experimental|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
16607750|NCT02561936|Experimental|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
16607751|NCT02561936|Experimental|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
16607752|NCT02561936|Experimental|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [yoghurt] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition).
16607753|NCT02561936|Experimental|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
16607754|NCT02561936|Experimental|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
16607755|NCT02561936|Experimental|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
16607756|NCT02561923|Experimental|Rivaroxaban|Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
16607757|NCT02561923|Experimental|Rivaroxaban plus tranexamic acid (TXA)|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
16607758|NCT02561923|Experimental|Rivaroxaban plus Kcentra|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 [international units per minute] IU/min) on Day 4 in Part 2.
16607759|NCT02561923|Experimental|Rivaroxaban plus Saline|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline [Kcentra saline control or TXA saline control] on Day 4 in Part 2.
16607760|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
16607761|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
16607762|NCT02561884|Experimental|AB|Olostar Tab. followed by Olmetec and Crestor
16607763|NCT02561884|Experimental|BA|Olmetec and Crestor followed by Olostar Tab.
16607764|NCT02561871|Experimental|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 169.
16607765|NCT02561871|Experimental|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
16607766|NCT02561871|Experimental|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
16607767|NCT02561858|Experimental|acid load test|
16607768|NCT02561845||rosuvastatin group|patients who received rosuvastatin
16607769|NCT02561832|Experimental|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
16607770|NCT02561806|Active Comparator|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants >100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
16607771|NCT02561806|Experimental|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
16607772|NCT02561793|Active Comparator|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
16607773|NCT02561793|Placebo Comparator|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
16607798|NCT02561611|No Intervention|Control Group|"Usual Working Condition Group (UWC)
~The no-intervention control condition will be asked to maintain their usual work and lifestyle throughout the study. Participants may be contacted by Pennington Biomedical staff during the intervention."
16607799|NCT02561611|Experimental|Intervention Group|"Combined Intervention (Walk More and Pedal Desk; WMPD)
~Participants in the WMPD condition will engage in both step-counting (Walk More, WM) and pedal desk (PD) intervention components."
16607774|NCT02561780|Active Comparator|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.
~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
16607775|NCT02561780|Active Comparator|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.
~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
16607776|NCT02561780|No Intervention|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
16607777|NCT02561767|Experimental|MSCs group|"Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
~The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx."
16607778|NCT02561767|Placebo Comparator|Control group|Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
16607779|NCT02561754|Active Comparator|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
16607780|NCT02561754|Experimental|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
16607781|NCT02561754|Experimental|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
16607782|NCT02561741|Experimental|COV155|
16607783|NCT02561728|Experimental|Plagiocephaly|Children with a misshaped head due to positioning. This is also known as flat head. Children with plagiocephaly will be treated with either the Hangar Helmet or the P-Pod helmet.
16607784|NCT02561728|Experimental|Craniosynostosis|Craniosynostosis occurs when one or multiple sutures fuse too early. Several sutures may be fused alone or in combination. An open or endoscopic surgical procedure to open the suture(s) is necessary to allow for normal brain growth and development. After surgery a cranial remolding helmet is used to direct skull growth. Children with craniosynostosis will be treated with either the Hangar Helmet or the P-Pod helmet
16607785|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
16607786|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
16607787|NCT02561689|Experimental|Fissure sealant material 1|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
16607788|NCT02561689|Experimental|Fissure sealant material 2|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
16607789|NCT02561676|Experimental|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
16607790|NCT02561676|Experimental|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
16607791|NCT02561663|Experimental|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
16607792|NCT02561663|Experimental|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
16607793|NCT02561650|Experimental|COV155|
16607794|NCT02561637|Experimental|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
16607795|NCT02561637|Other|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
16607796|NCT02561624|Experimental|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
16607797|NCT02561624|No Intervention|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
16607807|NCT02561546|Experimental|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
16607808|NCT02561546|Active Comparator|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
16607809|NCT02561533|Experimental|BRAF immunohistochemistry (IHC)|
16607810|NCT02561520|Experimental|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
16607811|NCT02561507||American College of Surgeons members|Survey participants
16607812|NCT02561494|Placebo Comparator|Control|Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
16607813|NCT02561494|Experimental|Nefopam|Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
16607814|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:
~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)
~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
16607815|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.
~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
16607816|NCT02561468|Experimental|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
16607817|NCT02561468|Placebo Comparator|Control|100 ml normal saline is infused before starting operation.
16607818|NCT02561455|Experimental|Gilteritinib 40 mg|Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
16607819|NCT02561455|Experimental|Gilteritinib 80 mg|Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
16607820|NCT02561455|Experimental|Gilteritinib 120 mg|Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
16607821|NCT02561455|Experimental|Gilteritinib 200 mg|Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
16607822|NCT02561442|Active Comparator|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
16607823|NCT02561442|Experimental|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
16607824|NCT02561442|Experimental|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
16607825|NCT02561429|Experimental|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
16607826|NCT02561416|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
16607827|NCT02561416|Active Comparator|Psycho-educational Program|Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
16607828|NCT02561416|Other|Treatment As Usual|Treatment As Usual.
16607829|NCT02561403|Experimental|EVO multitask video game|
16607830|NCT02561403|Experimental|EVO words video game|
16607831|NCT02561403|No Intervention|Assessment Only|
16607832|NCT02561390|Experimental|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
16607833|NCT02561390|Experimental|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
16607834|NCT02561377|Experimental|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
16607835|NCT02561377|Experimental|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
16607836|NCT02561377|No Intervention|standard care|standard care complied with the daily lifestyle.
16607837|NCT02561338|Experimental|HMS5552 dose 1|75mgQD oral administration
16607838|NCT02561338|Experimental|HMS5552 dose 2|100mgQD oral administration
16607839|NCT02561338|Experimental|HMS5552 dose 3|50mgBID oral administration
16607840|NCT02561338|Experimental|HMS5552 dose 4|75mgBID oral administration
16607842|NCT02561325|Experimental|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
16607843|NCT02561325|Placebo Comparator|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
16607844|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
16607845|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
16607846|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
16607847|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
16607848|NCT02561286|Experimental|HIV risk reduction|BRO HIV Risk Reduction Intervention
16607849|NCT02561286|Active Comparator|Health promotion control|Health Promotion Intervention
16607850|NCT02561273|Experimental|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:
~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.
~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16607851|NCT02561260||autoimmune encephalitis|
16607852|NCT02561260||unknowm encephalitis|
16607853|NCT02561260||other encephalopathy|
16607854|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 20 of the first 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
16607855|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 1|3 patients dosed at 0.01 mg/kg until MTD determined
16607856|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 2|4 patients dosed at 0.02 mg/kg until MTD determined
16607857|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 3|4 patients dosed at 0.04 mg/kg until MTD determined
16607858|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 4|4 patients dosed at 0.08 mg/kg until MTD determined
16607859|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 5|3 patients dosed at 0.12 mg/kg until MTD determined
16607860|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 6|4 patients dosed at 0.18 mg/kg until MTD determined
16607861|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 7|5 patients dosed at 0.27 mg/kg until MTD determined
16607862|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 8|7 patients dosed at 0.40 mg/kg until MTD determined
16607863|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 9|7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg
16607864|NCT02561234|Experimental|AEB1102 Expansion|Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg
16607865|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patients with obesity.
16607866|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
16607867|NCT02561208|Active Comparator|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
16607868|NCT02561208|No Intervention|Usual Care Group|Women with HPV self-collected tests receive usual care.
16607869|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
16607870|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
16607871|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
16607872|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
16607873|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
16607874|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
16607875|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
16607876|NCT02561169|Experimental|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
16607877|NCT02561169|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
16607878|NCT02561156|Experimental|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16608807|NCT02554812|Experimental|Cohort A2|NSCLC patients treated with avelumab + utomilumab (Dose level 2)
16607879|NCT02561156|Experimental|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16607880|NCT02561156|Experimental|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16607881|NCT02561156|Experimental|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16607882|NCT02561156|Experimental|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
16607883|NCT02561156|Experimental|Part 1 Cohort 6: TAK- 653 18 mg|TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
16607884|NCT02561156|Experimental|Part 1 Additional Cohorts: TAK- 653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
16607885|NCT02561156|Experimental|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
16607886|NCT02561156|Experimental|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
16607887|NCT02561156|Experimental|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
16607888|NCT02561156|Experimental|Part 2 Cohort 4: TAK-653 6 mg|TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
16607889|NCT02561156|Experimental|Part 2 Cohort 5: TAK-653 9 mg|TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
16607890|NCT02561156|Experimental|Part 2 Additional Cohorts: TAK-653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
16607891|NCT02561143|Experimental|Intervention group|Patients in the intervention group will be given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
16607892|NCT02561143|Placebo Comparator|Control group|Patients in the control group will be given whole wheat flour (100 g) daily along with nutritional counseling and physical activity counseling for six months.
16607893|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
16607894|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
16607895|NCT02561117|Active Comparator|q8h|Metronidazole given every 8 hours
16607896|NCT02561117|Experimental|q24h|Metronidazole given once daily
16607897|NCT02561104|Experimental|LenSx|Laser-assisted cataract surgery performed using the LenSx femtosecond laser.
16607898|NCT02561104|Experimental|Phaco|Traditional manual phacoemulsification cataract surgery
16607899|NCT02561091|Placebo Comparator|Placebo|Placebo gel for intratympanic use
16607900|NCT02561091|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
16607901|NCT02561091|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
16607902|NCT02561078|Experimental|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
16607903|NCT02561078|Active Comparator|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
16607904|NCT02561065|Experimental|Lifestyle intervention high risk group.|Participants in the intervention group will receive the intervention on top of standard care.
16607905|NCT02561065|No Intervention|Standard care high risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
16607906|NCT02561065|Experimental|Lifestyle intervention low risk group.|Participants in the intervention group will receive the intervention on top of standard care.
16607907|NCT02561065|No Intervention|Standard care low risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
16607908|NCT02561039|Experimental|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
16607909|NCT02561039|Experimental|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
16607910|NCT02561026|Experimental|FP Transfusion|patients randomized to receive frozen plasma transfusions
16607911|NCT02561026|No Intervention|no FP Transfusion|patients not receiving frozen plasma transfusions
16607912|NCT02561013|Experimental|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
16607949|NCT02560740|Placebo Comparator|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
16607913|NCT02561013|Active Comparator|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
16607914|NCT02561000|Experimental|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
16607915|NCT02561000|Experimental|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
16607916|NCT02561000|Placebo Comparator|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
16607917|NCT02560974|Experimental|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
16607918|NCT02560974|No Intervention|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
16607919|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
16607920|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
16607921|NCT02560948|Placebo Comparator|Placebo|
16607922|NCT02560948|Experimental|gpASIT+TM|
16607923|NCT02560935|Active Comparator|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
16607924|NCT02560935|Active Comparator|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
16607925|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
16607926|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
16607927|NCT02560909|Experimental|Experimental|The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.
16607928|NCT02560909|Active Comparator|Control|The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.
16607929|NCT02560870|Active Comparator|Aloe Vera mouthwash|mouthwash (Aleo Vera)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
16607930|NCT02560870|Active Comparator|Chlorhexidine mouthwash|mouthwash (Chlorhexidine )10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
16607931|NCT02560831|Experimental|Therapeutic exercise and Pompage|strengthening exercises, balance training and knee's pompage
16607932|NCT02560831|Active Comparator|Control|Educational lectures.
16607933|NCT02560818|Active Comparator|Control population : Healthy Volunteers|"20 Healthy Volunteers will be recruited:
~10 women to recover breast tissue (from surgical waste) : populations A and C
~10 women to recover ovarian tissue (from surgical waste) : population B"
16607934|NCT02560818|Experimental|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
16607935|NCT02560805|Experimental|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
16607936|NCT02560805|Experimental|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
16607937|NCT02560792|Experimental|Positive Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to positive affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to positive feelings.
16607938|NCT02560792|Experimental|Negative Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to negative affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to negative feelings.
16607939|NCT02560792|Experimental|Control Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise - affect was not mentioned.
16607940|NCT02560779|Experimental|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
16607941|NCT02560766|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
16607942|NCT02560766|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
16607943|NCT02560766|Placebo Comparator|Placebo|Placebo once daily
16607944|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
16607945|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
16607946|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
16607947|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
16607952|NCT02560688|Experimental|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
16607953|NCT02560688|Other|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
16607954|NCT02560688|Experimental|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
16607955|NCT02560675||120 healthy subjects|"One hundred and twenty healthy subjects (range 20-79; 20 subjects per age decade, 10 M and 10 F) will participate in the first phase of the study aimed to collect normative data from healthy population.
~Study design Phase I - Normative data collection for the inhibitory and excitatory pain modulation responses, a study on healthy subjects (no blood tests)"
16607956|NCT02560675||750 subjects wuith acute whiplash-injury|"Seven hundred and fifty acute whiplash-injury based mild TBI will participate in this study.
~Phase II - Multi-modal assessment of acute mild TBI whiplash patients and follow-up"
16607957|NCT02560662|Experimental|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
16607958|NCT02560662|No Intervention|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
16607959|NCT02560649|Experimental|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):
~HBsAg<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
16607960|NCT02560649|Active Comparator|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):
~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
16607961|NCT02560649|Active Comparator|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):
~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
16607962|NCT02560636|Experimental|Dose level 1a|Radiotherapy: 24Gy in 6f Pembrolizumab: 100mg
16607963|NCT02560636|Experimental|Dose level 1b|Radiotherapy: 24Gy in 6f Pembrolizumab: 200mg
16607964|NCT02560636|Experimental|Dose level 2a|Radiotherapy: 24Gy in 4f Pembrolizumab: 100mg
16607965|NCT02560636|Experimental|Dose level 2b|Radiotherapy: 24Gy in 4f Pembrolizumab: 200mg
16607966|NCT02560636|Experimental|Dose level 3a|Radiotherapy: 30Gy in 5f Pembrolizumab: 200mg
16607967|NCT02560623|Active Comparator|Cases - Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic brushings of the esophagus.
16607968|NCT02560623|Active Comparator|Controls - No Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic biopsies of the esophagus.
16607969|NCT02560610|Active Comparator|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
16607970|NCT02560610|Placebo Comparator|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
16607971|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
16607972|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)
~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.
~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
16607973|NCT02560571|Experimental|all patients|all study patients will undergo ultrasound and blood test
16607974|NCT02560558|Experimental|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
16607975|NCT02560558|Active Comparator|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
16607976|NCT02560545|Active Comparator|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
16607977|NCT02560545|Placebo Comparator|Placebo|Oil
16607978|NCT02560532|Experimental|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
16607979|NCT02560519|Active Comparator|Ringers acetate solution|Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
16607980|NCT02560519|Experimental|Albumin solution|Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
16607981|NCT02560506|Experimental|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
16607982|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
16607983|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
16607984|NCT02560480||groin injury (group A)|magnetic resonance imaging performed in all athletes with acute or subacute groin injury
16607985|NCT02560480||control (group B)|magnetic resonance imaging performed in selected asymptomatic control athletes
16607986|NCT02560467|Experimental|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
16607987|NCT02560454|Experimental|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.
~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
16607988|NCT02560454|Experimental|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.
~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
16607989|NCT02560454|No Intervention|Control|Control ( waiting list)
16607990|NCT02560441|Other|chemotherapy followed by radiotherapy|Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.
16607991|NCT02560441|Other|radiotherapy followed by chemotherapy|Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.
16607992|NCT02560441|Other|IPGDP regimen chemotherapy|Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.
16607993|NCT02560415|Experimental|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
16607994|NCT02560415|Active Comparator|2: Comparator|Treatment as usual
16607995|NCT02560402||Patients with sepsis or trauma|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma
16607996|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
16607997|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
16607998|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
16607999|NCT02560376|Experimental|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
16608000|NCT02560363|Experimental|Treatment sequence 1|Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
16608001|NCT02560363|Experimental|Treatment sequence 2|Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
16608002|NCT02560363|Experimental|Treatment sequence 3|Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
16608003|NCT02560363|Experimental|Treatment sequence 4|Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
16608004|NCT02560337|Experimental|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.
~Treatment continues until progression or unacceptable toxicity."
16608005|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.
~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
16608006|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.
~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.
~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
16608007|NCT02560311||HER2+ metastatic breast cancer|
16608008|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
16608009|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16608010|NCT02560285||Development / 2000 participants|"Age >18 years;
~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
16608047|NCT02559999|Other|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
16608011|NCT02560285||Validation / 1000 participants|"Age >18 years;
~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
16608012|NCT02560272|Experimental|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
16608013|NCT02560272|Active Comparator|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
16608014|NCT02560259|Active Comparator|Physiotherapy Group|Physiotherapy
16608015|NCT02560259|Placebo Comparator|Conservative group|Conservative treatment
16608016|NCT02560246||Preterm Labor|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
16608017|NCT02560246||Term Labor|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
16608018|NCT02560233|Experimental|Contingent|Contingent RT-fMRI-NF
16608019|NCT02560233|Sham Comparator|Non-contingent|Sham RT-fMRI-NF
16608020|NCT02560220|Experimental|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
16608021|NCT02560207|Active Comparator|Intermittent cefotaxime|Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
16608022|NCT02560207|Experimental|Continuous cefotaxime|After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .
16608023|NCT02560194|Active Comparator|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
16608024|NCT02560194|Placebo Comparator|FOBT only|People in this are offered fecal occult blood testing only.
16608025|NCT02560181|Other|HDR whole gland salvage treatment|Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart
16608026|NCT02560168|Experimental|Coronary artery disease|Patients scheduled for computed tomographic coronary angiography (CTA)
16608027|NCT02560155|No Intervention|Nose-SA-carriers control|Control Group, no intervention
16608028|NCT02560155|Active Comparator|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement
~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
16608029|NCT02560155|No Intervention|Non-nose-SA-carriers control|Control Group, no intervention
16608030|NCT02560155|Active Comparator|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
16608031|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
16608032|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
16608033|NCT02560103||Single group|No treatment
16608034|NCT02560090|Placebo Comparator|Control Group|Survey assessments as well as collection of medical records and billing information.
16608035|NCT02560090|Active Comparator|Telephonic Nurse Intervention|Survey assessments as well as collection of medical records and billing information. A nurse will communicate with participants via telephone to support diabetes self-management practices.
16608036|NCT02560090|Active Comparator|In-person Community Health Worker Intervention|Survey assessments as well as collection of medical records and billing information. A community health worker will work with participants in person to support diabetes self-management practices.
16608037|NCT02560077|Placebo Comparator|placebo|The placebo and cashew apple fruit juice had the same color and smell
16608038|NCT02560077|Active Comparator|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
16608039|NCT02560077|Active Comparator|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
16608040|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
16608041|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
16608042|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
16608043|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
16608044|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
16608045|NCT02560025|Experimental|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
16608046|NCT02560012|Other|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.
~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
16608190|NCT02559128||HF-T2D-|20 healthy control volunteers
16608048|NCT02559973|Experimental|RBP-6000 - Light MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a light molecular weight (MW) polymer.
16608049|NCT02559973|Experimental|RBP-6000 - Heavy MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a heavy molecular weight (MW) polymer.
16608050|NCT02559973|Active Comparator|RBP-6000 - Intermediate MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with an intermediate molecular weight (MW) polymer (reference).
16608051|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
16608052|NCT02559934|Experimental|SR-T100 gel|A single dose of 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 25 cm2 skin area covered by an occlusive dressing at least 20 hours a day and will be given once daily for sixteen consecutive weeks.
16608053|NCT02559921|Experimental|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
16608054|NCT02559921|Experimental|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
16608055|NCT02559921|Active Comparator|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
16608056|NCT02559921|Experimental|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
16608057|NCT02559921|Experimental|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
16608058|NCT02559921|Experimental|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
16608059|NCT02559921|Placebo Comparator|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
16608060|NCT02559908|Experimental|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
16608061|NCT02559908|Other|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
16608062|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
16608063|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
16608064|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
16608065|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
16608066|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
16608067|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
16608068|NCT02559856|Active Comparator|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
16608069|NCT02559856|Active Comparator|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
16608070|NCT02559843|Experimental|pomegranate juice|200 ml pomegranate juice + lifestyle modification
16608071|NCT02559843|Active Comparator|control|lifestyle modification including dietary recommendations
16608072|NCT02559830|Experimental|transduced CD34+ hematopoietic stem cell|Transplantation of autologous CD34+ hematopoietic stem cells transduced with ARSA/ABCD1 encoding lentiviral vector. Dosage: 2x10^6/Kg （Minimum）to 20x10^6/Kg （Maximum） transduced CD34+ cells at bedside for infusion
16608073|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg
~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg
~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
16608074|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg
~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg
~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
16608075|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg
~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg
~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
16608076|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
16608077|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast
~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age
~Placebo solid oral capsule in children 12-17 years of age"
16608078|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
16608079|NCT02559791|Experimental|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
16608221|NCT02558855|Sham Comparator|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
16608080|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
16608081|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
16608082|NCT02559752||Arm 1: NIH Toolbox Cognitive Battery testing|"This study will use the NIH Toolbox Cognitive Battery computer testing software to investigate the cognitive outcomes in children with CNS tumors receiving PBRT.
~Participants recruited for the study will complete one 45-minute testing session prior to the completion of the first week of radiation therapy.
~They will then complete serial tests 6-12 months after the completion of PBRT and then yearly thereafter."
16608083|NCT02559739||Sleep deficiency/fragmentation|Patients with sleep deficiency/fragmentation
16608084|NCT02559739||No sleep deficiency/fragmentation|Patients without sleep deficiency/fragmentation
16608085|NCT02559726|Experimental|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
16608086|NCT02559726|Experimental|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
16608087|NCT02559726|Other|healthy volunteers|20 healthy volunteers
16608088|NCT02559713|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
16608089|NCT02559700|Experimental|Brain training programme|Participants will complete a package of online brain training games focusing on reasoning and problem solving. The intervention will be accessed via a computer. There is no minimum or maximum dosage but participants will be recommended to complete the intervention five times a week. The package takes approximately 10 minutes to complete, depending on individual performance.
16608090|NCT02559687|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years)
16608091|NCT02559674|Experimental|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
16608092|NCT02559661||Medical students|Students with limited knowledge of the anatomy and pathology of the eye.
16608093|NCT02559661||Ophthalmological trainees|The trainees have never done eye surgery but have a better understanding of the eyes pathology and anatomy than the medical students.
16608094|NCT02559661||Vitreoretinal surgeons|The vitreoretinal surgeons knows the eyes anatomy and pathology well and have training and skills in vitreoretinal surgery.
16608095|NCT02559648|Active Comparator|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
16608096|NCT02559648|Placebo Comparator|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
16608097|NCT02559635|No Intervention|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
16608098|NCT02559635|Experimental|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
16608099|NCT02559622|Experimental|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
16608100|NCT02559622|Experimental|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
16608101|NCT02559622|Other|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
16608102|NCT02559622|Other|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
16608103|NCT02559609|Active Comparator|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
16608104|NCT02559609|Experimental|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
16608105|NCT02559609|Experimental|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
16608106|NCT02559609|Experimental|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
16608107|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
16608108|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
16608109|NCT02559583||Participants with Chronic Lymphocytic Leukemia (CLL)|This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.
16608110|NCT02559583||Participants with Multiple Myeloma (MM)|This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.
16608111|NCT02559583||Participants with Non-Hodgkin's lymphoma (NHL)|This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.
16608112|NCT02559570|Placebo Comparator|Placebo|Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
16608113|NCT02559570|Experimental|LIN Dose A (9 ug or 18 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
16608114|NCT02559570|Experimental|LIN Dose B (18 ug or 36 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
16608115|NCT02559570|Experimental|LIN Dose C (36 ug or 72 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
16608116|NCT02559570|Experimental|LIN 145 µg|Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
16608117|NCT02559557|Experimental|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.
~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
16608118|NCT02559531|Experimental|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
16608119|NCT02559518|Experimental|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
16608120|NCT02559518|Experimental|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
16608121|NCT02559518|Sham Comparator|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
16608122|NCT02559518|Experimental|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
16608123|NCT02559518|Experimental|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
16608124|NCT02559518|Sham Comparator|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
16608125|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
16608126|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
16608127|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
16608128|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
16608129|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
16608130|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
16608131|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
16608132|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
16608133|NCT02559492|Experimental|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
16608134|NCT02559492|Experimental|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
16608135|NCT02559479|Active Comparator|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
16608136|NCT02559479|Active Comparator|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
16608137|NCT02559466|Experimental|Patients stimulated with a H-TMS (deep)|20 sessions navigated with Deep Transcranial Magnetic Stimulation
16608138|NCT02559466|Other|Patients stimulated with a conventional TMS|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
16608139|NCT02559453|Active Comparator|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
16608140|NCT02559453|Active Comparator|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
16608141|NCT02559440|Active Comparator|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
16608142|NCT02559440|Placebo Comparator|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
16608143|NCT02559440|Active Comparator|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
16608144|NCT02559440|Placebo Comparator|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
16608145|NCT02559440|Active Comparator|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
16608146|NCT02559440|Active Comparator|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
16608147|NCT02559427|Active Comparator|Immediate SPA treatment|3-week immediate SPA treatment (soon after randomization)
16608148|NCT02559427|Sham Comparator|Late SPA treatment|3-week late SPA treatment (soon after primary endpoint at 4 1/2 months visit)
16608149|NCT02559414|No Intervention|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
16608150|NCT02559414|Active Comparator|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
16608151|NCT02559414|Active Comparator|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
16608152|NCT02559388|Active Comparator|montelukast|montelukast 10 milligram, daily for 30 days
16608153|NCT02559388|Placebo Comparator|placebo|Placebo one tablet for 30 days
16608154|NCT02559336|No Intervention|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
16608155|NCT02559336|Experimental|Intervention|Integrated oncology care and palliative care
16608156|NCT02559310|Experimental|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
16608157|NCT02559310|Active Comparator|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
16608158|NCT02559297|Active Comparator|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
16608159|NCT02559297|Experimental|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
16608160|NCT02559284|Experimental|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
16608161|NCT02559284|Active Comparator|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
16608162|NCT02559258|Experimental|Cohort 1|
16608163|NCT02559258|Experimental|Cohort 2|
16608164|NCT02559258|Experimental|Cohort 3|
16608165|NCT02559258|Experimental|Cohort 4|
16608166|NCT02559258|Experimental|Cohort 5|
16608167|NCT02559245|Experimental|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
16608168|NCT02559245|Experimental|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
16608169|NCT02559245|No Intervention|controled|participants will follow their usual diet
16608170|NCT02559232||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fibrillation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
16608171|NCT02559206|Experimental|30 μg linaclotide DR1 and placebo|
16608172|NCT02559206|Experimental|100 μg linaclotide DR1 and placebo|
16608173|NCT02559206|Experimental|300 μg linaclotide DR1 and placebo|
16608174|NCT02559206|Experimental|30 μg linaclotide DR2 and placebo|
16608175|NCT02559206|Experimental|100 μg linaclotide DR2 and placebo|
16608176|NCT02559206|Experimental|300 μg linaclotide DR2 and placebo|
16608177|NCT02559206|Experimental|290 μg linaclotide IR and placebo|
16608178|NCT02559206|Placebo Comparator|Placebo|
16608179|NCT02559193||No treatment.|Data collection only trial design.
16608180|NCT02559180|Experimental|Single Arm|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
16608181|NCT02559167|Active Comparator|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
16608182|NCT02559167|Placebo Comparator|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
16608183|NCT02559154|Experimental|modified BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
16608184|NCT02559154|Active Comparator|conventional BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
16608185|NCT02559141|Other|Study group (SG)|"Before induction of anaesthesia:
~Arterial line
~Nexfin Monitoring System
~Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)
~Baseline blood samples. Induction of anaesthesia
~Study Group:
~PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²
~Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
16608186|NCT02559141|No Intervention|Control group (CG)|"MAP ≥65 mmHg
~CVP ≤12 mmHg
~Haemoglobin level ≥8 g/dl.
~Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
16608187|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
16608188|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
16608189|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
16608191|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
16608192|NCT02559102|Experimental|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
16608193|NCT02559102|Active Comparator|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
16608194|NCT02559089||anti-NMDA receptor encephalitis|
16608195|NCT02559089||other autoimmune encephlitis|
16608196|NCT02559089||other encephalopathy|
16608197|NCT02559076|Experimental|Ten Steps Leaflet|Ten steps leaflet advice for healthy lifestyle
16608198|NCT02559076|No Intervention|Usual care|Usual care given
16608199|NCT02559063|Experimental|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
16608200|NCT02559063|Active Comparator|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience [and amount of time]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
16608201|NCT02559037|Experimental|Acupuncture-moxibustion group|Receiving acupuncture and moxibustion treatment.
16608202|NCT02559037|Sham Comparator|Sham acupuncture-moxibustion group|Receiving sham acupuncture and sham moxibustion.
16608203|NCT02559024|Experimental|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
16608204|NCT02559024|Experimental|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
16608205|NCT02559024|Experimental|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
16608206|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
16608207|NCT02558972|Placebo Comparator|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
16608208|NCT02558972|Placebo Comparator|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
16608209|NCT02558959|Experimental|Irinotecan and Capecitabine|irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w
16608210|NCT02558959|Active Comparator|Irinotecan|irinotecan 180mg/m2 d1, q2w
16608211|NCT02558946|Active Comparator|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
16608212|NCT02558946|Active Comparator|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
16608213|NCT02558933|Experimental|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
16608214|NCT02558894|Experimental|MEDI4736 monotherapy|MEDI4736 via IV infusion.
16608215|NCT02558894|Experimental|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
16608216|NCT02558881||Virtual colonoscopy|"With virtual colonoscopy, the patient does not need to be hospitalized for examination, which is usually done without hospitalization. A bowel preparation is necessary. It may vary from site to site, but it generally comprises polyethylene glycol or sodium phosphate. The residual stools are marked by ingestion of a radiopaque product to differentiate colic lesions. But no contrast agent is injected intravenously. The patient should be supine and a rectal probe is set up to inject either air or CO2. The vesting period does not exceed thirty seconds apnea, and overall completion time of the examination (patient table) is about 10 minutes."
16608217|NCT02558881||Colon capsule|The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
16608218|NCT02558868|Experimental|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
16608219|NCT02558868|Active Comparator|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
16608220|NCT02558855|Active Comparator|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
16608222|NCT02558842|Experimental|Education Strategy|Educational Strategy and Oversight Distance
16608226|NCT02558816|Experimental|Ibrutinib - GA101 - GDC_0199|STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibrutinib 560mg day 1-28 ; GA101 1000mg D 1 ; GDC-0199 20mg/d at W1, 50mg/d at W2, 100mg at W3, 200 mg/d at W4 / C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC-0199:400mg/d W1 and 400, 600 or 800mg/d W2-3-4 + 400, 600 or 800 mg/d C3-C6 (patients 1-12).Patients 13-24:GDC-199 400mg/d / C7(Maintenance phase)-C23:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2 cycles (from C8);GDC:400, 600 or 800 mg D1-28 (patient 1-12).Patients 13-24 : 400mg/d STEP C:C1-C1bis=Step B; C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC:400mg/d C7 (Maintenance phase)-C23 : Ibrutinib 560mg D1-28 (-->progression);GA101 1000mg D1/2 cycles (from C8);GDC-0199 400mg/d
16608227|NCT02558803|No Intervention|Usual Care|The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms
16608228|NCT02558803|Experimental|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
16608229|NCT02558790|Experimental|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
16608230|NCT02558777|Experimental|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
16608231|NCT02558777|No Intervention|Control Group|Usual care
16608232|NCT02558764|No Intervention|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
16608233|NCT02558764|Other|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
16608234|NCT02558751|Active Comparator|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
16608235|NCT02558751|Active Comparator|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
16608236|NCT02558751|Active Comparator|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
16608237|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
16608238|NCT02558738||Normison ear spray|treatment according to instruction for use
16608239|NCT02558725|No Intervention|one capsule of iron supplement|instructed to take one capsule at least 2 hours after consumption of dairy products
16608240|NCT02558725|Active Comparator|two capsules of iron supplement|instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
16608241|NCT02558712|Other|Face to face exam|Standard of clinical care, 8 point eye exam
16608242|NCT02558699|Active Comparator|conventional group|Group operating the atrial fibrillation by physician's personal experience, not by virtual simulation.
16608243|NCT02558699|Experimental|3D atrial computer model|Group choosing choose the best effective rotor mapping by simulating 3D atrial computer model which consider patinet's heart size and shape.
16608244|NCT02558686|Experimental|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
16608245|NCT02558686|Sham Comparator|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
16608246|NCT02558686|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
16608247|NCT02558673|Experimental|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
16608248|NCT02558673|Experimental|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef [Philly-Gourmet Beef Patties]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
16608249|NCT02558673|Experimental|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish [cod fillet]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
16608250|NCT02558673|Active Comparator|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
16608251|NCT02558660|Experimental|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
16608252|NCT02558647|Experimental|CBT for insomnia (CBT-I)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) comprises a fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention
16608253|NCT02558647|Active Comparator|Psychoeducation about Sleep (PE)|The PE intervention gives participants access to a website with information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
16608254|NCT02558634|Experimental|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on
~DBS system includes:
~Implantable Pulse Generator (IPG)
~DBS Lead
~DBS Lead Extension Kit"
16608379|NCT02557789|Experimental|Treatment B|Lefamulin as 600 mg API in capsule (three 200 mg capsules) in the fasted state
16608255|NCT02558634|Sham Comparator|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off
~DBS system includes:
~Implantable Pulse Generator (IPG)
~DBS Lead
~DBS Lead Extension Kit"
16608256|NCT02558621|Experimental|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
16608257|NCT02558608|Experimental|WR AND DIPL|patients undergo wedge resection and dissection the inferior pulmonary ligament by thoracoscopic surgery or video assisted thoracoscopic surgery
16608258|NCT02558608|Active Comparator|WR|patients undergo wedge resection by thoracoscopic surgery or video assisted thoracoscopic surgery without dissection the inferior pulmonary ligament
16608259|NCT02558595|Experimental|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
16608260|NCT02558595|Placebo Comparator|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
16608261|NCT02558582|Experimental|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
16608262|NCT02558582|Experimental|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
16608263|NCT02558582|Experimental|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
16608264|NCT02558582|Experimental|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
16608265|NCT02558569|Experimental|Levobupivacaine|Scalp nerve block with 0.5% Levobupivacaine adds up to intravenous fentanyl for intraoperative pain control during supratentorial craniotomy with brain tumor removal. The scalp block includes 4-6 nerves which give sensory supply to related location with the use of total 10-15 ml of 0.5% Levobupivacaine. Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given. is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
16608266|NCT02558569|Sham Comparator|NSS|Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
16608267|NCT02558556|Experimental|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.
~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.
~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.
~The complete procedure will be recorded on video."
16608268|NCT02558556|No Intervention|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.
~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.
~The complete procedure will be recorded on video.
~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
16608269|NCT02558543|Active Comparator|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
16608270|NCT02558543|Placebo Comparator|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
16608271|NCT02558530|Other|Low carbohydrate diet|Isocaloric diet, <20 g carbohydrates per day
16608272|NCT02558517|No Intervention|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
16608273|NCT02558517|Experimental|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
16608274|NCT02558504|Active Comparator|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
16608334|NCT02558036|Active Comparator|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
16608275|NCT02558504|Experimental|Radiofrequency ablation|"The equipment processing is:
~The radiofrequency generator,
~The radiofrequency balloon 360,
~the radiofrequency probe 90.
~The radiofrequency treatment should be carried out according to the following protocol:
~The radiofrequency treatment is done within 2 months following the last endoscopic assessment.
~The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.
~Endoscopy is performed under general anesthesia.
~The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.
~The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.
~During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
16608276|NCT02558491|Experimental|Decision Support System|Blinded CGM data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters that will be used during the Experimental Admission.
16608277|NCT02558491|No Intervention|Usual Care|Subjects will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
16608278|NCT02558465||Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxavban administration group
16608279|NCT02558439|Placebo Comparator|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
16608280|NCT02558439|Experimental|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
16608281|NCT02558439|Experimental|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
16608282|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
16608283|NCT02558413|Active Comparator|BTA-C585 oral capsules|25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg
16608284|NCT02558413|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
16608285|NCT02558400|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
16608286|NCT02558400|Active Comparator|AR-13324 Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
16608287|NCT02558400|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
16608288|NCT02558387|Experimental|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
16608289|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
16608290|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
16608291|NCT02558361|Other|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis [target joint] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR & ex vivo cytokine production assays. UA/pregnancy test.
~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.
~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
16608292|NCT02558348|Experimental|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.
~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
16608293|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
16608294|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
16608295|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
16608296|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.
~The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.
~A slit lamp examination and indirect ophthalmoscopy will be performed.
~Experimental:
~The subject's eye will be held open with an eye speculum during the exam.
~Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.
~Intraocular Pressure will be measured.
~An Optic Coherence Tomography (OCT) will be performed.
~At each step along the process of ICP reduction, the eye exam, IOP & OCT will be performed.
~Optional:
~The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.
~OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
16608297|NCT02558296|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
16608298|NCT02558296|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
16608299|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
16608300|NCT02558283|Active Comparator|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
16608301|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
16608302|NCT02558283|Active Comparator|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
16608303|NCT02558270|Active Comparator|patients dapa|Patients will be administered Dapagliflozin 10mg
16608304|NCT02558270|Placebo Comparator|patients placebo|Patients will be administered a placebo
16608305|NCT02558270|Active Comparator|controls dapa|controls will be administered Dapagliflozin 10mg
16608306|NCT02558270|Placebo Comparator|controls placebo|controls will be administered a placebo
16608307|NCT02558257||Palliative Care Survey|Initial consultation visit followed by phone survey within 1 week +/- 4 days of initial consultation.
16608308|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
16608309|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
16608310|NCT02558218|Active Comparator|Systane ultra group|Participants in this group were administered systane ultra quid (Alcon, Fort Worth) for two months postoperatively), additionally to tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.
16608311|NCT02558218|Active Comparator|Control group|Participants in this group were administered the standard postoperative medication [tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.]
16608312|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
16608313|NCT02558192|Experimental|Probiotics|Vials containing 3 x 10^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
16608314|NCT02558192|Placebo Comparator|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
16608315|NCT02558179||Nugent Score >/= 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Diagnosis of bacterial vaginosis (study group) according to Nugent score and/or diagnosis of vulvovaginal candidiasis; and/or diagnosis of Trichomonas vaginalis.
16608316|NCT02558179||Nugent Score< 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (<7).
16608317|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)
~with shock due sepsis/SIRS, cardiac failure or hemorrhage
~age > 18 years,
~noradrenalin support
~< 24 hours of ICU admission
~Signed informed consent"
16608318|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)
~without shock, without vasopressor support and without fluid dependent circulation
~age > 18 years
~< 24 hours of ICU admission
~Signed informed consent"
16608319|NCT02558153|Experimental|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
16608320|NCT02558153|Active Comparator|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
16608321|NCT02558140|Experimental|Part 1: Dose Escalation|All participants will be given RO6874813 as a single low dose of 0.5 milligrams per kilogram (mg/kg) via intravenous (IV) infusion in a 7-day pharmacokinetic (PK) run-in period (Cycle 0). This is followed by dose escalation (Cycle 1) for which participants will receive escalating doses of RO6874813 (starting dose = 1 mg/kg) via IV infusion every week (qw) or every 2 weeks (Q2W) for 28 to 42 days to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
16608322|NCT02558140|Experimental|Part 2: Tumor Biopsy and Imaging|The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.
16608323|NCT02558140|Experimental|Part 3: Preliminary Efficacy Assessment|Participants with locally advanced or metastatic non-resectable FAP+ sarcoma will be treated with RO6874813 at the RP2D and as per schedule determined upon completion of Part 1. Participants continuing treatment with RO6874813 beyond 36 weeks will enter the extension phase of Part 3 and will be monitored for disease status and clinical safety per routine standard of care.
16608324|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
16608325|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
16608326|NCT02558114|Other|Group A|Patients will receive ribavirin during 12 weeks
16608327|NCT02558114|Other|Group B|"Patients will receive:
~ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)
~- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
16608328|NCT02558101|Active Comparator|Control invitation materials|Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
16608329|NCT02558101|Experimental|Intervention invitation materials|A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
16608330|NCT02558088|Experimental|salmeterol|
16608331|NCT02558075|Experimental|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
16608332|NCT02558062|Experimental|BAC ONE administration|All participants in this clinical study will be dosed on one occasion with BAC ONE. The final dosage will be 80 µg (± 25%).
16608333|NCT02558049|Experimental|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
16608376|NCT02557802|Experimental|Group A|Nasal spray at day 0, intramuscular injection at day 28
16608335|NCT02558036|Active Comparator|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
16608336|NCT02558036|Active Comparator|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
16608337|NCT02558036|Active Comparator|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
16608338|NCT02558023|Experimental|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.
~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.
~Maximum dose of 30 mg.h-1."
16608339|NCT02558023|Active Comparator|Nicardipine|"Nicardipine : IV
~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.
~Maximum dose of 6 mg.h-1"
16608340|NCT02558010|Experimental|Methadone Group|Patients will receive a total of 0.2mg/kg IV methadone intraoperative (0.1mg / kg preincision and 0.1mg/kg prior to emergence) with a maximum dosing of 20 mg.
16608341|NCT02558010|Active Comparator|Control Group|Patient will receive normal saline placebo initially, then morphine prior to emergence.
16608342|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
16608343|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
16608344|NCT02557997||ART-controlled|ART-controlled HIV infected adults
16608345|NCT02557997||ART-failing|ART-failing HIV infected adults
16608346|NCT02557984|Placebo Comparator|Placebo|Placebo Pill
16608347|NCT02557984|Experimental|Amisulpride|400 mg Amisulpride (Solian®)
16608348|NCT02557984|Experimental|Naltrexone|50 mg Naltrexone (Naltrexin®)
16608349|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
16608350|NCT02557958|Experimental|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
16608351|NCT02557958|Placebo Comparator|Placebo|Placebo daily for 8 weeks
16608352|NCT02557945|Experimental|Gabapentin|Gabapentin 3600mg PO daily
16608353|NCT02557945|Placebo Comparator|Placebo|Matching placebo PO daily
16608354|NCT02557932|Active Comparator|Standard triple therapy|7 day-PPI based standard triple therapy
16608355|NCT02557932|Active Comparator|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
16608356|NCT02557919|Experimental|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
16608357|NCT02557919|Other|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
16608358|NCT02557906|Experimental|Implant and Surgimend|Breast reconstruction surgery with an implant and an ADM (Surgimend)
16608359|NCT02557906|Active Comparator|Autologous tissue|Breast reconstruction surgery with autologous tissue
16608360|NCT02557906|Active Comparator|Implant + dermal sling/LD flap|Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
16608361|NCT02557893|Experimental|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
16608362|NCT02557893|Sham Comparator|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
16608363|NCT02557893|Placebo Comparator|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
16608364|NCT02557880|Experimental|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
16608365|NCT02557880|Active Comparator|Treatment as Usual|Sleep hygiene counseling
16608366|NCT02557867|Experimental|Obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
16608367|NCT02557867|Experimental|Non-obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
16608368|NCT02557854|Experimental|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
16608369|NCT02557841|Experimental|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
16608370|NCT02557841|Experimental|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
16608371|NCT02557841|Sham Comparator|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
16608372|NCT02557828|Active Comparator|palpation|participants who are randomized to have radial arterial cannulation via palpation technique
16608373|NCT02557828|Active Comparator|ultrasound|participants who are randomized to have radial arterial cannulation via a new ultrasound technique
16608374|NCT02557815|Experimental|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
16608375|NCT02557815|Sham Comparator|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
16608380|NCT02557789|Experimental|Treatment C|Lefamulin as 150 mg i.v. in 250 mL citrate buffered saline infused over 1 h
16608381|NCT02557789|Experimental|Treatment D|Lefamulin as a 600 mg IR tablet one hour after breakfast
16608382|NCT02557776|Experimental|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
16608383|NCT02557763|Experimental|Severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
16608384|NCT02557763|Experimental|non severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
16608385|NCT02557737|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
16608386|NCT02557737|Experimental|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
16608387|NCT02557737|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
16608388|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
16608389|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
16608390|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
16608391|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
16608392|NCT02557685|No Intervention|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
16608393|NCT02557672|Active Comparator|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
16608394|NCT02557672|Experimental|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
16608395|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
16608396|NCT02557633|Placebo Comparator|Placebo|2% w/v L-Tyrosine
16608397|NCT02557633|Experimental|Grass MATA MPL 10200 SU|Grass MATA MPL cumulative dose 10200 SU given as six injections of placebo, placebo, 600SU, 1600SU, 4000SU and 4000SU.
16608398|NCT02557633|Experimental|Grass MATA MPL 18200 SU|Grass MATA MPL cumulative dose 18200 SU given as six injections of 600SU, 1600SU, 4000SU, 4000SU, 4000SU and 4000SU.
16608399|NCT02557620|Experimental|semaglutide OD + placebo semaglutide OW|
16608400|NCT02557620|Placebo Comparator|placebo semaglutide OW + placebo semaglutide OD|
16608401|NCT02557620|Experimental|semaglutide OW + placebo semaglutide OD|
16608402|NCT02557607|Other|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
16608403|NCT02557594|Experimental|Viread → DA-2802|"Viread 300mg(Tenofovir disoproxil fumarate)
~DA-2802 319mg(Tenofovir disoproxil orotate)"
16608404|NCT02557594|Experimental|DA-2802 → Viread|"Viread 300mg(Tenofovir disoproxil fumarate)
~DA-2802 319mg(Tenofovir disoproxil orotate)"
16608405|NCT02557581|Experimental|Terbutaline|Beta2-adrenergic stimulation with terbutaline
16608406|NCT02557581|Placebo Comparator|Placebo|Placebo
16608407|NCT02557581|Experimental|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
16608408|NCT02557568|Experimental|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
16608409|NCT02557568|Experimental|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
16608410|NCT02557542|Experimental|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
16608411|NCT02557542|Active Comparator|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
16608412|NCT02557529|Experimental|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
16608413|NCT02557529|Active Comparator|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
16608414|NCT02557516|Experimental|Phase 1 Level 1 - 1 mg/kg|In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
16608415|NCT02557516|Experimental|Phase 1 Level 2 - 2 mg/kg|In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
16608416|NCT02557516|Experimental|Phase 1 Level 3 - 4 mg/kg|In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
16608417|NCT02557516|Experimental|Phase 2 RP2D - 2 mg/kg|In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
16608418|NCT02557503|Experimental|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
16608419|NCT02557503|No Intervention|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
16608420|NCT02557490|Experimental|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
16608421|NCT02557490|No Intervention|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
16608422|NCT02557477|Active Comparator|Active|Participants received 3 capsules of Omega 3/6 fatty acids twice daily
16608423|NCT02557477|Placebo Comparator|Placebo|Participants received 3 capsules of identical placebo (palm oil) twice daily
16608424|NCT02557464|Experimental|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
16608425|NCT02557464|Active Comparator|control group|24 age matched controls participants
16608426|NCT02557451|Experimental|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
16608427|NCT02557451|Experimental|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
16608431|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
16608432|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
16608433|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
16608434|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
16608435|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
16608436|NCT02557412|Placebo Comparator|Conventional treatment|Hygiene and diet recommendations on sleep.
16608437|NCT02557412|Active Comparator|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
16608438|NCT02557412|Active Comparator|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
16608439|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
16608440|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
16608441|NCT02557386|Experimental|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
16608442|NCT02557386|Experimental|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
16608443|NCT02557386|Experimental|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
16608444|NCT02557386|Experimental|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
16608445|NCT02557386|Experimental|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
16608446|NCT02557386|Experimental|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
16608447|NCT02557373|Placebo Comparator|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
16608448|NCT02557373|Experimental|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
16608449|NCT02557360|Experimental|S-adenosyl-L-methionine|Patients with primary biliary cirrhosis will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
16608450|NCT02557347|Experimental|Intervention|Aggressive fluid management
16608451|NCT02557334|Experimental|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
16608452|NCT02557334|Experimental|High Dose Strawberry Powder|40 g freeze dried strawberry powder
16608453|NCT02557334|Placebo Comparator|Placebo Powder|40 g color and taste matched placebo powder
16608454|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
16608455|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
16608456|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
16608457|NCT02557308||Remsima™|Patients who are taking Remsima™ for the treatment
16608458|NCT02557308||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
16608459|NCT02557295||Remsima™|Patients who are taking Remsima™ for the treatment
16608460|NCT02557295||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
16608461|NCT02557295||Biologic naive patients|Biologic naive patients (in Korea only)
16608462|NCT02557282||Predicate software|Olea Sphere PACS with CT Perfusion Module
16608463|NCT02557282||Investigational software|Vue PACS 12.1.5 Computed Tomography (CT) Perfusion
16608464|NCT02557269|Active Comparator|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
16608465|NCT02557269|Placebo Comparator|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
16608466|NCT02557269|Other|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
16608467|NCT02557217|Experimental|NP202|1000mg oral NP202 daily for 90 days
16608468|NCT02557217|Placebo Comparator|Placebo|Oral placebo daily for 90 days
16608469|NCT02557204|Active Comparator|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
16608470|NCT02557204|Experimental|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
16608471|NCT02557204|Experimental|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
16608472|NCT02557204|Experimental|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
16608473|NCT02557191||Group 1|Preterm infants <32 weeks gestational age
16608474|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen. Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
16608475|NCT02557178|No Intervention|Control|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.
16608476|NCT02557165||COPD patients|Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
16608477|NCT02557165||Patients with normal lung function|Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
16608478|NCT02557152||Patients that were treated with the GentleWave System|
16608482|NCT02557126|Experimental|URC102|URC102
16608483|NCT02557126|Placebo Comparator|Placebo|Placebo
16608484|NCT02557113|Active Comparator|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
16608485|NCT02557113|Experimental|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
16608486|NCT02557100|Experimental|Treatment A|Abatacept Single Blind Treatment Period
16608487|NCT02557100|Active Comparator|Treatment B|Adalimumab Single Blind Treatment Period
16608488|NCT02557100|Active Comparator|Treatment C|Abatacept Cumulative Treatment Period
16608489|NCT02557087|Experimental|Hyoscine|Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
16608490|NCT02557087|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
16608491|NCT02557074|Experimental|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -
~IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment
~IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
16608492|NCT02557074|Placebo Comparator|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
16608493|NCT02557061|Experimental|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
16608808|NCT02554812|Experimental|Cohort A3|NSCLC patients treated with avelumab + utomilumab (Dose level 3)
16608494|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
16608495|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
16608496|NCT02556996|Experimental|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
16608497|NCT02556996|Placebo Comparator|Placebo|Three doses administered orally at 2-week intervals
16608498|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
16608499|NCT02556970|Experimental|Single-port surgery|"After induction of anaesthesia and lung isolation, a single intercostal incision will be placed laterally. This will usually be anterior to the border of the latissimus dorsi muscle, and in the 4th-7th space as appropriate to the planned surgery.
~A soft tissue wound protector can be used to protect the wound edges, but rigid intercostal retraction is not permitted. All instruments will be placed via this incision."
16608500|NCT02556970|Active Comparator|Multiple port surgery|Patients in this arm will have 3 separate incisions placed to site the camera and other instruments. This will involve three separate incisions.
16608501|NCT02556957|Experimental|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
16608502|NCT02556957|Active Comparator|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
16608503|NCT02556944|Experimental|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
16608504|NCT02556931|Experimental|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
16608505|NCT02556931|Experimental|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
16608506|NCT02556918|Experimental|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
~Interventions:
~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
16608507|NCT02556918|Placebo Comparator|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
~Interventions:
~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
16608508|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
16608509|NCT02556892|Experimental|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
16608510|NCT02556879|Other|Liver retransplantation|"Donor specific antibodies :Additional samples for Donor specific at each visit
~Serum bank : Additional samples for serum bank at each visit if possible
~DNA banq : Additional sample for DNA banq at inclusion visit if possible
~Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)
~Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
16608511|NCT02556866|Experimental|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
16608512|NCT02556866|Placebo Comparator|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
16608513|NCT02556853|Experimental|Ultrasound|Determination of correct placement of the double lumen tube by lung ultrasound.
16608514|NCT02556853|Active Comparator|Clinical|Determination of correct placement of the double lumen tube by clinical examination.
16608515|NCT02556840|Active Comparator|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose > 0.95g/l or post-prandial blood glucose > 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.
~Insulin administered to patients either by subcutaneous injections or by pump."
16608516|NCT02556840|Experimental|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.
~Insulin administered to patients either by subcutaneous injections or by pump."
16608517|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.
~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
16608518|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.
~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
16608519|NCT02556814|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
16608520|NCT02556814|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
16608521|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
16608522|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
16608523|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
16608524|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
16608525|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
16608526|NCT02556788|Placebo Comparator|Placebo Cream|Placebo Cream
16608527|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
16608528|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
16608529|NCT02556762|Experimental|SMART boost|Radiotherapy with simultaneous modulated accelerated boost
16608530|NCT02556762|Active Comparator|Standard dose RT|Standard dose radiotherapy
16608531|NCT02556749|Experimental|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
16608532|NCT02556749|Placebo Comparator|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
16608533|NCT02556736|Experimental|Group 1|Single intravitreal injection of RST-001
16608534|NCT02556723|Experimental|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
16608535|NCT02556710|Experimental|4 mL AMPION™|AMPION™, 4 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
16608536|NCT02556710|Placebo Comparator|4 mL Saline Placebo|Saline placebo, 4 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride.
16608537|NCT02556697|Experimental|patients with a suspicion of emphysema|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
16608538|NCT02556697|Experimental|patients with a suspicion of scleroderma|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
16608539|NCT02556671||Moderate CKD Patients Undergoing PCI|
16608540|NCT02556671||Normal renal function Patients Undergoing PCI|
16608541|NCT02556658|Experimental|Smartpilot View group|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
16608542|NCT02556658|Active Comparator|Control group|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
16608543|NCT02556645|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
16608544|NCT02556645|Active Comparator|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
16608545|NCT02556632|Experimental|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
16608809|NCT02554812|Experimental|Cohort A4|Melanoma patients treated with avelumab +utomilumab
16608546|NCT02556632|Experimental|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
16608547|NCT02556632|Placebo Comparator|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
16608548|NCT02556619|No Intervention|Standard Therapy|Patients will undergo standard medical care for Hepatocellular Carcinoma diagnosis.Patients however will not be denied early palliative care if requested.
16608549|NCT02556619|Experimental|Early Palliative Care/Symptom Control|"Patients will undergo palliative care services at time of Hepatocellular Carcinoma diagnosis.
~Palliative care and symptom control services are adapted from the National Consensus Project for Quality Palliative Care.
~Early referral, patients meeting inclusion criteria will be enrolled and referred to palliative care within 3 weeks of the index consultation with Medical-Oncology, Surgical-Oncology or Gastroenterology.
~Intervention will be:
~Establish palliative care goals
~Symptom Assessment and Control
~End-of-Life Care"
16608550|NCT02556606|Experimental|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
16608551|NCT02556606|Experimental|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
16608552|NCT02556606|Experimental|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
16608553|NCT02556606|Active Comparator|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
16608554|NCT02556593|Experimental|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
16608555|NCT02556593|Active Comparator|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
16608556|NCT02556580|Active Comparator|Conscious healthy volunteers|Intervention: intravenious infusion Drug: albumin 20%
16608557|NCT02556580|Experimental|Surgery under general anesthesia|Intervention: intravenious infusion Drug: albumin 20%
16608558|NCT02556580|Experimental|Post-surgical inflammation|Intervention: intravenious infusion Drug: albumin 20%
16608559|NCT02556567|Other|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
16608560|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
16608561|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
16608562|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
16608563|NCT02556528|Experimental|Health Coaching|
16608564|NCT02556515|Active Comparator|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
16608565|NCT02556515|Experimental|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
16608566|NCT02556502|Experimental|FDG PET positive or negative|
16608567|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
16608568|NCT02556463|Experimental|Escalation MEDI9197|MEDI9197
16608569|NCT02556463|Experimental|Escalation MEDI9197 with durvalumab|MEDI9197 in combination with durvalumab
16608570|NCT02556463|Experimental|Escalation MEDI9197 durvalumab radiation|MEDI9197 in combination with durvalumab and palliative radiation
16608571|NCT02556463|Experimental|MEDI9197 with palliative radiation|MEDI9197 in combination with palliative radiation
16608572|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
16608573|NCT02556450|No Intervention|Control group|Only background treatment
16608574|NCT02556437|Experimental|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
16608575|NCT02556437|Experimental|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
16608576|NCT02556424|Active Comparator|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
16608577|NCT02556424|Experimental|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
16608578|NCT02556411|Active Comparator|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
16608579|NCT02556411|Experimental|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
16608580|NCT02556398|Experimental|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
16608581|NCT02556385|Experimental|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
16608582|NCT02556385|Active Comparator|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
16608583|NCT02556372|Experimental|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
16608584|NCT02556346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16608585|NCT02556346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16608586|NCT02556346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16608587|NCT02556346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16608810|NCT02554812|Experimental|Cohort A5|SCCHN patients treated with avelumab + utomilumab
16608588|NCT02556346|Experimental|MT-3724 Phase 1b|MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
16608589|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
16608590|NCT02556320|Experimental|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
16608591|NCT02556307||Peginterferon alfa-2a + Ribavirin|
16608592|NCT02556294|Experimental|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
16608593|NCT02556294|Other|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
16608594|NCT02556281|Experimental|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
16608595|NCT02556268|Experimental|Riociguat and ATRIPLA|
16608596|NCT02556268|Experimental|Riociguat and COMPLERA|
16608597|NCT02556268|Experimental|Riociguat and STRIBILD|
16608598|NCT02556268|Experimental|Riociguat and TRIUMEQ|
16608599|NCT02556268|Experimental|Riociguat and antiretroviral protease inhibitor with TRIUMEQ|
16608600|NCT02556255|Experimental|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
16608601|NCT02556242|Experimental|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
16608602|NCT02556242|Active Comparator|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
16608603|NCT02556229|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
16608604|NCT02556203|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
16608605|NCT02556203|Active Comparator|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
16608606|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
16608607|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
16608608|NCT02556164|Experimental|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
16608609|NCT02556164|Sham Comparator|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
16608610|NCT02556151|Active Comparator|1 Hz|Six sessions of weekly therapy with 1 Hz magnetic stimulations of the lumbar and sacral regions.
16608611|NCT02556151|Active Comparator|5 Hz|Six sessions of weekly therapy with 5 Hz magnetic stimulations of the lumbar and sacral regions.
16608612|NCT02556151|Active Comparator|15 Hz|Six sessions of weekly therapy with 15 Hz magnetic stimulations of the lumbar and sacral regions.
16608613|NCT02556138|Experimental|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
16608614|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
16608615|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
16608616|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
16608617|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
16608618|NCT02556099|Experimental|Hydroxyurea Treatment|Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic clinical evaluations, laboratory tests, and transcranial doppler examinations every 6 months.
16608619|NCT02556086|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
16608811|NCT02554812|Experimental|Cohort A6|TNBC patients treated with avelumab + utomilumab
16608620|NCT02556073|Active Comparator|Usual care|"Usual care means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics."
16608621|NCT02556073|Experimental|Usual care+Smartphone action|Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
16608622|NCT02556060|Experimental|lamotrigine|lamotrigine extended release up to 200 mg/day,
16608623|NCT02556060|Placebo Comparator|Placebo|Identical Placebo
16608624|NCT02556047|Other|Injections|"Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length
~Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length
~Two injections of 0.1 ml saline per subject using Mantoux technique by N&S"
16608625|NCT02556034||Disease evaluation|Rheumatoid arthritis evaluations.
16608626|NCT02556021|Experimental|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
16608627|NCT02556021|Experimental|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
16608628|NCT02556021|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
16608629|NCT02555995|Experimental|All study participants|Patient's eyes are OCT-scanned with standard device and investigational device.
16608630|NCT02555982|Experimental|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:
~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
16608631|NCT02555982|Other|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:
~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
16608632|NCT02555943|Active Comparator|Prophylactic/Early anti-HBV treatment|"HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
~."
16608633|NCT02555943|Experimental|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
16608634|NCT02555917|Experimental|Remnant preserving|"Anterior cruciate ligament reconstruction:
~anterior cruciate ligament remnant will be preserved in the operation"
16608635|NCT02555917|Active Comparator|Remnant resecting|"Anterior cruciate ligament reconstruction:
~anterior cruciate ligament remnant will be removed in the operation"
16608636|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
16608637|NCT02555878|Experimental|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
16608638|NCT02555878|Experimental|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
16608639|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
16608640|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
16608641|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
16608642|NCT02555839||Pomalidomide and Dexamethasone|Pomalidomide 4mg capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
16608643|NCT02555839||Pomalidomide, Bortezomib and Dexamethasone|Cycle 1-8: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle until progression or unacceptable toxicity; from cycle 9 onwards: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 8, 9 of a 21 day cycle until progression or unacceptable toxicity
16608644|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
16608645|NCT02555800|Experimental|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
16608646|NCT02555800|Experimental|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
16608647|NCT02555800|Placebo Comparator|Saline|Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.
16608648|NCT02555787||Patients converted from tacrolimus BD to Advagraf|Oral
16608706|NCT02555488|Experimental|1|In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done
16608649|NCT02555774|Experimental|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
16608650|NCT02555774|Active Comparator|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
16608651|NCT02555774|No Intervention|No intervention|This group receives no intervention.
16608652|NCT02555761||Lastacaft®|One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.
16608653|NCT02555748|Active Comparator|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).
~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
16608654|NCT02555748|Active Comparator|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).
~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
16608655|NCT02555735||Metastatic Pancreatic Cancer|Participants with metastatic pancreatic cancer treated with physician-choice standard of care chemotherapy.
16608656|NCT02555722|Experimental|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
16608657|NCT02555722|Active Comparator|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
16608658|NCT02555709|Placebo Comparator|Placebo 1|healthy volunteers
16608659|NCT02555709|Experimental|VTP-43742 Dose 1|healthy volunteers
16608660|NCT02555709|Experimental|VTP-43742 Dose 2|healthy volunteers
16608661|NCT02555709|Experimental|VTP-43742 Dose 3|healthy volunteers
16608662|NCT02555709|Experimental|VTP-43742 Dose 4|healthy volunteers
16608663|NCT02555709|Experimental|VTP-43742 Dose 5|healthy volunteers
16608664|NCT02555709|Experimental|VTP-43742 Dose 6|healthy volunteers
16608665|NCT02555709|Experimental|VTP-43742 Dose 7|healthy volunteers
16608666|NCT02555709|Placebo Comparator|Placebo 2|psoriatic patients
16608667|NCT02555709|Experimental|VTP-43742 Dose 8|psoriatic patients
16608668|NCT02555709|Experimental|VTP-43742 Dose 9|psoriatic patients
16608669|NCT02555709|Experimental|VTP-43742 Dose 10|psoriatic patients
16608670|NCT02555709|Experimental|VTP-43742 Dose 11|psoriatic patients
16608671|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
16608672|NCT02555683|Experimental|QAW039 150 mg|QAW039 150 mg once daily
16608673|NCT02555683|Experimental|QAW039 450 mg|QAW039 450 mg once daily
16608674|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
16608675|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
16608676|NCT02555657|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations.
16608677|NCT02555657|Active Comparator|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
16608678|NCT02555644|Experimental|Prexasertib + Cisplatin + Radiation Therapy (Part A)|"Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.
~Cisplatin administered IV every 7 days over an approximately 49-day treatment period.
~Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.
~Participants may remain on treatment until completion of the treatment period."
16608679|NCT02555644|Experimental|Prexasertib + Cetuximab + Radiation Therapy (Part B)|"Prexasertib administered IV every 14 days over an approximately 56-day treatment period.
~Cetuximab administered IV every 7 days over an approximately 56-day treatment period.
~Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).
~Participants may remain on treatment until completion of the treatment period."
16608680|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
16608681|NCT02555618|Experimental|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.
16608682|NCT02555618|Active Comparator|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
16608683|NCT02555566|Experimental|Kidney transplant recipients|"blood sampling is done for determination of EPHX Lys55Arg and other polymorphisms status in Kidney transplant recipients.
~flow-mediated distal stimulation of the forearm radial artery by cutaneous heating is assessed for evaluation of EEts level in Kidney transplant recipients."
16608684|NCT02555553|No Intervention|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
16608704|NCT02555501|Active Comparator|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
16608805|NCT02554825|Other|Control|
16608685|NCT02555553|Experimental|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
16608686|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608687|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608688|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608689|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608690|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608691|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608692|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608693|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608694|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608695|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608696|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608697|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608698|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608699|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608700|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608701|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
16608702|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment >4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
16608703|NCT02555501|Experimental|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser
~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
16608705|NCT02555488|Experimental|2|in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals.
16608707|NCT02555475|No Intervention|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
16608708|NCT02555475|Experimental|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
16608709|NCT02555462|Experimental|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
16608710|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
16608711|NCT02555410||Brain Sentinel Seizure Detection and Warning System|To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
16608712|NCT02555397|Experimental|Single|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
16608713|NCT02555384|Active Comparator|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
16608714|NCT02555384|Placebo Comparator|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
16608715|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
16608716|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
16608717|NCT02555358|Experimental|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
16608718|NCT02555358|Active Comparator|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
16608719|NCT02555358|Active Comparator|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
16608720|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
16608721|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
16608722|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
16608723|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
16608724|NCT02555332||Women underwent screening for thyroid function|All these women underwent screening for thyroid function (TSH,FT4,TPOAb) at the first antenatal visit and the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The correlation between the combination of TSH level and TPOAb status and the risk of Gestational Diabetes Mellitus was analyzed.
16608725|NCT02555319|Experimental|Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
16608726|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
16608727|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
16608728|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
16608729|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
16608730|NCT02555293|Experimental|film-coated Rifaximin (550 mg)|(550 mg) tablet twice daily for at least 14 days but up to 28 days dependent on the need for a PVE and the period between PVE (portal vein embolization) or randomization and surgery. Preoperative Rifaximin treatment in case of a PVE will start the day after PVE and will last for 14-21 days. In case patients are not pre-treated with a PVE they will receive Rifaximin for 7-10 days prior to surgery. Regardless of PVE, patients will receive additional Rifaximin treatment the first 7 days postoperatively.
16608731|NCT02555293|No Intervention|standard therapy|Patients directed to the control group will not receive Rifaximin.
16608732|NCT02555280|Experimental|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
16608733|NCT02555280|Active Comparator|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
16608734|NCT02555267||Elderly patients with DLBCL|Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy
16608806|NCT02554812|Experimental|Cohort A1|NSCLC patients treated with avelumab + utomilumab (Dose level 1)
16608735|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
16608736|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
16608737|NCT02555241|Experimental|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
16608738|NCT02555241|Experimental|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
16608739|NCT02555241|Experimental|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
16608740|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
16608741|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
16608742|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
16608743|NCT02555189|Experimental|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16608744|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16608745|NCT02555176|Experimental|Low Carbohydrate Diet|Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
16608746|NCT02555163|Experimental|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
16608747|NCT02555163|Active Comparator|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
16608748|NCT02555150|Active Comparator|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
16608749|NCT02555150|Active Comparator|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
16608750|NCT02555150|Placebo Comparator|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
16608751|NCT02555137||outcome cohort study|'prediction score' and 'rule-out criteria'
16608752|NCT02555124|Experimental|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
16608753|NCT02555124|Experimental|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
16608754|NCT02555124|Experimental|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
16608755|NCT02555111|Experimental|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
16608756|NCT02555111|No Intervention|untreated|the patient won't receive any treatment during his study participation.
16608757|NCT02555098|Experimental|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
16608758|NCT02555098|Active Comparator|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
16608759|NCT02555085|Experimental|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608760|NCT02555085|Experimental|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608761|NCT02555085|Experimental|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608762|NCT02555085|Experimental|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608763|NCT02555085|Experimental|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608764|NCT02555085|Experimental|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608765|NCT02555085|Experimental|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
16608766|NCT02555085|Experimental|SC Dose|Single SC dose or matching placebo
16608767|NCT02555072|Other|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
16608768|NCT02555059||BAYQ3939|Pediatrics patients treated with Ciproxan injection in daily clinical practice.
16608769|NCT02555046|No Intervention|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
16608770|NCT02555046|Experimental|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
16608771|NCT02555033|Experimental|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
16608772|NCT02555033|Experimental|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
16608773|NCT02555033|Experimental|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
16608774|NCT02555020|Experimental|Allocated to MN NPO group,|"Patients was administered in hospital
~Randomization
~Patient was allocated to MN group
~Patients were NPO from mid night (MN) to Surgery"
16608775|NCT02555020|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Placebo group
~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
16608776|NCT02555020|Active Comparator|Allocated to Carbohydrated group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Carbohydrated group
~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
16608777|NCT02555007|Experimental|Oral Vinorelbine|
16608778|NCT02554994|Active Comparator|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.
~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
16608779|NCT02554994|Active Comparator|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
16608780|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
16608781|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
16608782|NCT02554955|Experimental|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram [mg/kg] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily [BID] within first week and 1 grams per day [g/day] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
16608783|NCT02554942|Experimental|Epoetin beta|Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram [IU/kg]) for 16 weeks.
16608784|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
16608785|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
16608786|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
16608787|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
16608788|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
16608789|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
16608790|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
16608791|NCT02554890|Experimental|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
16608792|NCT02554890|Active Comparator|Enalapril|"Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
~Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
16608793|NCT02554877|Placebo Comparator|Placebo|
16608794|NCT02554877|Experimental|PF-06291874, 30 mg|
16608795|NCT02554877|Experimental|PF-06291874, 60 mg|
16608796|NCT02554877|Experimental|PF-06291874, 100 mg|
16608797|NCT02554864|Active Comparator|Adductor Canal Block- Injection -Site A|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site A - after the sartorius muscle crosses over the femoral artery
16608798|NCT02554864|Active Comparator|Adductor Canal Block - Injection -Site B|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site B - before the sartorius muscle crosses over the femoral artery
16608799|NCT02554864|Active Comparator|Adductor Canal Block -Injection -Site C|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site C - as the sartorius muscle crosses over the femoral artery
16608800|NCT02554851|Placebo Comparator|placebo|This group will receive the standard medication and the placebo drug
16608801|NCT02554851|Experimental|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
16608802|NCT02554838|Active Comparator|Rehabilitation|"Rehabilitation :
~Physical activity
~Home assessment and modification"
16608803|NCT02554838|Experimental|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :
~Physical activity
~Home assessment and modification
~Cognitive behavioral therapy"
16608804|NCT02554825|Experimental|Healthy Futures|
16608812|NCT02554812|Experimental|Cohort A7|SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
16608813|NCT02554812|Experimental|Cohort A8|NSCLC first-line Stage IV treated with avelumab +PF-05082566
16608814|NCT02554812|Experimental|Combination B Dose Escalation|PF-04518600 + avelumab in selected tumor types
16608815|NCT02554812|Experimental|Combination B Expansion Cohorts|PF-04518600 + avelumab in selected tumor types
16608816|NCT02554812|Experimental|Combination C Dose escalation cohorts|PD 0360324 + avelumab in selected tumor types
16608817|NCT02554812|Experimental|Combination C Dose expansion cohorts|PD 0360324 + aveluamb in selected tumor types
16608818|NCT02554812|Experimental|Combination D Dose escalation cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
16608819|NCT02554812|Experimental|Combination D Dose expansion cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
16608820|NCT02554812|Experimental|Cohort A9|NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
16608821|NCT02554812|Experimental|Cohort A10|NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
16608822|NCT02554812|Experimental|Cohort F1|CMP-001 +avelumab in SCCHN
16608823|NCT02554812|Experimental|Cohort F2|CMP-001+avelumab+utomilumab in SCCHN
16608824|NCT02554812|Experimental|Cohort F3|CMP-001 +avelumab+PF-04518600 in SCCHN
16608825|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
16608826|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
16608827|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
16608828|NCT02554786|Experimental|QMF149 150/160 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.
16608829|NCT02554786|Experimental|QMF149 150/320 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.
16608830|NCT02554786|Active Comparator|MF 400 µg|Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening
16608831|NCT02554786|Active Comparator|Salmeterol /fluticasone 50/500 μg|Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.
16608832|NCT02554786|Active Comparator|MF 800 μg|MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.
16608834|NCT02554760|Experimental|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
16608835|NCT02554747|Experimental|Navigated laser|Aflibercept, Navilas®
16608836|NCT02554747|Active Comparator|Conventional laser|Aflibercept, Pascal
16608837|NCT02554734|Experimental|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
16608838|NCT02554734|Experimental|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
16608839|NCT02554734|Active Comparator|Stalevo|Levodopa, carbidopa, entacapone
16608840|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
16608841|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
16608842|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
16608843|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
16608844|NCT02554695|Placebo Comparator|placebo|single subcutaneous injection of placebo (normal saline)
16608845|NCT02554695|Active Comparator|Denosumab|single subcutaneous injection of denosumab 60 mg
16608846|NCT02554695|No Intervention|young normal premenopausal women|no intervention
16608847|NCT02554682|Other|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
16608848|NCT02554682|Other|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
16608849|NCT02554682|No Intervention|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
16608850|NCT02554682|Other|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
16608851|NCT02554682|No Intervention|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
16608852|NCT02554669|No Intervention|Control|No physical activity
16608853|NCT02554669|Experimental|Postabsorptive physical activity|Physical activity performed before breakfast
16608854|NCT02554669|Experimental|Postprandial physical activity|Physical activity performed in the postprandial period after breakfast
16608855|NCT02554643|Experimental|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks
~+ Soccer training, 3 times a week, during 12 weeks"
16608856|NCT02554643|Experimental|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks
~+ Running training, 3 times a week, during 12 weeks"
16608857|NCT02554643|Active Comparator|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
16608858|NCT02554630||Preterm Neonate|Neonates of gestational age 24-37 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
16608859|NCT02554630||Term Neonates|Neonates of gestational age 37-42 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
16608860|NCT02554630||Healthy Adult Control|Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
16608861|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
16608862|NCT02554578|Experimental|Pharmaceutical care programme supported by mHealth|
16608863|NCT02554578|No Intervention|Routine healthcare by the transplant team|
16608864|NCT02554565|Other|Tumor biopsies and blood sampling|
16608865|NCT02554552|Experimental|YY1201 2ml|YY1201 2ml
16608866|NCT02554552|Experimental|YY1201 3ml|YY1201 3ml
16608867|NCT02554552|Placebo Comparator|Placebo 2ml|Phosphate buffered saline 2ml
16608868|NCT02554552|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
16608869|NCT02554539|Experimental|Obese|Women, aged 21-45 with BMI >30
16608870|NCT02554539|Experimental|Normal weight|Women, aged 21-45 with BMI < 25
16608871|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
16608872|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
16608873|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
16608874|NCT02554500|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16608875|NCT02554500|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16608876|NCT02554500|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16608877|NCT02554500|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16608878|NCT02554500|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16608879|NCT02554487|Experimental|sSDB ASV+|sSDB ASV+: Patients with an AHI > 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
16608880|NCT02554487|No Intervention|sSDB ASV-|sSDB ASV-: Patients with an AHI > 20 no ASV treatment.
16608881|NCT02554487|No Intervention|no SDB|no SDB: Stroke patients without SDB (AHI < 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
16608927|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
16608928|NCT02554136|Experimental|Sequence 1|HGP0918 -> HGP0816 -> HGP0918 + HGP0816
16608882|NCT02554474|Active Comparator|Immediate Group|Time spent in Moderate/Vigorous Physical Activity (MVPA) was measured with a SenseWear Mini sensor over a 7-day period. The mean time was calculated in bouted MVPA per day. A bout is defined as >= 10 consecutive minutes or more at the level of >= 3 METs (i.e., the lower bound of MVPA), with allowance for interruption of up to two minutes below the threshold.
16608883|NCT02554474|Placebo Comparator|Delay Group|Time spent in sedentary activity was measured with a SenseWear Mini sensor over a 7-day period. The mean daily time spent in sedentary activity was calculated with an energy expenditure of <=1.5 METs, occurring in bouts of >= 20 minutes during waking hours.
16608884|NCT02554461||female players|national team players
16608885|NCT02554461||male players|national team players
16608886|NCT02554448|Experimental|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
16608887|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
16608888|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
16608889|NCT02554422|Experimental|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
16608890|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
16608891|NCT02554396|Experimental|PRX-100|PRX-100 ophthalmic solution
16608892|NCT02554396|Placebo Comparator|Placebo|saline solution
16608895|NCT02554370|Experimental|Psychoeducational programme|Psychoeducational programme
16608896|NCT02554370|No Intervention|Usual care|No psychoeducational programme
16608897|NCT02554357|Experimental|Exparel block in arthroscopic surgery|Evaluation of Exparel block in arthroscopic shoulder surgery.
16608898|NCT02554357|Experimental|Bupivacaine block in shoulder surgery|Evaluation of Bupivacaine block in shoulder surgery.
16608899|NCT02554344|Experimental|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
16608900|NCT02554331|Experimental|Patients RBD|Patients RBD subject to FP-CIT single-photon emission computed tomography and Neuropsychological evaluation and Gait recording with sensors
16608901|NCT02554331|Other|controls healthy volunteers|controls healthy volunteers subject to Neuropsychological evaluation and Gait recording with sensors
16608902|NCT02554318|Experimental|Intervention|"TB standard therapy with fixed dose combination :
~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,
~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets
~and 166.5 grams cooked fermented soybean (tempeh) daily for two months"
16608903|NCT02554318|Active Comparator|Control|"TB standard therapy with fixed dose combination :
~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,
~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets"
16608904|NCT02554305|Active Comparator|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
16608905|NCT02554305|Active Comparator|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
16608906|NCT02554305|No Intervention|Peripheral vascular procedure|No oxygenation machine will be used in this group
16608907|NCT02554305|No Intervention|percutaneous coronary intervention|No oxygenation machine will be used in this group
16608908|NCT02554279|Experimental|menotropin|menotropins for injection
16608909|NCT02554279|Active Comparator|recombinant FSH|
16608910|NCT02554253|Active Comparator|ketamine|Ketamine induction
16608911|NCT02554253|Active Comparator|Propofol|Propofol induction
16608912|NCT02554240|Experimental|DA-5202 High dose|- DA-5202 20mg
16608913|NCT02554240|Experimental|DA-5202 Low dose|- DA-5202 10mg
16608914|NCT02554240|Active Comparator|Na Hyaluronate 20mg|Na Hyaluronate 20mg
16608915|NCT02554227||Spondylodiscitis|vertebral osteomyelitis, erosive osteochondrose
16608916|NCT02554214|Experimental|Glafkos device|
16608917|NCT02554201|Experimental|Electrical pudendal nerve stimulation|Electrical pudendal nerve stimulation At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of four weeks
16608918|NCT02554201|Active Comparator|Transvaginal electrical stimulation|At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 30 min three times a week for a total of four weeks.
16608919|NCT02554188|Placebo Comparator|Control|Participants will receive Seasonal influenza (flu) vaccine.
16608920|NCT02554188|Experimental|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
16608921|NCT02554175|Experimental|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
16608922|NCT02554162|Active Comparator|Extruded wholegrain rye flakes|Rye products with varying structures
16608923|NCT02554162|Active Comparator|Extruded wholegrain rye puffs|Rye products with varying structures
16608924|NCT02554162|Active Comparator|Fresh wholegrain rye bread|Rye products with varying structures
16608925|NCT02554162|Active Comparator|Wholegrain rye beverage|Rye products with varying structures
16608926|NCT02554162|Active Comparator|Fresh wheat bread|Rye products with varying structures
16608929|NCT02554136|Experimental|Sequence 2|HGP0816 -> HGP0918 + HGP0816 -> HGP0918
16608930|NCT02554136|Experimental|Sequence 3|HGP0918 + HGP0816 -> HGP0918 -> HGP0816
16608931|NCT02554136|Experimental|Sequence 4|HGP0918 -> HGP0918 + HGP0816 -> HGP0816
16608932|NCT02554136|Experimental|Sequence 5|HGP0816 -> HGP0918 -> HGP0918 + HGP0816
16608933|NCT02554136|Experimental|Sequence 6|HGP0918 + HGP0816 -> HGP0816 -> HGP0918
16608934|NCT02554123|Experimental|Vitamin E ointment|Vitamin E ointment application. Every 12 hours during 7 days.
16608935|NCT02554123|Placebo Comparator|Vaseline ointment|Vaseline ointment application. Every 12 hours during 7 days.
16608936|NCT02554110|Experimental|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
16608937|NCT02554110|Sham Comparator|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
16608938|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
16608939|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
16608940|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
16608941|NCT02554084|Experimental|Dry Eye Disease|Optical Coherence Tomography
16608942|NCT02554084|Active Comparator|Normals|Optical Coherence Tomography
16608943|NCT02554071|Experimental|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
16608944|NCT02554058|Experimental|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
16608945|NCT02554045|Active Comparator|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
16608946|NCT02554045|Placebo Comparator|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
16608947|NCT02554032|Active Comparator|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
16608948|NCT02554032|Active Comparator|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
16608949|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
16608950|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
16608951|NCT02554006|Other|good clinical practice|all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
16608952|NCT02554006|Experimental|bundle group|patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
16608953|NCT02553993|Experimental|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
16608954|NCT02553993|Experimental|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.
~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
16608955|NCT02553993|Placebo Comparator|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
16608956|NCT02553980|Experimental|Physical activity promotion I|"Participants in this group attended the VT3 program (with Automatic HR detection)"
16608957|NCT02553980|Experimental|Physical activity promotion II|"Participants in this group attended the VT2 program (self PA report)"
16608958|NCT02553980|Placebo Comparator|Control|Participants in this group did not receive any VT treatment, and live as usual.
16608959|NCT02553967|Experimental|Immediate breast reconstruction|"Total mastectomy + immediate reconstructive surgery
~6 months after surgery : Functional MRI and questionnaires"
16608960|NCT02553967|Experimental|Secondary breast reconstruction|"Within 2 months before surgery : Functional MRI
~Reconstructive surgery
~6 months after surgery : Functional MRI and questionnaires"
16608962|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16608963|NCT02553928|Experimental|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
16608964|NCT02553928|Experimental|Memantine (twice daily)|Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
16608965|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
16608966|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
16608967|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
16608968|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
16608969|NCT02553902|Active Comparator|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.
~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
16608970|NCT02553902|Active Comparator|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
16608971|NCT02553889|Experimental|PK Cohort|A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC).
16608972|NCT02553889|Placebo Comparator|Cohort A|"Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used.
~For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.
~Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
16608973|NCT02553889|Placebo Comparator|Cohort B|"Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used.
~For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.
~Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
16608974|NCT02553876||Observational|All patients referred with pain in the hand and/or upper limb will be evaluated. Patients will first be assessed for suitability for neurostimulation implantation and then included in the study. Patients wiil fill in questionnaires (pain scores, Quality of Life and satisfaction) at baseline and post-operatively at regular intervals (as per standard of care in the Netherlands.)
16608975|NCT02553863|Experimental|Intervention group|Acupuncture for 30min [twice weekly for 8 weeks]
16608976|NCT02553863|Other|Control group|Standard care
16608977|NCT02553850||Ibandronate|Patients receiving ibandronate will be evaluated for bone turnover markers for 12 months. Ibandronate is not an investigational medicinal product (IMP) in this study.
16608978|NCT02553837|Experimental|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
16608979|NCT02553824|Experimental|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
16608980|NCT02553824|Placebo Comparator|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
16608981|NCT02553811|Experimental|intervention|accuracy diagnostic in carpal tunnel syndrome = evaluation and comparison ultrasonography X electromyography
16608982|NCT02553798|Experimental|Glycopyrronium|Glycopyrronium Topical Wipes
16608983|NCT02553785|Experimental|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
16608984|NCT02553772|Experimental|OM3 Tear|Carboxymethylcellulose based eye drop [Omega-3 (OM3) Tear] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
16608985|NCT02553772|Active Comparator|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
16608986|NCT02553759|Experimental|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
16608987|NCT02553759|Active Comparator|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
16608988|NCT02553746|Experimental|Ultrasound|
16608989|NCT02553746|Active Comparator|Landmarks|
16608990|NCT02553733|Active Comparator|Beetroot juice (Beet-It Organic Shot)|Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
16608991|NCT02553733|Placebo Comparator|Beetroot juice placebo (Beet-It Organic Placebo)|Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
16608992|NCT02553720|Experimental|Aquatic Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
16608993|NCT02553720|Other|Control Group|Conventional management without aquatic exercise
16608994|NCT02553707|Experimental|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
16608995|NCT02553694|Experimental|Enhanced education and Enhanced follow up|Subjects will watch a short video and will be contacted by an MD by phone
16608996|NCT02553694|Active Comparator|Usual education and Usual follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and will be contacted by a sleep center staff member by phone
16608997|NCT02553694|Experimental|Enhanced education and Usual follow up|Subjects will watch a short video immediately prior to the initiation of the in-laboratory polysomnogram and will be contacted by sleep center non-MD staff member by phone
16608998|NCT02553694|Experimental|Usual education with Enhanced follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and contacted by an MD by phone
16608999|NCT02553681|Experimental|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
16609000|NCT02553681|Active Comparator|untreated|untreated RGP contact lenses made from roflufocon D
16609001|NCT02553668|Experimental|Hyperoxia|Participants receive 100% oxygen
16609002|NCT02553655|Active Comparator|4x 5min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 5 minutes following by 5 minutes of rest. This will be repeated for 4 times.
16609003|NCT02553655|Active Comparator|3x 10min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
16609004|NCT02553655|Sham Comparator|3x 10min Sham Preconditioning|Either the right or left leg of the participant(s) will be squeezed without causing ischemia for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
16609005|NCT02553642|Experimental|melanoma and bladder cancer patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks OR nivolumab at dose of 480mg every 4 weeks for up to 2 years All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
16609006|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
16609007|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
16609008|NCT02553616|Experimental|Behavioral intervention|Intervention to promote healthy behaviors.
16609009|NCT02553603|Placebo Comparator|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
16609010|NCT02553603|Placebo Comparator|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
16609011|NCT02553603|Experimental|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
16609012|NCT02553603|Experimental|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
16609013|NCT02553577||Conventional cigarettes -only|Women who are pregnant and use conventional tobacco products -only
16609014|NCT02553577||Electronic Cigarette (ecig) (ENDS) -ONLY|Women who are pregnant and use electronic cigarettes (ecigs) -only
16609015|NCT02553577||Conventional + ecig use (DUAL)|Women who are pregnant and use conventional + ecigs (dual)
16609016|NCT02553564|Experimental|Intervention group|"Checklist driven clinical encounter after hospital discharge
~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.
~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
16609017|NCT02553564|No Intervention|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.
~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
16609018|NCT02553551|Experimental|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.
~After discharge, no additional vitamin C pill was given."
16609019|NCT02553551|Placebo Comparator|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.
~After discharge, no additional capsule was given."
16609020|NCT02553538|Experimental|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
16609021|NCT02553538|No Intervention|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
16609022|NCT02553525|Experimental|Therapeutic Stimulation Patterns|This group will receive temporal patterns of stimulation that are designed to suppress oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to alleviate motor symptoms.
16609023|NCT02553525|Experimental|Symptogenic Stimulation Patterns|This group will receive symptogenic patterns of stimulation that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to exacerbate motor symptoms.
16609024|NCT02553499|Experimental|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to ~3 months).
16609025|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to ~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
16609110|NCT02553083|Active Comparator|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
16609026|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
16609027|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
16609028|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
16609029|NCT02553460|Experimental|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.
~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
16609030|NCT02553447|Experimental|Arm I (high-dose cholecalciferol)|Patients receive high-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
16609031|NCT02553447|Experimental|Arm II (low-dose cholecalciferol)|Patients receive low-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
16609032|NCT02553447|No Intervention|Arm III (control)|Patients receive no intervention.
16609033|NCT02553434|Experimental|Pigtail catheter (case)|Inserting 14 French pigtail catheter
16609034|NCT02553434|No Intervention|Chest tube|inserting 32-36 French chest tube
16609035|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
16609036|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
16609037|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
16609038|NCT02553408|Other|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
16609039|NCT02553395|Experimental|Phenacite contact lens|Study Test Contact Lens
16609040|NCT02553395|Active Comparator|comfilcon A contact lens|Control Contact Lens
16609041|NCT02553382|Experimental|Dietary, Herbal|
16609042|NCT02553382|Placebo Comparator|Positive Control|
16609043|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
16609044|NCT02553356|Experimental|Fasted|PT2385 taken after fasting.
16609045|NCT02553356|Experimental|Non-Fasting|PT2385 taken after eating a high calorie meal.
16609046|NCT02553343|Experimental|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
16609047|NCT02553343|Experimental|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
16609048|NCT02553343|Active Comparator|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
16609049|NCT02553343|Active Comparator|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
16609050|NCT02553330|Experimental|Ruxolitinib Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;
~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
16609051|NCT02553330|Placebo Comparator|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
16609052|NCT02553317|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
16609053|NCT02553317|Placebo Comparator|Placebo|Placebo once daily
16609054|NCT02553291|Experimental|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
16609055|NCT02553291|Active Comparator|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
16609056|NCT02553278|Experimental|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:
~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
16609057|NCT02553278|Experimental|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:
~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
16609058|NCT02553265|Active Comparator|Placebo, Low Dose Carbidopa, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
16609059|NCT02553265|Active Comparator|High Dose Carbidopa, Placebo, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
16609060|NCT02553265|Active Comparator|Low Dose Carbidopa, High Dose Carbidopa, Placebo|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
16609061|NCT02553252|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
16609062|NCT02553252|No Intervention|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
16609063|NCT02553239|Experimental|Cryoablation|Cryoablation with the CoolLoop® catheter
16609064|NCT02553226|Active Comparator|Continued group|Recieve routine treatment with oxytocin according to the danish national guidelines.
16609065|NCT02553226|Placebo Comparator|discontinued group (placebo)|The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
16609066|NCT02553213|Experimental|LSG group|Laparoscopic sleeve gastrectomy
16609067|NCT02553213|Experimental|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
16609068|NCT02553213|Other|Control group|Caloric restriction
16609069|NCT02553200|Active Comparator|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
16609070|NCT02553200|Experimental|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
16609071|NCT02553200|Sham Comparator|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
16609072|NCT02553187|Experimental|Treatment group|Kanglaite Injection plus standard therapy.
16609073|NCT02553187|No Intervention|Control group|Blank control and standard therapy.
16609074|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
16609075|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
16609076|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
16609077|NCT02553161|Experimental|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food & Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
16609078|NCT02553161|Placebo Comparator|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
16609079|NCT02553161|No Intervention|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
16609080|NCT02553148||Argentina|One of the 23 countries studied
16609081|NCT02553148||Armenia|One of the 23 countries studied
16609082|NCT02553148||Australia|One of the 23 countries studied
16609083|NCT02553148||Brazil|One of the 23 countries studied
16609084|NCT02553148||China|One of the 23 countries studied
16609085|NCT02553148||Egypt|One of the 23 countries studied
16609086|NCT02553148||Ethiopia|One of the 23 countries studied
16609087|NCT02553148||Germany|One of the 23 countries studied
16609088|NCT02553148||India|One of the 23 countries studied
16609089|NCT02553148||Indonesia|One of the 23 countries studied
16609090|NCT02553148||Jordan|One of the 23 countries studied
16609091|NCT02553148||Kenya|One of the 23 countries studied
16609092|NCT02553148||Kyrgyzstan|One of the 23 countries studied
16609093|NCT02553148||Malaysia|One of the 23 countries studied
16609094|NCT02553148||Malawi|One of the 23 countries studied
16609095|NCT02553148||Mexico|One of the 23 countries studied
16609096|NCT02553148||Russia|One of the 23 countries studied
16609097|NCT02553148||Serbia|One of the 23 countries studied
16609098|NCT02553148||South Africa|One of the 23 countries studied
16609099|NCT02553148||Tajikistan|One of the 23 countries studied
16609100|NCT02553148||United Kingdom|One of the 23 countries studied
16609101|NCT02553148||United States|One of the 23 countries studied
16609102|NCT02553148||Zimbabwe|One of the 23 countries studied
16609103|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
16609104|NCT02553122|Other|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
16609105|NCT02553122|Active Comparator|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
16609106|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
16609107|NCT02553096|Experimental|ACCESS|ACCESS is used when participants experience more COPD symptoms.
16609108|NCT02553096|No Intervention|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
16609109|NCT02553083|Active Comparator|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
16609111|NCT02553083|Active Comparator|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
16609112|NCT02553070||Pharmacy Students|Participants will be asked to indicate their perception of poisoning severity by answering a short survey.
16609113|NCT02553057|Active Comparator|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
16609114|NCT02553057|Active Comparator|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
16609115|NCT02553057|Active Comparator|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
16609116|NCT02553044|Experimental|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
16609117|NCT02553044|Experimental|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
16609118|NCT02553044|Experimental|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
16609119|NCT02553044|No Intervention|Concurrent Control|Control group to receive no intervention.
16609120|NCT02553018|Experimental|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.
~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.
~Frequency: one injection per week Duration: until the end of the study"
16609121|NCT02553018|Active Comparator|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.
~Frequency: one injection per week Duration: until the end of the study"
16609122|NCT02553005|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
16609123|NCT02553005|Experimental|verum acupuncture|Real acupuncture treatment
16609124|NCT02553005|No Intervention|Control|
16609125|NCT02552992|Experimental|Yoga Classes|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
16609126|NCT02552992|Active Comparator|Self-Directed Mind-Body Program|Study Participants will receive: The Back Pain Helpbook, a mind-body self-care program for better living.
16609127|NCT02552966|Experimental|UESAD|Upper Esophageal Sphincter Assist Device
16609128|NCT02552953|Experimental|CYC065 - 4 hour infusion (Part 1 completed)|CYC065 will be administered by 4 -hour infusion every 3 weeks.
16609129|NCT02552953|Experimental|CYC065 - 1 hour infusion (Part 2 - ongoing)|CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks
16609130|NCT02552953|Experimental|CYC065 - Oral (Part 3 - ongoing)|CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks
16609131|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
16609132|NCT02552927|Experimental|CALF|Chest shield with aluminum foil
16609133|NCT02552927|Sham Comparator|SHIELD|Chest shield without aluminum foil
16609134|NCT02552901|Experimental|LFT Dye Detection Monitor|
16609135|NCT02552901|Active Comparator|Serial Blood Draws|
16609136|NCT02552888|Experimental|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
16609137|NCT02552888|Placebo Comparator|Placebos|identical placebos.
16609138|NCT02552875|Active Comparator|Tetanic Stimulation|50 Hz tetanic stimulation for 5 seconds before TOF-twitch stabilization at the one arm
16609139|NCT02552875|Active Comparator|Staircase Stimulation|TOF-twitch stabilisation without 50 Hz tetanic stimulation at the contralateral arm
16609140|NCT02552862|Active Comparator|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).
~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
16609141|NCT02552862|Placebo Comparator|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
16609142|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
16609143|NCT02552836|Experimental|Interpersonal Psychotherapy (IPT)|Patients assigned to IPT will receive 12 sessions of individual therapy of approximately 50 minutes duration. Therapy will be manualized and slightly adapted to meet the needs of patients with Parkinson's Disease. Therapy focuses on one of four interpersonal events that are linked with onset or maintenance of depression (role transition, role disputes, unresolved grief, and interpersonal deficits).
16609144|NCT02552836|Active Comparator|Supportive Psychotherapy (SP)|Patients assigned to SP will receive 12 sessions of individual therapy of approximately 50 minutes duration. SP strives to create a supportive therapeutic relationship by emphasizing non-specific therapeutic interactions and techniques. Therapy will be manualized,
16609186|NCT02552602|Active Comparator|Group B|Study participants in this arm will be given Multivitamin B
16609155|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
16609156|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
16609157|NCT02552797|Experimental|Using Power Up|Participants will use 'Power Up' to help them make shared decisions about their treatment or care
16609158|NCT02552797|No Intervention|Not using Power Up|Participants will continue treatment as usual
16609159|NCT02552784|Experimental|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
16609160|NCT02552771|Active Comparator|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
16609161|NCT02552771|Active Comparator|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
16609162|NCT02552758|Experimental|Omega-3 fatty acid|omega-3 fatty acid
16609163|NCT02552758|Placebo Comparator|placebo|placebo
16609164|NCT02552745||study group|parecoxib sodium was administered postoperatively
16609165|NCT02552745||control group|parecoxib sodium was not administered postoperatively
16609166|NCT02552732|Experimental|NHF with or without Oxygen|NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge
16609167|NCT02552706|Experimental|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
16609168|NCT02552706|Placebo Comparator|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
16609169|NCT02552693|Experimental|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.
~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
16609170|NCT02552693|No Intervention|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
16609171|NCT02552680|Experimental|Exercise + guideline|Participants will participate in eight meetings consisting of exercise and guidelines on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
16609172|NCT02552680|Active Comparator|brochure|Participants will receive a manual-brochure - containing information about general health.
16609173|NCT02552667|Experimental|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
16609174|NCT02552667|Active Comparator|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
16609175|NCT02552654|Experimental|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
16609176|NCT02552654|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
16609177|NCT02552641|Experimental|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
16609178|NCT02552641|Experimental|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
16609179|NCT02552641|Experimental|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
16609180|NCT02552628|Experimental|"Stimulation on"|"The deep brain stimulation is on"
16609181|NCT02552628|Sham Comparator|"Stimulation off"|"The deep brain stimulation is off"
16609182|NCT02552615|Experimental|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
16609183|NCT02552615|Active Comparator|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
16609184|NCT02552615|Experimental|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
16609185|NCT02552602|Active Comparator|Group A|Study participants in this arm will be given Multivitamin A
16609187|NCT02552602|Active Comparator|Group C|Study participants in this arm will be given Multivitamin C
16609188|NCT02552589|Experimental|Test group|Amine fluoride toothpaste
16609189|NCT02552589|Placebo Comparator|Control group|Placebo Sodium monofluorophosphate toothpaste
16609190|NCT02552576|Experimental|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
16609191|NCT02552563|No Intervention|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
16609192|NCT02552563|Active Comparator|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
16609193|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
16609194|NCT02552537|Active Comparator|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
16609195|NCT02552537|Sham Comparator|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
16609196|NCT02552524|Experimental|rTMS active then rTMS placebo|"A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo (rTMS active then rTMS placebo).
~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit."
16609197|NCT02552524|Experimental|rTMS placebo then rTMS active|"A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS active at the frequency of 10 Hz (rTMS placebo then rTMS active).
~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit"
16609198|NCT02552511||Exposure|Perinatal factors exposure
16609199|NCT02552498|Experimental|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
16609200|NCT02552498|Experimental|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
16609201|NCT02552498|Experimental|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
16609202|NCT02552459|Active Comparator|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
16609203|NCT02552459|Experimental|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
16609204|NCT02552459|Experimental|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
16609205|NCT02552459|Experimental|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
16609206|NCT02552446||All patients|All ICU patients mechanically ventilated staying more than 72 hours were included and indirect calorimetry was performed and compared to predictive energy expenditure formulas using different body weights.
16609207|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
16609208|NCT02552407||Manual Aspiration Thrombectomy with PCI|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to Manual Aspiration Thrombectomy followed by percutaneous coronary intervention (PCI).
16609209|NCT02552407||PCI Alone|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to percutaneous coronary intervention (PCI) alone without manual aspiration thrombectomy.
16609210|NCT02552394|Experimental|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
16609211|NCT02552381||Group I|"Patients without LMWH treatment.
~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.
~The following assays will be performed for these patients :
~Fibrin Structure measured at baseline and every month using prototype assays
~Other markers activity : sFVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
16609212|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.
~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.
~The following assays will be performed for these patients :
~Fibrin Structure measured at baseline and every month using prototype assays,
~Anti-FXa activity measured at baseline and every month,
~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
16609213|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.
~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.
~The following assays will be performed for these patients :
~Fibrin Structure measured at baseline and every month using prototype assays,
~Anti-FXa activity measured at baseline and every month,
~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
16609214|NCT02552368|Experimental|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
16609215|NCT02552355|Experimental|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
16609216|NCT02552355|Placebo Comparator|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
16609217|NCT02552355|Active Comparator|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
16609218|NCT02552355|Active Comparator|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
16609219|NCT02552342|Active Comparator|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
16609220|NCT02552342|Placebo Comparator|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
16609221|NCT02552329|No Intervention|Control group|Since no medication or other treatments are currently approved by Food and Drug Administration (FDA) for treatment of MCI, participants in the usual care group will not receive any form of treatment. They will receive an educational material about cognitive impairment. They will also be asked to maintain their daily routine.
16609222|NCT02552329|Experimental|Tai Chi exercise group|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down.
16609223|NCT02552316|Other|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
16609224|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
16609225|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
16609226|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
16609227|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
16609228|NCT02552290|Active Comparator|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
16609229|NCT02552290|Active Comparator|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.
~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
16609230|NCT02552290|Other|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
16609231|NCT02552277|Experimental|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
16609232|NCT02552277|Experimental|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
16609233|NCT02552277|Placebo Comparator|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
16609234|NCT02552264|Active Comparator|Immediate intervention|Acceptance and Commitment Therapy
16609235|NCT02552264|Placebo Comparator|Waitlist control|Acceptance and Commitment Therapy
16609236|NCT02552251|Experimental|A: hydrocortisone|hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
16609237|NCT02552251|Experimental|B :dexamethasone (DECTANCYL)|dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
16609238|NCT02552251|Experimental|C : prednisone (CORTANCYL)|prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
16609239|NCT02552238|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
16609242|NCT02552212|Experimental|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
16609243|NCT02552212|Placebo Comparator|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
16609244|NCT02552199||with hyperhidrosis|Patients with primary hyperhidrosis
16609245|NCT02552199||healthy|Healthy adult patients
16609246|NCT02552186|Active Comparator|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
16609247|NCT02552186|No Intervention|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
16609248|NCT02552173||stem anteversion|intraoperative surgeon's estimation and postopertive CT sacn were taken to measure stem anteversion
16609249|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
16609250|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
16609251|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
16609252|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
16609253|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
16609254|NCT02552134|Experimental|frequent participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence.
16609255|NCT02552134|Experimental|medium participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
16609256|NCT02552134|Experimental|low participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
16609257|NCT02552134|Active Comparator|recommendation to be active|"During the stay in the health care resort participants are introduced to be active in the future. They will receive a brochure Physical Activity: Health for all."
16609258|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
16609259|NCT02552108|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
16609260|NCT02552108|No Intervention|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
16609261|NCT02552095|Other|Triathlon PKR|Patient who receives the Triathlon.
16609262|NCT02552082||Scorpio NRG|
16609263|NCT02552069||Tritanium® cup|
16609264|NCT02552056|Experimental|CAMH training|"Intervention clinics will receive a CAMH integration package comprising of:
~Training PHC workers (midwives, nurses and/or clinical officers) on how to screen and refer for CAMH, based on WHO mhGAP implementation guide.
~Support supervision in the clinics to reinforce training and provide on-job support to PHC staff.
~Provision of job aids and training materials"
16609265|NCT02552056|No Intervention|No CAMH training|Clinics will continue to provide the standard of care.
16609266|NCT02552043|Experimental|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (>12 years and <13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
16609267|NCT02552043|No Intervention|Control group|The CG carried out their routine patient management
16609268|NCT02552030|Experimental|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
16609269|NCT02552017|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
16609270|NCT02552017|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
16609271|NCT02552004|Experimental|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
16609272|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
16609273|NCT02551978|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
16609274|NCT02551978|No Intervention|Control|Children in the same primary school, aged between 9 and 12 years do receive basic information during the study phase.
16609275|NCT02551965|Experimental|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
16609311|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
16609312|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
16609276|NCT02551952|Experimental|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
16609277|NCT02551952|Experimental|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
16609278|NCT02551952|Active Comparator|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
16609279|NCT02551952|Sham Comparator|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
16609280|NCT02551939|Experimental|fat graft|Autologous Fat Grafting
16609281|NCT02551926|Experimental|mobile text messaging|Patients will receive some SMS in a regular interval.
16609282|NCT02551926|Experimental|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
16609283|NCT02551926|Experimental|brochures|Patients will receive some messages by as a printed media
16609284|NCT02551926|Active Comparator|Control|control group will be included without any intervention
16609285|NCT02551913|Active Comparator|control|The adolescents will not receive any specific information
16609286|NCT02551913|Experimental|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
16609287|NCT02551900|Experimental|Warm water exercise & Cold water exercise|
16609288|NCT02551900|Active Comparator|Warm water exercise & Land cycling exercise|
16609289|NCT02551887|No Intervention|Usual Care|Usual Care Only
16609290|NCT02551887|Active Comparator|Automated Reminder|Reminder
16609291|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
16609292|NCT02551874|Experimental|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
16609293|NCT02551874|Active Comparator|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
16609294|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir|Daclatasvir 60mg tablet and Sofosbuvir 400mg tablet oral dosing once daily for 8 weeks
16609295|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir + Ribavirin|Daclatasvir 60mg tablet + Sofosbuvir 400mg tablet+ Ribavirin 1000-1200mg tablet(weight based dosing) oral dosing split into am and pm once daily for 8 weeks
16609296|NCT02551848|Experimental|Essential tremor treatment|"A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.
~Participants will be treated by BoNT-A injections every 12 weeks over 72 weeks. BoNT-A parameters will be determined solely by biomechanical analysis of tremulous movements in both upper extremity BoNT-A dose will range from 50-300 U per arm"
16609297|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
16609298|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
16609299|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
16609300|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <42 nmol/L.
16609301|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <55 nmol/L.
16609302|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values <75 nmol/L.
16609303|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values <50 nmol/L.
16609304|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values <50 nmol/L.
16609305|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents >70 years of age.
16609306|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values <25 nmol/L.
16609307|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons > 63 years of age.
16609308|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
16609309|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
16609310|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
16609313|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
16609314|NCT02551796|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
16609315|NCT02551796|Experimental|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
16609316|NCT02551796|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
16609317|NCT02551783|Experimental|Urethroplasty with buccal mucosa graft|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
16609318|NCT02551783|Active Comparator|Ventral Buccal|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
16609319|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
16609320|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
16609321|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
16609322|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
16609323|NCT02551744|Active Comparator|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
16609324|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
16609325|NCT02551731|Experimental|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
16609326|NCT02551718|Experimental|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
16609327|NCT02551705|Experimental|functional Imaging mutation carrier|Premanifest mutation carrier, behavioral and neural emotional memory processing
16609328|NCT02551705|Active Comparator|functional Imaging non-carrier|non-carrier family member, behavioral and neural emotional memory processing
16609329|NCT02551692|Placebo Comparator|NRT|
16609330|NCT02551692|Placebo Comparator|VAR|
16609331|NCT02551692|Placebo Comparator|PLAC|
16609332|NCT02551679|Active Comparator|ACP-01|Injection into lower extremity
16609333|NCT02551679|Placebo Comparator|Placebo|Injection into lower extremity
16609334|NCT02551666|Active Comparator|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
16609335|NCT02551666|Experimental|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
16609336|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
16609337|NCT02551640|Experimental|Group A|"Receive a Samsung smartphone
~Receive the FeatForward app
~Receive a Samsung smartwatch
~Continue to receive medical care as usual"
16609338|NCT02551640|No Intervention|Group B|"Receive a Samsung smartphone
~Receive a Samsung smartwatch
~Continue to receive medical care as usual"
16609339|NCT02551627|Experimental|Test Product|MMN fortified beverage powder [27 gram (g)] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
16609340|NCT02551627|Active Comparator|Control|Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
16609341|NCT02551614|Experimental|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
16609342|NCT02551614|Experimental|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
16609343|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
16609344|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.
~They were followed when possible one year after surgery."
16609345|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
16609346|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
16609347|NCT02551575|Active Comparator|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
16609348|NCT02551575|Experimental|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
16609349|NCT02551575|Experimental|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
16609350|NCT02551562|Placebo Comparator|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
16609351|NCT02551562|Experimental|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
16609352|NCT02551549|Experimental|CD101 IV|multiple ascending dose intravenous infusion
16609353|NCT02551549|Placebo Comparator|Placebo|normal saline
16609354|NCT02551536|Active Comparator|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
16609355|NCT02551536|Experimental|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
16609356|NCT02551523|Experimental|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
16609357|NCT02551523|Active Comparator|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
16609358|NCT02551510|Active Comparator|Suture|Skin incision closure with standard subcuticular technique
16609359|NCT02551510|Active Comparator|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl®
16609360|NCT02551497|Experimental|Other drug|Other drug BID
16609361|NCT02551497|Experimental|placebo|Placebo to match BID
16609362|NCT02551484|Experimental|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
16609363|NCT02551484|Experimental|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
16609364|NCT02551471||French patients|
16609365|NCT02551471||Australians patients|
16609366|NCT02551458|Experimental|Arm A: Systematic surgery|
16609367|NCT02551458|Experimental|Arm B: Surveillance and rescue surgery in cases of resectable|
16609368|NCT02551445|Experimental|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
16609369|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,
~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,
~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
16609370|NCT02551419|Experimental|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
16609371|NCT02551419|Placebo Comparator|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
16609372|NCT02551393|Experimental|Intervention Group|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home Blood pressure monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
16609373|NCT02551393|No Intervention|Control Group|Usual Care of hypertension in primary care clinic
16609374|NCT02551380|Experimental|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
16609375|NCT02551380|Placebo Comparator|control|treatment with one capsule of placebo twice a day during 12 weeks
16609376|NCT02551367|Experimental|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
16609377|NCT02551367|Active Comparator|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
16609378|NCT02551354|Experimental|Patients|"Pain assess by :
~Visual Analogic Scale (VAS).
~Portable video pupillometer"
16609379|NCT02551341|No Intervention|control|normal ventilation
16609380|NCT02551341|Experimental|intervention|higher PEEP ventilation
16609381|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
16609382|NCT02551328||Propofol|Patients with no preconditioning
16609383|NCT02551315||Type 2 diabetics, no fractures|Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
16609384|NCT02551315||Type 2 diabetics, prevalent fractures|Postmenopausal women and men with T2DM, with prevalent fragility fractures
16609385|NCT02551315||Controls, no fractures|Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
16609386|NCT02551315||Controls, prevalent fractures|Age and sex-matched non-diabetic controls
16609387|NCT02551302|Other|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
16609388|NCT02551302|Other|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
16609389|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
16609390|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
16609391|NCT02551276|Experimental|Experimental|Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
16609392|NCT02551276|Placebo Comparator|Control|Placebo and resistance training for 10 weeks
16609393|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
16609394|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
16609395|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with
~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with
~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
16609396|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.
~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
16609397|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
16609398|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
16609399|NCT02551211|Experimental|Patients with resectable non-small cell lung cancer|
16609400|NCT02551198|Active Comparator|HAPREP® (PEG-Asc)|"subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation
~: PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
16609401|NCT02551198|Experimental|SUCLEAR® (OSS)|"subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation
~: OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]"
16609402|NCT02551185|Experimental|ACY-241 in combination with Paclitaxel|
16609403|NCT02551172|Experimental|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
16609404|NCT02551172|Placebo Comparator|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
16609405|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
16609406|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
16609407|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
16609408|NCT02551146|Experimental|A Locator with retention elements|"GC Pilier Locator abutment with retention elements:
~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements."
16609409|NCT02551146|Active Comparator|B Locator without retention elements|"GC Pilier Locator abutment without retention elements:
~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants."
16609410|NCT02551133|Active Comparator|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
16609411|NCT02551133|Active Comparator|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
16609412|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
16609413|NCT02551107|Experimental|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.
~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
16609414|NCT02551107|Active Comparator|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
16609415|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
16609416|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
16609417|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
16609418|NCT02551068|Experimental|60% Oxgyen|While participants are exercising, they will be breathing 60% oxygen through a mask.
16609419|NCT02551068|Placebo Comparator|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
16609420|NCT02551055|Experimental|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
16609421|NCT02551055|Experimental|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
16609493|NCT02550665|Experimental|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
16609494|NCT02550665|Active Comparator|no titration of donepezil|no titration and direct escalation to 23mg donepezil
16609422|NCT02551055|Experimental|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
16609423|NCT02551055|Experimental|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
16609424|NCT02551055|Experimental|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
16609425|NCT02551055|Experimental|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
16609426|NCT02551055|Experimental|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
16609427|NCT02551042|Experimental|Active treatment arm|Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion
16609428|NCT02551042|Placebo Comparator|Placebo arm|Placebo will be 0.9 % Sodium chloride solution IV infusion
16609429|NCT02551029|Experimental|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum.
16609430|NCT02551029|Placebo Comparator|Placebo (saline)|Through a naso-duodenal tube, a saline solution will be infused into the duodenum.
16609431|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
16609432|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
16609433|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
16609434|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
16609435|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
16609436|NCT02550990|Active Comparator|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
16609437|NCT02550990|Active Comparator|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
16609438|NCT02550990|Experimental|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.
~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
16609439|NCT02550977|Experimental|Gestodene/EE Patch|
16609440|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
16609441|NCT02550951|Experimental|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
16609442|NCT02550951|Experimental|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
16609443|NCT02550938|Experimental|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
16609444|NCT02550938|Experimental|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
16609445|NCT02550938|Experimental|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
16609446|NCT02550938|Experimental|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
16609447|NCT02550925|Experimental|Acceptance and Commitment Therapy Group|
16609448|NCT02550925|Active Comparator|Usual Care|
16609449|NCT02550912|Active Comparator|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
16609450|NCT02550912|Placebo Comparator|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
16609451|NCT02550899|Active Comparator|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
16609452|NCT02550899|Active Comparator|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
16609453|NCT02550899|Active Comparator|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
16609454|NCT02550886||Patient/Caregiver Dyad|
16609455|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
16609456|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
16609457|NCT02550860|Active Comparator|soybean oil (SO)-based IVFE (Medialipide)|
16609458|NCT02550860|Active Comparator|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
16609459|NCT02550834|Experimental|Experimental : Curling group|
16609460|NCT02550834|No Intervention|Control : Usual care group|
16609461|NCT02550808||Heart failure|
16609462|NCT02550808||Chronic obstructive pulmonary disease|
16609463|NCT02550808||Chronic kidney disease|
16609464|NCT02550808||Malignancy|
16609465|NCT02550808||Controls|
16609466|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
16609467|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
16609468|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
16609469|NCT02550782|Active Comparator|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine
~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
16609470|NCT02550782|Experimental|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine
~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
16609471|NCT02550769|Experimental|TRANSANAL TOTAL MESORECTAL EXCISION|Transanal approach of total mesorectal excision.
16609472|NCT02550769|Active Comparator|Laparoscopic-LAR|Type of surgical intervention as control group: Laparoscopic low anterior resection with total mesorectal excision for rectal cancer
16609473|NCT02550756|Experimental|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
16609474|NCT02550756|Experimental|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
16609475|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose BYL719: 200mg/day
16609476|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose BYL719: 250mg/day
16609477|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose BYL719: 300mg/day
16609478|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose BYL719: 150mg/day
16609479|NCT02550730|Experimental|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
16609480|NCT02550730|Active Comparator|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
16609481|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
16609482|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
16609483|NCT02550704|Experimental|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
16609484|NCT02550691|Experimental|Subject carrying 3 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
16609485|NCT02550691|Other|Subject carrying 2 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
16609486|NCT02550691|Other|Subject carrying 3 copies of the SMN2 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
16609487|NCT02550678|Experimental|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
16609488|NCT02550678|Experimental|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
16609489|NCT02550678|Experimental|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
16609490|NCT02550678|Experimental|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
16609491|NCT02550678|Experimental|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
16609492|NCT02550665|Experimental|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
16609495|NCT02550652|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
16609496|NCT02550652|Placebo Comparator|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
16609497|NCT02550639|Active Comparator|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
16609498|NCT02550639|Experimental|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
16609499|NCT02550639|Active Comparator|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
16609500|NCT02550639|Experimental|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
16609501|NCT02550626||Delirium|occurrence of post-operative delirium
16609502|NCT02550626||No delirium|no presence of post-operative delirium
16609503|NCT02550600|Experimental|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
16609504|NCT02550600|Active Comparator|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.
~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
16609505|NCT02550574|Experimental|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
16609506|NCT02550574|Active Comparator|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
16609507|NCT02550561|Experimental|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
16609508|NCT02550548|Experimental|GIP infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
16609509|NCT02550548|Experimental|GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GLP-1 infused at 4 incremental dosages, (initial dose will be 1.0 ng/kg/min, followed by 2.0, 3.0, and 4.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
16609510|NCT02550548|Experimental|GIP + GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP + GLP-1 infused simultaneously at 4 incremental dosages (doses will be half the amounts described above). These doses will be infused continuously for 30 minutes, followed immediately by the next higher doses. The total time of this procedure is 240 minutes.
16609511|NCT02550548|Experimental|GIP + Ex-9 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages (as described above) with Ex-9 infused at a steady dose of 2.5 mcg/kg/min starting 90 minutes before the GIP infusion and maintained throughout the clamp experiment. The total time of this procedure is 240 minutes.
16609512|NCT02550535|Experimental|Gene-modified WT1 TCR-transduced T cells|A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen. Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
16609514|NCT02550509|Experimental|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
16609515|NCT02550496|Experimental|tinea capitis|
16609516|NCT02550483|Active Comparator|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
16609517|NCT02550483|Active Comparator|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
16609518|NCT02550483|Placebo Comparator|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
16609547|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
16609519|NCT02550470|Active Comparator|Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
16609520|NCT02550470|Active Comparator|Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
16609521|NCT02550470|Active Comparator|Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
16609522|NCT02550457|No Intervention|Control group|It will not apply any tape.
16609523|NCT02550457|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
16609524|NCT02550457|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
16609525|NCT02550457|Placebo Comparator|Placebo group|Apply Micropore tape in the erector spine muscles.
16609526|NCT02550444|Placebo Comparator|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
16609527|NCT02550444|Experimental|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
16609528|NCT02550444|Experimental|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
16609529|NCT02550418|Experimental|Budesonide|
16609530|NCT02550405|Experimental|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
16609531|NCT02550405|No Intervention|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
16609532|NCT02550392|Experimental|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) and usual care.
16609533|NCT02550392|No Intervention|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
16609534|NCT02550379|Placebo Comparator|Placebo|The placebo protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point at baseline. A test phase is then administered which is identical to the baseline phase to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
16609535|NCT02550379|Experimental|Intervention|The ER training protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point however this balance point is adjusted by 2 points on the 15 face continuum to train the participant to rate more faces as 'happy'. A test phase, identical to the baseline phase, is then administered to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
16609536|NCT02550366||CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
16609537|NCT02550353|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
16609538|NCT02550353|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
16609539|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
16609540|NCT02550327|Experimental|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.
~The patient will complete a total of 6 cycles of chemotherapy."
16609541|NCT02550314|Experimental|NPC-18,FBG-18|"Intervention drug:
~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue
~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
16609542|NCT02550301||Mean Platelet Volume|4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
16609543|NCT02550288|Active Comparator|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
16609544|NCT02550288|Active Comparator|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
16609545|NCT02550288|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
16609546|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
16609548|NCT02550275|Other|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
16609549|NCT02550275|Other|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
16609550|NCT02550275|Other|controls|unaffected patient with Huntington's disease
16609551|NCT02550262|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16609552|NCT02550262|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16609553|NCT02550262|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16609554|NCT02550262|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
16609555|NCT02550249|Experimental|Nivolumab|Nivolumab 3 mg every 2 weeks
16609556|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of 5.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair, stool and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of nine years also by the child itself.
16609557|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 500 obese children and adolescents that will be assessed and compared to a lean control group (N=500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, liver elastography, spirometry and actigraphy.
16609558|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of 1,000 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
16609559|NCT02550223|Experimental|Oblique|Ultrasound guided radial artery catheterization using oblique view obtained by tilting the US probe 30-45 degrees over the course of the artery
16609560|NCT02550223|Active Comparator|Transverse group|Ultrasound guided radial artery catheterization using transverse view
16609561|NCT02550223|Active Comparator|Longitudinal group|Ultrasound guided radial artery catheterization using longitudinal view
16609562|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
16609563|NCT02550197|Experimental|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
16609564|NCT02550197|Active Comparator|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
16609565|NCT02550184|Experimental|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.
~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
16609566|NCT02550184|Active Comparator|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.
~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
16609567|NCT02550158|Experimental|Educated Group|"Training of patients by the educational program EDU-MICI"
16609568|NCT02550158|Other|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
16609569|NCT02550145|Experimental|Exendin(9-39)|IV infusion of Exendin (9-39).
16609570|NCT02550145|Placebo Comparator|Placebo|IV infusion of normal saline
16609571|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
16609572|NCT02550119|Experimental|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
16609573|NCT02550119|Placebo Comparator|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
16609574|NCT02550106|Experimental|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
16609575|NCT02550093|Active Comparator|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing.
16609576|NCT02550093|Placebo Comparator|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing.
16609577|NCT02550080|Experimental|The prospective genetic screening arm|Prospective HLA-B*1301 screen before administrated treatment included dapsone
16609578|NCT02550080|Active Comparator|The control arm|No HLA-B*1301 screen before administrated treatment included dapsone
16609579|NCT02550067|Active Comparator|Depot medroxyprogesterone acetate (DMPA)|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
16609580|NCT02550067|Active Comparator|Levonorgestrel implant (LNG)|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
16609581|NCT02550067|Active Comparator|Copper T380a IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
16609582|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
16609583|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
16609584|NCT02550041|Other|Cystic fibrosis|
16609585|NCT02550028|Experimental|Oral levetiracetam|Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
16609586|NCT02550028|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance
16609587|NCT02550015|Experimental|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
16609588|NCT02550015|Other|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
16609589|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
16609590|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
16609591|NCT02549989|Experimental|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
16609592|NCT02549976|Experimental|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.
~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :
~Upper tract location : upper endoscopy
~Colorectal location : colonoscopy
~Perianal location : pelvic MRI
~All patients : abdominal MRI"
16609593|NCT02549963|Experimental|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
16609594|NCT02549963|Active Comparator|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
16609595|NCT02549950|Active Comparator|Conventional OrthodonticTreatment|Conventional orthodontic mechanics: canine and incisor retraction
16609596|NCT02549950|Experimental|Accelerated Tooth Movement|Accelerated orthodontics: Peizo-Corticision Accelerated canine and Incisor retraction
16609603|NCT02549924|Experimental|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
16609604|NCT02549924|Placebo Comparator|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
16609605|NCT02549911|Experimental|HIPEC,Chemotherapy AND surgery|"surgical exploration,if PCI<20,then we perform this study
~HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
~chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )
~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
16609606|NCT02549898|Experimental|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
16609607|NCT02549898|Experimental|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
16609608|NCT02549898|Experimental|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
16609609|NCT02549898|Experimental|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
16609610|NCT02549885|Experimental|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
16609611|NCT02549885|Experimental|Static stretching|Static stretching of neck muscles.
16609612|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
16609613|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
16609614|NCT02549859|Experimental|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
16609615|NCT02549846|Active Comparator|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
16609616|NCT02549846|Other|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
16609617|NCT02549833|Experimental|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
16609618|NCT02549833|Active Comparator|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
16609619|NCT02549820|Experimental|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
16609620|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
16609621|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
16609622|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
16609623|NCT02549794|Active Comparator|High concentration (370)|CT angiography with hign concentration iodine contrast agent of 370 mg iodine/ml
16609624|NCT02549794|Experimental|Low concentration (320)|CT angiography with low concentration iodine contrast agent of 320 mg iodine/ml
16609625|NCT02549794|Experimental|Low concentration (270)|CT angiography with low concentration iodine contrast agent of 270 mg iodine/ml
16609626|NCT02549781|Experimental|Gambler performing Go-Nogo|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
16609627|NCT02549781|Active Comparator|Social layer performing Go-Nogo|"In this study, social player performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
16609628|NCT02549781|Placebo Comparator|non-gamer witnesses performing Go-Nogo|"In this study, non-gamer witnesses performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
16609629|NCT02549768|Active Comparator|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
16609630|NCT02549768|Placebo Comparator|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
16609631|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
16609632|NCT02549742|Experimental|Electrochemotherapy|25 patients treated with electrochemotherapy
16609633|NCT02549729|No Intervention|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
16609634|NCT02549729|Experimental|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
16609635|NCT02549729|No Intervention|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
16609636|NCT02549729|Experimental|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
16609637|NCT02549716|Experimental|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
16609638|NCT02549716|Experimental|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
16609639|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
16609640|NCT02549703||Secondary Progressive Multiple Sclerosis|
16609641|NCT02549703||Primary Progressive Multiple Sclerosis|
16609642|NCT02549690|Active Comparator|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
16609643|NCT02549690|Active Comparator|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
16609644|NCT02549677|Experimental|EC regimen|Epirubicin, cyclophosphamide
16609645|NCT02549677|Active Comparator|TC regimen|docetaxel, cyclophosphamide
16609646|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
16609647|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
16609648|NCT02549651|Experimental|MEDI4736|
16609649|NCT02549651|Experimental|MEDI4736 and tremelimumab|
16609650|NCT02549651|Experimental|MEDI4736 and AZD9150|
16609651|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
16609652|NCT02549625|Experimental|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
16609653|NCT02549612|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
16609654|NCT02549612|No Intervention|Control|No intervention is used in this group.
16609655|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
16609656|NCT02549599|Experimental|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
16609657|NCT02549599|Other|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
16609658|NCT02549586|Experimental|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
16609659|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
16609660|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
16609661|NCT02549560|Active Comparator|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
16609662|NCT02549560|Sham Comparator|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
16609663|NCT02549547|Experimental|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
16609664|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:
~Are 18 to 85 years old at the time of enrollment;
~Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);
~Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;
~Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR
~Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);
~Are willing to participate in up to four study sessions."
16609665|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:
~Are 18 to 85 years old at the time of study enrollment;
~Can read, write, and understand English,
~Are willing to participate in three planned study sessions."
16609666|NCT02549521|Active Comparator|Oral magnesium substitution|Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
16609667|NCT02549521|Placebo Comparator|Magnesium + or Magnesium -|Placebo tablets without magnesium.
16609668|NCT02549508|Experimental|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
16609759|NCT02548962|Experimental|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
16609669|NCT02549508|Experimental|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
16609670|NCT02549495||Patients with Diabetes or Hypertension|All patients in the seven study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
16609671|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
16609672|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
16609673|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
16609674|NCT02549469|Active Comparator|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
16609675|NCT02549456|Experimental|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
16609676|NCT02549456|Experimental|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
16609677|NCT02549443|Active Comparator|Insulin|hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
16609678|NCT02549443|Active Comparator|Insulin and amino acids|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
~Amino Acids (AA) in amounts to preserve normal AA"
16609679|NCT02549443|Active Comparator|Insulin and hyperaminoacidemia|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
~AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)"
16609680|NCT02549430|Experimental|Arm A|Palbociclib monoterapy
16609681|NCT02549430|Experimental|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
16609682|NCT02549417|Experimental|KHK7580|
16609683|NCT02549404|Experimental|KHK7580|
16609684|NCT02549391|Experimental|KHK7580|
16609685|NCT02549391|Active Comparator|KRN1493|
16609686|NCT02549378|Experimental|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
16609687|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
16609688|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
16609689|NCT02549352|Experimental|LEO 43204 gel|Treatment once daily for 3 days
16609690|NCT02549352|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
16609691|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
16609692|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
16609693|NCT02549326|Placebo Comparator|Obese, placebo|Placebo daily for 12 weeks
16609694|NCT02549326|Active Comparator|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
16609695|NCT02549326|Placebo Comparator|Control, placebo|Placebo daily for 12 weeks
16609696|NCT02549326|Active Comparator|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
16609697|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
16609698|NCT02549300|No Intervention|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
16609699|NCT02549300|Experimental|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
16609700|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
16609701|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
16609702|NCT02549274|Experimental|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
16609703|NCT02549274|Active Comparator|physiotherapy|Patients will have only conventional physiotherapy
16609704|NCT02549261|Experimental|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
16609705|NCT02549261|Experimental|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
16609706|NCT02549261|Placebo Comparator|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
16609707|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.
~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
16609708|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.
~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
16609709|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
16609710|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
16609711|NCT02549209|Experimental|Investigational Treatment|"Subjects with no prior therapy:
~Pembrolizumab administered at 200 mg
~Paclitaxel administered at 175mg/m2
~Carboplatin administered at an AUC of 6
~Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:
~Pembrolizumab administered at 200 mg
~Paclitaxel administered at 135mg/m2
~Carboplatin administered at an AUC of 5"
16609712|NCT02549196|Experimental|Cohort 1|Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
16609713|NCT02549196|Experimental|Cohort 2|Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
16609714|NCT02549196|Experimental|Cohort 1b|Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
16609715|NCT02549196|Experimental|Cohort 3c|Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
16609716|NCT02549183|Active Comparator|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
16609717|NCT02549183|Active Comparator|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
16609718|NCT02549183|Active Comparator|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
16609719|NCT02549183|Active Comparator|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
16609720|NCT02549170|Experimental|Epoch 1: HYQVIA/HyQvia|Participants will receive HYQVIA/HyQvia at a dose of 80 Unit per gram (U/g) SC immunoglobulin (IgG) which will be same as the participants pre-randomization monthly equivalent IgG dose (or at matching infusion volume for participants in the placebo group) when administered at a dosing frequency of every 2, 3, or 4 weeks for 6 months or until relapse.
16609721|NCT02549170|Placebo Comparator|Epoch 1: Placebo with rHuPH20|Participants will receive sequential 0.25% albumin placebo with rHuPH20 at a dose of 80U/g IgG SC for 6 months or until relapse. Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
16609722|NCT02549170|Experimental|Epoch 2: IGIV|Participants will receive an induction dose of 2 gram per kilogram (g/kg) Intravenous immunoglobulin G (IGIV), followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks for 6 months or until relapse.
16609723|NCT02549144|Experimental|Low versus high fat/cholesterol diet|The first day of the study protocol a low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days was prescribed to the participants followed by a high-fat/high-cholesterol (HFHC) normocaloric diet for further 14 days.
16609724|NCT02549131|Active Comparator|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
16609725|NCT02549131|Active Comparator|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.
~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
16609726|NCT02549118|Experimental|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
16609727|NCT02549118|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
16609728|NCT02549105|Active Comparator|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
16609729|NCT02549105|Active Comparator|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
16609730|NCT02549092|Active Comparator|Optimized Medical Treatment (OMT)|"Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.
~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG."
16609731|NCT02549092|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.
~The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day.
~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG."
16609732|NCT02549053|Experimental|Barrett esophagus patients|esophagus biopsies (pathologic and healthy zones)
16609733|NCT02549053|Sham Comparator|control patients|esophagus biopsies (healthy zones)
16609760|NCT02548936|Experimental|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
16609761|NCT02548936|No Intervention|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
16609762|NCT02548923|Active Comparator|dexmedetomidine group|Patients who received dexmedetomidine for sedation
16609734|NCT02549040|Experimental|Doravirine fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
16609735|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
16609736|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
16609737|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
16609738|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
16609739|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609740|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609741|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609742|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609743|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609744|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609745|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609746|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609747|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
16609748|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
16609749|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
16609750|NCT02549001|Experimental|P-3058 10%|P-3058 10%
16609751|NCT02549001|Placebo Comparator|vehicle of P-3058 10%|vehicle of P-3058 10%
16609752|NCT02549001|Active Comparator|amorolfine 5%|Loceryl®
16609753|NCT02548988|Experimental|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
16609754|NCT02548988|Experimental|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
16609755|NCT02548975||Delirium|Patients diagnosed with delirium at any time postoperatively with the CAM-ICU.
16609756|NCT02548975||No delirium|Patients not diagnosed with delirium postoperatively.
16609757|NCT02548962|Experimental|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
16609758|NCT02548962|Experimental|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
16609763|NCT02548923|No Intervention|propofol group|Patients who received propofol for sedation
16609764|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
16609765|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
16609766|NCT02548897|Experimental|Freezing of gait in PD|All participants will undergo an deep brain stimulation (DBS) for the FOG, and an electroencephalography (EEG) to better understand the neurophysiological underpinnings of the symptom. In addition, review changes in scalp recorded EEG and gait parameters during natural FoG episodes while participants are ambulatory in an advanced gait laboratory setting using a wireless EEG amplifier with active electrodes.
16609767|NCT02548884|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
16609768|NCT02548884|Active Comparator|Double guide wire|Double guide wire technique used in difficult biliary cannulation
16609769|NCT02548871|Experimental|Teen Outreach Program|Teen Outreach Program
16609770|NCT02548871|No Intervention|Comparison|Business as usual
16609771|NCT02548858|Active Comparator|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
16609772|NCT02548858|Active Comparator|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
16609773|NCT02548832|Active Comparator|Berberine more Placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
16609774|NCT02548832|Active Comparator|Bezafibrate more placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
16609775|NCT02548832|Experimental|Berberine more Bezafibrate|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
16609776|NCT02548806|Experimental|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
16609777|NCT02548806|Experimental|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
16609778|NCT02548806|Active Comparator|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
16609779|NCT02548793|Active Comparator|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
16609780|NCT02548793|Experimental|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
16609781|NCT02548780|Experimental|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.
~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
16609782|NCT02548767|Experimental|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
16609783|NCT02548767|Placebo Comparator|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
16609784|NCT02548767|Experimental|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
16609785|NCT02548767|Placebo Comparator|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
16609786|NCT02548754|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
16609787|NCT02548754|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
16609788|NCT02548741|Active Comparator|Treatment (Metformin)|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the active comparator (metformin).
16609789|NCT02548741|Placebo Comparator|Placebo|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the placebo comparator.
16609790|NCT02548741|Other|Non-diabetic|Forty matched non-diabetic patients with HbA1C ≤ 5.6%. They will not receive either treatment (metformin) or placebo.
16609791|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
16609792|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
16609793|NCT02548715|Placebo Comparator|Control|Daily placebo
16609794|NCT02548715|Experimental|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
16609795|NCT02548702|Experimental|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
16609796|NCT02548702|No Intervention|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
16609797|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
16609798|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
16609799|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
16609800|NCT02548676||Healthy controls|age- and sex matched controls
16609801|NCT02548663|Experimental|active; sport therapy|active exercise carefully calibrated on residual capacities.
16609802|NCT02548663|Experimental|passive; osteopathic treatment|manipulative treatment according to osteopathic principles.
16609803|NCT02548650|Experimental|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
16609804|NCT02548650|Active Comparator|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
16609805|NCT02548637|Experimental|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
16609806|NCT02548611|Experimental|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
16609807|NCT02548611|Active Comparator|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
16609808|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
16609809|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
16609810|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
16609811|NCT02548585|Placebo Comparator|Placebo|Participants will receive placebo (matched to either 100 micrograms [mcg], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
16609812|NCT02548585|Experimental|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
16609813|NCT02548585|Experimental|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
16609814|NCT02548585|Experimental|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
16609815|NCT02548585|Experimental|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
16609816|NCT02548585|Experimental|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
16609817|NCT02548585|Experimental|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
16609818|NCT02548572|Experimental|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
16609819|NCT02548572|Placebo Comparator|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
16609820|NCT02548559|Experimental|Full-Spectrum Cannabidiol|1 ml of full-spectrum sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
16610011|NCT02547311|Experimental|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
16609821|NCT02548559|Experimental|Single-Compound Cannabidiol|1 ml of single-compound sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
16609822|NCT02548559|Placebo Comparator|Placebo|1 ml of placebo solution administered three times per day (TID) for four weeks.
16609823|NCT02548546|Active Comparator|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
16609824|NCT02548546|Active Comparator|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
16609825|NCT02548546|Active Comparator|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
16609826|NCT02548533|Active Comparator|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
16609827|NCT02548533|Experimental|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
16609828|NCT02548494|Placebo Comparator|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
16609829|NCT02548494|Experimental|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
16609830|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
16609831|NCT02548468|Experimental|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
16609832|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
16609833|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
16609834|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
16609835|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
16609836|NCT02548416|Active Comparator|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
16609837|NCT02548416|Active Comparator|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
16609838|NCT02548403|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
16609839|NCT02548403|Active Comparator|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
16609840|NCT02548390|Experimental|RXDX-107|
16609841|NCT02548377|Experimental|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
16609842|NCT02548377|Sham Comparator|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
16609843|NCT02548364|Experimental|Calcifediol|One capsule with 15,690 IU p.o. every two weeks
16609844|NCT02548364|Placebo Comparator|Placebo|One capsule with placebo p.o. every two weeks
16609845|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
16609846|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
16609847|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
16609848|NCT02548338|Other|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
16609849|NCT02548338|Other|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
16609850|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
16609851|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
16609852|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
16609853|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
16609854|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
16609855|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
16609856|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
16609857|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
16609858|NCT02548299|Experimental|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
16609914|NCT02547948|Experimental|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
16609859|NCT02548299|Experimental|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
16609860|NCT02548299|Experimental|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
16609861|NCT02548286|Active Comparator|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
16609862|NCT02548286|Experimental|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
16609863|NCT02548273||Diabetics|diabetics with cataract who opted for phacoemulsification surgery
16609864|NCT02548273||controls|non-diabetics with cataract who opted for phacoemulsification surgery (subjects without corneal opacity, PXF ,high myopia, uveitis)
16609865|NCT02548260|Experimental|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
16609866|NCT02548260|Experimental|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
16609867|NCT02548260|Experimental|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
16609868|NCT02548260|Experimental|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
16609869|NCT02548247|Experimental|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
16609870|NCT02548247|Placebo Comparator|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
16609871|NCT02548234|Experimental|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
16609872|NCT02548234|Experimental|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
16609873|NCT02548208|Active Comparator|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
16609874|NCT02548208|Sham Comparator|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
16609875|NCT02548208|No Intervention|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
16609876|NCT02548195|Experimental|GEMOX|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.
16609877|NCT02548195|Active Comparator|Capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
16609878|NCT02548182|No Intervention|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
16609879|NCT02548182|Active Comparator|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults [REF]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
16609880|NCT02548182|Active Comparator|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
16609881|NCT02548169|Active Comparator|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
16609882|NCT02548169|Active Comparator|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
16609883|NCT02548156|Other|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
16609884|NCT02548156|Other|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
16609885|NCT02548156|Other|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
16609915|NCT02547948|No Intervention|No Intervention|
16609916|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
16609917|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
16609918|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
16609919|NCT02547922|Experimental|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
16609920|NCT02547922|Experimental|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
16609921|NCT02547922|Placebo Comparator|Placebo|Placebo IV Q4W plus SOC
16609886|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
16609887|NCT02548130||Patients before MELD score|Recipients before the MELD score
16609888|NCT02548130||Patients after the MELD score|Recipients after the MELD score
16609889|NCT02548117|Active Comparator|Finasteride|ARM 1 subjects will receive finasteride 5 mg orally daily.
16609890|NCT02548117|No Intervention|No Treatment|The ARM 2 (control group) will not receive any study treatment.
16609891|NCT02548104|Active Comparator|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
16609892|NCT02548104|Experimental|Adductor canal ACB + genicular (IPACK)|Group II Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
16609893|NCT02548091|Active Comparator|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
16609894|NCT02548091|Other|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
16609895|NCT02548078|Experimental|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
16609896|NCT02548078|Experimental|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
16609897|NCT02548065|Active Comparator|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
16609898|NCT02548065|Placebo Comparator|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
16609899|NCT02548052|Experimental|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
16609900|NCT02548039||Asian Normogonadotrophic Anovulatory Women|Asian women with normal gonadotropin levels but do not ovulate.
16609901|NCT02548026|Experimental|High Eating Frequency (High EF)|8 Eating Occasions
16609902|NCT02548026|Experimental|Low Eating Frequency (High EF)|3 Eating Occasions
16609903|NCT02548013|Experimental|Home management|outpatient management patients if stable will be discharged to continue treatment at home
16609904|NCT02548013|Active Comparator|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
16609905|NCT02548000|Experimental|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
16609906|NCT02548000|Active Comparator|Stretching control|The control group will perform one stretching session a week.
16609907|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
16609908|NCT02547974|Experimental|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
16609909|NCT02547974|Experimental|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
16609910|NCT02547974|Experimental|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
16609911|NCT02547974|Placebo Comparator|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
16609912|NCT02547961|Experimental|HER2-CAR-T|In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
16609913|NCT02547961|No Intervention|No Intervention|
16610008|NCT02547337||Healthy subjects|
16609922|NCT02547909|Experimental|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
16609923|NCT02547896|Experimental|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
16609924|NCT02547896|Experimental|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
16609925|NCT02547883|Experimental|Patients stopping statin|
16609926|NCT02547883|No Intervention|Patients continuing statin|
16609927|NCT02547870|Experimental|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
16609928|NCT02547870|Experimental|Aged RPV-LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
16609929|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
16609930|NCT02547844|Active Comparator|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
16609931|NCT02547844|Experimental|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
16609932|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
16609933|NCT02547818|Active Comparator|Group I|ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
16609934|NCT02547818|Active Comparator|Group II|ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
16609935|NCT02547818|Active Comparator|Group III|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
16609936|NCT02547818|Placebo Comparator|Group IV|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
16609937|NCT02547805|Placebo Comparator|Placebo|Five (5) capsules of placebo by mouth (PO) three times per day (TID) with meals
16609938|NCT02547805|Experimental|ALLN-177|Five (5) capsules of ALLN-177 (1,500 units per capsule) PO TID with meals
16609939|NCT02547792|Experimental|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
16609940|NCT02547792|Experimental|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
16609941|NCT02547792|Placebo Comparator|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
16609942|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
16609943|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
16609944|NCT02547766|Experimental|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
16609945|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
16609946|NCT02547753||Control group|healthy patients who need tooth extraction
16609947|NCT02547740||Early Glaucomatous Damage|Patients with early functional glaucomatous damage.
16609948|NCT02547740||Ophthalmologically Healthy|Healthy subjects that are ophthalmologically normal
16609949|NCT02547727|Experimental|Four-site intradermal vaccination|0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
16609950|NCT02547727|Active Comparator|Intramuscular vaccination|0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
16609951|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
16609952|NCT02547701|Experimental|P-3058|
16609953|NCT02547688|Other|Nasal High Flow|All subjects are in this group
16609954|NCT02547662|Experimental|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16609955|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
16609956|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
16609957|NCT02547649|Active Comparator|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
16609958|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
16609959|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
16609960|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
16609961|NCT02547597|Experimental|Carvedilol|Carvedilol 25 mg twice a day
16609962|NCT02547597|Active Comparator|Atenolol|Atenolol 50 mg twice a day
16610009|NCT02547324|Experimental|Slump sitting|Slump sitting flexion of lumbar spine
16610010|NCT02547324|Active Comparator|Forward bending|Forward erect bending of lumbar spine
16609963|NCT02547584|Active Comparator|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
16609964|NCT02547584|Active Comparator|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40
16609965|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
16609966|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue|
16609967|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
16609968|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue|
16609969|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid|
16609970|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Low residue|
16609971|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
16609972|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue|
16609973|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
16609974|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue|
16609975|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid|
16609976|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Low residue|
16609977|NCT02547558|Experimental|Indacaterol|"Drug:
~-Indacaterol, inhaled, single dose, 300 mcg
~Diagnostic Interventions:
~Arterial blood gases
~Cardiac output
~Vital signs
~Exhaled breath
~Spirometry"
16609978|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
16609979|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
16609980|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
16609981|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
16609982|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
16609983|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
16609984|NCT02547519|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
16609985|NCT02547519|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
16609986|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
16609987|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
16609988|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
16609989|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
16609990|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
~Abatacept started on frst day."
16609991|NCT02547480|Experimental|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
16609992|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
16609993|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
16609994|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
16609995|NCT02547428|Experimental|CTN SR first, then Placebo|Participants will receive CTN SR at a TDD of 400 mg followed by placebo (after washout period). CTN SR will be titrated up from 100 to 400 mg daily, at specified increments, for 3 weeks. Placebo will be titrated in the same manner to protect the blind.
16609996|NCT02547428|Experimental|Placebo first, then CTN SR|Participants will receive placebo followed by CTN SR at a TDD of 400 mg (after washout period). CTN SR will be titrated up from 100 to 400 mg daily, at specified increments, for 3 weeks. Placebo will be titrated in the same manner to protect the blind.
16609997|NCT02547415||patients with questionnaires and psychological testing|children and adolescents with chronic pain without proven medical cause, type painful somatic complaints
16609998|NCT02547402|Experimental|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
16609999|NCT02547389|Active Comparator|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
16610000|NCT02547389|Other|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
16610001|NCT02547376||Eligible patients with Soft Tissue Sarcoma|Primary Soft Tissue Sarcoma group
16610002|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
16610003|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
16610004|NCT02547350|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy
16610005|NCT02547350|Experimental|single intravesical instillation|intravesical instillation within 24 hours postoperatively
16610006|NCT02547350|Experimental|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
16610007|NCT02547337||Type 1 diabetes|
16610012|NCT02547311|No Intervention|Standard Clinical Care - Control|Standard Clinical Care - Control
16610013|NCT02547298|Experimental|All patients|All patients in this study receive hydrodistension
16610014|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
16610015|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
16610016|NCT02547259|Experimental|schizophrenic pain words test|schizophrenic will have memory test with pain words on computer
16610017|NCT02547259|Experimental|schizophrenic negative words test|schizophrenic will have memory test with negative words on computer
16610018|NCT02547259|Other|Healthy volunteer pain words test|Healthy volunteer will have memory test with pain words on computer
16610019|NCT02547259|Other|Healthy volunteer negative words test|Healthy volunteer will have memory test with negative words on computer
16610020|NCT02547246|Experimental|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
16610021|NCT02547246|Placebo Comparator|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
16610022|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
16610023|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
16610024|NCT02547220|Experimental|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
16610025|NCT02547220|Placebo Comparator|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
16610026|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
16610027|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
16610028|NCT02547181|Experimental|Splint|Patients will be provided instructed to use a tensor bandage as well as specific behaviours to prevent movement of the injured part of the hand.
16610029|NCT02547181|Experimental|Behavioral Modification|Patients are given a removable plaster/fiberglass splint with a tensor bandage underneath
16610030|NCT02547168|Experimental|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
16610031|NCT02547155|Experimental|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
16610032|NCT02547155|Active Comparator|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
16610033|NCT02547142|Experimental|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
16610034|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
16610035|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
16610036|NCT02547116|No Intervention|Standard anti-staphylococcal antibiotic|
16610037|NCT02547116|Experimental|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
16610038|NCT02547103|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate-soaked cloths, clean topical area around catheter exit site with CHG 2% soaked cloths
16610039|NCT02547103|Active Comparator|Normal saline (usual care)|Normal saline, clean topical area around catheter exit site
16610040|NCT02547103|Active Comparator|Mupirocin ointment|Mupirocin ointment 2%, clean topical area around catheter exit site with Mupirocin ointment
16610041|NCT02547090||CP who underwent PSF by two attendings in 2012|
16610042|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
16610043|NCT02547077|Experimental|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
16610044|NCT02547077|Active Comparator|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
16610045|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
16610046|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
16610047|NCT02547051|Experimental|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
16610048|NCT02547038|Experimental|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
16610049|NCT02547038|Active Comparator|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
16610050|NCT02547025|Experimental|rabeprazole+3 antibiotics|patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
16610051|NCT02547025|Experimental|rabeprazole+bismuth+2 antibiotics|patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
16610052|NCT02547025|Active Comparator|rabeprazole+amox+tetr+levo|patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days
16610053|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
16610054|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
16610055|NCT02546999|Experimental|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
16610056|NCT02546999|Placebo Comparator|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
16610057|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
16610058|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
16610059|NCT02546973||Patients with anal cancer|All patients with anal cancer during 2011-2013 will be asked to participate
16610060|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
16610061|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
16610062|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
16610063|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
16610091|NCT02546752|Experimental|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
16610092|NCT02546752|No Intervention|Usual Care Arm|This arm will receive usual care.
16610064|NCT02546960|Experimental|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
16610065|NCT02546960|Placebo Comparator|Placebo|Participants will be stratified according to their age in 2 groups >= 18 to <50 years and >=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the IDMC.
16610066|NCT02546947|No Intervention|Appropriate clinical group|group of patients with clinical dose adjustment
16610067|NCT02546947|Active Comparator|TOF adapted group|group with an objective of less than 2 responses to TOF stimulation monitored
16610068|NCT02546934|Experimental|ABX, cisplatin|AP (ABX and cisplatin combination)
16610069|NCT02546934|Active Comparator|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
16610070|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
16610071|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of >0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
16610072|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
16610073|NCT02546882|Experimental|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
16610074|NCT02546882|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
16610075|NCT02546869|Experimental|Lebrikizumab|Participants will receive lebrikizumab SC using prefilled syringes (PFS), q4w up to Week 12.
16610076|NCT02546856|Active Comparator|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
16610077|NCT02546856|Experimental|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
16610078|NCT02546843|Experimental|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).
~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.
~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
16610079|NCT02546843|Active Comparator|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.
~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.
~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
16610080|NCT02546830|Experimental|FreeO2 v2.2 active|Automatic Oxygen Administration
16610081|NCT02546830|Active Comparator|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
16610082|NCT02546804|Experimental|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
16610083|NCT02546804|Experimental|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
16610084|NCT02546804|Active Comparator|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
16610085|NCT02546791||Chronic myeloid leukemia patients treated with Dasatinib|patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days
16610086|NCT02546778|Experimental|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
16610087|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU
~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
16610088|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.
~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
16610089|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
16610090|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
16610093|NCT02546739|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
16610094|NCT02546739|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
16610095|NCT02546739|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
16610096|NCT02546726|Experimental|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
16610097|NCT02546726|Active Comparator|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
16610098|NCT02546713|Other|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
16610099|NCT02546713|Other|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
16610100|NCT02546700|Experimental|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
16610101|NCT02546700|Experimental|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
16610102|NCT02546700|Placebo Comparator|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
16610103|NCT02546700|Placebo Comparator|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
16610104|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
16610105|NCT02546674|Experimental|Nilotinib|Patients with newly diagnosed CML in chronic phase will be enrolled.
16610106|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.
~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:
~The investigator believes it is in the patient's interest to receive durvalumab;
~The patient consents to the continued treatment;
~It is clinically appropriate for the patient to continue on durvalumab treatment;
~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
16610107|NCT02546661|Experimental|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
16610108|NCT02546661|Experimental|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
16610109|NCT02546661|Experimental|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
16610110|NCT02546661|Experimental|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
16610111|NCT02546661|Experimental|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
16610112|NCT02546661|Experimental|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
16610113|NCT02546661|Experimental|Module G: MEDI4736 + Selumetinib|
16610114|NCT02546648|Experimental|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
16610115|NCT02546648|Experimental|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
16610116|NCT02546635|Experimental|Potential food effect|
16610117|NCT02546635|Experimental|Multi-dosing|
16610118|NCT02546622||Arm A Prospective|"Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.
~These patients will be followed prospectively for up to 1 year."
16610119|NCT02546622||Arm B Retrospective|"Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.
~Patients must have switched products within the past 50 weeks at the time of enrollment.
~These patients will be assessed retrospectively and/or followed prospectively for up to 1 year."
16610120|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
16610121|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
16610122|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
16610123|NCT02546596|Experimental|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
16610124|NCT02546583|Experimental|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
16610125|NCT02546583|Experimental|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
16610126|NCT02546583|No Intervention|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
16610127|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
16610128|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
16610129|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
16610130|NCT02546557||OPTICABG|Patients undergoing a coronary artery bypass graft surgery for the repair of a multi-vessel disease or left main-coronary disease.
16610131|NCT02546544|Other|Linsitinib|Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
16610132|NCT02546531|Experimental|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.
~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.
~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.
~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
16610133|NCT02546531|Experimental|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.
~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.
~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.
~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
16610134|NCT02546518|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
16610135|NCT02546518|Active Comparator|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
16610136|NCT02546505|No Intervention|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
16610137|NCT02546505|Experimental|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
16610138|NCT02546505|Experimental|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
16610139|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
16610140|NCT02546479||Patientis|patients diagnosed with scoliosis and other spinal deformities
16610141|NCT02546466|Experimental|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
16610142|NCT02546466|Sham Comparator|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
16610143|NCT02546466|Active Comparator|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
16610216|NCT02545972|Experimental|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
16610217|NCT02545959|Active Comparator|Control group|receive a single pulse of methylprednisolone IV (120mg)
16610144|NCT02546453|Other|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
16610145|NCT02546440|Experimental|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
16610146|NCT02546427|Experimental|Treatment|"Step 1: Pelvic Lymph Node Irradiation
~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each
~Step 2: Treat boost volume to prostate and seminal vesicles
~Acceptable treatment modalities:
~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT
~Permanent prostate implant (PPI):
~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
16610147|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
16610148|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
16610149|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
16610150|NCT02546401|Experimental|Group 1|"Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF).
~Intervention: drug (insulin Aspart)"
16610151|NCT02546401|Experimental|Group 2|"Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE).
~Intervention: drug (insulin Aspart)"
16610152|NCT02546388|Experimental|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
16610153|NCT02546388|Experimental|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
16610154|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
16610155|NCT02546362|Experimental|Cefaly active device|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
16610156|NCT02546349|Experimental|high eNO: ICS/LABA|patients with eNO >=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
16610157|NCT02546349|Active Comparator|high eNO: LAMA|patients with eNO >=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
16610158|NCT02546349|Experimental|Low eNO: ICS/LABA|patients with eNO < 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
16610159|NCT02546349|Active Comparator|Low eNO: LAMA|patients with eNO < 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
16610160|NCT02546336|Experimental|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
16610161|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
16610162|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
16610163|NCT02546310|Experimental|HTL0009936 high dose|high dose infusion
16610164|NCT02546310|Experimental|HTL0009936 low dose|low dose infusion
16610165|NCT02546310|Placebo Comparator|HTL0009936 matching placebo|matching infusion
16610166|NCT02546297|Active Comparator|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，12 months.
16610167|NCT02546297|Active Comparator|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，12 months.
16610168|NCT02546297|Active Comparator|LAMA+LABA Group|Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.
16610169|NCT02546284|Experimental|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
16610170|NCT02546271|Experimental|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
16610171|NCT02546258|Other|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
16610172|NCT02546245|Experimental|Heroes of Knowledge Game|
16610173|NCT02546245|Active Comparator|Attention/Time Control Games|
16610174|NCT02546232|Active Comparator|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
16610175|NCT02546232|Experimental|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.
~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
16610176|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
16610177|NCT02546206|Experimental|Probiotic Yoghurt|Probiotic yoghurt consumption
16610178|NCT02546206|Placebo Comparator|Natural Yoghurt|Natural yoghurt consumption
16610571|NCT02543801|Active Comparator|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
16610179|NCT02546193|Experimental|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).
~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
16610180|NCT02546193|Active Comparator|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.
~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
16610181|NCT02546180|Experimental|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
16610182|NCT02546180|Active Comparator|Standard Education|Subjects in this arm were randomized to standard preoperative education.
16610183|NCT02546167|Experimental|Cohort 1|will receive 1-5x10^7 CART-BCMA cells given as a split dose infusion over 3 days.
16610184|NCT02546167|Experimental|Cohort 2|Cyclophosphamide infusion prior to 1-5x10^7 CART BCMA cells given as a split dose infusion over 3 days.
16610185|NCT02546167|Experimental|Cohort 3|Cyclophosphamide infusion prior to 1-5x10^8 CART BCMA cells given as a split dose infusion over 3 days.
16610186|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
16610187|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
16610188|NCT02546141|Active Comparator|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
16610189|NCT02546141|Active Comparator|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
16610190|NCT02546141|Active Comparator|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
16610191|NCT02546141|Active Comparator|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
16610192|NCT02546141|Active Comparator|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
16610193|NCT02546141|Active Comparator|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
16610194|NCT02546141|Active Comparator|whey protein|portion size that contains 25 g of protein, oral, single administration
16610195|NCT02546141|Active Comparator|micellar casein|portion size that contains 25 g of protein, oral, single administration
16610196|NCT02546128|Experimental|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
16610197|NCT02546128|Placebo Comparator|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
16610198|NCT02546115|Active Comparator|Intervention|standard practice (structured rehabilitation programme) + TNS
16610199|NCT02546115|Active Comparator|control|standard practice (structured rehabilitation programme)
16610200|NCT02546102|Experimental|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
16610201|NCT02546102|Placebo Comparator|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
16610202|NCT02546089|Active Comparator|intervention group|"local anaesthetic - lidocaine 1%, dry needling, autologous blood injection,
~+ structured rehab programme"
16610203|NCT02546089|Placebo Comparator|control group|"local anaesthetic - lidocaine 1%, dry needling,
~+ structured rehab programme"
16610204|NCT02546076|Active Comparator|Laser coagulation|Er:YAG laser treatment with coagulation modality
16610205|NCT02546076|Active Comparator|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
16610206|NCT02546063|Other|GoCARB app|Smartphone app
16610207|NCT02546063|No Intervention|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
16610208|NCT02546050|Experimental|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
16610209|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
16610210|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
16610211|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
16610212|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
16610213|NCT02545998|No Intervention|Standard care|Patients will receive a face-to-face asthma review
16610214|NCT02545998|Active Comparator|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
16610215|NCT02545985|Experimental|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
16610572|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
16610218|NCT02545959|Experimental|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
16610219|NCT02545959|Experimental|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
16610220|NCT02545946|Active Comparator|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
16610221|NCT02545946|Active Comparator|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
16610222|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
16610223|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
16610224|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
16610225|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:
~Level -1 - 27mg/m2
~Level 0 - 36mg/m2
~Level 1 - 45mg/m2
~Level 2 - 56mg/m2
~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
16610226|NCT02545894|No Intervention|BASELINE TESTING|Language and cognitive assessments conducted
16610227|NCT02545894|Experimental|Treatment|"Intervention given:
~visual tracking pressing a button every time a picture is seen on the screen
~playing dominoes and snap
~pressing a button every time a specific picture is seen on the screen
~Pressing a button every time a specific sound is heard
~Matching objects to a picture
~Matching gestures to objects
~Matching two connected objects
~Sorting objects by categories
~Matching sounds to objects
~Complete the category and odd on out with objects
~Choosing target objects by pointing
~Choosing objects to complete the category by pointing"
16610228|NCT02545894|No Intervention|Post intervention|Repeated testing
16610229|NCT02545868|Experimental|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
16610230|NCT02545868|Other|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period. Participants who complete the 12-week immunization study period will have the option to receive two single infusions of OCR 300 mg, on Day 84 and Day 98, and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
16610231|NCT02545855|Experimental|Arm A (myAIRVO2® + HOT, HOT)|Subjects will receive the myAIRVO2® therapy plus HOT for week 1-6 and HOT only for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
16610232|NCT02545855|Experimental|Arm B (HOT, myAIRVO2® + HOT)|Subjects will receive HOT only for week 1-6 and the myAIRVO2® therapy plus HOT for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
16610233|NCT02545842|Experimental|Group 1|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
16610234|NCT02545842|Experimental|Group 2|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
16610235|NCT02545842|Experimental|Group 3|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
16610236|NCT02545829|Experimental|Sequence 1|HGP1406 → HIP1302
16610237|NCT02545829|Experimental|Sequence 2|HIP1302 → HGP1406
16610238|NCT02545816|Other|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
16610239|NCT02545803|Other|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
16610240|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
16610241|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
16610242|NCT02545777|Active Comparator|treatment group|Take oral medicine of tonifying spleen and descending turbid, one bag each time, two times a day, continuous treatment for 10 days.The onset of the joints afford steeping washing and wet wrapping medicine of descending turbid and clearing heat, once per day, continuous treatment for 10 days.
16610243|NCT02545777|Active Comparator|Control group|Take diclofenac sodium enteric-coated, 50 mg, three times a day, continuous treatment for 10 days.
16610244|NCT02545764|Experimental|Intervention|Strength and neuromuscular exercise programme
16610245|NCT02545764|No Intervention|Control|Control group will receive opportunity for the training programme after data capturing is finished
16610276|NCT02545530|Active Comparator|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
16610246|NCT02545751|Experimental|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
16610247|NCT02545738|Experimental|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
16610248|NCT02545738|Placebo Comparator|Placebo|Placebo s.c. for 12 weeks.
16610249|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
16610250|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
16610251|NCT02545699|Experimental|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
16610252|NCT02545699|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
16610253|NCT02545686|Experimental|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:
~Chest wall movement assessment without CPAP
~Breath hold assessment without CPAP
~Chest wall movement assessment with CPAP
~Breath hold assessment with CPAP"
16610254|NCT02545673|Experimental|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
16610255|NCT02545673|Active Comparator|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
16610256|NCT02545660|Experimental|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
16610257|NCT02545660|Experimental|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
16610258|NCT02545647|No Intervention|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
16610259|NCT02545647|Active Comparator|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
16610260|NCT02545634|Placebo Comparator|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
16610261|NCT02545634|Experimental|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
16610262|NCT02545621||ARDS Group (acute respiratory distress syndrome)|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
16610263|NCT02545621||control group|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
16610264|NCT02545608|Experimental|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
16610265|NCT02545608|Other|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
16610266|NCT02545595|Experimental|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
16610267|NCT02545595|Experimental|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
16610268|NCT02545595|Experimental|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
16610269|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
16610270|NCT02545569|Active Comparator|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
16610271|NCT02545569|Experimental|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
16610272|NCT02545556|Experimental|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
16610273|NCT02545556|Placebo Comparator|control|liver cancer patients received traditional therapy
16610274|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
16610275|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
16610277|NCT02545530|No Intervention|transdermal clonidine-|regular antihypertensive treatment
16610278|NCT02545517|Experimental|Conv-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 and JE primary series regimen on days 1 and 29 in the parent study V49_23 were enrolled in the Conv-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
16610279|NCT02545517|Experimental|Acc-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study V49_23 were enrolled in the Acc-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
16610280|NCT02545517|Experimental|Conv-R Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 in the parent study V49_23 were enrolled into the Conv-R Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
16610281|NCT02545504|Experimental|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
16610282|NCT02545504|Placebo Comparator|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
16610283|NCT02545491|Experimental|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
16610284|NCT02545491|Active Comparator|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
16610285|NCT02545478||Infected Group|subjects with suspected infection
16610286|NCT02545478||Non-infected group|subjects without any infection
16610287|NCT02545465||BAY63-2521|Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
16610288|NCT02545452|Experimental|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
16610289|NCT02545452|Experimental|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
16610290|NCT02545452|Experimental|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
16610291|NCT02545452|Experimental|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
16610292|NCT02545439|Experimental|ALKS 5461|Sublingual tablet
16610293|NCT02545426|Active Comparator|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
16610294|NCT02545426|Active Comparator|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
16610295|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
16610296|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
16610297|NCT02545374|Experimental|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.
~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
16610298|NCT02545374|Active Comparator|Control|"In the control arm, patient care depend on his home, as is currently the case:
~If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.
~If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
16610299|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
16610300|NCT02545322|Experimental|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment
~Image-guided adaptive Radiotherapy arm:
~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
16610301|NCT02545309||SSC-CIP|Patients with secondary sclerosing cholangitis in critically ill patients
16610302|NCT02545309||control|Patients with similar degree of critical illness who do not develop secondary sclerosing cholangitis in critically ill patients
16610303|NCT02545296|Other|In-vitro Diagnostics|All infants are recruited into the same arm.
16610304|NCT02545283|Experimental|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
16610410|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA
~American Society of Anesthesiologists (ASA) score I/II
~Can be operated as #1 or #2
~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
16610484|NCT02544152|Experimental|Lubiprostone|Participants receive 8 mcg lubiprostone capsules twice daily (BID)
16610305|NCT02545283|Placebo Comparator|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
16610306|NCT02545270|Experimental|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
16610307|NCT02545270|Experimental|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
16610308|NCT02545270|Experimental|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
16610309|NCT02545257|Active Comparator|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
16610310|NCT02545257|No Intervention|Control group (standard care)|Normal, standard care (control group)
16610311|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
16610312|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
16610313|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
16610314|NCT02545231|Active Comparator|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
16610315|NCT02545231|Active Comparator|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
16610316|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
16610317|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
16610318|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
16610319|NCT02545205|Active Comparator|Conventional gait training|
16610320|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
16610321|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
16610322|NCT02545179|Experimental|intervention|web-based daily care training 12 week interactive web based caring training education
16610323|NCT02545179|No Intervention|control|Previous therapy
16610324|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
16610325|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
16610326|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
16610327|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
16610328|NCT02545153|Active Comparator|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
16610329|NCT02545153|Placebo Comparator|Control|Suturing the incision without fibrin glue
16610330|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:
~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
16610333|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
16610334|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
16610335|NCT02545088|Active Comparator|1st control group|
16610336|NCT02545088|Active Comparator|2nd control group|
16610337|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
16610338|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
16610339|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.
~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
16610340|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
16610341|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
16610342|NCT02545049|Placebo Comparator|Placebo|Matching placebo
16610485|NCT02544152|Placebo Comparator|Placebo|Participants receive 0 mcg capsules BID
16610343|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
16610344|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
16610345|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
16610346|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
16610347|NCT02544997|Experimental|Poziotinib|12mg P.O. for 2wks q21days
16610348|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
16610349|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
16610350|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
16610351|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
16610352|NCT02544971|Active Comparator|Control group|Treatment as usual
16610353|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
16610354|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
16610355|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
16610356|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
16610357|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
16610358|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
16610359|NCT02544919|No Intervention|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
16610360|NCT02544919|Active Comparator|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
16610361|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
16610362|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
16610363|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
16610364|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
16610365|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
16610366|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
16610367|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase I)|The first 6 participants will be enrolled in the open label Phase I portion of the study and will receive Tadalafil, Anti-mucin 1 (MUC1) Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
16610368|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
16610369|NCT02544880|Experimental|Tadalafil plus Vaccine Placebo Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, placebo for the Anti-MUC1 Vaccine and placebo for the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
16610370|NCT02544880|Experimental|Tadalafil Placebo plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
16610371|NCT02544880|Other|Control Group|For eligible participants who opt out of receiving study intervention. Participants in this group will receive SOC treatment only.
16610411|NCT02544607|Experimental|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
16610372|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
16610373|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
16610374|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
16610375|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
16610376|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
16610377|NCT02544841|Experimental|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
16610378|NCT02544841|Active Comparator|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
16610379|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
16610380|NCT02544828|Placebo Comparator|Control Group|placebo
16610381|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for three consecutive days.
16610382|NCT02544815|Placebo Comparator|Placebo|Oral placebo for three days.
16610383|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
16610384|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
16610385|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
16610386|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
16610387|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
16610388|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
16610389|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
16610390|NCT02544750|Experimental|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
16610391|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
16610392|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
16610393|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
16610394|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
16610395|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
16610396|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
16610397|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
16610398|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
16610399|NCT02544685|Active Comparator|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1
~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy
~Prophylaxis duration: 3 months"
16610400|NCT02544685|Placebo Comparator|Placebo group|"Interventions: administration of placebo
~Start: 5 days before or 2 days after starting chemotherapy
~Duration: 3 months"
16610401|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
16610402|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
16610403|NCT02544646|Other|trabeculectomy|
16610404|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
16610405|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
16610406|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
16610407|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
16610408|NCT02544620||Total Hip arthroplasty|"Unselected primary THA
~American Society of Anesthesiologists (ASA) score I/II
~Can be operated as #1 or #2
~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
16610409|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA
~American Society of Anesthesiologists (ASA) score I/II
~Can be operated as #1 or #2
~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
16610481|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
16610412|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
16610413|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
16610414|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
16610415|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
16610416|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
16610417|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
16610418|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
16610419|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
16610420|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
16610421|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
16610422|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
16610423|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
16610424|NCT02544529|Experimental|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
16610425|NCT02544529|Placebo Comparator|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
16610426|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
16610427|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
16610428|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
16610429|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
16610430|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
16610431|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
16610432|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
16610433|NCT02544464|Placebo Comparator|Control group|placebo
16610434|NCT02544451|Experimental|Treatment Period 1: LUM/IVA to LUM/IVA|
16610435|NCT02544451|Experimental|Treatment Period 1: Placebo (PBO) to LUM/IVA|
16610436|NCT02544451|No Intervention|Treatment Period 1: Observational Cohort|
16610437|NCT02544451|Experimental|Treatment Period 2: LUM/IVA|
16610438|NCT02544438|Experimental|Astarabine|Astarabine
16610439|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase
~Peripheral blood stem cell mobilization:Etoposide
~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
16610440|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
16610441|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
16610442|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
16610443|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
16610444|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
16610445|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
16610482|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
16610483|NCT02544165|No Intervention|Control group|no intervention group
16610446|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
16610447|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
16610448|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
16610449|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
16610450|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
16610451|NCT02544347|Other|Control group|gingival crevicular fluid was collected
16610452|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
16610453|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
16610454|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
16610455|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
16610456|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
16610457|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
16610458|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
16610459|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
16610460|NCT02544308|Active Comparator|No further treatment|No further treatment
16610461|NCT02544308|Experimental|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 & 22 Up to 9 cycles
16610462|NCT02544295|Experimental|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
16610463|NCT02544295|Experimental|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
16610464|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
16610465|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
16610466|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
16610467|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
16610468|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
16610469|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
16610470|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
16610471|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
16610474|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
16610475|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
16610476|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
16610477|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
16610478|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
16610479|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
16610480|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
16610486|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
16610487|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
16610488|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
16610489|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
16610490|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
16610491|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
16610492|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
16610493|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
16610494|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
16610495|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
16610496|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
16610497|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
16610498|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
16610499|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
16610500|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
16610501|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
16610502|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
16610503|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
16610504|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
16610505|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
16610506|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
16610507|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
16610508|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
16610509|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
16610510|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
16610511|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
16610512|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
16610513|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
16610514|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
16610515|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
16610516|NCT02544061|Experimental|NM-IL-12 plus Standard of Care (SOC)|"Single 12 µg unit subcutaneous dose of NM-IL-12 plus SOC.
~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
16610517|NCT02544061|Placebo Comparator|Placebo plus SOC|"Single subcutaneous dose of placebo plus SOC
~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
16610518|NCT02544035|Experimental|1|6-11 month-olds
16610519|NCT02544035|Experimental|10|36-71 month-olds (1.5-2 year olds)
16610520|NCT02544035|Experimental|11|72-107 month-olds (6-8 year-olds)
16610521|NCT02544035|Experimental|12|108-144 month-olds (9-12 year-olds)
16610522|NCT02544035|Experimental|2|12-18 month-olds (1-1.5 year olds)
16610523|NCT02544035|Experimental|3|19-35 month-olds (1.5-2 year-olds)
16610524|NCT02544035|Experimental|4|36-71 month-olds (3-5 year-olds)
16610525|NCT02544035|Experimental|5|72-107 month-olds (6-8 year-olds)
16610526|NCT02544035|Experimental|6|108-144 month-olds (9-12 year-olds)
16610527|NCT02544035|Experimental|7|6-11 month-olds
16610528|NCT02544035|Experimental|8|12-18 month-olds (1-1.5 year olds)
16610529|NCT02544035|Experimental|9|19-35 month-olds (1.5-2 year olds)
16610530|NCT02544022||1/Phase 1 Focus Group|Patients with NF1 who have PNs and report experiencing PN related pain and parents ofthese patients. (completed)
16610531|NCT02544022||2/Phase 1 Patients|Patients with NF1 who have PNs
16610532|NCT02544022||3/Phase 1 Parent|Parents of patients in cohort 2
16610533|NCT02544022||4/Phase 2 Patients|Patients with NF1 who have PNs
16610534|NCT02544022||5/Phase 2 Parents|Parents of patients enrolled in cohort 4
16610537|NCT02543983|Experimental|1|Participants will be administered open-label intravenous ketamine.
16610538|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.
~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.
~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
16610539|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.
~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.
~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
16610540|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
16610541|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
16610542|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
16610543|NCT02543918|Experimental|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.
~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
16610544|NCT02543918|Other|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
16610545|NCT02543905||Family History Cohort|"Caucasian men with a family history of prostate cancer defined as:
~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years
~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years
~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
16610546|NCT02543905||Black African / Black Caribbean Cohort|"Men of black African or black Caribbean ancestry defined as:
~Both parents and all 4 grandparents from that origin."
16610547|NCT02543905||High-risk gene mutation cohort|Men of any ethnicity who have been found to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol).
16610548|NCT02543892|Experimental|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
16610549|NCT02543892|Placebo Comparator|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
16610550|NCT02543892|Experimental|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
16610551|NCT02543892|Placebo Comparator|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
16610552|NCT02543892|Experimental|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
16610553|NCT02543892|Placebo Comparator|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
16610554|NCT02543892|Experimental|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
16610555|NCT02543892|Placebo Comparator|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
16610556|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
16610557|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
16610558|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
16610559|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
16610560|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
16610561|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
16610562|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
16610563|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
16610564|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
16610565|NCT02543827|Experimental|MV140 I|The subjects will receive daily dose of MV140 during 6 months
16610566|NCT02543827|Experimental|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
16610567|NCT02543827|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 6 month
16610568|NCT02543801|Active Comparator|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
16610569|NCT02543801|Active Comparator|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
16610570|NCT02543801|Active Comparator|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
16610574|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
16610575|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.
~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.
~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.
~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
16610576|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.
~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
16610577|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
16610578|NCT02543723|Active Comparator|Nurse Coach Intervention|The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
16610579|NCT02543723|No Intervention|Control|Patients received standard of care.
16610580|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
16610581|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
16610582|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
16610583|NCT02543684|Experimental|ready to eat mixed meal 1|
16610584|NCT02543684|Experimental|ready to eat mixed meal 2|
16610585|NCT02543684|Experimental|ready to eat mixed meal 3|
16610586|NCT02543684|Experimental|oral glucose load|
16610587|NCT02543671|Active Comparator|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
16610588|NCT02543671|Placebo Comparator|plain cheese|plain (non-fortified) reduced-fat yellow cheese
16610589|NCT02543658|Experimental|Neostigmine|Intramuscular injection of neostigmine on the basis of conventional conservative treatment
16610590|NCT02543658|Other|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
16610591|NCT02543645|Experimental|Varlilumab and Atezolizumab|
16610592|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
16610593|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
16610594|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
16610595|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
16610596|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
16610597|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
16610598|NCT02543593|Experimental|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
16610599|NCT02543593|Sham Comparator|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
16610600|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
16610601|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
16610602|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
16610603|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
16610604|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57
16610605|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57
16610606|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
16610607|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
16610608|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
16610609|NCT02543541|Active Comparator|Standard Supportive Care|
16610610|NCT02543541|Experimental|Structured Supportive Care|
16610611|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
16610612|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
16610613|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
16610614|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
16610615|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
16610616|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
16610617|NCT02543489|Other|Flex IM Rod|
16610618|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
16610619|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
16610620|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
16610621|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
16610622|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
16610623|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
16610624|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
16610625|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
16610626|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
16610627|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
16610628|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
16610629|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
16610630|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
16610631|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
16610632|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
16610633|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
16610634|NCT02543359|Experimental|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
16610635|NCT02543359|Experimental|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
16610636|NCT02543359|Experimental|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
16610637|NCT02543346|Other|cetirizine hydrochloride|
16610638|NCT02543346|Placebo Comparator|placebo|
16610639|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
16610640|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
16610641|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
16610642|NCT02543320|Experimental|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
16610643|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
16610644|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
16610645|NCT02543294|Experimental|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
16610646|NCT02543294|Experimental|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
16610647|NCT02543294|Experimental|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
16610648|NCT02543281|Active Comparator|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
16610649|NCT02543281|Experimental|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
16610650|NCT02543268|Experimental|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
16610651|NCT02543268|Experimental|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
16610652|NCT02543268|Experimental|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
16610653|NCT02543268|Experimental|Group 4|Placebo (0.9% saline)- single dose IM injection on Day 1 and Day 57
16610656|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
16610657|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
16610658|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
16610659|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
16610660|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
16610661|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
16610662|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
16610663|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
16610664|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
16610665|NCT02543203|Active Comparator|A/C - Reconnect, Then Coconut Oil Comparator|"Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.
~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.
~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
16610666|NCT02543203|Sham Comparator|C/A - Coconut oil Blend, Then Reconnect|"Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.
~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.
~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
16610698|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
16610667|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel
~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
16610668|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
16610669|NCT02543177|Experimental|group A|direct coronary angiography
16610670|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
16610671|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
16610672|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
16610673|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
16610674|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
16610675|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
16610676|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
16610677|NCT02543125|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O,R:30 per minute .
16610678|NCT02543125|Active Comparator|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O.
16610679|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
16610680|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
16610681|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.
~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).
~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
16610682|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
16610683|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
16610684|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
16610685|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
16610686|NCT02543047|Active Comparator|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
16610687|NCT02543047|Active Comparator|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
16610688|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
16610689|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
16610690|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
16610691|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
16610692|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
16610693|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
16610694|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
16610695|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
16610696|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
16610697|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:
~Workflow redesign:
~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms
~Communication improvement:
~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders
~Chronic disease QI projects:
~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
16610699|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
16610700|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
16610701|NCT02542956|Active Comparator|Exparel|Injection of Exparel
16610702|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
16610703|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
16610704|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
16610705|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
16610706|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
16610707|NCT02542917||All patients|IBDoc home test for faecal calprotectin
16610708|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
16610709|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
16610710|NCT02542891|Experimental|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.
~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
16610711|NCT02542891|Active Comparator|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.
~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
16610712|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.
~A brief explanation of this self-application will be showed prior the intervention."
16610713|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
16610714|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
16610715|NCT02542865|No Intervention|Control Group|No treatment was administered
16610716|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
16610717|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
16610718|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
16610719|NCT02542826|Experimental|Pulmonary Rehabilitation|
16610720|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
16610721|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
16610722|NCT02542800|Experimental|Healthy participants|
16610723|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
16610724|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
16610725|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
16610726|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
16610727|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
16610728|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
16610729|NCT02542735||Spanish di@bet.es cohort|Representative of Spanish population
16610730|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
16610731|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
16610732|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
16610733|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
16610734|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
16610735|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
16610736|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
16610737|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
16610738|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
16610739|NCT02542670||control group|Genetic: Whole genome Sequencing
16610740|NCT02542657|Experimental|Treatment (PiC-D therapy)|"Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY:
~Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16610741|NCT02542644|Other|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
16610742|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
16610743|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
16610744|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
16610745|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
16610746|NCT02542605|Other|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
16610747|NCT02542605|Placebo Comparator|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
16610748|NCT02542605|Experimental|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
16610749|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
16610750|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
16610751|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
16610752|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
16610753|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
16610754|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
16610755|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
16610756|NCT02542540|No Intervention|Children with OI without training|No training
16610757|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
16610758|NCT02542514|Experimental|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
16610759|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
16610760|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
16610761|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
16610762|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
16610763|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
16610764|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
16610765|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
16610766|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
16610767|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
16610768|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
16610769|NCT02542423|Other|patients undergoing cardiac surgery|
16610770|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
16610771|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
16610772|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
16610773|NCT02542384|Active Comparator|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
16610774|NCT02542384|Active Comparator|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
16610775|NCT02542384|Placebo Comparator|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
16610776|NCT02542371||HIV infected with known subclinical atherosclerosis|
16610777|NCT02542371||HIV infected without known subclinical atherosclerosis|
16610778|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
16610779|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
16610780|NCT02542345|Experimental|magnetic resonance imaging|
16610781|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
16610782|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
16610783|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
16610784|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
16610785|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
16610786|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
16610787|NCT02542293|Experimental|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
16610788|NCT02542293|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
16610789|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
16610790|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
16610791|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
16610792|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
16610793|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
16610794|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
16610795|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
16610796|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
16610797|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
16610798|NCT02542241|Experimental|Sodium Chloride [3%]|
16610799|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
16610800|NCT02542215|Experimental|Cobiprostone 30 mcg four times daily|Cobiprostone oral spray, four times daily, in addition to standard care radiation and chemotherapy
16610801|NCT02542215|Placebo Comparator|Placebo 0 mcg four times daily|Matching placebo oral spray, four times daily, in addition to standard care radiation and chemotherapy
16610802|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
16610803|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
16610804|NCT02542176|Placebo Comparator|Grape Powder Placebo|
16610805|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
16610806|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
16610807|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
16610808|NCT02542124|Experimental|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
16610809|NCT02542111|Experimental|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
16610810|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
16610811|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
16610812|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
16610813|NCT02542072|Active Comparator|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
16610814|NCT02542072|Active Comparator|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
16610815|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
16610816|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
16610817|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
16610818|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
16610819|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
16610820|NCT02542033|Active Comparator|verum|500mL treated apple juice with low sugar content given on one experimental day
16610821|NCT02542033|Placebo Comparator|control|500mL un-treated apple juice with normal sugar content given on one experimental day
16610822|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
16610823|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
16610824|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
16610825|NCT02541968|Active Comparator|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
16610826|NCT02541968|Experimental|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
16610827|NCT02541968|Experimental|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
16610828|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
16610829|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
16610830|NCT02541942|Other|Collection of specimen|
16610831|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
16610832|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
16610833|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
16610834|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
16610835|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
16610836|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
16610837|NCT02541877|Experimental|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
16610838|NCT02541877|Active Comparator|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
16610839|NCT02541877|Active Comparator|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
16610840|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
16610841|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
16610842|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
16610843|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
16610844|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
16610845|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
16610846|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
16610847|NCT02541799|Experimental|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
16610848|NCT02541799|Active Comparator|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
16610849|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
16610850|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
16610851|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
16610852|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
16610853|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
16610854|NCT02541760|No Intervention|Control|No intervention
16610855|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
16610856|NCT02541747|No Intervention|control|Rest as control
16610857|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
16610858|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
16610859|NCT02541721|Experimental|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
16610860|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
16610861|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
16610862|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.
~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
16610863|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.
~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
16610864|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
16610865|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
16610866|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
16610867|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
16610868|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
16610869|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
16610870|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
16610871|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
16610872|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
16610873|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
16610874|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
16610875|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
16610876|NCT02541604|Experimental|Atezolizumab|Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams [mg]) on Day 1 of each 21-day cycle.
16610877|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
16610878|NCT02541591|Active Comparator|Control|MAP>65mmHg
16610879|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16610880|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III
~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
16610881|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
16610882|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
16610883|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
16610884|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
16610885|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
16610886|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
16610887|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
16610888|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
16610889|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
16610890|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
16610891|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
16610892|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
16610893|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
16610894|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
16610895|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
16610896|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
16610897|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
16610898|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
16610899|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
16610900|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
16610901|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
16610902|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
16610903|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
16610904|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
16610905|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
16610906|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
16610907|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
16610908|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
16610909|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
16610910|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
16610911|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
16610912|NCT02541383|No Intervention|Arm A Part 2|Observation
16610913|NCT02541383|Experimental|Arm B Part 2|daratumumab
16610914|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
16610915|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
16610916|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
16610917|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
16610918|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
16610919|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
16610920|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
16610921|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
16610922|NCT02541331|Experimental|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
16610923|NCT02541331|Placebo Comparator|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
16610924|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
16610925|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
16610926|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
16610927|NCT02541305|Experimental|Experimental|Propioceptive program
16610928|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
16610929|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
16610930|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
16610931|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
16610932|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
16610933|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
16610934|NCT02541253|Experimental|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
16610935|NCT02541253|Active Comparator|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
16610936|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
16610937|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
16610938|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
16610939|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
16610940|NCT02541214|Experimental|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
16610941|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
16610942|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
16610943|NCT02541188||breast cancer in young women is in the Maghreb|breast cancer in young women (< 40years old) is in the Maghreb
16610944|NCT02541188||Breast cancer in young women in the western countries|Breast cancer in young women (< 40years old) in the western countries
16610945|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
16610946|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
16610947|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
16610948|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
16610949|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
16610950|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
16610951|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
16610952|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
16610953|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
16610954|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
16610955|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
16610956|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
16610957|NCT02541123||Cohort E|Uninjured control group
16610958|NCT02541097|Active Comparator|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
16610959|NCT02541097|Active Comparator|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
16610960|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
16610961|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
16610962|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
16610963|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
16610964|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
16610965|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
16610966|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
16610967|NCT02541058||Suspected 22q.11.2 deletion/duplication|
16610968|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
16610969|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
16610970|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
16610971|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
16610972|NCT02541019|Experimental|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
16610973|NCT02541019|Experimental|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
16610974|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
16610975|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
16610976|NCT02540993|Experimental|Finerenone (BAY94-8862)|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
16610977|NCT02540993|Placebo Comparator|Placebo|Participants received matching placebo once daily in addition to standard of care therapy
16610978|NCT02540967||BAY86-4875|Gadovist administration goup
16610979|NCT02540954|Experimental|Aflibercept extended dosing|Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
16610980|NCT02540954|Active Comparator|Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)|Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
16610981|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
16610982|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
16610983|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
16610984|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
16610985|NCT02540889|Experimental|trial arm|100 hours of therapy.
16610986|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
16610987|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
16610988|NCT02540863|Experimental|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:
~Suboccipital release.
~Compression - decompression of temporomandibular joint.
~Horizontal release of temporomandibular joint.
~Deep fascia release in temporal region.
~Masseter deep fascia release.
~Pterygoiddeep fascia release.
~Intraoral pterygoid deep fascia release."
16610989|NCT02540863|Active Comparator|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
16610990|NCT02540850||CRC group|stage 0-IV CRC subjects
16610991|NCT02540850||precancerous disease group|subjects with adenoma or polyps
16610992|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
16610993|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
16610994|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
16610995|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
16610996|NCT02540811|Experimental|dCELL® ACL Scaffold|
16610997|NCT02540785|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
16610998|NCT02540785|Experimental|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
16611256|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
16610999|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
16611000|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
16611001|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
16611002|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
16611003|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
16611004|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
16611005|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
16611006|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
16611007|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
16611008|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
16611009|NCT02540733||Diabetic stroke|
16611010|NCT02540733||Non-diabetic storke|
16611011|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
16611012|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
16611013|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
16611014|NCT02540707|Placebo Comparator|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
16611015|NCT02540707|Experimental|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
16611016|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
16611017|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
16611018|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
16611019|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
16611020|NCT02540668|Experimental|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
16611021|NCT02540668|Experimental|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
16611022|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
16611023|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
16611024|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
16611025|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
16611026|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
16611027|NCT02540629|Experimental|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
16611030|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
16611031|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
16611032|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
16611033|NCT02540551|Experimental|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
16611034|NCT02540538|Active Comparator|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
16611035|NCT02540538|Experimental|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
16611036|NCT02540538|Experimental|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.
~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
16611037|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
16611038|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
16611257|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
16611039|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
16611040|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
16611041|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
16611042|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.
~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
16611043|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
16611044|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
16611045|NCT02540473|Experimental|Group therapy|12 week manualized group therapy (one hour per week)
16611046|NCT02540473|Other|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
16611047|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
16611048|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
16611049|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
16611050|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
16611051|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
16611052|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
16611053|NCT02540434|Active Comparator|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
16611054|NCT02540434|Active Comparator|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
16611055|NCT02540421||Case|Recurrent lesions
16611056|NCT02540421||Control|Absence of lesions
16611057|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
16611058|NCT02540395|Active Comparator|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).
~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
16611059|NCT02540395|Experimental|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).
~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
16611060|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).
~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
16611061|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).
~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
16611062|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
16611063|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
16611064|NCT02540356|Experimental|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
16611065|NCT02540356|Experimental|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
16611066|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
16611067|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
16611068|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
16611069|NCT02540330|Active Comparator|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
16611070|NCT02540330|Experimental|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
16611071|NCT02540317|Experimental|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
16611072|NCT02540317|No Intervention|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
16611073|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
16611074|NCT02540304|No Intervention|Business as Usual|Business as usual
16611075|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
16611076|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
16611077|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
16611078|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
16611079|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
16611080|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
16611081|NCT02540239|Placebo Comparator|2L PEG|only used 2L PEG
16611082|NCT02540239|Experimental|Simethione+2L PEG|used 2L PEG+Simethione
16611083|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
16611084|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
16611085|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
16611086|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
16611087|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
16611088|NCT02540187||haemophilia A|"Blood specimen for measuring :
~Free TFPI and TFPI activity levels
~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)
~Thrombin generation assay (TGA) in fresh PRP and frozen PPP
~Hemorrhage score for each patient"
16611089|NCT02540187||Haemophilia B|"Blood specimen for measuring :
~Free TFPI and TFPI activity levels
~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)
~Thrombin generation assay (TGA) in fresh PRP and frozen PPP
~Hemorrhage score for each patient"
16611090|NCT02540174|Experimental|Arm A|integrated addiction treatment program
16611091|NCT02540174|Other|Arm B|standard of care
16611092|NCT02540161|Experimental|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
16611093|NCT02540161|Experimental|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
16611094|NCT02540161|Experimental|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
16611095|NCT02540161|Experimental|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
16611096|NCT02540148|Experimental|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
16611120|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
16611121|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
16611619|NCT02536807|Placebo Comparator|Control|Control placebo gel injection
16611097|NCT02540148|Sham Comparator|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
16611098|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
16611099|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
16611100|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
16611101|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
16611102|NCT02540109|Experimental|High-Definition tDCS (Active)|
16611103|NCT02540109|Experimental|High-Definition tDCS (Sham)|
16611104|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
16611105|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
16611106|NCT02540083|Experimental|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
16611107|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
16611108|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
16611109|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
16611110|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
16611111|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
16611112|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
16611113|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
16611114|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.
~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
16611115|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.
~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
16611116|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
16611117|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
16611118|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
16611119|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
16611122|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
16611123|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
16611124|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
16611125|NCT02539966|Experimental|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
16611126|NCT02539966|Experimental|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
16611127|NCT02539966|Experimental|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
16611128|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
16611129|NCT02539927||Controlled|
16611130|NCT02539927||Not controlled|
16611131|NCT02539927||Control status yet to be clarified|
16611132|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
16611133|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
16611134|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
16611135|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
16611136|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
16611137|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
16611138|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
16611139|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
16611140|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
16611141|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
16611142|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
16611143|NCT02539849|Other|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
16611144|NCT02539836|Experimental|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
16611145|NCT02539836|Active Comparator|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
16611146|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
16611147|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
16611148|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
16611149|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.
~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
16611150|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
16611151|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
16611152|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
16611153|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
16611154|NCT02539784|Experimental|Spinal Cord Stimulation|
16611155|NCT02539771|Other|Nocturnal VOC|
16611156|NCT02539771|Other|Diurnal VOC|
16611157|NCT02539771|Other|Slightly symptomatic|
16611158|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
16611159|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
16611160|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
16611161|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
16611162|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
16611163|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
16611164|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
16611165|NCT02539693|Experimental|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
16611166|NCT02539693|Experimental|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
16611167|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
16611168|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
16611169|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
16611170|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
16611171|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
16611172|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
16611173|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
16611174|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
16611175|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
16611176|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
16611177|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
16611178|NCT02539615|Experimental|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
16611179|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
16611180|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
16611181|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
16611182|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
16611183|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
16611184|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
16611185|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
16611186|NCT02539550|Placebo Comparator|Placebo|Placebo
16611187|NCT02539550|Experimental|PF-06266047|PF-06266047
16611188|NCT02539537|Active Comparator|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8, and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
16611189|NCT02539537|Experimental|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 minutes. The irinotecan will begin 30 minutes after the start of the folinic acid infusion.
~5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.
~Treatment will be continued for 24 weeks (12 cycles)."
16611190|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
16611191|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
16611192|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
16611193|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
16611194|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
16611195|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
16611196|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
16611197|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
16611198|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
16611199|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
16611200|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
16611201|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
16611202|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
16611203|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
16611204|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
16611205|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral
~Pharmacokinetics"
16611206|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
16611207|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
16611208|NCT02539381|Other|Gold Standard Assessments|"Formal perimetry (Goldman or Octopus visual field)
~Albert's visual inattention test
~Star cancellation visual inattention test
~line bisection test
~These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.
~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.
~Researcher will record a score (0-10) to quantify the participant's compliance"
16611209|NCT02539381|Other|Usual Clinical Screening Practice|"Visual field assessment to confrontation
~Visual inattention assessment to bilateral stimuli
~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.
~Researcher will record a score (0-10) to quantify the participant's compliance"
16611210|NCT02539381|Other|Stroke Vision App|"Digital tumbling E visual accuity assessment
~Digital visual field assessment
~Digital line crossing assessment
~Digital shape cancellation assessment
~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.
~Researcher will record a score (0-10) to quantify the participant's compliance"
16611211|NCT02539368||CT-P13|biosimilar infliximab
16611212|NCT02539368||Remicade|infliximab
16611213|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
16611214|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
16611215|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
16611216|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
16611217|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
16611218|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
16611219|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
16611220|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
16611221|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
16611222|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
16611223|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
16611224|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
16611225|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
16611226|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
16611227|NCT02539238|Active Comparator|control|Annual BLS training
16611228|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
16611229|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.
~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
16611230|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.
~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
16611231|NCT02539212|Active Comparator|microwave ablation|microwave ablation
16611232|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
16611233|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
16611234|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
16611235|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
16611236|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
16611237|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
16611238|NCT02539160|Active Comparator|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
16611239|NCT02539160|Experimental|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
16611240|NCT02539160|Active Comparator|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
16611241|NCT02539160|Experimental|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
16611242|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
16611243|NCT02539134|Experimental|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
16611244|NCT02539134|Experimental|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
16611245|NCT02539134|Experimental|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
16611246|NCT02539134|Experimental|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
16611247|NCT02539134|Experimental|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
16611248|NCT02539134|Experimental|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
16611249|NCT02539134|Experimental|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
16611250|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
16611251|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
16611252|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
16611253|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
16611254|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
16611255|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
16611258|NCT02539069|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
16611259|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
16611260|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
16611261|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
16611262|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
16611263|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
16611264|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
16611265|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
16611266|NCT02538991|Experimental|Bulkamid|
16611267|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
16611268|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
16611269|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
16611270|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
16611271|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
16611272|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
16611273|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
16611274|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
16611275|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
16611276|NCT02538913|Experimental|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
16611277|NCT02538913|Active Comparator|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
16611278|NCT02538900|Experimental|Group 1|Low-intensity, self-paced walking exercise. Home based exercise.
16611279|NCT02538900|Experimental|Group 2|Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.
16611280|NCT02538900|Active Comparator|Group 3|Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.
16611281|NCT02538887||Radio Frequency Surgical Detection|
16611282|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
16611283|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
16611284|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
16611285|NCT02538861|Active Comparator|ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
16611286|NCT02538861|Active Comparator|ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
16611287|NCT02538861|Active Comparator|ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
16611288|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
16611289|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
16611290|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
16611291|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
16611292|NCT02538835|Experimental|Metacognitive Therapy|
16611293|NCT02538835|Active Comparator|Mindfulness based cognitive therapy|
16611294|NCT02538835|Placebo Comparator|Support groups|
16611295|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
16611296|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
16611297|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
16611298|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
16611299|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
16611300|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
16611301|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
16611302|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
16611303|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
16611304|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
16611305|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
16611306|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
16611307|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
16611308|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
16611309|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
16611310|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
16611311|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
16611312|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
16611313|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
16611314|NCT02538705|Experimental|Neovasculgen|
16611315|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
16611316|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
16611317|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
16611318|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
16611319|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
16611320|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
16611321|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
16611322|NCT02538666|Placebo Comparator|Placebo|Placebo
16611323|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
16611324|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
16611325|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
16611326|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
16611327|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
16611328|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
16611329|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
16611330|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
16611331|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
16611332|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
16611615|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
16611333|NCT02538614|Experimental|Phase 1b: Idelalisib + BI 836826|Participants will receive escalating dose of idelalisib at dose levels, 50 mg, 100 mg, and 150 mg + BI 836826 10 mg on Day 8, 50 mg on Day 9 and Day 15, and 100 mg on Day 22, every 2 weeks through Week 18, and every 4 weeks through Week 46. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
16611334|NCT02538614|Experimental|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
16611335|NCT02538601|Experimental|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
16611336|NCT02538601|Active Comparator|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
16611337|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
16611338|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
16611339|NCT02538575|Experimental|6-minute walk test|
16611340|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
16611341|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
16611342|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
16611343|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
16611344|NCT02538523|Active Comparator|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
16611345|NCT02538523|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
16611346|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16611347|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
16611348|NCT02538497|Other|Routine care|
16611349|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
16611350|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
16611351|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
16611352|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.
~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.
~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
16611353|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
16611354|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.
~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
16611355|NCT02538445|Experimental|Patients group 1|Memorization of the verbs by miming the action
16611356|NCT02538445|Experimental|Patients group 2|Memorization of the verbs by imagining the action
16611357|NCT02538445|Experimental|Patients group 3|Memorization of the action verbs by means of another word
16611358|NCT02538445|Experimental|Patients group 4|Simple memorization of the verbs
16611359|NCT02538445|Active Comparator|Healthy volonteers group 1|Memorization of the verbs by miming the action
16611360|NCT02538445|Active Comparator|Healthy volonteers group 2|Memorization of the verbs by imagining the action
16611361|NCT02538445|Active Comparator|Healthy volonteers group 3|Memorization of the action verbs by means of another word
16611362|NCT02538445|Active Comparator|Healthy volonteers group 4|Simple memorization of the verbs
16611363|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
16611364|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
16611365|NCT02538419|Active Comparator|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.
~All participants will receive CPAP in addition to this intervention."
16611366|NCT02538419|Active Comparator|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.
~All participants will receive CPAP in addition to this intervention."
16611367|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
16611368|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
16611369|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
16611406|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
16611407|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
16611370|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
16611371|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
16611372|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
16611373|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
16611374|NCT02538367|Experimental|YH12852 IR 0.05mg|Once daily
16611375|NCT02538367|Experimental|YH12852 IR 0.1mg|Once daily
16611376|NCT02538367|Experimental|YH12852 IR 0.3mg|Once daily
16611377|NCT02538367|Experimental|YH12852 IR 0.5mg|Once daily
16611378|NCT02538367|Experimental|YH12852 IR 1mg|Once daily
16611379|NCT02538367|Experimental|YH12852 IR 2mg|Once daily
16611380|NCT02538367|Experimental|YH12852 IR 3mg|Once daily
16611381|NCT02538367|Experimental|YH12852 DR1 0.5mg|Once daily
16611382|NCT02538367|Experimental|YH12852 DR1 1mg|Once daily
16611383|NCT02538367|Experimental|YH12852 DR1 2mg|Once daily
16611384|NCT02538367|Experimental|YH12852 DR1 4mg|Once daily
16611385|NCT02538367|Experimental|YH12852 DR2 8mg|Once daily
16611386|NCT02538367|Active Comparator|Prucalopride 2mg|Once daily
16611387|NCT02538367|Placebo Comparator|Placebo|Once daily
16611388|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
16611389|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
16611390|NCT02538341|Active Comparator|Zoster Vaccine Live (Zostavax)|Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
16611391|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
16611392|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
16611393|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
16611394|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and [18F]FDOPA PET/CT
16611395|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
16611396|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
16611397|NCT02538289|Other|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
16611398|NCT02538289|Other|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
16611399|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
16611400|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
16611401|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
16611402|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
16611403|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
16611404|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
16611405|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
16611768|NCT02535754|Experimental|ALIVE + CCS BCY|Email + comprehensive program N=225
16611408|NCT02538211|Placebo Comparator|Control|"Control group - subjects will receive no antibiotics
~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
16611409|NCT02538211|Active Comparator|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:
~Ciprofloxacin 500mg 2dd1
~Vancomycin 250mg 3dd2
~Metronidazole 500mg 3dd1
~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
16611410|NCT02538211|Active Comparator|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:
~• Vancomycine 250mg 3dd2
~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
16611411|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
16611412|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);
~Left forearm, ID with classical syringe filled with vaccine (0.1mL);
~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
16611413|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);
~Left forearm, ID with classical syringe filled with placebo (0.1mL);
~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
16611414|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);
~Left forearm, ID with classical syringe filled with placebo (0.1mL);
~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
16611415|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
16611416|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
16611417|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
16611418|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
16611419|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
16611420|NCT02538133|Experimental|99mTc-Exametazime (HMPAO)-labeled leucocytes|
16611421|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
16611422|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
16611423|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
16611424|NCT02538094|Sham Comparator|Sham Stimulation First|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS first and then Anodal Stimulation second.
16611425|NCT02538094|Experimental|Anodal Stimulation First|Transcranial direct current stimulation using Anodal stimulation first over the area of interest and then Sham Stimulation second.
16611426|NCT02538081|Active Comparator|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
16611427|NCT02538081|Active Comparator|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
16611428|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
16611429|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
16611430|NCT02538055|Placebo Comparator|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
16611431|NCT02538055|Experimental|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
16611432|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
16611433|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
16611434|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
16611435|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
16611436|NCT02538016|Other|Tolvaptan|
16611437|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)
~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
16611438|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)
~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
16611439|NCT02537977|Experimental|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
16611616|NCT02536820|Other|Conventional treatment + PNIT|PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved
16611440|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
16611441|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
16611442|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
16611443|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
16611444|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
16611445|NCT02537938|Experimental|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
16611446|NCT02537938|No Intervention|Placebo|Placebo comparator given once a day for 14 days as a capsule.
16611447|NCT02537925|Active Comparator|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
16611448|NCT02537925|Experimental|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
16611449|NCT02537912|Active Comparator|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
16611450|NCT02537912|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
16611451|NCT02537899|Other|Treatment|NeuroAiD
16611452|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
16611453|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.
~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
16611454|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
16611455|NCT02537860|Experimental|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
16611456|NCT02537860|Experimental|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
16611457|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
16611458|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
16611459|NCT02537834|Experimental|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
16611460|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
16611461|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
16611462|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
16611463|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
16611464|NCT02537782|Other|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
16611465|NCT02537769|Experimental|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
16611466|NCT02537769|Active Comparator|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
16611467|NCT02537756|Experimental|1- Verbalize, Choice|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
16611468|NCT02537756|Experimental|2- Listen, Choice|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics they choose
16611469|NCT02537756|Experimental|3- Verbalize, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
16611470|NCT02537756|Experimental|4- Listen, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics assigned to them
16611471|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
16611472|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
16611473|NCT02537717|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
16611474|NCT02537717|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
16611475|NCT02537704|Experimental|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.
~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).
~The lifestyle objectives for participants will be as follows:
~To lose 5-10% of initial weight through healthy eating.
~To do 150 minutes of physical activity each week."
16611476|NCT02537691|Other|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of >/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
16611477|NCT02537678|Experimental|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
16611478|NCT02537678|Active Comparator|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
16611479|NCT02537665|Other|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
16611480|NCT02537665|Placebo Comparator|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
16611481|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
16611482|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
16611483|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
16611484|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
16611485|NCT02537626|Active Comparator|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
16611486|NCT02537626|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
16611487|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
16611488|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
16611489|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
16611490|NCT02537600|Experimental|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :
~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
16611491|NCT02537587|Active Comparator|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
16611492|NCT02537587|Active Comparator|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
16611493|NCT02537587|Experimental|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
16611494|NCT02537587|Experimental|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
16611495|NCT02537587|Experimental|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
16611496|NCT02537587|Experimental|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
16611497|NCT02537587|Experimental|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
16611498|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
16611499|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
16611500|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
16611501|NCT02537561|Experimental|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"Dose levels of the drugs will be dependent on which dose level the participants is enrolled.
~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.
~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.
~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.
~Cisplatin and gemcitabine will be given for a total of 6 cycles.
~Talazoparib may be continued as a single agent maintenance therapy."
16611537|NCT02537314|Active Comparator|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
16611538|NCT02537314|Placebo Comparator|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
16611617|NCT02536820|Active Comparator|Conventional treatment|Conventional treatment: Usual treatment that each diabetic patient recieved
16611502|NCT02537561|Experimental|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study
~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.
~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.
~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.
~Cisplatin and gemcitabine will be given for a total of 6 cycles.
~Talazoparib may be continued as a single agent maintenance therapy."
16611503|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
16611504|NCT02537522|Experimental|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
16611505|NCT02537522|Experimental|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
16611506|NCT02537522|Experimental|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
16611507|NCT02537522|Experimental|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
16611508|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
16611509|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
16611510|NCT02537496|Experimental|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
16611511|NCT02537496|Sham Comparator|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
16611512|NCT02537496|No Intervention|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
16611513|NCT02537483|Experimental|IDP-120 Gel|IDP-120 Gel, applied topically to the face once daily for 12 weeks.
16611514|NCT02537483|Active Comparator|IDP-120 Component A|IDP-120 Component A, applied topically to the face once daily for 12 weeks
16611515|NCT02537483|Active Comparator|IDP-120 Component B|IDP-120 Component B, applied topically to the face once daily for 12 weeks
16611516|NCT02537483|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks
16611517|NCT02537470|Other|Arm 1|Placebo
16611518|NCT02537470|Experimental|Arm 2|Biphasic remogliflozin etabonate
16611519|NCT02537457|Experimental|BAY59-7939 Rivaroxaban granule|
16611520|NCT02537457|Active Comparator|BAY59-7939 Rivaroxaban tablet|
16611521|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
16611522|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
16611523|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
16611524|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks
~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
16611525|NCT02537405|Experimental|BAY59-7939 granule|
16611526|NCT02537405|Active Comparator|BAY59-7939 tablet|
16611527|NCT02537392|Experimental|Vitamin B Complex and Folic Acid|Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
16611528|NCT02537392|Experimental|Iron and Folic Acid|Daily supplements of iron (60 mg) and folic acid (0.4 mg).
16611529|NCT02537392|Active Comparator|Folic Acid|Daily supplement of 0.4 mg folic acid.
16611530|NCT02537379||SOF+COPE|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
16611531|NCT02537366|Placebo Comparator|Placebo|Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
16611532|NCT02537366|Experimental|DEX|Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
16611533|NCT02537353|Placebo Comparator|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
16611534|NCT02537353|Active Comparator|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
16611535|NCT02537340||EMVI-MR positive|Patients with primary rectal cancer and extramural vascular invasion detected by staging MR
16611536|NCT02537340||EMVI-MR negative|Patients with primary rectal cancer and without extramural vascular invasion detected by staging MR
16611539|NCT02537301||ERCP-chat group|All the doctors who finished their ERCP training in Xijing Hospital of Digestive Diseases and were invited to join in a chatting group in a mobile social app (Wechat).
16611540|NCT02537288|Experimental|Placebo matched to fedovapagon|One dose of placebo (matched to fedovapagon)
16611541|NCT02537288|Experimental|Fedovapagon 2 mg|One dose of 2 mg fedovapagon
16611542|NCT02537288|Experimental|Fedovapagon 20 mg|One dose of 20 mg fedovapagon
16611543|NCT02537288|Experimental|Moxifloxacin 400 mg (open label)|One dose of moxifloxacin 400 mg (open label)
16611544|NCT02537275|Experimental|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
16611545|NCT02537262|Experimental|carbohydrate group|
16611546|NCT02537262|Placebo Comparator|NPO(None Per Oral) group|
16611547|NCT02537249|Experimental|Dexmedetomidine|
16611548|NCT02537249|Sham Comparator|Saline 0.9%|
16611549|NCT02537236|Experimental|Group one|20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids
16611550|NCT02537236|Active Comparator|Group two|20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids
16611551|NCT02537236|Experimental|Group three|20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.
16611552|NCT02537236|Active Comparator|Group four|20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids
16611553|NCT02537236|Placebo Comparator|Group five|20 subjects, control group received conventional diet.
16611554|NCT02537223|Experimental|BYL719, Cisplatin, and Radiation Therapy|BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.
16611555|NCT02537210|Active Comparator|Mesalazine|mesalazine 2g od po for 12 months
16611556|NCT02537210|Placebo Comparator|Placebo oral capsule|placebo 5 capsules od po for 12 months
16611557|NCT02537197|Experimental|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
16611558|NCT02537184|Other|Group 1 - Recall Interval of 4 months|"Oral clinical conditions:
~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
16611559|NCT02537184|Other|Group 2 - Recall Interval of 8 months|"Oral clinical conditions:
~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
16611560|NCT02537171|Active Comparator|Apatinib 750mg group|Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).
16611561|NCT02537171|Active Comparator|Apatinib 500mg group|Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
16611562|NCT02537158|Experimental|sorafenib group|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
16611563|NCT02537158|Experimental|TACE group|TACE group patients will accept TACE therapy once at a month after resection.
16611564|NCT02537158|No Intervention|control group|Control group patients will not accept any intervention,except necessary supportive treatment.
16611565|NCT02537145||Obese pregnant women|20 obese pregnant women (BMI ≥ 30)
16611566|NCT02537145||Lean pregnant women|20 lean pregnant women (BMI 18,5 - 25)
16611567|NCT02537132|Experimental|Home Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home
16611568|NCT02537132|Active Comparator|Outpatient Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic
16611569|NCT02537119|Experimental|Dynamic massage therapy|Rubbing on hamstrings combined with articular movement
16611570|NCT02537119|Active Comparator|Massage therapy|Rubbing on hamstrings
16611571|NCT02537106|Experimental|1.5% NaCl|After standardized induction to general anesthesia group A patients will be given the infusion of hyperosmotic 1.5% NaCl 5 ml/kg/BW during 15 min.
16611572|NCT02537106|Experimental|3% NaCl|After standardized induction to general anesthesia group B patients will be given the infusion of hyperosmotic 3% NaCl 5 ml/kg/BW during 15 min.
16611573|NCT02537093|Active Comparator|Synchronous telepsychiatry (STP)|Control Arm/Synchronous telepsychiatry (STP): After baseline assessment, subjects will be assessed by a psychiatrist using live interactive videoconferencing every 6 months for a 1 year follow up (3 STP assessments: baseline plus 2 assessments). A report with treatment recommendations following American Psychiatric Association guidelines will be sent to the PCP who will be able to have adlib telephone or email consultations with the telepsychiatrist. The telepsychiatrist will have access to all previous clinical information about the patients.
16611612|NCT02536833|Experimental|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
16611613|NCT02536833|Experimental|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
16611614|NCT02536833|Experimental|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
16611574|NCT02537093|Experimental|Asynchronous telepsychiatry (ATP)|Intervention Arm (ATP): All ATP assessments at 6 monthly intervals post baseline will be conducted by an ATP trained clinician. This interview will be video recorded.The ATP clinicians will then fill out a standardized medical template that will be reviewed by a psychiatrist who will provide a written assessment and psychiatric treatment plan. He will have access to any previous assessments and the PCP will also have continuing access to this psychiatrist by phone or email between the 3 consultations.
16611575|NCT02537080|Experimental|Nimodipine group|1 tbl of 30 mg nimodipine will be administered orally with premedication
16611576|NCT02537080|Experimental|Control group|1 tbl of placebo will be administered orally with premedication
16611577|NCT02537067|Experimental|Autologous cultured Chondrocyte|Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant.
16611578|NCT02537054|Experimental|Aflibercept|2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use
16611579|NCT02537041|Other|healthy volunteers|to obtain normal values diastolic myocardial stiffness references. The objective will be to confirm the increase with age in myocardial stiffness assessed by elastography in healthy subjects.
16611580|NCT02537041|Other|diastolic Heart Failure|older patients with isolated diastolic HF (EF> 45%, 60-80 years, n = 20) and infiltrative cardiomyopathy restrictive-type amyloidosis (n = 20) . The objective will be to study the results of elastography on two separate clinical types of IC diastolic well identified.
16611581|NCT02537041|Other|systolic Heart Failure|"elderly patients with heart failure with impaired ejection (<45%) fraction, but no segmental dysfunction.
~The evaluation of myocardial stiffness by elastography in all these patients will be compared to conventionally ultrasound and biological parameters currently used for diagnosis of elderly's diastolic HF"
16611582|NCT02537028|Experimental|MSC2364447C 25 mg|
16611583|NCT02537028|Experimental|MSC2364447C 75 mg|
16611584|NCT02537028|Placebo Comparator|Placebo|
16611585|NCT02537015|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
16611586|NCT02537002|Experimental|Cohort 1- PF-05230907 or Placebo|
16611587|NCT02537002|Experimental|Cohort 2- PF-05230907 or Placebo|
16611588|NCT02536989|Experimental|1|receive high dose PPI treament with intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
16611589|NCT02536989|Active Comparator|2|receive usual dose PPI treatment with ntravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
16611590|NCT02536976|Experimental|Active treatment|mirabegron
16611591|NCT02536976|Placebo Comparator|Placebo|Matching placebo
16611592|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
16611593|NCT02536950|No Intervention|Blinded Sensor|Subjects will wear a blinded Dexcom G4P (Generation 4 Platinum) AP (Artificial Pancreas) glucose sensor for a week
16611594|NCT02536950|Experimental|Fixed set point|Subjects will be in a hotel and use a fixed set point for glucose control for two days initialized at 130 mg/dl. The setpoint will be adjusted, if necessary, over the two days in the hotel before they are sent home for 5 days
16611595|NCT02536950|Experimental|Variable Set Point|"Subjects will begin using a variable setpoint which will make adjustments based on their past glucose control over the previous day"
16611596|NCT02536937|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
16611597|NCT02536937|Experimental|GZ385660 (subjects with mild renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
16611598|NCT02536937|Experimental|GZ385660 (subjects with moderate renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
16611599|NCT02536937|Experimental|GZ385660 (subjects with severe renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
16611600|NCT02536924|Experimental|Waiting room intervention plus TAU|The treatment group will receive waiting room intervention plus treatment as usual.
16611601|NCT02536924|Experimental|Only TAU.|The control group will receive only treatment as usual.
16611602|NCT02536911|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
16611603|NCT02536911|Experimental|GZ385660 (subjects with mild hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
16611604|NCT02536911|Experimental|GZ385660 (subjects with moderate hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
16611605|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice
~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.
~Blood samples
~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)
~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug
~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5
~Fracture patients with reduced kidney function will be treated with anti-RANKL
~Anti-osteoporosis drug prescribed by hospital physician
~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year
~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
16611606|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
16611607|NCT02536885|Experimental|Liberal group|During the surgery, blood pressure of the patients will be maintained within ± 25% of the patient's normal blood pressure.
16611608|NCT02536885|Experimental|Restrictive group|During the surgery, blood pressure of the patients will be maintained within ± 10% of the patient's normal blood pressure.
16611609|NCT02536859|Experimental|IDeg|
16611610|NCT02536859|Active Comparator|IGlar U300|
16611611|NCT02536846|Experimental|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
16611620|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
16611621|NCT02536781|Placebo Comparator|Placebol|Placebo
16611622|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
16611623|NCT02536768|Experimental|Intervention|Minimum package of interventions to improve ART adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
16611624|NCT02536768|No Intervention|Comparison|Standard of care HIV treatment
16611625|NCT02536755|Experimental|eliglustat|Cytochrome P450 (CYP) 2D6 Intermediate (IM), Extensive (EM) and Ultra-Rapid (URM) Metaboliser patients will be treated at 84 mg twice daily. CYP2D6 Poor Metabolisers (PM) will be treated at 84 mg once daily.
16611626|NCT02536742|Experimental|Experimental|Palbociclib plus Fulvestrant
16611627|NCT02536729||Oral Sodium Phosphate - Normal preparation|Oral sodium phospate exposure with special diet (Liquid)
16611628|NCT02536729||Oral Sodium Phosphate - Modified preparation|Oral sodium phospate exposure with special diet (Liquid), but the participant can normally lunch the day before the test
16611629|NCT02536729||polyethylene glycol + Electrolytes|polyethylene glycol + Electrolytes exosure with special diet (Liquid)
16611630|NCT02536716|Active Comparator|Platform-matched dental implant|Platform-matched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
16611631|NCT02536716|Experimental|Platform-switched dental implant|Platform-switched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
16611632|NCT02536703|Experimental|Lotus Valve System|Transcatheter Aortic Valve Implantation (TAVI) with Lotus Valve System
16611633|NCT02536690|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 1 mg/kg and will be adjusted as described in summary.
16611634|NCT02536690|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary.
16611635|NCT02536690|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by midazolam 0.03 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.
~Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary."
16611636|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
16611637|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
16611638|NCT02536638||Pyelonephritis Group|patients with pyelonephritis
16611639|NCT02536638||Without pyelonephritis Group|patients without pyelonephritis
16611640|NCT02536625||Everolimus|Immunomonitoring
16611641|NCT02536612|Experimental|Lottery|"Conditional economic incentive (CEI) lotto arm participants will get a chance to win a type of lottery or lotto ticket with a 50% chance of winning each time: (a) if they come back to the clinic and are still using a modern contraception method after 3 months (including IUD, injectable contraceptive, or implant); (b) if they come back to the clinic and are still using modern contraception after 6 months; and (c) if they come back to the clinic at 6 months and they don't have a new curable STD (such as syphilis).
~They will also will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months."
16611642|NCT02536612|Active Comparator|No Lottery|Participants in the Control (No CEI Lotto) group will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months; they will NOT have a chance to win a lottery even if they are still using a modern contraception and are free of new curable STDs.
16611643|NCT02536586|Experimental|LY3023414|LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
16611644|NCT02536573|No Intervention|Control|Intraoperative fluoroscopy of the hip is used to visually estimate the acetabular cup angle and make any necessary adjustments.
16611645|NCT02536573|Experimental|Radlink Surgical Positioning System|Fluoroscopic image of the hip joint is imported into the Radlink Surgical Positioning software. The software calculates a target cup position using bony landmarks, and the surgeon matches the cup to the target.
16611646|NCT02536560||Antibiotics|150 infants, (because of hospital protocol) treated with antibiotics because of a perinatal infection during the first week of life
16611647|NCT02536560||Controls|The control group comprises 300 healthy newborns, born in the hospital and needing clinical observation for 24-48 hours for several reasons like maternal comorbidity, low probability of neonatal infection, blood sugar monitoring, meconium containing amniotic fluid, or delivery by caesarean section
16611648|NCT02536547||patients with suspected VAP|"All patients with suspected VAP will be included in the study (new or extension of a radiological image in a patient in mechanical ventilation for at least 48 hours associated with at least two of the following:criteria :
~fever ≥38.5 ° C or <36, 5 ° C leukocytosis> 10 * 103 / ml or leukopenia <4 * 103 / ml secretions purulent tracheal reduction in PaO2 / FiO2 <300 or PaO 2 <60 mmHg"
16611649|NCT02536534||Patients with PAH and CTEPH|Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
16611650|NCT02536521||Hemodynamically stable|
16611651|NCT02536521||Hemodynamically unstable|Hemodynamically unstable patients are defined as those with a 20% decrease in systolic blood pressure according to the change of intraabdominal pressure.
16611652|NCT02536508|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
16611653|NCT02536508|Experimental|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
16611654|NCT02536508|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
16611655|NCT02536495|Experimental|Treatment (docetaxel, selinexor)|Patients receive docetaxel IV on day 1 and selinexor PO BID on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16611656|NCT02536482|Experimental|Amix|Dietary supplement. The formula is based in free amino-acid to treat children with cow's milk allergy. The children should have a minimum consumption of 400 mL, daily.
16611657|NCT02536469|Experimental|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
16611658|NCT02536430|Active Comparator|Buccal infiltration of Ketorolac|A buccal infiltration of 30 mg/mL of Ketorolac Tromethamine was applied for the patients in case group.
16611659|NCT02536430|Placebo Comparator|buccal infiltration of Normal Saline|A buccal infiltration of Normal Saline was applied for the patients in control group.
16611660|NCT02536417|Active Comparator|Treatment arm: melatonin|melatonin 0.5 mg as treatment, to be given daily at bedtime
16611661|NCT02536417|Placebo Comparator|Placebo arm|Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm
16611662|NCT02536404|Experimental|Etrasimod (APD334) High Dose|
16611663|NCT02536404|Active Comparator|Placebo|
16611664|NCT02536391|Experimental|Sequence 1: Tablet/Capsule/Tablet with food|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
16611665|NCT02536391|Experimental|Sequence 2: Tablet/Tablet with food/Capsule|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.
16611666|NCT02536391|Experimental|Sequence 3: Capsule/Tablet/Tablet with food|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
16611667|NCT02536391|Experimental|Sequence 4: Capsule/Tablet with food/Tablet|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.
16611668|NCT02536391|Experimental|Sequence 5: Tablet with food/Tablet/Capsule|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.
16611669|NCT02536391|Experimental|Sequence 6: Tablet with food/Capsule/Tablet|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.
16611670|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
16611671|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
16611672|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
16611673|NCT02536352|Experimental|Fluoride prenatal vitamin|Prenatal vitamin-mineral containing 3 mg fluoride
16611674|NCT02536352|Active Comparator|Standard prenatal vitamin|Prenatal vitamin-mineral containing 0 mg fluoride
16611675|NCT02536339|Experimental|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
16611676|NCT02536326|Experimental|renal denervation|
16611677|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
16611678|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
16611682|NCT02536287|Experimental|total PTX without autotransplantation|all parathyroid glands were found and removed
16611683|NCT02536287|Active Comparator|total PTX with autotransplantation|all parathyroid glands were found and removed,and then a portion of it is sliced into 1*1*1 mm pieces for autotransplantation
16611684|NCT02536274|Experimental|Schwertbad Aachen|20 Patients with specific back pain will get Lumbo Sensa® bandage. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
16611769|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
16611798|NCT02535585|Active Comparator|knotted anchors|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
16611685|NCT02536274|Experimental|Schön Klinik Fürth|20 Patients with specific back pain will get Dynaflex® flexion orthosis. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
16611686|NCT02536274|No Intervention|Schön Klinik Fürth & Schwertbad Aachen|20 Patients with specific back pain will get no intervention. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
16611687|NCT02536274|No Intervention|RPE|20 healthy Subjects of the same age without back pain participate in the course for one time to prove the significance of the procedures. (control group) Study related procedures include a course with 6 exercises: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
16611688|NCT02536261||Withdrawal group|Withdrawal observation after reaching the withdrawal standard
16611689|NCT02536261||Continue treatment group|Continue treatment obsevation after reaching the withdrawal standard
16611690|NCT02536248|Experimental|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks
~Wash-out 14 days
~Placebo for 6 weeks"
16611691|NCT02536248|Placebo Comparator|Placebo first, then Sitagliptin|"Placebo for 6 weeks
~Wash-out 14 days
~Sitagliptin 100 mg/d for 6 weeks"
16611692|NCT02536235|Experimental|Intervention: intraoperative topical heat|
16611693|NCT02536235|No Intervention|Control: no intraoperative heat|
16611694|NCT02536222|Experimental|Reactive case investigation : FT/FDA with DHA-PQ|All consenting household members eligible to receive DHA-PQ and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHA-PQ. If no one in the household tests RDT positive then no one in the household will receive DHA-PQ.
16611695|NCT02536222|No Intervention|No Intervention: Standard of Care (Control)|The standard of care arm will have the standard of care offered by the Ministry of Health which applies to all arms. This includes available mosquito net coverage and passive case detection of individuals seeking treatment from a health provider at a health post or community.
16611696|NCT02536209|Experimental|Regimen 1|Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
16611697|NCT02536209|Experimental|Regimen 2|Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
16611698|NCT02536209|Experimental|Regimen 3|Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
16611699|NCT02536209|Experimental|Regimen 4|Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
16611700|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
16611701|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
16611702|NCT02536183|Experimental|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
16611703|NCT02536183|Experimental|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
16611704|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
16611705|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
16611706|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
16611707|NCT02536157|Active Comparator|Dorsal block splint|Thermoplastic splint in 20 degrees flexion applied to the dorsum of the PIPJ.
16611708|NCT02536157|Experimental|Volar gutter splint|Thermoplastic splint in 0 degrees flexion applied to the volar surface of the finger.
16611709|NCT02536144|Experimental|MCCES|Magnetic -controlled capsule endoscopy system (MCCES) is a robot system that the capsule would be swallowed to observe the mucosa of the human alimentary canal especially the colon under the control of the magnetic-manipulator.
16611710|NCT02536144|Active Comparator|Colonoscopy|Colonoscopy has now been in use for many years to visualize and diagnose abnormalities of the colon and it is the gold standard for detecting colorectal lesions.In this study,the additional utility of the colonoscopy is to monitor the movement of the Magnetic -controlled capsule endoscopy.
16611711|NCT02536131|Other|Study group|7-10 sessions gut-directed hypnotherapy within 12 weeks
16611712|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
16611799|NCT02535585|Active Comparator|knotless anchors|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
16611713|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
16611714|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
16611715|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
16611716|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
16611717|NCT02536092|Experimental|755nm and 1064nm Nd:YAG laser|755nm and 1064nm Nd:YAG laser
16611718|NCT02536066|No Intervention|Control|maintain usual physical activity patterns
16611719|NCT02536066|Experimental|Intervention|Addition of daily postprandial physical activity in addition to usual activity patterns
16611720|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
16611721|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
16611722|NCT02536027|Experimental|septic AKI patients|septic AKI patients requiring CVVH
16611723|NCT02536014|Experimental|Dexmedetomidine|
16611724|NCT02536014|Active Comparator|Saline|
16611725|NCT02536001|Other|One mesh Endofast reliant system|Patients with anterior compartment stage III and uterus prolapse grade II will be treated with one mesh - Anterior Endofast reliant system (fixation of posterior arms to the sacrospinous ligament)
16611726|NCT02536001|Other|two meshes Endofast reliant system|intervention: Patients with anterior compartment stage III and uterus prolapse grade II will be treated with 2 meshes: anterior Endofast reliant system mesh to correct the anterior compartment and posterior Endofast reliant system mesh to correct the apical prolapse (fixation to the sacrospinous ligament)
16611727|NCT02535988|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of colorectal cancer receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy; Systemic agents are either capecitabine (Xeloda), paclitaxel or S-1;
16611728|NCT02535975|Experimental|Metformin|Metformin 500mg PO three times a day for 24 weeks
16611729|NCT02535975|Placebo Comparator|Placebo|Placebo tab. PO three times a day for 24 weeks
16611730|NCT02535962|Experimental|Corticosteriod + Probiotic Treatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.
~Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year."
16611731|NCT02535962|Placebo Comparator|Corticosteriod + PlaceboTreatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.
~Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product."
16611732|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
16611733|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
16611734|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
16611735|NCT02535936|Other|3Tesla MRI with DTI-MRI and rsfcMRI|Patients will receive 2 post-operative MRI's with DTI and rsfcMRI at 2 months and 12 months.
16611736|NCT02535923|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
16611770|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
16611771|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
16611800|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
16612293|NCT02532335|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
16611737|NCT02535923|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
16611738|NCT02535910|Experimental|breakfast rich in vitamin D3|subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
16611739|NCT02535910|Experimental|breakfast rich in 25(OH) D3|subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
16611740|NCT02535910|Placebo Comparator|Control|subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast
16611741|NCT02535897|Placebo Comparator|CON|500 ml of flavoured water
16611742|NCT02535897|Active Comparator|CHO|500 ml of flavoured water containing 80 g carbohydrate
16611743|NCT02535897|Active Comparator|CHO-PRO|500 ml of flavoured water containing 40 g carbohydrate and 40 g whey protein
16611744|NCT02535884|Experimental|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
16611745|NCT02535884|Sham Comparator|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
16611746|NCT02535871|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
16611747|NCT02535871|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
16611748|NCT02535858|Experimental|Heart and respiratory rate and video|To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication.
16611749|NCT02535858|Experimental|Heart and respiratory rate and VE|A second group has fifty adult volunteers (DG) ongoing outpatient chemical dependency clinic [treatment average's population: 5 months and 14 days]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
16611750|NCT02535845|Experimental|Self-persuasion group|HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
16611751|NCT02535845|Active Comparator|Information only group|HPV information only in a tablet-based application (HPV Informational Video)
16611752|NCT02535832|Placebo Comparator|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
16611753|NCT02535832|Active Comparator|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
16611754|NCT02535819|Experimental|Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
16611755|NCT02535819|Other|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
16611756|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.
~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.
~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
16611757|NCT02535793|Other|laboratory workers with symptoms in presence of drosophila|
16611758|NCT02535780|Experimental|TMS Treatment Group|15 sessions active Transcranial magnetic stimulation (TMS) treatment
16611759|NCT02535780|Sham Comparator|TMS Sham Group|15 sessions sham Transcranial magnetic stimulation (TMS) treatment
16611760|NCT02535780|Experimental|tDCS Treatment Group|15 sessions active Transcranial direct current stimulation (tDCS) treatment
16611761|NCT02535780|Sham Comparator|tDCS Sham Group|15 sessions sham Transcranial direct current stimulation (tDCS) treatment
16611762|NCT02535767|Experimental|A: 0.40 mg/kg PQ G6PDd|0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
16611763|NCT02535767|Experimental|B: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
16611764|NCT02535767|Experimental|C: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
16611765|NCT02535767|Experimental|D: PQ G6PDn|A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.
16611766|NCT02535754|Experimental|ALIVE|Email program N=170
16611767|NCT02535754|Experimental|CCS BCY|Comprehensive program N=285
16611772|NCT02535715|Experimental|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
16611781|NCT02535689|Active Comparator|1|ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
16611782|NCT02535689|Active Comparator|2|ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
16611783|NCT02535689|Placebo Comparator|3|ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.
16611784|NCT02535676|Active Comparator|Active tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 20 minutes.
16611785|NCT02535676|Sham Comparator|Sham tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 19 minutes.
16611786|NCT02535663|Experimental|test group|Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks
16611787|NCT02535663|Placebo Comparator|placebo|Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks
16611788|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
16611789|NCT02535637||Mothers-Infant|Mothers who were planning to exclusively breastfeed for six months were enrolled into the study along with their infant.
16611790|NCT02535624|Active Comparator|ANGIO|Patients with persistent hemodynamic instability (systolic blood pressure (SBP) <90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
16611791|NCT02535624|Active Comparator|PACKING|Indication for pelvic packing was persistent SBP<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units. These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
16611792|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
16611793|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
16611794|NCT02535598|Active Comparator|Normal presentation|Standard internet based CBT presentation.
16611795|NCT02535598|Experimental|Enhanced presentation|Enhanced internet CBT presentation.
16611796|NCT02535598|Active Comparator|Normal support|Standard internet based CBT support.
16611797|NCT02535598|Experimental|Enhanced support|Enhanced internet CBT support.
16611801|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
16611802|NCT02535559|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
16611803|NCT02535559|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
16611804|NCT02535533|Experimental|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.
~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.
~During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients."
16611805|NCT02535507|Experimental|Pyrotinib treatment arm|pyrotinib treatment arm
16611806|NCT02535494|No Intervention|Standard Training|Participants receive our standard overdose training.
16611807|NCT02535494|Experimental|Extensive Training|Participant receives an more in-depth, extensive training concerning opioid overdose.
16611808|NCT02535494|Experimental|Extensive Training w/ Significant Other|Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.
16611809|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
16611810|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
16611811|NCT02535468||Prospective Arm|
16611812|NCT02535468||Contrived Arm|
16611813|NCT02535455|Experimental|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
16611814|NCT02535429|Experimental|massage|massage
16611815|NCT02535429|No Intervention|Control|
16611816|NCT02535416|Experimental|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
16611817|NCT02535416|Experimental|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
16611818|NCT02535416|Experimental|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
16611819|NCT02535416|Experimental|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
16611820|NCT02535416|Experimental|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
16611821|NCT02535416|Experimental|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
16611822|NCT02535416|Experimental|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
16611823|NCT02535416|Experimental|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
16611824|NCT02535416|Experimental|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
16611825|NCT02535403|Experimental|ICBT|14 weeks of internet-based cognitive behavioral therapy with therapist support
16611826|NCT02535403|No Intervention|Wait-list|14 weeks wait-list control
16611827|NCT02535390|Experimental|Action based cognitive remediation|Participants in this condition will engage in simulated real world tasks in addition to standard cognitive remediation and group therapy sessions.
16611828|NCT02535390|Active Comparator|Standard cognitive remediation|Participants in this condition will engage in computerized cognitive training exercises in addition to standard cognitive remediation and group therapy sessions.
16611829|NCT02535377||High cryoresistance|High resistance to sperm cryopreservation (decreased sperm motility <20%)
16611830|NCT02535377||Low cryoresistance|Low resistance to sperm cryopreservation (decreased sperm motility >20%)
16611831|NCT02535364|Experimental|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
16611832|NCT02535351|Active Comparator|A: TKIs|sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
16611833|NCT02535351|Experimental|B: TKIs + Cytoreductive Nephrectomy|Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
16611834|NCT02535338|Experimental|Treatment (erlotinib hydrochloride, onalespib lactate)|Patients receive erlotinib hydrochloride PO daily and onalespib lactate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
16611835|NCT02535325|Experimental|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.
~CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.
~Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
16611836|NCT02535312|Experimental|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
16611899|NCT02534870|Experimental|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
16611837|NCT02535312|Experimental|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
16611838|NCT02535299|Experimental|insulin|basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
16611839|NCT02535286|Experimental|TG-1501 + Ublituximab + Umbralisib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals
16611840|NCT02535273|Experimental|Low-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery"
16611841|NCT02535273|Experimental|Moderate-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery"
16611842|NCT02535273|Experimental|High-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery"
16611843|NCT02535273|Placebo Comparator|normal saline Control group|Intravenous injection normal saline equal quantity，completed within 10 minutes. Local anesthesia: lidocaine Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
16611844|NCT02535260||Fertility Monitor|Clearblue Fertility Monitor
16611845|NCT02535247|Experimental|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
16611846|NCT02535247|Active Comparator|Combination|MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study
16611847|NCT02535234|Active Comparator|Arm 1|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Novel system followed by 7 nights with theTraditional system
16611848|NCT02535234|Active Comparator|Arm 2|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Traditional system followed by 7 nights with the Novel system
16611849|NCT02535221|Experimental|Endocrine therapy;|Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
16611850|NCT02535221|Active Comparator|Chemotherapy|Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
16611851|NCT02535208|Experimental|Restrictive transfusion group|
16611852|NCT02535208|Active Comparator|Liberal transfusion group|
16611853|NCT02535195|Active Comparator|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
16611854|NCT02535195|Placebo Comparator|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
16611855|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
16611856|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
16611857|NCT02535169|Experimental|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
16611858|NCT02535169|Placebo Comparator|Usual Care|1. Dietary consult only
16611859|NCT02535156|Experimental|Schizotypal Personality Disorder|Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).
16611860|NCT02535156|Experimental|Healthy controls|Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).
16611861|NCT02535143|Experimental|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
16611862|NCT02535143|Placebo Comparator|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
16611863|NCT02535130|Experimental|Nebulization combined to positive expiratory pressure|Experimental arm
16611864|NCT02535130|Active Comparator|Nebulization|Control arm
16611900|NCT02534857|Experimental|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
16611865|NCT02535117|Experimental|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
16611866|NCT02535117|Active Comparator|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
16611867|NCT02535104|Experimental|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
16611868|NCT02535104|Placebo Comparator|Control|Vehicle - innert gel
16611869|NCT02535091|Experimental|YKP3089|Multiple dose
16611870|NCT02535078|Experimental|Arm 1|IMCgp100 with durvalumab (MEDI4736)
16611871|NCT02535078|Experimental|Arm 2|IMCgp100 with tremelimumab
16611872|NCT02535078|Experimental|Arm 3|IMCgp100 with durvalumab (MEDI4736) and tremelimumab
16611873|NCT02535078|Experimental|Arm 4|IMCgp100 (single agent)
16611874|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
16611875|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
16611876|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
16611877|NCT02535039|Placebo Comparator|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
16611878|NCT02535039|Experimental|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg * d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
16611879|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
16611880|NCT02535013|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
16611881|NCT02535013|Active Comparator|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
16611882|NCT02535000|Experimental|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
16611883|NCT02535000|Active Comparator|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
16611884|NCT02534987|Experimental|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
16611885|NCT02534987|No Intervention|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
16611886|NCT02534961|Active Comparator|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
16611887|NCT02534961|No Intervention|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
16611888|NCT02534948|Experimental|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
16611889|NCT02534948|No Intervention|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
16611890|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:
~≥12 to <18 months and ≥18 to <24 months"
16611891|NCT02534935|Active Comparator|Control|"Arm stratified by age:
~≥12 to <18 months and ≥18 to <24 months"
16611892|NCT02534922|Experimental|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
16611893|NCT02534909|Experimental|LFG316|During the treatment period, all patients will receive LFG316
16611894|NCT02534896|Experimental|Treatment 1: Sunpharma1505 (Low dose) and Placebo|
16611895|NCT02534896|Experimental|Treatment II: Sunpharma1505 (High Dose) and Placebo|
16611896|NCT02534896|Active Comparator|Treatment III: Reference1505 and Placebo|
16611897|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
16611898|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
16611901|NCT02534857|Placebo Comparator|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
16611902|NCT02534844|Experimental|Parts A/B: Sham Control|Participants receive no study drug
16611903|NCT02534844|Other|Parts A/B: Adrabetadex|Participants receive adrabetadex
16611904|NCT02534831|Experimental|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
16611905|NCT02534818|Experimental|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
16611906|NCT02534818|Active Comparator|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
16611907|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
16611908|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
16611909|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
16611910|NCT02534779|Experimental|Placebo Vaginal Insert|Placebo insert
16611911|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
16611912|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
16611913|NCT02534753|Experimental|Single Group|
16611914|NCT02534740|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
16611915|NCT02534740|Experimental|48.8 mg tafamidis soft gel capsule formulation 1|
16611916|NCT02534740|Experimental|48.8 mg tafamidis soft get capsule formulation 2|
16611917|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 1|
16611918|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 2|
16611919|NCT02534727||Sputum and blood participants|These participants will contribute both blood and sputum to the study
16611920|NCT02534727||Sputum only participants|These participants will only contribute sputum to the study
16611921|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
16611922|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.
~(Screening period July 1, 2015-June 30, 2016)
~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
16611923|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
16611924|NCT02534688|Experimental|LNG-IUS group|Single intervention LNG IUS
16611925|NCT02534688|Experimental|DMPA group|Three intervention DmPA 12 wk apart
16611926|NCT02534662|Experimental|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
16611927|NCT02534649|Other|Experimental|Newly obtained biopsy and Blood samples collection
16611928|NCT02534636|Experimental|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
16611929|NCT02534636|Experimental|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
16611930|NCT02534636|Experimental|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
16611931|NCT02534636|Experimental|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
16611932|NCT02534623|Active Comparator|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
16611933|NCT02534623|Active Comparator|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
16611934|NCT02534610|Experimental|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
16611935|NCT02534610|Experimental|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
16611936|NCT02534610|Placebo Comparator|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
16611937|NCT02534597|Experimental|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
16611938|NCT02534597|Experimental|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
16611939|NCT02534597|Experimental|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
16611940|NCT02534597|Experimental|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
16611941|NCT02534597|Experimental|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
16611942|NCT02534597|Experimental|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
16611943|NCT02534597|Experimental|_pt|Receives the delayed Promotores training, followed by technical assistance.
16611944|NCT02534597|Experimental|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
16611945|NCT02534597|Experimental|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
16611946|NCT02534597|Experimental|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
16611947|NCT02534571|Experimental|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, <=150gm , once
16611948|NCT02534571|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clip or4 pulse , once only
16611949|NCT02534558|Experimental|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
16611950|NCT02534558|Experimental|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
16611951|NCT02534545|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
16611952|NCT02534545|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
16611953|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
16611954|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
16611955|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
16611956|NCT02534506|Experimental|Urelumab (+ Nivolumab) intravenous (IV) infusion|
16611957|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
16611958|NCT02534480|Active Comparator|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
16611959|NCT02534480|Active Comparator|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
16611960|NCT02534480|Active Comparator|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
16611961|NCT02534480|Active Comparator|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
16611962|NCT02534480|Active Comparator|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
16611963|NCT02534467|Experimental|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
16611964|NCT02534467|Active Comparator|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
16611965|NCT02534454|Experimental|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
16611966|NCT02534454|Experimental|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
16611967|NCT02534454|Experimental|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
16611968|NCT02534454|Experimental|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
16611969|NCT02534441|Experimental|Skin patch testing to 6 known and 3 novel surfactants|
16611970|NCT02534428|Experimental|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
16611971|NCT02534428|Active Comparator|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
16611972|NCT02534415|Active Comparator|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
16611973|NCT02534415|Experimental|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
16611974|NCT02534415|Experimental|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
16611975|NCT02534402|Experimental|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
16611976|NCT02534402|No Intervention|Control Group|no treatment
16611977|NCT02534389|Experimental|fish oil group|4 soft gel with omega-3 fish oil
16611978|NCT02534389|No Intervention|control group|without intervention
16611979|NCT02534376|Experimental|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
16611980|NCT02534363|Active Comparator|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
16611981|NCT02534363|Active Comparator|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
16611982|NCT02534363|Active Comparator|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
16611983|NCT02534350|Experimental|Presatovir|Presatovir 200 mg (4 x 50 mg) on Day 1, followed by 100 mg (2 x 50 mg) from Day 2 to Day 14
16611984|NCT02534350|Placebo Comparator|Placebo|Placebo tablets for a total of 14 days
16611985|NCT02534337|Experimental|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
16611986|NCT02534337|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
16611987|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
16611988|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
16611989|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks.
16611990|NCT02534298|Experimental|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
16611991|NCT02534298|Other|control group|Normal hearing subject functional magnetic resonance imaging
16611992|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
16611993|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
16611994|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
16611995|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
16611996|NCT02534246|Experimental|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
16611997|NCT02534246|Experimental|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
16611998|NCT02534233|Experimental|CryoBalloon ablation|Patients having ablation of dysplastic tissue in esophagus.
16611999|NCT02534220|Active Comparator|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
16612000|NCT02534220|Experimental|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
16612001|NCT02534207|Experimental|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
16612002|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
16612003|NCT02534181|Active Comparator|Intervention group|"Patients will undergo a caloric management protocol:
~Days 1 and 2:
~Reduction of caloric intake to 5kcal/kg/day;
~Replacement of serum phosforus, potassium and magnesium;
~Administration of 100mg intravenous thiamine, vitamins and microelements.
~From day 3:
~If serum phosphorus < 2.5mg/dL, protocol will be followed according to day 2;
~If serum phosphorus > 2.5mg/dL, a gradual increase to target caloric intake will ensue."
16612004|NCT02534181|No Intervention|Control group|"Nutritional management will be followed according to institutional protocol.
~Electrolyte replacement will be provided at the clinician's discretion."
16612005|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
16612006|NCT02534155|Active Comparator|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
16612007|NCT02534155|Active Comparator|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
16612008|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
16612009|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
16612010|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
16612011|NCT02534116|Experimental|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
16612012|NCT02534116|Active Comparator|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
16612013|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
16612014|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
16612015|NCT02534077|Experimental|1|Drug: Omegaven
16612016|NCT02534064|Experimental|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
16612017|NCT02534064|Experimental|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
16612018|NCT02534064|No Intervention|Group C: No yogurt|no changes in dietary habits during 24 weeks.
16612019|NCT02534051|Active Comparator|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
16612020|NCT02534051|No Intervention|Usual Care|The control group will receive the usual prenatal care.
16612021|NCT02534038|Placebo Comparator|Placebo|Placebo drug to be taken twice a day for 6 weeks
16612022|NCT02534038|Active Comparator|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
16612023|NCT02534025|Experimental|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
16612024|NCT02534025|No Intervention|C group|no intervention will be added to routine anesthetic mangement
16612025|NCT02534012|Experimental|PVB group|Patients will receive nerve stimulator guided paravertebral block
16612026|NCT02534012|Experimental|GA group|Patients will receive general anesthesia
16612027|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
16612367|NCT02531815|Experimental|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
16612028|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
16612029|NCT02533986|Placebo Comparator|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
16612030|NCT02533986|Experimental|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
16612031|NCT02533973|Active Comparator|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
16612032|NCT02533973|Active Comparator|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
16612033|NCT02533960||NOAC|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).
~Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs)."
16612034|NCT02533960||VKA|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).
~Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)"
16612035|NCT02533960||Without OAC|"Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.
~Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation."
16612036|NCT02533947|Experimental|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
16612037|NCT02533947|Other|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
16612038|NCT02533934|Experimental|Treatment with Sofosbuvir based HCV Therapy|Prospective and retrospective treatment for HCV
16612039|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
16612040|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
16612041|NCT02533908|Active Comparator|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
16612042|NCT02533908|Placebo Comparator|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
16612043|NCT02533895|Experimental|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.
~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
16612044|NCT02533895|Other|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
16612045|NCT02533882|Experimental|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
16612046|NCT02533882|Active Comparator|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
16612047|NCT02533882|No Intervention|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
16612048|NCT02533869|Experimental|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
16612049|NCT02533856|No Intervention|Usual Care|Discharge from emergency department by usual care
16612050|NCT02533856|Experimental|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
16612051|NCT02533843|Active Comparator|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
16612052|NCT02533843|Active Comparator|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
16612053|NCT02533843|Active Comparator|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
16612054|NCT02533830|Active Comparator|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
16612055|NCT02533830|Placebo Comparator|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
16612056|NCT02533817|Experimental|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
16612057|NCT02533817|Active Comparator|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
16612058|NCT02533791|Experimental|low dose group|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
16612059|NCT02533791|Experimental|high dose group|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
16612060|NCT02533791|Placebo Comparator|placebo group|placebo
16612061|NCT02533778|Experimental|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
16612062|NCT02533765|Experimental|Olaparib|Olaparib 300mg twice daily continuously
16612063|NCT02533752||Main Group|This an observational registry - there is only one group
16612064|NCT02533739|Experimental|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
16612065|NCT02533739|Sham Comparator|Control group|This group will consist of participants without vestibular/vertigo impairments.
16612066|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
16612067|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
16612068|NCT02533713|Experimental|Immediate gait training|Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
16612069|NCT02533713|Other|Delayed gait training|Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
16612070|NCT02533700|Experimental|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, epirubucin and prednisone),2 cycles of IVE(ifosfamide, epirubucin, etoposide)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
16612071|NCT02533700|Active Comparator|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,epirubucin and prednisone)
16612072|NCT02533687|Active Comparator|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
16612073|NCT02533687|Active Comparator|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
16612074|NCT02533687|Active Comparator|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
16612075|NCT02533674|Experimental|gemcitabine plus PM060184|
16612076|NCT02533661|Experimental|Family-centered intervention program|"The FCIP group received:
~In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.
~After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
16612077|NCT02533661|No Intervention|Usual care program|"The UCP group received:
~In-hospital intervention: environmental modulation and teaching of child development skills.
~After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
16612078|NCT02533648|Experimental|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
16612079|NCT02533648|Placebo Comparator|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
16612080|NCT02533635|Experimental|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
16612081|NCT02533635|Experimental|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
16612082|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
16612083|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
16612084|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
16612085|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
16612086|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
16612087|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
16612088|NCT02533570|Experimental|Brentuximab vedotin|4 dose groups
16612089|NCT02533570|Placebo Comparator|Placebo|Matching placebo
16612090|NCT02533557|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
16612091|NCT02533557|Active Comparator|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
16612092|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
16612155|NCT02533050|No Intervention|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10. After randomization, they will be not treated.
16612093|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
16612094|NCT02533518|Experimental|patients with lung cancer|
16612095|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
16612096|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
16612097|NCT02533492|Active Comparator|Vicryl|Vicryl suture for wound closure after total knee replacement
16612098|NCT02533492|Experimental|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
16612099|NCT02533479|Experimental|Caloric restriction|three alternate days weekly along 4 weeks.
16612100|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
16612101|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
16612102|NCT02533453|Experimental|Bydureon|exenatide once weekly
16612103|NCT02533440|Experimental|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
16612104|NCT02533440|Active Comparator|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
16612105|NCT02533427|Experimental|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.
~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
16612106|NCT02533414|Experimental|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
16612107|NCT02533414|Active Comparator|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
16612108|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
16612109|NCT02533388|Experimental|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
16612110|NCT02533388|Sham Comparator|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
16612111|NCT02533375|Experimental|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
16612112|NCT02533362|Experimental|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
16612113|NCT02533349|Active Comparator|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
16612114|NCT02533349|Placebo Comparator|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
16612115|NCT02533336|Experimental|DL+LLINs|DL treated with abamectin and fenpyroximate
16612116|NCT02533336|No Intervention|LLINs|LLINs only
16612117|NCT02533323|Experimental|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
16612118|NCT02533310|Experimental|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
16612119|NCT02533310|Experimental|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
16612120|NCT02533297|Experimental|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
16612121|NCT02533284|Experimental|Magnesium sulfate group|US guided TAP with magnesium sulfate
16612122|NCT02533284|Experimental|B group|TAP bupevecaine
16612123|NCT02533284|Placebo Comparator|C group|control TAP saline
16612156|NCT02533050|No Intervention|Control group|Patients with CAD but without SAS (AHI<15).
16612157|NCT02533037|Active Comparator|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
16612158|NCT02533037|Experimental|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
16612368|NCT02531815|Experimental|Cohort 2 (SC) PF-06741086, Placebo|
16612124|NCT02533271|Experimental|TNT group|The intervention of TNT group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
16612125|NCT02533271|Other|CRT group|The intervention of CRT group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
16612126|NCT02533245|Experimental|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.
~Intervention:
~Home-based individualized exercise training program
~Supervised group training sessions
~Climb of the Mont Ventoux"
16612127|NCT02533245|No Intervention|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
16612128|NCT02533245|Experimental|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.
~Intervention:
~Supervised group training sessions
~Climb of the mont ventoux"
16612129|NCT02533232|Placebo Comparator|placebo|Matching placebo for Minocycline
16612130|NCT02533232|Experimental|Minocycline|Minocycline 200mg once a day orally
16612131|NCT02533206|Experimental|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
16612132|NCT02533206|Active Comparator|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
16612133|NCT02533193|Active Comparator|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
16612134|NCT02533193|Active Comparator|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
16612135|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
16612136|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
16612137|NCT02533154|Experimental|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
16612138|NCT02533154|Active Comparator|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
16612139|NCT02533141|Experimental|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
16612140|NCT02533141|Placebo Comparator|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
16612141|NCT02533128|Placebo Comparator|Liberal blood pressure management|
16612142|NCT02533128|Active Comparator|Tight blood pressure management|
16612143|NCT02533102|Experimental|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
16612144|NCT02533102|Experimental|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
16612145|NCT02533102|Experimental|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
16612146|NCT02533102|Experimental|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
16612147|NCT02533102|Experimental|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
16612148|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
16612149|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
16612150|NCT02533076|Other|Cystinosis Patients|Cystinosis patients
16612151|NCT02533076|Other|Healthy volunteers|Healthy volunteers
16612152|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
16612153|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
16612154|NCT02533050|Experimental|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10. After randomization, they will be treated with CPAP treatment.
16612159|NCT02533024|Experimental|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
16612160|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
16612161|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
16612162|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
16612163|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612164|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612165|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612166|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612167|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612168|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612169|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612170|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
16612171|NCT02532985|Placebo Comparator|Negative control|No added fiber
16612172|NCT02532985|Active Comparator|Positive fiber control|90g positive control fiber
16612173|NCT02532985|Experimental|Novel fiber 30g|30g novel fiber
16612174|NCT02532985|Experimental|Novel fiber 60g|60g novel fiber
16612175|NCT02532985|Experimental|Novel fiber 90g|90g novel fiber
16612176|NCT02532972|Experimental|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
16612177|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
16612178|NCT02532946|Experimental|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
16612179|NCT02532946|No Intervention|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
16612180|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
16612181|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
16612182|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
16612183|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
16612184|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
16612185|NCT02532894|Experimental|Esmoke|Inhaling e-cigarette vapor
16612186|NCT02532894|No Intervention|Control|
16612187|NCT02532881|Experimental|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
16612188|NCT02532881|Placebo Comparator|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
16612189|NCT02532868|Experimental|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
16612211|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
16612212|NCT02532738|Experimental|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
16612213|NCT02532738|Experimental|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
16612190|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
16612191|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
16612192|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
16612193|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c<5.7%, BMI<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612194|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612195|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612196|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c<5.7%, No signs and history of T2D, and BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612197|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612198|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612199|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612200|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
16612201|NCT02532816|Experimental|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
16612202|NCT02532816|Active Comparator|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
16612203|NCT02532816|Placebo Comparator|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
16612204|NCT02532803|Experimental|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
16612205|NCT02532790|Experimental|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
16612206|NCT02532790|Experimental|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
16612207|NCT02532777|Experimental|Prednisone & Cyclophosphamide|"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).
~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
16612208|NCT02532777|Experimental|Prednisone & Mycophenolate mofetil|"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).
~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
16612209|NCT02532777|Experimental|Prednisone & Leflunomide|"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.
~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
16612210|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
16612369|NCT02531815|Experimental|Cohort 3 (SC) PF-06741086, Placebo|
16612214|NCT02532738|Placebo Comparator|Ctrl|Patients in this arms receive routine treatment with NS injection
16612215|NCT02532725||Lean|Men aged 35-55 years, having <20% body fat
16612216|NCT02532725||Obese|Men aged 35-55 years, having >29% body fat
16612217|NCT02532712|Experimental|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
16612218|NCT02532712|Placebo Comparator|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
16612219|NCT02532712|Experimental|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
16612220|NCT02532712|Placebo Comparator|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
16612221|NCT02532712|Experimental|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
16612222|NCT02532712|Placebo Comparator|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
16612223|NCT02532712|Experimental|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
16612224|NCT02532712|Placebo Comparator|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
16612225|NCT02532712|Experimental|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
16612226|NCT02532712|Placebo Comparator|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
16612227|NCT02532712|Experimental|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
16612228|NCT02532712|Placebo Comparator|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
16612229|NCT02532712|Experimental|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
16612230|NCT02532712|Placebo Comparator|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
16612231|NCT02532712|Experimental|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
16612232|NCT02532712|Placebo Comparator|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
16612233|NCT02532699|Active Comparator|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
16612234|NCT02532699|Placebo Comparator|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
16612235|NCT02532686|Experimental|DAAOI-2|DAAOI-2: 500-2000mg/d
16612236|NCT02532686|Placebo Comparator|placebo|
16612237|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or > 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
16612238|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
16612239|NCT02532660|Experimental|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
16612240|NCT02532660|Placebo Comparator|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
16612241|NCT02532660|Experimental|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
16612242|NCT02532647|Experimental|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
16612243|NCT02532647|Active Comparator|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
16612244|NCT02532647|Placebo Comparator|Placebo|"Placebo administered in double-blind manner.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
16612245|NCT02532634|Experimental|ramosetron, aprepitant, dexamethasone|"Ramosetron 0.3mg IV day1
~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3
~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
16612246|NCT02532634|Active Comparator|palonosetron, aprepitant, dexamethasone|"Palonosetron 0.25mg IV day1
~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3
~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
16612247|NCT02532621|Experimental|Venous InterGraft Connector|Venous InterGraft Connector will be implanted and used with a sutured arterial anastomosis to create a AV shunt for dialysis access.
16612248|NCT02532608|Experimental|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
16612249|NCT02532595|Active Comparator|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
16612250|NCT02532595|Experimental|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
16612251|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
16612252|NCT02532569|Other|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
16612253|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
16612254|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
16612255|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
16612256|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
16612257|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
16612258|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
16612259|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
16612260|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
16612261|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
16612262|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
16612263|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
16612264|NCT02532530|Other|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
16612265|NCT02532517|Experimental|Enterprise|
16612266|NCT02532504|Experimental|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
16612267|NCT02532504|No Intervention|Treatment As Usual|Treatment As Usual
16612268|NCT02532491|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
16612269|NCT02532491|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
16612270|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
16612271|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
16612272|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
16612273|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
16612274|NCT02532452|Experimental|Viral Specific VST Infusion|3rd party VST infusion
16612275|NCT02532439|Experimental|Patient group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
16612276|NCT02532439|Experimental|control group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
16612277|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2<55mmHg).
16612278|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
16612279|NCT02532413|Experimental|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.
~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
16612280|NCT02532413|Active Comparator|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
16612281|NCT02532413|Experimental|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.
~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
16612282|NCT02532413|Active Comparator|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
16612283|NCT02532400|Experimental|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
16612284|NCT02532400|Active Comparator|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
16612285|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.
~Intervention: Telephone follow-up at 7 and 30 days."
16612286|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.
~Intervention: Telephone follow-up at 7 and 30 days."
16612287|NCT02532387||Control subjects|"Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment
~Historical controls:
~Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.
~Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
16612288|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
16612289|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
16612290|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
16612291|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
16612292|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
16612294|NCT02532335|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
16612295|NCT02532335|Active Comparator|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
16612296|NCT02532335|Placebo Comparator|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
16612297|NCT02532322|Experimental|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
16612298|NCT02532322|Placebo Comparator|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
16612299|NCT02532309|Experimental|Rosuvastatin dose adjustment|
16612300|NCT02532309|Experimental|Rosuvastatin fixed dose|
16612301|NCT02532296|Active Comparator|Control|Receive usual hospital discharge, care transition and post-discharge care.
16612302|NCT02532296|Experimental|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
16612303|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
16612304|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
16612305|NCT02532270|Experimental|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
16612306|NCT02532270|Experimental|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
16612307|NCT02532257|Experimental|Treatment (lenalidomide, rituximab, ibrutinib)|Patients receive lenalidomide PO on days 1-21, rituximab IV over 4-6 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of all subsequent cycles, and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16612308|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line.
16612309|NCT02532231|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
16612310|NCT02532218|Active Comparator|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
16612311|NCT02532218|Placebo Comparator|Placebo|Matching Placebo 3g bid for 24 wks
16612312|NCT02532192|Experimental|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
16612313|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
16612314|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
16612315|NCT02532153|Other|Open-Label Ketamine|
16612316|NCT02532140|Experimental|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
16612317|NCT02532140|Experimental|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
16612318|NCT02532140|Experimental|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
16612319|NCT02532127|Experimental|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
16612320|NCT02532114|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
16612321|NCT02532101|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
16612322|NCT02532088|Active Comparator|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
16612323|NCT02532088|Placebo Comparator|Placebo|Placebo
16612324|NCT02532075|Experimental|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
16612325|NCT02532075|Experimental|Expiratory Warm Up|(EWU). Two sets of 15 breaths
16612326|NCT02532075|Experimental|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
16612327|NCT02532075|Other|Control Trial|No warm up
16612328|NCT02532062|Experimental|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
16612370|NCT02531815|Experimental|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
16612371|NCT02531815|Experimental|Cohort 5 (IV) PF-06741086, Placebo|
16612329|NCT02532062|Active Comparator|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
16612330|NCT02532049|Active Comparator|Group 1|ChAd63 Pfs25-IMX313 (5x10^9 vp)
16612331|NCT02532049|Active Comparator|Group 2A|ChAd63 Pfs25-IMX313 (5x10^10 vp)
16612332|NCT02532049|Active Comparator|Group 2B|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
16612333|NCT02532049|Active Comparator|Group 2C|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
16612334|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
16612335|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
16612336|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
16612337|NCT02532023|Active Comparator|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
16612338|NCT02532023|Active Comparator|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
16612339|NCT02532023|Placebo Comparator|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
16612340|NCT02532023|Placebo Comparator|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
16612341|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
16612342|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
16612343|NCT02531997|Active Comparator|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
16612344|NCT02531997|Other|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
16612345|NCT02531984|Experimental|Withdrawal of Azithromycin treatment|
16612346|NCT02531984|Other|ongoing Azithromycin treatment|
16612347|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
16612348|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
16612349|NCT02531958|Experimental|1 Egg|Consumption of 1 egg per day for 4 weeks
16612350|NCT02531958|Experimental|2 Eggs|Consumption of 2 eggs per day for 4 weeks
16612351|NCT02531958|Experimental|3 Eggs|Consumption of 3 eggs per day for 4 weeks
16612352|NCT02531945|Experimental|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.
~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
16612355|NCT02531919|Experimental|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
16612356|NCT02531906|Experimental|Arm I (gabapentin)|"Patients receive gabapentin PO TID for up to 7 weeks during radiotherapy.
~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
16612357|NCT02531906|Experimental|Arm II (gabapentin, methadone, oxycodone)|"Patients receive gabapentin PO TID, methadone hydrochloride PO BID, and oxycodone hydrochloride PO Q8H PRN for up to 7 weeks during radiotherapy.
~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
16612360|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
16612361|NCT02531854|Experimental|ADXS11-001 + Pemetrexed|
16612362|NCT02531854|Active Comparator|Pemetrexed Only|
16612363|NCT02531841|Active Comparator|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
~Rituximab 375 mg/m²/d i.v. (d0,5)
~Methotrexate 3.5 g/m² i.v. (d1)
~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
~Thiotepa 30 mg/m² i.v. (d4)
~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):
~Rituximab 375 mg/m²/d i.v. (d0)
~Dexamethasone 40 mg/d i.v. (d1-3)
~Etoposide 100 mg/m²/d i.v. (d1-3)
~Ifosfamide 1500 mg/m²/d i.v. (d1-3)
~Carboplatin 300 mg/m² i.v. (d1)"
16612364|NCT02531841|Active Comparator|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
~Rituximab 375 mg/m²/d i.v. (d0,5)
~Methotrexate 3.5 g/m² i.v. (d1)
~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
~Thiotepa 30 mg/m² i.v. (d4)
~Consolidation Treatment High-dose chemotherapy
~Carmustine* 400 mg/m² i.v. (d-6)
~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
~Autologous Stem Cell Transplantation (d0)
~*if not available at study site, Busulfan can be administered instead:
~Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))
~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
~Autologous Stem Cell Transplantation (d0)"
16612365|NCT02531828|Experimental|Biopolymer Film|Application of dressings for surgical correction.
16612366|NCT02531828|Active Comparator|Polyurethane Film, or the like|Application of dressings for surgical correction
16612375|NCT02531802|Experimental|Adult: ETVAX (Full)|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14
16612376|NCT02531802|Experimental|Adult: ETVAX (Full) + 10 ug dmLT|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
16612377|NCT02531802|Placebo Comparator|Adult: Placebo|Adult arm (18-45 year olds) receiving a placebo on days 0 and 14
16612378|NCT02531802|Experimental|24-59 months: ETVAX (1/4)|24-59 month old children receiving a quarter adult dose (2.5 x 10^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
16612379|NCT02531802|Experimental|24-59 months: ETVAX (1/2)|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
16612380|NCT02531802|Experimental|24-59 months: ETVAX (full)|24-59 month old children receiving a full adult dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
16612381|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 2.5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612382|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612383|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 10 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612384|NCT02531802|Placebo Comparator|24-59 months: Placebo|24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
16612385|NCT02531802|Experimental|12-23 months: ETVAX (1/4)|12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
16612386|NCT02531802|Experimental|12-23 months: ETVAX (1/2)|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
16612387|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612388|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612389|NCT02531802|Placebo Comparator|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
16612390|NCT02531802|Experimental|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
16612391|NCT02531802|Experimental|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
16612392|NCT02531802|Experimental|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
16612393|NCT02531802|Experimental|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612394|NCT02531802|Experimental|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
16612395|NCT02531802|Placebo Comparator|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
16612396|NCT02531789||Observation|45 patients receiving elective colorectal surgery
16612397|NCT02531776|Experimental|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
16612398|NCT02531763|No Intervention|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
16612399|NCT02531763|Active Comparator|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
16612400|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
16612401|NCT02531737|Experimental|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
16612402|NCT02531724|Active Comparator|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
16612403|NCT02531724|Placebo Comparator|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
16612404|NCT02531711|Experimental|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
16612405|NCT02531711|Active Comparator|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
16612689|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
16612406|NCT02531698|Experimental|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
16612407|NCT02531698|Other|Licensed pediatric hepatitis A vaccine|
16612408|NCT02531685|Experimental|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
16612409|NCT02531685|Experimental|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
16612410|NCT02531685|Experimental|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
16612411|NCT02531685|Experimental|Cohort 4|"A sentinel group of 5 subjects receive 2.0 mcg dmLT intradermally on days 1, 22, and 43. 1 subject receives placebo.
~Safety data from days 1-14 in sentinel will be reviewed and upon approval to proceed, 8 additional subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 2 subjects receive placebo."
16612412|NCT02531685|Experimental|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
16612413|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
16612414|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
16612415|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
16612416|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
16612417|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
16612418|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
16612419|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
16612420|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
16612421|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
16612422|NCT02531620|Experimental|Physiatry|Pre-operative Physiatry assessment and intervention
16612423|NCT02531620|Other|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
16612424|NCT02531594|Experimental|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.
~nicotine"
16612425|NCT02531594|Placebo Comparator|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
16612426|NCT02531581|Experimental|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output <500 cc / 24 at the 4th hour.
~Establishment of an infusion G5 500cc% in vein custody."
16612427|NCT02531581|Active Comparator|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
16612428|NCT02531568|Experimental|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
16612429|NCT02531555|Active Comparator|Group M|Mechanical periodontal treatment (Group M): Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
16612430|NCT02531555|Experimental|Group L|Pocket disinfection with diode laser (Group L): Subgingival irradiation with a GaAlAs diode laser (CHEESE®, Gigaa Laser, China) was applied to residual pockets each for 20 sec in continious mode. The diode laser had a wavelenght of 810 nm and power output of 1 W for subgingival irradiation (Maximum output power of device was 7 W). Diode laser application was performed parallel to root surface by a 200 µm fiber tip inserted at the bottom of periodontal pocket and slowly moved from apical to coronal direction in a sweeping motion without local anesthesia.
16612431|NCT02531555|Experimental|Group M+L|Combined treatment (Group M+L): Following mechanical periodontal treatment, pocket irradiation with diode laser was performed as mentioned above.
16612432|NCT02531542|Other|READ echography|
16612433|NCT02531529|Experimental|D group|intraoperative dexmedetomedine infusion
16612434|NCT02531529|Sham Comparator|F group|Intraoperative fentanyl infusion
16612435|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
16612436|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
16612437|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
16612438|NCT02531490|Active Comparator|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
16612439|NCT02531490|No Intervention|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
16612440|NCT02531490|No Intervention|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
16612441|NCT02531477|Experimental|experimental group|Intracarotid injection of propofol to detect efficacy and safety as a novel route for drug delivery
16612442|NCT02531464|Experimental|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
16612443|NCT02531464|No Intervention|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
16612444|NCT02531451|Experimental|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
16612445|NCT02531451|Active Comparator|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
16612446|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
16612447|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
16612448|NCT02531425|Experimental|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
16612449|NCT02531412|Experimental|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
16612450|NCT02531412|Placebo Comparator|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
16612451|NCT02531399|Experimental|Healthy Subjects|20 healthy female and male volunteers, age 18-45 years, non-smokers. Measurements with FDOCT, DVA, LDV and LSFG will be done in all healthy subjects.
16612452|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
16612453|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
16612454|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
16612455|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
16612456|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
16612457|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
16612458|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
16612459|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
16612460|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
16612461|NCT02531360|Experimental|[18F]MNI-815 (MNI-815)|At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815
16612462|NCT02531347|Experimental|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
16612463|NCT02531347|Active Comparator|Conventional blood pressure monitoring|Conventional blood pressure monitoring
16612464|NCT02531334|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
16612465|NCT02531334|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
16612690|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
16612466|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
16612467|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
16612468|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.
~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
16612469|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
16612470|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
16612471|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
16612472|NCT02531282|Experimental|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
16612473|NCT02531282|Active Comparator|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
16612474|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
16612475|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
16612476|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
16612477|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
16612478|NCT02531256|Experimental|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
16612479|NCT02531243|Experimental|CALMS|12 session family therapy using multi-user biofeedback games
16612480|NCT02531217|Experimental|ATYR1940|ATYR1940 will be given intravenously at a dose of 3.0 mg/kg, weekly
16612481|NCT02531204|Experimental|ASP1585 granules preceding group|
16612482|NCT02531204|Active Comparator|ASP1585 capsules preceding group|
16612483|NCT02531191|Experimental|New Tablet Preceding Group|Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
16612484|NCT02531191|Experimental|Current Tablet Preceding Group|Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
16612485|NCT02531178|Experimental|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
16612486|NCT02531178|Experimental|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
16612487|NCT02531178|Experimental|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
16612488|NCT02531165|Experimental|Morphine|"Pre-hospital Ticagrelor 180 mg loading dose orally.
~Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.
~Aspirin 500 mg loading dose orally (or intravenously).
~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
~Primary PCI."
16612489|NCT02531165|Experimental|Fentanyl|"Pre-hospital Ticagrelor 180 mg loading dose orally.
~Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.
~Aspirin 500 mg loading dose orally (or intravenously).
~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
~Primary PCI."
16612490|NCT02531152|Experimental|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
16612491|NCT02531152|Experimental|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
16612492|NCT02531152|Experimental|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
16612493|NCT02531152|Experimental|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
16612494|NCT02531152|Experimental|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
16612495|NCT02531152|Active Comparator|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
16612496|NCT02531139|Experimental|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
16612497|NCT02531139|Active Comparator|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
16612498|NCT02531126|Experimental|RPC0163 (Ozanimod)|
16612499|NCT02531113|Experimental|RPC1063 (Ozanimod)|
16612500|NCT02531100|Experimental|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
16612501|NCT02531100|Other|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
16612502|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
16612503|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
16612504|NCT02531074|Experimental|Mobile Application plus Usual Care|
16612505|NCT02531074|Active Comparator|Food Journal plus Usual Care|
16612506|NCT02531061|Experimental|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
16612507|NCT02531061|Experimental|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
16612508|NCT02531048|Experimental|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :
~laser stimulations on lower limbs
~laser stimulations cervical
~20 laser stimulations for each site on the upper limbs
~laser stimulations on face and neck"
16612509|NCT02531035|Placebo Comparator|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
16612510|NCT02531035|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
16612511|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
16612512|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
16612513|NCT02531009||Healthy|Approximately 10 healthy adults will be enrolled into this study
16612514|NCT02531009||SSc|Participants with dcSSc and lcSSc
16612515|NCT02530996|Experimental|Placebo before BH4|Six SSc received oral placebo 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral BH4 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
16612516|NCT02530996|Experimental|BH4 before Placebo|Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral placebo 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
16612517|NCT02530983||Esophagectomy/Esophageal Reconstruction|Patients who have undergone esophagectomy or esophageal reconstruction
16612518|NCT02530957|Experimental|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
16612519|NCT02530957|Other|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
16612520|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
16612521|NCT02530931|Experimental|patients with Meniere's disease|
16612522|NCT02530918|Experimental|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
16612523|NCT02530918|Experimental|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
16612524|NCT02530918|Active Comparator|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
16612525|NCT02530918|Experimental|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
16612526|NCT02530918|Experimental|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
16612527|NCT02530918|Experimental|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
16612528|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
16612529|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
16612530|NCT02530905|Experimental|SRP-4045 (open label extension period)|All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
16612531|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
16612532|NCT02530879|Experimental|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
16612533|NCT02530879|Active Comparator|Antireflux medication|"Intervention includes treatment with one of the following:
~Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day
~Lansoprazole-Dose range 15mg per day- 30mg twice a day
~Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day
~Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.
~Rantidine may be used in combination with any of the above"
16612534|NCT02530879|Experimental|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
16612535|NCT02530866|Active Comparator|Standard care|Women in this arm will target fasting blood glucose values <95 mg/dL and 1 hour post-prandial values <140 mg/dL
16612536|NCT02530866|Experimental|Intensive therapy|Women in the arm will target fasting blood glucose values <90 mg/dL and 1 hour post-prandial values <120 mg/dL.
16612539|NCT02530840|Experimental|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
16612540|NCT02530840|Experimental|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
16612541|NCT02530840|Experimental|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
16612542|NCT02530840|No Intervention|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
16612543|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
16612544|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
16612545|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
16612546|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
16612547|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
16612548|NCT02530801|Other|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
16612549|NCT02530788|Active Comparator|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
16612550|NCT02530788|Placebo Comparator|Placebo|Placebo arm receiving Sodium Chloride solution
16612551|NCT02530775|Active Comparator|instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion with use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
16612552|NCT02530775|Active Comparator|non-instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion without the use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
16612553|NCT02530762|Placebo Comparator|Negative control|No added fiber
16612554|NCT02530762|Active Comparator|Positive Fiber control|50g positive control fiber
16612555|NCT02530762|Experimental|Novel Fiber 10g|10g novel fiber
16612556|NCT02530762|Experimental|Novel Fiber 30g|30g novel fiber
16612557|NCT02530762|Experimental|Novel Fiber 50g|50g novel fiber
16612558|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
16612559|NCT02530723|Experimental|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
16612560|NCT02530723|Experimental|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
16612561|NCT02530723|Experimental|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
16612562|NCT02530723|No Intervention|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
16612563|NCT02530710|Experimental|Q203|Q203 drug products (10mg and 100mg tablets)
16612564|NCT02530710|Placebo Comparator|Placebo|Placebo tablets (same excipients used in Q203 drug products)
16612565|NCT02530697|Active Comparator|Group 1 - Mucosal Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 400mg 3x/daily for 28 days.
16612566|NCT02530697|Experimental|Group 2 - Mucosal Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Oral Pentoxifylline 400mg 3x/daily for 28 days.
16612567|NCT02530697|Experimental|Group 3 - Cutaneous Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 20 days Oral Pentoxifylline 400mg 3x/daily for 20 days.
16612568|NCT02530697|Experimental|Group 4 - Cutaneous Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily Oral Pentoxifylline 400mg 3x/daily for 20 days.
16612569|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
16612570|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
16612571|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
16612572|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
16612573|NCT02530658||Participants|"St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative.
~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
16612892|NCT02528422|Active Comparator|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
16612574|NCT02530645|Experimental|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
16612575|NCT02530645|Active Comparator|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
16612576|NCT02530632|Active Comparator|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
16612577|NCT02530632|Experimental|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
16612578|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16612579|NCT02530606|Experimental|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
16612580|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
16612581|NCT02530580|Experimental|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
16612582|NCT02530580|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
16612583|NCT02530567|Experimental|Intervention|"The measurement of portosystemic pressure gradient will be performed before liver biopsy.
~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.
~The MRI machine used is the Siemens 3T."
16612584|NCT02530554|Experimental|CHG Cloth|3 min application time
16612585|NCT02530554|Active Comparator|Comparator CHG|Marketed 2% CHG
16612586|NCT02530541|Experimental|CHG 1 min|1 min application time
16612587|NCT02530541|Experimental|CHG 2 min|2 min application time
16612588|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
16612589|NCT02530528|Experimental|2% CHG 1 min|single administration, 1 min application time
16612590|NCT02530528|Experimental|2% CHG 2 min|single administration, 2 min application time
16612591|NCT02530528|Experimental|2% CHG 3 min|single administration, 3 min application time
16612592|NCT02530528|Active Comparator|Comparator 2% CHG|Single administration, Marketed CHG
16612593|NCT02530515|Experimental|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
16612594|NCT02530502|Experimental|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.
~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
16612595|NCT02530489|Experimental|Treatment (atezolizumab, nab-paclitaxel)|"NEOADJUVANT: Patients receive atezolizumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo definitive breast surgery within 6 weeks of the completion of treatment.
~ADJUVANT: Within 4 weeks after surgery, patients receive atezolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
16612596|NCT02530476|Experimental|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.
~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.
~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
16612597|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.
~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
16612598|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.
~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
16612599|NCT02530476|Experimental|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.
~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.
~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
16612600|NCT02530463|Experimental|Cohort I (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.
16612601|NCT02530463|Experimental|Cohort II (ipilimumab)|Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.
16612602|NCT02530463|Experimental|Cohort III (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.
16612603|NCT02530463|Experimental|Cohort IV (azacitidine, nivolumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16612893|NCT02528422|Placebo Comparator|Isotonic Sodium Chloride|Intravenous injection on examination day.
16612604|NCT02530463|Experimental|Cohort V (azacitidine, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16612605|NCT02530463|Experimental|Cohort VI (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16612606|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
16612607|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
16612608|NCT02530437|Experimental|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
16612609|NCT02530437|Experimental|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
16612610|NCT02530424|Experimental|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
16612611|NCT02530411|Experimental|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
16612612|NCT02530411|Placebo Comparator|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
16612613|NCT02530398|Experimental|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
16612614|NCT02530385|Experimental|FMT|Active FMT capsules
16612615|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
16612616|NCT02530372|Experimental|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.
~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.
~The UriCap is held in position by means of a single-use medically approved adhesive tape."
16612617|NCT02530359|Active Comparator|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
16612618|NCT02530359|Active Comparator|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
16612619|NCT02530359|Placebo Comparator|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
16612620|NCT02530346|Active Comparator|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.
~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
16612621|NCT02530346|Experimental|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
16612622|NCT02530333|No Intervention|Basketball Control|Control group of basketball players
16612623|NCT02530333|Experimental|Basketball intervention|Intervention group of basketball players
16612624|NCT02530333|No Intervention|Soccer Control|Control group of soccer players
16612625|NCT02530333|Experimental|Soccer Intervention|intervention group of soccer players
16612626|NCT02530320|Experimental|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
16612627|NCT02530307|Experimental|HT-3951 (15mg)|HT-3951 capsules administered once daily
16612628|NCT02530307|Placebo Comparator|Placebo|Placebo capsules administered once daily
16612629|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
16612630|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
16612631|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
16612632|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
16612633|NCT02530268||Ankylosing Spondylitis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
16612634|NCT02530268||Psoriatic Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
16612635|NCT02530255|Placebo Comparator|Placebo|Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
16612636|NCT02530255|Active Comparator|cycloastragenol|Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
16612637|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
16612638|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
16612639|NCT02530229||Periprosthetic joint infection|Patients with suspected periprosthetic joint infection of the hip, knee and shoulder
16612640|NCT02530229||Septic arthritis|Patients with suspected septic arthritis of a native joint of the hip, knee and shoulder
16612641|NCT02530216|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
16612688|NCT02529904|Experimental|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.
~Adult participants will receive one dose of MF59-ATIV."
16612642|NCT02530216|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
16612643|NCT02530203|Other|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
16612644|NCT02530203|Experimental|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
16612645|NCT02530190|No Intervention|Control|20 minutes of supine rest
16612646|NCT02530190|Active Comparator|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
16612647|NCT02530190|Active Comparator|Massage|20 minutes of massage therapy
16612648|NCT02530177||Patients having CYTOTOXIC CHEMOTHERAPY|Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.
16612649|NCT02530177||Patients having ENDOCRINE THERAPY|Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.
16612650|NCT02530177||COMPARATOR (menopausal women)|Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.
16612651|NCT02530164|Active Comparator|real tDCS|
16612652|NCT02530164|Placebo Comparator|sham tDCS|
16612653|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
16612654|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
16612655|NCT02530138|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
16612656|NCT02530138|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
16612657|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
16612658|NCT02530112||Phase 1|First round of survey respondents.
16612659|NCT02530112||Phase 2|Second round of survey respondents.
16612660|NCT02530112||Phase 3|Third round of survey respondents.
16612661|NCT02530099|No Intervention|Control group|Receive no training.
16612662|NCT02530099|Experimental|CN-group|Receive basic camera navigation training.
16612663|NCT02530099|Experimental|Procedure-group|Receive training on a laparoscopic procedure.
16612664|NCT02530086|Active Comparator|Placement of a Nasogastric tube|Placement of a Nasogastric tube
16612665|NCT02530086|Experimental|No placement of a Nasogastric tube|No placement of a Nasogastric tube
16612666|NCT02530073|Experimental|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)
16612667|NCT02530060|Experimental|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
16612668|NCT02530047|Experimental|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
16612669|NCT02530034|Experimental|Treatment (Hu8F4)|Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16612670|NCT02530021||Heart rate monitor|"Hospitalized patients with chest pain and suspected ischemic heart disease who are candidates for non invasive exercise stress test by their treating physician.
~The patients will perform a one hour heart rate variability monitoring prior to the stress test."
16612671|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
16612672|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
16612673|NCT02529982|Active Comparator|intervention|500 mg curcumin capsule
16612674|NCT02529982|Placebo Comparator|control|placebo
16612675|NCT02529969|Active Comparator|intervention|500 mg curcumin capsule
16612676|NCT02529969|Placebo Comparator|placebo|500 mg placebo
16612677|NCT02529956|Experimental|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
16612678|NCT02529956|Experimental|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
16612679|NCT02529956|Experimental|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
16612680|NCT02529956|Experimental|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
16612681|NCT02529956|Experimental|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
16612682|NCT02529956|Placebo Comparator|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
16612683|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
16612684|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
16612685|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
16612691|NCT02529878|Experimental|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
16612692|NCT02529865|Experimental|ADRCs and Adipose tissue|Periurethral injection of autologous adipose derived regenerative cells and adipose tissue
16612693|NCT02529852|Experimental|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.
~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.
~Each study cycle is 21 days."
16612694|NCT02529839|Experimental|Experimental|"Fludarabine 30mg/m2 for 4 days, Cyclophosphamide 50mg/kg for 2 days, Alemtuzumab administered subcutaneously 24mg total dose.
~Autologous bone marrow transplantation"
16612695|NCT02529826|Experimental|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
16612696|NCT02529813|Experimental|Arm I (CD19 positive chimeric antigen receptor T-cells)|"LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of fludarabine phosphate IV over 1 hour and cyclophosphamide IV over 3 hours on days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the treating physician.
~Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0 and 1."
16612697|NCT02529800|Experimental|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
16612698|NCT02529800|Experimental|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
16612699|NCT02529800|Experimental|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
16612700|NCT02529787|Experimental|A Test|Test drug (Doxirazole) 1 capsule contains 60 mg of Dexlansoprazole
16612701|NCT02529787|Active Comparator|B Reference|Reference drug (Dexilant) 1 capsule contains 60 mg of Dexlansoprazole
16612702|NCT02529774|Experimental|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
16612703|NCT02529774|Active Comparator|Systemic Chemotherapy|
16612704|NCT02529761|Experimental|Sorafenib combined with TACE|220 subjects in this study group will receive the treatment of sorafenib combined with conventional TACE.
16612705|NCT02529761|Active Comparator|TACE monotherapy|110 subjects in this study group will receive the treatment of conventional TACE monotherapy.
16612706|NCT02529748|Experimental|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
16612707|NCT02529709|Experimental|High-protein meal condition|
16612708|NCT02529709|Active Comparator|High-monounsaturated fat meal condition|
16612709|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
16612710|NCT02529683|Experimental|Nuvaring (only arm)|Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
16612711|NCT02529670|Experimental|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
16612712|NCT02529670|Active Comparator|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
16612713|NCT02529670|Active Comparator|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
16612714|NCT02529657|Placebo Comparator|Placebo|23 patients were induced to think they will be getting the same treatment, although the LLLT is not operating.
16612715|NCT02529657|Experimental|Low level Laser Therapy|25 patients were submitted to spine surgery and have received low level laser therapy during surgery, 24 hours after surgery and 48 hours after surgery.
16612716|NCT02529644|Active Comparator|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
16612717|NCT02529644|Experimental|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
16612718|NCT02529631|Active Comparator|Drug: orlistat 60mg capsules|"A tailored blister-strip for one day contains
~three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with
~six placebo tablets Administration: 3 times daily 2 tablets with each main meal"
16613037|NCT02527473|No Intervention|Standard Education Group|Control group will receive standard basic life support training for one hour.
16612719|NCT02529631|Active Comparator|Medical device: polyglucosamine|"A tailored blister-strip for one day contains
~three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with
~six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine"
16612720|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.
~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
16612721|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.
~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
16612722|NCT02529605|Active Comparator|Product B® IsaGenesis®, Then IsaGenesis®|Participants will come into the clinic in a fasting state to receive the Product B® IsaGenesis®, which will be a one time dose of the liquid-gel formulation contained in 2 capsules, 1280 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the IsaGenesis®. This will be given for a comparison in a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule.
16612723|NCT02529605|Active Comparator|IsaGenesis®, Then Product B® IsaGenesis®|Participants will come into the clinic in a fasting state to receive the IsaGenesis®, which will be a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the Product B® IsaGenesis®. This will be given for a comparison in a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
16612724|NCT02529592|Experimental|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
16612725|NCT02529592|Placebo Comparator|Placebo|Placebo administered intravenously
16612726|NCT02529579|Active Comparator|Gemcitabine|Standard Gemcitabine Therapy
16612727|NCT02529579|Experimental|cellular immunotherapy & Gemcitabine|iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
16612728|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.
~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
16612729|NCT02529540|Other|Group 1|Self-refraction with adjustable glasses
16612730|NCT02529540|Other|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
16612731|NCT02529540|Other|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
16612732|NCT02529527|Experimental|MyFamilyPlan|Web-based health education tool (interactive self-assessment) provided for participant completion 7-10 days prior to a scheduled primary care visit.
16612733|NCT02529527|No Intervention|Control|Standard preconception health education document provided for participant review 7-10 days prior to a scheduled primary care visit.
16612734|NCT02529514|Active Comparator|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
16612735|NCT02529514|Placebo Comparator|Placebo|Placebo per os for 7 days at 10 pm every day
16612736|NCT02529501||SA|Patients undergoing spinal anesthesia
16612737|NCT02529501||GA|Patients undergoing short general anesthesia
16612738|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
16612739|NCT02529475|Experimental|Gadoteric acid|Gadoteric acid 0.2 mmol/kg
16612740|NCT02529462|Experimental|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
16612741|NCT02529462|Active Comparator|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
16612742|NCT02529449|Placebo Comparator|Placebo|once daily
16612743|NCT02529449|Experimental|ASP1941 Low dose group|once daily
16612744|NCT02529449|Experimental|ASP1941 Middle dose group|once daily
16612745|NCT02529449|Experimental|ASP1941 High dose group|once daily
16612746|NCT02529423|Placebo Comparator|Placebo|Placebo
16612747|NCT02529423|Experimental|Multi-nutrient supplement|Multi-nutrient supplement
16612748|NCT02529423|Experimental|Placebo + Behavioral Activation|Placebo + Behavioral Activation
16612749|NCT02529423|Experimental|Multi-nutrient + Behavioral Activation|Multi-nutrient + Behavioral Activation
16612750|NCT02529410|Experimental|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
16612751|NCT02529410|Active Comparator|Biventricular leads|1 left ventricular lead and one right ventricular lead
16612752|NCT02529397|Experimental|Adaptive Working Memory Training|The experimental group will receive working memory training through a commercial computerized program: five weeks of adaptive working memory training concurrently with a behavioral weight loss program. Adaptive working memory training becomes progressively more challenging depending on an individual's performance on a given task. They will attend weekly classes of a behavioral weight loss program.
16612753|NCT02529397|Placebo Comparator|Non-adaptive Working Memory Training|The control group will receive five weeks of non-adaptive (placebo) cognitive training concurrent with the identical behavioral weight loss program as in the experimental group. Non-adaptive cognitive training remains at a constant level.
16612754|NCT02529384||malignant group|The lesion which is malignant tumors in breast
16612755|NCT02529384||begin group|The lesion which is begin lesion in breast
16612756|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
16612757|NCT02529371|Experimental|UriCap-RM|The device is comprised of a reusable part and a single use adhesive tape. The device is removed once daily and the reusable part is rinsed, dried and reapplied with a new adhesive tape.
16612758|NCT02529358|Experimental|EG stand|Standardized text messages
16612759|NCT02529358|Experimental|EG ind|Personalized text messages
16612760|NCT02529358|Other|Control|Standardized text messages after 10 weeks
16612761|NCT02529345|Experimental|RoadSaver stent|patient treated with the RoadSaver stent of Terumo
16612762|NCT02529332|Experimental|Omega-3 Supplementation Group|Omega-3 supplementation
16612763|NCT02529332|No Intervention|Control Group|
16612764|NCT02529319|Experimental|MRI-Guided Ablation|"Surgery
~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
16612765|NCT02529319|Active Comparator|Conventional Ablation|"Surgery
~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
16612766|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
16612767|NCT02529293|Active Comparator|BioChaperone Lispro U-100|injection of 2 doses of 0.2 U/kg on separate visits
16612768|NCT02529293|Experimental|BioChaperone Lispro U-200|injection of 2 doses of 0.2 U/kg on separate visits
16612769|NCT02529280|Experimental|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
16612770|NCT02529280|No Intervention|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
16612771|NCT02529267||Experienced abuse|Experienced IPV in the past 12 months
16612772|NCT02529267||Did not experience abuse|Did not experience IPV in the past 12 months.
16612773|NCT02529254|Experimental|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
16612774|NCT02529254|No Intervention|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
16612775|NCT02529241|Experimental|Group 1: LCB01-0371|Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
16612776|NCT02529241|Experimental|Group 2: LCB01-0371|Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
16612777|NCT02529228|Experimental|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
16612778|NCT02529228|Experimental|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
16612779|NCT02529228|Experimental|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
16612780|NCT02529228|Experimental|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
16612781|NCT02529215|Experimental|Just-in-time training (JITT) group|Receive a 20min just-in-time simulation-based teaching session targeting: (1) CPR quality and (2) medication administration within 3 hours of the scheduled in situ simulation.
16612782|NCT02529215|No Intervention|No additional training (control) group|Control group who receives no additional training.
16612783|NCT02529202|Experimental|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
16612784|NCT02529189|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
16612785|NCT02529189|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
16612786|NCT02529176|Experimental|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
16612787|NCT02529176|No Intervention|No alert|Physicians will receive no best-practice alert from the electronic medical record.
16612788|NCT02529163|Active Comparator|Late-life Schizophrenia ICP|"The Late-Life Schizophrenia ICP arm will follow a medication algorithm composed of 3 trials and titration schedule with prompts.
~First trial is Risperidone (2- 4mg daily).
~Second trial: Quetiapine (100 - 400mg daily) OR Aripiprazole (100 - 200mg daily) OR OR Ziprasidone (80mg daily) OR Loxapine (100mg daily)
~Third trial: Clozapine (450mg daily) or Olanzapine (20mg daily)
~If non compliant depot preparation of: Paliperidone (50 - 150mg monthly), Risperidone (12.5 - 50mg q 2 weeks), Flupentixol (10 - 20mg q 2-3 weeks) or Aripiprazole ( up to 400mg monthly)
~Prompts will be given to for non-pharmacological interventions such as:
~metabolic monitoring
~skin hygiene
~pain management
~nutritional counseling
~counseling"
16612789|NCT02529163|Active Comparator|Treatment as Usual (TAU)|The TAU will not receive any prompts to follow a specific treatment. The TAU group will be treated according to the current standard of care by the treating physician. They will have an opportunity to be offered the same non-pharmacological interventions seen with the ICP group but at the discretion of the treating physician. Pharmacological interventions will include an anti-psychotic medication that is selected at the discretion of treating physician with no set titration schedule or timeline to meet a maximum dosage. Max dosage will be decided by the treating physician.
16612790|NCT02529150|Experimental|exercise|
16612791|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
16612792|NCT02529124|Placebo Comparator|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
16612793|NCT02529124|Active Comparator|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
16612794|NCT02529124|Active Comparator|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
16612795|NCT02529111|Experimental|intervention|"The Echonavigator software will be used on all patients. It will be used after the introduction of the percutaneous closure of ASD prosthesis. The image fusion on fluoroscopy will then be applied."
16612796|NCT02529098|Sham Comparator|asymptomatic patients|fMRI Asymptomatic patients
16612797|NCT02529098|Experimental|symptomatic patients|fMRI patients with visual difficulties
16612798|NCT02529085|Experimental|Infants with PWS|Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
16612799|NCT02529085|Other|control group|Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
16612800|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
16612801|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
16612802|NCT02529059|Experimental|Switch from Atripla to Eviplera|
16612803|NCT02529046|Active Comparator|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
16612804|NCT02529046|Placebo Comparator|Aerobic exercise|Placebo group received 4 g/day of olive oil.
16612805|NCT02529020|Experimental|Mouthguard|All subjects perform all tests wearing mouthguard.
16612806|NCT02529020|Experimental|No mouthguard|All subjects perform all tests without mouthguard
16612807|NCT02529007|Active Comparator|Standard|These patients have standard colonoscopy performed
16612808|NCT02529007|Experimental|Endocuff|These patients have colonoscopy performed with the endo-cuff attached to the end of the colonoscope
16612809|NCT02528994|Experimental|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
16612810|NCT02528994|Experimental|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
16612811|NCT02528994|Experimental|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
16612812|NCT02528994|Experimental|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
16612813|NCT02528981|Experimental|Probiotic|L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to 100 randomized pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU). These organisms have been previously shown to colonize the vagina after being taken orally (11) and displace the pathogens causing bacterial vaginosis (12) and vaginal yeast infections (13), and have been shown to be an effective treatment, or accessory to treatment of these conditions. (7- 9, 13)
16612814|NCT02528981|Placebo Comparator|Placebo|Placebo capsules will be supplied to 100 randomized pregnant people in gelatin capsules that are identical to the probiotics that the experimental group will receive.
16612815|NCT02528968|Other|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
16612816|NCT02528955|Active Comparator|A:De-Intensification Radiotherapy (RT) primary tumor region|"A:De-Intensification Radiotherapy (RT) primary tumor region
~≤ pT2, R ≥ 5 mm, L0, Pn0
~> 3 lymph node metastasis or patients with < 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection"
16612817|NCT02528955|Active Comparator|B:De-Intensification Radiotherapy contralateral lymph nodes|"> pT2 and/or R < 5mm and/or L1 and/or Pn1
~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
16612818|NCT02528955|Active Comparator|C:De-Intensification RT primary tumor region /contralateral LN|"≤ pT2, R ≥ 5 mm, L0, Pn0
~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
16612819|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
16612820|NCT02528929|Active Comparator|At-risk serology|Gluten-free diet
16612821|NCT02528929|Active Comparator|Not at-risk serology|Gluten-free diet
16612822|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
16612823|NCT02528903|Experimental|Cohort A|
16612824|NCT02528903|Experimental|Cohort B|
16612825|NCT02528903|Experimental|Cohort C|
16612826|NCT02528903|Experimental|Cohort D|
16612827|NCT02528903|Experimental|Cohort E|
16612828|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
16612894|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
16613070|NCT02527200|Experimental|Liraglutide|
16613071|NCT02527200|Placebo Comparator|Placebo|
16612829|NCT02528877|Experimental|Supportive care (ruxolitinib phosphate, tacrolimus, sirolimus)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV over 20 minutes on day -4. Beginning greater than 48 hours after completion of melphalan, patients undergo peripheral blood stem cell or bone marrow transplant according to standard guidelines on day 0.
~GVHD PROPHYLAXIS: Patients receive ruxolitinib phosphate PO BID on days -3 to 30 tapered to day 60, tacrolimus IV continuously or PO BID on days -3 to 100 , and sirolimus PO QD on day -3 to 100. Treatment continues in the absence of disease progression or unacceptable toxicity."
16612830|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
16612831|NCT02528864||Endometrial/uterine cancer|"1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.
~2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.
~3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
16612832|NCT02528851|Experimental|Higher CPAP|Infants extubated to CPAP level 2cm H2O higher than extubation EAP
16612833|NCT02528851|Active Comparator|Equivalent CPAP|Infants extubated to CPAP equivalent to extubation EAP
16612834|NCT02528838||Patients receiving Revlimid according to clinical practice|
16612835|NCT02528825|Experimental|smooth emergence|ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
16612836|NCT02528812|Experimental|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
16612837|NCT02528812|Experimental|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
16612838|NCT02528812|Sham Comparator|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
16612839|NCT02528812|Experimental|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
16612840|NCT02528812|No Intervention|control group|received no intervention
16612841|NCT02528799|Experimental|Nexvax2 DQ2.5 Homozygotes (Cohort 1)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
16612842|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
16612843|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
16612844|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
16612845|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
16612846|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
16612847|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
16612848|NCT02528773||HIV positive|Persons newly diagnosed with HIV.
16612849|NCT02528760|Experimental|Metaclopromide group|
16612850|NCT02528760|Experimental|Erythromycin group|
16612851|NCT02528760|Placebo Comparator|Placebo group|
16612852|NCT02528747||Study population|Breast cancer patients with metastatic bone disease
16612853|NCT02528721|Experimental|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
16612854|NCT02528721|Experimental|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
16612855|NCT02528708|Placebo Comparator|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
16612856|NCT02528708|Experimental|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
16612857|NCT02528695|Active Comparator|Healthy euglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
16612858|NCT02528695|Active Comparator|healthy hypoglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
16612859|NCT02528695|Experimental|Type 2 diabetes hypoglycemic clamp|In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
16612860|NCT02528682|Experimental|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
16612895|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
16612861|NCT02528669|Experimental|RX Navigait|Individuals in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals. In addition, they will be given additional education about the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
16612862|NCT02528669|No Intervention|Control Group|Participants in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals but will not receive additional education regarding the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
16612863|NCT02528656|Experimental|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
16612864|NCT02528656|Experimental|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
16612865|NCT02528643|Experimental|Enzalutamide|Participants received enzalutamide 160 mg once daily until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.
16612866|NCT02528643|Placebo Comparator|Placebo|Participants received placebo once daily until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.
16612867|NCT02528630|Experimental|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
16612868|NCT02528630|Active Comparator|Control group|Performed a session regarding joint protection and energy conservation
16612869|NCT02528617|Other|Gaucher Type 1 or 3|Velaglucerase alfa IV 60 units/kg every other week for duration of the study.
16612870|NCT02528604|Active Comparator|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
16612871|NCT02528604|Active Comparator|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
16612872|NCT02528604|Active Comparator|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
16612873|NCT02528591|Experimental|renal transplant patient|
16612874|NCT02528578|Experimental|healthy volunteers|
16612875|NCT02528565||Patients with failed RYGB (EWL <50%)|
16612876|NCT02528552|Active Comparator|LH80 PRO|Low level laser therapy
16612877|NCT02528552|Sham Comparator|Sham device|No low level laser therapy
16612878|NCT02528539|Experimental|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.
~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.
~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
16612879|NCT02528526|Experimental|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
16612880|NCT02528513|Experimental|midazolam|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
~After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation."
16612881|NCT02528513|Experimental|midazolam/propofol|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
~After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation."
16612882|NCT02528513|Experimental|midazolam/dexmedetomidine|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
~After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation."
16612883|NCT02528500|Experimental|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
16612884|NCT02528474|Experimental|Pantera Lux|
16612885|NCT02528474|Active Comparator|SeQuent Please|
16612886|NCT02528461||Sofosbuvir|"All patients receiving Sofosbuvir based treatment regimes during the study period will be included in the study.
~All patients will receive all interventions (galactose elimination capacity test, gastroscopy, fibroscan), except liver biopsy which the patients may decline to participate in without affecting the participation in the rest of the study. If varices are found during the gastroscopy a liver vein catheterization will be performed."
16612887|NCT02528448|Active Comparator|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
16612888|NCT02528448|Active Comparator|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
16612889|NCT02528435||JIA patients|observationational study including children diagnosed with JIA. Patients aged 9 years and above, whom are treated with low-dose MTX may be included.
16612890|NCT02528435||ALL patients|observationational study including children diagnosed with ALL. Patients aged 9 years and above, whom are in maintenance treatment with low-dose MTX may be included.
16612891|NCT02528422|Active Comparator|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
16612896|NCT02528396|Experimental|BioChaperone insulin lispro|
16612898|NCT02528383|Experimental|Vagifem|Postmenopausal women diagnosed with breast cancer, are currently on an anti-estrogen called an aromatase inhibitor and you have agreed to undergo treatment with Vagifem based on your physician's recommendation.
16612899|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
16612900|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.
~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
16612901|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
16612902|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
16612903|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
16612904|NCT02528344|Experimental|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
16612905|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
16612906|NCT02528318|Experimental|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP
~1 repeat dose allowed if repeat dosing criteria are met."
16612907|NCT02528318|Experimental|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP
~1 repeat dose allowed if repeat dosing criteria are met."
16612908|NCT02528318|Experimental|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP
~1 repeat dose allowed if repeat dosing criteria are met."
16612909|NCT02528318|Experimental|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP
~1 repeat dose will be allowed if repeat dosing criteria are met."
16612910|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
16612911|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
16612912|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
16612913|NCT02528279|Other|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:
~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
16612914|NCT02528266|Experimental|Nerve Capping Device|Implant with the experimental device
16612915|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
16612916|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
16612917|NCT02528253|Experimental|Tanezumab 5 mg SC|
16612918|NCT02528253|Experimental|Tanezumab 10 mg SC|
16612919|NCT02528253|Active Comparator|Tramadol PR oral|
16612920|NCT02528240|Experimental|+ L-PRF|With leukocyte and platelet rich fibrin
16612921|NCT02528240|Active Comparator|- L-PRF|Without leukocyte and platelet rich fibrin
16612922|NCT02528227|Experimental|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
16612923|NCT02528227|Placebo Comparator|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
16612924|NCT02528214|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
16612925|NCT02528214|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
16612926|NCT02528201|Active Comparator|Celecoxib 200 milligrams mg QD|celecoxib 200 milligrams (mg) once a day (QD)
16612927|NCT02528201|Active Comparator|Celexocib 400 mg QD|celecoxib 400 milligrams (mg) once a day (QD)
16612928|NCT02528201|Active Comparator|Diclofenac 50 mg TID|diclofenac 50 milligrams (mg) three times a day (TID)
16612929|NCT02528188|Active Comparator|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
16613169|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
16612930|NCT02528188|Experimental|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
16612931|NCT02528188|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
16612932|NCT02528175|Experimental|MRg-FU|Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
16612933|NCT02528149||patients with renal aneurysm|Patient with one or more renal artery aneurysm (RAA) operated and with tissue; adjacent part and aneurysm; cryopreserved. Blood sample performed at day 1.
16612934|NCT02528136|Experimental|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
16612935|NCT02528136|Active Comparator|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
16612936|NCT02528123|Experimental|Small incision lenticule extraction|Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.
16612937|NCT02528110|Sham Comparator|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
16612938|NCT02528110|Experimental|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
16612939|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
16612940|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
16612941|NCT02528084|Experimental|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
16612942|NCT02528084|Experimental|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
16612943|NCT02528084|No Intervention|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
16612944|NCT02528071||Patients|ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
16612945|NCT02528071||Control|Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT
16612946|NCT02528058||Myopic traction maculopathy|
16612947|NCT02528032|Other|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
16612948|NCT02528019|Active Comparator|DPP-4 inhibitors|sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)
16612949|NCT02528019|Active Comparator|SGLT2 inhibitors|ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)
16612950|NCT02528019|Active Comparator|Glimepiride|glimepiride (0.5-8mg daily)
16612951|NCT02528006|Other|Titanium Bridges|Surgery
16612952|NCT02527993|Experimental|Glucobay|Tablet Glucobay (acarbose) 50 mg x 6 daily for 7 days.
16612953|NCT02527993|Experimental|Januvia|Tablet Januvia (sitagliptin) 100 mg orally O.D for 7 days.
16612954|NCT02527993|Experimental|Verapamil|Tablet Verapamil 120 mg orally O.D for 7 days.
16612955|NCT02527993|Experimental|Victoza|Subcutaneous injection of Victoza (liraglutide) 0,6-1,2 mg O.D for three weeks.
16612956|NCT02527993|Experimental|Signifor|Subcutaneous injection of Signifor (pasireotide) 300 µg as a single dose prior to a meal tolerance test.
16612957|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
16612958|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
16612959|NCT02527967||Group 1 (≤4 days)|Group 1 consisted of patients whose hospital stay was shorter or equal to the target LOS (≤ 4 days).
16612960|NCT02527967||Group 1 (>4 days)|In group 2 were patients whose hospital stay was longer than 4 days.
16612961|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.
~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
16612962|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.
~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
16612963|NCT02527941|Experimental|metronidazole|50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).
16612964|NCT02527928||desoxycholate|Amphotericin B desoxicholate
16612965|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
16612966|NCT02527928||ABLiposomal|Amphotericin B liposomal
16612967|NCT02527915|Experimental|Mental Health eConsults|Primary care clinics that will receive the eConsults intervention at the start of the study.
16612968|NCT02527915|Active Comparator|Usual care|"Primary care clinics that will deliver care as usual for nine months, and will receive the eConsults intervention nine months subsequent to the eConsults intervention clinics."
16612969|NCT02527902|Experimental|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
16612970|NCT02527902|Experimental|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
16612971|NCT02527902|Experimental|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
16612972|NCT02527902|Experimental|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
16612973|NCT02527902|Experimental|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2.
16612974|NCT02527889|Experimental|Exercise Group|The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
16612975|NCT02527889|No Intervention|Control Group|The control group will receive no exercise training and continue to receive standard medical care.
16612976|NCT02527876|Experimental|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
16612977|NCT02527876|Experimental|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
16612978|NCT02527876|Placebo Comparator|Delayed Control/FtBit Flex|No exercise offered
16612979|NCT02527863|Active Comparator|60 mg Tolvaptan|Oral administration of 60 mg tolvaptan on each examination day.
16612980|NCT02527863|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet.
16612981|NCT02527850|Experimental|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
16612982|NCT02527850|Sham Comparator|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
16612983|NCT02527837|Active Comparator|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
16612984|NCT02527837|Placebo Comparator|Placebo|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
16612985|NCT02527824|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.
~Oxaliplatin 65 mg/m2 iv on day 1
~Irinotecan 135 mg/m2 iv on day 1
~S-1 80 mg/m2/day on day 1-7"
16612986|NCT02527811|Experimental|ulinastatin group|the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
16612987|NCT02527811|No Intervention|control group|patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
16612988|NCT02527798|Experimental|Furosemide Cohort 1|Within cohort 1, infants will be randomized using a 3:1 scheme to receive furosemide or placebo. Those randomized to receive furosemide will receive (1mg/kg daily intravenously or 2 mg/kg daily enterally for 28 days.
16612989|NCT02527798|Placebo Comparator|Placebo Cohort 1|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
16612990|NCT02527798|Experimental|Furosemide Cohort 2|Cohort 2 Infants will receive furosemide (1mg/kg every 6 hours intravenously or 2 mg/kg every 6 hours daily enterally) for 28 days.
16612991|NCT02527798|Experimental|Furosemide Cohort 3|Cohort 3 Infants will receive furosemide (2mg/kg every 6 hours intravenously or 4 mg/kg every 6 hours daily enterally) for 28 days.
16612992|NCT02527798|Placebo Comparator|Placebo Cohort 2|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
16612993|NCT02527798|Placebo Comparator|Placebo Cohort 3|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
16612994|NCT02527785|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"triple combination with oxaliplatin, irinotecan, and S-1.
~Treatment will be delivered as a 2-week cycle.
~Oxaliplatin 65 mg/m2 iv on day 1
~Irinotecan 135 mg/m2 iv on day 1
~S-1 80 mg/m2/day on day 1-7"
16612995|NCT02527772|Experimental|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
16612996|NCT02527772|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
16612997|NCT02527746|Experimental|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
16612998|NCT02527746|Experimental|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
16612999|NCT02527746|Experimental|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
16613000|NCT02527733|Active Comparator|Ranibizumab|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
16613001|NCT02527733|Active Comparator|Ranibizumab and laser|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
16613002|NCT02527720|Experimental|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
16613003|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg bid in combination with ritonavir 100 mg bid and escalating to lonafarnib 75 mg bid and then 100 mg bid as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
16613004|NCT02527694|Experimental|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
16613005|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
16613006|NCT02527681|Experimental|Ceftobiprole|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
16613007|NCT02527668|Experimental|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
16613008|NCT02527668|Active Comparator|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
16613009|NCT02527668|Placebo Comparator|Placebo|1 Placebo capsule per day for 6 months
16613010|NCT02527655|Experimental|Choice-Based Physical Activity and Active Transportation|Participants will meet one-on-one with an activity coach to develop a choice-based physical activity and active transportation plan based on their interest, abilities, and resources; attend group-based motivational meetings; and receive ongoing support and encouragement for physical activity and active transportation (e.g., telephone-assisted support, community centre and transit passes).
16613011|NCT02527655|No Intervention|Wait-List Control|Participants will be offered the Choice-Based Physical Activity and Active Transportation intervention after the experimental arm has completed the study.
16613012|NCT02527642|Active Comparator|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
16613013|NCT02527642|Active Comparator|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
16613014|NCT02527642|Experimental|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
16613015|NCT02527642|Experimental|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
16613016|NCT02527629||Decellularized human valves|Aortic heart valve replacement
16613017|NCT02527616|Experimental|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
16613018|NCT02527616|Experimental|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
16613019|NCT02527603|Experimental|Spaso Method|Randomized for Sp method + 1 initial dose of 50mg dexketoprofen IM or 25mg Oral
16613020|NCT02527603|Experimental|Boss-Holzach-Matter Method|Randomized for BHM method +1 initial dose of 50mg dexketoprofen IM or 25mg Oral
16613021|NCT02527590|Experimental|patient with neuropathic pain with allodynia|
16613022|NCT02527590|Experimental|healthy volunteers|
16613023|NCT02527577|Experimental|ropivacaïne chlorhydrate monohydrate|
16613024|NCT02527577|Placebo Comparator|placebo|
16613025|NCT02527564|Experimental|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
16613026|NCT02527564|Placebo Comparator|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
16613027|NCT02527551|Other|Haptic massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
16613028|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
16613029|NCT02527525|Experimental|Stepped Care|150 subjects will be randomized to the stepped care intervention. All 150 participants will be assigned a parent coach after randomization to stepped care condition. At the child's next follow up clinic visit participants who have elevated depression scores OR who's child has not met A1c target will move on to Step 2 of the intervention- 5 sessions with a study interventionist. At the following child's clinic visit, participants can either remain in Step 1, move to Step 2, or if needed, move on to Step 3- using a continuous glucose monitor for 1 week followed by a meeting with a certified diabetes educator and a diabetes team clinical psychologist.
16613030|NCT02527525|No Intervention|Usual Care|Participants randomized to usual care will participate in regular diabetes clinic visits and diabetes education, as they would have done without participation in this study.
16613031|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
16613032|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
16613033|NCT02527499|Experimental|ROCBT group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Ride-On Cars with Bimanual Training Program (ROCBT) group.
16613034|NCT02527499|Active Comparator|Early Mobility Training group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Early Mobility Training Program group.
16613035|NCT02527499|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Regular Therapy Program group.
16613036|NCT02527486||No predefined subgroups|
16613038|NCT02527473|Experimental|HEROS Group|HEROS group will receive the dispatcher-assisted basic life support training that includes standardized video-based CPR education, interactive role-playing with the dispatcher as well as group discussion for one hour.
16613039|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
16613042|NCT02527395|Other|Clinical pain models|Brief thermal sensitization. Heat pain detection threshold. Pain during 1 min. thermal stimulation
16613043|NCT02527382|Experimental|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
16613044|NCT02527382|No Intervention|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
16613045|NCT02527369|Experimental|XP1100RF group|Subjects in the XP1100RF group will be treated with the XP1100RF device.
16613046|NCT02527356|Experimental|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
16613047|NCT02527356|Active Comparator|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
16613048|NCT02527356|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
16613052|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
16613053|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=55%
16613054|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<55%.
16613055|NCT02527304|Experimental|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
16613056|NCT02527291||Study Group|"The Study group will comprise of seropositive CMV patients undergoing cardiothorathic surgery and having a complicated postoperative course.
~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done three times: at enrollment, follow up 1 (7 days post operation) and follow up 2 (14 days post operation).
~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
16613057|NCT02527291||Control Group 1|"The first control group will be comprised of patients who are seropositive CMV undergoing cardiothorathic surgery and having a normal postoperative course.
~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done two times: at enrollment and follow up 1 (7 days after discharge).
~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
16613058|NCT02527291||Control Group 2|"The second control group will include seronegative patients for CMV undergoing cardiothorathic surgery with complicated and uncomplicated post-operative course.
~Blood work for CMV PCR and IL28 will be done at enrollment. All other visits include data collection from computerized medical records only."
16613059|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
16613060|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
16613061|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
16613062|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
16613063|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.
~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
16613064|NCT02527252|Experimental|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:
~Pelvic Diaphragm Release.
~Respiratory Diaphragm Release.
~Thoracic Inlet Release.
~Hyoid release.
~Sacral technique for stabilize L5/sacrum.
~CV-4 Still Point Induction."
16613065|NCT02527252|Active Comparator|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
16613066|NCT02527226|No Intervention|No facial exercises|This group will not receive any training in facial exercises.
16613067|NCT02527226|Experimental|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
16613068|NCT02527213|Experimental|Sodium Thiosulfate|Sodium Thiosulfate at 25g in 100 ml normal sterile saline (NSS)
16613069|NCT02527213|Placebo Comparator|Placebo|similarly-formulated placebo in 100 ml NSS
16613072|NCT02527187|Experimental|Betula verrucosa allergen extract|"The investigational product contained the allergen extract of the pollen of Betula verrucosa and will be tested by administration onto skin. The test will be carried out on the forearm following prick test technique.
~The allergen extract of the pollen of Betula verrucosa will be tested in four concentrations (100, 50, 25 and 10 HEP/mL)."
16613073|NCT02527174|Experimental|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.
~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
16613074|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.
~They are intended for single use only."
16613075|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
16613076|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
16613077|NCT02527135|Experimental|Behavioural|Intervention arm receiving weekly HIV sensitization text messages
16613078|NCT02527135|No Intervention|Control|No weekly messages were sent to this group
16613079|NCT02527122|Experimental|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.
~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
16613080|NCT02527109|Placebo Comparator|Placebo|Intra-anal placebo administered BID.
16613081|NCT02527109|Experimental|Nifedipine 12 mg/day|Intra-anal Nifedipine 12 mg administered OD.
16613082|NCT02527109|Experimental|Nifedipine 24 mg/day|Intra-anal Nifedipine 12 mg administered BID.
16613083|NCT02527096|Experimental|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
16613084|NCT02527083|Active Comparator|BIA|Balanced Inhalational Anesthesia (consisting of a sevoflurane inhaled anesthestic only)
16613085|NCT02527083|Active Comparator|TIVA-K|Total intravenous anesthetic with ketamine
16613086|NCT02527083|Active Comparator|TIVA-R|Total intravenous anesthetic with remifentanil
16613087|NCT02527070|Experimental|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
16613088|NCT02527070|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
16613089|NCT02527044|Experimental|Functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered functional for score of 3."
16613090|NCT02527044|Active Comparator|Non functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered non functional for scores of 0 to 2."
16613091|NCT02527031|Active Comparator|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
16613092|NCT02527031|Active Comparator|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
16613093|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
16613094|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
16613095|NCT02527005|Active Comparator|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
16613096|NCT02527005|Active Comparator|Sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses
16613097|NCT02526992|Other|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
16613098|NCT02526979|Experimental|mirabegron|single dose
16613099|NCT02526966|Other|patient with primitive form of IgA nephropathy|
16613100|NCT02526953|Experimental|Paclitaxel|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.
16613101|NCT02526953|Active Comparator|Standard|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.
16613102|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART< 200/mm3.
~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
16613103|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
16613104|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART> 350/mm3.
~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
16613105|NCT02526927|Experimental|Patients 20 - 30 years-old|HR-pQCT and DEXA for measure bone quality and quantity
16613106|NCT02526927|Experimental|Patients 10 - 20 years-old|Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
16613107|NCT02526914|Experimental|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
16613108|NCT02526914|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
16613109|NCT02526914|Placebo Comparator|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
16613110|NCT02526901||No treatment|
16613111|NCT02526888|Experimental|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
16613112|NCT02526888|Experimental|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
16613113|NCT02526875|Experimental|night|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
16613114|NCT02526875|Active Comparator|morning|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
16613115|NCT02526862|No Intervention|A-Mask or direct interface|Mask or direct interface
16613116|NCT02526862|Active Comparator|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
16613117|NCT02526862|Active Comparator|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
16613118|NCT02526862|Active Comparator|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
16613119|NCT02526849|Experimental|Fecal microbiota transplantation (FMT)|On day 1-6, patients received 100ml fresh FMT by nasointestinal tube, once per day. The nasointestinal tube was placed in the patient's proximal jejunum through endoscopy. Then, donor fecal microbiota was infused within 5 minutes through nasointestinal tube.
16613120|NCT02526849|Experimental|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
16613121|NCT02526836|Other|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.
~Conventional surgery"
16613122|NCT02526836|Active Comparator|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.
~Complete mesocolic excision with central vascular ligation"
16613123|NCT02526823|Active Comparator|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses
16613124|NCT02526823|Experimental|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses
16613125|NCT02526810|Active Comparator|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
16613126|NCT02526810|Experimental|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
16613127|NCT02526784|Active Comparator|Injection A|Degarelix s.c. standard injections
16613128|NCT02526784|Experimental|Injection B|Degarelix s.c. optimised injections
16613129|NCT02526784|Experimental|Injection C|Degarelix i.m. injections
16613130|NCT02526771|Experimental|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
16613131|NCT02526771|Active Comparator|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
16613132|NCT02526758|Experimental|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
16613133|NCT02526758|Active Comparator|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
16613134|NCT02526745|Experimental|high doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
16613135|NCT02526745|Experimental|low doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
16613136|NCT02526745|Experimental|high doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
16613170|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
16613137|NCT02526745|Experimental|middle doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with middle doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
16613138|NCT02526745|Experimental|low doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
16613139|NCT02526745|Placebo Comparator|placebo|placebo in 100 adults aged 50-80 years old on day 0
16613140|NCT02526732|Experimental|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
16613141|NCT02526719|No Intervention|Standard Nipple-Sparing Mastectomy|Patients in the control group will receive usual care. The surgical oncologist will perform the NSM and sentinel lymph node biopsy if indicated (active breast cancer or DCIS). We will submit a nipple core biopsy and a 1cm thick biopsy of immediately retro-areolar ductal tissue for permanent section pathology for control patients, and all patients will have the mastectomy specimen submitted for permanent section pathology. Under the same general anaesthesia, the plastic surgeon will perform the IBR (2-stage tissue expander to implant or 1-stage direct to implant). Patients who later have a positive nipple core and retro-areolar biopsy will have a discussion with the surgical oncologist regarding the need for revision breast surgery to excise the NAC, as is current practice.
16613142|NCT02526719|Experimental|Nipple Delay Intervention|Patients in the experimental group will have a nipple-delay intervention in addition to usual care. The nipple delay procedure will be performed by the plastic surgeon in the minor clinic procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
16613143|NCT02526706|Experimental|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
16613144|NCT02526693|Other|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
16613145|NCT02526693|Other|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
16613146|NCT02526680|Experimental|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
16613147|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
16613148|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
16613149|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
16613150|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
16613151|NCT02526654|Experimental|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
16613152|NCT02526641||AbbVie|
16613153|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
16613154|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
16613155|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
16613156|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
16613157|NCT02526615|Placebo Comparator|Placebo|placebo, 2 tablets per day
16613158|NCT02526615|Active Comparator|Metformin|500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
16613159|NCT02526615|Active Comparator|Rosiglitazone|2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day
16613160|NCT02526602|Experimental|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
16613161|NCT02526602|Active Comparator|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
16613162|NCT02526576|Experimental|Stromal Vascular Fraction|Subjects will receive stromal vascular fraction assisted fat transfer.
16613163|NCT02526576|Active Comparator|Biopsy for Control -regular fat transfer|Subjects will receive regular fat transfer. A biopsy procedure will analyzes the different between experimental and control groups.
16613164|NCT02526563||Iliac crest wound catheter group|These patients will receive an iliac crest wound catheter after an iliac crest bone harvest to repair a palatal defect. This catheter is part of standard of care. This study will collect blood to measure unbound ropivicaine levels.
16613165|NCT02526550|Experimental|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
16613166|NCT02526537||Gefitinib|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
16613167|NCT02526537||Non-specific treatment|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
16613168|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
16613171|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
16613172|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
16613173|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
16613174|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
16613175|NCT02526511|Experimental|Diagnostic (pMRI)|Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.
16613176|NCT02526498|Experimental|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
16613177|NCT02526485||Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
16613178|NCT02526472|Experimental|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
16613179|NCT02526472|Experimental|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
16613180|NCT02526459|Experimental|birth plan|Use of birth plan
16613181|NCT02526459|No Intervention|no birth plan|No use of birth plan
16613182|NCT02526446|Experimental|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
16613183|NCT02526446|Other|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
16613184|NCT02526433||Pregnancy women and new mothers|The study tracks what interventions women are already registered in and compares these with their mental wellbeing.
16613185|NCT02526420|Experimental|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects >= 35 years of age
16613186|NCT02526420|Experimental|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects < 35 years of age
16613187|NCT02526420|Experimental|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
16613188|NCT02526407|No Intervention|Control|Participants continue with usual care. No planned intervention.
16613189|NCT02526407|Active Comparator|Group play|Participants take part in 10 weeks of group play activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
16613190|NCT02526407|Experimental|Singing|Participants take part in 10 weeks of group singing activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
16613191|NCT02526394|Active Comparator|1|Repevax + Meningitec
16613192|NCT02526394|Active Comparator|2|Repevax + Neis-VacC
16613193|NCT02526394|Active Comparator|3|Repevax + Menitorix
16613194|NCT02526394|Active Comparator|4|Boostrix + Meningitec
16613195|NCT02526394|Active Comparator|5|Boostrix + NeisVacC
16613196|NCT02526394|Active Comparator|6|Boostrix + Menitorix
16613197|NCT02526394|Active Comparator|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
16613198|NCT02526394|Active Comparator|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
16613199|NCT02526381|Experimental|Danlou Tablets|Danlou prescription is a tablet, each piece weighs 0.3 g, taken orally, three times a day, five at a time, from jilin Cornell's pharmaceutical corporation, Limited Liability Company .
16613200|NCT02526381|Experimental|Tongmai Yangxin Pills|Tongmai Yangxin prescription is a pill,each pill weighs 0.1 g,taken orally, 2 times a day,40 pills at a time,produced by tianjin new pharmaceutical group corporation, Limited Liability Company . LeRenTang pharmaceutical.
16613201|NCT02526381|No Intervention|no drugs|
16613202|NCT02526368|Experimental|Pre-surgical Prostate Cancer patients|Infusion of co-hyperpolarized 13C pyruvate and undergo and hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion High spatial resolution MRI/1H MRSI staging exam (PROSE) using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent radical prostatectomy. At least 20 patients will be required to have high risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
16613203|NCT02526355|Experimental|Mobile based Intervention|Mobile based Intervention (Learning Through Play Plus) comprised of both LTP and CBT
16613204|NCT02526355|No Intervention|Waiting List Control|Waiting List Control group will receive no intervention, but intervention will be offered to interested participants at the end of the study
16613205|NCT02526342|Active Comparator|Negative Pressure Wound Therapy|Patients receive a Negative Pressure Wound Therapy-Dressing (V.A.C. Ultra (KCI®,San Antonio, Texas, USA) with a subatmospheric pressure of 125mmHg to cover the muscle flap for five days following surgery.
16613206|NCT02526342|No Intervention|Conventional Dressing|Patients receive a conventional dressing for the muscle flap including fatty gauze and cotton gauze.
16613207|NCT02526329|Experimental|Treatment (donor regulatory T lymphocytes)|Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
16613208|NCT02526316|Other|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
16613253|NCT02526030|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
16613209|NCT02526303|Experimental|Anticoagulation|Drug: Nadroparin Calcium and Warfarin Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,along with Nadroparin Calcium 85IU／kg，subcutaneous, q12h,for the first 5 days at least.
16613210|NCT02526303|No Intervention|Non-anticoaglated|No anticoagulatoin or other treatment for PVT will be used in this group of patients.
16613211|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
16613212|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
16613213|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
16613214|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
16613215|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
16613216|NCT02526264|Experimental|Krankenhaus Nordwest Concept|specific preoperative education program realised by a specialized stoma-therapist containing individualized information on material maintenance, hygiene, nutrition, complications, activities of daily life and occupation
16613217|NCT02526264|Experimental|Standard concept|standard preoperative education program administered by a surgeon containing information on surgery, outcome, risks and alternatives
16613218|NCT02526238|Experimental|TMS and trunk rotation|TMS and trunk rotation
16613219|NCT02526238|Sham Comparator|Sham TMS and trunk rotation|Sham TMS and trunk rotation
16613220|NCT02526225|Active Comparator|ginkgo diterpene lactone meglumine injection|ginkgo diterpene lactone meglumine injection
16613221|NCT02526225|Placebo Comparator|Ginkgo diterpene lactone meglumine injection simulation|Ginkgo diterpene lactone meglumine injection simulation
16613222|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
16613223|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
16613224|NCT02526199|Active Comparator|Group BA|Bupivacaine + Adrenaline Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml
16613225|NCT02526199|Experimental|Group BAD|Bupivacine + Adrenaline + Dexamethasone Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml PLUS Dexamethsone 8 mg
16613226|NCT02526186|No Intervention|Standard of Care|Standard of Care only
16613227|NCT02526186|Experimental|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
16613228|NCT02526173|Experimental|dHACM|This group will receive RALP using full nerve sparing technique plus dHACM application.
16613229|NCT02526173|Other|Control|This group will receive RALP using full nerve sparing technique only.
16613230|NCT02526160|Experimental|Burosumab 1 mg/kg|Burosumab 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
16613231|NCT02526160|Placebo Comparator|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by burosumab 1 mg/kg, for the duration of the study.
16613232|NCT02526147|No Intervention|Control|Receives no intervention
16613233|NCT02526147|Experimental|Cash|Household receives cash transfer monthly for 6 months
16613234|NCT02526147|Experimental|Voucher|Household receives food voucher to use at local supermarket monthly for 6 months
16613235|NCT02526147|Experimental|Food|Household receives food transfer composed of rice, lentils, canned sardines, and vegetable oil, monthly for 6 months
16613236|NCT02526134|Experimental|Laying of medical devices|radio opaque markers
16613237|NCT02526121|Experimental|Phlebotomy associated with dietary and lifestyle counseling|
16613238|NCT02526121|Active Comparator|Dietary and lifestyle counseling.|
16613239|NCT02526108|Experimental|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
16613240|NCT02526082||Total, observational|Various cardiovascular risk groups described below
16613241|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
16613242|NCT02526082||High-risk control|Healthy but at high risk in 1974
16613243|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
16613244|NCT02526082||Sick control|Medications or clinical disease in 1974
16613245|NCT02526082||Refused|Refused or no response in 1974
16613246|NCT02526069|Other|SweetSpot users|Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview.
16613247|NCT02526056|Experimental|Physiotherapists|The physiotherapist have to play the exergame once.
16613248|NCT02526056|Experimental|elderly people|The elderly people have play the exergame twice.
16613249|NCT02526043|Experimental|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
16613250|NCT02526043|Experimental|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
16613251|NCT02526030|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
16613252|NCT02526030|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
16613254|NCT02526017|Experimental|Phase 1 a monotherapy dose escalation|FPA008: specified dose on specified days
16613255|NCT02526017|Experimental|Phase 1a combination therapy dose escalation|FPA008 + BMS-936558: specified dose on specified days
16613256|NCT02526017|Experimental|Phase 1b combination therapy dose expansion|FPA008 + BMS-936558: specified dose on specified days
16613257|NCT02526004|Active Comparator|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
16613258|NCT02526004|Experimental|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
16613259|NCT02525991|Experimental|Staccato® Delivery System Loxapine|Staccato® Delivery System Loxapine, 9.1 mg one dose
16613260|NCT02525978|Experimental|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
16613261|NCT02525978|Experimental|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
16613262|NCT02525965|Experimental|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
16613263|NCT02525965|Active Comparator|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of narrow resection margin <1cm
16613264|NCT02525952|Experimental|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
16613265|NCT02525952|Active Comparator|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
16613266|NCT02525952|Experimental|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
16613267|NCT02525952|Active Comparator|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
16613268|NCT02525939|Active Comparator|dalcetrapib|dalcetrapib 600 mg po QD
16613269|NCT02525939|Placebo Comparator|placebo|matching placebo tablet po QD
16613270|NCT02525926|Experimental|denervation|
16613271|NCT02525926|Sham Comparator|control group|
16613272|NCT02525913|Other|Bi-lateral mastectomy|
16613273|NCT02525900|Placebo Comparator|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
16613274|NCT02525900|Experimental|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
16613275|NCT02525900|Experimental|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
16613276|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
16613277|NCT02525861|Experimental|Cohort I: GLASSIA (High-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
16613278|NCT02525861|Experimental|Cohort II: GLASSIA (Low-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
16613279|NCT02525848|Active Comparator|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
16613280|NCT02525848|Active Comparator|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
16613281|NCT02525848|Active Comparator|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
16613282|NCT02525835|Experimental|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
16613283|NCT02525835|Experimental|High Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
16613284|NCT02525822|Experimental|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
16613285|NCT02525822|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
16613286|NCT02525822|Placebo Comparator|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
16613287|NCT02525822|Placebo Comparator|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
16613288|NCT02525809|Other|mobility insert with tripod attachment (Novae E®)|mobility insert with tripod attachment (Novae E®)
16613289|NCT02525809|Other|mobility insert with press fit pure (Sunfit®)|mobility insert with press fit pure (Sunfit®)
16613290|NCT02525809|Other|fixed insert (Quartz®).|fixed insert (Quartz®).
16613291|NCT02525796|Placebo Comparator|Placebo + Cinacalcet|Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks
16613292|NCT02525796|Active Comparator|Amiloride + Cinacalcet|Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks
16613293|NCT02525796|Experimental|Eplerenone + Cinacalcet|Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks
16613294|NCT02525770|Active Comparator|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
16613295|NCT02525770|Active Comparator|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
16613326|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
16613807|NCT02522351|Experimental|Cereal extract concentration 3|Cereal extract at concentration 3
16613298|NCT02525744|Experimental|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
16613299|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
16613300|NCT02525744|Experimental|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
16613301|NCT02525744|Experimental|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
16613302|NCT02525731||Patient Cohort|The TEACH patient cohort component will establish an observational cohort of HIV-infected patients on chronic opioid therapy.
16613303|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
16613304|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.
~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
16613305|NCT02525705|Experimental|Every EA patients|This is a one group interventional study. Every patient is included in the same arm.
16613306|NCT02525692|Experimental|A: GBM ONC201 Q3W|
16613307|NCT02525692|Experimental|B: GBM ONC201 Q1W|
16613308|NCT02525692|Experimental|C: GBM Surgical Cohort ONC201 Q1W|
16613309|NCT02525692|Experimental|D: H3 K27M Glioma ONC201 Q1W|
16613310|NCT02525692|Experimental|E: Diffuse Midline Glioma Surgical Cohort ONC201 Q1W|
16613311|NCT02525692|Experimental|F: Non-H3 K27M Diffuse Midline Glioma ONC201 Q1W|
16613312|NCT02525679|Experimental|BI 655130|
16613313|NCT02525679|Placebo Comparator|Placebo|
16613314|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
16613315|NCT02525640|Experimental|Hearing Aid|CROS hearing aid
16613316|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
16613317|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
16613318|NCT02525614|Active Comparator|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
16613319|NCT02525614|Active Comparator|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
16613320|NCT02525601|Active Comparator|Triathlon CR cemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented Peri-Apatite (PA) knee fixation and migration properties versus the cemented version.
16613321|NCT02525601|Active Comparator|Triathlon CR uncemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented PA knee fixation and migration properties versus the cemented version.
16613322|NCT02525588|Active Comparator|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
16613323|NCT02525588|Active Comparator|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
16613324|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
16613325|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
16613327|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
16613328|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
16613329|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
16613330|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
16613331|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
16613332|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
16613333|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
16613334|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
16613335|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
16613336|NCT02525510|Active Comparator|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.
16613337|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Right Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
16613338|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
16613339|NCT02525510|Active Comparator|Not Pump Eligible - Normothermia|Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
16613340|NCT02525510|Active Comparator|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
16613341|NCT02525497|Experimental|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h;
16613342|NCT02525497|Active Comparator|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h;
16613343|NCT02525484|Experimental|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
16613344|NCT02525484|Experimental|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
16613345|NCT02525484|Experimental|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
16613346|NCT02525484|Experimental|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
16613347|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 23 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.
~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
16613348|NCT02525458|Experimental|QAMS-containing PMMA|PMMA containing 5% QAMS
16613349|NCT02525458|Placebo Comparator|QAMS-free PMMA|PMMA containing 0% QAMS
16613350|NCT02525445|Active Comparator|acupuncture positive communication|Genuine acupuncture needles combined with positive communication regarding the expected treatment effects
16613351|NCT02525445|Sham Comparator|sham acupuncture positive communication|Sham acupuncture needles combined with positive communication regarding the expected treatment effects
16613352|NCT02525445|Active Comparator|acupuncture neutral communication|Genuine acupuncture needles combined with neutral communication regarding the expected treatment effects
16613353|NCT02525445|Sham Comparator|sham acupuncture neutral communication|Sham acupuncture needles combined with neutral communication regarding the expected treatment effects
16613354|NCT02525432|Experimental|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
16613355|NCT02525432|Placebo Comparator|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
16613356|NCT02525419|Experimental|Weight Loss Phase|12 week weight loss phase consisting of High Protein - Intermittent Fast-Low Calorie diet in 43 Obese Men and Women
16613357|NCT02525419|Experimental|Weight Loss Maintenance Phase|52 week weight loss maintenance phase consisting of either High Protein - Intermittent Fast (HP-IF) or Heart Healthy (HH) diet
16613358|NCT02525393|Experimental|tDCS+rTMS|Stroke patients were treated with an initial two weeks of transcranial direct current stimulation and after six months with two weeks of repetitive transcranial magnetic stimulation.
16613359|NCT02525393|Experimental|rTMS+tDCS|Stroke patients were treated with an initial two weeks of repetitive transcranial magnetic stimulation and after six months with two weeks of transcranial direct current stimulation.
16613360|NCT02525393|Sham Comparator|Sham stimulation|Stroke patients were treated with two weeks of sham transcranial direct current stimulation.
16613361|NCT02525380|Experimental|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.
~DC Bead is produced from polyvinyl alcohol."
16613362|NCT02525367|Experimental|PD-Experimental|PD patients using the online cognitive training for 8 weeks, 3 times a week
16613363|NCT02525367|Active Comparator|PD-Control|PD patients using the active control condition for 8 weeks, 3 times a week
16613364|NCT02525367|Experimental|MS-Experimental|MS patients using the online cognitive training for 8 weeks, 3 times a week
16613365|NCT02525367|Active Comparator|MS-Control|MS patients using the active control condition for 8 weeks, 3 times a week
16613366|NCT02525367|Experimental|postECT-Experimental|Depressed elderly treated with ECT patients using the online cognitive training for 8 weeks, 3 times a week
16613367|NCT02525367|Active Comparator|postECT-Control|Depressed elderly treated with ECT patients using the active control condition for 8 weeks, 3 times a week
16613368|NCT02525341|Experimental|Yoga Group|Participants in the yoga group received a total of eight weekly 45 minute yoga classes. A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
16613369|NCT02525341|Active Comparator|Aerobic and Strengthening Exercise Group|Participants in the exercise group received a total of eight weekly 45 minute exercise classes. A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants. Handouts were provided for participants to practice the program at home for 30 minutes a day, 3 days a week (on non-consecutive days).
16613370|NCT02525341|Active Comparator|General education|Participants in this group received a one-time OA educational brochures from the Arthritis Foundation including topics focusing on the disease process, diet and exercise and OA management education. Participants were instructed not to begin any new exercise programs during the study period.
16613371|NCT02525328||CT subjects|blood or saliva specimen
16613372|NCT02525328||subjects without CT|blood or saliva specimen
16613373|NCT02525315|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
16613374|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
16613375|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
16613376|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
16613377|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
16613378|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
16613379|NCT02525289|No Intervention|Control Group|six hours after extubation receiving breathing exercises. After 48 hour postoperative time, sitting on armchair and keeping the erect position and walking in the same place.
16613380|NCT02525289|Active Comparator|Bed Rotation Group|six hours after extubation receiving breathing exercises and submitted the continuous rotational bed therapy in the first postoperative day until 48 hours.
16613381|NCT02525289|Active Comparator|Orthostatic Group|six hours after extubation receiving breathing exercises and changing the body position following the sequence: sitting on the bed, sitting on the bed with the feet on the floor , standing and walking in the same place, in the first postoperative day until 48 hours.
16613382|NCT02525276|Experimental|training + HT|training + HT
16613383|NCT02525276|Experimental|training - HT|training - HT
16613384|NCT02525276|Placebo Comparator|-training + HT|-training + HT
16613385|NCT02525276|No Intervention|- training - HT|- training - HT
16613386|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
16613387|NCT02525250|Experimental|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
16613388|NCT02525237|Experimental|Apatinib plus S-1|Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
16613389|NCT02525224|Other|Nutritional Supplement|Proprietary nutritional supplement
16613390|NCT02525211|Experimental|Ropivacaine|Ropivacaine
16613391|NCT02525211|Placebo Comparator|placebo|physiological saline
16613392|NCT02525198|Placebo Comparator|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
16613393|NCT02525198|Experimental|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
16613394|NCT02525172|Experimental|ITT|immune modulation therapy
16613395|NCT02525159|Active Comparator|DIM pills|75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days
16613396|NCT02525159|Placebo Comparator|Placebo pills|2 pills once a day for 30 days
16613444|NCT02524925|No Intervention|conventional protocol|Oral intake after bowel mobilization Mobilization after the 1st postoperative day Check discharge criteria the 7th-15th postoperative day
16613397|NCT02525146|Experimental|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
16613398|NCT02525146|No Intervention|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
16613399|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
16613400|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
16613401|NCT02525120|Experimental|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
16613402|NCT02525120|Active Comparator|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
16613403|NCT02525107|Experimental|SCD patients on Hydroxyurea|Omega-3 capsules [750 mg], 4 capsules a day for 52 weeks. [Each capsule will contain 417.9mg Docosahexaenoic acid [DHA], 50.8 mg Eicosapentaenoic acid [EPA] and 11.9mg Arachidonic acid [AA] and 1000 IU Vitamin E]
16613404|NCT02525107|Experimental|SCD patients not on Hydroxyurea|Dietary Supplement: Placebo [730 mg], 4 capsules a day for 52 weeks.[Each capsule will contain 538.2mg Oleic Acid [OA] and 1000 IU Vitamin E]
16613405|NCT02525094|Experimental|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
16613406|NCT02525094|Placebo Comparator|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
16613407|NCT02525081|Experimental|ACE-inhibitor|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.
~Patients taking a dose of
~2,5 mg will take a half tablet a day
~5 mg will take one whole tablet a day
~10 mg will take two tablets a day"
16613408|NCT02525081|Placebo Comparator|Placebo|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.
~Patients taking a dose of
~2,5 mg will take a half tablet a day
~5 mg will take one whole tablet a day
~10 mg will take two tablets a day"
16613409|NCT02525068|Experimental|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose-levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
16613410|NCT02525068|Placebo Comparator|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
16613411|NCT02525068|Experimental|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
16613412|NCT02525055|Experimental|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus
16613413|NCT02525055|Experimental|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus
16613414|NCT02525055|Experimental|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus
16613415|NCT02525055|Experimental|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus
16613416|NCT02525055|Experimental|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
16613417|NCT02525055|Experimental|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
16613418|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
16613419|NCT02525042||Comparator 1|family controls
16613420|NCT02525042||Comparator 2|population controls
16613421|NCT02525029|Experimental|1: High-Risk aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.
~Individual patient dose reductions: If a patient has toxicity that meets the definition of dose limiting, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.
~Continue protocol treatment through day 7. Assess response at day 7:
~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.
~If no response, the patient will be taken off study treatment."
16613445|NCT02524899|Active Comparator|Cognitive Remediation Therapy and placebo|7.5 weeks of twice weekly cognitive remediation sessions
16613446|NCT02524899|Experimental|Guanfacine and CRT|7.5 weeks of twice weekly cognitive remediation sessions with 8 weeks of guanfacine
16613808|NCT02522338|Other|iohexol plasma clearance|patients had received iohexol for measuring GFR
16613422|NCT02525029|Experimental|2a: Steroid-Dependent aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.
~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.
~Continue protocol treatment through day 14. Assess response at day 14:
~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.
~If no response, the patient will be taken off study treatment"
16613423|NCT02525029|Experimental|2b: Steroid-Refractory aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses.
~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.
~Continue protocol treatment through day 14. Assess response at day 14:
~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.
~If no response, the patient will be taken off study treatment"
16613424|NCT02525016|Experimental|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
16613425|NCT02525003|Placebo Comparator|Group 1: placebo|Group 1: daily dose of regular bread (87 g/d) and placebo pill (0 µg of vitamin D/d) for 8 weeks
16613426|NCT02525003|Experimental|Group 2: Vitamin D2 supplement|Group 2: daily dose of regular bread (87 g/d) and D2 supplement (25 µg of vitamin D2/d.) for 8 weeks
16613427|NCT02525003|Experimental|Group 3: Vitamin D3 supplement|Group 3: daily dose of regular bread (87 g/d) and D3 supplement (25 µg of vitamin D3/d.) for 8 weeks
16613428|NCT02525003|Experimental|Group 4: Vitamin D2-fortified bread|Group 4: D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
16613429|NCT02524990|Experimental|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
16613430|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.
~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
16613431|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
16613432|NCT02524964|Experimental|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
16613433|NCT02524964|Sham Comparator|control|same volume/day of normal saline.
16613434|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 20 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 20 mg/m2. Drug infusions will last approximately 2 hours.
16613435|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 26 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 26 mg/m2. Drug infusions will last approximately 2 hours.
16613436|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 34 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 34 mg/m2 . Drug infusions will last approximately 2 hours.
16613437|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 44 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 44 mg/m2 . Drug infusions will last approximately 2 hours.
16613438|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 57 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 57 mg/m2. Drug infusions will last approximately 2 hours.
16613439|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 74 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 74 mg/m2 . Drug infusions will last approximately 2 hours.
16613440|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 96 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 96 mg/m2 . Drug infusions will last approximately 2 hours.
16613441|NCT02524938|Experimental|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
16613442|NCT02524938|Sham Comparator|Control group|Conventional coffee (habitual diet)
16613443|NCT02524925|Active Comparator|fast track protocol|Oral fluids intake (0.5 lt) 6 hours after operation Mobilization 4 hours after operation Check discharge criteria the 4th-6th postoperative day
16613447|NCT02524886|Active Comparator|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
16613448|NCT02524886|Sham Comparator|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
16613449|NCT02524860|Experimental|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
16613450|NCT02524847|Experimental|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
16613451|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
16613452|NCT02524821|Active Comparator|drugs only, fasted|1 x 850 mg metformin tablet, under fasting conditions.
16613453|NCT02524821|Experimental|Gelesis100 plus drugs, fasted|3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.
16613454|NCT02524821|Active Comparator|drugs only, fed|1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.
16613455|NCT02524821|Active Comparator|Gelesis100 plus drugs, fed|3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).
16613456|NCT02524795|Experimental|Hiomega-3 supplement|"Patients in the study group received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company). Participants were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.
~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
16613457|NCT02524795|No Intervention|Control group|"Patients in the control group did not receive the nutrient nor any kind of placebo. They were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.
~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
16613458|NCT02524782|Experimental|MEDI-4166|MEDI-4166 administered subcutaneously
16613459|NCT02524782|Placebo Comparator|Placebo|Placebo administered subcutaneously
16613460|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
16613461|NCT02524756|Active Comparator|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
16613462|NCT02524756|Active Comparator|Group (B)|laparoscopic radical hysterectomy type III/C2
16613463|NCT02524743|Placebo Comparator|Placebo (Group I)|"For pretreatment the patients were administered IV 5ml normal saline.
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
16613464|NCT02524743|Active Comparator|Group II|"For pretreatment the patients were administered IV acetaminophen 50 mg
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
16613465|NCT02524743|Active Comparator|Group III|"For pretreatment the patients were administered IV acetaminophen 25 mg.
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
16613466|NCT02524743|Active Comparator|Group IV|"For pretreatment the patients were administered IV lidocaine 20 mg
~The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
16613467|NCT02524743|Active Comparator|Group V|"For pretreatment the patients were administered IV lidocaine 40 mg.
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
16613468|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
16613469|NCT02524717|Experimental|JNJ-56021927|Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
16613622|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
16613623|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
16613470|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
16613471|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
16613472|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.
~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
16613473|NCT02524678|Placebo Comparator|Placebo|Placebo
16613474|NCT02524678|Active Comparator|URC102|URC102
16613475|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
16613476|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
16613477|NCT02524652|Experimental|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
16613478|NCT02524652|Active Comparator|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
16613479|NCT02524639|Experimental|Sirolimus|All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.
16613480|NCT02524626|Sham Comparator|Sham stimulation|no stimulation of vagus nerve
16613481|NCT02524626|Active Comparator|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
16613482|NCT02524600|Experimental|"New Technology IQ-SPECT applied to myocardial imaging"|
16613483|NCT02524587|Active Comparator|acetabular polyethylene vitamys®|acetabular polyethylene vitamys®
16613484|NCT02524587|Active Comparator|standard polyethylene acetabular irradiated at 3 Mrad|standard polyethylene acetabular irradiated at 3 Mrad
16613485|NCT02524574|Experimental|cardiac Rehabilitation|
16613486|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
16613487|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
16613488|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
16613489|NCT02524548|Experimental|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
16613490|NCT02524548|No Intervention|Standard care|Routine care
16613491|NCT02524535|Other|Therapetic alliance|
16613492|NCT02524522|Active Comparator|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
16613493|NCT02524522|Active Comparator|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 > 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI > 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
16613494|NCT02524509||CHONDRON|Patients who already received autologous chondrocyte implantation using CHONDRON (Autologous Cultured Chondrocyte) for knee cartilage defects
16613495|NCT02524509||Microfracture|patients already underwent microfracture
16613496|NCT02524483|Experimental|Therapeutic Challenge Group|The Therapeutic Challenge Group will complete the Therapeutic Challenge Program twice a day, five days each week for 6 weeks.
16613497|NCT02524483|Active Comparator|Therapeutic Exercise Group|The Therapeutic Exercise Group will complete the Therapeutic Exercise Program twice a day, five days each week for 6 weeks.
16613498|NCT02524470|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
16613499|NCT02524457||Premenopausal|Premenopausal women going through gynecological surgery
16613500|NCT02524457||Postmenopausal|Postemnopausal women going through gynecological surgery
16613501|NCT02524457||Postmenopausal + HT|Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum)
16613502|NCT02524444|Active Comparator|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
16613503|NCT02524444|Active Comparator|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
16613624|NCT02523573||Study population|Adult ARF ICU patients needing BAL with HFNC
16613504|NCT02524431|Active Comparator|Glaucoma subjects|During glaucoma surgery, collection of trabecular meshwork tissue during surgery that is not needed is cut away from the surgical site. The physician will keep this tissue for analysis by the researchers at Wills Eye Hospital and Thomas Jefferson University Center for Translational Medicine.
16613505|NCT02524431|Active Comparator|Control cadaver eyes|control cadaver eye are ordered and the collection of trabecular meshwork tissue during surgery and is processed at Thomas Jefferson University
16613506|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
16613507|NCT02524405||Normal Controls|Upto 85 normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
16613508|NCT02524405||Alzheimer's Disease (AD)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
16613509|NCT02524405||Mild Cognitive Impairment (VCI)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association criteria for amnestic or multi-domain MCI with MoCA score ≥18 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
16613510|NCT02524405||Subcortical Vascular Impairment (VCI)|Sixty-five subjects meeting the American Heart Association-American Stroke Association (AHA-ASA) criteria for probable vascular dementia (VaD) or probable vascular mild cognitive impairment (VaMCI) due to subcortical ischemic vascular disease , and probable or possible Cerebral Amyloid Angiopathy using the Modified Boston Criteria116 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
16613511|NCT02524405||LBD Spectrum|Sixty- five subjects with: Dementia with Lewy Bodies (DLB) meeting the criteria for probable Dementia with Lewy Bodies with MMSE score ≥20; or PD-MCI meeting the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's Disease with MoCA score 18-24; or; PDD meeting the criteria for probable Parkinson's Disease - Dementia and MMSE score ≥20 will be enrolled. All patients involved will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
16613512|NCT02524392|Experimental|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
16613513|NCT02524392|No Intervention|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
16613514|NCT02524379|Experimental|Glyburide Treatment Arm|Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
16613515|NCT02524366|Experimental|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
16613516|NCT02524366|Active Comparator|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
16613517|NCT02524353|Experimental|cardiac surgery|cardiac surgery
16613518|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
16613519|NCT02524327|Experimental|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.
~Objective of depth anesthesia: 40-60"
16613520|NCT02524327|Active Comparator|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.
~Objective of depth anesthesia: 40-60"
16613521|NCT02524301|Experimental|anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
16613522|NCT02524301|Experimental|Recovered anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
16613523|NCT02524301|Experimental|Healthy Volonteers|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
16613524|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
16613525|NCT02524275|Experimental|Treatment (docetaxel, capecitabine)|Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16613526|NCT02524262|Experimental|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
16613527|NCT02524262|Placebo Comparator|Placebo|Oral intake of identically-looking placebo capsules
16613528|NCT02524249|Active Comparator|Early caffeine group|90 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates >75% of fluid goals by feeds.
16613529|NCT02524249|Placebo Comparator|Late caffeine group|90 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates >75% of fluid goals by feeds.
16613625|NCT02523560|Experimental|telerehabilitation group|1 week hospital rehabilitation and 8 weeks home-based telerehabilitation and telemanagement (including HomeMonitoring)
16613724|NCT02522923|Experimental|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
16613530|NCT02524236|Active Comparator|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.
~Botox injection in the prostate"
16613531|NCT02524236|Active Comparator|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.
~Botox injection in the prostate"
16613532|NCT02524223|Other|Population of couples candidate for MAP program|MAP = medically assisted procreation
16613533|NCT02524210|Experimental|Arm A|"Period  Dabigatran
~Washout period (at least 6 days)
~Period  Rabeprazole + Dabigatran
~Washout period (at least 6 days)
~Period  Omeprazole + Dabigatran"
16613534|NCT02524210|Experimental|Arm B|"Period Rabeprazole + Dabigatran 
~Washout period (at least 6 days)
~Period  Dabigatran
~Washout period (at least 6 days)
~Period  Omeprazole + Dabigatran"
16613535|NCT02524210|Experimental|Arm C|"Period  Rabeprazole + Dabigatran
~Period  Omeprazole + Dabigatran
~Period  Dabigatran"
16613536|NCT02524197|Active Comparator|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
16613537|NCT02524197|Active Comparator|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
16613538|NCT02524197|Active Comparator|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
16613539|NCT02524197|Active Comparator|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
16613540|NCT02524184|Experimental|Sildenafil|Eleven patients receive sildenafil 100mg/day (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM)for 7 days.
16613541|NCT02524184|Placebo Comparator|Placebo group|An identical placebo for 7 days in placebo group.
16613542|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
16613543|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
16613544|NCT02524158|Experimental|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
16613545|NCT02524158|No Intervention|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
16613546|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.
~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
16613547|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.
~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
16613548|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.
~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
16613549|NCT02524132|Experimental|Physical Activity|5 minute movement breaks
16613550|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
16613551|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
16613552|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
16613626|NCT02523560|No Intervention|control group|Patients qualified to the control group will undergo a 9-week procedure appropriate to their clinical condition/status standardized for a particular center (usual care).
16613627|NCT02523547|Experimental|Cavir|entecavir/0.5mg/day
16613628|NCT02523547|Active Comparator|Baraclude|entecavir/0.5mg/day
16613553|NCT02524093|Experimental|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
16613554|NCT02524093|Placebo Comparator|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
16613555|NCT02524080|Other|Emergency Department|Triage to optimal healthcare level
16613556|NCT02524080|Other|Healthcare Center|Triage to optimal healthcare level
16613557|NCT02524067|Experimental|Intervention|Intervention: Circadian lighting, systematic information, music, foreclosure of the individual patient
16613558|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
16613559|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
16613560|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
16613561|NCT02524041|Experimental|secondary hyperparathyroidism|Blood specimen and HR-pQCT for measure bone quality and quantity
16613562|NCT02524028||Case Participant Cohort|Participants with atrial fibrillation
16613563|NCT02524028||Control Participant Cohort|Participants without atrial fibrillation or any other heart disease
16613564|NCT02524015|Other|Control|Standard Physical Therapy
16613565|NCT02524015|Experimental|Intervention|Novel Physical Therapy
16613566|NCT02524002|Placebo Comparator|Usual Clear Diet|This intervention consists of soup broth, variety of juices (apple, cranberry, grape), ginger ale, water, and ice.
16613567|NCT02524002|Experimental|Accel Gel|"This intervention is an enhanced clear liquid gel is Accel Gel, produced by PacificHealth Labs of Matawan, NJ. This gel has 4:1 carb to protein ratio formula, and ingredients that are not contraindicated in pregnancy (only the flavors with minimal caffeine are used).
~http://www.pacifichealthlabs.com/accel-gel-all-natural-rapid-energy-gel-product.html"
16613568|NCT02523989||study group|children confirmed to have developmental delays
16613569|NCT02523989||control group|children with typical development
16613570|NCT02523976|Experimental|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
16613571|NCT02523963|Experimental|study group|"children with developmental delays participated 6 sessions of family work shop
~The family work shop has 5 courses, with 6 families in one course.
~Intervention of one course: 2-3 hours per session, one time per week, for a total of 6 weeks."
16613572|NCT02523963|No Intervention|control|children with normal development not participate the work shop followed up at before, and 6 weeks later
16613573|NCT02523950|Active Comparator|Staged group|Procedure/Surgery: Phacoemulsification + IOL implantation is performed in the first stage and DMEK is performed secondarily.
16613574|NCT02523950|Active Comparator|Combined group|Procedure/Surgery: Phacoemulsification + IOL implantation and DMEK are performed simultaneously.
16613575|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.
~The criteria for exclusion of PE or DVT are:
~low or intermediate clinical probability and D-dimer <0,50 µg/mL
~low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)
~high clinical probability and negative CT and US.
~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
16613576|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.
~The criteria for confirmation of PE or DVT are:
~PE on spiral computed tomography (CT)
~proximal deep vein thrombosis on ultrasonography (US).
~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
16613577|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
16613578|NCT02523911|Active Comparator|Simethicone Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
16613579|NCT02523911|Placebo Comparator|Placebo Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
16613721|NCT02522949|Placebo Comparator|Placebo|Sugar based mouth spray manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
16613580|NCT02523898|Experimental|metformine and clomiphene citrate|. metformin will be given at a dose of 500 mg three times a day for 8weeks. .In case of failure of ovulation after the end of this period, metformin was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene. When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose.
16613581|NCT02523898|Active Comparator|placebo and clomiphene citrate|"The patients in group two will be receiving placebo. In case of failure of ovulation after the end of this period, placebo was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration .In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene.When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose. .
~10 days). ."
16613582|NCT02523872||Acute respiratory failure|Patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration
16613583|NCT02523859|Active Comparator|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
16613584|NCT02523859|Experimental|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
16613585|NCT02523846|Active Comparator|Background morphine infusion to IV-PCA Morphine|Calculate based on patient's age, in mg/hour
16613586|NCT02523846|Experimental|Patient re-education to IV-PCA Morphine|Using patient information leaflet
16613587|NCT02523833|Other|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
16613588|NCT02523820|Experimental|fluticasone propionate|Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation
16613589|NCT02523820|Placebo Comparator|placebo|Normal saline (NSS) 4 ml nebulized after extubation
16613590|NCT02523807||Patients with Parkinson's Disease|Patients with tremor due to Parkinson Disease
16613591|NCT02523807||Patients with Essential tremor|Patients with tremor due to Essential tremor
16613592|NCT02523794|Experimental|Electro-kinetically Modified Water|Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
16613593|NCT02523794|Placebo Comparator|Placebo|Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
16613594|NCT02523781|No Intervention|Control group|The control group does not receive the information pamphlet
16613595|NCT02523781|Experimental|Intervention group|The intervention group receives the information pamphlet
16613596|NCT02523768|Experimental|ATG-F|The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
16613597|NCT02523768|Active Comparator|Simulect|The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).
16613598|NCT02523755|Active Comparator|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
16613599|NCT02523755|Sham Comparator|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
16613600|NCT02523742|Other|Neuropsychiatric Disorders|Neuropsychiatric Disorders patients
16613601|NCT02523742|Other|Healthy volunteers|control subjects matched to patients by age, sex, socio-cultural level and laterality
16613602|NCT02523729|No Intervention|control|subjects drunk no Anke Malz product.
16613603|NCT02523729|Experimental|intervention one|subjects drunk one can Anke Malz product.
16613604|NCT02523729|Experimental|intervention two|subjects drunk two cans Anke Malz product.
16613605|NCT02523716|Experimental|Hypoxia|Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
16613606|NCT02523716|Sham Comparator|Normoxia|Exposure to normal, sea-level air
16613607|NCT02523703|Other|Healthy Volunteers|Healthy Volunteers
16613608|NCT02523703|Other|Multiple Sclerosis patient|Multiple Sclerosis patient
16613609|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
16613610|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
16613611|NCT02523664|Active Comparator|Hydrocortisone|10 mg hydrocortisone orally
16613612|NCT02523664|Placebo Comparator|Placebo|placebo orally
16613613|NCT02523651|Experimental|DPSC injection|20 patients will receive DPSC injection（1000000 cells/ 0.5ml） at the local periodontal defects immediately after periodontal scaling and root planing.
16613614|NCT02523651|Placebo Comparator|Placebo control|20 patients will receive saline injection at the local periodontal defects immediately after periodontal scaling and root planing.
16613615|NCT02523638|Other|Pegylated- Proline-Interferon alpha-2b|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
16613616|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
16613617|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
16613618|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
16613619|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
16613620|NCT02523612|Experimental|Patients with atypical lesions|
16613621|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
16613629|NCT02523534|Experimental|Recurrence Mapping|Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.
16613630|NCT02523521|No Intervention|Bronchopylmonary Dysplasia Control|Nothing
16613631|NCT02523521|Experimental|Bronchopylmonary Dysplasia Intervention|physical activity program.
16613632|NCT02523521|No Intervention|Healthy children|Nothing.
16613633|NCT02523508|Experimental|Experimental group|Passive manual lumbar mobilization on L2-3 level
16613634|NCT02523508|Placebo Comparator|Control group|Passive limb mobilization which did not involve the spine
16613635|NCT02523469|Experimental|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.
~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
16613636|NCT02523469|Experimental|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.
~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
16613637|NCT02523469|Experimental|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atzolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.
~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
16613638|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.
~For exploratory Arm 1:
~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
16613639|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.
~For exploratory Arm 1:
~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
16613640|NCT02523456|Experimental|Introduce EWS and Training on EWS|The group of patients who admitted to a ward where the staff has trained on EWS and EWS has been introduced.
16613641|NCT02523456|No Intervention|EWS not introduced|The group of patients who admitted to a ward where the staff has no special training on EWS and EWS has not been introduced.
16613642|NCT02523443|Active Comparator|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
16613643|NCT02523443|Experimental|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
16613644|NCT02523430|Experimental|HepaSphere|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
16613645|NCT02523430|Placebo Comparator|control|nasopharyngeal carcinoma patients received traditional therapy
16613646|NCT02523417|Experimental|HepaSphere|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
16613647|NCT02523417|Placebo Comparator|control|breast cancer patients received traditional therapy
16613648|NCT02523404|Experimental|HepaSphere|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
16613649|NCT02523404|Placebo Comparator|control|lung cancer patients received traditional therapy
16613650|NCT02523391|Experimental|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
16613651|NCT02523391|Experimental|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
16613652|NCT02523378|Experimental|ESAS Self-Administration - Group A|Participants complete the symptom questionnaire alone. It is then counterchecked by health care professional (HCP).
16613653|NCT02523378|Experimental|ESAS Assisted-Completion - Group B|Participants complete the symptom questionnaire with the help of the research nurse or assistant.
16613654|NCT02523365|Experimental|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
16613655|NCT02523365|Placebo Comparator|control|cervical carcinoma patients received traditional therapy
16613656|NCT02523352|Experimental|Treatment|Volunteers with a BMI > 35 Kg/m2 and central fat distribution, without any past medical history
16613657|NCT02523326||Group A|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
16613658|NCT02523326||Group B|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
16613659|NCT02523326||Group C|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
16613660|NCT02523313|Active Comparator|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
16613661|NCT02523313|Experimental|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
16613662|NCT02523313|Placebo Comparator|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
16613663|NCT02523300|Experimental|TEVAR+GC|The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR
16613664|NCT02523300|Placebo Comparator|TEVAR+Vehicle|The patients underwent TEVAR. Then saline will be given after TEVAR
16613665|NCT02523287|Active Comparator|Fluad - 5 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
16613666|NCT02523287|Active Comparator|Fluad - 3 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.
~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
16613667|NCT02523287|Placebo Comparator|Saline - 5 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
16613668|NCT02523287|Placebo Comparator|Saline - 3 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.
~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
16613669|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
16613670|NCT02523274|Experimental|Resveratrol 250 mg/day + exercise|250 mg/day resveratrol taken orally in combination with exercise
16613671|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
16613672|NCT02523261|Experimental|ADAPT|
16613673|NCT02523261|Active Comparator|Stent Retriever|
16613674|NCT02523248|Active Comparator|Tonsillectomy|Tonsillectomy with cold steel
16613675|NCT02523248|Active Comparator|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
16613676|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.
~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
16613677|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009
~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
16613678|NCT02523222|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
16613679|NCT02523222|Active Comparator|Dextrose Gel|Infants given 40% Dextrose gel (0.5ml/kg) in the buccal mucosa after their first feed, within the first hour of life.
16613680|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
16613681|NCT02523196|Other|(HVPG) and HepQuant-SHUNT (HQ-Shunt)|"Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.
~Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices."
16613682|NCT02523183||Subjects with medically refractory epilepsy|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.
16613683|NCT02523170|Experimental|EUS guided nCLE|For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
16613684|NCT02523157|Experimental|Intervention|Wellbeing Plan
16613685|NCT02523157|Active Comparator|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
16613686|NCT02523144|Active Comparator|Chloral Hydrate + placebo|Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
16613687|NCT02523144|Active Comparator|Dexmedetomidine 2mcg/kg + placebo|Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
16613688|NCT02523144|Active Comparator|Dexmedetomidine 3mcg/kg + placebo|Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
16613722|NCT02522936|Experimental|Biotene|Participants will be given Biotene oral spray to use as needed when taking oxybutynin.
16613723|NCT02522936|No Intervention|Routine care|Participants will be given routine care.
16613689|NCT02523131|Experimental|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
16613690|NCT02523131|Active Comparator|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
16613691|NCT02523105|Other|Participants diagnosed with depression.|EEG monitoring and evaluation
16613692|NCT02523105|Other|Healthy participants.|EEG monitoring and evaluation
16613693|NCT02523092|Experimental|Acthar gel|After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
16613694|NCT02523079|Experimental|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
16613695|NCT02523079|Experimental|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
16613696|NCT02523079|Experimental|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
16613697|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
16613698|NCT02523053|Active Comparator|Hepatectomy|Surgical removal of all lesions
16613699|NCT02523053|Experimental|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
16613700|NCT02523040|Experimental|Lenalidomide|"After the screening procedures confirm participation in the research study.
~- Lenalidomide Oral, Daily for 21 days of each cycle"
16613701|NCT02523027|Experimental|Experimental Group 1:|Oral nutritional supplement (List No S691/Z0) and dietary counseling
16613702|NCT02523027|Experimental|Experimental Group 2|Oral nutritional supplement (List No- P968/Z0) and dietary counseling.
16613703|NCT02523027|No Intervention|Control Group|Dietary Counselling only.
16613704|NCT02523014|Experimental|Arm A (vismodegib)|Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)
16613705|NCT02523014|Experimental|Arm B (FAK inhibitor GSK2256098)|Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)
16613706|NCT02523014|Experimental|Arm C (capivasertib)|Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.
16613707|NCT02523014|Experimental|Arm D (abemaciclib)|Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16613708|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
16613709|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
16613710|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
16613711|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
16613712|NCT02522988|Experimental|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
16613713|NCT02522988|No Intervention|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
16613714|NCT02522988|No Intervention|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
16613715|NCT02522988|Experimental|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
16613716|NCT02522975|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
16613717|NCT02522975|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
16613718|NCT02522962|Experimental|GroupCoreSIT|Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training. Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
16613719|NCT02522962|Active Comparator|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
16613720|NCT02522949|Active Comparator|ColdZyme|ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
16613725|NCT02522923|Active Comparator|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
16613726|NCT02522910|Experimental|Roniciclib with Docetaxel|
16613727|NCT02522897|Active Comparator|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
16613728|NCT02522897|Experimental|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
16613729|NCT02522884|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
16613730|NCT02522871|Experimental|OCS Liver System|OCS Liver System
16613731|NCT02522871|Other|Control|Standard of care (ice)
16613732|NCT02522858|Placebo Comparator|Placebo|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, normal saline 0.5mL would be injected intravenously.
16613733|NCT02522858|Experimental|Atropine|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, ,atropine 0.03mg/kg would be injected intravenously.
16613734|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
16613735|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
16613736|NCT02522832|Experimental|Titre 1|Low infectious titre of innoculum
16613737|NCT02522832|Experimental|Titre 2|Medium infectious titre of innoculum
16613738|NCT02522832|Experimental|Titre 3|High infectious titre of innoculum
16613739|NCT02522819|Experimental|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
16613740|NCT02522806|Experimental|Group A|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle.
16613741|NCT02522806|No Intervention|Group B|none endometrial biopsy
16613742|NCT02522780|Experimental|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
16613743|NCT02522780|Placebo Comparator|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
16613744|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
16613745|NCT02522767|Placebo Comparator|Placebo|Matching placebo
16613746|NCT02522754|Placebo Comparator|Placebo|Placebo
16613747|NCT02522754|Experimental|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
16613748|NCT02522754|Experimental|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
16613749|NCT02522754|Experimental|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
16613750|NCT02522741|Experimental|Parenting STAIR|
16613751|NCT02522728|Active Comparator|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
16613752|NCT02522728|Active Comparator|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
16613753|NCT02522715|Experimental|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of cycle 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
16613754|NCT02522702||Routine colonoscopy Cohort|
16613755|NCT02522689|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
16613756|NCT02522689|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
16613757|NCT02522676|Active Comparator|Conventional PCNL|Endoscopic kidney stone surgery: Patients will undergo conventional percutaneous nephrolithotripsy.
16613758|NCT02522676|Active Comparator|Mini PCNL|Endoscopic kidney stone surgery: Patients will undergo mini percutaneous nephrolithotripsy.
16613759|NCT02522676|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
16613760|NCT02522676|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
16613761|NCT02522676|Active Comparator|Retrograde intrarenal surgery|Endoscopic kidney stone surgery: Patients will undergo retrograde intrarenal surgery.
16613762|NCT02522676|Active Comparator|Extracorporeal shock wave lithotripsy|Non-invasive kidney stone treatment: Patients will undergo extracorporeal shock wave lithotripsy.
16613763|NCT02522663|No Intervention|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
16613764|NCT02522663|Experimental|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
16613765|NCT02522650|Experimental|Amiloride Phase|Subject receives 5mg of Amiloride twice daily for 8 weeks.
16613766|NCT02522650|Active Comparator|Triamterene Phase|Subject receives 50mg of Triamterene twice daily for 8 weeks.
16613767|NCT02522650|No Intervention|Washout Phase|Subject does not take any study medication for 4 weeks
16613768|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
16613806|NCT02522351|Experimental|Cereal extract concentration 2|Cereal extract at concentration 2
16613769|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
16613770|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
16613771|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
16613773|NCT02522598|Experimental|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
16613774|NCT02522598|Placebo Comparator|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
16613775|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
16613776|NCT02522572|Experimental|Group A|4 doses of plerixafor and plasmapheresis
16613777|NCT02522572|Experimental|Group B|4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
16613778|NCT02522572|Experimental|Group C|6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
16613779|NCT02522559|Experimental|Spice Intervention|Spice intervention: Student-approved vegetable recipes will be served in the school cafeteria.
16613780|NCT02522546||nasopharyngeal swab|Children ages 1-5 years and their household contacts
16613781|NCT02522533|Experimental|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
16613782|NCT02522520|Active Comparator|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.
~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
16613783|NCT02522520|Active Comparator|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity
~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
16613784|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
16613785|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
16613786|NCT02522494|Active Comparator|Intervention|Patients randomized to the intervention will view the video
16613787|NCT02522494|Other|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
16613788|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
16613789|NCT02522468|Experimental|Radioactive Seed Localization|Radioactive Seeds
16613790|NCT02522468|Active Comparator|Wire Localization|Wire
16613791|NCT02522455|Other|Preterm infants with RDS|
16613792|NCT02522442|Experimental|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
16613793|NCT02522442|Active Comparator|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
16613794|NCT02522429|Experimental|Low Intensity Focused Ultrasound Device|15 acute DOC patients, 15 chronic DOC patients
16613795|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
16613796|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
16613797|NCT02522390||Nutrition Researcher Cohort|This cohort study is an observational, one-group study. The intervention consists of research activities that participants are asked to perform throughout the cohort, including the use of do-it-yourself devices, filling out online-questionnaires and sample collection with supplied kits for the analysis of various health parameters. The frequency with which participants are asked to measure these health parameters varies, ranging from once to weekly.
16613798|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
16613799|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
16613800|NCT02522364|Active Comparator|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
16613801|NCT02522364|Active Comparator|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
16613802|NCT02522351|Active Comparator|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
16613803|NCT02522351|Active Comparator|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
16613804|NCT02522351|Active Comparator|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
16613805|NCT02522351|Experimental|Cereal extract concentration 1|Cereal extract at concentration 1
16613809|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16613810|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16613811|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
16613812|NCT02522299|Placebo Comparator|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
16613813|NCT02522299|Experimental|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
16613814|NCT02522299|Placebo Comparator|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
16613815|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
16613816|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
16613817|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
16613818|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
16613819|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
16613820|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
16613821|NCT02522260|Active Comparator|Group 3|Standard supportive care
16613822|NCT02522247|Active Comparator|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
16613823|NCT02522247|No Intervention|Controls|Only waiting 6 months
16613824|NCT02522234|Experimental|F-627 240 µg/kg|"F-627 at the dose of 240 mcg/kg administered by s.c. injection on Day 2 of each cycle for up to 6 cycles.
~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
16613825|NCT02522234|Experimental|F-627 320 µg/kg|"F-627 at the dose of 320 mcg/kg administered by s.c. injection on Day 2 of each cycle for 6 cycles.
~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
16613826|NCT02522221|Experimental|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
16613827|NCT02522221|Active Comparator|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
16613828|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
16613829|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
16613830|NCT02522182|Experimental|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
16613831|NCT02522182|Active Comparator|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
16613832|NCT02522169|Active Comparator|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:
~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
16613833|NCT02522169|Experimental|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
16613874|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
16613913|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
16613914|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
16613834|NCT02522156|Experimental|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:
~Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.
~Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.
~Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.
~Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
16613835|NCT02522156|Placebo Comparator|Control|"Four audiotape-guided imagery exercises, as follows:
~Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.
~Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.
~Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.
~Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
16613836|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
16613837|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
16613838|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
16613839|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
16613840|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
16613841|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
16613842|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
16613843|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
16613844|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
16613845|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
16613846|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
16613847|NCT02522091|Other|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
16613848|NCT02522091|Other|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
16613849|NCT02522091|Other|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
16613850|NCT02522091|Other|Alzheimer's Disease patient|Alzheimer's Disease patient
16613851|NCT02522091|Other|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
16613852|NCT02522078|Active Comparator|Dry Misoprostol|400 µg of dry misoprostol
16613853|NCT02522078|Experimental|Wet misoprostol|400 µg of wet misoprostol
16613854|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
16613855|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
16613856|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
16613857|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
16613858|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
16613859|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
16613860|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
16613861|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
16613862|NCT02522026||Healthy volunteers|
16613863|NCT02522026||Healthy smokers|
16613864|NCT02522026||COPD GOLD1|
16613865|NCT02522026||COPD GOLD2|
16613866|NCT02522026||COPD GOLD3/4|
16613867|NCT02522013|Experimental|Aminophylline group|IV injection of aminophylline
16613868|NCT02522013|Placebo Comparator|isotonic saline group|IV injection of isotonic saline group
16613869|NCT02522000||Patients with functional dyspepsia|
16613870|NCT02522000||Healthy controls|
16613871|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
16613872|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
16613873|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
16613875|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
16613876|NCT02521948|Experimental|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
16613877|NCT02521935|Active Comparator|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
16613878|NCT02521935|Active Comparator|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
16613879|NCT02521922|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
16613880|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
16613881|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
16613882|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
16613883|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
16613884|NCT02521870|Experimental|Dose Escalation Phase 1b|Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
16613885|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
16613886|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
16613887|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
16613888|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
16613889|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 5)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
16613890|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 6)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
16613891|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 7)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
16613892|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 8)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
16613893|NCT02521857|Experimental|ALKS 5461|Sublingual tablet
16613894|NCT02521844|Experimental|Dose Escalation|ETC-1922159 + pembrolizumab
16613895|NCT02521844|Experimental|Dose Expansion|ETC-1922159 as single agent until disease progression, then in combination with pembrolizumab at the recommended dose (RD) identified in the dose escalation segment
16613896|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.
~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
16613897|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.
~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.
~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
16613898|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
16613899|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
16613900|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
16613901|NCT02521805|Experimental|PAF|Animal protein added fiber
16613902|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
16613903|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
16613904|NCT02521792|Experimental|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
16613905|NCT02521779|Experimental|Test Meal Saturated Fat|Saturated-fat Treatment Meal
16613906|NCT02521779|Experimental|Test Meal N-6 Fat|N-6 fat Treatment Meal.
16613907|NCT02521779|Experimental|Test Meal N-3 Fat|N-3 fat Treatment Meal.
16613908|NCT02521779|Experimental|Test Meal Low-fat|Low-fat Treatment Meal.
16613909|NCT02521766|Experimental|All HMIOL Cohort|HMIOL implantation with or without optic exchange
16613910|NCT02521766|Experimental|Cohort 1|HMIOL implantation with no optic exchange
16613911|NCT02521766|Experimental|Cohort 2|HMIOL implantation with optic exchange
16613912|NCT02521766|Other|Fellow Eye|IOL implantation per standard of care
16613915|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
16613916|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
16613917|NCT02521740||controls|someone who lives with an healthy elderly
16613918|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.
~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
16613919|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.
~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.
~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
16613920|NCT02521714|Experimental|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
16613921|NCT02521714|Experimental|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
16613922|NCT02521714|Experimental|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
16613923|NCT02521701|Experimental|NFL101|"Level 1: 100 µg
~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29
~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.
~Level 2: 200 µg
~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29
~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
16613924|NCT02521688||Group I (PTD + CP)|include ten mothers exhibiting spontaneous preterm delivery with moderate to severe chronic periodontitis +incisional biopsy from placenta and GCF sample
16613925|NCT02521688||Group II (TD + CP)|include ten mothers exhibiting spontaneous term delivery with moderate to severe chronic periodontitis+incisional biopsy from placenta and GCF sample
16613926|NCT02521688||Group III (PTD + HP)|include tenmothersexhibiting spontaneous preterm delivery with healthy periodontium +incisional biopsy from placenta and GCF sample
16613927|NCT02521688||Group IV (TD + HP)|ten mothersexhibiting spontaneous term delivery with healthy periodontium(Armitage GC. 1999)+ incisional biopsy from placenta and GCF sample
16613928|NCT02521675|Other|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
16613929|NCT02521675|Other|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
16613930|NCT02521662|Active Comparator|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
16613931|NCT02521662|Active Comparator|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
16613932|NCT02521662|Active Comparator|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
16613933|NCT02521649|Experimental|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
16613934|NCT02521649|Experimental|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
16613935|NCT02521649|Experimental|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
16613936|NCT02521649|Experimental|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
16613937|NCT02521649|Experimental|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
16613938|NCT02521636|Placebo Comparator|Anibiotic therapy guided with actual french recommandations|Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.
16613939|NCT02521636|Experimental|Anibiotic therapy guided with serum PCT value|"Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:
~PCT <0.1 ng / mL: no antibiotics
~0.1 <PCT <0.25 ng / mL: antibiotic advised
~PCT> 0.25 ng / mL: highly recommended antibiotics"
16613940|NCT02521623|Experimental|Surgimend|Patients randomized to this arm will receive SurgiMend® Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
16613941|NCT02521623|Active Comparator|Strattice|Patients randomized to this arm will receive Strattice™ Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
16613997|NCT02521233|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
16613942|NCT02521610|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RG7625 as oral capsules once or twice daily for 8 days. Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin purified protein derivative [PPD], Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
16613943|NCT02521610|Experimental|RG7625|Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
16613944|NCT02521597|Experimental|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
16613945|NCT02521597|Active Comparator|Traditional otoscope|The control group will be using a classic otoscope
16613946|NCT02521571|Experimental|Intervention Group|
16613947|NCT02521571|Placebo Comparator|Control Group|
16613948|NCT02521558|Experimental|Intervention Group|In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
16613949|NCT02521558|Active Comparator|Control Group|The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.
16613950|NCT02521545|Experimental|BIIB061|Single oral dose of 30 mg BIIB061 of the new formulation
16613951|NCT02521532|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
16613952|NCT02521532|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
16613953|NCT02521519|Other|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
16613954|NCT02521519|Other|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
16613955|NCT02521506|Experimental|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
16613956|NCT02521506|Active Comparator|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
16613959|NCT02521480|Active Comparator|Active Transcranial Magnetic Stimulation|During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression.
16613960|NCT02521480|Sham Comparator|Sham Transcranial Magnetic Stimulation|During sham TMS, a coil will be placed on the left prefrontal area of the head. Sham TMS will simulate active treatment as described in active arm.
16613961|NCT02521467|Active Comparator|PRF|Platelets Rich Fibrin
16613962|NCT02521467|Placebo Comparator|palatal stent|Palatal stent
16613963|NCT02521454|Experimental|MBRT|Mindfulness-Based Resilience Training
16613964|NCT02521454|No Intervention|WL Control|waitlist control group
16614213|NCT02519725|No Intervention|Without diary|No diary is open during the ICU stay
16613965|NCT02521441|Experimental|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
16613966|NCT02521441|Experimental|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
16613967|NCT02521441|Experimental|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
16613968|NCT02521415|Experimental|ketamine|ketamine (1mg/kg)
16613969|NCT02521415|Active Comparator|fentanyl|fentanyl (1.5 micrograms/kg)
16613970|NCT02521402|Other|Keloid Revision Surgery with Biovance|All enrolled patients will have Biovance applied during Keloid Revision Surgery
16613971|NCT02521389|Experimental|Part 1|3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required.
16613972|NCT02521389|Experimental|Part 2|Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects.
16613973|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
16613974|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
16613975|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
16613976|NCT02521363|Experimental|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
16613977|NCT02521363|Experimental|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
16613978|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
16613979|NCT02521337||pregnant women not in active labor|
16613980|NCT02521337||pregnant women in preterm labor|
16613981|NCT02521337||pregnant women in term labor|
16613982|NCT02521324|Experimental|Immediate treatment (IT)|Subjects from this group will perform 2 weeks of DGB with the DGB2 system immediately after 1 week of baseline monitoring. All subjects will answer questionnaires pertaining to their sleep quality.
16613983|NCT02521324|Active Comparator|Wait list control (WLC)|The subjects from the WLC group will do the same (answer questionnaires and perform 2 weeks of DGB with the DGB2 system) at a 1 week delay.
16613984|NCT02521311|Experimental|Clemastine|Participants will receive clemastine until 3 months and then will be off treatment until 9 month time point.
16613985|NCT02521311|Placebo Comparator|Placebo|Participants will receive placebo until 3 months and then will be off treatment until 9 month time point.
16613986|NCT02521298|Active Comparator|Strength Training + Placebo|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.
~Placebo: Ultrasound-guided subcutaneous injection of 2 ml isotonic saline over the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
16613987|NCT02521298|Experimental|Strength Training + Cortico-Steroid Inj.|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.
~Cortico-Steroid Injection: Ultrasound-guided injection of 1 ml depomedrol 40 mg/ml + 1 ml lidocaine 10 mg/ml deep to the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
16613988|NCT02521298|Experimental|Strength Training + Dry Needling|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.
~Dry Needling: Ultrasound-guided penetration of the proximal part of the common extensor tendon origin is repeated 10 times using a 0,8 mm needle, followed by subcutaneous injection of 2 ml isotonic saline superficial to the tendon. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
16613989|NCT02521285|Experimental|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
16613990|NCT02521285|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
16613991|NCT02521272|Experimental|air pocket|Breathing in the simulated avalanche snow.
16613992|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
16613993|NCT02521259||normal BIS group|BIS range from 40 to 60
16613994|NCT02521246|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 12,5 mg) a day, in the morning.
16613995|NCT02521246|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 25 mg) a day, in the morning.
16613996|NCT02521246|Active Comparator|Comparator: Losartan+hydrochlorothiazide (Hyzaar®)|The patients will take 1 tablet (Losartan 100 mg + Hydrochlorothiazide 25 mg) a day, in the morning.
16614311|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
16613998|NCT02521233|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
16613999|NCT02521233|Active Comparator|Comparator: losartan+hydrochlorothiazide (Hyzaar®)|he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
16614000|NCT02521220|Experimental|L-citrulline|Oral food-supplemental amino-acid L-citrulline. 2 times 3g per day.
16614001|NCT02521220|Placebo Comparator|Maltodextrin|Maltodextrin as placebo. 2 times 3g per day
16614002|NCT02521207|Experimental|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
16614003|NCT02521207|Active Comparator|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
16614004|NCT02521207|Experimental|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
16614005|NCT02521207|Experimental|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
16614006|NCT02521194|Experimental|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
16614007|NCT02521194|Experimental|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
16614008|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
16614009|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
16614010|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
16614011|NCT02521168|Experimental|Oral triiodothyronine|Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
16614012|NCT02521168|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
16614013|NCT02521155|Experimental|Intervention group|Safeguard Your Smile an oral health literacy intervention.
16614014|NCT02521155|No Intervention|Control group|No intervention, only a conventional pamphlet will be given.
16614015|NCT02521142||AMD: treatment-naive|
16614016|NCT02521142||AMD: active neovascular AMD|
16614017|NCT02521129|Experimental|Ablation|Intervention: ablation of biopsy needle track with a new device
16614018|NCT02521116|Other|Healthy subjects|healthy study subjects, age 18-80 years
16614019|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
16614020|NCT02521090|Experimental|Treatment (EGFRBi-armed autologous T cells)|"PHASE I: Patients receive EGFRBi-armed autologous T cells IT twice weekly for 4 weeks.
~PHASE II: Patients receive EGFRBi-armed autologous T cells* IT twice weekly for 4 weeks and then IV over 15-30 minutes twice weekly for 2 weeks.
~*NOTE: Six selected patients receive EGFRBi-armed autologous T cells IV on day -3, -2, or -1 prior to first IT infusion."
16614021|NCT02521077|Experimental|Odd Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
16614022|NCT02521077|Experimental|Even Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
16614023|NCT02521064||Exclusive Enteral Nutrition (EEN)|The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
16614024|NCT02521064||Prednisone|Patients who receive the prednisone intervention will follow the Division of Pediatric Gastroenterology and Nutrition protocol for corticosteroid induction therapy, with 2 weeks of high dose IV/PO prednisone (maximum 40mg/day) followed by a 6 week wean (approximately decreasing 5mg/day per week). The patient will receive a phone call from the nurse practitioner at two weeks and will be seen in clinic at 4 weeks to assess progress and symptom improvement.
16614025|NCT02521051|Experimental|Alectinib and Bevacizumab.|"Phase 1
~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Alectinib, orally, twice a day, per cycle
~Bevacizumab, iv, once per cycle
~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
16614026|NCT02521025|Experimental|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
16614027|NCT02521025|Experimental|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
16614028|NCT02521012|Active Comparator|Vitamin D 10 micrograms|"Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as reference"
16614029|NCT02521012|Experimental|Vitamin D 100 micrograms|Vitamin D supplementation 100 micrograms/day given to depressed individuals
16614352|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
16614030|NCT02520999|Active Comparator|5days|5 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
16614031|NCT02520999|Active Comparator|35days|35 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
16614032|NCT02520986|Experimental|Carbon dioxide Laser ablation|Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
16614033|NCT02520986|Active Comparator|Electrocoagulation|Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
16614034|NCT02520973|Experimental|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
16614035|NCT02520973|Active Comparator|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
16614036|NCT02520947|Experimental|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
16614037|NCT02520947|Other|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
16614038|NCT02520934|Experimental|Case_Miglustat|Besides regular ERT, patients in this group also need to take Miglustat for 24 months.
16614039|NCT02520934|No Intervention|Control|Patients will be tested for their pupil cycle time.
16614040|NCT02520921|Active Comparator|Arm 1 : Novel strategy|enteric coated aspirin 100 mg in the morning and 100 mg in the evening
16614041|NCT02520921|Active Comparator|Arm 2 : Conventional strategy|enteric coated aspirin 100 mg in the morning
16614042|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
16614043|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
16614044|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
16614045|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
16614046|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
16614047|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
16614048|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
16614049|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
16614050|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
16614051|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
16614052|NCT02520882|Experimental|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
16614053|NCT02520869|Active Comparator|swim-up|swim-up technique for semen processing
16614054|NCT02520869|Active Comparator|zeta test|zeta test technique for semen processing
16614055|NCT02520856||Hypertrophic cardiomyopathy|"All patients with newly diagnosed unexplained HCM will be prospectively included.
~All patients will undergo both classical genetic analysis and WES technology."
16614056|NCT02520843|Experimental|Crohn's disease treated by SVF|Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
16614057|NCT02520830|Active Comparator|Blueberry Group|Dietary Supplement: 22 gram freeze-dried blueberry powder per day
16614058|NCT02520830|Placebo Comparator|Placebo Group|blueberry polyphenol deprived powder 22 gram per day
16614059|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
16614060|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
16614061|NCT02520804|Active Comparator|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
16614062|NCT02520804|Experimental|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
16614063|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16614064|NCT02520778|Experimental|Treatment (navitoclax, osimertinib)|Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
16614065|NCT02520752|Experimental|INC280|
16614066|NCT02520739|Placebo Comparator|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
16614067|NCT02520739|Experimental|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
16614068|NCT02520739|Experimental|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
16614353|NCT02518685|Sham Comparator|Control|Sham procedure plus Lifestyle Counseling
16614069|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
16614070|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
16614071|NCT02520713||Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
16614072|NCT02520700|Experimental|Study participants|This was split scalp design - so each patient had one half of scalp treated with daylight PDT and one side treated with the artificial white light PDT - a surgical light (Maquet Power 500 LED surgery light)
16614073|NCT02520687|Experimental|Dietary nitrate, beetroot juice|Once daily 70mL dose of beetroot juice, containing 400mg inorganic nitrate, for 7 consecutive days.
16614074|NCT02520687|Placebo Comparator|Nitrate-depleted beetroot juice|Once daily 70mL dose of beetroot juice, depleted of nitrate, for 7 consecutive days.
16614075|NCT02520674|Other|Glaucoma and Ocular Hypertension|Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy.
16614076|NCT02520661|No Intervention|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
16614077|NCT02520661|Active Comparator|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
16614078|NCT02520648|Active Comparator|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
16614079|NCT02520648|Experimental|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
16614080|NCT02520648|Experimental|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
16614081|NCT02520635||TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
16614082|NCT02520635||post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
16614083|NCT02520622|Experimental|Control|Patients use digital photographs loaded onto a mobile device
16614084|NCT02520622|Experimental|Reminders|Patients use digital photographs loaded onto a mobile device and receive skin exam reminders
16614085|NCT02520622|Experimental|Social Support|Patients use digital photographs loaded onto a mobile device and a social support network
16614086|NCT02520622|Experimental|Combined|Patients use digital photographs loaded onto a mobile device and a social support network and receive skin exam reminders
16614090|NCT02520583|Experimental|MICROBAC|Bacterial cultures
16614091|NCT02520583|Placebo Comparator|Placebo|Maltodextrin
16614092|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
16614093|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
16614094|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
16614095|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
16614096|NCT02520544|Active Comparator|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
16614097|NCT02520544|Active Comparator|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
16614098|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
16614099|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
16614100|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
16614101|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
16614102|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
16614103|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
16614104|NCT02520505|Other|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
16614105|NCT02520505|Active Comparator|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
16614106|NCT02520492|Experimental|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.
~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
16614107|NCT02520479|Experimental|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1] before radiotherapy(RT) and then two consolidation cycles after RT."
16614108|NCT02520466|Active Comparator|flavanol-containing drink|flavanol-containing drink
16614109|NCT02520466|Placebo Comparator|flavanol-free drink|flavanol-free drink matched for taste and calories
16614110|NCT02520453|Experimental|Durvalumab|Durvalumab 20 mg/Kg IV Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
16614111|NCT02520453|Placebo Comparator|Placebo|Placebo Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
16614112|NCT02520440||GIF and/or MOF patients|Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
16614113|NCT02520440||Controls|patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
16614119|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
16614120|NCT02520401|Experimental|Test|Probiotic tablet
16614121|NCT02520401|Placebo Comparator|Control|Control tablet
16614122|NCT02520388|Experimental|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)
~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
16614158|NCT02520141|Experimental|Treatment (ramucirumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16614123|NCT02520388|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
16614124|NCT02520375|Experimental|Prebiotic|This group will be administered a prebiotic mouthrinse and toothpaste
16614125|NCT02520375|Placebo Comparator|Control|This group will be administered a control mouthrinse and toothpaste
16614126|NCT02520362||Postmenopausal Women|Postmenopausal Women
16614127|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
16614128|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
16614129|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
16614130|NCT02520336|Experimental|active management|Laboratoy test request given postpartum with phone reminder prior to test
16614131|NCT02520336|No Intervention|Routine care|
16614132|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
16614133|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
16614134|NCT02520310|Experimental|AVJ-514|The AVJ-514 system
16614135|NCT02520297|Experimental|TRV130|Drug: TRV130
16614136|NCT02520284|Experimental|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
16614137|NCT02520284|Experimental|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
16614138|NCT02520284|Placebo Comparator|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
16614139|NCT02520271|Active Comparator|Depression|Behavioral activation only
16614140|NCT02520271|Active Comparator|Depression and SUD|Motivational interview and Behavioral activation
16614141|NCT02520258|Experimental|Aspartame Consumers - Cohort 1|"Experimental Group/Arm
~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).
~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
16614142|NCT02520258|Active Comparator|Aspartame Naive Participants - Cohort 2|"Control Group/Arm
~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).
~Phase II - Not applicable for this cohort."
16614143|NCT02520245|Experimental|Open-Label|
16614144|NCT02520232|Experimental|Physical activity program (A)|Physical exercises
16614145|NCT02520232|Experimental|Physical activity program (B)|Physical exercises
16614146|NCT02520232|No Intervention|Control|No physical exercices assigned by the protocol
16614147|NCT02520219|Experimental|GDP+Endostar|"Patients in this group will be given conventional chemotherapy medicine:
~GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma and Endostar."
16614148|NCT02520219|Active Comparator|GDP|"Patients in this group will be given conventional chemotherapy medicine:
~GDP (gemcitabine+dexamethasone+cis-platinum) chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma."
16614149|NCT02520206||Arthritis|subjects with arthritis
16614150|NCT02520206||Health control subjects|Health control
16614151|NCT02520193|No Intervention|Standard mobilization strategy|
16614152|NCT02520193|Experimental|protocolized early mobilization strategy|
16614153|NCT02520180|Experimental|Firehawk™ stent system|MicroPort Firehawk™ stent system
16614154|NCT02520180|Active Comparator|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
16614155|NCT02520167|Experimental|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
16614156|NCT02520167|No Intervention|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index > 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
16614157|NCT02520154|Experimental|Treatment (carboplatin, paclitaxel, and pembrolizumab)|"NACT: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
~ADJUVANT THERAPY: Beginning 3-6 weeks after surgery, paclitaxel IV over 1 hour on days 1, 8, and 15, patients receive carboplatin IV over 1 hour on day 1, and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity."
16614159|NCT02520128|Other|Cohort 1 (closed to recruitment)|"Cohort 1: Patients with Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)
~Dose schedules for Cohort 1:
~Pre-operative RT - 50 Gy in 25 daily fractions over 5 weeks
~Post-operative RT - 60 Gy in 30 daily fractions to the high dose planning target volume (PTV) and 52.2 Gy in 30 daily fractions to the low dose PTV treated concurrently over 6 weeks
~Post-operative RT (positive resection margins) - 66 Gy in 33 daily fractions to the high dose PTV, and 53.46Gy in 33 fractions to the low dose PTV treated concurrently over 6 ½ weeks."
16614160|NCT02520128|Other|Cohort 2|"Cohort 2: Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)
~Dose schedules for Cohort 2:
~Pre-operative RT - 50.4 Gy in 28 daily fractions over 5½ weeks
~Post-operative RT - 54 Gy in 30 daily fractions over 6 weeks
~Primary RT - 54 Gy in 30 daily fractions over 6 weeks."
16614161|NCT02520128|Other|Cohort 3|"Cohort 3: Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant Radiotherapy (Intensity Modulated Radiotherapy)
~Dose schedule for Cohort 3:
~Primary RT - 70 Gy in 35 daily fractions over 7 week
~Post-operative RT (non-chordoma) - primary bone sarcoma 60 Gy in 30 daily fractions over 6 weeks
~Post-operative RT (chordoma) - 70 Gy in 35 daily fractions over 7 weeks."
16614162|NCT02520115|Experimental|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
16614163|NCT02520115|Experimental|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
16614164|NCT02520102|Experimental|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
16614165|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
16614166|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
16614167|NCT02520076|Experimental|AAT treated group|Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
16614168|NCT02520063|Experimental|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
16614169|NCT02520063|Experimental|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
16614170|NCT02520063|Experimental|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
16614171|NCT02520063|Experimental|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
16614172|NCT02520050|Active Comparator|Traditional MNT|Will be instructed to follow a MNT plan as recommended by the ADA through consultation with a RD.
16614173|NCT02520050|Active Comparator|Structured MNT|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day.
16614174|NCT02520050|Active Comparator|Structured MNT plus Weekly Support|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal-replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day plus weekly coaching.
16614175|NCT02520024|Experimental|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
16614176|NCT02520024|No Intervention|Treatment as usual|Participants in the control condition will receive services as usual.
16614177|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
16614178|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
16614179|NCT02519998||Concussed patients|The clinical focus of this study will be on concussed athletes, both children and adults, and we will also include non-sports patients who have mild traumatic brain injury due to other situations including slip and fall, occupational, motor vehicle accidents, assault, and blast exposure.
16614180|NCT02519998||Non-concussed patients|Cohort control. Primarily athletes who undergo routine pre-season baseline assessment
16614210|NCT02519738|Active Comparator|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
16614181|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):
~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.
~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.
~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):
~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.
~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
16614182|NCT02519972|Experimental|Low dose computed tomography|All the Low dose computed tomography of lung was performed with 64 slices multidetectors CT in single hold breath covering entire lung. The protocol of scanning parameters (120KVp, 40-80 mA, 1.25 mm or less in thickness) was standardized. The raw data would be reconstructed to axial images (3 mm thickness and interval) and coronal images (3 mm thickness and interval). The scan should be finished in a single breath (15-20 second) from the thoracic inlet to adrenal glands.
16614183|NCT02519946|Experimental|On-Line Diet and Exercise Intervention|
16614184|NCT02519933|Active Comparator|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
16614185|NCT02519933|Active Comparator|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
16614186|NCT02519920|Experimental|group 1|This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.
16614187|NCT02519920|Experimental|group 2|This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.
16614188|NCT02519920|Experimental|group 3|This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.
16614189|NCT02519920|Active Comparator|group 4|This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.
16614190|NCT02519894|Experimental|Intervention group|Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
16614191|NCT02519894|Placebo Comparator|Controlled group|Standard education
16614192|NCT02519881|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
16614193|NCT02519881|Active Comparator|microfracture|simple microfracture for cartilage defect of ankle
16614194|NCT02519868|Experimental|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
16614195|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
16614196|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
16614197|NCT02519842|Experimental|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
16614198|NCT02519842|Placebo Comparator|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
16614199|NCT02519842|Experimental|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
16614200|NCT02519829|Active Comparator|Monocryl closure|"The skin incision is closed with monocryl dissolvable sutures and a topical adhesive (glue) called Dermabond and covered with a Tegaderm dressing.
~Intervention: Monocryl closure, Tegaderm dressing"
16614201|NCT02519829|Active Comparator|Vicryl and staple closure|"The skin incision is closed with vicryl and staples and covered with a gauze dressing.
~Intervention: Vicryl and Staple closure, Gauze dressing"
16614202|NCT02519816|Experimental|Intervention|Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
16614203|NCT02519777|Placebo Comparator|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A will receive placebo for MVC and placebo for DTG.
16614204|NCT02519777|Experimental|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B will receive DTG and placebo for MVC.
16614205|NCT02519777|Experimental|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C will receive MVC and DTG
16614206|NCT02519764|Experimental|Hydration when thirsty|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
16614207|NCT02519764|Experimental|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
16614208|NCT02519751|Experimental|D3 Creatine followed by creatine supplementation|Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
16614209|NCT02519738|Active Comparator|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
16614211|NCT02519738|Active Comparator|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
16614212|NCT02519725|Active Comparator|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
16614214|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
16614215|NCT02519699|Experimental|Norepinephrine|Noradrenaline continuous infusion IV
16614216|NCT02519686||Trendelenburg position maneuver|Trendelenburg (TD) positioning (supine with head tilt-down) is used in abdominal and gynecological surgery as well as during colonoscopy to allow better access to the pelvic organs, as gravity pulls the bowel out of the pelvic cavity and the rectosigmoid angle straightens.
16614217|NCT02519686||Left lateral position maneuver|Left Lateral (LL) position (patient laying on their side, traditionally used for colonoscopies)
16614218|NCT02519660|Experimental|Lidocaine/Tetracaine patch (Ralydan)|Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
16614219|NCT02519660|Active Comparator|Lidocaine/Prilocaine cream (EMLA)|EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
16614220|NCT02519647|Active Comparator|tracheal intubation with Gliderite|Gliderite will be used for intubation
16614221|NCT02519647|Experimental|Tracheal intubation with S-Guide|S-Guide will be used for intubation
16614222|NCT02519634|Other|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
16614223|NCT02519634|Other|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
16614224|NCT02519621|Active Comparator|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
16614225|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
16614226|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
16614227|NCT02519608|Active Comparator|Aspirin 100 mg + Clopidogrel 75 mg|dual antiplatelet therapy as suggested by guidelines with aspirin 100 mg and clopidogrel 75 mg daily
16614228|NCT02519608|Experimental|Aspirin 100 mg + Ticagrelor 90 mg x2|dual antiplatelet therapy with aspirin 100 mg and ticagrelor 90 mg x 2 daily
16614229|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
16614230|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
16614231|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
16614232|NCT02519582|Experimental|Niclosamid|Patients receive 2 g niclosamide orally per day until progression or toxicity
16614233|NCT02519569|Experimental|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
16614234|NCT02519556|Experimental|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
16614235|NCT02519556|Placebo Comparator|Placebo|Placebo of Maltodextrin in sachet
16614236|NCT02519543|Placebo Comparator|Placebo|Placebo comparator to be given twice daily, once with breakfast and once with supper
16614237|NCT02519543|Experimental|Metformin|Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper
16614238|NCT02519530|Experimental|Intervention|Behavioral: Teen Outreach Program
16614239|NCT02519530|No Intervention|Comparison|This group did not receive TOP, they received business as usual health curriculum offered through the public school system
16614240|NCT02519517|Experimental|permissive hypercapnia|during one lung ventilation, right ventricular function was assessed by TEE and the effect of rising PCO2 appreciated
16614241|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
16614242|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
16614243|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
16614244|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
16614245|NCT02519478|Experimental|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
16614246|NCT02519478|No Intervention|Control|Control group subjects participate in normal football activities as they would normally have during a football season
16614247|NCT02519465|Active Comparator|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
16614248|NCT02519465|Active Comparator|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
16614280|NCT02519296|Active Comparator|30 Danish veterans without PTSD|"A group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group.
~Observation with psychometrics, blood analyses and fMRI."
16614249|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
16614250|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
16614251|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
16614252|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
16614253|NCT02519452|Experimental|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
16614254|NCT02519439|Experimental|ganaxolone|Up to a maximum of 1800 mg/day
16614255|NCT02519426||Cumulative complexity score <9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score lower than 9.
16614256|NCT02519426||Cumulative complexity score y≥9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score higher than 9.
16614257|NCT02519426||Pell Gregory index <Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 1A, Class 1B, Class 1C, or Class 2A
16614258|NCT02519426||Pell Gregory index ≥Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 2B, Class 2C, Class 3A, Class 3B, or Class 3C
16614259|NCT02519426||Winter index <Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Mesio-Angular, Disto-Angular or Vertical impaction
16614260|NCT02519426||Winter index ≥Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Horizontal, Buccal / Lingual Obliquity, Transverse, Inverse impaction
16614261|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
16614262|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
16614263|NCT02519374|Placebo Comparator|Placebo|Placebo
16614264|NCT02519374|Active Comparator|PROMITOR® dose 1|Investigational product dose 1
16614265|NCT02519374|Active Comparator|PROMITOR® dose 2|Investigational product dose 2
16614266|NCT02519374|Active Comparator|PROMITOR® dose 3|Investigational product dose 3
16614267|NCT02519348|Experimental|Durvalumab & Tremelimumab (Regimen 1)|Durvalumab in combination with Tremelimumab (Regimen 1)
16614268|NCT02519348|Experimental|Durvalumab|Durvalumab given as monotherapy
16614269|NCT02519348|Experimental|Tremelimumab|Tremelimumab given as monotherapy
16614270|NCT02519348|Experimental|Durvalumab & Tremelimumab (Regimen 2)|Durvalumab in combination with Tremelimumab (Regimen 2)
16614271|NCT02519348|Experimental|Durvalumab & Bevacizumab|Durvalumab in combination with Bevacizumab
16614272|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.
~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
16614273|NCT02519322|Experimental|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
16614274|NCT02519322|Experimental|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
16614275|NCT02519322|Experimental|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
16614276|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
16614277|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
16614278|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
16614279|NCT02519296|Active Comparator|Prolonged Exposure Therapy|"In total 30 Danish veterans will be recruited, who meet the ICD-10 diagnostic criteria for PTSD, and treated with PE.
~Intervention with eight sessions of PE, psychometrics, blood analyses and fMRI."
16614310|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
16614281|NCT02519283|Active Comparator|Standard of Care|In keeping with the strategy-based pragmatic nature of the trial, the discharge procedures will largely be kept as they are in common practice. Investigators will standardize usual care for ED discharge to include HF medication reconciliation as well as encourage 7-day follow-up.
16614282|NCT02519283|Active Comparator|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
16614283|NCT02519270|Experimental|Dose Escalation Stage/ Expansion Stage|"The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.
~In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles."
16614284|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
16614285|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
16614286|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
16614287|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
16614288|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
16614289|NCT02519205||ED Nurses|ED triage nurses from Duke University Hospital (DUH) and Duke Regional Hospitals (DRH).
16614290|NCT02519192|Experimental|VAC Arm, Vac sponge irrigations|For patients who fall under the VAC arm, a physician will do the initial placement of the wound VAC (V.A.C.Ulta™ Negative Pressure Wound Therapy System) at the patient's bedside. An information sheet will be provided to the patient, and the patient will be taught how to irrigate the sponge system independently. While inpatient, nursing will perform VAC sponge irrigation.
16614291|NCT02519192|Active Comparator|NonVac, ostomy bag, wet to dry dressings|For patients who fall under the non-VAC arm, a physician or wound care nurse will perform the initial application of the ostomy bag or wet to dry dressing change. An information sheet will be provided to the patient. While inpatient, members from the nursing or physician team will perform ostomy bag application and ostomy dressing changes.
16614292|NCT02519179|Experimental|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
16614293|NCT02519166|Other|Patients with chronic wounds|
16614294|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
16614295|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
16614296|NCT02519140|Experimental|Cook medical EMR Gel|"Prospective study involving excised human stomachs and colon harvested from sleeve gastrectomies and colectomies performed for benign or malignant disease.
~Different Cook submucosal injections of varying viscosities will be injected into different areas of the excised stomachs or colons.
~Data collected will involve lifting characteristics and dissection adequacy of the varying viscosities of gel."
16614297|NCT02519127|Experimental|Low glycaemic load diet|Subjects will be following a low glycaemic load diet, typically high in polyphenols, proteins, vegetables, pulses, fibres and nuts, and low in glycemic carbohydrates, for six continuous weeks.
16614298|NCT02519127|Experimental|Western diet|Subjects will be following a western diet, typically high in saturated fat, refined sugars and salt, and low in fruit and vegetables and fibers, for six continuous weeks.
16614299|NCT02519114|Experimental|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
16614300|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
16614301|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
16614302|NCT02519036|Experimental|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
16614303|NCT02519036|Experimental|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
16614304|NCT02519036|Experimental|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
16614305|NCT02519036|Experimental|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
16614306|NCT02519036|Experimental|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
16614307|NCT02519036|Placebo Comparator|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
16614308|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
16614309|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
16614312|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
16614313|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
16614314|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
16614315|NCT02518958|Experimental|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
16614316|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
16614317|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
16614318|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
16614319|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
16614320|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
16614321|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
16614322|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
16614323|NCT02518906|Experimental|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
16614324|NCT02518906|Experimental|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
16614325|NCT02518880|Other|Plasma volume measurements|
16614326|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
16614327|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
16614328|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
16614329|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
16614330|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
16614331|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
16614332|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
16614333|NCT02518828|Active Comparator|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
16614334|NCT02518828|Active Comparator|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
16614335|NCT02518815|Experimental|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
16614336|NCT02518815|No Intervention|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
16614337|NCT02518802|Experimental|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
16614338|NCT02518802|Active Comparator|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
16614339|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
16614340|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
16614341|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
16614342|NCT02518776|Other|Neuropsychological tests|
16614343|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
16614344|NCT02518750|Experimental|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:
~Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.
~Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.
~Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
16614345|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
16614346|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
16614347|NCT02518724|Active Comparator|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:
~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).
~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
16614348|NCT02518724|Placebo Comparator|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:
~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).
~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
16614349|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
16614350|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
16614351|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
16614354|NCT02518672|Active Comparator|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
16614355|NCT02518672|Placebo Comparator|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
16614356|NCT02518659|Other|Inulin|Intervention by inulin, max 20gr per day
16614357|NCT02518659|No Intervention|No Inulin|Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
16614358|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
16614359|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
16614360|NCT02518620|Experimental|ALX-0061 150 mg q2w (+ MTX)|
16614361|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:
~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
16614362|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:
~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
16614363|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
16614364|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
16614365|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
16614366|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
16614367|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
16614368|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
16614369|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
16614370|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:
~Placebo, 1 liquid filled enterically coated capsule, single dose"
16614371|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
16614372|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
16614373|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
16614374|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
16614375|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
16614376|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
16614377|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
16614378|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
16614379|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
16614380|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
16614381|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
16614382|NCT02518581|Other|Doubly labelled water|
16614383|NCT02518568|Experimental|Drug|
16614384|NCT02518555|Experimental|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16614385|NCT02518555|Experimental|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
16614386|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
16614387|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
16614388|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
16614389|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
16614390|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
16614391|NCT02518516||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (rosuvastatin, high doses of atorvastatin, and high doses of simvastatin between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
16614392|NCT02518516||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
16614393|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
16614394|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
16614395|NCT02518490|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
16614396|NCT02518490|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
16614397|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.
~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
16614398|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
16614399|NCT02518464|Experimental|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
16614400|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
16614401|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
16614402|NCT02518438|Active Comparator|the tramadol group|A preprepared 20 ml solution (tramadol 2 mgkg-1 within a 0.9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
16614403|NCT02518438|Placebo Comparator|the placebo group|A preprepared 20 ml solution (0,9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
16614404|NCT02518412|Experimental|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
16614405|NCT02518412|Placebo Comparator|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
16614406|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
16614407|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
16614408|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period
~An Omeprazole Treatment Period 1 (Day -15 to Day -1)
~A G17DT treatment period (Day 0 to Day 85)
~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
16614409|NCT02518360|Experimental|OSTEOPATHIC PROTOCOL|"Physiotherapist applies an osteopathic treatment in non-specific low back pain patients.
~The experimental group is treated with osteopathy, three sessions (20 minutes/session) and a frequency one session/week. Osteopathic treatment osteopathic is a body adjustment protocol. This protocol adjusts the musculoskeletal disorders since neck to lower limbs in the experimental group. Before treatment, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry."
16614410|NCT02518360|Active Comparator|Auto Stretching|The patients realizes stretching protocol: two stretching global postures once a week (10 minutes for each posture) for three weeks: the first is for the anterior muscular chain and the second posture to stretch the posterior muscle chain. Before three stretching, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry.
16614411|NCT02518347|Experimental|FDS-Strawberry|Freeze-dried strawberry powder (50g/d)
16614412|NCT02518347|Placebo Comparator|Placebo|Powder matched for carbohydrates and fiber in the strawberries
16614413|NCT02518334|Experimental|Alcohol consumption|Alcohol consumption and wine consumption
16614414|NCT02518321|Experimental|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
16614415|NCT02518321|Experimental|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
16614416|NCT02518308|Experimental|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
16614417|NCT02518308|No Intervention|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
16614418|NCT02518295|Active Comparator|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
16614419|NCT02518295|Active Comparator|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
16614420|NCT02518295|Active Comparator|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
16614421|NCT02518295|Placebo Comparator|Negative control|Lactose free milk
16614422|NCT02518269|Active Comparator|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
16614423|NCT02518269|Active Comparator|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
16614424|NCT02518269|Active Comparator|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
16614425|NCT02518256|Other|(Suspected) Ovarian Epithelial Cancer|Lavage of the Cavum uteri and proximal fallopian tubes
16614426|NCT02518243|Experimental|Alzheimer's Disease|
16614427|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
16614428|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
16614429|NCT02518217|Active Comparator|Apps Only|
16614430|NCT02518217|Experimental|ShapeUp Empower|
16614431|NCT02518217|Experimental|ShapeUp Empower + Incentives|
16614432|NCT02518204|Experimental|BPT, NP|Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
16614433|NCT02518204|Experimental|NP, BPT|Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
16614434|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
16614435|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.
16614436|NCT02518178|Active Comparator|NFC Sticker|Participants will receive an NFC (Near Field Communication) sticker, placed on their existing immunization (MAMTA) card. This will serve as a comparator to the NFC necklace while still allowing for patient data to be digitized and utilized by the health service provider, Seva Mandir.
16614437|NCT02518178|Experimental|NFC Necklace|Participants will receive a necklace with an NFC pendant, which interfaces with the Khushi Baby mobile application to digitize the data. This arm will allow for the assessment of peer influence effects of the necklace as a social symbol.
16614438|NCT02518178|Experimental|NFC Necklace + Voice Reminder|In addition to the NFC necklace, mothers of the participants in this arm will receive dialect-specific voice call reminders, informing them about the next camp and the importance of vaccinations.
16614439|NCT02518165|Active Comparator|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
16614440|NCT02518165|Placebo Comparator|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
16614441|NCT02518152|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
16614442|NCT02518152|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
16614443|NCT02518152|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
16614444|NCT02518139|Experimental|TD-4208-1|88 mcg
16614445|NCT02518139|Experimental|TD-4208-2|175 mcg
16614446|NCT02518139|Active Comparator|Tiotropium|18 mcg
16614447|NCT02518126||control|Women with IUGR embryos so that their fetal weight estimate puts them in a percentile bellow 10th percentile
16614448|NCT02518126||IUGR|Women with AGA embryos so that their fetal weight estimate puts them in a percentile between 20th and 80th percentiles
16614449|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
16614450|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~There were no participants enrolled to Part B of the study."
16614451|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~There were no participants enrolled to Phase 2 of the study."
16614452|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~There were no participants enrolled to Phase 2 of the study."
16614453|NCT02518100|Experimental|VSP 3-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 3-lead (NEHB) configuration:
~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
16614454|NCT02518100|Experimental|VSP 1-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration. The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 1-lead (PAL) configuration:
~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
16614455|NCT02518087|Experimental|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
16614456|NCT02518087|No Intervention|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
16614457|NCT02518074|Other|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
16614458|NCT02518048|Active Comparator|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
16614459|NCT02518048|Active Comparator|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
16614460|NCT02518035|Placebo Comparator|Control|No silicone gel treatment after remove of stitches
16614461|NCT02518035|Experimental|Experimental|Silicone gel applied for twice per day
16614462|NCT02518022|Experimental|Intervention|For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours
16614463|NCT02518022|No Intervention|Standard|No Insulin Treatment of carbohydrates in beer.
16614464|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
16614465|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
16614466|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
16614467|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
16614468|NCT02517983||Chronic respiratory disease|
16614469|NCT02517970|Experimental|Classical Music versus Television show|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
16614470|NCT02517957|Experimental|Qinzhuliangxue Keli|Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
16614471|NCT02517957|Active Comparator|loratadine tablets|Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
16614472|NCT02517957|Active Comparator|Qinzhuliangxue and loratadine|Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
16614473|NCT02517944||Familial hypercholesterolemia patients|"clinical data
~biological data
~cardiac and aortic RMI with gadolinium"
16614474|NCT02517944||Control group|"clinical data
~biological data
~cardiac and aortic RMI with gadolinium"
16614475|NCT02517931|Active Comparator|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
16614476|NCT02517931|Placebo Comparator|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
16614477|NCT02517918|Experimental|Sirolimus combined with CP, MT and ZA|Drug : Metronomic Cyclophosphamide, Methotrexate, Sirolimus, Zoledronic acid Assessment of the maximum tolerated dose of sirolimus Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
16614478|NCT02517905|Experimental|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
16614479|NCT02517905|Placebo Comparator|Placebo|10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
16614480|NCT02517892|Experimental|Patients with metastatic oncogen-driven cancer|
16614481|NCT02517879|Experimental|Group 1 - 1-3 days|Community health worker hang-up visit 1-3 days after the community point distribution
16614482|NCT02517879|Experimental|Group 2 - 5-7 days|Community health worker hang-up visit 5-7 days after the community point distribution
16614483|NCT02517879|Experimental|Group 3 - 10-12 days|Community health worker hang-up visit 10-12 days after the community point distribution
16614484|NCT02517879|Experimental|Group 4 - 15-17 days|Community health worker hang-up visit 15-17 days after the community point distribution
16614485|NCT02517879|Placebo Comparator|Group 5 - No hang-up visit|Did not receive any hang-up visit after the community point distribution
16614486|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
16614487|NCT02517853|Experimental|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
16614488|NCT02517853|Sham Comparator|Sham comparator|Sham tibial nerve stimulation during 16 sessions
16614489|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
16614490|NCT02517827|Active Comparator|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
16614491|NCT02517827|Active Comparator|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
16614492|NCT02517814|Experimental|Patients with cardiomyopathy|Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months.
16614493|NCT02517801|Experimental|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily)
16614494|NCT02517801|Placebo Comparator|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily)
16614495|NCT02517788|Experimental|Part A: Interferon beta-1a in HSA-free solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a without albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
16614636|NCT02516839|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
16614496|NCT02517788|Experimental|Part A: Interferon beta-1a combined with HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
16614497|NCT02517788|Active Comparator|Part A: Interferon beta-1a in marketed HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU original interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
16614498|NCT02517788|Experimental|Part B: Interferon beta-1a in HSA-free solution|Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
16614499|NCT02517788|Active Comparator|Part B: Interferon beta-1a in marketed HSA+ solution|Part B: Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU original interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
16614500|NCT02517775|Active Comparator|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
16614501|NCT02517775|Active Comparator|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
16614502|NCT02517775|Active Comparator|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
16614503|NCT02517775|Active Comparator|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
16614504|NCT02517775|Active Comparator|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
16614505|NCT02517775|Placebo Comparator|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
16614506|NCT02517762|Experimental|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
16614507|NCT02517762|Experimental|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
16614508|NCT02517749|Active Comparator|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
16614509|NCT02517749|Active Comparator|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
16614510|NCT02517736|Experimental|sorafenib at a dose of 800 mg / day|
16614511|NCT02517723|Experimental|SIC + NET|Waiting List + Standard Inpatient Care + Narrative Exposure Therapy
16614512|NCT02517723|Active Comparator|SIC + DBT|Waiting List + Standard Inpatient Care + Dialectical Behavior Therapy
16614513|NCT02517710|Placebo Comparator|Control|Group of patients receiving standard hysterotomy closure with synthetic braided suture
16614514|NCT02517710|Experimental|Stratfix|group of patients having the hysterotomy incision closed with barbed synthetic suture. Time to closure, blood loss, and postoperative pain
16614515|NCT02517697|Experimental|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
16614516|NCT02517697|Placebo Comparator|Placebo|placebo capsules three time daily (TID)
16614517|NCT02517684|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
16614518|NCT02517684|Active Comparator|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
16614519|NCT02517671|Other|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
16614520|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
16614521|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
16614522|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
16614523|NCT02517632|Experimental|Exercise group|This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
16614524|NCT02517632|Other|Control group|This arm will have only the counseling from pharmaceutical and nutritional professionals.
16614525|NCT02517619|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
16614526|NCT02517619|Active Comparator|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
16614527|NCT02517606|Experimental|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
16614528|NCT02517606|Active Comparator|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
16614529|NCT02517593|Other|PRS|Providing polygenic risk score (PRS)
16614530|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
16614531|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
16614674|NCT02516618|Experimental|Cohort 5|Participants in this cohort will receive dose 5 of Fasinumab or placebo
16614532|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
16614533|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
16614534|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
16614535|NCT02517554||Remote cancer genetic services by videoconference|
16614536|NCT02517554||Remote cancer genetic services by telephone|
16614537|NCT02517554||Usual Care|
16614538|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
16614539|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
16614540|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
16614541|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
16614542|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
16614543|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
16614544|NCT02517489|Experimental|Hydrocortisone|Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
16614545|NCT02517489|Placebo Comparator|Placebo|Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
16614546|NCT02517476|Experimental|Nutritional support|For the purpose of this study, we have developed nutritional guidelines by consensus and adapted to current guidelines (e.g., ESPEN, ASPEN). These guidelines specify a reinforced nutritional therapy strategy to cover nutritional requirements, focusing on nutritional targets based on the specific nutritional diagnoses defined by the IDNT. The nutritional guidelines may vary according to important medical diagnoses (i.e. renal failure). They specify not only nutritional targets, but also escalation of the route (i.e. food fortification, oral, enteral, parenteral) if targets cannot be achieved (≤75%) every 5 hours. Nutritional goals are being assessed daily in patients in the intervention group.
16614547|NCT02517476|No Intervention|"Usual care (appetite-guided) controls"|"In control patients, we will use conventional nutrition according to the ability and desire of the patient to eat, using standard care food provided by the hospital kitchen (appetite-guided)."
16614548|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
16614549|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
16614550|NCT02517450|Experimental|experimental group|The subjects had to participate an adventure-based training programme.
16614551|NCT02517450|Placebo Comparator|placebo control group|The subjects had to participate a placebo control programme
16614552|NCT02517437|Active Comparator|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
16614553|NCT02517437|Active Comparator|Interscalene block|Interscalene block.
16614554|NCT02517424|Experimental|High THC/Low CBD Cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
16614555|NCT02517424|Experimental|High THC/High CBD cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
16614556|NCT02517424|Placebo Comparator|Low THC/Low CBD cannabis|Product will be administered via vaporization up to 2 grams per day as needed.
16614557|NCT02517411|Experimental|Experimental group|COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
16614558|NCT02517411|Other|Control group|COPD patients with stable disease will be recruited and they will receive standard care.
16614559|NCT02517398|Experimental|MSB0011359C (M7824)|
16614560|NCT02517385|Experimental|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
16614561|NCT02517372|Active Comparator|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
16614562|NCT02517372|Active Comparator|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
16614563|NCT02517372|Active Comparator|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
16614564|NCT02517359|Experimental|Single dose, healthy volunteers|
16614565|NCT02517359|Experimental|14 day repeat dose, healthy volunteers|
16614566|NCT02517359|Experimental|28 day repeat dose, healthy volunteers|
16614567|NCT02517359|Experimental|14 day repeat dose, asthma patients|
16614568|NCT02517359|Experimental|14 day repeat dose, smokers|
16614569|NCT02517346|Active Comparator|Standard follow up-Sleep Unit|Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit
16614570|NCT02517346|Experimental|Telemonitoring|Patients diagnosed as OSA and treated with CPAP in sleep unit, followed up by telemonitoring system
16614607|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
16614608|NCT02517008|Experimental|Mama kits intervention|"Health facilities randomized to this arm provided mama kits - packages of childcare materials including a cloth (chitenge), baby blanket, and diaper - to all mothers who delivered at these facilities between June 1, 2013 - Aug 31, 2013."
16614571|NCT02517333|Other|Proof-of-principle (PoP)|"Proof-of-principle phase of the study. All participants undergo the exercise intervention as part of the feasibility.
~Screen within Year 9 Class
~Targeted recruitment for those scoring in bottom 5th percentile
~Invite students to take part in 6-week intervention
~Enroll students participating
~Pre-intervention assessment
~Start 6-week Epic Club gym intervention (1-2 times weekly for 45-60 mins) consisting of 30 min cardiovascular exercise and 25-30 min strength/resistance and weight training
~Post-intervention assessment
~Exit to longer-term sport/physical activity"
16614572|NCT02517320|Experimental|MT-3995 Low|
16614573|NCT02517320|Experimental|MT-3995 Middle|
16614574|NCT02517320|Experimental|MT-3995 High|
16614575|NCT02517320|Placebo Comparator|Placebo|
16614576|NCT02517307|Experimental|glycerol/saline|Glycerol/Saline infusion
16614577|NCT02517307|Experimental|intralipid|Intralipid/Heparin infusion
16614578|NCT02517294|Active Comparator|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
16614579|NCT02517294|Active Comparator|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
16614580|NCT02517281|Experimental|Patients having received targeted therapies|Patients treated using targeted therapies
16614581|NCT02517268|Active Comparator|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
16614582|NCT02517268|Experimental|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
16614583|NCT02517255|Experimental|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed within 7 days of rescue percutaneous coronary intervention (PCI) and after 3 and 6 months.
16614584|NCT02517242|Experimental|Pens Device|All patients will receive pens device, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
16614585|NCT02517242|Active Comparator|Syringe|All patients will receive syringe to insulin, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
16614586|NCT02517229|Other|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
16614587|NCT02517216|Other|parabolic flight and MRI scans|
16614588|NCT02517190|Other|Stress response measurements|
16614589|NCT02517177|Other|Cardiovascular parameters measurements|
16614590|NCT02517164||Fallers|patients aged 50 years and over who already fell
16614591|NCT02517164||At risk of falls|patients aged 50 years and over at risk of falls
16614592|NCT02517151|Experimental|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
16614593|NCT02517151|Placebo Comparator|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
16614594|NCT02517138|Other|Measurements of eye movements and perception|
16614595|NCT02517125|Experimental|Patients with head and neck cancer|
16614596|NCT02517112|Other|Cardiovascular parameters measurements|
16614597|NCT02517099|Active Comparator|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
16614598|NCT02517099|Active Comparator|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
16614599|NCT02517086|Active Comparator|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
16614600|NCT02517086|Active Comparator|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
16614601|NCT02517086|Active Comparator|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
16614602|NCT02517060||Healthy participants|Male or female healthy participants
16614603|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
16614604|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
16614605|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
16614606|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
16614609|NCT02517008|No Intervention|No intervention|Health facilities randomized to this arm provided obstetric services as normal.
16614611|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:
~Section 1: Demographic information survey
~Section 2: Whooley questions
~Section 3: Edinburgh Postnatal Depression Scale
~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
16614612|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:
~Section 1: Demographic information survey
~Section 2: Whooley questions
~Section 3: Edinburgh Postnatal Depression Scale
~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
16614613|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
16614614|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
16614615|NCT02516969|Experimental|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes <25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
16614616|NCT02516956|Experimental|Breakfast meal 1|"Breakfast meal 1 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 2 and health-related cognitive perception as Breakfast meal 3.
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
16614617|NCT02516956|Experimental|Breakfast meal 2|"Breakfast meal 2 is isocaloric (330 kcal) and balanced for protein and fiber contents with regard to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 1 but a higher health-related cognitive perception than the other two experimental breakfasts.
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
16614618|NCT02516956|Experimental|Breakfast meal 3|"Breakfast meal 3 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same health-related cognitive perception as Breakfast meal 1 but lower lipid and higher sugar amounts than the other two experimental breakfasts.
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
16614619|NCT02516956|Placebo Comparator|Breakfast meal 4|"Breakfast meal 4 is a non-caloric meal representing fasting condition (control arm).
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
16614620|NCT02516943|Active Comparator|Control|The patient were retrospectively included according to the last digit of their admission number (odd number). The had arterial blood gas analysis every 4 hour during the ICU stay.
16614621|NCT02516943|Active Comparator|Guideline|The patient were prospectively included and they had arterial blood gas analysis following the pathological- based guidelines for arterial blood gas analysis in patients aftercardiac surgery
16614622|NCT02516930|Other|Crowdsourced video|One-minute crowd-sourced video promoting condom use among men who have sex with men and transgender individuals.
16614623|NCT02516930|Other|Social marketing video|One-minute social marketing video promoting condom use among men who have sex with men and transgender individuals
16614624|NCT02516917|Experimental|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
16614625|NCT02516904|Experimental|CD101 IV|single intravenous infusion ascending dose
16614626|NCT02516904|Placebo Comparator|Placebo|normal saline
16614627|NCT02516891|Experimental|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
16614628|NCT02516891|No Intervention|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
16614629|NCT02516878|Experimental|Acupuncture group|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.
~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
16614630|NCT02516878|Sham Comparator|Control group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion.
~The Semen Vaccariae embedded tape used in treatment group will be applied on 4 non-acupoints at the helix unilaterally, retained until the next visit and then the alternate ear will be used."
16614631|NCT02516865|Experimental|Group 1|
16614632|NCT02516865|Experimental|Group 2|
16614633|NCT02516865|No Intervention|Group 3|
16614637|NCT02516839|Experimental|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
16614638|NCT02516839|Experimental|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
16614639|NCT02516839|Active Comparator|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
16614640|NCT02516826|Experimental|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
16614641|NCT02516826|Experimental|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
16614642|NCT02516826|Experimental|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
16614643|NCT02516813|Experimental|Phase Ia Arm A: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 10 times, for two consecutive weeks in concomitance with fractionated radiotherapy (RT) (5 fractions /week).
16614644|NCT02516813|Experimental|Phase Ia Arm B: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A capsule once daily up to 35 times, for 7 consecutive weeks in concomitance with fractionated RT and Cisplatin (5 fractions/week).
16614645|NCT02516813|Experimental|Phase Ib Arm A Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week).
16614646|NCT02516813|Experimental|Phase Ib Arm B Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week) and cisplatin.
16614647|NCT02516813|Experimental|Ancillary cPoP: MSC2490484A+Fractionated RT|Ancillary Clinical proof-of-principle (cPOP) study, subjects will receive first dose of RT on Day 1, and will receive MSC2490484A capsule or Tablet formulation within 1.5 hour before the second dose of RT on Day 2.
16614648|NCT02516800||Aortic valve calcification|Patients with calcific aortic valve disease, age = 65 years or below
16614649|NCT02516800||Control group|Matched control group
16614650|NCT02516787|Other|EEG and NIRS measurements|
16614651|NCT02516774|Experimental|Dose escalation|Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
16614652|NCT02516761|Experimental|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
16614653|NCT02516761|Experimental|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
16614654|NCT02516761|Active Comparator|Control group|With this group no intervention is done, but they are assessed like the other groups.
16614655|NCT02516735|Experimental|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
16614656|NCT02516735|Active Comparator|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
16614657|NCT02516722|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
16614658|NCT02516696|Experimental|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
16614659|NCT02516696|Active Comparator|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
16614660|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
16614661|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
16614662|NCT02516670|Experimental|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
16614663|NCT02516670|Placebo Comparator|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
16614664|NCT02516657|Experimental|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
16614665|NCT02516644|Experimental|Virtual reality|Xbox Kinect + treadmill training
16614666|NCT02516644|Active Comparator|Conventional Therapy|Specific conventional training for Parkinson's Disease
16614667|NCT02516631|Active Comparator|Oral (A)|One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
16614668|NCT02516631|Active Comparator|Oral (B)|Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
16614669|NCT02516631|Active Comparator|Sublingual (C)|Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
16614670|NCT02516618|Experimental|Cohort 1|Participants in this cohort will receive dose 1 of Fasinumab or placebo
16614671|NCT02516618|Experimental|Cohort 2|Participants in this cohort will receive dose 2 of Fasinumab or placebo
16614672|NCT02516618|Experimental|Cohort 3|Participants in this cohort will receive dose 3 of Fasinumab or placebo
16614673|NCT02516618|Experimental|Cohort 4|Participants in this cohort will receive dose 4 of Fasinumab or placebo
16614675|NCT02516605|Experimental|LJN452|
16614677|NCT02516592|Experimental|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
16614678|NCT02516592|Active Comparator|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
16614679|NCT02516566|Experimental|PEEP group|Mechanical ventilation with PEEP 8 cmH2O
16614680|NCT02516566|No Intervention|No PEEP group|Mechanical ventilation with no PEEP
16614681|NCT02516553|Experimental|arm A|once daily continuous oral intake in 3-week cycles
16614682|NCT02516553|Experimental|arm B|once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles
16614683|NCT02516553|Experimental|arm C|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
16614684|NCT02516540|No Intervention|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
16614685|NCT02516540|Experimental|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
16614686|NCT02516527|Experimental|Induction Phase:Ipilimumab|Ipilimumab dose as specified
16614687|NCT02516527|Experimental|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
16614688|NCT02516514|Experimental|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
16614689|NCT02516514|Active Comparator|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
16614690|NCT02516501|Active Comparator|Control|Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.
16614691|NCT02516501|Experimental|Intervention group 1|Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).
16614692|NCT02516501|Experimental|Intervention group 2|Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.
16614693|NCT02516475|Active Comparator|zinc sulfate|1 zinc sulfate capsule for 15 weeks
16614694|NCT02516475|Placebo Comparator|starch|1 corn starch capsule for 15 weeks
16614695|NCT02516462|Experimental|IVM|Immature oocytes recovered from each subject will be placed into IVM media for maturation.
16614696|NCT02516449|Experimental|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
16614697|NCT02516449|No Intervention|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
16614698|NCT02516436|Experimental|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
16614699|NCT02516436|Active Comparator|Buprenorphine|Buprenorphine in a buccal film
16614700|NCT02516423|Experimental|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
16614701|NCT02516423|Active Comparator|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
16614702|NCT02516410|Experimental|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
16614703|NCT02516410|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
16614704|NCT02516397|Experimental|Omnia group|After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks.
16614705|NCT02516397|Placebo Comparator|Placebo group|After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks.
16614706|NCT02516384|Experimental|Fecal Microbiota Transplantation|Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.
16614707|NCT02516371|Other|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
16614708|NCT02516345|Active Comparator|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.
~Step Targets for Children in CBI arm:
~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week
~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week
~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
16614709|NCT02516345|Experimental|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.
~Step targets for children and parents in FBI arm:
~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week
~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week
~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
16614739|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.
~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.
~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
16614710|NCT02516332|Experimental|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
16614711|NCT02516332|Experimental|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
16614712|NCT02516332|Placebo Comparator|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
16614713|NCT02516319|Active Comparator|Serial Blood Draws|Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.
16614714|NCT02516319|Experimental|Liver Funtion Test Dye Detection Monitor|All cohorts receive continuous LFT monitoring post ICG injection.
16614715|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
16614716|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
16614717|NCT02516293|Experimental|Intervention group|"Physical exercise intervention
~Nutritional counseling
~Pharmaceutical counseling"
16614718|NCT02516280|Experimental|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
16614719|NCT02516280|Active Comparator|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
16614720|NCT02516267|No Intervention|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
16614721|NCT02516267|Active Comparator|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
16614722|NCT02516254|Experimental|fortified bread|daily intake of fortified bread (1000IU vitamin D per 50 g) plus placebo
16614723|NCT02516254|Experimental|supplement|daily intake of plain bread (50 g) plus supplement (1000 IU per tablet)
16614724|NCT02516254|Placebo Comparator|placebo|daily intake of plain bread plus placebo
16614725|NCT02516241|Experimental|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
16614726|NCT02516241|Experimental|Monotherapy|MEDI4736 (Durvalumab)
16614727|NCT02516241|Active Comparator|Standard of Care|Standard of Care Chemotherapy Treatment
16614728|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
16614729|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
16614730|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
16614731|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
16614732|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
16614733|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
16614734|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
16614735|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
16614736|NCT02516215||8_Anemia|Patients with diagnosed anemia
16614737|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.
~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
16614738|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.
~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).
~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
16614740|NCT02516189|Experimental|Group A|group of elderly participants of strength training program
16614741|NCT02516189|No Intervention|Group B|group of seniors who did not practice strength training program
16614742|NCT02516176|Experimental|Treadmill Training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
16614743|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.
~They are intended for single use only."
16614744|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
16614745|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
16614746|NCT02516137|Experimental|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
16614747|NCT02516137|Sham Comparator|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
16614748|NCT02516137|Placebo Comparator|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
16614749|NCT02516124||NISSC|Autologous HSCT
16614750|NCT02516111|Active Comparator|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
16614751|NCT02516111|Active Comparator|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
16614752|NCT02516111|Active Comparator|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
16614753|NCT02516111|Active Comparator|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
16614754|NCT02516098|Active Comparator|Hyoscine butylbromide SCT|
16614755|NCT02516098|Experimental|Hyoscine butylbromide|
16614756|NCT02516085|Experimental|L-arginine and metformin|7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks
16614757|NCT02516072|No Intervention|Control|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR.
16614758|NCT02516072|Experimental|Remote Ischaemic preconditioning (RIPC)|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR. Additionally, patients will receive RIPC; a blood pressure cuff will be placed around one arm of the patient, it will then be inflated to a pressure of 250mmHg for 5 minutes. The cuff will then be deflated and the arm allowed to reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles immediately prior to the procedure.
16614759|NCT02516059|Active Comparator|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
16614760|NCT02516059|Active Comparator|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
16614761|NCT02516059|Placebo Comparator|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
16614762|NCT02516046|Experimental|Flortaucipir PET Scan|
16614763|NCT02516020|Active Comparator|Global|EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)
16614764|NCT02516020|Active Comparator|Origio|Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)
16614765|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
16614766|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
16614767|NCT02515981|Experimental|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
16614768|NCT02515981|Experimental|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
16614769|NCT02515968|Active Comparator|Desflurane|Anesthesia is maintained with desflurane during surgery.
16614770|NCT02515968|Experimental|Propofol|Anesthesia is maintained with propofol during surgery.
16614771|NCT02515955|Experimental|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614772|NCT02515955|Experimental|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614773|NCT02515955|Experimental|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614774|NCT02515955|Experimental|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614775|NCT02515955|Experimental|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614776|NCT02515955|Experimental|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614777|NCT02515955|Experimental|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614778|NCT02515955|Experimental|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
16614779|NCT02515942|Experimental|CLG561|CLG561 10 mg, one IVT injection every 28 days for a total of 12 injections
16614780|NCT02515942|Experimental|CLG561+LFG316|CLG561 5mg + LFG316 5 mg, one IVT injection every 28 days for a total of 12 injections
16614781|NCT02515942|Sham Comparator|Sham Injection|One sham injection every 28 days for total of 12 sham injections
16614782|NCT02515929|Experimental|Oligomeric Proanthocyanidins|90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
16614783|NCT02515929|Placebo Comparator|Placebo|Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
16614784|NCT02515903|Experimental|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
16614785|NCT02515903|Placebo Comparator|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
16614786|NCT02515890|Experimental|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
16614787|NCT02515890|Experimental|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
16614788|NCT02515890|Experimental|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
16614789|NCT02515890|Experimental|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
16614790|NCT02515890|Experimental|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
16614791|NCT02515877|Experimental|Radiotherapy + Vistide + Chemoterapy|
16614792|NCT02515864|Experimental|FYU-981 anticipated therapeutic dose|Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)
16614793|NCT02515864|Experimental|FYU-981 supratherapeutic dose|Drug: FYU-981, Moxifloxacin Placebo (Oral)
16614794|NCT02515864|Placebo Comparator|Placebo|Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)
16614795|NCT02515864|Active Comparator|Moxifloxacin|Drug: Moxifloxacin, FYU-981 Placebo (Oral)
16614796|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
16614797|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
16614798|NCT02515838|Placebo Comparator|Placebo|Placebo infusion
16614799|NCT02515838|Experimental|Sevuparin|Sevuparin infusion
16614800|NCT02515825||AMBIENCE|CADence System testing followed by coronary angiogram
16614801|NCT02515825||AMBIENCE plus R&R Substudy|CADence System testing for repeatibility and reproducibility (4x by 2 operators) followed by coronary angiogram
16614802|NCT02515812|Experimental|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
16614803|NCT02515812|Active Comparator|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
16614804|NCT02515799|Active Comparator|Tacholiquine|Inhalation
16614805|NCT02515799|Placebo Comparator|Saline Solution 0,9%|Inhalation
16614806|NCT02515786|Experimental|oxygen humidification|Oxygen by nasal catheter delivery will be humidified by bubles.
16614807|NCT02515786|No Intervention|Dry oxygen|oxygen by nasal catheter delivery will be dry
16614808|NCT02515773|Experimental|MET and LIFE|Participants randomized to this group will receive both Metformin and lifestyle intervention.Participants randomized to treatment with MET will start at a dose of 500 mg orally at night and slowly titrated in 2-week intervals to ensure that each patient achieves maximum insulin-sensitizing effects of the drug while minimizing the chance of side effects. Investigators will also recommend that MET be taken with food to minimize side effects. If a participant's BMI percentile <5% (=underweight) his/her treatment with MET will be discontinued. Although the risk of low vitamin B12 while taking MET is associated with age > 50 years and having type II diabetes, Investigator will monitor B12 levels and a CBC throughout study participation.
16614809|NCT02515773|Experimental|Healthy lifestyle intervention (LIFE)|Participants randomized to this group will receive just lifestyle intervention alone.This healthy lifestyle intervention (LIFE) consists of counseling participants and families regarding a healthy eating plan, physical activity and sedentary activities. Prior to study initiation, clinical site staff will participate in a live (or taped) training session from a dietician to lean to administer LIFE. A trained site staff member (e.g. medical assistant or case manager) will meet with participants and their families for a 15-20 minute session at baseline that will focus on nutritional issues using the Traffic Light Plan (TLP).
16614810|NCT02515760|Experimental|Lung cancer group|Bone marrow puncture in patients with non-small cell lung cancer
16614811|NCT02515760|Experimental|Control group (healthy donors)|Bone marrow puncture in healthy donors
16614812|NCT02515747|No Intervention|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
16614813|NCT02515747|Active Comparator|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
16614814|NCT02515747|Active Comparator|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
16614815|NCT02515734|Active Comparator|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
16614816|NCT02515734|Experimental|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
16614817|NCT02515721|Experimental|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
16614818|NCT02515721|Experimental|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
16614819|NCT02515708|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device.
16614820|NCT02515708|Other|Normothermic Machine Perfusion (single pump)|This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.
16614821|NCT02515695|Experimental|0.5 MIU i.v. and 1.5 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
16614822|NCT02515695|Experimental|1 MIU i.v. and 3 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
16614823|NCT02515695|Experimental|2 MIU i.v. and 6 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
16614824|NCT02515695|Experimental|4 MIU i.v. and 12 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
16614825|NCT02515682|Active Comparator|High equol|High equol group will be given natural S-equol supplementation 20mg per day for 24 week.
16614826|NCT02515682|Active Comparator|Low equol|Low equol group will be given natural S-equol supplementation 10mg/d (+10mg starch) for 24 weeks
16614827|NCT02515682|Placebo Comparator|Placebo|Placebo group will be given placebo control (made from starch) 20 mg per day for 24 weeks.
16614828|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
16614829|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
16614830|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
16614831|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
16614832|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
16614833|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
16614834|NCT02515630|Experimental|Momelotinib|MMB for 24 weeks (± 7 days)
16614835|NCT02515617|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
16614836|NCT02515617|Experimental|Period with endotracheal tubes allowing SSD|During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
16614837|NCT02515604|Active Comparator|Single dose group|
16614838|NCT02515604|Active Comparator|Repeated dose group|
16614839|NCT02515578|Active Comparator|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
16614840|NCT02515578|Experimental|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
16614841|NCT02515565|Experimental|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
16614842|NCT02515565|Other|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
16614843|NCT02515552|Other|All applicants|Study applicants who consented and completed the application to participate in the Fibromyalgia Wellness Project. From that point forward all subjects used the intervention program to at whatever frequency they chose voluntarily. It was recommended subjects complete a SMARTLog at least three times per week for at least three months.
16614844|NCT02515539|Experimental|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
16614845|NCT02515526|Active Comparator|Reference|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam
16614846|NCT02515526|Experimental|Test|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.
16614847|NCT02515513|Active Comparator|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
16614848|NCT02515513|Active Comparator|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
16614849|NCT02515500|Active Comparator|Gradual Cessation|
16614850|NCT02515500|Experimental|Gradual Cessation w/ Quitbit|
16614851|NCT02515487|Experimental|Breast cancer patients receiving chemotherapy treatment|
16614852|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
16614853|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
16614854|NCT02515461|Experimental|Intervention: Low energy shockwave therapy|Low energy shockwave therapy performed on both kidneys applying 3000 shocks on each kidney.
16614855|NCT02515448|Experimental|Gentamicine injectable(day 1+2)and then gentamicine inhalation|
16614856|NCT02515435|Experimental|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
16614857|NCT02515422|Active Comparator|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
16614858|NCT02515422|Active Comparator|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
16614859|NCT02515422|Active Comparator|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
16614860|NCT02515422|Placebo Comparator|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
16614861|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
16614862|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
16614863|NCT02515396|Experimental|Treatment Group A|MMI-0100 Inhaled, once daily x 5, followed by 3 week washout period, followed by Placebo Inhaled, once daily x 5
16614864|NCT02515396|Experimental|Treatment Group B|Placebo Inhaled, once daily x 5, followed by 3 week washout period, followed by MMI-0100 Inhaled, once daily x 5
16614865|NCT02515383||Part 1 (MDASI questionnaire, interview)|Patients complete the MDASI questionnaire and then complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
16614866|NCT02515383||Part 2 (MDASI questionnaires, interview)|Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1 week after beginning standard of care treatment, patients complete the MDASI questionnaire at 4 additional time points, each 1 week apart. Patients may also complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
16614867|NCT02515370|Other|Friends for Life Circles|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
16614868|NCT02515370|No Intervention|Standard|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
16614869|NCT02515357|Placebo Comparator|Control group|This arm will receive standard care, i.e. CPAP prescription and brief written healthy lifestyle advice.
16614870|NCT02515357|Experimental|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle on top of standard care.
16614871|NCT02515357|Experimental|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern on top of standard care.
16614872|NCT02515344|Experimental|A: nominative list|"Providing a list of patients not compliant with CRC sreening
~General Practitioners allocated to the intervention group (A) will receive:
~a nominative list of their patients who were not compliant to colorectal cancer screening.
~a document providing general information about colorectal cancer screening"
16614940|NCT02514915|Other|Stereotactic Radiosurgery|Subjects will receive stereotactic radiosurgery prior to resection
16615034|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (800 μg/d)|
16614873|NCT02515344|Active Comparator|B: general information|"Providing general information about CRC screening
~General Practitioners allocated to group (B) will receive:
~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
16614874|NCT02515344|No Intervention|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
16614875|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
16614876|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
16614877|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
16614878|NCT02515318|Experimental|Physiotherapy program|Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment
16614879|NCT02515318|Active Comparator|Control group|Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
16614880|NCT02515305|Experimental|Test product|
16614881|NCT02515305|Active Comparator|Reference product|
16614882|NCT02515305|Placebo Comparator|Placebo product|
16614883|NCT02515292||IUGR: newborn with intrauterine growth restriction|"Inclusion criteria:
~newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction
~agreement of the parents that their child to be included in the study"
16614884|NCT02515292||control: newborn without intrauterine growth restriction|"Inclusion criteria:
~- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group"
16614885|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
16614886|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
16614887|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
16614888|NCT02515240|Active Comparator|healthy controls|healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
16614889|NCT02515240|Active Comparator|newly diagnosed HIV >200|Newly diagnosed HIV positive patients with CD4 count >200, immunized with one shot of PPV23 vaccine.
16614890|NCT02515240|Active Comparator|newly diagnosed HIV <200|Newly diagnosed HIVpositive patients with CD4 count <200, immediately immunized with one shot of PPV23 vaccine.
16614891|NCT02515240|Active Comparator|newly diagnosed HIV <200 delayed|Newly diagnosed HIV positive patients with CD4 count <200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
16614892|NCT02515240|Active Comparator|HAART experienced HIV>200|HIV positive, on HAART treatment for 5 years, nadir CD4 count <200, but at present CD4 count is >200, immunized with one shot of PPV23 vaccine.
16614893|NCT02515240|Active Comparator|HAART experienced HIV<200|HIVpositive, on HAART treatment for 5 years, nadir CD4 count <200, and at present CD4 count is <200, immunized with one shot of PPV23 vaccine.
16614894|NCT02515227|Experimental|6MHP + Pembrolizumab|6 MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
16614895|NCT02515201|Active Comparator|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
16614896|NCT02515201|Active Comparator|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
16614897|NCT02515188|Experimental|propacetamol group|
16614898|NCT02515188|Placebo Comparator|placebo group|
16614899|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
16614900|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
16614901|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
16614902|NCT02515162|Experimental|Fischer Cone Biopsy Excisor|Conization Methode using a triangular electrode , i.e. Fischer Cone Biopsy Excisor
16614903|NCT02515162|Active Comparator|Loop Excision Procedure|Conization Methode using a circular electrode , i.e. Loop excision Procedure
16614904|NCT02515149|No Intervention|Standard of care|Referral laboratory based CD4 measurement after home-based HIV testing
16614905|NCT02515149|Experimental|Point of care|POC CD4 testing after home-based HIV testing
16614906|NCT02515136|Experimental|Parkinson's disease|Parkinson's disease patients
16614907|NCT02515136|Other|Controls|Healthy volunteers paired with Parkinson's disease patients on sex and age group, whose data will be extracted from a CNRS existing database
16614908|NCT02515123|Experimental|E-Motion System|E-motion tube + E-motion EPG 1000
16614909|NCT02515123|Sham Comparator|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
16614910|NCT02515110|Experimental|Treatment (EBRT)|"External Beam Radiation Therapy (EBRT). Within 10 weeks after the last breast cancer surgery or the last dose of adjuvant chemotherapy, patients undergo hypofractionated RNI five days a week over 3-4 weeks.
~The two subgroups are Cohort (A) sentinel lymph node (SLN) and Cohort (B) axillary lymph node (ALN) dissection. They are categorized depending on type of axillary surgery and treatment group. The type of axillary surgery is Sentinel lymph node (SLN) biopsy only vs axillary dissection with or without previous SLN biopsy. The treatment groups are lumpectomy vs mastectomy vs mastectomy/reconstruction."
16614911|NCT02515097|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
16614912|NCT02515097|Placebo Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
16614913|NCT02515084|Experimental|18F-FDG-PET and dw-MRI|At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
16614914|NCT02515071|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
16614915|NCT02515071|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
16614916|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
16614917|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
16614918|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
16614919|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
16614920|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
16614921|NCT02515032|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
16614922|NCT02515032|Placebo Comparator|Placebo|An isocaloric placebo comparator
16614923|NCT02515019|No Intervention|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
16614924|NCT02515019|Experimental|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
16614925|NCT02515006|Experimental|Homeopathy|Individualized homeopathy treatment as a supportive care
16614926|NCT02515006|No Intervention|Control|Usual Care
16614927|NCT02514993||Study group|Inclusion criteria for the study were (a) sternal fracture and concomitant thoracic spine fracture, (b) Injury Severity scale (ISS) ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
16614928|NCT02514993||Control group|The inclusion criteria for the control group included: (a) Thoracic spine fracture without concomitant sternal fracture, (b) ISS ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
16614929|NCT02514980|Active Comparator|Bupivacaine group|Infraorbital nerve block using bupivacaine 0.25% on each side.
16614930|NCT02514980|Active Comparator|Bupivacaine-Ketamine group.|Infraorbital nerve block using bupivacaine 0.25% combined with 0.5mg/kg ketamine on each side.
16614931|NCT02514967|Experimental|Blisibimod|
16614932|NCT02514967|Placebo Comparator|Placebo|
16614933|NCT02514954|Experimental|BioChaperone® Combo|1 single dose 400 U/mL
16614934|NCT02514954|Active Comparator|Humalog® Mix25|1 single dose 100 U/mL
16614935|NCT02514941|Experimental|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
16614936|NCT02514941|Experimental|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
16614937|NCT02514941|Experimental|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
16614938|NCT02514928|Experimental|pancreatoduodenectomy & nerve resection|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
16614939|NCT02514928|Active Comparator|pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
16614941|NCT02514902|Experimental|Lateral Flow Device|Determine the feasibility of testing whole blood samples from patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. No diagnostic or treatment decisions will be based on the results for any patient and the patient will not be told of the results.
16614942|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
16614943|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
16614944|NCT02514876|Experimental|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
16614945|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:
~CMR
~EV with an inter-electrode gap (lower pair) of 5 cm
~EV with an inter-electrode gap (lower pair) of 15 cm"
16614946|NCT02514850|Experimental|Biochaperone Combo|single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
16614947|NCT02514850|Active Comparator|Humalog Mix25|single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
16614948|NCT02514850|Active Comparator|Humalog and Lantus|simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
16614949|NCT02514837|Experimental|Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
16614950|NCT02514824|Experimental|Dose Level 1: MLN01283 3 mg (Phase 1)|"Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle.
~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
16614951|NCT02514824|Experimental|Dose Level 2: MLN01283 4 mg (Phase 1)|"Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.
~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
16614952|NCT02514824|Experimental|Dose Level 3: MLN01283 5 mg (Phase 1)|"Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle.
~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
16614953|NCT02514824|Experimental|MLN01283 RP2D (Phase 2)|"Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle.
~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
16614954|NCT02514811|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
16614955|NCT02514811|No Intervention|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
16614956|NCT02514798|Experimental|High-flow humidified nasal oxygen delivery system|We will describe effects of varying settings of high-flow nasal oxygen (10-30-45-60 L/min) on respiratory rate, tidal volume, and diaphragmatic work of breathing in patients with severe COPD. We will also describe changes in gas exchange and effects on the subjects' comfort and dyspnea. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system.
16614957|NCT02514798|Active Comparator|CPAP (Positive Control)|"We want to describe the breathing responses to varying setting of CPAP in the subject population. We plan to use the CPAP response as a positive control, to determine if our population responds as described by CPAP studies in the literature. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system."
16614958|NCT02514772|Experimental|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
16614959|NCT02514772|Active Comparator|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
16614960|NCT02514759|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions (one per week at 40-50 minutes each) and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
16614961|NCT02514759|No Intervention|Control group|The control group received business as usual.
16615032|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (200 μg/d)|
16614962|NCT02514746|Experimental|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
16614963|NCT02514733||Young donor|Kidney transplant recipient > 60 years of age who received organ from donor <=40 years of age
16614964|NCT02514733||Old donor|Kidney transplant recipient >= 60 years of age who received organ from donor >=50 years of age
16614965|NCT02514720|Other|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
16614966|NCT02514720|Other|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
16614967|NCT02514694|Active Comparator|LEO 32731|Active
16614968|NCT02514694|Placebo Comparator|Placebo|Placebo
16614969|NCT02514681|Active Comparator|Trastuzumab + chemotherapy|Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
16614970|NCT02514681|Experimental|Trastuzumab+ pertuzumab + chemotherapy|Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
16614971|NCT02514668|Experimental|Isatuximab|Isatuximab (escalating dose) on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression
16614972|NCT02514655|Experimental|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
16614973|NCT02514655|Active Comparator|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
16614974|NCT02514642|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
16614975|NCT02514642|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
16614976|NCT02514629|Placebo Comparator|Placebo|Placebo for 52 weeks
16614977|NCT02514629|Experimental|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
16614978|NCT02514629|Experimental|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
16614979|NCT02514629|Experimental|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
16614980|NCT02514616|Active Comparator|Active Electric Stimulation Therapy|The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
16614981|NCT02514616|Sham Comparator|Delayed Electric Stimulation Therapy|The subject receives no active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject will receive Active Electric Stimulation Therapy at week 14 visit, and an extended open-label follow-up phase includes annual visits through 5 years.
16614982|NCT02514603|Experimental|Prexasertib|Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
16614983|NCT02514590|Experimental|Freedom SCS System - 1500 HZ|Epidural Space covering vertebrae level T8-T11 determined by paresthesia mapping for painful area.
16614984|NCT02514577|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
16614985|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
16614986|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
16614987|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
16614988|NCT02514564||Control|This group will not perform exercise.
16614989|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
16614990|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
16614991|NCT02514538|Experimental|Non-effervescent tablets|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
16614992|NCT02514538|Active Comparator|Effervescent Paracetamol|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
16614993|NCT02514525|Other|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
16614994|NCT02514512|No Intervention|Standard SABR|Patients receive standard treatment
16614995|NCT02514512|Experimental|MLC Tracking SABR|Patients are treated with MLC tracking
16614996|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
16614997|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
16614998|NCT02514460|Active Comparator|Intervention: Stents|Stents group
16614999|NCT02514460|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
16615000|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan|All patients in Part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy, topotecan. Patients will have PK assessment completed on days 1 and 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
16615033|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (400 μg/d)|
16615001|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan -PART 2|All patients in Part 2 will be randomized 2:1 to receive trilaciclib (G1T28) to be administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
16615002|NCT02514447|Experimental|Placebo + Topotecan -PART 2|All patients in Part 2 will be randomized 1:2 to receive placebo administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
16615003|NCT02514434|Experimental|Ultrasonography|Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
16615004|NCT02514434|Experimental|Non-contrast MRI|Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
16615005|NCT02514421|Experimental|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
16615006|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
16615007|NCT02514382|Experimental|Treatment (dexamethasone, bortezomib, wild-type reovirus)|Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16615008|NCT02514356|Active Comparator|Own adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own Adherence'.
16615009|NCT02514356|Active Comparator|Own and group level adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own and Group Adherence'.
16615010|NCT02514343|Experimental|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
16615011|NCT02514343|Experimental|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
16615012|NCT02514330|Experimental|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
16615013|NCT02514330|Experimental|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
16615014|NCT02514330|No Intervention|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
16615015|NCT02514317|Experimental|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
16615016|NCT02514291|Experimental|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
16615017|NCT02514291|No Intervention|Standard care|Standard pediatric neurology care
16615018|NCT02514278|Experimental|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:
~oxaliplatin: 85 mg/m2
~irinotecan: 180 mg/m²
~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)
~5FU: 2400 mg/m2
~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
16615019|NCT02514278|Active Comparator|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
16615020|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
16615021|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
16615022|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.2 μg/d)|
16615023|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.4 μg/d)|
16615024|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.8 μg/d)|
16615025|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (1.6 μg/d)|
16615026|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (3.2 μg/d)|
16615027|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (6.5 μg/d)|
16615028|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (13 μg/d)|
16615029|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (25 μg/d)|
16615030|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (50 μg/d)|
16615031|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (100 μg/d)|
16615035|NCT02514226|Placebo Comparator|G1-control group|"Arm description: G1 - control group - (n = 30) dental hygiene orientation (DHO) + supragingival treatment + simulation of using photodynamic therapy (PDT).
~In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes and ultrasound. Supragingival treatment will be performed above the gingival margin. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed."
16615036|NCT02514226|Active Comparator|G2- positive control group|"Arm description: G2 - positive control group (gold standard) - (n = 30) - DHO + periodontal treatment + simulation of using PDT.
~All participants will receive periodontal treatment - scaling and root planning (SRP) by an experienced specialist with universal curetes and ultrasound in a full mouth manner. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed"
16615037|NCT02514226|Active Comparator|G3 -experimental active comparator group|"Arm description: G3 - experimental group - (n = 30) DHO +SRP + PDT with methylene blue
~In G3, periodontal treatment and photodynamic therapy (PDT) will be performed. The scaling and root planing will be performed identical as G2. The PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the photosensitizer"
16615038|NCT02514213|Experimental|Arm A|2mg INO-5150 and electroporation device CELLECTRA®-5P
16615039|NCT02514213|Experimental|Arm B|8.5mg INO-5150 and electroporation device CELLECTRA®-5P
16615040|NCT02514213|Experimental|Arm C|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
16615041|NCT02514213|Experimental|Arm D|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
16615042|NCT02514200|Experimental|Topography-based CXL (KXL2)|Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
16615043|NCT02514200|Active Comparator|Conventional pulsed CXL (pCXL)|Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
16615044|NCT02514187|Other|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
16615045|NCT02514187|Other|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
16615046|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
16615047|NCT02514161|Active Comparator|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.
~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:
~First week: 30% Maximum Inspiratory Pressure (MIP)
~Second week: 40% MIP
~Third week: 50% MIP
~Fourth week: 60% MIP
~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
16615048|NCT02514161|Experimental|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:
~- MT:
~Upper cervical region mobilization in flexion
~Lower cervical postero-anterior mobilization + maintained traction
~Costovertebral joint postero-anterior mobilization
~Thoracic vertebral posteroanterior mobilization
~Thrust dorsal
~- MCE:
~Isometric contraction of the deep neck flexors.
~Isometric contraction of the neck extensors.
~Neural self-mobilization.
~Cervical retraction with theraband.
~Sphinx.
~Scapular adduction exercises in prone.
~Scapular adduction exercises in sitting position with theraband."
16615054|NCT02514135||Elevated Intra-abdominal Pressure|Patients with intra-abdominal pressure > 12 mmHg at any time throughout admission
16615055|NCT02514135||Normal Intra-abdominal Pressure|Patients with intra-abdominal pressure < 12 mmHg throughout admission
16615056|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
16615057|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
16615760|NCT02509182|Experimental|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
16615058|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
16615059|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
16615060|NCT02514083|Experimental|Ibrutinib and short-course fludarabine|"Ibrutinib 420 mg PO daily for the duration of the study
~Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4"
16615061|NCT02514070|Experimental|EPA-rich fish oil arm then DHA-rich fish oil arm|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
16615062|NCT02514070|Experimental|DHA-rich fish oil arm then EPA-rich fish oil arm|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
16615063|NCT02514057||Healthy|Volunteers over 18 years
16615064|NCT02514057||Gastrointestinal disorders|Over 18 and with any gastrointestinal or liver disorder
16615065|NCT02514057||Non-gastrointestinal disorders|Over 18 and with any medical condition requiring hospital attention in which there is no primary gastrointestinal or liver disease
16615066|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
16615067|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
16615068|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
16615069|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
16615070|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
16615071|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
16615072|NCT02514031|Experimental|ARQ-761|"A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study
~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin."
16615073|NCT02514018|Other|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
16615074|NCT02514018|Other|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
16615075|NCT02514005|Active Comparator|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
16615076|NCT02514005|Experimental|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
16615077|NCT02513992|Experimental|intra-arterial injection of tracer|The perfusion tracer 99m-Technetium Ethyl Cysteinate Dimer will be injected via an intra-arterial catheter by a pressure injector to obtain a subtracted ictal SPECT co-registered with MRI (SISCOM)
16615078|NCT02513979|Active Comparator|angiotensin type II receptor antagonists|Hypertensive patients treated with angiotensin type II receptor antagonists
16615079|NCT02513979|No Intervention|No treatment|Normotensive patients
16615080|NCT02513953|Experimental|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
16615081|NCT02513940|Experimental|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
16615082|NCT02513940|Experimental|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
16615083|NCT02513940|Experimental|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
16615084|NCT02513940|Experimental|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
16615085|NCT02513940|Experimental|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
16615086|NCT02513940|Experimental|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
16615087|NCT02513927|Active Comparator|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
16615088|NCT02513927|Active Comparator|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
16615089|NCT02513914|Experimental|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
16615090|NCT02513914|Active Comparator|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
16615091|NCT02513901|Experimental|Chidamide|"Step 1 - Six participants will receive Chidamide 10 mg twice a week(BIW) for 4 consecutive weeks.
~Step 2 - Another six participants will receive Chidamide 30 mg twice a week(BIW) for 4 consecutive weeks.
~Participants will be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety concerns are noted, Step 2 will be enrolled."
16615092|NCT02513888|Experimental|Vitamin D + diet and lifestyle|subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification
16615093|NCT02513888|Placebo Comparator|placebo + diet and lifestyle|Subjects will be given placebo with diet and lifestyle
16615094|NCT02513875|Experimental|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
16615095|NCT02513875|Placebo Comparator|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
16615096|NCT02513862|Experimental|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
16615097|NCT02513862|No Intervention|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
16615098|NCT02513849|Experimental|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
16615099|NCT02513836|Experimental|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
16615100|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. They will repeat the questionnaire (POEM) after this education on opioid knowledge on the same day.
16615101|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
16615102|NCT02513810|Experimental|Short-term DAPT after Biofreedom|
16615103|NCT02513810|Active Comparator|Long-term DAPT after BioMatrix or Ultimaster|
16615104|NCT02513797|Experimental|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
16615105|NCT02513797|Active Comparator|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
16615106|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
16615107|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
16615108|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
16615109|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
16615110|NCT02513758||HIV patients|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
16615111|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
16615795|NCT02509000|Active Comparator|Active-mode|Air purifier in active-mode
16615112|NCT02513745|Active Comparator|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
16615113|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
16615114|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
16615115|NCT02513693|Experimental|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine
~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
16615116|NCT02513693|Experimental|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex
~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).
~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.
~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
16615117|NCT02513680|Active Comparator|LASER and LED therapy application|The first group will use the two techniques under study combined: Infrared Laser + Amber LED (830 nm - 150mW + 590 nm - 1.500 mW)
16615118|NCT02513680|Active Comparator|LED Therapy application|The second group will use only Amber LED (590 nm - 1.500 mW)
16615119|NCT02513667|Experimental|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
16615120|NCT02513667|Experimental|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
16615121|NCT02513654|Experimental|Lamotrigine dispersible tablets 25mg, 50mg, 100mg|Each subjects will start dosing with lamotrigine 25mg dispersible tablet once daily at Day 1 and remain at this dose level for 2 weeks (Days1-14), then will be titrated to 50 mg once daily at Day 15 and last for weeks 3-4 (Days 15-28), and then titrated to 100 mg once daily at Day 29 during weeks 5-6 (Days 29-42).
16615122|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
16615123|NCT02513602||TEST group (kidney transplanted)|"Kidney transplanted patients, passed through dialysis phase presenting a mandibular edentulism. It will be scheduled one or two dental implants to be inserted in mandible.
~This group will be subjected to a dental implant insertion procedure."
16615124|NCT02513602||CONTROL group (healthy patients)|Healthy patients, with an inserted mandibular implant, retrospectively enrolled with a preoperative cbct scan.
16615125|NCT02513589|Experimental|Experimental arm|
16615126|NCT02513576|Experimental|Physiotherapy exercises|Two strategies of abdominal exercises with and without movement of the upper limbs applied in patients with sternal instability as randomization.
16615127|NCT02513563|Experimental|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
16615128|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
16615129|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
16615130|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
16615131|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
16615132|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
16615133|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
16615189|NCT02513108|No Intervention|standard care|standard care where patients are discharged the day after procedure after adequate observation
16615796|NCT02509000|Sham Comparator|Sham-mode|Air purifier in sham-mode
16615134|NCT02513524||Direct Observed Therapy test|Patients with resistant hypertension (as defined in the eligibility criteria) will be enrolled. They will all have undergone 24 hour ambulatory blood pressure monitoring (ABPM) before enrollment. As part of the study, the subjects will undergo direct observed therapy testing, followed by another 24 hour ABPM, which will be repeated at 1 month.
16615135|NCT02513511|Experimental|Hypnosis|the investigators will put the patient into a hypnotic state and analyze laryngoscopy under hypnosis, followed by intubation.
16615136|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
16615137|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
16615138|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
16615139|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
16615140|NCT02513459|Experimental|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
16615141|NCT02513446|Experimental|BI 1026706|Single dose
16615142|NCT02513446|Experimental|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
16615143|NCT02513433|Active Comparator|Bupivacaine & Levobupivacaine|Bupivacaine 15 ml 0.5% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
16615144|NCT02513433|Active Comparator|Bupivacaine & Ropivacaine|Bupivacaine 15 ml 0.5% and Ropivacaine 15 ml 0.75% in epidural route before surgery
16615145|NCT02513433|Active Comparator|Ropivacaine & Levobupivacaine|Ropivacaine 15 ml 0.75% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
16615146|NCT02513420|Experimental|Perineal muscle training|This group will recibe a training of a combination of perineal massage and pelvic floor muscle excersice that will start after 33 weeks of gestation. Every week until the childbith, They will be evaluated with a diary.
16615147|NCT02513420|No Intervention|Usual prental care|Usually pregnant women have not a training focused in pelvic floor muscle, so this group won't receive any indication of pelvic floor training except if They complains of urinary incontinence.
16615148|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
16615149|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
16615150|NCT02513394|Experimental|Arm A|Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.
16615151|NCT02513394|Other|Arm B|Standard adjuvant endocrine therapy for a duration of at least 5 years.
16615152|NCT02513381|Active Comparator|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
16615153|NCT02513381|Placebo Comparator|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
16615154|NCT02513368|Experimental|Bio-Oss®, Bio-Gide®|augmentation procedure with Bio-Oss® and Bio-Gide®
16615155|NCT02513368|Active Comparator|connective tissue graft|augmentation procedure with connective tissue graft
16615156|NCT02513355|Experimental|NP(Changchun marina+cisplatin)+Endostar|Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
16615157|NCT02513355|Experimental|TP(Taxol+cisplatin or parapl) +Endostar|"Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.
~Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4."
16615158|NCT02513342|Experimental|Endostar+Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.
16615159|NCT02513342|Active Comparator|Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.
16615160|NCT02513329|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivacaine
16615161|NCT02513329|Sham Comparator|Saline|Saline injection
16615190|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
16615191|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
16615162|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
16615163|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
16615164|NCT02513303|Experimental|Treatment Group|AV fistula surgery Single administration of sirolimus-eluting Collagen implant
16615165|NCT02513303|Other|Control Group|AV fistula surgery
16615166|NCT02513290|Experimental|Bilastine group|Bilastine 20 mg administered once a day for ten days.
16615167|NCT02513290|Experimental|Loratadine group|Loratadine 10 mg administered once a day for ten days.
16615168|NCT02513251||Case group|Chronic pain patient
16615169|NCT02513238|Active Comparator|Stemcells injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.
16615170|NCT02513238|Placebo Comparator|Saltwater injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%.
16615171|NCT02513225|Experimental|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
16615172|NCT02513225|Other|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
16615173|NCT02513212|Other|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
16615174|NCT02513212|Other|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
16615175|NCT02513199|Experimental|TACE/SBRT combination|
16615176|NCT02513199|Active Comparator|TACE alone|
16615180|NCT02513160|Experimental|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
16615181|NCT02513160|Experimental|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
16615182|NCT02513160|Active Comparator|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
16615183|NCT02513160|Placebo Comparator|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
16615184|NCT02513147|Experimental|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
16615185|NCT02513147|Active Comparator|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
16615186|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
16615187|NCT02513121|No Intervention|Observational Arm|Standard of care
16615188|NCT02513108|Active Comparator|same day discharge|patients discharged same day after uncomplicated PCI
16615928|NCT02508181|Active Comparator|LMA Supreme intra ocular pressure|supraglottic airway device
16615192|NCT02513082|Experimental|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
16615193|NCT02513082|Active Comparator|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
16615194|NCT02513069|Experimental|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
16615195|NCT02513069|Active Comparator|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
16615196|NCT02513030||Replacement of defibrillator|
16615197|NCT02513017|Experimental|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.
~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
16615198|NCT02513017|Experimental|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
16615199|NCT02513017|No Intervention|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
16615200|NCT02513004|Experimental|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
16615201|NCT02513004|Active Comparator|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
16615202|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
16615203|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
16615204|NCT02512978|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
16615205|NCT02512978|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
16615206|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
16615207|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
16615208|NCT02512952|Active Comparator|Group 1|SRP with Open flap debridement (OFD) alone for treating periodontal pocket
16615209|NCT02512952|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into bone defect
16615210|NCT02512952|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into bone defect
16615211|NCT02512939|Experimental|Contacts of TB cases|Blood test, not yet marketed, development phase
16615212|NCT02512926|Experimental|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
16615213|NCT02512913|Experimental|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
16615214|NCT02512913|No Intervention|Usual Care|Couples in the control condition will receive usual care
16615215|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
16615248|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.
~Drug to be given in combination of Busulfan, Campath and Fludarabine"
16615216|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
16615217|NCT02512887|Experimental|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
16615218|NCT02512887|Active Comparator|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
16615219|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
16615220|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
16615221|NCT02512861|Placebo Comparator|Placebo|Normal Saline
16615222|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
16615223|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
16615224|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
16615225|NCT02512822|Experimental|Participants|Noninvasive Radiofrequency
16615226|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
16615227|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
16615228|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
16615229|NCT02512796||Transplant patients, MRI with Gadolinium contrast dye|Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.
16615230|NCT02512796||Non-transplant patients, MRI with Gadolinium contrast dye|Non-transplant patients exposed to gadolinium contrast.
16615231|NCT02512796||Healthy controls, no transplant no Gadolinium contrast dye|Age- and sex-matched healthy controls not exposed to gadolinium contrast.
16615232|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
16615233|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
16615234|NCT02512770|Experimental|dilatation|esaphageal dilatation group
16615235|NCT02512770|No Intervention|control|control group ( only endoscopy for control)
16615236|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
16615237|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample.
16615238|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
16615239|NCT02512744|No Intervention|Capping trial protocol|"Decannulation protocol based on tolerance to 24 hours capping trial to decide when to decannulate.
~Decapping during the capping trial for aspiration of respiratory secretions is considered a failure criteria of the trial.
~High flow conditioned oxygen therapy through tracheal cannula will be applied during periods out of capping trials."
16615240|NCT02512744|Experimental|Suctioning frequency protocol|"Decannulation protocol based on suctioning frequency to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
~Intervention: suctioning frequency of respiratory secretions will be recorded untill fulfill decannulation criteria. Capping trials will not be allowed in this group.
~High flow conditioned oxygen therapy will be applied through tracheal cannula during all the study period."
16615241|NCT02512731|Active Comparator|Goal directed fluid therapy using esophageal doppler monitor|The esophageal doppler monitor directs the fluid therapy.
16615242|NCT02512731|No Intervention|Fluid therapy using standard management|The esophageal doppler monitor is in place however blinded to the healthcare providers, fluid management is as per standard clinical practice.
16615243|NCT02512718|Experimental|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
16615244|NCT02512718|Active Comparator|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
16615245|NCT02512705|Other|Seclusion Room|The current practice is followed as a control group A.
16615246|NCT02512705|Experimental|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
16615247|NCT02512692|Experimental|90Y TARE with Gemcitabine and Cisplatin|"90Y TARE will be given on day 3 or 4 of cycle 1 and start at 75% of the dose calculated by the body surface area formula and escalated by 25% per cohort in combination with cisplatin 25 mg/m2 and gemcitabine 300 mg/m2 in cycles 1 and 2.
~Once the 90Y TARE has reached the 100% dose level, the gemcitabine dose will increase to 600mg/m2 in dose level 3 and 1000mg/m2 in dose level 4. The cisplatin dose will remain at 25/mg/m2.
~For all dose levels, from cycle 3 to cycle 8, the cisplatin dose will be 25mg/m2 and the gemcitabine dose will be 1000mg/m2."
16615249|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
16615250|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
16615251|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
16615252|NCT02512666|Experimental|Non-Invasive Imaging|"Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients.
~For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery"
16615253|NCT02512653|Experimental|1|Cupressus arizonica allergen extract at 4 different concentrations. Positive control. Negative control
16615254|NCT02512640|Active Comparator|Volume-controlled ventilation|Volume-controlled ventilation throughout the surgery
16615255|NCT02512640|Active Comparator|Pressure-controlled ventilation|Pressure-controlled ventilation throughout the surgery
16615256|NCT02512627|Active Comparator|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
16615257|NCT02512627|Active Comparator|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
16615258|NCT02512627|Experimental|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
16615259|NCT02512627|Experimental|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
16615260|NCT02512614|No Intervention|Comparison|Hand hygiene education.
16615261|NCT02512614|Experimental|Intervention|Hand hygiene education and 4 antimicrobial hand towels
16615262|NCT02512601|Experimental|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
16615263|NCT02512588|Experimental|BTD-001|
16615264|NCT02512588|Experimental|Placebo|
16615265|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).
~In Part B: one cohort with a single dose"
16615266|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
16615267|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.
~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
16615268|NCT02512562|Active Comparator|Group 1: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
16615269|NCT02512562|Active Comparator|Group 2: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
16615270|NCT02512549|Active Comparator|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
16615271|NCT02512549|No Intervention|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
16615272|NCT02512536|Experimental|Experimental|"Intervention:
~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.
~Drug: Dysport 300 units im. One single injection over course of study."
16615273|NCT02512523|Experimental|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
16615274|NCT02512523|Active Comparator|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
16615275|NCT02512510|Active Comparator|TD-4208-1|88 mcg
16615276|NCT02512510|Active Comparator|TD-4208-2|175 mcg
16615277|NCT02512510|Placebo Comparator|Placebo|Placebo
16615278|NCT02512497|Experimental|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:
~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.
~Romidepsin Maintenance Therapy - Part 2:
~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
16615404|NCT02511652|Active Comparator|Ambu AuraGain|Insertion of the supraglottic device and evaluation of its clinical performance
16615279|NCT02512484||high risk TB individuals attending A&E Departments|Assessment against inclusion/exclusion criteria in terms of risk of TB. If eligible, assessment and testing as appropriate for active or latent TB
16615280|NCT02512471|Experimental|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
16615281|NCT02512471|Active Comparator|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
16615282|NCT02512458|Experimental|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
16615283|NCT02512445|Experimental|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
16615284|NCT02512445|Active Comparator|Supportive Care Therapy|6-session psychotherapy intervention
16615285|NCT02512432|Other|Keratoconus|
16615286|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
16615287|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
16615288|NCT02512406||Patients with Tourette Syndrome|Questionnaires including the Sensory Profile or the Adult/Adolescent Sensory profile and Children's Yale-Brown Obsessive Compulsive Scale or Yale Global Tic Severity Scale will be administered. When time permits, the Children's Yale-Brown Obsessive Compulsive Scale or Yale-Brown Obsessive Compulsive Scale will also be administered. Demographic data will also be collected for each study patient.
16615289|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
16615290|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
16615291|NCT02512380|Experimental|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
16615292|NCT02512380|Active Comparator|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
16615293|NCT02512367|Experimental|Intervention|
16615294|NCT02512367|Placebo Comparator|Surveillance|
16615295|NCT02512354||Fetus|
16615296|NCT02512328|No Intervention|Regular colonoscopy preparation|Comparison group. Regular colonoscopy preparation
16615297|NCT02512328|Experimental|APP supported colonoscopy preparation|APP as additional device for colonoscopy preparation
16615298|NCT02512315|Active Comparator|CCRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CCRT).
16615299|NCT02512315|Experimental|NACT-CCRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CCRT.
16615300|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
16615301|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
16615302|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
16615303|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
16615304|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
16615305|NCT02512289|Active Comparator|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
16615306|NCT02512289|Sham Comparator|Sham stimulation|Sham tDCS associated with RAT
16615307|NCT02512276|Experimental|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications [defined as combined (average of averages) proportion of days covered (PDC) < 80%] who also have poor or worsening disease control.
16615308|NCT02512276|No Intervention|Usual care|Patients randomized to this arm will receive usual care.
16615309|NCT02512263|Experimental|Intervention group|They will have to do all the tests and to follow the home-based training program during 9 weeks.
16615310|NCT02512263|No Intervention|control group|They will have to do all the tests but not to follow the home-based training program.
16615311|NCT02512237|Experimental|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
16615312|NCT02512237|Experimental|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
16615313|NCT02512237|Experimental|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
16615314|NCT02512237|Experimental|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
16615315|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
16615316|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
16615317|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
16615318|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
16615319|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
16615320|NCT02512198|Experimental|Bronchodilators|"Prescription Data Feedback to GP Practices - practices will be fed back data for people with presumed asthma who have either been dispensed more than 12 short-acting beta-agonist bronchodilators in the last 12 months who are not concurrently prescribed inhaled corticosteroids (poor asthma control with inadequate prevention) or been dispensed a long-acting beta-agonist bronchodilator as a single agent in the last 12 months who are not or are only infrequently concurrently prescribed inhaled corticosteroids (potentially harmful prescribing). To minimise inclusion of people with COPD, patient aged 35 years and older prescribed long-acting antimuscarinic bronchodilators will be excluded.
~Practices in the bronchodilator arm are controls for the antibiotic experimental arm (below)."
16615321|NCT02512198|Experimental|Antibiotics|"Prescription Data Feedback to GP Practices - number of women in the GP practice aged 12 years and older dispensed more than 6 courses of urinary tract infection (UTI) antibiotics in the last year. UTI antibiotics are defined as trimethoprim, nitrofurantoin, co-trimoxazole, quinolones and cefalexin.
~Practices in the antibiotic arm are controls for the bronchodilator experimental arm (above)."
16615322|NCT02512185||Chemotherapy|Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
16615323|NCT02512185||Abiraterone|Men with mCRPC starting Abiraterone
16615324|NCT02512185||Enzalutamide|Men with mCRPC starting Enzalutamide
16615325|NCT02512172|Experimental|Oral CC - 486 & MK-3475|Oral CC - 486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
16615326|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
16615327|NCT02512172|Experimental|Oral CC - 486 & Romidepsin & MK-3475|Oral CC - 486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
16615328|NCT02512159|Experimental|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
16615329|NCT02512159|Active Comparator|Healing|"Patients who were managed with traditional conservative treatment."
16615330|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
16615331|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.
~Intervention: colonoscopy."
16615332|NCT02512133|Experimental|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
16615333|NCT02512133|Experimental|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
16615334|NCT02512120|Experimental|volume controlled ventilation|Randomized 23 patients will be applied VCV during RALP.
16615335|NCT02512120|Active Comparator|autoflow-volume controlled ventilation|Randomized 23 patients will be applied autoflow-VCV during RALP.
16615336|NCT02512107|Active Comparator|Juice Plus+|Subject will be taking supplement.
16615337|NCT02512107|Placebo Comparator|Placebo|Subjects will be taking the placebo.
16615338|NCT02512068|Experimental|Trelagliptin 25 mg|Trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period I + II)
16615339|NCT02512068|Experimental|Placebo and Trelagliptin 25 mg|Placebo tablet, orally, once weekly before breakfast for up to Week 12 (Period I), followed by trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period II)
16615340|NCT02512055|Experimental|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
16615341|NCT02512042|Experimental|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
16615342|NCT02512042|Active Comparator|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
16615343|NCT02512029|Experimental|TBI Subjects|Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.
16615344|NCT02512029|Experimental|Control|Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451.
16615345|NCT02512016|Other|Nulliparous Women in Third Trimester|Study Procedures
16615346|NCT02512003|Experimental|Fantom Treatment group|
16615347|NCT02511990|Experimental|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml
~3 mg/kg, single dose IV administration of 10-1074"
16615348|NCT02511990|Experimental|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml
~10 mg/kg, single dose IV administration of 10-1074"
16615405|NCT02511652|Active Comparator|LMA Supreme|Insertion of the supraglottic device and evaluation of its clinical performance
16615349|NCT02511990|Experimental|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml
~30 mg/kg, single dose IV administration of 10-1074"
16615350|NCT02511990|Experimental|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml
~30 mg/kg, single dose IV administration of 10-1074"
16615351|NCT02511990|Experimental|Group 2A|"HIV-uninfected individuals
~3 mg/kg, single dose IV administration of 10-1074"
16615352|NCT02511990|Experimental|Group 2B|"HIV-uninfected individuals
~10 mg/kg, single dose IV administration of 10-1074"
16615353|NCT02511990|Experimental|Group 2C|"HIV-uninfected individuals
~30 mg/kg, single dose IV administration of 10-1074"
16615354|NCT02511990|Experimental|Group 2D|"HIV-uninfected individuals
~30 mg/kg, single dose IV administration of 10-1074"
16615355|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
16615356|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
16615357|NCT02511964|Experimental|Interval Training at 1% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 1% incline; Group metabolically balanced.
16615358|NCT02511964|Experimental|Interval Training at 10% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 10% incline; Group metabolically balanced.
16615359|NCT02511964|No Intervention|Control|Only Dependent Variables Measures
16615360|NCT02511951|Experimental|one-layer duct-to-mucosa anastomosis|one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
16615361|NCT02511951|Active Comparator|two-layer duct-to-mucosa anastomosis|two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
16615362|NCT02511938|Experimental|Menu Only intervention|Restaurants will receive a new healthy kids' menu
16615363|NCT02511938|Experimental|Menu Plus Intervention|Restaurants will receive a new healthy kids' menu, supporting marketing materials, and brief trainings for customer service staff and kitchen staff to support and promote the new menu items.
16615364|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
16615365|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
16615366|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
16615367|NCT02511912|Experimental|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.
~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
16615368|NCT02511899|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
16615369|NCT02511899|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
16615370|NCT02511886|Experimental|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
16615371|NCT02511886|Placebo Comparator|Placebo|Subjects remain on placebo for entire study
16615372|NCT02511873|Experimental|Fycompa|Fycompa dose is chosen based on tolerability and efficacy. 2mg to 8mg daily for 6 weeks then washed out.
16615373|NCT02511873|Placebo Comparator|Placebo|Inactive ingredient equal to 2mg tablets
16615374|NCT02511860|Placebo Comparator|Placebo|Patients will consume a placebo pill containing methylcellulose.
16615375|NCT02511860|Active Comparator|Active|Patients will consume 850 mg of burdock twice per day.
16615376|NCT02511847|Other|single-arm|"Drug: Afatinib (single group assignment)
~First phase: Afatinib montherapy
~The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
16615377|NCT02511834|Experimental|VEST supported|Vein graft supported by VEST
16615378|NCT02511834|Active Comparator|Control|Vein grafts unsupported by VEST
16615379|NCT02511821|Experimental|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
16615380|NCT02511808|Active Comparator|Step-up Treatment: MI|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive two sessions of MI.
16615381|NCT02511808|Other|Control: BA|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive one additional session of BA.
16615382|NCT02511808|Active Comparator|Step-up Treatment: Specialist Care|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive four sessions of BSCT if they received MI at the previous randomization or five sessions of combined MI and BSCT if they received BA at the previous randomization.
16615383|NCT02511808|Other|Control: MI|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive one session of MI if they received MI at the previous randomization or two sessions of MI if they received BA at the previous randomization.
16615384|NCT02511795|Experimental|AZD1775 (6 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 3 days (6 doses) on Days 1-3 of Week 1 and Days 8-10 of Week 2. Olaparib will be given orally BID on Days 1-14.
~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
16615385|NCT02511795|Experimental|AZD1775 (10 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 5 days (10 doses) on Days 1-5 of Week 1 and Days 8-12 of Week 2. Olaparib will be given orally BID on Days 1-14.
~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
16615386|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
16615387|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
16615388|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
16615389|NCT02511769|Experimental|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
16615390|NCT02511769|Active Comparator|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
16615391|NCT02511756|Other|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
16615392|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
16615393|NCT02511730|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
16615394|NCT02511730|Active Comparator|FFDM Alone|Breast Images with FFDM alone
16615395|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
16615396|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
16615397|NCT02511704|Experimental|Electronic cigarette|"Multiple dose
~Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) + Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) separated by 60 minutes"
16615398|NCT02511704|Active Comparator|Cigarette|"Multiple dose
~Nicotine 0.8 mg, administrated by cigarette (10 puffs) + Nicotine 0.8 mg, administrated by cigarette (10 puffs) separated by 60 minutes"
16615399|NCT02511691|Other|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
16615400|NCT02511678|Experimental|Cryoablation|All participants will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles within 14 days of screening. In the case of participants with multiple metastatic lesions involving bone, the most painful lesion is to be selected for cryoablation. If treatment could not be completed within 14 days of screening, the participant will be re-screened using the inclusion and exclusion criteria. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators.
16615401|NCT02511665|Experimental|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
16615402|NCT02511665|Placebo Comparator|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
16615403|NCT02511665|Experimental|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
16615406|NCT02511639|Experimental|Arm A: Everolimus & Aromatase inhibitors|Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
16615407|NCT02511639|Active Comparator|Arm B: Aromatase inhibitors|Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
16615408|NCT02511626||Case group|Women with a surgically confirmed diagnosis of endometriosis
16615409|NCT02511626||Control group 1|Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)
16615410|NCT02511626||Control group 2|Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)
16615411|NCT02511613|Placebo Comparator|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
16615412|NCT02511613|Active Comparator|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
16615413|NCT02511600|Experimental|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
16615414|NCT02511600|Active Comparator|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
16615415|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
16615416|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
16615417|NCT02511574|Experimental|cervical pessary|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
16615418|NCT02511574|Active Comparator|natural progesterone|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
16615419|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
16615420|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
16615421|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
16615422|NCT02511548|Experimental|Intervention|Financial incentive
16615423|NCT02511548|No Intervention|Control|No financial incentive
16615424|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
16615425|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
16615426|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
16615427|NCT02511522|Active Comparator|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
16615428|NCT02511522|Experimental|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
16615429|NCT02511509|Experimental|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
16615430|NCT02511509|Active Comparator|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
16615431|NCT02511483|Placebo Comparator|IV-PCA morphine + Placebo PO|"Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.
~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
16615432|NCT02511483|Experimental|IV-PCA morphine + Propranolol PO|"The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .
~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
16615433|NCT02511470|Other|CPR with metronome on|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome on. Data for compression rate and depth will be collected during this time interval.
16615434|NCT02511470|Other|CPR with metronome off|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome off. Data for compression rate and depth will be collected during this time interval.
16615435|NCT02511444|Other|single arm|All patients will have GBS culture and real time PCR performed.
16615436|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
16615437|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
16615438|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
16615439|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
16615440|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
16615441|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
16615442|NCT02511405|Experimental|Arm 1|VB-111 + Bevacizumab
16615443|NCT02511405|Active Comparator|Arm 2|Bevacizumab
16615444|NCT02511392|Active Comparator|Group 1: Real rTMS-1 Hz|Included 15 patients, they received 1 Hz rTMS with intensity of 100% of the RMT continuous with total 2000 applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval
16615445|NCT02511392|Active Comparator|Group 2: Real rTMS-10 Hz|Included 15 patients, they received 10 Hz rTMS with intensity of 100% of the RMT applied in 10 trains, each of them 200 pulses, with 20 seconds intertrain interval
16615545|NCT02510729|Active Comparator|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
16615446|NCT02511392|Sham Comparator|Group 3: Sham rTMS|Included 15 patients; they received the same number of pulses 2000 pulse applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval, but coil was placed over the same area but perpendicular to the scalp.
16615447|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
16615448|NCT02511366|Experimental|ileal infusion of casein|Ileal infusion of casein
16615449|NCT02511366|Placebo Comparator|ileal infusion of tap water|ileal infusion of tap water
16615450|NCT02511353|Placebo Comparator|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
16615451|NCT02511353|Experimental|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
16615452|NCT02511353|Experimental|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
16615453|NCT02511340|Experimental|Flumatinib mesylate tablet 600 mg qd|Flumatinib, 600mg, qd
16615454|NCT02511327||Preterm born infants of vaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
16615455|NCT02511327||Term born infants vaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
16615456|NCT02511327||Term born infants unvaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy. Infant vaccination against pertussis is performed according to the national recommended schedule.
16615457|NCT02511327||Preterm born infants unvaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy.Infant vaccination against pertussis is performed according to the national recommended schedule.
16615458|NCT02511314|Experimental|Intervention|"Tena Identifi is an integrated electronic monitoring system based upon a wearable continence pad which allows registration of resident's micturition patterns over a 72 hour period, allowing caregivers to construct an individualised continence care plan, including use of appropriate products.
~To create a voiding report, a resident wears the Identifi Sensor Wear with an attached Identifi Logger for three consecutive days (72 hours). The logger continuously logs the moisture status of the brief. The resulting data is sent to a server via 3 G signal where it is mapped onto a graph indicating voiding times and volumes."
16615459|NCT02511314|No Intervention|Control Intervention|"The control portion of the study is usual care, defined as the routine practices and procedures, including continence assessment approach, prescribed in the nursing home unit or facility."
16615460|NCT02511301|Experimental|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.There are no interventions after the CBR™ is removed from the Study Subject
16615461|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
16615462|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
16615463|NCT02511288||Cohort 3|Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
16615464|NCT02511275|Other|renal microdialysis|patient with renal microdialysis
16615465|NCT02511262||Specimen Collection|Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
16615466|NCT02511249||cohort|"1 evaluation day : The evaluation team included a neuropsychologist, a speech therapist and either a pediatric neurologist or a pediatric physical and rehabilitation medicine practitioner.
~tests carried out : Global intellectual functioning (WISC-IV), Oral language (N-EEL), Gross and fine motor abilities (clinical examination, Box & Block test, 9 Hole Peg test)"
16615467|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
16615468|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
16615469|NCT02511223|Experimental|Single Arm|Only one Arm,All patients will receive Olaparib 300 mg (MILIGRAM)bid p.o till disease progression
16615470|NCT02511210|Active Comparator|regional anesthesia|spinal anesthesia or peripheral nerve block
16615471|NCT02511210|Active Comparator|general anesthesia|intubated patients
16615472|NCT02511197|Experimental|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
16615473|NCT02511184|Experimental|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
16615474|NCT02511171|No Intervention|No intervention|Subjects do not receive osteopathic care
16615475|NCT02511171|Experimental|Cranial osteopathic manipulative treatment|Subjects receive individualised osteopathic treatment
16615476|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
16615477|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
16615478|NCT02511145|Active Comparator|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
16615479|NCT02511145|Active Comparator|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
16615480|NCT02511145|Active Comparator|Metvixia|minizone with Metvixia cream application, without pretreatment
16615546|NCT02510729|Placebo Comparator|Sham Stimulation|Sham stimulation with amplitude=0
16615481|NCT02511145|Active Comparator|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
16615482|NCT02511145|Experimental|Microneedles pretreatment only|minizone with Microneedles pretreatment only
16615483|NCT02511145|Experimental|Laser pretreatment only|minizone with Laser pretreatment only
16615484|NCT02511145|No Intervention|Normal skin|Normal skin control mini-zone
16615485|NCT02511132|Experimental|Vigil + temozolomide + irinotecan|(i) oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle), (ii) irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle), intravenously (iii) peg-filgrastim 100μg/kg (Day 6) subcutaneously (optional and may be administered at home), and (iv) Vigil 1.0 x 10e7 cells/injection, intradermally on Day 15 and every 43 weeks thereafter. One cycle = 21 days.
16615488|NCT02511093|Experimental|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:
~BP measurements;
~an educational and counselling intervention on patient adherence;
~an educational and counselling intervention on lifestyle (physical activity and diet).
~Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
16615489|NCT02511093|No Intervention|Usual care|
16615490|NCT02511080|Active Comparator|Spot-on group|Use active measures against intraoperative hypothermia
16615491|NCT02511080|No Intervention|control|standard measures against intraoperative hipothermia
16615492|NCT02511067|Active Comparator|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
16615493|NCT02511067|Experimental|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
16615494|NCT02511067|Experimental|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
16615495|NCT02511054|Experimental|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples > 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
16615496|NCT02511054|Experimental|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
16615497|NCT02511054|Experimental|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
16615498|NCT02511054|Experimental|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
16615499|NCT02511041|Experimental|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
16615501|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
16615502|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
16615503|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
16615505|NCT02510976|Active Comparator|Prucalopride|Prucalopride tablet 2 mg
16615506|NCT02510976|Placebo Comparator|Placebo|matching placebo tablet
16615507|NCT02510963|Experimental|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
16615508|NCT02510963|Experimental|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
16615509|NCT02510963|Active Comparator|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
16615510|NCT02510950|Experimental|Arm 1: Peptide/poly-ICLC|"For all patients, concurrent chemoradiation with temozolomide will be given per standard of care and is outside the scope of this study as per standard of care.
~The long peptide + poly-ICLC will be given on Cycle 1 Day 1 of maintenance temozolomide.
~If the vaccine is not ready by this time, the first vaccination will begin on Day 1 of the next cycle of maintenance temozolomide.
~The peptide + poly-ICLC vaccine will be given again on Days 8, 15, and 22 of the first cycle, as a priming strategy.
~On all subsequent cycles, the peptide vaccine + poly-ICLC will be given on Day 22 (+/-3 days)."
16615511|NCT02510937|Experimental|Low dose CC-90001|Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks
16615512|NCT02510937|Experimental|High dose CC-90001|High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks
16615513|NCT02510924|Active Comparator|Tracheal intubation with Airtraq sp|Tracheal intubation with Airtraq sp.
16615514|NCT02510924|Experimental|Tracheal intubation with Airtraq Mobile|Tracheal intubation with Airtraq Mobile
16615515|NCT02510911|Experimental|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
16615516|NCT02510911|Experimental|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
16615517|NCT02510911|Placebo Comparator|corn starch (250 mg approx.)|approx. 250 mg corn starch as placebo
16615518|NCT02510898|Experimental|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
16615519|NCT02510885|Experimental|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
16615520|NCT02510872|Experimental|18F-FDG PET combined with CT with iodinated contrast injection|18F-FDG PET combined with CT with iodinated contrast injection
16615521|NCT02510872|Sham Comparator|18F-FDG PET combined with CT without injection|18F-FDG PET combined with CT without injection
16615522|NCT02510859|Experimental|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
16615523|NCT02510859|No Intervention|Traditional nutritional follow up|Traditional nutritional follow up that is to say with a nutritional consultation before starting treatment and then when necessary on medical advice
16615524|NCT02510846|Experimental|Intensive educative program|5 hours a week
16615525|NCT02510846|Active Comparator|Usual practice of educative program|1 hour a week
16615526|NCT02510833|Experimental|Continuing Intervention Group|
16615527|NCT02510833|Active Comparator|Control Group|
16615528|NCT02510820|Active Comparator|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
16615529|NCT02510820|Active Comparator|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
16615530|NCT02510807|Experimental|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
16615531|NCT02510807|No Intervention|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
16615532|NCT02510794|Experimental|Port Delivery System with Ranibizumab 10mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 10-mg/mL ,approximately 0.2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 10-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
16615533|NCT02510794|Experimental|Port Delivery System with Ranibizumab 40mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 40-mg/mL, approximately 0.8 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 40-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
16615534|NCT02510794|Experimental|Port Delivery System with Ranibizumab 100mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 100-mg/mL, approximately 2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 100-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
16615535|NCT02510794|Active Comparator|Intravitreal Injection with Ranibizumab 0.5mg|Participants received ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
16615536|NCT02510781|Experimental|A group|docetaxel+carboplatin+trastuzumab
16615537|NCT02510781|Active Comparator|B group|Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab
16615538|NCT02510768|Experimental|ELAPR002f|ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
16615539|NCT02510768|Experimental|ELAPR002g|ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
16615540|NCT02510768|Placebo Comparator|Saline|Saline
16615541|NCT02510755|Other|PTSD group|PTSD group
16615542|NCT02510755|Other|Healthy Volunteers|Healthy Volunteers, age-matched controls.
16615543|NCT02510742|Active Comparator|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
16615544|NCT02510742|Sham Comparator|Control|Sham neurostimulation of amplitude=0
16615547|NCT02510716|Experimental|Scheduled Gradual Reduction (SGR)|Four week SGR program plus support text messages.
16615548|NCT02510716|Active Comparator|Support Message Only|Support text messages only.
16615549|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
16615550|NCT02510703|Other|no diabetes|no diabetes
16615551|NCT02510677|Other|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
16615552|NCT02510664|Experimental|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
16615553|NCT02510651|Experimental|ORSHFS|Melanocyte-keratinocyte suspension.
16615554|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
16615555|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
16615556|NCT02510612|Experimental|Dexmedetomidine|Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h
16615557|NCT02510612|Placebo Comparator|placebo|Patients in group P will be given normal saline during anesthesia induction and maintenance phase
16615558|NCT02510599|Experimental|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
16615559|NCT02510586|Experimental|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
16615560|NCT02510586|No Intervention|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
16615561|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
16615562|NCT02510560|Experimental|NTRA-2112 A|NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.
16615563|NCT02510560|Experimental|NTRA-2112 B|NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.
16615564|NCT02510560|Placebo Comparator|Placebo|Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.
16615565|NCT02510547|Active Comparator|CrossBoss Catheter|Crossing the CTO with upfront use of the CrossBoss catheter
16615566|NCT02510547|Active Comparator|Antegrade Wire Escalation Strategy|Crossing the CTO with upfront antegrade wire escalation strategy
16615567|NCT02510534|Active Comparator|Control|This arm receives Menopur 150 international units x 1 dose
16615568|NCT02510534|Active Comparator|Treatment|This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
16615569|NCT02510521|Placebo Comparator|in rest situation|No intervention during one week. Daily usual activities are allowed.
16615570|NCT02510521|Experimental|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:
~warming-up sequence
~work sequence (starting at 50% of the intensity achieved during warm-up)
~relaxation sequence
~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
16615571|NCT02510521|Experimental|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :
~warming-up sequence
~work sequence (starting at 50% of the intensity achieved during warm-up)
~relaxation sequence
~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
16615572|NCT02510508|Experimental|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
16615573|NCT02510508|Active Comparator|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
16615574|NCT02510508|No Intervention|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
16615575|NCT02510495|No Intervention|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
16615576|NCT02510495|Experimental|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
16615633|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
16615634|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
16615577|NCT02510495|Experimental|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
16615578|NCT02510495|Experimental|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
16615579|NCT02510495|Experimental|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
16615580|NCT02510482||Aortic valve stenosis|Individuals with clinically stable moderate aortic valve stenosis
16615581|NCT02510469|Experimental|Apatinib Maintenance Therapy After Adjuvant Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
16615582|NCT02510469|No Intervention|Only Adjuvant Chemotherapy|No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
16615583|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Neoadjuvant Chemo (NAC) Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 6 time points.
16615584|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Non-NAC Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 1 time point.
16615585|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
16615586|NCT02510430|Experimental|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
16615587|NCT02510430|Experimental|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
16615588|NCT02510430|Placebo Comparator|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
16615589|NCT02510417|Experimental|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
16615590|NCT02510404|Experimental|mCTLs against three viruss|The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
16615591|NCT02510391|Experimental|PIPA|Modularized treatment for anxiety in children ages 3-7 years old
16615592|NCT02510378|Experimental|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
16615593|NCT02510365|Experimental|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
16615594|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
16615595|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
16615596|NCT02510313|No Intervention|Classic VUP (Control)|Families receive benefits (cash) in exchange for state-sanctioned labour intensive work.
16615597|NCT02510313|No Intervention|Expanded VUP|Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
16615598|NCT02510313|Experimental|Sugira Muryango & Classic VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned labour intensive work.
16615599|NCT02510313|Experimental|Sugira Muryango & Expanded VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
16615600|NCT02510287|Active Comparator|Continuous Epidural Infusion|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.
~A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.
~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
16615635|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
16615636|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
16615601|NCT02510287|Experimental|Programmed Intermittent Epidural Bolus|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.
~A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.
~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
16615602|NCT02510274|Experimental|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
16615603|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
16615604|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
16615606|NCT02510248|Experimental|Study Drug|Study drug will be AL-704 once or twice daily for up to 7 days in dosages ranging from 100 mg to 1500 mg.
16615607|NCT02510248|Placebo Comparator|Placebo|Placebo to match study drug dosing.
16615608|NCT02510235|Experimental|Lubricin|Lubricin 150 µg/ml eye drops solution
16615609|NCT02510235|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
16615610|NCT02510222|Experimental|Oral Magnesium sulfate|Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
16615611|NCT02510222|Placebo Comparator|Control|Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
16615612|NCT02510209|Experimental|Teen Outreach Program|
16615613|NCT02510209|No Intervention|Control|Business as usual.
16615614|NCT02510196|Active Comparator|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
16615615|NCT02510196|No Intervention|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
16615616|NCT02510183|Active Comparator|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
16615617|NCT02510183|Placebo Comparator|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
16615618|NCT02510183|No Intervention|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
16615619|NCT02510157|Active Comparator|dexamethasone|Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
16615620|NCT02510157|Placebo Comparator|normal saline|Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
16615621|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
16615622|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
16615623|NCT02510131|Active Comparator|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.
~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.
~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.
~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
16615624|NCT02510131|Experimental|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.
~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.
~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.
~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
16615625|NCT02510118|Experimental|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
16615626|NCT02510118|Experimental|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
16615627|NCT02510105|Experimental|ARDS patients|
16615628|NCT02510092|Active Comparator|Coronary artery diseae with revascularization indicated|Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.
16615629|NCT02510092|No Intervention|Coronary artery disease not requiring revascularization|Subjects with coronary artery disease that do not require revascularization.
16615630|NCT02510066|Experimental|Acupuncture|Acupuncture participants would receive electroacupuncture on Jiaji (Ex-B2) points for 3 times in a week.
16615631|NCT02510066|Placebo Comparator|Placebo acupuncture|Placebo acupuncture participants would receive placebo acupuncture on non-point points for the same period.
16615632|NCT02510053|Other|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
16615759|NCT02509182|Active Comparator|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
16615637|NCT02510014|Experimental|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
16615638|NCT02510014|Experimental|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
16615639|NCT02510001|Experimental|Dose Escalation Phase Cohort 1 Dose level 1|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
16615640|NCT02510001|Experimental|Dose Escalation Phase Cohort 2 Dose level 2|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
16615641|NCT02510001|Experimental|Dose Escalation Phase Cohort 3 Dose level 3|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle
16615642|NCT02510001|Experimental|Dose Escalation Phase Cohort 4 Dose level 4|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
16615643|NCT02510001|Experimental|Dose Escalation Phase Cohort 7 Dose level 5|Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
16615644|NCT02510001|Experimental|Dose Escalation Phase Cohort 13 Dose level 5a|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
16615645|NCT02510001|Experimental|Dose Expansion Phase|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.
16615646|NCT02510001|Experimental|Dose Escalation Phase Cohort 12 Dose level 5 (Interval dosing)|Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
16615647|NCT02509988|Experimental|Intervention (study nutritional drink)|"Study nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).
~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
16615648|NCT02509988|Active Comparator|Control (standard nutritional drink)|"Standard nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).
~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
16615649|NCT02509975|Experimental|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
16615650|NCT02509962|Experimental|Slow sodium tablets|Increased dietary salt intake
16615651|NCT02509949|Experimental|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
16615652|NCT02509949|Placebo Comparator|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
16615653|NCT02509936|Active Comparator|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
16615654|NCT02509936|Experimental|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
16615655|NCT02509923|Experimental|1|3-way cross-over, Z-215 10 mg/day / Z-215 20 mg/day / Rabeprazole Sodium 10 mg/day
16615656|NCT02509923|Experimental|2|3-way cross-over, Z-215 20 mg/day / Z-215 40 mg/day / Rabeprazole Sodium 20 mg/day
16615657|NCT02509923|Experimental|3|3-way cross-over, Z-215 20 mg/day (before breakfast) / Z-215 20 mg/day (after breakfast) / Rabeprazole Sodium 10 mg/day (after breakfast)
16615658|NCT02509910||Standard therapy|intraoperative standard fluid therapy for major abdominal surgery
16615659|NCT02509910||Goal directed therapy|intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients
16615660|NCT02509897|Active Comparator|Hypoxic training|Endurance training
16615661|NCT02509897|Placebo Comparator|Normoxic training|Endurance training
16615662|NCT02509871|Other|Body composition measurement|DXA, impedance
16615663|NCT02509858|Active Comparator|thyroxine in eythyroid diabetics|50 μg of thyroxine once daily, for 2 months.
16615664|NCT02509858|Active Comparator|thyroxine in euthyroid healthy humans|50 μg of thyroxine once daily, for 2 months.
16615665|NCT02509858|Placebo Comparator|placebo in euthyroid diabetics|50 μg of placebo once daily, for 2 months.
16615666|NCT02509845|Experimental|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
16615667|NCT02509845|Experimental|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
16615668|NCT02509845|Experimental|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
16615669|NCT02509832|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
16615721|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
16615670|NCT02509832|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
16615671|NCT02509819|Experimental|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
16615672|NCT02509806|Experimental|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
16615673|NCT02509806|No Intervention|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
16615674|NCT02509793|Experimental|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
16615675|NCT02509780|Experimental|Vichy|
16615676|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
16615677|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
16615678|NCT02509754|Experimental|Atrial fibrillation catheter ablation|Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
16615679|NCT02509754|Experimental|Rate control arm|Patients randomized to rate control only arm will undergo ICD implantation and optimization of the rate control therapy. In case of uncontrolled ventricular rate at 24-h ECG Holter, defined as a mean resting heart rate higher than 90 bpm, patients will receive atrioventricular (AV) node ablation and resyncronization therapy (CRT-D) implantation, performed following common practice at each Center. In case of failure or technical difficulties of the transvenous approach, epicardial screw-in or steroid-eluting passive lead is implanted via a limited thoracotomy. Transcatheter AV node ablation is performed as follows: a non-irrigated tip ablation catheter is introduced on the right side of the interatrial septum and ablation performed on the fast pathway region or the smallest His bundle signal. The goal of the procedure is AV modulation below 30 bpm or complete AV block.
16615680|NCT02509741|Experimental|Educational intervention|High-protein and low-GI diet education
16615681|NCT02509741|Experimental|Dietary intervention|High-protein and low-GI diet plus education
16615682|NCT02509741|Experimental|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
16615683|NCT02509741|No Intervention|control|Routine diet recommendation
16615684|NCT02509728|Active Comparator|standard nutrition|standard nutrition
16615685|NCT02509728|Experimental|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
16615686|NCT02509728|Experimental|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
16615687|NCT02509728|Experimental|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
16615688|NCT02509715|No Intervention|Standard Conventional group|Standard conventional thyroid surgery
16615689|NCT02509715|Active Comparator|IONM group|Intraoperative nerve monitoring used thyroid surgery
16615690|NCT02509702|Experimental|Connected to Care|The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
16615691|NCT02509702|No Intervention|Control|The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
16615692|NCT02509689|Experimental|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.
~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
16615693|NCT02509676|Experimental|dynamic stretching exercise|This group will perform dynamic stretching exercise to their left side gastrocnemius muscles for 5 weeks (5 days a week, 3 sets of exercise a day, each set including 5 repetitions of dynamic stretching lasting 45 seconds)
16615694|NCT02509676|No Intervention|control|this group will not perform any stretching exercises for 5 weeks
16615695|NCT02509663|Active Comparator|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
16615696|NCT02509663|Active Comparator|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
16615697|NCT02509637|Active Comparator|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
16615698|NCT02509637|Active Comparator|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
16615699|NCT02509637|Active Comparator|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
16615700|NCT02509624|Experimental|Moderate hepatic impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
16615701|NCT02509624|Experimental|Severe hepatic impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
16615702|NCT02509624|Experimental|Mild hepatic impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
16615703|NCT02509611|Experimental|Immediate treatment|Participants who are randomly assigned to the immediate treatment group will receive 60-minute biweekly Hatha yoga for 12 weeks.
16615704|NCT02509611|Active Comparator|Waitlist control|Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
16615705|NCT02509598|Experimental|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
16615706|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
16615707|NCT02509572|Experimental|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
16615708|NCT02509572|No Intervention|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
16615709|NCT02509559|Active Comparator|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
16615710|NCT02509559|Placebo Comparator|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
16615711|NCT02509546|Experimental|Treatment (8-chloro-adenosine)|Patients receive 8-chloro-adenosine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16615712|NCT02509533|Experimental|V.A.C.® Therapy|In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.
16615713|NCT02509533|Active Comparator|usual dressing method (compresses)|In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.
16615714|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
16615715|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
16615718|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
16615719|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
16615720|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
16615722|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
16615723|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
16615724|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
16615725|NCT02509468|No Intervention|Observational|"Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).
~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)"
16615726|NCT02509468|Experimental|Experimental|At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)
16615727|NCT02509455||Normal 1|SwayStar device used 1st, Sensoro used 2nd
16615728|NCT02509455||Normal 2|Sensoro device used 1st, SwayStar used 2nd
16615730|NCT02509429|Experimental|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:
~the first with Control-to-Range algorithm (CTR),
~the second with Threshold Low Glucose Suspend (TLGS)."
16615731|NCT02509429|Experimental|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:
~the first with Threshold Low Glucose Suspend (TLGS),
~the second with Control-to-Range algorithm (CTR)."
16615732|NCT02509403|Experimental|Intervention|Essential oils infused Perineal Hygiene wipe
16615733|NCT02509390|Experimental|Severe trauma patients|All severe trauma patients (ISS>15) admitted in our trauma center Blood samples (additional blood tubing)
16615734|NCT02509377|Experimental|BMI 35.0 to 40.0|"Mothers who meet all inclusion exclusion criteria for open fetal repair of myelomeningocele except BMI.
~These mothers have a BMI between 35.0 and 40.0"
16615735|NCT02509364||AE-IPF|"Diagnosis criteria for AE-IPF:
~Diagnosed IPF patient experiences unexplained dyspnea within 1 month
~With objective evidence of hypoxia and new onset of pulmonary infiltration based on imaging examination
~With other diagnosis like pulmonary embolism, pneumothorax or heart failure excluded."
16615736|NCT02509364||Stable-IPF|"Diagnosis criteria for Stable-IPF:
~Exclusion of other known causes of ILDs
~Presence of a usual interstitial pneumonitis (UIP) pattern on high-resolution computed tomography (HRCT)
~Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy."
16615737|NCT02509364||Health control|Healthy volunteer
16615738|NCT02509351|Experimental|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
16615739|NCT02509351|Active Comparator|placeboo|women receiving placebo
16615740|NCT02509338|Experimental|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
16615741|NCT02509312|Experimental|Experimental|Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours
16615742|NCT02509312|Placebo Comparator|Control|Patients in this arm will be given a placebo medication at cord clamp, and then 3 additional doses of placebo every 6 hours.
16615743|NCT02509299|Experimental|Experimental group 1|patients will be involved in the Physiotherapy program 1. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises added to standard treatment.
16615744|NCT02509299|Experimental|Experimental group 2|patients will be involved in the physiotherapy program 2. The program was a combined intervention including the Control Group treatment plus neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises.
16615745|NCT02509299|Other|Control group|patients will receive standard medical treatment without physiotherapy intervention.
16615746|NCT02509286|Experimental|Perioperative Chemotherapy (FLOT):|"The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.
~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
16615747|NCT02509286|Active Comparator|Neoadjuvant Chemoradiation (CROSS):|"The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.
~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
16615748|NCT02509273|Experimental|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
16615749|NCT02509273|Active Comparator|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
16615750|NCT02509260|Experimental|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
16615751|NCT02509260|Active Comparator|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
16615752|NCT02509247|Experimental|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
16615753|NCT02509247|No Intervention|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
16615754|NCT02509221||Less than 30 minutes|
16615755|NCT02509221||30-60 minutes|
16615756|NCT02509221||More than 60 minutes|
16615757|NCT02509208|Experimental|SurgiClot|All qualified subjects will be treated with the SurgiClot haemostatic dressing
16615758|NCT02509195|Experimental|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
16615761|NCT02509169|Experimental|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
16615762|NCT02509169|Active Comparator|TAE|Trans-catheter embolization (TAE) will be given once per month
16615763|NCT02509156|Experimental|Allo-MSCs|Target dose of 100 million allo-MSCs
16615764|NCT02509156|Placebo Comparator|Placebo|Buminate solution
16615765|NCT02509143|Experimental|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture on the points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4), Pericardium 6 (PC6), Heart 8 (HT8), and Gall Bladder 41 (GB41) within 48 hours after surgery
16615766|NCT02509143|Active Comparator|P6 stimulation with intravenous infusion of ramosetron|P6 stimulation by wearing a study wristband within 48 hours after surgery
16615767|NCT02509143|Active Comparator|Intravenous infusion of ramosetron|A mixture of standard antiemetic medication (5-Hydroxytryptophan receptor antagonist; ramosetron hydrochloride 0.3 mg) and analgesics, including anon-steroidal anti-inflammatory drug (NSAID) (ketorolac tromethamine 120 mg), and a semi-synthesized opioid (oxycodone 20 mg), will be infused by intravenous patient-controlled analgesia (1ml bolus/20 min lockout, 1ml/hr continuous infusion).
16615768|NCT02509130||Patients who attended RAAC/SAAC.|Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study. Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
16615769|NCT02509130||Patients eligible for RAAC, but DNA'd|Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
16615770|NCT02509130||Asthma Outpatients|Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
16615771|NCT02509130||Healthcare Professionals|Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
16615772|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
16615773|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
16615774|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
16615775|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
16615776|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
16615777|NCT02509104|Experimental|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
16615778|NCT02509104|Experimental|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
16615779|NCT02509091|Experimental|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
16615780|NCT02509091|No Intervention|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
16615781|NCT02509078|Active Comparator|Early Neuromuscular Blockade (NMB)|Patients will receive cisatracurium besylate for the first 48 hours of the trial.
16615782|NCT02509078|No Intervention|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
16615783|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
16615784|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
16615785|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
16615786|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
16615787|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
16615788|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
16615789|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
16615790|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
16615791|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
16615792|NCT02509052|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16615793|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
16615794|NCT02509026|Experimental|Etanercept|etanercept 50 mg QW
16615797|NCT02508987||Group 1|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as periodontally healthy.Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 18.50-24.99 kg/m2: Normal-weight"
16615798|NCT02508987||Group 2|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as gingivitis. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index.
~18.50-24.99 kg/m2: Normal-weight"
16615799|NCT02508987||Group 3|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index.18.50-24.99 kg/m2: Normal-weight"
16615800|NCT02508987||Group 4|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as either 'periodontally healthy'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
16615801|NCT02508987||Group 5|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'gingivitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
16615802|NCT02508987||Group 6|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
16615803|NCT02508961|Experimental|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
16615804|NCT02508961|Active Comparator|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
16615805|NCT02508935|Experimental|XARTEMIS XR|All participants received XARTEMIS XR
16615806|NCT02508922|Experimental|Vitamin D3|2000iu vitamin D will be taken daily for 20 weeks.
16615807|NCT02508922|Placebo Comparator|Placebo|Matching placebo drops will be taken daily for 20 weeks
16615808|NCT02508909|Experimental|Videoscopic ilioinguinal lymphadenectomy for melanoma|Melanoma groin lymph node metastasis.
16615809|NCT02508896|Experimental|AFFITOPE® AT04A+adjuvant|3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
16615810|NCT02508896|Experimental|AFFITOPE® AT06A+adjuvant|3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
16615811|NCT02508896|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization
16615812|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
16615813|NCT02508870|Experimental|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
16615814|NCT02508870|Experimental|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
16615929|NCT02508168|Experimental|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
16615815|NCT02508870|Experimental|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
16615816|NCT02508870|Experimental|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
16615817|NCT02508870|Experimental|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
16615818|NCT02508870|Experimental|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
16615819|NCT02508857|Active Comparator|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
16615820|NCT02508857|Experimental|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
16615821|NCT02508857|Placebo Comparator|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
16615822|NCT02508844|Experimental|Vivomixx®|Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus
16615823|NCT02508844|Placebo Comparator|Placebo|microcrytalline cellulose, magnesium stearate and silicon dioxide.
16615824|NCT02508831|Experimental|Bilateral amputation of upper limb|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
16615825|NCT02508818|Other|Cardiovascular measurements|
16615826|NCT02508805|Experimental|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.
~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
16615827|NCT02508805|Active Comparator|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
16615828|NCT02508792|Active Comparator|LASER|"Subject will receive application of LASER before muscle fatigue protocol.
~Note: this is a crossover study."
16615829|NCT02508792|Placebo Comparator|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.
~Note: this is a crossover study."
16615830|NCT02508779|Experimental|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
16615831|NCT02508779|Active Comparator|Routine Care|Routine care provided by subject's medical team
16615832|NCT02508766|Experimental|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
16615833|NCT02508766|No Intervention|Control group|Volunteers received no intervention. They just sat there for 20 minutes before being evaluated.
16615834|NCT02508753|Experimental|CXA-101/tazobactam therapeutic dose|
16615835|NCT02508753|Experimental|CXA-101/tazobactam supra-therapeutic dose|
16615836|NCT02508753|Active Comparator|Moxifloxacin|
16615837|NCT02508753|Placebo Comparator|Placebo|
16615838|NCT02508740|Experimental|normal renal function|Healthy subjects with normal renal function (Stage 1, >90 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
16615839|NCT02508740|Experimental|mild renal impairment|Patients with mild renal impairment (Stage 2, 60-89 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
16615840|NCT02508740|Experimental|moderate renal impairment|Patients with moderate renal impairment (Stage 3, 30-59 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
16615841|NCT02508740|Experimental|severe renal impairment|Patients with severe renal impairment (Stage 4, <30 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
16615842|NCT02508740|Experimental|End Stage Renal Disease (ESRD)|Patients with End Stage Renal Disease (ESRD) receiving dialysis for at least 3 months preceding the initial dose in this study (Stage 5) will participate in 2 treatment periods and will receive a single oral dose of 0.25 mg bevenopran at 3 hours after completion of the last hemodialysis session of the week in Period 1 and a single oral dose of 0.25 mg bevenopran at 3 hours before initiation of the last hemodialysis session of the week in Period 2
16615843|NCT02508727|Other|Healthy volunteers|Healthy volunteers
16615844|NCT02508727|Other|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
16615845|NCT02508727|Other|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
16616343|NCT02505243||HCV patients|HCV patients treated with direct acting antivirals and ribavirin
16615846|NCT02508714|Active Comparator|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
16615847|NCT02508714|Active Comparator|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
16615848|NCT02508701|Other|Altruistic inside-dorm|"Altruistic & personal message with direct recommendation and access to the vaccine on-site
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
16615849|NCT02508701|Other|Generic inside-dorm|"Generic message and access to the vaccine on-site
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
16615850|NCT02508701|Other|Generic outside-dorm|"Generic message and off-site access to the vaccine
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
16615851|NCT02508701|Other|Altruistic outside-dorm|"Altruistic & personal message with direct recommendation and off-site access to the vaccine
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
16615852|NCT02508688|Experimental|thoracoscopic mesh repair group|63 patients with refractory HH (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair were included in this study.
16615853|NCT02508662||Advanced Cancer (Refractory) with Genomic Mutation|Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
16615854|NCT02508649|Placebo Comparator|Placebo|
16615855|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
16615856|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
16615857|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
16615858|NCT02508649|Experimental|Selepressin 4|"Starting dose 5.0 ng/kg/min
~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
16615859|NCT02508636|Experimental|Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy|"Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months.
~Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks."
16615860|NCT02508623|Experimental|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
16615861|NCT02508623|Placebo Comparator|Placebo|Placebo 1 tablet BID for +60 days
16615862|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
16615863|NCT02508584|Experimental|Intervention|This is a single patient treatment IND
16615864|NCT02508571|Sham Comparator|Control|Two 15-minute sessions of sham intervention/day, five days a week
16615865|NCT02508571|Experimental|DST group|One session of DST and the other of sham intervention/day, five days a week
16615866|NCT02508571|Experimental|DST+OSMS group|One session of DST and the other of OSMS/day, five days a week
16615867|NCT02508558|Other|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
16615868|NCT02508545|Other|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
16615869|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 30 mg QD|"Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation."
16615870|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 60 mg QD|"Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation."
16615871|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 90 mg QD|"Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation."
16615872|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 135 mg QD|"Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation."
16615873|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 200 mg QD|"Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation. ."
16615874|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 300 mg QD|"Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
16615932|NCT02508155|Placebo Comparator|IV Placebo|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
16615875|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 400 mg QD|"Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation.
~Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
16615876|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 600 mg QD|"Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.
~Patients received avapritinib in continuous 28 day cycles until discontinuation."
16615877|NCT02508532|Experimental|Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD|"Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.
~Patients received avapritinib in continuous 28 day cycles until discontinuation."
16615878|NCT02508519|Experimental|Zonal|The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
16615879|NCT02508519|Experimental|Balance|The balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
16615880|NCT02508519|No Intervention|Control|The control group will provide only the estimation of the the pain level according to a visual analog pain scale (VAS) but receive no acupuncture treatment. Then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded.
16615881|NCT02508506|Experimental|ALKS 5461|Sublingual tablet
16615884|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
16615885|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
16615886|NCT02508467|Experimental|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
16615887|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
16615888|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
16615889|NCT02508441|Experimental|Andes-1537 for Injection|Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
16615890|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
16615891|NCT02508428|Active Comparator|Noncrosslinked Enduron polyethylene|The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.
16615892|NCT02508415|Experimental|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
16615893|NCT02508415|No Intervention|No Non Surgical Periodontal Therapy|No treatment received
16615894|NCT02508402|Active Comparator|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
16615895|NCT02508402|Placebo Comparator|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
16615896|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
16615897|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
16615898|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
16615899|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (10 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
16615900|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
16615901|NCT02508376|Experimental|ID93 (10 mcg) + GLA-SE (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
16615902|NCT02508376|Experimental|ID93 (10 mcg) alone|N=10 subjects will receive intervention on Days 1, 29, 57
16615930|NCT02508168|Experimental|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
16615931|NCT02508155|Experimental|MEDI7352 IV|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
16615903|NCT02508363|Active Comparator|Health Fair Alone (Control)|"No Follow Up Participant does not require referrals or assistance and was not advised to see a provider in the next three months.
~Regular follow-up call within two weeks of health fair by IHCD intern or staff. Participant has abnormal values, requires referrals or assistance or was advised to see a provider in the next three months.
~Up to 3 call attempts to get participant into needed care. Further contact only by participant request.
~Urgent follow-up call or in-person assistance within 1 day of health fair by IHCD intern or staff Participant advised to seek urgent care within one week.
~Three total call or in-person attempts to get participant into needed care. Further contact only by participant request The follow up call attempts may extend up to 3 months past the date of health fair to complete any needs the driver may have."
16615904|NCT02508363|Experimental|Health Fair + Navigator Case Management|"• Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.
~Navigator Case Management by trained staff
~Tailored assistance for any health needs a minimum of once a month 12 months. Assistance includes pre-appointment reminder calls, post-appointment follow up calls, and health promotion reminders.
~NCM case management will continue follow-up at a minimum of once per month or as requested by the participant for the study duration and will consistently offer appointment reminders and follow-ups."
16615905|NCT02508363|Experimental|Health Fair + Taxi Health Improvement Promoters|"Health Fair standard services Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.
~Taxi health Improvement Promoters (TIPs)
~Weekly check-ins with each participant, in person or by phone, about scheduling of, and attendance at, primary care appointments along with other health or study questions Mosio Text Messaging Program
~Send primary care provider recommendations to participant up to three times
~Two pre-appointment reminders & one post-appointment check-in
~Twice weekly health promotion reminders after primary care appointment"
16615906|NCT02508350|Experimental|daptomycin|Daptomycin for injection 10-12mg/kg/day,determination of plasma concentration
16615907|NCT02508337|Experimental|XG-102|sterile ophthalmic solution for sub-conjunctival injection
16615908|NCT02508337|Placebo Comparator|placebo|sterile ophthalmic solution for sub-conjunctival injection
16615909|NCT02508324|Other|Intervention|"All potential recipients will have complete (HLA) typing and determination of HLA antibodies. An appropriate umbilical cord blood unit (CBU) will be identified or in the absence of an appropriate CBU, a haplo-identical cells (donor) will be identified.
~Within 72 hours after completion of the chemotherapy regimen, and no sooner than 24 hours after administration of the last dose of chemotherapy, umbilical cord graft or haplo-graft will be administered."
16615910|NCT02508311|Active Comparator|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
16615911|NCT02508311|Placebo Comparator|Placebo|Subjects will receive 16 weeks of placebo medication.
16615912|NCT02508298|Active Comparator|Indocyanine green retention test|A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
16615913|NCT02508298|Active Comparator|Liver stiffness measurement|ARFI measurements of the liver will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
16615914|NCT02508298|Active Comparator|Spleen stiffness measurement|ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
16615915|NCT02508272||Trauma patients|age ≥18 y ISS ≥ 17 points admission < 6 h.
16615916|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
16615917|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
16615918|NCT02508246|Experimental|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
16615919|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
16615920|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
16615921|NCT02508220|Other|Oxy-Placebo|Syntocinon first, Placebo second 2 puffs in each nostril
16615922|NCT02508220|Other|Placebo-Oxy|Placebo first, Syntocinon second 2 puffs in each nostril
16615923|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
16615924|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
16615925|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
16615926|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
16615927|NCT02508181|Active Comparator|I-gel intra ocular pressure|supraglottic airway device
16615933|NCT02508155|Experimental|MEDI7352 Subcutaneous Injection|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
16615934|NCT02508155|Placebo Comparator|Subcutaneous Placebo|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
16615935|NCT02508142|Active Comparator|Hyoscine-N-Butylbromide|20 mg Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL)
16615936|NCT02508142|Placebo Comparator|Placebo|100 mL normal saline
16615937|NCT02508129|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
16615938|NCT02508129|Experimental|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
16615939|NCT02508129|Placebo Comparator|Enhanced Usual Care (EUC)|EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
16615940|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
16615941|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
16615942|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.
~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
16615943|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.
~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
16615944|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
16615945|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
16615946|NCT02508064|Experimental|Part 1|BMS-663068 1 × 600 mg extended-release (ER) tablet formulation
16615947|NCT02508064|Experimental|Part 1: Prototype 1|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)
16615948|NCT02508064|Experimental|Part 1: Prototype 2|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)
16615949|NCT02508064|Experimental|Part 1: Prototype 3|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)
16615950|NCT02508064|Experimental|Part 1: Prototype 4|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)
16615951|NCT02508064|Experimental|Part 1: Prototype 5|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)
16615952|NCT02508064|Experimental|Part 2|BMS-663068 1 × 600 mg ER tablet formulation
16615953|NCT02508064|Experimental|Part 2: Prototype 1|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)
16615954|NCT02508064|Experimental|Part 2: Prototype 2|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)
16615955|NCT02508064|Experimental|Part 2: Prototype 3|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)
16615956|NCT02508064|Experimental|Part 2: Prototype 4|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)
16615957|NCT02508051|No Intervention|No daily emails|The usual care group will receive no intervention except for a reminder every six months to take a test of journal-based CME questions from 2 anesthesiology journals
16615958|NCT02508051|Placebo Comparator|Article email links|The email link group will get e-mailed web links to different specific articles, including articles on which the CME questions are based, published in 2 anesthesiology journals Monday through Friday with a reminder to take the same test every six months
16615959|NCT02508051|Experimental|Blog email links|The experimental group will get e-mailed web links to blogs Monday through Friday based on the same specific articles as in group 2; each daily blog will focus on a specific article, including articles on which CME questions are based, the blogs will have web links to the articles on which they are based and every six months group 3 will get a reminder to take the same test.
16615961|NCT02508012|Experimental|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
16615962|NCT02508012|No Intervention|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
16615963|NCT02507999|Experimental|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
16615964|NCT02507999|No Intervention|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
16615965|NCT02507986|Active Comparator|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
16615966|NCT02507986|Experimental|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
16616131|NCT02506790|Experimental|Toremifene and metformin|Toremifene 60 mg daily with metformin 850 mg BID
16615967|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
16615968|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
16615969|NCT02507960|Other|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
16615970|NCT02507934|Experimental|Lubricin|Lubricin 150 μg/ml eye drops solution
16615971|NCT02507934|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
16615972|NCT02507895|Experimental|MI-BCI training|subjects will undergo 12 sessions over 4 weeks of MI-BCI training
16615973|NCT02507882|Experimental|HCC|This group will include patients with chronic hepatitis C (no. =135)
16615974|NCT02507882|Experimental|HCC with Cirrhosis|This group will include patients with chronic hepatitis C (no. =135) with cirrhosis (F4).
16615975|NCT02507882|Experimental|HCV related HCC patients|This group will include patients with HCV related HCC (no. =135) This is confirmed by presence of focal lesion detected by Imaging (computed tomography (CT) and ultrasound), and elevated serum AFP.
16615976|NCT02507869|Experimental|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
16615977|NCT02507869|Active Comparator|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
16615978|NCT02507856||investigational group|early/late dabigatran
16615979|NCT02507856||control group|vitamin k antagonist (vka)
16615980|NCT02507843|Active Comparator|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
16615981|NCT02507843|Placebo Comparator|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
16615982|NCT02507830||Glubran 2 fixation|Mesh fixation with Glubran 2 glue in primary inguinal hernia repair
16615983|NCT02507817||31-32 with Mg for neuroprotection|"Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection.
~blood sample and tissue sample (placenta)."
16615984|NCT02507817||33-34 without Mg for neuroprotection|"Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection.
~blood sample and tissue sample (placenta)."
16615985|NCT02507817||PET with Mg after 34 weeks|"Women that had severe preeclamsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivere after 34 weeks of gestation.
~blood sample and tissue sample (placenta)."
16615986|NCT02507817||control|"Low risk pregnanacies in similar weeks to group 3 that did not require any special teatment and delivered after 34 weeks of gestation.
~blood sample and tissue sample (placenta)."
16615987|NCT02507804|Experimental|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
16615988|NCT02507804|Active Comparator|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
16615989|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
16615990|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
16615991|NCT02507778|Other|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
16615992|NCT02507765|Experimental|Treatment (SBRT, TACE)|Patients undergo SBRT on day 1 and TACE on day 2.
16615993|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
16615994|NCT02507739|Other|possibility to walk during labor|possibility to walk during labor
16615995|NCT02507739|Other|no possibility to walk during labor|no possibility to walk during labor
16615996|NCT02507726|Experimental|Flexima Active Soft convexe|Flexima Active soft convexe (1 to 3 appliances per day)
16615997|NCT02507700|Active Comparator|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
16615998|NCT02507700|Sham Comparator|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
16615999|NCT02507687|Experimental|Bimatoprost Sustained-Release (SR)|Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
16616000|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Assigned Primary Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
16616001|NCT02507661|Experimental|alveolar ridge preservation - 2 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
16616002|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 2 months|no-preservation of alveolar ridge - 2 months
16616003|NCT02507661|Experimental|preservation of alveolar ridge - 4 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
16616004|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 4 months|no-preservation of alveolar ridge - 4 months
16616005|NCT02507661|Experimental|preservation of alveolar ridge - 9 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
16616006|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 9 months|no-preservation of alveolar ridge - 9 months
16616007|NCT02507648|Experimental|A Test|Test drug (Oseltamivir) 1 tablet contains 75 mg Oseltamivir
16616008|NCT02507648|Active Comparator|B Reference|Reference drug (Tamiflu®) 1 tablet contains 75 mg Oseltamivir
16616009|NCT02507635|No Intervention|healthy volunteers|healthy volunteers
16616010|NCT02507635|Active Comparator|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
16616011|NCT02507635|Active Comparator|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
16616012|NCT02507622|Other|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
16616013|NCT02507609|Active Comparator|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
16616014|NCT02507609|Active Comparator|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
16616015|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
16616016|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
16616017|NCT02507583|Experimental|Cohort 1|After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.
16616018|NCT02507570|Experimental|Open label|Single arm study to evaluate safety and tolerability of Enzalutamide with concurrent administration of Radium ra 223 dichloride in subjects with symptomatic metastatic prostate cancer.
16616019|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
16616020|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
16616021|NCT02507544|Experimental|TRX-818|
16616022|NCT02507531|Experimental|Treatment|Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.
16616023|NCT02507518|Experimental|Experimental|Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
16616024|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
16616025|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
16616026|NCT02507492|Experimental|RM-493 Once Daily|Dose once daily in the morning
16616027|NCT02507479|Experimental|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
16616028|NCT02507466|Experimental|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
16616029|NCT02507466|Active Comparator|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
16616030|NCT02507466|Active Comparator|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
16616031|NCT02507453|Other|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
16616032|NCT02507440|Active Comparator|Viscous Lidocaine|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of 2% lidocaine viscous solution and swallow.
16616033|NCT02507440|Placebo Comparator|Placebo|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of placebo and then swallow. Placebo will be 3% methylcellulose which will be flavored and colored to match the characteristics of 2 % lidocaine.
16616034|NCT02507427|Experimental|Nerve monitoring arm|They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
16616035|NCT02507414|Experimental|Group 1|"Patients under going Whipple's procedure, gastric resection and liver resection (n=75).
~Interventions:
~Blood samples obtained pre-, intra-, and one day postoperatively (n=15).
~Measurements of microcirculation using LSCI from procedure start and up to 60 min during surgery.
~Head down tilt of 20 degrees at three time points."
16616036|NCT02507401||Total laryngectomy patients|Users of voice prostheses
16616037|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
16616038|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
16616039|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
16616040|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
16616041|NCT02507362|Experimental|experimental|Radiation: adjusted corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 7 minutes after 30 mitunes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
16616042|NCT02507362|Active Comparator|control|radiation: accelerated corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 10 minutes after 30 minutes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
16616043|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
16616044|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
16616045|NCT02507336|Experimental|Group A - CR+Thalidomide|Patients who achieved complete response (CR) in 20030165 and continue to receive maintenance Thalidomide. Patients in Group A will receive daily oral thalidomide (THALOMID®) as per standard of care and THALOMID® REMS™ guidelines. Patients will continue with thalidomide (THALOMID®) as per standard of care guidelines, until progression of disease, discontinuation due to toxicity, death or study withdrawal. Patients will receive annual clinical/laboratory evaluations.
16616046|NCT02507336|No Intervention|Group B - CR+No Thalidomide|Patients who achieved complete response (CR) in 20030165, but are not receiving maintenance Thalidomide. Patients will receive annual clinical/laboratory evaluations.
16616047|NCT02507336|No Intervention|Group C - PD or Expired|All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
16616048|NCT02507323|Active Comparator|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
16616049|NCT02507323|Active Comparator|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
16616050|NCT02507310|Active Comparator|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
16616051|NCT02507310|Experimental|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
16616052|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
16616053|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
16616054|NCT02507284|Experimental|SRX246 120mg BID|SRX246 capsules, administered orally, in divided doses twice daily
16616055|NCT02507284|Experimental|SRX246 160mg BID|SRX246 capsules, administered orally, in divided doses twice daily
16616056|NCT02507284|Placebo Comparator|Placebo|Placebo capsules, administered orally, in divided doses twice daily
16616057|NCT02507271|Experimental|Experimental Group|
16616058|NCT02507271|Placebo Comparator|Control Group|
16616059|NCT02507258||PROFEMUR® Am Femoral Stem|Single study group previously implanted with a primary PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component
16616060|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
16616061|NCT02507232|Active Comparator|Arm A|NovoTTF-200A
16616062|NCT02507232|Active Comparator|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
16616063|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
16616064|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
16616065|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
16616066|NCT02507206|Experimental|DAR 0-100A then Placebo|15 mg is dissolved in 150 cc NS administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
16616067|NCT02507206|Placebo Comparator|Placebo then DAR 0-100A|15 mg dissolved in 150 cc NS saline is administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
16616068|NCT02507206|No Intervention|Healthy Control|patients without diagnosis of SPD
16616132|NCT02506790|Experimental|Toremifene and melatonin|Toremifene 60 mg daily with melatonin 3 mg before sleep daily
16616133|NCT02506790|Active Comparator|Toremifene|Toremifene 60 mg daily
16617577|NCT02497560|Other|Treatment + Omega-3s|all natural dietary supplement + omega-3s
16616069|NCT02507193|Active Comparator|Open reduction internal fixation(ORIF)|This surgical intervention is performed using a plate and screws.Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
16616070|NCT02507193|Active Comparator|Intermedullary (IM) Nail|This surgical intervention is performed using an intermedullary nail. Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
16616071|NCT02507180||Pregnant women with suspected DVT|Pregnant women presenting with suspected DVT will have the LEFt clinical decision rule applied by the attending physician and will have a clinical D-dimer test done.
16616072|NCT02507167|Placebo Comparator|mixed meal|
16616073|NCT02507167|Active Comparator|mixed meal 2 h after single dose rifampin (600 mg)|
16616074|NCT02507154|Experimental|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
16616075|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
16616076|NCT02507128|Experimental|GLP-1 group|The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
16616077|NCT02507128|Placebo Comparator|Control group|the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).
16616078|NCT02507115|Experimental|TMAP|Alcohol-related Text messages 4 days/week for 6 weeks
16616079|NCT02507115|Sham Comparator|Control|Motivational Text messages 4 days/week for 6 weeks
16616080|NCT02507102|Experimental|Investigational Voyager Therapy|Investigational treatment with Voyager Therapy
16616081|NCT02507089|Experimental|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
16616082|NCT02507089|Active Comparator|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
16616083|NCT02507076|Experimental|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
16616084|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
16616085|NCT02507050|Experimental|Intervention|Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.
16616086|NCT02507050|No Intervention|Standard therapy|Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).
16616087|NCT02507037|Experimental|gum+PEG|used 2L PEG+sugarless gum
16616088|NCT02507037|Placebo Comparator|PEG|only used 2L PEG
16616089|NCT02507024||Intervention|The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
16616090|NCT02507011|Experimental|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
16616091|NCT02507011|Placebo Comparator|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
16616092|NCT02506998|Experimental|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.
~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
16616093|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
16616094|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
16616095|NCT02506972|Other|30g oats|Classic Quick Quaker Oats
16616096|NCT02506972|Other|30g oats plus 9g sugar|Classic Quick Quaker Oats
16616097|NCT02506972|Other|40g oats|Classic Quick Quaker Oats
16616098|NCT02506972|Other|60g oats|Classic Quick Quaker Oats
16616099|NCT02506972|Other|22g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
16616100|NCT02506972|Other|29g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
16616101|NCT02506972|Other|33g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
16616102|NCT02506972|Other|44g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
16616134|NCT02506777|Experimental|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID
16617578|NCT02497560|Placebo Comparator|Placebo|vegetable oil
16616103|NCT02506959|Experimental|Treatment (panobinostat, Gem/Bu/Mel, ASCT)|Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.
16616104|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
16616105|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
16616106|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
16616107|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
16616108|NCT02506920|Active Comparator|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
16616109|NCT02506920|Active Comparator|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
16616110|NCT02506920|Active Comparator|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
16616111|NCT02506920|Active Comparator|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
16616112|NCT02506920|Active Comparator|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
16616113|NCT02506920|Active Comparator|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
16616114|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
16616115|NCT02506894|Active Comparator|magnesium sulfate|this group will receive magnesium sulfate loading dose 6 g in 500 cc of ringer solution over 20 minutes then maintenance dose of 1 g/ hour for 24 hours.
16616116|NCT02506894|Placebo Comparator|placebo group|this group will receive sodium chloride 0.9% solution for 24 hours.
16616117|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
16616118|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
16616119|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
16616120|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
16616121|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
16616122|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
16616123|NCT02506855|Experimental|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:
~Weight <70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)
~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
16616124|NCT02506855|Placebo Comparator|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:
~Weight <70kg: 20mL each side
~Weight greater than or equal to 70kg: 20mL each side"
16616125|NCT02506842|Experimental|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
16616126|NCT02506842|Experimental|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m^2 on days 8 and 22, folinic acid at 200mg/m^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m^2 on days 1,8,15 and 22.
16616127|NCT02506829|Active Comparator|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
16616128|NCT02506829|Experimental|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
16616129|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
16616130|NCT02506803|Experimental|NAC-GEMABR|Neoadjuvant chemotherapy 2 courses of NAC-GEMABR for subsequent 10 patients.
16616135|NCT02506777|Experimental|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily
16616136|NCT02506777|Active Comparator|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days
16616137|NCT02506751|Experimental|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:
~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)
~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)
~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)
~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
16616138|NCT02506738|Active Comparator|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
16616139|NCT02506738|No Intervention|Control|Patients in the control group received the usual care.
16616140|NCT02506725|Experimental|Prenatal Care in groups|We will do prenatal care using centering care pregnancy methodology in 10 sessions
16616141|NCT02506725|No Intervention|Control Group|We will do in this arm conventional Prenatal care available in the family clinics
16616142|NCT02506712|Experimental|spinal cord injury|use a wheelchair with and without a assisting device to power manuel wheelchair
16616143|NCT02506712|Other|volunteer|push a wheelchair with and without a assisting device to power manuel wheelchair
16616144|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
16616145|NCT02506686|Experimental|Meropenem|Meropenem i.v.
16616146|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
16616147|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
16616148|NCT02506660|Active Comparator|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
16616149|NCT02506660|Experimental|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
16616150|NCT02506647|Experimental|Sequence 1|Gan & Lee insulin glargine followed by Lantus
16616151|NCT02506647|Active Comparator|Sequence 2|Lantus followed by Gan & Lee insulin glargine
16616152|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
16616153|NCT02506621|Experimental|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be
~R test
~Nuubo
~TECHNOMED pocket ECG
~ZIO xt patch
~MoMe"
16616154|NCT02506608|Experimental|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:
~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)
~TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)
~Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)
~Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)
~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
16616155|NCT02506595|Experimental|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
16616156|NCT02506595|No Intervention|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
16616157|NCT02506582|Experimental|Test group|jerusalem artichoke and fermented soybeans powder mixture supplementation
16616158|NCT02506582|Placebo Comparator|Placebo group|placebo supplementation
16616159|NCT02506556|Experimental|experimental|BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
16616160|NCT02506543|Experimental|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
16616161|NCT02506543|Active Comparator|Wait-list control|No intervention
16616162|NCT02506530|Active Comparator|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
16616163|NCT02506530|Experimental|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
16616164|NCT02506530|Active Comparator|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
16616165|NCT02506517|Experimental|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
16616166|NCT02506504|Experimental|Inspiratory help then sham ventilation|The initial evaluation is performed using an Inspiratory Pressure Support. After the training, the final evaluation is performed using an Inspiratory help (sham ventilation).
16617668|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
16616167|NCT02506504|Experimental|Sham ventilation then Inspiratory help|"The initial evaluation is performed using an inspiratory help (sham ventilation).
~After the training, the final evaluation is performed using an Inspiratory Pressure Support."
16616168|NCT02506491|Experimental|Pilates exercise program|Incorporate Pilates principles to stimulate core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
16616169|NCT02506491|Experimental|Muscular exercise program|To train core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
16616170|NCT02506491|Active Comparator|Control group|Healthy active but nonexercising old women
16616171|NCT02506478||ED patients|All ED patients who are able to drink water/juice, and be able to communicate juice preference.
16616172|NCT02506465|Experimental|iTind arm|iTind implant is implant during the study for 5-7 days.
16616173|NCT02506465|Sham Comparator|Sham arm|Foley catheter is used during the study
16616174|NCT02506452|Active Comparator|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
16616175|NCT02506452|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
16616176|NCT02506439|Experimental|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg [400 IU] daily
16616177|NCT02506439|Experimental|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg [800 IU] daily
16616178|NCT02506439|Placebo Comparator|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
16616179|NCT02506426|Active Comparator|Endoscopic Sinus Surgery + Septoplasty|A surgery that uses special telescopes through the nostrils to make the nasal septum straight and open the facial sinuses without any incisions. The sinuses are opened using special microscopic instruments and the procedure takes approximately 90 - 120 minutes.
16616180|NCT02506426|Experimental|Septoplasty alone|A surgery that is performed to straighten a bent nasal septum. It is shorter (take approximately 25 - 30 minutes) and less invasive (do not open the facial sinuses) that might provide the same benefits compared to the larger and longer endoscopic sinus surgery.
16616181|NCT02506413|Other|MNCH Intervention Package|"The division assigned to this arm received a comprehensive Maternal and Newborn Health (MNH) intervention package using the 'MamaToto Process'. Key intervention activities included:
~engaging district leaders in district health system strengthening;
~strengthening health facility-based MNH services; and
~establishing a Maternal, Newborn, and Child Health focused lay Community Health Worker program."
16616182|NCT02506387||Mitraclip patients|Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.
16616183|NCT02506348|Experimental|Diclofenac+Nepafenac|one drop Diclofenac in one eye one drop Nepafenac in other eye
16616184|NCT02506335|Other|Hep quant cholate testing|diagnostic measure of liver function
16616185|NCT02506322|Experimental|SEKT Cognitive-Behavioral-Emotional|Specific psychotherapy (SEKT - 4 modules) for typical problems of Bipolar patients to maintain remission and to prevent relapse. Including classical elements of self observation, psychoeducation, cognitive and behavioral interventions, social rhythm but also emotion regulation and meta-cognitive techniques. Delivered in a group setting in 4 one day treatment workshops, each one month apart. Homework assignment and electronical monitoring during time between sessions.
16616186|NCT02506322|Active Comparator|FEST Clinical Supportive Educational|This supportive, active control psychotherapy (FEST) is using general principals and non-specific interventions such as positive attitude, optimism, support, empathy, focus on emotion, self-help, strengthening and eliciting own resources, time and room for discussion of personal experiences. Psychoeducation about illness and drug treatment (mood stabilizer) to facilitate compliance.
16616187|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
16616188|NCT02506309|Active Comparator|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
16616189|NCT02506296|Other|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:
~Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol
~Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol
~Groups will be compared for:
~glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)
~glycaemic response to standard DPPIV inhibitor therapy"
16616190|NCT02506283|Experimental|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
16616191|NCT02506283|Sham Comparator|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
16616192|NCT02506270|Active Comparator|AirSeal Trocar valveless|patients are treated with the AirSeal-CO2-insufflator and trocar-system
16616193|NCT02506270|Sham Comparator|Conventional trocar|patients are treated with a conventional insufflation and trocar system
16616194|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
16616195|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
16616196|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
16616197|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
16616198|NCT02506244|Experimental|Immediate Monitoring|"Individuals randomized to immediate monitoring will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of the 4 month monitoring period of time 0 to 4 months.
~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) continuously over the 4 month monitoring period."
16616199|NCT02506244|Active Comparator|Delayed Monitoring|"Individuals randomized to delayed monitoring will receive usual care for 4 months after which they will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of study months 4 through 8.
~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) daily for months 4 through 8."
16616200|NCT02506231|Experimental|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
16616201|NCT02506231|Placebo Comparator|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
16616202|NCT02506218|Experimental|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
16616203|NCT02506218|Active Comparator|30 g protein breakfast|
16616204|NCT02506218|Active Comparator|10 g protein breakfast|
16616205|NCT02506205|Experimental|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, & Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
16616206|NCT02506192|Experimental|Delayed-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
16616207|NCT02506192|Placebo Comparator|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
16616208|NCT02506179||Open-label cohort|Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
16616209|NCT02506166|No Intervention|No or Mild Sleep Apnea Group (Group 1)|"ICM patients with no or mild sleep apnea enrolled in this arm will continue with standard therapy (ICD/CRT-D implant + maximal medical therapy), but will receive no active Positive Airway Pressure (PAP) therapy for sleep apnea treatment. See Part: Study Population for more details.
~In all ICM patients enrolled into ESCAPE-SCD Study, the ICD/CRT-D devices will be implanted based on current ESC Guidelines for primary prevention of sudden cardiac death (see Section: References)"
16616210|NCT02506166|No Intervention|Obstructive Sleep Apnea - Control Group (Group 2)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), but no PAP therapy for sleep apnea treatment. See Part: Study Population for more details."
16616211|NCT02506166|Active Comparator|Obstructive Sleep Apnea - Active Group (Group 3)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), plus as intervention, all patinets in this group will receive sleep apnea treatment by using PAP device. See Part: Study Population for more details."
16616212|NCT02506166|No Intervention|Central Sleep Apnea Group (Group 4)|"ICM patients with predominant central sleep apnea enrolled in this group will receive standard therapy (ICD/CRT-D implant + maximal medical therapy). Because the SERVE-HF Trial demonstrated a negative effect of predominantly central sleep apnea treatment on cardiovascular mortality in patients with HFrEF by using adaptive servo-ventilation therapy, patients in Group 4 will not receive any PAP therapy for treatment of sleep disordered breathing. See Part: Study Population for more details."
16616213|NCT02506153|Active Comparator|Arm I (high-dose recombinant interferon alfa-2B, ipilimumab)|"INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20 minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for a total of 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC) on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity."
16616214|NCT02506153|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
16616215|NCT02506140|Experimental|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
16616216|NCT02506140|Active Comparator|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
16616217|NCT02506127|Experimental|Open-label|"Theta burst stimulation (TBS) is a form of repetitive transcranial magnetic stimulation (TMS). Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.
~Each treatment session thus involves < 10 minutes of stimulation. The subject and researchers know what treatment is being administered."
16616218|NCT02506127|Active Comparator|Blinded Active|"Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.
~Each treatment session thus involves < 10 minutes of stimulation. The subject and researcher will not know what type of treatment will be administered."
16618108|NCT02494024|Experimental|Single dose C2N-8E12 level 2|Single IV infusion of C2N-8E12
16616219|NCT02506127|Sham Comparator|Blinded Sham|"This is a sham treatment which will mimic the open-label and blinded active to enable the effects of the supposedly active treatment to be assessed objectively. The subject and researcher will not know what type of treatment will be administered.
~Each treatment session will be < 10 minutes in duration."
16616220|NCT02506114|Experimental|Arm A: PROSTVAC-V/F|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.
16616221|NCT02506114|Experimental|Arm B: Ipilimumab Monotherapy|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
16616222|NCT02506114|Experimental|Arm C: Combined PROSTVAC-V/F + Ipilimumab|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
16616223|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
16616224|NCT02506101|No Intervention|no intervention|untreated
16616225|NCT02506088|Experimental|Your Voice Your View|Participants in schools assigned to the treatment group will engage in a four session intervention aimed at prevention of sexual violence. Your Voice Your View is grounded in social norms theory and bystander intervention training. The intervention also includes a social norms marketing campaign.
16616226|NCT02506088|No Intervention|Wait List Control Group|Participants in schools assigned to the wait list control group will complete survey assessments at the same schedule as schools assigned to the treatment group. Schools will have the option to implement Your Voice Your View following completion of the 6-month survey.
16616227|NCT02506075|Experimental|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.
~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
16616228|NCT02506075|Experimental|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
16616229|NCT02506075|No Intervention|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
16616230|NCT02506062|Experimental|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
16616231|NCT02506062|Placebo Comparator|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
16616232|NCT02506049|Other|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
16616233|NCT02506036|Active Comparator|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
16616234|NCT02506036|Experimental|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
16616235|NCT02506023|Active Comparator|Hemophilia A carriers with mild mutation|Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
16616236|NCT02506023|Active Comparator|Hemophilia A Carriers with severe mutation|Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
16616237|NCT02506023|Active Comparator|Control|Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
16616238|NCT02505997|Experimental|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
16616239|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
16616240|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
16616241|NCT02505971|Active Comparator|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
16616242|NCT02505971|Active Comparator|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
16616243|NCT02505958|Other|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories. Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
16616244|NCT02505958|Other|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
16616245|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
16616246|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
16616247|NCT02505932||Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
16616248|NCT02505932||Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
16616249|NCT02505919|Experimental|Treatment|AQUABEAM System
16616250|NCT02505919|Active Comparator|Control|Transurethral Resection of the Prostate (TURP)
16616311|NCT02505477|Placebo Comparator|Placebo|Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
16616849|NCT02502136|Placebo Comparator|Air in deep sedated panendoscopy|Room air insufflation during panendoscopy with deep sedation
16616251|NCT02505893|Experimental|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
16616252|NCT02505880|Active Comparator|1: General anesthesia|General anesthesia
16616253|NCT02505880|Experimental|2: Hypnosis|Hypnosis with local anesthesia
16616254|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
16616255|NCT02505867|No Intervention|Control|No device provided
16616256|NCT02505854|Active Comparator|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin
16616257|NCT02505854|Active Comparator|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide
16616258|NCT02505854|Placebo Comparator|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin
16616259|NCT02505841|Active Comparator|Group 1|Curare: Atracurium injection at 0.5 mg/kg
16616260|NCT02505841|Experimental|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
16616261|NCT02505841|Experimental|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
16616262|NCT02505828|Other|Septic arthritis|with bacteriological identification
16616263|NCT02505828|Other|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
16616264|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
16616265|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
16616266|NCT02505802|Experimental|BoNT-A treatment group|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu). Both groups received comprehensive rehabilitation for 8 weeks.
16616267|NCT02505802|No Intervention|Control group|No special treatment was performed in the control group. Both groups received comprehensive rehabilitation for 8 weeks.
16616268|NCT02505776||GLASH VISTA™|Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.
16616269|NCT02505763|Experimental|Strategy with thoracic ultrasound|"Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.
~Use of other examinations like chest CT if necessary"
16616270|NCT02505763|No Intervention|Strategy without thoracic ultrasound|"Usual care : without thoracic ultrasound
~Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.
~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
16616273|NCT02505737|Experimental|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
16616274|NCT02505737|Other|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
16616275|NCT02505724|Active Comparator|Conventional training|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice
16616276|NCT02505724|Experimental|Intervention|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice. In addition, they received two 1/2 hour peer-coaching sessions
16616277|NCT02505711|Experimental|Homestead Food Production|Enrolled in Homestead Food Production program from 2015 to 2019, 48 clusters, approx. 1350 women and 750 children
16616278|NCT02505711|No Intervention|Control|(Health system strengthening in the study area), 48 clusters, approx. 1350 women and 750 children
16616279|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
16616280|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
16616281|NCT02505659|Experimental|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
16616282|NCT02505659|No Intervention|CONTRL GROUP|a control group (without preoperative reeducation)
16616283|NCT02505633|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
16616284|NCT02505633|Active Comparator|1P1I group|After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
16616285|NCT02505620||Surgical|Surgical correction of OSAS disease
16616286|NCT02505620||Conservative|Conservative treatment of OSAS disease
16616287|NCT02505607|No Intervention|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
16616288|NCT02505607|Experimental|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
16616289|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
16616290|NCT02505594||Control Group|Apnea-hypopnea index (AHI) < 5 events/h
16616291|NCT02505581|Experimental|Oral + Parenteral prophylaxis|
16616292|NCT02505581|Active Comparator|Only Parenteral prophylaxis|
16616293|NCT02505568|Experimental|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
16616294|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
16616295|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
16616296|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.
~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
16616297|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
16616298|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
16616299|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
16616300|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
16616301|NCT02505529|Experimental|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
16616302|NCT02505529|Experimental|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
16616303|NCT02505529|No Intervention|Control Group|6-weeks of no change in lifestyle.
16616304|NCT02505516|Placebo Comparator|metformin|metformin 500mg
16616305|NCT02505516|No Intervention|not on metformin|
16616306|NCT02505503|Active Comparator|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
16616307|NCT02505503|Placebo Comparator|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
16616308|NCT02505490|Experimental|No Television|The purpose is to determine whether a change in liking of food will occur with a lack of television.
16616309|NCT02505490|Experimental|Television|The purpose is to determine whether a change in liking of food will occur while watching television.
16616310|NCT02505477|Experimental|N-acetylcysteine|Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
16616312|NCT02505464||Pregnant Women & their fetuses/infants|Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
16616313|NCT02505451|Experimental|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
16616314|NCT02505451|Experimental|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
16616315|NCT02505451|Experimental|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
16616316|NCT02505438|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
16616317|NCT02505438|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
16616318|NCT02505438|Experimental|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
16616319|NCT02505438|Experimental|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
16616320|NCT02505425|Experimental|Active Intervention|"Behavioral: behavioral support
~Usual HF Care + ENABLE CHF-PC"
16616321|NCT02505425|Active Comparator|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
16616322|NCT02505399|Experimental|ticagrelor|"In the intervention group, Ticagrelor will be administered orally, according to the following scheme:
~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
~90 mg the following morning (D Day before rotational atherectomy and angioplasty),
~90 mg the following evening (D Day after rotational atherectomy and angioplasty),
~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
16616323|NCT02505399|Active Comparator|clopidogrel|"In the control group, Clopidogrel will be administered orally, according to the following scheme:
~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
~75 mg the following morning (D Day before rotational atherectomy and angioplasty),
~0 mg the following evening (D Day after rotational atherectomy and angioplasty),
~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
16616324|NCT02505386|Active Comparator|Ertapenem IV|IV administration of ertapenem
16616325|NCT02505386|Experimental|Ertapenem SC|SC administration of ertapenem
16616326|NCT02505373|Experimental|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
16616327|NCT02505373|Active Comparator|Control Group CG|Control Group CG (structured interview)
16616328|NCT02505360|Other|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
16616329|NCT02505347|Experimental|No splint|will be able to move the arm as tolerated following surgery.
16616330|NCT02505347|Active Comparator|Splint|will receive a splint following surgery for 6 weeks.
16616331|NCT02505334|Experimental|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
16616332|NCT02505334|Active Comparator|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
16616333|NCT02505321|Experimental|fATDIVA - OTTT (Cases)|"Individuals identified with the polygenic lipodystrophy genetic variants of interest will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
16616334|NCT02505321|Experimental|fATDIVA - OTTT (Controls)|"Control individuals carrying the average number of risk alleles and matched to individuals identified with the polygenic lipodystrophy genetic variants of interest for gender, age and BMI, will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
16616335|NCT02505308|Experimental|DIVA-1 CCND2|Individuals carrying a genetic change in the CCND2 gene and controls matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
16616336|NCT02505308|Experimental|DIVA-2 Low Risk of Diabetes|Individuals carrying the fewest genetic risk alleles for diabetes and controls carrying the average number of genetic risk alleles, matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
16616337|NCT02505295|Active Comparator|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
16616338|NCT02505295|Placebo Comparator|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
16616339|NCT02505282||Orthostatic Hypotension|>20mmHg systolic BP drop or >10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
16616340|NCT02505282||Control|No fall in BP or <20mmHg systolic BP drop and <10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
16616341|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:
~- Participants will receive combination therapy:
~Brentuximab Vedotin intravenously on predetermined days per cycle
~Adriamycin intravenously on predetermined days per cycle
~Dacarbazine intravenously on predetermined days per cycle"
16616342|NCT02505256||case group|cases who presented as breast pain or breast lumps, and no intervention will be administered.
16616344|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
16616345|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
16616346|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
16616347|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
16616348|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
16616349|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
16616350|NCT02505191|Experimental|Test|St. John's wort prolonged-release tablet 500 mg
16616351|NCT02505191|Active Comparator|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
16616352|NCT02505178|Experimental|Problem Solving Therapy|Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).
16616353|NCT02505165|Experimental|Parent Uncertainty Intervention|A pediatric cancer-specific, clinic based, six-module interdisciplinary uncertainty intervention. Modules one through three target uncertainty prevention. Modules four through six target uncertainty responses for situations in which uncertainty cannot be prevented or avoided.
16616354|NCT02505165|Other|Education/Support Only|"Sessions in this condition aim to provide education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Information presented will be based upon, Young People with Cancer: A Handbook for Parents, a parent resource developed by the National Cancer Institute. Parents will also be provided with relevant educational brochures from COG. Each session will also include a structured set of questions that will facilitate discussion. All ESO interventionists will be trained in non-directive approaches including reflective listening. Content provided in the ESO sessions will offer valuable information to parents without providing the specific skills of the IMPACT."
16616355|NCT02505152|Experimental|Shunt|Perform percutaneous transhepatic intrahepatic portosystemic shunt
16616356|NCT02505139||Study Group|
16616357|NCT02505126|Experimental|Active tDCS group|Active tDCS
16616358|NCT02505126|Placebo Comparator|Placebo tDCS group|Placebo tDCS : Inactive tDCS
16616359|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
16616360|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
16616361|NCT02505100|Experimental|Touching relaxant|session of massage
16616362|NCT02505100|Experimental|Hypnoses|session of hypnoses
16616363|NCT02505100|No Intervention|Standared care|standard care
16616364|NCT02505087|Active Comparator|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
16616365|NCT02505087|Experimental|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
16616366|NCT02505087|No Intervention|Healthy volunteers|The purpose of this group is to collect reference values for biochemical markers.
16616367|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
16616368|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
16616369|NCT02505061|Experimental|Program|"The participants performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively"
16616370|NCT02505048|Experimental|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.
~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
16616695|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
16616371|NCT02505035|Active Comparator|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
16616372|NCT02505035|No Intervention|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
16616373|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
16616374|NCT02505009|Experimental|entecavir pretreated vaccine arm|Arm A,case group: 75 cases will be enrolled to receive Engerix-B injection and compared with histological non-vaccine treated controls
16616375|NCT02505009|Experimental|tenofovir pretreated vaccine arm|Arm B case group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
16616376|NCT02505009|Active Comparator|Entecavir pretreated control arm|Arm A control group: Age, gender and pretreatment DNA matched histological controls
16616377|NCT02505009|Active Comparator|tenofovir pretreated control arm|Arm B control group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
16616378|NCT02504996|Active Comparator|Paracetamol|1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.
16616379|NCT02504996|Active Comparator|morphine|0.1 mg/kg morphine in 100 ml saline with a rapid infusion.
16616380|NCT02504996|Placebo Comparator|placebo|100 ml saline
16616381|NCT02504983|Active Comparator|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
16616382|NCT02504983|Active Comparator|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
16616383|NCT02504983|Experimental|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
16616384|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
16616385|NCT02504957|Other|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
16616386|NCT02504944|Experimental|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.
16616387|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.
~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
16616388|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.
~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
16616389|NCT02504905|Experimental|PAR-CD|CD and age/sex matched HV control
16616390|NCT02504905|Experimental|PAR-WC|WC and age/sex matched HV control
16616391|NCT02504892|Experimental|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
16616392|NCT02504892|Experimental|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
16616393|NCT02504879||Melorheostosis patients|Patients aged > 18 years with possible and confirmed melorheostosis.
16616394|NCT02504879||Relatives of patients with melorheostosis|Relatives of patients with melorheostosis may be included for genetic testing only.
16616395|NCT02504866|Experimental|AET|Aerobic exercise will be performed on an elliptical trainer at a vigorous intensity
16616396|NCT02504866|No Intervention|Control|Wait-list control that performs no exercise for first 12 weeks; randomized to an exercise intervention(either AET or RET) after 12 weeks
16616397|NCT02504866|No Intervention|Healthy Volunteer|Healthy volunteers will perform specific measures for asingle study visit
16616398|NCT02504866|Experimental|RET|Rapid reciprocal exercise will be performed on an elliptical trainer at light to moderate intensity
16616399|NCT02504853||Affected genetic|Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs)
16616400|NCT02504853||Affected non-syndromic food|Individuals with a clinical history of immediate hypersensitivity reaction to foods and sensitized to food allergen(s) as evidenced by SPT or allergen-specific IgE testing.
16616401|NCT02504853||Allergic GI Disease|Individuals with a diagnosis or clinical suspicion of eosinophilic esophagitis (EoE), as determined by the principal investigator (PI) or associate investigators (AIs).
16616402|NCT02504853||Unaffected relative / healthy volunteer|Unaffected relatives are relatives of affected; unaffected by food allergy or the genetic condition under study. Healthy volunteers are not related to affected and serve as controls.
16616403|NCT02504840||healthy volunteers|healthy volunteers
16616404|NCT02504840||patient controls|Participants with diseases that share features with MS.
16616405|NCT02504840||patients with suspected or confirmed multiple sclerosis|Participants with definite, probable, or possible MS.
16616406|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
16616407|NCT02504814|Experimental|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
16616408|NCT02504801|Active Comparator|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
16616409|NCT02504801|Placebo Comparator|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
16616410|NCT02504788|Experimental|Hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) if the role of RT was considered either adjuvant following craniotomy with tumor removal or therapeutic for treating oligometastatic brain disease.
16616411|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
16616412|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
16616413|NCT02504762|Experimental|Treatment: HCR|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
16616414|NCT02504762|Active Comparator|Control: Conventional CABG|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
16616415|NCT02504749|Active Comparator|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
16616416|NCT02504749|Active Comparator|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.
~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
16616417|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
16616418|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
16616419|NCT02504710|Active Comparator|Traditional Learning System|Traditional systems of manual therapy teaching
16616420|NCT02504710|Experimental|Kinematic Real-Time Feedback|Kinematic real time feedback to learn Manual therapy
16616421|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer > 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
16616422|NCT02504684|Active Comparator|1470-nm|Endovenous 1470-nm diode laser
16616423|NCT02504684|Experimental|1920-nm Group|Endovenous 1920-nm diode laser
16616424|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
16616425|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
16616426|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
16616427|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
16616428|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
16616429|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
16616430|NCT02504658|Experimental|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
16616431|NCT02504658|Active Comparator|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
16616432|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
16616433|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
16616434|NCT02504632|Experimental|test group|Patient with severe, symptomatic AS (Aortic valve area < 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.
16616435|NCT02504632|Other|control group|Patient with stable coronary artery disease, unscathed of AS Patient under aspirin treatment (75-160 mg/d for at least one week)
16616436|NCT02504619|Experimental|CordIn|Transplantation of CordIn
16616437|NCT02504606|Experimental|Besylsartan|amlodipine besylate 6.944mg+losartan K 100mg
16616438|NCT02504606|Active Comparator|Amosartan|amlodipine besylate 7.841mg+losartan K 100mg
16616439|NCT02504593|Other|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
16616440|NCT02504580|Experimental|Part A Cohort A|200 mg of HTX-011 by injection
16616441|NCT02504580|Experimental|Part A Cohort B|400 mg of HTX-011 by injection
16616442|NCT02504580|Experimental|Part A Cohort C|200 mg of HTX-011 by instillation
16616443|NCT02504580|Experimental|Part A Cohort D|400 mg of HTX-011 by instillation
16616444|NCT02504580|Experimental|Part A Cohort E|200 mg HTX-011 injection and 200 mg instillation
16616445|NCT02504580|Placebo Comparator|Part A Cohort F|Saline solution by injection
16616446|NCT02504580|Experimental|Part B Cohort A|200 mg HTX-011A by injection
16616447|NCT02504580|Experimental|Part B Cohort B|400 mg HTX-011A by injection
16616448|NCT02504580|Experimental|Part B Cohort C|200 mg HTX-011B by injection
16616449|NCT02504580|Experimental|Part B Cohort D|400 mg HTX-011B by injection
16616450|NCT02504580|Placebo Comparator|Part B Cohort E|Saline solution by injection
16616451|NCT02504580|Experimental|Part C Cohort A|200 mg HTX-002 by infiltration
16616452|NCT02504580|Experimental|Part B Cohort F|400 mg HTX-002 by infiltration
16616453|NCT02504580|Experimental|Part C Cohort B|200 mg HTX-011B by instillation
16616454|NCT02504580|Experimental|Part B Cohort G|400 mg HTX-011B by instillation
16616455|NCT02504580|Placebo Comparator|Part C Cohort C|Saline Solution by instillation
16616456|NCT02504580|Active Comparator|Part C Cohort D|0.25% bupivacaine hydrochloride injection
16616457|NCT02504580|Experimental|Part D Cohort A|400 mg HTX-011B via a combination of injection and instillation
16616458|NCT02504580|Experimental|Part E Cohort A|HTX-009 by injection
16616459|NCT02504580|Experimental|Part E Cohort B|HTX-009 by instillation
16616460|NCT02504580|Experimental|Part F Cohort A|300 mg of HTX-011B
16616461|NCT02504580|Experimental|Part F Cohort B|75 mg of 0.25% Marcaine
16616462|NCT02504580|Placebo Comparator|Part F Cohort C|10.26 mL of normal saline
16616463|NCT02504567|Other|Laser ablation|Ablation with laser catheter
16616464|NCT02504567|Other|RF ablation|Ablation with RF catheter
16616465|NCT02504554|Experimental|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
16616466|NCT02504554|Experimental|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
16616467|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
16616468|NCT02504528|Experimental|allergic asthma|asthma patients that sensitive to house dust mites.
16616469|NCT02504528|Experimental|normal controls|normal controls with or without sensitive to house dust mites.
16616470|NCT02504515|Active Comparator|Homeopathy|
16616471|NCT02504515|Active Comparator|Allopathy homeopathy control|
16616472|NCT02504515|Active Comparator|Acupuncture|
16616473|NCT02504515|Active Comparator|Allopathy acupuncture control|
16616474|NCT02504515|Active Comparator|Anthroposophic medicine|
16616475|NCT02504515|Active Comparator|Allopathy anthroposophy control|
16616476|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
16616477|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
16616510|NCT02504320|Experimental|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
16616478|NCT02504489|Active Comparator|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
16616479|NCT02504489|Experimental|Docetaxel + Plinabulin (DP)|The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade >1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
16616480|NCT02504476|Active Comparator|AMG 581 - Dose 1|
16616481|NCT02504476|Active Comparator|AMG 581 - Dose 2|
16616482|NCT02504476|Active Comparator|AMG 581 - Dose 3|
16616483|NCT02504476|Active Comparator|AMG 581 - Dose 4|
16616484|NCT02504476|Placebo Comparator|Placebo - Dose 1|
16616485|NCT02504476|Placebo Comparator|Placebo - Dose 2|
16616486|NCT02504476|Placebo Comparator|Placebo - Dose 3|
16616487|NCT02504476|Placebo Comparator|Placebo - Dose 4|
16616488|NCT02504476|Other|AMG 581/Midazolam - Drug Interaction|
16616489|NCT02504463|Experimental|Samidorphan IV|Samidorphan solution for IV administration
16616490|NCT02504463|Experimental|Samidorphan sublingual|[14c]-Samidorphan for sublingual administration
16616491|NCT02504463|Experimental|Samidorphan oral|[14c]-Samidorphan for oral administration
16616492|NCT02504437|Experimental|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
16616493|NCT02504437|Active Comparator|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
16616494|NCT02504437|Sham Comparator|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
16616495|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
16616496|NCT02504411|Experimental|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
16616497|NCT02504411|Active Comparator|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
16616498|NCT02504398|Experimental|Fast injection|Vaccine injections will be given at a rate of approximately 2-4 ml/sec by the immunizer
16616499|NCT02504398|Active Comparator|Slow injection|Vaccine injections will be given at a rate of approximately 10 ml/sec by the immunizer
16616500|NCT02504385|Experimental|Virtual Reality Timocco|The study group will integrate the use of Timocco in occupational therapy sessions. The session will begin with 15 minutes of spatial activity involving sensory-motor practice, 15 minutes of activity in a virtual environment, and 15 minutes of structured activity at a desk.
16616501|NCT02504385|Active Comparator|Conventional OT intervention|The control group will be given conventional occupational therapy without using Timocco. In order to ensure that the therapy sessions in this group have a structure similar to that one used in the study group, each session will include 25 to 30 minutes of spatial sensory-motor activity, followed by 15 to 20 minutes of structured practice at a desk.
16616502|NCT02504372|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).
16616503|NCT02504372|Placebo Comparator|Placebo|Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).
16616504|NCT02504359|Experimental|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.
~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.
~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
16616505|NCT02504346|Experimental|Treatment|Non-randomized trial, all patients receive therapy - singel-arm
16616506|NCT02504333|Active Comparator|AG|nab-Paclitaxel followed by Gemcitabine
16616507|NCT02504333|Experimental|AG-mFOLFOX|nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial
16616508|NCT02504320|Experimental|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
16616509|NCT02504320|Experimental|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
16616546|NCT02504060|Placebo Comparator|Starch capsule|During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.
16616511|NCT02504320|Experimental|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
16616512|NCT02504307|Experimental|Inspiron|Sirolimus Eluting Stent Inspiron
16616513|NCT02504307|Active Comparator|Cronus|Bare Metal Stent
16616514|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
16616515|NCT02504294|Other|Standard of Care|Standard of care arm
16616516|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 2 times) in our IVF institute.
16616517|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
16616518|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
16616519|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
16616520|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
16616521|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
16616522|NCT02504255||Patients with Crohn's Disease|patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
16616523|NCT02504242|Experimental|Inject BMP|ExcelOS Inject / rhBMP-2
16616524|NCT02504242|Active Comparator|Locally Harvested Bone|Locally Harvested Bone
16616525|NCT02504229|Experimental|Chemotherapy+DC-CIK|Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
16616526|NCT02504229|Active Comparator|Chemotherapy alone|Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.
16616527|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
16616528|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
16616529|NCT02504203|Active Comparator|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
16616530|NCT02504203|No Intervention|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
16616531|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
16616532|NCT02504177|Experimental|The group of keep medication NOAC|The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
16616533|NCT02504177|Active Comparator|The group of stop medication NOAC 1 day|The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
16616534|NCT02504164|Experimental|No premedication|No premedication before sedation
16616535|NCT02504164|Active Comparator|Midazolam|Premedication with midazolam before sedation
16616536|NCT02504151|Experimental|Order 1|The subject will receive treatment with CBD for four weeks, followed by a two week washout period, followed by four weeks of placebo.
16616537|NCT02504151|Experimental|Order 2|The subject will receive placebo for four weeks, followed by a 2 week washout period, followed by four weeks of treatment with CBD.
16616538|NCT02504138|Experimental|Desflurane balanced anesthesia group|
16616539|NCT02504138|Active Comparator|Propofol total intravenous anesthesia group|
16616540|NCT02504125|Experimental|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
16616541|NCT02504125|Placebo Comparator|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
16616542|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
16616543|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
16616544|NCT02504086|Experimental|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
16616545|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.
~There is no intervention."
16616655|NCT02503319|Experimental|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
16616547|NCT02504060|Experimental|N-acetyl-D-glucosamine|During the 12- weeks treatment phase of the study, the daily dose of 100mg*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.
16616548|NCT02504047|Experimental|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
16616549|NCT02504034|Experimental|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
16616550|NCT02504021|Experimental|Family Consultation Condition|The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
16616551|NCT02504021|No Intervention|Treatment as Usual Control Condition|Standard of care for the nephrology unit.
16616552|NCT02504008|Experimental|AXS-02 (oral zoledronate)|Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36
16616553|NCT02504008|Placebo Comparator|Placebo|Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36
16616554|NCT02503995|Active Comparator|No intervention|Participants not undertaking any additional exercise
16616555|NCT02503995|Experimental|Water-based exercise group|Participants assigned to a water-based exercise group
16616556|NCT02503995|Experimental|Land-based exercise group|Participants assigned to a land-based exercise group
16616557|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
16616558|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
16616559|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
16616560|NCT02503956|Experimental|Treated group|Patients treated with perforated punctal plugs
16616561|NCT02503956|Active Comparator|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
16616562|NCT02503943|Experimental|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide(50mg, 3/d)"
16616563|NCT02503943|Active Comparator|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
16616564|NCT02503943|Active Comparator|"Mitiglinide"|"Mitiglinide(50mg, 3/d)"
16616565|NCT02503930|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
16616566|NCT02503930|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
16616567|NCT02503917||Healthy volunteers|Healthy female adult volunteers
16616568|NCT02503917||Cervical cancer patients|Patients receiving radiotherapy for cervical cancer at the Royal Marsden who will receive a planning CT scan and daily CBCT scanning as part of their treatment.
16616569|NCT02503904|Active Comparator|TAD+IVAD|
16616570|NCT02503904|Active Comparator|IVAD|
16616571|NCT02503891|Experimental|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
16616572|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
16616573|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
16616574|NCT02503865|No Intervention|Healthy people|64 healthy people
16616575|NCT02503852|Experimental|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
16616576|NCT02503852|Experimental|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
16616577|NCT02503852|Active Comparator|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
16616578|NCT02503852|Placebo Comparator|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
16616579|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.
~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
16616580|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
16616581|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
16616582|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
16616583|NCT02503826|Experimental|1.5 SF|Sufentanil,1.5mcg/kg
16616584|NCT02503826|Experimental|2.0 SF|Sufentanil, 2.0mcg/kg
16616585|NCT02503826|Experimental|2.5 SF|Sufentanil, 2.5mcg/kg
16616586|NCT02503813|Experimental|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
16616587|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
16616588|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
16616589|NCT02503774|Experimental|Monotherapy|MEDI9447 (oleclumab) only
16616590|NCT02503774|Experimental|Combination|MEDI9447 (oleclumab) and MEDI4736 (durvalumab)
16616591|NCT02503761|Active Comparator|Infusion arm|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
16616592|NCT02503761|Active Comparator|Bolus group|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.
16616593|NCT02503748|Experimental|Intervention|Online Tutorial
16616594|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
16616595|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16616596|NCT02503709|Experimental|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
16616597|NCT02503696||IBD|Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
16616598|NCT02503683|Active Comparator|ALN-AAT|
16616599|NCT02503683|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16616600|NCT02503670|Other|HealthyDads.ca web-based program|An on-line self-help psychoeducational website tailored to new dads. Psychoeducational learning modules and tools, including a 6 week physical activity challenge..
16616601|NCT02503670|Other|Control group|No access to the intervention. Will complete the same questionnaires as the Healthydads.ca group over the study period.
16616602|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.
~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
16616603|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
16616604|NCT02503644|Active Comparator|IVA337 800mg|Patients receive twice daily 400mg IVA337.
16616605|NCT02503644|Active Comparator|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
16616606|NCT02503644|Placebo Comparator|Placebo|Patients receive twice daily placebo.
16616607|NCT02503631||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.
16616608|NCT02503618||HIV-negative YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-negative
16616609|NCT02503618||HIV-positive YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-positive
16616610|NCT02503605|Active Comparator|Biosimilar recombinant FSH|Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
16616611|NCT02503605|Active Comparator|Urinary FSH|Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
16616612|NCT02503592|Active Comparator|Cochlear Implant group - Vestibular testing|Adult patients who have been implanted with a Med-El Cochlear implant device within the last 3 months who completed pre-op vestibular testing as standard of care. These subjects will undergo a series of post-op vestibular testing, at the 3 month and 12 month follow up visits
16616613|NCT02503592|No Intervention|Control Group - existing historical vestibular data|This group will consist of existing historical vestibular testing data only. No subjects will be enrolled on this arm.
16616614|NCT02503579|Experimental|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
16616615|NCT02503579|No Intervention|control|"1 training at the beginning of the study
~1 training at the end of the study"
16616616|NCT02503566|Experimental|All patients|Optical coherence tomography will be performed in all patients
16616617|NCT02503553|Experimental|Decision aid|"Option grid for cerebral aneurysm treatment
~Patients will receive an option grid during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded."
16616618|NCT02503553|Placebo Comparator|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
16616619|NCT02503540|Other|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
16616620|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
16616621|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
16616622|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
16616623|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
16616624|NCT02503488|Experimental|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
16616625|NCT02503488|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
16616626|NCT02503475|Other|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:
~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
16616627|NCT02503475|Experimental|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:
~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
16616628|NCT02503475|Other|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:
~Verum- Experimental Sham- Sham comparator"
16616629|NCT02503462|Experimental|darunavir/ritonavir vs cobicistat|All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.
16616630|NCT02503423|Experimental|Phase 1 - Part 1 (completed)|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
16616631|NCT02503423|Experimental|Phase 1 - Part 2 (completed)|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
16616632|NCT02503423|Experimental|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
16616633|NCT02503423|Experimental|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
16616634|NCT02503423|Experimental|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
16616635|NCT02503423|Experimental|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
16616636|NCT02503423|Experimental|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
16616637|NCT02503423|Experimental|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
16616638|NCT02503423|Experimental|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
16616639|NCT02503410|Active Comparator|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
16616640|NCT02503410|Experimental|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
16616641|NCT02503397||Latent iron deficiency|Infants with cord serum ferritin levels ≤ 75 ng/mL
16616642|NCT02503397||Normal iron status|Infants with cord serum ferritin levels > 75 ng/mL.
16616643|NCT02503371||Women under IVF stimulation at the begining and end|Coagulation parameters will be measured for all parturients at the beginning and conclusion of an IVF simulation cycle with the use of thromboelastogram
16616644|NCT02503358|Experimental|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over a fixed rate on days 1 and 8.
16616645|NCT02503358|Experimental|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
16616646|NCT02503358|Experimental|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
16616647|NCT02503345|Placebo Comparator|Placebo|Placebo capsules (1, 2 or 5) PO TID
16616648|NCT02503345|Experimental|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
16616649|NCT02503345|Experimental|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
16616650|NCT02503345|Experimental|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
16616651|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
16616652|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
16616653|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
16616654|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
16616656|NCT02503319|Experimental|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
16616657|NCT02503319|Active Comparator|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
16616658|NCT02503306|Experimental|Avanafil dose 1|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
16616659|NCT02503306|Experimental|Avanafil dose 2|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
16616660|NCT02503306|Placebo Comparator|Placebo|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
16616661|NCT02503293|Other|Chrono Super PID then Generic Syringe - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
~• Chrono Super PID then Generic Syringe-Gammanorm"
16616662|NCT02503293|Other|Generic Syringe then Chrono Super PID - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
~• Generic Syringe then Chrono Super PID-Gammanorm"
16616663|NCT02503280|Experimental|Group A - Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
16616664|NCT02503280|Experimental|Group B - Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
16616665|NCT02503280|Placebo Comparator|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
16616666|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
16616667|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
16616668|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
16616669|NCT02503241|Experimental|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.
~Intervention : PEEP INCREMENTAL"
16616670|NCT02503241|Experimental|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.
~Intervention :PEEP DECREMENTAL"
16616671|NCT02503228||MOPS|Transplanted tissue preserved using the MOPS method and obtained from one AATB-approved tissue bank
16616672|NCT02503228||Standard Preservation|Transplanted tissue preserved using standard preservation methods and obtained from one of three AATB-approved tissue banks
16616673|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
16616674|NCT02503202|Experimental|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
16616675|NCT02503202|Experimental|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
16616676|NCT02503202|Experimental|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
16616677|NCT02503202|Experimental|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
16616678|NCT02503202|Placebo Comparator|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
16616679|NCT02503189|Experimental|KCT-0809|
16616680|NCT02503189|Placebo Comparator|Placebo|
16616681|NCT02503176|Experimental|KCT-0809|
16616682|NCT02503163|Experimental|KCT-0809|
16616683|NCT02503150|Experimental|APDC + Chemotherapy|Patients in Arm APDC + Chemotherapy will receive APDC combined with chemotherapy.
16616684|NCT02503150|Active Comparator|Chemotherapy|Patients in Arm Chemotherapy will receive chemotherapy only.
16616685|NCT02503137|Experimental|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
16616686|NCT02503137|Experimental|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
16616687|NCT02503137|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for approximately 90 days
16616688|NCT02503124|Experimental|Chronobiological intervention|Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
16616689|NCT02503124|Active Comparator|Control|Treatment as usual including a private educational meeting in sleep hygiene.
16616690|NCT02503111|Experimental|Ablative therapy|Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
16616691|NCT02503111|Active Comparator|Active Surveillance|The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.
16616692|NCT02503098|Experimental|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
16616693|NCT02503098|Active Comparator|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
16616694|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
16618109|NCT02494024|Experimental|Single dose C2N-8E12 level 3|Single IV infusion of C2N-8E12
16616696|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
16616697|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
16616698|NCT02503072|Active Comparator|Prizes conditional on adherence|Participants in this group are eligible for a prize drawing if they come on their scheduled clinic day. They receive the intervention 'Behavioral: Small lottery prizes based on adherence'.
16616699|NCT02503072|Active Comparator|Prizes conditional on clinic visits|Participants in this group are eligible for a prize drawing if they show 95% adherence or higher based on their MEMS-cap measured adherence. They receive the intervention 'Behavioral: Small lottery prizes based on timely clinic visits'.
16616700|NCT02503046||Arthritis with Periodontitis|"Patients aged between 30-65 years with 6 positive diagnostic criteria for Rhematoid Arthritis. Patients should have Clinical attachment loss >6mm, and Probing pocket depth>5mm in more than 6 teeth to satisfy criteria for periodontitis.
~5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA) Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels."
16616701|NCT02503046||Periodontitis group|"Patients aged between 30-65 years with Periodontal findings being presence of atleast 20 teeth in the mouth .More than 6 teeth with Clinical attachment loss >6mm and Probing pocket depth>5mm to satisfy criteria for periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).
~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
16616702|NCT02503046||Healthy Subjects|"Subjects aged between 30-65 years with no systemic diseases and periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).
~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
16616703|NCT02503033|Experimental|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.
~At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily."
16616704|NCT02503020|Active Comparator|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
16616705|NCT02503020|Active Comparator|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
16616706|NCT02503007|Placebo Comparator|Placebo|A placebo similar in composition and appearance to the experimental treatment.
16616707|NCT02503007|Experimental|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
16616708|NCT02502994|Other|Intervention|Single arm of the castration resistant prostate cancer
16616709|NCT02502981|Experimental|CKD stage 2 & 3|"Patients with CKD stage 2 & 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.
~Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20."
16616710|NCT02502968|Experimental|Cytarabine & BL8040|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle
~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle"
16616711|NCT02502968|Active Comparator|Cytarabine & Placebo|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle
~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle"
16616712|NCT02502942|Experimental|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) > 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
16616713|NCT02502942|Experimental|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study > 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
16616714|NCT02502942|Experimental|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI > 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
16616715|NCT02502942|Active Comparator|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
16616716|NCT02502929|Active Comparator|Social Services|Participants in this arm will receive referrals for social services as indicated.
16616717|NCT02502929|Experimental|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
16616718|NCT02502929|Experimental|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
16616719|NCT02502916||Preterm infant|Preterm infants born from October 2009 to June 2010 at a gestational age of less than 32 weeks or with birth weight of less than 1,200 g
16616720|NCT02502903|Placebo Comparator|Part A|Single ascending dose (SAD) in NHVs, 7 cohorts, BIVV009 by IV infusion (0.3,1, 3, 10, 30, 60, or 100 mg/kg) or placebo.
16616721|NCT02502903|Placebo Comparator|Part B|Multiple ascending dose (MAD) in NHVs, 2 cohorts, 4 weekly IV doses of BIVV009 (30 or 60mg/kg) or placebo.
16616722|NCT02502903|Experimental|Part C|Multiple dose (MD) in a single cohort of patients with various complement-mediated disorders. All patients in Part C will receive a single IV test dose of BIVV009 of 10 mg/kg followed by 4 weekly doses of 60 mg/kg.
16616845|NCT02502136|Placebo Comparator|Air in deep sedated colonoscopy|Room air insufflation during colonoscopy with deep sedation
16616723|NCT02502903|Experimental|Part E|Multiple dose (MD) in a single cohort of patients with cold agglutinin disease previously treated with BIVV009. All patients in Part E will receive a single IV test dose at week 0, week 1, and every 2 weeks thereafter until EOT. Patients who weigh less than 75 kg will receive fixed doses of 6.5 grams of BIVV009; patients who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009. Dose will be increased from 6.5g to 7.5g dose level if patients current weight is >= 75 kg and there is evidence of hematologic breakthrough OR patients current weight is >= 75 kg and there has been at least a 10 percent increase from the patients last recorded weight. Dose will be decreased from 7.5g to 6.5g for patients whose last weight was >= 75 kg and current weight decreased to < 75 kg. Dose decrease will require Sponsor approval.
16616724|NCT02502877|Other|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
16616725|NCT02502877|Active Comparator|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
16616726|NCT02502864|Experimental|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
16616727|NCT02502851|Active Comparator|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
16616728|NCT02502851|Active Comparator|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
16616729|NCT02502838||Prolapse surgery without TVT|Patients who plan to undergo prolapse repair alone
16616730|NCT02502838||Prolapse surgery with TVT|Patients who plan to undergo prolapse repair with an additional TVT procedure
16616731|NCT02502825|Experimental|asthma|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
16616732|NCT02502825|Experimental|normal controls|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
16616733|NCT02502812|Experimental|Treatment Sequence A (Innovator) - B (Clop F1) - C (Clop F2)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
16616734|NCT02502812|Experimental|Treatment Sequence A(Innovator) -C(Clop F2)-B (Clop F1)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
16616735|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - A (Innovator) - C (Clop F2)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
16616736|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - C (Clop F2) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
16616737|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - A (Innovator) - B (Clop F1)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
16616738|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - B (Clop F1) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
16616739|NCT02502799|Active Comparator|Continued Monitoring and Assessment|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. Participants randomized to the continued monitoring and assessment arm will receive no additional intervention. Primary and secondary outcomes will be monitored.
16616740|NCT02502799|Active Comparator|PT with ACBT|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
16616741|NCT02502799|Active Comparator|PT with ACBT and Methylphenidate|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT and Methylphenidate arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (ACBT). Adolescents will also receive methylphenidate.
16616742|NCT02502786|Experimental|humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF|One cycle consists of treatment with hu3F8 at a dose of 2.4mg/kg/dose for 3 days (day 1, 3, and 5) in the presence of subcutaneous (sc) GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. Cycles are repeated at ~2-4 week intervals between first days of hu3F8, through 5 cycles. A maximum of 5 cycles will be administered on protocol.
16616846|NCT02502136|Experimental|CO2 in sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with sedation
16616743|NCT02502773|Experimental|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
16616744|NCT02502773|Experimental|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
16616745|NCT02502760|Experimental|Prehabilitation|"Immediately after randomization and until surgery, patients in this arm will:
~- Receive a personalized physical exercise program
~- Receive nutritional counselling with Whey protein isolate powder
~- Receive relaxation techniques"
16616746|NCT02502760|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patients in the other arm but to be started after surgery.
16616747|NCT02502747|Experimental|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
16616748|NCT02502747|Active Comparator|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
16616749|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
16616750|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
16616751|NCT02502721|Experimental|Part A|To study effect of DWC20151 on DWC20152 PK
16616752|NCT02502721|Experimental|Part B|To study effect of DWC20152 on DWC20151 PK
16616753|NCT02502708|Experimental|Group 1 (CLOSED)|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.
~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
16616754|NCT02502708|Experimental|Group 2 (CLOSED)|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.
~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
16616755|NCT02502708|Experimental|Group 3 (CLOSED)|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.
~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
16616756|NCT02502708|Experimental|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).
~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
16616757|NCT02502708|Experimental|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.
~Indoximod will be administered at 32 mg/kg/dose divided twice daily.
~Cyclophosphamide to be given at 2.5 mg/kg/dose daily
~Etoposide to be given at 50 mg/m2/dose daily"
16616758|NCT02502695||Cohort 1-VATS-associated best practices|"Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.
~After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
16616759|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
16616760|NCT02502682|No Intervention|Control|Receive the bathing standard of care.
16616761|NCT02502682|Experimental|Interventional|Receive daily bathing with 2% Chlorhexidine gluconate bathing wipes.
16616762|NCT02502669|Active Comparator|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
16616763|NCT02502669|Active Comparator|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
16616764|NCT02502669|Placebo Comparator|Placebo group|Large and small placebo tablets once per week
16616765|NCT02502643|Experimental|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
16616766|NCT02502643|Active Comparator|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
16616767|NCT02502630|Experimental|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
16616768|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
16616769|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
16616847|NCT02502136|Placebo Comparator|Air in sedated panendoscopy|Room air insufflation during panendoscopy with sedation
16616770|NCT02502604|Experimental|Goal Management Training|Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
16616771|NCT02502604|No Intervention|Wait List Control|Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.
16616772|NCT02502591|Experimental|intervention|Additional pain relief (a Pudendal Nerve Block (PNB)) will be administered during surgery in addition to routine care.
16616773|NCT02502591|No Intervention|control|routine care only
16616774|NCT02502578|Experimental|CNT-01|Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
16616775|NCT02502565||Uric Acid Level|
16616776|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
16616777|NCT02502539|Experimental|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
16616778|NCT02502526|Experimental|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
16616779|NCT02502526|Active Comparator|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
16616780|NCT02502526|Active Comparator|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
16616781|NCT02502513|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department and completion of intrusive memory diary"
16616782|NCT02502513|No Intervention|Control|Usual care in the maternity department plus completion of intrusive memory diary
16616783|NCT02502500|Active Comparator|Celecoxib|Celecoxib
16616784|NCT02502500|Experimental|AKB-6548 and Celecoxib|AKB-6548; celecoxib
16616785|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
16616786|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
16616787|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
16616788|NCT02502474|Experimental|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
16616789|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
16616790|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
16616791|NCT02502448|No Intervention|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
16616792|NCT02502448|Active Comparator|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
16616793|NCT02502435||Patients with Night-Eating Syndrome|Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
16616794|NCT02502435||Matched Healthy Controls|Healthy volunteers; 18-65 years of age; eating <25% of their caloric intake after dinner; no nocturnal ingestions
16616795|NCT02502422|Other|Classic laryngeal mask airway|single arm
16616796|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
16616797|NCT02502383|Experimental|ACTION PAC|
16616798|NCT02502383|Active Comparator|Comparison|
16616799|NCT02502370|Active Comparator|Group1 Arm A Observation|
16616800|NCT02502370|Experimental|Group 1 Arm B LV5FU2|
16616801|NCT02502370|Active Comparator|Group 2 Arm C LV5FU2|
16616802|NCT02502370|Experimental|Group 2 ARM D FOLFOX|
16616803|NCT02502357|Experimental|Healing Statements|Patients in the healing statements group will be read healing statements during anesthesia induction, prior to undergoing surgery.
16616804|NCT02502357|No Intervention|No Healing Statements|Patients in the no healing statements group will not be read healing statements during anesthesia induction prior to undergoing surgery. They will receive standard of care.
16616805|NCT02502344|Experimental|medical intervention group|subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.
16616806|NCT02502344|No Intervention|clinical observeral group|subjects in this group will not accept medical interventions
16616807|NCT02502331|Experimental|study group|Test Oral Cholera Vaccine
16616808|NCT02502331|Active Comparator|comparator group|Euvichol®
16616809|NCT02502318|Experimental|Lobectomy using video-thoracoscopy|
16616810|NCT02502318|Active Comparator|Lobectomy using thoracotomy|
16616811|NCT02502305|Experimental|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
16616812|NCT02502305|No Intervention|Control group|control group receives 3 questionnaires at an interval of 6 weeks
16616848|NCT02502136|Experimental|CO2 in mild sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with mild sedation
16616813|NCT02502292|Experimental|Intervention: Fotonovela|The Photo Novel Intervention is presented to users of four different facilities (sports clubs, senior homes) who are older than 50 years. The researchers welcome scheduled eligible participants, introduce the study and ask them for their consent. Afterwards, the participants are asked to fill in the questionnaire. Then, participants are randomized to one of the four groups and are presented with the photo novel or traditional brochure either as a hard copy brochure or as pdf on a tablet computer (2x2 group design). They are instructed to read the material in their own pace and answer the accompanying questions after each story / tip.and the accompanying questionnaire.
16616814|NCT02502279|No Intervention|Control|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters with 0 PEEP/CPAP.
16616815|NCT02502279|Active Comparator|Lung Recruitment- PEEP group|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
16616816|NCT02502279|Active Comparator|Lung Recruitment- PEEP and CPAP group|"Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus
~lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
~Postoperative CPAP mask immediately after extubation"
16616824|NCT02502253|Experimental|Low dose|
16616825|NCT02502253|Experimental|moderate dose|
16616826|NCT02502253|Experimental|High dose|
16616827|NCT02502227|Active Comparator|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
16616828|NCT02502227|Active Comparator|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
16616829|NCT02502227|No Intervention|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
16616830|NCT02502201|Active Comparator|six-minute walk study indoors first|Participants randomized to indoor six-minute walk test first
16616831|NCT02502201|Experimental|six-minute walk study outdoors first|Participants randomized to outdoor six-minute walk test first
16616832|NCT02502201|Active Comparator|six-minute walk study indoors second|Participants randomized to indoor six-minute walk test second
16616833|NCT02502201|Experimental|six-minute walk study outdoors second|Participants randomized to outdoor six-minute walk test second
16616834|NCT02502188|Experimental|Part 1 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
16616835|NCT02502188|Experimental|Part 2 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
16616836|NCT02502175|Experimental|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
16616837|NCT02502175|Active Comparator|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
16616838|NCT02502162|Experimental|LDN|Naltrexone HCL, 4.5 mg, Once a day.
16616839|NCT02502162|Placebo Comparator|Placebo|Sugar pill
16616840|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
16616841|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
16616842|NCT02502136|Experimental|CO2 in sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with sedation
16616843|NCT02502136|Placebo Comparator|Air in sedated colonoscopy|Room air insufflation during colonoscopy with sedation
16616844|NCT02502136|Experimental|CO2 in mild sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with mild sedation
16616850|NCT02502123||OnabotulinumtoxinA (BOTOX®)|Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
16616851|NCT02502110|Experimental|rosuvastatin 20mg/day|To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.
16616852|NCT02502110|No Intervention|blank control|Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.
16616853|NCT02502097|Experimental|Gefapixant>Placebo Pre-Amendment 3|Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
16616854|NCT02502097|Experimental|Placebo>Gefapixant Pre-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
16616855|NCT02502097|Experimental|Gefapixant>Placebo Post-Amendment 3|Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
16616856|NCT02502097|Experimental|Placebo>Gefapixant Post-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
16616857|NCT02502084|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
16616858|NCT02502071|Experimental|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
16616859|NCT02502045|Experimental|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days. A flexible window of has been allowed to accommodate participants and care routines.
16616860|NCT02502045|Placebo Comparator|Non-Therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
16616861|NCT02502032|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
16616862|NCT02502032|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg.
16616863|NCT02502032|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg.
16616864|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
16616865|NCT02502006|Experimental|High Dose|During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
16616866|NCT02502006|Experimental|Low dose|During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
16616867|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
16616868|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
16616869|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
16616870|NCT02501967|Experimental|COMET|The intervention consists of completion of the tool (COMET) by means of a 30 minute telephone interview prior to the primary care visit and provision of the tool's output to the patient and primary care physician. The COMET tool takes information about the patient's medications and chronic conditions from the electronic health record, and then supplements this with information obtained by a telephone interview assessing the patient's cognition, social supports, medication adherence, home medication regimen, medication side effects, and health status. In addition, there is a chart review screen to record renal function, blood pressure, and hemoglobin A1C. All of this information is run through a set of algorithms to identify medication reconciliation errors and potentially inappropriate medications.
16616871|NCT02501967|No Intervention|Usual Care|
16616872|NCT02501954|Experimental|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
16616873|NCT02501954|Active Comparator|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
16616874|NCT02501941|Experimental|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
16616875|NCT02501941|Experimental|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
16616876|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
16616877|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
16616878|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
16616879|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
16616880|NCT02501915|Experimental|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
16616881|NCT02501915|Experimental|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
16616911|NCT02501720|Experimental|Tumescent technique group|Post burn flexion contractures will be released using Tumescent solution
16616882|NCT02501902|Experimental|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
16616883|NCT02501889|Experimental|Walnut-rich weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. All participants will have contact with the project coordinator a minimum of every 1-2 weeks. Walnuts will be provided to participants in the walnut-rich study arm.
16616884|NCT02501889|Active Comparator|Standard weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Participants assigned to this arm will be instructed to abstain from the consumption of nuts during the study. All participants will have contact with the project coordinator a minimum of every 1-2 weeks.
16616885|NCT02501876||T2D-MCI|110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.
16616886|NCT02501876||nonT2D-MCI|110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.
16616887|NCT02501863|Experimental|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl
~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
16616888|NCT02501863|Experimental|Ropivacaine|"Femoral nerve block with ropivacaine
~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
16616889|NCT02501850|Experimental|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
16616890|NCT02501850|Active Comparator|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
16616891|NCT02501837|Experimental|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
16616892|NCT02501837|Placebo Comparator|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
16616893|NCT02501824|Experimental|speech therapy first|11 sessions of speech therapy (anthroposophic therapeutic speech), then waiting phase
16616894|NCT02501824|Experimental|speech therapy second|10 weeks of waiting, then 11 sessions of speech therapy (anthroposophic therapeutic speech)
16616895|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
16616896|NCT02501811|Experimental|c-kit+ cells|Target dose of 5 million c-kit+ cells
16616897|NCT02501811|Experimental|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
16616898|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
16616899|NCT02501798|Experimental|Drug: Methylphenidate|Drug: Methylphenidate 7 days dosage as (prior to study) clinically titrated long acting Equasym (brand)
16616900|NCT02501798|Active Comparator|Drug: Placebo|Drug: Placebo 7 days Empty green-yellow capsule
16616901|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
16616902|NCT02501772|Experimental|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
16616903|NCT02501772|Sham Comparator|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
16616904|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
16616905|NCT02501746|Active Comparator|Usual Clinical Care (UC)|This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension.
16616906|NCT02501746|Experimental|Usual clinical care plus microfinance groups only (MF)|Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program.
16616907|NCT02501746|Experimental|Group medical visits only (GMV)|Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
16616908|NCT02501746|Experimental|GMV integrated into GMV-MF|Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit.
16616910|NCT02501720|Active Comparator|Tourniquet Group|Post burn flexion contractures will be released under tourniquet control
16616912|NCT02501681|Active Comparator|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
16616913|NCT02501681|Active Comparator|colloid|Group B (n=20); colloids as priming solution used in patients
16616914|NCT02501668||Lung cancer in population|Lung cancer cases in sample population (670,258 cases)
16616915|NCT02501668||COPD in population|COPD cases (670,258 cases)
16616916|NCT02501668||COPD with lung cancer|Lung cancer in COPD
16616917|NCT02501668||ILD without IPF|Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
16616918|NCT02501668||ILD with lung cancer|Lung cancer cases in ILD
16616919|NCT02501668||Idiopathic pulmonary fibrosis|Idiopathic pulmonary fibrosis cases
16616920|NCT02501668||IPF with lung cancer|Lung cancer cases in IPF patients
16616921|NCT02501668||Connective tissue disorder with ILD|CTD with ILD cases
16616922|NCT02501668||CTD ILD with lung cancer|Lung cancer cases in CTD with ILD
16616923|NCT02501668||CTD without ILD|CTD with ILD cases in sample population
16616924|NCT02501668||CTD without ILD with lung cancer|Lung cancer in CTD without ILD
16616925|NCT02501655|Active Comparator|Phase 1|Jet Nebulizer - control group
16616926|NCT02501655|Experimental|Phase 2|Mesh nebulizers
16616929|NCT02501629|Experimental|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
16616930|NCT02501629|Placebo Comparator|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
16616931|NCT02501616|Active Comparator|Metformin first|"Metformin first 8 wks --> Dapagliflozin 8wks.
~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
16616932|NCT02501616|Active Comparator|Dapagliflozin first|"Dapagliflozin first 8 wks --> Metformin 8wks.
~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
16616933|NCT02501603|Experimental|afatinib plus paclitaxel|afatinib plus paclitaxel
16616934|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.
~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
16616935|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.
~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
16616936|NCT02501577|Experimental|SAD 1|FOI for placement
16616937|NCT02501577|Experimental|SAD 2|FOI für placement
16616938|NCT02501564|Experimental|Naproxen Sodium Codeine|One tablet twice a day
16616939|NCT02501564|Placebo Comparator|Placebo|One tablet twice a day
16616940|NCT02501551|Experimental|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
16616941|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
16616942|NCT02501525|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
16616943|NCT02501525|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
16616944|NCT02501499||Breastfeeding Buddies participants|Mothers that participated in Me Breastfeed workshops. Half will have been in the education-only group and half will have a buddy/peer support person in addition to the workshop.
16616945|NCT02501499||Volunteer Focus Group|Breastfeeding buddies volunteers that deliver education and support programs.
16616946|NCT02501486|Other|ACTH stimulation test|this is a single arm study. An ACTH-stimulation test will be done
16616947|NCT02501473|Experimental|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
16616948|NCT02501473|Experimental|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
16616949|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
16616950|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
16616951|NCT02501473|Experimental|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors [injectable lymphoma mass(es) ≥ 4 cm in total size] for up to 8 weeks.
16616952|NCT02501473|Experimental|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
16616953|NCT02501473|Experimental|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
16617390|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
16616954|NCT02501473|Experimental|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m^2 on Day 0 and then QW for up to 3 weeks.
16616955|NCT02501460|Active Comparator|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
16616956|NCT02501460|Placebo Comparator|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
16616957|NCT02501447|Experimental|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
16616958|NCT02501447|No Intervention|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
16616959|NCT02501434|No Intervention|Control|Standard of Care
16616960|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
16616961|NCT02501421|Active Comparator|TB/FLU-04L|Live recombinant influenza vectored tuberculosis vaccine
16616962|NCT02501421|Placebo Comparator|Placebo|Buffer
16616963|NCT02501408|Experimental|Propriofoot prosthesis|New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month
16616964|NCT02501408|No Intervention|Control|Usual prosthesis is worn for 1 month
16616965|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
16616966|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
16616967|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
16616968|NCT02501369|Experimental|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.
~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
16616969|NCT02501356|Active Comparator|ISOThrive supplement 1|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
16616970|NCT02501356|Active Comparator|ISOThrive supplement 2|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
16616971|NCT02501356|Placebo Comparator|Placebo supplement|Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
16616972|NCT02501343|Experimental|Sodium bicarbonate|High acid load meal (Western style meal) with Sodium bicarbonate (Sodibic 840mg*2)
16616973|NCT02501343|Placebo Comparator|Placebo|High acid load meal (Western style meal) with sodibic-matching placebo
16616974|NCT02501330||Bosutinib|
16616975|NCT02501317|Experimental|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
16616976|NCT02501317|Active Comparator|Kari Bo protocol|control group will be treated with the protocol already widely used
16616977|NCT02501304|Experimental|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
16616978|NCT02501291|Experimental|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
16616979|NCT02501278|Experimental|Arm A: Immunotherapy during and after CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.
16616980|NCT02501278|Experimental|Arm B: Immunotherapy during CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.
16616981|NCT02501278|Active Comparator|CRT without immunotherapy|Standard chemoradiotherapy without immunotherapy
16616982|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
16616983|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
16617049|NCT02500953|Experimental|Japanese female multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
16617489|NCT02498184|Experimental|real acupuncture|traditional chinese acupuncture
16616984|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
16616985|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
16616986|NCT02501252|Experimental|CORN Based at health post|Trained CORN based at health post will provide SBA and other RH services on demand at health post or household levels on an outreach bases.
16616987|NCT02501252|Active Comparator|CORN Based at health center|Trained CORN based at health center, but working in the community in an outreach basis will provide SBA and other RH services
16616988|NCT02501252|No Intervention|Control|will be composed of a randomly selected comparable controls clusters. Control clusters (arm) will be similar with the other two arms (groups) except for the intervention.
16616989|NCT02501239|Experimental|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
16616990|NCT02501239|Active Comparator|Behavioral Weight Loss|Weight Watchers groups
16616991|NCT02501226|Other|Control group|Treatment as usual
16616992|NCT02501226|Experimental|Interventional group|ENVIE psychoeducational program
16616993|NCT02501213|No Intervention|A : observation|Clinical monitoring and best supportive care.
16616994|NCT02501213|Active Comparator|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
16616995|NCT02501200|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
16616996|NCT02501200|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
16616997|NCT02501187|Experimental|Patients operated for ptosis by levator advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- levator advancement.
16616998|NCT02501187|Experimental|Patients operated for ptosis by white line advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- white line advancement
16616999|NCT02501187|Experimental|Patients operated for ptosis by Müller resection|patients undergoing surgical repair for aponeurotic ptosis by the procedure- Müller's muscle-conjunctival resection.
16617000|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
16617001|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
16617002|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
16617003|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
16617004|NCT02501122||Adenotonsillectomy|Measuring quality of care in patients undergoing adenotonsillectomy.
16617005|NCT02501109|Experimental|Group A|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
16617006|NCT02501109|Experimental|Group B|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
16617007|NCT02501109|Experimental|Gruop C|Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
16617008|NCT02501096|Experimental|Lenvatinib + Pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma.
16617009|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
16617010|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
16617011|NCT02501057|Active Comparator|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
16617012|NCT02501057|Active Comparator|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
16617013|NCT02501057|Experimental|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
16617014|NCT02501044||Hemodialysis Patients|
16617015|NCT02501031|Experimental|Flaxseed (ground)|
16617016|NCT02501031|No Intervention|Usual diet|
16617017|NCT02501018|Experimental|CLI Due to ASO with CLBS12 + SOC|This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
16617018|NCT02501018|Active Comparator|CLI Due to ASO with SOC|This group of subjects with CLI due to ASO will be administered with SOC only.
16617019|NCT02501018|Experimental|CLI Due to BD with CLBS12|CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.
16617020|NCT02501005|Experimental|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
16617021|NCT02501005|Other|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
16617022|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
16617023|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
16617024|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
16617025|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
16617026|NCT02500966|Experimental|DUDA device|"The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).
~Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)"
16617027|NCT02500966|Active Comparator|Control group|"The number of patients to be recruited in this arm will be 120.
~Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device"
16617028|NCT02500953|Experimental|Japanese male single fasted ASP dose-1|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617029|NCT02500953|Experimental|Japanese male single fasted ASP dose-2|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617030|NCT02500953|Experimental|Japanese male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617031|NCT02500953|Experimental|Japanese male single fasted ASP dose-4|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617032|NCT02500953|Experimental|Japanese male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617033|NCT02500953|Experimental|Japanese male single fasted ASP dose-6|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617034|NCT02500953|Experimental|Japanese male single fasted ASP dose-7|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617035|NCT02500953|Experimental|Japanese female single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617036|NCT02500953|Experimental|Japanese female single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617037|NCT02500953|Experimental|Caucasian male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617038|NCT02500953|Experimental|Caucasian male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617039|NCT02500953|Experimental|Japanese male single fed ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects after a meal.
16617040|NCT02500953|Experimental|Japanese male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617041|NCT02500953|Experimental|Japanese female single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617042|NCT02500953|Experimental|Caucasian male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
16617043|NCT02500953|Experimental|Japanese male single fed placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects after a meal.
16617044|NCT02500953|Experimental|Japanese male multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
16617045|NCT02500953|Experimental|Japanese male multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
16617046|NCT02500953|Experimental|Japanese male multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
16617047|NCT02500953|Experimental|Japanese female multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
16617048|NCT02500953|Experimental|Japanese female multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
16617490|NCT02498184|Sham Comparator|sham acupuncture|non effective acupuncture
16617050|NCT02500953|Experimental|Japanese male multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
16617051|NCT02500953|Experimental|Japanese female multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
16617052|NCT02500953|Experimental|Japanese male ASP dose-5 before a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
16617053|NCT02500953|Experimental|Japanese male ASP dose-5 during a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
16617054|NCT02500953|Experimental|Japanese male ASP dose-5 after a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
16617055|NCT02500940|Experimental|Control group|Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
16617056|NCT02500940|Active Comparator|Test group|Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
16617057|NCT02500927|Experimental|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
16617058|NCT02500914|Experimental|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.
~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
16617059|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
16617060|NCT02500888|Experimental|Treatment|Radiosurgery by linear accelerator.
16617061|NCT02500875|Experimental|PTNiA|"Topical negative pressure therapy with instillation of saline solution (6 times daily).
~During the instillation of saline solution, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.
~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
16617062|NCT02500875|Experimental|PTNiB|"Topical negative pressure therapy with instillation of Amukine Med 0,05% (6 times daily).
~During the instillation of Amukine Med 0,05%, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.
~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
16617063|NCT02500875|Active Comparator|PTN|"Topical negative pressure therapy (without instillation). The device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.
~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
16617064|NCT02500849|Experimental|Cohort 1:|target busulfan AUC levels: 8,000 µM*min (+/- 1,000)
16617065|NCT02500849|Experimental|Cohort 2:|busulfan AUC levels: 12,000 µM*min (+/- 1,000)
16617066|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
16617067|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
16617068|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
16617069|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
16617070|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
16617071|NCT02500810|Experimental|monosialoganglioside|patients receive monosialoganglioside.
16617072|NCT02500810|No Intervention|control|blank control
16617073|NCT02500797|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
16617074|NCT02500797|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
16617075|NCT02500784|Active Comparator|Formoterol A|12 months, formoterol, 20microgram/2ml, inhaler, BID
16617076|NCT02500784|Placebo Comparator|Formoterol B|12 months, normal saline, 2ml, inhaler, BID
16617077|NCT02500771|Experimental|children and tutors using V-Motive|"The following intervention will be administered:
~ABA therapy enhanced with V-Motive software
~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
16617078|NCT02500758|Experimental|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
16617079|NCT02500758|Active Comparator|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
16617080|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
16617081|NCT02500732|Placebo Comparator|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
16617082|NCT02500732|Active Comparator|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
16617083|NCT02500719|Experimental|Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
16617084|NCT02500719|Experimental|PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
16617085|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
16617086|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
16617087|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
16617088|NCT02500693|Experimental|Screening|
16617089|NCT02500680|Experimental|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 1µg (Standard Dose) Single Dose
16617090|NCT02500680|Experimental|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 3µg (Standard Dose) Single Dose
16617091|NCT02500680|Experimental|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 5µg (Standard Dose) Single Dose
16617092|NCT02500680|Experimental|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg (Standard Dose) Single Dose
16617093|NCT02500680|Active Comparator|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
16617094|NCT02500680|Active Comparator|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
16617095|NCT02500680|Experimental|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
16617096|NCT02500680|Experimental|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
16617097|NCT02500680|Active Comparator|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
16617098|NCT02500680|Experimental|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose (as 2 x 0.25 mL in each arm)
16617099|NCT02500680|Active Comparator|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose (0.5 mL) in one arm and 0.5 mL of PBS in the other arm
16617100|NCT02500667|Experimental|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
16617101|NCT02500654|Experimental|Surgery and Emdogain®|access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline
16617102|NCT02500654|Placebo Comparator|Surgery alone|access peri-implant surgery and cleaning of implant surface with saline
16617103|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.
~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
16617163|NCT02500238||Vaping|This group will provide 2 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
16617104|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.
~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
16617105|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
16617106|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
16617107|NCT02500615|Experimental|0 PG: 100 VG|
16617108|NCT02500615|Experimental|30 PG: 70 VG|
16617109|NCT02500615|Experimental|50 PG: 50 VG|
16617110|NCT02500615|Experimental|70 PG: 30 VG|
16617111|NCT02500615|Experimental|100 PG: 0 VG|
16617112|NCT02500602|Experimental|Doxazosin|Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
16617113|NCT02500602|Placebo Comparator|Placebo|Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
16617114|NCT02500589|Experimental|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
16617115|NCT02500589|Other|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
16617116|NCT02500576|Experimental|Arm I (pembrolizumab, high-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide IV over 2 hours on days -7 and -6 followed by fludarabine phosphate IVPB over 15-30 minutes on days -5 to -1. Patients also receive therapeutic tumor infiltrating lymphocytes IV over 15-60 minutes on day 0 followed by high-dose aldesleukin IV over 15 minutes every 8-16 hours for up to 15 doses on days 1-5. Beginning between 21-28 days after TIL infusion, patients receive maintenance therapy comprising pembrolizumab IV over 30 minutes every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16617117|NCT02500576|Experimental|Arm II (pembrolizumab, low-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide and fludarabine phosphate and therapeutic tumor infiltrating lymphocytes as in Arm I, followed approximately 6 hours later by low-dose aldesleukin SC for 14 days. Patients also receive pembrolizumab as in Arm I.
16617118|NCT02500563|Active Comparator|Amino acid based infant formula|
16617119|NCT02500563|Experimental|Extensively hydrolyzed casein infant formula|
16617120|NCT02500563|Other|Mother's own breast milk|
16617121|NCT02500550|Experimental|ATIR101|
16617122|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.
~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
16617123|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.
~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
16617124|NCT02500524|Experimental|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
16617125|NCT02500524|Active Comparator|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
16617126|NCT02500485|Experimental|SHR3824 20mg/SP2086 100mg|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
16617127|NCT02500472|Experimental|Kava Supplement|See intervention description.
16617128|NCT02500459|Experimental|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
16617129|NCT02500446|Active Comparator|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
16617130|NCT02500446|Placebo Comparator|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
16617131|NCT02500433|Experimental|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
16617164|NCT02500225|Active Comparator|Etomidate|0.2 mg/kg etomidate during anesthesia induction
16617165|NCT02500225|Active Comparator|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
16617132|NCT02500433|Other|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.
~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
16617133|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).
~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
16617134|NCT02500407|Experimental|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
16617135|NCT02500407|Experimental|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) as a single-agent or in combination with atezolizumab.
16617136|NCT02500394|Placebo Comparator|standard care|Patients in the standard care population receive - if biomarkers are elevated -treatment of AKI in accordance with KDIGO 2012 guidelines
16617137|NCT02500394|Active Comparator|interventional care|Patients in the interventional population receive - if biomarkers are elevated - individualized treatment/volume substitution (balanced electrolyte solution = Ionosteril; 1,25-5 ml/kg/bw/6 hours) ) on the basis of predefined criteria
16617138|NCT02500381|Experimental|SRP-4045|Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
16617139|NCT02500381|Experimental|SRP-4053|Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
16617140|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
16617141|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
16617142|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
16617143|NCT02500355|Active Comparator|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
16617144|NCT02500355|Active Comparator|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
16617145|NCT02500355|Placebo Comparator|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
16617146|NCT02500342|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
16617147|NCT02500342|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
16617148|NCT02500329|Experimental|gemigliptin|gemigliptin for 4 weeks
16617149|NCT02500329|Active Comparator|acarbose|acarbose for 4 weeks
16617150|NCT02500316|Experimental|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
16617151|NCT02500290||Acute coronary syndrome|
16617152|NCT02500277|Active Comparator|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
16617153|NCT02500277|Active Comparator|Forceps biopsy|Pleural biopsy with a flexible forceps
16617154|NCT02500264|Active Comparator|Protocol #1|interventions: 1.6Hz, Rampdown 0.4S, electrodes position - both L.Rectus Abdominis, 5cmX5cm Size, on inspirium
16617155|NCT02500264|Active Comparator|Protocol #2|1Hz, Rampdown 0.6S, electrodes position - both Rectus Abdominis, 5cmX5cm Size, on inspirium
16617156|NCT02500264|Active Comparator|Protocol #3|1.6Hz, Rampdown 0.4S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium Oblique
16617157|NCT02500264|Active Comparator|Protocol #4|1Hz, Rampdown 0.6S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium
16617158|NCT02500251|Experimental|Group A (5 subjects)|Subjects will receive bortezomib and plasmapheresis.
16617159|NCT02500251|Experimental|Group B (5 subjects)|Subjects will receive belimumab, bortezomib, and plasmapheresis.
16617160|NCT02500251|Experimental|Group C (5 subjects)|Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.
16617161|NCT02500238||Control|This group will provide 2 breath carbon monoxide (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings will be taken from this group.
16617162|NCT02500238||Smoking|This group will provide 1 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
16617166|NCT02500212|Experimental|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.
~Envarsus® tablets will be administered orally once daily in the morning"
16617167|NCT02500212|Active Comparator|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.
~Advagraf® capsules will be administered orally once daily in the morning"
16617168|NCT02500199|Experimental|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
16617169|NCT02500186|Experimental|High GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.
16617170|NCT02500186|Experimental|Low GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet
16617171|NCT02500186|Experimental|High GI meal containing 40% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.
16617172|NCT02500160|Experimental|patient specific instrumentation (MRI)|MRI based patient-specific instrumentation
16617173|NCT02500160|Active Comparator|patient specific instrumentation (CT)|CT based patient-specific instrumentation
16617174|NCT02500147|Experimental|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
16617175|NCT02500147|Placebo Comparator|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
16617176|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
16617177|NCT02500121|Placebo Comparator|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
16617178|NCT02500121|Experimental|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
16617179|NCT02500108||Treated with domperidone|Patients who received a new prescription for domperidone (ATC A03FA03) in the year prior to the index date.
16617180|NCT02500108||Unexposed (reference) group|Patients with no prescription for domperidone in the year prior to the index date.
16617181|NCT02500095|No Intervention|Control|12 hours of fasting
16617182|NCT02500095|Experimental|Fasting and saline|72 hours of fasting and concomitant saline
16617183|NCT02500095|Experimental|Fasting and GHR blockade|72 hours of fasting and concomitant Growth hormone receptor (GHR) blockade with Pegvisomant (Somavert) for inhibition of the fasting-induced GH secretion
16617184|NCT02500069|Placebo Comparator|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
16617185|NCT02500069|Experimental|Duodenum|Infusion of casein in duodenum
16617186|NCT02500069|Experimental|Jejunum|Infusion of casein in jejunum
16617187|NCT02500069|Experimental|Ileum|Infusion of casein in ileum
16617188|NCT02500056|Active Comparator|OM group|Optilene LP mesh
16617189|NCT02500056|Active Comparator|UM group|Ultrapro mesh
16617190|NCT02500043|Experimental|TAS-102+BSC|Participants received 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
16617191|NCT02500043|Experimental|Placebo+BSC|Participants received 35 mg/m^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
16617192|NCT02500030|Experimental|Air Stacking|Air Stacking was performed with the subject seated in his wheelchair using a manual resuscitation bag (LIFESAVER® model 5345, Hudson, Temecula, USA) connected to a corrugated tube with an internal diameter of 22 mm, a one-way valve and a pipette. The maximum capacity of the bag was 1600 mL. A chest physiotherapist insufflated the patient during the inspiratory phase, requesting that inspire as much air as possible
16617193|NCT02500030|Experimental|Glossopharyngeal Breathing|"Glossopharyngeal Breathing was also performed with the subject seated in his wheelchair and performing successive maneuvers of swallowing air until the maximum volume achieve was maintained. Then, the patient was instructed to breathe through ventilometer to register the MIC. Three measurements for each of the techniques were performed, and the highest reading was recorded. A difference of <10% between the measurements was used as the repeatability criterion"
16617194|NCT02500017|Experimental|Melatonin|A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
16617195|NCT02500017|Placebo Comparator|Placebo|Matching placebo capsules to be administered once a day for a total of 8 weeks
16617196|NCT02500004|Active Comparator|Cachectic pancreatic cancer|"Cachectic patients with pancreatic cancer
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
16617228|NCT02499796|Experimental|Single Arm|"Every patient receives 20 minutes of invasive mechanical ventilation with each of the three humidification systems in random sequence:
~Heated and moisture exchanger (HME)
~Heated humidifier (HH)
~Hygrovent Gold"
16617197|NCT02500004|Active Comparator|Cachectic NSCLC|"Cachectic patients with non-small cell lung cancer
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
16617198|NCT02500004|Active Comparator|Cachectic COPD|"Cachectic COPD patients.
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
16617199|NCT02500004|Active Comparator|Non-cachectic COPD|"Non-cachectic COPD patients.
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
16617200|NCT02500004|Other|Healthy individuals|"BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
16617201|NCT02499991|Experimental|Treatment|"Treatment group will keep diary of social events according to training instructions.
~Memory intervention will be used."
16617202|NCT02499991|No Intervention|Control|Control group will use own memory of social events without training instructions.
16617203|NCT02499978|Experimental|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
16617204|NCT02499978|Active Comparator|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
16617205|NCT02499965|Active Comparator|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
16617206|NCT02499965|Placebo Comparator|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
16617207|NCT02499952|Experimental|Experimental Arm|Pembrolizumab
16617208|NCT02499939|Active Comparator|Standard Care|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home.
16617209|NCT02499939|Experimental|Experimental: Ultrasound Therapy|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
16617210|NCT02499926|Experimental|Dietary supplement: Arginine|Graded arginine excess intake
16617211|NCT02499913|Active Comparator|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
16617212|NCT02499913|Experimental|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
16617213|NCT02499900|Experimental|Copaxone® 40 mg/mL|Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
16617214|NCT02499900|Active Comparator|Copaxone® 20 mg/mL|Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
16617215|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)
~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
16617216|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days
~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
16617217|NCT02499874|Experimental|Single treatment arm|All subjects will be administered oral Efavirenz 400mg together with the rest of the oral antiretroviral combination (tenofovir 245 mg/emtricitabine 200mg or tenofovir 245mg/lamivudine 300mg or lamivudine 300mg/zidovudine 600mg) throughout the study period
16617218|NCT02499861|Experimental|Decitabine and Genistein|continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
16617219|NCT02499848|Experimental|Intraprostatic administration|PRX302
16617220|NCT02499835|Experimental|Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
16617221|NCT02499835|Experimental|Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
16617222|NCT02499835|Experimental|Extended Treatment Arm III|pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
16617223|NCT02499835|Experimental|Extended Treatment Arm IV|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
16617224|NCT02499822|Experimental|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
16617225|NCT02499822|Experimental|Ramipril 10 mg|Ramipril 10 mg in tablets.
16617226|NCT02499809|Experimental|Passive|Passive recovery
16617227|NCT02499809|Experimental|Vibration|Vibration recovery
16617229|NCT02499783|Experimental|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.
~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
16617230|NCT02499783|Experimental|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.
~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
16617231|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
16617232|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
16617233|NCT02499757|Experimental|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
16617234|NCT02499757|Experimental|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
16617235|NCT02499757|Experimental|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
16617236|NCT02499757|Experimental|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
16617237|NCT02499744|Active Comparator|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
16617238|NCT02499744|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
16617239|NCT02499731|Experimental|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
16617240|NCT02499731|Experimental|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
16617241|NCT02499718|Experimental|Noninvasive ventilator|noninvasive positive pressure ventilation combined with long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
16617242|NCT02499718|No Intervention|LTOT|long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
16617243|NCT02499705|Experimental|Sucralose|Flavored beverage with sucralose.
16617244|NCT02499705|Experimental|Sucrose|Flavored beverage with sucrose.
16617245|NCT02499705|Experimental|Sucralose + maltodextrin|Flavored beverage with Splenda + maltodextrin .
16617246|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
16617247|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
16617248|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
16617249|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
16617250|NCT02499653|Experimental|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
16617251|NCT02499653|Active Comparator|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
16617252|NCT02499640|No Intervention|GC|Control group - CG (n = 20), which suffered no recuperative technique
16617253|NCT02499640|Experimental|G1|G1 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
16617254|NCT02499640|Experimental|G2|G2 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
16617255|NCT02499640|Experimental|G3|G3 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
16617256|NCT02499640|Experimental|G4|G4 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
16617257|NCT02499627|Experimental|Bendamustine + Brentuximab for 6 cycles|Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
16617258|NCT02499614|Experimental|Patients with MET amplification or MET exon 14 mutation|Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
16617259|NCT02499614|Experimental|Patients with ROS1 translocation|Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
16617260|NCT02499601|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
16617261|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
16617262|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
16617263|NCT02499562|Experimental|Hydronidone(180mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.
~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
16617264|NCT02499562|Experimental|Hydronidone(270mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.
~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
16617265|NCT02499562|Experimental|Hydronidone(360mg) & Entecavir|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.
~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
16617266|NCT02499562|Experimental|Entecavir & Placebo(360mg)|placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
16617267|NCT02499549|Experimental|10% Cocamide diethanolamine 8 hours|Cocamide DEA topical lotion applied 8 hours/overnight with drying
16617268|NCT02499549|Experimental|10% Cocamide diethanolamine 2 hours|Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days
16617269|NCT02499536|Experimental|Study participants|After general anesthesia development of the atelectasis will be investigated by the lung ultrasound
16617270|NCT02499523|Active Comparator|THR with conventional technique|Use of conventional technique in THR
16617271|NCT02499523|Experimental|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
16617272|NCT02499510|Experimental|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
16617273|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
16617274|NCT02499497|Active Comparator|LY2452473 Dose 1|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
16617275|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
16617276|NCT02499497|Active Comparator|LY2452473 Dose 3|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
16617277|NCT02499484|Active Comparator|GTN and eccentric exercises|Participants will complete a 12 week eccentric exercise program and use 0.5cm of glyceryl trinitrate ointment daily for 24 weeks
16617278|NCT02499484|Placebo Comparator|Placebo and eccentric exercises|Participants will use a placebo ointment with no active ingredient for 24 weeks and complete an eccentric exercise program for 12 weeks
16617279|NCT02499471|Other|Before levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure 6.8 ± 2.8 weeks after thyroidectomy, when plasma free T4-levels were at the minimum, before daily levothyroxine therapy 137.75 ± 25.75 μg.
16617280|NCT02499471|Other|After levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure four to six months after the initial measurements, after daily levothyroxine therapy 137.75 μg (fT4 levels 23.1 ± 3.9 pmol/L, TSH 0.5 ± 0.6 mU/L)
16617281|NCT02499445|Active Comparator|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
16617282|NCT02499445|Active Comparator|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
16617283|NCT02499445|Active Comparator|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
16617284|NCT02499432|Experimental|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
16617285|NCT02499432|No Intervention|Standard training|Training as usual
16617286|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
16617287|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter > 40 mm Atrial fibrillation Age ≥ 50
16617288|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
16617289|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF < 50% MR ≥ moderate
16617290|NCT02499406|Other|Skills group|Dialectical behavior therapy skills group
16617328|NCT02499224|Experimental|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
16617291|NCT02499393|Experimental|TH+MgSO4|Therapeutic hypothermia plus magnesium sulphate intravenous infusion Neonates who were randomized to the study group (TH+MgSO4) received three 250 mg/kg doses of magnesium sulfate given as one - hour continuous infusion spaced 24 hours apart on three consecutive days. 20% Magnesium Sulfuricum (Polpharma), 2 g /10 ml were used.
16617292|NCT02499393|No Intervention|TH- therapeutic hypothermia|therapeutic hypothermia without magnesium sulphate
16617293|NCT02499380||Treatment|Patients treated with PneumRx Coil System
16617294|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
16617295|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
16617296|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
16617297|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
16617298|NCT02499367|Active Comparator|No induction treatment|
16617299|NCT02499354|Active Comparator|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
16617300|NCT02499354|Active Comparator|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
16617301|NCT02499341|Active Comparator|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
16617302|NCT02499341|Active Comparator|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
16617303|NCT02499328|Experimental|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
16617304|NCT02499328|Experimental|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
16617305|NCT02499328|Experimental|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
16617306|NCT02499328|Experimental|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
16617307|NCT02499328|Experimental|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
16617308|NCT02499328|Experimental|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
16617309|NCT02499328|Experimental|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
16617310|NCT02499328|Experimental|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
16617311|NCT02499328|Experimental|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
16617312|NCT02499328|Experimental|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
16617313|NCT02499328|Experimental|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
16617314|NCT02499328|Experimental|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
16617315|NCT02499328|Experimental|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
16617316|NCT02499328|Experimental|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
16617317|NCT02499328|Experimental|Part B8: AZD9150 (every other week)+MEDI4736: naive 1L|Patients in Arm B8 will be evaluated for efficacy until disease progression and then followed up for safety and survival
16617318|NCT02499315|Experimental|AMG 357|
16617319|NCT02499315|Placebo Comparator|Placebo|
16617320|NCT02499302|Experimental|Mental training|"The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:
~Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale
~Relaxation: Bodily stress reduction, mindfulness
~Visualization: Contact with positive emotions, techniques of worrying reduction
~Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'
~Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis"
16617321|NCT02499302|No Intervention|Routine follow-up|Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.
16617322|NCT02499276|Experimental|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
16617323|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
16617324|NCT02499250|Experimental|RIPC arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
16617325|NCT02499250|Active Comparator|Control arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
16617326|NCT02499237|Active Comparator|Denosumab|Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
16617327|NCT02499237|Experimental|Denosumab plus zoledronic acid|Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
16617329|NCT02499211|Experimental|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
16617330|NCT02499211|No Intervention|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
16617331|NCT02499185|Experimental|Nephro Check Test|We take urine samples and analyse the level of [TIMP-2]●[IGFBP-7] using the NephroCheck Test to diagnose AKI
16617332|NCT02499185|Active Comparator|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
16617333|NCT02499172|Experimental|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
16617334|NCT02499172|No Intervention|Cohort 2|Cohort 2: Women who received at least one dose and who became pregnant after the mass vaccination campaign; hence their fetuses were not exposed to the vaccine.
16617335|NCT02499172|No Intervention|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
16617336|NCT02499172|No Intervention|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
16617337|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
16617338|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
16617339|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
16617340|NCT02499133|Other|adult who suffered traumatic brain injury|
16617341|NCT02499133|Other|control group|
16617342|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
16617343|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
16617344|NCT02499107|Experimental|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
16617345|NCT02499107|Experimental|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
16617346|NCT02499107|Experimental|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
16617347|NCT02499107|Experimental|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
16617348|NCT02499107|Experimental|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
16617349|NCT02499094|Experimental|Intervention A- Heuristic based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as simple heuristic-based behavioral measures
16617350|NCT02499094|Experimental|Intervention B- Machine Learning Based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as machine learning model-based behavioral measures
16617351|NCT02499094|No Intervention|Control|No intervention
16617352|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
16617353|NCT02499068|Experimental|COPD, Telehealth|Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
16617354|NCT02499068|No Intervention|COPD, Normal clinical practice|Patients would do the usual clinical practice.
16617355|NCT02499055|Experimental|FearFighter|The experimental group will use the program FearFighter™.
16617356|NCT02499055|No Intervention|Control group|The control group receive no intervention for nine weeks.
16617357|NCT02499042|Experimental|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
16617358|NCT02499042|Active Comparator|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
16617359|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
16617360|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
16617361|NCT02499016|Experimental|suprapubic single-incision laparoscopic appendectomy|single incision laparoscopic surgery will be performed for patients in this group.
16617362|NCT02499016|Active Comparator|conventional multiport appendectomy|Conventional laparoscopic surgery will be performed for patients in this group.
16617363|NCT02499003|Experimental|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
16617364|NCT02498990|Experimental|Weight reduction|
16617365|NCT02498977|Active Comparator|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
16618110|NCT02494024|Experimental|Single dose C2N-8E12 level 4|Single IV infusion of C2N-8E12
16617366|NCT02498977|Active Comparator|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
16617367|NCT02498977|Active Comparator|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
16617368|NCT02498951|Experimental|Arm I (obinutuzumab)|Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity
16617369|NCT02498951|Active Comparator|Arm II (observation)|Patients undergo observation for a total of 2 years.
16617370|NCT02498938||SERPINA1 gene in COPD and periodontitis|patients aged between 30-70 yrs with COPD (satisfying Gold's criteria) and chronic periodontitis (>4mm pocket probing depth)
16617371|NCT02498925|Experimental|Behavioral Activation|"12 weeks (1 50-min session per week) of Behavioral Activation for the anhedonic adolescents.
~Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral strategies to improve mood and places little emphasis on cognitive restructuring techniques."
16617372|NCT02498912|Experimental|Cyclophosphamide followed by Autologous T Cells|Cohorts of 3-6 pts will be infused with escalating doses of modified T cells to establish the MTD of modified T cells. There are 5 planned dose levels: 3 x 10^5, 1 x 10^6, 3 x 10^6, & 1 x 10^7 & 3 x 10^7 4H11-28z/fIL-12/EGFRt+ T cells/kg. Cohort I-IV & VI will be treated escalating dose levels. Once the MTD of T cells is established, the next cohort will receive lymphodepleting cyclophosphamide dose of 750 mg/m^2 or a regimen of cyclophosphamide dose 300 mg/m2 x 3 days concurrent with fludarabine dose 25-30 mg/m2 x 3 days 2-7 days prior to starting the T cell infusion at one dose level below the MTD. If MTD isn't established after Cohort IV, Cohort V will receive conditioning chemotherapy 2-7 days prior to starting the T cell infusion at the same dose as Cohort III. Pts in Cohort V received cyclophosphamide chemotherapy on Day 1 or cyclophosphamide concurrent with fludarabine on Day 1-3, followed 2 to 4 days later by T cell infusion. This cohort is closed to further accrual.
16617373|NCT02498899|Experimental|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
16617374|NCT02498899|Experimental|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
16617375|NCT02498886|Experimental|Iron deficient anaemic: IDA|"Iron deficient anaemic women.
~Interventions: two iron supplements will be used:
~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.
~Each compound will be labelled with a stable isotope of iron:
~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.
~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
16617376|NCT02498886|Experimental|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.
~Interventions: two iron supplements will be used:
~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.
~Each compound will be labelled with a stable isotope of iron:
~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.
~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
16617377|NCT02498886|Experimental|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.
~Interventions: two iron supplements will be used:
~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.
~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.
~Each compound will be labelled with a stable isotope of iron:
~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.
~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
16617378|NCT02498873|Active Comparator|Linear Periodization|Linear Periodization Running (Crossover Design)
16617379|NCT02498873|Active Comparator|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
16617380|NCT02498860|Experimental|Pemebit plus Cisplatin|Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles
16617381|NCT02498847|Experimental|ENGAGE intervention|8 in-person weekly treatment sessions with an occupational therapist of 30 minutes - 1 hour duration intervention content provided on website, homework assigned each week after intervention period, monthly calls conducted to check on health status
16617382|NCT02498847|No Intervention|Usual Care|participated in usual care and received monthly calls to check on health status
16617383|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
16617384|NCT02498834|No Intervention|Control group|Standard of care will be used
16617385|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
16617386|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
16617387|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
16617388|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
16617389|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
16617391|NCT02498795|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.
~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
16617392|NCT02498795|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.
~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
16617393|NCT02498795|Placebo Comparator|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
16617394|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 2 weeks|1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)
16617395|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 4 weeks|1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)
16617396|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 8 weeks|1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)
16617397|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 2 weeks|1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)
16617398|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 4 weeks|1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)
16617399|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 8 weeks|1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)
16617400|NCT02498782|Placebo Comparator|Placebo|Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.
16617401|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
16617402|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
16617403|NCT02498756|Experimental|IP plus CIK|Patients receive ipilimumab and CIK.
16617404|NCT02498756|Active Comparator|IP alone|Patients receive ipilimumab alone.
16617405|NCT02498743|Experimental|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
16617406|NCT02498743|No Intervention|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
16617407|NCT02498730|Active Comparator|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
16617408|NCT02498730|Active Comparator|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
16617409|NCT02498730|Sham Comparator|Control|Only Dependent Variables Measures
16617410|NCT02498717|Active Comparator|RICE (control)|Standard of Care procedures including ice and elevation.
16617411|NCT02498717|Experimental|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
16617412|NCT02498704|Sham Comparator|Sham Needling intervention, Control|Sham dry needling, group does not receive true dry needling intervention.
16617413|NCT02498704|Experimental|Dry Needling Intervention, experimental|Group receives true dry needling intervention.
16617414|NCT02498691|Experimental|Type exposed|endometriosis
16617415|NCT02498691|Experimental|Type unexposed|Without endometriosis
16617416|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
16617417|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
16617418|NCT02498665|Experimental|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
16617419|NCT02498665|Experimental|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
16617420|NCT02498665|Experimental|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
16617421|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
16617422|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
16617423|NCT02498639|Active Comparator|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
16617424|NCT02498639|Active Comparator|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
16617425|NCT02498626||venous saturations|venous saturations from the central venous line, venous side of the heart lung machine and from the pulmonary artery
16617427|NCT02498600|Active Comparator|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
16617428|NCT02498600|Experimental|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
16617429|NCT02498574|Experimental|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
16617430|NCT02498574|Placebo Comparator|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
16617431|NCT02498561|Active Comparator|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
16617432|NCT02498561|Placebo Comparator|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
16617433|NCT02498561|Active Comparator|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
16617434|NCT02498561|Placebo Comparator|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
16617435|NCT02498548|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
16617436|NCT02498548|No Intervention|Unexercised SCI Knee or Hip|"Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. This group will serve as unexercised control for the Trained SCI Knee group or trained SCI Hip group"
16617437|NCT02498548|Experimental|Trained SCI Knee or Trained SCI Hip|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will specifically focus on rehabilitation of the knee joint or the hip joint.
16617438|NCT02498535|Experimental|Nitric oxide gas at 160 ppm|Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
16617439|NCT02498535|Placebo Comparator|Breathing 20.3% oxygen|Breathing 20.3% oxygen inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days.. 100% nitrogen will be injected into the breathing circuit (instead of 99.5% nitrogen and 0.5% NO).
16617440|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
16617441|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
16617442|NCT02498509|Experimental|Treatment|CKD-342
16617443|NCT02498509|Active Comparator|Control 1|Mometasone furoate
16617444|NCT02498509|Active Comparator|Control 2|Levocabastine HCL
16617445|NCT02498496|Experimental|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
16617446|NCT02498496|Placebo Comparator|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
16617447|NCT02498483|Experimental|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
16617448|NCT02498483|No Intervention|Non-treatment Arm|Routine circumcision without acetaminophen.
16617449|NCT02498457|Active Comparator|low calcium dialysis|patients in this group will be dialyzed using a dialysate with a calcium concentration 1.25mmol/L.
16617450|NCT02498457|Other|Routine dialysis|Patients in this groups will be dialyzed using routine dialysate with a calcium concentration 1.5mmol/L.
16617451|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
16617452|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
16617453|NCT02498431|Experimental|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
16617454|NCT02498431|Active Comparator|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
16617455|NCT02498431|Active Comparator|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
16617456|NCT02498418|Experimental|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
16617457|NCT02498418|Active Comparator|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
16617458|NCT02498418|Placebo Comparator|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
16617459|NCT02498392|Placebo Comparator|Responders-Placebo|Participants who responded in the placebo lead-in period will be administered with Matching Placebo orally.
16617460|NCT02498392|Experimental|Responders-JNJ-42165279|Participants who responded in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 milligrams (mg) tablets once daily for 6 weeks.
16617461|NCT02498392|Placebo Comparator|Non Responders-Placebo|Participants who did not respond in the placebo lead-in period will be administered with Matching Placebo orally.
16617462|NCT02498392|Experimental|Non Responders-JNJ-42165279|Participants who did not respond in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 mg tablets once daily for 6 weeks.
16617463|NCT02498379|Experimental|Cu[64]-25%CANF-Comb|Single IV injection of 4-8 mCi Cu[64]-25%CANF-Comb followed by PET-CT scan at 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours post injection.
16617464|NCT02498366|Experimental|experimental protocol|50 healthy, male, trained and aged 18-30 will be recruited and asked to undergo a series of physical tests.
16617465|NCT02498353|Experimental|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.
~TME surgery after radiotherapy."
16617466|NCT02498353|Active Comparator|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.
~TME surgery after radiotherapy."
16617467|NCT02498340|Experimental|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
16617468|NCT02498327|Placebo Comparator|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
16617469|NCT02498327|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
16617470|NCT02498314|Experimental|Grade I-II SZ mobilization|Grade I-IISZ hip traction in resting position
16617471|NCT02498314|Experimental|Grade II TZ mobilization|Grade IITZ hip traction in resting position
16617472|NCT02498314|Experimental|Grade III mobilization|Grade III hip traction in resting position
16617473|NCT02498301|Experimental|Rifaximin 550 mg once/day|rifaximin, 550 mg, once daily, by mouth
16617474|NCT02498301|Experimental|Rifaximin 550 mg twice/day|rifaximin, 550 mg, twice daily, by mouth
16617475|NCT02498301|Placebo Comparator|Placebo|Placebo pills, twice daily, by mouth
16617476|NCT02498288|Experimental|Isotretinoin Arm|All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
16617477|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
16617478|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
16617479|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
16617480|NCT02498262|Experimental|Virtual Reality Training System|
16617481|NCT02498249|Experimental|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.
~Individuals will be subject to application of low level laser with a total dose of 18 J"
16617482|NCT02498249|Placebo Comparator|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.
~Individuals will be subject to application of low level laser with a total dose of 0 J"
16617483|NCT02498236|Experimental|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
16617484|NCT02498236|Placebo Comparator|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
16617485|NCT02498223|Experimental|research arm|50 subjects (healthy soldiers, male and female) from combat units will undergo the experiment protocol.
16617486|NCT02498210|Experimental|IVF after IVM|"If the patients will not concive during the IVM cycle . results of this following IVF cycle will be compared to the initial IVF preformance
~Intervention : In Vitro Maturation Procedure"
16617487|NCT02498197|Experimental|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
16617488|NCT02498197|Active Comparator|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
16617491|NCT02498171|Experimental|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
16617492|NCT02498171|Active Comparator|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
16617493|NCT02498158||experimental protocol|Functional neural connectivity at rest of 3 groups (heat tolerant, heat intolerant and healthy subjects) will be assessed using the anatomical and functional MRI scans and compared.
16617494|NCT02498145|Experimental|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
16617495|NCT02498145|Active Comparator|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
16617496|NCT02498132|Experimental|Behavioral Activation|Behavioral Activation will be administered via Moodivate will mirror the core BA components outlined above. Moodivate will also be modified for a mobile environment in key ways, with the most salient being: 1) Elimination of the need for a therapist: By eliminating the need for a therapist, we will be able to reach a broad patient/consumer base that may not utilize traditional therapy resources and will combat the primary barrier to PCPs recommending psychotherapy to their patients with elevated depressive symptoms and 2) Elimination of paper forms: By eliminating paper forms, we will increase the sensitivity of BA to motivational and organizational deficits frequently observed in patients with elevated depressive symptoms while also increasing treatment fidelity by prompting the patient to complete activities at scheduled times and giving the patient reinforcement for completing activities.
16617497|NCT02498132|Active Comparator|Cognitive Based Therapy|Moodkit will be used to administer cognitive based therapy which is commonly compared to behavioral activation.
16617498|NCT02498132|Active Comparator|Treatment as Usual|TAU will be provided to individuals. These subject will be provided with therapy but will not utilize a mobile application.
16617499|NCT02498119||Normal|Patient sample within the normal range of blood results.
16617500|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
16617501|NCT02498106|Active Comparator|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
16617502|NCT02498106|Placebo Comparator|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
16617503|NCT02498093|Experimental|Maximal strength training|Maximal strength training supervised by a physiotherapist
16617504|NCT02498093|Active Comparator|Control|Conventional rehabilitation supervised by a physiotherapist
16617505|NCT02498080|Experimental|DEB PTA|Devices: paclitaxel drug eluting balloon PTA
16617506|NCT02498080|Active Comparator|standard PTA|devices: standard balloon PTA
16617507|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
16617508|NCT02498054|Experimental|Education with new meter feature.|Subjects experience a computer stimulation of a new meter feature ( colour range indicator) to help subjects interpret whether blood glucose results are low, in-range or high based on accepted guidance.
16617509|NCT02498041|Experimental|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
16617510|NCT02498041|Active Comparator|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
16617511|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
16617512|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
16617513|NCT02498015|Experimental|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
16617514|NCT02498015|Experimental|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
16617515|NCT02498002|Active Comparator|Daily Calorie Restriction (DCR)|During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis.
16617516|NCT02498002|Experimental|Fasting with Weight Loss (IMF-WL)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake).
16617517|NCT02498002|Experimental|Fasting without Weight Loss (IMF-WS)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake).
16617518|NCT02497989|Experimental|Inter-personal Communication (IPC)|Interpersonal communication will entail delivery of intervention massages that are custom-made to address individual participants' specific barriers and facilitators of VMMC. RAs will discuss with uncircumcised men why they have not gone for VMMC using the 'VMMC Demand Creation Toolkit'. The aim will be to fully address their barriers and re-enforce their facilitators. RAS will be trained behavioral counselors, circumcised men, female partners, CHWs, or any other cadre of individuals identified during the formative phase.
16617547|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
16617548|NCT02497768|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (pistachios or Brazils) on two separate visit days.
16617549|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
16617519|NCT02497989|Experimental|Dedicated Service Outlets (DSO)|RAs shall visit all households with eligible men to inform them about the availability of, and give information on location of DSO sites in the Location. DSOs are sites: where services are offered exclusively to men aged ≥25 years by male service providers in the same age bracket; providing services in the evenings/weekends/designated days of the week, and through special mobile services for older men. DSO sites we will strive to shorten the waiting time to ≤ three hours. They will be informed that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do.
16617520|NCT02497989|Experimental|Combined IPC & DSO|Both Inter-personal Communication (IPC) and Dedicated Service Outlets (DSO) interventions (as described above) will be implemented concurrently. This will be done to determine the effect of both interventions delivered jointly compared to each delivered singly, and compared to no intervention.
16617521|NCT02497989|No Intervention|Control|In these Locations, participants will only be given the 'All You Need to Know About VMMC' booklet at the time of enrollment, which is the standard of care.
16617522|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
16617523|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
16617524|NCT02497963|Experimental|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
16617525|NCT02497963|Active Comparator|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
16617526|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
16617527|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
16617528|NCT02497924|Experimental|GBT440|GBT440 / [C14] GBT440
16617529|NCT02497911|Experimental|Adductor Canal Catheter|Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
16617530|NCT02497911|Experimental|Intraarticular Catheter|Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
16617531|NCT02497898|No Intervention|regular chemotherapy|Patients after chemotherapy are just followed up.
16617532|NCT02497898|Experimental|CIK regimen|Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.
16617533|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
16617534|NCT02497872|Experimental|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
16617535|NCT02497872|Active Comparator|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
16617536|NCT02497859|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:
~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
16617537|NCT02497859|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:
~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
16617538|NCT02497846|Experimental|TEOSYAL® PureSense Redensity [I]/MicronJet®|"injection of the acid hyaluronic gel with lidocaine as an anesthetic and a dermo-restructuring complex (including 8 amino acids , 3 antioxidants Acid, vitamin B6 and 2 minerals).
~Product will be injected in a unique device group:
~in crow's feet in order to cover the zone to be treated. Quantity of product injected will be determined by the injector and noted (up to 1 ml by side). A subject can be injected in the left or/and right side.
~using a MicronJet microneedle for the superficial wrinkles."
16617539|NCT02497833|Placebo Comparator|control|the participants in this arm are instruted to consume placebo capsules
16617540|NCT02497833|Experimental|treatment|the participants in this arm are instruted to consume retinoic acid capsules
16617541|NCT02497820|Active Comparator|100 mg daily aspirin|They will receive one small tablets each day for two years in a blinded fashion
16617542|NCT02497820|Active Comparator|300 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
16617543|NCT02497820|Active Comparator|600 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
16617544|NCT02497794|Active Comparator|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
16617545|NCT02497794|Placebo Comparator|without postoperative chew gum|The control group will be followed without chew gum.
16617546|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
16617550|NCT02497742|Active Comparator|Once daily BMP|Patient in this arm will receive once daily basic metabolic panel to monitor electrolytes
16617551|NCT02497742|Active Comparator|Twice daily BMP|Patient in this arm will receive twice daily basic metabolic panel to monitor electrolytes
16617552|NCT02497729|No Intervention|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
16617553|NCT02497729|Active Comparator|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
16617554|NCT02497729|Active Comparator|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
16617555|NCT02497729|Active Comparator|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
16617556|NCT02497716|Experimental|Rivaroxaban|Single arm, open label study
16617557|NCT02497703|Experimental|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
16617558|NCT02497690|Active Comparator|In-person ART|In-person approach to provide ART.
16617559|NCT02497690|Experimental|Telehealth ART|Telemedicine technology approach (e.g. interactive video) to provide ART.
16617560|NCT02497677|Experimental|Circle of Security-Parenting|Circle of Security-Parenting (COS-P) is a brief educative group program for parents
16617561|NCT02497677|Active Comparator|Care as Usual (CAU)|Care as usual (CAU) i.e. the active control condition will be standard practices for infants and families at risk in Copenhagen.
16617562|NCT02497664|Other|Active Breathing Control|Planning-CT will be made of patients using the Active Breathing Control Technique (in expiration and inspiration phase)
16617563|NCT02497651|Experimental|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
16617564|NCT02497651|Experimental|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
16617565|NCT02497638|Experimental|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
16617566|NCT02497638|Placebo Comparator|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
16617567|NCT02497625|Experimental|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
16617568|NCT02497625|Active Comparator|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
16617569|NCT02497625|Other|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
16617570|NCT02497612|Experimental|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams [mg]) oral suspension as follows: BW greater than or equal to (>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW >=24 kg to less than (<) 35 kg: FQ 300 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 200 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 150 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 100 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 75 mg + OZ439 150 mg.
16617571|NCT02497612|Experimental|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 600 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 450 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 300 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 225 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 150 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 115 mg + OZ439 150 mg.
16617572|NCT02497612|Experimental|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 900 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 675 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 450 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 335 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 225 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 170 mg + OZ439 150 mg.
16617573|NCT02497612|Experimental|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 1200 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 900 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 600 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 450 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 300 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 225 mg + OZ439 150 mg.
16617574|NCT02497599|Experimental|Intraoperative dual-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW. At day 4 or 5 after antibody injection a whole body planar scan and SPECT/CT scan will be acquired. At day 7 standard of care (partial) nephrectomy will be performed. This will be extended with the use of dual-modality imaging.
16617575|NCT02497586|Experimental|MRS|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.
16617576|NCT02497560|Active Comparator|Treatment|all natural dietary supplement
16617579|NCT02497547|Experimental|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
16617580|NCT02497547|Experimental|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
16617581|NCT02497547|Placebo Comparator|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
16617582|NCT02497534||Affected with Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
16617583|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
16617584|NCT02497534||Carriers of Friedreich's ataxia|An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
16617585|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
16617586|NCT02497508|Experimental|Nivolumab|Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg
16617587|NCT02497495|No Intervention|GC|Control group - CG (n = 21), which suffered no recuperative technique
16617588|NCT02497495|Experimental|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
16617589|NCT02497495|Experimental|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
16617590|NCT02497495|Experimental|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
16617591|NCT02497495|Experimental|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
16617592|NCT02497469|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
16617593|NCT02497469|Active Comparator|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
16617594|NCT02497456|Experimental|Follow-up counselling|Participants in the experimental arm will receive home-based HIV counselling and testing and referral for HIV care if found to have HIV infection. Additionally, participants will receive home-based follow-up counselling at 1 and 2 months after HIV diagnosis.
16617595|NCT02497456|No Intervention|Standard of care|Participants in this arm will receive only home-based HIV counselling and testing and referral for HIV care if found to have HIV infection.
16617596|NCT02497443|Experimental|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells
16617597|NCT02497443|No Intervention|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
16617598|NCT02497404|Experimental|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
16617599|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
16617600|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
16617601|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
16617602|NCT02497378|Experimental|JNJ-54767414 (Daratumumab) +Bortezomib+Dexamethasone|Participants will be administered JNJ-54767414 (daratumumab) intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, then on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks), First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles. Bortezomib at a dose of 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle for 8 treatment cycles and Dexamethasone orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles.
16617603|NCT02497365|Experimental|Group A: Besifloxacin|Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
16617604|NCT02497365|Active Comparator|Group B: Fortified Antibiotics|Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.
16617605|NCT02497352|Experimental|Flaxseed|30 g milled brown flaxseed + lifestyle modification
16617606|NCT02497352|Active Comparator|control|lifestyle modification including dietary and physical activity recommendation
16617607|NCT02497339|Experimental|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
16617608|NCT02497339|Experimental|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
16617609|NCT02497326|Active Comparator|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
16617610|NCT02497326|Experimental|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
16617611|NCT02497313|Placebo Comparator|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
16617612|NCT02497313|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
16617613|NCT02497313|Active Comparator|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
16617614|NCT02497313|Active Comparator|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
16617615|NCT02497300|Experimental|Spironolactone|Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.
16617616|NCT02497300|Active Comparator|Amiloride|Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.
16617617|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
16617618|NCT02497274|Experimental|Roux Y gastric bypass|candidates for bariatric surgery by Roux Y gastric bypass with taste assessment and epithelium gustatory smear and biopsy
16617619|NCT02497274|Experimental|Sleeve gastrectomy|candidates for bariatric surgery by sleeve gastrectomy with taste assessment and epithelium gustatory smear and biopsy
16617620|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
16617621|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
16617622|NCT02497248||- Patients with paroxysmal AF.|Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.
16617623|NCT02497248||- Patients with persistent AF.|Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..
16617624|NCT02497248||- Patients with mitral stenosis.|- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..
16617625|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
16617626|NCT02497222|Experimental|RNS60|RNS60 4 ml, inhaled twice daily by nebulization for 21 days.
16617627|NCT02497222|Placebo Comparator|Normal Saline|Normal Saline 4 ml, inhaled twice daily by nebulization for 21 days.
16617628|NCT02497196|Experimental|Part 1:Active tPCS, Active tDCS|12 out of the 48 total health subjects will receive active tPCS and active tDCS. This will be done for 20 minutes simultaneously.
16617629|NCT02497196|Experimental|Part 1: Active tPCS, Sham tDCS|12 out of the 48 total health subjects will receive active tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
16617630|NCT02497196|Experimental|Part 1:Sham tPCS, Active tDCS|12 out of the 48 total health subjects will receive sham tPCS and active tDCS. This will be done for 20 minutes simultaneously.
16617631|NCT02497196|Sham Comparator|Part 1: Sham tDCS, Sham tDCS|12 out of the 48 total health subjects will receive sham tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
16617632|NCT02497196|Experimental|Part 2: Active tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and active tDCS (1/4 combinations all subjects will receive).
16617633|NCT02497196|Experimental|Part 2: Active tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and sham tDCS (1/4 combinations all subjects will receive).
16617634|NCT02497196|Experimental|Part 2: Sham tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and active tDCS (1/4 combinations all subjects will receive).
16617667|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
16617635|NCT02497196|Sham Comparator|2: Sham tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and sham tDCS (1/4 combinations all subjects will receive).
16617636|NCT02497183|Experimental|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
16617637|NCT02497170|Other|Life style changes|Pre and post after education intervention Education program
16617638|NCT02497157|Experimental|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
16617639|NCT02497144|Active Comparator|NMES Group|"Intervention: NMES group will receive neuromuscular electrical stimulation using high frequency galvanic stimulation and breathing exercises.
~Neuromuscular electrical stimulation will be applied bilaterally to quadriceps femoris muscle for 3days/6 weeks by a physiotherapist.
~NMES group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
16617640|NCT02497144|Sham Comparator|Control Group|"Sham: Control group will receive breathing exercises. Control group will perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.
~Control group will be followed-up by telephone once a week."
16617641|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
16617642|NCT02497118|Experimental|Endostatin plus NP|drug:Endostatins Intravenous drip， 7.5mg/m^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
16617643|NCT02497118|Active Comparator|NP neoadjuvant chemotherapy|drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
16617644|NCT02497105|Experimental|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
16617645|NCT02497105|No Intervention|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
16617646|NCT02497092|Active Comparator|Slow angled injection|Slow and angled insertion of the needle through the sclera
16617647|NCT02497092|Active Comparator|Slow straight injection|Slow and straight insertion of the needle through the sclera
16617648|NCT02497092|Active Comparator|Fast angled injection|fast and angled insertion of the needle through the sclera
16617649|NCT02497092|Active Comparator|Fast straight injection|fast and straight insertion of the needle through the sclera
16617650|NCT02497079|Experimental|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
16617651|NCT02497079|Experimental|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
16617652|NCT02497079|Experimental|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
16617653|NCT02497066|Placebo Comparator|Neuropathic Pain|Subjects with neuropathic pain will receive a neuropathic pain cream combined of Ketamine 10%/Gabapentin 6%/Clonidine 0.2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
16617654|NCT02497066|Placebo Comparator|Nociceptive pain|Subjects with nociceptive pain will receive a nociceptive pain cream combined of Ketoprofen 10%/Baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
16617655|NCT02497066|Placebo Comparator|Mixed pain|Subjects who have a mixed (nociceptive and neuropathic) pain conditions will receive a mixed pain cream combined of Ketamine 10%/Gabapentin 6%/Diclofenac 3%/baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
16617656|NCT02497053|Experimental|Arm A|Four cycles of pemetrexed/platinum
16617657|NCT02497053|Active Comparator|Arm B|Six cycles of pemetrexed/platinum
16617658|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
16617659|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
16617660|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
16617661|NCT02497027|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
16617662|NCT02497027|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
16617663|NCT02497014|Experimental|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
16617664|NCT02497014|Experimental|2 Stents|Patients who are going to receive 2 stents in both vessels
16617665|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
16617666|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
16617669|NCT02496988|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
16617670|NCT02496988|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
16617671|NCT02496975|Experimental|Cyclosporine A|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
16617672|NCT02496975|Active Comparator|Placebo|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
16617673|NCT02496962|Experimental|Statin group|drug: atorvastatin (Pfizer, U.S.); the frequency: 20mg atorvastatin was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
16617674|NCT02496962|Placebo Comparator|Control group|drug: placebo (Pfizer, U.S.); the frequency: Placebo was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
16617675|NCT02496949|Experimental|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
16617676|NCT02496936|Experimental|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
16617677|NCT02496936|Experimental|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
16617678|NCT02496936|Experimental|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
16617679|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
16617680|NCT02496936|Experimental|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
16617681|NCT02496923|Experimental|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
16617682|NCT02496923|Active Comparator|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
16617683|NCT02496910|Active Comparator|Group 1 - Period 1|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
16617684|NCT02496910|Experimental|Group 2 - Period 1|YH22162 FDC tablet of Yuhan Corporation
16617685|NCT02496910|Experimental|Group 1 - Period 2|YH22162 FDC tablet of Yuhan Corporation
16617686|NCT02496910|Active Comparator|Group 2 - Period 2|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
16617687|NCT02496897|Experimental|FP-02.2 Low Dose|A low dose of the FP-02.2 vaccine.
16617688|NCT02496897|Experimental|FP-02.2 High Dose|A high dose of the FP-02.2 vaccine.
16617689|NCT02496897|Experimental|FP-02.2 Low Dose with IC31® Adjuvant|A low dose of the FP-02.2 vaccine with IC31® Adjuvant.
16617690|NCT02496897|Experimental|FP-02.2 High Dose with IC31® Adjuvant|A high dose of the FP-02.2 vaccine with IC31® Adjuvant.
16617691|NCT02496897|Placebo Comparator|Placebo|Placebo component.
16617692|NCT02496897|Experimental|IC31® Adjuvant|IC31® Adjuvant alone.
16617693|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
16617694|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
16617695|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
16617696|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
16617697|NCT02496871|Active Comparator|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
16617698|NCT02496871|Experimental|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
16617699|NCT02496858||Early-onset CAD|The anticipated 2000 young CAD patients who aged ≤45years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
16617700|NCT02496858||Late-onset CAD|The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
16617701|NCT02496858||Age-matched controls|The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
16617702|NCT02496845|Experimental|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
16617703|NCT02496845|Experimental|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
16617704|NCT02496832|Experimental|FAZA PET-CT scan|"FAZA PET-CT imaging within 14 days of treatment from the EMR200592-001 study.
~FAZA PET-CT imaging about 5 weeks after start of treatment from the EMR200592-001 study."
16617705|NCT02496819|Experimental|Metacognitive self-regulated learning intervention|It involves training of daily tasks using a self-correct strategy. Participants' performance will be video-taped and they will then watch the video playback for reflection and self-correction under the guidance of the occupational therapist.
16617706|NCT02496819|Experimental|Sensory Integration intervention|It involves active, fun physical activity completing 8 stations of activities involving tactile, proprioceptive and vestibular tasks. Frequent breaks will be given to avoid exhaustion and fatigue throughout the activities.
16617707|NCT02496819|Active Comparator|Activity-Based Intervention|It provides constructional, drawing and crafts activity. Participants are guided to complete these tasks
16617708|NCT02496806|Experimental|Treatment|400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)
16617709|NCT02496793|Experimental|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
16617710|NCT02496793|No Intervention|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
16617711|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
16617712|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
16617713|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
16617714|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
16617715|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
16617716|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
16617717|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
16617718|NCT02496754|Experimental|New protocol group|Use long term GnRH-a 3.75mg at day 2 of menstrual cycle. Around 30 days later, controlled ovarian hyperstimulation using gonadotropins is initiated.
16617719|NCT02496754|Active Comparator|Standard GnRH-a long protocol|Use short GnRH-a 0.1mg at luteal phase of last menstrual cycle for 10 days and 0.05mg for another 4 days. Once pituitary down regulation is achieved,controlled ovarian hyperstimulation using gonadotropins is initiated. During ovarian stimulation, short GnRH-a is used daily at the dose of 0.05mg until human chorionic gonadotrophin (HCG) trigger.
16617720|NCT02496741|Experimental|Metformin and chloroquine combination|"Metformin will be administered in a 3+3 dose-escalation schedule.
~Chloroquine will be administered in a fixed dose."
16617721|NCT02496728|Experimental|Cardiovascular Health|Participants will be given the results of their health assessment and feedback regarding their health behaviors and overall health. Recommendations for change will be given if warranted. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor health behaviors that are not already at ideal levels using the study application (environmental cues). Participants will be asked to join a secret Facebook group where informational materials will be posted, participants can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
16617722|NCT02496728|Active Comparator|Whole Health|Participants will be given the results of their health assessment. They will then receive educational materials about sunscreen use, safe sex, hydration and vehicular safety. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor how much water they drink using the study application. Participants will be asked to join a secret Facebook group where informational materials will be posted, they can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
16617723|NCT02496715|Experimental|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
16617724|NCT02496715|Experimental|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
16617725|NCT02496715|Placebo Comparator|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
16617726|NCT02496702|Experimental|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.
~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
16617727|NCT02496702|No Intervention|Control|No training.
16617728|NCT02496676|Active Comparator|magnesium threonate|Participants will receive 12 weeks of magnesium threonate and 12 weeks of placebo. Will be dose escalated based on weight.
16617729|NCT02496676|Placebo Comparator|Placebo|Participants will receive 12 weeks of placebo and 12 weeks of magnesium threonate
16617730|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16617731|NCT02496650|Experimental|Group D|Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
16617732|NCT02496650|No Intervention|Group C|Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
16617733|NCT02496637|Experimental|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
16617734|NCT02496637|Active Comparator|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
16617735|NCT02496637|No Intervention|No Treatment Control|No intervention, assessment only
16617736|NCT02496624|Other|Lung cancer|
16617737|NCT02496611|Experimental|Meal Replacement Therapy|A short-term (1-3 month) meal replacement induction period design to achieve ≥5% BMI reduction. If participants achieve ≥5% BMI they will be randomized to drug or placebo in phase 2 of the trail.
16617738|NCT02496611|Placebo Comparator|Weight Loss Maintenance with Pharmacotherapy|We hypothesize that adolescents with severe obesity receiving GLP-1RA treatment following a short-term meal replacement induction period will demonstrate superior maintenance of initial BMI reduction 52 weeks following randomization compared to those assigned to placebo (primary endpoint) and that a higher proportion of those assigned to GLP-1RA treatment vs. placebo will maintain ≥5% BMI reduction from baseline to the 52-week time point (secondary endpoint)
16617739|NCT02496598|Experimental|In Vitro Follicle Activation (IVA)|Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.
16617740|NCT02496585|Experimental|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
16617741|NCT02496585|Experimental|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
16617742|NCT02496572||Short-course MDR-TB regimen patients|"Short course MDR-TB treatment regimen. New presumptively diagnosed MDR TB patients (adults and children) with Xpert® MTB/RIF or Hain MTBDR, or confirmed with Hain MTBDR plus on positive cultures if initial molecular tests negative or confirmed from MGIT culture/DST if initial molecular tests negative;
~Children (<14 years old) suspected of MDR TB without bacteriological confirmation but documented as a close contact of a confirmed MDR TB patient"
16617743|NCT02496559|Active Comparator|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
16617744|NCT02496559|No Intervention|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
16617745|NCT02496546|Experimental|LEO 32731 cream|Topical application
16617746|NCT02496546|Placebo Comparator|LEO 32731 cream vehicle|Topical application
16617747|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
16617748|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
16617749|NCT02496520|Experimental|Vaccines with autologous dendritic cells|Vaccines with autologous dendritic cells
16617750|NCT02496507|Experimental|Intervention|Provision of a sit-stand workstation for use at work.
16617751|NCT02496507|No Intervention|Control|Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
16617752|NCT02496494|Experimental|Tacrolimus conversion group|Cyclosprine was converted to tacrolimus in kidney transplant recipients.
16617753|NCT02496481|Experimental|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
16617754|NCT02496481|Experimental|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
16617755|NCT02496481|Experimental|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
16617756|NCT02496481|No Intervention|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
16618111|NCT02494024|Placebo Comparator|Single dose placebo|Single IV infusion of placebo
16617757|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
16617758|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
16617759|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
16617760|NCT02496442|Active Comparator|using Aqueduct|Patients passing procedures with Aqueduct
16617761|NCT02496442|No Intervention|Not using Aqueduct|Patients passing the standard procedures
16617762|NCT02496429|Other|BrownieForSymphony use|Each participant will use the BrownieForSymphony pumpset
16617763|NCT02496416|Experimental|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Randolph, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
16617764|NCT02496416|Active Comparator|Control|The control group will participate in an eight week stretching program during weeks 2-9 of the study. The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
16617765|NCT02496403|Experimental|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
16617766|NCT02496403|No Intervention|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
16617767|NCT02496390|Placebo Comparator|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).
~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
16617768|NCT02496390|Active Comparator|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).
~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
16617769|NCT02496377|Active Comparator|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
16617770|NCT02496377|Experimental|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
16617771|NCT02496364|Other|Observation|Clinical data analysis
16617772|NCT02496351|Active Comparator|TENS INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours. The intensity of the impulse will be determined in a test carried out 3 days before surgery. The other parameters will be continuous, biphasic, compensated and symmetric impulse, frequency of 80 Hz, time impulse between 250 and 290 microseconds, modulation time 5´´
16617773|NCT02496351|Placebo Comparator|TENS NO INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours, but in this case TENS just will be on. No intensity impulse should be programmed.
16617774|NCT02496338|Experimental|Intervention group|Training program about menopausal health isues
16617775|NCT02496338|No Intervention|Control group|No training program about menopausal health isues
16617776|NCT02496325|Other|perineal technic|
16617777|NCT02496312|Experimental|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
16617778|NCT02496299|Active Comparator|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
16617779|NCT02496299|Active Comparator|Bupivacaine,B|B ,1ml/kg bupivacaine:
16617780|NCT02496286|Experimental|Eligible patients requiring paracentesis for symptom control|
16617781|NCT02496273|Experimental|CEA Specific CTL|Patients receiving CEA-specific CTLs as therapy for Gastric Cancer
16617782|NCT02496247|Experimental|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
16617783|NCT02496247|No Intervention|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
16617807|NCT02496052|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
16617835|NCT02495870|Active Comparator|Pork, 160°C (until 58°C in core)|Pork muscle (semitendinosus) oven cooked at 160°C until 58° in core.
16617784|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
16617785|NCT02496208|Experimental|Part I (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 22 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity.
16617786|NCT02496208|Experimental|Part II (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of 4 cycles with ipilimumab, patients continue receiving cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 21 cycles in the absence of disease progression or unacceptable toxicity. After 26 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity.
16617787|NCT02496182|Placebo Comparator|Placebo|Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.
16617788|NCT02496182|Experimental|Pirfenidone 1800 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day
16617789|NCT02496182|Experimental|Pirfenidone 1200 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day
16617790|NCT02496169|Experimental|eucaLimus|Percutaneous Coronary Intervention (PCI)
16617791|NCT02496156|Active Comparator|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
16617792|NCT02496156|Experimental|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
16617793|NCT02496143|Experimental|Cohort 1|500 mg EC-18 dose or placebo
16617794|NCT02496143|Experimental|Cohort 2|1000 mg EC-18 dose orplacebo
16617795|NCT02496143|Experimental|Cohort 3|2000 mg EC-18 dose or placebo
16617796|NCT02496143|Experimental|Cohort 4|4000 mg EC-18 dose or placebo
16617797|NCT02496130||minilaparotomy|Subjects in this group will have tissue (uterus) extracted via mini-laparotomy incision with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
16617798|NCT02496130||vaginal extraction|Subjects in this group will have tissue (uterus) extracted via vaginal extraction with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
16617799|NCT02496117|Active Comparator|RNS-checked RDN|20 patients with hypertension will be enrolled undergoing RNS-checked RDN
16617800|NCT02496117|Experimental|RNS-guided RDN|20 patients with hypertension will be enrolled undergoing RNS-guided RDN
16617801|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
16617802|NCT02496104||Term newborns|Infant born at term
16617803|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
16617804|NCT02496078|Active Comparator|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week
~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
16617805|NCT02496078|Placebo Comparator|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week
~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
16617806|NCT02496065|Experimental|BLZ-100|
16618869|NCT02488629|Experimental|SCB01A|This study is a single arm, open-label, Phase II trial
16617808|NCT02496052|Sham Comparator|Foley catheter balloon only|patients, who are with IUA, treated by uterine application of Foley balloon only+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
16617809|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
16617810|NCT02496026|Experimental|tDCS plus wrist robot therapy|In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
16617811|NCT02496026|Sham Comparator|Sham tDCS plus wrist robot therapy|Group B is treated as Group A, but tDCS, even if the cap is applied on the patient head, is not activated and no current is delivered.
16617812|NCT02496013|Experimental|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:
~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30~45min after the injection.
~Patients for lymph node imaging:
~The patients were locally injected 10~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
16617813|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
16617814|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
16617815|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
16617816|NCT02495974||Patients with mCRPC prescribed enzalutamide|Oral
16617817|NCT02495961||Low risk population|Colombian children, between 6 and 12 years old, regular students of a Primary school.
16617818|NCT02495961||High risk population|Mexican children, between 6 and 12 years old, regular students of a Primary school.
16617819|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
16617820|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
16617821|NCT02495935|Experimental|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
16617822|NCT02495935|Sham Comparator|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
16617823|NCT02495922|Active Comparator|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
16617824|NCT02495922|Experimental|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
16617825|NCT02495922|Experimental|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
16617826|NCT02495922|Experimental|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
16617827|NCT02495896|Experimental|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16617828|NCT02495896|Experimental|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16617829|NCT02495896|Experimental|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16617830|NCT02495883|Other|Essential Tremor Group|Patients will be randomized to start in one of two treatment arms: 1) 50ml of 40% ethanol or 2) Propranolol SR 60-120mg. In patients who receive ethanol first, they will return for a second visit when they will receive Propranolol, and vice versa. Ethanol will be administered to participants diagnosed with Essential Tremor during the study visit, whereas patients receiving Propranolol SR will be administered daily over an estimated period of two weeks prior to the fMRI visit.
16617831|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers will receive no interventions.
16617832|NCT02495870|Experimental|Pork, 58°C, 72 minutes|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 72 minutes
16617833|NCT02495870|Experimental|Pork, 58°C, 17 hours|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 17 hours
16617834|NCT02495870|Experimental|Meat balls, 58°C, 17 hours|Meat balls made from pork Semitendinosus. Sous-vide cooked at 58°C for 17 hours
16617836|NCT02495857|Experimental|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
16617837|NCT02495857|Active Comparator|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
16617838|NCT02495857|Placebo Comparator|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
16617839|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
16617840|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
16617841|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
16617842|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
16617843|NCT02495818|Experimental|Lidocaine|Suprascapular nerve block with infusion of 5ml lidocaine at 2%, guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
16617844|NCT02495818|Sham Comparator|Saline solution|Intervention with suprascapular nerve block with 5ml saline solution guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
16617845|NCT02495805|Active Comparator|adductor canal block (ACB)|Subjects randomized to this groups receive a continuous proximal adductor canal block (ACB) during surgery.
16617846|NCT02495805|Active Comparator|femoral nerve block (FNB)|Subjects randomized to this groups receive a continuous femoral nerve block (FNB) during surgery.
16617847|NCT02495792|No Intervention|Control group|Group does not receive the biofeedback sensor
16617848|NCT02495792|Experimental|Biofeedback group|Group does receive the biofeedback sensor
16617849|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
16617850|NCT02495766|Experimental|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
16617851|NCT02495766|Experimental|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
16617852|NCT02495753|Experimental|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
16617853|NCT02495753|Active Comparator|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
16617854|NCT02495740|Experimental|E-bike intervention|Intervention is active commuting to work by an electric assisted bike to work for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
16617855|NCT02495740|Active Comparator|Bike intervention|Intervention is active commuting to work by classic bike for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
16617856|NCT02495727|Experimental|Control Group|This group will undertake two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
16617857|NCT02495727|Experimental|Pre-Training Group|This group will undertake four weeks of strength training exercise (10 sessions) before two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
16617858|NCT02495727|Experimental|Exercise Snacking Group|This group will undertake home-based 'exercise snacks' of simple lower limb movement (5 minutes, 3 times a day) whilst undertaking two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
16617859|NCT02495714|Experimental|Intervention schools|Active Learning; One hour each schoolday of physical Activity as part of academic learning Dietary councelling; teaching children and parents about a healty diet
16617860|NCT02495714|No Intervention|Control schools|No intervention
16617861|NCT02495701||Patients|Patients having Hip arthroscopic surgery
16617862|NCT02495688|Experimental|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
16617863|NCT02495688|Active Comparator|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
16617864|NCT02495675|No Intervention|No flow|Subjects will be spontaneously breathing in room air with no flow.
16617865|NCT02495675|Experimental|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
16617866|NCT02495675|Experimental|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
16617867|NCT02495675|Experimental|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
16617868|NCT02495675|Experimental|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
16617869|NCT02495662|Experimental|Liposomal prednisolone|Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
16617870|NCT02495662|Placebo Comparator|Placebo|Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
16617871|NCT02495649|Other|[18F]-DOPA|evaluate the added value of PET-CT with [18F]-DOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.
16617872|NCT02495636|Experimental|Safety Run Up Group|The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
16617901|NCT02495428|Experimental|Kinesio Tape Group|muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method
16619338|NCT02485509|Experimental|40 mg VM-1500/Placebo Healthy group|VM-1500 40 mg or placebo single dose.
16617873|NCT02495636|Experimental|Expanded Trial Group|If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
16617874|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
16617875|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
16617876|NCT02495623|Placebo Comparator|Placebo|Placebo
16617877|NCT02495610|Other|Gait analysis and MRI|"Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.
~MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
16617878|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
16617879|NCT02495597||Control Group|age- and sex matched to subject-group
16617880|NCT02495584|Experimental|Treatment 1|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
16617881|NCT02495584|Experimental|Treatment 2|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (placebo) daily for 24 weeks
16617882|NCT02495584|Experimental|Treatment 3|500ml unfortified milk (placebo) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
16617883|NCT02495584|Placebo Comparator|Treatment 4|500ml unfortified milk (placebo) +1 supplement capsule (placebo) daily for 24 weeks
16617884|NCT02495571|Experimental|ALS Patients|Study Group: Evaluation of the cough reflex and the voluntary cough by spirometer and nebulizer
16617885|NCT02495571|Other|Healthy Subjects|Control group matched by aged and sex with the study group
16617886|NCT02495558|Experimental|Patients with Tracheostomy|Assessment of reflex cough Assessment of the deccanultation outcome (follow-up)
16617887|NCT02495545|Experimental|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
16617888|NCT02495545|Active Comparator|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
16617889|NCT02495532|Active Comparator|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.
~Intervention A: Carnoy solution Intervention B: GEWF solution"
16617890|NCT02495532|Active Comparator|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.
~Intervention A: Carnoy solution Intervention B: GEWF solution"
16617891|NCT02495519|Experimental|imatinib|Imatinib 400 mg/day until disease progression
16617892|NCT02495506|Experimental|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
16617893|NCT02495506|Active Comparator|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
16617894|NCT02495493|Experimental|Induction DCS chemotherapy|"Induction chemotherapy -- S-1 35mg/m2 bid day 1-14
~Docetaxel 30 mg/m2 day1, 8
~Cisplatin 30 mg/m2 day1, 8
~Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy"
16617895|NCT02495480|Experimental|sheathed group|The sterilized disposable sheath covered the outer surface of the colonoscope, then colonoscope will be performed in conventional way;a new sheath will be placed on the endoscope in sheathed group as a intervention
16617896|NCT02495480|No Intervention|conventional group|Colonoscopy will be performed with air insufflation during insertion
16617897|NCT02495467|Experimental|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
16617898|NCT02495467|Experimental|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
16617899|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).
~GA101-miniCHOP regimen:
~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
16617900|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
16617972|NCT02494960|Placebo Comparator|Control Group|The doctor will offer a placebo intervention.
16617902|NCT02495428|No Intervention|Control group|They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention
16617903|NCT02495415|Experimental|Fenretinide emulsion|Patients enrolled will receive 600 mg fenretinide/m2/day on Day 1, followed by 1200 mg fenretinide/m2/day on Days 2 - 5 as a continuous intravenous infusion via central line over 5 days. Cycles are repeated every 3 weeks.
16617904|NCT02495402|No Intervention|No Intervention: Control|No Intervention
16617905|NCT02495402|Experimental|Motivational Interviewing|A brief interview intervention for substance abuse
16617906|NCT02495389|Experimental|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
16617907|NCT02495376|Active Comparator|Group A|Group A participates in the first available MBSR course.
16617908|NCT02495376|Active Comparator|Group B|Group B waits 16 weeks before participating in the MBSR course.
16617909|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.
~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
16617910|NCT02495350||Initially didn't want an epidural and didn't receive one.|
16617911|NCT02495350||Initially didn't want an epidural and did receive one.|
16617912|NCT02495350||Initially wanted an epidural and didn't received one|
16617913|NCT02495350||Initially wanted an epidural and did receive one.|
16617914|NCT02495337||TIssue Collection|Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
16617915|NCT02495324|Experimental|Fimasartan|Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
16617916|NCT02495324|Active Comparator|Valsartan|Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
16617917|NCT02495324|Other|Olmesartan medoxomil|Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks
16617918|NCT02495311||Women with uterine myoma|Women with uterine myoma
16617919|NCT02495311||Women with adenomyosis|Women with adenomyosis
16617920|NCT02495311||Women without uterine myoma or adenomyosis|Control group
16617921|NCT02495298|Experimental|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
16617922|NCT02495298|Sham Comparator|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
16617923|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
16617924|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
16617925|NCT02495272|Active Comparator|Control Group|Oxytocin 10IU im was administered after placental delivery
16617926|NCT02495272|Experimental|Study Group|Oxytocin 10IU im was administered after the anterior shoulder could be seen.
16617927|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
16617928|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
16617929|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
16617930|NCT02495246|Active Comparator|Group 1|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 28 days later.
16617931|NCT02495246|Active Comparator|Group 2|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 28 days later.
16617932|NCT02495246|Active Comparator|Group 3|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 56 days later.
16617933|NCT02495246|Active Comparator|Group 4|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 56 days later.
16617934|NCT02495233|Experimental|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
16617935|NCT02495233|Experimental|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
16617936|NCT02495220|Experimental|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
16617937|NCT02495220|Experimental|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
16617938|NCT02495207|No Intervention|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
16617939|NCT02495207|Experimental|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
16617940|NCT02495194|Experimental|Active Horticultural Therapy|15 sessions of Horticultural Therapy program teaching the elderly about gardening techniques and for them to benefit from the therapeutic effects of the parks
16617941|NCT02495194|Other|Waitlist Control Group|Participants will receive the same horticultural therapy program at the end of the assessments
16617942|NCT02495181|Sham Comparator|Aflibercept Monotherapy|IVT Aflibercept 2 mg + Sham PDT
16617943|NCT02495181|Active Comparator|Aflibercept + verteporfin PDT|IVT Aflibercept 2 mg + Verteporfin PDT
16617944|NCT02495168|Experimental|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
16617945|NCT02495168|Active Comparator|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
16617946|NCT02495168|Placebo Comparator|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
16617947|NCT02495155|Active Comparator|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
16617948|NCT02495155|Active Comparator|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
16617949|NCT02495155|Active Comparator|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
16617950|NCT02495129|Experimental|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
16617951|NCT02495129|Experimental|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
16617952|NCT02495103|Experimental|Phase I Component - Vandetanib|Phase I Component
16617953|NCT02495103|Experimental|Phase II Component- Vandetanib/Metformin|Phase II Component
16617954|NCT02495090|Other|Hypospadias|Familial hypospadias trios (patients + parents)
16617955|NCT02495077|Experimental|Experimental Arm|rATG is co-administered with anti-TNFa (infliximab/Remicade®) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
16617956|NCT02495077|Active Comparator|Control group|Rabbit anti-thymocyte globulin (rATG/Thymoglobulin®) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
16617957|NCT02495064|Experimental|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.
~MF Brief introduction:
~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.
~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.
~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
16617958|NCT02495064|No Intervention|Chemoradiotherapy|conventional Chemoradiotherapy only
16617959|NCT02495051||single group-study|
16617960|NCT02495038|No Intervention|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium
~ED95, dose causing on average 95% suppression of neuromuscular response."
16617961|NCT02495038|Experimental|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
16617962|NCT02495038|Experimental|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
16617963|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
16617964|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
16617965|NCT02495012|Placebo Comparator|control|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
16617966|NCT02495012|Active Comparator|treatment|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
16617967|NCT02494999|Experimental|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
16617968|NCT02494999|Active Comparator|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
16617970|NCT02494973|Active Comparator|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:
~Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
~Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
16617971|NCT02494973|Experimental|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:
~Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,
~Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
16617973|NCT02494960|Experimental|Intervention Group A|"The doctor will offer the brief smoking cessation AWARD model .
~At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model ."
16617974|NCT02494960|Experimental|Intervention Group B|The doctor will offer the brief smoking cessation AWARD model.
16617975|NCT02494947|Experimental|interval training|high intensity interval-based aerobic exercise
16617976|NCT02494947|Other|controls|usual care
16617977|NCT02494934|Experimental|Cognitive-behavioural therapy|Eight sessions of psychotherapy incorporating cognitive-behavioural and sex therapy interventions.
16617978|NCT02494934|Experimental|physical therapy|Eight sessions of physical therapy targeting the pelvic floor muscles.
16617979|NCT02494921|Experimental|Treatment|Docetaxel: 75 mg/m^2; Day 1 of 21-Day Cycle Ribociclib: 200 mg/day; Days 2-14 of 21-Day Cycle Prednisone: 5 mg, oral, twice a day Filgrastim: as clinically indicated
16617980|NCT02494921|Experimental|Alternate Treatment|Docetaxel: 35 mg/m^2; Days 1, 8 , 15 of 21-Day Cycle Ribociclib: 200 mg/day; Days 2-14 of 21-Day Cycle Prednisone: 5 mg, oral, twice a day Filgrastim: as clinically indicated
16617981|NCT02494908|Active Comparator|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
16617982|NCT02494908|Active Comparator|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
16617983|NCT02494895|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
16617984|NCT02494895|Active Comparator|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
16617985|NCT02494882|Experimental|Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone|"Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).
~Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.
~Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.
~Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.
~Or, post-remission induction (consolidation) therapy to be determined per the treating physician"
16617986|NCT02494869|Experimental|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
16617987|NCT02494869|Experimental|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
16617988|NCT02494869|Experimental|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
16617989|NCT02494869|Active Comparator|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
16617990|NCT02494856|Experimental|Surgery with Naproxen|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg.
16617991|NCT02494856|Experimental|Surgery with Naproxen and Esomeprazole|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg and esomeprazole 20mg.
16617992|NCT02494843|Active Comparator|Online haemodiafiltration|
16617993|NCT02494843|Active Comparator|Haemodialysis|
16617994|NCT02494830|Experimental|ketamine 5 mg intravenous|
16617995|NCT02494830|Experimental|ketamine 10 mg oral|
16617996|NCT02494830|Experimental|ketamine 20 mg oral|
16617997|NCT02494830|Experimental|ketamine 40 mg oral|
16617998|NCT02494830|Experimental|ketamine 80 mg oral|
16617999|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
16618069|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
16618139|NCT02493803|Experimental|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
16618000|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
16618001|NCT02494804|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
16618002|NCT02494804|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
16618003|NCT02494791|Other|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
16618004|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
16618005|NCT02494765|Active Comparator|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
16618006|NCT02494765|Active Comparator|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
16618007|NCT02494752|Experimental|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
16618008|NCT02494752|Active Comparator|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
16618009|NCT02494739|Experimental|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
16618010|NCT02494739|Placebo Comparator|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
16618011|NCT02494726||Ischemic Stroke|Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
16618012|NCT02494726||Healthy Controls|Healthy controls who have had their blood analyzed using thromboelastography (TEG)
16618013|NCT02494726||Hemorrhagic Stroke|Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
16618014|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
16618015|NCT02494700|Experimental|Treatment (low dose orbital EBRT)|Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
16618016|NCT02494674|Experimental|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
16618017|NCT02494661|Experimental|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
16618018|NCT02494661|Active Comparator|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
16618019|NCT02494648|Experimental|Inspiratory muscles strengthening|"The device used is : POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK).
~Class I, CE labelled. POWERbreathe fitness Plus uses the technique of training against resistance to increase the strength, the power and the endurance of the respiratory muscles (diaphragm and rib cage)."
16618020|NCT02494648|Placebo Comparator|Control|No intervention
16618021|NCT02494635||Diagnostic (ultrasound, biomarker studies)|Previously collected tumor tissue samples, bladder washings, and urine cells are stained with calcium dye, washed and immersed in external buffer solution, and then transferred to the ultrasound imaging system. Tissue, bladder wash cells and urine cells samples are also analyzed for biomarkers of invasiveness derived from or related to REST gene via qRT-PCR, Western blot, and FISH.
16618022|NCT02494609|Experimental|Treatment A|once daily dosing for 7 days, followed by 7-day washout
16618023|NCT02494609|Experimental|Treatment B|once daily dosing for 28 days
16618024|NCT02494609|Experimental|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
16618025|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
16618026|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
16618105|NCT02494050|Experimental|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
16618106|NCT02494050|Active Comparator|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
16618027|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
16618028|NCT02494583|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
16618029|NCT02494583|Experimental|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
16618030|NCT02494583|Placebo Comparator|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
16618031|NCT02494570|Experimental|ABI-009|
16618032|NCT02494544|Active Comparator|ConforMIS iTotal Knee replacement|iTotal patient-specific knee replacement system
16618033|NCT02494544|Active Comparator|DePuy total knee replacement|Off the shelf knee replacement system
16618034|NCT02494544|Active Comparator|Zimmer total knee replacement|Off the shelf knee replacement system
16618035|NCT02494544|Active Comparator|Biomet total knee replacement|Off the shelf knee replacement system
16618036|NCT02494544|Active Comparator|Smith & Nephew total knee replacement|Off the shelf knee replacement system
16618037|NCT02494544|Active Comparator|Stryker total knee replacement|Off the shelf knee replacement system
16618038|NCT02494531|Other|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
16618039|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:
~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
~45 minutes of upper extremity repetitive arm exercises"
16618040|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:
~45 minutes of cycling on a recumbent stationary bike at your self-selected speed
~45 minutes of upper extremity repetitive arm exercises"
16618041|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:
~45 minutes of stroke education
~45 minutes of upper extremity repetitive arm exercises"
16618042|NCT02494505|Experimental|mycophenolate mofetil|
16618043|NCT02494505|Placebo Comparator|placebo|placebo pills
16618044|NCT02494492|Experimental|IVT of regulator T-cells|intravitreous administration of regulator T-cells
16618045|NCT02494479|Active Comparator|50mg of Purisol daily|One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
16618046|NCT02494479|Active Comparator|100mg of Purisol daily|One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
16618047|NCT02494479|Active Comparator|200mg of Purisol daily|Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
16618048|NCT02494479|Placebo Comparator|Placebo daily|Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
16618049|NCT02494466|Active Comparator|Group E (n=10)|Patients with high Ig E levels
16618050|NCT02494466|Active Comparator|Group C (n=10)|Patients with normal Ig E levels
16618051|NCT02494466|Active Comparator|Group M (n=10)|Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE
16618052|NCT02494453||Cardiac MRI|
16618053|NCT02494427|Experimental|1|CAD/CAM manufactured fixed unitary dental prostheses
16618054|NCT02494427|Active Comparator|2|Conventionally manufactured unitary dental prostheses
16618055|NCT02494414||French prospective cohort of cardiac arrest survivors|Outcome of cardiac arrest survivors: prospective cohort of Ile-de-France
16618056|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
16618057|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
16618058|NCT02494388||Serous cystadenoma|Serous cystadenoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
16618059|NCT02494388||Mucinous cystic neoplasms|Mucinous cystic neoplasms patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
16618060|NCT02494388||Intraductal papillary mucinous neoplasms (IPMN)|IPMN patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
16618061|NCT02494388||Mucinous cystdenocarcinoma|Mucinous cystadenocarcinoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
16618062|NCT02494388||Other cystic lesions|Other cystic lesions patients (cystic neuroendocrine tumors, solid pseudopapillary neoplasms, cystic lymphangioma, etc.) Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients..
16618063|NCT02494375|Experimental|Sleep and glucose assessement.|
16618064|NCT02494362|Experimental|Experimental Group|Computer gaming hand exercise regimen.
16618065|NCT02494349|Experimental|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
16618066|NCT02494349|Experimental|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
16618067|NCT02494336|Active Comparator|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
16618068|NCT02494336|Active Comparator|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
16618107|NCT02494024|Experimental|Single dose C2N-8E12 level 1|Single IV infusion of C2N-8E12
16618070|NCT02494310|Experimental|HRME - Prevention Mobile Unit|Procedures to be done in the mobile unit (van): Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
16618071|NCT02494310|Experimental|HRME - Barretos Cancer Hospital|Procedures to be done at Barretos Cancer Hospital: Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
16618072|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
16618073|NCT02494284|Experimental|Short term dual therapy|
16618074|NCT02494284|Active Comparator|Long term dual therapy|
16618075|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
16618076|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
16618077|NCT02494258|Experimental|Oral Azacitidine (CC-486)|This study is an open-label, single-arm study and is divided into the screening period, treatment period and follow-up period. It is intended to evaluate the long-term safety of CC-486 and is to be taken at the same dose, schedule and frequency used from the last dose of CC-486 given in the parent study.
16618078|NCT02494245|Active Comparator|Intervention|128 participants will take part in the STARFISH intervention
16618079|NCT02494245|No Intervention|Control|Participants allocated to the control group will be given a booklet with general advice on physical activity.
16618080|NCT02494232||minor blunt thoracic trauma patient|demographic data, physical examination findings
16618081|NCT02494219|Experimental|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
16618082|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
16618083|NCT02494193|Active Comparator|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
16618084|NCT02494193|Experimental|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
16618085|NCT02494180|Placebo Comparator|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
16618086|NCT02494180|Placebo Comparator|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
16618087|NCT02494167|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
16618088|NCT02494167|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
16618089|NCT02494154|Active Comparator|Conventional flow via nasal prongs|Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.
16618090|NCT02494154|Experimental|High flow nasal cannulas 20L/min|Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
16618091|NCT02494154|Experimental|High flow nasal cannulas 40L/min|Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
16618092|NCT02494154|Experimental|High flow nasal cannulas 60L/min|Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
16618093|NCT02494141|Experimental|Curcumin|25/mg/kg per day for 1 year.
16618094|NCT02494141|Placebo Comparator|Placebo|Equivalent placebo for 1 year.
16618095|NCT02494128|Active Comparator|Intervention group|Education in group leadership
16618096|NCT02494128|No Intervention|Control group|This group fills in the questionnaire. No intervention given.
16618097|NCT02494115|Experimental|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
16618098|NCT02494102|Placebo Comparator|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
16618099|NCT02494102|Active Comparator|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
16618100|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
16618101|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
16618102|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
16618103|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
16618104|NCT02494050|Experimental|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
16618112|NCT02494011|Experimental|traditional exercise (group I)|"Mobilization:2 strokes per one second and repeated 6 times during session
~stretching exercise: 15 to 20 minutes
~passive range of motion: 5 minutes at beginning and at end
~active range of motion: 20 repetition
~oedema control: 15s active contraction of fingers of 15s relax for 3 times"
16618113|NCT02494011|Experimental|russian current stimulation (group II)|The frequency was 2.5 kHz for 15 minutes
16618114|NCT02494011|Experimental|CKC (group III)|"wall press exercise - plyometric exercise-Quadruped rhythmic stabilization- press up exercise
~closed kinetic chain exercises performed 10 times and each week 2 more repetitions added as a progression"
16618115|NCT02493985|Active Comparator|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
16618116|NCT02493985|Experimental|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
16618117|NCT02493972|Experimental|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
16618118|NCT02493959|Experimental|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
16618119|NCT02493946|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
16618120|NCT02493946|Placebo Comparator|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
16618121|NCT02493933|Active Comparator|Phytoestrogen|Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
16618122|NCT02493933|Active Comparator|Isosorbid mononitrate|Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
16618123|NCT02493933|Active Comparator|N-Acetyl cysteine|Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
16618124|NCT02493920|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
16618125|NCT02493920|No Intervention|Control|Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
16618126|NCT02493907||heart failure|heart failure patients with CRT
16618127|NCT02493894|Experimental|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
16618128|NCT02493894|Sham Comparator|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
16618129|NCT02493881|Active Comparator|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
16618130|NCT02493881|Active Comparator|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
16618131|NCT02493868|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
16618132|NCT02493868|Experimental|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
16618133|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
16618134|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
16618135|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
16618136|NCT02493842|Experimental|Invasive nerve stimulation|"Invasive nerve stimulation using the following experimental devices
~Transverse Intrafascicular Multichannel Electrode for human (TIME-4H)
~The STIMEP stimulator
~The EPIONE Psychophysical Testing Platform software for stimulator control
~Nerve stimulation therapy is provided while providing visual guidance to the subject and without the use of hand prosthetic devices"
16618137|NCT02493829|Experimental|AML Cell Vaccine|
16618138|NCT02493816|Experimental|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
16618140|NCT02493803|No Intervention|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
16618141|NCT02493790||Volunteers|Cognitive and motor performances were measured in a single and dual task situations.
16618142|NCT02493790||COPD patients|Cognitive and motor performances were measured in a single and dual task situations, before rehabilitation, and compared to those of healthy subjects. Then, Chronic Obstructive Pulmonary Disease patients were re-evaluated after rehabilitation.
16618143|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
16618144|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
16618145|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
16618146|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
16618147|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
16618148|NCT02493738|Experimental|Lozanoc 50mg|Lozanoc 50mg, oral administration
16618149|NCT02493738|Active Comparator|Sporanox 100mg|Sporanox 100mg, oral administration
16618150|NCT02493725|Active Comparator|Eculizumab|Eculizumab, 900 mg intravenously once a week
16618151|NCT02493725|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
16618155|NCT02493699|Experimental|Exercise|physical exercise- based intervention (Karate techniques training)
16618156|NCT02493699|No Intervention|Control|Not participating in physical exercise- based intervention (Karate techniques training)
16618157|NCT02493673|Active Comparator|CPAP therapy|Continuous positive airway pressure therapy
16618158|NCT02493673|Sham Comparator|Sham CPAP|Sham- Continuous positive airway pressure
16618159|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
16618160|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
16618161|NCT02493647|Experimental|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
16618162|NCT02493647|No Intervention|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
16618163|NCT02493634|Other|pressure gradient measurement|Diagnostic procedure to measure pressure gradient in series of patients. Focus is on safety and absence of adverse events
16618164|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
16618165|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
16618166|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
16618167|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
16618168|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
16618169|NCT02493582|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
16618170|NCT02493582|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
16618171|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
16618172|NCT02493556|Experimental|LLLT before muscle damage|Low Level Laser Therapy (LLLT) will be applied before the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
16618173|NCT02493556|Placebo Comparator|Placebo LLLT before muscle damage|Placebo LLLT will be applied before the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
16618174|NCT02493556|Active Comparator|LLLT after muscle damage|Low Level Laser Therapy (LLLT) will be applied after the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
16618175|NCT02493556|Placebo Comparator|Placebo LLLT after muscle damage|Placebo LLLT will be applied after the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
16618252|NCT02492919|Experimental|Medixair®|Cardiac reanimation unit bed with Medixair®
16618176|NCT02493543||Spinal cord injury|Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
16618177|NCT02493543||Controls|Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.
16618178|NCT02493530|Experimental|Escalation and expansion|TGR1202 and Ruxolitinib combination
16618179|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
16618180|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
16618181|NCT02493504|Experimental|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
16618182|NCT02493504|No Intervention|Control|75 received no intraoperative heparin injection.
16618183|NCT02493465|Experimental|LVH everolimus|Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.
16618184|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
16618185|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
16618186|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
16618187|NCT02493439|Experimental|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
16618188|NCT02493439|Placebo Comparator|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
16618189|NCT02493426|Placebo Comparator|Placebo|Saline Nasal spray designed to look and feel like the drug intervention
16618190|NCT02493426|Experimental|Intranasal Oxytocin|Oxytocin nasal spray designed to look as seem exactly like Placebo
16618191|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
16618192|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
16618193|NCT02493400||Exercise group|A follow up from 3 months detraining from the exercise group. Patients follows their earlier randomisation.
16618194|NCT02493400||Active Comparator: PAP group|A follow up from 3 months detraining from the active comparator group. Patients follows their earlier randomisation.
16618195|NCT02493387|Experimental|Exercise group|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the RPE 6-20 scale
16618196|NCT02493387|Active Comparator|PAP group|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
16618197|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
16618198|NCT02493348|Experimental|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
16618199|NCT02493348|Active Comparator|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
16618200|NCT02493335|Experimental|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
16618201|NCT02493335|Experimental|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
16618202|NCT02493335|Placebo Comparator|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
16618203|NCT02493322|Experimental|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
16618204|NCT02493322|Experimental|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
16618205|NCT02493322|Experimental|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
16618206|NCT02493309|Experimental|Prolonged sitting|
16618207|NCT02493309|Active Comparator|Light activity breaks|
16618208|NCT02493296||Observational|The cohort will have their central aortic pressure, and carotid-femoral and brachio-femoral pulse-wave velocities measured. These measurements will take place pre-operatively, within a week of surgery, 6-weeks and 1-year post-operatively also. The surgery will be abdominal aortic aneurysm repair.
16618209|NCT02493283|Active Comparator|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
16618210|NCT02493283|Active Comparator|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
16618211|NCT02493270|Experimental|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
16618253|NCT02492919|No Intervention|NO Medixair®|Cardiac reanimation unit bed with NO Medixair®
16618254|NCT02492906||Osteoarthrosis group|Patients with primary severe knee osteoarthrosis or with chronic knee pain.
16618255|NCT02492906||Healthy patients|Healthy patients
16618212|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
16618213|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
16618214|NCT02493244|Experimental|Treatment|Participants clean their eyelids with Cliradex wipes before going to bed at night.
16618215|NCT02493244|No Intervention|Control|No treatment
16618216|NCT02493231|Active Comparator|Nefopam|The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr
16618217|NCT02493231|Active Comparator|Ketamine|It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr
16618218|NCT02493231|Placebo Comparator|Saline|It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr
16618219|NCT02493218|Experimental|Mindfulness Instruction|Instruction on mindfulness concepts and practices. Classes are 45-90 minutes each and held weekly for 12 weeks.
16618220|NCT02493218|Active Comparator|Health Education Instruction|Instruction on general health and wellness. Classes are 45-90 minutes each and held weekly for 12 weeks.
16618221|NCT02493192|Active Comparator|Meperidine|Use pethidine and haloperidol injection as a pain relief.
16618222|NCT02493192|Experimental|birth ball|Use birth ball as a pain relief.
16618223|NCT02493179|Active Comparator|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
16618224|NCT02493179|Placebo Comparator|Placebo|Placebo
16618225|NCT02493166|Active Comparator|patients with Multiple sclerosis Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
16618226|NCT02493166|Active Comparator|Healthy volontiers Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
16618227|NCT02493140|Active Comparator|Cashew apple extract (Cashewin)|
16618228|NCT02493140|Placebo Comparator|Placebo|
16618229|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
16618230|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
16618231|NCT02493114||Patients with lung cancer|No study intervention
16618232|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
16618233|NCT02493101||Control|Healthy controls
16618234|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
16618235|NCT02493075|Experimental|CF guided group|Ablation will be performed with smart-touch catheter.The operator will kown the real-time contact force (CF), ablation time, FTI, etc during the procedure.
16618236|NCT02493075|Active Comparator|Usual ablation group|Although we use the same catheter,operator will be blinded to CF data during the procedure.
16618237|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
16618238|NCT02493049|Experimental|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
16618239|NCT02493049|No Intervention|No add on treatment|No add on treatment. Control group
16618240|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
16618241|NCT02493023|Experimental|navigated bronchoscopy|
16618242|NCT02493010|Experimental|Intervention|Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.
16618243|NCT02493010|No Intervention|Waitlist Control|Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
16618244|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
16618245|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
16618246|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
16618247|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
16618248|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
16618249|NCT02492945|Experimental|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
16618250|NCT02492945|Active Comparator|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
16618251|NCT02492932|Experimental|IJV_2nd|Ultrasonography examination of the patients who are assumed to take second attempt of internal jugular venous catheterization
16618256|NCT02492893|Experimental|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
16618257|NCT02492893|No Intervention|Treatment as Usual|
16618258|NCT02492867|Experimental|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
16618259|NCT02492854|Active Comparator|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
16618260|NCT02492854|Experimental|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
16618261|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
16618262|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
16618263|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
16618264|NCT02492828||Patients for filled prescriptions for apixaban|
16618265|NCT02492828||Patients for filled prescriptions for warfarin|
16618266|NCT02492815||Population with condition and without condition|Participating in EAP
16618267|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
16618268|NCT02492789|Experimental|INCSHR01210|"3 dose levels are designed in this study.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle)."
16618269|NCT02492776|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
16618270|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
16618271|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
16618272|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
16618273|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
16618274|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
16618275|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16618276|NCT02492737|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
16618279|NCT02492698|Experimental|Probiotic group|consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.
16618280|NCT02492698|Placebo Comparator|Placebo group|consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.
16618281|NCT02492685|Experimental|Contrast enhanced EUS group|Contrast enhanced EUS with quantitative analysis
16618282|NCT02492659|Experimental|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
16618283|NCT02492659|Other|control group|the control group underwent conventional phacoemulsification
16618284|NCT02492646|Experimental|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
16618285|NCT02492646|Experimental|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
16618286|NCT02492633|Active Comparator|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
16618287|NCT02492633|Experimental|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
16618288|NCT02492620|Active Comparator|Ferric Citrate|Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
16618289|NCT02492620|No Intervention|Standard of Care (SOC)|Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.
16618290|NCT02492607|Active Comparator|Standard treatment|"Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.
~Follow-up:by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years."
16618421|NCT02491710|Active Comparator|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
16618291|NCT02492607|Experimental|Active surveillance|Active surveillance : monitoring by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.
16618292|NCT02492594||Pediatric patients with febrile neutropenia|Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed
16618293|NCT02492594||Adult patients with febrile neutropenia|Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed
16618294|NCT02492568|Experimental|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
16618295|NCT02492568|Active Comparator|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
16618296|NCT02492555|Experimental|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
16618297|NCT02492555|Active Comparator|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
16618298|NCT02492542|Experimental|Electric Stimulation Treatment|Patients in the intervention group were treated with electric stimulation based on the routine clinical nursing.
16618299|NCT02492542|No Intervention|control group|patients in this group only received routine clinical nursing without electric stimulation
16618300|NCT02492529|Other|Healthy volunteers|"60 old healthy volunteers (aged 25-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Neuropsychological tests
~Experimental procedure"
16618301|NCT02492529|Experimental|Patients with early Alzheimer disease|"20 patients (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Neuropsychological tests
~Experimental procedure
~A cranial MRI"
16618302|NCT02492529|Experimental|Old healthy volunteers|"20 healthy volunteers (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Neuropsychological tests
~Experimental procedure
~A cranial MRI"
16618303|NCT02492516|Experimental|Stem cell|The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.
16618304|NCT02492503|Active Comparator|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
16618305|NCT02492503|Active Comparator|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
16618306|NCT02492490|Experimental|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.
~Subjects with uremia in the intervention group will undergo puncture to collect SVF
~SVF will be cultured to abstain MSC
~The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
16618307|NCT02492490|Active Comparator|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
16618308|NCT02492477|Experimental|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
16618309|NCT02492477|Experimental|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
16618310|NCT02492464|Active Comparator|Red yeast rice|Red yeast rice extract 200 mg, containing 10 mg monacolin K per daily dose, 1 capsule per day, per 6 months
16618311|NCT02492464|Placebo Comparator|Placebo|Placebo 200 mg (neutral fibre), 1 capsule per day, per 6 months
16618312|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
16618313|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
16618314|NCT02492451|No Intervention|Control group|Only IUI
16618315|NCT02492438|Active Comparator|PPV23 naive, PPV23 vaccination|vaccination with PPV-23 in 40 PPV-23 naive patients
16618316|NCT02492438|Experimental|PPV23 naive, PCV13 vaccination|vaccination with PCV-13 in 40 PPV-23 naive patients
16618317|NCT02492438|Experimental|PPV23 > 4 years ago, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago
16618318|NCT02492438|Experimental|PPV23 < 4 years, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago
16618319|NCT02492412|Experimental|HE10|Drug: HE10 1~2 drops b.i.d at 12 hour interval for 12 weeks
16618320|NCT02492412|Active Comparator|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1~2 drops b.i.d at 12 hour interval for 12 weeks
16618321|NCT02492399|Other|myectomy by Morrow|"Procedure: myectomy by Morrow.
~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.
~Evaluation results will be made myoectomy as TEE and direct tensiometer."
16618322|NCT02492399|Other|extended myectomy|"Procedure: extended myectomy.
~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.
~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
16618323|NCT02492386|Experimental|Treatment|Bioabsorbable everolimus-eluting stent deployment
16618324|NCT02492373|Active Comparator|laser+steroid 2 days before and after laser|Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.
16618325|NCT02492373|Other|laser+steroid 2 days after laser|Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment
16618326|NCT02492360||Severe Toxicity Group|Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
16618327|NCT02492360||Control Group|Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
16618328|NCT02492347|Active Comparator|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
16618329|NCT02492347|Other|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
16618330|NCT02492321|Active Comparator|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
16618331|NCT02492321|Placebo Comparator|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
16618332|NCT02492308|Experimental|SVF-MSC induction|"collection of autologous SVF
~culture of SVF to abstain MSC
~infusion of MSC during and after living-relative kidney transplantation"
16618333|NCT02492308|Active Comparator|Basiliximab induction|The control group will be inducted with Basiliximab
16618334|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
16618335|NCT02492282|Experimental|Closed-Loop|This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
16618336|NCT02492282|Active Comparator|Open-Loop|This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.
16618337|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
16618338|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
16618339|NCT02492256|Active Comparator|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
16618340|NCT02492256|Experimental|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
16618341|NCT02492243|Experimental|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction >=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
16618342|NCT02492230|Active Comparator|Control Group|After successful PCI the control group will take Triple therapy (warfarin + clopidogrel+aspirin) during 45 days and after combination of warfarin+clopidogrel to 6 months after procedure and then only warfarin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up.
16618343|NCT02492230|Experimental|Study Group|Left Atrial Appendage Closure Device will be implanted immediately after successful PCI procedure. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The study group will take Triple therapy (warfarin+clopidogrel+aspirin) during 45 days following PCI and after control TEE, warfarin will be discontinued. Then patients from the study group will take DAPT combination (clopidogrel+aspirin) to 6 months after procedure and then only aspirin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up
16618344|NCT02492217|Experimental|Adalimumab|Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.
16618345|NCT02492204||Survivors|
16618346|NCT02492204||Non survivors|
16618347|NCT02492191|Active Comparator|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
16618348|NCT02492191|No Intervention|Control|The control group will receive standard care; i.e., no follow-up
16618459|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
16618349|NCT02492178|Experimental|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
16618350|NCT02492178|Experimental|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
16618351|NCT02492165|Experimental|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
16618352|NCT02492165|Experimental|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
16618353|NCT02492165|Experimental|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
16618354|NCT02492165|Experimental|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
16618355|NCT02492152|No Intervention|Control group|Women who will not be using this medicine that is checked.
16618356|NCT02492152|Experimental|Study group|Women who will use DIANATAL according to manufacturer's protocol from the stage of active labor.
16618357|NCT02492139|Other|Pumping|Each particpant will pump with the current pumpset one week and then two weeks with the pumpset
16618358|NCT02492126||Chronic Cough|Subjects with chronic cough will undergo cough reflex sensitivity testing to citric acid. The dose, starting at 0.03 mol/L citric acid will be administered as single breath inhalations using flow-limited calibrated pots and a dosimeter with 3 placebo inhalations of normal saline randomly interspersed. Following each inhalation, the number of coughs in the subsequent 15 seconds will be counted and recorded. The challenge will be terminated once the citric acid has induced 5 or more coughs.
16618359|NCT02492113|Experimental|Patients with BMI > 35|"ICU patients with a BMI > 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation
~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
16618360|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant
~Patient Enrollment and Baseline Data Collection
~First Intervention Visit:
~Comprehensive assessment of sexual dysfunction
~Normalization & Education
~Therapeutic interventions
~Referral to Sexual Health Clinic if applicable
~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
16618361|NCT02492087|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
16618362|NCT02492087|Sham Comparator|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
16618363|NCT02492074|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
16618364|NCT02492074|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
16618365|NCT02492074|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)
16618366|NCT02492074|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
16618367|NCT02492061|Active Comparator|Demand creation|In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
16618368|NCT02492061|No Intervention|Standard of care|In the standard of care arm, participants receive general adult health talks to educate them about the importance of HIV testing (including couples' HCT) but no invitations are issued to invite couples to test for HIV together with their partners at a designated health facility. However, couples can seek HCT out of their own volition. The sessions are not stratified by marital status, and attendants include all those who are willing and are able to attend.
16618369|NCT02492048|Active Comparator|Split Thickness Skin Graft Harvest|Retrospective review
16618370|NCT02492048|Experimental|Cellutome Epidermal Harvesting System|Prospective patients will receive a skin graft utilizing the Cellutome Epidermal Harvesting System
16618371|NCT02492035|Experimental|Physical activity|Tailoring intervention with kinesiologist
16618372|NCT02492035|Experimental|Diet|Tailoring intervention with nutritionist
16618373|NCT02492035|Experimental|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
16618374|NCT02492035|No Intervention|Standard medical care|Follow with family doctor as usual care.
16618375|NCT02492022|Experimental|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
16618376|NCT02492022|Experimental|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
16618377|NCT02492022|Placebo Comparator|Placebo|Encapsuled non active ingredients
16618419|NCT02491723|Experimental|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
16618420|NCT02491710|Experimental|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
16618380|NCT02491996|Experimental|DTIG|Outpatients who treated by DTIG at Outpatient Unit for Gambling Disorder of Kurihama Medical and Addiction Center
16618381|NCT02491983|Active Comparator|Arm A|Combination of Palbociclib and Letrozole
16618382|NCT02491983|Experimental|Arm B|Combination of Palbociclib and Fulvestrant
16618383|NCT02491970|Experimental|Fluticasone/Formoterol|Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
16618384|NCT02491970|Active Comparator|Fluticasone/Salmeterol|Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
16618385|NCT02491957|Experimental|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
16618386|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
16618387|NCT02491931|Active Comparator|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
16618388|NCT02491931|Placebo Comparator|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
16618389|NCT02491918|Active Comparator|In the bag IOL|Cataract surgery with IOL implantation in the capsular bag
16618390|NCT02491918|Active Comparator|Optic Capture of IOL|intraocular lens implantation in the capsular bag with posterior optic capture
16618391|NCT02491905|Experimental|low dose HL tablet|HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal
16618392|NCT02491905|Experimental|high dose HL tablet|HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal
16618393|NCT02491905|Placebo Comparator|placebo group|Placebo by oral administration, twice daily in an hour after meal
16618394|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
16618395|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
16618396|NCT02491879|Experimental|Ketoprofen|Ketoprofen gel
16618397|NCT02491879|Placebo Comparator|Placebo|Placebo form of ketoprofen gel
16618398|NCT02491866|Other|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
16618399|NCT02491840|Experimental|Gastric and cardia adenocarcinomas|Biopsy of Gastric and cardia adenocarcinomas
16618400|NCT02491827||Cellvizio mini laser probe|Cellvizio mini laser probe will be administered via the endoscopic device used for the neurosurgical procedure to provide confocal laser endomicroscopy in patients requiring neurosurgery due to glioma multiforme or subcranial tumors
16618401|NCT02491814|Experimental|1% M.F. Milk and Breakfast Cereal|Breakfast meal: 250 ml 1% M.F. Milk, 54 g Cheerios breakfast cereal, 100 mL water
16618402|NCT02491814|Experimental|Yogurt Beverage and Breakfast Cereal|Breakfast meal: 250 ml Yogurt Beverage, 54 g Cheerios breakfast cereal, 100 mL water
16618403|NCT02491814|Experimental|Soy Beverage and Breakfast Cereal|Breakfast meal: 250 ml Soy Beverage, 54 g Cheerios breakfast cereal, 100 mL water
16618404|NCT02491814|Experimental|Almond Beverage and Breakfast Cereal|Breakfast meal: 250 ml Almond Beverage, 54 g Cheerios breakfast cereal, 100 mL water
16618405|NCT02491814|Experimental|Water (control) and Breakfast Cereal|Breakfast meal: 250 ml Water, 54 g Cheerios breakfast cereal, 100 mL water
16618406|NCT02491801|Experimental|3.25% M.F. Milk|3.25% M.F. Milk
16618407|NCT02491801|Experimental|Greek Yogurt|Greek Yogurt (2% M.F.)
16618408|NCT02491801|Experimental|Cheddar Cheese|Regular Fat Cheddar Cheese
16618409|NCT02491801|Experimental|Control 1|Skim milk
16618410|NCT02491801|Experimental|Control 2|Filtered water, calorie-free control
16618411|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
16618412|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
16618413|NCT02491762||bilateral|bilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
16618414|NCT02491762||unilateral|unilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
16618415|NCT02491749|Experimental|Ultra Fast-Track Anesthesia|Patients who fulfilled the extubation criteria were extubated at the end of surgery and transferred to the ICU for follow up.
16618416|NCT02491749|Experimental|Conventional|patients who did not fulfill extubation criteria were left intubated and sedated and transferred to the ICU for later management
16618417|NCT02491736|Experimental|ketoprofen|2.5% ketoprofen gel
16618418|NCT02491736|Placebo Comparator|Placebo|Placebo gel
16618422|NCT02491697|Active Comparator|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.
~Drug: Capecitabine"
16618423|NCT02491697|Experimental|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.
~Drug: Capecitabine"
16618424|NCT02491684|Placebo Comparator|Placebo (matching)|Placebo, once daily inhalation for 14 days
16618425|NCT02491684|Experimental|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
16618426|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
16618427|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
16618428|NCT02491658|Experimental|Treat Psoriasis Vulgaris with UC-MSCs|Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1×10^6/kg) within 8 weeks.
16618429|NCT02491645|Experimental|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,
~Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .
~Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
16618430|NCT02491645|No Intervention|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
16618431|NCT02491632|Experimental|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
16618432|NCT02491632|Experimental|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
16618433|NCT02491619|Experimental|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
16618434|NCT02491606|Experimental|Load only|Loading with tafenoquine 400 mg base for three days followed by placebo weekly.
16618435|NCT02491606|Experimental|Low weekly dose|Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.
16618436|NCT02491606|Experimental|High weekly dose|Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.
16618437|NCT02491606|Experimental|Placebo|Loading with placebo for 3 days followed by placebo once weekly.
16618438|NCT02491580||KTx Uppsala|Patients who have received a kidney transplant in Uppsala.
16618439|NCT02491580||KTx Europe|Patients who have received a kidney transplant in Uppsala.
16618440|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
16618441|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
16618442|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
16618443|NCT02491554|Active Comparator|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
16618444|NCT02491554|Experimental|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
16618445|NCT02491541|Experimental|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
16618446|NCT02491541|Active Comparator|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
16618447|NCT02491528|Experimental|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
16618448|NCT02491528|Active Comparator|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
16618449|NCT02491502|Experimental|Echopulse|Echopulse HIFU
16618450|NCT02491489|Experimental|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
16618451|NCT02491489|Active Comparator|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
16618452|NCT02491476|Experimental|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
16618453|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
16618454|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
16618455|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
16618456|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
16618457|NCT02491450|Experimental|A Test|Test drug (Heterosofir)1 tablet contains 400 mg Sofosbuvir
16618458|NCT02491450|Active Comparator|B Reference|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
16618460|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
16618461|NCT02491424|Experimental|Fixation of ITAP to lower limb amputees.|"Direct skeletal fixation of ITAP to lower limb amputees. 20 patients in the study will be fitted with Intraosseous Transcutaneous Amputation Prosthesis.
~The device has been designed to be surgically implanted in a one stage procedure."
16618462|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
16618463|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
16618464|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
16618465|NCT02491385|Experimental|TEA|thoracic epidural analgesia group
16618466|NCT02491385|Active Comparator|iv-PCA|intravenous patient controlled analgesia group
16618467|NCT02491372|Experimental|Intervention|Acceptance and commitment therapy group
16618468|NCT02491372|No Intervention|Comparison|Treatment as usual
16618469|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16618470|NCT02491346|Active Comparator|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
16618471|NCT02491346|Experimental|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
16618472|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.
~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
16618473|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.
~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.
~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
16618474|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.
~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.
~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
16618475|NCT02491320|Experimental|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
16618476|NCT02491320|Active Comparator|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
16618477|NCT02491307|Experimental|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
16618478|NCT02491307|No Intervention|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
16618479|NCT02491294|Experimental|School Only|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components
16618480|NCT02491294|Experimental|School + Family|Students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs)
16618481|NCT02491294|Experimental|School + About Eating|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components and their parents are invited to participate in the online 6 lesson About Eating program.
16618482|NCT02491294|Experimental|School + Family + About Eating|students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs) and their parents are invited to participate in the online 6 lesson About Eating program.
16618483|NCT02491294|No Intervention|Control|students and their parents in all schools during cohort 1 and 4 (and Ponderosa students in cohort 3) are tested but provided no intervention
16618484|NCT02491281|Experimental|LNA043|LNA043 given intra-articularly
16618485|NCT02491281|Placebo Comparator|Placebo|Placebo given intra-articularly
16618486|NCT02491268|Experimental|Cilostazol 50mg B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.
~Protocol treatment defines as follows;
~Investigational Treatment:
~Cilostazol 50mg B.I.D. p.o. 96 Weeks"
16618487|NCT02491268|Placebo Comparator|Placebo B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.
~Protocol treatment defines as follows;
~Comparative Treatment:
~Placebo B.I.D. p.o. 96 Weeks"
16618488|NCT02491255|Experimental|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
16618489|NCT02491229|Other|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
16618490|NCT02491229|Other|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
16618491|NCT02491216|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
16618492|NCT02491216|No Intervention|Control Group|No acupressure therapy will be provided during the study.
16618493|NCT02491203|No Intervention|Usual care|All study participants in the control group will receive a 4-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
16618494|NCT02491203|Experimental|Telerehabilitation system|Participants in the experimental group will receive four weeks written home exercise program provided by a clinician, i.e. usual care discharge home program plus virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and the program adapted to ensure it remains at an appropriate level for the patient.
16618495|NCT02491190|Experimental|Treatment|Empower educational module: After the patient activation measure/s are collected, for parents or patients assigned to the intervention arm, they will be given an opportunity to launch the EMPOWER video and interactive powerpoint. They will be able to pause on reviewing the educational material and come back to it, as with other assigned education, and they will be able to review it again if they would like. Discharge surveys will be assigned 24 hours prior to the estimated discharge time in Apex. Oneview will display notifications that the surveys have been assigned.
16618496|NCT02491190|No Intervention|Control|Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
16618497|NCT02491177|Other|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
16618498|NCT02491177|Other|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
16618499|NCT02491177|Other|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
16618500|NCT02491177|No Intervention|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
16618501|NCT02491164|Experimental|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
16618502|NCT02491138|Placebo Comparator|Standard information|In this arm, participants will receive standard information pamphlets about the benefits of good sleeping habits.
16618503|NCT02491138|Experimental|Appearance-based information|In this arm, participants will receive information about how sleep modifies their physical appearance. This will involve a computer transformation that morphs their face according to hours of sleep obtained.
16618504|NCT02491125|Placebo Comparator|Placebo|12 weeks placebo maltodextrin 15g/day ( 5 g in beverage, to be consumed three times a day)
16618505|NCT02491125|Experimental|soluble wheat bran fibre|12 weeks soluble wheat bran fibre 15g/day (5 g in beverage, to be consumed three times a day)
16618506|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
16618533|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.
~Patients who meet the criteria for clinical progression will be treated as per treating MD."
16618732|NCT02489656|Experimental|Coloplast Hydrocoated silicone JJ stent|Double loop ureteral stent endoscopic placement
16618507|NCT02491086|Experimental|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling [25-27]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
16618508|NCT02491086|Active Comparator|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
16618509|NCT02491073||Eslicarbazepine acetate treated|
16618510|NCT02491073||Non-Eslicarbazepine acetate treated|
16618511|NCT02491060|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
16618512|NCT02491060|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
16618513|NCT02491047|Experimental|BonyPid-1000|Implantation of BonyPid-1000 medical device, constructed of bone filler coated with controlled release antibiotic formulation, concomitantly with standard of care treatment (SOC)
16618514|NCT02491047|Other|Study control arm|Standard of care treatment (SOC) only
16618515|NCT02491034|Other|Intervention|Depression Education Intervention
16618516|NCT02491021|Active Comparator|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
16618517|NCT02491021|No Intervention|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
16618518|NCT02491008|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
16618519|NCT02491008|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
16618520|NCT02490995|No Intervention|Group A|Information given by the anaesthetist during the consultation
16618521|NCT02490995|Experimental|Group B|Movie + Information given by the anaesthetist during the consultation
16618522|NCT02490982||Teriflunomide|Patient-reported outcomes and clinical assessment
16618523|NCT02490956|Experimental|Rabies vaccination|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
16618524|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
16618525|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
16618526|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
16618527|NCT02490930|Experimental|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
16618528|NCT02490917|Experimental|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
16618529|NCT02490917|Other|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
16618530|NCT02490904|Experimental|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
16618531|NCT02490904|Placebo Comparator|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
16618532|NCT02490891|Experimental|PET scan with RGD K5 imaging|PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
16618634|NCT02490267||control group|age matched children without eye and vision problems.
16618635|NCT02490254||1|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.
16618636|NCT02490228|Other|surgical group|transurethral resection of urethral caruncle
16618637|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
16618534|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.
~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
16618535|NCT02490865|Experimental|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
16618536|NCT02490865|Placebo Comparator|Normal Saline|Administration of normal saline used as control
16618537|NCT02490852|Experimental|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
16618538|NCT02490852|Active Comparator|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
16618539|NCT02490852|Active Comparator|Human milk|Healthy term infants fed exclusively human milk
16618540|NCT02490839|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
16618541|NCT02490839|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
16618542|NCT02490826|Active Comparator|Table-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a table top material version.
~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
16618543|NCT02490826|Active Comparator|Tablet-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a tablet (digital) material version.
~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
16618544|NCT02490813|Placebo Comparator|Control|This arm will receive the placebo.
16618545|NCT02490813|Experimental|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
16618546|NCT02490800|Experimental|Drug: BAL101553|Oral daily administration of BAL101553
16618547|NCT02490787|Experimental|Concizumab|
16618548|NCT02490787|Placebo Comparator|Placebo|
16618549|NCT02490774|Experimental|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
16618550|NCT02490774|Experimental|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
16618551|NCT02490774|Experimental|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
16618552|NCT02490774|Experimental|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
16618553|NCT02490774|Active Comparator|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
16618554|NCT02490774|Active Comparator|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
16618555|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
16618556|NCT02490748|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
16618557|NCT02490748|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
16618558|NCT02490735|No Intervention|No-CIK|After accepting chemotherapy, patients will regularly follow up.
16618559|NCT02490735|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year
16618560|NCT02490722|Active Comparator|Intervention|Four times two hours interdisciplinary patient education and usual care
16618561|NCT02490722|No Intervention|Control|Usual care
16618562|NCT02490709|Experimental|Local excision|Local excision for rectal cancer with good response
16618563|NCT02490696|Experimental|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
16618564|NCT02490696|Experimental|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
16618565|NCT02490683|Experimental|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
16618566|NCT02490683|Experimental|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
16618567|NCT02490683|Placebo Comparator|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
16618568|NCT02490670|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
16618569|NCT02490670|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
16618570|NCT02490657|Experimental|Iloprost group|
16618571|NCT02490657|Placebo Comparator|normal saline|
16618572|NCT02490644||MGB1 in valvular heart surgery|Evaluation of the high mobility group box 1 as a prognostic biomarker in patients undergoing valvular heart surgery
16618573|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
16618574|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
16618575|NCT02490618|Experimental|Test|Probiotic tablet
16618576|NCT02490618|Placebo Comparator|Control|Control tablet
16618577|NCT02490605|Experimental|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
16618578|NCT02490605|Active Comparator|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
16618579|NCT02490592|Experimental|G1|Thirty children aged seven to twelve years who had seventy one active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride foam, Flúor Care (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
16618580|NCT02490592|Experimental|G2|Twenty-eight children aged seven to twelve years who had seventy five active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride gel, Flugel FFA (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
16618581|NCT02490579||Facebook Survey Group|"During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and ad copy followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics."
16618582|NCT02490579||Clinical Survey Group|During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
16618583|NCT02490579||Social Network Group|Once a pregnant participant completes the survey, she will be asked to provide her email address. If she is willing to do so, Qualtrics will automatically send her an email containing a weblink to the survey for her social network. She can then provide this link to 1 or 2 social network members that she feels influence her health behaviors during pregnancy. These members are asked similar questions about their response to the video, as well as some additional questions about how they advise their pregnant person about different health topics. It is necessary to provide a unique weblink to her, so that the survey responses from the pregnant woman and her unique social network members can be linked.
16618584|NCT02490566|Experimental|Technology Arm|Tablet computer with chronic disease apps will be given to patients. This tablet will also be used for follow-up visits done via video conferencing. Intervention: Telehealth.
16618585|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of ~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
16618586|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of ~1 million inhabitants, the fourth urban area in France)
16618587|NCT02490540|Experimental|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
16618588|NCT02490540|Experimental|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
16618589|NCT02490540|Experimental|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
16618590|NCT02490527|Placebo Comparator|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
16618591|NCT02490527|Experimental|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
16618592|NCT02490514||Mircera|Patients with stage III-IV CKD received open-label Mircera for 12 months at a dose to be determined by the investigator.
16618593|NCT02490501|Active Comparator|SC0806|Intervention with SC0806 (implantation of device with FGF1 and peripheral nerves) in addition to rehabilitation
16618594|NCT02490501|Other|Controls|Rehabilitation only
16618595|NCT02490488|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
16618596|NCT02490488|Placebo Comparator|Placebo & gemcitabine|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
16618597|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
16618638|NCT02490202|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
16618639|NCT02490202|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
16618733|NCT02489656|Active Comparator|Boston Percuflex Plus JJ stent|Double loop ureteral stent endoscopic placement
16618598|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
16618599|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
16618600|NCT02490462|Experimental|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
16618601|NCT02490462|Active Comparator|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
16618602|NCT02490449|Experimental|Exprerimental group|medication after diet
16618603|NCT02490449|Active Comparator|control group|medication before diet
16618604|NCT02490436|Experimental|A: active drug first|Cetuximab in treatment period 1, placebo in treatment period 2, and open-label cetuximab in treatment period 3.
16618605|NCT02490436|Experimental|B: placebo first|Placebo in treatment period 1, cetuximab in treatment period 2, and open-label cetuximab in treatment period 3.
16618606|NCT02490423|Active Comparator|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
16618607|NCT02490423|No Intervention|Standard of Care|The standard of care arm will utilize Intermountain cardiovascular clinical program care processes as they are in place today for treatment of the study subjects.
16618608|NCT02490410|Experimental|whey protein|2 x 10g whey protein per day orally for 6 months
16618609|NCT02490410|Other|whey protein+soy protein|10g whey protein + 10g soy protein per day orally for 6 months
16618610|NCT02490410|Other|soy protein|2 x 10g soy protein per day orally for 6 months
16618611|NCT02490397|Experimental|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
16618612|NCT02490397|Sham Comparator|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
16618613|NCT02490384|Active Comparator|Physical exam indicated cerclage|Cerclage
16618614|NCT02490384|No Intervention|Expectant management|No cerclage
16618615|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.
~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
16618616|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.
~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
16618617|NCT02490358||1|Healthy smoking subjects
16618618|NCT02490358||2|COPD smoking subjects
16618619|NCT02490358||3|COPD ex-smoker subjects
16618620|NCT02490345|Active Comparator|Gabapentin Administration|gabapentin 600mg orally every 8 hours x 48 hours
16618621|NCT02490345|Placebo Comparator|Placebo|Placebo , 1 tablet, orally every 8 hours x 48 hours
16618622|NCT02490332|Experimental|Ventilation tube treatment|Ventilation tube insertion in the tympanic membrane
16618623|NCT02490332|No Intervention|Conservative treatment|Conventional treatment
16618624|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
16618625|NCT02490306|Experimental|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
~Interventions: Strokefinder MD100 measurement"
16618626|NCT02490306|Experimental|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.
~Interventions: Strokefinder MD100 measurement"
16618627|NCT02490306|Experimental|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
~Interventions: Strokefinder MD100 measurement"
16618628|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.
~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
16618629|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.
~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
16618630|NCT02490280|Experimental|Trier Social Stress Test|Participants will be administered the Trier Social Stress Test (TSST). The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
16618631|NCT02490267||1|children with primary or secondary glaucoma
16618632|NCT02490267||2|children w/ cataract or previously treated for cataract
16618633|NCT02490267||3|children w/ microphthalmia, anophthalmia or coloboma
16618640|NCT02490189|Experimental|Mindfulness-Based Intervention|Participants in the mindfulness-based intervention arm will receive 12 weekly sessions of 2 to 2.5 hours duration. The intervention will be delivered in a group format. Participants will be assigned weekly homework.
16618641|NCT02490189|Active Comparator|Cognitive Behavior Group Therapy|Participants in the cognitive behavior group therapy arm will receive 12 weekly sessions of 2 to 2.5 hours in duration. Participants will be assigned weekly homework.
16618642|NCT02490176|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
16618643|NCT02490176|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
16618644|NCT02490163|Experimental|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
16618645|NCT02490163|Active Comparator|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
16618646|NCT02490150|Experimental|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
16618647|NCT02490150|Active Comparator|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
16618648|NCT02490137|Experimental|Game Players|Participants that will play video game
16618649|NCT02490137|No Intervention|Control|No video game experience
16618650|NCT02490124||Type 1 Diabetic|Type 1 Diabetic
16618651|NCT02490124||Control|normal healthy control
16618652|NCT02490111|Experimental|DWJ1319 300 mg BID|DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
16618653|NCT02490111|Experimental|DWJ1319 300 mg QD|DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
16618654|NCT02490111|Placebo Comparator|Placebo|Placebo, orally, twice daily (BID) for up to 12 months
16618655|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
16618656|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
16618657|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
16618658|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
16618659|NCT02490098|Active Comparator|Sensor-augmented pump therapy|Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
16618660|NCT02490085|Active Comparator|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
16618661|NCT02490085|Active Comparator|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
16618662|NCT02490072|Experimental|Dexmedetomidine group|
16618663|NCT02490072|Placebo Comparator|normal saline|
16618664|NCT02490059|Active Comparator|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
16618665|NCT02490059|Experimental|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
16618666|NCT02490046|Experimental|MS and rec UTIs not using a catheter|people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose
16618667|NCT02490046|Experimental|MS and rec UTIs using a catheter|people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose
16618668|NCT02490033|Other|Contact force unblinded|
16618669|NCT02490033|Other|Contact force blinded|
16618670|NCT02490033|Other|ECI unblinded|
16618671|NCT02490033|Other|ECI blinded|
16618672|NCT02490020|Experimental|iv of BMSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)
16618673|NCT02490020|No Intervention|routine treatment protocol to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
16618674|NCT02490020|Experimental|ia and iv of MSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)
16618675|NCT02490020|No Intervention|routine treatment to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
16618676|NCT02490020|Experimental|Routine CMR treatment plus MSC to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)
16618677|NCT02490020|No Intervention|Routine CMR treatment to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)
16618678|NCT02490020|Experimental|Routine AMR treatment plus MSC to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)
16618679|NCT02490020|No Intervention|Routine AMR treatment to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)
16618680|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
16618681|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
16618682|NCT02489994|Experimental|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
16618683|NCT02489981||Spiriva|Patients with severe persistent asthma
16618684|NCT02489968|Experimental|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
16618685|NCT02489968|Experimental|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
16618686|NCT02489968|Experimental|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
16618687|NCT02489968|Experimental|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
16618688|NCT02489955|Experimental|AUC group|
16618689|NCT02489955|Active Comparator|Trough dose monitoring|
16618690|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
16618691|NCT02489929|Experimental|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
16618692|NCT02489916|Experimental|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
16618693|NCT02489903|Experimental|Small Cell Lung Cancer (Arm 1)|RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).
16618694|NCT02489903|Active Comparator|Small Cell Lung Cancer (Arm 2)|Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity
16618695|NCT02489903|Experimental|Non Small Cell Lung Cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
16618696|NCT02489903|Experimental|Neuroendocrine tumors|RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
16618697|NCT02489903|Experimental|Ovarian epithelial cancer (Arm 1)|RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).
16618698|NCT02489903|Active Comparator|Ovarian epithelial cancer (Arm 2)|Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity
16618699|NCT02489890|No Intervention|Non-CIK|After accepting chemotherapy, patients will regularly follow up.
16618700|NCT02489890|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year.
16618701|NCT02489877||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis
16618702|NCT02489877||without Multiple Sclerosis|Healthy individuals without neurological disease associated
16618703|NCT02489877||with other neurological diseases|Patients diagnosed with the following diseases: Lateral Amniotrofic Sclerosis, Headache , Parkinson's disease, Dementia and Epilepsy.
16618704|NCT02489864|Active Comparator|Terlipressin and albumin|"Patients in this group received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
~albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day."
16618705|NCT02489864|Placebo Comparator|Albumin|Only albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day.
16618706|NCT02489851|Active Comparator|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)
~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
16618707|NCT02489851|Active Comparator|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)
~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
16618708|NCT02489825|Other|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
16618709|NCT02489825|Other|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
16618710|NCT02489812|Experimental|music|The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
16618711|NCT02489799|Active Comparator|Intervention|Advance care planning video
16618712|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
16618713|NCT02489786|Active Comparator|Regimen 1|patient takes 0.25mg of digoxin daily except friday
16618714|NCT02489786|Active Comparator|Regimen 2|patient takes 0.25mg of digoxin daily except Thursday and Friday
16618715|NCT02489786|Active Comparator|Regimen 3|patient takes 0.125mg of digoxin daily
16618716|NCT02489786|Active Comparator|Regimen 4|digoxin dose is calculated using Jusko-Koup method and given daily
16618717|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
16618718|NCT02489773||Group 2|HbA1c values <7.5%
16618719|NCT02489760|Experimental|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
16618720|NCT02489760|Experimental|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
16618721|NCT02489747|Experimental|WBE group|wheat bran extract
16618722|NCT02489747|Placebo Comparator|Placebo group|placebo
16618723|NCT02489734|Experimental|low concentration (LC)|low concentration group
16618724|NCT02489734|Experimental|high concentration (HC)|high concentration group
16618725|NCT02489708|Experimental|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
16618726|NCT02489695|Experimental|axitinib|axitinib 10mg twice a day
16618727|NCT02489682|Experimental|Informed Consent Format - short written|"Intervention to be administered:
~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
16618728|NCT02489682|Experimental|Informed Consent Format - long written|"Intervention to be administered:
~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
16618729|NCT02489682|Experimental|Informed Consent Format - video|"Intervention to be administered:
~- Video informed consent information, followed immediately by outcomes questionnaire"
16618730|NCT02489669|No Intervention|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for >18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
16618731|NCT02489669|Experimental|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP >18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
16618734|NCT02489643|Experimental|Receiving training|Patients will be visited and receive information about the prescribed topical treatment according to the normal course and procedure of an outpatient visit at our institution. At the end of the visit, they will also receive practical instructions on dosages and application modalities of the topical therapy.
16618735|NCT02489643|No Intervention|No-receiving training|
16618736|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
16618737|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
16618738|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).
~-- Pathologic evaluation of excised tissue"
16618739|NCT02489604|Experimental|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
16618740|NCT02489604|Experimental|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
16618741|NCT02489591|No Intervention|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
16618742|NCT02489591|Experimental|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
16618743|NCT02489565|No Intervention|Tertiary care|Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
16618744|NCT02489565|Experimental|Primary care|Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
16618745|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
16618746|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
16618747|NCT02489526|Experimental|VVZ-149 Injections|
16618748|NCT02489526|Placebo Comparator|Placebo|
16618749|NCT02489513|Other|Single group assignment|[14C]-AG-120
16618750|NCT02489500|Active Comparator|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
16618751|NCT02489500|Experimental|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
16618752|NCT02489487|Experimental|VM-1500 + Raltegravir|VM-1500 40 mg in combination with 400 mg Raltegravir
16618753|NCT02489487|Experimental|VM-1500 +Darunavir|VM-1500 40 mg in combination with 600 mg Darunavir boosted with 100 mg Ritonavir
16618754|NCT02489487|Experimental|VM-1500|VM-1500 40 mg alone
16618755|NCT02489474||Recipients undergoing liver transplantation|Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury.
16618756|NCT02489461|Experimental|VM-1500 20 mg + ART|VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
16618757|NCT02489461|Experimental|VM-1500 40 mg + ART|VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
16618758|NCT02489461|Active Comparator|Efavirenz 600 mg + ART|Efavirenz 600 mg (Stage I and Stage II), ART
16618759|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.
~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
16618760|NCT02489435|Experimental|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
16618761|NCT02489435|Experimental|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
16618762|NCT02489435|Experimental|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
16618763|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
16618764|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
16618765|NCT02489409|Experimental|Experimental group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).
16618766|NCT02489409|Active Comparator|Control group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.
16618767|NCT02489396||Grocery Customers|All customers who shop on the Rosie site during the intervention period.
16618768|NCT02489383|Active Comparator|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
16618769|NCT02489383|Active Comparator|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
16618770|NCT02489370|Experimental|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.
~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
16618771|NCT02489370|No Intervention|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
16619022|NCT02487602|Experimental|D|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a radiolabeled water.
16618772|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
16618773|NCT02489344|Experimental|GZ/SAR402671|Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
16618774|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
16618775|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
16618776|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
16618777|NCT02489292|Experimental|HepaStem|Target total dose 50x10E6 cells/kg
16618778|NCT02489279|Experimental|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
16618779|NCT02489279|Active Comparator|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
16618780|NCT02489266|Experimental|Arm 1|Patients will receive cyclophosphamide and fludarabine followed by infusion of the AKTi-treated TIL, followed by high dose aldesleukin.
16618781|NCT02489253||polygenic hypercholesterolemia|patients with high cholesterol level where no mutation was found in their FH-causing genes and had to gene score in their six LDL-C raising gene score undergo a carotid ultrasound, a CT coronary angiogram and a blood test
16618782|NCT02489253||monogenic FH|patients with a mutation in FH-causing gene undergo a carotid ultrasound, a CT coronary angiogram and a blood test
16618783|NCT02489240|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
16618784|NCT02489240|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
16618785|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
16618786|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
16618787|NCT02489214|Experimental|donafenib tosilate tablets|200mg bid
16618788|NCT02489201|Experimental|donafenib tosilate tablets|200mg bid
16618789|NCT02489188||ankle osteoarthritis|patients with ankle osteoarthritis scheduled for arthroplasty
16618790|NCT02489188||knee osteoarthritis|patients with knee osteoarthritis scheduled for arthroplasty
16618791|NCT02489188||hip osteoarthritis|patients with hip osteoarthritis scheduled for arthroplasty
16618792|NCT02489188||lumbar spinal stenosis|patients with lumbar spinal stenosis scheduled for lumbar spinal stenosis decompression
16618793|NCT02489188||muscle contracture|patients with functionally limited range of motion at the knee because of muscle contracture scheduled for manual therapy
16618794|NCT02489188||healthy subjects|healthy subjects
16618795|NCT02489175|Experimental|Stomaplasty KoringTM group|The KoringTM is a stomaplasty ring made of propylene, flexible and non-absorbable. It is fixed to the anterior sheath of the abdominal wall in order to prevent PSH.
16618796|NCT02489175|No Intervention|No preventive measure|In these patients, the stoma creation will be traditional, with no mesh implanted
16618797|NCT02489162|Experimental|MyotonPRO|Experimental: Measurement of biomechanical properties of mimic muscles on the ipsilateral palsy side with the healthy contralateral side ( case - control design)
16618798|NCT02489162|Active Comparator|Non-invasive electromyography (EMG)|Comparing experimental intervention with gold standard
16618799|NCT02489149|Experimental|Multi-sector interventions|"Multi-sector interventions
~Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.
~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.
~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.
~Helping families to have more knowledge about your citizen rights."
16618800|NCT02489149|Placebo Comparator|Control|Conventional approach of current public food and nutrition policies.
16618801|NCT02489136|Other|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
16618802|NCT02489136|Placebo Comparator|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
16618803|NCT02489136|No Intervention|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
16618804|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
16618839|NCT02488863||Older Adults without Musculoskeletal Pain|Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
16618805|NCT02489110|Experimental|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
16618806|NCT02489110|Active Comparator|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
16618807|NCT02489097|Active Comparator|Nitrous Oxide|Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
16618808|NCT02489097|Placebo Comparator|Air/Oxygen (placebo)|Receives a mixture of 70% Air in 30% Oxygen
16618809|NCT02489071|Experimental|Brain Training|8-session cognitive training program
16618810|NCT02489071|Experimental|Brain Health|8-session cognitive education program
16618811|NCT02489071|No Intervention|Control|Wait-list control group
16618812|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
16618813|NCT02489032|Experimental|SBIRT Training & Support Tool|The SBIRT Training & Support Tool has two components, both of which will be evaluated: (1) online SBIRT Training for EAP and behavioral health practitioners conducting alcohol SBIRT with their adult clients and (2) mobile/web interactive alcohol screening tools and brief intervention protocols to facilitate use of SBIRT by practitioners.
16618814|NCT02489032|Other|Waitlist control|Subjects randomized to the control condition will be placed on a wait-list and given access to the SBIRT Training & Support Tool after 3 months and completion of the 3-month follow-up assessment.
16618815|NCT02489019|Placebo Comparator|Control|Individuals assigned to this condition will receive 0.9 mcg/kg sodium chloride (NaCL)
16618816|NCT02489019|Experimental|Low Dose|Individuals assigned to this condition will receive 1 mcg/kg fentanyl
16618817|NCT02489019|Experimental|High Dose|Individuals assigned to this condition will receive 2 mcg/kg fentanyl
16618818|NCT02489006|Experimental|Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery|"Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery.
~Platinum-based chemotherapy chosen by the study doctor and per standard of care after surgery.
~Olaparib, orally, at 300 mg twice per day, continuously, after chemotherapy."
16618819|NCT02489006|Experimental|Olaparib Prior to Surgery and Post Surgery|Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery and after surgery.
16618820|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
16618821|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
16618822|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
16618823|NCT02488980|Experimental|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
16618824|NCT02488980|Active Comparator|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
16618825|NCT02488980|Placebo Comparator|Placebo|Placebo
16618826|NCT02488967|Active Comparator|Arm I (AC-->WP)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
16618827|NCT02488967|Experimental|Arm II (AC-->WP + carboplatin)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16618828|NCT02488954|Experimental|Probiotics|Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks
16618829|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
16618830|NCT02488902|Placebo Comparator|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
16618831|NCT02488902|Experimental|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
16618832|NCT02488902|Experimental|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
16618833|NCT02488902|Experimental|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
16618834|NCT02488902|Experimental|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
16618835|NCT02488902|Experimental|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
16618836|NCT02488889|Active Comparator|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
16618837|NCT02488889|Active Comparator|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
16618838|NCT02488863||Older Adults with Musculoskeletal Pain|Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
16618840|NCT02488863||Young Controls|Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
16618841|NCT02488850|Active Comparator|Surgery|An anatomical surgical resection of primary tumor
16618842|NCT02488850|Active Comparator|Radiotherapy|Stereotactic Ablative Radiotherapy (SABR), outpatient treatment that is typically delivered in between 3-8 fractions
16618843|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
16618844|NCT02488824|Experimental|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
16618845|NCT02488824|Active Comparator|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
16618846|NCT02488798||postmenopausal bleeding group|"100 women with postmenopausal bleeding undergoing 2D greyscale vaginal ultrasound and 3D Endometrial power Doppler and the features were classified using six different vascular patterns described by IETA group including the following patterns; single dominant vessel without branching, with branching, multiple vessels with focal origin, with multifocal origin at the myometrium-endometrium junction, scattered vessels or circular flow (Kucur et al., 2013 ).
~All patients then had Office hysteroscopy carried out in the outpatient clinic using vaginoscopic approach (Cooper et al., 2010). With endometrial samples from lesions or from the cavity for histopathological analysis."
16618847|NCT02488785|No Intervention|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
16618848|NCT02488785|Experimental|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
16618849|NCT02488772|Experimental|Treatment Group|Patients allocated to treatment group will be supplied with sleep interventions (sleep mask and ear plugs), and standardized instructions of use.
16618850|NCT02488772|Active Comparator|Control Group|Patients allocated to control group will be assessed for sleep quality, but not offered sleep mask and ear plugs. They will receive standard of care as decided by treating emergency physician.
16618851|NCT02488759|Experimental|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified
~**Not participating: Japan, Korea, and Taiwan"
16618852|NCT02488759|Experimental|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
16618853|NCT02488759|Experimental|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified
~**Not participating: Belgium, France and Germany
~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico
~**Not participating in cohort expansion: France, Germany, Korea and Taiwan"
16618854|NCT02488759|Experimental|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified
~** Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands
~Enrollment is closed for this cohort"
16618855|NCT02488759|Experimental|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified
~**Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands
~Enrollment is closed for this cohort"
16618856|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
16618857|NCT02488733|Experimental|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
16618858|NCT02488733|Other|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
16618860|NCT02488707|Active Comparator|LISR group|Cases which undergo rectal resection with laparoscopic intersphincteric resection.
16618861|NCT02488707|Active Comparator|TAMIS Group|Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.
16618862|NCT02488694|Experimental|Arm A: Afatinib|105 patients to be treated with afatinib
16618863|NCT02488694|Active Comparator|Arm B: Pemetrexed|105 patients to be treated with pemetrexed
16618864|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
16618865|NCT02488668|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
16618867|NCT02488642|Experimental|isosorbide dinitrate-oxytocin|"Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
~If the cervical conditions (<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening."
16618868|NCT02488642|Placebo Comparator|misoprostol-oxytocin|"Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
~If the cervical conditions (<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening."
16618870|NCT02488616|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
16618871|NCT02488616|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
16618872|NCT02488603|Experimental|Decision aids|
16618873|NCT02488603|No Intervention|usual care|
16618874|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease
~Clinical intervention:
~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
16618875|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry
~Clinical intervention: Inhaled corticosteroids (ICS)"
16618876|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma
~Clinical Intervention: LABA + LAMA + ICS"
16618877|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma
~Clinical Intervention: LABA + ICS inhaled therapy"
16618878|NCT02488590||OTHER|"patients with another diagnosis or healthy persons
~clinical Intervention: undefined - according to diagnosis"
16618879|NCT02488577|Active Comparator|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
16618880|NCT02488577|Active Comparator|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
16618881|NCT02488564|Experimental|Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin|"Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.
~Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment."
16618882|NCT02488551|Experimental|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
16618883|NCT02488551|Active Comparator|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
16618884|NCT02488538|Active Comparator|Combined oral contraceptives and Fuoxetine|Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. .
16618885|NCT02488538|Active Comparator|Combined oral contraceptives|Group 2 will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
16618886|NCT02488538|Placebo Comparator|Placebo|Group 3 will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine.
16618887|NCT02488525|Experimental|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
16618888|NCT02488525|No Intervention|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
16618889|NCT02488512|Experimental|90Y-DOTATOC|90Y-DOTATOC
16618890|NCT02488499|Active Comparator|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
16618891|NCT02488499|Experimental|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
16618892|NCT02488486|Experimental|Automated postoperative sedation|Postoperative sedation is provided automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 40 and 60.
16618893|NCT02488473|Experimental|Ropivacaine + Dexmedetomidine|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Dexmedetomidine 100ug/ml
16618894|NCT02488473|Placebo Comparator|Ropivacaine + Placebo|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Saline
16618895|NCT02488460|No Intervention|Normal math|This arm serves as the control group receiving regular math lessons
16618896|NCT02488460|Experimental|Active math|This arm serves as the intervention group receiving physically active math lessons
16618897|NCT02488434|Active Comparator|fertile chip|sperm selection by using fertile chip and conventional methods
16618898|NCT02488434|No Intervention|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
16618899|NCT02488421||Patient treated with Apixaban|
16618900|NCT02488421||Patient treated with Rivaroxaban|
16618901|NCT02488421||Patient treated with Dabigatran|
16618902|NCT02488421||Patient treated with vitamin K antagonists|
16618957|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
16618958|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
16619437|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
16618905|NCT02488395||de novo Parkinson's patients|"This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.
~This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
16618906|NCT02488395||matching controls|"This group includes age-matching control participants to the first Parkinson group.
~This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
16618907|NCT02488382|Experimental|Lonquek|treatment with Lonquek for autologous stem cell collection
16618908|NCT02488369|Experimental|Patients with non-Hodgkin's lymphoma|
16618909|NCT02488356|Experimental|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
16618910|NCT02488356|Placebo Comparator|Placebo|Inert fillers that is manufactured to look and taste the same as verum
16618911|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
16618912|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
16618913|NCT02488330|Experimental|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
16618914|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
16618915|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
16618916|NCT02488304|Experimental|HRCT scans|High Resolution Computed Tomography scans will be taken
16618917|NCT02488291|Experimental|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
16618918|NCT02488291|Experimental|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
16618919|NCT02488278|No Intervention|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
16618920|NCT02488265|Experimental|Motor training|Balance training, Screening to prevent falls
16618921|NCT02488265|Experimental|Balance RhytmicalTraining|Balance training, Screening to prevent falls
16618922|NCT02488252|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin at stable dose
16618923|NCT02488252|Experimental|Chinese Medicine on top of standard medical care|"Semi-individualised Chinese Medicine treatment on top of standard medical care The treatment plan consists of 5 different formulas and will be prescribed to patients categorised to 5 subgroups according to clinical manifestation. Patients having multiple manifestations that fit more than 1 subgroup will not be included.
~Minor adjustment of the medication will be allowed and determined by the Chinese Medicine practitioner to reflect actual clinical practice. Dosage will follow strictly the China Pharmacopeia.
~A: spleen and kidney Qi deficiency, B: spleen and kidney Yang deficiency, C: spleen and kidney Qi and Ying deficiency, D: liver and kidney Ying deficiency, E: Ying and Yang deficiency
~Rehmannia-6 decoction: Wolfiporia cocos, Rehmannia glutinosa, Common macrocarpium Fruit, Dioscorea opposita , Paeonia suffruticosa Andr., Oriental waterplantain rhizome
~Rehmannia-8 decoction: Radix Aconiti Lateralis preparata, Cinnamomum cassia Presl, Rehmannia-6 decoction"
16618924|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
16618925|NCT02488226|Experimental|Gaze Contingent|Participants will view social videos using Gaze-contingent eye-tracking technology . If the participants looking patterns deviate from a normative pattern, they will be redirected to the normative point of regard using gaze-contingent cues.
16618926|NCT02488226|No Intervention|Control Condition|Participants will view unaltered social videos which do not change based on where the participant is looking.
16618927|NCT02488213|Active Comparator|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
16618928|NCT02488213|Experimental|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
16618929|NCT02488187|Other|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
16618930|NCT02488187|Other|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
16618931|NCT02488174|Active Comparator|Standard Care|The pre-intervention control condition will be usual care: that is, clinicians practice as usual without clinician notification of risk and without prompting on care practices as recommended by PROOFcheck.
16618932|NCT02488174|Experimental|PROOFcheck|The intervention for this study will consist of 3 parts: 1) Education of clinicians on prevention of severe ARF and MOF in and out of the ICU, and best practice with regards to patients with severe ARF; 2) Clinicians will be notified that a patient they are taking care of has been identified as being at high risk for developing severe ARF requiring prolong MV; 3) Notified clinicians will be directed to PROOFcheck with a bundle of recommendations for best care for patients with ARF.
16618933|NCT02488161||Patients with colorectal cancer|One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.
16618934|NCT02488148|Experimental|Hot yoga|3 hot yoga classes per week to be completed at local studios in Austin, TX.
16618935|NCT02488148|Experimental|Non-heated yoga|3 yoga classes to be completed at local studios in Austin, TX.
16618936|NCT02488148|No Intervention|Control|Maintain usual activities for the 12-week duration of the study.
16618937|NCT02488135|Experimental|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
16618938|NCT02488135|Active Comparator|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
16618939|NCT02488122|Experimental|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
16618940|NCT02488122|Sham Comparator|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
16618941|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
16618942|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
16618943|NCT02488096|Active Comparator|TRUS-Guided Biopsy|Transrectal Ultrasound (TRUS)-guided biopsy systematic 12-core biopsy (standard care)
16618944|NCT02488096|Experimental|MRI + TRUS-Guided biopsy|Prostate MRI later followed by systematic 12-score TRUS-guided biopsy + targeted biopsy of additional MRI-detected scores.
16618945|NCT02488083|Experimental|all subjects treated by UltraShape|all the patients undergo fat reduction treatment by UltraShape
16618946|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
16618947|NCT02488057|Active Comparator|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
16618948|NCT02488057|Active Comparator|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
16618949|NCT02488044|Experimental|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.
~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
16618950|NCT02488031|Experimental|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
16618951|NCT02488031|Experimental|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
16618952|NCT02488018|Experimental|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
16618953|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
16618954|NCT02487992|Experimental|CIK plus S-1 and Bevacizumab|"Cytokine-Induced Killer Cells are used to treat advanced colorectal cancer patients with S-1 and Bevacizumab.
~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress.
~Cytokine-induced killer cells 3 cycles,every 1 year. Continue until the disease progress."
16618955|NCT02487992|No Intervention|S-1 and Bevacizumab|"S-1 is an oral anticancer agent, is a derivative of fluorouracil. Bevacizumab (Avastin) is a recombinant human monoclonal IgG1 antibody, which plays a role in the biological activity of human vascular endothelial growth factor. Bevacizumab is mainly used in the treatment of advanced colorectal cancer.
~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress."
16618956|NCT02487979|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
16619438|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
16618959|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
16618960|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
16618961|NCT02487953|Experimental|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
16618962|NCT02487953|Active Comparator|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
16618963|NCT02487953|Active Comparator|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
16618964|NCT02487940|Active Comparator|Intralipid|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
16618965|NCT02487940|Placebo Comparator|Placebo|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
16618966|NCT02487927||Weaning success|patients pass SBT and weaning without any ventilation in 48 hours
16618967|NCT02487927||weaning failure|patients do not pass SBT or ventilation with any ventilation in 48 hours
16618968|NCT02487914|Active Comparator|lidocaine iontophoresis using interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the iontophoresis of Lidocaine using interferential current.
16618969|NCT02487914|Active Comparator|interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of interferential current.
16618970|NCT02487914|Active Comparator|lidocaine|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of topical Lidocaine.
16618971|NCT02487901|Active Comparator|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
16618972|NCT02487901|Sham Comparator|Drill|making gutter on the hinge side of lamina with conventional drill
16618973|NCT02487888|Experimental|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
16618974|NCT02487888|Experimental|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
16618975|NCT02487888|Experimental|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
16618976|NCT02487888|Experimental|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
16618977|NCT02487888|Experimental|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
16618978|NCT02487875|Experimental|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
16618979|NCT02487875|Active Comparator|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
16618980|NCT02487862|No Intervention|Screening|Participants were screened for the inclusion and exclusion criteria to select the study group. No intervention has been done.
16618981|NCT02487862|Placebo Comparator|catagerizing the study population|The selected participants where assigned into respective groups
16618982|NCT02487862|No Intervention|Stress Reduction Protocol|Participants were evaluated for the outcome of the intervention.
16618983|NCT02487849|Experimental|HIPEC|If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.
16618984|NCT02487836|Other|First attempt stenting (T0 = date of the first act)|Efficacy of laying of a biliary stent for chemotherapy realization
16618985|NCT02487823|Experimental|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
16618986|NCT02487823|Experimental|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
16618987|NCT02487823|Experimental|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
16619883|NCT02481830|Experimental|Arm A Nivolumab|Nivolumab intravenous infusion as specified
16618988|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
16618989|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
16618990|NCT02487797|Experimental|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
16618991|NCT02487797|Active Comparator|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
16618992|NCT02487784|Experimental|Particulate allograft + autogenous bone.|In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
16618993|NCT02487784|Active Comparator|Block allograft|The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
16618994|NCT02487771|Placebo Comparator|Placebo Capsule|
16618995|NCT02487771|Experimental|DHA Capsule|
16618996|NCT02487758|Experimental|Ridge preservation Flap|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
16618997|NCT02487758|Experimental|Ridge preservation Flapless|The test will be a flapless technique with tunneling and an intramucosal vertical incision on the buccal.
16618998|NCT02487745|Active Comparator|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
16618999|NCT02487745|Experimental|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
16619000|NCT02487732|Active Comparator|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
16619001|NCT02487732|Active Comparator|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
16619002|NCT02487719|Active Comparator|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.
~intervention: oral iron sulfate 1 tbl daily until birth"
16619003|NCT02487719|Active Comparator|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.
~intervention: oral iron polymaltose 1 tbl daily until birth"
16619004|NCT02487719|No Intervention|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level > 50 mcg/L at inclusion. No additional iron supplementation.
~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
16619005|NCT02487706|Experimental|Dolutegravir 50mg/day per 5 days|Dolutegravir 50mg/day per 5 days
16619006|NCT02487693|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
16619007|NCT02487693|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
16619008|NCT02487680|Experimental|Breakfast meal|A breakfast like meal will be provided together with a drink to overnight fasted subjects
16619009|NCT02487680|Experimental|Lunch meal|A lunch like meal will be provided together with a drink to overnight fasted subjects
16619010|NCT02487667|Active Comparator|Intervention Group|Therapeutic exercise
16619011|NCT02487667|No Intervention|Control Group|No treatment
16619012|NCT02487654|Active Comparator|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
16619013|NCT02487654|Experimental|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
16619014|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
16619015|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
16619016|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
16619017|NCT02487628|Experimental|HQ® Matrix Soft Tissue Mesh|HQ® Matrix Soft Tissue Mesh is a warp-knitted, multifilament, bioengineered scaffold which is comprised of the silk fibroin protein of the Bombyx mori (B. mori) silkworm. The porous network structure makes it soft and pliable and convenient to implant. The mesh is mechanically strong, biocompatible, and long-term bioresorbable. The pore size is suitable for macrophage migration and recruitment, which hinders bacteria growth. The mesh is provided in single sheets of varying widths and lengths and may be cut to the shape or size desired for a specific application. It is sterile and for single-patient use only.
16619018|NCT02487628|Active Comparator|ULTRAPRO® Partially Absorbable Lightweight Mesh|ULTRAPRO® Partially Absorbable Lightweight Mesh (Ethicon, Inc.) is manufactured from approximately equal parts of absorbable poliglecaprone-25 monofilament fiber and non-absorbable polypropylene monofilament fiber. Designed for open and laparoscopic hernia repairs, it allows surgeons the versatility to perform various hernia repairs with a single technology. It offers excellent strength with minimal foreign body mass, to allow patients to heal more naturally with increased comfort and mobility.
16619019|NCT02487602|Active Comparator|A|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
16619020|NCT02487602|Active Comparator|B|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
16619021|NCT02487602|Placebo Comparator|C|Placebo capsules 30 minutes before a standard radiolabeled lunch.
16619023|NCT02487602|Experimental|E|Up to 5 Gelesis100 and/or placebo capsules 10 minutes before a radiolabeled meal.
16619024|NCT02487589|No Intervention|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).
~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
16619025|NCT02487589|Experimental|Treated group|Telephone support, telemonitoring and tele-exercise
16619026|NCT02487576|Other|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
16619027|NCT02487576|Other|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
16619028|NCT02487563|Experimental|Experimental Group 1|Decitabine in combination with rhTPO.
16619029|NCT02487563|Experimental|Experimental Group 2|Decitabine
16619030|NCT02487563|Active Comparator|Control Group|Conventional treatment except decitabine.
16619031|NCT02487550|Experimental|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
16619032|NCT02487550|Other|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
16619033|NCT02487537|Placebo Comparator|Non-sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day; soft drink does not contain glucose or any kind of sweet tasting substance
16619034|NCT02487537|Active Comparator|Sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day, soft drinks contains an amount of sweetener, which is isosweet compared to 100 g of sucrose in one liter of beverage
16619035|NCT02487524|Other|Nerve resection with pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
16619036|NCT02487524|Other|Nerve resection without pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
16619037|NCT02487524|Other|No nerve resection but pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
16619038|NCT02487511|Active Comparator|14 days|14 days treatment regimen
16619039|NCT02487511|No Intervention|7 days|7 days treatment regimen
16619040|NCT02487498|Experimental|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
16619041|NCT02487498|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
16619042|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
16619043|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
16619044|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
16619045|NCT02487459|Experimental|BPX-501 and AP1903|"Three cohorts, 3 patients each, will receive two infusions (at the same dose) of BPX-501.
~If needed to treat aGVHD, a single dose of AP1903 will be administered IV."
16619046|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
16619047|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
16619048|NCT02487433|Experimental|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
16619049|NCT02487433|Experimental|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
16619050|NCT02487420|Other|Arm 18m|arm 18m: 6 months between step 1 and step 2; 6 months between step 2 and step 3, 3 months between all other steps step by step gradual introduction of egg containing food products during 18 months, unless next step can not be taken
16619051|NCT02487420|Other|arm 30 m|arm 30m: 9 months between step 1 and step 2; 9 months between step 2 and step 3, 6 months between all other steps step by step gradual introduction of egg containing food products during 30 months, unless next step can not be taken
16619052|NCT02487407|Experimental|ODM-109|ODM-109 capsules for oral administration
16619053|NCT02487407|Placebo Comparator|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
16619054|NCT02487394|Active Comparator|Asthma, Smokers and Non-Smokers|In Phase I, One arm will contain subjects who are active smokers and the other arm will contain subjects with no active smoking. Active smoking will be defined as daily use of cigarettes, pipes, cigarillos or cigars at time of entry into the study and through duration of study. No active smoking defined as never smoking or having stopped smoking for 5 years or greater.
16619055|NCT02487394|Active Comparator|COPD, Smokers and Non-Smokers|For Phase II, Phase II will again be divided into two arms based on active smoking status as discussed previously.
16619056|NCT02487381|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
16619057|NCT02487381|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
16619058|NCT02487381|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) a
16619059|NCT02487381|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
16619339|NCT02485509|Experimental|20 mg VM-1500/Placebo Patient group|VM-1500 20 mg or placebo once daily for 7 days.
16619060|NCT02487368|Experimental|Needle stimulation pad|a self-administered treatment with a mechanical needle stimulation pad, a mechanical device to be used for 30 minutes daily for 14 days.
16619061|NCT02487355|Active Comparator|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
16619062|NCT02487355|Active Comparator|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
16619063|NCT02487355|Active Comparator|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
16619064|NCT02487355|Active Comparator|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
16619065|NCT02487342|Experimental|milk|semi-skimmed milk (< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
16619066|NCT02487342|Active Comparator|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
16619067|NCT02487329|Active Comparator|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
16619068|NCT02487329|Experimental|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
16619069|NCT02487329|Experimental|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
16619070|NCT02487329|Experimental|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
16619071|NCT02487316|Experimental|crizotinib combined with chemotherapy|crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
16619072|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
16619073|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
16619074|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
16619075|NCT02487290|Experimental|Treatment|Aneufix ACP-T5
16619076|NCT02487277|Experimental|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4
~1 cycle = 28 days
~PEGPH20: 3ug/kg on Days 1, 8, 15
~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
16619077|NCT02487277|Experimental|Combination therapy alone|"1 cycle = 28 days
~PEGPH20: 3ug/kg on Days 1, 8, 15
~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
16619078|NCT02487251|Experimental|Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
16619079|NCT02487251|Experimental|Supports for Family Mealtimes|"In Phase 1 of the study, participants receive one or more interventions intended to promote the frequency of family meals as an obesity prevention strategy. Supports range from the least to the most comprehensive. The interventions include: Meal Delivery, Ingredient Delivery, Community Kitchen, Healthy Eating Classes, Cooking Demonstrations and Provision of Cookware. The goal of this phase was to identify intervention components most robustly related to primary outcomes.
~The goal of Phase 2 is to test the finalized intervention in a randomized controlled trial. In Phase 2 of the study, participants are randomly assigned to a meal delivery/cookware provision intervention or to a usual exposure group. Participants in the intervention group receive two meals per week for 12 weeks and a set of cookware/dinnerware."
16619080|NCT02487238|Experimental|Fecal Microbiota Enema|Live, healthy, human donor stool prepared as fecal enemas. Fecal enemas are prepared and collected by Rebiotix(®) (RBX2660), using extensively screened donor stool. Enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
16619081|NCT02487238|Placebo Comparator|Normal Saline Enema|Normal saline enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
16619082|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
16619083|NCT02487225|Placebo Comparator|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
16619084|NCT02487212|Active Comparator|Laser+Topical corticosteroid|Hypertrophic scars were treated with fractional Erbium: Yttrium aluminium garnet (YAG) (2,940-nm) laser, then 0.05% Clobetasol propionate ointment was immediately applied on the perforated scar on one side
16619085|NCT02487212|Placebo Comparator|Laser+Petrolatum gel|Hypertrophic scars were treated with fractional Erbium: YAG (2,940-nm) laser, then topical petrolatum gel was immediately applied on the perforated scar on the other side
16619086|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
16619087|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
16619088|NCT02487186|Active Comparator|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
16619089|NCT02487186|Active Comparator|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)
~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
16619090|NCT02487173|Experimental|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:
~Respirio Flu Test
~Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
~Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
16619091|NCT02487160|Experimental|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
16619092|NCT02487160|Active Comparator|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
16619305|NCT02485756|No Intervention|Control (no educational handout)|Those in the standard care group will not receive the educational handout.
16619093|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
16619094|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
16619095|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
16619096|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
16619097|NCT02487121|Experimental|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
16619098|NCT02487121|Active Comparator|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
16619099|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 5.0 mg/325 mg|every 4 to 6 hours
16619100|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 7.5 mg/325 mg|every 4 to 6 hours
16619101|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 10 mg/325 mg|every 4 to 6 hours
16619102|NCT02487108|Placebo Comparator|Matching placebo|every 4 to 6 hours
16619103|NCT02487095|Experimental|1/Phase I|VX-970 + (M6620) topotecan at escalating doses
16619104|NCT02487095|Experimental|2/Phase II|VX-970 (M6620) + topotecan at MTD/RP2D
16619105|NCT02487082|Other|Group A|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
16619106|NCT02487082|Other|Group B|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
16619107|NCT02487069|Experimental|MSD group|The patients will received HSCT from MSD.
16619108|NCT02487069|Experimental|MUD group|The patients will received HSCT from MUD.
16619109|NCT02487069|Experimental|HRD group|The patients will received HSCT from HRD.
16619110|NCT02487043|Experimental|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
16619111|NCT02487043|No Intervention|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
16619112|NCT02487030|Experimental|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
16619113|NCT02487030|Experimental|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
16619114|NCT02487030|Experimental|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
16619115|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
16619116|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
16619117|NCT02487030|Experimental|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
16619118|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
16619119|NCT02487017|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
16619120|NCT02487017|Experimental|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
16619121|NCT02487004||chronic hemodialysis patients|
16619122|NCT02486991|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
16619123|NCT02486991|Experimental|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
16619124|NCT02486978|Placebo Comparator|Control (no supplement)|Reference will be white bread to give 50 g available carbohydrates with placebo capsule
16619125|NCT02486978|Experimental|Dose 1|Test will comprise white bread to give 50 g available carbohydrates and one capsule of pomegranate/olive and one capsule placebo
16619126|NCT02486978|Experimental|Dose 2|Test will comprise white bread to give 50 g available carbohydrates and 2 capsules of pomegranate/olive.
16619127|NCT02486965|Experimental|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.
~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.
~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
16619128|NCT02486965|Placebo Comparator|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
16619129|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
16619130|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
16619131|NCT02486926|Placebo Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
16619132|NCT02486926|Active Comparator|Remifentanil|Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
16619133|NCT02486926|Active Comparator|Alfentanil|"Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.
~The incidence and severity of emergence agitation was compared with sevoflurane group."
16619134|NCT02486926|Other|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
16619135|NCT02486926|Other|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
16619136|NCT02486913|No Intervention|Conventional Health Check|Patients undergoing conventional National Health Service Health Check
16619137|NCT02486913|Experimental|Enhanced Health Check|Patients undergoing National Health Service Health Check enhanced by risk report
16619138|NCT02486900|Experimental|Neurofeedback training group|The neurofeedback group will perform 6 training sessions over a period of 4 months: 4 fortnightly sessions in the first two months will be followed by 2 monthly 'booster' sessions. Each session will include several behavioural assessments and fMRI-based neurofeedback training in an MRI scanner (1 h). The neurofeedback training phase will be be followed-up by two behavioural assessments 8 and 12 months after the first training.
16619139|NCT02486900|No Intervention|Treatment-as-usual control group|The control group will receive treatment as usual (e.g. medication, counselling) but no neurofeedback training during the study period. Patients in the control group will be invited for four behavioural assessment sessions (baseline assessment, follow-up assessments 4/8/12 months after baseline).
16619140|NCT02486887|Experimental|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
16619141|NCT02486887|No Intervention|conventional follow-up|conventional follow-up
16619142|NCT02486874|Experimental|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
16619143|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
16619144|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
16619145|NCT02486848|Placebo Comparator|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
16619146|NCT02486848|Active Comparator|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
16619147|NCT02486835|Experimental|"Cough Syrup for adults and children"|Marked (authorized) medical device acting by protecting the oropharynx, in a non pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris.Dosage form: syrup Dosage: 5 ml three times a day. Frequency: the duration of the study for each patient is 4 nights, 3 days.
16619148|NCT02486835|Placebo Comparator|Placebo|The placebo intervention is a syrup of same taste and colour without the protective components. Dosage form: syrup. Dosage: 5 ml three times a day Frequency: the duration of the study for each patient is 4 nights, 3 days.
16619149|NCT02486822|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
16619150|NCT02486822|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
16619151|NCT02486809|Experimental|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
16619152|NCT02486809|Experimental|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
16619153|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
16619154|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
16619155|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
16619156|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
16619157|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
16619158|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
16619159|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
16619160|NCT02486770|Experimental|Group 1|Aerucin 2.0mg/kg
16619161|NCT02486770|Experimental|Group 2|Aerucin 8.0mg/kg
16619162|NCT02486770|Experimental|Group 3|Aerucin 20.0mg/kg
16619163|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
16619164|NCT02486744|Active Comparator|80 Units of Acthar|Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
16619165|NCT02486744|Active Comparator|40 Units of Acthar|Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months
16619166|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
16619167|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
16619168|NCT02486731||Controls|Healthy subjects
16619169|NCT02486718|Experimental|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
16619335|NCT02485522||Fecal incontinence|Women age >18 years old with a diagnosis of fecal incontinence
16619170|NCT02486718|Active Comparator|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
16619171|NCT02486705|Active Comparator|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
16619172|NCT02486705|Experimental|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
16619173|NCT02486692|Experimental|Phase II- Experimental Group|Participants were provided with instructions and a web link for accessing the AboutFace website after the baseline assessment.
16619174|NCT02486692|No Intervention|Phase II- Usual Care Group|Participants were provided with instructions and a web link for accessing some online PTSD education materials after the baseline assessment.
16619175|NCT02486679|Active Comparator|PGE2|Patients allocated to vaginal PGE2 (Prostin) for cervical ripening
16619176|NCT02486679|Active Comparator|Foley catheter|Patients allocated to foley catheter placement for cervical ripening
16619177|NCT02486666|Experimental|Experimental Arm|"Experimental Arm:patients will not have any dose titration regardless of anti-Xa level.
~Premature neonates will receive enoxaparin 2.0 mg/kg/dose rounded to nearest whole mg twice daily, while term neonates will receive enoxaparin 1.7 mg/kg/dose rounded to nearest whole mg twice daily. Children≥1 month corrected age will receive 1.5 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing) while children≥2 month corrected age will receive 1.0 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing)."
16619178|NCT02486666|Other|Control Arm|Control Arm: patients who will have dose titration based on anti-Xa levels to maintain a therapeutic range of 0.5-1.0 u/mL (standard of care).
16619179|NCT02486653|Experimental|Tamsulosin|
16619180|NCT02486653|Placebo Comparator|Placebo|
16619181|NCT02486640||Betaferon|
16619182|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
16619183|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
16619184|NCT02486601|Experimental|nab-paclitaxel + FOLFOX|nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)
16619185|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
16619186|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
16619187|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
16619188|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
16619189|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
16619190|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
16619191|NCT02486575|Other|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
16619192|NCT02486575|Other|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.
~Intervention Type: Behavioral (tutored learning)"
16619193|NCT02486562||People diagnosed with Multiple Sclerosis|
16619194|NCT02486549|Experimental|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
16619195|NCT02486549|Active Comparator|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
16619196|NCT02486536|Active Comparator|Group A|Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
16619197|NCT02486536|Active Comparator|Group B|the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
16619198|NCT02486536|Active Comparator|Group C|the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
16619199|NCT02486536|Active Comparator|Group D|Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
16619200|NCT02486536|Active Comparator|Group E|Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
16619201|NCT02486523|Active Comparator|Control group|"Outpatient management of children diagnosed with severe acute malnutrition.
~Interventions allocated:
~Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
16619202|NCT02486523|Experimental|Intervention group|"Outpatient management of children diagnosed with severe acute malnutrition + household WASH package
~Interventions allocated:
~Behavioral: Hygiene promotion sessions Device: Household WASH package The content of the kit: soap and aquatab for 3 months, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
~Behavioral: Household visits during the OTP phase Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
16619304|NCT02485756|Experimental|Educational handout|Participants in the intervention group will read an educational handout on hormonal contraceptives/antiepileptic interactions.
16619203|NCT02486510|No Intervention|Group 1 (Control)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.
~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)"
16619204|NCT02486510|Experimental|Group 2 (Treatment)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.
~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc."
16619205|NCT02486497|Active Comparator|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
16619206|NCT02486497|Active Comparator|Gemcitabine group|Grade of hENT1 immunostaining is 2.
16619207|NCT02486484|Experimental|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
16619208|NCT02486471|Other|Observational approach|Wait and see
16619209|NCT02486471|Active Comparator|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
16619210|NCT02486458|No Intervention|Negative control|No treatment will be applied
16619211|NCT02486458|Experimental|Varnish 4 h|Fluoride varnish will be applied on teeth and removed after 4 hours
16619212|NCT02486458|Experimental|Varnish 24 h|Fluoride varnish will be applied on teeth and removed after 24 hours
16619213|NCT02486458|Experimental|Fluoride Gel|Fluoride gell will be applied on teeth and removed after 4 minutes
16619214|NCT02486445|Experimental|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours.
16619215|NCT02486432|Experimental|Single arm Levodopa/Carbidopa|The intervention is dosing with Sinemet® which is an oral tablet containing Levodopa/Carbidopa. Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
16619216|NCT02486419||Summer|
16619217|NCT02486419||Winter|
16619218|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 1|Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
16619219|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 2|Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.
16619220|NCT02486406|Experimental|Mini tablet, 9-11 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
16619221|NCT02486406|Experimental|Mini tablet, 3-8 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
16619222|NCT02486393||type of surgery|patients undergoing parotid surgery
16619223|NCT02486380|Experimental|Full face/Nasal masks|Simplus/Eson
16619224|NCT02486367|Active Comparator|Standard care/clopidogrel|300mg load followed by 75mg daily.
16619225|NCT02486367|Experimental|Ticagrelor|180mg load followed by 90mg twice daily for 30 days.
16619226|NCT02486354|Experimental|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
16619227|NCT02486341|Experimental|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
16619228|NCT02486341|Experimental|Long-acting basal insulin analogues|
16619229|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
16619230|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
16619231|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) <70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
16619232|NCT02486302||Observation Group|
16619233|NCT02486289|Experimental|NBMI (Emeramide) 100mg|NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
16619336|NCT02485522||Controls|Women age >18 without a diangosis of fecal incontinence
16619234|NCT02486289|Experimental|NBMI (Emeramide) 300mg|NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.
16619235|NCT02486289|Placebo Comparator|Placebo|Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.
16619236|NCT02486276|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
16619237|NCT02486276|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo
16619238|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
16619239|NCT02486263|Other|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
16619240|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
16619241|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
16619242|NCT02486250||ReVeRe 1|A subset of 250 participants from the Main Study Recruits and all MRI & PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
16619243|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI & PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
16619244|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
16619245|NCT02486224|Experimental|Kona Deep|Subjects will receive Kona Deep post-exercise
16619246|NCT02486224|Placebo Comparator|Spring Water|Subjects will receive commercially available Spring Water post-exercise
16619247|NCT02486224|Active Comparator|Sports Drink|Subjects will receive commercially available Sports Drink post-exercise
16619248|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
16619249|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
16619250|NCT02486198|Placebo Comparator|placebo+oxaliplatin-based chemotherapy|equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
16619251|NCT02486198|Experimental|GM+oxaliplatin-based chemotherapy|monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
16619252|NCT02486185|Other|SARC-F|screening test for sarcopenia being studied, the SARC-F
16619253|NCT02486172|Other|Peer supporter|Peer support program
16619254|NCT02486159|Experimental|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.
~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
16619255|NCT02486133|Experimental|A|Prezista & Norvir & Tivicay
16619256|NCT02486133|Active Comparator|B|Prezista & Norvir & Truvada or Prezista & Norvir & Kivexa
16619257|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
16619258|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
16619259|NCT02486107||ACDF|anterior cervical discectomy and fusion
16619260|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
16619261|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
16619262|NCT02486068|Experimental|ABSORB scaffold|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with ABSORB scaffold.
16619263|NCT02486068|Active Comparator|Xience|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with Xience Prime.
16619264|NCT02486055|Active Comparator|Cohort 1|In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
16619265|NCT02486055|Active Comparator|Cohort 2|In Cohort 2 doses BPM31510 Oral Nanosuspension 4% will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
16619266|NCT02486042|Other|Standard Nutrition|Infants in this group will receive the standard intravenous nutrition with predominantly Omega-6 fatty acids.
16619267|NCT02486042|Experimental|Omega-3 Group/Added Nutrition|Infants in this group will receive the experimental intravenous nutrition with Omega-3 fatty acids known as Omegaven in addition to standard nutrition.
16619268|NCT02486016|Experimental|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
16619269|NCT02486016|Active Comparator|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
16619270|NCT02486016|Active Comparator|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
16619271|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
16619272|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
16619273|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
16619274|NCT02485990|Experimental|Arm A: Tremelimumab Alone|25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
16619275|NCT02485990|Experimental|Arm B1: DESE Tremelimumab and Olaparib|18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
16619276|NCT02485990|Experimental|Arm B2: Tremelimumab and Olaparib|25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
16619277|NCT02485977||Pulmonary Hypertension|Adult patients with pulmonary hypertension referred for cardiac catheterization in the PI institution
16619278|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
16619279|NCT02485951|Active Comparator|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
16619280|NCT02485951|Active Comparator|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
16619281|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
16619282|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
16619283|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
16619284|NCT02485912|Active Comparator|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
16619285|NCT02485912|Active Comparator|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
16619286|NCT02485899|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
16619287|NCT02485886|Experimental|68Ga-BMV101 injection and PET/CT scan|The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
16619288|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
16619289|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
16619290|NCT02485860|No Intervention|standard dressings|
16619291|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
16619292|NCT02485834|Active Comparator|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
16619293|NCT02485834|Experimental|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
16619294|NCT02485821|Experimental|Estradiol + Misoprostol|100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.
16619295|NCT02485821|Placebo Comparator|Placebo + Misoprostol|100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.
16619296|NCT02485808||Surgical|"Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.
~There will be no interventions, as this is an observational cohort."
16619297|NCT02485808||Medical|"Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.
~There will be no interventions, as this is an observational cohort."
16619298|NCT02485808||Controls|"Men and women who are not experiencing lower urinary tract symptoms.
~This group will undergo MRI, pain and auditory sensitivity testing."
16619299|NCT02485808||Neuroimaging & Sensory Testing|"Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.
~This group will undergo MRI, pain and auditory sensitivity testing."
16619300|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
16619301|NCT02485782||Hemodialysis patients|"midweek dialysis session
~patients on maintenance hemodialysis at least 3 months
~stable dry weight
~single-pool Kt/V >1.4
~no clinical cardiovascular disease during the 6 months preceding entry"
16619302|NCT02485769|Experimental|PF-06650833|Active arm , PF-06650833 kinase.
16619303|NCT02485769|Placebo Comparator|Placebo|Placebo arm
16619337|NCT02485509|Experimental|20 mg VM-1500/Placebo Healthy group|VM-1500 20 mg or placebo single dose.
16619306|NCT02485743|Active Comparator|Active Diet Products|A range of products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
16619307|NCT02485743|Placebo Comparator|Placebo Diet Products|A range of products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
16619308|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
16619309|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
16619310|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
16619311|NCT02485704|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
16619312|NCT02485704|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
16619313|NCT02485691|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m^2 intravenously in 1 hour every 3 weeks + prednisone 10 mg orally given daily + Primary prophylactic G-CSF (the choice of the G-CSF product is left to the Investigator's decision). Treatment will continue until confirmed disease progression or unacceptable toxicity.
16619314|NCT02485691|Experimental|Abiraterone acetate or enzalutamide|Abiraterone acetate oral 1000 mg once daily continuously + prednisone 5 mg orally given twice daily OR enzalutamide oral 160 mg once daily continuously. Treatment will continue until confirmed disease progression or unacceptable toxicity.
16619315|NCT02485678|Experimental|Proactive Telephone Toxicity Management|Proactive Telephone Toxicity Management
16619316|NCT02485678|Active Comparator|Control Arm|Control
16619317|NCT02485665|No Intervention|Kegel exercise education|Prostate cancer patients of control group will received Kegel exercise education for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
16619318|NCT02485665|Experimental|Extracorporeal biofeedback device|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
16619319|NCT02485652|Experimental|HM61713|HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
16619320|NCT02485639|Experimental|Arm 1|All study participants will receive licensed inactivated influenza vaccine intramuscularly on Day 1.
16619321|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
16619322|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
16619323|NCT02485613||bortezominb and dexamethasone group|
16619324|NCT02485600||DUODOPA patients.|Patients starting DUODOPA treatment at time of enrollment.
16619325|NCT02485587|Experimental|Individualized Arousal-Biofeedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 20 sessions of arousal (electrodermal activity) feedback, 1 session/week. Each session will last about 1 hour. After the first 10 sessions (10 weeks after the beginning of the training phase), parents/caregivers will be asked to evaluate behavioral measures of aggression.
~After training completion (approximately 20 weeks after the beginning of the training phase), subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the training phase)."
16619326|NCT02485587|Active Comparator|Treatment as usual|After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
16619327|NCT02485587|No Intervention|Typically developing (TD) control group|Healthy, typically developing children will only undergo baseline assessment (observational) for comparison
16619328|NCT02485574|Experimental|Bone bridging|To compare bone bridging between anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in left side of disc space and anterior bridging cages augmented with auto bone in rt side of disc space in transforaminal lumbar interbody arthrodesis
16619329|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
16619330|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
16619331|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
16619332|NCT02485548|Experimental|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
16619333|NCT02485548|Active Comparator|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
16619334|NCT02485535|Experimental|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16619340|NCT02485509|Experimental|40 mg VM-1500/Placebo Patient group|VM-1500 40 mg or placebo once daily for 7 days.
16619341|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
16619342|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
16619343|NCT02485470|Experimental|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
16619344|NCT02485470|No Intervention|Usual Care|
16619345|NCT02485457|Experimental|Low volume|"The protocol will follow the following steps :
~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
16619346|NCT02485457|Experimental|High volume|"The protocol will follow the following steps :
~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
16619347|NCT02485444|Active Comparator|Oxytocin|
16619348|NCT02485444|No Intervention|Observation|
16619349|NCT02485431|Experimental|Deflazacort, fasted|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water in Fasted state.
16619350|NCT02485431|Experimental|Deflazacort, high-fat meal|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water with high fat meal served 30 minutes prior to dosing.
16619351|NCT02485431|Experimental|Deflazacort, crushed, fasted|36mg of Deflazacort crushed and mixed with apple sauce.
16619352|NCT02485431|Experimental|Deflazacort alternate strength,fasted|Investigational Formulation Deflazacort tablet (6 X 6mg).
16619353|NCT02485431|Experimental|Deflazacort suspension with apple juice|Deflazacort oral suspension (36mg) mixed with 100ml apple juice in fasted state.
16619354|NCT02485418|Experimental|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:
~20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes"
16619355|NCT02485405||stressed|stressed volunteers perform Trier social stress test
16619356|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
16619357|NCT02485392|Active Comparator|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
16619358|NCT02485392|Active Comparator|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
16619359|NCT02485379|Other|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
16619360|NCT02485366|Experimental|Rejuvenated PRBCs|The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).
16619361|NCT02485353|Other|Vosaroxin and Cytarabine|
16619362|NCT02485340|Active Comparator|Sumatriptan|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
16619363|NCT02485340|Placebo Comparator|Placebo|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)
16619364|NCT02485327|Experimental|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.
~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
16619365|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
16619366|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
16619367|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
16619368|NCT02485249|Experimental|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
16619369|NCT02485236|Active Comparator|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
16619370|NCT02485236|Active Comparator|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
16619371|NCT02485210|Active Comparator|Covencional treatment|"Convencional endodontic treatment for deciduous teeth, with Surgical chemical preparation with series of Kerr files appropriate for each case, using initial file and an additional two files of larger size, with irrigation and aspiration with 1% sodium hypochlorite (Milton's solution) and endo PTC (Fórmula & Ação) with each change of file.
~Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session."
16619372|NCT02485210|Experimental|Photodynamic therapy|Endodontic Treatment with photodynamic terapy Irrigation of the root canal system Insertion of sterile paper cone immersed in Chimiolux® methylene blue for three minutes; administration of wireless Therapy XT EC laser device (DMC - São Carlos, Brazil) after removal of cone; energy density: 4 J/cm², power: 100 mw; wavelength: 660 nm; exposure time: 40 seconds Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session
16619373|NCT02485197|Other|Low 25(OH)D|We will recruit individuals with low 25(OH)D (<30ng/mL).
16619374|NCT02485197|Other|High 25(OH)D|"We will recruit individuals with higher 25(OH)D (at least 20ng/mL units higher then that of the low 25(OH)D group)."
16619375|NCT02485184|Active Comparator|TIPS group|Transjugular intrahepatic portosystemic shunt
16619376|NCT02485184|Active Comparator|ET & drugs groups|"Endoscopic therapy.
~Non-selective beta blockers.
~Anticoagulation therapy."
16619377|NCT02485171|Experimental|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
16619378|NCT02485171|No Intervention|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
16619379|NCT02485158|Experimental|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
16619380|NCT02485158|Experimental|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
16619381|NCT02485145|Experimental|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
16619382|NCT02485145|Experimental|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
16619383|NCT02485132||T2DM at SU initiation|T2DM newly prescribed a SU
16619384|NCT02485119|Experimental|BAY94-9343|"Cohort 1: Safety, tolerability and PK of 4.5 mg/kg dose given Q3W. Proceeding to Cohort 2 or not will be decided based on both safety variables during Cycle 1 (21 days) of 3 to 6 subjects in Cohort 1 and PK obtained from Cycle 1 (at least Day 1 to Day 5).
~Cohort 2: Safety, tolerability and PK of 6.5 mg/kg dose given Q3W. Whether recruitment will be continued up to 9 subjects for Cohort 2 or not will be decided based on safety variables during Cycle 1 (21 days) of the first 3 subjects in Cohort 2. The safety and tolerability of 6.5 mg/kg will be assessed based on the data of 9 subjects during Cycle 1 in Cohort 2, and considering long term toxicity, the safety and tolerability of BAY94-9343 will be assessed all safety data by the end of 3 cycles in Cohort 2."
16619385|NCT02485106|Active Comparator|Rifaximin group|Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days
16619386|NCT02485106|Active Comparator|Control group|Corticosteroid or Pentoxifylline for 28 days
16619387|NCT02485093|Active Comparator|No pacing|Ventricular intrinsic conduction enhanced
16619388|NCT02485093|Experimental|Pacing|Septal ventricular pacing with optimized AV delay
16619389|NCT02485080|Experimental|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
16619390|NCT02485067|Experimental|THVD-201|"1. Treatment period(12 weeks)
~Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)
~One capsule and One tablet bid on an empty stomach
~2. Open-label extension period(An additional 12 weeks)
~Regardless of the previous type of arm, all patients only take THVD-201 during this period.
~One capsule bid on an empty stomach"
16619391|NCT02485067|Active Comparator|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)
~Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet
~One capsule and One tablet bid on an empty stomach
~2. Open-label extension period(An additional 12 weeks)
~Regardless of the previous type of arm , all patients only take THVD-201 during this period.
~One capsule bid on an empty stomach"
16619392|NCT02485054||Eligible patients|Adults having had a transient visual disturbance during the last 8 days, except a diplopia
16619393|NCT02485041|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
16619394|NCT02485041|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
16619395|NCT02485041|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
16619396|NCT02485041|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
16619397|NCT02485041|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
16619398|NCT02485041|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
16619399|NCT02485028|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
16619400|NCT02485028|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
16619401|NCT02485028|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
16619402|NCT02485028|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
16619403|NCT02485028|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
16619404|NCT02485028|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
16619405|NCT02485015|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
16619406|NCT02485015|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
16619407|NCT02485002|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
16619408|NCT02485002|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
16619409|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
16619410|NCT02484976|Experimental|Family Based Behavioral Treatment|Central satiety brain and hormonal responses will be compared pre-and post-Family Based Behavioral Treatment, as well, as to a non-obese sample.
16619411|NCT02484963|Experimental|zolpidem|Tablet zolpidem 5mg once daily will be given for 4 weeks
16619412|NCT02484963|Placebo Comparator|Placebo|One tablet of placebo will be given for 4 weeks
16619413|NCT02484950|Experimental|Rotator cuff repair with stem cells|Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
16619414|NCT02484950|Placebo Comparator|Rotator cuff repair without stem cells|Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.
16619415|NCT02484937|Active Comparator|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
16619416|NCT02484937|Experimental|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
16619417|NCT02484924||Clopidogrel Group|Those patients treated with clopidogrel for ACS (before new guideline implementation)
16619418|NCT02484924||Ticagrelor Group|Those patients treated with ticagrelor for ACS (after new guideline implementation)
16619419|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
16619420|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
16619421|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
16619422|NCT02484885|Other|Healthy Volunteers|Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
16619423|NCT02484872||Lung neoplasms|Lung neoplasms irrespective of stage and histology
16619424|NCT02484859|Active Comparator|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
16619425|NCT02484859|Active Comparator|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
16619426|NCT02484846|Experimental|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
16619427|NCT02484846|Experimental|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
16619428|NCT02484846|Experimental|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
16619429|NCT02484846|Experimental|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
16619430|NCT02484846|Active Comparator|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
16619431|NCT02484846|Experimental|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
16619432|NCT02484846|Experimental|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
16619433|NCT02484833|Active Comparator|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
16619434|NCT02484833|Experimental|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
16619435|NCT02484820|Experimental|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
16619436|NCT02484820|No Intervention|Control|Standard care only, No silicone pessary will be placed in the vagina.
16619439|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
16619440|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
16619441|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
16619442|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
16619443|NCT02484794|Active Comparator|Treatment as Usual|Patients will receive standard outpatient treatment that consists of group psychotherapy, skills training, self-monitoring, nutritional counselling, and meal support.
16619444|NCT02484794|Experimental|Treatment with Smartphone App|Patients will receive the same standard outpatient treatment but will use the smartphone application instead of the paper food record. Patients in this group will receive daily feedback through the app, as opposed to weekly, but will still attend the weekly nutritional counselling group.
16619445|NCT02484781|Active Comparator|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
16619446|NCT02484781|Active Comparator|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
16619447|NCT02484768|Experimental|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
16619448|NCT02484768|Placebo Comparator|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
16619449|NCT02484755|Experimental|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
16619450|NCT02484742|No Intervention|Sleep control condition|8 hours of sleep throughout the 18-day stay in the Clinical Research Center
16619451|NCT02484742|Experimental|Insomnia symptom induction condition|4 4-day cycles, each consisting of 3 nights with sleep disruption followed by one night of recovery sleep.
16619452|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
16619453|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
16619454|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
16619457|NCT02484703|Placebo Comparator|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
16619458|NCT02484703|Experimental|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
16619459|NCT02484703|Experimental|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
16619460|NCT02484703|Experimental|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
16619461|NCT02484690|Active Comparator|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
16619462|NCT02484690|Experimental|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
16619463|NCT02484690|Experimental|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
16619464|NCT02484690|Experimental|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
16619465|NCT02484690|Experimental|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
16619466|NCT02484677|Experimental|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
16619467|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
16619468|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
16619469|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
16619470|NCT02484638|Experimental|CSL689 low-dose|"Part 1: single injection of low-dose CSL689 for PK evaluation
~Part 2: up to 2 injections of low-dose CSL689 per bleeding event (bleeding events 1 to 3*)
~Part 3: up to 3 injections of low-dose CSL689 per bleeding event * Note: All subjects in the low-dose arm will be treated with high-dose CSL689 for bleeding events 4-6 in Part 2"
16619471|NCT02484638|Experimental|CSL689 high-dose|"Part 1: single injection of high-dose CSL689 for PK evaluation
~Part 2: up to 2 injections of high-dose CSL689 per bleeding event (bleeding events 4 to 6*)
~Part 3: up to 3 injections of high-dose CSL689 per bleeding event
~Note: All subjects in the high-dose arm will be treated with low-dose CSL689 for bleeding events 1-3 in Part 2"
16619472|NCT02484638|Active Comparator|Eptacog alfa low-dose|Single injection of low-dose Eptacog alfa in Part 1 for PK evaluation
16619473|NCT02484638|Active Comparator|Eptacog alfa high-dose|Single injection of high-dose Eptacog alfa in Part 1 for PK evaluation
16619474|NCT02484625|Experimental|Potato chips|Commercial potato chips, 180 kcal
16619475|NCT02484625|Experimental|Greek yogurt|Greek yogurt, 180 kcal
16619476|NCT02484625|Experimental|Cookies|Sandwich-type cookies, 180 kcal
16619477|NCT02484625|Experimental|Cheese|Mozzarella cheese, 180 kcal
16619478|NCT02484625|Experimental|Milk (fluid)|Milk, 2% m.f., 180 kcal
16619884|NCT02481830|Active Comparator|Arm B Chemotherapy Topotecan|Topotecan as specified
16619479|NCT02484612|Experimental|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
16619480|NCT02484612|Experimental|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
16619481|NCT02484599|Experimental|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, & Jansen, 2014).
16619482|NCT02484599|Placebo Comparator|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
16619483|NCT02484586|Other|Presbyope group|"40 years and over with a reading add.
~Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA
~Test lens: Etafilcon A
~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
16619484|NCT02484586|Other|Non-Presbyope group|"18-39 years with no reading add.
~Control lens: Etafilcon A, Nelfilcon A, Omafilcon A
~Test lens: Etafilcon A
~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
16619485|NCT02484573|Experimental|Propanolol|Patients will take the non-selective beta blocker propranolol for approximately 4 weeks starting immediately after endoscopy for esophageal variceal ligation. Patients will be initiated on a dose of 20mg by mouth every 12 hrs before titration to maximum tolerated dose. Patients will undergo testing before and after treatment for the variables listed in the outcomes section below.
16619486|NCT02484560|Experimental|Ambulatory Patients|Ambulatory patients receiving stem cell therapy
16619487|NCT02484560|Experimental|Non-Ambulatory Patients|non-ambulatory patients receiving stem cell therapy
16619488|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
16619489|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
16619490|NCT02484521|Active Comparator|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
16619491|NCT02484521|Other|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
16619492|NCT02484508|Experimental|Guli capsule|Guli capsule, the tested drug of this study
16619493|NCT02484508|Active Comparator|Kangguzengsheng capsule|Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study
16619494|NCT02484495|Experimental|Program evaluation in intervention areas|"A quasi-experimental matched-control cluster design will be used in which outcomes are compared in intervention and non-intervention areas. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Sixty intervention clusters have been purposively selected whereas the data will be collected from randomly selected subjects. The following interventions will be provided:
~Processed complementary food rations will be distributed to all children 6-23 months of age, from a grain bank based on bartering of raw materials.
~Monthly 15 sachets of MNP will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification."
16619495|NCT02484495|No Intervention|Non intervention areas|A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
16619496|NCT02484482|Experimental|Group 1|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Fasting→Standard Meal→High Fat Meal"
16619497|NCT02484482|Experimental|Group 2|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Standard Meal→High Fat Meal→Fasting"
16619498|NCT02484482|Experimental|Group 3|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~High Fat Meal→Fasting→Standard Meal"
16619499|NCT02484482|Experimental|Group 4|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Fasting→High Fat Meal→Standard Meal"
16619500|NCT02484482|Experimental|Group 5|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Standard Meal→Fasting→High Fat Meal"
16619501|NCT02484482|Experimental|Group 6|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~High Fat Meal→Standard Meal→Fasting"
16619502|NCT02484469|Experimental|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
16619503|NCT02484469|Placebo Comparator|Unexposed|Standard Team-Based learning session about leprosy
16619504|NCT02484456|Experimental|Test Session 1|2 weeks of 1,080 or 1,440 mg/day (single daily dose) of study drug
16619505|NCT02484456|Placebo Comparator|Test Session 2|2 weeks of single daily dose of placebo pill
16619581|NCT02483988|Experimental|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
16619507|NCT02484430|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16619508|NCT02484417|Experimental|Cohort 1: RSV A2 10^5 PFU/dose|Challenge 4 subjects with low dose and proceed to larger cohort after safety review.
16619509|NCT02484417|Experimental|Cohort 2: RSV A2 10^5 PFU/dose|Challenge 12 subjects with the low dose and proceed to high dose after safety review.
16619510|NCT02484417|Experimental|Cohort 3: RSV A2 10^6.3 PFU/dose|Challenge 12 subjects with the high dose
16619511|NCT02484404|Experimental|P1 Durvalumab+C|Ph I Durvalumab + cediranib dose escalation
16619512|NCT02484404|Experimental|P1 Durvalumab+O|Ph I Durvalumab + olaparib dose escalation
16619513|NCT02484404|Experimental|P1 Durvalumab+O+C|Ph I Durvalumab + olaparib + cediranib dose escalation
16619514|NCT02484404|Experimental|P2 Durvalumab+C|Ph II Durvalumab + cediranib at RP2D
16619515|NCT02484404|Experimental|P2 Durvalumab+O|Ph II Durvalumab + olaparib at RP2D
16619516|NCT02484404|Experimental|P2 Durvalumab+O+C|Ph II Durvalumab + olaparib + cediranib at RP2D
16619517|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
16619518|NCT02484378|Experimental|CER-001|CER-001 infusion
16619519|NCT02484378|Placebo Comparator|Placebo|Placebo infusion
16619520|NCT02484365||single arm study|No treatment or intervention will given to the patients
16619521|NCT02484352|Other|0 mg/kg of oxycodone|Intervention: patients receive 10 ml of normal saline without oxycodone through intravenous route before intubation.
16619522|NCT02484352|Other|0.05 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.05 mg/kg of oxycodone in normal saline through intravenous route before intubation.
16619523|NCT02484352|Other|0.1 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.1 mg/kg of oxycodone in normal saline through intravenous route before intubation.
16619524|NCT02484352|Other|0.15 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.15 mg/kg of oxycodone in normal saline through intravenous route before intubation.
16619525|NCT02484352|Other|0.2 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.2 mg/kg of oxycodone in normal saline through intravenous route before intubation.
16619526|NCT02484339|Experimental|Treatment Group A|"Radium-223 dichloride (Xofigo®) 55 kilobecquerel (kBq)/kgbw (6 i.v. injections every 4 weeks)
~External beam radiotherapy (EBRT)->conventional or high dose radiotherapy"
16619527|NCT02484339|Other|Treatment Group B|External beam radiotherapy (EBRT) ->conventional or high dose radiotherapy
16619528|NCT02484313|Experimental|Greek yogurt|25 g available carbohydrates
16619529|NCT02484313|Experimental|Cookies|25 g available carbohydrates
16619530|NCT02484300|Experimental|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
16619531|NCT02484300|Experimental|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
16619532|NCT02484300|Experimental|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
16619533|NCT02484300|Placebo Comparator|Placebo|Placebo outcomes versus melatonin
16619534|NCT02484287|Active Comparator|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
16619535|NCT02484287|Active Comparator|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
16619536|NCT02484287|Active Comparator|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
16619537|NCT02484274|Other|infants followed by pediatrician|
16619538|NCT02484261|No Intervention|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
16619539|NCT02484261|Experimental|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
16619540|NCT02484248|Active Comparator|cross-over of Ketotifen|Patients will begin the active ketotifen treatment first and cross over to placebo.
16619541|NCT02484248|Placebo Comparator|cross-over of Placebo|Patients will begin the placebo treatment first and cross over to the active ketotifen.
16619542|NCT02484235|Experimental|Group HIIT|Only Aerobic Training with HIIT
16619543|NCT02484235|Experimental|Group Strength|Only Strength Training
16619544|NCT02484235|Experimental|HIIT and Strength|Both intervention HIIT and Strength training
16619545|NCT02484209|Experimental|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
16619546|NCT02484209|Active Comparator|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
16619547|NCT02484196||Couples|Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
16619548|NCT02484196||Women|Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
16619549|NCT02484183|No Intervention|Low-flow oxygen|Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is <90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (>70 breaths/minute if 1-11 months; >60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
16619550|NCT02484183|Experimental|bubble CPAP|Bubble continuous positive airway pressure (bCPAP) patients are eligible if respiratory danger signs are present or if oxygen saturation is <90%. bCPAP will be initiated at 7 centimeters (cm) water (H20) if 1-2 months of age or 8cm H20 if 2-59 months of age using the minimum oxygen flow necessary to achieve these pressures. Gradual weaning can be attempted after 24-48 hours of treatment. All changes will be followed by 60 minutes of monitoring.
16619551|NCT02484170|Active Comparator|mannitol in vehicle cream /vehicle cream|one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
16619552|NCT02484170|Active Comparator|vehicle cream /mannitol in vehicle cream|one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
16619553|NCT02484157|Experimental|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
16619554|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
16619555|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
16619556|NCT02484131|Experimental|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
16619557|NCT02484131|Experimental|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
16619558|NCT02484131|No Intervention|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
16619559|NCT02484118|Experimental|Targeted blood flow rate 320 ml/min|Hemodialysis blood flow will be targeted at 320 ml/min during hemodialysis for two weeks
16619560|NCT02484118|Experimental|Targeted blood flow rate 380 ml/min|Hemodialysis blood flow will be targeted at 380 ml/min during hemodialysis for two weeks
16619561|NCT02484105|Experimental|Comforting Conversation|Conversation according to the initital qualitative study.
16619562|NCT02484105|Active Comparator|Standard Communication|Standard information prior to and during endoscopy.
16619563|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
16619564|NCT02484079|Active Comparator|Cold polypectomy|"Patients in this arm will have their polyps removed by cold polypectomy, i.e. a metal sling that is closed around the basis of the polyp, and the polyp is cut off.
~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
16619565|NCT02484079|Active Comparator|Hot polypectomy|"Patients in this arm will have their polyps removed by hot polypectomy, i.e. a metal sling taht is closed around the basis of the polyp, electrical currents is applied, and the polyp is cut off.
~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
16619566|NCT02484066|Experimental|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
16619567|NCT02484066|Active Comparator|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
16619568|NCT02484053|Experimental|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
16619569|NCT02484053|Experimental|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
16619570|NCT02484040|Experimental|Two-week course arm|"Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.
~Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid"
16619571|NCT02484040|No Intervention|Conventional arm|conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid
16619572|NCT02484027|Experimental|statin-therapy|Rosuvastatin orally at a dose of 20mg daily is assigned to patients immediately for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
16619573|NCT02484027|Sham Comparator|non-statin-therapy|No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
16619574|NCT02484014|Experimental|TSM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by teachers as SEHER Mitra)
16619575|NCT02484014|Experimental|SM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by SEHER Mitra)
16619576|NCT02484014|Other|Comparison Arm|Tarang Adolescence Education Programme
16619577|NCT02484001|Experimental|ESL 800 mg|ESL will be administered orally once daily (QD)
16619578|NCT02484001|Experimental|ESL 1200 mg|ESL will be administered orally once daily (QD)
16619579|NCT02484001|Experimental|ESL 1600 mg|ESL will be administered orally once daily (QD)
16619580|NCT02484001|Experimental|ESL 400 mg|ESL will be administered orally once daily (QD)
16619582|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
16619583|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
16619584|NCT02483962|Placebo Comparator|Gelatine capsule|Gelatine capsules containing no active ingredients, will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
16619585|NCT02483962|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butcher's broom extract and 3,2 mg of vitamin B6, will be taken once per day, in the morning after breakfast, for 30 days.
16619586|NCT02483949|No Intervention|Control|
16619587|NCT02483949|Experimental|Intervention|Lifestyle intervention with peer-counseling follow-up
16619588|NCT02483936|Experimental|Test 1: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
16619589|NCT02483936|Experimental|Test 2: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
16619590|NCT02483936|Active Comparator|Comparator 1: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
16619591|NCT02483936|Active Comparator|Comparator 2: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
16619592|NCT02483923|Experimental|Group S|
16619593|NCT02483923|Placebo Comparator|Group C|
16619594|NCT02483910|Experimental|DI-LL via telehealth|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
16619595|NCT02483910|Active Comparator|Standard of care delivered via telehealth|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.
~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
16619596|NCT02483897|Experimental|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
16619597|NCT02483897|Placebo Comparator|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
16619598|NCT02483884|Experimental|Low risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with low risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
16619599|NCT02483884|Experimental|Intermediate risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with intermediate risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
16619600|NCT02483884|Experimental|High risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with high risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
16619601|NCT02483871|Experimental|Rosuvastatin|Two Cohorts, one at 20 mg and one at 40 mg will enroll in a dose escalation of rosuvastatin
16619602|NCT02483858|Experimental|PQR309|Different dose Evaluation (continous and intermittent) 20-160mg daily
16619603|NCT02483845|Experimental|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
16619604|NCT02483832|Active Comparator|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
16619605|NCT02483832|Active Comparator|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
16619606|NCT02483806|Experimental|PEEP 0 cmH2O|PEEP 0 cmH2O (zero end expiratory pressure, ZEEP)
16619607|NCT02483806|Experimental|PEEP 5 cmH2O|
16619608|NCT02483806|Experimental|EEP 10 cmH2O|
16619609|NCT02483793|Active Comparator|Oxybutynin group|This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.
16619610|NCT02483793|Active Comparator|Tamsulosin group|This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age ≥ 4.
16619611|NCT02483780|Experimental|Storytelling intervention|"Two communes will be assigned to intervention group. Within each commune, 25 adults with HTN will be enrolled.
~Patients will receive 2 DVDs with stories of patients who have successfully controlled their hypertension and Learn More section, which will be coordinated with specific patient stories and will fill in gaps not covered by the storytellers."
16619612|NCT02483780|No Intervention|Usual care|"Two communes will be assigned to usual care group. Within each commune, 25 adults with HTN will be enrolled.
~Patients will receive 2 DVDs with only didactic material about common non-communicable diseases but without hypertension related stories."
16619613|NCT02483767|Experimental|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
16619614|NCT02483767|Active Comparator|standard chemotherapy without goserelin|standard chemotherapy without goserelin
16619615|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
16619616|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
16619617|NCT02483741|Experimental|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
16619618|NCT02483741|No Intervention|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
16619676|NCT02483312|Experimental|IL-12|A single dose of IL-12, given intravenously.
16619993|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
16619619|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test +|These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
16619620|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test -|These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
16619621|NCT02483715|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
16619622|NCT02483715|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
16619623|NCT02483702|Experimental|Patients under 4 months Receive Irradiated Blood|Patients under 4 months of age will receive irradiated blood products, as per hospital protocol. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
16619624|NCT02483702|Experimental|Patients Over 4 Months Recieve Non-Irradiated Blood|Patients over 4 months of age will receive non-irradiated blood products. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
16619625|NCT02483689|Placebo Comparator|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
16619626|NCT02483689|Experimental|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
16619627|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
16619628|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
16619629|NCT02483663||27 Monozygotic Pairs|
16619630|NCT02483663||27 Dizygotic Pairs|
16619631|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
16619632|NCT02483624|Experimental|Low Dose|10 patients 225 mg of BR-DIM. 2 capsules AM and 1 PM. 52 weeks duration.
16619633|NCT02483624|Experimental|High Dose|10 patients 375 mg of BR-DIM. 3 capsules AM and 2 PM. 52 weeks duration.
16619634|NCT02483624|Placebo Comparator|Placebo|10 patients receiving weight matched placebo. 5 for high dose and 5 for low dose. 52 weeks of weight matched pills.
16619635|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.
~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
16619636|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.
~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
16619637|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.
~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
16619638|NCT02483598|Experimental|Buspirone|Buspirone alone
16619639|NCT02483598|Active Comparator|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
16619640|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
16619641|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
16619642|NCT02483572|Experimental|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
16619643|NCT02483572|No Intervention|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
16619644|NCT02483559|Other|Amber Lenses|Participants will be randomized to participate in the amber lens condition first or second. Outcome measures to assess the effects of wearing amber lenses to block the blue light spectrum of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
16620094|NCT02480335|Experimental|Usual care and bosentan|Usual care and also treatment with bosentan.
16619645|NCT02483559|Other|Placebo Lenses|Participants will be randomized to participate in the placebo lens condition first or second. Outcome measures to assess the effects of wearing placebo lenses to allow all spectrums of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
16619646|NCT02483546|Experimental|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
16619647|NCT02483546|Active Comparator|traditionally teaching|students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
16619648|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
16619649|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
16619650|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
16619651|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
16619652|NCT02483507|Active Comparator|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
16619653|NCT02483507|Active Comparator|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
16619654|NCT02483507|Active Comparator|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
16619655|NCT02483494|Experimental|APN-led Telemedicine|Participants will receive APN-led Telemedicine in addition to usual care.
16619656|NCT02483494|No Intervention|Usual care|Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.
16619657|NCT02483468|Experimental|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
16619658|NCT02483468|Sham Comparator|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
16619659|NCT02483455|Experimental|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
16619660|NCT02483455|Placebo Comparator|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
16619661|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer < 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer < 500ug/L
16619662|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer > or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer > or = 500 ug/L and High Clinical Pretest Probability
16619663|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
16619664|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
16619665|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
16619666|NCT02483416||group 1|Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
16619667|NCT02483416||group 2|Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
16619668|NCT02483403|Other|Healthy Volunteers|Healthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
16619669|NCT02483390|Experimental|Intervention group: All dyads are in the intervention arm.|
16619670|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
16619671|NCT02483364|Experimental|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
16619672|NCT02483351|Experimental|Liberal RBC Transfusion Strategy|
16619673|NCT02483351|Active Comparator|Restrictive RBC Transfusion Strategy|
16619674|NCT02483338|Other|Children surgery|
16619675|NCT02483325|Other|Busulfan with adapted doses|Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)
16619677|NCT02483299|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
16619678|NCT02483299|Active Comparator|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
16619679|NCT02483286|Experimental|ICG|Integrated Care Group
16619680|NCT02483286|Experimental|MTG|Muscle Training Group
16619681|NCT02483286|Experimental|XBG|X-box Group
16619682|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
16619683|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
16619684|NCT02483260|Other|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
16619685|NCT02483247|Experimental|Combo with Capecitabine|
16619686|NCT02483247|Experimental|Combo with Doxorubicin|
16619687|NCT02483247|Experimental|Combo with Nivolumab (US only)|
16619688|NCT02483247|Experimental|Combo with Pembrolizumab|
16619689|NCT02483247|Experimental|Combo with Paclitaxel|
16619690|NCT02483247|Experimental|Combo with Sunitinib|
16619691|NCT02483234|Experimental|Psoriasis/Psoriatic arthritis|Patients with Psoriasis and inflammatory and/or structural lesions and/or erosions in the MRI/HR-qCT scan will be treated with Secukinumab. Patients with psoriatic arthritis will be treated with Secukinumab. Bone changes will be evaluated influenced by IL-17 blockade
16619692|NCT02483221|Active Comparator|TCI-PCA|
16619693|NCT02483221|Active Comparator|PCA|
16619694|NCT02483208|Experimental|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
16619695|NCT02483208|Other|Advate|Advate infusion to analyze pharmacokinetics.
16619696|NCT02483195|Active Comparator|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
16619697|NCT02483195|Active Comparator|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
16619698|NCT02483182|Experimental|ZEP-3 ointment 1.0%|Topical administration
16619699|NCT02483182|Active Comparator|Acyclovir cream 5%|Topical administration
16619700|NCT02483169|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
16619701|NCT02483169|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
16619702|NCT02483169|Experimental|Cilostazol|cilostazol plus placebo of aspirin
16619703|NCT02483169|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
16619704|NCT02483156|Active Comparator|SOF + RBV|Sofosbuvir 400 mg once daily +RBV (1000 mg/day) for 12-24 weeks
16619705|NCT02483156|Experimental|sof + RBV + AH|Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg for 12-24 weeks
16619706|NCT02483143|Active Comparator|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
16619707|NCT02483143|Active Comparator|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
16619708|NCT02483143|Placebo Comparator|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
16619709|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
16619710|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
16619711|NCT02483104|Experimental|veliparib (ABT-888)|
16619712|NCT02483091|Experimental|Multifaceted KT intervention|Webinars, online vignettes and e-module, copy of guideline recommendations
16619713|NCT02483091|No Intervention|Control|Printed copy of guideline recommendations
16619714|NCT02483078|Active Comparator|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
16619715|NCT02483078|Placebo Comparator|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
16619716|NCT02483065||inpatients with dementia|
16619717|NCT02483065||inpatients without dementia|
16619718|NCT02483052|Experimental|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
16619719|NCT02483039|Experimental|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
16619775|NCT02482636|Other|Group 2|"Group 2 will receive the following interventions:
~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months
~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)
~Rotavirus vaccine oral 1.5ml at 2 and 3 months
~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months
~Meningococcal C/Hib vaccine IM 0.5ml at 12 months
~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
16619994|NCT02480998|Experimental|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
16619720|NCT02483039|No Intervention|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
16619721|NCT02483026|Experimental|Intensive supplements care pre-surgery|Multi vitamins pills vitamin D
16619722|NCT02483026|Other|Standard supplements care pre-surgery|vitamin D (Vitamin D will be given in a reduced doses compared to the intervention group)
16619723|NCT02483013|Active Comparator|Whitening dentifrices|Two groups used whitening dentifrices, three times per day during four weeks
16619724|NCT02483013|Placebo Comparator|Placebo|One group used conventional dentifrice, three times per day during four weeks
16619725|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.
~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.
~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.
~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.
~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
16619726|NCT02482987|Experimental|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
16619727|NCT02482987|Experimental|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
16619728|NCT02482948|Active Comparator|Collagenase|This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
16619729|NCT02482948|Active Comparator|Active leptospermum honey|This is an active medicinal grade honey used to promote autolytic debridement and applied daily
16619730|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
16619731|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
16619732|NCT02482922|Experimental|IET and Nutrition|3 times per week of interval exercise training Once daily meal replacement
16619733|NCT02482909|Experimental|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
16619734|NCT02482909|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
16619735|NCT02482883|Active Comparator|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
16619736|NCT02482883|Sham Comparator|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
16619737|NCT02482870|Active Comparator|Macintosh|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a Macintosh laryngoscope.
16619738|NCT02482870|Active Comparator|KingVision|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a King Vision video laryngoscope.
16619739|NCT02482857|Experimental|Acetylsalicylic acid 75 mg twice daily|Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.
16619740|NCT02482857|Active Comparator|Acetylsalicylic acid 160 mg once daily|Aspirin 160 mg OD is an accepted and used dosage after CABG.
16619741|NCT02482857|Active Comparator|Acetylsalicylic acid 75 mg once daily|Aspirin 75 mg OD is an accepted and used dosage after CABG.
16619742|NCT02482844|Other|Pacemaker|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
16619743|NCT02482844|Other|holter implantable|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
16619744|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
16619745|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
16619746|NCT02482818|Placebo Comparator|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.
~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).
~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.
~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
16619776|NCT02482623|Experimental|Intervention|Dyads in this arm will receive care provided by an interprofessional team trained through the DSM-H to provide patient/caregiver-centered dementia care through home healthcare.
16619747|NCT02482818|Experimental|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.
~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).
~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.
~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.
~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
16619748|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
16619749|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
16619750|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
16619751|NCT02482792|Experimental|Norwegian Psychomotor Physiotherapy|NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
16619752|NCT02482792|Active Comparator|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.They will receive one session weekly with COPE, given by a physiotherapist, maximum 4 times, followed by active individual Physiotherapy (PT).
16619753|NCT02482766|Experimental|INRECSURE|Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
16619754|NCT02482766|Active Comparator|INSURE|Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.
16619755|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16619756|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16619757|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16619758|NCT02482740|Experimental|tamoxifen|tamoxifen 20 mg given everyday for 12 months
16619759|NCT02482740|Active Comparator|letrozole|letrozole 2.5 mg given everyday for 12 months
16619760|NCT02482727|No Intervention|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
16619761|NCT02482727|Experimental|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
16619762|NCT02482714|Experimental|Rehab Institute|This group will do some physical activity in a specialized institute
16619763|NCT02482714|Active Comparator|Club structure|This group will do some physical activity in a club.
16619764|NCT02482688|Experimental|Multisensory Acute|Multisensory intervention delivered within 2 months post-stroke.
16619765|NCT02482688|Experimental|Multisensory Chronic|Multisensory intervention delivered 6 months post-stroke.
16619766|NCT02482688|Active Comparator|Unisensory Acute|Unisensory intervention delivered within 2 months post-stroke.
16619767|NCT02482688|Active Comparator|Unisensory Chronic|Unisensory intervention delivered 6 months post-stroke.
16619768|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619769|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619770|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619771|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619772|NCT02482649|Experimental|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
16619773|NCT02482649|Active Comparator|Drugs|Methylphenidate or Atomoxetine
16619774|NCT02482636|Other|Group 1|"Group 1 will receive the following interventions:
~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months
~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months
~Rotavirus vaccine oral 1.5ml at 2 and 3 months
~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months
~Meningococcal C/Hib vaccine IM 0.5ml at 12 months
~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
16619777|NCT02482623|No Intervention|Control|Dyads in this arm will receive usual care provided in the home healthcare setting.
16619778|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619779|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619780|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
16619781|NCT02482597|Experimental|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
16619782|NCT02482597|Active Comparator|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
16619783|NCT02482584|Active Comparator|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
16619784|NCT02482584|Other|Control group|Control group
16619785|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
16619786|NCT02482558|Experimental|High GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day high glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
16619787|NCT02482558|Experimental|Low GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day low glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
16619788|NCT02482545|Experimental|Breakfast Meal Replacement|Once daily of a powdered meal replacement (high fat, high protein) will be consumed, mixed with water, at breakfast.
16619789|NCT02482545|No Intervention|Control|No placebo or intervention
16619790|NCT02482532|Experimental|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
16619791|NCT02482519|Other|10 day overfeeding/fasting|10 day high calorie diet followed by a 10 day fast
16619792|NCT02482506|Other|SG-WLP|Self-guided weight loss program
16619793|NCT02482506|Active Comparator|MF-WLP|Moving Forward Weight Loss Program
16619794|NCT02482493|Active Comparator|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
16619795|NCT02482493|Active Comparator|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
16619796|NCT02482480|Experimental|Interventional group|"Participants followed a 8-week intervention program with a total of 24 sessions (12 of those were supervised). The aim of the supervision was to increase the adherence to the treatment and to control the compliance of patients. General physical activity consisted in walking along previously standardized urban parks designed for the urban EPOC training project (Arbillaga-Etxarri et al, 2016). The duration of walking were 30 minutes. The physiotherapist supervised the accomplishment of other activities such as oropharyngeal exercises and diet control.
~Oropharyngeal exercises:
~Expiratory muscle strength training (EMST):
~Masako Manoeuvre
~Shaker Head Lift:
~Facial exercise"
16619797|NCT02482480|Sham Comparator|Control Group|Control group participants only received general recommendations regarding general physical activity, diet and sleep hygiene. After 8-weeks of control, they were re-evaluated with the same evaluation test used in the beginning of the study period. Recommendations for general physical activity were walking during 30 minutes at least 3 times a week maintaining the greatest possible pace. Also, control group patients received the same diet control document as intervention group and verbal advice for sleep hygiene. Approximately 1 month after enrolment, a follow-up phone call was completed were we also informed about the new re-evaluation data.
16619798|NCT02482467|Other|Cases|Prenatal diagnosis of ovarian cyst
16619799|NCT02482467|Other|controls|No prenatal diagnosis of cyst
16619800|NCT02482454|Other|RFA alone|Patients undergo radiofrequency ablation alone.
16619801|NCT02482454|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA
16619802|NCT02482441|Experimental|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
16619803|NCT02482441|Experimental|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
16619804|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
16619805|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
16619806|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
16619807|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
16619808|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
16619809|NCT02482415|Experimental|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
16619810|NCT02482415|No Intervention|Control|
16619811|NCT02482402|Experimental|Inhaled Iloprost|2 inhalations per day of 2.5 µg Iloprost [Ventavis®] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg) will be performed according to each patient's health condition.
16619812|NCT02482402|Placebo Comparator|Placebo inhaled|2 to a maximum of 6 inhalations per day of placebo solution (PLA) will be performed. Study medication will be inhaled using the portable, hand-held I-Neb AAD vibrating mesh technology nebulizer system.
16619813|NCT02482389|Experimental|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
16619814|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
16619815|NCT02482363|Active Comparator|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
16619816|NCT02482363|Sham Comparator|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
16619817|NCT02482350|Experimental|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
16619818|NCT02482337|Experimental|POEM procedure|Patients who underwent POEM
16619819|NCT02482324|Other|Treatment A-B|12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
16619820|NCT02482324|Other|Treatment B-A|12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
16619821|NCT02482311|Experimental|AZD1775|"Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.
~This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types."
16619822|NCT02482298|Experimental|Dose A|
16619823|NCT02482298|Experimental|Dose B|
16619824|NCT02482298|Placebo Comparator|Placebo|
16619825|NCT02482272|Active Comparator|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
16619826|NCT02482272|Experimental|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
16619827|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)
~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)
~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week
~Both groups will receive:
~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
16619828|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.
~Both groups will receive:
~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
16619829|NCT02482220|Experimental|High intensity|in this group, the participants will follow a high intensity physical activity program (High Intensity Interval exercise from 75 to 95% VO2max)
16619830|NCT02482220|Experimental|Moderate intensity|in this group, the participants will follow a moderate intensity physical activity program (Intensity from 50 to 65% VO2max)
16619831|NCT02482207|Experimental|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
16619832|NCT02482207|Placebo Comparator|Placebo|Life style modification alone
16619833|NCT02482194|Experimental|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
16619834|NCT02482168|Experimental|APX005M every 3 week|Subjects receive APX005M intravenously every 3 week until disease progression, unacceptable toxicity or death.
16619835|NCT02482168|Experimental|APX005M every 2 week|Subjects receive APX005M intravenously every 2 week until disease progression, unacceptable toxicity or death.
16619836|NCT02482168|Experimental|APX005M every 1 week|Subjects receive APX005M intravenously every 1 week until disease progression, unacceptable toxicity or death.
16619837|NCT02482155|Experimental|ibuprofen|ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
16619838|NCT02482142|Placebo Comparator|phosphorus alone|Effect of phosphorus (500mg) ingestion alone. No meal. Needed to determine the impact of phosphorus alone on DIT
16619839|NCT02482142|Placebo Comparator|high CHO meal alone|Ingestion of placebo tablets with the high carbohydrate meal
16619840|NCT02482142|Active Comparator|High CHO meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high carbohydrate meal
16619841|NCT02482142|Active Comparator|High protein meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high protein meal
16619842|NCT02482142|Placebo Comparator|High protein meal alone|Ingestion of placebo tablets with the high protein meal
16619843|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
16619844|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
16619845|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
16619846|NCT02482090|Experimental|Patient group|"All patients receive the same treatment. Alle patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.
~Stem Cells are harvested a minimum of 3 weeks before treatment for potential later use if the patients are having difficulties recovering from the lymphodepleting chemotherapy.
~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1.
~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5.
~Interleukin-2 is administered in an i.v. continous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days.
~Stem Cells can be administered after treatment if needed."
16619847|NCT02482077|Experimental|SOF+RBV 8 wk|Participants will receive SOF+RBV for 8 weeks.
16619848|NCT02482077|Experimental|SOF+RBV 12 wk|Participants will receive SOF+RBV for 12 weeks.
16619849|NCT02482077|Experimental|SOF+DCV 8 wk|Participants will receive SOF+DCV for 8 weeks.
16619850|NCT02482077|Experimental|SOF+DCV 12 wk|Participants will receive SOF+DCV for 12 weeks.
16619851|NCT02482077|Experimental|LDV/SOF 8 wk|Participants will receive LDV/SOF for 8 weeks.
16619852|NCT02482077|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF for 12 weeks.
16619853|NCT02482064|No Intervention|Traditional Obturators|Patients will use traditional obturators which are going to be made from ordinary heat-activated acrylic resin.
16619854|NCT02482064|Experimental|Flexible Obturators|Patients will use the new obturators made from flexible resin.
16619855|NCT02482038|Experimental|geko device|
16619856|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
16619857|NCT02482025|Active Comparator|SMMRT|Receives Usual Care PLUS SMMRT Intervention
16619858|NCT02482012||Staff|Staff nurses and physicians in the NICU
16619859|NCT02482012||Parents|Parents of infants in the NICU and a smaller group of parents of infants in the well baby nursery.
16619860|NCT02481999||Study group: Patients|"470 children for elective surgery 0,5 to 8 years
~Analysis of EEG data will divided in four age-related groups because of the different baseline EEG activity:
~0.5 - 12 month: 5-7 Hz activity / blocked by eye opening
~12 - 36 month: 7-8 Hz activity / Variability 5 - 10 Hz
~3 - 6 years: 8 Hz activity / amplitude 100µV
~6 - 8 years 10Hz activity / amplitude 100 µV"
16619861|NCT02481999||Control group: Healthy children for POCD assessment|80 healthy children (siblings of study group children and children from Kindergarten) 0,5 to 8 years with no operation
16619862|NCT02481986|Experimental|Community health worker|Participants in this arm will be offered 10 home visits in a 12-month period from community health workers (CHWs). Visits will cover a core asthma curriculum and provide social support.
16619863|NCT02481986|Active Comparator|Certified asthma educator|Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
16619864|NCT02481973|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
16619865|NCT02481960|Experimental|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
16619866|NCT02481947|Experimental|BLI400 Laxative|21 gm BLI400 powder
16619867|NCT02481947|Active Comparator|Lubiprostone|24 mcg capsule bid
16619868|NCT02481934|Experimental|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
16619869|NCT02481921|Experimental|MEDIC-HF|Multidisciplinary Education & Intervention Class in Heart Failure
16619870|NCT02481921|No Intervention|Usual Care|Usual heart failure care
16619871|NCT02481895|Experimental|Experimental|E-neurocognitive module training.
16619872|NCT02481895|No Intervention|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
16619873|NCT02481882|Other|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
16619874|NCT02481882|Other|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
16619875|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.
~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.
~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
16619876|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.
~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.
~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
16619877|NCT02481856|Experimental|12 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
16619878|NCT02481856|Experimental|7 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
16619879|NCT02481856|Experimental|2 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
16619880|NCT02481856|Placebo Comparator|Placebo|No active ingredient, Oral lyophilisate
16619885|NCT02481830|Active Comparator|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
16619887|NCT02481804|Experimental|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
16619888|NCT02481791|Experimental|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
16619889|NCT02481765|Experimental|Direct current Stimulation|High definition transcranial direct current stimulation (HD-tDCS)
16619890|NCT02481752|Experimental|AAT Training Group|Individuals in this condition will receive four sessions of AAT training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
16619891|NCT02481752|Sham Comparator|SHAM Training Group|Individuals in this condition will receive four sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
16619892|NCT02481726|Experimental|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
16619893|NCT02481713|Experimental|MI condition|motivational interview condition
16619894|NCT02481713|Sham Comparator|CI condition|learning style interview condition
16619895|NCT02481687||Ulcerative colitis|"Consecutively admitted patients with active ulcerative colitis, confirmed by histopathology.
~I-SCAN and pCLE will be applied in all patients."
16619896|NCT02481687||Crohn's disease|"Consecutively admitted patients with active Crohn's disease, confirmed by histopathology.
~I-SCAN and pCLE will be applied in all patients."
16619897|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
16619898|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
16619899|NCT02481661|Experimental|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
16619900|NCT02481661|Active Comparator|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
16619901|NCT02481648|Experimental|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.
~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
16619902|NCT02481648|No Intervention|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
16619903|NCT02481635|Experimental|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.
~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.
~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)
~Surgery: Tumor resection and arterial resection/reconstruction"
16619904|NCT02481609|Experimental|NAC arm|Topical intranasal N-acetyl cysteine (NAC 200 mg/2 ml vials) BID for one month
16619905|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.
~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
16619906|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).
~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
16619907|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).
~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
16620089|NCT02480387|Experimental|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
16619908|NCT02481583|Experimental|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
16619909|NCT02481583|Experimental|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
16619910|NCT02481570|Experimental|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
16619911|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
16619912|NCT02481557|No Intervention|No Treatment|No Treatment
16619913|NCT02481544|Experimental|Gratitude Journaling Plus Standard of Care|"The most often used gratitude intervention consists of journaling, writing lists of things for which the individual is grateful. This technique was first employed and found to be effectual for enhancing wellbeing by Emmons and McCullough and has been suggested to be as effective as methods frequently used in clinical therapy. We are proposing an 8-week intervention in which the participant records 3-5 things for which they are grateful most days of the week. A longer intervention was chosen because Emmons and McCullough (2003) suggest that healthy behavior changes only occurred in a prolonged multi-week intervention. To ensure some conformity in the intervention, instructions that will be used will be similar to Emmons and McCullough (2003): There are many things in our lives, both large and small, that we might be grateful about. Think back over your day (week) and write down on the lines below up to five things in your life that you are grateful or thankful for."
16619914|NCT02481544|Sham Comparator|Memorable Events Journaling Plus Standard of Care|"In the sham control condition, individuals will record memorable events with methods identical to the gratitude journaling condition: Patients will be asked to record 3-5 memorable events in a given day, on most days of the week. Patients will be contacted once per week to remind them to continue with the memorable events journal. Patients will be given 2 journals during their first testing session (one journal is for the first four weeks and the second is for the second four weeks of journaling). Patients will be contacted once per week to remind them to continue with gratitude journal writing. Patients will be instructed to record the date of each journal entry next to each new day of journaling Patients will be provided with materials to return their first journal by mail and will and return their second journal at the T2 laboratory testing session."
16619915|NCT02481544|No Intervention|Standard of Care|SOC consists of medical care that is included in post-MI treatment, such as physician visits and medication adjustments and cardiac rehabilitation. These patients will not have any active intervention, but will undergo the same testing routine as the gratitude intervention group. These patients will be given the opportunity to participate in the gratitude journaling intervention after they have completed the study. Patient records will be evaluated at each timepoint for changes in medications and medical treatment.
16619916|NCT02481531|Active Comparator|Previously marketed infant formula|Cow's milk-based infant formula
16619917|NCT02481531|Experimental|Previously marketed formula using a similar protein|Cow's milk-based infant formula
16619918|NCT02481518|Experimental|Magnesium|Magnesium preloading group : Magnesium preloading for Cisplatin treatment
16619919|NCT02481518|Active Comparator|Control|Control group : Normal saline preloading for cisplatin treatment
16619920|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
16619921|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
16619922|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
16619923|NCT02481492|Experimental|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
16619924|NCT02481492|Experimental|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
16619925|NCT02481479|Other|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
16619926|NCT02481466|Experimental|Portfolio diet and structured exercise|Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
16619927|NCT02481466|Active Comparator|DASH-like diet and structured exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program-a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
16619928|NCT02481466|Experimental|Portfolio diet and routine exercise|Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
16619929|NCT02481466|Active Comparator|DASH-like diet and routine exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
16619930|NCT02481453|Experimental|Rapamycin|rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year
16619931|NCT02481453|Placebo Comparator|Placebo|Placebo oral solution, 2 ml/day, once a day, during one year
16619987|NCT02481063|Active Comparator|Eccentric|6 Weeks Training with eccentric Overload (Squat with Yoyo Technology) 3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
16619932|NCT02481440|Experimental|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
16619933|NCT02481427|Experimental|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
16619934|NCT02481427|Experimental|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
16619935|NCT02481414|Experimental|PepCan|Four injections (one every 3 weeks) of PepCan
16619936|NCT02481414|Active Comparator|Candin|Four injections (one every 3 weeks) of Candin
16619937|NCT02481401|No Intervention|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for 4 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
16619938|NCT02481401|Experimental|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
16619939|NCT02481401|Active Comparator|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors, for a total of 12 months.
16619940|NCT02481388||Weakness Group (WG)|Patients with heart failure and a maximum inspiratory pressure (MIP) <70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
16619941|NCT02481388||Control group (CG)|Patients with heart failure and do not have a maximum inspiratory pressure (MIP) > 70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
16619942|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.
~Women will receive the multiple micronutrient with iron for 12 weeks."
16619943|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.
~Women will receive the multiple micronutrient without iron for 12 weeks."
16619944|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.
~Women will receive iron for 12 weeks."
16619945|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.
~Women will receive a placebo for 12 weeks."
16619946|NCT02481362|Active Comparator|Order 1|Order for sessions: Cake, apricots
16619947|NCT02481362|Active Comparator|Order 2|Order for sessions: apricots, Cake
16619948|NCT02481349|Experimental|Arm I (couple-based Hatha yoga program)|Patients and their partners attend up to 15, 45-60 minute sessions of Hatha yoga over the course of radiation therapy 5 times a week for 5-6 weeks. The program comprises four main components: joint loosening with breath synchronization; postures with deep relaxation techniques; breath energization with sound resonance; and meditation. At the fifth session, patients and their partners receive a DVD and are encouraged to practice on their own (individually and/or together) on the days when they do not meet with the instructor.
16619949|NCT02481349|Active Comparator|Arm II (waitlist control)|Patients receive standard of care provided by the health care team and complete questionnaires before and after radiation therapy.
16619950|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin
~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin
~Stage III & high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX
~Questionnaires
~Peripheral nervous system examination
~Whole Genome Sequence"
16619951|NCT02481323|Active Comparator|Group 1|Isosorbide mononitrate 25mg bd
16619952|NCT02481323|Active Comparator|Group 2|Cilostazol 100mg bd
16619953|NCT02481323|Active Comparator|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
16619954|NCT02481323|Other|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
16619988|NCT02481063|Active Comparator|Control|3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
16619989|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
16619990|NCT02481037|Experimental|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
16619991|NCT02481037|No Intervention|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
16619955|NCT02481310|Experimental|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:
~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.
~CNS PROPHYLAXIS:
~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.
~MAINTENANCE:
~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
16619956|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
16619957|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
16619958|NCT02481284||Laser Doppler Perfusion Imaging|20 consequetive cases undergoing breast reconstruction with Deep inferior epigastric artery perforator flap who had evaluation of the microcirculation of the abdominal skin with laser Doppler perfusion imaging
16619959|NCT02481271|No Intervention|Usual care|Does not receive a specific study intervention
16619960|NCT02481271|Experimental|preoperative relaxation program|preoperative relaxation program
16619961|NCT02481271|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
16619962|NCT02481271|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
16619963|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
16619964|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
16619965|NCT02481245|Experimental|Bipolar I and Bipolar II Disorder|30 currently depressed patients with DSM-IV bipolar I or bipolar II disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment.
16619966|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 4μg|4μg group: vaccines serial number is A0001-A0100（18-55 years-old group A0001-A0020，7-17 years-old group A0021-A0040，1-6 years-old group A0041-A0060，7-10 months-old group A0061-A0080，2 months-old group A0081-A0100）
16619967|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 8μg|8μg group: vaccines serial number is B0001-B0100（18-55 years-old group B0001-B0020，7-17 years-old group B0021-B0040，1-6 years-old group B0041-B0060，7-10 months-old group B0061-B0080，2 months-old group B0081-B0100）
16619968|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:
~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
16619969|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:
~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
16619970|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
16619971|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
16619972|NCT02481193|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
16619973|NCT02481193|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
16619974|NCT02481193|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
16619975|NCT02481180|Experimental|T0001|
16619976|NCT02481180|Active Comparator|Enbrel|
16619977|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
16619978|NCT02481154|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
16619979|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:
~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
16619980|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:
~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
16619981|NCT02481128|No Intervention|A (access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy with preoperative access to lymphoscintigraphy findings
16619982|NCT02481128|Experimental|B (no access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
16619983|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
16619984|NCT02481089||training group|
16619985|NCT02481076|Experimental|compression therapy|"Intervention arm: administration of
~Flowtron Hydroven boot in the Emergency Department
~Coban2 Lite after surgery
~Flowtron Hydroven boot after surger, before discharge"
16619986|NCT02481076|Other|controle|"The leg is elevated on a Braun frame. This is the old fashioned conservative treatment to prevent swelling."
16619992|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
16619995|NCT02480998|Active Comparator|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
16619996|NCT02480985|Other|Pituitary function evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to determine the risk factors and the outcome associated with pituitary disorders.
16619997|NCT02480972|Other|Magnetic resonance imaging|multiparametric MRI including perfusion, diffusion, MR fat quantification and MR elastography
16619998|NCT02480959|Other|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
16619999|NCT02480959|Other|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
16620000|NCT02480946|Experimental|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
16620001|NCT02480946|Experimental|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
16620002|NCT02480946|Experimental|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
16620003|NCT02480946|Experimental|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
16620004|NCT02480933|Experimental|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
16620005|NCT02480933|Experimental|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
16620006|NCT02480907|Active Comparator|Workshop Group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
16620007|NCT02480907|Active Comparator|Internet-based support group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the Internet-based support group for parents, including material from the manual and the DVD and additional information available online within a structured program. Over the course of three months, parents will get access to the 8 support sessions online with the instruction to work out the program at home. Additionally email support is offered after completing each session.
16620008|NCT02480907|No Intervention|Control group - TAU|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will get treatment as usual and take part in conventional parental intervention groups.
16620009|NCT02480894|Experimental|Sequential Dosing|Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
16620010|NCT02480881|Experimental|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
16620011|NCT02480868|Experimental|ARTEBONE|Bone Void Filler
16620012|NCT02480855|Other|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
16620013|NCT02480855|No Intervention|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
16620014|NCT02480842|Experimental|Alloplastic group A|"After randomization (15 days after surgery):
~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
16620015|NCT02480842|Experimental|Alloplastic group B|"After randomization (15 days after surgery):
~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
16620016|NCT02480842|Experimental|Oncoplastic group A|"After randomization (15 days after surgery):
~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
16620017|NCT02480842|Experimental|Oncoplastic group B|"After randomization (15 days after surgery):
~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
16620018|NCT02480816|Experimental|Bicarbonated mineral water (BW)|Bicarbonated mineral water
16620019|NCT02480816|Active Comparator|Control mineral water (CW)|Mineral water low in mineral content (control)
16620020|NCT02480803|Active Comparator|continuous levodopa infusion|continuous intrajejunal infusion of levodopa-carbidopa
16620021|NCT02480803|Active Comparator|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
16620022|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
16620023|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
16620024|NCT02480764|Experimental|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
16620090|NCT02480374|Experimental|Single Arm|
16620091|NCT02480361|Experimental|Acupuncture|The patients who were received acupuncture after gastric cancer surgery
16620095|NCT02480335|No Intervention|Usual care|Usual care only.
16620025|NCT02480764|Experimental|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
16620026|NCT02480764|Active Comparator|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
16620027|NCT02480751|Experimental|1: Exprimental (TRK-100STP)|high dose
16620028|NCT02480751|Experimental|2: Exprimental (TRK-100STP)|low dose
16620029|NCT02480751|Placebo Comparator|3: Placebo Comparator|Placebo
16620030|NCT02480738|Experimental|Mild cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
16620031|NCT02480738|Experimental|Subjective cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
16620032|NCT02480738|Active Comparator|Normal controls|Intervention: Computerized Cognitive Training Apparatus
16620033|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).
~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.
~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.
~We plan to collect CSF samples for thrombin activity assay."
16620034|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).
~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.
~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.
~We plan to collect CSF samples for thrombin activity assay."
16620035|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
16620036|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
16620037|NCT02480699|Experimental|Hemodialysed patients|
16620038|NCT02480686|Experimental|SOF+PEG+RBV|Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.
16620039|NCT02480673|Experimental|Free diet plus Chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days without changing their diet
16620040|NCT02480673|Experimental|Normocaloric diet plus chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days along with a normocaloric diet
16620041|NCT02480673|Active Comparator|Normocaloric diet plus oatmeal|This subjects will consume 1 cookie oatmeal before breakfast and dinner for 90 days along with a normocaloric diet
16620042|NCT02480673|Active Comparator|Normocaloric diet|This subjects will only go under a normocaloric diet for 90 days
16620043|NCT02480660|Experimental|Video Intervention Group|Subjects will be randomized to intervention group where participants will be asked to watch a 7 minute educational video.
16620044|NCT02480660|No Intervention|Control Group|Subjects will be randomized to control group ( no intervention) and receive standard of educational care on adolescent to adult oriented health care transitions.
16620045|NCT02480647|Experimental|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system
~Other names:
~Mirena."
16620046|NCT02480647|Active Comparator|etonogestrel|"Etonogestrel implant:
~Other name: Implanon Releasing 20μg/day."
16620047|NCT02480634|Active Comparator|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
16620048|NCT02480634|Experimental|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
16620049|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
16620050|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
16620051|NCT02480608|Experimental|combination Imatinib + Hydroxyurea|Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.
16620052|NCT02480608|Active Comparator|monotherapy Imatinib|Imatinib monotherapy
16620053|NCT02480595||EVAR|Patients undergoing endovascular repair with the latest generation Aorfix™ AAA Flexible Stent Graft System for treatment of abdominal aortic and aorto-iliac aneurysms where the aorta in the aneurysm neck is bent through an angle between 0° and 90°
16620054|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
16620055|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
16620092|NCT02480361|No Intervention|Non-acupuncture|The patients who were not received acupuncture after gastric cancer surgery
16620056|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
16620057|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
16620058|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
16620059|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
16620060|NCT02480569|Experimental|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
16620061|NCT02480569|Experimental|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
16620062|NCT02480556|Experimental|Group A|manual seperation of the placenta
16620063|NCT02480556|Active Comparator|Group B|Conservative separation of placenta
16620064|NCT02480543|Active Comparator|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
16620065|NCT02480543|Active Comparator|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
16620066|NCT02480543|Active Comparator|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
16620067|NCT02480530|No Intervention|Control|Patients will be given educational material on the importance of adherence to statin medications. The GlowCaps device will be set to only record adherence.
16620068|NCT02480530|Experimental|Individual Feedback|In addition to educational material on adherence to statin medications, the research coordinator will review set-up of personal reminders for the GlowCaps device which will be set to glow and buzz when the medication is missed. In addition, patients will receive information on the weekly adherence feedback report.
16620069|NCT02480530|Experimental|Feedback Friend|The patient will be given educational material on the importance of adhering to statin medications. The research coordinator will review set-up of alarm features of GlowCaps device. Similar to Arm 2, patients will be given information on interpretation of weekly adherence feedback report. If the patient chooses a family/friend, they will be called and provided information on the interpretation of weekly adherence feedback report. If the patient chooses a reciprocal partner, they will be assigned to another patient who has made a similar choice
16620070|NCT02480517|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
16620071|NCT02480517|Sham Comparator|Sham Control|Blinded Sham Control Arm
16620072|NCT02480504|Experimental|intermittent energy restriction|dietary intervention, intermittent energy restriction. Participants in the experimental group will follow av 5:2 diet and consume a very low calorie diet providing 400 (females) to 600 (males) calories of energy to days a week and for an average male participant, this will reduce energy intake approximately 22%.
16620073|NCT02480504|Active Comparator|continuous energy restriction|dietary intervention, continuous energy restrictions.Participants in the active comparator group will be asked to reduce daily energy intake by 22-23%
16620074|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
16620075|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
16620076|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
16620077|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
16620078|NCT02480465|Experimental|Lobelitazone 0.5mg|Lobelitazone 0.5mg
16620079|NCT02480465|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg
16620080|NCT02480452||CVI|All children consulting at the CVI clinic (with suspicion of CVI) receiving a diagnosis of CVI
16620081|NCT02480452||no CVI|All children consulting at the CVI clinic (with suspicion of CVI) not receiving a diagnosis of CVI
16620082|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
16620083|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
16620084|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
16620085|NCT02480426|Experimental|CT-image guidance|Previously acquired portal venous phase of CT datasets and intra-operative CT datasets were registered on a dedicated workstation. The selected volume of interest of the CT-image showing portal vein vasculature was overlaid onto the fluoroscopic display as real-time 3D CT-image guidance during the procedure.
16620086|NCT02480426|Active Comparator|CO2 portography|two two-dimensional (2D) CO2 portograms
16620087|NCT02480400|Experimental|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
16620088|NCT02480400|Active Comparator|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
16620096|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
16620097|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
16620098|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
16620099|NCT02480322||BMI-matched control group|
16620100|NCT02480322||Normal-weight control group|
16620101|NCT02480296|Experimental|MYK-461|Oral Tablet x 28 days
16620102|NCT02480296|Placebo Comparator|Placebo|Oral Tablet x 28 days
16620103|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
16620104|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
16620105|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
16620106|NCT02480244|Experimental|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
16620107|NCT02480244|Active Comparator|Control|Control arm receives no health-related behavioral intervention
16620108|NCT02480231|Active Comparator|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
16620109|NCT02480231|Active Comparator|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
16620110|NCT02480218||Tamoxifen|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed tamoxifen.
16620111|NCT02480218||Aromatase Inhibitors|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed aromatase inhibitors.
16620112|NCT02480205|Experimental|NeuroBox to deliver the NeuroPAP|
16620113|NCT02480192|Experimental|Experimental Group (CBT-Meno)|After an initial assessment, the experimental group received 12 weekly sessions (2 hours each) of group-based cognitive-behavioural therapy for menopausal symptoms (CBT-Meno) (up to n=8 per group). Symptoms that were targeted included vasomotor symptoms (hot flashes/night sweats), depressive symptoms, anxiety, poor sleep, and sexual concerns. Participants were re-assessed at 12-weeks post-baseline and at 3 months post-treatment.
16620114|NCT02480192|No Intervention|Waitlist|After an initial assessment, the waitlist comparison group did not receive any treatment for 12 weeks. They were then re-assessed at 12-weeks post-baseline and this data was used to compare this group to the experimental group to determine the effectiveness of the CBT-Meno treatment. After this re-assessment participants in the waitlist condition were offered the same CBT-Meno treatment as the experimental group: 12 weekly sessions (2 hours long) of cognitive-behavioural therapy for menopausal symptoms.
16620115|NCT02480179|Experimental|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
16620116|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
16620117|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
16620118|NCT02480153|Experimental|PF-06410293|
16620119|NCT02480153|Active Comparator|Adalimumab|
16620120|NCT02480140|Experimental|Self-regulated constraint-induced movement therapy|Self-regulated constraint-induced movement therapy (SR-CIMT) - participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days) (CIMT) (the same CIMT protocol as in the CIMT group described under 'comparator/control treatment'); participants were taught using the self-regulation (SR) strategy to relearn the tasks; SR strategy involved participants self reflecting on their abilities and deficits in performing the tasks, identifying problems and solutions in achieving the most independence in the tasks, and then actually carrying out the tasks.
16620121|NCT02480140|Active Comparator|Constraint-induced movement therapy|In the constraint-induced movement therapy group (CIMT), participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days); therapist provided demonstration on the adapted task performance with one arm (the side of participants' hemiplegic arm), and participants to practice the tasks with the unrestrained hemiplegic arm under supervision.
16620122|NCT02480140|Active Comparator|Conventional occupational therapy|It involved therapist to demonstrate the adapted task performance followed by patient's practice under supervision.
16620123|NCT02480127|Experimental|Endometrial injury|In the intervention group, endometrial sampling is obtained twice by Pipelle [one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
16620124|NCT02480127|No Intervention|Control|In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
16620125|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
16620126|NCT02480114|Experimental|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
16620127|NCT02480101|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine
16620128|NCT02480101|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
16620129|NCT02480088|Experimental|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
16620130|NCT02480088|Active Comparator|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
16620131|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
16620132|NCT02480062|Experimental|mWELLCARE software arm|The doctor and nurse care coordinators (NCCs) in the mWELLCARE intervention arm will be trained on the use of mWELLCARE software loaded on a tablet computer. Patients diagnosed with hypertension and/or diabetes will be registered by the nurse using mWellcare application. The nurse will record patient parameters, medical history, medication etc and generate a management plan (including drug recommendation, lifestyle advise) using the mWellcare application based on standard treatment guidelines. The doctor will review the recommendation and agree or disagree giving reasons. Patient will be followed up using SMS.
16620133|NCT02480062|Active Comparator|Usual care arm|"In the control arm or the usual care arm CHCs, the doctor and Nurse will get refresher training in the detection, management and follow up of hypertension and diabetes patients based on standard guidelines. They will be provided with charts for quick reference to standard treatment guidelines. Patients diagnosed with hypertension and/or diabetes will be managed by the doctor at the CHC. The nurse will assist in recording blood pressure, height, weight etc, providing lifestyle advise and follow up advice to patients."
16620134|NCT02480049|Experimental|A Test|test drug (Asmakast)1 tablet contains 10 mg Montelukast
16620135|NCT02480049|Active Comparator|B Reference|reference drug (Singulair) 1 tablet contains 10 mg Montelukast
16620136|NCT02480036|Experimental|Combined IORT and Kyphoplasty|IORT with Kyphoplasty IORT Device: Intrabeam®
16620137|NCT02480023|Experimental|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
16620138|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
16620139|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
16620140|NCT02479997|Active Comparator|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.
~Interventions - patient assigend RI groups are injected only RI
~fill the Primay Case Report Form during surgery
~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
16620141|NCT02479997|Active Comparator|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.
~Interventions - patient assigend RI groups are injected RI +ICG
~prepare fluorescence camera when the surgery begin
~surgeon uses the camera to decect fluorescence flow on SLN
~fill the Primay Case Report Form during surgery
~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
16620142|NCT02479984|Experimental|Staging laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.
~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
16620143|NCT02479971|Active Comparator|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
16620144|NCT02479971|Experimental|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin and clyndamycin solution will be performed.
16620145|NCT02479958|Experimental|Control|
16620146|NCT02479958|Experimental|APDT 1|
16620147|NCT02479958|Experimental|APDT 2|
16620148|NCT02479945|Other|Selective internal iliac vein sampling|
16620149|NCT02479932|Active Comparator|Extraperitoneal cesarean|
16620150|NCT02479932|Active Comparator|Transperitoneal cesarean|
16620151|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
16620152|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
16620153|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
16620154|NCT02479906|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
16620155|NCT02479906|Experimental|Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.
16620156|NCT02479893||cold snare polypectomy|CSP: In this group polyps will be removed with the cold snare polypectomy technique, as a single piece. Additionally, a 1-2mm of normal tissue around the small polyp will also be ensnared in the CSP.
16620157|NCT02479893||hot snare polypectomy|HSP: In this group polyps will be removed with the hot snare polypectomy technique as a single piece with a electrosurgical snare and monopolar current with a setting of 30-35 W in the endocut function.
16620291|NCT02479035|Active Comparator|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
16620158|NCT02479893||APC polyp destruction-polypectomy|APC: In APC group polyps will be cauterized by application of high power argon plasma coagulation on small waves at 50-60W and flow at 2lt/min,as result the polyp destruction.
16620159|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
16620160|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
16620161|NCT02479867|Experimental|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
16620162|NCT02479867|Experimental|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
16620163|NCT02479854|Experimental|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
16620164|NCT02479854|Active Comparator|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
16620165|NCT02479841|Experimental|self management program|Participation in an 11 week self-management program
16620166|NCT02479841|No Intervention|Control group|
16620167|NCT02479828|Active Comparator|Fascia iliaca compartment block (FICB)|Under ultrasound guidance performing fascia iliaca compartment block, in which 40 ml ropivacaine 0,5% are injected under the fascia iliaca.
16620168|NCT02479828|Placebo Comparator|Placebo (not FICB)|Half of the patients will not receive FICB
16620169|NCT02479815|Other|1gm MNP, 15 sachets per month|Quasi experimental matched control cluster design where for every child 1gm Micronutrient Powder (MNP) for two days, is given which totlas to 15 sachets per month
16620170|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
16620171|NCT02479789|Experimental|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
16620172|NCT02479789|Placebo Comparator|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
16620173|NCT02479776|Active Comparator|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
16620174|NCT02479776|Placebo Comparator|saline injection|saline is injected and patients crossed over to active arm at 6 months
16620175|NCT02479763|No Intervention|Conventional loss-of-resistance|
16620176|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
16620177|NCT02479750|Experimental|ColdZyme|ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
16620178|NCT02479750|Placebo Comparator|Placebo|Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
16620179|NCT02479711|Experimental|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
16620180|NCT02479711|Active Comparator|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
16620181|NCT02479698|Experimental|Treatment (BK-specific cytotoxic T lymphocytes)|Patients receive allogeneic BK-specific cytotoxic T-lymphocytes IV over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 19 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.
16620182|NCT02479685|Experimental|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
16620183|NCT02479685|Active Comparator|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
16620184|NCT02479672|Active Comparator|VividTrac video laryngoscope|VividTrac® Videolaryngoscope, A device for endotracheal intubation
16620185|NCT02479672|Active Comparator|Direct laryngoscopy|Direct laryngoscopy, A device for endotracheal intubation
16620186|NCT02479659|No Intervention|Control|Facilities in this arm maintained status quo HIV testing and routine childhood immunization services
16620187|NCT02479659|Experimental|Simple Intervention|This included: 1) HIV testing commodity reinforcement and 2) a policy reinforcement meeting
16620188|NCT02479659|Experimental|Comprehensive Intervention|This arm included: 1) HIV testing commodity reinforcement, 2) a policy reinforcement meeting, 3) community sensitization, 4) Opt-out HIV testing for mothers and newborns, and 5) Operational support for service integration
16620189|NCT02479646|Experimental|Treatment A|MYL-1401H: single subcutaneous injection (2mg)
16620190|NCT02479646|Active Comparator|Treatment B|EU-Neulasta: single subcutaneous injection (2mg)
16620191|NCT02479646|Active Comparator|Treatment C|US-Neulasta: single subcutaneous injection (2mg)
16620192|NCT02479633|Other|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
16620193|NCT02479633|Other|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
16620219|NCT02479451|Experimental|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
16620220|NCT02479438||Diagnosed with GERD|Collect data on GERD patients
16620221|NCT02479425|Active Comparator|3 point turning|patients nursed by the traditional re-positioning (two hours on back, two hours on right and two hours on left).
16620222|NCT02479425|Experimental|2 points turning|patients nursed on the right and left side sonly in 30ْ avoiding the back
16620194|NCT02479620|Active Comparator|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.
~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
16620195|NCT02479620|No Intervention|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.
~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
16620196|NCT02479607|Experimental|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
16620197|NCT02479607|No Intervention|Control group|Standard care according to the clinic's routines.
16620198|NCT02479594|Experimental|competence-feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
16620199|NCT02479594|Placebo Comparator|control|Therapists assigned to this group will receive no competence-feedback.
16620200|NCT02479581|Experimental|ERAS group|Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program
16620201|NCT02479581|Experimental|Conventional control group|Perioperative management follows the conventional program
16620202|NCT02479568|Active Comparator|Control|Control drink (placebo)
16620203|NCT02479568|Experimental|Natural Florida orange juice|100% Florida orange juice (OJ) (natural content of hesperidin)
16620204|NCT02479568|Experimental|Enriched Florida orange juice|100% Florida orange juice (OJ) (enriched hesperidin content)
16620205|NCT02479555|Active Comparator|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.
~Patients will be randomized 1:1 to receive either the active treatment or control therapy.
~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
16620206|NCT02479555|No Intervention|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.
~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
16620207|NCT02479542|Active Comparator|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
16620208|NCT02479542|Experimental|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
16620209|NCT02479529|Experimental|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
16620210|NCT02479529|Other|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
16620211|NCT02479516|Experimental|CHAPP intervention communities|"CHAPP intervention: The proposed CHAPP intervention will include:
~Diabetes risk assessment (modified FINRISK and assessment of lifestyle risk behaviours) sessions be at least every 2 weeks in accessible community locations, manned by trained volunteers of LLO
~Volunteers educate CHAPP participants regarding their diabetes risk factors and ways to practice healthy lifestyle (including referral to local resources/activities) using diabetes education materials adapted for local context
~Use of an accepted process have participant data transmitted to a central web database system through a combination of cell-phone and computer-based technology
~Have participant assessment result forwarded to the Municipal Health Officer (doctor) for follow-up and screening"
16620212|NCT02479516|No Intervention|Delayed Intervention communities|
16620213|NCT02479503||French Adult Heart Transplantation Center|All center performing adult heart transplantation in France in 2015.
16620214|NCT02479490|Experimental|Prednisone + Everolimus|Prednisone + Everolimus
16620215|NCT02479477|Experimental|kinesio therapy|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.
~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase."
16620216|NCT02479477|No Intervention|control|the control group will continue their daily tasks uring eitgh weeks. To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase.
16620217|NCT02479464|No Intervention|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
16620218|NCT02479464|Other|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
16620292|NCT02479035|Placebo Comparator|Control meal|0 g red raspberry
16620223|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
16620224|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
16620225|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
16620226|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
16620227|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
16620228|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
16620229|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
16620230|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
16620231|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
16620232|NCT02479399||Suglat group|Tablets
16620233|NCT02479386||Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
16620234|NCT02479373|Experimental|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
16620235|NCT02479373|Other|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
16620236|NCT02479360||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
16620237|NCT02479347|Experimental|Chloraprep|Preoperative skin preparation with chlorhexidine 2% in alcohol 70% solution
16620238|NCT02479347|Active Comparator|Povidone-iodine|Preoperative skin preparation with povidone-iodine 10% solution
16620239|NCT02479334|Placebo Comparator|Fat challenge breakfast|200 ml control drink (non-energy flavored water) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
16620240|NCT02479334|Experimental|Fat challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
16620241|NCT02479334|Placebo Comparator|Carbohydrate challenge breakfast|200 ml control drink (non-energy flavored water) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
16620242|NCT02479334|Experimental|Carbohydrate challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
16620243|NCT02479321|No Intervention|Control group|Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative period hemodynamic monitoring will be done by management of blood pressure, heart rate and oxygen saturation
16620244|NCT02479321|Experimental|GDT noninvasive monitoring group|GDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®
16620245|NCT02479308|Active Comparator|Moxifloxacin|Oral tablet
16620246|NCT02479308|Experimental|ALKS 5461|Sublingual tablet
16620247|NCT02479308|Placebo Comparator|Placebo|
16620248|NCT02479295|Active Comparator|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
16620249|NCT02479295|Active Comparator|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
16620250|NCT02479282|Other|group A|natural cesarean section
16620251|NCT02479282|Other|group B|traditional cesarean section
16620252|NCT02479269|Experimental|intervention|Aerobic exercise+ blood sampling
16620253|NCT02479269|No Intervention|control|Blood sampling
16620254|NCT02479256|Experimental|Clomiphene citrate + placebo|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily), and one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
16620255|NCT02479256|Experimental|Tamoxifen + placebo|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily), and one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
16620256|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
16620289|NCT02479048|Placebo Comparator|Control meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
16620290|NCT02479035|Active Comparator|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
16620257|NCT02479230|Experimental|vaccine: gemcitabine hydrochloride|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
16620258|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
16620259|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
16620260|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
16620261|NCT02479204|Experimental|Part A ACT-334441 + atenolol|4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
16620262|NCT02479204|Experimental|Part A ACT-334441 + diltiazem|4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
16620263|NCT02479204|Experimental|Part B ACT-334441 + atenolol|12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
16620264|NCT02479204|Experimental|Part B ACT-334441 + diltiazem|12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
16620265|NCT02479191||Female (Treatment Group)|Device: Ovation Abdominal Stent Graft Platform
16620266|NCT02479191||Male (Control Group)|Device: Ovation Abdominal Stent Graft Platform
16620267|NCT02479165|Active Comparator|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.
~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
16620268|NCT02479165|Active Comparator|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.
~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
16620269|NCT02479152|Active Comparator|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
16620270|NCT02479152|Other|LUCAS2|LUCAS2 will be used for CPR
16620271|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
16620272|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
16620273|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
16620274|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
16620275|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
16620276|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
16620277|NCT02479126||Interstitial Lung Disease|Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
16620278|NCT02479113||Lean with normal glucose tolerance|"Pregnant women who are lean with normal glucose tolerance
~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
16620279|NCT02479113||Obese with Normal glucose tolerance|"Pregnant women who are obese with normal glucose tolerance
~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
16620280|NCT02479113||Gestational diabetes mellitus|"Pregnant women who have Gestational Diabetes Mellitus
~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
16620281|NCT02479100|Other|Undergo a CESM|Patients will undergo an experimental Contrast Enhanced Spectral Mammogram (CESM) in addition to standard diagnostic procedures
16620282|NCT02479100|No Intervention|Follow Standard care|Patient will follow standard care pathway.
16620283|NCT02479087|Experimental|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.
~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.
~The initial dosage can be then adjusted on the base of response."
16620284|NCT02479074|Active Comparator|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
16620285|NCT02479074|Active Comparator|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
16620286|NCT02479074|Active Comparator|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
16620287|NCT02479048|Active Comparator|Test meal 1 (TM1)|High fat meal (HF) with ½ avocado (~68g)
16620288|NCT02479048|Active Comparator|Test meal 2 (TM2)|High fat meal (HF) with 1 avocado (~136g)
16620294|NCT02478996|Experimental|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
16620295|NCT02478996|No Intervention|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
16620296|NCT02478983|Experimental|LMA Supreme|1 arm will receive LMA supreme for airway management
16620297|NCT02478983|Active Comparator|LMA Proseal|1 arm will receive LMA Proseal for airway management
16620298|NCT02478970|Experimental|Corneal endotheliopathy|Patients with primary corneal endotheliopathies, such as posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome will be evaluated with the NIDEK CEM-350 and Konan SP4000
16620299|NCT02478970|Placebo Comparator|Normal|Patients without corneal endotheliopathies will be evaluated with the NIDEK CEM-350 and Konan SP4000
16620300|NCT02478957|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 6 weeks
16620301|NCT02478957|Placebo Comparator|Placebo|Placebo, administered via inhalation three times daily for 6 weeks
16620302|NCT02478944|Experimental|Inflammatory bowel disease|Patients with Crohn's disease and ulcerative colitis undergoing manometry
16620303|NCT02478918|Experimental|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
16620304|NCT02478918|No Intervention|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
16620305|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
16620306|NCT02478879|Experimental|ZP-PTH Patch|Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment
16620307|NCT02478879|Active Comparator|FORTEO(R) Pen|Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.
16620308|NCT02478866|Experimental|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg, 600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
16620309|NCT02478840|Experimental|Lamazym|1 mg Lamazym/kg Body weight
16620310|NCT02478827|Experimental|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
16620311|NCT02478827|Experimental|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
16620312|NCT02478827|No Intervention|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
16620313|NCT02478814|Experimental|Active, Young Adult Males|Subjects will receive different levels of amino acid intakes varying from 0.2 to 2.6 g/kg/day.
16620314|NCT02478801|Experimental|Endurance trained|subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day.
16620315|NCT02478788|Experimental|LR-MAS - Low-risk ADHD adolescents|ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
16620316|NCT02478788|Experimental|HR-MAS - High-risk ADHD adolescents|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD."
16620317|NCT02478788|Placebo Comparator|HR-P - High-risk ADHD on Placebo|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed."
16620318|NCT02478788|No Intervention|HC (Healthy Controls)|Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo MR scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging evaluations will be performed at baseline and Week 12 (or termination).
16620319|NCT02478775|Experimental|Frequent Blood Sampling|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period.
16620320|NCT02478762|Active Comparator|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
16620321|NCT02478762|Experimental|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
16620325|NCT02478736||delirium group|the patients with delirum after on-pump cardiac surgery
16620326|NCT02478736||no delirium group|the patients without delirum after on-pump cardiac surgery
16620327|NCT02478710|Placebo Comparator|Aerosolized Placebo|Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.
16620328|NCT02478710|Experimental|Aerosolized Tobramycin or Vancomycin|Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
16620329|NCT02478697|Experimental|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
16620330|NCT02478697|No Intervention|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
16620331|NCT02478684|Active Comparator|30 seconds of DCC|30 Seconds of placental blood transfusion
16620332|NCT02478684|Active Comparator|60 seconds DCC|60 Seconds of placental blood transfusion
16620333|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
16620334|NCT02478658|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:
~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
16620335|NCT02478658|No Intervention|Control|No intervention
16620336|NCT02478645|Experimental|ramosetron 0.3|
16620337|NCT02478645|Active Comparator|ramosetron 0.45|
16620338|NCT02478645|Active Comparator|ramosetron 0.6|
16620339|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
16620340|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
16620341|NCT02478619|Active Comparator|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
16620342|NCT02478619|Placebo Comparator|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
16620343|NCT02478606|No Intervention|Control Group|Without intervention
16620344|NCT02478606|Experimental|Static Group|Will receive passive static stretching in hamstring muscle
16620345|NCT02478606|Experimental|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
16620346|NCT02478593|Experimental|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
16620347|NCT02478593|No Intervention|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
16620348|NCT02478580|Experimental|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
16620349|NCT02478580|Placebo Comparator|Placebo|A single oral placebo will be given in preoperative area
16620350|NCT02478567|Experimental|Scapular Training|Initiated scapular training exercise for the first 4 weeks followed by addition of rotator cuff exercises the next four weeks
16620351|NCT02478567|Experimental|Rotator Cuff Training|initiated rotator cuff training exercise for the first 4 weeks followed by addition of scapular training exercises the next four weeks.
16620352|NCT02478554|No Intervention|Population-based|Participants will be randomly assigned to population-based fetal growth curves
16620353|NCT02478554|Active Comparator|Customized-based|Participants will be randomly assigned to customized-based fetal growth curves (intervention)
16620354|NCT02478541|Active Comparator|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
16620355|NCT02478541|Active Comparator|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
16620356|NCT02478528|Experimental|Experimental|
16620357|NCT02478515|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
16620358|NCT02478502|Experimental|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
16620359|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
16620360|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
16620390|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
16620361|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
16620362|NCT02478450|Experimental|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
16620363|NCT02478450|Experimental|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
16620364|NCT02478450|Experimental|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
16620365|NCT02478450|Experimental|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
16620366|NCT02478450|Experimental|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
16620367|NCT02478450|Experimental|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
16620368|NCT02478437|Active Comparator|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
16620369|NCT02478437|Active Comparator|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
16620370|NCT02478424|Experimental|Cannabidiol arm|Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
16620371|NCT02478411|Experimental|Cycle ergometer physiotherapy|15 minutes of cycle ergometer physiotherapy plus 15 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
16620372|NCT02478411|Active Comparator|Conventional physiotherapy|30 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
16620373|NCT02478398|Experimental|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
16620374|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
16620375|NCT02478385|Active Comparator|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
16620376|NCT02478385|Placebo Comparator|Labour in a standard labour room|The woman gives labour in a standard labour room
16620377|NCT02478372|Active Comparator|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
16620378|NCT02478372|Experimental|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
16620379|NCT02478359|No Intervention|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
16620380|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
16620381|NCT02478346|Experimental|All Patients|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used).
16620382|NCT02478333|Experimental|ALS-008176 (250 mg) or Placebo|Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
16620383|NCT02478333|Experimental|ALS-008176 (500 mg) or Placebo|Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
16620384|NCT02478333|Experimental|ALS-008176 (750 mg) or Placebo|Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
16620385|NCT02478320|Experimental|Ilorasertib (ABT-348)|"Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
~Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle."
16620386|NCT02478307|Active Comparator|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
16620387|NCT02478307|Active Comparator|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
16620388|NCT02478307|Active Comparator|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
16620389|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
16620429|NCT02478021|Placebo Comparator|Placebo|1 pill Placebo
16620391|NCT02478281|Experimental|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
16620392|NCT02478268|Active Comparator|Patients with idiopathic pulmonary fibrosis|
16620393|NCT02478268|Active Comparator|Healthy volunteers|
16620394|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
16620395|NCT02478255|Active Comparator|Healthy volunteers|
16620396|NCT02478242|Active Comparator|Nafamostat mesilate group|Nafamostat mesilate was used for maintenance anticoagulation during continuous renal replacement therapy.
16620397|NCT02478242|Placebo Comparator|No anticoagulation group|Normal saline was used for maintenance anticoagulation during continuous renal replacement therapy.
16620398|NCT02478229|Experimental|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
16620399|NCT02478216|No Intervention|C group|Remote ischemic preconditioning will not be applied
16620400|NCT02478216|Experimental|R group|Remote ischemic preconditioning will be applied.
16620401|NCT02478203|Placebo Comparator|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
16620402|NCT02478203|Active Comparator|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
16620403|NCT02478203|Active Comparator|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
16620404|NCT02478190|Experimental|Tight control|Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
16620405|NCT02478190|Experimental|Loose control|Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
16620406|NCT02478177||Stroke|Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants
16620407|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
16620408|NCT02478151|Experimental|OrganOx Metra|OrganOx Metra Device
16620409|NCT02478138|Other|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
16620410|NCT02478125|Active Comparator|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
16620411|NCT02478125|Active Comparator|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
16620412|NCT02478125|Experimental|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.
~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
16620413|NCT02478112|Experimental|Biodegradable Balloon Implant|Biodegradable balloon implanted before radiotherapy
16620414|NCT02478099|Experimental|1 Treatment with MPDL3280A|Treatment with MPDL3280A
16620415|NCT02478086|Experimental|use amine acids parenteral 3.5g|"Amino acids parenteral (Levamin Nomo 10% ®) Group A with an initial doses of amino acids until reaching 3.5 g/kg/day during 28 days.For the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
16620416|NCT02478086|Experimental|use amine acids parenteral 4g|"Group B with an initial doses of 2.5 g/kg/day with daily increments of 0.5 g/kg/day until reaching 4 g/kg/day during 34 days.Weight, urea, creatinine and blood urea nitrogen (BUN) were measured weeklyFor the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
16620417|NCT02478060|Experimental|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
16620418|NCT02478060|Experimental|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
16620419|NCT02478060|Experimental|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
16620420|NCT02478060|Experimental|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
16620421|NCT02478060|Experimental|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
16620422|NCT02478047|Active Comparator|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
16620423|NCT02478047|Experimental|Matching points ST36+CV12|
16620424|NCT02478047|Experimental|Matching points PC6+CV12|
16620425|NCT02478047|Experimental|Matching points CV3+CV12|
16620426|NCT02478034|Experimental|fludrocortisone|effects of fludrocortisone on cognition compared to placebo
16620427|NCT02478034|Placebo Comparator|Placebo|effects of fludrocortisone on cognition compared to placebo
16620428|NCT02478021|Experimental|Hydrocortisone|10 mg hydrocortisone
16620431|NCT02477995|Experimental|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
16620432|NCT02477995|Active Comparator|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
16620433|NCT02477982||control group|BMI ≤ 25 kgm-2
16620434|NCT02477982||obese group|BMI ≥ 30 kgm-2
16620435|NCT02477969|Experimental|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
16620436|NCT02477969|Experimental|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
16620437|NCT02477969|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
16620438|NCT02477956|Experimental|vitamin D3|subjects taking the standard vitamin D protocol with added monthly high dose cholecalciferol of 100,000 IU cholecalciferol
16620439|NCT02477956|Active Comparator|Control|group of subjects taking the standard vitamin D
16620440|NCT02477943||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
16620441|NCT02477943||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
16620442|NCT02477917|Experimental|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
16620443|NCT02477904|Experimental|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
16620444|NCT02477904|Active Comparator|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
16620445|NCT02477904|Active Comparator|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
16620446|NCT02477878|Experimental|BPX-501 and Rimiducid|"All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).
~Two doses of Rimiducid ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
16620447|NCT02477865|Experimental|PEX168(100µg)|PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.
16620448|NCT02477865|Experimental|PEX168(200µg)|PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.
16620449|NCT02477865|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.
16620450|NCT02477852|Experimental|anti-tuberculosis treatment two weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
16620451|NCT02477852|Experimental|anti-tuberculosis treatment four weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
16620452|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
16620453|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
16620454|NCT02477826|Experimental|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
16620455|NCT02477826|Experimental|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
16620456|NCT02477826|Experimental|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
16620457|NCT02477826|Experimental|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy
16620458|NCT02477813|Experimental|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
16620459|NCT02477800|Experimental|Low Dose|Monthly intravenous (IV) infusion
16620460|NCT02477800|Experimental|High Dose|Monthly intravenous (IV) infusion
16620461|NCT02477787|Experimental|treatment|patients will receive donor-derived NK cell infusion after haploidentical HCT
16620462|NCT02477787|No Intervention|control|patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT
16620463|NCT02477774|Experimental|Arista|Arista to ALT donor site
16620464|NCT02477774|No Intervention|Control|No Arista to ALT donor site
16620465|NCT02477761|No Intervention|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
16620466|NCT02477761|Experimental|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
16620467|NCT02477748|Active Comparator|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
16620468|NCT02477748|Placebo Comparator|Placebo|Inert tablets
16620469|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
16620470|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
16620471|NCT02477722|Experimental|EFP-NF|Subjects are asked to change their brain activity in response to feedback they receive from the brain itself, mediated via various visual or auditory stimuli.
16620473|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
16620474|NCT02477696|Experimental|ACP-196|acalabrutinib 100 mg BID (Arm A; N=250)
16620475|NCT02477696|Active Comparator|ibrutinib|ibrutinib 420 mg QD (Arm B; N=250)
16620476|NCT02477670|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
16620477|NCT02477670|Experimental|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
16620478|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
16620479|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
16620480|NCT02477631|Experimental|Deferiprone|patient treated with study drug
16620481|NCT02477618|Active Comparator|SAGE-547|Intravenous
16620482|NCT02477618|Placebo Comparator|Placebo|Intravenous
16620483|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
16620484|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
16620485|NCT02477592|Experimental|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
16620486|NCT02477592|Active Comparator|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
16620487|NCT02477579|Experimental|NovaCross|NovaCross microcatheter will be used.
16620488|NCT02477566|Experimental|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
16620489|NCT02477566|Active Comparator|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
16620490|NCT02477553|Experimental|Quantitative|"Subjects view:
~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.
~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
16620491|NCT02477553|Active Comparator|Verbal|"Subjects view:
~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.
~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
16620492|NCT02477540|Experimental|2-time injection group : Cellgram-CLI|Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
16620493|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
16620494|NCT02477514|Experimental|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
16620495|NCT02477501|Active Comparator|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
16620496|NCT02477501|Active Comparator|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
16620497|NCT02477488|Experimental|Allopurinol HS|Allopurinol at bedtime compared to AM administration
16620498|NCT02477475||NEXIUM|Oral dose 20mg/day
16620499|NCT02477462||Primary Biliary Cirrhosis|Subjects meeting internationally accepted criteria for the diagnosis of primary biliary cirrhosis
16620500|NCT02477462||Control|Subjects without evidence of primary biliary cirrhosis, liver disease, or inflammatory condition who are of similar age and sex distribution to the Primary Biliary Cirrhosis group
16620501|NCT02477449|Experimental|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
16620502|NCT02477449|Experimental|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
16620503|NCT02477449|Experimental|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
16620504|NCT02477436|Experimental|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
16620505|NCT02477436|Experimental|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
16620506|NCT02477436|Experimental|Avanafil 200mg group|Avanafil 100mg 2 tablets
16620507|NCT02477436|Placebo Comparator|Placebo group|Placebo 100mg 2tablets
16620508|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
16620543|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
16620945|NCT02474524|Active Comparator|Social intervention|+ treatment as usual
16620509|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
16620510|NCT02477410|Experimental|Hydrolysed porcine protein from blood|Dietary intervention with hydrolysed porcine protein from blood
16620511|NCT02477410|Experimental|Hydrolysed porcine protein from muscle|Dietary intervention with hydrolysed porcine protein from muscle
16620512|NCT02477410|Experimental|Hydrolysed whey protein|Dietary intervention with hydrolysed whey protein
16620513|NCT02477397|Experimental|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
16620514|NCT02477397|Active Comparator|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
16620515|NCT02477384|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
16620516|NCT02477384|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
16620517|NCT02477371|Experimental|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR > 0,8 are deferred.
16620518|NCT02477371|Active Comparator|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
16620521|NCT02477332|Experimental|QGE031 24 mg s.c. q4w|ligelizumab 24 mg injection subcutaneous every 4 weeks
16620522|NCT02477332|Experimental|QGE031 72 mg s.c. q4w|ligelizumab 72 mg injection subcutaneous every 4 weeks
16620523|NCT02477332|Experimental|QGE031 240 mg s.c. q4w|ligelizumab 240 mg injection subcutaneous every 4 weeks
16620524|NCT02477332|Active Comparator|Omalizumab 300 mg s.c. q4w|omalizumab 300 mg injection subcutaneous every 4 weeks
16620525|NCT02477332|Placebo Comparator|Placebo s.c. q4w|placebo injection subcutaneous every 4 weeks
16620526|NCT02477332|Experimental|QGE031 120 mg s.c. s.d.|ligelizumab 120 mg injection subcutaneous single dose
16620527|NCT02477319||Part A|"Cohort 1: Healthy Controls
~Cohort 2: Partial CFTR function CF (class IV/V)
~Cohort 3: Absent CFTR function CF (Class I/II)"
16620528|NCT02477319||Part B|CF patients who are homozygous for the F508del
16620529|NCT02477306|Experimental|Study group|60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods
16620530|NCT02477293|Experimental|Hyeonggaeyeongyo-tang|
16620531|NCT02477280|Experimental|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
16620532|NCT02477280|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
16620533|NCT02477267|Experimental|Test-Reference Sequence|SL spray, followed by SL film
16620534|NCT02477267|Experimental|Reference-Test Sequence|SL film followed by SL spray
16620535|NCT02477254||SLE patients|SLE patients who received HPV vaccination
16620536|NCT02477254||Control subjects|Healthy subjects who received HPV vaccination
16620537|NCT02477241|Other|Healthy female subjects|Healthy female subjects with or without overactive bladder undergoing functional MRI brain and urodynamic study.
16620538|NCT02477228|Active Comparator|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
16620539|NCT02477228|Active Comparator|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
16620540|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.
~Dexamethasone 40 mg oral weekly.
~Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2"
16620541|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.
~Dexamethasone 40 mg oral weekly.
~Bendamustine dose levels: MTD given on days 1 and 2"
16620542|NCT02477202|Experimental|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (<30/30+ kg/m^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
16620544|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
16620545|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
16620546|NCT02477150|Active Comparator|SLE (vaccine)|Zostavax SC injection (0.65ml)
16620547|NCT02477150|Placebo Comparator|SLE (placebo)|Placebo SC injection (normal saline 0.65ml)
16620548|NCT02477137|Experimental|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
16620549|NCT02477137|No Intervention|Control group|Usual care according to the routines at the clinic.
16620550|NCT02477124|Active Comparator|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
16620551|NCT02477124|Active Comparator|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
16620552|NCT02477098|Experimental|Pre RSB|patients who receive preoperative rectus sheath block of ropivacaine hydrochloride and receive postoperative rectus sheath block of saline
16620553|NCT02477098|Experimental|Post RSB|patients who receive preoperative rectus sheath block of saline and receive postoperative rectus sheath block of Ropivacaine hydrochloride
16620554|NCT02477085||all women with an induced labor|prospective population-based cohort of all women who have an induced labor during one month in seven perinatal networks
16620555|NCT02477072|Active Comparator|Fixed heparin dose (general anesthesia)|Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
16620556|NCT02477072|Experimental|Weight-adjusted doses of heparin|Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
16620557|NCT02477072|Active Comparator|Fixed heparin dose (regional anesthesia)|For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
16620558|NCT02477059|Experimental|tocilizumab|2 infusions four weeks apart
16620559|NCT02477059|Placebo Comparator|saline solution|2 infusions four weeks apart
16620560|NCT02477046|Experimental|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
16620561|NCT02477046|Experimental|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
16620562|NCT02477046|Experimental|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
16620563|NCT02477033|Active Comparator|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
16620564|NCT02477033|Placebo Comparator|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
16620565|NCT02477020|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
16620566|NCT02477020|Placebo Comparator|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
16620567|NCT02477007|Experimental|Ibuprofen+placebo of paracetamol|Patients will receive in addition to morphine (usual care) ibuprofen and placebo of paracetamol
16620568|NCT02477007|Experimental|Paracetamol + placebo of ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and placebo of ibuprofen
16620569|NCT02477007|Experimental|Paracetamol + ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and ibuprofen
16620570|NCT02477007|Placebo Comparator|Placebo of paracetamol + placebo of ibuprofen|Patients will receive morphine alone(usual care).
16620571|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
16620572|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
16620573|NCT02476981|Experimental|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
16620574|NCT02476981|Experimental|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
16620575|NCT02476981|Other|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
16620576|NCT02476981|Other|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
16620577|NCT02476981|Other|ephedrine|Adrenergic agonist to treat hypotension
16620578|NCT02476968|Other|Olaparib|Open Label Drug
16620579|NCT02476955|Experimental|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 milligrams (mg) every day (QD), 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
16620742|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
16620580|NCT02476942||Cohort A: Adults and Adolescents with FVIII Inhibitors|Adults and adolescents with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
16620581|NCT02476942||Cohort B: Children with FVIII Inhibitors|Children with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
16620582|NCT02476942||Cohort C: Adults and Adolescents without FVIII Inhibitors|Adults and adolescents with severe hemophilia A without the presence of FVIII inhibitors will be observed.
16620583|NCT02476929|Active Comparator|Nasal nitrous oxide|Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
16620584|NCT02476929|Active Comparator|Electronic nose|Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
16620585|NCT02476916|Experimental|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
16620586|NCT02476916|Experimental|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
16620587|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
16620588|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
16620589|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
16620590|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
16620591|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
16620592|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
16620593|NCT02476864|Experimental|Sequence AB|Subjects receive treatment A in Period 1 followed by treatment B in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
16620594|NCT02476864|Experimental|Sequence BA|Subjects receive treatment B in Period 1 followed by treatment A in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
16620595|NCT02476851|Experimental|Supernatant Hemoglobin|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of < 100mg/dL. In instances where resulting supernatant hemoglobin levels are > 100 mg/dL for the INA, if supernatant hemoglobin levels are > 100 mg/dL for the Kawasumi needle assembly (the control needle assembly or CNA), then there would be justification for removing these data from analyses."
16620596|NCT02476838|Other|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
16620597|NCT02476825|Active Comparator|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler [Accuhaler]), 500 micrograms b.i.d. for 4 weeks
16620598|NCT02476825|No Intervention|Observational|Observation
16620599|NCT02476812|Experimental|Positive Piggy Bank|"Patients randomized to this group will meet with a research assistant who provides an overview of the intervention, explains the rationale for this treatment, and then gives the patients the instructions, piggy bank, and currency slips. Participants in this group will receive instructions. At the end of the monitoring period, 30 days, they are to close their account by opening the piggy bank and reviewing all of the slips of paper.
~Study personnel will contact patients within 72 hours to answer questions. Participants will also be contacted at 30 days to let patients know that they should read all of their currency slips in one sitting. They are also told that the intervention part of the study is over and are asked they complete the follow up questionnaires. Then, study personnel will call again to let the participant know that the second set of questionnaires will be arriving by mail."
16620600|NCT02476812|No Intervention|Waitlist Control|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.
16620601|NCT02476799|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
16620743|NCT02475876|Other|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
16620602|NCT02476799|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
16620603|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen
~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment
~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy
~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire
~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
16620604|NCT02476773|Experimental|Group 1|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
16620605|NCT02476773|Experimental|Group 2|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
16620606|NCT02476773|Experimental|Group 3|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
16620607|NCT02476773|Experimental|Group 4|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
16620608|NCT02476773|Experimental|Group 5|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
16620609|NCT02476773|Experimental|Group 6|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
16620610|NCT02476760||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
16620611|NCT02476760||Treated with insulin|Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
16620612|NCT02476760||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
16620613|NCT02476760||Treated with a single oral agent|Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
16620614|NCT02476760||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.
16620615|NCT02476747|Experimental|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
16620616|NCT02476747|Active Comparator|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
16620617|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
16620618|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
16620619|NCT02476708|Experimental|Curcumin 1800mg|curcumin capsule 600mg taken 3 times per day for 8 weeks
16620620|NCT02476708|Placebo Comparator|Placebo|placebo capsule taken 3 times per day for 8 weeks
16620621|NCT02476695||S0/1|S0 = no fibrosis and S1 = portal fibrosis without septa
16620622|NCT02476695||S2|S2 = portal fibrosis with few septa
16620623|NCT02476695||S3|S3 = numerous septa without cirrhosis
16620624|NCT02476695||S4|S4 = liver cirrhosis (compensatory stage)
16620625|NCT02476682||Normal subjects|blood or stool samples will be collected from people referred for screening colonoscopy
16620626|NCT02476682||Colorectal cancer|blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
16620627|NCT02476682||Polyps <10mm and no high risk features|blood or stool samples will be collected from people with no polyps or low risk polyps (<10mm, no villous component or dysplasia) detected at colonoscopy
16620628|NCT02476682||Advanced Mucosal Neoplasia|blood or stool samples will be collected from people with AMN detected at resection
16620629|NCT02476682||Sessile Serrated Adenoma|blood or stool samples will be collected from people with SSP detected at resection
16620746|NCT02475863|Active Comparator|Standard practice|Dosing adjustments according to the normal unit protocol
16620630|NCT02476682||non-colorectal neoplastic disease|Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
16620631|NCT02476656||GPNC|CenteringPregnancy group prenatal care
16620632|NCT02476656||IPNC|Individual prenatal care
16620633|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
~Patients are admitted to the hospital ward for 14 days."
16620634|NCT02476630||Study subjects|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
16620635|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
16620636|NCT02476604|Experimental|Electronic Messaging|Subjects randomized to the intervention arm will receive health coaching and electronic messages at the rate of up to six times per week over an 8 week period.
16620637|NCT02476604|No Intervention|Control|Subjects randomized to the control arm will undergo all of the same measurements for baseline and follow up data but will not receive the intervention of health coaching and electronic messaging.
16620638|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
16620639|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
16620640|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
16620641|NCT02476578|No Intervention|Control|No email is sent.
16620642|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
16620643|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
16620644|NCT02476552|Experimental|Niraparib Oral and IV|Single Oral dose of Niraparib capsules (unlabeled active pharmaceutical ingredient) orally and a 15-minute IV infusion of Niraparib (labeled active pharmaceutical ingredient)
16620645|NCT02476552|Experimental|Niraparib Oral|Single Oral dose of Niraparib capsules (labeled active pharmaceutical ingredient)
16620646|NCT02476539|Experimental|Hemay022|"Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days.
~Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days."
16620647|NCT02476526|Experimental|Low Volume Contrast|Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
16620648|NCT02476526|Sham Comparator|Control|Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
16620649|NCT02476500|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
16620650|NCT02476500|Experimental|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
16620651|NCT02476487|Experimental|FDG PET CT|FDG PET CT
16620652|NCT02476474|Active Comparator|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
16620653|NCT02476474|Active Comparator|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
16620654|NCT02476461|Active Comparator|xiapex|1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
16620655|NCT02476461|Experimental|PNF|percutaneous needle fasciotomi is performed at affected cords
16620656|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
16620657|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
16620658|NCT02476448|Experimental|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
16620659|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
16620660|NCT02476435|Active Comparator|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
16620661|NCT02476435|Placebo Comparator|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
16620662|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
16620663|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
16620664|NCT02476409|Experimental|Tolvaptan|Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily
16620665|NCT02476409|Placebo Comparator|Placebo|Augmentation of current dose of loop diuretic
16620666|NCT02476396||patient-subject|Patients will be recruited from the population of patients scheduled to undergo carotid endarterectomy for established clinical indications. These indications include patients scheduled to have a carotid endarterectomy due to the presence of a high-grade atherosclerotic cervical internal carotid artery stenosis with or without clinical symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater without clinical symptoms; stenosis 70% or greater with clinical symptoms).
16620667|NCT02476396||patient-control|The controls will be recruited by the patient-subjects. The investigators will ask their patient-subjects to speak to a spouse or family member to see if they are interested in participating. If they do have an interest they will contact the research team/study coordinator(s). In case, a spouse or a family member is accompanying the patient-subject, they will be recruited at the same time as the patient-subject.
16620668|NCT02476383|Active Comparator|augmented spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner interacting in a warm and friendly way who is free to respond to participant conversation. Participants in this group will receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
16620669|NCT02476383|Active Comparator|neutral spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner engaging in minimal interaction. Participants in this group will not receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
16620670|NCT02476370|No Intervention|Usual care|Does not receive a specific study intervention
16620671|NCT02476370|Experimental|preoperative relaxation program|preoperative relaxation program
16620672|NCT02476370|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
16620673|NCT02476370|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
16620674|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
16620675|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
16620676|NCT02476344|Experimental|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
16620677|NCT02476331|Experimental|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
16620678|NCT02476331|No Intervention|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
16620679|NCT02476318|Experimental|ArterX Vascular Sealant|
16620680|NCT02476305|Experimental|cryoablation|patients undergo cryoablation procedure for desmoid tumor
16620681|NCT02476279|Experimental|Indomethacin alone|Indomethacin 100 mg rectally immediately after ERCP
16620682|NCT02476279|Active Comparator|Indomethacin+pancreatic stent|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
16620683|NCT02476266|No Intervention|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
16620684|NCT02476266|Active Comparator|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
16620685|NCT02476266|Experimental|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
16620686|NCT02476253|Experimental|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
16620687|NCT02476253|No Intervention|Control|No intervention
16620744|NCT02475876|Other|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
16620688|NCT02476240|Active Comparator|Internally Focused PD-SAFEx|While performing the exercises in PD-SAFEx™, participants will be instructed to focus their attention on sensory feedback. This will include focusing participants' attention on the stretch in their limbs while walking, on the straightness of their backs while sitting, on limb and body orientation in space while coordinating their movements, and on chest movements during breathing exercises. Throughout each exercise session, the instructor and volunteers will constantly provide attention-directing instructions.
16620689|NCT02476240|Experimental|Externally Focused PD-SAFEx|While performing the exercises from the PD-SAFEx™ program, participants will be instructed to focus their attention externally on the movement of coloured labels attached to their feet, knees, elbows and hands. Participants will be reminded and encouraged by the exercise instructor and volunteers to perform all exercises while focusing attention on the labels.
16620690|NCT02476240|No Intervention|Control Group|This group will be asked to refrain from changing activities of their daily lives throughout the 20-week duration of the experiment (from pre-assessment to washout).
16620691|NCT02476227|Experimental|Visitag group|Ablation using CARTO system. Visitag module: automated algorithm to collect RF ablation points using Visitag module. Criteria of ablation point: catheter stability range of motion ≤2.5mm, catheter stability time >15sec, contact force >5g over >50% of time. Optimal contact force suggested: 10-40g.
16620692|NCT02476227|Active Comparator|Control group|Ablation using CARTO system. Manual collection of RF ablation points by operator or by assistant. Optimal contact force suggested: 10-40g.
16620693|NCT02476214|Experimental|Intervention group|Group prenatal care- receiving prenatal care through a group
16620694|NCT02476214|No Intervention|Control group|Individual prenatal care - receiving regular individual prenatal care
16620695|NCT02476201|Experimental|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
16620696|NCT02476188|Experimental|Patients|Samples of blood at H0, H+6, H+24 and H+72
16620697|NCT02476188|Experimental|Patients control|Samples of blood at H0
16620698|NCT02476188|Active Comparator|Control (healthy person)|Samples of blood at H0
16620699|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
16620700|NCT02476162||Group 1: Daily for 3 Months|Participants randomly assigned to this group will be instructed to measure their blood pressure (BP) every day during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
16620701|NCT02476162||Group 2: Daily for 1 Week/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
16620702|NCT02476162||Group 3: 3 Consecutive Days Once/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
16620703|NCT02476136||Placebo group|Patients participating in one of the included randomized controlled trials, assigned to the placebo group
16620704|NCT02476136||Intervention group|Patients participating in one of the included randomized controlled trials, assigned to the investigational antidepressant (paroxetine, duloxetine or fluoxetine) or active comparator (venlafaxine) group.
16620705|NCT02476123|Experimental|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.
~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.
~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
16620706|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
16620707|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
16620708|NCT02476084||Conventional synthetic DMARD naïve|"Naive RA patients commencing Methotrexate and Hydroxychloroquine.
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
16620709|NCT02476084||DMARD-IR: anti-TNF|"Conventional synthetic DMARD inadequate responders commencing Anti-TNF
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
16620710|NCT02476084||DMARD-IR: anti-IL6|"Conventional synthetic DMARD inadequate responders commencing anti-IL6
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
16620711|NCT02476084||DMARD-IR: anti-CTLA-4|"Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
16620712|NCT02476084||DMARD-IR: anti-CD20|"Conventional synthetic DMARD inadequate responders commencing anti-CD20
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
16620713|NCT02476071|Experimental|Mass Media and Stylish Events|Mass Media (radio messages/posters promoting HIV prevention) plus one annual Stylish Man Event (SMEvent), a multimedia/community mobilization event promoting VMC.
16620714|NCT02476071|Active Comparator|Control arm: mass media only|Mass media (radio messages and posters which promote VMC for HIV prevention). .
16620715|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
16620716|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
16620717|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
16620718|NCT02476045|Active Comparator|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.
~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
16620745|NCT02475863|Experimental|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
16620719|NCT02476045|Experimental|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.
~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
16620720|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
16620721|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
16620722|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
16620723|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
16620724|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
16620725|NCT02476006|Experimental|Alirocumab|Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.
16620726|NCT02475993|Experimental|SMART app|SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
16620727|NCT02475993|No Intervention|Standard of care control group|The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit
16620728|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
16620729|NCT02475967|Experimental|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
16620730|NCT02475967|Active Comparator|Control group|The control group patients receive conventional cardiac care alone.
16620731|NCT02475954|Active Comparator|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
16620732|NCT02475954|Other|Standard Care|VA standard care depression in Parkinson's Disease (PD)
16620733|NCT02475941|Experimental|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
16620734|NCT02475941|Active Comparator|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
16620735|NCT02475928|Placebo Comparator|100 mg placebo|100 mg Placebo plus nutritional education
16620736|NCT02475928|Experimental|100 mg zinc supplement|Nutritional education plus 100 mg of zinc gluconate
16620737|NCT02475915|Experimental|ART + VHM|"Group 1: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
~Plus: 3 X 14-day cycles of vorinostat administered at weeks 0, 4 and 8; hydroxychloroquine and maraviroc prescribed at week 0 for a period of 10 weeks."
16620738|NCT02475915|Active Comparator|ART alone|Group 2: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and either an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
16620739|NCT02475902|Experimental|Computer guided home exercise program|"A laptop computer & MS Kinect camera will be connected to a 40 TV to deliver guided fall prevention exercises. Research staff will train the participants in the use of the computerized program and be supervised performing the exercises during the instruction period. Then participants will be instructed to exercise 3 times per week for 4 weeks. Half of the participants will begin the study with the computerized version of the home exercise program while the other half begins with the paper booklet version of the home exercise program. After one month the arms will cross over."
16620740|NCT02475902|Active Comparator|Paper guided home exercise program|A paper booklet with pictures and written instructions, and an exercise log for the home exercise program will be given to half of the participants. Participants will be carefully instructed in performing the exercises correctly and then asked to perform the exercises 3 times per week for one month. Participants who began the study with the paper exercise program will switch to the computerized version of the exercise program for the second month.
16620741|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
16620747|NCT02475850|Other|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
16620748|NCT02475850|Other|Control|Usual fall prevention care
16620749|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.
~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
16620750|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.
~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
16620751|NCT02475824|Experimental|MMD arm|Both midazolam® (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea) are given intravenously at the initiation of sedation. In addition, a continuous IV infusion of dexmedetomidine (1ug/kg/h, Precedex; Hospira, Seoul, Republic of Korea) is administered 15 min before the ERCP till complete procedure
16620752|NCT02475824|Active Comparator|BPS arm|IV bolus dose of midazolam® (0.06mg/kg, 50% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea). Repeated doses of 10-20 mg propofol® are titrated to achieve the target level of sedation. 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
16620753|NCT02475785|Experimental|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.
~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
16620754|NCT02475785|Active Comparator|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.
~Insertion of FFRD with application over the lower archwire"
16620755|NCT02475785|No Intervention|untreated control group|Patients will be observed for an average duration of 6-8 months
16620756|NCT02475772|Experimental|Cisplatin and doxorubicin|Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
16620757|NCT02475759|Active Comparator|two weeks prehabilitation group|optimal caloric intake for two weeks in malnourished congenital heart disease children
16620758|NCT02475759|Active Comparator|one week prehabilitation group|optimal caloric intake for one week in malnourished congenital heart disease children
16620759|NCT02475746|Experimental|PF-06372865 treatment arm|treatment arm includes two treatment periods, a single dose of PF-06372865 (period 1) followed by 8-days itraconazole with a single dose of PF-06372865 co-administered on Day 4
16620760|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
16620761|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
16620762|NCT02475707|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
16620763|NCT02475707|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
16620764|NCT02475681|Active Comparator|Obinutuzumab in Combination with Chlorambucil|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
16620765|NCT02475681|Experimental|Acalabrutinib in Combination with Obinutuzumab|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. ACP-196 will be orally administered starting on Cycle 1 Day 1. Daily administration of ACP-196 will continue until disease progression or unacceptable toxicity.
16620766|NCT02475681|Experimental|Acalabrutinib Monotherapy|Acalabrutinib will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
16620767|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
16620768|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
16620769|NCT02475642|Active Comparator|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
16620770|NCT02475642|Active Comparator|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
16620771|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
16620772|NCT02475616|Experimental|PCO371|Single oral dose of PCO371
16620773|NCT02475616|Placebo Comparator|Placebo Comparator|Single oral dose of placebo
16620774|NCT02475603|Experimental|tourniquet|Total knee arthroplasty will be performed with tourniquet
16620775|NCT02475603|Experimental|non-tourniquet|Total knee arthroplasty will be performed without tourniquet
16620776|NCT02475590|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
16620777|NCT02475590|Experimental|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
16620778|NCT02475577|Experimental|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
16620779|NCT02475577|Experimental|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
16620780|NCT02475577|Experimental|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
16620781|NCT02475564|Placebo Comparator|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
16620782|NCT02475564|Experimental|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
16620783|NCT02475551|Experimental|Treatment|IdeS as a single infusion
16620784|NCT02475538|Experimental|Electroacupuncture|"Subjects in this group will be treated with electroacupuncture along with a gradual tapering schedule.
~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.
~Subjects will receive electroacupuncture 2 times per week for 4 consecutive weeks. Electroacupuncture involves acupuncture needling at traditionally used acupoints according to Chinese medicine theory."
16620785|NCT02475538|Placebo Comparator|Placebo acupuncture|"Subjects in this group will be treated with placebo acupuncture along with a gradual tapering schedule.
~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.
~The subjects will be receive placebo acupuncture 2 times per week for 4 consecutive weeks. Placebo acupuncture is a treatment that simulates the procedure of acupuncture treatment but may not have the effects of acupuncture."
16620786|NCT02475525|Experimental|Arginine enriched oral nutritional supplement group|Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
16620787|NCT02475525|No Intervention|Control|This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
16620788|NCT02475512|Experimental|Wash wipes|Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
16620789|NCT02475512|Placebo Comparator|Standard care|Washing will be done using water and pH neutral soap. No other preventive barrier or hydration products will be allowed in the genital-anal region.
16620790|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) between (and including) base cohort entry and the index day - 365 days.
16620791|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
16620792|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
16620793|NCT02475486|Other|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is > 5
16620794|NCT02475486|Other|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is < or equal to 5
16620795|NCT02475473|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:
~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
16620796|NCT02475473|No Intervention|Control|Control
16620797|NCT02475460|Experimental|HM 3 LIS|All patients implanted with the HM 3 LVAD via less invasive surgical technique
16620798|NCT02475447|Placebo Comparator|Placebo|Placebo-matched tablets twice daily for 4 weeks.
16620799|NCT02475447|Experimental|Asimadoline|Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.
16620942|NCT02474537|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
16620800|NCT02475434|Experimental|Cream Supplement group|Infants randomized to the cream supplement group will receive an exclusive HM-based diet with the addition of a HM-derived cream caloric supplement.
16620801|NCT02475434|No Intervention|Control Group|Infants randomized to the Control group will receive the standard regimen of an exclusive HM-based diet (no cream supplement).
16620802|NCT02475421|Experimental|Healthy, lean subjects|Healthy subjects with BMI < 27 kg/m^2
16620803|NCT02475421|Experimental|Healthy, obese subjects|Healthy subjects with BMI > 33 kg/m^2
16620804|NCT02475421|Experimental|Diabetic, lean subjects|Diabetic subjects with BMI < 27 kg/m^2
16620805|NCT02475421|Experimental|Diabetic, obese subjects|Diabetic subjects with BMI > 33 kg/m^2
16620806|NCT02475408|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
16620807|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
16620808|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
16620809|NCT02475369|Other|PES, Then Placebo|Participants first received Pancreatic Enzyme Supplementation (PES) for 10 days. PES taken 6 times daily with gluten free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received placebo tablets (matching PES treatment) 6 times daily for 10 days.
16620810|NCT02475369|Other|Placebo, Then PES|Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
16620811|NCT02475356||Mirena|Mirena treatment group
16620812|NCT02475343|Experimental|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
16620813|NCT02475343|Experimental|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
16620814|NCT02475343|Experimental|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
16620815|NCT02475330|Experimental|Dietary Supplement: Flaxseed|
16620816|NCT02475317|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.
16620817|NCT02475317|Experimental|Maralixibat 10mg|Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.
16620818|NCT02475317|Experimental|Volixibat 10mg|Participants will receive volixibat 10 mg capsule orally QD for 7 days.
16620819|NCT02475317|Experimental|Maralixibat 20mg|Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.
16620820|NCT02475317|Experimental|Volixibat 20mg|Participants will receive volixibat 20 mg capsule orally QD for 7 days.
16620821|NCT02475317|Experimental|Maralixibat 50mg|Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.
16620822|NCT02475317|Experimental|Maralixibat 50mg BID|Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.
16620823|NCT02475317|Experimental|Maralixibat 100mg|Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.
16620824|NCT02475304|Experimental|Experimental FP187|Treatment with a daily dose of 500mg FP187 (twice daily). Other names: Dimethyl fumarate
16620825|NCT02475304|Placebo Comparator|Placebo Comparator|Patients will receive the same number of tablets as patients randomized to FP187 arm in order to maintain the blind. The colour and shape of the FP187 and placebo tablets will be the same so that no visible difference is detectable
16620826|NCT02475291||Significant coronary lesions|Significant lesions with more than 70% diameter stenosis at proximal major coronary arteri(es).
16620827|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
16620828|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
16620829|NCT02475252|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
16620830|NCT02475252|Experimental|Novices|Medical students will perform a hysteroscopy on a training model.
16620831|NCT02475239|Experimental|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
16620832|NCT02475239|Active Comparator|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
16620833|NCT02475226||Patients with body and head trauma|type of the brain injury in patients with brain damage associated both general body and head trauma
16620834|NCT02475226||Patients with pure head trauma|type of the brain injury in patients with brain damage associated pure head trauma
16620835|NCT02475226||Patients with spontaneous hemorrhage|type of the brain injury in Patients with brain damage associated spontaneous hemorrhage
16620836|NCT02475213|Experimental|Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
16620837|NCT02475213|Experimental|Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
16620943|NCT02474537|Experimental|Severe hepatic impairment|Subjects with severe hepatic impairment
16620838|NCT02475213|Experimental|Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
16620839|NCT02475213|Experimental|Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg|enoblituzumab 15 mg/kg IV weekly plus MGA012 375 mg
16620840|NCT02475174|Experimental|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
16620841|NCT02475174|Experimental|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
16620842|NCT02475161|Experimental|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
16620843|NCT02475148|Experimental|Part 1: Cohort 1|Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.
16620844|NCT02475148|Experimental|Part 1: Cohort 2|Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.
16620845|NCT02475148|Experimental|Part 1: Cohort 3|Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.
16620846|NCT02475148|Experimental|Part 1: Cohort 4|Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.
16620847|NCT02475148|Experimental|Part 1: Cohort 5|Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.
16620848|NCT02475148|Experimental|Part 1: Cohort 6|Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.
16620849|NCT02475148|Experimental|Part 2: Cohort 7|Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
16620850|NCT02475148|Experimental|Part 3: Cohort 8|Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
16620851|NCT02475135|Experimental|Panel 1: Group 1|Subject will receive a single oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) (D/C/F/TAF) under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 1 and by FDC of elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/ tenofovir alafenamide (TAF) (E/C/F/TAF) under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 2.
16620852|NCT02475135|Experimental|Panel 1: Group 2|Subject will receive a single oral tablet of FDC containing E/C/F/TAF under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 1 and a single oral tablet of FDC containing D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 2.
16620853|NCT02475135|Experimental|Panel 2: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 1 and a single oral tablet of DRV, a tablet of emtricitabine/ tenofovir alafenamide (FTC/TAF) and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2.
16620854|NCT02475135|Experimental|Panel 2: Group 2|Subject will receive a single oral tablet of DRV, a tablet of FTC/TAF and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2 and a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 2.
16620855|NCT02475135|Experimental|Panel 3: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 1 and a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 2.
16620856|NCT02475135|Experimental|Panel 3: Group 2|Subject will receive a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 1 followed by a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 2.
16620857|NCT02475122|Other|open-label study|open-label study
16620858|NCT02475109|Experimental|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
16620859|NCT02475096|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
16620860|NCT02475083|Experimental|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
16620861|NCT02475083|Active Comparator|Conventional Group|Conventional physiotherapy with exercises for balance training.
16620862|NCT02475070|Active Comparator|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
16620863|NCT02475070|Active Comparator|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
16620864|NCT02475057|Experimental|Degarelix (LHRH antagonist)|Degarelix (LHRH antagonist) EndoPAT2000
16620865|NCT02475057|Active Comparator|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000
16620866|NCT02475044|No Intervention|Treatment as usual (TAU)|Participants recive Psycho-education and neuro-psycological diagnosis.
16620867|NCT02475044|Experimental|Cognitive-Behavioral Therapy (CBT)|Participants recive 16 sessions of CBT in addition to arm TAU treatment.
16620868|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
16620869|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
16620870|NCT02475018|Experimental|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
16620871|NCT02475018|Placebo Comparator|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
16620872|NCT02475018|No Intervention|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
16620873|NCT02475005|Experimental|Mobile self management app on smartphone|Mobile self management app on smartphone
16620874|NCT02475005|No Intervention|Treatment as usual|Treatment as usual (control group)
16620875|NCT02474992|Experimental|Intervention|This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
16620876|NCT02474992|No Intervention|Comparison|This arm is not eligible for participation in the intervention during the first twelve months of the study. Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group. Participants in this arm will still have access to standard HIV care at the facility of their choice. At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
16620877|NCT02474979|Experimental|CBPM-system|CBPM-system (Continuous Bedside Pressure Mapping System): the bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure. The CBPM-system will be used in addition to standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
16620878|NCT02474979|Experimental|Control|Standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
16620879|NCT02474966|Experimental|Real-Sham dTMS|This arm will be treated before with real deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with sham dTMS (the second day)
16620880|NCT02474966|Experimental|Sham-Real dTMS|This arm will be treated before with sham deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with real dTMS (the second day)
16620881|NCT02474953|Experimental|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
16620882|NCT02474953|Experimental|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
16620883|NCT02474940|Experimental|Intervention #1|NF-HYP
16620884|NCT02474940|Experimental|Intervention #2|MM-HYP
16620885|NCT02474940|Experimental|Intervention #3|HYP-ONLY
16620886|NCT02474927|Experimental|Carfilzomib Treatment Arm|Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.
16620887|NCT02474914|Active Comparator|Octreotide|Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
16620888|NCT02474914|Placebo Comparator|Placebo|pancreaticoduodenectomy without octreotide postoperative
16620889|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
16620890|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
16620891|NCT02474888||Rituximab|a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
16620892|NCT02474875|Active Comparator|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
16620893|NCT02474875|Experimental|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
16620894|NCT02474875|Experimental|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
16620895|NCT02474875|Experimental|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
16620896|NCT02474862|Experimental|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
16620897|NCT02474862|Active Comparator|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
16620898|NCT02474849|Active Comparator|Conventional cigarette|
16620899|NCT02474849|Experimental|First-generation e-cigarette|
16620900|NCT02474849|Experimental|Rechargeable cig-like e-cigarette|
16620901|NCT02474849|Experimental|Closed modular system e-cigarette A|
16620902|NCT02474849|Experimental|Closed modular system e-cigarette B|
16620903|NCT02474836|Active Comparator|Atopic subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
16620904|NCT02474836|Active Comparator|Non atopic subjects|Healthy volunteers
16620905|NCT02474836|Other|Allergic Subjects|
16620906|NCT02474823|Other|Sleep Apnea assessment|all participants are in the same arm & undergo the same assessments: PSG, HST, ESAP
16620907|NCT02474810|Experimental|Intensive|In the Intensive Protocol, alteplase intervention is administered to all catheters based on blood flow and/or line reversal
16620908|NCT02474810|Experimental|Standard|In the Standard Protocol, alteplase intervention is administered to all catheters based only on blood flow.
16620909|NCT02474797|Experimental|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
16620944|NCT02474524|Experimental|Health intervention|+ treatment as usual
16620910|NCT02474745|Experimental|INTERVENTION GROUP|"Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:
~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
16620911|NCT02474745|Other|CONTROL GROUP|"Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:
~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
16620912|NCT02474732|Other|Usability|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
16620913|NCT02474719|Experimental|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).
~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
16620914|NCT02474719|Experimental|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.
~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
16620915|NCT02474706|Experimental|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
16620916|NCT02474706|Active Comparator|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
16620917|NCT02474680||Care Coordination Group|Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'
16620918|NCT02474667|Active Comparator|BB3|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
16620919|NCT02474667|Placebo Comparator|Normal Saline|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
16620920|NCT02474654|Experimental|Arm 1: PI+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
16620921|NCT02474654|Experimental|Arm 2:NS+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml
16620922|NCT02474654|Experimental|Arm 3: PI+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
16620923|NCT02474654|Experimental|Arm 4: PI+FNB+NS|Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
16620924|NCT02474654|Active Comparator|Arm 5:NS+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml
16620925|NCT02474641|Active Comparator|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or
~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or
~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
16620926|NCT02474641|Experimental|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
16620927|NCT02474628|Placebo Comparator|Placebo|0.3 g∙kg-1body mass of calcium carbonate
16620928|NCT02474628|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
16620929|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
16620930|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
16620931|NCT02474602|Experimental|Group A - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
16620932|NCT02474602|Experimental|Group B - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
16620933|NCT02474602|Experimental|Group C - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
16620934|NCT02474602|Experimental|Group D - Active or Placebo Phototherapy'|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
16620935|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
16620936|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
16620937|NCT02474576|Experimental|Percutaneous aponeurotomy|Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy
16620938|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
16620939|NCT02474550||CISL 14-03|"Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).
~Aged 19 or more
~Treated with R-CHOP therapy"
16620940|NCT02474537|Experimental|Normal hepatic function|Subjects with normal hepatic function
16620941|NCT02474537|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
16620946|NCT02474511||general anesthesia|In this group，the patient is received radiofrequency ablation under general anesthesia.
16620947|NCT02474511||local anesthesia|In this group，the patient is received radiofrequency ablation under local anesthesia.
16620948|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
16620949|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
16620950|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
16620951|NCT02474485|Active Comparator|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:
~BVS Absorb implantation. For in stent restenosis treatment during index procedure.
~OCT visualization.During index procedure and at 9 month follow-up.
~Control coronary angiography. Control angiography will be performed at 9 month follow-up.
~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
16620952|NCT02474485|Active Comparator|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:
~DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.
~OCT visualization.During index procedure and at 9 month follow-up.
~Control coronary angiography. Control angiography will be performed at 9 month follow-up.
~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
16620953|NCT02474459|Active Comparator|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
16620954|NCT02474459|Active Comparator|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
16620955|NCT02474446|Experimental|1|"Anthropometry measurement, Skin colour grading using Fitzpatrick scale, Dietary intake of calcium and vitamin D using food frequency questionnaire (FFQ), Baseline fasting blood samples for vitamin D, VDBP, VDBP genotype, Calcium, Phosphorus, Albumin, Parathyroid Hormone(PTH), Alkaline Phosphatase, Bone turnover markers(P1NP, CTX).
~Fasting urine for Calcium Creatinine ratio. Saliva for bio-available Free Vitamin D measurement.
~Vitamin D administration under direct supervision. Spot Urine sample for calcium : creatinine ratio after a week. Repeat all measurements done at baseline except VDBP genotype 4 weeks from baseline."
16620956|NCT02474433|Active Comparator|PO Misoprostol|Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
16620957|NCT02474433|Active Comparator|PV Misoprostol|Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
16620958|NCT02474433|Active Comparator|Buccal Misoprostol|Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
16620959|NCT02474420|Active Comparator|Deferasirox|deferasirox iron chelation therapy and standard of care by the treating physician
16620960|NCT02474420|Experimental|Deferasirox plus amlodipine|deferasirox iron chelation therapy with amlodipine
16620961|NCT02474407|Experimental|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
16620962|NCT02474407|Active Comparator|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
16620963|NCT02474394|Active Comparator|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
16620964|NCT02474394|Active Comparator|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
16620965|NCT02474381|Experimental|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
16620966|NCT02474381|Active Comparator|Single PTA|Angioplasty of arteries below tibial plateau level only
16620967|NCT02474368|Experimental|Cohort 1|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)
~Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks
~Cisplatin will be administered intravenously on predetermined days
~Stereotactic Body Radiotherapy (SBRT)"
16620968|NCT02474368|Experimental|Cohort 2|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
16620970|NCT02474342|Experimental|Autologous Adipose Tissue derived MSCs|
16621030|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
16621031|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
16621032|NCT02473900|Experimental|Sequence 1|HIP1403→HGP0919
16620971|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
16620972|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
16620973|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
16620974|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
16620975|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
16620976|NCT02474316|Experimental|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
16620977|NCT02474316|Active Comparator|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
16620978|NCT02474303|Other|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
16620979|NCT02474290|Experimental|Sorafenib group|Sorafenib will be used from day 30 to 180 post-transplantation.
16620980|NCT02474290|No Intervention|non-Sorafenib group|
16620981|NCT02474277|Other|30 sec chair stand test|all patients in this Group receives a diagnostic test for functional impairment
16620982|NCT02474264|Other|male BRCA mutations carriers|Endothelial function assessment and Cardiovascular biomarkers
16620983|NCT02474264|Other|healthy males - control group|Endothelial function assessment and Cardiovascular biomarkers
16620984|NCT02474251|Active Comparator|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
16620985|NCT02474251|Active Comparator|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index [AHI]-all >30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
16620986|NCT02474238|Experimental|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
16620987|NCT02474238|Active Comparator|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
16620988|NCT02474212|Active Comparator|Enoxaparin 40 mg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
16620989|NCT02474212|Active Comparator|Enoxaparin 40 mg i.v.|Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
16620990|NCT02474212|Active Comparator|Enoxaparin 0.5 mg/kg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
16620991|NCT02474212|Active Comparator|Enoxaparin 1 mg/kg i.v.|Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
16620992|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
16620993|NCT02474186|Experimental|Radiation therapy|"Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol"
16621033|NCT02473900|Experimental|Sequence 2|HGP0919→HIP1403
16621034|NCT02473887|Experimental|gastroenteritis with persistent vomiting.|patients with gastroenteritis with persistent vomiting received single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
16620994|NCT02474173|Experimental|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.
~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of cycle 1 and on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16620995|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
16620996|NCT02474147|Experimental|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
16620997|NCT02474147|Active Comparator|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
16620998|NCT02474147|Active Comparator|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
16620999|NCT02474134|Other|PF530/Betaferon|Single subcutaneous injection of two interferon beta-1b products (PF530 and Betaferon) 0.25 mg
16621000|NCT02474134|Other|Betaferon/PF530|Single subcutaneous injection of two interferon beta-1b products (Betaferon and PF530) 0.25 mg
16621001|NCT02474108|Placebo Comparator|without prevention|isolated mitral valve replacement or reconstruction, implantation of cardiac monitor
16621002|NCT02474108|Active Comparator|group of prevention|"mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.
~Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe."
16621003|NCT02474095|Experimental|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
16621004|NCT02474095|Active Comparator|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
16621005|NCT02474082|Experimental|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
16621006|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
16621007|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
16621008|NCT02474069|Active Comparator|Secukinumab 4-weekly|
16621009|NCT02474056||trauma patients|patients with decreased blood volume
16621010|NCT02474056||surgical patients|patients with decreased blood volume
16621011|NCT02474056||non surgical patients|patients with decreased blood voloume
16621012|NCT02474043|Active Comparator|Usual care|Standard health education and prevention counseling by trained staff
16621013|NCT02474043|Experimental|Hep-Net Intervention|Computerized tailored behavioral intervention
16621014|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
16621015|NCT02474004|Experimental|medial meniscus repair|patients receiving medial meniscus repair
16621016|NCT02474004|Active Comparator|medial partial meniscectomy|patients having medial partial meniscectomy
16621017|NCT02473978||Participants undergoing cesarean sections|The participants preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
16621018|NCT02473978||Participants throughout cesarean sections|The participants intraoperative data will be compared to preoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
16621019|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
16621020|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
16621021|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.
~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
16621022|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
16621023|NCT02473939|Experimental|VR942 Dose 1|VR942 Dose 1
16621024|NCT02473939|Experimental|VR942 Dose 2|VR942 Dose 2
16621025|NCT02473939|Experimental|VR942 Dose 3|VR942 Dose 3
16621026|NCT02473939|Experimental|VR942 Dose 4|VR942 Dose 4
16621027|NCT02473939|Experimental|VR942 Dose 5|VR942 Dose 5
16621028|NCT02473926|Experimental|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.
~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
16621029|NCT02473926|Other|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
16621037|NCT02473861|Experimental|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
16621038|NCT02473861|Experimental|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require >1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
16621039|NCT02473848|Experimental|Ingenol mebutate 500 ucg|active arm
16621040|NCT02473835|Experimental|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
16621041|NCT02473809|Experimental|Liraglutide|"Liraglutide (Victoza), subcutaneous 1,8 mg once daily for 180 days"
16621042|NCT02473809|Placebo Comparator|Placebo|Saline, subcutaneous once daily for 180 days
16621043|NCT02473796|Experimental|Home based child care|The home based child care included treatment of various various childhood illnessed by locally avialable trained village health workers, improving hygiene and nutrition among children and women throgh health education. This care was in adiition to the local health care provided by the Government's primary health care services.
16621044|NCT02473796|No Intervention|control|The control arm included population where the home based neonatal care was not implimented. The health services were provided by the Government run primary health care services. Vital statistics data was collected by VHWs.
16621045|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
16621046|NCT02473770||Disaster responders|Conducting emergency disaster relief.
16621047|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
16621048|NCT02473744|Experimental|Oedematous lower limb subcutaneous drainage|In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
16621049|NCT02473731|Experimental|A|Treatment with KTN3379 in HPV positive head and neck cancer patients
16621050|NCT02473731|Experimental|B|Treatment with KTN3379 in HPV negative head and neck cancer patients
16621051|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
16621052|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
16621053|NCT02473705|Active Comparator|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
16621054|NCT02473705|Active Comparator|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
16621055|NCT02473705|Experimental|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
16621056|NCT02473705|Placebo Comparator|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
16621057|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
16621058|NCT02473666||All Health Conditions.|All Health Conditions. Area of Focus: Transfusions of blood products.
16621059|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
16621060|NCT02473627|Experimental|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
16621061|NCT02473627|Experimental|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .
~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:
~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
16621062|NCT02473614|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
16621063|NCT02473614|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
16621064|NCT02473601|Experimental|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
16621065|NCT02473601|Other|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
16621066|NCT02473588|Other|LTIA Group|Patients in the LTIA Group (all patients) will have blood pressure recorded continuously. LTIA will be used to measure stroke volume and cardiac output after the completion of data collection
16621067|NCT02473575|Experimental|Caffeine gum|caffeine (300 mg) in gum form x 1 ingestion
16621068|NCT02473575|Placebo Comparator|Placebo gum|placebo gum consumed x 1 ingestion
16621069|NCT02473575|No Intervention|Non-intervention group|A third group of runners will be used to adjust for changes in environmental conditions. They will complete 2 runs without consuming either placebo or experimental treatment
16621070|NCT02473562|Experimental|Varenicline|Varenicline capsule 1 mg BID
16621071|NCT02473562|Placebo Comparator|Placebo|Placebo capsule
16621072|NCT02473549|Experimental|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
16621073|NCT02473536|Experimental|Stereotactic ablative radiation therapy|SABR
16621074|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.
~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
16621075|NCT02473510|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
16621076|NCT02473510|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
16621077|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
16621078|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
16621079|NCT02473458|Placebo Comparator|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
16621080|NCT02473458|Experimental|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
16621081|NCT02473458|Experimental|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
16621082|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
16621083|NCT02473432|Experimental|RMT + usual care|Device: Orygen-Dual® valve trainer Intensity: 30% of maximal respiratory pressures (increasing intervals: 10 cmH2O per week) Training schedule: 5 sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, two sessions per day, 5 days per week, for 3 weeks.
16621084|NCT02473432|Experimental|NMES + usual care|Device: Vital Stim (Chattanooga Group, Hixson, TN, USA) Administration of 80 Hz transcutaneous electrical biphasic stimulus Schedule: 40 minutes per day, 5 sessions per week during hospitalization in the Neurorehabilitation ward (3 weeks approx).
16621085|NCT02473432|Active Comparator|Usual care|Usual care (standard multidisciplinary inpatient rehabilitation program) consisting of physical, occupational and speech therapy sessions to improve activities of daily life, mobility and communication skills (minimum 3 hours per day, 5 days a week, during 3 weeks), Standard swallow therapy (usual care of dysphagia in stroke patients) consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
16621086|NCT02473419||Vayarin|Vayarin x 16 weeks
16621087|NCT02473419||Placebo|Placebo x 16 weeks
16621088|NCT02473419||Vayarin and Placebo|Placebo x 8 weeks and then Vayarin x 8 weeks
16621089|NCT02473406|Experimental|Thymosin|Thymosin alpha 1 has been shown to have immunomodulatory properties
16621090|NCT02473406|Placebo Comparator|Placebo|normal saline;
16621091|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
16621092|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
16621093|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
16621094|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
16621095|NCT02473380|Experimental|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
16621157|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
16621096|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
16621097|NCT02473354|Other|Resp Depression Sequence 1 - 3|"Sequence #1: breathe 21% through the facemask and increase ventilation to achieve a target hypocapnic ET CO2 of 25 - 30 mmHg. Subject will then breathe a gas mixture containing 6% CO2 / 30% O2 to achieve a target hypercapnic ET CO2 up to 60 mmHg or HCVR is terminated at the discretion of the PI.
~Sequence #2: breathe 21% O2 (normoxia) before remifentanil administration Sequence #3: breathe 50% O2 (hyperoxia) before remifentanil administration"
16621098|NCT02473341|Experimental|Bovine colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.
~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
16621099|NCT02473341|Placebo Comparator|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks
~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
16621100|NCT02473328|Experimental|non comparative open study|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4), switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.
~The administration will be done once a day orally for 48 weeks."
16621101|NCT02473315|Experimental|cryotherapy|
16621102|NCT02473315|Placebo Comparator|light cryotherapy|
16621103|NCT02473302|Placebo Comparator|ham|160g per day during 4 days
16621104|NCT02473302|Experimental|ham + pomegranate extract|160g per day during 4 days
16621105|NCT02473302|Experimental|ham + tocopherol|160g per day during 4 days
16621106|NCT02473302|Placebo Comparator|rare sirloin steak|110g per day during 4 days
16621107|NCT02473302|Experimental|marinated rare sirloin steak|110g per day during 4 days
16621108|NCT02473302|Experimental|marinated cooked sirloin steak|110g per day during 4 days
16621109|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
16621110|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
16621111|NCT02473276|Active Comparator|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
16621112|NCT02473276|Sham Comparator|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
16621113|NCT02473276|Active Comparator|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
16621114|NCT02473276|Sham Comparator|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
16621115|NCT02473263|No Intervention|Conventional|No antibiotic administration and no hemodynamic target are required
16621116|NCT02473263|Active Comparator|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
16621117|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
16621118|NCT02473237|Experimental|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
16621119|NCT02473237|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
16621120|NCT02473224|Experimental|Cohort 1|9 secretor-positive subjects will receive 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
16621121|NCT02473224|Experimental|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10^2GEC, or 1.2 x10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
16621122|NCT02473224|Experimental|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, 1.2 x 10^6 GEC, or 1.2 x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
16621123|NCT02473224|Experimental|Cohort 4|8 secretor-negative and 3 secretor-positive subjects will receive 1.2 x 10^7 GEC oral dose on Day 1, n=11
16621124|NCT02473211|Experimental|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
16621125|NCT02473198|Active Comparator|Femoral Nerve Block (Group 1)|"In group1 (standard group) all patients receive the standard current perioperative pain management protocol for TKR.
~The patient will then undergo an ultrasound guided femoral nerve block with bupivacaine 0.25% 20 cc. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint. Postoperatively patients will receive narcotic pain medication on a PRN basis."
16621126|NCT02473198|Experimental|Exparel (Group 2)|Group 2 will receive standard perioperative pain management for TKR; will undergo placebo femoral nerve block under ultrasound guidance with normal saline (NS) 20 cc. Following femoral bone cuts they will receive local anesthetic injection mixture of 30cc 0.25% bupivicaine with epinephrine 20 cc of preservative free normal saline, 30mg of toradol and 10 mg of morphine sulfate into the periarticular tissues including periosteum, joint capsule and posterior capsule of the knee joint and collateral ligaments and subcutaneous tissues. Prior to cementing prosthesis, a second injection with mixture of 20mL 1.3% Exparel and 40mL normal saline solution will be injected into the same tissues, joint capsules and collateral ligaments.
16621127|NCT02473185|Experimental|Methylphenidate|Methylfenidate 20 mg Tablet single-dose per os
16621128|NCT02473185|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
16621129|NCT02473172|Experimental|Pressure Support Ventilation|Assisted mechanical ventilation
16621130|NCT02473172|Experimental|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
16621131|NCT02473159|Experimental|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
16621132|NCT02473146|Experimental|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:
~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
16621133|NCT02473146|No Intervention|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
16621134|NCT02473133|Experimental|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
16621135|NCT02473133|Sham Comparator|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
16621136|NCT02473120|Experimental|Determination of ESR1 mutations|Blood sample will be collected every 3 months during two years to determine ESR1 mutations
16621137|NCT02473107|Other|Control Caries Detection Strategy|Detection and treatment based on more advanced lesions, despite activity status - Advanced caries lesions detection (no activity assessment)
16621138|NCT02473107|Other|Test Caries Detection Strategy|Detection and treatment based on all detected caries lesions, considering their activity status as a differential in clinical decision-making - All caries lesions detection (+activity assessment)
16621139|NCT02473094|Experimental|Neoadjuvant capecitabine and metformin|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;
~Metformin 2500mg/d for five weeks;
~3D radiotherapy 50,4Gy divided in 25 fractions"
16621140|NCT02473094|Placebo Comparator|Neoadjuvant capecitabine and placebo|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;
~Placebo 2500mg/d for five weeks;
~3D radiotherapy 50,4Gy divided in 25 fractions"
16621141|NCT02473081|Experimental|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
16621142|NCT02473081|Other|Usual care|Participants in this group received usual care only.
16621143|NCT02473068|Active Comparator|Group 1|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 31°C.
16621144|NCT02473068|Experimental|Group 2|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 27°C.
16621145|NCT02473055|Experimental|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
16621146|NCT02473055|No Intervention|control|control infants remained prone in an incubator wearing only diaper
16621147|NCT02473042|Experimental|Electrical Stimulation + Standard of Care Antiemetics|"Participants receive light electrical stimulation to the wrist area during surgery. Participants also receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).
~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
16621148|NCT02473042|Active Comparator|Standard of Care Antiemetics|"Participants receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).
~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
16621149|NCT02473029||Cases|Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease
16621150|NCT02473016|Experimental|Treatment|All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
16621151|NCT02473003|Experimental|High intensity|high intensity exercise 80-90%
16621152|NCT02473003|Experimental|Low/Medium intensity|low/medium intensity exercise 40-50%
16621153|NCT02473003|Experimental|High Intensity with BM|high intensity exercise with Behavioral medicine strategies¨ 80-90%
16621154|NCT02473003|Experimental|Low/Medium intensity with BM|low/medium intensity exercise with Behavioral medicine strategies 40-50%
16621155|NCT02472990|Other|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)
~Measurement of leg strength using a dynamometer
~Measurement of Motor Function
~Walk test 6 minutes
~Walk test 10 meters
~Walk analysis: 3D recording of walking
~Muscle MRI"
16621156|NCT02472990|Other|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)
~Measurement of leg strength using a dynamometer
~Measurement of Motor Function
~Walk test 6 minutes
~Walk test 10 meters
~Walk analysis: 3D recording of walking
~Muscle MRI"
16621256|NCT02472340||Sedentary, Pre-frail|10 sedentary, pre-frail elderly, >61 year of age
16621158|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
16621159|NCT02472964|Active Comparator|Herceptin© + Taxane|"Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.
~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal ."
16621160|NCT02472964|Experimental|MYL- 1401O + Taxane|"Part 1:MYL-1401O Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.
~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to MYL-1401O alone once every 3 weeks until DP or subject withdrawal."
16621161|NCT02472951|Active Comparator|Type 2 diabetic subjects|
16621162|NCT02472951|Active Comparator|Prediabetic subjects|
16621163|NCT02472951|Active Comparator|Healthy subjects|
16621164|NCT02472938|Experimental|BG00012|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
16621165|NCT02472938|Placebo Comparator|Placebo|Placebo capsules orally twice a day.
16621166|NCT02472925|Other|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
16621167|NCT02472925|Experimental|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is >30 hours (greater than 6 hours overdue).
16621168|NCT02472925|Experimental|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect >85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
16621169|NCT02472912|Experimental|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
16621170|NCT02472912|Active Comparator|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
16621171|NCT02472912|Active Comparator|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
16621172|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
16621173|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
16621174|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
16621175|NCT02472886|Experimental|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
16621176|NCT02472886|Experimental|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
16621177|NCT02472886|Experimental|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
16621178|NCT02472873|Experimental|study group - sclerotherapy|Aspiration and Sclerotherapy of endometriomas.
16621179|NCT02472873|Other|control group - cystectomy|cystectomy of endometriomas.
16621180|NCT02472860|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
16621181|NCT02472860|Placebo Comparator|Control Condition|Youth appropriate online games
16621182|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
16621183|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
16621184|NCT02472834|Experimental|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
16621185|NCT02472834|No Intervention|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
16621186|NCT02472821|Active Comparator|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
16621187|NCT02472821|Active Comparator|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
16621188|NCT02472821|No Intervention|No-intervention control|No interventions; pre- and post- measures only.
16621189|NCT02472808|Other|cTBNA without ROSE|Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
16621190|NCT02472808|Other|cTBNA with ROSE|Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
16621191|NCT02472808|Other|EBUS-TBNA without ROSE|Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
16621192|NCT02472808|Other|EBUS-TBNA with ROSE|Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
16621193|NCT02472795|Experimental|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
16621194|NCT02472795|Experimental|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
16621195|NCT02472795|Experimental|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
16621255|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
16621196|NCT02472795|Experimental|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
16621197|NCT02472795|Placebo Comparator|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
16621198|NCT02472769|Active Comparator|IBP-9414|IBP-9414 Oral Daily
16621199|NCT02472769|Placebo Comparator|Placebo|Sterile water
16621200|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
16621201|NCT02472743|Experimental|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:
~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).
~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.
~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes)."
16621202|NCT02472730|Experimental|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
16621203|NCT02472730|No Intervention|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
16621204|NCT02472717|Experimental|Interventional arm|liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
16621205|NCT02472717|Placebo Comparator|Placebo arm|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
16621206|NCT02472704|Active Comparator|Gluten challenge|Gluten powder (10 g every 12 hours), 24 weeks
16621207|NCT02472704|Placebo Comparator|Placebo challenge|Placebo (maltodextrin; 10 g every 12 hours), 24 weeks
16621208|NCT02472691|Experimental|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
16621209|NCT02472678|Other|Standard care|The control group will receive standard care.
16621210|NCT02472678|Experimental|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
16621211|NCT02472665|Experimental|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
16621212|NCT02472652|Other|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
16621213|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
16621214|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
16621215|NCT02472626|Experimental|Treatment (CPI-613, cytarabine, daunorubicin hydrochloride)|"INDUCTION: Patients receive cytarabine IV continuously on days 1-7, daunorubicin hydrochloride IV on days 1-3, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 3-7. Patients then undergo biopsy on day 14. Patients experiencing significant residual disease receive cytarabine IV continuously on days 1-5, daunorubicin hydrochloride IV on days 1-2, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5.
~CONSOLIDATION: Beginning 42 days later, patients receive cytarabine IV continuously on days 1-16 and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 2-6. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients not undergoing transplant after consolidation receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
16621216|NCT02472613|Experimental|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
16621217|NCT02472613|Active Comparator|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
16621218|NCT02472600|Active Comparator|colistin + neomycin followed by FMT|"CAPSULE APPROACH:
~Treatment days 1-5
~Colistin sulphate 2 million IU per os 4x/day (for 5 days)
~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment
~Treatment days 7 and 8:
~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day
~NASOGASTRIC TUBE APPROACH:
~Treatment days 1-5
~Colistin sulphate 2 million IU per os 4x/day (for 5 days)
~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)
~Treatment day 6 and 7:
~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7
~Treatment day 7:
~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
16621219|NCT02472600|No Intervention|No intervention|Control arm without any intervention
16621220|NCT02472587||Pap test|Women attending our institute in order to do Pap test
16621221|NCT02472574|Experimental|0.3 mg|Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
16621222|NCT02472574|Experimental|0.5 mg|Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
16621223|NCT02472574|Experimental|1.0 mg|Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
16621224|NCT02472561|Experimental|Mobile Health Application Group 1|"Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease; patients will be asked to read approximately one chapter per week for educational purposes."
16621225|NCT02472561|No Intervention|Usual Care Group 2|"Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments."
16621226|NCT02472548|Experimental|Group A, DPX-RSV(A) low dose (Step 1)|
16621227|NCT02472548|Experimental|Group B, RSV(A)-Alum low dose (Step 1)|
16621228|NCT02472548|Experimental|Group D, DPX-RSV(A) high dose (Step 2)|
16621229|NCT02472548|Experimental|Group E, RSV(A)-Alum high dose (Step 2)|
16621230|NCT02472548|Placebo Comparator|Group C & F, Placebo control (Step 1 and 2)|
16621231|NCT02472535|Experimental|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
16621232|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
16621233|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
16621234|NCT02472509|Experimental|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
16621235|NCT02472483|Experimental|bipolar disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT
~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
16621236|NCT02472483|Experimental|anxious disorders|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT
~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
16621237|NCT02472483|Experimental|alcohol disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT
~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
16621238|NCT02472470|Experimental|Treatment|intermitten TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 2 weeks.
16621239|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
16621240|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
16621241|NCT02472431|Experimental|ADRC injection|
16621242|NCT02472418|Experimental|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
16621243|NCT02472418|Experimental|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
16621244|NCT02472418|Placebo Comparator|Placebo (treatment C)|Placebo (treatment C)
16621245|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
16621246|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
16621247|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
16621248|NCT02472392|Active Comparator|Treatment Plan A|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.
16621249|NCT02472392|Active Comparator|Treatment Plan B|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
16621250|NCT02472379|Experimental|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
16621251|NCT02472379|Placebo Comparator|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
16621252|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
16621253|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
16621254|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
16621257|NCT02472340||Active, Healthy|10 Active, healthy elderly, >61 years of age
16621258|NCT02472327|No Intervention|Typical Care|These patients will receive normal peripartum care and support.
16621259|NCT02472327|Experimental|Pre-operative support|These patients will receive additional emotional support prior to undergoing an unplanned cesarean section during labor.
16621260|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
16621261|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
16621262|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
16621263|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
16621264|NCT02472301|Experimental|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
16621265|NCT02472301|Experimental|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
16621266|NCT02472301|Active Comparator|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
16621267|NCT02472288|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)
~BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)
~20 minutes duration, middle frequency (30 Hz) of electrical stimulation
~conventional treatments permitted"
16621268|NCT02472288|Sham Comparator|Sham group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)
~BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)
~20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)
~conventional treatments permitted"
16621269|NCT02472275|Experimental|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
16621270|NCT02472262|Experimental|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
16621271|NCT02472262|Experimental|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
16621272|NCT02472262|Active Comparator|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
16621273|NCT02472249|Experimental|Norepinephrine intra-arteriel/hepatic|This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
16621274|NCT02472236|Experimental|Digoxin and PEX168(200µg)|Digoxin: 0.5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
16621275|NCT02472223|Active Comparator|Betadine 5%|One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
16621276|NCT02472223|Placebo Comparator|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
16621277|NCT02472210|Placebo Comparator|Placebo|Saline IM Injection
16621278|NCT02472210|Active Comparator|Onabotulinum Toxin A|IM Injection
16621279|NCT02472197|Experimental|morcellation|
16621280|NCT02472197|Active Comparator|standard resection|
16621281|NCT02472184|Active Comparator|Office Hysteroscopy|Group of patients in which office hysteroscopy will be performed prior to endometrial biopsy
16621282|NCT02472184|Active Comparator|Endometrial biopsy|Group of patients in which endometrial biopsy will be performed prior to office hysteroscopy
16621283|NCT02472171|Experimental|Group 1|"Order of treatments:
~A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
16621284|NCT02472171|Experimental|Group 2|"Order of treatments:
~A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil"
16621285|NCT02472171|Experimental|Group 3|"Order of treatments:
~B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
16621286|NCT02472171|Experimental|Group 4|"Order of treatments:
~B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil"
16621287|NCT02472171|Experimental|Group 5|"Order of treatments:
~C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil"
16621288|NCT02472171|Experimental|Group 6|"Order of treatments:
~C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil"
16621289|NCT02472158|Experimental|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
16621290|NCT02472158|Active Comparator|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
16621291|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.
~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
16621292|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
16621293|NCT02472132|Experimental|Intervention|Prospective implantation of POC US for CVC tip placement.
16621294|NCT02472132|No Intervention|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
16621295|NCT02472119|Experimental|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
16621296|NCT02472119|Active Comparator|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
16621297|NCT02472093|Active Comparator|Physical exercises treatment|The types of exercises included: low-impact to moderate aerobic training (gradually starting from 50% of the Fc max to 70%-80% of Fc max); walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing.
16621298|NCT02472093|Experimental|Perceptive Rehabilitation Treatment|Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
16621299|NCT02472093|Active Comparator|Control group|The control group did brief educational sessions.
16621300|NCT02472080|Experimental|gemcitabine -oxaliplatine combination|
16621301|NCT02472067|No Intervention|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
16621302|NCT02472067|Experimental|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
16621303|NCT02472054|Experimental|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)
~Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)
~The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).
~Maintenance treatment (D4 to D14)
~MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14
~CSA IVC or PO at a target rate of 150-200 ng / ml"
16621304|NCT02472041|Experimental|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
16621305|NCT02472041|Experimental|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
16621306|NCT02472028|Experimental|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to <135 mmHg
16621307|NCT02472028|Active Comparator|usual strategy|usual strategy based on the usual care of routine care
16621308|NCT02472015|No Intervention|normal care|patients who will have normal care
16621309|NCT02472015|Experimental|telemedicine|patients who will have telemedicine
16621310|NCT02472002|Experimental|Mesenchymal cell therapy|
16621311|NCT02471989|Experimental|Low-FODMAP diet|FOS in diet
16621312|NCT02471989|Active Comparator|Classical GERD diet|avoid fatty meals, head of bed elevation...
16621313|NCT02471976|No Intervention|Group A|the centres applies their usual practices
16621314|NCT02471976|Other|Group B|strategy promoting early consideration and collegiate vulnerability of patients
16621315|NCT02471963|Active Comparator|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
16621316|NCT02471963|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
16621317|NCT02471950||Elective Cardiac surgery|Those patients scheduled for elective heart surgery requiring cardiopulmonary bypass who will be given 2.5% isoflurane while on bypass.
16621318|NCT02471937|Experimental|Pregnant women negative for GBS colonization|Only women negative for GBS during all the study will be included.
16621319|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Trans thoraciq cardiac ultrasonography wil be perforfomed for pregnant women having a spinal or spinal-epidural anesthesia for elective caesarean section. All patients are more 18 years old and more 37 weeks pregnancy
16621320|NCT02471911|Experimental|All subjects|"All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.
~RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone."
16621321|NCT02471898|Experimental|HTX-011|Evaluate the analgesic efficacy of HTX-011
16621322|NCT02471898|Placebo Comparator|Placebo|Saline
16621323|NCT02471885|Experimental|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
16621324|NCT02471885|Placebo Comparator|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
16621325|NCT02471872|Experimental|Air Pollution Education|Students are presented with a one-hour interactive information session about air pollution and the environment.
16621326|NCT02471872|Placebo Comparator|Non-Air Pollution Education|Students are presented with a one-hour interactive information session about vaccines.
16621327|NCT02471859|Experimental|Part A: GDC-3280|Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.
16621328|NCT02471859|Placebo Comparator|Part A: Placebo|Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.
16621329|NCT02471859|Experimental|Part B: GCD-3280|Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\n
16621330|NCT02471859|Placebo Comparator|Part B: Placebo|Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\n
16621331|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort I|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade and achieved best response of confirmed complete or partial response, or stable disease will receive GDC-0919, at the MTD or maximum administered dose (MAD) determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
16621332|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort II|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
16621333|NCT02471846|Experimental|Biopsy Cohort A|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive GDC-0919 during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
16621334|NCT02471846|Experimental|Biopsy Cohort B|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive atezolizumab during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
16621335|NCT02471846|Experimental|Dose-Escalation Cohort(s)|Approximately 6 to 65 participants will be enrolled and treated at escalating doses of GDC-0919 in combination with fixed-dose atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio. Successive groups of at least 3 participants will be evaluated during a 21-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage. The MTD or MAD, whichever is reached first, will be considered for the expansion stage.
16621336|NCT02471846|Experimental|Expansion Cohorts|Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
16621337|NCT02471833|Experimental|Telmisartan 20mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 20mg once a day orally.
16621338|NCT02471833|Experimental|Telmisartan 40mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 40mg once a day orally.
16621339|NCT02471833|Placebo Comparator|Placebo|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive placebo once a day orally.
16621340|NCT02471820|Experimental|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 & 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 & 22 of every cycle for 4 cycles
16621341|NCT02471807|Experimental|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
16621342|NCT02471794|No Intervention|Standard Shared Medical Appointment|The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
16621343|NCT02471794|Experimental|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
16621344|NCT02471794|No Intervention|Retrospective|A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention. The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
16621345|NCT02471755|Active Comparator|Electro-acupuncture Group|
16621346|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
16621347|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
16621348|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
16621349|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
16621350|NCT02471729|Experimental|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
16621554|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
16621351|NCT02471716|Experimental|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
16621352|NCT02471716|Experimental|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
16621353|NCT02471703||SMF mini-stem hip replacement recipient|Received the device via total hip arthroplasty
16621354|NCT02471690|Active Comparator|Oritavancin|IV -Single Dose - 1200 mg Oritavancin
16621355|NCT02471690|Placebo Comparator|Placebo|250 mL Dextrose 5% in Water
16621356|NCT02471677|Active Comparator|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
16621357|NCT02471677|Experimental|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
16621358|NCT02471664|Experimental|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
16621359|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
16621360|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
16621361|NCT02471638|Experimental|Single arm study|PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
16621362|NCT02471625||Traumatic Brain Injury|Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
16621363|NCT02471625||Control|Men and women ages 18-65 with no history of head trauma and a score of 15 on the GCS scale.
16621364|NCT02471599|Experimental|tonsillectomy group|The case group will receive tonsillectomy.
16621365|NCT02471599|Active Comparator|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
16621366|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.
~At the end of the procedure, a final IVUS imaging run must be performed.
~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
16621367|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.
~At the end of the procedure, a final OCT imaging run must be performed."
16621368|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with angiography guidance according to local standard practice.
~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
16621369|NCT02471573|Active Comparator|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
16621370|NCT02471573|Active Comparator|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
16621371|NCT02471560|Experimental|dimethyl fumarate|As prescribed by the Investigator according to the local Summary of Product Characteristics.
16621372|NCT02471560|Active Comparator|injectable MS DMT|As prescribed by the Investigator according to the local Summary of Product Characteristics.
16621373|NCT02471547|No Intervention|TURBT ONLY|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.
~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
16621374|NCT02471547|Experimental|BWT with Mitomycin-C prior TURBT|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.
~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
16621375|NCT02471534|Experimental|Pediatric patients with hypovolemia|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
16621376|NCT02471521|Experimental|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
16621377|NCT02471521|Active Comparator|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
16621412|NCT02471235|No Intervention|Control group|The control group will receive no physiotherapy training by physiotherapist and no phone calls from case manager for reinforcement of home exercise. .
16621413|NCT02471222|Experimental|ADS-5102 (amantadine HCl extended release)|
16621378|NCT02471508|Experimental|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
16621379|NCT02471495|Experimental|Synergo® RITE + MMC|"Induction
~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).
~Maintenance
~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
16621380|NCT02471482|Experimental|Music First group|"Mozart music lullaby for 30 minutes with recording of cerebral oxygenation (by using Near infrared spectroscopy) and vital signs (respiratory rate, heart rate, oxygen saturations and frequency of apneic episodes continuously) followed by 10 minutes of washout period and then period of no music for next 30 minutes (with same variables recorded as outlined for music session).
~This cycle is repeated every 6 hours for 24 hours. In addition, the behavioral response of baby is observed during the study period by video recording which will be in 'Mute' video mode and then reviewed by our developmental staff"
16621381|NCT02471482|Experimental|No Music First group|"No music in first 30 minutes of study followed by 10 minutes of washout period and then 30 minutes of Mozart music lullaby while recording same variables. This cycle was repeated every 6 hours for 24 hours."
16621382|NCT02471456||EVH|Patients that have undergone Endoscopic Vein Harvesting (EVH)
16621383|NCT02471456||OVH|Patients that have undergone open vein harvest (OVH)
16621384|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
16621385|NCT02471430|Experimental|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.
16621386|NCT02471430|Experimental|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
16621387|NCT02471430|Experimental|Arm C|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.
16621388|NCT02471417|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
16621389|NCT02471417|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
16621390|NCT02471404|Active Comparator|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
16621391|NCT02471404|Active Comparator|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
16621392|NCT02471404|Active Comparator|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
16621393|NCT02471391|Experimental|Ibrutinib + ABT-199|
16621394|NCT02471378||Pregnant Women 15-25 years old|Malaria-infected pregnant Women
16621398|NCT02471339|Experimental|1/ACT|2 ACT Training Sessions followed by weekly emails and video chats
16621399|NCT02471339|Active Comparator|2/WL|Waitlist group - no intervention for first 8 weeks (then will receive ACT intervention as Arm 1)
16621400|NCT02471326|Experimental|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
16621401|NCT02471313|Experimental|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent [18F] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
16621402|NCT02471300||1|stable mild-moderate asthmatic subjects
16621403|NCT02471287||Affected Patients|Participants with eye disease
16621404|NCT02471287||Healthy Volunteers|Unaffected first degree relatives of participants with a known or suspected inherited eyedisease.
16621405|NCT02471274|Experimental|Group 1|healthy control subjects with normal hepatic function
16621406|NCT02471274|Experimental|Group 2|subjects with mild hepatic impairment
16621407|NCT02471274|Experimental|Group 3|subjects with moderate hepatic impairment
16621408|NCT02471274|Experimental|Group 4|subjects with severe hepatic impairment
16621409|NCT02471248|Experimental|Ankle Robot with Power Assistance|In this experimental group, the Ankle Robot assists the ankle dorsiflexion when the stroke patients voluntarily perform the swing phase gait movement.
16621410|NCT02471248|Placebo Comparator|Sham group|In this sham group, the Ankle Robot provides very low assistance to generate tactile feedback to the stroke patients indicating they are performing the swing phase gait movement, but no assistance will be given to support their ankle dorsiflexion.
16621411|NCT02471235|Experimental|Intervention group|The physiotherapist will provide every patient an individualized physical training programme that fits their cardiopulmonary status. Patients will have the training as out-patient in the physiotherapy department for 4-8 sessions, 2 hours each time, 1-2 times weekly. Home exercise will be taught. Our case manager will give phone calls to the subject every 2 weeks to provide support and reinforcement for having continuous exercise at home for one year. Patients will be invited to attend reinforcement out-patient physiotherapy training once very month or every 2 months if they are willing to attend.
16621414|NCT02471222|Placebo Comparator|Placebo|
16621555|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
16621415|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
16621416|NCT02471196|Experimental|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
16621417|NCT02471196|Experimental|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
16621418|NCT02471196|Placebo Comparator|Placebo|Placebo twice a day for 12 weeks.
16621419|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.
~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
16621420|NCT02471157||Eugonadal|Eugonadal men
16621421|NCT02471157||Hypogonadal|Hypogonadal men
16621422|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
16621423|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
16621424|NCT02471144|Placebo Comparator|Placebo|Placebo
16621425|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
16621426|NCT02471131|Experimental|WATCHMAN Implantation|
16621429|NCT02471105|Experimental|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
16621430|NCT02471105|Experimental|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
16621431|NCT02471092|Placebo Comparator|Water Control|Skim milk products. Water and permeate control; 250mL serving.
16621432|NCT02471092|Active Comparator|Skim Milk|Skim milk products. Skim milk (regular 80:20 protein ratio); 250mL serving.
16621433|NCT02471092|Experimental|High Protein Milk|Skim milk products. High protein milk (regular 80:20 protein ratio); 250mL serving.
16621434|NCT02471092|Experimental|High Protein Milk (Modified Ratio)|Skim milk products. High protein milk with modified protein ratio (40:60 ratio); 250 mL serving.
16621435|NCT02471092|Experimental|Skim Milk (Modified Ratio)|Skim milk products. Skim milk with modified protein ratio (40:60 ratio); 250 mL serving.
16621436|NCT02471066|Experimental|active rTMS|12 patients will be enrolled in this arm.
16621437|NCT02471066|Sham Comparator|sham rTMS|12 patients will be enrolled in this arm.
16621438|NCT02471053|Experimental|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
16621439|NCT02471040|Experimental|Type 1 diabetic subjects|Subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
16621440|NCT02471040|Active Comparator|Healthy Subjects|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
16621441|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
16621442|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
16621443|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
16621444|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
16621445|NCT02471001||Heart Surgery Using Heart-lung Machine|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being two additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
16621479|NCT02470767||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fribilation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
16621446|NCT02470988|Active Comparator|CBASP|Cognitive Behavioural Analysis System of Psychotherapy (CBASP) is a form of therapy specifically designed to treat individuals with chronic depression. CBASP combines a number of elements, with a focus on teaching the client to become aware of their interpersonal behaviour and its consequences.
16621447|NCT02470988|Experimental|CBASP Without DPI|In this arm CBASP will be delivered without Disciplined Personal Involvement (DPI) by the therapist.
16621448|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
16621449|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
16621450|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
16621451|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
16621452|NCT02470936|Experimental|Group 1- Lifestyle Intervention|Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to the website composed of four topic areas (get active, eat well, stop smoking, and find support), receive a Fitbit and access to a Fitbit account and community group, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
16621453|NCT02470936|No Intervention|Group 2 - Control|Men randomized to the control group will receive standard of care. They will receive access to the website and personalized lifestyle recommendations on the 8 healthy habits targeted in the study after the 3 month trial.
16621454|NCT02470923|Other|Group 1|Usual care including medical advice to quit and confrontation with abnormal spirometry results if relevant.
16621455|NCT02470923|Other|Group 2|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, and follow up for at least 5 weeks after discharge (will be done weekly by phone for five consecutive weeks).
16621456|NCT02470923|Other|Group 3|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, offering and providing nicotine replacement therapy (NRT) and follow up (will be done weekly by phone for five consecutive weeks).
16621457|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
16621458|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.
~SBRT: 8.0Gy escalated dose"
16621459|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.
~SBRT: 7.5Gy conventional dose"
16621460|NCT02470884|Experimental|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
16621461|NCT02470871|Experimental|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose
16621462|NCT02470871|Experimental|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.
16621463|NCT02470858|Experimental|LDV/SOF+ASV|Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
16621464|NCT02470858|Experimental|SOF+DCV+SMV|Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
16621465|NCT02470858|Experimental|SOF+DCV+ASV|Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks
16621466|NCT02470845|Experimental|Tian Jiu group|The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
16621467|NCT02470845|Sham Comparator|Placebo-control group|The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
16621468|NCT02470845|No Intervention|Waitlist-control group|The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
16621469|NCT02470832|Experimental|Combination therapy RG1662 + itraconazole|Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food
16621470|NCT02470832|Experimental|RG1662 Monotherapy|Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)
16621471|NCT02470832|Experimental|itraconazole Monotherapy|Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)
16621472|NCT02470819|Experimental|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
16621473|NCT02470806|Experimental|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
16621474|NCT02470806|Active Comparator|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
16621475|NCT02470793|Active Comparator|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
16621476|NCT02470793|Experimental|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
16621477|NCT02470780|Experimental|Three-month follow-up|
16621478|NCT02470780|Experimental|Six-month follow-up|
16621519|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
16621480|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
16621481|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
16621482|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
16621483|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
16621484|NCT02470728|No Intervention|Control Group|Those randomized into the control group will receive the current standard of care for pain management. This standard care pathway involves a pain management specialist consultation only at the request of the primary admitting team. The pain management consultation can occur at any time during the patient's inpatient stay and care by these specialists ends at discharge.
16621485|NCT02470728|Experimental|Treatment Group|Subjects randomized into the treatment (early intervention) group will receive the New Clinical Pathway: pain management care coordinated by pain-management specialists from inpatient admission through 60 days after discharge.
16621486|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
16621487|NCT02470702|Experimental|Oritavancin|Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
16621488|NCT02470702|Placebo Comparator|Placebo|Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
16621489|NCT02470689|Active Comparator|Diacerin cream 1%|
16621490|NCT02470689|Placebo Comparator|ultraphil cream|
16621491|NCT02470676|Active Comparator|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
16621492|NCT02470676|Experimental|Progesterone plus Experimental device|Experimental device + 200 mg daily progesterone vaginal suppositories (Utrogestan)
16621493|NCT02470663|Experimental|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
16621494|NCT02470663|Active Comparator|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
16621495|NCT02470650|Experimental|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
16621496|NCT02470650|Active Comparator|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
16621497|NCT02470650|Active Comparator|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
16621498|NCT02470637|Experimental|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
16621499|NCT02470624||treatment following current guideline|
16621500|NCT02470611|Experimental|Sodium Alendronate|Adjunctive use of 1% sodium alendronate gel as part of periodontitis treatment
16621501|NCT02470611|Placebo Comparator|Placebo|Adjunctive use of placebo gel as part of periodontitis treatment
16621502|NCT02470585|Active Comparator|Placebo + Carboplatin + Paclitaxel -> Placebo|Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
16621503|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Placebo|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
16621504|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Veliparib|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.
16621505|NCT02470572|Active Comparator|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
16621506|NCT02470572|Placebo Comparator|Conventional light microscope|conventional light microscope
16621507|NCT02470559|Experimental|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
16621508|NCT02470546|Active Comparator|Metformin|Patients receiving metformin
16621509|NCT02470546|Placebo Comparator|Placebo|Patients receiving placebo
16621510|NCT02470533|Active Comparator|Transarterial chemoembolization|Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
16621511|NCT02470533|Experimental|Stereotactic body radiation therapy|Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) < of 5%
16621512|NCT02470520||AKI without CRRT|Patients with AKI who are not treated with continuous renal replacement therapy
16621513|NCT02470520||AKI with CRRT|Patients with AKI who are treated with continuous renal replacement therapy
16621514|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
16621515|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
16621516|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
16621517|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
16621518|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
16621520|NCT02470468|Experimental|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
16621521|NCT02470468|Experimental|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
16621522|NCT02470468|Other|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
16621523|NCT02470455||Normoglycemic group|25 patients were recruited who were on Atorvastatin and with normal blood glucose and Hb1Ac level.
16621524|NCT02470455||Prediabetic with normal GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with normal GTT.
16621525|NCT02470455||Prediabetic with impaired GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with impaired GTT.
16621526|NCT02470442|Experimental|Sevoflurane/Desflurane|After induction of general anesthesia with sevoflurane, anesthesia was maintained with desflurane.
16621527|NCT02470442|Experimental|Sevoflurane|the anesthetic induction and maintenance with sevoflurane.
16621528|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
16621529|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
16621530|NCT02470416|Active Comparator|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
16621531|NCT02470416|Active Comparator|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
16621532|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
16621533|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
16621534|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
16621535|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
16621536|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
16621537|NCT02470390|Active Comparator|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.
~Will be administered on either study day 1 or 3 per protocol and randomization."
16621538|NCT02470390|Active Comparator|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.
~Will be administered on either study day 1 or 3 per protocol and randomization."
16621539|NCT02470390|Active Comparator|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.
~Will be administered on study day 5 per protocol."
16621540|NCT02470377|Experimental|Transcranial Magnetic Stimulation|After determination of the motor threshold, the TMS coil will be positioned at predetermined locations over the brain using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses (repetitive TMS) at 1Hz up to 10Hz or in theta burst mode will be delivered at one or more locations over the head, depending on the brain location under study (brain locations determined by MRI data). Real or active sham conditions will be used in the study but all participants will receive real treatment at some point during their enrollment. Real rTMS over one area may also be compared to real rTMS over another area.
16621541|NCT02470338|Active Comparator|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
16621542|NCT02470338|Sham Comparator|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
16621543|NCT02470325|Active Comparator|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
16621544|NCT02470325|Active Comparator|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
16621545|NCT02470325|Active Comparator|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
16621546|NCT02470325|Active Comparator|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
16621547|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
16621548|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
16621549|NCT02470299|Experimental|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
16621550|NCT02470299|Placebo Comparator|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
16621551|NCT02470286|Experimental|SA001|Dose escalation
16621552|NCT02470286|Placebo Comparator|Placebo|Dose escalation
16621553|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
16621556|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (< 5.7%)
16621557|NCT02470247|Experimental|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.
~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
16621558|NCT02470247|Sham Comparator|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
16621559|NCT02470234|Experimental|Methylphenidate HCl ER Capsules|Active drug, administered once
16621560|NCT02470221||Goal-directed fluid therapy|The fluid in group Goal-directed fluid therapy will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the Flo-Trac monitoring system.
16621561|NCT02470221||Conventional fluid therapy|The fluid in group Conventional fluid therapy will be administered based on the principle crystalloid solution: colloid solution =2-3:1. The total volume of fluid will be adjusted in accordance with blood pressure, heart rate and urine output of each patient.
16621562|NCT02470195|Experimental|workshop|workshop of procedural simulation
16621563|NCT02470195|No Intervention|control|no specific workshop of procedural simulation
16621564|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
16621565|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
16621566|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
16621567|NCT02470169|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
16621568|NCT02470169|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
16621569|NCT02470169|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
16621570|NCT02470156|Experimental|High Intensity Arm (Intervention)|"Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a full dose of the intervention."
16621571|NCT02470156|Active Comparator|Low Intensity Arm (Comparison)|Women in the Low Intensity (comparison) arm are interviewed and coached four times during the study (at baseline, 4 months, 8 months, and 12 months).
16621572|NCT02470143||Bike application arm|The bike application arm contains cardiac patients that will be instructed to use the cycling application during a one month period.
16621573|NCT02470130|Active Comparator|relax actor|actor during simulation and relaxation before debriefing
16621574|NCT02470130|No Intervention|no relax actor|actor during simulation and no relaxation before debriefing
16621575|NCT02470130|Active Comparator|relax observer|observer during simulation and relaxation before debriefing
16621576|NCT02470130|No Intervention|no relax observer|observer during simulation and no relaxation before debriefing
16621577|NCT02470117|Active Comparator|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
16621578|NCT02470117|Sham Comparator|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
16621579|NCT02470104|Experimental|Enteral Donor Breastmilk|"Donor milk will be pasteurized prior to use.
~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.
~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.
~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
16621580|NCT02470104|No Intervention|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
16621581|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
16621582|NCT02470078|Experimental|Pharyngeal electrical stimulation|Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.
16621583|NCT02470078|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days.
16621584|NCT02470065|Experimental|Neo adjuvant afatinib|once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
16621585|NCT02470065|Active Comparator|Immediate surgery|immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
16621586|NCT02470052|Experimental|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
16621587|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
16621588|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
16621589|NCT02470026|Experimental|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
16621812|NCT02468518|Active Comparator|Arsenic exposed controls|Vitamin E capsule 200 IU bd x 12 weeks
16621590|NCT02470026|Experimental|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
16621591|NCT02470013|Experimental|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
16621592|NCT02470013|No Intervention|Control Group|Nutrition counselling upon hospital discharge (usual care)
16621593|NCT02470000|Experimental|Experimental Group|Intravascular laser irradiation of blood (ILIB, output power 0.3mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
16621594|NCT02470000|Sham Comparator|Control Group|Intravascular laser irradiation of blood (ILIB, output power 0mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
16621595|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
16621596|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
16621597|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
16621598|NCT02469974|Experimental|Ruxolitinib / INC 424|Ruxolitinib, Jakafi ®, will be given orally at standard dose daily for 16 weeks pre ASCT and up to 3 months post-ASCT for 10 patients (allowing for 2 additional screen failures). Patients will restart ruxolitinib at 100 days after the ASCT as long as their platelet count is at least 50 x103. For patients whose platelet count is below 50 x103 at day 100, ruxolitinib should be restarted once platelet count reaches 50 x103. The dose of ruxolitinib can be titrated up as per clinical guidelines. PBSC mobilization will include G-CSF 10 mcg/kg/day. HDC for ASCT will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2.
16621599|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
16621600|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
16621601|NCT02469948|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
16621602|NCT02469948|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
16621603|NCT02469922|Experimental|Positron emission tomography|Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed
16621604|NCT02469909|Other|immediate decannulation|In the immediate decannulation group - the tracheostomy tube is removed and the patient would be monitored overnight in an intermediate monitored unit. On the next day a clinical evaluation would be held, and the patient would be discharge or transferred to his department according to the clinical course of the patient
16621605|NCT02469909|Other|Gradual tracheostomy tube decrease|In the gradual decannulation group The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
16621606|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
16621607|NCT02469896|Active Comparator|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
16621608|NCT02469883|Experimental|Sinotecean|
16621609|NCT02469870|Experimental|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
16621610|NCT02469870|Active Comparator|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
16621611|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
16621612|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
16621613|NCT02469844||Patients with epilepsy having seizures in sleep|
16621614|NCT02469831|Active Comparator|group D|deep neuromuscular block by rocuronium defined :post tetanic (PTC) >1 but no response to a train of four (TOF) stimulation.
16621615|NCT02469831|Active Comparator|group I|intermediate neuromuscular block by rocuronium defined as TOF count of 1-3.
16621616|NCT02469805|Active Comparator|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
16621617|NCT02469805|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
16621618|NCT02469805|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
16621813|NCT02468518|Active Comparator|Healthy volunteers|Vitamin E capsule 200 IU bd x 12 weeks
16621619|NCT02469792|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
16621620|NCT02469779|Experimental|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
16621621|NCT02469779|Active Comparator|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
16621622|NCT02469766|Active Comparator|Extracorporeal Shockwaves|Patients in this arm will undergo SWL
16621623|NCT02469766|Active Comparator|Semirigid URS|Patients in this arm will undergo Semirigid Ureteroscopy
16621624|NCT02469766|Active Comparator|Flexible URS|Patients in this arm will undergo Flexible Ureteroscopy
16621625|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
16621626|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
16621627|NCT02469740|Experimental|Ticagrelor|Patients in this group will be prescribed ticagrelor 90 mg BD for 4 weeks.
16621628|NCT02469740|Active Comparator|Clopidogrel|Patients in this group will be prescribed clopidogrel 75 mg OD for 4 weeks
16621629|NCT02469727|Experimental|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
16621630|NCT02469727|No Intervention|Usual care control|No intervention provided.
16621631|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
16621632|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
16621633|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.
~Either cryoablation or thermal ablation may be performed as per standard institutional policies.
~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
16621634|NCT02469688|Experimental|Part1 ASP4070 intramuscular vaccination group|ASP4070 high dose x 4 times
16621635|NCT02469688|Experimental|Part1 ASP4070 intradermal vaccination group|ASP4070 high dose x 4 times
16621636|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 1|ASP4070 high dose x 4 times
16621637|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 2|ASP4070 high dose x 1 time, Placebo x 3 times
16621638|NCT02469688|Placebo Comparator|Part2 Placebo intramuscular vaccination group|Placebo x 4 times
16621639|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 1|ASP4070 high dose x 4 times
16621640|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 2|ASP4070 low dose x 4 times
16621641|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 3|ASP4070 high dose x 1 time, Placebo x 3 times
16621642|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 4|ASP4070 low dose x 1 time, Placebo x 3 times
16621643|NCT02469688|Placebo Comparator|Part2 Placebo intradermal vaccination group|Placebo x 4 times
16621644|NCT02469675|Experimental|All subjects|"All subjects undergo same full protocol, including different combinations of stimulation on different days:
~Transcranial Magnetic Stimulation Cervical Transcutaneous Stimulation Median Nerve Stimulation"
16621645|NCT02469662|Experimental|Retrospective|Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available
16621646|NCT02469662|Experimental|Prospective|Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow
16621647|NCT02469623|Experimental|Dipole Density Mapping|
16621648|NCT02469610|Experimental|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
16621649|NCT02469610|Other|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
16621650|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
16621651|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
16621652|NCT02469584|Experimental|1|symptomatic cystocele described as Points Aa or Ba >= 0 according to the International Continence Society pelvic organ prolapse quantification system (POP-Q). The changes in POPQ score preoperatively and three months after the anterior colporrhaphy with the new small stitch technic will be analyzed.
16621653|NCT02469571|Active Comparator|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
16621654|NCT02469571|Placebo Comparator|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
16621716|NCT02469246|Experimental|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
16621810|NCT02468531|Experimental|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
16621655|NCT02469558|Active Comparator|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
16621656|NCT02469558|Placebo Comparator|placebo|a similar looking and tasting placebo without bacteria
16621657|NCT02469545|Active Comparator|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
16621658|NCT02469545|Placebo Comparator|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
16621659|NCT02469532||Atherectomy|"Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures."
16621660|NCT02469532||Angioplasty|"Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures."
16621661|NCT02469519|Experimental|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone [12 mg intramuscular injection, 24 hours apart X 2 doses] or if unavailable may give Dexamethasone [6 mg intramuscularly 12 hours apart x 4 doses]
16621662|NCT02469519|Placebo Comparator|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
16621663|NCT02469506|Experimental|NMES group|Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
16621664|NCT02469506|No Intervention|Control group|Patients will receive daily visits by the investigator to check progress.
16621665|NCT02469493|Experimental|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
16621666|NCT02469493|Experimental|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
16621667|NCT02469493|Sham Comparator|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
16621668|NCT02469493|No Intervention|Waitinglist control|In this group, patients received no electroacupuncture
16621669|NCT02469480|Experimental|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
16621670|NCT02469480|Active Comparator|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
16621671|NCT02469467|Experimental|VS-505|750 mg capsule
16621672|NCT02469454|Experimental|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
16621673|NCT02469454|Active Comparator|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted after 6 week of the delivery. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
16621674|NCT02469441||Arm A|Arm A (treatment arm: coffee): patients after colorectal surgery receive coffee in addition to the regular infusion therapy and/or alimentation
16621675|NCT02469441||Arm B|Arm B (control arm: water / tea): patients after colorectal surgery receive water or tea (excluding black tea) and no coffee until the first bowel movement in addition to the regular infusion therapy and/or alimentation
16621676|NCT02469428|Sham Comparator|Clean air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16621677|NCT02469428|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16621678|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.
~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
16621679|NCT02469402|Active Comparator|Standard infant formula|Standard infant formula
16621680|NCT02469402|Experimental|Protein reduced formula|Protein reduced alpha-lactalbumin formula
16621681|NCT02469402|No Intervention|Breast-feeding|Exclusive breast-feeding
16621682|NCT02469389|Experimental|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
16621923|NCT02467777|Active Comparator|Forced Air|Bair Hugger
16621683|NCT02469389|Active Comparator|Health & Wellness (H&W)|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
16621684|NCT02469376|Experimental|Diagnosis with GP1|Injection and scanning of [18F]-GP1
16621685|NCT02469363|Active Comparator|Macintosh laryngoscope|Endotracheal intubation with classic (Macintosh) laryngoscope
16621686|NCT02469363|Active Comparator|Mc-Coy laryngoscope|Endotracheal intubation with Mc-Coy laryngoscope
16621687|NCT02469363|Active Comparator|C-Mac videolaryngoscope|Endotracheal intubation with C-Mac videolaryngoscope
16621688|NCT02469363|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation with McGrath videolaryngoscope
16621689|NCT02469350|Experimental|Rehabilitation with serious game|18 rehabilitation sessions with serious game during a 6-8 weeks period
16621690|NCT02469337|Active Comparator|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
16621691|NCT02469337|Active Comparator|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
16621692|NCT02469337|Active Comparator|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)*0.7 under close supervision and monitoring of their vital parameters.
16621693|NCT02469337|No Intervention|Control|Patients in this group will have surgery as standard practice with none of the above interventions
16621694|NCT02469324|Active Comparator|Cognitive-Behavioral Therapy|see intervention explanation
16621695|NCT02469324|Experimental|Compassionate Mind Training|
16621696|NCT02469311|Sham Comparator|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
16621697|NCT02469311|Active Comparator|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
16621698|NCT02469311|Active Comparator|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
16621699|NCT02469311|Sham Comparator|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
16621700|NCT02469311|Sham Comparator|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
16621701|NCT02469311|Active Comparator|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
16621702|NCT02469311|Sham Comparator|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
16621703|NCT02469311|Active Comparator|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
16621704|NCT02469298|Experimental|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
16621705|NCT02469298|Placebo Comparator|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
16621706|NCT02469298|Experimental|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
16621707|NCT02469298|Active Comparator|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
16621708|NCT02469285|Experimental|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
16621709|NCT02469285|Active Comparator|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
16621710|NCT02469285|Experimental|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
16621711|NCT02469272|Experimental|Fecal Microbiota Transplantation|Intervention: standardized preparation of frozen fecal material from lean healthy donors Route: infused into the duodenum through the working channel of the instrument at upper endoscopy Dosing: 1 dose
16621712|NCT02469259|Experimental|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
16621713|NCT02469259|Placebo Comparator|Placebo|Subjects will receive intranasal saline spray
16621714|NCT02469246|Experimental|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks
~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
16621715|NCT02469246|Active Comparator|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks
~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
16621717|NCT02469233|Experimental|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
16621718|NCT02469233|Active Comparator|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
16621719|NCT02469220|Experimental|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
16621720|NCT02469220|Active Comparator|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
16621721|NCT02469220|No Intervention|Control|Watchful waiting. No diets or food supplements are administered
16621722|NCT02469207||Deceased organ donors|Patients with consent for organ donation towards transplantation and research. Organs not used for transplantation will be used for this study if determined appropriate and necessary.
16621723|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
16621724|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
16621725|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
16621726|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
16621727|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
16621728|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
16621729|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
16621730|NCT02469142|Experimental|ADM tension-free hernia reparation|Use ADM to repair incarcerated inguinal hernia by tension-free
16621731|NCT02469142|Placebo Comparator|traditional tension hernia reparation|Just repair incarcerated inguinal hernia by nothing in tension condition
16621732|NCT02469129|Experimental|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace.
16621733|NCT02469129|Experimental|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism
16621734|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles
~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
16621735|NCT02469103|Experimental|C2 & colonoscopy|C2 and colonoscopy
16621736|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
16621737|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
16621738|NCT02469077|Experimental|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
16621739|NCT02469077|Active Comparator|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
16621740|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
16621741|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
16621742|NCT02469051|Other|Breathhold SPECT-MPI vs. standard freebreathing SPECT-MPI|
16621743|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
16621744|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
16621745|NCT02469025|Experimental|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.
~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
16621746|NCT02469025|Experimental|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.
~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
16621747|NCT02469012|Experimental|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
16621748|NCT02468999|Active Comparator|insulin nasal spray|160 Units of human insulin as nasal spray
16621749|NCT02468999|Placebo Comparator|placebo nasal spray|Nasal spray containing placebo solution
16621750|NCT02468986||Uncontrolled Rheumatoid Arthritis|"18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is >3.2 and C-reactive protein (mg/dL) elevated above normal range.
~Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing."
16621751|NCT02468986||Controlled Rheumatoid Arthritis|18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) <3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
16621752|NCT02468986||Healthy Controls|18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
16621753|NCT02468973|Other|Life style counseling|Students will meet chronic patients and will counsel for life style
16621754|NCT02468960|Other|OPN strategy (study group)|"Interventions planned in this arm are as follows:
~Predilatation with OPN NC balloon catheter.
~Absorb BVS implantation.
~Treated segment visualization by OCT.
~Clinical FU at 12 months."
16621755|NCT02468960|Other|Standard strategy (control group)|"Interventions planned in this arm are as follows:
~Predilatation with standard compliant balloon.
~Absorb BVS implantation.
~Treated segment visualization by OCT.
~Clinical FU at 12 months."
16621756|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
16621757|NCT02468908|Experimental|Molgramostim nebuliser solution, inhaled|Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
16621758|NCT02468908|Placebo Comparator|Nebuliser solution, inhaled|Inhaled nebuliser solution
16621759|NCT02468895||Idiopathic Inflammatory Myopathy|PM, DM, sIBM, necrotizing myopathy, anti-synthetase syndrome, suspected myopathy
16621760|NCT02468882|Experimental|Intervention group|"Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily therapeutic dose."
16621761|NCT02468882|No Intervention|Control group|The control group will receive the standard of care, thus will maintain their ad libitum diet.
16621762|NCT02468869|Experimental|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
16621763|NCT02468869|Active Comparator|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
16621764|NCT02468856|Active Comparator|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
16621765|NCT02468856|Placebo Comparator|Placebo|one time administration per study session in the morning of day 2
16621766|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
16621767|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
16621768|NCT02468817|Active Comparator|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
16621769|NCT02468817|Experimental|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
16621770|NCT02468804|Experimental|Parkinson's Disease Subjects, (rTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
16621771|NCT02468804|Experimental|Control Subjects (rTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
16621772|NCT02468804|Sham Comparator|Parkinson's Disease Subjects, (sTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
16621773|NCT02468804|Sham Comparator|Control Subjects (sTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
16621774|NCT02468791|Experimental|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
16621775|NCT02468791|Active Comparator|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
16621809|NCT02468531|Other|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
16621776|NCT02468778|Experimental|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
16621777|NCT02468778|Active Comparator|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® Device approved for use in high-risk PCI.
16621778|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
16621779|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
16621780|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
16621781|NCT02468752|Sham Comparator|Air|Normobaric air breathing
16621782|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
16621783|NCT02468739|Experimental|Ganglioside-monosialic acid arm|"Patients will receive treatment of adjuvant chemotherapy. Ganglioside-monosialic acid(GM1, 80mg per day) will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).
~Chemotherapy regimens:
~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.
~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
16621784|NCT02468739|Placebo Comparator|placebo arm|"Patients will receive treatment of adjuvant chemotherapy. Placebo will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).
~Chemotherapy regimens:
~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.
~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
16621785|NCT02468726|Experimental|NER1008|Use of NER1008 enema for bowel cleansing
16621786|NCT02468726|Active Comparator|Fleet|Use of Fleet enema for bowel cleansing
16621787|NCT02468713|Experimental|Group 1|Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)
16621788|NCT02468713|Experimental|Group 2|Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)
16621789|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
16621790|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
16621791|NCT02468687|Other|N-methyl-pyrrolidone|NMP dose escalation in accelerated phase and standard phase
16621792|NCT02468674|Other|Follow-up (arm 1)|Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
16621793|NCT02468674|No Intervention|Follow-up (arm 2)|Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
16621794|NCT02468661|Experimental|INC280 200mg BID + ERL 150mg QD|Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
16621795|NCT02468661|Experimental|INC280 400mg BID + ERL 150mg QD|Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
16621796|NCT02468648|Experimental|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
16621797|NCT02468635|Other|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
16621798|NCT02468635|Other|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
16621799|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
16621800|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
16621801|NCT02468609|Other|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
16621802|NCT02468596|Experimental|Patients|Patients suffering from anti-MAG neuropathy
16621803|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
16621804|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
16621805|NCT02468557|Experimental|Idelalisib 150 mg|Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
16621806|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
16621807|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
16621808|NCT02468544|Experimental|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
16621811|NCT02468518|Experimental|Patients|Vitamin E capsule 200 IU bd x 12 weeks
16621814|NCT02468505|Experimental|STEPS|structured psychosocial transition support that includes individual counseling, and education/training for parent and school personnel
16621815|NCT02468505|No Intervention|TAU|typical transition services and supports
16621816|NCT02468492|Experimental|Platelet Rich Plasma|Approximately 5mL of intraarticular PRP once at baseline
16621817|NCT02468492|Other|Normal Saline|Approximately 5mL of intraarticular normal saline once at baseline
16621818|NCT02468466|Experimental|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
16621819|NCT02468466|Active Comparator|Community intervention as usual|Suicide prevention program as usual
16621820|NCT02468453|Experimental|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
16621821|NCT02468453|Experimental|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
16621822|NCT02468453|Experimental|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
16621823|NCT02468453|Experimental|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
16621824|NCT02468440|Experimental|ESPAIR|Patients with an educational therapy's program since registration in transplant list.
16621825|NCT02468440|No Intervention|normal care|Patients without educational therapy
16621826|NCT02468427|Experimental|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
16621827|NCT02468427|Active Comparator|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
16621828|NCT02468414|Experimental|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
16621829|NCT02468401|Experimental|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
16621830|NCT02468388|Experimental|maltitol|
16621831|NCT02468388|Active Comparator|xylitol|
16621832|NCT02468388|Placebo Comparator|gum base|
16621833|NCT02468388|No Intervention|no gum|
16621834|NCT02468375|Experimental|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
16621835|NCT02468362|Active Comparator|Laparoscopic group|
16621836|NCT02468362|Active Comparator|Open group|
16621837|NCT02468349|Experimental|Telemedicine|The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.
16621838|NCT02468349|No Intervention|Standard care|The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.
16621839|NCT02468336|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after BA occlusion by a standard upper arm sphygmomanometric blood pressure (BP) cuff. The procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis.
16621840|NCT02468336|Active Comparator|Brachial Artery Ultrasound Imaging|A non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery (BA) using high resolution continuous ECG-gated B-mode (2D) ultrasound imaging during reactive hyperemia, a state of transient increase in tissue blood flow that occurs following a brief period of ischemia, e.g., BA occlusion. BA diameter is measured at end-diastole, coincident with the R wave of a simultaneously recorded ECG.
16621841|NCT02468323|Placebo Comparator|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
16621842|NCT02468323|Experimental|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
16621843|NCT02468323|Experimental|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
16621844|NCT02468310|Experimental|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
16621845|NCT02468310|No Intervention|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
16621846|NCT02468297|Experimental|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
16621847|NCT02468297|Placebo Comparator|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
16621848|NCT02468284|Experimental|Degarelix|
16621849|NCT02468258|Active Comparator|endometrial flushing (A)|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected in a sterile container and was centrifuged at 600 rpm for 10 min at room temperature and a 5-ml sample of the supernatant was obtained for laboratory workup, while the remaining amount of supernatant was used to flush the endometrium through an applied uterine catheter in FF group and was discarded in the other group.
16621850|NCT02468258|No Intervention|B|no intervention Control group included 40 women would not have FF endometrial flushing.
16621924|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
16621851|NCT02468245|Active Comparator|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
16621852|NCT02468245|Experimental|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
16621853|NCT02468232|Experimental|LCZ696|Before randomization, all patients receive 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm will start with 100 mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 200 mg b.i.d. at week 4 if they are tolerant to 100 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
16621854|NCT02468232|Active Comparator|Enalapril|In double blind period, all randomized patients in this arm will receive enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 10 mg b.i.d. at week 4 if they are tolerant to 5 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
16621855|NCT02468219|Active Comparator|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
16621856|NCT02468219|Experimental|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
16621857|NCT02468206|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
16621858|NCT02468206|Active Comparator|NBCA|Endoscopic Cyanoacrylate injection in the gastric varix
16621859|NCT02468193|Experimental|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
16621860|NCT02468180|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
16621861|NCT02468180|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
16621862|NCT02468167|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
16621863|NCT02468167|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
16621864|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
16621865|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
16621866|NCT02468141|Experimental|SJDBT group|Herbal medicine
16621867|NCT02468141|Placebo Comparator|Placebo|Placebo control
16621868|NCT02468128|Experimental|SDE 150mg|Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)
16621869|NCT02468128|Placebo Comparator|placebo|Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)
16621870|NCT02468115|Experimental|VIS410|Single intravenous fixed dose of VIS410
16621871|NCT02468115|Placebo Comparator|Placebo|Single intravenous infusion of placebo
16621872|NCT02468102||Rivaroxaban / Cohort 1|Patients who have filled a prescription for rivaroxaban in any pharmacy in Sweden during the study period.
16621873|NCT02468102||Standard of care drugs / Cohort 2|Patients who have filled a prescription for standard of care drugs (warfarin, aspirin, clopidogrel, ticlopidine, prasugrel or ticagrelor) in any pharmacy in Sweden during the study period.
16621874|NCT02468089|Experimental|Carbepenem+albumin+GMCSF.|
16621875|NCT02468089|Active Comparator|Carbepenem+albumin|
16621876|NCT02468076|Experimental|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
16621877|NCT02468063|Experimental|Noradrenaline + low dose terlipressin|
16621878|NCT02468063|Active Comparator|Noradrenaline|
16621879|NCT02468050|Experimental|Self Management|In addition to the weekly supervised exercise session, participants in this arm will view an instructional video. The video will deliver theory driven training of cognitive behavioural strategies for self management of exercise. It is expected that this will improve adherence to the exercise program.
16621880|NCT02468050|Experimental|Exercise|Personalized 6 week moderate intensity (50 - 75% of heart rate reserve) facility and home based exercise program including cardiovascular and muscular conditioning.
16621881|NCT02468050|No Intervention|Prospective Cohort Control|Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
16621882|NCT02468037|Experimental|Phlebotomy|All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (<50 ng/mL for females and <70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described
16621883|NCT02468037|No Intervention|Control|Subjects receive counseling to follow a healthy diet and regular exercise.
16621884|NCT02468024|Active Comparator|Arm 1 lung surgery|Sublobar Resection (SR)
16621885|NCT02468024|Experimental|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
16621886|NCT02468011|Experimental|Vibration|Whole body vibration with 35 Hz
16621887|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
16621888|NCT02467985|No Intervention|Control|
16621889|NCT02467985|Experimental|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
16621890|NCT02467972|Experimental|UBF group|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
16621891|NCT02467972|Placebo Comparator|Control|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
16621892|NCT02467972|Experimental|Inulin group|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
16621893|NCT02467972|Experimental|Nisin group|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
16621894|NCT02467959||Ultrasound|Ultrasound evaluation
16621895|NCT02467946|Experimental|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
16621896|NCT02467933|Placebo Comparator|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
16621897|NCT02467933|Experimental|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
16621898|NCT02467920|Experimental|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
16621899|NCT02467920|Active Comparator|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
16621900|NCT02467907|Experimental|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
16621901|NCT02467894|Experimental|Group-based Care|Participants who are randomized to group-based care will attend monthly outpatient clinic visits as part of a group of 8-10 patients with CKD and hypertension.
16621902|NCT02467894|No Intervention|Usual Care|Participants who are randomized to usual care will see their provider on clinic days when there is no group meeting.
16621903|NCT02467881|Active Comparator|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
16621904|NCT02467881|Active Comparator|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
16621905|NCT02467881|Other|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
16621906|NCT02467868|Experimental|MYL-1401H|MYL-1401H
16621907|NCT02467868|Active Comparator|Neulasta|Neulasta
16621908|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
16621909|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
16621910|NCT02467842|Experimental|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
16621911|NCT02467842|Active Comparator|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
16621912|NCT02467842|Active Comparator|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
16621913|NCT02467829|No Intervention|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
16621914|NCT02467829|Experimental|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
16621915|NCT02467829|Experimental|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
16621916|NCT02467816|Experimental|School lunch intervention|Intervention schools (6 middle and 6 high) will receive the complete school lunch intervention for two school years.
16621917|NCT02467816|No Intervention|School lunch control|Control schools (6 middle and 6 high) will not receive the school lunch intervention for two school years. Lunch delivery will proceed as normal.
16621918|NCT02467803|Active Comparator|Intervention|We applied scapula mobilization with shoulder ROM exercises
16621919|NCT02467803|Other|Control|We applied only shoulder ROM exercises
16621920|NCT02467790|Experimental|Mild renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
16621921|NCT02467790|Experimental|Moderate renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
16621922|NCT02467790|Experimental|Normal renal function|PEX 168: 200µg,Subcutaneous,one time.
16621925|NCT02467738|Experimental|Cesium-131 Brachytherapy|Patients undergo brachytherapy using Cesium-131 during surgical resection
16621926|NCT02467725|Experimental|Dynamic Culture Platform|Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
16621927|NCT02467725|No Intervention|Static Culture|The embryos randomized to the static or control arm of the study will be placed directly into the incubator and will not have any additional vibration, per routine care. The embryos will be placed in the incubator at the two pronucleur stage of development and remain in the incubator until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
16621928|NCT02467686|Active Comparator|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.
~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.
~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.
~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
16621929|NCT02467686|Placebo Comparator|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.
~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.
~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
16621930|NCT02467673|Active Comparator|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.
~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
16621931|NCT02467673|Active Comparator|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.
~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
16621932|NCT02467660|Experimental|Online Mindfulness Meditation Training|Weekly 1-hr online training and daily meditation for 30-45 min for 6 wks
16621933|NCT02467660|Experimental|Online Health & Wellness Education|6-week training entails completing weekly 1-hour online training and listening to educational podcasts for 30-45 minutes per day
16621934|NCT02467660|No Intervention|Wait List Control|No training
16621935|NCT02467647|Experimental|A|Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
16621936|NCT02467647|Active Comparator|B|Arm B: Thalidomide 100mg oral once per day for 6 months
16621937|NCT02467634|Experimental|HuCNS-SC|HuCNS-SC sub-retinal transplantation
16621938|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
16621939|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
16621940|NCT02467608|Experimental|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.
~Dosage is as below:
~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
16621941|NCT02467608|Other|Isoniazid|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.
~Dosage is as below:
~Isoniazid (H):300mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
16621942|NCT02467595|Experimental|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group
~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1
~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.
~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .
~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
16621943|NCT02467595|Active Comparator|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group
~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1
~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.
~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .
~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
16621944|NCT02467595|Placebo Comparator|S group|"saline
~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.
~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.
~When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
16621945|NCT02467582|Experimental|Aspirin 100 mg|Asprin 100 mg daily for 3 years standard chemo if indicated
16621946|NCT02467582|Active Comparator|Placebo|Placebo daily for 3 years standard chemo if indicated
16621947|NCT02467569|Experimental|Hemay020|"Part one: Dose Escalation Group Hemay020 capsules will be taken orally in doses of 25mg, 50mg, 100mg, 200mg or 300mg once daily for 28 days.
~Part two: Extension Group Hemay020 capsules will be taken in two dose groups that assessed by Part one for 28 days."
16621948|NCT02467556|Other|intervention|Open label study with psychological intervention and physiotherapy intervention with medication of morphine, memantine for ten weeks (morphine 30mg tbl per day and memantine up to 40mg tbl per day if tolerated).
16621949|NCT02467543|Placebo Comparator|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
16621950|NCT02467543|Experimental|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
16621951|NCT02467530|Experimental|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
16621952|NCT02467530|No Intervention|Original diet|Patients will continue their original diet.
16621953|NCT02467517|Experimental|INTRAVENOUS KETAMINE|
16621954|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
16621955|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
16621956|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
16621957|NCT02467478|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
16621958|NCT02467478|Active Comparator|Linagliptin|Linagliptin 5mg once daily for 12 weeks
16621959|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
16621960|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
16621963|NCT02467439|Active Comparator|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
16621964|NCT02467439|No Intervention|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
16621965|NCT02467426||Chemotherapy|intraarterial chemotherapy with cisplatin and mitoxantrone
16621966|NCT02467413|Active Comparator|BAC treatment group|BAC, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
16621967|NCT02467413|Placebo Comparator|BAC Matched vehicle|BAC Matched vehicle, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
16621968|NCT02467400|Placebo Comparator|placebo|Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
16621969|NCT02467400|Active Comparator|Atenolol|Atenolol 50 mg 1/day for 20 weeks
16621970|NCT02467400|Active Comparator|Nebivolol|Nebivolol 5 mg/day for 20 weeks
16621971|NCT02467400|Active Comparator|Propranolol 40 mg|Propranolol 20 mg bid for 20 weeks
16621972|NCT02467400|Active Comparator|Propranolol 80 mg|Propranolol 40 mg bid for 20 weeks
16621973|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
16621974|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
16622007|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
16622008|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
16621975|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
16621976|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
16621977|NCT02467361|Experimental|Combo with Ipilimumab|
16621978|NCT02467361|Experimental|Combo with Nivolumab|
16621979|NCT02467361|Experimental|Combo with Pembrolizumab|
16621980|NCT02467348|Experimental|Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
16621981|NCT02467348|Active Comparator|No Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.
16621982|NCT02467335|Active Comparator|Healthy Subjects|Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.
16621983|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Mild Rating|Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
16621984|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Moderate Rating|Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
16621985|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Severe Rating|Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
16621986|NCT02467322|Experimental|Albumin|MVP (Moderate Volume Paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid.
16621987|NCT02467322|Active Comparator|No Albumin|MVP(Moderate Volume Paracentesis) of less than 5 liters without albumin.
16621988|NCT02467296|Active Comparator|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
16621989|NCT02467296|Active Comparator|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
16621990|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.
~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
16621991|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
16621992|NCT02467270|Experimental|Cohort A: Ponatinib 45 mg|Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
16621993|NCT02467270|Experimental|Cohort B: Ponatinib 30 mg|Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
16621994|NCT02467270|Experimental|Cohort C: Ponatinib 15 mg|Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle.
16621995|NCT02467257|Experimental|Intrevention arm|Patients received Gum Arabic as intervention
16621996|NCT02467244||Euthyroid group|Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
16621997|NCT02467244||Hypothyroid group|Fifty (50) hypothyroid patients attending the outpatient department of General Medicine, AIIMS, Bhubaneswar, will be recruited for the present study following inclusion and exclusion criteria.
16621998|NCT02467231||Exposed|Females ages 11-35 to be exposed to alkylating agent chemotherapy
16621999|NCT02467218|Experimental|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
16622000|NCT02467218|Experimental|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
16622001|NCT02467205|Other|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
16622002|NCT02467205|No Intervention|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
16622003|NCT02467192|Experimental|Low dose CT|All patients will have Thoracic CT scan
16622004|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
16622005|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
16622006|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
16622845|NCT02461823|Active Comparator|PFM Crown|A Porcelain metal crown will provided to patients.
16622009|NCT02467140|Active Comparator|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
16622010|NCT02467140|Active Comparator|Tack fixation|During surgery, the mesh will be fixated with tacks.
16622011|NCT02467127|No Intervention|control group|Patients without headache. No drugs will be administered
16622012|NCT02467127|Experimental|Chronic Headache|Patients with headache > 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
16622013|NCT02467127|Experimental|Chronic headache with drug overuse|Patients with headache > 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
16622014|NCT02467127|Experimental|Acute Headache|Patients without chronic headache but with an history of headache < 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
16622015|NCT02467114|Experimental|All study participants|Stimulation with TMS, a sham coil & no intervention
16622016|NCT02467101|Experimental|Corticosteroid/Saline|"Corticosteroid/Saline
~Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.
~In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).
~The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).
~This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6)."
16622017|NCT02467088|Experimental|Individualised Homoeopathic Remedy|Each participant will receive an individualised homoeopathic remedy, in a vehicle of sucrose pillules, according to the symptoms of their PMS. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing as outlined by De Schepper.
16622018|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
16622019|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
16622020|NCT02467062|Active Comparator|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
16622021|NCT02467062|Other|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
16622022|NCT02467049|Active Comparator|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
16622023|NCT02467049|Experimental|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
16622024|NCT02467036|Experimental|Family Based Behavioral Treatment Egg|The FBT+Egg group will participate in group-based FBT and will be assigned to eat eggs a minimum of 5 days a week for breakfast. Families are provided eggs each week to facilitate compliance, along with recipes
16622025|NCT02467036|Active Comparator|Family Based Behavioral Treatment Cereal|The FBT+Cereal group will participate in group-based FBT and will be assigned to eat cereal a minimum of 5 days a week for breakfast. Families are provided cereal each week to facilitate compliance.
16622026|NCT02467023|Experimental|effective muscle stimulation group|Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.
16622027|NCT02467023|Active Comparator|ineffective muscle stimulation group|Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.
16622028|NCT02467010|Experimental|Bortezomib, cyclophosphamide, dexamethason|"To assess the efficacy of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy.
~To assess the safety of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy in patients with refractory or relapsed multiple myeloma."
16622029|NCT02466997|Experimental|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
16622030|NCT02466997|Placebo Comparator|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.
~Counselling on natural light exposure during the duration of the trial will be given."
16622031|NCT02466984|Experimental|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
16622032|NCT02466984|Active Comparator|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
16622101|NCT02466490|Active Comparator|Fimasartan; Hydrochlorothiazide 60/12.5|FMS 60 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 4 weeks (treatment weeks 8 to 12)
16622035|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
16622036|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
16622037|NCT02466945|Other|V063B-DP3003|all patients will received the study product (V063B-DP3003)
16622038|NCT02466932||Birth Weight|
16622039|NCT02466919|Experimental|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10
16622040|NCT02466919|Active Comparator|Sequential|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10
16622041|NCT02466906|Experimental|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
16622042|NCT02466906|Placebo Comparator|placebo group|Placebo was injected subcutaneously perioperation.
16622043|NCT02466893|Other|ADAPT Technique/Standard SR Group|
16622044|NCT02466880|Experimental|Telemedicine|Diabetes education and support via telemedicine
16622045|NCT02466880|Active Comparator|Usual care|Diabetes education and support in person
16622046|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
16622047|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
16622048|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
16622049|NCT02466828|Experimental|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
16622050|NCT02466815|Experimental|Treatment A, then Treatment B and then Treatment C|Participants will receive treatment A (JNJ-42756493 10 milligram [mg] tablet, current clinical formulation [G-018] which uses milled active pharmaceutical ingredient [API]) in period 1, treatment B (JNJ-42756493 10 mg tablet, Prototype Formulation I [G-025] which uses coarser API) in period 2 and then treatment C (JNJ-42756493 10 mg tablet, Prototype Formulation II [G-025] which uses coarser API) in period 3.
16622051|NCT02466815|Experimental|Treatment B, then Treatment C and then Treatment A|Participants will receive treatment B in period 1, treatment C in period 2 and then treatment A in period 3.
16622052|NCT02466815|Experimental|Treatment C, then Treatment A and then Treatment B|Participants will receive treatment C in period 1, treatment A in period 2 and then treatment B in period 3.
16622053|NCT02466815|Experimental|Treatment A, then Treatment C and then Treatment B|Participants will receive treatment A in period 1, treatment C in period 2 and then treatment B in period 3.
16622054|NCT02466815|Experimental|Treatment B, then Treatment A and then Treatment C|Participants will receive treatment B in period 1, treatment A in period 2 and then treatment C in period 3.
16622055|NCT02466815|Experimental|Treatment C, then Treatment B and then Treatment A|Participants will receive treatment C in period 1, treatment B in period 2 and then treatment A in period 3.
16622056|NCT02466802|Experimental|A: regorafenib and sildenafil citrate|Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16622057|NCT02466776|Active Comparator|Stainless steel staples|Patients in this arm will receive stainless steel staples for skin closure at time of cesarean section.
16622058|NCT02466776|Active Comparator|Absorbable subcuticular Suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
16622059|NCT02466763|Active Comparator|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
16622060|NCT02466763|Active Comparator|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
16622061|NCT02466750|Experimental|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
16622062|NCT02466750|Experimental|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
16622063|NCT02466737|Experimental|no axillary surgery|
16622064|NCT02466737|Active Comparator|sentinel lymph node biopsy|standard arm in first randomization
16622065|NCT02466737|Experimental|sentinel lymph node biopsy alone|
16622066|NCT02466737|Active Comparator|completion axillary lymph node dissection|standard arm in second randomization
16622067|NCT02466724|Experimental|Web Group|Patients given web site (aiddly) instructions for colonoscopy
16622068|NCT02466724|No Intervention|Paper Group|Patients given paper instructions for colonoscopy
16622069|NCT02466711|Active Comparator|Relamorelin|
16622070|NCT02466711|Placebo Comparator|Placebo|
16622102|NCT02466490|Experimental|Fimasartan; Hydrochlorothiazide 120/12.5|FMS 120 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 12 weeks (treatment weeks 12 to 24)
16622071|NCT02466698|Experimental|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
16622072|NCT02466698|Active Comparator|Usual Care|Patients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
16622073|NCT02466685|Experimental|JNJ-18038683|Subjects will be randomized to receive JNJ-18038683 or placebo after the completion of the baseline assessments. Subjects randomized to JNJ-18038683 will receive 10 mg for one week, then titrate to 20 mg for the duration of the trial, with the provision for a single, downward dose adjustment for intolerance, based upon investigator judgment.
16622074|NCT02466685|Placebo Comparator|Placebo|Placebo treatment for 8 weeks.
16622075|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
16622076|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
16622077|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
16622078|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
16622079|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
16622080|NCT02466633|Experimental|Change in in-hospital cardiac monitoring method|Pre- and post-intervention, where the intervention is a change in in-hospital cardiac monitoring method
16622081|NCT02466607|Other|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
16622082|NCT02466607|Other|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
16622083|NCT02466594|Other|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
16622084|NCT02466581|Active Comparator|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:
~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids
~Cimzia plus Methotrexate and steroids
~Orencia plus Methotrexate and steroids
~RoActemra plus Methotrexate and steroids
~This intervention is de-escalated starting at randomization."
16622085|NCT02466581|Active Comparator|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:
~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids
~Cimzia plus Methotrexate and steroids
~Orencia plus Methotrexate and steroids
~RoActemra plus Methotrexate and steroids
~This intervention is de-escalated starting 24 weeks after randomization."
16622086|NCT02466568|Experimental|Phase I and Phase II Treatment Arm|Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.
16622087|NCT02466568|Active Comparator|Phase II Control Arm|Nivolumab treatment without GM.CD40L. Nivolumab will be given every 2 weeks at a dose of 3mg/kg.
16622088|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
16622089|NCT02466542|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
16622090|NCT02466542|Active Comparator|Esmolol group|Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
16622091|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
16622092|NCT02466516|Experimental|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
16622093|NCT02466516|Experimental|SEL 18 mg|SEL 18 mg for 24 weeks.
16622094|NCT02466516|Experimental|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
16622095|NCT02466516|Experimental|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
16622096|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks.
16622097|NCT02466503|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
16622098|NCT02466503|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
16622099|NCT02466490|Experimental|Fimasartan 60 mg Tablets|FMS 60 mg tablets once a day during the initial 8 treatment weeks of the study
16622100|NCT02466490|Active Comparator|Fimasartan 120 mg Tablets|FMS 120 mg tablets once a day during 4 weeks (treatment weeks 8 to 12)
16622158|NCT02466087|No Intervention|Control|No intervention
16622103|NCT02466477|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
16622104|NCT02466477|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
16622105|NCT02466477|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.
~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
16622106|NCT02466464|Active Comparator|Microporous Polysaccharide Hemospheres (MPH)|Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
16622107|NCT02466464|Active Comparator|Merocel (Control)|Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
16622108|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, >4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
16622109|NCT02466438|Experimental|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).
~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.
~Patients with Normal Renal function:
~Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)
~Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)
~Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)
~Patients with Acute Kidney injury:
~Pediatric and surgery units: 2 months-6 years (10)
~PICU: 2 months-6 years (10)
~Haematology-oncology unit: 2 months-6 years (10)"
16622110|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
16622111|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
16622112|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:
~Day -1 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of CHTP 1.1 M)
~Day 2 = Wash-out
~Day 3 = 2nd intervention (single product use of mCC)."
16622113|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:
~Day -1 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mCC)
~Day 2 = Wash-out
~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
16622114|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
16622115|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
16622116|NCT02466386|Experimental|SPD489|Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
16622117|NCT02466373|No Intervention|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
16622118|NCT02466373|Experimental|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
16622119|NCT02466373|Experimental|Clonidine 1200mcg|"4 patients receive 1200 µg/day of clonidine without loading schedule.
~4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
16622120|NCT02466373|Experimental|Clonidine 1800mcg|"4 patients receive 1800 µg/day of clonidine without loading schedule.
~4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
16622121|NCT02466360||chronic lower back pain|
16622122|NCT02466347|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
16622123|NCT02466347|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
16622124|NCT02466334|Active Comparator|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
16622125|NCT02466334|Placebo Comparator|Placebo|IV placebo for 20 minutes
16622126|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
16622127|NCT02466308|Experimental|SAM Ultrasound Diathermy Device|SAM (sam Professional System) 3 MHz ultrasound diathermy device: 4 hours/day, at least 5 days per week, for 6 weeks
16622128|NCT02466295|Experimental|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
16622129|NCT02466295|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
16622130|NCT02466282|Active Comparator|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
16622131|NCT02466282|Experimental|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
16622132|NCT02466269||the preauricular approach|A classic preauricular incision was used to treat diacapitular condylar fractures
16622133|NCT02466256|Placebo Comparator|Autosert Group|Procedure / Surgery : Intraocular lens implantation with Autosert injector
16622134|NCT02466256|Placebo Comparator|Royale Group|Procedure / Surgery : Intraocular lens implantation with Royale Injector
16622135|NCT02466256|Placebo Comparator|Monarch III Injector|Procedure / Surgery : Intraocular lens implantation with Monarch III group
16622136|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.
~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
16622137|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.
~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
16622138|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
16622139|NCT02466217||1: AID groups|Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes
16622140|NCT02466217||2: Control groups|knee arthritis, hip arthritis, muscular dystrophy, healthy subject
16622141|NCT02466204|Active Comparator|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
16622142|NCT02466204|Active Comparator|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
16622143|NCT02466191|Experimental|memantine first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
16622144|NCT02466191|Experimental|gabapentin first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
16622145|NCT02466178||Serene RF System|Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.
16622146|NCT02466165|Experimental|MS patients intervention group|the feasibilty and influence of high intense interval exercise on the cardiometabolic risk state in MS patients will be investigated in a pilot trial.
16622147|NCT02466165|No Intervention|healthy controls|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
16622148|NCT02466165|No Intervention|larger group of MS patients|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
16622149|NCT02466152|Experimental|GSK2894512 2.0% Cohort|Subjects will apply a thin layer of GSK2894512 2.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
16622150|NCT02466152|Experimental|GSK2894512 1.0% Cohort|Subjects will apply a thin layer of GSK2894512 1.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
16622151|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
16622152|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
16622153|NCT02466113|Experimental|An experimental group|A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
16622154|NCT02466113|Other|A control group|A classic stratified tool is applied in this group. Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
16622155|NCT02466100|Experimental|Goc Intervention|Patient education materials, study nurse phone call, tip sheet, provider tip sheet
16622156|NCT02466100|No Intervention|usual care|care as usual in the community
16622157|NCT02466087|Experimental|Mg Cl|500mg Mg Cl per day for 6 weeks
16622159|NCT02466074|Experimental|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
16622160|NCT02466074|Placebo Comparator|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
16622161|NCT02466061|Experimental|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.
~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).
~Month 12 followup weight data also will be collected through medical record abstraction."
16622162|NCT02466061|Experimental|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.
~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).
~Month 12 follow up weight data also will be collected through medical record abstraction."
16622163|NCT02466061|Active Comparator|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.
~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).
~Month 12 follow up weight data also will be collected through medical record abstraction."
16622164|NCT02466048|Experimental|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
16622165|NCT02466048|Active Comparator|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
16622166|NCT02466035|Experimental|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
16622167|NCT02466035|No Intervention|Other formula|Children assuming other hypoallergenic formulas
16622168|NCT02466022|Experimental|Dexmedetomidine|Patients will receive one 0.5ug/kg bolus of Dexmedetomidine over 10 minutes for sedation prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
16622169|NCT02466022|Placebo Comparator|Normal Saline|Patients will receive 0.1cc/kg Normal Saline bolus delivered over 10 minutes for control arm prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
16622170|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)
~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
16622171|NCT02465996|Other|postprandial distress syndrome (PDS)|"FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).
~pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination."
16622172|NCT02465996|Other|epigastric pain syndrome (EPS)|pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.
16622173|NCT02465983|Experimental|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
16622174|NCT02465970|Experimental|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
16622175|NCT02465970|Placebo Comparator|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
16622176|NCT02465957|Experimental|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
16622177|NCT02465944|Experimental|FFP104 - 2.5 mg/kg|FFP104
16622178|NCT02465944|Experimental|FFP104 - 5.0 mg/kg|FFP104
16622179|NCT02465944|Placebo Comparator|Placebo|Placebo
16622180|NCT02465931|Other|Comparison Condition|Paper and pencil informed consent
16622181|NCT02465931|Experimental|Intervention condition|Digital informed consent tool
16622182|NCT02465918|Active Comparator|Original Setting- MCS 30 min off/0 min off|Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.
16622183|NCT02465918|Experimental|MCS 25 min on/5 min off|Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.
16622184|NCT02465918|Experimental|MCS 20 min on/10 min off|Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.
16622185|NCT02465918|Experimental|MCS 15 min on/15 min off|Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.
16622186|NCT02465905|Active Comparator|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
16622187|NCT02465905|Active Comparator|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
16622188|NCT02465892|No Intervention|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
16622189|NCT02465892|Experimental|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
16622190|NCT02465879|Experimental|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
16622191|NCT02465866|Experimental|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
16622192|NCT02465866|Experimental|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
16622193|NCT02465866|Active Comparator|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
16622194|NCT02465866|Active Comparator|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
16622195|NCT02465853|Placebo Comparator|Placebo group|Injection 0.9% Physiological saline solution<2.5 ml and physical therapy and occupational therapy
16622196|NCT02465853|Experimental|Hyaluronic Acid|injection Hyaluronic Acid 2.5ml and physical therapy and occupational therapy
16622197|NCT02465840|Placebo Comparator|Immobilization programs|custom-made protective hand splint physical therapy and occupational therapy
16622198|NCT02465840|Experimental|Kleinert programs|custom-made dynamic hand splint physical therapy and occupational therapy
16622199|NCT02465827|Active Comparator|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.
~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
16622200|NCT02465827|Active Comparator|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
16622201|NCT02465827|Placebo Comparator|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
~Saline for nerve blockades for both nerves mentioned."
16622202|NCT02465814|Experimental|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
16622203|NCT02465814|Experimental|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
16622204|NCT02465814|Experimental|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
16622205|NCT02465814|Experimental|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
16622206|NCT02465814|Active Comparator|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
16622207|NCT02465814|Active Comparator|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
16622208|NCT02465814|Active Comparator|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
16622209|NCT02465801|Experimental|Group 1|"Intervention: HSA-GCSF 1.2 mg
~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
16622210|NCT02465801|Experimental|Group 2|"Intervention:HSA-GCSF 1.5 mg
~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.
~Intervention: Drug: TE or TEC"
16622211|NCT02465801|Active Comparator|Group 3|"Intervention: GCSF
~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o'clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.
~Intervention: Drug: TE or TEC"
16622212|NCT02465788|Experimental|755nm alexandrite laser with bipolar RF|GentleTouch (Helos) combines 755nm alexandrite laser energy with bipolar RF energy.
16622213|NCT02465775|Experimental|UltraShape treatment in all subjects|UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
16622214|NCT02465762|Experimental|ultrashape fat reduction treatment|all patient undergo non-invasive fat and circumference reduction at the flanks area
16622215|NCT02465749|Experimental|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
16622216|NCT02465749|Experimental|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
16622217|NCT02465749|Experimental|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
16622218|NCT02465749|Other|control|Routine drug treatment
16622219|NCT02465736|Experimental|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.
~Interventions:
~Radiation: (44 Gy/20 fractions)
~Drug: Docetaxel
~Drug: Cisplatin"
16622220|NCT02465736|Experimental|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.
~Interventions:
~Radiation: (44 Gy/20 fractions)
~Drug: Vinorelbine
~Drug: Cisplatin"
16622846|NCT02461810|Experimental|SpineJack® system|VCF treatment system Vertebral fracture surgery
16622221|NCT02465723|Experimental|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
16622222|NCT02465710||pelvic organ prolapse|All women who underwent surgical treatment of pelvic organ prolapse in this study.
16622223|NCT02465697|Experimental|BPD Emotion Regulation Training|Guided practice in reappraisal
16622224|NCT02465697|No Intervention|BPD Control|no training in reappraisal
16622225|NCT02465697|Experimental|APD Emotion Regulation Training|Guided practice in reappraisal
16622226|NCT02465697|No Intervention|APD Controls|no training in reappraisal
16622227|NCT02465697|Experimental|Healthy Controls Emotion Regulation Training|Guided practice in reappraisal
16622228|NCT02465697|No Intervention|Healthy Controls|no training in reappraisal
16622229|NCT02465684|Experimental|tourniquet|UKA surgery with tourniquet
16622230|NCT02465684|Experimental|no tourniquet|UKA without tourniquet
16622231|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
16622232|NCT02465645|Experimental|Carvedilol + Simvastatin|"Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
~Simvastatin will be administered orally at a start dose of 20 mg for 15 days followed by 40 mg OD for the next 3 months. Along with Simvastatin, Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min."
16622233|NCT02465645|Active Comparator|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
16622234|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
16622235|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
16622236|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
16622237|NCT02465619||Severe acute hepatitis|Severe acute hepatitis without ascites.
16622238|NCT02465619||Non-cirrhotic|
16622239|NCT02465619||Cirrhotic patients with ascites|
16622240|NCT02465619||decompensated cirrhosis|
16622241|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
16622242|NCT02465606|Active Comparator|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
16622243|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
16622244|NCT02465580|Active Comparator|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
16622245|NCT02465580|Placebo Comparator|hrIL-2 placebo|1 million U doses of placebo s.c. injection
16622246|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
16622247|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
16622248|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
16622249|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
16622250|NCT02465554||No atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of 0. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into No atherosclerosis/endothelial function normal and No atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
16622251|NCT02465554||Atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into atherosclerosis/endothelial function normal and atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
16622252|NCT02465541|Experimental|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
16622253|NCT02465541|Active Comparator|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
16622254|NCT02465528|Experimental|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
16622255|NCT02465528|Experimental|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
16622256|NCT02465528|Experimental|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
16622257|NCT02465528|Experimental|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
16622258|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
16622259|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
16622260|NCT02465502|Experimental|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
16622261|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
16622262|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
16622263|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
16622264|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
16622265|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
16622266|NCT02465476|No Intervention|normal care|patient who will have normal treatment pathway
16622267|NCT02465476|Experimental|telemedicine|patient who will have telemedicine
16622268|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
16622269|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
16622270|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
16622271|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
16622272|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
16622273|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
16622274|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
16622275|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
16622276|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
16622277|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
16622278|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
16622279|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
16622280|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
16622281|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
16622282|NCT02465411|Experimental|Long-term CGM|Continuous glucose monitoring with DexCom G4 platina or later generations during 12 months following participation in the CGMMDI trial
16622283|NCT02465398|Other|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
16622284|NCT02465385|Experimental|Intervention|Linaclotide 290mcg
16622285|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
16622286|NCT02465372|No Intervention|Control|Standard practice.
16622287|NCT02465359|Experimental|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
16622288|NCT02465346|Experimental|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-> primary hospital with regional stroke unit.
16622289|NCT02465346|Active Comparator|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
16622290|NCT02465333|Other|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:
~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
16622291|NCT02465333|Other|Pathway B|"Screening visit followed by:
~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A
~Heel fat grafting procedure and local anesthetic and visits at:
~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
16622292|NCT02465320|Active Comparator|COL-1077|lidocaine bioadhesive gel, 10%
16622293|NCT02465320|Placebo Comparator|Placebo|placebo bioadhesive gel
16622294|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
16622295|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
16622296|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
16622297|NCT02465294|Placebo Comparator|Potato starch and magnesium stearate|This arm will be used as a control to asses the efficacy of the other probiotic arms. The placebo will contain encapsulated potato starch and magnesium stearate which is used the matrix in the probiotic supplements. The placebo refers only to the intervention supplement, not the behavioral lifestyle intervention. All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
16622298|NCT02465294|Experimental|Lactobacillus|Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
16622299|NCT02465294|Experimental|Mix of Bifidobacterium and Lactobacillus|A blend of Bifidobacterium and Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
16622300|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
16622301|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
16622302|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
16622303|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
16622304|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
16622305|NCT02465255|Experimental|Ketorolac|Ketorolac 0.5 mg/kg administrated by sublingual route
16622306|NCT02465255|Active Comparator|Tramadol|Tramadol 2.0 mg/kg administrated by sublingual route
16622307|NCT02465255|Active Comparator|Acetaminophen (paracetamol)|Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route
16622308|NCT02465242||NPi greather than 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi greater than 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
16622309|NCT02465242||NPi less than or equal to 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi less than or equal to 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
16622310|NCT02465229|Experimental|Diagnostic methods of indeterminate biliary stricture|
16622311|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
16622312|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
16622313|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
16622314|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
16622315|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
16622316|NCT02465203|Other|Follow up from feeder studies|Follow up arm
16622317|NCT02465164|Other|Cook catheter|Control
16622318|NCT02465164|Active Comparator|Cook catheter plus low dose oxytocin|Test group
16622319|NCT02465151|Experimental|No Protein|
16622320|NCT02465151|Experimental|Low Protein|
16622321|NCT02465151|Experimental|Medium Protein|
16622322|NCT02465151|Experimental|High Protein|
16622323|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
16622324|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
16622325|NCT02465125|Active Comparator|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
16622326|NCT02465125|Active Comparator|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
16622327|NCT02465112|Experimental|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
16622328|NCT02465112|Active Comparator|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
16622329|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
16622330|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
16622331|NCT02465086|Experimental|Training|This arm, which is a half of the sample size, will be receiving training of linguistic recursion
16622332|NCT02465086|No Intervention|No training|The no intervention group, which is a half of the sample size, will not be recieving training in linguistic recursion.
16622333|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
16622334|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
16622335|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
16622374|NCT02465047|Experimental|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
16622375|NCT02465047|No Intervention|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
16622376|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
16622377|NCT02465034|Active Comparator|Healthy Control|Healthy individuals matched for age, gender and handedness with the subcortical stroke group will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
16622378|NCT02465021|Experimental|Snack bar 1|Dietary intervention: 190 Kcal, 12g fat, 14g carbohydrate, 5g fibre, 6g sugar, 10g protein
16622379|NCT02465021|Experimental|Snack bar 2|Dietary intervention: 200 Kcal, 15g fat, 12g carbohydrate, 5g fibre, 4g sugar, 8g protein
16622380|NCT02465021|Experimental|Snack bar 3|Dietary intervention: 210 Kcal, 16g fat, 12g carbohydrate, 2g fibre, 6g sugar, 6g protein
16622381|NCT02465021|Experimental|Control 1|Dietary intervention: Water (500 g)
16622382|NCT02465021|Experimental|Control 2|Dietary intervention: White bread (190 Kcal, 2g fat, 37g carbohydrate, 2g fibre, 3g sugar, 6g protein)
16622847|NCT02461810|Active Comparator|Balloon Kyphoplasty|VCF treatment system Vertebral fracture surgery
16622383|NCT02465021|Experimental|Control 3|Dietary intervention: Soft baked pretzel (190 Kcal, 2g fat, 38g carbohydrate, 2g fibre, 6g sugar, 4g protein)
16622384|NCT02465008|Experimental|levobupivaciane group|Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
16622385|NCT02465008|Placebo Comparator|Placebo Comparator (saline solution)|Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
16622386|NCT02464995|Experimental|Thermoplasty group|Procedure: Bronchial thermoplasty with the Alair System and conventional therapy
16622387|NCT02464995|No Intervention|Control group|Conventional therapy
16622388|NCT02464982||Women with 1 year non-invasive technology areola tattoo|Women with 1 year non-invasive technology areola tattoo realized in standard care as part of 1 breast mammary reconstruction following an operated breast cancer
16622391|NCT02464930||No-GERD Controls|"NERD controls will be enrolled from subjects presenting to the endoscopy unit who are being evaluated for reasons other than GERD or BE surveillance. These are patients who are referred to the endoscopy unit for: evaluation of anemia, dysphagia, occult blood positivity, gastrointestinal blood loss etc.
~No history of GERD
~Response no to presence of symptoms on a standardized GERD questionnaire
~No prescriptions for acid suppressive medication over the past 2 years as documented in electronic pharmacy records.
~Normal endoscopy that does not find Barrett's esophagus, hiatus hernia or erosive esophagitis."
16622392|NCT02464930||GERD Controls|"Respond yes to the presence of symptoms on a standardized GERD questionnaire
~Prescriptions for acid suppressive medication as documented in electronic pharmacy records."
16622393|NCT02464930||BE Cases|• Patients who present for evaluation of reflux symptoms and are found to have at least 1 cm of columnar lined esophagus on endoscopy with intestinal metaplasia on biopsies. This will include patients with esophageal adenocarcinoma
16622394|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
16622395|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
16622396|NCT02464904|Experimental|Cryotherapy|Cryospray and biopsies
16622397|NCT02464904|Other|Control|Biopsies
16622398|NCT02464891|Experimental|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
16622399|NCT02464865|Experimental|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
16622400|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
16622401|NCT02464865|Experimental|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
16622402|NCT02464852|Other|Snood|All recruited participants will try out the snood
16622403|NCT02464839||Hallux valgus patients|All of participants will perform a potassium hydroxide (KOH) examination and fungal culture to prove a fungal nail and feet fungal infection
16622404|NCT02464826|Experimental|Edit arms|Nailprotex apply to the abnormal nail twice daily
16622405|NCT02464813|Active Comparator|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
16622406|NCT02464813|Placebo Comparator|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
16622407|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
16622408|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
16622409|NCT02464787|Experimental|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
16622410|NCT02464774|Experimental|Breast-Conserving Therapy|"Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:
~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.
~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.
~Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:
~N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes."
16622411|NCT02464774|Active Comparator|Mastectomy|"Patients undergo mastectomy (MT) with surgical axillary staging.
~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:
~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.
~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles."
16622412|NCT02464761|Experimental|Dose escalating PDT|
16622443|NCT02464618|No Intervention|Usual care|The social contact of patients in this arm will not be contacted
16622413|NCT02464748|Experimental|Intervention|Patients and their primary carer will use a weekly telehealth system. This involves a series of questions on a tablet computer that is transmitted to their regional MND care centre for review and action.
16622414|NCT02464748|No Intervention|Control|Usual care
16622415|NCT02464722|Experimental|Dexmedetomidine|"Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.
~Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1
~After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done
~Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.
~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
~At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
16622416|NCT02464722|Active Comparator|Remifentanil|"Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1
~Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.
~After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.
~Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.
~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
~At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
16622417|NCT02464709|Experimental|Actinic keratosis patients|Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
16622418|NCT02464696|Experimental|Arm A (NIPPV therapy)|Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
16622419|NCT02464696|Active Comparator|Arm B (high flow oxygen therapy)|Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
16622420|NCT02464683|Placebo Comparator|Placebo|The patient will take a single tablet of placebo daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
16622421|NCT02464683|Experimental|VitaminD|The patient will take a single tablet of Vitamin D (200 International Units) daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
16622422|NCT02464670|Experimental|Group 1|INO-4201 IM + EP, 2 mg, 3 doses
16622423|NCT02464670|Experimental|Group 2|INO-4202 IM + EP, 2 mg, 3 doses
16622424|NCT02464670|Experimental|Group 3|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
16622425|NCT02464670|Experimental|Group 4|INO-4212 IM + EP, 4 mg, 3 doses
16622426|NCT02464670|Experimental|Group 5|INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
16622427|NCT02464670|Experimental|Group 6|INO-4201 ID + EP 0.2A, 1 mg, 3 doses
16622428|NCT02464670|Experimental|Group 7|INO-4201 ID + EP 0.2A, 2 mg, 2 doses
16622429|NCT02464670|Experimental|Group 8|INO-4201 ID + EP 0.2A, 1 mg, 2 doses
16622430|NCT02464670|Experimental|Group 9|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
16622431|NCT02464670|Experimental|Group 10|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
16622432|NCT02464670|Experimental|Group 11|INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
16622433|NCT02464670|Experimental|Part II: Group 3A|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
16622434|NCT02464670|Experimental|Part II: Group 3B|INO-4201 ID + EP 0.1A, 2 mg, 3 doses
16622435|NCT02464657|Experimental|Ph 1 Nivolumab (1mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
16622436|NCT02464657|Experimental|Ph 1 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
16622437|NCT02464657|Experimental|Ph 2 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase II dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
16622438|NCT02464644|Experimental|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.
~They will be directed to appropriate questions, according to answers to the previous questions."
16622439|NCT02464644|Other|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.
~They will be directed to appropriate questions, according to answers to the previous questions."
16622440|NCT02464631|Active Comparator|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
16622441|NCT02464631|Experimental|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
16622442|NCT02464631|Experimental|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
16622444|NCT02464618|Active Comparator|Social contact intervention|The social contact of patients in this arm will be contacted and asked to facilitate the endoscopy care plan of the patient
16622445|NCT02464605|Experimental|SEL-037 (pegsiticase)|Pegylated uricase
16622446|NCT02464592|Active Comparator|Biopsy with Cryoprobes|Transbronchial lung biopsy with a cryoprobe.
16622447|NCT02464592|Active Comparator|Biopsy with Conventional Forceps|Transbronchial lung biopsy with conventional forceps.
16622448|NCT02464566|Experimental|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).
~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:
~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
16622449|NCT02464566|Active Comparator|C Group|One session regarding diet restriction and physical activity with printed health education papers.
16622450|NCT02464553|Experimental|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
16622451|NCT02464553|Experimental|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
16622452|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
16622453|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
16622454|NCT02464527|Experimental|Stimulus-stimulus pairing (SSP)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
16622455|NCT02464527|Active Comparator|Waitlist Control (Delayed Treatment)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations will be randomly assigned to the Waitlist Control group. During the waitlist control subject's assigned session block of six weeks, s/he will not receive any treatment. The subjects will receive the stimulus-stimulus pairing procedure (delayed procedure) after the completion of the assigned 6-week block as a waitlist control participant. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
16622456|NCT02464514|Other|Healthy obese children|High carbohydrate meal High fat meal
16622457|NCT02464514|Other|Children with Prader Willi Syndrome|High carbohydrate meal High fat meal
16622458|NCT02464501|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
16622459|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
16622460|NCT02464475|Experimental|OMT|
16622461|NCT02464475|Sham Comparator|Sham|
16622462|NCT02464462|Experimental|CaD Group|This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium
16622463|NCT02464462|Placebo Comparator|Placebo Group|This arm received rice powder pills
16622464|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
16622465|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
16622466|NCT02464436|Experimental|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
16622467|NCT02464423|No Intervention|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
16622468|NCT02464423|Active Comparator|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
16622469|NCT02464410|Experimental|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
16622470|NCT02464410|Active Comparator|Enhanced Usual Care|In addition to covering the VHA's long-term OA informed consent process, the enhanced usual care (EUC) condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic. This EUC condition will include some information related to risks of opioid use as part of the informed consent and will consequently have sufficient face validity as an intervention on opioid safety to effectively blind participant to randomization. However, the EUC therapist will not use the motivational enhancement approach of discussing strategies for avoiding these risks. It is designed to be equal in length to the motivational intervention.
16622471|NCT02464397|Experimental|OPTIMAX-BAS 1|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 1 month after the index procedure.
16622643|NCT02463110|Other|3: Control|ACS, no depression, no treatment
16622472|NCT02464397|Active Comparator|SYNERGY-EES 1|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
16622473|NCT02464397|Experimental|OPTIMAX-OCT 6|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 6 months after the index procedure.
16622474|NCT02464397|Active Comparator|SYNERGY-EES 6|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 6 months after the index procedure.
16622475|NCT02464384|Other|cohort study|Collection of blood samples and ultrasound / MRI and x-ray examination.
16622476|NCT02464371||ICU acquired muscle weakness (IAMW) group +|"The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).
~Kinetic of microRNAs is measured"
16622477|NCT02464371||ICU acquired muscle weakness (IAMW) group -|The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured
16622478|NCT02464358|Experimental|IMB Intervention Group|"The IMB group received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, they received the following:
~Additional educational content related to HPV, Cervical Cancer, and HPV vaccination,
~Motivational content to help identify and problem-solve benefits and barriers to vaccination,
~Skills-building content, including brief communication skills training and ways to access the vaccine."
16622479|NCT02464358|Active Comparator|Attention Control Group|The attention control group also received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, to maintain consistency with the treatment's presentation format, participants watched a set of short video clips encompassing aspects of women's general and sexual health.
16622480|NCT02464345|Experimental|HAPIFED|HAPIFED therapy
16622481|NCT02464345|Active Comparator|CBT-E|CBT-E therapy
16622482|NCT02464332|Experimental|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.
~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.
~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
16622483|NCT02464319|Active Comparator|Experimental: hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
16622484|NCT02464319|Placebo Comparator|Placebo Comparator: hrIL-2 placebo|1 million U doses of placebo s.c. injection
16622485|NCT02464306|Experimental|SOT Recipients|SOT recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with a first-episode of CDI. Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days. The rate of sustained clinical response (SCR; cure without recurrence at 30 days) will be assessed.
16622486|NCT02464306|No Intervention|Historical Cohort|Historical cohort of SOT recipients who received standard of care therapy for CDI at our institution.
16622487|NCT02464293|Experimental|mindfulness-based cognitive therapy|
16622488|NCT02464280||Patients scheduled for lung imaging|"Patients with lung changes and scheduled for lung imaging will undergo:
~the scheduled conventional X-ray examination
~the scheduled CT scan
~the tomosynthesis scan"
16622489|NCT02464280||Patients scheduled for wrist imaging|"Patients with wrist fracture or with osteoprotetic material in the wrist and scheduled for wrist imaging will undergo:
~the scheduled conventional X-ray examination
~the scheduled CT scan
~the tomosynthesis scan"
16622490|NCT02464254|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
16622491|NCT02464254|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
16622492|NCT02464241||normal control|normal control
16622493|NCT02464241||patients|patients with optic or macular pathology or amblyopia
16622494|NCT02464228|Experimental|Tipifarnib|tipifarnib, oral
16622495|NCT02464215|Active Comparator|open surgery|Conventional procedure,Open surgery
16622496|NCT02464215|Experimental|laparoscopic surgery|Minimum invasive procedure，Laparoscopic surgery
16622497|NCT02464202|Experimental|stereolithography tooth replica|stereolithographic tooth replica used as a guide for tooth autotransplantation decreases extra-alveolar time and reduces trauma to periodontal ligament tissue therefore increasing the success rate after transplantation
16622498|NCT02464189||Children with asthma|
16622499|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
16622500|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
16622501|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
16622502|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
16622503|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
16622504|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
16622505|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
16622506|NCT02464150|Experimental|Participants|Participants are subjected to gluten intervention in an unblinded fashion.
16622507|NCT02464137|Experimental|Radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
16622508|NCT02464124|Experimental|lactulose plus nitazoxanide|"Nitazoxanide dosing: 500 mg tablets twice daily
~Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day"
16622509|NCT02464124|Active Comparator|Lactulose alone|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
16622510|NCT02464111|Experimental|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
16622511|NCT02464111|Experimental|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
16622512|NCT02464111|Experimental|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
16622513|NCT02464111|Experimental|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
16622514|NCT02464111|Experimental|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
16622515|NCT02464111|Experimental|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
16622516|NCT02464098||Group 1|Participants with diagnosis of hematological malignancy or solid tumor.
16622517|NCT02464098||Group 2|Participants undergoing hematopoietic stem cell transplantation (HSCT).
16622518|NCT02464085||Longitudinal evaluation of recovery|Stroke survivors with subacute and severe upper limb disability
16622519|NCT02464072|Experimental|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
16622520|NCT02464072|Active Comparator|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
16622521|NCT02464072|Experimental|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
16622522|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
16622523|NCT02464046|Experimental|JNJ-42847922 then Placebo|Participants receive 2*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
16622524|NCT02464046|Experimental|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
16622525|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
16622526|NCT02464020|Experimental|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
16622527|NCT02464020|No Intervention|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
16622528|NCT02464007|Experimental|sSIFN-co|Dose escalation of rSIFN-co
16622529|NCT02463994|Experimental|MPDL3280A + HIGRT|
16622530|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
16622531|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
16622532|NCT02463968||CHRONIC CHIKUNGUNYA|Twenty participants with chronic chikungunya defined as continued knee joint effusion at least three months after diagnosis of chikungunya will be enrolled in the study.
16622533|NCT02463968||ACUTE CHIKUNGUNYA|Ten participants with acute chikungunya defined as clinical symptoms of chikungunya with acute fever and joint pain within 10 days the onset of symptoms.
16622534|NCT02463968||HEALTHY CONTROLS|Five healthy controls will have only blood drawn once.
16622535|NCT02463955|Experimental|Thoracoscopy|"experimental intervention (flexible video endoscope)
~reference procedure (video-rigid thoracoscope)"
16622536|NCT02463942|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
16622537|NCT02463942|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
16622538|NCT02463942|Other|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
16622539|NCT02463929|Experimental|diphenhydramine|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5mg/kg diphenhydramine intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
16622540|NCT02463929|Placebo Comparator|control|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5cc/kg normal saline intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
16622541|NCT02463916|Active Comparator|Immediate exercise|This group will immediately commence an 8 week exercise programme.
16622848|NCT02461797|Other|healthy controls|biopsy of nasal mucosa healthy controls
16622542|NCT02463916|Active Comparator|Delayed exercise|This group will continue regular activities for 8 weeks and then commence 8 week exercise programme.
16622543|NCT02463903|Experimental|Coping effectiveness Training (CET)|The intervention consists of Coping Effectiveness Training (CET), a manual-based group intervention based on a cognitive transactional theory of stress and coping. The purpose of CET is to improve skills to appraise stress, teach a number of techniques to cope with stress, and to give an opportunity to interact with other people with similar experiences of living with CHF. The CET program will, in this study, be modified for patients with CHF. The intervention consists of seven, 90-minute weekly sessions led by a nurse with a Masters degree in nursing science and extensive experience in heart failure care in collaboration with a professional psychologist. Each group consisted of 8 to 12 patients.
16622544|NCT02463903|No Intervention|Control|The control group will receive standard health care and will not take part of the intervention.
16622545|NCT02463890|Experimental|Training|"In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
16622546|NCT02463890|Other|Control|In this group, patients will receive only diets and physical activity counselling
16622547|NCT02463877|Other|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
16622548|NCT02463864|Experimental|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
16622549|NCT02463864|Sham Comparator|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
16622550|NCT02463851|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
16622551|NCT02463851|Active Comparator|AF-Ablation with Contact Force single-tip electrode|Regular AF-ablation with a regular Contact Force single-tip ablation catheter
16622552|NCT02463838|Experimental|Care Support Intervention|Eligible members are assigned a CareSupport Coordinator who carries a caseload of 25-35 members. A team of 5 Coordinators is supervised by a master's level Social Worker. Community Coordinators work with members to conduct standardized assessments to develop a Care Plan shared with other providers within and outside of SFHP. Coordinators provide members advocacy and navigation across systems of care, to improve coordination focus on treatment goals. Coordinator focus on prevention and early intervention around disease management, advocacy, appointment reminders and accompaniment, home visits, and regular communication with primary care and other providers. Coordinators are encouraged to be accountable for coordinating and following through on all aspects of a member's needs.
16622553|NCT02463838|No Intervention|Usual Care|All eligible SFHP members randomized to usual care will receive medical and health plan by virtue of enrollment in the SFHP and Medi-Cal. Services include assignment to a primary care physician and access to all services available through Medi-Cal in the county of San Francisco.
16622554|NCT02463825|Experimental|Group 1 Pimozide (2mg per day)|Pimozide will be initiated at 1 mg twice daily and maintained on 2mg/day for 50 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will then be stopped.
16622555|NCT02463825|Experimental|Group 2 Pimozide (4mg per day)|Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
16622556|NCT02463825|Placebo Comparator|Group 3 Placebo (Lactose tablet)|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 3
16622557|NCT02463812|Experimental|Intralipid|Patients will receive Intralipid infusion in the recovery room.
16622558|NCT02463812|Placebo Comparator|Control|Patients will receive infusion of normal saline in the recovery room.
16622559|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20
~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
16622560|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
16622561|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
16622562|NCT02463747|Experimental|Prolonged Infusion of antibiotics|"Prolonged (4 hours) Infusion of antibiotics.
~Intervention:
~Primary care would be one of three options:
~Piperacillin/tazobactam : 4.5gr, TID, I.V.
~Or
~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.
~Or
~Meropenem: 1.0gr, TID, I.V.
~Supplementation of Vancomycin will be at the discretion of the treating physician."
16622563|NCT02463747|Active Comparator|Fixed time infusion of antibiotics|"Fixed time (half and hour) infusion of antibiotics.
~Intervention:
~Primary care would be one of three options:
~Piperacillin/tazobactam : 4.5gr, TID, I.V.
~Or
~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.
~Or
~Meropenem: 1.0gr, TID, I.V.
~Supplementation of Vancomycin will be at the discretion of the treating physician/"
16622564|NCT02463721|Other|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
16622565|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
16622566|NCT02463695|Experimental|vestibular deficit|"Initial clinical assessment including otoneurological examination, pure tone audiometry, tympanometry vestibular screening tests and Magnetic Resonance Imaging as clinically indicated.
~The cortical vestibular evoked potentials will add approximately add an extra 30 minutes to the test sequence but is minimally invasive and will not cause any pain or discomfort. It will be conducted on both the affected and non-affected ears."
16622567|NCT02463695|Active Comparator|otologically normal controll|Normative data will be collected from 36 normal ears from subjects that have no history of audiovestibular symptoms and are not being investigated for any balance disorders. The cortical vestibular evoked potentials will be recorded from both ears
16622568|NCT02463682|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 1)|The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
16622569|NCT02463682|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
16622570|NCT02463643|Experimental|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
16622571|NCT02463643|Experimental|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
16622572|NCT02463643|Experimental|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
16622573|NCT02463643|Active Comparator|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
16622574|NCT02463630|Experimental|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
16622575|NCT02463617|Other|PD patients|
16622576|NCT02463604|Experimental|Remote Ischemic Preconditioning|"A blood pressure cuff is placed on upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.
~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
16622577|NCT02463604|Sham Comparator|Control|"A blood pressure cuff is placed on upper arm and inflated to 10 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.
~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
16622578|NCT02463591|Experimental|Beriplex 50 IU/Kg|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Placebo).
16622579|NCT02463591|Placebo Comparator|Placebo|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Placebo identically in appearance to Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Beriplex).
16622580|NCT02463565||hospitalized patients|
16622581|NCT02463552|Placebo Comparator|Placebo|
16622582|NCT02463552|Experimental|Naproxen|
16622583|NCT02463526|Experimental|Group 1 - MWM condition/Sham condition|Subjects will receive treatment for 4 times with Mulligan's Mobilization with Movement (MWM) condition, and after 72 hrs, will be treated 4 times with the sham condition.
16622584|NCT02463526|Experimental|Group 2 - Sham condition/MWM condition|Subjects will receive treatment for 4 times with sham condition, and after 72 hrs, will be treated 4 times with the Mulligan's Mobilization with Movement (MWM) condition.
16622585|NCT02463513|Placebo Comparator|Treatment 1|
16622586|NCT02463513|Active Comparator|Treatment 2|
16622587|NCT02463513|Active Comparator|Treatment 3|
16622588|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
16622589|NCT02463487|Active Comparator|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
16622590|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
16622591|NCT02463474|Experimental|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
16622592|NCT02463461|Experimental|ActiSleep Activity Monitor|Subjects placed in this group will given an ActiSleep Activity Monitor for the one night of the study.
16622593|NCT02463461|Experimental|Jawbone Activity Monitor|Subjects placed in this group will given a Jawbone Activity Monitor for the one night of the study.
16622594|NCT02463461|Experimental|Actiwatch 2 Activity Monitor|Subjects placed in this group will given an Actiwatch 2 Activity Monitor for the one night of the study.
16622595|NCT02463461|Experimental|FitBit Activity Monitor|Subjects placed in this group will given a FitBit Activity Monitor for the one night of the study.
16622596|NCT02463461|Experimental|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects placed in this group will given an Actigraph by Ambulatory Monitoring Activity Monitor for the one night of the study.
16622597|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
16622598|NCT02463435|Active Comparator|Nutritional intervention|Patients under only nutritional intervention for weight loss
16622599|NCT02463435|Experimental|Nutritional intervention plus olive oil|Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
16622600|NCT02463435|Experimental|Olive oil|Patient under habitual food consumption plus extra virgin olive oil supplementation
16622601|NCT02463422||San Diego, CA|Toddlers detected with ASD and other disorders based on the Get SET Early Model in San Diego.
16622602|NCT02463422||Phoenix, AZ|Toddlers detected with ASD and other disorders based on the Get SET Early Model in Phoenix.
16622603|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
16622604|NCT02463396|Experimental|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
16622605|NCT02463396|No Intervention|Treatment as usual (TAU)|Usually medication & psycho-education
16622606|NCT02463383|Experimental|Sequence 1|"Ibuprofen Tab 400MG
~Placebo Tab"
16622607|NCT02463383|Experimental|Sequence 2|"Placebo tab
~Ibuprofen Tab 400MG"
16622608|NCT02463370|Experimental|Group II|Group II patients will receive local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas and the remaining injections are placebo (saline).
16622609|NCT02463370|Experimental|Group V|Group V patients will receive local anesthesia in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum. The remaining maxillary injection is placebo.
16622610|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
16622611|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
16622612|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
16622613|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
16622614|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
16622615|NCT02463344||MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE
~Cohort 1 50,000 cells
~Cohort 2 100,000 cells
~Cohort 2a Better Vision 100,000 cells
~Cohort 3 150,000 cells
~Cohort 4 200,000 cells"
16622616|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
16622617|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
16622618|NCT02463318|Experimental|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
16622619|NCT02463318|Experimental|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
16622620|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
16622621|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
16622622|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
16622623|NCT02463292||patient group|The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
16622624|NCT02463292||peer control group|The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.
16622625|NCT02463279|Experimental|SinuSys Dilation System|Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
16622626|NCT02463266||SUSTAIN Monitoring and Care Management|SUSTAIN program participants who complete an initial clinical assessment and, if indicated, agree to follow-up services including Monitoring and/or Care Management.
16622627|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.
~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
16622629|NCT02463214|No Intervention|Standard Room|Standard bone marrow transplant recovery, single occupancy, room
16622630|NCT02463214|Experimental|Engineered Room|Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.
16622631|NCT02463201||Obese children and adolescents|Attending a weightloss programme, that consist of lifestyle counseling, dietary restriction and exercise. The prevalence of obstructive sleep apnea (OSA) will be investigated in group. Children diagnosed with OSA will be followed to investigate if weight loss changes the condition.
16622632|NCT02463188|Experimental|Sleep Fitness Intervention|The intervention consists of 5-7 sessions on sleep science, the connection between sleep and substance use, behavior change strategies, and motivation to change behavior.
16622633|NCT02463188|No Intervention|Psychoeducation (PE)|The control classes will receive an 1-session psycho-educational (PE) intervention that provides information on sleep but does not provide guidance for implementing behavior change and does not explicitly teach about sleep's relationship to substance use.
16622634|NCT02463175|Experimental|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
16622635|NCT02463175|Experimental|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
16622636|NCT02463162|No Intervention|Control|"This group will receive usual care which is to receive no intervention."
16622637|NCT02463162|Experimental|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
16622638|NCT02463149|Experimental|Youth Chef Academy|Receives intervention
16622639|NCT02463149|No Intervention|Control|Usual classroom curriculum
16622640|NCT02463136|Experimental|Behaviour and brain training|fMRI-based neurofeedback
16622641|NCT02463110|Experimental|1: Sertraline|ACS, depression
16622642|NCT02463110|Placebo Comparator|2: Placebo|ACS, depression
16622644|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
16622645|NCT02463084|Experimental|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
16622646|NCT02463084|Experimental|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
16622647|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
16622648|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
16622649|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
16622650|NCT02463058|Experimental|Research arm|"10 young and healthy civilian volunteers will participate in this study. The subjects will undergo 5 experiment days:
~Recruitment , medical examination and VO2max test.
~Acclimatization day by performing moderate exercise protocol under hot and humid climate.
~3 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:
~Protective garment in current use + NBC mask.
~The new BC protective undergarment + standard combat uniforms
~The new BC protective undergarment + standard combat uniforms + NBC mask"
16622651|NCT02463045|Experimental|TOP1288 1mg (or placebo)|TOP1288 1mg single dose or placebo
16622652|NCT02463045|Experimental|TOP1288 10mg (or placebo)|TOP1288 10mg single dose or placebo
16622653|NCT02463045|Experimental|TOP1288 100mg (or placebo)|TOP1288 100mg single dose or placebo
16622654|NCT02463045|Experimental|TOP1288 200mg single dose or placebo|TOP1288 200mg single dose or placebo
16622655|NCT02463045|Experimental|TOP1288 400mg dose or placebo|TOP1288 400mg (200mg bid) dose or placebo
16622656|NCT02463045|Experimental|TOP1288 A mg or placebo|TOP1288 A mg daily for 4 days
16622657|NCT02463045|Experimental|TOP1288 B mg or placebo|TOP1288 B mg daily for 4 days
16622658|NCT02463045|Experimental|TOP1288 C mg or placebo|TOP1288 C mg daily for 4 days
16622659|NCT02463045|Experimental|TOP1288 D mg or placebo|TOP1288 D mg bid for 4 days
16622660|NCT02463045|Experimental|TOP1288 Xmg or placebo|TOP1288 X mg od or bid for 4 days
16622661|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
16622662|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
16622663|NCT02463019|Other|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
16622664|NCT02463006|Experimental|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
16622665|NCT02463006|Active Comparator|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
16622666|NCT02462993|Experimental|Aloe vera group|Group recieving scaling and root planing and aloe vera gel local drug delivery
16622667|NCT02462993|No Intervention|SRP group|Group recieving only scaling and root planing
16622668|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
16622669|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
16622670|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
16622671|NCT02462954|Experimental|ContraGel|ContraGel, a personal lubricant has a Conformite Europeenne (CE) mark and has been used with barrier devices in Europe and other countries outside the US, but it is not currently approved by the US FDA.
16622672|NCT02462954|Placebo Comparator|HEC Placebo|The placebo gel is supplied by CONRAD in pre-filled individual applicators, each applicator containing 4.0 mL of HEC gel. Placebo gel contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
16622673|NCT02462941|Experimental|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
16622674|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
16622675|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
16622676|NCT02462928|Active Comparator|Ranibizumab 0.5 mg (rQ4)|Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
16622677|NCT02462915|Experimental|i-gel, an brand of supraglottic airway device|a supraglottic airway devices with a gastric suction channel
16622678|NCT02462915|Experimental|endotracheal tube|traditional use for protect airway during the surgery
16622679|NCT02462902|Experimental|5% albumin Infusion|(250 ml over 15 to 30 minutes)
16622680|NCT02462902|Active Comparator|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)
16622681|NCT02462889|Experimental|Intravitreal aflibercept injection|Subjects will be randomized to receive intravitreal aflibercept injection every three months for 24 months.
16622682|NCT02462889|Placebo Comparator|Placebo|Subjects will be randomized to receive sham injection every three months for 24 months.
16622683|NCT02462863|Experimental|Immunonutrient treatment|Administration of arginine and fish oil.
16622684|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
16622993|NCT02460965||Patients with hearing impairment|
16622685|NCT02462837|Experimental|Treatment Arm|after stent placement, patient will be given Mirabegron 50 mg, PO, once daily, for 2 weeks
16622686|NCT02462837|Placebo Comparator|Placebo Arm|after stent placement, patient will be given placebo PO, once daily, for 2 weeks
16622687|NCT02462824|Experimental|Home-based exercise intervention|PAD Participants randomized to the home-based exercise intervention will be asked to take part in walking exercise to determine whether a patient-centered home-based exercise program improves walking ability, mobility, pain, and social functioning.
16622688|NCT02462824|No Intervention|Usual care group|PAD participants randomized to usual care will not receive any study interventions. Rather, they will receive usual care from their own physicians.
16622689|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
16622690|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
16622691|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
16622692|NCT02462798|Placebo Comparator|Whole grain rye bread|Whole grain rye bread, 200 g/d. Control intervention.
16622693|NCT02462798|Experimental|Whole grain sourdough rye bread|Whole grain rye bread, 200 g/d. Experimental intervention.
16622694|NCT02462785|Active Comparator|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
16622695|NCT02462785|Experimental|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
16622696|NCT02462772|Experimental|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
16622697|NCT02462772|Placebo Comparator|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
16622698|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
16622699|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
16622700|NCT02462746|No Intervention|No supplement|This group subjects will not receive the supplement
16622701|NCT02462746|Active Comparator|1.5 gram of l-cysteine|Intervention: single dose of 1.5 g L-Cysteine.
16622702|NCT02462746|Active Comparator|3 grams of l-cysteine|Intervention: single dose of 3.0 g L-Cysteine.
16622703|NCT02462733|Active Comparator|Tools of the Mind (TOM)|These 10 classrooms will be exposed to the TOM program.
16622704|NCT02462733|Active Comparator|Playing to Learn (PTL)|These 10 classrooms will be exposed to the PTL program.
16622705|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
16622706|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
16622707|NCT02462707|Experimental|PF-03084014|
16622708|NCT02462694|Active Comparator|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
16622709|NCT02462694|Experimental|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
16622710|NCT02462681|Active Comparator|bupivacaine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
16622711|NCT02462681|Active Comparator|bupivacaine + 0.5 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
16622712|NCT02462681|Active Comparator|bupivacaine + 1 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 1mg/kg ketamine paravertebrally divide into 3-4 ml in each level
16622713|NCT02462668|Placebo Comparator|Control|"Preoxygenation with Bag-mask ventilation before fibreoptic bronchoscopy assisted intubation.
~Intervention: Bag-mask ventilation."
16622714|NCT02462668|Experimental|NIPPV|"The NIPPV group preoxygenation with noninvasive positive pressure ventilation(NIPPV), And then receives fibreoptic bronchoscopy intubation through a face mask (there is a small hole allow to insert the tracheal tube through the mask into trachea) during NIPPV.
~Intervention: noninvasive positive pressure ventilation(NIPPV)"
16622715|NCT02462655|Experimental|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
16622716|NCT02462655|Experimental|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
16622717|NCT02462642|Experimental|Brahmi - 36 subjects|36 subjects both male and female will consume 2 capsules of Brahmi for 84 days.
16622718|NCT02462642|Placebo Comparator|Placebo- 36 subjects|36 subjects male and female who will take 2 capsules of placebo every day
16622719|NCT02462642|Experimental|Brahmi - 8 Subjects|For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
16622720|NCT02462642|Placebo Comparator|Placebo- 4 subjects|4 male subjects in PK part will be in the placebo arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
16622721|NCT02462629|Experimental|BLZ-100|
16622722|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
16622723|NCT02462603|Experimental|EPI-589 500 milligrams (mg) twice daily (bid)|All enrolled participants will receive treatment with EPI-589
16622747|NCT02462434|Experimental|Early palliative care team consultation|Early pediatric palliative care team consultation for single ventricle patients will occur in this group following birth but prior to the first stage palliative surgery.
16622724|NCT02462590|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
16622725|NCT02462590|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population [Morrow 2010]. This has also been used successfully in the PROSPECT Pilot Trial.
16622726|NCT02462577|Active Comparator|local instillation of morphine 5 mg|5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
16622727|NCT02462577|Active Comparator|local instillation of morphine 10 mg|5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
16622728|NCT02462577|Active Comparator|local instillation of morphine 15 mg|5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
16622729|NCT02462577|Placebo Comparator|local instillation of local anesthetics|5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
16622730|NCT02462564||postoperative cognitive dysfunction|Z score>1.96
16622731|NCT02462564||non-postoperative cognitive dysfunction|Z score<1.96
16622732|NCT02462551|Experimental|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
16622733|NCT02462538|Experimental|Brentuximab vedotin and Imatinib|Brentuximab vedotin (every 3 weeks i.v., 1.8 mg/kg) and imatinib (200mg daily orally, escalated from 100mg daily) for up to 48 weeks
16622734|NCT02462525|Experimental|ABBV-838 dose escalation|Varying doses of ABBV-838
16622735|NCT02462525|Experimental|ABBV-838 plus pomalidomide/dexamethasone|ABBV-838 to be evaluated with pomalidomide/dexamethasone.
16622736|NCT02462512||FNAB of Thyroid nodule|The Patients with thyroid nodule who are scheduled for FNAB
16622737|NCT02462499|Experimental|Treatment|Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
16622738|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
16622739|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
16622740|NCT02462486|Active Comparator|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
16622741|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
16622742|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
16622743|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
16622744|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
16622745|NCT02462447||Prostate Cancer|Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.
16622746|NCT02462447||Healthy Volunteer|Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.
16622843|NCT02461836|Experimental|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
16622748|NCT02462434|No Intervention|Usual care|Usual care for single ventricle patients will be provided with palliative care team consultation occurring at any point (if it is determined the child and family would benefit from palliative care consultation) during the child's neonatal hospital stay.
16622749|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
16622750|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
16622751|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
16622752|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
16622753|NCT02462408|Experimental|Posterior approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
16622754|NCT02462408|Active Comparator|Conventional approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
16622755|NCT02462395|Experimental|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
16622756|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
16622757|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
16622758|NCT02462369|Experimental|Saxagliptin|Saxagliptin 5mg/d, 52 weeks
16622759|NCT02462369|Active Comparator|glimepiride|glimepiride 1~4mg/d,52 weeks
16622760|NCT02462356|Active Comparator|Conventional VATS|Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
16622761|NCT02462356|Experimental|Uniportal VATS|Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
16622762|NCT02462343|Other|2 minute walk test|
16622763|NCT02462343|Other|6 minute walk test|
16622766|NCT02462317|Active Comparator|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
16622767|NCT02462317|Active Comparator|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
16622768|NCT02462317|Placebo Comparator|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
16622769|NCT02462304|Experimental|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
16622770|NCT02462304|Active Comparator|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
16622771|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
16622772|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
16622773|NCT02462278|Experimental|TempuRing|Women will wear the continuous temperature sensor, TempuRing, for 3 menstrual cycles.
16622774|NCT02462265|Experimental|'Oshadi D & Oshadi R; salvage therapy'|Oshadi D (180mg/tid) & Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
16622775|NCT02462252|Experimental|BL-8040 plus hATG, methylprednisolone, cyclosporine|"BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.
~Standard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.
~Standard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.
~Standard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)"
16622776|NCT02462239|Experimental|Whole-body FDG PET-CT|Whole-body FDG PET-CT (Experimental arm)
16622777|NCT02462239|No Intervention|No PET-CT|No PET-CT (Control arm)
16622778|NCT02462226|Active Comparator|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.
~Patients will be given access to the website to learn about the arm precaution program."
16622806|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
16622844|NCT02461823|Experimental|Z Crown|A Zirconia crown will be provided to patients.
16622779|NCT02462226|Experimental|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.
~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
16622780|NCT02462213||Amyloidosis|Patients being managed for amyloidosis without prior history of cardiac involvement
16622781|NCT02462213||Cardiac amyloidosis|Patients being managed for cardiac amyloidosis
16622782|NCT02462200|Active Comparator|BCS Arm (breast-conserving surgery - standard of care)|"Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization
~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).
~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken."
16622783|NCT02462200|Experimental|CSM Arm (breast-conserving surgery with cavity shave margins)|"Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained
~A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation
~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).
~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken."
16622784|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
16622785|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
16622786|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
16622787|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
16622788|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
16622789|NCT02462174|Active Comparator|Topical ketamine and topical bupivacaine|0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.
16622790|NCT02462174|Active Comparator|Caudal ketamine and caudal bupivacaine|0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.
16622791|NCT02462161|Experimental|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
16622792|NCT02462161|Placebo Comparator|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
16622793|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
16622794|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
16622795|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
16622796|NCT02462135|Experimental|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
16622797|NCT02462135|Active Comparator|Passive information activities|The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
16622798|NCT02462122|Experimental|IDP-118 Lotion|Lotion
16622799|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
16622800|NCT02462109|Experimental|Lorazepam|"Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative."
16622801|NCT02462096|Experimental|Treatment|Subject to undergo the ReLeaf study procedure.
16622802|NCT02462083|Experimental|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
16622803|NCT02462070|Experimental|IDP-118 Lotion|Lotion
16622804|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
16622805|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
16622994|NCT02460965||Patients with visual loss|
16622807|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
16622808|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
16622809|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:
~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths
~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
16622810|NCT02462044|Experimental|240|Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s
16622811|NCT02462044|Experimental|300|Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s
16622812|NCT02462044|Experimental|370|Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s
16622813|NCT02462031|Experimental|KD101|
16622814|NCT02462031|Placebo Comparator|KD101 placebo|
16622815|NCT02462018|Experimental|WalkAide|
16622816|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
16622817|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
16622818|NCT02461979|Other|Hepatocellular carcinoma (HCC)|The VDR genotype in 20 HCV cirrhotic patient with HCC
16622819|NCT02461979|Other|Liver cirrhosis|The VDR genotype in 20 HCV cirrhotic patient without HCC
16622820|NCT02461979|Other|Control group|The The VDR genotype in 10 healthy individuals as control
16622821|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
16622822|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
16622823|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
16622824|NCT02461953|Experimental|low flux hemodialysis|low flux hemodialysis alone, 3 times a week, 4 hours per session
16622825|NCT02461953|Experimental|high flux hemodialysis|high flux hemodialysis alone, 3 times a week, 4 hours per session
16622826|NCT02461953|Experimental|low flux hemodialysis + hemoperfusion|low flux hemodialysis 2times a week and the HD+HP once a week
16622827|NCT02461953|Experimental|high flux hemodialysis + hemoperfusion|high flux hemodialysis 2times a week and the HD+HP once a week
16622828|NCT02461940|No Intervention|Standard care|The control group will receive the standard care provided by the STI clinic.
16622829|NCT02461940|Active Comparator|Adolescent Behavioral intervention|Participants allocated to the intervention arm receive 4 on-site personalised counselling and 2 phone/online sessions over a 12-month period, targeting individual, relational, sociocultural and environmental factors pertaining to the acquisition of STI/HIV.
16622830|NCT02461927|Experimental|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
16622831|NCT02461927|Experimental|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
16622832|NCT02461927|Placebo Comparator|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
16622833|NCT02461914|Experimental|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
16622834|NCT02461901||Fidaxomicin treatment|Patients being treat with fidaxomicin (on the decision of their treating physician)
16622835|NCT02461901||Metronidazole or vancomycin treatment|Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)
16622836|NCT02461888|Experimental|Ixazomib, CD|"Ixazomib, cyclophosphamide and dexamethasone (ICD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Ixazomib 4mg orally on days 1, 8 and 15
~Cyclophosphamide 500mg orally on days 1, 8 and 15
~Dexamethasone 40mg orally on days 1-4 and 12-15"
16622837|NCT02461888|Active Comparator|CD|"Cyclophosphamide and dexamethasone (CD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Cyclophosphamide 500mg orally on days 1, 8 and 15
~Dexamethasone 40mg orally on days 1-4 and 12-15"
16622838|NCT02461875|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
16622839|NCT02461875|Experimental|GnRH antagonist rescue & cabergoline group|Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.
16622840|NCT02461862||Intra Uternine Device|Women who came to the medical service, to insert an intra uterine Device (IUD) of Cu or a Levonorgestrel Intra Uterine System( Lng- IUS) after have been attended in the Family Planning Service of Federal University of São Paulo . All patient have had the pain evaluated by Application of the Visual Analog Scale of Pain (VAS), and also their vital signs ( Evaluation of blood pressure,Evaluation of radial pulse) evaluated pre and five minutes after the IUD/ IUS insertion.
16622841|NCT02461849|Experimental|Imatinib|Imatinib 400mg qd daily Until disease progression, patient's refusal
16622842|NCT02461836|Experimental|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
16622849|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray
16622850|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control
16622851|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
16622852|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
16622853|NCT02461771|Experimental|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
16622854|NCT02461771|Experimental|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
16622855|NCT02461771|Experimental|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
16622856|NCT02461758|Other|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
16622857|NCT02461758|Other|Vedolizumab Group + standard dose influenza vaccine (SDIV)|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
16622858|NCT02461758|Other|High dose influenza vaccine (HDIV)|"This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
16622859|NCT02461758|Other|Standard dose influenza vaccine (SDIV)|"This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
16622860|NCT02461745|Active Comparator|Genotype 1a|Study participants with chronic Hepatitis C Genotype 1A receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) and RBV (ribavirin tablets) for 12 weeks.
16622861|NCT02461745|Active Comparator|Genotype 1b|Study participants with chronic Hepatitis C Genotype 1B receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) for 12 weeks.
16622862|NCT02461732|Active Comparator|CBT for Substance Dependence|Standard CBT for substance use disorders
16622863|NCT02461732|Experimental|Integrated CBT for PTSD and Substance Dependence|Integrated CBT for PTSD and substance use disorders, combining elements of cognitive processing therapy for PTSD with coping skills and relapse prevention for substance use disorders
16622864|NCT02461719|Experimental|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes
16622865|NCT02461719|Active Comparator|Restasis eye drop|Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes
16622866|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
16622867|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
16622868|NCT02461680|Experimental|Tangential resection|the tendon's injury is treated with a tangential resection
16622869|NCT02461680|Active Comparator|Suture|The tendon's injury is sutured
16622870|NCT02461667|Placebo Comparator|placebo|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
16622871|NCT02461667|Active Comparator|Metformin|SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally
16622872|NCT02461667|Active Comparator|Alendronate|SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
16622873|NCT02461641|Other|Standard of Care|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe.
16622874|NCT02461641|Experimental|NuShield|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.
16622875|NCT02461641|Experimental|Affinity|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a fresh hypothermically stored amniotic membrane, Affinity, for up to 4 weeks.
16622876|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
16622877|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
16622878|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
16622879|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
16622880|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
16622881|NCT02461589|Placebo Comparator|Placebo 50 µL|
16622882|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
16622883|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
16622884|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
16622885|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
16622886|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
16622887|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
16622888|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
16622889|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
16622890|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
16622891|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
16622892|NCT02461576||HIV-1 infected|this is a study comparing Xpert HIV-1 VL assay quantitation to an already FDA approved HIV-1 quantitative HIV-1 RNA assay in known HIV-1 infected individuals
16622893|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
16622894|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
16622895|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
16622896|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
16622897|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
16622898|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
16622899|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
16622900|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
16622901|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
16622902|NCT02461524|Other|Endovasculair repair|Endurant Evo AAA Stent graft system
16622903|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
16622904|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
16622905|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
16622906|NCT02461485|Experimental|1=BOW_01|1= Fermented Milk Product containing Probiotics
16622907|NCT02461485|Experimental|2=BOW_01 + fiber C|2= Fermented Milk Product containing Probiotics + Fibers C
16622908|NCT02461485|Experimental|3 =BOW_01 + fiber W|3= Fermented Milk Product containing Probiotics + Fibers W
16622909|NCT02461485|Placebo Comparator|4 = Control|4= Non fermented Milk Product with same color, texture and organoleptic properties as investigational products 1 to 3.
16622910|NCT02461472||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
16622911|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
16622912|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
16622913|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
16622914|NCT02461446||Controls|Healthy control group
16622915|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
16622916|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
16622917|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
16622918|NCT02461407|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16622919|NCT02461407|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16622920|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
16622921|NCT02461368|Experimental|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
16622922|NCT02461368|Active Comparator|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
16622923|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
16622924|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
16622925|NCT02461342||Dr.Tang's research group|Dr.Tang's research group for genetic, environment and its interaction analysis of human complex disease
16622926|NCT02461329|Experimental|Gelatine solution|"Gelofusine will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).
~The blood pressure and heart rate before and after fluid challenge will be recorded."
16622927|NCT02461329|Experimental|Balanced Crystaloid solution|"Ringerfundin will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).
~The blood pressure and heart rate before and after fluid challenge will be recorded."
16622928|NCT02461316||Combination Treatment in Chronic Lymphocytic Leukemia (CLL)|All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
16622929|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
16622930|NCT02461277|Active Comparator|Fast-track protocol|Before surgery, patients are informed about the surgical procedure, anesthesia and rehabilitation protocol. The surgery occurs in accordance with the principles of the Fast-track: minimal invasive surgery, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization.
16622931|NCT02461277|No Intervention|Conventional care|Usual care routine postoperative
16622995|NCT02460965||Patients with Parkinson's Disease|
16622996|NCT02460965||Patients with Alzheimer's Disease|
16622997|NCT02460965||Patients with dementia with Lewy Bodies|
16622998|NCT02460965||Healthy participants|
16622932|NCT02461264|Active Comparator|ARM A|Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, two new packed red blood cells are transfused and so on.
16622933|NCT02461264|Experimental|ARM B|Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, a single unit is transfused and so on.
16622934|NCT02461251|Experimental|Rotational thromboelastometry (ROTEM)|"Rotational thromboelastometry results are used to guide the treatment of major obstetric hemorrhage, eg. administration of prothrombin complex concentrate, fresh-frozen plasma, fibrinogen concentrate or platelets. In case of massive hemorrhage, shock packs of blood products in 1:1:1 ratio are administered."
16622935|NCT02461251|No Intervention|Standard care|"Patients are treated according to clinical decision making and conventional coagulation tests, and in case of massive hemorrhage, shock packs are administered."
16622936|NCT02461238|Active Comparator|Vouchers|Families included in the Voucher arm will receive vouchers for fruits and vegetables by mail every month for a period of 1 year coupled to nutritional education from a dietician
16622937|NCT02461238|Other|Control|Families included in the control arm will only receive nutritional education
16622938|NCT02461225|Active Comparator|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
16622939|NCT02461225|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.
16622940|NCT02461225|Active Comparator|Erchonia® FX-635™ Placebo Cross-over|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
16622941|NCT02461212|Experimental|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
16622942|NCT02461212|Experimental|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
16622943|NCT02461199||Fecal microbiota transplantation|Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.
16622944|NCT02461186|Experimental|Arterolane maleate-piperaquine phosphate (Synriam)|
16622945|NCT02461186|Experimental|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
16622946|NCT02461173|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
16622947|NCT02461173|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
16622948|NCT02461173|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
16622949|NCT02461160|Placebo Comparator|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
16622950|NCT02461160|Experimental|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
16622951|NCT02461160|Experimental|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
16622952|NCT02461160|Experimental|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
16622953|NCT02461160|Placebo Comparator|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
16622954|NCT02461160|Experimental|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
16622955|NCT02461160|Experimental|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
16622956|NCT02461160|Experimental|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
16622957|NCT02461160|Experimental|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
16622958|NCT02461160|Experimental|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
16622959|NCT02461160|Experimental|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
16623022|NCT02460783|Experimental|5-2 CR|Healthy living diet for 5 days/week; Calorie Restriction(530 Kcal in the form of a shake) for 2 days/week
16623023|NCT02460783|Active Comparator|Healthy Living|Healthy living diet for 7 days/week
16622960|NCT02461160|Experimental|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
16622961|NCT02461160|Experimental|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
16622962|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
16622963|NCT02461134|Experimental|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
16622964|NCT02461121|Experimental|MST（microtransplantation）|The microtransplantation conditioning regimen included high-dose Ara-C chemotherapy (2.0 to 2.5 g/m2 per 12 hours intravenously on days -4 to -2) followed by an infusion of HLA mismatched stem cell 24 hours (day 0) after the completion of cytarabine.
16622965|NCT02461121|Active Comparator|NST（nonmyeloablative transplantation）|The NST（nonmyeloablative transplantation）conditioning regimen consisted of 30 mg/m2/d fludarabine for days -6 to -2, 1.5-2 mg/kg/d anti-lymphocyte globulin for days -5 to -2, 40 mg/kg/d cyclophosphamide for days -4 and -2 and 2.0-3.0 g/m2/d cytarabine for days -6 to -4，followed by an infusion of HLA matched stem cell after the completion of regimen. The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
16622966|NCT02461108|Experimental|Price difference|Introduce a 10% price difference between foods labeled as nutritious and foods labeled as less nutritious and frame the price difference as either a Subsidy, Tax, or combination of a Tax and Subsidy.
16622967|NCT02461108|No Intervention|No price difference|No price difference between nutritious and less nutritious foods.
16622968|NCT02461095|Active Comparator|Impairment based approach|The intervention will address the patients impairments found during evaluation. Treatment will based on the Physical therapist evaluation and will be individualized to each patient.
16622969|NCT02461095|Experimental|PFPS algorithm|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
16622970|NCT02461082|Other|EMST and sham-TMS|Active expiratory muscle strength training in combination with sham transcranial magnetic stimulation
16622971|NCT02461082|Other|sham-EMST and TMS|Sham expiratory muscle strength training in combination with active transcranial magnetic stimulation
16622972|NCT02461082|Other|EMST and TMS|Active expiratory muscle strength training in combination with active transcranial magnetic stimulation
16622973|NCT02461082|Other|sham-EMST and sham-TMS|Sham expiratory muscle strength training in combination with sham transcranial magnetic stimulation
16622974|NCT02461069|Active Comparator|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
16622975|NCT02461069|No Intervention|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
16622976|NCT02461056|Active Comparator|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
16622977|NCT02461056|Active Comparator|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
16622978|NCT02461056|Active Comparator|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
16622979|NCT02461043|Experimental|Arm A|chemotherapy and radiotherapy
16622980|NCT02461043|Active Comparator|Arm B|radiotherapy
16622981|NCT02461030|Experimental|CSPR + NS treatment|"In-office and at home Colgate sensitive pro-relief - CSPR
~Intervention: Non-surgical periodontal treatment (full-mouth debridement, scaling and root planing with ultrasonic/hand instruments) associated with In-office application of Colgate Sensitive Pro-Relief (CSPR) + tooth brushing with at home CSPR toothpaste during 8 weeks."
16622982|NCT02461030|Placebo Comparator|Villevie® + NS treatment|"In-office Villevie® prophy paste + Colgate Toothpaste
~Treatment: In-office application of a Villevie® (fluoride-free) prophy paste + tooth brushing with a Colgate Cavity Protection Toothpaste during 8 weeks, after non-surgical periodontal treatment. (Full-mouth debridment/ Scaling and root planing with ultrasonic/hand instruments)"
16622983|NCT02461017||Endotracheal Leak|Assess for Audible Endotracheal Leak; Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
16622984|NCT02461004|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
16622985|NCT02461004|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
16622986|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
16622987|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
16622988|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
16622989|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
16622990|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
16622991|NCT02460965||Patients with schizophrenia|
16622992|NCT02460965||Patients with borderline personality disorder|
16622999|NCT02460926|Experimental|Scaling & Root Planing - Quadrant|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. Q-SRP patients received four quadrants sessions of PT with an interval of 1 week between sessions
16623000|NCT02460926|Experimental|Scaling & Root Planing - Full Mouth|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. FM-SRP patients received treatment within 24 hrs in two separate sessions, one side of the mouth for each session: two quadrants were instrumented in an afternoon session, whereas the other two were instrumented the following morning
16623001|NCT02460913|Experimental|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
16623002|NCT02460913|Active Comparator|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
16623003|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
16623004|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will receive placebo and standard of care
16623005|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
16623006|NCT02460900|Active Comparator|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
16623007|NCT02460887|Experimental|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
16623008|NCT02460887|Active Comparator|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
16623009|NCT02460874|Experimental|Pilot Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS. Treatment planning MRI may be done within 21 days prior to SRS treatment.
~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day).
~Step 3: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring.
~Step 4: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI.
~Step 5: 3 months after SRS, undergo MRI."
16623010|NCT02460874|Placebo Comparator|Randomized Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS.Treatment planning MRI may be done within 21 days prior to SRS treatment.
~Step 2: Randomization (1:1)
~Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.
~Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.
~Step 3: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring.
~Step 4: 1 month after SRS, discontinue investigation medication, undergo MRI.
~Step 5: 3 months after SRS, undergo MRI."
16623011|NCT02460861|Active Comparator|PCA Magdeburg|Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg
16623012|NCT02460861|Active Comparator|Non-prostate cancer Magdeburg/Gronau|Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau
16623013|NCT02460861|Active Comparator|PCA Gronau|Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa
16623014|NCT02460848|Experimental|Outpatient therapeutic program, counseling and cash transfer|Ten outpatient therapeutic program sites (OTP) will be randomly allocated to unconditional cash transfer for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
16623015|NCT02460848|Active Comparator|Outpatient therapeutic program and counseling|Ten outpatient therapeutic program sites (OTP) will be randomly allocated for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
16623016|NCT02460835|Experimental|Adaptive Radiation Therapy|
16623017|NCT02460822|Experimental|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
16623018|NCT02460809|Active Comparator|In-lab tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in a controlled laboratory environment with an investigator.
16623019|NCT02460809|Experimental|In-home tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in their own home. Patients will be taught how to use a blue-tooth enabled telerehabilitation module that is being controlled by an investigator in the lab on the University campus. For safety, an investigator will be in the home with each patient during tDCS use and finger tracking training but will only be supervising procedures.
16623020|NCT02460796||hippotherapy group or study group|8 weeks of hippotherapy therapy: Familiarization sessions were initially 15 minutes and gradually evolved to 30 minutes in order to allow all participants to adapt to the horse's rhythmic movements and to the act of mounting the horse. Each session had warm up before the training and exercises for relaxation in the end of each session.
16623021|NCT02460796||control group|8 weeks of Parkinson's disease lectures: this group did not hippotherapy classes in the same period.
16623024|NCT02460770|Experimental|autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery
16623025|NCT02460757||Patients with COPD|
16623026|NCT02460757||Patients with interstitial lung disease|
16623027|NCT02460757||Healthy subjects|
16623028|NCT02460744|Experimental|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
16623029|NCT02460731|Experimental|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors]
16623030|NCT02460718|No Intervention|control group|Participants received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight.
16623031|NCT02460718|Experimental|Encourage study|"Participants in the intervention arm were paired with a peer coach, interacting by telephone weekly for the first 8 weeks and then monthly for a total of 10 months.
~Participants also received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight."
16623032|NCT02460705|Experimental|IBD patients receiving FMT|IBD patients receiving biologically active human fecal material sourced from OpenBiome. The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL, through the endoscope. The material will be delivered to the most proximal point of insertion.
16623033|NCT02460692|Placebo Comparator|Placebos|The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
16623034|NCT02460692|Active Comparator|Dronabinol|A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
16623035|NCT02460692|Experimental|Vaporized Cannabis 3.7% THC/5.6% CBD|The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
16623036|NCT02460679|Experimental|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
16623037|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
16623038|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
16623039|NCT02460653|No Intervention|Current|Current level of HFNC support
16623040|NCT02460653|Experimental|Low|Low flow range per kg.
16623041|NCT02460653|Experimental|Medium|Medium flow range per kg.
16623042|NCT02460653|Experimental|High|High flow range per kg
16623043|NCT02460640|Active Comparator|Tap Block|the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
16623044|NCT02460640|Active Comparator|No Tap Block|the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia
16623045|NCT02460627|Experimental|Lidocaine adhesive tape|
16623046|NCT02460627|Placebo Comparator|Adhesive tape|
16623047|NCT02460614|Experimental|Rhinopharyngeal clearance + 0.9% saline|The retrograde rhinopharyngeal clearance (RRC) is based on the inspiratory reflex that follows a slow and prolonged expiration (passive exhalation technique performed using a slow thoracic-abdominal compression that begins at the end of a spontaneous exhalation and continues until the expiratory reserve volume). At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver. The instillation of saline (0.9%) preceded this step, resulting in the inhalation of the substance during the forced inspiration, contributing to the nasopharyngeal clearance.
16623048|NCT02460614|Active Comparator|Aspiration + 0.9% saline|Nasopharyngeal aspiration consisted in the introduction of a catheter that, by using negative pressure (vacuum), promotes the suction of secretion from the airways. In order to do that, a sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient. The saline instillation of 0.9% was used for humidification before the procedure.
16623049|NCT02460601|Experimental|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
16623050|NCT02460601|Placebo Comparator|Placebo|2.5g/time,tid,oral administration,6 weeks
16623051|NCT02460588|Placebo Comparator|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
~All patients will receive non experimental medication with high dose of corticosteroid."
16623052|NCT02460588|Experimental|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
~All patients will receive non experimental medication with high dose of corticosteroid.
~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
16623053|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
16623054|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
16623055|NCT02460562|Active Comparator|PMMA resin|A denture base will be made with PMMA resin as a standard material.
16623056|NCT02460562|Experimental|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin & S-PRG filler for subject to wear.
16623057|NCT02460549|Experimental|therapeutic education program|patients attend three sessions of therapeutic education
16623130|NCT02460016|Experimental|AK0529|AK0529 pellets
16623058|NCT02460536|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
16623059|NCT02460536|Active Comparator|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
16623060|NCT02460536|Active Comparator|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
16623061|NCT02460536|Placebo Comparator|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
16623062|NCT02460523|Active Comparator|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
~Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.
~No improvement: the patient will undergo ERCP and then LC."
16623063|NCT02460523|Active Comparator|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.
~b- No improvement: the patient will undergo ERCP and then LC."
16623064|NCT02460510|Experimental|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity >320mm
16623065|NCT02460510|Active Comparator|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of <160 mmol/L.
16623066|NCT02460497|Experimental|Treatment|
16623067|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
16623068|NCT02460471|Experimental|palliative radiation therapy|25 Gy in 5 daily fractions
16623069|NCT02460458||Type 3 Von Willebrand's Disease (VWD3)|Patients with diagnosis of Type 3 Von Willebrand's Disease
16623070|NCT02460445|Experimental|Intervention|Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.
16623071|NCT02460445|Active Comparator|Control|Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.
16623072|NCT02460432|Experimental|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
16623073|NCT02460432|Active Comparator|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
16623074|NCT02460419|Experimental|maintenance capecitabine|maintenance capecitabine plus best supportive care(BSC)
16623075|NCT02460419|Other|best supportive care|Best supportive care and following-up every 6-8 weeks
16623076|NCT02460406|Other|control group|traditional physiotherapy (stretching, normal range of movement, walking)
16623077|NCT02460406|Active Comparator|intervention group|progressive functional strength training protocol on lower extremities consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises.
16623078|NCT02460393|Placebo Comparator|Placebo group|The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
16623079|NCT02460393|Experimental|experimental group|The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
16623080|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
16623081|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
16623082|NCT02460367|Experimental|Phase 1: Dose Escalation|Up to 18 participants will be enrolled and treated at escalating doses of Indoximod with a fixed dose of tergenpumatucel-L and docetaxel. Treatment may continue until definitive disease progression or significant toxicology.
16623083|NCT02460354|Experimental|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
16623084|NCT02460341|Experimental|ondansetron-8|Single dose of 8 mg ondansetron (crossover with single dose of placebo)
16623085|NCT02460341|Experimental|ondansetron-16|Single dose of 16 mg ondansetron (crossover with single dose of placebo)
16623086|NCT02460341|Experimental|ondansetron-24|Single dose of 24 mg ondansetron (crossover with single dose of placebo)
16623087|NCT02460315|Active Comparator|early cholecystectomy|group (A) will be managed by early laparoscopic cholecystectomy after clearness ERCP
16623088|NCT02460315|Active Comparator|late cholecystectomy|group (B) will be managed by late LC one month after ERCP.
16623089|NCT02460302|Experimental|Vaginal Progesterone|"In the experimental arm, the participants will be randomized (1:1 allocation) to receive a vaginal progesterone suppository (100mg) as the intervention.
~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the drug three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
16623090|NCT02460302|Placebo Comparator|Placebo Comparator|"In the placebo arm, the participants will be randomized (1:1 allocation) to receive a vaginal suppository (100mg) containing hard fat without any active hormonal ingredient as the intervention.
~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the placebo three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
16623091|NCT02460289|Experimental|Treatment|
16623092|NCT02460276|Experimental|Lenalidomide, ibrutinib and rituximab.|
16623093|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
16623094|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
16623095|NCT02460250|Experimental|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
16623096|NCT02460237|Experimental|Arm I (intervention)|Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
16623097|NCT02460237|Active Comparator|Arm II (control)|Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
16623098|NCT02460224|Experimental|Arm A|Single agent treatment arm with LAG525
16623099|NCT02460224|Experimental|Arm B: combination of LAG525 and PDR001|Combination treatment arm with LAG525 and PDR001
16623100|NCT02460224|Experimental|Arm C|Single agent treatment arm with LAG525 in Japanese pts
16623101|NCT02460211|Active Comparator|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
16623102|NCT02460211|Placebo Comparator|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
16623103|NCT02460198|Experimental|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 4 years).
16623104|NCT02460198|Experimental|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 4 years).
16623105|NCT02460185|No Intervention|Control|Without maternal physical exercise practice
16623106|NCT02460185|Active Comparator|Study Group|Behavioral: 30 minutes of walking, 3 times a week at 4 Km/h. Induction of labor was performed at 41 weeks.
16623107|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
16623108|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
16623109|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
16623110|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
16623111|NCT02460146|Active Comparator|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
16623112|NCT02460146|Placebo Comparator|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
16623113|NCT02460133|Other|HCV Genotype 1, with and without cirrhosis|
16623114|NCT02460120|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
16623115|NCT02460107|Placebo Comparator|Normal saline|Normal saline
16623116|NCT02460107|Active Comparator|Botulinum toxin type A 50U|Botulinum toxin 50U
16623117|NCT02460107|Active Comparator|Botulinum toxin type A 100U|Botulinum toxin 100U
16623118|NCT02460094|Experimental|Panel 1: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
16623119|NCT02460094|Experimental|Panel 2: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
16623120|NCT02460094|Experimental|Panel 3: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
16623121|NCT02460094|Experimental|Panel 4: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
16623122|NCT02460081|Experimental|PDA-002 -3x10^6 cells|Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.
16623123|NCT02460081|Experimental|PDA-002 - 30X10^6 cells|Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.
16623124|NCT02460081|Placebo Comparator|Placebo|Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.
16623125|NCT02460068|Active Comparator|fotemustine|fotemustine alone
16623126|NCT02460068|Experimental|fotemustine and ipilimumab|fotemustine in combination with ipilimumab
16623127|NCT02460068|Experimental|ipilimumab and nivolumab|ipilimumab in combination with nivolumab
16623128|NCT02460055|Active Comparator|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
16623129|NCT02460055|Active Comparator|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
16623131|NCT02460003|Experimental|Physiotherapy program|Physiotherapy program and usual drugs
16623132|NCT02460003|Active Comparator|Home exercise program|Home exercise program and usual drugs
16623133|NCT02459977|Experimental|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
16623134|NCT02459977|Active Comparator|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
16623135|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).
~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
16623136|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
16623137|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
16623138|NCT02459938|Experimental|ZP-Glucagon 0.5 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
16623139|NCT02459938|Experimental|ZP-Glucagon 1.0 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
16623140|NCT02459938|Active Comparator|Glucagon by injection, 0.5 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
16623141|NCT02459938|Active Comparator|Glucagon by injection, 1.0 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
16623142|NCT02459925|Active Comparator|CBT- Mental Health Program|Cognitive Behavioral Therapy. Manualized Stress Management class; brief individual behavioral counseling.
16623143|NCT02459925|Active Comparator|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
16623144|NCT02459912|Other|Unilateral Nerve-Sparing Cryoablation|Unilateral Nerve-Sparing Cryoablation of the Prostate using Galil Medical Precise Cryoablation System with IceRod Needles.
16623145|NCT02459899|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
16623146|NCT02459899|Experimental|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
16623147|NCT02459899|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
16623148|NCT02459899|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
16623149|NCT02459886|Experimental|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
16623150|NCT02459886|Experimental|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
16623151|NCT02459886|Experimental|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
16623152|NCT02459886|Experimental|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
16623153|NCT02459886|Experimental|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
16623154|NCT02459886|Experimental|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
16623155|NCT02459886|Experimental|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
16623156|NCT02459873|Experimental|Computer games to assess change in executive function skills|Children in Intervention group get to train using executive function games at more difficult levels.
16623157|NCT02459873|Active Comparator|Easy games as active comparators for executive function skills|Children in Non-intervention group get to play executive function games at an easy level.
16623158|NCT02459860|Experimental|Problem Solving Treatment|Problem Solving Treatment Individual, face-to-face PST sessions over a span of 8 weeks and 3 monthly booster sessions. The PST protocol is highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies.
16623159|NCT02459860|Active Comparator|Enhanced Usual Care|Enhanced Usual Care EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
16623160|NCT02459847|Experimental|Mindfulness|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant listening to a 19-minute audio-recorded body scan (i.e., mindfulness training), followed by standard care.
16623161|NCT02459847|Experimental|Biofeedback|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant receiving 20 minutes of visual biofeedback training using sonographic imaging (i.e., sonographic biofeedback), followed by standard care.
16623162|NCT02459834|Experimental|Allulose + 75g OGTT|Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
16623163|NCT02459834|Experimental|Fructose + 75g OGTT|Fructose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
16623164|NCT02459834|Active Comparator|75g OGTT (Control)|A 75 g OGTT (alone) of 500 mL will be given to each participant. The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
16623194|NCT02459626||HFpEF and servere diastolic dysfuntion|Left ventricular ejection fraction (LV-EF) > 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=>2, Diagnostic P-V-loops and MRI
16623195|NCT02459626||HFpEF no servere diastolic dysfuntion|LV-EF > 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=>2, Diagnostic P-V-loops and MRI
16623165|NCT02459821|Experimental|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
16623166|NCT02459821|Active Comparator|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
16623167|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
16623168|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
16623169|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
16623170|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
16623171|NCT02459782|Other|US Guided Dual Quadrant Peribulbar block|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
16623172|NCT02459769|Active Comparator|Dyadic Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks). Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
16623173|NCT02459769|Other|Individual Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks). The caregiver is told not to change his/her exercise behavior in any way.
16623174|NCT02459756|Active Comparator|Intervention|Spray dried blackcurrant powder dissolved in water
16623175|NCT02459756|Placebo Comparator|Placebo|(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
16623176|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
16623177|NCT02459730|Experimental|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
16623178|NCT02459730|Active Comparator|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
16623179|NCT02459717|Experimental|Probiotics and prebiotic|fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
16623180|NCT02459717|Placebo Comparator|Placebo|pasteurized fermented milk (125 grams) without prebiotics
16623181|NCT02459704|Experimental|SCPF + EMD (TEST)|Semilunar coronally positioned flap with Enamel matrix derivative (Emdogain)
16623182|NCT02459704|Active Comparator|SCPF (CONTROL)|Semilunar coronally positioned flap alone
16623183|NCT02459691|Active Comparator|Usual Care Only|Patients assigned to this group will continue medical care as usual.
16623184|NCT02459691|Experimental|Vida Sana|Patients assigned to this group will continue medical care as usual and in addition will receive the culturally adapted intervention.
16623185|NCT02459678|Other|Standard of Care|The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.
16623186|NCT02459678|Experimental|Enhanced adherence package|The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.
16623187|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
16623188|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
16623189|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
16623190|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
16623191|NCT02459652|Experimental|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
16623192|NCT02459639||Anthroposophic integrative care|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.
~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
16623193|NCT02459639||Multimodal pain rehabilitation|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.
~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
16623196|NCT02459626||No HF or diastolic dysfunction|LV-EF > 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI
16623198|NCT02459600|Experimental|All participants|"The measurement will be done at all the participants. the results will the divides in the following way:
~Refraction measurements under general anesthesia without cycloplegic eye drops.
~Refraction measurements under general anesthesia with cycloplegic eye drops."
16623199|NCT02459587|Experimental|Crisis Line Facilitation (CLF)|Crisis Line Facilitation
16623200|NCT02459587|Placebo Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care
16623201|NCT02459574|Active Comparator|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
16623202|NCT02459574|Active Comparator|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
16623203|NCT02459574|Experimental|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
16623204|NCT02459561|Experimental|EndoBarrier Arm|The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
16623205|NCT02459561|Other|Medical Therapy Arm|"The standard medical therapy arm will be carried out in accordance with the guidelines of the American Diabetes Association. These guidelines have been chosen as they are applicable to an International audience and thus would adhere to the current best worldwide practice that would still be likely to be relevant when the results are published following study completion.
~Diabetes reviews appointments with a Diabetologist/Endocrinologist will be performed with the control arm patients at visits 2, 4, 6, 7, 9, 11, 12, 13 and 15.
~At study visit 4, 80 subjects will arrive at Mary's Hospital or Southampton Hospital and receive the best Medical Care and dietary advice as part of the Medical Therapy Arm Interventions."
16623206|NCT02459548|Experimental|Primary Care Group|This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
16623207|NCT02459548|Other|Sleep Unit Group|This group will be follow up in Sleep unit at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
16623208|NCT02459535|Active Comparator|Glucose only|oral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623209|NCT02459535|Active Comparator|Glucose + Saccharin|oral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623210|NCT02459535|Active Comparator|Saccharin only|oral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623211|NCT02459535|Active Comparator|Glucose + Aspartame|oral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623212|NCT02459535|Active Comparator|Aspartame only|oral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623213|NCT02459535|Active Comparator|Glucose + Sucralose|oral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623214|NCT02459535|Active Comparator|Sucralose only|oral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
16623215|NCT02459522||Dr.Tang's research group|This group included participants with completed both the short-term HRV test and Ewing's test.
16623216|NCT02459509|Active Comparator|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
16623217|NCT02459509|Active Comparator|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
16623218|NCT02459496|Active Comparator|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
16623219|NCT02459496|Active Comparator|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
16623220|NCT02459483|Experimental|Nurse phone call|a nurse will interview patients by phone every 14 +/- 2 days for 6 months
16623221|NCT02459483|No Intervention|Control Group|Common practice
16623222|NCT02459470|Experimental|SVV and PPV|"SVV(stroke volume variation): recorded using the Flotrac/Vigileo system (Edwards Lifesciences)
~PPV(pulse pressure variation): recorded using philips Intelivue MP70 monitors (Philips Medical System)
~Intervention: Other: Fluid loading using HES 130/0.4; voluven; Fresenius Kabi; Stans, Switzerland"
16623223|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
16623224|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
16623225|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
16623226|NCT02459444|Experimental|IMT group and physiotherapy|Inspiratory muscle training with POWERBREATHE an approximate load of 50 % of MIP , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
16623227|NCT02459444|Placebo Comparator|Sham IMT group|Inspiratory muscle training with the same device in the experimental group , however without charge , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
16623228|NCT02459431|Active Comparator|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
16623229|NCT02459431|Active Comparator|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
16623230|NCT02459418|Experimental|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
16623231|NCT02459418|Active Comparator|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
16623232|NCT02459405|Experimental|NIR anastomotic perfusion assessment|"Patient will have their anastomosis assessed after they receive 7.5 to 9 mg of Indocyanine green intravenously (at a concentration of 2.5mg/ml).
~The microvascularisation assessment will be performed using a near infrared device(Pinpoint device), allowing to increase reality.
~This procedure will be repeated twice during the surgery, the first time before and the second time after the anastomosis has been done."
16623233|NCT02459392|Other|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
16623234|NCT02459392|Experimental|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
16623235|NCT02459392|Other|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
16623236|NCT02459392|Experimental|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
16623237|NCT02459366||control|establish the reliability of measurement of lumbopelvic asymmetry, mechanical and physical properties of thoracolumbar fascia, and the norm of different age
16623238|NCT02459366||low back pain|compare the differences among asymptomatic subjects and patients with and without lumbopelvic asymmetry, and investigate whether lumbopelvic symmetry, core muscle contractility, proprioception and standing balance change after manipulating thoracolumbar fascia tissue by physical therapy
16623239|NCT02459353|Experimental|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
16623240|NCT02459353|Placebo Comparator|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
16623241|NCT02459340|Experimental|patient group|Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)
16623242|NCT02459340|No Intervention|healthy control group|passive control group
16623243|NCT02459327|Experimental|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
16623244|NCT02459327|No Intervention|Control|
16623245|NCT02459314|Placebo Comparator|soymilk|Soymilk (SM) contained 5 gm soy protein and 6.5 gm sugar per 180 mL package.
16623246|NCT02459314|Active Comparator|sterol/fiber-enriched soymilk|PLant sterol and soluble fiber-enriched soymilk (SFSM) contained 1 gm free plant sterol, 5 gm inulin (soluble fiber), 5 gm soy protein and 6.5 gm sugar per 180 mL package
16623247|NCT02459301|Experimental|IPH2201|"Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.
~Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1"
16623248|NCT02459288|Experimental|Clopidogrel first|Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks
16623249|NCT02459288|Experimental|Ticagrelor first|Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks
16623250|NCT02459275|Experimental|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
16623251|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
16623252|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
16623253|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
16623254|NCT02459249|Experimental|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
16623255|NCT02459249|Placebo Comparator|Treatment of Mexican Health Minister|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
16623256|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
16623257|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
16623258|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
16623259|NCT02459223|Active Comparator|Test Group|Treated with nutritional biscuits and khichadi. Nutritional biscuits providing 2.5 to 3 gm Protein and 90-100kcal/kg body Weight/day, as well as local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
16623260|NCT02459223|Active Comparator|Control Group|Treated with only local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
16623261|NCT02459210|Experimental|CLUES|active treatment
16623262|NCT02459210|Active Comparator|therapy and computer games|supportive therapy + computer games
16623263|NCT02459197|Active Comparator|T4P1001|
16623264|NCT02459197|Sham Comparator|Placebo|
16623265|NCT02459184|Experimental|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
16623266|NCT02459184|Active Comparator|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
16623267|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.
~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
16623268|NCT02459158|Experimental|Low dose of ME1100|
16623269|NCT02459158|Experimental|High dose of ME1100|
16623270|NCT02459145|Active Comparator|Graduated Exercise Protocol|Intervention involves exercise starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation. The exercise protocol includes treadmill speed and track minutes per lap conversion, rate of perceived exertion and talk test for each stage of exercise plus total time to execute for 5 days each week.
16623271|NCT02459145|Other|Rest followed by Protocol|No activity in weeks 1 - 8. In week 9 we will begin their intervention phase as described in graduated exercise protocol
16623272|NCT02459132|Experimental|Exercise Group|Subjects in the exercise group will attend supervised exercise sessions three times a week, for 12 weeks. The exercise intervention will consist of uphill walking or jogging on a treadmill between 50% and 95% of VO2peak for 35 minutes (including a 5-minute warm up and cool down). The participants will complete four, 4-minute, high-intensity intervals at 85-95% of VO2peak. The work period intervals will be interspersed with three, 3-minute periods of active recovery at an intensity below that of their ventilatory threshold.
16623273|NCT02459132|No Intervention|Usual Care|The usual care group will not receive an intervention, and they will be asked to maintain baseline physical activity levels throughout the observation period.
16623274|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
16623275|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
16623276|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
16623277|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
16623278|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
16623279|NCT02459080|Active Comparator|TD-4208-1|88 mcg
16623280|NCT02459080|Active Comparator|TD-4208-2|175 mcg
16623281|NCT02459080|Placebo Comparator|Placebo|Placebo
16623282|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
16623283|NCT02459054|Experimental|Primary Pediatric Arm|Cardiac transplant-eligible pediatric patients at imminent risk of death from biventricular failure who are 10 - 18 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
16623284|NCT02459054|Experimental|Primary Adult Arm|Cardiac transplant-eligible adult patients at imminent risk of death from biventricular failure who are 19 - 75 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
16623317|NCT02458820|No Intervention|Usual Care|Patients will be recorded and interpreted as per standard of care. If a seizure is noted by the neurology service, the standard seizure treatment protocol will be used by the clinical team.
16623285|NCT02459054|Experimental|Secondary Arm|Cardiac transplant-eligible pediatric and adult patients at imminent risk of death from biventricular failure who do not meet enrollment criteria for a Primary Arm, but meet less restrictive enrollment criteria for the Secondary Arm. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
16623286|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.
~EG-EUS and CE-EUS will be applied in all patients."
16623287|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.
~EG-EUS and CE-EUS will be applied in all patients."
16623288|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.
~EG-EUS will be applied in all patients."
16623289|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.
~EG-EUS will be applied in all patients."
16623290|NCT02459028|Experimental|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
16623291|NCT02459028|Active Comparator|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
16623292|NCT02459015|Experimental|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
16623293|NCT02459015|Active Comparator|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
16623294|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
16623295|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
16623296|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
16623297|NCT02458989|Active Comparator|Scalpel|Use of a scalpel as a first incision during thyroid operation.
16623298|NCT02458989|Experimental|Electrocautery|Use of an electrocautery as a first incision during thyroid operation.
16623299|NCT02458976|Experimental|PDL|Pre-treatment of surgical area with PDL
16623300|NCT02458963|Active Comparator|IVF group|Women will undergo one full IVF cycle
16623301|NCT02458963|Active Comparator|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
16623302|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.
~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
16623303|NCT02458924|Active Comparator|Schizophrenia|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
16623304|NCT02458924|Active Comparator|Bipolar disorder|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
16623305|NCT02458924|Active Comparator|First degree relatives|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
16623306|NCT02458924|Active Comparator|Health controls|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
16623307|NCT02458898|Experimental|Text Message Intervention|A series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
16623308|NCT02458898|No Intervention|Control (No Text Messages)|Routine care by primary gastroenterologist with no text messages.
16623309|NCT02458872|Experimental|Intervention Arm|Safety huddle alarm intervention.
16623310|NCT02458872|No Intervention|Control Arm|Usual care.
16623311|NCT02458859|Active Comparator|PICO|PICO Negative Pressure Wound Therapy (NPWT) system
16623312|NCT02458859|No Intervention|Standard care|Standard care
16623313|NCT02458846|Experimental|Screened Schools|25 schools. Screening involved: crowded HOTV acuity test, Preschool Randot Stereoacuity Test, and Plusoptix autorefractor. Referral criteria followed AAPOS guidelines for screening for amblyopia and amblyopia risk factors. Children who fail any one of the three tests (including uncooperative/unable children) will be given a referral letter, which includes an assigned appointment time for a comprehensive eye exam at school with a licensed optometrist. Any needed glasses will be dispensed at no cost to the parents. 6 months after the eye exam, we will follow up with a phone call to parents to offer any additional support (such as replacing broken/lost glasses)
16623314|NCT02458846|No Intervention|Care As Usual Schools|"25 schools were randomly allocated to the care as usual schools. No intervention was provided by the research team, however, children may have received optometry/ophthalmology care via regular referral channels (e.g., family physicians, teachers)"
16623315|NCT02458833|Experimental|Intervention|Behavioral: Home Plate intervention
16623316|NCT02458833|Experimental|Delayed Entry Control|This Arm will receive the Home Plate intervention 3 months after the Intervention Arm completes the intervention.
16623318|NCT02458820|Experimental|DSA EEG + Usual Care|Patients will undergo at least hourly interpretation of DSA by the ICU bedside care provider. If the bedside care provider is concerned that there is a seizure on DSA they will contact the EEG tech on call for confirmation. If a seizure is confirmed by neurology, the standard seizure treatment protocol will be used by the clinical team.
16623319|NCT02458794|Active Comparator|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
16623320|NCT02458794|Active Comparator|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
16623321|NCT02458781|Placebo Comparator|Placebo|"Placebo capsule:
~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
16623322|NCT02458781|Active Comparator|Ciprofloxacin|"Ciprofloxacin 250mg capsule:
~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
16623323|NCT02458781|Active Comparator|Metronidazole|"Metronidazole 250mg capsule:
~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
16623324|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.
~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
16623325|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.
~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
16623326|NCT02458755|Experimental|High-dose statin treatment|Atorvastatin (40mg) or Rosuvastatin (20mg)
16623327|NCT02458742|Experimental|Morphine|0.5%Bupivacaine 2 ml with morphine 50 mcg for spinal anesthesia
16623328|NCT02458742|Placebo Comparator|Placebo|0.5%Bupivacaine 2 ml for spinal anesthesia
16623329|NCT02458729|Placebo Comparator|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
16623330|NCT02458729|Active Comparator|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
16623331|NCT02458729|Active Comparator|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
16623332|NCT02458716|Experimental|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
16623333|NCT02458703|Experimental|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
16623334|NCT02458703|Experimental|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
16623335|NCT02458690|Experimental|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
16623336|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
16623337|NCT02458677|Experimental|PRX003|
16623338|NCT02458677|Placebo Comparator|Placebo|
16623339|NCT02458664||Colo-rectal cancer|All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
16623340|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
16623341|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
16623342|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
16623343|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
16623344|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
16623345|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
16623443|NCT02458027|Placebo Comparator|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
16623346|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
16623347|NCT02458625|Active Comparator|Iron sucrose 500 mg|One treatment arm will receive a single dose of I.V iron sucrose 500 mg.
16623348|NCT02458625|Active Comparator|Iron sucrose 500 mg+60 mg Iron bisglycinate|Second treatment arm will receive a single dose of I.V iron sucrose 500 mg and oral treatment with 60 mg Iron bisglycinate for 6 weeks after giving birth.
16623349|NCT02458612|Other|control group|We will apply only upper limbs exercises with traditional therapy.
16623350|NCT02458612|Active Comparator|intervention group|We will apply mirror therapy and progressive strength training for upper extremities.
16623351|NCT02458599|Experimental|Test product|One ready-to-drink beverage of 500 milliliter (mL) volume, containing 20 gram (g) protein will be administered orally, twice daily for four days.
16623352|NCT02458599|Active Comparator|Reference product 1|One ready-to-drink beverage of 500 mL volume, containing 20 g carbohydrate will be administered orally, twice daily for four days.
16623353|NCT02458599|Placebo Comparator|Reference product 2|One ready-to-drink beverage of 500 mL volume, containing 0 g carbohydrate will be administered orally, twice daily for four days.
16623354|NCT02458586|Placebo Comparator|MUFA|daily intake of 50 g of olive oil over a period of 8 weeks
16623355|NCT02458586|Active Comparator|PUFA|daily intake of 50 g of canola oil (rapeseed oil) over a period of 8 weeks
16623356|NCT02458573|Experimental|continuous epidural analgesia group|
16623357|NCT02458573|Active Comparator|continuous intravenous analgesia group|
16623359|NCT02458547|Experimental|Group D|General anesthesia with desflurane
16623360|NCT02458547|Active Comparator|Group P|General anesthesia with propofol total intravenous anesthesia
16623361|NCT02458547|Active Comparator|Group S|Spinal anesthesia with 0.5% bupivacaine
16623362|NCT02458534|Experimental|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
16623363|NCT02458534|Experimental|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
16623364|NCT02458534|Active Comparator|Macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
16623365|NCT02458521|Experimental|Transcranial Magnetic Stimulation|TMS sessions will consist of both 10Hz left pre-frontal stimulation for 3,500 pulses followed by 1Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session.
16623366|NCT02458521|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7.
16623367|NCT02458508||GBM patients|patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation
16623368|NCT02458495|No Intervention|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.
~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
16623369|NCT02458495|Experimental|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
16623370|NCT02458482|Active Comparator|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
16623371|NCT02458482|Experimental|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
16623372|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
16623373|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
16623374|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
16623375|NCT02458456|Sham Comparator|IHG 5% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
16623376|NCT02458456|Experimental|IHG 30% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
16623377|NCT02458456|Experimental|IHG 30% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
16623378|NCT02458456|Sham Comparator|IHG 5% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
16623465|NCT02457897|Experimental|Patients with insulin receptor mutation|
16623466|NCT02457884|Active Comparator|Temporal Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
16623379|NCT02458456|Experimental|IHG 10% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
16623380|NCT02458456|Experimental|IHG 10% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
16623381|NCT02458443|Sham Comparator|IHG 5% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip (IHG) exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
16623382|NCT02458443|Sham Comparator|IHG 5% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
16623383|NCT02458443|Experimental|IHG 30% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
16623384|NCT02458443|Experimental|IHG 30% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
16623385|NCT02458417|Active Comparator|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
16623386|NCT02458417|Experimental|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
16623387|NCT02458417|Experimental|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
16623388|NCT02458417|No Intervention|Control|No intervention
16623389|NCT02458391|Experimental|Treatment 2x/wk|Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
16623390|NCT02458391|Experimental|Treatment 4x/wk|Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
16623391|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
16623392|NCT02458365|Other|Comparison|Health In Motion
16623393|NCT02458352|Other|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
16623394|NCT02458339|Experimental|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
16623395|NCT02458326|Experimental|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
16623396|NCT02458326|Other|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
16623397|NCT02458313|Experimental|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
16623398|NCT02458313|Placebo Comparator|Placebo|Placebo capsules b.i.d. for 12 weeks.
16623399|NCT02458300|Placebo Comparator|Control Arm|Nebulized hypertonic saline. Aspiration of secretions
16623400|NCT02458300|Active Comparator|Intervention Arm.|Nebulization of hypertonic saline. Application of Prolonged slow expiration technique (PSE) expiratory volume. Patient coughing Provocation (TP) Inspiratory maneuver to rhinopharyngeal cleaning DRR Aspiration of secretions
16623401|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
16623402|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
16623403|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
16623404|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
16623405|NCT02458274||Patient without bronchiolitis obliterans syndrome|Lung transplanted patient without bronchiolitis obliterans syndrome
16623406|NCT02458274||Patient with bronchiolitis obliterans syndrome|Patient with bronchiolitis obliterans syndrome three years after lung transplantation.
16623407|NCT02458248|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
16623515|NCT02457559|Experimental|Tirabrutinib|Participant will receive tirabrutinib once or twice daily for up to 5 years.
16623408|NCT02458248|No Intervention|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
16623409|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
16623410|NCT02458222|Experimental|game therapy then standard therapy|participants will take part in language game therapy followed by standard aphasia therapy
16623411|NCT02458222|Experimental|standard therapy then game therapy|participants will have standard aphasia therapy first then will take part in language game therapy
16623412|NCT02458209|Active Comparator|Treatment A|150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Pfizer Andover
16623413|NCT02458209|Experimental|Treatment B|• Treatment B: 150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma
16623414|NCT02458209|Experimental|Treatment C|150 mg SC dose administered in a prefilled pen using drug substance manufactured at Pfizer Andover.
16623415|NCT02458196|Experimental|Prednisone|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
16623416|NCT02458196|Experimental|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
16623417|NCT02458183|Experimental|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
16623418|NCT02458183|Active Comparator|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.
~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
16623419|NCT02458157|Experimental|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP < 50 or mottling beyond the edge of kneecaps).
~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.
~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
16623420|NCT02458157|Active Comparator|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
16623421|NCT02458144|Other|"MIS anterior group"|"Total Hip Arthroplasty anterior surgical approach"
16623422|NCT02458144|Other|"MIS anterolateral group"|"Total Hip Arthroplasty anterolateral surgical approach"
16623423|NCT02458131|Experimental|TEEN HEED|Adolescent pre-diabetics will receive 8-12 weekly peer-led diabetes prevention educational workshops in community sites. The in-person group workshops will be supplemented by support through mobile health technologies such as text messaging and social media.
16623424|NCT02458131|No Intervention|Wait List Control|Adolescent pre-diabetics in this group will not receive any intervention until collection of all follow up data and will then be offered the same intervention as the participants in the experimental arm.
16623425|NCT02458118|Experimental|Secretin|Secretin 1 IU/kg over 3 min
16623426|NCT02458105|Experimental|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
16623427|NCT02458105|Active Comparator|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
16623428|NCT02458092|Experimental|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
16623429|NCT02458092|Experimental|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
16623430|NCT02458079|Experimental|Pentoxiphylline|
16623431|NCT02458079|Active Comparator|Stool Microbiota Transplantation|
16623432|NCT02458066|Active Comparator|Bendiocarb|IRS: bendiocarb
16623433|NCT02458066|Active Comparator|Deltamethrin|IRS: deltamethrin
16623434|NCT02458053|Experimental|TEAM Enhanced|The enhanced intervention will include group sessions where the participant attends with partner ( including a couples skill training session), weekly tailored feedback, and weekly lessons.
16623435|NCT02458053|Active Comparator|TEAM Traditional|The intervention will include group sessions where the male attends alone, weekly tailored feedback, and weekly lessons.
16623436|NCT02458040||Biomarker-positive patients|
16623437|NCT02458040||Biomarker-negative patients|
16623438|NCT02458040||All patients|
16623439|NCT02458027|Experimental|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
16623440|NCT02458027|Experimental|40 g Hemp Protein Shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
16623441|NCT02458027|Active Comparator|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
16623442|NCT02458027|Experimental|40 g Soybean Protein Shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
16623444|NCT02458014|Experimental|Treatment (blinatumomab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
16623445|NCT02458001|Experimental|SAFFRON stepped care|3 level intervention: level 1:Self help booklet level 2: CNS delivered intervention level 3: psychologist delivered intervention
16623446|NCT02458001|No Intervention|enhanced treatment as usual (ETU)|level 1 intervention: self help booklet Non study trained CNS will offer assessment, advice, vaginal dilator training where appropriate, arrange topical oestrogens or other creams
16623447|NCT02457988|Experimental|Vivify Kit|Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.
16623448|NCT02457988|No Intervention|Standard of Care|Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.
16623449|NCT02457975|Active Comparator|Intravitreous VEGF-inhibitors|Three intravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
16623450|NCT02457975|Experimental|670nm PBM plus VEGF-inhibitors|Subjects in the 670 nm Photobiomodulation (PBM) intervention arm will be treated (in addition to Anti-VEGF treatment) with 670nm light (WARP10, Quantum, Devices, Inc, Barneveld, WI). The portable, battery-operated 670 nm LED array specifically designed not to generate heat will be held 1 inch from the closed treatment eye. A 90-sec light treatment will be delivered. After 90 sec a timer turns off the light. The dose of light delivered at the surface of the cornea is calculated to be 4.5 J/cm2 (90 sec x 0.05 W/cm2 = 4.5 J/cm2). PBM treatment will be applied for 90 sec once per day, three consecutive days per week for 8 weeks. Previous clinical studies, have shown this treatment regimen and dose to be safe and effective in the treatment of dry AMD and non-center involving DME
16623451|NCT02457949|No Intervention|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
16623452|NCT02457949|Experimental|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
16623453|NCT02457949|Experimental|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
16623454|NCT02457936|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
16623455|NCT02457936|Active Comparator|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
16623456|NCT02457923|Experimental|Mobile phone counselling|"The intervention will include:
~An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.
~Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.
~Server generated reminders and alerts, delivered to the mother, ASHA and ANM.
~An App for field supervisor to monitor ASHAs
~Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
16623457|NCT02457923|No Intervention|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
16623458|NCT02457910|Experimental|Taselisib 2 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
16623459|NCT02457910|Active Comparator|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib
16623460|NCT02457910|Experimental|Taselisib 4 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
16623461|NCT02457910|Experimental|Taselisib 6 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
16623462|NCT02457910|Experimental|Taselisib 8 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
16623463|NCT02457910|Experimental|Enzalutamide + Taselisib|Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16623464|NCT02457910|Experimental|Cross-Over|Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD
16623467|NCT02457884|Active Comparator|Spatial Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
16623468|NCT02457884|Active Comparator|Combined Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
16623469|NCT02457884|Placebo Comparator|Control Group|Receive 6 weekly 1-hour training sessions of leisure reading activities
16623470|NCT02457871|Experimental|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
16623471|NCT02457871|No Intervention|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
16623472|NCT02457858|Experimental|BMX-010 treated islets|Islet isolation using BMX-010
16623473|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
~Intervention: Biological: G207"
16623474|NCT02457832|Experimental|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
16623475|NCT02457832|Experimental|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
16623476|NCT02457832|Active Comparator|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
16623477|NCT02457832|No Intervention|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
16623478|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
16623479|NCT02457806|Experimental|Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart
16623480|NCT02457806|Active Comparator|Kovacaine Mist and Placebo|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart
16623481|NCT02457806|Active Comparator|Placebo and Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart
16623482|NCT02457806|Placebo Comparator|Placebo spray|3 sprays of placebo in each nostril administered 4 minutes apart
16623483|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
16623484|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
16623485|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
16623486|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
16623487|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
16623488|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
16623489|NCT02457780|Experimental|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
16623490|NCT02457780|Active Comparator|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
16623491|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
16623492|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
16623493|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
16623494|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
16623495|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
16623496|NCT02457702|Experimental|Orally administered Labeled Glycerol|Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
16623497|NCT02457689|Placebo Comparator|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
16623498|NCT02457689|Active Comparator|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
16623499|NCT02457689|Placebo Comparator|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
16623500|NCT02457689|Active Comparator|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
16623501|NCT02457676|Experimental|Alert Program for Self-Regulation|Participants with FASD who received the Alert Program for Self-Regulation therapy between the two testing periods.
16623502|NCT02457676|No Intervention|FASD Alert Waitlist|Participants with FASD who did not receive therapy between the two testing periods but were provided intervention on study completion.
16623503|NCT02457676|No Intervention|Typically Developing Control|Normally developing controls not exposed to alcohol in utero who were not treated between the two testing periods.
16623504|NCT02457650|Experimental|Anti-NY ESO-1 TCR-transduced T cells|Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
16623505|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.
~ALI(acute liver injury): including [ALT>3NL(normal level),AST>3NL or TB>2NL within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB>5NL)within 1 month before enrollment)].
~Standary therapy"
16623506|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
16623507|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
16623508|NCT02457598|Experimental|Tirabrutinib + Idelalisib (Combination I)|"Dose Escalation:
~Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib 20 mg + idelalisib 50 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 20 mg + idelalisib 50 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + idelalisib up to 100 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + idelalisib for an additional 6 years from the date of Protocol Amendment 8."
16623509|NCT02457598|Experimental|Tirabrutinib + Entospletinib (Combination II)|"Dose Escalation:
~Participants will receive a single dose of tirabrutinib 40 mg on Day 1 of Cycle 1 and tirabrutinib 40 mg + entospletinib 200 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 40 mg + entospletinib 200 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + entospletinib up to 400 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + entospletinib for an additional 6 years from the date of Protocol Amendment 8."
16623510|NCT02457598|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)|"Dose escalation:
~Participants will receive tirabrutinib + idelalisib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and idelalisib doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
16623511|NCT02457598|Experimental|Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)|"Dose escalation:
~Participants will receive tirabrutinib + entospletinib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and entospletinib doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
16623512|NCT02457598|Experimental|Single Agent Tirabrutinib (Combination V)|Participants with relapsed or refractory chronic lymphocytic leukemia (CLL) may be enrolled to receive tirabrutinib 80 mg once daily.
16623513|NCT02457585|Experimental|experimental group|"anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).
~evaluation of response at 30weeks by PET CT, acute phase reactants, symptom
~No placebo group"
16623514|NCT02457572||Valsalva maneuver|This is an observational study and as a diagnostic intervention, subjects in the study would receive valsalva maneuver. Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration. The investigators perform this procedure to every patients and do not assign this intervention to the subjects of the study.
16623516|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
16623517|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
16623518|NCT02457533|No Intervention|Control|Only SF-36 and CAT
16623519|NCT02457533|Active Comparator|Active|Lifestyle behavioral. Health plan, telephone support
16623520|NCT02457520|Experimental|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
16623521|NCT02457507|Experimental|Vitamin B12|Vitamin B12, 1mg, daily, 27 months
16623522|NCT02457507|Placebo Comparator|Placebo|Placebo comparator
16623523|NCT02457481|Experimental|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
16623524|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
16623525|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
16623526|NCT02457442|Active Comparator|PR1|Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)
16623527|NCT02457442|Active Comparator|PR2|Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)
16623528|NCT02457442|Active Comparator|SR1|Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)
16623529|NCT02457442|Active Comparator|SR2|Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)
16623530|NCT02457442|Active Comparator|SPR1|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.
16623531|NCT02457442|Active Comparator|SPR2|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.
16623532|NCT02457429|Other|Routine oesophageal pH monitoring|Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
16623533|NCT02457416|Active Comparator|Peanut oral immunotherapy|Oral immunotherapy with peanut
16623534|NCT02457416|No Intervention|Controls|Avoid peanut exposure
16623535|NCT02457403|Experimental|ROTEM|Transfusion guided by ROTEM during OLT
16623536|NCT02457403|Active Comparator|Conventional|Transfusion guided by conventional labs
16623537|NCT02457390|Experimental|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.
~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.
~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
16623538|NCT02457377|Experimental|Laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
16623539|NCT02457351|Experimental|Roniciclib + Itraconazole|Pharmacokinetics and safety in patients with advanced solid tumor
16623540|NCT02457338|Experimental|Supplement Group|This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.
16623541|NCT02457338|No Intervention|Control Group|This group will receive standard care plus lactation consultation only.
16623542|NCT02457325|Experimental|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
16623543|NCT02457325|Experimental|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
16623544|NCT02457312|Active Comparator|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
16623545|NCT02457312|Placebo Comparator|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
16623546|NCT02457299|Active Comparator|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
16623547|NCT02457299|Active Comparator|One Stage Esophagectomy|Esophagectomy alone
16623548|NCT02457286|Experimental|Metformin|Metformin is being compared to exercise and diet modifications. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
16623581|NCT02457078|Experimental|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
16623549|NCT02457286|Experimental|Lifestyle modification|The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating participants condition or disorder. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
16623550|NCT02457273|Experimental|Assigned Interventions|TLC 388
16623551|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
16623552|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
16623553|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
16623554|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
16623555|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
16623556|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
16623557|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
16623558|NCT02457234|Experimental|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
16623559|NCT02457234|Active Comparator|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
16623560|NCT02457234|No Intervention|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
16623561|NCT02457221|Experimental|Tacrolimus group|Tacrolimus capsules + steroid
16623562|NCT02457221|Active Comparator|Cyclophosphamide group|Cyclophosphamide injections + steroid
16623563|NCT02457208|Experimental|2HRZE/4HR|"2HRZE/4HR
~Intensive phase: 2 months HRZE - once daily
~Continuation phase: 4 months HR - once daily
~Adults will be treated with fixed dose combination (FDC) tablets containing:
~Intensive phase (content per tablet)
~Isoniazid -75 mg,
~Rifampicin - 150 mg,
~Pyrazinamide - 400 mg,
~Ethambutol - 275 mg
~Continuation phase (content per tablet)
~Isoniazid 150 mg
~Rifampicin 300 mg
~*Drug dosing will be adjusted by patient body weight."
16623564|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
16623565|NCT02457182|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
16623566|NCT02457182|Placebo Comparator|Usual Care|Usual medical therapy
16623567|NCT02457169|Experimental|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
16623568|NCT02457169|Other|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
16623569|NCT02457156|Experimental|Blumgart Anastomosis|"Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a Blumgart method of pancreatico-jejunostomy.
~Octreotide will be administered."
16623570|NCT02457156|Active Comparator|Cattell-Warren Anastomosis|"Re-construction of the pancreatic remnant following pancreato-duodenectomy using a Cattell-Warren method of pancreatico-jejunostomy.
~Octreotide will be administered."
16623571|NCT02457143|Experimental|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
16623572|NCT02457143|Experimental|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
16623573|NCT02457130|Experimental|Group A|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.
~Ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week; washout period of 2-4 weeks; crossover to clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week."
16623574|NCT02457130|Experimental|Group B|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.
~Clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week; washout period of 2-4 weeks; crossover to ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week."
16623575|NCT02457104||normal weight individuals not taking PPI|
16623576|NCT02457104||normal weight individuals taking PPI|
16623577|NCT02457104||obese individuals not taking PPI|
16623578|NCT02457104||obese individuals taking PPI|
16623579|NCT02457091|Active Comparator|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
16623580|NCT02457091|Experimental|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
16623609|NCT02456935|Active Comparator|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
16623582|NCT02457078|Placebo Comparator|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
16623583|NCT02457065|Experimental|Receive Plaque|"Treatment
~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
16623584|NCT02457065|No Intervention|Do Not Receive Plaque|"Control
~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
16623585|NCT02457052|Experimental|DATP +|Introduction of a device allowing a custom sitting to help patients with swallowing disorders .
16623586|NCT02457052|No Intervention|DATP -|No introduction of a device allowing a custom sitting to help patients with swallowing disorders .
16623587|NCT02457039|Active Comparator|Comprehensive acupuncture (CAI)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Dense cranial electroacupuncture stimulation (DCEAS) and Body acupuncture (BA).
16623588|NCT02457039|Sham Comparator|Least acupuncture stimulation (LAS)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Least acupuncture stimulation (LAS)
16623589|NCT02457026|Experimental|Adjunctive PDT + Aflibercept|Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
16623590|NCT02457026|Active Comparator|Aflibercept Alone|"Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3. At Study Visit 4, participants will have repeat assessment of disease activity. From Study Visit 4 onwards, aflibercept will be administered according to a treat-and-extend strategy. If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially extended from every 28 days to every 42 days. If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments. For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time."
16623591|NCT02457013|Experimental|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
16623592|NCT02457013|Active Comparator|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
16623593|NCT02457000||Normal, healthy volunteers|Normal, healthy volunteers without any skin pathology will be asked to undergo various procedures to evaluate their sleep and skin health.
16623594|NCT02457000||Volunteers with skin pathology|Volunteers with skin pathology including but not limited to eczema, psoriasis, acne, and other inflammatory dermatoses will be asked to undergo various procedures to evaluate their sleep and skin health.
16623595|NCT02456987|Experimental|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
16623596|NCT02456987|No Intervention|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
16623597|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
16623598|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
16623599|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
16623600|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
16623601|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
16623602|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
16623603|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
16623604|NCT02456961|Active Comparator|Standard epithelium-off CXL|Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)
16623605|NCT02456961|Experimental|Transepithelial CXL via iontophoresis of riboflavin|"impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.
~Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes"
16623606|NCT02456948|Experimental|Minocycline|Minocycline and standard antidepressant treatment
16623607|NCT02456948|Placebo Comparator|Placebo|Placebo and standard antidepressant treatment
16623608|NCT02456935|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
16623610|NCT02456922|Other|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
16623611|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
16623612|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
16623613|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
16623614|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
16623615|NCT02456883|Experimental|gilteritinib and 14C-labeled gilteritinib|Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
16623616|NCT02456870|Other|MA|Middle-aged overweight and obese men (age 25-40yr)
16623617|NCT02456870|Other|OA|Older overweight and obese men (age 55-75yr)
16623618|NCT02456857|Experimental|Treatment (DAE)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during cycle 4 of therapy. Patients then undergo surgery.
16623619|NCT02456844|Experimental|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
16623620|NCT02456844|Experimental|Group 2|Methotrexate,Leucovorin and BMS-986142
16623621|NCT02456831|Active Comparator|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
16623622|NCT02456831|Experimental|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
16623623|NCT02456831|Experimental|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
16623624|NCT02456831|Experimental|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
16623625|NCT02456818||Centers using contact isolation|"Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures
~Contact isolation terminated, after at least two negative consecutive fecal screening cultures
~Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions
~Contact isolation must include:
~Patient placement in single rooms
~Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical
~Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room"
16623626|NCT02456818||Centers using no contact isolation|"not regularly isolating for ESBL-EC
~ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (>3 loose bowel movements/day) isolated in single rooms with above described contact precautions"
16623627|NCT02456805|Active Comparator|Infant Formula 1|A standard commercial milk-based infant formula
16623628|NCT02456805|Experimental|Infant Formula 2|A standard commercial soy-based infant formula.
16623629|NCT02456792|Active Comparator|IVF group|Women will undergo one full IVF cycle
16623630|NCT02456792|Active Comparator|LOD group|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
16623631|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.
~RDQ greater or equal to 12
~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
16623632|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.
~RDQ greater or equal to 12
~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
16623633|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9
~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
16623634|NCT02456766||F0|Liver Steatosis Grade: <5%
16623635|NCT02456766||F1|Liver Steatosis Grade: 5-33%
16623636|NCT02456766||F2|Liver Steatosis Grade: 34-66%
16623637|NCT02456766||F3|Liver Steatosis Grade: > 66%
16623638|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.
~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
16623639|NCT02456740|Placebo Comparator|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
16623640|NCT02456740|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
16623641|NCT02456740|Experimental|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
16623642|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
16623643|NCT02456727|Active Comparator|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
16623644|NCT02456714|Experimental|Progressive cholangiocarcinoma, second line treatment|FOLFIRINOX
16623645|NCT02456701|Experimental|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
16623646|NCT02456688|Experimental|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
16623684|NCT02456480|Experimental|CLS001 topical gel 1%|
16623647|NCT02456688|Experimental|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
16623648|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
16623649|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
16623650|NCT02456662|Placebo Comparator|Placebo|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
16623651|NCT02456662|Active Comparator|Ondansetron|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
16623652|NCT02456649|Experimental|MarginProbe|Single arm study - MarginProbe in addition to standard procedure
16623653|NCT02456636|Active Comparator|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
16623654|NCT02456636|Active Comparator|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
16623655|NCT02456636|Active Comparator|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
16623656|NCT02456623|Experimental|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
16623657|NCT02456623|Active Comparator|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
16623658|NCT02456610|Experimental|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
16623659|NCT02456597|Active Comparator|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
16623660|NCT02456597|Placebo Comparator|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
16623661|NCT02456584|Experimental|DMPA 150|single subcutaneous injection of 150mg/mL of DMPA in the abdomen
16623662|NCT02456584|Experimental|DMPA 300|single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
16623663|NCT02456584|Active Comparator|DMPA 104|two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen
16623664|NCT02456571||Group A|men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.
16623665|NCT02456571||Group B|men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
16623666|NCT02456571||Group C|men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
16623667|NCT02456571||Group D|men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)
16623668|NCT02456558|Experimental|Intravenous deferiprone, 1.5 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 1.5 g, twice-daily
16623669|NCT02456558|Experimental|Intravenous deferiprone, 2 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 2 g, twice-daily
16623670|NCT02456558|Placebo Comparator|Placebo|Subjects in this arm will receive an infusion of placebo twice-daily for 10 days, at a volume equivalent to that of the active product in the respective cohort
16623671|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)
~anticipated n = 500"
16623672|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)
~anticipated n = 500"
16623673|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)
~anticipated n = 150"
16623674|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study
~anticipated n = 500"
16623675|NCT02456532|Placebo Comparator|Placebo|Intervention: Six months of nightly placebo
16623676|NCT02456532|Active Comparator|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
16623677|NCT02456532|Active Comparator|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
16623678|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
16623679|NCT02456506|Experimental|Hyperfractionated IMRT Group|IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)
16623680|NCT02456506|Active Comparator|Conventional Fraction IMRT Group|IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)
16623681|NCT02456493||increased carotid IMT group|Patients who have increased carotid IMT (intima media thickness)
16623682|NCT02456493||normal carotid IMT group|Patients who have normal carotid IMT
16623683|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
16623686|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
16623687|NCT02456454|Experimental|Risperidone|Risperidone, PO 0.25-2 mg/day
16623688|NCT02456454|Experimental|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
16623689|NCT02456454|Placebo Comparator|Placebo|Liquid placebo PO matched for color and taste.
16623690|NCT02456441|Experimental|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
16623691|NCT02456441|Placebo Comparator|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
16623692|NCT02456428||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
16623693|NCT02456428||Treated with insulin|Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
16623694|NCT02456428||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
16623695|NCT02456428||Treated with single oral agent|Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
16623696|NCT02456428||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.
16623697|NCT02456415|Experimental|K-MET™ Bioresorbable Bone screw|The K-MET™ Bioresorbable Bone Screw, intended to be used for trauma therapy, consists of Cortex screws, Cannulated headless screws. For Headless screw and Cannulated headless screws, the design is similar to normal headless compression screws but the compression function was achieved by using different lengths for the front and rear pitches. These screws are dynamic and allow therewith the fracture at the Carpal, metacarpal, and small hand bone.
16623698|NCT02456402|Experimental|Drug Coated Balloon|PCB (SeQuent Please®, paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany)
16623699|NCT02456402|Active Comparator|Bare Metal Stent|BMS (Vision®)
16623700|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
16623701|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
16623702|NCT02456376|Experimental|Children with Cerebral palsy|"Sensory integration testing
~SR stimulation and Sensory integration testing"
16623703|NCT02456376|Active Comparator|Children with Typical Development|"Sensory integration testing
~SR stimulation and Sensory integration testing"
16623704|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
16623705|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
16623706|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
16623707|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
16623708|NCT02456350|Experimental|Anti-CD19-CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
16623709|NCT02456337|Experimental|CAF+MC+EMD|Coronally Advanced Flap with Mucograft and Emdogain
16623710|NCT02456337|Active Comparator|CAF+MC|Coronally Advanced Flap with Mucograft
16623711|NCT02456337|Active Comparator|CAF+EMD|Coronally Advanced Flap with Emdogain
16623712|NCT02456337|Active Comparator|CAF|Coronally Advanced Flap alone
16623713|NCT02456324|Experimental|Treatment Group|Patients Treated with PICS-AF device
16623714|NCT02456324|Other|Historical Controls|Patients Treated with Commercially Available Fistula Plug Devices at Same Sites
16623715|NCT02456311|Other|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
16623716|NCT02456298|Active Comparator|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
16623717|NCT02456298|Experimental|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
16623718|NCT02456272|Experimental|External hearing aid & Otosclerosis surgery|Trying an hearing aid for at least two months and then undergo otosclerosis surgery
16623719|NCT02456259||Neck cannula group|Patients in this group are indicated for neck cannula insertion due to tzpu of cardiac surgery (MICS)
16623720|NCT02456259||Central venous catheter only group|Patients in this group are indicated for central venous catheter insertion only.
16623721|NCT02456246|Experimental|FLT-PET|"Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy.
~Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT
~Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence."
16623722|NCT02456233|Active Comparator|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
16623723|NCT02456233|Experimental|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
16623724|NCT02456220|Experimental|Herbst Group|Patients treated with Herbst appliance.
16623725|NCT02456220|No Intervention|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
16623726|NCT02456207|Experimental|Experimental|SCT400:375 mg/m2, iv, one infusion
16623727|NCT02456207|Active Comparator|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
16623728|NCT02456194|Experimental|Calcium Sulfate + Antibiotics + Internal Fixation|
16623729|NCT02456181|Experimental|JumpMath|"The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude 3)."
16623730|NCT02456168||SLE|
16623731|NCT02456168||Healthy control|
16623732|NCT02456155|Experimental|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
16623733|NCT02456155|Placebo Comparator|endoscope group|Conventional methods for placing Nasal Jejunal Tube
16623734|NCT02456142|Experimental|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
16623735|NCT02456142|Active Comparator|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
16623736|NCT02456129|Experimental|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
16623737|NCT02456116|Experimental|acupuncture/PCA/NSAID|"standard program with defined points:
~Ear acupuncture needles bitten once (day 0-5)
~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
16623738|NCT02456116|Sham Comparator|sham acupuncture/PCA/NSAID|"standard program with defined points:
~Ear sham-acupuncture needles bitten once (day 0-5)
~Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
16623739|NCT02456116|Other|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
16623740|NCT02456103|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
16623741|NCT02456077|Experimental|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
16623742|NCT02456077|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
16623743|NCT02456064|Experimental|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
16623744|NCT02456064|No Intervention|Normal group|In this group will be controlled as usual in the consultations.
16623745|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
16623746|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
16623747|NCT02456038|Experimental|Asfotase Alfa (ALXN1215)|Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.
16623748|NCT02456025|Active Comparator|Topical tacrolimus|20 eyes with active Vernal Keratoconjunctivitis
16623749|NCT02456025|Placebo Comparator|Placebo|20 eyes with active Vernal Keratoconjunctivitis
16623750|NCT02456012|Experimental|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
16623751|NCT02456012|Experimental|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
16623752|NCT02456012|No Intervention|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
16623753|NCT02455999|Experimental|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
16623754|NCT02455999|Experimental|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
16623755|NCT02455999|Placebo Comparator|Placebo|Placebo eye drops administration via the ophthalmic route
16623756|NCT02455986|Experimental|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.
~School and team based competition. 27/05/15 - 22/06/15 (8 weeks)
~Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)
~Prizes of low monetary value will be given to participants based on competition performance"
16623757|NCT02455986|No Intervention|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
16623758|NCT02455973|Experimental|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
16623759|NCT02455973|Placebo Comparator|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
16623760|NCT02455960|Experimental|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
16623833|NCT02455518|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
16623761|NCT02455960|Placebo Comparator|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
16623762|NCT02455947|Experimental|Inquiry Based Stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie.It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
16623763|NCT02455947|No Intervention|Control group|A non interventional group/ The participants completed questionnaires before and after the intervention.
16623764|NCT02455934|Placebo Comparator|Sucrose|Sucrose 50 g
16623765|NCT02455934|Active Comparator|SAlloulose2.5|Sucrose 50 g + D-allulose (psicose) 2.5 g
16623766|NCT02455934|Active Comparator|SAllulose5|Sucrose 50 g + D-allulose (psicose) 5 g
16623767|NCT02455934|Active Comparator|SAllulose7.5|Sucrose 50 g + D-allulose (psicose) 7.5 g
16623768|NCT02455934|Active Comparator|SAllulose10|Sucrose 50 g + D-allulose (psicose) 10 g
16623769|NCT02455921|Active Comparator|sugammadex|iv sugammadex 2 mg/Kg
16623770|NCT02455921|Active Comparator|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg
~Efficacy, safety and effect on cognitive and behavioural function"
16623771|NCT02455908|Experimental|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:
~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.
~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.
~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
16623772|NCT02455895|Active Comparator|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
16623773|NCT02455895|Placebo Comparator|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
16623774|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
16623775|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
16623776|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
16623777|NCT02455869|Placebo Comparator|Placebo group|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
16623778|NCT02455869|Active Comparator|Atorvastatin group|SRP plus Atorvastatin SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
16623779|NCT02455869|Active Comparator|Alendronate Group|Alendronate SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
16623780|NCT02455856|Experimental|JNJ-42847922 plus Itraconazole|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
16623781|NCT02455843|Experimental|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
16623782|NCT02455843|Placebo Comparator|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
16623783|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
16623784|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
16623785|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
16623786|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
16623787|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
16623788|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
16623789|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
16623790|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
16623791|NCT02455804|Other|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
16623792|NCT02455791|Experimental|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
16623793|NCT02455778|Experimental|Cinnamon|3 grams of oral cinnamon per day in form of capsules (6) along with standard diet and exercise protocol
16623794|NCT02455778|Placebo Comparator|Placebo|2.5 grams of wheat flour per day in form of capsules ( 6) along with standard diet and exercise protocol
16623795|NCT02455765|Experimental|White rice control|Subjects will consume white rice as control (50g carbohydrate)
16623796|NCT02455765|Experimental|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
16623797|NCT02455765|Experimental|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
16623798|NCT02455765|Experimental|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
16623799|NCT02455765|Experimental|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
16623800|NCT02455765|Experimental|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
16623801|NCT02455765|Experimental|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
16623802|NCT02455752|Active Comparator|Reroperitoneal Group|LE-TME
16623803|NCT02455739|Experimental|chewing gum positive|chewing gum group will chew gum
16623804|NCT02455739|No Intervention|chewing gum negative|chewing gum group will not chew gum
16623805|NCT02455726|Experimental|Mg-group|"Standard therapy plus magnesium oxide.
~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
16623806|NCT02455726|Placebo Comparator|C-group|"Standard therapy plus fructose.
~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
16623807|NCT02455713||Intervention|Alter PEEP and PIP and measure hemodynamic outcomes.
16623808|NCT02455700|Active Comparator|Hand driven enamel reduction|This group will have enamel reduction in the lower incisor region carried out using hand held devices
16623809|NCT02455700|Active Comparator|Rotary ( motor driven) device|This group will ahve enamel reduction in the lower incisor region carried out using a rotary (motor driven) device
16623810|NCT02455687|Active Comparator|Hi-Mg + Bud|Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.
16623811|NCT02455687|Placebo Comparator|Hi-Mg + P|Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.
16623812|NCT02455687|Active Comparator|Std-Mg + Bud|Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.
16623813|NCT02455687|Placebo Comparator|St-Mg + P|Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline
16623814|NCT02455674||Age under 6 years|"All children 1 to 6 years
~Used formula for weight calculation:
~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
16623815|NCT02455674||Age over 6 years|"All children 6 to 12 years
~Used formula for weight calculation:
~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
16623816|NCT02455661|Experimental|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
16623817|NCT02455661|Active Comparator|Femoral PCI with AngioSeal device|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
16623818|NCT02455661|Active Comparator|Femoral PCI with StarClose device|
16623819|NCT02455648|Experimental|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
16623820|NCT02455648|Sham Comparator|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
16623821|NCT02455635|Active Comparator|women with pain|women who felt pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
16623822|NCT02455635|Active Comparator|women without pain|women who didn't feel pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
16623823|NCT02455622|Experimental|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
16623824|NCT02455609|Active Comparator|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
16623825|NCT02455609|Active Comparator|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
16623826|NCT02455609|Active Comparator|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
16623827|NCT02455596|Experimental|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
16623828|NCT02455583|No Intervention|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
16623829|NCT02455583|Experimental|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
16623830|NCT02455557|Experimental|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
16623831|NCT02455544||Pregnant Women|Any pregnant women that is referred to or presents to our tertiary care facility with concern for preeclampsia, will have a Congo Red Dot test preformed by research nurses. The research nurses are not involved in patient management and the results are blinded to the clinical providers and have no impact on clinical diagnosis or patient management.
16623832|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
16623834|NCT02455518|Active Comparator|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
16623835|NCT02455518|Active Comparator|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
16623836|NCT02455518|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
16623837|NCT02455505||Risk Screening tool & Cognitive Interview|
16623838|NCT02455479|Other|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
16623839|NCT02455479|Other|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
16623840|NCT02455479|Other|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
16623841|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans
~First one prior to estradiol challenge test
~Second one immediately following one day of estradiol challenge test
~(1) FDG-PET/CT scan at screening
~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
16623842|NCT02455440|Active Comparator|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
16623843|NCT02455440|Placebo Comparator|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
16623844|NCT02455427|Active Comparator|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
16623845|NCT02455427|Sham Comparator|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.
~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
16623846|NCT02455414||Wolfram Syndrome Group|"Participant has confirmation of a WFS1 mutation OR
~Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old"
16623847|NCT02455414||WFS Pre-symptomatic Sibling Group|"Has had genotyping
~Willingness to share result of genotyping
~Participant has confirmation of WFS1 (+/+) mutation but is asymptomatic."
16623848|NCT02455414||WFS Control Sibling Group|"Has had genotyping
~Willingness to share result of genotyping
~Patient has confirmation of NO WFS1 mutation (-/-) or confirmation as a carrier (+/- or -/+)."
16623849|NCT02455414||T1DM Group|"Age within the 0-28 yrs age range of WS participant
~Dx of T1 diabetes mellitus"
16623850|NCT02455414||Healthy Control (HC) Group|• Age within the 0-28 yrs age range of WFS participants
16623851|NCT02455414||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
16623852|NCT02455401|Experimental|high dose remifentanil group|Intervention: high dose remifentanil will be administrated.
16623853|NCT02455401|Experimental|low dose remifentanil group|Intervention: low dose remifentanil will be administrated
16623854|NCT02455401|Placebo Comparator|No remifentanil group|Intervention: no remifenatnil will be administrated
16623855|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
16623856|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
16623857|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
16623858|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:
~detection of PUUV RNA in plasma collected at admission.
~or/and detection of IgM and IgG against PUUV in serum collected at admission,
~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
16623859|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
16623860|NCT02455362|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
16623861|NCT02455362|Experimental|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
16623862|NCT02455362|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
16623863|NCT02455362|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
16623864|NCT02455362|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
16623865|NCT02455362|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
16623866|NCT02455362|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
16623867|NCT02455362|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
16623868|NCT02455362|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
16623869|NCT02455362|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
16623870|NCT02455362|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
16623871|NCT02455362|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
16623872|NCT02455336|Experimental|Fenofibrate|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
16623941|NCT02454881|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
16623873|NCT02455336|Other|No Intervention|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive no therapy for 4 months
16623874|NCT02455323|Experimental|Suboccipital inhibitory|Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
16623875|NCT02455323|Experimental|Spinal Manipulative|Suboccipital inhibitory pressure technique. This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility.
16623876|NCT02455323|Experimental|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
16623877|NCT02455323|Placebo Comparator|Control group|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
16623878|NCT02455310||Outpatients with dementia|Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
16623879|NCT02455310||Nursing home residents|Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
16623880|NCT02455297|Experimental|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
16623881|NCT02455284|Experimental|Healthy subjects|MRI and neuropsychological evaluation
16623882|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
16623883|NCT02455258|Experimental|Dance/Movement Therapy (DMT)|
16623884|NCT02455258|Active Comparator|Aerobics Exercise (AE)|
16623885|NCT02455258|No Intervention|Waiting List|This group is placed on a waiting list and asked to refrain from making any changes to their current lifestyle.
16623886|NCT02455245|Active Comparator|Carboplatine and Vincristine|"Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
~Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC >1,000/µL and platelet count >100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
~Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children <12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle."
16623887|NCT02455245|Experimental|Carboplatin alone|"Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks).
~Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks"
16623888|NCT02455232|Experimental|hemiplegic patient|muscle participation in upper limb spasticity
16623889|NCT02455206|Active Comparator|Usual Care|outpatient pulmonary Rehabilitation program
16623890|NCT02455206|Experimental|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
16623891|NCT02455193|Experimental|Exercise intervention|10 weeks of a moderate exercise intervention
16623892|NCT02455193|Active Comparator|Diet intervention|10 weeks of a diet intervention
16623893|NCT02455180|Experimental|4x 1 gram bolus (q12H) dosage regimen|1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).
16623894|NCT02455180|Experimental|4x 5 grams bolus (q12H) dosage regimen|5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).
16623895|NCT02455180|Experimental|4 gram continuous dosage regimen|1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
16623896|NCT02455180|Experimental|20 gram continuous dosage regimen|5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
16623897|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
16623898|NCT02455154|Placebo Comparator|Letrozole|"Early Breast Cancer patients receiving adjuvant endocrine therapy
~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po."
16623899|NCT02455154|Active Comparator|Letrozole + Xinglinggubao|"Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao
~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.
~Xinglinggubao: 0.5g bid po"
16623900|NCT02455154|Active Comparator|Letrozole + Zhongyaofufang|"Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)
~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.
~Zhongyaofufang: qow po"
16623901|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
16623902|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
16623903|NCT02455128|Experimental|Experimental Group|This group will receive the therapeutic listening.
16623904|NCT02455128|No Intervention|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
16623905|NCT02455115|Experimental|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
16623906|NCT02455115|Experimental|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
16623907|NCT02455115|Experimental|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
16623908|NCT02455102|Active Comparator|Electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
16623909|NCT02455102|No Intervention|No electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.
16623910|NCT02455089|Experimental|Test group|"250 SLE patients : All SLE patients included in the study. Intervention : Blood analysis including GADD34 RNA level measurement every 3 months up to 1 year.
~They will provided a blood sample every 3 months during a year. The result of GADD34 RNA level in mononuclear blood cells will be correlated to the clinical assessment of a SLE flare during the next 3 months.
~A flare occurence will the group"
16623911|NCT02455076|Active Comparator|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
16623912|NCT02455076|Active Comparator|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
16623913|NCT02455076|Active Comparator|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
16623914|NCT02455076|Active Comparator|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
16623915|NCT02455076|Active Comparator|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
16623916|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
16623917|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
16623918|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
16623919|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
16623920|NCT02455037|No Intervention|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
16623921|NCT02455037|Experimental|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
16623922|NCT02455011|Experimental|REMD-477 Treatment A|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
16623923|NCT02455011|Placebo Comparator|Matching placebo|Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
16623924|NCT02455011|Experimental|REMD-477 Treatment B|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
16623925|NCT02455011|Experimental|REMD-477 Treatment C|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
16623926|NCT02455011|Experimental|REMD-477 Treatment D|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
16623927|NCT02455011|Experimental|REMD-477 Treatment E|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
16623928|NCT02454998|Experimental|Orthodontic treatment arm|Previous to the surgical alveolar bone grafting, orthodontic treatment is performed several months before surgery
16623929|NCT02454998|No Intervention|No orthodontic treatment arm|No orthodontic treatment previous to surgical alveolar bone grafting
16623930|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
16623931|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
16623932|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
16623935|NCT02454907|Active Comparator|Control|One kind of communication with the clinic will be used.
16623936|NCT02454907|Experimental|Experimental|A different kind of communication with the clinic will be used.
16623937|NCT02454894|Experimental|Group 1|no anesthesia; postoperative management
16623938|NCT02454894|No Intervention|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
16623939|NCT02454894|Experimental|Group 3|surface anesthesia with lidocaine; postoperative management
16623940|NCT02454894|Experimental|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
16623942|NCT02454881|Active Comparator|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
16623943|NCT02454881|Active Comparator|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
16623944|NCT02454881|Active Comparator|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
16623945|NCT02454868|Experimental|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
16623946|NCT02454855|Experimental|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
16623947|NCT02454855|Placebo Comparator|"Group Placebo"|standard anticancer treatment + placebo (3 months)
16623948|NCT02454842|Experimental|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
16623949|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
16623950|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
16623951|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
16623952|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
16623953|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
16623954|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
16623955|NCT02454816|Experimental|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
16623956|NCT02454816|Active Comparator|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
16623957|NCT02454777|Experimental|ARM I (HIT group)|Participants undergo HIT exercises over 30 minutes, thrice weekly for 8 weeks.
16623958|NCT02454777|Active Comparator|Arm II (Delayed group)|Participants maintain their current sedentary activity level (< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT program as in Arm I.
16623959|NCT02454764|Experimental|Tenofovir + Interferon alpha 2 b|
16623960|NCT02454764|Active Comparator|Tenofovir|
16623961|NCT02454751|Experimental|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
16623962|NCT02454738|Experimental|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
16623963|NCT02454725|Experimental|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
16623964|NCT02454725|Active Comparator|Comparison|HIV counseling and testing
16623965|NCT02454712|Experimental|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
16623966|NCT02454712|Active Comparator|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
16623967|NCT02454699|Experimental|1000mg MBX400|6 subjects receive 1000 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
16623968|NCT02454699|Experimental|100mg MBX400|6 subjects receive 100 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
16623969|NCT02454699|Experimental|350mg MBX400|6 subjects receive 350 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
16623970|NCT02454699|Experimental|750mg MBX400|6 subjects receive 750 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
16623971|NCT02454673||Group A|"3-4 cycles of preoperative chemotherapy
~Surgery"
16623972|NCT02454673||Group B|"3-4 cycles of induction chemotherapy
~Radiotherapy with concurrent chemotherapy for 5 weeks
~Surgery"
16623973|NCT02454660|Experimental|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
16623974|NCT02454660|No Intervention|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
16623975|NCT02454634|Experimental|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
16624013|NCT02454387|Experimental|Experimental: ONO-4474 Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624014|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624015|NCT02454387|Experimental|Experimental: ONO-4474 Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
16623976|NCT02454621|Active Comparator|Control|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation and are asked to tick critical situations/appropriate responses that might be useful to them."
16623977|NCT02454621|Experimental|Volitional help sheet|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation. Implementation intentions are formed by linking critical situations with appropriate responses by drawing lines between critical situations and appropriate responses."
16623978|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
16623979|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
16623980|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
16623981|NCT02454582|Other|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
16623982|NCT02454582|Other|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
16623983|NCT02454556|Experimental|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
16623984|NCT02454556|Active Comparator|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
16623985|NCT02454543|Other|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
16623986|NCT02454543|Other|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
16623987|NCT02454530||Cancer patients treated with Nivestim®|
16623990|NCT02454504|Active Comparator|sugammadex|this arm will receive sugammadex at the end of the surgery
16623991|NCT02454504|Active Comparator|neostigmine|this arm will receive neostigmine at the end of the surgery
16623992|NCT02454491|Active Comparator|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
16623993|NCT02454491|Experimental|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
16623994|NCT02454478|Experimental|Lenvatinib plus Everolimus|
16623995|NCT02454465|Experimental|Intervention group|The first group at the top of the waiting list will receive the Acceptance and Commitment Therapy group intervention, which is 1 hour per week for six weeks.
16623996|NCT02454465|No Intervention|Waiting list group|The outcomes of those on the waiting list will be compared with those in the intervention group. Once the intervention group completes, those on the waiting list will be invited to attend the Acceptance and Commitment Therapy group intervention.
16623997|NCT02454452|Active Comparator|Saphenous vein stripping|Saphenous venous stripping surgical technique
16623998|NCT02454452|Active Comparator|CHIVA|conservative hemodynamic treatment venous insufficiency (CHIVA)
16623999|NCT02454452|Experimental|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
16624000|NCT02454439|Experimental|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
16624001|NCT02454439|Other|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
16624002|NCT02454426|Experimental|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
16624003|NCT02454413|Sham Comparator|brush + water|denture brushing with water and soap + overnight storage in water
16624004|NCT02454413|Active Comparator|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
16624005|NCT02454413|Sham Comparator|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
16624006|NCT02454413|Active Comparator|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
16624007|NCT02454400|Other|Pre-surgery physiotherapy|Twice a week, in 9 weeks
16624008|NCT02454400|Other|Waiting-list|Standard information by the orthopedic surgeon
16624009|NCT02454387|Experimental|Experimental: ONO-4474 Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624010|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624011|NCT02454387|Experimental|Experimental: ONO-4474 Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624012|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624016|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
16624017|NCT02454387|Experimental|Experimental: ONO-4474 Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624018|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
16624019|NCT02454374|Experimental|Knee Loading|Progressive joint loading intervention will be taught by a program of exercises by the treating physiotherapist. The intervention consists of knee flexion (bending) and knee extension (straightening). Participants will be assessed for their immediate response to treatment during each assessment or treatment session and advised on the appropriate level of self-directed exercises to be performed twice daily. The clinician will review the patient at follow up appointments during the treatment period, progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate. The physiotherapist will encourage compliance during the treatment period and beyond
16624020|NCT02454374|Active Comparator|Routine physiotherapy care|Normal care delivered to the control group will be based on current NICE guidelines (2014) for non-pharmacological management of OA which includes verbal and written advice/education; education regarding weight loss; exercise to include local muscle strengthening and general aerobic fitness; with or without manual therapy. Clinicians will be asked to refrain from using the progression of techniques specifically documented in the progressive loading protocol (not currently considered to constitute 'normal care'). Treating clinicians will be asked to record specific exercises and manual therapy techniques employed in the patient's records. Participants will be asked to complete a home treatment record sheet.
16624021|NCT02454361|Experimental|KBP-7072 cohort 1|KBP-7072 by mouth once
16624022|NCT02454361|Experimental|KBP-7072 cohort 2|KBP-7072 by mouth once
16624023|NCT02454361|Experimental|KBP-7072 cohort 3|KBP-7072 by mouth once
16624024|NCT02454361|Experimental|KBP-7072 cohort 4|KBP-7072 by mouth once
16624025|NCT02454361|Experimental|KBP-7072 cohort 5|KBP-7072 by mouth once
16624026|NCT02454361|Experimental|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
16624027|NCT02454348|Active Comparator|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
16624028|NCT02454348|Active Comparator|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
16624029|NCT02454335|Active Comparator|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
16624030|NCT02454335|Active Comparator|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
16624031|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
16624032|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
16624033|NCT02454309|Experimental|Cranberry concentrate|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
16624034|NCT02454309|Placebo Comparator|Placebo|A capsule containing control formulation
16624035|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
16624036|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
16624037|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
16624038|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
16624039|NCT02454270|Experimental|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
16624040|NCT02454270|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
16624041|NCT02454270|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
16624042|NCT02454270|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
16624043|NCT02454270|Experimental|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
16624044|NCT02454270|Experimental|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
16624045|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
16624046|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
16624047|NCT02454244|Experimental|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
16624080|NCT02454049|Active Comparator|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
16624048|NCT02454244|Experimental|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
16624049|NCT02454244|Active Comparator|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
16624050|NCT02454231|Experimental|peripheral blood EPC injection|
16624051|NCT02454231|Active Comparator|bone marrow MNC injection|
16624052|NCT02454218|Active Comparator|Transcranial Direct Current Stimulation|The intensity of the asset is little perceived and painless.
16624053|NCT02454218|Placebo Comparator|Simulation Transcranial Current|Will receive only simulation.
16624054|NCT02454205|Active Comparator|Conventional treatment 21-24 months|"Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.
~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.
~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol."
16624055|NCT02454205|Experimental|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:
~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.
~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
16624056|NCT02454192|Other|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
16624057|NCT02454192|No Intervention|Usual Care|Usual asthma care and management
16624058|NCT02454179|Experimental|Arm 1|pembrolizumab
16624059|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
16624060|NCT02454153|Active Comparator|REMStar Positive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
16624061|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
16624062|NCT02454140|Experimental|Cohort 1|SBRT 40 Gy in 5 fractions
16624063|NCT02454140|Experimental|Cohort 2|SBRT 45 Gy in 5 fractions (starting dose level)
16624064|NCT02454140|Experimental|Cohort 3|SBRT 50 Gy in 5 fractions
16624065|NCT02454140|Experimental|Cohort 4|SBRT 55 Gy in 5 fractions
16624066|NCT02454140|Experimental|Cohort 5|SBRT 60 Gy in 5 fractions
16624067|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
16624068|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
16624069|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
16624070|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
16624071|NCT02454114|Active Comparator|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
16624072|NCT02454114|Active Comparator|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.
~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
16624073|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
16624074|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
16624075|NCT02454088|Active Comparator|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
16624076|NCT02454088|Placebo Comparator|Placebo|Injection of Calcium hydroxylapatite with a placebo
16624077|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
16624078|NCT02454062|Experimental|Dose Escalation TAS-114 (PART 1)|Each cycle will be 21 days: 14 days of treatment and 7 days recovery. TAS-114 and S-1 will be escalated according to a defined dosing table and specific DLT criteria.
16624079|NCT02454062|Experimental|Expansion phase TAS-114 (PART 2)|"The TAS-114 and S-1 MTD established in the Dose Escalation Phase will be administered BID for 14 days followed by a 7 day recovery period.
~This regimen is repeated every 21 days thereafter. Approximately 40 to 60 evaluable patients will be enrolled in the Expansion Phase. PGx, PD and PK analysis will be performed based on specific criteria."
16626291|NCT02439528|Other|Emphysema|Genetic analysis on patients with emphysema.
16624081|NCT02454049|Active Comparator|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
16624082|NCT02454049|Placebo Comparator|water|85ml of plain water, ingested 3 hours before the exercise test
16624083|NCT02454036|Experimental|BBI Intervention|Biobehavioral Intervention
16624084|NCT02454023|Active Comparator|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
16624085|NCT02454023|Experimental|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
16624086|NCT02454010|Experimental|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
16624087|NCT02454010|Experimental|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
16624088|NCT02454010|Experimental|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
16624089|NCT02454010|Experimental|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
16624090|NCT02454010|Experimental|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
16624091|NCT02454010|Experimental|Expansion Phase (Cohort 6), Ovarian|In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)
16624092|NCT02454010|Experimental|Expansion Phase (Cohort 7), Adv Tumors|In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)
16624093|NCT02453984|Experimental|1|89Zr-MPDL3280A-PET scan
16624094|NCT02453971|Experimental|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
16624095|NCT02453971|No Intervention|control|It is an assessment only condition.
16624096|NCT02453958|Experimental|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
16624097|NCT02453958|Experimental|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
16624098|NCT02453945|Experimental|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
16624099|NCT02453945|No Intervention|Control|Usual Care
16624100|NCT02453932|Experimental|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
16624101|NCT02453932|Active Comparator|Donepezil|Donepezil and placebo identified to Tianzhi granule
16624102|NCT02453932|Placebo Comparator|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
16624103|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.
~Collection of clinical information and biochemical laboratory results."
16624104|NCT02453906|Experimental|healthy subjects|they receive XNKQ acupuncture, as well as control 1, control 2, and control 3 in a randomized order.
16624105|NCT02453893|Experimental|oral iloperidone|2~12mg/day for 2 weeks,12~24mg/day for 6 weeks.
16624106|NCT02453893|Active Comparator|oral risperidone|1~3mg/day for 2 weeks,3~6mg/day for 6 weeks.
16624107|NCT02453880|Experimental|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
16624108|NCT02453867|Active Comparator|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels >5 ng/ml), mycophenolate mofetil >1g/d in MMF or >720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
16624109|NCT02453867|Experimental|Reduced immunosuppression|"The Intervention is stopping medication:
~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels >5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
16624110|NCT02453854|Active Comparator|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
16624111|NCT02453854|Experimental|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
16624112|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
16624113|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
16624114|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
16624115|NCT02453828|Experimental|Checklist|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care with an additional, electronically pre-populated checklist displayed on the anesthesia record keeping system
16624116|NCT02453828|Active Comparator|Standard of Care|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care
16624117|NCT02453815|Experimental|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
16624118|NCT02453815|Placebo Comparator|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
16624225|NCT02453204|Experimental|Walking|The walking condition will be identical to standing, but the breaks in sitting time will be punctuated with five minute bouts of self-paced walking rather than standing.
16624119|NCT02453802|Active Comparator|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
16624120|NCT02453802|Active Comparator|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.
~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
16624121|NCT02453802|Placebo Comparator|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.
~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
16624122|NCT02453789|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
16624123|NCT02453789|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
16624124|NCT02453776|Experimental|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
16624125|NCT02453776|No Intervention|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
16624126|NCT02453763||Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation and an magnetic resonance imaging (MRI).
16624127|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
16624128|NCT02453737|Other|Catheter-based brachytherapy APBI|7 Gy x 3 fractions
16624129|NCT02453737|Other|3D-CRT APBI|7.3 Gy x 3 fractions
16624130|NCT02453737|Other|Proton APBI|7.3 Gy x 3 fractions
16624131|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
16624132|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
16624133|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
16624134|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
16624135|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
16624136|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
16624137|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
16624138|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
16624139|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
16624140|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
16624141|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
16624142|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
16624143|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
16624144|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
16624145|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
16624146|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
16624147|NCT02453698|Experimental|Methylphenidate|
16624148|NCT02453698|Placebo Comparator|Control Group|
16624149|NCT02453685|Experimental|BIAsp|
16624150|NCT02453685|Active Comparator|IGlar + IAsp|
16624151|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
16624152|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
16624153|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
16624154|NCT02453659|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
16624155|NCT02453659|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
16624156|NCT02453646|Experimental|NexSite HD Patients|NexSite HD patient catheter device placement
16624157|NCT02453633|Experimental|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
16624158|NCT02453633|Active Comparator|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
16624160|NCT02453607||CD Monotherapy|Crohn's disease treated with infliximab (monotherapy)
16624161|NCT02453607||CD Combo therapy|Crohn's disease treated with infliximab in combination with thiopurine (a 6MP metabolite) (combo therapy)
16624162|NCT02453594|Experimental|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
16624163|NCT02453594|Experimental|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
16624164|NCT02453594|Experimental|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
16624165|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
16624166|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
16624167|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
16624168|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
16624169|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
16624170|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
16624171|NCT02453555|Placebo Comparator|Linagliptin placebo|
16624172|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin high dose placebo|
16624173|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin low dose placebo|
16624174|NCT02453529|Experimental|WCK 4873|Oral tablets
16624175|NCT02453516|Experimental|Serratus Block Group|Patients will receive a preoperative ultrasound-guided serratus block with 0.4ml/kg (max.30ml) of ropivacaine 0.5% with 1:4000,000 epinephrine injected between the serratus anterior (superficial) and external intercostal (deep) muscles followed by subsequent general anesthesia
16624176|NCT02453516|Placebo Comparator|Placebo Block - Control Group|Patients will receive a preoperative placebo injection with a subcutaneous injection of 1ml normal sterile saline solution in the midaxillary line and the ultrasound probe will be used to simulate the pressure and block duration associated with the serratus block. These patients will then receive general anesthesia.
16624177|NCT02453503|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
16624178|NCT02453503|Experimental|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
16624179|NCT02453490|Experimental|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
16624180|NCT02453490|Active Comparator|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
16624181|NCT02453477|Experimental|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.
~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.
~The product will be injected intraosseously."
16624182|NCT02453477|Experimental|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.
~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.
~The product will be injected intraosseously."
16624183|NCT02453477|Experimental|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.
~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.
~The product will be injected intraosseously."
16624184|NCT02453464|Experimental|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
16624185|NCT02453451|Experimental|2D-/3D-TTE; 3D-TEE, Walking Test|6 months after the MitraClip procedure
16624186|NCT02453425|Active Comparator|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
16624187|NCT02453425|Active Comparator|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
16624188|NCT02453425|Active Comparator|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
16624189|NCT02453412|No Intervention|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
16624190|NCT02453412|Experimental|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
16624191|NCT02453386|Experimental|Tozadenant 60 mg BID|"During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.
~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
16624192|NCT02453386|Experimental|Tozadenant 120 mg BID|"During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.
~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
16624193|NCT02453386|Placebo Comparator|Placebo BID|"During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.
~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
16624194|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
16624195|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
16624226|NCT02453191|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy
~Talimogene Laherparepvec Dose Levels:
~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
16624196|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
16624197|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
16624198|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
16624199|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
16624200|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
16624201|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
16624202|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
16624203|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
16624204|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
16624205|NCT02453308|Active Comparator|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.
~1.2 Dihydroartemisinin-piperaquine for 3 days
~1.3 Artesunate-Mefloquine for 3 days"
16624206|NCT02453308|Active Comparator|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.
~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.
~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
16624207|NCT02453295|Experimental|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
16624208|NCT02453295|No Intervention|Comparison Group|The CG will receive LE treatment as usual, without the hope intervention. They will be administered the same questionnaires (by phone) as the IG at the same timepoints. Potential participants (n=46) will be screened based MIQ. The individuals scoring in the top ~30% (n=16) will be excluded from the study. The remaining 30 individuals scoring the lowest level of hope will be admitted into the study.
16624212|NCT02453269|Experimental|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
16624213|NCT02453269|No Intervention|Control group|The children in the control group (G2) were not exposed to interventions.
16624214|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
16624215|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
16624216|NCT02453243|No Intervention|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
16624217|NCT02453243|Other|Intervention|"Safety Plan Intervention: Clinician training in safety planning, and
~A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean
~Combine, this is expected to increase safety planning by clinicians."
16624218|NCT02453243|No Intervention|Maintenance|Test sustainability of safety planning during the Maintenance phase.
16624219|NCT02453230|Active Comparator|light on|BPP done with lights on
16624220|NCT02453230|No Intervention|light off|Biophysical profile examinations done with the light off
16624221|NCT02453217|Experimental|Chinese CHIP|Chinese Health Improvement Profile (CHIP) screening and intervention
16624222|NCT02453217|No Intervention|Treatment as usual|Routine community mental health care and medical outpatient appointments
16624223|NCT02453204|Experimental|Sitting|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
16624224|NCT02453204|Experimental|Standing|Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
16624279|NCT02452775|Experimental|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
16624227|NCT02453178|Experimental|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
16624228|NCT02453178|Active Comparator|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
16624229|NCT02453165|Experimental|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
16624230|NCT02453165|Active Comparator|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
16624231|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
16624232|NCT02453139|Experimental|Exercise group|6 month supervised and home based moderate intensity aerobic exercise programme
16624233|NCT02453139|No Intervention|Control|Non-exercising control group receiving usual care
16624234|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
16624235|NCT02453100|Experimental|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.
~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
16624236|NCT02453100|Placebo Comparator|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
16624237|NCT02453087|Experimental|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
16624238|NCT02453087|Experimental|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
16624239|NCT02453087|Experimental|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
16624240|NCT02453061|Placebo Comparator|Placebo group|Subjects will receive safflower oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
16624241|NCT02453061|Active Comparator|Triheptanoin group|Subjects will receive triheptanoin oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
16624242|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
16624243|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
16624244|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
16624245|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
16624246|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
16624247|NCT02453022|Experimental|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
16624248|NCT02453009|Experimental|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
16624249|NCT02453009|Active Comparator|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
16624250|NCT02452996|Active Comparator|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
16624251|NCT02452996|Active Comparator|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
16624252|NCT02452996|Active Comparator|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
16624253|NCT02452983|Experimental|Sertraline|Sertraline tablets 100mg daily for 4 (28-day) cycles
16624254|NCT02452970|Experimental|RRx-001 the cisplatin and gemcitabine|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
16624255|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.
~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.
~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
16624256|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)
~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.
~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
16624257|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
16624258|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
16624259|NCT02452918|Experimental|oritavancin|oritavancin, a single 1200mg IV dose, over 3 hours
16624260|NCT02452905|Active Comparator|Nitazoxanide|Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
16624261|NCT02452905|Placebo Comparator|Placebo|The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide. It is reconstitutes, administered and dosed as per the active study drug.
16624262|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
16624263|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
16624264|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
16624265|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
16624266|NCT02452879|Experimental|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
16624267|NCT02452879|Placebo Comparator|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
16624268|NCT02452879|Active Comparator|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
16624269|NCT02452866|Experimental|SYM-1219|All pateints recieved single dose SYM-1219 Containing 2 Grams of Secnidazole
16624270|NCT02452853|Experimental|HR combined with FOLFOX4|"HR ;
~FOLFOX4 4 weeks after HR"
16624272|NCT02452827||Primary Chronic Neck Pain|Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.
16624273|NCT02452827||Control|Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated.
16624274|NCT02452814||Cohort|
16624275|NCT02452801|Experimental|ALKS 5461|Sublingual tablet
16624276|NCT02452788|Other|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
16624277|NCT02452788|No Intervention|Usual Care|Usual Care
16624278|NCT02452775|Experimental|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
16624280|NCT02452775|Experimental|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
16624281|NCT02452775|Experimental|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
16624282|NCT02452762|Experimental|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
16624283|NCT02452762|Placebo Comparator|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
16624284|NCT02452749|Experimental|Cardiovascular Health Dietary Supplement|The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months
16624285|NCT02452736|Experimental|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|This is a Single arm, Non-randomized Study. All patients meet the eligibility criteria and sign the informed consent form will participate in this study.
16624286|NCT02452723|Experimental|ISC-hpNSC|
16624287|NCT02452710|Experimental|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
16624288|NCT02452710|No Intervention|NT-Control|- No Placebo Tablets
16624289|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
16624290|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
16624291|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
16624292|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
16624293|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
16624294|NCT02452658|Experimental|Changed menu|All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions.
16624295|NCT02452645|Experimental|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
16624296|NCT02452645|Active Comparator|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
16624297|NCT02452632|Experimental|ASP1941 group|once daily over a 24 week treatment
16624298|NCT02452632|Placebo Comparator|Placebo group|once daily over a 24 week treatment
16624299|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
16624300|NCT02452606|Experimental|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
16624301|NCT02452593|Active Comparator|"Tibial Nerve Stimulation"|"This group will do transcutaneous electrical stimulation of the tibial nerve at home.
~Development of an innovative portable equipment, with domestic technology for home application of the posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Frequency: 20 Hz, Pulse width: 200 us; duration: 15min daily"
16624302|NCT02452593|Active Comparator|"Pelvic Floor Exercises"|This group will make pelvic muscle training 3 times a day . In decubit dorsal posture, legs flexed and abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions keeping 4 seconds and relaxing 8 seconds for 10 times.
16624303|NCT02452580||Family Centered Care Unit|Cohort of premature infants and their families receiving Family Centered Care hospitalized at VVHF
16624304|NCT02452580||Open-bay Care Unit|Cohort of premature infants and their families receiving and traditional open-bay care hospitalized at HUH
16624305|NCT02452567|Experimental|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
16624306|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
16624307|NCT02452541|Other|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
16624308|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.
~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
16624309|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.
~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
16624310|NCT02452515|Experimental|BAY1142524 (5 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
16624311|NCT02452515|Experimental|BAY1142524 (10 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
16624312|NCT02452515|Experimental|BAY1142524 (25 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
16624313|NCT02452515|Experimental|BAY1142524 (50 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
16624537|NCT02451111|Active Comparator|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
16624314|NCT02452502|Active Comparator|moderate dose|Drug: Atorvastatin Atorvastatin 20 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
16624315|NCT02452502|Experimental|high dose|Drug: Atorvastatin Atorvastatin 80 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
16624316|NCT02452489|Other|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
16624317|NCT02452489|Other|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
16624318|NCT02452489|Other|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
16624319|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
16624320|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
16624321|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16624322|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16624323|NCT02452463|Experimental|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
16624324|NCT02452450|Experimental|Ibuprofen lysine|
16624325|NCT02452450|Experimental|Ibuprofen sodium|
16624326|NCT02452450|Experimental|Ibuprofen liquid capsules|
16624327|NCT02452450|Active Comparator|Ibuprofen acid|
16624328|NCT02452450|Active Comparator|Paracetamol|
16624329|NCT02452437|Experimental|control|Oxycodone will be administered and subjects will undergo hemodialysis
16624330|NCT02452437|Experimental|hemodialysis|Oxycodone will be administered and subjects will undergo hemodialysis
16624331|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.
~(Enrollment complete- 33 enrolled)"
16624332|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors
~(Enrollment Complete- 45 enrolled)"
16624333|NCT02452411|Experimental|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
16624334|NCT02452411|Experimental|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
16624335|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
16624336|NCT02452398|Placebo Comparator|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
16624337|NCT02452385|Experimental|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
16624338|NCT02452372|Active Comparator|givosiran (ALN-AS1)|
16624339|NCT02452372|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16624340|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
16624341|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
16624342|NCT02452333|Experimental|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
16624343|NCT02452333|Experimental|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
16624344|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
16624345|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
16624346|NCT02452307|Experimental|Peptide vaccine|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51
16624347|NCT02452307|Experimental|Peptide vaccine + GM-CSF|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)
16624348|NCT02452307|Experimental|Peptide vaccine + local hyperthermia|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia
16624349|NCT02452307|Experimental|Peptide vaccine + Imiquimod|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod
16624350|NCT02452307|Experimental|Peptide vaccine + mRNA/Protamin|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin
16624351|NCT02452294|Experimental|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
16624390|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
16624352|NCT02452281|Experimental|ipilimumab + HSPPC-96|"Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
~HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.
~Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.
~Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine."
16624353|NCT02452268|Experimental|NIZ985|"Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.
~Cycle length 28 days.
~Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.
~MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.
~Following identification of the MTD / RDE, dose expansion will follow."
16624354|NCT02452268|Experimental|NIZ985 + PDR001|"The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.
~On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.
~Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
16624355|NCT02452255|Active Comparator|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
16624356|NCT02452255|Active Comparator|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
16624357|NCT02452255|Placebo Comparator|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
16624358|NCT02452255|Active Comparator|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
16624359|NCT02452242|Experimental|ABX464|
16624360|NCT02452242|Placebo Comparator|Placebo|
16624361|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
16624362|NCT02452216|Experimental|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
16624363|NCT02452203|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for 90 minutes.
16624364|NCT02452203|Placebo Comparator|Chair|The participant will lay in the supine position while reclined in a zero-gravity chair for 90 minutes.
16624365|NCT02452190|Experimental|Reslizumab|Reslizumab
16624366|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
16624367|NCT02452177|Experimental|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
16624368|NCT02452177|Placebo Comparator|Placebo|
16624369|NCT02452164|Active Comparator|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
16624370|NCT02452164|Other|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
16624371|NCT02452151|Experimental|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
16624372|NCT02452151|Active Comparator|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
16624373|NCT02452138||Low EAA|Endotoxin Activity Assay [EAA] level < 0.40 EAA units
16624374|NCT02452138||Intermediate EAA|Endotoxin Activity Assay [EAA] level between 0.40-0.59 EAA units
16624375|NCT02452138||High EAA|Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
16624376|NCT02452125|Experimental|Nicotine Gum|Nicotine chewing gum administered for 30 minutes
16624377|NCT02452112|Active Comparator|Lidocaine|Active arm with administration of active 5% Lidocaine patch
16624378|NCT02452112|Placebo Comparator|Placebo|Placebo arm with administration of placebo patch
16624379|NCT02452099|Other|5% DMSO|
16624380|NCT02452099|Other|7.5% DMSO|
16624381|NCT02452099|Other|10% DMSO|
16624382|NCT02452086|Active Comparator|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt
~, 3 days/week, for 4 weeks (12 sessions)"
16624383|NCT02452086|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
16624384|NCT02452073||CRE group|patients with chronic radiation enteritis
16624385|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
16624386|NCT02452073||control group|age-matched healthy volunteers
16624387|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
16624388|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
16624389|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
16624502|NCT02451319|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
16624391|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
16624392|NCT02452034|Experimental|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
16624393|NCT02452034|Experimental|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
16624394|NCT02452034|Experimental|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
16624395|NCT02452034|Experimental|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
16624396|NCT02452034|Experimental|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
16624397|NCT02452034|Experimental|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
16624398|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
16624399|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
16624400|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
16624401|NCT02451995|Active Comparator|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
16624405|NCT02451969|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Intervention: investigational 23-valent PPV"
16624406|NCT02451969|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0
~Intervention: control 23-valent PPV"
16624407|NCT02451956|Experimental|AZD5363 in combination with paclitaxel|AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.If paclitaxel therapy is stopped then AZD5363 can be given on a 4on/3off continuous schedule.
16624503|NCT02451319|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
16624410|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:
~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).
~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:
~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.
~Part C were Japan participants. Part C were Japan participants."
16624411|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
16624412|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.
~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
16624413|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
16624414|NCT02451904||Uncomplicated Malaria|Intensive monitoring
16624415|NCT02451904||Sepsis|Intensive monitoring
16624416|NCT02451904||Acidosis|Intensive monitoring
16624417|NCT02451904||Encephalitis|Intensive monitoring
16624418|NCT02451904||Healthy Individuals|Monitoring
16624419|NCT02451891|Active Comparator|Group 1a|MVA-EBO Z (1 x 10^8 pfu)
16624420|NCT02451891|Active Comparator|Group 1b|MVA-EBO Z (1.5 x 10^8 pfu)
16624421|NCT02451891|Active Comparator|Group 2|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 14 days
16624422|NCT02451891|Active Comparator|Group 3|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 28 days
16624423|NCT02451891|Active Comparator|Group 4|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1.5 x 10^8 pfu) after 28 days
16624424|NCT02451878|Experimental|Intervention|The E-Couch self-help social anxiety module which is based on cognitive behavioural therapy principles. This module contains a literacy section and 5 toolkits comprising exposure practice, cognitive restructuring (modifying your thinking), attention practice, social skills training and relaxation. E-Couch is designed to be completed at the participant's own pace. It is free to use, browser-based and widely accessible on a range of connected devices.
16624425|NCT02451878|No Intervention|Control|Wait list control (WLC)
16624426|NCT02451865|Experimental|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
16624427|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
16624428|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
16624429|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
16624430|NCT02451826|Active Comparator|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
16624431|NCT02451826|Active Comparator|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
16624432|NCT02451813|Experimental|Intervention|"A 22 GA 5 cm nerve block needle will be advanced to the following conditions:
~Needle tip slightly indenting the fascia iliaca
~Needle tip advanced through fascia iliaca
~Needle tip slightly indenting the anterior surface of the femoral nerve
~Needle tip withdrawn 1 mm from nerve.
~At each of these conditions, 1 ml of dextrose solution will be injected and spread of injectate observed sonographically. A blinded observer will measure injection pressure. If opening pressure reaches 15 psi, this investigator will halt the injection. In addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4."
16624433|NCT02451800|Experimental|in-class yoga|"The intervention is a in-class yoga course taught by yoga instructors for 3 times per week for 3 months. This class is based on Peggy Cappy's Program: More Yoga for Every Body. Class is taught at Sanford Wellness Centers in Sioux Falls, South Dakota and Fargo, North Dakota. Each class in 1 hour in length."
16624434|NCT02451800|Active Comparator|yoga by DVD|"For the intervention participants are asked to do yoga at home following the Peggy Cappy's Program: More Yoga for Every Body DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
16624435|NCT02451800|Active Comparator|stretching by DVD|"For the intervention participants are asked to do stretching exercises at home following Bob Anderson's DVD-Stretching: the DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
16624436|NCT02451787|Experimental|Active|vitamin D supplementation group (2500 IU day for 3 months)
16624437|NCT02451787|Placebo Comparator|Control|no vitamin D supplementation
16624504|NCT02451319|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
16624438|NCT02451774|Experimental|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.
~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
16624439|NCT02451774|Placebo Comparator|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
16624440|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
16624441|NCT02451748|Other|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28<2.6). The subjects that achieve remission (DAS28<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
16624442|NCT02451748|Other|DMARD's plus Cimzia (Certolizumab pegol)|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
16624443|NCT02451735|No Intervention|Intervention Development|Psychoeducational Intervention (PEI) development. PEIs include printed and DVD materials, and represent a commonly used and effective approach to implement theoretically based individual-level interventions. These materials serve as important sources of information for the general public, cancer patients, and survivors from a variety of backgrounds, including populations with limited health literacy. An interview and feedback collection process will take place to provide data to improve current PEI materials.
16624444|NCT02451735|Experimental|Intervention Pilot - Intervention Group|The intervention group will receive the PEI materials: video and booklet. Self-reported feedback will be collected and reviewed to compare response with the control group.
16624445|NCT02451735|Active Comparator|Intervention Pilot - Control Group|The control group will receive a patient factsheet about Genetic Counseling (GC). Self-reported feedback will be collected and reviewed to compare response with the intervention group.
16624446|NCT02451722|Active Comparator|Healthy subjects|"Kyboot shoes will be administered to the healthy subjects.
~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
16624447|NCT02451722|Active Comparator|Diabetic patients|"Kyboot shoes will be administered to the diabetic patients.
~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
16624448|NCT02451709|Experimental|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.
~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.
~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
16624449|NCT02451709|Active Comparator|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.
~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.
~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.
~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
16624450|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
16624451|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
16624452|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
16624453|NCT02451683|Experimental|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
16624454|NCT02451683|Active Comparator|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
16624455|NCT02451670|Experimental|Prioritized Clinical Decision Support|Patients receiving care in clinics randomized to the intervention arm of the study and their primary care providers were presented with patient-specific written advice as to prioritized treatment and lifestyle changes that could reduce their cardiovascular risk, prompted by an electronic health record-based alert during their primary care visit.
16624456|NCT02451670|No Intervention|Usual Care|Patients receiving care in clinics randomized to the usual care arm of the study and their providers were not presented with the prioritized clinical decision support.
16624457|NCT02451657||Cohort|
16624458|NCT02451644|Experimental|high risk for PTD with pedometer|Patient with high risk for preterm delivery including short cervix or rapture of membranes
16624459|NCT02451631|Active Comparator|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
16624460|NCT02451631|Experimental|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
16624461|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
16624462|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
16624463|NCT02451605|Active Comparator|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
16624538|NCT02451111|Placebo Comparator|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
16624464|NCT02451605|Active Comparator|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
16624465|NCT02451605|Active Comparator|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
16624466|NCT02451579|Active Comparator|Cetirizine Hydrochloride|Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
16624467|NCT02451579|Placebo Comparator|Placebo|Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
16624468|NCT02451566||Fast-Track Group|Includes subject who complete the Fast-Track EVAR protocol.
16624469|NCT02451566||Standard P-EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access.
16624470|NCT02451566||Standard EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair).
16624471|NCT02451553|Experimental|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16624472|NCT02451540|Active Comparator|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
16624473|NCT02451540|Placebo Comparator|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
16624474|NCT02451527|Experimental|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
16624475|NCT02451514|Experimental|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
16624476|NCT02451514|Experimental|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
16624477|NCT02451514|Experimental|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
16624478|NCT02451501|Experimental|Lying|Nebulization in lying position
16624479|NCT02451501|Active Comparator|Sitting|Nebulization in sitting position
16624480|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
16624481|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
16624482|NCT02451475|Other|Amitriptyline|Amitriptyline 25 mg/day
16624483|NCT02451475|Active Comparator|Venlafaxine|Venlafaxine 75 mg/day
16624484|NCT02451475|Active Comparator|Paroxetine|Paroxetine 25 mg/day
16624485|NCT02451462|Experimental|Zoledronic acid arm|Zoledronic acid
16624486|NCT02451462|No Intervention|placebo arm|placebo
16624487|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
16624488|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
16624489|NCT02451423|Experimental|MPDL3280A|MPDL3280A: Intravenously; Day 1 of each 21-day Cycle
16624490|NCT02451410|Experimental|Nutrition and physical activity|This arm includes all preschool classes receiving the educational and behavioral intervention to improve nutrition and physical activity
16624491|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
16624492|NCT02451384|Experimental|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
16624493|NCT02451384|Experimental|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
16624494|NCT02451384|Experimental|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
16624495|NCT02451371|Experimental|tDCS|Patients with schizophrenia to receive tDCS treatment
16624496|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
16624497|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
16624498|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
16624499|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged >=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
16624500|NCT02451345|Experimental|Intervention|Personalized risk model+website+phone coaching
16624501|NCT02451332|Experimental|vaccinated|These women will have received the seasonal influenza vaccine.
16624505|NCT02451306|Experimental|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.
~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
16624506|NCT02451306|Placebo Comparator|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.
~The placebo does not contain any psychoactive substance."
16624507|NCT02451306|No Intervention|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
16624508|NCT02451293|Active Comparator|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
16624509|NCT02451293|Placebo Comparator|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
16624510|NCT02451280|Experimental|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
16624511|NCT02451280|Experimental|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
16624512|NCT02451280|Experimental|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
16624513|NCT02451267|Experimental|positive CPR: research group|physical therapy treatment with aerobic exercise
16624514|NCT02451267|Experimental|negative CPR: research group|physical therapy treatment with aerobic exercise
16624515|NCT02451267|Active Comparator|positive CPR: control group|physical therapy treatment
16624516|NCT02451267|Active Comparator|negative CPR: control group|physical therapy treatment
16624517|NCT02451254|Experimental|Atrial Fibrillation|Atrial Fibrillation patients electively admitted for circumferential ablation of the pulmonary veins.
16624518|NCT02451254|Active Comparator|control|patients electively admitted for SVT ablation
16624519|NCT02451241|Sham Comparator|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
16624520|NCT02451241|Experimental|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
16624521|NCT02451228||Single-group|Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.
16624522|NCT02451215|Experimental|Laser interstitial thermotherapy (LITT) treated patients|All patients enrolled on the trial will undergo LITT therapy per protocol. Side-effects and outcomes will be monitored and compared with disease matched historical controls.
16624523|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.
~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
16624524|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.
~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
16624525|NCT02451189|Experimental|Inulin acetate ester|Inulin acetate ester, 10g/day for 30 days
16624526|NCT02451189|Experimental|Inulin propionate ester|Inulin propionate ester, 10g/day for 30 days
16624527|NCT02451189|Experimental|Inulin butyrate ester|Inulin butyrate ester, 10g/day for 30 days
16624528|NCT02451176|Active Comparator|Active Comparator: Davol Bard ®Soft Mesh|Device: Davol Bard ®Soft Mesh Synthetic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: synthetic mesh SoftMesh™ (CR Bard)
16624529|NCT02451176|Active Comparator|Active Comparator: LifeCell Strattice®|Device: LifeCell Strattice® Reconstructive Tissue Matrix Biologic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: Biologic mesh Strattice
16624530|NCT02451163|Active Comparator|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
16624531|NCT02451163|Placebo Comparator|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
16624532|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
16624533|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
16624534|NCT02451137|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre [U/mL]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
16624535|NCT02451137|Active Comparator|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
16624536|NCT02451124|Experimental|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
16624539|NCT02451098|Experimental|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)
16624540|NCT02451098|Active Comparator|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, placebo will be administered (Duration 8 weeks)
16624541|NCT02451098|Experimental|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)
16624542|NCT02451098|Active Comparator|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, placebo will be administered (Duration 8 weeks)
16624543|NCT02451098|Experimental|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)
16624544|NCT02451098|Active Comparator|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, placebo will be administered (Duration 8 weeks)
16624545|NCT02451085|Experimental|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
16624546|NCT02451085|Other|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
16624547|NCT02451072|Experimental|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
16624548|NCT02451059|Experimental|Intervention-WE CARE|"The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.
~Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.
~A peer patient navigator will offer personalized guidance to families with accessing community resources. The patient navigator will be available for at least a 1/2 day per week at each intervention health center to meet with families and offer guidance. Providers can communicate the patient navigator to refer families via the electronic medical record and families will also have the opportunity to contact the peer navigator at any time via the hotline number listed on the referral information sheets."
16624549|NCT02451059|No Intervention|Control-Standard of Care|Participants in the delayed-intervention control group will receive standard pediatric care. However, since the health centers share a common EMR, and for ethical reasons, investigators will also embed the health IT referral mechanism into the EMR at the control sites. Control providers will be made aware of this prior to the start of the study. Although this may potentially reduce the effect size, the investigator's prior study found that the impact on referral rates of provider access to resource information was minimal. Families at control health centers will not receive the WE CARE surveys at health supervision visits and will not have access to the peer patient navigators
16624550|NCT02451033|Active Comparator|standard medical therapy|Standard medical therapy
16624551|NCT02451033|Active Comparator|G-CSF|Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
16624552|NCT02451033|Active Comparator|G-CSF plus growth hormone|Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.
16624553|NCT02451020|Experimental|Altitude exposure|Stay at 3200 m for 3 weeks
16624554|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
16624555|NCT02450994|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
16624556|NCT02450994|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
16624557|NCT02450981|Experimental|BCD-021 group|BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.
16624558|NCT02450968|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
16624559|NCT02450968|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
16624560|NCT02450955|Active Comparator|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading.
16624561|NCT02450955|Experimental|Occiput-Atlas-Axis Technique|The technique is applied in two stages: in the first stage, a light core decompression is performed and then small circumductions are made with the aim of increasing viscoelasticity of tissues. Subsequently the appropriate joint barrier is sought by selective tension and high-velocity rotation manipulation is performed in a cranial helical motion without raising the subjects head.
16624562|NCT02450942|Experimental|18F-FDS injection and PET/CT scan|The patients were intravenously injected with 18F-FDS and underwent PET/CT scan 1 h after the injection.
16624563|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
16624564|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
16624565|NCT02450903|Experimental|LDK378 (Ceritinib)|Participants who received LDK378 750mg once daily on a 28 day cycle.
16624566|NCT02450890|Placebo Comparator|Placebo First, then ORADUR®|Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
16624567|NCT02450890|Experimental|ORADUR® First, then Placebo|ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)
16624568|NCT02450877|Experimental|Azacitidine Treatment|: Subjects randomized to the experimental arm will receive up to 3 cycles of IV azacitidine on Days 1 through 7 at the dose selected from the safety run-in part.
16624633|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16624569|NCT02450877|Other|Control Arm: 'Watch and Wait'|Subjects randomized to the control arm will undergo 'watch and wait' until clinical relapse (defined as at least 5% blasts in PB (peripheral blood) and/or BM (bone marrow) and/or proven histological extramedullary relapse).
16624570|NCT02450864|Experimental|patient with ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
16624571|NCT02450864|Sham Comparator|patient without ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
16624572|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders
16624573|NCT02450838|Experimental|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
16624574|NCT02450838|Experimental|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
16624575|NCT02450838|Placebo Comparator|Placebo|Participants will receive one IM injection of placebo at study entry.
16624576|NCT02450825|Other|Mechanically ventilated patients|Mechanically ventilated patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 and Day 2 to 4. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
16624577|NCT02450825|Other|Spontaneously breathing patients|Spontaneously breathing patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 only. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
16624578|NCT02450812||Radium-223-dichloride (Xofigo, BAY88-8223)|patients with mCRPC with symptomatic bone metastases
16624579|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
16624580|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
16624581|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
16624582|NCT02450786|Experimental|Donepezil group|Donepezil is started in 5mg for 8 weeks followed by dose escalation to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
16624583|NCT02450786|No Intervention|control group|No administration of any therapeutic medications for dementia including cholinesterase inhibitor or NMDA receptor blocking agents. Standard treatment protocol of Parkinson's disease with mild cognitive impairment would be fulfilled including dopaminergic or nondopaminergic medications as well as nootropic drugs.
16624584|NCT02450773|Experimental|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
16624585|NCT02450773|Placebo Comparator|Placebo|Placebo #1, Placebo #2
16624586|NCT02450760|Other|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
16624587|NCT02450760|Other|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
16624588|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
16624589|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
16624590|NCT02450721||Acute stroke|"Patients in the acute phase of atherothrombotic stroke or TIAs with 50-99% ACAS within the first 3 days af vascular event.
~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE, National Institutes of Health Stroke Scale (NIHSS)"
16624591|NCT02450721||Stable carotid artery stenosis|"Patients with 50-99% ACAS without history of vascular events during one month before enrollment.
~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE"
16624592|NCT02450721||Control group|Healthy volunteers without ACAS Interventions to be administered:Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE
16624593|NCT02450708||For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
16624594|NCT02450708||For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
16624595|NCT02450695|Experimental|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
16624596|NCT02450695|Sham Comparator|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
16624597|NCT02450682|Active Comparator|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
16624598|NCT02450682|Other|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
16624599|NCT02450656|Experimental|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
16624600|NCT02450656|Active Comparator|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
16624601|NCT02450643|Active Comparator|Test then Control|Subjects will perform a DBPCFC with the Test formula followed by the Control formula
16624602|NCT02450643|Active Comparator|Control then Test|Subjects will perform a DBPCFC with the Control formula followed by the Test formula
16624603|NCT02450630|Experimental|training on diagnosis, treatment and referral of children|Intervention Arm : training in diagnosis, treatment and referral of sick children
16624604|NCT02450630|No Intervention|Presumptive treament of sick children|Control Arm - Training of private providers in completing study tools i.e. filling in register and referral forms. No training in diagnosis, treatment and referral and no community awareness on referral
16624605|NCT02450617|Experimental|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
16624606|NCT02450617|Active Comparator|Conventional Individual treatment - PTSD|Conventional individual treatment.
16624607|NCT02450617|Experimental|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
16624608|NCT02450617|Active Comparator|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
16624609|NCT02450604|Other|Patients with chronic pains of unknown aetiology|
16624610|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
16624611|NCT02450578|Experimental|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
16624612|NCT02450578|Active Comparator|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
16624613|NCT02450578|Experimental|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
16624614|NCT02450578|Experimental|Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
16624615|NCT02450565||Neuropathic pain subjects|The diagnosis of neuropathic pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
16624616|NCT02450565||Nociceptive pain subjects|The diagnosis of nociceptive pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
16624617|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
16624618|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
16624619|NCT02450552|Placebo Comparator|Placebo|
16624620|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16624621|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16624622|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
16624623|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
16624624|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
16624625|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
16624626|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
16624627|NCT02450500|Experimental|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
16624628|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
16624629|NCT02450474|Other|A: baseline - IPC|"A: baseline - IPC - washout - NMES - washout - follow up
~The baseline phase, washout phase and follow up phase will consist of treatment as normal. IPC phase will consist of normal care plus IPC of the lower limbs for the duration of each dialysis session."
16624630|NCT02450474|Other|B: baseline - NMES|"B: baseline - NMES - washout - IPC - washout follow up
~The baseline phase, washout phase and follow up phase will consist of treatment as normal. NMES phase will consist of normal care plus stimulation of the foot and calf muscles for a period of one hour during dialysis."
16624631|NCT02450461||Asthma|20 patients with asthma
16624632|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
16624634|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16624635|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16624636|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16624637|NCT02450435||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16624638|NCT02450435||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16624639|NCT02450435||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16624640|NCT02450435||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16624641|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16624642|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16624643|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16624644|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16624645|NCT02450409|Active Comparator|gap technique (GT)|"The patients receive a total knee arthroplasty using the established gap technique (gold standard serving as control). The intervention is the implantation of a total knee arthroplasty with this specific technique.
~Implantation of TKA using the gap technique is the intervention. Intervention is not a drug but a specific operative technique."
16624646|NCT02450409|Experimental|anatomical alignment (AA)|"The patients receive a total knee arthroplasty using the new anatomical alignment technique (experimental). The intervention is the implantation of a total knee arthroplasty with this specific technique.
~Implantation of TKA using anatomical alignment Intervention is not a drug but a specific operative technique."
16624647|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
16624648|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
16624649|NCT02450370|Active Comparator|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
16624650|NCT02450370|Experimental|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
16624651|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16624652|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16624653|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16624654|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16624655|NCT02450344|Experimental|Internet intervention|Interactive health promotion
16624656|NCT02450344|Active Comparator|Conventional intervention|Passive health promotion
16624657|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
16624658|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
16624659|NCT02450318|Experimental|Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
16624660|NCT02450305||Treated with HBO|QOL questionnaires at 5 time points for those having HBO therapy at least one year post radiation therapy for head and neck cancer, daily x6 weeks
16624661|NCT02450305||Not treated with HBO|QOL questionnaires for those at least one year post radiation therapy for head and neck cancer at 5 times points.
16624662|NCT02450279|Active Comparator|Nebulization with a vibrating-mesh nebulizer|Nebulization performed with a vibrating-mesh nebulizer
16624663|NCT02450279|Active Comparator|Nebulization with a jet nebulizer|Nebulization performed with a jet nebulizer
16624664|NCT02450266|Active Comparator|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
16624665|NCT02450266|Experimental|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
16624666|NCT02450253|Active Comparator|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
16624667|NCT02450253|Placebo Comparator|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
16624668|NCT02450240||Depression and Anxiety Disorders|"350 subjects who screen positive for anxiety or depressive symptoms on the Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
16624669|NCT02450240||Eating Disorders|"350 subjects who screen positive for problems related to eating behavior on the Eating Disorder Screen (SCOFF), score ≥ 2.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
16624670|NCT02450240||Substance Use Disorders|"350 subjects who screen positive for problems related to substance use on the Drug Abuse Screening Test (DAST-10), score > 2.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
16624671|NCT02450240||Healthy Controls|"150 subjects who do not screen positive for anxiety and depression symptoms or problems related to eating behavior and/or substance use.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
16624672|NCT02450227|Active Comparator|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.
~Followed by:
~Minced spinach (10 mg lutein) given every second day for a 15 days period."
16624673|NCT02450227|Experimental|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.
~Followed by:
~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
16624674|NCT02450214|Sham Comparator|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
16624675|NCT02450214|Experimental|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
16624676|NCT02450214|Experimental|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
16624677|NCT02450201|Experimental|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
16624678|NCT02450201|Experimental|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
16624679|NCT02450188|Active Comparator|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
16624680|NCT02450188|Active Comparator|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).
~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
16624681|NCT02450175|No Intervention|Cases|Patients with cancer whose platelets are examined
16624682|NCT02450175|Placebo Comparator|Control|Patients without cancer whose platelets are examined for comparison
16624683|NCT02450162||conventional lateral rectus recession|This is the standard technique for recession with two single-armed sutures.Exposure of the rectus muscle insertion includes freeing the insertion and proximal muscle borders sufficiently to place the sutures. And the needle is passed through the tendon avoiding the anterior ciliary arteries. If the sutures are passed as shown a true knot is formed, and the muscle is detached. Then a caliper measures from the limbus or the original insertion. A passage of the needle through sclera. The recessed muscle is ideally parallel to the old insertion (or nearly so). Conjunctival incision was finally sutured.
16624684|NCT02450162||hang-back lateral rectus recession|"The hang-back recession has been described as a simple, safe alternative to conventional recession. The procedure is said to be less likely to result in scleral perforation because needles are placed through relatively thicker sclera near the insertion site. It is the modified techique for recession with one double-armed sutures."
16624685|NCT02450149|Experimental|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
16624686|NCT02450136|Experimental|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
16624687|NCT02450123|Experimental|sunitinib|sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.
16624688|NCT02450110|Experimental|Intervention|Spinal cord stimulation on top of standard treatment
16624689|NCT02450110|No Intervention|Control|Standard treatment
16624690|NCT02450097|Other|Lifestyle counseling|"Intermittent Caloric restriction in 3 Groups:
~I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat"
16624691|NCT02450084|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
16624692|NCT02450084|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
16624693|NCT02450058|Active Comparator|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
16624694|NCT02450058|Active Comparator|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
16624695|NCT02450045|Active Comparator|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
16624696|NCT02450045|No Intervention|Control|Patients will receive standard care without a continuous femoral nerve block.
16624697|NCT02450032|Experimental|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
16624698|NCT02450019|Other|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP. Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to protective.
16624699|NCT02450019|Other|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2). Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to traditional.
16624700|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
16624701|NCT02449980|Active Comparator|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
16624702|NCT02449980|Active Comparator|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
16624703|NCT02449967|Experimental|HepaSphere|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
16624704|NCT02449967|No Intervention|control|pancreatic cancer patients did not receive any interventional therapy
16624705|NCT02449954|Active Comparator|morphine group|intravenous 0.1mg/kg morphine
16624706|NCT02449954|Active Comparator|tramadol group|intravenous 2 mg/kg tramadol
16624707|NCT02449954|Active Comparator|ketorolac group|intravenous30 mg ketorolac
16624708|NCT02449941||Helicobacter pylori(HP) positive|Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
16624709|NCT02449928|Active Comparator|lactate group,|
16624710|NCT02449928|Active Comparator|control group|
16624711|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
16624712|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
16624713|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
16624714|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
16624715|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
16624716|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
16624717|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
16624718|NCT02449876|Experimental|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
16624719|NCT02449863||Low risk ultrasound|Patients with a low risk ultrasound
16624720|NCT02449863||High risk ultrasound|Patients with a high risk ultrasound
16624721|NCT02449850|No Intervention|Observation only|Observation only
16624722|NCT02449850|Experimental|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
16624723|NCT02449850|Experimental|Skin care|Intervention: regular baths with bath-oil 0.5-9 months of age
16624724|NCT02449850|Experimental|Food intervention and skin care|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age Intervention: regular baths with bath-oil 0.5-9 months of age
16624735|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
16624736|NCT02449811||Perindopril|Treatment period 1: Perindopril 5mg, oral, once daily, for 4 weeks Treatment period 2: Perindopril 10mg, oral, once daily, for 4 weeks
16624737|NCT02449811||Olmesartan|Treatment period 1: Olmesartan 20mg, oral, once daily, for 4 weeks Treatment period 2: Olmesartan 40mg, oral, once daily, for 4 weeks
16624738|NCT02449811||Amlodipine|Treatment period 1: Amlodipine 5mg, oral, once daily, for 4 weeks Treatment period 2: Amlodipine 10mg, oral, once daily, for 4 weeks
16624739|NCT02449811||Hydrochlorothiazide|Treatment period 1: Hydrochlorothiazide 25mg, oral, once daily, for 4 weeks Treatment period 2: Hydrochlorothiazide 50mg, oral, once daily, for 4 weeks
16624740|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
16624741|NCT02449785|Experimental|Cystic fibrosis adults|
16624742|NCT02449759|Experimental|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
16624743|NCT02449759|No Intervention|Control Group|This group will receive no intervention
16624744|NCT02449746|Active Comparator|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.
~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
16624745|NCT02449746|Active Comparator|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
16624746|NCT02449733|Experimental|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
16624747|NCT02449733|Experimental|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).
~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
16624748|NCT02449720|Active Comparator|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
16624749|NCT02449720|Placebo Comparator|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
16624750|NCT02449720|Active Comparator|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
16624798|NCT02449421|Experimental|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
16626292|NCT02439528|Other|Healthy subject|Genetic analysis on healthy subject.
16624751|NCT02449720|Placebo Comparator|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
16624752|NCT02449707|Active Comparator|Control|Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
16624753|NCT02449707|Experimental|Ultrasonic Pins|Lateral Window Technique Augmentation for Maxillary Sinus with the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of the Purus® Cancellous Allograft, and Resorb X Membrane.Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
16624754|NCT02449694|Experimental|OCS Liver|OCS Liver will be used to preserve the donor liver
16624755|NCT02449681|Experimental|TH-4000 (Tarloxotinib)|
16624756|NCT02449668|Sham Comparator|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
16624757|NCT02449668|Experimental|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
16624758|NCT02449655|Experimental|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
16624759|NCT02449655|Active Comparator|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
16624760|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
16624761|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
16624762|NCT02449629||TGMY in HIV Care|TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit (AMTU) site or elsewhere.
16624763|NCT02449629||TGMY Not in HIV Care|TGMY (16-24 years of age) not currently in care who are living with HIV, not living with HIV, or those who are unaware of their HIV status.
16624764|NCT02449629||Health Care and Social Service Providers|Health care and social service providers who work with TGMY at AMTU sites or elsewhere that serve TGMY within the AMTU cities.
16624765|NCT02449616|Experimental|Study Drug|MST-188
16624766|NCT02449603|Experimental|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
16624767|NCT02449603|Active Comparator|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper <7 mmol/L.
16624768|NCT02449590|Active Comparator|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
16624769|NCT02449590|Placebo Comparator|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
16624770|NCT02449577|Experimental|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624771|NCT02449577|Experimental|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624772|NCT02449577|Experimental|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624773|NCT02449577|Experimental|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624926|NCT02448628|Experimental|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
16624774|NCT02449577|Experimental|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624775|NCT02449577|Experimental|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624776|NCT02449577|Experimental|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624777|NCT02449577|Experimental|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624778|NCT02449577|Experimental|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624779|NCT02449577|Experimental|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624780|NCT02449577|Experimental|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
16624781|NCT02449564|Experimental|sirolimus|sirolimus 1mg daily
16624782|NCT02449551|Experimental|Volitinib|Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
16624783|NCT02449538|Experimental|everolimus|everolimus 10 mg qd daily
16624784|NCT02449525|Experimental|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
16624785|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
16624786|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
16624787|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
16624788|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
16624789|NCT02449486|Active Comparator|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
16624790|NCT02449486|Placebo Comparator|Placebo|Saline infusion 4 ml/h for 48 hours
16624791|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
16624792|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
16624793|NCT02449447|Experimental|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
16624794|NCT02449447|Active Comparator|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
16624795|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study
~There was no intervention - just a questionnaire for each group"
16624796|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study
~There was no intervention - just a questionnaire for each group"
16624797|NCT02449421|Experimental|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
16624799|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
16624800|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
16624801|NCT02449382|Active Comparator|continuous venovenous hemofiltration|CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.
16624802|NCT02449382|Active Comparator|Control group|Treatment of hypernatremia is correction of water deficit.
16624803|NCT02449369|Active Comparator|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
16624804|NCT02449369|Active Comparator|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
16624805|NCT02449369|Experimental|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
16624806|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
16624807|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
16624808|NCT02449343|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16624809|NCT02449343|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16624810|NCT02449330|Experimental|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
16624811|NCT02449330|No Intervention|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
16624812|NCT02449330|Experimental|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
16624813|NCT02449330|No Intervention|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
16624814|NCT02449317|Other|Control|standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
16624815|NCT02449317|Experimental|Bioimpedance guided|"Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water
~extracellular water/total body water < 0.36 : 4 ml/kg/hr
~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr
~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
16624816|NCT02449304|Experimental|Endometrial Ablation (4th gen)|A single-centre uncontrolled observational study is proposed. All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents, who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo RFA G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
16624817|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
16624818|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
16624819|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
16624820|NCT02449278|Experimental|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .
~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
16624821|NCT02449278|Active Comparator|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
16624822|NCT02449265|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
16624823|NCT02449265|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).
~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
16624824|NCT02449252|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
16624853|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
16624825|NCT02449252|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
16624826|NCT02449239|Experimental|Vicinium|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.
~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
16624827|NCT02449200|Experimental|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
16624828|NCT02449200|No Intervention|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
16624829|NCT02449187|Experimental|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing
~Interventions:
~Drug: JLP-1310"
16624830|NCT02449187|Experimental|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing
~Interventions:
~Drug: JLP-1310"
16624831|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
16624832|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
16624833|NCT02449161|Experimental|MPA|medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation
16624834|NCT02449161|Placebo Comparator|placebo|1 placebo/day, for 90 days, following endometrial ablation
16624835|NCT02449148|Experimental|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
16624836|NCT02449148|Experimental|Continuous Calorie Restriction|daily energy intake of 80 %
16624837|NCT02449148|No Intervention|Healthy Nutrition|general advice on healthy nutrition
16624838|NCT02449122|Experimental|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
16624839|NCT02449122|Active Comparator|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
16624840|NCT02449122|No Intervention|Control|Liver cancer patients never received any interventional therapy.
16624841|NCT02449109|No Intervention|Control|Liver cancer patients never received any interventional therapy.
16624842|NCT02449109|Experimental|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
16624843|NCT02449109|Active Comparator|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
16624844|NCT02449096|Other|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation
~All Patients will be operated following a standardized protocol of our foot and ankle department:
~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.
~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.
~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.
~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
16624845|NCT02449096|Active Comparator|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
16624846|NCT02449083||Arm 1|Patients with indication for MRI and coronary angiography
16624847|NCT02449083||Arm 2|Patients with atrioseptal or ventriculoseptal Shunt with indication to coronary angiography
16624848|NCT02449083||Arm 3|Patients with chronic obstructive pulmonary disease with indication to coronary angiography
16624849|NCT02449070|Experimental|Nicorandil|Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.
16624850|NCT02449070|No Intervention|Control|Receive primary PCI and the standard therapy.
16624851|NCT02449057|Experimental|JUST|Juveniles Under Supervision and Treatment. This entails swift, certain, and modest sanctions for violations of terms of community supervision.
16624852|NCT02449057|No Intervention|Probation-as-Usual|Juvenile probation-as-usual.
16624854|NCT02449031||TOBI Podhaler cohort|
16624855|NCT02449031||non-TOBI Podhaler cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
16624856|NCT02449018|Experimental|QBW251|QBW251 will be provided to participants during 70 days
16624857|NCT02449018|Placebo Comparator|Placebo|Placebo will be provided to participants during 70 days
16624858|NCT02449005|Experimental|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
16624859|NCT02449005|Experimental|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
16624860|NCT02449005|Active Comparator|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
16624861|NCT02448992|Experimental|PCI via hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian-iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole-brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
16624862|NCT02448992|No Intervention|observation without PCI|
16624863|NCT02448979|Active Comparator|Left thoracotomy|Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
16624864|NCT02448979|Active Comparator|Right thoracotomy|Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)
16624865|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
16624866|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
16624867|NCT02448953|Active Comparator|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
16624868|NCT02448953|Active Comparator|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
16624869|NCT02448940|Experimental|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
16624870|NCT02448940|Placebo Comparator|lactose|2 capsule/day Containing lactose
16624871|NCT02448927|Other|TAVI patients without balloon aortic valvuloplasty|Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
16624872|NCT02448927|Active Comparator|TAVI patients with balloon aortic valvuloplasty|Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
16624873|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).
~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).
~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).
~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.
~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
16624874|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).
~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).
~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).
~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.
~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
16624875|NCT02448888|Experimental|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
16624876|NCT02448888|Experimental|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
16624877|NCT02448875|Active Comparator|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
16624878|NCT02448875|Experimental|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
16624879|NCT02448875|Experimental|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
16624880|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
16624881|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
16624882|NCT02448849|Experimental|MSC recipients|The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.
16624883|NCT02448849|Placebo Comparator|Placebo|The patients with nonunion fracture who underwent percutaneous injection of placebo.
16624923|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
16624924|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
16624884|NCT02448836|Experimental|Active dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of dTMS active treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
16624885|NCT02448836|Sham Comparator|Sham dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
16624886|NCT02448823|Experimental|Stylish Events and Mass Media|Mass Media (radio, posters) and annual Stylish Man/Stylish Living Event (SMLEvent), a multimedia event promoting CHP.
16624887|NCT02448823|Active Comparator|Control arm: mass media only|Mass media
16624888|NCT02448810|Experimental|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
16624889|NCT02448810|Experimental|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
16624890|NCT02448810|Experimental|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
16624891|NCT02448810|Experimental|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
16624892|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
16624893|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
16624894|NCT02448797|Experimental|icotinib|125 mg three times daily (375 mg per day) orally for two years.
16624895|NCT02448797|Active Comparator|standard chemotherapy|"Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.
~cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.
~For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles."
16624896|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
16624897|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"Palbociclib 125 mg Oral on days 1-21 per cycle Bazedoxifene 40 mg Oral on days 1-28 per cycle
~One cycle is 28 days."
16624898|NCT02448745|No Intervention|Control|21 clusters composed of one or more villages with a total number of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is the only malaria control intervention.
16624899|NCT02448745|Experimental|Intervention|21 clusters composed of one or more villages with a total of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is available and in addition insecticide treated wall lining is installed in all sleeping areas with homeowner consent. All 4 walls and the ceiling are covered with lining.
16624900|NCT02448732|Experimental|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
16624901|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
16624902|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
16624903|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
16624904|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
16624905|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
16624906|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
16624907|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
16624908|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
16624909|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
16624910|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
16624911|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
16624912|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
16624913|NCT02448706|Active Comparator|Hearing Aid Fitting Order A|High level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
16624914|NCT02448706|Active Comparator|Hearing Aid Fitting Order B|Low level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
16624915|NCT02448693|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging. All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
16624916|NCT02448693|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly Narrow Band Imaging and secondly High Definition White Light Endoscopy (WLE). All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
16624917|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
16624918|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
16624919|NCT02448667|Experimental|FAXE Kondi - a sugary soft-drink|100 ml FAXE Kondi (10 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
16624920|NCT02448667|Placebo Comparator|FAXE Kondi Free - a sugarfree soft-drink|100 ml FAXE Kondi Free (0 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
16624921|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
16624922|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
16624927|NCT02448615||Birth Cohort|The cohort will comprise approximately 1500 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02208960).
16624928|NCT02448602|Other|Single point group (Shenmen)|Patients will be acupuncture with Shenmen(HT7).
16624929|NCT02448602|Other|Sancai coordinated points group|Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).
16624930|NCT02448602|Other|Control group|Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.
16624931|NCT02448589|Experimental|TAS-119 Monotherapy|"Dose Escalation:
~A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:
~Dose Expansion:
~A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)"
16624932|NCT02448576|Experimental|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
16624933|NCT02448576|No Intervention|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
16624934|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
16624935|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
16624936|NCT02448550|Experimental|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
16624937|NCT02448550|Active Comparator|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
16624938|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.
~PM01183 predetermined dose daily via IV per cycle
~Doxorubicin predetermined dose daily via IV per cycle"
16624939|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure
~PM01183 predetermined dose given twice via IV per cycle
~Gemcitabine predetermined dose given twice via IV per cycle"
16624940|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine
~-PM01183 predetermined dose once via IV per cycle"
16624941|NCT02448524|Experimental|MiStentTM|MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).
16624942|NCT02448524|Active Comparator|TIVOLI|TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.
16624943|NCT02448511|Experimental|Ozone|this group received local application of ozone gas in addition to conventional treatment.
16624944|NCT02448511|Sham Comparator|Placebo|This group received sham treatment in addition to conventional treatment
16624945|NCT02448498|Experimental|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
16624946|NCT02448498|Experimental|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
16624947|NCT02448498|Experimental|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
16624950|NCT02448459|Experimental|COOL-COS|All women will receive Letrozole, Clomiphene, and Corifollitropin Alfa for controlled ovarian stimulation
16624951|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
16624952|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
16624953|NCT02448433|Other|Phototherapy|
16624954|NCT02448420|Experimental|Arm A: HER2-positive/Hormone receptor-negative|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.
~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
16624955|NCT02448420|Experimental|Arm B1: HER2+/Hormone receptor-positive|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.
~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
16624956|NCT02448420|Experimental|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
~Letrozole: daily oral dose of 2.5 mg."
16624957|NCT02448420|Experimental|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy
~Trastuzumab or biosimilar: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.
~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
16626321|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
16624958|NCT02448420|Active Comparator|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab.
16624959|NCT02448407|Experimental|Platelet rich plasma|Three intraarticular injection, one each fifteen days
16624960|NCT02448407|Active Comparator|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
16624961|NCT02448394|Experimental|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
16624962|NCT02448394|No Intervention|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
16624963|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.
~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.
~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.
~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
16624964|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
16624965|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
16624966|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
16624967|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
16624968|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
16624969|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
16624970|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
16624971|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
16624972|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
16624973|NCT02448355|Experimental|Patient undergoing carotid endarterectomy|"All patients undergoing carotid endarterectomy in Shaare Zedek Medical Center Visual acuity measurement (Snellen) SS-OCT (DRI-Atlantis, Topcon) 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
~On pre-op visit (Monday)
~Day 1 post-surgery
~Discharge day
~Week 1 post-surgery
~Month 1 post-surgery"
16624974|NCT02448342|Experimental|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
16624975|NCT02448342|Active Comparator|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
16624976|NCT02448329|Experimental|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
16624977|NCT02448316|Active Comparator|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
16624978|NCT02448316|Active Comparator|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
16624979|NCT02448303|Experimental|Arm 1|pembrolizumab
16624980|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
16624981|NCT02448290|Experimental|docetaxel+selumetinib|Selumetinib 75 mg will be administered orally twice a day with continuous dosing schedule Docetaxel 60 mg/m2 will be administered via intravenous access every 3 weeks.
16624982|NCT02448277|Experimental|Macintosh Laryngoscope|experimental Macintosh Laryngoscope group: laryngoscope is used to assist for nasotracheal intubation.
16624983|NCT02448277|Experimental|Pentax Airway scope|experimental Pentax Airway scope group:Pentax Airway scope is used to assist for nasotracheal intubation.
16624984|NCT02448277|Experimental|Glidescope|experimental Glidescope group:Glidescope is used to assist nasotracheal tube into trachea
16624985|NCT02448264|Experimental|BCX7353|BCX7353 capsules administered orally
16624986|NCT02448264|Placebo Comparator|Placebo|Placebo to Match BCX7353 capsules, administered orally
16624987|NCT02448251|Experimental|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
16624988|NCT02448251|Experimental|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
16626455|NCT02438371|Active Comparator|Combination|They will receive nifedipine plus indomethacin
16624989|NCT02448238|Experimental|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
16624990|NCT02448225|Experimental|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
16624991|NCT02448212|Experimental|PART 1 (Test/Retest)|Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121
16624992|NCT02448212|Experimental|PART 2 (PET Receptor Occupancy Study)|Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121
16624993|NCT02448199|Experimental|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
16624994|NCT02448199|Active Comparator|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
16624995|NCT02448199|Active Comparator|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
16624996|NCT02448186|Experimental|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
16624997|NCT02448186|No Intervention|Waitlist|3-month waitlist control
16624998|NCT02448173|Experimental|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
16624999|NCT02448173|Active Comparator|Surgery|Surgical resection of Stage II colon cancer
16625000|NCT02448160|Experimental|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
16625001|NCT02448147|Active Comparator|Interval training|
16625002|NCT02448147|Active Comparator|Continuous training|
16625003|NCT02448147|No Intervention|Control|
16625004|NCT02448134|Experimental|Youth Access|"Youth Engagement in Prosocial Alcohol-Free Activities Participate in the Reward and Reminder program in their community"
16625005|NCT02448134|No Intervention|Control|Student will receive regular information and programs.
16625006|NCT02448121|Experimental|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
16625007|NCT02448108|Experimental|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
16625008|NCT02448108|Experimental|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
16625009|NCT02448108|Other|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
16625010|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
16625011|NCT02448082|Placebo Comparator|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
16625012|NCT02448082|Experimental|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
16625013|NCT02448069|Experimental|Argatroban treatment|Intravenous Argatroban delivered at 100mcg/kg bolus, then 12-hour infusion initiated at 3mcg/kg/min.
16625014|NCT02448056||Pre-treatment|All enrolled HCC patients.
16625015|NCT02448056||Post-treatment one week|All enrolled HCC patients.
16625016|NCT02448056||Post-treatment one month|All enrolled HCC patients.
16625017|NCT02448043|Other|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.
~Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
16625018|NCT02448043|Other|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.
~Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
16625019|NCT02448030|Experimental|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
16625020|NCT02448030|Placebo Comparator|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
16625021|NCT02448017|Active Comparator|The Herbst appliance|Orthodontic functional appliance
16625022|NCT02448017|Active Comparator|Twin block appliance|Orthodontic functional appliance
16625023|NCT02448004|Experimental|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
16625024|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
16625025|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
16625026|NCT02447978||PCR-positive pertussis cases|Cases will be all individuals who tested PCR-positive for pertussis and negative for parapertussis during the study period and who received 5 doses of DTaP vaccines (either manufactured by GSK or any brand, depending on study objective) through 84 months of age before testing PCR-positive.
16625142|NCT02447237|Experimental|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
16626491|NCT02438111||age related macular degeneration|metagenome AMD
16625027|NCT02447978||PCR-negative pertussis controls|Controls will consist of persons who tested PCR-negative for both pertussis and parapertussis and who received 5 DTaP doses (either manufactured by GSK or any brand, depending on study objective) before testing PCR negative.
16625028|NCT02447978||KPNC-matched controls|Controls will consist of all KPNC members of the same sex, age (year and quarter of birth), race or ethnic group (7 groups; 6 for reported, 1 for imputed), and medical centre as each pertussis case and who were members on the date the case tested PCR-positive (anchor date).
16625029|NCT02447965|Active Comparator|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
16625030|NCT02447965|Placebo Comparator|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
16625031|NCT02447952|Experimental|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
16625032|NCT02447939|Experimental|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
16625033|NCT02447926|Other|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
16625034|NCT02447913|Experimental|Voucher|
16625035|NCT02447913|No Intervention|Control|
16625036|NCT02447900|Other|Treatment|
16625037|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
16625038|NCT02447874|Experimental|Standard dose|Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
16625039|NCT02447874|Experimental|Loading dose + standard dose|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
16625040|NCT02447874|Experimental|Loading dose + continuous infusion|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
16625041|NCT02447861||3q29 deletion|Individuals with 3q29 deletion
16625042|NCT02447861||3q29 duplication|Individuals with 3q29 duplication
16625043|NCT02447861||Unaffected siblings|Unaffected siblings of 3q29 deletion or duplication individuals
16625044|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
16625045|NCT02447848|Experimental|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
16625046|NCT02447835|Active Comparator|Olanzapine|Olanzapine administration
16625047|NCT02447835|Placebo Comparator|Placebo|Placebo administration
16625048|NCT02447822|Active Comparator|6.0ATG|Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
16625049|NCT02447822|Active Comparator|4.5ATG|Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
16625050|NCT02447809|Experimental|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
16625051|NCT02447809|Active Comparator|Regular DAPT(IPA>60%)|ASA and Clopidogrel
16625052|NCT02447796|Active Comparator|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
16625053|NCT02447796|Active Comparator|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
16625054|NCT02447783|Placebo Comparator|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
16625055|NCT02447783|Active Comparator|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
16625056|NCT02447770|Experimental|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
16625057|NCT02447757||Parturients with remifentanil analgesia|Parturients after induction of remifentanyl analgesia during the delivery
16625058|NCT02447744|Experimental|Mindfulness group|This arm receives an 8-week mindfulness based behavioral intervention program.
16625059|NCT02447744|Other|Waitlist control group|This arm waits while the mindfulness group receives their intervention, and then receives the mindfulness based intervention after their waiting period.
16625100|NCT02447484|Experimental|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
16626492|NCT02438111||controls|metagenome controls
16625060|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
16625061|NCT02447718|Active Comparator|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
16625062|NCT02447718|No Intervention|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
16625063|NCT02447705|No Intervention|Lamivudine group|continue Lamivudine
16625064|NCT02447705|Experimental|Telbivudine group|Telbivudine replaces Lamivudine
16625067|NCT02447679|Experimental|thalidomine|"Thalidomide 400mg/day for 1 year
~tegafur-uracil 2 tables for 1 year."
16625068|NCT02447666|Experimental|Azacitidine Myelodysplastic Syndrome (MDS)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
16625069|NCT02447666|Experimental|Azacitidine Juvenile Myelomonocytic Leukemia (JMML)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
16625070|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
16625071|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
16625072|NCT02447640|Experimental|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
16625073|NCT02447640|Experimental|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
16625074|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
16625075|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
16625076|NCT02447614|Experimental|Surgery|Adenotonsillectomy
16625077|NCT02447614|Experimental|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
16625078|NCT02447614|Experimental|no treatment|just regular follow-up
16625079|NCT02447601|Experimental|Simvastatin and PEX168(200µg)|Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
16625080|NCT02447588|Other|Group 1|Intrauterine insemination with sperm donor (IAD) at 36 hours post-hCG. Cases where the IAD is scheduled at 36 hours post-administration of hCG.
16625081|NCT02447588|Experimental|Group 2|Intrauterine insemination with sperm donor (IAD) at 24 hours post-hCG. Cases where the IAD is scheduled at 24 hours post-administration of hCG.
16625082|NCT02447575|Other|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.
~The inhaler technique is also evaluated by study staff prior to an education demonstration."
16625083|NCT02447562|Active Comparator|G_AH|Usual care group
16625084|NCT02447562|Other|G_SP|Phone-based care
16625085|NCT02447562|Experimental|G_NOMHAD|Intervention group with a health platform NOMHADchronic
16625086|NCT02447549|Active Comparator|WBRT|Standard dose whole bladder radiotherapy
16625087|NCT02447549|Experimental|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
16625088|NCT02447549|Experimental|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
16625089|NCT02447536|Active Comparator|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
16625090|NCT02447536|Active Comparator|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
16625091|NCT02447523||Patients with metabolic syndrome|Patients fulfilling criteria to establish the diagnosis of metabolic syndrome
16625092|NCT02447523||Patients without metabolic syndrome|Patients not fulfilling criteria of the metabolic syndrome
16625093|NCT02447510|Other|group 1|bone substitute grafting material applied to the defect site control (n=10)
16625094|NCT02447510|Other|group 2|experimental platelet rich growth factor PRGF applied to the defect site (n=10) G2
16625095|NCT02447510|Other|group 3|platelet rich fibrin PRF applied to the defect site (n=10) G3.
16625096|NCT02447497|Experimental|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
16625097|NCT02447497|Placebo Comparator|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
16625098|NCT02447497|Experimental|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
16625099|NCT02447497|Placebo Comparator|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
16625101|NCT02447484|Active Comparator|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
16625102|NCT02447471||study group|all participants
16625103|NCT02447458|Experimental|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
16625104|NCT02447458|Experimental|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
16625105|NCT02447458|Experimental|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
16625106|NCT02447458|Experimental|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
16625107|NCT02447458|Experimental|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
16625108|NCT02447458|Experimental|Cohort 6|Did not take place due to termination of the study.
16625109|NCT02447458|Placebo Comparator|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
16625110|NCT02447445||Older inpatient at MOP|The group includes older patients who are admitted to one of the Medicine for Older Patients (MOP) wards. Grip strength will be part of the routine assessment of older patient when admitted to MOP.
16625111|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
16625112|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
16625113|NCT02447419|Experimental|Gefitinib|Gefitinib 250 mg will be administered orally daily
16625114|NCT02447406|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Phase Ib:Volitinib should be administered at least 200mg orally once a day in 21 days for achieving appropriate antitumor activity.
~Phase II: Subjects will receive Volitinib once daily ( at the MTD determined from Phase Ib) for 21 days as one cycle.
~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
16625115|NCT02447393|Other|levocetirizine|Study Drug
16625116|NCT02447393|Other|cetirizine|Study Drug
16625117|NCT02447393|Other|placebo|Study Drug
16625118|NCT02447380|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.
~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
16625119|NCT02447367|Experimental|JLP-1207, Fasted followed by fed|JLP-1207 dosing in the fasted state followed by fed dosing
16625120|NCT02447367|Experimental|JLP-1207, Fed followed by fasted|JLP-1207 dosing in the fed state followed by fasted dosing
16625121|NCT02447341||In patients|
16625122|NCT02447341||Out patients|
16625123|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
16625124|NCT02447315|Experimental|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
16625125|NCT02447315|Experimental|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
16625126|NCT02447315|Experimental|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
16625127|NCT02447315|Experimental|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
16625128|NCT02447302|Experimental|Etrasimod Low Dose|Oral, low dose, daily for 12 Weeks
16625129|NCT02447302|Experimental|Etrasimod High Dose|Oral, high dose, daily for 12 weeks
16625130|NCT02447302|Placebo Comparator|Placebo|Oral, placebo, daily for 12 weeks.
16625131|NCT02447289|Experimental|Experimental|Intranasal administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.2 mg/kg, max. 5 mg)
16625132|NCT02447289|Active Comparator|Comparator|Oral administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.5 mg/kg, max. 20 mg)
16625133|NCT02447289|Active Comparator|Control|Oral administration of midazolam (1.0 mg/kg, max. 20 mg)
16625134|NCT02447276|Experimental|Group A|Group A will receive REGN475 dosing regimen 1
16625135|NCT02447276|Experimental|Group B|Group B will receive REGN475 dosing regimen 2
16625136|NCT02447276|Experimental|Group C|Group C will receive REGN475 dosing regimen 3
16625137|NCT02447276|Experimental|Group D|Group D will receive REGN475 dosing regimen 4
16625138|NCT02447276|Experimental|Group E|Group E will receive matching placebo
16625139|NCT02447263|Experimental|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
16625140|NCT02447263|No Intervention|control|liver cancer patients did not receive any interventional therapy
16625141|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
16625143|NCT02447237|Other|solid food|dietary counselling in fulfilling need of protein and energy through solid food
16625144|NCT02447224|Experimental|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
16625145|NCT02447224|Active Comparator|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
16625146|NCT02447211|Active Comparator|doxepin cream|Patients use doxepin cream 5% twice daily for two weeks
16625147|NCT02447211|Placebo Comparator|Placebo|Patients use cream without doxepin ingredient twice daily for two weeks
16625148|NCT02447185|Experimental|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.
~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.
~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
16625149|NCT02447185|Active Comparator|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.
~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.
~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
16625150|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
16625151|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
16625152|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
16625153|NCT02447159|Experimental|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
16625154|NCT02447159|No Intervention|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
16625155|NCT02447146|Experimental|Training group|9-week resistance training program
16625156|NCT02447146|Other|Control group|'Lectures on the disease'
16625157|NCT02447133|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Maestro device
16625158|NCT02447120|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the Maestro device
16625159|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
16625160|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
16625161|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
16625162|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
16625163|NCT02447068|No Intervention|Non-treatment Control|Control arm will not have any intervention
16625164|NCT02447068|Active Comparator|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
16625165|NCT02447068|Active Comparator|Luma Light|A NBUVB light will be used as an active comparator.
16625166|NCT02447068|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
16625167|NCT02447055|Experimental|Arm 1 (Flu/Mel/PT-Cy & Tac/MMF for certain cases)|"Fludarabine 30 mg/m^2 intravenously (IV) on Days -5, -4, -3, and -2
~Melphalan 140 mg/m^2 IV on Day -2
~Tocilizumab 8 mg/m^2 (capped at 800 mg) IV on Day -1
~Stem cell infusion on Day 0
~Cyclophosphamide 50 mg/kg IV on Days +3 and +4
~Tacrolimus 1 mg/day IV on Day +5 (for unrelated & haploidentical cases)
~Mycophenolate mofetil 15 mg/kg orally three times per day on Day +5 (for unrelated & haploidentical cases)
~Filgrastim 10 ug/kg/day subcutaneously until neutrophil recovery starting on Day +5"
16625168|NCT02447042|Experimental|2 ml/Kg|Fluid challenge with crystalloids (2 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
16625169|NCT02447042|Experimental|3 ml/Kg|Fluid challenge with crystalloids (3 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
16625170|NCT02447042|Experimental|4 ml/kg|Fluid challenge with crystalloids (4 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
16625171|NCT02447042|Experimental|5 ml/Kg|Fluid challenge with crystalloids (5 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
16625172|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
16625173|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
16625174|NCT02447016|Experimental|eviplera (complera)|Tab eviplera QD
16625175|NCT02447016|Active Comparator|atripla|Tab Atripla QD
16625176|NCT02447003|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants will be administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
16625177|NCT02447003|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants will be administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
16625178|NCT02446990|Experimental|Ivabradine|
16625179|NCT02446990|Placebo Comparator|Placebo|
16625180|NCT02446977|Experimental|Vitamin B2 Streuli®|20mg IV
16625181|NCT02446977|Placebo Comparator|Solution for injection|4ml IV
16625182|NCT02446964|Experimental|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.
~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.
~GHVD PROPHYLAXIS: Patients receive tacrolimus* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.
~*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
16625183|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
16625184|NCT02446925|Experimental|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
16625185|NCT02446925|Active Comparator|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
16625186|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
16625187|NCT02446912|Placebo Comparator|Placebo|Placebo
16625188|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
16625189|NCT02446899|Experimental|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
16625190|NCT02446899|Placebo Comparator|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
16625191|NCT02446886|Active Comparator|One Time Treatment|"MS patients enrolled in this study will be randomized into:
~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
16625192|NCT02446886|Experimental|Monthly Treatments|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
16625193|NCT02446873|No Intervention|Control|Control group
16625194|NCT02446873|Experimental|Treatment|Egg supplementation
16625195|NCT02446860|Experimental|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
16625196|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
16625197|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
16625198|NCT02446834|Experimental|intensive lifestyle intervention|3 months intensive lifestyle intervention, including low GI diet and exercise.
16625199|NCT02446834|Experimental|GLP-1 Receptor Agonists|3 months GLP-1 Receptor Agonists treatment
16625200|NCT02446834|Experimental|metformin|3 months metformin treatment
16625201|NCT02446834|Experimental|acarbose|3 months acarbose treatment
16625202|NCT02446821|Experimental|VeraCept IUD System|All women will receive VeraCept.
16625203|NCT02446808|Experimental|Intraoperative nerve monitoring|Patients for which intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
16625204|NCT02446795|Experimental|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
16625205|NCT02446795|Placebo Comparator|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
16625206|NCT02446782|Experimental|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
16625207|NCT02446782|Placebo Comparator|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
16625208|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
16625209|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
16625210|NCT02446756|Experimental|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
16625211|NCT02446756|Active Comparator|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
16625212|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
16625213|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
16625214|NCT02446730|Active Comparator|BES with Prasugel 5mg|Biolimus-eluting stent with Prasugrel 5mg once daily MD
16625215|NCT02446730|Active Comparator|BES with Clopidogrel 75mg|Biolimus-eluting stent with Clopidogrel 75mg once daily MD
16625216|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
16625217|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
16625218|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
16625219|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
16625220|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
16625221|NCT02446704|Experimental|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.
~Olaparib- Oral, on determined days per cycle
~Temozolomide- Oral, on determined days per cycle"
16625222|NCT02446691|Experimental|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
16625223|NCT02446678|Active Comparator|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
16625224|NCT02446678|No Intervention|Standard group|Perform standard esophagogastroduodenoscopy
16625225|NCT02446665|Experimental|PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
16625226|NCT02446665|Active Comparator|Non-PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
16625227|NCT02446652|Experimental|Hydralazine/Magnesium valproate + QT|This group will receive TRANSKRIP® (Hydralazine/Magnesium valproate) + Carboplatin plus Paclitaxel
16625228|NCT02446652|Placebo Comparator|placebo + QT|This group will receive placebo + Carboplatin plus Paclitaxel
16625234|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
16625235|NCT02446600|Active Comparator|Arm I (platinum-based chemotherapy)|"REGIMEN I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
~REGIMEN II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
~REGIMEN III: Patients receive pegylated liposomal doxorubicin hydrochloride IV and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity."
16625236|NCT02446600|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16625237|NCT02446600|Experimental|Arm III (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16625238|NCT02446587||Stroke with Mechanical Thrombectomy|Eligible patients will be adults ≥18 with the final diagnosis of an acute ischemic infarction and large artery occlusion in anterior circulation strokes who undergo endovascular therapy with mechanical thrombectomy utilizing stent retrievers
16625239|NCT02446587||Stroke without Mechanical Thrombectomy|Patients who would have large artery occlusion treated with best medical management (IV-tPA if eligible) and not receiving endovascular therapy will be collected for a secondary analysis as a comparison group and to evaluate the selection methods in them as well
16625240|NCT02446574|Experimental|Arm A|"During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy
~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy"
16625241|NCT02446561|Active Comparator|MRXXX|Active comparator
16625242|NCT02446561|Experimental|MR1XXX|MR1XXX
16625243|NCT02446561|Experimental|MR2XXX|MR2XXX
16625244|NCT02446561|Experimental|MR3XXX|MR3XXX
16625245|NCT02446548|Experimental|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
16625246|NCT02446548|Experimental|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
16625247|NCT02446535|Experimental|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
16625248|NCT02446522|Active Comparator|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
16625249|NCT02446522|Active Comparator|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
16625250|NCT02446509|Experimental|Experimental Group|The experimental group will receive a 7-week group psychoeducation intervention. Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
16625251|NCT02446509|Active Comparator|Wait List Control Group|Subjects in the wait list control group will receive the same 7 psychoeducation sessions after the experimental group receives these sessions.
16625252|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
16625253|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
16625254|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
16625255|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
16625256|NCT02446470|Experimental|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
16625257|NCT02446470|Active Comparator|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
16625258|NCT02446457|Experimental|Cohort I (rituximab, pembrolizumab)|Patients receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 16 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
16625259|NCT02446457|Experimental|Cohort II (rituximab, pembrolizumab, lenalidomide)|Patients receive rituximab IV over 4-8 hours on days 1, 8 and 15 of cycle 1, and day 1 of cycle 2. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 2 years, and lenalidomide PO on days 1-14 every 3 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
16625260|NCT02446444|Experimental|Enzalutamide|Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
16625261|NCT02446444|Active Comparator|Conventional Non-steroidal Anti-androgen (NSAA)|"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.
~All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)"
16625262|NCT02446431|Experimental|Metronomic Therapy|"There is only one arm in this study. All subjects receive the same therapy for a period of 420 days (42 day cycles x 10 cycles).
~Bevacizumab: IV, 10 mg/kg, Days 1, 8
~Cyclophosphamide: PO, 25 mg/m2 Days 1-14 (max dose = 50mg/dose)
~Valproic Acid: PO, 5 mg/kg, three times per day (TID), Days 22-35
~Temsirolimus: IV, 25 mg/m2, Days 22, 29"
16625263|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
16625264|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
16625265|NCT02446405|Experimental|Enzalutamide|"Enzalutamide is 160 mg daily, by mouth, until clinical disease progression or prohibitive toxicity.
~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
16625266|NCT02446405|Active Comparator|Conventional NSAA|"Conventional NSAA, by mouth until clinical disease progression or prohibitive toxicity.
~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
16625267|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.
~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
16625268|NCT02446366|Experimental|Treatment (hypofractionated SBRT)|Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.
16625269|NCT02446353|Experimental|Megace : fed|Megace / Apetrol ES : comparator / test, fed
16625270|NCT02446353|Experimental|Apetrol ES : fed|Apetrol ES / Megace : test / comparator, fed, cross-over
16625271|NCT02446353|Experimental|Megace : fasting|Megace / Apetrol ES : comparator / test, fasting
16625272|NCT02446353|Experimental|Apetrol ES : fasting|Apetrol ES / Megace : test / comparator, fasting, cross-over
16625273|NCT02446340|Experimental|dalazatide 5ug|8 subjects, 6 given active agent and 2 given placebo
16625274|NCT02446340|Experimental|dalazatide 15ug|8 subjects, 6 given active agent and 2 given placebo
16625275|NCT02446340|Experimental|dalazatide 30ug|8 subjects, 6 given active agent and 2 given placebo
16625276|NCT02446340|Experimental|dalazatide 60ug|8 subjects, 6 given active agent and 2 given placebo
16625277|NCT02446327|Other|Diastolic heart failure cohort|This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
16625278|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
16625279|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
16625280|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
16625281|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
16625282|NCT02446301|Experimental|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
16625283|NCT02446301|Experimental|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
16625284|NCT02446288|Active Comparator|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
16625285|NCT02446288|Active Comparator|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
16625286|NCT02446275|Experimental|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression.
16625287|NCT02446275|Experimental|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid.
16625288|NCT02446262|Other|Substudy 1: Instructed subjects|Participants are instructed about outcomes
16625289|NCT02446262|Other|Substudy 1: Uninstructed subjects|Participants learn through experience
16625290|NCT02446262|Other|Substudy 2: heat group|Participants learn about heat outcomes through conditioning
16625291|NCT02446262|Other|Substudy 2: salt group|Participants learn about salt outcomes through conditioning
16625292|NCT02446262|Other|Substudy 2: sugar group|Participants learn about sugar outcomes through conditioning
16625293|NCT02446262|Other|Substudy 3: healthy volunteers|All participants experience all outcomes, within subjects designs
16625294|NCT02446262|Other|Substudy 4: healthy volunteers|Participants are instructed to attend toward or away from the stimulus
16625295|NCT02446262|Other|Substudy 5: healthy volunteers|Participants experience both placebo and cue-based expectations within subjects
16625296|NCT02446249|Experimental|single arm dose escalation|single arm dose escalation
16625297|NCT02446236|Experimental|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
16625298|NCT02446223|Experimental|Active|
16625299|NCT02446210|Active Comparator|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
16625300|NCT02446210|Active Comparator|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
16625301|NCT02446197|Experimental|Patient Directed Exercise Group|Participants will complete a combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
16625302|NCT02446197|No Intervention|Standard of care|Standard of care comprehensive inpatient rehabilitation program.
16625303|NCT02446184|Experimental|Fetal cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
16625304|NCT02446184|Active Comparator|Vesicoamniotic shunt|The fetal vesicoamniotic shunt is considered the standard prenatal therapy for severe LUTO. Amnioinfusion and vesicoamniotic shunt placement will be performed under ultrasound guidance.
16625305|NCT02446184|No Intervention|No fetal intervention group|Those patients that refuse fetal intervention and do not elect to terminate the pregnancy will be followed as part of the no fetal intervention group.
16625306|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
16625307|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
16625308|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
16625309|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
16625310|NCT02446158|Experimental|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
16625311|NCT02446158|No Intervention|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
16625312|NCT02446145|Experimental|Experimental intervention arm|"Eltrombopag daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)
~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes
~one cycle lasts 28 days"
16625313|NCT02446145|Placebo Comparator|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)
~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes
~one cycle lasts 28 days"
16625314|NCT02446132|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
16625315|NCT02446132|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
16625316|NCT02446132|Experimental|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
16625317|NCT02446119||Gastroparesis|"Inclusion criteria:
~1. Subjects will be of either sex, 18 to 70 years of age.
~patients with an established diagnosis of gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects will have delayed gastric emptying on gastric scintigraphy defined as greater than 60% retention at 2 hours and/or greater than 10% retention at 4 hours. This gastric emptying test would have been done prior to the endoscopy and is not part of the research study. Patients will undergo EndoFlip during upper endoscopy."
16625318|NCT02446119||Normals|"Inclusion criteria:
~1. Subjects will be of either sex, 18 to 70 years of age.
~control subjects will be nondiabetic patients without gastroparesis or gastroesophageal reflux symptoms undergoing upper endoscopy. Patients will undergo EndoFlip during upper endoscopy."
16625319|NCT02446106|Active Comparator|Soup with MSG|0.5% MSG incorporated into a soup preload
16625320|NCT02446106|Placebo Comparator|Control Soup|Negative control match for sodium (no MSG + 0.635% salt)
16625321|NCT02446093|Experimental|Test Arm|GMCI + chemoradiation + surgery
16625322|NCT02446093|Active Comparator|Control Arm|Chemoradiation + surgery
16625323|NCT02446080|Experimental|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
16625324|NCT02446080|Active Comparator|Control Group|Milk drink (150 mL/daily) for 60 days.
16625325|NCT02446067|No Intervention|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
16625326|NCT02446067|Active Comparator|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
16625327|NCT02446067|Sham Comparator|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
16625328|NCT02446054|Experimental|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
16625329|NCT02446041||ICS/LABA Patients|ICS/LABA Patients following standard of care
16625330|NCT02446028|Experimental|BIOD-531|BIOD-531 injected twice daily
16625331|NCT02446028|Active Comparator|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
16625332|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
16625333|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
16625334|NCT02446002|Experimental|Lofexidine + Naltrexone|
16625335|NCT02445989|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
16625336|NCT02445989|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
16625337|NCT02445976|Experimental|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
16625338|NCT02445976|Experimental|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
16625339|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
16625340|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
16625341|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
16625342|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
16625343|NCT02445950|Experimental|Technology-aided counseling|Customers receive intervention via technology-aided phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. The customers are able to view their change change needs and choose tasks/goals for the coaching. The independent phase lasts 13 weeks and coaching is done via a digital tool.
16625344|NCT02445950|Active Comparator|Traditional counseling|Customers receive intervention via traditional phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. Change needs and goals are set during the phone calls. The independent phase lasts 13 weeks and includes 3 phone calls.
16625345|NCT02445937|No Intervention|Control|The control group will receive usual care, in which the frequency and content of physician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
16625346|NCT02445937|Experimental|Behavioral: The PARTNER II Intervention|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
16625347|NCT02445924||Control group 1|ten non smoker volunteers
16625348|NCT02445924||Control group 2|ten smoker volunteers
16625349|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
16625350|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
16625351|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
16625352|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
16625353|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
16625354|NCT02445898|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
16625355|NCT02445898|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
16625356|NCT02445885|Experimental|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
16625357|NCT02445885|Active Comparator|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
16625358|NCT02445872|Experimental|Arm A|Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
16625359|NCT02445872|Active Comparator|Arm B|Palonosetron: 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 7.5mg PO on days 4-5.
16625360|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
16625361|NCT02445859|Experimental|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
16625362|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
16625363|NCT02445833|Experimental|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
16625364|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
16625365|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
16625366|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
16625367|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
16625368|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
16625369|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
16625370|NCT02445781|Experimental|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
16625371|NCT02445781|Experimental|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
16625372|NCT02445781|Experimental|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
16625373|NCT02445781|Experimental|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
16625374|NCT02445768|Experimental|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
16625375|NCT02445742|Experimental|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
16625376|NCT02445729|Active Comparator|Dressing Removal at 24 Hours|These patients are randomly assigned to have their dressing removed 24 hours after cesarean section.
16625377|NCT02445729|Active Comparator|Dressing Removal at 48 Hours|These patients are randomly assigned to have their dressing removed 48 hours after cesarean section.
16625378|NCT02445716|Active Comparator|Testosterone 500 mcg / Biolipid B2|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.
~The arm have 35 women. It consists of a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment."
16625379|NCT02445716|Placebo Comparator|Placebo|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.
~The arm have 35 women. It consists of a 4-week screening period plus a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment.
~Participants will be attended at the Federal University of São Paulo / Post Graduation Program in São Paulo, Brazil for their study visits."
16625380|NCT02445703|Experimental|Group 1 (HAV + HAV)|"Intervention: Inactivated Hepatitis A vaccine (HAV);
~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);
~Route of administration: intramuscular injection in deltoid region;"
16625381|NCT02445703|Experimental|Group 2 (HAV + HABV)|"Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);
~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.
~Route of administration: intramuscular injection in deltoid region;"
16625382|NCT02445703|Experimental|Group 3 (HABV + HABV)|"Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);
~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);
~Route of administration: intramuscular injection in deltoid region;"
16625383|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
16625384|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
16625385|NCT02445677|Experimental|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
16625386|NCT02445677|Placebo Comparator|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
16625387|NCT02445664|Experimental|Video intervention|A tablet-administered educational video (10 minutes duration).
16625388|NCT02445664|No Intervention|Control|No intervention (no video)
16625389|NCT02445651|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
16625390|NCT02445651|No Intervention|Control Cohort|Standard of Care Treatment
16625391|NCT02445638|Active Comparator|Whole egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 whole eggs for 4 weeks.
16625392|NCT02445638|Placebo Comparator|Yolk-free egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 yolk-free eggs for 4 weeks.
16625393|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
16625394|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
16625395|NCT02445599|Experimental|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.
~Every patient recieved additional thoracic epidural analgesia during and after the surgery.
~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
16625396|NCT02445599|Experimental|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.
~Every patient recieved additional thoracic epidural analgesia during and after the surgery.
~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
16625397|NCT02445586|Experimental|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
16625398|NCT02445573|Active Comparator|EA group|
16625399|NCT02445573|Placebo Comparator|Sham EA group|
16625400|NCT02445560|Experimental|Probiotic capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
16625401|NCT02445560|Experimental|Probiotic capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
16625402|NCT02445560|Experimental|Placebo capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
16625403|NCT02445560|Placebo Comparator|Placebo capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
16625404|NCT02445547|Experimental|UC-MSCs|UC-MSCs by peripheral intravenous infusion
16625405|NCT02445547|Active Comparator|control|received hormone maintenance therapy
16625406|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
16625407|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
16625408|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
16625409|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
16625410|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
16625411|NCT02445508|Placebo Comparator|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
16625412|NCT02445508|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
16625413|NCT02445508|Active Comparator|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
16625414|NCT02445508|Active Comparator|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
16625415|NCT02445469|Other|Parkinson's disease|MRI exam of the brain
16625416|NCT02445469|Other|Multiple System Atrophy|MRI exam of the brain
16625417|NCT02445469|Other|Progressive Supranuclear Palsy|MRI exam of the brain
16625418|NCT02445469|Other|Vascular parkinsonism|MRI exam of the brain
16625419|NCT02445469|Other|Healthy volunteers|MRI exam of the brain
16625420|NCT02445456|Experimental|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
16625421|NCT02445456|Experimental|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
16625422|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
16625423|NCT02445417||EES|Epidermal Electronic System
16625424|NCT02445417||Hydrogel Electrode|Hydrogel based EEG electrode
16625425|NCT02445404|Active Comparator|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
16625426|NCT02445404|Experimental|Fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
16625427|NCT02445391|Active Comparator|Arm A (observation) (closed to accrual 05/16/2016)|Patients undergo observation.
16625428|NCT02445391|Experimental|Arm B (cisplatin or carboplatin)|Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16625496|NCT02444884|Experimental|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
16625429|NCT02445391|Experimental|Arm C (capecitabine)|Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16625430|NCT02445378|Experimental|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
16625431|NCT02445378|Experimental|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
16625432|NCT02445365|Experimental|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
16625433|NCT02445365|Sham Comparator|Sham|As above with a cuff pressure of 20 mmHg
16625434|NCT02445352|Active Comparator|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
16625435|NCT02445352|Experimental|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
16625436|NCT02445352|Active Comparator|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
16625437|NCT02445352|Experimental|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
16625438|NCT02445352|Active Comparator|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
16625439|NCT02445352|Experimental|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
16625440|NCT02445339|Active Comparator|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
16625441|NCT02445339|No Intervention|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
16625442|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
16625443|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
16625444|NCT02445313||Control|Normal, healthy participants
16625445|NCT02445313||AMD|Age-related Macular Degeneration participants
16625446|NCT02445300|Active Comparator|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
16625447|NCT02445300|Active Comparator|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
16625448|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
16625449|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
16625450|NCT02445274|Experimental|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
16625451|NCT02445274|No Intervention|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
16625452|NCT02445261|Active Comparator|normal growth|120 woman with normal fetal growth will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations were assessed
16625453|NCT02445261|Active Comparator|growth restricted group|70 woman with l growth restricted fetus will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations
16625454|NCT02445248|Experimental|CTL019|Single arm
16625455|NCT02445222|Other|Previously treated CAR-T patients|Patients who previously were exposed to lentiviral-based CART cell therapy
16625456|NCT02445209|Active Comparator|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).
~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
16625457|NCT02445209|Active Comparator|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).
~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
16625458|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
16626493|NCT02438098|Other|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
16625459|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.
~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
16625460|NCT02445183||Lung Cancer|Confirmed diagnosis of lung cancer
16625461|NCT02445183||No Lung Cancer Controls|Unconfirmed lung cancer diagnosis, false positive
16625462|NCT02445170||Below-knee amputees|The present group consists of diabetic below-knee prosthetic user
16625463|NCT02445170||Transmetatarsal amputees|The present group consists of diabetic transmetatarsal amputees
16625464|NCT02445157||IPF_Reliability|Patients diagnosed with IPF according to NICE guidelines.
16625465|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
16625466|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
16625467|NCT02445131|Experimental|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
16625468|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
16625469|NCT02445105|Active Comparator|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
16625470|NCT02445105|Experimental|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
16625471|NCT02445092|Experimental|Catheter prewashing|"Intervention: prewashing the catheter before IUI.
~450 patients randomly included in this group will have their insemination catheter prewashed with the same media used to wash the sperm, prior to performing the insemination using the washed catheter."
16625472|NCT02445092|No Intervention|Control group|450 patients randomly assigned in this group will have their insemination performed routinely, without washing the insemination catheter..
16625473|NCT02445079||HIV infected|HIV infected sub-group
16625474|NCT02445079||HIV uninfected|HIV uninfected sub-group, age and gender matched to the HIV-infected group
16625475|NCT02445066|Other|Open label|Vitamin D3 - 4,000 IU/day for 4 months
16625476|NCT02445040|Experimental|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
16625477|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
16625478|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
16625479|NCT02445001|Experimental|ICG loaded erythrocytes|Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.
16625480|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
16625481|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
16625482|NCT02444975|Experimental|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
16625483|NCT02444975|Other|No intervention|No intervention
16625484|NCT02444962|Experimental|HAVD implant|
16625485|NCT02444949|Experimental|endostar+DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)+endostar (150mg/5d; civ; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
16625486|NCT02444949|Other|DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
16625487|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
16625488|NCT02444936|No Intervention|Control|There is no drug given in this arm.
16625489|NCT02444923|Experimental|Scleral rigid gas permeable contact lenses|The experimental intervention is the Scleral Rigid Gas Permeable contact lens (SRGPcl), Zenlens™. These lenses are designed to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with corneal contact.
16625490|NCT02444923|Placebo Comparator|Corneal rigid gas permeable contact lenses|The control intervention is the RoseK2™ Corneal Rigid Gas Permeable contact lens (CRGPcl). Corneal lenses are considered the gold standard in the management of the visual disability due to keratoconus and other related irregular cornea disorders.
16625491|NCT02444910|Experimental|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
16625492|NCT02444897|Experimental|Epidural PCA group|Epidural patient-controlled analgesia group
16625493|NCT02444897|Active Comparator|IV PCA group|Intravenous patient-controlled analgesia
16625494|NCT02444884|Experimental|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
16625495|NCT02444884|Experimental|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
16625497|NCT02444858|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous injection
16625498|NCT02444858|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
16625499|NCT02444845||Study Population|Hypertensive and diabetic patients who meet eligibility criteria will be enrolled and evaluated for the presence of anemia secondary to CKD. The first visit will capture medical history including risk factors for CKD; laboratory assessments will be performed at the second and third visits to evaluate glomerular filtration rate (eGFR) and anemia profile, respectively. Participants who are not diagnosted with CKD based upon the second visit will not return for the third visit.
16625500|NCT02444819|Experimental|HM61713|Subjects who entered the study will be administered HM61713 800 mg per day.
16625501|NCT02444806|Active Comparator|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
16625502|NCT02444806|Active Comparator|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
16625503|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
16625504|NCT02444780||elective cardiac surgery patients|consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period
16625505|NCT02444767|Experimental|13mg Bimatoprost Insert|Subjects in this arm have 13mg Bimatoprost Ocular Inserts placed in both eyes for 7 days.
16625506|NCT02444754||Health services research (surveys, questionnaires)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
16625507|NCT02444741|Experimental|Group I, Phase I (pembrolizumab + SBRT)|Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
16625508|NCT02444741|Experimental|Group I, Phase II (pembrolizumab + SBRT)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
16625509|NCT02444741|Experimental|Group II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT)|Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.
16625510|NCT02444741|Experimental|Group II, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will be salvaged with IMRT, PBRT, or 3D-CRT and analyzed as part of the fourth treatment group.
16625511|NCT02444741|Experimental|Group III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61.
16625512|NCT02444741|Experimental|Group IV, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.
16625513|NCT02444741|Experimental|Group V, Phase II (low dose radiation therapy)|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.
16625514|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
16625515|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.
~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
16625516|NCT02444715|Active Comparator|Standard care (SC)|
16625517|NCT02444715|Experimental|Interventional care (IC)|
16625518|NCT02444702||CLBP and degenerative lumbar spine|Participants with CLBP (>12 weeks) and degenerative changes of the lumbar spine confirmed by CT imaging who were recommended surgery and chose to undergo surgery will be recruited from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel. Included participants will be men or women, aged 40-80 years, of any race or ethnic background. Participants' diagnosis may include unstable degenerative spondylolisthesis, radicular pain, or documented stenosis with referred pain.
16625519|NCT02444689|Experimental|Electronic Media Application|Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
16625760|NCT02443012|Placebo Comparator|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
16625520|NCT02444689|Active Comparator|Control|Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
16625521|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
16625522|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
16625523|NCT02444663|Experimental|Device Valgus|Device performed fluoroscopic valgus stress X-rays
16625524|NCT02444663|Experimental|Device Varus|Device performed fluoroscopic varus stress X-rays
16625525|NCT02444637|Experimental|Rivastigmine (Exelon) Patch|For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
16625526|NCT02444624||not necrotizing enterocolitis group|not necrotizing enterocolitis preterm neonates matched with necrotizing enterocolitis preterm neonates
16625527|NCT02444624||necrotizing enterocolitis group|necrotizing enterocolitis preterm neonates of gestational age less than or equal to 31+6 weeks of amenorrhoea with confirmed NEC diagnosis (Bell stage II or III)
16625528|NCT02444611|Active Comparator|Group 1|BCG vaccine, 0,05ml intradermally at birth
16625529|NCT02444611|Active Comparator|Group 2|BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
16625530|NCT02444611|Active Comparator|Group 3|Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
16625531|NCT02444611|No Intervention|Group 4|No birth vaccines
16625532|NCT02444598|Experimental|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
16625533|NCT02444598|Active Comparator|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
16625534|NCT02444585|Experimental|Denosumab|Drug for prevention of bone loss
16625535|NCT02444585|Placebo Comparator|Control|Hip Replacement Patient without Drug
16625536|NCT02444572|Experimental|ENOXA® group|"Patients under ENOXA® 4000 IU according to randomization:
~Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion
~Start injections 12 hours after the surgical procedure
~Administer ENOXA® subcutaneously
~The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
16625537|NCT02444572|Active Comparator|LOVENOX® group|"Patients under LOVENOX® 4000 IU according to randomization:
~Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion
~Start injections 12 hours after the surgical procedure
~Administer LOVENOX® subcutaneously
~The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
16625538|NCT02444559|Experimental|Ropivacaine+Clonidine|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
16625539|NCT02444559|Placebo Comparator|Ropivacaine+Placebo|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ saline
16625540|NCT02444546|Experimental|Treatment (sargramostim, wild-type reovirus)|Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
16625541|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
16625542|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
16625543|NCT02444520|Experimental|Integrated GP Care|"GP training in utilising cognitive behavioural skills during 10-minute consultations;
~GP Supervision;
~Audio-visual and written materials/guidelines for GP's;
~Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;
~Booklets for patients once consent gained."
16625544|NCT02444520|No Intervention|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
16625545|NCT02444507|Active Comparator|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
16625546|NCT02444507|Active Comparator|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
16625547|NCT02444481|Experimental|Polygynax, antibiotic, vaginal treatment|Polygynax combinaison of nystatine, polymyxin, neomycin, Local treatment of vaginal infection during 12 days. One vaginal capsule every evening.
16625548|NCT02444468|Experimental|IPC and bandage|Pneumatic device and bandage
16625549|NCT02444468|Active Comparator|Bandage only|Bandage only
16625550|NCT02444455|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous infusion
16625551|NCT02444442|Active Comparator|Renal Denervation|participants randomised to undergo renal denervation
16625552|NCT02444442|Sham Comparator|Sham control|participants randomised to undergo sham procedure
16625553|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
16625554|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
16625555|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
16625556|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
16625761|NCT02442999|No Intervention|Usual care|
16626494|NCT02438085||ACS patients|prospective collection of data and follow-up
16625557|NCT02444403|Other|Police Education Program (PEP)|The entire police force mandated for periodic refresher training will be assigned to classes which receive one PEP course over 2 years.
16625558|NCT02444390|Other|Exemestane+everolimus|Exemestane+everolimus are administered as per their approved indication
16625559|NCT02444377|Experimental|High-intensity interval -2min|5 bouts of 2 min cycling at varying intensities of VO2peak (80-100%) with 1 min recovery.
16625560|NCT02444377|Experimental|High-intensity interval -1min|10 bouts of 1 min cycling at 90% of VO2peak with 1 min rest periods
16625561|NCT02444377|No Intervention|Control|No exercise
16625562|NCT02444364|Experimental|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
16625563|NCT02444351|Active Comparator|control group|
16625564|NCT02444351|Experimental|botox group|
16625565|NCT02444338|Active Comparator|Control Group|optimal standard of care therapy
16625566|NCT02444338|Experimental|Device Group|MitraClip device plus optimal standard of care therapy
16625567|NCT02444325|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
16625568|NCT02444325|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a four session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 4-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by 2 CenteringPregnancy trained providers at each site and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
16625569|NCT02444312|Experimental|Benefit-finding Writing Activity|For two weeks, on six days of their choice, caregivers will be instructed to write about their thoughts and feelings in a diary/ notebook about the benefits of caring.
16625570|NCT02444312|Active Comparator|Neutral Writing activity|For two weeks, on six days of their choice, caregivers will be instructed to write about a neutral topic.
16625571|NCT02444286||standard care group|optimal standard of care therapy
16625572|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
16625573|NCT02444273|No Intervention|Control Group|Subjects will receive standard care both pre and post transplant.
16625574|NCT02444273|Experimental|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
16625575|NCT02444260|Sham Comparator|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
16625576|NCT02444260|Active Comparator|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
16625577|NCT02444247|Other|High Dose Exercise vs Sedentary Option|Relative Reinforcing Value of high dose exercise (300 kcal expenditure per session) versus sedentary activity will be determined.
16625578|NCT02444247|Other|Low Dose Exercise vs Sedentary Option|Relative Reinforcing Value of low dose exercise (150 kcal expenditure per session) versus sedentary activity will be determined.
16625579|NCT02444247|Other|No Exercise vs Sedentary Option|Relative Reinforcing Value of no exercise (0 kcal expenditure per session) versus sedentary activity will be determined.
16625580|NCT02444234|Experimental|Tedizolid PO|Tedizolid phophate 200mg tablet
16625581|NCT02444234|Experimental|Tedizolid IV|Tedizolid phophate 200mg IV
16625582|NCT02444208|Experimental|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
16625583|NCT02444208|Placebo Comparator|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
16625584|NCT02444195|Experimental|Guided Imagery|Guided Imagery With Audio Media
16625585|NCT02444195|No Intervention|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
16625586|NCT02444182|Experimental|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
16625587|NCT02444182|Placebo Comparator|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
16625588|NCT02444156|Experimental|Exercise training|All participants will receive usual care, including standard advice about diet and physical activity. In addition to usual care, participants will be asked to take part in a 12-week exercise programme. Participants will use an indoor rower (Concept 2, Model E) three times per week at Leicester Diabetes Centre. Each session will be supervised and the investigators will liaise with the participants to arrange convenient times to exercise, including mornings and evenings. The supervisors will teach the participants how to row correctly.
16625589|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
16625590|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
16625591|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
16625592|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
16625762|NCT02442999|Experimental|Screen for Sleep Apnea|Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea
16625593|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
16625594|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
16625595|NCT02444091|Experimental|Cyclophosphamide|Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2
16625596|NCT02444078|Experimental|Exercise|Exercise sessions will be done in groups of three-to-eight persons; whilst being a group-based exercise program, participants will be guided and the exercises will be adapted in an individual basis, which may increase adherence and compliance rates.
16625597|NCT02444078|Active Comparator|Social activity|Participants in this group will participate in group-based activities such as music (percussion instruments), arts and board games; no intervention on physical activity will be provided to these participants.
16625598|NCT02444065|Experimental|Cognitive Behavior Therapy (CBT)|In this arm, participants receive the Cognitive behavior therapy (CBT) intervention as an augmentative treatment to standard day hospital treatment as usual.
16625599|NCT02444065|Active Comparator|Motivational Interviewing (MI)|In this arm, participants receive the Motivational Interviewing intervention as an augmentative treatment to standard day hospital treatment as usual.
16625600|NCT02444052|Experimental|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
16625601|NCT02444052|Experimental|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
16625602|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
16625603|NCT02444026|Experimental|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
16625604|NCT02444026|No Intervention|Control|The control group will be offered the intervention AFTER the study
16625605|NCT02444013|Active Comparator|Folic acid|Oral folic acid (5 mg, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
16625606|NCT02444013|Placebo Comparator|Placebo|Oral placebo (1 tablet, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
16625607|NCT02444000|Experimental|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
16625608|NCT02444000|Active Comparator|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
16625609|NCT02443987|Experimental|Received intravenous fluids|The patient will receive 500ml of 0.9% NaCl fluid intravenously during the operation.
16625610|NCT02443987|No Intervention|Control Arm|The patient will receive no intravenous fluid as per current routine protocol
16625611|NCT02443974|Experimental|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
16625612|NCT02443974|Experimental|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
16625613|NCT02443974|No Intervention|Control group|Keep medication usual
16625614|NCT02443961|Experimental|Mesenchymal Stem Cell (MSC) therapy|There will only be one treatment arm to evaluate the security of the treatment with MSC.
16625615|NCT02443948||adjuvant/follow up setting|
16625616|NCT02443948||neo-adjuvant setting|
16625617|NCT02443948||advanced disease|
16625618|NCT02443935|Experimental|MGN1703|TLR-9 agonist MGN1703 administered to HIV-1 positive patients on cART
16625619|NCT02443922|Experimental|Glimepiride|Glimepiride 2mg qam
16625620|NCT02443922|Experimental|Sitagliptin|Sitagliptin 100mg qam
16625621|NCT02443922|Active Comparator|Metformin|Metformin as prescribed
16625622|NCT02443909|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w Holmium laser device who have 2-3 cm kidney stones
16625623|NCT02443909|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power) who have 2-3 cm kidney stones
16625624|NCT02443909|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power) who have 2-3 cm kidney ston
16625625|NCT02443896|Experimental|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.
~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
16625626|NCT02443896|Sham Comparator|No sealant applied to molars.|No molars will be sealed.
16625627|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
16625628|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
16625629|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
16625630|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
16625631|NCT02443857|Experimental|ChARMin|Single-arm only
16625632|NCT02443844|Active Comparator|First group|Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer
16625633|NCT02443844|Active Comparator|Second Group|Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer
16625634|NCT02443831|Experimental|CD19 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19CAR T-cells.
16625635|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
16625636|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
16625637|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
16625638|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
16625639|NCT02443779||Early Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
16625640|NCT02443779||Advanced Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
16625641|NCT02443766||Healthy Subjects|Healthy subjects will attend the weeklong meditation retreat.
16625642|NCT02443753|Experimental|Device|Subjects who receive the device
16625643|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
16625644|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
16625645|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of BIIB118 administered to healthy volunteers to assess the PK of BIIB118 in CSF
16625646|NCT02443727|Experimental|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
16625647|NCT02443727|Placebo Comparator|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.
~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
16625648|NCT02443714|Experimental|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
16625649|NCT02443714|Experimental|Conventional pen|Conventional insulin administration with insulin pens.
16625650|NCT02443701|Experimental|Exercise|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).
16625651|NCT02443701|Experimental|NEMES|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).The healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation, medium frequency current (1kHz), modulated at 70Hz, cycle Work 10%, intensity used will vary according to the capacity and tolerable for each individua. The stimulated muscle group will be the quadriceps femoris
16625652|NCT02443701|Experimental|Phototherapy|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump). The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. Phototherapy will be conducted through a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J. The application sites will be six points on the belly of the quadriceps femoris muscles bilaterally.
16625653|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
16625654|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
16625655|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
16625656|NCT02443649|Experimental|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
16625657|NCT02443649|Active Comparator|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
16625658|NCT02443623|Experimental|Single Arm Vaccinated with ACAM2000|"To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
~To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
16625659|NCT02443597||obese pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:
~Fetal nuchal translucency thickness.
~Nasal bone.
~Fetal facio-maxillary angle.
~The flow across the tricuspid valve as normal or regurgitated.
~A-wave in the ductus venosus as normal or reversed."
16625660|NCT02443597||lean pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:
~Fetal nuchal translucency thickness.
~Nasal bone.
~Fetal facio-maxillary angle.
~The flow across the tricuspid valve as normal or regurgitated.
~A-wave in the ductus venosus as normal or reversed."
16625661|NCT02443584|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
16625662|NCT02443584|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
16625663|NCT02443558|Experimental|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
16625664|NCT02443558|Experimental|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
16625665|NCT02443558|Active Comparator|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
16625666|NCT02443558|Active Comparator|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
16625667|NCT02443545|Experimental|Group 1: Deferiprone 3 years|Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study)..
16625668|NCT02443545|Experimental|Group 2: Deferiprone 2 years|Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).
16625669|NCT02443532|Experimental|Structured Group education|Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
16625670|NCT02443532|Other|Individual education|Usual care (individual consultations as routinely performed)
16625671|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
16625672|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
16625673|NCT02443506|Experimental|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
16625674|NCT02443506|Placebo Comparator|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
16625675|NCT02443493|Experimental|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
16625676|NCT02443493|Sham Comparator|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
16625677|NCT02443467||HER2-positive early breast cancer|Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer treated with loading dose of Herceptin (trastuzumab) administered as 6 mg/kg followed by once in 3 weeks administration at 4 mg/kg up to 12 months of treatment
16625678|NCT02443454||Patients after kidney transplantation|Short and Long-term results containing first 10 years after KTx.
16625679|NCT02443454||Healthy subjects|Medical staff: medical doctors, nurses
16625680|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
16625681|NCT02443415||Healthy Controls|Non-diabetic subjects
16625682|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
16625683|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
16625684|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
16625685|NCT02443402|Experimental|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
16625686|NCT02443402|Placebo Comparator|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
16625687|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
16625688|NCT02443376||Hemodialysis patients|Stable end-stage renal disease patients on maintenance conventional hemodialysis received 4-5 hours of treatment thrice weekly. Pulse wave velocity and central aortic pressure was measured before and after the midweek dialysis session.Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM) was measured before the midweek dialysis session just after Complior device
16625689|NCT02443376||Healthy subjects|Medical staff: medical doctors, nurses
16625690|NCT02443363||Patients After Kidney Transplantation|A total of 300 consecutive patients admitted to routine visit in Transplant Centre with functioning graft longer than 3 months to 10 years
16625691|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
16625692|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)|Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625693|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)|Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625694|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A)|Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625695|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)|BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625696|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)|Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625697|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort B)|Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625698|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort C)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625699|NCT02443324|Experimental|Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)|Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625700|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort E)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
16625701|NCT02443311|Experimental|Group I|Pimecrolimus 1% cream (Elidel, Novartis Pharmaceuticals, East Hanover, NJ)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
16625702|NCT02443311|Active Comparator|Group II|Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
16625703|NCT02443298|Experimental|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
16625704|NCT02443298|Placebo Comparator|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
16625705|NCT02443285|Active Comparator|Cefotaxime|cefotaxime 2gm every 12 hours daily for 5 days
16625706|NCT02443285|Active Comparator|Ceftriaxone|ceftriaxone 2 gm every 24 hours for 5 days.
16625707|NCT02443272|Active Comparator|Control Arm|Receive standard incision and drainage
16625708|NCT02443272|Experimental|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
16625709|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
16625710|NCT02443259||late preterms|late preterm neonates
16625711|NCT02443246|Experimental|Vitamin D deficiency|Group 1
16625712|NCT02443246|Experimental|Vitamin D deficiency (Low)|Group 2
16625713|NCT02443233||Maternal hepatitis B carrier|
16625714|NCT02443233||Paternal hepatitis B carrier|
16625715|NCT02443220|Experimental|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
16625716|NCT02443220|Active Comparator|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
16625717|NCT02443220|Sham Comparator|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
16625718|NCT02443194|Active Comparator|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:
~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
16625719|NCT02443194|Placebo Comparator|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
16625720|NCT02443181|Experimental|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
16625721|NCT02443168|Experimental|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
16625722|NCT02443168|Experimental|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms [14C] AG-221
16625723|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
16625724|NCT02443155|Experimental|NNC0114-0006 + Placebo|
16625725|NCT02443155|Active Comparator|Liraglutide + Placebo|
16625726|NCT02443155|Placebo Comparator|Placebo|
16625759|NCT02443012|Experimental|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
16625727|NCT02443142|Experimental|Ibuprofen|Ibuprofen is a nonselective NSAID that inhibits both COX-1 and COX-2 isoenzymes. COX-2 inhibition prevents arachidonic acid from converting to vasoactive prostaglandins and reactive oxygen species in brain cell. The analgesic, antipyretic, and antiinflammatory activity of ibuprofen operates mainly through inhibition of COX-2. The experimental treatment oral doses of either ibuprofen (800 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
16625728|NCT02443142|Active Comparator|Acetaminophen|Acetaminophen is a poor inhibitor of both COX isoenzymes in the CNS and has significantly weaker antiinflammatory effects than NSAIDs. Acetaminophen does not inhibit COX in peripheral tissues and is less effective in the presence of peroxides. The active comparator treatment is oral doses of acetaminophen (1000 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
16625729|NCT02443129|Experimental|control group|"18-99 year old male + female
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
16625730|NCT02443129|Experimental|mydramide only|"Patients in the clinics undergoing pupil dilation
~Intervention:
~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
16625731|NCT02443129|Experimental|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation
~Intervention:
~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
16625732|NCT02443129|Experimental|All patients presenting with RD|"Patients with retinal detachment
~Intervention:
~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
16625733|NCT02443129|Experimental|Impact of previous grid treatment|"Patients after grid laser
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
16625734|NCT02443129|Experimental|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment
~Intervention:
~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
16625735|NCT02443129|Experimental|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).
~Longitudinal arm with newly diagnosed patients for 2 years follow-up
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
16625736|NCT02443129|Experimental|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
16625737|NCT02443129|Experimental|Retrospective analysis|"All patients pictured with DRI-OCT
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
16625738|NCT02443116|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 - Placebo
16625739|NCT02443116|Experimental|Cohort 1 - NGM282 3mg|Cohort 1 - NGM282 3mg
16625740|NCT02443116|Experimental|Cohort 1 - NGM282 6mg|Cohort 1 - NGM282 6mg
16625741|NCT02443116|Experimental|Cohort 2 - NGM282 0.3mg|Cohort 2 - NGM282 0.3mg
16625742|NCT02443116|Placebo Comparator|Cohort 2 - NGM282 1mg|Cohort 2 - NGM282 1mg
16625743|NCT02443116|Experimental|Cohort 2 - NGM282 3mg|Cohort 2 - NGM282 3mg
16625744|NCT02443116|Experimental|Cohort 3 - NGM282 1mg|Cohort 3 - NGM282 1mg
16625745|NCT02443116|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 - Placebo
16625746|NCT02443116|Experimental|Cohort 4 - NGM282 1mg|Cohort 4 - NGM282 1mg
16625747|NCT02443103|Experimental|Guanabenz|
16625748|NCT02443090|Experimental|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
16625749|NCT02443090|Placebo Comparator|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
16625752|NCT02443064|Experimental|MRSA blood stream infection patient|"Intervention:Vancomycin
~Dosing:
~15-20mg/kg, IV,q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1~2 h/ dosing, IV
~Drug combination:
~Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.
~Duration:
~Septicemia: 2~4 weeks Endocarditis: 6~8 weeks"
16625753|NCT02443051|Experimental|Attention Bias Modification|Training in bias modification for 80% of experimental trials
16625754|NCT02443051|Active Comparator|Control|Bias modification for 50% of trials
16625755|NCT02443038|Active Comparator|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
16625756|NCT02443038|Placebo Comparator|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
16625757|NCT02443025|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
16625758|NCT02443025|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
16625763|NCT02442986||Septic Shock or severe sepsis|Septic patients on ICU with severe sepsis or septic shock.
16625764|NCT02442986||Non-Septic, Surgical Patients|Non-septic patients after surgical treatment and anesthesia on ICU.
16625765|NCT02442986||Non-Septic, Non-Surgical Patients|Patients without sepsis criteria treated on ICU, non-surgical patients.
16625766|NCT02442973||Control group (CG):|Standard practice group
16625767|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
16625768|NCT02442960|Active Comparator|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
16625769|NCT02442960|Active Comparator|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
16625770|NCT02442947|Experimental|Research arm|"1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.
~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.
~4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:
~NBC protective garment (charcoal base).
~combat garment.
~2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
16625771|NCT02442934|Experimental|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
16625772|NCT02442934|Active Comparator|Standard Care|Standard care
16625773|NCT02442921|Experimental|Colchicine|20 patients will receive up to 2 mg of colchicine for 18 months
16625774|NCT02442921|Placebo Comparator|Placebo|20 patients will receive placebo for 18 months
16625775|NCT02442908|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
16625776|NCT02442908|Placebo Comparator|Placebo|An isocaloric placebo comparator
16625777|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
16625778|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
16625779|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.
~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
16625780|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
16625781|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 CAMS|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks
~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to
~Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
16625782|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 DBT|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks
~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to
~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
16625783|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks
~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to
~Additional Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
16625784|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 DBT|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks
~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to
~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
16625785|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
16625786|NCT02442843|Experimental|active tDCS|Investigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
16625787|NCT02442843|Sham Comparator|sham tDCS|Participants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
16625788|NCT02442843|No Intervention|Combat Controls|Participants without PTSD will undergo neuropsychological testing and a single fMRI scan.
16625789|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
16626495|NCT02438072|Other|Overall population|
16625790|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
16625791|NCT02442817|Active Comparator|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
16625792|NCT02442817|Active Comparator|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
16625793|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
16625794|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
16625795|NCT02442791|Experimental|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:
~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).
~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
16625796|NCT02442791|Placebo Comparator|Placebo|"Half of the participants will receive placebo, that will be given as follows:
~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
16625797|NCT02442778|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
16625798|NCT02442778|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
16625799|NCT02442778|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
16625800|NCT02442765|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
16625801|NCT02442765|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
16625802|NCT02442765|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
16625803|NCT02442752|Experimental|Regimen A: Dexlansoprazole 10 mg|Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.
16625804|NCT02442752|Experimental|Regimen B: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.
16625805|NCT02442752|Experimental|Regimen C: Dexlansoprazole 20 mg|Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.
16625806|NCT02442752|Experimental|Regimen D: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.
16625807|NCT02442739|Experimental|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
16625808|NCT02442739|Placebo Comparator|Placebo|oral placebo (syrup)
16625809|NCT02442726|Active Comparator|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
16625810|NCT02442726|Sham Comparator|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
16625811|NCT02442713|Experimental|fluvoxamine|fluvoxamine: 50-300mg/day
16625812|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
16625813|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
16625814|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
16625815|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
16625816|NCT02442687|Placebo Comparator|C|Identical appearing placebo
16625817|NCT02442674|Active Comparator|Tolvaptan|Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)
16625818|NCT02442674|Placebo Comparator|Placebo|Placebo tablet matching active drug
16625819|NCT02442648|Experimental|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
16625820|NCT02442648|Experimental|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
16625821|NCT02442648|Experimental|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
16625822|NCT02442648|Experimental|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
16625823|NCT02442635|Experimental|Condition 1|Yoga Breathing
16625824|NCT02442635|Experimental|Condition 2|Static Yoga
16625825|NCT02442635|Experimental|Condition 3|Flowing Yoga
16625826|NCT02442622|Active Comparator|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
16625827|NCT02442622|Experimental|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
16625828|NCT02442609||patient|patient schedulled for elective surgery, adult (> 18yrs), non emergency procedure, able to read questionaire
16625829|NCT02442596||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
16625830|NCT02442583|No Intervention|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
16625831|NCT02442583|No Intervention|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
16625832|NCT02442583|Experimental|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
16625833|NCT02442570|Active Comparator|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
16625834|NCT02442570|Active Comparator|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
16625835|NCT02442570|Active Comparator|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
16625836|NCT02442570|Placebo Comparator|placebo|three intravenous injections of placebo, 2 months apart
16625837|NCT02442557|Active Comparator|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
16625838|NCT02442557|Active Comparator|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
16625839|NCT02442557|Active Comparator|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
16625840|NCT02442557|Active Comparator|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
16625841|NCT02442557|Placebo Comparator|single dose placebo|a single intravenous injection of placebo
16625842|NCT02442557|Active Comparator|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
16625843|NCT02442557|Active Comparator|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
16625844|NCT02442557|Active Comparator|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
16625845|NCT02442557|Placebo Comparator|multiple dose placebo|three consecutive daily intravenous injections of placebo
16625846|NCT02442544|Placebo Comparator|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
16625847|NCT02442544|Experimental|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
16625848|NCT02442531|Experimental|CriPec® docetaxel|Docetaxel containing nanoparticle
16625849|NCT02442518||women with placenta praevia|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of pregnancy (lower placental edge within 20 mm from the internal os above 26 week's gestation)
16625850|NCT02442492|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
16625851|NCT02442492|Placebo Comparator|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
16625852|NCT02442479|Active Comparator|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
16625853|NCT02442479|Experimental|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
16625854|NCT02442479|Experimental|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
16625855|NCT02442479|Experimental|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
16625856|NCT02442466|Experimental|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
16625857|NCT02442466|Experimental|PBS|Intra-lesion administration of vehicle
16625858|NCT02442453|Active Comparator|curcuma longa|"curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.
~Test group:Topical application twice daily for ten minutes after brushing for four weeks."
16625859|NCT02442453|Placebo Comparator|Placebo gel|Placebo gel consists of corbopol 934 polymer and triethonalamine. Control group:Topical application twice daily for ten minutes after brushing for four weeks.
16625860|NCT02442440|Experimental|anisodamine group|administration of the drug
16625861|NCT02442440|No Intervention|control group|these arm do not use anisodamine, other resuscitation protocol is as usual.
16625862|NCT02442427|Active Comparator|Palivizumab|A single dose of IV palivizumab
16625863|NCT02442427|Placebo Comparator|Placebo|An equivalent volume of 0.9% normal saline.
16625864|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
16625865|NCT02442401|Experimental|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
16625866|NCT02442401|No Intervention|Control group|Conventional method was used to the donor site
16625867|NCT02442388|Experimental|Hand file|Instrumentation technique
16625868|NCT02442388|Experimental|ProTaper file|Instrumentation technique
16625869|NCT02442388|Experimental|Wave-One file|Instrumentation technique
16625870|NCT02442375|Active Comparator|standard dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning
~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
16625871|NCT02442375|Experimental|FDG-PET guided gradient dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning
~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
16625872|NCT02442362|Active Comparator|TOF Group|"Patients in the TOF group received chemotherapy with paclitaxel+oxaliplatin+fluorouracil"
16625873|NCT02442362|Experimental|SOX Group|The patients in the SOX group received chemotherapy with 'oxaliplatin+S1'
16625874|NCT02442349|Experimental|AZD9291|Once daily tablet 80 mg
16625875|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
16626496|NCT02438059|Experimental|Intervention|Access to the SoSu-liv website and app for 38 weeks.
16625876|NCT02442323|Experimental|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
16625877|NCT02442323|No Intervention|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
16625878|NCT02442310|Experimental|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
16625879|NCT02442310|Experimental|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
16625880|NCT02442310|Experimental|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
16625881|NCT02442310|Active Comparator|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
16625882|NCT02442297|Experimental|HER2-specific T cells - High Risk|Subjects with HER2 staining of Grade 3 (51-100% of cells staining for HER2) and intensity scores of 3+ will be assigned to the High Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
16625883|NCT02442297|Experimental|HER2-specific T cells - Standard Risk|All other patients not meeting the high risk description will be assigned to the Standard Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
16625884|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
16625885|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
16625886|NCT02442258|Experimental|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
16625887|NCT02442258|Experimental|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
16625888|NCT02442258|Experimental|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
16625889|NCT02442258|Experimental|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range < 15 mL/min/1.73 m2 as determined at Screening.
16625890|NCT02442258|Experimental|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
16625891|NCT02442258|Experimental|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) < 15 mL/min/1.73 m2 as determined at Screening.
16625892|NCT02442245|Placebo Comparator|Placebo|Placebo group will receive microcrystalline cellulose
16625893|NCT02442245|Active Comparator|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
16625894|NCT02442245|Sham Comparator|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
16625895|NCT02442232||Normotensive|
16625896|NCT02442232||Hypertensive taking ACEi|
16625897|NCT02442232||Hypertensive not taking ACEi|
16625898|NCT02442219||Coeliac|Persons with coeliac disease on a gluten free diet where diagnosis is confirmed by duodenal biopsy.
16625899|NCT02442219||Non coeliac gluten sensitive|Persons on a gluten free diet where coeliac disease is excluded by duodenal biopsy.
16625900|NCT02442219||Healthy control group|Persons on a gluten containing diet without known coeliac disease.
16625901|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
16625902|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
16625903|NCT02442193|Experimental|Individual Placement and Support|Individual Placement and Support
16625904|NCT02442193|No Intervention|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
16625905|NCT02442180|Experimental|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
16625906|NCT02442180|Placebo Comparator|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
16625907|NCT02442180|Experimental|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
16625908|NCT02442180|Placebo Comparator|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
16625909|NCT02442154|Experimental|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
16625910|NCT02442154|No Intervention|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
16625911|NCT02442128|Active Comparator|Group1|comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
16625912|NCT02442128|Active Comparator|Group 2|comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
16626497|NCT02438059|No Intervention|Control|No treatment for 38 weeks.
16625913|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
16625914|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
16625915|NCT02442102|Experimental|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
16625916|NCT02442089|No Intervention|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
16625917|NCT02442089|Experimental|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
16625918|NCT02442063|Experimental|Radium Ra 223 dichloride|Radium Ra 223 dichloride (Xofigo, BAY88-8223)
16625919|NCT02442050|Experimental|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
16625920|NCT02442050|Active Comparator|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
16625921|NCT02442037|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
16625922|NCT02442037|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
16625923|NCT02442024|Experimental|Modified diet|This group will follow a modified diet over a period of two months.
16625924|NCT02442024|Active Comparator|Standard diet|This group will follow a standardized diet over a period of two months.
16625925|NCT02441985|Experimental|Real rTMS Stimulation|rTMS will be delivered over each cerebellar hemisphere, using a 70mm figure-of-eight coil connected to a Magstim RapidStim2 machine while positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. The inion will be taken as the boundary between the posterior cerebellum and the occipital cortex. Therefore the area stimulated will be caudal to the inion to stimulate the posterior cerebellum.
16625926|NCT02441985|Sham Comparator|Sham rTMS Stimulation|Patients randomized to receive sham treatment will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham Magstim RapidStim2 Placebo which produces discharge noise and vibration similar to the real coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. The investigator will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp. The investigator will use an electromyography to administer electrical shocks to the scalp simultaneous to each simulated rTMS train.
16625927|NCT02441972|Experimental|18F-Al-NOTA-PRGD2 PET/CT|Imaging with 18F-Al-NOTA-PRGD2 PET/CT.
16625928|NCT02441959|Active Comparator|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
16625929|NCT02441959|Active Comparator|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
16625930|NCT02441959|Other|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
16625931|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams [mg]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.
~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
16625932|NCT02441946|Experimental|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.
~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
16625933|NCT02441946|Active Comparator|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.
~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
16625934|NCT02441933|Active Comparator|control group|
16625935|NCT02441933|Experimental|carboplatin group|
16625936|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
16625937|NCT02441907|Other|aflibercept treatment|aflibercept, 40 mg/mL Solution for Intravitreal Injection
16625938|NCT02441894|Experimental|Cabazitaxel|"25 mg/m^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks.
~Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles."
16625939|NCT02441881|Active Comparator|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
16625940|NCT02441881|Active Comparator|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
16625941|NCT02441881|Active Comparator|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
16625942|NCT02441868|Experimental|Intervention|all participants will receive the training
16625943|NCT02441855||pneumonia|patients with community-acquired pneumonia
16625944|NCT02441855||control|patients admitted to emergency department with shortness of breath
16625945|NCT02441842|Active Comparator|Group A : Atenolol|oral atenolol (50mg)
16625946|NCT02441842|Placebo Comparator|Group C: Placebo|glucose tablet (10mg)
16625947|NCT02441842|Active Comparator|Group L: Lisinopril|oral lisinopril (5mg)
16625948|NCT02441829|Experimental|Mild Renal Impairment (CLcr 60-89 mL/min)|Participants with mild renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
16625949|NCT02441829|Experimental|Moderate Renal Impairment (CLcr 30-59 mL/min)|Participants with moderate impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
16625950|NCT02441829|Experimental|Severe Renal Impairment (CLcr 15-29 mL/min)|Participants with severe renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
16625951|NCT02441816|Other|Eylea Treatment|The intravitreal dose of Eylea will be 2mg (in 0.05ml) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks in the first year of treatment before applying a treat and extend paradigm to patient visits in year 2. This is an open-label study.
16625952|NCT02441803|Experimental|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.
~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
16625953|NCT02441803|Experimental|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.
~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
16625954|NCT02441803|Experimental|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.
~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
16625955|NCT02441790|Experimental|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
16625956|NCT02441790|Active Comparator|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
16625957|NCT02441777|Experimental|Control: Healthy|Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.
16625958|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
16625959|NCT02441751||bleeding|intraoperative blood loss > 500 ml
16625960|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
16625961|NCT02441738|Active Comparator|Hybrid Ablation|Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).
16625962|NCT02441738|Active Comparator|Catheter Ablation|Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).
16625963|NCT02441725|Other|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:
~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
16625964|NCT02441725|Other|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:
~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
16625965|NCT02441712|Experimental|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
16625966|NCT02441712|Sham Comparator|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
16625967|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
16625968|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
16626005|NCT02441426||Brazil|"Birth cohort study community in Brazil is urban, and located within the Papoco area of Fortaleza.
~Case control study is being conducted in the same area as the cohort study. Cases are children 6 - 24 months of age, with <-2 WAZ (weight for age) score, controls are age and community matched children with >-1 WAZ."
16625969|NCT02441686|Experimental|Bortezomib, Lenalidomide, Dexamethasone|"After the screening procedures confirm eligibility to participate in the research study: Each participant will be given a study drug-dosing diary for each treatment cycle. The diary will also include special instructions for taking the study drugs.
~- Study Drugs:
~Bortezomib- subcutaneous injection on predetermined days of each cycle
~Lenalidomide oral daily on predetermined days of each cycle.
~Dexamethasone oral on predetermined days of each cycle"
16625970|NCT02441673|Active Comparator|Nefopam|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.
~0.15mg/kg of Acupan(Nefopam) would be administered IV after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.
~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Acupan is not satisfactory."
16625971|NCT02441673|Active Comparator|Tramadol|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.
~1mg/kg of tramadol would be administered after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.
~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Tramadol is not satisfactory."
16625972|NCT02441660|Experimental|experimental group|Qutenza, Capsaicin 8% Patch will be used
16625973|NCT02441660|Active Comparator|control group|Active control with low dose capsaicin
16625974|NCT02441647|Experimental|Experimental group|
16625975|NCT02441621|Other|Passive leg raising|
16625976|NCT02441621|Other|premedication|
16625977|NCT02441621|Other|intubation and mechanical ventilation|
16625978|NCT02441621|Other|central venous catheter|
16625979|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
16625980|NCT02441621|Other|transesophageal echocardiography|
16625981|NCT02441621|Other|transpulmonary thermodilution catheter|
16625982|NCT02441608|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
16625983|NCT02441595|Experimental|MBCP intervention|The intervention involves eight 2.5 h weekly group sessions in which exercises in mindfulness are practiced and associated theory is taught to increase metacognition, emotional regulation and body awareness.
16625984|NCT02441595|Active Comparator|Control condition|Participants in the control condition are being offered a standardized course in psychoprophylaxis.
16625985|NCT02441582|Experimental|Telemetry|In this group, participants will have a prehospital 12 lead ECG taken and sent through to the receiving facility.
16625986|NCT02441582|Other|Non-Telemetry|In this group, participants will have a prehospital 12 lead ECG taken which will not be sent through to the receiving facility.
16625987|NCT02441569|Experimental|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
16625988|NCT02441569|Active Comparator|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
16625989|NCT02441556|Active Comparator|standard medical therapy|Patients receive standard medical therapy alone.
16625990|NCT02441556|Experimental|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
16625991|NCT02441530|Experimental|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
16625992|NCT02441530|Experimental|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
16625993|NCT02441530|Experimental|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
16625994|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
16625995|NCT02441504|Active Comparator|Low intensity exercise|physical inactivity
16625996|NCT02441491|Experimental|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.
~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
16625997|NCT02441478|Experimental|Patients|
16625998|NCT02441478|Active Comparator|Controls|
16625999|NCT02441465|Experimental|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
16626000|NCT02441452|Active Comparator|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
16626001|NCT02441452|No Intervention|Conventional care|Usual care routine postoperative.
16626002|NCT02441439|Other|Iron sucrose 200 mg|first arm will be treated with iron sucrose 200 mg 2-3 times a week
16626003|NCT02441439|Active Comparator|Iron sucrose 500 mg|Second arm will be treated with iron sucrose 500 mg once a week
16626004|NCT02441426||Bangladesh|"Birth cohort study community in Bangladesh is urban, and located in the Mirpur neighborhood of Dhaka.
~Case control study is being conducted in the same catchment area. Cases defined as children 6-24 months of age with <-2WAZ (weight for age) score, controls are age and community matched with >-1WAZ."
16626006|NCT02441426||India|Birth cohort study community in India is urban, and located in the southern state of Tamil Nadu, specifically in Vellore.
16626007|NCT02441426||Nepal|Birth cohort study community in Nepal is semi-urban, and located in Bhaktapur, approximately 25km from Kathmandu.
16626008|NCT02441426||Pakistan|Birth cohort study community in Pakistan is rural, and located in Naushero Feroze, Sindh.
16626009|NCT02441426||Peru|Birth cohort study community in Peru is rural, and located approximately 15km from Iquitos in Loreto.
16626010|NCT02441426||South Africa|Birth cohort study community in South Africa is rural/peri-urban, and comprised of nine settlements within Limpopo Province.
16626011|NCT02441426||Tanzania|Birth cohort study community in Tanzania is rural, and located within Haydom.
16626012|NCT02441413|Experimental|HRCT scans|HRCT scan will be taken
16626013|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
16626014|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:
~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
16626015|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
16626016|NCT02441374|Experimental|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
16626017|NCT02441374|Active Comparator|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
16626018|NCT02441361|No Intervention|control|Subjects will undergo bariatric surgery and no exercise training will be prescribed.
16626019|NCT02441361|Experimental|exercise training|Subjects will undergo bariatric surgery and exercise training will be prescribed.
16626020|NCT02441348||CTT group|CTT will be initiated in a prospective fashion to study population
16626021|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
16626022|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
16626023|NCT02441335||Group 3 (PTB-medically indicated)|Singleton pregnancy between 20 0/7 34 5/6 weeks gestational age who is admitted with a medically indicated preterm birth (IOL for abruption, non reassuring fetal heart tones, intrauterine growth restriction, preeclampsia, trauma, etc.)
16626024|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
16626025|NCT02441309|Experimental|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):
~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.
~Treatment Weeks 7-12 (post 2nd biopsy/resection):
~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.
~Treatment Weeks 13-36:
~Mifamurtide 2mg/m2, IV infusion, once/week."
16626026|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).
~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.
~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
16626027|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:
~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).
~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.
~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.
~Treatment Weeks 7-12 (post 2nd biopsy/resection):
~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).
~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.
~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
16626028|NCT02441296|Experimental|Formula with lactose|Carbohydrate-free formula with added lactose
16626029|NCT02441296|Experimental|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
16626030|NCT02441296|No Intervention|Breastfeeding|Breastfed reference group
16626031|NCT02441283|No Intervention|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
16626032|NCT02441270|Experimental|Cyclophosphamide|
16626033|NCT02441257|Experimental|control ventilation|patients are scheduled to receive control or spontaneous ventilation
16626034|NCT02441244|Experimental|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
16626035|NCT02441244|Placebo Comparator|Placebo Group|Placebo comparator group
16626036|NCT02441231|Experimental|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
16626037|NCT02441231|Placebo Comparator|Placebo Group|Placebo comparator group
16626038|NCT02441218|Experimental|Ivabradine|
16626039|NCT02441218|Placebo Comparator|Placebo|
16626040|NCT02441205|Experimental|HIIT Aging|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
16626532|NCT02437786|Experimental|GRAZAX|GRAZAX
16626041|NCT02441192|Experimental|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
16626042|NCT02441192|Experimental|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
16626043|NCT02441192|Experimental|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
16626044|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
16626045|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
16626046|NCT02441166|Other|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
16626047|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
16626048|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
16626049|NCT02441140|Experimental|Culdocentesis|"Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.
~During Surgery:
~Blood Collection
~Vaginal Swab
~Chromopertubation
~Culdocentesis
~Tissue Collection"
16626050|NCT02441127|Experimental|Diode laser group|In the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1W) was applied in continuous mode.
16626051|NCT02441127|Active Comparator|Scalpel control group|The surgical technique used in the control group was a FGG harvested by two horizontal and two vertical incisions by scalpel defining the area to be harvested .
16626052|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.
~The periods were separated with a washout period of 14 days."
16626053|NCT02441101|Experimental|RV DDD(R)-60 with AV optimization|RBBB pacing
16626054|NCT02441101|Placebo Comparator|RV DDD(R)-60|Standard demand pacing
16626055|NCT02441088|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|A radiopharmaceutical, 90Y--DOTA-tyr3-Octreotide, and a renal protectant, Aminosyn II, in a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Radiopharmaceutical will be administered IV in 3 doses, 6 weeks apart, with Aminosyn II administered concomittantly with each dose. Two followup visits are required at three and 6 months following third dose of 90Y-DOTA-tyr3-Octreotide.
16626056|NCT02441075|Experimental|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
16626057|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
16626058|NCT02441049|Experimental|Home-based promotora intervention|Study participants and their families received the home-based promotora family intervention
16626059|NCT02441049|No Intervention|Delayed treatment control|Study participants received intervention materials after the final study evaluation measures were taken, 10 months post-baseline.
16626060|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
16626061|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
16626062|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
16626063|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
16626064|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
16626065|NCT02441023|Experimental|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
16626066|NCT02441023|No Intervention|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
16626067|NCT02441010|No Intervention|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
16626068|NCT02441010|Sham Comparator|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
16626322|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
16626069|NCT02441010|Sham Comparator|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
16626070|NCT02441010|Active Comparator|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
16626071|NCT02441010|Active Comparator|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
16626072|NCT02441010|Experimental|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
16626073|NCT02441010|Experimental|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
16626074|NCT02440997|Placebo Comparator|foot bath only|10 minute foot bath with addition of jojoba only
16626075|NCT02440997|Experimental|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
16626076|NCT02440984|Other|Enteric nervous system dysfunction|colonic biopsies and usual care
16626077|NCT02440958|Experimental|modified FOLFIRINOX|
16626078|NCT02440945|Experimental|collection of blood|160 old people for the collection of blood
16626079|NCT02440932|Experimental|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich [low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).
~Dinner: ad libitum buffet meal"
16626080|NCT02440932|Other|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
16626081|NCT02440919|Other|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
16626082|NCT02440919|Other|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
16626083|NCT02440919|Other|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
16626084|NCT02440919|Other|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
16626085|NCT02440906|Experimental|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
16626086|NCT02440906|No Intervention|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
16626087|NCT02440906|No Intervention|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
16626088|NCT02440893||Corus CAD (ASGES) Post-metformin|Corus CAD (ASGES) second sample draw results to compare to Corus CAD (ASGES) first draw results (per patient).
16626089|NCT02440880|Placebo Comparator|CONTROL|TAP block without Dexamethasone neither intravenous nor in combination with the block
16626090|NCT02440880|Experimental|Group 2 (TD8IS)|Dexamethasone in combination with TAP block in dose of 8 mg
16626091|NCT02440880|Experimental|Group 3(TD4IS)|Dexamethasone in addition to TAP block in dose of 4 mg
16626092|NCT02440880|Experimental|Group 4 (TSID8):|Dexamethasone intravenous in addition to TAP block in dose of 8 mg
16626093|NCT02440880|Experimental|Group5(TSID4)|Dexamethasone intravenous 4mg+ TAP block
16626094|NCT02440867|No Intervention|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
16626095|NCT02440867|Experimental|TBS-MPC|"Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia
~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Continuous actimetry acquisition"
16626096|NCT02440867|Active Comparator|TBS-CPDLF|"Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia
~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Continuous actimetry acquisition"
16626097|NCT02440867|Sham Comparator|TBS-Sham|"Intervention with Sham TBS in 8 patients with schizophrenia
~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Continuous actimetry acquisition"
16626098|NCT02440854||Afatinib|
16626099|NCT02440841|Experimental|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
16626100|NCT02440841|Experimental|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
16626101|NCT02440828|Experimental|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
16626102|NCT02440828|Placebo Comparator|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
16626323|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
16626103|NCT02440815|Other|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
16626104|NCT02440802||Gonadoliberin antagonist treatment|Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.
16626105|NCT02440789|Experimental|Sirolimus|
16626106|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
16626107|NCT02440750|Experimental|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
16626108|NCT02440750|Experimental|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
16626109|NCT02440737|Experimental|NEST Intervention|Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.
16626110|NCT02440724|Experimental|winged stent group|participants who are assigned to winged-stent group will be treated with deployment of a winged stent(partially covered or uncovered SEMS).
16626111|NCT02440711|Experimental|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
16626112|NCT02440711|Experimental|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
16626113|NCT02440685|Experimental|ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
16626114|NCT02440685|Experimental|ASN002 Recommended dose (RD) - DLBCL|ASN002 administered at the recommended dose in subjects with DLBCL. Arm Closed
16626115|NCT02440685|Experimental|ASN002 RD - Mantle Cell Lymphoma|ASN002 administered at the recommended dose in subjects with MCL. Arm Closed
16626116|NCT02440685|Experimental|ASN002 RD - Follicular Lymphoma|ASN002 administered at the recommended dose in subjects with FL.
16626117|NCT02440685|Experimental|ASN002 RD - Peripheral T-cell Lymphoma|ASN002 administered at the recommended dose in subjects with PTCL.
16626118|NCT02440685|Experimental|ASN002 RD - Myelofibrosis|ASN002 administered at the recommended dose in subjects with MF.
16626119|NCT02440685|Experimental|ASN002 RD - Chronic Lymphocytic Leukemia|ASN002 administered at the recommended dose in subjects with CLL.
16626120|NCT02440672|Other|Device:JOURNEY™ II CR Total Knee System (J II CR TKS)|Subjects having TKA with JOURNEY™ II CR Total Knee System
16626121|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
16626122|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
16626123|NCT02440646||CCTA group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) without further immediate quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (PCI).
16626124|NCT02440646||CCTA + Invasive group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR, and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) with further quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) with or without implantation of a stent.
16626125|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
16626126|NCT02440607|Experimental|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
16626127|NCT02440607|Active Comparator|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
16626128|NCT02440594|Experimental|Enhanced Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
16626167|NCT02440360|Placebo Comparator|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health & Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
16626129|NCT02440594|Active Comparator|Standard Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
16626130|NCT02440594|Experimental|Enhanced Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Enhanced BHL Program Services, which for this group include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Monitoring via a one-time BHP follow-up call with the enrollee after 6 weeks to discuss continuing versus discontinuing the medication.
16626131|NCT02440594|Active Comparator|Standard Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
16626132|NCT02440594|Experimental|Enhanced Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
16626133|NCT02440594|Active Comparator|Standard Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
16626134|NCT02440594|Experimental|Caregiver TEP Intervention|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Enhanced BHL Program Services which include: 1) a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services, and 2) the Telehealth Education Program (TEP) - BHPs provide manual and workbook-guided psychoeducation, support, and skills training.
16626135|NCT02440594|Active Comparator|Caregiver Control|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Standard BHL Program Services, which include a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services
16626136|NCT02440581|No Intervention|Control, low turnover|No intervention in low turnover osteoporosis control group.
16626137|NCT02440581|Experimental|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
16626138|NCT02440581|No Intervention|Control, high turnover|No intervention in high turnover osteoporosis control group.
16626139|NCT02440581|Experimental|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
16626140|NCT02440568|Experimental|Cohort 1: Omacetaxine at Dose level at 0.625mg/m^2|Patients will receive Omacetaxine at Dose level 0.625mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
16626141|NCT02440568|Experimental|Cohort 2: Omacetaxine at Dose level at 1.25mg/m^|Patients will receive Omacetaxine at Dose level 1.25mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
16626142|NCT02440568|Experimental|Cohort 3: Omacetaxine at Dose level at 2.0mg/m^|Patients will receive Omacetaxine at Dose level 2.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
16626290|NCT02439528|Other|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
16626143|NCT02440568|Experimental|Cohort 4: Omacetaxine at Dose level at 3.0mg/m^|Patients will receive Omacetaxine at Dose level 3.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
16626144|NCT02440555||patients included|fulfill the self-administered questionnaire.
16626145|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
16626146|NCT02440529|Active Comparator|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
16626147|NCT02440529|Active Comparator|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
16626148|NCT02440516|Active Comparator|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
16626149|NCT02440516|Placebo Comparator|Waiting list|Waiting list
16626150|NCT02440490|Experimental|Computerised cognitive training|The cognitive training protocol will be run using pre-validated software, HappyNeuronPro, that delivers cognitive training games. The games are designed to be visually interesting and engaging, and are varied so that each session will comprise multiple different games, to avoid boredom. They begin with easy-to-follow instructions and demonstrations, then as the participant progresses, the difficulty is automatically increased in correspondence with their performance, to avoid ceiling or plateau effects. Participants will be assigned a program targeting multiple facets of cognition found to be compromised in chronic pain states, including divided attention, working memory, mentally planning a sequence of items to form a pattern or complete a puzzle, and response inhibition.
16626151|NCT02440490|Active Comparator|Video watching|This group will be provided with a variety of videos to watch, the content of which will be in the style of documentaries on general interest topics such as nature, travel, culture, and history. Each video is followed by multiple-choice questions that participants will answer, to ensure attention was engaged. The videos are visually stimulating and engaging, but involve no increment in difficulty or requirement to improve skills. They may provide some distraction from pain and may be relaxing, interesting and informative.
16626152|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
16626153|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
16626154|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
16626155|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
16626156|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
16626157|NCT02440438|Experimental|Clostridium difficile infection|
16626158|NCT02440425|Experimental|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
16626159|NCT02440412|Experimental|Massage Therapy|A 45 minutes massage therapy (manual) standardized session, based in Swedish techniques.
16626160|NCT02440412|Placebo Comparator|Rest condition|45 minutes of rest in supine position, listening music with headphones, and warm condition.
16626161|NCT02440412|No Intervention|Control|Normal working condition, as a office workers (secretaries and managements employees)
16626162|NCT02440399|Experimental|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):
~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams
~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).
~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.
~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.
~The total amount of paracetamol is limited to 4 gr per day."
16626163|NCT02440399|Experimental|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
16626164|NCT02440386|No Intervention|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
16626165|NCT02440386|Experimental|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
16626166|NCT02440360|Active Comparator|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
16626168|NCT02440347|Experimental|Computer controlled anesthetic delivery by Anaeject|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by computer controlled anesthetic delivery system (C-CLADS) for AMSA nerve block
16626169|NCT02440347|Active Comparator|Conventional anesthetic delivery by carpule syringe|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by conventional anesthetic delivery for AMSA nerve block
16626170|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
16626171|NCT02440321|Experimental|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
16626172|NCT02440321|Active Comparator|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
16626173|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
16626174|NCT02440295||Lower Extremity Amputations|"All patients >= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.
~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
16626175|NCT02440282||Group A|patients undergo general anesthesia
16626176|NCT02440282||Group B|spinal anesthesia
16626177|NCT02440282||Group C|ultrasound-guided sciatic nerve block
16626178|NCT02440269||A：day|the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm
16626179|NCT02440269||B：night|the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day
16626180|NCT02440256|Other|Cluster 1|Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
16626181|NCT02440256|Other|Cluster 2|Cluster 2 is the second OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the twelfth month of the trial. Cluster 2 will be a 'no intervention' arm in the first 12 months of the study, and will cross-over to a experimental arm for month 12-24.
16626182|NCT02440256|Other|Cluster 3|Cluster 3 is the final OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the 18th month of the trial. As such, Cluster 3 will be a 'no intervention' arm in the first 18 months of the study, and will cross-over to an experimental arm for months 18-24.
16626183|NCT02440243|Active Comparator|Patients active|Purethal Grass
16626184|NCT02440243|Placebo Comparator|Patients placebo|Placebo
16626185|NCT02440230|Experimental|OFS + Anastrozole|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
16626186|NCT02440230|Active Comparator|OFS + Exemestane|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
16626187|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
16626188|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
16626189|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
16626190|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
16626191|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
16626192|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
16626193|NCT02440191|Active Comparator|3DCRT|conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.
16626194|NCT02440191|Experimental|IMRT (Intensity modulated radiotherapy)|"Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.
~Unlike 3DCRT, concomittant boost technique is used in the IMRT arm."
16626195|NCT02440178|Experimental|micafungin prophylaxis|
16626196|NCT02440165|Experimental|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:
~Information and advice;
~Examples of energy and protein rich meals;
~patients will be asked to register their nutritional intake for two days at home;
~after a week, the nurse will call the patients to answer questions and to give advice.
~This nutrition care plan will be tailored to the individual patient requirements.
~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
16626197|NCT02440165|No Intervention|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
16626198|NCT02440152|Experimental|Deep brain stimulation|
16626199|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
16626200|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
16626201|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
16626202|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
16626203|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
16626204|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
16626205|NCT02440113||Nellix|Patients with endovascular Nellix repair
16626206|NCT02440100|Experimental|Multiple Doses PF-06648671 (Cohort1)|Healthy subjects receive 14-day repeated dose once a day at 4 mg of PF-06648671 or matching placebo
16626207|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 2)|Healthy subject receive 14-day repeated dose once a day at 12 mg of PF-06648671 or matching placebo
16626208|NCT02440100|Experimental|Multiple doses PF-06648671 (cohort 3)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo and CSF LP is collected at baseline and steady state predose on day 1 and 14
16626209|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 4)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo
16626210|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 5)|Healthy subject receive 14-day repeated dose once a day at 100 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours after last dosing on day 14
16626211|NCT02440100|Experimental|Multiple Doses in Healthy Elderly (cohort 7)|Healthy Elderly subjects receive 14-day repeated dose once a day at MTD PF-06648671 defined in healthy adult subjects (part 1)
16626212|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 8)|Healthy subjects receive 14-day repeated dose once a day at 360 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours post last dose
16626213|NCT02440100|Experimental|Midazolam DDI (optional cohort 9)|Healthy Subjects receive single dose of 2 mg midazolam in period 1 followed by 14 days PF-06648671 once a day and coadministration of PF-06648671 and midazolam 2 mg in period 2 (Optional cohort)
16626214|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 6)|Healthy subject receive 14-day repeated dose once a day at 200 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 25, 24 hours after last dosing on day 14
16626215|NCT02440074|Experimental|MSV autologous transplantation|
16626216|NCT02440061|Active Comparator|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
16626217|NCT02440061|Active Comparator|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
16626218|NCT02440048|Experimental|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
16626219|NCT02440048|Active Comparator|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
16626220|NCT02440048|No Intervention|extraction|10 extraction sockets with no use of bone substitute as negative control.
16626221|NCT02440035|Experimental|Group 1|Two subsequent Intramuscular injections of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
16626222|NCT02440035|Experimental|Group 2|Intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1, an intramuscular injection of placebo control on Day 85 and an injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 169.
16626223|NCT02440035|Experimental|Group 3|One intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1 and an intramuscular injection of placebo control on Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
16626224|NCT02440035|Experimental|Group 4|Two subsequent intramuscular injections of placebo control on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169.
16626225|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
16626226|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
16626227|NCT02440009|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
16626228|NCT02440009|Experimental|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
16626229|NCT02439996|Experimental|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
16626230|NCT02439996|Experimental|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
16626231|NCT02439996|Active Comparator|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
16626232|NCT02439983|Placebo Comparator|Placebo|
16626233|NCT02439983|Experimental|Proprietary Nutritional Supplement|
16626234|NCT02439970|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; 1 tablet) administered orally twice weekly, plus valganciclovir (vGCV) placebo (2 tablets) administered orally once daily.
16626235|NCT02439970|Active Comparator|Treatment 2|900 mg valganciclovir (vGCV; two 450 mg tablets) administered orally once daily, plus brincidofovir (BCV) placebo (1 tablet) administered orally twice weekly.
16626236|NCT02439957|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
16626237|NCT02439957|Active Comparator|Treatment 2|900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
16626238|NCT02439944|Experimental|Experimental Arm|Escalating nicotine patch dose to satiety over 6 weeks with dosage depending on the number of cigarettes smoked per day and the occurrence of adverse effects
16626239|NCT02439944|Active Comparator|Positive Control Arm|Nicotine patch dose of 21mg coupled with nicotine mouthspray which is to be used as needed.
16626240|NCT02439931|Experimental|Remote psychosocial intervention|10 sessions of remotely delivered psychoeducation and support
16626241|NCT02439905|Experimental|Dexmedetomidine group|
16626242|NCT02439905|Placebo Comparator|Normal saline group|
16626243|NCT02439892|Experimental|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
16626244|NCT02439892|Active Comparator|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
16626245|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
16626246|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
16626247|NCT02439866|Placebo Comparator|prescription placebo|control Group consisted of 30 patients who received gelatinous capsules filled with sugar as placebo
16626248|NCT02439866|Active Comparator|prescription Intravenous methylprednisolone|Group 2 or steroid consisted of 30 patients received methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day
16626249|NCT02439866|Active Comparator|prescription normobaric oxygen with face mask|Thirty patients in group 3 or oxygen received 100% normobaric oxygen with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
16626250|NCT02439853|Experimental|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
16626251|NCT02439853|No Intervention|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
16626252|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
16626253|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
16626254|NCT02439827|Experimental|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
16626255|NCT02439827|No Intervention|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
16626256|NCT02439814|Experimental|Pregnenolone|
16626257|NCT02439814|Placebo Comparator|Placebo|
16626258|NCT02439801||Compliance|"Pulmonary compliance (or lung compliance) is a measure of the lung's ability to stretch and expand. In clinical practice it is separated into two different measurements, static compliance and dynamic compliance. Static lung compliance is the change in volume for any given applied pressure. Dynamic lung compliance is the compliance of the lung at any given time during actual movement of air.
~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on static and dynamic compliance levels will be investigate."
16626259|NCT02439801||Pulmonary Function tests|"Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease.
~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on pulmonary function test values will be investigate."
16626562|NCT02437591|Experimental|fidaxomicin|tablet twice daily
16626260|NCT02439801||volatil agent elimination time|"Volatile anaesthetics are eliminated in the terminal phase via the lungs. A low blood:gas partition coefficient is therefore necessary for quick removal of the anaesthetic.
~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on volatil agent elimination time will be investigate."
16626261|NCT02439788|Experimental|GINAKIT Cells plus chemotherapy|Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)
16626262|NCT02439775|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
16626263|NCT02439775|Sham Comparator|Sham Procedure|Renal angiography
16626264|NCT02439762|Experimental|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
16626265|NCT02439762|Active Comparator|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
16626266|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
16626267|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
16626268|NCT02439736||CT positive for acute intracranial lesion|
16626269|NCT02439723|Experimental|Regorafenib|All patients will be treated with 160 mg regorafenib taken orally once daily for the first 21 days of each 28-day cycle. Doses are to be taken immediately following a light breakfast. During the seven-day break period of cycle 1, patients will start pantoprazole 40 mg twice daily for 8 days
16626270|NCT02439697|Experimental|Darbepoetin alfa (NESP®) same dose|Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)
16626271|NCT02439697|Experimental|Extended dosing Darbepoetin alfa (NESP®)|Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.
16626272|NCT02439697|Experimental|Darbepoetin alfa (NESP®) 120mcg|Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion
16626273|NCT02439671|Experimental|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
16626274|NCT02439671|No Intervention|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
16626275|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
16626276|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
16626277|NCT02439632|Experimental|prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.
~Placebo of levofloxacin hydrochloride tablet without active components."
16626278|NCT02439632|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
~Placebo of prulifloxacin film-coated tablet, without active components."
16626279|NCT02439619|Experimental|Feasibility Trial|
16626280|NCT02439606|Active Comparator|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
16626281|NCT02439606|Experimental|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
16626282|NCT02439593|Active Comparator|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:
~Drug and Radiation
~Intervention name:
~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)
~Intervention description:
~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
16626283|NCT02439593|Experimental|Thermochemoradiotherapy (CTRTHT)|"Intervention type:
~Drug, Radiation and Hyperthermia
~Intervention name:
~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),
~Intervention description:
~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
16626284|NCT02439580|Experimental|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
16626285|NCT02439580|Placebo Comparator|Placebo|Maltose capsule, 300 mg/day, for eight weeks
16626286|NCT02439567|Experimental|Patients|Treatment with new oral antiviral drugs for HCV infection, Fibroscan: Liver and Spleen elastography
16626287|NCT02439541|Experimental|UCMSC group|Patients in this arm received umbilical cord MSCs by intracoronary injection
16626288|NCT02439541|No Intervention|Control group|Patients in this arm did not receive any intervention.
16626289|NCT02439528|Other|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
16626293|NCT02439515|Experimental|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.
~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
16626294|NCT02439515|Active Comparator|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
16626295|NCT02439502|Experimental|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
16626296|NCT02439489|Experimental|BKM120-CIS|BKM120 (60, 80 100 mg po continuously) and Cisplatin (iv 75 mg/m2)
16626297|NCT02439489|Experimental|BKM120-CARBO|BKM120 and (60, 80 100 mg po continuously) and Carboplatin (iv AUC 5)
16626298|NCT02439476||Relapsed multiple myeloma patients who are considered eligible|Patients mobilized using G-CSF+Plerixafor according to Plerixafor label in France will be included. Apheresis will be performed according to standard practice and local guidelines. Once the autologous stem cell product becomes available, patients will undergo ASCT conditioned by high dose Melphalan according to standard practice in each centre
16626299|NCT02439450|Experimental|Arm 5: Viagenpumatucel-L + Nivolumab|Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
16626300|NCT02439450|Experimental|Arm 6: Viagenpumatucel-L + pembrolizumab +/- pemetrexed|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab ± pemetrexed every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab ± pemetrexed until confirmed disease progression or unacceptable toxicity, whichever occurs first.
16626301|NCT02439437|Active Comparator|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
16626302|NCT02439437|No Intervention|Treatment as usual|Treatment as usual
16626303|NCT02439424|Experimental|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
16626304|NCT02439411||Dabrafenib|
16626305|NCT02439411||Dabrafenib plus Trametinib|Patients treated with Dabrafenib plus Trametinib
16626306|NCT02439398|Experimental|Allogeneic human cardiac stem cells|After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
16626307|NCT02439398|Placebo Comparator|Placebo: Human Serum Albumin-HSA 5%|After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
16626308|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
16626309|NCT02439359|Placebo Comparator|Placebo|Placebo
16626310|NCT02439359|Experimental|CF-301|CF-301
16626311|NCT02439346|Experimental|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
16626312|NCT02439346|Experimental|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
16626313|NCT02439346|Experimental|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
16626314|NCT02439346|Experimental|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
16626315|NCT02439333|Active Comparator|Nasal high flow therapy|AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.
16626316|NCT02439333|Active Comparator|Conventional oxygen therapy|AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.
16626317|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
16626318|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
16626319|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
16626320|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
16626324|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
16626325|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
16626326|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
16626327|NCT02439255|Experimental|Arm I (BRB nectar)|Participants receive BRB nectar PO QD for 12 weeks.
16626328|NCT02439255|Placebo Comparator|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
16626329|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
16626330|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
16626331|NCT02439216|Placebo Comparator|Placebo|Matching placebo
16626332|NCT02439203|Experimental|JM-010|JM-010
16626333|NCT02439203|Placebo Comparator|Placebo|Placebo
16626334|NCT02439190|Active Comparator|Treatment A: BMS-986120|BMS-986120 on specified days
16626335|NCT02439190|Active Comparator|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
16626336|NCT02439177|Experimental|Omnitest 3|Blood glucose monitoring system
16626337|NCT02439177|Experimental|Omnitest 5|Blood glucose monitoring system
16626338|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
16626339|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
16626340|NCT02439151|Experimental|New Strategy|New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients
16626341|NCT02439151|Other|Conventional Strategy|Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients
16626342|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.
~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
16626343|NCT02439125|Experimental|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
16626344|NCT02439125|Experimental|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
16626345|NCT02439125|Experimental|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
16626346|NCT02439125|Placebo Comparator|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
16626347|NCT02439112|Active Comparator|Exercise|Supervised exercise combined with home based exercise and physical activity
16626348|NCT02439112|No Intervention|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
16626349|NCT02439099||MDD|Currently unmedicated patients with a depressive episode in the context of unipolar major depression
16626350|NCT02439099||Control|Healthy Controls
16626351|NCT02439099||Alzheimer's Disease|Patients with Alzheimer's disease
16626352|NCT02439099||Alcoholism|Subjects with alcoholism
16626353|NCT02439099||Schizophrenia|Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
16626354|NCT02439086|Experimental|Long Course Radiotherapy|all patients diagnosed with rectal cancer, amenable for neoadjuvant chemoradiotherapy, who agree to participate in this study will undergo 2 PET-CT scans: at baseline and 9 weeks after commencing therapy.
16626355|NCT02439073|Experimental|early initiated rehabilitation|A supervised 12-week rehabilitation program, initiated two weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
16626356|NCT02439073|Active Comparator|late initiated rehabilitation|A supervised 12-week rehabilitation program, initiated 14 weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
16626357|NCT02439060|Experimental|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
16626358|NCT02439060|No Intervention|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
16626359|NCT02439047|Experimental|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery
~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum
~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
16626360|NCT02439034|Active Comparator|Arm A|Paracetamol
16626361|NCT02439034|Experimental|Arm B|Paracetamol + Ketoprofen
16626362|NCT02439021|Experimental|CobraPLA|Patients will randomly assign to either LMA or Cobra PLATM
16626363|NCT02439021|Experimental|LMA|Patients will randomly assign to either LMA or Cobra PLATM
16626364|NCT02439008|Experimental|Blood samples collection|"Nine blood samples will be collected in each patient before, during and after radiotherapy treatment.
~Interventions :
~Blood samples collection before radiotherapy (T0)
~Blood samples collection during radiotherapy (T1-T3)
~Blood samples collection after radiotherapy (T4-T8)"
16626365|NCT02438995|Experimental|Cetuximab with Radiation Therapy|For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.
16626366|NCT02438995|Experimental|Cetuximab Alone|For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.
16626367|NCT02438982|Active Comparator|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
16626368|NCT02438982|Experimental|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 , it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
16626369|NCT02438969||Cohort 1|Treatment-seeking or non-treatment-seeking individuals with AUD and ELS exposure
16626370|NCT02438969||Cohort 2|Treatment-seeking or non-treatment-seeking individuals with AUD without ELS exposure
16626371|NCT02438969||Cohort 3|Healthy volunteers with ELS exposure
16626372|NCT02438969||Cohort 4|Healthy volunteers without ELS exposure
16626373|NCT02438956|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
16626374|NCT02438956|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
16626375|NCT02438943|Active Comparator|Audit and Physician intervention|The intervention will comprise the feedback of the results of the baseline audit, training in motivational interviewing for clinic staff, use of a physician reminder stamp in the patients' charts and distribution of patient education cards
16626376|NCT02438943|Sham Comparator|Audit only|The intervention will comprise the feedback of the results of the baseline audit only
16626377|NCT02438930|Experimental|Motivational interviewing counseling|"The brief intervention is adapted from the OPTIONS project, which is a brief client-centered risk reduction intervention for HIV-positive patients in clinical care. The OPTIONS intervention content is based upon the IMB model of health behavior change, and uses motivational interviewing techniques to create client-centered discussions in which HIV counselors and patients collaborate to identify patients' HIV transmission risk behaviors and to mutually identify strategies and goals for reducing the patient's risky behavior.
~The brief intervention will be facilitated by health care providers (nurses, lab technicians) specifically trained in the intervention protocol and will consist of 2 brief counseling sessions occurring during the same-day rapid HIV-testing procedure"
16626378|NCT02438930|Active Comparator|Standard of care counseling|Participants in this study condition will receive standard-of-care counseling that is usually implemented during HIV testing.
16626379|NCT02438917||Hepatitis C|Patients who are about to begin HCV treatment
16626380|NCT02438904|Experimental|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
16626381|NCT02438891|Experimental|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
16626382|NCT02438878|Experimental|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.
~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
16626383|NCT02438878|No Intervention|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
16626384|NCT02438865|Active Comparator|Single instillation group|will receive single intravesical dose of epirubicin intravesical therapy (50 mg) within 48 hours of radical nephroureterectomy with open bladder cuff excision.
16626385|NCT02438865|Active Comparator|Maintainance therapy group|will receive a single intravesical dose of epirubicin and an additional 6 weekly doses of intravesical therapy (50 mg) after surgery then monthly maintenance therapy for 1 year.
16626386|NCT02438852|Experimental|Arm I (ropivacaine hydrochloride)|Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.
16626387|NCT02438852|Placebo Comparator|Arm II (placebo)|Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.
16626388|NCT02438826|Experimental|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.
~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
16626389|NCT02438826|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.
~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
16626390|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
16626391|NCT02438800|No Intervention|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
16626392|NCT02438800|Experimental|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
16626451|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
16626452|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
16626453|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
16626393|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
16626394|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
16626395|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
16626396|NCT02438774|Active Comparator|Routine agriculture extension services|Routine agriculture extension services alone
16626397|NCT02438774|Experimental|Post-harvest intervention package|Post-harvest intervention package and routine agriculture extension services
16626398|NCT02438761|Experimental|PF-05212384|150 mg Intra-venous every week
16626399|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
16626400|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
16626401|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
16626402|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.
~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
16626403|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
16626404|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16626405|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16626406|NCT02438709|Experimental|COX-2 Inhibitor|Patients who take COX-2 inhibitor
16626407|NCT02438696|Experimental|3 BI 1060469 low dose|TF2 followed by iFF followed by TF1
16626408|NCT02438696|Experimental|1 BI 1060469 high dose|TF1 followed by TF2 followed by iFF
16626409|NCT02438696|Experimental|2 BI 1060469 high dose|iFF followed by TF1 followed by TF2
16626410|NCT02438696|Experimental|3 BI 1060469 high dose|TF2 followed by iFF followed by TF1
16626411|NCT02438696|Experimental|1 BI 1060469 low dose|TF1 followed by TF2 followed by iFF
16626412|NCT02438696|Experimental|2 BI 1060469 low dose|iFF followed by TF1 followed by TF2
16626413|NCT02438683|Placebo Comparator|1 Placebo|2 x single doses (1x resting conditions, 1 x exercise conditions)
16626414|NCT02438683|Experimental|2 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
16626415|NCT02438683|Experimental|3 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
16626416|NCT02438670|No Intervention|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
16626417|NCT02438670|Experimental|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.
~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
16626418|NCT02438670|Experimental|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.
~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
16626419|NCT02438657|Experimental|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:
~increase of the volume (0.5 mL) in case of failure,
~no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
16626420|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
16626421|NCT02438618|Experimental|Minimally invasive punch technique|New surgical technique for Ponto bone anchored hearing implants
16626422|NCT02438618|Other|Hultcrantz technique|Standard surgical technique for bone anchored hearing implants
16626423|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
16626454|NCT02438371|Active Comparator|Single|They will receive nifedipine for the treatment of preterm labor
16626424|NCT02438579|Experimental|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
16626425|NCT02438579|No Intervention|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
16626426|NCT02438566|Active Comparator|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
16626427|NCT02438566|Active Comparator|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
16626428|NCT02438553|Experimental|OSTNS Neurostimulator|Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
16626429|NCT02438553|Placebo Comparator|Placebo OSTNS Neurostimulator|Placebo Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
16626430|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
16626431|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
16626432|NCT02438527|Experimental|Chest Compressions Only|"After recruitment and consenting, volunteers in the chest compressions only arm will receive a chart with a description of Basic Life Support without mouth to mouth ventilations. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
16626433|NCT02438527|Experimental|Standard CPR|"After recruitment and consenting, volunteers in the standard CPR arm will receive a chart with a description of Basic Life Support. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart (including the initial check, chest compressions and mouth to mouth ventilations) for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
16626434|NCT02438501|Experimental|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
16626435|NCT02438501|Active Comparator|IFRT group|Chemotherapy / Involved-field radiotherapy
16626436|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
16626437|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
16626438|NCT02438462||Group with PE|"The criteria for confirmation of PE are:
~PE on spiral computed tomography (CT)
~proximal deep vein thrombosis on ultrasound (US)
~thromboembolic events objectively confirmed during the follow up"
16626439|NCT02438462||Group without PE|"The criteria for exclusion of PE are:
~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up
~low and moderate clinical probability and negative CT and negative follow up
~high clinical probability and negative CT, US and follow up."
16626440|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
16626441|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
16626442|NCT02438436|Experimental|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
16626443|NCT02438436|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
16626444|NCT02438436|No Intervention|empty control|
16626445|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
16626446|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
16626447|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
16626448|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
16626449|NCT02438397|Active Comparator|metformin+premix insulin|metformin:500mg tid
16626450|NCT02438397|Experimental|acarbose+premix insulin|acarbose:100mg tid
16626456|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
16626457|NCT02438345|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
16626458|NCT02438345|Placebo Comparator|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
16626459|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
16626460|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
16626461|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
16626462|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
16626463|NCT02438319||patients with open angle glaucoma|patients with open angle glaucoma who had their optic discs routinely documented by fundus photography. Optic disc photographs will be analyzied by manual planimetry or automated planimetry.
16626464|NCT02438306|Experimental|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
16626465|NCT02438306|Sham Comparator|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
16626466|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
16626467|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
16626468|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
16626469|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
16626470|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
16626471|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
16626472|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
16626473|NCT02438241|Active Comparator|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
16626474|NCT02438241|Placebo Comparator|Placebo TENS Group|Will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
16626475|NCT02438241|Experimental|TENS group|Patients randomized to this group will receive conventional physical therapy for the control group, and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
16626476|NCT02438228|Other|Cardiac output measurement|
16626477|NCT02438215|Experimental|IRX4204|IRX4204 20 mg QD for Days 1-30
16626478|NCT02438202|Experimental|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
16626479|NCT02438189|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
16626480|NCT02438189|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
16626481|NCT02438176|Experimental|single puncture group|single trans-septal puncture
16626482|NCT02438176|Active Comparator|conventional group|conventional bilateral groin puncture
16626483|NCT02438163|Experimental|Patients with MDD|the group of depressed patients undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
16626484|NCT02438163|Experimental|healthy Controls|the group of healthy controls undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
16626485|NCT02438150|Experimental|Intervention|Will receive hospital fire video training
16626486|NCT02438150|Placebo Comparator|Control|Will receive non-fire video training
16626487|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
16626488|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
16626489|NCT02438124|Experimental|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
16626490|NCT02438124|Experimental|Contrôle|normal control with walking test and neuropsychological evaluation
16626498|NCT02438046|Experimental|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
16626499|NCT02438046|Placebo Comparator|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
16626500|NCT02438033|Experimental|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
16626501|NCT02438020|Experimental|Metformin|500 mg metformin oral intake before main meal
16626502|NCT02438020|Placebo Comparator|Placebo|Placebo tablet before main meal.
16626503|NCT02438007|Experimental|Galeterone|
16626504|NCT02438007|Active Comparator|Enzalutamide|
16626505|NCT02437994|Experimental|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include supervised exercise training (interval exercise and resistance exercises), breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability.
16626506|NCT02437994|No Intervention|Control|In addition, a control group (Group C) which will not participate in the rehabilitation program (usual care) will be include at the same time as patients in Group A and B so as to be able and independently address study objectives 2 and 3 and 4. Group C will also randomized to those into paper-pencil version and electronic version.
16626507|NCT02437968|Experimental|Wave 1|South New Jersey school service providers.
16626508|NCT02437968|Experimental|Wave 2|Philadelphia suburbs and surrounding community service providers
16626509|NCT02437968|Experimental|Wave 3|Mississauga, ON (Canada) school district service providers.
16626510|NCT02437955|Experimental|FESO4+T|Ferrous sulfate fortified bread with tea
16626511|NCT02437955|Experimental|FESO4+W|Ferrous sulfate fortified bread with water
16626512|NCT02437955|Experimental|FeFu+T|Ferrous fumarate fortified bread with tea
16626513|NCT02437955|Experimental|FeFu+W|Ferrous fumarate fortified bread with water
16626514|NCT02437942|Experimental|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
16626515|NCT02437929||Patients receiving standard procedures|
16626516|NCT02437916|Experimental|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
16626517|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
16626518|NCT02437890|Placebo Comparator|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).
~***
~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:
~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
16626519|NCT02437890|Experimental|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).
~***
~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:
~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
16626520|NCT02437890|Experimental|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).
~***
~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:
~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.
~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
16626521|NCT02437890|Experimental|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).
~***
~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:
~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
16626522|NCT02437890|Experimental|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).
~***
~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:
~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
16626523|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
16626524|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
16626525|NCT02437864|No Intervention|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
16626526|NCT02437864|Experimental|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
16626527|NCT02437851|Experimental|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
16626528|NCT02437825|Experimental|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
16626529|NCT02437825|Placebo Comparator|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
16626530|NCT02437812|Experimental|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)
~The regimen will be administered as a dose dense schedule."
16626531|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
16626533|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adolescents|12 Cognitive-Behavioral Therapy sessions scheduled weekly over a 12-week period.
16626534|NCT02437773|Other|Stress Management Therapy - Adolescents|"12 SMT sessions scheduled weekly over a 12-week period.
~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
16626535|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adults|12 CBT sessions scheduled weekly over a 12-week period.
16626536|NCT02437773|Other|Stress Management Therapy - Adults|"12 SMT sessions scheduled weekly over a 12-week period.
~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
16626537|NCT02437773|Other|Healthy Control - Adolescents|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with adolescent patients with OCD will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
16626538|NCT02437773|Other|Healthy Control - Adults|Healthy control adults matched to gender, race and socioeconomic status (SES) with adult patients with OCD will be enrolled. These healthy adults will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
16626539|NCT02437773|Other|Optional CBT - Adolescents|OCD adolescent participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
16626540|NCT02437773|Other|Optional CBT - Adults|OCD adult participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
16626541|NCT02437747|Experimental|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
16626542|NCT02437747|Sham Comparator|SRP Group|Only scaling and root planing was done on the opposite side.
16626543|NCT02437734|Other|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
16626544|NCT02437721|Active Comparator|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
16626545|NCT02437721|Experimental|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
16626546|NCT02437721|No Intervention|Breast milk|non randomized reference group
16626547|NCT02437708|Experimental|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
16626548|NCT02437708|Active Comparator|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
16626549|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
16626550|NCT02437656|Experimental|Metformin treatment|"J1 : dosimetric scan
~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)
~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy
~J44 : end of the radiochemotherapy
~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
16626551|NCT02437643|Placebo Comparator|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein ~0.8g/kg). Participants will be provided one serving of dairy protein daily.
16626552|NCT02437643|Active Comparator|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein ~1.2 g/kg with > 30g per meal and >60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
16626553|NCT02437630||Patients with COPD|Patients with COPD aged >40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
16626554|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
16626555|NCT02437617||Control Group #1|Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
16626556|NCT02437617||Control Group #2|Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
16626557|NCT02437617||Matched Targeted Therapy Group|Participants with tumor aberrations who received matched targeted therapy.
16626558|NCT02437604|Experimental|Treatment A|Fp MDPI 200 mcg, 1 inhalation
16626559|NCT02437604|Experimental|Treatment B|FS MDPI 200/12.5 mcg, 1 inhalation
16626560|NCT02437604|Active Comparator|Treatment C|fluticasone propionate (FLOVENT DISKUS) 250 mcg, 2 inhalations
16626561|NCT02437604|Active Comparator|Treatment D|fluticasone propionate/salmeterol (ADVAIR DISKUS) 500/50 mcg, 1 inhalation
16626563|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
16626564|NCT02437565|Active Comparator|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
16626565|NCT02437565|Experimental|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
16626566|NCT02437552|Placebo Comparator|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
16626567|NCT02437552|Active Comparator|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
16626568|NCT02437539|Experimental|68Ga-NOTA-AE105 PET|One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
16626569|NCT02437526|Experimental|Treatment interruption|Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.
16626570|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.
~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
16626571|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
16626572|NCT02437487|Placebo Comparator|Placebo|Placebo
16626573|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
16626574|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
16626575|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
16626576|NCT02437461|Active Comparator|single dose 20 mg|Intraarticular injection of triamcinolone hexacetonide
16626577|NCT02437461|Experimental|single dose 40 mg|Intraarticular injection of triamcinolone hexacetonide
16626578|NCT02437448||Idiopathic lung fibrosis|20 IPF patients
16626579|NCT02437448||Controls|20 subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
16626580|NCT02437435|Experimental|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.
~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.
~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
16626581|NCT02437435|Placebo Comparator|Placebo technique|The researcher puts his right hand on the right shoulder of the patient for 20 times Metronome.
16626582|NCT02437422|Experimental|SANGUINATE|Single infusion of SANGUINATE
16626583|NCT02437396||Treatment naive GD1|Type 1 Gaucher disease subjects who are naive to any treatment
16626584|NCT02437396||Treated GD1|Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)
16626585|NCT02437396||Healthy Volunteers (No longer recruiting)|Age matched healthy controls. No new participants will be enrolled to this arm.
16626586|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
16626587|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
16626588|NCT02437370|Experimental|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
16626589|NCT02437370|Experimental|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
16626590|NCT02437357|Experimental|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
16626591|NCT02437357|Active Comparator|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
16626592|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
16626593|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF<40%.
16626594|NCT02437318|Experimental|fulvestrant + alpelisib|Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
16627514|NCT02431325|Placebo Comparator|Placebo|Placebo, subcutaneous injection, 6 months duration
16626595|NCT02437318|Placebo Comparator|fulvestrant + placebo|Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
16626596|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
16626597|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
16626598|NCT02437292|Experimental|Ischemic compression with stretching|The participants will receive the ischemic compression with stretching onto the trapezius muscle
16626599|NCT02437292|No Intervention|Control|Rest on the bed
16626600|NCT02437279|Active Comparator|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
16626601|NCT02437279|Active Comparator|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
16626602|NCT02437266|Experimental|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
16626603|NCT02437266|No Intervention|Control|Rest on the bed for twenty minutes
16626604|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
16626605|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
16626606|NCT02437240|Experimental|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
16626607|NCT02437240|Active Comparator|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
16626608|NCT02437227|Experimental|Experimental: CCT3833|The starting dose of CCT3833 is 20 mg, taken as two 10 mg capsules. The starting schedule is a once daily continuous dosing schedule, but other dosing regimens may be considered depending on tolerability and exposures.The first dose of continuous dosing defines Cycle 1 Day 1. All treatment cycles have a duration of 28 days.
16626609|NCT02437214|Experimental|Use of music for anxiety in children|Children in the Exp group received the usual medical care in combination with the intervention. The intervention was started by the patients nurse without the knowledge of the research associate. In the intervention group, music was played until the CT scan was completed.
16626610|NCT02437214|No Intervention|Control|Children in the Con group received the usual medical care without listening to the music intervention.
16626611|NCT02437201|Experimental|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
16626612|NCT02437201|No Intervention|Control group|
16626613|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
16626614|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
16626615|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
16626616|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
16626617|NCT02437162|Placebo Comparator|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
16626618|NCT02437162|Experimental|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
16626646|NCT02436993|Experimental|Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
16626680|NCT02436785|Active Comparator|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
16626619|NCT02437162|Experimental|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
16626620|NCT02437149|Experimental|Video and Brochure|Real stories video presentation and a brochure with information about distracted driving will be given to the participant.
16626621|NCT02437149|Experimental|Power Point and Brochure|Brief power point presentation and a brochure with information about distracted driving will be given to the participant.
16626622|NCT02437149|Experimental|Brochure Only|Only a brochure with information about distracting driving will be given to the participant.
16626623|NCT02437136|Experimental|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
16626624|NCT02437136|Experimental|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
16626625|NCT02437136|Experimental|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
16626626|NCT02437136|Experimental|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
16626627|NCT02437123|Experimental|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
16626628|NCT02437123|No Intervention|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
16626629|NCT02437110|Experimental|ALS|20 participants with ALS and a level of HERV-K >1000 copies/ml
16626630|NCT02437097|Experimental|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
16626631|NCT02437097|Experimental|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
16626632|NCT02437097|Experimental|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
16626633|NCT02437097|Placebo Comparator|Control|Participants will sit quietly for 30 minutes
16626634|NCT02437084|Other|Individuals without diabetes eligible to receive statin therapy|Eligible participants will receive 40 mg of atorvastatin
16626635|NCT02437071|Experimental|Pembrolizumab Plus Radiotherapy|pembrolizumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy
16626636|NCT02437071|Experimental|Pembrolizumab Plus Ablation|pembrolizumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy
16626637|NCT02437045|Active Comparator|Meropenem|Meropenem 1g every 8 hrs IV to day 4
16626638|NCT02437045|Experimental|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
16626639|NCT02437032|Active Comparator|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
16626640|NCT02437032|Active Comparator|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
16626641|NCT02437032|Active Comparator|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
16626642|NCT02437006|No Intervention|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
16626643|NCT02437006|Experimental|Low-intensity exercise|Low-intensity exercise plus rehabilitation
16626644|NCT02437006|Experimental|High-intensity exercise|High-intensity exercise plus rehabilitation
16626645|NCT02436993|Experimental|Carboplatin+Paclitaxel+Bevacizumab (HER2-)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
16626647|NCT02436980|Active Comparator|tramadol|1mg/kg of tramadol drop (Contramal® drop, Abdi Ibrahim Ilaç San.,istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, Group T who were separated randomly to two premedication groups.
16626648|NCT02436980|Active Comparator|midazolam|0.15 mg/kg of midazolam (Dormicum®, ampoule, Roche Products A.Ş., istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, to Group M who were separated randomly to two premedication groups.
16626649|NCT02436954|Placebo Comparator|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
16626650|NCT02436954|Active Comparator|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
16626651|NCT02436928|Experimental|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
16626652|NCT02436928|Experimental|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
16626653|NCT02436928|Experimental|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
16626654|NCT02436928|Experimental|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
16626655|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
16626656|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
16626657|NCT02436902|Experimental|TACE|Transarterial chemoembolization (TACE) is performed two to four weeks after hepatic resection.
16626658|NCT02436902|Active Comparator|sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection.
16626659|NCT02436902|Other|TACE plus sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
16626660|NCT02436902|No Intervention|empty control|This group patients will receive best supportive care.
16626661|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
16626662|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
16626663|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
16626664|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
16626665|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
16626666|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
16626667|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
16626668|NCT02436850|Experimental|Intervention group|The intervention group will receive large volume thoracentesis.
16626669|NCT02436850|No Intervention|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
16626670|NCT02436837|Active Comparator|young|20 to 30 years old individuals used as a comparator for elderly group
16626671|NCT02436837|Experimental|elderly|target of treatment to improve the balance.
16626672|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
16626673|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
16626674|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
16626675|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
16626676|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
16626677|NCT02436798||Pediatric patients|"Children <6 months to 18 years of age receiving ondansetron for management of:
~Post-operative nausea and vomiting
~Chemotherapy-induced nausea and vomiting"
16626678|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:
~Hyperemesis gravidarum
~Post-operative nausea and vomiting"
16626679|NCT02436785|Active Comparator|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
16626683|NCT02436746||Neurofibromatosis type I (NF1)|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I
16626684|NCT02436746||Tuberous Sclerosis Complex (TSC)|Monozygotic twin pairs with genetically confirmed Tuberous Sclerosis Complex
16626685|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
16626686|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
16626687|NCT02436707|Active Comparator|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);
~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;
~Dexamethasone - 40 mg daily PO D1 - D4;
~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
16626688|NCT02436707|Experimental|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21
~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)
~Gemcitabine 1000 mg/m2 IV 30 min D1, D8
~Dexamethasone 40 mg daily PO -- D1 - D4
~Cisplatin 75 mg/m2 IV 1 hour D1"
16626689|NCT02436707|Experimental|R-DICEP|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin
~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4
~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4
~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4
~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4
~G-CSF 300 mcg (<60kg); 480 mcg (60-90kg); 600 mcg (>90kg); SC, Daily, starting Day 15 until apheresis completed."
16626690|NCT02436707|Experimental|Selinexor + R-GDP|"Selinexor - 40mg PO, D1, D3, D8
~Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);
~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;
~Dexamethasone - 40 mg daily PO D1 - D4;
~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
16626691|NCT02436694|Active Comparator|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
16626692|NCT02436694|Experimental|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
16626693|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
16626694|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:
~Nab-paclitaxel and gemcitabine"
16626695|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:
~Nab-paclitaxel and gemcitabine"
16626696|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
16626697|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
16626698|NCT02436629|Active Comparator|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
16626699|NCT02436629|Placebo Comparator|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
16626700|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
16626701|NCT02436603|Other|Nutrition/Mind-Body Coaching|The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.
16626702|NCT02436603|No Intervention|Waitlist Control Group|Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.
16626703|NCT02436590|Active Comparator|Active PEMF|Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization
16626704|NCT02436590|Placebo Comparator|Control/no PEMF|Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization
16626705|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
16626706|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
16626707|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
16626708|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
16626709|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
16626710|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
16626711|NCT02436551||Pregnant women in Tajikistan|
16626712|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
16626713|NCT02436525|Active Comparator|Group I:|"will be treated using conventional stainless steel orthodontic brackets ligated with stainless steel ligature. Oromco - USA.
~."
16626714|NCT02436525|Experimental|Group II|: will be treated using passive self-ligating stainless steel orthodontic brackets Oromco - USA.
16626715|NCT02436525|Experimental|Group III:|will be treated by active self-ligating stainless steel orthodontic brackets Oromco - USA .
16626716|NCT02436512|Experimental|Inhaled Nitric Oxide|Active Comparator: Nitric Oxide
16626717|NCT02436499|Experimental|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
16626718|NCT02436486|Placebo Comparator|Placebo|
16626719|NCT02436486|Experimental|Idalopirdine 120 mg|Therapeutic dosages
16626720|NCT02436486|Experimental|Idalopirdine 360 mg|Supra-therapeutic dosages
16626722|NCT02436473|Experimental|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
16626723|NCT02436473|Placebo Comparator|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
16626724|NCT02436473|Active Comparator|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
16626725|NCT02436473|Active Comparator|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
16626726|NCT02436460|Experimental|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
16626727|NCT02436447|Experimental|Normal renal function|
16626728|NCT02436447|Experimental|Mild renal impairment|
16626729|NCT02436447|Experimental|Moderate renal impairment|
16626730|NCT02436447|Experimental|Severe renal impairment|
16626731|NCT02436434|Active Comparator|pulsed radiofrequency|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
16626732|NCT02436434|Sham Comparator|Sham pulsed radiofrequency|Sham intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in controlled joint
16626733|NCT02436421|Other|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
16626734|NCT02436421|Other|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
16626735|NCT02436421|Other|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
16626737|NCT02436395|Experimental|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.
~We declare that we have no conflicts of interest."
16626738|NCT02436395|Experimental|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.
~We declare that we have no conflicts of interest."
16626739|NCT02436382|No Intervention|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
16626740|NCT02436382|Active Comparator|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
16626741|NCT02436369|Experimental|low fat yogurt enriched with flaxseed|200 gr low fat yogurt enriched with 30 gr flaxseed
16626742|NCT02436369|Placebo Comparator|low fat yogurt|200 gr low fat yogurt
16626743|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
16626744|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
16626745|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
16626746|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.
~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
16626747|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.
~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
16626748|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
16626749|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
16626750|NCT02436317|Experimental|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe [Saote/ Mylab 5/ Italy] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.
~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
16626751|NCT02436317|No Intervention|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
16626752|NCT02436304|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
16626753|NCT02436304|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
16626754|NCT02436304|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
16626755|NCT02436291|Experimental|CURE-EX device|twice daily treatment with CURE-EX device for 24-30 weeks
16626756|NCT02436278||IPF_MORT|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
16626757|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
16626892|NCT02435342|Experimental|30ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
16626758|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
16626759|NCT02436252|Experimental|DSP-7888|
16626760|NCT02436239|Experimental|Vilazodone|
16626761|NCT02436226|Active Comparator|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
16626762|NCT02436226|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
16626763|NCT02436213|Experimental|Healthy control|A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
16626764|NCT02436213|Experimental|Pulmonary AVM|A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
16626765|NCT02436213|Experimental|HHT but no pulmonary AVM|Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
16626766|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
16626767|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
16626768|NCT02436161|Experimental|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
16626769|NCT02436161|No Intervention|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
16626770|NCT02436135|Experimental|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
16626771|NCT02436135|Experimental|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
16626772|NCT02436135|Experimental|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
16626773|NCT02436135|Experimental|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
16626774|NCT02436109||study group|elective cesarean delivery patients
16626775|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
16626776|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
16626777|NCT02436083|No Intervention|control|no antibiotics
16626778|NCT02436083|Active Comparator|experimental group|drug administration (antibiotic)
16626779|NCT02436070|Active Comparator|Control|Subjects receive general, health-related text messages applicable for children with asthma.
16626780|NCT02436070|Experimental|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
16626781|NCT02436057|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
16626782|NCT02436057|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
16626783|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
16626784|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
16626785|NCT02436018|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
16626786|NCT02436018|Experimental|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
16626787|NCT02436018|Experimental|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
16626788|NCT02436005|Experimental|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
16626789|NCT02436005|Active Comparator|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
16626790|NCT02435992|Experimental|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
16626791|NCT02435992|Placebo Comparator|Placebo|Daily oral administration during Induction and Maintenance periods.
16626792|NCT02435979|Experimental|Proximal strengthening + hand therapy|Patients in this group will perform traditional hand therapy for 30 minutes and proximal strengthening of the core, cervical spine, and shoulder complex for up to 30 minutes
16626793|NCT02435979|Active Comparator|Traditional hand therapy|This group will receive traditional hand therapy for 45-60 minutes each session.
16626794|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
16626795|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
16626796|NCT02435966|No Intervention|Untreated control|Natural history of the condition
16626797|NCT02435953|Experimental|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
16626798|NCT02435953|Active Comparator|TACE alone|TACE treatment several times till tumor progress to advance stage
16626799|NCT02435927|Experimental|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
16626800|NCT02435927|Experimental|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
16627071|NCT02434042|Active Comparator|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
16626801|NCT02435914|Experimental|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
16626802|NCT02435914|Experimental|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
16626803|NCT02435914|Experimental|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
16626804|NCT02435914|Placebo Comparator|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
16626805|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
16626806|NCT02435888||Polycystic ovary syndrome|
16626807|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
16626808|NCT02435875||nonhypertensive|systolic blood pressure <140 mmHg and diastolic blood pressure<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
16626809|NCT02435862|Experimental|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
16626810|NCT02435862|Experimental|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
16626811|NCT02435862|Experimental|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
16626812|NCT02435862|Placebo Comparator|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
16626813|NCT02435849|Experimental|Single dose of CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
16626814|NCT02435836|Experimental|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
16626815|NCT02435823|Experimental|PulseRider|Endovascular treatment of intracranial aneurysms
16626818|NCT02435797|Active Comparator|Nicorandil|Nicorandil for injection
16626819|NCT02435797|Placebo Comparator|normal saline|normal saline
16626820|NCT02435784|Active Comparator|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
16626821|NCT02435784|Placebo Comparator|TAU group|Treatment as usual (TAU) group.
16626822|NCT02435771|Experimental|BMI <25|Normal BMI
16626823|NCT02435771|Experimental|BMI 25-35|Overweight and obese by BMI
16626824|NCT02435771|Experimental|BMI >35|Obese by BMI
16626825|NCT02435758|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
16626826|NCT02435758|No Intervention|Excision of Denonvilliers Fascia|Standard TME surgery (U-shaped excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
16626827|NCT02435745||Ehlers-Danlos Syndrome|Patients with the diagnosis of Ehlers-Danlos syndrome
16626828|NCT02435745||Controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
16626829|NCT02435732|Placebo Comparator|Control group|Standard donor management + vehicle treatment (n=9)- placebo saline solution
16626830|NCT02435732|Experimental|CINRYZE 200 U/Kg IV|Intervention is CINRYZE 200 U/Kg IV single dose
16626831|NCT02435732|Experimental|200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV|CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery
16626832|NCT02435706|Experimental|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
16626833|NCT02435706|Active Comparator|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
16626834|NCT02435693|Experimental|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
16626835|NCT02435693|Other|control|without pharmaceutical care programe (control)
16626836|NCT02435680|Experimental|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
16626837|NCT02435680|Active Comparator|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
16626862|NCT02435498|Experimental|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
16626863|NCT02435498|Active Comparator|Video|The online video will contain the same information within the website.
16626838|NCT02435667|Experimental|Resistance Exercise Training|Entails 36 supervised resistance exercise training sessions (3 sessions per week for 12 weeks). Each exercise session will be supervised by a trained, certified Exercise Physiologist specializing in Cardiac Rehabilitation. The specific resistance exercise training will include Aerobic Exercise, Resistance Exercise, and Core Strengthening Exercises. Other baseline and follow-up tests include: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
16626839|NCT02435667|Placebo Comparator|Standard Care|No resistance exercise training. Patients will stay on their current healthcare regimen as previously assigned by their physician. Patients will still undergo baseline and follow-up tests similar to the Resistance Exercise Training group, including: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
16626840|NCT02435654|Experimental|Treatment group|All EOS patients will receive olanzapine treatment with flexible dose(2.5 to 20 mg/day)according to standard body weight,olanzapine will be initiated at 2.5 or 5 mg/day and the dose could be increased by 2.5 or 5 mg/day dose increments at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,the investigator could decrease the dose at any time and in any number of dose decrements if patients experienced an adverse event.
16626841|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.
~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
16626842|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.
~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
16626843|NCT02435615|Experimental|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
16626844|NCT02435602|Active Comparator|NBI endoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy
~Biopsy at the visually abnormal lesions
~Pathologic examination of all biopsy tissue specimens
~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
16626845|NCT02435602|Active Comparator|lugol chromoendoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy
~Biopsy at the unstained lesions >= 5 mm diameter
~Pathologic examination of all biopsy tissue specimens
~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
16626846|NCT02435589|Experimental|Intervention group|"Intervention:
~systematic pain assessment
~Notification of results of assessments to nurses and physicians. Pain Assessments will be done with the use of 2 different behavioral pain tools by independent assessors and the results of the assessments will be notified to the nurses and physicians and their respond will be observed and documented"
16626847|NCT02435589|Active Comparator|Control Group|Intervention. Systematic pain assessments. Assessments of pain will be done by independent assessors but results will not be notified to nurses or physicians
16626848|NCT02435563|Experimental|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
16626849|NCT02435563|Experimental|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
16626850|NCT02435550|Experimental|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
16626851|NCT02435550|Experimental|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
16626852|NCT02435550|Experimental|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
16626853|NCT02435550|Experimental|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
16626854|NCT02435550|Experimental|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
16626855|NCT02435537|Active Comparator|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
16626856|NCT02435537|Active Comparator|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
16626857|NCT02435537|Active Comparator|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
16626858|NCT02435524|Experimental|A&T Intervention Communes|
16626859|NCT02435524|No Intervention|Control Communes|
16626860|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
16626861|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
16626864|NCT02435498|Active Comparator|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
16627072|NCT02434042|Placebo Comparator|Placebo|100% dextrin
16626865|NCT02435485|Experimental|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
16626866|NCT02435485|Active Comparator|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
16626867|NCT02435485|Active Comparator|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
16626868|NCT02435472|Experimental|Arm A: Exercise|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test (CPET) performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. Archival biopsy tissue samples from before and after the intervention will also be requested.
16626869|NCT02435472|No Intervention|Arm B: Usual Care|"Arm B will receive print material with physical activity guidance which includes general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
16626870|NCT02435472|Active Comparator|Arm C: Exploratory|Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
16626871|NCT02435472|Active Comparator|Observational Non-Randomized Group|There is also a non-randomized observational component to the study where biospecimens and survey data will be collected and one CPET will be administered. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research.
16626872|NCT02435459|Placebo Comparator|No lining|No lining material placed under amalgam dental restoration
16626873|NCT02435459|Active Comparator|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
16626874|NCT02435459|Active Comparator|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
16626875|NCT02435459|Active Comparator|RMGI cement|Placement of rmgi lining under amalgam dental restorations
16626876|NCT02435446|Experimental|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
16626877|NCT02435433|Experimental|Ramucirumab|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
16626878|NCT02435433|Placebo Comparator|Placebo|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
16626879|NCT02435433|Experimental|Open Label Ramucirumab|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
16626880|NCT02435433|Experimental|Ramucirumab ME2 Cohort|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
16626881|NCT02435433|Placebo Comparator|Placebo ME2 Cohort|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
16626882|NCT02435420||EMPERION Modular Primary Stem subjects|All subjects have previously been implanted with the EMPERION Modular Primary Stem for primary total hip arthroplasty.
16626883|NCT02435407|Experimental|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
16626884|NCT02435407|Active Comparator|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
16626885|NCT02435394|Experimental|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
16626886|NCT02435394|Experimental|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
16626887|NCT02435394|Active Comparator|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
16626888|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
16626889|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
16626890|NCT02435355|No Intervention|standard support|All patients in this study underwent this procedure, which is the regular procedure in France.
16626891|NCT02435355|Experimental|coached group|In the coached group (CG), patients received standard support completed by 5 sessions (day 3, 10, 30, 60, 90 with equipment at home) of telephone-based counselling session by competent staff. Sessions were performed by a qualified person in education, qualifies by a university degree (Paul Sabatier University, Toulouse, France). The dates of phone calls were planned with the patient availabilities.
16627073|NCT02434029|Experimental|Budesonide|Budesonide 1mg orodispersible tablet twice daily
16626893|NCT02435342|Experimental|60ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
16626894|NCT02435329||Healthy volunteers|"10 healthy volunteers
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
16626895|NCT02435329||Type 2 diabetes without neuropathy|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
16626896|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
16626897|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
16626898|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
16626899|NCT02435316|Active Comparator|Group 1|Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later
16626900|NCT02435316|Active Comparator|Group 2|Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later
16626901|NCT02435303|Experimental|Sildenafil|Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
16626902|NCT02435303|Placebo Comparator|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
16626903|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
16626904|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
16626905|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
16626906|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
16626907|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
16626908|NCT02435264|Experimental|Healthier Dining Program Intervention|Food centers that receive the Healthier Dining Program (HDP)
16626909|NCT02435264|No Intervention|Control centers|Food centers that do not receive the Healthier Dining Program (HDP)
16626910|NCT02435225|Experimental|Mindfulness group|Participation in a 12 week mindfulness therapy group.
16626913|NCT02435199|Experimental|EMA401 600mg|2 X 150mg BID
16626914|NCT02435199|Placebo Comparator|Placebo|Placebo to match, 2 capsules BID
16626915|NCT02435186|Experimental|p53 gene plus chemotherapy|Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv
16626916|NCT02435186|Active Comparator|chemotherapy|Intraperitoneal cisplatin, and paclitaxel iv
16626917|NCT02435173|Experimental|Part I: CDZ173|Part I was with-in patient dose escalation with CDZ173 10, 30 and 70 mg bid
16626918|NCT02435173|Placebo Comparator|Part II: Placebo|Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo
16626919|NCT02435173|Experimental|Part II: CDZ173|Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo
16626920|NCT02435160|Experimental|Ulcerative Colitis|
16626921|NCT02435134||Healthy participants|
16626922|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
16626923|NCT02435108|Experimental|crizotinib arm|crizotinib medication
16626924|NCT02435095|Active Comparator|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
16627074|NCT02434029|Placebo Comparator|Placebo|Placebo orodispersible tablet twice daily
16627075|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
16626925|NCT02435095|Experimental|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.
~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
16626926|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
16626927|NCT02435069|No Intervention|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
16626928|NCT02435069|Experimental|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
16626929|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
16626930|NCT02435056|No Intervention|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
16626931|NCT02435056|Experimental|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
16626932|NCT02435043|Experimental|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management
16626933|NCT02435043|Active Comparator|Treatment as usual|standard management after stroke
16626934|NCT02435030||NP-C Patients|NPC type 1 or 2 patients aged 2-18 years
16626935|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
16626936|NCT02435004|Other|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
16626937|NCT02434991|Experimental|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
16626938|NCT02434978|Active Comparator|Supplementary doppler-guided endoscopic therapy|
16626939|NCT02434978|Placebo Comparator|control group|
16626940|NCT02434965|Experimental|Autologous Cord Blood and HPDSC|Autologous cord blood and placental blood will be collected after birth of child and administered in divided aliquots during the first week of life.
16626941|NCT02434952|Experimental|DHA PP plus primaquine, G6PD deficiency|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
16626942|NCT02434952|Active Comparator|DHA PP plus primaquine, G6PD normal|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
16626943|NCT02434952|Active Comparator|DHA PP alone, G6PD deficiency|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
16626944|NCT02434952|Active Comparator|DHA PP alone, G6PD normal|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
16626945|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
16626946|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
16626947|NCT02434887|Experimental|Experimental group|
16626948|NCT02434874|Experimental|Immediate Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated immediately.
16626949|NCT02434874|Other|Delayed Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated after 90 days.
16626950|NCT02434861|Experimental|Part A|Rolapitant IV and Digoxin
16626951|NCT02434861|Experimental|Part B|Rolapitant IV and Sulfasalazine
16626952|NCT02434861|Experimental|Part C|Rolapitant IV and Cooperstown Cocktail
16626953|NCT02434848|Active Comparator|Engerix B|15 subjects per group (n = 30 in total)
16626954|NCT02434848|Active Comparator|Fendrix|15 subjects per group (n = 30 in total)
16626955|NCT02434835|Experimental|[14C]KWA-0711|
16626956|NCT02434822|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
16626957|NCT02434822|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
16626958|NCT02434822|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
16626959|NCT02434809|Experimental|Patients with lung cancer|Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.
16626960|NCT02434796|Experimental|Arm 1 Male Peer Groups (MPG)|Women participate in savings groups and male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. This intervention aims to improve knowledge and attitudes about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals (e.g. caring for one's family) and to challenge gender stereotypes (e.g. women are not equal to men); and the ability to formulate positive outcome expectations regarding IPV (intolerance of violence perpetrated by themselves or others) and healthy relationships with their spouses and communities.
16626961|NCT02434796|Experimental|Arm 2 MPG & Community Dialogues|This arm will include women participants in savings groups, male peer groups and community dialogues. Village community leaders will engage in community dialogues on gender norms, IPV and HIV prevention.
16626962|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
16626963|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
16626964|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
16626965|NCT02434783||No arterial insufficiency|Healthy individuals (control)
16626966|NCT02434770|Experimental|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
16626967|NCT02434770|Experimental|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
16626968|NCT02434770|Active Comparator|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
16626969|NCT02434757|Experimental|Acthar 40 U|Acthar 40 U (0.5mL)
16626970|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
16626971|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
16626972|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
16626973|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
16626974|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
16626975|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
16626976|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
16626977|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
16626978|NCT02434731|Experimental|Buzzy® device|The Buzzy® device will be applied just above the selected site of the venipuncture; a ice pack will be attached under the device; the device will be turned on and after 15 second the procedure will be carried out.
16626979|NCT02434731|No Intervention|No intervention|No intervention for pain relief
16626980|NCT02434718|Experimental|Cohort 1|IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
16626981|NCT02434718|Experimental|Cohort 2|IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
16626982|NCT02434718|Experimental|Cohort 3|IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
16626983|NCT02434718|Experimental|Cohort 4|IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
16626984|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.
~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.
~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
16626985|NCT02434692|Experimental|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
16626986|NCT02434666|Experimental|CPC-201|
16626987|NCT02434653|Experimental|Postpartum anemia diagnosis following symptoms|Post partum anemia will be assessed by taking hemoglobin level following symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL in the first 5 days following delivery
16626988|NCT02434653|Experimental|Postpartum anemia diagnosis following patients screening|Post partum anemia will be assessed by taking hemoglobin level in patients at increased risk to develop post-partum anemia in the first 5 days following delivery, defined as patients with initial (before or immediately after delivery) hemoglobin level of 10.5 g/dl or less regardless of symptoms, or in cases of severe post partum hemorrhage.
16626989|NCT02434640|Experimental|BAY1128688 [Dose1]|BAY1128688 dose level 1
16626990|NCT02434640|Experimental|BAY1128688 [Dose2]|BAY1128688 dose level 2
16626991|NCT02434640|Experimental|BAY1128688 [Dose3]|BAY1128688 dose level 3
16626992|NCT02434640|Experimental|BAY1128688 [Dose4]|BAY1128688 dose level 4
16626993|NCT02434640|Placebo Comparator|Placebo|Placebo to match arm 1,2, 3 and 4
16626994|NCT02434627|Experimental|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
16626995|NCT02434614|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
16626996|NCT02434614|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
16626997|NCT02434601|Other|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
16626998|NCT02434601|Experimental|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
16626999|NCT02434601|Experimental|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
16627000|NCT02434588|Experimental|Bhattacharjee ring|
16627001|NCT02434575||PAE|Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.
16627002|NCT02434575||TURP|Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.
16627003|NCT02434575||Other|Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.
16627004|NCT02434562||Medical castration|Patients treated with androgen deprivation therapy (e.g. for hypersexuality, transgender subjects, ...)
16627005|NCT02434562||Male hypogonadism|Patients treated with testosterone replacement therapy (e.g. for late-onset hypogonadism, secondary hypogonadism)
16627006|NCT02434562||Thyroid disorders|Patients treated for hyperthyroidism or hypothyroidism (incl. during treatment for thyroid cancer)
16627007|NCT02434562||Obesity and weight loss|Patients treated for obesity with weight loss interventions (mainly bariatric surgery)
16627008|NCT02434562||Miscellaneous|Various disorders associated with alterations in SHBG, androgens and/or estrogens
16627009|NCT02434549|Active Comparator|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
16627010|NCT02434549|Placebo Comparator|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
16627011|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
16627012|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
16627013|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
16627014|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
16627015|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
16627016|NCT02434484||Symbenda|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.
16627017|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
16627018|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
16627019|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
16627020|NCT02434458||Control|Healthy control subjects
16627021|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
16627022|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
16627023|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
16627024|NCT02434432|Experimental|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
16627025|NCT02434432|Active Comparator|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
16627026|NCT02434432|No Intervention|Condition 3|Infants in this arm will have the headphones applied but no music played.
16627027|NCT02434419|Experimental|PENS with training|Patients undergoing percutaneous electrostimulation (PENS) of the pectoral muscle combined with specific training during 12 weeks postoperatively
16627028|NCT02434419|Active Comparator|Specific training|Patients undergoing specific training during 12 weeks postoperatively
16627029|NCT02434419|No Intervention|No intervention|No specific treatment was assigned to these patients postoperatively
16627106|NCT02433808|Placebo Comparator|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
16627648|NCT02430415|Experimental|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
16627030|NCT02434406|Experimental|Web-based intervention|Participants get access to the web-based intervention and are asked to work through the 8 modules of the intervention within eight weeks. The intervention program sends automated weekly email reminders about the current session. In addition, users are offered weekly optional 30-minute telephone support with a trained intervention coach.
16627031|NCT02434406|No Intervention|Wait-list control|Participants get standard care and will be offered access to the web-based intervention at 8-weeks post-randomization.
16627032|NCT02434393||Late Life Depression|120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)
16627033|NCT02434380|Active Comparator|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
16627034|NCT02434380|Active Comparator|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
16627035|NCT02434367|Experimental|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
16627036|NCT02434367|No Intervention|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
16627037|NCT02434354|Experimental|neo-adjuvant/adjuvant pembrolizaumab 200 mg IV|All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year
16627038|NCT02434341||septic patients|wake septic patients on mechanical ventilation
16627039|NCT02434341||COPD patients|wake COPD patients on mechanical ventilation
16627040|NCT02434328|Experimental|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
16627041|NCT02434328|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
16627042|NCT02434315|Active Comparator|Group A - Control|FreeStyle Libre Pro 3 sensor wears
16627043|NCT02434315|Experimental|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
16627044|NCT02434315|Experimental|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
16627045|NCT02434289|Experimental|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
16627046|NCT02434276|Experimental|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
16627047|NCT02434276|Experimental|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
16627048|NCT02434276|Active Comparator|Control|Fluzone Quadrivalent vaccine
16627050|NCT02434250|Experimental|SLT arm|Patient receiving 'Selective Laser Trabeculoplasty' (SLT) due to failed Phacoemulsification Cataract Extraction with Intraocular Lens Implantation combined with Eximer Laser Trabeculectomy (phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension to control intraocular pressure and/or glaucoma progression.
16627051|NCT02434237||patients|
16627052|NCT02434237||healthy subjects|
16627053|NCT02434224|Experimental|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants' chest (or back) in order to continuously assess the infants' breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants' behavioral state, facial and gestural expression, the therapist transforms the infants' rhythms and subtle expressions into infant-directed improvised humming.
16627054|NCT02434224|No Intervention|control|standard care
16627055|NCT02434211|Experimental|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
16627056|NCT02434172||Screening|There are no arms to the study. All participants will undergo screening. Preemptive treatment will only be provided to those who are CrAg positive.
16627057|NCT02434159|Active Comparator|Scan|Heart scan prior to device insertion
16627058|NCT02434159|No Intervention|No scan|No heart scan prior to device insertion
16627059|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
16627060|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
16627061|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).
~(Blood Draw)"
16627062|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
16627063|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.
~(Blood Draw)"
16627064|NCT02434107|Experimental|Completion Lymphadenectomy|Completion Lymphadenectomy and monitoring afterwards
16627065|NCT02434107|Experimental|Clinical Monitoring (Palpation and node ultrasound)|Monitoring only
16627066|NCT02434094||T1DM Clinicians|Clinicals currently teaching T1DM patients how to use insulin pumps and continuous glucose monitors will be asked to complete the eDAPT on-line training program.
16627067|NCT02434094||T1DM Subjects with DiAs experience|T1DM subjects will prior DiAs experience will be asked to complete the eDAPT on-line training program.
16627068|NCT02434094||T1DM Subjects with no prior DiAs experience|T1DM subjects will no prior DiAs experience will be asked to complete the eDAPT on-line training program.
16627070|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
16627076|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study
~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day
~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)
~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
16627077|NCT02433964|Experimental|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
16627078|NCT02433964|Placebo Comparator|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
16627079|NCT02433951||healthy individuals|Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
16627080|NCT02433951||CABG patients|Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
16627081|NCT02433951||endo-ACAB patients|Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
16627082|NCT02433938|Experimental|Underwent tibial nerve stimulation|Patients that underwent standard postoperative protocol + tibial nerve stimulation for 3 days
16627083|NCT02433938|Sham Comparator|Did not undergo tibial nerve stimulation|Patients that underwent standard postoperative protocol + sham tibial nerve stimulation (standard postoperative protocol+sham tns)
16627084|NCT02433925|Active Comparator|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
16627085|NCT02433925|Placebo Comparator|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
16627086|NCT02433912|Experimental|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
16627087|NCT02433912|Active Comparator|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
16627088|NCT02433899|Experimental|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.
~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
16627089|NCT02433899|Active Comparator|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
16627090|NCT02433886|Experimental|Gamma Ventral Capsulotomy|
16627091|NCT02433873|Placebo Comparator|Placebo|Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
16627092|NCT02433873|Experimental|Supplement A|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
16627093|NCT02433873|Experimental|Supplement B|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
16627094|NCT02433860|Experimental|pregnant nicotine users|watch video and tobacco cessation counselling using SCRIPT protocol
16627095|NCT02433847|Experimental|mosapride|
16627096|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
16627097|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
16627098|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
16627099|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
16627100|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
16627101|NCT02433834|Placebo Comparator|Placebo|Placebo
16627102|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
16627103|NCT02433821|Experimental|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
16627104|NCT02433821|No Intervention|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
16627105|NCT02433808|Experimental|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
16627107|NCT02433795|Experimental|Bendamustine plus rituximab(BR)|Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).
16627108|NCT02433782|Experimental|Experimental group|Treatment through myofascial therapy for the treatment of pain and restricted mobility in patients with hemophilic arthropathy of the knee and ankle
16627109|NCT02433782|No Intervention|Control group|No myofascial intervention. Patients continue their treatment with FVIII or FIX concentrates, normally
16627110|NCT02433769|Active Comparator|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
16627111|NCT02433769|Experimental|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
16627112|NCT02433743|No Intervention|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
16627113|NCT02433743|Experimental|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
16627114|NCT02433730|Active Comparator|placebo|intramuscular injection
16627115|NCT02433730|Active Comparator|testosterone|intramuscular injection
16627116|NCT02433717|Experimental|Paliperidone ER|Six-week paliperidone ER
16627117|NCT02433704|Active Comparator|Intraosseous Administration|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
16627118|NCT02433704|No Intervention|Systemic Intravenous Administration|Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.
16627119|NCT02433691|Active Comparator|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
16627120|NCT02433691|Experimental|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
16627121|NCT02433691|Placebo Comparator|Stretching and Toning|Anerobic stretching and toning followed by memory training
16627122|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
16627123|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
16627124|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
16627125|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
16627126|NCT02433652|Experimental|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
16627127|NCT02433652|Experimental|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
16627128|NCT02433639|Experimental|treatment|single arm study: TH-302 monotherapy is given
16627129|NCT02433626|Experimental|COTI2|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
16627130|NCT02433626|Experimental|COTI2 + cisplatin|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 3 weeks of treatment as described (5 days on, 2 days off per week). Cisplatin 60 mg/m2 IV will be administered on Day 1 of each 3 week cycle. Participants will remain on treatment until they experience a lack of benefit.
16627131|NCT02433600|Active Comparator|Cow's milk-based infant formula|
16627132|NCT02433600|Experimental|Cow milk-based infant formula with enriched protein fractions|
16627133|NCT02433587|Experimental|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
16627134|NCT02433587|Experimental|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
16627135|NCT02433574|Experimental|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
16627136|NCT02433561|Active Comparator|Intraplexic catheter|Intraplexic approach (Patients will have the catheter placed within the plexus, classical approach)
16627137|NCT02433561|Experimental|Extraplexic catheter|Extraplexic approach (Patients will have the catheter placed out of the plexus.)
16627138|NCT02433548|Experimental|Fascia iliaca block|Fascia iliaca block (Injection of 30 mLs of bupivacaine 0.5% with epinephrine 5 mcg/mL below the fascia iliaca, Carbostesin®)
16627139|NCT02433548|Sham Comparator|Sham injection|No fascia iliaca block (Sham injection = Subcutaneous injection of 5 cc of normal saline, no intervention)
16627140|NCT02433535|Experimental|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
16627141|NCT02433535|Placebo Comparator|Placebo|A placebo capsule will be given daily for 12 weeks.
16627142|NCT02433522|Experimental|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
16627143|NCT02433522|Placebo Comparator|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
16627144|NCT02433509|Experimental|HUCB monocyte cells w/ Mannitol in acute ischemic stroke|"The cord blood need to be infusion within less than 10 days after the onset of stroke, with the cord blood mononuclear cells 200 million ~ 500 million will used.
~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
16627208|NCT02433093|Experimental|Basimglurant: Healthy Cohort (4)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
16627649|NCT02430415|Experimental|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
16627145|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
16627146|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
16627147|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.
~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
~Interventions:
~Cycle 1: cytarabine, HPC-A donor infusion
~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
16627148|NCT02433470|Active Comparator|Active tDCS|Active transcranial direct current stimulation
16627149|NCT02433470|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
16627150|NCT02433457|Experimental|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
16627151|NCT02433457|Experimental|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
16627152|NCT02433457|Experimental|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
16627153|NCT02433457|Experimental|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
16627154|NCT02433457|Experimental|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
16627155|NCT02433457|Experimental|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
16627156|NCT02433457|Experimental|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
16627157|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
16627158|NCT02433431|Active Comparator|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
16627159|NCT02433431|Active Comparator|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
16627160|NCT02433431|Active Comparator|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
16627161|NCT02433418|Active Comparator|Tubal flushing with Urografin®|Women will have HSG using water soluble media
16627162|NCT02433418|No Intervention|Control group|Women will not receive any intervention
16627163|NCT02433405||Group 1|Chronic Periodontitis-serum amyloid A, Fetuin-A
16627164|NCT02433405||Group 2|Plaque induced Gingivitis-serum amyloid A, Fetuin-A
16627165|NCT02433405||Group 3|Control Group-serum amyloid A, Fetuin-A
16627166|NCT02433392|Experimental|CM-BC2|Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
16627167|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
16627168|NCT02433366||Patients|
16627169|NCT02433366||Physicians|
16627170|NCT02433353|Experimental|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
16627171|NCT02433353|Placebo Comparator|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
16627172|NCT02433340|Experimental|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
16627173|NCT02433327|Active Comparator|PEWS - trigger tool|"Paediatric Early Warning Score:
~Children randomized to PEWS - trigger tool"
16627174|NCT02433327|Active Comparator|RM - trigger tool|"Paediatric Early Warning Score:
~Children randomized to Central Denmark Region (RM)- trigger tool"
16627175|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
16627176|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
16627177|NCT02433262|Placebo Comparator|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:
~Fasting glucose >6 2 hour glucose >7.7"
16627178|NCT02433262|Active Comparator|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes & Pregnancy Study Group) Fasting glucose >5 2 hour glucose >8.4
16627179|NCT02433249|Active Comparator|1 Physical Activity|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. All participant receive Fitbit Ones and are asked to use them on a daily basis.
16627300|NCT02432482|Experimental|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers
~offer of nicotine patches"
16627180|NCT02433249|Experimental|2 Interpersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
16627181|NCT02433249|Experimental|3.Intrapersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
16627182|NCT02433249|Experimental|4.Full Intervention|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal and interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
16627183|NCT02433236|Experimental|Fostamatinib Disodium tablet 100 mg|Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months
16627184|NCT02433236|Experimental|Fostamatinib Disodium tablet 150 mg|Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months
16627185|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
16627186|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
16627187|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
16627188|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
16627189|NCT02433210|Active Comparator|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
16627190|NCT02433210|Active Comparator|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
16627191|NCT02433210|Active Comparator|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
16627192|NCT02433197|Experimental|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
16627193|NCT02433197|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
16627194|NCT02433184|Experimental|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
16627195|NCT02433184|Active Comparator|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
16627196|NCT02433171||Melanoma Brain Metastases|Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
16627197|NCT02433171||Lung Cancer Brain Metastases|Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
16627198|NCT02433158|Experimental|Cohort 1|Includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
16627199|NCT02433158|Experimental|Cohort 2|Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
16627200|NCT02433132|Other|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
16627201|NCT02433119|Experimental|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
16627202|NCT02433119|Active Comparator|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
16627203|NCT02433106|Experimental|Intervention|GAA 15 Specific neuromuscular exercise training
16627204|NCT02433106|Active Comparator|Control|Control Usual training
16627205|NCT02433093|Experimental|Basimglurant: Healthy Cohort (1)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
16627206|NCT02433093|Experimental|Basimglurant: Healthy Cohort (2)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
16627207|NCT02433093|Experimental|Basimglurant: Healthy Cohort (3)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
16627209|NCT02433093|Experimental|Basimglurant: MDD Cohort (5)|Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
16627210|NCT02433093|Placebo Comparator|Placebo: Healthy Cohorts (1 to 4)|Healthy participants will receive a 22-day regimen of matching placebo capsules.
16627211|NCT02433093|Placebo Comparator|Placebo: MDD Cohort (5)|Participants with MDD will receive a 22-day regimen of matching placebo capsules.
16627212|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
16627213|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.
~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
16627214|NCT02433067|Experimental|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
16627215|NCT02433067|Active Comparator|Control group|"- Arm B (control group) standard oncologic care"
16627216|NCT02433054||CE-certified dedicated venous stents|Patients receiving self-expanding venous nitinol stents.
16627217|NCT02433041|Active Comparator|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
16627218|NCT02433041|Active Comparator|Ketamine|Ketamine 1mg/kg at induction of anesthesia
16627219|NCT02433041|Active Comparator|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
16627220|NCT02433041|Placebo Comparator|Saline solution (NaCl 0.9%)|Placebo
16627221|NCT02433015|Active Comparator|Tobacco Cigarette Group|This group will not receive an electronic cigarette and will continue to smoke combustible tobacco cigarettes as previously.
16627222|NCT02433015|Experimental|Electronic Cigarette Group|This group will receive an electronic cigarette to use for the duration of the study.
16627223|NCT02433002||Main study|1300 participants will undergo baseline (month 0) and final (month 36) reference GFR, estimated GFR (eGFR) and urinary albumin-to-creatinine ratio (ACR) tests. Additionally they will provide ACR and eGFR tests at 6-monthly intervals.
16627224|NCT02433002||Sub-study of patterns of progression|A subset of the cohort (n=375) will receive annual reference GFR tests.
16627225|NCT02433002||Biological variability study|In a further sub-study 20 participants will undergo the reference test four times over four weeks.
16627226|NCT02432989|No Intervention|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
16627227|NCT02432989|Experimental|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
16627228|NCT02432976|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.
~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .
~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
16627229|NCT02432976|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.
~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.
~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
16627230|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
16627231|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
16627232|NCT02432937|Placebo Comparator|Corever middle dose|
16627233|NCT02432937|Placebo Comparator|Corever high dose|
16627234|NCT02432937|Placebo Comparator|Placebo|
16627266|NCT02432716|Experimental|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
16627477|NCT02431481|Experimental|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
16627235|NCT02432924|Experimental|Feedback Group|Participants randomised into the intervention group will be invited to return to the university for a one-off 60 minute set-up session once their physical activity monitor has been returned and processed. Within this session the participant will be given detailed instructions on how to use and wear the activity monitor and real time display and upload their data to and navigate the multidimensional feedback web platform (See materials section for details). They will also be introduced to the concept of goal setting and talked through the different aspects of the instantaneous feedback display and how that might benefit them. Following this visit the participant will be given licence to wear and use the physical activity monitoring devices for a 6-week period and encouraged to self-monitor their behaviour using the combined instantaneous and multidimensional feedback.
16627236|NCT02432924|No Intervention|Waiting List Control Group|Participants who have been randomised into the control arm will be put on a 3 month waiting list to receive the intervention described above. They will still attend assessment visits at week 6 and week 12 while they are not receiving any advice or feedback. Following their 12 week assessment, participants in the control arm will be invited to attend the same 60 minute set-up session as received by the intervention group and then provided with the armband monitor and display to then receive the intervention in full. No further post-intervention or follow-up assessments will be taken from these participants.
16627237|NCT02432911|Experimental|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
16627238|NCT02432911|Active Comparator|Low dose cytarabine|cytarabine 20mg bid for 10 days.
16627239|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
16627240|NCT02432885|Experimental|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
16627241|NCT02432885|No Intervention|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
16627242|NCT02432872|Experimental|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
16627243|NCT02432872|Active Comparator|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
16627244|NCT02432872|Experimental|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
16627245|NCT02432872|Active Comparator|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
16627246|NCT02432859|Active Comparator|Electrical stimulation|In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
16627247|NCT02432859|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero
16627248|NCT02432846|Experimental|Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib|Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
16627249|NCT02432846|Active Comparator|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
16627250|NCT02432833|Experimental|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
16627251|NCT02432833|Active Comparator|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
16627252|NCT02432807|Experimental|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
16627253|NCT02432807|Placebo Comparator|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
16627254|NCT02432794|Experimental|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.
~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
16627255|NCT02432794|No Intervention|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
16627256|NCT02432781|Experimental|Carbohydrate group|Carbohydrate-rich drink 400 mL 3 h before surgery
16627257|NCT02432781|Active Comparator|Control group|10% dextrose solution mixed with insulin 16 unit 100 mL/h
16627258|NCT02432768|Active Comparator|Triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
16627259|NCT02432768|Placebo Comparator|Placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day.
16627260|NCT02432755|Experimental|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
16627261|NCT02432755|Active Comparator|hospital-based therapy|hospital-based individualized occupational therapy
16627262|NCT02432755|Experimental|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
16627263|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
16627264|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
16627265|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.
~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
16627650|NCT02430402|Experimental|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
16627267|NCT02432716|Experimental|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
16627268|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
16627269|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
16627270|NCT02432690|Experimental|Arm A|
16627271|NCT02432677|Experimental|Remifentanil + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.
~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
16627272|NCT02432677|Other|Placebo + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.
~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
16627273|NCT02432677|Other|Remifentanil + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
16627274|NCT02432677|Other|Placebo + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
16627275|NCT02432664|Experimental|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
16627276|NCT02432664|Placebo Comparator|Placebo Part I|Oral capsules given once daily for one day
16627277|NCT02432664|Experimental|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
16627278|NCT02432664|Placebo Comparator|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
16627279|NCT02432664|Experimental|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
16627280|NCT02432664|Active Comparator|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
16627281|NCT02432651|Other|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
16627282|NCT02432651|Other|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
16627283|NCT02432651|Other|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
16627284|NCT02432612|Experimental|Sativex|Sativex will be administered by trained, clinical trial personnel, via a pump action oromucosal spray. Sativex will be administered as 2 actuations (sprays) under the tongue or inside the cheeks every 4 minutes until 6 sprays have been administered. Following the administration of the first and second set of 2 actuations, patients will be offered 50 mL water to drink; and following the final set of 2 actuations, 100 mL of water will be offered (i.e., a total of 200 mL water will be offered during the Sativex dosing). There must be a period of at least 2 minutes and no more than 3 minutes between Sativex administration and consumption of water. Patients will not be permitted their regular medication until 2 hours post dose of investigational medicinal product (IMP) to minimize any possible drug interactions.
16627285|NCT02432599|Experimental|F18-choline PET|F18-choline PET examination will be performed before surgery
16627286|NCT02432586|Other|Intensive Education|Attendance of 2 intensive education sessions
16627287|NCT02432573|No Intervention|Standard care|Postpartum patients that receive physician rounding at current time
16627288|NCT02432573|Experimental|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
16627289|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
16627290|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
16627291|NCT02432547|Active Comparator|Aflibercept Monotherapy|Intravitreal aflibercept injections according to a treat and extend regimen.
16627292|NCT02432547|Experimental|Targeted laser therapy with Aflibercept|Targeted laser photocoagulation therapy to areas of peripheral retinal ischaemia and intravitreal aflibercept injections using a treat and extend regimen.
16627293|NCT02432534|Experimental|UVB + treatement|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
16627294|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
16627295|NCT02432508|Active Comparator|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
16627296|NCT02432508|Sham Comparator|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
16627297|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
16627298|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
16627299|NCT02432482|Active Comparator|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
16627301|NCT02432469|Experimental|Intervention group|APP specific for this study, with reminder, education materials and feedback mechanism for improving secondary medications
16627302|NCT02432469|No Intervention|Control group|Usual Care
16627303|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.
~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
16627304|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.
~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
16627305|NCT02432443|Experimental|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
16627306|NCT02432443|Active Comparator|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
16627307|NCT02432430|Experimental|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
16627308|NCT02432430|Active Comparator|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
16627309|NCT02432417|No Intervention|Standard|Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
16627310|NCT02432417|Experimental|Experimental arm|"Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
~In addition this treatment will be combined with a daily intake of the recommended phase two dose (RPTD) of chloroquine (CQ)."
16627311|NCT02432404|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
16627312|NCT02432404|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
16627313|NCT02432391|No Intervention|Routine Care|Participants continue their routine medical care for type 2 diabetes
16627314|NCT02432391|Experimental|GEM|Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.
16627315|NCT02432378|Experimental|Cisplatin + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
16627316|NCT02432378|Experimental|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
16627317|NCT02432365|Experimental|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
16627318|NCT02432352|Experimental|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
16627319|NCT02432352|No Intervention|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
16627320|NCT02432339|Experimental|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
16627321|NCT02432339|Placebo Comparator|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
16627322|NCT02432326|Experimental|Arm A|
16627323|NCT02432313|Experimental|Modified Release Formulation x (MRx)|Various formulations of Modified Release anatabine citrate tablets
16627324|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
16627325|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
16627326|NCT02432287|Experimental|Placebo|Placebo
16627327|NCT02432274|Experimental|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
16627328|NCT02432274|Experimental|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
16627329|NCT02432274|Experimental|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
16627330|NCT02432274|Experimental|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
16627331|NCT02432274|Experimental|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
16627332|NCT02432261|Experimental|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
16627333|NCT02432261|Experimental|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
16627334|NCT02432248|Experimental|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
16627335|NCT02432248|Placebo Comparator|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
16627336|NCT02432235|Experimental|3 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
16627337|NCT02432235|Experimental|5 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.
16627338|NCT02432235|Experimental|8 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
16627339|NCT02432235|Experimental|13 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.
16627340|NCT02432235|Experimental|20 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
16627341|NCT02432235|Experimental|30 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
16627342|NCT02432235|Experimental|45 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
16627343|NCT02432235|Experimental|60 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.
16627344|NCT02432235|Experimental|80 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.
16627345|NCT02432235|Experimental|100 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.
16627346|NCT02432235|Experimental|150 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
16627347|NCT02432235|Experimental|300 μg/kg|A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).
16627348|NCT02432222|Experimental|Music Training|Music training
16627349|NCT02432222|Experimental|Visual Arts Training|Visual arts training
16627350|NCT02432222|No Intervention|Control|Waitlist control
16627351|NCT02432209|Active Comparator|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
16627352|NCT02432209|Placebo Comparator|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
16627353|NCT02432196|Experimental|Harpoon Medical TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
16627354|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
16627355|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
16627356|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
16627357|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
16627358|NCT02432170|Experimental|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle
~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
16627359|NCT02432157|Experimental|Hypertonic saline (HTS)|A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
16627360|NCT02432157|Active Comparator|Standard fluid|Routine fluid management strategy as pre-specified by our SAH management protocol at Jefferson University Hospital according to the American Heart Association and Neurocritical Care Guidelines for the management of SAH (this includes conventional intravenous fluids or normal saline solutions to maintain a normal hydration status and guided by the treating doctor and daily assessments of fluid balance).
16627361|NCT02432144|Experimental|UX003|4 mg/kg UX003 every other week (QOW)
16627362|NCT02432131||Divers with PFO|
16627363|NCT02432131||Divers without PFO|
16627364|NCT02432118|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
16627365|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
16627366|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
16627367|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
16627368|NCT02432092||Affected|participants with cardiomyopathy
16627369|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
16627370|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
16627371|NCT02432066|Active Comparator|GTS-21|Participants in the GTS-21 arm will receive 150 mg/BID GTS-21 over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
16627372|NCT02432066|Placebo Comparator|Placebo|Participants in the Placebo arm will receive placebo compound twice daily over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
16627373|NCT02432053|Experimental|Transplantation|Advagraf
16627374|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
16627375|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
16627376|NCT02432027|Experimental|IMP 1|C-82 Topical Gel, 1%
16627377|NCT02432027|Placebo Comparator|IMP 2|C-82 Topical Gel, placebo
16627378|NCT02432027|Active Comparator|IMP 3|Daivonex cream
16627379|NCT02432027|Active Comparator|IMP 4|Diprosis gel
16627380|NCT02432014|Other|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
16627381|NCT02432014|Other|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
16627382|NCT02432014|Other|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
16627383|NCT02432014|Other|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
16627384|NCT02432001||Image-Guided Biopsies|Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.
16627385|NCT02431988|Experimental|CAR19 T-cells|"Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.
~The CAR19 T-cells are to be administered on day 0."
16627386|NCT02431975|Experimental|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
16627387|NCT02431962|Experimental|Screening arm|Annual low dose screening chest CT scan x 3.
16627388|NCT02431962|Experimental|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
16627389|NCT02431962|Active Comparator|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
16627390|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
16627391|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
16627392|NCT02431936|Experimental|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
16627393|NCT02431936|Placebo Comparator|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
16627397|NCT02431910|No Intervention|Control group|The control group remains at rest for 10 minutes, which is not applied KT in the RF, VL and VM muscles. The volunteers of this group perform all evaluation without the application of KT
16627398|NCT02431910|Placebo Comparator|Placebo group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 0%.
16627399|NCT02431910|Experimental|Kinesio Taping group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 50%. This application will be held with subjects standing on one foot, with the hip of the non-dominant limb at 0º and knee flexed at 90º.
16627400|NCT02431897|Experimental|Estrogen Cream|
16627401|NCT02431897|Placebo Comparator|Placebo Cream|
16627402|NCT02431884||body fluids/tissues & history|collect body fluids/tissues & med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
16627403|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
16627404|NCT02431871||Control|Age an sex matched controls of DDH patients
16627405|NCT02431858|Experimental|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
16627406|NCT02431858|Active Comparator|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
16627407|NCT02431845|Experimental|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
16627408|NCT02431832|Experimental|Augmentin tab|
16627409|NCT02431819|Experimental|contention socks|Patients wear evolutive contention socks during 15 days.
16627410|NCT02431806|Placebo Comparator|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
16627411|NCT02431806|Experimental|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
16627412|NCT02431806|Experimental|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
16627413|NCT02431806|Active Comparator|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
16627414|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
16627415|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.
~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.
~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.
~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
16627416|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
16627417|NCT02431780|No Intervention|non ANSeR Software System|Routine clinical EEG monitoring
16627418|NCT02431780|Experimental|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
16627419|NCT02431767|Experimental|Group 1: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.6 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL by intradermal (ID) injection over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
16627420|NCT02431767|Placebo Comparator|Group 1: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
16627421|NCT02431767|Experimental|Group 2: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
16627422|NCT02431767|Placebo Comparator|Group 2: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
16627423|NCT02431767|Experimental|Group 3: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
16627424|NCT02431767|Placebo Comparator|Group 3: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
16627425|NCT02431767|Experimental|Group 4: Treatment|Participants will receive the PENNVAX®-GP vaccine 8 mg admixed with IL-12 DNA 1 mg to be administered as 1 mL intramuscular (IM) injection in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
16627426|NCT02431767|Placebo Comparator|Group 4: Placebo|Participants will receive placebo to be administered as 1 mL IM in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
16627427|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.
~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.
~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
16627428|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.
~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.
~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
16627429|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
16627430|NCT02431728|Active Comparator|Melatonin|capsule containing 5mg melatonin plus cellulose
16627431|NCT02431728|Placebo Comparator|Matched Placebo|capsule containing cellulose
16627432|NCT02431702|Active Comparator|Part-1: Oral Antipsychotics (OAP)|All Participants will receive Paliperidone Extended Release (ER) 1.5 to 12 milligram (mg) or risperidone 1 to 6 mg once daily orally for 2 months. Subjects who tolerate paliperidone ER/risperidone but find it inadequately efficacious after treatment for an adequate duration at an adequate dosage (per clinical judgment), may be switched to another protocol-specified OAP at the discretion of the investigator.
16627433|NCT02431702|Experimental|Part-2: Paliperidone Palmitate (PP)|Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
16627434|NCT02431702|Active Comparator|Part-2: OAP|Participants who will complete Part-1 will be randomized to receive Oral Antipsychotics for 9 months.
16627435|NCT02431702|Experimental|Part-3: PP - PP|Participants who will complete Part-2 (with PP treatment) will continue to receive Paliperidone Palmitate for 9 months.
16627436|NCT02431702|Experimental|Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive PP treatment for 9 months. PP treatment includes PP1M and PP3M. Participants will be subsequently switched to PP3M following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
16627437|NCT02431702|Active Comparator|Part-3: OAP - OAP|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive OAP treatment for additional 9 months.
16627438|NCT02431689|Active Comparator|Antagonist|"Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.
~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
16627439|NCT02431689|Active Comparator|Short|"Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.
~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
16627440|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
16627441|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
16627442|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
16627443|NCT02431663|Experimental|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
16627444|NCT02431663|Active Comparator|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.
~Maximum duration of infusion for each drug will be 48 hours."
16627445|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).
~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
16627446|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).
~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
16627447|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
16627448|NCT02431624|Experimental|Test treatment|BTDS 40 milligram
16627449|NCT02431624|Active Comparator|Reference treatment|BTDS 20 milligram
16627450|NCT02431611|Active Comparator|Control condition|Control behavioral phone-based smoking cessation intervention
16627451|NCT02431611|Experimental|Biomarker Feedback Intervention|Biomarker feedback plus behavioral phone-based smoking cessation intervention
16627452|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
16627478|NCT02431468|Experimental|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
16627453|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
16627454|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
16627455|NCT02431585|Other|rechallenge|Double blind placebo controlled cross over
16627456|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)
~Immunotherapy
~Assess Inflammation (PBR PET)"
16627457|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)
~Immunotherapy
~Assess Inflammation (PBR PET)"
16627458|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation
~Assess inflammation (PBR PET)
~Follow Patients"
16627459|NCT02431559|Experimental|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
16627460|NCT02431559|Experimental|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
16627461|NCT02431559|Experimental|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
16627462|NCT02431559|Experimental|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
16627463|NCT02431546|Experimental|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.
~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
16627464|NCT02431546|No Intervention|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
16627465|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
16627466|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
16627467|NCT02431520|Experimental|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for Hybrid Capture II (HCII).
16627468|NCT02431520|Active Comparator|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
16627469|NCT02431507|Experimental|Treatment Arm with Magnetic Apnea Device|The treatment arm with magnetic apnea device includes: surgical implantation of the magnetic apnea device(MAGNAP) to treat obstructive sleep apnea in each eligible enrolled subject . A custom fitted external brace will be created for wear throughout the 13 months of treatment and evaluated for improvement of symptoms..
16627470|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
16627471|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
16627472|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
16627473|NCT02431481|Experimental|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
16627474|NCT02431481|Experimental|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
16627475|NCT02431481|Experimental|End Stage Renal Disease|End stage renal disease not on dialysis; GFR <15 ml/min
16627476|NCT02431481|Experimental|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
16627479|NCT02431468|Experimental|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
16627480|NCT02431468|Placebo Comparator|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
16627481|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
16627482|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
16627483|NCT02431442|Active Comparator|Cohort 1: RM-493 SC Infusion 14 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)
16627484|NCT02431442|Active Comparator|Cohort 2: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
16627485|NCT02431442|Active Comparator|Cohort 3: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
16627486|NCT02431442|Active Comparator|Cohort 4: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
16627487|NCT02431442|Active Comparator|Cohort 5: RM-493 SC Injection 14 days|Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)
16627488|NCT02431442|Active Comparator|Cohort 6: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
16627489|NCT02431442|Placebo Comparator|Cohort 1: Placebo SC Infusion 14 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)
16627490|NCT02431442|Placebo Comparator|Cohort 2: Placebo SC Infusion 28 Days|Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)
16627491|NCT02431442|Placebo Comparator|Cohort 3: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
16627492|NCT02431442|Placebo Comparator|Cohort 4: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
16627493|NCT02431442|Placebo Comparator|Cohort 5: Placebo SC Injection 14 days|Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)
16627494|NCT02431442|Placebo Comparator|Cohort 6: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
16627495|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
16627496|NCT02431416|Active Comparator|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
16627497|NCT02431416|Placebo Comparator|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
16627498|NCT02431403|Experimental|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
16627499|NCT02431403|Experimental|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
16627500|NCT02431403|Experimental|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
16627501|NCT02431403|Experimental|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
16627502|NCT02431390|Experimental|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
16627503|NCT02431390|Active Comparator|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
16627504|NCT02431377|Experimental|S-26 Gold|Standard Infant Formula containing enriched with alpha-lactalbumin
16627505|NCT02431364|Placebo Comparator|Placebo|Participants received matched placebo tablets to verdinexor tablets orally once daily on Days 1 and 3.
16627506|NCT02431364|Experimental|Verdinexor 5 mg|Participants received verdinexor 5 milligrams (mg) (2 tablets of 2.5 mg each) orally once daily on Days 1 and 3.
16627507|NCT02431364|Experimental|Verdinexor 10 mg|Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
16627508|NCT02431364|Experimental|Verdinexor 20 mg|Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
16627509|NCT02431364|Experimental|Verdinexor 40 mg|Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
16627510|NCT02431351|Experimental|Selinexor|60 mg once weekly
16627511|NCT02431338|Experimental|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
16627512|NCT02431338|No Intervention|Control group|Standard treatment with primary percutaneous coronary intervention alone.
16627513|NCT02431325|Experimental|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
16627515|NCT02431312|Experimental|Group A: low dose, standard regimen|Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
16627516|NCT02431312|Experimental|Group A: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
16627517|NCT02431312|Experimental|Group A: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
16627518|NCT02431312|Experimental|Group B: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
16627519|NCT02431312|Experimental|Group B: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
16627520|NCT02431312|Active Comparator|Active Control: nucleos(t)ide analogue treatment|Participants continued treatment with nucleos(t)ide analogue treatment.
16627521|NCT02431286|Experimental|Aprepitant|patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
16627522|NCT02431286|Placebo Comparator|placebo|patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
16627523|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
16627524|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
16627525|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
16627526|NCT02431260|Experimental|INCB054329 Monotherapy|
16627527|NCT02431247|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
16627528|NCT02431247|Active Comparator|DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC|Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
16627529|NCT02431221|Experimental|Intervention|Perhexiline maleate will be supplied in 100 mg and 25 mg tablets. It will be initially administered at a dose of 200 mg once a day in tablet form for at least six months. After initiation of dosing, perhexiline dosing will be determined using plasma level guided dose adjustment. Dosing decisions will be made by an unblinded dose control center.
16627530|NCT02431221|Placebo Comparator|Placebo|Placebo will be administered once a day in tablet form for at least six months. Tablets will be identical in size and shape to perhexiline tablets. Adjustments in placebo dosing will be made by an unblinded dose control center to mimic decisions made for subjects in the experimental arm.
16627531|NCT02431208|Experimental|Cohort A: ATZ (Run-In)|Cohort A will involve a safety run-in to evaluate atezolizumab administered as a single agent in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
16627532|NCT02431208|Experimental|Cohort B1: ATZ + LEN (Dose Escalation)|Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
16627533|NCT02431208|Experimental|Cohort C: ATZ + LEN (Post-ASCT):|Cohort C will evaluate atezolizumab administered in combination with lenalidomide in participants with MM who have measureable disease after ASCT. NOTE: This cohort is closed to enrollment.
16627534|NCT02431208|Experimental|Cohort D1: ATZ + DAR (Run-in)|Cohort D1 will involve a safety run-in to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment.
16627535|NCT02431208|Experimental|Cohort D2: ATZ + DAR (Expansion)|Cohort D2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received 2 but no more than 3 lines of prior treatment that must have included a PI and IMiD and are refractory to the last line of treatment.
16627536|NCT02431208|Experimental|Cohort D3: ATZ + DAR (Progressed)|Cohort D3 will involve an expansion to evaluate atezolizumab in combination with daratumumab in participants with relapsed or refractory MM who have received 2 or more lines of prior treatment and have progressed with an anti-cluster of differentiation (CD) 38 monoclonal antibody, either alone or in combination, and are refractory to both a proteasome inhibitor (PI) and immunomodulatory drug (IMiD).
16627537|NCT02431208|Experimental|Cohort E1: ATZ + DAR + LEN (Dose Escalation)|Cohort E1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
16627538|NCT02431208|Experimental|Cohort E2: ATZ + DAR + LEN (Expansion)|Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
16627570|NCT02430974|No Intervention|Chemotherapy|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).
16627651|NCT02430402|No Intervention|Usual care|Usual care provided as needed / agreed between patient and health care providers
16627539|NCT02431208|Experimental|Cohort F1: ATZ + DAR + POM (Dose Escalation)|Cohort F1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose pomalidomide in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort has been completed.
16627540|NCT02431208|Active Comparator|Cohort F2: ATZ + DAR + POM (Expansion)|Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
16627541|NCT02431208|Active Comparator|Cohort F3: DAR + POM + Dexamethasone|Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
16627542|NCT02431182|Experimental|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.
~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
16627543|NCT02431182|No Intervention|Control group|No intervention will be administred until the delayed post-test is finished
16627544|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
16627545|NCT02431143|Experimental|Miltefosine|allometric dosing
16627546|NCT02431130|Experimental|Low-fidelty instructor driven simulation training|participants receive simulation training
16627547|NCT02431130|No Intervention|No simulation training|
16627548|NCT02431104|Experimental|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
16627549|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.
~Optical Coherence Tomography is performed in all definite cases"
16627550|NCT02431091|Active Comparator|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.
~Optical Coherence Tomography is performed in matched control A patients"
16627551|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values>the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
16627552|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values<the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
16627553|NCT02431065|Experimental|Group 3, Direct injection group|Test group 2, Rectus sheath block will be performed under direct visualization. Ropivacaine (0.75%, 10ml) will be directly injected into the right and left rectus sheath at the end of the operation.
16627554|NCT02431065|Active Comparator|Group 2, ultrasonography group|Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
16627555|NCT02431065|Placebo Comparator|Group 1|Control group, Rectus sheath block will be performed under sonographic guidance. Normal saline 10 ml will be injected into the right, left rectus sheath under ultrasonography guidance at the end of the operation.
16627556|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
16627557|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
16627558|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
16627559|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
16627560|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
16627561|NCT02431039|Experimental|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
16627562|NCT02431039|Active Comparator|NEOSORB|Subjects who are treated by NEOSORB
16627563|NCT02431026|Experimental|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
16627564|NCT02431026|No Intervention|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
16627565|NCT02431013|Experimental|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
16627566|NCT02431013|Active Comparator|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
16627567|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.
~This is a prospective observational cohort study."
16627568|NCT02430987|Active Comparator|Metabolic syndrome|"The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol < 50mg/dL; (3) triglycerides > 150mg/dL; (4) arterial blood pressure (SAH) > 130/85mmHg; and (5) fasting glucose > 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
~Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese"
16627569|NCT02430987|Placebo Comparator|Obesity|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese
16627687|NCT02430194|Experimental|lonafarnib/ritonavir - V|lonafarnib 100 mg BID + ritonavir 50 mg BID;
16627571|NCT02430974|Experimental|Chemotherapy & Icotinib|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).Two weeks after chemotherapy completed, patients assigned to the consolidation therapy group began oral icotinib treatment (125 mg, thrice daily). Icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity.
16627572|NCT02430948|Active Comparator|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
16627573|NCT02430948|Experimental|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
16627574|NCT02430948|Experimental|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
16627575|NCT02430948|Experimental|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
16627576|NCT02430935|Experimental|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
16627577|NCT02430935|Active Comparator|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
16627578|NCT02430922|Experimental|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
16627579|NCT02430909|Placebo Comparator|CZP / CZP + PBO / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30
~+Placebo from Week 8 to Week 18"
16627580|NCT02430909|Experimental|CZP / CZP + UCB4940 / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30
~+ UCB4940 from Week 8 until Week 18"
16627581|NCT02430909|Other|CZP / CZP/ CZP|Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30
16627582|NCT02430896||ADHD group|Children and adolescents who met the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD and needed pharmacotherapy. Subjects will be taking Methylphenidate or Atomoxetine for 52 weeks.
16627583|NCT02430896||Normal control group|Children and adolescents will be recruited by advertisement, and will be assigned to normal group if they do not meet the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD .
16627584|NCT02430883|Active Comparator|first group|patients who have upper pole kidney stones treated with flexible renoscopy
16627585|NCT02430883|Active Comparator|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
16627586|NCT02430883|Active Comparator|third group|patients who have lower pole kidney stones treated with flexible renoscopy
16627587|NCT02430883|Active Comparator|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
16627588|NCT02430883|Active Comparator|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
16627589|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
16627590|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
16627591|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
16627592|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
16627593|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
16627594|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
16627595|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
16627596|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
16627597|NCT02430857|Experimental|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
16627598|NCT02430857|No Intervention|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
16627599|NCT02430831|Active Comparator|Reuteri group|Milk formula added with probiotic L reuterii DSM 17938
16627600|NCT02430831|Placebo Comparator|Placebo|Milk formula without probiotic L reuterii DSM 17938
16627647|NCT02430428|Experimental|VisuMax lenticule removal|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
16627601|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
16627602|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
16627603|NCT02430805|Other|NOE|multicentric family-based cohort. prospective and transversal study
16627604|NCT02430792|Active Comparator|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
16627605|NCT02430792|No Intervention|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
16627606|NCT02430779|Experimental|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
16627607|NCT02430779|No Intervention|Control|The patients without treatment
16627608|NCT02430766|Experimental|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
16627609|NCT02430766|No Intervention|Control|The patients without treatment
16627610|NCT02430753|Experimental|IRE Group|irreversible electroporation for Lung Neoplasms accompanied by Respiratory Function Insufficiency
16627611|NCT02430753|No Intervention|Control|The patients without treatment
16627612|NCT02430740|Other|control group|standard care recFSH
16627613|NCT02430740|Experimental|study group|modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC
16627614|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
16627615|NCT02430701|Experimental|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
16627616|NCT02430701|No Intervention|Control|The patients without treatment
16627617|NCT02430688|Experimental|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
16627618|NCT02430688|No Intervention|Control|The patients without treatment
16627619|NCT02430675|Experimental|Group A|irreversible electroporation for Unresectable Laryngeal Neoplasms
16627620|NCT02430675|No Intervention|Control|The patients without treatment
16627621|NCT02430662|Experimental|IRE Group|irreversible electroporation for Unresectable Gallbladder Neoplasms
16627622|NCT02430662|No Intervention|Control|The patients without treatment
16627623|NCT02430649|Experimental|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
16627624|NCT02430649|No Intervention|Control|The patients without treatment
16627625|NCT02430636|Experimental|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
16627626|NCT02430636|No Intervention|Control|The patients without treatment
16627627|NCT02430623|Experimental|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
16627628|NCT02430623|No Intervention|Control|The patients without treatment
16627629|NCT02430610|Experimental|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
16627630|NCT02430610|No Intervention|Control|The patients without treatment
16627631|NCT02430597|Experimental|IRE Group|irreversible electroporation for Unresectable Hilus Pulmonis Neoplasms
16627632|NCT02430597|No Intervention|Control|The patients without treatment
16627633|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
16627634|NCT02430545|Experimental|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
16627635|NCT02430532|Experimental|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
16627636|NCT02430532|Experimental|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
16627637|NCT02430519|Experimental|11 Patients with Grade II Manibular Molar Furcation|Group A- Furcation Treatment with PRF
16627638|NCT02430519|Experimental|11 Patients with Grade II Mandibular Molar Furcation D|Group B- Furcation Treatment with Allograft and GTR
16627639|NCT02430506|Placebo Comparator|Placebo|1.0 mL sterile buffer administered by intramuscular (IM) injection to deltoid area on days 0 and 56.
16627640|NCT02430506|Experimental|AERAS-402|1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non-animal source) and water. Administered intramuscular (IM) injection to deltoid area on days 0 and 56.
16627641|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
16627642|NCT02430480|Experimental|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
16627643|NCT02430467|Active Comparator|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
16627644|NCT02430467|Active Comparator|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
16627645|NCT02430454|Experimental|Experimental|Subjected to increased cognitive load
16627646|NCT02430454|No Intervention|Control|Not subjected to increased cognitive load
16627652|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
16627653|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
16627654|NCT02430363|Active Comparator|MK-3475|"Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.
~Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.
~MK-3475 will be given intravenously over the course of 30 minutes"
16627655|NCT02430363|Experimental|Suppressor of the PI3K/Akt pathways|"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks.
~BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1.
~Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks.
~Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 .
~Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks.
~The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home"
16627656|NCT02430350|Experimental|Compound Edaravone|Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
16627657|NCT02430350|Active Comparator|Edaravone|Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days
16627658|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
16627659|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
16627660|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
16627661|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
16627662|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
16627663|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
16627664|NCT02430298|Placebo Comparator|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
16627665|NCT02430298|Active Comparator|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
16627666|NCT02430285|Other|Endoscopic Ultrasound|All consecutive patients entering the emergency department due to acute abdominal pain and showing biochemical and/or radiological findings consistent with possible acute biliary pancreatitis, undergo Endoscopic Ultrasound with linear array Olympus 180 series echoendoscopes (Olympus Europa Holding, Hamburg, Germany).
16627667|NCT02430272|Experimental|Anticholinergic premedication|Premedication with 0.005mg/Kg of glycopyrrolate
16627668|NCT02430272|No Intervention|Control group|Same volume of normal saline
16627669|NCT02430259|Experimental|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
16627670|NCT02430259|No Intervention|No preventive treatment|Follow up without intervention
16627671|NCT02430246|Experimental|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
16627672|NCT02430246|Placebo Comparator|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
16627673|NCT02430246|Experimental|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
16627674|NCT02430246|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
16627675|NCT02430246|Experimental|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
16627676|NCT02430246|Placebo Comparator|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
16627677|NCT02430246|Other|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
16627678|NCT02430246|Other|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
16627679|NCT02430233|Experimental|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
16627680|NCT02430233|No Intervention|No treatment|No treatment
16627681|NCT02430207|Experimental|Femoral Vein|patients receiving temporary pacing via femoral vein
16627682|NCT02430207|Experimental|Subclavian Vein|patients receiving temporary pacing via subclavian vein
16627683|NCT02430194|Experimental|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD;
16627684|NCT02430194|Experimental|lonafarnib/ritonavir - II|lonafarnib 150 mg QD + ritonavir 100 mg QD;
16627685|NCT02430194|Experimental|lonafarnib/ritonavir - III|lonafarnib 75 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
16627686|NCT02430194|Experimental|lonafarnib/ritonavir - IV|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
16627688|NCT02430194|Experimental|lonafarnib/ritonavir - VI|lonafarnib 100 mg QD + ritonavir 100 mg QD;
16627689|NCT02430194|Experimental|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW;
16627690|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW;
16627691|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 50 mg BID + ritonavir 100 mg BID
16627692|NCT02430194|Experimental|lonafarnib/ritonavir - X|lonafarnib 25 mg BID + ritonavir 100 mg BID
16627693|NCT02430181|Experimental|lonafarnib 200 mg BID|lonafarnib 200 mg BID; n=3
16627694|NCT02430181|Experimental|lonafarnib 300 mg BID|lonafarnib 300 mg BID; n=3
16627695|NCT02430181|Experimental|lonafarnib 100 mg TID|lonafarnib 100 mg TID; n=3
16627696|NCT02430181|Experimental|100 mg BID lonafarnib/PEG IFN-a|lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
16627697|NCT02430181|Experimental|200 mg BID lonafarnib/PEG IFN-a|lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
16627698|NCT02430181|Experimental|300 mg BID lonafarnib/PEG IFN-a|lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=3
16627699|NCT02430181|Experimental|lonafarnib/ritonavir|lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
16627700|NCT02430168|Active Comparator|RIRS|Retrograde intrarenal surgery
16627701|NCT02430168|Active Comparator|PCNL|Percutaneous nephrolithotomy
16627702|NCT02430155|Active Comparator|Bakri balloon group|The women in this group will be managed by Bakri balloon
16627703|NCT02430155|Active Comparator|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
16627704|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
16627705|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
16627706|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
16627707|NCT02430129|Active Comparator|Total knee arthroplasty/Persona|Total knee arthroplasty with Zimmer Persona posterior cruciate retaining prosthesis (Zimmer, Warsaw, IN)
16627708|NCT02430129|Experimental|Unicompartment knee arthroplasty/Oxford|Unicompartmental knee arthroplasty with Biomet Oxford mobile-bearing unicompartmental knee prosthesis (Biomet, Warsaw, IN)
16627709|NCT02430116|No Intervention|negative control group|The myocardial tissues of the right atrial appendage were obtained at 3 min before CPB was established in the NEG group.
16627710|NCT02430116|Active Comparator|I/R group|The myocardial tissues of the right atrial appendage were obtained at 45 min after opening the aorta in the I/R group.
16627711|NCT02430116|Experimental|I-postC group|The procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
16627712|NCT02430103||Chemotherapy plus GnRHa|Patients of the group will receive (neo)chemotherapy plus GnRHa ( Goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration).
16627713|NCT02430103||Chemotherapy|Patients of the group will receive (neo)chemotherapy merely.
16627714|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
~Injection Surgical anaesthesia
~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block
~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
16627715|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.
~Indications:
~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.
~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
16627716|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.
~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.
~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
16627717|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
16627718|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
16627719|NCT02430064|Experimental|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
16627720|NCT02430051|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
16627721|NCT02430051|Experimental|Sensory Adapted Dental Environment|In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
16627722|NCT02430038||Acceptability and feasibilty|Where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls
16627723|NCT02430038||Predictive Model|Nulliparous term labouring women with cephalic presentation
16627724|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
16627725|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one <50% stenotic lesion on coronary angiography.
16627726|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
16627727|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
16627728|NCT02430012|Active Comparator|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
16627729|NCT02430012|No Intervention|Control group|The control goup will maintain the routine practice pattern.
16627730|NCT02429999|Active Comparator|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
16627731|NCT02429999|Active Comparator|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
16627732|NCT02429986|Other|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
16627733|NCT02429973|Experimental|Experimental|6 cycles of gemcitabine plus rapamycin
16627734|NCT02429960|Other|Analgesia monitoring|Remifentanil is increased step-by-step according to the study protocol. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli consisting of the intracutaneous pain model and tetanic stimulation for the time period of 30 s with 80 milliampere, 50 Hz are applied. All stimulations are accompanied by the measurement of the analgesic monitoring-devices (PhysioDoloris®, SPI® and AlgiScan®). Moreover the investigators measure and inspect changes in heart rate and blood pressure as well as occurrence of defensive movements of the patients.
16627735|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
16627736|NCT02429934|Active Comparator|Abatacept also known as Orencia also known as CTLA4Ig|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
16627737|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks
16627738|NCT02429921|Experimental|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
16627739|NCT02429921|Experimental|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
16627740|NCT02429908|Other|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
16627741|NCT02429895|Experimental|All subjects (open-label extension)|All subjects will start treatment with ABT-122
16627742|NCT02429882|Experimental|Brodalumab|
16627743|NCT02429882|Placebo Comparator|Placebo|
16627744|NCT02429869|Experimental|Everolimus|
16627745|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
16627746|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
16627747|NCT02429843|Experimental|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
16627748|NCT02429830|Other|Single arm study|Previous LSG patient will be treated with the LINX device and serve as their own control
16627749|NCT02429817|Active Comparator|Aeroneb Solo|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo connected to the high flow nasal cannula.
16627750|NCT02429817|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via the jet nebulizer connected to the high flow nasal cannula.
16627751|NCT02429804|Experimental|Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI)|Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.
16627754|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
16627755|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
16627756|NCT02429765|Active Comparator|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
16628015|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
16627757|NCT02429765|Placebo Comparator|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
16627758|NCT02429752|Experimental|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
16627759|NCT02429739|Experimental|Working Memory Training|Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
16627760|NCT02429739|No Intervention|Passive control group|"The control group will receive treatment as usual (Ordinary school days, special education if normally received)."
16627761|NCT02429726|Experimental|rAdp53|2 x 10^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21
16627762|NCT02429726|Active Comparator|cisplatin|cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
16627763|NCT02429726|Experimental|rAdp53 plus cisplatin|2 x 10^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
16627764|NCT02429713|Experimental|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
16627765|NCT02429713|Active Comparator|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
16627766|NCT02429700|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
16627767|NCT02429700|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
16627768|NCT02429687|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
16627769|NCT02429687|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
16627770|NCT02429674|Other|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
16627771|NCT02429661|Experimental|RC (Girls First Resilience Curriculum)|The Girls First Resilience Curriculum is delivered in peer support groups of 12-15 students per group over 23 weekly 1-hour sessions. The curriculum draws from fields such as positive psychology, emotional competence/intelligence, and restorative practices, and aims to improve students' psychosocial assets and wellbeing.
16627772|NCT02429661|Experimental|HC (Girls First Health Curriculum)|The Girls First Health Curriculum is delivered in peer support groups of 12-15 students per group over 21 weekly 1-hour sessions. The curriculum covers topics such as nutrition, sexual and reproductive health, clean water, hygiene, and common diseases, and aims to improve students' physical health and wellbeing.
16627773|NCT02429661|Experimental|RC+HC (Girls First)|Girls First is a combination of the Girls First Resilience Curriculum (RC) and the Girls First Health Curriculum (HC).
16627774|NCT02429661|No Intervention|SC (School-as-usual control)|Participants receive no intervention and attend school as they usually would.
16627775|NCT02429648|Active Comparator|PVI performed in Normal Sinus Rhythm|DCC first then PVI
16627776|NCT02429648|Active Comparator|PVI performed in Atrial Fibrillation|PVI then DCC after if patient remains in Atrial Fibrillation
16627777|NCT02429635|Experimental|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.
~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.
~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
16627778|NCT02429635|Experimental|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.
~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
16627779|NCT02429622|Experimental|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
16627780|NCT02429622|Experimental|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
16627798|NCT02429531|Experimental|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
16627799|NCT02429518||Miltefosine|Miltefosine: target of 2.5 mg/kg/day for 28 days
16627781|NCT02429622|Experimental|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
16627782|NCT02429622|Experimental|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
16627783|NCT02429609|Experimental|Keratoconic subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)
~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)
~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)
~Anterior eye examination (approx. 4 minutes)
~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)
~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)
~Two measurements of visual acuity will be made:
~Standard ETDRS logMAR acuity measurement (5 minutes)
~Vanishing Optotype logMAR acuity measurement (5 minutes)"
16627784|NCT02429609|Experimental|Healthy subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)
~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)
~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)
~Anterior eye examination (approx. 4 minutes)
~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)
~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)
~Two measurements of visual acuity will be made:
~Standard ETDRS logMAR acuity measurement (5 minutes)
~Vanishing Optotype logMAR acuity measurement (5 minutes)"
16627785|NCT02429596|Experimental|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
16627786|NCT02429596|No Intervention|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
16627787|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
16627788|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
16627789|NCT02429570|Experimental|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
16627790|NCT02429557|Experimental|Abdominal compression and placebo pill|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
16627791|NCT02429557|Sham Comparator|Sham abdominal compression and placebo|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
16627792|NCT02429557|Experimental|Abdominal compression and midodrine|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
16627793|NCT02429557|Active Comparator|Sham abdominal compression and midodrine|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
16627794|NCT02429544|Experimental|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
16627795|NCT02429544|Experimental|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
16627796|NCT02429544|Other|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
16627797|NCT02429531|Experimental|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
16627909|NCT02428660|Active Comparator|Group 2|MTM + software-based drug & gene interaction risk analysis only
16627800|NCT02429505||Miltefosine|Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed >75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
16627801|NCT02429492|Experimental|ALS patients|Patients with amyotrophy lateral sclerosis (ALS)
16627802|NCT02429492|Experimental|Control subjetcs|Neurologically intact subjects sex and age-matched to ALS patients
16627803|NCT02429479|Active Comparator|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
16627804|NCT02429479|Experimental|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
16627805|NCT02429479|Active Comparator|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
16627806|NCT02429479|Experimental|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
16627807|NCT02429466|Experimental|Guadecitabine (SGI-110)|
16627808|NCT02429453|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
16627809|NCT02429453|Experimental|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
16627810|NCT02429440|Experimental|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
16627811|NCT02429440|Active Comparator|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
16627812|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
16627813|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
16627814|NCT02429414|Experimental|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
16627815|NCT02429414|Experimental|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
16627816|NCT02429401|Experimental|Culturally adapted brief intervention|
16627817|NCT02429401|Active Comparator|Non-adapted brief intervention|
16627818|NCT02429388|Experimental|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
16627819|NCT02429388|No Intervention|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
16627820|NCT02429375|Experimental|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
16627821|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
16627822|NCT02429349|Experimental|Diagnostic Procedure|Surgery - Unilateral surgical removal of ovary, freezing of tissue, post cancer cure autotransplant
16627823|NCT02429323|Active Comparator|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
16627824|NCT02429323|Active Comparator|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
16627825|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
16627826|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
16627827|NCT02429297|Experimental|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
16627828|NCT02429297|Experimental|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
16627829|NCT02429297|Experimental|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
16627830|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
16627831|NCT02429271|Active Comparator|Ticagrelor|1st day 270 mg & from then onwards 180 mg per day
16627832|NCT02429271|Active Comparator|Clopidogrel|1st day 300 mg & from then onwards 75 mg per day
16627833|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
16627834|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
16627835|NCT02429232|Experimental|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
16627836|NCT02429232|Active Comparator|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
16627837|NCT02429219|Active Comparator|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
16627838|NCT02429219|Experimental|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
16627839|NCT02429206|Active Comparator|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
16627840|NCT02429206|Experimental|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
16627841|NCT02429193|Experimental|Abiraterone / enzalutamide|Abiraterone + prednisone; Enzalutamide
16627842|NCT02429180|Experimental|Rehabilitation training|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.
~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals
~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.
~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme
~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
16627843|NCT02429180|No Intervention|Control|Control: treatment as usual plus receipt of a UK Stroke Association booklet on exercise after stroke.
16627844|NCT02429167|Experimental|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
16627845|NCT02429167|Sham Comparator|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
16627846|NCT02429154|Active Comparator|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
16627847|NCT02429154|Other|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
16627848|NCT02429141|Experimental|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
16627849|NCT02429141|Experimental|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
16627850|NCT02429128|Active Comparator|Lean PCOS training|14 weeks exercise training
16627851|NCT02429128|Other|Lean healthy controls|14 weeks exercise training
16627852|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
16627853|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
16627854|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
16627855|NCT02429102|Experimental|Single ascending dose, MT-8554 or Placebo|
16627856|NCT02429102|Experimental|Multiple ascending dose, MT-8554 or Placebo|
16627857|NCT02429089|Experimental|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
16627858|NCT02429076|Experimental|Propofol|Subjects in this arm will receive propofol general anesthesia
16627859|NCT02429076|Experimental|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
16627860|NCT02429063|Experimental|Bright White Light|Participants use the bright white light intervention for 30 minutes upon waking each morning for 60 days.
16627861|NCT02429063|Experimental|Dim Red Light|Participants use the dim red light intervention for 30 minutes upon waking each morning for 60 days.
16627862|NCT02429050|Active Comparator|intervention|sustained release morphine
16627863|NCT02429050|Placebo Comparator|control|placebo
16627864|NCT02429037|Experimental|rAd-p53 plus radiation and chemotherapy|rAd-p53 tumor injection combined with radio- and chemo-therapy.
16627865|NCT02429037|Active Comparator|radiation and chemotherapy|radiation combined with chemotherapy
16627866|NCT02429024|No Intervention|Control|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.
16627867|NCT02429024|Experimental|Intervention|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.
16627868|NCT02429011||MDD|patients with current MDD
16627869|NCT02429011||Healthy Control (HC)|healthy control volunteers
16627870|NCT02428998|Experimental|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
16627871|NCT02428998|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
16627873|NCT02428972|Experimental|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
16627874|NCT02428972|Active Comparator|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
16628016|NCT02427984||Controls|Patients free from hip devices
16627875|NCT02428959|Experimental|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
16627876|NCT02428946|Active Comparator|Morning bromocriptine|Bromocriptine is taken in the morning
16627877|NCT02428946|Active Comparator|Evening bromocriptine|Bromocriptine is taken in te evening
16627878|NCT02428933|Other|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
16627879|NCT02428920|Experimental|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
16627880|NCT02428920|No Intervention|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
16627881|NCT02428894||LVAD recipients|
16627882|NCT02428881|Experimental|Complete retention- onabotulinumtoxinA|Women in complete urinary retention receiving onabotulinumtoxinA
16627883|NCT02428881|Experimental|Obstructed voiding- onabotulinumtoxinA|Women with obstructed voiding receiving onabotulinumtoxinA
16627884|NCT02428868|Experimental|Tranexamic acid - intravenous iron|"IV iron (Ferroven®) : 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
~IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later."
16627885|NCT02428868|Active Comparator|Tranexamic acid|IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.
16627886|NCT02428868|Placebo Comparator|Placebo|20 mL saline, in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
16627887|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen
~Dasatinib, oral, daily, predetermined dosage per cycle
~Radiologic Response Assessment every 2 cycles"
16627888|NCT02428842|Other|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.
~Blood and tumor sampling will also be performed at disease progression/relapse."
16627889|NCT02428829|Experimental|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
16627890|NCT02428829|Active Comparator|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
16627891|NCT02428816|Experimental|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
16627892|NCT02428816|Experimental|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
16627893|NCT02428816|Experimental|Controls|30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit
16627894|NCT02428790||ABI Patients|Patients with acquired brain injury.
16627895|NCT02428777|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
16627896|NCT02428777|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
16627897|NCT02428777|Placebo Comparator|Placebo|Women will receive an oral placebo 1 hour before the procedure
16627898|NCT02428764|Experimental|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
16627899|NCT02428751|Active Comparator|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
16627900|NCT02428751|Experimental|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
16627901|NCT02428725|Experimental|Acute coronary syndrome patient|Acute coronary syndrome patient undergoing PCI and eligible for ticagrelor therapy according to the guidelines accepting blood samples measuring platelets reactivity
16627902|NCT02428712|Experimental|PLX8394|"Group A: Phase 1-Dose Escalation: Adult patients.
~Phase 2a-RP2D Confirmation/Redefinition (Formulation 2): Adult and adolescent patients.
~Phase 2a-Dose Extension: Adult and adolescent patients with advanced unresectable solid tumors will be enrolled among two cohorts.
~Cohort 1: Activating BRAF V600 mutations (glioma patients only)
~Cohort 2: Activating BRAF non-V600 mutations"
16627903|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
16627904|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
16627905|NCT02428686|Experimental|epoetin beta|
16627906|NCT02428673|Other|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
16627907|NCT02428660|Other|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
16627908|NCT02428660|Experimental|Group 1|MTM + software-based drug & gene interaction risk analysis + pharmacogenetic testing
16627910|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
16627911|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
16627912|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
16627913|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
16627914|NCT02428634|Experimental|Program SI! for Elementary 6 levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. The intervention is implemented during all the elementary levels (PSIE13+PSIE46).
16627915|NCT02428634|No Intervention|Normal curriculum|The schools on the control group keep their normal curriculum and don't join any school program about health until the end of the study.
16627916|NCT02428634|Experimental|Program SI! for Elementary first levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the first three levels (PSIE13).
16627917|NCT02428634|Experimental|Program SI! for Elementary last levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the last three levels (PSIE46).
16627918|NCT02428621|Experimental|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
16627919|NCT02428621|Active Comparator|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
16627920|NCT02428621|No Intervention|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
16627921|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
16627922|NCT02428595|Experimental|Treatment|Eclipse™ System
16627923|NCT02428582|Active Comparator|bare stent inserted|Standard bare stent will be placed
16627924|NCT02428582|Experimental|Covered stent inserted|Covered stent will be placed
16627925|NCT02428569|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
16627926|NCT02428569|Experimental|PREPARED Decision Support|Participants randomized to this arm of the study will receive the PREPARED educational book and video.
16627927|NCT02428556|Active Comparator|Facts only|"Scenario describes study results without breakthrough language, promising language, no cautions about conditional approval"
16627928|NCT02428556|Active Comparator|promising language|"study description describes drug as promising; no warning about conditional approval"
16627929|NCT02428556|Active Comparator|"breakthrough with may warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
16627930|NCT02428556|Active Comparator|"breakthrough with is warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
16627931|NCT02428556|Experimental|breakthrough only|"Scenario describes study results with breakthrough language, no cautions about conditional approval"
16627932|NCT02428543|Experimental|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
16627933|NCT02428517||Young/MSD|Patients who are <55 years old, and will receive alloHCT for Young/MSD
16627934|NCT02428517||Young/MUD&FMD|Patients who are <55 years old, and will receive alloHCT for Young/MUD&FMD
16627935|NCT02428517||Old/MSD|Patients who are >=55 years old, and will receive alloHCT for Old/MSD
16627936|NCT02428517||Old/MUD&FMD|Patients who are >=55 years old, and will receive alloHCT for Old/MUD&FMD
16627937|NCT02428504||End of life decision|
16627938|NCT02428491|Experimental|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
16627939|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
16628013|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
16627940|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
16627941|NCT02428465|Experimental|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
16627942|NCT02428465|No Intervention|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
16627943|NCT02428452|Experimental|Treatment|Six-month Social ABCs parent-training program received immediately
16627944|NCT02428452|No Intervention|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
16627945|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
16627946|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
16627947|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
16627948|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
16627949|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
16627950|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
16627951|NCT02428400|Experimental|TG1050|"TG1050 SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~TG1050 Part B cohort, dose(s) and schedule to be determined"
16627952|NCT02428400|Placebo Comparator|Placebo|"Placebo SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~Placebo Part B cohort, dose(s) and schedule to be determined"
16627953|NCT02428387|Experimental|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
16627954|NCT02428387|No Intervention|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
16627955|NCT02428374|Active Comparator|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
16627956|NCT02428374|Active Comparator|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
16627957|NCT02428374|Active Comparator|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
16627958|NCT02428374|Active Comparator|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
16627959|NCT02428361|Experimental|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
16627960|NCT02428348|Experimental|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
16627961|NCT02428322|Experimental|Intervention|2,000iu vitamin D3 per day for 15 weeks
16627962|NCT02428322|Placebo Comparator|Placebo|An identical placebo capsule daily for 15 weeks.
16627963|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
16627964|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
16627965|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
16627966|NCT02428296|Experimental|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
16627967|NCT02428283|Experimental|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
16627968|NCT02428283|Active Comparator|Control|Remifentanil was administered intravenously.
16627969|NCT02428270|Experimental|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.
~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
16627970|NCT02428257|Experimental|hypobaric|continuous spinal anesthesia with 2,5 mg boluses of hypobaric bupivacaine, prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
16627971|NCT02428257|Active Comparator|isobaric|continuous spinal anesthesia with 2,5 mg boluses of 0.5% isboaric bupivacaine
16627972|NCT02428244|No Intervention|Arm 1, Control|Standard of care intervention: All patients at the University as a standard of care receive informational materials about smoking cessation. They are referred to the patient resource center at our institution. Patients will be provided this, also they will be provided with a smoking cessation Quitline Brochure
16627973|NCT02428244|Experimental|Standard of care + brief counseling|Patients who are randomized into this arm will receive the standard of care (outlined above). Additionally, patients will also receive a smoking education/counseling session. Patients will receive 10-30 minutes of guided discussion regarding the risks and benefits with regards to smoking and the healing of their traumatic injuries. The smoking educators, who will be trained in accordance with the guidelines provided by MdQuit.org will utilize motivational interviewing techniques to enhance interest in quitting. Patients will receive a description of the quitline, and the quitlined will be the recommended resource. If patients elect to enroll in the quitline, they will be consented using the standardized quitline protocols.
16627974|NCT02428244|Experimental|Standard of care + counseling/follow-up|"Patients who are randomized into this arm will receive the same intervention as patients in Arm 2, except when patients arrive for their follow-up, the smoking educator will check-in with their progress for approximately 5 minutes. The techniques utilized during this check-in visit will include repetition of previously described motivational interviewing, at this point patients who elect to be referred to the quitline will be given this opportunity."
16627975|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
16627976|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
16627977|NCT02428218|Experimental|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
16627978|NCT02428218|Experimental|Placebo|Participants will receive matching placebo capsule(s) taken orally.
16627979|NCT02428205|Experimental|Propranolol arm|Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing > 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing < 15 kg will be excluded for safety reasons.
16627980|NCT02428205|Placebo Comparator|Placebo arm|Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
16627981|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
16627982|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16627983|NCT02428179||Control group without Study intervention|Control group without Study intervention
16627984|NCT02428179||Group with Study intervention|Group with Study intervention
16627985|NCT02428153|Experimental|cases|static and dynamic stretching exercises
16627986|NCT02428140|Experimental|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
16627987|NCT02428140|Experimental|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
16627988|NCT02428127|Experimental|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
16627989|NCT02428127|Active Comparator|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
16627990|NCT02428127|Placebo Comparator|Control|200mL lukewarm water given twice a day
16627991|NCT02428114||5 days of filgrastim|Standard of care
16627992|NCT02428114||7 days of filgrastim|Standard of care
16627993|NCT02428114||10 days of filgrastim|Standard of care
16627994|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
16627995|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
16627996|NCT02428088|Placebo Comparator|Placebo|Placebo
16627997|NCT02428075|Experimental|FCHV visit-normotensive|
16627998|NCT02428075|No Intervention|FCHV no visit-normotensive|
16627999|NCT02428075|Experimental|FCHV visit-prehypertensive|
16628000|NCT02428075|No Intervention|FCHV no visit-prehypertensive|
16628001|NCT02428075|Experimental|FCHV visit-hypertensive|
16628002|NCT02428075|No Intervention|FCHV no visit-hypertensive|
16628003|NCT02428062|No Intervention|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
16628004|NCT02428062|Experimental|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
16628005|NCT02428062|No Intervention|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
16628006|NCT02428049||Lung cancer patients|Lung cancer patients in stages IA-IIIA destined to have stereotactic radiotherapy or conventional radiotherapy and chemotherapy in curative intent
16628007|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
16628008|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
16628009|NCT02428023||GrThalasaemia|estimation of IMT of the carotides arteries and calcium scoring
16628010|NCT02428023||GrNormal|estimation of IMT of the carotides arteries and calcium scoring
16628011|NCT02428010|Experimental|Treatment|TMVR Implant
16628012|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
16628014|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
16628017|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
16628018|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
16628019|NCT02427958|Experimental|Leuprorelin|Participants with body weight greater than or equal to (>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
16628020|NCT02427945|Experimental|Control|Provision of information on safe water
16628021|NCT02427945|Experimental|Treatment traditional|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.
16628022|NCT02427945|Experimental|Treatment couple|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old, and her husband.
16628023|NCT02427932||Pregnant/Ampicillin|pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus
16628024|NCT02427932||Non-pregnant/Ampicillin|non-pregnant participants who will receive Ampicillin for a qualifying hospital admission
16628025|NCT02427932||Pregnant and Non-pregnant/Ampicillin and Gentamicin|pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission
16628026|NCT02427932||Non-Pregnant/Gentamicin|non-pregnant participants who will receive Gentamicin for a qualifying hospital admission
16628027|NCT02427919|Experimental|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7~D+10 when blasts disappear from peripheral blood smear.
~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.
~Intervention type : Drug Intervention name : G-CSF (Filgrastim)
~-> Comparison of the effect of G-CSF (Filgrastim) use"
16628028|NCT02427919|Active Comparator|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.
~Intervention type : Drug Intervention name : G-CSF (Filgrastim)
~-> Comparison of the effect of G-CSF (Filgrastim) use"
16628029|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
16628030|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
16628031|NCT02427893|Active Comparator|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
16628032|NCT02427893|Active Comparator|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
16628033|NCT02427880|Experimental|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
16628034|NCT02427880|Active Comparator|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
16628035|NCT02427867|Experimental|remote ischemic preconditioning|Three cycles of 5 minutes ischemia will be applied to the upper left arm (or right arm or legs if the left arm will not be deemed suitable by the attending physician), achieved by inflation of a blood-pressure cuff to 200 mm Hg, followed by 5 minutes reperfusion while the cuff will be deflated.
16628036|NCT02427867|Placebo Comparator|no ischemic preconditioning|The cuff will be placed around the arm but not inflated.
16628037|NCT02427854|No Intervention|No training|Incidence of obstetric perineal injuries in the participating hospitals before implementation of the manual perineal protection method.
16628038|NCT02427854|Active Comparator|Education by animated training video|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video only.
16628039|NCT02427854|Active Comparator|Interactive hands on bedside training|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video and additionally by an interactive hands-on bedside training.
16628040|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.
~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.
~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
16628041|NCT02427828|Active Comparator|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
16628042|NCT02427828|No Intervention|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
16628043|NCT02427802|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
16628044|NCT02427802|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
16628045|NCT02427802|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
16628046|NCT02427789|No Intervention|Control|In this group patients will not have physical exercises
16628047|NCT02427789|Active Comparator|Physical Exercise|In this group patients will make physical exercise
16628048|NCT02427776|Experimental|IMP|
16628049|NCT02427763|Active Comparator|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours
~Interventions:
~hours of use
~collect biofilm
~collect saliva
~collect epithelium"
16628050|NCT02427763|Active Comparator|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours
~Interventions:
~hours of use
~collect biofilm
~collect saliva
~collect epithelium"
16628051|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
16628052|NCT02427737|Experimental|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
16628053|NCT02427737|No Intervention|Control|MRI sites not trained in Comfort Talk®.
16628054|NCT02427724|Active Comparator|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
16628055|NCT02427724|Active Comparator|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
16628056|NCT02427724|Placebo Comparator|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
16628057|NCT02427711|Active Comparator|Bipolar sealer|Prospective use of bipolar sealer for skin and knee capsule incision revisions of non-septic knee arthroplasty.
16628058|NCT02427711|Placebo Comparator|Scalpel|Conventional surgical incision with scalpel - data extracted from a retrospective group.
16628059|NCT02427698|Active Comparator|cyrolipolysis|
16628060|NCT02427698|Active Comparator|cryolipolysis plus subcision|
16628061|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
16628062|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
16628063|NCT02427659|Other|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
16628064|NCT02427659|Other|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
16628065|NCT02427659|Other|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
16628066|NCT02427646|Experimental|ET BoNT-A treatment|ET participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
16628067|NCT02427646|Experimental|PD tremor BoNT-A treatment|PD participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
16628068|NCT02427633|No Intervention|Control|Randomized to standard care (control group) - observations only
16628069|NCT02427633|Experimental|UKRC 1997|Randomized to modified UKRC 1997 - Intervention and Observations
16628070|NCT02427633|Experimental|UKRC 2010|Randomized to modified UKRC 2010 - Intervention and Observations
16628071|NCT02427620|Experimental|Treatment (ibrutinib, rituximab, consolidation chemotherapy)|"PART I (IBRUTINIB PLUS RITUXIMAB): Patients receive ibrutinib PO QD on days 1-28 and rituximab IV over 6-8 hours on days 1, 8, 15, and 22 of cycle 1 and then over 4 hours on day 1 of cycles 3-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve complete response.
~PART II (CONSOLIDATION THERAPY): Patients receive rituximab IV over 6 hours on day 1; dexamethasone PO or IV on days 1-4; cyclophosphamide IV over 3 hours BID on days 2-4; doxorubicin hydrochloride IV over 15-30 minutes on day 5; and vincristine sulfate IV over 15-30 minutes on day 5 of cycles 1, 3, 5, and 7. Patients also receive rituximab IV over 6 hours on day 1; methotrexate IV over 24 hours on day 2; and cytarabine IV over 2 hours BID on days 3 and 4 of cycles 2, 4, 6, and 8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
16628072|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
16628073|NCT02427594|Experimental|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
16628074|NCT02427594|Experimental|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
16628075|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.
~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.
~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
16628076|NCT02427568|Placebo Comparator|Placebo with therapy|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
16628077|NCT02427568|Active Comparator|MDMA-assisted therapy (125 mg)|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg MDMA.
16628078|NCT02427555|Experimental|Barley kernel bread|
16628079|NCT02427555|Sham Comparator|Whit wheat flour bread|
16628080|NCT02427542|Active Comparator|CBT for DP|Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
16628081|NCT02427542|Placebo Comparator|Treatment as usual|Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
16628082|NCT02427529|Experimental|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
16628083|NCT02427529|Placebo Comparator|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
16628084|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
16628085|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
16628086|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
16628087|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
16628090|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
16628091|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
16628092|NCT02427464|Experimental|VM202|"Subjects randomized to the VM202 treatment arm will receive the following intramuscular injections in each calf:
~Day 0 - 16 injections of 0.5mL of VM202 / calf
~Day 14 - 16 injections of 0.5mL of VM202 / calf
~Day 90 - 16 injections of 0.5mL of VM202 / calf
~Day 104 - 16 injections of 0.5mL of VM202 / calf"
16628093|NCT02427464|Placebo Comparator|Placebo|"Subjects in the placebo control group will receive the following intramuscular injections in each calf:
~Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf
~Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf
~Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf
~Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
16628094|NCT02427451|Experimental|Treatment (obinutuzumab, ibrutinib, Bcl-2 inhibitor GDC-0199)|Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
16628095|NCT02427438|Active Comparator|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
16628096|NCT02427438|Active Comparator|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
16628097|NCT02427425|Experimental|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
16628098|NCT02427425|Placebo Comparator|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
16628099|NCT02427412|Active Comparator|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
16628100|NCT02427412|Placebo Comparator|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
16628134|NCT02427230|Active Comparator|PFMT and electrical stimulation|Pelvic floor muscle training and intravaginal neuromuscular electrical stimulation daily during 12 weeks.
16628101|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
16628102|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
16628103|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
16628104|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
16628105|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
16628106|NCT02427386|Active Comparator|dynamized estrogen in alcohol solution|Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
16628107|NCT02427386|Placebo Comparator|placebo (alcohol solution)|This arm received alcohol solution during the 24-week study duration.
16628108|NCT02427373|Active Comparator|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
16628109|NCT02427373|Active Comparator|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
16628110|NCT02427373|Active Comparator|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
16628111|NCT02427347|Experimental|Intervention group|Intervention including acupuncture treatment and healthy education.
16628112|NCT02427347|Other|Control group|Healthy education is given as a baseline treatment.
16628113|NCT02427334|Active Comparator|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
16628114|NCT02427334|Active Comparator|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
16628115|NCT02427334|Placebo Comparator|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
16628116|NCT02427321||Cystoscopy cohort|"Video recording of flexible cystoscopic examination. All participants enrolled on the study will have video from their flexible cystoscopic examination recorded.
~Diagnosis and pathology information will be collected from the participants medical notes for a period of eight weeks following the recorded cystoscopy."
16628117|NCT02427308||miltefosine patients that become pregnant|
16628118|NCT02427295|Experimental|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 >600 ng/ml
~medical treatment : Sandostatin (Octreotide Acetate)"
16628119|NCT02427295|No Intervention|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
16628120|NCT02427295|No Intervention|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation
~and IGF-1 <600ng/ml"
16628121|NCT02427282|Active Comparator|MS. Frog|miniscrew-supported frog molar distalizing appliance
16628122|NCT02427282|Experimental|Stand. Frog|Standard Frog appliance
16628123|NCT02427269||Barrett's Esophagus (BE) Surveillance|Patients who have never received ablative therapy for Barrett's Esophagus and are receiving routine care surveillance upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
16628124|NCT02427269||Barrett's Esophagus (BE) Pre-Ablation|Patients who are receiving routine care upper endoscopy with ablative therapy for their Barrett's Esophagus for the first time. Subjects will have esophageal biopsies, blood, and data collected for this study.
16628125|NCT02427269||Barrett's Esophagus (BE) Post-Ablation|Patients with a history of Barrett's Esophagus who are status post ablation and are receiving routine care follow-up EGD for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
16628126|NCT02427269||Esophageal Cancer(ECA/IMC)|Patients with esophageal cancer who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
16628127|NCT02427269||Squamous Cell Carcinoma (SCC)|Patients with squamous cell cancer of the esophagus who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
16628128|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
16628129|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
16628130|NCT02427256||Pathologic Adults age 29-80 yrs|
16628131|NCT02427243|Experimental|Crenezumab Formulation 2|A single dose given as two subcutaneous injections on Day 1
16628132|NCT02427243|Experimental|Crenezumab Formulation 3|A single dose given as two subcutaneous injections on Day 1
16628133|NCT02427230|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training daily during 12 weeks.
16628135|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
16628136|NCT02427191|Experimental|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
16628137|NCT02427191|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
16628138|NCT02427178|Experimental|Open label|"Hematopoietic allogeneic stem cells will be transplanted:
~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
16628139|NCT02427165|Placebo Comparator|Placebo|Single dose of nebulised placebo solution
16628140|NCT02427165|Experimental|RPL554 Dose 1|0.4 mg single dose nebulised RPL554
16628141|NCT02427165|Experimental|RPL554 Dose 2|1.5 mg single dose nebulised RPL554
16628142|NCT02427165|Experimental|RPL554 Dose 3|6 mg single dose nebulised RPL554
16628143|NCT02427165|Experimental|RPL554 Dose 4|24 mg single dose nebulised RPL554
16628144|NCT02427165|Active Comparator|Salbutamol Dose 1|2.5 mg single dose nebulised salbutamol
16628145|NCT02427165|Active Comparator|Salbutamol Dose 2|7.5 mg single dose nebulised salbutamol
16628146|NCT02427152||Lean|body mass index: 18-25 kg/m²
16628147|NCT02427152||Overweight/Obese|body mass index: >25 kg/m²
16628148|NCT02427139|Experimental|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.
~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
16628149|NCT02427126|Experimental|Apixaban|Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake
16628150|NCT02427126|Active Comparator|Aspirin|Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake
16628151|NCT02427113|Active Comparator|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
16628152|NCT02427113|Active Comparator|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
16628153|NCT02427100|No Intervention|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
16628154|NCT02427100|Active Comparator|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
16628155|NCT02427087|Active Comparator|Continuous Aerobic training|Aerobic training continuous (n=19 patients) carry a protocol continuous aerobic training twice a week for 24 weeks and the session will last 60 minutes/2 days/week with recommendation for healthy diet.
16628156|NCT02427087|Active Comparator|Healthy diet|Diet group (n=21 patients) only recommendation for healthy diet.
16628157|NCT02427074|Active Comparator|Balloon Compression Rhizotomy|Patients that are submitted to Balloon Compression Rhizotomy
16628158|NCT02427074|Active Comparator|Radiofrequency Thermal Coagulation Rhizotomy|Patients that are submitted to Radiofrequency Thermal Coagulation Rhizotomy
16628159|NCT02427061|Experimental|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.
~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
16628160|NCT02427061|Active Comparator|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.
~The control intervention focuses on job skills development."
16628161|NCT02427048|No Intervention|Pre-Intervention|Delayed feedback and peer comparison
16628162|NCT02427048|Experimental|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
16628163|NCT02427035|Experimental|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
16628164|NCT02427035|Experimental|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
16628165|NCT02427022|Experimental|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
16628166|NCT02427022|Active Comparator|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
16628194|NCT02426814|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.
~Intervention: inhaler sensor"
16628167|NCT02427009|Experimental|The study population|"The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.
~Intervention: Prone position for 1 hour after blood patch"
16628168|NCT02426996|Experimental|Study population|"The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.
~Intervention: Scan of shoulder"
16628169|NCT02426983|Active Comparator|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
16628170|NCT02426983|Sham Comparator|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
16628171|NCT02426983|Active Comparator|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
16628172|NCT02426983|Placebo Comparator|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
16628173|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
16628174|NCT02426957|Experimental|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
16628175|NCT02426957|No Intervention|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
16628176|NCT02426944|Experimental|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
16628177|NCT02426944|Experimental|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
16628178|NCT02426931|Experimental|tf-URS|Participants in tf-URS group undergo ureteroscopy using the tip-flexible ureterorenoscope.
16628179|NCT02426931|Active Comparator|f-URS|Participants in f-URS group undergo ureteroscopy using the classic flexible ureteroscope.
16628180|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
16628181|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
16628182|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
16628183|NCT02426905|No Intervention|Retrospective|
16628184|NCT02426905|Other|Prospective|
16628185|NCT02426892|Experimental|ISA101 + Nivolumab|"HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
~Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose.
~There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond."
16628186|NCT02426879|Other|surgery|esophagectomy with three-field lymphnode dissection
16628187|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
16628188|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
16628189|NCT02426853|Experimental|Group 1 - UV Photography Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds. At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
16628190|NCT02426853|Active Comparator|Group 2 - Comparison Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
16628191|NCT02426840|Experimental|High dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily plus vitamin D2 (20,000 IU/cap) administered once weekly (a total of 1,200 mg of elemental calcium and 3,200 IU of vitamin D daily)
16628192|NCT02426840|Active Comparator|Normal dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily (a total of 1,200 mg of elemental calcium and 400 IU of vitamin D daily)
16628193|NCT02426827|Experimental|SCS in CV|
16628267|NCT02426437|Other|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
16628195|NCT02426814|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.
~Interventions: inhaler sensor and mobile application for asthma adherence"
16628196|NCT02426801|No Intervention|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
16628197|NCT02426801|Sham Comparator|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.
~Intervention: inhaler sensor"
16628198|NCT02426801|Experimental|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).
~Interventions: inhaler sensor and mobile application for asthma adherence"
16628199|NCT02426788|Experimental|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):
~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
16628200|NCT02426788|No Intervention|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
16628201|NCT02426775|No Intervention|Methylmalonic Acidemia Control Arm|patients with Methylmalonic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
16628202|NCT02426775|Experimental|Methylmalonic Acidemia Active arm|patients with Methylmalonic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
16628203|NCT02426775|No Intervention|Propionic Acidemia Control Arm|patients with Propionic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and biotin)
16628204|NCT02426775|Experimental|Propionic Acidemia Active arm|patients with Propionic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and biotin)
16628205|NCT02426762|Experimental|Sealant skin closure|A quick skin sealant would be applied after laparoscopic surgery. All abdominal wounds are sealed by smearing the quick sealant (skin adhesive) twice. No additional gauges should be appended on wound areas. No further wound care should be applied unless any effusion or bleeding emerged around it.
16628206|NCT02426749|Active Comparator|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
16628207|NCT02426749|Sham Comparator|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
16628208|NCT02426736|Active Comparator|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16628209|NCT02426736|Active Comparator|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16628210|NCT02426736|Active Comparator|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16628211|NCT02426736|Active Comparator|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
16628212|NCT02426723|Experimental|CWP232291|"Phase 1a: single administration of CWP232291 ,
~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
16628213|NCT02426710|Experimental|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
16628214|NCT02426710|Active Comparator|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
16628215|NCT02426697|Experimental|Pecfent|Patients will receive 100 µg of transmucosal Pecfent before radiotherapy session (or 200 µg in patients with a stable opioid background pain treatment)
16628216|NCT02426697|Placebo Comparator|Placebo|Patients will receive 100 µg of transmucosal placebo before radiotherapy session or 200 µg in patients with a stable opioid background pain treatment)
16628217|NCT02426684|Experimental|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
16628218|NCT02426671|Experimental|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
16628219|NCT02426658|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
16628220|NCT02426632|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
16628221|NCT02426632|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
16628222|NCT02426632|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
16628223|NCT02426632|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
16628224|NCT02426632|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
16628225|NCT02426632|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
16628600|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
16628226|NCT02426632|Experimental|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
16628227|NCT02426632|Experimental|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
16628228|NCT02426632|Experimental|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
16628229|NCT02426632|Experimental|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
16628230|NCT02426632|Experimental|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
16628231|NCT02426632|Experimental|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
16628232|NCT02426619|Experimental|SDF regular|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush regularly once a year
16628233|NCT02426619|Experimental|SDF intensive|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
16628234|NCT02426619|Active Comparator|NaF varnish|3 applications of a 5% NaF varnish will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
16628235|NCT02426606|Experimental|White bread|
16628236|NCT02426606|Experimental|Lentil 1 + white rice|
16628237|NCT02426606|Experimental|Lentil 2 + white rice|
16628238|NCT02426606|Experimental|Lentil 3 + white rice|
16628239|NCT02426606|Experimental|White rice|
16628240|NCT02426606|Experimental|Lentil 1 + potato|
16628241|NCT02426606|Experimental|Lentil 2 + potato|
16628242|NCT02426606|Experimental|Lentil 3 + potato|
16628243|NCT02426606|Experimental|Potato|
16628244|NCT02426593||Subjects without heart failure|
16628245|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
16628246|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
16628247|NCT02426567|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
16628248|NCT02426567|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
16628249|NCT02426554|Active Comparator|Group 1|
16628250|NCT02426554|Placebo Comparator|Group 2|
16628251|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
16628252|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
16628253|NCT02426528|Experimental|Cultural and Social exposure A|Cultural and Social exposure
16628254|NCT02426528|No Intervention|Cultural and Social exposure B|Non Intervention (Control Group)
16628255|NCT02426515|Experimental|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
16628256|NCT02426515|No Intervention|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
16628257|NCT02426502|Experimental|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
16628258|NCT02426489|No Intervention|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
16628259|NCT02426489|Experimental|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
16628260|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
16628261|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
16628262|NCT02426463|Active Comparator|Propofol|Plasma samples and patient data are collected prospectively from 40 neonates who receive propofol as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
16628263|NCT02426463|Active Comparator|Oxycodone|Plasma samples and patient data are collected prospectively from 40 neonates who receive oxycodone as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
16628264|NCT02426450|Experimental|RFA+FOLFOX4|"RFA:
~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
~Oxaliplatin + 5-Fluorouracil/Leucovorin:
~4 weeks after RFA; Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.
~Repeated every 2 weeks"
16628265|NCT02426437|Other|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
16628266|NCT02426437|Other|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
16628268|NCT02426424|Experimental|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
16628269|NCT02426424|Experimental|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
16628270|NCT02426411|Experimental|EMA401 200 mg|2 X 50 mg capsules BID
16628271|NCT02426411|Experimental|EMA401 600 mg|2 X 150 mg capsules BID
16628272|NCT02426411|Placebo Comparator|Placebo|Placebo to match 2 capsules BID
16628273|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
16628274|NCT02426398||Healthy volunteers|Healthy volunteers
16628275|NCT02426385||1POD26PFT|Patients implanted with the POD 26% FineVision Toric
16628276|NCT02426385||2POD26PT|Patients implanted with the POD 26% Toric
16628277|NCT02426372|Experimental|QBECO SSI 0.02 mL|0.02 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
16628278|NCT02426372|Experimental|QBECO SSI 0.05 mL|0.05 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
16628279|NCT02426372|Experimental|QBECO SSI 0.1 mL|0.1 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
16628280|NCT02426359|Experimental|Q301 Cream|Q301 Cream
16628281|NCT02426359|Placebo Comparator|Vehicle|Vehicle
16628282|NCT02426346|Active Comparator|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
16628283|NCT02426346|Experimental|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
16628284|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
16628285|NCT02426320|Active Comparator|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
16628286|NCT02426320|Active Comparator|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
16628287|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
16628288|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
16628289|NCT02426294|Experimental|Pioglitazone|Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet. It is administered once-daily with 15mg, with or without meals. The once-daily administration begins with 15mg, and if need increase, researchers can increase up to 30mg at week 12.
16628290|NCT02426294|Active Comparator|Glimepiride|The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
16628291|NCT02426281|Experimental|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
16628292|NCT02426255||ICU patients|Patients with severe trauma (with or without brain injury) or Patients with hemorrhagic shock Data concerning the ICU stay will be collected for these patients
16628293|NCT02426242||ICU PATIENTS|Patients with brain-injury
16628294|NCT02426229|Experimental|dabigatran 75mg|dabigatran etexilate 75mg orally twice daily for 6 months
16628295|NCT02426216||Group A|Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.
16628296|NCT02426216||Group B|Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.
16628297|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
16628298|NCT02426190|Active Comparator|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols. The warm-up phase in the study refers to therapeutic exercise. The therapeutic exercise aims to condition and prepare patients for subsequent functional or therapeutic activities. The active comparator (Arm 1) is to ask participants to use modalities, such as a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
16628299|NCT02426190|Experimental|Arm 2|Patients in Arm 2 will use an anti-gravity treadmill (AlterG) during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
16628300|NCT02426190|Experimental|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
16628301|NCT02426190|Experimental|Arm 4|Patients in Arm 4 will use both an anti-gravity treadmill (AlterG) and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
16628302|NCT02426177|Active Comparator|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
16628303|NCT02426177|Active Comparator|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
16628304|NCT02426164|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
16628305|NCT02426164|Active Comparator|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
16628306|NCT02426151|Experimental|BEPO-A|Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process)
16628307|NCT02426151|Active Comparator|REPO-A|Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process)
16628308|NCT02426138|Experimental|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
16628309|NCT02426138|Active Comparator|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
16628310|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
16628311|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
16628312|NCT02426112|Active Comparator|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.
~10-20 kg: 250 mg
~20-29 kg: 500 mg
~30-39 kg: 750 mg
~40-49 kg: 1250 mg"
16628313|NCT02426112|Placebo Comparator|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.
~10-20 kg: 250 mg
~20-29 kg: 500 mg
~30-39 kg: 750 mg
~40-49 kg: 1250 mg"
16628314|NCT02426099|Experimental|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
16628315|NCT02426099|Active Comparator|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
16628316|NCT02426086|Experimental|Imetelstat 4.7 mg/kg|
16628317|NCT02426086|Experimental|Imetelstat 9.4 mg/kg|
16628318|NCT02426073||HE|Healthy elderlies
16628319|NCT02426073||DM|Elderlies with type 2 diabetes
16628320|NCT02426073||SA|Elderlies with sarcopenia
16628321|NCT02426073||DS|Elderlies with both type 2 diabetes and sarcopenia
16628322|NCT02426060|Experimental|Imrecoxib&Warfarin|
16628323|NCT02426047|Experimental|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
16628324|NCT02426034|Experimental|Treatment group|Apatinib Tablets
16628325|NCT02426021|Experimental|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
16628326|NCT02426021|Experimental|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
16628327|NCT02426021|Experimental|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
16628328|NCT02426021|Experimental|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
16628329|NCT02426021|Experimental|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
16628330|NCT02426021|Experimental|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
16628331|NCT02426021|Experimental|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
16628332|NCT02426021|Experimental|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
16628333|NCT02426021|Experimental|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
16628334|NCT02426021|Experimental|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
16628335|NCT02426008|Experimental|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
16628336|NCT02426008|Placebo Comparator|In Vitro culture media|culture media to monitor the embryological outcome as control group
16628337|NCT02425995|Experimental|Arthroscopic intercondylar and posteromedial portal|
16628338|NCT02425982||Conservative treatment|Patients who will opt conservative treatment or patients treated conservatively by surgeon decision.
16628339|NCT02425982||Operative treatment|Patients who opt for surgery when offered.
16628340|NCT02425969|Experimental|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
16628341|NCT02425969|Active Comparator|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
16628342|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
16628343|NCT02425943|Experimental|Sculptra Aesthetic|
16628344|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
16628415|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
16628345|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
16628346|NCT02425917|Experimental|geko|
16628347|NCT02425917|Active Comparator|ipc-calf|intermittent pneumatic compression of the calf
16628348|NCT02425904|Experimental|1-Recurrent or Refractory LCH|"Participants with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.
~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.
~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
16628349|NCT02425904|Experimental|2-LCH-related disorders|"Participants with LCH-related disorders who require systemic chemotherapy including:
~Participants with RDD who have not responded to or recurred after treatment with corticosteroids. ECD subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.
~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.
~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
16628352|NCT02425878|Experimental|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
16628353|NCT02425878|Placebo Comparator|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
16628354|NCT02425865|Other|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if > 80 kg
16628355|NCT02425852|Active Comparator|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
16628356|NCT02425852|Active Comparator|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.
~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
16628357|NCT02425839|Experimental|Experimental group|"ultrasound exam by Supersonic Shear Imaging® technique
~EMG examination by electromyograph Keypoint system."
16628358|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
16628359|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
16628360|NCT02425813|Experimental|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.
~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.
~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
16628361|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
16628368|NCT02425774|Placebo Comparator|Sham stimulation + Placebo|"no stimulation
~1 placebo tablet at two different timepoints before surgery"
16628369|NCT02425774|Active Comparator|Vagus stimulation + placebo|"Stimulation at the beginning and the end of the surgery
~1 placebo tablet at two different timepoints before surgery"
16628370|NCT02425774|Active Comparator|Prucalopride + sham stimulation|"1 prucalopride tablet at two different timepoints before surgery
~no stimulation"
16628486|NCT02425007|No Intervention|Control|Control group
16628371|NCT02425761|Active Comparator|Anterior Entry SIte|"Anterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the coronal suture, on the top of the head and near the front. Specifically, anterior entry is defined as ventricular catheter entry less than 1 centimeter anterior to the coronal suture near the mid-pupillary line.
~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using an anterior entry site."
16628372|NCT02425761|Active Comparator|Posterior Entry Site|"Posterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the lambdoid suture, on the back of the head. Specifically, posterior entry is defined as ventricular catheter entry 4 to 7 centimeters above the external occipital protuberance (inion), near the mid-pupillary line.
~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using a posterior entry site."
16628373|NCT02425748|Experimental|Group A|DC-CIK cells will be used against tumor cells.
16628374|NCT02425748|Experimental|Group B|γδ T cells will be used against tumor cells.
16628375|NCT02425748|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
16628376|NCT02425735|Experimental|Group A|DC-CIK cells will be used against tumor cells.
16628377|NCT02425735|Experimental|Group B|γδ T cells will be used against tumor cells.
16628378|NCT02425735|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
16628379|NCT02425722|Experimental|ASP0456 0.0625mg|oral
16628380|NCT02425722|Experimental|ASP0456 0.125mg|oral
16628381|NCT02425722|Experimental|ASP0456 0.25mg|oral
16628382|NCT02425722|Experimental|ASP0456 0.5mg|oral
16628383|NCT02425722|Placebo Comparator|Placebo group|oral
16628384|NCT02425709|Active Comparator|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
16628385|NCT02425709|Active Comparator|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
16628386|NCT02425709|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
16628387|NCT02425696||group 1|Normal individuals without migraine
16628388|NCT02425696||group 2|Migraineurs
16628389|NCT02425683|Experimental|Regorafenib|Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
16628390|NCT02425683|No Intervention|Standard of Care (No Treatment)|No study drug (which is the standard care for Stage IIIC colorectal cancer patients after they've received FOLFOX chemotherapy).
16628391|NCT02425670|Experimental|Bone marrow derived stem cells (BMSCs)|BMSCs 30-500 million plus conventional management
16628392|NCT02425670|No Intervention|Control|Control: conventional management
16628393|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
16628394|NCT02425644|Experimental|Ponesimod|Subjects to receive 20 mg ponesimod
16628395|NCT02425644|Active Comparator|Teriflunomide|Subjects to receive 14 mg teriflunomide
16628396|NCT02425605|Experimental|CCRT-sorafenib group|
16628397|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) <20, clinical stage <cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
16628398|NCT02425579|Experimental|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
16628399|NCT02425579|Placebo Comparator|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
16628400|NCT02425579|Experimental|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
16628401|NCT02425579|Placebo Comparator|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
16628402|NCT02425566|Experimental|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
16628403|NCT02425566|Experimental|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
16628404|NCT02425553||Faculty and Delegates of Ascona II Meeting|
16628405|NCT02425540||patients with unclassified ovarian mass|
16628406|NCT02425527|Experimental|The rehabilitation gaming|The rehabilitation gaming group (n=30) will use an internet browser-based digital brain training program CogniFit (https://www.cognifit.com), with a selection of about 33 games.The participants will use the rehabilitation gaming for at least 30 min per day over a period of 8 weeks.
16628407|NCT02425527|Active Comparator|The entertaining gaming|The entertaining gaming group (n = 30) will use commercial digital games with Sony Playstation 3 (PS3) consoles, played with wireless Sony DualShock gamepad controllers. The participants will be guided to play the console for at least 30 min per day over a period of 8 weeks
16628408|NCT02425527|No Intervention|"Do-nothing"|"The passive control group Do-nothing group (n = 30) will not have gaming activities organized by the project."
16628409|NCT02425514|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
16628410|NCT02425514|Experimental|NovoMax™|The ACDF surgery will be carried out with NovoMax™, which is the bioactive glass ceramic intervertebral spacer
16628411|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
16628412|NCT02425488|Experimental|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
16628413|NCT02425488|No Intervention|Non NET|People who receive basic information without follow the educational program but clinically controlled
16628414|NCT02425475||Mole|Patients with suspicious moles
16628416|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
16628417|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
16628418|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
16628419|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
16628420|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
16628421|NCT02425436|Active Comparator|Ginkgo Biloba Extract group|This group received Ginko Biloba, two tablets per day
16628422|NCT02425436|Placebo Comparator|Placebo group|This group received placebo two tablets per day .
16628423|NCT02425423|Experimental|New thickened infant formula|
16628424|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
16628425|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
16628426|NCT02425397||patients controls with no signs of ototoxicity|
16628427|NCT02425384|Experimental|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
16628428|NCT02425384|Active Comparator|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
16628429|NCT02425384|Placebo Comparator|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
16628430|NCT02425371|Experimental|Intervention|screening and treatment of comorbidities
16628431|NCT02425371|Placebo Comparator|Control|No screening of comorbidity
16628432|NCT02425358|Experimental|BMC therapy within 24 hours|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 24 hours after successful primary PCI.
16628433|NCT02425358|Experimental|BMC therapy within 3-7 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 3-7days after successful primary PCI.
16628434|NCT02425358|Experimental|BMC therapy within 7-30 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 7-30days after successful primary PCI.
16628435|NCT02425358|Active Comparator|PCI only|Patients with acute myocardial infarction who were performed successful primary PCI.
16628436|NCT02425345|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
16628437|NCT02425345|No Intervention|Usual Activity Control|Usual activity
16628438|NCT02425332|Experimental|Lokomat assessment|
16628439|NCT02425319||patients with CapFlex-PIP© implant|
16628440|NCT02425319||patients with silicone implant|
16628441|NCT02425319||patients with healthy PIP joints|
16628442|NCT02425306|Experimental|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
16628443|NCT02425306|Experimental|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:
~Day -6 (Cycle 1)
~Day 8 (Cycle 2)
~Day 22 (Cycle 3)
~Day 36 (Cycle 4)
~Day 50 (Cycle 5)"
16628444|NCT02425306|Experimental|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
16628445|NCT02425306|Experimental|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:
~Day -6 (Cycle 1)
~Day 8 (Cycle 2)
~Day 22 (Cycle 3)
~Day 36 (Cycle 4)
~Day 50 (Cycle 5)"
16628446|NCT02425293|Experimental|Intervention|Patients participating in a patient education seminar
16628447|NCT02425293|No Intervention|Control|Patients not participating in a patient education seminar
16628448|NCT02425280|Experimental|Narrative Exposure Therapy|For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
16628449|NCT02425280|Active Comparator|Treatment as Usual|For the TAU control group, participants will receive the usual care for posttraumatic stress symptoms currently offered by each unit.
16628450|NCT02425267|Experimental|Telerehabilitation|Telerehabilitation at home from a clinic
16628451|NCT02425267|Active Comparator|Face-to-face intervention in a clinic|Conventional physiotherapy
16628487|NCT02424981|Experimental|inspiratory muscle training|Muscle training
16628488|NCT02424981|No Intervention|control|Control group
16628452|NCT02425254|Experimental|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
16628453|NCT02425254|Active Comparator|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
16628454|NCT02425241|Experimental|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.
~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
16628455|NCT02425241|Placebo Comparator|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.
~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
16628456|NCT02425202|Active Comparator|Ketamine infusion|Ketamine infusion at 0.1 mg/kg/hr up to maximum of 10 mg/hr
16628457|NCT02425202|Placebo Comparator|Saline infusion|Saline infusion
16628458|NCT02425189||LQT Positive (Group 1)|"Gene-positive LQTS patients
~Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
16628459|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
16628460|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:
~Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.
~Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.
~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
16628461|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:
~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.
~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
16628462|NCT02425176|Active Comparator|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:
~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.
~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
16628463|NCT02425163|Active Comparator|suspicious for Prostate Cancer|"PSA >4ng/ml or PSA-Velocity >0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.
~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
16628464|NCT02425150|Experimental|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
16628465|NCT02425150|Active Comparator|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
16628466|NCT02425150|No Intervention|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
16628467|NCT02425150|No Intervention|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
16628468|NCT02425137|Experimental|S-1/Gemcitabine|single-arm
16628469|NCT02425124|Active Comparator|Control|PC101 Enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.
16628470|NCT02425124|Experimental|Intervention|PC101 + Mental Health Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
16628471|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
16628472|NCT02425098|Experimental|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine [HD-TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
16628473|NCT02425098|Experimental|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine [TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^3 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
16628474|NCT02425085|Experimental|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
16628475|NCT02425085|Active Comparator|relaxing retinectomy|Patients receive relaxing retinectomy
16628476|NCT02425072|Experimental|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
16628477|NCT02425059|Experimental|IRE Group|irreversible electroporation for Unresectable Rectal Neoplasms
16628478|NCT02425059|No Intervention|Control|The patients without treatment
16628479|NCT02425046|Experimental|health coaching and community screening|Family Health Coaching and community benefits screening
16628480|NCT02425046|Other|community screening|community benefits screening only
16628481|NCT02425033|Experimental|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
16628482|NCT02425020|Experimental|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
16628483|NCT02425020|Experimental|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
16628484|NCT02425020|Active Comparator|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
16628485|NCT02425007|Experimental|Spiro|Incentive spirometry
16628489|NCT02424968|Experimental|Infusion of Allogeneic CD8+ Memory T-cells|All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).
16628490|NCT02424955|Experimental|3D Perfusion Ultrasound|undergo 3D ultrasound perfusion imaging with perflutren
16628491|NCT02424942|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
16628492|NCT02424942|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
16628493|NCT02424929|Other|Awake|"Original surgery intervention.
~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
16628494|NCT02424929|Other|Asleep|"Sedation intervention.
~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
16628495|NCT02424916|Experimental|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
16628496|NCT02424903||with prosthetic joint infection|Patients admitted for a septic revision surgery
16628497|NCT02424903||without prosthetic joint infection|Patients admitted for an aseptic revision surgery
16628498|NCT02424890|Active Comparator|Repetitive Sim Group|9 simulation sessions
16628499|NCT02424890|Active Comparator|Control Group|3 simulation sessions
16628500|NCT02424877|Experimental|SandRA|cell phone monitoring
16628501|NCT02424877|No Intervention|Control|conventional monitoring
16628502|NCT02424864|Other|4D PET-CT|Other intervention: 4D PET-CT
16628503|NCT02424851|Active Comparator|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
16628504|NCT02424851|Active Comparator|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
16628505|NCT02424838|Active Comparator|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
16628506|NCT02424838|Active Comparator|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
16628507|NCT02424838|Active Comparator|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
16628508|NCT02424838|Active Comparator|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
16628509|NCT02424825|Experimental|Rouxbe|Subjects will attend a one-month online cooking course, and be followed before, during, and after their participation for quality-of-life, fatigue, and blood biomarker changes.
16628510|NCT02424812|Experimental|Intervention|school based handwashing education programme
16628511|NCT02424812|No Intervention|Control|no intervention
16628512|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
16628513|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
16628514|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
16628515|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
16628516|NCT02424786|Other|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.
~Feedback of this screening will be given to the team responsible for patient treatment."
16628517|NCT02424786|No Intervention|Control|Patients in this arm will receive standard pharmacological treatment
16628518|NCT02424773|Active Comparator|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
16628519|NCT02424773|Experimental|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
16628520|NCT02424747||De Novo Acute Kidney Injury|Patients who developed Acute Kidney Injury during intensive care admission and not previously diagnosed with chronic kidney disease or end stage renal disease.
16628521|NCT02424747||No Acute Kidney Injury.|Intensive care patients not diagnosed with acute kidney Injury during admission and not previously diagnosed with Chronic Kidney Disease or End Stage Renal Disease.
16628522|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
16628523|NCT02424708|Placebo Comparator|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
16628524|NCT02424708|Active Comparator|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
16628525|NCT02424708|Active Comparator|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
16628526|NCT02424695|Experimental|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks
~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
16628527|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
16628528|NCT02424669|Experimental|recently diagnosed ALS patients|
16628529|NCT02424669|Experimental|not recently diagnosed ALS patients|
16628530|NCT02424669|Active Comparator|patients with peripheral neuropathy, recently diagnosed|
16628531|NCT02424656||1|"Patients with TBI and DOC.
~Experimental measures (MRI, TMS-EEG, and clinical scales) will be performed at 4 time points: within 2 weeks of admission, 6-10 weeks after admission, at discharge, 1-year follow-up after TBI episode. FDG-PET will be performed in a subset of 25 patients at 3 time points: at admission, at discharge, and at 1-year follow-up."
16628532|NCT02424656||2|"Healthy patient-matched controls.
~Experimental measures (MRI, TMS-EEG, and FDG-PET) will be performed at 2 time points: within patient admission, and within patient discharge."
16628533|NCT02424643|No Intervention|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
16628534|NCT02424643|Experimental|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
16628535|NCT02424643|Experimental|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
16628536|NCT02424643|Experimental|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
16628537|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
16628538|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
16628543|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
16628544|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
16628545|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
16628546|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
16628547|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
16628548|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
16628549|NCT02424552|Experimental|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
16628550|NCT02424552|Placebo Comparator|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
16628551|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
16628552|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
16628553|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
16628554|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
16628555|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
16628556|NCT02424513|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
16628557|NCT02424500|Experimental|d-Nav Device|"d-Nav Device: daily use to provide insulin dosage updates weekly - or sooner when needed based on analyzes and evaluates the historical blood glucose patterns.
~Insulin dosage is adjusted as required"
16628558|NCT02424500|Active Comparator|Blood Glucose Monitoring System|"Patient's personal Over the Counter Blood Glucose Monitoring System (OTC BGMS) for daily glucose testing to determine insulin dosage needed.
~Insulin dosage is adjusted as required"
16628559|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
16628560|NCT02424474|Experimental|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
16628561|NCT02424461|Active Comparator|7 day-antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days
~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days
~Placebo of ofloxacine for 7 days"
16628562|NCT02424461|Active Comparator|14-day antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days
~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
16628563|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
16628564|NCT02424435|Experimental|Methylprednisolone|This is an open-label study of methylprednisolone in patients with FRDA. Subjects will begin oral administration of 48 mg methylprednisolone at day 1 and will decrease their administered dose by 8 mg per day. After 6 days, subjects will spend 22 days off medication before repeating the same treatment cycle. Last dosing cycle of methylprednisolone will be administered at 24 weeks after baseline. Visits will occur at weeks 2, 6, 14, 26, and 30 following baseline.
16628565|NCT02424409|Active Comparator|1: Control|
16628566|NCT02424409|Experimental|2: Intervention|
16628567|NCT02424396|Experimental|1 : IL2|Interleukin-2 (ILT-101)
16628568|NCT02424396|Placebo Comparator|2 : Placebo|Placebo
16628569|NCT02424383|Experimental|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
16628570|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
16628571|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
16628572|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
16628573|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
16628574|NCT02424331|Experimental|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
16628575|NCT02424318|Experimental|Topiramate|topiramate 25mg twice for 1 week -> topiramate 50mg twice for 7 weeks
16628576|NCT02424305|Experimental|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
16628577|NCT02424305|Experimental|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
16628578|NCT02424305|Experimental|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
16628579|NCT02424292||Physical activity|Physical activity in a personalised program
16628580|NCT02424279|Active Comparator|Surgical treatment|Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
16628581|NCT02424279|No Intervention|Conservative Treatment|Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
16628582|NCT02424266||Healthy subjects|None invasive imaging of the tear film for subjects with no eye disease
16628583|NCT02424266||keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)|None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
16628584|NCT02424253|Experimental|ZPL-3893787|30 mg ZPL-3893787 orally once daily for 8 weeks.
16628585|NCT02424253|Placebo Comparator|Placebo|1 capsule orally once daily for 8 weeks.
16628586|NCT02424240||IGF-I/ IGFBP-3 ratio group|
16628587|NCT02424240||IGF-1 and IGFBP-3|
16628588|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
16628589|NCT02424214|Experimental|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
16628590|NCT02424214|Experimental|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
16628591|NCT02424214|No Intervention|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
16628592|NCT02424201|Experimental|study|Intramuscular oxytocin 10 units, 400 micrograms of misoprostol
16628593|NCT02424201|Other|control|Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c
16628594|NCT02424188|Experimental|TRIUMPH intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
16628595|NCT02424188|No Intervention|Treatment as Usual|referral to quit line
16628596|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
16628597|NCT02424162|Experimental|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
16628598|NCT02424162|Active Comparator|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
16628599|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
16628601|NCT02424136|Other|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
16628602|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
16628603|NCT02424110|Experimental|Argon beam coagulator ablation group|In the bipolar left atrial radiofrequency ablation, when the linear ablation was performed through along the lower edge of interatrial groove incision up to the mitral annulus, there is a gap between the ends of the ablation line and the mitral annulus And in the bipolar right atrial radiofrequency ablation, when the linear ablation was performed along the lower edge of the coronary sinus ostium up to the inferoseptal commissure and through the vertical incision on anterior wall of the right atrium up to the tricuspid annulus. There also have gaps between ends of the ablation line and the tricuspid annulus. In the experimental group the investigators plan to use conventional bipolar radiofrequency ablation and use argon beam coagulator to ablate these gaps.
16628604|NCT02424110|Experimental|Bipolar radiofrequency ablation group|Only use conventional bipolar radiofrequency ablation and do not deal with these gaps.
16628605|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
16628606|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
16628607|NCT02424084|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16628608|NCT02424084|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16628609|NCT02424084|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16628610|NCT02424084|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16628611|NCT02424084|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16628612|NCT02424071|Active Comparator|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
16628613|NCT02424071|Placebo Comparator|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
16628614|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
16628615|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
16628616|NCT02424045|Other|BCD chemotherapy|"All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).
~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV"
16628617|NCT02424032|Experimental|Exercise and connective tissue massage|Stabilization exercise and connective tissue massage have been applied
16628618|NCT02424032|Active Comparator|Exercise|Only stabilization exercise has been applied
16628619|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
16628620|NCT02424006|Experimental|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
16628621|NCT02424006|Active Comparator|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
16628622|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
16628623|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
16628624|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
16628625|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
16628626|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
16628627|NCT02423967|Active Comparator|Transplant uses fresh familial stool|Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
16628628|NCT02423967|Experimental|Transplant uses frozen anonymous stool|Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
16628629|NCT02423954|Experimental|Arm 1|Temsirolimus 25 mg every 14 days + nivolumab
16628630|NCT02423954|Experimental|Arm 2|Irinotecan 150 mg/m2 every 14 days + nivolumab
16628631|NCT02423954|Experimental|Arm 3|Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
16628632|NCT02423941|Experimental|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
16628633|NCT02423941|Active Comparator|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
16628634|NCT02423928|Experimental|Cryoimmunotherapy|"Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.
~Update January 2019: The protocol was changed as approved by the Norwegian Medicines Agency and the Regional Ethical Committee in Western Norway for the 3 last patients of altogether 18 patients. Consequently, the 3 last patients received 200 mg i.v. of pembrolizumab (and no ipilimumab) post-CryoIT."
16628635|NCT02423915|Experimental|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Mesna administered on Day -8 immediately following completion of the Fludarabine.
~Total body radiation 2 Gy delivered on Day -4.
~3rd party CB Treg infusion on Day -1.
~Three (3) participants treated at cell dose level 1: 1 x 10^6/kg fucosylated T-reg cells. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD transplant on Day 0.
~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
16628636|NCT02423915|Experimental|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Total body radiation 2 Gy delivered on Day -4.
~3rd party CB Treg infusion on Day -1.
~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10^7/kg T-reg cells. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD infused on Day 0.
~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
16628637|NCT02423915|Experimental|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Total body radiation 2 Gy delivered on Day -4.
~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD infused on Day 0.
~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
16628638|NCT02423915|Experimental|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Total body radiation 2 Gy delivered on Day -4.
~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD infused on Day 0.
~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
16628639|NCT02423902|Experimental|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
16628640|NCT02423889|Experimental|1|Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty
16628693|NCT02423486|Experimental|Electromagnetic stimulation therapy with biofeedback|Electromagnetic stimulation therapy with biofeedback group
16628836|NCT02422615|Placebo Comparator|Ribociclib placebo + fulvestrant|Ribociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
16628643|NCT02423863|Experimental|Hiltonol Poly-ICLC|"Open labeled, non randomized adaptive 2-stage design protocol. 21 study subjects were enrolled in stage I of the protocol. Up to an additional 60 patients. . Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.
~For purposes of analysis patients enrolled in Stage II of this study will be prospectively identified at initial screening as belonging to statistical Cohorts A, B, or C, which are based on patient status with regard to aPD1/aPDL1 therapy at study entry, (PD, SD, or treatment naïve). For purposes of this study, patient status is considered to be the primary eligibility variable, although sub analyses will also consider histology and particular checkpoint blocker used when possible."
16628644|NCT02423850||Diabetic foot ulcers|Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
16628645|NCT02423824|Active Comparator|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
16628646|NCT02423824|Active Comparator|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
16628647|NCT02423811|Experimental|CCRT plus Fursultiamine|"Fursultiamine 100mg tid, po Radiotherapy 36Gy/18Fx Chemotherapy will include Cisplatin and 5-FU. Cisplatin 60-75 mg/m2 on days 1 and 29 with standard prehydration and antiemetic therapy.
~5-FU 600-1000 mg/m2day administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1 through 4 and 29 through 32"
16628648|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).
~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
16628649|NCT02423772|Experimental|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
16628650|NCT02423772|No Intervention|Treatment as Usual|
16628651|NCT02423759|Active Comparator|ciprofloxacin|standard chemoprophylaxis [500mg ciprofloxacin twice daily for 3 days]
16628652|NCT02423759|Experimental|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis [standard chemoprophylaxis plus 160mg]
16628653|NCT02423759|Experimental|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
16628654|NCT02423746|Placebo Comparator|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.
~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
16628655|NCT02423746|Experimental|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.
~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
16628656|NCT02423733|No Intervention|Control|In addition to their usual clinical care will also be given written information about web sites that provide information on depression but will not be specifically directed to The Journal.
16628657|NCT02423733|Experimental|Computerized Therapy|In addition to their usual clinical care they will receive an invitation to use The Journal supported by an e-therapy coach who will provide patients with weekly email or telephone contact. The e-therapy coach will have a guideline script for each lesson of The Journal to reinforce the topic of each lesson, help identify and support patients in their goals and to coach them in goal setting and the techniques of problem solving.
16628658|NCT02423720|Other|Study Intervention|Audio-based mindfulness intervention A 8-week single arm pilot study will be conducted among Helen Diller Famiily Comprehensive Cancer Center (HDFCCC) patients with metastatic colorectal cancer receiving chemotherapy and their caregivers (44 participants, total). Participants will receive an informational booklet containing a practice log and an MP3 player containing an introductory lecture and guided meditations. Practice reminders will be sent via text messages. Weekly emails will contain practice instructions and links to validated questionnaires.
16628659|NCT02423707|Active Comparator|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
16628660|NCT02423707|Placebo Comparator|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
16628661|NCT02423694|Experimental|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).
~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
16628662|NCT02423694|Active Comparator|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
16628663|NCT02423681|Active Comparator|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
16628664|NCT02423681|Placebo Comparator|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
16628764|NCT02422966|Experimental|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
16628765|NCT02422966|Active Comparator|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
16628665|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
16628666|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
16628667|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
16628668|NCT02423655|Experimental|Deffered Dialysis Initiation|"Algorithm for deferred dialysis intervention:
~initiating dialysis in the absence of symptoms in patients with an eGFR of 5 ml/min /1.73 m2 or less"
16628669|NCT02423655|Active Comparator|Routine dialysis Initiation|"Algorithm for routine dialysis intervention:
~initiating dialysis in the absence of symptoms in patients with an eGFR of 7 ml/min /1.73 m2 (which is the average GFR for patients in Beijing to start dialysis )"
16628670|NCT02423642|Experimental|AKI requring CRRT and use regional citrate anticoagulation|CRRT use regional citrate anticoagulation
16628671|NCT02423642|Experimental|AKI requring CRRT and not use regional citrate anticoagulation|CRRT not use regional citrate anticoagulation
16628672|NCT02423629|Other|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
16628673|NCT02423616|Experimental|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
16628674|NCT02423603|Active Comparator|Paclitaxel + AZD5363|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
16628675|NCT02423603|Placebo Comparator|Paclitaxel + Placebo|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
16628676|NCT02423590|Active Comparator|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.
~Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.
~On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
16628677|NCT02423590|Experimental|Gemcitabine/carboplatin + Apatorsen|"Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.
~Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.
~Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
16628678|NCT02423577|Experimental|FF-3 dry powder|FF-3
16628679|NCT02423577|Placebo Comparator|Placebo|
16628680|NCT02423564|Active Comparator|Healthy Population with Digesta Lac|Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
16628681|NCT02423564|Placebo Comparator|Healthy Population with Placebo|Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
16628682|NCT02423551|No Intervention|Control|Usual diet
16628683|NCT02423551|Experimental|MRE|MRE consumption
16628684|NCT02423538|Experimental|single ascending doses|single ascending doses, oral tablets
16628685|NCT02423538|Placebo Comparator|Placebo|Placebo Comparator, oral tablets
16628686|NCT02423525|Experimental|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
16628687|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
16628688|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
16628689|NCT02423499||Autism Spectrum Disorder|Autism Spectrum Disorder adults without intellectual disability
16628690|NCT02423499||Bipolar Disorder|Bipolar Disorder adults during normothymic phase of illness
16628691|NCT02423499||Healthy Volonteers|Healthy adults
16628692|NCT02423486|Experimental|Electromagnetic stimulation therapy|Electromagnetic stimulation therapy group
16628694|NCT02423473|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
16628695|NCT02423473|Experimental|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
16628696|NCT02423460|Experimental|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
16628697|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
16628698|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
16628699|NCT02423434||Corneal Confocal Microscopy subjects|
16628700|NCT02423421|Active Comparator|Treatment group|The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor
16628701|NCT02423421|Placebo Comparator|Placebo group|The placebo group will have autologous faecal microbiota transplantation performed.
16628702|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
16628703|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
16628704|NCT02423395|Experimental|Orphenadrine(Norflex)|50 patients will be treated with orphenadrine 100 mg twice daily for 1 month
16628705|NCT02423395|Placebo Comparator|Placebo|50 patients will be given placebo
16628706|NCT02423382|Other|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
16628707|NCT02423382|Other|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
16628708|NCT02423382|Other|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
16628709|NCT02423369|Experimental|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
16628710|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
16628711|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 1) Phase 1b|50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
16628712|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 2) Phase 1b|50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
16628713|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 3) Phase 1b|80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
16628714|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 4) Phase 1b|150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
16628715|NCT02423343|Experimental|Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16628716|NCT02423343|Experimental|Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16628717|NCT02423330|Experimental|Strattice-LIFT|
16628718|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
16628719|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
16628720|NCT02423304||test|"50 periodontitis patients
~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
16628721|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
16628766|NCT02422953|Experimental|Intervention|Wheat Soya Blend, Wawa Mum, Micronutrient Powders, Behavior change and preventive health massages
16628767|NCT02422953|No Intervention|Control|Control group will receive routine public and private health services available in the area.
16628722|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
16628723|NCT02423278|Experimental|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.
~Under this arm, main therapeutic measures are listed as follows:
~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy
~radical gastrectomy plus D4 lymphadenectomy
~five-cycle SOX chemo as adjuvant chemotherapy
~five-year follow-up program to evaluate the prognosis."
16628724|NCT02423278|Experimental|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.
~Under this arm, main therapeutic measures are included as follows:
~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy
~radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)
~five-cycle SOX chemo as adjuvant chemotherapy
~five-year follow-up program to evaluate the prognosis."
16628725|NCT02423265|Active Comparator|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
16628726|NCT02423265|Placebo Comparator|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
16628727|NCT02423252|Experimental|Intervention group|Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
16628728|NCT02423252|No Intervention|Control|Patients in control group will receive standard care only. Same records and outcome measures with intervention group will apply for control group as well.
16628729|NCT02423239|Experimental|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
16628730|NCT02423239|Experimental|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
16628731|NCT02423239|Experimental|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
16628732|NCT02423226|Active Comparator|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
16628733|NCT02423226|Experimental|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
16628734|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
16628735|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
16628736|NCT02423187||Arm 1|Participants with combination therapy (rabeprazole and low-dose aspirin)
16628737|NCT02423174||Total Mesorectal Excision|Patients with an indication for surgical intervention for a total mesorectal excision
16628738|NCT02423148|Experimental|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-
~Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system
~Treatment will be administered on an inpatient basis"
16628739|NCT02423135|Experimental|Blood bags without DEHP|Intervention : Autologous blood transfusion
16628740|NCT02423135|Experimental|Blood bags with DEHP|Intervention : Autologous blood transfusion
16628741|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
16628742|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
16628743|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
16628744|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
16628745|NCT02423096||Schizophrenia|Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).
16628746|NCT02423096||Healthy controls|No special intervention will be provided for healthy controls.
16628747|NCT02423083|Experimental|Treatment arm|
16628752|NCT02423018|Active Comparator|Pregabalin|Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
16628753|NCT02423018|Placebo Comparator|Placebo|Placebo for 10 days
16628754|NCT02423005|Experimental|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
16628755|NCT02423005|Active Comparator|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
16628756|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
16628757|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
16628758|NCT02422979|Experimental|PART 1 - Cohort 1|3-6 patients
16628759|NCT02422979|Experimental|PART 1 - Cohort 2|3-6 patients
16628760|NCT02422979|Experimental|PART 1 - Cohort 3|3-6 patients
16628761|NCT02422979|Experimental|PART 2 - Cohort 1|Number of patients depend on Part 1
16628762|NCT02422979|Experimental|PART 2 - Cohort 2|Number of patients depend on Part 1
16628763|NCT02422979|Experimental|PART 3|Up to 30 patients
16628834|NCT02422628||Healthy Volunteers|Blood samples once.
16628768|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.
~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
16628769|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.
~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
16628770|NCT02422927|Placebo Comparator|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
16628771|NCT02422927|Active Comparator|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
16628772|NCT02422914|Experimental|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
16628773|NCT02422914|Placebo Comparator|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
16628774|NCT02422914|Active Comparator|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
16628775|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
16628776|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
16628777|NCT02422888|Experimental|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
16628778|NCT02422888|Active Comparator|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
16628779|NCT02422875||Healthy Controls|Subjects are healthy persons without any autoimmune conditions or infectious diseases
16628780|NCT02422875||Autoimmune Disease|Subjects diagnosed with autoimmune disease including but not limited to: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome (SS), Scleroderma, Myositis, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), inflammatory arthritis, undifferentiated connective tissue disease, idiopathic thrombocytopenic purpura (ITP), Graft vs Host Disease (GVHD), Autoimmune Lymphoproliferative Syndrome (ALPS) and IgG4-related disease
16628781|NCT02422875||Infectious Disease|Subjects diagnosed with an infectious disease including but not limited to: Hepatitis C, Epstein Barr Virus (infectious mononucleosis - EBV), Sepsis, Guillain-Barre syndrome (GBS), Mycoplasma pneumoniae or Human Immunodeficiency Virus (HIV)
16628782|NCT02422875||Autoimmune - Family|Subjects have a brother, sister, mother, father, or child with an autoimmune disease
16628783|NCT02422875||Vaccination|Subjects have received or will receive a vaccination as part of regular standard of care from their healthcare provider or other outside source
16628784|NCT02422862|Experimental|UC-TSM|Upper cervical translatoric spinal mobilization (UC-TSM). UC-TSM is a physical therapy technique used to improve range of movement, consisting on a manual stretching of the cervical spine of the patient during 30 minutes.
16628785|NCT02422862|No Intervention|Control|The control group receive no treatment intervention during 30 minutes (a similar time as the UC-TSM group).
16628786|NCT02422849|Other|own GP|The patient is cared for by own General Practitioner in the acute stage
16628787|NCT02422849|Other|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
16628788|NCT02422836|Experimental|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:
~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
16628789|NCT02422823|Experimental|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
16628790|NCT02422823|Experimental|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
16628791|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
16628792|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
16628793|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
16628796|NCT02422784|Placebo Comparator|Control|Participants will be instructed to consume 240 mL of iced-tea daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
16628797|NCT02422784|Active Comparator|Rooibos Tea - Vitamin D3|Participants will be instructed to consume 240 mL of iced-tea fortified with 1000 IU water-soluable vitamin D3 daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
16628835|NCT02422615|Experimental|Ribociclib + fulvestrant|Ribociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
16629427|NCT02418780|No Intervention|Usual Care|Waitlist control group receiving usual medical care alone
16628798|NCT02422784|Active Comparator|Rooibos Tea- Vitamin D3 & Calcium|Participants will be instructed to consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water-soluable vitamin D3 and 360 mg of calcium daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
16628799|NCT02422771|No Intervention|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
16628800|NCT02422771|Experimental|Intervention group|FIFA 11+ warm-up
16628801|NCT02422758|Experimental|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
16628802|NCT02422758|Placebo Comparator|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
16628803|NCT02422745|Active Comparator|Cocoa extract + multivitamin|
16628804|NCT02422745|Active Comparator|Cocoa extract + multivitamin placebo|
16628805|NCT02422745|Active Comparator|Cocoa extract placebo + multivitamin|
16628806|NCT02422745|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
16628807|NCT02422732|Other|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
16628808|NCT02422732|Other|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
16628809|NCT02422719|Experimental|Radotinib|Radotinib treatement single arm
16628810|NCT02422706|Active Comparator|group I|"Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)& Clarithromycin 500 mg twice daily .for 14 days .
~40 patients"
16628811|NCT02422706|Experimental|Group II|"Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily & Clarithromycin 500 mg twice daily for 14 days.
~40 patients."
16628812|NCT02422706|Experimental|Group III|"Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily & Doxicycline 100 mg once daily (LOND).
~40 patients"
16628813|NCT02422693|Experimental|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
16628814|NCT02422693|Active Comparator|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
16628815|NCT02422680||Patients referred to a colonoscopy|A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.
16628816|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
16628817|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
16628818|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
16628819|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
16628820|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
16628821|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628822|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628823|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628824|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628825|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628826|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628827|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628828|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628829|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628830|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
16628831|NCT02422641|Experimental|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
16628832|NCT02422628||EGFR mutation postive|Blood samples every 3 months till disease progression or intolerable due to side effect.
16628833|NCT02422628||EGFR mutation wild type|Blood samples before treatment once.
16628837|NCT02422602|Active Comparator|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
16628838|NCT02422602|Experimental|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
16628839|NCT02422589|Experimental|Ceritinib|
16628840|NCT02422576|Active Comparator|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
16628841|NCT02422576|Active Comparator|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
16628842|NCT02422576|Active Comparator|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
16628843|NCT02422563|Experimental|Arm A: NACT+radical hysterectomy|Arm A includes patients for dose dense chemotherapy using TP (paclitaxel, carboplatin) or TIP (cisplatin, paclitaxel, ifosfamide) weekly for six cycles. Radical hysterectomy is performed after the 6th week + lymphadenectomy
16628844|NCT02422563|Other|Arm B: Chemoradiation|Arm B includes patients undergoing primary cisplatin based chemo-radiation
16628846|NCT02422537|Active Comparator|Unmodified wheat bran|One single dose om 20 g
16628847|NCT02422537|Active Comparator|Wheat bran with reduced particle size|One single dose of 20 g
16628848|NCT02422537|Active Comparator|Destarched pericarp-enriched wheat bran|One single dose of 20 g
16628849|NCT02422537|Other|No bran-based dietary platform|No wheat bran fractions is administered
16628854|NCT02422511|Active Comparator|Well Baby Family History Only|Parents of newborns in well-baby units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
16628855|NCT02422511|Experimental|Well Baby Family History + Exome Sequencing|Parents of newborns in well-baby units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
16628856|NCT02422511|Active Comparator|ICU Baby Family History Only|Parents of newborns in intensive care units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
16628857|NCT02422511|Experimental|ICU Baby Family History + Exome Sequencing|Parents of newborns in intensive care units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
16628858|NCT02422498|Experimental|Concurrent Cisplatin & Radiation Therapy|
16628859|NCT02422485|Experimental|Salsalate|All participants will be administered 2,250 mg daily [1,500 mg every day before noon (every AM) and 750 mg every night at bedtime (every HS)] for 6 months.
16628860|NCT02422472|No Intervention|Standard|Standard of care ultrasound guided peripheral IV placement
16628861|NCT02422472|Experimental|Experimental|Ultrasound guided peripheral IV placement with the use of a guidewire
16628862|NCT02422459|Experimental|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
16628863|NCT02422459|No Intervention|Wait-list control|No treatment assigned
16628864|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
16628865|NCT02422446|No Intervention|Control|Control group will not receive EPA
16628866|NCT02422433|Experimental|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
16628867|NCT02422420|Experimental|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
16628868|NCT02422420|Experimental|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
16628869|NCT02422420|Other|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
16628870|NCT02422407||Subgroup 1|Healthy Volunteers - subset of which 10 will receive salivary gland biopsy.
16628871|NCT02422407||Subgroup 2|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with positive biopsy result.
16628872|NCT02422407||Subgroup 3|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with negative biopsy result.
16628873|NCT02422407||Subgroup 4|Presenting with sicca but not satisfying the criteria of the AECCSS for diagnosis of pSS.
16628999|NCT02421549|No Intervention|Interrogation with Programmer|Interrogation with programmer Interrogation with programmer according to usual standard of care
16628874|NCT02422394|Experimental|Eltrombopag|"Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.
~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day."
16628875|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
16628876|NCT02422368|Experimental|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months
~Methylprednisolone includes :
~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
16628877|NCT02422368|Placebo Comparator|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
16628878|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
16628879|NCT02422329|Experimental|Educational Video|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
16628880|NCT02422329|Experimental|Fact Sheet|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants read educational material describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
16628881|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
16628882|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
16628883|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
16628884|NCT02422277|Active Comparator|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
16628885|NCT02422277|Active Comparator|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :
~- Oral intake of 50 mg once daily for 6 months."
16628886|NCT02422277|No Intervention|Control group|Patients will be only followed up without any therapy for assisting erection.
16628887|NCT02422264|Experimental|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
16628888|NCT02422264|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
16628889|NCT02422251|Experimental|Mobile high congruency bearing|Device B Braun Columbus total knee system using a rotating platform tibia and high congruency mobile bearing.
16628890|NCT02422251|Experimental|Fixed high congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and high congruency bearing.
16628891|NCT02422251|Experimental|Fixed low congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and low congruency bearing.
16628892|NCT02422251|No Intervention|Control|Healthy control group
16628893|NCT02422225|Experimental|Eldith DC-STIMULATOR group|"Intervention:
~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
16628894|NCT02422225|Sham Comparator|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
16628895|NCT02422212|Active Comparator|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
16628896|NCT02422212|Other|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
16628897|NCT02422212|Active Comparator|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
16628898|NCT02422199|Experimental|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
16628899|NCT02422199|Active Comparator|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
16629324|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
16628900|NCT02422186|Experimental|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16628901|NCT02422186|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16628902|NCT02422173|Experimental|Anodal tDCS|Participants in the acute post-stroke stage will receive anodal transcranial direct current stimulation
16628903|NCT02422173|Experimental|Cathodal tDCS|Participants in the acute post-stroke stage will receive cathodal transcranial direct current stimulation
16628904|NCT02422173|Experimental|Bilateral tDCS|Participants in the acute post-stroke stage will receive bilateral transcranial direct current stimulation
16628905|NCT02422173|Sham Comparator|Sham tDCS|Participants in the acute post-stroke stage will receive sham transcranial direct current stimulation
16628906|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
16628907|NCT02422134|Active Comparator|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
16628908|NCT02422134|No Intervention|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
16628909|NCT02422121|Experimental|RNS60|RNS60, 4 ml twice daily
16628910|NCT02422121|Placebo Comparator|Placebo|Normal Saline, 4 ml twice daily
16628911|NCT02422108|Experimental|intervention|Denosumab (Prolia) 60 mg s.c.
16628912|NCT02422095||Pancreatic fluid collections|Patients with pancreatic fluid collections undergoing endoscopy-based (EUS-guided) interventions
16628913|NCT02422095||Pancreatic cysts|Patients with pancreatic cysts undergoing EUS examination and possible EUS-guided sampling of cystic fluid.
16628914|NCT02422082|Active Comparator|L. reuteri|Lactobacillus reuteri (L. reuteri) ATCC PTA 6475 at a dose of 5 000 000 000 CFU as a powder in a stick-pack, orally twice daily (morning and evening) yielding a total daily dose of 10 000 000 000 CFU per day, for 12 months.
16628915|NCT02422082|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 12 months.
16628916|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
16628917|NCT02422056|Placebo Comparator|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
16628918|NCT02422056|Experimental|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
16628919|NCT02422043|Experimental|type 1 diabetes adolescents cohort|The participants of the prospective cohort of adolescents will be 12 to 17 years of age, type 1 diabetics with insulin, included in TPE program
16628920|NCT02422030|Experimental|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
16628921|NCT02422030|Experimental|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
16628922|NCT02422030|Experimental|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
16628923|NCT02422030|Experimental|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
16628924|NCT02422030|Experimental|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
16628925|NCT02422030|Experimental|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
16628926|NCT02422017|Experimental|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks in combination with dressings and compression.
16628927|NCT02422017|Other|Control|Local care treatment only (dressing and compression applied every other day)
16628928|NCT02422004|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have partial weight-bearing from day 0 and full weight-bearing from week 4. Furthermore, they were instructed in tendon strain exercise identical with the range of motion group.
16628929|NCT02422004|Experimental|Range of motion|Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
16629521|NCT02418130|Experimental|UDCA004|UDCA004
16628930|NCT02422004|Experimental|Immobilization|Delayed weight-bearing or range of motion (IMMOB). The immobilization group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks.
16628931|NCT02421991|Experimental|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
16628932|NCT02421991|Active Comparator|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
16628933|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
16628934|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
16628935|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
16628936|NCT02421965|Experimental|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
16628937|NCT02421965|Active Comparator|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
16628938|NCT02421952||Single Cohort|All subjects will be asked to assess their pain and nausea using the visual analogue scales (VAS), the modified faces scale and the BARF scale as described below in the preoperative and postoperative areas.
16628939|NCT02421939|Experimental|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
16628940|NCT02421939|Active Comparator|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
16628941|NCT02421926||IDEAL-E observational group|Subjects who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to 'IDEAL' study, finished the total study period of 'IDEAL' study or were dropped during the study period.
16628942|NCT02421913|Active Comparator|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
16628943|NCT02421913|Placebo Comparator|placebo group (PG)|PG received the same dose of saline.
16628944|NCT02421900||group 1|Atrial fibrillation patients
16628945|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
16628946|NCT02421887|Placebo Comparator|Placebo|
16628947|NCT02421874|Experimental|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
16628948|NCT02421874|Active Comparator|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
16628949|NCT02421861|Experimental|Anxiety Management (AM)|
16628950|NCT02421861|Placebo Comparator|Usual Care (UC)|
16628951|NCT02421848||Cirrhotic Patients With Ascites|Cirrhotic Patients With Ascites
16628952|NCT02421835|Placebo Comparator|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
16628953|NCT02421835|Active Comparator|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
16628954|NCT02421835|Placebo Comparator|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
16628955|NCT02421835|Active Comparator|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
16628956|NCT02421822|Experimental|Fitwits Intervention|Fitwits office tool and games
16628957|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
16628958|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
16628959|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
16628960|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
16628961|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
16628962|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
16628963|NCT02421783||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
16628964|NCT02421783||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group
16628965|NCT02421783||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group
16628966|NCT02421770|Experimental|Experimental Chamaemelum Nobile|"Experimental Chamaemelum Nobile 2% gel During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel twice daily with occlusion on the affected are"
16628967|NCT02421770|Placebo Comparator|Placebo|During the 6-week double-blind phase, all patients will be randomly assigned to receive vehicle ( placebo)twice daily with occlusion on the affected are
16628968|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
16628969|NCT02421757|Placebo Comparator|Sham Device|Sham Device
16628970|NCT02421744|Experimental|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
16628971|NCT02421744|Active Comparator|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
16628972|NCT02421731|Experimental|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
16628973|NCT02421731|Active Comparator|Conventional therapy|This group will receive conventional rehabilitation therapy.
16628974|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
16628975|NCT02421692|No Intervention|Usual Care|SNF rehabilitation therapists provide all patients with usual standard of care.
16628976|NCT02421692|Experimental|Progressive Rehabilitation|SNF rehabilitation therapists have been trained on principles of progressive rehabilitation strategies and will implement to all eligible patients as new standard of care.
16628977|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
16628978|NCT02421666|Experimental|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
16628979|NCT02421666|No Intervention|control|eligible chronic HBV patients received standard care
16628980|NCT02421653|Experimental|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
16628981|NCT02421653|Experimental|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
16628982|NCT02421653|Experimental|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
16628983|NCT02421653|Active Comparator|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
16628984|NCT02421640|Experimental|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
16628985|NCT02421640|Active Comparator|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
16628986|NCT02421627|Experimental|Moxibustion group|Receiving moxibustion treatment
16628987|NCT02421627|Sham Comparator|Sham moxibustion group|Receiving sham moxibustion.
16628988|NCT02421614|Experimental|high olive oli|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The percentage of olive oil will be half of total fat.
16628989|NCT02421614|Experimental|high sunflower oil|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The total fat will be sunflower oil.
16628990|NCT02421614|No Intervention|kitchen formula|A high protein kitchen diet for tube feeding will be administered to acute respiratory failure patients.
16628991|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
16628992|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
16628993|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin
~OR
~topotecan"
16628994|NCT02421575|Experimental|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
16628995|NCT02421575|Experimental|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
16628996|NCT02421575|Experimental|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
16628997|NCT02421562|Experimental|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
16628998|NCT02421549|Active Comparator|Interrogation with unpaired remote monitoring transmitter|Interrogation with unpaired remote monitoring transmitter Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
16629000|NCT02421536|Experimental|Vibrent Smartphone Application|"We propose to pilot the application of the mobile application VibrentTM (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline out of clinic assessment with the Vibrent smartphone application (research procedure)."
16629001|NCT02421523|Experimental|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of ~three times/week for 12 weeks.
16629002|NCT02421523|Active Comparator|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
16629003|NCT02421523|Experimental|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
16629004|NCT02421510|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
16629005|NCT02421510|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
16629006|NCT02421510|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
16629007|NCT02421497||Normal Healthy Volunteer|
16629008|NCT02421497||Non-CKD Control|
16629009|NCT02421497||Chronic Kidney Disease (CKD)|
16629010|NCT02421497||Dialysis Patients|
16629011|NCT02421497||Renal Transplant Recipients|
16629012|NCT02421484|Experimental|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
16629013|NCT02421471||Ingenol mebutate treatment cohort|Patients who are prescribed ingenol mebutate gel for the first time by investigator's medical judgment.
16629014|NCT02421458|Active Comparator|arm 1: 6 fractions of radiation|radiation in a 6 fractions scheme and a daily dose of 6 Gy
16629015|NCT02421458|Active Comparator|arm 2: 16 fractrions of radiation|radiation in a 16 fractions scheme and a daily dose of 3.125 Gy
16629016|NCT02421432|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
16629017|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
16629018|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
16629019|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
16629020|NCT02421406|Experimental|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
16629021|NCT02421406|Active Comparator|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
16629022|NCT02421393|Experimental|Exercise|Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
16629023|NCT02421393|No Intervention|Control|Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
16629024|NCT02421380|Experimental|Hyperpolarized Pyruvate MRI Reproducibility|This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
16629025|NCT02421367|Experimental|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.
~The placebo is sodium chloride.
~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.
~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
16629026|NCT02421367|Experimental|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.
~The placebo is sodium chloride.
~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.
~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
16629027|NCT02421367|Experimental|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.
~The placebo is sodium chloride.
~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.
~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
16629028|NCT02421354|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
16629053|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
16629054|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
16629029|NCT02421341|Experimental|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
16629030|NCT02421341|Placebo Comparator|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
16629031|NCT02421328|Active Comparator|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
16629032|NCT02421328|Active Comparator|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
16629033|NCT02421315|Experimental|OCD|Participants will have a current diagnosis of OCD.
16629034|NCT02421302|No Intervention|Well-nourished HIV+ ART naive|These children aged between 6months-12years will be followed up for 12weeks to look at their nutrition, immune and pharmacological responses. They will receive routine nutritional and ART adherence counseling
16629035|NCT02421302|Active Comparator|Moderately-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
16629036|NCT02421302|Active Comparator|Severely acute-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
16629037|NCT02421289|Experimental|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
16629038|NCT02421289|No Intervention|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
16629039|NCT02421276|Other|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
16629040|NCT02421276|Other|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
16629041|NCT02421263|Experimental|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
16629042|NCT02421263|Active Comparator|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
16629043|NCT02421250|Experimental|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
16629044|NCT02421250|No Intervention|Control|We will use standard-of-care for control group and not use the SpHb monitor.
16629045|NCT02421237|Experimental|Experimental condition|Narrative enhancement and cognitive therapy (NECT) groups. Structured psychoeducational and skills-training groups focused on self-stigma and its impact on people with schizophrenia
16629046|NCT02421237|Active Comparator|Control condition|Supportive group therapy groups. Unstructured supportive groups not focused on self-stigma.
16629047|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
16629048|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
16629049|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
16629050|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
16629051|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
16629052|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
16629522|NCT02418130|Placebo Comparator|Placebo of UDCA004|Placebo of UDCA004
16629055|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
16629056|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
16629057|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
16629058|NCT02421198|Experimental|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
16629059|NCT02421198|Experimental|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
16629060|NCT02421185|Experimental|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.
~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
16629061|NCT02421172|Experimental|Period 1: CJM112 High Dose|Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
16629062|NCT02421172|Placebo Comparator|Period 1: Placebo|Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
16629063|NCT02421172|Placebo Comparator|Period 2: CJM112 High Dose (Period 1) / Placebo (Period 2)|Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on CJM112 High Dose in Period 1
16629064|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 Low Dose (Period 2)|Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
16629065|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 High Dose (Period 2)|Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
16629066|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
16629067|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
16629068|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
16629069|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
16629070|NCT02421133|Experimental|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
16629071|NCT02421133|Other|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
16629072|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
16629073|NCT02421107|Other|all patients|all patients
16629074|NCT02421094|Active Comparator|GR-MD-02|Active
16629075|NCT02421094|Placebo Comparator|Placebo|Placebo
16629076|NCT02421081|Active Comparator|having arteriel cut|30 patients who refer to Erciyes University emergency department because of wrist laceration with radial and/or ulnar artery incision,will be presenting to the study.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery,under a microscope using microsurgical techniques and polyamide suture will be held vascular repair.Patients will be assessed by Doppler ultrasonography again 4 weeks after surgery;flow velocity and vessel diameter will be measured at the anastomoses line and patient will be divided to 4 groups. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; The relationship between the anastomosis opening will be evaluated statistically.
16629109|NCT02420834|Experimental|Tear Supplement Carboxymethylcellulose|Tear Supplement 3: Preservative free 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears) applied as required for 1 month
16629110|NCT02420834|Experimental|Tear Supplement Liposomal spray|Preservative free Phospholipid liposomal spray (Tears Again) applied as required for 1 month
16629325|NCT02419456|Experimental|MK-2048A Intravaginal Ring (IVR) (Low Dose)|The MK-2048A IVR (Low Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
16629077|NCT02421081|Active Comparator|having tendon cut|10 patients having similar age and sex with first group, who refer to Erciyes University emergency department because of wrist laceration without radial or ulnar artery cutting,will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery to repair tendons and/or nerves. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; and will compare with first group.
16629078|NCT02421081|No Intervention|healthy control|10 healty having similar age and sex with first group,controls who accept to give blood to determine normal range of serum CD34,CD133 and CD 309 will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.
16629079|NCT02421068||Preterm neonates|All neonates that receive at least one of the 9 drugs (phenobarbital, paracetamol, levetiracetam, midazolam, sildenafil, fentanyl, doxapram, ibuprofen, fluconazole) are included in the studied cohort
16629080|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
16629081|NCT02421055||Group 2|Sleeve Gastrectomy
16629082|NCT02421042|Experimental|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
16629083|NCT02421029|Experimental|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
16629084|NCT02421016|Experimental|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
16629085|NCT02421016|Active Comparator|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
16629086|NCT02421003|Experimental|Patients|Patients undergoing heart surgery
16629087|NCT02420990|Active Comparator|Behavioral Only- Treatment|All participants will receive behavioral interventions (CASH-AA): family psycho-education in ADHD symptoms, executive functioning, and developmental impacts; family-based motivation and ADHD accommodation interventions; and academic training focused on home environment support and organizational skills.
16629088|NCT02420990|Experimental|Integrated Treatment|Half of the participants will also receive medication decision-making interventions (MIP): ADHD medication psychoeducation, family decision-making interventions, and (for those who elect to start medication) coordinated medication management.
16629089|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT
~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
16629090|NCT02420964|Other|Nurse instruction|Traditional injection teaching method. No video instruction
16629091|NCT02420964|Other|Video instruction|Video instruction that can be paused/repeated by subject
16629092|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
16629093|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
16629094|NCT02420938|Experimental|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
16629095|NCT02420925|Experimental|Celiac Plexus Block|There is one treatment arm who undergoes celiac plexus block.
16629096|NCT02420912|Experimental|Cohort I (nivolumab, ibrutinib)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16629097|NCT02420912|Experimental|Cohort II (nivolumab, previous ibrutinib)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
16629098|NCT02420912|Experimental|Cohort III (nivolumab, ibrutinib)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16629099|NCT02420899|Experimental|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
16629100|NCT02420886|Active Comparator|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
16629101|NCT02420886|No Intervention|Traditional Single step culture media|
16629102|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
16629103|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
16629104|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
16629105|NCT02420860|Experimental|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16629106|NCT02420847|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|Patients receive ixazomib citrate PO, gemcitabine hydrochloride IV over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16629107|NCT02420834|Experimental|Tear Supplement Hypromellose 0.15%|Preservative free Hypromellose Eye Drops BP 0.15% applied as required for 1 month
16629108|NCT02420834|Experimental|Tear Supplement Hypromellose 0.4%|Preservative free Hypromellose Eye Drops BP 0.4% applied as required for 1 month
16629113|NCT02420795|Experimental|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16629114|NCT02420782|Experimental|ASP6282 single ascending dose (fasted)|Part 1
16629115|NCT02420782|Placebo Comparator|Placebo single ascending dose (fasted)|Part 1
16629116|NCT02420782|Experimental|ASP6282 single dose (fed)|Part 1
16629117|NCT02420782|Placebo Comparator|Placebo single dose (fed)|Part 1
16629118|NCT02420782|Experimental|ASP6282 single dose (fasted)|Part 1 Period 1
16629119|NCT02420782|Experimental|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
16629120|NCT02420782|Experimental|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
16629121|NCT02420782|Placebo Comparator|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
16629122|NCT02420782|Experimental|ASP6282 and pilocarpine|Part 3
16629123|NCT02420782|Other|Placebo and pilocarpine|Part 3
16629124|NCT02420769||Threatened abortion|Pregnant patients > 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.
16629125|NCT02420730|Experimental|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
16629126|NCT02420730|Experimental|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
16629127|NCT02420730|Experimental|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
16629128|NCT02420730|Placebo Comparator|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
16629129|NCT02420730|Experimental|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
16629130|NCT02420730|Experimental|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
16629131|NCT02420730|Experimental|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
16629132|NCT02420730|Placebo Comparator|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
16629133|NCT02420717|Experimental|Cohort A (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16629134|NCT02420717|Experimental|Cohort B (dasatinib)|Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16629135|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
16629136|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
16629137|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
16629138|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
16629139|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
16629140|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
16629141|NCT02420691|Experimental|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16629255|NCT02419820|Experimental|APD791 40mg|APD791 40mg single dose + Aspirin + Clopidogrel
16629256|NCT02419820|Experimental|APD791 80mg|APD791 80mg single dose + Aspirin + Clopidogrel
16629257|NCT02419820|Experimental|APD791 160mg|APD791 160mg single dose + Aspirin + Clopidogrel
16629258|NCT02419820|Experimental|APD791 240mg|APD791 240mg single dose + Aspirin + Clopidogrel
16629142|NCT02420665|Experimental|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
16629143|NCT02420652|Experimental|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
16629144|NCT02420652|Placebo Comparator|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
16629145|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
16629146|NCT02420613|Experimental|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.
~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
16629147|NCT02420613|Experimental|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
16629148|NCT02420587|Experimental|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
16629149|NCT02420574|Active Comparator|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
16629150|NCT02420574|Active Comparator|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
16629151|NCT02420561|Experimental|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
16629152|NCT02420561|Active Comparator|Control|Participants received a brochure on alcohol and drug use risks.
16629153|NCT02420548|Active Comparator|Services as Usual|Participants continue with any services they may be receiving outside of the study.
16629154|NCT02420548|Experimental|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
16629155|NCT02420535|Experimental|Immediately Receive Tool|Caregiver/Care Recipient Dyad will be randomly assigned to immediately receive the WeCareAdvisor Tool for 4 weeks.
16629156|NCT02420535|Active Comparator|One Month Delay|Caregiver/Care Recipient Dyad will be randomly assigned to a 4 week delay (usual care activities only) before receiving the WeCareAdvisor Tool for 4 weeks.
16629157|NCT02420522|Experimental|Active-first|Participants randomly assigned to this arm will receive one week of active Repetitive Transcranial Magnetic Stimulation prior to one week of Sham Transcranial Magnetic Stimulation, separated by at least one week.
16629158|NCT02420522|Experimental|Sham-first|Participants randomly assigned to this arm will receive one week of Sham Transcranial Magnetic Stimulation prior to one week of active Repetitive Transcranial Magnetic Stimulation, separated by at least one week.
16629159|NCT02420522|Active Comparator|Full-course Active|Participants in this arm will receive three weeks (30 session, twice-daily) of active Repetitive Transcranial Magnetic Stimulation. This arm will not involve random assignment.
16629160|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
16629161|NCT02420496|Experimental|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
16629162|NCT02420496|Active Comparator|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
16629163|NCT02420496|Placebo Comparator|Placebo|Infant will receive placebo in two daily doses given enterally
16629164|NCT02420483|Experimental|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
16629165|NCT02420470||healthy control group|fasting plasma glucose(FPG)<6.11mmol/L，and 2-h plasma glucose(2hPG)<7.77mmol/L；
16629166|NCT02420470||prodromal diabetes group|IFG：fasting plasma glucose(FPG) ≥5.6mmol/L (100mg/dl)，and<7.0mmol/L (126mg/dl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) <7.8 mmol/L ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol/L (140mg/dl)，and<11.1mmol/L (200mg/dl)，fasting plasma glucose(FPG)< 5.6mmol/L
16629167|NCT02420470||diabetes group|fasting plasma glucose(FPG)>7.0mmol/L, or 2-h plasma glucose(2hPG)>11.1mmol/L
16629168|NCT02420457||Back pain receiving epidural injection|Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
16629169|NCT02420444|Placebo Comparator|BCG SSI prime with Placebo|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.
~Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231."
16629259|NCT02419820|Experimental|APD791 320mg|APD791 320mg single dose + Aspirin + Clopidogrel
16629260|NCT02419820|Placebo Comparator|APD791 Placebo|APD791 placebo for single dose + Aspirin + Clopidogrel
16629170|NCT02420444|Experimental|BCG SSI prime with Placebo and AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.
~Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231.
~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:
~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.
~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
16629171|NCT02420444|Experimental|BCG SSI prime with AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.
~AERAS-404 50/500 on Study Days 0, 56, and 231.
~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:
~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.
~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
16629172|NCT02420431|Experimental|metacognitive therapy plus CR|Group psychological treatment focused on reducing worry and rumination and modifying beliefs about thinking in addition to treatment as usual (standard cardiac rehabilitation)
16629173|NCT02420431|Active Comparator|CR alone (control)|Usual group-based cardiac rehabilitation (treatment as usual) involving stress management, exercise, education
16629174|NCT02420418|Active Comparator|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .
~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
16629175|NCT02420418|Placebo Comparator|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.
~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .
~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
16629176|NCT02420405|Placebo Comparator|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
16629177|NCT02420405|Experimental|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
16629178|NCT02420392|Experimental|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
16629179|NCT02420392|No Intervention|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
16629180|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
16629181|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
16629182|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
16629183|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
16629184|NCT02420340|Other|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
16629185|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
16629186|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
16629187|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
16629188|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
16629189|NCT02420314|Experimental|Ascorbate, paclitaxel, carboplatin|Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks
16629190|NCT02420301|Experimental|Exercises on real points|Self administered exercises were done in real treatment points
16629191|NCT02420301|Placebo Comparator|Exercises on false points|Self administered exercises were done in false treatment points
16629192|NCT02420288|No Intervention|Control Group|Pregnant women not participating in supervised physical exercise program. The subjects in this group will be monitored during pregnancy to know if they make any kind of exercise on your own, to know which are really sedentary pregnant women.
16629193|NCT02420288|Experimental|Exercise Group|Pregnant women participating in supervised physical exercise program.
16629194|NCT02420275|Placebo Comparator|Severe brain injury patient|Severe brain injury patients with placebo
16629195|NCT02420275|Experimental|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
16629196|NCT02420262|Experimental|IDegLira|
16629197|NCT02420262|Active Comparator|IGlar plus IAsp|
16629198|NCT02420249|Experimental|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
16629199|NCT02420249|No Intervention|Control group|Participants in the control group will receive no Qigong training.
16629200|NCT02420236|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
16629261|NCT02419820|Experimental|APD791 2mg MD|APD791 2mg multiple dose + Aspirin + Clopidogrel
16629262|NCT02419820|Experimental|APD791 5mg MD|APD791 5mg multiple dose + Aspirin + Clopidogrel
16629263|NCT02419820|Experimental|APD791 10mg MD|APD791 10mg multiple dose + Aspirin + Clopidogrel
16629201|NCT02420236|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
16629202|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
16629203|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
16629204|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16629205|NCT02420197|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
16629206|NCT02420197|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
16629207|NCT02420184|Experimental|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
16629208|NCT02420184|Placebo Comparator|No CPAP|Participants will receive standard medical care for CKD.
16629209|NCT02420171|Active Comparator|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
16629210|NCT02420171|No Intervention|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
16629211|NCT02420158|Experimental|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
16629212|NCT02420145|Experimental|Yoga|This group will participate in 12 weeks of yoga
16629213|NCT02420145|No Intervention|Waitlist|No intervention
16629214|NCT02420132||Main Study|Decentralized participant recruitment, participant and local ophthalmologist compliance, and use of the mVT mobile medical application in a more geographically diverse, decentralized cohort of participants with DME or nAMD receiving intravitreal ranibizumab therapy as part of standard-of-care treatment.
16629215|NCT02420132||Traditional Substudy|"Subset of participants enrolled through a single investigator who will determine visual acuity and anatomical markers of disease status using clinical gold standard assessments (certified ETDRS protocol visual acuity and macula OCT)."
16629216|NCT02420106|Active Comparator|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
16629217|NCT02420106|Active Comparator|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
16629218|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
16629219|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
16629220|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:
~Clinical progression to probable or definitive disseminated AdV disease Death"
16629221|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
16629222|NCT02420054|Active Comparator|Intermittent fasting|Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
16629223|NCT02420054|Active Comparator|Time control|A time control period.
16629224|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
16629264|NCT02419820|Experimental|APD791 20mg MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
16629265|NCT02419820|Placebo Comparator|APD791 placebo MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
16629422|NCT02418793|Experimental|Dose Cohort 3|MOD-5014 Dose cohort 3
16629225|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
16629226|NCT02420028|Experimental|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
16629227|NCT02420028|Active Comparator|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
16629228|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
16629229|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
16629230|NCT02420002|Active Comparator|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.
~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
16629231|NCT02420002|Experimental|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).
~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
16629232|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
16629233|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
16629234|NCT02419963|Other|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
16629235|NCT02419963|Other|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
16629236|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
16629237|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
16629238|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
16629239|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
16629240|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
16629241|NCT02419911|Other|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
16629242|NCT02419911|Other|Clearify|Clearify Visualization System used during laparoscopic surgery
16629243|NCT02419898||Feasibility Study|Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
16629244|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
16629245|NCT02419859|Experimental|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
16629246|NCT02419846|Experimental|Men over 40: Screening with intervention|Participants over the age of 40 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences. Participants may undergo a screening exam comprising a prostate specific antigen level and digital rectal exam.
16629247|NCT02419846|Experimental|Men 18-39: Educational intervention|Participants between 18 and 39 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences.
16629248|NCT02419833|Experimental|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
16629249|NCT02419833|Active Comparator|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and within 2-72 hours of admission
16629250|NCT02419820|Experimental|APD791 10mg single dose|APD791 10mg single dose
16629251|NCT02419820|Experimental|APD791 20mg single dose|APD791 20mg single dose
16629252|NCT02419820|Experimental|APD791 40mg single dose|APD791 40mg single dose
16629253|NCT02419820|Experimental|APD791 10mg|APD791 10mg single dose + Aspirin + Clopidogrel
16629254|NCT02419820|Experimental|APD791 20mg|APD791 20mg single dose + Aspirin + Clopidogrel
16629423|NCT02418793|Experimental|Dose Cohort 4|MOD-5014 Dose cohort 4
16629266|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
16629267|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
16629268|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
16629269|NCT02419781|Active Comparator|Group with endovascular treatment|Group with additional endovascular treatment
16629270|NCT02419781|Active Comparator|Group without endovascular treatment|Group without additional endovascular treatment
16629271|NCT02419768|Experimental|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
16629272|NCT02419768|No Intervention|Control|All patients will not change their physical activities
16629273|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
16629274|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
16629275|NCT02419742|Experimental|Trastuzumab|Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
16629276|NCT02419729|Experimental|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
16629277|NCT02419729|Active Comparator|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
16629278|NCT02419729|Sham Comparator|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
16629279|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
16629280|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
16629281|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
16629282|NCT02419677|Other|RFA alone|Patients undergo radiofrequency ablation alone.
16629283|NCT02419677|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA.
16629284|NCT02419664|Experimental|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT
~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
16629285|NCT02419651|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
16629286|NCT02419651|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
16629287|NCT02419651|Placebo Comparator|Placebo|Women will receive oral placebo 1 hour before the procedure.
16629288|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
16629289|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
16629290|NCT02419625|Other|subgroup-specific HEV in Israel|The study will involve patient interviews using questionnaires
16629291|NCT02419612|Experimental|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
16629292|NCT02419612|Experimental|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
16629293|NCT02419599|Experimental|Group A|The group who will receive high energy density, low volume oral nutritional supplement, to be taken for 4 weeks (28 days)
16629294|NCT02419599|Active Comparator|Group B|The group who will receive the standard energy density oral nutritional supplement, to be taken for 4 weeks (28 days)
16629295|NCT02419586|Experimental|bubble gum chewing and routine care|Start chewing gum on postoperative day at three times daily with no more than 30 minutes till discharged
16629296|NCT02419586|No Intervention|routine care|Non interventional group will receive existing routine care as usual
16629297|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
16629298|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
16629299|NCT02419560|Experimental|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
16629300|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
16629320|NCT02419495|Experimental|Arms N and O (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1, and ipilimumab PO QD on day 1. Cycles repeat every 3 weeks for 4 cycles. Starting cycle 5, patients receive selinexor PO on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16629321|NCT02419482|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
16629301|NCT02419534|Active Comparator|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
16629302|NCT02419534|Active Comparator|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
16629303|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
16629304|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
16629305|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
16629306|NCT02419495|Experimental|Arm A (selinexor, carboplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
16629307|NCT02419495|Experimental|Arm B (selinexor, paclitaxel)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) on days 1-14. Patients then receive selinexor PO on days 1, 3, 8 and 10 and paclitaxel IV over 3 hours on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After 8 cycles of combination treatment, patients can continue single agent selinexor until disease progression.
16629308|NCT02419495|Experimental|Arm C (selinexor, eribulin)|Patients receive selinexor PO on days 1, 8, and 15 and eribulin IV over 1 hour on days 1 and 8. Combination treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
16629309|NCT02419495|Experimental|Arm D (selinexor, doxorubicin, cyclophosphamide) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15, doxorubicin IV over 90 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
16629310|NCT02419495|Experimental|Arm E (selinexor, carboplatin, paclitaxel) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for up to 8 cycles depending con cancer type (6 cycles for non-small cell lung cancer, up to 8 cycles for ovarian cancer and other histological malignancies) in the absence of disease progression or unacceptable toxicity. After 6 to 8 cycles, patients can continue single agent selinexor until disease progression.
16629311|NCT02419495|Experimental|Arm F (selinexor, carboplatin, pemetrexed) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
16629312|NCT02419495|Experimental|Arm G (selinexor, topotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
16629313|NCT02419495|Experimental|Arm H (selinexor, FOLFIRI) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15 and 22, irinotecan hydrochloride IV over 90 minutes, fluorouracil IV continuously over 48 hours and leucovorin calcium IV over 2 hours on days 1 and 15. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
16629314|NCT02419495|Experimental|Arm I (selinexor, irinotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
16629315|NCT02419495|Experimental|Arm J (selinexor, capecitabine, oxaliplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15, capecitabine PO twice daily (BID) on days 1-14 and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
16629316|NCT02419495|Experimental|Arm K (selinexor, olaparib) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15, and 22 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16629317|NCT02419495|Experimental|Arm L (selinexor, pembrolizumab)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16629318|NCT02419495|Experimental|Arm M (selinexor, nivolumab|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16629319|NCT02419495|Experimental|Arm P (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, 15, 22, 29, and 36, nivolumab IV over 30 minutes on days 1, 15, and 29, and ipilimumab PO QD on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16629322|NCT02419482|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
16629323|NCT02419482|No Intervention|control|Physical activity recommended
16629424|NCT02418793|Experimental|Dose Cohort 5|MOD-5014 Dose cohort 5
16629326|NCT02419456|Experimental|MK-2048A IVR (Original Dose)|The MK-2048A IVR (Original Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
16629327|NCT02419443|Placebo Comparator|Placebo|Patients randomized to the placebo-group were administered placebo-pills orally one hour prior to surgery, then three times a day for a maximum of 6 total doses.
16629328|NCT02419443|Active Comparator|Gabapentin|Patients randomized to the gabapentin-group were administered 300 mg orally one hour prior to surgery, then three times a day for a maximum of 6 total dose.
16629329|NCT02419430|Active Comparator|MBRT ClassRoom and Phone Application|MBRT ClassRoom and Phone Application
16629330|NCT02419430|Active Comparator|Phone application only|Phone application only
16629331|NCT02419430|Active Comparator|Questionnaires|Questionnaires
16629332|NCT02419417|Experimental|Monotherapy Treatment|Patients treated at various doses and schedules
16629333|NCT02419417|Experimental|Combination Therapy|Patients treated at selected doses and schdules
16629334|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
16629335|NCT02419391|Experimental|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
16629336|NCT02419391|Experimental|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
16629337|NCT02419391|Experimental|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
16629339|NCT02419365||PCD|Individuals with Primary Ciliary Dyskinesia will be assessed in a pure observational design without intervention
16629340|NCT02419352|Active Comparator|Sugammadex|Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
16629341|NCT02419352|Active Comparator|Neostigmine/atropine|Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
16629342|NCT02419326|Experimental|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
16629343|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
16629344|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
16629345|NCT02419287|Experimental|crizotinib|250mg BID
16629346|NCT02419261|Active Comparator|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
16629347|NCT02419261|Active Comparator|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
16629348|NCT02419235|Placebo Comparator|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
16629349|NCT02419235|Experimental|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
16629350|NCT02419222|Experimental|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
16629351|NCT02419209|Experimental|Individualised Homeopathic Remedy|A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.
16629352|NCT02419196||abdominal surgery|27 patients undergoing abdominal surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
16629353|NCT02419196||limb surgery|27 patients undergoing upper and lower limb surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
16629354|NCT02419196||flail chest|10 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
16629355|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
16629356|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
16629357|NCT02419170|Experimental|Surgery/Apheresis/Cyclophosphamide/Vaccine|"Standard of care surgery
~Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery
~Cyclophosphamide 300 mg/m^2 intravenously (Day -4)
~Personalized vaccine (Day 1)
~Booster dose of personalized vaccine (Day 43)
~Booster dose of personalized vaccine (Day 85)"
16629358|NCT02419157|Active Comparator|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~Selective enamel etching with 36% phosphoric acid"
16629359|NCT02419157|Active Comparator|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~Selective enamel etching with 36% phosphoric acid"
16629360|NCT02419157|Active Comparator|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~No selective enamel etching with 36% phosphoric acid"
16629361|NCT02419157|Active Comparator|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~No selective enamel etching with 36% phosphoric acid"
16629362|NCT02419144|Active Comparator|AMI followed by campaigns|Behavioral interventions
16629363|NCT02419144|Active Comparator|Campaigns followed by AMI|Behavioral interventions
16629364|NCT02419131|Experimental|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
16629365|NCT02419131|Experimental|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
16629366|NCT02419131|Active Comparator|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
16629367|NCT02419118|Experimental|Dara len dex|Daratumumab in combination with lenalidomide and dexamethasone
16629368|NCT02419118|Active Comparator|Len dex|Lenalidomide in combination with dexamethasone
16629369|NCT02419105|Active Comparator|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
16629370|NCT02419105|Active Comparator|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
16629371|NCT02419105|Active Comparator|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
16629372|NCT02419105|Placebo Comparator|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
16629373|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
16629374|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
16629375|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 >=350
16629376|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 >=350
16629377|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 <200
16629378|NCT02419053||Pre-checklist|Surgical interventions performed for children before the introduction of the surgical safety checklist in Ontario, from October 2008 to September 2009.
16629379|NCT02419053||Post-checklist|Surgical interventions performed for children after the introduction of the surgical safety checklist in Ontario, from October 2010 to September 2011.
16629380|NCT02419040|Experimental|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
16629381|NCT02419040|Active Comparator|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
16629382|NCT02419040|Sham Comparator|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
16629383|NCT02419027|Experimental|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
16629384|NCT02419027|Placebo Comparator|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
16629385|NCT02419014|No Intervention|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
16629386|NCT02419014|Active Comparator|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
16629387|NCT02419014|Placebo Comparator|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
16629425|NCT02418793|Experimental|Dose Cohort 6|Highest MOD-5014 dose tested in the study
16629426|NCT02418780|Experimental|Tai Chi|6-month Tai Chi training program combined with usual medical care
16629388|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:
~Period 1: Ceftriaxone 1 g infused IV over 30 minutes
~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
16629389|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes
~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
16629390|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:
~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]
~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
16629391|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]
~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
16629392|NCT02418988|Experimental|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
16629393|NCT02418988|Active Comparator|TACE|TACE will be applied alone
16629394|NCT02418975|Experimental|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
16629395|NCT02418975|Active Comparator|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
16629396|NCT02418962|Experimental|Group 1 (pilot group)|Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10^5 and 2.7x10^5 PfSPZ.
16629397|NCT02418962|Experimental|Group 2|The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks
16629398|NCT02418962|Placebo Comparator|Group 3|The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.
16629399|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
16629400|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.
~Dose will be titrated down to zero in the 2 weeks following treatment."
16629401|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.
~Dose will be titrated down to zero in the 2 weeks following treatment."
16629402|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
16629403|NCT02418936||WS|WS diagositic kit
16629404|NCT02418936||LVAS|LVAS diagositic kit
16629405|NCT02418910||bipolar outpatients|Patients with Bipolar Disorder in any clinical state
16629406|NCT02418884|Other|CAD+DM|Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.
16629407|NCT02418871|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
16629408|NCT02418858|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
16629409|NCT02418858|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
16629410|NCT02418845|Experimental|SYM-1219|Administered orally
16629411|NCT02418845|Placebo Comparator|Placebo|Administered orally
16629412|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
16629413|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
16629414|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
16629415|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
16629416|NCT02418819|Placebo Comparator|Placebo|Placebo BID
16629417|NCT02418806|Experimental|Therapy group with follow up sessions|Weekly psychotherapy groups during 4 months with a monthly follow up period (12 months)
16629418|NCT02418806|Experimental|Therapy group without follow up sessions|Weekly psychotherapy groups during 4 months
16629419|NCT02418806|Active Comparator|Active comparator group|Weekly self-help groups during 4 months with a monthly follow up period (12 months)
16629420|NCT02418793|Experimental|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
16629421|NCT02418793|Experimental|Dose Cohort 2|MOD-5014 Dose cohort 2
16629428|NCT02418767|Experimental|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
16629429|NCT02418767|Experimental|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
16629430|NCT02418767|Experimental|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
16629431|NCT02418754|Experimental|REGN2176-3 (1 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
16629432|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
16629433|NCT02418754|Experimental|Intravitreal Aflibercept Injection (IAI) 2 mg|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
16629434|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg) to IAI 2 mg|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
16629435|NCT02418754|Experimental|IAI 2 mg to REGN2176-3 (3 mg:2 mg)|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
16629436|NCT02418741|Experimental|Degree of neck flextion|Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow
16629437|NCT02418728||persons with obesity|
16629438|NCT02418728||lean persons|
16629439|NCT02418715|Experimental|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
16629440|NCT02418715|No Intervention|Control|No training, no intervention.
16629441|NCT02418702|Experimental|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
16629442|NCT02418702|Placebo Comparator|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
16629443|NCT02418689|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
16629444|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
16629445|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
16629446|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
16629447|NCT02418663|Other|Postoperative elective surgical patients|Patients undergoing major elective thoracic and abdominal, the latter group including upper gastrointestinal, esophageal, and colorectal procedures. In this group FR will predicted by administering a fluid challenge of 250 ml of Lactated Ringer's solution and measuring SV with the ccNexfin
16629448|NCT02418650|Experimental|Part 1|A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
16629449|NCT02418650|Experimental|Part 2|A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
16629450|NCT02418637|Experimental|Farm workers|This is a one arm intervention including farm workers and owners
16629451|NCT02418624|Experimental|Dose escalation|carboplatin, olaparib
16629452|NCT02418598|Experimental|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
16629453|NCT02418598|Experimental|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
16629454|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16629455|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16629456|NCT02418572|Experimental|Transdermal testosterone gel|"Patients will receive once daily application of 0.55 gr TTG (Testosterone gel 1%; Laboratories Besins International,Paris,France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.
~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.
~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.
~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
16629457|NCT02418572|Placebo Comparator|Placebo transdermal gel|"Patients will receive once daily application of 0.55 gr identical placebo gel starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.
~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.
~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.
~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
16629458|NCT02418559|Experimental|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
16629459|NCT02418559|Experimental|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
16629460|NCT02418559|Experimental|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
16629461|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
16629462|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
16629463|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
16629464|NCT02418533|Experimental|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
16629465|NCT02418533|Experimental|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
16629466|NCT02418520|Experimental|Miswak chewing|Chewing Sticks
16629467|NCT02418520|No Intervention|H.Pylori|Oral H.Pylori
16629468|NCT02418507|Active Comparator|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
16629469|NCT02418507|Placebo Comparator|Placebo|The placebo is administered to randomized healthy participants
16629470|NCT02418494||Observational (ANCHOR HRQoL interview, cognitive interview)|Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
16629471|NCT02418481|Experimental|Group A|DC-CIK cells will be used against tumor cells.
16629472|NCT02418481|Experimental|Group B|γδ T cells will be used against tumor cells.
16629473|NCT02418481|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
16629474|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
16629475|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
16629476|NCT02418455|Experimental|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
16629477|NCT02418429|Active Comparator|waxy maize starch|pancake test meal - waxy maize starch
16629478|NCT02418429|Active Comparator|waxy maize starch and whey protein|pancake test meal - waxy maize starch and whey protein
16629479|NCT02418429|Active Comparator|resistant starch|pancake test meal - resistant starch
16629480|NCT02418429|Active Comparator|resistant starch and whey protein|pancake test meal - resistant starch and whey protein
16629481|NCT02418416|Experimental|Double activation|The Oocytes in this arm will undergo double activation with Ca ionophore 5 micro mol for 20 min them Strontium chloride 10 micro mol for 60 min.
16629482|NCT02418416|No Intervention|Control arm|The Oocytes will undergo Intracytoplasmic sperm injection only
16629483|NCT02418403|Active Comparator|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
16629967|NCT02415582|Experimental|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
16629484|NCT02418403|Experimental|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
16629485|NCT02418390|No Intervention|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
16629486|NCT02418390|Active Comparator|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
16629487|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:
~Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile
~Overweight before 10 years of age
~Informed consent from both obese children subject and legal representative e.g. parents"
16629488|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:
~Must be parent or direct sibling of obese subject
~Informed consent from both subject and parent is subject is below 21 years of age"
16629489|NCT02418364|Placebo Comparator|placebo reflexology|Placebo reflexology treatment
16629490|NCT02418364|No Intervention|control group|Data will be taken from questionnaires
16629491|NCT02418364|Experimental|reflexology treatment|Reflexology treatment
16629492|NCT02418338|Experimental|dmd children|echocardiography
16629493|NCT02418338|Other|healthy children|echocardiography
16629494|NCT02418325|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
16629495|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
16629496|NCT02418312|Placebo Comparator|placebo group|placebo for 6 months.
16629497|NCT02418299|Experimental|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
16629498|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
16629499|NCT02418273|Experimental|Denosumab|These subjects will receive two sequential doses of denosumab
16629500|NCT02418273|No Intervention|No drug intervention|These subjects do not receive denosumab
16629501|NCT02418260|Active Comparator|Open reduction and plate osteosynthesis|Open reduction and internal fixation with DCP 4.5mm plate.
16629502|NCT02418260|Experimental|Bridge Plate|Patients will be submitted to closed reduction and anterior bridge plate osteosynthesis (narrow 4.5mm DCP plate will be used)
16629503|NCT02418260|Experimental|Intramedullary nail|Patients will be submitted to closed reduction and locked intramedullary nail osteosynthesis.
16629504|NCT02418247|Active Comparator|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
16629505|NCT02418247|Sham Comparator|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
16629506|NCT02418221|Experimental|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure & pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
16629507|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
16629508|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
16629513|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
16629514|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
16629515|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
16629516|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
16629517|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
16629518|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
16629519|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
16629520|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
16629523|NCT02418117|Experimental|Stereolitographic template's accuracy|Evaluating the accuracy of stereolitographic template comparing the final implant insertion to the planned implant position at coronal and apical level
16629524|NCT02418104|Experimental|CHS-1701|CHS-1701 followed by CHS-1701
16629525|NCT02418104|Active Comparator|Neulasta|Neulasta followed by Neulasta
16629526|NCT02418091|Experimental|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
16629527|NCT02418091|No Intervention|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
16629528|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
16629529|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
16629530|NCT02418065|Experimental|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
16629531|NCT02418065|Other|control group|oral nutritional supplementation
16629532|NCT02418052|Experimental|neck flexion group|Patients who fixed in neck flexion position after MIE
16629533|NCT02418052|No Intervention|control group|Patients without posture intervention after MIE
16629534|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
16629535|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
16629536|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
16629537|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
16629538|NCT02418013|Experimental|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
16629539|NCT02418013|Experimental|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
16629540|NCT02418013|Experimental|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
16629541|NCT02418013|Placebo Comparator|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
16629542|NCT02418000|Experimental|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
16629543|NCT02418000|Experimental|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
16629544|NCT02418000|Experimental|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
16629545|NCT02418000|Experimental|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
16629546|NCT02418000|Experimental|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
16629547|NCT02417987|Active Comparator|High Volume injection|"A total volume of 50 ml:
~10 mls 0.5% bupivacaine hydrochloride and
~20 mg of Depomedrol (hydrocortisone)
~40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
16629548|NCT02417987|Active Comparator|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).
~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
16629549|NCT02417987|Sham Comparator|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
16629550|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
16629551|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
16629552|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
16629553|NCT02417948|Experimental|Arm I (educational brochure, online educational tutorial)|Participants receive a skin cancer educational and preventive brochure distributed by the National Cancer Institute and watch a 30-minute online tutorial video called X-Plain about skin cancer, preventative behaviors, and skin self-examinations.
16629554|NCT02417948|Active Comparator|Arm II (educational brochure)|Participants receive an educational brochure as in Arm I.
16629555|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
16629556|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
16629557|NCT02417922|Experimental|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).
~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
16629558|NCT02417922|Placebo Comparator|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
16629559|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
16629560|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
16629561|NCT02417896|Experimental|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
16629562|NCT02417896|No Intervention|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
16629563|NCT02417883|Experimental|Furosemide Stress Test|Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.
16629564|NCT02417870|Experimental|aldesleukin|
16629565|NCT02417857|Experimental|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
16629566|NCT02417857|Experimental|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
16629567|NCT02417844|Active Comparator|Tamsulosin HCl|
16629568|NCT02417844|Active Comparator|Tamsulosin|
16629569|NCT02417831|Active Comparator|tamsulosin capsules|
16629570|NCT02417831|Active Comparator|tamsulosin HCl capsules|
16629571|NCT02417818|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Plasma Therapy (PlasmaDerm)"
16629572|NCT02417818|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
~Intervention: Plasma Therapy (PlasmaDerm)"
16629573|NCT02417818|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Plasma Therapy (PlasmaDerm)"
16629574|NCT02417818|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Plasma Therapy (PlasmaDerm)"
16629575|NCT02417818|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629576|NCT02417818|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629577|NCT02417818|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629578|NCT02417818|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629579|NCT02417818|Experimental|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629580|NCT02417818|Experimental|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629581|NCT02417818|Experimental|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629582|NCT02417818|Experimental|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
16629583|NCT02417805|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16629584|NCT02417805|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16629585|NCT02417805|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16629586|NCT02417805|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
16629587|NCT02417792||control|group of healthy participants
16629588|NCT02417792||Topical psoriasis treatment|Group of patients who are treated with topical medications for psoriasis
16629589|NCT02417792||Systemic psoriasis treatment|Group of patients who are treated with systematic medications for psoriasis
16630041|NCT02415166|Experimental|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
16629590|NCT02417779|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629591|NCT02417779|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629592|NCT02417779|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629593|NCT02417779|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629594|NCT02417779|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629595|NCT02417779|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629596|NCT02417779|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629597|NCT02417779|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629598|NCT02417779|Experimental|Hypertrophic burn scar|"Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629599|NCT02417779|Experimental|Hypertrophic burn scar (repetitive)|"Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629600|NCT02417779|Experimental|Flap|"Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629601|NCT02417779|Experimental|Flap (repetitive)|"Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
16629604|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
16629609|NCT02417714||Body CT group|100 subjects for a body CT
16629610|NCT02417714||Chest Ct Group|100 subjects for a chest CT
16629611|NCT02417701|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16629612|NCT02417688|Experimental|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
16629613|NCT02417675|Active Comparator|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.
~Infants receive the same care in each arm, according to the Standard of Care for Infants."
16629614|NCT02417675|Experimental|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.
~Infants receive the same care in each arm, according to the Standard of Care for Infants."
16629615|NCT02417662|Active Comparator|Systemic Anti-Cancer Therapy (SACT) alone|The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
16629616|NCT02417662|Experimental|SACT + Radical Radiotherapy (Conventional RT and SABR)|"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.
~The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines."
16629617|NCT02417649|Experimental|Ismigen|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
16629618|NCT02417649|Placebo Comparator|Placebo|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
16629683|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
16629619|NCT02417636|Experimental|Nurse-initiated and monitored ART|This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
16629620|NCT02417636|Active Comparator|Clinician - initiated and monitored ART|This is Standard of Care for the Uganda Ministry of Health to compared with the experimental task shifting. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Clinicians (Clinical Officer or Medical Officer) and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually.
16629621|NCT02417623|Experimental|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
16629622|NCT02417623|No Intervention|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
16629623|NCT02417610|Experimental|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
16629624|NCT02417610|Active Comparator|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
16629625|NCT02417597|Experimental|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
16629626|NCT02417597|Active Comparator|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
16629627|NCT02417597|No Intervention|Safety Control Group|Participants in this arm are aged over 65 years.
16629628|NCT02417584|Experimental|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
16629629|NCT02417571|Experimental|ABPM group|"Ambulatory blood pressure monitoring (ABPM) performed at 3, 6 months after randomization; adjusting drugs/doses based on ABPM results.
~Target BP: daytime ABP < 135/85 mm Hg according to British NICE clinical guideline 127."
16629630|NCT02417571|No Intervention|Office BP group|"Conventional BP management using office BP according to KDIGO guideline on BP management.
~Target BP: <140/90 mm Hg."
16629631|NCT02417558|Experimental|Alterniity Augmented Reality (AAR)|AAR training Participants use the patent pending AAR exercise and gaming (exergaming) platform that combines a physical training component (PTC) and a cognitive training component (CTC) in closed-feedback loop with Personalized Brain Network Activity (PBNA) test from a portable EEG.
16629632|NCT02417558|No Intervention|Passive Control Participants|Passive Control Participants do not receive an intervention serving as passive controls
16629633|NCT02417558|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the Aristotle University of Thessaloniki. The software is called VideoGrade and uses videos from Youtube (YouTube) documentaries (VideoGrade).
16629634|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
16629635|NCT02417519|Experimental|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
16629636|NCT02417519|Experimental|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
16629637|NCT02417519|Experimental|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
16629638|NCT02417519|Experimental|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
16629639|NCT02417519|Experimental|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
16629640|NCT02417519|Experimental|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
16629641|NCT02417506|Experimental|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
16629642|NCT02417506|Active Comparator|Ibuprofen|200 mg two capsule to be taken stat at the site
16629643|NCT02417493|Experimental|Simulation of Epinephrine Self-Injection|The patient will self-inject an empty syringe into his/her thigh simulating a self-injection of epinephrine during a routine outpatient visit to the allergist.
16629644|NCT02417493|No Intervention|Control Group|The patient will be encouraged to speak to their physician about self-injection, but will not undergo the self-injection protocol during a routine outpatient visit to the allergist.
16629645|NCT02417480|Active Comparator|Vegan arm|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. Researchers will ask participants on a vegan diet to follow their usual diet and exercise habits consistent for the two week study period.
16629646|NCT02417480|Experimental|Omnivorous arm|A diet containing all food groups. Researchers will ask participants on an omnivorous diet to follow habitual, usual diet and exercise habits for the first week. During the second week, participants will be asked to switch to a vegan diet for one week and to maintain their usual exercise habits.
16629682|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
16630042|NCT02415166|Placebo Comparator|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
16629647|NCT02417467|Experimental|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.
~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
16629648|NCT02417467|Other|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.
~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
16629649|NCT02417467|Other|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
16629650|NCT02417454|Experimental|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
16629651|NCT02417454|Placebo Comparator|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
16629652|NCT02417441|Experimental|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
16629653|NCT02417441|No Intervention|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
16629654|NCT02417428|Experimental|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
16629655|NCT02417428|Placebo Comparator|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
16629656|NCT02417428|Experimental|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
16629657|NCT02417428|Other|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
16629658|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
16629659|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
16629660|NCT02417402|Active Comparator|Untrained Physical Therapists|The patients allocated to the Control group will be treated by physical therapists who did not receive any training about clinical practice guidelines and pain management. These patients will receive the usual care from their physical therapists.
16629661|NCT02417402|Experimental|Trained Physical Therapists|The patients allocated to the Experimental group will be treated by physical therapists who received training about clinical practice guidelines and pain management.
16629662|NCT02417389|Experimental|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
16629663|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:
~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and
~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
16629664|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
16629665|NCT02417363||Group A|the control group,healthy individuals
16629666|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
16629667|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
16629668|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
16629669|NCT02417350|Experimental|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
16629670|NCT02417350|Experimental|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
16629671|NCT02417337|Active Comparator|Group I|paracetamol 1000mg
16629672|NCT02417337|Experimental|Group II|ibuprofen 600mg + paracetamol 1000mg,
16629673|NCT02417337|Experimental|Group III|Mefenamic acid 500mg + Paracetamol 1000mg
16629674|NCT02417337|Experimental|Group IV|Diclofenac K 50mg + paracetamol 1000 mg
16629675|NCT02417337|Placebo Comparator|Group V|No medication
16629676|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
16629677|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
16629678|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
16629679|NCT02417298|Active Comparator|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
16629680|NCT02417298|Placebo Comparator|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
16629803|NCT02416531|Experimental|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
16629684|NCT02417246|Active Comparator|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
16629685|NCT02417246|Active Comparator|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
16629686|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
16629687|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
16629688|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
16629689|NCT02417220|Active Comparator|Weight Watchers Online 2015|
16629690|NCT02417220|Experimental|Weight Watchers Online 2015 Enhanced|
16629691|NCT02417207|Sham Comparator|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
16629692|NCT02417207|Active Comparator|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
16629693|NCT02417181|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the out-of-hours primary care service
16629694|NCT02417181|Experimental|Physician Assistants Care|Medical care provided by the Physician Assistant at the out-of-hours primary care service
16629695|NCT02417155|Experimental|HTR|The 'Hoftraining' group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
16629696|NCT02417155|Active Comparator|EIN|The 'extensive instruction' group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
16629697|NCT02417155|Active Comparator|STR|The 'short training' group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
16629698|NCT02417155|Active Comparator|SIN|The 'short instruction' group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
16629699|NCT02417142|Experimental|Experimental|Exenatide 2mg subcutaneous injection, once weekly
16629700|NCT02417142|Placebo Comparator|Placebo|Placebo
16629701|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
16629702|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
16629703|NCT02417116|Placebo Comparator|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
16629704|NCT02417116|Active Comparator|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
16629705|NCT02417116|Active Comparator|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
16629706|NCT02417103|Active Comparator|GLP-1 (Liraglutide)|Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
16629707|NCT02417103|Placebo Comparator|Placebo Comparator|Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
16629708|NCT02417090||Metformin therapy|9-year-old children whose mothers used metformin for gestational diabetes
16629709|NCT02417090||Insulin therapy|9-year-old children whose mothers used insulin for gestational diabetes
16629710|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
16629711|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16629768|NCT02416726|Experimental|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
16629804|NCT02416531|Experimental|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
16629712|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16629713|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
16629714|NCT02417051|Experimental|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
16629715|NCT02417051|No Intervention|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
16629716|NCT02417025|Experimental|PE-HBT|Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
16629717|NCT02417025|Active Comparator|PE-SD|Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
16629718|NCT02417012|Experimental|U-TURN intervention|"The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.
~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
16629719|NCT02417012|Active Comparator|Standard care|"The reference group will receive diabetes education and support by trained nurses.
~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
16629720|NCT02416999|Experimental|patient group|
16629721|NCT02416973|Other|Sham of Provant|Sham of Provant
16629722|NCT02416973|Other|Active Treatment|Active Provant Treatment
16629723|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
16629724|NCT02416960|Experimental|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
16629725|NCT02416960|Active Comparator|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
16629726|NCT02416960|No Intervention|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
16629727|NCT02416947|Placebo Comparator|0g SCF|Subjects will consume 0 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
16629728|NCT02416947|Active Comparator|10 g SCF|Subjects will consume 10 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
16629729|NCT02416947|Active Comparator|20g SCF|Subjects will consume 20 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
16629730|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
16629731|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
16629732|NCT02416921|Experimental|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
16629733|NCT02416921|Active Comparator|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
16629734|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.
~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).
~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.
~G-CSF will be given 300 mcg SC once daily on Days 3-8.
~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.
~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
16629735|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.
~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).
~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.
~G-CSF will be given 300 mcg SC once daily on Days 3-8.
~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.
~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
16629802|NCT02416531|Active Comparator|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
16630043|NCT02415166|Experimental|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
16629736|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.
~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).
~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.
~G-CSF will be given 300 mcg SC once daily on Days 3-8.
~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.
~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
16629737|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
16629738|NCT02416882|Other|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
16629739|NCT02416882|Other|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
16629740|NCT02416869|Active Comparator|Intramuscular application|Intramuscular application of 4mg Dexamethasone
16629741|NCT02416869|Experimental|Submucosal application|Submucosal application of 4mg Dexamethasone
16629742|NCT02416869|Active Comparator|4mg Dexamethasone submucosal|4mg Dexamethasone submucosal application
16629743|NCT02416869|Experimental|8mg Dexamethasone submucosal|8mg Dexamethasone submucosal application
16629744|NCT02416869|Active Comparator|4mg Dexamethasone postoperative|4mg Dexamethasone postoperative application
16629745|NCT02416869|Experimental|4mg Dexamethasone preoperative|4mg Dexamethasone postoperative application
16629746|NCT02416843|Experimental|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
16629747|NCT02416843|Experimental|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
16629748|NCT02416843|Experimental|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
16629749|NCT02416817|Experimental|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
16629750|NCT02416817|Experimental|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
16629751|NCT02416804|Experimental|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
16629752|NCT02416804|Active Comparator|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
16629753|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.
~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
16629754|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.
~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
16629755|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
16629756|NCT02416778|Experimental|Treatment Arm|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
16629757|NCT02416765|Active Comparator|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
16629758|NCT02416765|Active Comparator|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
16629759|NCT02416765|Active Comparator|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
16629760|NCT02416765|Active Comparator|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
16629761|NCT02416765|Active Comparator|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
16629762|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
16629763|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
16629764|NCT02416739|Experimental|Nicotinamide|"Nicotinamide with EGFR-TKI:
~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day
~nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
16629765|NCT02416739|Placebo Comparator|Placebo|"Placebo tablet with EGFR-TKI:
~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day
~placebo tablet - per oral, twice a day, until the event or censoring occurs"
16629766|NCT02416726|Experimental|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
16629767|NCT02416726|Experimental|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
16630044|NCT02415166|Placebo Comparator|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
16629769|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
16629770|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
16629771|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
16629772|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
16629773|NCT02416700|Experimental|immediate implant surgery|Immediate implant surgery in one site.
16629774|NCT02416700|Active Comparator|conventional implant surgery|Conventional implant surgery in another site
16629775|NCT02416687|Active Comparator|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
16629776|NCT02416687|No Intervention|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
16629777|NCT02416674|Experimental|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
16629778|NCT02416661||Participants diagnosed with Gaucher disease|Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old
16629779|NCT02416648|Experimental|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
16629780|NCT02416648|Experimental|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
16629781|NCT02416648|No Intervention|Routine care|The control group received routine clinic care.
16629782|NCT02416635||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16629783|NCT02416635||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16629784|NCT02416635||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16629785|NCT02416635||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16629786|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
16629787|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
16629788|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
16629789|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
16629790|NCT02416609|Experimental|Gem-based doublets with LDR & sequential SBRT|Four Gem-based doublets cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered.
16629791|NCT02416596|Experimental|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
16629792|NCT02416596|No Intervention|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
16629793|NCT02416583|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
16629794|NCT02416583|Active Comparator|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
16629795|NCT02416570|Active Comparator|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
16629796|NCT02416570|Placebo Comparator|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
16629797|NCT02416557|Experimental|Group P|Patients using positive end-expiratory pressure (PEEP) of 10 cmH2O (centimeter of water) intraoperatively
16629798|NCT02416557|No Intervention|Group C|Patients using no positive end-expiratory pressure (zero PEEP) intraoperatively
16629799|NCT02416544|Experimental|Full participation|Participants in this group receive lunch which is calorie-restricted and low-salt during 12 weeks, the total duration of this study.
16629800|NCT02416544|Experimental|Two thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 4 weeks from the beginning of the study and maintain the diet during 8 weeks.
16629801|NCT02416544|Experimental|One thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 8 weeks from the beginning of the study and maintain the diet during 4 weeks.
16630421|NCT02412735|Experimental|rexlemestrocel-L + HA|"rexlemestrocel-L + HA: 2.0mL 6 million rexlemestrocel-L cells"
16629805|NCT02416505|No Intervention|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.
~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
16629806|NCT02416505|Active Comparator|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.
~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
16629807|NCT02416505|Active Comparator|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.
~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
16629808|NCT02416492|Experimental|SB623 Cells|SB623 Cells: 2.5, 5 or 10 million cells surgically implanted adjacent to the injured cerebral region.
16629809|NCT02416492|Sham Comparator|Sham Surgery|Control Sham Surgery (partial burr hole only)
16629810|NCT02416479|Experimental|SystemCHANGE|SystemCHANGE supports patient-designed, interventionist-guided, small experiments to: 1) assess individual systems (including important others who shape medication taking) and the system's impact on medication taking and propose individual system solutions to improve MA, 2) implement the proposed individual systems' solutions to improve MA, 3) track MA data, and 4) evaluate MA data.
16629811|NCT02416479|Active Comparator|Patient-education attention-control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
16629812|NCT02416466|Experimental|anti-CEA CAR-T cells + Sir-Spheres|Three infusions of gene-modified anti-CEA T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2. A single dose of Sir-Spheres will be given 2 weeks following the final T cell dose.
16629813|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
16629814|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
16629815|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
16629816|NCT02416440||screening for diabetes prevalence|blood samples
16629817|NCT02416427|Experimental|Arm A|Atorvastatin 80 mg/day for 3 weeks
16629818|NCT02416427|No Intervention|Arm B|Observation
16629819|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
16629820|NCT02416414||Healthy Controls|Healthy individuals.
16629821|NCT02416401|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
16629822|NCT02416401|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
16629823|NCT02416388|Experimental|R1-IDA|Idarubicin
16629824|NCT02416388|Active Comparator|R1-DAUNO|Daunorubicin
16629825|NCT02416388|Active Comparator|R2-HDAC|High dose cytarabine
16629826|NCT02416388|Experimental|R2-IDAC|Intermediate dose cytarabine
16629827|NCT02416388|Active Comparator|R3-MAC-MTX|Methotrexate and mycophenolic acid
16629828|NCT02416388|Experimental|R3-MAC-MPA|Cyclosporine and mycophenolic acid
16629829|NCT02416388|Active Comparator|R3-RIC-CICLO|Cyclosporine
16629830|NCT02416388|Experimental|R3-RIC-MPA|Cyclosporine and mycophenolic acid
16629831|NCT02416388|Experimental|R4-VOS-IDAC|Intermediate dose cytarabine and vosaroxin
16629832|NCT02416388|Active Comparator|R4-IDAC (without VOS)|Intermediate dose cytarabine alone
16629833|NCT02416388|Experimental|R4-DEX-HDAC|High dose cytarabine and dexamethasone
16629834|NCT02416388|Active Comparator|R4-HDAC (without DEX)|High dose cytarabine alone
16629835|NCT02416388|Experimental|R4-VEN-IDAC|Intermediate dose cytarabine and venetoclax
16629836|NCT02416388|Active Comparator|R4-IDAC (without VEN)|Intermediate dose cytarabine alone
16629837|NCT02416375||Observation|Adult Cystic Fibrosis patients
16629838|NCT02416362|No Intervention|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
16629839|NCT02416362|Experimental|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
16629840|NCT02416362|Experimental|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
16630422|NCT02412735|Placebo Comparator|Placebo|saline control: 2.0 mL saline solution
16629841|NCT02416349|Active Comparator|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
16629842|NCT02416349|Placebo Comparator|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
16629843|NCT02416336|Experimental|Sentinella intraoperative use|"Standard of care intraoperative protocol
~Localize SLN with the Gamma Probe for In vivo count
~Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)
~Surgically remove/excise localized SLN
~Ex vivo count - excised SLN with Gamma Probe
~In vivo background/roaming count with Gamma Probe
~Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)
~Sentinella intraoperative imaging protocol
~Survey surgical field/Post-excision control with Sentinella for remaining SLNs
~If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs
~Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
16629844|NCT02416323|No Intervention|Usual Care|Community therapist delivers routine care to participant child with no training in AIM HI.
16629845|NCT02416323|Other|AIM HI Training|Therapist enrolls in AIM HI training
16629846|NCT02416310|Experimental|TEAS group|TEAS are performed by a specific investigator on the specially acupoint.
16629847|NCT02416310|Sham Comparator|Sham group|TEAS are performed by a specific investigator on the non-acupoint.
16629848|NCT02416310|Placebo Comparator|Control group|Only place cutted electrodes but do not give any electrical stimulation.
16629849|NCT02416297|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
16629850|NCT02416297|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
16629851|NCT02416284|Experimental|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
16629852|NCT02416271|Experimental|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
16629853|NCT02416271|Active Comparator|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
16629854|NCT02416258|Active Comparator|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
16629855|NCT02416258|Placebo Comparator|Aerosol spray vehicle|No active ingredient, topical
16629856|NCT02416258|Active Comparator|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
16629857|NCT02416258|Active Comparator|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
16629858|NCT02416258|Active Comparator|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
16629859|NCT02416258|Active Comparator|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
16629860|NCT02416245|Experimental|Test beverage powder|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
16629861|NCT02416245|Placebo Comparator|Control beverage powder|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
16629862|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
16629863|NCT02416206|Experimental|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
16629864|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
16629865|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
16629866|NCT02416180|Experimental|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
16629867|NCT02416167|Active Comparator|FYU-981 High dose|Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
16629868|NCT02416167|Active Comparator|FYU-981 High middle dose|Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
16629869|NCT02416167|Active Comparator|FYU-981 Middle dose|FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
16629870|NCT02416167|Active Comparator|FYU-981 Low dose|Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
16629871|NCT02416167|Placebo Comparator|Placebo|Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
16629872|NCT02416154||Follicular phase|Normally cycling women in the follicular phase of menses
16629873|NCT02416154||Luteal phase|Normally cycling women in the luteal phase of menses
16629874|NCT02416141|Active Comparator|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.
~Intervention: use of fast release oro dispersible tramadol 50 mg"
16629875|NCT02416141|Placebo Comparator|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.
~Intervention: use of placebo"
16629876|NCT02416128|Active Comparator|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
16629877|NCT02416128|Experimental|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
16629878|NCT02416115|Active Comparator|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
16629879|NCT02416115|Active Comparator|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
16629880|NCT02416115|Experimental|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
16629881|NCT02416102|Active Comparator|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
16629882|NCT02416102|Experimental|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
16629883|NCT02416102|Experimental|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
16629884|NCT02416089|Experimental|Tampostat|Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)
16629885|NCT02416089|Active Comparator|Condom catheter tamponade|Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
16629886|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level [EL2].
16629887|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level [EL2] .
16629888|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
16629889|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level [EL4] .
16629890|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
16629891|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level [EL4].
16629892|NCT02416063|Active Comparator|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .
~Drug:caudal Dexmedetomidine 1μg /kg.
~Intravenous :10 ml normal saline
~Anesthesia was induced and maintained with sevoflurane"
16629893|NCT02416063|Active Comparator|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg
~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline
~Anesthesia was induced and maintained with sevoflurane"
16629894|NCT02416063|Placebo Comparator|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .
~Intravenous: 10 ml Normal saline
~Anesthesia was induced and maintained with sevoflurane"
16629895|NCT02416037|Experimental|Prone Proseva|
16629896|NCT02416037|Active Comparator|Prone Talmor|
16629897|NCT02416024||No Refractory hypotension group|Patient who did not require more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia.
16629898|NCT02416024||Control|Patient who required more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia
16629899|NCT02416011|No Intervention|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
16629900|NCT02416011|Active Comparator|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
16629901|NCT02416011|Experimental|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
16629902|NCT02415998||TEE|
16629903|NCT02415985|Other|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
16629904|NCT02415985|Other|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
16629905|NCT02415972||All study participants|Patients with Stroke
16629906|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
16629907|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
16629908|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
16629909|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
16629910|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
16629911|NCT02415946|Active Comparator|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
16629912|NCT02415946|Experimental|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
16629913|NCT02415933|Experimental|Trickle Up|Economic empowerment
16629914|NCT02415933|Experimental|Trickle Up Plus|Economic empowerment + child rights sensitization
16629915|NCT02415933|No Intervention|Wait-list|Women in villages assigned to the control arm do not receive any intervention during the study period, but are placed on a wait-list to receive the intervention upon completion of the evaluation phase.
16629916|NCT02415920|Experimental|Experimental|These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
16629917|NCT02415920|Placebo Comparator|Control - Placebo|These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
16629918|NCT02415907|Experimental|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.
~Period II: Administration of Lu AF67708 single dose (week 4)"
16629919|NCT02415881|Experimental|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
16629920|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
16629921|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
16629922|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
16629923|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
16629924|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
16629925|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
16629926|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
16629927|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
16629928|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
16629929|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
16629930|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
16629931|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
16629932|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
16629933|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
16629934|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
16629964|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
16629965|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
16629966|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
16629935|NCT02415829|Experimental|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
16629936|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
16629937|NCT02415803|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
16629938|NCT02415803|Active Comparator|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
16629939|NCT02415803|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
16629940|NCT02415790|Experimental|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
16629941|NCT02415790|Experimental|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
16629942|NCT02415790|Experimental|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
16629943|NCT02415790|Experimental|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
16629944|NCT02415777|Experimental|udca003|udca003
16629945|NCT02415777|Placebo Comparator|placebo|placebo of udca003
16629946|NCT02415764|Other|Pilot test Intervention OnTrack>The Game|"Consumers who have been referred to OnTrackNY sites at Washington Heights Community Service or Mental Health Association Westchester in the past six months will be recruited to participate in a product evaluation of OnTrack>The Game.
~Intervention: This is a behavioral/attitudinal intervention, using OnTrack>The Game, which will include each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes)."
16629947|NCT02415751||self-care education|All patients in the study will receive self-care education
16629948|NCT02415725|Experimental|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
16629949|NCT02415712||Fomepizole Intravenous Infusion|Fomepizole Intravenous Infusion
16629950|NCT02415699|Experimental|DC-CIK Immunotherapy Plus Chemotherapy|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
16629951|NCT02415699|Active Comparator|Chemotherapy Alone|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
16629952|NCT02415673|Experimental|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
16629953|NCT02415673|Experimental|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
16629954|NCT02415660|Experimental|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
16629955|NCT02415660|Sham Comparator|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
16629956|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
16629957|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
16629958|NCT02415634|Experimental|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
16629959|NCT02415634|Active Comparator|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
16629960|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
16629961|NCT02415608|Experimental|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
16629962|NCT02415608|Experimental|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
16629963|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
16629968|NCT02415582|Experimental|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
16629969|NCT02415582|Sham Comparator|Control|Participants do not exercise and remain sitting for 45 minutes
16629970|NCT02415569|Experimental|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
16629971|NCT02415569|Experimental|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
16629972|NCT02415569|Active Comparator|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
16629973|NCT02415556|Experimental|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
16629974|NCT02415556|Placebo Comparator|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
16629975|NCT02415556|Experimental|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
16629976|NCT02415556|Placebo Comparator|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
16629977|NCT02415543|Active Comparator|GROUP A|Group A will undergo SIL-TEP inguinal hernia repair with a single port LESS (12 to 15 mm paraumbilical)
16629978|NCT02415543|Active Comparator|GROUP B|Group B will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
16629979|NCT02415530|Placebo Comparator|Term infant control|term infant without intervention
16629980|NCT02415530|Placebo Comparator|VLBW infant control|very low birth weight infant without intervention
16629981|NCT02415530|Experimental|VLBW infant intervention|Combined home visiting and group intervention for very low birth weight infant
16629982|NCT02415517|Experimental|Experimental group|Intervention: Cognitive Training
16629983|NCT02415517|Active Comparator|Active control group|Intervention: Test of general knowledge
16629984|NCT02415517|No Intervention|Passive control group|No intervention
16629985|NCT02415504|Experimental|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
16629986|NCT02415504|Other|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
16629987|NCT02415491|Experimental|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
16629988|NCT02415465|Active Comparator|Combined Spinal Epidural|Spinal Intraoperative Anesthesia with standard Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus) with standard post-operative analgesics.
16629989|NCT02415465|Active Comparator|General+Continuous Adductor Canal Block|General Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
16629990|NCT02415465|Active Comparator|Spinal+Continuous Adductor Canal Block|Spinal Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
16629991|NCT02415452||Acute Coronary Syndrome (ACS) patients|Acute coronary syndrome (ACS) patients who underwent coronary angiography ,drug-eluting stent (DES) implantation, and eye fundus examination.
16629992|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
16629993|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
16629994|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
16629995|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
16629996|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
16629997|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
16629998|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
16629999|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
16630000|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
16630001|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
16630002|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
16630003|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
16630004|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
16630045|NCT02415153|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
16630046|NCT02415140||COPD|Spirometry confirmed COPD patients
16630047|NCT02415140||Control|normal geriatric patients without lung disease
16630455|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
16630005|NCT02415413|Experimental|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.
~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).
~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).
~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
16630006|NCT02415400|Active Comparator|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
16630007|NCT02415400|Active Comparator|Vitamin K Antagonist|VKA tablets orally once daily
16630008|NCT02415400|Placebo Comparator|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
16630009|NCT02415400|Placebo Comparator|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
16630010|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
16630011|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
16630012|NCT02415374|Placebo Comparator|Low-AVA oat flour cookies|Three low-AVA oat flour cookies
16630013|NCT02415374|Experimental|High-AVA oat flour cookies|Three high-AVA cookies
16630014|NCT02415361|No Intervention|Arm A|"Standard care consists of:
~a phone call from a CLP-nurse after the referral from the local birth hospital has been received
~telephone service at parents request and at the staffs availability
~invitation to a one-day-information course before surgery"
16630015|NCT02415361|Active Comparator|Arm B|"Systematic follow up by a special trained nurse consists of:
~telephone contact with the parents shortly after birth
~visit at the maternity ward within 36 hours after the referral has been received
~telephone follow ups at specific times and at parents request
~guidance and support in feeding and treatment
~written information
~cooperation with the staff at the maternity unit and the health centre
~follow up in accordance with a check-list and log
~invitation to a one-day-information course before surgery"
16630016|NCT02415348|Experimental|Fibroscan|Fibroscan under simultaneous cardiac monitoring
16630017|NCT02415335|Placebo Comparator|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
16630018|NCT02415335|Experimental|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
16630019|NCT02415309|Active Comparator|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
16630020|NCT02415309|Active Comparator|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
16630021|NCT02415309|Placebo Comparator|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
16630022|NCT02415296||stage 1|French online gamblers.
16630023|NCT02415296||stage 2|Validation of problematic gamblers score on possible problematic gamblers.
16630024|NCT02415296||stage 3|240 problematic gamblers.
16630025|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
16630026|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
16630027|NCT02415270|Experimental|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
16630028|NCT02415270|Experimental|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
16630029|NCT02415270|Placebo Comparator|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
16630030|NCT02415257|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.
~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
16630031|NCT02415257|No Intervention|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
16630032|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
16630033|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
16630034|NCT02415231|Experimental|humor|humor group will watch humor video for 20 minutes
16630035|NCT02415231|No Intervention|control non humor|control group did not watch humor, they sat quietly for 20 minutes.
16630036|NCT02415218|Experimental|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
16630037|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.
~The number of this group will be double than the control group to get more information about safety and efficacy."
16630038|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
16630039|NCT02415179|Experimental|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
16630040|NCT02415179|Active Comparator|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
16630048|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
16630049|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
16630050|NCT02415114|Active Comparator|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
16630051|NCT02415114|Active Comparator|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
16630052|NCT02415101|Active Comparator|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
16630053|NCT02415101|Active Comparator|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
16630054|NCT02415088|Active Comparator|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
16630055|NCT02415088|Active Comparator|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
16630056|NCT02415062|Experimental|high dose donepezil (23mg)|Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
16630057|NCT02415062|Active Comparator|standard dose denepezil (10mg)|Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
16630058|NCT02415049|Active Comparator|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
16630059|NCT02415049|Experimental|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
16630060|NCT02415036|Experimental|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).
~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
16630061|NCT02415036|Experimental|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).
~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
16630062|NCT02415023|Experimental|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
16630063|NCT02414997|Experimental|RIPC group|Surround left upper limb with cuff, inflate cuff to 200 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
16630064|NCT02414997|Sham Comparator|Sham RIPC group|Surround left upper limb with cuff, inflate cuff to 20 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
16630065|NCT02414984||Golimumab|Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
16630066|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
16630067|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
16630068|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
16630069|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
16630070|NCT02414945|Experimental|Tumor Infiltrating lymphocytes (TILs)|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days
~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10^10 - 1.6x10^11 cells
~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
16630071|NCT02414932|Experimental|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate >110/minute or systolic/diastolic blood pressure (BP) >180/100 or >20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
16630072|NCT02414932|Active Comparator|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
16630073|NCT02414919||HERC|Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
16630074|NCT02414906|Experimental|Intervention group|Goal-directed therapy
16630075|NCT02414906|No Intervention|Control group|Control group
16630076|NCT02414893||Non obese|
16630077|NCT02414893||Morbidly obese|
16630078|NCT02414893||Sleeve gastrectomy|
16630079|NCT02414880|Active Comparator|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
16630080|NCT02414880|Active Comparator|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
16630539|NCT02411942|Active Comparator|Differin®|Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)
16630081|NCT02414880|Active Comparator|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
16630082|NCT02414880|Active Comparator|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
16630083|NCT02414867||1|Normal weight mothers
16630084|NCT02414867||2|Overweight/Obese mothers
16630085|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
16630086|NCT02414854|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
16630087|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
16630088|NCT02414854|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
16630089|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
16630090|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation
16630091|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
16630092|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
16630093|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
16630094|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
16630095|NCT02414815|Experimental|AF group|Atrial fibrillation
16630096|NCT02414802|Experimental|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
16630097|NCT02414802|Other|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4-6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
16630098|NCT02414789|Experimental|SRM / MS-MS|
16630099|NCT02414776|Experimental|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
16630100|NCT02414763|No Intervention|Care as Usual|Participants will receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
16630101|NCT02414763|Experimental|Teachable Moment Brief Intervention|The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, functional analysis of the suicidal ideation and behaviors, and crisis response planning. Participants will also receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
16630102|NCT02414750|Experimental|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.
~During the study biopsies and blood will be taken from the patients."
16630103|NCT02414737|Experimental|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
16630104|NCT02414724|Experimental|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16630105|NCT02414711|Other|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.
~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
16630106|NCT02414711|Other|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.
~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
16630107|NCT02414698|Active Comparator|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
16630108|NCT02414698|Active Comparator|TESI|Transforaminal Epidural Steroid Injections
16630109|NCT02414685|Experimental|intravenous chemotherapy|"TIP regimen:
~Paclitaxel 250 mg/ m2 iv on day 1
~Ifosfamide 1,2 g/ m2/ day iv x 5 days
~Cisplatin 20 mg/ m2/ day iv x 5 days"
16630110|NCT02414672|Experimental|CareSTEPS|CareSTEPS provides skills training in six domains that are central to the caregiving role: self-care, stress management, symptom management, effective communication, problem-solving, and social support.
16630111|NCT02414672|No Intervention|Usual Medical Care (UMC)|Patients receive standard oncologic and generalist palliative care from their healthcare team.
16630112|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
16630113|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
16630114|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
16630115|NCT02414620|Experimental|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
16630116|NCT02414607|Experimental|Elderberry Juice|Participants will drink 5ml of elderberry juice, diluted in 8oz of water, 3 times per day for three months.
16630117|NCT02414607|Placebo Comparator|Placebo|Participants will drink 5ml of colored water, diluted in 8oz of water, 3 times per day for three months.
16630118|NCT02414594|Experimental|IONIS-APO(a)-LRx|Drug: IONIS-APO(a)-LRx
16630119|NCT02414594|Placebo Comparator|Placebo (Normal Saline)|Drug: Sterile Normal Saline (0.9% NaCl)
16630120|NCT02414581|Experimental|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
16630121|NCT02414581|Active Comparator|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
16630122|NCT02414581|Experimental|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
16630123|NCT02414568|Experimental|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
16630124|NCT02414555|Active Comparator|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
16630125|NCT02414555|Active Comparator|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
16630126|NCT02414529|Placebo Comparator|Placebo group|"Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.
~Subjects are blinded then they will crossover groups"
16630127|NCT02414529|Active Comparator|Treatment group|"Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.
~Subjects are blinded then they will crossover groups."
16630128|NCT02414516|Experimental|OBP-801|
16630129|NCT02414503|Active Comparator|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
16630130|NCT02414503|Active Comparator|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
16630131|NCT02414503|Placebo Comparator|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
16630132|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
16630133|NCT02414464|Experimental|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
16630134|NCT02414464|Experimental|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
16630135|NCT02414464|Experimental|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
16630136|NCT02414451|Experimental|Propranolol arm|"Propranolol will be administered via oral capsule(s) daily for a period of 10 weeks, involving gradual titration up from 40mg to 100mg and subsequent tapering off of the drug. The titration/tapering schedule will be as follows:
~Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules"
16630137|NCT02414451|Placebo Comparator|Placebo arm|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:
~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
16630138|NCT02414438|No Intervention|Current Practice Arm|Physicians follow current care procedures
16630139|NCT02414438|Experimental|FirstStep and NextStep Information|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are able to order test results in Round 2
16630140|NCT02414438|Experimental|FirstStep and NextStep Results|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are specifically prompted to order test results in Round 2
16630141|NCT02414425|Experimental|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.
~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
16630142|NCT02414425|Placebo Comparator|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.
~Anorectal manometry will be performed for evaluation of efficacy of placebo"
16630143|NCT02414412|Active Comparator|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
16630144|NCT02414412|Placebo Comparator|Placebo|placebo 250mg orally 2 times a day for 4 weeks
16630145|NCT02414399|Experimental|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
16630146|NCT02414399|Placebo Comparator|Placebo|5 days of taste/appearance/bottle-matched placebo
16630147|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
16630148|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
16630149|NCT02414373|Experimental|Ropivacaine|Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)
16630150|NCT02414373|Active Comparator|Bupivacaine|Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)
16630151|NCT02414360|Experimental|Shortened Format|Shortened format of a systematic review
16630152|NCT02414360|Active Comparator|Control|Full length systematic review
16630153|NCT02414347||Experimental F 18 T807|
16630154|NCT02414334|Active Comparator|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
16630155|NCT02414334|Experimental|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
16630159|NCT02414308|Experimental|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
16630160|NCT02414295|Experimental|Mesenchymal stem cell injection|Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery
16630161|NCT02414282||Experimental F 18 T807|
16630162|NCT02414269|Experimental|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
16630163|NCT02414269|Experimental|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
16630164|NCT02414269|Experimental|CAR T cell and pembrolizumab|Pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration. Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by reassessment. Those responding or deriving clinical benefit, without unacceptable toxicity, will continue pembrolizumab. Patients will be followed weekly for the first four weeks. Patients in cohorts 9 and in Phase II will receive pembrolizumab 4 weeks(+3/- 1 week window) following CAR T cell administration.
16630165|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
16630166|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
16630167|NCT02414230||Experimental F 18 T807|
16630168|NCT02414217|Experimental|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
16630169|NCT02414217|Experimental|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
16630170|NCT02414217|No Intervention|Control|Participants were given written educational materials about diabetes.
16630171|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
16630172|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
16630173|NCT02414191|No Intervention|Control|Participants in this study arm will receive no form of feedback.
16630174|NCT02414191|Other|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
16630175|NCT02414191|Other|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
16630176|NCT02414178||Experimental F 18 T807|
16630177|NCT02414165|Experimental|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)
~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
16630178|NCT02414165|Active Comparator|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:
~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.
~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.
~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:
~at a dose of 50 mg/m2 PO once daily continuously, or
~at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
16630179|NCT02414152|Experimental|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
16630187|NCT02414126|Active Comparator|Children with dilated cardiomyopathy with an ejection fraction|
16630188|NCT02414126|Active Comparator|Children with univentricular congenital heart disease|
16630189|NCT02414126|Active Comparator|Children with left valvulopathy|
16630190|NCT02414113||Low GNOS donors|
16630191|NCT02414113||High GNOS donors|
16630192|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
16630193|NCT02414087|Active Comparator|study group|ICB Medical Insoles
16630194|NCT02414087|Placebo Comparator|control group|without ICB Medical insoles
16630195|NCT02414074|Other|Youth Behavioral Intervention|Teen Intervene Program
16630196|NCT02414074|Other|Parent Education|Everyday Parenting Program
16630197|NCT02414061|Experimental|Breakfast - Carbohydrate + Whey Protein|Addition of whey protein isolate (20 g dissolved in flavoured water) to breakfast meal composition
16630198|NCT02414061|Placebo Comparator|Breakfast - Carbohydrate|Only flavoured water consumed with breakfast meal
16630199|NCT02414061|No Intervention|No Breakfast|Only water consumed at breakfast time point
16630200|NCT02414048|Other|Pimonidazole|All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour
16630201|NCT02414009|Experimental|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
16630202|NCT02414009|Active Comparator|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day
~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
16630203|NCT02413996|Experimental|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
16630204|NCT02413996|Active Comparator|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
16630205|NCT02413983||CI (conventional incision)|The living liver donors underwent hepatectomy using right subcostal incision with a midline extension (conventional incision)
16630206|NCT02413983||MI (midline incision)|The living liver donors underwent hepatectomy using upper midline incision (10cm) without laparoscopic assistance
16630207|NCT02413983||TI (transverse incision)|The living liver donors underwent hepatectomy using transverse incision with laparosocpic assistance
16630208|NCT02413970|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System.
16630209|NCT02413957|No Intervention|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
16630210|NCT02413957|Experimental|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
16630211|NCT02413957|Experimental|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
16630212|NCT02413944|Experimental|healthy volunteers|ACTH stimulation test
16630213|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
16630214|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
16630215|NCT02413905||Senegal|Stool samples on Children with and without severe acute malnutrition in Senegal recruited in 3 locations (Dakar, Dielmo and Ndiop)
16630216|NCT02413905||Niger|Stool samples Children with and without severe acute malnutrition in Niger recruited in Niamey
16630217|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
16630218|NCT02413866|Experimental|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
16630219|NCT02413866|Experimental|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
16630323|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
16631577|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
16630220|NCT02413853|Experimental|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16630221|NCT02413853|Experimental|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16630222|NCT02413840|Experimental|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
16630223|NCT02413840|No Intervention|control group|Psychological counseling only.
16630224|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
16630225|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
16630226|NCT02413814|Experimental|Anger Reduction Treatment|The treatment consists of eight 30-minute IBM sessions. Participants will be presented with ambiguous scenarios and asked imagine themselves in these situations. In the first task, the scenario will be followed by a benign interpretation of the situation. Participants will answer a comprehension question designed to have participants endorse this benign interpretation. In the second task, participants will be presented with a word denoting an interpretation with either a negative/hostile or positive/benign connotation. Following this word, an ambiguous scenario will appear. Participants will indicate whether the word and the scenario were related. They will receive feedback training them to endorse positive interpretations and reject negative interpretations.
16630227|NCT02413814|Placebo Comparator|Control Condition|Participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors (i.e., topics of exercise, diet, hygiene, social support, healthy activities, and sleep, taken from protocols developed from our ongoing research). These participants will also view relaxing videos consisting of brief guided meditation instructions, pictures of nature scenes, and soft music. These sessions (psychoeducation and relaxing videos) will be matched for time with the active treatment condition, lasting 30 minutes each.
16630228|NCT02413801||Psoriasis|Individuals with psoriasis
16630229|NCT02413801||Healthy|Individuals that are healthy
16630230|NCT02413788|Experimental|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
16630231|NCT02413788|Active Comparator|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
16630232|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
16630233|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
16630234|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
16630235|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
16630236|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
16630237|NCT02413749||Stable PsA response to treatment|Individuals with psoriatic arthritis who are being treated standard of care with a stable DMARD or a biologic
16630238|NCT02413749||PsA inadequate response to DMARD|Individuals with psoriatic arthritis who have had an inadequate response to a DMARD and are being treated standard of care with a biologic.
16630239|NCT02413736|Experimental|Imatinib|Imatinib 400 mg/day for 24 months.
16630240|NCT02413736|No Intervention|No imatinib|No further imatinib.
16630241|NCT02413723|Active Comparator|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
16630242|NCT02413723|Placebo Comparator|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
16630243|NCT02413710|Active Comparator|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
16630244|NCT02413710|Experimental|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
16630245|NCT02413697|Active Comparator|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
16630246|NCT02413697|Experimental|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
16630247|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
16630248|NCT02413671|Other|Lupin Protein|Subjects received a test meal rich in carbohydrates and supplemented with lupin protein.
16630249|NCT02413671|Other|Whey Protein|Subjects received a test meal rich in carbohydrates and supplemented with whey protein.
16630250|NCT02413671|Other|Reference|Subjects received a test meal rich in carbohydrates not supplemented with any protein.
16630251|NCT02413658|Active Comparator|Control|Dressings of best current clinical practice, sugar solution.
16630252|NCT02413658|Experimental|Phenytoin 1|Dressings using phenytoin solution 20mg/ml
16630253|NCT02413658|Experimental|Phenytoin 2|Dressings using phenytoin solution 40mg/ml
16630254|NCT02413645|Other|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
16630255|NCT02413645|Other|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
16630256|NCT02413645|Experimental|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
16630257|NCT02413645|Experimental|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
16630258|NCT02413645|Experimental|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
16630259|NCT02413632|Other|First period|"creation of a STIs score risk
~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
16630260|NCT02413632|Other|Second period|"validation of a STIs score risk
~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
16630261|NCT02413619|Active Comparator|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
16630262|NCT02413619|Active Comparator|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
16630263|NCT02413619|Active Comparator|combined surgery|Combined cataract surgery and vitrectomy at the same time
16630264|NCT02413606|Experimental|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
16630265|NCT02413606|No Intervention|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
16630266|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
16630267|NCT02413580|Experimental|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
16630268|NCT02413567|Experimental|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
16630269|NCT02413554|Experimental|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.
~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
16630270|NCT02413554|No Intervention|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
16630271|NCT02413541|Experimental|High EAA and use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
16630272|NCT02413541|Experimental|High EAA and not use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
16630273|NCT02413541|Active Comparator|Low EAA|EAA level < 0.6 and not use Polymyxin-B Hemoperfusion
16630274|NCT02413528|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.
~Intervention: Inhaler sensor"
16630275|NCT02413528|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.
~Interventions: Inhaler sensor and mobile application for asthma adherence"
16630276|NCT02413515|Experimental|Arm 1|Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
16630277|NCT02413502|Experimental|Bacillus Calmette-Guérin (BCG)|Tice brand BCG used to vaccinate BCG-Naïve adults.
16630278|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
16630279|NCT02413476|Experimental|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
16630280|NCT02413476|Active Comparator|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
16630281|NCT02413463|Active Comparator|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
16630282|NCT02413463|Active Comparator|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
16630283|NCT02413437|Experimental|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided
16630284|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided
16630285|NCT02413424|Experimental|Drink Sucralose|Subjects will drink sucralose 10 min before drinking a glucose load
16630286|NCT02413424|Placebo Comparator|Drink Water|Subjects will drink water 10 min before drinking a glucose load
16630287|NCT02413424|Experimental|Taste and spit Sucralose|Subjects will taste and spit up sucralose 10 min before drinking a glucose load
16630288|NCT02413411|Experimental|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
16630289|NCT02413411|Active Comparator|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
16630290|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
16630291|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
16630292|NCT02413385|Experimental|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
16630293|NCT02413385|No Intervention|Usual-care wait-list control|No active intervention (usual care).
16630294|NCT02413372|Experimental|Treatment Group A: BMS-986036|Administered as specified on specified days
16630295|NCT02413372|Experimental|Treatment Group B: BMS-986036|Administered as specified on specified days
16630296|NCT02413372|Placebo Comparator|Treatment Group C: Placebo|Administered as specified on specified days
16630297|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
16630298|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
16630299|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
16630300|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
16630301|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
16630302|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
16630303|NCT02413307|Experimental|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
16630304|NCT02413307|No Intervention|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
16630305|NCT02413294|Experimental|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
16630306|NCT02413281|Experimental|ALKS 5461 Dose 1|Sublingual tablets
16630307|NCT02413281|Experimental|ALKS 5461 Dose 2|Sublingual tablets
16630308|NCT02413281|Experimental|ALKS 5461 Dose 3|Sublingual tablets
16630309|NCT02413281|Active Comparator|Buprenorphine Dose 1|Sublingual tablets
16630310|NCT02413281|Active Comparator|Buprenorphine Dose 2|Sublingual tablets
16630311|NCT02413281|Placebo Comparator|Placebo|Sublingual tablets
16630312|NCT02413268|Placebo Comparator|Placebo|Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.
16630313|NCT02413268|Active Comparator|Nitropaste|Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.
16630314|NCT02413255|Placebo Comparator|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
16630315|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
16630316|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
16630317|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
16630318|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
16630319|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
16630320|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
16630321|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
16630322|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
16630324|NCT02413255|Placebo Comparator|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
16630325|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
16630326|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
16630327|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
16630328|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
16630329|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
16630330|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
16630331|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.
~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
16630332|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.
~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
16630333|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
16630334|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
16630335|NCT02413216|Experimental|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
16630336|NCT02413216|Active Comparator|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
16630337|NCT02413203|Experimental|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
16630338|NCT02413203|Placebo Comparator|Placebo|Oral administration of a single placebo pill.
16630339|NCT02413177|Active Comparator|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
16630340|NCT02413177|Active Comparator|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
16630341|NCT02413164|Experimental|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
16630342|NCT02413164|No Intervention|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
16630343|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
16630344|NCT02413151|Active Comparator|Control|Regular lifestyle
16630345|NCT02413138|Experimental|Phase 2: Somavaratan (VRS-317)|Active treatment arm
16630346|NCT02413138|Experimental|Phase 3: Somavaratan (VRS-317)|Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
16630347|NCT02413125|Experimental|ChitoRino irrigation solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer 1 packet of ChitoRhino irrigation solution (premixed from manufacturer containing sea salt, Chitosan, and sodium bicarbonate). An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
16630348|NCT02413125|Experimental|Normal saline solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer nasal saline (250mL of 0.9% sodium chloride) irrigation solution. An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
16630349|NCT02413112|Experimental|Training once per week|Subjects train once per week in the University gym. All training sessions are supervised by the researchers.
16630350|NCT02413112|Experimental|Training twice per week|Subjects train twice per week in the University gym. All training sessions are supervised by the researchers.
16630351|NCT02413112|Experimental|Thrice per week|Subjects train three times per week in the University gym. All training sessions are supervised by the researchers.
16630352|NCT02413112|No Intervention|Non-training Control group|Subjects continue with their normal daily lives, just performing measurements
16630353|NCT02413099|Experimental|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
16630354|NCT02413099|Placebo Comparator|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
16630355|NCT02413086|Experimental|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
16630356|NCT02413086|Experimental|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
16630357|NCT02413086|Experimental|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
16630358|NCT02413086|Experimental|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
16630359|NCT02413073|Sham Comparator|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
16630360|NCT02413073|Experimental|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
16630361|NCT02413060|Experimental|Resistance training|Patients of treatment group will undergo resistance training every week sessions
16630362|NCT02413060|Other|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
16630363|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
16630364|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
16630365|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
16630366|NCT02413021|Experimental|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
16630367|NCT02413021|Active Comparator|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
16630368|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
16630369|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
16630370|NCT02412995|Experimental|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
16630371|NCT02412995|Experimental|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
16630372|NCT02412995|Experimental|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
16630373|NCT02412995|Experimental|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
16630374|NCT02412995|Experimental|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
16630375|NCT02412995|Experimental|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
16630379|NCT02412969|Active Comparator|Lumbar Epidural|Control group will have standard of care Lumbar Epidural
16630380|NCT02412969|Experimental|Dural Puncture Epidural|Will receive Dural Puncture Epidural
16630381|NCT02412956|No Intervention|Control|pamphlet
16630382|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
16630383|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
16630384|NCT02412943|Experimental|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
16630385|NCT02412930|Active Comparator|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
16630386|NCT02412930|Placebo Comparator|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
16630387|NCT02412917|Experimental|FV-100 400 mg QD|FV-100 400mg QD
16630388|NCT02412917|Experimental|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
16630389|NCT02412917|Active Comparator|valacyclovir|valacyclovir 1000mg TID
16630390|NCT02412904|Other|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
16630391|NCT02412904|Other|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
16630392|NCT02412891|Active Comparator|Patients receive active UroShield device|Patients receive active UroShield device
16630393|NCT02412891|Sham Comparator|Patients receive inactive UroShield device|Patients receive inactive UroShield device
16630394|NCT02412878|Experimental|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).
~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
16630395|NCT02412878|Experimental|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).
~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
16630396|NCT02412865|Experimental|Intervention|quit4baby + text4baby
16630397|NCT02412865|Other|Control|text4baby
16630398|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
16630399|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
16630400|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
16630401|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
16630402|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
16630403|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
16630404|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
16630405|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
16630406|NCT02412813|Active Comparator|LEGION OXINIUM femoral component|
16630407|NCT02412813|Active Comparator|LEGION Cobalt Chrome femoral components|
16630408|NCT02412800||Acute lung injury|Postoperative acute lung injury was diagnosed according to the latest 2012 Berlin definition of acute respiratory distress syndrome by the PaO2/FiO2< 300 and acute onset of bilateral infiltrates on the chest radiograph that were not fully explained by cardiac failure during postoperative day 1 to postoperative day 3.
16630409|NCT02412787|Experimental|Idursulfase-IT|Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than [>] 8 months to 30 months of age) and 10 mg (>30 months to 3 years of age) of idursulfase-IT.
16630410|NCT02412774|Experimental|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
16630411|NCT02412774|Experimental|Water|Water after the main meal+ Diet
16630412|NCT02412761|Active Comparator|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
16630413|NCT02412761|Active Comparator|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
16630414|NCT02412761|Active Comparator|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
16630415|NCT02412761|Active Comparator|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
16630416|NCT02412761|Active Comparator|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
16630417|NCT02412761|Active Comparator|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
16630418|NCT02412748|Active Comparator|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
16630419|NCT02412748|Experimental|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
16630420|NCT02412735|Experimental|rexlemestrocel-L|"rexlemestrocel-L alone: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells"
16630423|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
16630424|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
16630425|NCT02412722|Experimental|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
16630426|NCT02412722|Experimental|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
16630427|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
16630428|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
16630429|NCT02412709|Experimental|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
16630430|NCT02412709|Active Comparator|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
16630431|NCT02412696|Active Comparator|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
16630432|NCT02412696|Placebo Comparator|Nasal Dilator Strips|Nasal dilator strips during sleep.
16630433|NCT02412670|Experimental|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Pegfilgrastim at 6 mg is given once 24-48 hours after completion of chemotherapy. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
16630434|NCT02412670|Experimental|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
16630435|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
16630436|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
16630437|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
16630438|NCT02412644|Active Comparator|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
16630439|NCT02412644|Placebo Comparator|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
16630440|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
16630441|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
16630442|NCT02412618|Active Comparator|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
16630443|NCT02412618|Placebo Comparator|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
16630444|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
16630445|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
16630446|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
16630447|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
16630448|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
16630449|NCT02412553|Active Comparator|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
16630450|NCT02412553|Active Comparator|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
16630451|NCT02412540|No Intervention|Weight Loss Surgery|Adolescents who will have Weight Loss Surgery and had biopsy-confirmed NASH. The Weight Loss Surgery is not part of the study. The investigators are following the adolescents after the surgery.
16630452|NCT02412540|Experimental|Comprehensive Lifestyle Intervention|Comprehensive Lifestyle Intervention - Dietary, activity and behavioral interventions. Adolescents who have biopsy-confirmed NASH and wish to participate in a Comprehensive Lifestyle Intervention (26+ contact hours) including individual meetings with a study dietitian, group nutrition classes, behavior management modules and physical activity goals.
16630453|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
16630454|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
16630456|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
16630457|NCT02412514|Active Comparator|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
16630458|NCT02412514|Active Comparator|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
16630459|NCT02412501|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
16630460|NCT02412488|Experimental|Out of CathLab setting|Out of cathlab insertion
16630461|NCT02412475|Experimental|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
16630462|NCT02412462|Experimental|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
16630463|NCT02412449|Experimental|Treatment A|AKB-6548
16630464|NCT02412449|Experimental|Treatment B|AKB-6548
16630465|NCT02412449|Experimental|Treatment C|AKB-6548
16630466|NCT02412436|Experimental|Arm A: Depot medroxyprogesterone acetate|At study entry/week 0, participants received depot medroxyprogesterone acetate (DMPA) 150 mg administered intramuscularly as a single dose and co-administered with rifampicin (RIF) and efavirenz (EFV).
16630467|NCT02412423|Experimental|treatment group|post-transplantation cyclophosphamide
16630468|NCT02412410|Experimental|Single|Single arm pilot study analyzing sleep data and calculated efficacy before and after fatigue avoidance education (comparator is same group after intervention)
16630469|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16630470|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16630471|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16630472|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16630473|NCT02412371|Experimental|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
16630474|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
16630475|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
16630476|NCT02412371|Active Comparator|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
16630477|NCT02412358|Active Comparator|Pulsar|Patients use Pulsar toothbrush for plaque removal
16630478|NCT02412358|Active Comparator|Crossaction|Patients use Crossaction toothbrush for plaque removal
16630479|NCT02412358|Active Comparator|Butler|Patients use Butler toothbrush for plaque removal
16630480|NCT02412345|Experimental|Extracorporeal Shockwave therapy|Extracorporeal shockwave therapy at the penis. 6 sessions.
16630481|NCT02412345|Sham Comparator|Sham treatment|Extracorporal shockwave therapy with a placebo probe. 6 sessions
16630482|NCT02412332|No Intervention|Group 1 - Control|The patients will be followed during the course of 12 months and evaluated regarding disease progression. No interventions will be performed other than conventional (in-course) treatment.
16630483|NCT02412332|Experimental|Group 2 - BMMC|Patients will be submitted to bone marrow harvesting. Bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation and returned to patients by systemic infusion (1x10^8 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
16630484|NCT02412332|Experimental|Group 3 - ASC|Patients will be submitted to liposuction. The obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) will be returned to patients by systemic infusion (1x10^8 ASC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
16630485|NCT02412332|Experimental|Group 4 - BMMC + ASC|Patients will be submitted to liposuction and the obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) obtained. Patients will be submitted to bone marrow harvesting and bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation. BMMC and ASC will be returned to patients by systemic infusion (5x10^7 ASC + 5x10^7 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
16630540|NCT02411942|Placebo Comparator|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
16630486|NCT02412319|Experimental|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
16630487|NCT02412319|Placebo Comparator|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
16630488|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
16630489|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
16630490|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
16630491|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
16630492|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
16630493|NCT02412293|Experimental|Intervention|"Health Education & Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.
~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.
~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
16630494|NCT02412293|No Intervention|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
16630495|NCT02412267|Experimental|O-ICE|"O-ICE:
~Ofatumumab 1000mg intravenous (IV) infusion on Day 1 and Day 8 of cycle 1 of the salvage chemotherapy, and thereafter on Day 1 of each cycle; Ifosfamide 1667 mg/m2 IV infusion over 2 hours on days 1,2,3 of each cycle; Carboplatin 5 x ((25 + Creatinine clearance (CrCl)) IV in 250 ml Normal Saline over 1 hour on day 1 of each cycle; Etoposide 100mg/m2/day IV infusion day 1,2,3 over 45 to 60 minutes of each cycle."
16630496|NCT02412254|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
16630497|NCT02412254|Placebo Comparator|Successful aging intervention|Successful aging intervention
16630498|NCT02412241|Other|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).
~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.
~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
16630499|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18
~Maintenance:
~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
16630500|NCT02412215|Experimental|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
16630501|NCT02412202|Other|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
16630502|NCT02412189|No Intervention|control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
16630503|NCT02412189|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
16630504|NCT02412176|Experimental|Pacing site - right ventricular apex|The intervention will be the implantation of the lead into the right ventricular apex
16630505|NCT02412176|Experimental|Pacing site - septum|The intervention will be the implantation of the lead into the septum.
16630506|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
16630507|NCT02412150|Experimental|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.
~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.
~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.
~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.
~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
16630572|NCT02411773|Active Comparator|Stretching/Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
16631821|NCT02403284|Placebo Comparator|Sugar pill|matching placebo and titration
16630508|NCT02412150|Placebo Comparator|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.
~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.
~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.
~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
16630509|NCT02412137|Experimental|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
16630510|NCT02412137|Placebo Comparator|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
16630511|NCT02412124|Experimental|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
16630512|NCT02412111|Experimental|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
16630513|NCT02412111|Experimental|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
16630514|NCT02412111|Active Comparator|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
16630515|NCT02412098|Experimental|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
16630516|NCT02412098|Experimental|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
16630517|NCT02412098|Experimental|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
16630518|NCT02412085|Experimental|Golimumab|Subcutaneous golimumab
16630519|NCT02412059|Experimental|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
16630520|NCT02412059|No Intervention|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
16630521|NCT02412046|Active Comparator|Time of the first biopsy: H0|For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
16630522|NCT02412046|Active Comparator|Time of the first biopsy: H1|For a patient in arm H1, it is done after 1 hour lying on the air mattress.
16630523|NCT02412046|Active Comparator|Time of the first biopsy: H2|For a patient in arm H2, it is done after 2 hour lying on the air mattress.
16630524|NCT02412046|Active Comparator|Time of the first biopsy: H3|For a patient in arm H3, it is done after 3 hour lying on the air mattress.
16630525|NCT02412033|Active Comparator|Misoprostol group|Going to receive 400 µg misoprostol vaginally 3 hours before IUD insertion.
16630526|NCT02412033|Placebo Comparator|Placebo group|Going to receive placebo.
16630527|NCT02412020|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 14 days
16630528|NCT02412020|Placebo Comparator|Placebo|Placebo PA101, administered via inhalation three times daily for 14 days
16630529|NCT02412007|Experimental|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.
~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
16630530|NCT02412007|Active Comparator|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to
~Passive stretching exercises for spasticity reduction
~Gait exercises
~Walking on treadmill
~Lower limb strengthening exercises
~Exercises for balance improvenet"
16630531|NCT02411994|Experimental|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
16630532|NCT02411994|Active Comparator|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
16630533|NCT02411981|Other|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.
~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
16630534|NCT02411968||111In-Girentuximab DOTA SPECT|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
16630535|NCT02411955|Experimental|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% (Taro Pharmaceuticals Inc.)
16630536|NCT02411955|Active Comparator|Tazorac®|Tazorac® (tazarotene cream 0.1%) (Allergan LLC)
16630537|NCT02411955|Placebo Comparator|Placebo|Placebo (Vehicle of the test product) (Taro Pharmaceuticals Inc.)
16630538|NCT02411942|Experimental|Adapalene Gel 0.3%|Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)
16630609|NCT02411500|Experimental|Formulation B|
16630541|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
16630542|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
16630543|NCT02411916|No Intervention|controls|patients not receiving misoprostol
16630544|NCT02411903|Active Comparator|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
16630545|NCT02411903|Experimental|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
16630546|NCT02411890|Experimental|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
16630547|NCT02411890|Active Comparator|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
16630548|NCT02411877|Active Comparator|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.
16630549|NCT02411877|Experimental|Mild hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.
16630550|NCT02411864||Group 1|Low b=(0,50,150,200)，NEX=(1,3,2,2)
16630551|NCT02411864||Group 2|Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
16630552|NCT02411864||Group 3|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
16630553|NCT02411864||Group 4|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
16630554|NCT02411864||Group 5|Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
16630555|NCT02411851|Active Comparator|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
16630556|NCT02411851|Experimental|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
16630557|NCT02411838|No Intervention|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
16630558|NCT02411838|Experimental|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).
~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).
~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
16630559|NCT02411825|Experimental|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
16630560|NCT02411825|Placebo Comparator|Placebo (healthy subjects)|Once daily SC doses of placebo
16630561|NCT02411825|Experimental|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
16630562|NCT02411825|Placebo Comparator|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
16630563|NCT02411812|Experimental|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
16630564|NCT02411812|Active Comparator|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
16630565|NCT02411812|Active Comparator|Twin-Block appliances|Group treated with Twin-Block appliance.
16630566|NCT02411786|Experimental|pTVG-AR biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
16630567|NCT02411786|Experimental|pTVG-AR staggered biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
16630568|NCT02411786|Experimental|pTVG-AR with rhGM-CSF biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
16630569|NCT02411786|Experimental|pTVG-AR with rhGM-CSF staggered biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
16630570|NCT02411773|Active Comparator|Exercise Training/Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
16630571|NCT02411773|Active Comparator|Exercise Training/Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
16630610|NCT02411500|Experimental|Formulation C|
16630611|NCT02411500|Experimental|Formulation D|
16630573|NCT02411773|Placebo Comparator|Stretching/Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
16630574|NCT02411773|No Intervention|Control|Healthy subjects without CKD will not receive any interventions.
16630575|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
16630576|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
16630577|NCT02411721|Experimental|Animal assisted intervention|The Effects of Dog Intervention on Anxiety Levels in Children. The experimental group will receive standard training on the imaging process by the MRI technician plus intervention activity with a dog
16630578|NCT02411721|No Intervention|control group|The control group will receive the standard training on the imaging process by the MRI technician.
16630579|NCT02411708|Experimental|SANGUINATE|320 mg/kg
16630580|NCT02411708|Placebo Comparator|Placebo|Normal saline IV infusion
16630581|NCT02411695|Experimental|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
16630582|NCT02411695|Experimental|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
16630583|NCT02411695|Experimental|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
16630584|NCT02411695|Experimental|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
16630585|NCT02411695|Experimental|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
16630586|NCT02411682|Active Comparator|YesB|On YesB day the patients will consume breakfast , lunch and dinner
16630587|NCT02411682|Experimental|NoB|On NoB Day The patient will consume only lunch and dinner
16630588|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
16630589|NCT02411656|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over approximately 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16630590|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
16630591|NCT02411630||Interactive Questionnaire System (iQS)|An Interactive Questionnaire System (iQS) will be administered twice. First at study entry (ATN 110/113 week 24 visit) and second at week 24 (ATN 110/113 week 48 visit). The questionnaire will assess adherence as well as how structural (physical settings) and partnership factors affect adherence of YMSM to PrEP with FTC/TDF (Truvada®).
16630592|NCT02411617|Active Comparator|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
16630593|NCT02411617|Active Comparator|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
16630594|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.
~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.
~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.
~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
16630595|NCT02411578|Experimental|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).
~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
16630596|NCT02411578|Active Comparator|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).
~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
16630597|NCT02411565|Active Comparator|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
16630598|NCT02411565|Placebo Comparator|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
16630599|NCT02411552||Intervention schools|These schools were promoting 4 strategies to increase physical activity in students.
16630600|NCT02411552||Control schools|These schools continued with standard programming for activity during year 1, and implemented intervention during years 2 and 3.
16630601|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
16630602|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
16630603|NCT02411526|Experimental|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
16630604|NCT02411526|Experimental|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
16630605|NCT02411526|Experimental|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
16630606|NCT02411526|Active Comparator|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
16630607|NCT02411513|Experimental|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
16630608|NCT02411500|Experimental|Formulation A|
16630614|NCT02411474||With or without newly diagnosed chronic GVHD after SCT|The patients developed chronic GVHD after SCT/ The patients did not developed chronic GVHD after SCT
16630615|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
16630616|NCT02411461||Healthy siblings|Control group
16630617|NCT02411461||Obese patients|Control group
16630618|NCT02411448|Experimental|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.
~Participants may continue to receive treatment until discontinuation criteria are met.
~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
16630619|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.
~Participants may continue to receive treatment until discontinuation criteria are met."
16630620|NCT02411448|Experimental|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.
~Ramucirumab and gefitinib administered during period 1.
~Ramucirumab and osimertinib administered during period 2."
16630621|NCT02411435|Experimental|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
16630622|NCT02411422|Experimental|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.
~Two kinds of endotracheal tube will be used
~Conventional endotracheal tube
~Reinforced endotracheal tube"
16630623|NCT02411422|Experimental|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.
~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.
~Two kinds of endotracheal tube will be used
~Conventional endotracheal tube
~Reinforced endotracheal tube"
16630624|NCT02411422|Experimental|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.
~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.
~Two kinds of endotracheal tube will be used
~Conventional endotracheal tube
~Reinforced endotracheal tube"
16630625|NCT02411409|Experimental|Intervention group|This group of patients receives the HealtheRx.
16630626|NCT02411409|No Intervention|Control group|This group of patients does not receive the HealtheRx
16630627|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
16630628|NCT02411383|Experimental|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
16630629|NCT02411357|Active Comparator|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
16630630|NCT02411357|Experimental|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
16630631|NCT02411357|Experimental|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
16630632|NCT02411344|Experimental|Pertuzumab, Trastuzumab, Letrozole|
16630633|NCT02411331|Experimental|Experimental group|90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
16630634|NCT02411331|Other|control group|90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study
16630635|NCT02411318|Experimental|Cardiovascular Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes. For example, a 30 year old will have a target heart rate zone of 95-162 beats per minute. A baseline blood sample will be acquired before the participant begins exercising. In the following 30 minutes, participants will ride the exercise bike, and their heart rate and general status will be assessed continuously. Specifically, heart rate will be monitored using a chest strap heart rate monitor. Two additional lancet punctures will be performed after the exercise to measure the changes in neutrophil function: one immediately following the 30 minute exercise period and one 30 minutes after the exercise has been completed.
16630636|NCT02411318|Experimental|Caffeine Consumption|Participants will be exposed to a moderate dose of caffeine (200 mg capsule in one sitting) from a common commercial product. After consent and screening, a baseline blood sample will be acquired using the lancet puncture procedure. The participant will then be instructed to swallow a 200 mg caffeine capsule. Two additional lancet punctures will be performed after the caffeine ingestion: one after 30 minutes post-ingestion and another one after 60 minutes.
16630637|NCT02411318|Experimental|Ethanol Ingestion|Participants will be weighed and their required alcohol dose determined according to the equation used by the Madison Police Department during alcohol training workshops: 1 mL of 80 proof (40%) alcohol per pound of body weight. Participants will be permitted to consume the drink at their own pace, although no slower than one drink per hour. Breath Alcohol Concentration (BAC) will be tested 20 minutes after drinking has ceased in order to clear mouth alcohol that may affect the BAC reading. Participants at 0.05 BAC and above will have blood drawn via lancet puncture. In addition to the lancet puncture done once the alcohol level is reached, an additional lancet puncture will be performed 1 hour later.
16630638|NCT02411318|Experimental|Glucose Ingestion|After a baseline blood sample is acquired, participants will consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
16630639|NCT02411318|Experimental|Glucose and Caffeine Ingestion|After a baseline blood sample is acquired, participants will swallow 200mg of caffeine in capsule form and consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the caffeine and glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
16630640|NCT02411305||PCRC Palliative Care Clinicians|
16630641|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
16630642|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
16630643|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
16630644|NCT02411266|Placebo Comparator|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
16630645|NCT02411266|Active Comparator|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
16630646|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,
~1MIU/day for adults.
~Subcutaneous injection every day (5 days) then:
~Regimen A injection every two weeks between D15 and D351,
~Regimen B injections every week between D15 and D351"
16630647|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:
~Regimen A injection every two weeks between D15 and D351
~Regimen B injections every week between D15 and D351"
16630648|NCT02411240|Other|Air filtering in the living room|GENANO tubes, GENANO Benelux; Heusen-Zolder, Belgium
16630649|NCT02411227|Experimental|1|Immediate Intervention
16630650|NCT02411227|No Intervention|2|Wait list
16630651|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
16630652|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
16630653|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
16630654|NCT02411201|Experimental|DOTAREM|
16630655|NCT02411188|Experimental|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
16630656|NCT02411188|No Intervention|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
16630657|NCT02411175|Experimental|20% Ethanol|20% ethanol will be medicated with the individualised homeopathic remedy as determined by the researcher and administered as drops. The potency, dose and frequency of the medicated 20% ethanol drops will be determined for each prescription, in accordance with the laws that govern homeopathic prescribing.
16630658|NCT02411162|Experimental|Open Label Arm|In Cohort 1, study medication (Cream A, 1%) will be applied as a thin layer onto a predefined area of the volar region of the forearm that is large enough to image and collect 3 biopsies (4 mm per biopsy). Vehicle will be applied on Day 1 only, onto a symmetrical location on the opposite forearm from Cream A. In cohort 2, subjects will be enrolled to evaluate Cream A (1%) and a different GSK2894512 Cream, Cream B (1%). Cream A, 1% and Cream B, 1% will be applied as a thin layer to the opposite forearms of the subject. Vehicle will be applied only on Day 1 to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied. Both Cream A and Cream B will continue to be applied OD to the same area of the same forearm for 7 days.
16630659|NCT02411149|Placebo Comparator|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:
~30 ml normal saline
~3ml 0.5% preservative-free bupivacaine"
16630660|NCT02411149|Active Comparator|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:
~ropivacaine 0.5% with 1:400,000 epinephrine
~3ml 0.5% preservative-free bupivacaine"
16630661|NCT02411149|Active Comparator|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:
~ropivacaine 0.5% with 1:400,000 epinephrine
~3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
16630662|NCT02411136|Experimental|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
16630663|NCT02411136|Placebo Comparator|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
16630664|NCT02411123|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
16630665|NCT02411123|No Intervention|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
16630666|NCT02411110|Experimental|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
16630667|NCT02411110|Other|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
16630668|NCT02411097|Experimental|femoral nerve block|femoral nerve block will be administered before or after the surgery
16630758|NCT02410564|Active Comparator|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
16630669|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
16630670|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
16630671|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
16630672|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
16630673|NCT02411058|Experimental|Uninformed|Condition 1
16630674|NCT02411058|Experimental|Informed about Incentives and Purpose|Condition 2
16630675|NCT02411045|Active Comparator|Group 1: Control|Ask participants to take a picture of themselves
16630676|NCT02411045|Experimental|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
16630677|NCT02411045|Experimental|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
16630678|NCT02411032|Experimental|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
16630679|NCT02411032|Experimental|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
16630680|NCT02411032|Experimental|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
16630681|NCT02411032|Experimental|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
16630682|NCT02411032|Experimental|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
16630683|NCT02411019||Observational group|Subjects in the period less than 24 weeks after the final administration of GX-188E
16630684|NCT02411006|No Intervention|Usual care control|No intervention, just usual care from the insurance company
16630685|NCT02411006|Experimental|Reminder control|Send a reminder to subjects every month
16630686|NCT02411006|Experimental|Anonymous prediction|Ask subjects to anonymously predict their upcoming medication adherence
16630687|NCT02411006|Experimental|Anonymous commitment|Ask subjects to anonymously commit to their upcoming medication adherence
16630688|NCT02411006|Experimental|Identified prediction|Ask subjects to predict their upcoming medication adherence and report it
16630689|NCT02411006|Experimental|Identified commitment|Ask subjects to commit to their upcoming medication adherence and report it
16630690|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
16630691|NCT02410980|Experimental|Tretinoin cream 0.1%|Assessment of the skin change
16630692|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
16630693|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
16630694|NCT02410954|Experimental|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
16630695|NCT02410954|Placebo Comparator|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
16630696|NCT02410941|Experimental|Decision-support for MTBI|Clinical decision support will be provided on ordering CT scans for patients suspected to have Minor Traumatic Brain Injury (MTBI) to treating physicians randomized into this group. This arm will also serve as a control for the PE group.
16630697|NCT02410941|Experimental|Decision-support for PE|Clinical decision support will be provided on ordering CT scans for patients suspected to have Pulmonary Embolism (PE) to treating physicians randomized into this group. This arm will also serve as a control for the MTBI group.
16630698|NCT02410928|Experimental|fiberoptic nasal laringoscopy|the vocal cords ill be visualized with fiberoptic nasal laringoscopy
16630699|NCT02410928|Experimental|ultrasonography|the vocal cords ill be visualized with ultrasonography
16630700|NCT02410928|Active Comparator|Direct laringoscopy|the vocal cords ill be visualized with direct laringoscopy
16630701|NCT02410915|Experimental|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
16630702|NCT02410915|Active Comparator|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
16630703|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
16630704|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
16630705|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
16630706|NCT02410876||Controls|No lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
16630707|NCT02410876||Spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.
~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
16630708|NCT02410876||Spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.
~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
16630709|NCT02410876||Prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.
~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
16630710|NCT02410876||Prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
16630711|NCT02410863|Experimental|Cohort A (BRAFi naïve)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily.
16630712|NCT02410863|Experimental|Cohort B (BRAFi / MEKi rechallenge)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily
16630713|NCT02410850||University of Montreal|Patients from University of Montreal in Canada
16630714|NCT02410850||University of Antwerp|Patients from University of Antwerp in Belgium.
16630715|NCT02410850||University of Sydney|Patients from University of Sydney in Australia.
16630716|NCT02410850||Angers University Hospital|Patients from Angers University Hospital in France.
16630717|NCT02410850||University of Gronigen|Patients from University of Gronigen in Netherlands.
16630718|NCT02410850||Kaiser Permanente|Patients from Kaiser Permanente from USA.
16630719|NCT02410850||Stanford University|Patients from Stanford University from USA.
16630720|NCT02410850||Laval University|Patients from Laval University in Canada.
16630721|NCT02410850||Cambridge University|Patients from Cambridge University in UK.
16630722|NCT02410850||Kyushu University|Patients from Kyushu University in Japan
16630723|NCT02410850||Japan Somnology Center|Patients from Japan Somnology Center in Japan.
16630724|NCT02410850||Uniformed Services University|Patients from the Uniformed Services University in USA.
16630725|NCT02410850||University of British Columbia|Patients from the University of British Columbia in Canada.
16630726|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
16630727|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
16630728|NCT02410811||Age Stratum A|"Age 6 to 13.99 years
~Cardiac magnetic resonance imaging (CMR)"
16630729|NCT02410811||Age Stratum B|"Age 14 to 20.99 years
~Detectible and quantifiable TRJV with reported value
~Cardiac magnetic resonance imaging (CMR)"
16630730|NCT02410811||Age Stratum C|"Age ≥21 years
~Detectible and quantifiable TRJV with reported value
~Cardiac magnetic resonance imaging (CMR)"
16630731|NCT02410811||Age Stratum D|"Age ≥6 years.
~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.
~Cardiac magnetic resonance imaging (CMR)"
16630732|NCT02410798|Experimental|TransLoc electrode|Electrode placement
16630733|NCT02410785|Active Comparator|Medical device polyglucosamine|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
16630734|NCT02410785|Placebo Comparator|Placebo|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
16630735|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid
~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
16630736|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid
~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
16631647|NCT02404454|Experimental|hysteroscopic metroplasty|women undergoing hysteroscopic metroplasty for uterine septum resection
16630737|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin
~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
16630738|NCT02410759|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
16630739|NCT02410759|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
16630740|NCT02410746|Active Comparator|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
16630741|NCT02410746|Experimental|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
16630742|NCT02410733|Experimental|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
16630743|NCT02410720|Active Comparator|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
16630744|NCT02410720|Experimental|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
16630745|NCT02410707|Experimental|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
16630746|NCT02410694|Experimental|Ixazomib-Thalidomide-Dexamethasone|"Combination therapy of:
~Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.
~After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months."
16630747|NCT02410668|Active Comparator|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
16630748|NCT02410668|Placebo Comparator|control|dietary and exercise recommendation
16630749|NCT02410655|Active Comparator|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
16630750|NCT02410655|Active Comparator|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
16630751|NCT02410629|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
16630752|NCT02410629|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
16630753|NCT02410616|Experimental|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
16630754|NCT02410616|Active Comparator|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
16630755|NCT02410590|Experimental|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
16630756|NCT02410590|Active Comparator|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
16630757|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
16630759|NCT02410564|Placebo Comparator|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
16630760|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
16630761|NCT02410538||"families that received the list of FAQ"|"The intervention consists of the delivery to the relatives of ICU patients a list of 21 key issues in intensive care during the first 48h period of ICU stay, only for intubated and mechanically ventilated patients A formal interview is scheduled to relatives of ICU patients on D3 of inclusion"
16630762|NCT02410538||families that received information as usual|A formal interview is scheduled relatives of ICU patients on D3 inclusion
16630763|NCT02410525|Experimental|[11C]PF-06427878|Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
16630764|NCT02410525|Experimental|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
16630765|NCT02410525|Experimental|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
16630766|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
16630767|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
16630768|NCT02410499|Placebo Comparator|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
16630769|NCT02410499|Experimental|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
16630770|NCT02410499|Experimental|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
16630771|NCT02410499|Experimental|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
16630772|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
16630773|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
16630774|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
16630775|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
16630776|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
16630777|NCT02410460|Other|PKA-BIS (intravenous anesthesia)|"Received the following medications:
~clonidine 0.1-0.2mg glycopyrrolate 0.2mg propofol infusion titrated to BIS of 60-75 ketamine 50mg + additional ketamine not to exceed 200mg aggregate dosage throughout the case local anesthetic (lidocaine/marcaine mix)"
16630778|NCT02410460|Other|Inhalational anesthesia|"Received the following:
~Pre-operatively:
~famotidine 20mg scopolamine 1.5mg transdermal patch midazolam 2mg ondansetron 8mg metoclopramide 10mg glycopyrrolate - dose determined by anesthesiologist
~During the case, medication choices and dosing were dependent on the anesthesiologist - all general anesthesia cases received inhalational anesthetic (type of anesthetic - desfluorane vs. sevofluorane - also varied based on anesthesiologist's choice)"
16630779|NCT02410447|Experimental|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).
~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
16630780|NCT02410434|Experimental|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
16630781|NCT02410421|Experimental|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.
~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).
~The procedure will be repeated twice a day for 10 days over 2 weeks."
16630878|NCT02409745|Experimental|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
16630782|NCT02410421|Active Comparator|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
~Coil and stimulator will remain the same between individualized and as usual proceedures."
16630783|NCT02410421|Active Comparator|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
16630784|NCT02410408|Active Comparator|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
16630785|NCT02410408|Experimental|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
16630786|NCT02410395|Active Comparator|Conventional technique|Closure of the uterotomy with a conventional two-layer technique
16630787|NCT02410395|Experimental|Modified technique|Closure of the uterotomy with a modified two-layer technique
16630788|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
16630789|NCT02410382|Active Comparator|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
16630790|NCT02410369|Active Comparator|S-588410|Subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
16630791|NCT02410369|Placebo Comparator|Placebo|Subjects with HLA-A*2402 in the placebo arm will receive the subcutaneous administration of placebo.
16630792|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
16630793|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
16630794|NCT02410343|Placebo Comparator|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
16630795|NCT02410343|Experimental|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
16630796|NCT02410330||Group I|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with Therapeutic ultrasound with 20 usec: custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 MI designed for the 1.7 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
16630797|NCT02410330||Group II|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low MI perfusion imaging detected microbubbles within the microvasculature. Treatment will be applied while patient waits for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
16630798|NCT02410330||Group III|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) while few limited diagnostic high MI impulses (n<5 per patient) will be applied to assess myocardial perfusion before and after percutaneous coronary intervention (PCI).
16630799|NCT02410317|Experimental|Continuous wound infusion group|Patients receive analgesia through a multiorifice wound catheter connected to ropivacaine infusion. Saline solution is given in the epidural bolus.
16630800|NCT02410317|Active Comparator|Epidural morphine group|Patients receive epidural analgesia through an epidural bolus of morphine. Saline solution is perfused through the wound catheter.
16630801|NCT02410304|Other|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
16630802|NCT02410304|Other|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
16630803|NCT02410304|Other|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
16630804|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
16630805|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
16630806|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
16630807|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
16630845|NCT02409979|Active Comparator|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
16631648|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
16630808|NCT02410265|Experimental|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
16630809|NCT02410265|Experimental|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
16630810|NCT02410265|No Intervention|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
16630811|NCT02410252|Experimental|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
16630812|NCT02410239|Experimental|Mesenchymal Stem Cell|Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
16630813|NCT02410226|Active Comparator|Palpation|Double-space combined spinal-epidural anesthesia, Sham ultrasound procedure
16630814|NCT02410226|Experimental|Ultrasound|Double-space combined spinal-epidural anesthesia, Preprocedure spinal ultrasound
16630815|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
16630816|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
16630817|NCT02410187|Active Comparator|Arm 1|systemic therapy+palliative RT
16630818|NCT02410187|Experimental|Arm 2|systemic therapy+SBRT
16630819|NCT02410174|Experimental|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
16630820|NCT02410161|Experimental|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
16630821|NCT02410148|Active Comparator|Papilledema|non-invasive aICP measurement in patientes with papilledema
16630822|NCT02410148|Active Comparator|open angle glaucoma|non-invasive aICP measurement in patients with glaucoma
16630823|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
16630824|NCT02410109|Experimental|SCRIPT intervention|
16630825|NCT02410109|No Intervention|Historical Control|
16630826|NCT02410096|Active Comparator|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
16630827|NCT02410096|Placebo Comparator|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
16630828|NCT02410083|Experimental|Clopirin 1|Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.
16630829|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 1|Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.
16630830|NCT02410083|Experimental|Clopirin 2|Clopirin single-administration. Before this clinical trial Aspirin single-administration.
16630831|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 2|Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.
16630832|NCT02410070|Experimental|Though Volar Minimal Incision|Patients in group A were treated through a small Incision.
16630833|NCT02410070|Active Comparator|Though Convectional Incision|Patients in group B were treated through the conventional Incision
16630834|NCT02410057|Active Comparator|Standard infant formula|Standard infant formula
16630835|NCT02410057|Experimental|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
16630836|NCT02410057|Experimental|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula
16630837|NCT02410057|No Intervention|Breast-feeding|Exclusive breast-feeding
16630838|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
16630839|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.
~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
16630840|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.
~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
16630841|NCT02410005|Active Comparator|Losartan alone|In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.
16630842|NCT02410005|Experimental|Losartan and Calcitriol|In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.
16630843|NCT02409992|Experimental|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting intervention.
16630844|NCT02409992|Active Comparator|Parent Training Only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
16632209|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
16630846|NCT02409979|Experimental|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
16630847|NCT02409979|Experimental|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
16630848|NCT02409966|Active Comparator|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
16630849|NCT02409966|Experimental|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
16630850|NCT02409953|Experimental|Bath|
16630851|NCT02409953|Placebo Comparator|Bed|
16630852|NCT02409940|Experimental|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
16630853|NCT02409940|Active Comparator|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
16630854|NCT02409940|No Intervention|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
16630855|NCT02409927|Other|Healthy participant|Each participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
16630856|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
16630857|NCT02409901|Experimental|Exercise Rehabiliation|12 month personalized exercise rehabilitation in addition to standard clinical care
16630858|NCT02409901|No Intervention|Control|Standard clinical care only
16630859|NCT02409888|Experimental|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
16630860|NCT02409888|Experimental|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
16630861|NCT02409875||Risk groups|"For families that both parents have BMI>=24 or at least one of them BMI>=28, then calculated as high-risk group.
~For families that both parents have BMI<24 or one parents with BMI<24 and one with 24<=BMI<28, then grouped as low-risk group."
16630862|NCT02409862|Experimental|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
16630863|NCT02409862|Placebo Comparator|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
16630864|NCT02409849|No Intervention|control group|
16630865|NCT02409849|Experimental|Octreotide LAR treatment|The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression.
16630866|NCT02409836|Active Comparator|Crest Cavity Protection|Marketed Dentifrice
16630867|NCT02409836|Active Comparator|Crest for Kids Hawaiian Punch Paste|Marketed Dentifrice
16630868|NCT02409836|Active Comparator|Crest for Kids Bubble Gum Paste|Marketed Dentifrice
16630869|NCT02409823||patients on atypical antipsychotics|
16630870|NCT02409810|Experimental|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
16630871|NCT02409797|Experimental|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
16630872|NCT02409784|Experimental|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).
~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet
~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
16630873|NCT02409771|Experimental|Intervention arm|Bilateral implantation with PRECIZON Presbyopic intraocular lens
16630874|NCT02409758|Active Comparator|VFE voice therapy|Voice therapy: Vocal Function Exercises applied during 6 weeks
16630875|NCT02409758|Experimental|CVRP voice therapy|Voice therapy: Comprehensive Voice Rehabilitation Program applied during 6 weeks
16630876|NCT02409745|Experimental|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
16630877|NCT02409745|Active Comparator|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
16632210|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
16630879|NCT02409745|Active Comparator|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
16630880|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
16630881|NCT02409719|Active Comparator|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
16630882|NCT02409719|Experimental|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
16630883|NCT02409693||Myringotomy with tube insertion|Patients who received surgically inserted ear tubes.
16630884|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
16630885|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
16630886|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
16630887|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
16630888|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
16630889|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
16630892|NCT02409641|Experimental|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
16630893|NCT02409628|Experimental|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
16630894|NCT02409615|Active Comparator|Hypnosis Group|Hypnosis Group: fifteen participants will receive Hypnosis therapy in addition to the standard postoperative pain management protocol
16630895|NCT02409615|Active Comparator|Healing Touch Group|Healing Touch Group: fifteen participants will receive Healing Touch therapy in addition to the standard postoperative pain management protocol
16630896|NCT02409615|No Intervention|Control Group|Control Group will receive standard postoperative pain management protocol
16630897|NCT02409602||Women with BIIAL|Women who underwent bilateral internal iliac artery ligation due to postpartum hemorrhage within last 2 months
16630898|NCT02409602||Healthy puerperal women|Age-matched healthy puerperal women who delivered within last 2 months
16630899|NCT02409589|Experimental|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
16630900|NCT02409589|Active Comparator|Conventional|Surface prediction length method
16630901|NCT02409576|Experimental|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
16630902|NCT02409563|Experimental|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
16630903|NCT02409563|Experimental|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
16630904|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
16632420|NCT02399150||Acute Abdominal Pain|patients presenting to the ED with acute abdomen
16630905|NCT02409537|Active Comparator|non cholesterolemic individuals|Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
16630906|NCT02409537|Active Comparator|Asymptomatic Hypercholesterolemics|individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
16630907|NCT02409524|Experimental|Treatment|The treatment schedule of AlloVax includes: (1) Priming segment with ID injections of AlloStim on Days 0, 3, 7 and 10. (2) Vaccination segment with ID injections of AlloStim+CRCL on Days 14, 17, 21 and 24. (3) Activation segment with IV push infusion of AlloStim on Day 28. (4) Booster Segment with monthly (every 28 days) ID injections of CRCL alone beginning on Day 56. These injections will continue until all the vaccine is used or the death of the subject
16630908|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
16630909|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
16630910|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
16630911|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
16630912|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
16630913|NCT02409498|Active Comparator|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
16630914|NCT02409498|Placebo Comparator|no pudendal block|Saline
16630915|NCT02409485|Experimental|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
16630916|NCT02409485|No Intervention|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
16630917|NCT02409472|Other|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography* at 8, and 20 months.
16630918|NCT02409472|Other|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
16630919|NCT02409459|Experimental|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
16630920|NCT02409459|Placebo Comparator|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
16630921|NCT02409446|Experimental|Anthocyanin|34 patients will receive anthocyanin. We will analyze their blood samples both prior and after taking anthocyanin.
16630922|NCT02409446|No Intervention|Controls|Healthy Controls, 20 persons. Will be giving blood samples at study start and study end.
16630923|NCT02409433|Experimental|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
16630924|NCT02409433|Active Comparator|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
16630925|NCT02409420|Experimental|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
16630926|NCT02409420|No Intervention|Control|Usual care
16630927|NCT02409407|Experimental|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
16630928|NCT02409407|Experimental|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
16630929|NCT02409407|Placebo Comparator|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
16630930|NCT02409394|Experimental|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
16630931|NCT02409394|Experimental|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
16630932|NCT02409381|Experimental|Motore|Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
16630933|NCT02409381|Active Comparator|Alivium|Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
16630934|NCT02409368|Experimental|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
16630935|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
16630936|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
16630952|NCT02409264|Experimental|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
16632285|NCT02400190|Experimental|Endocrine therapy alone|Patients receive endocrine therapy alone without radiotherapy
16630937|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
16630938|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
16630939|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.
~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
16630940|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.
~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
16630941|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).
~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
16630942|NCT02409316|Experimental|FES PET/CT|All subjects will receive an [18F]FES PET/CT scan.
16630943|NCT02409303|Experimental|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
16630944|NCT02409303|No Intervention|Control|No intervention received.
16630945|NCT02409290|Active Comparator|Regimen A|Regimen A locally-used WHO-approved MDR-TB regimen in accordance with 2011 WHO MDR-TB treatment guidelines.
16630946|NCT02409290|Active Comparator|Regimen B|"Regimen B is based on the regimen described by Van Deun 2010. With Version 8.0 of the protocol Regimen B (Regimen Bmox) is modified by replacement of moxifloxacin with levofloxacin (Regimen Blev). Regimen B without specification of which fluoroquinolone is in the regimen refers to either (Bmox or Blev).
~Product and dose for [<33 kg, 33-50kg, >50 kg] respectively:
~Moxifloxacin [400mg, 600mg, 800mg] OR Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg,100mg,100mg]; Ethambutol [800mg,800mg,1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid 300mg, 400mg, 600mg]; Prothionamide [250mg,500mg,750mg]; Kanamycin [15mg per kilogram body weight (maximum 1g)]."
16630947|NCT02409290|Experimental|Regimen C|"Regimen C is a 40-week all-oral regimen consisting of bedaquiline, clofazimine, ethambutol, levofloxacin, and pyrazinamide given for 40 weeks supplemented by isoniazid and prothionamide for the first 16 weeks (intensive phase).
~Product and dose for [<33kg, 33-50kg, >50 kg] respectively:
~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg, 100mg, 100mg]; Ethambutol [800mg, 800mg, 1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid [300mg, 400mg, 600mg]; Prothionamide [250mg, 500mg,750mg]."
16630948|NCT02409290|Experimental|Regimen D|"Regimen D is a 28-week regimen consisting of bedaquiline, clofazimine, levofloxacin, and pyrazinamide given for 28 weeks supplemented by isoniazid and kanamycin for the first 8 weeks (intensive phase).
~Product and dose for [<33kg, 33 to<40kg, 40-50kg, >50-60 kg, >60 kg] respectively:
~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin [750mg, 750mg, 750mg, 1000mg, 1000mg]; Clofazimine [50mg, 100mg, 100mg, 100mg, 100mg]; Pyrazinamide [1000mg,1500mg, 1500mg, 2000mg, 2000mg]; Isoniazid [400mg, 500mg, 600mg, 800mg, 900mg]; Kanamycin [15 mg per kilogram body weight (maximum 1g)]."
16630949|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
16630950|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
16630951|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
16630953|NCT02409251|Experimental|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
16630954|NCT02409238|Experimental|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
16630955|NCT02409238|Active Comparator|Standard Level of Care|Standard lifestyle recommendations for the Control groups
16630956|NCT02409225|Experimental|Home Monitoring|Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.
16630957|NCT02409225|Active Comparator|HM option not active.|Regular visits in outpatient clinic. Device: no HM
16630958|NCT02409212|Experimental|Intervention|12 months of aerobic exercise training with behaviour change support
16630959|NCT02409212|Placebo Comparator|Comparison|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
16630960|NCT02409199|Experimental|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16630961|NCT02409199|Active Comparator|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16630962|NCT02409186|Active Comparator|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
16630963|NCT02409186|Placebo Comparator|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
16630964|NCT02409173|Experimental|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
16630965|NCT02409173|No Intervention|Control Group|
16630966|NCT02409160|Experimental|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
16630967|NCT02409160|No Intervention|Control Group|
16630968|NCT02409147|Experimental|Patients|Healthy female volunteers wishing to have a childbirth via uterine transplantation
16630969|NCT02409121|Experimental|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
16630970|NCT02409108|Experimental|Exatherm-TBH system|One treatment of Total Body Hyperthermia
16630971|NCT02409095|Experimental|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
16630972|NCT02409095|Active Comparator|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
16630973|NCT02409069|Experimental|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the ramus auricularis of the vagus nerve (ear)
16630974|NCT02409069|Sham Comparator|Sham stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the earlobe
16630975|NCT02409069|No Intervention|No stimulation|No stimulation
16630976|NCT02409056|Experimental|workplace-tailored CDSMP|Group will receive the CDSMP program which has been modified to fit the unique characteristics of the workplace.
16630977|NCT02409056|Active Comparator|CDSMP usual care|Group will receive the standard CDSMP program which is currently being offered in a variety of community settings.
16630978|NCT02409056|No Intervention|control|Group will receive no intervention for the first 6 months (pre / post), then be randomly assigned to one of the above interventions.
16630979|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
16630980|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
16630981|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
16630982|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
16630983|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.
~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
16630984|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
16630985|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
16630986|NCT02409017|Active Comparator|Protocol A|Our current standard during labor
16630987|NCT02409017|Active Comparator|Protocol B|Another commonly accepted alternative for insulin drip management during labor
16630988|NCT02409004|Experimental|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
16630989|NCT02408991|Experimental|AA and Neopogen|Patient undergoes treatment with Art-assist device and Neupogen
16630990|NCT02408978|Experimental|OXP005|1g naproxen
16630991|NCT02408978|Active Comparator|naproxen|1g naproxen
16630992|NCT02408965|Experimental|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
16630993|NCT02408965|Placebo Comparator|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
16630994|NCT02408952|Experimental|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
16630995|NCT02408952|Experimental|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
16630996|NCT02408952|No Intervention|Usual Care|Care is administered as usual
16630997|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
16630998|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
16630999|NCT02408926|Experimental|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
16631000|NCT02408926|Active Comparator|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
16631001|NCT02408913|Experimental|Group 2|MVA-EbolaZ 1x10(8) PFU
16631002|NCT02408913|Experimental|Group 3|cAd3-EBO 2x10(11) PU followed by MVAEbolaZ 1x10(8) PFU at 8 weeks
16631003|NCT02408913|Experimental|Group1|MVA-EbolaZ 1x10(7) PFU
16631004|NCT02408913|Experimental|Groups 4 to 7|MVA-EbolaZ 1x10(8) PFU administered in VRC 208 to participants who received cAd3-EBO or cAd3-EBOZ in VRC 207.
16631008|NCT02408835|Active Comparator|PICO™|Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.
16631009|NCT02408835|No Intervention|Conventional wound care|Usual wound dressings will be used as comparison group.
16631010|NCT02408822|Active Comparator|PBA (Plain Balloon Angioplasty)|"Patient receiving endovascular treatment of a vascular access stenosis by plain balloon angioplasty (mechanical action, without drug)
~2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure"
16631011|NCT02408822|Experimental|PTX|(PacliTaXel-coated balloon angioplasty) Patient receiving endovascular treatment of a vascular access stenosis by drug-eluting balloon angioplasty (mechanical action + antiproliferative drug - Paclitaxel) 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
16631012|NCT02408809|Active Comparator|Control|
16631013|NCT02408809|Active Comparator|Intervention|
16631014|NCT02408796|Experimental|OTO-201|6 mg OTO-201
16631015|NCT02408770|Experimental|treatment|ulipristal acetate 5mg daily for 3 months
16631016|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
16631017|NCT02408744|Experimental|Pirfenidone|Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
16631018|NCT02408731|Experimental|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
16631019|NCT02408731|Experimental|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
16631020|NCT02408731|Experimental|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
16631021|NCT02408731|Experimental|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
16631022|NCT02408731|Experimental|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
16631023|NCT02408731|Experimental|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
16631024|NCT02408718|Active Comparator|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
16631025|NCT02408718|No Intervention|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
16631026|NCT02408705|Active Comparator|Liraglutide|3-month treatment of liraglutide
16631027|NCT02408705|Placebo Comparator|Placebo|3-month treatment of placebo
16631028|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
16631029|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
16631030|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
16632310|NCT02399995||patients following hepatectomy|
16631031|NCT02408679||All subjects|300 eligible subjects will perform a blood sampling for a dosage of serum vitamin D and will fill up a study questionnaire during one visit.
16631032|NCT02408666|Other|Interview|"Interview of epilepsy patients and their family about their experience with epilepsy, EEG registrations and daily life.
~Interview of EEG-technologists and neurologists about their experience with EEG registrations and expections when thinking of a ideal EEG-cap."
16631033|NCT02408653|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
16631034|NCT02408653|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
16631035|NCT02408653|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
16631036|NCT02408640|Experimental|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.
~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
16631037|NCT02408640|No Intervention|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).
~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
16631038|NCT02408627|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
16631039|NCT02408627|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
16631040|NCT02408627|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
16631041|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
16631042|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
16631043|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
16631044|NCT02408601|Active Comparator|Group 1|"split mouth study. one side of the arch that is the lower left permanent 1st molar will be receiving resin based sealants.
~Application of the resin sealants as per the standard instructions of the manufacturer
~Helioseal -F ( Resin based sealant)
~isolate the tooth surface
~etch the fissure anatomy with 37% phosphoric acid for 20 seconds
~wash the tooth surface and dry it. No salivary contamination is accepted
~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.
~light cure the sealant
~check for high points and the occlusion"
16631045|NCT02408601|Experimental|Group 2|"split mouth study. one side of the arch that is the lower right permanent 1st molar will be receiving ART sealants.
~Application of the ART sealants as per the standard instructions of the manufacturer
~isolate the tooth surface
~condition the fissure anatomy using a GC conditioner for 10 seconds
~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.
~dry the tooth surface
~mix the GIC according to the standard powder: liquid ratio
~place the mix onto the fissures using a plastic spatula
~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)
~apply pressure for 10-15 sec and withdraw the finger in a sideways motion
~scrap out the excess material
~check for the high points and the occlusion
~apply petroleum jelly onto the GIC mix
~advice patient not to eat or drink for 30 minutes."
16631046|NCT02408588||Childbirth and epidural|Pregnant women giving childbirth who receive an epidural.
16631047|NCT02408588||Childbirth and general anesthesia|Pregnant women giving childbirth who receive general anesthesia
16631048|NCT02408588||Fetal Intervention and epidural|Pregnant women receiving fetal intervention and an epidural
16631049|NCT02408588||Fetal Intervention and general anesthesia|Pregnant women receiving fetal intervention and general anesthesia
16631050|NCT02408575|Experimental|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
16631051|NCT02408575|Experimental|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3
~No notched filtering
~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
16631052|NCT02408562|Experimental|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
16631053|NCT02408562|Placebo Comparator|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
16631054|NCT02408549|Experimental|Lacosamide|"Start dose
~SP982 completers at V1:
~LCM 10 mg/kg/day for pediatric subjects weighing <30 kg
~LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to <50 kg
~LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg
~SP982 Baseline failures at V1:
~LCM 2 mg/kg/day for pediatric subjects weighing <50 kg
~LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg
~Oral solution (pediatric subjects <50 kg):
~Minimum LCM dose: 4 mg/kg/day
~Maximum LCM dose: 12 mg/kg/day
~Tablets (pediatric subjects ≥50kg):
~Minimum LCM dose: 200 mg/day
~Minimum LCM dose: 600 mg/day
~Tablets (adult subjects):
~Minimum LCM dose: 200 mg/day
~Maximum LCM dose: 800 mg/day"
16631055|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
16631056|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.
~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.)
~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg.)"
16631057|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.
~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.)
~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg.)"
16631058|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
16631059|NCT02408471|Other|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
16631060|NCT02408458|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
16631061|NCT02408445|Experimental|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
16631062|NCT02408445|No Intervention|No treatment|Subjects will not receive any testosterone during the study period.
16631063|NCT02408432|Experimental|Arm I (hMSCs)|Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.
16631064|NCT02408432|Active Comparator|Arm II (standard of care drugs)|Patients receive only standard of care drugs for heart failure.
16631065|NCT02408419|Experimental|Local anesthetic|15 ml. of local anesthetic
16631066|NCT02408419|Placebo Comparator|Saline|15 ml. of saline
16631067|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
16631068|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
16631069|NCT02408393|Placebo Comparator|Placebo|Saline (30 mL maximum)
16631070|NCT02408393|Experimental|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
16631071|NCT02408367||Exercise|30 minutes of active training at 75% of the Maximum heart rate achieved in a cardiopulmonary exercise test
16631072|NCT02408367||Relaxation|30 Minutes of passive relaxation
16631073|NCT02408354|Active Comparator|Triheptanoin|"Triheptanoin/ Placebo Randomized to receive active Triheptanoin first for 12 weeks. At cross-over, participants will receive placebo for 12 weeks.
~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between triheptanoine and placebo phases."
16631074|NCT02408354|Placebo Comparator|Placebo|"Placebo / Triheptanoin Randomized to receive active Placebo first for 12 weeks. At cross-over, participants will receive Triheptanoin for 12 weeks.
~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between placebo and triheptanoin phases."
16631075|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
16631076|NCT02408328|Active Comparator|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
16631077|NCT02408328|Active Comparator|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
16631078|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
16631079|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
16631080|NCT02408302|Active Comparator|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
16631081|NCT02408302|Active Comparator|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
16631082|NCT02408302|Active Comparator|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
16631083|NCT02408289|Placebo Comparator|Lo-Flav|Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage
16631084|NCT02408289|Active Comparator|Hi-Flav|Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
16631085|NCT02408289|Active Comparator|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.
16631086|NCT02408289|Active Comparator|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
16631087|NCT02408276||dGEMERIC MRI technique|All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
16632311|NCT02399982|Active Comparator|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
16631088|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
16631089|NCT02408237|Active Comparator|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
16631090|NCT02408237|Active Comparator|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
16631091|NCT02408224||one arm|patients on Ticagrelor
16631092|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
16631093|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
16631094|NCT02408185|Experimental|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
16631095|NCT02408185|Experimental|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
16631096|NCT02408172|Experimental|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
16631097|NCT02408172|Experimental|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
16631098|NCT02408159|Experimental|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
16631099|NCT02408159|Placebo Comparator|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.
~A single dose will be administered to subjects at baseline."
16631100|NCT02408146|Experimental|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
16631101|NCT02408146|Experimental|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
16631102|NCT02408146|Experimental|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
16631103|NCT02408133|No Intervention|Control|The control group will be accompanied according to the service routine.
16631104|NCT02408133|Experimental|Exercise|The group will be instructed to perform home exercises autonomously for range of motion and muscular fitness
16631105|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
16631106|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
16631107|NCT02408107|Experimental|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
16631108|NCT02408107|No Intervention|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
16631109|NCT02408081|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
16631110|NCT02408081|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
16631111|NCT02408068|Active Comparator|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
16631112|NCT02408068|Active Comparator|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
16631113|NCT02408068|Active Comparator|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
16631114|NCT02408055|Experimental|Radiolabelled TA-8995|
16631115|NCT02408042|Active Comparator|RICE and Pembrolizumab|non-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
16631116|NCT02408042|Active Comparator|ICE and Pembrolizumab|classical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
16631243|NCT02407171|Experimental|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
16631117|NCT02408042|Active Comparator|brentuximab vedotin and Pembrolizumab|classical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
16631118|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
16631119|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
16631120|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
16631121|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
16631122|NCT02408003|Experimental|Levosimendan|"st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.
~nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
16631123|NCT02408003|Experimental|Milrinone|"st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.
~nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
16631124|NCT02407990|Experimental|BGB-A317 Phase 1A|
16631125|NCT02407990|Experimental|BGB-A317 Phase 1B|
16631126|NCT02407951|Experimental|CBIT group|
16631127|NCT02407951|Placebo Comparator|Psycho-Educational group|
16631128|NCT02407938|Experimental|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
16631129|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
16631130|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
16631131|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
16631132|NCT02407912|Experimental|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
16631133|NCT02407912|No Intervention|Control|No intervention was applied.
16631134|NCT02407899|Experimental|Metformin (and insulin) + saxagliptin|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5mg/d and Metformin 1.5g/d (and insulin at individual dose) for 104-week.
16631135|NCT02407899|Experimental|Metformin(insulin)+saxagliptin +vitamin D3|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg/d, vitamin D drop 2000IU/d, Metformin 1.5g/d (and insulin at individual dose) for 104-week.
16631136|NCT02407899|Active Comparator|Metformin (and insulin)|Patients who have diagnosed LADA are assigned to receive Metformin 1.5g/d(and insulin at individual dose) for 104-week.
16631137|NCT02407873||Cardiac surgery|
16631138|NCT02407860|Experimental|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
16631139|NCT02407860|Active Comparator|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
16631140|NCT02407847|No Intervention|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
16631141|NCT02407847|Experimental|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
16631142|NCT02407834|Experimental|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
16631143|NCT02407834|Experimental|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
16631144|NCT02407834|Experimental|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
16631145|NCT02407834|Placebo Comparator|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
16631146|NCT02407821|Active Comparator|Escitalopram|
16631147|NCT02407821|Placebo Comparator|Placebo|
16631148|NCT02407808|Active Comparator|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
16631149|NCT02407808|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
16631150|NCT02407795|Active Comparator|Arm 1|Conventional radiotherapy, 1x8Gy
16631151|NCT02407795|Experimental|Arm 2|Stereotactic radiotherapy, 1x20Gy
16631152|NCT02407782|Experimental|Ivermectin|
16631153|NCT02407782|Experimental|Permethrin|
16631154|NCT02407769|Experimental|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
16631155|NCT02407769|Sham Comparator|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
16631156|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
16631157|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
16631158|NCT02407743||Surgical patients' clinical progression|Patients undergoing non-ambulatory surgery will be asked questions and complete surveys in an effort to characterize postoperative pain experience profiles. A blood sample will be obtained for genetic markers exploring a variety of pain-related genes.
16631244|NCT02407171|Experimental|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
16631159|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.
~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.
~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
16631160|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.
~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
16631161|NCT02407691|Experimental|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
16631162|NCT02407691|Active Comparator|Standard of care|Primary Care 101 standard version guideline
16631163|NCT02407678|Experimental|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
16631164|NCT02407678|No Intervention|Control|Untreated eye
16631165|NCT02407665|Experimental|Tai Chi|Participants who practice Tai Chi 2X/week for 12-weeks
16631166|NCT02407665|No Intervention|Healthy Control|24 healthy controls
16631167|NCT02407652|Experimental|cognitive control training|internet-delivered, 2 weeks
16631168|NCT02407652|Active Comparator|low cognitive load training|internet-delivered, 2 weeks
16631169|NCT02407639|Active Comparator|co2 arm|insufflation with CO2
16631170|NCT02407639|Placebo Comparator|air arm|insufflation with air
16631171|NCT02407626|Experimental|Sevoflurane|Volatile anesthesia for elective cardiac surgery
16631172|NCT02407626|Active Comparator|Propofol|Total intravenous anesthesia for elective cardiac surgery
16631173|NCT02407613|Experimental|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
16631174|NCT02407600|Active Comparator|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
16631175|NCT02407600|Sham Comparator|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
16631176|NCT02407587|Experimental|unilateral cochlear implants|"Study Group
~PET scans for the mature patients with unilateral cochlear implants and preserved hearing
~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
16631177|NCT02407587|No Intervention|Healthy volunteers|4 states and each state will be repeated 3 times Auditory stimulation Left ear only Auditory stimulation right ear only Binaural auditory stimulation Silence
16631178|NCT02407574|Experimental|Spontaneous rhythm first|Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing.
16631179|NCT02407574|Experimental|Atrial pacing first|Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm.
16631180|NCT02407548|Experimental|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
16631181|NCT02407548|Experimental|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
16631182|NCT02407548|Other|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
16631183|NCT02407535|Experimental|Endometrial carcinoma patient|
16631184|NCT02407522|Experimental|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
16631185|NCT02407522|Placebo Comparator|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
16631186|NCT02407509|Experimental|Twice weekly|RO5126766 will be administered twice weekly in 4 week cycles.
16631187|NCT02407509|Experimental|Three times weekly|RO5126766 will be administered three times weekly in 4 week cycles.
16631188|NCT02407509|Experimental|RO5126766 & Everolimus|RO5126766 and Everolimus will be given in combination once or twice weekly for 3 weeks of a 4 week cycle.
16631189|NCT02407496||ADHD|Adults with Attention Deficit Hyperactivity Disorder (ADHD)
16631190|NCT02407496||Control|Healthy individuals without ADHD
16631191|NCT02407483|Experimental|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
16631192|NCT02407483|Active Comparator|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
16631193|NCT02407470|Active Comparator|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
16631336|NCT02406625|Experimental|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
16631194|NCT02407470|Experimental|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
16631195|NCT02407470|Experimental|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
16631196|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
16631197|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
16631198|NCT02407444|Experimental|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.
~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.
~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
16631199|NCT02407444|Active Comparator|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.
~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
16631200|NCT02407418|Active Comparator|Spinal Manipulation|In a repeated measures, crossover design, all subjects received spinal manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
16631201|NCT02407418|Sham Comparator|Sham Manipulation|In a repeated measures, crossover design, all subjects received the sham manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
16631202|NCT02407405|Experimental|1|selumetinib 50 mg BID daily
16631203|NCT02407392|Active Comparator|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
16631204|NCT02407392|Experimental|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
16631205|NCT02407379|Active Comparator|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
16631206|NCT02407379|Sham Comparator|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
16631207|NCT02407366|Experimental|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
16631208|NCT02407366|Active Comparator|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
16631209|NCT02407353|Experimental|PF-06648671 High dose group|subjects receive a single oral dose of PF-06648671 at 300 mg
16631210|NCT02407353|Experimental|PF-06648671 Low dose group|Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
16631211|NCT02407353|Placebo Comparator|Placebo group|Subjects receive matching placebo
16631212|NCT02407353|Experimental|PF-06648671 Low dose group (2)|Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
16631213|NCT02407340|Active Comparator|Oxytocin|intranasal oxytocin - 40 International Units (IU) dose administered 3 times daily for 1 week
16631214|NCT02407340|Placebo Comparator|Placebo|Intranasal placebo administered 3 times daily for 1 week
16631215|NCT02407314|Sham Comparator|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
16631216|NCT02407314|Experimental|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
16631217|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
16631218|NCT02407288|Active Comparator|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
16631219|NCT02407288|Placebo Comparator|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
16631220|NCT02407275|Other|biological sample|Genomic & culturomic analyses
16631221|NCT02407262|Active Comparator|Treatment|"Black seed oil capsules
~1g/day for 4 weeks"
16631222|NCT02407262|Placebo Comparator|Placebo|"Placebo (olive oil) capsules
~1g/day for 4 weeks"
16632665|NCT02397421|Active Comparator|Treatment|Dapagliflozin 10mg once daily
16631233|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
16631234|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
16631235|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
16631236|NCT02407210|Experimental|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
16631237|NCT02407210|Active Comparator|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
16631238|NCT02407184|No Intervention|Scheduled C-section|Babies that are scheduled to be born in a hospital via standard C-section procedure.
16631239|NCT02407184|No Intervention|Vaginal Delivery|Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.
16631240|NCT02407184|Experimental|Scheduled C-section with Exposure|Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.
16631241|NCT02407171|Experimental|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
16631242|NCT02407171|Experimental|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
16631337|NCT02406625|Experimental|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
16631245|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
16631246|NCT02407132|Active Comparator|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
16631247|NCT02407132|Experimental|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
16631248|NCT02407119|Active Comparator|7 day H.pylori eradication|Treatment: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
16631249|NCT02407119|Placebo Comparator|Placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + Placebo for two antibiotics (clarithromycin and amoxicillin) bid for 7 days
16631250|NCT02407106|Experimental|BLIS K12 treatment|Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month
16631251|NCT02407093|Experimental|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
16631252|NCT02407093|Active Comparator|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
16631253|NCT02407080|Experimental|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.
~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
16631254|NCT02407067|Active Comparator|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
16631255|NCT02407067|Experimental|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
16631256|NCT02407054|Experimental|Part A: 200 mg LY3023414 BID + 160 mg of Enzalutamide QD|Participants received 200 milligrams (mg) LY3023414 orally twice daily (BID) during the initial week to assess pharmacokinetics (PK). Thereafter, participants received 200 mg of LY3023414 BID in combination with 160 mg of enzalutamide QD beginning Cycle 1 Day 1. A treatment cycle was defined as 28 days.
16631257|NCT02407054|Experimental|Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD|Participants received 200 mg LY3023414 orally BID in combination with 160 mg enzalutamide orally once daily (QD).
16631258|NCT02407054|Active Comparator|Part B: Placebo + 160 mg Enzalutamide QD|Participants received placebo in combination with 160 mg enzalutamide QD.
16631259|NCT02407041|Experimental|GR-MD-02|active arm
16631260|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA, no NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
16631261|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA, no NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
16631262|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA, no NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
16631263|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA + NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
16631264|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA + NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
16631265|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA + NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
16631266|NCT02407028|Experimental|Normobaric Hyperoxia (NBH)|Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
16631267|NCT02407028|Active Comparator|Usual care|Usual care for severe TBI
16631268|NCT02407015|Active Comparator|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
16631269|NCT02407015|Active Comparator|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
16631270|NCT02406989|Experimental|MS-553|MS-553 oral tablet BID x 14 days
16631271|NCT02406989|Placebo Comparator|Placebo|Placebo oral tablet BID x 14 days
16631272|NCT02406976|Experimental|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
16631273|NCT02406976|Experimental|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.
~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
16631274|NCT02406976|Active Comparator|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
16631338|NCT02406625|No Intervention|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
16631275|NCT02406963|Active Comparator|TTC|Current standard of care- a telephone call with the NP in the event of a post-operative concern where advice/interventions/reassurance is provided based on information provided by family
16631276|NCT02406963|Experimental|PEC|Experimental arm, the standard telephone call with the NP and the addition of a digital photograph of the surgical site for assessment prior to the administration of advice
16631277|NCT02406950|Experimental|Sitagliptin|All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
16631278|NCT02406950|Placebo Comparator|Placebo|After brachial artery FMD measurement, IR injury for each 15 minutes will be performed, and brachial artery FMD will be measured again. After randomization, placebo group will be treated by nothing. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
16631279|NCT02406950|Other|Sitagliptin and glibenclimide|If sitagliptin treatment show preventive effects of IR injury, the investigator will perform additional experiment to explore the mechanism (Protocol 2 study). Additional 15 healthy volunteers will be treated 5 mg of glibenclamide (Euglucon) 1 hour before administration of 50 m g of sitagliptin. In 2 hours after sitagliptin administration, FMD measurement before and after IR injury will be performed as described above.
16631280|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
16631281|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
16631282|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
16631283|NCT02406924|Experimental|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
16631284|NCT02406924|Active Comparator|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
16631285|NCT02406911|Experimental|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
16631286|NCT02406911|Active Comparator|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
16631287|NCT02406898|Experimental|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.
~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
16631288|NCT02406898|Active Comparator|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.
~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
16631289|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
16631290|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
16631291|NCT02406872|Experimental|Remimazolam Tosilate 1|IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction
16631292|NCT02406872|Experimental|Remimazolam Tosilate 2|intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction
16631293|NCT02406872|Experimental|Remimazolam Tosilate 3|intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction
16631294|NCT02406872|Active Comparator|Propofol|single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction
16631295|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
16631296|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
16631297|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
16631298|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
16631299|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
16631300|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
16631301|NCT02406833|Experimental|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses
~Post-Study Follow-up: until 1 year after administration"
16631432|NCT02405897|Active Comparator|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
16631302|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
16631303|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
16631304|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
16631305|NCT02406807|Experimental|HVLA manipulation|Osteopathic high velocity, and low amplitude spinal lumbar manipulation
16631306|NCT02406807|Sham Comparator|Sham Spinal lumbar manipulation|Just position in the side lying and not performed the high velocity and low amplitude
16631307|NCT02406794|Experimental|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
16631308|NCT02406794|No Intervention|No Kinesio taping|No Kinesio taping
16631309|NCT02406781|Experimental|Treatment strategy A|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.
16631310|NCT02406781|Experimental|Treatment strategy B|Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.
16631311|NCT02406768||HIV negative unexposed|HIV negative controls
16631312|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
16631313|NCT02406755|No Intervention|Control|This control group will not receive an intervention.
16631314|NCT02406755|Active Comparator|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
16631315|NCT02406755|Active Comparator|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
16631316|NCT02406755|Active Comparator|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
16631317|NCT02406742|Experimental|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
16631318|NCT02406742|Experimental|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
16631319|NCT02406742|Experimental|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
16631320|NCT02406729|Experimental|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
16631321|NCT02406729|Placebo Comparator|Placebo|Placebo Single dose, SC
16631322|NCT02406716||HF|Heart failure patients
16631323|NCT02406716||Controls|Healthy donors
16631324|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
16631325|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
16631326|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
16631327|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
16631328|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
16631329|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
16631330|NCT02406664|Experimental|Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
16631331|NCT02406664|No Intervention|Control patients|15 matched controls receiving Intensive medical therapy
16631332|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
16631333|NCT02406638||TVT Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT 3 years before clinical and 3D pelvic floor ultrasound evaluation.
16631334|NCT02406638||TVT-O Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT Obturator System, inside-out approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation.
16631335|NCT02406638||TVT-S Group|"Women who underwent to stress urinary incontinence surgery using GynecareTVT-Secur System, in U approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation."
16633205|NCT02393729|Other|control children|Neuropsychological assessment and MRI study
16631339|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
16631340|NCT02406599|Other|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
16631341|NCT02406599|Other|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
16631342|NCT02406586|Experimental|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
16631343|NCT02406586|Experimental|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
16631344|NCT02406586|Placebo Comparator|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
16631345|NCT02406573|Experimental|Crest® Sensi-Stop™ Strips|Professionally Applied
16631346|NCT02406560|Experimental|4 tablets of 12.2 mg tafamdis free acid|
16631347|NCT02406560|Experimental|4 tablets of 12.2 mg tafamidis free acid|
16631348|NCT02406560|Experimental|5 tablets of 12.2 mg tafamidis free acid|
16631349|NCT02406547|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
16631350|NCT02406547|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
16631351|NCT02406534||Normal Pulmonary Function|
16631352|NCT02406534||Reduced Pulmonary Function|
16631353|NCT02406521|Experimental|Arm A: Pazopanib with Radium-223|"No prior targeted therapy
~Pazopanib oral, daily and at predetermined dosage per cycle
~Radium-223 predetermined dosage via IV, per cycle"
16631354|NCT02406521|Experimental|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:
~Sorafenib at predetermined dosage, mouth twice daily
~Radium-223 predetermined dosage via IV, per cycle"
16631355|NCT02406508|Experimental|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.
~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.
~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
16631356|NCT02406495|Experimental|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
16631357|NCT02406482|Experimental|HIVRR + MF|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)) followed by financial literacy, micro-savings and vocational training (Behavioral: Microfinance intervention (MF)).
16631358|NCT02406482|Active Comparator|HIVRR only|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)).
16631359|NCT02406469|Experimental|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
16631360|NCT02406469|Placebo Comparator|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
16631361|NCT02406456|Experimental|Neurofeedback|
16631362|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
16631363|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
16631364|NCT02406417|Experimental|Investigation for pituitary dysfunction|Further investigation for pituitary dysfunction by blood tests, dynamic function tests and pituitary imaging e.g. CT Scan with contrast. Patients identified as being at high risk of having pituitary dysfunction based on preliminary blood tests will have further tests added. If these results point to a likely pituitary dysfunction, the patient will be referred to the Endocrine team for further investigations including dynamic function tests and/or imaging.
16631365|NCT02406404|Experimental|spirometer training group|incentive spirometer training group
16631366|NCT02406404|No Intervention|No intervention group|no intervention group
16631367|NCT02406365|Experimental|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.
~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
16631459|NCT02405663|Experimental|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
16633206|NCT02393716|Other|Endovascular repair|Endurant Evo AAA Stent Graft System
16631368|NCT02406352|Experimental|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
16631369|NCT02406339|No Intervention|Control|Are not subject to any intervention.
16631370|NCT02406339|Experimental|Electrotherapy|The athletes will be submitted to NMES of bilateral quadriceps. The stimulation will be held in order to induce the move flexion / extension involuntary knee in extension machine, with resistance of 30% of maximum voluntary strength.
16631371|NCT02406339|Experimental|Electrotherapy + Vascular Occlusion|The same as in Electrotherapy group, athletes are subjected to NMES associated total vascular occlusion of the members below the level of the groin.
16631372|NCT02406313|Experimental|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
16631373|NCT02406313|Active Comparator|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
16631374|NCT02406300|Active Comparator|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.
~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
16631375|NCT02406300|Active Comparator|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
16631376|NCT02406287|Experimental|Active|Netarsudil (AR-13324) Ophthalmic Solution
16631377|NCT02406287|Placebo Comparator|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
16631378|NCT02406274|Experimental|Contrast Enhanced Spectral Mammography|
16631379|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;
~20 mg simvastatin, single oral dose on Days 2 and 36;
~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;
~50 mg lanabecestat, single oral dose on Day 4;
~50 mg lanabecestat, single oral dose, Days 10 to 37"
16631380|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;
~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;
~5 mg donepezil, single oral dose on Day 28, Period 2"
16631381|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
16631382|NCT02406222|Active Comparator|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Pomalidomide 4mg orally on days 1-21
~Dexamethasone 40mg orally on days 1, 8, 15 and 22"
16631383|NCT02406222|Experimental|Pomalidomide Dexamethasone Cylcophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Pomalidomide 4mg orally on days 1-21
~Dexamethasone 40mg orally on days 1, 8, 15 and 22
~Cyclophosphamide 500mg orally on days 1, 8 and 15"
16631384|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
16631385|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
16631386|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
16631387|NCT02406183|Experimental|Treatment (SBRT, Ipilimumab)|"Drug: Ipilimumab Dosage: Ipilimumab will be administered intravenously at 3 mg/kg every 3 weeks for 4 cycles,
~Radiation: Stereotactic Body Radiotherapy Radiation therapy 24 Grays in 8 Grays fractions, Radiation therapy 30 Grays in 10 Grays fractions, Radiation therapy 36 Grays in 12 Grays fractions"
16631388|NCT02406170|Experimental|Regorafenib+Paclitaxel|Regorafenib tolerability will be tested in a dose escalation scheme with a cytotoxic backbone of paclitaxel 80mg/m2.
16631389|NCT02406157|Experimental|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
16631390|NCT02406157|Active Comparator|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
16631391|NCT02406144|Active Comparator|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
16631392|NCT02406144|Experimental|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
16631393|NCT02406131|No Intervention|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
16631394|NCT02406131|Active Comparator|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
16631395|NCT02406118|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
16631396|NCT02406105|Experimental|Radiosurgical thalamotomy|Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy
16631460|NCT02405663|Experimental|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
16631397|NCT02406092|Experimental|Rituximab|Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP [cyclophosphamide+doxorubicin+vincristine+prednisone], CVP [cyclophosphamide+vincristine+prednisone] or FC [fludarabine+cyclophosphamide]) during induction.
16631398|NCT02406079|Experimental|tracheotomy|
16631399|NCT02406066|Placebo Comparator|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
16631400|NCT02406066|Active Comparator|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
16631401|NCT02406066|Active Comparator|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
16631402|NCT02406066|Active Comparator|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
16631403|NCT02406053||OSAS|Obstructive sleep apnea syndrome
16631404|NCT02406053||COPD|Chronic obstructive pulmonary disease
16631405|NCT02406053||LC|Lung cancer
16631406|NCT02406053||HC|Healthy controls
16631407|NCT02406040|Experimental|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
16631408|NCT02406040|Experimental|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
16631409|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
16631410|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
16631411|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
16631412|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
16631413|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
16631414|NCT02406014|Active Comparator|Treatment Group A|Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
16631415|NCT02406014|Active Comparator|Treatment Group B|Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.
16631416|NCT02406001|Experimental|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
16631417|NCT02406001|Other|Control|Surgical intervention: open flap debridement
16631418|NCT02405988|Experimental|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
16631419|NCT02405975|No Intervention|Control|These participants will not receive the educational intervention
16631420|NCT02405975|Experimental|Intervention|"These participants will receive the online educational intervention SCRIPT"
16631421|NCT02405962|Placebo Comparator|Control group|Parents of children with asthma will receive one session of asthma educational talk as the usual care, plus three weekly sessions of telephone calls to assess the child's asthma symptoms
16631422|NCT02405962|Experimental|ACT group|Parents of children with asthma will receive four sessions of group-based ACT intervention integrated with asthma education (its content will be the same as that of the Control Group).
16631423|NCT02405949||T2D 40%EWL|15 pacients who had type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
16631424|NCT02405949||nonT2D40%EWL|15 pacients without type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
16631425|NCT02405949||T2D75%EWL|35 pacients who had type 2 diabetes befor bariatric surgery and presented with more than 75% of the excess weight loss after 12 month from surgery.
16631426|NCT02405949||nonT2D75%EWL|35 pacients without type 2 diabetes befor bariatric surgery and who presented with more than 75% of the excess weight loss after 12 month from surgery.
16631427|NCT02405923|Experimental|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
16631428|NCT02405923|Placebo Comparator|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
16631429|NCT02405910|Experimental|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
16631430|NCT02405910|Experimental|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
16631431|NCT02405897|Experimental|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
16631433|NCT02405884|Other|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
16631434|NCT02405858|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.
16631435|NCT02405845|Other|CT Angiogram|A research CTA scan may be required if there is no change of the imaging on the 3 CTA scans prior.
16631436|NCT02405832|Experimental|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
16631437|NCT02405832|Placebo Comparator|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
16631438|NCT02405819|Other|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
16631439|NCT02405819|Other|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
16631440|NCT02405806|Experimental|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.
~Intervention: Food: Low carbohydrate food"
16631441|NCT02405806|Active Comparator|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
16631442|NCT02405793|Experimental|Meloxicam low dose test capsule|Meloxicam SoluMatrix Capsules - low dose QD
16631443|NCT02405793|Experimental|Meloxicam high dose test capsule|Meloxicam SoluMatrix Capsules - high dose QD
16631444|NCT02405793|Active Comparator|Meloxicam tablets|Meloxicam Tablets QD
16631445|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
16631446|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
16631447|NCT02405767|Experimental|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
16631448|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
16631449|NCT02405728|Experimental|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
16631450|NCT02405728|Active Comparator|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
16631451|NCT02405715|Placebo Comparator|Placebo Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
16631452|NCT02405715|Experimental|Oxytocin Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.
16631453|NCT02405689|Active Comparator|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
16631454|NCT02405689|Active Comparator|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
16631455|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
16631456|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
16631457|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
16631458|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
16631461|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:
~abdominal and pelvic Magnetic Resonance Imaging (MRI) scan
~400 meter walk test for physical fitness"
16631462|NCT02405637|Experimental|SAFE group|simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
16631463|NCT02405637|Placebo Comparator|placebo|distilled water 2.5 ml/kg every 3 hours enterally
16631464|NCT02405624|Experimental|CPAP training|Patients will be instructed and follow the continuous positive airway pressure (CPAP) training procedure
16631465|NCT02405611|Active Comparator|active control|mothers and children are in active control group and only receive the questionnaires
16631466|NCT02405611|Experimental|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
16631467|NCT02405611|Experimental|children|only the children receive the intervention and mothers and children receive the questionnaires
16631468|NCT02405598|Experimental|Salbutamol|"age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)
~age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)
~age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
16631469|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy
~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.
~Post adjuvant therapy: 6 monthly immunizations with HAPa"
16631470|NCT02405572|Active Comparator|Formula 1|infant formula
16631471|NCT02405572|Active Comparator|Formula 2|infant formula
16631472|NCT02405559|Experimental|Lymphatic occlusion pressure lower limb|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
16631473|NCT02405546|Experimental|Pre-Rotated Technique (Group R)|90° counterclockwise rotation of bevel of ETT
16631474|NCT02405546|Active Comparator|No rotation|No rotation of bevel of ETT
16631475|NCT02405533|Experimental|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
16631476|NCT02405533|Placebo Comparator|Group 2|Placebo once a day on an empty stomach x 12 months
16631477|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
16631478|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
16631479|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
16631480|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
16631481|NCT02405507|Experimental|wheat bread with wheat germ|wheat bread with wheat germ supplementation
16631482|NCT02405507|Placebo Comparator|wheat bread without wheat germ|wheat bread without wheat germ supplementation
16631483|NCT02405494|Other|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
16631484|NCT02405494|Other|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
16631485|NCT02405494|Other|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
16631486|NCT02405494|Other|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
16631487|NCT02405494|Other|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
16631488|NCT02405494|Other|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
16631489|NCT02405494|Other|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
16631490|NCT02405494|Other|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
16631491|NCT02405494|Other|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
16631492|NCT02405481|No Intervention|Wait List Control|
16631493|NCT02405481|Experimental|SEPA III Intervention|SEPA brings together two important theoretical perspectives that will be effective and sustainable for HIV/AIDS prevention among Hispanic women in an inner city environment. The content and learning strategies of SEPA are based on the social cognitive theory and of HIV/AIDS prevention that prior research has shown to be the most effective in increasing HIV/AIDS prevention behaviors, modified to take into account the special needs of Hispanic women related to gender inequality and cultural values and practices. SEPA's conceptual framework integrates the Social Cognitive Model of behavioral change with Freire's Pedagogy of the Oppressed that guides the delivery and contextual tailoring.
16631494|NCT02405468||case|patients with a myocardial infarction within one month to one year before the inclusion
16631495|NCT02405468||control|"patients without history of myocardial infarction, free of coronary disease in the view of one of the following test performed within one year before the inclusion : Effort test Echocardiographic stress test Myocardial perfusion scintigraphy Coronarography with >= 2 major cardiovascular risk factors :
~Treated hypertension
~Treated dyslipidemia
~Current smoking
~Diabetes mellitus"
16631496|NCT02405455|Experimental|Cerclage|Cervical cerclage.
16631497|NCT02405455|Experimental|Cervical pessary|Cervical pessary
16631498|NCT02405442|Experimental|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
16631499|NCT02405442|Experimental|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
16631576|NCT02404831|Experimental|Web-based PR|web-based pulmonary rehab
16631500|NCT02405442|Experimental|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
16631501|NCT02405442|Placebo Comparator|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
16631502|NCT02405416|Experimental|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
16631503|NCT02405416|Active Comparator|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
16631504|NCT02405403|Experimental|amyotrophic lateral sclerosis (ALS)|[18F]DPA-714 PET
16631505|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
16631506|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
16631507|NCT02405377|Experimental|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
16631508|NCT02405377|Active Comparator|Control|The control group was hydrated at 1 mL/kg per h.
16631509|NCT02405364|Experimental|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
16631510|NCT02405351|Experimental|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
16631511|NCT02405338|Experimental|WT1/PRAME vaccination|
16631512|NCT02405325|Experimental|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
16631513|NCT02405325|No Intervention|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
16631514|NCT02405312|Experimental|advance care planning|nephrologist empowers social worker to meet with patient and family.
16631515|NCT02405299|Experimental|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
16631516|NCT02405299|Placebo Comparator|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
16631517|NCT02405286||Upeer gastrointestinal bleeding|"Adult Egyptian patients.
~Patients with acute upper G.I hemorrhage.
~Informed consent."
16631518|NCT02405273|Experimental|Interventional Group|Pulmonary rehabilitation
16631519|NCT02405273|Active Comparator|Control Group|Standard Care
16631520|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
16631521|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
16631522|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
16631523|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
16631524|NCT02405247||NSCLC without T790M mutation|NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
16631525|NCT02405234|Experimental|Carbon Modular Radial Head|PyroCarbon Modular Radial Head replacement
16631526|NCT02405234|Active Comparator|Metal Radial Head|Metal Radial Head replacement
16631527|NCT02405221|Experimental|TA-CIN administration via thigh|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
16631528|NCT02405221|Experimental|TA-CIN administration via arm|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
16631529|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
16631530|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
16631531|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
16631532|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
16631533|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
16631534|NCT02405156|Experimental|letrozole + misoprostol|Women will receive three tablets of letrozole vaginal as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for three days and will be followed by 200 mcg vaginal misoprostol or 100mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
16631535|NCT02405156|Placebo Comparator|placebo + misoprostol|Women will receive three tablets of placebo vaginal as a single dose, for three days and will be followed by 200 mcg vaginal misoprostol or 100 mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
16631536|NCT02405143|Experimental|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
16631537|NCT02405143|Sham Comparator|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
16631538|NCT02405130|Active Comparator|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
16631539|NCT02405130|Other|no intracoronary epinephrine|no epinephrine
16631540|NCT02405117|Experimental|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
16631541|NCT02405117|No Intervention|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
16631542|NCT02405104|Active Comparator|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
16631543|NCT02405104|Placebo Comparator|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
16631544|NCT02405104|Active Comparator|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
16631545|NCT02405104|Placebo Comparator|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
16631546|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
16631547|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
16631548|NCT02405078|Experimental|Diagnostic (PET/CT, clonotype, metabolic profile)|"Patients receive standard salvage chemotherapy as determined by the treating physician.
~Patients undergo FDG PET/CT scans at baseline (between days -21 to 0), on day 4 after completion of first high-dose chemotherapy, on day 21 after completion of the first course of chemotherapy, and on day 42 after the end of the second course of chemotherapy. Blood samples are also collected for tumor-specific clonotype and metabolic profile at baseline (days -5 to 0) and on days 4, 8, 21, and 42."
16631549|NCT02405065|Experimental|HM95573|single arm
16631550|NCT02405052||Patients|Emergency department patients with unexplained chest pain
16631551|NCT02405039|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
16631552|NCT02405039|Placebo Comparator|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
16631553|NCT02405026||HIV infected patients|HIV infected patients with asthma
16631554|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
16631555|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
16631556|NCT02405013|Experimental|Sofosbuvir+Ribavirin|Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
16631557|NCT02405013|Experimental|Sofosbuvir+Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
16631558|NCT02405000|Experimental|Intraoperative CT imaging|
16631559|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
16631560|NCT02404974|Experimental|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
16631561|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
16631562|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
16631563|NCT02404935|Experimental|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
16631564|NCT02404935|Other|Arm B observation|observation until progression
16631565|NCT02404922|Experimental|CTP-730 Low Dose or Matching Placebo|Capsule, once daily.
16631566|NCT02404922|Experimental|CTP-730 Mid Dose or Matching Placebo|Capsule, once daily
16631567|NCT02404922|Experimental|CTP-730 High Dose or Matching Placebo|Capsule, once daily.
16631568|NCT02404909||Patients with liver tumors candidate to hepatectomy|
16631569|NCT02404883|No Intervention|control group|care as usual (fertility preservation counseling)
16631570|NCT02404883|Experimental|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
16631571|NCT02404870|Experimental|Admission 1 or 2|Canagliflozin
16631572|NCT02404870|Placebo Comparator|Admission 2 or 1|Placebo
16631573|NCT02404857|Experimental|Chronic post-stroke|Patients >6 months post-stroke with little to no hand movement. use of EEG based BCI in the neurorehabilitation process
16631574|NCT02404844|Experimental|BKM120 + Tamoxifen|"BKM120 (Buparlisib): 100 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle
~Tamoxifen: 20 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle"
16631575|NCT02404831|Active Comparator|Traditional hospital-based PR|Class based pulmonary rehabilitation
16631578|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
16631579|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
16631580|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
16631581|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
16631582|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
16631583|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
16631584|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
16631585|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
16631586|NCT02404779|Experimental|CISATRACURIUM|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
16631587|NCT02404779|Placebo Comparator|PLACEBO|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
16631588|NCT02404766|Experimental|Intervention group|C0-C1 dorsal glide mobilization in the cervical neutral position.
16631589|NCT02404766|Experimental|Intervention group 2|C7-T1 ventral cranial glide mobilization in the cervical neutral position
16631590|NCT02404766|No Intervention|Control group|Not receiving any intervention
16631591|NCT02404753|Experimental|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
16631592|NCT02404753|Active Comparator|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
16631593|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
16631594|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
16631595|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
16631596|NCT02404727|Active Comparator|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
16631597|NCT02404727|Active Comparator|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
16631598|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.
~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
16631599|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.
~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
16631600|NCT02404701|Experimental|Aloe vera with cactus|1 capsule (500 mg), 2 times/day
16631601|NCT02404701|Experimental|Cranberry|3 capsules (810 mg), 2 times/day
16631602|NCT02404701|Experimental|Green tea extract|2 capsules (630 mg), 2 times/day
16631603|NCT02404701|Experimental|Bilberry|1 softgel (1000 mg), 2 times/day
16631604|NCT02404701|Experimental|Cinnamon|1 capsule (500 mg), 2 times/day
16631605|NCT02404701|Experimental|Milk thistle|1 capsule (250 mg), 3 times/day
16631606|NCT02404701|Experimental|Turmeric|1 capsule (450 mg turmeric + 50 mg turmeric extract), 1 time/day
16631607|NCT02404701|Experimental|Aloe vera|1 capsule (470 mg), 2 times/day
16631608|NCT02404688|Experimental|Active THC and Placebo Ethanol|
16631609|NCT02404688|Experimental|Active THC and Active Ethanol|
16631610|NCT02404688|Experimental|Placebo THC and Active Ethanol|
16631611|NCT02404688|Placebo Comparator|Placebo THC and Placebo Ethanol|
16631612|NCT02404675|Experimental|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
16631613|NCT02404675|Active Comparator|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
16631614|NCT02404675|Experimental|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
16631649|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
16631650|NCT02404428|Active Comparator|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
16634261|NCT02386631|Experimental|Orthotic|Custom made orthotic provided for study
16631615|NCT02404662|Experimental|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
16631616|NCT02404662|Active Comparator|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
16631617|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
16631618|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
16631619|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
16631620|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
16631621|NCT02404623|Experimental|Intervention Group|800 IU of Vitamin D once daily
16631622|NCT02404623|Other|Control Group|400 IU of Vitamin D once daily, the standard of care
16631623|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
16631624|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
16631625|NCT02404597|Experimental|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure < 65 or a systolic blood pressure < 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.
~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
16631626|NCT02404597|No Intervention|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
16631627|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.
~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
16631628|NCT02404571|Experimental|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
16631629|NCT02404558|Experimental|Sarilumab|Single subcutaneous (SC) dose of sarilumab
16631630|NCT02404558|Active Comparator|Tocilizumab|Single SC dose of tocilizumab
16631631|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
16631632|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
16631633|NCT02404532|Experimental|1|
16631634|NCT02404519|Active Comparator|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
16631635|NCT02404519|Placebo Comparator|Placebo|Placebo tablet, by mouth, daily for 1 year
16631636|NCT02404506|Experimental|Arm: Eribulin mesilate|
16631637|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
16631638|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
16631639|NCT02404480|Experimental|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
16631640|NCT02404480|Experimental|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
16631641|NCT02404480|Experimental|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
16631642|NCT02404480|Experimental|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
16631643|NCT02404480|Experimental|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
16631644|NCT02404480|Experimental|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
16631645|NCT02404480|Experimental|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
16631646|NCT02404467||Patients receiving transfermoral TAVI|TF TAVI
16631651|NCT02404428|Experimental|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
16631652|NCT02404402|Experimental|Active LED|Active LED Treatment
16631653|NCT02404402|Sham Comparator|Sham LED|Inactive (sham) LED Treatment
16631654|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
16631655|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
16631656|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
16631657|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
16631658|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
16631659|NCT02404376|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning + placebo
16631660|NCT02404376|Active Comparator|Combined treatment|Remote Ischemic Conditioning + exenatide
16631661|NCT02404376|Placebo Comparator|Placebo|Sham Remote Ischemic Conditioning + placebo
16631662|NCT02404376|Active Comparator|Exenatide|Sham Remote Ischemic Conditioning + exenatide
16631663|NCT02404363|Experimental|Clopidogrel|Clopidogrel tablets 75 mg for six months:
16631664|NCT02404363|Placebo Comparator|Comparator|Placebo tablet 75 mg for six months:
16631665|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
16631666|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
16631667|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
16631668|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
16631669|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
16631670|NCT02404337|Experimental|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
16631671|NCT02404337|Experimental|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
16631672|NCT02404324|Experimental|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.
~Intervention: Prescription of spectacles"
16631673|NCT02404311|Active Comparator|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
16631674|NCT02404311|Placebo Comparator|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
16631675|NCT02404311|Active Comparator|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
16631676|NCT02404311|Active Comparator|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
16631677|NCT02404311|Placebo Comparator|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
16631678|NCT02404298|Experimental|IVIg|
16631679|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:
~Lesions will be counted and right, left and forward facing photographs will be taken
~Investigator Global Assessment
~Acne Quality of Life Questionnaire
~Treatment Area Assessment by Investigator"
16631680|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:
~Lesions will be counted and right, left and forward facing photographs will be taken
~Investigator Global Assessment
~Acne Quality of Life Questionnaire
~Treatment Area Assessment by Investigator"
16631681|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
16631682|NCT02404259|Other|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
16631683|NCT02404259|Other|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
16631684|NCT02404246|Experimental|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
16631685|NCT02404246|No Intervention|Usual Care|Usual Care
16631686|NCT02404233|Experimental|Darunavir/ cobicistat and Rilpivirine|"Single arm study:
~Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food Rilpivirine tablet 25 mg once daily taken with food"
16631687|NCT02404220|Experimental|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response [PR]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
16631688|NCT02404220|Experimental|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
16631689|NCT02404220|Experimental|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
16631690|NCT02404220|Experimental|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
16631691|NCT02404207|Active Comparator|Soybean oil|
16631692|NCT02404207|Experimental|High-oleic soybean oil|
16631693|NCT02404207|Experimental|High-oleic soybean oil + fully hydrogenated soybean oil|
16631694|NCT02404207|Active Comparator|Palm olein + palm stearin|
16631695|NCT02404194|Experimental|Targeted Cognitive Training|40 hours of computerized cognitive training
16631696|NCT02404194|Placebo Comparator|Computer Games|40 hours of computer games
16631697|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
16631698|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
16631699|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
16631700|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
16631702|NCT02404142|Placebo Comparator|Control group (saline isotonic solution)|saline isotonic solution
16631703|NCT02404142|Experimental|Curar (Atracurium) group|Curar (Atracurium)
16631704|NCT02404129|Other|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
16631705|NCT02404129|Other|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
16631706|NCT02404129|Other|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
16631707|NCT02404116|Experimental|Metacognitive Therapy|12 weeks of Metacognitive Therapy
16631708|NCT02404116|Other|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
16631709|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
16631710|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
16631711|NCT02404077||Clonidine|Patients who received clonidine following prolonged dexmedetomidine infusions
16631712|NCT02404064|Other|Antibiotics perioperative|dose of perioperative antibiotics (cefamezin 1g IV; metronidazole 500 mg IV) This is the standard of care of the department
16631713|NCT02404064|Placebo Comparator|placebo - No Antibiotics perioperative|The intervention is No Antibiotics perioperative
16631714|NCT02404051|Experimental|ARM 1|Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)
16631715|NCT02404051|Experimental|ARM 2|Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)
16631716|NCT02404038|Active Comparator|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
16631717|NCT02404038|Active Comparator|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
16631718|NCT02404038|Active Comparator|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
16631719|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
16631720|NCT02404012|Active Comparator|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
16631721|NCT02404012|Experimental|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
16631722|NCT02403999|Experimental|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
16631723|NCT02403999|Experimental|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
16631724|NCT02403999|Experimental|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
16631725|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
16631726|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
16631727|NCT02403973|Other|Patient hotel group|
16631728|NCT02403973|Other|Ward group|
16631729|NCT02403960|Active Comparator|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
16631730|NCT02403960|Placebo Comparator|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
16631731|NCT02403947|Experimental|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
16631732|NCT02403947|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
16631733|NCT02403908|Experimental|PADN groups (radiofrequency denervation)|An 8-F long sheath will be inserted through the femoral vein and advanced to the main PA (MPA). The nMARQ Circular or Crescent (Biosense Webster) catheter will be advanced along this long sheath. After gently withdrawing the sheath and pushing the PADN catheter, the tip will be released from the sheath. Then, the tip of the catheter will be positioned first at the ostium of the left PA (Level 1 of ablation, <2 mm distal to orifice. After ablation at this level, the catheter tip will be positioned at the ostium of right PA (Level 2 of ablation, <2mm proximal to the bifurcation level). Finally, denervation of main pulmonary artery will be done by pulling the denervation catheter back into Level 3 of ablation (<2 mm proximal to both ostia of right and left PA-s) into main pulmonary artery.
16631734|NCT02403908|No Intervention|SHAM group|non-treated patients (controls)
16631735|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
16631736|NCT02403882|Experimental|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
16631737|NCT02403882|Experimental|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
16631738|NCT02403882|Experimental|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
16631739|NCT02403882|Experimental|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
16631740|NCT02403882|Experimental|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
16631741|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
16631742|NCT02403856|Experimental|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
16631743|NCT02403856|Active Comparator|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
16631744|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
16631745|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
16631746|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
16631747|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
16631748|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
16631749|NCT02403804|Other|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.
~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm
~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm
~Week 3: Betaine anhydrous 1000 mg BID"
16631750|NCT02403791|Experimental|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
16631751|NCT02403791|Active Comparator|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
16631752|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
16631753|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
16631754|NCT02403765||Family cases|Family-based Parkinson patients carrying genetic variants associated with the disease
16631755|NCT02403765||Family controls|Family-based Control subjects
16631756|NCT02403752|Experimental|exercise intervention|"Exercise protocol based on the PLIÉ protocol, developed in consultation with experts worldwide, incl. traditional strength-building exercises, yoga, Tai Chi and Feldenkrais, that engage the muscles most needed to maintain independence--including lower body strength, balance, upper body strength, fine motor exercises , and pelvic floor exercises- combined them into a unique integrative exercise program, to be purposeful and to build procedural ('muscle') memory.
~To be practiced at home in dyads of affected individuals and caregivers, called Paired PLIE Program."
16631757|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
16631758|NCT02403713|Experimental|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
16631759|NCT02403713|Active Comparator|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
16631760|NCT02403713|Active Comparator|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
16631761|NCT02403713|Active Comparator|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
16631762|NCT02403713|Active Comparator|Active Comparator 4|Formoterol (12 µg) without spacer
16631763|NCT02403700||All study participants|One group observation study
16631764|NCT02403674|Experimental|Doravirine, Tenofovir, Lamivudine|Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
16631765|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
16631766|NCT02403661|Active Comparator|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
16631767|NCT02403661|Placebo Comparator|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
16631768|NCT02403648|Experimental|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
16631769|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
16631770|NCT02403648|Active Comparator|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
16631771|NCT02403648|Experimental|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
16631772|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
16631773|NCT02403648|Active Comparator|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
16631774|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
16631775|NCT02403622|Experimental|Intervention: Fecal Microbiota Preparation|"Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.
~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor"
16631776|NCT02403609|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) on two consecutive days
16631777|NCT02403596|Experimental|Group 1: Exacyl®: Standard treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 then 1g Exacyl® placebo at H+7 and H+11
16631778|NCT02403596|Experimental|Group 2: Exacyl®: Extended treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 / H+7 and H+11
16631779|NCT02403596|Placebo Comparator|Group 3: Placebo|This group will receive a placebo of Exacyl®: 1g placebo of Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g placebo of Exacyl® at H+3 / H+7 and H+11
16631780|NCT02403583|Other|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
16631781|NCT02403583|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
16631782|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
16631783|NCT02403557|Experimental|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
16631784|NCT02403557|Active Comparator|Waitlist|Weekly check-up.
16631785|NCT02403544|Experimental|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
16631786|NCT02403531|Active Comparator|Concurrent chemoradiotherapy|Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
16631787|NCT02403531|Experimental|Induction chemotherapy plus chemoradiotherapy|Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
16631788|NCT02403518|Active Comparator|Back Pain Only|Pain localized to the low back or buttocks.
16631789|NCT02403518|Active Comparator|Leg Pain Only|Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
16631790|NCT02403518|Active Comparator|Back and Leg Pain|Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).
16631791|NCT02403505|Experimental|ABIRATERONE - Group 1|"ZYTIGA - ABIRATERONE ACETATE TABLET
~Combined Chemotherapy
~DELTASONE - PREDNISONE TABLET
~ELIGARD - Leuprolide Acetate Kit"
16631792|NCT02403505|Experimental|ABIRATERONE - Group 2|"ZYTIGA - ABIRATERONE ACETATE TABLET
~Combined Chemotherapy
~DELTASONE - PREDNISONE TABLET
~TRELSTAR - Triptorelin Pamoate Kit"
16631793|NCT02403492|No Intervention|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
16631794|NCT02403492|Experimental|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
16631795|NCT02403492|Experimental|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
16631796|NCT02403479|Experimental|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
16631797|NCT02403479|Experimental|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
16631798|NCT02403466|Experimental|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
16631799|NCT02403440|Experimental|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
16631800|NCT02403427|Experimental|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
16631801|NCT02403427|No Intervention|manual calculation|manula insulin calculation before every main meal; three times per day
16631802|NCT02403401|Experimental|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
16631803|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
16631804|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
16631805|NCT02403375|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
16631806|NCT02403362|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
16631807|NCT02403362|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
16631808|NCT02403362|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
16631809|NCT02403349|Experimental|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
16631810|NCT02403349|Active Comparator|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
16631811|NCT02403349|Active Comparator|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
16631812|NCT02403336|Experimental|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
16631813|NCT02403336|Active Comparator|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
16631814|NCT02403323|Experimental|Part 1: Etrolizumab Open-Label Extension|Participants will receive open-label treatment with etrolizumab once every 4 weeks until commercial availability in their country or sponsor's decision to terminate the study, whichever is earlier (up to approximately 10 years after the first patient is enrolled).
16631815|NCT02403323|No Intervention|Part 2: Safety Monitoring|Participants who have stopped etrolizumab treatment (either by exiting Part 1 of this study or by entering directly from Study GA29144 [NCT02394028]) will be monitored for 92 weeks for progressive multifocal leukoencephalopathy (PML) and other safety events.
16631816|NCT02403310|Experimental|Dose Escalation - Selinexor|"Dose escalation of selinexor with fixed doses of daunorubicin and cytarabine.
~Induction Therapy may be followed by Consolidation Phase and Maintenance Phase as outlined in the Detailed Description and Intervention Descriptions."
16631817|NCT02403297||Healthy|"Saliva will be collected from 58 subjects determined to be healthy according to the protocol."
16631818|NCT02403297||Gingivitis|Saliva will be collected from 58 subjects determined to have gingivitis according to the protocol.
16631819|NCT02403297||Periodontal disease|Saliva will be collected from 58 subjects determined to have periodontal disease according to the protocol.
16631820|NCT02403284|Experimental|Liraglutide|Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
16631822|NCT02403271|Experimental|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
16631823|NCT02403271|Experimental|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
16631824|NCT02403258|Experimental|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
16631825|NCT02403258|Active Comparator|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
16631826|NCT02403245|Experimental|Psychosocial stimulation|One session of a social stimulation
16631827|NCT02403245|No Intervention|Control group|Residents are in a social controlled condition but without direct stimulation.
16631828|NCT02403232|Experimental|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
16631829|NCT02403219|Experimental|Botulinum toxin type A injection|An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
16631830|NCT02403219|Sham Comparator|Sham injection|An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
16631831|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
16631832|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
16631833|NCT02403193|Experimental|PBF-509_80 mg|
16631834|NCT02403193|Experimental|PBF-509_160 mg|
16631835|NCT02403193|Experimental|PBF-509_320 mg|
16631836|NCT02403193|Experimental|PBF-509_640 mg|
16631837|NCT02403193|Experimental|PBF509_160 mg +PDR001|
16631838|NCT02403193|Experimental|PBF509_320 mg+PDR001|
16631839|NCT02403193|Experimental|PBF509_640 mg +PDR001|
16631840|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
16631841|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
16631842|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
16631843|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
16631844|NCT02403154|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
16631845|NCT02403154|Experimental|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
16631846|NCT02403154|Other|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
16631847|NCT02403154|Other|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
16631848|NCT02403141||Normal glucose tolerance|Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
16631849|NCT02403141||Impaired fasting glycaemia|Patients with blood glucose between 5.6mmol/L - 7mmol/L
16631850|NCT02403141||Type 2 diabetes|Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
16631851|NCT02403141||Type 1 diabetes|Patients on insulin and with positive IA2 and/or GAD antibodies.
16631852|NCT02403128|Experimental|Patients with macular edema from RAM|Intravitreal aflibercept 2.0 mg injection for eyes meeting eligibility criteria will be administered at baseline. Reinjection of the drug for protocol-defined criteria at least two months after previous injection.
16631853|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
16631854|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
16632312|NCT02399982|Experimental|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
16631855|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
16631856|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
16631857|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
16631858|NCT02403089||neonates|neonates 24-41 weeks gestational age
16631859|NCT02403089||children|hematopoietic stem cell transplant recipient children (< 18 years old, donor source: cord blood or genoidentical donor)
16631860|NCT02403063|Active Comparator|sugammadex|Selective relaxant binding agent
16631861|NCT02403063|Active Comparator|neostigmine|Acetylcholinesterase inhibitor
16631862|NCT02403063|Experimental|neostigmine-sugammadex|Acetylcholinesterase inhibitor followed by a selective relaxant binding agent
16631863|NCT02403050||Fiducial Markers Prospective cohort|2 fiducial markers (Visicoils) to be placed in the tumor area at the routine endoscopic ultrasound (EUS) appointment.
16631864|NCT02403050||Retrospective cohort|Images and clinical data from a retrospective group of patients without fiducial markers
16631865|NCT02403037|Experimental|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
16631866|NCT02403037|Sham Comparator|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
16631867|NCT02403037|Other|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
16631868|NCT02403024|Experimental|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
16631869|NCT02403024|Other|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
16631870|NCT02403011|Experimental|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
16631871|NCT02403011|Experimental|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
16631872|NCT02402998|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
16631873|NCT02402985|Other|High animal protein diet group AP|6-weeks diet intervention with high animal protein
16631874|NCT02402985|Other|High plant protein diet group PP|6-weeks diet intervention with high plant protein
16631875|NCT02402972|Experimental|IPC plus AC|"patients treated with intraoperative intraportal chemotherapy (IPC) plus adjuvant chemotherapy (AC; mFOLFOX6).; IPC: During the operation, one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein within 5 minutes just before ligation.
~AC: All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0."
16631876|NCT02402972|Active Comparator|AC|patients treated with adjuvant chemotherapy (AC; mFOLFOX6) alone after surgery; Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0.
16631877|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631878|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631879|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631880|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631881|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631882|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631883|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631884|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631885|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631886|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
16631887|NCT02402946|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
16631888|NCT02402946|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
16631889|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
16631890|NCT02402920|Experimental|Part A (LS-SCLC, pembrolizumab, chemoradiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
16631891|NCT02402920|Experimental|Part B (ES-SCLC, pembrolizumab, radiation therapy)|Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
16631892|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
16631893|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
16631894|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
16631895|NCT02402881|No Intervention|Control|Patients will receive only the standard practices of care
16631896|NCT02402868|Experimental|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
16631897|NCT02402868|Active Comparator|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
16631898|NCT02402855|Experimental|Group Intervention: Financial support|
16631899|NCT02402855|Active Comparator|Group Control: no financial support|
16631900|NCT02402842|Experimental|DCF regimen|docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
16631901|NCT02402829||Hemophilia Patients|Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.
16631902|NCT02402816|Experimental|MPP ON|Patients will be randomized to the MPP-ON Arm vs Standard ICD
16631903|NCT02402816|Active Comparator|Standard ICD|Patients will be randomized to the MPP-ON Arm vs Standard ICD
16632421|NCT02399137|Experimental|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
16631904|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.
~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.
~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
16631905|NCT02402751|Experimental|Acquisition of normative database|Development, implementation and initiation of normative database (image and data) quantitative ultra high field MRI paramaters
16631906|NCT02402738|Experimental|Interpersonal and Social Rhythm Therapy|Participants may be randomized to receive up to 20 outpatient sessions of Interpersonal and Social Rhythm Therapy, provided as an adjunct to community treatment as usual. Intervention sessions begin during pregnancy and continue through 8 weeks postpartum.
16631907|NCT02402738|Active Comparator|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a monthly standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
16631908|NCT02402725|Experimental|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
16631909|NCT02402712|Experimental|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
16631910|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
16631911|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
16631912|NCT02402673|Other|Intervention|
16631913|NCT02402660|Experimental|ALK-001|Daily, oral administration of one capsule. See details below.
16631914|NCT02402660|Placebo Comparator|Placebo|Daily, oral administration of one capsule. See details below.
16631915|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.
~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
16631916|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
16631917|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
16631918|NCT02402621|Active Comparator|Conventional analgesic group|fentanyl
16631919|NCT02402621|Experimental|Model based analgesic group|fentanyl
16631920|NCT02402608|Active Comparator|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
16631921|NCT02402608|Placebo Comparator|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
16631922|NCT02402595|Experimental|Sequence 1 - Period 1|AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
16631923|NCT02402595|Experimental|Sequence 1 - Period 2 (after 3-week washout)|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
16631924|NCT02402595|Experimental|Sequence 2 - Period 1|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
16631925|NCT02402595|Experimental|Sequence 2 - Period 2 (after 3-week washout)|AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
16631926|NCT02402582|Experimental|Family-Centered Empowerment Model|Have the same in-patient, pre-intervention, and post-intervention follow-up care as Control Group. However, rather than routine care and follow-up during the intervention period, they recieved than 4 stage intervention using the Family Centered Empowerment Model.
16631927|NCT02402582|Active Comparator|Control|Same in-patient, pre-intervention, and post-intervention follow-up care as Experimental Group. However, rather than 4 stage intervention they receive routine care and follow-up.
16631928|NCT02402569|Experimental|Multi-electrodes / single electrode|Multi stimulation / single stimulation
16631929|NCT02402569|Experimental|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
16631930|NCT02402556|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
16631931|NCT02402556|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
16631932|NCT02402543|Placebo Comparator|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
16632422|NCT02399137|Active Comparator|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
16631933|NCT02402543|Experimental|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
16631934|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
16631935|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
16631936|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
16631937|NCT02402517|Placebo Comparator|Extruded snack control|100% corn flour
16631938|NCT02402517|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
16631939|NCT02402517|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
16631940|NCT02402517|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
16631941|NCT02402517|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
16631942|NCT02402517|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
16631943|NCT02402504|Placebo Comparator|Extruded snack control|100% corn flour
16631944|NCT02402504|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
16631945|NCT02402504|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
16631946|NCT02402504|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
16631947|NCT02402504|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
16631948|NCT02402504|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
16631949|NCT02402491|Active Comparator|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
16631950|NCT02402491|Placebo Comparator|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
16631951|NCT02402478||Stable coronary artery disease|Patients with chest pain
16631952|NCT02402465|Placebo Comparator|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
16631953|NCT02402465|Experimental|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
16631954|NCT02402465|Experimental|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
16631955|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
16631956|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
16631957|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
16631958|NCT02402413|Experimental|PCOS women|
16631959|NCT02402400|Active Comparator|Oral Ticagrelor|
16631960|NCT02402400|Experimental|Sub Lingual Ticagrelor|
16631961|NCT02402387|Active Comparator|Neutral|The patient's head will be in neutral position.
16631962|NCT02402387|Experimental|Flexed|The patient's head will be flexed.
16631963|NCT02402387|Experimental|Extended|The patient's head will be extended.
16631964|NCT02402387|Experimental|Rotated|The patient's head will be rotated.
16631965|NCT02402374|Experimental|PRP gel|Autologous platelet rich plasma gel
16631966|NCT02402374|Placebo Comparator|Placebo|Saline gel
16631967|NCT02402348|Experimental|Metformin|Metformin 850 mg orally once a day for 3 days, then 850 mg orally twice daily starting day 4 until 24hrs before surgery.
16631968|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
16631969|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
16631970|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
16631971|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
16631972|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
16631973|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
16631974|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
16631975|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
16631976|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
16631977|NCT02402283|Experimental|Test Product|Metronidazole benzoate oral granules
16631978|NCT02402283|Active Comparator|Reference Product|Flagyl 400 mg Tablets
16631979|NCT02402270|Experimental|ECP-019 A (Group A)|
16631980|NCT02402270|Experimental|ECP-019 B (Group B)|
16631981|NCT02402270|Experimental|ECP-019 C (Group C)|
16631982|NCT02402270|Active Comparator|Group D|
16631983|NCT02402270|Active Comparator|Group E|
16631984|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
16631985|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
16632009|NCT02402101|Active Comparator|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
16631987|NCT02402231|Experimental|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
16631988|NCT02402218|Active Comparator|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
16631989|NCT02402218|Experimental|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
16631990|NCT02402218|Experimental|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
16631991|NCT02402205|Experimental|Web Implementation of TF-CBT|"Web implementation (W)provides only web-based (distance learning) training and consultation to mental health therapists providing TF-CBT treatment to adjudicated youth in RTF. Therapists access the initial 10 hour training course(www.musc.edu/tfcbt) and follow-up consultation (www.musc.edu/tfcbtconsult) at their own convenience and as needed during the course of the study, with RTF administrators guaranteeing that therapists have time to do so. This implementation strategy is free and more convenient to therapists and administrators as it can be accessed whenever desired."
16631992|NCT02402205|Experimental|Web + Live Implementation of TF-CBT|"Web + Live (W+L) implementation provides web-based training and consultation as described in W, and also provides 1) face-to-face training and 2) twice monthly phone consultation with an expert TF-CBT trainer. W+L requires greater resource commitment from therapists and administrators and is less convenient, but provides more specific consultation on the therapists' personal TF-CBT treatment cases."
16631993|NCT02402192|Active Comparator|Corifollitropin alfa|Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.
16631994|NCT02402192|Active Comparator|recombinant FSH|Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.
16631995|NCT02402192|Active Comparator|HP- hMG|Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
16631996|NCT02402179|Experimental|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
16631997|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
16631998|NCT02402153|Other|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
16631999|NCT02402140|Experimental|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.
~No more interventions were applied."
16632000|NCT02402140|No Intervention|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.
~It was not a intervention, it was the control group"
16632001|NCT02402127|Other|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
16632002|NCT02402127|Other|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
16632003|NCT02402127|Other|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
16632004|NCT02402127|Other|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
16632005|NCT02402127|Other|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
16632006|NCT02402127|Other|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
16632007|NCT02402114|Experimental|Intervention|Subject randomized to this group receives 1 oral dose of Hydrocortisone 120 mg
16632008|NCT02402114|Placebo Comparator|Placebo|Subject randomized to this group will receive an oral sugar/placebo pill that looks similar to the Hydrocortisone pill.
16632010|NCT02402101|Placebo Comparator|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
16632011|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
16632012|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
16632013|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
16632014|NCT02402075||Brain tumor|patients with glioma
16632015|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
16632016|NCT02402049|Active Comparator|1: Natrum muriaticum 30C|Natrum muriaticum 30C
16632017|NCT02402049|Active Comparator|2: Lachesis 30C|Lachesis 30C
16632018|NCT02402049|Active Comparator|3: Sepia 30C|Sepia 30C
16632019|NCT02402049|Active Comparator|4: Nux vomica 30C|Nux vomica 30C
16632020|NCT02402049|Active Comparator|5: Pulsatilla 30C|Pulsatilla 30C
16632021|NCT02402049|Active Comparator|6 Folliculinum 30C|Folliculinum 30C
16632022|NCT02402049|Placebo Comparator|1: Placebo Natrum muriaticum|Placebo Natrum muriaticum
16632023|NCT02402049|Placebo Comparator|2: Placebo Lachesis|Placebo Lachesis
16632024|NCT02402049|Placebo Comparator|3: Placebo Sepia|Placebo Sepia
16632025|NCT02402049|Placebo Comparator|4: Placebo Nux vomica|Placebo Nux vomica
16632026|NCT02402049|Placebo Comparator|5: Placebo pulsatilla|Placebo pulsatilla
16632027|NCT02402049|Placebo Comparator|6: Placebo Folliculinum|Placebo Folliculinum
16632028|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
16632029|NCT02402023|Active Comparator|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
16632030|NCT02402023|Experimental|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
16632031|NCT02402010|Experimental|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
16632032|NCT02402010|Other|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
16632033|NCT02401997|Active Comparator|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
16632034|NCT02401997|Active Comparator|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
16632035|NCT02401997|Active Comparator|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
16632036|NCT02401984||Screening|A Screening tool will be administered to the participants.
16632037|NCT02401971|Experimental|Arm A (thalidomide+CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.
16632038|NCT02401971|Experimental|Arm B (CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.
16632039|NCT02401958|Experimental|Rheumatoid Arthritis Group|Resistance Training
16632040|NCT02401958|Active Comparator|Healthy control Group|Resistance Training
16632041|NCT02401945|Experimental|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
16632042|NCT02401945|Experimental|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
16632043|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
16632044|NCT02401919|Experimental|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
16632045|NCT02401919|No Intervention|Care as usual|In the control arm, patients will receive care as usual.
16632046|NCT02401880|Active Comparator|Empagliflozin plus Linagliptin|Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
16632047|NCT02401880|Placebo Comparator|Empagliflozin plus Placebo|Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
16632048|NCT02401880|Other|Empagliflozin|Empagliflozin 25mg will be adminstered for 30 days in T2DM patients
16632049|NCT02401841||Sugammadex|Patients treated with Sugammadex
16632050|NCT02401841||Neostigmine|Patients treated with Neostigmine
16632051|NCT02401828|Experimental|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
16632052|NCT02401828|Experimental|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
16632053|NCT02401815|Experimental|Part 1: PLX9486 250 mg QD|Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632054|NCT02401815|Experimental|Part 1: PLX9486 350 mg QD|Participants will receive PLX9486 350 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632423|NCT02399137|No Intervention|Observational Group|
16632055|NCT02401815|Experimental|Part 1: PLX9486 500 mg QD|Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632056|NCT02401815|Experimental|Part 1: PLX9486 1000 mg QD|Participants will receive PLX9486 1000 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632057|NCT02401815|Experimental|Part 1: PLX9486 500 mg BID|Participants will receive PLX9486 500 mg orally twice daily (BID) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632058|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Fasting)|Participants in fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632059|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Non-Fasting)|Participants in non-fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632060|NCT02401815|Experimental|Part 2e: PLX9486 500 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 500 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632061|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632062|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 37.5 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 37.5 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
16632063|NCT02401802|Experimental|Low-residue diet|The experimental group will receive 4 days of low-residue diet Laxative 4 liters polyethylene glycol 4000 in split fashion.
16632064|NCT02401802|Active Comparator|Usual care|"The control group will receive 3 days of low-residue diet followed by 24 hours of liquid diet.
~Laxative 4 liters polyethylene glycol 4000 in split fashion."
16632065|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
16632066|NCT02401789|No Intervention|control- natural healing|
16632067|NCT02401776|Experimental|small dose monster energy drink|This will be a small dose of monster energy drink
16632068|NCT02401776|Experimental|medium dose monster energy drink|This will be a medium dose of monster energy drink
16632069|NCT02401776|Active Comparator|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
16632070|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
16632071|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
16632072|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
16632073|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
16632074|NCT02401737|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 28 days
16632075|NCT02401737|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
16632076|NCT02401737|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
16632077|NCT02401737|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
16632078|NCT02401724|Active Comparator|Action Training|Training exercise which involves patients lifting up rods of different sizes and shifting their grip if this is too far to one side
16632079|NCT02401724|Experimental|tDCS|A constant 1mA current will be applied to the left (undamaged) side of the scalp with an electrode covered with a damp cotton pad (25 cm2). The current will be applied for 15 minutes per day, with a total of 10 sessions over 3 weeks.
16632080|NCT02401724|Experimental|Action Training + tDCs|This will involve the same procedure as in action training only but with tDCS applied for 15 minutes during the rodlifting.
16632081|NCT02401724|Placebo Comparator|Control training|For the control training, patients will be asked to simply reach for the right hand side of each rod with their right (unaffected) hand and lift it
16632082|NCT02401711|Active Comparator|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
16632083|NCT02401711|Experimental|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
16632084|NCT02401685|Experimental|Adjuvant therapy alone|Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
16632085|NCT02401685|Active Comparator|Adjuvant therapy plus axillary treatment|Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
16632086|NCT02401672|Active Comparator|Active TMS|Repetitive TMS pulse stimulation
16634060|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
16632087|NCT02401672|Sham Comparator|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
16632088|NCT02401659||naïve with CareLink|patients with a first implant of an implanted cardiac device naïve in CareLink or patients with a refill who have not used CareLink until the implant
16632089|NCT02401659||users of CareLink|patients with an implanted cardiac device who have used CareLink for more than one year
16632090|NCT02401646|Experimental|Polygoni Multiflori Radix complex|Participants randomized to the experimental group will take one capsule of Polygoni Multiflori Radix complex extract (250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
16632091|NCT02401646|Placebo Comparator|Starch|Participants randomized to the placebo group will take one capsule of placebo(250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
16632092|NCT02401633|Experimental|CO-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions only
16632093|NCT02401633|Active Comparator|S-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
16632094|NCT02401620||single-group studies|Patients with RA diagnosed
16632095|NCT02401594|Experimental|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
16632096|NCT02401594|Active Comparator|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
16632097|NCT02401581|Experimental|rate of early removal of the catheter|In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .
16632098|NCT02401568|Other|Normal subjects|"No morphologic changes in carpal ligaments or clinical signs of wrist instability.
~Dynamic CT of the wrist will be performed before and after arthrography."
16632099|NCT02401568|Other|Wrist instability|Morphologic ligament changes (e.g. partial or complete rupture) Dynamic CT of the wrist will be performed before and after arthrography.
16632100|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
16632101|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
16632102|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
16632103|NCT02401542|Active Comparator|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.
~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
16632104|NCT02401542|Placebo Comparator|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.
~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
16632105|NCT02401542|Experimental|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.
~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
16632106|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
16632107|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
16632108|NCT02401516|Active Comparator|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
16632109|NCT02401516|Placebo Comparator|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
16632110|NCT02401503|Experimental|Bendamustine + GA101 + ABT-199|Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.
16632111|NCT02401490|Active Comparator|Human albumin|human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.
16632112|NCT02401490|Placebo Comparator|placebo|saline serum 0.9%
16632113|NCT02401477|Experimental|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
16632114|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
16632173|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
16632174|NCT02400957|Experimental|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized.
16632115|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
16632116|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
16632117|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
16632118|NCT02401451|Experimental|ECG acquisition|"ECG acquisition using the standard ECG machine
~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
16632119|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
16632120|NCT02401425|Active Comparator|letrozole|Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
16632121|NCT02401425|Placebo Comparator|placebo|Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
16632122|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
16632123|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
16632124|NCT02401399|Placebo Comparator|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
16632125|NCT02401399|Active Comparator|high protein formula|The patients receive high protein formula during 15 days before surgery
16632126|NCT02401399|Experimental|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
16632127|NCT02401386|Experimental|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
16632128|NCT02401386|No Intervention|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
16632129|NCT02401373|Experimental|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
16632130|NCT02401373|Experimental|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
16632131|NCT02401360|Experimental|Experimental Group|Oral care regimen
16632132|NCT02401360|Placebo Comparator|Control Group|Toothbrush and toothpaste
16632133|NCT02401347|Experimental|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.
~Participants receive talazoparib 1 mg by mouth daily."
16632134|NCT02401347|Experimental|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:
~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.
~Participants receive talazoparib 1 mg by mouth daily."
16632135|NCT02401334|Experimental|Hernia Repair|Surgical repair for hernia with implantation of the Cook® Antimicrobial Hernia Repair Device.
16632136|NCT02401321|Experimental|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
16632175|NCT02400957|Experimental|Placebo|Half of the mouth was applied placebo. Allocation was randomized.
16632176|NCT02400944||patients with bladder cancer|
16632177|NCT02400931|Active Comparator|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
16632178|NCT02400931|Experimental|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
16632243|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.
~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
16632139|NCT02401295|Experimental|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.
~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.
~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.
~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
16632140|NCT02401282|Experimental|ABM|Attention bias modification
16632141|NCT02401282|Placebo Comparator|Placebo|Dot-probe task
16632142|NCT02401269|Experimental|Aspirin|Aspirin 325mg daily
16632143|NCT02401269|Placebo Comparator|Placebo|Placebo
16632144|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.
~Included drugs:
~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home
~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
16632145|NCT02401243|Experimental|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
16632146|NCT02401243|Experimental|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
16632147|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
16632148|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
16632149|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
16632150|NCT02401217|Experimental|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
16632151|NCT02401217|Active Comparator|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
16632152|NCT02401217|Experimental|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
16632153|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
16632154|NCT02401191|Experimental|FEX60/PE10|Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
16632155|NCT02401178||Well baby|"For cross-sectional study design:
~The dependent variables are LCPUFA composition from buccal. The independent variables are 17 SNP from FADS genes.
~For extended cross-sectional study design:
~The dependent variable is atopic dermatitis, while independent variables are:
~17 SNP; LCPUFA and FLG gene mutation"
16632156|NCT02401165|Other|patient|patient
16632157|NCT02401152|Placebo Comparator|Placebo group|Sports drink containing maltodextrin
16632158|NCT02401152|Active Comparator|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
16632159|NCT02401152|Active Comparator|Sports drink 2|Sports drink with a specific source of CHO.
16632160|NCT02401139|Active Comparator|Treatment arm|Ketamine
16632161|NCT02401139|Placebo Comparator|Placebo arm|Placebo
16632162|NCT02401126|Active Comparator|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
16632163|NCT02401126|Placebo Comparator|Placebo|Nitrate-depleted beetroot juice
16632164|NCT02401113|Experimental|UA group|UA group who takes Ursolic acid of Loquat Extract , 500 mg/ day during 12 weeks for treatment of muscle function improvement with relatively health adults
16632165|NCT02401113|Placebo Comparator|placebo group|placebo group who takes a placebo, 500 mg/day for 12 weeks
16632166|NCT02401074|Experimental|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
16632167|NCT02401061|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
16632168|NCT02401048|Experimental|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
16632169|NCT02401048|Experimental|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
16632170|NCT02401035|Experimental|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
16632171|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
16632172|NCT02401022|Active Comparator|AZD8529 high dose|40mg
16632208|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
16632179|NCT02400918|Experimental|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
16632180|NCT02400918|No Intervention|Control|Waitlist control
16632181|NCT02400905|Experimental|BioMimics 3D Vascular Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System
16632182|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
16632183|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
16632184|NCT02400879|Active Comparator|Remifentanil|For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60
16632185|NCT02400879|Placebo Comparator|sevoflurane and sufentanil|TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60
16632186|NCT02400866|Placebo Comparator|Control|palonosetron + dexamethasone + placebo
16632187|NCT02400866|Experimental|Experimental|palonosetron + dexamethasone + olanzapine
16632188|NCT02400853|Experimental|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
16632189|NCT02400853|Active Comparator|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
16632190|NCT02400840|Experimental|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
16632191|NCT02400840|Active Comparator|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
16632192|NCT02400827||cryopreservation|
16632193|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
16632194|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
16632195|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
16632196|NCT02400801|Active Comparator|oral oestroprogestogen pre-treatment|preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
16632197|NCT02400801|Experimental|gonadotropin-releasing hormone (GnRH) pre-treatment|preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
16632198|NCT02400788|Experimental|Resminostat + Sorafenib|oral administration
16632199|NCT02400788|Active Comparator|Sorafenib|oral administration
16632200|NCT02400775|Experimental|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
16632201|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
16632202|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
16632203|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) competitive employment: IPS assists participants to enter into competitive jobs; 2) eligibility based on client choice, i.e. zero exclusion; 3) integration of IPS and treatment team, i.e. the PACT; 4) patient-centered job match for competitive employment; 5) personalized benefits counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) rapid job search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) job development: IPS specialists build an employer network based on Veterans' interests; 8) time-unlimited and individualized support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
16632204|NCT02400736|Active Comparator|Treatment as Usual Vocational Rehabilitation/Transitional Work (TAU-VR)|Treatment as Usual Vocational Rehabilitation includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW) which involves 1) time-limited set-aside work experiences: short-term transitional work experiences in a brokered or set-aside work setting; 2) no strict entrance criteria other than general medical clearance; 3) limited integration of TW and clinical Services; 4) not patient-centered: TW jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) personalized benefits counseling; 6) limited job search: TW specialists provide variable and limited guidance for competitive job search; 7) no job development: TW specialists do not engage in community based job development; 8) time limited: The TW specialist does not provide long-term follow-up after the first job is obtained.
16632205|NCT02400723|Experimental|BREATHE|Four weeks of DVD-delivered behavioral intervention. Intervention consists of diaphragmatic breathing and progressive muscle relaxation.
16632206|NCT02400723|Placebo Comparator|Psychoeducation|Four weeks of DVD-delivered psychoeducation as an attention placebo control.
16632207|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
16632211|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
16632212|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
16632213|NCT02400671|Experimental|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
16632214|NCT02400671|Experimental|One-Way SMS|Participants will receive weekly push SMS messaging
16632215|NCT02400671|No Intervention|Control|Participants will receive standard of care (no intervention)
16632216|NCT02400658|Experimental|IORT with CT-Guided HDR Brachytherapy|Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery.
16632217|NCT02400645|Active Comparator|Group A: pre-incisional bupivacaine|Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.
16632218|NCT02400645|Active Comparator|Group B: laparoscope to place TAP block|Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.
16632219|NCT02400632|Experimental|MAGIC-TOUCH Drug-eluting balloon|in-stent restenosis treated with drug-eluting balloon
16632220|NCT02400619|Active Comparator|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
16632221|NCT02400619|Active Comparator|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
16632222|NCT02400606|Experimental|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
16632223|NCT02400606|Active Comparator|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
16632224|NCT02400593|Experimental|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
16632225|NCT02400593|Placebo Comparator|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
16632226|NCT02400580|Experimental|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
16632227|NCT02400580|Placebo Comparator|Normal Saline|The patients in the placebo arm will receive normal saline.
16632228|NCT02400567|Active Comparator|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
16632229|NCT02400567|Experimental|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
16632230|NCT02400554|No Intervention|Wait List Control|Participants wait one year before receiving the intervention. Three assessments are taken over this period: Month 3, Month 9, and Month 12.
16632231|NCT02400554|Experimental|Yappalli|Yappalli: Participants attend a 12-month behavioral intervention.
16632232|NCT02400541|Experimental|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
16632233|NCT02400541|Placebo Comparator|relaxation therapy|10 relaxation sessions during 5 weeks
16632234|NCT02400528|Other|Patients With Profound and Multiple Disabilities|
16632235|NCT02400515|Other|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
16632236|NCT02400502|Experimental|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
16632237|NCT02400476|Experimental|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
16632238|NCT02400476|Experimental|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
16632239|NCT02400476|Experimental|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
16632240|NCT02400476|Experimental|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
16632241|NCT02400476|Experimental|Neratinib Dose Escalation 1|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
16632242|NCT02400476|Experimental|Neratinib Dose Escalation 2|160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.
16632244|NCT02400450|Experimental|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
16632245|NCT02400450|Placebo Comparator|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
16632246|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity
~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.
~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase
~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase
~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
16632247|NCT02400424|Experimental|SBRT|Study treatment = SBRT for peripheral primary tumor.
16632248|NCT02400411|Experimental|Wheat bread|Bread-based meal
16632249|NCT02400411|Experimental|Wheat bread with margarine and ham|Bread-based meal
16632250|NCT02400411|Experimental|Wheat bread with margarine, ham and soup|Bread-based meal
16632251|NCT02400411|Experimental|Rye bread|Bread-based meal
16632252|NCT02400411|Experimental|Rye bread with margarine and ham|Bread-based meal
16632253|NCT02400411|Experimental|Rye bread with margarine, ham and soup|Bread-based meal
16632254|NCT02400398||Tube feeding with peptide-base formula|The peptide-based formula (Peptamen) will be administered through a gastrojejunal or jejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered for three 28-day cycles.
16632255|NCT02400385|Experimental|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
16632256|NCT02400372|Experimental|research group|Medihoney Dressing
16632257|NCT02400372|No Intervention|control group|Paraffin gauze with saline Dressing
16632258|NCT02400372|No Intervention|3. Comparison group|Polymem dressing
16632259|NCT02400359|Placebo Comparator|Placebo|Subjects will be randomized to either placebo or Lorcaserin HCl.
16632260|NCT02400359|Active Comparator|Active|Subjects will be randomized to either placebo or Lorcaserin HCl.
16632261|NCT02400346|Experimental|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
16632262|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
16632263|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
16632264|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
16632265|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
16632266|NCT02400320|Active Comparator|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
16632267|NCT02400320|Experimental|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
16632268|NCT02400320|Other|Saline|Saline
16632269|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
16632270|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
16632271|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
16632272|NCT02400281|Experimental|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
16632273|NCT02400281|Experimental|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
16632274|NCT02400268|Experimental|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
16632275|NCT02400268|Active Comparator|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
16632276|NCT02400255|Experimental|Cohort A|Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
16632277|NCT02400255|Experimental|Cohort B|Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
16632278|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
16632279|NCT02400229|Experimental|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
16632280|NCT02400229|Active Comparator|Invasive coronary angiography (ICA)|Invasive coronary angiography
16632283|NCT02400203|Active Comparator|Control|54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day
16632284|NCT02400203|Experimental|Hemp foods|60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day
16632286|NCT02400177|Experimental|Emotion regulation training|This is a 4 sessions group workshop and 1 session individual pre-screening about parental emotion regulation and emotion co-regulation. In this study the facilitators will give information about efficient strategies to regulate parent emotions and their children's emotions.
16632287|NCT02400177|No Intervention|Control group|"In this condition we will take all the measurement before and after the waiting list period.
~This group will go through the workshop after the measurements will be taken."
16632288|NCT02400164|Experimental|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
16632289|NCT02400151|Other|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.
~Intervention: Normal control"
16632290|NCT02400151|Experimental|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.
~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
16632291|NCT02400151|Placebo Comparator|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.
~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
16632292|NCT02400138|Experimental|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
16632293|NCT02400138|Sham Comparator|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
16632294|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
16632295|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
16632296|NCT02400112|Experimental|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
16632297|NCT02400112|No Intervention|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
16632298|NCT02400099|Active Comparator|High-protein low calorie diet (HPLC)|900 Kcal; Protein 90 g (39%); CHO 75 g (30%); Lipid 32 g (31%)
16632299|NCT02400099|Placebo Comparator|Control low calorie diet (CLC)|900 Kcal; Protein. 50 g (22%); CHO 119 g (48%); Lipid 31 g (30%)
16632300|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
16632301|NCT02400060|Experimental|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
16632302|NCT02400047|Experimental|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
16632303|NCT02400047|Experimental|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
16632304|NCT02400047|Active Comparator|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
16632305|NCT02400034|Active Comparator|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale >50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is <500 the patient will be discharged WITHOUT a catheter; If PVR is >500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
16632306|NCT02400034|Active Comparator|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids < 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
16632307|NCT02400021|Experimental|Prometrium|Prometrium (progesterone capsules) intervention
16632308|NCT02400021|No Intervention|No treatment|no treatment arm
16632309|NCT02400008|Experimental|Patient with bilateral vocal fold paralysis|Patient with bilateral vocal fold paralysis in a closure position between 6 months to 36 months before et who has been treated by endoscopic treatment without satisfying result (voice or breathing).
16632313|NCT02399969|Experimental|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
16632314|NCT02399969|No Intervention|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
16632315|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.
~Intervention: Survey"
16632316|NCT02399943|Experimental|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.
~Panitumumab: 6 mg/kg, intravenously, Q2W"
16632317|NCT02399917|Experimental|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~5-Azacitidine 75mg/m^2 Lirilumab 1.0 mg/kg"
16632318|NCT02399917|Experimental|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
16632319|NCT02399917|Experimental|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
16632320|NCT02399904|Experimental|1|
16632321|NCT02399891||Retrospective|MI prior to December 11, 2011
16632322|NCT02399891||Prospective|MI on or after December 11, 2011
16632323|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
16632324|NCT02399865|Experimental|YSBNT Group|Six 50 minute YSBNT sessions (delivered by a trained YSBNT practitioner) for over a maximum period of 12 weeks
16632325|NCT02399865|No Intervention|Treatment as Usual Group|Usual care delivered by treatment-as-usual practitioners
16632326|NCT02399826|Other|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
16632327|NCT02399826|Experimental|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
16632328|NCT02399813|Experimental|ADXS11-001|
16632329|NCT02399800|Experimental|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
16632330|NCT02399800|Active Comparator|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
16632331|NCT02399787||infertile patients|Infertile patients with more than 5 oocytes retrieved and no endometriosis
16632332|NCT02399774|Experimental|Post-partum primi and multiparous women|"Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
~Control group: participants will not receive any device for breastfeeding pain control"
16632333|NCT02399774|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
16632334|NCT02399735|Experimental|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
16632335|NCT02399735|Experimental|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
16632336|NCT02399735|Experimental|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
16632337|NCT02399722|Active Comparator|VAC mono therapy|negative pressure wound therapy alone
16632338|NCT02399722|Active Comparator|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
16632339|NCT02399709|Experimental|simvastatin|oral administration, capsule of 20mg.
16632340|NCT02399709|Placebo Comparator|microcrystalline cellulose|oral administration, capsule of 20mg
16632341|NCT02399696|Experimental|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum.
16632342|NCT02399696|Active Comparator|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
16632343|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
16632344|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
16632345|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
16632346|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
16632347|NCT02399657|Experimental|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
16632348|NCT02399644|Experimental|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
16632349|NCT02399644|Experimental|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
16632389|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
16632350|NCT02399644|No Intervention|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
16632351|NCT02399631|Experimental|ERAS group|early recovery program with no preoperative mechanical bowel preparation, early diet initiation, and prevention of postoperative ileus after elective laparoscopic colon cancer surgery
16632352|NCT02399631|No Intervention|Congrol group|Traditional, conventional perioperative treatment
16632353|NCT02399618|Experimental|Capsulized freeze-dried FMT|Reconstitution of normal flora with capsulized freeze-dried fecal inoculum
16632354|NCT02399605|No Intervention|Control|No intervention, group control.
16632355|NCT02399605|Experimental|Stimulation|Subcutaneous Electrical Intervention
16632356|NCT02399592|Experimental|Bevacizumab and Tocotrienol|
16632357|NCT02399579|Experimental|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
16632358|NCT02399566|Experimental|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
16632359|NCT02399566|Active Comparator|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
16632360|NCT02399553|Experimental|Soccer 2G|Soccer players who trained in second generation artificial turf
16632361|NCT02399553|Experimental|Soccer 3G|Soccer players who trained in third generation artificial turf
16632362|NCT02399553|Experimental|Soccer NG|Soccer players who trained in natural grass
16632363|NCT02399553|Experimental|Soccer NON-NG|Soccer players who trained in non-natural grass
16632364|NCT02399553|No Intervention|Control group|
16632365|NCT02399540|Sham Comparator|Sham|Day 1: sham stimulation Day 2: sham stimulation
16632366|NCT02399540|Active Comparator|Conventional Paired tDCS|Day 1: sham stimulation Day 2: conventional tDCS
16632367|NCT02399540|Active Comparator|Conventional Unpaired tDCS|Day 1: conventional tDCS Day 2: sham stimulation
16632368|NCT02399540|Experimental|Late LTP-like Plasticity tDCS|Day 1: late LTP-like Plasticity tDCS Day 2: sham stimulation
16632369|NCT02399514|Other|RePneum coils|Patients who needed lung volume reduction with RePneum coils
16632370|NCT02399501|Experimental|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
16632371|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
16632372|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
16632373|NCT02399462|Experimental|Study Drug Arm|Acthar SC injections
16632374|NCT02399449|Active Comparator|sodium ferric gluconate (brand)|brand-name sodium ferric gluconate
16632375|NCT02399449|Active Comparator|sodium ferric gluconate (generic)|generic sodium ferric gluconate
16632376|NCT02399436|Experimental|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
16632377|NCT02399436|No Intervention|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
16632378|NCT02399436|Experimental|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
16632379|NCT02399423|Other|South Asian participants|30 South Asian male participants
16632380|NCT02399423|Other|European participants|30 European male participants
16632381|NCT02399410|Experimental|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
16632382|NCT02399397|Active Comparator|Control group|Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
16632383|NCT02399397|Experimental|Sepsis group|Adult patients (18-50 years old) ASAII and III with sepsis, systemic inflammatory response syndrome or septic shock submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
16632384|NCT02399397|Experimental|Elderly group|Elderly patients (> 65 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
16632385|NCT02399384||HIV+/CAD+|HIV+/CAD+
16632386|NCT02399384||HIV+/CAD-|HIV+/CAD-
16632387|NCT02399384||HIV-/CAD+|HIV-/CAD+
16632388|NCT02399371|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.
16632390|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
16632391|NCT02399332|Experimental|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.
~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
16632392|NCT02399332|No Intervention|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
16632393|NCT02399319|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal fixator.
16632394|NCT02399319|Experimental|Randomized to Symphyseal Plate|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal plating of the symphysis.
16632395|NCT02399319|Active Comparator|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and the treating physician selected the internal fixator intervention based on their opinion of how best to treat the specific case.
16632396|NCT02399319|Active Comparator|Observational - Symphyseal Plate|Patient signed consent but did not want to randomize their procedure and the treating physician selected internal plating of the symphysis based on their opinion of how best to treat the specific case.
16632397|NCT02399306|Experimental|Arm A|chemoradiotherapy with Enteral Nutrition intervention
16632398|NCT02399306|Placebo Comparator|Arm B|chemoradiotherapy
16632399|NCT02399293|Experimental|Patient N-back|Patients training the N-back task
16632400|NCT02399293|Active Comparator|Patient Visual Search|Patients training the Visual-Search task
16632401|NCT02399293|Experimental|Non-impaired N-back|Non-impaired training the N-back task
16632402|NCT02399293|Active Comparator|Non-impaired Visual Search|Non-impaired training the Visual-Search task
16632403|NCT02399280|Experimental|Lunch|Lunch as main meal(LM)+ Diet
16632404|NCT02399280|Experimental|Dinner|Dinner as main meal(DM)+ Diet
16632405|NCT02399267|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
16632406|NCT02399267|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
16632407|NCT02399267|Active Comparator|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =< 8 cm H2O with PEEP =< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
16632408|NCT02399267|Active Comparator|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
16632409|NCT02399254||Pulmonary Rehabilitation|Chronic Obstructive Pulmonary Disease (COPD) patients following pulmonary rehabilitation
16632410|NCT02399241|Experimental|Remote telemonitoring of clinical data|Bluetooth enabled nebuliser device (I-neb) providing breathing parameters and adherence data.
16632411|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
16632412|NCT02399215|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16632413|NCT02399202|Experimental|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
16632414|NCT02399189|Experimental|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles
~Auto-HSCT conditioning regimen:
~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
16632415|NCT02399176|Experimental|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
16632416|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
16632417|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
16632418|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
16632419|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
16632424|NCT02399124|Other|single arm, open label, treatment|single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
16632425|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
16632426|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
16632427|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
16632428|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
16632429|NCT02399098|Experimental|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
16632430|NCT02399098|Experimental|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
16632431|NCT02399098|No Intervention|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
16632432|NCT02399085|Experimental|Treatment (MOR00208, lenalidomide)|"MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 week cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.
~Lenalidomide (Revlimid®), PO, daily, 4 week cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16632433|NCT02399072||Geographic Atrophy Participants|Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.
16632434|NCT02399059|Experimental|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
16632435|NCT02399059|Active Comparator|Normal saline lavage|Peritoneal irrigation with normal saline
16632436|NCT02399046|Experimental|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
16632437|NCT02399046|Active Comparator|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
16632438|NCT02399033|No Intervention|the control group|Patients in Control group were not received Xihuang Capsules.
16632439|NCT02399033|Experimental|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
16632440|NCT02399020|Experimental|SCIT group|Social Cognition and Interaction Training intervention group
16632441|NCT02399007|Experimental|Total Hip System made in China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
16632442|NCT02399007|Active Comparator|Total Hip System made outside of China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
16632443|NCT02398994|Active Comparator|Intravenous Methylprednisolone|"Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.
~Adult patients - 1g/day for 5 days."
16632444|NCT02398994|Experimental|Intravenous Immunoglobulin|"Paediatric patients <41.2kg - total dose of 2g/kg in divided doses over 2 days.
~All other patients - total dose of 2g/kg in divided doses over 5 days.
~PLUS Intravenous Methylprednisolone
~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.
~Adult patients - 1g/day for 5 days."
16632445|NCT02398981|No Intervention|Baseline|Baseline data collection ( 20 patients per ICU)
16632446|NCT02398981|Experimental|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
16632447|NCT02398968|Active Comparator|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
16632448|NCT02398968|Active Comparator|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
16632449|NCT02398968|No Intervention|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia followed up for 12 months
16632450|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
16632451|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
16632452|NCT02398929|Other|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily following run-in placebo for 2 weeks
16632453|NCT02398916|Experimental|Music|"Listening to relaxing music for the entire period starting from waiting period in the surgical waiting area until the end of the LEEP procedure
~Undergoing LEEP according to the usual protocol"
16632454|NCT02398916|No Intervention|Control|- Undergoing LEEP according to the usual protocol without listening to music
16632455|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
16632456|NCT02398903||Normal weight women|Normal weight women
16632457|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
16632458|NCT02398877|Experimental|Depression with early trauma|stress
16632459|NCT02398877|Experimental|Depression without early trauma|stress
16632460|NCT02398877|Experimental|Healthy with early trauma|stress
16632461|NCT02398877|Experimental|Healthy without early trauma|stress
16632462|NCT02398864|Experimental|endobronchial ultrasound bronchoscopy|EBUS with TBNA
16632463|NCT02398851|Other|TacTIC care model|Compare the 30-day readmission rate in adult patients who receive care in a trans-disciplinary chronic disease continuity of care model with integrated technology (mobile devices such as tablets, iPads and smartphones)
16632464|NCT02398851|Other|Standard of Care|Compare standard practice (patient-centered, coordinated care model without the integration of technology
16632465|NCT02398838|Experimental|Home administration of mifepristone|Home administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
16632466|NCT02398838|Active Comparator|Clinic administration of mifepristone|Clinic administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
16632467|NCT02398825|Experimental|Ponatinib|
16632468|NCT02398812|Active Comparator|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
16632469|NCT02398812|No Intervention|Usual care|Usual care (reference group).
16632470|NCT02398799|No Intervention|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
16632471|NCT02398799|Experimental|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
16632473|NCT02398760|Experimental|Motor Control Exercises|(Costa LOP et al. 2009; Hodges PW et al. 2009)
16632474|NCT02398747|Experimental|AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD|50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
16632475|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
16632476|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
16632477|NCT02398721|Other|FNAC|patients will then be randomized routine FNAC strategy
16632478|NCT02398721|No Intervention|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
16632479|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
16632480|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
16632481|NCT02398695||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
16632482|NCT02398695||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
16632483|NCT02398682|Experimental|After study Intervention arm Heartlands|"The trial has 4 arms in a Before and After design:
~Arm 3. After/Heartlands area patients receiving the experimental intervention
~Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include:
~Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI."
16632484|NCT02398682|Active Comparator|After study Control arm Good Hope|"The trial has 4 arms in a Before and After design:
~Arm 4. After/Good Hope area patients observed whilst receiving active comparator
~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
16632485|NCT02398682|Active Comparator|Before study Heartlands area|"The trial has 4 arms in a Before and After design:
~Arm 1. Before/Heartlands area patients observed whilst receiving active comparator
~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
16632486|NCT02398682|Active Comparator|Before study Good Hope area|"The trial has 4 arms in a Before and After design:
~Arm 2. Before/Good Hope area patients observed whilst receiving active comparator
~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
16632487|NCT02398669|Experimental|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
16632488|NCT02398656|Experimental|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
16632554|NCT02398214|Experimental|Sleep hygiene & standard care|Participants receive a light, activity, and sleep training (LAST) intervention consists of behavioral and educational strategies for increasing light exposure and physical activity to minimize sleep disturbance.
16632489|NCT02398656|Active Comparator|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
16632490|NCT02398643|Other|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
16632491|NCT02398643|Other|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
16632492|NCT02398630|Other|Open Label|"This is a single arm open label study.
~Its procedures involve:
~Transvaginal Echography
~Conventional Virtual Histerosalpingography
~Virtual Histerosalpingography by MRI
~Blood draw for Antimullerian Hormone Dosing"
16632494|NCT02398604|Experimental|Group A - Allo-hMSCs|Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
16632495|NCT02398604|Placebo Comparator|Group B|Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
16632496|NCT02398591|Experimental|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
16632497|NCT02398591|Experimental|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
16632498|NCT02398591|Experimental|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
16632499|NCT02398578|Experimental|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
16632500|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy
~Ventral hernia repair - perioperative factors of interest:
~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,
~Pregnancy and delivery - factors of interest:
~- vaginal vs caesearan section, single vs multiple pregnancy
~Subgroup of patients with mesh repair:
~- subanalysis on main attributes
~Subgroup of patients with sutured repair:
~- mono- vs multifilament, slowly vs rapidly absorbable"
16632501|NCT02398552|Active Comparator|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
16632502|NCT02398552|Experimental|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
16632503|NCT02398539|Active Comparator|Group 1|Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
16632504|NCT02398539|Active Comparator|Group 2|Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
16632505|NCT02398526||Radium-223 dichloride|Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.
16632506|NCT02398513|Experimental|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
16632507|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
16632508|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
16632509|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
16632510|NCT02398487|Active Comparator|Personal Vaporizer|Personal Vaporizer loaded with nicotine
16632511|NCT02398487|Active Comparator|Cigalike|Cigalike loaded with nicotine
16632512|NCT02398487|No Intervention|Usual smoking|
16632513|NCT02398474|Experimental|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
16632514|NCT02398474|Active Comparator|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
16632515|NCT02398461|Experimental|rHIgM22|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
16632516|NCT02398461|Placebo Comparator|Placebo|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
16632555|NCT02398214|No Intervention|Standard care|Participants receive usual care.
16632556|NCT02398201|Experimental|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
16632517|NCT02398448|Experimental|Zyloprim® 300 mg and three dissolution test formulations|Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3
16632518|NCT02398435|Experimental|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
16632519|NCT02398435|Experimental|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
16632520|NCT02398422|Experimental|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
16632521|NCT02398422|Experimental|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
16632522|NCT02398422|No Intervention|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
16632523|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
16632524|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
16632526|NCT02398383|Experimental|CF with Normal Glucose Tolerance|Individuals with CF without cystic fibrosis related diabetes
16632527|NCT02398383|Experimental|Cystic Fibrosis Related Diabetes|Individuals with cystic fibrosis and cystic fibrosis related diabetes
16632528|NCT02398383|Active Comparator|Control|Age matched control subjects
16632529|NCT02398370|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.
16632530|NCT02398357|No Intervention|Control|No anticoagulation，just routine follow-up
16632531|NCT02398357|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
16632532|NCT02398344|Experimental|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
16632533|NCT02398344|Experimental|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
16632534|NCT02398331|Experimental|arm|Standardised information and education on sexuality in women with spinal cord injury
16632535|NCT02398331|No Intervention|Control arm|Usual care (no structured information or education on sexuality)
16632536|NCT02398318|Active Comparator|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
16632537|NCT02398318|Sham Comparator|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
16632538|NCT02398305|Active Comparator|TR Band accelerated|Diminishing air pressure in the TR Band using accelerated protocol
16632539|NCT02398305|Other|TR band standard|Diminishing air pressure in the TR band according to standard care
16632540|NCT02398292|Other|M3 Program|Non-randomized experimental group. The program is a six-week multi-modal intervention, including nutrition education and cooking classes, physical activity, and mindfulness. Outcomes will be compared to a non-randomized control group.
16632541|NCT02398292|Other|Control|Non-randomized control group. Outcomes will be compared at same time points (baseline, 6 weeks, 12 weeks).
16632542|NCT02398279|Experimental|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
16632543|NCT02398279|Experimental|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
16632544|NCT02398266|Experimental|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
16632545|NCT02398266|Experimental|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
16632546|NCT02398266|Experimental|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
16632547|NCT02398253|Experimental|CBT + Hypo-energetic Diet|
16632548|NCT02398253|Experimental|Hypo-energetic Diet only|
16632549|NCT02398240|Experimental|Low Risk|Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
16632550|NCT02398240|Experimental|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
16632551|NCT02398240|Experimental|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
16632552|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
16632553|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
16632559|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age < 18), (ISS > 16) with thoracic injuries
16632560|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
16632561|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
16632562|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
16632563|NCT02398149||PwMS receiving care at the Mandell Center|
16632564|NCT02398136|Experimental|Ketamine|Intranasal ketamine up to 75 mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
16632565|NCT02398136|Active Comparator|Midazolam|Intranasal midazolam 3.75mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
16632566|NCT02398123|Active Comparator|Transversus abdominis plane block|Transversus Abdominis Plane block
16632567|NCT02398123|Placebo Comparator|Caudal block|Caudal block
16632568|NCT02398110|Experimental|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
16632569|NCT02398110|Active Comparator|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
16632570|NCT02398097|Active Comparator|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
16632571|NCT02398097|Active Comparator|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
16632572|NCT02398097|Active Comparator|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
16632573|NCT02398084|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
16632574|NCT02398071|Experimental|PEP interventon|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
16632575|NCT02398071|Sham Comparator|Sham intervention|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
16632576|NCT02398058|Experimental|Trabectedin plus olaparib|"All patients will be treated with trabectedin and olaparib in an open-label fashion.
~The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment."
16632577|NCT02398045|Experimental|Computerised CBT|Computerised CBT for OCD
16632578|NCT02398032|Experimental|CPAP nasal|Nasal continuous positive airway pressure, during the night
16632579|NCT02398032|Sham Comparator|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
16632580|NCT02398019|Experimental|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
16632581|NCT02398019|No Intervention|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
16632582|NCT02398006|Active Comparator|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
16632583|NCT02398006|Active Comparator|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
16632584|NCT02397993||FNA, blood collection|blood collection prior to fine needle aspiration Endoscopic ultrasonography-guided fine needle aspiration of the pancreas blood collection after to fine needle aspiration
16632585|NCT02397980|No Intervention|Control|Basic information about dementia
16632586|NCT02397980|Active Comparator|Behavioral intervention|"Individual, 90 min a day, with an interval of 2 weeks
~Education about dementia
~psychological counselling
~cognitive behavioral therapy"
16632587|NCT02397967|Experimental|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
16632588|NCT02397967|Placebo Comparator|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
16632589|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
16632590|NCT02397941||non-pregnant women|20 non-pregnant women, BMI < 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
16632591|NCT02397941||pregnant women|40 pregnant women, BMI < 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
16632592|NCT02397941||women who deliverd|20 pregnant women, BMI < 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
16632593|NCT02397928|Experimental|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
16632594|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
16632595|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
16632596|NCT02397902|Experimental|Dairy|Add 4 daily servings of high fat dairy to diet for a period of 4 weeks
16632597|NCT02397902|Active Comparator|Plant-based|Add 4 daily servings of fruit to diet and/or plant-based milk, remove all dairy from diet for a period of 4 weeks
16632598|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
16632599|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
16632600|NCT02397876|Experimental|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
16632601|NCT02397876|No Intervention|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
16632602|NCT02397850|Experimental|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
16632603|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
16632604|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
16632605|NCT02397811|Experimental|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
16632606|NCT02397811|Experimental|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
16632607|NCT02397811|Experimental|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
16632608|NCT02397811|Experimental|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
16632609|NCT02397811|Experimental|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
16632610|NCT02397811|Experimental|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
16632611|NCT02397798|Experimental|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
16632612|NCT02397798|Active Comparator|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
16632613|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
16632614|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
16632615|NCT02397772|Active Comparator|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
16632616|NCT02397772|Experimental|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
16632617|NCT02397772|Experimental|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
16632618|NCT02397759|Experimental|Patients with severe SAH and vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) and presenting vasospasm
16632619|NCT02397759|Experimental|Patients with severe SAH without vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) without vasospasm
16632620|NCT02397759|Active Comparator|Patients with severe SAH without external ventricular derivati|Patients with severe severe SAH from ruptured aneurysm without necessitating a EVD subarachnoid hemorrhage
16632621|NCT02397746||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
16632622|NCT02397733|Active Comparator|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
16632623|NCT02397733|Experimental|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
16632624|NCT02397720|Experimental|Arm I (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16632625|NCT02397720|Experimental|Arm II (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
16632626|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
16632627|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
16632666|NCT02397421|Placebo Comparator|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
16634061|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
16632628|NCT02397694|Experimental|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.
~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
16632629|NCT02397694|Active Comparator|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.
~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
16632630|NCT02397694|Experimental|Open Label Extension Phase|After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
16632631|NCT02397681|Experimental|Experimental|
16632632|NCT02397668|Experimental|CorMatrix Cor TRICUSPID ECM Valve|Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease. Enrollment will include up to 10 adults subjects and up to 5 pediatric subjects.
16632633|NCT02397642|Active Comparator|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
16632634|NCT02397642|Active Comparator|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
16632635|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
16632636|NCT02397603|Active Comparator|bupivacaine saline group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter
16632637|NCT02397603|Active Comparator|Dexmedetomidine- bupivacaine group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.
16632638|NCT02397590|Other|A Group|Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
16632639|NCT02397590|Other|B Group|Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)
16632640|NCT02397590|Other|C Group|Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
16632641|NCT02397590|Other|D Group|Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
16632642|NCT02397590|Other|E Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)
16632643|NCT02397590|Other|F Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
16632644|NCT02397577|Other|gastric emptying measurements|
16632645|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
16632646|NCT02397551|Active Comparator|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
16632647|NCT02397551|Active Comparator|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
16632648|NCT02397538|Other|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
16632649|NCT02397538|Other|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
16632650|NCT02397525|Experimental|LIPO-202|
16632651|NCT02397512|Experimental|Lactulose group|Subjects will ingest 50g of lactulose once
16632652|NCT02397512|Placebo Comparator|Control group|Subjects will ingest 50g of sucrose once
16632653|NCT02397499|Experimental|LIPO-202|Experimental arm
16632654|NCT02397499|Placebo Comparator|Placebo|Placebo comparator
16632655|NCT02397486|Experimental|Intervention Group|"Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
16632656|NCT02397486|Active Comparator|Control Group|Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
16632657|NCT02397473|Experimental|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
16632658|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
16632659|NCT02397460|Experimental|Gefapixant 50 mg|Gefapixant 50 mg (1 tablet) administered as a single dose
16632660|NCT02397460|Experimental|Gefapixant 300 mg|Gefapixant 300 mg (6 tablets) administered as a single dose
16632661|NCT02397460|Placebo Comparator|Placebo|Placebo-matching tablets administered as a single dose
16632662|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
16632663|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
16632664|NCT02397434|Experimental|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
16632667|NCT02397408|Experimental|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
16632668|NCT02397395|Experimental|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
16632669|NCT02397382|Experimental|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
16632670|NCT02397369|Experimental|Tobacco users: Self Help|Self-help intervention is defined as any manual or programme to be used by individuals to assist a quit attempt not aided by counsellors or group support.They include written materials on the health effects of tobacco, audio-or video tape or computer programmes.
16632671|NCT02397369|Experimental|Tobacco users:Telephonic counseling|Telephone counseling is a way of providing individual counseling via telephone conversation or telephone hotlines. It can be proactive or reactive.
16632672|NCT02397369|Experimental|Tobacco users:Behavioural therapy Only|Behavioural therapy includes multiple sessions of Focus Group Discussion (FGD) and individual tobacco cessation counseling sessions. The participants in this group will be given advice to quit tobacco via multisession formal cognitive-behavioural therapy as per the Tobacco Cessation Clinic (TCC) guidelines.
16632673|NCT02397369|Experimental|Tobacco users:Pharmacologic|Pharmacotherapy in the form of Nicotine Replacement Therapy based on individual need assessment to relieve withdrawal symptoms in tobacco users when trying to quit.
16632674|NCT02397356|Experimental|Ketamine first AB|Patients in this group will first receive a dose of ketamine in the nebulised form when they ask for pain relief. The second time they ask for pain relief, they will receive physiological salt in the nebulised form.
16632675|NCT02397356|Active Comparator|Placebo first BA|Patients in this group will first receive physiological salt in the nebulised form form when they ask for pain relief. The second time they ask for pain relief, they will receive a dose of ketamine in the nebulised.
16632676|NCT02397343|Other|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
16632677|NCT02397343|Other|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
16632678|NCT02397330|Active Comparator|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
16632679|NCT02397330|Experimental|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
16632680|NCT02397317|Experimental|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
16632681|NCT02397304|Experimental|Pre-exercise food|Pre-exercise food provision
16632682|NCT02397304|Experimental|Post-exercise food|Post-exercise food provision
16632683|NCT02397291|Placebo Comparator|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
16632684|NCT02397291|Active Comparator|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
16632685|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
16632686|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
16632687|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
16632688|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
16632689|NCT02397265|Placebo Comparator|Insulin only|Insulin only closed loop
16632690|NCT02397252|Experimental|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
16632691|NCT02397252|Placebo Comparator|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
16632692|NCT02397252|Placebo Comparator|Physician-collected sampling|Routine colposcopy sample collected by a physician.
16632693|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
16632694|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
16632695|NCT02397226|Active Comparator|Radiofrequency ablation|Treatment with radiofrequency ablation using radiofrequency ablation catheter. This intervention implies tumescent anesthesia.
16632696|NCT02397226|Active Comparator|High ligation/stripping|Treatment with high ligation/stripping using a vein stripping catheter. This intervention implies general anesthesia.
16633031|NCT02394782||Relapsing-remitting Multiple Sclerosis|
16632697|NCT02397213|Placebo Comparator|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
16632698|NCT02397213|Active Comparator|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.
16632699|NCT02397200|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
16632700|NCT02397200|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals.
16632701|NCT02397187|Experimental|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.
~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
16632702|NCT02397187|Active Comparator|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
16632703|NCT02397174|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
16632704|NCT02397174|Active Comparator|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
16632705|NCT02397161|Experimental|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
16632706|NCT02397161|Experimental|NMT alone|NMT group - will receive a 12-week neuromuscular training
16632707|NCT02397161|Experimental|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
16632708|NCT02397161|No Intervention|Control|Control group - no intervention for 12 weeks
16632709|NCT02397148|Experimental|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
16632710|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
16632711|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
16632712|NCT02397096|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
16632713|NCT02397096|Active Comparator|Delayed Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
16632714|NCT02397083|Experimental|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
16632715|NCT02397083|Experimental|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
16632716|NCT02397070|Experimental|Jaw exercise program|
16632717|NCT02397070|Active Comparator|Occlusal splint and counseling|
16632718|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
16632719|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
16632720|NCT02397044||Implant loading Immediate|Dental implant surgery with immediate loading
16632721|NCT02397044||Implant Loading Early|Dental implant surgery with delayed loading
16632722|NCT02397031|Experimental|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient's attentional control and emotional regulation.
16632723|NCT02397031|Active Comparator|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient's ability to display social effective behavior.
16632724|NCT02397018|Experimental|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
16632725|NCT02397005|Active Comparator|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
16632726|NCT02397005|Placebo Comparator|Placebo|Placebo matching ZL-2102
16632727|NCT02396992|Other|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
16632728|NCT02396979|Experimental|Methadone Maintenance|Methadone induction and management provided
16632729|NCT02396979|Experimental|Holistic Health Recovery Program|Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.
16632730|NCT02396979|Experimental|Methadone Maintenance and Holistic Health Recovery Prorgram|Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).
16632731|NCT02396979|No Intervention|Standard of Care|Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.
16632732|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
16632733|NCT02396940|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
16632734|NCT02396940|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
16632735|NCT02396927|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
16632736|NCT02396927|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
16632737|NCT02396901|Experimental|GDT group|Patients randomized to the GDT Group will care from a protective strategy with the suspension of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 48 hours before surgery and receive hydration with lactated Ringer's solution at the rate of 1 mL/kg/h in the night before the surgery until the surgical procedure and perioperative hemodynamic therapy.
16632738|NCT02396901|Placebo Comparator|Control group|Patients randomized to the control group will be treated in accordance with the care in the institution's routine.
16632739|NCT02396888|Experimental|Insulin|Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized.
16632740|NCT02396888|Placebo Comparator|Placebo|Half of the wound surface was treated daily with normal saline. Allocation was randomized.
16632741|NCT02396875|Experimental|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
16632742|NCT02396875|Active Comparator|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
16632743|NCT02396875|Active Comparator|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
16632744|NCT02396875|Experimental|Group A|"10 patients from Group 1
~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.
~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
16632745|NCT02396875|Active Comparator|Group B|"5 patients form Group 2.
~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
16632746|NCT02396875|Active Comparator|Group C|"5 patients form Group 3
~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
16632747|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
16632748|NCT02396849|Experimental|Continuous Positive Airway Pressure (CPAP)|Use of a CPAP machine for at least 5 days per week for 28 days
16632749|NCT02396849|Sham Comparator|Continuous Positive Airway Pressure (CPAP) Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
16632750|NCT02396836|Active Comparator|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
16632751|NCT02396836|Experimental|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
16632752|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
16632753|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
16632754|NCT02396810|Placebo Comparator|No intra-operative MRI|Patients undergo transsphenoidal surgery without an intra-operative MRI.
16632755|NCT02396810|Experimental|intra-operative MRI|Patients undergo transspheonidal surgery followed by intra-operative MRI.
16632756|NCT02396797|Experimental|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
16632757|NCT02396797|Active Comparator|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
16632758|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
16632759|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
16632760|NCT02396771|Experimental|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
16632761|NCT02396771|Experimental|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
16632762|NCT02396758|Experimental|APT/2 Hours-r-tPA/2 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 2 mg/hour [hr]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
16632763|NCT02396758|Experimental|APT/4 Hours-r-tPA/1 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
16632764|NCT02396758|Experimental|APT/6 Hours-r-tPA/1 mg/hr/Catheter|A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
16632765|NCT02396758|Experimental|APT/6 Hours-r-tPA/2 mg/hr/Catheter|A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
16632766|NCT02396745|Experimental|TECR & ECM|Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
16632767|NCT02396732|Experimental|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
16632768|NCT02396732|Active Comparator|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
16632769|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
16632770|NCT02396706|Active Comparator|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
16632771|NCT02396706|Placebo Comparator|Placebo|Placebo
16632772|NCT02396693|Experimental|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
16632773|NCT02396693|Placebo Comparator|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
16632774|NCT02396693|Placebo Comparator|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
16632775|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
16632776|NCT02396667||pregnant women with macrosomia|Pregnant wo.en between 37 and 42 weeks with fetal macrosomia as suspected by clinical estimation and 2D ultrasound.
16632777|NCT02396654||normal pregnant women|Normal pregnant women between 37 and 42 weeks gestation.
16632778|NCT02396641|Experimental|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
16632779|NCT02396628|Experimental|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
16632780|NCT02396628|Active Comparator|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
16632781|NCT02396615|Active Comparator|Active|Satin pineapple. Active juice with fibre and ginseng
16632782|NCT02396615|Placebo Comparator|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
16632783|NCT02396602|Experimental|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
16632784|NCT02396602|No Intervention|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
16632785|NCT02396589|Active Comparator|Education Group|Participants in the Education group receive five 90 minute tailored stroke education sessions in the home.
16632786|NCT02396589|Experimental|Home Modifications Group|Participants in the treatment group receive a home assessment and home modifications tailored to functional abilities (pre discharge) and then five 90 minute occupational therapy treatment sessions at home (post discharge) to improve functional abilities and community participation.
16632787|NCT02396576|No Intervention|Usual Care|NEVHC has two main Department of Mental Health (DMH) contracted clinical partners where the majority of the patients are referred to -these are Child and Family Guidance Center (CFGC) in the San Fernando Valley and Child and Family Center (CFC) in the Santa Clarita Valley.
16632788|NCT02396576|Experimental|Telehealth Intervention|The telehealth model will enhance patient coordination as well as clinician communication via live videoconferencing. Developmental behavioral services will be provided by a Developmental Behavioral Pediatrician (DBP) housed at UCLA from Children's Hospital Los Angeles (CHLA). Mental Health services will be provided by Child Family Center (CFC) and Child Family Guidance Center (CFGC). The location of the telehealth visit will be at the same clinic location as the index PCP visit with a telehealth coordinator facilitating the encounter between patient and clinicians.The clinician communication will be enhanced through monthly telehealth topic-based educational sessions as well as case-based educational sessions for the transfer cases.
16632789|NCT02396563||epidural analgesia|women in labor with epidural analgesia
16632790|NCT02396563||no epidural analgesia|
16632791|NCT02396550|Experimental|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
16632792|NCT02396550|Experimental|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
16632793|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
16632794|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
16632795|NCT02396524|Experimental|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
16632796|NCT02396524|No Intervention|Usual-care wait-list control|No active intervention (usual care)
16632797|NCT02396511|Experimental|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
16633199|NCT02393755|Experimental|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
16632798|NCT02396498|Placebo Comparator|D2 radical gastrectomy+Systemic chemotherapy|8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.
16632799|NCT02396498|Experimental|D2 radical gastrectomy+HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
16632800|NCT02396485|Experimental|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
16632801|NCT02396485|No Intervention|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
16632802|NCT02396472|Placebo Comparator|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.
~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
16632803|NCT02396472|Active Comparator|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
16632804|NCT02396472|Active Comparator|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
16632805|NCT02396472|Active Comparator|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
16632806|NCT02396472|Active Comparator|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
16632807|NCT02396459|Experimental|MCT8 deficiency patients|Triac treatment
16632808|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
16632809|NCT02396433|Experimental|Carboplatin, eribulin, and E7449|This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
16632810|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
16632811|NCT02396407|Active Comparator|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
16632812|NCT02396407|No Intervention|Non-intervention arm|None. Households will continue their usual practices.
16632813|NCT02396394|Experimental|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
16632814|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
16632815|NCT02396381|Active Comparator|CC|Ad libitum use of CC
16632816|NCT02396368|Experimental|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.
~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
16632817|NCT02396355||All subjects|This is a single arm study. Samples from each subject will be tested with the Investigational BD FACSPresto System, the BD FACSCalibur flow cytometer, and the Sysmex hematology analyzer KX-21.
16632818|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
16632819|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
16632820|NCT02396329|Experimental|chlorhexidine _based antisepsis|"Including cases undergoing elective&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.
~."
16632821|NCT02396329|Active Comparator|povidone_iodine based antisepsis|Including cases undergoing elective&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
16632822|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
16632823|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
16632824|NCT02396303|Experimental|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
16632825|NCT02396303|Active Comparator|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
16632826|NCT02396290|Experimental|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
16632827|NCT02396290|Active Comparator|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
16632828|NCT02396264|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
16632829|NCT02396264|Active Comparator|normocaloric diet|50% carbohydrates, 30% total lipids and 20% proteins. After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
16632830|NCT02396251|Experimental|HA experimental|HA experimental only
16632831|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
16632832|NCT02396238|Experimental|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
16632833|NCT02396238|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
16632834|NCT02396225|Experimental|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
16632835|NCT02396225|Active Comparator|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
16632836|NCT02396212|Experimental|Canakinumab|All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.
16632837|NCT02396199|Experimental|Endovascular|Endovascular treatment using the Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
16632838|NCT02396173|Experimental|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
16632839|NCT02396173|No Intervention|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
16632840|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
16632841|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
16632842|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
16632843|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
16632844|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
16632845|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
16632846|NCT02396121|Experimental|Interventional|Administration of 1 bottle of an oral nutritional supplement, Renutryl® Booster (600 kcal), during 28 days.
16632847|NCT02396108|Experimental|Paclitaxel + Carboplatin + ASLAN001|"Phase I:
~A modified 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdraws consent. In the presence of intolerable toxicities to one or more of the drugs in the regimen (but not all 3), the drug in question may be discontinued and the other drugs continued with the patient remaining in the study, if the patient is deemed to be benefiting, after discussion with the Principal Investigator.
~Phase II:
~Patients with stage I-III HER2-positive breast cancer with a primary breast tumour of 2cm or greater will receive up to 4 cycles of pre-operative ASLAN001 and weekly paclitaxel/ carboplatin delivered in 21-day cycles. Prior to administration of chemotherapy, there will be lead-in dosing of single-agent ASLAN001 administered daily for 2 weeks at the recommended phase II dose."
16632848|NCT02396082|Experimental|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
16632849|NCT02396082|Other|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
16632850|NCT02396069|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
16632851|NCT02396069|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
16632852|NCT02396056|Sham Comparator|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
16632853|NCT02396056|Experimental|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
16633200|NCT02393742|Experimental|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
16632854|NCT02396043|Experimental|Modifed BFM-95|All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate [MTX] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.
16632855|NCT02396030|Active Comparator|Magnesium sulfate 50% - 1g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
16632856|NCT02396030|Experimental|Magnesium sulfate 50% - 2g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours
16632857|NCT02396017|Active Comparator|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
16632858|NCT02396017|Experimental|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
16632859|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
16632860|NCT02395978|Experimental|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
16632861|NCT02395978|Experimental|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
16632862|NCT02395978|Experimental|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
16632863|NCT02395978|Experimental|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
16632864|NCT02395978|Placebo Comparator|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
16632865|NCT02395952|Active Comparator|Lubrication|
16632866|NCT02395952|Active Comparator|Bandage Contact Lens|Acuvue Oasys Contact Lens
16632867|NCT02395952|Active Comparator|Prokera|Wet amniotic membrane mounted on plastic retaining ring
16632868|NCT02395952|Active Comparator|Ambiodisk|Freeze dried amniotic membrane
16632869|NCT02395939|Active Comparator|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
16632870|NCT02395939|Active Comparator|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.
~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
16632871|NCT02395926|Active Comparator|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
16632872|NCT02395926|Experimental|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
16632873|NCT02395926|Experimental|T2|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
16632874|NCT02395913|Active Comparator|R|
16632875|NCT02395913|Experimental|T1|
16632876|NCT02395913|Experimental|T3|
16632877|NCT02395913|Experimental|T4|
16632878|NCT02395900|Active Comparator|Flaxseed|30 grams Flaxseed powder
16632879|NCT02395900|Placebo Comparator|control|dietary and exercise recommendation
16632880|NCT02395887||Intervational|Patients with back or neck pain who are a candidates for operational intervention.
16632881|NCT02395887||Control|Men or women who haven't seek for spine surgery consultation.
16632882|NCT02395874|Experimental|verum-tDCS|verum-tDCS+ speech therapy
16632883|NCT02395874|Sham Comparator|sham-tDCS|sham-tDCS + speech therapy
16632884|NCT02395861|Experimental|Electrophysiologic analyses|
16632885|NCT02395848|Experimental|Fidaxomicin|30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.
16632886|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) > = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.
~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
16632887|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) < 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.
~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
16632888|NCT02395822|Experimental|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide
~IL-15 Activation of Donor NK Cells:
~IL-15 to Facilitate NK Cell Survival and Expansion"
16632889|NCT02395809|Active Comparator|LIS group|Lateral internal shincterotomy: A blade knife (No 11) was inserted between internal and external sphincter. The tip of the blade was angled medially pointing just above the dentate line and IS was divided. When the knife was felt beneath the intact mucosa, it was withdrawn.
16632890|NCT02395809|Active Comparator|TENS group|Posterior tibial nerve stimulation by transcutaneous electrical nerve stimulation by through a stimulating TENS unit.
16632891|NCT02395796|Experimental|Epidural Pressure Waveform|"Study Population:
~Term pregnancy
~in labour
~18 years of age or older."
16632892|NCT02395783|Active Comparator|Melatonin dose1|Melatonin 10 µg
16632893|NCT02395783|Active Comparator|Melatonin dose2|Melatonin 20 µg
16632894|NCT02395783|Placebo Comparator|Placebo|Placebo
16633201|NCT02393742|Placebo Comparator|Placebo|placebo 2x/day for 3 months
16632895|NCT02395770|Experimental|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
16632896|NCT02395757|Experimental|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
16632897|NCT02395744|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
16632898|NCT02395731|Experimental|MIND at Home- Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
16632899|NCT02395718|Experimental|QDU|Patients will undergo a fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation. Patients will have immediate access to all diagnostic tests and treatments that will be carried out all day (24 hours) on demand from the responsible physician. The QDU is both organisationally and physically integrated in the ED. Point of care ultrasonography can be performed round the clock. Additionally the Department of Radiology provides the QDU with more advanced diagnostic procedures such as e.g. CT scans or MRI scans on a fast track basis. There is access to additional specialist evaluations from the ED staff or from various in house specialists, when needed. Simultaneously to the medical treatment, physical therapists and occupational therapists train and optimise patients' level of functioning, including prevention of loss of function.
16632900|NCT02395718|Active Comparator|DIM|Patients in the control group are treated as conventionally at one of seven wards at the DIM. After initial admission including initial diagnostics and treatment have been carried out in the ED, patients are transferred to the DIM. Usually patients are seen primarily by the on-call physician for evaluation of acute symptoms. The following day, a Chief physician will work out a plan for further diagnostics and treatment. Treatment by physiotherapists and occupational therapists is available on request from a physician. Analyses of blood samples are performed at the central laboratory and radiological procedures at the Department of Radiology.
16632901|NCT02395705|Experimental|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
~Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
~Surgery:
~2-3weeks after Neo-adjuvant chemotherapy
~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
16632902|NCT02395705|No Intervention|Surgery alone group|"Surgery:
~2-3weeks after Neo-adjuvant chemotherapy
~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
16632903|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16632904|NCT02395679|Experimental|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
16632905|NCT02395666|Experimental|DFMO twice daily|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
16632906|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
16632909|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
16632910|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
16632911|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
16632912|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
16632913|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
16632914|NCT02395601|Experimental|CPI-1205|
16632915|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.
~Phone call 48 hours after discharge. Discharge instructions will be reinforced.
~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.
~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
16632916|NCT02395562||OTR and viral reactivation|Organ transplant recipients with and without viral reactivation and skin cancer
16632917|NCT02395549|Experimental|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
16632918|NCT02395549|Experimental|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
16632919|NCT02395549|Experimental|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
16632920|NCT02395549|Placebo Comparator|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
16632921|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
16632922|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
16632923|NCT02395523|Experimental|Proton Beam Therapy|"Definition of target volume:
~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan
~Clinical target volume (CTV) = GTV + internal target volume
~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.
~Radiation dose and planning
~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week
~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
16632924|NCT02395510|Other|Flexible, open label dosing|Flexible dosing 5-20mg
16632925|NCT02395497|Experimental|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
16632926|NCT02395484||constipation|collect stool samples from constipation patients
16632927|NCT02395484||healthy controls|collect stool samples from healthy controls patients
16632928|NCT02395471|Experimental|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
16632929|NCT02395471|Experimental|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
16632930|NCT02395458|Experimental|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
16632931|NCT02395458|Active Comparator|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
16632932|NCT02395445|Active Comparator|Totaltrack|Indirect laryngoscopy
16632933|NCT02395445|Active Comparator|Macintosh Laryngoscope|Direct laryngoscopy
16632934|NCT02395432|Active Comparator|Totaltrack|OTI with Totaltrack
16632935|NCT02395432|Active Comparator|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
16632936|NCT02395419|Active Comparator|Totaltrack|OTI with TotalTrack
16632937|NCT02395419|Active Comparator|Airtraq|OTI with Airtraq
16632938|NCT02395406|Active Comparator|Totaltrack|OTI with Totaltrack
16632939|NCT02395406|Active Comparator|Airtraq|OTI with Airtraq
16632940|NCT02395393|Other|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
16632941|NCT02395380|Experimental|C-reactive protein dosage|
16632942|NCT02395354|Other|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
16632943|NCT02395354|Other|A balloon dilatation|A balloon dilatation
16632944|NCT02395328|Experimental|Care worker home visitation|Care Workers provide biweekly home visits and offer residing caregivers and children information and psychosocial support, and encourage their awareness and accessing of external health and social services.
16632945|NCT02395328|No Intervention|Wait List|Access to homework classes are made available to all participants' children at schools supported by the implementing organization.
16632946|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
16632947|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
16632948|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
16632949|NCT02395289|Experimental|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
16632950|NCT02395289|Active Comparator|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
16632951|NCT02395276|Active Comparator|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
16632952|NCT02395276|Placebo Comparator|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
16632953|NCT02395276|No Intervention|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
16632954|NCT02395263|Experimental|Yuxintine 200mg per day|Yuxintine 200mg oral, once a day, 6 weeks
16632955|NCT02395263|Experimental|Yuxintine 300mg per day|Yuxintine 300mg oral, once a day, 6 weeks
16632956|NCT02395263|Experimental|Yuxintine 400mg per day|Yuxintine 400mg oral, once a day, 6 weeks
16632957|NCT02395263|Placebo Comparator|Placebo|Placebo oral, once a day, 6 weeks
16632958|NCT02395250|Experimental|anti-GPC3 CAR T|
16632959|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
16632960|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
16632961|NCT02395211|Active Comparator|Usual Physiotherapy|
16632962|NCT02395211|Experimental|Gloreha device|
16632963|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
16632964|NCT02395185|Experimental|Milk|Milk bottle administration
16632965|NCT02395185|Experimental|Water|Water bottle administration
16632966|NCT02395185|Experimental|Sucrose|Sucrose bottle administration
16632967|NCT02395172|Experimental|Avelumab|
16632968|NCT02395172|Active Comparator|Docetaxel|
16632969|NCT02395159|Experimental|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
16632970|NCT02395159|Other|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
16632971|NCT02395146|Experimental|Monitoring|intraoperative EBSLN monitoring will take place
16632972|NCT02395146|No Intervention|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
16632973|NCT02395133|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
16632974|NCT02395133|Experimental|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
16632975|NCT02395133|Experimental|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
16632976|NCT02395133|Experimental|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
16632977|NCT02395120|Active Comparator|Standard letter|Modified standard letter will be sent to caregivers.
16632978|NCT02395120|Experimental|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
16632979|NCT02395120|Experimental|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
16632980|NCT02395120|Experimental|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
16632981|NCT02395120|Experimental|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
16632982|NCT02395094|No Intervention|Group 1 (Standard Procedure)|Group 1 (Standard Procedure) will receive BCCH standard care, which consists of topical anesthetic cream, waiting with parents in the playroom in the surgical daycare unit preoperatively, parental presence in the OR, the BCCH 'parent hug' and standard distraction techniques
16632983|NCT02395094|Experimental|Group 2 (Child Life)|Group 2 (Child Life) will receive Child Life intervention applicable to the individual patient, on the day of surgery in addition to standard practices
16632984|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
16632985|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
16632986|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
16632987|NCT02395068|Experimental|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
16632988|NCT02395068|Experimental|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
16632989|NCT02395068|Experimental|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
16632990|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
16632991|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
16632992|NCT02395042|Placebo Comparator|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period (Tx 1): Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 10 and then removed and a second matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 14 and removed on Day 28. Treatment 2 Period (Tx 2): optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and removed on Day 14.
16632993|NCT02395042|Experimental|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period: LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 then removed and a second LiRIS® 400 mg inserted into the bladder on Day 14 and removed on Day 28. Treatment 2 Period: optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and then removed on Day 14.
16632994|NCT02395042|Experimental|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment 1 Period: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 0 and then removed and LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 14 then removed on Day 28. Treatment 2 Period: optional LiRIS® 400 mg inserted into the bladder by cystoscopy on Day 0 then removed on Day 14.
16632995|NCT02395029|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
16632996|NCT02395016|Experimental|Nimotuzumab and Gemcitabine|"nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
16632997|NCT02395016|Placebo Comparator|Placebo and Gemcitabine|"placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
16632998|NCT02395003||High VAT/SAT high Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks
16632999|NCT02395003||Low VAT/SAT|Subjects with a low ratio of visceral to subcutaneous fat
16633000|NCT02395003||Lean Controls|Lean control
16633001|NCT02395003||High VAT/SAT- low Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks
16633002|NCT02394990|Experimental|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
16633003|NCT02394990|Active Comparator|Control|Participants receive only ABI
16633004|NCT02394977|Experimental|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
16633005|NCT02394977|Active Comparator|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
16633006|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
16633007|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
16633008|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
16633009|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
16633010|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
16633011|NCT02394951|Experimental|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
16633012|NCT02394951|Placebo Comparator|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
16633013|NCT02394938|Experimental|MUSIC|In addition to the standard care, heart failure patients assigned to the music group will listen recorded classical music.
16633014|NCT02394938|No Intervention|CONTROL|Heart Failure patients assigned to the control group will receive standard care only. The standard care will consist in nursing and medical counselling, self-care education and medication.
16633015|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
16633016|NCT02394912|Experimental|Single-arm|
16633017|NCT02394899|No Intervention|Control|The control dyad will receive usual care.
16633018|NCT02394899|Experimental|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
16633019|NCT02394886|Experimental|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
16633020|NCT02394873|Experimental|ALLO-ASC-DFU|
16633021|NCT02394860||blood and cardiological examination|
16633022|NCT02394847|Other|propofol|dose of propofol according to the number of therapies
16633023|NCT02394834|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
16633024|NCT02394834|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
16633025|NCT02394821|Experimental|Metronidazole|metronidazole 0.8% solution - topical
16633026|NCT02394821|Experimental|Polihexanide|Polihexanide 2%
16633027|NCT02394808|Experimental|Test Lens 1|senofilcon A (Approved contact lens material)
16633028|NCT02394808|Active Comparator|Test Lens 2|lotrafilcon B (Approved contact lens material)
16633029|NCT02394795|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
16633030|NCT02394795|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
16633032|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
16633033|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
16633034|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
16633035|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
16633036|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
16633037|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
16633038|NCT02394743||eGFR > 90|group whose eGFR is more than 90
16633039|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
16633040|NCT02394743||eGFR < 60|group whose eGFR is less than 60
16633041|NCT02394730|Experimental|vorapaxar|2.5mg of vorapaxar po qd
16633042|NCT02394730|Placebo Comparator|Placebo|sugar pill po qd
16633043|NCT02394717|Other|Intervention|All YMCA programs will receive the Healthy Eating and Physical Activity Intervention throughout the study. All programs will receive the HEPA Strategies intervetion to assist them with achievement of the HEPA Standards.
16633044|NCT02394704|Experimental|Graded sensory attention training|Sensory stimuli will begin at a maximal tolerable intensity and decrease in intensity throughout the training, to shift from involuntary to voluntary attentional focus.
16633045|NCT02394704|Active Comparator|Non-graded sensory attention training|Sensory stimuli will begin and be maintained at a minimal detectable intensity to maximize voluntary attentional training.
16633046|NCT02394691|Active Comparator|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
16633047|NCT02394691|Placebo Comparator|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
16633048|NCT02394678|Experimental|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
16633049|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;
~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;
~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;
~Adjuvant Temozolomide Therapy for up to 12 cycles."
16633050|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:
~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;
~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;
~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;
~Adjuvant Temozolomide Therapy for up to 12 cycles."
16633051|NCT02394652|Experimental|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.
~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.
~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
16633052|NCT02394652|Active Comparator|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.
~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
16633053|NCT02394639|Active Comparator|conventional video-EEG monitoring|conventional video-EEG monitoring with cup-electrodes and collodion
16633054|NCT02394639|Experimental|video-EEG monitoring with prototype|video-EEG monitoring of 5 hours with EEG-cap with dry electrodes
16633055|NCT02394626|Experimental|Surgery followed by adjuvant second-line therapy|Surgery followed by adjuvant second-line therapy
16633056|NCT02394626|Active Comparator|Second-line therapy alone|Second-line therapy alone
16633057|NCT02394613|Experimental|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
16633058|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
16633059|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
16633202|NCT02393729|Other|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
16633060|NCT02394587|Experimental|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
16633061|NCT02394587|Other|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
16633062|NCT02394574|Active Comparator|Clean Cookstove|Subjects will use ethanol stoves using bioethanol
16633063|NCT02394574|Other|Traditional Cookstove|Subjects will use traditional firewood or kerosine cookstove and receive education on how to reduce air pollution exposures
16633064|NCT02394561|Experimental|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
16633065|NCT02394561|Experimental|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
16633066|NCT02394548|Experimental|Contralateral Esophagus Sparing Technique (CEST)|IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
16633067|NCT02394535|Experimental|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
16633068|NCT02394522|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
16633069|NCT02394522|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
16633070|NCT02394509|Experimental|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
16633071|NCT02394509|Experimental|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
16633072|NCT02394509|Other|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
16633073|NCT02394496|Experimental|ARM 1|Fulvestrant + Placebo Lapatinib
16633074|NCT02394496|Experimental|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
16633075|NCT02394496|Experimental|ARM 3|Fulvestrant + Lapatinib
16633076|NCT02394496|Experimental|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
16633077|NCT02394483|Experimental|Cohort A active|2 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
16633078|NCT02394483|Placebo Comparator|Cohort A placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
16633079|NCT02394483|Experimental|Cohort B active|4 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
16633080|NCT02394483|Placebo Comparator|Cohort B placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
16633081|NCT02394483|Experimental|Cohort C active|6 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
16633082|NCT02394483|Placebo Comparator|Cohort C placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
16633083|NCT02394483|Experimental|Cohort D active|8 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
16633084|NCT02394483|Placebo Comparator|Cohort D placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
16633085|NCT02394483|Experimental|Cohort E active|10 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
16633086|NCT02394483|Placebo Comparator|Cohort E placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
16633087|NCT02394470|Other|Acute heart failure HF,Chronic HF,Advanced chronic HF|patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure
16633088|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
16633089|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
16633156|NCT02394028|Placebo Comparator|Induction Phase - Cohort 3 (Pivotal): Placebo|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
16633203|NCT02393729|Other|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
16633090|NCT02394444|Experimental|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :
~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
16633091|NCT02394444|No Intervention|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
16633092|NCT02394444|No Intervention|Full-term control group|Parents with full-term infants without intervention program TRT
16633093|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
16633094|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
16633095|NCT02394418|Active Comparator|Sevoflurane|Treatment of delirium by inhaled sevoflurane
16633096|NCT02394418|Active Comparator|Propofol|Treatment of delirium by propofol i.v. infusion
16633097|NCT02394418|Active Comparator|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
16633098|NCT02394405||valve surgery|valve plasty/replacement surgery
16633099|NCT02394405||off-pump CABG|off-pump CABG
16633100|NCT02394405||CPB-CABG|CABG with CardioPulmonal Bypass
16633101|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
16633102|NCT02394366|Experimental|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
16633103|NCT02394366|Placebo Comparator|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
16633104|NCT02394353|Active Comparator|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
16633105|NCT02394353|Active Comparator|Gastric Bypass|Patients undergoing the gastric bypass surgery
16633106|NCT02394340|Experimental|Luliconazole Cream 1%|Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
16633107|NCT02394327|Active Comparator|Endoscopic nasogallbladder drainage|If GB cannulation was achieved and the wire was coiled in the GB, 5 to 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
16633108|NCT02394327|Active Comparator|Endoscopic gallbladder stenting|If GB cannulation was achieved and the wire was coiled in the GB, 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
16633109|NCT02394314|Placebo Comparator|Placebo|Placebo administered subcutaneously
16633110|NCT02394314|Experimental|MEDI0382|MEDI0382 administered subcutaneously
16633111|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
16633113|NCT02394262|Experimental|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
16633114|NCT02394249|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
16633115|NCT02394249|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
16633116|NCT02394236|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
16633117|NCT02394236|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
16633118|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
16633119|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
16633120|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:
~Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or
~Upon a significant relapse of paraprotein, defined as:
~Duplication of M-component in two consecutive readings taken ≤2 months apart; or
~An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or
~Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
16633157|NCT02394028|Placebo Comparator|Maintenance Phase - Placebo Responders: Placebo|Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.
16633204|NCT02393729|Other|children with DCD + DD|Neuropsychological assessment and MRI study
16633121|NCT02394197|Active Comparator|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).
~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
16633122|NCT02394197|Experimental|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).
~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
16633123|NCT02394184||patients with bicuspid aortic valve stenosis|
16633124|NCT02394171|Experimental|Physical Activity|Women completed a physical activity group cohesion intervention which included six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase physical activity. A small team structure was used for peer problem solving and support throughout the intervention. Teams were given weekly physical activity goals, with slowly increasing weekly minutes milestones to gradually meet recommended amounts of physical activity. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a brisk 15-minute walk.
16633125|NCT02394171|Active Comparator|Fruit and Vegetable|Women completed a fruit and vegetable group cohesion intervention which involved six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase fruit and vegetable consumption. A small team structure was used for peer problem solving and support throughout. Teams were given weekly fruit and vegetable consumption goals at each session, with slowly increasing weekly servings milestones to gradually meet recommended amounts of fruit and vegetable consumption. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a fruit and vegetable taste test.
16633126|NCT02394158|Active Comparator|Intervention arm Metformin|Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
16633127|NCT02394158|Placebo Comparator|Control arm placebo|Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
16633128|NCT02394145|Experimental|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
16633129|NCT02394145|Active Comparator|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
16633130|NCT02394145|Active Comparator|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
16633131|NCT02394145|Active Comparator|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
16633132|NCT02394145|Active Comparator|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
16633133|NCT02394132|Experimental|Imiquimod|"Topical imiquimod 5% cream
~application to treatment area for 5 days/week for a total of 12 weeks
~dispensed at baseline visit along with patient diary"
16633134|NCT02394132|Experimental|Radiotherapy|"Radiotherapy
~treatment regimen determined by treating radiation oncologist and as per standard practice at local institution
~treatment to commence within 8 weeks of randomisation"
16633135|NCT02394119|Experimental|Ofatumumab|"Drug Name: Ofatumumab
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities
~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions
~How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.
~When and how much: once; diluted in 1000 ml of normal saline."
16633136|NCT02394119|Active Comparator|Rituximab|"Drug Name: Rituximab (RTX)
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities
~Procedures: the same as for Ofatumumab Arm
~How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
~When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
16633195|NCT02393794|Experimental|Romidepsin Dose Expansion|Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
16633196|NCT02393768||patients|patients with documented atherosclerosis on a CCTA
16633137|NCT02394106|Experimental|Ofatumumab|"Drug Name: Ofatumumab
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities
~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions
~Who provides: registered nurse
~How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.
~Where: in Hospital
~When and how much: once; diluted in 1000 ml of normal saline
~Tailoring: 1500 mg/1.73m2
~How well: expert nurse would assist administration"
16633138|NCT02394106|Placebo Comparator|Placebo|"Drug Name: Normal Saline (NaCl 0,9%)
~Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.
~Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
16633139|NCT02394093|Experimental|Aspirin dry powder|500 mg Acetylsalicylic Acid (ASA) dry powder
16633140|NCT02394093|Active Comparator|Aspirin coated tablet|500 mg ASA coated tablet
16633141|NCT02394093|Active Comparator|Aspirin effervescent tablet|500 mg ASA effervescent tablet
16633142|NCT02394080|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
16633143|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
16633144|NCT02394054|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
16633145|NCT02394054|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
16633146|NCT02394041|Experimental|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.
~One or more additional session will be performed in the delivery room."
16633147|NCT02394041|Sham Comparator|Sham acupuncture|The same as active arm but with sham needles.
16633148|NCT02394041|No Intervention|control group|Standard care, no acupuncture session.
16633149|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
16633150|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
16633151|NCT02394028|Placebo Comparator|Induction Phase - Cohort 1 (Exploratory): Placebo|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
16633152|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
16633153|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
16633154|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
16633155|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
16633197|NCT02393768||controls|patients without atherosclerosis on a CCTA
16633198|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
16633158|NCT02394028|Placebo Comparator|Maintenance Phase - Etrolizumab Responders: Placebo|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.
16633159|NCT02394028|Experimental|Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.
16633160|NCT02394028|No Intervention|Maintenance Phase - Non-Responders: Safety Follow-Up/GA29145|All participants from Cohorts 1-3 who are considered non-responders after the Induction Phase at Week 14 may be eligible to enter the open-label extension study GA29145 (NCT02403323) and/or undergo a 12-week safety follow-up.
16633161|NCT02394015||Trabectedin+ PLD|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
16633162|NCT02394002|Experimental|Brain surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
16633163|NCT02394002|Experimental|Spine surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
16633164|NCT02394002|Active Comparator|General surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
16633165|NCT02393989|Experimental|Active comparator|posterior restorations
16633166|NCT02393976|Other|CONTROL|STANDARD NUTRITION
16633167|NCT02393976|Experimental|IMMUNONUTRITION|INMUNONUTRITION
16633168|NCT02393963|Experimental|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
16633169|NCT02393963|Placebo Comparator|Placebo|Sodium Chloride
16633170|NCT02393950|Experimental|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
16633171|NCT02393950|Placebo Comparator|Drug: Placebo|Oral capsules given once daily for one day
16633172|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
16633173|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
16633174|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
16633175|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
16633176|NCT02393911|Active Comparator|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
16633177|NCT02393911|Active Comparator|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
16633178|NCT02393911|Active Comparator|Control|Healthy women without LPV, not treated by Low Oxalate Diet
16633179|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
16633180|NCT02393885|Experimental|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
16633181|NCT02393872|Experimental|High-risk families component|School-based intervention and counselling sessions.
16633182|NCT02393872|Experimental|All-families component|School-based intervention.
16633183|NCT02393872|No Intervention|Control|Control group.
16633184|NCT02393859|Active Comparator|High Risk Consolidation 3 (HC3) Chemotherapy|One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m^2/day intravenous [IV] on Days 1-6), vincrisitne (1.5 mg/m^2/day IV on Days 1 and 6), daunorubicin (30 mg/m^2 IV over 24 hours on Day 5), methotrexate (1 g/m^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m^2 IV for 1 hour on Days 2-4), and pegylated [PEG]-asparaginase (1000 U/m^2 IV for 2 hours or intramuscularly [IM] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m^2 IV or IM every 48 hours for a total of 6 doses).
16633185|NCT02393859|Experimental|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
16633186|NCT02393846|Experimental|ketoprofen|Topical ketoprofen (gel) is the experimental drug that is applied to the ankle in a dose of 2 gr.
16633187|NCT02393846|Placebo Comparator|Placebo|Topical placebo (gel) is identical in colour, form and smell with the ketoprofen gel.
16633188|NCT02393833|Active Comparator|Induction chemotherapy|Approved induction CT regimen after randomization
16633189|NCT02393833|Experimental|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
16633190|NCT02393820|Experimental|pazopanib|Pazopanib per os, 800mg daily until progression
16633191|NCT02393807|Experimental|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
16633192|NCT02393794|Experimental|Romidepsin (8mg/m2) + Cisplatin (75mg/m2)|Romidepsin 8mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
16633193|NCT02393794|Experimental|Romidepsin (10mg/m2) + Cisplatin (75mg/m2)|Romidepsin 10mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
16633194|NCT02393794|Experimental|Romidepsin (12mg/m2) + Cisplatin (75mg/m2)|Romidepsin 12mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
16633207|NCT02393690|Experimental|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
16633208|NCT02393690|Active Comparator|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
16633209|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
16633210|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
16633211|NCT02393664|Experimental|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
16633212|NCT02393664|Active Comparator|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
16633213|NCT02393651|Placebo Comparator|Sham|Motor training of the affected upper extremity combined with sham tDCS.
16633214|NCT02393651|Experimental|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
16633215|NCT02393638|Experimental|study group|Simulation and lecture
16633216|NCT02393638|Active Comparator|control group|Lecture only
16633217|NCT02393625|Experimental|Dose Escalation|
16633218|NCT02393625|Experimental|Dose Expansion|
16633219|NCT02393612|Experimental|DP-R202|Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks
16633220|NCT02393612|Active Comparator|Anplag tab|Patients administrate Anplag tab (Sarpogrelate 100mg) 3 times a day for 12 weeks
16633221|NCT02393599|Experimental|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
16633222|NCT02393599|Placebo Comparator|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
16633223|NCT02393586|Experimental|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
16633224|NCT02393586|Experimental|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
16633225|NCT02393586|Experimental|Rifampicin|Rifampicin 10mg/kg
16633226|NCT02393573|Active Comparator|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
16633227|NCT02393573|Placebo Comparator|Placebo|Placebo will be administered exactly in the similar way to Metformin
16633228|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
16633229|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
16633230|NCT02393534|No Intervention|Usual Care|Eligible patients that are randomized to the usual care arm will have a standard in-person clinic visit with their primary care provider.
16633231|NCT02393534|Experimental|Telephone visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
16633232|NCT02393521|Experimental|Vibration group|Patients in the vibration therapy group received 10 self-administered sessions of vibration therapy (45-50 Hz), one session per day, remaining on their Shindo® vibration mattress at home in supine for 15 min.
16633233|NCT02393521|No Intervention|Control group|Subjects in the control group did not receive vibration therapy
16633234|NCT02393508|Active Comparator|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
16633235|NCT02393508|Active Comparator|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
16633236|NCT02393495|Experimental|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
16633237|NCT02393495|Experimental|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
16633238|NCT02393482|Active Comparator|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
16633239|NCT02393482|Active Comparator|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
16633240|NCT02393469|Placebo Comparator|Group phase 1|Two months of education and self-management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
16633241|NCT02393469|Experimental|Group phase 2|Pulmonary rehabilitation for two months: The same patients enter phase 1 phase 2 performing this two months of pulmonary rehabilitation are also included new patients who participate directly in phase 2
16633242|NCT02393469|Experimental|Group phase 3|Pulmonary rehabilitation for ten months: Participate participants of phases 1 + 2 and 2, as well as new participants enter directly in phase 3
16633243|NCT02393456|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
16633244|NCT02393456|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
16633245|NCT02393443|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
16633246|NCT02393443|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
16633247|NCT02393430|Experimental|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
16633248|NCT02393430|Placebo Comparator|control|The control group were only optimized their life style.
16633249|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
16633250|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
16633251|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
16633252|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
16633253|NCT02393404|Experimental|PT-FMT|Functional movement-power training group
16633254|NCT02393404|Experimental|FMT alone|Functional movement training group
16633255|NCT02393404|No Intervention|Control|No intervention control group
16633256|NCT02393391|Active Comparator|NIBS tDCS/tACS stimulation|Each patient will undergo initial diagnosis with NIBS algorithm utilizing EEG measurements combined with TMS. Initial diagnosis will last 10 minutes in which EEG measurement will be recorded 5 minutes and then in combination with TMS for another 5 minutes with no more than 500 TMS stimuli applied to cortex at low frequency of up to 5Hz. EEG recording will be analyzed by NIBS algorithm which will propose a course of treatment with the following limitations: stimulation of 2mA (32, 33) current after 30 seconds ramp up of 0.1mA increments, 20 min for each session, twice a week
16633257|NCT02393391|Placebo Comparator|inactive electrodes|diagnosis and monitoring will be performed as in active treatment, but during treatment anodal/cathodal/alternate stimulation will begin and automatically stop after 30 seconds leaving subject with an inactive electrodes in place for the remainder of treatment duration
16633258|NCT02393378|Experimental|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
16633259|NCT02393378|Active Comparator|Namilumab 150 mg|Namilumab 150*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
16633260|NCT02393365|Other|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
16633261|NCT02393352|Experimental|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
16633262|NCT02393352|Active Comparator|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
16633263|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
16633264|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
16633265|NCT02393326|Experimental|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
16633266|NCT02393326|Other|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
16633267|NCT02393313|Experimental|Cataract surgery toric intraocular lens|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
16633268|NCT02393300|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
16633269|NCT02393300|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' before the tourniquet deflation and the second dose at 180' after the first dosage
16633270|NCT02393300|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
16633271|NCT02393287||Reproline|this is an observational trial ; there is no intervention
16633272|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
16633273|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
16633274|NCT02393261|Experimental|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
16633275|NCT02393261|Active Comparator|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
16633276|NCT02393248|Experimental|Dose Escalation|"Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.
~Dose Expansion
~Combination therapy:
~Gemcitabine + Cisplatin + Pemigatinib
~Pembrolizumab + Pemigatinib
~Docetaxel + Pemigatinib
~Trastuzumab + Pemigatinib
~INCMGA00012 + Pemigatinib"
16633277|NCT02393235||unexplained infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
16633278|NCT02393235||tubal infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
16633279|NCT02393235||fertile group(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
16633337|NCT02392819|Placebo Comparator|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
16633280|NCT02393222||Patients with ESRD on HD|Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
16633281|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
16633282|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
16633283|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
16633284|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
16633285|NCT02393196|Active Comparator|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
16633286|NCT02393196|Active Comparator|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
16633287|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED (ASTED):
~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)
~β- Carotene (3 mg)
~Vit C (100 mg)
~Vit E (Alpha-Tocopherol Acetate): 60 IU
~Vit D (500 IU)
~Zinc (4 mg, elemental)
~Copper (0.5 mg, elemental)
~Selenium 100 µg (as Sodium Selenite)"
16633288|NCT02393183|Active Comparator|Selenium|Selenium (100mic) Twice daily
16633289|NCT02393183|Placebo Comparator|Placebo|Placebo Twice daily
16633290|NCT02393170|Experimental|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
16633291|NCT02393170|Active Comparator|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
16633292|NCT02393157|Experimental|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
16633293|NCT02393157|Experimental|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
16633294|NCT02393144|Other|Spontaneous labor arm|Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
16633295|NCT02393144|Other|Induced labor arm|Women with term pregnancies who are induced for birth before the onset of spontaneous labor. Labor will be induced with either oxytocin infusion for women with high Bishop score, or labor will be induced with dinoprostone pessary for women requiring cervical ripening, i.e. poor. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
16633296|NCT02393131|Experimental|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
16633297|NCT02393131|Active Comparator|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
16633298|NCT02393118|Experimental|BrainPort V200 Device|Single Arm
16633299|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
16633300|NCT02393092|Experimental|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
16633301|NCT02393092|Experimental|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
16633424|NCT02392312||ATF-Fresenius S|intravenous
16633302|NCT02393092|Experimental|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
16633303|NCT02393079|Experimental|Active helmet LED|15 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
16633304|NCT02393079|Sham Comparator|Sham group|15 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
16633305|NCT02393066|Active Comparator|propofol|these patients are sedated with propofol infusion during ICU admission
16633306|NCT02393066|Active Comparator|dexmedetomidine|these patients are sedated with dexmedetomidine infusion during ICU admission
16633307|NCT02393053|Sham Comparator|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
16633308|NCT02393053|Experimental|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
16633309|NCT02393040|Experimental|PRP/Saline|"PRP/Saline
~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.
~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).
~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
16633310|NCT02393027|Experimental|patients|10 idopathic parkinson disease
16633311|NCT02393027|Active Comparator|controls subjects|10 healthy controls (no parkinson disease)
16633312|NCT02393014|Experimental|Low fall risk|low fall risk patients
16633313|NCT02393014|Experimental|Medium fall risk|medium fall risk patients
16633314|NCT02393014|Experimental|High fall risk|high fall risk patients
16633315|NCT02393001||Dermatology patients|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.
16633316|NCT02392988|Placebo Comparator|Group receives sham treatment|Sham treatment will be given on points on the back, points that are not acupuncture points, so that the patient will not be able to know whether she is receiving sham treatment or a real treatment. The treatment will be every 48-72 hours, a maximum of three treatments.
16633317|NCT02392988|Experimental|Group receives acupuncture treatment|The women in this group will receive acupuncture treatment every 48-72 hours, a maximum of three treatments.
16633318|NCT02392988|No Intervention|Group doesn't receive any treatment|The women in this group will come for a follow-up check a week later, unless a spontaneous birth will develop.
16633319|NCT02392975|Experimental|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
16633320|NCT02392962|Experimental|Experimental I|This group performed static stretching
16633321|NCT02392962|Active Comparator|Experimental II|This group performed dynamic stretching
16633322|NCT02392949|Experimental|Experimental group|Passive mobilization on cervical spine
16633323|NCT02392949|Placebo Comparator|Control|Placebo exercise on arms
16633324|NCT02392910|Other|Group A|Placebo
16633325|NCT02392910|Other|Group B|Iron Sucrose
16633326|NCT02392897|Experimental|High Eating Frequency|6 Eating Occasions
16633327|NCT02392897|Experimental|Low Eating Frequency|3 Eating Occasions
16633328|NCT02392884|Active Comparator|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
16633329|NCT02392884|Active Comparator|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
16633330|NCT02392884|No Intervention|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
16633331|NCT02392871|Experimental|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.
~Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.
~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
16633332|NCT02392858|Other|influenza cohort|"Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.
~1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.
~Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms."
16633333|NCT02392845|Experimental|Combination of Docetaxel (DTX) and Epirubicin (EPI)|
16633334|NCT02392832|Experimental|Intervention arm|Fourstar® granule formulation, 90day and 180 day briquettes Bti/Bs in larval habitats of malaria vectors.
16633335|NCT02392832|No Intervention|Control arm|No larvicide application.
16633336|NCT02392819|Experimental|test product|Arm: Panax ginseng
16634062|NCT02387931|Experimental|Vitamin D|Vitamin D3 2000 IU daily taken for 6 months
16633338|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
16633339|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
16633340|NCT02392793|Active Comparator|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
~Arm A is closed to enrollment."
16633341|NCT02392793|Active Comparator|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
16633342|NCT02392780|Experimental|Cannabidiol|
16633343|NCT02392767|Active Comparator|Verum|2 times 2 tablets a day for 4 weeks.
16633344|NCT02392767|Placebo Comparator|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
16633345|NCT02392754|Experimental|Screening|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
16633346|NCT02392754|No Intervention|Control|The control group receives standard care for 6 months (including a pulse check and heart auscultation by a physician at 6 months).
16633347|NCT02392741|No Intervention|Control|The control group will follow the IMIP prenatal routine.
16633348|NCT02392741|Experimental|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
16633349|NCT02392728|Experimental|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
16633350|NCT02392728|Active Comparator|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
16633351|NCT02392715|Experimental|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week
~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics
~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
16633352|NCT02392715|Sham Comparator|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week
~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics
~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
16633353|NCT02392702|Active Comparator|C-10355, 25 mg|single oral dose.
16633354|NCT02392702|Active Comparator|C-10358, 25 mg|single oral dose.
16633355|NCT02392702|Active Comparator|C-10355 or C-10358, 75 mg|single oral dose.
16633356|NCT02392702|Active Comparator|C-10355 or C-10358, 150 mg|single oral dose.
16633357|NCT02392702|Active Comparator|Kalydeco, 150 mg|single oral dose.
16633358|NCT02392702|Active Comparator|C-10355 or C-10358, 300 mg|single oral dose.
16633359|NCT02392689|Experimental|PCT-guided|"Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.
~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended"
16633360|NCT02392689|No Intervention|Standard of Care|Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.
16633361|NCT02392676|Experimental|1/OLAPARIB|olaparib 300 mg oral tablets; twice daily
16633362|NCT02392676|Placebo Comparator|2/PLACEBO|placebo matching olaparib 300 mg oral tablets; twice daily
16633363|NCT02392663|Active Comparator|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).
~Both patients and physiotherapist will be blind to the intervention."
16633364|NCT02392663|Active Comparator|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline [7%]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).
~Both patients and physiotherapist will be blind to the intervention."
16633365|NCT02392663|Placebo Comparator|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).
~Both patients and physiotherapist will be blind to the intervention."
16633366|NCT02392637|Experimental|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16633367|NCT02392624|Experimental|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
16633425|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
16633368|NCT02392624|Placebo Comparator|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
16633369|NCT02392611|Experimental|Monotherapy: Alobresib 0.6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 0.6 mg to determine the MTD.
16633370|NCT02392611|Experimental|Monotherapy: Alobresib 1.4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 1.4 mg to determine the MTD.
16633371|NCT02392611|Experimental|Monotherapy: Alobresib 2 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 2 mg to determine the MTD.
16633372|NCT02392611|Experimental|Monotherapy: Alobresib 3 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 3 mg to determine the MTD.
16633373|NCT02392611|Experimental|Monotherapy: Alobresib 4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 4 mg to determine the MTD.
16633374|NCT02392611|Experimental|Monotherapy: Alobresib 6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 6 mg to determine the MTD.
16633375|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Exemestane|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with exemestane 25 mg.
16633376|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with fulvestrant 500 mg.
16633377|NCT02392611|Experimental|Combination Therapy: Alobresib 3 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 3 mg in combination with fulvestrant 500 mg.
16633378|NCT02392585|Active Comparator|Single tourniquet|
16633379|NCT02392585|Active Comparator|Triple tourniquet|
16633380|NCT02392572|Experimental|Arm A: ONC201 Once Every 3 Weeks|"ONC201 dosed orally once every three weeks. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
16633381|NCT02392572|Experimental|Arm B: ONC201 Once Every 1 Week|"ONC201 dosed orally once every 1 week. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
16633382|NCT02392572|Experimental|Arm C: ONC201 On First Two Consecutive Days of Every Week|"ONC201 dosed orally on the first two consecutive days of every week. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
16633383|NCT02392572|Experimental|Arm D: ONC201 Once Daily|"ONC201 dosed orally once daily. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
16633384|NCT02392572|Experimental|Arm E: ONC201 Once Daily + Cytarabine|"ONC201 orally once daily in combination with low Cytarabine 20 mg subcutaneous twice daily for 10 days. One cycle defined as 28 days (4 weeks).
~Once the highest dose for Arm D (625 mg) are deemed safe (<2/6 DLTs) or the MTD is reached before that, then Phase I part of the study for Arm E will begin. The starting dose of ONC201 will be 625 mg or the MTD with the same schedule as that in Arm D. 3 + 3 algorithm will be applied for dose de-escalation."
16633385|NCT02392559|Placebo Comparator|Placebo|Matching subcutaneous injection every 4 weeks (QM)
16633386|NCT02392559|Experimental|EvoMab 420 mg QM|Evolocumab subcutaneous injection QM
16633387|NCT02392546|Experimental|Elobixibat 10 mg|elobixibat
16633388|NCT02392546|Experimental|Elobixibat 15 mg|elobixibat
16633389|NCT02392546|Experimental|Elobixibat 20 mg|elobixibat
16633390|NCT02392546|Placebo Comparator|Placebo|placebo
16633426|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
16633427|NCT02392260|Experimental|Vasculight prototype zero level|
16633698|NCT02390349|Experimental|CuraMed (BCM-95)|67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks
16633391|NCT02392533||Pre cohort group|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
16633392|NCT02392533||Post cohort group.|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
16633393|NCT02392520|Experimental|Antagonist|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
16633394|NCT02392520|Placebo Comparator|Conventional|Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.
16633395|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.
~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).
~Participants may continue to receive treatment until discontinuation criteria are met."
16633396|NCT02392494|Experimental|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
16633397|NCT02392494|Experimental|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
16633398|NCT02392494|Experimental|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
16633399|NCT02392494|Experimental|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
16633400|NCT02392481||Healthy subjects|
16633401|NCT02392481||Mild asthma|
16633402|NCT02392481||Moderate asthma|
16633403|NCT02392481||Severe asthma|
16633404|NCT02392468|Experimental|BI 409306 low dose|low dose of BI 409306
16633405|NCT02392468|Experimental|BI 409306 high dose|high dose of BI 409306
16633406|NCT02392455||A|
16633407|NCT02392442|Experimental|1 - Endotoxin|6 hour lavage post endotoxin
16633408|NCT02392442|Experimental|2 - Endotoxin|24 hour lavage post endotoxin
16633409|NCT02392442|Experimental|3 - Endotoxin|48 hour lavage post endotoxin
16633410|NCT02392442|Placebo Comparator|4 Placebo comparator|6 hour control lavage
16633411|NCT02392429|Experimental|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment.
16633412|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
16633413|NCT02392390|Experimental|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.
~Intervention: Topical Dynamic Phototherapy (TDP)"
16633414|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).
~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).
~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
16633415|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).
~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.
~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
16633416|NCT02392364|Active Comparator|Variable Treatment Dosing Arm|Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
16633417|NCT02392364|Active Comparator|Monthly Treatment Arm|Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
16633418|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
16633419|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
16633420|NCT02392338|No Intervention|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
16633421|NCT02392338|Active Comparator|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
16633422|NCT02392325|Experimental|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
16633423|NCT02392325|Experimental|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
16633428|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
16633429|NCT02392234|Experimental|VX-661/Ivacaftor combination|
16633430|NCT02392234|Experimental|Ivacaftor monotherapy|
16633431|NCT02392234|Placebo Comparator|Placebo|
16633432|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
16633433|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
16633434|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
16633435|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
16633436|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
16633437|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
16633438|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
16633439|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
16633440|NCT02392143|Active Comparator|Printed Education Material|Participants received printed education materials (PEM) sent by first class mail.
16633441|NCT02392143|Active Comparator|Academic Detailing|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices.
16633442|NCT02392143|Active Comparator|Academic Detailing+Telephone Education|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices and participants received tailored telephone education (TTE).
16633443|NCT02392130|Active Comparator|Active Drug|Clobetasol propionate 0.05% ointment
16633444|NCT02392130|Experimental|Experimental Drug|LEO 130852A gel 1%
16633445|NCT02392130|Placebo Comparator|Placebo Drug|LEO 130852A placebo gel
16633446|NCT02392117||Insulin degludec|
16633447|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
16633448|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
16633449|NCT02392052|Experimental|Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
16633450|NCT02392052|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
16633451|NCT02392039|Experimental|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
~Cycle 1 and 3:
~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Cycle 2 and 4:
~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
16633452|NCT02392039|Experimental|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
~Cycle 1 and 3:
~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Cycle 2 and 4:
~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
16633453|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
16633454|NCT02392013|Experimental|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
16633455|NCT02392013|No Intervention|Usual Care Group|Usual care by an Area Agency on Aging
16633456|NCT02392000|Experimental|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
16633457|NCT02391987|Active Comparator|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
16633458|NCT02391987|No Intervention|Standard Care|Standard care is defined as Heart Failure (HF) care based on current American College of Cardiology (ACC) and American Heart Association (AHA) HF guidelines implemented and orchestrated by a cardiologist and support staff at the participating institution.
16633459|NCT02391974|Experimental|PERIOSYAL FILL|n=15
16633460|NCT02391974|No Intervention|No treatment (untreated control)|n=15
16633461|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
16633692|NCT02390388|Active Comparator|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
16633462|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
16633463|NCT02391935|Experimental|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
16633464|NCT02391935|Placebo Comparator|Placebo|cryomedium
16633465|NCT02391922|No Intervention|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
16633466|NCT02391922|Active Comparator|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
16633467|NCT02391922|Active Comparator|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
16633468|NCT02391922|Active Comparator|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
16633469|NCT02391909||Group A|Vivotif 6.9-10.0 x109 CFU/capsule
16633470|NCT02391909||Group B|Vivotif 4.0-6.8 x109 CFU/capsule
16633471|NCT02391896|Other|Digital Tomosynthesis|Patient will get tomosynthesis scan
16633472|NCT02391896|Other|Dual energy|Patient will get dual energy scan
16633473|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
16633474|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated <24 hours after admission.
16633475|NCT02391870|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
16633476|NCT02391857|Experimental|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
16633477|NCT02391844|Other|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
16633478|NCT02391818||Breast Cancer Patients receiving ACT|Adraimycin/Cytoxan/Taxol
16633479|NCT02391818||Breast Cancer patients receiving RT only|radiation therapy
16633480|NCT02391805|Placebo Comparator|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
16633481|NCT02391805|Placebo Comparator|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
16633482|NCT02391805|Experimental|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
16633483|NCT02391805|Experimental|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
16633484|NCT02391805|Experimental|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
16633485|NCT02391805|Experimental|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
16633486|NCT02391792||patients|patients with septic shock
16633487|NCT02391792||control|patients without septic shock
16633488|NCT02391792||healthy volunteers|
16633489|NCT02391779|Experimental|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
16633490|NCT02391779|Placebo Comparator|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
16633491|NCT02391779|Experimental|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
16633492|NCT02391779|Sham Comparator|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
16633493|NCT02391766|Active Comparator|empowerment group|empowerment intervention by us for us guides
16633494|NCT02391766|Placebo Comparator|no treatment group|dementia patients treatment as usual
16633495|NCT02391727|Other|SYN004|open label study
16633496|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.
~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
16633497|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.
~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
16633498|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
16633499|NCT02391701|No Intervention|Control|No intervention
16633500|NCT02391688|Experimental|Treatment A|"Oral intake of:
~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
16633501|NCT02391688|Experimental|Treatment B|"Oral intake of:
~fexofenadine 25 mg"
16633502|NCT02391688|Experimental|Treatment C|"Oral intake of:
~bupropion 20 mg"
16633503|NCT02391688|Experimental|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):
~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
16633504|NCT02391675||Appendicitis patients|Patients presenting with acute appendicitis
16633505|NCT02391662|Experimental|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 & 15 in a 28 days cycle
16633506|NCT02391649|Experimental|Self-learning program|The participants in the Problem-solving Based Self-learning Program will complete the self-help and problem-solving manual developed by the research team for caregivers of people with psychotic disorders over 20 weeks. In addition to the orientation, understanding about psychosis and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
16633507|NCT02391649|Active Comparator|Psycho-education (in Phase 2)|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for psychosis. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the self-learning program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
16633508|NCT02391649|No Intervention|Routine community care|Participants in the control group (and treatment groups) will receive routine psychiatric outpatient and family services.
16633509|NCT02391636|Experimental|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
16633510|NCT02391636|Active Comparator|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
16633511|NCT02391623|Experimental|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16633512|NCT02391623|Experimental|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16633513|NCT02391623|Experimental|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16633514|NCT02391623|Experimental|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16633515|NCT02391623|Experimental|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16633516|NCT02391623|Experimental|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16633517|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
16633518|NCT02391584|Other|Control|Continued medical management
16633519|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
16633520|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
16633521|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
16633522|NCT02391545|Experimental|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.
~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
16633523|NCT02391545|Experimental|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.
~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
16633524|NCT02391532|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
16633525|NCT02391532|Placebo Comparator|Placebo|Placebo lozenges twice daily for 12 weeks
16633526|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
16633527|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
16633528|NCT02391506|Experimental|Cartiva|Synthetic Cartilage Implant
16633529|NCT02391493|Experimental|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
16633530|NCT02391493|Experimental|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
16633531|NCT02391493|Experimental|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
16633532|NCT02391480|Experimental|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
16633533|NCT02391480|Experimental|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
16633534|NCT02391480|Experimental|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
16633535|NCT02391454|Other|Group A|usual care
16633536|NCT02391454|Experimental|Group B|usual care + RunKeeper app
16633537|NCT02391441||Pulmonary arterial hypertension|Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
16633538|NCT02391441||Control group|Control patients without increased pulmonary artery pressure (i.e. RV peak pressure <35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.
16633539|NCT02391428|Experimental|Children who diagnosed with ADHD|The ADHD children will be asked to consume omega3 capsules for 6 months. Blood will be taken for omega3 analysis in day 0, after 3 and 6 months.
16633693|NCT02390388|Active Comparator|Caudal block group|caudal block performed under general anesthesia
16633694|NCT02390375|Experimental|A|DW-0929
16633695|NCT02390375|Active Comparator|B|Rosuvastatin
16633540|NCT02391428|Experimental|Control group of children without ADHD|"Blood test:
~The control group of 30 children (age and gender match) without ADHD and related neuropsychiatric syndromes, who were hospitalized due to surgical or orthopedic problems. Only when blood will be taken for clinical purposes, the investigators will ask the children and their parents to allow the collection of an additional small blood tube."
16633541|NCT02391415|Experimental|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
16633542|NCT02391415|Active Comparator|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
16633543|NCT02391415|Experimental|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
16633544|NCT02391415|Active Comparator|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
16633545|NCT02391415|Experimental|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
16633546|NCT02391402|Experimental|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
16633547|NCT02391402|Placebo Comparator|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
16633548|NCT02391389|Experimental|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
16633549|NCT02391376|Experimental|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
16633550|NCT02391376|Experimental|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
16633551|NCT02391376|Experimental|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
16633552|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
16633553|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
16633554|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
16633555|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
16633556|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
16633557|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
16633558|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
16633559|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
16633560|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
16634063|NCT02387931|Experimental|Fish Oil|Fish Oil 1000 mg daily for 6 months
16633561|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
16633562|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
16633563|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
16633564|NCT02391298|Experimental|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
16633565|NCT02391285|Experimental|pelvic floor dynamometry|
16633566|NCT02391272|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
16633567|NCT02391259|Experimental|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
16633568|NCT02391259|Placebo Comparator|Placebo|No active drug
16633569|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
16633570|NCT02391233|Experimental|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
16633571|NCT02391233|Active Comparator|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
16633572|NCT02391220|Active Comparator|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
16633573|NCT02391220|Placebo Comparator|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
16633574|NCT02391207||patients having at least one CLM|Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography
16633575|NCT02391194|Experimental|AVB-620|Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.
16633576|NCT02391181|Experimental|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
16633577|NCT02391181|Active Comparator|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
16633578|NCT02391155|Active Comparator|single lumen|Single lumen needle in oocyte retrieval
16633579|NCT02391155|Active Comparator|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
16633580|NCT02391142|Experimental|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
16633581|NCT02391142|No Intervention|non-cardiac sympathetic nerve block|
16633582|NCT02391129||Hyperion Prosthesis|Patients treated with the second generation long-stem revision prosthesis
16633583|NCT02391129||Helios Prosthesis|Patients treated with the first generation long-stem revision prosthesis
16633584|NCT02391129||Locking compression plate|Patients treated with LCP
16633585|NCT02391116|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
16633586|NCT02391103|Experimental|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
16633587|NCT02391103|Sham Comparator|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
16633588|NCT02391090|Experimental|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.
~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
16633589|NCT02391090|Sham Comparator|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).
~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
16633590|NCT02391077|No Intervention|Control Arm|Standard PrePex Procedure
16633591|NCT02391077|Experimental|Arm 1 - Maximal intervention|"Foreskin disinfection with Povidone-Iodine
~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
~Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
16633592|NCT02391077|Experimental|Arm 2 - Medium intervention|"Foreskin disinfection with Povidone-Iodine
~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
16633593|NCT02391064|Experimental|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
16633594|NCT02391064|Experimental|Control|healthy subject
16633595|NCT02391051|Experimental|Focal Brachytherapy|HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy
16633596|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).
~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
16633597|NCT02391025|Experimental|Gallium-68 citrate|
16633598|NCT02391012|Experimental|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
16633599|NCT02390999|No Intervention|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
16633600|NCT02390999|Experimental|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
16633601|NCT02390973|Active Comparator|Sleeve gastrectomy|
16633602|NCT02390973|Active Comparator|Roux-en-Y Gastric Bypass|
16633603|NCT02390973|Active Comparator|Biliopancreatic Diversion|
16633604|NCT02390973|Active Comparator|Control|the best medical management of their diabetes, non-surgical group
16633605|NCT02390960|Active Comparator|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
16633606|NCT02390960|Placebo Comparator|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
16633607|NCT02390947|Experimental|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
16633608|NCT02390947|Placebo Comparator|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
16633609|NCT02390934|Experimental|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
16633610|NCT02390921|Active Comparator|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
16633611|NCT02390921|Experimental|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
16633612|NCT02390908|Experimental|Site 1 Immediate PLUS intervention|Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
16633613|NCT02390908|Active Comparator|Wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
16633614|NCT02390908|Experimental|Site 2 Immediate PLUS intervention|Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
16633615|NCT02390908|Experimental|Site 3 Immediate PLUS intervention|Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
16633616|NCT02390895|Experimental|Minimally-invasive endoscopic repair|endoscopic repair of myelomeningocele before 26 SA
16633617|NCT02390882|Placebo Comparator|Placebo|Tamsulosin placebo (12 weeks)
16633618|NCT02390882|Experimental|Treatment 1|HGP0412 capsule (12 weeks)
16633619|NCT02390882|Experimental|Treatment2|HIP1402 capsule (12 weeks)
16633620|NCT02390869|Experimental|R2-MANT|A) Rituximab B) Lenalidomide
16633621|NCT02390869|Active Comparator|R-MANT|A) Rituximab
16633622|NCT02390856|Active Comparator|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
16633623|NCT02390856|Experimental|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
16633624|NCT02390843|Experimental|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
16633625|NCT02390830|Experimental|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
16633626|NCT02390830|Active Comparator|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
16633627|NCT02390817|Active Comparator|Sugammadex|At the wakeup status Sugammadex 2 mg/kg single dose will perform.
16633628|NCT02390817|Placebo Comparator|Neostigmine|At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.
16633629|NCT02390804|Experimental|single-port laparoscopic hysterectomy|total laparoscopic hysterectomy via transumbilical single port
16633630|NCT02390804|Active Comparator|multi-port laparoscopic hysterectomy|total laparoscopic hysterectomy via multi-port (3 port)
16633631|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
16633632|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
16633696|NCT02390362|Experimental|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 & 3.
16633699|NCT02390349|Experimental|Curamin|67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks
16633633|NCT02390778|Experimental|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
16633634|NCT02390778|Placebo Comparator|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
16633638|NCT02390739|Experimental|Single Arm|All patients will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by antithyroglobulin mTCR PBL and aldesleukin.
16633639|NCT02390726|Sham Comparator|Control|Sham FMT and Sham Microbial Maintenance plus standard therapy
16633640|NCT02390726|Experimental|Treatment|FMT and microbial maintenance plus standard therapy
16633641|NCT02390713|Experimental|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
16633642|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
16633643|NCT02390687|Placebo Comparator|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
16633644|NCT02390687|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
16633645|NCT02390674|Active Comparator|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
16633646|NCT02390674|Placebo Comparator|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
16633647|NCT02390661|No Intervention|No drain|Control group
16633648|NCT02390661|Experimental|Penrose drain placement|Placement of a penrose drain after irradiation catheter is removed
16633649|NCT02390648|Experimental|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
16633650|NCT02390648|Placebo Comparator|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
16633651|NCT02390635|Experimental|Diagnostic (18F-FDG PET/CT, whole body PET/MRI)|Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.
16633652|NCT02390622|Other|FMT treatment|Treat the patients by fecal microbiota transplantation
16633653|NCT02390609|Experimental|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.
16633654|NCT02390609|Experimental|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633655|NCT02390609|Experimental|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633656|NCT02390609|Experimental|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633657|NCT02390609|Experimental|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633658|NCT02390609|Experimental|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633659|NCT02390609|Experimental|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633697|NCT02390362|Active Comparator|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
16633660|NCT02390609|Experimental|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633661|NCT02390609|Experimental|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633662|NCT02390609|Experimental|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
16633663|NCT02390596|Experimental|Anakinra|
16633664|NCT02390583|Active Comparator|control|CBT treatment of internet dependence each two weeks during 3 months
16633665|NCT02390583|Experimental|intervention|CBT treatment of internet dependence plus CBT treatment of sleep disorders during 3 months
16633666|NCT02390570|Experimental|Implementation Arm|
16633667|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
16633668|NCT02390557|Experimental|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
16633669|NCT02390557|Experimental|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
16633670|NCT02390544|Experimental|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.
~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
16633673|NCT02390505|Experimental|Vitamin C|Patients receive vitamin C at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
16633674|NCT02390505|Placebo Comparator|Placebo|Patients receive placebo at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
16633675|NCT02390492|Experimental|Ipatasertib/[14C]-ipatasertib|
16633676|NCT02390479|Active Comparator|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
16633677|NCT02390479|Placebo Comparator|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
16633678|NCT02390466|Experimental|VAC-3S|32µg/ml corresponding to 16µg/vaccination
16633679|NCT02390453|Experimental|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
16633680|NCT02390453|Active Comparator|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
16633681|NCT02390453|Active Comparator|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
16633682|NCT02390453|Sham Comparator|Control|This consists of 45 minutes of group discussion and instruction in health self-management and successful aging, 2 days a week for 12 weeks (24 sessions).
16633683|NCT02390440|Experimental|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
16633684|NCT02390427|Experimental|Arm A|"Arm A
~- Taselisib with Trastuzumab emtansine (also called T-DM1)
~Taselisib administered orally, daily in each treatment cycle (3 weeks).
~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
16633685|NCT02390427|Experimental|Arm B|"Arm B
~-Taselisib with T-DM1 and Pertuzumab
~Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).
~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).
~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
16633686|NCT02390427|Experimental|Arm C|"Arm C:
~Taselisib with Pertuzumab and Trastuzumab
~Cohort C will not open without additional authorization from Genentech
~Taselisib is administered oral, daily in each treatment cycle (3 weeks).
~Trastuzumab administered once via IV per treatment cycle (3 weeks).
~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
16633687|NCT02390427|Experimental|Arm D|"Arm D
~Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel
~Cohort will not be opened without additional authorization from Genentech
~Taselisib- administered oral, daily in each treatment cycle (3 weeks).
~Pertuzumab- administered once via IV per treatment cycle (3 weeks).
~Trastuzumab administered once via IV per treatment cycle (3 weeks).
~Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
16633688|NCT02390414||Gets HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT and actually undergo HSCT.
16633689|NCT02390414||No HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT but do not undergo HSCT.
16633690|NCT02390401|Experimental|Vacuum-assisted closure (VAC)|Prevena (VAC) device
16633691|NCT02390401|Active Comparator|Standard sterile dressing|Standard sterile dressing
16633700|NCT02390349|Placebo Comparator|Placebo|67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks
16633701|NCT02390336|Experimental|Real mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.
~Next, the therapist will performed the real mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
16633702|NCT02390336|Sham Comparator|Sham mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.
~Next, the therapist will performed the sham mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
16633703|NCT02390323|Experimental|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
16633704|NCT02390310|Active Comparator|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
16633705|NCT02390310|Active Comparator|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
16633706|NCT02390310|Active Comparator|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
16633707|NCT02390310|Active Comparator|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
16633708|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
16633709|NCT02390284|No Intervention|Abnormal PERG Untreated|Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
16633710|NCT02390284|Experimental|Abnormal PERG Treated|"Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.
~Drugs could be:
~Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.
~If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure."
16633711|NCT02390284|No Intervention|Normal|Patients with a normal PERG test that will go through the study under observation.
16633712|NCT02390271|Experimental|emotion focused therapy training CCT|The general training includes in an individual adjusted way the following techniques: biofeedback-assisted breathing classes that erase negative emotion involving the cardiac and limbic neural pathways, control one's own and other's emotions, mastering positive cognition and enhance self-concept, anchoring positive memories, learning how to recognize psychological reversal in others
16633713|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 1|8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)
16633714|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 2|8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)
16633715|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 3|8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)
16633716|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 4|8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)
16633717|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 5|8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)
16633718|NCT02390258|Experimental|Part 2: Fed-Fasted|17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.
16633719|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 1|10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
16633720|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 2|10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
16633721|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 3|10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)
16633722|NCT02390245|Experimental|Enhanced Intervention Group|Use of patient navigation and social worker: Patients randomized to Group 1 will be referred to a general ophthalmologist close to the current health center or PCP office where they received the undilated eye exam. Prior to all follow-up visits, patients in the enhanced group who have scheduled an appointment will receive a personal phone call reminding them to attend. These patients will receive any necessary interpretation services and educational materials.
16633723|NCT02390245|No Intervention|Usual care group|Patients randomized to Group 2 will be recommended to follow-up for eye care with a local ophthalmologist. These patients will be scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team is able to track outcomes. Group 2 represents a realistic choice currently available for patients. Practice patterns will vary depending on the resources, staff time, and services available within each local ophthalmology practice.
16633724|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
16633725|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
16633726|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
16633727|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
16633728|NCT02390193|Experimental|Hemodialysis|Chronic kidney disease patients undergoing hemodialysis will be recruited consecutively and screened for eligibility using a standardised protocol.
16633729|NCT02390180||Sorting all tastes|This group will receive 15 samples to taste and sort into groups. The samples included: a blank solution, hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, sodium chloride (2), citric acid, acetic acid, quinine, urea, monosodium glutamate, and inosine monophosphate.
16633730|NCT02390180||Sorting bitter tastes|This group will receive 12 samples to taste and sort into groups. The samples included: blank solutions (2), decenoic acid, oleic acid, linoleic acid, quinine (2), urea (2),caffeine, sucrose octaacetate, and propylthiouracil.
16633731|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
16633732|NCT02390154|Experimental|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
16633733|NCT02390154|Experimental|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
16633734|NCT02390141|Experimental|ZP4207|Five multiple doses of ZP4207 in ascending doses
16633735|NCT02390141|Placebo Comparator|Placebo|Five multiple doses of corresponding placebo in ascending doses
16633736|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
16633737|NCT02390115|Active Comparator|Elastic Tape|"Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as paper tension and it is equivalent to 10-15% of the total elastic tape tension."
16633738|NCT02390115|Sham Comparator|Sham|The sham elastic tape will be placed using the same tape to the paretic shoulder. However, the rigid tape will be placed without tension with the upper limb supporting at 90 degree elbow flexion, 0 degrees abduction and adduction of the shoulder.
16633739|NCT02390102|Active Comparator|Erythropoietin|Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.
16633740|NCT02390102|Placebo Comparator|Placebo|Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.
16633741|NCT02390089|Active Comparator|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
16633742|NCT02390089|Experimental|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
16633743|NCT02390089|Experimental|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
16633744|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
16633745|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
16633746|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
16633747|NCT02390063|Experimental|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
16633748|NCT02390063|Experimental|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
16633749|NCT02390063|Active Comparator|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
16633750|NCT02390063|Active Comparator|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
16633751|NCT02390063|Experimental|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
16633752|NCT02390063|Experimental|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
16633753|NCT02390063|Experimental|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
16633754|NCT02390063|Experimental|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
16633755|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
16633756|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
16633757|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
16633758|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
16633759|NCT02390024||Critically ill patients|Mechanical Ventilation
16633760|NCT02390011||MRI|Day 1
16633761|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
16633762|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
16633763|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
16633764|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
16634064|NCT02387931|Placebo Comparator|Placebo|Placebo taken daily for 6 months.
16633765|NCT02389959|Experimental|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
16633766|NCT02389959|Placebo Comparator|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
16633767|NCT02389946|Experimental|Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
16633768|NCT02389946|Active Comparator|Xience everolimus coronary stent system|Intervention with a Xience DES.
16633769|NCT02389920|Experimental|Nilotinib|nilotinib 400mg BID for 12 months
16633770|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
16633771|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
16633772|NCT02389894|Active Comparator|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
16633773|NCT02389894|Active Comparator|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
16633774|NCT02389894|No Intervention|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
16633775|NCT02389881|Experimental|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
16633776|NCT02389881|Experimental|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
16633777|NCT02389881|Experimental|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
16633778|NCT02389881|Experimental|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
16633779|NCT02389881|Placebo Comparator|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
16633780|NCT02389881|Placebo Comparator|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
16633781|NCT02389881|Placebo Comparator|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
16633782|NCT02389868|Experimental|Lovastatin|
16633783|NCT02389842|Experimental|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
16633784|NCT02389842|Experimental|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
16633785|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
16633786|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.
~Patients can receive second 10mg dose at 1 hour."
16633787|NCT02389816|Placebo Comparator|Placebo|Placebo tablets, orally, once daily for up to Week 8
16633788|NCT02389816|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
16633789|NCT02389816|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
16633790|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
16633791|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
16633792|NCT02389790|Experimental|MT-1303|
16633793|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
16633794|NCT02389777|Active Comparator|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
16633795|NCT02389777|Active Comparator|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
16633796|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
16634099|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
16633797|NCT02389751|Experimental|Treatment (ganetespib, paclitaxel, carboplatin, radiation)|Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
16633798|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.
~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
16633799|NCT02389725|Active Comparator|disposable elastic tourniquet|
16633800|NCT02389725|Active Comparator|manual blood pressure cuff|manual blood pressure cuff inflated to 150 milliliters mercury (mmHg)
16633801|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
16633802|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
16633803|NCT02389699|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
16633804|NCT02389699|Active Comparator|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
16633805|NCT02389686|No Intervention|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
16633806|NCT02389686|Experimental|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
16633807|NCT02389673|No Intervention|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
16633808|NCT02389673|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
16633809|NCT02389660|Experimental|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
16633810|NCT02389660|Active Comparator|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
16633811|NCT02389647||Endovascular group|Subjects undergoing elective endovascular catheterization for coiling of unruptured cerebral aneurysms. Four blood draws of 5mL each: (1) prior to initiation of procedure; (2) at the time of catheterization of major cerebral vessels, (3) immediately after the procedure, and (4) 24-hours after the procedure.
16633812|NCT02389647||Ischemic stroke group|Subjects who present to the emergency department with ischemic infarcts of <6 hours. Four blood draws of 5mL each: (1) at time of enrollment but prior to tPA, (2) 6 hours post-tPA, (3) 12 hours post-tPA, and (4) 24 hours post-tPA.
16633813|NCT02389647||Intracranial hemorrhage|Subjects who present to the emergency department with intracranial hemorrhage. One 5mL blood draw within 24 hours of onset.
16633814|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
16633815|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
16633816|NCT02389608|Experimental|1- tDCS 2--FES|"Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
~Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
16633817|NCT02389595||HIV positive subjects|This group will provide a blood sample.
16633818|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
16633819|NCT02389582|Experimental|Dabigatran|Dabigatran 150mg twice a day for five days
16633820|NCT02389582|Active Comparator|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
16633821|NCT02389569|Experimental|Adhesive system treatment|Four groups ( Two will be treat with Etch-and-Rinse Adhesive System and two will be treated with two step Self-Etch Adhesive System).
16633822|NCT02389569|Experimental|Restoration protocol|Four groups ( Two will be treat with experimental Biosilicate and two will be the control groups).
16633823|NCT02389543|Experimental|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
16633824|NCT02389543|Experimental|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
16633825|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
16633826|NCT02389517|Experimental|Arm I (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
16633827|NCT02389517|Active Comparator|Arm II (lenalidomide)|Patients receive lenalidomide PO as in Arm I.
16633828|NCT02389504|Active Comparator|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
16633829|NCT02389504|Experimental|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
16633830|NCT02389491|Active Comparator|normal density formula (Neocate)|In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days
16633831|NCT02389491|Experimental|high density formula (Infatrini)|In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days
16633832|NCT02389478|Experimental|colostrums|Oropharyngeal administration of colostrums, every 4 hours，continue for 7days
16633833|NCT02389478|Other|Normal saline|Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days
16633834|NCT02389465|No Intervention|Control|This arm is for participants who are not depressed.
16633835|NCT02389465|Experimental|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
16633836|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
16633837|NCT02389439|Experimental|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.
~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.
~20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs"
16633838|NCT02389426|Experimental|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
16633839|NCT02389426|Experimental|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
16633840|NCT02389413|Experimental|PQ912 oral|PQ912 will be administered orally twice daily for 12 weeks.
16633841|NCT02389413|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 12 weeks.
16633842|NCT02389400|Experimental|Experimental arm|methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5
16633843|NCT02389387|No Intervention|Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
16633844|NCT02389387|Experimental|Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
16633845|NCT02389374|Other|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
16633846|NCT02389374|Other|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
16633847|NCT02389374|Other|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
16633848|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
16633849|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
16633850|NCT02389348|Experimental|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.
~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
16633851|NCT02389335||Group 1a|Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
16633852|NCT02389335||Group 1b|Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
16633853|NCT02389335||Group 1c|Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
16633854|NCT02389335||Control|Healthy subjects
16634170|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
16633855|NCT02389322|Experimental|5μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
16633856|NCT02389322|Experimental|10μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
16633857|NCT02389322|Placebo Comparator|5μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
16633858|NCT02389322|Placebo Comparator|10μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.
16633859|NCT02389309|Experimental|Treatment (dasatinib, cyclophosphamide, temsirolimus)|Patients receive dasatinib PO BID on days 1-21, cyclophosphamide PO QD on days 1-21, and temsirolimus IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing stable disease or better may continue treatment with the approval of the Study Chair.
16633860|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
16633861|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
16633862|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
16633863|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
16633864|NCT02389257|Experimental|MINIMAG / MEG|Cerebral magnetic fields
16633865|NCT02389257|Experimental|MINIMAG / ECG|Cardiac magnetic fields
16633866|NCT02389244|Experimental|Regorafenib|"For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .
~For children Age ≥10 years to <18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
16633867|NCT02389244|Placebo Comparator|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
16633868|NCT02389231|Experimental|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
16633869|NCT02389218|Experimental|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
16633870|NCT02389218|Active Comparator|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
16633871|NCT02389205|Placebo Comparator|control group|physical therapy
16633872|NCT02389205|Active Comparator|kinesio group|kinesio taping for ankle joint
16633873|NCT02389192|Experimental|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
16633874|NCT02389179|Active Comparator|25 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
16633875|NCT02389179|Active Comparator|50 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
16633876|NCT02389179|Active Comparator|50 000 IU bi-weekly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
16633877|NCT02389166|Experimental|Optiflow group|
16633878|NCT02389166|Active Comparator|Control group|
16633879|NCT02389153|Experimental|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
16633880|NCT02389153|Active Comparator|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
16633881|NCT02389140|Experimental|Trigger point treatment|Trigger point release
16633882|NCT02389140|Sham Comparator|Ultrasound|Sham US at Trigger point
16633883|NCT02389127||Group A|"Cirrhosis, either clinically- or biopsy-proven
~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)
~Random glucose <200 mg/dL on at least 3 occasions
~No use of insulin or any hypoglycemic agent
~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
16633905|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
16634758|NCT02383225|Experimental|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
16633884|NCT02389127||Group B|"Cirrhosis, either clinically- or biopsy-proven
~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)
~Prior diagnosis of T2DM as based on any of ADA criteria
~Use of insulin or any hypoglycemic agent
~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
16633885|NCT02389127||Control|"Age 18 to 75
~No known chronic liver disease
~Prior diagnosis of T2DM as based on any of ADA criteria
~Use of insulin or any hypoglycemic agent"
16633886|NCT02389114|Active Comparator|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
16633887|NCT02389114|Experimental|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
16633888|NCT02389114|Experimental|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
16633889|NCT02389114|Experimental|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
16633890|NCT02389101|Experimental|Lymphoma|Newly diagnosed lymphoma, all subtypes allowed
16633891|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.
~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
16633892|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.
~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
16633896|NCT02389062|Experimental|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
16633897|NCT02389062|Experimental|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
16633898|NCT02389062|Experimental|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
16633899|NCT02389036|No Intervention|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
16633900|NCT02389036|Experimental|SDD intervention group|"The intervention will entail:
~A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
~A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
~A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
16633901|NCT02389023|Other|standard gauze dressing|a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site
16633902|NCT02389023|Other|Prevena Incision Management System|the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.
16633903|NCT02389010|Experimental|Allogeneic Cord Blood Platelet Gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
16633904|NCT02389010|Active Comparator|Standard Local Medications-SLM|1 administration every 3-4 days for 4 weeks. Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
16634058|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
16633906|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
16633907|NCT02388984|Experimental|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
16633908|NCT02388984|Placebo Comparator|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
16633909|NCT02388971|Experimental|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
16633910|NCT02388971|Experimental|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
16633911|NCT02388958||Women with GDM|
16633912|NCT02388958||Women without GDM|
16633913|NCT02388945|Experimental|A APDGroup|PDGO APD machines used in the PD patients for 8 weeks
16633914|NCT02388945|Active Comparator|B CAPDGroup|CAPD used in the PD Patients for 8 weeks
16633915|NCT02388932|Experimental|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.
~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.
~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
16633916|NCT02388919|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
16633917|NCT02388919|Placebo Comparator|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
16633918|NCT02388906|Experimental|Ipilimumab and Placebo matching Nivolumab|
16633919|NCT02388906|Experimental|Nivolumab and Placebo matching Ipilimumab|
16633920|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
16633921|NCT02388867|Experimental|Group I|Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
16633922|NCT02388867|Experimental|Group II|Intervention: Autogenous vein bypass grafting.
16633923|NCT02388854||Endometriosis|Sardinian Women with diagnosis of endometriosis
16633924|NCT02388854||Controls|Healthy blood Sardinian donors
16633925|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
16633926|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
16633927|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
16633928|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
16633929|NCT02388802|Experimental|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
16633930|NCT02388789|Experimental|active movement|use a light treadmill run to raise feet temperature
16633931|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
16633932|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
16633933|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
16633934|NCT02388750|Other|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment
~No previous nausea and vomiting 24 hours prior to radiotherapy"
16633935|NCT02388750|Other|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment
~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
16633936|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.
~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
16633937|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.
~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
16633938|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.
~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
16633939|NCT02388724|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
16633940|NCT02388724|Active Comparator|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
16634059|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
16633941|NCT02388711|Experimental|Usual Care with C-TraC Intervention|Patients/caregivers randomized to this group will receive all routine hospital discharge education/materials (same as usual care group), but will also be enrolled in the C-TraC Program. C-TraC is a low-resource, telephone-based, protocol-driven program designed to reduce 30-day rehospitalizations and to improve care transitions during the early post-hospital period.
16633942|NCT02388711|No Intervention|Usual Care|Usual care group patients will receive all routine University of Wisconsin Hospital and Clinics (UWHC) discharge education/materials. This includes pharmacy-led medication teaching, physician discussions and routine nursing education. No post hospital education/contact is performed by these providers. Caregivers are sometimes, but not always, involved. Patients may receive home health services, depending on their physician's discharge plan.
16633943|NCT02388698|Experimental|Cervical Swab, PET-CT and plasma HPV|Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
16633944|NCT02388685|Experimental|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
16633945|NCT02388685|No Intervention|No exercise|Patients will continue with usual care
16633946|NCT02388672|Experimental|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
16633947|NCT02388672|Placebo Comparator|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
16633948|NCT02388672|Experimental|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
16633949|NCT02388672|Placebo Comparator|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
16633950|NCT02388672|No Intervention|Control|No treatment control group
16633951|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
16633952|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
16633953|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
16633954|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
16633955|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
16633956|NCT02388620|Experimental|Normal Hepatic Function|Normal hepatic function; matched demography to hepatic impairment cohorts
16633957|NCT02388620|Experimental|Mild Hepatic Impairment|Child-Pugh Classification A (score 5-6)
16633958|NCT02388620|Experimental|Moderate Hepatic Impairment|Child-Pugh Classification B (score 7-9)
16633959|NCT02388620|Experimental|Severe Hepatic Impairment|Child-Pugh Classification C (score 10-15)
16633960|NCT02388607||assessing attention span|"Electrophysiological measurements (evocated potentials and spectral densities)
~Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
16633961|NCT02388594|Experimental|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
16633962|NCT02388594|Experimental|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
16633963|NCT02388581|Experimental|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
16633964|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
16633965|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
16633966|NCT02388555||Pre-operative group|Respectively recruited patients with DLS. Patients in this group were not surgically treatment. Only pre-operative radiographic parameters were measured.
16633967|NCT02388555||Surgically treated group|All DLS patients received posterior osteotomy correction of spinal deformity. The immediate post-operative radiographic measurements were performed.
16633968|NCT02388542|Experimental|lifestyle counseling|we will have a trained peer mentor educating employees regarding lifestyle modification for control of cardiovascular disease risk factors and following them up for a duration of 3 months
16633969|NCT02388529|Experimental|Low dose|
16633970|NCT02388529|Experimental|Intermediate dose|
16633971|NCT02388529|Experimental|High dose|
16633972|NCT02388529|Placebo Comparator|Placebo|
16633973|NCT02388516|Placebo Comparator|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
16633974|NCT02388516|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
16633975|NCT02388516|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
16633976|NCT02388516|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
16633977|NCT02388516|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
16633978|NCT02388503|Placebo Comparator|Reference|No added fruit extract
16633979|NCT02388503|Active Comparator|Active 1|lowest dose of fruit extract
16633980|NCT02388503|Active Comparator|Active 2|low dose of fruit extract
16633981|NCT02388503|Active Comparator|Active 3|medium dose of fruit extract
16633982|NCT02388503|Active Comparator|Active 4|high dose of fruit extract
16633983|NCT02388490|Experimental|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
16633984|NCT02388477|Active Comparator|Doxycycline|oral doxycycline, 2 weeks, twice a day,
16633985|NCT02388477|Placebo Comparator|sugar pill|sugar pill, same size, shape, and color as comparator, twice a day for 2 weeks.
16633986|NCT02388464|Experimental|Low dose|
16633987|NCT02388464|Experimental|Intermediate dose|
16633988|NCT02388464|Experimental|High dose|
16633989|NCT02388464|Experimental|Placebo|
16633990|NCT02388451|Experimental|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
16633991|NCT02388438|Experimental|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
16633992|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels.
16633993|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
16633994|NCT02388399||OCT and Pressure wire pullback tracing|This study is pilot study evaluating the feasibility of invasive measurement and estimation of hemodynamic stress acting on plaque as well as co-registration of hemodynamic data with plaque geometric data, which is obtained by optical coherence tomography
16633995|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
16633996|NCT02388373|Active Comparator|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
16633997|NCT02388373|Active Comparator|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
16633998|NCT02388373|Active Comparator|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
16633999|NCT02388360|Other|topical prostaglandin analogs|
16634000|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
16634001|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
16634002|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
16634003|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
16634004|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
16634005|NCT02388321|Experimental|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
16634006|NCT02388321|Active Comparator|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
16634007|NCT02388308||Patient volunteers|Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.
16634008|NCT02388308||Gold fiducial marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
16634009|NCT02388308||Electromagnetic marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
16634010|NCT02388308||General patients|Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
16634011|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
16634012|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
16634013|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.
~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
16634014|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.
~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
16634015|NCT02388256|Experimental|Acupuncture|Manual and electroacupuncture
16634016|NCT02388256|Active Comparator|Enhanced recovery program after surgery|Enhanced recovery program after surgery
16634017|NCT02388243|Experimental|Brief Intervention in Public Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in public clinic.
16634018|NCT02388243|Active Comparator|Screening results in Public Clinic|Written information after screening; No brief intervention; in public clinic.
16634019|NCT02388243|Experimental|Brief Intervention in Private Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in private clinic.
16634020|NCT02388243|Active Comparator|Screening results in Private Clinic|Written information after screening; No brief intervention; in private clinic.
16634021|NCT02388230||Patients 4 or more years post radiotherapy|IMPORT or FAST trial patients who received breast RT previously and are receiving four years (or more) follow-up assessment and have hardening of their breast as a result of breast radiotherapy.
16634022|NCT02388230||Patients 0 to 2 years post breast radiotherapy|Patients who are (1) undergoing, or undergone recently breast RT (general population) and have undergone a clinical assessment either during RT or at 3 month follow-up that found moderate or severe oedema, or (2) IMPORT patients who have received RT and are receiving one or two year follow-up, at which moderate or severe oedema is reported.
16634023|NCT02388204|Experimental|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
16634024|NCT02388204|Experimental|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.
~Intervention: Implantable spinal cord stimulation."
16634025|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
16634026|NCT02388191|Placebo Comparator|Placebo|Placebo
16634027|NCT02388178|Placebo Comparator|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
16634028|NCT02388178|Experimental|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
16634029|NCT02388178|Active Comparator|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
16634030|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
16634031|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
16634032|NCT02388152|Experimental|Lu AF20513, low dose (Cohort 1)|10 Patients with mild Alzheimer's.
16634033|NCT02388152|Experimental|Lu AF20513, medium dose (Cohort 2)|10 Patients with mild Alzheimer's.
16634034|NCT02388152|Experimental|Lu AF20513, high dose (Cohort 3)|15 Patients with mild Alzheimer's.
16634035|NCT02388152|Experimental|Lu AF20513, double high dose (Cohort 4)|15 Patients with mild Alzheimer's.
16634036|NCT02388126|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
16634037|NCT02388113|Experimental|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
16634038|NCT02388113|Active Comparator|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
16634039|NCT02388087|Active Comparator|ROX COUPLER|Iliac arterio-venous anastamosis created by insertion of ROX coupler device.
16634040|NCT02388087|Sham Comparator|ROUTINE CARE|Right heart catheterisation and Routine care of Neurally mediated syncope.
16634041|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
16634042|NCT02388061|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
16634043|NCT02388061|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
16634044|NCT02388048|Experimental|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).
~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.
~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
16634045|NCT02388035|Experimental|SBP-group 1|Spontanous bacterial peritonitis
16634046|NCT02388035|Experimental|CNNA-group 2|Culture negative neutrocytic ascites
16634047|NCT02388035|Experimental|MNBA-group 3|monomicrobial non-neutrocytic ascites
16634048|NCT02388035|No Intervention|group 4|no evidence of ascitic fluid infection
16634049|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
16634050|NCT02388009|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
16634051|NCT02388009|Active Comparator|Flexyn2a plus adjuvant|2 doses of 10 μg of Flexyn2a plus adjuvant will be injected intramuscularly 4 weeks apart
16634052|NCT02388009|Placebo Comparator|Placebo|2 doses of saline buffer plus adjuvant will be injected intramuscularly 4 weeks apart
16634053|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
16634054|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
16634055|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
16634056|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
16634057|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
16634065|NCT02387918|Active Comparator|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
16634066|NCT02387918|Active Comparator|Acupuncture|Acupuncture at point Neiguan (Pericardium-6) bilaterally and at point CV13 (Shang Wen) with acupuncture needles (0.25x25 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed after 20 minutes
16634067|NCT02387905|Active Comparator|Arm I (standard of care)|Patients undergo stereotactic spinal radiosurgery per standard of care.
16634068|NCT02387905|Experimental|Arm II (vertebral body cement augmentation)|Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
16634069|NCT02387892|Placebo Comparator|Control|Cheese & yogurt
16634070|NCT02387892|Experimental|Treatment|Cheese & yogurt + Vitamin D
16634071|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.
~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
16634072|NCT02387866|Experimental|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
16634073|NCT02387866|Experimental|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
16634074|NCT02387866|Experimental|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
16634075|NCT02387853|Experimental|LEO 90100|
16634076|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
16634077|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
16634078|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
16634079|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
16634080|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
16634081|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
16634082|NCT02387827|Experimental|Diet+ short -term physical activity (DST)|
16634083|NCT02387827|Experimental|Diet+ long -term physical activity (DLT)|
16634084|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
16634085|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
16634086|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
16634087|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
16634088|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
16634089|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
16634090|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
16634091|NCT02387775|Experimental|Esophageal temperature control|The Esophageal Cooling Device (ECD) will be inserted and utilized for temperature control for up to 36 hours in this arm. The ECD will be used for all three phases of therapeutic hypothermia; induction, maintenance, and rewarming. Conventional cooling or warming techniques (e.g. cold saline, ice packs, cooling or warming blankets) will still be made available to the treating ICU team to be used at their discretion.
16634092|NCT02387762|Experimental|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
16634093|NCT02387762|Placebo Comparator|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
16634094|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
16634095|NCT02387736|Experimental|Dialectical Behaviour Therapy-6 months|6 months of standard dialectical behaviour therapy treatment.
16634096|NCT02387736|Active Comparator|Dialectical Behaviour Therapy-12 months|12 months of standard dialectical behaviour therapy treatment
16634097|NCT02387723|Experimental|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
16634098|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
16634100|NCT02387697|Experimental|Group A|Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.
16634101|NCT02387697|No Intervention|Group B|Control group (no surgery) with optimal medical treatment.
16634102|NCT02387671|Experimental|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
16634103|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) < 11 mmHg regardless if revascularization is done or not.
16634104|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) > 11 mmHg regardless if revascularization is done or not.
16634105|NCT02387645|Experimental|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
16634106|NCT02387619|Experimental|Group 1 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2
16634107|NCT02387619|Experimental|Group 2 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2
16634108|NCT02387619|Experimental|Group 1 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2
16634109|NCT02387619|Experimental|Group 2 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2
16634110|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
16634111|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
16634112|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
16634113|NCT02387593|Experimental|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
16634114|NCT02387593|No Intervention|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
16634115|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
16634116|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
16634117|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
16634118|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
16634119|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
16634120|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
16634121|NCT02387567|Experimental|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
16634122|NCT02387567|Sham Comparator|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
16634123|NCT02387567|Active Comparator|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
16634124|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
16634125|NCT02387554|Active Comparator|HGP0904|amlodipine
16634126|NCT02387554|Active Comparator|HGP0608|losartan
16634127|NCT02387554|Active Comparator|HGP1405|chlorthalidone
16634128|NCT02387528|Experimental|1- Mindfulness Intervention|"Mindfulness-Based Intervention: The intervention model tested was Breathworks for Stress.The mindfulness intervention used in the study had a total of eight encounters, lasting 120 minutes, that took place once a week. In order to accommodate employees' schedule. There was a recommendation of daily practice lasting an average of 15 minutes, as well as the suggestion to use the tools in everyday life.
~In each session a theme was presented, with distinct practices and well-defined objectives"
16634129|NCT02387528|Placebo Comparator|2- Relaxation Intervention|Relaxation-Based Intervention was composed of four meetings, of two hours duration, held every two weeks. The activities involved mutual help conversations about work situations, psychoeducation on stress and various techniques of stress inoculation, such as: diaphragmatic breathing, progressive muscle relaxation, relaxing visualization and stretching. Each session had its own objective to promote the relaxation response effect.
16634130|NCT02387528|Other|3- Wait List Control Group|The wait list passive control group did not receive any intervention while the study was been enrolling.
16634131|NCT02387515|Experimental|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
16634132|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
16634133|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
16634134|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
16634135|NCT02387489|Active Comparator|NBI|Nurse-delivered Brief Intervention
16634136|NCT02387489|Experimental|CBI|Computerized Brief Intervention
16634137|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
16634138|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
16634139|NCT02387450|Active Comparator|Treated group|Sildenafil, oral, 100mg per day
16634140|NCT02387450|Placebo Comparator|Control group|placebo oral
16634141|NCT02387437|Experimental|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
16634142|NCT02387437|Experimental|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
16634143|NCT02387437|Experimental|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
16634144|NCT02387424|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
16634145|NCT02387424|Active Comparator|OAR|Ongoing Assessment and Referral (OAR)
16634146|NCT02387411|Active Comparator|Interval group|high-intensity interval exercise training
16634147|NCT02387411|Active Comparator|Combined group|combined exercise training
16634148|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
16634149|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
16634150|NCT02387385|Active Comparator|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
16634151|NCT02387385|No Intervention|Standard of Care|Standard of care
16634152|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:
~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours
~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours
~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
16634153|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
16634154|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
16634155|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
16634156|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
16634157|NCT02387346|Experimental|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
16634158|NCT02387346|Sham Comparator|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
16634159|NCT02387333|Experimental|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
16634160|NCT02387333|Sham Comparator|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
16634161|NCT02387320|Experimental|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
16634162|NCT02387320|No Intervention|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
16634163|NCT02387307|Experimental|Cohort: Dose-Escalation and Expansion|"Dose-Escalation: Dose escalation in solid tumors utilizing a 3+3 design with intra-subject dose escalation. 4 dose levels of rSIFN-co are planned for determining the RD. Dose of rSIFN-co: 15, 21, 24, 27 and 30 ug.
~Dose-Expansion: The Expansion Cohort will be initiated at the RD. Depending on the RD, the lead in period will occur accordingly. After the lead in period, a period from Cycle 1 to the final administration will be performed as the Treatment Phase during which subjects will undergo a standardized evaluation for the safety and efficacy of rSIFN-co at the RD. Follow-up evaluations will be performed 28 days (±5 days) after the last rSIFN-co administration."
16634164|NCT02387294|Experimental|Age group 1: children (3-11 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.
~Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly."
16634165|NCT02387294|Experimental|Age group 2: adolescents (12-18 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.
~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
16634166|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
16634167|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
16634168|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
16634169|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
16634171|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
16634172|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
16634173|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
16634174|NCT02387242|Experimental|Group 1|10mg/kg Rifampicin
16634175|NCT02387242|Experimental|Group 2|20mg/kg Rifampicin
16634176|NCT02387242|Experimental|Group 3|30mg/kg Rifampicin
16634177|NCT02387229|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg, orally, once daily, preferably at the same time of the day throughout the study.
16634178|NCT02387229|Active Comparator|standard of care|standard of care
16634179|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
16634180|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
16634181|NCT02387203|Experimental|PrevPac|"Study intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)twice daily x 14 days for 2 courses (preoperative and post-operative).
~All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac.
~After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5."
16634182|NCT02387203|No Intervention|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
16634183|NCT02387190|Experimental|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
16634184|NCT02387190|No Intervention|Control group|Placebo is considered as standardized education
16634185|NCT02387177|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
16634186|NCT02387177|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
16634187|NCT02387164|Experimental|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
16634188|NCT02387164|Placebo Comparator|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
16634189|NCT02387151|Experimental|mesenchymal stromal cells|allogeneic mesenchymal stromal cell infusion
16634190|NCT02387138|Experimental|SIRINOX|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.
~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).
~Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle G-csf : d8 to d13 systematically"
16634191|NCT02387125|Experimental|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
16634192|NCT02387125|Experimental|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
16634193|NCT02387112|Experimental|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
16634194|NCT02387112|No Intervention|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
16634195|NCT02387099|Active Comparator|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)
~+ further treatment according to standard of care"
16634196|NCT02387099|Experimental|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)
~+ further treatment according to standard of care"
16634197|NCT02387086|Experimental|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
16634759|NCT02383212|Experimental|Monotherapy Cohort|Cemiplimab will be administered alone
16634198|NCT02387086|Placebo Comparator|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
16634199|NCT02387073||Electrical version|Electrical version patient reported outcome questionnaire was used for patients who had filled-up same questionnaire in a paper version
16634200|NCT02387060|Experimental|H-Bupivacaine 11.5 mg + fentanyl 25 mcg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75% plus fentanyl 25 mcg.
16634201|NCT02387060|Active Comparator|H-Bupivacaine 11.5 mg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75%
16634202|NCT02387034|Experimental|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
16634203|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
16634204|NCT02387021|Active Comparator|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
16634205|NCT02387021|Experimental|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
16634206|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
16634207|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
16634208|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
16634209|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
16634210|NCT02386982|Experimental|HMS5552 dose 1|HMS5552 75mg.Oral administration,twice per day.
16634211|NCT02386982|Experimental|HMS5552 dose 2|HMS5552 75mg.Oral administration,once per day.
16634212|NCT02386969|Experimental|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
16634213|NCT02386969|Experimental|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
16634214|NCT02386956|Experimental|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
16634215|NCT02386956|Experimental|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
16634216|NCT02386956|Placebo Comparator|Control|10 minutes with the patient lying on a machine off of magnetotherapy
16634217|NCT02386943|Experimental|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
16634218|NCT02386943|Experimental|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
16634219|NCT02386943|Experimental|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
16634220|NCT02386930|Experimental|Behavrioal Lifestyle modification|
16634221|NCT02386930|No Intervention|Control|
16634222|NCT02386917|Active Comparator|Gastric bypass|40 patients will undergo gastric bypass
16634223|NCT02386917|Active Comparator|Very low calorie diet|40 patients will undergo a very low calorie diet
16634224|NCT02386917|No Intervention|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
16634225|NCT02386904|Experimental|Phosphate Enema|Phosphate Enema consisting on Monobasic Sodium Phosphate (USP) 19.2 gm /120 ml and Dibasic Sodium Phosphate (USP) 7.2 gm/120 ml Dosage Form: Enema Frequency: One time; 30 minutes before Sigmoidoscopy
16634226|NCT02386891|Experimental|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
16634227|NCT02386891|Experimental|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
16634228|NCT02386878|Experimental|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
16634229|NCT02386878|Experimental|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
16634230|NCT02386878|Experimental|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
16634231|NCT02386878|No Intervention|No Intervention|No intervention
16634232|NCT02386852|Experimental|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
16634233|NCT02386852|Experimental|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
16634234|NCT02386852|Experimental|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
16634235|NCT02386839|Experimental|All Participants|Participants who were treated with rhIGF-1/rhIGFBP-3 and standard neonatal care in study ROPP-2008-01 (NCT01096784) will be enrolled to this study for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes versus standard neonatal care up to 5.5 years.
16634260|NCT02386644|Experimental|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
16634236|NCT02386826|Experimental|INC280 + Bevacizumab|"Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.
~Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:
~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.
~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
16634237|NCT02386813||Training cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;
~Patients treated with non-anthracycline based therapy as an initial treatment."
16634238|NCT02386813||Validation cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;
~Patients treated with non-anthracycline based therapy as an initial treatment."
16634239|NCT02386800|Experimental|ruxolitinib monotherapy|ruxolitinib monotherapy. Patients are to use the study treatment based on the parent protocol.
16634240|NCT02386800|Experimental|combination of ruxolitinib + panobinostat|combination of ruxolitinib and panobinostat. Patients are to use the study treatment based on the parent protocol.
16634241|NCT02386787|Experimental|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
16634242|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
16634243|NCT02386774|Other|diabetic patients|
16634244|NCT02386761|Experimental|Single Ascending Dose (SAD)|"Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg
~Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg
~Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.
~In case the actual doses are modified, the number of inhalations will be adapted accordingly."
16634245|NCT02386761|Experimental|Multiple Ascending Dose (MAD)|"Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo
~Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo
~Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo
~Duration 14 days b.i.d."
16634246|NCT02386748|Experimental|Chewing gum|Chewing sugarless gum
16634247|NCT02386748|Active Comparator|Oral fluids|Clear oral fluids
16634248|NCT02386748|Other|Intravenous fluids|No chewing gum No oral fluids Only intravenous fluids (Lactated Ringer's solution)
16634249|NCT02386735|Experimental|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
16634250|NCT02386735|Active Comparator|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
16634251|NCT02386722|Experimental|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
16634252|NCT02386722|No Intervention|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
16634253|NCT02386709|Experimental|Experimental Arm|"Diagnostic
~PET1 : before the neoadjuvant treatment
~start neoadjuvant treatment
~PET2: two weeks after the start of the first course of chemotherapy
~surgery"
16634254|NCT02386696|Experimental|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:
~Apnea;
~Spontaneous regular breathing;
~Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;
~Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;
~Hyperventilation."
16634255|NCT02386683|Active Comparator|Group L|lung-protective ventilation applied in anesthesia
16634256|NCT02386683|No Intervention|Group T|traditional ventilation applied in anesthesia
16634257|NCT02386670|Experimental|tDCS + CR|"Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session.
~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions promotes transfer of cognitive gains to everyday tasks.
~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
16634258|NCT02386670|Sham Comparator|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.
~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.
~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
16634259|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
16634262|NCT02386618|Other|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
16634263|NCT02386605|Experimental|Treatment|Motivational Interviewing Treatment group
16634264|NCT02386605|Active Comparator|Control|Relaxation Skills Training group
16634265|NCT02386592|Experimental|Intervention|Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text
16634266|NCT02386579||Diabetics with Charcot foot|
16634267|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
16634268|NCT02386553|Experimental|Nusinersen|Nusinersen administered as an intrathecal injection
16634269|NCT02386540|Experimental|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
16634270|NCT02386540|No Intervention|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
16634271|NCT02386501|Experimental|ADXS31-164|Dose/Potency 5 x 108 CFU; 1 x 109 CFU; 5 x 109 CFU; 1 x 1010 CFU
16634272|NCT02386488|Experimental|Vortioxetine 10 mg single dose|8 men and 8 women
16634273|NCT02386488|Experimental|Vortioxetine 20 mg single dose|8 men and 8 women
16634274|NCT02386488|Experimental|Vortioxetine 10 mg multiple dose|8 men and 8 women
16634275|NCT02386488|Experimental|Vortioxetine 20 mg multiple dose|8 men and 8 women
16634276|NCT02386475|Placebo Comparator|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
16634277|NCT02386475|Active Comparator|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
16634278|NCT02386475|Active Comparator|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
16634279|NCT02386475|Active Comparator|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
16634280|NCT02386462|Experimental|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
16634281|NCT02386449|Experimental|Picoprep|sodium picosulfate, magnesium oxide and citric acid
16634282|NCT02386449|Active Comparator|Mannitol and Bisacodyl|
16634283|NCT02386436|Experimental|Cohort 1- GSK2330811(0.1 mg/kg)|Subjects will be randomised to receive either 0.1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
16634284|NCT02386436|Experimental|Cohort 2- GSK2330811(0.3 mg/kg)|Subjects will be randomised to receive either 0.3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
16634285|NCT02386436|Experimental|Cohort 3- GSK2330811(1 mg/kg)|Subjects will be randomised to receive either 1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
16634286|NCT02386436|Experimental|Cohort 4- GSK2330811(3 mg/kg)|Subjects will be randomised to receive either 3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
16634287|NCT02386436|Experimental|Cohort 5- GSK2330811(6 mg/kg)|Subjects will be randomised to receive either 6 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
16634288|NCT02386423|Experimental|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
16634289|NCT02386410|Experimental|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
16634290|NCT02386410|Experimental|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
16634291|NCT02386410|No Intervention|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
16634292|NCT02386397|Experimental|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8
~Gemcitabine 900 mg/m² IV in 30 minutes
~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
16634293|NCT02386397|Other|Standard treatment|"mGEMOX: infusion on days 1 and 8
~Gemcitabine 900 mg/m² IV in 30 minutes
~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
16634294|NCT02386384||Control|Normal fertile
16634295|NCT02386384||Implantation Failure|Failure to conceive
16634296|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
16634297|NCT02386371|Experimental|surgery and Intra Operative Radiotherapy|"Surgery :
~Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.
~Intra Operative Radiotherapy (IORT):
~After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure."
16634298|NCT02386358|Active Comparator|Benznidazole|Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
16634299|NCT02386358|Placebo Comparator|Placebo|Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
16634329|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
16634823|NCT02382796|Experimental|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
16634300|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
16634301|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
16634302|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.
~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
16634303|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
16634304|NCT02386306|Experimental|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
16634305|NCT02386306|Placebo Comparator|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
16634306|NCT02386306|Experimental|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
16634307|NCT02386306|Placebo Comparator|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
16634308|NCT02386306|Experimental|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
16634309|NCT02386306|Placebo Comparator|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
16634310|NCT02386293|Placebo Comparator|Placebo|Sugar pill identical to Avapro provided for 7 day prescription
16634311|NCT02386293|Active Comparator|Irbesartan|150 mg of Avapro once daily for 7 days.
16634312|NCT02386280|Experimental|Motivational Interviewing for Change of Parenting Styles|After measured parental style across the scale, the motivational interviewing will be applied in order to modify the parenting styles of risk for involvement with drug use and maintenance of protective factors. This approach will occur in 5 segments .
16634313|NCT02386280|Sham Comparator|Psicoeducation|General information about drugs and ways of prevention
16634314|NCT02386267|Experimental|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
16634315|NCT02386215|Experimental|HIV Self-test|Following a baseline interview, participants in the intervention group will be shown how to correctly use the self-tests and given two HIV self-tests. Subsequently, we will contact participants periodically over a 3 month period to see if they have used the test(s) with their sexual partners and conduct a follow-up interview.
16634316|NCT02386215|No Intervention|Control|Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling & Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
16634317|NCT02386202||Patients with hemorrhagic stroke|All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
16634318|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
16634319|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
16634320|NCT02386150|Experimental|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
16634321|NCT02386150|Experimental|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
16634322|NCT02386137|Experimental|Patient|Woman aged more than 18 years having one or two symptomatic fibroid with size < 15cm.
16634323|NCT02386124|Other|frailty evaluation|"all consecutive patients admitted to hospital for acute cardiac disease aged more than 69 years will be evaluated with Short Portable Mental Status Questionnaire (SPMSQ), handgrip and Short Physical Performance Battery (SPPB).
~These three tests (SPMSQ, SPPB and handgrip) are the intervention of the study. They are the assays to establish the frailty status"
16634324|NCT02386111|Experimental|Varlilumab and Sunitinib|
16634325|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
16634326|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
16634327|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
16634328|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
16634330|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
16634331|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
16634332|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
16634333|NCT02386059|Placebo Comparator|PLACEBO Group|Received normal saline
16634334|NCT02386059|Active Comparator|DEXAMETHASONE Group|Received 4 mg Dexamethasone.
16634335|NCT02386059|Active Comparator|ONDANSETRON|Received 4 mg Ondansetron
16634336|NCT02386059|Active Comparator|DEXAMETHASONE + ONDANSETRON|Received 4mg Dexamethasone + 4mg Ondansetron
16634337|NCT02386046||Reference Group|Late preterm infants without any pathology. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
16634338|NCT02386046||Study Group|Infants born 26-35 weeks requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital before and after caffeine instituted, and weekly thereafter until 46 weeks postconceptional age.
16634339|NCT02386046||Control Group|Infants born 26-35 weeks not requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
16634340|NCT02386033|Placebo Comparator|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
16634341|NCT02386033|Active Comparator|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
16634342|NCT02386020|Placebo Comparator|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
16634343|NCT02386020|Active Comparator|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
16634344|NCT02386007|Experimental|DW-3101_150mg|150mg a day
16634345|NCT02386007|Experimental|DW-3101_300mg|300mg a day
16634346|NCT02386007|Experimental|DW-3101_600mg|600mg a day
16634347|NCT02386007|Placebo Comparator|a tablet same as experimental agents in formation and shape|Placebo
16634348|NCT02385994|Experimental|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
16634349|NCT02385994|No Intervention|Control|Melasma subjects randomized to non-treatment will receive no treatments.
16634350|NCT02385981|Experimental|Stivax|an intermittent stimulation of afferent vagus nerve at earlap
16634351|NCT02385955|Experimental|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
16634352|NCT02385942|Other|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
16634353|NCT02385929|Experimental|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.
~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
16634354|NCT02385929|No Intervention|Standard Care|Patients in this arm are randomized to usual care / control group
16634355|NCT02385916|Experimental|EstroSense®/MD|3 capsules per day during the study period
16634356|NCT02385916|Placebo Comparator|Placebo|3 capsules per day during the study period
16634357|NCT02385903|Other|Standard dressing procedure|One arm receive standard dressing procedure according to the wound
16634358|NCT02385903|Active Comparator|Flammacerium|"Necrosis covering with Flammacerium 3 mm thick each day during one week then one day on two.
~On each dressing, remove excess and add flammacerium. Not to remove crust forming until eliminating furrow appears.
~Cover Flammacerium by compress."
16634359|NCT02385890|Experimental|Bagel control|100% wheat flour
16634360|NCT02385890|Experimental|Bagel with pea flour|Pea flour
16634361|NCT02385890|Experimental|Bagel with pea fibre|Pea fibre
16634362|NCT02385890|Experimental|Bagel with pea protein|Pea protein
16634363|NCT02385890|Experimental|Bagel with pea flour + pea protein|Pea flour + pea protein
16634364|NCT02385890|Experimental|Bagel with pea fibre + pea protein|Pea fibre + pea protein
16634365|NCT02385877|Experimental|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
16634366|NCT02385877|Experimental|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
16634367|NCT02385877|Experimental|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
16634368|NCT02385851|Experimental|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
16634369|NCT02385851|Experimental|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
16634370|NCT02385838|Experimental|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
16634371|NCT02385838|Experimental|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
16634372|NCT02385838|Experimental|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
16634373|NCT02385838|Experimental|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
16634374|NCT02385838|No Intervention|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
16634375|NCT02385825|Experimental|Group 1: 10 μg RVEc|10 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
16634376|NCT02385825|Experimental|Group 2: 50 μg RVEc|50 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
16634377|NCT02385825|Experimental|Group 3: 75 μg RVEc|75 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
16634378|NCT02385812|Experimental|High lung cancer risk|Individuals with lung cancer risk >= 1.5% over 6 years
16634379|NCT02385812|Experimental|Low lung cancer risk|Individuals with lung cancer risk <1.5% over 6 years
16634380|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
16634381|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
16634382|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
16634383|NCT02385773|Experimental|PTM202|PTM202
16634384|NCT02385773|Placebo Comparator|Enfamil Puramino|Formal Placebo
16634385|NCT02385760|Experimental|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
16634386|NCT02385760|Placebo Comparator|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
16634387|NCT02385747|Experimental|women with anbormal bleeding|women with perimenopausal and postmenopausal bleeding who will be evaluated with transvaginal ultrasound, saline sonohysterography,hystroscopy and endometrial currettage
16634388|NCT02385734|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
16634389|NCT02385734|Active Comparator|Coronally Advanced Flap|Periodontal plastic surgery procedure in the treatment of gingival recession
16634390|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
16634391|NCT02385708|Active Comparator|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
16634392|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
16634393|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
16634394|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
16634395|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
16634396|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.
~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
16634397|NCT02385656|Experimental|Intervention group|Subjects who take modafinil for cancer-related fatigue for 4 weeks.
16634398|NCT02385643|Experimental|Intervention group|This group of subjects receives mobile support system and conventional treatment
16634399|NCT02385643|No Intervention|Control group|This group of patients receive conventional treatment only
16634400|NCT02385630|Experimental|Esophagectomy|"Serial assessment:
~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
16634401|NCT02385630|Experimental|Gastrectomy|"Serial assessment:
~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
16634402|NCT02385617|Experimental|Esophagectomy|Double blind single dose placebo-octreotide crossover
16634403|NCT02385617|Experimental|Total gastrectomy|Double blind single dose placebo-octreotide crossover
16634404|NCT02385617|Active Comparator|Control - no surgery|Double blind single dose placebo-octreotide crossover
16634405|NCT02385617|Experimental|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
16634406|NCT02385591|Experimental|Telephone Support|Participants will receive bi-weekly 20 minute telephone calls from a trained professional facilitator offering physical activity advice with the goal of increasing moderate-to-vigorous intensity physical activity.
16634407|NCT02385591|Experimental|SMS Support|Participants will receive weekly text messages (3-5 text messages per week) offering physical activity advice with the aim of increasing moderate-to-vigorous intensity physical activity.
16634408|NCT02385591|Active Comparator|Attention-control|Participants will receive telephone-based general nutrition advice.
16634409|NCT02385578|No Intervention|The control group|no intervention
16634410|NCT02385578|Experimental|The experimental group|an educational intervention
16634411|NCT02385565|Experimental|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
16634412|NCT02385565|Placebo Comparator|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
16634413|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
16634451|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
16634452|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
16634453|NCT02385305|Other|Pressure support ventilation|Usual anesthesia management
16634414|NCT02385539|Active Comparator|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
16634415|NCT02385539|Active Comparator|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
16634416|NCT02385539|Placebo Comparator|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.
~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
16634417|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
16634418|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
16634419|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
16634420|NCT02385513|Active Comparator|6 + 10 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
16634421|NCT02385513|Active Comparator|6 + 14 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule
16634422|NCT02385500|Placebo Comparator|Placebo|Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
16634423|NCT02385500|Experimental|Fesoterodine|Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
16634424|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
16634425|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
16634426|NCT02385474|Experimental|38% SDF semi-annual|semi-annual application of 38% SDF
16634427|NCT02385474|Experimental|38% SDF annual|annual application of 38% SDF
16634428|NCT02385474|Active Comparator|12% SDF semi-annual|semi-annual application of 12% SDF
16634429|NCT02385474|Active Comparator|12% SDF annual|annual application of 12% SDF
16634430|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
16634431|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
16634432|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
16634433|NCT02385448|Experimental|Dienogest|
16634434|NCT02385448|Active Comparator|Combined oral contraceptive pills|
16634435|NCT02385435|Active Comparator|Bupivacaine|single shot caudal plain bupivacaine at a dose of 2mg/kg is used as a reference control drug.
16634436|NCT02385435|Active Comparator|dexmedetomidine 1μg.kg-1|Single shot Caudal dexmedetomidine 1μg.kg-1 used as the second arm intervention
16634437|NCT02385435|Active Comparator|dexmedetomidine 2μg.kg-1|Single shot Caudal dexmedetomidine 2 μg.kg-1 used as the second arm intervention
16634438|NCT02385422|Experimental|Carvedilol|Carvedilol，6.25mg-25mg/d,oral,6 months
16634439|NCT02385422|Active Comparator|Propranolol|Propranolol,30mg-160mg/d,oral,6 months
16634440|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
16634441|NCT02385396|Placebo Comparator|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
16634442|NCT02385396|Experimental|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
16634443|NCT02385396|Placebo Comparator|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
16634444|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
16634445|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
16634446|NCT02385370|Active Comparator|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
16634447|NCT02385370|Active Comparator|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
16634448|NCT02385357|Placebo Comparator|Control|330 ml of commercial protein-enriched drink (2.5 g/100 ml of protein)
16634449|NCT02385357|Experimental|Experimental|330 ml of protein-enriched drink (6 g/100 ml of protein)
16634450|NCT02385318|Experimental|Test Product|Ingenol Mebutate
16634456|NCT02385279|Experimental|MiStent®|Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
16634457|NCT02385279|Active Comparator|XIENCE EES|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
16634458|NCT02385266|Experimental|D-Cycloserine and Acetominophen|D-cycloserine 200mg/bid and Acetaminophen prn
16634459|NCT02385266|Placebo Comparator|Placebo and Acetominophen|Placebo capsules (lactose)/bid and Acetaminophen prn
16634460|NCT02385253|Active Comparator|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
16634461|NCT02385253|No Intervention|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
16634465|NCT02385227|Experimental|Cohort A1|Exclusive blu™ e-cigarette A1
16634466|NCT02385227|Experimental|Cohort A2|Exclusive blu™ e-cigarette A2
16634467|NCT02385227|Experimental|Cohort A3|Exclusive blu™ e-cigarette A3
16634468|NCT02385227|Experimental|Cohort B1|Dual blu™ e-cigarette and usual brand B1
16634469|NCT02385227|Experimental|Cohort B2|Dual blu™ e-cigarette and usual brand B2
16634470|NCT02385227|Experimental|Cohort B3|Dual blu™ e-cigarette and usual brand B3
16634471|NCT02385227|Experimental|Cohort C|Nicotine product cessation C
16634472|NCT02385214|Experimental|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy
~+/- Reconstruction"
16634473|NCT02385214|Active Comparator|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy
~+/- Reconstruction"
16634474|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
16634475|NCT02385188|Experimental|Imiquimod|Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.
16634476|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
16634477|NCT02385162||Observation|Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease
16634478|NCT02385149|Experimental|whole grain wheat|98g whole grain wheat per day for 12 weeks
16634479|NCT02385149|Experimental|refined wheat|coloured refined wheat control intervention
16634480|NCT02385136|Experimental|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
16634481|NCT02385136|No Intervention|WBRT|whole brain radiotherapy (WBRT)
16634482|NCT02385123|Experimental|Seasonal flu vaccine|0.5 ml of seasonal inactivated influenza vaccine (IIV) will be administered intramuscularly (IM) on day 0 of each study season. The study will enroll 10 subjects each season, in years 1, 2, 4 ,5, and 6 of the study for a total of n=50.
16634483|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
~Dexamethasone by vein on Days 1-7 of the induction phase.
~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week during the maintenance phase. Participants who have evidence of budding relapse during the maintenance phase may revert back to receiving Etoposide.
~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
16634484|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2 of the Induction phase. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week during the maintenance phase.
~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
16634485|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
16634486|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
16634487|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
16634488|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
16634489|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
16634490|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
16634491|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
16634558|NCT02384655|Experimental|Fenugreek|Mothers will take fenugreek for 14 days
16634875|NCT02382445|Sham Comparator|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
16634492|NCT02385071|Experimental|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3*50 mg capsules of SMV [including 50 mini-tablets of 1 mg each] with water under fed conditions) in Period 2; followed by Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634493|NCT02385071|Experimental|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634494|NCT02385071|Experimental|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634495|NCT02385071|Experimental|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634496|NCT02385071|Experimental|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634497|NCT02385071|Experimental|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634498|NCT02385071|Experimental|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634499|NCT02385071|Experimental|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634500|NCT02385071|Experimental|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634501|NCT02385071|Experimental|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634502|NCT02385071|Experimental|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634503|NCT02385071|Experimental|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16634504|NCT02385058|Experimental|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
16634505|NCT02385058|Experimental|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
16634506|NCT02385045|Placebo Comparator|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
16634507|NCT02385045|Experimental|i-scan imaging|i-scan imaging (Pentax endoscopes)
16634508|NCT02385032|Experimental|AB|Ursodiol followed by URSO Forte
16634509|NCT02385032|Experimental|BA|URSO Forte followed by Ursodiol
16634510|NCT02385019|Experimental|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
16634511|NCT02385019|Experimental|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
16634512|NCT02385019|Experimental|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
16634513|NCT02385019|Experimental|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
16634514|NCT02385006|Other|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
16634515|NCT02385006|Other|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
16634516|NCT02384993|Experimental|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
16634517|NCT02384993|No Intervention|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise & Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
16634876|NCT02382432|Active Comparator|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
16634518|NCT02384980|No Intervention|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
16634519|NCT02384980|Experimental|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
16634520|NCT02384967|Experimental|Darunavir 400mg/d|Tri-therapy containing Darunavir at dose of 400 mg/d.
16634521|NCT02384954|Experimental|Phase I/II ALT-803 w/rituximab for rel/ref iNHL|
16634522|NCT02384941|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
16634523|NCT02384941|Experimental|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
16634524|NCT02384941|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
16634525|NCT02384928|Experimental|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
16634526|NCT02384928|Active Comparator|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
16634527|NCT02384928|Active Comparator|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
16634528|NCT02384915|Experimental|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
16634529|NCT02384915|Active Comparator|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
16634530|NCT02384902|Experimental|low GI|low GI: participants were asked to consume low GI foods (GI<55) in abundant, medium GI in moderate and high GI (GI>70) rarely.
16634531|NCT02384902|Experimental|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
16634532|NCT02384902|Experimental|conventional diet|conventional diet: all carbohydrate were treated as the same.
16634533|NCT02384889|Experimental|Difluoromethylornithine|Subjects may be given daily dose of DFMO
16634534|NCT02384889|Placebo Comparator|Placebo|Subjects may be given daily dose of placebo
16634535|NCT02384876|Experimental|Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Dose escalation: 6 successive cohorts with a maximal increasing dose
16634536|NCT02384876|Active Comparator|Ephedrine, dose : 0.1 mg/kG, reference dose|Reference dose
16634537|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
16634538|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (>=1)
16634539|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
16634540|NCT02384811|Experimental|Radiation group|Radiation therapy
16634541|NCT02384798|Experimental|ventilatory support|noninvasive ventilatory support to 5cmH2O used before the session of interval training and resistance exercises performed three times a week for 12 weeks
16634542|NCT02384798|Active Comparator|interval training|sessions of interval training and resistance exercises performed three times a week for 12 weeks
16634543|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.
~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
16634544|NCT02384759|Experimental|A|Aflibercept + LV5FU2
16634545|NCT02384759|Active Comparator|B|LV5FU2
16634546|NCT02384746|Experimental|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
16634547|NCT02384733|Experimental|Hypofractionated loco-regional RT|40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly
16634548|NCT02384733|Active Comparator|Normofractionated loco-regional RT|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
16634549|NCT02384720||A|Gender: 10 Males, 10 Females
16634550|NCT02384720||B|Gender: 10 Males, 10 Females
16634551|NCT02384720||C|Gender: 10 Males, 10 Females
16634552|NCT02384707|Experimental|allergic food|"Reintroduction procedure for small doses :
~Administration of the first dose the first dose must be allergic food or placebo
~Clinical monitoring for 45 minutes
~Administration of the second dose"
16634553|NCT02384694|Experimental|Intervention|Zumba dance intervention
16634554|NCT02384681||Exposed|Medical regulation assistants working with headset
16634555|NCT02384681||Non-Exposed|Participants working without headset
16634556|NCT02384668|Active Comparator|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
16634557|NCT02384668|Placebo Comparator|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
~The placebo regimen is identical to the vitamin D3 regimen."
16634559|NCT02384642|Active Comparator|COMPASS|The COMPASS program will involve a structured intervention for girls between the ages of 10-14 that is intended to engage adolescent girls, those who are influential in their lives, service providers and other stakeholders, with the ultimate goal of co-creating environments in which girls are valued and safe. The program is centered on establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
16634560|NCT02384642|Experimental|COMPASS plus parenting|In the COMPASS plus parenting intervention arm, girls will receive the COMPASS intervention, and In addition to the safe spaces for girls, the COMPASS project will also implement structured activities for the parents and caregivers of participants. The study will examine the relative impact of the parenting initiative in addition to the program for adolescent girls. The study will seek to determine whether the structured intervention with girls' parents has an added impact on outcomes improve girls' safety and well-being.
16634561|NCT02384629|Experimental|AXXESS stent1|AXXESS stent (OCT-guided)
16634562|NCT02384629|Experimental|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
16634563|NCT02384629|Active Comparator|AXXESS stent2|AXXESS stent (Angio-guided)
16634564|NCT02384629|Active Comparator|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
16634565|NCT02384616|Active Comparator|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
16634566|NCT02384616|Active Comparator|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
16634567|NCT02384603|Experimental|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
16634568|NCT02384603|Active Comparator|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
16634569|NCT02384590|Experimental|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
16634570|NCT02384590|No Intervention|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
16634571|NCT02384577||Single group prospective treatment|
16634572|NCT02384564|Experimental|Ambu King Vision Video Laryngoscope aBlade System|The trachea will be intubated using the Ambu King Vision Video Laryngoscope with the appropriate sized blade (size 1 or 2) based on manufacturer guidelines and clinical judgement.
16634573|NCT02384564|Active Comparator|Direct Laryngoscope|The trachea will be intubated via direct laryngoscopy using a traditional straight blade laryngoscope, with appropriately sized blade based on manufacturer guidelines and clinical judgement.
16634578|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
16634579|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
16634580|NCT02384525|Experimental|clinical-based ultrafiltration|
16634581|NCT02384525|Active Comparator|BIA-based ultrafiltration|
16634582|NCT02384499|Experimental|ALLO-ASC group|Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
16634583|NCT02384499|Placebo Comparator|Normal saline group|0.9% normal saline with fibrin glue injection to the anal sphincter
16634584|NCT02384486|Experimental|intervention group|"intervention group will receive the Training to Reduce Stress in Mothers of Children with (ASD)"
16634585|NCT02384486|Other|control group|control group will receive nothing but for ethical purposes will receive the same intervention after the end of the trial for the intervention group
16634586|NCT02384473|Experimental|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
16634587|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
16634588|NCT02384460|Placebo Comparator|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
16634589|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
16634590|NCT02384434|Other|Single Arm|Low Level Laser Therapy
16634591|NCT02384421|Experimental|Activa PC+S Neurostimulator|Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool
16634592|NCT02384408|Placebo Comparator|Control|Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
16634909|NCT02382198|Active Comparator|Active Group|This arm will receive the study drug glycopyrrolate.
16634593|NCT02384408|Experimental|Hormone treatment|"Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.
~Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.
~Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study"
16634594|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
16634595|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
16634596|NCT02384369|Experimental|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
16634597|NCT02384369|Placebo Comparator|Placebo|Placebo tablet for oral administration, BID for 8 weeks
16634598|NCT02384343|Active Comparator|Dexmedetomidine|Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
16634599|NCT02384343|Placebo Comparator|Normal saline|NaCl 0,9% 7,5 ml, single intravenous bolus
16634600|NCT02384330||Dysport® (abobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
16634601|NCT02384330||Botox® (onabotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
16634602|NCT02384330||Xeomin® (incobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
16634603|NCT02384317|Experimental|CCX168|BID for 84 days
16634604|NCT02384304|Experimental|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
16634605|NCT02384304|Experimental|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
16634606|NCT02384304|Active Comparator|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
16634607|NCT02384291|Experimental|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
16634608|NCT02384291|Active Comparator|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
16634609|NCT02384278|Experimental|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
16634610|NCT02384265|Experimental|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
16634611|NCT02384265|No Intervention|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
16634612|NCT02384252||obese patients|patients with BMI > 30
16634613|NCT02384252||no obese patients|norma weight patient (BMI<25) overweight patients ( 25< BMI >30)
16634614|NCT02384239|Experimental|Palbociclib 100mg|Treatment arm palbociclib dose 100mg + fulvestrant or tamoxifen
16634615|NCT02384239|Experimental|Palbociclib 125mg|Treatment arm palbociclib dose 125mg + fulvestrant or tamoxifen
16634616|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).
~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
16634617|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
16634618|NCT02384187|Placebo Comparator|Group C|Patients in this group will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
16634619|NCT02384187|Experimental|Group GAB|Patients in this group will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
16634620|NCT02384174|Experimental|Resistant starch (RS)|Resistant starch (RS3)
16634621|NCT02384174|Experimental|Dietary fibre|Dietary fibre (Arabinogalactan, gum guar, pectin)
16634622|NCT02384161|Experimental|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
16634623|NCT02384161|Experimental|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
16634624|NCT02384161|Placebo Comparator|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
16634625|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
16634626|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
16634627|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
16634628|NCT02384148||obese|Obese non diabetic patients with HbA1c<6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
16634629|NCT02384135|Other|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
16634630|NCT02384122|Active Comparator|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
16634631|NCT02384122|No Intervention|Standard of care|Patients receive standard of care without a placebo.
16634632|NCT02384109|Experimental|Intervention|Pharmacist-coordinated shared decision making about treatment for pre-diabetes (lifestyle change and/or metformin), using a decision tool
16634633|NCT02384109|Placebo Comparator|Usual Care|Usual care for patients with a diagnosis of pre-diabetes
16634634|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
16634635|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
16634636|NCT02384083|Experimental|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22
16634637|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
16634638|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
16634639|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
16634640|NCT02384057|Experimental|C8 sciences|cognitive rehabilitation with C8 sciences
16634641|NCT02384057|Active Comparator|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
16634642|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
16634643|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
16634644|NCT02384031|Active Comparator|Traumatic group|Traumatic needle
16634645|NCT02384031|Active Comparator|Atraumatic group|Atraumatic needle
16634646|NCT02384018|No Intervention|Control|Patients will receive standard islet transplantation.
16634647|NCT02384018|Experimental|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
16634648|NCT02384005|Other|Self-anal exam arm|Study only has one arm.
16634649|NCT02383992|Active Comparator|Hydrogen Peroxide|Post-operative wound will be treated with 3% H2O2 solution, Subjects will also clean the sutured wounds with 3% H2O2 solution or twice daily then dress the wounds with petroleum jelly and a bandage.
16634650|NCT02383992|Active Comparator|Saline|Post-operative wound will be treated with 0.9% normal saline. Subjects will also clean the sutured wounds with normal saline twice daily then dress the wounds with petroleum jelly and a bandage.
16634651|NCT02383979|Sham Comparator|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
16634652|NCT02383979|Experimental|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
16634653|NCT02383979|No Intervention|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
16634654|NCT02383966|Experimental|Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil|
16634655|NCT02383966|Active Comparator|Cisplatin/Carboplatin + 5-Flurouracil|
16634656|NCT02383940|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
16634657|NCT02383940|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
16634658|NCT02383927|Experimental|Cohort 1|Thyroid Cancer
16634659|NCT02383927|Experimental|Cohort 2|Squamous Head and Neck Cancer
16634660|NCT02383914||Subscapularis rupture|
16634661|NCT02383888|Placebo Comparator|Matching placebo for each dose groups|
16634662|NCT02383888|Experimental|BI 425809 Active dose group 1|
16634663|NCT02383888|Experimental|BI 425809 Active dose group 2|
16634664|NCT02383888|Experimental|Bi 425809 Active dose group 3|
16634760|NCT02383212|Experimental|Dual Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy
~Doses of cemiplimab will be administered in combination with Cyclophosphamide
~Doses of cemiplimab will be administered in combination with Docetaxel"
16634665|NCT02383875|Experimental|Opticourses education intervention|People living in the northern districts of Marseille with in very deprived social situation: very low incomes, heavy financial dependence on social benefits, over-representation of people covered by arrangements for controlling poverty and people covered by free social security
16634666|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
16634667|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
16634668|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
16634669|NCT02383849||Arm 2|Breastfeeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
16634670|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
16634671|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
16634672|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 4000 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
16634673|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
16634674|NCT02383823|Active Comparator|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
16634675|NCT02383823|No Intervention|Menopausal men|comparative to menopausal women, age span 45-55
16634676|NCT02383823|No Intervention|Elderly women|comparative to menopausal women, age span 65-80
16634677|NCT02383823|No Intervention|Elderly men|comparative to menopausal women, age span 65-80
16634678|NCT02383823|Placebo Comparator|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
16634679|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
16634680|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
16634681|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
16634682|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
16634683|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
16634684|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
16634685|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
16634686|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
16634687|NCT02383797|Experimental|Cartilage-hair hypoplasia (CHH)|Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
16634688|NCT02383784|Experimental|Low-GI diet|Low glycemic index diet
16634689|NCT02383784|Experimental|High-GI diet|High glycemic index diet
16634690|NCT02383771|Experimental|Single Anti-platelet Treatment|Ticagrelor
16634691|NCT02383771|Experimental|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
16634692|NCT02383771|Sham Comparator|Control|No Drug
16634693|NCT02383771|Other|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
16634694|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
16634726|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
16634695|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
16634696|NCT02383732|Experimental|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
16634697|NCT02383732|Active Comparator|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
16634698|NCT02383719|Experimental|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
16634699|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
16634700|NCT02383693|Active Comparator|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
16634701|NCT02383693|Sham Comparator|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
16634702|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
16634703|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
16634704|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.
~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
16634705|NCT02383654|Other|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
16634706|NCT02383641||Observation|Patients with Wolman disease or high-grade suspicion for Wolman disease
16634707|NCT02383615|Active Comparator|DTSNB|Distal transsartorial saphenous nerve block
16634708|NCT02383615|Active Comparator|ACSNB|Adductor canal saphenous nerve block
16634709|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
16634710|NCT02383589|Active Comparator|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
16634711|NCT02383589|Experimental|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
16634712|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
16634713|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
16634714|NCT02383563|Active Comparator|Metformin Treatment Arm|500 mg metformin Extended Release tablets - one tablet daily increased at 4 weeks to 2 tablets (1000 mg) daily.
16634715|NCT02383563|No Intervention|Observational Arm|Observation only
16634716|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
16634717|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
16634718|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
16634719|NCT02383511|Other|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
16634720|NCT02383511|Other|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
16634721|NCT02383511|Other|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
16634722|NCT02383498|Experimental|Vaccine|Radiation + GI-6301 Vaccine + Actigraph
16634723|NCT02383498|Placebo Comparator|Placebo|Radiation + GI-6301 Placebo + Actigraph
16634724|NCT02383485|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
16634725|NCT02383485|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
16634910|NCT02382198|Placebo Comparator|Placebo Group|Control arm to receive placebo
16634727|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
16634728|NCT02383446|Experimental|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
16634729|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16634730|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
16634731|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
16634732|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
16634733|NCT02383407|Experimental|Stimulation group 2 Hz|Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
16634734|NCT02383407|Experimental|Stimulation group 5 Hz|Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
16634735|NCT02383394||aborted women|women who got pregnant and have 2nd trimesteric abortion, follow up antenatal care by ultrasound and clinical monitoring
16634736|NCT02383394||continued women|women who got pregnant and completed her pregnancy follow up antenatal care by ultrasound and clinical monitoring
16634737|NCT02383368|Experimental|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:
~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
16634738|NCT02383368|Experimental|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
16634739|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
16634740|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
16634741|NCT02383329|Experimental|Oral Nutritional Supplement (ONS)|Diet consultation for the child/family + ONS
16634742|NCT02383329|No Intervention|No Oran Nutritional Supplement (ONS)|Diet consultation for the child/family
16634743|NCT02383316|Experimental|Noonan Syndrome Children|"Children with Noonan Syndrome will be compared with age- and sex-matched healthy children. We hypothesize than Noonan Syndrome children have an increased insulin sensitivity compared to GHD children.
~Study parameters will be collected including: clinical measurements (height, weight, body mass index, waist circumference, and blood pressure), glucose and insulin levels at baseline and after an oral glucose tolerance test (OGTT), body composition measured by dual-energy x-ray absorptiometry (DXA)."
16634744|NCT02383303|Experimental|Program|The program group is eligible to participate in the Individual Development Account savings program.
16634745|NCT02383303|No Intervention|Comparison|The comparison group cannot enter the Individual Development Account program.
16634746|NCT02383290|Experimental|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
16634747|NCT02383277|Experimental|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
16634748|NCT02383277|Sham Comparator|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
16634749|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
16634750|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
16634751|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :
~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.
~Then:
~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.
~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
16634752|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :
~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15
~every 28 days until progression of disease or toxicity"
16634753|NCT02383238|Active Comparator|Dapagliflozin|Dapagliflozin, 10 mg/day, oral administration, 6 weeks
16634754|NCT02383238|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
16634755|NCT02383225|Experimental|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
16634756|NCT02383225|Experimental|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
16634757|NCT02383225|Experimental|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
16634761|NCT02383212|Experimental|Triple Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide
~Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF
~Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel
~Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed
~Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel"
16634762|NCT02383212|Experimental|Quadruple Combination Cohorts|Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
16634763|NCT02383186|Active Comparator|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
16634764|NCT02383186|Active Comparator|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
16634765|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
16634766|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
16634767|NCT02383160|Active Comparator|Active LIPUS Unit|Low-intensity pulsed ultrasound treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
16634768|NCT02383160|Sham Comparator|Sham LIPUS Unit|Sham device treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
16634769|NCT02383147|Experimental|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
16634770|NCT02383147|Active Comparator|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
16634771|NCT02383121||No patients|Study has been withdrawn
16634772|NCT02383108|Active Comparator|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
16634773|NCT02383108|Experimental|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
16634774|NCT02383095|Experimental|Art-therapy|16 Art-therapy sessions
16634775|NCT02383095|Active Comparator|Metacognitive therapy|16 Metacognitive therapy sessions
16634776|NCT02383069|Experimental|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
16634777|NCT02383069|Active Comparator|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
16634778|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
16634779|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
16634780|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
16634781|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
16634782|NCT02383030|Experimental|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
16634783|NCT02383030|No Intervention|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
16634784|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
16634785|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
16634786|NCT02383004|Experimental|Acupuncture|"Same premedication, induction and maintenance protocol as the No Acupuncture (Standard of Care) group.
~The intervention will be placement of 4 acupuncture needles. The needles will be placed after inhalational anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the HT7 point and one in each ear at the shen men point."
16634787|NCT02383004|No Intervention|No Acupuncture (Standard of Care)|"If needed, the patient will receive a standard does of oral midazolam (0.5 mg /kg or less, up to 15mg) plus acetaminophen 12.5 mg/kg (V group). If the patient does not require premedication with midazolam, oral acetaminophen 12.5mg/kg will be given alone (NV group).
~Induction of anesthesia by mask ventilation with sevoflurane in 50% nitrous oxide mixed with 50% oxygen. Sevoflurane will be incrementally titrated from 0% up to 8%. Nitrous oxide will be discontinued after induction. Anesthesia will be maintained with sevoflurane in an oxygen/air mixture. Sevoflurane concentration will be titrated to maintain the adequate depth of anesthesia. Prior to leaving the operating room, a dose of ketorolac 0.5mg/kg will be given intramuscularly."
16634788|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
16634789|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
16634790|NCT02382978|Experimental|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
16634791|NCT02382965|Experimental|ultrasound|
16634792|NCT02382952|Experimental|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
16634793|NCT02382952|Active Comparator|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
16634794|NCT02382939|Experimental|somapacitan|
16634795|NCT02382939|Active Comparator|hGH (somatropin)|
16634796|NCT02382926|Experimental|contactless heart-, breathing rate, ECG|
16634797|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
16634798|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
16634799|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
16634800|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
16634801|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
16634802|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
16634803|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
16634804|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
16634805|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
16634806|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
16634807|NCT02382900|Experimental|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
16634808|NCT02382900|Active Comparator|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
16634809|NCT02382900|Active Comparator|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
16634810|NCT02382887|Active Comparator|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
16634811|NCT02382887|Experimental|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
16634812|NCT02382874|Experimental|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
16634813|NCT02382861|Experimental|NAVA group|Management of the difficult weaning from mechanical ventilation by the NAVA.
16634814|NCT02382861|Active Comparator|Control group|Conventional management of the difficult weaning from mechanical ventilation, with the pressure ventilation.
16634815|NCT02382848|Active Comparator|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
16634816|NCT02382848|Placebo Comparator|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
16634817|NCT02382835||Metal-on-Metal Hip Replacement|
16634818|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
16634819|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
16634820|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
16634821|NCT02382809|Experimental|DC071 (0.2% chlorhexidine digluconate)|
16634822|NCT02382809|Placebo Comparator|Placebo|
16634824|NCT02382783|Other|FLARE Intervention Group|"In the FLARE Intervention Group, we ask that you participate in all of the following, over the course of two years:
~Baseline Study Visit
~Monthly: Complete FLARE Questionnaires, at home, and report results. The last question on this questionnaire will ask you if you feel you are having a flare of your disease.
~FLARE Study Visit (if applicable): We will schedule you to be seen when/if you feel you are having a flare of your disease.
~Follow-up Visits (minimum of every 6 months): These are done as the standard of care for your RA.
~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound
~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year
~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
16634825|NCT02382783|No Intervention|Standard of Care (SOC) Group|"If you are randomized to the SOC Group, your care will not be any different than your usual care of rheumatoid arthritis (RA). You will be seen by a rheumatologist at a minimum of every six months, which is the standard of care for RA.
~Additionally (for research), we ask the following of you...
~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound
~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year
~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
16634826|NCT02382770||Open Abdomen patients|All patients underwent to open abdomen procedure
16634827|NCT02382757||Children|
16634828|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
16634829|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
16634830|NCT02382731|No Intervention|Usual care|Usual care (no intervention)
16634831|NCT02382731|Experimental|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
16634832|NCT02382731|Experimental|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
16634833|NCT02382718|Experimental|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.
~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.
~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
16634834|NCT02382718|Placebo Comparator|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
16634835|NCT02382679|Placebo Comparator|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
16634836|NCT02382679|Experimental|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
16634837|NCT02382666|Experimental|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
16634838|NCT02382666|Experimental|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
16634839|NCT02382666|Experimental|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
16634840|NCT02382666|Experimental|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
16634841|NCT02382666|Experimental|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
16634842|NCT02382666|Experimental|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
16634843|NCT02382653|Other|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
16634844|NCT02382653|No Intervention|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
16634845|NCT02382640|Experimental|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
16634846|NCT02382640|Experimental|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
16634877|NCT02382432|Active Comparator|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
16634908|NCT02382224|Placebo Comparator|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
16634847|NCT02382640|Experimental|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
16634848|NCT02382640|Experimental|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
16634849|NCT02382614|Experimental|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
16634850|NCT02382614|No Intervention|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
16634851|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
16634852|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
16634853|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
16634854|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
16634855|NCT02382575|Active Comparator|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
16634856|NCT02382575|Experimental|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
16634857|NCT02382562|Experimental|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
16634858|NCT02382549|Experimental|6MHP and dabrafenib and trametinib|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.
~Dabrafenib is a small molecular BRAF inhibitor and will be administered in accordance with the prescribing information: 150 mg orally twice daily taken at least 1 hour before or at least 2 hours after a meal; the doses will be approximately 12 hours apart. Trametinib is a small molecular MEK1 and MEK2 inhibitor and will be administered in accordance with the prescribing information: 2 mg orally once daily taken at least 1 hour before or at least 2 hours after a meal. The medication will be taken at the same time each day with either the morning or evening dose of dabrafenib."
16634859|NCT02382536||Infusion set|Each subject will receive a total of 4 simultaneous subcutaneous infusions of insulin diluent, two using the investigational device (BD Scarlett Infusion Set) and two using the the comparator (Medtronic QuickSet Infusion Set).
16634860|NCT02382523|Experimental|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
16634861|NCT02382523|Experimental|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
16634862|NCT02382510|Experimental|TRN-157|
16634863|NCT02382510|Placebo Comparator|Placebo|
16634864|NCT02382510|Active Comparator|Tiotropium|
16634865|NCT02382497|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
16634866|NCT02382497|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
16634867|NCT02382497|Experimental|BED Active tDCS|"Treatment as usual plus experimental treatment"
16634868|NCT02382497|Sham Comparator|BED Sham tDCS|"Treatment as usual plus placebo treatment"
16634869|NCT02382484|Experimental|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.
~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.
~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
16634870|NCT02382471|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
16634871|NCT02382471|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
16634872|NCT02382458|Experimental|Lifestyle intervention|Participants will receive a year-long comprehensive, dietary, exercise, and stress management intervention. They will be asked to bring a partner of their choosing with them for support. The intervention will include a behavioral program to reduce inflammation.
16634873|NCT02382458|Active Comparator|Information intervention|Participants will receive a year-long intervention that will involve receiving weekly (for the first 3 months) and then monthly (for the following 9 months) newsletters on cancer prevention and control (via e-mail or mail) that will provide the participant with information about cancer prevention and control strategies.
16634874|NCT02382445|Experimental|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
16634878|NCT02382432|Active Comparator|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
16634879|NCT02382432|Active Comparator|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
16634880|NCT02382419|Experimental|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
16634881|NCT02382419|Placebo Comparator|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
16634882|NCT02382406|Experimental|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles
~Phase I, Cohort 1 Maintenance Therapy:
~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.
~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
16634883|NCT02382406|Experimental|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).
~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.
~*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
16634884|NCT02382393|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) and then a third party validated assessment battery.
16634885|NCT02382393|Experimental|Computerized Assessment, BPT|Participants will take a third party validated assessment battery and then the Brain Performance Test (BPT).
16634886|NCT02382380|Experimental|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
16634887|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
16634888|NCT02382367|Experimental|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
16634889|NCT02382354|Experimental|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
16634890|NCT02382354|Active Comparator|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
16634891|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
16634892|NCT02382328|Experimental|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
16634893|NCT02382328|Placebo Comparator|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
16634894|NCT02382315|Experimental|Intervention Group|Fear of Cancer Recurrence Intervention.
16634895|NCT02382315|No Intervention|Wait-list Control Group|Patients assigned to this arm will be asked to wait 6 weeks before being offered the fear of cancer recurrence intervention.
16634896|NCT02382302|Experimental|Telemedicine system|Telemedicine system
16634897|NCT02382289|Active Comparator|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
16634898|NCT02382289|Active Comparator|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
16634899|NCT02382289|Active Comparator|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
16634900|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
16634901|NCT02382263|Experimental|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
16634902|NCT02382263|Experimental|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
16634903|NCT02382263|Experimental|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
16634904|NCT02382263|Experimental|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
16634905|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
16634906|NCT02382237|Other|PET/TDM|Evaluation by PET/TDM at 2 times
16634907|NCT02382224|Experimental|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
16634911|NCT02382185|Experimental|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
16634912|NCT02382185|Experimental|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at>10g/dL with blood transfusion as required.
16634913|NCT02382172|Experimental|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
16634914|NCT02382172|Other|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
16634915|NCT02382146|Experimental|dexamethasone and ondansetron|dexamethasone 8 mg with ondansetron 4mg administered in group DO
16634916|NCT02382146|Active Comparator|dexamethasone and dimenhydrinate|dexamethasone 8 mg with dimenhydrinate 1mg/kg administered in group DD
16634917|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
16634918|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
16634919|NCT02382094|Experimental|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
16634920|NCT02382094|Other|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
16634921|NCT02382081|Experimental|Patient-initiated shared care|"Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient.
~Access to nurse-run telephone helpline with direct access to a contact nurse."
16634922|NCT02382081|No Intervention|Control|Traditional, routine hospital reviews every three-fourth month.
16634923|NCT02382068|Experimental|Supportive care (intratympanic dexamethasone)|Patients receive dexamethasone via intratympanic injection in one ear and placebo via intratympanic injection in the other ear. Cisplatin standard of care treatment.
16634924|NCT02382055|Experimental|REACH|Psychotherapy
16634925|NCT02382055|Active Comparator|Supportive Psychotherapy|Psychotherapy
16634926|NCT02382042|Active Comparator|Intensive Referral Intervention|
16634927|NCT02382042|No Intervention|Standard Care|
16634928|NCT02382029|Active Comparator|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
16634929|NCT02382029|Experimental|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).
~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
16634930|NCT02382016|Experimental|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
16634931|NCT02382016|Placebo Comparator|Placebo|Matching placebo tablet once daily.
16634932|NCT02382003|Experimental|Positive Training+Anxious Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
16634933|NCT02382003|Experimental|Positive Training+Neutral Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
16634934|NCT02382003|Active Comparator|50/50 Training+Anxious Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Anxious Imagery Prime
16634935|NCT02382003|Active Comparator|50/50 Training+Neutral Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Neutral Imagery Prime
16634936|NCT02382003|Other|No Scenario+Anxious Imagery Prime|No scenarios paired with a preceding Anxious Imagery Prime
16634937|NCT02382003|Other|No Scenario+Neutral Imagery Prime|No scenarios paired with a preceding Neutral Imagery Prime
16634938|NCT02381964|Placebo Comparator|Placebo|Matched placebo
16634939|NCT02381964|Experimental|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
16634940|NCT02381964|Experimental|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
16634941|NCT02381951|Experimental|Spinal cord stimulation|
16634942|NCT02381938|Experimental|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
16634943|NCT02381938|Other|Control|6-month intervention to educate and improve financial health
16634944|NCT02381912||Hematuria - NMIBC|Primary hematuria due to NMIBC.
16634945|NCT02381912||Hematuria - other cause|Other non-malignant cause of hematuria.
16634977|NCT02381613|Experimental|Pickled herring|A meal based on pickled herring
16634946|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
16634947|NCT02381886|Experimental|IDH305|
16634948|NCT02381860|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
16634949|NCT02381860|Active Comparator|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
16634950|NCT02381847|No Intervention|without HIPEC|Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).
16634951|NCT02381847|Experimental|with HIPEC|"Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.
~Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )"
16634952|NCT02381834|Experimental|Bladder stimulation technique|This is a two-person technique. A health care aide or nurse (RN) begins by holding the infant under the axillae with its legs dangling. A second RN or physician then performs bladder stimulation by gentle finger tapping on the lower abdomen in the midline just above the pubic symphysis at a frequency of 100 taps/min. If this is unsuccessful after 30 seconds, lower back stimulation in the lumbar paravertebral zone is performed by light massage in a circular motion using both thumbs. This too is performed for 30 seconds maximum. These two manoeuvres are repeated in succession, for a maximum of 5 minutes total, until urination occurs. Unsuccessful attempts at midstream urine collection will be followed by further feeding/fluid administration and bladder catheterization.
16634953|NCT02381821||pregnant|women undergoing ICSI who became pregnant
16634954|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
16634955|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
16634956|NCT02381769|Experimental|Parenteral Nutrition|Soybean based lipid emulsion
16634957|NCT02381743|No Intervention|Group 1|Weekly non-medical SMS messages
16634958|NCT02381743|Experimental|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
16634959|NCT02381743|Experimental|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
16634960|NCT02381730|Experimental|Aflibercept|
16634961|NCT02381717|Experimental|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
16634962|NCT02381717|Active Comparator|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
16634963|NCT02381691|Experimental|maternal breast milk odor|"In the first group breast milk, venipuncture was performed to the neonate while his mother's milk odor was being diffused."
16634964|NCT02381691|Placebo Comparator|no odor|In a second control group, venipuncture was performed to the neonate with an odorless diffusor.
16634965|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
16634966|NCT02381665|Experimental|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
16634967|NCT02381665|Placebo Comparator|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
16634968|NCT02381652|Experimental|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
16634969|NCT02381652|Experimental|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
16634970|NCT02381652|Experimental|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
16634971|NCT02381639|Other|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
16634972|NCT02381639|Other|Healthy volunteers|control subjects matched for age and sex with the patients
16634973|NCT02381626|Experimental|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
16634974|NCT02381626|Experimental|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
16634975|NCT02381613|Active Comparator|Baked beef|A meal based on baked beef
16634976|NCT02381613|Experimental|Baked herring|A meal based on baked herring
16634978|NCT02381600|Experimental|Intervention group- vitamin D|Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment
16634979|NCT02381561|Experimental|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
16634980|NCT02381548|Experimental|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
16634984|NCT02381509||IVC Filter|IVC filter for the prevention of PE
16634985|NCT02381496|Experimental|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
16634986|NCT02381496|Experimental|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
16634987|NCT02381496|Experimental|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
16634988|NCT02381496|Experimental|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
16634989|NCT02381496|Experimental|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo
~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
16634990|NCT02381496|Experimental|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
16634991|NCT02381496|Experimental|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
16634992|NCT02381496|Experimental|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state
~Three male subjects will receive ACT-453859
~Three female subjects will receive ACT-453859
~One male subject will receive matching placebo
~One female subject will receive matching placebo"
16634993|NCT02381496|Experimental|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state
~Three male subjects will receive ACT-453859
~Three female subjects will receive ACT-453859
~One male subject will receive matching placebo
~One female subject will receive matching placebo"
16634994|NCT02381496|Experimental|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state
~Three male subjects will receive ACT-453859
~Three female subjects will receive ACT-453859
~One male subject will receive matching placebo
~One female subject will receive matching placebo"
16634995|NCT02381496|Experimental|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)
~Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.
~Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.
~There will be a washout period of 10 days between TPI and TPII"
16634996|NCT02381483|Experimental|Lean|Cold exposure
16634997|NCT02381483|Experimental|Obese|Cold exposure
16634998|NCT02381470|Experimental|Faropenem|Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
16634999|NCT02381470|Experimental|Cefadroxil|Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
16635000|NCT02381470|Active Comparator|Control|Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
16635001|NCT02381457||Pregnancies undergoing prenatal microdeletion screening|"Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.
~No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis."
16635002|NCT02381444||Standard of Care|Participants with advanced Parkinson's Disease
16635003|NCT02381444||Levodopa Carbidopa Intestinal Gel|Participants with advanced Parkinson's Disease
16635004|NCT02381431|Experimental|Thermal Imaging|imaging using a thermal camera
16635005|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
16635006|NCT02381405|Active Comparator|A|Enterade beverage
16635007|NCT02381405|No Intervention|B|Standard of care
16635008|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
16635009|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
16635010|NCT02381379|Active Comparator|Peginterferon-α-2a (Pegasys®)|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year
16635011|NCT02381379|No Intervention|Observation|Stop tyrosine kinase inhibitor that was on and no active medication that might affect CML, for example any immune-modulatory agents, traditional herbs or medications, chemotherapeutic agents, growth factors, or colony stimulating factors is allowed during the trial period.
16635012|NCT02381366|Experimental|PNEUMOSTEM®|Dose A: PNEUMOSTEM® 10 million cells per kg Dose B: PNEUMOSTEM® 20 million cells per kg
16635013|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
16635014|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
16635015|NCT02381327|Experimental|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
16635016|NCT02381327|Experimental|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
16635017|NCT02381314|Experimental|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
16635018|NCT02381301||Venous blood sampling prior to CCTA.|In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.
16635019|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
16635020|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
16635021|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
16635022|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
16635023|NCT02381262|Experimental|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.
~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
16635024|NCT02381262|No Intervention|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.
~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.
~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
16635025|NCT02381262|No Intervention|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
16635026|NCT02381249|Experimental|Esophagectomy|Double-blind single dose octreotide-placebo crossover
16635027|NCT02381249|Experimental|Gastrectomy|Double-blind single dose octreotide-placebo crossover
16635028|NCT02381249|Active Comparator|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
16635029|NCT02381249|Experimental|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
16635030|NCT02381236|Experimental|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
16635031|NCT02381210||CLINICALLY CONFIRMED PREECLAMPSIA|Pregnant women with clinical diagnosis of preeclampsia (severe, mild or superimposed) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
16635032|NCT02381210||CLINICALLY HEALTHY|Pregnant women admitted to the hospital for delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
16635033|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
16635034|NCT02381184|Active Comparator|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
16635063|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
16635064|NCT02381002|Experimental|Weight reduction|weight reduction program for 6 months
16635065|NCT02380989|Experimental|Ayurveda|
16635035|NCT02381184|Active Comparator|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
16635036|NCT02381171|Sham Comparator|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
16635037|NCT02381171|Sham Comparator|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
16635038|NCT02381171|Sham Comparator|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
16635039|NCT02381171|Active Comparator|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
16635040|NCT02381158|Experimental|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
16635041|NCT02381145|Placebo Comparator|Placebo|micro-cellulose-filled Placebo
16635042|NCT02381145|Active Comparator|EGCG+RSV-supplementation|EGCG+RSV: 300mg/d + 80mg/d
16635043|NCT02381132|Active Comparator|MNK155|Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
16635044|NCT02381132|Active Comparator|Norco 7.5mg/325mg|Norco 7.5mg/325mg
16635045|NCT02381119|Experimental|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
16635046|NCT02381119|Active Comparator|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
16635047|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
16635048|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
16635049|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
16635050|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
16635051|NCT02381093|Active Comparator|Standard BLS Course|Participants will partake in a standard BLS course.
16635052|NCT02381093|Experimental|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
16635053|NCT02381080|Experimental|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
16635054|NCT02381080|Experimental|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
16635055|NCT02381067|Other|NuCel with Allograft Bone|NuCel will be used with allograft bone for the surgical treatment of one, two or three level degenerative disease of the cervical spine.
16635056|NCT02381054||Translation and cross-cultural adaptation phase|In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
16635057|NCT02381054||Test-retest phase|In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.
16635058|NCT02381028|Experimental|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
16635059|NCT02381028|Active Comparator|Control area|Emollient: Apobase creme® (Actavis Norway AS)
16635060|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
16635061|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
16635062|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
16635066|NCT02380989|Placebo Comparator|Placebo|
16635067|NCT02380976|Experimental|Test 1|First phase: DW330SR+DW1030 7 days after Second phase: DW340
16635068|NCT02380976|Experimental|Test 2|First phase: DW340 7 days after Second phase: DW330SR+DW1030
16635069|NCT02380963|Experimental|Colorado Diet with soy protein|
16635070|NCT02380963|Active Comparator|Colorado Diet|
16635071|NCT02380950|Other|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
16635072|NCT02380937|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
16635073|NCT02380924|Active Comparator|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
16635074|NCT02380924|Sham Comparator|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
16635075|NCT02380911|Experimental|Intervention Group|The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
16635076|NCT02380911|No Intervention|No Intervention Group|This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health
16635077|NCT02380898|Experimental|Ketorolac|
16635078|NCT02380898|Placebo Comparator|Normal saline 0.9%|
16635079|NCT02380885|Experimental|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
16635080|NCT02380885|Experimental|TAFT|Therapeutic Alliance Focused Therapy
16635081|NCT02380885|No Intervention|TAU|Treatment as Usual
16635082|NCT02380872|Active Comparator|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
16635083|NCT02380872|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
16635084|NCT02380859|Active Comparator|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
16635085|NCT02380859|Sham Comparator|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
16635086|NCT02380846|Other|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
16635087|NCT02380846|Active Comparator|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
16635088|NCT02380846|Active Comparator|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
16635089|NCT02380846|Active Comparator|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
16635090|NCT02380846|Active Comparator|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
16635091|NCT02380833|Active Comparator|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
16635092|NCT02380833|Active Comparator|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
16635093|NCT02380833|Active Comparator|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
16635094|NCT02380833|Active Comparator|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
16635095|NCT02380820|Experimental|AirsoftDuo first|"Patients randomized to this arm will be placed on the Airsoft Duo mattress, and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Softform Premium mattress (in static mode). The patient will then continue his/her stay with the Softform Premium mattress (in static mode) for 1 month.
~Intervention: Airsoft Duo mattress Intervention: Softform Premier mattress (in static mode)"
16635096|NCT02380820|Experimental|Softform Premium first|"Patients randomized to this arm will be placed on the Softform Premium mattress (in static mode), and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Airsoft Duo mattress. The patient will then continue his/her stay with the Airsoft Duo mattress for 1 month.
~Intervention: Softform Premier mattress (in static mode) Intervention: Airsoft Duo mattress"
16635097|NCT02380807|Experimental|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
16635098|NCT02380807|Active Comparator|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
16635099|NCT02380794|Active Comparator|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
16635100|NCT02380794|Placebo Comparator|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
16635101|NCT02380781|No Intervention|Control|Patients will receive current standard postpartum contraceptive counseling.
16635102|NCT02380781|Experimental|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
16635103|NCT02380768|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
16635104|NCT02380768|Active Comparator|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
16635105|NCT02380755|Placebo Comparator|Placebo|One pill every other day during 12 weeks
16635106|NCT02380755|Active Comparator|Clomiphene Citrate|Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks
16635107|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
16635108|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
16635109|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.
~Investigation: First Gene Panel Sequencing and if no mutation ist found > Whole Genome Sequencing (WGS)"
16635110|NCT02380729||Parents of the index patient|"Both parents of the index patient.
~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
16635111|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
16635112|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
16635113|NCT02380690|Experimental|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
16635114|NCT02380690|No Intervention|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
16635115|NCT02380677|Experimental|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
16635116|NCT02380677|Experimental|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
16635117|NCT02380677|Experimental|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
16635118|NCT02380677|Experimental|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
16635119|NCT02380677|Experimental|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
16635120|NCT02380677|Experimental|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
16635121|NCT02380677|Experimental|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
16635122|NCT02380677|Experimental|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
16635123|NCT02380677|Experimental|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
16635124|NCT02380677|Experimental|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
16635125|NCT02380677|Experimental|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
16635126|NCT02380677|Experimental|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
16635127|NCT02380664|No Intervention|Swimmers|Swimmers that continue their normal swimming activity
16635128|NCT02380664|Experimental|WBV swimmers|Swimmers that perform a whole-body vibration training
16635129|NCT02380664|Experimental|Plyometric swimmers|Swimmers that perform a plyometric training
16635130|NCT02380664|No Intervention|Sedentary controls|Controls that do not perform swimming or other physical activities
16635131|NCT02380638|Experimental|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
16635132|NCT02380638|No Intervention|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
16635133|NCT02380638|Experimental|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
16635134|NCT02380638|No Intervention|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
16635135|NCT02380625|Experimental|Azithromycin|Azithromycin, IV fluids and laboratory testing
16635136|NCT02380625|Experimental|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
16635137|NCT02380625|Experimental|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
16635138|NCT02380625|Other|IV fluids and laboratory testing|no additional treatment
16635139|NCT02380612|Experimental|All Participants (within patient control)|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
16635140|NCT02380599|Experimental|Experimental Group|Crossover assignment of mid-thoracic spinal manipulation, spinal mobilization, or sham ultrasound
16635141|NCT02380586||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
16635142|NCT02380573|Experimental|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635143|NCT02380573|Placebo Comparator|Healthy Aging Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635144|NCT02380573|Experimental|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635145|NCT02380573|Placebo Comparator|Mild Cognitive Impairment (MCI) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635146|NCT02380573|Experimental|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635147|NCT02380573|Placebo Comparator|Mild Alzheimer's Disease (AD) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635148|NCT02380573|Experimental|Healthy Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635149|NCT02380573|Placebo Comparator|Healthy Middle Age Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
16635150|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
16635151|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
16635152|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
16635153|NCT02380534|Experimental|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
16635154|NCT02380521|Experimental|60 patients with T2DM|These patients will be treated with exenatide once weekly for a period of 8 months
16635155|NCT02380508|Experimental|Group 1|32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10^5 cfu) via Intradermal route.
16635156|NCT02380508|Experimental|Group 2|8-16 control volunteers receiving no vaccination.
16635157|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
16635158|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
16635159|NCT02380482|Other|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients
~Glasgow score < or = 9 or
~Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:
~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
16635160|NCT02380482|Other|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:
~Intubated and mechanically ventilated
~Undergoing urgent non severe surgery"
16635161|NCT02380469|Experimental|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
16635162|NCT02380469|Other|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
16635163|NCT02380443|Experimental|Dosing Schedule A|"The priming step with ID injections of AlloStim on Days 0, 7, and 14
~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21
~The activation step with IV infusion of AlloStim on Day 28
~The booster step with two IV booster infusions of AlloStim on Days 56 and 84
~Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
16635164|NCT02380443|Experimental|Dosing Schedule B|"The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10
~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14
~The activation step with IV infusion of AlloStim on Day 21
~The booster step with two IV booster infusions of AlloStim on Days 49 and 77
~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
16635165|NCT02380443|Experimental|Dosing Schedule C|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14
~IV AlloStim on Day 21
~The booster step with two IV booster infusions of AlloStim on Days 49 and 77
~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
16635166|NCT02380443|Experimental|Dosing Schedule D (reducing dose)|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14
~IV AlloStim on Day 21
~The booster step with two IV booster infusions of AlloStim on Days 49 and 77
~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
16635167|NCT02380430||ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
16635168|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
16635169|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
16635170|NCT02380404||Edentulous maxilla|Ibuprofen (600 mg - Film-coated Tablets) 3x/day before the surgery. Duration : 5 days Amoxicilline Teva (500 mg - dispersible tablets) 3x/day before the surgery. Duration : 16 days
16635171|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
16635172|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
16635173|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
16635174|NCT02380365||Outpatients on the Waiting List and after Lung Transplantation|Electrocardiography
16635175|NCT02380352|Experimental|Short-course|5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
16635176|NCT02380352|Active Comparator|Standard|5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID
16635263|NCT02379845|Active Comparator|Arm B|Radiotherapy alone
16635264|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
16635265|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
16635177|NCT02380339|Active Comparator|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
16635178|NCT02380339|Experimental|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
16635179|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
16635180|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
16635181|NCT02380313|Experimental|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
16635182|NCT02380313|Experimental|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
16635183|NCT02380313|Experimental|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
16635184|NCT02380313|Experimental|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
16635185|NCT02380313|Experimental|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
16635186|NCT02380313|Experimental|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
16635187|NCT02380313|Experimental|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
16635188|NCT02380313|Experimental|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
16635189|NCT02380313|Experimental|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
16635190|NCT02380313|Experimental|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
16635191|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
16635192|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
16635193|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
16635266|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
16635267|NCT02379806|Active Comparator|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
16635268|NCT02379806|Placebo Comparator|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
16635450|NCT02378662|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
16635194|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
16635195|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
16635196|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
16635197|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
16635198|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
16635199|NCT02380274||Patients with CRPC|Patients with CRPC
16635200|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
16635201|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
16635202|NCT02380235|Experimental|PEG-somatropin|0.12mg/kg/w
16635203|NCT02380235|Experimental|PEG-Somatropin|0.20mg/kg/w
16635204|NCT02380222||ASM|
16635205|NCT02380222||SM-AHNMD|
16635206|NCT02380222||MCL|
16635207|NCT02380222||SSM|
16635208|NCT02380222||ISM|
16635209|NCT02380209|Experimental|Optimization|CEST MRI of the breast for estimation of tumor pH.
16635210|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
16635211|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
16635212|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
16635213|NCT02380157|Experimental|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
16635214|NCT02380157|Placebo Comparator|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
16635215|NCT02380144|Experimental|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:
~1st: Orange fruit; 2nd: Orange juice"
16635216|NCT02380144|Experimental|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:
~1st: Orange juice; 2nd: Orange fruit"
16635217|NCT02380131|Experimental|Herceptin|"drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
~To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis"
16635218|NCT02380118|Experimental|Olanzapine|intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
16635219|NCT02380118|Active Comparator|Haloperidol|intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
16635220|NCT02380118|Active Comparator|Midazolam|intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
16635221|NCT02380105|Experimental|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
16635269|NCT02379793|Experimental|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
16635294|NCT02379624|Placebo Comparator|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
16635222|NCT02380105|Active Comparator|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
16635223|NCT02380079|Experimental|SCD-101|SCD-101 dosed TID for 28-days
16635224|NCT02380079|Placebo Comparator|Placebo|Placebo dosed TID for 28-days
16635225|NCT02380066|Experimental|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
16635226|NCT02380066|Experimental|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
16635227|NCT02380066|Experimental|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
16635228|NCT02380066|Experimental|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
16635229|NCT02380066|Placebo Comparator|Placebo|Placebo,oral, twice per day
16635230|NCT02380053|Experimental|Bisoprolol|2.5mg once daily for 2 weeks then 5mg once daily for 2 weeks.
16635231|NCT02380053|Experimental|Celiprolol|200mg once daily for 2 weeks then 400mg once daily for 2 weeks.
16635232|NCT02380040||Term|Normal Term Newborn Intervention: PPG
16635233|NCT02380040||Preterm|Preterm babies admitted to the NICU not suffering from the conditions to be studied Intervention: PPG
16635234|NCT02380040||PDA|Patent Ductus Arteriosus Intervention: PPG
16635235|NCT02380040||PPHN|Persistent Pulmonary Hypertension Intervention: PPG
16635236|NCT02380027|Experimental|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
16635237|NCT02380027|Active Comparator|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
16635238|NCT02380001|Experimental|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
16635239|NCT02380001|Placebo Comparator|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
16635240|NCT02379988|Experimental|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
16635241|NCT02379975|Experimental|rheumatoid arthristis|individuals with rheumatoid arthritis
16635242|NCT02379975|Active Comparator|health|healthy individuals
16635243|NCT02379949|Experimental|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
16635244|NCT02379949|Active Comparator|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
16635245|NCT02379949|No Intervention|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
16635246|NCT02379936|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
16635247|NCT02379936|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
16635248|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
16635249|NCT02379910|Experimental|SAD 1|AM1030-CREAM
16635250|NCT02379910|Experimental|SAD 2|AM1030-CREAM
16635251|NCT02379910|Experimental|SAD 3|AM1030-CREAM
16635252|NCT02379910|Experimental|MAD 1|AM1030-CREAM
16635253|NCT02379910|Experimental|MAD 2|AM1030-CREAM
16635254|NCT02379897|Experimental|LowGI+ModCarb|Low glycemic index + moderate carbohydrate/moderate fat diet
16635255|NCT02379897|Experimental|LowGI+HighCarb|Low glycemic index + high carbohydrate/low fat diet
16635256|NCT02379897|Experimental|HighGI+ModCarb|High glycemic index + moderate carbohydrate/moderate fat diet
16635257|NCT02379897|Experimental|HighGI+HighCarb|High glycemic index + high carbohydrate/low fat diet
16635258|NCT02379871|Experimental|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
16635259|NCT02379871|Sham Comparator|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
16635260|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
16635261|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
16635262|NCT02379845|Experimental|Arm A|NBTXR3 + Radiotherapy
16635270|NCT02379780|Active Comparator|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
16635271|NCT02379780|Active Comparator|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
16635272|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
16635273|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
16635274|NCT02379754|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.
~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
16635275|NCT02379754|No Intervention|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
16635276|NCT02379741|Experimental|ADC-1013 intratumoral|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
16635277|NCT02379741|Experimental|ADC-1013 intravenous|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.
16635278|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
16635279|NCT02379728|Experimental|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
16635280|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
16635281|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
16635282|NCT02379715|Experimental|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
16635283|NCT02379689|Active Comparator|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
16635284|NCT02379689|Placebo Comparator|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
16635285|NCT02379676|Experimental|Ticagrelor|Ticagrelor 90mg twice daily
16635286|NCT02379676|Active Comparator|Clopidogrel|Clopidogrel 75mg once daily
16635287|NCT02379663|Active Comparator|Oral direct Factor Xa inhibitor|Rivaroxaban
16635288|NCT02379663|Active Comparator|Low molecular weight heparin|Enoxaparin
16635289|NCT02379663|Placebo Comparator|Normal Saline|Normal Saline
16635290|NCT02379650|Experimental|Hydroxychloroquine (HCQ)|Subjects in the experimental arm will take 400 mg hydroxychloroquine pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
16635291|NCT02379650|Placebo Comparator|Placebo|Subjects in the experimental arm will take placebo pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
16635292|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
16635293|NCT02379637|Placebo Comparator|B Placebo|Placebo
16635402|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
16635295|NCT02379624|Experimental|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
16635298|NCT02379598||Amino acid based formula|
16635299|NCT02379598||Whey protein formula|
16635300|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
16635301|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
16635304|NCT02379559|Experimental|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
16635305|NCT02379559|Active Comparator|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
16635306|NCT02379546|Experimental|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
16635307|NCT02379546|Active Comparator|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
16635308|NCT02379533|No Intervention|sedentary control|
16635309|NCT02379533|Experimental|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
16635310|NCT02379533|Active Comparator|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
16635311|NCT02379520|Experimental|Group A|HPV Specific T Cells
16635312|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
16635313|NCT02379507|Experimental|DEC033 Study Product|Apply twice a day
16635314|NCT02379481|Experimental|NS 550mg|NS 550mg/day
16635315|NCT02379481|Experimental|NS 1100mg|NS 1100mg/day
16635316|NCT02379481|Placebo Comparator|placebo|placebo
16635317|NCT02379468|Experimental|Pedyphar|Ointment
16635318|NCT02379468|Active Comparator|Panthenol|Ointment
16635319|NCT02379455|Experimental|Comprehensive drug review|
16635320|NCT02379455|No Intervention|Control group|"Follow-up by family physician as usual."
16635321|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
16635324|NCT02379416|Experimental|treatment|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
16635325|NCT02379390|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
16635326|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
16635327|NCT02379377|Experimental|Diagnostic (18F-FSPG PET)|Patients undergo an 18F-FSPG PET scan within 4 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
16635328|NCT02379377|Experimental|Diagnostic (11C-Acetate PET or 18F-FDG PET)|Patients may undergo either carbon-11 (11C)-Acetate PET or 18F-FDG PET scans within 4 weeks of surgery or OLT.
16635329|NCT02379364|Experimental|Intervention group|Diacutaneous Fibrolysis treatment
16635403|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
16635330|NCT02379351|Experimental|In-Home Non-Stress Test Device|Patients with physician-ordered twice-weekly NSTs scheduled in the OB Diagnostic Center at University of Utah Hospital will be eligible for enrollment. After being taught how to use the Airstrip® Sense4Baby™ system machine, participants will use the device on a weekly basis (at home) until the time of delivery. Participants will also receive an in clinic NST once a week.
16635331|NCT02379338|Experimental|Dynamic Brain Cohort|The Dynamic Brain cohort will include up to 10 patients who will undergo a dynamic brain [18F]Fluortriopride PET/CT scan over a period of approximately 2 hours. Subjects in this cohort will also undergo a research brain MRI, generally on a separate day from the PET/CT.
16635332|NCT02379338|Experimental|Biodistribution Cohort|The Biodistribution cohort will include up to10 patients who will undergo a series of whole body biodistribution [18F]Fluortriopride PET/CT scans over a period of approximately 4 hours.
16635333|NCT02379325|Experimental|Lets Quit|Given text message
16635334|NCT02379325|Active Comparator|Pamplets education|Given pamplets on smoking and complication
16635335|NCT02379312|Active Comparator|Very low energy aerated beverage|Very low energy aerated beverage
16635336|NCT02379312|Active Comparator|Normal energy aerated beverage 1|Normal energy aerated beverage 1
16635337|NCT02379312|Active Comparator|Normal energy aerated beverage 2|Normal energy aerated beverage 2
16635338|NCT02379312|Active Comparator|Normal energy aerated beverage 3|Normal energy aerated beverage 3
16635339|NCT02379299|Active Comparator|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
16635340|NCT02379299|Experimental|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
16635341|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
16635342|NCT02379273|Experimental|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
16635343|NCT02379260|Other|Interview|Patients and urologists will be interview by a sociologist.
16635344|NCT02379260|Other|Focus Groups|Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
16635345|NCT02379247|Experimental|Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 250mg daily on day 1-28
~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
16635346|NCT02379247|Experimental|Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle
~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
16635347|NCT02379247|Experimental|Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle
~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
16635348|NCT02379247|Experimental|BYL-719 (alpelisib) Dose Expansion|"BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle
~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
16635349|NCT02379234|No Intervention|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
16635350|NCT02379234|Experimental|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
16635351|NCT02379221|Experimental|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
16635352|NCT02379195|Experimental|A|"All patients receive the same treatment.
~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.
~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.
~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.
~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days
~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
16635353|NCT02379182|Active Comparator|Control group|Will not receive any treatment procedure. Patients allocated in the control group will be treated according to the standard clinical care of patients with dysphagia at our center, that includes: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary.
16635354|NCT02379182|Experimental|Sensory Group|Patients allocated in the sensory group will be treated with transcutaneous electrical stimulation at sensory level. In addition, they will receive the standard clinical care described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
16635404|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
16635448|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
16635449|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
16635355|NCT02379182|Experimental|Motor Group|Patients allocated in the motor group will be treated with transcutaneous electrical stimulation at motor level. In addition, they will receive the standard clinical care of patients with dysphagia described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
16635356|NCT02379169|Experimental|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
16635357|NCT02379169|Placebo Comparator|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
16635358|NCT02379156|Experimental|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
16635359|NCT02379156|Experimental|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
16635360|NCT02379130|Experimental|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
16635361|NCT02379130|Active Comparator|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
16635362|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion & exclusion criteria.
16635363|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
16635364|NCT02379104||Healthy Volunteers|Healthy volunteers fulfilling inclusion/exclusion criteria for reference interval sample group are tested with ROTEM sigma
16635365|NCT02379104||Patients with expected coagulopathy|Patients with expected bleeding and coagulation problems during elective surgery or at the ICU, or trauma patients are tested with ROTEM sigma and ROTEM delta comparatively
16635366|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
16635367|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
16635368|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
16635369|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
16635370|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers
~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
16635445|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
16635371|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers
~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients
~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
16635372|NCT02379065|Active Comparator|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.
~Interventions:
~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician
~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)
~Arterial blood gas changes - pH, pO2, pCO2"
16635373|NCT02379065|Experimental|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.
~Interventions:
~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician
~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)
~Arterial blood gas changes - pH, pO2, pCO2"
16635374|NCT02379052|Experimental|Dupilumab 300 mg QW|Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
16635375|NCT02379052|Experimental|Placebo|Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
16635376|NCT02379026|Experimental|Exercise & Protein Drink/Diet|High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
16635377|NCT02379026|Active Comparator|Exercise|A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
16635378|NCT02379013|Experimental|Volunteer with MRI|All volunteer will be included in the arm MRI
16635379|NCT02379000|Active Comparator|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
16635380|NCT02379000|Active Comparator|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
16635381|NCT02378987||Typical developmental children|Normal children
16635382|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
16635383|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
16635384|NCT02378974|Other|Cohort 1|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0
16635385|NCT02378974|Other|Cohort 2|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7
16635386|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
16635387|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
16635388|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
16635389|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
16635390|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
16635391|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
16635392|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
16635393|NCT02378948|Experimental|Early oral feeding|Liquid oral feeding directly after esophagectomy.
16635394|NCT02378948|No Intervention|Delayed oral feeding|Liquid oral feeding 5 days after esophagectomy
16635395|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
16635396|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
16635397|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
16635398|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
16635399|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
16635400|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
16635401|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
16635405|NCT02378922|Experimental|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.
~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.
~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
16635406|NCT02378909|Active Comparator|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
16635407|NCT02378909|No Intervention|Group 2|Diabetic neuropathy with standard of care.
16635408|NCT02378909|Active Comparator|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
16635409|NCT02378909|No Intervention|Group 4|Diabetic neuroischemia with standard of care.
16635410|NCT02378896|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
16635411|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
16635412|NCT02378870|Experimental|A:Osteodex|3.0 mg/kg bodyweight solution for infusion
16635413|NCT02378870|Placebo Comparator|B: Placebo|NaCl 0.9% solution for infusion
16635414|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
16635415|NCT02378857||Control group|Age- and gender-matched healthy individuals
16635416|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
16635417|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
16635418|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
16635419|NCT02378818|Other|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
16635420|NCT02378818|Other|Healthy volunteers (schizophrenia)|35 healthy volunteers
16635421|NCT02378818|Other|Depressive patients|
16635422|NCT02378818|Other|Healthy volunteers (depression)|
16635423|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
16635424|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
16635425|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria >0.3 g/day or per gCreatinine
16635426|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
16635427|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
16635428|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
16635429|NCT02378792|Experimental|Vagus Verve Stimulation is on|
16635430|NCT02378792|Sham Comparator|Placebo Vagus Verve Stimulation is off|
16635431|NCT02378779|Other|Interventional GP : GP trainned in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.
~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.
~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
16635432|NCT02378779|Other|Usual care : GP did not trainnd in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.
~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
16635433|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
16635434|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
16635435|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
16635436|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
16635437|NCT02378740|Placebo Comparator|Placebo|Placebo (.9 sterile normal saline) administered IV
16635438|NCT02378740|Active Comparator|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:
~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
16635439|NCT02378727|Active Comparator|A Standard Care Group (SCG)|Standard Care Conventional Group (SCG): 158 subjects to receive lumbar epidural procedure with the loss of resistance syringe used to identify the epidural space
16635440|NCT02378727|Experimental|Experimental Procedure Group (EPG).|158 of subjects to receive lumbar epidural procedure with the CompuFlo® Epidural System used to identify the epidural space
16635441|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
16635442|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
16635443|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
16635444|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
16635451|NCT02378662|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
16635452|NCT02378649|Experimental|Sildenafil|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.
~PDEI or placebo will continue up to 8 days or discharge."
16635453|NCT02378649|Placebo Comparator|Placebo|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.
~PDEI or placebo will continue up to 8 days or discharge."
16635454|NCT02378636|Experimental|600S|Modified 600C (axis marks) monofocal aspheric intraocular lens
16635455|NCT02378623|Active Comparator|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
16635456|NCT02378623|Placebo Comparator|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
16635457|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
16635458|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
16635459|NCT02378597|Active Comparator|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
16635460|NCT02378597|Experimental|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
16635461|NCT02378584|Other|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
16635462|NCT02378584|Active Comparator|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
16635463|NCT02378571|No Intervention|Usual care|Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes. This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later. Participants will not be provided with any advice on heart failure adherence.
16635464|NCT02378571|Experimental|Medication adherence telemonitoring|At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician. A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis. The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
16635465|NCT02378558|Experimental|Investigational Device|All patients will undergo breast localization and excision of a lesion using the MagneMark system. The radiologist will insert the MagneMarker clip into the area of concern using the MagneJector device. The surgeon will then locate the MagneMaker clip using the MagneProbe. The clip and breast tissue of concern will then be removed.
16635466|NCT02378545|Active Comparator|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
16635467|NCT02378545|Active Comparator|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
16635468|NCT02378532|Experimental|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.
~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients. Based on the results of the DSMB, an additional level of 300mg was added."
16635469|NCT02378519|Experimental|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
16635470|NCT02378519|Active Comparator|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
16635471|NCT02378506|Experimental|ETN 50mg QW|
16635472|NCT02378493||Exposure: Concordance between tests|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients whose antibiogrammes and Antibiofilmogrammes are concordant will fall into this group (the exposed group).
~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
16635510|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
16635511|NCT02378246|Experimental|Iodine containing multivitamin|multivitamin tablet containing 150 ug iodine, 1 tablet daily
16635473|NCT02378493||Non exposure: Not concordance between tests.|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients who do not fall into the concordance (exposure) group, will fall into the non exposure group. The latter includes semi-concordance or discordance between antibiogrammes and Antiobiofilmogrammes.
~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
16635474|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
16635475|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
16635476|NCT02378467|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
16635477|NCT02378467|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
16635478|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
16635479|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
16635480|NCT02378441|Experimental|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
16635481|NCT02378441|Experimental|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
16635482|NCT02378428|Experimental|MIBG|Research participants with MIBG avid tumors
16635483|NCT02378415|Placebo Comparator|Normal Saline Infusion|A single IV bolus dose of normal saline solution.
16635484|NCT02378415|Experimental|Subanesthetic IV Bolus Ketamine|a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
16635485|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
16635486|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
16635487|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
16635488|NCT02378389|Experimental|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
16635489|NCT02378376|Experimental|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
16635490|NCT02378376|Experimental|Wheat derived fiber fraction 2|Dietary fiber enriched bran
16635491|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
16635492|NCT02378350|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
16635493|NCT02378350|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
16635494|NCT02378337||Retrospective development cohort|A total of 85 18F-FDG-PET adult studies were gathered over a 3-month period and retrospectively evaluated.
16635495|NCT02378337||Prospective validation cohort|To verify the application of methodology in clinical routine, we conducted a second phase of the study prospectively in 250 subjects (phase 2) using inclusion and exclusion criteria of the retrospective study (phase 1).
16635496|NCT02378324|Active Comparator|Intervention and control|Intervention arm: screening without fee.
16635497|NCT02378324|No Intervention|Control group|Control arm: screening with the regular fee, 100SEK.
16635498|NCT02378311||Cases|Those satisfying the inclusion & exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
16635499|NCT02378311||Controls|Those satisfying the inclusion & exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
16635500|NCT02378298|Active Comparator|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS <2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.
~rituximab and methotrexate"
16635501|NCT02378298|Active Comparator|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
16635502|NCT02378298|Active Comparator|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.
~methotrexate and methylprednisolone"
16635503|NCT02378298|No Intervention|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
16635504|NCT02378298|Active Comparator|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
16635505|NCT02378285|Active Comparator|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
16635506|NCT02378285|Placebo Comparator|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
16635507|NCT02378272|Experimental|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
16635508|NCT02378272|No Intervention|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
16635509|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
16635512|NCT02378246|Placebo Comparator|Placebo: non-iodine containing multivitamin|non-iodine containing multivitamin, 1 tablet daily
16635513|NCT02378233|Experimental|iodine|"iodine containing multivitamin
~150 ug, 1 tablet daily"
16635514|NCT02378233|Placebo Comparator|placebo|placebo, 1 tablet Daily of a non-iodine containing multivitamin
16635515|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
16635516|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
16635517|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
16635518|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
16635519|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
16635520|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
16635521|NCT02378194|Placebo Comparator|Placebo group|
16635522|NCT02378194|Experimental|HD-003 (800mg/day)|
16635523|NCT02378194|Experimental|HD-003 (1600mg/day)|
16635524|NCT02378181|Experimental|Toolkit (TK)|Patients in the TK condition will receive counseling sessions from participating counselors who have been trained to use the Health Education Toolkit (TK).
16635525|NCT02378181|Active Comparator|Treatment-as-usual (TAU)|Patients in the treatment-as-usual (TAU) condition will receive the same number of counseling sessions as patients in the TK condition from participating counselors who have not been trained to use the Health Education Toolkit. Counselors working with patients in this condition will receive a control training of the same length and intensity on recovery topics that are covered in the Health Education Toolkit, but will not be equipped with the Toolkit.
16635526|NCT02378168||cohort of RCT (StV 5-2007; NCT00924222)|Patient group with either sevoflurane or propofol sedation of the RCT (StV 5-2007; NCT00924222)
16635527|NCT02378155|Other|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
16635528|NCT02378155|Other|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
16635529|NCT02378142|Experimental|Arm 1|Pazopanib 800mg oral daily
16635530|NCT02378129|Experimental|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
16635531|NCT02378129|Active Comparator|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
16635532|NCT02378116|No Intervention|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
16635533|NCT02378116|Active Comparator|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
16635534|NCT02378103||Case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. Simple aortic aneurysm and pseudoaneurysm were excluded. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
16635535|NCT02378103||Control|As the control group, patients without AD were obtained from the hospitalized patients in the same period.
16635536|NCT02378077|Experimental|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
16635537|NCT02378077|Experimental|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
16635538|NCT02378064|Experimental|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
16635539|NCT02378064|Experimental|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
16635540|NCT02378064|Active Comparator|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
16635541|NCT02378064|Active Comparator|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
16635542|NCT02378051|Experimental|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
16635543|NCT02378051|Placebo Comparator|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
16635544|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
16635545|NCT02378025|Experimental|Yoga Group|Postures, meditation, breathing exercises
16635546|NCT02378025|Active Comparator|Pain Management Wellness Group|Behavioral medicine
16635612|NCT02377505|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
16635613|NCT02377505|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
16635547|NCT02378012|Active Comparator|GROUP A (participants provide own computer or tablet device)|A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
16635548|NCT02378012|Experimental|GROUP B (Apple BuckiPad)|Participants receive an iPad for days -5 to 10. Participants also receive the BuckiPad manual for instructions on how to use the iPad and Netflix, Skype, and Spotify applications. Participants are also directed to the official Apple's iPad user's manual on their device and have questions answered by research personnel on day -5.
16635549|NCT02378012|No Intervention|GROUP C (no intervention)|Participants do not receive an iPad for days -5 to 10.
16635550|NCT02377999|Experimental|Treatment of genetial warts with Picato|
16635551|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
16635552|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
16635553|NCT02377960|Active Comparator|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
16635554|NCT02377960|Experimental|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive
~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
16635555|NCT02377960|Experimental|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.
~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
16635556|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
16635557|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
16635558|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
16635559|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
16635560|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
16635561|NCT02377856|Active Comparator|intervention|40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'
16635562|NCT02377856|No Intervention|observation|40 patients without treatment will be followed for the clinical course for 1.5 year
16635563|NCT02377843|Experimental|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
16635564|NCT02377843|Experimental|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
16635565|NCT02377843|No Intervention|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
16635566|NCT02377830|Experimental|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
16635567|NCT02377830|Active Comparator|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
16635568|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
16635569|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
16635570|NCT02377804|Experimental|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
16635571|NCT02377804|Active Comparator|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
16635572|NCT02377778|Experimental|Propofol|In this arm patients will be receiving propofol for anaesthesia at doses 3-5mg depending on the time needed to complete oocyte retrieval
16635573|NCT02377778|Active Comparator|Thiopental|In this arm patients will receive thiopental for anaesthesia at doses 7mg and a repeat dose of 2-3mg depending on the time needed to completed oocyte retrieval
16635574|NCT02377765|Active Comparator|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
16635575|NCT02377765|Experimental|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
16635576|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|"15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met
~."
16635577|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
16635578|NCT02377752|Experimental|Part A cohort 3 Olaratumab + Doxorubicin|20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
16635579|NCT02377752|Experimental|Part B: Olaratumab|15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16635580|NCT02377739|Experimental|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
16635581|NCT02377726|Experimental|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
16635582|NCT02377726|Experimental|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
16635583|NCT02377726|Active Comparator|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
16635584|NCT02377713|Experimental|KHK6640|KHK6640
16635585|NCT02377713|Placebo Comparator|Placebo|Placebo
16635586|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
16635587|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
16635588|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
16635589|NCT02377661|No Intervention|Standard Care|Treatment of hypertension according to current guidelines
16635590|NCT02377661|Experimental|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
16635591|NCT02377648|Experimental|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
16635592|NCT02377635|Experimental|Treatment|Drug: Anhydrous selenite (Se-77), single dose 0.8mg, orally administered as a 100 ml purified water solution
16635593|NCT02377635|Placebo Comparator|Control|Drug: Placebo sodium chloride (table salt), orally administered as a 100 ml purified water solution
16635594|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
16635595|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
16635596|NCT02377622|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
16635597|NCT02377622|Active Comparator|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
16635598|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
16635599|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
16635600|NCT02377583||Diabetic children|"physical examination
~Glucocorticoid sensitivity index
~DNA sample
~Anxiety and depression questionnaires
~depression questionnaire
~MRI"
16635601|NCT02377583||Controls|"physical examination
~Glucocorticoid sensitivity index
~DNA sample
~Anxiety and depression questionnaires
~depression questionnaire
~MRI
~Laboratory tests"
16635602|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
16635603|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
16635604|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
16635605|NCT02377570|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
16635606|NCT02377544|Placebo Comparator|Placebo|Saccharum lactis
16635607|NCT02377544|Experimental|Probiotic|Bifidobacterium animalis lactis
16635608|NCT02377531|Other|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
16635609|NCT02377531|Other|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
16635610|NCT02377518|Experimental|oncologic patients|"Prediction of postoperative pulmonary function.
~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
16635611|NCT02377518|Experimental|lung transplant recipients|"Detection of BOS
~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
16635614|NCT02377492|Experimental|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
16635615|NCT02377492|Active Comparator|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
16635616|NCT02377479|Active Comparator|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
16635617|NCT02377479|Active Comparator|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
16635618|NCT02377479|Experimental|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
16635619|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
16635620|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
16635621|NCT02377453||Control|Control: Healthy adult
16635622|NCT02377453||Experimental|Experimental: patients with stroke
16635623|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
16635624|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
16635625|NCT02377414|Experimental|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
16635626|NCT02377414|Experimental|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
16635627|NCT02377401|Experimental|Zanamivir 300 mg|Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour [mL/hr]).
16635628|NCT02377401|Experimental|Zanamivir 600 mg|Subjects will receive a single dose of IV zanamivir 600 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will be receive IV zanamivir 600 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 mL/hr).
16635629|NCT02377388|Active Comparator|treatment: DPP4 -i|"Use of DPP4-i :
~sitagliptin 50 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 100 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)
~OR
~saxagliptin 2,5 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 5 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)"
16635630|NCT02377388|Placebo Comparator|control|placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD
16635631|NCT02377375|Experimental|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
16635632|NCT02377375|Active Comparator|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
16635633|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
16635634|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
16635635|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
16635636|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
16635637|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
16635638|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
16635639|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
16635640|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
16635641|NCT02377336|Experimental|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
16635642|NCT02377336|Placebo Comparator|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
16635643|NCT02377323|Other|Treatment with Rebif|Patients treated with Rebif only, for at least two years, and for up to 18 years
16635644|NCT02377323|Other|Never treated|Patients never treated with a disease-modifying drug (DMD)
16635645|NCT02377310||All patients|All patients will undergo coronary physiological study with measurement of resting Pd/Pa, iFR™, hyperaemic iFR and FFR.
16635646|NCT02377297|Active Comparator|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
16635647|NCT02377297|Experimental|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
16635648|NCT02377297|Experimental|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
16635649|NCT02377284|Experimental|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
16635650|NCT02377284|No Intervention|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
16635651|NCT02377271|Experimental|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
16635652|NCT02377271|Placebo Comparator|Placebo|placebo drug , twice a day, during eight weeks
16635653|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
16635654|NCT02377258||2|with on-going anti-TNF monotherapy
16635655|NCT02377258||3|with thiopurines monotherapy
16635656|NCT02377258||4|with on-going combination therapy
16635657|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
16635658|NCT02377258||6|patients on ustekinumab (alone or on combination therapy)
16635659|NCT02377245||Juvenile Inflammatory Rheumatism|Juvenile Inflammatory Rheumatism patients
16635660|NCT02377232|Active Comparator|Usual Care Outreach for Colon Cancer Screening|Receives standard of care outreach concerning colon cancer screening.
16635661|NCT02377232|Active Comparator|Decision Aid for Colon Cancer Screening|Receives colon cancer screening decision aid intervention in addition to outreach.
16635662|NCT02377219|Experimental|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
16635663|NCT02377206|Experimental|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714
16635664|NCT02377193|Experimental|Simulect|Simulect IV 40 mg D0 and D4
16635665|NCT02377193|Active Comparator|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
16635666|NCT02377180|Experimental|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
16635667|NCT02377180|Active Comparator|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
16635668|NCT02377180|Active Comparator|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
16635669|NCT02377167|Experimental|Early Tracheostomy|"Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 5 days from intubation.
~Intervention: Procedure: Early Tracheostomy"
16635670|NCT02377167|Active Comparator|Prolonged Intubation|"Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy after intubation day 10.
~Intervention: Procedure: Late Tracheostomy"
16635671|NCT02377154|Other|Opthalmologically healthy individuals|Slit lamp, Autorefractor, IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
16635672|NCT02377141|Active Comparator|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
16635673|NCT02377141|Active Comparator|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
16635674|NCT02377128|Experimental|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
16635675|NCT02377128|Active Comparator|Tubal ligation|Cesarean section with tubal ligation
16635676|NCT02377128|No Intervention|No intervention|Cesarean section with no additional intervention
16635677|NCT02377115|Other|Study cohort|Tablet computer application
16635678|NCT02377102|No Intervention|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
16635679|NCT02377102|Active Comparator|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
16635680|NCT02377089|Sham Comparator|Sham|The stimulators are the same device for the active and sham treatment conditions.
16635681|NCT02377089|Active Comparator|Active|The stimulators are the same device for the active and sham treatment conditions.
16635682|NCT02377076|Experimental|DAIRY|Dietary calcium supplementation
16635683|NCT02377076|Placebo Comparator|CONTROL|Control
16635684|NCT02377063|Other|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
16635685|NCT02377050|Active Comparator|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
16635686|NCT02377050|No Intervention|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
16635687|NCT02377037|Experimental|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
16635688|NCT02377037|Experimental|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
16635689|NCT02377037|Experimental|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
16635690|NCT02377024|Experimental|TF 600mg|TF 600mg/day
16635691|NCT02377024|Experimental|TF 1200mg|TF 1200mg/day
16635693|NCT02377011|Experimental|PS CBT|"Problem solving cognitive behaviour therapy (PS CBT) will be delivered remotely by means of telephone or video calling by a cognitive behaviour therapist in addition to their usual care.
~The duration of the intervention will be 10 sessions. Research measures will be completed at baseline, 3,6,9 and 12 months"
16635694|NCT02377011|No Intervention|Treatment as Usual|Participants will not receive any CBT therapy in addition to their usual care. Research measures will be completed at baseline,3,6,9 and 12 months.
16635695|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
16635696|NCT02376985|Placebo Comparator|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.
~Oral treatment:
~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
16635697|NCT02376985|Experimental|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.
~Oral treatment:
~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.
~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
16635698|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
16635699|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
16635700|NCT02376972|Placebo Comparator|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
16635701|NCT02376972|Active Comparator|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
16635702|NCT02376959|Placebo Comparator|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
16635703|NCT02376959|Active Comparator|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
16635704|NCT02376946|Active Comparator|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
16635705|NCT02376946|Placebo Comparator|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
16635706|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
16635707|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
16635708|NCT02376881|Experimental|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
16635709|NCT02376881|Placebo Comparator|control group|100 ml normal saline in 2 hr for 3 successive days
16635710|NCT02376868|Other|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
16635711|NCT02376868|Other|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
16635712|NCT02376868|Other|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
16635713|NCT02376855|No Intervention|Control|Providers in the Control group followed standard care protocols. If they deemed a patient was in need of cardiology consultation, a referral was created using the standard process. The referral was processed by a referral coordinator and transmitted to an appropriate cardiologist. An appointment was then scheduled for the patient to have an in-person consultation with a cardiologist.
16635714|NCT02376855|Experimental|eConsult|"The intervention consisted of an eConsult pathway and standardized protocol for PCPs to obtain cardiology consults using a secure messaging peer to peer (P2P) module embedded within the EHR. Intervention providers were asked to send all cardiology referrals for their adult patients through the eConsult system. Providers could bypass the eConsult pathway for patients with established relationships with a cardiologist or for whom providers felt a consult was urgent (required a face-to-face visit within a week or less). eConsults contain reason for consult, relevant test results, records or reports but are sent electronically to a Cardiology Consultant for review. eConsults were responded to within two business days. Responses were case-specific and generally contained recommendations for management, additional testing, or a face-to-face cardiology visit. The PCP was responsible for considering/acting upon recommendations and determining when an eConsult was complete."
16635715|NCT02376842|Active Comparator|Severe sepsis early warning best practice alert|Patients in this arm will actively generate the alert.
16635716|NCT02376842|Placebo Comparator|Standard care|This arm will be the current standard of care and will not generate the alert.
16635717|NCT02376829|Experimental|The Invisalign System|Class II correction of malocclusions
16635718|NCT02376816|Experimental|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
16635719|NCT02376816|Experimental|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
16635720|NCT02376803|Experimental|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
16635721|NCT02376803|Active Comparator|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
16635722|NCT02376790|Active Comparator|Methotrexate Monotherapy|Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
16635723|NCT02376790|Experimental|Etanercept Monotherapy|Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
16635724|NCT02376790|Experimental|Methotrexate + Etanercept|Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.
16635725|NCT02376777||Patient receiving NOAC|Follow up of patients receiving new oral anticoagulants (NOAC) medication
16635726|NCT02376777||Patient receiving VKA|Follow up of patients receiving vitamin K antagonist (VKA) medication
16635727|NCT02376725|Active Comparator|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
16635728|NCT02376725|Active Comparator|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
16635729|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:
~Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.
~AKI recovery in less than 72 hours after AKI identification.
~Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
16635730|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:
~Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.
~AKI persistence 72 hours after AKI identification.
~Normal or increased renal blood flow measured by TEE."
16635731|NCT02376699|Experimental|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
16635732|NCT02376699|Experimental|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
16635733|NCT02376699|Experimental|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
16635734|NCT02376699|Experimental|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
16635735|NCT02376699|Experimental|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
16635736|NCT02376699|Experimental|Combination Therapy in Pancreatic Cancer|SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel
16635737|NCT02376686|Experimental|Music intervention|Patient receives Music Intervention before going to sleep.
16635738|NCT02376686|No Intervention|treatment as usual|Patient receives Treatment as usual.
16635739|NCT02376673|Active Comparator|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
16635740|NCT02376673|Experimental|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
16635741|NCT02376660|Experimental|Oats|70 grams oats
16635742|NCT02376660|Placebo Comparator|usual diet and exercise|usual diet and exercise
16635743|NCT02376647|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
16635744|NCT02376647|Active Comparator|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
16635745|NCT02376634|Active Comparator|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
16635746|NCT02376634|No Intervention|Control|This group will receive the standard of care of Nationwide Children's Hospital.
16635747|NCT02376621|Active Comparator|PronovaPure 150:500 triglycerides|3 × PronovaPure 150:500 triglycerides (TG) European Union (EU)
16635748|NCT02376621|Active Comparator|Pronovum PRF-048|3 × Pronovum PRF-048
16635749|NCT02376621|Active Comparator|Pronovum PRF-037|3 × Pronovum PRF-037
16635750|NCT02376621|Active Comparator|PronovaPure 500:200 TG|3 × PronovaPure 500:200 TG EU
16635751|NCT02376621|Active Comparator|Pronovum PRF-047|3 × Pronovum PRF-047
16635752|NCT02376608|Active Comparator|Pronova Pure 150:500 EE EU|2 × PronovaPure 150:500 EE EU
16635753|NCT02376608|Active Comparator|Pronovum PRF-037|2 × Pronovum PRF-037
16635754|NCT02376608|Active Comparator|Pronovum PRF-041|2 × Pronovum PRF-041
16635755|NCT02376608|Active Comparator|Eskimo-3|3 × Eskimo-3
16635756|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
16635757|NCT02376582|Experimental|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
16635758|NCT02376582|Active Comparator|Vaccination without S. mansoni infection|DNA Protein
16635759|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
16635760|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
16635761|NCT02376543|Active Comparator|19 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
16635762|NCT02376543|Active Comparator|22 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
16635763|NCT02376530|No Intervention|Usual shopping|No change in condition.
16635764|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
16635765|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
16635766|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
16635909|NCT02375633|Active Comparator|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
16635767|NCT02376517|Active Comparator|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
16635768|NCT02376517|No Intervention|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
16635769|NCT02376504|Experimental|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
16635770|NCT02376504|Experimental|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
16635771|NCT02376504|No Intervention|Control|Participants will be asked to engage in three 10 min walking bouts each work day
16635772|NCT02376491|Active Comparator|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
16635773|NCT02376491|Experimental|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
16635774|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
16635775|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
16635776|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
16635777|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
16635778|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
16635779|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
16635780|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
16635781|NCT02376452|Experimental|RALIRI|Raltitrexed combined with irinotecan
16635782|NCT02376452|Placebo Comparator|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
16635783|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
16635784|NCT02376426|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
16635785|NCT02376426|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
16635786|NCT02376426|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
16635787|NCT02376426|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
16635788|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
16635789|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.
~Superior pedicle mammoplasty / inverted T
~Superior pedicle mammoplasty / V scar
~Batwing
~Inferior pedicle mammoplasty
~Racquet mammoplasty/radial scar
~vertical-scar mammoplasty"
16635790|NCT02376400|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
16635791|NCT02376400|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
16635792|NCT02376400|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
16635793|NCT02376400|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
16635794|NCT02376374|Experimental|10% OPV|In this arm, 10% of the households in this community will receive OPV.
16635795|NCT02376374|Experimental|30% OPV|In this arm, 30% of the households in this community will receive OPV.
16635796|NCT02376374|Experimental|70% OPV|In this arm, 70% of the households in this community will receive OPV.
16635797|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
16635798|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
16635799|NCT02376348|No Intervention|Control|Individuals receiving the standard Ministry of Health Package
16635800|NCT02376348|Experimental|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
16635801|NCT02376335|Active Comparator|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
16635802|NCT02376335|Placebo Comparator|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
16635803|NCT02376322|Experimental|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
16635804|NCT02376309|Experimental|Leu during inactivity|Leucine supplements
16635805|NCT02376309|Experimental|ND during inactivity|Nandrolone injection
16635806|NCT02376296||hormone naïve|Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.
16635807|NCT02376296||castrate resistant|Subjects with castrate resistant prostate cancer (CRPC) [defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.
16635808|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
16635809|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
16635810|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
16635811|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
16635812|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
16635813|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
16635814|NCT02376270|Experimental|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
16635815|NCT02376270|Placebo Comparator|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
16635816|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
16635817|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
16635818|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
16635819|NCT02376244|Experimental|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.
~Patients will exercise once a week for 8 weeks."
16635820|NCT02376244|Active Comparator|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.
~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.
~Patients will exercise once a week for 8 weeks."
16635821|NCT02376231|No Intervention|Standard Surgery without trial (PJ) device|Standard debulking surgery for EOC without interventional device
16635822|NCT02376231|Active Comparator|Surgery with trial (PJ) device|Debulking surgery for EOC with interventional trial device (PJ)
16635823|NCT02376218|Experimental|Hypertonic 50% dextrose pleurodesis|
16635824|NCT02376205|Experimental|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
16635825|NCT02376205|Placebo Comparator|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
16635826|NCT02376192|Experimental|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
16635827|NCT02376192|Experimental|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
16635828|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
16635829|NCT02376166|Experimental|Metformin|850 mg PO once daily for 4 weeks
16635830|NCT02376153|Experimental|ABS deployed and active|Air Barrier System (ABS) will be deployed onto the surgical field and activated.
16635831|NCT02376153|Sham Comparator|ABS deployed and NOT active|Air Barrier System (ABS) will be deployed onto the surgical field and NOT activated. This is a sham comparator to reduce the influence of the presence of the device and provide user blinding.
16635832|NCT02376140||Women|Mothers of children 36-59 months old No intervention
16635833|NCT02376140||Children|Children 36-59 months old No intervention
16635834|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
16635835|NCT02376114|Other|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
16635836|NCT02376114|Other|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
16635837|NCT02376101|Active Comparator|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
16635838|NCT02376101|Experimental|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
16635839|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
16635840|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
16635841|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
16635842|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
16635843|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
16635844|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
16635845|NCT02376088||NC|age-matched healthy checkup subjects
16635846|NCT02376075|Placebo Comparator|Placebo|Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment
16635847|NCT02376075|Active Comparator|Linagliptin|Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment
16635848|NCT02376062|Experimental|Bundled Intervention|"On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu
~Weekly case conferences
~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
16635849|NCT02376049|Active Comparator|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
16635850|NCT02376049|Active Comparator|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
16635851|NCT02376049|Active Comparator|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
16635852|NCT02376049|Placebo Comparator|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
16635853|NCT02376036|Experimental|MGD010|Subjects will receive MGD010 through IV infusion.
16635854|NCT02376036|Placebo Comparator|Placebo|Subjects will receive placebo through IV infusion.
16635855|NCT02376036|Experimental|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
16635856|NCT02376036|Placebo Comparator|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
16635857|NCT02376023|Experimental|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
16635858|NCT02376023|No Intervention|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
16635859|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
16635860|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
16635861|NCT02375997|Experimental|Standard oncology care plus palliative care|
16635862|NCT02375997|No Intervention|Standard oncology care|
16635863|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
16635864|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
16635865|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
16635866|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
16635867|NCT02375958|Experimental|Triple Negative Breast Cancer|
16635868|NCT02375958|Experimental|Head and Neck Cancer|
16635869|NCT02375958|Experimental|Esophageal Cancer|
16635870|NCT02375945|Active Comparator|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
16635871|NCT02375945|Experimental|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.
~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.
~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
16635872|NCT02375932|Experimental|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
16635873|NCT02375932|Active Comparator|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
16635874|NCT02375919|No Intervention|Control|Emergency physician will assess low risk patients for PE with conventional strategy, using D-Dimer testing with subsequent CTPA if positive
16635907|NCT02375646|Active Comparator|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
16635875|NCT02375919|Other|Intervention|PERC based Strategy : Emergency physician will assess low risk patients for PE first with calculation of PERC score. If all PERC criteria are negative, then no further testing for PE is recommended. If at least one criterion is positive, then the patient undergoes D-Dimer testing with subsequent CTPA if positive
16635876|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
16635877|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
16635878|NCT02375880|Experimental|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
16635879|NCT02375880|Experimental|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
16635880|NCT02375880|Experimental|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
16635881|NCT02375867|Active Comparator|prednisolone|This group includes patients with FHF without encephalopathy
16635882|NCT02375867|Active Comparator|methylprednisolone|This group includes patients with FHF with encephalopathy
16635883|NCT02375867|No Intervention|Non-intervention|FHF patients without any of the proposed intervention as controls
16635884|NCT02375854||Preterm infants|Less than 32 weeks' gestation
16635885|NCT02375841||Physicians, Patients, and Caregivers|This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
16635886|NCT02375828|Experimental|Patients with neonatal diabetes|Patients with neonatal diabetes
16635887|NCT02375815|Experimental|Statin Choice Implementation|
16635888|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
16635889|NCT02375789|Active Comparator|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.
~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.
~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.
~The patient remains in the trial until two separate migraines have been treated."
16635890|NCT02375789|Placebo Comparator|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.
~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.
~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.
~The patient remains in the trial until two separate migraines have been treated."
16635891|NCT02375776|Experimental|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
16635892|NCT02375776|No Intervention|Control|Usual Care - The control group will not use the study's mobile health application during the study.
16635893|NCT02375763|Experimental|Sortware suggestions|Children will fill a questionnaire regarding their dietary habits. Afterwards a dietary analysis will be performed using a computer software, and dietary instructions will be given to the children.
16635894|NCT02375763|Placebo Comparator|Traditional suggestions|
16635895|NCT02375750|Experimental|GBO and GBG|0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
16635896|NCT02375750|Active Comparator|Standard treatment|Decontamination of surface of implant
16635897|NCT02375737|Experimental|m-health|Patients will receive text message, emails, and monthly phone calls
16635898|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
16635899|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
16635900|NCT02375711|Experimental|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
16635901|NCT02375698|Experimental|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
16635902|NCT02375698|Placebo Comparator|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
16635903|NCT02375685|Experimental|gevokizumab|
16635904|NCT02375672|Experimental|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:
~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
16635905|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
16635906|NCT02375646|Experimental|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
16635908|NCT02375633|Experimental|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
16635910|NCT02375620|Experimental|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
16635911|NCT02375620|Experimental|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
16635912|NCT02375607|Other|Algometer|Algometer used patients
16635913|NCT02375594|Experimental|Exercise in park equipment|Participants in the intervention arm will attend a 3-month long program of 2 weekly one-hour exercise sessions in the exercise park equipment, guided by a physical therapist. The sessions will comprise a combination of aerobic, strength, balance and flexibility exercises. Up to 20 participants exercising simultaneously in the equipment under the guidance of an experienced LAPPSET physical therapist.
16635914|NCT02375594|No Intervention|Control|Participants in the control arm will receive usual advice on healthy habits. During the study, they will be offered to attend the talks on healthy living for elderly periodically organised by their primary care centre (CAP Vallcarca - Sant Gervasi). At the end of the study, they will be invited to an exercise session at the exercise park equipment, conducted by the study physical therapist.
16635915|NCT02375581|Experimental|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
16635916|NCT02375581|Active Comparator|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
16635917|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
16635918|NCT02375555|Experimental|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.
~Elotuzumab will be administered by intravenous (IV) infusion
~Bortezomib as a subcutaneous injection
~Lenalidomide single daily oral dose
~Dexamethasone as oral tablets and IV infusion
~Stem cell mobilization will be performed for all subjects at the end of Cycle 4.
~Subjects may elect to stop E-RVD Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive 8 cycles of induction therapy.
~- The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.
~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
16635919|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
16635920|NCT02375529|Experimental|Single Incision Cholesystectomy (SILC)|Single Incision Laparoscopic Cholecystectomy (SILC): The umbilicus is grasped and a 2 cm vertical skin and fascial incision is performed. A multiport (TriPort®) is inserted under direct vision. Principles of cholecystectomy are the same as traditional laparoscopic cholecystectomy.
16635921|NCT02375529|Active Comparator|Four Ports Cholecystectomy (4PCL)|Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
16635922|NCT02375516|Experimental|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions.
16635923|NCT02375516|No Intervention|Control group|Youths assigned to the control arm will receive no intervention.
16635924|NCT02375503|Experimental|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
16635925|NCT02375503|Placebo Comparator|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
16635926|NCT02375490|Experimental|Intervention arm|The intervention arm will participate in Healthy Start.
16635927|NCT02375490|No Intervention|Control arm|Control arm will pursue daily activities at early childcare center as usual.
16635928|NCT02375477|Experimental|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
16635929|NCT02375451||Radioiodine|Patients with a history of childhood treatment with radioiodine will be assessed for symptoms of salivary function and measurement of saliva production. These data will be compared to a normal control group.
16635930|NCT02375451||Control|Patients who are similar in age to those in the Radioiodine group, but who did not recieve I-131 therapy.
16635931|NCT02375438||Cohort Group|Patients with a clinical presentation suggestive of mitochondrial cytopathy, in whom mitochondrial deletions above 20% have been found in muscle are considered eligible if they are older than 18 years and are willing and able to give written informed consent.
16635932|NCT02375438||Control Group|Twenty healthy individuals matched for age and gender will be included in the study and considered as controls.
16635933|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
16635934|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
16635935|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
16635936|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
16635937|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
16635938|NCT02375386|Experimental|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
16635939|NCT02375386|Sham Comparator|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
16635998|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
16635940|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
16635941|NCT02375360||Children 8-12- control|Children aged 8-12 years with food allergy who are not undergoing oral immunoterapy
16635942|NCT02375360||Parents 0-12 - control|Parents to children aged 0-12 years with food allergy who are not undergoing oral immunoterapy
16635943|NCT02375360||Children 8-12 - OIT|Children aged 8-12 years with food allergy who are undergoing oral immunoterapy
16635944|NCT02375360||Teenagers 13-17 - OIT|Teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
16635945|NCT02375360||Adults >18 - OIT|Adults> 18 years with food allergy who are undergoing oral immunoterapy
16635946|NCT02375360||Parents 0-12 - OIT|Parents to children aged 0-12 years with food allergy who are undergoing oral immunoterapy
16635947|NCT02375360||Parents 13-17 - OIT|Parents to teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
16635948|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
16635949|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
16635950|NCT02375321|Experimental|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
16635951|NCT02375321|No Intervention|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
16635952|NCT02375308|Experimental|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
16635953|NCT02375308|Experimental|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
16635954|NCT02375295|Experimental|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
16635955|NCT02375295|Active Comparator|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
16635956|NCT02375282|Experimental|Ambulation Orderly Intervention|Patients that are in this group are those randomized to receive visits from the ambulation orderly (ambulation group). The patients in this group will receive the visits from the ambulation orderly in addition to the standard of care that occurs with the rest of the hospital and with the control group.
16635957|NCT02375282|No Intervention|Control Group|This is for the patients who are randomized to receive the standard care of Baystate Medical Center. The standard of care will be nurse-directed ambulation, as is currently done in all other nursing floors at Baystate Medical Center. Nurses will be instructed to walk with the patients as they did before the initiation of the ambulation orderly and as they do when the orderly is on vacation, at conferences, training, or away for illness. These patients will not receive visits from the ambulation orderly.
16635958|NCT02375269|Experimental|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
16635959|NCT02375269|No Intervention|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
16635960|NCT02375256|Experimental|AERAS-402|3 x10^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
16635961|NCT02375256|Active Comparator|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
16635962|NCT02375243|Experimental|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
16635963|NCT02375243|No Intervention|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
16635964|NCT02375230|Placebo Comparator|Control|"Control group
~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
16635965|NCT02375230|Active Comparator|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.
~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
16635966|NCT02375217|Active Comparator|Group 1 : (NS)|"Group 1 Drug combination:
~patients receive half of the recommended dose of sugammadex plus dose of neostigmine
~Sugammadex IV= -1 mg/kg( moderate NMB) or
~2 mg/kg (deep NMB)
~neostigmine IV = 50mcg/kg
~glycopyrrolate 10 mcg/kg"
16635967|NCT02375217|Active Comparator|Group 2 : (S)|"patients receive Full recommended dose of sugammadex
~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)"
16635999|NCT02374983||Research group|The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
16636276|NCT02373215|Experimental|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
16635968|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.
~Cycles 1-4 (1 cycle = 21 days)
~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)
~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol
~cisplatin 25 mg/m^2 IV daily on Days 2-5
~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18
~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
16635969|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.
~Cycles 1-2 (1 cycle = 14 days)
~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)
~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol
~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)
~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1
~Cycles 3-5 (1 cycle = 21 days)
~carboplatin daily on Days 1-3
~etoposide 400 mg/m^2 daily on Days 1-3
~stem cell reinfusion on day 5
~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15
~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
16635970|NCT02375191|Active Comparator|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
16635971|NCT02375191|Experimental|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
16635972|NCT02375178|Active Comparator|Sterile saline solution|sterile Saline solution 0,9%
16635973|NCT02375178|Experimental|chlorhexidine|chlorhexidine 0,12% mouthwash
16635974|NCT02375178|Experimental|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
16635975|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.
16635976|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
16635977|NCT02375152|Experimental|Surgical Intervention|
16635978|NCT02375139|Experimental|DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
16635979|NCT02375139|Experimental|E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
16635980|NCT02375126||Ages 18-35, no antidepressant use|Ages 18-35, up to 15 males and 15 females, no antidepressant use
16635981|NCT02375126||Ages 36-55, no antidepressant use|Ages 36-55, up to 15 males and 15 females, no antidepressant use
16635982|NCT02375126||Ages 18-55, with antidepressant use|Ages 18-55, up to 10 males and 10 females, taking antidepressants
16635983|NCT02375113|Experimental|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
16635984|NCT02375113|Placebo Comparator|Control|Placebo capsules + 25 gram whey protein / day
16635985|NCT02375100|Active Comparator|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
16635986|NCT02375100|Experimental|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
16635987|NCT02375100|Experimental|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
16635988|NCT02375074|Experimental|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
16635989|NCT02375074|Experimental|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
16635990|NCT02375061|Experimental|e-BPS intervention|"Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously."
16635991|NCT02375061|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
16635992|NCT02375048|Active Comparator|Hypofractionated WBI|Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).
16635993|NCT02375048|Experimental|Accelerated Partial Breast Irradiation|Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).
16635994|NCT02375022|Experimental|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
16635995|NCT02375009|Experimental|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
16635996|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
16635997|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
16636000|NCT02374970|Experimental|Intervention group|Actual Lumbar stability exercises involving co-contraction of the transversus abdominis and Protocolized Physiotherapy (therapeutic exercises and thermotherapy during 12 sessions)
16636001|NCT02374970|Active Comparator|Control group|Protocolized Physiotherapy treatment: therapeutic exercises and thermotherapy during 12 sessions.
16636002|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
16636003|NCT02374957|No Intervention|Control|No Cilostazol
16636004|NCT02374944|Experimental|Hardware Removal|Removal of hardware at 6 months.
16636005|NCT02374944|No Intervention|Hardware Retention|Retention of hardware at 6 months
16636006|NCT02374931|Experimental|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
16636007|NCT02374918|Experimental|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
16636008|NCT02374918|Placebo Comparator|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
16636009|NCT02374918|Experimental|HC wavelength-1 bright light|30 minutes of light exposure
16636010|NCT02374918|Placebo Comparator|HC wavelength-2 bright light|30 minutes of light exposure
16636011|NCT02374905|Experimental|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
16636012|NCT02374905|Active Comparator|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
16636013|NCT02374892|Experimental|Intervention|"Adolescents will attend a single one-on-one session with a nurse. Sessions will be youth-oriented, interactive, and engaging. They will make a health passport, go over their cardiac anatomy, watch videos among other things.
~The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up."
16636014|NCT02374892|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
16636015|NCT02374879|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
16636016|NCT02374866|No Intervention|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
16636017|NCT02374866|Experimental|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.
~Follow by email or mail is identical to the control group."
16636018|NCT02374853|Experimental|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
16636019|NCT02374853|Placebo Comparator|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
16636020|NCT02374827|Active Comparator|Standard postpartum tubal ligation|In this arm, patients will receive the standard postpartum tubal ligation by accepted methods (procedure names are the following: Modified pomeroy technique or Parkland method). These methods are procedures for completing a partial salpingectomy.
16636021|NCT02374827|Experimental|Complete Salpingectomy|In this arm, patients will receive a complete salpingectomy by documented accepted methods.
16636022|NCT02374814|Active Comparator|Rabies vaccine IM 3 dose|This is standard FDA approved schedule
16636023|NCT02374814|Experimental|Rabies vaccine ID 3 dose|This is using alternative administration method
16636024|NCT02374814|Experimental|Rabies vaccine IM 2 dose|This is using alternative dose schedule
16636025|NCT02374814|Experimental|Rabies vaccine ID 2 dose|This is using alternative dose schedule and administration
16636026|NCT02374814|Placebo Comparator|Placebo IM 1 dose|Albumin and saline comparator
16636027|NCT02374814|Placebo Comparator|Placebo ID 1 dose|Albumin and saline comparator
16636028|NCT02374801|Experimental|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
16636029|NCT02374788|Experimental|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
16636030|NCT02374788|Experimental|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
16636031|NCT02374788|No Intervention|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
16636032|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
16636033|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
16636034|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
16636035|NCT02374749|Active Comparator|comorbidities|Evaluation of the prevalence and the presence of the risks factors of the four most frequently observed comorbidities in spondyloarthritis (cardiovascular diseases, cancers, infections osteoporosis and gastro-intestinal) as it is recommended by the French Society of Rheumatology.
16636248|NCT02373410|Experimental|Umbilicus|The height of the operating table which set at the needle insertion point, is the level of umbilicus of the anesthesiologist in a standing posture.
16636036|NCT02374749|Active Comparator|self-assessment|"During the initial visit, the clinical research nurse exempt a learning program of assessment of disease activity/severity :
~for assessing the activity in SpA;
~for the calculation of BASDAI and the ASDAS-CRP
~for the transfer technique and for the calculation of the disease activity on a monthly basis during the next 12 months.
~for the risk of tobacco exposure
~for the benefit of an NSAID intake in case of painful episode of the disease
~for the benefit of home exercises
~for the spine and indication of a treatment under the supervision of a physiotherapist in case of severe disease
~for learning the patient to calculate his BASDAI and ASDAS-CRP Then, the patient will return home with his calculator and his notebook. Each month, the patient will be asked to perform the BASDAI and ASDAS-CRP calculations and to report the data on the notebook. 12 months later, the patient comes for a visit in the current practice to assess both such program and comorbidities."
16636037|NCT02374736|Experimental|Human normal immunoglobulin G (IgG > 98 % purity)|"All subjects will be treated for 6 months. The treatment will start the day of inclusion (M0).
~Privigen will be given as 2 g/kg for 2 days/month. The maximum daily dose authorized will be 80g.
~The infusion rates are the recommended rates for Privigen in other indications and are in line with the market authorization for Privigen:
~Infusions should start at a rate of 0.5 mg/kg/min (0.005 mL/kg/min; 0.3 mL/kg/h; 30 mg/kg/h). If well tolerated within 30 min, the rate can be increased in a first step to 1.0 mg/kg/min (0.01 mL/kg/min; 0.6 mL/kg/h; 60 mg/kg/h) for another 30 min.
~If well tolerated, a stepwise increase to a maximum of 8 mg/kg/min (0.08 mL/kg/min; 4.8 mL/kg/h; 480 mg/kg/h) is allowed at the discretion of the investigator."
16636038|NCT02374723|Experimental|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
16636039|NCT02374723|Active Comparator|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
16636040|NCT02374710|Experimental|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
16636041|NCT02374710|Active Comparator|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
16636042|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
16636043|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
16636044|NCT02374684|Experimental|Methosulide|Methosulide, oral administration
16636045|NCT02374684|Placebo Comparator|Placebo|Placebo, oral administration
16636046|NCT02374671|Experimental|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
16636047|NCT02374671|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
16636048|NCT02374671|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
16636049|NCT02374658|Experimental|Arts Intervention|This group will receive the weekly one-hour Living Through the Arts program in addition to their standard program of rehabilitation activities
16636050|NCT02374658|No Intervention|Control Group|This group of patients will only receive their standard program of rehabilitation activities
16636051|NCT02374645|Experimental|Volitinib (AZD6094) 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
16636052|NCT02374645|Experimental|Volitinib (AZD6094) 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
16636053|NCT02374632|Other|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) <50%.
~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
16636054|NCT02374632|Other|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) >70% matched with respect to age, gender and preoperative BMI in the LowEBL group.
~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
16636055|NCT02374619|Experimental|Iron supplement|Oral supplementation
16636056|NCT02374619|Placebo Comparator|Control|Oral supplementation
16636057|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
16636058|NCT02374567|Experimental|Psychiatric drugs|
16636059|NCT02374554|Other|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
16636060|NCT02374541|Experimental|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
16636061|NCT02374541|No Intervention|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
16636062|NCT02374528|Experimental|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
16636063|NCT02374528|Active Comparator|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
16636064|NCT02374515|Active Comparator|Endocuff assisted Colonoscopy|Endocuff assisted Colonoscopy
16636065|NCT02374515|Active Comparator|Standard Colonoscopy|Standard colonoscopy
16636249|NCT02373410|Active Comparator|Lowest rib margin|The height of the operating table which set at the needle insertion point, is the level of lowest rib margin of the anesthesiologist in a standing posture.
16636066|NCT02374502|Experimental|Brief Intervention Group|Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
16636067|NCT02374502|No Intervention|Control Group|Participants in this control group will be asked to continue with their current levels of physical activity.
16636068|NCT02374489|Experimental|single-arm studies|"LDK378 in suitable patients:
~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
16636069|NCT02374476|Experimental|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
16636070|NCT02374463|Experimental|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
16636071|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention
16636073|NCT02374437|Active Comparator|PART A (single dose)-200 mg|200 mg ARAMCHOL
16636074|NCT02374437|Active Comparator|PART A (single dose)-400 mg|400 mg ARAMCHOL
16636075|NCT02374437|Active Comparator|Part B ( food effect)- -Fasting|600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
16636076|NCT02374437|Active Comparator|Part B ( food effect)- -Fed|600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)
16636077|NCT02374437|Active Comparator|Part C ( multiple doses)- 200 mg|200 mg Aramchol tablets for ten consecutive days.
16636078|NCT02374437|Active Comparator|Part C ( multiple doses)- 400 mg|400 mg Aramchol tablets for ten consecutive days.
16636079|NCT02374437|Active Comparator|Part C ( multiple doses)- 600 mg|600 mg Aramchol tablets for ten consecutive days.
16636080|NCT02374437|Placebo Comparator|Part C ( multiple doses)- Placebo|Placebo tablets for ten consecutive days.
16636081|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).
~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
16636082|NCT02374411||HIPEC surgeons|
16636083|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
16636084|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
16636085|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
16636086|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
16636087|NCT02374385|Experimental|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
16636088|NCT02374385|Experimental|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
16636089|NCT02374385|Experimental|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
16636090|NCT02374385|Placebo Comparator|Group 4|Group 4 will receive placebo (normal saline).
16636091|NCT02374372|Active Comparator|conventional hemodialysis|conventional hemodialysis
16636092|NCT02374372|Active Comparator|hemodiafiltration On-line|hemodiafiltration On-line
16636093|NCT02374359||atrial tachycardia group|Patients diagnosed of cryptogenic stroke with atrial tachycardia in holter
16636094|NCT02374359||Non atrial tachycardia group (control group)|Patients diagnosed of cryptogenic stroke with a normal holter
16636095|NCT02374333|Experimental|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
16636096|NCT02374320|Experimental|Exparel|20 mL liposomal bupivacaine injected once
16636097|NCT02374307|Experimental|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
16636098|NCT02374307|No Intervention|Control|The control group performs activities as usual.
16636120|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
16636099|NCT02374294|Experimental|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
16636100|NCT02374294|No Intervention|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
16636101|NCT02374281|Experimental|Glucose sucking|"The newborn will receive one minute before the painful care either a compress with sucrose.
~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
~Glucose 30% by oral route (1 ml)."
16636102|NCT02374281|Active Comparator|Water sucking|"The newborn will receive one minute before the painful care either a compress with water.
~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
~Sterile water by oral route (1 ml)."
16636103|NCT02374281|Placebo Comparator|No sucking|The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
16636104|NCT02374268|Experimental|Exercise program alone|There will be 2 site sessions and 1 home session per week for 12 weeks. Each site exercise session will begin and end with a 5-10 minute warm-up and cool-down routine. The first part of the exercise program consists of 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body. To target the development of muscle power in both the lower and upper extremities, participants will be instructed to perform each concentric movement 'as rapidly as possible,' and the eccentric movement in a slow and controlled manner. A 5-minute rest period will be given prior to the start of the second part of the exercise program that consists of aerobic exercises such as ball games using fitballs or Taichi. Participants will be asked to spend an hour/week on home exercise. Thera-Bands and a leaflet showing the exercise procedures will be given to them and their caregivers.
16636105|NCT02374268|Experimental|Exercise program plus nutrition supplement|This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.
16636106|NCT02374268|Other|Waitlist control group|This group will be asked to maintain their usual physical activities and dietary habits during the first 6 months of study period. After they complete the 24-week measurement, they will receive the same 12-week exercise program as of the exercise program alone group.
16636107|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
16636108|NCT02374255|No Intervention|Usual Care|
16636109|NCT02374242|Active Comparator|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
16636110|NCT02374242|Active Comparator|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
16636111|NCT02374242|Active Comparator|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
16636112|NCT02374229|Experimental|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.
~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.
~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.
~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
16636113|NCT02374229|Active Comparator|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.
~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
16636114|NCT02374216|Other|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
16636115|NCT02374203|Experimental|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
16636116|NCT02374190||Hospital Admitted STEMI Patients|The analytical cohort for this study consisted of STEMI patients aged over 18 years admitted directly to '24/7' PPCI-capable hospitals for PPCI. STEMI patients were identified based on their discharge diagnoses and were selected as having received PPCI according to their initial reperfusion strategy. Hospitals performing only sporadic PPCI procedures, which we defined as less than 20 procedures per year, and only performing PPCIs during regular hours were not included in the analysis. Interhospital transfers were not included in the analysis, and we limited our analysis to PPCIs conducted within 6 hours on hospital arrival on the assumption that patients with a DTB time beyond this did not receive PCI as a primary reperfusion strategy. The analysis was conducted for the time period for which data were available-1 January 2007 to 31 December 2012. We conducted a complete-case analysis.
16636117|NCT02374177||Propofol group|Patient anesthetized using propofol
16636118|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
16636119|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
16636121|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
16636122|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
16636123|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
16636124|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
16636125|NCT02374125|Experimental|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
16636126|NCT02374125|Experimental|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
16636127|NCT02374125|Active Comparator|Control Group|Protocolized physiotherapy
16636128|NCT02374112|Experimental|Experimental|Creatine supplementation
16636129|NCT02374112|Placebo Comparator|Control|Placebo supplementation
16636130|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
16636131|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
16636132|NCT02374086|Experimental|Exercise Training|Subjects will exercise for 8 weeks
16636133|NCT02374073|Experimental|Intervention group|Treated with protocolized physiotherapy and functional massage
16636134|NCT02374073|Experimental|Control group|Treated with protocolized physiotherapy
16636135|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0
~Second injection permitted at Week 8 IF:
~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
16636136|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0
~Second injection permitted at Week 8 IF:
~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
16636137|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0
~Second injection permitted at Week 12 IF:
~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
16636138|NCT02374047|Experimental|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
16636139|NCT02374047|Experimental|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
16636140|NCT02374047|Experimental|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
16636141|NCT02374047|Experimental|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
16636142|NCT02374047|Experimental|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
16636143|NCT02374047|Experimental|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
16636144|NCT02374047|Experimental|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
16636145|NCT02374047|Experimental|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
16636146|NCT02374047|Experimental|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
16636147|NCT02374047|Experimental|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
16636148|NCT02374047|Experimental|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
16636149|NCT02374047|Experimental|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
16636150|NCT02374034|Experimental|Treatment|Experimental group (n=20) completed a corrective exercise routine, as per the Egoscue Method, at least five days per week for two weeks.
16636151|NCT02374034|No Intervention|Control|The control group maintained their current lifestyle for the two-week duration of the study.
16636152|NCT02374021|Active Comparator|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
16636153|NCT02374021|Active Comparator|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
16636154|NCT02374008|Experimental|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
16636155|NCT02374008|Active Comparator|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
16636156|NCT02373995|Active Comparator|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
16636157|NCT02373995|Placebo Comparator|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
16636158|NCT02373956|Experimental|MELECTIS G|"In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.
~Intervention: Usual care Intervention: MELECTIS G"
16636179|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
16636159|NCT02373956|Active Comparator|Usual care|"Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
~Intervention: Usual care"
16636160|NCT02373943|Experimental|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
16636161|NCT02373943|Active Comparator|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
16636162|NCT02373943|Sham Comparator|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
16636163|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
16636164|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
16636165|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
16636166|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
16636167|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
16636168|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
16636169|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636170|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636171|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636172|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636173|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636174|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636175|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636176|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636177|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
16636178|NCT02373917||study group|patient who in the biopsy showed lung cancer
16636180|NCT02373904|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
16636181|NCT02373891|Experimental|T1|
16636182|NCT02373891|Experimental|T0|
16636183|NCT02373878|Active Comparator|Telecoaching plus plate|Telecoaching plus portion control plate
16636184|NCT02373878|Active Comparator|Usual Care|Usual Care
16636185|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
16636186|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
16636187|NCT02373839|Other|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
16636188|NCT02373839|No Intervention|Controls|induction of labour at 37 weeks of gestation.
16636189|NCT02373813|Experimental|Open Label Run-In: Etanercept plus Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
16636190|NCT02373813|Experimental|Double-Blind Treatment: Methotrexate Monotherapy|"Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.
~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
16636191|NCT02373813|Experimental|Double-Blind Treatment: Etanercept Monotherapy|"Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.
~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
16636192|NCT02373813|Experimental|Double-Blind Treatment: Etanercept plus Methotrexate|"Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.
~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment)."
16636193|NCT02373800||The study population|"The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.
~Intervention: Cervical ultrasound with elastography"
16636194|NCT02373787|Experimental|creos xenoprotect|resorbable collagen membrane
16636195|NCT02373787|Active Comparator|Bio-Gide|Bio-Gide, resorbable collagen membrane
16636196|NCT02373774|No Intervention|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
16636197|NCT02373774|Experimental|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
16636198|NCT02373748|Experimental|BioGaming YuGo System|
16636199|NCT02373735|Active Comparator|Group A (SVV <10% group)|"infuse crystalloid (Hartmann's solution) 6-10 ml/kg/hr continuously during surgery
~infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery
~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte)"
16636200|NCT02373735|Experimental|Group B (SVV 10-20% group)|"infuse crystalloid (Hartmann's solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
~infuse colloid (Volulyte) 200 ml if SVV is > 20%
~infuse mannitol 0.5 g/kg or lasix 5 mg if SVV < 10%
~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte), mannitol, lasix"
16636201|NCT02373722|Experimental|Group I (video, text message)|Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
16636202|NCT02373722|Experimental|Group II (educational video)|Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
16636203|NCT02373722|Experimental|Group III (text message)|Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
16636204|NCT02373722|Experimental|Group IV (control)|Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
16636205|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
16636206|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score < 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
16636207|NCT02373683|Experimental|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
16636208|NCT02373683|No Intervention|Standard Care|Care dictated by clinical team.
16636209|NCT02373670|Experimental|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
16636210|NCT02373670|Active Comparator|Education|Community health workers providing health education to promote healthy behaviors
16636245|NCT02373436|Other|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
16636246|NCT02373423|Experimental|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
16636211|NCT02373657|Experimental|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
16636212|NCT02373657|No Intervention|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
16636213|NCT02373644|Experimental|HVLA Thrust Manipulation and DN|
16636214|NCT02373644|Active Comparator|Conventional Physical Therapy|
16636215|NCT02373631|Experimental|Dry Needling, Conventional PT|
16636216|NCT02373631|Active Comparator|Conventional PT|
16636217|NCT02373618|Experimental|Experimental: DN and Conventional PT|
16636218|NCT02373618|Active Comparator|Active Comparator: Conventional PT|
16636219|NCT02373605|Experimental|Dry Needling,Thrust Manipulation|
16636220|NCT02373605|Active Comparator|Exercise,Non-thrust Mobilization|
16636221|NCT02373592|Placebo Comparator|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.
~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
16636222|NCT02373592|Experimental|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.
~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.
~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
16636223|NCT02373579|Active Comparator|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .
~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
16636224|NCT02373579|Active Comparator|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
16636225|NCT02373566|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
16636226|NCT02373566|No Intervention|STSG alone|STSG alone
16636227|NCT02373553|No Intervention|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
16636228|NCT02373553|Experimental|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
16636229|NCT02373553|Experimental|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
16636230|NCT02373527|No Intervention|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
16636231|NCT02373527|Experimental|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
16636232|NCT02373514|Active Comparator|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
16636233|NCT02373514|Active Comparator|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
16636234|NCT02373501|Experimental|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
16636235|NCT02373501|Experimental|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
16636236|NCT02373488|Other|control|lifestyle advice
16636237|NCT02373488|Active Comparator|intervention-1|connective tissue manipulation
16636238|NCT02373488|Active Comparator|intervention-2|abdominal massage
16636239|NCT02373475|Experimental|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
16636240|NCT02373475|Active Comparator|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
16636241|NCT02373462|Experimental|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP <140/90 mmHg)
16636242|NCT02373462|Active Comparator|other group|other anti-hypertensive drug (titrating BP <140/90 mmHg)
16636243|NCT02373449|Experimental|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
16636244|NCT02373436|Experimental|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.
~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
16636250|NCT02373410|Active Comparator|Xiphoid|The height of the operating table which set at the needle insertion point, is the level of xiphoid of the anesthesiologist in a standing posture.
16636251|NCT02373410|Active Comparator|Nipple|The height of the operating table which set at the needle insertion point, is the level of nipple of the anesthesiologist in a standing posture.
16636252|NCT02373397|Experimental|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
16636253|NCT02373397|Placebo Comparator|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
16636254|NCT02373384|Experimental|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;
~Oral alkalinization
~Potassium citrate 20 mEq three times daily
~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.
~Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.
~Dietary recommendations
~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;
~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
16636255|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
16636256|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
16636257|NCT02373358|Experimental|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
16636258|NCT02373332||Healthy subjects|Healthy subjects for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
16636259|NCT02373332||Type 2 diabetes mellitus (T2DM) patients|T2DM patients for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
16636260|NCT02373319|Experimental|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
16636261|NCT02373319|Experimental|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
16636262|NCT02373319|Active Comparator|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
16636263|NCT02373319|Active Comparator|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
16636264|NCT02373306|Active Comparator|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
16636265|NCT02373306|No Intervention|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
16636266|NCT02373280|Active Comparator|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
16636267|NCT02373280|Experimental|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.
16636268|NCT02373280|Experimental|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.
16636269|NCT02373280|Experimental|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
16636270|NCT02373254|Active Comparator|Ibuprofen 400 mg|Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
16636271|NCT02373254|Active Comparator|Ibuprofen 800 mg|Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
16636272|NCT02373254|Active Comparator|Norco|Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.
16636273|NCT02373241|Active Comparator|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <95th percentile
16636274|NCT02373241|Experimental|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <75th percentile
16636275|NCT02373228|Experimental|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
16636277|NCT02373215|Experimental|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
16636278|NCT02373215|Experimental|Cohort 2|Healthy patients dosing up to 180mg BID
16636279|NCT02373202|Experimental|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
16636280|NCT02373202|Experimental|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
16636281|NCT02373202|Experimental|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
16636282|NCT02373202|Experimental|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
16636283|NCT02373189|Experimental|Bright light|
16636284|NCT02373176|Experimental|[14C] PRC-4016 (Icosabutate)|Investigational medicinal product (IMP), [14C] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 μCi [7.4 MBq]). The radiochemical purity of [14C]PRC-4016 will be at least 97%.
16636285|NCT02373163|Active Comparator|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
16636286|NCT02373163|Active Comparator|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
16636287|NCT02373163|Active Comparator|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
16636288|NCT02373150|Experimental|Group A1|Dose 1 or placebo
16636289|NCT02373150|Experimental|Group A2|Dose 2 or placebo
16636290|NCT02373150|Experimental|Group A3|Dose 3 or placebo
16636291|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
16636292|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
16636293|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
16636294|NCT02373111|Active Comparator|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
16636295|NCT02373111|Placebo Comparator|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
16636296|NCT02373098|Experimental|FTY720|
16636297|NCT02373098|No Intervention|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
16636298|NCT02373085|Experimental|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
16636299|NCT02373085|No Intervention|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
16636300|NCT02373072|Experimental|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
16636301|NCT02373072|Experimental|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
16636302|NCT02373059|Experimental|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
16636303|NCT02373059|Active Comparator|Usual Pharmaceutical care|Usual Care
16636304|NCT02373046|Experimental|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
16636305|NCT02373046|Experimental|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
16636306|NCT02373033|Active Comparator|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
16636307|NCT02373033|Active Comparator|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
16636308|NCT02373033|Placebo Comparator|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
16636309|NCT02373020||group 1|colonoscopic biopsies from patients with colorectal cancer patients
16636310|NCT02373020||(Group 2|colonoscopic biopsies from healthy controls
16636311|NCT02373007|Other|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
16636312|NCT02373007|Other|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
16636313|NCT02372994|Experimental|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
16636314|NCT02372994|No Intervention|Control Group|Participants receive usual care.
16636315|NCT02372981|Experimental|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
16636316|NCT02372981|Active Comparator|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
16636317|NCT02372955|Experimental|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
16636318|NCT02372955|Active Comparator|glimpiride|glimpiride 4 mg daily for 16 weeks
16636319|NCT02372942|Experimental|Lattoferrin|Use of Lattoferin for prevention of preterm delivery
16636320|NCT02372942|Experimental|Progesterone|Use of Progesterone for prevention of preterm delivery
16636321|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
16636322|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
16636323|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
16636324|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
16636325|NCT02372903|Experimental|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
16636326|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
16636327|NCT02372877|Experimental|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
16636328|NCT02372864|No Intervention|Care as usual|"All participants in the intervention and control group receive the care as usual. The care as usual consists of a clinic appointment with the research nurse. In this appointment the RRSO-induced menopausal complaints will be discussed in more detail. Depending on the complaints at hand, information, reassurance and life style advice will be offered. A leaflet with relevant information will be provided for. Furthermore, the usual medical care may include prescription of (non-)hormonal medicationsTwelve weeks after the clinic appointment, the research nurse will contact all participants per telephone to ask whether there are issues that remain to be addressed.
~Participants are allowed to continue the use of all their current medication."
16636329|NCT02372864|Experimental|Mindfullness based stress reduction|
16636330|NCT02372851|Active Comparator|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
16636331|NCT02372851|No Intervention|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
16636332|NCT02372812|Active Comparator|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
16636333|NCT02372812|Placebo Comparator|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
16636334|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
16636335|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
16636336|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
16636337|NCT02372786|Other|Acne Keloidalis Nuchae|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.
16636338|NCT02372786|Other|Tattoo|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.
16636339|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
16636340|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
16636341|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
16636342|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
16636343|NCT02372760|Experimental|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
16636344|NCT02372760|Active Comparator|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
16636345|NCT02372747|Experimental|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
16636346|NCT02372747|Experimental|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
16636347|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
16636348|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
16636349|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
16636350|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
16636351|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
16636409|NCT02372331|Experimental|ERAS perioperative management|"behavioral intervention (counselling, audit)
~dietary supplement
~procedure (preoperative and postoperative)
~drug"
16636352|NCT02372708||Experimental|diluted dinitrophenyl(DNP) Vaseline (which equaled to 2% DNP 0.1ml) was started to be directly spread on the surfaces of primary or metastatic tumors of malignant melanoma patients since the first day of every circle of chemotherapy, simultaneously laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2. The tumors were wrapped and blocked for two days to induce contact dermatitis. If lymph nodes had been cleared, sensibilization of 2×2cm was performed at occipital region. It was repeated once a week.
16636353|NCT02372708||Control|only diluted DNP Vaseline was spread and the operation were the same with the treatment group
16636354|NCT02372695|Experimental|Treatment|Patient will take one pill of paricalcitol a day.
16636355|NCT02372695|No Intervention|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
16636356|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.
~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
16636357|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
16636358|NCT02372669|Experimental|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
16636359|NCT02372669|Active Comparator|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
16636360|NCT02372656|Placebo Comparator|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
16636361|NCT02372656|Active Comparator|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
16636362|NCT02372656|Active Comparator|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
16636363|NCT02372643|Other|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
16636364|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
16636365|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
16636366|NCT02372617||Group A|bone graft - autologous
16636367|NCT02372617||Group B|bone graft - ceramic
16636368|NCT02372604|Active Comparator|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).
~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
16636369|NCT02372604|Experimental|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).
~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
16636370|NCT02372591|Placebo Comparator|Placebo|
16636371|NCT02372591|Active Comparator|Hydromorphone|
16636372|NCT02372591|Experimental|Buprenorphine|
16636373|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
16636374|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
16636375|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
16636376|NCT02372565|Experimental|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
16636377|NCT02372565|Active Comparator|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
16636378|NCT02372552|Experimental|CROMA|Microwave coagulation of small blood vessels
16636379|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
16636380|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
16636381|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
16636382|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
16636383|NCT02372500|Experimental|Chewing gum|Patients will chew sugar free gum three times a day
16636384|NCT02372500|No Intervention|Control|Normal post operative care
16636797|NCT02369822|No Intervention|None supplemented|followed up for 1 month
16636385|NCT02372487|Active Comparator|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
16636386|NCT02372487|Active Comparator|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
16636387|NCT02372474|Experimental|Stem Cell therapy in POF|POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted.
16636388|NCT02372461|Placebo Comparator|Experimental|Placebo
16636389|NCT02372461|Active Comparator|Control|Amoxicillin Liquid
16636390|NCT02372448|Other|ALK-positive|ALK positive analysis on CTCs detected by ISET
16636391|NCT02372448|Other|ALK-negative|ALK negative analysis on CTCs detected by ISET
16636392|NCT02372435|Experimental|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
16636393|NCT02372435|Active Comparator|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
16636394|NCT02372422|Experimental|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
16636395|NCT02372422|Other|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
16636396|NCT02372409|Experimental|Arm A (MRI-guided laser ablation)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
~Participants will undergo DCE and DSC-MRI imaging at the following time points:
~no more than 3 weeks prior to MLA (OPTIONAL)
~within approximately 4 days after MLA
~2-4 weeks after MLA
~Every 12 weeks (+/- 7 days) for the first year or until disease progression"
16636397|NCT02372409|Experimental|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
~Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes
~Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)
~Participants will undergo DCE and DSC-MRI imaging at the following time points:
~no more than 3 weeks prior to MLA (OPTIONAL)
~within approximately 4 days after MLA
~2-4 weeks after MLA
~every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
16636398|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
16636399|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
16636400|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes
~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)
~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)
~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)
~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
16636401|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).
~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)
~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)
~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)
~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
16636402|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes
~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)
~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)
~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)
~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
16636403|NCT02372370|Active Comparator|Interventions|All participants receive all interventions.
16636404|NCT02372357|Experimental|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.
~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
16636405|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
16636406|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
16636407|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
16636408|NCT02372331|No Intervention|Conventional perioperative management|"Preop usual biliary drainage
~Preop smoking and alcohol
~Preop parenteral nutrition
~Oral bowel preparation (mechanical bowel preparation )
~Preoperative fasting > 12 hours
~Pre-anesthetic medication
~Anti-thrombotic prophylaxis
~Antimicrobial prophylaxis and skin preparation
~Intravenous analgesia : PCA
~Prevention of postoperative nausea and vomiting (PONV) (X)
~Incision : surgeon direction
~Avoiding hypothermia
~Nasogastric intubation (O)
~Postop glycemic control
~Positive fluid balance
~Perianastomotic drain removal over POD #5
~Somatostatin analogues
~Transurethral catheter removal
~Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)
~Postop routine artificial nutrition (O), soft diet at POD #5
~Early and scheduled mobilization"
16636410|NCT02372318|Experimental|Nalmefene Challenge|Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
16636411|NCT02372318|Placebo Comparator|Placebo|Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
16636412|NCT02372305|Active Comparator|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
16636413|NCT02372305|Active Comparator|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
16636414|NCT02372292|Active Comparator|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
16636415|NCT02372292|Active Comparator|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
16636416|NCT02372279|No Intervention|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
16636417|NCT02372279|Experimental|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
16636418|NCT02372266|Experimental|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
16636419|NCT02372266|Active Comparator|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
16636420|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
16636421|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
16636422|NCT02372240|Experimental|VLX1570 and dexamethasone|"VLX1570 IV (0.05, 0.15, 0.3, 0.6, 1.2, 2.0 mg/kg) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
~Dexamethasone 20 mg PO/IV"
16636423|NCT02372227|Experimental|VS-5584 and VS-6063|
16636424|NCT02372214|No Intervention|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
16636425|NCT02372214|Experimental|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
16636426|NCT02372201|Experimental|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
16636427|NCT02372188|Experimental|Water|125 mL water are administered during or before gastric pH measurement
16636428|NCT02372188|Experimental|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
16636429|NCT02372188|Experimental|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
16636430|NCT02372188|Experimental|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
16636431|NCT02372175|Experimental|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
16636432|NCT02372175|Experimental|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10^4 PFU/mL) inoculated subcutaneously
16636433|NCT02372175|Experimental|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10^5 PFU/mL) inoculated subcutaneously
16636434|NCT02372162||Group A - TACE|"Patients with transarterial chemoembolization (TACE) will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
16636435|NCT02372162||Group B - Sorafenib|"Patients with Sorafenib treatment will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
16636436|NCT02372149|Experimental|IVIg--Washout--0.9% NaCl (CROSSOVER)|"10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)
~Washout period
~0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
16636437|NCT02372149|Experimental|0.9% NaCl--Washout--IVIg (CROSSOVER)|"0.9% sodium chloride in water - equal volume to IVIg - Monthly x4
~Washout period
~10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
16636438|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
16636439|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
16636440|NCT02372123|Other|control|lifestyle advice
16636441|NCT02372123|Active Comparator|intervention|connective tissue manipulation
16636442|NCT02372110|Experimental|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
16636443|NCT02372110|Placebo Comparator|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
16636444|NCT02372097|Experimental|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
16636445|NCT02372097|Experimental|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
16636509|NCT02371694|Experimental|Fat Test drink (25g)|This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
16636446|NCT02372084|Experimental|osilodrostat (LCI699)|Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).
16636447|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
16636448|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:
~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
16636449|NCT02372032|Experimental|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
16636450|NCT02372032|Active Comparator|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
16636451|NCT02372019|Experimental|CBM With Active Fear Reactivation|
16636452|NCT02372019|Active Comparator|CBM With Inert Fear Reactivation|
16636453|NCT02372019|Placebo Comparator|Inert CBM With Inert Fear Reactivation|
16636454|NCT02372006|Experimental|afatinib|dose escalation
16636455|NCT02371993|Experimental|Choline 650 mg twice daily|See above
16636456|NCT02371993|Placebo Comparator|Placebo|See above
16636457|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
16636458|NCT02371980|Placebo Comparator|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
16636459|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
16636460|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
16636461|NCT02371980|Placebo Comparator|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
16636462|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
16636463|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
16636464|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
16636465|NCT02371954|Experimental|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
16636466|NCT02371954|Active Comparator|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
16636467|NCT02371941|Experimental|Oral cromolyn|"Subjects randomized to the experimental arm will receive oral cromolyn sodium. The dose will be per current package insert for oral cromolyn:
~Subjects 2-12 years of age - 100 mg (1 ampule) 4 times daily Subjects 13-18 years of age - 200 mg (2 ampules) 4 times daily"
16636468|NCT02371941|Placebo Comparator|Placebo|Subjects randomized to placebo will receive normal saline ampules Subjects 2-12 years of age - 1 ampule 4 times daily Subjects 13-18 years of age - 2 ampules 4 times daily
16636469|NCT02371928|Active Comparator|Neuromuscular exercise program|"A 12-week physiotherapeutic, supervised exercise program with focus on neuromuscular shoulder control besides incorporation of kinetic chain exercises.
~The exercise program contains the following focal points: Scapula and glenohumeral setting/control, dynamic shoulder stability, muscle co-contractions (weight-bearing upper extremity exercises) and proprioceptive training."
16636470|NCT02371928|Active Comparator|Standard home exercise program|"One physiotherapeutic-supervised instruction in 12 weeks of active exercises for the rotator cuff and scapular muscles.
~Information about the shoulder injury and how to avoid pain provoking movements besides future implications is given. Also, participants receives one phone call after six weeks of training from a physiotherapist to ensure good compliance and answer any questions that the patient may have."
16636471|NCT02371915|Experimental|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
16636510|NCT02371694|Experimental|Fat Test drink (13g)|This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
16636472|NCT02371915|No Intervention|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
16636473|NCT02371902|Active Comparator|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
16636474|NCT02371902|Active Comparator|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
16636475|NCT02371889|Experimental|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
16636476|NCT02371889|Placebo Comparator|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
16636477|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
16636478|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
16636479|NCT02371837|Experimental|pilates group|Pilates based protocol for 6 weeks
16636480|NCT02371837|No Intervention|control group|No treatment group
16636481|NCT02371824||MRI Sequence|
16636482|NCT02371811|Experimental|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
16636483|NCT02371811|No Intervention|control group|In this group we will do abdominal hysterectomy without v care.
16636484|NCT02371798|Experimental|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
16636485|NCT02371785|Experimental|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
16636486|NCT02371772|Other|Self-management anticoagulation treatment|Trained to monitor INR and dose warfarin
16636487|NCT02371772|No Intervention|Conventional anticoagulation treatment|Before enrolment
16636488|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
16636489|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
16636490|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
16636491|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
16636492|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
16636493|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
16636494|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
16636495|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
16636496|NCT02371746|Experimental|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
16636497|NCT02371746|Experimental|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
16636498|NCT02371746|Experimental|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
16636499|NCT02371733|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
16636500|NCT02371733|Sham Comparator|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
16636501|NCT02371720|Experimental|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
16636502|NCT02371720|Active Comparator|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
16636503|NCT02371720|Experimental|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
16636504|NCT02371720|Active Comparator|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
16636505|NCT02371707|Experimental|Idalopirdine 60 mg formulation A (test)|
16636506|NCT02371707|Experimental|Idalopirdine 60 mg formulation B (reference)|
16636507|NCT02371694|Experimental|Fat Test drink (50g)|This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
16636508|NCT02371694|Experimental|Fat Test drink (38g)|This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
16636550|NCT02371408|Experimental|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
16636511|NCT02371694|Placebo Comparator|Fat Test drink (3g)|This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
16636512|NCT02371694|Active Comparator|Carbohydrate Test drink|This drink contains 20g of glucose from de-gassed lucozade energy.
16636514|NCT02371668|Placebo Comparator|Placebo|Placebo, 5% dextrose (D-glucose) water
16636515|NCT02371668|Experimental|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
16636516|NCT02371655|Active Comparator|Diet included|Diet is included in bowel preparation
16636517|NCT02371655|Experimental|Diet not included|Diet is not included in bowel preparation
16636518|NCT02371629|Experimental|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
16636519|NCT02371629|Experimental|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
16636520|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
16636521|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
16636522|NCT02371603|Experimental|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
16636523|NCT02371603|Experimental|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
16636524|NCT02371590|Experimental|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
16636525|NCT02371577|Experimental|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
16636526|NCT02371564|Active Comparator|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
16636527|NCT02371564|Active Comparator|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
16636528|NCT02371551||1|All patients
16636529|NCT02371538|Experimental|Donor Breastmilk|Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.
16636530|NCT02371525|No Intervention|Standard of Care|
16636531|NCT02371525|Experimental|Prepmate|
16636532|NCT02371512|Experimental|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
16636533|NCT02371512|Active Comparator|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
16636534|NCT02371499|Experimental|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
16636535|NCT02371499|Placebo Comparator|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
16636536|NCT02371486|Experimental|Nich Repair|"Interventions to be administered:
~Ultrasound Scan
~Diagnostic Hysteroscopy
~hysteroscopic repair of cesarean section defect
~IVF cycle"
16636537|NCT02371486|Sham Comparator|No Repair|"Interventions to be administered:
~Ultrasound Scan
~Diagnostic Hysteroscopy
~IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
16636538|NCT02371473|Experimental|#1 (Acetazolamide-placebo)|The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
16636539|NCT02371473|Experimental|#2 (Placebo-acetazolamide)|The arm #2 consists of 6 eligible patients who receive placebo once daily an hour before sleep for first six nights and after two weeks washout they receive acetazolamide 250mg for six nights in the same order. After each six-day period they undergo polysomnography.
16636540|NCT02371460|Experimental|DHA-rich algal oil|1200mg DHA per day
16636541|NCT02371460|Placebo Comparator|Placebo|No supplementation in DHA
16636542|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:
~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)
~Phase 2:
~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)
~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
16636543|NCT02371434|Experimental|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):
~nTregs
~Prednisolone
~MMF
~Tacrolimus"
16636544|NCT02371421||Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
16636545|NCT02371408|Experimental|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
16636546|NCT02371408|Experimental|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
16636547|NCT02371408|Experimental|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
16636548|NCT02371408|Experimental|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
16636549|NCT02371408|Experimental|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
16636551|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
16636552|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
16636553|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
16636554|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
16636555|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
16636556|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
16636557|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
16636558|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
16636559|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
16636560|NCT02371343|Active Comparator|Fish-Oil|"The pregnants with gestational diabetes given fish oil:
~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
16636561|NCT02371343|Placebo Comparator|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:
~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
16636562|NCT02371317|Experimental|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
16636563|NCT02371317|Active Comparator|Stress Management Education|The Stress Management Education intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
16636564|NCT02371317|Other|AHA Recommended Self-Care|All participants will receive the American Heart Association - Understanding and Controlling Your High Blood Pressure Brochure and information on the Dietary Approach to Stop Hypertension from the National Institutes of Health. These brochures describe ways that individuals can improve their lifestyle through better diet and exercise. Participants will get a chance to try and make healthy lifestyle changes on their own, using this information.
16636565|NCT02371304|Active Comparator|Total Mesorectal Excision|After local excision patients will receive additional TME surgery
16636566|NCT02371304|Experimental|Adjuvant chemoradiotherapy|After local excision. Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
16636567|NCT02371291|Experimental|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
16636568|NCT02371291|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
16636569|NCT02371278|Other|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.
~Placebo with meals for 3 days, and leucine with meals for 3 days."
16636570|NCT02371278|Other|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.
~Placebo with meals for 3 days, and leucine with meals for 3 days."
16636571|NCT02371265|Experimental|Adherence and retention intervention|Implementation of adherence and retention package
16636572|NCT02371265|No Intervention|Control|Clusters continue without intervention package
16636573|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
16636574|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
16636575|NCT02371239|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
16636576|NCT02371239|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
16636577|NCT02371239|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
16636959|NCT02368717|Placebo Comparator|Placebo|Placebo Enema
16636578|NCT02371226|Experimental|Cohort 1|1 mg/kg AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) administered once weekly x 8 weeks
16636579|NCT02371226|Experimental|Cohort 2|3 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
16636580|NCT02371226|Experimental|Cohort 3|6-9 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
16636581|NCT02371213|Experimental|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
16636582|NCT02371213|No Intervention|no social networking on mobile phone|usual antenatal care group-health education
16636583|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
16636584|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
16636585|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
16636586|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
16636587|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
16636588|NCT02371161|Experimental|R-DHAP/R-ICE|High-dose myeloablative therapy (R-DHAP or R-ICE) and conditioning therapy (BEAM or FEAM) in elderly patients with relapsed NHL or resistant to firs line therapy
16636589|NCT02371148|Experimental|Bortezomib-Rituximab-Bendamustine|Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.
16636590|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
16636591|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
16636592|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
16636593|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
16636594|NCT02371122|Sham Comparator|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
16636595|NCT02371109||selftaken vs clinical taken swabs|
16636596|NCT02371096|Experimental|RGB-03|
16636597|NCT02371096|Active Comparator|MabThera (rituximab)|
16636598|NCT02371083|No Intervention|Routine|Subjects will continue with regular pessary care every 12 weeks.
16636599|NCT02371083|Experimental|Extended|Subjects will have extended time between pessary care visits which will occur every 24 weeks.
16636600|NCT02371070||Rivaroxaban|N=20
16636601|NCT02371070||Apixaban|N=20
16636602|NCT02371070||Dabigatran|N=20
16636603|NCT02371057||patients under follow-up known to have sleep apnoea|
16636604|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
16636605|NCT02371044||Rivaroxaban|N=20
16636606|NCT02371044||Apixaban|N=20
16636607|NCT02371044||Dabigatran|N=20
16636608|NCT02371031|Experimental|Arm 1: FDOPA-PET/MRI|"Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.
~In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.
~When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
16636609|NCT02371018|No Intervention|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
16636610|NCT02371018|Experimental|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
16636611|NCT02371018|Experimental|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
16636612|NCT02371005|Other|Measurement of the periodontal ligament space|Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
16636613|NCT02371005|Other|Radiographic analysis of oro-facial manifestations|Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
16636614|NCT02370992||Receiving I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
16636615|NCT02370979|Experimental|Dolutegravir|
16636616|NCT02370966|Placebo Comparator|Potato starch|Potato powder will be incorporated in the placebo product.
16636617|NCT02370966|Active Comparator|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
16636618|NCT02370953|Experimental|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
16636619|NCT02370953|Active Comparator|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
16636620|NCT02370940|Experimental|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
16636621|NCT02370940|Experimental|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
16636622|NCT02370927|Placebo Comparator|Control|100% Wheat Flour
16636623|NCT02370927|Experimental|Cereal w/ pea protein|Pea protein
16636624|NCT02370927|Experimental|Cereal w/ pea starch|Pea starch
16636625|NCT02370927|Experimental|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
16636626|NCT02370927|Experimental|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
16636627|NCT02370927|Experimental|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
16636628|NCT02370914|Experimental|Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a SCAT test.
16636629|NCT02370914|Experimental|Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a SCAT test.
16636632|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.
~The dose levels of lenalidomide will be as follows:
~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles
~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles
~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles
~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
16636633|NCT02370875|Experimental|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
16636634|NCT02370875|Sham Comparator|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
16636635|NCT02370862|Experimental|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
16636636|NCT02370849|Experimental|NCS|nimotuzumab plus cisplatin and S-1
16636637|NCT02370849|Active Comparator|CS|cisplatin and S-1
16636638|NCT02370836|Experimental|Psycho-oncological education|One 60 minute psycho-oncological education session on late effects, fatigue and stress management.
16636639|NCT02370836|No Intervention|Usual Care|Usual care includes completion of a symptom checklist by the nurse practitioner
16636640|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
16636641|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
16636642|NCT02370810|Other|weekly check-in group with delayed treatment|will complete weekly measures and commence the treatment once the experimental group completes the intervention
16636643|NCT02370797|Experimental|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
16636644|NCT02370784|Active Comparator|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
16636645|NCT02370784|Placebo Comparator|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
16636646|NCT02370771|Experimental|Patient with hand osteoarthritis|Biological sampling and Radiographic evaluation of patient with erosive and non erosive hand osteoarthritis
16636647|NCT02370758|Active Comparator|Low CMV CMI|Patients that show low levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) continued for an additional 2 months at half dose.
16636648|NCT02370758|No Intervention|High CMV CMI|Patients that show high levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) stopped.
16636649|NCT02370745|Experimental|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.
~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
16636650|NCT02370745|Experimental|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.
~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
16636651|NCT02370745|Experimental|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.
~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
16636652|NCT02370745|Experimental|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.
~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
16636653|NCT02370745|Experimental|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.
~The intervention here is: 15g of mixed essential amino acid drink."
16636654|NCT02370745|Experimental|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.
~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
16636655|NCT02370745|Experimental|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.
~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
16636656|NCT02370745|Experimental|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.
~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
16636657|NCT02370732|Other|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.
~2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.
~2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
16636658|NCT02370719|Experimental|Intervention Group|Mobile application plus standard of care
16636659|NCT02370719|No Intervention|Control Group|Standard of care
16636660|NCT02370706|Experimental|Dose Escalation Arm 1|
16636661|NCT02370706|Experimental|Dose Escalation Arm 2|
16636662|NCT02370706|Experimental|Dose Escalation Arm 3|
16636663|NCT02370706|Experimental|Dose Expansion Arm 1|
16636664|NCT02370706|Experimental|Dose Expansion Arm 2|
16636665|NCT02370706|Experimental|Dose Expansion Arm 3|
16636666|NCT02370693|Active Comparator|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
16636667|NCT02370693|Placebo Comparator|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
16636668|NCT02370680|Experimental|Durlaza™, 1 capsule|Aspirin run-in, followed with Durlaza™, one capsule QD (quaque die), for 14 ± 4 days and an in-patient visit
16636669|NCT02370680|Experimental|Durlaza™, 2 capsules|in a rollover with 10 subjects from the first arm, an aspirin run-in, followed by Durlaza™, two capsules QD, for 14 ± 4 days and an in-patient visit
16636670|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
16636671|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
16636703|NCT02370524|Experimental|[18F]T807|At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807
16636672|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
16636673|NCT02370654|Experimental|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
16636674|NCT02370654|Active Comparator|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
16636675|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
16636676|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
16636677|NCT02370628|Experimental|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
16636678|NCT02370628|Active Comparator|Facet block|injection of anti-inflammatory and analgesic drugs
16636679|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
16636680|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
16636681|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
16636682|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
16636683|NCT02370589|Experimental|Group A|Day 0: Base Dose EBOV GP Vaccine; IM Day 21: Base Dose EBOV GP Vaccine; IM
16636684|NCT02370589|Experimental|Group B|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
16636685|NCT02370589|Experimental|Group C|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
16636686|NCT02370589|Experimental|Group D|Day 0: 2x Base Dose EBOV GP Vaccine; IM Day 21: 2x Base Dose EBOV GP Vaccine; IM
16636687|NCT02370589|Experimental|Group E|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
16636688|NCT02370589|Experimental|Group F|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
16636689|NCT02370589|Experimental|Group G|Day 0: 4x Base Dose EBOV GP Vaccine; IM Day 21: 4x Base Dose EBOV GP Vaccine; IM
16636690|NCT02370589|Experimental|Group H|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
16636691|NCT02370589|Experimental|Group J|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
16636692|NCT02370589|Experimental|Group K|Day 0: 8x Base Dose EBOV GP Vaccine; IM Day 21: 8x Base Dose EBOV GP Vaccine; IM
16636693|NCT02370589|Experimental|Group L|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
16636694|NCT02370589|Experimental|Group M|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
16636695|NCT02370589|Placebo Comparator|Group N|Day 0: Placebo; IM Day 21: Placebo; IM
16636696|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
16636697|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
16636698|NCT02370563|Experimental|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
16636699|NCT02370550|Experimental|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease >15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
16636700|NCT02370550|Placebo Comparator|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
16636701|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
16636702|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
16636704|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
16636705|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
16636706|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
16636707|NCT02370498|Experimental|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
16636708|NCT02370498|Active Comparator|Paclitaxel|Participants receive 80 mg/m^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
16636709|NCT02370485|Experimental|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
16636710|NCT02370485|Experimental|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
16636711|NCT02370485|Experimental|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
16636712|NCT02370472|No Intervention|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
16636713|NCT02370472|Experimental|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
16636714|NCT02370459|No Intervention|control|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive no AFIX consultation.
16636715|NCT02370459|Experimental|AFIX in-person consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
16636716|NCT02370459|Experimental|AFIX webinar consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff.
16636717|NCT02370446||patient gets personalized medication log|Patients in the intervention group will receive a personalized medication log that includes all treatment medications (IV and oral), days of treatment and medication specific information such as timing or diet restrictions. The personalized medication log and patient education materials (fact cards) will be placed in a clear plastic envelope that the patient can carry with them throughout treatment.
16636718|NCT02370446||patient gets standard of care|Current MSKCC standards of professional nursing practice require the professional nurse to develop a plan of care that includes teaching the patient and support system the prescribed prescriptions / regimen and all doses, route, length of treatment, side effects and safety precautions.
16636719|NCT02370433|Experimental|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
16636720|NCT02370433|Experimental|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
16636721|NCT02370433|Experimental|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
16636722|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
16636723|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
16636724|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
16636725|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
16636726|NCT02370394|Experimental|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
16636727|NCT02370394|No Intervention|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
16636728|NCT02370381||Epistaxis|Patients with active anterior epistaxis
16636729|NCT02370368|Experimental|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.
~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
16636730|NCT02370368|Active Comparator|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
16636731|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
16636732|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
16636733|NCT02370342|Experimental|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
16636734|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16636735|NCT02370316|Experimental|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
16636736|NCT02370316|Active Comparator|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
16636737|NCT02370290||Observational (QIM)|Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.
16636738|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
16636739|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
16636740|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
16636741|NCT02370264|Experimental|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
16636742|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
16636743|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.
~continuing from D 1 to Day 21 of 28-day cycle"
16636744|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
16636745|NCT02370225|Experimental|aerobic exercise|Subjects were submitted to a supervised walking, 3 times a week for 16 weeks.
16636746|NCT02370225|No Intervention|no exercise|Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group.
16636747|NCT02370212|Experimental|Creatine|"Creatine will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.05 g/kg body mass of creatine with 0.05 g/kg flavoured dextrose per dose).
~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
16636748|NCT02370212|Placebo Comparator|Placebo|"The placebo will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.1 g/kg flavoured dextrose per dose, isocaloric to the creatine).
~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
16636749|NCT02370199|Experimental|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
16636750|NCT02370173|Experimental|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
16636751|NCT02370173|Placebo Comparator|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
16636752|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
16636753|NCT02370147|Experimental|Smoking reduction intervention arm|Smoking reduction intervention arm (SRI) consisting of a minimal face-to-face individual smoking reduction intervention lasted for about one minute, and five follow-up interventions lasted for about one minute each.
16636754|NCT02370147|Active Comparator|Control arm|Control arm (UC) consisting of a brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and five follow-up interventions lasted for about one minute each with different intervention contents.
16636755|NCT02370134|Experimental|Parkinson's glove|Parkinson's glove 14 days use with 4 times follow-up
16636756|NCT02370134|Placebo Comparator|sham glove|sham glove (with light and sound)14 days use with 4 times follow-up
16636757|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
16636758|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
16636759|NCT02370108|Experimental|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
16636760|NCT02370108|Experimental|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
16636761|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
16636762|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
16636763|NCT02370082|Experimental|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
16636796|NCT02369822|Experimental|Vitamin C supplemented|patients with refractory idiopathic epilepsy will receive vitamin C supplement according to age for 1 month
16636764|NCT02370069|Active Comparator|Previous immunization with PPV23|Participants who have received a previous vaccination with 1 or more dose of PPV23 at least 12 months previously will receive one dose of 0.5 mL Prevnar 13 study vaccine.
16636765|NCT02370069|Active Comparator|Naive to PPV23|Participants who have never received a previous vaccination with PPV23 will receive one dose of 0.5 mL Prevnar 13 study vaccine.
16636766|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.
~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
16636767|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.
~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
16636768|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
16636769|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
16636770|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
16636771|NCT02370030|Active Comparator|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
16636772|NCT02370030|Placebo Comparator|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
16636773|NCT02370017|Experimental|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
16636774|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
16636775|NCT02369978|Experimental|Nifurtimox (NFX)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
16636776|NCT02369978|Active Comparator|Benznidazole (BZN)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
16636777|NCT02369978|Placebo Comparator|Placebo|120 days of treatment with matching placebo
16636778|NCT02369965|Experimental|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
16636779|NCT02369965|Active Comparator|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
16636780|NCT02369939|Active Comparator|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33
16636781|NCT02369939|Experimental|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6
16636782|NCT02369926|Active Comparator|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
16636783|NCT02369926|Active Comparator|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
16636784|NCT02369913||Heart failure subjects|Heart failure subjects undergoing cardiac resynchronization will have a blood drawn for this study.
16636785|NCT02369913||Heart arrhythmia patients|Heart arrhythmia patients undergoing ablation will have a blood drawn for this study.
16636786|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.
~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
16636787|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
16636788|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
16636789|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
16636790|NCT02369874|Active Comparator|Standard of Care|Standard of Care
16636791|NCT02369861|Experimental|ST266|Eye drops
16636792|NCT02369861|Placebo Comparator|Artificial tears|Refresh lubricant eye drops
16636793|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
16636794|NCT02369835|Experimental|Arm I (modified Dakin's solution)|Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
16636795|NCT02369835|Placebo Comparator|Arm II (placebo)|Participants apply placebo solution (saline) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
16636798|NCT02369809|Experimental|Neovasculgen®|Single group prospective treatment
16636799|NCT02369809|Active Comparator|standard care|
16636800|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
16636801|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
16636802|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
16636803|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
16636804|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
16636805|NCT02369783|Experimental|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
16636806|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
16636807|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
16636808|NCT02369757|Experimental|Intervention of navigators|Navigators accompany the target population towards OCCS.
16636809|NCT02369757|No Intervention|No Intervention|Population is not accompanied by navigators
16636810|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
16636811|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
16636812|NCT02369731||Translarna|Participants with nmDMD receiving Translarna will be followed for at least 5 years from their date of enrollment, or until participant withdrawal of consent or death, whichever occurs first.
16636813|NCT02369718|Experimental|Implanted subjects|Listening to 12 Fournier's lists of words
16636814|NCT02369718|Active Comparator|Normal hearing subjects|Listening to 48 Fournier's lists of words
16636815|NCT02369679|Experimental|Precast Adjustable Compression Wrap|Precast Adjustable Compression Wrap will be adjusted by the physiotherapist each visit
16636816|NCT02369679|Active Comparator|Multilayer Compression Bandages|Multilayer Compression Bandages will be adjusted by the physiotherapist each visit
16636817|NCT02369666|Experimental|LycoRed (code 40051) product|Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
16636818|NCT02369666|Placebo Comparator|Placebo|Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks.
16636819|NCT02369653|Experimental|Apixaban|"Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.
~Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only"
16636820|NCT02369653|Placebo Comparator|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
16636821|NCT02369640|Experimental|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
16636822|NCT02369640|Experimental|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
16636823|NCT02369627|Experimental|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
16636824|NCT02369627|Active Comparator|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
16636825|NCT02369627|Active Comparator|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
16636826|NCT02369614|Active Comparator|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
16636827|NCT02369614|Active Comparator|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
16636828|NCT02369614|Sham Comparator|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
16636829|NCT02369614|No Intervention|OASIS treatment as usual|OASIS treatment as usual
16636830|NCT02369588|Experimental|100% Portion Sizes|Food portion size Test meal consists of baseline (100%) portion size of all foods
16636831|NCT02369588|Experimental|133% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 133% the size of baseline portions
16636832|NCT02369588|Experimental|167% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 167% the size of baseline portions
16636833|NCT02369588|Experimental|200% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 200% the size of baseline portions
16636834|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
16636835|NCT02369549|Active Comparator|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.
~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
16636836|NCT02369549|Placebo Comparator|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.
~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
16636837|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
16636838|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
16636839|NCT02369523|Active Comparator|liposomal bupivacaine (LB) (Exparel)|Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
16636840|NCT02369523|Active Comparator|Ropivacaine cocktail (PIC)|400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
16636841|NCT02369523|Active Comparator|continuous femoral nerve blocks (cFNB)|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.
~Sciatic nerve block - 0.125% bupivacaine"
16636842|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
16636843|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
16636844|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
16636845|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
16636846|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
16636847|NCT02369471|Experimental|Group 1a|Subjects on inducer AEDs will administer GWP42006.
16636848|NCT02369471|Active Comparator|Group 2a|Subjects on inhibitor AEDs will administer GWP42006.
16636849|NCT02369471|Experimental|Group 3a|Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
16636850|NCT02369471|Placebo Comparator|Group 1b|Matching placebo control for Group 1a.
16636851|NCT02369471|Placebo Comparator|Group 2b|Matching placebo control for Group 2a.
16636852|NCT02369471|Placebo Comparator|Group 3b|Matching placebo control for Group 3a.
16636855|NCT02369445|Experimental|Moisture Pager (MP) Intervention Group|"This group receives the innovative toilet training intervention comprised of a wireless moisture pager (i.e., an app based on an iPod that communicates via electronic signal with a disposable moisture sensor located in the child's underwear)."
16636856|NCT02369445|Active Comparator|Standard Behavioral Intervention Group|This group receives standard-of-care intervention as presented in the Autism Treatment Network's Toilet Training Tool Kit (https://www.autismspeaks.org/site-wide/atn-tool-kits).
16636857|NCT02369432|Experimental|Group of healthy volunteers and group of patients|"Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed
~Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed"
16636858|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
16636859|NCT02369406|Experimental|Antepartum Cohort|"40 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART < 7 days after birth. This cohort will include at least 15 children who start ART < 3 days after birth.
~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
16636860|NCT02369406|Experimental|Peripartum Cohort|"10 children who test HIV-negative within 96 hours after birth but test HIV-positive <57 days after birth (peripartum HIV infection) and who are able to initiate ART <57 days after birth. This cohort will include at least 10 children who start ART < 21 days after birth.
~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
16636861|NCT02369406|No Intervention|Control Cohort|25 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
16636862|NCT02369393|Experimental|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
16636863|NCT02369393|No Intervention|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
16636864|NCT02369393|Experimental|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
16636865|NCT02369380|Experimental|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
16636866|NCT02369354|No Intervention|Usual Care|Usual medical care at the Duke Kidney Transplant Clinic
16636867|NCT02369354|Other|TALKS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings
16636868|NCT02369354|Other|TALKS PLUS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings plus live donor financial assistance intervention
16636987|NCT02368509|Placebo Comparator|Control group|Healthy individuals will perform sensory tests before and after a 6-week period without chemotherapy.
16636869|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
16636870|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
16636871|NCT02369328|Experimental|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
16636872|NCT02369328|Active Comparator|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
16636873|NCT02369315|Experimental|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
16636874|NCT02369315|Experimental|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
16636875|NCT02369302|Experimental|DWC20141|multiple dose of DWC20141
16636876|NCT02369302|Experimental|DWC20142|multiple dose of DWC20142
16636877|NCT02369302|Experimental|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
16636878|NCT02369289||vegans|a vegan diet in the last 3 years
16636879|NCT02369289||omnivores|aminal-based diet, comsumption of aminal products at least 3 times a week
16636880|NCT02369276||post SND within 3 months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 3 months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
16636881|NCT02369276||post SND within >3- 6months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within >3- 6months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
16636882|NCT02369276||post SND within 6 months -1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 6 months -1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
16636883|NCT02369276||post SND within more than 1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within more than 1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
16636884|NCT02369276||without shoulder disability|20 Head and Neck Cancer(HNC) post SND without shoulder complication at the control group, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
16636885|NCT02369250|Placebo Comparator|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
16636886|NCT02369250|Active Comparator|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
16636887|NCT02369250|Experimental|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
16636888|NCT02369211|Experimental|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
16636889|NCT02369211|Placebo Comparator|Placebo|Patient receives saline injection instead of the study drug
16636890|NCT02369198|Experimental|Single arm, open label TargomiRs|"TargomiRs are IV injected.
~Phase 1 Planned dose levels
~Dose level 1: 5 billion once a week Dose level 2: 5 billion twice a week Dose level 3: 5 billion once a week with cardiac monitoring Dose level 4: 2.5 billion twice a week with cardiac monitoring Dose level 5: as for dose level #3 with a dexamethasone challenge
~All patients begin on a micro dose of one billion and increase their dose over 2 weeks and reach their phase 1 dose level on week 3.
~Schedule of assessments includes laboratory and physical assessments in the 24 hours after each treatment as well as periodic assessments such as PET and CT scans for tumour assessment.
~100% of the data will be source data verified. Analysis will be simple phase 1 analysis based on a 3+3 model."
16636891|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
16636892|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.
~Subjects ≥12 years will receive a dose of 600 mg.
~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).
~Subjects < 6 months will receive a dose of 8 mg/kg."
16636893|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.
~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).
~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
16636894|NCT02369146|Experimental|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
16636895|NCT02369146|Experimental|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
16636896|NCT02369133|Active Comparator|Group Paracetamol (Group P),|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol
16636897|NCT02369133|Placebo Comparator|Group Saline (Group S)|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline
16636898|NCT02369120|Active Comparator|Normal care by GP|"Control group: Will follow conventional treatment provided by the family physician in primary care. This treatment is based on the clinical guidelines of the Institut Català de la Salut (http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf)."
16636899|NCT02369120|Experimental|Educational intervention using a website|This group of subjects will be given access to our web-site in where they will find information related to CLBP. This information will be provided in different formats: explanatory video by the author, animated video about the neurophysiology of pain, written format using metaphors, and FAQs. All this information will be based on the information provided by the subjects on QUAL. The aim of this educational intervention is to change patient´s misbeliefs about CLBP with the last outcome of reducing pain intensity, improving function, and reducing disability.
16636900|NCT02369107|Experimental|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
16636901|NCT02369107|Sham Comparator|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
16636902|NCT02369094|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
16636903|NCT02369094|Other|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.
~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
16636904|NCT02369081|Active Comparator|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
16636905|NCT02369081|Placebo Comparator|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
16636906|NCT02369081|Active Comparator|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
16636907|NCT02369081|Active Comparator|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
16636908|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.
~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
16636909|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.
~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
16636910|NCT02369055||Stroke survivors in North Norway|Patients with ischemic or heamorrhagic stroke admitted to stroke units in UNN Tromso, Narvik or Harstad (Norway), and living in the defined geographic area of these 3 hospitals.
16636911|NCT02369055||Stroke survivors in Denmark|Patients with ischemic og heamorrhagic stroke admitted to a stroke unit in Aarhus University Hospital and living in the municipalities of Randars or Favrskov in Central Denmark Region
16636912|NCT02369042|Experimental|Cohort I|Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.
16636913|NCT02369042|Experimental|Cohort II|Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.
16636914|NCT02369029|Experimental|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
16636915|NCT02369016|Experimental|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
16636916|NCT02369003|Experimental|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
16636917|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
16636960|NCT02368704||control|"control subjects with :
~Nondiabetic subjects (blood glucose <7.0 mmol/l without hypoglycemic treatment).
~The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
16636918|NCT02368977|Experimental|All subjects|All subjects will undergo examination with a Third Eye Panoramic device in conjunction with a standard colonoscope to evaluate the feasibility of using the study device to provide video imaging of areas of the colon that are difficult to evaluate with the colonoscope alone.
16636919|NCT02368964|Experimental|High dose hCG|The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration
16636920|NCT02368964|Experimental|Double trigger|Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration
16636921|NCT02368951|Experimental|BAY1187982|"Dose-escalation phase:
~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.
~MTD expansion phase:
~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:
~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
16636922|NCT02368938||Several communities in the north of Shanghai|
16636923|NCT02368925|Experimental|Ultherapy™ System|Ultherapy™ System
16636924|NCT02368912|Experimental|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
16636925|NCT02368912|Experimental|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
16636926|NCT02368912|Experimental|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
16636927|NCT02368912|Experimental|4. Food effect (FE), ASP1707 fed|Fed healthy young male
16636928|NCT02368912|Experimental|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
16636929|NCT02368912|Experimental|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
16636930|NCT02368912|Experimental|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
16636931|NCT02368912|Experimental|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
16636932|NCT02368912|Experimental|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
16636933|NCT02368912|Experimental|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
16636934|NCT02368899|Experimental|Computerized Alcohol Misuse Intervention|Arm 1 is a cross-over randomized controlled trial (XRCT) comparing the short-term effects of the computerized alcohol misuse intervention (CAMI) vs. a generic health education attention-control (AC) condition in reducing past 30 day: (a) days of alcohol use, (b) days of heavy episodic drinking, (c) typical number of drinks consumed on a day of drinking, and (d) alcohol use in dangerous situations; (2) investigate changes in (a) patient motivation and (b) perceived norms as mediators of intervention effectiveness.
16636935|NCT02368899|Placebo Comparator|Attention Control (AC)|Arm 2 is not an active intervention but an attention control condition - it is not expected to exert any real intervention effect. Hence, any observed effects for the AC condition can be attributed to natural change via regression-to-the-mean, assessment reactivity, or a placebo effect. The effect size estimate of the intervention, both from an efficacy standpoint (i.e., above and beyond what change would have normally occurred) and an effectiveness standpoint (i.e., the magnitude of behavior change that can be expected in real-world implementation), can be readily calculated.
16636936|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
16636937|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
16636938|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
16636939|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
16636940|NCT02368873|Active Comparator|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
16636941|NCT02368873|No Intervention|Control group|Patients with the straight permanent colostomy without a mesh.
16636942|NCT02368860|Experimental|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
16636943|NCT02368847|Other|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
16636944|NCT02368834|Experimental|intervention group|A psychoeducation program was delivered to the parents/caregivers
16636945|NCT02368834|No Intervention|control group|This group waited for 3 months, only receiving general consultation.
16636946|NCT02368821||normal pregnancy|placental from normal pregnancy
16636947|NCT02368821||complacted pregnancy|placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete
16636948|NCT02368808|Experimental|Abangane Support Group|Bereavement support group for adolescents
16636949|NCT02368808|No Intervention|Wait List|Wait-listed adolescents will be able to participate in Abangane at the close of the study.
16636950|NCT02368795|Placebo Comparator|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
16636951|NCT02368795|Active Comparator|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
16636952|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
16636953|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
16636954|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
16636955|NCT02368769||Before tele-expertise|Usual (on site) frozen section
16636956|NCT02368743||mesalazine|Treatment according to standard clinical practice.
16636957|NCT02368730||desmopressin|Treatment according to standard clinical practice.
16636958|NCT02368717|Experimental|Mesalazine|Mesalazine Enema
16636961|NCT02368704||case|"Diabetic patients with :
~Having type 2 diabetes for at least 6 months
~HbA1c ≤ 8%
~Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin
~No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
16636962|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
16636963|NCT02368678|Active Comparator|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
16636964|NCT02368678|Active Comparator|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
16636965|NCT02368665|Experimental|AML 5mg|- Amlodipine 5mg, once a day for 8 weeks
16636966|NCT02368665|Experimental|AML 5mg / CC 16mg|- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks
16636967|NCT02368665|Experimental|AML 10mg / CC 16mg|- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
16636968|NCT02368652|Experimental|CC 16mg|Candesartan ceilexetil 16mg, once a day for 8 weeks
16636969|NCT02368652|Experimental|AML 10mg / CC 16mg|Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
16636970|NCT02368639|Experimental|Positive airway pressure (PAP) device|Fisher & Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
16636971|NCT02368626|Experimental|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
16636972|NCT02368613|Placebo Comparator|placebo group|Placebo
16636973|NCT02368613|Active Comparator|test1 group|DW-3102 125mg
16636974|NCT02368613|Active Comparator|test2 group|DW-3102 250mg
16636975|NCT02368613|Active Comparator|test3 group|DW-3102 500mg
16636976|NCT02368600|Experimental|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
16636977|NCT02368600|No Intervention|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
16636978|NCT02368587|Placebo Comparator|Intracoronary infusion WJMSCs|Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure
16636979|NCT02368587|Placebo Comparator|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure.
16636980|NCT02368574|No Intervention|Class III hysterectomy Arm|Class III hysterectomy (radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. Perivesical space and perirectal space should be opened, and the ureteral tunnel is completely separated and pushed down to the junction of ureter and urinary bladder. The uterine arteries are ligated at the level of internal iliac artery, and all the supporting ligaments and connective tissues around the uterus should be separated and abscised. The uterosacral ligament is removed near the sacrum, the cardinal ligament is removed near the pelvic wall, and the vagina is removed after the excision of peivaginal connective tissues, about 3-4cm from the cervical lesion. The pelvic lymph nodes are usually dissected at the same time.
16636981|NCT02368574|Experimental|Class II hysterectomy Arm|Class II hysterectomy (modified radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. The scope of surgery is more extensive than Class I epifascial panhysterectomy, demanding the excision of more parametrium but reservation of the blood supply for distal ureter and urinary bladder. The ureter is separated from the ureteral tunnel, the vesicouterine ligament should be intact, and 1/2 uterosacral ligament and 1cm vagina are excised. The pelvic lymph nodes are usually dissected at the same time.
16636982|NCT02368561|Experimental|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
16636983|NCT02368548|Experimental|Pharmaceutical care program|"Initiated in the Emergency Department (ED):
~Review of home medication and medication reconciliation based on Primary Care data
~Patient interview. Assessment of the patient's knowledge on the pharmacological treatment
~Development of the pharmacological history and registration in the medical record
~Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team
~Pharmacotherapy monitoring
~Treatment validation and medication reconciliation at discharge
~During the hospitalization (if admission from the ED):
~Treatment review and medication reconciliation
~Pharmacokinetics monitoring
~Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team
~Pharmacotherapy monitoring
~Validation and medication reconciliation at discharge
~Patient education at discharge"
16636984|NCT02368548|Other|Standard Care|"Stages:
~Pharmaceutical care program in the episode at the Emergency Department:
~a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.
~During the hospitalization (if admission from the ED):
~Pharmacokinetics monitoring
~Retrospective validation of prescriptions and assessment of drugs appropriateness."
16636985|NCT02368522||Patients treated with and without exposure|
16636986|NCT02368509|Experimental|Bronchial cancer|Patients with bronchial cancer will perform sensory tests before and after a 6-week period of chemotherapy.
16636988|NCT02368496|Experimental|Children and young adults on long-term parenteral nutrition|long-term parenteral nutrition : 2 years
16636990|NCT02368470|Active Comparator|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
16636991|NCT02368470|Experimental|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
16636992|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
16636993|NCT02368457|No Intervention|CONTROL|No drug treatment
16636994|NCT02368444|Experimental|Intervention Group|Cognitive Behavioral Therapy and Yoga
16636995|NCT02368431|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
16636996|NCT02368431|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
16636997|NCT02368418||PCP and SRS|participants had received two interventions (PCP and SRS)
16636998|NCT02368418||PCP only|participants had received PCP intervention only
16636999|NCT02368418||SRS only|participants had received SRS intervention only
16637000|NCT02368418||control group|participants had received usual care (neither PCP nor SRS)
16637001|NCT02368405|Active Comparator|Control|Control group will receive standard of care
16637002|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
16637003|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
16637004|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
16637005|NCT02368379|Other|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
16637006|NCT02368366|Experimental|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
16637007|NCT02368366|Experimental|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
16637008|NCT02368366|Experimental|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
16637009|NCT02368353|Experimental|Cognitive behavioral therapy group|weekly group stress-management CBT (SM-CBT) - 1/week 3 months
16637010|NCT02368353|Active Comparator|Reference group|weekly supportive therapy - 1/week 3 months
16637011|NCT02368340||Adults with pulmonary fibrosis|This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.
16637012|NCT02368340||Adults at-risk|"This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.
~Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens."
16637013|NCT02368340||HPS adults not at-risk|"This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.
~Subjects in this group will provide blood and urine specimens."
16637014|NCT02368340||Children with HPS at-risk|This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.
16637015|NCT02368327|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine
16637016|NCT02368327|Active Comparator|Fendrix|Participants receive one dose of Fendrix vaccine
16637017|NCT02368327|Placebo Comparator|Placebo|Participants receive one dose of saline placebo
16637018|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
16637019|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
16637020|NCT02368288|Experimental|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
16637021|NCT02368288|No Intervention|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
16637022|NCT02368275||prospective cohort of patients undergoing mastectomy|Prospective cohort
16637023|NCT02368275||cross sectional cohort of patients|Cross sectional cohort
16637024|NCT02368262||CP- incontinent|Children with CP and daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
16637025|NCT02368262||CP- continent|Children with CP without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
16637026|NCT02368262||NoDev - incontinent|Children with normal development with daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
16637027|NCT02368262||NoDev - continent|Children with normal development without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
16637028|NCT02368249|Placebo Comparator|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
16637029|NCT02368249|Experimental|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
16637030|NCT02368236|Other|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
16637031|NCT02368236|No Intervention|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
16637032|NCT02368236|No Intervention|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
16637033|NCT02368223|Experimental|YouGrabber training|Home-based YouGrabber training
16637034|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
16637035|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
16637036|NCT02368197|Active Comparator|Standard balloon angioplasty|Dilatation of stenosis with standard non drug eluting balloon catheter
16637037|NCT02368197|Experimental|Drug eluting balloon angioplasty|Dilatation of stenosis with paclitaxel eluting balloon catheter
16637038|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo
16637039|NCT02368171||control|patients with AHI<5/h and RVSP<35 mmHg on Echo
16637040|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI>5/h, but RVSP<35 mmHg on Echo
16637041|NCT02368158|Experimental|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
16637042|NCT02368158|Experimental|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
16637043|NCT02368132|No Intervention|Usual Care|Caregivers randomized to UC will be sent general material about VA and community resources for patients with dementia and their CGs. With the exception of this material, individuals in this group will receive usual care and will be contacted again at 3, 6, and 12 months for follow-up research assessments.
16637044|NCT02368132|Active Comparator|Individual Delivered TEP Arm|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
16637045|NCT02368132|Active Comparator|Group Delivered TEP Arm|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
16637046|NCT02368119|Experimental|Group 1|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=10) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=10). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
16637047|NCT02368119|Experimental|Group 2|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=20) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=20). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
16637048|NCT02368106||Radiation Therapy|Participants receiving one of the 11 listed therapy modalities.
16637049|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
16637050|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
16637051|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
16637052|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
16637053|NCT02368067|Active Comparator|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
16637054|NCT02368067|Experimental|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
16637055|NCT02368054|Active Comparator|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
16637056|NCT02368054|Active Comparator|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
16637057|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
16637058|NCT02368028||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
16637059|NCT02368028||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
16637060|NCT02368015|Other|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.
~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
16637061|NCT02368002|Experimental|Behavioral weight loss therapy|Emphasizes 1) identifying behaviors in need of change, 2) setting goals for change, 3) monitoring progress, 4) modifying environmental cues to facilitate change, and 5) modifying consequences to motivate change.
16637062|NCT02368002|Experimental|Meal replacements|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive meal replacements in addition to standard behavioral weight loss therapy.
16637063|NCT02368002|Experimental|Enhanced behavioral weight loss therapy|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive an enhanced version of behavioral weight loss therapy.
16637064|NCT02367989|Placebo Comparator|Control without fibre|"Intervention: 0g barley β-glucan no fibre.
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
16637065|NCT02367989|Experimental|low barley β-glucan|"Intervention: 2g barley β-glucan
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
16637066|NCT02367989|Experimental|medium barley β-glucan|"Intervention: 4g barley β-glucan
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
16637067|NCT02367989|Experimental|high barley β-glucan|"Intervention: 6g barley β-glucan
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
16637068|NCT02367989|Placebo Comparator|control with fibre|"Intervention: 0g barley β-glucan with fibre
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
16637069|NCT02367976|Experimental|rhprouk|rhprouk to be administrated in 60 minutes.
16637070|NCT02367976|No Intervention|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
16637071|NCT02367963|Experimental|Intervention|A Training period and a Peer-group intervention are asigned to this arm. Peer-group intervention is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
16637072|NCT02367963|Other|Control|"A Training period intervention is asigned to this arm. Once the workshops have been carried out, the control group will be provided with written and visual documentation of risk factors and overall health habits. The members of this group will have access to the study website, where they will be able to find information on risk factors and health habits and links to the same websites related to health as the intervention group.
~They won't participate in the sessions of peer education group dynamics for a period of 12 months."
16637073|NCT02367950|Experimental|Single Arm Study|All participants receive active treatment (exercise) tailored to their level of health ad fitness
16637074|NCT02367937|Experimental|PRC-4016 (Icosabutate)|
16637075|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
16637076|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
16637077|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
16637078|NCT02367898|Experimental|Cognitive Training|Lumosity cognitive training program.
16637079|NCT02367898|Active Comparator|Crossword Puzzles|Timed online crossword puzzles
16637080|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
16637081|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
16637082|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
16637083|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
16637084|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637085|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637086|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637087|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637088|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637089|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637090|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
16637091|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
16637092|NCT02367846|Experimental|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
16637093|NCT02367846|Experimental|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
16637094|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
16637095|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
16637096|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
16637097|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
16637098|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
16637099|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
16637100|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
16637101|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
16637102|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
16637103|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.
16637104|NCT02367755|Experimental|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
16637105|NCT02367755|Active Comparator|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
16637106|NCT02367742|Other|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
16637107|NCT02367742|Other|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
16637108|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
16637109|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
16637110|NCT02367703|Experimental|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
16637111|NCT02367703|Other|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
16637112|NCT02367690|Experimental|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:
~a) Standard-of-care (SOC) + Selinexor gel, 10 μM
~, b) SOC + vehicle gel c) SOC alone."
16637113|NCT02367690|Experimental|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:
~Standard-of-care (SOC) + Selinexor gel, 30 μM
~SOC + vehicle gel
~SOC alone."
16637114|NCT02367690|Experimental|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:
~Standard-of-care (SOC) + Selinexor gel, 70 μM
~SOC + vehicle gel
~SOC alone."
16637115|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
16637116|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
16637117|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
16637118|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
16637119|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
16637120|NCT02367664|Active Comparator|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
16637121|NCT02367651|Experimental|Pazopanib|Subjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
16637122|NCT02367651|Placebo Comparator|Placebo|Subjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
16637123|NCT02367638|Experimental|MG1111|
16637124|NCT02367638|Active Comparator|VARIVAX|
16637125|NCT02367625|Experimental|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
16637126|NCT02367625|Active Comparator|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
16637127|NCT02367612|Experimental|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
16637128|NCT02367612|Placebo Comparator|Placebo|Placebo
16637129|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
16637130|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
16637131|NCT02367573|Active Comparator|2D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with two dimensional view
16637132|NCT02367573|Experimental|3D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with three dimensional view
16637133|NCT02367560|Active Comparator|NDSSI|Participants in this arm of the trial will be referred for Needle decompression with subacromial steroid (Depo medrol) injection (NDSSI) as their treatment for calcific tendinitis
16637134|NCT02367560|Active Comparator|SWT|Participants in this arm of the trial will be referred for Shockwave therapy (SWT) using an Ultrasound device, delivered by a physiotherapist, as their treatment for calcific tendinitis
16637135|NCT02367547|Experimental|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
16637136|NCT02367547|Experimental|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
16637137|NCT02367547|Active Comparator|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
16637138|NCT02367534|Experimental|Umbilical vein|umbilical vein catheterization
16637139|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
16637140|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
16637141|NCT02367508|Experimental|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
16637142|NCT02367495|Experimental|PCB|Paclitacel-coated balloon (Agent, Boston Scientific)
16637143|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
16637144|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
16637147|NCT02367443|Experimental|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
16637148|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
16637149|NCT02367404|No Intervention|Control|Keigel's exercise
16637150|NCT02367404|Active Comparator|Duloxetine|Duloxetine 60mg for 3 months
16637151|NCT02367404|Active Comparator|Duloxetine + PMFT|Duloxetine 60mg for 3 months PMFT weekly for 3 months
16637152|NCT02367404|Active Comparator|Pelvic Floor Muscle Training|PMFT weekly for 3 months
16637153|NCT02367391|Experimental|Motivational Text Messages|
16637154|NCT02367391|Sham Comparator|Control|
16637155|NCT02367378||MIS|Those who received minimally invasive surgical procedures
16637156|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
16637157|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
16637158|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
16637159|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
16637160|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
16637161|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
16637162|NCT02367326||Patients with Inflammatory Bowel Disease|patients with Crohn's Disease or Ulcerative Colitis meeting clinical, endoscopic and histological criteria and on thiopurines at stable doses for at least 3 months, monotherapy or combined with corticotherapy
16637163|NCT02367313|Placebo Comparator|Placebo|Placebo
16637164|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
16637165|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
16637166|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
16637167|NCT02367261|Experimental|SPI dental implant|Subjects implanted with SPI implant
16637168|NCT02367248|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 500 mg of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water.
16637169|NCT02367248|Active Comparator|Xingnaojing injection|Xingnaojing injection supplied in vials containing 20 ml liquid xingnaojing.
16637170|NCT02367248|Placebo Comparator|Normal Saline|0.9% sodium chloride
16637171|NCT02367235|Experimental|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
16637172|NCT02367235|Experimental|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
16637173|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
16637174|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
16637175|NCT02367196|Experimental|Part A: CC-90002|CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
16637176|NCT02367196|Experimental|Part B: CC-90002 with Rituximab|CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL
16637177|NCT02367183|Experimental|GED-0301 160mg QD 12 WK|GED-0301 160 mg once daily (QD) for 12 weeks
16637178|NCT02367183|Experimental|GED-0301 160 mg QD 8 WK|GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
16637179|NCT02367183|Experimental|GED-0301 160 mg QD 4 WK|GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
16637180|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
16637181|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
16637182|NCT02367157|Experimental|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
16637183|NCT02367157|No Intervention|No intervention: Control|
16637184|NCT02367131||Jardiance|
16637185|NCT02367118|Experimental|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
16637186|NCT02367118|Placebo Comparator|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
16637251|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
16637187|NCT02367105|Active Comparator|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
16637188|NCT02367105|Placebo Comparator|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
16637189|NCT02367092|Experimental|Exercise Program|The exercise intervention consists of a 30 minute exercise session led by an instructor through a DVD or a video available on the internet.
16637190|NCT02367092|No Intervention|Standard of care|Standard of care which consists of encouragement to exercise by the subject's transplant clinician.
16637191|NCT02367079|Active Comparator|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
16637192|NCT02367079|Sham Comparator|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
16637193|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
16637194|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
16637195|NCT02367053|Experimental|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
16637196|NCT02367053|Active Comparator|native glucagon|single fixed dose of glucagon
16637197|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
16637198|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
16637199|NCT02367027|Experimental|Arm 1 - BAY59-7939|10 mg oral suspension (dry powder) in fasted conditions
16637200|NCT02367027|Experimental|Arn 2 - BAY59-7939|20 mg oral suspension (dry powder) in fed conditions.
16637201|NCT02367027|Experimental|Arm 3 - BAY59-7939|10 mg oral suspension in fasted conditions
16637202|NCT02367027|Experimental|Arm 4 - BAY59-7939|10 mg tablet in fasted conditions.
16637203|NCT02367014|Experimental|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
16637204|NCT02367014|Experimental|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
16637205|NCT02367014|Experimental|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
16637206|NCT02367014|Placebo Comparator|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
16637207|NCT02367001|Other|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)
~Intervention : Normal invitation"
16637208|NCT02367001|Experimental|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)
~Intervention : revised invitation signed by the coordinating doctor"
16637209|NCT02367001|Experimental|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)
~Intervention : Revised invitation signed by the attending physician"
16637210|NCT02366988|Active Comparator|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
16637211|NCT02366988|Active Comparator|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
16637212|NCT02366975|No Intervention|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
16637213|NCT02366975|Active Comparator|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
16637214|NCT02366975|Placebo Comparator|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
16637215|NCT02366962|Experimental|ASP7374 group|
16637216|NCT02366949|Experimental|Arm 1|Experimental Treatment (combination of BAY1217389 with paclitaxel in an intermittent dosing schedule) Expansion Cohort - Maximum tolerated dose of BAY1217389 and Paclitaxel
16637217|NCT02366949|Placebo Comparator|Arm 2|Standard Treatment (Single-agent Paclitaxel )
16637218|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
16637219|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
16637220|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
16637221|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
16637222|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
16637223|NCT02366897|Other|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
16637224|NCT02366884|Experimental|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
16637225|NCT02366884|Experimental|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
16637226|NCT02366884|Experimental|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
16637227|NCT02366884|Experimental|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
16637228|NCT02366871|Experimental|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
16637229|NCT02366871|Active Comparator|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
16637230|NCT02366858|Active Comparator|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.
16637231|NCT02366858|Active Comparator|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.
16637249|NCT02366715|Experimental|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
16637250|NCT02366702||Individuals with Bilateral Transfemoral Amputation|
16637232|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.
~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
16637233|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.
~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
16637234|NCT02366832|Experimental|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
16637235|NCT02366819|Experimental|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo conventional surgery.
~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
16637236|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
16637237|NCT02366793|Experimental|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
16637238|NCT02366793|Experimental|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
16637239|NCT02366780|Experimental|Manual expression followed by electric pump|Mothers will be assigned to first express breast milk manually followed by electric pump
16637240|NCT02366780|Experimental|Electric pump followed by manual expression|Mothers will be assigned to first express breast milk by electric pump followed by manual expression
16637241|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
16637242|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
16637243|NCT02366754|Experimental|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
16637244|NCT02366754|Sham Comparator|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
16637245|NCT02366741|Other|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
16637246|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
16637247|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td), 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
16637248|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DC vaccines #1 and #2 with Td pre-conditioning 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
16637252|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
16637253|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
16637254|NCT02366676|Experimental|treatment group|-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd~5th month:once a month)
16637255|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
16637256|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
16637257|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
16637258|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
16637259|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
16637260|NCT02366650||Bern ED|appr 100 patients at Bern ED
16637261|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
16637262|NCT02366637|Experimental|PF-03715455|
16637263|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
16637264|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
16637265|NCT02366598|Experimental|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
16637266|NCT02366598|Experimental|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
16637267|NCT02366598|Active Comparator|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
16637268|NCT02366598|Experimental|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
16637269|NCT02366598|Placebo Comparator|Control shake|non-protein control shake, given once, at beginning of acute trial
16637270|NCT02366585|Experimental|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
16637271|NCT02366572|Placebo Comparator|Cereal control|100% Wheat Flour
16637272|NCT02366572|Experimental|Cereal with pea protein|Pea protein
16637273|NCT02366572|Experimental|Cereal with pea starch|Pea starch
16637274|NCT02366572|Experimental|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
16637275|NCT02366572|Experimental|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
16637276|NCT02366572|Experimental|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
16637277|NCT02366559|Active Comparator|electrocautery|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
16637278|NCT02366559|Active Comparator|532 nm Nd:YAG laser|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
16637279|NCT02366546|Experimental|Low dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
16637280|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
16637281|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 2|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
16637282|NCT02366546|Experimental|TBI-1301 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
16637283|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
16637284|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
16637285|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
16637286|NCT02366494||Androgen blockade|Androgen DeprivationTherapy or Complete Androgen Blockade
16637287|NCT02366494||Hormonal Therapy and Chemotherapy|Hormonal therapy, novel oral hormonal therapy (abiraterone/apalutamide/enzalutamide) and chemotherapy (docetaxel)
16637288|NCT02366481|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
16637289|NCT02366481|Active Comparator|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
16637290|NCT02366481|Active Comparator|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
16637457|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre|Pea flour (30%) + pea fibre (11g)
16637458|NCT02365363|Experimental|Bagel w/ pea flour + pea protein|Pea flour (30%) + pea protein (24g)
16637291|NCT02366468|Experimental|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
16637292|NCT02366468|Active Comparator|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
16637293|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
16637294|NCT02366429|Experimental|ICBT|Internet-based CBT for antenatal depression
16637295|NCT02366429|Active Comparator|TAU|Treatment as usual provided at antenatal clinics and other health care instances
16637296|NCT02366416|Experimental|Exercise training|12 weeks of one hour exercise training twice weekly
16637297|NCT02366403|Experimental|SKY|a standardized meditation program
16637298|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
16637299|NCT02366390|Experimental|Psychoeducative intervention|A psychoeducative dialogue and one telephone booster session
16637300|NCT02366390|No Intervention|Usual care|Usual care according to current guidelines.
16637301|NCT02366377|Experimental|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
16637302|NCT02366377|Experimental|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
16637303|NCT02366377|Experimental|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
16637304|NCT02366377|Experimental|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
16637305|NCT02366364|Placebo Comparator|Drug: Placebo|Single oral administration on Day 1
16637306|NCT02366364|Experimental|Drug: NRX-1074 375 mg|Single oral administration on Day 1
16637307|NCT02366364|Experimental|Drug: NRX-1074 500 mg|Single oral administration on Day 1
16637308|NCT02366364|Experimental|Drug: NRX-1074 750 mg|Single oral administration on Day 1
16637309|NCT02366351|Experimental|SHR3824 Placebo|once daily, 12 weeks
16637310|NCT02366351|Experimental|SHR3824 5 mg|once daily, 12 weeks
16637311|NCT02366351|Experimental|SHR3824 10 mg|once daily, 12 weeks
16637312|NCT02366351|Experimental|SHR3824 20 mg|once daily, 12 weeks
16637313|NCT02366325|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
16637314|NCT02366325|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
16637315|NCT02366325|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
16637316|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
16637317|NCT02366299|Active Comparator|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
16637318|NCT02366299|Active Comparator|propofol|Treatment of delirium by propofol i.v. infusion
16637319|NCT02366247|Experimental|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
16637320|NCT02366247|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
16637321|NCT02366234||Fracture of Distal Tubercle of Scaphoid|"Questionnaires
~Quick DASH after trauma (< 2 weeks)
~11-point ordinal measure of overall pain intensity 6 months after trauma
~11-point ordinal measure of satisfaction with treatment 6 months after trauma"
16637322|NCT02366221||All subjects|Subjects with a history of complex arm trauma
16637323|NCT02366208|Experimental|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
16637324|NCT02366208|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
16637326|NCT02366156|Placebo Comparator|Placebo|Inactive capsules
16637327|NCT02366156|Active Comparator|Low Dose Grape Blend|Low dose grape blend providing 375 mg whole grape extract + 375 mg grape seed extract/d (750 mg total botanical extracts/d).
16637328|NCT02366156|Active Comparator|High Dose Grape Blend|High dose grape blend providing 500 mg whole grape extract + 500 mg grape seed extract/d (1000 mg total botanical extracts/d)
16637329|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
16637459|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre + pea protein|Pea flour (30%) + pea fibre (11g) + pea protein (24g)
16637502|NCT02365103|Other|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
16637330|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
16637331|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
16637332|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.
~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
16637333|NCT02366117|Experimental|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.
~This training intervention will be applied to the facilities presenting half the patient sample size."
16637334|NCT02366117|No Intervention|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
16637339|NCT02366078|Experimental|Stress management|Participants will receive SMART traiing
16637340|NCT02366065|Experimental|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
16637341|NCT02366052|Active Comparator|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
16637342|NCT02366052|Experimental|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
16637343|NCT02366052|Experimental|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
16637345|NCT02366026|Experimental|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
16637346|NCT02366026|Placebo Comparator|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
16637347|NCT02366013|Experimental|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
16637348|NCT02366013|Experimental|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
16637349|NCT02366013|Experimental|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
16637350|NCT02366013|Experimental|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
16637351|NCT02366000|Experimental|Brief Parental Training Intervention|Participants will have to attend two 3-hour Brief Parental Training Intervention Programme, with three weeks apart. There will also be two telephone follow-up sessions to reinforce learnt strategies and skills for home practice between workshops.
16637352|NCT02366000|Other|Wait-list Group|Participants will receive the same Brief Parental Training Intervention Programme as the intervention group. However, they will wait until the questionnaires have been completed by the intervention group for the second time (i.e. immediately after intervention) before they receive their programme.
16637353|NCT02365987|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
16637354|NCT02365987|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
16637355|NCT02365974|Active Comparator|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
16637356|NCT02365974|Sham Comparator|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
16637357|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
16637358|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
16637359|NCT02365948|Experimental|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.
~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
16637360|NCT02365948|Experimental|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
16637361|NCT02365948|Experimental|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
16637362|NCT02365948|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
16637363|NCT02365935|Experimental|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
16637364|NCT02365935|Experimental|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
16637365|NCT02365922||Patients with FTLD or family members|Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.
16637366|NCT02365909|Active Comparator|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
16637367|NCT02365909|Placebo Comparator|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
16637368|NCT02365896|Other|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
16637369|NCT02365883||Prostate Cancer Group|
16637370|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
16637371|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
16637372|NCT02365857|Active Comparator|DEX-5|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
16637373|NCT02365857|Active Comparator|DEX-10|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
16637374|NCT02365857|Active Comparator|DEX-15|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
16637375|NCT02365857|Active Comparator|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
16637376|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
16637377|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
16637378|NCT02365818|Experimental|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
16637379|NCT02365805|Active Comparator|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
16637380|NCT02365805|Experimental|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
16637381|NCT02365805|Experimental|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
16637382|NCT02365792|Active Comparator|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
16637383|NCT02365792|Active Comparator|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
16637384|NCT02365792|Placebo Comparator|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
16637385|NCT02365779|Experimental|bilateral laparoscopic salpingectomy|
16637386|NCT02365766|Experimental|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
16637387|NCT02365766|Experimental|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
16637452|NCT02365389|Active Comparator|Group A received in situ MTZ vaginal gel|Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
16637388|NCT02365766|Experimental|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
16637389|NCT02365753|Placebo Comparator|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
16637390|NCT02365753|Active Comparator|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
16637391|NCT02365740|Experimental|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
16637392|NCT02365740|Sham Comparator|Controls|gastric emptying test gut hormones determination
16637393|NCT02365727|Experimental|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
16637394|NCT02365727|Placebo Comparator|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
16637395|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
16637396|NCT02365701|Experimental|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
16637397|NCT02365701|Placebo Comparator|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
16637398|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
16637399|NCT02365675|Active Comparator|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
16637400|NCT02365675|Active Comparator|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
16637401|NCT02365675|Active Comparator|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic 'nanocrystals' of metallic silver.
16637402|NCT02365675|Active Comparator|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
16637403|NCT02365662|Experimental|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
16637404|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
16637405|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
16637406|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
16637407|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
16637408|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
16637409|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
16637410|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
16637411|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
16637412|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
16637413|NCT02365636|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
16637414|NCT02365636|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
16637415|NCT02365636|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
16637416|NCT02365623|Experimental|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
16637417|NCT02365610|Experimental|GWP42006|GWP42006
16637418|NCT02365610|Placebo Comparator|Placebo control|Placebo
16637453|NCT02365389|Active Comparator|Group B received conventional MTZ vaginal gel|Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
16637454|NCT02365363|Experimental|Bagel control|100% wheat flour
16637419|NCT02365597|Experimental|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression.
16637420|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
16637421|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
16637422|NCT02365571|Experimental|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
16637423|NCT02365571|Placebo Comparator|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
16637424|NCT02365571|Experimental|LY3154207 (Part B)|LY3154207 administered once orally.
16637425|NCT02365571|Placebo Comparator|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
16637426|NCT02365571|Experimental|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
16637427|NCT02365571|Experimental|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
16637428|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
16637429|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.
~Evacetrapib will be co-administered once, orally on Day 14."
16637430|NCT02365532|Placebo Comparator|Placebo to match GS-6615|Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
16637431|NCT02365532|Experimental|GS-6615|GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
16637432|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
16637433|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
16637434|NCT02365506|Experimental|Eleclazine 24 mg + Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3.
16637435|NCT02365506|Experimental|Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3.
16637436|NCT02365506|Placebo Comparator|Placebo|Participants will receive placebo to match eleclazine on Days 1 to 4.
16637437|NCT02365493|No Intervention|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).
~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
16637438|NCT02365493|Experimental|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
16637439|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
16637440|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
16637441|NCT02365454|Experimental|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
16637442|NCT02365441|Active Comparator|Arm A|imatinib 400mg orally daily continuously
16637443|NCT02365441|Experimental|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
16637444|NCT02365428|Experimental|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
16637445|NCT02365428|Experimental|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
16637446|NCT02365428|Experimental|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
16637447|NCT02365428|Experimental|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
16637448|NCT02365415|Experimental|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
16637449|NCT02365415|No Intervention|Control|No treatment.
16637450|NCT02365402|Experimental|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
16637451|NCT02365402|No Intervention|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
16637460|NCT02365350|Experimental|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
16637461|NCT02365350|Active Comparator|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
16637462|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels < 20ng/ ml
16637463|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels >20ng/ ml
16637464|NCT02365324|Experimental|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
16637465|NCT02365324|Other|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
16637466|NCT02365311|Experimental|one lung group|
16637467|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
16637468|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
16637469|NCT02365285|Experimental|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
16637470|NCT02365285|Placebo Comparator|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
16637471|NCT02365272|Active Comparator|amikacin standard dose|amikacin in a single standard dose
16637472|NCT02365272|Active Comparator|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
16637473|NCT02365259|Experimental|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
16637474|NCT02365259|Placebo Comparator|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
16637475|NCT02365246|Experimental|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
16637476|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
16637477|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
16637478|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
16637479|NCT02365220|Active Comparator|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training
16637480|NCT02365220|Experimental|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training"
16637481|NCT02365220|Experimental|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training"
16637482|NCT02365220|Experimental|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training"
16637483|NCT02365207|Experimental|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
16637484|NCT02365194|Other|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
16637485|NCT02365194|Other|Standard Counseling|initial clinic counseling
16637486|NCT02365181|Experimental|IAL|intra-articular local anesthetic infiltration with catheter
16637487|NCT02365181|Active Comparator|ISB|interscalene block with catheter
16637488|NCT02365168|Experimental|Food Challenge with cod|
16637489|NCT02365168|Experimental|Food Challenge with salmon|
16637490|NCT02365168|Experimental|Food Challenge with mackerel|
16637491|NCT02365168|Placebo Comparator|Food Challenge with placebo|
16637492|NCT02365155|Experimental|Intervention group.|Multicomponent training intervention; Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
16637493|NCT02365155|Active Comparator|Control group.|Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
16637494|NCT02365142|Active Comparator|Platelet Rich Plasma (PRGF)|Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
16637495|NCT02365142|Active Comparator|BMMSC with Platelet Rich Plasma (PRGF)|Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
16637496|NCT02365129|No Intervention|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
16637497|NCT02365129|Experimental|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
16637498|NCT02365129|Experimental|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
16637499|NCT02365116|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
16637500|NCT02365116|Active Comparator|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
16637501|NCT02365103|Other|Test meal I (given with water)|Test meal with water
16637544|NCT02364869|Placebo Comparator|Maltodextrin|12g daily, for 12 weeks
16637503|NCT02365103|Other|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
16637504|NCT02365103|Other|Reference Iron Dose|Reference iron dose administered
16637505|NCT02365090|Active Comparator|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
16637506|NCT02365090|Experimental|binocular games|1 hour per day (5 days per week) binocular game play
16637507|NCT02365077||Control|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.
16637508|NCT02365077||Necrosis|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.
16637509|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
16637510|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
16637511|NCT02365051|No Intervention|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
16637512|NCT02365051|Experimental|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
16637513|NCT02365038|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation
16637514|NCT02365038|Active Comparator|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
16637515|NCT02365025|Experimental|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.
~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
16637516|NCT02365025|No Intervention|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.
~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.
~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.
~Step 5: 3 months follow up."
16637517|NCT02365012|Placebo Comparator|Placebo|Placebo given three times a day for 2 weeks
16637518|NCT02365012|Active Comparator|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
16637519|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
16637520|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
16637521|NCT02364986|Experimental|Rebif/Avonex|Rebif® 44µg (day 1, 3, 5 and 8) s.c. Avonex 30µg (day 1 and 8) i.m.
16637522|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
16637523|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|
16637524|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|
16637525|NCT02364947|Placebo Comparator|Placebo|
16637526|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
16637527|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
16637528|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
16637529|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
16637530|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
16637531|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
16637532|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
16637533|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
16637534|NCT02364921|Experimental|Two-layer compression bandage|Two multilayer compression bandage: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.Measure the ankle circumference and choose the correct kit accordingly (ankle size 18-25cm or 25-32cm). Apply one to seven days
16637535|NCT02364921|Active Comparator|crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
16637536|NCT02364908|Other|Patients with Systemic Lupus|
16637537|NCT02364895|Experimental|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
16637538|NCT02364895|Experimental|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
16637539|NCT02364882|Placebo Comparator|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
16637540|NCT02364882|Active Comparator|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
16637541|NCT02364882|Active Comparator|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
16637542|NCT02364882|Active Comparator|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
16637543|NCT02364869|Experimental|Fructooligosaccharide|12g daily, for 12 weeks
16637546|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
16637547|NCT02364830|Active Comparator|Anise-oil EC|Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks. Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
16637548|NCT02364830|Placebo Comparator|Placebo|Placebo Group: One Placebo Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
16637549|NCT02364830|Active Comparator|Colpermin®|Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
16637550|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).
~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
16637551|NCT02364791|Active Comparator|standard treatment|standard techniques to achieve air leak control after complex thoracic surgical procedures
16637552|NCT02364791|Experimental|standard treatment plus hemopatch|the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures
16637553|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
16637554|NCT02364765|Other|Orthognatic surgery|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour.
16637555|NCT02364752|Experimental|Healthy|Part 1: Blood is obtained from healthy participants on 3 consecutive days, and participants undergo Cardiac Magnetic Resonance Imaging (CMR) and two-dimensional speckle tracking echocardiography (2DSTE) on one of those 3 days.
16637556|NCT02364752|Experimental|Mild/moderate heart failure (HF)|Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
16637557|NCT02364752|Experimental|Severe HF|Part 1: Blood is obtained from participants with severe HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
16637558|NCT02364739|Experimental|Written information|Written information
16637559|NCT02364739|Experimental|Written and oral information|Written and oral information
16637560|NCT02364739|No Intervention|No intervention|Control
16637561|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.
~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
16637562|NCT02364713|Experimental|Arm A (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16637563|NCT02364713|Active Comparator|Arm B (DOXIL, GEM, TOPA, TAXOL)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15, or paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may also receive bevacizumab IV over 30-90 minutes on days 1 and 15 with pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, or paclitaxel. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16637564|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
16637565|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
16637566|NCT02364674|Experimental|HRCT scans|HRCT scan will be taken
16637567|NCT02364661|Experimental|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
16637568|NCT02364648|Experimental|MitoQ|4 week 20mg oral daily dose of MitoQ
16637569|NCT02364648|Placebo Comparator|Placebo|4 week 20mg oral daily placebo
16637570|NCT02364635|Experimental|Icosabutate dose 1|Dose 1
16637571|NCT02364635|Experimental|Icosabutate dose 2|Dose 2
16637572|NCT02364635|Experimental|Icosabutate dose 3|Dose 3
16637573|NCT02364635|Placebo Comparator|Placebo|Placebo (medium chain triglycerides)
16637574|NCT02364635|Experimental|Icosabutate dose 4|Dose 4
16637575|NCT02364622|Sham Comparator|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
16637576|NCT02364622|Experimental|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
16637577|NCT02364622|Experimental|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
16637578|NCT02364609|Experimental|Arm I (afatinib dimaleate, pembrolizumab)|DOSE DE-ESCALATION COHORT: Patients receive afatinib dimaleate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days (for up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
16637579|NCT02364609|Experimental|Arm II (pembrolizumab, afatinib dimaleate)|EXPANSION COHORT: Patients receive pembrolizumab IV over 30 minutes on day 1 for 2 courses. Beginning course 3, patients receive afatinib dimaleate PO and pembrolizumab IV as in Arm I. Courses repeat every 21 days (up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
16637580|NCT02364596|Experimental|1|SA4Ag vaccine
16637581|NCT02364583|Active Comparator|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
16637582|NCT02364583|Active Comparator|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
16637583|NCT02364583|Active Comparator|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
16637584|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
16637585|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
16637586|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
16637587|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
16637588|NCT02364557|No Intervention|Arm 1 (standard of care)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician.
16637589|NCT02364557|Experimental|Arm 2 (stereotactic radiosurgery, surgery)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician. Patients also undergo stereotactic radiosurgery in 1, 3, or 5 fractions within 3 weeks and/or surgery at the discretion of the treating physician.
16637590|NCT02364544|Other|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program
~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
16637591|NCT02364531||Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
16637592|NCT02364518|Experimental|Snoreplasty|Treatment of Snoring and/or mild obstructive sleep apnea with snoreplasty.
16637593|NCT02364505|Experimental|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
16637594|NCT02364505|Active Comparator|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
16637595|NCT02364492|Experimental|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.
~For each dose patient will receive 6 injections at 3 interval weeks."
16637596|NCT02364479|Experimental|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
16637597|NCT02364479|Experimental|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
16637598|NCT02364479|Placebo Comparator|Placebo|Placebo, Subcutaneous injection per week
16637599|NCT02364453|Experimental|Placebo to PACAP38|Pre-treatment with placebo. PACAP38 8pmol/kg/min
16637600|NCT02364453|Experimental|Clemastin 1 mg/ml to PACAP38 8pmol/kg/min|Pre-treatment with Clemastin 1 mg/ml PACAP38 8 pmol/kg/min
16637601|NCT02364440|Experimental|Ultherapy™ System|Ultherapy™ System
16637602|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
16637603|NCT02364414|Other|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
16637604|NCT02364401|Experimental|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
16637605|NCT02364401|Active Comparator|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
16637606|NCT02364388|Active Comparator|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
16637607|NCT02364388|Other|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
16637608|NCT02364375|Experimental|Full Face|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (full face) and Comparison Menai Standard mask (full face) for 7 nights each.
16637609|NCT02364375|Experimental|Nasal|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (nasal) and Comparison Menai Standard mask (nasal) for 7 nights each.
16637610|NCT02364375|Experimental|Pillows|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (pillows) and Comparison Menai Standard mask (pillows) for 7 nights each.
16637611|NCT02364362|Experimental|Famitinib + docetaxel|Low, medium and high dose of famitinib and 60 mg/m^2 docetaxel every 3 weeks
16637612|NCT02364349|Active Comparator|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
16637613|NCT02364349|Experimental|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
16637614|NCT02364336|Experimental|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
16637615|NCT02364336|Experimental|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
16637616|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
16637617|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
16637618|NCT02364310|Experimental|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
16637619|NCT02364310|No Intervention|Best medical care|Best medical care
16637620|NCT02364297|Active Comparator|Early TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.
~Performance of TIPS in the first 5 days following acute gastric variceal bleeding."
16637621|NCT02364297|Placebo Comparator|Control|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.
~Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices)."
16637622|NCT02364284||Urinary Tract Infection (cUTI)|Patients ≥18 years with diagnosis of urinary tract infection.
16637623|NCT02364284||Intra Abdominal Infection(cIAI)|Patients ≥ 18 years with diagnosis of Intra Abdominal Infection
16637624|NCT02364284||Nosocomial Pneumonia (NP)|Patients ≥ 18 years with diagnosis of Hospital acquired pneumonia
16637625|NCT02364271||Not low risk for MACE in 30 days|"Patients with not low risk of major adverse cardiac events within 30 days Patients with TIMI>0 or mHEART>2
~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients
~Protocol amendment:
~In October 2014, mHEART score of the study patients was determined retrospectively"
16637626|NCT02364271||Low risk for MACE in 30 days|"Patients with low risk of major adverse cardiac events within 30 days
~Patients with TIMI=0 and mHEART<=2
~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients
~Protocol amendment:
~In October 2014, mHEART score of the study patients was determined retrospectively"
16637627|NCT02364258|Experimental|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
16637628|NCT02364258|Experimental|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
16637629|NCT02364245|Experimental|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
16637630|NCT02364245|Placebo Comparator|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
16637631|NCT02364232|Experimental|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.
~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
16637632|NCT02364232|Active Comparator|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.
~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
16637633|NCT02364219|No Intervention|Standard|"Study arm in which patients are treated according to standard operating procedures. Acting as control arm."
16637634|NCT02364219|Experimental|Standard + Microdialysis|Study arm in which patients are treated according to standard operating procedures but also receive Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue.
16637635|NCT02364219|Experimental|Prewarm|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
16637636|NCT02364219|Experimental|Prewarm + Microdialysis|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia and Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue
16637637|NCT02364206|Experimental|LY2228820 + TMZ + Radiotherapy|"addition of LY2228820 to standard radiotherapy and concomitant treatment by temozolomide (TMZ).
~LY2228820 will be administered orally for two 28 day cycles, from one week before the beginning of radiotherapy, and during standard chemoradiotherapy. Three dose levels of LY2228820 will be tested.
~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
16637638|NCT02364193|Experimental|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:
~Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.
~CO, phase contrast angiography.
~Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).
~DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).
~BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
16637639|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
16637640|NCT02364167|Experimental|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
16637641|NCT02364167|Placebo Comparator|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
16637642|NCT02364167|Active Comparator|Standard therapy|Each patient will receive just standard postoperative analgesia
16637643|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
16637644|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
16637645|NCT02364141|Experimental|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
16637646|NCT02364141|Active Comparator|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
16637647|NCT02364128|No Intervention|Control|Potential bariatric surgery patients who receive both the baseline questionnaire and follow-up questionnaire.
16637648|NCT02364128|Other|Decision Aid|Potential bariatric surgery patients who receive both the baseline questionnaire decision aid/conjoint analysis and follow-up questionnaire.
16637649|NCT02364115|Experimental|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
16637650|NCT02364115|No Intervention|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
16637651|NCT02364089|Experimental|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
16637652|NCT02364089|Active Comparator|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
16637653|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
16637654|NCT02364063|Experimental|Children with CP - Therapy|Children receive incontinence treatment during one year, after which a follow-up period of 6 months will be applied. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
16637655|NCT02364063|No Intervention|Children with CP - Control|Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
16637656|NCT02364063|Active Comparator|Children without CP|Children receive incontinence treatment during 1 year. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
16637657|NCT02364050||Elderly patients with DLBCL|Elderly patients (Age ≥ 65 years) with large B-cell lymphoma classified FIT or UNFIT or FRAIL by Multidimensional Geriatric Assessment (MGA)
16637658|NCT02364037|Other|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
16637659|NCT02364037|Other|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
16637660|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
16637661|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
16637662|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
16637663|NCT02363985|Other|Multiple vitamin A exposer|"55 children who are using
~Mega-dose vitamin A supplementation
~Food diversification (promotion and education on vitamin A rich food consumption)
~Promotion of orange flash sweet potato production and consumption in collaboration with international potato center (CIP) in one of the study area"
16637664|NCT02363985|Other|Only vitamin A supplementation|"55 children who are using
~Mega-dose vitamin A supplementation
~Food diversification (promotion and education on vitamin A rich food consumption)"
16637665|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
16637666|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
16637667|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
16637668|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
16637669|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
16637670|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
16637671|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
16637672|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
16637673|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
16637674|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
16637675|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
16637676|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
16637677|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
16637678|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
16637679|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
16637680|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
16637681|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
16637682|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
16637683|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
16637684|NCT02363920|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
16637685|NCT02363920|Active Comparator|HOF20|the patients will be asked to breathe with HOF of 20 L/min
16637686|NCT02363920|Active Comparator|HOF30|the patients will be asked to breathe with HOF of 30 L/min
16637687|NCT02363920|Active Comparator|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
16637688|NCT02363894||Subjects enrolled in DEFINITIVE AR|
16637689|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
16637690|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
16637691|NCT02363855|Experimental|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
16637692|NCT02363842|Experimental|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
16637693|NCT02363842|Active Comparator|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
16637694|NCT02363829|Experimental|Treatment|Nelfinavir and Cisplatin
16637695|NCT02363803|Placebo Comparator|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
16637696|NCT02363803|Active Comparator|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
16637697|NCT02363790|Other|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)
~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).
~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
16637698|NCT02363790|Other|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
16637699|NCT02363777|Active Comparator|Standard of Care|Epidural placed for postoperative pain control
16637700|NCT02363777|Experimental|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
16637701|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)
~Nasal swab
~Cough swab
~Spontaneous expectorated sputum
~Questionnaire"
16637702|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)
~Nasal swab
~Cough swab
~Induced sputum after inhalation of hypertonic saline (NaCl 6%)
~Questionnaire"
16637703|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)
~Nasal swab
~Cough swab
~Induced sputum after inhalation of hypertonic saline (NaCl 6%)
~Bronchoalveolar lavage (BAL)"
16637704|NCT02363751|Experimental|1|Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab)
16637705|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
16637706|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
16637707|NCT02363725|Other|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):
~Double anti-aggregation
~IEC (or sartan) at best tolerated dose
~Beta-blocker at best tolerated dose
~High dose statin (usually atorvastatin 80 mg daily)
~If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)
~Any other treatment will be logged."
16637708|NCT02363725|Experimental|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
16637709|NCT02363712|Experimental|APOS|APOS(All Phase Of Step)-shoe
16637710|NCT02363712|Sham Comparator|Sham APOS|Sham APOS(All Phase Of Step)-shoe
16637711|NCT02363699|Active Comparator|Lidocaine|Group treated with lidocaine solution
16637712|NCT02363699|Placebo Comparator|Placebo|Group treated with saline solution
16637713|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
16637714|NCT02363673|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy in aqua distilla according to their symptoms and characteristic manifestations of their disorder. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Remedies will be dispensed in aqua distilla. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing.
16637715|NCT02363660|Experimental|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
16637716|NCT02363660|Experimental|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
16637717|NCT02363660|Experimental|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
16637718|NCT02363647|Experimental|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
16637719|NCT02363634|Active Comparator|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
16637720|NCT02363634|Placebo Comparator|Placebo|Those randomized to placebo
16637721|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
16637722|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
16637723|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
16637724|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
16637758|NCT02363374|Active Comparator|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
16637725|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
16637726|NCT02363595||Papillary Microcarcinoma|This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
16637727|NCT02363582|No Intervention|Breast fed|healthy term infants on exclusively breast feeding , enrollment age: 30-50days old
16637728|NCT02363582|Experimental|Formula fed|healthy term infants on exclusively formula fed , enrollment age: 30-50days old
16637729|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
16637730|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
16637731|NCT02363556|Experimental|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
16637732|NCT02363556|Experimental|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
16637733|NCT02363543|Active Comparator|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
16637734|NCT02363543|Active Comparator|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
16637735|NCT02363530|Experimental|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
16637736|NCT02363530|Placebo Comparator|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
16637737|NCT02363517|No Intervention|Group A|"Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).
~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
16637738|NCT02363517|Active Comparator|Group B|"Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.
~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
16637739|NCT02363517|Active Comparator|Group C|Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
16637740|NCT02363504||Healthy older controls|7 Tesla MRI with memory task and non-invasive neurostimulation
16637741|NCT02363504||Prodromal Alzheimer's disease patients|7 Tesla MRI with memory task and non-invasive neurostimulation
16637742|NCT02363491|Experimental|OPN-305|OPN-305
16637743|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
16637744|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
16637745|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
16637746|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
16637747|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
16637748|NCT02363452|Experimental|AGS|Reverse transcriptase inhibitors
16637749|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
16637750|NCT02363426|Other|Medical Device: INVOcell Culture Device|5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
16637751|NCT02363426|Active Comparator|Medical Device: IVF Incubator|5 day oocyte incubation using traditional IVF incubation.
16637752|NCT02363413|Active Comparator|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
16637753|NCT02363413|Experimental|IniVAD|Initiation of the NIV at home : experimental care.
16637754|NCT02363400|Experimental|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
16637755|NCT02363400|No Intervention|control arm|closely followed with frequency similar to the experiemental arm
16637756|NCT02363387|Experimental|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
16637757|NCT02363387|Other|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
16637837|NCT02362854|Experimental|DL application in peri-implantitis|Adjunct Diode Laser application.
16637759|NCT02363374|Experimental|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
16637760|NCT02363361|Experimental|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
16637761|NCT02363348|Placebo Comparator|Placebo (A)|"were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.
~dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner."
16637762|NCT02363348|Experimental|L arginine (B)|were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
16637763|NCT02363335|Placebo Comparator|Placebo|Randomized, double blind, placebo-controlled cross-over study
16637764|NCT02363335|Experimental|Roflumilast|Randomized, double blind, placebo-controlled cross-over study
16637765|NCT02363335|Experimental|Roflumilast/Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
16637766|NCT02363335|Experimental|Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
16637767|NCT02363322|Active Comparator|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
16637768|NCT02363322|Experimental|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
~ZMapp 50mg/kg IV administered every third day for 3 infusions."
16637769|NCT02363309||Healthy Volunteers|Subjects without liver disease or metabolic syndrome
16637770|NCT02363309||NAFLD subjects|Subjects with Non-Alcoholic Fatty Liver Disease
16637771|NCT02363309||non-NAFLD metabolic syndrome|Subjects who have metabolic syndrome but do not have Non-Alcoholic Fatty Liver Disease
16637773|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
16637774|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
16637775|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
16637776|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
16637777|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
16637778|NCT02363231||patients under mechanical ventilation|
16637779|NCT02363218|Experimental|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
16637780|NCT02363205|No Intervention|control|Weekly check-up
16637781|NCT02363205|Experimental|internet-delivered CBT|Tailored Internet-administrated CBT-Treatment
16637782|NCT02363192|Experimental|Pharmacist Intervention Group|
16637783|NCT02363192|No Intervention|Usual Care Group|
16637784|NCT02363179|No Intervention|Non Music Group|500 non-intervention patients will be consented to serve as the control group
16637785|NCT02363179|Experimental|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
16637786|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
16637787|NCT02363153|Experimental|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
16637788|NCT02363140|No Intervention|Group One patients in age group 18--20 years,|"Patients should be aged 18--20 years or 35--45years
~Asymptomatic knee for past 6 months.
~Painless flexion-extension movements at knee joint."
16637789|NCT02363140|Active Comparator|Group Two patients in age group 35-45 years,|"Patients should be aged 18--20 years or 35--45years
~Asymptomatic knee for past 6 months.
~Painless flexion-extension movements at knee joint."
16637790|NCT02363140|Active Comparator|Group Three Patients aged 75|"Patients should be aged 75 or older
~Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis
~No clinical suspicion of meniscus tear
~Painless flexion-extension movements at knee joint."
16637791|NCT02363140|Active Comparator|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
16637792|NCT02363127|Experimental|Prolutex|Subcutaneous progesterone
16637793|NCT02363127|Active Comparator|Progeffik|Vaginal progesterone
16637794|NCT02363114||Stroke Prevention Clinic Patients|All consecutive patients presenting to six high volume Regional Stroke Prevention Clinics.
16637795|NCT02363088|No Intervention|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
16637796|NCT02363088|Experimental|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
16637797|NCT02363088|No Intervention|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
16637798|NCT02363088|Experimental|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
16637799|NCT02363088|Experimental|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
16637800|NCT02363088|Experimental|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
16637801|NCT02363088|Experimental|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
16637802|NCT02363088|Other|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
16637803|NCT02363088|Experimental|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
16637804|NCT02363075|Experimental|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
16637805|NCT02363075|Placebo Comparator|placebo|Aspect tablets identical to the active
16637806|NCT02363049|Experimental|colectomy|surgery followed by chemotherapy +/- targeted therapy regime according to each centre
16637807|NCT02363049|Active Comparator|no colectomy|Chemotherapy +/- targeted therapy alone, regime according to each centre.
16637808|NCT02363036||Active labor|Women in active labor normal pregnancy at term.
16637809|NCT02363036||Planned Cesarian Section|Women, normal pregnancy at term who came for elective Cesarean Section without signs of labor (pain/contractions, etc).
16637810|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
16637811|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
16637812|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
16637813|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
16637814|NCT02362997|Experimental|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
16637815|NCT02362997|Experimental|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
16637816|NCT02362997|Experimental|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
16637817|NCT02362984|Placebo Comparator|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
16637818|NCT02362984|Experimental|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
16637819|NCT02362971||Included|Patients included into the randomized controlled trial
16637820|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
16637821|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
16637822|NCT02362958|Experimental|Lapatinib and Capecitabine or Vinorelbine|Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)
16637823|NCT02362945|Experimental|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
16637824|NCT02362945|No Intervention|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
16637825|NCT02362932|Experimental|Intervention|Sanitation
16637826|NCT02362932|No Intervention|Control|No sanitation
16637827|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
16637828|NCT02362906|Experimental|Injection,medications and application|"Intravenous injection:
~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
16637829|NCT02362906|Experimental|Injection and medications|"Intravenous injection:
~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
16637830|NCT02362906|Experimental|Injection and application|"Intravenous injection:
~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
16637831|NCT02362893|Experimental|Direct Observed Therapy|Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
16637832|NCT02362893|No Intervention|Control|Standard care
16637833|NCT02362880|Active Comparator|mutation carrier|
16637834|NCT02362880|Sham Comparator|mutation non-carrier|
16637835|NCT02362867|No Intervention|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
16637836|NCT02362854|Active Comparator|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
16637838|NCT02362815|Active Comparator|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
16637839|NCT02362815|No Intervention|Control|Patient are not allowed to drink
16637840|NCT02362802|Active Comparator|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
16637841|NCT02362802|No Intervention|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.
~Apart from that usual standard of care."
16637842|NCT02362789|Experimental|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
16637843|NCT02362789|Placebo Comparator|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
16637844|NCT02362776||breast cancer patients|
16637845|NCT02362776||lung cancer patients|
16637846|NCT02362776||control subjects|
16637847|NCT02362763|Experimental|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
16637848|NCT02362763|Active Comparator|Controls|Controls received five acupuncture sessions designed for sedation
16637849|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
16637850|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:
~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
16637851|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
16637852|NCT02362737|Experimental|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
16637853|NCT02362737|No Intervention|Control|Usual care.
16637854|NCT02362724|Experimental|Sapphire|Subjects randomized to the experimental contact lens over the study duration
16637855|NCT02362724|Active Comparator|Pearl|Subjects randomized to the active comparator contact lens over the study duration
16637856|NCT02362711|Experimental|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
16637857|NCT02362711|Experimental|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
16637858|NCT02362711|Placebo Comparator|Placebo Group|Placebo for NPC-16
16637859|NCT02362698|Experimental|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
16637860|NCT02362698|Active Comparator|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
16637861|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
16637862|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
16637863|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
16637864|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
16637865|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
16637866|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
16637867|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
16637868|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
16637869|NCT02362633|Experimental|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
16637870|NCT02362633|Sham Comparator|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
16637871|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
16637872|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
16637873|NCT02362607|Experimental|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
16637874|NCT02362607|Active Comparator|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
16637875|NCT02362594|Experimental|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
16637876|NCT02362594|Placebo Comparator|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
16637877|NCT02362581|Experimental|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.
~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
16637878|NCT02362568|No Intervention|Cervical ultrasound exploration|A cervical ultrasound exploration will be performed in all patients admitted for a planned surgery performed under general anesthesia during the stay in the postoperative room.
16637879|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
16637880|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
16637881|NCT02362542|Experimental|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
16637882|NCT02362542|Experimental|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
16637883|NCT02362529|Experimental|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
16637884|NCT02362529|Placebo Comparator|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
16637885|NCT02362529|Other|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
16637886|NCT02362516|Experimental|BI 425809|
16637887|NCT02362503|Experimental|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
16637888|NCT02362503|Active Comparator|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
16637889|NCT02362503|Experimental|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
16637890|NCT02362490|Experimental|peginterferon alpha 2a|in this group, patients who were on treatment of Nucleoside (Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will switch to treatment of peginterferon alpha 2a for 72 week.
16637891|NCT02362490|No Intervention|control group|in this group, patients who were on treatment of Nucleoside(Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will be continue to treatment of Nucleoside(Acid) Analogues for 72 week.
16637892|NCT02362477|Active Comparator|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
16637893|NCT02362477|Experimental|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
16637894|NCT02362464|Experimental|1|intradermally given vaccine given at weeks 3, 6, 9, 12, 15 and 24.
16637895|NCT02362451|Experimental|1/Lead-in TARP DC vaccine treatment|All patients to receive autologous multi-epitope TARP DC vaccine before randomization
16637896|NCT02362451|Experimental|2/Active TARP DC vaccine treatment|Autologous multi-epitope TARP DC vaccine after randomization
16637897|NCT02362451|Placebo Comparator|3/Placebo|Autologous elutriated monocyte vaccine placeboafter randomization
16637902|NCT02362425|Active Comparator|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
16637903|NCT02362425|Placebo Comparator|RYR1-RM Patients Administered Placebo|Placebo
16637904|NCT02362425|No Intervention|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
16637905|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
16637906|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
16637907|NCT02362399|Active Comparator|sildenafil citrate|50 mg single oral dose
16637908|NCT02362399|Active Comparator|placebo|single tablet of placebo
16637909|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
16637910|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
16637911|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
16637912|NCT02362347|Active Comparator|Usual care + exercise|Usual care + exercise
16637913|NCT02362347|No Intervention|No care, no exercise|No care, no exercise
16637914|NCT02362347|Experimental|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
16637915|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
16637916|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
16637917|NCT02362308||Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
16637918|NCT02362308||Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
16637919|NCT02362295||census|qualitative interview
16637920|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
16637921|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
16637922|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
16637923|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
16637924|NCT02362256|Experimental|Intervention|"Opioid antagonist induction. Day 4. Duration 12-16 hours.
~Naltrexone gradual increase from 50 µg p/o to a total dose of 12,5 mg according to a predefined protocol:
~st hour 50 µg
~nd hour 50 µg
~rd hour 100 µg
~th hour 100 µg
~th hour 200 µg
~th hour 400 µg
~th hour 800 µg
~th hour 1600 µg
~th hour 3200 µg
~th hour 6000 µg
~Correction of symptoms for opioid abstinence:
~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
16637925|NCT02362256|Active Comparator|Control|"Opioid antagonist induction. Day 4. Duration 12-16 hours. Naltrexone single dose 12,5 mg p/o
~Correction of symptoms for opioid abstinence:
~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
16637926|NCT02362243|Placebo Comparator|Control Group|Participants in the control arm will complete the placebo comparator intervention.
16637927|NCT02362243|Experimental|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
16637928|NCT02362243|Experimental|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
16637929|NCT02362230|Experimental|Icotinib|Icotinib 125 mg BID
16637930|NCT02362217|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.
~Subjects: 8 healthy volunteers."
16637931|NCT02362217|Experimental|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8.
~Subjects: 8 healthy volunteers."
16637932|NCT02362217|Experimental|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8.
~Subjects: 16 healthy volunteers."
16637933|NCT02362191|Experimental|Single Session tACS Across Menstrual Cycle|Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.
16637934|NCT02362178|Experimental|Thromboelastography (TEG)|Patients in the TEG group received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, only if INR was higher than 1.8 and r time longer than 40 minutes. They received platelets at the amount of 1 apheresis Unit, only if platelets count was lower than 50000/μl and MA was shorter than 30 millimeter.
16637935|NCT02362178|Active Comparator|Standard of Care (SOC)|In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.
16637936|NCT02362165|Experimental|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
16637937|NCT02362165|Active Comparator|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
16637938|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
16637939|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
16637940|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
16637941|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
16637942|NCT02362139|Experimental|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
16637943|NCT02362139|No Intervention|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
16637944|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
16637945|NCT02362113||Isfahani adults|GI/GL
16637946|NCT02362100|Placebo Comparator|nonoperative management|"Treatment will consist of sling immobilization for a period of 6 weeks. Details and treatment timeline as follows:
~0 - 3 weeks: immobilization with a shoulder sling, range of motion of elbow, hand and wrist
~3 - 6 weeks: same as 0-3 weeks, with addition of pendulum exercises every two hours
~After 6 weeks: Active mobilization and removal of sling. Light activity permitted and physiotherapy for range of motion permitted as tolerated.
~After 6 months: no further restriction will be placed. Full home and work activity permitted."
16637947|NCT02362100|Active Comparator|locking plate surgical fixation|"Standardized operative management protocol as follows:
~Pre-operative medical clearance established via anesthesia consults if required for medically complex patients.
~Provision of pre-operative intravenous (IV) antibiotic prophylaxis:
~Administration of general anesthetic.
~Patient positioning and preparation:
~Patient is carefully placed in the beach-chair position,
~Deltopectoral approach Fracture reduction and fixation with confirmation with intraoperative fluoroscopy images."
16637948|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
16637949|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
16637950|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
16637951|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
16637952|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
16637953|NCT02362035|Experimental|ACP-196 (Acalabrutinib) +PEM|"PART 1 & PART 2- Acalabrutinib 100 mg will be orally administered (PO) twice daily (BID) in combination with Pembrolizumab 200 mg will be administered every 3 weeks (Q3W) by IV infusion.
~PART 3 - Acalabrutinib 100 mg will be orally administered (PO) twice daily (BID) for 6 weeks followed by continuation of acalabrutinib monotherapy or combination therapy with acalabrutinib 100mg BID and pembrolizumab 200 mg Q3W as per Investigator discretion."
16637954|NCT02362022|Placebo Comparator|Group Saline|Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30)
16639762|NCT02349724|Other|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
16637955|NCT02362022|Active Comparator|Group Morphine 1|Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30)
16637956|NCT02362022|Active Comparator|Group Morphine 2|Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30)
16637957|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:
~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.
~list of medication timely related to the procedure
~signed informed consent
~exclusion criteria:
~intolerance to contrast agent
~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
~renal failure
~severe arrhythmia
~pregnancy
~reduction of cognitive capabilities to understand the purpose and the extent of the study
~participation in a medical-scientific study using X-rays in the last ten years
~lack of Russian knowledge to fill the forms
~lack of signed study agreement"
16637958|NCT02361996||Coronary Stenting|"inclusion criteria:
~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.
~list of medication timely related to the procedure
~signed informed consent
~exclusion criteria:
~intolerance to contrast agent
~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
~renal failure
~severe arrhythmia
~pregnancy
~reduction of cognitive capabilities to understand the purpose and the extant of the study
~participation in a medical-scientific study using X-rays in the last ten years
~lack of Russian knowledge to fill the forms
~lack of signed study agreement"
16637959|NCT02361996||Aortic Valve Replacement|"inclusion criteria:
~presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%
~list of medication timely related to the procedure
~signed informed consent
~exclusion criteria:
~intolerance to contrast agent
~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
~renal failure
~severe arrhythmia
~pregnancy
~reduction of cognitive capabilities to understand the purpose and the extent of the study
~participation in a medical-scientific study using X-rays in the last ten years
~lack of Russian knowledge to fill the forms
~lack of signed study agreement"
16637960|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
16637961|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
16637962|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
16637963|NCT02361970||volunteer|Health persons
16637964|NCT02361957|Active Comparator|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
16637965|NCT02361957|Placebo Comparator|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
16637966|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
16637967|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
16637968|NCT02361931|Experimental|Treatment group (erythropoietin)|10 patients receive RMD-G1 (gel with 2000 IU/ml of erythropoietin) as an adjunct therapy to standard of care (SOC). Topical application on wound bed, daily for 12 weeks.
16637969|NCT02361931|Placebo Comparator|Control group (standard of care)|10 patients receive SOC alone daily for 12 weeks. A moisturizing gel is applied on wound bed as a part of SOC.
16637970|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
16637971|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
16637972|NCT02361905|Experimental|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
16637973|NCT02361905|Active Comparator|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
16637974|NCT02361892|Experimental|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
16637975|NCT02361879|Experimental|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
16637976|NCT02361879|Active Comparator|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
16637977|NCT02361866|Experimental|GC1107|0.5ml, intramuscular, a single dosing
16637978|NCT02361866|Active Comparator|Tetanus and Diphtheria(Td vaccine)|0.5ml, intramuscular, a single dosing
16637979|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
16637980|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
16637981|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
16637982|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI > or = 0.05ng/ml We call Event to the onset of ARDS
16637983|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (<0.05ng/ml) We call Event to the onset of ARDS
16637984|NCT02361827||A, Vitamin D deficient|Vitamin D level on the day of HCG administraion < 20 ng/mL Embryo transfer after oocyte retrieval.
16637985|NCT02361827||B, Vitamin D insufficient|Vitamin D level on the day of HCG administraion 20-29.9 ng/mL Embryo transfer after oocyte retrieval.
16637986|NCT02361827||C, Vitamin D replete|Vitamin D level on the day of HCG administraion > 30 ng/mL Embryo transfer after oocyte retrieval.
16637987|NCT02361814|Experimental|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
16637988|NCT02361801|Active Comparator|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
16637989|NCT02361801|Active Comparator|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
16637990|NCT02361775|Experimental|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
16637991|NCT02361775|Active Comparator|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
16637992|NCT02361762|Experimental|Training|Computerized executive control training
16637993|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
16637994|NCT02361749|Active Comparator|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
16637995|NCT02361749|Active Comparator|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
16637996|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
16637997|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
16637998|NCT02361723|Experimental|ovarian cancer, fallopian cancer, or primary peritoneal cancer|60mg BID oral.
16637999|NCT02361723|Experimental|Breast Cancer|60mg BID Ora
16638000|NCT02361723|Experimental|Prostate Cancer|60mg BID Oral
16638001|NCT02361723|Experimental|Small Cell Lung Cancer|60mg BID Oral
16638002|NCT02361723|Experimental|Gastric Cancer|60mg BID Oral
16638003|NCT02361710||vitamin D deficient patients|Serum 25- (hydroxide) OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
16638004|NCT02361710||vitamin D sufficient patients|Serum 25- (hydroxide) OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
16638005|NCT02361697|Other|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
16638006|NCT02361684|Experimental|Blended CBT treatment|
16638007|NCT02361684|Active Comparator|Treatment as usual|
16638008|NCT02361645|No Intervention|Control Group|No NSAIDs were administered prior to surgery
16638009|NCT02361645|Experimental|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
16638010|NCT02361645|Experimental|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
16638011|NCT02361645|Experimental|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
16638012|NCT02361645|Experimental|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
16638013|NCT02361632|Experimental|Group 1|"Dietary Supplement. Participants drink coffee with or without milk in following order:
~Black coffee
~Coffee with 20% milk added
~Coffee with 50% milk added"
16638014|NCT02361632|Experimental|Group 2|"Dietary supplement. Participants drink coffee with or without milk in following order:
~Coffee with 20% milk added
~Black coffee
~Coffee with 50% milk added"
16638015|NCT02361632|Experimental|Group 3|"Dietary supplement. Participants drink coffee with or without milk in following order:
~Black coffee
~Coffee with 50% milk added
~Coffee with 20% milk added"
16638016|NCT02361619|Experimental|1|
16638017|NCT02361606|Experimental|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
16638018|NCT02361593|Experimental|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
16638019|NCT02361593|Active Comparator|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
16638020|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
16638021|NCT02361580|No Intervention|No Diary|Control Group
16638022|NCT02361567|Active Comparator|Tramacet|Tramacet 1-2 tabs PO q4h prn
16638023|NCT02361567|Active Comparator|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
16638024|NCT02361554|Experimental|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
16638025|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
16638026|NCT02361528|Experimental|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
16638027|NCT02361528|Placebo Comparator|placebo|placebo, once per day during 5 days by subcutaneous route
16638028|NCT02361515|Active Comparator|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
16638029|NCT02361515|Experimental|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
16638030|NCT02361502|Placebo Comparator|placebo|mirabegron placebo qd
16638031|NCT02361502|Experimental|mirabegron|mirabegron 50mg qd
16638032|NCT02361489|Active Comparator|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
16638033|NCT02361489|Active Comparator|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
16638034|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
16638035|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
16638036|NCT02361463|Experimental|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
16638037|NCT02361463|Active Comparator|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
16638038|NCT02361450|Experimental|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
16638039|NCT02361450|Active Comparator|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
16638040|NCT02361437|Placebo Comparator|placebo|placebo
16638041|NCT02361437|Experimental|Vasculera|diosmin
16638042|NCT02361424|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
16638043|NCT02361424|Experimental|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .
~These 2 capsules are taken orally b.i.d. during 8 weeks."
16638044|NCT02361424|Experimental|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .
~These 2 capsules are taken orally b.i.d. during 8 weeks."
16638045|NCT02361424|Placebo Comparator|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .
~These 2 capsules are taken orally b.i.d. during 4 weeks"
16638046|NCT02361398|Experimental|EIT group|the Individualized PEEP titration by EIT was administered to the patients in the EIT group.
16638047|NCT02361398|No Intervention|control group|If patients are assigned to the control group, the Individualized PEEP Setting was by PEEP-FiO2 table based on ARDS-net protocol.
16638048|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
16638049|NCT02361372|Experimental|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
16638050|NCT02361372|Placebo Comparator|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
16638051|NCT02361346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|Phase 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16638052|NCT02361346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|Phase 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16638053|NCT02361346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|Phase 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16638054|NCT02361346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|Phase 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16638055|NCT02361346|Experimental|MT-3724 Phase 1 100 mcg/kg/dose|Phase 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
16638056|NCT02361346|Experimental|MT-3724 Phase 1 75 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
16638057|NCT02361346|Experimental|MT-3724 Phase 1b 50 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724
16638058|NCT02361346|Experimental|MT-3724 Phase 2 50 mcg/kg/dose|Phase 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
16638059|NCT02361333|Experimental|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
16638060|NCT02361333|No Intervention|No Intervention|Patients will not be taught how to install and use a remote monitor
16638061|NCT02361320|Experimental|Computed Tomography Scans (CT)|Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.
16638062|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
16638063|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
16638064|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
16638065|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
16638066|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
16638067|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
16638068|NCT02361268|Experimental|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
16638069|NCT02361268|Active Comparator|Educational program|The active comparator for the study is an educational program.
16638070|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
16638071|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
16638072|NCT02361242|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.
16638073|NCT02361242|Experimental|PXT00864 Dose 2|1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.
16638074|NCT02361242|Experimental|PXT00864 Dose 3|1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.
16638075|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
16638076|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
16638077|NCT02361203|No Intervention|No Exercise|
16638078|NCT02361203|Experimental|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
16638079|NCT02361190|Placebo Comparator|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
16638080|NCT02361190|Experimental|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
16638081|NCT02361177|Experimental|oxytocin|Intranasal 24 IU oxytocin self-administration.
16638781|NCT02356770|Experimental|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
16638082|NCT02361177|Placebo Comparator|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
16638083|NCT02361164||Mother/child pair|Mother/child pair.
16638084|NCT02361151|Active Comparator|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)
~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
16638085|NCT02361151|Experimental|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website
~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
16638086|NCT02361138|Experimental|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
16638087|NCT02361138|Experimental|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
16638088|NCT02361138|Experimental|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
16638089|NCT02361138|Experimental|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
16638090|NCT02361138|Experimental|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
16638091|NCT02361138|Experimental|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
16638092|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).
~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
16638093|NCT02361112|Experimental|pyrotinib combined with capecitabine|
16638094|NCT02361099|Experimental|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
16638095|NCT02361099|No Intervention|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
16638096|NCT02361086|Experimental|Regimen 1: 7dayPM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week with a 2-week dose titration.
16638097|NCT02361086|Experimental|Regimen 2: 7dayPM-DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week without dose titration.
16638098|NCT02361086|Experimental|Regimen 3: 7dayAM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the morning 7-days a week with a 2-week dose titration.
16638099|NCT02361086|Experimental|Regimen 4: 7dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 7-days a week without dose titration.
16638100|NCT02361086|Experimental|Regimen 5: 5dayPM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the evening before bed 5-days a week without dose titration.
16638101|NCT02361086|Experimental|Regimen 6: 5dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 5-days a week without dose titration.
16638102|NCT02361073||Takotsubo|
16638103|NCT02361073||Healthy|
16638104|NCT02361073||ACS|
16638105|NCT02361060|Experimental|Sugammadex|sugammadex 4 mg/kg
16638106|NCT02361060|Active Comparator|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
16638107|NCT02361047|Experimental|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
16638108|NCT02361047|No Intervention|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
16638109|NCT02361034|Active Comparator|GRC 27864|Test treatment GRC 27864
16638110|NCT02361034|Placebo Comparator|Placebo|Placebo treatment
16638111|NCT02361008|Experimental|TPDC group|Patients who matched inclusion criteria and randomly divided into TPDC group underwent the TEE-guided perventricular device closure without CBP. But of them,who underwent TPDC failure during the procedure would be dropped out of the trial.
16638112|NCT02361008|Experimental|SR group|Patients who matched inclusion criteria and randomly assigned into SR group underwent the surgery repair with CBP.
16638113|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
16638114|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
16638115|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
16638116|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
16638117|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.
~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
16638118|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
16638119|NCT02360956|Experimental|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
16638120|NCT02360956|Active Comparator|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).
~The drug dose must be individualized."
16638121|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
16638122|NCT02360930||Tanner Stage </=2|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
16638123|NCT02360930||Tanner Stage >/= 4|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
16638124|NCT02360917|Experimental|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
16638125|NCT02360917|Other|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
16638126|NCT02360904|Experimental|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
16638127|NCT02360904|Active Comparator|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
16638128|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
16638129|NCT02360891||neurological controls|patients with other neurological disease
16638130|NCT02360891||healthy controls|age matched healthy controls
16638131|NCT02360878||Non-diabetic subjects|Obese (BMI > 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
16638132|NCT02360878||T2DM subjects|Obese (BMI > 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
16638133|NCT02360865|Experimental|COPD|Acute exercise bouts
16638134|NCT02360865|Active Comparator|Healthy|Acute exercise bouts
16638135|NCT02360852|Experimental|A4250|A4250 once daily
16638136|NCT02360839|No Intervention|Early|Study subjects (patients) undergoing endoscopic ultrasound (with or without FNA/TCB) for clinical reasons during 2005-2011.
16638137|NCT02360839|Other|Late|"Study subjects (patients) undergoing endoscopic ultrasound with EUS-guided sampling of various lesions for clinical reasons during 20012-2015.
~Subjects sampled with both EUS-FNA and EUS-FNB on the same lesion. Randomization on first needle order."
16638138|NCT02360826|Experimental|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.
16638139|NCT02360826|Experimental|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.
16638140|NCT02360813|Experimental|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
16638141|NCT02360813|Active Comparator|Treatment as Usual|Usual care.
16638142|NCT02360800|Experimental|TISSEEL|Spray Fibrin Sealant
16638143|NCT02360800|Active Comparator|CONTROL|Traditional hemostasis and chest closure routine
16638144|NCT02360787|Experimental|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
16638145|NCT02360787|Experimental|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
16638146|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
16638147|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
16638148|NCT02360761|Active Comparator|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
16638149|NCT02360761|Experimental|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
16638150|NCT02360748|Experimental|single|Pilot Study in which patients will be adding food items to improve their nutritional status
16638151|NCT02360735|Active Comparator|Control|Patients randomized to this arm will follow the current standard for post-operative care.
16638152|NCT02360735|Experimental|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
16638153|NCT02360722|Experimental|Oral Nutritional Supplement|ONS + Nutritional education
16638154|NCT02360722|Other|Control Group|Nutritional education only
16638155|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
16638156|NCT02360696||Peds/Adol Pts w/ FD - CMH GI APT clinic|"Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.
~Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.
~Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis."
16638157|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
16638158|NCT02360670|Placebo Comparator|Control imaging (NCCT)|Standard imaging
16638159|NCT02360670|Experimental|additional multimodal imaging|CT + CTA + CTP
16638160|NCT02360657|Experimental|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2*5 mg tablet) orally once daily for 4 weeks.
16638161|NCT02360657|Experimental|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
16638162|NCT02360657|Placebo Comparator|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
16638163|NCT02360644|Experimental|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.
~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters [P-gp, MRP2, and MATE1/2K] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
16638164|NCT02360644|Experimental|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled [30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)], as well as 30 healthy controls.
16638165|NCT02360631|Experimental|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
16638166|NCT02360631|Placebo Comparator|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
16638167|NCT02360618|Experimental|Metformin and Simvastatin Treatment|Patients in this group will receive 850 mg of Metformin and 20 mg of Simvastatin daily from the time they are enrolled in the study until the day before their surgery (approximately 12 weeks), in the absence of any safety or tolerability concerns.
16638168|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
16638169|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
16638170|NCT02360592|Active Comparator|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
16638171|NCT02360592|Experimental|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
16638172|NCT02360592|Experimental|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
16638173|NCT02360579|Experimental|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
16638174|NCT02360579|Experimental|Cohort 2|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
16638175|NCT02360579|Experimental|Cohort 3|Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
16638176|NCT02360579|Experimental|Cohort 4|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
16638177|NCT02360566|Experimental|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
16638178|NCT02360553|Experimental|Intervention|ObeseGO!-web-based intervention
16638179|NCT02360553|Other|Control|Given pamphlets education mainly on diet and physical activity
16638180|NCT02360527||Type 2 diabetic patients with AD|35 patients
16638181|NCT02360527||Type 2 diabetic patients with MCI|35 patients
16638182|NCT02360527||Type 2 diabetic patients controls|35 patients
16638183|NCT02360527||Non-diabetic patients with AD|35 patients
16638184|NCT02360514|Experimental|hantaan virus vaccine|
16638185|NCT02360501|Experimental|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
16638215|NCT02360319|Experimental|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
16638186|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
16638187|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
16638188|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
16638189|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
16638190|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
16638191|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
16638192|NCT02360462|Experimental|Active tDCS|Active tDCS will be applied in the head of the patients in 20 minute sessions, twice. First session will be applied in the night before and the second session, in the morning before the surgical procedure. The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current
16638193|NCT02360462|Sham Comparator|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
16638194|NCT02360449|No Intervention|Wait List|
16638195|NCT02360449|Experimental|Social Initiation Motivation Intervention|
16638196|NCT02360423|Experimental|CRE8 group|CRE8 sirolimus-eluting stent system
16638197|NCT02360423|Active Comparator|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
16638198|NCT02360410|Experimental|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
16638199|NCT02360410|No Intervention|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
16638200|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
16638201|NCT02360384|Placebo Comparator|Sham diet|The placebo intervention will be healthy eating advice in patients with irritable bowel syndrome of the alternating subtype for 28 days.
16638202|NCT02360384|Active Comparator|Lincalotide|All patients with constipation predominant IBS will receive linaclotide 280mcg po od for 28 days.
16638203|NCT02360384|Experimental|FODMAP diet|The FODMAP diet will be introduced in patients with irritable bowel syndrome of the alternating subtype for 28 days.
16638204|NCT02360371|Placebo Comparator|Placebo (oral)|Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.
16638205|NCT02360371|Experimental|Hydromorphone (oral) 2mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
16638206|NCT02360371|Experimental|Hydromorphone (oral) 4mg|Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.
16638207|NCT02360371|Experimental|Hydromorphone (oral) 8mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
16638208|NCT02360358|Experimental|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
16638209|NCT02360358|Active Comparator|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.
~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
16638210|NCT02360345|Experimental|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
16638211|NCT02360345|Experimental|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
16638212|NCT02360332|Experimental|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
16638213|NCT02360332|No Intervention|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
16638214|NCT02360319|Active Comparator|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
16638373|NCT02359357|Experimental|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
16638216|NCT02360306|Active Comparator|Conventional EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the conventional EBUS scope rather than the hybrid EBUS scope. Subjects in this arm, like in the Hybrid EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
16638217|NCT02360306|Experimental|Hybrid EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the hybrid EBUS scope rather than the conventional EBUS scope. Subjects in this arm, like in the conventional EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
16638218|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
16638219|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
16638220|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
16638221|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
16638222|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
16638223|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
16638224|NCT02360241|Experimental|Robot|A robot will be used and it's position will be evaluated
16638225|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
16638226|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
16638227|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
16638228|NCT02360215|Experimental|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
16638229|NCT02360215|Experimental|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
16638230|NCT02360202|Experimental|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
16638231|NCT02360176|Experimental|Sleeve gastrectomy single port|Sleeve gastrectomy single port
16638232|NCT02360176|Active Comparator|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
16638233|NCT02360163|Active Comparator|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
16638234|NCT02360163|Experimental|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
16638235|NCT02360150|Experimental|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
16638236|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
16638237|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
16638238|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
16638239|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
16638240|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
16638241|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
16638242|NCT02360072||AR group|Allergic rhinitis without any typical asthma symptoms
16638243|NCT02360072||Asthma|Accompanied by typical asthma symptoms and Δ FEV1≥12% in response to a short-acting bronchodilator or bronchial hyperreactivity(BHR) in the methacholine provocation test (PC20≤2.504mg)
16638244|NCT02360072||AR+Asthma|Diagnosed allergic rhinitis concomitant asthma symptoms
16638245|NCT02360072||Control group|non-atopic subjects with neither a history of rhinitis nor asthma
16638246|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.
~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
16638247|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
16638248|NCT02360046|Other|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
16638249|NCT02360046|Other|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
16638250|NCT02360033|Experimental|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
16638251|NCT02360033|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
16638252|NCT02360020|Experimental|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, >70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends >= 90°, or three or more bends of 45-90° proximal to the diseased segment.
16638253|NCT02360007|Experimental|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
16638254|NCT02360007|No Intervention|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
16638255|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
16638256|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.
~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.
~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
16638257|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.
~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
16638258|NCT02359981|Active Comparator|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
16638259|NCT02359981|Experimental|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
16638262|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
16638263|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
16638264|NCT02359942|Experimental|Citric acid group|Giving the citric acid (4g) as test meal before UBT
16638265|NCT02359942|No Intervention|Controlled group|No use of test meal
16638266|NCT02359929|Experimental|Dose Level 1: Infusion of MSCs|First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight
16639763|NCT02349724|Other|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
16638267|NCT02359929|Experimental|Dose Level 2: Infusion of MSCs|Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight
16638268|NCT02359929|Experimental|Dose Level 3: Infusion of MSCs|Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight
16638269|NCT02359916||A|Snacks sold under equal pricing, no delays
16638270|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
16638271|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
16638272|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
16638273|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
16638274|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
16638275|NCT02359916||G|Snacks sold under equal pricing, no delays
16638276|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
16638277|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
16638278|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
16638279|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
16638280|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
16638281|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
16638284|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
16638285|NCT02359838|Other|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
16638286|NCT02359838|Active Comparator|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
16638293|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
16638294|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
16638295|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
16638296|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
16638297|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
16638298|NCT02359786||Topicals Subjects using topical compounds|
16638299|NCT02359786||Patients undergoing Spinal Surgery using IOM|
16638300|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
16638301|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
16638302|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
16638303|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
16638304|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
16638305|NCT02359760|Experimental|Piezocision group|The experimental group will consist of 14 adults, subjects from 18 to 40 years-old (10 women, 4 men).
16638306|NCT02359760|No Intervention|conventional orthodontics|The control group will consist of 30 matched patients with the same inclusion and exclusion criteria, who have been already treated by conventional orthodontics in the orthodontic clinic of the University of Montreal.
16638307|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
16638374|NCT02359357|Experimental|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
16638308|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
16638309|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
16638310|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
16638311|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
16638312|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
16638313|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
16638314|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
16638315|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
16638316|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
16638317|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
16638318|NCT02359721|Experimental|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
16638319|NCT02359721|No Intervention|control|scaling and root planing
16638320|NCT02359708|Experimental|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
16638321|NCT02359708|Experimental|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
16638322|NCT02359695|Experimental|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
16638323|NCT02359682||Age 20-39|Patients aged from 20 to 39 years old.
16638324|NCT02359682||Age 40-59|Patients aged from 40 to 59 years old.
16638325|NCT02359682||Age 60-79|Patients aged from 60 to 79 years old.
16638326|NCT02359669|Active Comparator|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
16638327|NCT02359669|Placebo Comparator|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
16638328|NCT02359656|Other|non operative treatment|specif non operative treatment protocol
16638329|NCT02359656|Other|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
16638330|NCT02359643|Placebo Comparator|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
16638331|NCT02359643|Experimental|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
16638332|NCT02359630|Active Comparator|EasyTube|Use of EasyTube during general anesthesia
16638333|NCT02359630|Experimental|Endotracheal tube|Use of endotrachel tube during general anesthesia
16638334|NCT02359617|Experimental|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.
~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
16638335|NCT02359604|Other|Single Arm Study -microbiome|This is a single-arm study. The patients will serve as their own controls. The PPI administered for PPI-therapy is already FDA approved. A stool sample will be obtained for intestinal microbiome testing before PPI, under PPI and after PPI therapy.
16638336|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
16638337|NCT02359578|Experimental|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
16640028|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
16638339|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.
~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
16638340|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.
~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
16638341|NCT02359539|Experimental|PRF|Platelets rich fibrin,
16638342|NCT02359539|Experimental|MPP|Marginal periosteal pedicle
16638343|NCT02359526|Experimental|ILUVIEN 190 ug intravitreal implant|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
16638344|NCT02359513|Experimental|boulimic|Analyse of serotoninergic brain activity (determined by positron emission tomography using [18F]MPPF) from bulimic patients treated with serotoninergic antidepressants during 3 months. The serotoninergic brain activity is measured before adnd after the serotoninergic antidepressant treatment.
16638345|NCT02359500|Experimental|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
16638346|NCT02359487|Experimental|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
16638347|NCT02359487|Placebo Comparator|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
16638348|NCT02359474|Experimental|Trabectedin with regional hyperthermia|"Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
~Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs)."
16638349|NCT02359474|Active Comparator|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
16638350|NCT02359461|Experimental|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
16638351|NCT02359461|Other|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
16638352|NCT02359448|Experimental|Melatonin|Patients will be prescribed and dispensed from pharmacy sustained -release Melatonin (Circadin) 2mg. This will be taken every night for twelve weeks.
16638353|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
16638354|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
16638355|NCT02359422|Experimental|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
16638356|NCT02359422|No Intervention|Wait-list control|
16638357|NCT02359409|Active Comparator|water immersion only|Colonoscopy will be performed using the water immersion technique.
16638358|NCT02359409|Experimental|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
16638359|NCT02359396|Experimental|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
16638360|NCT02359396|Experimental|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
16638361|NCT02359396|Experimental|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
16638362|NCT02359383|Active Comparator|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
16638363|NCT02359383|No Intervention|Control grup|Conventional medical treatment
16638364|NCT02359370|Active Comparator|Magnesium Group|Magnesium Sulphate was administered through continuous infusion, immediately before induction of anesthesia
16638365|NCT02359370|Active Comparator|Lidocaine Group|Lidocaine was administered through continuous infusion, immediately before induction of anesthesia
16638366|NCT02359357|Placebo Comparator|Placebo single dose|Placebo administered as a single dose
16638367|NCT02359357|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
16638368|NCT02359357|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
16638369|NCT02359357|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
16638370|NCT02359357|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
16638371|NCT02359357|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
16638372|NCT02359357|Experimental|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
16640029|NCT02347917|Experimental|BBI608 puls pemetrexed and cisplatin|
16638375|NCT02359357|Experimental|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638376|NCT02359357|Experimental|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638377|NCT02359357|Experimental|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638378|NCT02359357|Experimental|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638379|NCT02359357|Experimental|Food effect - fasted|Single dose of FDL169 in fasted conditions
16638380|NCT02359357|Experimental|Food effect - fed|Single dose of FDL169 in fed conditions
16638381|NCT02359357|Placebo Comparator|Placebo - multiple dose|Repeat doses of placebo
16638382|NCT02359357|Experimental|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638383|NCT02359357|Experimental|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638384|NCT02359357|Experimental|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638385|NCT02359357|Experimental|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638386|NCT02359357|Experimental|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638387|NCT02359357|Experimental|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
16638388|NCT02359344|Experimental|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
16638389|NCT02359344|Placebo Comparator|Placebo|Placebo tid 7 days plus a single dose on day 8
16638390|NCT02359331|Active Comparator|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
16638391|NCT02359331|Experimental|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
16638392|NCT02359318|Experimental|Resin infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the no infiltration and de-bonding arm. The teeth that are included in this intervention arm are treated by resin infiltration using Icon (DMG, Germany) according to the manufacturers´ instruction. This is followed by bonding of new brackets (Gemini metal brackets, 3M Unitek). These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.
~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
16638393|NCT02359318|Placebo Comparator|No infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the resin infiltration and de-bonding arm. The teeth that are included in this intervention arm are left untreated new brackets (Gemini metal brackets, 3M Unitek) are bonded. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.
~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
16638394|NCT02359318|Other|Control and de-bonding|"Patients with brackets and without white spots are included in this group. After removal of the old brackets, new brackets (Gemini metal brackets, 3M Unitek) are bonded again. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.
~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
16638395|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
16638396|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
16638397|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI|High Strength fixed combination
16638398|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI|Medium Strength fixed combination
16638399|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|High Strength fixed combination plus Charcoal Block
16638400|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|Medium Strength fixed combination plus Charcoal Block
16638401|NCT02359292|Placebo Comparator|Placebo pMDI|Placebo
16638402|NCT02359279|Experimental|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
16638403|NCT02359266|Experimental|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
16638404|NCT02359266|No Intervention|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
16638405|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
16638406|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
16638407|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
16638408|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
16638409|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
16638410|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
16638411|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
16638412|NCT02359214|Active Comparator|Vitamin D3 Supplement|This group will receive a daily dose of 5000IU (125µg) vitamin D3 (which is half of the recommended safe tolerable upper intake level of vitamin D for healthy individuals) for eight weeks.
16638413|NCT02359214|Placebo Comparator|Placebo|This group will receive 100% lactose placebo daily for eight weeks.
16638414|NCT02359201|Experimental|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
16638415|NCT02359201|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
16638416|NCT02359188|Active Comparator|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
16638417|NCT02359188|Sham Comparator|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
16638418|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
16638419|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
16638420|NCT02359162|Experimental|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
16638421|NCT02359162|Active Comparator|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.
~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
16638422|NCT02359149|Experimental|nurse|intravitreal injections with anti-VEGF agents given by a nurse
16638423|NCT02359149|Active Comparator|physician|intravitreal injections with anti-VEGF agents given by a physician
16638424|NCT02359136|Placebo Comparator|LIA placebo|local infiltration anesthesia using saline i addition to multimodal analgesic regimen
16638425|NCT02359136|Experimental|LIA Ropivacaine|local infiltration anesthesia using Ropivacaine and Epinephrine i addition to multimodal analgesic regimen
16638426|NCT02359123|Experimental|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
16638427|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
16638428|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
16638429|NCT02359097|Experimental|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
16638430|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
16638431|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
16638432|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
16638433|NCT02359071||handovers with higher durations|Higher than 20 minutes
16638434|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
16638465|NCT02358850|Active Comparator|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
16638435|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
16638436|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16638437|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
16638438|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
16638439|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose|ASP6858 arm
16638440|NCT02359032|Placebo Comparator|Part 1: Placebo single ascending dose|Placebo arm
16638441|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
16638442|NCT02359032|Experimental|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
16638443|NCT02359032|Experimental|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
16638444|NCT02359019|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
16638445|NCT02359006|Active Comparator|minocycline|200mg minocycline
16638446|NCT02359006|Placebo Comparator|Placebo|Sugar pill
16638447|NCT02358993|Experimental|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
16638448|NCT02358993|Active Comparator|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
16638449|NCT02358980||Study group|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.
16638450|NCT02358967|Placebo Comparator|Placebo|Standard renal care + 300 mg placebo daily for 1 year
16638451|NCT02358967|Active Comparator|Treatment|Standard renal care + 300 mg TRF daily for 1 year
16638452|NCT02358954|Experimental|Vestibular Pain interactions|
16638453|NCT02358941|Experimental|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.
~Half of the children will be assigned to NF training, the other half to CCT."
16638454|NCT02358941|Experimental|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).
~Half of the children will be assigned to NF training, the other half to CCT."
16638455|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
16638456|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
16638457|NCT02358915|Experimental|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
16638458|NCT02358902|Experimental|Group A|tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
16638459|NCT02358902|Experimental|Group B|AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
16638460|NCT02358902|Experimental|Group C|tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
16638461|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
16638462|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
16638463|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
16638464|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:
~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
16638466|NCT02358850|Active Comparator|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
16638467|NCT02358850|Active Comparator|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
16638468|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
16638469|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
16638470|NCT02358824|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
16638471|NCT02358824|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
16638472|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 70 years old and more
16638473|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI<10) 70 years old and more
16638474|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 18 < Age < 55 years old
16638475|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI<10) 18 < Age < 55 years old
16638476|NCT02358798|Experimental|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
16638477|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
16638478|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
16638479|NCT02358759|Active Comparator|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
16638480|NCT02358759|Active Comparator|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
16638481|NCT02358746|Experimental|combined endo/epicardial approach|combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
16638482|NCT02358746|Active Comparator|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
16638483|NCT02358733|Experimental|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
16638484|NCT02358733|Active Comparator|Control|Intracytoplasmic sperm injection (ICSI)
16638485|NCT02358720|Experimental|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
16638486|NCT02358720|Active Comparator|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
16638487|NCT02358707|Experimental|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
16638488|NCT02358694|Experimental|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
16638489|NCT02358694|Placebo Comparator|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
16638490|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.
~Placebo, intravenous."
16638491|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.
~Placebo, intranasal."
16638492|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
16638493|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
16638494|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
16638495|NCT02358655|Other|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
16638496|NCT02358655|Other|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
16638497|NCT02358655|Other|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
16638498|NCT02358642|Experimental|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
16638499|NCT02358642|Placebo Comparator|Placebo|Placebo
16638500|NCT02358629|Experimental|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
16638501|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
16638502|NCT02358603|Experimental|Case group|At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
16638503|NCT02358603|Placebo Comparator|Control group|Each subject of the control group will do the same test and examination with the subjects in the case group.
16638504|NCT02358590|Experimental|HAPA menu-based mini-video|This group will watch mini-videos, which are multi-target menu-based interventions designed to deliver information about vitamin D adherence and its effect on osteoporosis
16638505|NCT02358590|Active Comparator|Standard care|This group will be advised by the treating physician to take vitamin D
16638684|NCT02357394|Experimental|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
16638506|NCT02358577|Experimental|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
16638507|NCT02358577|Active Comparator|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
16638508|NCT02358564|Active Comparator|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
16638509|NCT02358564|Experimental|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
16638510|NCT02358551|Other|Axillary vein|Lead Placement Through the Axillary Vein Technique
16638511|NCT02358551|Other|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
16638512|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
16638513|NCT02358512|Experimental|Intermittent enteral feeding|The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours).
16638514|NCT02358512|Active Comparator|Continuous enteral feeding|The continuous feeding regimen consists of the total volume of feed administered over 24 hours.
16638515|NCT02358499|Experimental|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
16638516|NCT02358486|Experimental|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
16638517|NCT02358486|Sham Comparator|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
16638518|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.
~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
16638519|NCT02358460|Active Comparator|Pressure-limited ventilation|
16638520|NCT02358460|Active Comparator|Volume-targeted ventilation|
16638521|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
16638522|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
16638523|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
16638524|NCT02358395|Experimental|BBI608 puls Sorafenib|
16638525|NCT02358382|No Intervention|Alpha Stat|Standard CPB blood gas management conditions
16638526|NCT02358382|Experimental|pH Stat|pH stat blood gas management conditions.
16638527|NCT02358369|Experimental|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
16638528|NCT02358369|Experimental|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
16638529|NCT02358369|Active Comparator|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.
~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
16638530|NCT02358356|Active Comparator|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
16638531|NCT02358356|Active Comparator|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
16638532|NCT02358356|Experimental|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
16638533|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
16638534|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
16638535|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.
~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
16638536|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
16638537|NCT02358343|No Intervention|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
16638720|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin
~Maintenance Phase - Amatuximab"
16638538|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
16638539|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
16638540|NCT02358317|Experimental|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
16638541|NCT02358317|Active Comparator|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
16638542|NCT02358304|Active Comparator|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
16638543|NCT02358304|Placebo Comparator|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
16638544|NCT02358291|Active Comparator|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
16638545|NCT02358291|Active Comparator|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
16638546|NCT02358291|Active Comparator|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
16638547|NCT02358265|Active Comparator|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
16638548|NCT02358265|Active Comparator|10 mg Rupatadin|Rupatadine 10 mg, continuously
16638549|NCT02358265|Active Comparator|20 mg Rupatadine|Rupatadine 20 mg, continuously
16638550|NCT02358265|Active Comparator|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
16638551|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).
~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
16638552|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
16638553|NCT02358239|Experimental|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
16638554|NCT02358226|Experimental|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
16638555|NCT02358226|Experimental|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
16638556|NCT02358226|No Intervention|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
16638557|NCT02358213|Other|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
16638558|NCT02358200|Experimental|Treatment|BMN-673: Oral, every day, Days 1-21; Carboplatin: intravenous, every week, 750 μg/day; Paclitaxel: intravenous, every week, 0.75 x Maximum Tolerated Dose μg/day
16638559|NCT02358187|Experimental|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
16638560|NCT02358174|Experimental|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
16638721|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin
~Maintenance Phase - Placebo"
16638561|NCT02358174|Experimental|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
16638562|NCT02358161|Experimental|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
16638563|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
16638564|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
16638565|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
16638566|NCT02358135|Experimental|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
16638567|NCT02358122|Active Comparator|Refined wheat|Refined wheat grain, a variety of cereal foods providing no wholegrain
16638568|NCT02358122|Experimental|Wholegrain wheat|Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
16638569|NCT02358122|Experimental|Wholegrain rye|Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
16638570|NCT02358109|Experimental|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
16638571|NCT02358109|No Intervention|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
16638572|NCT02358096|Experimental|ASP8232|ASP8232 administered once daily
16638573|NCT02358096|Placebo Comparator|Placebo|Placebo administered once daily
16638574|NCT02358083|No Intervention|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
16638575|NCT02358083|Experimental|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
16638576|NCT02358083|Experimental|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
16638577|NCT02358083|Experimental|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
16638578|NCT02358083|Experimental|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
16638579|NCT02358083|Experimental|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
16638580|NCT02358083|No Intervention|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
16638581|NCT02358083|Experimental|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
16638582|NCT02358083|Experimental|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
16638583|NCT02358083|Experimental|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
16638584|NCT02358083|Experimental|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
16638585|NCT02358083|Experimental|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
16638586|NCT02358070||HCC group|
16638587|NCT02358070||control group|
16638588|NCT02358057|Experimental|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.
~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.
~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.
~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine
~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.
~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN > 50.
~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
16638589|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
16638590|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
16638591|NCT02358031|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months.
16638592|NCT02358031|Experimental|Pembrolizumab + Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months; plus cisplatin 100 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
16638593|NCT02358031|Active Comparator|Cetuximab + Chemotherapy (Control)|Participants receive cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each 3-week cycle (6 cycle maximum for platinum-based therapy); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
16638594|NCT02358005|Experimental|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
16638595|NCT02358005|Experimental|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
16638596|NCT02358005|Placebo Comparator|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
16638597|NCT02357992|Experimental|Stereotactic Radiotherapy (SRT)|"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.
~50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor."
16638598|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
16638599|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
16638600|NCT02357966|Experimental|514G3|Phase I of the study will include a single dose of 514G3 at three different dose levels. Phase II utilizes a single dose of 514G3 at the highest dose level. Standard antibiotic therapies will be used in both phases.
16638601|NCT02357966|Placebo Comparator|Placebo|Both Phase I and II will include a single dose of placebo in addition to standard antibiotic therapies.
16638602|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
16638603|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
16638604|NCT02357927|Placebo Comparator|control|simple general telephone call
16638605|NCT02357927|Experimental|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
16638606|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
16638607|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.
~In addition, participants received individual drug counseling (IDC) at least once a week."
16638608|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.
~In addition, participants received individual drug counseling (IDC) at least once a week."
16638609|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).
~In addition, participants received individual drug counseling (IDC) at least once a week."
16638610|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.
~In addition, participants received individual drug counseling (IDC) at least once a week."
16638611|NCT02357888|Experimental|Sequence 1|Treatment group sequence: Test Product on Day 1 and Placebo on Day 2
16638612|NCT02357888|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product on Day 2
16638613|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
16638614|NCT02357849|Active Comparator|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
16638615|NCT02357849|Active Comparator|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
16638616|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
16638617|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
16638618|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
16638619|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count < 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
16638620|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count > 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
16638621|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
16638622|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16638623|NCT02357797|Active Comparator|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
16638624|NCT02357797|Placebo Comparator|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
16638625|NCT02357784|Experimental|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
16638626|NCT02357771|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
16638627|NCT02357771|Experimental|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
16638628|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
16638629|NCT02357758|No Intervention|Healthy Population|Healthy population
16638630|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
16638631|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
16638632|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
16638633|NCT02357732|Experimental|Nivolumab and Dabrafenib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV every 2 weeks (q2 weeks); Dabrafenib 100mg by mouth (PO) twice a day(BID) every day (QD); Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD;
16638634|NCT02357732|Experimental|Nivolumab and Trametinib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Trametinib 2mg PO QD;
16638635|NCT02357732|Experimental|Nivolumab, Dabrafenib and Trametinib Combination (triplet)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD;
16638636|NCT02357719|Experimental|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
16638637|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
16638638|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
16638639|NCT02357693|Experimental|aprepitant|aprepitant 80 mg one hour before surgery
16638640|NCT02357693|Placebo Comparator|placebo|oral placebo one hour before surgery
16638641|NCT02357680|Experimental|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.
~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.
~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
16638642|NCT02357680|No Intervention|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
16638722|NCT02357134|Experimental|Arm I (high-flow oxygen)|Patients receive high-flow oxygen via nasal prongs during a structured stationary bicycle exercise session.
16638643|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
16638644|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
16638645|NCT02357654|Experimental|GnRH agonist|
16638646|NCT02357654|Placebo Comparator|Placebo|
16638647|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.
~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
16638648|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
16638649|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
16638650|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
16638651|NCT02357615|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
16638652|NCT02357615|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
16638653|NCT02357602|Experimental|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
16638654|NCT02357602|Experimental|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
16638655|NCT02357602|Experimental|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
16638656|NCT02357589|Active Comparator|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
16638657|NCT02357589|Experimental|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
16638658|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
16638659|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
16638660|NCT02357563|Experimental|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
16638661|NCT02357563|Active Comparator|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
16638662|NCT02357550|Placebo Comparator|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
16638663|NCT02357550|Experimental|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
16638664|NCT02357537|Active Comparator|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).
~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
16638665|NCT02357537|Active Comparator|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.
~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
16638666|NCT02357524|Experimental|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
16638667|NCT02357511|Experimental|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
16638668|NCT02357498|Active Comparator|microscopic|Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)
16638669|NCT02357498|Active Comparator|endoscopic|Fully endoscopic transsphenoidal surgery (350 subjects)
16638670|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
16638671|NCT02357472|Experimental|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
16638672|NCT02357472|Experimental|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
16638673|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
16638674|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
16638675|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
16638676|NCT02357433|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization
16638677|NCT02357433|No Intervention|Control Group|Standard practice
16638678|NCT02357420|Experimental|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
16638679|NCT02357420|Experimental|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
16638680|NCT02357420|Experimental|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
16638681|NCT02357420|Placebo Comparator|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
16638682|NCT02357407|Experimental|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
16638683|NCT02357407|Experimental|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
16638685|NCT02357394|No Intervention|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
16638686|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
16638687|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
16638688|NCT02357368|Experimental|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
16638689|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
16638690|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
16638691|NCT02357355|Active Comparator|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
16638692|NCT02357355|Active Comparator|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
16638693|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
16638694|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
16638695|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
16638696|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
16638697|NCT02357303|Placebo Comparator|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
16638698|NCT02357303|Active Comparator|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
16638699|NCT02357303|Active Comparator|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
16638700|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:
~Subjects ages 5-12:
~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM
~Subjects ages 13-17:
~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM
~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
16638701|NCT02357277|Experimental|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
16638702|NCT02357277|Experimental|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
16638703|NCT02357277|Placebo Comparator|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
16638704|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
16638705|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
16638706|NCT02357251|Active Comparator|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
16638707|NCT02357251|No Intervention|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
16638708|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
16638709|NCT02357225|Experimental|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
16638710|NCT02357225|Experimental|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
16638711|NCT02357212|Other|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
16638712|NCT02357212|Other|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
16638713|NCT02357199|Experimental|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
16638714|NCT02357199|No Intervention|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
16638715|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
16638716|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
16638717|NCT02357160|Experimental|Choice|Patients given choice over artwork on wall
16638718|NCT02357160|Active Comparator|No choice|Patients not given choice over artwork on wall
16638719|NCT02357160|Placebo Comparator|No artwork|Patients not receiving any artwork on wall
16638723|NCT02357134|Experimental|Arm II (high-flow air)|Patients receive high-flow air via nasal prongs during a structured stationary bicycle exercise session
16638724|NCT02357134|Active Comparator|Arm III (low-flow oxygen)|Patients receive low-flow oxygen via a nasal cannula during a structured stationary bicycle exercise session.
16638725|NCT02357134|Active Comparator|Arm IV (low-flow air)|Patients receive low-flow air via a nasal cannula during a structured stationary bicycle exercise session.
16638726|NCT02357121|Experimental|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
16638727|NCT02357108|Active Comparator|Group 1: Video/Doctor Sequence 1|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
16638728|NCT02357108|Active Comparator|Group 2: Video/Doctor Sequence 2|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
16638729|NCT02357108|Active Comparator|Group 3: Video/Doctor Sequence 3|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
16638730|NCT02357108|Active Comparator|Group 4: Video/Doctor Sequence 4|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
16638731|NCT02357095|Experimental|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
16638732|NCT02357095|Experimental|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
16638733|NCT02357095|Experimental|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
16638734|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
16638735|NCT02357069|Experimental|LBEC0101|Etanercept
16638736|NCT02357069|Active Comparator|Enbrel|Etanercept
16638737|NCT02357056|Active Comparator|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
16638738|NCT02357056|Active Comparator|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
16638739|NCT02357056|Active Comparator|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
16638740|NCT02357056|No Intervention|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
16638741|NCT02357043|Experimental|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
16638742|NCT02357030|Experimental|Methyl-P plus GWI Nutrient Formula|Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.
16638743|NCT02357017|Active Comparator|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
16638744|NCT02357017|Active Comparator|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
16638745|NCT02357004|Experimental|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
16638746|NCT02357004|Experimental|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
16638747|NCT02356991|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
16638748|NCT02356991|Placebo Comparator|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
16638749|NCT02356978|Experimental|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.
~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
16638750|NCT02356965|Experimental|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
16638751|NCT02356965|Experimental|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
16638752|NCT02356965|Placebo Comparator|Placebo|Single dose of placebo sublingual wafer
16638753|NCT02356952|Experimental|Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
16638754|NCT02356952|Experimental|Low Glycemic Index Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
16638755|NCT02356952|Experimental|Low Glycemic Index Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
16638758|NCT02356926||Control|Usual care and routine management
16638759|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
16638760|NCT02356913|Experimental|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
16638761|NCT02356913|Experimental|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
16638762|NCT02356913|Experimental|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
16638763|NCT02356913|Active Comparator|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
16638764|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
16638765|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
16638766|NCT02356887|Experimental|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
16638767|NCT02356874|Experimental|Exercise group|Exercise
16638768|NCT02356874|No Intervention|Control group|Participants in the control group will be asked to continue their usual physical activity habits
16638769|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
16638770|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
16638771|NCT02356848|Experimental|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
16638772|NCT02356848|Placebo Comparator|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
16638773|NCT02356835|Experimental|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
16638774|NCT02356835|Sham Comparator|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
16638775|NCT02356809|Experimental|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
16638776|NCT02356809|No Intervention|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
16638777|NCT02356796|Experimental|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.
~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
16638778|NCT02356796|Active Comparator|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
16638779|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.
~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
16638780|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.
~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
16638782|NCT02356770|Other|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
16638785|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
16638786|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
16638787|NCT02356718|Experimental|Experimental|Computerized cognitive training activities
16638788|NCT02356718|Active Comparator|Control|Non-adaptive computerized cognitive training activities
16638789|NCT02356705|Placebo Comparator|Saline Placebo|Control patients will receive intranasal saline
16638790|NCT02356705|Active Comparator|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
16638791|NCT02356705|Active Comparator|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
16638792|NCT02356692|Experimental|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
16638793|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
16638794|NCT02356679|Experimental|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
16638795|NCT02356679|Active Comparator|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
16638796|NCT02356653|Experimental|Expanded access to CliniMACs device for T cell depletion|access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.
16638797|NCT02356640|Active Comparator|EUS-guided celiac ganglion neurolysis|Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
16638798|NCT02356640|Active Comparator|Percutaneous celiac plexus neurolysis|Percutaneous celiac plexus neurolysis would be performed
16638799|NCT02356627|Experimental|The Cancer Home Life Intervention|"One or more of the following:
~prioritisation of resources and everyday activities
~adaptation of activities
~adaptation of posture and seating positioning
~provision of assistive devices
~modification of the physical home environment And usual care from hospital and municipality"
16638800|NCT02356627|No Intervention|Control|Usual care from hospital and municipality
16638801|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
16638802|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
16638803|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
16638804|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
16638805|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
16638806|NCT02356549|Active Comparator|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
16638807|NCT02356549|Active Comparator|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
16638808|NCT02356549|Active Comparator|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
16638809|NCT02356549|Active Comparator|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
16638810|NCT02356536|Experimental|Experimental|
16638811|NCT02356523||Cardiac Intensive Care Unit Patients|Patients admitted at Cardiac Intensive Care Unit for any condition
16638812|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
16638813|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
16638814|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
16638815|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
16638816|NCT02356458|Experimental|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
16638817|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
16638818|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
16638819|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
16638820|NCT02356419|Experimental|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
16638821|NCT02356419|Experimental|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
16638822|NCT02356419|Experimental|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
16638823|NCT02356419|Experimental|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
16638824|NCT02356406|Experimental|Celiac Plexus Radiosurgery|"The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.
~All eligible patients will receive the same protocol of celiac plexus radiosurgery"
16638825|NCT02356380|Experimental|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.
~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
16638826|NCT02356354|Other|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
16638827|NCT02356341||NovaTears®|
16638828|NCT02356328||NovaTears®|
16638829|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
16638830|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
16638835|NCT02356289|Experimental|MYK-461|single-dose, tablet formulation
16638836|NCT02356289|Placebo Comparator|Placebo|single-dose, tablet formulation
16638837|NCT02356276|Experimental|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
~Systemic chemotherapy (XELOX or SOX regimens):
~XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
16638838|NCT02356276|Placebo Comparator|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.
~XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
16638839|NCT02356250||PORTAL HYPERTENSION|PAIEBT WITH PORTAL HYPERTENSION
16638840|NCT02356237|Experimental|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
16638841|NCT02356237|No Intervention|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
16638842|NCT02356224|Experimental|Cohort 1|SHR3824 2.5 mg/day or placebo.
16638843|NCT02356224|Experimental|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
16638844|NCT02356224|Experimental|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
16638845|NCT02356224|Experimental|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
16638846|NCT02356224|Experimental|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
16638847|NCT02356224|Experimental|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
16638848|NCT02356224|Experimental|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
16638849|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
16638850|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
16638851|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
16638852|NCT02356198|Active Comparator|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
16638853|NCT02356172||Healthy Controls|Healthy males or females who are greater than or equal to 18 years old.
16638854|NCT02356172||Patients|Males or females with a diagnosis of IGD (Isolated GnRH Deficiency) who are greater than or equal to 18 years old.
16638857|NCT02356146||All KT recipient|
16638858|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
16638859|NCT02356107|Experimental|Open label treatment with 5-HTP and Creatine|
16638860|NCT02356094||Cases|Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination
16638861|NCT02356094||Controls|Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination
16638862|NCT02356081|Experimental|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
16638863|NCT02356081|No Intervention|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
16638864|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
16638865|NCT02356055|Experimental|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
16638866|NCT02356055|Active Comparator|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
16638867|NCT02356042||Nursing home residents practicing GIA activity|
16638868|NCT02356042||Nursing home residents no practicing GIA activity|
16638869|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
16638870|NCT02356016|Active Comparator|Whole body Electromyostimulation (WB-EMS)|18 min of WB-EMS/week (one session/week)
16638871|NCT02356016|Active Comparator|WB-EMS and Nutritional Supplements|18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
16638872|NCT02356016|Sham Comparator|Control|Monthly dietary counseling for 6 months
16638873|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
16638874|NCT02355990|Experimental|MIMS|Minimally Invasive Micro Sclerostomy
16638875|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
16638876|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
16638877|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
16638878|NCT02355964|Experimental|exercise|exercise (Aerobe training) 3 times per week
16638879|NCT02355964|Experimental|Diet|A diet with an overall high protein content and a low glycemic index
16638880|NCT02355964|Experimental|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
16638881|NCT02355964|No Intervention|control|Regular lifestyle (no intervention)
16638882|NCT02355938|Experimental|Fidaxomicin Arm|Oral Fidaxomicin 200 mg every 12 hours (Placebo for 2 doses) for 10 days
16638883|NCT02355938|Active Comparator|Vancomycin Arm|Oral Vancomycin 125 mg every 6 hours for 10 days
16638884|NCT02355925|Experimental|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
16638885|NCT02355925|Placebo Comparator|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
16638886|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
16638887|NCT02355912|Experimental|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
16638888|NCT02355899|Experimental|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
16638889|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
16638890|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
16638891|NCT02355873|Experimental|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
16638892|NCT02355873|Active Comparator|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
16638893|NCT02355847|Other|Healthcare Worker Education|Educational Lectures
16638894|NCT02355834|Experimental|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
16638895|NCT02355834|No Intervention|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
16638896|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
16638897|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
16638898|NCT02355808|No Intervention|Non Superfast|
16638899|NCT02355808|Other|Non Superfast GP intervention|
16638900|NCT02355808|Other|Non Superfast Tailored Leaflet|
16638901|NCT02355808|Other|Non Superfast GP + Tailored Leaflet|
16638902|NCT02355808|No Intervention|Superfast|
16638903|NCT02355808|Other|Non Superfast GP|
16638904|NCT02355808|Other|Superfast Tailored Leaflet|
16638905|NCT02355808|Other|Superfast GP + Tailored Leaflet|
16638906|NCT02355795|Experimental|low-fat diet|Participants will be provided low-fat diet for 6 months
16638907|NCT02355795|Experimental|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
16638908|NCT02355795|Experimental|high-fat diet|Participants will be provided high-fat diet for 6 months
16638909|NCT02355756|Experimental|Active|Intradermal injection of maxadilan solution
16638910|NCT02355756|Placebo Comparator|Placebo|Intradermal injection of placebo (=vehicle) solution
16638911|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
16638912|NCT02355730|Experimental|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
16638913|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
16638914|NCT02355704|Active Comparator|Atorvastatin|22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
16638915|NCT02355704|Placebo Comparator|Placebo|22 patients received oral placebo 40 mg 1 time for day for 4 weeks
16638916|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
16638917|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
16638918|NCT02355678|Experimental|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
16638919|NCT02355678|Experimental|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
16638920|NCT02355665|Experimental|Nicotine|Nicotine Spray
16638921|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
16638922|NCT02355652|Active Comparator|Cemented TKA|
16638923|NCT02355652|Active Comparator|Uncemented TKA|
16638924|NCT02355639|Experimental|Clobetasol propionate 0.05 % ointment|Active drug
16638925|NCT02355639|Experimental|Betamethasone dipropionate 0.064 % ointment|Active drug
16638926|NCT02355639|Placebo Comparator|Petrolatum ointment|Placebo drug
16638927|NCT02355613|Active Comparator|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
16638928|NCT02355613|Active Comparator|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
16638929|NCT02355561|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram [mg] formulation 1 [reference] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 [test] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16638930|NCT02355561|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16638931|NCT02355561|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16638932|NCT02355561|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16638933|NCT02355561|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16638934|NCT02355561|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
16638935|NCT02355548||Outpatient Treatment|All patients eligible for the study will have their PE treated in the outpatient setting.
16638936|NCT02355535|Experimental|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
16638937|NCT02355522|Active Comparator|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
16638938|NCT02355522|Active Comparator|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
16638939|NCT02355522|Placebo Comparator|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
16638940|NCT02355509|Placebo Comparator|Placebo|A placebo drug is given for three months
16638941|NCT02355509|Experimental|Acarbose|Acarbose is given for three months
16638942|NCT02355496|Experimental|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
16638943|NCT02355496|No Intervention|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
16638944|NCT02355470|Experimental|Intervention|Participants will receive the GIFTSS intervention provided by college health center staff and clinicians
16638945|NCT02355470|Active Comparator|Control|Participants will receive a brief alcohol use reduction intervention based on NIAAA guidelines provided by college health center staff and clinicians
16638946|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
16638947|NCT02355444|Experimental|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
16638948|NCT02355444|Placebo Comparator|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
16638949|NCT02355431|Experimental|Itacitinib plus erlotinib|
16638950|NCT02355431|Active Comparator|Placebo plus erlotinib|
16638951|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
16638952|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
16638953|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
16638954|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
16638955|NCT02355379|Experimental|GROUP2- ARM C|Observation
16638956|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
16638957|NCT02355366|Experimental|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
16638958|NCT02355366|Active Comparator|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
16638959|NCT02355353|Experimental|Imaging arm|
16638960|NCT02355340||DXA and pQCT Scan|"Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density
~Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
16638961|NCT02355327|Experimental|Laselle Kegel Exerciser|
16638962|NCT02355327|Active Comparator|Pelvic floor muscle exercises|
16638963|NCT02355314|Experimental|ICU patients requiring mechanical ventilation|
16638964|NCT02355301||patients with orthopedic disorders|Patients with muscular skeletal impairments receiving a treatment (A, B, C...). The investigators compare these treatments (A, B, C...) in function of ICF model in order to improve the quality of care in orthopedic department.
16638965|NCT02355288|Active Comparator|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
16638966|NCT02355288|Active Comparator|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
16638967|NCT02355275|Experimental|Home Exercise Program|
16638968|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
16639035|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
16638969|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
16638970|NCT02355249|Experimental|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
16638971|NCT02355249|Active Comparator|B group (OE)|Via traditional three incisions esophagectomy.
16638972|NCT02355236|Experimental|Test Group|Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks
16638973|NCT02355236|Active Comparator|Comparator Group|Celecoxib 200mg and Naxozol-Placebo for 12 weeks
16638974|NCT02355223|Other|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
16638975|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
16638976|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
16638977|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
16638978|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
16638979|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
16638980|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
16638981|NCT02355197|Active Comparator|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
16638982|NCT02355197|No Intervention|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
16638983|NCT02355184|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
16638984|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
16638985|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
16638986|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
16638987|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
16638988|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
16638989|NCT02355119|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
16638990|NCT02355119|Experimental|FOLFOXIRI|
16638991|NCT02355106|Experimental|Treatment|Atrial flutter Ablation
16638992|NCT02355093|Experimental|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
16638993|NCT02355093|Active Comparator|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
16638994|NCT02355080|Experimental|On-site bundled rapid HIV/HCV testing|Participants will receive the on-site bundled rapid HIV/HCV testing intervention. In the intervention group, all patients will receive an offer to participate in rapid HIV/HCV testing. Those who accept this offer will: receive pre-test information about testing procedures and education, be tested, receive results during the same visit as testing, and be provided post-test counseling and support services by trained test counselors. Patients with a preliminary positive (i.e., reactive) HIV and/or HCV test result(s) will be actively linked immediately to a health care provider for further evaluation and confirmatory HIV and/or HCV RNA testing.
16638995|NCT02355080|Active Comparator|Standard of care (SOC)|Participants will receive the standard of care (SOC) at the study sites. The SOC entails venipuncture whole blood HIV testing + venipuncture whole blood HCV testing. Blood draws are sent to an external laboratory for processing, and patients must return for test results in another visit. Patients may not receive pre-test information or results and post-test counseling, especially if non-reactive or negative test result(s). Reflex testing is not standard practice, therefore some patients may require another visit and blood draw for confirmatory HIV and/or HCV RNA testing. Linkage to care in the SOC is accomplished by referral to a health care provider, either within the participating substance use disorder treatment organization or passive referral to other health facilities.
16638996|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
16638997|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
16638998|NCT02355041|Experimental|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
16639036|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
16639037|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
16638999|NCT02355041|Active Comparator|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
16639000|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
16639001|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
16639002|NCT02355002|Experimental|Active Transcranial Magnetic Stimulation (TMS) treatment|In this arm subjects will receive real, active TMS with a standard, water-cooled, figure-8 shaped TMS coil.
16639003|NCT02355002|Sham Comparator|Sham-TMS treatment|This arm serves as the sham/placebo control. In TMS a sham coil is used to create a sensory experience which is similar to active TMS, but in which the magnetic field is blocked by a metal shield built into the coil.
16639004|NCT02354989|Active Comparator|RR on first|Rate Response on first
16639005|NCT02354989|Active Comparator|RR off first|Rate Response off first
16639006|NCT02354976|Placebo Comparator|Placebo|
16639007|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
16639008|NCT02354976|Active Comparator|Fenofibrate 200mg|
16639009|NCT02354963|No Intervention|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
16639010|NCT02354963|Experimental|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.
~Assessment of antral follicle count. IVF treatment."
16639011|NCT02354950|Experimental|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
16639012|NCT02354950|Experimental|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
16639013|NCT02354950|Experimental|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
16639014|NCT02354950|Experimental|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
16639015|NCT02354937|Experimental|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
16639016|NCT02354937|Active Comparator|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
16639017|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
16639018|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
16639019|NCT02354911|Experimental|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
16639020|NCT02354911|Placebo Comparator|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
16639021|NCT02354898|Experimental|BBI503, BBI503 and Sorafenib|
16639022|NCT02354885|No Intervention|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
16639023|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
16639024|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
16639025|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
16639026|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
16639027|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
16639028|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
16639029|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
16639030|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
16639031|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
16639032|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
16639033|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
16639034|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
16639038|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
16639039|NCT02354859|Active Comparator|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
16639040|NCT02354859|Placebo Comparator|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
16639041|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
16639042|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
16639043|NCT02354820|No Intervention|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
16639044|NCT02354820|Experimental|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
16639045|NCT02354807|Experimental|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
16639046|NCT02354794|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.
~Intervention: see below"
16639047|NCT02354781|Experimental|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
16639048|NCT02354768|Experimental|lanreotide and anti-diarrheal treatments|"Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)
~Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)
~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)
~hydration"
16639049|NCT02354768|Active Comparator|Current anti-diarrheal treatments alone|"Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)
~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)
~Hydration"
16639050|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
16639051|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
16639052|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
16639053|NCT02354742|Active Comparator|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
16639054|NCT02354742|Experimental|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
16639055|NCT02354729|Experimental|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
16639056|NCT02354729|No Intervention|Control|Participants received text messages.
16639057|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
16639058|NCT02354703|Experimental|ondansetron-responsive genotype|"ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:
~if European ancestry:
~SLC6A4 gene:
~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT
~HTR3A gene:
~rs1150226:AG; or rs1176713:GG
~HTR3B gene:
~rs17619942:AC
~If African ancestry:
~HTR3B gene:
~rs176744: CC or CA
~SLC6A4 gene:
~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
16639059|NCT02354703|Experimental|ondansetron--non-responsive genotype|ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
16639060|NCT02354703|Placebo Comparator|placebo--responsive genotype|"placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:
~if European ancestry:
~SLC6A4 gene:
~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT
~HTR3A gene:
~rs1150226:AG; or rs1176713:GG
~HTR3B gene:
~rs17619942:AC
~If African ancestry:
~HTR3B gene:
~rs176744: CC or CA
~SLC6A4 gene:
~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
16639061|NCT02354703|Placebo Comparator|placebo--non-responsive genotype|placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
16639062|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
16639063|NCT02354677|Experimental|Heathy volunteers, smokers and COPD|
16639096|NCT02354430|No Intervention|Control group|
16640436|NCT02345278|Placebo Comparator|Placebo|once daily sublingual administration for 1 month
16639064|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
16639065|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
16639066|NCT02354651||Pompe subjects receiving NeuDx DPS|Patients will receive resting breathing pattern evaluation, phrenic nerve stimulation, maximal inspiratory pressure (MIP) testing, forced expiratory testing, and EMG.
16639067|NCT02354638|Experimental|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
16639068|NCT02354638|No Intervention|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
16639069|NCT02354625|Experimental|ahSC transplantation|Autologous human Schwann cells
16639070|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639071|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639072|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639073|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639074|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639075|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639076|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
16639077|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
16639079|NCT02354573|Active Comparator|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
16639080|NCT02354573|Placebo Comparator|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
16639081|NCT02354560|Experimental|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
16639082|NCT02354547|Experimental|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
16639083|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
16639084|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
16639085|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
16639086|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
16639087|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
16639088|NCT02354495|Experimental|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
16639089|NCT02354482||Diverse, high-risk patient populations|
16639090|NCT02354469||Contact/Collision Sport Athletes|Collegiate athletes who participate in contact or collision sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
16639091|NCT02354469||Non-contact Sport Athletes|Collegiate athletes who participate in non-contact sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
16639092|NCT02354469||Post-Concussion|Collegiate athletes who sustain a concussion will be assessed on a comprehensive battery of tests from the time of injury and incrementally throughout the following year post-injury.
16639093|NCT02354469||Healthy Control|Collegiate athletes who do not sustain a concussion but match the demographic profile of an individual enrolled as a post-concussion subject, will be assessed on the same tests and in a similar timeline as post-concussion subjects.
16639094|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
16639095|NCT02354430|Active Comparator|Water-exercise|
16639097|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.
~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:
~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.
~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
16639098|NCT02354404|Experimental|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
16639099|NCT02354404|Experimental|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
16639100|NCT02354404|Experimental|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
16639101|NCT02354404|Experimental|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
16639102|NCT02354404|Experimental|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
16639103|NCT02354404|Experimental|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
16639104|NCT02354391|Experimental|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
16639105|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
16639106|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
16639107|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
16639108|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
16639109|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
16639110|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
16639111|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
16639112|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
16639113|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
16639114|NCT02354326||Diagnostic (VNC DECT)|Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.
16639115|NCT02354313|Experimental|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
16639116|NCT02354313|No Intervention|Observation|no therapy is planned but only observation
16639117|NCT02354300||TCD Ultrasound|Transcranial doppler ultrasound monitoring during flow diverter placement.
16639118|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
16639119|NCT02354274|Active Comparator|Standard: Homogeneous dose plan|Treatment will be given over 33 treatments. The dose is 66 Gy.
16639120|NCT02354274|Experimental|Escalation: Inhomogeneous dose plan|"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.
~Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration"
16639121|NCT02354261|Experimental|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
16639122|NCT02354248|Experimental|Stroke patients|The patients will be submitted to a triple stimulation examination.
16639123|NCT02354248|Active Comparator|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
16639124|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
16639125|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
16639126|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
16639127|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
16639128|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.
~The following procedures will be carried out:
~Questionnaire on compliance and adherence
~Clinic Visit
~20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
16639129|NCT02354196||CCTA|Subjects who underwent a CCTA
16639130|NCT02354183|Experimental|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
16639131|NCT02354183|Active Comparator|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
16639132|NCT02354170|Experimental|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
16639133|NCT02354170|Experimental|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
16639134|NCT02354170|Placebo Comparator|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
16639135|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:
~a commercially available gel that contains carrageenan.
~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.
~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
16639136|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:
~a commercially available gel that does not contain carrageenan.
~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.
~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
16639137|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
16639138|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
16639139|NCT02354118|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
16639140|NCT02354118|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
16639141|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
16639142|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include
~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
~Local anesthetic for tenaculum placement
~Sham Paracervical Block done with capped spinal needle
~osmotic dilators placed in the usual fashion
~postprocedural assessment"
16639143|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include
~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
~Local anesthetic for tenaculum placement
~18 ml 1% buffered lidocaine Paracervical Block
~osmotic dilators placed in the usual fashion
~postprocedural assessment"
16639144|NCT02354079|Other|genetic analysis|
16639145|NCT02354066|Experimental|Hallux valgus Surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy, Chevron, SCARF, Austin, etc.)
16639146|NCT02354066|Experimental|Hallux valgus and forefoot surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy; Chevron, Austin, SCARF, etc.) and additional forefoot surgery (PIP arthrodesis, second/third/etc. metatarsal osteotomy, etc.; Peg-in-Hole, WEIL-Osteotomy, etc.)
16639147|NCT02354066|Experimental|Control Run|Measurement of the Brake Response Time by Healthy Participants; control run; brake response time measurement with normal shoe and both foot orthoses
16639148|NCT02354053|Active Comparator|Current ART|Current ART + adherence support
16639149|NCT02354053|Experimental|Triumeq|Triumeq + adherence support
16639150|NCT02354040|Experimental|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
16639151|NCT02354040|No Intervention|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
16639152|NCT02354027|Experimental|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
16639188|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
16639189|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
16639190|NCT02353702|Experimental|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :
~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
16639154|NCT02354001|Experimental|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
16639155|NCT02354001|Placebo Comparator|placebo tablet|1 tablet daily for 12 weeks
16639156|NCT02353988|Experimental|bicalutamide|This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
16639157|NCT02353988|Active Comparator|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable
16639158|NCT02353975|Experimental|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
16639159|NCT02353975|Experimental|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
16639160|NCT02353962|Experimental|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
16639161|NCT02353949|Experimental|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
16639162|NCT02353936|Experimental|afatinib group|
16639163|NCT02353923|Experimental|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
16639164|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
16639165|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
16639166|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
16639167|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
16639168|NCT02353858|Experimental|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
16639169|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
16639170|NCT02353845||normal control|
16639171|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
16639172|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
16639173|NCT02353832|Other|No Arm|
16639174|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
16639175|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
16639176|NCT02353793|Experimental|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
16639177|NCT02353793|Active Comparator|Cotton wool blanket|Patient warming with cotton wool blanket
16639178|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
16639179|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
16639180|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
16639181|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
16639182|NCT02353767||Controls|"age ± 7 years from cases
~duration of HIV-1 infection ± 3 years from cases
~HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or > 1000 copies/mL"
16639183|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
16639184|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
16639185|NCT02353741|Experimental|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
16639186|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
16639187|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
16639191|NCT02353702|Placebo Comparator|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :
~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
16639192|NCT02353689|Experimental|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
16639193|NCT02353689|Experimental|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
16639194|NCT02353689|Experimental|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
16639195|NCT02353676|Experimental|BUPIVACAINE GROUP|1.5 ml of 0.5% Bupivacaine solution to be injected into the operative site postoperatively.
16639196|NCT02353676|Placebo Comparator|PLACEBO GROUP|1.5 ml of saline solution to be injected into the opposite site postoperatively.
16639197|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
16639198|NCT02353637|Active Comparator|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
16639199|NCT02353637|Active Comparator|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
16639200|NCT02353611|Experimental|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
16639201|NCT02353611|Active Comparator|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
16639202|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 1|Participants will recieve crenezumab dose level 1 once every 4 weeks.
16639203|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 2|Participants will receive crenezumab dose level 2 once every 4 weeks.
16639204|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 3|Participants will receive crenezumab dose level 3 once every 4 weeks.
16639205|NCT02353598|Placebo Comparator|Double-blind treatment window: Placebo|Participants will receive placebo matched to crenezumab once every 4 weeks.
16639206|NCT02353598|Experimental|Optional OLE window: Crenezumab|Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
16639207|NCT02353585||Intracranial hemorrhage|Intracranial hemorrhage occuring in patients on novel oral anticoagulants (NOAC) or vitamin-K antagonists
16639208|NCT02353585||Acute ischemic stroke|Acute ischemic stroke occuring in patients on novel oral anticoagulants (NOAC) or vitamin K antagonists (VKA)
16639209|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
16639210|NCT02353559|Experimental|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
16639211|NCT02353559|No Intervention|Usual Care|Usual care
16639212|NCT02353546|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
16639213|NCT02353546|No Intervention|Usual Care|
16639214|NCT02353533|Other|EMR|Standard EMR technique
16639215|NCT02353533|Experimental|FTRD|
16639216|NCT02353507|Active Comparator|Opticell Ag+|Absorbent, antibacterial, barrier dressing
16639217|NCT02353507|Active Comparator|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
16639218|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
16639219|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.
~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.
~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
16639220|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.
~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
16639221|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
16639222|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
16639223|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
16639764|NCT02349724|Other|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
16639224|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:
~placebo ultrasound during 5min ;
~scapular squeezing in the sitting position (3x10repetitions);
~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
16639225|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:
~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);
~external rotators strengthening in sidelying positions with load (3x10repetitions);
~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
16639226|NCT02353429|Experimental|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
16639227|NCT02353416|Placebo Comparator|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
16639228|NCT02353416|Active Comparator|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
16639229|NCT02353403|Placebo Comparator|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
16639230|NCT02353403|Experimental|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
16639231|NCT02353390|Active Comparator|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
16639232|NCT02353390|No Intervention|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
16639233|NCT02353364|Experimental|Group A|Transfer of 1 or 2 biopsied euploid embryo of high morphological grade based on NGS testing using CNV-Seq (PGS)
16639234|NCT02353364|No Intervention|Group B|Transfer of 1 or 2 non-biopsied embryo of high morphological grade (no PGS)
16639235|NCT02353338|Experimental|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
16639236|NCT02353338|Active Comparator|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
16639237|NCT02353325|Experimental|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
16639238|NCT02353325|Experimental|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
16639239|NCT02353325|Experimental|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
16639240|NCT02353325|Experimental|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
16639241|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
16639242|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
16639243|NCT02353312|Experimental|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
16639244|NCT02353312|Active Comparator|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
16639245|NCT02353299|Active Comparator|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
16639246|NCT02353299|Placebo Comparator|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
16639247|NCT02353299|Active Comparator|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
16639248|NCT02353299|Placebo Comparator|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
16639249|NCT02353286|Experimental|Post-cholecystecomy bile leak|Endoscopic insertion of biodegradable biliary stent
16639250|NCT02353286|Experimental|Benign biliary stricture|Endoscopic insertion of biodegradable biliary stent
16639251|NCT02353273|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
16639252|NCT02353260|Experimental|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:
~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
~The treatments will be administrated in accord with the guideline for other types of cancer.
~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
16639253|NCT02353260|Active Comparator|Chemotherapy|"Chemotherapy:
~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)
~The treatments will be administrated in accord with the guideline for other types of cancer."
16639254|NCT02353247|Other|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
16639255|NCT02353234|Active Comparator|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
16639256|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
16639257|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
16639281|NCT02353065|Experimental|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
16639582|NCT02351037|Experimental|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
16639258|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
16639259|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
16639260|NCT02353208|Active Comparator|Sham Feeding of Bacon Bits|"In addition to the standard procedure, subjects will be asked to perform sham feeding on two occasions: 1) Immediately after having swallowed the capsule and 2) One hour after having swallowed the capsule.
~Sham feeding will be performed as follows: The patients will be asked to chew 10 times on a piece of bacon over a period of 30 seconds, prior to spitting saliva and bacon into a container. This will be repeated 10 times at one minute intervals.
~The patient will then complete the capsule study as per the standard procedure.
~Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada."
16639261|NCT02353208|Placebo Comparator|Placebo|The control group will not chew bacon bits while undergoing capsule endoscopy.
16639262|NCT02353195|Experimental|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
16639263|NCT02353195|Placebo Comparator|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
16639264|NCT02353182|Experimental|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.
~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed
~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed
~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
16639265|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
16639266|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
16639267|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
16639268|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
16639269|NCT02353156|Experimental|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
16639270|NCT02353156|Active Comparator|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
16639271|NCT02353143|Experimental|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
16639272|NCT02353130||Memantine-XR|Boys ages 8-12 with ASD treated with Memantine-XR daily for 8 weeks
16639273|NCT02353117|Active Comparator|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
16639274|NCT02353117|No Intervention|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
16639275|NCT02353104|Experimental|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
16639276|NCT02353091|No Intervention|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
16639277|NCT02353091|Experimental|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
16639278|NCT02353078|Experimental|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
16639279|NCT02353078|Experimental|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
16639280|NCT02353065|Active Comparator|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
16639282|NCT02353052||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
16639283|NCT02353052||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
16639284|NCT02353039|Experimental|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
16639285|NCT02353039|Experimental|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
16639286|NCT02353039|Experimental|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
16639287|NCT02353039|Placebo Comparator|Placebo|Administer placebo t.i.d for 2 weeks.
16639288|NCT02353026|Experimental|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
16639289|NCT02353013|Active Comparator|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
16639290|NCT02353013|Experimental|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
16639291|NCT02353000|Experimental|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
16639292|NCT02353000|Other|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
16639293|NCT02352987|Experimental|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
16639294|NCT02352987|Active Comparator|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
16639295|NCT02352974|Experimental|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
16639296|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
16639297|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
16639298|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
16639299|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
16639300|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
16639301|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
16639302|NCT02352935|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
16639303|NCT02352935|No Intervention|Control|The patients without any treatment
16639304|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
16639305|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
16639306|NCT02352909|Active Comparator|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
16639307|NCT02352909|Experimental|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
16639308|NCT02352909|Experimental|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
16639310|NCT02352883|Experimental|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
16639311|NCT02352883|Experimental|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
16639312|NCT02352883|Experimental|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
16639313|NCT02352883|Experimental|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
16639314|NCT02352883|Experimental|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
16639315|NCT02352870|Experimental|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:
~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.
~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future
~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
16639316|NCT02352870|Active Comparator|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:
~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.
~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
16639317|NCT02352857|Placebo Comparator|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
16639318|NCT02352857|Experimental|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
16639319|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
16639320|NCT02352831|Experimental|Phase I (tosedostat + capecitabine)|"The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion.
~Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat.
~Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle
~Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain."
16639321|NCT02352831|Experimental|Phase II (tosedostat + capecitabine)|"Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle
~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
16639322|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
16639323|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
16639324|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
16639325|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
16639326|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
16639327|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
16639328|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
16639329|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
16639330|NCT02352792|Active Comparator|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
16639331|NCT02352792|Experimental|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
16639332|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
16639333|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
16639334|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
16639335|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
16639336|NCT02352753|Experimental|Denosumab|Single Arm Study
16639337|NCT02352740|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.
~Intervention : A form arginine and B form arginine"
16639338|NCT02352740|Experimental|Healthy subjects|"Control subjects, i.e. without overweight, elevated waist circumference and elevated fasting triglyceridemia.
~Intervention : A form arginine and B form arginine"
16639339|NCT02352714|Active Comparator|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
16639340|NCT02352714|Sham Comparator|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
16639341|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
16639342|NCT02352688|Active Comparator|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
16639343|NCT02352688|No Intervention|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
16639344|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
16639345|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
16639346|NCT02352662||Study Group|Three blood samples will be collected intra-operatively from each subject enrolled
16639347|NCT02352649|Experimental|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
16639348|NCT02352649|Experimental|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
16639349|NCT02352649|Placebo Comparator|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
16639350|NCT02352636|Active Comparator|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
16639351|NCT02352636|Active Comparator|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
16639352|NCT02352636|Experimental|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
16639353|NCT02352636|Placebo Comparator|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
16639354|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
16639355|NCT02352610|Active Comparator|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
16639356|NCT02352610|Active Comparator|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
16639357|NCT02352597|Active Comparator|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
16639358|NCT02352597|Active Comparator|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
16639359|NCT02352597|Active Comparator|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
16639360|NCT02352584|Experimental|GC3110A(Quadrivalent)|0.5ml, intramuscular, a single dosing
16639361|NCT02352584|Active Comparator|GC Flu (Trivalent)|0.5ml,intramuscular,a single dosing
16639362|NCT02352584|Active Comparator|GC3110A(Trivalent)|0.5ml,intramuscular,a single dosing
16639363|NCT02352571|Experimental|Single group assignment|GC1118 recombinant human anti-EGFR antibody
16639364|NCT02352558|Experimental|Arm 1|Patients with multiple myeloma treated with BBI608
16639365|NCT02352558|Experimental|Arm 2|Patients with lymphoma treated with BBI608
16639366|NCT02352558|Experimental|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
16639367|NCT02352558|Experimental|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
16639368|NCT02352558|Experimental|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
16639369|NCT02352558|Experimental|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
16639370|NCT02352558|Experimental|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
16639371|NCT02352558|Experimental|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
16639372|NCT02352558|Experimental|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
16639373|NCT02352545|Experimental|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
16639374|NCT02352545|Placebo Comparator|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
16639375|NCT02352532|Experimental|Low Back Pain - Dry Needling|
16639376|NCT02352532|Sham Comparator|Low Back Pain - Sham|
16639377|NCT02352532|Active Comparator|Asymmptomatic - Dry Needling|
16639378|NCT02352519|Experimental|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
16639379|NCT02352519|Active Comparator|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
16639380|NCT02352506||AKI|Patients developing AKI during the ICU stay
16639381|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
16639382|NCT02352493|Active Comparator|ALN-CC5|
16639383|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16639384|NCT02352480|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
16639385|NCT02352480|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
16639411|NCT02352285|Placebo Comparator|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
16639386|NCT02352467|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
16639387|NCT02352467|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
16639388|NCT02352454|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
16639389|NCT02352454|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
16639390|NCT02352441|Experimental|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
16639391|NCT02352441|No Intervention|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
16639392|NCT02352428|Experimental|Skin Cancer Screening Training|Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
16639393|NCT02352428|No Intervention|No Skin Cancer Screening Training|Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
16639394|NCT02352402|Experimental|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
16639395|NCT02352402|Placebo Comparator|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
16639396|NCT02352389||Influenza|"Children and young adults identified as having influenza infections by the St. Jude Children's Research Hospital diagnostic microbiology will be approached to participate in the study. Biological samples will be collected on Day 0 within 72 hours of the diagnosis of influenza, and at 7, 14, 21, and 28 days later.
~Interventions: Symptom checklist, Blood sample, Nasal swab, Oropharyngeal swab, Stool sample."
16639397|NCT02352376|Other|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
16639398|NCT02352376|Other|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
16639399|NCT02352363|Experimental|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
16639400|NCT02352363|Other|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
16639401|NCT02352350||Cardiac Arrest Patients|All adult patients with non traumatic cardiac arrest in Alachua County Florida will have blood lactate levels taken and neurological outcomes performed based on the Cerebral Performance Categories (CPC) Scale
16639402|NCT02352337|Active Comparator|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
16639403|NCT02352337|Experimental|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:
~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
16639404|NCT02352337|Experimental|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:
~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over
~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
16639405|NCT02352324|Experimental|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
16639406|NCT02352311|Experimental|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
16639407|NCT02352311|Experimental|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
16639408|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
16639409|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
16639410|NCT02352285|Experimental|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
16639412|NCT02352272|Experimental|Sleep extension|Subject spend 10 hours Time in bed per day during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
16639413|NCT02352272|Sham Comparator|Habitual sleep|Subject respect their habitual Time in bed during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
16639414|NCT02352259|Experimental|Electrochemotherapy|
16639415|NCT02352246|Experimental|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
16639416|NCT02352246|Other|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
16639417|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
16639418|NCT02352207||identification of a pulmonary malformation in the fetus|pregnant women referred to a prenatal Center, because of the identification of a pulmonary malformation in the fetus
16639419|NCT02352194||Assessment|"One part of this study is to quantify physical capacity of patients with Multiple sclerosis.
~Thirty patients will be enrolled in this study and performed assessments."
16639420|NCT02352194||Rehabilitation|A second part of this study is to quantify the benefit of a usual rehabilitation program in the day hospital. Thirty patients will be enrolled in this study and receive rehabilitation. They will be assessed before and after the rehabilitation program (physiotherapy and physical activity)
16639421|NCT02352181|Placebo Comparator|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
16639422|NCT02352181|Experimental|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
16639423|NCT02352168|Active Comparator|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
16639424|NCT02352168|Placebo Comparator|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
16639425|NCT02352155|Active Comparator|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
16639426|NCT02352155|Placebo Comparator|observation only|NO second look endoscopy (Observation)
16639427|NCT02352142|No Intervention|Standard Care|Mothers are given infant care instruction as part of standard care
16639428|NCT02352142|Experimental|Facilitated infant care|Family Nurture Intervention
16639429|NCT02352142|Other|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
16639430|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
16639431|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
16639432|NCT02352116|Experimental|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
16639433|NCT02352116|Active Comparator|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
16639434|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
16639435|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
16639436|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
16639437|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
16639438|NCT02352090|Active Comparator|Progestin-Only|Dienogest
16639439|NCT02352077|Experimental|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
16639440|NCT02352064|Experimental|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
16639441|NCT02352051|Active Comparator|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
16639442|NCT02352051|Active Comparator|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
16639443|NCT02352038|Experimental|LLLT group|LLLT group: orthodontic treatment and low-level laser therapy
16639444|NCT02352038|Placebo Comparator|control group|Control group: orthodontic treatment and no laser treatment.
16639445|NCT02352025|Experimental|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
16639446|NCT02352012|Experimental|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
16639447|NCT02352012|Experimental|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
16639448|NCT02352012|No Intervention|control group|Control group was given to continuous negative pressure drainage
16639449|NCT02351999|Experimental|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
16639450|NCT02351986|Experimental|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
16639451|NCT02351986|No Intervention|Control|Healthy subjects between 18 to 45 years.
16639765|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16639452|NCT02351973|Active Comparator|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
16639453|NCT02351973|Active Comparator|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
16639454|NCT02351973|Active Comparator|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
16639455|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
16639456|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
16639457|NCT02351947|Experimental|persons with chronic stroke|upper limb rehabilitation for chronic stroke
16639458|NCT02351947|No Intervention|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
16639459|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
16639460|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
16639461|NCT02351921|Experimental|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
16639462|NCT02351921|Experimental|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
16639463|NCT02351921|Sham Comparator|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
16639464|NCT02351908|Experimental|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
16639465|NCT02351908|Experimental|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
16639466|NCT02351908|Experimental|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
16639467|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
16639468|NCT02351882|Active Comparator|Nabilone|Participants randomized into the nabilone arm will be prescribed nabilone for 6 weeks. After one-week placebo washout, they will be taking placebo for an additional 6 weeks.
16639469|NCT02351882|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 6 weeks. After one-week placebo washout, they will be prescribed nabilone for an additional 6 weeks.
16639470|NCT02351869|Active Comparator|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
16639471|NCT02351869|Placebo Comparator|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
16639472|NCT02351856|Experimental|ARRY-371797|
16639473|NCT02351843|Experimental|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
16639474|NCT02351843|Active Comparator|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
16639475|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.
~Baseline product: the subject's usual product
~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces
~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
16639476|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.
~Baseline product: the subject's usual product
~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces
~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
16639477|NCT02351804|Experimental|Ropivacaine + dexamethasone|20 ml ropivacaine 0.5% + 0.5 ml dexamethasone 4 mg7ml
16639478|NCT02351804|Placebo Comparator|Ropivacaine + placebo|20 ml ropivacaine 0.5% + 0.5 ml isotonic saline ad
16639479|NCT02351791|Experimental|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin.
~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
16639480|NCT02351791|Experimental|Patch 2, 4 and 6|"Patch 2, Patch 4 and Patch 6 applied on peristomal skin.
~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
16639507|NCT02351609|Experimental|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
16639481|NCT02351765|Experimental|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.
~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
16639482|NCT02351752|Experimental|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR >60)
16639483|NCT02351739|Other|Pembrolizumab|Arm 1: pembrolizumab monotherapy
16639484|NCT02351739|Other|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
16639485|NCT02351726|Experimental|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
16639486|NCT02351713|Experimental|Threshold based method|Exercise Week 1 Heart rate (HR) < first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR < VT1 4 days 25 min/day Week 3 HR < VT1 4 days 30 min/day Week 4 HR < VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to < second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to < VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
16639487|NCT02351713|Experimental|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
16639488|NCT02351713|No Intervention|Control|Non-exercise control group
16639491|NCT02351687|No Intervention|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
16639492|NCT02351687|Experimental|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
16639493|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
16639494|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
16639495|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
16639496|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate>90bpm
16639497|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
16639498|NCT02351648|Experimental|Intervention'|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge
~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge
~Intervention after discharge:
~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
16639499|NCT02351648|Active Comparator|Control'|Patients receive usual standard of care from the internal medicine team
16639500|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
16639501|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
16639502|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
16639503|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
16639504|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
16639505|NCT02351622|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
16639506|NCT02351622|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
16641423|NCT02338739|Active Comparator|SMS; Outreach if Failure; Stop SMS if Success|
16639508|NCT02351609|Active Comparator|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
16639509|NCT02351596|Active Comparator|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).
~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
16639510|NCT02351596|Active Comparator|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
16639511|NCT02351596|Active Comparator|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).
~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
16639512|NCT02351596|Active Comparator|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
16639513|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
16639514|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
16639515|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
16639516|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
16639517|NCT02351544|Experimental|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
16639518|NCT02351544|Experimental|Surgery|Patients in this arm will receive surgery for migraine headaches
16639519|NCT02351531|Experimental|New Thickened Extensively Hydrolyzed formula|
16639520|NCT02351505|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16639521|NCT02351492|Active Comparator|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography (IOC) to investigate bile ducts.
16639522|NCT02351492|Active Comparator|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography (MRCP) first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
16639523|NCT02351479|Other|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
16639524|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
16639525|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
16639526|NCT02351440|Experimental|Duloxetine|duloxetine 60mg PO
16639527|NCT02351440|Placebo Comparator|Placebo|placebo
16639528|NCT02351427|Active Comparator|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7
~with
~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
16639529|NCT02351427|Active Comparator|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
16639530|NCT02351414||Primary Total Knee Arthroplasty|Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts
16639531|NCT02351401|Experimental|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
16639532|NCT02351401|No Intervention|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
16639533|NCT02351388|Active Comparator|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
16639534|NCT02351388|Sham Comparator|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
16639535|NCT02351375|Experimental|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
16639536|NCT02351375|Experimental|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
16639537|NCT02351362|Experimental|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
16639538|NCT02351362|No Intervention|Control Group|Standard of care
16639539|NCT02351349|Experimental|multidisciplinary intervention|Due to the problem of randomization, the study became a before and after assessment in the one group that completed the 12 week exercise program and received nutritional support
16639540|NCT02351349|No Intervention|Non adherence|Those who were offered the program but did not complete the prescription
16639541|NCT02351336||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :
~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )
~Cervical dilataion >1cm, &/or
~Cervical effacement ≥ 80%"
16639542|NCT02351323|Experimental|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
16639543|NCT02351323|Placebo Comparator|No glutamine + Lifestyle change|Lifestyle change
16641424|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure|
16639544|NCT02351310|Active Comparator|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
16639545|NCT02351310|Placebo Comparator|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
16639546|NCT02351297|Experimental|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
16639547|NCT02351297|Experimental|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
16639548|NCT02351297|Placebo Comparator|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
16639549|NCT02351271|Experimental|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
16639550|NCT02351271|Active Comparator|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
16639551|NCT02351258|Experimental|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
16639552|NCT02351258|Experimental|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
16639553|NCT02351245||lip hemangiomas|
16639554|NCT02351232|Experimental|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
16639555|NCT02351232|Placebo Comparator|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
16639556|NCT02351219|Experimental|FOLFOXIRI|
16639557|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
16639558|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
16639559|NCT02351193||Group I|poor responder females with age less than 35
16639560|NCT02351193||Group II|poor responder females with age more than 35
16639561|NCT02351180|Experimental|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
16639562|NCT02351180|Placebo Comparator|Placebo|Inhaled placebo twice daily for 180 days.
16639563|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
16639564|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
16639565|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
16639566|NCT02351154|Other|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
16639567|NCT02351141|Other|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
16639568|NCT02351128|Experimental|Only one arm|All patients receive Lanreotide.
16639569|NCT02351115|Experimental|Sequence BEADC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
16639570|NCT02351115|Experimental|Sequence CDAEB|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
16639571|NCT02351115|Experimental|Sequence DEBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
16639572|NCT02351115|Experimental|Sequence EDBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
16639573|NCT02351115|Experimental|Sequence CABED|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
16639574|NCT02351102|Active Comparator|Valacyclovir|Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
16639575|NCT02351102|Placebo Comparator|Placebo|Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
16639576|NCT02351089|Placebo Comparator|Placebo|capsules containing corn starch
16639577|NCT02351089|Active Comparator|Probiotic low dose|capsules containing probiotic powder and corn starch
16639578|NCT02351089|Active Comparator|Probiotic high dose|capsules containing probiotic powder and corn starch
16639579|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
16639580|NCT02351050|Experimental|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
16639581|NCT02351050|Placebo Comparator|placebo|sham transcranial Doppler monitoring during endovascular procedure
16639583|NCT02351037|Experimental|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
16639584|NCT02351037|Experimental|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
16639585|NCT02351024|Experimental|OXP005|
16639586|NCT02351024|Active Comparator|Naproxen|
16639587|NCT02351011|Experimental|Cohort 1|1 x 10^6 MSCs
16639588|NCT02351011|Experimental|Cohort 2|10 x 10^6 MSCs
16639589|NCT02351011|Experimental|Cohort 3|50 x 10^6 MSCs
16639590|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
16639591|NCT02350985|Active Comparator|Propranolol|Propranolol up to 160 mg/day
16639592|NCT02350985|Active Comparator|Venlafaxine|Venlafaxine up to 150 mg/day
16639593|NCT02350972|Experimental|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
16639594|NCT02350959|Experimental|High dose statin|In high dose statin group, atorvastatin 40mg will be used
16639595|NCT02350959|Active Comparator|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
16639596|NCT02350946|Experimental|Cross over Oxytocin and Placebo|fMRI measurement and blood examinations following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14
16639597|NCT02350946|Experimental|Cross over Placebo and Oxytocin|fMRI measurement and blood examinations following placebo on day 1 and following 26 IU Oxytocin (Syntocinon) on day 14
16639598|NCT02350933|Other|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
16639599|NCT02350920|Active Comparator|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
16639600|NCT02350920|No Intervention|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
16639601|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
16639602|NCT02350868|Experimental|Arm 1|Subjects will be treated with oral doses of MPT0E028 in consecutive, 28-day cycles, and will be evaluated regularly for safety. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive MPT0E028 at the discretion of the principal Investigator for up to 6 cycles.
16639603|NCT02350855|Experimental|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
16639604|NCT02350855|Other|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
16639605|NCT02350842|Experimental|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
16639606|NCT02350842|Active Comparator|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
16639607|NCT02350829|Active Comparator|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy
~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
16639608|NCT02350829|Active Comparator|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan
~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
16639609|NCT02350829|Active Comparator|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
16639610|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
~HGT-SAN-093 = NCT02060526"
16639611|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
16639612|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
16639613|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
16639614|NCT02350803|Placebo Comparator|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
16639615|NCT02350803|Active Comparator|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
16639616|NCT02350790|Active Comparator|Robotic ablation|Half of the patients in the study will be randomized to robotic ablation of endometriosis with the argon beam coagulator (ABC).
16639617|NCT02350790|Active Comparator|Robotic Excision|Half of the patients in the study will be randomized to robotic excision of endometriosis.
16639618|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
16639619|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
16639620|NCT02350764|Experimental|Nivolumab|Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease*, withdrawal of consent, or death.
16639621|NCT02350751|Experimental|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
16639622|NCT02350751|Placebo Comparator|Placebo|Solution containing no active ingredients
16639623|NCT02350738|Experimental|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
16639624|NCT02350738|Experimental|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
16639625|NCT02350725|Experimental|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
16639626|NCT02350725|Experimental|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
16639627|NCT02350712|Experimental|All Participants - Period 1|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin) in Period 1 - Initial phase of the trial.
16639628|NCT02350712|Experimental|All Participants - Period 2|Participants deriving clinical benefit enter Period 2 - Extension phase, during which they continue to receive patritumab with cetuximab, but not platinum-based therapy.
16639629|NCT02350699||Control|Nautilus BrainPulse
16639630|NCT02350686|Experimental|capecitabine+oxaliplatin|XELOX every 3 weeks
16639631|NCT02350673|Experimental|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
16639632|NCT02350673|Experimental|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
16639633|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
16639634|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
16639635|NCT02350647|Experimental|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
16639636|NCT02350647|Active Comparator|Twinfix Ultra HA|Suture anchor for rotator cuff repair
16639637|NCT02350634|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
16639638|NCT02350621|Active Comparator|ACDF|Anterior Cervical Discectomy and Fusion
16639639|NCT02350621|Active Comparator|miPCF|minimal invasive Posterior Cervical Foraminotomy
16639640|NCT02350595|Experimental|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
16639641|NCT02350595|Experimental|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
16639642|NCT02350595|No Intervention|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
16639643|NCT02350582|Experimental|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
16639644|NCT02350582|No Intervention|Control group|usual care offered to patients during chemotherapy treatment
16639645|NCT02350569|Experimental|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
16639646|NCT02350556|Other|hemiplegic patients|Dynamic Avoidance Task
16639647|NCT02350556|Other|healthy volunteers|Dynamic Avoidance Task
16639648|NCT02350543|Active Comparator|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
16639649|NCT02350543|No Intervention|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
16639650|NCT02350530|Experimental|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
16639651|NCT02350530|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
16639652|NCT02350517|Experimental|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
16639653|NCT02350504|Experimental|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
16639654|NCT02350504|Placebo Comparator|Partial instruction|Partial instruction which included the booklet only.
16639655|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
16639656|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
16639657|NCT02350491||healthy group|Healthy pregnant woman.
16639658|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
16639659|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
16639660|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
16639661|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
16639662|NCT02350452|Experimental|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
16639663|NCT02350452|Active Comparator|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
16639664|NCT02350439|Experimental|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
16639665|NCT02350426|Experimental|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
16639666|NCT02350426|Experimental|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
16639667|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
16639668|NCT02350400|Experimental|DEBIRI|For unilobar disease, two treatments will be planned, separated by four weeks. For bilobar disease, there will be four treatments planned, alternating between right and left lobe, separated by 2 weeks duration.
16639669|NCT02350387|Experimental|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
16639670|NCT02350387|Experimental|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
16639671|NCT02350374|Other|carbohydrate counting|patients must fill their logbook during 28 days
16639672|NCT02350361|Experimental|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
16639673|NCT02350361|Active Comparator|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
16639674|NCT02350335|Active Comparator|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.
~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.
~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
16639675|NCT02350335|No Intervention|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
16639676|NCT02350335|No Intervention|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
16639677|NCT02350322|Experimental|Schoolmeal with fatty fish|Fatty fish diet
16639678|NCT02350322|Experimental|Schoolmeal without fish|Meat/cheese diet (non-seafood)
16639679|NCT02350322|Experimental|Supplement|Omega-3 capsules
16639680|NCT02350309|Experimental|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
16639681|NCT02350309|Experimental|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
16639682|NCT02350309|Placebo Comparator|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
16639683|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
16639684|NCT02350296|Experimental|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release tablets 40 mg, corresponding to 25 mg of ketoprofen free acid
16639685|NCT02350296|Active Comparator|OKi® 80 mg|OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid)
16639686|NCT02350283|Experimental|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
16639687|NCT02350283|No Intervention|Medical treatment|Standard medical treatment alone.
16639688|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
16639689|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
16640064|NCT02347696|Other|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
16639690|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
16639691|NCT02350257|Experimental|ICBT|Internet-based cognitive behavior therapy
16639692|NCT02350257|No Intervention|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
16639693|NCT02350244|Experimental|Experimental group|Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work
16639694|NCT02350244|Other|Control group|Control group patients had no intervention
16639695|NCT02350231|Active Comparator|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
16639696|NCT02350231|Placebo Comparator|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
16639697|NCT02350218|Experimental|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
16639698|NCT02350218|Active Comparator|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
16639699|NCT02350205|Experimental|Treatment (SASS)|All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
16639700|NCT02350205|Active Comparator|Control (split-thickness autograft)|All patients will receive both SASS and Split-thickness autograft (paired samples).
16639701|NCT02350192|Experimental|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
16639702|NCT02350192|No Intervention|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
16639703|NCT02350179|Experimental|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
16639704|NCT02350179|Placebo Comparator|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
16639705|NCT02350166|Experimental|Laparoscopic group|Laparoscopic group, laparoscopic surgery or laparoscopic-assisted small-incision for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis
16639706|NCT02350166|No Intervention|Conventional group|Conventional group, conventional laparotomy for simultaneously resection of both primary colorectal tumor and liver metastasis
16639707|NCT02350153||Patients with verified Cushing's Disease|Patients with verified Cushing's Disease
16639708|NCT02350140|Experimental|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
16639709|NCT02350140|Active Comparator|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
16639710|NCT02350127|Experimental|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
16639711|NCT02350127|Active Comparator|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
16639712|NCT02350114|Experimental|Functional Capacity|6 Minute Walk Test
16639713|NCT02350088|Active Comparator|Fast-track Surgery|probiotics,oral,b.i.d.
16639714|NCT02350088|Active Comparator|Traditional Group|placebo,oral,b.i.d.
16639715|NCT02350075|Experimental|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
16639716|NCT02350075|Other|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
16639717|NCT02350049||Investigational|Cementless Medial Partial Knee
16639718|NCT02350049||Control|Cemented Medial Partial Knee
16639719|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
16639720|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
16639721|NCT02350023|Active Comparator|Topical latanoprost|Topical latanoprost 0.005%
16639722|NCT02350023|Active Comparator|Topical betamethasone|Topical betamethasone 0.05%
16639758|NCT02349750|No Intervention|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
16639759|NCT02349737||Electromagnetic Interference|
16639760|NCT02349724|Other|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
16639723|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.
~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.
~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
16639724|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.
~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.
~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
16639725|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
16639726|NCT02349958|Other|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
16639727|NCT02349958|Other|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
16639728|NCT02349958|Other|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
16639729|NCT02349958|Other|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
16639730|NCT02349945|Experimental|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
16639731|NCT02349945|Experimental|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
16639732|NCT02349932||Healthy Adults|The following samples will be collected: fecal, blood, and saliva
16639733|NCT02349919|Experimental|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
16639734|NCT02349919|Placebo Comparator|Placebo|Placebo twice daily for 4 weeks
16639735|NCT02349906|Experimental|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.
~The dose has to be calculated as follows:
~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.
~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.
~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
16639736|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
16639737|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
16639738|NCT02349880|Active Comparator|control|5 hour cognitive training
16639739|NCT02349880|Experimental|intervention|5 hour shared decision making training
16639741|NCT02349854||Cases|patients with scalp itch and seborrheic dermatitis who will get biopsy
16639742|NCT02349854||Controls|patients without scalp itch and without seborrheic dermatitis who will get biopsy
16639743|NCT02349841|Experimental|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
16639744|NCT02349841|Experimental|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
16639745|NCT02349841|Active Comparator|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
16639746|NCT02349828|Active Comparator|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
16639747|NCT02349828|No Intervention|No treatment|standard of care
16639748|NCT02349815||Group 1|Women prescribed JAYDESS in Sweden
16639749|NCT02349802|Experimental|Arm 1|exenatide suspension - 9 mg / 0.85 mL
16639750|NCT02349802|Experimental|Arm 2|exenatide suspension - 9 mg / 0.85 mL
16639751|NCT02349802|Experimental|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
16639752|NCT02349802|Experimental|Arm 4|exenatide suspension - 9 mg / 1.1 mL
16639753|NCT02349802|Experimental|Arm 5|exenatide suspension - 9 mg / 1.5 mL
16639754|NCT02349776|Experimental|All patients for allograft transplant|For the testimonial part all patients who have received an allograft transplant in the last five years will be eligible for participation if they have capacity to consent and can speak English fluently.
16639755|NCT02349763|Active Comparator|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
16639756|NCT02349763|Experimental|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
16639757|NCT02349750|Active Comparator|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
16639761|NCT02349724|Other|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
16639766|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16639767|NCT02349698|Other|Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells targeting CD19.
16639768|NCT02349698|Other|Chronic Lymphcytic Leukemia|Chronic lymphocytic leukemia with chimeric antigen receptor modified T cells targeting CD19.
16639769|NCT02349698|Other|Non-Hodgkin Lymphoma|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells targeting CD19.
16639770|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
16639771|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
16639772|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
16639773|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
16639774|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
16639775|NCT02349659|No Intervention|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
16639776|NCT02349659|Active Comparator|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
16639777|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
16639778|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
16639779|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
16639780|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
16639781|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
16639782|NCT02349620|Active Comparator|A:partialy edutolus patients|In this group surface treated implant with PRF will be inserted.Immediately after the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequency analysis (RFA), using the smart peg type 1, then stability will be measured every 2 weeks up to 3 months .Bone height will be measured in mesial and distal side immediately after placement and in months 3 and 6 with Intra Oral Peri Apical xray (IOPA x-ray)
16639783|NCT02349620|Placebo Comparator|B: partialy edutolus patients|In this group implant with out PRF will be inserted.Immediately after the surgery the implant stability will be measured with the Osstell mentor to verify the resonance frequence analysis (RFA ), using the smartpeg type 1, then stability will be measured every 2 weeks up to 3 months. Bone height was measured in mesial and distal side immediately after placement and in months 3 and 6 with IOPA xray
16639784|NCT02349607|Experimental|PF-05089771 300 mg|
16639785|NCT02349607|Experimental|PF-05089771 300 mg + pregabalin 300 mg|
16639786|NCT02349607|Placebo Comparator|Placebo|
16639787|NCT02349607|Active Comparator|pregabalin 300 mg|
16639788|NCT02349607|Active Comparator|ibuprofen 600 mg|
16639789|NCT02349594|Active Comparator|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
16639790|NCT02349594|Active Comparator|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
16639791|NCT02349581|Experimental|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
16639792|NCT02349581|No Intervention|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
16639793|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
16639794|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
16639795|NCT02349555|Experimental|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
16639796|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
16639797|NCT02349529|Experimental|Psychosocial group intervention|
16639798|NCT02349529|Other|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
16639799|NCT02349516|Experimental|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
16639800|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
16640030|NCT02347904|Experimental|Adjuvant S-1 and Oxaliplatin|Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer
16639801|NCT02349516|Experimental|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
16639802|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
16639803|NCT02349503|Experimental|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
16639804|NCT02349503|Experimental|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
16639805|NCT02349503|Experimental|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
16639806|NCT02349490|Active Comparator|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
16639807|NCT02349490|Active Comparator|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
16639808|NCT02349477|Experimental|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
16639809|NCT02349477|Placebo Comparator|placebo|matching placebo
16639810|NCT02349464|Active Comparator|Intervention|For infants receiving pediatric care at one of the seven intervention practices, mothers will receive the Specialized Preterm Infant/Mother Dyad Lactation Support which includes home equipment and pediatric clinic-lactation support to support lactation for four months post-hospital discharge.
16639811|NCT02349464|No Intervention|Control|For infants receiving pediatric care at one of the seven control practices, mothers will receive standard support.
16639812|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
16639813|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
16639814|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
16639815|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
16639816|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
16639817|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
16639818|NCT02349425|Experimental|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
16639819|NCT02349425|Experimental|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
16639820|NCT02349425|Experimental|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
16639821|NCT02349425|Experimental|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
16639822|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
16639823|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
16639824|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
16639825|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
16639826|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
16639827|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
16639828|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
16639829|NCT02349373|Active Comparator|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed >80% VO2max (maximal oxygen uptake).
16639830|NCT02349373|Active Comparator|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.
~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
16639831|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
16639832|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
16639833|NCT02349334|Sham Comparator|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
16639834|NCT02349334|Active Comparator|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
16640062|NCT02347696|Other|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
16639835|NCT02349321|Experimental|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
16639836|NCT02349321|Experimental|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.
~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
16639837|NCT02349321|No Intervention|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
16639838|NCT02349308||CentrosFLO Long Term Hemodialysis Catheter|Schedule placement of catheter. Arterial tip of the catheter should be placed at or just above the junction of the right atrium and superior vena cava, with the arterial lumen on the left side of the catheter. The venous limb will extend into the right atrium. Catheter will be locked with the usual heparin lock solution for a newly placed catheter (at least 500 units per lumen). Fluoroscopic images will document tip position.
16639839|NCT02349295|Experimental|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
16639840|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
16639841|NCT02349295|Placebo Comparator|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
16639842|NCT02349282|Experimental|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
16639843|NCT02349282|Experimental|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
16639844|NCT02349282|Placebo Comparator|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
16639845|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
16639846|NCT02349243|Experimental|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
16639847|NCT02349243|Placebo Comparator|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
16639848|NCT02349230|Experimental|Astym treatment|Astym treatment is a manual therapy intervention applied by certified therapists with specialized instruments
16639849|NCT02349230|Sham Comparator|Sham Astym|A sham Astym treatment applied with non-therapeutic pressure and
16639850|NCT02349230|No Intervention|Control|12 minutes of rest
16639851|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
16639919|NCT02348788|Active Comparator|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet.
~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, <35kg = 0.5mg/kg"
16639852|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.
~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
16639853|NCT02349204|Experimental|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
16639854|NCT02349204|No Intervention|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
16639855|NCT02349191|Experimental|Interventional cohort|Omental transposition for mild Alzheimers Disease
16639856|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
16639857|NCT02349165|Active Comparator|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
16639858|NCT02349165|Experimental|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
16639859|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
16639860|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
16639861|NCT02349139|Experimental|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
16639862|NCT02349126|Experimental|Treatment Group|ARC-520 Injection
16639863|NCT02349113|Experimental|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
16639864|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
16639865|NCT02349074|Experimental|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
16639866|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
16639867|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
16639868|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
16639869|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
16639870|NCT02349035|Experimental|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
16639871|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
16639872|NCT02349009|Placebo Comparator|placebo|C-82 Topical Gel, Placebo
16639873|NCT02349009|Active Comparator|Active|C-82 Topical Gel, 1%
16639874|NCT02348996|Other|Clinical assessment|Patients would have dry weight determined by clinical evaluation (blood pressure levels, peripheral edema, pulmonary auscultation and symptoms).
16639875|NCT02348996|Experimental|Bioimpedance|Patients would have dry weight determined according to volume status with a body composition monitor (BCM)
16639876|NCT02348983|Experimental|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
16639877|NCT02348970|Experimental|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
16639878|NCT02348970|Active Comparator|laboratory devices TALI|The patients will use the laboratory devices TALI
16639879|NCT02348944||15 healthy volunteers|Other: serum and urine sample
16639880|NCT02348931|Active Comparator|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
16639881|NCT02348931|Experimental|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
16639882|NCT02348931|Active Comparator|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
16639883|NCT02348918|Active Comparator|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
16639884|NCT02348918|Active Comparator|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
16639885|NCT02348918|Active Comparator|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
16639886|NCT02348918|Active Comparator|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
16639887|NCT02348918|Active Comparator|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
16639888|NCT02348918|Active Comparator|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
16639889|NCT02348918|Active Comparator|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
16639890|NCT02348918|Active Comparator|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
16639891|NCT02348918|Active Comparator|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
16639892|NCT02348905|Experimental|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
16639893|NCT02348905|Experimental|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
16639894|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
16639895|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
16639896|NCT02348879|Experimental|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
16639897|NCT02348879|Placebo Comparator|Placebo|No active drug
16639898|NCT02348866|Active Comparator|Group 1|home laundered/home-donned
16639899|NCT02348866|Active Comparator|Group 2|Hospital laundered/home-donned
16639900|NCT02348866|Active Comparator|Group 3|Home laundered/hospital donned
16639901|NCT02348866|Active Comparator|Group 4|Hospital laundered/hospital donned
16639902|NCT02348853|Experimental|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
16639903|NCT02348853|Experimental|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
16639904|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
16639905|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
16639906|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
16639907|NCT02348827|Experimental|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
16639908|NCT02348827|Active Comparator|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
16639909|NCT02348814||normal weight|BMI 20-25
16639910|NCT02348814||overweight|BMI 25-30
16639911|NCT02348814||obese|BMI 30-35
16639912|NCT02348814||morbidly obese|BMI > 35
16639913|NCT02348814||non-diabetic|HgbA1c (<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
16639914|NCT02348814||diabetic|HgbA1c (>6.5%) and blood glucose (>100 mg/dL) as defined at UCLA Clinical Lab
16639915|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
16639916|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol >170 mg/dL, LDL >100 mg/dL, HDL >130 mg/dL, triglycerides >150 mg/dL) as defined at UCLA Clinical Lab
16639917|NCT02348801|Active Comparator|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
16639918|NCT02348801|Experimental|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
16640063|NCT02347696|Other|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
16639920|NCT02348788|Active Comparator|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.
~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, 10-35kg = 0.5mg/kg"
16639921|NCT02348775|Experimental|GlyNAC|HIV infected subjects will be studied before and after taking oral glycine and n-acetylcysteine for 3 months
16639922|NCT02348762|Experimental|Cysteine/glycine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
16639923|NCT02348749|Experimental|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. Patients who show lesion detection by MFBG may be eligible for repeat imaging scan with 18 F- MFBG, at the discretion of PI or study investigator(s). All parameters and technical details of scanning will be as per the study and first imaging.
16639924|NCT02348736|Experimental|SensaScope|Time for tracheal intubation with the SensaScope
16639925|NCT02348736|Experimental|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
16639926|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
16639927|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
16639928|NCT02348710|Experimental|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
16639929|NCT02348710|Active Comparator|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
16639930|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
16639931|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
16639932|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
16639933|NCT02348645|Active Comparator|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
16639934|NCT02348645|Active Comparator|Decompression alone|Midline-sparing spinal decompression alone
16639935|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
16639936|NCT02348619|Active Comparator|75, 150, 300 mg of JZP-110|Once Daily Dosing
16639937|NCT02348619|Active Comparator|Placebo|Once Daily Dosing
16639938|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
16639939|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
16639940|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
16639941|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
16639942|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
16639943|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
16639944|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
16639945|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
16639946|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
16639947|NCT02348580|No Intervention|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
16639948|NCT02348580|Experimental|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
16639949|NCT02348567|Active Comparator|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
16639950|NCT02348567|Experimental|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
16639951|NCT02348554|Experimental|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
16639952|NCT02348554|Experimental|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
16639953|NCT02348541|Other|CollaGUARD|
16639992|NCT02348268|Active Comparator|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
16640065|NCT02347696|Other|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
16639954|NCT02348528|Experimental|Lenalidomide and dexamethasone|"Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
~The starting doses of Rd regimen will be the same last doses that the subjects received in Study CC-5013-MM-021, unless event(s) that require dose adjustments (dose modifications, reductions and interruptions) per protocol occurred prior to roll-over."
16639955|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
16639956|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
16639957|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
16639958|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
16639959|NCT02348489|Experimental|SGI-110 (guadecitabine)|Guadecitabine 60 mg/m^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.
16639960|NCT02348489|Active Comparator|Treatment Choice|One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.
16639961|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
16639962|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
16639963|NCT02348450|Experimental|Irinotecan plus Cisplatin|first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
16639964|NCT02348450|Experimental|Etoposide plus Cisplatin|first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
16639965|NCT02348437|Experimental|Repair|Repair of the pronator quadratus muscle
16639966|NCT02348437|Active Comparator|Non-repair|Non-repair of the pronator quadratus muscle
16639967|NCT02348424|Experimental|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
16639968|NCT02348424|Experimental|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
16639969|NCT02348411|Experimental|ExAblate Treatment group|
16639970|NCT02348398|Experimental|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.
~During follow up if disease gets worse, participant called by study staff every 3 months."
16639971|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
16639972|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
16639973|NCT02348372|Placebo Comparator|GSK1278863A Placebo|5, 25 and 100 mg matched
16639974|NCT02348372|Experimental|GSK1278863A 10mg|A round, biconvex, white film coated tablet
16639975|NCT02348372|Experimental|GSK1278863A 25mg|A round, biconvex, white film coated tablet
16639976|NCT02348372|Experimental|GSK1278863A 50mg|A round, biconvex, white film coated tablet
16639977|NCT02348372|Experimental|GSK1278863A 100mg|A round, biconvex, white film coated tablet
16639978|NCT02348359|Experimental|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
16639979|NCT02348359|Experimental|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
16639980|NCT02348359|Experimental|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
16639981|NCT02348359|Placebo Comparator|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
16639982|NCT02348333|Active Comparator|FYU-981|
16639983|NCT02348333|Placebo Comparator|Placebo|
16639984|NCT02348320|Experimental|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
16639985|NCT02348307|Active Comparator|FYU-981|
16639986|NCT02348307|Placebo Comparator|Placebo|
16639987|NCT02348294|Other|Healthy volunteers|Shear- force 19 newton and 3,9 kpa pressure for half an hour
16639988|NCT02348294|Other|Diabetes Mellitus type 2 without neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
16639989|NCT02348294|Other|Diabetes Mellitus type 2 with neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
16639990|NCT02348294|Other|Charcot Osteoarhtopathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
16639991|NCT02348281|Experimental|bicalutamide|150mg, po, qd, d1-28
16640025|NCT02347995|Experimental|Resistive Training + Protein|Participants will drink 30 grams of whey protein after each resistance training session.
16640026|NCT02347969|Experimental|X34|Arm supplemented with X34
16639993|NCT02348268|Experimental|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
16639994|NCT02348255|Experimental|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
16639995|NCT02348242|Experimental|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
16639996|NCT02348242|Experimental|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
16639997|NCT02348229|Experimental|ERAS group|ERAS protocols
16639998|NCT02348229|Other|conventional pathway group|using conventional pathway
16639999|NCT02348216|Experimental|Axicabtagene Ciloleucel|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.
16640000|NCT02348203|Experimental|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
16640001|NCT02348203|Placebo Comparator|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
16640002|NCT02348190|Active Comparator|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
16640003|NCT02348190|Placebo Comparator|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
16640004|NCT02348177|Experimental|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
16640005|NCT02348164|Experimental|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
16640006|NCT02348164|Experimental|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
16640007|NCT02348151|Experimental|Treadmill|The Shuttle is going to play on treadmill
16640008|NCT02348151|Active Comparator|Corridor|The Shuttle is going to play on corridor
16640009|NCT02348138|Experimental|Home-based isometric handgrip training|All participants that will be assigned to home-based isometric handgrip training (HBT) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction; however, the training will be performed without daily supervision. Therefore, the subjects will receive a logbook to record the exercise sessions. In addition, visits will be scheduled at weeks 1, 3, 6, 9 and 11 to provide feedback to individuals and discuss potential problems in conducting training.
16640010|NCT02348138|Experimental|Supervised isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training (ST) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction with. The training will be performed with daily supervision.
16640011|NCT02348138|No Intervention|Control group|Subjects randomized to the control group (CG) will be encouraged to increase the level of physical activity and make healthy eating, without, however, receive specific recommendations
16640012|NCT02348125|Experimental|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:
~ubiquinol (liquid form, 150 mg/kg subject weight/day
~carnitine, 50 mg/kg subject weight/day
~alpha-lipoic acid, 100 mg/ day"
16640013|NCT02348112||Altis Sling|Subjects will have an Altis sling placed to treat stress urinary incontinence.
16640014|NCT02348112||Transobturator or Retropubic Sling|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
16640015|NCT02348073|Active Comparator|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
16640016|NCT02348073|Placebo Comparator|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
16640017|NCT02348047|Active Comparator|Conventional ventilation|Conventional ventilation - manual mode
16640018|NCT02348047|Experimental|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
16640019|NCT02348034|Experimental|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
16640020|NCT02348034|No Intervention|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
16640021|NCT02348021|Other|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
16640022|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.
~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.
~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
16640023|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
16640024|NCT02347995|Placebo Comparator|Resistive Training|Participants will drink a placebo beverage after each resistance training session.
16640031|NCT02347891|Experimental|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.
~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
16640032|NCT02347891|Active Comparator|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.
~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
16640033|NCT02347878|Experimental|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
16640034|NCT02347878|No Intervention|control arm|this arm will received nothing 1 hour before lumbar puncture
16640035|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
16640036|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
16640037|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
16640038|NCT02347839|Experimental|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
16640039|NCT02347813|Other|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
16640040|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
16640041|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
16640042|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
16640043|NCT02347774|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
16640044|NCT02347774|Experimental|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
16640045|NCT02347774|Placebo Comparator|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
16640046|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
16640047|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
16640048|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
16640049|NCT02347748|Experimental|Group A - Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
16640050|NCT02347748|Experimental|Group B - Reading pre-extubation script|Patients will be read a pre-extubation script;
16640051|NCT02347748|Experimental|Group C - Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area Patients will be read a pre-extubation script
16640052|NCT02347748|No Intervention|Group D|Patients will not be read any script
16640053|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
16640054|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
16640055|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
16640056|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
16640057|NCT02347722||Healthy volunteers|Age matched healthy volunteers for comparison with heart failure patients
16640058|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
16640059|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
16640060|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
16640061|NCT02347696|Other|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
16640192|NCT02346890|Experimental|AZD1722 alone|15 mg BID
16640066|NCT02347696|Other|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
16640067|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
16640068|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
16640069|NCT02347670|Active Comparator|Group 1M- Community Site|"Participants randomized to Group 1-Main will attend follow-up visits at one of the four main community sites. A glaucoma specialist will perform the comprehensive eye examination and a ophthalmic technician will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.
~Intervention: Efficacy-patient navigator to improve follow-up adherence"
16640070|NCT02347670|Active Comparator|Group 2- Office-Based|"Office-Based, Follow-Up Eye Care with Patient Navigation Protocol: Participants randomized to Group 2 will attend follow-up visits at the Wills Eye Hospital Glaucoma Research Center. A glaucoma specialist will perform the eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.
~Intervention: Efficacy-patient navigator to improve follow-up adherence"
16640071|NCT02347670|Active Comparator|Group 3- Office-Based|"Group 3- follow-up eye care at the Wills Eye Hospital. There will be no charge or co-pay for these visits. Those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire. These participants will receive a phone number to call and schedule their appointment and will receive a reminder phone call similar to the standard appointment-reminding procedure commonly used at the Wills Eye Hospital. Group 3 represents a realistic choice currently available for patients and thus will be used to compare with usual care and will have 2-3 visits over the one-year period depending on diagnosis.
~Intervention: Office-Based Usual Care"
16640072|NCT02347670|Active Comparator|Group 1R- Community Site|"Participants randomized to Group 1-Randomized will attend follow-up visits at one of the four main community sites, these participants were randomized from the 40 community sites to the closest community location. A glaucoma specialist will perform the comprehensive eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.
~Intervention: Efficacy-patient navigator to improve follow-up adherence"
16640073|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
16640074|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
16640075|NCT02347644|Experimental|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
16640076|NCT02347644|No Intervention|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
16640077|NCT02347631|Experimental|Alcon DAILIES TOTAL1, and ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
16640078|NCT02347631|Active Comparator|ACUVUE TruEye and Alcon Dailies Total 1|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
16640079|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
16640080|NCT02347605|Experimental|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
16640081|NCT02347605|Placebo Comparator|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
16640082|NCT02347605|Other|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
16640083|NCT02347592|Active Comparator|straight Tenckhoff|The straight Tenckhoff catheter (sT) is the most common used catheter for peritoneal dialysis (PD).
16640084|NCT02347592|Active Comparator|self-locating catheter|A new, more expensive, self-locating catheter (sLC) has been developed by Di Paolo.
16640085|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
16640086|NCT02347579||Patients with CLBP|Patients with chronic low back pain
16640087|NCT02347579||Healthy controls|
16640088|NCT02347566|Experimental|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, [S]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
16640089|NCT02347566|Other|Control|Usual care (control, [C]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
16640090|NCT02347540||PE|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.
~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
16640193|NCT02346890|Experimental|AD1722 with Renvela|AZD1722 15 mg BID and Renvela 800 mg TID
16640091|NCT02347540||Control|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
16640092|NCT02347527|Experimental|Active Implicit Priming|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
16640093|NCT02347527|Placebo Comparator|Control Implicit Priming|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
16640094|NCT02347514|Experimental|Diabetes Group Visit|"Subjects in this arm will be asked to attend one group visit at their health center each month for six months. The group visits will involve various staff and providers at the health center who will teach them how to take care of their diabetes. Subjects will be scheduled to attend the same group visit appointments as the other subjects, and health center staff will encourage the group to share their own experiences about living with diabetes with the rest of the group.
~If subjects at the health center additionally implementing the text-messaging intervention consent to enroll in the study, their phone number will also be entered into a secure system that will allow the group visit healthcare team to send them text messages during the course of the six months they are in the program. These text messages are intended to offer the subjects additional support in taking care of their diabetes."
16640095|NCT02347514|No Intervention|Usual care|Patients in the control arm will be selected after the follow-up period is over for the intervention arm. They will receive the care they normally receive at their health center.
16640096|NCT02347501|Experimental|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.
~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
16640097|NCT02347501|No Intervention|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.
~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
16640098|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
16640099|NCT02347462|Experimental|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
16640100|NCT02347462|Active Comparator|Standard care alone|Standard care according to the hospital's severe asthma protocol
16640101|NCT02347449|Experimental|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
16640102|NCT02347436||benign prostatic hypertrophy|patients who are diagnosed with lower urinary tract symptoms caused by prostatic hypertrophy, undergo transurethral resection of the prostate, and post-surgery 24-hr ambulatory blood pressure measurement.
16640103|NCT02347436||inguinal hernia or hydrocele|patients who are diagnosed with lower urinary tract symptoms caused by inguinal hernia or hydrocele, undergo surgical inguinal hernia repair or hydrocele repair, and post-surgery 24-hr ambulatory blood pressure measurement
16640104|NCT02347423|Experimental|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
16640105|NCT02347423|Experimental|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
16640106|NCT02347423|Experimental|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
16640107|NCT02347423|Active Comparator|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
16640109|NCT02347397|Experimental|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head & SL-TWIN Stem
16640110|NCT02347397|Active Comparator|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head & SL-PLUS Stem
16640111|NCT02347384|Experimental|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
16640112|NCT02347384|Active Comparator|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
16640113|NCT02347358|Experimental|IV r-tPA with JRecanTM blood FR device|Dual IV r-tPA therapy and adjunctive treatment with JRecanTM blood flow recanalisation device
16640114|NCT02347358|Active Comparator|IV r-tPA|IV infusion of r-tPA
16640115|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
16640116|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
16640117|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
16640118|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
16640119|NCT02347332|Active Comparator|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
16640120|NCT02347319|Experimental|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
16640121|NCT02347319|Active Comparator|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
16640122|NCT02347319|Placebo Comparator|Placebo|This group will treated with Placebo for 12 weeks.
16640123|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
16640124|NCT02347293|Experimental|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
16640125|NCT02347293|Experimental|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
16641425|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure; Stop SMS if Success|
16640126|NCT02347280|Experimental|Loop ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
16640127|NCT02347280|Active Comparator|Total abdominal colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
16640128|NCT02347267|Experimental|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
16640129|NCT02347267|Active Comparator|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
16640130|NCT02347267|No Intervention|All beverages|Beverages were not restricted
16640131|NCT02347254|Experimental|Transcranial ExAblate|Transcranial ExAblate MRgFUS
16640132|NCT02347241|No Intervention|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
16640133|NCT02347241|Experimental|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
16640134|NCT02347228|Experimental|OB318 capsule|
16640135|NCT02347215|Other|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
16640136|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
16640137|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
16640138|NCT02347189|Other|Melody TPV PB1016|
16640139|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
16640140|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
16640141|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
16640142|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
16640143|NCT02347163|Experimental|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
16640144|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
16640145|NCT02347137|Active Comparator|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
16640146|NCT02347137|Experimental|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
16640147|NCT02347137|Experimental|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
16640148|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
16640149|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
16640150|NCT02347111|Experimental|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
16640151|NCT02347111|Experimental|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
16640152|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
16640153|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
16640154|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
16640155|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
16640156|NCT02347072|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
16640157|NCT02347072|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
16640158|NCT02347072|Active Comparator|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
16640159|NCT02347059|Experimental|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
16640160|NCT02347059|Active Comparator|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
16640161|NCT02347046|Experimental|Moderately-decreased group|(eGFR: >=30mL/min/1.73m^2 and < 60mL/min/1.73m^2)
16640162|NCT02347046|Experimental|Slightly-decreased group|(eGFR: >=60mL/min/1.73m^2 and < 90mL/min/1.73m^2)
16640163|NCT02347046|Experimental|Normal group|(eGFR: >=90mL/min/1.73m^2)
16640164|NCT02347033|Active Comparator|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
16640279|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
16640165|NCT02347033|Active Comparator|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
16640166|NCT02347020|Experimental|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
16640167|NCT02347020|Experimental|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
16640168|NCT02347020|Experimental|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
16640169|NCT02347020|Experimental|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
16640170|NCT02347007|Experimental|Almond|
16640171|NCT02347007|Active Comparator|Cereal Bar|
16640172|NCT02346994|Experimental|Melt test blend 3.2|
16640173|NCT02346994|Active Comparator|Corn Oil|
16640174|NCT02346981|Experimental|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
16640175|NCT02346981|No Intervention|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
16640176|NCT02346968||All study participants|Patients with end stage renal disease (ESRD) planned to undergo kidney transplantation.
16640177|NCT02346955|Experimental|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
16640178|NCT02346955|Experimental|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
16640179|NCT02346955|Experimental|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
16640180|NCT02346955|Experimental|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
16640181|NCT02346955|Experimental|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
16640182|NCT02346955|Experimental|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
16640183|NCT02346955|Experimental|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
16640184|NCT02346955|Experimental|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
16640185|NCT02346955|Experimental|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
16640186|NCT02346942||Patients who have no history of bDMARD therapy use|
16640187|NCT02346942||Patients who have a prior history of bDMARD therapy use|
16640188|NCT02346929|Experimental|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
16640189|NCT02346929|No Intervention|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
16640190|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
16640191|NCT02346903|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
16640194|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
16640195|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
16640196|NCT02346864|Experimental|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
16640197|NCT02346864|Other|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
16640198|NCT02346851|Experimental|triggered FES|
16640199|NCT02346851|Active Comparator|conventional FES|
16640200|NCT02346851|No Intervention|control group|
16640201|NCT02346838|Experimental|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
16640202|NCT02346838|Placebo Comparator|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
16640203|NCT02346825|Experimental|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
16640204|NCT02346825|Experimental|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
16640205|NCT02346825|Experimental|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
16640206|NCT02346812|Experimental|Brassica|Brassica vegetables will be consumed daily as part of a controlled diet.
16640207|NCT02346812|Other|Control|Typical American diet will be consumed, without any Brassica vegetables.
16640208|NCT02346799|Experimental|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
16640209|NCT02346799|Experimental|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
16640210|NCT02346799|Experimental|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
16640211|NCT02346799|Experimental|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
16640212|NCT02346799|No Intervention|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
16640213|NCT02346786|Experimental|Mineral Water|mineral water
16640214|NCT02346786|Active Comparator|Tap Water|usual water intake
16640215|NCT02346773|Active Comparator|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
16640216|NCT02346773|Placebo Comparator|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
16640217|NCT02346760|Experimental|UB-621|Intervention drug: UB-621
16640220|NCT02346734|Active Comparator|MSHAT|The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and the intervention group will receive access to the MSHAT system via a website in which they will utilize each day. The study participants in the intervention group will login to the MSHAT system, go through a pre-exercise symptom diary to determine their eligibility to exercise, perform exercise while watching a video demonstration and report results real-time. The intervention group will also be able to send and receive messages via the MSHAT system. The time to complete the daily exercises will vary from patient to patient ranging for 10-30 minutes.
16640280|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
16640340|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
16640221|NCT02346734|No Intervention|Control|The study participants randomized to group 2 will serve as the control. The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and will be given a paper diary to report their exercise completion. The control group will bring their paper diary showing their exercise completion results to their 3 month and 6 month follow-up visits.
16640222|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16640223|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
16640224|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
16640225|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
16640226|NCT02346695||Controls|Normotensive individuals
16640227|NCT02346682|Active Comparator|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.
~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
16640228|NCT02346682|Active Comparator|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.
~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
16640229|NCT02346682|No Intervention|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
16640230|NCT02346669|Active Comparator|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:
~at time 0
~after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
16640231|NCT02346669|Sham Comparator|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:
~at time 0
~after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
16640232|NCT02346669|Active Comparator|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:
~at time 0
~after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
16640233|NCT02346656||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
16640234|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
16640235|NCT02346630|Active Comparator|Levodopa / Carbidopa + Armeo|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
16640236|NCT02346630|Placebo Comparator|Placebo + Armeo|Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
16640237|NCT02346617|Experimental|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
16640238|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
16640239|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
16640240|NCT02346591|Experimental|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
16640241|NCT02346591|Active Comparator|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
16640242|NCT02346578|Experimental|Enzalutamide|Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
16640243|NCT02346578|Active Comparator|Flutamide|Flutamide 125 mg administered orally three times a day as one tablet after meal
16640244|NCT02346565|Other|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, >2mm ST depression on ECG), hypertension (systolic BP>220mmHg), hypotension, pre-syncope or arrhythmia.
16640245|NCT02346565|Other|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.
~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.
~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
16640246|NCT02346552|Experimental|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
16640247|NCT02346552|No Intervention|Group 2|Procedures will be performed with the assistance of human camera holder.
16640248|NCT02346539|Experimental|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.
~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
16640249|NCT02346539|Placebo Comparator|Placebo|Placebo comparator
16640250|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.
~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.
~Blood Tests
~CT scan
~Bone scan
~FACBC PET/MRI in a subset of participants"
16640251|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)
~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)
~Subgroup A3: Consist of bilateral ceramic on metal THAs"
16640252|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
16640253|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
16640254|NCT02346500|Experimental|Transrectal ultrasound|TRUS and TRUS-Robot will be used during PVP
16640255|NCT02346487|Experimental|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
16640256|NCT02346461|Active Comparator|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
16640257|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
16640258|NCT02346448|Active Comparator|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
16640259|NCT02346448|Active Comparator|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
16640260|NCT02346448|Active Comparator|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
16640264|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
16640265|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
16640266|NCT02346409|Experimental|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
16640267|NCT02346409|Active Comparator|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
16640268|NCT02346396|Experimental|Patients with neuropathic chronic pain|
16640269|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
16640270|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
16640271|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
16640272|NCT02346370|Experimental|PEGPH20 + Docetaxel|PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m^2)) was administered on Day 2 of each 21-day cycle.
16640273|NCT02346357|Active Comparator|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
16640274|NCT02346357|Placebo Comparator|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
16640275|NCT02346331|Experimental|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
16640276|NCT02346331|No Intervention|Standard care|This arm will be managed per standard care by the hospital clinicians.
16640277|NCT02346318|Experimental|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
16640278|NCT02346318|No Intervention|Control arm|Radiation and chemotherapy
16640305|NCT02346123||Single group|Group which contains all the patients of the study.
16641426|NCT02338739|Active Comparator|SMS; Navigator if Failure|
16640281|NCT02346266|Active Comparator|SMART|The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
16640282|NCT02346266|No Intervention|Usual Care|This group will not receive stroke education.
16640283|NCT02346253|Experimental|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
16640284|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
16640285|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
16640286|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
16640287|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
16640288|NCT02346227|Active Comparator|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
16640289|NCT02346227|Placebo Comparator|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
16640290|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
16640291|NCT02346201|Active Comparator|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
16640292|NCT02346201|Placebo Comparator|Placebo|Matching over-encapsulated placebo and psychosocial intervention
16640293|NCT02346188|Experimental|Ferrous fumarate|Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
16640294|NCT02346188|Experimental|Zinc oxide|Tablet formulated as zinc oxide, 30 mg. Given once daily by mouth for 6 months.
16640295|NCT02346188|Experimental|Ferrous fumarate and zinc oxide|Tablet, formulated as ferrous fumarate 30 mg plus zinc oxide 30 mg. Given once daily by mouth for 6 months.
16640296|NCT02346188|Placebo Comparator|Placebo|Sugar tablet formulated to look like the experimental arms of the study. Given daily by mouth for 6 months.
16640297|NCT02346175|Experimental|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
16640298|NCT02346175|Experimental|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
16640299|NCT02346175|Experimental|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
16640300|NCT02346162|Experimental|Intervention|Weight management intervention
16640301|NCT02346162|Other|Usual Care Control|Usual Care for planning healthy pregnancy
16640302|NCT02346149|Other|Patient with impaired glucose tolerance|Bold-MRI before and after glucose injection
16640303|NCT02346136|Experimental|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice Digital Versatile Disc (DVD), DVD players if necessary, and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
16640304|NCT02346136|Active Comparator|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
16640306|NCT02346110|Active Comparator|Bupivacaine-adrenalin + sodium chloride|"Single shot saphenous block:
~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin
~1 mL sodium chloride solution"
16640307|NCT02346110|Experimental|Bupivacaine-adrenaline + Dexamethasone|"Single shot saphenous block:
~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin
~1 mL of 4 mg/mL dexamethasone = 4 mg dexamethasone"
16640308|NCT02346097|Experimental|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.
~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.
~Programming of the VV interval to obtain the narrowest QRS-width"
16640309|NCT02346097|Active Comparator|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.
~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.
~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
16640310|NCT02346084|Experimental|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences
~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV
~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO
~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR
~3 Biopsy Schedules D8- (~2-hr after the 8th dose) D9- (~24-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
16640311|NCT02346084|Experimental|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules
~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR
~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO
~Biopsy Schedule D8- (~2-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
16640312|NCT02346071|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
16640313|NCT02346071|Experimental|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
16640314|NCT02346058|Experimental|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.
~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.
~Duration: 28 days."
16640315|NCT02346045|Experimental|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
16640316|NCT02346045|Sham Comparator|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
16640317|NCT02346032|Experimental|refametinib|refametinib medication
16640318|NCT02346019|Experimental|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
16640319|NCT02346006|Experimental|Physical activity|Subject from schools with more physical activity.
16640320|NCT02345993|Active Comparator|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation
~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
16640321|NCT02345993|Placebo Comparator|Placebo|"Group receiving placebo additional to standard treatment consisting in:
~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation
~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
16640322|NCT02345980|Active Comparator|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
16640323|NCT02345980|Placebo Comparator|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
16640324|NCT02345967|Experimental|Study Group|Device: Model 100 Sensor
16640325|NCT02345954|Experimental|Supracervical Hysterectomy and Sacropexy|Laparoscopic Supracervical Hysterectomy and Sacropexy
16640326|NCT02345954|Experimental|Hysteropexy|Laparoscopic Hysteropexy
16640327|NCT02345941|Experimental|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
16640328|NCT02345941|Active Comparator|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
16640329|NCT02345928|Experimental|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
16640330|NCT02345928|Experimental|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
16640331|NCT02345928|Experimental|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
16640332|NCT02345928|Experimental|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
16640333|NCT02345928|Experimental|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
16640334|NCT02345928|Experimental|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
16640335|NCT02345928|Experimental|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
16640336|NCT02345928|Experimental|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
16640337|NCT02345928|Experimental|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
16640338|NCT02345928|Experimental|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
16640339|NCT02345928|Experimental|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
16640341|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
16640342|NCT02345915|Other|Young adult acute leukemia-survivor|
16640343|NCT02345902|Experimental|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days
~Non-pharmacologic measures:
~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
16640344|NCT02345902|Active Comparator|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.
~Non-pharmacologic measures:
~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
16640345|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
16640346|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
16640347|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
16640348|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
16640349|NCT02345876||Dyslexic children|Longitudinal follow-up without intervention
16640350|NCT02345876||Normal reading children|Longitudinal follow-up without intervention
16640351|NCT02345863|Experimental|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v
~GA101: 1000 mg iv
~Ibrutinib: 420 mg po daily"
16640352|NCT02345850|Active Comparator|Tacrolimus/Methotrexate Control Arm|"Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.
~Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice."
16640353|NCT02345850|Experimental|CD34 Selection Arm|"Mobilized CD34-selected Peripheral Blood Stem Cell graft
~Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.
~Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).
~Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products."
16640354|NCT02345850|Experimental|Post Transplant Cyclophosphamide|Unmanipulated Bone Marrow Graft with Cyclophosphamide
16640355|NCT02345837|Active Comparator|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
16640356|NCT02345837|Active Comparator|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
16640357|NCT02345824|Experimental|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
16640358|NCT02345811|Experimental|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
16640359|NCT02345811|Active Comparator|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
16640360|NCT02345798|Active Comparator|Arm I (standard care)|Patients and caregivers receive standard care during routine clinic visits.
16640361|NCT02345798|Experimental|Arm II (video-assisted intervention)|Patients view Parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. Patients then receive an educational handbook and discuss the video with a nurse. After surgery and before hospital discharge, patients view Part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home.
16640362|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
16640363|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
16640364|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
16640365|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
16640366|NCT02345746|Experimental|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
16640367|NCT02345733|Experimental|Ulcerative Colitis Diet|Patients will receive a structured novel diet termed the UCD for 6 weeks, and those in remission at week 6 will receive the step down diet for another 6 weeks.
16640368|NCT02345733|Experimental|Antibiotic Treatment|This antibiotic treatment will be given as an open label for patients who refuse diet therapy or for patients who show no improvement by week 3 , deteriorate by week 6, or patients who are not in full remission by week 6 will receive a 14 day course of antibiotics as previously described by Kato and colleagues.
16640369|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
16640370|NCT02345707|Experimental|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
16640371|NCT02345707|Experimental|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
16640372|NCT02345694|Experimental|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
16640373|NCT02345694|Sham Comparator|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
16640374|NCT02345681|Experimental|Test Furosemide|We will test our furosemide algorithm in one arm
16640375|NCT02345681|No Intervention|Classical Strategy|It's a classical strategy without diuretics
16640376|NCT02345668|Experimental|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
16640377|NCT02345668|Experimental|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
16640378|NCT02345655|Experimental|Urine Drug Testing|GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
16640379|NCT02345655|Other|No test|Patients will not have to performed the OS-UDT test
16640380|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
16640381|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
16640382|NCT02345629|Experimental|Cordotomy Group|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours. Quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call. Participants undergo quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Sensory testing to include sharpness and heat detection.
16640383|NCT02345629|Active Comparator|Comprehensive Medical Management Group|Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
16640384|NCT02345616|Experimental|Nitric oxyde|
16640385|NCT02345603|Experimental|Cryo-therapy|Cryo-therapy of renal arteries
16640386|NCT02345603|No Intervention|Control|No intervention in renal arteries
16640387|NCT02345590|Experimental|Eplerenone|25mg Eplerenone once daily for 12 months
16640388|NCT02345590|Placebo Comparator|Matching placebo|Matching placebo once daily for 12 months
16640389|NCT02345577|Active Comparator|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
16640390|NCT02345577|Sham Comparator|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
16640391|NCT02345564|Other|osteochondral lesions in knee/ankle|patients with traumatic and atraumatic osteochondral lesions in knee/ankle, implantation of MaioRegen fleece into osteochondral lesion
16640392|NCT02345551|Experimental|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
16640393|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
16640394|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
16640395|NCT02345525|Active Comparator|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
16640396|NCT02345525|Experimental|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.
~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
16640397|NCT02345512|Other|Falls|Wearing of Lycra splinting garment
16640398|NCT02345499|Experimental|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
16640399|NCT02345499|Active Comparator|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
16640400|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
16640401|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
16640402|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
16640403|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
16640404|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16640405|NCT02345447|Active Comparator|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.
~Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
16640406|NCT02345447|Placebo Comparator|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
16640407|NCT02345434|No Intervention|No informative letter|This is the control arm and it involves no contact with the prescriber
16640408|NCT02345434|Experimental|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
16640409|NCT02345421||At risk population|
16640410|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
16640411|NCT02345395|Experimental|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
16640412|NCT02345395|Experimental|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
16640413|NCT02345395|Sham Comparator|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
16640414|NCT02345382|Experimental|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640415|NCT02345382|Experimental|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640416|NCT02345382|Experimental|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640417|NCT02345382|Experimental|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640418|NCT02345382|Experimental|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640419|NCT02345382|Experimental|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640420|NCT02345382|Experimental|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
16640421|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
16640422|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
16640423|NCT02345356||Standard-of-Care|the standard clinical approach will be followed
16640424|NCT02345356||Genotype-guided|algorithmically guided personalized therapy of warfarin, using a pharmacogenetic model developed in Caribbean Hispanics
16640425|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
16640426|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
16640427|NCT02345304|Experimental|Treatment 3|single dose of midazolam + BI drug
16640428|NCT02345304|Experimental|Treatment 4|single dose of probe drugs + BI drug
16640429|NCT02345304|Experimental|Treatment 5|single dose of digoxin + BI drug
16640430|NCT02345304|Experimental|Treatment 1|single doses of probe drugs
16640431|NCT02345304|Experimental|Treatment 2|single dose of digoxin
16640432|NCT02345291|Experimental|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
16640433|NCT02345291|Experimental|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
16640434|NCT02345291|Experimental|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
16640435|NCT02345291|Placebo Comparator|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
16640437|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
16640438|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
16640439|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
16640440|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
16640441|NCT02345265|Experimental|Treatment (olaparib and cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16640442|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
16640443|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
16640444|NCT02345252|Experimental|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
16640445|NCT02345239|Experimental|Pantoprazole|Pantoprazole
16640446|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
16640447|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
16640448|NCT02345226|Experimental|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
16640449|NCT02345213|Experimental|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.
~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
16640450|NCT02345213|Placebo Comparator|Placebo|"Treatment period: Weeks 1-12 placebo
~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
16640451|NCT02345200|Active Comparator|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
16640452|NCT02345200|Active Comparator|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
16640453|NCT02345187|Active Comparator|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
16640454|NCT02345187|Placebo Comparator|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
16640455|NCT02345174|Experimental|Imaging Phase + Continuation Phase|In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
16640456|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
16640457|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
16640458|NCT02345148|Experimental|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
16640459|NCT02345148|Experimental|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
16640460|NCT02345135|Active Comparator|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
16640461|NCT02345135|Active Comparator|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
16640462|NCT02345122|Other|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
16640545|NCT02344589|Placebo Comparator|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
16641427|NCT02338739|Active Comparator|SMS; Navigator if Failure; Stop SMS if Success|
16640463|NCT02345122|Experimental|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
16640464|NCT02345109|Experimental|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
16640465|NCT02345109|Experimental|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
16640466|NCT02345096|Active Comparator|Saccharomyces cerevisiae CNCM I-3856|In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
16640467|NCT02345096|Placebo Comparator|placebo|In this arm, subjects will be asked to consume one capsule of placebo per day.
16640468|NCT02345070|Placebo Comparator|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
16640469|NCT02345070|Experimental|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
16640470|NCT02345070|Experimental|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
16640471|NCT02345057|Experimental|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
16640472|NCT02345057|Experimental|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
16640473|NCT02345057|Experimental|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
16640474|NCT02345057|Experimental|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
16640475|NCT02345057|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
16640476|NCT02345044|Experimental|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
16640477|NCT02345044|Experimental|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
16640478|NCT02345044|Experimental|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
16640479|NCT02345044|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
16640480|NCT02345044|Active Comparator|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
16640481|NCT02345031|Active Comparator|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
16640482|NCT02345031|Placebo Comparator|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
16640483|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
16640484|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
16640485|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
16640486|NCT02344992|Experimental|Biochaperone Insulin Lispro|
16640487|NCT02344992|Active Comparator|Humalog®|
16640488|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
16640489|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
16640490|NCT02344940|Experimental|toremifene|patients who will be treated with toremifene.
16640491|NCT02344940|Active Comparator|tamoxifen|patients who will be treated with tamoxifen.
16640492|NCT02344927|Active Comparator|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice
~Continuance of oral intake (if appropriate)
~Regular (4 hourly) mouth care
~Standard management of pain and other symptoms in the terminal phase."
16640493|NCT02344927|Active Comparator|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice
~Continuance of oral intake (if appropriate)
~Regular (4 hourly) mouth care
~Clinically-assisted hydration
~Standard management of pain and other symptoms in the terminal phase"
16640494|NCT02344914|Experimental|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
16640495|NCT02344914|No Intervention|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
16640496|NCT02344901||atrial fibrillation patients|>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
16640497|NCT02344888|Active Comparator|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
16640498|NCT02344888|Active Comparator|Clomiphene citrate-placebo group|Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
16640499|NCT02344875|Experimental|Male elder subjects|Male 65- Years
16640500|NCT02344875|Experimental|Male non-elder subjects|Male 20-35 Years
16640501|NCT02344875|Experimental|Female elder subjects|Female 65- Years
16640502|NCT02344875|Experimental|Female non-elder subjects|Female 20-35 Years
16640503|NCT02344862|Active Comparator|FYU-981 High dose|
16640504|NCT02344862|Active Comparator|FYU-981 Middle dose|
16640505|NCT02344862|Active Comparator|FYU-981 Low dose|
16640506|NCT02344862|Placebo Comparator|Placebo|
16640507|NCT02344849|Experimental|Mesenchymal stem cell|Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.
16640508|NCT02344836|Active Comparator|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).
~Intervention: podcast + mobile diet app"
16640509|NCT02344836|Experimental|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).
~Intervention: podcast + theory-based mobile diet app"
16640510|NCT02344823|Active Comparator|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
16640511|NCT02344823|Placebo Comparator|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
16640512|NCT02344823|Active Comparator|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
16640513|NCT02344823|Placebo Comparator|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
16640514|NCT02344810|Experimental|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
16640515|NCT02344810|Active Comparator|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
16640516|NCT02344797|Active Comparator|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
16640517|NCT02344797|No Intervention|Control|
16640518|NCT02344758|Experimental|Celiac adult|Patient >16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
16640519|NCT02344758|Experimental|Celiac child|Patient <16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
16640520|NCT02344758|Active Comparator|Healthy adult|Healthy individual > 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
16640521|NCT02344758|Active Comparator|Healthy child|Healthy individual < 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
16640522|NCT02344745|Placebo Comparator|Control|Distilled water
16640523|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
16640524|NCT02344732|Active Comparator|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
16640525|NCT02344732|Experimental|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
16640526|NCT02344719|Active Comparator|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
16640527|NCT02344719|Placebo Comparator|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
16640528|NCT02344706||Mini-EEG, NCSE|Unconscious patients due to seizures, of whom EEG is registered
16640529|NCT02344680||HIV-HBV co-infected|HIV-HBV co-infected patients receiving anti-retroviral therapy
16640530|NCT02344667|Experimental|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
16640531|NCT02344667|Experimental|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
16640532|NCT02344654|Experimental|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
16640533|NCT02344654|Active Comparator|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
16640534|NCT02344641|Experimental|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
16640535|NCT02344641|No Intervention|control group|control group do not receive exenatide
16640536|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
16640537|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
16640538|NCT02344615|Active Comparator|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
16640539|NCT02344615|Experimental|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
16640540|NCT02344602|Experimental|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
16640541|NCT02344589|Experimental|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
16640542|NCT02344589|Experimental|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
16640543|NCT02344589|Experimental|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
16640544|NCT02344589|Active Comparator|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
16640546|NCT02344576|No Intervention|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
16640547|NCT02344576|Experimental|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
16640548|NCT02344563|Experimental|Meropem|0.5g/vial,one vial
16640549|NCT02344563|Active Comparator|Mepem|0.25g/vial ,two vials
16640550|NCT02344550|Experimental|Everolimus arm|Everolimus 10mg p.o. daily Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
16640551|NCT02344550|Active Comparator|Control arm|Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
16640552|NCT02344537|Experimental|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
16640553|NCT02344537|No Intervention|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
16640554|NCT02344524|Experimental|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
16640555|NCT02344524|Active Comparator|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
16640556|NCT02344511|Experimental|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.
~• Patients with CrCl < 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.
~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
16640557|NCT02344511|Active Comparator|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label
~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
16640558|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
16640559|NCT02344498||Rural|HBV patients in Harar. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
16640560|NCT02344485|Experimental|OMM treatment|Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care
16640561|NCT02344485|No Intervention|Control|Subjects will continue with their routine care. No OMM will be performed during this study period
16640562|NCT02344472|Experimental|Chemotherapy with docetaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
16640563|NCT02344472|Experimental|Chemotherapy with paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel.Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
16640564|NCT02344472|Experimental|Chemotherapy with vinorelbine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
16640565|NCT02344472|Experimental|Chemotherapy with capecitabine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
16640566|NCT02344472|Experimental|endocrine therapy with exemestane|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus exemestane.
16640567|NCT02344472|Experimental|endocrine therapy with fulvestrant|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus fulvestrant.
16640568|NCT02344472|Experimental|endocrine therapy with anastrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus anastrozole.
16640569|NCT02344472|Experimental|endocrine therapy with letrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus letrozole.
16640570|NCT02344472|Experimental|Chemotherapy with nab-Paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus nab-Paclitaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
16640571|NCT02344472|Experimental|Chemotherapy with eribulin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus eribulin. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
16640572|NCT02344472|Experimental|endocrine therapy with leuprorelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus leuprorelin.
16640573|NCT02344472|Experimental|endocrine therapy with goserelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus goserelin.
16640574|NCT02344459|Experimental|80mL double balloon catheter (Cook catheter®)|
16640575|NCT02344459|Active Comparator|30mL single Foley balloon catheter|
16640576|NCT02344446|Experimental|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
16640577|NCT02344433|Experimental|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
16640578|NCT02344433|Active Comparator|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
16640580|NCT02344407|Experimental|2|ChAd3-EBO Z
16640581|NCT02344407|Experimental|3|VSVG-ZEBOV
16640582|NCT02344407|Placebo Comparator|1|Placebo (Saline)
16640583|NCT02344394|Other|Hybrid Ablation-cryoballoon alone|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation consisting of pulmonary vein isolation with no further catheter ablation. This will be achieved using the nContact and Medtronic cryoballoon
16640584|NCT02344394|Other|Hybrid ablation-cryoballoon plus RF|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation. Endocardial portion consists of pulmonary vein isolation using the cryoballoon with further catheter ablation, which may consist of ablation of complex fractionated electrograms and linear lesions. This will be achieved using the nContact and Medtronic Cryoballoon plus Thermocool Catheter.
16640585|NCT02344381|Experimental|Sucrose|Sucrose ingestion post-exercise
16640586|NCT02344381|Active Comparator|Glucose|Glucose ingestion post-exercise
16640587|NCT02344368|Experimental|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
16640588|NCT02344368|Experimental|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
16640589|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:
~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions
~Adjuvant therapy:
~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
16640590|NCT02344342|Experimental|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
16640591|NCT02344342|Experimental|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
16640592|NCT02344329|Active Comparator|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
16640593|NCT02344329|Experimental|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
16640594|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
16640595|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
16640596|NCT02344303|Experimental|Part A|Fixed sequence, open label
16640597|NCT02344303|Experimental|Part B|4 way cross over, double blind
16640600|NCT02344264|Other|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
16640601|NCT02344264|Other|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
16640602|NCT02344251|Other|Group 1|Adherence measured by MEMS Cap
16640603|NCT02344251|Other|Group 2|Adherence measured by ID-Cap technology.
16640604|NCT02344238|Other|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
16640605|NCT02344238|Other|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
16640606|NCT02344238|Other|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
16640607|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
16640608|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
16640675|NCT02343614|Experimental|ARM A|Patients undergoing treatment with oral celecoxib
16641428|NCT02338739|Active Comparator|Voucher; Outreach if Failure|
16640609|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
16640610|NCT02344212|Experimental|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
16640611|NCT02344186|Experimental|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
16640612|NCT02344186|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks.
16640613|NCT02344134|Experimental|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
16640614|NCT02344134|Active Comparator|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
16640615|NCT02344108|Experimental|Inspire® Upper Airway Simulation System|Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
16640616|NCT02344095|Experimental|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
16640617|NCT02344095|Experimental|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
16640618|NCT02344082|No Intervention|Standard of Care|The control arm will receive face-to-face pharmacy clinic visits per usual care.
16640619|NCT02344082|Active Comparator|Intervention Arm|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
16640620|NCT02344069|Active Comparator|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
16640621|NCT02344069|Placebo Comparator|Placebo|Saline 0.9%
16640622|NCT02344056|Experimental|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
16640623|NCT02344056|Experimental|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
16640624|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
16640625|NCT02344030|Experimental|standard blade|Standard Blade: tracheal intubation with standard blade
16640626|NCT02344030|Experimental|channeled blade|Channeled Blade: tracheal intubation with channeled blade
16640627|NCT02344017|Experimental|ODM-204 Phase I dose escalation|Dose escalation
16640628|NCT02344017|Experimental|ODM-204 Phase II dose expansion|
16640629|NCT02344004|No Intervention|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] Guidelines)
16640630|NCT02344004|Experimental|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)
~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
16640631|NCT02343991|Experimental|Transcranial ExAblate|MR Guided Focused Ultrasound
16640632|NCT02343978|Experimental|KWA-0711 High dose|
16640633|NCT02343978|Experimental|KWA-0711 Low dose|
16640634|NCT02343965|Experimental|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
16640635|NCT02343965|No Intervention|without touch-massage group|
16640636|NCT02343952|Experimental|Experimental Arm|Pembrolizumab
16640637|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.
~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
16640638|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.
~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
16640639|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.
~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
16640640|NCT02343926|Experimental|Gemigliptin|GEMIGLIPTIN LS15-0444 administered once a day for 24 weeks as add-on therapy to metformin
16640641|NCT02343926|Active Comparator|Vildagliptin|Vildagliptin administered twice a day for 24 weeks as add-on therapy to metformin
16640642|NCT02343913|Experimental|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
16640676|NCT02343601|No Intervention|Control group|Control group using a hemodynamic standard protocol
16640643|NCT02343887|Active Comparator|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and
~if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12
~or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
16640644|NCT02343887|Experimental|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then
~Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,
~or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
16640645|NCT02343887|Experimental|group with psychological support.|"patients treated with counseling for six months (period 1) and
~Stop if the situation improves with neuropsychological assessment and monitoring to M12,
~or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
16640646|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).
~No intervention is going to be administered but exposure to alcohol will be analysed"
16640647|NCT02343861|Active Comparator|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
16640648|NCT02343861|Placebo Comparator|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
16640649|NCT02343848|Experimental|treatment|smart bracelet.
16640650|NCT02343835|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
16640651|NCT02343835|No Intervention|Control|The patients without treatment
16640652|NCT02343822|Experimental|Multiple PRP Injection|2 PRP Injections 2 months apart
16640653|NCT02343822|Experimental|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
16640654|NCT02343822|Active Comparator|Saline Injection|2 Saline Injections 2 months apart
16640655|NCT02343809|Experimental|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
16640656|NCT02343809|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
16640657|NCT02343809|Other|Control Group|Protocolized Physiotherapy
16640658|NCT02343796|Experimental|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
16640659|NCT02343783|Experimental|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
16640660|NCT02343770|Experimental|idiopathic juvenile arthritis|blood sample
16640661|NCT02343770|Other|control|blood sample
16640662|NCT02343757|Other|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.
~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
16640663|NCT02343744|Experimental|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
16640664|NCT02343731|Experimental|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
16640665|NCT02343718|Experimental|Vinblastine and Temsirolimus|"Vinblastine starting dose:
~Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.
~Temsirolimus starting dose:
~Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
16640666|NCT02343705|Experimental|Latella Knee Implant System|
16640667|NCT02343692|Experimental|Radiofrequency abalation|"Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas
~Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)
~Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.
~Ablation of cystic tumours of the pancreas"
16640668|NCT02343679|Experimental|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
16640669|NCT02343666|Experimental|Treatment (gene modified HPSC)|See Detailed Description.
16640670|NCT02343653|Active Comparator|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
16640671|NCT02343653|Experimental|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
16640672|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
16640673|NCT02343627|Experimental|NVXT Solution|NVXT Solution once daily for 60 days
16640674|NCT02343627|Placebo Comparator|Vehicle of test product|Vehicle of test product, once daily for 60 days
16640677|NCT02343601|Other|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
16640678|NCT02343588|Experimental|The Health Lifestyles Interventions|"Creating a supportive school, family and community environment;
~Health lifestyles educational strategies;
~Instruct and promote school physical education;
~The monitoring and instruction of obesity related behaviors (focus group)"
16640679|NCT02343588|No Intervention|Receive no intervention|Usual practice
16640680|NCT02343575|Experimental|Valproic Acid|"Start:
~VPA PO/NGT 500 mg BID
~If need to increase in 24 or more hours:
~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS
~If need to increase in 24 or more hours:
~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS
~If need to increase in 24 or more hours:
~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
16640681|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID
~Rescue: HAL IV 2-5 mg Q4hr PRN"
16640682|NCT02343562|Active Comparator|Probiotics Group|Will receive Sachet-form probiotics
16640683|NCT02343562|Placebo Comparator|Placebo Group|Will receive off-the-shelf oral multivitamin
16640685|NCT02343536|Experimental|Oral Azacitidine (CC-486) and R-CHOP|Will examine four escalating dose-levels of CC- 486 (100 mg, 150 mg, 200 mg and 300 mg).
16640686|NCT02343536|Active Comparator|R-CHOP|R-CHOP, (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) * rituximab, cyclophosphamide, doxorubicin, and vincristine are administered on Day 1; while prednisone is administered Days 1-5
16640687|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
16640688|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
16640689|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
16640690|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
16640691|NCT02343497|Experimental|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
16640692|NCT02343497|Placebo Comparator|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
16640693|NCT02343484|Active Comparator|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
16640694|NCT02343484|Active Comparator|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
16640695|NCT02343471|Experimental|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
16640696|NCT02343471|Placebo Comparator|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
16640697|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
16640698|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
16640699|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
16640700|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
16640701|NCT02343445|Experimental|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
16640702|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
16640703|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
16640704|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
16640705|NCT02343432|Experimental|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
16640706|NCT02343432|Experimental|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
16640707|NCT02343432|Experimental|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
16640708|NCT02343419|Experimental|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
16640709|NCT02343406|Experimental|ABT-414/temozolomide|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks in combination with temozolomide (TMZ) to adult participants
16640710|NCT02343406|Experimental|ABT-414_adult|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to adult participants
16640711|NCT02343406|Active Comparator|Control_lomustine|Adult participants relapsing during temozolomide (TMZ) treatment or within the first 16 weeks after the first day of the last TMZ cycle received lomustine on Day 1 of every 42-day treatment period until one of the treatment withdrawal criteria was met, up to a maximum of 1 year.
16640740|NCT02343224|Experimental|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
16640712|NCT02343406|Active Comparator|Control_ temozolomide|Adult participants relapsing 16 weeks or more after the first day of the last temozolomide (TMZ) cycle received TMZ on Day 1 to Day 5 for the first 28-day cycle, with dose escalation in subsequent cycles in case of adequate tolerance and treatment continuing until one of the treatment withdrawal criteria was met.
16640713|NCT02343406|Experimental|ABT-414_ pediatric|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to pediatric participants. Temozolomide (TMZ) was only allowed for pediatric participants if its use was in accordance with local clinical practice, and was not considered an investigational product for the study (unless this was a local requirement).
16640714|NCT02343393|Experimental|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
16640715|NCT02343393|No Intervention|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
16640716|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
16640717|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
16640718|NCT02343367|Active Comparator|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
16640719|NCT02343367|Experimental|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
16640720|NCT02343354|Experimental|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
16640721|NCT02343341|Experimental|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive a 4-month health promotion education program along with their parents/caregivers and teachers.
16640722|NCT02343341|Other|Control:Standard Curriculum|"The Standard curriculum control arm will receive the standard curriculum in their schools.
~Children randomized to the control arm will receive the health promotion education program for 4 months after the intervention arm has completed it"
16640723|NCT02343328|Active Comparator|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
16640724|NCT02343328|Placebo Comparator|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
16640725|NCT02343315|Experimental|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
16640726|NCT02343315|Experimental|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
16640727|NCT02343315|Active Comparator|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
16640728|NCT02343302|Other|Soft Pancreatic Gland|This arm will be patients with glands felt to have a soft texture during surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
16640729|NCT02343302|Other|Hard Pancreatic Gland|This arm will include patients felt to have a hard gland tecture at the time of surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
16640730|NCT02343289|Experimental|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
16640731|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
16640732|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
16640733|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
16640734|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
16640735|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
16640736|NCT02343250|Experimental|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
16640737|NCT02343250|Active Comparator|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
16640738|NCT02343237|Experimental|Osteopathy +|75 patients will make 6 osteopathic sessions
16640739|NCT02343237|Active Comparator|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
16640742|NCT02343198|Experimental|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
16640743|NCT02343198|Placebo Comparator|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
16640744|NCT02343185|Experimental|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
16640745|NCT02343185|Placebo Comparator|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
16640746|NCT02343172|Experimental|HDM201+LEE011|
16640747|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
16640748|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
16640749|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
16640750|NCT02343146|Experimental|Type One Training (TOT)|The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
16640751|NCT02343146|No Intervention|Comparison|The comparison group will receive usual care with the diabetes team.
16640752|NCT02343133|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
16640753|NCT02343133|Placebo Comparator|Placebo|Single subcutaneous dose
16640754|NCT02343120|Experimental|BGB-3111|All patients will undertake 160MG BID of BGB-3111.
16640755|NCT02343107|Experimental|1|Subgroup of subjects who benefit of the e-coaching
16640756|NCT02343107|No Intervention|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
16640757|NCT02343094|Experimental|PBA 7,5g/d|Treatment for 14 days
16640758|NCT02343094|Experimental|PBA 15g/d|Treatment for 14 days
16640759|NCT02343081|Active Comparator|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
16640760|NCT02343081|Experimental|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
16640761|NCT02343055|Experimental|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
16640762|NCT02343055|Placebo Comparator|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
16640763|NCT02343042|Experimental|1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)|"Each cycle is of 28 days
~Cohort 1.1: Selinexor (SEL) 60/80/100 mg orally (PO) once weekly (QW); Dexamethasone (DEX) 40 mg PO once weekly; Pomalidomide (POM) 2/3/4 mg PO Days 1-21.
~Cohort 1.2: SEL 40/60/80 mg PO twice weekly (BIW); DEX 20 mg PO twice weekly; POM 3/4 mg PO Days 1-21.
~Cohort 1.3: Selinexor, Dexamethasone and Pomalidomide will be dosed at RP2D-1.
~Cohort 1.4: SEL 40 mg PO QW; DEX 40 mg PO QW; POM 4mg PO once daily (QD) Days 1-21."
16640764|NCT02343042|Experimental|2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)|"Each cycle is of 35 days
~Cohort 2.1: SEL 60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Bortezomib (BOR) 1.3 milligram per meter square (mg/m^2) subcutaneous (SC) once weekly.
~Cohort 2.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.
~Cohort 2.3: Selinexor, Dexamethasone and Bortezomib will be dosed at RP2D-2."
16640765|NCT02343042|Experimental|3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM|"Each cycle is of 28 days
~Cohort 3.1: SEL 40/60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Lenalidomide (LEN) 15/25 mg PO Days 1-21.
~Cohort 3.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; LEN 15/25 mg PO Days 1-21.
~Cohort 3.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-3."
16640766|NCT02343042|Experimental|4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)|"PK Run-in Period: Selinexor and Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days.
~Cohort 4.1:
~SEL 40/60 mg PO once weekly; DEX 40 mg PO once weekly; POM 4 mg PO Days 1-21; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.
~Cohort 4.3: Selinexor, Dexamethasone, Pomalidomide, Velcade (Bortezomib) will be dosed at RP2D-4."
16640767|NCT02343042|Experimental|5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)|"Each cycle is of 28 days
~Cohort 5.1:
~SEL 80/100 mg PO once weekly; DEX 40 mg once weekly (IV or PO); DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.
~Cohort 5.2:
~SEL: 60 mg PO twice weekly; DEX: 40 mg weekly (IV or PO); DARA: 16 milligram per kilogram (mg/kg) IV infusion Cycle 1-2: Once. weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.
~Cohort 5.3: Selinexor, Dexamethasone and Daratumumab will be dosed at RP2D-5."
16640791|NCT02342912|Active Comparator|Social Media Contact Control|Participants randomly assigned to this treatment arm receive health information via text messages, Facebook postings, on-line videos, and weekly reports. Topics relate to having a healthy body weight through a healthy mind, body, and energy. Some topics include stress management, importance of sleep, and importance of accepting one's body. Participants will receive a suggestion to track stress, body image, and energy levels.
16640768|NCT02343042|Experimental|6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)|"PK Run-in Period: Selinexor and Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-Escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days
~Cohort 6.1:
~SEL 40/60/80/100 mg PO once weekly on days 1, 8, 15, and 22; DEX 40 mg IV or PO once weekly; Carfilzomib (CAR) 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.
~Cohort 6.2:
~SEL 60/80/100 mg PO once weekly on days 1, 8, and 15; DEX 40 mg IV or PO once weekly; CAR 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.
~Cohort 6.3: Selinexor, Dexamethasone and Carfilzomib will be dosed at RP2D-6."
16640769|NCT02343042|Experimental|7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM|"Each cycle is of 28 days
~Cohort 7.1:
~SEL 40/60/80 mg PO once weekly; DEX 40 mg PO once weekly; LEN 25 mg PO Days 1-21.
~Cohort 7.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-7."
16640770|NCT02343042|Experimental|8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)|"PK Run-in Period: Selinexor & Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-Escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days
~Cohort 8.1:
~SEL 40/60/80/100 mg PO once weekly; DEX 20 mg PO twice weekly; IXA 3/4 mg PO once weekly.
~Cohort 8.3: Selinexor, Dexamethasone and Ixazomib will be dosed at RP2D-8."
16640771|NCT02343042|Experimental|9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)|"PK Run-in Period: Selinexor and Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-Escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days
~Cohort 9.1:
~SEL 20/40/60 mg PO once weekly; DEX 28/20 mg PO twice weekly; POM 4 mg PO QD Days 1-21; Elotuzumab (ELO) 10/20 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.
~Cohort 9.3: Selinexor, Dexamethasone, Pomalidomide and Elotuzumab will be dosed at RP2D-9."
16640772|NCT02343042|Experimental|10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)|"Each cycle is of 21 days
~Cohort 10.1:
~SEL 40/60/80 mg PO once weekly on Days 1, 8, and 15; DEX 40 mg PO QW on Days 1, 8, and 15; Belantamab Mafodotin (BEL) 2.5 mg/kg IV infusion every 3 weeks (Q3W) Day 1 of each cycle.
~Cohort 10.3:
~Selinexor, Dexamethasone, and Belantamab Mafodotin will be dosed at RP2D-10."
16640773|NCT02343042|Experimental|11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)|"Each Cycle is of 28 days
~Cohort 11.1 SEL 40/60 mg PO once weekly on Days 1, 8, and 15; DEX total 40 mg weekly (IV or PO) single or divided doses on Days 1, 8, 15, and 22; POM 4 mg PO QW Days 1-21; DARA 16 mg/kg IV or SC QW on Days 1, 8, 15 and 22 of Cycles 1-2 and on Days 1 and 15 of Cycles 3-6, Day 1 of every Cycle greater than (>6).
~Cohort 11.3 Selinexor, Dexamethasone, Pomalidomide, and Daratumumab will be dosed at RP2D-11."
16640774|NCT02343029|Experimental|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
16640775|NCT02343029|Active Comparator|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
16640776|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
16640777|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
16640778|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
16640779|NCT02342990|Experimental|Cluster B|After the first neuropsychological assessment (T1), children will start CogMed working memory training. Children will be retested (T2) about six or seven weeks later.
16640780|NCT02342990|Other|Cluster A|After the first neuropsychological assessment (T1), children will not start any training. Children will be retested (T2) about six or seven weeks later and will start CogMed working memory training. The group will be again retest (T3) after six or seven weeks after ended training.
16640781|NCT02342977|Placebo Comparator|Placebo|Patient will randomly receive a placebo
16640782|NCT02342977|Experimental|Experimental|Patients will randomly receive experimental drug (lacosamide).
16640783|NCT02342964|Other|MUCO-FIBRO|Measures of hepatic elasticity
16640784|NCT02342951|Other|LCI|Measure of lung clearance index
16640785|NCT02342938|Experimental|Patient|
16640786|NCT02342938|Experimental|Volunteers|
16640787|NCT02342925|Experimental|RG1662 plus metformin|
16640788|NCT02342925|Experimental|metformin alone|
16640789|NCT02342912|Experimental|Social Media Targeted Treatment|Participants randomly assigned to this treatment arm will receive weight loss materials via text messages, Facebook postings, on-line videos, and weekly reports. The topics relate to relate to behavioral and lifestyle changes associated with weight-loss (e.g., nutrition, exercise, social support, and self-monitoring). Calorie and physical activity targets also are set. Participants will receive a suggestion to track diet, physical activity, and weight.
16640790|NCT02342912|Experimental|Social Media Tailored Treatment|Participants randomly assigned to this treatment arm receive all of the same weight loss materials (as well as weight, calorie, and physical activity targets) as the Targeted group above. Weekly reports will be more personalized to help participants track diet, physical activity, and weight. Additionally, participants will be asked to report on their weight, exercise and calorie goals, and receive feedback.
16640792|NCT02342899|Active Comparator|Control Goup|Inpatient initiation of noninvasive ventilation.
16640793|NCT02342899|Active Comparator|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
16640794|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
16640795|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:
~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight
~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight
~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
16640796|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
16640797|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
16640798|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
16640799|NCT02342873|Active Comparator|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
16640800|NCT02342873|Experimental|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
16640801|NCT02342860|Experimental|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
16640802|NCT02342860|No Intervention|Control|Schools in the control group will receive no additional WinS programming.
16640803|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.
~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.
~The follow-up of patients will be performed according to standard clinical practice of each site"
16640804|NCT02342834|No Intervention|Control|"During the control study, each subject ingest 500 ml of water 30 minutes before a standard 75 g Oral Glucose Tolerance Test"
16640805|NCT02342834|Experimental|Small mixed protein and lipid meal|"During the preload study, each subject ingest a small mixed meal 30 minutes before a standard 75 g Oral Glucose Tolerance Test. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
16640806|NCT02342808|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
16640807|NCT02342808|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
16640808|NCT02342795|Experimental|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
16640809|NCT02342795|Experimental|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
16640810|NCT02342795|Experimental|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
16640811|NCT02342795|Experimental|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
16640812|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
16640813|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
16640814|NCT02342756|Experimental|Group 1: CMV - HFOV|"Patients in group 1 will start with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O) and then will be ventilated with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O)
~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
16640815|NCT02342756|Experimental|Group 2: HFOV - CMV|"Patients in group 2 will start with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O) and then will be ventilated with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O).
~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
16640816|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
16640860|NCT02342522|Active Comparator|Remote ischemic conditioning|AutoRIC device will be placed on the upper arm and an active RIC protocol will be delivered (4x5 min cycles of inflation to 200mmHg and deflation) prior to PPCI.
16640817|NCT02342730|Experimental|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
16640818|NCT02342717|Experimental|Reference|single dose BI 425809
16640819|NCT02342717|Experimental|Test|multiple doses of Itraconazole + single dose BI 425809
16640820|NCT02342704|Experimental|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
16640821|NCT02342704|Active Comparator|fingolimod|Open-label fingolimod 0.5 mg once daily orally
16640822|NCT02342691|Experimental|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
16640823|NCT02342691|Placebo Comparator|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
16640824|NCT02342691|No Intervention|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
16640825|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
16640826|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
16640827|NCT02342665|Experimental|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
16640828|NCT02342652|Experimental|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
16640829|NCT02342652|Placebo Comparator|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
16640830|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
16640831|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
16640832|NCT02342626|No Intervention|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
16640833|NCT02342626|Experimental|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
16640834|NCT02342613|Experimental|MILs treatment|Patients treated with the activated PTCy-MILs
16640835|NCT02342600|Experimental|Trametinib with Pazopanib|Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
16640836|NCT02342587|Experimental|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
16640837|NCT02342574|Experimental|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
16640838|NCT02342574|Placebo Comparator|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
16640839|NCT02342574|Experimental|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
16640840|NCT02342574|Placebo Comparator|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
16640841|NCT02342574|Experimental|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
16640842|NCT02342574|Placebo Comparator|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
16640843|NCT02342574|Experimental|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
16640844|NCT02342574|Placebo Comparator|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
16640845|NCT02342574|Experimental|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
16640846|NCT02342574|Placebo Comparator|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
16640847|NCT02342574|Experimental|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
16640848|NCT02342574|Placebo Comparator|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
16640849|NCT02342574|Experimental|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
16640850|NCT02342574|Placebo Comparator|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
16640851|NCT02342574|Experimental|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
16640852|NCT02342574|Placebo Comparator|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
16640853|NCT02342574|Experimental|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
16640854|NCT02342574|Placebo Comparator|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
16640855|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
16640856|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
16640857|NCT02342548|Experimental|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
16640858|NCT02342548|Experimental|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
16640859|NCT02342535|Other|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.
~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
16641429|NCT02338739|Active Comparator|Voucher; Outreach if Failure; Stop Voucher if Success|
16640861|NCT02342522|Sham Comparator|Sham control|Sham AutoRIC device will be placed on the upper arm and a sham RIC protocol will be delivered prior to PPCI.
16640862|NCT02342509|Experimental|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
16640863|NCT02342509|Experimental|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
16640864|NCT02342509|Active Comparator|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
16640865|NCT02342496|Placebo Comparator|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
16640866|NCT02342496|Active Comparator|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
16640867|NCT02342496|Active Comparator|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
16640868|NCT02342483|Active Comparator|1g|METHYLSULFONYLMETHANE
16640869|NCT02342483|Active Comparator|3g|METHYLSULFONYLMETHANE
16640870|NCT02342483|Active Comparator|6g|METHYLSULFONYLMETHANE
16640871|NCT02342470|Placebo Comparator|Placebo|Placebo Comparator / Bid
16640872|NCT02342470|Experimental|PMK-S005 1|Total 50mg, by mouth, bid
16640873|NCT02342470|Experimental|PMK-S005 2|Total 100mg, by mouth, bid
16640874|NCT02342470|Experimental|PMK-S005 3|Total 150mg, by mouth, bid
16640875|NCT02342457|Experimental|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
16640876|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
16640877|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
16640878|NCT02342431|Active Comparator|Forced air compressible warming|Warming with a compressible forced air mattress
16640879|NCT02342431|Experimental|Forced air non-compressible|Warming with a non-compressible forced air mattress
16640880|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
16640881|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
16640882|NCT02342405|Placebo Comparator|30% oxygen|Inhalation of 30% oxygen
16640883|NCT02342405|Experimental|80% oxygen|Inhalation of 80% oxygen
16640884|NCT02342392|Active Comparator|treatment group|intralesional ranibizumab injected
16640885|NCT02342392|No Intervention|control group|no intralesional ranibizumab injected.
16640886|NCT02342379|Experimental|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
16640887|NCT02342366|Placebo Comparator|Placebo|Placebo
16640888|NCT02342366|Experimental|GHB|GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)
16640889|NCT02342353|Experimental|Phase I (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.
~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.
~A 28-day interval is defined as a cycle"
16640890|NCT02342353|Experimental|Phase II (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.
~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.
~A 28-day interval is defined as a cycle"
16640891|NCT02342340|Active Comparator|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
16640892|NCT02342340|Active Comparator|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
16640893|NCT02342340|Active Comparator|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
16640928|NCT02342145|Experimental|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
16640929|NCT02342132|Experimental|Respiratoy Therapy Devices|Non-Invasive Bipap Ventilator, Mechanical Insufflator-Exsufflator, and High Frequency Percussive Oscillator are the three respiratory therapy devices that all participants will be using in a random order, in three consecutive days, one device per day.
16641430|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure|
16640894|NCT02342340|Active Comparator|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
16640895|NCT02342340|Active Comparator|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
16640896|NCT02342340|Placebo Comparator|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
16640897|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
16640898|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
16640899|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
16640900|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
16640901|NCT02342314|Placebo Comparator|Placebo (Part A)|Single SC injection of normal saline on Day 1
16640902|NCT02342314|Active Comparator|rGlucagon (Part B)|Single SC injection on Day 1
16640903|NCT02342314|Placebo Comparator|Placebo (Part B)|Single SC injection of normal saline on Day 1
16640904|NCT02342301|Experimental|Standing Desk|Will use standing desk for 3 months
16640905|NCT02342301|Active Comparator|Traditional Desk|Will use traditional desk for 3 months
16640906|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
16640907|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
16640908|NCT02342275|Active Comparator|Propranolol|Propranolol
16640909|NCT02342275|Active Comparator|Atenolol|Atenolol
16640910|NCT02342262|Experimental|Probiotics|EcologicBarrier, 5x10E9 cfu/day
16640911|NCT02342262|Placebo Comparator|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
16640912|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
16640913|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
16640914|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
16640915|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
16640916|NCT02342236|Other|cemented|Primary hip arthroplasty with bone cement use.
16640917|NCT02342236|Other|cementless|Primary hip arthroplasty without bone cement use.
16640918|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.
~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.
~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.
~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.
~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
16640919|NCT02342210|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
16640920|NCT02342210|Other|Group-B - Delayed Intervention|3 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP).
16640921|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
16640922|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
16640923|NCT02342184|Experimental|GB-0998|
16640924|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
16640925|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
16640926|NCT02342158|Experimental|Locally advanced /metastatic cancer|
16640927|NCT02342145|Active Comparator|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
16640930|NCT02342119|Experimental|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
16640931|NCT02342119|Active Comparator|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
16640932|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
16640933|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.
~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.
~Excellent pregnancy success rates."
16640934|NCT02342093|Active Comparator|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
16640935|NCT02342093|Active Comparator|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
16640936|NCT02342080|Experimental|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
16640937|NCT02342067|Experimental|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
16640938|NCT02342067|Experimental|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
16640939|NCT02342054|Experimental|MRI-TRUS fusion guided Single Frac HDR|Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)
16640940|NCT02342041|Placebo Comparator|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
16640941|NCT02342041|Placebo Comparator|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
16640942|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements
~20~60 years ago, female or males
~Agree participate the study and sign informed consent
~Has not received any treatment for OSA
~No obvious comorbidities (including autoimmune diseases)
~No history of sarcoidosis and tuberculosis
~No use of steroid and immunosuppressant"
16640943|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements
~20~60 years ago, female or males
~Agree participate the study and sign informed consent
~No obvious comorbidities (including autoimmune diseases)
~No history of sarcoidosis and tuberculosis
~No use of steroid and immunosuppressant"
16640944|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
16640945|NCT02342002|Experimental|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
16640946|NCT02342002|Placebo Comparator|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
16640947|NCT02341989|Experimental|Bleomycin-Etoposide-Cisplatin|One course of adjuvant BEP.
16640948|NCT02341989|Active Comparator|Carboplatin|One course of adjuvant carboplatin AUC7
16640949|NCT02341976|Other|Vibratory platform exercises|Vibratory platform exercises: different positions on a vibratory platform in different frequencies
16640950|NCT02341963|Experimental|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
16640951|NCT02341950|Experimental|SCI Hard|This arm plays the SCI HARD game
16640952|NCT02341950|No Intervention|Control|Plays an alternate, publicly available game
16640953|NCT02341924|Experimental|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.
~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
16640954|NCT02341924|Placebo Comparator|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
16640955|NCT02341911|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
16640956|NCT02341911|Active Comparator|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
16640957|NCT02341898|Experimental|Updated original programme|Educational programme for all nurses (90 min. single information session); training and structured support for nominated key nurses (one-day training workshop); provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
16641431|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
16640958|NCT02341898|Experimental|Concise updated programme|Training and structured support for nominated key nurses (one-day training workshop); nurses' training will be carried out by key nurses as facultative option; key nurses receive an additional train-the-trainer module to apply the educational programme; provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
16640959|NCT02341898|Active Comparator|Optimized usual care|Provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives) only
16640960|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
16640961|NCT02341872|No Intervention|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
16640962|NCT02341872|Active Comparator|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
16640963|NCT02341872|Experimental|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
16640964|NCT02341872|Experimental|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
16640965|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
16640966|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
16640967|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
16640968|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
16640969|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
16640970|NCT02341833|Active Comparator|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
16640971|NCT02341833|No Intervention|No intervention|No volatile anesthetics during organs procurement
16640972|NCT02341807|Experimental|Dose Group 1|Single, unilateral administration of a single low dose range of AAV2-hCHM.
16640973|NCT02341807|Experimental|Dose Group 2|Single, unilateral administration of a single high dose range of AAV2-hCHM.
16640974|NCT02341794|Experimental|Rosuvastatin|
16640975|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
16640976|NCT02341742||Patients|follow up of patients (children and adolescent) with inflammatory bowel disease in looking for the relationship between the bone mineral density and physical activity.
16640977|NCT02341729|Other|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.
~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
16640978|NCT02341716|Active Comparator|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
16640979|NCT02341716|Active Comparator|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
16640980|NCT02341716|Active Comparator|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
16640981|NCT02341703|Active Comparator|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.
~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
16640982|NCT02341703|Active Comparator|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.
~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
16640983|NCT02341690|Active Comparator|Control|Standard rehabilitation with exercise
16641240|NCT02340039|Experimental|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
16640984|NCT02341690|Experimental|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into
~a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.
~a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.
~After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).
~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
16640985|NCT02341677|Experimental|Biopsy|Single Arm Study. Biopsy Intervention.
16640986|NCT02341651|Experimental|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
16640987|NCT02341651|No Intervention|Usual Care|No active intervention
16640988|NCT02341638|Experimental|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
16640989|NCT02341638|Experimental|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
16640990|NCT02341638|Experimental|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
16640991|NCT02341638|Experimental|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
16640992|NCT02341638|Experimental|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
16640993|NCT02341638|Experimental|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
16640994|NCT02341638|Experimental|Part A Panel 7: BMS-986141|Single dose by mouth as specified
16640995|NCT02341638|Experimental|Part A Panel 8: BMS-986141|Single dose by mouth as specified
16640996|NCT02341638|Experimental|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
16640997|NCT02341638|Experimental|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
16640998|NCT02341638|Experimental|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
16640999|NCT02341638|Experimental|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
16641000|NCT02341638|Experimental|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
16641001|NCT02341638|Experimental|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
16641002|NCT02341638|Experimental|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
16641003|NCT02341638|Placebo Comparator|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
16641004|NCT02341638|Experimental|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
16641005|NCT02341625|Experimental|Part 1: Ascending dose of BMS-986148|BMS-986148 Intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer. Alternate dose and schedules may be explored.
16641006|NCT02341625|Experimental|Part 2: Expansion dose of BMS-986148|BMS-986148 Intravenous injection of Maximum tolerated dose (MTD) on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
16641007|NCT02341625|Experimental|Part 3A: Ascending dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
16641008|NCT02341625|Experimental|Part 3B: Expansion dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at or below maximum tolerated dose on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
16641009|NCT02341612|Experimental|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
16641010|NCT02341612|Experimental|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
16641011|NCT02341612|Experimental|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
16641012|NCT02341612|Experimental|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
16641013|NCT02341612|Experimental|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
16641014|NCT02341599|Experimental|Group A: Healthy|Healthy participants with normal renal function (Stage 1: eGFR ≥90 mL/min/1.73m^2).
16641015|NCT02341599|Experimental|Group B: Mild RI|Participants with mild RI (Stage 2: eGFR ≥60 to <90 mL/min/1.73m^2).
16641016|NCT02341599|Experimental|Group C: Moderate RI|Participants with moderate RI (Stage 3: eGFR ≥30 to <60 mL/min/1.73m^2).
16641017|NCT02341599|Experimental|Group D: Severe RI|Participants with severe RI (Stage 4: eGFR <30 mL/min/1.73m^2) not receiving HD.
16641018|NCT02341599|Experimental|Group E: ESRD-HD|Participants with ESRD who are receiving HD for at least 3 months preceding the initial dose in this study (Stage 5).
16641019|NCT02341586|Experimental|Lucky Iron Fish|This group will receive a Lucky Iron Fish to use during cooking.
16641020|NCT02341586|Active Comparator|18 mg iron|This group will receive a daily oral iron supplement.
16641021|NCT02341586|Other|Control group|This group will receive nutrition education
16641128|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
16641241|NCT02340039|Experimental|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
16641022|NCT02341573|Experimental|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
16641023|NCT02341573|Active Comparator|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
16641024|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
16641025|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
16641026|NCT02341560|Sham Comparator|Sham|Sham injection procedure
16641027|NCT02341534|Other|BioMonitor arm|BioMonitor group (standard of care and implantation with investigational device)
16641028|NCT02341534|No Intervention|Control arm|Control group (standard of care)
16641029|NCT02341521|Experimental|OC000459 50 mg|OC000459 50 mg daily for 8 days
16641030|NCT02341508|Experimental|Lpathomab|0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
16641031|NCT02341508|Placebo Comparator|Placebo|Saline solution for intravenous infusion
16641032|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
16641033|NCT02341482|Experimental|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.
~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
16641034|NCT02341469|No Intervention|Standard-of-care|
16641035|NCT02341469|Experimental|integrated ediagnostic approach|
16641036|NCT02341456|Experimental|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
16641037|NCT02341456|Experimental|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
16641038|NCT02341456|Experimental|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg*min/mL)*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
16641039|NCT02341443|Experimental|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
16641040|NCT02341443|Active Comparator|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
16641041|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.
~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
16641042|NCT02341404|Experimental|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
16641043|NCT02341391|Experimental|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
16641044|NCT02341391|Experimental|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
16641045|NCT02341391|Experimental|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
16641046|NCT02341378|Experimental|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10^6 cells
16641047|NCT02341378|Experimental|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
16641048|NCT02341352|No Intervention|Control|Only behavioral education for Caregiver
16641049|NCT02341352|Experimental|fluoride varnish|fluoride varnish every 6 months
16641050|NCT02341352|Experimental|ImmunoglobulinY|anti-S.mutans Immunoglobulin yolk for everyday use
16641051|NCT02341352|Experimental|Probiotics|Probiotics use for 1 months
16641052|NCT02341339|Experimental|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
16641053|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2
~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.
~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
16641233|NCT02340065|Active Comparator|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
16641054|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3
~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.
~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
16641055|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3
~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.
~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
16641056|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
16641057|NCT02341300|Experimental|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
16641058|NCT02341300|Placebo Comparator|Aluminum Pot|12 inch nonstick aluminum fry pan
16641059|NCT02341287|Active Comparator|Warming hydrogel glove|"Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
~Warming hydrogel device"
16641060|NCT02341287|Placebo Comparator|Non thermal hydrogel glove|"Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
~Non thermal hydrogel device"
16641061|NCT02341274|Active Comparator|Fresh Brand Name Tacrolimus (Prograf®)|Oral administration of 5 mg capsule of fresh brand name tacrolimus (Prograf®) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
16641062|NCT02341274|Active Comparator|Fresh Generic Tacrolimus|Oral administration of 5 mg capsule of fresh generic tacrolimus to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
16641063|NCT02341274|Active Comparator|Low Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 10-30% crystallized generic tacrolimus (Low Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
16641064|NCT02341274|Active Comparator|High Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 40-60% crystallized generic tacrolimus (High Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
16641065|NCT02341261|Experimental|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
16641066|NCT02341261|Experimental|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
16641067|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease [children who are found not to have Crohn's disease will not participate further].
~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day] per day"
16641068|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.
~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day]"
16641069|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
16641070|NCT02341235|Experimental|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
16641071|NCT02341235|Active Comparator|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
16641072|NCT02341222|Experimental|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
16641103|NCT02340975|Experimental|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
16641432|NCT02338739|Active Comparator|Voucher; Navigator if Failure|
16641073|NCT02341222|Active Comparator|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
16641074|NCT02341209|Experimental|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
16641075|NCT02341196|Experimental|CEA + Polyester patch|225 Patients
16641076|NCT02341196|Experimental|CEA + Patch Polyurethane|225 Patients
16641077|NCT02341183|Active Comparator|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
16641078|NCT02341183|Active Comparator|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
16641079|NCT02341170|Experimental|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
16641080|NCT02341170|No Intervention|Observation|Observation
16641081|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
16641082|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
16641083|NCT02341131|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes & Reeder, 2005)
16641084|NCT02341131|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
16641085|NCT02341131|No Intervention|Healthy Controls|No intervention
16641086|NCT02341105|Active Comparator|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
16641087|NCT02341105|Active Comparator|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
16641088|NCT02341079|Active Comparator|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
16641089|NCT02341079|Experimental|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
16641090|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
16641091|NCT02341053|Other|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
16641092|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
16641093|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
16641094|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
16641095|NCT02341001|No Intervention|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
16641096|NCT02341001|Experimental|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
16641097|NCT02340988|Experimental|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
16641098|NCT02340988|Experimental|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
16641099|NCT02340975|Experimental|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
16641100|NCT02340975|Experimental|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
16641101|NCT02340975|Experimental|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
16641102|NCT02340975|Experimental|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
16641127|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
16641104|NCT02340975|Experimental|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
16641105|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
16641106|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
16641107|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:
~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².
~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.
~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
16641108|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:
~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².
~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
16641109|NCT02340936|Experimental|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
16641110|NCT02340936|Experimental|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
16641111|NCT02340936|Experimental|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
16641112|NCT02340936|Experimental|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
16641113|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
16641114|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
16641115|NCT02340910|Experimental|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
16641116|NCT02340910|Experimental|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
16641117|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
16641118|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
16641119|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
16641120|NCT02340884|Experimental|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
16641121|NCT02340884|No Intervention|Control|Standard psychosocial supportive care
16641122|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
16641123|NCT02340858|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
16641124|NCT02340858|No Intervention|Control|The patients without treatment
16641125|NCT02340845|Active Comparator|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
16641126|NCT02340845|Active Comparator|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
16641129|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
16641130|NCT02340793|Experimental|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
16641131|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
16641132|NCT02340767|No Intervention|No Device Clinicians|The clinicians will not receive any additional training.
16641133|NCT02340767|Experimental|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
16641134|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
16641135|NCT02340754|Experimental|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
16641136|NCT02340754|Active Comparator|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
16641137|NCT02340741|Other|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.
~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
16641138|NCT02340741|Other|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.
~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
16641139|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
16641140|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
16641141|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
16641142|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
16641143|NCT02340689||Genetic testing|Genetic Analysis
16641144|NCT02340676|Experimental|ECP plus IL-2|"Extracorporeal Photopheresis (ECP) standard-of-care
~Daily subcutaneous (SC) interleukin-2 (IL-2) (Proleukin®) during predetermined weeks of treatment cycle"
16641145|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
16641146|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
16641147|NCT02340650||Bladder Cancer Patients|High resolution images of normal bladder tissue and suspicious bladder lesions will be collected from patients who present to the study site for clinical evaluation.
16641148|NCT02340637|Experimental|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.
~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.
~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
16641234|NCT02340065|Active Comparator|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
16641235|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
16641149|NCT02340637|Active Comparator|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
16641150|NCT02340624|No Intervention|Control group|No intervention(control group)
16641151|NCT02340624|Experimental|condition 2|Intervention:Smokefreemoms texting
16641152|NCT02340624|Experimental|condition 3|Intervention: Quitline referral
16641153|NCT02340624|Experimental|condition 4|Intervention:Smokefreemoms texting and quitline referral
16641154|NCT02340624|Experimental|condition 5|Intervention: Brief intervention
16641155|NCT02340624|Experimental|condition 6|Intervention:Smokefreemoms texting and Brief intervention
16641156|NCT02340624|Experimental|condition 7|Intervention: Quitline referral and Brief intervention
16641157|NCT02340624|Experimental|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
16641158|NCT02340611|Experimental|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
16641159|NCT02340598|Experimental|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
16641160|NCT02340598|No Intervention|control|No intervention, just recording of risk factors and basal metabolic rate.
16641161|NCT02340585|Experimental|Next Generation Neuroform Stent System|The Next Generation Stent System is a self-expanding, open cell, nitinol stent designed to provide support of the coil mass within the aneurysm and minimize stent deflection.
16641162|NCT02340572|Experimental|PRS-080#022-DP|hepcidin antagonist, single administration, ascending doses
16641163|NCT02340572|Placebo Comparator|PRS-080-Placebo#001|Comparotor treatment, single administration
16641164|NCT02340559|Experimental|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
16641165|NCT02340559|Active Comparator|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
16641166|NCT02340533|Experimental|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
16641167|NCT02340520|Experimental|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
16641168|NCT02340507|Experimental|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
16641169|NCT02340507|Experimental|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
16641170|NCT02340494|No Intervention|Control group|Women without access to the website.
16641171|NCT02340494|Experimental|Intervention group|Women with access to the website.
16641172|NCT02340481|Experimental|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
16641173|NCT02340481|Active Comparator|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
16641174|NCT02340455|Experimental|Pregabalin_male|
16641175|NCT02340455|Experimental|Pregabalin_female|
16641176|NCT02340455|Active Comparator|Placebo_male|
16641177|NCT02340455|Active Comparator|Placebo_female|
16641178|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
16641179|NCT02340442||High risk group|"40 pregnant women:
~20 Pregnant women with preeclampsia
~20 Obese pregnant women"
16641180|NCT02340442||Healthy control subjects|40 subjects
16641181|NCT02340429|Experimental|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
16641182|NCT02340429|No Intervention|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
16641183|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
16641184|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
16641185|NCT02340390|Experimental|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
16641186|NCT02340390|Experimental|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
16641187|NCT02340364|Experimental|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
16641188|NCT02340364|Active Comparator|Educational Control Arm|- 208 patients randomized to self-care education alone.
16641189|NCT02340351|Active Comparator|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
16641190|NCT02340351|Active Comparator|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
16641191|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
16641192|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
16641193|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
16641194|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
16641195|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
16641196|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
16641197|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
16641198|NCT02340325|Other|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
16641199|NCT02340325|Other|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
16641200|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.
~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.
~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
16641201|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.
~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.
~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
16641202|NCT02340273|Experimental|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
16641203|NCT02340273|Placebo Comparator|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
16641204|NCT02340260|Other|High intensity interval training|High intensity interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 10x1-minute intervals at 90 % of HRmax, with 75 seconds of active recovery at 70 % of HRmax between each interval. Exercise is completed with a three minute cool down. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
16641236|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
16641237|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
16641238|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
16641239|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
16641205|NCT02340260|Other|Sprint interval training|Sprint interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 2x20 seconds of maximum intensity intervals, with 3 minutes and 20 seconds of active recovery at 70 % of HRmax between each interval, followed by 3 minutes cooling down at the same intensity. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
16641206|NCT02340247|Experimental|Placebo|150mL water
16641207|NCT02340247|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
16641208|NCT02340247|Experimental|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
16641209|NCT02340234|Experimental|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
16641210|NCT02340234|Experimental|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
16641211|NCT02340234|Experimental|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
16641212|NCT02340234|Placebo Comparator|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
16641213|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
16641214|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
16641215|NCT02340208|Experimental|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
16641216|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
16641217|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
16641218|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B
~8 patients with moderate renal impairment"
16641219|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B
~8 patients with mild renal impairment"
16641220|NCT02340182|Experimental|Antibiotics|"All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):
~Vancomycin 250mg 3dd2;
~Ciprofloxacin 500mg 2dd1;
~Metronidazole 500mg 3dd1."
16641221|NCT02340169|Experimental|Topicort® Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25%, twice a day for 28 days
16641222|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
16641223|NCT02340143|Active Comparator|Control|Marketed partially hydrolyzed cow's milk protein infant formula
16641224|NCT02340143|Experimental|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
16641225|NCT02340130|Experimental|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
16641226|NCT02340130|Experimental|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
16641227|NCT02340117|Experimental|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. SGT-53, at 3.6 mg DNA/infusion, will be administered bi-weekly on days 1 and 5 in weeks 1-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive two additional courses (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on SGT-53/gemcitabine/nab-paclitaxel at investigator discretion with the approval of the sponsor.
16641228|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
16641229|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
16641230|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
16641231|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
16641232|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
16641242|NCT02340039|Placebo Comparator|Control drink|No polyphenols delivered in a low sugar fruit drink
16641243|NCT02340026|Experimental|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
16641244|NCT02340026|Experimental|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
16641245|NCT02340013|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
16641246|NCT02340013|No Intervention|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
16641247|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
16641248|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
16641249|NCT02339974|Experimental|Severe Tricuspid Regurgitation|
16641250|NCT02339948|Active Comparator|SBRT only|Patients assigned to this arm receive 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
16641251|NCT02339948|Active Comparator|IMRT plus SBRT Boost|Patients assigned to this arm receive 1.8 Gy per fraction for 25 fractions over 5 weeks for a total of 45.0 Gy followed by an SBRT boost of 5.5 Gy per fraction for 4 fractions after IMRT for a total of 22.0 Gy
16641252|NCT02339935|Experimental|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
16641253|NCT02339935|Other|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
16641255|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
16641256|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
16641257|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
16641258|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
16641259|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
16641260|NCT02339870|Experimental|Arm I (expressive disclosure)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.
16641261|NCT02339870|Experimental|Arm II (benefit finding)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.
16641262|NCT02339870|Sham Comparator|Arm III (control)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
16641263|NCT02339857||No-touch vein grafts to LAD|
16641264|NCT02339844|Active Comparator|antipsychotic treatment|individual doses of aripiprazole for all patients
16641265|NCT02339844|No Intervention|no treatment|no treatment for all healthy controls
16641266|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
16641267|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
16641268|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
16641269|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
16641270|NCT02339805|Experimental|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
16641271|NCT02339792|Other|Intervention|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
16641272|NCT02339792|Other|Control|e-learning program of medical education, focused on teaching only geriatric pharmacological notions (GPNs)
16641273|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
16641274|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
16641278|NCT02339753|Experimental|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days
~Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days
~MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days
~MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days
~MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
16641279|NCT02339740|Experimental|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
16641280|NCT02339727|Active Comparator|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
16641281|NCT02339727|Active Comparator|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
16641282|NCT02339714|Experimental|Acupuncture combined moxibustion|Acupuncture at Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Needle warming moxibustion at Dazhui(Du14). Patients will be treated once per day for 30 min, 3 times in a weeks for 4 weeks.
16641283|NCT02339714|Active Comparator|loratadine|Loratadine taken orally, 10mg/day in the morning
16641284|NCT02339701|Other|IMRT|Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.
16641285|NCT02339701|Other|SBRT|Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.
16641286|NCT02339688|Other|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
16641287|NCT02339675|Other|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
16641288|NCT02339662|Active Comparator|gabapentin|900 mg per day total, 3 pills of 300mg.
16641289|NCT02339662|Active Comparator|amitriptyline|20 mg total, 1pill
16641290|NCT02339649|Other|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).
~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
16641291|NCT02339649|Other|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:
~Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU
~Duration of ICU stay must be a minimum of 24 hours.
~Mini-Mental State Examination (MMSE) Score of 25 or above
~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
16641292|NCT02339649|Other|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.
~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
16641293|NCT02339636||case group|100 patients with vulgaris psoriasi without arthritis
16641294|NCT02339636||control group|100 age-matched patients with other skin diseases without arthritis
16641295|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :
~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )
~Cervical dilataion >1cm, &/or
~Cervical effacement ≥ 80%"
16641296|NCT02339610||ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:
~(CR FB, CR RP, PS FB, PS RP)."
16641297|NCT02339597|Experimental|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
16641298|NCT02339597|Experimental|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
16641299|NCT02339584|Experimental|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
16641300|NCT02339584|Active Comparator|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
16641303|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16641304|NCT02339545||All Enrolled Subjects|All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
16641305|NCT02339532|Experimental|TOP2A amplified|"If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w
~5-Fluorouracil (5-FU) 500 mg/m²
~Epirubicin 100 mg/m²
~Cyclophosphamide 500 mg/m²
~Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:
~Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
~DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w"
16641306|NCT02339532|Experimental|TOP2A not amplified|"If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles
~Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.
~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
~DOCETAXEL 75 mg/m² IV q3w
~CARBOPLATIN AUC 6 IV q3w
~The Calvert formula will be used to calculate the dose of carboplatin:
~Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25] Dose (mg) = 6 x [GFR mL/min + 25] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg."
16641307|NCT02339519|Active Comparator|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
16641308|NCT02339519|Active Comparator|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
16641309|NCT02339519|Active Comparator|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
16641310|NCT02339506|Active Comparator|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
16641311|NCT02339506|Placebo Comparator|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
16641312|NCT02339493|Experimental|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
16641313|NCT02339493|No Intervention|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
16641314|NCT02339480|No Intervention|Healthy volunteers|Healthy volunteers'hypothalamus picture of fMRI will compare with Obesity group' , no intervention and remaining unchanged lifestyle.
16641315|NCT02339480|Active Comparator|Obesity group|An intervention group of patients is put on a waiting list for massage therapy.Observing the Curative effect and hypothalamus picture of fMRI compare with healthy volunteers
16641316|NCT02339467|Experimental|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
16641317|NCT02339467|Active Comparator|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
16641318|NCT02339454|Active Comparator|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.
~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).
~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).
~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
16641319|NCT02339454|Placebo Comparator|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
16641320|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
16641321|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
16641322|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
16641323|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
16641324|NCT02339428|Experimental|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
16641325|NCT02339428|Placebo Comparator|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
16641326|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
16641327|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
16641328|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
16641329|NCT02339376|Experimental|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
16641330|NCT02339376|Experimental|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
16641433|NCT02338739|Active Comparator|Voucher; Navigator if Failure; Stop Voucher if Success|
16641331|NCT02339376|Sham Comparator|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
16641332|NCT02339363|Experimental|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
16641333|NCT02339363|Experimental|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
16641334|NCT02339363|No Intervention|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
16641335|NCT02339350|No Intervention|Rapid early responder group|"RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol
~RER Interim Maintenance #1
~RER Delayed Intensification
~RER Interim Maintenance #2
~RER Maintenance (12 weeks=84 days)"
16641336|NCT02339350|Experimental|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL
~1. SER Consolidation
~Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1
~high dose methotrexate included
~Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1
~Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2
~high dose methotrexate included
~Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2
~Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance
~Intrathecal triple chemotherapy at d0"
16641337|NCT02339337|Experimental|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, < 400000 IU/mL) and RVR (defined asHCV RNA <50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
16641338|NCT02339337|Active Comparator|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
16641339|NCT02339324|Experimental|This study has one arm that consists of 3 phases or steps.|"Induction phase (first 6 weeks): Pembrolizumab and High Dose IFNα-2b (HDI) Pembrolizumab I.V. every 3-4 weeks for 2 doses concurrently with HDI I.V. x 5 consecutive days every week for 4 weeks, followed by S.C. every other day 3x each week for 2 weeks.
~Surgery phase (week 6-8).
~Maintenance phase (following recovery from surgery): Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD (e.g. M,W,F) TIW every week for 46 additional weeks"
16641340|NCT02339298|Active Comparator|Music group|music application
16641341|NCT02339298|Sham Comparator|Control group|only headphones
16641342|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
16641343|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
16641344|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
16641345|NCT02339272||NOA|Infertile males with non obstructive azoospermia
16641346|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
16641347|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
16641348|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
16641349|NCT02339246|Active Comparator|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
16641350|NCT02339246|Active Comparator|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
16641351|NCT02339233|Experimental|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord
16641352|NCT02339220|Experimental|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
16641353|NCT02339220|Experimental|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
16641354|NCT02339220|Active Comparator|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
16641355|NCT02339220|Active Comparator|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
16641356|NCT02339207|Placebo Comparator|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
16641357|NCT02339207|Experimental|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
16641384|NCT02338999|Experimental|Placebo, then Pioglitazone|Treatment with placebo orally daily for three months. Followed by a two-month washout period before cross over to pioglitazone up to 45 mg daily orally for an additional three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
16641358|NCT02339194|Experimental|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:
~Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.
~Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.
~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.
~Insertion of finished dentures."
16641359|NCT02339194|No Intervention|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:
~Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.
~Mandibular second impression with border molding using compound and impression rubber in custom tray.
~Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.
~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.
~Finished dentures insertion."
16641360|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16641361|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
16641362|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
16641363|NCT02339142|Experimental|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks
~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
16641364|NCT02339142|Active Comparator|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
16641365|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
16641366|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
16641367|NCT02339116|Experimental|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):
~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
16641368|NCT02339116|Active Comparator|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1
~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):
~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
16641369|NCT02339103|No Intervention|Shivering only|Pt placed in sleeping bag and warmed by shivering only
16641370|NCT02339103|Experimental|Warmed IV fluids|2 Liter of 42 degree celsius normal saline
16641371|NCT02339103|Experimental|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
16641372|NCT02339090|Experimental|somavaratan|somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
16641373|NCT02339090|Active Comparator|Daily rhGH|Daily recombinant growth hormone therapy administered subcutaneously every day
16641374|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
16641375|NCT02339051|Experimental|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
16641376|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
16641377|NCT02339025||Tricare Participants|From WRNMC
16641383|NCT02338999|Experimental|Pioglitazone, then placebo|Treatment with pioglitazone up to 45 mg orally daily for three months. Followed by a two-month washout period before cross over to placebo orally daily for three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
16641386|NCT02338973|Experimental|Interferon Gamma-1b|Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks
16641387|NCT02338960|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks
~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
16641388|NCT02338960|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks
~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
16641389|NCT02338947|Active Comparator|Off-pump coronary-artery bypass grafting - OPCAB|"Pre-frail and frail patients will be randomly assigned to OPCAB after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
16641390|NCT02338947|Active Comparator|On-pump coronary-artery bypass grafting - CABG|"Pre-frail and frail patients will be randomly assigned to CABG after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
16641391|NCT02338934|Experimental|Cinacalcet with Vitamin D arm|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
16641392|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor
~Sitagliptin"
16641393|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors
~Dapagliflozin"
16641394|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist
~Lobeglitazone"
16641395|NCT02338908|Experimental|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
16641396|NCT02338908|Active Comparator|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
16641397|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
16641398|NCT02338882|Experimental|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
16641399|NCT02338882|Active Comparator|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
16641400|NCT02338869|Experimental|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
16641401|NCT02338869|No Intervention|Usual care Control group|Participants receive usual rehabilitation and care.
16641402|NCT02338856|Experimental|MB12066 200mg|
16641403|NCT02338856|Placebo Comparator|Placebo|
16641404|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
16641405|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
16641406|NCT02338830|Active Comparator|Progesterone group|Women received vaginal progesterone suppositories
16641407|NCT02338830|No Intervention|No treatment group|Women received no treatment
16641408|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
16641409|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
16641410|NCT02338804|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
16641411|NCT02338804|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
16641412|NCT02338791|Experimental|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
16641413|NCT02338778|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
16641414|NCT02338778|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
16641415|NCT02338765|Experimental|Buddy|Physical activity plus having a buddy
16641416|NCT02338765|Active Comparator|Control|Physical activity only
16641417|NCT02338752|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
16641418|NCT02338752|Active Comparator|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
16641419|NCT02338739|Active Comparator|REC; Outreach if Failure|
16641420|NCT02338739|Active Comparator|REC; SMS + Voucher if Failure|
16641434|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
16641435|NCT02338700|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
16641436|NCT02338700|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
16641437|NCT02338687|Active Comparator|Education|Educational sessions
16641438|NCT02338687|Experimental|Education plus supplement|Educational sessions and 500 mg calcium per day
16641439|NCT02338674|Experimental|COM|COM group receives combination therapy of tenofovir and telbivudine (TDF and LdT) for at least 48 weeks
16641440|NCT02338674|Active Comparator|TDF|TDF group receives single therapy of tenofovir (TDF) for at least 48 weeks
16641441|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
16641442|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
16641443|NCT02338635|Experimental|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
16641444|NCT02338635|Placebo Comparator|Placebo group|Placebo drug 1 tablet tid for 6 months
16641445|NCT02338622|Experimental|Schedule A: 4 days on, 3 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 4 days on, 3 days off
~Schema for dose escalation in schedule A (4-days-on, 3-days-off AZD5363)
~-1. Olaparib: 200mg, AZD5363 240mg
~Olaparib: 300mg, AZD5363 320mg
~Olaparib: 300mg, AZD5363 400mg
~Olaparib: 300mg, AZD5363 480mg"
16641446|NCT02338622|Experimental|Schedule B: 2 days on, 5 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 2 days on, 5 days off
~Schema for dose escalation in schedule B (2-days-on, 5-days-off AZD5363)
~-1. Olaparib: 200mg, AZD5363 400mg
~Olaparib: 300mg, AZD5363 480mg
~Olaparib: 300mg, AZD5363 560mg
~Olaparib: 300mg, AZD5363 640mg"
16641447|NCT02338609|Experimental|Everolimus|All patients will have been previously treated with everolimus as part of CRAD001M2301. Continued treatment with everolimus is allowed but not required for participation in this study. However, the physician may choose to place the patient on another treatment.
16641448|NCT02338609|Experimental|Physician Choice|
16641449|NCT02338596|Experimental|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
16641450|NCT02338596|Active Comparator|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
16641451|NCT02338570|Other|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
16641452|NCT02338557|Experimental|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
16641453|NCT02338557|Active Comparator|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
16641454|NCT02338531|Experimental|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
16641455|NCT02338518|Experimental|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
16641456|NCT02338518|Active Comparator|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
16641457|NCT02338505|Experimental|Telelap ALF-X in obese patients with gynecological disease|
16641458|NCT02338492|Experimental|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
16641459|NCT02338466|Placebo Comparator|rt-PA|"Patients treated by thrombolysis with rt -PA within 4h30 of the onset of symptoms to a proximal middle cerebral artery occlusion visible on a MRI 1 are pre- included. A second MRI ( IRM2 ) is performed between 1 hour and 1.5 hours after administration of rt-PA in the usual way .
~After the treatment by rt-PA, if there is no recanalization (TIMI score: 0,1, 2a), the patient is included. A patient included will be randomized either in the arm rt-PA treatment only or in the arm rt-PA + tenecteplase treatment. If he is included in the arm rt-PA only, he will not receive any other treatment for the study."
16641460|NCT02338466|Active Comparator|rt-PA + tenecteplase|"If patient is in the arm rt-PA + tenecteplase, he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications."
16641461|NCT02338453|Active Comparator|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
16641462|NCT02338453|Placebo Comparator|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
16641565|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
16641463|NCT02338440|Experimental|lipoprostaglandin E1 treatment arm|"lipoprostaglandin E1 1mcg/kg/day, continuous infusion
~lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
16641464|NCT02338427|Experimental|proteomic|
16641465|NCT02338414|Other|Romiplostim|Patients receiving romiplostim due to ITP
16641466|NCT02338401|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
16641467|NCT02338401|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
16641468|NCT02338388|Active Comparator|Single-layer unlocked closure|
16641469|NCT02338388|Active Comparator|Single-layer locked closure|
16641470|NCT02338388|Active Comparator|Double-layer closure|The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture.
16641471|NCT02338375|Experimental|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
16641472|NCT02338375|Active Comparator|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
16641473|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
16641474|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
16641475|NCT02338349|Experimental|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.
~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.
~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.
~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
16641476|NCT02338336|Placebo Comparator|Placebo|Placebo
16641477|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
16641478|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
16641479|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
16641480|NCT02338323|Experimental|Febuxostat|take orally, 40mg per day, for 1 year
16641481|NCT02338323|Experimental|Benzbromarone|take orally, 50mg per day, for 1 year
16641482|NCT02338310|No Intervention|No Aromatase Inhibitor|No aromatase inhibitor given around the time of surgery
16641483|NCT02338310|Experimental|Aromatase Inhibitor|Aromatase Inhibitor given perioperatively for 4 weeks (two weeks before and two weeks after surgery) Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day)
16641484|NCT02338297|Experimental|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
16641485|NCT02338297|Active Comparator|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
16641486|NCT02338271|Other|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study
~: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
16641487|NCT02338258|Experimental|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
16641488|NCT02338258|Placebo Comparator|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
16641489|NCT02338245|Experimental|Treatment Arm A|ASLAN001 + Capecitabine
16641490|NCT02338245|Active Comparator|Treatment Arm B|Lapatinib + Capecitabine
16641491|NCT02338232|Experimental|160 mg Telmisartan|60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days
16641492|NCT02338219|Active Comparator|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
16641493|NCT02338219|Active Comparator|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
16641494|NCT02338219|Active Comparator|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
16641495|NCT02338206|Active Comparator|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
16641496|NCT02338206|No Intervention|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
16641497|NCT02338193|Experimental|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
16641498|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
16641499|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
16641500|NCT02338180|No Intervention|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
16641501|NCT02338180|Experimental|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
16641502|NCT02338180|Experimental|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
16641503|NCT02338167||Advanced/metastatic breast cancer|3,500 patients with locally advanced, inoperable/metastatic breast cancer in any line of treatment (e.g. 1st, 2nd, 3rd, or ≥ 4th line).
16641504|NCT02338167||Early breast cancer|10,000 patients with breast cancer in the neoadjuvant and adjuvant (early breast cancer) setting independent of treatment regimen.
16641505|NCT02338141|Experimental|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
16641506|NCT02338141|Active Comparator|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
16641507|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
16641508|NCT02338102|Experimental|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
16641509|NCT02338102|No Intervention|Control Group|Subjects randomized to this arm receive no intervention.
16641510|NCT02338089|No Intervention|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
16641511|NCT02338089|Active Comparator|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
16641512|NCT02338089|Active Comparator|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
16641513|NCT02338076|Experimental|Interventional arm|petrolatum application under occlusion
16641514|NCT02338063|Experimental|1|Virtual Reality
16641515|NCT02338063|Experimental|2|Health Promotion
16641516|NCT02338050|Experimental|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
16641517|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16641518|NCT02338024|Experimental|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
16641519|NCT02338024|No Intervention|Standard of care|"Oral referrals to a network of government AIDS Centers or their departments (Trust offices) located in each study region."
16641520|NCT02338011|Experimental|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
16641521|NCT02338011|Experimental|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
16641522|NCT02337998|Experimental|Healthy men|each individual will serve as his own control by comparing baseline values to post intervention values
16641523|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
16641524|NCT02337972|Experimental|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
16641525|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
16641526|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
16641527|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
16641566|NCT02337764|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.
16641528|NCT02337946|Active Comparator|Group A|Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV), at Day 1, oxaliplatin (OXA) 85 mg/m^2, DIV, at Day 1, levofolinate (l LV) 200 mg/m^2, DIV, at Day 1, fluorouracil (5-FU) 400 mg/m^2, intravenous (IV) at Day 1, 5-FU 2400 mg/m^2, continuous intravenous infusion (CIV), at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
16641529|NCT02337946|Experimental|Group B|Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
16641530|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
16641531|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
16641532|NCT02337907|Placebo Comparator|Placebo comparator|
16641533|NCT02337907|Experimental|BI 409306 dose 1|
16641534|NCT02337907|Experimental|BI 409306 dose 2|
16641535|NCT02337907|Experimental|BI 409306 dose 3|
16641536|NCT02337907|Active Comparator|Active Comparator Donepezil|
16641537|NCT02337907|Experimental|BI 409306 dose 4|
16641538|NCT02337894|Experimental|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
16641539|NCT02337894|Placebo Comparator|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
16641540|NCT02337881|Active Comparator|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
16641541|NCT02337881|Active Comparator|nifedipen only|nifedipine alone in the same regimen and duration described before.
16641542|NCT02337868|Experimental|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
16641543|NCT02337868|Experimental|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
16641544|NCT02337868|Experimental|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
16641545|NCT02337868|Experimental|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
16641546|NCT02337855|Experimental|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
16641547|NCT02337855|Experimental|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
16641548|NCT02337855|Placebo Comparator|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
16641549|NCT02337855|Experimental|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
16641550|NCT02337855|Experimental|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
16641551|NCT02337855|Placebo Comparator|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
16641552|NCT02337855|Experimental|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
16641553|NCT02337855|Experimental|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
16641554|NCT02337855|Placebo Comparator|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
16641555|NCT02337842|Experimental|Cohort 1|N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units and N=1 single oral dose Placebo.
16641556|NCT02337842|Experimental|Cohort 2|N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units and N=1 single oral dose of Placebo.
16641557|NCT02337842|Experimental|Cohort 4|N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo
16641558|NCT02337842|Experimental|Cohort 3|N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units and N=2 single oral dose of Placebo
16641561|NCT02337816||Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
16641562|NCT02337816||Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
16641563|NCT02337803|Experimental|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
16641564|NCT02337803|Active Comparator|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
16641645|NCT02337205|Experimental|KX2-391 Ointment|
16641567|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
16641568|NCT02337738|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
16641569|NCT02337738|Experimental|TVP-1012 0.5mg|TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
16641570|NCT02337738|Placebo Comparator|Placebo|One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
16641571|NCT02337725|Experimental|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
16641572|NCT02337725|Placebo Comparator|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
16641573|NCT02337712|Experimental|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and concurrent etoposide and cisplatin
16641574|NCT02337712|Active Comparator|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and concurrent etoposide and cisplatin
16641575|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
16641576|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
16641577|NCT02337686|Experimental|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16641578|NCT02337660|Experimental|Healthy, lean|"15 healthy, lean subjects.
~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
16641579|NCT02337660|Experimental|Obese, otherwise healthy|"15 obese, otherwise healthy subjects
~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
16641580|NCT02337647|Other|DCDC app|Subjects will evaluate the DCDC app
16641581|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
16641582|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
16641583|NCT02337621||pectus excavatum surgical candidates|Any person who is eligible to undergo the Nuss procedure for surgical correction of pectus excavatum
16641584|NCT02337608|Experimental|GLPG1205 100mg QD|GLPG1205 100mg daily dosing in the morning
16641585|NCT02337608|Placebo Comparator|Placebo|Placebo daily dosing in the morning
16641586|NCT02337582|Active Comparator|Intervention|
16641587|NCT02337582|Other|Control|
16641588|NCT02337569|Experimental|NPC-02|Oral dose
16641589|NCT02337569|Placebo Comparator|Placebo|Oral dose
16641590|NCT02337556|Experimental|Intervention Group|Peptamen Bariatric
16641591|NCT02337556|Active Comparator|Control Group|Replete
16641592|NCT02337543|Experimental|Active: NEO6860|NEO6860 suspension is the drug under evaluation
16641593|NCT02337543|Placebo Comparator|placebo|Placebo matching NEO6860 suspension formulation
16641594|NCT02337530|Active Comparator|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m^2 & Cisplatin or Carboplatin*: AUC6: 75mg/m^2 given on day 1 Schedule = q 21 days
~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
16641595|NCT02337530|Active Comparator|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days
~**Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
16641596|NCT02337530|Active Comparator|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days
~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
16641597|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
16641598|NCT02337504|No Intervention|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
16641599|NCT02337504|Active Comparator|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
16641600|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle
~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
16641601|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle
~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
16641602|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle
~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
16641603|NCT02337478|Experimental|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16641604|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
16641646|NCT02337192|Experimental|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
16641647|NCT02337192|Experimental|Group 2|Mouthwash with Swish with Curcumin
16641605|NCT02337452||Observational (family outreach program)|Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.
16641606|NCT02337439|Experimental|Sensory Information Processing Training|Computerized training designed to improve sensory processing
16641607|NCT02337439|Active Comparator|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
16641608|NCT02337426|Experimental|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions
~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
16641609|NCT02337413|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
16641610|NCT02337413|Other|Urothearpy alone|This group will receive standard behavioral urotherapy alone
16641611|NCT02337400|Experimental|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
16641612|NCT02337400|Active Comparator|Counseling Interview|15 minute counseling interview
16641613|NCT02337400|No Intervention|Waiting Control Group|
16641614|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
16641615|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
16641616|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
16641617|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
16641618|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
16641619|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
16641620|NCT02337348|Experimental|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
16641621|NCT02337348|Active Comparator|Conventional coronary intervention|Coronary angiography
16641622|NCT02337322|Active Comparator|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
16641623|NCT02337322|Active Comparator|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
16641624|NCT02337309|Other|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
16641625|NCT02337296|Other|Phase 1 - Intervention|Five patients will be enrolled consecutively for the ADHERE intervention and be followed in order to refine the intervention as needed. This permits the investigation of the process of change at baseline, after the intervention, and across the phases.
16641626|NCT02337296|No Intervention|Phase 2 - Control Group|Following completion of Phase 1 and prior to initiation of enrollment in the intervention group, patients will be enrolled in the control group and will receive usual care.
16641627|NCT02337296|Experimental|Phase 2 - Intervention Group|Following enrollment of all control group patients, the intervention group will be recruited and enrolled and the ADHERE intervention will be conducted by the trained APRN interventionist at cancer center.
16641628|NCT02337283|Experimental|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
16641629|NCT02337283|Placebo Comparator|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
16641630|NCT02337283|Experimental|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
16641631|NCT02337283|Experimental|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
16641632|NCT02337283|Experimental|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
16641633|NCT02337283|Experimental|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
16641634|NCT02337283|Experimental|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
16641635|NCT02337270|Experimental|Group 1 Aerosol|Receive 10^6 Ad5Ag85A by aerosol at day 0
16641636|NCT02337270|Experimental|Group 2 Aerosol|Receive 2x10^6 Ad5Ag85A by aerosol at day 0
16641637|NCT02337270|Experimental|Group 3 Intramuscular|Receive 10^8 Ad5Ag85A by intramuscular injection at day 0
16641638|NCT02337257|Active Comparator|cholecalciferol|Subjects will take 4000 IU per day for 30 days
16641639|NCT02337257|Placebo Comparator|Placebo|Subjects will take placebo everyday for 30 days
16641640|NCT02337231|Other|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
16641641|NCT02337231|Other|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
16641642|NCT02337231|Other|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
16641643|NCT02337218|Active Comparator|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
16641644|NCT02337218|Sham Comparator|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
16641648|NCT02337192|Experimental|Group 3|Moutwash with Swish with Curcumin + SDS
16641649|NCT02337192|Experimental|Group 4|Experiment use dental irradiation with blue light (LED) only.
16641650|NCT02337192|Experimental|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
16641651|NCT02337192|Experimental|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
16641652|NCT02337192|Experimental|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
16641653|NCT02337179|Experimental|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
16641654|NCT02337166|Active Comparator|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
16641655|NCT02337166|Experimental|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
16641656|NCT02337140|Experimental|Pacemaker|Patient who have been implanted with a pacemaker after TAVI
16641657|NCT02337140|Active Comparator|No Pacemaker|Patient who have not been implanted with a pacemaker after TAVI
16641658|NCT02337127|Active Comparator|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
16641659|NCT02337127|No Intervention|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
16641660|NCT02337114|Experimental|Intervention group|Treatment as Usual and Acceptance & Commitment Therapy
16641661|NCT02337114|Other|Comparison group|Treatment as Usual
16641662|NCT02337101|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
16641663|NCT02337101|Experimental|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
16641664|NCT02337088|Active Comparator|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
16641665|NCT02337088|Experimental|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
16641666|NCT02337075|Experimental|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
16641667|NCT02337075|Active Comparator|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
16641668|NCT02337062|Experimental|APD421 + standard anti-emetic|Single dose of IV APD421
16641669|NCT02337062|Placebo Comparator|Placebo + standard anti-emetic|Single dose of IV placebo
16641670|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
16641671|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
16641672|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
16641673|NCT02337036|Experimental|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
16641674|NCT02337023||healthy subjects|
16641675|NCT02337023||patients with Kleine-Levin Syndrome|
16641676|NCT02337010|Active Comparator|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
16641677|NCT02337010|Experimental|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
16641678|NCT02336997|Experimental|FAT-GRAFT|Fat graft transplantation
16641679|NCT02336997|Experimental|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
16641680|NCT02336997|Placebo Comparator|CONTROL|Same volume saline injection
16641681|NCT02336984|Experimental|Combination Therapy|Combination Therapy: HER-2 pulsed DC1 vaccine with trastuzumab and pertuzumab.
16641682|NCT02336971|Experimental|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.
~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
16641683|NCT02336971|Experimental|Prolonged Exposure|"PE for combat-related stress disorders [13-14] serves as the comparison treatment.
~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE [1-3] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
16641684|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
16641685|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
16641686|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
16641757|NCT02336516|Experimental|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ®
16641758|NCT02336516|Placebo Comparator|Glucose solution 10%|Glucose solution 10%
16641687|NCT02336919|Experimental|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
16641688|NCT02336919|No Intervention|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
16641689|NCT02336906|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
16641690|NCT02336906|Other|Urotherapy alone|This group will receive standard behavioral urotherapy alone.
16641691|NCT02336893|No Intervention|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
16641692|NCT02336893|Experimental|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
16641693|NCT02336880|Experimental|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
16641694|NCT02336880|No Intervention|Control group|Care as usual
16641695|NCT02336867|Experimental|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
16641696|NCT02336867|Other|Control group|advancement flap technique
16641697|NCT02336854|Experimental|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
16641698|NCT02336854|Active Comparator|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I & II D1(crossover)
16641699|NCT02336841|Experimental|Intervention|Participants in this condition will receive the guided self-help intervention.
16641700|NCT02336841|Active Comparator|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
16641701|NCT02336828||MEWS alarm and mortality|Reach MEWS Alarm, Not reach MEWS Alarm, With 7 day mortality, Without 7 day mortality
16641702|NCT02336815|Experimental|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
16641703|NCT02336815|Experimental|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
16641704|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
16641705|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
16641706|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
16641707|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
16641708|NCT02336789|Placebo Comparator|placebo|250 ml of normal saline (sham transplantation).
16641709|NCT02336789|Active Comparator|intervention|250 ml of diluted fecal material prepared from a screened donor
16641710|NCT02336776|Experimental|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
16641711|NCT02336776|No Intervention|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
16641712|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
16641713|NCT02336750|Experimental|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
16641714|NCT02336750|Experimental|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
16641715|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.
~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
16641716|NCT02336724|Experimental|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
16641717|NCT02336711|Experimental|Dose escalation|Dose escalation
16641718|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
16641719|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
16641720|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
16641759|NCT02336503|Experimental|BBI-4000 Dose 1|Low concentration of BBI-4000
16641721|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
16641722|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
16641723|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
16641724|NCT02336672|No Intervention|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
16641725|NCT02336672|Experimental|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
16641726|NCT02336659|Placebo Comparator|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
16641727|NCT02336659|Experimental|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
16641728|NCT02336659|Experimental|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2
16641729|NCT02336659|Experimental|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2
16641730|NCT02336646|Experimental|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
16641731|NCT02336646|Experimental|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
16641732|NCT02336646|Placebo Comparator|Placebo|normal saline with Intramuscular injection
16641733|NCT02336633|Experimental|1|Resveratrol (80mg/j = 4 capsules/day)
16641734|NCT02336633|Placebo Comparator|2|Placebo (4 capsules/day)
16641735|NCT02336620|Experimental|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
16641736|NCT02336620|Active Comparator|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
16641737|NCT02336607|Experimental|Felodipine tablet (Plendil)|
16641738|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
16641739|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
16641740|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
16641741|NCT02336594|Experimental|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
16641742|NCT02336594|Experimental|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
16641743|NCT02336594|Experimental|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
16641744|NCT02336594|Experimental|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
16641745|NCT02336581|Experimental|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
16641746|NCT02336581|Active Comparator|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
16641747|NCT02336568|Experimental|intervention|intervention: Oxytoine treatments - 20 PTSD patients
16641748|NCT02336568|Placebo Comparator|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
16641749|NCT02336555|Experimental|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
16641750|NCT02336555|Experimental|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
16641751|NCT02336542|Experimental|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
16641752|NCT02336542|Active Comparator|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
16641753|NCT02336529|Experimental|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
16641754|NCT02336529|Placebo Comparator|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
16641755|NCT02336529|Experimental|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
16641756|NCT02336529|Placebo Comparator|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
16641760|NCT02336503|Experimental|BBI-4000 Dose 2|Middle concentration of BBI-4000
16641761|NCT02336503|Experimental|BBI-4000 Dose 3|High concentration of BBI-4000
16641762|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo)
16641763|NCT02336490|No Intervention|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
16641764|NCT02336490|Active Comparator|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
16641765|NCT02336477|Experimental|1|Mexiletine / Placebo
16641766|NCT02336477|Experimental|2|Placebo / Mexiletine
16641767|NCT02336451|Experimental|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
16641768|NCT02336451|Experimental|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
16641769|NCT02336451|Experimental|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
16641770|NCT02336451|Experimental|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
16641771|NCT02336451|Experimental|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
16641772|NCT02336438|No Intervention|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).
~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
16641773|NCT02336438|Experimental|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).
~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.
~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
16641774|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
16641775|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
16641776|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
16641777|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
16641778|NCT02336412|Experimental|SMS reminder|Daily SMS medication reminder
16641779|NCT02336412|No Intervention|No SMS reminder|No daily SMS medication reminder
16641780|NCT02336386|Experimental|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
16641781|NCT02336386|Active Comparator|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
16641782|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
16641783|NCT02336360|Experimental|Urine Analysis|Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
16641784|NCT02336347|Experimental|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
16641785|NCT02336347|Active Comparator|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
16641786|NCT02336347|Active Comparator|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
16641787|NCT02336347|Experimental|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
16641788|NCT02336334|Experimental|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types
~Interventions:
~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
16641789|NCT02336334|Experimental|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types
~Interventions:
~Positioning measurement Patient feedback Usefulness of a sketch"
16641790|NCT02336321|Experimental|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
16641791|NCT02336308|Active Comparator|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
16641910|NCT02335281|Active Comparator|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
16641792|NCT02336308|Placebo Comparator|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
16641793|NCT02336295|Other|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
16641794|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.
~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.
~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
16641795|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.
~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.
~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
16641796|NCT02336256|Experimental|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
16641797|NCT02336256|Active Comparator|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
16641798|NCT02336243|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
16641799|NCT02336243|Placebo Comparator|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
16641800|NCT02336230|Experimental|Active Treatment|
16641801|NCT02336217|Experimental|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
16641802|NCT02336217|Placebo Comparator|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
16641803|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
16641804|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
16641805|NCT02336165|Experimental|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
16641806|NCT02336165|Experimental|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
16641807|NCT02336165|Experimental|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
16641808|NCT02336165|Experimental|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
16641809|NCT02336165|Experimental|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
16641810|NCT02336152|Experimental|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
16641811|NCT02336152|Active Comparator|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
16641812|NCT02336139|Experimental|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
16641813|NCT02336126|Experimental|Biopsychological intervention|
16641814|NCT02336113|No Intervention|Control group|Standard care during hospital stay, without pharmacist involved
16641815|NCT02336113|Experimental|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
16641816|NCT02336100|Experimental|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
16641817|NCT02336100|Experimental|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
16641818|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16641819|NCT02336074|Active Comparator|Control|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
16641820|NCT02336074|Experimental|Intervention|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
16641821|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
16641822|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
16641823|NCT02336048|Active Comparator|Placebo + Obinutuzumab + Chlorambucil|Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
16642022|NCT02334631|Experimental|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
16641824|NCT02336048|Experimental|Tocilizumab + Obinutuzumab + Chlorambucil|Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
16641825|NCT02336035|No Intervention|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.
~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
16641826|NCT02336035|Experimental|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.
~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
16641827|NCT02336009|Experimental|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
16641828|NCT02335996|Active Comparator|patients with active hypercortisolism|
16641829|NCT02335996|Active Comparator|Patients in remission of their hypercortisolism after surgery|
16641830|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
16641831|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
16641832|NCT02335983|Experimental|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
16641833|NCT02335983|Experimental|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
16641834|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
16641835|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
16641836|NCT02335970|Experimental|Training group|Training program: Daily exercises for 3 months
16641837|NCT02335970|No Intervention|Controls|Standard care
16641838|NCT02335957|Other|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
16641839|NCT02335957|Experimental|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
16641840|NCT02335944|Experimental|INC280 plus EGF816|Recruitment in Phase I dose escalation part is completed. Recruitment in Phase II dose expansion is ongoing.
16641841|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
16641842|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
16641843|NCT02335918|Experimental|Varlilumab and Nivolumab|
16641844|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
16641845|NCT02335879|Experimental|Recombinant Human Follitropin|
16641846|NCT02335866|Experimental|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
16641847|NCT02335866|Active Comparator|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
16641882|NCT02335554|Active Comparator|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
16641848|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:
~Abdominal obesity, defined as a waist circumference in men ≥88 cm
~Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides
~Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C
~Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
~Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
16641849|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
16641850|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
16641851|NCT02335840|Experimental|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
16641852|NCT02335840|Experimental|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
16641853|NCT02335840|Experimental|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
16641854|NCT02335840|Experimental|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
16641855|NCT02335827|Experimental|Group A|irreversible electroporation with voltage in level A for renal tumors
16641856|NCT02335827|Experimental|Group B|irreversible electroporation with voltage in level B for renal tumors
16641857|NCT02335827|Experimental|Group C|irreversible electroporation with voltage in level C for renal tumors
16641858|NCT02335814|Experimental|FLX925|
16641859|NCT02335788|Other|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
16641860|NCT02335749|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the distal thigh, can be reduced.
16641861|NCT02335736|Active Comparator|Normal|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
16641862|NCT02335736|Active Comparator|Poor responders|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
16641863|NCT02335736|Active Comparator|Polycystic ovarian disease|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
16641864|NCT02335723|Active Comparator|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
16641865|NCT02335723|Placebo Comparator|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
16641866|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
16641867|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
16641868|NCT02335697|Other|Intervention|Attitude change towards female circumcision
16641869|NCT02335697|Other|No intervention|No intervention
16641870|NCT02335684|Experimental|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
16641871|NCT02335671|Experimental|Intra-operative Magnetic Resonance Imaging (MRI)|"Preoperative diagnostic MRI
~Intra-operative MRI
~Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated
~Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
16641872|NCT02335658|Experimental|DSP-5423P|Percutaneous
16641873|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
16641874|NCT02335632|Placebo Comparator|Placebo|For Probiotics, 7 days
16641875|NCT02335632|Active Comparator|Probiotics|Probiotics of 120 mg/day for 7days
16641876|NCT02335619|Active Comparator|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
16641877|NCT02335619|No Intervention|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
16641878|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
16641879|NCT02335593|Experimental|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
16641880|NCT02335593|Active Comparator|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
16641881|NCT02335554|Experimental|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
16641883|NCT02335528|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
16641884|NCT02335528|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
16641885|NCT02335528|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
16641886|NCT02335515|Experimental|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
16641887|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
16641888|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
16641889|NCT02335450|Experimental|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
16641890|NCT02335437||Acute EBV infection|
16641891|NCT02335437||Healthy controls|
16641892|NCT02335424|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to 24 months.
16641893|NCT02335411|Experimental|Cohort 1: Pembro monotherapy, previously treated|Participants receive pembrolizumab (Pembro) 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
16641894|NCT02335411|Experimental|Cohort 2: Pembro combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV Q3W for up to 24 months + cisplatin 80 mg/m^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
16641895|NCT02335411|Experimental|Cohort 3: Pembro monotherapy, treatment naive|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 24 months
16641896|NCT02335398|Experimental|methadone|single group
16641897|NCT02335385|Active Comparator|SIL-V|single incision laparoscopic varicocelectomy
16641898|NCT02335385|Active Comparator|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
16641899|NCT02335372|Experimental|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
16641900|NCT02335359|Experimental|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
16641901|NCT02335359|Placebo Comparator|Placebo|Saline
16641902|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
16641903|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
16641904|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
16641905|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
16641906|NCT02335294|Experimental|TRV130|
16641907|NCT02335294|Active Comparator|Morphine|
16641908|NCT02335294|Placebo Comparator|Placebo|
16641909|NCT02335281|Experimental|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
16642090|NCT02334176|Active Comparator|single injection|Axillary plexus block performed with single injection dorsally to the artery
16641911|NCT02335268|Experimental|Group 1|"Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3
~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
16641912|NCT02335268|Experimental|Group 2|"Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2
~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
16641913|NCT02335268|Experimental|Group 3|"Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6
~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
16641914|NCT02335255|Experimental|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
16641915|NCT02335255|Active Comparator|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
16641916|NCT02335255|Placebo Comparator|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
16641917|NCT02335242|Placebo Comparator|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
16641918|NCT02335242|Experimental|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
16641919|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
16641920|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
16641921|NCT02335203|Experimental|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
16641922|NCT02335203|Placebo Comparator|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
16641923|NCT02335190|Experimental|PSN block and RF ablation|Participants will first undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. On a separate visit, participants will then undergo ablation of the PSN at the lateral crest under ultrasound-guidance.
16641924|NCT02335177|Active Comparator|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
16641925|NCT02335177|No Intervention|Control arm|Control arm : patients with usual care home
16641926|NCT02335164|Experimental|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
16641927|NCT02335164|Experimental|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
16641928|NCT02335164|Experimental|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
16641929|NCT02335164|Experimental|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
16641930|NCT02335164|Experimental|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
16641931|NCT02335164|Experimental|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
16641932|NCT02335164|Experimental|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
16641933|NCT02335164|Experimental|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
16641934|NCT02335164|Experimental|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
16641935|NCT02335151|Experimental|Desflurane|General anesthesia with Desflurane
16641936|NCT02335151|No Intervention|Propofol|General anesthesia with Propofol
16641937|NCT02335138|Placebo Comparator|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
16641938|NCT02335138|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
16641939|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
16641940|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
16641941|NCT02335112|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Head and Neck Neoplasms
16641942|NCT02335112|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Head and Neck Neoplasms
16641943|NCT02335112|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Head and Neck Neoplasms
16641944|NCT02335099|Active Comparator|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
16641945|NCT02335099|Placebo Comparator|Placebo|Placebo drug to be given twice a day for 6 months
16641946|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.
~Clinical and angiographic exclusion criteria as stated in the study protocol."
16641947|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :
~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:
~Symptoms of ischaemia
~Development of pathologic Q waves in the electrocardiogram (ECG)
~New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.
~Identification of an intracoronary thrombus by angiography.
~Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
16641948|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
16641949|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
16641950|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
16641951|NCT02335060|Placebo Comparator|Placebo and Placebo|
16641952|NCT02335047|Other|lower back pain|
16641953|NCT02335034|Experimental|Study group|Intervention: study group will attend two days of classes (two months apart) with the seven professional teams, covering what is the disease arthritis, its causes and treatment options; what is disease, being ill, and the role of the patient in the treatment to obtain behavioral change; the importance of exercise in relieving symptoms, the importance of rest and proper ergonomics at home and at work; proper alimentation; the difference between labor work and regular physical activity as well as the importance of strength resistance and stretching exercises; and the importance of leisure. The second intervention verifies the acquired concepts.
16641954|NCT02335034|Experimental|Control Group|The control group will only make evaluations / consultations with all professional teams without classes for 2 years, then will attend the courses and will be followed by two more years.
16641955|NCT02335021|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
16641956|NCT02335021|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
16641957|NCT02335021|Experimental|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
16641958|NCT02335021|Experimental|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
16641959|NCT02335008|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
16641960|NCT02335008|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
16641961|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
16641962|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
16641963|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
16641964|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
16641965|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
16641966|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
16641967|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
16641968|NCT02334969|Experimental|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
16641969|NCT02334969|Active Comparator|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
16641970|NCT02334956|Experimental|Patient|Patient with addiction
16641971|NCT02334956|Experimental|Control|healthy subject
16641972|NCT02334943|Experimental|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
16641973|NCT02334943|Experimental|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
16641974|NCT02334943|Experimental|Healthy witness|Healthy witness for Blood test
16641975|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
16641976|NCT02334917|Experimental|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
16641977|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
16641978|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
16641979|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
16641980|NCT02334878|Experimental|Stem cells,Mesenchymal|Periurethral injection of autologous bone-marrow derived stem cells.
16641981|NCT02334878|Active Comparator|surgery (TVT)|Tension-free vaginal tape operation: a midurethral sling operation
16641982|NCT02334865|Experimental|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
16641983|NCT02334865|Experimental|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
16641984|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
16641985|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
16641986|NCT02334839||healthy|women without gestational hypertension or preeclampsia
16641987|NCT02334826|Active Comparator|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
16641988|NCT02334826|Active Comparator|CABG|coronary artery bypass grafting
16642023|NCT02334631|Active Comparator|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
16642154|NCT02333773|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
16641989|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
16641990|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
16641991|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
16641992|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
16641993|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
16641994|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
16641995|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
16641996|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
16641997|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
16641998|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
16641999|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
16642000|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
16642001|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
16642002|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
16642003|NCT02334774|Experimental|Participants receiving an SOC Program|Participants following prolonged endotracheal intubation receiving a up to 14-day daily Swallowing and Oral Care Program.
16642004|NCT02334748|Experimental|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
16642005|NCT02334735|Experimental|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:
~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
16642006|NCT02334735|Active Comparator|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:
~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
16642007|NCT02334722|Experimental|1 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for one week.
16642008|NCT02334722|Active Comparator|6 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for six weeks.
16642009|NCT02334709|Experimental|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
16642010|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
16642011|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
16642012|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
16642013|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months.
16642014|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
16642015|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
16642016|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
16642017|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
16642018|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
16642019|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
16642020|NCT02334644|Experimental|1|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
16642021|NCT02334644|Placebo Comparator|2|Placebo
16642194|NCT02333500|Active Comparator|other workshop|Influence of other workshop on the rate of oxytocin
16642024|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.
~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
16642025|NCT02334605|Other|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
16642026|NCT02334605|Other|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
16642027|NCT02334592|Experimental|Low Pressure 100W sunbed|
16642028|NCT02334592|Experimental|Low Pressure 160W sunbed|
16642029|NCT02334592|Experimental|High Pressure sunbed|
16642030|NCT02334592|No Intervention|Control group|
16642031|NCT02334579|Experimental|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
16642032|NCT02334566|Experimental|NET TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
16642033|NCT02334566|Active Comparator|Delayed TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis, started following a three-month wait period
16642034|NCT02334553|Active Comparator|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
16642035|NCT02334553|Placebo Comparator|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
16642036|NCT02334540|Other|purses or a calorie/protein matched smoothie|
16642037|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
16642038|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
16642039|NCT02334501|Experimental|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
16642040|NCT02334488|Active Comparator|Everolimus-Tacrolimus|"Tacrolimus (Prograf®) started at 0,1 mg/kg/day since Day0, then adapted to C0 concentration (4-7 ng/ml),
~Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml)."
16642041|NCT02334488|Experimental|Everolimus-Mycophenolate sodium|"Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml),
~Tacrolimus (Prograg®) started at 0,1 mg/kg/day from J0 then to be adapted to C0 concentration (4-7 ng/ml), then replacement by mycophenolate sodium (Myfortic®) at M3 (3 months visit) started at 1440 mg/day."
16642042|NCT02334475|Experimental|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
16642043|NCT02334475|Active Comparator|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
16642044|NCT02334462|Experimental|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
16642045|NCT02334462|Experimental|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
16642046|NCT02334462|Experimental|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
16642047|NCT02334462|Experimental|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
16642048|NCT02334462|Experimental|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
16642049|NCT02334462|Experimental|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
16642050|NCT02334462|Active Comparator|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
16642051|NCT02334449|Experimental|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
16642052|NCT02334449|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
16642053|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
16642054|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
16642055|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
16642056|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
16642057|NCT02334410|No Intervention|Reference|
16642058|NCT02334410|Experimental|Whole body vibration (WBV)|Vibration therapy
16642059|NCT02334397|Active Comparator|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
16642060|NCT02334397|No Intervention|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
16642061|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
16642062|NCT02334384|No Intervention|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
16642063|NCT02334371|Other|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
16642064|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
16642065|NCT02334345|Experimental|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
16642066|NCT02334345|Active Comparator|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
16642067|NCT02334332|Active Comparator|Cohort I (standard care)|Participants receive standard post-operative care.
16642068|NCT02334332|Experimental|Cohort II (educational brochure)|Participants receive a 2-page educational brochure after surgery and prior to discharge home.
16642069|NCT02334319|Experimental|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
16642070|NCT02334306|Experimental|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
16642071|NCT02334306|Placebo Comparator|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
16642072|NCT02334293|Other|Omegaven|
16642073|NCT02334280|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
16642074|NCT02334280|No Intervention|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
16642075|NCT02334267|Active Comparator|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
16642076|NCT02334267|Active Comparator|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
16642077|NCT02334254|Experimental|Dual antithrombotic therapy (DAT)|Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban 2.5mg/5mg b.i.d. plus ticagrelor 90mg b.i.d.
16642078|NCT02334254|Active Comparator|Triple antithrombotic therapy (TAT)|Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
16642079|NCT02334241|Experimental|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
16642080|NCT02334241|Active Comparator|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
16642081|NCT02334228|Experimental|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
16642082|NCT02334228|Active Comparator|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
16642083|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
16642084|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
16642085|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
16642086|NCT02334202|Active Comparator|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
16642087|NCT02334202|Experimental|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
16642088|NCT02334189|Experimental|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
16642089|NCT02334189|No Intervention|No letter|Patients receive no letter (this is the usual care).
16642091|NCT02334176|Active Comparator|Double injection|Axillary plexus block performed with 2 injections: one over musculocutaneous nerve the second one dorsally to the artery
16642092|NCT02334163|Experimental|Nitazoxanide group|"12 patients will receive the following for 7 days:
~Oral lactulose
~500 mg nitazoxanide tablets twice daily"
16642093|NCT02334163|Active Comparator|Metronidazole group|"12 patients will receive the following for 7 days:
~Oral lactulose
~250 mg metronidazole tablets every 8 hours"
16642094|NCT02334163|Active Comparator|Rifaximine group|"12 patients will receive the following for 7 days:
~Oral lactulose
~Two 200 mg rifaximine tablets every 8 hours"
16642095|NCT02334150|Experimental|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
16642096|NCT02334150|No Intervention|Control group|Women in the control group were not provided any analgesia during labor.
16642097|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
16642098|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
16642099|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
16642100|NCT02334124|Experimental|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
16642101|NCT02334124|Active Comparator|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
16642102|NCT02334111|No Intervention|(Control)|Patients will receive standard of care
16642103|NCT02334111|Experimental|(Intervention)|Patients will receive RESPECT-Plus intervention
16642104|NCT02334098|Experimental|Omega-3 supplemented drink|A 200 ml. drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
16642105|NCT02334098|Placebo Comparator|Placebo Drink|exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
16642106|NCT02334098|No Intervention|treatment-as-usual controls|No drinks are taken.
16642107|NCT02334085||HOW study participants|
16642108|NCT02334072|Experimental|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
16642109|NCT02334072|Experimental|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
16642110|NCT02334072|Experimental|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
16642111|NCT02334072|Experimental|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
16642112|NCT02334072|Experimental|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
16642113|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
16642114|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
16642115|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
16642116|NCT02334046|Experimental|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
16642117|NCT02334046|Active Comparator|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
16642118|NCT02334020|Experimental|Training course|12 hour training course in Mental Health First-aid
16642119|NCT02334020|Other|Waiting list|Waiting list design, hence delayed offering of Mental Health First-aid
16642120|NCT02334007|Experimental|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
16642121|NCT02334007|Placebo Comparator|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
16642122|NCT02333994|Experimental|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
16642123|NCT02333994|Active Comparator|GROUP B|BALANCE EXERCISES
16642155|NCT02333773|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
16642156|NCT02333773|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
16642124|NCT02333981|Experimental|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
16642125|NCT02333968|Experimental|Intervention group|Self-management support
16642126|NCT02333968|No Intervention|Control group|Care as usual
16642127|NCT02333955|Experimental|3 mg IV push|GCS-100
16642128|NCT02333942||Alzheimer's Disease|Nautilus NeuroWaveTM System'
16642129|NCT02333942||Mild Cognitive Impairment|Nautilus NeuroWaveTM System'
16642130|NCT02333942||Frontotemporal Lobar Degeneration|Nautilus NeuroWaveTM System'
16642131|NCT02333942||Age-Matched Controls|Nautilus NeuroWaveTM System'
16642132|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
16642133|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
16642134|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
16642135|NCT02333916|Experimental|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.
~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).
~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
16642136|NCT02333903|Experimental|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
16642137|NCT02333903|No Intervention|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
16642138|NCT02333890|Experimental|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
16642139|NCT02333890|Placebo Comparator|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
16642140|NCT02333877|Experimental|Skinlink|applying Skinlink on simple laceration (length < 5cm)
16642141|NCT02333877|Other|Nylon|applying conventional suture using nylon on simple laceration (length < 5cm)
16642142|NCT02333864||PWD testing POGO® BGMS|All enrolled persons with diabetes
16642143|NCT02333851|Experimental|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
16642144|NCT02333851|Experimental|Basal-bolus|'Lantus® once daily and Apidra® before meals
16642145|NCT02333838|Experimental|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.
~The conditioning regimen will include:
~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)
~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
~IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)
~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:
~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
~IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
16642146|NCT02333825|Other|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
16642147|NCT02333825|Other|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
16642148|NCT02333812||copd patients|Adult patients with COPD
16642149|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
16642150|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
16642151|NCT02333799|Experimental|Bedaquiline + PA-824 + Linezolid|bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily .
16642152|NCT02333786|Experimental|Infant|Radial artery or posterior tibial artery of patients younger than 1 year old are either cannulated with short-axis/out-of-plane or long-axis/in-plane US-guided arterial catheterization technique.
16642153|NCT02333786|Experimental|Preschool child|Radial artery or posterior tibial artery of patients older than 1 year old and younger than 5 years old are either cannulated with long-axis/in-plane or short-axis/out-of-plane US-guided arterial catheterization technique.
16642193|NCT02333500|Experimental|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
16642157|NCT02333747|Experimental|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
16642158|NCT02333747|Sham Comparator|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
16642159|NCT02333734|Experimental|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
16642160|NCT02333734|Experimental|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
16642161|NCT02333721|Experimental|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
16642162|NCT02333721|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
16642163|NCT02333708||GCA group|
16642164|NCT02333708||Inflammatory syndrome (without GCA) group|
16642165|NCT02333708||Without inflammatory syndrome and without GCA group|
16642166|NCT02333695|Experimental|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
16642167|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
16642168|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
16642169|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
16642170|NCT02333682|Active Comparator|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
16642171|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
16642172|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
16642173|NCT02333656|No Intervention|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
16642174|NCT02333656|Experimental|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
16642175|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
16642176|NCT02333643|Experimental|Digoxin topical formulation|
16642177|NCT02333643|Experimental|Furosemide topical formulation|
16642178|NCT02333643|Placebo Comparator|Vehicle topical formulation|
16642179|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
16642180|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
16642181|NCT02333617|Experimental|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
16642182|NCT02333617|Active Comparator|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
16642183|NCT02333617|Placebo Comparator|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
16642184|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.
~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
16642185|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
16642186|NCT02333591|Placebo Comparator|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
16642187|NCT02333578|Experimental|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
16642188|NCT02333565|Experimental|Combinaison everolimus and octreotide|
16642189|NCT02333539|Experimental|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
16642190|NCT02333539|Experimental|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
16642191|NCT02333539|No Intervention|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
16642192|NCT02333513|Experimental|case group|
16642195|NCT02333500|Other|control group|Rate of oxytocin of the control group
16642196|NCT02333487|Experimental|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
16642197|NCT02333487|Experimental|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
16642198|NCT02333487|Experimental|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
16642199|NCT02333474|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.
16642200|NCT02333474|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given
16642201|NCT02333461|Placebo Comparator|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
16642202|NCT02333461|Experimental|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
16642203|NCT02333461|Experimental|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
16642204|NCT02333461|Experimental|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
16642205|NCT02333461|Experimental|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
16642206|NCT02333448||patients with suspected invasive candidiasis|
16642207|NCT02333435|Experimental|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
16642208|NCT02333435|Experimental|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
16642209|NCT02333422|Experimental|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
16642210|NCT02333409|Active Comparator|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
16642211|NCT02333409|Sham Comparator|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
16642212|NCT02333396|Experimental|PICU Supports|Participants will receive the PICU Supports intervention.
16642213|NCT02333396|Active Comparator|Educational Brochure|Participants will receive an educational brochure about the pediatric intensive care unit.
16642214|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
16642215|NCT02333370|Experimental|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
16642216|NCT02333370|Experimental|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
16642217|NCT02333370|Experimental|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
16642218|NCT02333357|Experimental|Toolkit|Counselors randomized to the toolkit (TK) condition will receive a one to three hour standardized toolkit orientation that will include a description of the overall goal of the toolkit curriculum comprised of five modules, the purpose of each individual element of the toolkit, and an introduction to the toolkit teaching aids such as counselor guides, posters, and patient materials (hand-outs, sampling menus, worksheets, etc). TK counselor participants then conduct group treatment sessions using the toolkit materials with their patient participants.
16642219|NCT02333357|Active Comparator|Treatment as Usual|Counselors assigned to the Treatment as Usual (TAU) attention control condition complete a training that reviews the same five 12-step topics that are included in the toolkit, but they do not receive any toolkit materials. TAU counselor participants then conduct group treatment sessions on the 12-step topics without using toolkit materials.
16642220|NCT02333344|Experimental|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
16642221|NCT02333344|No Intervention|blank|blank group
16642222|NCT02333331|Experimental|BYM338 70 mg|BYM338 70 mg intravenous infusion
16642223|NCT02333331|Experimental|BYM338 210 mg|BYM338 210 mg intravenous infusion
16642224|NCT02333331|Experimental|BYM338 700 mg|BYM338 700 mg intravenous infusion
16642225|NCT02333331|Placebo Comparator|Placebo|Placebo intravenous infusion
16642226|NCT02333318|Experimental|Single Dose_VVZ-149 injection|"Cohort A (50-64 years old), Cohort B (65-84 years old)
~For 2.5, 5mg/kg
~4-hr intravenous infusion of VVZ-149 injection
~6 subjects will be administered within each age group. Total 24 subjects will participate."
16642227|NCT02333318|Experimental|Loading/Maintenance_VVZ-149 injection|"Cohort A (50-64 years old) This trial is conducted only in the Cohort A one week after the single IV infusion.
~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h
~intravenous infusion
~4 subjects will be randomly assigned within each dose group, respectively. Total 8 subjects will participate."
16642228|NCT02333318|Placebo Comparator|Loading/Maintenance_Placebo|"Cohort A (50-64 years old)
~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h
~intravenous infusion
~2 subjects will be randomly assigned within each dose group, respectively. Total 4 subjects will participate."
16642229|NCT02333305|Experimental|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
16642230|NCT02333305|Placebo Comparator|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
16642231|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
16642232|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
16642233|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
16642234|NCT02333266||Candidemia|0
16642235|NCT02333253|Active Comparator|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach >12 mm, HCG was given only if we have at least 3 mature follicles >14 mm and the leading one >17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
16642236|NCT02333253|Active Comparator|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF >12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
16642237|NCT02333240|No Intervention|Usual care|"Women randomised to usual care will have their blood pressure monitored by their community midwife, and will have their anti-hypertensive medication adjusted by their general practitioner. There will be no intervention in this group.
~All women will be followed up at ten days, four and six weeks, then three and six months postpartum and have their blood pressure measured by one of the study team."
16642238|NCT02333240|Experimental|Self-management|Self-management of postnatal anti-hypertensive treatment. Women will be provided with, and taught to use, a validated home blood pressure monitor, and perform daily BP readings. When treatment is discontinued we will ask them to continue daily BP measurements for 1 week. Provided these are <140/90 mmHg they will be asked to check their BP weekly for the remainder of the trial period. The self-monitoring BP data will be collated centrally through the use of a smart phone app or SMS based system. This service will respond to participants regarding the level of their BP and what action is required. Women in the self-management group will have an individualised medication adjustment schedule developed by the research team in conjunction with the participant's obstetric team.
16642239|NCT02333227|No Intervention|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
16642240|NCT02333227|Experimental|Xylitol|Cluster of sites receiving xylitol gum.
16642241|NCT02333214|Experimental|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
16642242|NCT02333214|Active Comparator|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
16642243|NCT02333188|Experimental|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
16642244|NCT02333175|Active Comparator|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
16642245|NCT02333175|No Intervention|Care as usual|Care as usual
16642246|NCT02333162|Experimental|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.
~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
16642247|NCT02333149|Experimental|Melatonin|Dietary supplement: Melatonin 3 mg or 6 mg
16642248|NCT02333149|Placebo Comparator|Placebo|Drug: Placebo
16642249|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
16642250|NCT02333123|Experimental|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
16642251|NCT02333123|Placebo Comparator|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
16642252|NCT02333110|Experimental|GRID radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
16642253|NCT02333084|Experimental|Joint Health Product|natural dietary supplement
16642254|NCT02333084|Placebo Comparator|Placebo|vegetable oil placebo
16642255|NCT02333084|Active Comparator|Combination with Omega-3|combination with omega-3 fish oil
16642256|NCT02333071|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks
~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
16642257|NCT02333071|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks
~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
16642258|NCT02333058|Experimental|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.
~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.
~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
16642259|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
16642260|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
16642261|NCT02333032|Experimental|hemiplegic patient|
16642262|NCT02333019|Experimental|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
16642263|NCT02333019|Active Comparator|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
16642264|NCT02333006|Other|Traumatic brain injury questionnaires|Traumatic brain injury patients with anosognosia will answer to quetionnaires about Anosognosia compare to the answer of participant without neurological deficits
16642265|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
16642266|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
16642267|NCT02332980|Experimental|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.
~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
16642268|NCT02332967|Active Comparator|Whey predominant starter formula|Whey predominant starter formula
16642269|NCT02332967|Experimental|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
16642270|NCT02332967|Experimental|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
16642271|NCT02332954|Other|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
16642272|NCT02332954|Other|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
16642273|NCT02332941|Experimental|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
16642276|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
16642277|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
16642278|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
16642279|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
16642280|NCT02332876|Experimental|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
16642281|NCT02332876|Active Comparator|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
16642282|NCT02332863|Active Comparator|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
16642515|NCT02331576|Placebo Comparator|rocaine|continuous femoral nerve block with ropivacaine alone.
16644948|NCT02315495|No Intervention|control|
16642283|NCT02332863|Experimental|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
16642284|NCT02332850|Experimental|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.
~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
16642285|NCT02332850|Experimental|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).
~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
16642286|NCT02332837|Experimental|Digital informed consent|"Traditional digitally signed text based informed consent
~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
16642287|NCT02332837|Experimental|Multi-media informed consent|"Informed consent with images, text and auditory presentation
~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
16642288|NCT02332837|Experimental|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them
~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
16642289|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
16642290|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
16642291|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
16642292|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
16642293|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
16642294|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
16642295|NCT02332811|Experimental|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
16642296|NCT02332811|Experimental|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
16642297|NCT02332811|Experimental|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
16642298|NCT02332811|Experimental|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
16642302|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports & electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
16642303|NCT02332772||Data Collection Endoscopy of Colon Polyps|Data collected from endoscopy reports and electronic medical record system to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025.
16642304|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
16642305|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
16642306|NCT02332733|Experimental|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
16642307|NCT02332733|Placebo Comparator|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
16642331|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
16642332|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
16642308|NCT02332720|Experimental|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
16642309|NCT02332720|Experimental|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
16642310|NCT02332720|Experimental|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
16642311|NCT02332720|Experimental|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
16642312|NCT02332720|Experimental|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
16642313|NCT02332720|Experimental|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
16642314|NCT02332720|Experimental|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
16642315|NCT02332720|Experimental|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
16642316|NCT02332720|Experimental|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
16642317|NCT02332720|Experimental|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
16642318|NCT02332720|Experimental|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
16642319|NCT02332720|Experimental|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
16642320|NCT02332720|Experimental|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
16642321|NCT02332720|Experimental|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
16642322|NCT02332720|Experimental|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
16642323|NCT02332720|Experimental|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
16642324|NCT02332720|Experimental|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
16642325|NCT02332720|Experimental|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
16642326|NCT02332720|Experimental|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
16642327|NCT02332720|Experimental|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
16642328|NCT02332720|Experimental|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
16642329|NCT02332720|Experimental|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
16642330|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
16657697|NCT02230618||Ryzodeg™|
16642333|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
16642334|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
16642335|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
16642336|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
16642337|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
16642338|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
16642339|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
16642340|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
16642341|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
16642342|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
16642343|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
16642344|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
16642345|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
16642346|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
16642347|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
16642348|NCT02332694|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
16642349|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
16642350|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
16642351|NCT02332668|Experimental|Melanoma|Participants aged 6 months to <18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants aged 6 months to <12 years with melanoma was closed with Amendment 8. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues.
16642352|NCT02332668|Experimental|Solid Tumors and Other Lymphomas|Participants aged 6 months to <18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed. Enrollment of participants with solid tumors and other lymphomas was closed with Amendment 8.
16642353|NCT02332668|Experimental|rrcHL|Participants aged 3 years to <18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
16642354|NCT02332668|Experimental|MSI-H|Participants aged 6 months to <18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
16642355|NCT02332668|Experimental|TMB-H|Participants aged 6 months to <18 years with tumor-mutational burden-high ≥10 mutation/Mb (TMB-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
16642356|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
16642357|NCT02332629|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
16642358|NCT02332629|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
16642359|NCT02332616|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
16642360|NCT02332616|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
16642361|NCT02332603|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
16642362|NCT02332603|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
16642404|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
16642405|NCT02332278|Experimental|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
16642406|NCT02332278|Active Comparator|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
16642685|NCT02330484|No Intervention|Group with no incentives|
16642363|NCT02332590|Active Comparator|Adalimumab 40 mg|Adalimumab 40 mg subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during randomized treatment period. The dosing frequency of adalimumab may be adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (<20% improvement from baseline tender joint count [TJC] and swollen joint count [SJC] for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
16642364|NCT02332590|Experimental|Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during randomized treatment period. The dosing frequency of placebo for adalimumab may be adjusted to qw dosing in case of participants with inadequate response (<20% improvement from baseline TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
16642367|NCT02332564||Coronary Artery Disease|Patient with significant coronary artery disease
16642368|NCT02332564||No Coronary Artery Disease|Patient without significant coronary artery disease
16642369|NCT02332551|Experimental|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
16642370|NCT02332551|No Intervention|Control|
16642371|NCT02332538|Active Comparator|Greenlight (532nm-laser) PVEP|532nm-laser photoselective vapo-enucleation of the prostate)
16642372|NCT02332538|Active Comparator|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prostate
16642373|NCT02332538|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
16642374|NCT02332525|Experimental|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
16642375|NCT02332512|Experimental|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
16642376|NCT02332512|Placebo Comparator|Placebo|Placebo tablet administered orally, once a day until progression
16642377|NCT02332499|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16642378|NCT02332499|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16642379|NCT02332486|Active Comparator|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
16642380|NCT02332486|No Intervention|Blank|There is no intervention for people in the blank group.
16642381|NCT02332473|Active Comparator|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
16642382|NCT02332473|Experimental|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
16642383|NCT02332460||Infliximab|Patients treated with Infliximab
16642384|NCT02332447|Experimental|NALOXONE|
16642385|NCT02332447|Placebo Comparator|PLACEBO|
16642386|NCT02332434|Experimental|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
16642387|NCT02332434|Experimental|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
16642388|NCT02332421|Experimental|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
16642389|NCT02332421|No Intervention|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
16642390|NCT02332408|Experimental|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
16642391|NCT02332408|Active Comparator|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
16642392|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
16642393|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
16642394|NCT02332369|Experimental|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
16642395|NCT02332356|Active Comparator|step up|Procedure: MREC patients receive therapeutic step up
16642396|NCT02332356|No Intervention|observation step up|
16642397|NCT02332356|Active Comparator|step down|Procedure: MREC patients receive therapeutic step down
16642398|NCT02332356|No Intervention|observation step down|
16642399|NCT02332330|Experimental|VEST|
16642400|NCT02332317|No Intervention|Control arm|150 patients will receive standard oncology treatment.
16642401|NCT02332317|Active Comparator|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
16642402|NCT02332304|Other|Preterm fetus|Patients with pregnancies between 26 and 36 6/7 weeks of pregnancy. Before the birth, a sample of amniotic fluid was taken and analyzed using optical density at 650nm. A value above 0.15 was considered an indication of fetal lung maturity.
16642403|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
16666723|NCT02171663|Experimental|BIBW 2992|
16642407|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).
~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;
~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
16642408|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
16642409|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
16642410|NCT02332252|Active Comparator|Scalpel|Skin incision performed with a scalpel during cesarean section.
16642411|NCT02332252|Experimental|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
16642412|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention
~Eight-week longitudinal tailored CBT-based text-message program"
16642413|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition
~Eight-week longitudinal home safety & nutrition text-message program"
16642414|NCT02332226|Experimental|Representational approach|Four sessions with a nurse. For each session, the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's knowledge of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed.
16642415|NCT02332226|No Intervention|Control|Standard care as per ward protocol.
16642416|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
16642417|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
16642418|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
16642419|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
16642420|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
16642421|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
16642422|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
16642423|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
16642424|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
16642425|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
16642426|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is >10 weeks.
16642427|NCT02332187|Sham Comparator|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
16642428|NCT02332187|Active Comparator|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
16642429|NCT02332174|Experimental|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
16642430|NCT02332174|Experimental|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
16642431|NCT02332174|Experimental|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
16642432|NCT02332174|Experimental|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
16642433|NCT02332148|Experimental|3Vm1001|3VM1001 topical cream containing 10 mg/day of copper, for 30 days
16642434|NCT02332148|Placebo Comparator|Placebo|Placebo for 3VM1001, topical cream without 3VM1001
16642435|NCT02332135|Experimental|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
16642436|NCT02332135|Active Comparator|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
16642437|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.
~Additional for this study are:
~Sputum induction, Skin prick test, Questionnaires"
16642438|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.
~Additional for this study are:
~Sputum induction, Skin prick test, Questionnaires"
16642439|NCT02332109||ODM 5-group|
16642440|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
16642441|NCT02332083|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & Exergame) - T2
16642442|NCT02332083|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
16642443|NCT02332057|Active Comparator|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
16642444|NCT02332057|Placebo Comparator|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
16642445|NCT02332044|Experimental|Erdosteine 300mg|
16642446|NCT02332044|Experimental|Bepotastine besilate 10mg|
16642447|NCT02332044|Experimental|Erdosteine 300mg + Bepotastine besilate 10mg|
16642448|NCT02332031|Experimental|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
16642449|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
16642450|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
16642451|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
16642452|NCT02332005|Active Comparator|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
16642453|NCT02332005|Active Comparator|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
16642454|NCT02332005|Placebo Comparator|Group 3|Tablet administered twice daily morning and evening containing placebo
16642455|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
16642456|NCT02331979|Experimental|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
16642457|NCT02331979|Experimental|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
16642458|NCT02331979|Experimental|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
16642459|NCT02331953||delirium group|the patients with delirium after spine surgery
16642460|NCT02331953||no delirium group|the patients without delirium after spine surgery
16642461|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
16642462|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
16642463|NCT02331927|No Intervention|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
16642464|NCT02331927|Experimental|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
16642465|NCT02331914||Gastro-intestinal stromal tumors|"A bio-databank consisting of TKI drug level and serum for analysis of mutations in circulating tumor DNA will be set up. This bio-databank will be used to study whether changes in the amount of the primary KIT mutation is an early predictor of treatment response and/of failure. Moreover, secondary TKI resistant mutations in circulating tumor DNA will be assessed.
~To be able to assess those mutations, a tumor biopsy will be performed at the time of radiologic progressive disease. Vena puncture for blood collection will be performed at routine out patient visits."
16642466|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
16642467|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
16642468|NCT02331888|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
16642469|NCT02331875|Experimental|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
16642470|NCT02331862|Experimental|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
16642471|NCT02331862|No Intervention|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
16642472|NCT02331849|Other|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
16642473|NCT02331836|Active Comparator|Arc Endocuff (AEC 110, 120, 130, 140)|Endocuff-assisted colonoscopy Colonoscopy with the Endocuff attached at the distal tip of the scope
16642474|NCT02331836|Active Comparator|Cap|Cap-assisted colonoscopy Colonoscopy with the transparent Cap attached at the distal tip of the scope
16642475|NCT02331836|Active Comparator|Standard Colonoscope|Standard colonoscopy without any additional device
16642476|NCT02331823|Experimental|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
16642477|NCT02331823|Active Comparator|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
16642478|NCT02331810|Experimental|SAR113244|Single subcutaneous dose of SAR113244
16642479|NCT02331810|Placebo Comparator|Placebo|Single subcutaneous dose of placebo
16642480|NCT02331797|Experimental|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
16642481|NCT02331797|Active Comparator|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
16642482|NCT02331784|Experimental|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
16642483|NCT02331784|Active Comparator|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
16642484|NCT02331771|Active Comparator|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
16642485|NCT02331771|Placebo Comparator|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
16642486|NCT02331758|Experimental|Lifestyle counseling|The investigators use several methods to educate patients of controllable factors like lifestyle counseling, and monitor the factors like BMI and other index until the statistics become normal.
16642487|NCT02331758|No Intervention|No treatment|Patients without any intervention and still have abnormal factors like BMI, etc.
16642488|NCT02331745|Experimental|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
16642489|NCT02331745|Active Comparator|standard treatment|Standard treatment alone
16642490|NCT02331732|Active Comparator|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
16642491|NCT02331732|Experimental|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
16642492|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
16642493|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
16642494|NCT02331706|Experimental|Subject Recipients|
16642495|NCT02331706|Experimental|Subject Donors|
16642496|NCT02331693|Experimental|anti-EGFR CAR T|
16642497|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
16642498|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
16642499|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
16642500|NCT02331667|Experimental|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
16642501|NCT02331667|Experimental|Non-seafood|Intervention with meals constisting of non-seafood (meat).
16642502|NCT02331654|Experimental|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
16642503|NCT02331654|Placebo Comparator|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
16642504|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
16642505|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
16642506|NCT02331628|No Intervention|Control|Usual care only will be provided during Baseline period and Follow-up period.
16642507|NCT02331628|Experimental|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
16642508|NCT02331615|Experimental|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
16642509|NCT02331615|Experimental|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
16642510|NCT02331615|Sham Comparator|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
16642511|NCT02331602|Active Comparator|rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
16642512|NCT02331602|Active Comparator|dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
16642513|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
16642514|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
16642516|NCT02331576|Active Comparator|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
16642517|NCT02331563|Experimental|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
16642518|NCT02331563|Active Comparator|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
16642519|NCT02331550|Experimental|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
16642520|NCT02331550|Experimental|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
16642521|NCT02331537|Experimental|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
16642522|NCT02331537|No Intervention|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
16642523|NCT02331524|No Intervention|Control/Usual Care|Usual care only
16642524|NCT02331524|Experimental|Activity Feedback and Encouragement|Weekly Feedback about daily activity using the FitBit Zip
16642525|NCT02331524|Experimental|Health Coaching/Home Exercise|Weekly contact from physical therapist to develop and progress home exercise program and by health coach for goal setting and support
16642526|NCT02331511|Placebo Comparator|placebo|No antiplatelet drug
16642527|NCT02331511|Active Comparator|Aspirin|Aspirin 80 mg daily
16642528|NCT02331511|Active Comparator|Clopidogrel|Clopidogrel 75mg daily
16642529|NCT02331498|Other|A Pazopanib|Open label study with one group
16642530|NCT02331485|Experimental|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith & Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
16642531|NCT02331485|Active Comparator|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
16642532|NCT02331472||Interstitial cystitis|Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy
16642533|NCT02331472||Control|Adult participants without history of interstitial cystitis/bladder pain syndrome
16642534|NCT02331459|Experimental|Intervention group|"Multicomponent training intervention :
~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
16642535|NCT02331459|Placebo Comparator|Control group|Normal routine during 24 weeks.
16642536|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
16642537|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
16642538|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
16642539|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
16642540|NCT02331433|Experimental|Experimental: 1|
16642541|NCT02331433|Placebo Comparator|Placebo Comparator: 2|
16642542|NCT02331420|Experimental|Bariatric Surgery|Gastric bypass
16642543|NCT02331420|Active Comparator|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
16642544|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
16642545|NCT02331394|Experimental|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer.
16642546|NCT02331381|Experimental|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
16642547|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:
~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.
~Study Treatment:
~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
16642548|NCT02331316|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake
~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642549|NCT02331316|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake
~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642686|NCT02330471|Experimental|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
16666724|NCT02171650|Experimental|BIBW 2992|
16642550|NCT02331316|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake
~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642551|NCT02331316|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake
~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642552|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.
~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
16642553|NCT02331290||All patients|20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV
16642554|NCT02331277|Experimental|Multiple dose|Weekly dosing for four weeks
16642555|NCT02331277|Placebo Comparator|Placebo|Placebo
16642556|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
16642557|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
16642558|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
16642559|NCT02331251|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
16642560|NCT02331251|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
16642561|NCT02331251|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
16642562|NCT02331251|Experimental|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
16642563|NCT02331251|Experimental|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
16642564|NCT02331251|Experimental|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
16642565|NCT02331238|No Intervention|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
16642566|NCT02331238|Experimental|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).
~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
16642567|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
16642568|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
16642569|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
16642570|NCT02331212||Ancillary-correlative (role of HAS2+ in CSCs)|Blood and bone marrow samples are collected and analyzed via flow cytometry and PCR. Cells are also transplanted into mice and studied.
16642571|NCT02331199|Experimental|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
16642572|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
16642573|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
16642574|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
16642575|NCT02331160|Experimental|Rebozo|Intervention by Rebozo
16642576|NCT02331160|No Intervention|Control|Standard
16642577|NCT02331147|Sham Comparator|Standard of Care|Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading
16642578|NCT02331147|Active Comparator|Human Dermis|"Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.
~If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion"
16642579|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
16642580|NCT02331121|Active Comparator|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief & first aid
16642581|NCT02331121|Experimental|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief & first aid
16642582|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
16642687|NCT02330471|Active Comparator|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
16642583|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
16642584|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
16642585|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
16642586|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
16642587|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
16642588|NCT02331095|Active Comparator|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
16642589|NCT02331095|Experimental|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
16642590|NCT02331082|Active Comparator|Control|Existing healthcare system
16642591|NCT02331082|Experimental|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
16642592|NCT02331069|Active Comparator|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
16642593|NCT02331069|Active Comparator|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
16642594|NCT02331056||thoracoscopic pulmonary lobectomy|to observe a fluid responsiveness in patients who receives scheduled thoracoscopic pulmonary lobectomy
16642595|NCT02331056||open pulmonary lobectomy(thoracotomy)|to observe a fluid responsiveness in patients who receives scheduled open pulmonary lobectomy(thoracotomy)
16642596|NCT02331043|Placebo Comparator|Placebo biscuit|Biscuit without plant stanol ester
16642597|NCT02331043|Experimental|Plant stanol ester biscuit|Biscuit with plant stanol esters
16642598|NCT02331030|Experimental|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
16642599|NCT02331030|Active Comparator|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
16642600|NCT02331017|Experimental|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.
~Administration of Speech perception tests and self-rating questionnaire"
16642601|NCT02331004|Active Comparator|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
16642602|NCT02331004|Placebo Comparator|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
16642603|NCT02330991|Experimental|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
16642604|NCT02330991|Experimental|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
16642605|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
16642606|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
16642607|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
16642608|NCT02330952|Experimental|Prednisone|
16642609|NCT02330952|Placebo Comparator|Placebo|
16642610|NCT02330939|Active Comparator|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
16642611|NCT02330939|Experimental|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
16642612|NCT02330939|Experimental|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
16642613|NCT02330939|Active Comparator|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
16642614|NCT02330939|Experimental|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
16642615|NCT02330939|Experimental|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
16642616|NCT02330926|Experimental|multimodal intervention|standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)
16642617|NCT02330926|Active Comparator|standard care|standard palliative care
16642618|NCT02330913|Experimental|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
16642619|NCT02330900|No Intervention|Study group|Evaluation of interference
16642620|NCT02330887|Experimental|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
16642621|NCT02330887|Active Comparator|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
16642622|NCT02330861|Other|Normal coronary artery|
16642788|NCT02329808||Tacrolimus|Patients treated for their regular patient care with tacrolimus.
16666725|NCT02171637|Experimental|BIBW 2992|
16642623|NCT02330848|Active Comparator|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
16642624|NCT02330848|Active Comparator|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
16642625|NCT02330835|Experimental|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
16642626|NCT02330835|Active Comparator|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
16642627|NCT02330822|Experimental|Hyaluronic Acid Group|In this Group, Hyaluronic acid will be injected following extraction.
16642628|NCT02330822|No Intervention|Traditional Extraction Group|In this group, traditional extraction procedures will be followed.
16642629|NCT02330809|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642630|NCT02330809|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642631|NCT02330809|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals
~Intervention-B: Drink extra water at anytime over 24 hours"
16642632|NCT02330809|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.
~Intervention-B: Drink extra water at anytime over 24 hours"
16642633|NCT02330796|Experimental|Arm A|Bucillamine (900 mg total dose over 7 days)
16642634|NCT02330796|Experimental|Arm B|Bucillamine (1,800 mg total dose over 7 days)
16642635|NCT02330796|Active Comparator|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
16642636|NCT02330783|Experimental|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
16642637|NCT02330783|Active Comparator|Sorafenib|Sorafenib 400mg Bid
16642638|NCT02330770|Active Comparator|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
16642639|NCT02330770|Active Comparator|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
16642640|NCT02330770|Active Comparator|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
16642641|NCT02330757|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
16642642|NCT02330757|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
16642643|NCT02330744|Experimental|Approach-positive AAT|Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
16642644|NCT02330744|Placebo Comparator|Control AAT|Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
16642645|NCT02330731|Other|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
16642646|NCT02330731|Other|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
16642647|NCT02330731|Other|72% chromated glycerin|injection sclerotherapy for gastric varices
16642648|NCT02330705|Active Comparator|Group A|IUI at time of HCG
16642649|NCT02330705|Active Comparator|Group B|IUI 12 hours after HCG
16642650|NCT02330705|Active Comparator|Group C|IUI 34-36 hours after HCG
16642651|NCT02330679|Other|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
16642652|NCT02330666|No Intervention|Comparison|Standard care
16642653|NCT02330666|Experimental|Intervention|Communication skills training Mission Possible: Parents & Kids Who Listen
16642654|NCT02330653|Experimental|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
16642721|NCT02330250|Experimental|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
16676035|NCT02110420|Experimental|Placebo|
16642655|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
16642656|NCT02330640|Experimental|ticagrelor|90mg Bid for 30days after first dose
16642657|NCT02330640|Active Comparator|clopidogrel|75mg Qd for 30days first dose
16642658|NCT02330640|Other|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
16642659|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
16642660|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
16642661|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
16642662|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
16642663|NCT02330601|No Intervention|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
16642664|NCT02330601|Other|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
16642665|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
16642666|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
16642667|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
16642668|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
16642669|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
16642670|NCT02330575|Active Comparator|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
16642671|NCT02330575|Experimental|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
16642672|NCT02330562|Experimental|Phase 1: MRZ + BEV; Phase 2: MRZ alone|"Part1-Phase1: MRZ 10 minute IV infusion on Days 1, 8, and 15 plus BEV IV infusion on Days 1 and 15 of each 28-day cycle.
~Part2-Phase2: MRZ 10 minute IV infusion administered on Days 1, 8, and 15 of each 28-day cycle.
~Part3-Phase2: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion on Days 1, 8, and 15 of every 28-day cycle using intra-patient dose escalation. Starting dose will be 0.8 mg/m2.
~Part4- Phase1: All subjects will receive MRZ enterally by NG tube as a bolus on Days 1, 8 and 15 of the first 28-day cycle and BEV IV infusion on Day 15 of the first 28-day cycle. For subsequent 28-day treatment cycles, MRZ will be administered as an IV at the recommended dose and schedule determined in Part 1, with BEV IV on Days 1 and 15.
~Part5-Phase1: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion at 0.8 mg/m2 on Days 1, 8, and 15 of every 28-day cycle 0.8 mg/m2"
16642673|NCT02330549|Experimental|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
16642674|NCT02330549|Placebo Comparator|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
16642675|NCT02330536|Experimental|Flowrate A|insufflation of carbon dioxide at 8L/min, 8mmHg
16642676|NCT02330536|Experimental|Flowrate B|insufflation of carbon dioxide at 20 L/min, 8mmHg
16642677|NCT02330523|Active Comparator|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
16642678|NCT02330523|Active Comparator|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
16642679|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
16642680|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
16642681|NCT02330497|Experimental|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
16642682|NCT02330484|Experimental|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
16642683|NCT02330484|Experimental|incentives to patients|Give incentives to patients according to their HbA1c improvement
16642684|NCT02330484|Experimental|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
16642688|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
16642689|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
16642690|NCT02330432|Experimental|Mycobacterium w group|Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
16642691|NCT02330432|Active Comparator|Best standard care|Best standard care for sepsis
16642692|NCT02330419|Placebo Comparator|Placebo|Placebo 50mg, as needed
16642693|NCT02330419|Active Comparator|Naltrexone|Naltrexone 50mg, as needed
16642694|NCT02330406|Active Comparator|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
16642695|NCT02330406|Active Comparator|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
16642696|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
16642697|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is <100Kg or 90mg if the patient is >100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
16642698|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
16642699|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
16642700|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is <80Kg or 35mg if the patient is >80Kg.
16642701|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
16642702|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
16642703|NCT02330367|Experimental|AC0010|Oral AC0010 monotherapy
16642704|NCT02330354|Experimental|Intervention group|Centers in this group will participate in the Healthy Me, Healthy We program.
16642705|NCT02330354|Other|Control Group|Centers in this group will participate in the Healthy Me, Healthy We program after follow-up measures are collected.
16642706|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
16642707|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
16642708|NCT02330328|Experimental|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
16642709|NCT02330328|Active Comparator|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
16642710|NCT02330315|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
16642711|NCT02330315|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
16642712|NCT02330302|Active Comparator|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
16642713|NCT02330302|Active Comparator|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
16642714|NCT02330289|Experimental|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
16642715|NCT02330289|No Intervention|Control arm|Physicians in the control arm will not receive the email or website link.
16642716|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
16642717|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
16642718|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
16642719|NCT02330263|Experimental|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
16642720|NCT02330263|No Intervention|control group|Patients in the control group consume no food or drink after midnight before surgery.
16676226|NCT02109094||Pregnant|
16642722|NCT02330250|Sham Comparator|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
16642723|NCT02330237|Active Comparator|patients|natural gels
16642724|NCT02330237|Placebo Comparator|subjects|These patients will receive that placebo (vehicle) products.
16642725|NCT02330224|Experimental|Hypertension Management Intervention|Multifaceted hypertension management intervention
16642726|NCT02330224|No Intervention|Usual Care|Control group
16642727|NCT02330185|Experimental|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
16642728|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.
~When the end of operation, a injection of neostigmine or sugammadex will be administered."
16642729|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.
~When the end of operation,, a injection of neostigmine or sugammadex be administered."
16642730|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
16642731|NCT02330146|Experimental|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
16642732|NCT02330146|Placebo Comparator|Placebo|cryomedium
16642733|NCT02330133|Experimental|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
16642734|NCT02330133|Active Comparator|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
16642735|NCT02330120|Experimental|propofol|Propofol infusion 0.5-2 mg/kg/h for sedation in mechanically ventilated patients
16642736|NCT02330120|Active Comparator|dexmedetomidine|dexmedetomidine infusion 0.2-0.7 mcg/kg/h for sedation in mechanically ventilated patients
16642737|NCT02330107|Experimental|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
16642738|NCT02330107|Experimental|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
16642739|NCT02330107|Placebo Comparator|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
16642740|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
16642741|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
16642742|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:
~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.
~radio-labeled platelets derived from subjects untreated fresh whole blood."
16642743|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
16642744|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
16642745|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.
~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
16642746|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.
~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
16642747|NCT02330042||Group A|"Patients with:
~Type 1 or Type 2 diabetes mellitus
~severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR)."
16642748|NCT02330042||Group B|"Patients with:
~Type 1 or Type 2 diabetes mellitus
~with or without mild to moderate NPDR"
16642749|NCT02330042||Group C (controls)|Patients without diabetes or evidence of any form of eye disease
16642750|NCT02330029|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
16642751|NCT02330029|Active Comparator|Pinaverium|
16642752|NCT02330029|Placebo Comparator|Placebo|Placebo is blindly given to patients
16642787|NCT02329808||Cyclosporin|Patients treated for their regular patient care with cyclosporin.
16676227|NCT02109094||Not Pregnant|
16642753|NCT02330016|Experimental|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
16642754|NCT02330003|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
16642755|NCT02330003|Active Comparator|TIV PFS|Fluarix Prefilled Syringe
16642756|NCT02329990|Active Comparator|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
16642757|NCT02329990|Placebo Comparator|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
16642758|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
16642759|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
16642760|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group
~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg
~Muscle relaxant agent : Rocuronium 1mg/kg
~After endotracheal intubation : normal saline(0.025 ml/kg)
~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg
~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
16642761|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group
~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg
~Muscle relaxant agent :Succinylcholine 1mg/kg
~After endotracheal intubation : Cisatracurium 0.08mg/kg
~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg
~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
16642762|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
16642763|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
16642764|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
16642765|NCT02329938|Active Comparator|Lichtenstein tension free reair|mesh repair of inguinal hernia
16642766|NCT02329938|Active Comparator|Desarda's repair|non-mesh repair of inguinal hernia
16642767|NCT02329925|Experimental|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
16642768|NCT02329912|Experimental|Patients after abdominal surgery|SmartPill application after abdominal surgery
16642769|NCT02329912|Sham Comparator|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
16642770|NCT02329899||Possible MBD|"Defined by:
~a bleeding score >= 4 in adults;
~a bleeding score >= 2 in children (for girls, up to menses);
~a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;
~a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.
~In this group, the second step of investigations will be performed."
16642771|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.
~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
16642772|NCT02329873|Experimental|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
16642773|NCT02329873|No Intervention|Control group|Control group received usual care and health education.
16642774|NCT02329860|Experimental|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
16642775|NCT02329860|Placebo Comparator|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
16642776|NCT02329847|Experimental|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
16642777|NCT02329847|Experimental|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
16642778|NCT02329847|Experimental|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
16642779|NCT02329847|Experimental|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
16642780|NCT02329847|Experimental|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
16642781|NCT02329847|Experimental|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
16642782|NCT02329834|Experimental|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
16642783|NCT02329834|Experimental|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
16642784|NCT02329821||HCC group|patients with hepatocellular carcinoma
16642785|NCT02329821||donor group|patient for liver transplantation donation
16642786|NCT02329808||Mycophenolic acid|Patients treated for their regular patient care with mycophenolic acid.
16642789|NCT02329808||Sirolimus|Patients treated for their regular patient care with sirolimus.
16642790|NCT02329808||Everolimus|Patients treated for their regular patient care with everolimus.
16642791|NCT02329808||Voriconazole|Patients treated for their regular patient care with voriconazole.
16642792|NCT02329808||Posaconazole|Patients treated for their regular patient care with posaconazole.
16642793|NCT02329808||Itraconazole+metabolite|Patients treated for their regular patient care with itraconazole.
16642794|NCT02329808||Fluconazole|Patients treated for their regular patient care with fluconazole.
16642795|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
16642796|NCT02329782|Experimental|ARP intervention|Adherence counseling intervention
16642797|NCT02329782|No Intervention|usual care|no intervention, standard care practices regarding adherence support
16642798|NCT02329769|Experimental|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
16642799|NCT02329769|Experimental|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
16642800|NCT02329769|Experimental|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
16642801|NCT02329756|Active Comparator|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
16642802|NCT02329756|Placebo Comparator|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
16642803|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
16642804|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
16642805|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
16642806|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
16642807|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
16642808|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
16642809|NCT02329717|Experimental|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
16642810|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min
~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
16642811|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min
~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
16642812|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
16642813|NCT02329678|Active Comparator|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
16642814|NCT02329678|Active Comparator|Control group|Control Group:No membrane was placed after periapical surgery.
16642815|NCT02329665|Experimental|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
16642816|NCT02329652|Experimental|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
16642817|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
16642818|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
16642819|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.
~Intervention: PET CT 18 FDG"
16642820|NCT02329613|Active Comparator|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.
~Intervention: Standard evening meals."
16642821|NCT02329613|Experimental|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
~Intervention: Improved evening meal"
16642822|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
16642823|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
16642897|NCT02329106|Experimental|NanoKnife LEDC System|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System, alao called Irreversible electroporation (IRE), 90 pulses of 70 microseconds each in duration will be administered per electrode pair.
16642824|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
16642825|NCT02329587|Experimental|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
16642826|NCT02329587|Active Comparator|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
16642827|NCT02329561|Active Comparator|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
16642828|NCT02329561|Placebo Comparator|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
16642829|NCT02329548|Experimental|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
16642830|NCT02329535|Experimental|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
16642831|NCT02329535|No Intervention|No treatment|No treatment. Regular follow up
16642832|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
16642833|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
16642834|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
16642835|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
16642836|NCT02329509|Active Comparator|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
16642837|NCT02329509|Active Comparator|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
16642838|NCT02329496|Experimental|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
16642839|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
16642840|NCT02329470|Experimental|No device, n=50|Withdrawal of device, continuous positive airway pressure treatment during 5 nights
16642841|NCT02329470|No Intervention|Continue using device, continuous positive airway pressure treatment n=50|Control group, Continue with device, continuous positive airway pressure treatment
16642842|NCT02329457|Experimental|ID varicella zoster vaccine (VZVv) group|intradermal 0.65 mL Zostavax
16642843|NCT02329457|Active Comparator|SC VZVv group|subcutaneous 0.65 mL Zostavax
16642844|NCT02329457|Placebo Comparator|ID NS Group|intradermal 0.65 mL normal saline
16642845|NCT02329457|Placebo Comparator|SC NS Group|subcutaneous 0.65 mL normal saline
16642846|NCT02329444|Experimental|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
16642847|NCT02329444|Active Comparator|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
16642848|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
16642849|NCT02329431|Active Comparator|support group|Parent-directed support group
16642850|NCT02329418|Experimental|Written document|Accompanying relatives with a written document when discussing withholding and withdrawing life-sustaining therapies . All other procedures are standard.
16642851|NCT02329418|Active Comparator|Standard|Discussing withholding and withdrawing life-sustaining therapies following standard procedure without written document
16642852|NCT02329405|Experimental|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
16642853|NCT02329405|Placebo Comparator|Placebo|Placebo tablet once a day orally for a week.
16642854|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
16642855|NCT02329379|Experimental|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
16642856|NCT02329379|Active Comparator|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
16642857|NCT02329379|No Intervention|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
16642858|NCT02329379|No Intervention|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
16642859|NCT02329379|Experimental|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
16642860|NCT02329379|Active Comparator|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
16642861|NCT02329379|No Intervention|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
16642862|NCT02329379|No Intervention|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
16642863|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
16642864|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
16642865|NCT02329353|Experimental|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
16642866|NCT02329353|Experimental|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
16642867|NCT02329340|Active Comparator|Am Academy of Pediatrics print materials|In-person session to read online version of American Academy of Pediatrics The Injury Prevention Program (TIPP sheets) childhood injury prevention print materials, followed by access to the TIPP sheets for 30 days.
16642868|NCT02329340|Experimental|Family Safety 1-2-3|In-person session to view video and text-based interactive web site on injury prevention information and strategies, followed by 8 emails delivered over a 30-day period inviting participant to view additional child safety videos.
16642869|NCT02329327|Experimental|Andexanet|Participants received andexanet as an intravenous bolus administered over ~15 to 30 minutes, followed immediately by a continuous infusion administered over ~120 minutes.
16642870|NCT02329301|Experimental|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
16642871|NCT02329301|Experimental|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
16642872|NCT02329301|No Intervention|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
16642873|NCT02329288|Active Comparator|Triamcinolone Acetonide|40mg/1ml
16642874|NCT02329288|Placebo Comparator|placebo|1ml
16642875|NCT02329275||Azoospermic men|
16642876|NCT02329275||Men with proven fertility|
16642877|NCT02329262|Experimental|Mentoring to be Active|Trained teen mentors will deliver the physical activity curriculum to high school students in a school setting. Physical activity will be measured with accelerometers.
16642878|NCT02329262|Active Comparator|Planning to be Active|High school teachers will deliver the physical activity curriculum (usual care) to high school students enrolled in health education courses. Physical activity will be measured with accelerometers.
16642879|NCT02329249|Experimental|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
16642880|NCT02329249|Other|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
16642881|NCT02329236||children with constitutional growth delay|
16642882|NCT02329236||children with Familial short stature|
16642883|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
16642884|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
16642885|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
16642886|NCT02329197|Experimental|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
16642887|NCT02329197|No Intervention|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
16642888|NCT02329184|Experimental|MYK-461|
16642889|NCT02329171|Experimental|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
16642890|NCT02329171|Active Comparator|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
16642891|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
16642892|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
16642893|NCT02329145|Experimental|Active treatment|Renal denervation
16642894|NCT02329145|No Intervention|Observational|
16642895|NCT02329119|Experimental|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
16642896|NCT02329119|Active Comparator|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
16642898|NCT02329106|No Intervention|Control|The patients without treatment
16642899|NCT02329093|Experimental|Bone Signal Changes|
16642900|NCT02329080|Experimental|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 & d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5
~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4
~*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.
~Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 & d-4 ASCT: 5 x 106 CD34+cells/kg d0
~**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 & d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
16642901|NCT02329067|Experimental|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
16642902|NCT02329067|Experimental|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
16642903|NCT02329067|Experimental|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
16642904|NCT02329067|No Intervention|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
16642905|NCT02329054|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
16642906|NCT02329041|Experimental|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
16642907|NCT02329041|Active Comparator|Airtraq|DLT intubation with Airtraq videolaryngoscope
16642908|NCT02329028||Prehospital mini-EEG|Feasibility of prehospital EEG device in unconscious patients.
16642909|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
16642910|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
16642911|NCT02328989|Experimental|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
16642912|NCT02328989|No Intervention|No pessary|No pessary will be placed in the vagina.
16642913|NCT02328976|Experimental|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
16642914|NCT02328976|Experimental|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
16642915|NCT02328963|Experimental|Everolimus|Everolimus + reduced dose of cyclosporine A
16642916|NCT02328963|Active Comparator|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
16642917|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
16642918|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
16642919|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
16642920|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
16642921|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
16642922|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
16642923|NCT02328924|Other|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
16642924|NCT02328924|Other|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
16642925|NCT02328911|Experimental|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
16642926|NCT02328911|Sham Comparator|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
16642927|NCT02328898|Experimental|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
16642928|NCT02328898|Active Comparator|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
16642929|NCT02328885|Experimental|Experimental|DLI of the 20 fraction of the UCBT
16642930|NCT02328872|Experimental|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
16642931|NCT02328872|Active Comparator|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
16642932|NCT02328859|Experimental|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
16642933|NCT02328859|Active Comparator|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
16642934|NCT02328833|Experimental|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
16642935|NCT02328833|No Intervention|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
16642936|NCT02328820|Other|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
16642937|NCT02328807|Experimental|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
16642938|NCT02328794|Active Comparator|Control|Participants randomized to this arm will receive a standardized Vitality program aimed at promoting tobacco cessation. This program includes existing employee benefits for quitting and the use of text/email messages to encourage tobacco cessation. No incentives will be given to participants randomized to this arm. Free cessation aids will not be available to participants in this arm. They will receive compensation for completing study related activities (sample submissions).
16642939|NCT02328794|Experimental|E-cigarette free access|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes only. These products can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
16642940|NCT02328794|Experimental|E-cigarette/NRT/Zyban/Chantix Choice|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes, conventional Nicotine Replacement Therapy (NRT), Zyban, or Chantix. Each of these can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
16642941|NCT02328794|Experimental|Outcome Incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition, they will also be able to earn incentives across six months for testing negative for tobacco use (see Incentive payout, below). They will also receive compensation for completing study related activities (sample submissions).
16642942|NCT02328794|Experimental|Loss framing incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition they will also be able to earnincentives across six months through a pre-funded deposit or precommitment account. They will be notified that money has been placed into an account for them. At each time point they will lose a portion (see below) of this initial funding if they do not provide biochemical evidence of abstinence. They will also receive compensation for completing study related activities (sample submissions).
16642943|NCT02328781|Experimental|Experimental|Drug-eluting stent
16642944|NCT02328768|Experimental|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 8-24 hours every day until the patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
16642945|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.
~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
16642946|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)
~Intervention: Hysteroscopy + endometrial biopsy
~Intervention: Telephone call"
16642947|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.
~Intervention: Hysteroscopy + endometrial biopsy
~Intervention: Resection + endometrial biopsy
~Intervention: Follow-up hysteroscopy + endometrial biopsy
~Intervention: Telephone call"
16642948|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.
~Intervention: Hysteroscopy + endometrial biopsy
~Intervention: Resection + endometrial biopsy
~Intervention: Follow-up hysteroscopy + endometrial biopsy
~Intervention: Telephone call"
16642949|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
16642950|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
16642951|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
16642952|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
16642953|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
16642954|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
16642955|NCT02328716|Active Comparator|Comparator|Comparator
16642956|NCT02328716|Experimental|Experimental|Experimental
16642957|NCT02328703|Experimental|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
16642958|NCT02328703|Placebo Comparator|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
16642959|NCT02328690|Experimental|Music with BBT|Music embedded with special tones.
16642960|NCT02328690|Placebo Comparator|Music without BBT|Music not embedded with special tones.
16642961|NCT02328677||ColoCare FHCRC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=611
16642962|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=835
16642963|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=683
16642964|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=294
16642965|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=203
16642966|NCT02328677||University of Washington St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=195
16643137|NCT02327377|Experimental|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
16642967|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=153
16642968|NCT02328664|Other|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
16642969|NCT02328651|Experimental|Ribavirin treatment plus testing drug|
16642970|NCT02328651|Active Comparator|Ribavirin treatment|
16642971|NCT02328638|Active Comparator|Manual-based Behavioral Treatment|up to 16 weekly behavioral therapy sessions (intervention) following the CHANGE obesity manual, lasting approximately 45 minutes and nutritional therapy sessions, lasting approximately 30 to 60 minutes.
16642972|NCT02328638|Placebo Comparator|Parent Education Program|up to 16 weekly behavioral therapy sessions following the parent education program
16642973|NCT02328612|Experimental|First arm|250,000 cells/kg will be administered via intravenous infusion.
16642974|NCT02328612|Experimental|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
16642975|NCT02328612|Experimental|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
16642976|NCT02328612|Placebo Comparator|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
16642977|NCT02328599||Surgical|Prior Bariatric surgery
16642978|NCT02328599||Non-surgical|Medical / Lifestyle management
16642979|NCT02328586|Experimental|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
16642980|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
16642981|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
16642982|NCT02328560||Paramedical ad consultation|Monitoring will be the same in the 2 groups; That paramedical consultation announcement is made in current practice.
16642983|NCT02328560||No paramedical ad consultation|Monitoring will be the same in the 2 groups
16642984|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
16642985|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
16642986|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by
~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
16642987|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by
~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
16642988|NCT02328521|Experimental|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
16642989|NCT02328521|Placebo Comparator|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
16642990|NCT02328508|Experimental|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
16642991|NCT02328508|No Intervention|Control|The control group received only routine care.
16642992|NCT02328495|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
16642993|NCT02328495|Active Comparator|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
16642994|NCT02328482|Experimental|Arm 1|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
16642995|NCT02328482|No Intervention|Arm 2|no-treatment concurrent control; follow-up over 52 weeks
16642996|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
16642997|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
16642998|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
16642999|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
16643000|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
16643001|NCT02328456|Other|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
16643002|NCT02328456|No Intervention|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
16643003|NCT02328443|Experimental|midazolam alone|midazolam administration alone
16643004|NCT02328443|Experimental|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
16643005|NCT02328443|Experimental|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
16643138|NCT02327377|Active Comparator|Online Education|Educational information about pain
16643006|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
16643007|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:
~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
16643008|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
16643009|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
16643010|NCT02328378|Active Comparator|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
16643011|NCT02328378|Placebo Comparator|Control Group|patients will receive a bilateral placebo block
16643012|NCT02328365|No Intervention|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
16643013|NCT02328365|Experimental|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
16643014|NCT02328352|Experimental|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
16643015|NCT02328352|Active Comparator|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.
~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
16643016|NCT02328352|Experimental|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
16643017|NCT02328352|Active Comparator|control group|Five rabbits (R26-R30) will be used as control group.
16643018|NCT02328339|Experimental|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
16643019|NCT02328339|Placebo Comparator|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
16643020|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
16643021|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
16643022|NCT02328313|Experimental|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
16643023|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.
~All participants will receive a FLT PET/MR scan."
16643024|NCT02328287|Experimental|ALLOB® Implantation|
16643025|NCT02328261|Experimental|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
16643026|NCT02328248|Experimental|Biological patch|Use biological patch (Biodesign Surgisis Tissue Graft from Cook Biotech Incorporated) to repair hiatal hernia laparoscopically
16643027|NCT02328248|Placebo Comparator|Plastic patch|Use plastic patch (Parietex Composite from Sofradim Production) to repair hiatal hernia laparoscopically
16643028|NCT02328235|Experimental|High Saturated Fat Diet|Subjects will receive a high fat diet for 5 day following a 2 week lead in diet. Measurements will be made pre-post high fat diet
16643029|NCT02328222|No Intervention|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
16643030|NCT02328222|Experimental|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
16643031|NCT02328209|Experimental|ranibizumab|ranibizumab
16643032|NCT02328183|Experimental|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
16643033|NCT02328170||EUROIMMUN Allergy|Immunoblot assay
16643034|NCT02328170||ImmunoCap|Fluoroallergosorbent test
16643035|NCT02328157|Experimental|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
16643036|NCT02328144|Active Comparator|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
16643037|NCT02328144|Placebo Comparator|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
16643038|NCT02328118|Experimental|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
16643039|NCT02328118|Experimental|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
16643040|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
16643041|NCT02328092|Active Comparator|Real group|The real group received biphasic rSMS using a Magstim Super Rapid (Magstim, Whitland, UK) stimulator connected to a 120-mm outer diameter figure-of-8 air film cooling coil positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2). Stimulation was delivered at 15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upward. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off.
16643042|NCT02328092|Sham Comparator|Sham Group|The control group received sham rSMS stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
16643043|NCT02328079|Active Comparator|Steroid Group|prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
16643044|NCT02328079|Active Comparator|Steroid + Antiviral Group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
16643045|NCT02328066|Experimental|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
16643046|NCT02328053|Experimental|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
16643047|NCT02328053|Active Comparator|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
16643048|NCT02328040|Placebo Comparator|Part A|Placebo and Insulin monotherapy via CL
16643049|NCT02328040|Active Comparator|Part B|Sitagliptin and insulin/novolog via CL
16643050|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
16643051|NCT02328014|Experimental|Dose Escalation and Expansion|"The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.
~Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals."
16643052|NCT02328001|No Intervention|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
16643053|NCT02328001|Other|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
16643054|NCT02327988|Experimental|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
16643055|NCT02327988|Experimental|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
16643056|NCT02327988|No Intervention|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
16643057|NCT02327975|Experimental|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
16643058|NCT02327975|Experimental|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
16643059|NCT02327975|Other|Control group|No received intervention.
16643060|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
16643061|NCT02327962||Control|Hemodynamic measurements with PWV
16643062|NCT02327949|Experimental|WP group|WP group:treated with W-Shaped Angular Plate
16643063|NCT02327949|Active Comparator|RP group|RP group:treated with Reconstruction Plate
16643064|NCT02327936|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 4 weeks, for a total of 8 weeks
16643065|NCT02327936|Active Comparator|Oxybutynin XL 10mg|Oxybutynin XL 10 mg Po Die, dose could be increased to 20 mg Po Die after 4 weeks, for a total of 8 weeks
16643066|NCT02327923|Active Comparator|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
16643067|NCT02327923|Active Comparator|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
16643068|NCT02327910|No Intervention|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
16643069|NCT02327910|Experimental|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
16643070|NCT02327910|Experimental|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
16643073|NCT02327884||Group 1|Healthy Volunteers matched with Sjogren's Syndrome patients
16643074|NCT02327884||Group 2|Family Members, affected and unaffected
16643075|NCT02327884||Group 3|any other cause salivary gland dysfunction
16643210|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
16643076|NCT02327871|Experimental|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
16643077|NCT02327858|Experimental|Supportive text message group|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months .
16643078|NCT02327858|No Intervention|No supportive text message group|Patients in the control group will only receive a text message once every two weeks thanking them for participating in the study. The aim of this will be to help increase the retention rate for the study.
16643079|NCT02327845||Affected|Affected with any of the diseases that are the focus of study by the CReATe Consortium, including ALS, ALS-FTD, HSP, PLS, PMA and MSP.
16643080|NCT02327845||Unaffected|Unaffected family members of enrolled affected individuals.
16643081|NCT02327832|Experimental|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
16643082|NCT02327819|Active Comparator|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
16643083|NCT02327819|Sham Comparator|non-BCAA protein supplement|non-BCAA protein supplement
16643084|NCT02327806|Other|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
16643085|NCT02327806|Other|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
16643086|NCT02327806|Other|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
16643087|NCT02327793|No Intervention|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure <100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
16643088|NCT02327793|Experimental|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
16643089|NCT02327793|Experimental|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure >120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
16643090|NCT02327780|Other|FODMAP diet|participants will be put on a low FODMAP diet.
16643091|NCT02327767|Experimental|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
16643092|NCT02327767|No Intervention|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
16643093|NCT02327754|Active Comparator|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
16643094|NCT02327754|Placebo Comparator|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
16643095|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
16643096|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
16643097|NCT02327728|Experimental|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
16643098|NCT02327728|Active Comparator|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
16643099|NCT02327715|Experimental|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
16643100|NCT02327702|Experimental|Chinese naive pregnant chronice hepatitis B|Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
16643101|NCT02327689|Experimental|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
16643102|NCT02327689|Experimental|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
16643103|NCT02327676|Experimental|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
16643104|NCT02327663|Experimental|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
16643105|NCT02327663|Experimental|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
16643106|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
16643107|NCT02327637|No Intervention|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:
~Receive recommendation for bedrest (standard of care).
~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).
~Wear a pedometer to measure activity when out of bed (observational study procedure)."
16643108|NCT02327637|Experimental|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:
~Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).
~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).
~Wear a pedometer to measure activity when out of bed (observational study procedure)."
16643109|NCT02327624|Active Comparator|Clopidogrel|The standard antiplatelet treatment for patients is pretreatment with aspirin and clopidogrel. In this trial patients will be randomised in clopidogrel orTicagrelor of two doses
16643110|NCT02327624|Experimental|Ticagrelor 60|Ticagrelor 60 is a new dosage to be tried in this trial.
16643111|NCT02327624|Experimental|Ticagrelor 90|Ticagrelor 90 is used following clopidogrel as maintenance therapy with aspirin 75 mg daily and clopidogrel 75 mg daily following PCI for at least 1 month.
16643112|NCT02327611|Experimental|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
16643113|NCT02327611|Active Comparator|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
16643114|NCT02327585|Experimental|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
16643115|NCT02327559|Experimental|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
16643116|NCT02327559|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
16643117|NCT02327546|Experimental|AKB-6548|AKB-6548
16643118|NCT02327546|Experimental|AKB-6548 plus Ferrous Sulfate|AKB-6548 plus ferrous sulfate
16643119|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
16643120|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
16643121|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
16643122|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
16643123|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
16643124|NCT02327481|Experimental|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
16643125|NCT02327481|Active Comparator|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
16643126|NCT02327455|Experimental|Stress Dobutamine Echocardiographic 4DE Image System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
16643127|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
16643128|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
16643129|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
16643130|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
16643131|NCT02327416|Active Comparator|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
16643132|NCT02327416|Experimental|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
16643133|NCT02327416|Experimental|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
16643134|NCT02327403|Active Comparator|B7-1 positivity on kidney allograft biopsy|Belatacept conversion
16643135|NCT02327403|Active Comparator|B7-1 negativity on kidney allograft biopsy|Belatacept conversion
16643136|NCT02327390|Experimental|X-ACT lymph node cell dose and schedule|"All patients will begin at dose level 1 and will be moved to higher dosing levels as long as the patient does not experience two or more dose limiting toxicities and maintains an acceptable performance status. A minimum of three patients will be enrolled per dose level and no patients will be enrolled on higher dose levels if dose limiting toxicities are encountered.
~Dose level 1: 0.5 x 10^10 X-ACT cells. 2 infusions 4 weeks apart
~Dose level 2: 1.0 x 10^10 X-ACT cells. 1 infusion
~Dose level 3: 0.5 x 10^10 X-ACT cells. 4 infusions 4 weeks apart
~Dose level 4: 1.0 x 10^10 X-ACT cells. 2 infusions 4 weeks apart
~Dose level -1: 0.5 x 10^10 X-ACT cells. 1 infusion (if necessary)"
16643457|NCT02325414|Experimental|Placebo|Intravenous infusion of placebo at baseline.
16643139|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
16643140|NCT02327338|Experimental|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
16643141|NCT02327338|Experimental|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
16643142|NCT02327338|No Intervention|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
16643143|NCT02327338|Sham Comparator|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
16643144|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
16643145|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
16643146|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
16643147|NCT02327312|Experimental|Surgical|Implantation of two Trabecular Meshwork stents into the study eye
16643148|NCT02327312|Active Comparator|Laser|Laser Trabeculoplasty
16643149|NCT02327299|Experimental|FePP|Bouillon fortified with 4mg FePP
16643150|NCT02327299|Experimental|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
16643151|NCT02327299|Experimental|FeSO4|Bouillon fortified with 4mg FeSO4
16643152|NCT02327299|Experimental|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
16643153|NCT02327286|Experimental|Intervention|Promote and support healthy behaviors
16643154|NCT02327286|No Intervention|Control|Conventional care for women with prior GDM.
16643155|NCT02327273|Experimental|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
16643156|NCT02327273|Experimental|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
16643157|NCT02327260|Experimental|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
16643158|NCT02327260|Experimental|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications.
16643159|NCT02327260|No Intervention|Control group (standard care)|The control group receives standard care while hospitalized.
16643160|NCT02327247|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
16643161|NCT02327247|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
16643162|NCT02327234|Experimental|Ibuprofen|400mg (2X200mg) ibuprofen single dose once
16643163|NCT02327234|Placebo Comparator|Placebo|identical appearing lactose capsules single dose 2 capsules once
16643164|NCT02327221|Active Comparator|Ovasave - Dose 10e4|
16643165|NCT02327221|Active Comparator|Ovasave - Dose 10e6|
16643166|NCT02327221|Active Comparator|Ovasave - Dose 10e7|
16643167|NCT02327221|Placebo Comparator|Placebo|
16643168|NCT02327208|Placebo Comparator|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
16643169|NCT02327208|Active Comparator|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
16643170|NCT02327208|Active Comparator|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
16643171|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
16643172|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
16643173|NCT02327182|Experimental|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
16643174|NCT02327182|Experimental|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
16643175|NCT02327169|Experimental|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
16643176|NCT02327169|Experimental|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
16643177|NCT02327169|Experimental|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
16643211|NCT02326987|Active Comparator|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
16643499|NCT02325076|Experimental|Spirodoc|One time during examination at the outpatient unit
16643178|NCT02327169|Experimental|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m^2 (cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
16643179|NCT02327169|Experimental|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
16643180|NCT02327169|Experimental|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
16643181|NCT02327156|No Intervention|group L|receive 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline
16643182|NCT02327156|Active Comparator|group LD|4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
16643183|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
16643184|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
16643185|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
16643186|NCT02327117|Experimental|Tranexamic acid|
16643187|NCT02327117|Placebo Comparator|Normal Saline|
16643188|NCT02327104|Experimental|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
16643189|NCT02327104|Other|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
16643190|NCT02327091|Placebo Comparator|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
16643191|NCT02327091|Active Comparator|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
16643192|NCT02327078|Experimental|(Phase 1, Part 1) : Nivolumab + Epacadostat|
16643193|NCT02327078|Experimental|(Phase 2): Nivolumab + Epacadostat|
16643194|NCT02327078|Experimental|(Phase 1, Part 2): Nivolumab + Epacadostat + Chemotherapy|
16643195|NCT02327065|Active Comparator|EUS-FNA Group|FNA,Fine needle aspiration
16643196|NCT02327065|Active Comparator|EUS-FNB Group|FNB,Fine needle biopsy
16643197|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
16643198|NCT02327039|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
16643199|NCT02327039|Placebo Comparator|Placebo|Placebo 10 mg tablet once daily for 12 weeks
16643200|NCT02327026|Experimental|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
16643201|NCT02327026|Active Comparator|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
16643202|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.
~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
16643203|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.
~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
16643204|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.
~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
16643205|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
16643206|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
16643207|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 450mg|GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
16643208|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 600mg|GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
16643209|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
16643212|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
16643213|NCT02326961|Experimental|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
16643214|NCT02326961|Experimental|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
16643215|NCT02326961|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
16643216|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
16643217|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
16643218|NCT02326935|Experimental|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection
~Other Names:
~ADSC, mesenchymal cells, stromal cells"
16643219|NCT02326922|Experimental|Metraplant-E First prototype|Metraplant-E (first prototype) levonorgestrel-releasing intrauterine device
16643220|NCT02326922|Experimental|Metraplant-E second prototype|Metraplant-E (second prototype) levonorgestrel-releasing intrauterine device
16643221|NCT02326909|Experimental|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
16643225|NCT02326870|Experimental|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
16643226|NCT02326857||Women with breast cancer|Observational study of women with Stage II/III locally advanced breast cancer in Latin America
16643227|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
16643228|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
16643229|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
16643230|NCT02326792|Experimental|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
16643231|NCT02326792|Experimental|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
16643232|NCT02326792|No Intervention|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
16643233|NCT02326779|Experimental|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
16643234|NCT02326779|No Intervention|Comparator Arm|Non-aspirin use arm as comparator
16643235|NCT02326766|Experimental|KRG|5g Korea red ginseng (KRG)
16643236|NCT02326766|Placebo Comparator|Placebo|5 g placebo (corn starch)
16643237|NCT02326753|Experimental|No. 7 oral airway|
16643238|NCT02326753|Experimental|No. 8 oral airway|
16643239|NCT02326753|Active Comparator|No. 9 oral airway|
16643240|NCT02326740|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
16643241|NCT02326740|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
16643242|NCT02326740|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
16643243|NCT02326727|Active Comparator|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
16643244|NCT02326727|Active Comparator|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
16643245|NCT02326714|Experimental|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
16643246|NCT02326714|Placebo Comparator|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
16643247|NCT02326688|Experimental|stroke patients|"Kinematic measurement of the amount of trunk displacement during a grasping task
~Two separated measurements are recorded with a 6-hours interval
~A third measurement provided by a second examinator is conducted"
16643280|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
16643248|NCT02326688|Experimental|control patients|"Kinematic measurement of the amount of trunk displacement during a grasping task
~Two separated measurements are recorded with a 6-hours interval
~A third measurement provided by a second examinator is conducted"
16643249|NCT02326675|Active Comparator|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
16643250|NCT02326675|Active Comparator|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
16643251|NCT02326662|Experimental|Paraplegics Acute|Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
16643252|NCT02326662|Experimental|Paraplegics Sub-chronic|Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
16643253|NCT02326662|Experimental|Paraplegics Chronic|"Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.
~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
16643254|NCT02326662|Experimental|Tetraplegics Acute|Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
16643255|NCT02326662|Experimental|Tetraplegics Sub-chronic|"sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.
~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
16643256|NCT02326662|Experimental|Tetraplegics Chronic|Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation & Biomatrix
16643257|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
16643258|NCT02326623|Experimental|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
16643259|NCT02326623|Other|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
16643260|NCT02326610|Active Comparator|hGH, ZOMACTON® (somatropin)|For infants in the treatment group receiving ZOMACTON® (somatropin) growth hormone by injection
16643261|NCT02326610|No Intervention|No human growth hormone|No growth hormone is given.
16643262|NCT02326597|Active Comparator|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
16643263|NCT02326597|Experimental|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
16643264|NCT02326584|Experimental|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
16643265|NCT02326584|Experimental|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
16643266|NCT02326584|Experimental|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
16643267|NCT02326584|Experimental|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
16643268|NCT02326571||spontaneous intracerebral hemorrhage|
16643269|NCT02326558|Experimental|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
16643270|NCT02326558|Active Comparator|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
16643271|NCT02326545|Experimental|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
16643272|NCT02326545|Active Comparator|Online CBT|Online CBT program for children
16643273|NCT02326532|Experimental|PRO data utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm and provided to the treating physicians.
16643274|NCT02326532|Sham Comparator|PRO data not utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm but will not be provided to the treating physicians.
16643275|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
16643276|NCT02326506|Experimental|Pump speed variation|VA-ELS pump speed variations
16643277|NCT02326493|Experimental|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
16643278|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
16643279|NCT02326480||Familial obesity|Identification of genetic causes of obesity
16643281|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
16643282|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
16643283|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
16643284|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
16643285|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
16643286|NCT02326441|Experimental|KX2-361|
16643287|NCT02326428|Experimental|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
16643288|NCT02326428|Active Comparator|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
16643289|NCT02326415|Active Comparator|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
16643290|NCT02326415|Active Comparator|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
16643291|NCT02326389|Experimental|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
16643292|NCT02326389|Active Comparator|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
16643293|NCT02326376||CAPS patients|CAPS patients treated with anakinra, using the Kineret graduated syringe
16643294|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
16643295|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
16643296|NCT02326350|Experimental|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
16643297|NCT02326350|Placebo Comparator|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
16643298|NCT02326337|Active Comparator|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.
~Other Names:
~Topical Wound Oxygen Therapy
~TWO2"
16643299|NCT02326337|Placebo Comparator|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
16643300|NCT02326311|Active Comparator|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
16643301|NCT02326311|Experimental|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
16643302|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.
~Treatment received from Week 16-48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.
~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
16643303|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
16643304|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.
~PASI75 responders at Week 16 continue to receive Placebo.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
16643305|NCT02326285|Experimental|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
16643306|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.
~Treatment received from Week 16-48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.
~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
16643307|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
16643308|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.
~PASI75 responders at Week 16 continue to receive Placebo.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
16643309|NCT02326246|Experimental|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
16643310|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
16643311|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
16643312|NCT02326220|Experimental|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
16643313|NCT02326220|Experimental|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
16643314|NCT02326220|Experimental|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
16643315|NCT02326207|Experimental|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
16643316|NCT02326207|Active Comparator|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
16643317|NCT02326194|Placebo Comparator|Placebo group (one shot)|one dose
16643318|NCT02326194|Placebo Comparator|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
16643319|NCT02326194|Experimental|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
16643320|NCT02326194|Experimental|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
16643321|NCT02326181|No Intervention|control group|without inspiratory and expiratory pressure threshold training
16643322|NCT02326181|Experimental|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
16643565|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
16688939|NCT02024035||Arctherapy Rapid'Arc|
16643323|NCT02326181|Experimental|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
16643324|NCT02326168|Experimental|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.
~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
16643325|NCT02326155||Remsima™|Patients who are taking Remsima™ for the treatment
16643326|NCT02326142|Experimental|OBE001|
16643327|NCT02326142|Placebo Comparator|Placebo|
16643328|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
16643329|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
16643330|NCT02326129||Normal weight|Normal weight adolescents
16643331|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
16643332|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
16643333|NCT02326103|Active Comparator|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
16643334|NCT02326103|Placebo Comparator|Placebo|Oral administration of Placebo pill twice daily
16643335|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 1.0%|One drop in each eye
16643336|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 2.5%|One drop in each eye
16643337|NCT02326090|Placebo Comparator|Placebo ophthalmic solution|One drop in each eye
16643338|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.
~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.
~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
16643339|NCT02326051|Active Comparator|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
16643340|NCT02326051|Active Comparator|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
16643341|NCT02326038|Experimental|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
16643342|NCT02326038|Placebo Comparator|Placebo|Placebo, capsule, single oral administration
16643343|NCT02326025|Experimental|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).
~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.
~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.
~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
16643344|NCT02326025|Experimental|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV
~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.
~Olaratumab + Doxorubicin:
~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.
~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.
~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
16643345|NCT02326012|Experimental|Emotion Regulation Individual Therapy for Adolescents|
16643346|NCT02325999|Experimental|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
16643347|NCT02325999|No Intervention|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
16643348|NCT02325986|Experimental|Weekly PF with radiation|4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).
16643349|NCT02325973|Other|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
16643350|NCT02325960|Active Comparator|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter
16643351|NCT02325960|Active Comparator|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
16643352|NCT02325947|Experimental|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
16643353|NCT02325947|Sham Comparator|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
16643354|NCT02325934|Active Comparator|Reference|Stribild Standardized breakfast followed by a single dose of STB (whole tablet).
16643355|NCT02325934|Experimental|Intervention I|Stribild, crushed Standardized breakfast followed by a single dose of crushed and suspended STB.
16643356|NCT02325934|Experimental|Intervention II|Stribild, crushed 350 mL of drip feed (type) followed by a single dose of crushed and suspended STB.
16643357|NCT02325921||Renal tumor.|Patients >18 years of age with histopathologically confirmed renal tumor diagnosis.
16643358|NCT02325908||Hemodialysis patients|Dialysis patients will have their estimated dry weight measured with calf segmental bioimpedance. Based on these measurements, their dry weight will be adjusted and the amount of fluid removed during subsequent dialysis treatments will be increased by 200-300mL. The additional fluid removal will occur during 3 consecutive hemodialysis sessions. In addition, these subjects will also use VStim during these treatments. to prevent common intradialytic symptoms by promoting vascular refilling.
16643359|NCT02325908||Healthy Controls|No Intervention was administered. Both groups had their hydration status measured with segmental bioimpedance The group of healthy subjects was studied in order to obtain a range of values for normal hydration status.
16643360|NCT02325895|No Intervention|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
16643361|NCT02325895|Experimental|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
16643362|NCT02325895|Experimental|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
16643363|NCT02325882|Active Comparator|Conventional fentanyl-based epidural PCA|
16643364|NCT02325882|Experimental|dexmedetomidine to fentanyl-based intravenous PCA|
16643365|NCT02325882|Active Comparator|Conventional fentanyl-based intravenous PCA|
16643366|NCT02325869|Experimental|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
16643367|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
16643368|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
16643369|NCT02325843|Experimental|human bone marrow MSC|5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
16643370|NCT02325830|Experimental|Treatment Group|Implantation of the CARILLON Mitral Contour System
16643371|NCT02325830|No Intervention|Control Group|Optimized stable medical therapy
16643372|NCT02325817|Experimental|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
16643373|NCT02325817|Active Comparator|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
16643374|NCT02325804|Active Comparator|Conventional lifestyle counseling|Randomized, open label study to assess effect of 8 weeks of Conventional lifestyle counseling (low calorie diet and exercise) on body composition, physical fitness, and metabolic parameters
16643375|NCT02325804|Active Comparator|Unconventional lifestyle counseling|"Randomized, open label study to assess effect of 8 weeks of unconventional lifestyle counseling (low calorie metabolic stairs diet and circuit-based exercise) on body composition, physical fitness, and metabolic parameters"
16643376|NCT02325791|Experimental|Part A: Suptavumab 30 mg/kg|
16643377|NCT02325791|Experimental|Part B: Placebo Matched to Suptavumab|
16643378|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg- 1 Dose|
16643379|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg - 2 Doses|
16643380|NCT02325778|Experimental|CTI First|CTI ablation prior to left atrial ablation
16643381|NCT02325778|Experimental|CTI second|CTI ablation after left atrial ablation
16643382|NCT02325765||category of RACHS-2 for cardiac surgery|ASD & VSD repair; VSD repair; Tetralogy repair; Tetralogy repair
16643383|NCT02325765||category of RACHS-3 for cardiac surgery|DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation & VSD repair
16643384|NCT02325752|No Intervention|Control|Patients in the control group received usual care by the hospital. There was no contact between the patients in the control group and the study team throughout the 3 months interval. A scheduled telephone call was made at the end of 3 months when they were invited to participate in a telephone survey.
16643385|NCT02325752|Active Comparator|Intervention|Intervention
16643386|NCT02325739|Experimental|Phase I: FGF401 50 mg fasted|Participants received single agent FGF401 50 mg while fasted
16643387|NCT02325739|Experimental|Phase I: FGF401 80 mg fasted|Participants received single agent FGF401 80 mg while fasted
16643388|NCT02325739|Experimental|Phase I: FGF401 80 mg fed|Participants received single agent FGF401 80 mg while fed
16643389|NCT02325739|Experimental|Phase I: FGF401 120 mg fasted|Participants received single agent FGF401 120 mg while fasted
16643390|NCT02325739|Experimental|Phase I: FGF401 120 mg fed|Participants received single agent FGF401 120 mg while fed
16643391|NCT02325739|Experimental|Phase I: FGF401 150 mg fasted|Participants received single agent FGF401 150 mg while fasted
16643392|NCT02325739|Experimental|Phase I: FGF401 80 mg + PDR001 300 mg|Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
16643393|NCT02325739|Experimental|Phase I: FGF401 120 mg + PDR001 300 mg|Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
16643394|NCT02325739|Experimental|Phase II: Group 1 - FGF401 120 mg QD|Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
16643395|NCT02325739|Experimental|Phase II: Group 2 - FGF401 120 mg QD|Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
16643396|NCT02325739|Experimental|Phase II: Group 3 - FGF401 120 mg QD|Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted
16643397|NCT02325726||Renal Resistive Index/Nephrocheck test|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are at risk to develop postoperative Acute Kidney Injury.
16643398|NCT02325713|Experimental|Sequence A-B-C1-D1|
16643399|NCT02325713|Experimental|Sequence A-B-C1-D2|
16643400|NCT02325713|Experimental|Sequence A-B-C2-D1|
16643401|NCT02325713|Experimental|Sequence A-B-C2-D2|
16643402|NCT02325713|Experimental|Sequence A-B-D1-C1|
16643403|NCT02325713|Experimental|Sequence A-B-D2-C1|
16643404|NCT02325713|Experimental|Sequence A-B-D1-C2|
16643405|NCT02325713|Experimental|Sequence A-B-D2-C2|
16643406|NCT02325713|Experimental|Sequence B-A-C1-D1|
16643407|NCT02325713|Experimental|Sequence B-A-C1-D2|
16643408|NCT02325713|Experimental|Sequence B-A-C2-D1|
16643409|NCT02325713|Experimental|Sequence B-A-C2-D2|
16643410|NCT02325713|Experimental|Sequence B-A-D1-C1|
16643411|NCT02325713|Experimental|Sequence B-A-D2-C1|
16643412|NCT02325713|Experimental|Sequence B-A-D1-C2|
16643413|NCT02325713|Experimental|Sequence B-A-D2-C2|
16643414|NCT02325700||Open aortic repair|145 patients with open aortic repair for abdominal aortic aneurysmal disease (n=139) or abdominal aortic occlusive disease (n=89)
16643415|NCT02325700||Laparoscopic aortic repair|83 patients with Laparoscopic aortic repair for abdominal aortic aneurysmal disease (n=30) or abdominal aortic occlusive disease (n=53)
16643454|NCT02325427|Sham Comparator|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
16643455|NCT02325427|No Intervention|no stimulation|Subjects will not received any intervention.
16643416|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.
~Intervention: Lumbar Puncture (Standard-of-Care)"
16643417|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.
~Intervention: Lumbar Puncture (Standard-of-Care)"
16643418|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.
~Intervention: Lumbar Puncture (Standard-of-Care)"
16643419|NCT02325674||Metreleptin|Generalised lipodystrophy patients treated with Metreleptin
16643420|NCT02325661|Other|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
16643421|NCT02325648||HIPEC cytoreductive surgery|
16643422|NCT02325635|Experimental|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
16643423|NCT02325635|No Intervention|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
16643424|NCT02325596||control|Patients with only nasal septum deviation
16643425|NCT02325596||CRS sNP|Chronic Rhinosinusitis patients without nasal polyps
16643426|NCT02325596||atopic CRS wNP|Chronic Rhinosinusitis patients with allergic constitution and nasal polyps
16643427|NCT02325596||non-atopic CRS wNP|Chronic Rhinosinusitis patients with nasal polyps but not allergic constitution
16643428|NCT02325583|Experimental|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
16643429|NCT02325570|Experimental|KLOX BioPhotonic OraLum Gel + SRP|Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
16643430|NCT02325570|Other|Scaling and Root Planing (SRP)|The second half-mouth will be treated with SRP alone.
16643431|NCT02325557|Experimental|Part A|Patients will receive ADXS31-142 monotherapy. Dosing will start at 1 x 10^9 cfu IV and escalate to 1 x 10^10 if appropriate.
16643432|NCT02325557|Experimental|Part B/Expansion|Patients will receive ADXS31-142 and pembrolizumab (MK-3475) in combination. Dosing of ADXS31-142 will start at one dose level less that appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate
16643433|NCT02325544|Experimental|CBT+SMC|12 sessions of Cognitive Behavioural Therapy adapted for DS (plus one booster session) plus standardised medical care
16643434|NCT02325544|Active Comparator|SMC|Standardised medical care provide by neurologist and/or psychiatrist
16643435|NCT02325531|Other|Low support|EHR-based toolkit Basic webinar
16643436|NCT02325531|Other|Medium support|Support provided to the low support arm, PLUS Staff training Adaptive webinars
16643437|NCT02325531|Other|High support|Support provided to the low and medium support arms, PLUS Practice facilitation
16643438|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
16643439|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
16643440|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
16643441|NCT02325492|Experimental|Aramchol 400 mg|• One tablet of Aramchol 400 mg and one tablet of Placebo
16643442|NCT02325492|Experimental|Aramchol 600 mg|• One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
16643443|NCT02325492|Placebo Comparator|Placebo|• Two tablet of Aramchol matching placebo.
16643444|NCT02325479|Experimental|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
16643445|NCT02325479|Placebo Comparator|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
16643446|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
16643447|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
16643448|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
16643449|NCT02325453||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
16643450|NCT02325453||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
16643451|NCT02325453||Open Surgery|Patients underwent gastric surgery with open approach.
16643452|NCT02325440|Experimental|Natalizumab - Washout - Fingolimod|One experimental arm: Patients receive one final dose of natalizumab 300mg followed by an 8-week washout Phase and subsequent 32-week treatment Phase with fingolimod 0.5mg o.i.d.
16643453|NCT02325427|Experimental|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
16643456|NCT02325414|Experimental|Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
16643458|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
16643459|NCT02325388|Experimental|Treatment group with ForeSite PT™ system|Inpatients assigned to the treatment group with the ForeSite PT™ system will have its LCD monitor turned on (i.e., real-time images of interface pressure will be displayed on the monitor) during their enrolment in the trial.
16643460|NCT02325388|No Intervention|Control group|Inpatients assigned to the control group will have the ForeSite PT™ system's LCD monitor turned off and hidden (i.e., real-time images of interface pressure will not be displayed on the monitor). As the ForeSite PT™ system will continue to record interface pressure with the display turned off, this enables patients enrolled in the control group to undergo silent monitoring.
16643461|NCT02325375||ALS newly diagnosed|
16643462|NCT02325375||ALS treated|
16643463|NCT02325375||controls|
16643464|NCT02325362|Experimental|Miglustat then placebo|10 patients will received Miglustat then the placebo
16643465|NCT02325362|Experimental|Placebo then Miglustat|10 patients will received Placebo then Miglustat
16643466|NCT02325349|Experimental|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
16643467|NCT02325336|Experimental|bar-code-assisted administration|during administration rounds, nurses will use the BCMA system to help preventing administration errors
16643468|NCT02325336|No Intervention|control|during administration rounds, nurses will administer drugs as usual
16643469|NCT02325310|Experimental|Breastfeeding women|70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
16643470|NCT02325297|Experimental|Letter of condolence|Letter of condolence 15 days after the death of the relative.
16643471|NCT02325297|No Intervention|No letter of condolence|No letter of condolence
16643472|NCT02325284||Healthy adults|
16643473|NCT02325271||Control group|Subjects with normal glucose tolerance
16643474|NCT02325271||Diabetes group|Patients with type 2 diabetes
16643475|NCT02325258|Experimental|Telephone call|Telephone call to physicians in charge of patients who have just had blood cultures drawn. Diagnostic and therapeutic recommendations to physicians in charge.
16643476|NCT02325258|No Intervention|No telephone call|control arm: no intervention
16643477|NCT02325245|Experimental|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
16643478|NCT02325245|Placebo Comparator|Placebo|Placebo tablet three times a day for 16 weeks.
16643479|NCT02325232|Experimental|Enteroscopy|Capsule endoscopy, double balloon enteroscopy sequential use
16643480|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
16643481|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
16643482|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
16643483|NCT02325206|Experimental|dapafliflozin|one administration of 10mg dapagliflozin as tablet
16643484|NCT02325206|Placebo Comparator|placebo|one administration as tablet identical to the experimental drug
16643485|NCT02325180|Experimental|DHA-PQ|One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).
16643486|NCT02325180|Active Comparator|AL|Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).
16643487|NCT02325167|Experimental|EBT|
16643488|NCT02325167|Experimental|Treatment-as-usual|
16643489|NCT02325154||THA Patients|Patients undergoing unilateral total hip arthroplasty
16643490|NCT02325141|Active Comparator|LSG|patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
16643491|NCT02325141|Active Comparator|BTX-LSG|patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
16643492|NCT02325128|Experimental|Post-Exposure Nap|Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
16643493|NCT02325128|Active Comparator|Post-Exposure Wake|At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.
16643494|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
16643495|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
16643496|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
16643497|NCT02325089|Experimental|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
16643498|NCT02325089|Placebo Comparator|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
16700493|NCT01947387||Local Tissue Flap|
16643500|NCT02325063|Experimental|PRP-L Group|"Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).
~Intervention: PRP-L Injection"
16643501|NCT02325063|Active Comparator|Botox Group|"Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).
~Intervention: Botox injection"
16643502|NCT02325063|Active Comparator|Corticoid Group|"Patients randomized to this group will be treated with an injection of Corticoids.
~Intervention: Corticoid injection"
16643503|NCT02325050|Experimental|Group 1|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
16643504|NCT02325050|Experimental|Group 2|Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
16643505|NCT02325050|Experimental|Group 3|Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
16643506|NCT02325050|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
16643507|NCT02325050|Experimental|Group 5|Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
16643508|NCT02325050|Experimental|Group 6|Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1*10^8 TCID50) on Day 360.
16643509|NCT02325050|Experimental|Group 7|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
16643510|NCT02325050|Experimental|Group 8|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10^11 vp) on Day 360.
16643511|NCT02325050|Experimental|Group 9|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
16643512|NCT02325050|Experimental|Group 10|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
16643513|NCT02325037|Experimental|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
16643514|NCT02325037|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
16643515|NCT02325037|Experimental|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
16643516|NCT02325037|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
16643517|NCT02325024|Experimental|Renally Impaired Subjects|"Treatment group consists of subjects with severe renal impairment or ESRD and in accordance with the following criteria;
~Clinically significantly abnormal creatinine and creatinine clearance (CLcr <30 mL/min) and not requiring dialysis.
~Onset of renal impairment must have been documented at least 3 months prior to study start."
16643518|NCT02325024|Experimental|Matched subjects with Normal Renal Function|Group consists of healthy subjects (as determined by medical history, physical examination, biochemistry, hematology, urinalysis, hepatitis B and C, and HIV testing) who demonstrate normal renal function (CLcr > 80 mL/min) and are individually matched to renally impaired subjects with respect to age (within the decile or five years, whichever is less), gender, and Body Mass Index (BMI) (+/- 10% BMI).
16643519|NCT02325011|Experimental|Treatment Sequence 1|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.
~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 1 is as follows;
~Visit 2 (Treatment A)
~Visit 3 (Treatment B)
~Visit 4 (Treatment A)
~Visit 5 (Treatment B)
~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
16643520|NCT02325011|Experimental|Treatment Sequence 2|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.
~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 2 is as follows;
~Visit 2 (Treatment B)
~Visit 3 (Treatment A)
~Visit 4 (Treatment B)
~Visit 5 (Treatment A)
~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
16643521|NCT02324998|Experimental|Group A|Olaparib Monotherapy
16643522|NCT02324998|Experimental|Group B|Olaparib in combination with degarelix
16643523|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
16643524|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
16643525|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
16643526|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
16643527|NCT02324959|Active Comparator|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
16643528|NCT02324959|Active Comparator|Computer-based|Computer-based attention training (RehaCom).
16643529|NCT02324959|Experimental|ACoTrain|A combination of computer-based attention training with acupuncture.
16643530|NCT02324946||Study Group|Mass Screening
16643531|NCT02324933|Experimental|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate < 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:
~50% of the hourly dose is given as a basal infusion
~The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using < 1 demand dose per hour, the basal rate is decreased by 20%. In patients using > 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
16643566|NCT02324686|Other|Vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
16643532|NCT02324933|Active Comparator|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain & Palliative Care team in order to make adjustments in pain management as required by the patients."
16643533|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
16643534|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
16643535|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
16643536|NCT02324894|Other|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
16643537|NCT02324881|Experimental|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
16643538|NCT02324868|Experimental|Shower patch IV catheter protection|Newly developed waterproof catheter dressing may be used for bathing activities
16643539|NCT02324868|Other|Conventional IV catheter protection|No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.
16643540|NCT02324855|No Intervention|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
16643541|NCT02324855|Experimental|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
16643542|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
16643543|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
16643544|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
16643545|NCT02324829||Total joint replacement|Patients who has undergone lower body total joint replacement surgery.
16643546|NCT02324816|Experimental|Lateral Thigh Treatment Group|CoolSculpting treatment in the lateral thighs for non-invasive subcutaneous fat reduction.
16643547|NCT02324803|Experimental|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
16643548|NCT02324790|Experimental|Treatment|Treated with iNAP® Sleep Therapy System on the treatment PSG night.
16643549|NCT02324777|Experimental|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
16643550|NCT02324777|Experimental|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
16643551|NCT02324777|Experimental|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
16643552|NCT02324777|Experimental|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
16643553|NCT02324777|Experimental|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
16643554|NCT02324777|Placebo Comparator|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
16643555|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
16643556|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
16643557|NCT02324751|Experimental|Vi-TCV|Single intramuscular injection
16643558|NCT02324751|Active Comparator|Vi-PS Vaccine|Single intramuscular injection
16643559|NCT02324751|Other|Control (Men ACWY)|Single intramuscular injection
16643560|NCT02324738|Experimental|Healthy Volunteer|All subjects will receive Mefloquine and Dihydroartemisinin-piperaquine, wash out then will receive Mefloquine
16643561|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
16643562|NCT02324712|Active Comparator|Acupuncture|Acupuncture treatment for TMD
16643563|NCT02324712|Sham Comparator|Sham Acupuncture|Acupuncture treatment for TMD using the non-penetrating Park Sham Acupuncture Device
16643564|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
16643567|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
16643568|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
16643569|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
16643570|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
16643571|NCT02324634|Experimental|ES intervention|Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
16643572|NCT02324634|No Intervention|Control|Usual care only
16643573|NCT02324621|Experimental|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16643574|NCT02324608|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes once weekly for 8 weeks.
16643575|NCT02324595|Experimental|Laparoscopic Interval Debulking Surgery|Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
16643576|NCT02324582|Experimental|Intravenous MK-3475/ Intravesical BCG|3 subjects will be treated at a dose of 100 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses 12 subjects will be treated at a dose of 200 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses
16643577|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
16643578|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
16643579|NCT02324556||Laparoscopic total mesorectal excision|Patients operated with laparoscopic total mesorectal surgery for rectal cancer
16643580|NCT02324556||transanal total mesorectal excision|Patients operated with a combined transanal and laparosocopic total mesorectal surgery for rectal cancer
16643581|NCT02324543|Experimental|Dose level 1 - Phase 1|"Gemcitabine - 400 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/twice daily (BID)
~Cisplatin - 15 mg/m^2
~Irinotecan - 20 mg/m^2"
16643582|NCT02324543|Experimental|Dose Level 2 - Phase 1|"Gemcitabine - 400 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 15 mg/m^2
~Irinotecan - 40 mg/m^2"
16643583|NCT02324543|Experimental|Dose Level 3 - Phase 1|"Gemcitabine - 400 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 15 mg/m^2
~Irinotecan - 60 mg/m^2"
16643584|NCT02324543|Experimental|Dose Level 1a - Phase 1|"Gemcitabine - 500 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 20 mg/m^2
~Irinotecan - 20 mg/m^2"
16643585|NCT02324543|Experimental|Dose level 1b - Phase 1|"Gemcitabine - 500 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 20 mg/m^2
~Irinotecan - 40 mg/m^2"
16643586|NCT02324543|Experimental|Phase 2|"Gemcitabine - 500 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 20 mg/m^2
~Irinotecan - 20 mg/m^2"
16643587|NCT02324530|Experimental|Lung tumors|Patients with > 1 cm tumor motion simulated using 4DCT with and without CPAP
16643588|NCT02324530|Experimental|Left sided Breast cancer|Patients with heart abutting chest wall will be simulated using 4DCT with and without CPAP
16643589|NCT02324530|Experimental|Abdominal tumors|Patient with liver metastases for SBRT or pancreatic tumors will be simulated using 4DCT with and without CPAP
16643590|NCT02324517||Hemophilia|Patients with Hemophilia A OR B
16643591|NCT02324517||inhibitor patients|Hemophilia or FXI def with inhibitors
16643592|NCT02324517||anticoagulants|patients under therapy with various anticoagulant drugs
16643593|NCT02324517||thrombocytopenia|patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia
16643594|NCT02324517||platelet function disorders|Glanzmann, Bernard Soulier, antiplatelet therapy
16643595|NCT02324517||Fibrinogen disordsers|hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
16643596|NCT02324517||acquired hemophilia|patients with autoimmune Ab's to FVIII
16643597|NCT02324517||RBD|FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF
16643598|NCT02324517||THROMBOLYTICS|Patients treated by thrombolytic agents
16643599|NCT02324517||Hypercoag|thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)
16643600|NCT02324504|Experimental|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
16643601|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
16643602|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
16643603|NCT02324491|Placebo Comparator|Placebo|ZGN-440 Placebo for Injectable Suspension
16643604|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
16643605|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
16643606|NCT02324452|Experimental|heterozygous carrier of DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for one of these SNPs
16643607|NCT02324452|Experimental|wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
16643608|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
16643609|NCT02324426|Experimental|Reduced Glutathione|The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.
16643610|NCT02324413|Active Comparator|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
16643611|NCT02324413|Placebo Comparator|Placebo|
16643612|NCT02324400|Active Comparator|Treatment|
16643613|NCT02324400|Sham Comparator|Control|
16643614|NCT02324387|Experimental|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
16643615|NCT02324374|Experimental|Endocytoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
16643616|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.
~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.
~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
16643617|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.
~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.
~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
16643618|NCT02324348|Placebo Comparator|Immediate coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate coronary stenting group
16643619|NCT02324348|Active Comparator|Deferred coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred after 5-7 days admission in the deferred coronary stenting group.
16643620|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
16643621|NCT02324335|Active Comparator|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
16643622|NCT02324322|Experimental|Exoskeleton training|"To examine the effectiveness of robotic exoskeleton-assisted over ground walking (5 hrs. p/wk, 100 sessions, 20 wks = 100 hrs) to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI. Combined with our current training protocol where people step 1500-2000/session we predict that the 2,000 lower extremity muscle contractions will be sufficient in our proposed exoskeletal study.
~MRI's will be performed to accurately assess muscle CSA of each lower limb to determine individual's muscle thigh and shank volume.
~Muscle Biopsies for the quadricep muscle will be performed to determine changes in BMD and bone structure due to intensive exoskeleton assisted walking."
16643623|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
16643624|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
16643625|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
16643626|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
16643627|NCT02324283|Active Comparator|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
16643628|NCT02324283|Active Comparator|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
16643629|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
16643630|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
16643631|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
16643632|NCT02324257|Experimental|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
16643689|NCT02323841|Experimental|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
16643633|NCT02324257|Experimental|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive RO6958688 with or without obinutuzumab pretreatment QW, Q3W, or according to a combined QW/Q3W step up dosing schedule. Doses will start at 40mg and increase with each administration up to the MTD or 1200mg, whichever is lower.
16643634|NCT02324244||immunocompetent patients underwent heart surgery|
16643635|NCT02324231|Other|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
16643636|NCT02324231|Other|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
16643637|NCT02324218||Diabetes mellitus Group|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD database of UK, from the Year 2000 to 2012.
16643638|NCT02324218||Non-Diabetes mellitus Group|All the subjects with hepatitis B who are diagnosed negative diabetes mellitus, reported in the CPRD database of UK, from the Year 2000 to 2012.
16643639|NCT02324205|Experimental|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
16643640|NCT02324192|Other|Normal ultrasonography|Patients with normal ultrasonography findings
16643641|NCT02324192|Other|Inflammatory ultrasonography|Patients with inflammatory ultrasonography findings
16643642|NCT02324179||HIV positive|people with HIV diagnosis
16643643|NCT02324179||Control (HIV negative)|people without HIV
16643644|NCT02324166|Active Comparator|Cefazolin|For the control group, cefazolin will be drawn into a 1 mL syringe and 0.5 mL will be injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery.
16643645|NCT02324166|Active Comparator|Cefazolin + Lidocaine|For the comparator group, the cefazolin and 0.2 mL lidocaine 2% will be mixed together in the same 1 mL syringe and 0.5 mL of the mixed solution injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery surgery.
16643646|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
16643647|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
16643648|NCT02324140||Minimized extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the minimized extracorporeal circulation (MECC, group 1)
16643649|NCT02324140||Conventional extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the conventional extracorporeal circulation (CECC, group 2)
16643650|NCT02324140||Transcatheter aortic valve implantation, transfemoral access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transfemoral access route
16643651|NCT02324140||Transcatheter aortic valve implantation, transapical access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transapical access route
16643652|NCT02324127|Experimental|liver cancer|Detect plasma Hsp90α concentration of liver cancer patients
16643653|NCT02324114|Experimental|Rectal cancer|Detect plasma Hsp90α concentration of patients,
16643654|NCT02324101|Experimental|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
16643655|NCT02324088|Active Comparator|Arm A|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy
16643656|NCT02324088|Experimental|Arm B|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy followed by 4 cycles of D-5FU (D 85 mg/m², day 1 and 5FU 2500 mg/m²/day continuous infusion, days 1-5 every 3 weeks)
16643657|NCT02324075|Experimental|Behavior change|Behavior change messaging with facilitating hardware
16643658|NCT02324075|No Intervention|Control Arm|Standard habits and practices
16643659|NCT02324062||Pathogenic group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~Patients identified with a mutation in a gene not commonly tested for prior to the advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not meet clinical criteria for the underlying syndrome (n = 124). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
16643660|NCT02324062||VUS group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~Patients identified with a variant of unknown significance of any gene of any nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and EPCAM).
~Target accrual is 100. These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
16643661|NCT02324062||Negative Group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~Patients who test negative for all the genes tested. Target goal is 50 for Stanford (100 for the study). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
16643690|NCT02323828|Experimental|Investigational product|"The investigational products are RS starch cookies (40 g resistant starch) from high amylose maize starch.
~Nine young healthy volunteers (males and females) consumed RS rich cookies (40 g RS) in two separate occasions."
16645096|NCT02314559|Experimental|Propofol (manual titration)|
16643662|NCT02324062||No follow-up intervention group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~All other participants who do not meet any of the above criteria or fall into one of these groups after the target goal is met for that group."
16643663|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.
~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.
~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
16643664|NCT02324036|Experimental|Coached Care+EMPATHy;|EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
16643665|NCT02324036|Active Comparator|Routine Coached Care|Patient coaching only
16643666|NCT02324023|Experimental|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
16643667|NCT02324010|Experimental|Sitaglipltin (100mg)|Active drug (sitagliptin)
16643668|NCT02324010|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
16643669|NCT02323984||Hypoactive Delirium - Delirious|Hypoactive delirious patients presenting with lethargy and sedation and are slow to respond to questions and demonstrate little spontaneous movement. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
16643670|NCT02323984||Hyperactive Delirium - Delirious|Hyperactive delirious patients presenting with restlessness, agitation, hyper vigilance, and occaionally hallucinations. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
16643671|NCT02323984||No Delirium - Nondelirious|Patients not presenting any symptoms of hypoactive or hyperactive postoperative delirium. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
16643672|NCT02323958|Experimental|Acupoint stimulation|Electrical stimulation is given through electrodes attached to acupoints
16643673|NCT02323958|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation is given through electrodes attached to non-acupoints
16643674|NCT02323958|Sham Comparator|Control stimulation|Electrode attached but no stimulation is given
16643675|NCT02323945|Active Comparator|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
16643676|NCT02323945|Active Comparator|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
16643677|NCT02323932|Active Comparator|Bilateral Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: each of the CI alone and bilateral (CI/CI) conditions.
16643678|NCT02323932|Active Comparator|Bimodal Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: CI alone, HA alone and bimodal (CI/HA) conditions.
16643679|NCT02323919|Active Comparator|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
16643680|NCT02323919|Active Comparator|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
16643681|NCT02323919|Placebo Comparator|Usual Care|Usual Care
16643682|NCT02323906|Experimental|CC-122 + Fixed-dose Sorafenib|"A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.
~The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part."
16643683|NCT02323893|Experimental|18F-FAraG|A single dose intravenous injection of 18F-FAraG followed by PET scanning.
16643684|NCT02323880|Experimental|Treatment (selinexor)|Patients receive selinexor PO once weekly (days 1, 8, 15, and 22). Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16643685|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment
~11 ATG
~10 ATG
~9 ATG
~8 TBI
~7 TBI
~6 TBI
~5 Thiotepa
~4 Thiotepa
~3 Cyclophosphamide
~2 Cyclophosphamide
~1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
16643686|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment
~9 ATG
~8 ATG
~7 Thiotepa + ATG
~6 Thiotepa
~5 Cyclophosphamide
~4 Cyclophosphamide
~3 TBI
~2 TBI
~1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
16643687|NCT02323867|Experimental|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment
~9 Busulfan + ATG
~8 Busulfan + ATG
~7 Busulfan +ATG
~6 Busulfan
~5 Thiotepa
~4 Thiotepa
~3 Cyclophosphamide
~2 Cyclophosphamide
~1 0 Transplant with alpha beta T cell depleted stem cells"
16643688|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
16643691|NCT02323828|Placebo Comparator|Placebo|The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
16643692|NCT02323815|Active Comparator|Control|Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
16643693|NCT02323815|Experimental|PROMIS intervention|"Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
~Caregivers with children 6-23 months of age that attend Counselling meetings will be provided with a monthly dose of SQ-LNS (20g/day)"
16643694|NCT02323802|Experimental|educational group intervention|"The group educational food intervention: it provides the delivery of information leaflet and inclusion in groups on a weekly basis for the first 3 meetings, and then, there are other 2 meetings on the third and sixth month by the AMI.
~The meetings will cover education to self-nutrition, physical activity and learning techniques for stimulus control and management of high-risk situations."
16643695|NCT02323802|Active Comparator|prescriptive diet|An objectives food scheme elaborated for each patients will provide the reduction in caloric intake (equivalent to 500-600 calories in deficit if compared to the estimated daily requirement, based on the RDAs) and a reduced intake of lipids, which does not exceed 30% of total calories introduced, with a contribution of saturated fat no more than 7-9% .
16643696|NCT02323789|Experimental|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
16643697|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
16643698|NCT02323737|Active Comparator|Irinotecan and cisplatin|The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
16643699|NCT02323737|Active Comparator|Etoposide and Cisplatin|The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
16643700|NCT02323724||Selected Papillary carcinoma|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.
16643701|NCT02323711|No Intervention|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
16643702|NCT02323711|Experimental|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
16643703|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
16643704|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
16643705|NCT02323698|Active Comparator|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
16643706|NCT02323685|Experimental|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
16643707|NCT02323672||oral premalignant patients|15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.
16643708|NCT02323672||oral malignant patients|15 patients suffering from oral malignant lesions
16643709|NCT02323672||control subjects|15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.
16643710|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
16643711|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
16643712|NCT02323646|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
16643713|NCT02323646|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
16643714|NCT02323646|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
16643715|NCT02323633|Active Comparator|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
16643716|NCT02323633|Sham Comparator|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
16643717|NCT02323620|No Intervention|Standard care|Optimal standard care after myocardial infarction.
16643718|NCT02323620|Experimental|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.
16643719|NCT02323607|Experimental|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
16643755|NCT02323373|Experimental|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
16645024|NCT02314975|Active Comparator|Fixed appliance only|Fixed appliances only
16643720|NCT02323607|Experimental|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16643721|NCT02323594|Experimental|Group 1: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV pediatric chewable tablet
16643722|NCT02323594|Experimental|Group 2: Daclatasvir|Single oral dose of Daclatasvir (DCV) pediatric chewable tablet and single oral dose of DCV pediatric chewable tablet
16643723|NCT02323594|Experimental|Group 3: Asunaprevir|Single oral dose of Asunaprevir (ASV) tablet, single oral dose of ASV pediatric chewable tablet and single oral dose of ASV pediatric chewable tablets
16643724|NCT02323594|Experimental|Group 4: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV tablets
16643725|NCT02323581|Experimental|TAAA (thoracoabdominal aortic aneurysm) Study Arm|"Either the TAAA device or the Physician-Specified TAAA Device will be implanted.
~The TAAA Device is a standard configuration branched stent graft with a combination of two branches for the mesenteric arteries and two fenestrations for the renal arteries.
~The Physician-Specified TAAA Devices are designed on a per patient basis and may include a combination of up to 4 fenestrations and branches for mesenteric and renal arteries. An additional 5th branch or fenestration may be included if there is a large accessory renal artery. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
16643726|NCT02323581|Experimental|Aortic Arch Study Arm|Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.
16643727|NCT02323568|Other|Gynecological consulation|
16643728|NCT02323555|Experimental|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
16643729|NCT02323542|Experimental|High-SDS biscuit|Biscuit with high Slowly Digestible Starch content
16643730|NCT02323542|Active Comparator|Low-SDS cereal product|Cereal product with low Slowly Digestible Starch content
16643731|NCT02323529|Experimental|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
16643732|NCT02323516|Experimental|Acetylsalicylic acid + loperamide|Acetylsalicylic acid + loperamide
16643733|NCT02323516|Active Comparator|diosmectite + loperamide|Acetylsalicylic acid + loperamide
16643734|NCT02323490|Experimental|with microfractures|Standardized meniscal repair with bone marrow stimulation techniques (microfractures)
16643735|NCT02323490|Placebo Comparator|without microfractures|Standardized meniscal repair without augmentation
16643736|NCT02323477|Experimental|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
16643737|NCT02323477|Active Comparator|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
16643738|NCT02323477|No Intervention|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation
16643739|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
16643740|NCT02323464||Open surgery for colorectal cancer|investigated after open surgery of colorectal cancer
16643741|NCT02323464||Laparoscopic or robotic surgery|investigated after laparoscopic or robot surgery of colorectal cancer
16643742|NCT02323464||Control subjects|Controls from the population without colorectal cancer
16643743|NCT02323451|Experimental|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
16643744|NCT02323451|Active Comparator|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
16643745|NCT02323438|Active Comparator|Usual Brand (UB) Cigarettes|Usual Brand Cigarette
16643746|NCT02323438|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 29 mg nicotine)
16643747|NCT02323438|Experimental|Electronic Cigarette #2|VUSE® (menthol flavor, 26 mg nicotine)
16643748|NCT02323438|Experimental|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
16643749|NCT02323425|Experimental|Remote Ischemic Postconditioning|remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.
16643750|NCT02323425|No Intervention|Control|Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).
16643751|NCT02323412|Experimental|Amoxicillin|Amoxicillin (Amoksicillintrihydrat) tablets 750 mg 1x3 for 100 days (oral intake). The tablets will be encapsulated in Capsugel DB-caps AAel Swedish orange.
16643752|NCT02323412|Placebo Comparator|Placebo|Placebo capsules for 100 days of daily (1x3), oral intake. The placebo tablets will also be encapsulated in Capsugel DB-caps AAel Swedish orange.
16643753|NCT02323399|Experimental|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
16643754|NCT02323386|Experimental|ATTUNE knee system|The patients will undergo primary Total Knee Arthroplasty (ATTUNE knee system)
16643756|NCT02323373|Active Comparator|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
16643757|NCT02323373|Placebo Comparator|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
16643758|NCT02323360|Experimental|Stereotactic body radiation therapy|HCC after incomplete TAE or TACE treated by SBRT
16643759|NCT02323360|Active Comparator|TACE/TAE|HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE
16643760|NCT02323334|Placebo Comparator|Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg|"Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.
~Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626."
16643761|NCT02323334|Experimental|Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.
~Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626."
16643762|NCT02323334|Experimental|Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.
~Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO."
16643763|NCT02323334|Experimental|Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.
~Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole."
16643764|NCT02323334|Experimental|Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.
~Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
16643765|NCT02323334|Experimental|Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra|"Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.
~Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
16643766|NCT02323334|Experimental|Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.
16643767|NCT02323334|Experimental|Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.
16643768|NCT02323334|Experimental|Part B Cohort 4: 1.6mg|Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.
16643769|NCT02323334|Experimental|Part B Cohort 5: 10mg|Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.
16643770|NCT02323334|Experimental|Part B Cohort 6: 26mg|Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.
16643771|NCT02323334|Placebo Comparator|Part B Cohort 4, 5, 6: Placebo Comparator|Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.
16643772|NCT02323334|Experimental|Part C Cohort 7: 1mg|Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
16643773|NCT02323334|Experimental|Part C Cohort 8: 6mg|Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
16643774|NCT02323334|Experimental|Part C Cohort 9: 26mg|Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
16643775|NCT02323334|Placebo Comparator|Part C Cohort 7, 8 ,9: Placebo Comparator|Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.
16643776|NCT02323334|Experimental|Part D Cohort 10: 6mg|Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
16643777|NCT02323321|Experimental|OCS Preservation|OCS Preservation and Assessment
16643778|NCT02323308||vaccination|Anti-HBV vaccine injection
16643779|NCT02323295|Experimental|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
16643780|NCT02323295|Experimental|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
16643781|NCT02323282|Other|ropivacine|
16643782|NCT02323269||Treatment naive to dimethyl fumarate|Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
16643783|NCT02323269||Switch to dimethyl fumarate|Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
16643784|NCT02323256|Experimental|newly cochlear implanted adult patients|longitudinal group
16643785|NCT02323256|Experimental|newly cochlear implanted children|longitudinal group
16643786|NCT02323256|Active Comparator|cochlear implanted adult patients (CI>1 year)|transversal group
16643787|NCT02323256|Active Comparator|normal hearing adult subjects|transversal group
16643788|NCT02323243|Experimental|Allium BUS|Temporary urethral stent
16643789|NCT02323230|Experimental|DPX-Survivac + low dose cyclophosphamide|
16643790|NCT02323217|Experimental|Healthy Volunteers|
16643791|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
16643792|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
16643793|NCT02323191|Experimental|Part 1 (Dose-finding): Emactuzumab + Atezolizumab|Participants will receive escalating doses of emactuzumab along with atezolizumab every 3 weeks (q3w).
16643794|NCT02323191|Experimental|Part 2 (Expansion): Emactuzumab + Atezolizumab|Participants will receive emactuzumab at or below the MTDs for the combination treatments that are determined during Part 1 along with atezolizumab.
16643795|NCT02323178|Experimental|eltrombopag|
16643796|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
16643797|NCT02323152|Experimental|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
16643798|NCT02323152|Active Comparator|Control group|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment.
16643799|NCT02323139|Experimental|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
16643800|NCT02323126|Experimental|Nivolumab and EGF816|Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.
16643801|NCT02323126|Experimental|Nivolumab and INC280|Arm 2 (INC280 + nivolumab) is open and enrolling as planned.
16643802|NCT02323113|Experimental|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
16643803|NCT02323113|Experimental|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
16643804|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
16643805|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
16643806|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
16643807|NCT02323087|Active Comparator|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
16643808|NCT02323087|Active Comparator|Culture|Point of care culture will be performed using ID FlexicultTM
16643809|NCT02323074|Experimental|fBCI-robot|focalized BCI-robot hand training
16643810|NCT02323074|Experimental|gBCI-robot|generalized BCI-robot hand training
16643811|NCT02323074|Sham Comparator|sham-BCI|Sham BCI
16643812|NCT02323061|Experimental|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
16643813|NCT02323061|Experimental|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
16643814|NCT02323061|Placebo Comparator|robot|Training for 20 sessions
16643815|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
16643816|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
16643817|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
16643818|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
16643819|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
16643820|NCT02323035|Experimental|Headgear|Investigative Headgear with CPAP Mask.
16643821|NCT02323022|Experimental|IAC regimen|Patients in this arm will receive an IAC induction therapy
16643822|NCT02323022|Active Comparator|High-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 10mg/msq/d
16643823|NCT02323022|Active Comparator|Intermediate-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 12mg/msq/d
16643824|NCT02323009|Active Comparator|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
16643825|NCT02323009|Active Comparator|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
16643826|NCT02323009|No Intervention|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
16643827|NCT02322996||open label|After the surgery and the onset of moderate-severe pain, QST and PROMIS questionnaires will be repeated. Throughout these procedures, patients will rate their pain perception using a numeric rating scale. Approximately 2-3 hours after surgery at the onset of moderate pain, the rescue analgesic (toradol) will be administered via intramuscular injection. Again, QST and PROMIS protocols will be repeated after the drug is given and when patients report pain relief. A standard naproxen dose of 500 mg will be given to patients upon leaving the clinic and they will be instructed to take one pill orally each day before returning for evaluation after 48 hours.
16643828|NCT02322983|Experimental|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
16643829|NCT02322970||Intracranial Pressure monitoring|Invasive Intracranial Pressure monitoring will be compared to non invasive intracranial monitoring ( through use of transcranial Doppler ).
16643830|NCT02322957|Experimental|Treatment Regimen A|FV-100 400mg OD as a single dose fasted (>/= 8 hours)
16643831|NCT02322957|Experimental|Treatment Regimen B|FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (>/= 8 hours)
16643832|NCT02322944|Experimental|Intervention group|The intervention group will take the treatment quality improvement strategies and tools into implementation.
16643833|NCT02322944|No Intervention|Control group|The control group will maintain the routine practice pattern.
16643834|NCT02322944|Experimental|Process optimization group|The process optimization group's clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process.
16643835|NCT02322931|Experimental|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
16643836|NCT02322918||Participants admitted to BCPP|Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
16643837|NCT02322905|Experimental|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
16643838|NCT02322905|No Intervention|Usual Medical Care|No planned psychotherapy.
16643839|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
16643840|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
16643841|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.
~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.
~The total study time is 6 weeks."
16643842|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.
~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.
~The total study time is 6 weeks."
16643843|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
16643844|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
16643845|NCT02322853|Active Comparator|TAMOXIFEN|"Tamoxifen will be administered daily orally
~Patients will receive study medication until disease progression or unacceptable toxicity"
16643846|NCT02322853|Experimental|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally
~Patients will receive study medication until disease progression or unacceptable toxicity"
16643847|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
16643848|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
16643849|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
16643850|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
16643851|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
16643852|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
16643853|NCT02322801||Cohort|
16643854|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
16643855|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
16643856|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
16643857|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
16643858|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
16643859|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
16643860|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
16643861|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
16643862|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
16643863|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
16643864|NCT02322736||WT RAS mCRC|Wild Type RAS metastatic colorectal cancer patients
16643865|NCT02322723||Moderately to severely active RA patients|Moderately to severely active RA patients aged 18 years or older, both male and female
16643866|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
16643867|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
16643868|NCT02322697|Experimental|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
16643869|NCT02322697|No Intervention|control group|No intervention
16643870|NCT02322684|Active Comparator|Group Q|Blind endotracheal intubation will be performed through the air-Q
16644036|NCT02321579|Experimental|Supplement 2|500 mg/d Glutathione
16643871|NCT02322684|Active Comparator|Group B|Blind endotracheal intubation will be performed through the air-Q with bougie assisted
16643872|NCT02322671|Experimental|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
16643873|NCT02322671|Experimental|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
16643874|NCT02322671|Experimental|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
16643875|NCT02322671|Experimental|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
16643876|NCT02322671|Experimental|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
16643877|NCT02322671|Experimental|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
16643878|NCT02322658|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
16643879|NCT02322658|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
16643880|NCT02322645|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
16643881|NCT02322645|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
16643882|NCT02322632|Experimental|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
16643883|NCT02322632|Experimental|Zemplar Capsules, 4 mcg|Zemplar Capsules, 4 mcg of Abott Laboratories USA
16643884|NCT02322619|Experimental|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
16643885|NCT02322619|Active Comparator|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
16643886|NCT02322606|Other|Cohort 1: TAK-137 5 mg, TAK-137 placebo|Single-dose administration in a fasting state
16643887|NCT02322606|Other|Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet|Single-dose administration in a fasting state
16643888|NCT02322606|Other|Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo|Single-dose administration in a fasting state
16643889|NCT02322606|Other|Cohort 4: TAK-137 5mg, TAK-137 placebo|Once daily for 7 days in a fasting state
16643890|NCT02322606|Other|Cohort 5: TAK-137 10 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
16643891|NCT02322606|Other|Cohort 6: TAK-137 15 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
16643892|NCT02322593|Experimental|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
16643893|NCT02322593|Active Comparator|S-1/Cisplatin|S-1 plus Cisplatin
16643894|NCT02322580||Psoriasis patients who receive Enbrel® therapy|
16643895|NCT02322567||LV diastolic dysfunction|
16643896|NCT02322567||No LV diastolic dysfunction|
16643897|NCT02322554||wounds treated with CTPs|All cellular and tissue based products currently reimbursed in the hospital based outpatient department, administered at intervals as determined in the course of clinical practice
16643898|NCT02322541|Experimental|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
16643899|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
16643900|NCT02322515|Experimental|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
16643901|NCT02322515|Placebo Comparator|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
16643902|NCT02322502|Experimental|desflurane|Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
16643903|NCT02322502|Active Comparator|sevoflurane|"Sevoflurane:
~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application"
16643904|NCT02322502|Active Comparator|propofol|Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application
16643905|NCT02322489|Sham Comparator|Sham microcurrent therapy|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but it lasts only for 5 seconds.
16643906|NCT02322489|Experimental|Microcurrent Group|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started.
16643907|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
16643908|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
16643909|NCT02322450|Experimental|A: P1-QGC001 - Washout-placebo - P2-placebo|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
16643910|NCT02322450|Experimental|B: P1-placebo - Washout-placebo - P2-QGC001|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
16643911|NCT02322437|Experimental|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
16643912|NCT02322437|Active Comparator|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
16643913|NCT02322424||Patients who undergo pancreaticoduodenectomy|
16643914|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
16643915|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
16643916|NCT02322398||Group A|Patients who had been stimulated with a starting dose of 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio.
16643917|NCT02322398||Group B|Patients who had been stimulated with a starting dose of 150-300 IU/d hMG.
16643918|NCT02322372|Active Comparator|Group F|"Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
~."
16643919|NCT02322372|Active Comparator|Group S|The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
16643920|NCT02322346|Placebo Comparator|Group S|Preincisional bilateral peritonsillar infiltration of a total of 6 mL of saline
16643921|NCT02322346|Active Comparator|Group LL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.25% (3 mL to each tonsil).
16643922|NCT02322346|Active Comparator|Group HL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.5% (3 mL to each tonsil).
16643923|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
16643924|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
16643925|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
16643926|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
16643927|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
16643928|NCT02322307|Experimental|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
16643929|NCT02322307|Placebo Comparator|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
16643930|NCT02322294|Experimental|Glucodia™|
16643931|NCT02322294|Placebo Comparator|Placebo|
16643932|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
16644037|NCT02321579|Experimental|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
16700494|NCT01947387||NPWT|
16643933|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
16643934|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed
~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.
~Gemcitabine
~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.
~Docetaxel
~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.
~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.
~Paclitaxel
~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
16643935|NCT02322268|Experimental|Diabetic Cosmos caudatus treated group|Subjects in this arm will receive Cosmos caudatus for 8 weeks.
16643936|NCT02322268|No Intervention|Diabetic control group|Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.
16643937|NCT02322255||All Subjects|All subjects enrolled in the study.
16643938|NCT02322242|Active Comparator|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
16643939|NCT02322242|Other|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
16643940|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
16643941|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
16643942|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
16643943|NCT02322203|Experimental|Niacin ER in healthy participants and its effects on lipoprotein composition and function|Niacin extended release (ER) to be given as follows: 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks in healthy participants.
16643944|NCT02322190|No Intervention|Investigator chosen second line therapy|Investigator chosen second line therapy
16643945|NCT02322190|Experimental|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
16643947|NCT02322138|Experimental|Experimental 1 Infant Formula|Milk-based infant formula without prebiotics
16643948|NCT02322138|Experimental|Experimental 2 Infant Formula|Milk-based infant formula with prebiotics
16643949|NCT02322138|Other|Human Milk-Fed Reference Group|Breast fed infants
16643950|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
16643951|NCT02322112|Placebo Comparator|Microcrystalline Cellulose (Control)|Microcrystalline cellulose will be used as a placebo control, as it is known to be an insoluble, non-viscous fiber that is essentially not fermented by the human gut microbiota. However, it is important to note that cellulose does have fermentation potential within the gastrointestinal tract and may be associated with improved health benefits; indicating a role as an active comparator.
16643952|NCT02322112|Experimental|Acacia Gum|Acacia gum is composed largely of arabinogalactan, and is considered to be a relatively non-viscous, soluble fiber this is highly fermented by the gut microbiota and well tolerated.
16643953|NCT02322112|Experimental|Resistant Starch Type 4|Cross-linked phosphorylated resistant starch (type IV) is generally insoluble and with low viscosity; yet it tends to have physiologic properties similar to soluble fibers, such as fermentability.
16643954|NCT02322099|Active Comparator|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
16643955|NCT02322099|Placebo Comparator|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
16643956|NCT02322086|Experimental|PH-10|Active treatment
16643961|NCT02322060||Primary ovarian insufficiency|"Primary ovarian insufficiency (POI; also known as premature ovarian failure/dysfunction/insufficiency or premature menopause) is characterised by amenorrhoea, sex hormone (oestrogen, progesterone and testosterone) deficiency and elevated gonadotrophins levels in a woman aged more than two standard deviations below the mean age of menopause estimated for her reference population. POI is defined as a disorder in ovarian function in any woman before the age of 40 years, irrespective of the cause.
~In our study, we mainly recruit POI patients who also desire to have a baby of their own."
16643962|NCT02322060||Ovarian resistance syndrome|We currently also include patients diagnosed with Ovarian resistance syndrome, which means that follicles exist, but do not response to FSH.
16643963|NCT02322047|Experimental|Praz/Nal|"Prazosin and Naltrexone.
~Prazosin will be taken following this titration schedule:
~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
16643964|NCT02322047|Active Comparator|Praz/Pl|"Prazosin and Placebo (Naltrexone)
~Prazosin will be taken following this titration schedule:
~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
16644231|NCT02320084||HT-1 patients on Orfadin treatment|HT-1 patients on Orfadin (nitisinone) treatment
16701425|NCT01940874||Cerebral oximetry|
16643965|NCT02322047|Active Comparator|Nal/Pl|"Naltrexone and Placebo (Prazosin)
~Prazosin Placebo will be taken following this titration schedule:
~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
16643966|NCT02322047|Placebo Comparator|Pl/Pl|"Placebo (Prazosin) and Placebo (Naltrexone)
~Prazosin Placebo will be taken following this titration schedule:
~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
16643967|NCT02322034|Experimental|Interval Training|Hospital outpatient-based regimen (3 times/week for 24 weeks) exercise program will be performed by cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
16643968|NCT02322034|No Intervention|Controls|CHF patients allocated to the control group (no intervention) will undergo biochemical and hormonal sampling, Doppler-echocardiography, cardiopulmonary exercise stress testing at study enrollment and at 24-week follow-up.
16643969|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of E2609 will be assessed.
16643970|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of E2609 will be assessed.
16643971|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of E2609 will be assessed.
16643972|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|
16643973|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of E2609 will be assessed.
16643974|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of E2609 will be assessed.
16643975|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|
16643976|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of E2609 will be assessed.
16643977|NCT02321982|No Intervention|Separate-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation in advance of the day of the procedure.
16643978|NCT02321982|Experimental|Same-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation on the day same day as the procedure.
16643979|NCT02321969|No Intervention|Control|Without green tea extract (GTE) supplementation
16643980|NCT02321969|Experimental|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
16643981|NCT02321956|Experimental|Ultrasound|Using ultrasound measurement of the subglottic area to choose endotracheal tube size
16643982|NCT02321956|No Intervention|Formula|Using Cole's formula to choose endotracheal tube size
16643983|NCT02321943||Follow-Up Group|"An earlier investigated cohort with first episode psychosis patients from two Norwegian counties. Being between 18 - 65 years old and being consecutive in- or outpatient referred to first adequate treatment for a DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychosis."
16643984|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
16643985|NCT02321917|Active Comparator|Rheoparin coating|MECC system with rheoparin coating
16643986|NCT02321917|No Intervention|No rheoparin coating|MECC system without rheoparin coating
16643987|NCT02321904||Diabetic cases|Children with Type 1 Diabetes 8 to 18 years old followed at the Alberta Children's Hospital Diabetes Clinic with duration of diabetes for at least 5 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
16643988|NCT02321904||Normal controls|Healthy children aged 8 to 18 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
16643989|NCT02321891|Experimental|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
16643990|NCT02321891|Experimental|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
16643991|NCT02321878||Liraglutide|
16643992|NCT02321865|Experimental|NPC-02|
16643993|NCT02321852|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo
16643994|NCT02321852|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
16643995|NCT02321839|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
16643996|NCT02321826|Experimental|Music|Listening to music for 45 minutes at bedtime
16643997|NCT02321826|Active Comparator|Audiobook|Listening to audiobook for 45 minutes at bedtime
16643998|NCT02321826|No Intervention|Control|No intervention control group
16643999|NCT02321813|Experimental|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient's QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
16644000|NCT02321813|Placebo Comparator|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
16644001|NCT02321800|Experimental|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
16644002|NCT02321800|Active Comparator|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
16644003|NCT02321787|No Intervention|Traditional Methods of Assessment|The caudal block will be done using traditional means of assessment, not confirmed by ultrasound.
16644004|NCT02321787|Experimental|Ultrasound for Confirmation|The caudal block will be performed utilizing ultrasound as an additional method of assessment for successful block (in addition to all traditional means of assessment).
16644005|NCT02321761|Experimental|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg
~days 57-70 no drug will be given"
16644006|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
16644007|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
16644008|NCT02321735|Other|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
16644009|NCT02321709|Experimental|SAR113244 cohort 1|Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)
16644010|NCT02321709|Experimental|SAR113244 cohort 2|Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)
16644011|NCT02321709|Experimental|SAR113244 cohort 3|Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)
16644012|NCT02321696|Experimental|Acupuncture and eccentric exercise|Treatment will be performed according to traditional Chinese methods (STRICTA: Standards for reporting interventions in controlled trials of acupunc-ture). Therapists will select points frequently recommended for the treatment of LE. As local point, LI11 and LI10 over the muscular origin of the lateral extensor group of the forearm will be used, and LU5 in the cubical region. LI4 and TE5 will be regional points for pain therapy in the upper limb, GB34 will be used as a distal point for treatment of tendinosis in general, and ST36 for treatment of pain. Needles will be inserted down to the musculature and obtaining De Qi sensation and will remain in situ for 20 min. All patients will receive four treatment sessions; this may be extended to eight depending on patient's pain report and the therapists' clinical evaluation. Maximum treatment period is 4 weeks. Patients will also be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
16644013|NCT02321696|Experimental|Physiotherapy and eccentric exercise|"Manual techniques as gliding mobilization of elbow, therapists are spezialised in manual therapy. At least four treatment sessions will be performed, but depending on the patient's perceived intensity of pain and the therapists' clinical evaluation, a maximum of eight treatment session can be given. All treatment session will be performed during a period of maximum 4 weeks.
~In addition, patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward."
16644014|NCT02321696|Active Comparator|Watchful waiting and eccentric exercise|Patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
16644015|NCT02321683|Experimental|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
16644016|NCT02321683|Active Comparator|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
16644017|NCT02321670|Active Comparator|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
16644018|NCT02321670|Active Comparator|Graft|Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
16644019|NCT02321657|Experimental|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
16644020|NCT02321657|Active Comparator|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
16644021|NCT02321644|Experimental|CC-90001|"Part 1: All subjects will receive the following doses of CC-90001 in the fixed sequence below:
~Treatment A: 60 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment B: 160 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment C: 400 mg of CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days"
16644022|NCT02321644|Experimental|CC-90001 2 X 100mg fasted|Treatment D: 2 x 100 mg CC-90001 as Active-Ingredient-in-Capsule, single oral dose administered under fasted conditions.
16644023|NCT02321644|Experimental|CC-90001 1 X 200mg fasted|Treatment E: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fasted conditions
16644024|NCT02321644|Experimental|CC-90001 1 X 200mg fed|Treatment F: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fed conditions (standard high fat breakfast).
16644025|NCT02321631|Experimental|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
16644026|NCT02321631|Placebo Comparator|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
16644027|NCT02321618|Experimental|BP measurement & pharmacy|BP measurements performed by barber, role model poster exposure in barbershop, and BP medication management visits with study pharmacist
16644028|NCT02321618|Other|BP educational materials|Exposure to hypertension educational materials in barbershop
16644029|NCT02321605|Experimental|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
16644030|NCT02321605|Placebo Comparator|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
16644031|NCT02321592|Active Comparator|Arm A|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.
~Arm A ist closed."
16644032|NCT02321592|Active Comparator|Arm B|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.
~Arm B is closed."
16644033|NCT02321592|Active Comparator|Arm C|AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
16644034|NCT02321579|Placebo Comparator|Negative control|Dextrins
16644035|NCT02321579|Experimental|Supplement 1|50 mg/d vitamin B-6
16644038|NCT02321566|Experimental|Treatment Arm|A craniotomy will be performed for the placement of an epidural motor cortex stimulation lead in the context of subjects with chronic facial, upper extremity, and throat pain. If the stimulation is successful during a trial period with externalized lead cabling, the system cabling will be internalized and connected to an internal implantable pulse generator to power and control the system for the duration of the trial.
16644039|NCT02321553|Experimental|Brown Rice|Eat 100g of brown rice cake (3 packets) per day for 5 weeks
16644040|NCT02321553|Experimental|White Rice|Eat 100g of white rice cake (3 packets) per day for 5 weeks
16644041|NCT02321540|Experimental|Ibrutinib|"Participants in Part 1 receive dose level of Ibrutinib depending on study joined. First group of participants receive lowest dose level of Ibrutinib. Each new group receives a higher dose of Ibrutinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ibrutinib is found.
~Participants in Part 2 receive Ibrutinib at highest dose that was tolerated in Part 1 or 840 mg daily.
~Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle."
16644042|NCT02321527|Experimental|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
16644043|NCT02321514|Experimental|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement
16644044|NCT02321501|Experimental|Treatment (ceritinib, everolimus)|Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16644045|NCT02321475||Psycho-emotional symptoms, added to cognitive disorders|Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.
16644046|NCT02321462|Experimental|Eziclen|
16644047|NCT02321462|Active Comparator|Fortrans®|
16644048|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
16644049|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
16644050|NCT02321410|Other|Imaging of carotid plaque|Patient undergo contrast enhanced ultrasound of the carotid plaque and dynamic contrast-enhanced carotid plaque MRI
16644051|NCT02321397|Experimental|OXN PR HST|Prolonged release oxycodone/naloxone higher strength tablets
16644052|NCT02321397|Active Comparator|OXN PR LST|Prolonged release oxycodone/naloxone lower strength tablets
16644053|NCT02321384|Experimental|A: SAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 6 planned SAD cohorts to receive single dose of RO6889678/matching placebo in fasted state as per anticipated dose escalation sequence (30 milligrams [mg], 100 mg, 300 mg, 600 mg, 1000 mg and 1500 mg). Cohort 1 will be split in 2 groups: 2 participants will be dosed 1 day (1 on RO6889678 and 1 on matching placebo) and 3 participants (2 on RO6889678 and 1 on matching placebo) will be dosed at least 24 hours afterward following satisfactory safety assessment for first 2 participants. Cohort 2 & beyond will include 8 healthy participants with 6 participants randomly assigned to RO6889678 & 2 randomly assigned to placebo. Participants who will tolerate fasted dose and agree to continue in food-effect SAD cohort, will receive single dose (dose level, either 300 mg or 600 mg, decided based on PK and safety data of first 2 SAD cohorts) of RO6889678/matching placebo with US FDA recommended high-fat and high-calorie breakfast on Day 16.
16644054|NCT02321384|Experimental|B: MAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms [mcg]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
16644055|NCT02321384|Experimental|C:RTV-Boosted SAD & MAD Cohorts-RO6889678/Matching Placebo+RTV|Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
16644056|NCT02321371|Experimental|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
16644057|NCT02321371|Active Comparator|Lactulose therapy|
16644058|NCT02321358|Experimental|Two-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention and a booster again six weeks following.
16644059|NCT02321358|Active Comparator|One-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention.
16644060|NCT02321358|Sham Comparator|Sham Comparator Group|Group will receive Canada's Food Guide which contains a small amount of physical activity information.
16644061|NCT02321345|Experimental|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
16644062|NCT02321332|Active Comparator|B-ETS|Bilateral simultaneous endoscopic thoracic sympathectomy: bilateral simultaneous T2-T3 ganglionectomy.
16644063|NCT02321332|Active Comparator|S-ETS|unilateral sequential endoscopic thoracic sympathectomy: unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval
16644064|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
16644065|NCT02321306|Experimental|LUM001|LUM001 administered orally once each day.
16644066|NCT02321293|Experimental|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.
~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)
~Tyrosine Kinase Inhibitors:
~Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .
~Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .
~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
16644067|NCT02321280|Experimental|Single arm single dose of denosumab|Open label = Single dose administration of single dose Denosumab 120 mg subcutaneously
16644068|NCT02321267|Other|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
16644069|NCT02321254|Experimental|The RehaARM-Robot|Receive 45 min of robot-assisted therapy for the shoulder and 1 hour of daily standard rehabilitation therapy.
16644070|NCT02321241||Group 1|According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection
16644071|NCT02321228|Experimental|Salpingectomy with delayed oophorectomy|Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).
16644072|NCT02321228|Active Comparator|Risk-reducing salpingo-oophorectomy|Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).
16644073|NCT02321215|No Intervention|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
16644074|NCT02321215|Active Comparator|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
16644075|NCT02321202|Active Comparator|Control group|For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
16644076|NCT02321202|Experimental|Trial group|For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.
16644077|NCT02321189|Placebo Comparator|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
16644078|NCT02321189|Placebo Comparator|placebo|The Effect of placebo on Choroidal Thickness
16644079|NCT02321176|Experimental|pharmacokinetics,trans-resveratrol|tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
16644080|NCT02321163|Experimental|NMES new paradigm|For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
16644081|NCT02321163|Active Comparator|NMES conventional|For NMES conventional, the experimental protocol will be the conventional electrical stimulation protocol i.e frequency: 50 Hz; intensity: maximum intensity tolerated by the subject; duration: 30 min.
16644082|NCT02321163|Sham Comparator|Placebo|For placebo, electrodes will be applied and all conditions will be similar to those in the NMES group, except that the amplitude will be set to 0 mA so that no muscle stimulation occurs.
16644083|NCT02321150|Active Comparator|Sutures|After pterygium removal the conjunctival graft to cover bare sclera will be secured with interrupted 8.0 polyglactin sutures.
16644084|NCT02321150|Experimental|Cautery|After pterygium removal the conjunctival graft to cover bare sclera will be secured with bipolar electrocautery, power set at 25 until whitening of tissue observed.
16644085|NCT02321137|Active Comparator|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
16644086|NCT02321137|Placebo Comparator|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
16644087|NCT02321124|Active Comparator|intervention|we will apply connective tissue manipulation and life style advice.
16644088|NCT02321124|Other|control group|We will apply only life style advice.
16644089|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
16644090|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
16644091|NCT02321111|Active Comparator|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
16644092|NCT02321098|Experimental|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
16644093|NCT02321098|Experimental|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
16644272|NCT02319863|Active Comparator|conventional resection|Perform hepatectomy with conventional method for HCC patients.
16644094|NCT02321085|Active Comparator|Sinus Rhythm Control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
~Cardioversion after 1 month
~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
~If AF recur, RFCA"
16644095|NCT02321085|Active Comparator|Pulse Rate Control Group|"No AAD, just anticoagulation
~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
~Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study."
16644096|NCT02321072|Active Comparator|High-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
16644097|NCT02321072|Active Comparator|Low-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
16644098|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
16644099|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
16644100|NCT02321033|Experimental|low glycemic index|palatinose in soft drinks
16644101|NCT02321033|Experimental|high glycemic index|sucrose plus maltodextrin in soft drinks
16644102|NCT02320994||stroke patients|post-rehabilitation stroke patients
16644103|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
16644104|NCT02320968|Experimental|Patients with nocturnal extraesophageal reflux|This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.
16644105|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
16644106|NCT02320942|Experimental|Exercise Intervention|At discharge from the inpatient unit, participants will receive a practical introduction by an exercise specialist and enrolled in the 12-week exercise intervention
16644107|NCT02320929|Experimental|Intraoperative irrigation only|The infected tendon sheath is irrigated intraoperatively, the catheter is removed, and small rubber srains are left in small incisions.
16644108|NCT02320929|Active Comparator|Intra- and postoperative irrigation|The infected tendon sheath is irrigated intraoperatively, the catheter is kept in place, the irrigation is continued postoperatively 3 times a day for 3 days.
16644109|NCT02320916|Active Comparator|23Gauge|Arterial blood puncture will be performed using a 23Gauge needle
16644110|NCT02320916|Active Comparator|25Gauge|Arterial blood puncture will be performed using a 25Gauge needle
16644111|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
16644112|NCT02320890|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 3 days a week for 12 weeks (total of 36 applications)
16644113|NCT02320890|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 3 days a week for 12 weeks (total of 36 applications)
16644114|NCT02320877|Experimental|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
16644115|NCT02320864||Non-surgical group|Adults who have knee osteoarthritis, but do not elect to have a total knee replacement surgery.
16644116|NCT02320864||Surgical group|Adults who have knee osteoarthritis and elect to have total knee replacement surgery.
16644117|NCT02320851|Experimental|SVD-tailored Integrative Psychotherapy (IPT)|IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
16644118|NCT02320851|Active Comparator|Self-help group (SHG)|The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions. Those can be classified as low-level non-placebo control. Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
16644119|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
16644120|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
16644121|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
16644122|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
16644333|NCT02319499|Experimental|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
16644123|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
16644124|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
16644125|NCT02320799|Active Comparator|treatment as usual|Usual Clinic psychosocial treatment
16644126|NCT02320799|Experimental|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
16644127|NCT02320786|Experimental|CoPILOT|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (one hour, four times per week for three weeks).
16644128|NCT02320786|No Intervention|Standard of Care|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair, consisting of 12 hour protocols in a standard power wheelchair (one hour, four times per week for three weeks).
16644129|NCT02320773||1. OAB patients taking Betmiga®|OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
16644130|NCT02320760|Experimental|Physical activity on prescription|
16644131|NCT02320760|No Intervention|Ordinary care|
16644132|NCT02320747|Experimental|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
16644133|NCT02320747|No Intervention|Control Group|
16644134|NCT02320734|Active Comparator|deep neuromuscular relaxation|continuous infusion of rocuronium 0.6 mg/kg/hr (group 1). On demand bolus rocuronium can be given if demanded by anesthesiologist or surgeon
16644135|NCT02320734|No Intervention|on demand neuromuscular relaxation|continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2) On demand bolus of Rocuronium will be given when demanded by anesthesiologist or surgeon.
16644136|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
16644137|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
16644138|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
16644139|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
16644140|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
16644141|NCT02320708|Placebo Comparator|Placebo|
16644142|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
16644143|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
16644144|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
16644145|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
16644146|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
16644147|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
16644148|NCT02320682|Active Comparator|Exeter femur component and Delta TT acetabular component|
16644149|NCT02320682|Active Comparator|SP-CL femur component and Delta TT acetabular component|
16644150|NCT02320682|Active Comparator|SP-CL femoral component and Delta PF acetabular component|
16644151|NCT02320682|Active Comparator|Exeter femoral component and Delta PF acetabular component|
16644152|NCT02320669|Experimental|Triostat|Active Medication - Synthetic Thyroid Hormone
16644153|NCT02320669|Placebo Comparator|Placebo|Placebo Control
16644154|NCT02320656|Experimental|Acute leukemia/myelodysplastic or myeloproliferative disease|
16644155|NCT02320643|Experimental|Seratom® PA mesh|Partially absorbable mesh
16644156|NCT02320630|Experimental|A|Maintenance treatment group
16644157|NCT02320630|Experimental|B|Combination treatment group
16644158|NCT02320630|Experimental|C|Single drug group
16644159|NCT02320617|Experimental|DW-MRI group|To evaluate the efficacy of chemoradiotherapy in lung cancer patients by DW-MRI when compared with conventional imaging modalities(CT, ultrasound et al.)
16644160|NCT02320604|Experimental|Obese Subjects 1mg/kg|8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes
16644161|NCT02320604|Experimental|Obese Subjects 2mg/kg|8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes
16644162|NCT02320591|Experimental|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
16644163|NCT02320591|No Intervention|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
16644164|NCT02320578|Experimental|3D Laparoscopy|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.
~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
16644334|NCT02319499|Placebo Comparator|Placebo|No minerals/vitamin
16644165|NCT02320578|Active Comparator|Standard Laparoscopy|Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
16644166|NCT02320565|Experimental|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.
~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
16644167|NCT02320565|Active Comparator|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
16644168|NCT02320552||PD patients|Patients receiving peritoneal dialysis. No intervention
16644169|NCT02320552||HD patients|Patients receiving hemodialysis. No intervention
16644170|NCT02320539||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
16644171|NCT02320539||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
16644172|NCT02320539||SAH good grade|SAH without external ventricular drainage
16644173|NCT02320539||Healthy controls|Blood sample in healthy donors registered in the National Donor Registry.
16644174|NCT02320526|Experimental|Control|Control intervention: Subjects will continue their life unaltered during the 14 days intervention period
16644175|NCT02320526|Experimental|Continuous walking|Training intervention: Subjects will perform continuous walking for one hour per day at every weekday during the 14 days intervention period
16644176|NCT02320526|Experimental|Interval Walking|Training intervention: Subjects will perform interval walking for one hour per day at every weekday during the 14 days intervention period. Interval walking will be performed as repeated cycles of three minutes of slow and hree minutes of fast walking during the entire training session
16644177|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
16644178|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
16644179|NCT02320500|Active Comparator|standard physiotherapy|Standard of care physiotherapy for knee osteoarthritis (OA) patients who have been diagnosed with knee OA and may be candidates for total knee replacement (TKA)
16644180|NCT02320500|Experimental|Myofascial-specific therapy|Patient undergo myofascial pain-specific therapy which includes trigger point injections at the same time points as the comparator (1 session every 2 weeks for 8 weeks)
16644181|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
16644182|NCT02320474|Experimental|Aflibercept|
16644183|NCT02320448|Experimental|PIPAC|"PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.
~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy."
16644184|NCT02320435|Experimental|Pertuzumab (Single-Agent or Combination Therapy)|Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
16644185|NCT02320422|Experimental|Behavioral Telehealth|
16644186|NCT02320409|Experimental|Sulfatinib ,after general diet|First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
16644187|NCT02320409|Experimental|Sulfatinib, before general diet|First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
16644188|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
16644189|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
16644190|NCT02320383|Experimental|B + GA101|"Induction:
~Bendamustine + GA101; a maximum of 6 cycles of BG will be administered; each cycle with a duration of 28 days
~Maintenance:
~GA101 i.v. 1000 mg (flat dose): every 84 days starting on final restaging continued until progression or to a maximum of 2 years"
16644191|NCT02320370|Experimental|Treatment 1|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
16644192|NCT02320370|Experimental|Treatment 2|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
16644193|NCT02320357|Experimental|Clopidogrel|
16644194|NCT02320344|Experimental|Partners in Care|
16644195|NCT02320331|Experimental|PILI Lifestyle Program|
16644196|NCT02320318|Experimental|Ibodutant 10 mg|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
16644197|NCT02320318|Placebo Comparator|Placebo|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
16644198|NCT02320305|Experimental|Arm I (MART-1 antigen and TLR4 antagonist GLA-SE)|Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16644199|NCT02320305|Experimental|Arm II (MART-1 antigen)|Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16644200|NCT02320292|Active Comparator|Arm A (rituximab)|Patients receive rituximab IV on days 1, 8, 15, and 22.
16644201|NCT02320292|Experimental|Arm B (rituximab, yttrium Y-90 ibritumomab tiuxetan)|Patients receive rituximab IV on days 1 and 8 and yttrium Y-90 ibritumomab tiuxetan over 10 minutes on day 8.
16644202|NCT02320279||Women in labor|Pregnant women, women in labor, and women who are admitted to labor and delivery for scheduled c-sections will form the eligible population for recruitment into our study.
16644203|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
16644204|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
16644205|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
16644206|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
16644207|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
16644208|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
16644209|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
16644210|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
16644211|NCT02320240||SNRI Exposure Group|Patients who received a new prescription for an SNRI (duloxetine, venlafaxine, or desvenlafaxine at any dosage) with no prescriptions for either SNRI or SSRI in the prior year.
16644212|NCT02320240||SSRI Exposure Group|Patients who received a new prescription for an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline at any dosage) with no prescriptions for either SSRI or SNRI in the prior year.
16644213|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
16644214|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
16644215|NCT02320201|Experimental|Electrical stimulation|Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
16644216|NCT02320188|Experimental|Eccentric exercise|Thirty sessions of Eccentric training in twelve weeks. Average of two sessions per week without spacing higher than eight days between two sessions.
16644217|NCT02320188|Experimental|Concentric exercise|Thirty sessions of Concentric training in twelve weeks. Average of three sessions per week without spacing higher than eight days between two sessions.
16644218|NCT02320188|No Intervention|No training (control)|Usual activities. No further training during the observation period
16644219|NCT02320175|No Intervention|Pre-intervention|Before implementation of Patient and Family Centered I-PASS.
16644220|NCT02320175|Experimental|Post-intervention|After implementation of Patient and Family Centered I-PASS.
16644221|NCT02320162|Experimental|Experiential learning|Oral health education using experiential learning (EL)
16644222|NCT02320162|Placebo Comparator|Traditional lecturing|Oral health education using traditional lecturing (TL)
16644223|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
16644224|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
16644225|NCT02320136||epilepsy|epilepsy patients
16644226|NCT02320136||tumor with epilepsy|tumor patients with epileptic seizures
16644227|NCT02320136||tumor without epilepsy|tumor patients without epileptic seizures
16644228|NCT02320123|Experimental|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
16644229|NCT02320123|No Intervention|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
16644230|NCT02320097|Other|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.
~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
16701426|NCT01940861||Traumatic brain injury|
16644232|NCT02320071||Patients with incisional hernia|Patients with one or more incisional hernias, combined horizontal fascial defect 3-8 cm, planned for laparoscopic mesh repair. Patients are examined before and one and three months postoperative in regard to abdominal wall function, pain, discomfort, hernia-related quality of life and physical activity level.
16644233|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously
~Maintenance Phase: Nivolumab infusion intravenously"
16644234|NCT02320045|Experimental|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
16644235|NCT02320045|Experimental|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
16644236|NCT02320045|Experimental|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
16644237|NCT02320045|Experimental|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) >30-44 mL/min/1.73 m2
16644238|NCT02320032|Experimental|Aripiprazole Lauroxil - A|Intramuscular (IM) injection Dose and Dosing Sequence A
16644239|NCT02320032|Experimental|Aripiprazole Lauroxil - B|Intramuscular (IM) injection Dose and Dosing Sequence B
16644240|NCT02320032|Experimental|Aripiprazole Lauroxil - C|Intramuscular (IM) injection Dose and Dosing Sequence C
16644241|NCT02320032|Experimental|Aripiprazole Lauroxil - D|Intramuscular (IM) injection Dose and Dosing Sequence D
16644242|NCT02320019|Placebo Comparator|Placebo group|Placebo
16644243|NCT02320019|Experimental|Group A|YH14618 A mg/disc
16644244|NCT02320019|Experimental|Group B|YH14618 B mg/disc
16644245|NCT02320019|Experimental|Group C|YH14618 C mg/disc
16644246|NCT02320019|Experimental|Group D|YH14618 D mg/disc
16644247|NCT02320006|Active Comparator|True acupuncture plus hydrotubation|The treatment group will receive true acupuncture and hydrotubation,Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performedwithin 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles. The points (points used for every participant of treatment group) include bilateral RN4、CV6、CV3、EX-CA1、ST36、SP6,All the needles will be keep in positions for 30 min.Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk)
16644248|NCT02320006|Sham Comparator|control acupuncture plus hydrotubation|The control group will receive control acupuncture and hydrotubation.Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performed within 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles.Two needles will be inserted in each arm, one in each shoulder and one in each upper arm at nonacupuncture pointsAll the needles will be keep in positions for 30 min. Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk).
16644249|NCT02319993|Experimental|TIAN WANG BU XIN DAN|"Drug:TIAN WANG BU XIN DAN CONCENRATED GRANULES CHUANG SONG ZONG"
16644250|NCT02319993|Experimental|Suan Tzao Ren Tang|"Drug:Suan Tzao Ren Tang Granula Subtilae CHUANG SONG ZONG"
16644251|NCT02319993|Placebo Comparator|Placebo|Drug:1/10 TIAN WANG BU XIN DAN
16644252|NCT02319980|Active Comparator|Surgical intervention|All participants in this group will be assigned to receive extracranial-intracranial arterial bypass surgery.
16644253|NCT02319980|No Intervention|Conservative management(medical management)|All participants in this group will be assigned to receive conservative management or medical management which involves drug therapy as considered appropriate for medical symptoms by the treating investigator.
16644254|NCT02319967|No Intervention|Enhanced usual care|Inhaler technique education and distribution of spacers to all participants.
16644255|NCT02319967|Experimental|ED-only|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
16644256|NCT02319967|Experimental|ED-plus-home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
~Home visits by a community health worker (CHW)."
16644257|NCT02319954|Active Comparator|Compression|Each patient will be randomized to receive compression of their nose on either the left or right for 5 continuous minutes after performing a lateral rhinotomy.
16644258|NCT02319954|No Intervention|No compression|Each patient will serve as their own control with the other side not receiving any compression after a lateral rhinotomy.
16644259|NCT02319941|Experimental|Low dose ticagrelor|60mg bid
16644260|NCT02319941|Active Comparator|standard dose ticagrelor|90mg bid
16644261|NCT02319941|Active Comparator|standard dose clopidogrel|75mg qd
16644262|NCT02319928|Active Comparator|Short-term surveillance|Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.
16644263|NCT02319928|Experimental|Long-term surveillance|Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
16644264|NCT02319915|Experimental|Tranexamic acid|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.
16644265|NCT02319915|Active Comparator|Tranexamic acid + adrenalin|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.
16644266|NCT02319902|Placebo Comparator|Standard cold carbon dioxide gas|Standard cold carbon dioxide gas
16644267|NCT02319902|Active Comparator|Heated humidified carbon dioxide gas|Heated humidified carbon dioxide gas
16644268|NCT02319889|Experimental|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16644269|NCT02319876||Severe sepsis|Patients with severe sepsis
16644270|NCT02319876||SIRS patient|Patients after elective surgeries presented with SIRS but without sepsis
16644271|NCT02319876||Volunteer|Volunteers
16644273|NCT02319863|Experimental|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
16644274|NCT02319850||Reference Group|18 - 29 years of age; apparently healthy younger participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
16644275|NCT02319850||Comparison Group|55 - 75 years of age; apparently healthy older participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
16644276|NCT02319837|Experimental|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks
16644277|NCT02319837|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
16644278|NCT02319837|Active Comparator|Placebo plus leuprolide|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks
16644279|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
16644280|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
16644281|NCT02319798|Active Comparator|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital as usual.
16644282|NCT02319798|Experimental|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
16644283|NCT02319785|Experimental|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
16644284|NCT02319785|Experimental|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
16644285|NCT02319785|Active Comparator|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
16644286|NCT02319785|Experimental|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
16644287|NCT02319785|Active Comparator|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
16644288|NCT02319785|Active Comparator|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
16644289|NCT02319772|Experimental|BCX4430|BCX4430 administered as an IM injection
16644290|NCT02319772|Placebo Comparator|Placebo|Matched placebo administered as an IM injection
16644291|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
16644292|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
16644293|NCT02319746|Experimental|Experimental group|The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
16644294|NCT02319746|Active Comparator|Control group|The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
16644295|NCT02319733|Experimental|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
16644296|NCT02319720|Experimental|BMA/Cultured Bone Marrow Cells|The subjects in this arm will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. Part of the aspirate will be cultured. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate and up to three applications of cultured cells derived from that aspirate. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by direct application of fresh bone marrow to the wound and up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
16644297|NCT02319720|Experimental|Cultured Bone Marrow Cells|In this group, the bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of up to three applications of cultured cells derived from a single bone marrow aspiration. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
16644298|NCT02319720|Experimental|Bone Marrow Aspirate|The subjects in this group will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate. If the wound has not healed, up to three additional bone marrow biopsies may be performed. If the wound heals at any point during this protocol, no additional bone marrow biopsy procedures will be performed and no additional cells will be applied.
16644335|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
16644376|NCT02319200|Experimental|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)
~Metformin daily during 36 months"
16644299|NCT02319720|Active Comparator|Control|In this arm, subjects will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressing and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
16644300|NCT02319707|Experimental|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
16644301|NCT02319707|Experimental|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
16644302|NCT02319707|Active Comparator|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
16644303|NCT02319681|Experimental|Simple Reminiscence (SR) caregiver|Subjects are caregivers for a persons with EAD and will be administered SR intervention and an attention control treatment four times
16644304|NCT02319681|Experimental|Simple Reminiscence (SR) EAD|Subjects are persons with EAD and will be administered SR intervention and an attention control treatment four times
16644305|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
16644306|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
16644307|NCT02319655|Active Comparator|Air tamponade|Air is injected after vitrectomy/membrane peeling
16644308|NCT02319655|Active Comparator|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
16644309|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.
~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
16644310|NCT02319629|Experimental|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
16644311|NCT02319629|Placebo Comparator|placebo|placebo twice a day
16644312|NCT02319616|Experimental|Clobetasol 0.05% ointment|All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.
16644313|NCT02319616|Placebo Comparator|Placebo|All patients will have one arm assigned to receive the placebo treatment (topical petrolatum ointment) applied daily for a period of fourteen days.
16644314|NCT02319603|Active Comparator|Low dose WenXin keli|"Low dose group (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
16644315|NCT02319603|Experimental|High dose WenXin keli|"High dose group(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
16644316|NCT02319590||heart failure, no CAD, QRS < 150ms|no CAD, QRS < 150ms
16644317|NCT02319590||heart failure, CAD QRS < 150ms|CAD, QRS < 150ms
16644318|NCT02319590||heart failure, CAD > 150ms|CAD, QRS > 150ms
16644319|NCT02319590||heart failure, no CAD, > 150ms|no CAD, QRS > 150ms
16644320|NCT02319577|Experimental|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):
~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
16644321|NCT02319577|Active Comparator|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):
~Gefitinib 250 mg daily from day 1 to day 21"
16644322|NCT02319564|Active Comparator|beclomethasone|"beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.
~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
16644323|NCT02319564|Active Comparator|beclomethasone and salbutamol|"beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.
~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
16644324|NCT02319564|Placebo Comparator|Placebo|"placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.
~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
16644325|NCT02319538|No Intervention|Non-surgical treatment only|Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.
16644326|NCT02319538|Active Comparator|Total thyroidectomy performed|Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.
16644327|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
16644328|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
16644329|NCT02319512|Experimental|Chewing gum|Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
16644330|NCT02319512|Sham Comparator|Control|Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum
16644331|NCT02319499|Experimental|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
16644332|NCT02319499|Experimental|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
16645097|NCT02314559|Active Comparator|Propofol (target controlled infusion)|
16644336|NCT02319460||Retrospective|Retrospective cohort of adults hospitalized for major bleeding during 2008 to 2013 who receive plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
16644337|NCT02319460||Prospective|Prospective parallel cohort of adults hospitalized for major bleeding during 2014 to 2020 who either receive Kcentra® or plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
16644338|NCT02319447|No Intervention|Usual Care|After randomization, these study participants will receive the Usual Care received by all listed kidney transplant candidates at our center.
16644339|NCT02319447|Experimental|Additional education|These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
16644340|NCT02319421|Experimental|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
16644341|NCT02319408|No Intervention|No radiation|Lobectomy for lung cancer without preoperative radiation
16644342|NCT02319408|Experimental|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
16644343|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
16644344|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
16644345|NCT02319382|Experimental|2 markers: 18F-DPA-714 and 11C-PE2I|PET with the tracer [18F]DPA-714 and second PET with the tracer [11C]-PE2I. [18F]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. [11C]-PE2I allow measures dopaminergic neuronal loss.
16644346|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
16644347|NCT02319369|Experimental|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
16644348|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
16644349|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
16644350|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
16644351|NCT02319356|Active Comparator|Beetroot juice (BRJ)|beetroot juice
16644352|NCT02319356|Placebo Comparator|Placebo (PL)|placebo juice
16644353|NCT02319343|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
16644354|NCT02319343|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
16644355|NCT02319330|Experimental|Phone counseling intervention|Treatment as usual (TAU) plus a nurse-delivered mobile phone counseling intervention delivered at weeks 1 to 12, 14, and 16 post-randomization.
16644356|NCT02319330|Active Comparator|Treatment as Usual|Routine HIV clinic-based counseling
16644357|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
16644358|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
16644359|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:
~FOLFOX: combination of drugs administered in a specific sequence as perscribed below.
~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours
~Leucovorin: 200 mg/m2 IV bolus over 2 hours
~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours
~Part II:
~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
16644360|NCT02319291||Participants|P.F.C. Sigma PS150 RP Total Knee System
16644361|NCT02319278|Active Comparator|Myocarditis|
16644362|NCT02319278|Active Comparator|Cardiac sarcoid|
16644363|NCT02319278|Active Comparator|Cardiac Transplant|
16644364|NCT02319278|Placebo Comparator|Healthy Volunteers|
16644365|NCT02319265|Experimental|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
16644366|NCT02319265|Placebo Comparator|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
16644367|NCT02319252|Active Comparator|Gastric tube|A gastric tube is used
16644368|NCT02319252|Active Comparator|Jejunal tube|A jejunal tube is used
16644369|NCT02319239|Active Comparator|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
16644370|NCT02319239|Experimental|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
16644371|NCT02319239|Experimental|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
16644372|NCT02319213|No Intervention|Group C|The control group (Group C) was not subjected to laparoscopic intervention
16644373|NCT02319213|Experimental|Group L|Intraocular pressure measurement with 9 mmHg insufflation
16644374|NCT02319213|Experimental|Group M|Intraocular pressure measurement with 12 mmHg insufflation
16644375|NCT02319213|Experimental|Group H|Intraocular pressure measurement with 15 mmHg insufflation
16707142|NCT01902511|Active Comparator|G-CSF|
16644377|NCT02319200|Placebo Comparator|placebo tablet|2 tablets at morning and 2 tablets at afternoon 4 tablets per day
16644378|NCT02319187|Active Comparator|Arm A|S1
16644379|NCT02319187|Experimental|Arm B|S1 and irinotecan
16644380|NCT02319174|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
16644381|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
16644382|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
16644383|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
16644384|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
16644385|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
16644386|NCT02319135|Active Comparator|fludarabine cytarabine|"Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis> 25 x 109/l), followed by:
~Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR
~Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).
~Treatment cycles every 28 days"
16644387|NCT02319135|Experimental|Azacitidine|Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
16644388|NCT02319122|Other|Progressive Resistance Training|"The key for the PRT is the timely progression of load, based on the child's individual level of strength, which ensures progressive overload.
~Every training session will consist of a warm up, progressive resistance exercises and a cool down period. During warm up and cool down periods.These exercises will be the same for both training groups.
~The strength training exercises have been chosen to strengthen the main lower extremity muscle groups which are important for the gait: sit-to-stand, lateral step-ups, the half knee rise, heel-rises and bridging.
~All these exercises are performed loaded according to the individual level. Three sets of 8 to 10 repetitions of each exercise will be practiced on 3 non-consecutive days with moderate velocity."
16644389|NCT02319122|Other|High Intensity Interval Training|The High Intensity Circuit Training is a sub form of High Intensity Interval Training. The key feature is the very little rest between the exercises which causes a consistent elevation of the participant's heart rate and a short duration of the whole exercise session. Every training session consists of a warm-up, a circuit of 5 exercises (the same as these in the PRT group) and a cool-down period. The children will be asked to train 3 times a week on non-consecutive days and to perform 3 sets. Exercise workload is controlled by determination of time intervals (30 seconds). The children will be instructed to perform as many repetitions as possible during the exercise interval and to keep the rest between the exercises short (it must not exceed 30 seconds).
16644390|NCT02319096|Experimental|Patients with stress incontinence|Patients who present to urogynaecology clinic with proven stress urinary incontinence who will be offered Whole body vibration therapy.
16644391|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
16644392|NCT02319070||Cohort 1|Adult patients with severe Hemophilia A.(25 patients on Secondary Prophylaxis treatment)
16644393|NCT02319070||Cohort 2|Adult patients with severe Hemophilia A.(50 patients on On Demand treatment)
16644394|NCT02319057|Experimental|Panel 1|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
16644395|NCT02319057|Experimental|Panel 2|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
16644396|NCT02319057|Experimental|Panel 3|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
16644397|NCT02319057|Experimental|Panel 4|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
16644398|NCT02319057|Experimental|Panel 5|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
16644399|NCT02319057|Experimental|Panel 6|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
16644400|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
16644401|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
16644402|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
16644403|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
16644404|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
16644405|NCT02319018|Experimental|Treatment (alisertib, mFOLFOX)|Patients receive alisertib PO BID on days 1-3 and mFOLFOX regimen comprising oxaliplatin IV over 2 hours on day 2, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV continuously over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16644406|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
16644407|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
16645098|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
16644408|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
16644409|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
16644410|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
16644411|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
16644412|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
16644413|NCT02318966|Active Comparator|Glycosade|Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
16644414|NCT02318966|Placebo Comparator|Uncooked corn starch|Participants will be randomised to receive uncooked corn starch as a starch load with a maximum dose of 100g. Uncooked corn starch to be taken as one dose.
16644415|NCT02318953|Experimental|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
16644416|NCT02318953|Active Comparator|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
16644417|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.
~access will be through the femoral vein only"
16644418|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
16644419|NCT02318927|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
16644420|NCT02318914|Experimental|gevokizumab|Solution for subcutaneous injection
16644421|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
16644422|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
16644423|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
16644424|NCT02318888|Experimental|Surgery and Icodextrin|Icodextrin 4% instilled every 30 minutes during surgery and 1000 ml instilled before closure of abdomen
16644425|NCT02318888|Active Comparator|Surgery|No instillations during surgery
16644426|NCT02318875|Experimental|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
16644427|NCT02318875|Placebo Comparator|Placebo group|Subjects take 1 placebo capsule per day
16644428|NCT02318862|Other|GERD|Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
16644429|NCT02318862|Other|non-GERD|Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
16644430|NCT02318849|Experimental|Web intervention|Online intervention that uses information, engaging contests, and advocacy drives to encourage college students to become designated organ donor on driver's license
16644431|NCT02318849|No Intervention|Control|No intervention provided
16644432|NCT02318836|Active Comparator|Normal Hepatic function|
16644433|NCT02318836|Active Comparator|Mild Hepatic Impairment|(Child-Pugh score 5-6)
16644434|NCT02318836|Active Comparator|Moderate Hepatic Impairment|(Child-Pugh score 7-9)
16644435|NCT02318836|Active Comparator|Severe Hepatic Impairment|(Child-Pugh score 10-15)
16644436|NCT02318823|Other|Beer (alcoholic) followed by placebo (non-alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
16644437|NCT02318823|Other|Placebo (non-acoholic beer) followed by Beer (alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
16644438|NCT02318810|Active Comparator|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
16644439|NCT02318810|Active Comparator|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
16644440|NCT02318810|Active Comparator|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
16644441|NCT02318810|Placebo Comparator|Placebo|Patients receive saline
16644442|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
16644443|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
16644444|NCT02318784|Experimental|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.
~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV
~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
16644445|NCT02318771|Experimental|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16644446|NCT02318771|Experimental|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
16644447|NCT02318771|Experimental|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
16644448|NCT02318771|Experimental|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
16644449|NCT02318758|Active Comparator|Comparison 1|UT-15C 1 mg alone
16644450|NCT02318758|Active Comparator|Comparison 2|UT-15C 1 mg plus ethanol (simultaneously)
16644451|NCT02318758|Active Comparator|Comparison 3|UT-15C 1 mg administered 1 hour before ethanol
16644452|NCT02318758|Active Comparator|Comparison 4|UT-15C 1 mg administered 1 hour after ethanol
16644453|NCT02318745|Experimental|Culturally Informed Family Treatment for Adolescents|CIFTA focuses on improving parenting practices, parent-adolescent attachment, adolescent ability to meet developmental challenges, increasing family support and decreasing family conflict/negativity, increasing knowledge of drug effects and triggers to use. Parents are taught general parenting and how to help a son or daughter with depression, conduct problems, and/or ADHD. Psycho-educational modules complement the family therapy and culturally relevant information is infused throughout the treatment. In family therapy sessions family members practice the skills and psycho-educational material they have learned. Treatment last approximately 4 months and includes approximately 6 session per month. Session may be family therapy sessions, individual sessions, or psycho-educational modules.
16644454|NCT02318745|Active Comparator|Individual Treatment As Usual|The active comparison condition reflects the typical individually-oriented services that behavior problem youth receive in the community. It was designed to isolate the effects of the CIFTA family interventions. A community agency helped us to standardize the individually-oriented services that were normally provided and a therapist trained by that agency was hired to work on the study to provide continuity to the services. The adolescent individual sessions addressed depression, ADHD, and/or conduct disorder through Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, and assertiveness training. The ITAU therapists were expected to hold 6 sessions per month with the youth.
16644455|NCT02318732|Experimental|Group 1|APPS intervention will be implemented in Group 1 communities prior to implementation in Group 2 communities.
16644456|NCT02318732|Active Comparator|Group 2|APPS intervention will be implemented in Group 2 communities following implementation in Group 1 communities.
16644457|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
16644458|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
16644459|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
16644460|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
16644461|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
16644462|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
16644463|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
16644464|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
16644465|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
16644466|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
16644467|NCT02318680|Experimental|Intervention|Review of follow home visits after discharge from Nykøbing Falster Hospital
16644468|NCT02318680|No Intervention|Control|Standard health care and discharge services
16644469|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
16644470|NCT02318654|Active Comparator|Ice Pack|
16644471|NCT02318654|Active Comparator|Topical EMLA cream|
16644472|NCT02318615|Experimental|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
16644473|NCT02318615|No Intervention|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
16644719|NCT02316925|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
16644474|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.
~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.
~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
16644475|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.
~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.
~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
16644476|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.
~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.
~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
16644477|NCT02318576|No Intervention|Control|This group will do nothing for the 12 week program.
16644478|NCT02318576|Experimental|Cognitive Trained Group|This group will train three time a week for one hour on the given computerized cognitive training website for the 12 week program.
16644479|NCT02318563|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
16644480|NCT02318563|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
16644481|NCT02318537|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
16644482|NCT02318537|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
16644483|NCT02318511|Experimental|ReNu amniotic allograft|Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
16644484|NCT02318511|Placebo Comparator|Saline|Knee injection with saline. Injectable saline will be used as the placebo control.
16644485|NCT02318511|Active Comparator|HA injection|Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
16644486|NCT02318498|Active Comparator|Prospective MINCA patients|Patients with MINCA prospectively investigated with an early CMR with latest technique
16644487|NCT02318498|Placebo Comparator|Historical MINCA patients|Patients with MINCA investigated earlier with a late CMR (median 12 days)
16644488|NCT02318485|Experimental|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
16644489|NCT02318472|Experimental|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
16644490|NCT02318472|Active Comparator|Immobilization|Treatment as usual using plaster cast immobilization
16644491|NCT02318459|Experimental|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
16644492|NCT02318459|Active Comparator|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
16644493|NCT02318446|Placebo Comparator|Control group|Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
16644494|NCT02318446|Experimental|Test group|Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
16644495|NCT02318433|Experimental|Dexamethasone|Subjects receive dexamethasone (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
16644496|NCT02318433|Placebo Comparator|Saline|Subjects receive sterile saline (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
16644497|NCT02318420|Experimental|Women in labour|"All women in labour during the study period (4 months baseline and the 9th-12th month of the intervention) will be included for this pre- vs. post-study of the PartoMa intervention.
~The following subgroups will be studied in-depth:
~All stillbirths
~All maternal deaths
~All women with severe hypertensive disorders
~A randomized selected group of women delivering a the study site, approximately 300-600 each year."
16644498|NCT02318420|Experimental|Health care providers|All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
16644499|NCT02318407|Experimental|AMG 403|AMG 403 administered as subcutaneous doses
16644500|NCT02318407|Placebo Comparator|Placebo|No active drug
16644501|NCT02318394|Experimental|Monotherapy Arm|MEDI0562 monotherapy
16644502|NCT02318381|No Intervention|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
16713184|NCT01862068||Healthy Blood Donors|
16644503|NCT02318381|Other|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.
~Arthroscopic dissection of the superior transverse scapular ligament"
16644504|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
16644505|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
16644506|NCT02318355|No Intervention|Control|Control group that receives no intravenous fluid after blood donation
16644507|NCT02318355|Experimental|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
16644508|NCT02318355|Experimental|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
16644509|NCT02318342|Experimental|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
16644510|NCT02318329|Experimental|Part 1A: FPA144 Dose Escalation Solid Tumors|Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
16644511|NCT02318329|Experimental|Part 1B: FPA144 Dose Escalation Gastric Cancer|Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
16644512|NCT02318329|Experimental|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression
16644513|NCT02318316||EBC level|Exhaled breath condensate level of allogeneic stem cell transplantation patients
16644514|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
16644515|NCT02318303|Experimental|GSP 301-1 NS (QD)|
16644516|NCT02318303|Experimental|GSP 301-2 NS (BID)|
16644517|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
16644518|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
16644519|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
16644520|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
16644521|NCT02318290||Critically ill patients|Mechanically ventilated critically ill patients receiveing opiates for more than 96 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opiates
16644522|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
16644523|NCT02318264|Experimental|Distal to Proximal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting distal by knee and ending proximal by hip.
16644524|NCT02318264|Experimental|Proximal to Distal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting proximal by hip and ending distal by knee.
16644525|NCT02318251|Experimental|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
16644526|NCT02318251|Active Comparator|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
16644527|NCT02318238|Active Comparator|6 minute walking test|walking during 6 minutes
16644528|NCT02318238|Experimental|6 minute step test|stepping during 6 minutes
16644529|NCT02318238|Experimental|4 meter gait speed|walking as fast as possible on 4 meters
16644530|NCT02318225|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
16644531|NCT02318225|Placebo Comparator|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
16644532|NCT02318199||Agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 5-7 during the first 12 hours after surgery.
16644533|NCT02318199||Non-agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 1-4 during the first 12 hours after surgery.
16644534|NCT02318186||0 months - 1 year|
16644535|NCT02318186||11-16 years|
16644536|NCT02318186||7-11 years|
16644537|NCT02318186||4-6 years|
16644538|NCT02318186||1-3 years|
16644539|NCT02318147|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
16644540|NCT02318147|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
16644541|NCT02318134|Experimental|FMT group|In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.
16644542|NCT02318134|Placebo Comparator|Control group|In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.
16644543|NCT02318121|Active Comparator|Amniotomy first|Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.
16644544|NCT02318121|Active Comparator|Oxytocin first|The starting dose will be the low dose rate equal or less than 4 m unit\minute (4 drops\minute doubled every 15 minutes up to 40 drops \minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.
16644545|NCT02318121|Active Comparator|Amniotomy and oxytocin|Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.
16644546|NCT02318108|Experimental|Intervention|Mentored organizational change and feedback.
16644547|NCT02318108|Other|Education only|Education and feedback.
16644720|NCT02316925|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
16644721|NCT02316912|Active Comparator|Single dose level 1 active|Six subjects ATX2417 I mg tablet once.
16644548|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
16644549|NCT02318082|Experimental|Interleukin-2 (IL-2)|Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
16644550|NCT02318069|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
16644551|NCT02318069|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
16644552|NCT02318069|Active Comparator|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
16644553|NCT02318069|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
16644554|NCT02318069|Active Comparator|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
16644555|NCT02318056|Experimental|Aquacel® Ag Burn Glove|Application of Aquacel® Ag Burn Glove burn dressing
16644556|NCT02318056|Active Comparator|Mepilex® Transfer Ag|Application of Mepilex® Transfer Ag burn dressing
16644557|NCT02318056|Active Comparator|Xeroform®/Bacitracin®|Application of Xeroform® burn dressing and Bacitracin® topical antibiotic
16644558|NCT02318043|Active Comparator|AMP-BPT|Methods of AMP-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
16644559|NCT02318043|Active Comparator|His-BPT|Methods of His-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
16644560|NCT02318030||Solid organ transplant|
16644561|NCT02318030||Hematopoietic Stem Cell Transplant|
16644562|NCT02318017|Active Comparator|Methylphenidate|Methylphenidate 0.5mg/kg - once
16644563|NCT02318017|Placebo Comparator|Placebo|Placebo - once
16644564|NCT02318004|Experimental|Home monitoring|Home monitoring via the EarlySense non-invasive nocturnal monitoring system. Movement, heart rate and respiratory rates will be monitored while subject is in his bed. The trends of monitored values will be daily reported to a central repository. No intervention will be attempted and care will be coordinated by the family physician and treating cardiologist as usual.
16644565|NCT02317991|Experimental|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).
~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
16644566|NCT02317978||Subfertility without polycystic ovarian syndrome|The records of all women with infertility who had IVF/ICSI without polycystic ovarian syndrome (PCO) will be reviewed
16644567|NCT02317965||Pregnant Women|"Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure
~Intervention: Single Maternal blood draw of 20mL"
16644568|NCT02317952|Experimental|New Extensively Hydrolyzed Formula|Administered in context of oral food challenge and then for 16 weeks.
16644569|NCT02317952|Active Comparator|Comparator Formula|Administered in context of oral food challenge and then for 16 weeks.
16644570|NCT02317939|Experimental|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
16644571|NCT02317939|Active Comparator|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
16644572|NCT02317926|Active Comparator|Levothyroxine Plus Liothyronine Group|Levothyroxine Plus Liothyronine Group
16644573|NCT02317926|Active Comparator|Levothyroxine Group|Levothyroxine Group
16644574|NCT02317926|Active Comparator|Desiccated Thyroid Extract Group|Desiccated Thyroid Extract Group
16644575|NCT02317900|Experimental|TV005 and rDEN2∆30-7169|Participants will receive one injection of TV005 at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
16644576|NCT02317900|Placebo Comparator|Placebo and rDEN2∆30-7169|Participants will receive one injection of placebo at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
16644577|NCT02317887|Experimental|Group 1|1e9 vg/eye
16644578|NCT02317887|Experimental|Group 2|1e10 vg/eye
16644579|NCT02317887|Experimental|Group 3|1e11 vg/eye
16644580|NCT02317887|Experimental|Group 4|1e11 vg/eye
16644581|NCT02317887|Experimental|Group 5|Not to exceed 3e11 vg/eye
16644582|NCT02317887|Experimental|Group 6|Not to exceed 6e11 vg/eye
16644722|NCT02316912|Active Comparator|Single dose level 2 active|Six subjects ATX2417 2x1 mg tablet once.
16644583|NCT02317874|Experimental|Schedule A (7-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-7, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.
~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
16644584|NCT02317874|Experimental|Schedule B (3-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-3, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.
~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
16644585|NCT02317861|Experimental|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
16644586|NCT02317861|Experimental|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
16644587|NCT02317861|Experimental|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
16644588|NCT02317861|Experimental|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
16644589|NCT02317861|Experimental|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
16644590|NCT02317861|Experimental|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
16644591|NCT02317848|Other|patients with acute heart failure|polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
16644592|NCT02317835|Other|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
16644593|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
16644594|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
16644595|NCT02317796|Placebo Comparator|Placebo|
16644596|NCT02317796|Active Comparator|100 mg q.d.|
16644597|NCT02317796|Active Comparator|100 mg b.i.d.|
16644598|NCT02317796|Active Comparator|200 mg q.d.|
16644599|NCT02317796|Active Comparator|200 mg b.i.d.|
16644600|NCT02317783|Experimental|All Participants|All enrolled subjects will complete three imaging sessions on separate days that consist of: 1) [18F]Flutemetamol-PET/CT, 2) FDG-PET/CT, and 3) MRI. The order of the performance of these studies will be based upon subject and radioisotope availability, but they will all be completed within 2 months of each other.
16644601|NCT02317770|Active Comparator|Lidocaine Spray|20 puffs of 10% Lidocaine spray
16644602|NCT02317770|Active Comparator|Nebulized Lidocaine|2.5 mL of 10% Lidocaine
16644603|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
16644604|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
16644605|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
16644606|NCT02317731|No Intervention|Routine|Subjects will ingest the bowel preparation from a cup
16644607|NCT02317731|Experimental|Straw|Subjects will ingest the bowel preparation with a straw
16644608|NCT02317718||Normal vitamin D levels group|MORE THAN 20 NG/ML VITAMIN D LEVELS
16644609|NCT02317718||Deficient Vitamin D GROUP|LESS THAN 20 NG/ML LEVELS
16644610|NCT02317705|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
16644611|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
16644612|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
16644613|NCT02317679|Experimental|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
16644614|NCT02317666|Experimental|Medication Review|Structured 5-step multidisciplinary medication review (STRIP method) performed by the pharmacist in collaboration with the general practitioner.
16644615|NCT02317666|No Intervention|Delayed Medication Review|Patients in the control group will not undergo a medication review during the study period (delayed medication review).
16644616|NCT02317653||Overweight/Obese|Archive blood, archive breast milk, and clinical assessment data from 15 participants who were considered overweight or obese at enrollment in the Expecting Success study conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent the overweight and obese sample for study investigations.
16644617|NCT02317653||Normal Weight|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior to pregnancy will be enrolled in the study.
16644723|NCT02316912|Active Comparator|Single dose level 3 active|Six subjects ATX2417 5 mg tablet once.
16647079|NCT02300857|Active Comparator|Moderate carbohydrate diet|
16644618|NCT02317640|Active Comparator|Stand Training Alone|Standing training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
16644619|NCT02317640|Experimental|ST with placebo or testosterone|Stand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
16644620|NCT02317640|Experimental|ST with Placebo or Testosterone and ES|"Stand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One RT300 portable stimulator (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation."
16644621|NCT02317640|Experimental|ST with ES|Stand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
16644622|NCT02317627|Experimental|Cohort 1|KD025 will be orally administered to subjects at 400 mg once daily for 12 weeks
16644623|NCT02317627|Experimental|Cohort 2|KD025 will be orally administered to subjects at 200mg twice daily for 12 weeks
16644624|NCT02317627|Experimental|Cohort 3|KD025 will be orally administered to subjects at 400mg twice daily for 12 weeks
16644625|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
16644626|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
16644627|NCT02317601|Active Comparator|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
16644628|NCT02317601|Placebo Comparator|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
16644629|NCT02317588|Active Comparator|Flax Oil|Flax oil 4 grams of ALA per day for 28 days (4 weeks).
16644630|NCT02317588|Active Comparator|Fish Oil|Fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day for 28 days (4 weeks).
16644631|NCT02317575|Experimental|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
16644632|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
16644633|NCT02317575|Experimental|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
16644634|NCT02317575|Experimental|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
16644635|NCT02317575|Experimental|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
16644636|NCT02317575|Experimental|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
16644637|NCT02317562|Experimental|I10E Arm|
16644638|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
16644639|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
16644640|NCT02317536|Experimental|Carnipure Product 1|Carnitine-based product 1, subjects will take one dose once daily for 56 days.
16644641|NCT02317536|Experimental|Carnipure Product 2|Carnitine-based product 2, subjects will take one dose once daily for 56 days.
16644642|NCT02317536|Placebo Comparator|Placebo|Placebo, subjects will take one dose once daily for 56 days.
16644643|NCT02317523|Experimental|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
16644644|NCT02317523|Active Comparator|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
16644645|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
16644646|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
16644716|NCT02316990||patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]|"The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study
~)"
16644724|NCT02316912|Active Comparator|Single dose level 4 active|Six subjects ATX2417 4x5 mg tablets once.
16644725|NCT02316912|Active Comparator|Single dose level 5 active|Six subjects ATX2417 to be determined.
16644647|NCT02317497|Experimental|Moderate sedation (M)|1. Moderate sedation defined by target RASS of >= -3. The intervention (M) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of >= -3 (patient responds to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be deepened below the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the intervention group again.
16644648|NCT02317497|Active Comparator|Deep sedation (D)|2. Deep sedation defined by target RASS of < -3. The control (D) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of < -3 (patient does not respond to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be reduced above the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the control group again.
16644649|NCT02317484||Ipragliflozin (SGLT2 inhibitor)|
16644650|NCT02317471|Experimental|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
16644651|NCT02317471|Other|control group|Oxaliplatin+S-1
16644652|NCT02317458|Experimental|Active arm|One arm with standard of care and C3BS-CQR-1 injection (treatment group) using intramyocardial catheter injection.
16644653|NCT02317458|Sham Comparator|Control arm|One arm with standard of care undergoing a sham procedure (control group)using intramyocardial catheter injection. .
16644654|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
16644655|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
16644656|NCT02317419|Experimental|Part A MAD Phase RO6927005 Monotherapy|RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
16644657|NCT02317419|Experimental|Part A Extension Phase Group 1|RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
16644658|NCT02317419|Experimental|Part A Extension Phase Group 2|RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
16644659|NCT02317419|Experimental|Part B MAD Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
16644660|NCT02317419|Experimental|Part B Extension Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA
16644661|NCT02317406|Active Comparator|Probiotics|Biostime probiotics sachet children's formula, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
16644662|NCT02317406|Placebo Comparator|Probiotics simulation|Biostime probiotics sachet children's formula（placebo）, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
16644663|NCT02317393|Other|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
16644664|NCT02317367||adult women|Women who drink seven or more drinks per week
16644665|NCT02317367||adults a|Individuals who eat fewer than five servings of fruits and vegetables per day, on average, based on an NCI screener for fruit and vegetable consumption.
16644666|NCT02317367||adults b|Individuals who exercise (moderate or vigorous intensity) less than 75 minutes per week.
16644667|NCT02317341|Experimental|1|Single intravenous dose given over 40 minutes
16644668|NCT02317341|Active Comparator|2|Single intravenous dose goven over 40 minutes
16644669|NCT02317328||Affected participants|Participants with ocular conditions
16644670|NCT02317328||Healthy Volunteers|Healthy volunteers
16644671|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
16644672|NCT02317302|Experimental|FDG-PET/CT or FDG-PET/MR|"Standard of care FDG-PET/CT or FDG-PET/MR at baseline
~FDG-PET/CT or FDG-PET/MR after the 2nd but before the 3rd brachytherapy treatment
~Standard of care 3 month post treatment FDG-PET/CT or FDG-PET/MR
~We will perform the research-related FDG-PET on the PET/MR rather than the PET/CT if the patient is safe to undergo MR and agrees to undergo MR.
~The standard of care imaging may be performed on the PET/CT scanner or the PET/MR scanner."
16644673|NCT02317289|Experimental|Detection of freezing|freezing parkinsonian patients
16644674|NCT02317276|Experimental|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
16644675|NCT02317263|Active Comparator|Testosterone gel|Apply gel once a day for 96 weeks
16644676|NCT02317263|Placebo Comparator|Placebo gel|Apply gel once a day for 96 weeks
16644677|NCT02317250|Experimental|prompt amyloid imaging, delayed FDG-PET|Subject's managing physicians will be given the results of amyloid imaging scans immediately. FDG-PET results will be released two years after scanning.
16644678|NCT02317250|Experimental|prompt FDG-PET, delayed amyloid imaging|Subject's managing physicians will be given the results of FDG-PET scans immediately. Amyloid imaging results will be released two years after scanning.
16644679|NCT02317250|Experimental|prompt FDG-PET, prompt amyloid imaging|Both FDG-PET and amyloid imaging scan results will be made immediately available to the managing physician.
16644680|NCT02317250|Active Comparator|delayed FDG-PET, delayed amyloid imaging|Neither FDG-PET nor amyloid imaging scan results will be released to the managing physician for 2 years.
16644681|NCT02317237|No Intervention|General Anesthesia|The patients, who will receive general anesthesia during intervention
16644682|NCT02317237|Experimental|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
16644717|NCT02316964|Experimental|Treatment (decitabine, allogeneic NK cells, aldesleukin)|Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
16644683|NCT02317224|Experimental|"3-Hole subxiphorid and subcostal approach"|The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole. Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively. Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection. Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
16644684|NCT02317224|Experimental|Trans sternal approach|
16644685|NCT02317224|Experimental|VATS approach|
16644686|NCT02317211|Placebo Comparator|control|placebo 320 mg daily for twelve weeks
16644687|NCT02317211|Experimental|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
16644688|NCT02317198|Experimental|Intervention|Clopidogrel
16644689|NCT02317198|Active Comparator|Control|Ticagrelor/Prasugrel
16644690|NCT02317172|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
16644691|NCT02317159|Experimental|imatinib，Capsule|400mg imatinib qd
16644692|NCT02317146|Experimental|Six Hours Postpartum|The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
16644693|NCT02317146|Active Comparator|Twenty-four hours Postpartum|The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.
16644694|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.
~Intervention: Blood samples Intervention: Stool samples"
16644695|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.
~Intervention: Blood samples Intervention: Stool samples"
16644696|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.
~Intervention: Blood samples Intervention: Stool samples"
16644697|NCT02317107||Concussion|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they receive a diagnosis of concussion, defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. If they agree to participate, they will be placed in the concussion group and assessed at each visit to the clinic. No intervention will be administered.
16644698|NCT02317107||Control|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they come to the clinic for an injury unrelated to brain function or a lower extremity function (which may affect normal gait patterns). If they agree to participate, they will be placed in the control group and assessed at each visit to the clinic. No intervention will be administered.
16644699|NCT02317094|Other|Control|Participants receive care as usual (various DMARDs, different from patient to patient).
16644700|NCT02317094|Experimental|Blood-flow restricted tranining|Participants will receive care as usual (various DMARDs, different from patient to patient) + 12 wks of low-intensity blood-flow restricted training twice per week.
16644701|NCT02317081|Experimental|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
16644702|NCT02317068|Experimental|High Atrial Base Rate Pacing|The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
16644703|NCT02317068|Active Comparator|Device Default|The base rate of pacemaker will be determined 60 beats/minute
16644704|NCT02317055|Other|Patient|Imaging
16644705|NCT02317055|Other|healthy subject|Imaging
16644706|NCT02317042|Active Comparator|Standard ST Mode|"Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device Juno. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy."
16644707|NCT02317042|Experimental|AutoEPAP iVAPS|"Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.
~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
16644708|NCT02317042|Active Comparator|Fixed EPAP iVAPS|"Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.
~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
16644709|NCT02317029|Experimental|"1 (Standard: Oxygen / LIFEPAK 20)"|"Intervention: Cardioversion with a biphasic truncated exponential waveform
~Intervention: Hyperoxia during cardioversion"
16644710|NCT02317029|Active Comparator|2 (room air / LIFEPAK 20)|"Intervention: Cardioversion with a biphasic truncated exponential waveform
~Intervention: Normoxia during cardioversion"
16644711|NCT02317029|Active Comparator|3 (Oxygen / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform
~Intervention: Hyperoxia during cardioversion"
16644712|NCT02317029|Active Comparator|4 (Room air / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform
~Intervention: Normoxia during cardioversion"
16644713|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
16644714|NCT02317003|Experimental|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
16644715|NCT02317003|Active Comparator|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
16644718|NCT02316951||single-arm study group|Study participants will be adult patients recovering from orthopedic surgery. The study group will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room.
16644726|NCT02316912|Active Comparator|Multiple dose level 1 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
16644727|NCT02316912|Active Comparator|Multiple dose level 2 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
16644728|NCT02316912|Placebo Comparator|Single dose level 1 placebo|Two subjects one placebo tablet once.
16644729|NCT02316912|Placebo Comparator|Single dose level 2 placebo|Two subjects one placebo tablet x2 once.
16644730|NCT02316912|Placebo Comparator|Single dose level 3 placebo|Two subjects one placebo tablet once.
16644731|NCT02316912|Placebo Comparator|Single dose level 4 placebo|Two subjects two placebo tablets once.
16644732|NCT02316912|Placebo Comparator|Single dose level 5 placebo|Two subjects four placebo tablets once.
16644733|NCT02316912|Placebo Comparator|Multiple dose level 1 placebo|Two subjects matching placebo(s) once daily for 8 days
16644734|NCT02316912|Placebo Comparator|Multiple dose level 2 placebo|Two subjects matching placebo(s) once daily for 8 days.
16644735|NCT02316912|Active Comparator|Single dose level 6 active|Six subjects ATX2417 to be determined.
16644736|NCT02316912|Active Comparator|Single dose level 7 active|Six subjects ATX2417 to be determined.
16644737|NCT02316912|Placebo Comparator|Single dose level 6 placebo|Six subjects placeboto be determined.
16644738|NCT02316912|Placebo Comparator|Single dose level 7 placebo|Six subjects placebo to be determined.
16644739|NCT02316899|Experimental|ASP0456 (Period I)|Up to 12 weeks
16644740|NCT02316899|Placebo Comparator|Placebo (Period I)|Up to 12 weeks
16644741|NCT02316899|Experimental|ASP0456 (Period II)|From 12 weeks to 52 weeks
16644742|NCT02316886|Experimental|Coronary intervention|Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment
16644743|NCT02316886|Active Comparator|Optimal Medical Treatment|Optimal Medical Treatment
16644744|NCT02316873|Experimental|Music training|twice a week one hour for 30 weeks, music training
16644745|NCT02316873|Active Comparator|Visual arts|twice a week one hour for 30 weeks, visual arts training
16644746|NCT02316860|Other|History of reflex syncope|Passive tilt test in athletes with a history of reflex syncope
16644747|NCT02316860|Other|No history of reflex syncope|Passive tilt test in athletes without history of reflex syncope
16644748|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
16644749|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
16644750|NCT02316834|Experimental|BMN 673|
16644751|NCT02316821|Experimental|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
16644752|NCT02316821|Placebo Comparator|Placebo|Placebo capsules, once daily for 16 weeks
16644753|NCT02316808|Placebo Comparator|Placebo smoothie|
16644754|NCT02316808|Experimental|Plant stanol ester smoothie|
16644755|NCT02316795|Experimental|SLN biopsy with ICG injection|"During the SLN biopsy, the patient will undergo injection of ICG around the breast tumor or melanoma per standard techniques. 1.6 mL of 500 micro-molar ICG will be injected periareolarly (for breast cancer) or peri-tumorly (for melanoma). This will be performed after standard of care technetium-colloid injection. Patients will then undergo the standard SLN biopsy procedure.
~After gamma-probe identification of the SLN, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Findings with the goggles will be recorded but will not change how the SLN biopsy is performed."
16644756|NCT02316782||Non-blinded IVUS assessment|The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
16644757|NCT02316782||Blinded IVUS assessment|After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
16644758|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
16644759|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
16644760|NCT02316756|Experimental|Single Ascending Doses Cohort 1|subjects receive 3 active doses and one placebo
16644761|NCT02316756|Experimental|Single Ascending Doses Cohort 2|subjects receive 3 doses and one placebo
16644762|NCT02316756|Experimental|Cohort 3|optional cohort
16644763|NCT02316743|Experimental|Levothyroxine|Levothyroxine supplementation
16644764|NCT02316730|Experimental|Sanchi-Tongshu Capsule (Enteric coated pellets)|Sanchi-Tongshu Capsule (Enteric coated pellets) is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.35g/capsule, containing 100mg of panaxatriol saponins (PTS).
16644765|NCT02316730|Active Comparator|Sanchi-Tongshu Capsule|Sanchi-Tongshu Capsule is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.2g/capsule, containing 100mg of panaxatriol saponins (PTS).
16644766|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
16644767|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
16644768|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
16644769|NCT02316704|Active Comparator|OsseoTi™ G7 large|OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
16644770|NCT02316704|Active Comparator|OsseoTi™ G7 32|OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
16644771|NCT02316704|Active Comparator|conventional PPS coated G7 large|conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
16644772|NCT02316704|Active Comparator|conventional PPS coated G7 32|conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
16644773|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
16644774|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
16644775|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
16644776|NCT02316665|Experimental|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
16644777|NCT02316665|Sham Comparator|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
16644778|NCT02316652|No Intervention|Healthy sites|Healthy sites with no inflammation; observational only
16644779|NCT02316652|Placebo Comparator|Scaling and root planing sites|Inflamed pocket receiving mechanical instrumentation
16644780|NCT02316652|Active Comparator|Scaling and root planing with solution|Inflamed pocket receiving mechanical instrumentation with sodium hypochlorite solution
16644781|NCT02316639|Experimental|Neuromuscular Training - No Exercise|Subjects will participate in 5 weeks of neuromuscular training followed by 5 weeks of no exercise intervention
16644782|NCT02316639|Experimental|No Exercise - Neuromuscular Training|No exercises will be administered for 5 weeks, followed by 5 weeks of neuromuscular Training.
16644783|NCT02316626|Experimental|Subcutaneous progesterone|Luteal phase support cycles will involve once-daily administration of 25 mg of SC P from the day after insemination for 14 days.
16644784|NCT02316626|Active Comparator|Vaginal Progesterone|Luteal phase support cycles will involve once-daily administration of 90 mg vaginal gel from the day after insemination for 14 days.
16644785|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
16644786|NCT02316600|No Intervention|Control|30 frail volunteers of the control group in the second phase won't be equipped with the smart insole.
16644787|NCT02316600|Experimental|Intervention|30 frail volunteers of the intervention group in the second phase will be equipped with the smart insole for 3 months, to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
16644788|NCT02316574|Experimental|Cognitive Behavioral Coping Skills|Cognitive Behavioral Coping Skills Therapy is an individual psychotherapy for alcohol use disorders that has been previously shown to reduce drinking. The focus of this treatment is the teaching of coping skills for managing alcohol craving and negative emotions as a way to reduce drinking behavior.
16644789|NCT02316561|Experimental|Single dose ablative radiotherapy|Eligible patients for single dose ablative radiotherapy according to inclusion and exclusion criteria
16644790|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
16644791|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
16644792|NCT02316535|Active Comparator|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
16644793|NCT02316535|Experimental|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
16644794|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
16644795|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
16644796|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
16644797|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
16644798|NCT02316509|Experimental|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
16644799|NCT02316509|Experimental|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
16644800|NCT02316496|Experimental|open label , single arm|cetuximab - irinotecan until progression or unacceptable toxicity
16644801|NCT02316483||Group I: T2D and Charcot foot|Individuals with confirmed diagnosis of type 2 diabetes, using the American Diabetes Association guidelines and confirmed diagnosis of Charcot foot, based on clinical and radiological evidence of Charcot foot.
16644802|NCT02316483||Group II: T2D neuropathy, no charcot|Individuals with type 2 diabetes and presence of neuropathy but the absence of Charcot foot.
16644803|NCT02316483||Group III: Control, non-diabetic|Individuals without history of type 2 diabetes.
16644804|NCT02316470|Active Comparator|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
16644805|NCT02316470|Active Comparator|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
16644806|NCT02316470|Active Comparator|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
16644807|NCT02316470|Placebo Comparator|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
16644808|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
16644809|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
16644945|NCT02315495|Experimental|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:
~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
16644810|NCT02316457|Experimental|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
16644811|NCT02316444|Other|HAART exposed|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
16644812|NCT02316444|Other|HAART naive|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
16644813|NCT02316418|Experimental|Hairstetics™ anchoring system|Prosthetic hair implantation using the Hairstetics™ anchoring system, followed by attachment of hair extensions.
16644814|NCT02316405|Experimental|Test Group|5 weeks of arm and leg cycling, 3 times per week for 30 minute of total exercise per session
16644815|NCT02316392||Post transplant subjects|Hyperpolarized Helium-3 MRI. Subjects who have had or are scheduled to have a lung transplant
16644816|NCT02316379|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
16644817|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
16644818|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
16644819|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
16644820|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
16644821|NCT02316340|Experimental|Study Arm - VOR with HCQ|Patients will be given vorinostat 400 mg daily and hydroxychloroquine 600 mg daily in 4 week cycles.
16644822|NCT02316340|Active Comparator|Control Arm - Regorafenib|Patients will be given oral RGF 160 mg daily for 3 weeks in 4 week cycles.
16644823|NCT02316327|Experimental|gemcitabine, cisplatin and bevacizumab|"Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days
~Cisplatin 80 mg/m2 I.V on day 1
~Gemcitabine 1250 mg/m2 I.V on day 1 & 8
~Treatment cycles will be repeated every three weeks up to 6 cycles
~Bevacizumab monotherapy as maintenance allowed in non-progressive tumors"
16644824|NCT02316314||Individuals diagnosed with FRDA|Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
16644825|NCT02316314||Healthy controls|Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
16644826|NCT02316301|Experimental|Long interval misoprostol|A small envelope including two labeled plastic bags (A & B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
16644827|NCT02316301|Active Comparator|Short interval misoprostol|A small envelope including two labeled plastic bags (A& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
16644828|NCT02316288|Experimental|Therapy|Mindfulness and Acceptance Therapy
16644829|NCT02316288|Active Comparator|Education|Health Education
16644830|NCT02316275|Active Comparator|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
16644831|NCT02316275|Experimental|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
16644832|NCT02316262|Experimental|TR|All subjects enrolled in this study will undergo pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally.Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle.
16644833|NCT02316249|Active Comparator|Gellhorn Pessary|Patients who are fitted with a Gellhorn pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
16644834|NCT02316249|Active Comparator|Ring with Support Pessary|Patients who are fitted with a Ring with Support Pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
16644835|NCT02316236|Experimental|dexmedetomidine loading dose|dexmedetomidine is given at load dose
16644836|NCT02316236|Experimental|dexmedetomidine sustaining dose|dexmedetomidine is given at sustaining dose
16644837|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
16644838|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
16644839|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
16644840|NCT02316210|Experimental|Digitimer stimulation|
16644841|NCT02316197|Experimental|MSC2490484A 100 mg QD|Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644842|NCT02316197|Experimental|MSC2490484A 200 mg QD|Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644843|NCT02316197|Experimental|MSC2490484A 150 mg BID|Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644844|NCT02316197|Experimental|MSC2490484A 200 mg BID|Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644845|NCT02316197|Experimental|MSC2490484A 300 mg BID|Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644846|NCT02316197|Experimental|MSC2490484A 400 mg BID|Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644847|NCT02316197|Experimental|MSC2490484A 400 mg BID RP2D|Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
16644848|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
16644849|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
16644850|NCT02316171|Experimental|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
16644851|NCT02316171|Experimental|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
16644852|NCT02316158|Experimental|Webb-based support and education|It contains of two parts 1) evidence based information (about mental diseases, early signs, coping strategies, what you can do for your relative or close friend, what you can do for yourself, addresses to networks and web sites, relevant juridical issues, etc), 2) FAQ, where you directly can find answers to common questions.
16644853|NCT02316158|Active Comparator|Available support in society|Available support in society for young persons presented in a brochure
16644854|NCT02316145|Other|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
16644855|NCT02316132|Active Comparator|Stress|Injection of corticotropin releasing factor
16644856|NCT02316132|Placebo Comparator|Control|Injection of 0.9% saline 10 ml
16644857|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
16644858|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
16644859|NCT02316106|Experimental|Arm A (Long Intense)|
16644860|NCT02316106|Experimental|Arm B (Intermediate)|
16644861|NCT02316106|Experimental|Arm C (Short Intense)|
16644862|NCT02316093||obese-chronic periodontitis patients|
16644863|NCT02316093||obese-gingivitis patients|
16644864|NCT02316093||obese-periodontally healthy controls|
16644865|NCT02316093||normal weight-chronic periodontitis patients|
16644866|NCT02316093||normal weight-gingivitis patients|
16644867|NCT02316093||normal weight-periodontally healthy controls|
16644868|NCT02316080|Experimental|Desensitizing therapy|14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
16644869|NCT02316080|Experimental|Dental Bleaching|2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
16644870|NCT02316067|Experimental|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
16644871|NCT02316067|No Intervention|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
16644872|NCT02316054||diabetes and MPHI|myocardial perfusion heterogeneity imaging
16644873|NCT02316041|Experimental|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
16644946|NCT02315495|Experimental|5 mg saxagliptin|"Acute dosing:
~5 mg saxagliptin is given 60 min before a test meal,"
16644874|NCT02316028|Experimental|decitabine|"administration of decitabine by hepatic arterial infusion
~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.
~Proposed dose levels:
~10 mg/m2 per course
~15 mg/m2 per course
~20 mg/m2 per course"
16644875|NCT02316015|Experimental|Intervention group|Children in the intervention group will receive a protein-energy enriched milk (Infatrini®, or in the case of children on a partial or fully hydrolized milk Infatrini Peptisorb®). The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day). The intervention will be carried out during the first 7 days of hospitalisation, or until the day of discharge (if hospitalized for less than 7 days).
16644876|NCT02316015|No Intervention|Control group|Children in the control group will receive their regular milk. The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day).
16644877|NCT02316002|Experimental|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
16644878|NCT02315989|Other|safety|proton therapy
16644879|NCT02315976|Experimental|Propatyl nitrate|Patients treated with propatyl nitrate 10mg thrice daily
16644880|NCT02315963|No Intervention|No intervention group|Patients in stroke rehabilitation receiving standard therapy
16644881|NCT02315963|Active Comparator|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
16644882|NCT02315950|Other|Arm 1|Botulinum toxin and cineMRI-UDS
16644883|NCT02315924|Experimental|coronary and cerebral stenosis|
16644884|NCT02315924|Active Comparator|coronary or cerebral stenosis|
16644885|NCT02315911|No Intervention|expectancy for mild-moderate OSA|6 months expectancy
16644886|NCT02315911|Experimental|ATE for mild-moderate OSA|adeno-tonsillectomy
16644887|NCT02315911|Experimental|ATE for severe OSA|adeno-tonsillectomy
16644888|NCT02315911|Experimental|APP for severe OSA|adeno-pharyngoplasty
16644890|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
16644891|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
16644892|NCT02315859||All patients|All patients
16644893|NCT02315833|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
16644894|NCT02315833|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for three months
16644895|NCT02315820|Experimental|Induction of Labor (IOL)|Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
16644896|NCT02315820|No Intervention|Expectant|Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
16644897|NCT02315807|Experimental|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
16644898|NCT02315807|Experimental|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
16644899|NCT02315807|Active Comparator|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
16644900|NCT02315794|Experimental|SPI®ART|in test group after a three month healing period a zirconia abutment was connected to the implant to realize the prosthetic restoration
16644901|NCT02315794|Active Comparator|SPI®EASY|in control group a three month healing period a titanium abutment was connected to the implant for the prosthetic restoration
16644902|NCT02315781|Active Comparator|Active tDCS|active tDCS will be used on half of the study participants
16644903|NCT02315781|Sham Comparator|Sham tDCS|Sham tDCS will be used on half of the study participants
16644904|NCT02315768|Experimental|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.
~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:
~Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.
~Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.
~Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.
~Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
16644905|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
16644906|NCT02315742|Experimental|Let's Move Program|Patients will take part in a 12-week exercise program.
16644907|NCT02315716|Experimental|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
16644908|NCT02315716|Active Comparator|ASCT|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
16732350|NCT01732211|Experimental|PD 0360324|
16644917|NCT02315690|Active Comparator|Reactive case detection (RACD)|Individuals in RACD Target Areas will be tested by RDT (rapid diagnostic test) and if positive, taken to the nearest health facility for treatment with artemether-lumefantrine per national policy.
16644918|NCT02315690|Experimental|Reactive focal mass drug administration (fMDA)|In the fMDA arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
16644919|NCT02315677|Active Comparator|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
16644920|NCT02315677|Active Comparator|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
16644921|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
16644922|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
16644923|NCT02315651|Experimental|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
16644924|NCT02315651|Placebo Comparator|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
16644925|NCT02315638||Dosed subjects|There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,
16644926|NCT02315625|Experimental|1/ Arm 1 Sunitinib|Sunitinib
16644927|NCT02315625|Experimental|2/ Arm 2 Everolimus|Everolimus
16644930|NCT02315599||1|Patients screening for, participating in, or have participated in a POB gene therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
16644933|NCT02315573|Experimental|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.
~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
16644934|NCT02315573|Experimental|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.
~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
16644935|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
16644936|NCT02315547|Other|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
16644937|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
16644938|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
16644939|NCT02315521||Group 1|Fetuses with LUTO before 18 weeks
16644940|NCT02315521||Group 2|Fetuses with LUTO between 18 and 30 weeks
16644941|NCT02315521||Group 3|Fetuses with LUTO between 30 and 34 weeks
16644942|NCT02315521||Group 4|Fetuses with LUTO after 34 weeks
16644943|NCT02315508|Experimental|AUT00063|4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
16644944|NCT02315508|Placebo Comparator|Placebo|4 capsules of placebo, to take orally with food for 4 weeks.
16644947|NCT02315495|Experimental|100 mg acarbose|"Acute dosing:
~100 mg acarbose is given with a test meal"
16644949|NCT02315482|Experimental|Group A|after induction of general anesthesia (i) a pneumoperitoneum is induced then (ii) patient is placed in steep trendelenburg position at 25 degrees head down
16644950|NCT02315482|Experimental|Group B|after induction of general anesthesia (i) the patient is placed in steep trendelenburg position at 25 degrees head down then (ii) a pneumoperitoneum is induced
16644951|NCT02315469||Observational (geriatric assessment)|At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
16644952|NCT02315456|Other|Capsule centration|Capsulorhexis made with capsule centration
16644953|NCT02315456|Other|Pupil centration|Capsulorhexis made with pupil centration
16644954|NCT02315443|Experimental|NA-1|2.60 mg/kg of NA-1 (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
16644955|NCT02315443|Placebo Comparator|Placebo|Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
16644956|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16644957|NCT02315417|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
16644958|NCT02315417|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
16644959|NCT02315417|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
16644960|NCT02315404|Placebo Comparator|No cap|enteroscopy performed without a cap
16644961|NCT02315404|Active Comparator|Enteroscopy with a cap|Enteroscopy performed with a CAP fitted to the end of the scope
16644962|NCT02315391|Experimental|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine
16644963|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine
16644964|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline
16644965|NCT02315378|Other|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
16644966|NCT02315378|Other|TAU|Treatment as Usual
16644967|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
16644968|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
16644969|NCT02315326|Experimental|Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).
16644970|NCT02315326|Experimental|Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity
16644971|NCT02315326|Experimental|Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
16644972|NCT02315326|Experimental|Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
16644973|NCT02315313||group1|RHR≤60bpm
16644974|NCT02315313||group2|RHR 61-70bpm
16644975|NCT02315313||group3|RHR 71-80bpm
16644976|NCT02315313||group4|RHR >80bpm
16644977|NCT02315300|Experimental|Study Tretament|Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
16644978|NCT02315287|Active Comparator|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
16644979|NCT02315287|Active Comparator|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
16644980|NCT02315274|Experimental|Single arm, remote contact.|Between visit remote contact.
16644981|NCT02315235|Active Comparator|control|The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
16644982|NCT02315235|Active Comparator|stem cell (mononuclear cell)|The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia. The volume of one site injection is 0.5 to 1.0 ml. The depth of needle injection would be 1.5cm.
16644983|NCT02315222|Active Comparator|Test|Dietary Supplementation
16644984|NCT02315222|Placebo Comparator|Control|Placebo Supplementation
16645025|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
16645099|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
16644985|NCT02315196|Experimental|Treatment (doxil, carboplatin, surgery, paclitaxel)|"NEOADJUVANT: Patients receive pegylated liposomal doxorubicin hydrochloride* IV over 90 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~ADJUVANT: Patients undergo definitive surgery at the discretion of the treating physician. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
~*NOTE: If there is a shortage of pegylated liposomal doxorubicin hydrochloride, patients receive epirubicin hydrochloride IV over 15-20 minutes on day 1."
16644986|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
16644987|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
16644988|NCT02315157|Experimental|Bendamustine 200 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).
16644989|NCT02315157|Experimental|Bendamustine 250 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).
16644990|NCT02315144|Experimental|TV48108 - Healthy Volunteers|Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg
16644991|NCT02315144|Placebo Comparator|Placebo - Healthy Volunteers|Placebo
16644992|NCT02315144|Experimental|TV48108 15 µg COPD|Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.
16644993|NCT02315144|Experimental|TV48108 60 µg COPD|Stage 2
16644994|NCT02315144|Experimental|TV48108 120 µg COPD|Stage 2 .
16644995|NCT02315131|Experimental|TV46017- Healthy Volunteers|Stage 1 includes a single-dose treatment period
16644996|NCT02315131|Placebo Comparator|Placebo - Healthy Volunteers|Some healthy subjects will be randomized to receive placebo.
16644997|NCT02315131|Experimental|TV46017 15 μg- COPD|Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered
16644998|NCT02315131|Experimental|TV46017 60 μg- COPD|Stage 2
16644999|NCT02315131|Experimental|TV46017 120 μg- COPD|Stage 2
16645000|NCT02315131|Experimental|TV46017 240 μg- COPD|Stage 2
16645001|NCT02315118|Experimental|T-cell therapy + Rituximab + IL-2|"Patients will undergo apheresis procedure and T cell expansion will be done in the laboratory. All patients will receive Rituximab on day -2 and IL-2 three times per week for one week starting on day -1 (dose 1 of 3). IL-2 dosing will be continued 3 times per week for one week (3 doses total).
~On Day 0, T cell modification in the laboratory and T cell infusion in the patient will be done.
~A disease status evaluation will be conducted approximately 4 weeks post-T cell infusion."
16645002|NCT02315105|Experimental|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
16645003|NCT02315092||Diabetic foot ulcers|Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
16645004|NCT02315079||Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
16645005|NCT02315079||Without eye inflammation|This group will have a regular eye exam with the collection of tears.
16645006|NCT02315066|Experimental|PF-04518600|OX40 agonist
16645007|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
16645008|NCT02315053|Other|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
16645009|NCT02315040|Active Comparator|IUI|standard intrauterine insemination method
16645010|NCT02315040|Experimental|EVIE|Slow release insemination method (SRI)
16645011|NCT02315027|Experimental|1 dose of 1 × 10(7) MSCs|Group 1: Participants will receive a single intrathecal dose of 1 × 10(7) mesenchymal stem cells (MSCs)
16645012|NCT02315027|Experimental|2 doses of 5 × 10(7) MSCs|Group 2: Participants will receive one intrathecal dose of 5 × 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 × 10(7) MSCs approximately one month later
16645013|NCT02315027|Experimental|2 doses of 1 × 10(8) MSCs|Group 3: Participants will receive one intrathecal dose of 1 × 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 × 10(8) MSCs approximately one month later
16645014|NCT02315027|Experimental|10 doses of 5 x 10(7) (±20%) MSCs|Group 4: Participants will receive up to 10 doses of 5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
16645015|NCT02315027|Experimental|10 doses of 2.5 x 10(7) (±20%) MSCs|Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
16645016|NCT02315014|Experimental|whey protein|whey protein micelles
16645017|NCT02315014|Placebo Comparator|placebo|calorie-free placebo
16645018|NCT02315001|Active Comparator|Liraglutide|"Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection
~Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection
~Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection"
16645019|NCT02315001|Placebo Comparator|Saline Placebo|"Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection
~Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection
~Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection"
16645020|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
16645021|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
16645022|NCT02314975|Experimental|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
16645023|NCT02314975|Sham Comparator|Sham AcceleDent device|Fixed appliances with supplementary sham device
16745381|NCT01644552||eye examinations|
16645026|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
16645027|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
16645028|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
16645029|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
16645030|NCT02314923|Experimental|3x10^3 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
16645031|NCT02314923|Experimental|3x10^4 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.
16645032|NCT02314923|Experimental|3x10^5 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.
16645033|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.
16645034|NCT02314923|Experimental|9x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.
16645035|NCT02314923|Experimental|2x10^7 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.
16645036|NCT02314923|Experimental|1x10^8 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.
16645037|NCT02314923|Placebo Comparator|Placebo Cohort 1|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
16645038|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
16645039|NCT02314923|Placebo Comparator|Placebo Cohort 2|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
16645040|NCT02314910||Failed implant|There is only one group, being the group of patients of which the oral implant needed to be removed for clinical reasons.
16645041|NCT02314897|Experimental|LV pacing|Left ventricular pacing lead implanted via coronary sinus
16645042|NCT02314897|Active Comparator|RV pacing|Conventional right ventricular pacing lead.
16645043|NCT02314884|Experimental|Cafusertib Hydrochloride|Cafusertib Hydrochloride d1q3w
16645044|NCT02314871|Active Comparator|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
16645045|NCT02314871|Active Comparator|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
16645046|NCT02314871|Active Comparator|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
16645047|NCT02314858|Experimental|Brief Personalized Video (BPV)|Our BPV intervention focuses on augmenting risk perception and reducing optimistic bias by showing the patient a dramatic video of his/her own apnea (which shows them struggle to breathe), as well as by explaining the physiological processes involved in an apneic event. Specific apneic events are highlighted and associated decreases in blood oxygen levels are demonstrated via oxygen saturation recording superimposed on the video. This group will receive educational information about OSA, its consequences and the need for treatment.
16645048|NCT02314858|Active Comparator|Non-Personalized Video (NPV)|NPV will include a video of someone having apnea, but it will not be personalized. This group will receive educational information about OSA, its consequences and the need for treatment.
16645049|NCT02314858|Placebo Comparator|Treatment As Usual (TAU)|The TAU group will receive no special treatment from study interventionist team and will not view a video.
16645050|NCT02314845|Experimental|Optimal PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using Optimal PEEP determined by Electrical Impedance and FIO2 of 0.5."
16645051|NCT02314845|Other|Low PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure EIT. In this arm, the ventilator will be set with a PEEP=4 cmH2O (Low PEEP) and FIO2 of 0.5 during intraoperative period."
16645052|NCT02314832|Active Comparator|Continuous femoral nerve block|patients receiving continuous femoral nerve block for analgesia after total knee arthroplasty
16645053|NCT02314832|Active Comparator|adductor canal block|adductor canal block group will receive adductor canal block for analgesia after TKA
16645054|NCT02314819|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
16645055|NCT02314819|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
16645056|NCT02314806|Experimental|Irrigation with Gentamicin solution|The surgical bed is irrigated with a gentamicin solution
16645057|NCT02314806|Experimental|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
16645058|NCT02314806|Placebo Comparator|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
16645059|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
16645060|NCT02314793|Placebo Comparator|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
16645061|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
16645062|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
16645063|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
16645064|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
16645065|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
16645066|NCT02314780|Experimental|Heme arginate (high dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
16645067|NCT02314780|Experimental|Heme arginate (low dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
16645068|NCT02314780|Placebo Comparator|Placebo|24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
16645069|NCT02314767|Active Comparator|Interpersonal Psychotherapy|Interpersonal Psychotherapy treatment for MDD patients was implemented with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention:Interpersonal psychotherapy as ADD-on method. Outcome was compared with patients in treatment as usual group.
16645070|NCT02314767|Active Comparator|Psychoeducational Group Therapy|Psychoeducational Group Therapy arm for MDD patients with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention: Psychoeducational Group Treatment as ADD-on method.
16645071|NCT02314767|No Intervention|Treatment as Usual|Treatment as usual ( consisting of supportive psychodynamic-oriented treatment) with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression
16645072|NCT02314754|Experimental|71-77 days gestational age|Women whose pregnancies are estimated to have a gestational age of 71-77 days.
16645073|NCT02314754|No Intervention|64-70 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days.( Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
16645074|NCT02314741|Experimental|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
16645075|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
16645076|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
16645077|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
16645078|NCT02314715||Controls|Participants without knee osteoarthritis
16645079|NCT02314702||Revision Total Hip Arthroplasty|Single study group previously implanted with a PROFEMUR® L Revision Femoral Stem
16645080|NCT02314689|Experimental|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
16645081|NCT02314676|Experimental|PEG-somatropin|
16645082|NCT02314663|Experimental|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.
~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
16645083|NCT02314663|No Intervention|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
16645084|NCT02314650|Experimental|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
16645085|NCT02314650|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
16645086|NCT02314650|Sham Comparator|Control|patients were with electrodes attached but no stimulation was given
16645087|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
16645088|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
16645089|NCT02314624|Experimental|PracticeGround|Clinicians have access to PracticeGround's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
16645090|NCT02314624|Active Comparator|Care-as-Usual|Usual care without access to PracticeGround.
16645091|NCT02314611||PROFEMUR® Gladiator HA Coated Stem|Single study group previously implanted with a primary PROFEMUR® Gladiator HA Coated Modular Femoral Stem (HA = Hydroxyapatite)
16645092|NCT02314598||No treatment|
16645093|NCT02314585|Other|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
16645094|NCT02314585|Other|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
16645095|NCT02314572|Other|Single-arm|
16645100|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
16645101|NCT02314533|Experimental|fenofibrate|Fenofibrate 200mg capsule will be administered orally with breakfast once daily according to the Chinese prescription information of Lipanthyl, while previous type and dose of statin will be administered in the evening.
16645102|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
16645103|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
16645104|NCT02314507|Experimental|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
16645105|NCT02314507|Active Comparator|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
16645106|NCT02314494||Infants at risk|Infants identified as at risk of obesity using the ProAsk intervention
16645107|NCT02314494||Infants not at risk|Infants identified as not at risk of obesity using the ProAsk intervention.
16645108|NCT02314481|Experimental|No actionable mutation - MPDL3280A|"MPDL3280A 1200mg IV infusion - 3 weekly for 24 cycles monotherapy
~Or in combination with chemotherapy:
~For non-squamous: Cisplatin or Carboplatin plus pemetrexed & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A and pemetrexed 3 weekly for 20 cycles
~For squamous: Carboplatin plus paclitaxel & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A 3 weekly for 20 cycles
~Until progression, unacceptable toxicity or completion of a total of 24 cycles."
16645109|NCT02314481|Experimental|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
16645110|NCT02314481|Experimental|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
16645111|NCT02314481|Experimental|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD IV infusion
16645112|NCT02314468|Active Comparator|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
16645113|NCT02314468|Active Comparator|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
16645114|NCT02314455|Experimental|D-xylose, water, honey|"25 grams of D-xylose
~10 cc of water
~2 teaspoons of honey"
16645115|NCT02314442|Active Comparator|ALN-PCSSC|
16645116|NCT02314442|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16645117|NCT02314429|Experimental|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
16645118|NCT02314416|Active Comparator|Standard Treatment|Patients in the Control Arm will receive collagen matrix for wound coverage and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
16645119|NCT02314416|Experimental|Amniotic Stem Cells and Collagen Matrix|Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage, and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
16645121|NCT02314390|Experimental|G-MBCT|Group-Mindfulness-Based Cognitive Therapy
16645122|NCT02314390|Experimental|I-MBCT|Individual-Mindfulness-Based Cognitive Therapy
16645123|NCT02314377|Experimental|AVM treatment with Bevacizumab|Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
16645124|NCT02314364|Experimental|SBRT with protons or photons|"Dosage determined by treating physician
~If there is more than one active site of cancer, additional site(s) will be treated with stereotactic treatment courses. The total duration of SBRT courses (from the first day of any SBRT course to the last day of any SBRT course) will not exceed 4 months."
16645125|NCT02314351|Active Comparator|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
16645126|NCT02314351|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
16645127|NCT02314338|Experimental|Pulmonary rehabilitation|Multi-disciplinary pulmonary rehabilitation
16645128|NCT02314325|Active Comparator|Standard prophylaxis|Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days
16645129|NCT02314325|Experimental|Pharmacokinetic tailored prophylaxis|Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
16645130|NCT02314312|Experimental|A: investigation arm|De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
16645131|NCT02314312|Other|B: control arm|De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
16645132|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
16645133|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
16645134|NCT02314286|Placebo Comparator|control|"After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.
~Control group will be treated with placebo."
16645168|NCT02314065|Experimental|Conventional CBT|Cognitive Behavioural Therapy delivered in a conventional manner
16645135|NCT02314286|Experimental|treatment|50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.
16645136|NCT02314273|Experimental|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
16645137|NCT02314273|No Intervention|control group|control group
16645138|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
16645139|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
16645140|NCT02314234||Control group|did not receive muscle relaxant during anesthesia
16645141|NCT02314234||Sugammadex group|received single dose of rocuronium for anesthesia and sugammadex at skin incision
16645142|NCT02314221|Experimental|Exoskeletal-Assisted Walking (WALK)|WALK first for 12 weeks (36 sessions)
16645143|NCT02314221|No Intervention|Usual Activities (UA)|Usual activities first for 12 weeks
16645144|NCT02314208|Active Comparator|Xenbilox|Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months
16645145|NCT02314208|Active Comparator|Resveratrol|Resveratrol 80mg capsule by mouth every day for 2 months
16645146|NCT02314208|Active Comparator|Tahor|Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months
16645147|NCT02314195|Active Comparator|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
16645148|NCT02314195|Active Comparator|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
16645149|NCT02314182|Experimental|A Primary tumor resection + chemotherapy|PT resection + systemic chemotherapy +/- target therapy
16645150|NCT02314182|Other|B Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Chemotherapy (+/- target therapy)
16645154|NCT02314156|Experimental|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
16645155|NCT02314156|Active Comparator|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
16645156|NCT02314143|Experimental|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
16645157|NCT02314143|Experimental|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
16645158|NCT02314143|Experimental|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
16645159|NCT02314130|Experimental|Dietary therapy Standardized diet|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
16645160|NCT02314130|No Intervention|Dietary therapy Commercial diet group|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
16645161|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
16645162|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
16645163|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
16645164|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
16645165|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
16645166|NCT02314091|Experimental|Onlay|Onlay mesh repair group
16645167|NCT02314091|Experimental|sublay|Sublay mesh repair group
16645169|NCT02314065|Experimental|Internet-delivered CBT|Cognitive Behavioural Therapy delivered via the Internet
16645170|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
16645171|NCT02314026|Experimental|Suspected NASH|13C-Octanoate, 13C-Methacetin
16645172|NCT02314013|Active Comparator|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
16645173|NCT02314013|No Intervention|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
16645174|NCT02314000|Active Comparator|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
16645175|NCT02314000|Experimental|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
16645176|NCT02313987||A-Usual care- Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis) and normal Endothelial function as defined by EndoScore.
~These subjects will receive the standard care usually provided in each facility for patients with NOCAD"
16645177|NCT02313987||B1-Usual Care-Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis ) and abnormal Endothelial function as defined by EndoScore.
~These subjects will receive the standard care usually provided in each facility for patients with NOCAD. (Same care as Group A)"
16645178|NCT02313987||B2- Endothelial function guid care|"Subjects with non obstructive CAD and abnormal Endothelial function as defined by EndoScore.
~These subjects will receive the an Endothelial Function-guided Therapy."
16645179|NCT02313961|Experimental|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
16645180|NCT02313961|No Intervention|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
16645181|NCT02313935|Experimental|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
16645182|NCT02313935|Experimental|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
16645183|NCT02313935|Experimental|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
16645184|NCT02313935|No Intervention|Passive|Passive Control Participants do not receive an intervention serving as passive controls
16645185|NCT02313935|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
16645186|NCT02313922|Experimental|etanercept combined with methotrexate|patients treated with etanercept combined with methotrexate
16645187|NCT02313922|Experimental|etanercept as monotherapy|patients treated with etanercept combined with placebo
16645188|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
16645189|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
16645190|NCT02313896|No Intervention|Standard of Care|Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
16645191|NCT02313896|Experimental|Phone calls|On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.
16645192|NCT02313883|Placebo Comparator|SRP only|Scaling and root planing only
16645193|NCT02313883|Placebo Comparator|SRP and Placebo|Scaling and root planing followed by placebo drug administration
16645194|NCT02313883|Experimental|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
16645195|NCT02313883|Experimental|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
16645196|NCT02313883|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
16645197|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
16645198|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
16645199|NCT02313857|Experimental|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-C/m2 as a single infusion.
~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
16645200|NCT02313844|Experimental|Viralym-B|"Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-B/m2 as a single infusion.
~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
16645201|NCT02313831|Experimental|Exercise training|Patients of this group will be submitted to an interval training
16645202|NCT02313818|Experimental|CPT-C|Cognitive Processing Therapy-Cognitive Only (CPT-C) conducted twice weekly for 4-24 sessions based on good end state functioning.
16645203|NCT02313805|Experimental|With checklist|Students will simulate insulin initiation with the aid of a checklist
16645204|NCT02313805|No Intervention|Without checklist|Students will simulate insulin initiation without the aid of a checklist
16645205|NCT02313792|Active Comparator|Palifermin|The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion
16645302|NCT02313090|No Intervention|usual standard care|patients under usual standard of diabetic care
16645206|NCT02313792|Placebo Comparator|Normal saline|The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.
16645207|NCT02313779|Placebo Comparator|Neutral|Reading passage about brain function which is masked as a news article.
16645208|NCT02313779|Experimental|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
16645209|NCT02313779|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
16645210|NCT02313779|Experimental|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
16645211|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.
~End of preoxygenation FEO2=90%"
16645212|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.
~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
16645213|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.
~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
16645214|NCT02313753|Active Comparator|SAFE|Safety Assessment and Follow-up Evaluation Protocol
16645215|NCT02313753|Experimental|CLASP|Coping Long Term with Active Suicide Program Protocol
16645216|NCT02313740||Healthy adults group|Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
16645217|NCT02313740||Elderly group|Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine
16645218|NCT02313727|Active Comparator|pamidronate|pamidronate
16645219|NCT02313727|Placebo Comparator|placebo|placebo
16645220|NCT02313714|Experimental|Neuromuscular stimulation|The patients will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
16645221|NCT02313714|Placebo Comparator|Sham Group|The patients will receive very low electric muscular stimulation with a no biological or clinical effects
16645222|NCT02313701|No Intervention|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
16645223|NCT02313701|Experimental|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
16645224|NCT02313701|No Intervention|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
16645225|NCT02313701|Experimental|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
16645226|NCT02313701|No Intervention|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
16645227|NCT02313701|Experimental|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
16645228|NCT02313688|Experimental|Group A|Group A: Patients in the Group A will underwent D2 total gastrectomy and with 3±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
16645303|NCT02313077|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
16645229|NCT02313688|Experimental|Group B|Patients in the Group B will underwent D2 total gastrectomy and with 5±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
16645230|NCT02313675|Experimental|IV tylenol|One time intra-operative IV acetaminophen administration
16645231|NCT02313675|Experimental|IV toradol|One time intra-operative IV ketorolac thromethamine administration
16645232|NCT02313675|Experimental|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
16645233|NCT02313675|Placebo Comparator|saline|One time intra-operative 50ml IV normal saline administration
16645234|NCT02313623||Patient Scheduled for Prostate Fusion Biopsies|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
16645235|NCT02313610|Experimental|Qinbudan|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months
16645236|NCT02313610|Placebo Comparator|Control Qinbudan Placebo|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months
16645237|NCT02313597|Placebo Comparator|SETON|Silk suture will be used as SETON
16645238|NCT02313597|Experimental|VAAFT|Video assisted anal fistula treatment
16645239|NCT02313584|Active Comparator|Short Group|The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
16645240|NCT02313584|Placebo Comparator|Conventional Group|The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
16645241|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
16645242|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
16645243|NCT02313545|Experimental|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
16645244|NCT02313519|Placebo Comparator|Placebo|Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
16645245|NCT02313519|Active Comparator|Probiotics|Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
16645246|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
16645247|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
16645248|NCT02313493|Experimental|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
16645249|NCT02313493|No Intervention|Care as usual control group|
16645250|NCT02313480|Active Comparator|non-massage group|received exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
16645251|NCT02313480|Experimental|massage group|Received massage, exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
16645252|NCT02313467|Active Comparator|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
16645253|NCT02313467|Sham Comparator|Control|Topical application of sham control per every other day around acne lesions in the face
16645254|NCT02313454|Experimental|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
16645255|NCT02313454|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
16645256|NCT02313441|Active Comparator|RIPC (Remote Ischemic Pre-Conditioning)|Patients used RIPC had a blood pressure cuff placed around their upper arm at < 2 hours before the PCI procedure. The blood pressure cuff was inflated to for 5 minutes, followed by 5 minutes of deflation. This procedure was repeated 3 times
16645257|NCT02313441|Placebo Comparator|Control|Control participants did not experience this procedure of transient upper-limb ischemia.
16645258|NCT02313428|Experimental|Standard of Care with Topical Oxygen Treatment|patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
16645259|NCT02313428|No Intervention|Standard of Care only|patients that have a chronic wound will receive only their standard of care treatment.
16645260|NCT02313415|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
16645261|NCT02313402|Experimental|EOL (Eye On Line)|training program allowing a gradual acquisition of the eye-writing
16645262|NCT02313389|Experimental|maintenance chemotherapy|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.
~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
16645263|NCT02313389|No Intervention|observation|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.
~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
16645264|NCT02313376|Experimental|GAP3KO|
16645265|NCT02313363|Experimental|PSDCS|using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks
16645266|NCT02313350|Experimental|Chemonucleolysis with Discogel|Discogel® is a class III medical device (CE0459 mark on 28/09/2007) constituted by a radiopaque jellified ethanol. Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia. A volume of 0.9 ml of Discogel® is finally slowly injected during 10 to 15 minutes
16645267|NCT02313350|Active Comparator|Open discectomy|surgery : The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root
16645268|NCT02313337|Experimental|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
16645269|NCT02313337|Experimental|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
16645270|NCT02313337|Experimental|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
16645271|NCT02313337|Experimental|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
16645272|NCT02313324|Experimental|ESWT group|The patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
16645273|NCT02313324|Active Comparator|SWD combined IFC group|The patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
16645274|NCT02313298|Experimental|Stereotactic Body Radiotherapy|An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
16645277|NCT02313272|Experimental|HFSRT with Pembrolizumab and Bevacizumab|Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.
16645278|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
16645279|NCT02313259||Age-matched controls|15 drivers without ocular disease.
16645280|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
16645281|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
16645282|NCT02313246|Experimental|Group Cognitive Behaviour Therapy|Patients will complete an 11-session group cognitive behaviour therapy for IBS that will be led by two clinicians, one of whom will be a registered clinical psychologist, at the Digestive Diseases Clinic at McMaster University Medical Centre. The group cognitive behaviour therapy will include weekly 2-hour sessions for 11 weeks. Sessions will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
16645283|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
16645284|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
16645285|NCT02313220|Experimental|Dapagliflozin and exenatide|Dapagliflozin 10 mg film-coated tablet once daily and exenatide 2 mg once weekly injection combined treatment for 24 weeks
16645286|NCT02313220|Placebo Comparator|Placebo|Placebo film-coated tablet once daily and placebo once weekly injection combined treatment for 24 weeks
16645287|NCT02313207|Active Comparator|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
16645288|NCT02313207|Active Comparator|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
16645289|NCT02313194|Experimental|Stimulation|Determine if epidural stimulation can improve motor function.
16645290|NCT02313181|Experimental|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
16645291|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
16645292|NCT02313168||1|preoperative FRONT score
16645293|NCT02313168||2|intraoperative FRONT score
16645294|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
16645295|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
16645296|NCT02313142|Experimental|Subjects|
16645297|NCT02313129||Rheumatoid Arthritis|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history and detailed menstrual history. They will also have a physical exam and blood tests.
16645298|NCT02313129||Healthy Controls|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history detailed menstrual history, and blood tests.
16645299|NCT02313103|Other|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
16645300|NCT02313103|Other|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
16645301|NCT02313090|Experimental|Welltang|patients using Welltang
16645304|NCT02313077|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
16645305|NCT02313077|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
16645306|NCT02313077|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
16645307|NCT02313077|Experimental|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
16645308|NCT02313064|Active Comparator|CXA-10|single dose of CXA-10 oral formulation
16645309|NCT02313064|Placebo Comparator|CXA-10 placebo|single oral doses of CXA-10 placebo
16645310|NCT02313051|Experimental|Everolimus arm|Everolimus+letrozole
16645311|NCT02313051|Active Comparator|Controll arm|letrozole alone, and when progress, followed by everolimus
16645312|NCT02313025|Experimental|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
16645313|NCT02313025|Active Comparator|World-project|This group receives the WORLD intervention for four months.
16645314|NCT02313012|Experimental|Dose Level 1 CC-90003|CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.
16645315|NCT02312999|Experimental|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
16645316|NCT02312999|Active Comparator|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
16645317|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
16645318|NCT02312973|Experimental|Arm 1|Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)
16645319|NCT02312973|Experimental|Arm 2|Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)
16645320|NCT02312973|Experimental|Arm 3|Single oral dose of 75 mg molidustat (fasted) in healthy subjects
16645322|NCT02312947|Active Comparator|coblation|coblation adenoidectomy
16645323|NCT02312947|Active Comparator|cold dissection|cold dissection adenoidectomy
16645324|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:
~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
16645325|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
16645326|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.
~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
16645327|NCT02312921||Control|Usual care
16645328|NCT02312908|Experimental|Clonazepam|Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks
16645329|NCT02312908|Placebo Comparator|Placebo|Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks
16645330|NCT02312895|Experimental|Dry Needling|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive dry needling, patient education, and a home exercise program.
16645331|NCT02312895|Experimental|Manual Therapy|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive manual therapy, patient education, and a home exercise program.
16645332|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
16645333|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
16645359|NCT02312661|Experimental|Carboplatin / paclitaxel /metformin|Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment
16645360|NCT02312648|Active Comparator|Early mobilization Group|Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
16645361|NCT02312648|Other|Control Group - Respiratory exercise|Respiratory exercises with patient sitting in bed with a high headboard 45, the same breathing exercises will be held
16645489|NCT02311855|Other|Influenza vaccination|all patients are vaccinated per protocol
16645334|NCT02312843|Active Comparator|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5[HRmax-HRrest] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
16645335|NCT02312843|Placebo Comparator|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
16645336|NCT02312817|No Intervention|Group 1|Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
16645337|NCT02312817|Experimental|Group 2|Individuals randomized to Group 2 will receive mailed outreach invitation.
16645338|NCT02312817|Experimental|Group 3|Individuals randomized to Group 3 will receive mailed outreach invitation and patient navigation.
16645339|NCT02312804|Experimental|Dose Escalation|To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
16645340|NCT02312804|Experimental|Expansion Cervical Cancer|To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
16645341|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
16645342|NCT02312778|Experimental|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation is delivered to the subjects in the side lying position. The more restricted lumbar segment (mobility restriction) will be the target region for the manipulative procedure.
16645343|NCT02312778|No Intervention|Sham Manipulation|Control Group who receives a simulated manipulation.
16645344|NCT02312765|Experimental|Intervention|Study participants will receive a tablet computer with the AirCare system.
16645345|NCT02312765|No Intervention|Control|Standard care
16645346|NCT02312752|Other|Intra-epidermal stimulation|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
16645347|NCT02312739|Active Comparator|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.
~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
16645348|NCT02312739|Experimental|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.
~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
16645349|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
16645350|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
16645351|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
16645352|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
16645353|NCT02312713|No Intervention|Wait list control|no intervention
16645354|NCT02312700|Experimental|Interactive empowerment (IEm) group|Intervention: Patients fill in the questionnaire online and their profile (obtained from their answers) is immediately sent to the physician
16645355|NCT02312700|Sham Comparator|Control|Intervention: Patients fill in the questionnaire online, but their profile (obtained from their answers) is not sent to the physician
16645356|NCT02312687|Experimental|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
16645357|NCT02312674|Experimental|Intervention|Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
16645358|NCT02312674|No Intervention|Control|Patients group which takes no oral nutritional supplements
16749532|NCT01615653|Active Comparator|EUS 2|
16645362|NCT02312635|Experimental|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
16645363|NCT02312635|Placebo Comparator|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
16645364|NCT02312622|Experimental|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
16645365|NCT02312622|Experimental|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
16645366|NCT02312622|Experimental|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
16645367|NCT02312609|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
16645368|NCT02312609|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
16645369|NCT02312596|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix
16645370|NCT02312596|Active Comparator|Usual and customary practice|Usual and customary practice
16645371|NCT02312583|Sham Comparator|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment.
16645372|NCT02312583|Experimental|iFightDepression online programme.|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
16645373|NCT02312570|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
16645374|NCT02312570|Other|Usual and Customary Practice|Usual and customary practice for non-healing pressure wounds
16645375|NCT02312557|Experimental|Treatment (pembrolizumab)|"INITIAL TREATMENT PHASE: Patients who are progressing on enzalutamide will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily.
~MONITORING PHASE: After completion of the initial treatment phase, patients continue to receive standard of care enzalutamide PO daily for the duration of the trial.
~RETREATMENT PHASE: Patients with disease response or stability after the initial treatment phase will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily for the duration of the trial."
16645376|NCT02312544|Active Comparator|OTX-TP treatment|OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately
16645377|NCT02312544|Active Comparator|Timolol control|Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV).
16645378|NCT02312531|Experimental|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
16645379|NCT02312531|No Intervention|Control group|Mothers in control group had no HBIG injection during pregnancy.
16645380|NCT02312518|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
16645381|NCT02312518|Other|Usual and Customary Practice|usual and customary practice
16645382|NCT02312505|Other|COPFX|cardiac output by PulsioFlex® Monitoring system (COPFX)
16645383|NCT02312492|Experimental|18:1 diet|Oleic Diet - volunteers will consume oleic enriched food for a period of 5 weeks.
16645384|NCT02312492|Experimental|16:0 diet|Palmitic diet - Volunteers will consume palmitic enriched food for a period of 5 weeks.
16645385|NCT02312492|Experimental|18:0|Stearic Diet - Volunteers will receive Stearic enriched food for a period of 5 weeks.
16645386|NCT02312479|Experimental|Nyxoah SAT therapy|
16645387|NCT02312466||School aged children|
16645388|NCT02312466||Pregnant women|
16645389|NCT02312466||Women of reproductive age|
16645390|NCT02312453|Experimental|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture [Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
16645391|NCT02312440|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
16645392|NCT02312440|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' prior to skin incision and the second dose at 180' after the first dosage.
16645393|NCT02312440|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
16645394|NCT02312427|Experimental|Outpatient arm|After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
16645395|NCT02312427|Experimental|Hospitalization arm 1|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
16645396|NCT02312427|Experimental|Hospitalization arm 2|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
16645397|NCT02312414|No Intervention|IVIR|Patients given IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 1 to week 4
16645398|NCT02312414|Experimental|IVIR Carnitine|Patients given Carnitine (20mg/kg, IV) perior to IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 4 to week 8.
16645399|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
16645400|NCT02312388|Experimental|Catheter-over-the-needle technique|to use the 22G angiocatheter for central venous catheterization
16645401|NCT02312388|Experimental|Thin-wall needle technique|to use the sharp hollow 23G needle for central venous catheterization
16645402|NCT02312375|Experimental|Fimasartan|Expreimental drug is fimasartan.
16645403|NCT02312375|Active Comparator|Amlodipine|Active comparator is amlodipine.
16645404|NCT02312362|Experimental|Combined sclerotomy ab interno and phaco|Combined sclerotomy ab interno and phacoemulsification with IOL implantation
16645405|NCT02312362|Active Comparator|Phacoemulsification with IOL implantation|Phacoemulsification with IOL implantation
16645406|NCT02312336|Placebo Comparator|Cohort A|Cohort A - Room temperature coronary perfusate
16645407|NCT02312336|Active Comparator|Cohort B|Cohort B - Cooled coronary perfusate
16645408|NCT02312323|Experimental|Definitive 65 HPT|The Test product were the Definitive 65 (Filcon V4) lenses with Hydra PEG surface coating. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
16645409|NCT02312323|Active Comparator|Definitive 65|The Control product was the commercially available Definitive 65 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
16645410|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
16645411|NCT02312310|Active Comparator|F 260 mg|"daily consumption of capsules containing 260 mg* cocoa flavanol for 12 weeks
~*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
16645412|NCT02312310|Active Comparator|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
16645413|NCT02312310|Active Comparator|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
16645414|NCT02312297|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
16645415|NCT02312297|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
16645416|NCT02312284||Radiotherapy/Chemoradiotherapy|Pre- or postoperative or palliative radiotherapy/chemoradiotherapy based on 5-fluorouracil or Capecitabine +/-Oxaliplatin
16645417|NCT02312284||Surgery|Transabdominal resection or transanal excision
16645418|NCT02312284||Chemotherapy|Pre- or postoperative chemotherapy including 5-fluorouracil/leucovorin with oxaliplatin, Capecitabine, etc
16645419|NCT02312271||enterally fed adults|adult subjects with established enteral access receiving standard tube feeding formula
16645420|NCT02312258|Experimental|Placebo|Ixazomib placebo-matching capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (Up to data cut-off 12 August 2019).
16645421|NCT02312258|Placebo Comparator|Ixazomib|Ixazomib 3 mg, capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (Up to data cut-off 12 August 2019).
16645422|NCT02312245|Experimental|Arm A (Avatar-directed paclitaxel)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
16645423|NCT02312245|Experimental|Arm B (Avatar-directed gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16645424|NCT02312245|Experimental|Arm C (Avatar-directed liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16645425|NCT02312245|Experimental|Arm D (Avatar-directed topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
16645426|NCT02312232|Experimental|Levodopa formulation A|Levodopa formulation A together with ODM-104 100 mg and carbidopa
16645427|NCT02312232|Experimental|levodopa formulation B|levodopa formulation B together with ODM-104 100 mg and carbidopa
16645428|NCT02312232|Experimental|levodopa formulation C|levodopa formulation C together with ODM-104 100 mg and carbidopa
16645429|NCT02312232|Active Comparator|Sinemet IR 100/25 mg|Sinemet IR 100/25 mg together with ODM-104 100 mg
16645430|NCT02312232|Active Comparator|Half Sinemet CR 100/25 mg|Half Sinemet CR 100/25 mg together with ODM-104 100 mg
16645431|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
16645432|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
16750221|NCT01610791|Experimental|Single Arm|
16645433|NCT02312206|Experimental|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
16645434|NCT02312206|Placebo Comparator|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
16645435|NCT02312193||Case|Hypertensive subjects
16645436|NCT02312193||Control|Normotensive subjects
16645437|NCT02312180|Experimental|Cohort 1|low dose group of 2 mg/kg Plasminogen (Human) Intravenous
16645438|NCT02312180|Experimental|Cohort 2|mid-dose group of 6 mg/kg Plasminogen (Human) Intravenous
16645439|NCT02312167|Experimental|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
16645440|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.
~(We performed split face study)"
16645441|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
16645442|NCT02312128|Active Comparator|Early Mobilisation|"receives a removable plastic cast for one week and is allowed to move the wrist directly postoperative.
~Interventions:
~Range of Motion measurement (ROM),
~Grip strength measurement,
~VAS Score according to the visual analogue scale ().
~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.
~X- Rays in two planes.
~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
16645443|NCT02312128|Active Comparator|Cast Group|"receives a non removable cast for 5 weeks
~Interventions:
~Range of Motion measurement (ROM),
~Grip strength measurement,
~VAS Score according to the visual analogue scale ().
~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.
~X- Rays in two planes.
~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
16645444|NCT02312115|Active Comparator|Furosemide|Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.
16645445|NCT02312115|Placebo Comparator|Saline|All patients assigned to the saline group will receive saline that is equal in volume as compared to the treatment group. The amount of saline given to the patients in the placebo arm is so small that its effect on these patients is negligible. All other aspects of care for the enrolled patient will be managed per primary team and any consultants.
16645446|NCT02312102|Experimental|Velcade and Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Each treatment cycle lasts 28 days (4 weeks). The first two cycles are called the induction cycles. If the participant respond to treatment during the first two cycles, they can continue on to the maintenance cycles.
~During the induction and maintenance cycles, patients receive up to the MTD of lenalidomide on days 1-21 days only. During days 22-28 (4th week) there is a rest period.
~Bortezomib: During the induction cycles, the medication will be given on days 2, 5, 9, and 12 followed by a 17-day rest period. During the maintenance cycles, bortezomib will be given on days 2, and 5 followed by 23-day rest period."
16645447|NCT02312089|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
16645448|NCT02312089|No Intervention|Control group|No GnRHa administration in luteal phase
16645449|NCT02312076|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
16645450|NCT02312076|No Intervention|Control group|No GnRHa administration in luteal phase
16645451|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
16645452|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
16645453|NCT02312050|Experimental|GCS-100 1 mg|Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
16645454|NCT02312050|Experimental|GCS-100 3 mg|Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
16645455|NCT02312050|Experimental|GCS-100 9 mg|Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
16645456|NCT02312050|Placebo Comparator|Normal Saline Solution 0.9%|Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
16645457|NCT02312024||Patients with severe sepsis/septic shock|Use of CytoSorb adsorber in patients with severe sepsis/septic shock
16645458|NCT02312024||Cardiac surgery with CPB: preemptive use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: preemptive use
16645459|NCT02312024||Cardiac surgery with CPB: postop. use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: postoperative use
16645460|NCT02312024||Patients with other indications|Use of CytoSorb adsorber in patients with other indications
16645461|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.
~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
16645462|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
16645463|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin)|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16645464|NCT02311985|Active Comparator|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
16647080|NCT02300857|Active Comparator|High carbohydrate diet|
16645465|NCT02311985|Experimental|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
16645466|NCT02311985|Experimental|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
16645467|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
16645468|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
16645469|NCT02311959|Experimental|Invasive or in situ breast carcinoma.|
16645470|NCT02311946|Experimental|Cohort 1|Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid
16645471|NCT02311946|Experimental|Cohort 2|Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3
16645472|NCT02311946|Experimental|Cohort 3|Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.
16645473|NCT02311946|Experimental|Cohort 4|Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.
16645474|NCT02311946|Experimental|Cohort 5|Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.
16645475|NCT02311946|Experimental|Cohort 6|Cohort 6 will receive a 125 mg palbociclib oral solution
16645476|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16645477|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
16645478|NCT02311920|Experimental|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
16645479|NCT02311920|Experimental|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
16645480|NCT02311920|Experimental|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
16645481|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
16645482|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
16645483|NCT02311894|Experimental|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
16645484|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
16645485|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
16645486|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
16645487|NCT02311868|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 day
16645488|NCT02311868|Placebo Comparator|Placebo|patients of this group received 5g of placebo 3 times a day for 30 days
16645490|NCT02311829|Experimental|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.
~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
16645491|NCT02311829|No Intervention|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist
~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
16645492|NCT02311816||Infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
16645493|NCT02311816||No infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
16645494|NCT02311803|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
16645495|NCT02311803|Active Comparator|Excision of Denonvilliers Fascia|Excision of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
16645496|NCT02311790|Experimental|Trans-C16:1 supplement|Volunteers will take trans-C16:1 supplement for 3 weeks
16645497|NCT02311790|Experimental|Cis-C16:1 supplement|Volunteers will take cis-C16:1 supplement for 3 weeks
16645498|NCT02311777|Active Comparator|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
16645499|NCT02311777|Placebo Comparator|Placebo|Placebo will be given preoperative period
16645500|NCT02311764|Experimental|Carboplatin|Carboplatin will be administered weekly
16645501|NCT02311751|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
16645502|NCT02311751|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
16645503|NCT02311738|Experimental|High intensity training group|"HIE will consist of the following:
~10 minute warm up at 70% of maximal heart rate.
~4 minute exercise intervals at 90-95% of maximal heart rate.
~4 minute interval bouts repeated 4 times.
~Between each bouts there will be a 3 minute active recovery at 70% of maximal heart rate
~After all four bouts are completed; 5 minute cool-down at 70% of maximal heart rate."
16645504|NCT02311738|Experimental|Moderate intensity training group|"MIE will consist of the following:
~10 minute warm up at 50% of maximal heart rate.
~35 minutes exercise at 70% of maximal heart rate.
~4 minute cool-down at 50% of maximal heart rate."
16645505|NCT02311725|Experimental|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.
~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.
~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
16645506|NCT02311725|Active Comparator|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.
~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
16645507|NCT02311712|Active Comparator|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
16645508|NCT02311712|No Intervention|Control|No intervention
16645509|NCT02311699|Experimental|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
16645510|NCT02311699|Experimental|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
16645511|NCT02311699|Experimental|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
16645512|NCT02311699|No Intervention|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
16645513|NCT02311686|Experimental|10 g ethanol|Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
16645514|NCT02311686|Experimental|20 g ethanol|Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
16645515|NCT02311686|Experimental|40 g ethanol|Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
16645516|NCT02311686|Experimental|60 g ethanol|Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
16645517|NCT02311686|Experimental|80 g ethanol|Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
16645518|NCT02311673|Active Comparator|RM-493 Once Daily Dose 1|Dose 1 once daily in the morning
16645519|NCT02311673|Active Comparator|RM-493 Once Daily Dose 2|Dose 2 once daily in the morning
16645520|NCT02311673|Placebo Comparator|Placebo|Placebo in the morning
16645521|NCT02311660|Experimental|vagus nerve stimulation|Patients will have an implanted vagus nerve stimulation device.
16645522|NCT02311647||Post Tamoxifen exposure group|Breast cancer patients receiving or formerly received Tamoxifen for at least 1 year.
16645523|NCT02311647||Control group|Breast cancer patients who did not receive endocrine treatment
16645524|NCT02311634|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of three weeks
16645525|NCT02311634|Active Comparator|Transvaginal ES|At a current intensity of < 60 mA (in 5% increments from 0 mA to the intensity that is sensed without obvious discomfort) and frequencies of 12.5 to 30 Hz, 45 min three times a week for a total of four weeks.
16645526|NCT02311621|Experimental|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.
~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.
~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
16645527|NCT02311621|Experimental|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.
~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.
~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
16645528|NCT02311621|Experimental|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.
~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.
~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
16645529|NCT02311608||High Dose Somatostatin/Octreotide|continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
16645530|NCT02311608||Terlipressin as salvage|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
16645531|NCT02311608||Terlipr+usual dose somato/Octreo|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
16645532|NCT02311608||Control:Usual Dose Somato/Octreo|Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide
16645533|NCT02311608||Control: Initial Terlipressin|Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h
16645534|NCT02311595|Experimental|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
16645539|NCT02311569|Experimental|Arm Mirabegron|Mirabegron treatment of at least 24 weeks with an initial dose of 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
16645540|NCT02311556|Experimental|DSC-PMR|DSC-PMR (dynamic susceptibility-weighted contrast- enhanced perfusion magnetic resonance imaging) at baseline (screening or time of radiosurgery) and after radiosurgery
16645541|NCT02311543|No Intervention|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
16645542|NCT02311543|Active Comparator|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
16645543|NCT02311530|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
16645544|NCT02311530|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
16645545|NCT02311517|Experimental|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
16645546|NCT02311517|Placebo Comparator|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
16645547|NCT02311504||DiabCheck ophta OCTplus|persons with diabetes undergoing OCT examination
16645548|NCT02311491|Experimental|Ceramic Coated Orthodontic Archwire|Ceramic coated orthodontic archwires will be evaluated in a limited clinical study at the university of North Carolina to test their efficacy in early and intermediate stages of tooth straightening in orthodontic patients.
16645549|NCT02311491|No Intervention|Control|The patients will receive the ordinary archwires. There is no intervention to the standard treatment.
16645550|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
16645551|NCT02311465|Experimental|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
16645552|NCT02311465|No Intervention|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
16645553|NCT02311452||Acute Osteomyelitis|
16645554|NCT02311452||Complicated Pneumonia|
16645555|NCT02311452||Complicated Appendicitis|
16645556|NCT02311439|Experimental|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
16645557|NCT02311426||Norway|500 consecutive patients with stroke from the stroke units at the University Hospital of North Norway located in the cities Narvik, Harstad and Tromsø.
16645558|NCT02311426||Denmark|500 consecutive patients from the stroke unit at Århus Hospital in Denmark.
16645559|NCT02311413|Experimental|Cat-PAD|Subjects will be treated with four monthly doses of Cat-PAD, a peptide immunotherapy product consisting of Fel d 1 synthetic peptide immunoregulatory epitopes (SPIRE).
16645560|NCT02311413|Placebo Comparator|Placebo|Subjects will be treated with 4 monthly doses of Placebo.
16645563|NCT02311361|Experimental|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
16645564|NCT02311361|Experimental|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
16645565|NCT02311361|Experimental|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
16645566|NCT02311361|Experimental|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
16645567|NCT02311361|Experimental|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
16645568|NCT02311361|Experimental|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
16645569|NCT02311335||1|Dyslipidemia patients
16645570|NCT02311322||Children with growth disorders|Children with growth disorders
16645571|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
16645572|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
16645573|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
16645574|NCT02311231|Experimental|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
16645575|NCT02311231|Active Comparator|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
16645576|NCT02311218|Active Comparator|Test group with L. reuteri|Subjects in the test group take one Lactobacillus reuteri DSM 17938 and PTA 5289 containing lozenge in the morning and one in the evening.
16645577|NCT02311218|Placebo Comparator|Placebo group without L. reuteri|Subjects in the placebo group take one placebo lozenges with same look, taste and smell as the test lozenge but lacking the Lactobacillii the morning and one in the evening.
16645578|NCT02311205|Experimental|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
16645604|NCT02311049|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
16645579|NCT02311192|Experimental|Ultrasonography B-scan|Patients of uveitis who are included in the study will be imaged using ultrasound B-scan
16645580|NCT02311179|Active Comparator|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
16645581|NCT02311179|Active Comparator|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
16645582|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
16645583|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
16645584|NCT02311140||Cystic Fibrosis patients with G551D mutation|Cohort Description Ten participants (6 Jena/4 Innsbruck) were included, of whom 6 were female and 4 were male. At the start of the study, patients were aged 7-45 years (mean age: 16.55 ± 13.42 years). Results of sweat tests and lung function FEV1 were available only from 8 patients. Lung function at baseline, as obtained from those patients, ranged from 0.96 to 4.07 L (mean FEV1: 99.7 ± 20.3% predicted, median: 103.6% predicted, IQR=20.4% predicted).
16645585|NCT02311127|Experimental|SecurAcath|Subcutaneous securement
16645586|NCT02311127|Active Comparator|StatLock|Adhesive securement
16645587|NCT02311114||Telehomecare patients|Observational fieldwork, in depth interviews and surveys up to 4 times will be conducted.
16645588|NCT02311114||Health care providers|In-Depth interviews, observational fieldwork and one time survey will be conducted.
16645589|NCT02311114||Telehomecare administrators|In depth interviews will be conducted
16645590|NCT02311114||Telehomecare technicians|In-depth interviews, observational fieldwork will be conducted.
16645591|NCT02311101|Experimental|Therapy Group MMC 10/BCG Half|"Intravesical Mitomycin C and intravesical BCG
~First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (half dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The first 3 participants received 10mg of MMC and half dose of BCG. The dose was assigned in order of enrollment."
16645592|NCT02311101|Experimental|Therapy Group MMC 10/BCG Full|First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The following 3 participants received 10mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
16645593|NCT02311101|Experimental|Therapy Group MMC 20/BCG Full|First intravesical mitomycin C (20 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The next 3 participants enrolled received 20mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
16645594|NCT02311101|Experimental|Therapy Group MMC 40/BCG Full|First intravesical mitomycin C (40 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The last 3 participants received 40mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
16645595|NCT02311088|Experimental|Caffeine|Caffeine capsules. 200 mg twice daily orally for 7-10 days.
16645596|NCT02311088|Placebo Comparator|Placebo|Matching placebo capsules twice daily orally for 7-10 days.
16645597|NCT02311075|Experimental|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
16645598|NCT02311075|Experimental|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
16645599|NCT02311075|Experimental|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
16645600|NCT02311062|Experimental|Eccentric hamstring exercises|Three workouts per week on non-consecutive days for 6 weeks. 1)Assisted Nordic Curl: Kneeling on the ground with ankles fixed by a partner, participant lowering the trunk to the ground by eccentrically contracting the hamstrings. 2) Eccentric single stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the support leg knee and raising the other leg until form an straight line with the trunk4 3) Eccentric double stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the knees until the body parallel with the floor.
16645601|NCT02311062|Experimental|Unistable exercises|Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
16645602|NCT02311062|Active Comparator|Control|Participants did not undergo any resistance training and continued with their regular soccer training.
16645603|NCT02311049|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
16753654|NCT01587443||Hemodialysis|
16645605|NCT02311036|Other|Comorbidity_Comprehensive Rehabilitation|Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. For a physician, it is helpful in knowing how aggressively to treat a condition. Higher scores indicating greater comorbidity (patients with a score > 5 have essentially a 100% risk of dying at one year).
16645606|NCT02311036|Other|MRS_Comprehensive Rehabilitation|The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
16645607|NCT02311036|Other|MMSE_Comprehensive Rehabilitation|The mini mental state examination (MMSE) is the most commonly used instrument for screening cognitive function. This examination is not suitable for making a diagnosis but can be used to indicate the presence of cognitive impairment, such as in a person with suspected dementia or following a head injury. The examination has been validated in a number of populations. Scores of 25-30 out of 30 are considered normal; the National Institute for Health and Care Excellence (NICE) classifies 21-24 as mild, 10-20 as moderate and <10 as severe impairment. The MMSE may not be an appropriate assessment if the patient has learning, linguistic/communication or other disabilities (eg, sensory impairments).
16645608|NCT02311036|Other|BSRS_Comprehensive Rehabilitation|Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
16645609|NCT02311023|Experimental|Intermittent fasting|Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.
16645610|NCT02311010|No Intervention|CYP 3 A 5 *3/*3 control group|CYP 3 A 5 *3/*3 control group will receive 0,20 mg/kg of Advagraf®
16645611|NCT02311010|Active Comparator|CYP 3 A 5 *3/*3|CYP 3 A 5 *3/*3 will receive 0,25 mg/kg of Advagraf®
16645612|NCT02311010|Active Comparator|CYP 3 A 5 *1/*3|CYP 3 A 5 *1/*3 will receive 0,30 mg/kg of Advagraf®
16645613|NCT02311010|Active Comparator|CYP 3 A 5 *1/*1|CYP 3 A 5 *1/*1 will receive 0,35 mg/kg of Advagraf®
16645614|NCT02310997|Experimental|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
~Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
16645615|NCT02310997|Experimental|Busulfan + Cyclophosphamide + Melphalan|"Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2"
16645616|NCT02310971|Experimental|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
16645617|NCT02310958||Children with inguinal hernia|Laparoscopic surgical hernia repair in children aged between 1 day and 16 years
16645618|NCT02310945||Knee osteoarthritis|People with moderate/severe symptomatic knee osteoarthritis referred for physiotherapy
16645619|NCT02310932|Experimental|Healthy Living Intervention|The Healthy Living Intervention group will participate in an intervention designed to improve depression, anxiety, diabetes and CVD outcomes. This will be achieved through a 12 month intervention which consists of participation in healthy living groups and integrated collaborative clinic care at their Primary Health Clinic (PHC).
16645620|NCT02310932|Placebo Comparator|Enhanced Standard Care Model|"Patients in control groups will receive an enhanced standard care model, which includes providing referrals for mental health needs."
16645621|NCT02310919|Experimental|Low dose hCG plus FSH co-trigger|On the day of ovulation trigger the patient will receive hCG 1,500 IU SQ plus FSH 450 IU SQ
16645622|NCT02310919|Active Comparator|Standard dose of hCG alone|On the day of ovulation trigger the patient will receive standard dose of hCG (10,000 or 5,000 IU SQ)
16645623|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
16645624|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
16645625|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
16645626|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
16645627|NCT02310893|Active Comparator|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
16645628|NCT02310893|Active Comparator|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
16645629|NCT02310893|Experimental|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
16645630|NCT02310893|No Intervention|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
16647081|NCT02300844|Experimental|NNC0174-0833 10 mg/mL|
16645631|NCT02310880||Low vision (virtual street training)|Low vision subjects trained in virtual streets and observed in real streets
16645632|NCT02310880||Low vision (real street training)|Low vision subjects trained in real streets and observed in real streets
16645633|NCT02310867|Experimental|Hand transplant with Belatacept|
16645634|NCT02310854|Active Comparator|ACL Reconstruction|Primary reconstructive surgery of ACL with hamstring autograft (All-inside, Arthrex, Napels, Florida, USA)
16645635|NCT02310854|Experimental|ACL Repair|Primary augmented suture of ACL using Dynamic Intraligament Stabilization (DIS; Mathys Medical Bettlach, Switzerland)
16645636|NCT02310841|Experimental|unilateral transfemoral amputees|
16645637|NCT02310828|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
16645638|NCT02310828|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for one month
16645639|NCT02310802|Experimental|OBE001 dose 1|
16645640|NCT02310802|Experimental|OBE001 dose 2|
16645641|NCT02310802|Experimental|OBE001 dose 3|
16645642|NCT02310802|Placebo Comparator|Placebo|
16645643|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
16645644|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.
~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
16645645|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
16645646|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
16645647|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
16645648|NCT02310750|Experimental|PF-06700841 Tablet|
16645649|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
16645650|NCT02310737|Active Comparator|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
16645651|NCT02310737|Active Comparator|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
16645652|NCT02310724||TODAY cohort|All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2. The study performs long-term observation only and administers no treatment, care, or management.
16645653|NCT02310698||Breast Cancer Screening Patients|"Women presenting for screening full field digital mammography (FFDM) and WBUS on the same day or within 30 days of one another.
~o These women will be offered CEDM instead of the FFDM.
~Women that are scheduled for CEDM alone.
~o These women will be offered WBUS in addition to the CEDM.
~Women scheduled for both CEDM and WBUS on the same day or within 30 days of one another."
16645654|NCT02310685|Active Comparator|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
16645655|NCT02310685|No Intervention|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
16645656|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
16645657|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score <400
16645658|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
16645659|NCT02310646|Active Comparator|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
16645660|NCT02310646|Active Comparator|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
16645661|NCT02310633|Active Comparator|Memory Strategy Training|This arm involves intervention that teaches participants to use active encoding strategies to learn and remember new information.
16645662|NCT02310633|Active Comparator|Errorless Learning|This arm involves intervention that enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase.
16645663|NCT02310633|Active Comparator|Retrieval Practice|This arm involves intervention that enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue.
16645664|NCT02310620|Experimental|Cognitive Training|
16645665|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
16645666|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
16645667|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
16646208|NCT02306889|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
16645668|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
16645669|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
16645670|NCT02310568|Experimental|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
16645671|NCT02310568|Experimental|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
16645672|NCT02310568|Experimental|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
16645673|NCT02310568|Experimental|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
16645674|NCT02310568|Placebo Comparator|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
16645675|NCT02310555|Active Comparator|Gastric bypass|classic Gastric bypass
16645676|NCT02310555|Active Comparator|Modified gastric bypass.|Modified gastric bypass. Resection body and fundus gastric
16645677|NCT02310555|Active Comparator|Slevee Gastrectomy|Slevee Gastrectomy
16645678|NCT02310542|Experimental|MARS-SPAD|Patients will receive first the MARS albumin dialysis system and then, in a second time, the SPAD albumin dialysis system.
16645679|NCT02310542|Experimental|SPAD-MARS|Patients will receive first the SPAD albumin dialysis system and then, in a second time, the MARS albumin dialysis system.
16645680|NCT02310529|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
16645681|NCT02310529|No Intervention|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
16645682|NCT02310516|Experimental|Patient with preoperative device|patients undergoing brain awake surgery with adequate explanations which are provided preoperatively. Preoperative device corresponds to a pre/ perioperative coaching involving the provision of a comprehensive information support on the awake surgery (short video and information brochure) and an interview with an operating room nurse
16645683|NCT02310516|Active Comparator|Patient with standard procedure|patients undergoing brain awake surgery with standard procedure (without adequate explanations)
16645684|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
16645685|NCT02310490|Active Comparator|Right Side DermaVeil, Left Side Sculptra|DermaVeil right with left side Sculptra left side
16645686|NCT02310490|Active Comparator|Left Side DermaVeil, Right Side Sculptra|DermaVeil left with left side Sculptra right side
16645687|NCT02310464|Experimental|Dose escalation|Each subject will be given a total of 10 doses of OBI-833/OBI-821 subcutaneously at weeks 1,2,3,4,6,8,12,16,20,and 24 (Visits 1,2,3,4,5,6,7,8,9 and 10, respectively). Post treatment, subjects will be continually evaluated for safety and immune response every 4 weeks until the end of study, which is 12 weeks after the last dose, i.e., week 36. Subsequently, subjects will be followed for survival every 8 weeks up to 12 months after the end of study.
16645688|NCT02310464|Experimental|Cohort expansion phase|Each subject will be given OBI-833/OBI-821 at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and every 8 weeks thereafter (Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and every 8 weeks thereafter) until disease progression. For the subjects discontinued treatment because of disease progression, subjects will be continually evaluated for safety and immune response every 8 weeks until the end of the study, which is 24 weeks after the last dose.
16645689|NCT02310451|Experimental|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
16645690|NCT02310438|Experimental|Early intervention music therapy|"music therapy:
~6 stroke patients with hemiparesis begin music therapy treatment in their home as soon as they have completed statutory NHS community rehabilitation."
16645691|NCT02310438|Active Comparator|Delayed intervention music therapy|"music therapy:
~6 stroke patients with hemiparesis begin music therapy treatment in their home 9 weeks after they have been randomised into the wait list group."
16645692|NCT02310425|Active Comparator|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
16645693|NCT02310425|Placebo Comparator|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
16645694|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
16645695|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
16646209|NCT02306876|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
16645696|NCT02310399|Experimental|Pre-lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
16645697|NCT02310399|Experimental|Post-Lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age
16645698|NCT02310386|Active Comparator|activated BEMER-device|Activated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
16645699|NCT02310386|Sham Comparator|inactivated BEMER-device|Inactivated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
16645700|NCT02310373|Experimental|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
16645701|NCT02310360||Healthy volunteers|
16645702|NCT02310347|Experimental|Marinol|"generic name: dronabinol
~dosage: 0.1 mg/kg
~frequency: 2 times a single dose
~duration: acute adminstration"
16645703|NCT02310347|Placebo Comparator|Placebo|Empty hard gelatin capsules
16645704|NCT02310334|Experimental|Unguided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the first visit, the participant will partake in an unguided exercise session.
16645705|NCT02310334|Experimental|Guided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
16645709|NCT02310308|Active Comparator|xylitol chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
16645710|NCT02310308|Experimental|Xylitol-magnolia chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
16645711|NCT02310308|Placebo Comparator|Control chewing gum|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
16645712|NCT02310295|Active Comparator|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
16645713|NCT02310295|Active Comparator|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
16645714|NCT02310295|Active Comparator|Laser|focal laser therapy
16645715|NCT02310282||Telemedicine|In-hospital telemedicine by a stroke expert aiming to assess stroke severity using the Unassisted TeleStroke Scale.
16645716|NCT02310269||Pasireotide|
16645717|NCT02310256|No Intervention|Usual care|
16645718|NCT02310256|Active Comparator|Five Plus|Exercise training
16645719|NCT02310243|Experimental|Palbociclib|"Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.
~phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest."
16645720|NCT02310230|Other|Blinded Group|Data from the ExSpiron Respiratory Variation Monitor (minute ventilation, tidal volume, and respiratory rate) will not be displayed. The anesthesia provider will care for the patient in the usual manner.
16645721|NCT02310230|Experimental|Monitor Group|The ExSpiron Respiratory Variation Monitor will display continuous real-time measurements of minute ventilation, tidal volume, and respiratory rate, and the anesthesia provider will be instructed to utilize this information in the care of the patient as they deem appropriate.
16645722|NCT02310217||1|Hypertensive
16645723|NCT02310217||2|Normotensive
16645724|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
16645725|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
16645726|NCT02310191||Stenting|Carotid stenting
16645727|NCT02310178|Other|Group/Cohort|all of the current bariatric surgeries are allowed in this prospective cohort study
16645728|NCT02310165|Other|Z-tract Insertion Technique|For this technique, the skin is pulled 2 cm downward before the paracentesis needle is inserted and advanced.
16645729|NCT02310165|Other|Coaxial Insertion Technique|For this technique, the needle is directly inserted to minimize the distance between he cutaneous tissue and ascites
16645730|NCT02310152|Active Comparator|Active Treatment: CBT|Cognitive Behavioral Therapy
16645731|NCT02310152|Experimental|Experimental Treatment: SPACE|Parent-Based Treatment of Childhood and Adolescent Anxiety Disorders
16645732|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
16645733|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
16645764|NCT02309918|Other|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
16645734|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
16645735|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
16645736|NCT02310100|Experimental|TactiCath Quartz|TactiCath Quartz treatment
16645737|NCT02310087|Active Comparator|astaxanthin with vitamin E|The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
16645738|NCT02310087|Placebo Comparator|placebo|The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
16645739|NCT02310074|Experimental|Pulsatile Gonadotropin Releasing Hormone|Pulsatile Gonadotropin Releasing Hormone: subjects in the GnRH group initiated a regimen of pulsatile GnRH administered subcutaneously via a portable infusion pump for 18 months.
16645740|NCT02310074|Active Comparator|combination gonadotropin therapy|combined human chorionic gonadotropin (hCG)/urinary Follicle-Stimulating Hormone (uFSH) therapy:HCG treatment was maintained alone for 6 months and then uFSH was added for the next 12 months
16645741|NCT02310061|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
16645742|NCT02310061|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
16645743|NCT02310048|Experimental|MT-1303-FormA|MT-1303, Capsule Formulation A
16645744|NCT02310048|Experimental|MT-1303-FormB|MT-1303, Capsule Formulation B
16645745|NCT02310022|Experimental|Drug Omega 3|4g (4 capsules) once a day, administered with food Other name MAT9001
16645746|NCT02310022|Active Comparator|Drug Omega 3 Comparator|4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
16645747|NCT02310009|Experimental|Control (CON)|Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
16645748|NCT02310009|Experimental|Anakinra (AN)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
16645749|NCT02310009|Experimental|Exercise (EX)|1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
16645750|NCT02310009|Experimental|Anakinra + Exercise (ANEX)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
16645751|NCT02309996|Experimental|Supervisor Training Program|All supervisors from work units randomized to the intervention will receive a supervisor training program, the Supervisor/Manager Accommodation Recognition & Training (SMART) Program. This training program is modeled on a program developed by Shaw and colleagues of the Liberty Mutual Research Institute for Safety (LMRIS). The aim of the training program is to prevent/reduce work disability by improving supervisor communication, response to workplace injury, and problem solving mechanisms. The training program is designed to be administered by two facilitators to groups of 10 to 12 supervisors, during one 4-hour session or two 2-hour sessions. The training program delivery mode includes PowerPoint presentation with supplementary audio or video segments, case studies, and group discussion.
16645752|NCT02309996|No Intervention|No Supervisor Training Program|All supervisors from work units randomized to the control group will not receive the supervisor training program.
16645753|NCT02309983|Active Comparator|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN [Respond Select Neuromuscular Stimulation]. There will be 60 sessions/3x week for 20 weeks.
16645754|NCT02309983|Placebo Comparator|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
16645755|NCT02309983|Experimental|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
16645756|NCT02309970||Conservative|patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology
16645757|NCT02309970||IV tPA|patient will receive intravenous thrombolysis treatment
16645758|NCT02309970||Endovascular treatment|patient who will receive endovascular treatment
16645759|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
16645760|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
16645761|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
16645762|NCT02309931|Active Comparator|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
16645763|NCT02309931|Active Comparator|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
16645875|NCT02309164|Active Comparator|Acupuncture|acupuncture
16645765|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
16645766|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
16645767|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
16645768|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
16645769|NCT02309892|Experimental|Pemetrexed and Carboplatin plus L-DOS47|Patients will be recruited into cohorts of L DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L DOS47 will be 0.59 µg/kg; further possible dose levels that may be assessed are 0.78, 1.04, 1.38 and 1.84 µg/kg. The standard of care doses of pemetrexed [500 mg/m2] and carboplatin [AUC6], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
16645770|NCT02309879|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
16645771|NCT02309879|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
16645772|NCT02309879|Active Comparator|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
16645773|NCT02309879|Active Comparator|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
16645774|NCT02309866||Genetic Testing|All participants determined eligible for the study will be placed into genetic testing arm.
16645775|NCT02309853|Experimental|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space combined with trunk rotation
16645776|NCT02309853|Active Comparator|Unimodal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training
16645777|NCT02309840|No Intervention|control|Students received standard meals in a standard cafeteria environment
16645778|NCT02309840|Experimental|Chef|Students were exposed to chef-enhanced meals
16645779|NCT02309840|Experimental|choice architecture|"Students were exposed to modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
16645780|NCT02309840|Experimental|Chef and choice architecture|"Students were exposed to both chef-enhanced meals and modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
16645781|NCT02309827|Experimental|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645782|NCT02309827|Experimental|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645783|NCT02309827|Experimental|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645784|NCT02309827|Experimental|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645785|NCT02309827|Experimental|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645786|NCT02309827|Experimental|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645787|NCT02309827|Experimental|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645788|NCT02309827|Experimental|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645789|NCT02309827|Experimental|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
16645790|NCT02309814|Experimental|eyelid motion sensor device|all volunteers will wear the monitor eyelid sensor device (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance.
16645791|NCT02309801|Experimental|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).
~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
16645792|NCT02309801|Active Comparator|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
16645793|NCT02309788||RT|Resectable HCC patients adjuvant RT for PVT or NM
16645794|NCT02309788||No RT|Resectable HCC patients adjuvant other treatment for PVT or NM
16645795|NCT02309775|Active Comparator|Auriculotherapy Group|The placement, points according to Souza (1997), will be: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. The point descriptions are: Shen Men, is located in the vertex of the angle formed by the lower root and the upper root of the antihelix; the Sympathetic is situated in the middle of the lower root below the Helix membrane (located at the lower end of the Lobe); the Kidney point is situated in cymba concha, near its junction with the lower root of the antihelix, in the same line as the Shen Men point; the Subcortex is situated on upward curve towards the apex of the antitragus, on the upper edge of the concha; the Adrenal is located at the apex of the tragus, on its projection towards the concha cava; the Cerebral point is situated above the edge of the antitragus. As sessions will held twice a week for a total of 10 sessions.
16645796|NCT02309775|Placebo Comparator|Placebo Grup|The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
16645797|NCT02309762|Experimental|FB825|6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg
16645798|NCT02309762|Placebo Comparator|Placebo|Placebo
16645799|NCT02309749||Naive cohort|
16645800|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
16645801|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
16645802|NCT02309723|No Intervention|No beta amyloid information|
16645803|NCT02309710|Experimental|ShangRing|ShangRing administered to men seeking medical male circumcision
16645804|NCT02309697||Full Term|Children born at full term on or after Jan 1, 2011
16645805|NCT02309697||PreTerm|Children born preterm on or after Jan 1, 2011
16645806|NCT02309684||Study Population|Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
16645807|NCT02309671|Experimental|FE 999049 6 µg|
16645808|NCT02309671|Experimental|FE 999049 9 µg|
16645809|NCT02309671|Experimental|FE 999049 12 µg|
16645810|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
16645811|NCT02309658|Experimental|Interventional|Treatment consisted of gemcitabine at a dose of 1000 mg/m2, followed by cisplatin 35 mg/m2 administered on day 1 and 8, for two cycles. After that, weekly cisplatin 40mg/m2 is administered concomitant with radiotherapy (45-55Gy) in 1,8-2,0 daily fractions and a 10Gy boost when there was parametrial involvement. Low-dose rate brachytherapy, in 4 fractions of 7Gy, in a total of 28Gy will complete the protocol.
16645812|NCT02309645|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
16645813|NCT02309645|Other|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
16645814|NCT02309632|Active Comparator|Pathway 1|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
16645815|NCT02309632|Active Comparator|Pathway2|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
16645816|NCT02309619|Experimental|trans-substernal group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-substernal path.
16645817|NCT02309619|Experimental|trans-esophageal bed group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-esophageal bed path.
16645818|NCT02309606||Migraine without aura|Migraine patients suffering from migraine 0-4 days per month.
16645819|NCT02309606||Healthy controls|Healthy controls with no history of migraine or other primary headaches.
16645820|NCT02309606||Chronic migraine|Migraine patients with chronic migraine
16645821|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, with any type of Acetabular Shells.
16645822|NCT02309580|Experimental|Ibrutinib|This will be a standard dose-escalation study to determine the MTD of ibrutinib in relapsed/refractory PTCL or CTCL. At each dose 6 patients with TCL (PTCL or CTCL) will be enrolled. The first 6 patients will be enrolled at dose level 1. Dose escalation to the next dose level will proceed after DLT assessment of all 6 patients at the end of cycle 1 (28-days).
16645823|NCT02309554|Active Comparator|SILCS Diaphragm alone|Participants will complete a post-coital test cycle with SILCS diaphragm alone.
16645824|NCT02309554|Active Comparator|SILCS Diaphragm with 3% Nonoxynol-9 Gel|Participants will complete a post-coital test cycle with SILCS diaphragm used with 3% nonoxynol-9 gel.
16645825|NCT02309554|Experimental|SILCS Diarphragm with ContraGel|Participants will complete a post-coital test cycle with SILCS diaphragm used with ContraGel.
16645826|NCT02309541|Experimental|Firmware N|New feedback canceller algorithm
16645827|NCT02309541|Active Comparator|Firmware R|Current feedback canceller algorithm (reference)
16645828|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
16645829|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
16645830|NCT02309502|Experimental|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms
16645831|NCT02309502|Experimental|Yellow Pascal|Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management:70%
16645832|NCT02309502|No Intervention|Observation|Observation
16645833|NCT02309489|Experimental|Intervention|"Receive standard maternity care
~Woman and partner attend one extra couple counselling session during pregnancy (A)
~Partner attends one group education session for men (B)
~Partner participates in pre-discharge consultation (C)"
16645834|NCT02309489|No Intervention|Control|"Receive standard maternity care
~No active encouragement of partner involvement, no extra sessions offered"
16645835|NCT02309476|Experimental|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
16645836|NCT02309476|Experimental|PASCAL Laser, Green Laser 1 burn|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
16645837|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
16645838|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
16645937|NCT02308696|Experimental|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
16645839|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
16645840|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
16645841|NCT02309450|Experimental|Asunaprevir, Daclatasvir and BMS - 791325|
16645842|NCT02309437|Experimental|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
16645843|NCT02309437|Active Comparator|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
16645844|NCT02309424|Active Comparator|Vinegar|0,50mmol vinegar (6% acetic acid)
16645845|NCT02309424|Placebo Comparator|Placebo|50 ml water
16645846|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
16645847|NCT02309385|Experimental|8% DSP-Visulex|8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
16645848|NCT02309385|Experimental|15% DSP-Visulex|15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
16645849|NCT02309385|Active Comparator|Pred Forte|Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.
16645850|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
16645851|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
16645852|NCT02309359|Placebo Comparator|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
16645853|NCT02309359|Experimental|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
16645854|NCT02309359|Experimental|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
16645855|NCT02309359|Experimental|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
16645856|NCT02309359|Experimental|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
~The last study drug administration was at the Week 22 visit."
16645857|NCT02309346|Experimental|clindamycin once a day|Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day until clinical improvement
16645858|NCT02309346|Active Comparator|clindamycin thrice a day|Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
16645859|NCT02309320|Experimental|ALX-0171|Inhalation of ALX-0171 during 3 consecutive days
16645860|NCT02309320|Placebo Comparator|Placebo|Inhalation of Placebo during 3 consecutive days
16645861|NCT02309307|Experimental|Arm 1 Tissue Repair Device|Tissue Repair Device
16645862|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
16645863|NCT02309281|Other|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
16645864|NCT02309255||coronary heart disease patients|
16645865|NCT02309242|No Intervention|Neuropsychological assessment, MRI|This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.
16645866|NCT02309229||Cystic fibrosis patients|patients with cystic fibrosis
16645867|NCT02309203|Experimental|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
16645868|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
16645869|NCT02309177|Experimental|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
16645870|NCT02309177|Experimental|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
16645871|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
16645872|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
16645873|NCT02309177|Experimental|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
16645874|NCT02309177|Experimental|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
16645876|NCT02309164|Sham Comparator|orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
16645877|NCT02309151|Experimental|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
16645878|NCT02309151|No Intervention|Not immediate coronary angiography|Coronary angiography with possible coronary intervention may be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice.
16645879|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
16645880|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
16645881|NCT02309125|Experimental|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
16645882|NCT02309125|Other|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
16645883|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
16645884|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
16645885|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
16645886|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
16645887|NCT02309086|Experimental|Single arm|Autologous dendritic cells transduced with Ad encoding NS3
16645890|NCT02309060|Experimental|Storytelling Video Intervention (sTVi)|"We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.
~We will add a short, non-narrative, epilogue at the end of each of the 4 episodes that summarizes key messages and provides information on identifying signs of depression and suggestions for efficacious treatments.
~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
16645892|NCT02309034|Experimental|Jump exercise|rebound exercises.
16645893|NCT02309034|Experimental|Aquatic exercise|Hydrogimnastic.
16645894|NCT02309034|Active Comparator|Nutritional guidance|Nutritional counseling classes.
16645895|NCT02309021|Other|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
16645896|NCT02309021|Other|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
16645897|NCT02309008|Placebo Comparator|placebo|vehicle cream, dermal administration, multiple dosing
16645898|NCT02309008|Experimental|drug|PAC-14028 cream, dermal administration, multiple dosing, dose escalation
16645899|NCT02308995|Experimental|Cystectomy using barbed sutures|Endometrioma bed is sutured with barbed sutures
16645900|NCT02308995|Active Comparator|Cystectomy using conventional sutures|Endometrioma bed is sutured with conventional sutures
16645901|NCT02308982|Active Comparator|Intravenous immunoglobulin|Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days
16645902|NCT02308982|Placebo Comparator|Placebo|Equivalent volume to 1g/kg of IVIG per day for 2 consecutive days
16645972|NCT02308527|Experimental|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
16645903|NCT02308969|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
16645904|NCT02308956|Experimental|Integrated mental health in primary care|Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders.
16645905|NCT02308956|Active Comparator|Psychiatric nurse-led specialist care|Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
16645906|NCT02308930|Experimental|Vitamins + DHA supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg algal oil (containing 150mg DHA).
16645907|NCT02308930|Other|Vitamins supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg corn oil (free of omega-3 fatty acids).
16645908|NCT02308904|Other|Laboratory Studies for Pituitary-Gonadal Function|"Females: We expect to enroll approximately 15 females ages 12 years and older.
~Males: We expect to enroll approximately 15 males ages 12 years and older."
16645909|NCT02308904|Other|Data on iron burden and chelation history|"Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.
~Iron burden data
~Assay for non-transferrin bound iron (NTBI)
~Chelation data
~Oxidant stress
~History or presence of hypogonadism"
16645910|NCT02308904|Other|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
16645911|NCT02308891|Experimental|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.
~Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP
~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.
~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
16645912|NCT02308891|Active Comparator|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.
~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
16645913|NCT02308878|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for opioid dependence syndrome.
16645914|NCT02308878|Experimental|Mobile health cognitive stimulation|Cognitive stimulation using mobile technology with m-Health applications.
16645915|NCT02308865|No Intervention|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
16645916|NCT02308865|Experimental|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
16645917|NCT02308852|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the brain areas involved in cognitive aptitudes.
~tDCS will be applied during 20 minutes while patients will perform motor bimanual tasks"
16645918|NCT02308852|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
16645919|NCT02308826|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
16645920|NCT02308826|Active Comparator|Cool Little Kids|A 6-week parent psychoeducation group administered over an 8-week period.
16645921|NCT02308813|Experimental|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
16645922|NCT02308813|Experimental|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
16645923|NCT02308800|Active Comparator|Quantum™ Therapy/NPWT with Prontosan|Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
16645924|NCT02308800|Active Comparator|Quantum™ Therapy|Quantum™ Negative Pressure Wound Therapy without irrigant.
16645925|NCT02308761|Experimental|RO6870810|Participants with RR-AML and HMA-refractory MDS will receive RO6870810, as per schedule described in intervention description.
16645926|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
16645927|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
16645928|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
16645929|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
16645930|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
16645931|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
16645932|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
16645933|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
16645934|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
16645935|NCT02308722|Experimental|5-fraction stereotactic body radiation therapy|See intervention
16645936|NCT02308709|Experimental|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
16753655|NCT01587443||Peritoneal dialysis|
16645938|NCT02308696|Active Comparator|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
16645939|NCT02308683|Experimental|hsCRP, Hgba1c|Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
16645940|NCT02308670||RRMS changing from 20mg to 40mg GA|Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
16645941|NCT02308644|Experimental|Bevacizumab|Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
16645942|NCT02308644|Sham Comparator|Sham|Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
16645943|NCT02308631|Experimental|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
16645944|NCT02308618|Experimental|Traditional Immobilization|45 days of plaster cast immobilization After the immobilization period, subjects received instructions on how to perform a home-based exercise program
16645945|NCT02308618|Experimental|Early mobilization|Six weeks of physical therapy program
16645946|NCT02308618|No Intervention|Control|Subjects had no history of lower limb injury, and were matched in age and anthropometric measurements to subjects that performed physical rehabilitation and to subjects that remained immobilized.
16645947|NCT02308605||Suspected stroke patients and subset|"Blood samples taken on admission and at 24 hours, MRI scan between 24 and 48 hours
~Subset: Blood samples repeated once per hour for six hours"
16645948|NCT02308605||Control participants (relatives)|To donate blood on two occasions, 24 hours apart, to draw comparison with stroke patients
16645949|NCT02308605||Feeding control participants|To donate a baseline blood sample, eat a simple purine rich meal (meat sandwich), then donate 4 more blood samples at 10, 30, 60 and 120 minutes following the meal
16645950|NCT02308592|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
16645951|NCT02308592|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
16645952|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
16645953|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
16645954|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
16645955|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
16645956|NCT02308566|Active Comparator|Conventional Extracorporeal Circulation Technique|Conventional Extracorporeal Circulation Technique
16645957|NCT02308566|Experimental|Minimized Extracorporeal Circulation Technique|Minimized Extracorporeal Circulation Technique
16645958|NCT02308553|Experimental|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
16645959|NCT02308553|Placebo Comparator|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
16645960|NCT02308540|Experimental|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
16645961|NCT02308540|Active Comparator|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
16645962|NCT02308540|Experimental|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
16645963|NCT02308540|Active Comparator|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
16645964|NCT02308540|Experimental|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
16645965|NCT02308540|Active Comparator|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
16645966|NCT02308540|Experimental|Infant Booster Dose SIILPCV 10|One dose of SIILPCV 10 at 9 months of age
16645967|NCT02308540|Active Comparator|Infant Booster Dose Prevenar 13|One dose of SIILPCV 10 at 9 months of age
16645968|NCT02308527|Active Comparator|Temozolomide|Temozolomide Days 1-5 every 4 weeks
16645969|NCT02308527|Experimental|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
16645970|NCT02308527|Experimental|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
16645971|NCT02308527|Experimental|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
16645973|NCT02308527|Experimental|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
16645974|NCT02308527|Experimental|Dinutuximab beta + Temozolomide|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
16645975|NCT02308527|Experimental|Dinutuximab beta + Temozolomide + Topotecan|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
16645976|NCT02308527|Other|Dinutuximab beta + Topotecan + Cyclophosphamide|Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
16645977|NCT02308514|Active Comparator|conservative care|this group of patients will receive the conservative care: myofascial point release and radial head mobilisation
16645978|NCT02308514|Experimental|cryostimulation|this group of patients will receive the conservative care :myofascial point release and radial haed mobilisation and the cryostimulation (30-40 second of cold air application (-70 celsius degree) in order to lower skin temperature around the lateral epicondyle at 4 celsius degree.
16645979|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
16645980|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
16645981|NCT02308488|Other|Radiation|The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks. Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions
16645982|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
16645983|NCT02308462|Experimental|CHIMPs intervention|Family-Intervention
16645984|NCT02308462|No Intervention|Control|"The long-term effectiveness of the CHIMPs intervention under conditions of practice will be examined in comparison to a control condition receiving the usual after care (Treatment as usual = TAU); this testing of effectiveness will be performed in due consideration of the health economic aspects.
~The treatment as usual implies that families of the control Group receive the Treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every Family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system."
16645985|NCT02308449|Placebo Comparator|Iron-deficient, given placebo|Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit
16645986|NCT02308449|Active Comparator|Iron-deficient, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
16645987|NCT02308449|Placebo Comparator|Iron-replete, given placebo|Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit
16645988|NCT02308449|Active Comparator|Iron-replete, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
16645989|NCT02308436|Experimental|Candida Mouthwash with Curolox™ Peptide|Repeated applications 2.5 ml or 5 ml twice daily
16645990|NCT02308410||Tourniquet group|This group received a pneumatic tourniquet during total knee arthroplasty.
16645991|NCT02308410||Non-tourniquet group|This group received no tourniquet during total knee arthroplasty.
16645992|NCT02308397|Experimental|Group 1|Begins with Normal gluten containing bread
16645993|NCT02308397|Experimental|Group 2|Begins with Bread with reduced gliadins content
16645994|NCT02308397|Experimental|Group 3|Begins with Bread with reduced ATIs content
16645995|NCT02308397|Experimental|Group 4|Begins with Bread with reduced overall protein content
16645996|NCT02308384|No Intervention|Before intervention|GPs in this group have not yet received intervention.
16645997|NCT02308384|Experimental|After intervention|GPs in this group have received the intervention.
16645998|NCT02308371|Experimental|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV> 13 (in addition to standard clinical data) until PPV < 13.
16645999|NCT02308371|No Intervention|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
16646000|NCT02308358||Allograft Transplantation|Subjects with femoral condyle osteochondral defects ≥10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for allograft transplantation.
16646001|NCT02308358||Microfracture Treatment|Subjects with femoral condyle osteochondral defects <10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for microfracture treatment.
16646002|NCT02308345|Experimental|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
16646003|NCT02308332|Active Comparator|Intervention|patients switching from Atripla to Eviplera
16646004|NCT02308332|No Intervention|Control|patients remaining on Atripla
16646005|NCT02308319|Active Comparator|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
16646006|NCT02308319|Other|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present [defined as HBV DNA >2,000 IU/ml and abnormal ALT (>40 IU/ml)]
16646007|NCT02308306||Opioid analgesics|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
16646008|NCT02308293|Experimental|High intensity exercise|Subjects will preform a high intensity training exercise (3* 30 seconds all out sprint on a cycle ergometer) to raise plasma lactate levels
16646009|NCT02308293|Sham Comparator|Lay down comfortably|As a control conditions, subjects wil lay down comfortably and rest
16763032|NCT01523808|Experimental|GRASPA 25|
16646010|NCT02308280|Experimental|Bortezomib post-transplantation|"Non myeloablative allogeneic transplantation followed by Bortezomib for 1 year after a Bortezomib-based induction and autologous stem cell transplantation.
~Bortezomib: 1,3 mg/m2 subcutaneously every 2 weeks for 26 injections."
16646011|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
16646012|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
16646013|NCT02308254|Active Comparator|Lixisenatide|Lixisenatide: 10 mcg, one subcutaneous injection dose
16646014|NCT02308254|Placebo Comparator|Placebo|Matching placebo: one subcutaneous injection dose
16646015|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
16646016|NCT02308228|Experimental|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
16646017|NCT02308228|Placebo Comparator|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
16646018|NCT02308202|Active Comparator|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
16646019|NCT02308202|Active Comparator|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
16646020|NCT02308202|Placebo Comparator|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
16646021|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
16646022|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
16646023|NCT02308176|Experimental|intervention group|health advice and app installation in patient's mobile
16646024|NCT02308176|Placebo Comparator|control group|health advice
16646025|NCT02308163|Placebo Comparator|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
16646026|NCT02308163|Experimental|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
16646027|NCT02308163|Experimental|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
16646028|NCT02308163|Active Comparator|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
16646029|NCT02308137|Experimental|Domperidone|Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year
16646033|NCT02308111|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and Child Pugh Score).
16646034|NCT02308111|Placebo Comparator|Placebo|
16646035|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
16646036|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
16646037|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
16646038|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh
16646039|NCT02308085|Experimental|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
16646040|NCT02308072|Experimental|Olaparib + Cisplatin + IMRT|"Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5
~Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment."
16646041|NCT02308059||Patients with diabetes mellitus|Group I; the patients with diabetes mellitus who had peripheral neuropathy as diagnosed.
16646042|NCT02308059||Control|Group II; healthy volunteers
16646043|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
16646044|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
16646045|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
16646046|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
16646075|NCT02307864|Experimental|Treatment Sequence 4|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
16646076|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
16646047|NCT02308020|Experimental|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16646048|NCT02308020|Experimental|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).
~Participants may continue to receive treatment until discontinuation criteria are met."
16646049|NCT02308020|Experimental|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16646050|NCT02308020|Experimental|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16646051|NCT02308020|Experimental|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16646052|NCT02308020|Experimental|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16646053|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
16646054|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
16646055|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
16646056|NCT02307994|Experimental|75IU uFSH|75IU uFSH (Livzon Pharm Group Inc., China) being injected into severe oligospermia patients or azoospermia patients every 3 days for 6 months
16646057|NCT02307981||Visual field defect with vision teacher|Patients With occipital ischemic stroke and Visual Field defect that live in a geographical region where training With vision teacher is an available service (vision Teachers are a Limited Resource in Norway)
16646058|NCT02307981||Visual field defect without vision teacher|Patients With occipital ischemic stroke and a Visual Field defect, who live in a geographical area where training With vision teacher is not an available service.
16646059|NCT02307968||inner thigh insulin injection|inject insulin at inner thigh site is the intervention arm. So we inject insulin at this site to see if this site is suitable for insulin injection.
16646060|NCT02307968||outer thigh insulin injection|outer thigh site for insulin therapy is the usual site
16646061|NCT02307955|Experimental|firefly|participants treated with firefly device
16646062|NCT02307955|Other|Control|Standard of care
16646065|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
16646066|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
16646067|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
16646068|NCT02307903||End-stage renal failure (ESRF)|end-stage renal failure (ESRF)
16646069|NCT02307890||Liver transplantation group|Participants will include all deceased adult liver transplant donors (>16 years of age) whose livers are being utilised for transplantation in the Scottish Liver Transplant Unit in the Royal Infirmary of Edinburgh. Exclusion criteria will include paediatric liver transplant donors (<16 years of age).
16646070|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
16646071|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
16646072|NCT02307864|Experimental|Treatment Sequence 1|Participants will receive treatment A (2*50 milligram [mg] tramadol hydrochloride [HCl] immediate release [IR] tablet + 1 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 2*50 mg tramadol HCl IR tablet + 1 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); treatment B (3*50 mg tramadol HCl IR tablet every 6 hours on Days 1, 2, and 3, along with single dose of 3*50 mg tramadol HCl IR tablet + 1 moxifloxacin placebo on Day 4); treatment C (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); and treatment D (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4) in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
16646073|NCT02307864|Experimental|Treatment Sequence 2|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
16646074|NCT02307864|Experimental|Treatment Sequence 3|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
16646077|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
16646210|NCT02306876|Placebo Comparator|Placebo|Placebo BID
16646078|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
16646079|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
16646080|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
16646081|NCT02307825|Active Comparator|Azithromycin|Patients will receive the active study drug, azithromycin, as well as sinus irrigations with budesonide.
16646082|NCT02307825|Placebo Comparator|Placebo|Patients will receive a placebo as well as sinus irrigations with budesonide.
16646083|NCT02307786||Beta-Thalassemiall -Transplantation|
16646084|NCT02307786||Beta-Thalassemia Supportive Care|
16646085|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
16646086|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
16646087|NCT02307760|Active Comparator|Study Human Milk Fortifier A|Acidified processing method.
16646088|NCT02307760|Experimental|Study Human Milk Fortifier B|Non-acidified processing method.
16646089|NCT02307747|Experimental|trauma patients|Blood samples will be collected every 4 hours during 24 h, between day 2 and day 4 after inclusion
16646090|NCT02307734|Experimental|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately.
16646091|NCT02307734|Active Comparator|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
16646092|NCT02307721|Experimental|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
16646093|NCT02307721|Active Comparator|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
16646094|NCT02307708|Experimental|8° incline shoe|"The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.
~During the walk we will have:
~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).
~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
16646095|NCT02307708|Active Comparator|kinesitherapy|The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish
16646096|NCT02307695|Experimental|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
16646097|NCT02307695|Active Comparator|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
16646098|NCT02307682|Experimental|Brolucizumab 3 mg|Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
16646099|NCT02307682|Experimental|Brolucizumab 6 mg|Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
16646100|NCT02307682|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
16646101|NCT02307669|Placebo Comparator|Routine inhaler adherence care|"Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.
~The core features of the usual care group are:
~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.
~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.
~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.
~In follow up, medication changes in response to the above will be directed by these, as suggested by GINA management guidelines using a standardised digital script."
16646102|NCT02307669|Active Comparator|INCA feedback|"The patient's treatment goal is established and used as the focus of the conversation.
~Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.
~Data from the electronic PEF and AQLQ are correlated with digitally recorded adherence so that these can be used to account for improvements or declines in these measures.
~In follow up, medication changes in response to the above (adherence, PEF, ACT and exacerbations) are made using a standardised digital script."
16646103|NCT02307656|Other|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)
~Stage 2:Taste Optimization using API (flavours and sweeteners)
~Stage 3:Prototypes of the API - containing clinical trial materials"
16646104|NCT02307643|Experimental|Part 1|MT-1303 Low dose+Corticosteroid
16646105|NCT02307643|Experimental|Part 2-A|MT-1303 High dose+Corticosteroid
16646106|NCT02307643|Experimental|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
16646107|NCT02307630|Experimental|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
16763033|NCT01523808|Experimental|GRASPA 50|
16646108|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
16646109|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
16646110|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
16646111|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
16646112|NCT02307604||Brain cancer|Patients with diagnosis of brain cancer at any stage
16646113|NCT02307591|Active Comparator|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
16646114|NCT02307591|Experimental|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .
~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).
~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.
~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.
~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).
~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:
~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)
~Children < 29 kg: 5 mg/kg 3 times a day"
16646115|NCT02307565|Experimental|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
16646116|NCT02307565|Placebo Comparator|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
16646117|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
16646118|NCT02307539|Experimental|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
16646119|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
16646120|NCT02307513|Experimental|Placebo / Apremilast|Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
16646121|NCT02307513|Experimental|Apremilast|Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
16646122|NCT02307500|Experimental|Regorafenib|Regorafenib 160 mg (40 mg tablets), po, every day for 3 weeks of every 4 week cycle
16646123|NCT02307487|Experimental|Cohort A2|120 mg MMC in 90ml gel
16646124|NCT02307487|Experimental|Cohort B2|140 mg MMC in 90ml gel
16646125|NCT02307487|Experimental|Cohort C2|160 mg MMC in 90ml gel
16646126|NCT02307487|Experimental|Cohort A|120 mg MMC in 60ml gel
16646127|NCT02307487|Experimental|Cohort B|140 mg MMC in 60ml gel
16646128|NCT02307487|Experimental|Cohort C|160 mg MMC in 60ml gel
16646129|NCT02307474|Experimental|Treatment (Stereotactic Radiosurgery, pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO daily for up to 60 days. Patients then continue to receive pazopanib hydrochloride PO daily and undergo stereotactic radiosurgery (SBRT) every other day over days 60-65.
16646130|NCT02307461|Experimental|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
16646131|NCT02307461|Experimental|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
16646132|NCT02307461|Experimental|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
16646133|NCT02307448|Active Comparator|PRP Group|Patients will receive weekly PRP treatments
16646134|NCT02307448|Placebo Comparator|Standard of Care|Patients will receive weekly standard of care.
16646135|NCT02307435|Experimental|implantation group|implantation group will receive MSC and HA-CaSo4
16646136|NCT02307422||Case|Diabetic patients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
16646211|NCT02306876|Experimental|PF-06412562 15mg|PF-06412562 15mg BID
16646137|NCT02307422||Control|Non-diabeticpatients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
16646138|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
16646139|NCT02307409||Healthy Controls|Healthy Controls will be enrol
16646140|NCT02307396|Experimental|Intervention|"Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (gradual discontinuation, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life."
16646141|NCT02307396|Active Comparator|Control|The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
16646142|NCT02307383|Experimental|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.
~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
16646143|NCT02307370|Experimental|Turbo-Elite Atherectomy|
16646144|NCT02307357|Experimental|newcomball players|active newcomball women players will perform physical fitness tests
16646145|NCT02307357|Experimental|control|not physically active women will perform physical fitness tests
16646146|NCT02307344|Active Comparator|Nigella Sativa Supplement|Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
16646147|NCT02307344|Active Comparator|Patients receiving a placebo tablet|Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
16646148|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
16646149|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
16646150|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
16646151|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
16646152|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
16646153|NCT02307305|Experimental|Duloxetin group|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)
~Phase II (titration): POD#1~6 (30mg for another 6 days)
~Phase III (maintenance): POD#7~13(60mg for 7 days)
~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)
~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)
~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
16646154|NCT02307305|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
16646155|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
16646156|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
16646157|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
16646158|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
16646159|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
16646160|NCT02307253|Experimental|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
16646161|NCT02307240|Experimental|CUDC-907 - five days on/two days off|60 mg/day CUDC-907, oral administration, five days on/two days off until disease progression or other discontinuation criteria are met.
16646162|NCT02307227|Experimental|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):
~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
16646163|NCT02307227|Experimental|Locally advanced HER2- breast cancer pts|"HER2 negative:
~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
16646164|NCT02307214|Other|Coronary X syndrome|BaroReflex Sensitivity, endothelial function measurement
16646165|NCT02307214|Other|Tako-tsubo cardiomyopathy|BaroReflex Sensitivity, endothelial function measurement
16646166|NCT02307214|Other|Healty Volunteers|BaroReflex Sensitivity, endothelial function measurement
16646167|NCT02307201|Experimental|Postpartum Magnesium sulfate|The patient will receive magnesium sulfate as usual for 24 hours postpartum
16646168|NCT02307201|No Intervention|No postpartum treatment|The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum
16646169|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
16647082|NCT02300844|Placebo Comparator|Placebo|
16646170|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
16646171|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
16646172|NCT02307162|Placebo Comparator|Dummy solution|Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)
16646173|NCT02307162|Experimental|RPL554 suspension|"Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C).
~Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B"
16646174|NCT02307149|Experimental|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
16646175|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
16646176|NCT02307110|Other|1 arm study|cross-sectional observation
16646177|NCT02307097|Experimental|CBB|
16646178|NCT02307097|Experimental|CBT|
16646179|NCT02307097|Active Comparator|WAIT|
16646180|NCT02307084|Experimental|Pre-operative ultrasound imaging|Subjects that are randomly allocated to this group will have ultrasound imaging assessment of the long saphenous vein in both legs. This will allow assessment of the suitability of the long saphenous vein and marking of the distribution prior to heart bypass surgery to allow targeted harvesting of a bypass conduit.
16646181|NCT02307084|No Intervention|Current protocol|This group will not undergo pre-operative ultrasound imaging of the long saphenous vein in accordance with current Trust protocols.
16646182|NCT02307071|Experimental|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
16646183|NCT02307058|Experimental|LEAD RT Group|Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
16646184|NCT02307058|Experimental|HEIGHT RT Group|Participants in this group will receive the Hypofractionated Extended Image-Guided Highly Targeted (HEIGHT) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 7 and a half weeks.
16646185|NCT02307045|Active Comparator|varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
16646186|NCT02307045|Active Comparator|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
16646187|NCT02307019|Experimental|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
16646188|NCT02307019|Active Comparator|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
16646189|NCT02307006|Experimental|Ceftaroline|Experimental comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
16646190|NCT02307006|Active Comparator|Cefazolin / Vancomycin|Standard of care comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
16646191|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
16646192|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
16646193|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
16646194|NCT02306980|Experimental|Colostrum|Colostrum administration
16646195|NCT02306980|No Intervention|Control|Routine care
16646196|NCT02306967|Active Comparator|Standard Resection|Oral resection will be guided by usual practice. This involves identifying the tumour with white light and then marking surgical margins and resection the primary cancer.
16646197|NCT02306967|Experimental|FV Guided Resection|The oral resection will be guided by fluorescent visualization (FV).
16646198|NCT02306954|Active Comparator|High Dose IL-2|"Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
~Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2."
16646199|NCT02306954|Experimental|High Dose IL-2 and SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
16646200|NCT02306941|Experimental|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
16646201|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
16646202|NCT02306915|Experimental|lipegfilgrastim 30|
16646203|NCT02306915|Experimental|lipegfilgrastim 60|
16646204|NCT02306915|Experimental|lipegfilgrastim 100|
16646205|NCT02306902|Experimental|Test|Fenofibrate Capsules, USP 130 mg
16646206|NCT02306902|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
16646207|NCT02306889|Experimental|Test|Fenofibrate Capsules, USP 130 mg
16646212|NCT02306863|Experimental|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
16646213|NCT02306863|Sham Comparator|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
16646214|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
16646215|NCT02306837|Experimental|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
16646216|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
16646217|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
16646218|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
16646219|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
16646220|NCT02306798|Experimental|Formulation D|TP05
16646221|NCT02306785|Experimental|Formulation D|TP05 Coating D
16646222|NCT02306785|Experimental|Formulation E|TP05 Coating E
16646223|NCT02306785|Experimental|Formulation H|TP05 Coating H
16646224|NCT02306772|Experimental|Formulation A|TP05 Coating A
16646225|NCT02306772|Experimental|Formulation B|TP05 Coating B
16646226|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
16646227|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
16646228|NCT02306746|Experimental|TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
16646229|NCT02306746|Active Comparator|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
16646230|NCT02306733|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv)
16646231|NCT02306733|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon® Novartis, Switzerland) slowly intravenous.
16646232|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
16646233|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
16646234|NCT02306681||SAQ-Self-Assessment Questionnaire|
16646235|NCT02306668||Ocular surface discomfort|There are no interventions with this observational study
16646236|NCT02306642||Premature Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have experienced acute kidney injury based on the modified KDIGO guidelines for acute kidney injury.
16646237|NCT02306642||Premature No Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have not experienced acute kidney injury in the NICU.
16646238|NCT02306642||Term No Acute Kidney Injury|This group of babies born at term will have not experienced any acute kidney injury.
16646239|NCT02306629|Experimental|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
16646240|NCT02306629|Experimental|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
16646241|NCT02306629|Experimental|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
16646242|NCT02306629|Active Comparator|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
16646243|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
16646244|NCT02306590|Experimental|Study Intervention|High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day
16646245|NCT02306590|Placebo Comparator|Placebo|Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care
16646246|NCT02306577||Vancouver|HIV infected people who are current of recent illicit drug users and receive Stribild for their HIV treatment at Vancouver Infectious Diseases Centre and Regina General Hospital.
16646247|NCT02306564|Experimental|Group A|Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
16646248|NCT02306564|No Intervention|Group B|Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
16646249|NCT02306564|No Intervention|Group C|Group C will serve as a control group and will include age & BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
16646250|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
16646251|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
16646252|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
16646253|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
16646254|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
16646255|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
16646256|NCT02306512|Active Comparator|Standard vs. IF MART-1|"Samples removed with MMS within the first 3 mm margin from the tumor will be the first section. They will be processed as a conventional H&E frozen section and section stained with IHC MART-1. Samples removed with MMS within 3-6 mm from tumor margin will be the second section. They will be processed with fluorescent MART-1 antibodies. Based on the pre-defined characteristics MMS surgeon will evaluate each MART-1 immunofluorescent section as no evident melanoma or possible melanoma or present melanoma. Dermatopathologist will secondarily review each section scoring them in the same manner. If standard H&E, IHC, or immunofluorescence is recorded as present melanoma or possible melanoma a third section from 6-9mm will have the same procedure described before."
16646257|NCT02306512|Active Comparator|IF MART-1 versus IF cocktail|In the second arm of the study, assuming that immunofluorescence with MART-1 proves to be superior or at least equivocal to regular MART-1 IHC, the same method will be applied, but the control sections will be stained with fluorescent MART-1 antibodies and compared to a section stained with a cocktail of fluorescent melanocytic antibodies.
16646258|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH VARICOCELE|ICSI cases using cryopreserved testicular sperm from infertile azoospermic men, with proven diagnosis of varicocele (clinical & sonographic), which will be used for ICSI in an ART program
16646259|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH NO VARICOCELE|ICSI cases using cryopreserved testicular sperms from infertile azoospermic men due to etiologies other than varicocele
16646260|NCT02306486|Placebo Comparator|z250 resin composite|(n=31) Treated with distilled water (placebo) and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
16646261|NCT02306486|Active Comparator|z250 resin composite + oxalic acid|(n=31) treated with 0.5% oxalic acid (Desenssiv, SSWhite)(intervention)// and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
16646262|NCT02306486|Placebo Comparator|p 90 resin composite|(n=31) Treated with distilled water (placebo) and restored with a silorane resin-based-composite.
16646263|NCT02306486|Active Comparator|p 90 resin composite + oxalic acid|(n=31) treated with 0,5% oxalic acid (Desenssiv SSWhite)(Intervention)/ and restored with a silorane resin-based-composite (Filtek Silorane p90, £M ESPE, shade:)
16646264|NCT02306473|Experimental|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
16646265|NCT02306473|Experimental|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
16646266|NCT02306460||left atrial catheter ablation|
16646267|NCT02306460||left atrial appendix closure|
16646268|NCT02306460||paroxysmal atrial fibrillation control group|
16646269|NCT02306460||persistent atrial fibrillation control group|
16646270|NCT02306447|Experimental|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.
~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.
~For stimulation we use MagPro X100 (Medtronic, Denmark)."
16646271|NCT02306434|Active Comparator|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
16646272|NCT02306434|Other|Standard care-Counselling|Counselling for childbirth fear is given by the antenatal care midwife and by specially trained midwives working in collaboration with obstetricians at approximately 3-5 face to face counselling sessions. Often a visit to the delivery unit is included in the program and a care plan for the coming birth.
16646273|NCT02306421|Active Comparator|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
16646274|NCT02306421|Active Comparator|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
16646275|NCT02306421|Active Comparator|R P H|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
16646276|NCT02306421|Active Comparator|P P H|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids-PPH.In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
16646277|NCT02306421|Active Comparator|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
16648082|NCT02293889|Placebo Comparator|Placebo|Placebo capsule: edible oil
16646278|NCT02306395|Experimental|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
16646279|NCT02306395|No Intervention|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
16646280|NCT02306382|Experimental|ultrasonography, abscess|The experimental group will be treated after examination with 3D ultrasonography. Follow up after two months and one year.
16646281|NCT02306382|Other|Control group with clincial inscision|The control group will have drainage of their perianal abscess in the OR without ultrasound. Follow-up after two months and one year.
16646282|NCT02306369|No Intervention|Treatment as usual|A wait-list control.
16646283|NCT02306369|Experimental|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
16646284|NCT02306356|Experimental|Interventional|Behavioral: Internet-delivered Cognitive Behavior Therapy
16646285|NCT02306343|Experimental|Test (with the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, the InsuPad device was placed on the abdomen of the subject. The InsuPad device was activated and insulin bolus (0.2 units/kg body weight) was injected right before study start. The injection was given to the subject's abdomen through the injection window of the InsuPad device. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.
~In the daily life setting - Up to 12 months with the device (test). Subjects were asked to perform at least 3 blood glucose measurements during the day."
16646286|NCT02306343|No Intervention|Control (without the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, insulin bolus (0.2 units/kg body weight) was injected to the abdomen right before study start. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.
~In the daily life setting - Up to 12 months without the device (control). Subjects were asked to perform at least 3 blood glucose measurements during the day."
16646287|NCT02306330|Experimental|Malditof|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
16646288|NCT02306330|Active Comparator|Routine clinical microbiology|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
16646289|NCT02306317|Active Comparator|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
16646290|NCT02306317|Experimental|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
16646291|NCT02306304|Other|Israeli Arab men|Single arm study. The arm includes all enrolled patients screened by duplex ultra sound for abdominal aortic aneurysms.
16646292|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
16646293|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
16646294|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
16646295|NCT02306278|Placebo Comparator|vitamin capsules|vitamin capsules orally at the night before operation and 2 hours before surgery,respectively
16646296|NCT02306278|Experimental|gabapentin|gabapentin 600mg orally at the night before operation and 2 hours before surgery,respectively
16646297|NCT02306265|Other|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
16646298|NCT02306252|Experimental|CARE Intervention|This group will be contacted to make an appointment for outpatient Occupational and Physical therapy. The therapist will determine the type, frequency and length of treatment. Follow up phone calls will be made to ensure appointments are made, kept and rescheduled as needed.
16646299|NCT02306252|No Intervention|CARE Control|Patients randomized to this arm will receive contact information and a brochure outlining the services available within the supportive care program. The study coordinator will provide the information based on their results and assist the patient with contacting the program if desired.
16646300|NCT02306239|Active Comparator|norepinephrine|patients received norepinephrine
16646301|NCT02306239|Experimental|terlipressin|patients received terlipressin
16646302|NCT02306213|Experimental|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
16646303|NCT02306213|Active Comparator|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
16646304|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
16646305|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
16646306|NCT02306187|Experimental|Non-Alfacaocidol|Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
16646307|NCT02306187|Experimental|Alfacalcidol|Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
16646401|NCT02305550|Experimental|electrical synthesis nitric oxide|Participants will breath 20 minutes of electrical pulsed plasma discharge synthesis of nitric oxide at 25 parts per million
16646402|NCT02305537|Experimental|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
16646308|NCT02306174|Experimental|Cognitive Rehabilitation and Exposure-based Class for Compulsi|"Cognitive training is to improve thinking by learning new skills and strategies. The class begins with cognitive training to increase ability to carry out the skills learned later in treatment.
~Exposure therapy for discarding and acquiring helps to improve ability to make choices about possessions and learn to tolerate anxiety. Participants will face making difficult choices about items and potentially letting them go. Through repeated exposure to decisions about discarding and acquiring, distress about letting go or making choices about items will decrease over time."
16646311|NCT02306148|Placebo Comparator|Control Group|Group will practice 15 seconds isometric lower limb stretching protocol and must continue practicing running as usual.
16646312|NCT02306148|Experimental|Foot and ankle strengthening|Group will be trained during 2 months by a physiotherapist for foot and ankle strengthening and must continue to exercise at home with a training software supervision. Must continue practicing running as usual.
16646313|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
16646314|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
16646315|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
16646316|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
16646317|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
16646318|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
16646319|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
16646320|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
16646321|NCT02306122|Experimental|Default patient default doctor status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
16646322|NCT02306122|Experimental|Information patient default doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
16646323|NCT02306122|Experimental|Choice patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
16646324|NCT02306122|Experimental|Information patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
16646325|NCT02306122|Experimental|Information patient info doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
16646326|NCT02306109|Active Comparator|Standard motor rehabilitation treatment|
16646327|NCT02306109|Experimental|Intensive motor rehabilitation treatment|
16646328|NCT02306083|Placebo Comparator|Administration of the Placebo|Placebo three times a day.
16646329|NCT02306083|Placebo Comparator|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
16646330|NCT02306070|Experimental|Metformin + lifestyle modification|Metformin + lifestyle modification pre, during and post HCV antiviral therapy
16646331|NCT02306070|Placebo Comparator|No Metformin + Lifestyle modification|No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
16646332|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
16646333|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
16646334|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
16646335|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
16646336|NCT02306031|Placebo Comparator|placebo (ARTIFICIAL TEAR)|control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations.
16646337|NCT02306031|Active Comparator|diclofenac sodium drop|case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.. Theses drops continued up to 6 weeks with the same dose after operations.
16646338|NCT02306018||EV1000™/volumeView™|
16646339|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
16646340|NCT02305992|Experimental|Axillary Block with 0.5% Ropivicaine|Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
16646341|NCT02305992|Experimental|Stellate Ganglion Block with 0.2% Ropivicaine|Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
16646342|NCT02305992|Active Comparator|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
16646343|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
16646344|NCT02305966|Active Comparator|pressfit humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is -pressfit humerus & non-lateralized glenoid.
16646345|NCT02305966|Active Comparator|pressfit humerus & lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is - pressfit humerus & lateralized glenoid.
16646346|NCT02305966|Active Comparator|cemented humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component. Therefore, 4 randomization groups will be created and one of them is cemented humerus & non-lateralized glenoid
16646347|NCT02305966|Active Comparator|cemented humerus & lateralized glenoid.|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is cemented humerus & lateralized glenoid.
16646348|NCT02305953||Frozen serum|The cohort consists of original subjects from the Inno-6025 Trial who previously consented to measuring protein in the blood involved in skin inflammation.
16646349|NCT02305940|Active Comparator|Doxycycline|Doxycycline: oral dose of 100 mg once daily, for a total duration of 52 weeks.
16646350|NCT02305940|Placebo Comparator|Placebo|Placebo: an oral dose of one capsule once daily, for a total duration of 52 weeks.
16646351|NCT02305927|Experimental|Vitamin D3 (cholecalciferol)|
16646352|NCT02305927|Placebo Comparator|Placebo|
16646353|NCT02305914||follow-up visit|Patients who come for follow-up visit will fill in the questionnaire and undergo regular laboratory examination such as liver function test and CRP,faecal elastase-1 as well as CT scanning.Additionally,blood sample of every patient will be collected and sent to the Lab for storage and further experimented.
16646354|NCT02305901|Experimental|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
16646355|NCT02305888|Experimental|LEO 43204, 0.018% once daily for 3 days|
16646356|NCT02305888|Experimental|LEO 43204, 0.037% once daily for 3 days|
16646357|NCT02305888|Experimental|LEO 43204, 0.1% once daily for 3 days|
16646358|NCT02305875|Experimental|MCN scoring|Scoring of the mcn nerve's position in the axillary sheat using MRI
16646359|NCT02305862|Experimental|low dose group (5mg)|low dose Rosuvastatin
16646360|NCT02305862|Experimental|high dose group (20mg)|high dose Rosuvastatin
16646361|NCT02305849|Experimental|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
16646362|NCT02305849|Experimental|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
16646363|NCT02305849|Placebo Comparator|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
16646364|NCT02305836|Experimental|Electroacupuncture combined with donepezil|Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
16646365|NCT02305836|Active Comparator|donepezil|Donepezil will be given once daily before bed-time for the first 4-6 weeks. Based on the treatment effect, the dosage may be increased to 10 mg once daily before bed-time for the next 6-8 weeks. Donepezil will be taken for continuous 24 weeks. The full course of treatment is 36 weeks.
16646366|NCT02305823|Active Comparator|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
16646367|NCT02305823|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
16646368|NCT02305823|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
16646369|NCT02305810|Experimental|Single arm receiving everolimus|single treatment arm receiving everolimus 10 mg daily
16646370|NCT02305797|Experimental|EDG004|EDG004 - Extended release lorazepam capsules
16646371|NCT02305797|Placebo Comparator|Placebo|Placebo
16646372|NCT02305771|Other|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Electroencephalography
~MRI"
16646373|NCT02305758|Experimental|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
16646374|NCT02305758|Placebo Comparator|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
16646375|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
16646376|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
16646377|NCT02305719||Epidural anesthesia|Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
16646378|NCT02305719||Serratus-anterior-plane-Block|"Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery.
~Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered."
16646379|NCT02305719||Local infiltration|Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
16646380|NCT02305706|Experimental|Right|patients will be positioned on the right-lateral position at the start of colonoscopy
16646381|NCT02305706|Active Comparator|Left|patients will be positioned on the left-lateral position at the start of colonoscopy
16646382|NCT02305693|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
16646383|NCT02305693|Active Comparator|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
16646384|NCT02305667|Placebo Comparator|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
16646385|NCT02305667|Active Comparator|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
16646386|NCT02305667|Active Comparator|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
16646387|NCT02305667|Active Comparator|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
16646388|NCT02305654|Active Comparator|Arm A - Standard Surgery (ILND)|"Part of randomisation 1.
~The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery."
16646389|NCT02305654|Experimental|Arm B - neoadjuvant chemotherapy|"Part of randomisation 1.
~Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).
~Administration on an outpatient basis:
~Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5
~Administration on an inpatient basis:
~Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3"
16646390|NCT02305654|Experimental|Arm C - neoadjuvant chemoradiotherapy|"Part of randomisation 1.
~Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.
~Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min."
16646391|NCT02305654|Experimental|Arm P - prophylactic PLND|"Part of randomisation 2.
~Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.
~Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:
~Cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.
~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour
~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:
~Any macroscopic tumour or pathological lymph nodes
~Electively to external iliac nodes in patient with high disease burden
~Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone."
16646392|NCT02305654|No Intervention|Arm Q - Surveillance no prophylactic PLND|"no prophylactic PLND Part of randomisation 2.
~For patients who have NOT received neoadjuvant chemoradiotherapy:
~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour
~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:
~Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden"
16646394|NCT02305628||Cohort|Method of continuous surveillance per standard of care
16646395|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
16646396|NCT02305602|Experimental|Post Myocardial Infarction|VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
16646397|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
16646398|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
16646399|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
16646400|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
16646852|NCT02302430|Placebo Comparator|Placebo|Placebo group will receive a saline nasal spray
16646403|NCT02305537|No Intervention|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
16646404|NCT02305524|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16646405|NCT02305524|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
16646406|NCT02305511|Experimental|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
16646407|NCT02305511|Experimental|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
16646408|NCT02305498|Experimental|Vigorous yoga practice|Supervised vigorous yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
16646409|NCT02305498|Active Comparator|Restorative (gentle) yoga practice|Supervised restorative (gentle) yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
16646410|NCT02305485|Experimental|NeoVas|"The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA- based polymer scaffold and contains the antiproliferative drug sirolimus.
~Intervention: Device: NeoVas BCS"
16646411|NCT02305485|Active Comparator|XIENCE PRIME|XIENCE PRIME Everolimus Eluting Coronary Stent System is a balloon expandable metallic platform stent manufactured from a flexible cobalt chromium alloy with a multicellular design and coated with a thin nonadhesive, durable, biocompatible acrylic, and fluorinated everolimus-releasing copolymer. Intervention: Device: XIENCE PRIME EECSS
16646412|NCT02305472|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
16646413|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.
~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with the Hepatocellular carcinoma (HCC) Module to measure changes in the quality of life of the patient."
16646414|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
16646415|NCT02305433|Experimental|Physiotherapy (physical exercise) for frail elderly|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
16646416|NCT02305433|Experimental|Physiotherapy (physical exercise) for operated hip fracture|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
16646417|NCT02305433|No Intervention|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
16646418|NCT02305433|No Intervention|Usual care for operated hip fracture|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
16646419|NCT02305420|Experimental|EmbryoGen/BlastGen|"EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm
~The intervention is to use EmbryoGen/BlastGen"
16646420|NCT02305420|Active Comparator|Control|Standard Cook sequential media
16646421|NCT02305407|Experimental|surgical revascularization|Patients will be assigned to either surgical or conservative treatment depending on their clinical symptoms and radiological assessment.
16646422|NCT02305407|Experimental|conservative treatment|Normal conservative treatment without surgical intervention.
16646423|NCT02305394|Experimental|PK group (ketamine and propofol)|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
16646424|NCT02305394|Active Comparator|P group (propofol group)|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
16646425|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
16646426|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
16646427|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
16646428|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
16646429|NCT02305368||Oncogramme|Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
16646430|NCT02305355|Experimental|Omega-3-acids ethylesters 90 4g, any statin|
16646431|NCT02305355|Active Comparator|any statin|
16646432|NCT02305342||Urinary Tract Infections (UTIs)|Uncomplicated UTIs
16646433|NCT02305329|Experimental|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
16646434|NCT02305329|Experimental|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
16646435|NCT02305329|Experimental|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
16646436|NCT02305329|Experimental|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
16646437|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
16646438|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
16646441|NCT02305290||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.
16646442|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
~CM - clinical micronized TBM - to-be-marketed"
16646443|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
~CM - clinical micronized TBM - to-be-marketed"
16646444|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
~CM - clinical micronized TBM - to-be-marketed"
16646445|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
~CM - clinical micronized TBM - to-be-marketed"
16646446|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
~CM - clinical micronized TBM - to-be-marketed"
16646447|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
~CM - clinical micronized TBM - to-be-marketed"
16646448|NCT02305264|Experimental|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.
~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
16646449|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
16646450|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
16646451|NCT02305225|Experimental|SDSR|first total then partial Sleep deprivation
16646452|NCT02305225|Experimental|SRSD|first partial then total Sleep deprivation
16646453|NCT02305212|Experimental|Cogmed|Cogmed is a cognitive rehabilitation protocol designed to improve working memory. The Cogmed sessions are on a computer at home for 30-40 min per day, 5 days per week for 5 weeks.
16646454|NCT02305212|No Intervention|Wait list|
16646455|NCT02305199|Active Comparator|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.
~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.
~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
16646456|NCT02305199|Active Comparator|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.
~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.
~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
16646457|NCT02305186|Experimental|Neodjuvant CRT + Pembrolizumab|Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
16646458|NCT02305186|Active Comparator|Neoadjuvant CRT|Standard neoadjuvant chemoradiation treatment (CRT) alone
16646459|NCT02305173|Active Comparator|dexamethasone group|patients receive one single dose of intravenous dexamethasone 8 mg.
16646460|NCT02305173|Placebo Comparator|placebo group|patients receive one single dose of intravenous placebo.
16646461|NCT02305160|Experimental|Butantan|The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
16646462|NCT02305160|Active Comparator|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
16646463|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
16646464|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:
~subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50
~subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
16646465|NCT02305147||Controls|Healthy controls: N=50
16646466|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
16646467|NCT02305134|Active Comparator|Tipepidine Hibenzate|Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
16646468|NCT02305134|Placebo Comparator|Placebo|Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
16646469|NCT02305108|Experimental|fascial manipolation and standard|
16646470|NCT02305108|Active Comparator|standard treatment|
16646471|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
16646505|NCT02304848|Experimental|DBS (Deep Brain Stimulation)|DBS ( Deep Brain Stimulation) ( both high and low frequency deep brain stimulation will be applied to the subthalamic nucleus)
16763034|NCT01523808|Experimental|GRASPA 100|
16646472|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
16646473|NCT02305082||Fast-track group|Patients treated according to the enhanced recovery pathway. This group is examined prospectively.
16646474|NCT02305082||Control group|Patients treated according to the historic recovery pathway. This group is examined retrospectively.
16646475|NCT02305069|Placebo Comparator|Placebo|"Placebo tablet taken once daily for 12 weeks.
~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
16646476|NCT02305069|Experimental|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.
~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
16646477|NCT02305056|Experimental|C13 N15 Valine|Intervention C13 N15 Valine
16646478|NCT02305030|Experimental|BIA 9-1067 / Warfarin|BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
16646479|NCT02305017|Experimental|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
16646480|NCT02305017|Experimental|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
16646481|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
16646482|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
16646483|NCT02304978|Experimental|Group CRC|patient with a colorectal cancer
16646484|NCT02304978|Experimental|Group control|Control - volunteers
16646485|NCT02304965|Experimental|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
16646486|NCT02304952|Active Comparator|Eccentric exercise|Conservative treatment with eccentric exercise as self-training
16646487|NCT02304952|Active Comparator|Radiofrequency microtenotomy|A minimally invasive surgery (Topaz) and eccentric exercise as postoperative treatment
16646488|NCT02304939|Active Comparator|Quick change|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps at the same speed of the first, wait for a first drop at the end of the tubing.
~Close the first syringe, disconnect it and connect the second syringe, open the valve on and stop the first syringe."
16646489|NCT02304939|Experimental|Double Pumping|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps, open the second syringe while leaving the first syringe open. Wait until the blood pressure rises 5 mmHg (SBP, DBP or MAP).
~Once the blood pressure increased or 2 minutes from the start of the relay if no increase in blood pressure is observed, close the first syringe."
16646490|NCT02304939|Experimental|Smart infusion pump|For this automatic changeover : When the syringe of norepinephrine stops (pre alarm), oversee the progress of the automatic relay.
16646491|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
16646492|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
16646493|NCT02304913|Experimental|Hypoglossal acupuncture|Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.
16646494|NCT02304913|Sham Comparator|Sham acupuncture|Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.
16646495|NCT02304913|Active Comparator|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
16646496|NCT02304900|Experimental|Group 1 : white implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
16646497|NCT02304900|Experimental|Group 2 : yellow implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
16646498|NCT02304887||Bisphosphonate|
16646499|NCT02304887||Selective estrogen receptor modulator|
16646500|NCT02304887||Teriparatide|
16646501|NCT02304887||Senosumab|
16646502|NCT02304874|Other|Phlebotomy|Phlebotomies will be performed every 14 days at the Clinical Investigation Unit (CIU) until the value of ferritin level is below 50 µg/mL and/or the value of hemoglobin level is below 12 g/dL.
16646503|NCT02304861|Active Comparator|Viscoat group|Patients operated using Viscoat OVD
16646504|NCT02304861|Active Comparator|Visthesia group|Patients operated using Visthesia OVD
16646506|NCT02304822|Active Comparator|Multiple-dose of ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
16646507|NCT02304822|Experimental|Single-dose of ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only
16646508|NCT02304822|Experimental|Zero-dose of ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
16646509|NCT02304809|Experimental|VEMURAFENIB|"all eligible patients entering the study will receive oral Vemurafenib as monotherapy.
~Vemurafenib ZELBORAF 240 mg tablets Per OS 960 mg twice daily, to a total daily dose of 1,920 mg Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks Safety will be assessed continuously
~Treatment will be pursed until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal."
16646510|NCT02304796|Experimental|Unified CBT|Group psychotherapy according to the principles of the Cognitive-Behavioral Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011).
16646511|NCT02304796|Experimental|Combined CBT-DMT|Group psychotherapy combining cognitive-behavioral principles and techniques with dance/movement therapy techniques.
16646512|NCT02304783|Active Comparator|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days
16646513|NCT02304783|Placebo Comparator|Placebo|Placebo: one pill per day for five days
16646514|NCT02304783|Active Comparator|paracetamol|paracetamol: 1000mg per day for five days
16646515|NCT02304770|Experimental|cervical persistent high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection
16646516|NCT02304770|Experimental|CIN 1 with high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection
16646517|NCT02304770|Experimental|CIN 2/3|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3
16646522|NCT02304731|Experimental|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
16646523|NCT02304718|Experimental|exercise intervention group|Pregnant women randomised to the exercise intervention group will complete three supervised, exercise sessions each week, exercise sessions completed on alternate days, and lasts until they give birth by using a stational bike. And also they will have regular prenatal care.
16646524|NCT02304718|No Intervention|control group|Pregnant women randomised to the control group only have regular prenatal care.
16646525|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
16646526|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
16646527|NCT02304692|Sham Comparator|Oticon Medical Machined Abutment|A non surface modified abutment is used
16646528|NCT02304692|Experimental|Oticon Medical Modified Abutment|A surface modified abutment is used
16646529|NCT02304679|Experimental|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).
~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
16646530|NCT02304679|Placebo Comparator|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.
~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
16646531|NCT02304666|Experimental|Crohn disease's Patients|Patients with Crohn disease or presenting an ulcerative colitis
16646532|NCT02304666|Other|Control patient|Patients with programmed colonoscopy screening for familial colon cancer history, polyps or for irritbale bowel syndrome
16646533|NCT02304640||Early-stage breast cancer patients|
16646534|NCT02304640||Healthy control|
16646535|NCT02304627|Experimental|Eating meal immediately after dosing|
16646536|NCT02304627|Experimental|Eating meal 30 min after dosing|
16646537|NCT02304627|Experimental|Eating meal 1 hour after dosing|
16646538|NCT02304627|Experimental|Eating meal 6 hour after dosing|
16646539|NCT02304614||Group 1|Patients who have undergone Breast conserving Therapy
16646540|NCT02304601||Comorbid symptoms|
16646541|NCT02304601||No comorbid symptoms|
16646542|NCT02304588|Experimental|Mesenchymal stem cells|Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight).
16646543|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
16646544|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
16650105|NCT02280564|No Intervention|Control|Standard diabetes care
16646545|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
16646546|NCT02304562|Experimental|UCB Mesenchymal Stem Cells|UCB Mesenchymal Stem Cells treatment of patients with skin injury
16646547|NCT02304549||patients with BPH undergoing TUV-P|patients with Benign Prostatic Hyperplasia undergoing TUV-P
16646548|NCT02304536|Active Comparator|FSH|will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day.
16646549|NCT02304536|Active Comparator|Ovarian drilling|70 women will have laparoscopic ovarian drilling in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
16646550|NCT02304523|Experimental|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.
~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
16646551|NCT02304523|Experimental|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.
~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
16646552|NCT02304523|Active Comparator|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 * 500mL) within 1 hour. After then, take additional 500ml water.
~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
16646553|NCT02304510||females|females aged between 18 and 50 years old living in Beijing
16646554|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
16646555|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
16646556|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
16646557|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
16646558|NCT02304484|Experimental|Evolocumab|Participants received 420 mg evolocumab once a month for up to 2 years.
16646559|NCT02304471||Control|healthy subjects
16646560|NCT02304471||CKD|chronic kidney disease
16646561|NCT02304471||ESRD|end-stage renal disease
16646562|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
16646563|NCT02304445|Active Comparator|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
16646564|NCT02304445|Experimental|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
16646565|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
16646566|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
16646567|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
16646568|NCT02304419|Experimental|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
16646569|NCT02304393|Experimental|Part IA: Selicrelumab (IV) + Atezolizumab|Selicrelumab at a dose of 16 milligrams (mg) will be administered intravenously (IV) on Day 1 of Cycle 1 (first cycle in this group was of 42 days, and subsequent 21-day cycles); and atezolizumab 1200 mg will be administered IV after 6 weeks on Day 1 of Cycle 2, followed by every 3 weeks during Part IA until disease progression, death, loss of follow-up, or withdrawal of consent.
16646570|NCT02304393|Experimental|Part IA: Selicrelumab(SC) + Atezolizumab|Selicrelumab at a starting dose of 1 mg will be administered subcutaneously (SC) on Day 1 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 2, and followed by every 3 weeks during Part IA as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
16646571|NCT02304393|Experimental|Part IB: Selicrelumab + Atezolizumab|Selicrelumab will be administered at a starting dose of 1 mg SC on Day 2 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks during Part IB as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
16646572|NCT02304393|Experimental|Part II: Selicrelumab + Atezolizumab|Atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks; and Selicrelumab will be administered at the dose defined in Part IB (not exceeding 80 mg SC [unless IV administration in Part IB demonstrates better benefit/risk ratio]) on Day 2 (1 day after atezolizumab administration) of every second cycle from Cycles 1 to 7, and every fourth cycle thereafter during Part II as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
16646573|NCT02304367|Experimental|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
16646574|NCT02304354|Experimental|Rituximab|two intravenous infusions of 1000 mg with a two-week interval between them
16646575|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
16646576|NCT02304328||No clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients without clinical signs of brain herniation syndrome
16646577|NCT02304328||Clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients with clinical signs of brain herniation syndrome
16646578|NCT02304315|Experimental|GC1102 50,000 IU|Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.
16646579|NCT02304315|Experimental|GC1102 80,000 IU|Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.
16646580|NCT02304302|Placebo Comparator|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
16646581|NCT02304302|Experimental|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
16646583|NCT02304276|Active Comparator|1 (Explanted valves)|"10 subjects who are due to undergo repeat aortic valve replacement surgery
~Investigations:
~Baseline 18F-Fluoride PET-CT scan
~Retrieval of explanted bioprosthetic aortic valve at time of surgery for analysis"
16646584|NCT02304276|Experimental|2 (AVR)|"70 subjects with surgical bioprosthetic AVR, to include 10 subjects who have had a valve replacement < 1 month; 20 at 2 years; 20 at 5 years and 20 at >10 years.
~Investigations:
~Baseline 18F-Fluoride PET-CT scan
~Repeat CT calcium score of aortic valve at 2 years
~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
16646585|NCT02304276|Experimental|3 (TAVI)|"50 subjects who have undergone TAVI with the COREVALVE and 50 subjects with the SAPIEN valve. In each group this will include 10 subjects who have had TAVI < 1 month; 20 at 2 years and 20 at 5 years.
~Investigations:
~Baseline 18F-Fluoride PET-CT scan
~Repeat CT calcium score of aortic valve at 2 years
~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
16646586|NCT02304263||Younger (18-35 years old)|iohexol
16646587|NCT02304263||Older (>60 years old)|iohexol
16646588|NCT02304250|Active Comparator|Group D|Group D: dexamethasone group
16646589|NCT02304250|Placebo Comparator|Group S|Group S: saline group
16646590|NCT02304237|Experimental|Vaginal progesterone|Vaginal progesterone(Utrogestan)200mg/day, during 14~21 weeks.
16646591|NCT02304237|Active Comparator|Intramuscular progesterone|Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14~21 weeks.
16646592|NCT02304224|No Intervention|Control|the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
16646593|NCT02304224|Experimental|Eye masks|the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
16646594|NCT02304211|Experimental|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
16646595|NCT02304211|Active Comparator|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
16646596|NCT02304198|Experimental|Udenafil|Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)
16646597|NCT02304185|Experimental|gp140, 50 mcg|
16646598|NCT02304185|Experimental|gp140, 50 mcg + Adjuvant|
16646599|NCT02304185|Placebo Comparator|Placebo 1|
16646600|NCT02304185|Experimental|gp140, 250 mcg|
16646601|NCT02304185|Experimental|gp140, 250 mcg + Adjuvant|
16646602|NCT02304185|Placebo Comparator|Placebo 2|
16646603|NCT02304172|Active Comparator|Thunderbeat (Group A)|Patients submitted to thyroidectomy with the use of the Thunderbeat device.
16646604|NCT02304172|Active Comparator|Harmonic (Group B)|Patients submitted to thyroidectomy with the use of the Harmonic scalpel device
16646605|NCT02304159|Experimental|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
16646606|NCT02304159|Active Comparator|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
16646607|NCT02304146||High ligation and stripping (surgery)|6-10 years post classical stripping of the great saphenous vein.
16646608|NCT02304146||Foam sclerotherapy|6-10 years post post ultrasound guided foam sclerotherapy of the great saphenous vein.
16646609|NCT02304133|Active Comparator|Intervention|participating in a four-hour course in abdominal POC US
16646610|NCT02304133|Placebo Comparator|Control|no training
16646611|NCT02304120|Experimental|Sensorimotor|"The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device (Posturomed®, see section 3.2). The Posturomed allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured."
16646612|NCT02304120|Active Comparator|Low-intensity activity|Added to conventional therapy, as administered to all participants, the control group will do added treadmill walking. The control intervention will consist of 10 minutes of walking at comfortable pace. The patient will be instructed in treadmill functions and asked to set the speed between 2 and 4 km/h. The speed should be adjusted to the level where the patient would still be able to talk comfortably.
16646613|NCT02304107|Active Comparator|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
16646614|NCT02304107|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
16646615|NCT02304094|Experimental|manipulation|Those in the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique. They will be asked to return once each week for a further five weeks. At each visit the VAS and PTM measurements shall be repeated, as will the manual manipulation. They shall also be asked to return for a review in the sixth week.
16646616|NCT02304094|Active Comparator|Steroid|Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine. They shall then be asked to return for review in six weeks. A second injection may be offered at this point if clinically indicated.
16646617|NCT02304081|Active Comparator|Saxagliptin|Metformin and Dapagliflozin background therapy
16646618|NCT02304081|Placebo Comparator|Placebo|Metformin and Dapagliflozin background therapy
16646619|NCT02304068|Other|Intra-vitreal injection|
16646620|NCT02304055|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
16646621|NCT02304055|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
16646622|NCT02304042|Active Comparator|Carbetocin|125 women will receive carbetocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
16646623|NCT02304042|Active Comparator|Oxytocin|125 women will receive carbetocin oxytocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
16646624|NCT02304029|Experimental|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
16646625|NCT02304016|Experimental|Pelvic floor physical therapy|
16646626|NCT02304016|No Intervention|Observatoin|
16646627|NCT02304003|Experimental|Structured Physiotherapy regimen|Heavy-slow resistance training of rotator cuff . Scapular exercises. Manual mobilisation of glenohumeral joint . Stretching. Low Level Laser therapy
16646628|NCT02304003|Other|Standard care|Standard care offered in primary care while waiting for surgery , this may be but are not limited to : Wait and see, Drugs ( NSAIDS ), Corticosteroid injections, physiotherapy or other conservative treatment options.
16646629|NCT02303990|Experimental|Single arm|Hypofractionated RT and Pembro
16646630|NCT02303977|Experimental|Gemcitabine + Paciltaxel|All patients were treated intravenously with albumin-bound paclitaxel at 100 mg/m2 plus gemcitabine at 1000 mg/m2 on days 1 and 8 of each three-week cycle.
16646631|NCT02303964|Active Comparator|Type A Thawed Plasma|"Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders.
~An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained."
16646632|NCT02303964|Placebo Comparator|Normal saline|Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
16646633|NCT02303951|Experimental|vemurafenib + cobimetinib + atezolizumab|"Run-In (week 1-4):
~Day 1-21: vemurafenib 960 mg bid orally + cobimetinib 60 mg od orally
~Day 22-28: vemurafenib 720 mg bid orally
~Triple-Treatment (week 5 ongoing):
~atezolizumab 840 mg Q2W i.v. + vemurafenib 720 mg bid orally + cobimetinib 60 mg od 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)"
16646634|NCT02303938|Experimental|physical exercise|Patients will exercise three times per week for 6 months home-based exercise intervention. Session duration will vary between 20 minutes and 45 minutes.
16646635|NCT02303938|No Intervention|Active control group|Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl
16646636|NCT02303925|Experimental|coils|
16646637|NCT02303912|Other|Open label dose escalation|"Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days.
~Dose escalation will be done using 3+3 dose escalation design"
16646638|NCT02303899|Experimental|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
16646639|NCT02303886|Active Comparator|A Methylene blue 10 mg/ml 2mg/kg|ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
16646640|NCT02303886|Placebo Comparator|B Methylene blue 10 mg/ml 0.02 mg/kg|Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
16646641|NCT02303873|Experimental|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
16646642|NCT02303860|Experimental|Panel 1|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
16646643|NCT02303860|Experimental|Panel 2|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
16646644|NCT02303847|Active Comparator|Active Drug|ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week
16646645|NCT02303847|Placebo Comparator|Placebo|Flavored syrup (without ketamine) by mouth twice daily for 2 weeks
16646646|NCT02303834|No Intervention|Control|The control group will not be fitted with CPAP.
16646647|NCT02303834|Experimental|CPAP group|The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).
16763035|NCT01523808|Experimental|GRASPA 150|
16646648|NCT02303821|Experimental|Phase 1b: Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.
~Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.
~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
16646649|NCT02303821|Experimental|Phase 1b: Dose Escalation 2|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.
~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy and then have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
16646650|NCT02303821|Experimental|Phase 2: Aged ≥ 12 months at screening|"All subjects aged ≥ 12 months at screening.
~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.
~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 4 week cycle of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine) if subjects showed no disease progression at the end of the Induction Cycle."
16646651|NCT02303821|Experimental|Phase 2: Aged < 12 months at screening|"All subjects aged < 12 months at screening.
~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.
~Subjects will receive a modified 5 week cycle (based on Interfant-06) of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 5 week cycle (modified based on Interfant-06) of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if subjects showed no disease progression at the end of the Induction Cycle."
16646652|NCT02303808|No Intervention|USUAL CARE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
16646653|NCT02303808|Active Comparator|INHALATION WITH PEP DEVICE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) combined with a PEP device (Acapella Duet) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
16646654|NCT02303795|Active Comparator|Rivaroxaban 20mg|Oral Rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
16646655|NCT02303795|Active Comparator|Warfarin|Warfarin Warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
16646656|NCT02303782|Experimental|OTX015 + azacitidine|
16646657|NCT02303782|Experimental|Azacitidine|
16646658|NCT02303769|Active Comparator|Tamsulosin HCL 0.2mg|Harnal-D tablet (Tamsulosin HCL 0.2mg)
16646659|NCT02303769|Experimental|Tamsulosin HCL 0.4mg|GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)
16646660|NCT02303756|Experimental|Pillcam® COLON Capsule|Detection of neoplastic lesions in colon and rectum compared to colonoscopy
16646661|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
16646662|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
16646663|NCT02303730|Experimental|Exenatide|Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks
16646664|NCT02303730|Active Comparator|Insulin glargine|Insulin glargine subcutaneously, once daily, for 24 weeks
16646665|NCT02303717|Active Comparator|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
16646666|NCT02303717|Experimental|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
16646667|NCT02303704|Active Comparator|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
16646668|NCT02303704|Active Comparator|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
16646669|NCT02303691|Experimental|Computerized Attention Bias Modification|
16646670|NCT02303691|Sham Comparator|Computerized Neutral Training|
16646671|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
16646672|NCT02303665|No Intervention|The control group|No Intervention
16646673|NCT02303665|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
16646716|NCT02303405|Experimental|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
16646674|NCT02303665|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
16646675|NCT02303639|Experimental|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
16646676|NCT02303639|Active Comparator|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
16646677|NCT02303626|Experimental|BCX4161 300 mg three times daily|Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
16646678|NCT02303626|Experimental|BCX4161 500 mg three times daily|Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
16646679|NCT02303626|Placebo Comparator|Placebo three times daily|Five placebo capsules to be taken three times daily by mouth
16646680|NCT02303600|Experimental|biomarker treatment arm|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate).
16646681|NCT02303600|Active Comparator|standard treatment arm|Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
16646682|NCT02303587|Experimental|low dose group|methylprednisolone 2mg-4mg/Kg
16646683|NCT02303587|Experimental|high dose group|methylprednisolone 10mg/Kg
16646684|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
16646685|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
16646686|NCT02303561|Experimental|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
16646687|NCT02303561|Active Comparator|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
16646688|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
16646689|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
16646690|NCT02303535||Congenital|"All patients with congential and acquired heart disease treated by cardiac surgery and therapeutic cardiac catheterisations procedures .
~For acquired heart disease, the audit covers all arrhythmias & cardiomyopathies in patients less than 16 years old only.
~For congenital heart disease, the audit collects data on both children and adult patients."
16646691|NCT02303522||All subjects|All subjects will be included in a unique cohort
16646692|NCT02303509|Experimental|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
16646693|NCT02303509|Experimental|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
16646694|NCT02303496|Experimental|PRP Cream Application|Application of Cream Containing Platelet Rich Plasma and Oleaginous Base
16646695|NCT02303496|Active Comparator|SW Cream Application - Placebo|Application of Cream Containing Sterile Water and Oleaginous Base
16646696|NCT02303483|Placebo Comparator|Placebo|lime tablets
16646697|NCT02303483|Experimental|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
16646698|NCT02303470|Experimental|Vigorous Exercise|High-intensity interval training for 15 minutes daily, 5 days per week for 8 weeks
16646699|NCT02303470|Experimental|Moderate Exercise|Brisk walking for 30 minutes daily, 5 days per week for 8 weeks
16646700|NCT02303457|Experimental|CO2 laser surgery|CO2 Laser surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved. All patients, under general anesthesia, underwent endoscopic excision of the lesion using a carbon dioxide (CO2) laser (Sharplan 100) coupled with a microscope (Zeiss) set to an output power of between 5 and 12 W in superpulse mode. The lesion's resection was accomplished in a radical fashion, with a free margin of 2 mm. For lesions which involved the anterior commissure, the excision plane always uncovered the cartilage.
16646701|NCT02303457|Other|Open surgery|"Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved.
~open surgery :Frontolateral Vertical Partial Laryngectomy or laryngofissure with cordectomy was accomplished in a radical fashion, with a free margin of 2 mm."
16646702|NCT02303444||MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
16646703|NCT02303444||non-MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
16646704|NCT02303431|Experimental|Cohort 1a|12 to < 18 years of age: edoxaban low dose group
16646705|NCT02303431|Experimental|Cohort 1b|12 to < 18 years of age: edoxaban high dose group
16646706|NCT02303431|Experimental|Cohort 2a|6 to < 12 years of age: edoxaban low dose group
16646707|NCT02303431|Experimental|Cohort 2b|6 to < 12 years of age: edoxaban high dose group
16646708|NCT02303431|Experimental|Cohort 3a|2 to < 6 years of age: edoxaban low dose group
16646709|NCT02303431|Experimental|Cohort 3b|2 to < 6 years of age: edoxaban high dose group
16646710|NCT02303431|Experimental|Cohort 4a|6 months to <2 years of age: edoxaban low dose group
16646711|NCT02303431|Experimental|Cohort 4b|6 months to <2 years of age: edoxaban high dose group
16646712|NCT02303431|Experimental|Cohort 5a|0 to 6 months of age: edoxaban low dose group
16646713|NCT02303431|Experimental|Cohort 5b|0 to 6 months: edoxaban high dose group
16646714|NCT02303418|Active Comparator|Carbetocin|100 µgm of Carbetocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
16646715|NCT02303418|Active Comparator|Oxytocin|5 mg of oxytocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
16646786|NCT02302872|Experimental|ARTO system|
16646717|NCT02303405|Active Comparator|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
16646718|NCT02303392|Experimental|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16646719|NCT02303379|Active Comparator|Continuous Endurance training|Endurance training with constant work load 31min at 65-75% maximal heart rate (HRmax)
16646720|NCT02303379|Experimental|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
16646721|NCT02303379|Experimental|High-intensity intervall training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
16646722|NCT02303366|Experimental|SABR + MK-3475|SABR treatment (20Gy in 1 fraction) to at least one metastases (to a maximum of 5 metastases) followed by 8 cycles of 3 weekly treatment with MK-3475 (200mg IV per dose).
16646723|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
16646724|NCT02303340||Study Group|Any patient who enrolled and signed informed consent will be sent to bone mineral density DEXA Scan, and for blood testing for PTH, Phosphor, Calcium ,Vitamin D and Creatinine levels. Density measurements will be done in specific sites on the CBCT's of the jaws.
16646725|NCT02303327|Other|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
16646726|NCT02303327|Active Comparator|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
16646727|NCT02303314|Other|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
16646728|NCT02303314|Other|Drug: Placebo|in this group patients use placebo twice daily.
16646729|NCT02303301|Active Comparator|Probiotics|Patients gurgle twice a day with a suspension of two probiotic strains of bacteria- Contains also a filling material - maltodextrin
16646730|NCT02303301|Placebo Comparator|Control|Patients gurgle twice a day with a suspension of the filling material - maltodextrin
16646731|NCT02303275|Other|Lifestyle Change|Lifestyle Change
16646732|NCT02303262|Experimental|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
16646733|NCT02303249|Experimental|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
16646734|NCT02303249|No Intervention|Control|Standard health care services
16646735|NCT02303223|Other|Propofol|Single intravenous bolus dose of Propofol 2.5mg/kg for induction of anesthesia
16646736|NCT02303210|Other|hearing aid NaidaUP|Within subject design: compare frequency lowering one with frequency lowering two.
16646737|NCT02303210|Other|hearing aid NaidaSP|Within subject design: compare frequency lowering one with frequency lowering two.
16646738|NCT02303197|Experimental|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
16646739|NCT02303197|No Intervention|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
16646740|NCT02303184|Experimental|4 mg CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
16646741|NCT02303184|Active Comparator|sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
16646742|NCT02303171|Active Comparator|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
16646743|NCT02303171|Active Comparator|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
16646744|NCT02303145||Breast cancer survivor Group|Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
16646745|NCT02303145||Control Group|Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
16646746|NCT02303132|Other|Active MC|Patients with active MC will be included
16646747|NCT02303132|Other|MC in remission|Patients with MC in remission will be included
16646748|NCT02303132|Other|Controls|Patients without MC will be included
16646749|NCT02303119|Active Comparator|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
16646750|NCT02303119|Experimental|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
16646751|NCT02303119|Experimental|Arm C : Rituximab SC first cycle|8 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
16646752|NCT02303106|Active Comparator|lamotrigine|lamotrigine alone
16646753|NCT02303106|Experimental|Lamotrigine + paracetamol|Lamotrigine + paracetamol
16646754|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
16646755|NCT02303093||Panzyga|Patient receiving panzyga
16646756|NCT02303080|Placebo Comparator|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
16646757|NCT02303080|Active Comparator|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
16646758|NCT02303080|Active Comparator|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
16646759|NCT02303080|Active Comparator|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
16646760|NCT02303054|Experimental|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on an Prostatic multi-parametric MRI (mpMRI) of the prostate will be considered for enrollment. If followed by a positive MRI-US targeted biopsy of the prostate, men who be offered enrollment into the study. All men enrolled in the study will undergo bipolar radiofrequency ablation. Efficacy will be assessed through MRI-US biopsy after focal bipolar RFA.
16646761|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
16646762|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
16646763|NCT02303028|Experimental|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
16646764|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
16646765|NCT02303002|Experimental|Dose A|Dose A: Botulinum Toxin Type A
16646766|NCT02303002|Experimental|Dose B|Dose B: Botulinum Toxin Type A
16646767|NCT02303002|Experimental|Dose C|Dose C: Botulinum Toxin Type A
16646768|NCT02303002|Active Comparator|Dose D|Dose D: Botulinum Toxin Type A
16646769|NCT02303002|Placebo Comparator|Dose E|Dose E: Placebo
16646770|NCT02302989|No Intervention|Observation|No treatment. Observation only
16646771|NCT02302989|Active Comparator|Quarterly Ranibizumab 0.5|Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg
16646772|NCT02302976|Experimental|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
16646773|NCT02302976|Experimental|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
16646774|NCT02302976|Placebo Comparator|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
16646775|NCT02302976|Placebo Comparator|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
16646776|NCT02302963|Experimental|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
16646777|NCT02302963|Placebo Comparator|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
16646778|NCT02302950||women that picked up raltegravir 2013|minority women that picked up raltegravir at Thomas street Health Center 2013
16646779|NCT02302937|Active Comparator|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
16646780|NCT02302937|Active Comparator|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
16646781|NCT02302911||Early intensive behavioral intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive behavioral Intervention at one of the participating centres.
16646782|NCT02302911||Early intensive eclectic intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive eclectic Intervention at the participating centre.
16646783|NCT02302911||Control group|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving treatment as usual or no treatment at all.
16646784|NCT02302898||Wt maintenance|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
16646785|NCT02302898||Wt Regain|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
16646787|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.
~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.
~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.
~Participants complete saliva cotinine test 3 months after intervention."
16646788|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.
~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.
~Participants complete saliva cotinine test 3 months after intervention."
16646789|NCT02302846|Experimental|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
16646790|NCT02302833|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16646791|NCT02302820|Active Comparator|Make Your Wishes Known|"A Decision Aid that uses interactions, videos, vignettes.
~A formatted Advance Directive; saved data that may be revisited to produce a revised Advance Directive"
16646792|NCT02302820|Active Comparator|Mayo Clinic-Advance Health Care Planning|"Not an online decision aid
~Written instructions, worksheets, and Advance Directive to complete"
16646793|NCT02302820|Active Comparator|Mydirectives.com|"Online decision aid that uses interactions, videos, and vignettes.
~An electronically stored Advance Directive that may be printed."
16646794|NCT02302820|Active Comparator|Prepare|"An online decision aid that uses interactions, videos and vignettes.
~A printed summary useful for transposing values and treatment wishes into an Advance Directive; a list of action steps."
16646795|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
16646796|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
16646797|NCT02302794|Active Comparator|open surgery|Conventional procedure
16646798|NCT02302794|Experimental|laparoscopic surgery|Minimum invasive procedure
16646799|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
16646800|NCT02302768|Placebo Comparator|Placebo|Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.
16646801|NCT02302768|Active Comparator|80-Semet|Patients randomized to receive selenomethionine at 80 mcg per day.
16646802|NCT02302768|Active Comparator|160-Semet|Patients randomized to receive selenomethionine at 160 mcg per day.
16646803|NCT02302755|Experimental|Screening/ Active Treatment Arm|"Screening Period: This includes diagnosis confirmation, consent, required tests and vaccinations.
~Treatment Period: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific TP10 dose-escalation scheme during the Induction Period and subsequent dose adjustments based on complement levels during the Maintenance Period"
16646804|NCT02302742||Triple Negative Breast Cancer patients|No intervention
16646805|NCT02302742||Germline HBOC Mutation Carriers|No intervention
16646806|NCT02302729|Experimental|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
16646807|NCT02302729|Placebo Comparator|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
16646808|NCT02302729|Experimental|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
16646809|NCT02302729|Placebo Comparator|Placebo and No responsive caregiving|Placebo and No responsive caregiving
16646810|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
16646811|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
16646812|NCT02302703|Active Comparator|the low FODMAP diet|
16646813|NCT02302703|Active Comparator|Gluten free diet|
16646814|NCT02302664|Active Comparator|PRP Injection|Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
16646849|NCT02302443|Experimental|Cohort 5|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
16646850|NCT02302443|Experimental|Cohort 6|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
16646851|NCT02302430|Experimental|Treatment|Treatment group will receive either 20IU or 40IU intranasal oxytocin
16646815|NCT02302664|Sham Comparator|Imitation Injection|Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
16646816|NCT02302651|Other|Osteoid Osteoma|MR guided High Intensity focused ultrasound
16646817|NCT02302638|Active Comparator|Sage 1-step|"Embryo culture in different single-step media:
~Half of each patient's oocytes will be randomly allocated to be cultured in Sage 1-step medium for up to six days following oocyte retrieval."
16646818|NCT02302638|Active Comparator|CSCM|"Embryo culture in different single-step media:
~Half of each patient's oocytes will be randomly allocated to be cultured in CSC medium for up to six days following oocyte retrieval."
16646819|NCT02302625|Experimental|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
16646820|NCT02302612|Experimental|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE disease management program.
16646821|NCT02302612|Active Comparator|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
16646822|NCT02302599|Experimental|Umbilical cord mesenchymal stem cells|Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
16646823|NCT02302599|Experimental|Controlled suspension liquid|Patients receive Controlled suspension liquid
16646824|NCT02302586|Active Comparator|Patient Controlled Analgesia (IV PCA)|Postoperative intravenous (IV) morphine PCA is being used for acute pain control: Basal infusion: 0.3 mg/kg/h Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
16646825|NCT02302586|Active Comparator|Thoracic Paravertebral Block (TPVB)|Preoperative thoracic paravertebral block (TPVB) at 4 levels from T4 to T8 is being performed and total of 20 mL Bupivacaine 0.5% is deposited (5 mL per level by using landmark technique)
16646826|NCT02302573|Experimental|placenta accreta|contast-enhanced ultrasound with sonovue
16646827|NCT02302560||Patients with elective hip surgery|Patients with elective hip surgery (implementation or replacement of hip joint endoprotheses).
16646828|NCT02302547|Active Comparator|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
16646829|NCT02302547|Experimental|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
16646830|NCT02302534|Experimental|patients|"2 groups with MRI :
~- 8 right thoracic AIS participants (Cobb angle between 20 and 40°)"
16646831|NCT02302534|Experimental|controls subjects|- 8 healthy controls (no clinical scoliosis)
16646832|NCT02302521||Healthy Younger Adults|Age: 20-30. Gender: male or female. No neurological conditions.
16646833|NCT02302521||Healthy Older Adults|Age: 50-70. Gender: male or female. No neurological conditions.
16646834|NCT02302521||Parkinson's disease|Gender: male or female. Tremor dominant Parkinson's disease.
16646835|NCT02302521||Healthy Children|Age: 4-8. Gender:male or female. No neurological conditions.
16646836|NCT02302508|Experimental|T2D patients with A1C ≤7.0|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
16646837|NCT02302508|Experimental|T2D patients with A1C>7.5|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
16646838|NCT02302508|Experimental|Insulino-treated|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
16646839|NCT02302508|Active Comparator|Non-diabetic healthy subjects|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
16646840|NCT02302495|Other|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
16646841|NCT02302482|Experimental|Functional autonomy level collection|Collection of the Functional autonomy level every 6 - 12 months by phone
16646842|NCT02302469|Other|revlimid|a dose-escalation of revlimid
16646843|NCT02302456|Experimental|TXA|Intravenous administration of 1g of tranexamic acid within 2 minutes after birth and prophylactic oxytocin administration
16646844|NCT02302456|Placebo Comparator|Placebo|Intravenous administration of placebo within 2 minutes after birth and prophylactic oxytocin administration
16646845|NCT02302443|Experimental|Cohort 1|Very low dose of HM12470 (single dose, subcutaneous injection)
16646846|NCT02302443|Experimental|Cohort 2|Low dose of HM12470 (single dose, subcutaneous injection)
16646847|NCT02302443|Experimental|Cohort 3|Intermediate dose of HM12470 (single dose, subcutaneous injection)
16646848|NCT02302443|Experimental|Cohort 4|High dose of HM12470 (single dose, subcutaneous injection)
16646853|NCT02302417|Other|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
16646854|NCT02302404|Experimental|Cohort 1: GSK2982772 Single Ascending Dose (Part A) (0.1-10mg)|Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through approximately 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 0.1, 0.5, 2.5, and 10mg. A sequential design will be used including approximately weekly dose escalations while allowing for a sufficient washout period. The proposed doses may be adjusted based on emerging safety and PK
16646855|NCT02302404|Experimental|Cohort 2: GSK2982772 Single Ascending Dose (Part A) (40-240mg)|Eight subjects will be randomized equally to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having 4 dose periods (3 active dose of GSK2982772 +1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 40, 100, 180, and 240 mg. A sequential design with weekly dose escalations and sufficient washout period will be used. The proposed doses may be adjusted based on emerging safety and PK. After the completion of the fasted treatment periods, subjects will receive a high fat meal within 30 minutes of dosing with GSK2982772 during a final treatment period.
16646856|NCT02302404|Experimental|Cohort 3: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A data
16646857|NCT02302404|Experimental|Cohort 4: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in Part A or any preceding repeat dose cohorts in Part B
16646858|NCT02302404|Experimental|Cohort 5: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A or any preceding repeat dose cohorts in Part B.
16646859|NCT02302404|Experimental|Cohort 6: GSK2982772 Single Ascending Dose (Part A)|This additional cohort in Part A of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied. Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
16646860|NCT02302404|Experimental|Cohort 7: GSK2982772 Repeat Dose (Part B)|This additional cohort in Part B of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
16646861|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
16646862|NCT02302378|Active Comparator|Taylor's approach|This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
16646863|NCT02302378|Active Comparator|Lumbar approach|This arm will have the procedure of spinal anesthetic performed via a paramedian 'Lumbar approach' at interspace L3-L4. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
16646864|NCT02302352|Active Comparator|Probiotic|Oral probiotic 1g, once/day, containing: Lactobacillus paracasei, 10x9 CFU; Lactobacillus rhamnosus,10x9 CFU; Lactobacillus acidophillus, 10x9 CFU; Bifidobacterium lactis 10x9 CFU per sachet
16646865|NCT02302352|Placebo Comparator|Placebo|Maltodextrin 1g per sachet, once/day
16646866|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
16646867|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
16646868|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
16646957|NCT02301702|Experimental|Tdap Vaccine|Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
16646869|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
16646870|NCT02302326|Experimental|Metformin|PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.
16646871|NCT02302326|Experimental|Myo-inositol + folic acid|PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks
16646872|NCT02302326|No Intervention|Healthy women|Healthy untreated women adjusted for age and body mass index
16646873|NCT02302313|Other|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
16646874|NCT02302300|Experimental|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
16646875|NCT02302300|No Intervention|Control Group|Standard preparation
16646876|NCT02302287|Experimental|Group A|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
~Mediterranean diet and ketoacids for 6 months"
16646877|NCT02302287|Experimental|Group B|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day;
~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
~Mediterranean diet and ketoacids for 6 months"
16646878|NCT02302287|Other|Group control|Free diet: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day
16646879|NCT02302274||flecainide infusion test|Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
16646880|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
16646881|NCT02302248|Experimental|Crowdsourced Reappraisal|Participants received the web-based crowdsourcing reappraisal intervention.
16646882|NCT02302248|Active Comparator|Expressive Writing|Participants received the web-based expressive writing intervention.
16646883|NCT02302235|Active Comparator|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
16646884|NCT02302235|Other|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
16646885|NCT02302222|Active Comparator|Standard of Care|dry sterile dressing/gauze and steristrips
16646886|NCT02302222|Experimental|Customizable|Prevena Customizable Dressing with ActiV.A.C. Therapy Unit
16646887|NCT02302209|Experimental|Oxytocin|40 IU Oxytocin Intranasal
16646888|NCT02302209|Placebo Comparator|Placebo|Saline Nasal Spray
16646889|NCT02302196||Autologous Fat Grafting of the breast|Approximately 100 women who have had a lumpectomy and qualify, will be offered Autologous Fat Grafting (AFG) procedure. Patients will be assessed 3 months post grafting for safety and efficacy by Breast-Q survey, mammography BIRADS scoring and physical assessment. The AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. Repeat mammogram will be done 1 year post AFG.
16646890|NCT02302196||Control arm standard treatment|Retrospective chart review will be done in 100 women who have undergone standard treatment for breast contour defect after lumpectomy.The control group will be measured by compiling BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy.
16646891|NCT02302183|Experimental|Experimental: device FreeO.|Automatic adjustment of oxygen
16646892|NCT02302183|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
16646893|NCT02302170|Experimental|H. pylori vaccine in children|H. pylori vaccine (15mg/dose) in children between 6-15 years of age
16646894|NCT02302170|Placebo Comparator|placebo in children|placebo (0mg/dose) in children between 6-15 years of age
16646895|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
16646896|NCT02302144|Experimental|Early Multi-Ex-PD|Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
16646930|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
16646958|NCT02301702|Active Comparator|Td Vaccine|Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
16646897|NCT02302144|Experimental|Late Multi-Ex-PD|Three months after enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
16646898|NCT02302131||pulmonary valve replacement|SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
16646899|NCT02302118||Surgical approach|Group A: Esophagogastrectomy Group B: Extended gastrectomy
16646900|NCT02302105|Active Comparator|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
16646901|NCT02302105|Experimental|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
16646902|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
16646903|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
16646904|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
16646905|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
16646906|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
16646907|NCT02302066|Experimental|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 365.
16646908|NCT02302066|Experimental|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 91 and 365.
16646909|NCT02302066|Experimental|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 91.
16646910|NCT02302066|Placebo Comparator|Group 4 (Placebo Control)|Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
16646911|NCT02302053|Active Comparator|New Viviscal Professional Supplement|New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
16646912|NCT02302053|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
16646913|NCT02302040|Experimental|AIM2ACT|AIM2ACT uses existing mHealth technology developed by the study team to elucidate tailored intervention targets for each family. AIM2ACT then facilitates collaborative caregiver/adolescent asthma management by automatically guiding dyads through a structured process that includes the supportive behavioral management strategies of goal setting, contingency management, and problem solving communication. Skills-training videos for adolescents and caregivers provide guidance on how to complete each collaborative asthma management component.
16646914|NCT02302040|Active Comparator|Self-Guided|Participants in the self-guided control condition will be given general information on supportive behavioral management techniques they can use to target improvement in asthma self-management behaviors. The control condition will serve as an attention control and is designed to optimize recruitment and sustain interest while concurrently having a minimal impact on asthma management.
16646915|NCT02302027|Experimental|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
16646916|NCT02302014|Experimental|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
16646917|NCT02302014|No Intervention|Usual Care|Usual Care
16646918|NCT02302001|Experimental|Primary Breast Augmentation|
16646919|NCT02301988|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
16646920|NCT02301988|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
16646921|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
16646922|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
16646923|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
16646924|NCT02301962|Experimental|Panitumumab arm|Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
16646925|NCT02301949|Active Comparator|Thalidomide Retreatment Group|
16646926|NCT02301949|Placebo Comparator|Placebo Group|
16646927|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
16646928|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
16646929|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
16646931|NCT02301910|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
16646932|NCT02301910|Active Comparator|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)
~55 to <60 30 mg 6 ml
~60 to <70 35 mg 7 ml
~70 to <80 40 mg 8 ml
~80 to <90 45 mg 9 ml
~90 50 mg 10 ml"
16646933|NCT02301897|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
16646934|NCT02301897|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
16646935|NCT02301897|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
16646936|NCT02301884|Experimental|Allergen extract|"Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.
~Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection"
16646937|NCT02301871|Active Comparator|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
16646938|NCT02301871|Experimental|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
16646939|NCT02301871|Experimental|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
16646940|NCT02301858|Other|Study arm|Genome analysis of tissue samples.
16646941|NCT02301845|Experimental|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
16646942|NCT02301819|Active Comparator|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
16646943|NCT02301819|Active Comparator|Conservative|Early conservative therapy according to standard practice
16646944|NCT02301806|Experimental|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
16646945|NCT02301806|Active Comparator|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
16646946|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.
~Intervention: Nurse education in contemporary format"
16646947|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.
~Intervention: Nurse education in traditional format"
16646948|NCT02301780|Placebo Comparator|Control Group|Placebo
16646949|NCT02301780|Active Comparator|Intervention Group|Aspirin
16646950|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
16646951|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
16646952|NCT02301754|Experimental|INVAC-1|"INVAC-1 at escalating doses of 100, 400 and 800 µg will be given as a single agent by intradermal injection (Q 4 weeks x 3 cycles), always combined with electroporation.
~Each patient will receive 3 cycles, unless motivated treatment interruption."
16646953|NCT02301741|Experimental|Game Condition|Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
16646954|NCT02301741|No Intervention|Control Condition|Participants in the CONTROL condition will complete baseline and post-test standardized reaching tasks, but will not play the game in the intervening three days.
16646955|NCT02301715|Active Comparator|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
16646956|NCT02301715|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
16646959|NCT02301689||Heart Failure patients|
16763384|NCT01521416||Cohort Group|
16646960|NCT02301676|Active Comparator|General anesthesia & Control|"After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention Korean version of telephone interview for cognitive status (TICS). The test will be administered to spouse simultaneously by telephone."
16646961|NCT02301676|Active Comparator|Sevoflurane & Propofol & Dexmedetomidine|The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
16646962|NCT02301663|Experimental|Women w/microvascular disease|10 women with microvascular disease
16646963|NCT02301663|Experimental|Normal controls|10 age-matched women with no evidence of microvascular disease
16646964|NCT02301663|Experimental|calibration|10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
16646965|NCT02301650||group A|The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
16646966|NCT02301650||group B|The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
16646967|NCT02301650||group C|The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
16646968|NCT02301650||group D|The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy
16646969|NCT02301624|Experimental|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams [mg]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.
~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.
~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
16646970|NCT02301624|Experimental|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.
~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.
~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
16646971|NCT02301611|Experimental|Treatment|autologous TLPLDC (active vaccine)
16646972|NCT02301611|Placebo Comparator|Placebo|unloaded YCWP + autologous DC (control)
16646973|NCT02301598|Experimental|FS-ALK|Femtosecond laser-assisted maximum thickness anterior lamellar keratoplasty (FS-ALK) was performed for 11 eyes of 11 patients with advanced keratoconus and 2 eyes of 2 patients with superficial corneal scattering.
16646974|NCT02301585|Experimental|Passive Leg Raising|Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
16646975|NCT02301585|Active Comparator|Standard of care|Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.
16646976|NCT02301572||Aggressive onset MS|Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
16646977|NCT02301559|Experimental|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
16646978|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
16646979|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
16646980|NCT02301533|Experimental|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
16646981|NCT02301533|Other|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
16646982|NCT02301507|Experimental|SMS (texting) Arm|texts received
16646983|NCT02301494|Experimental|Fluocinonide (Vanos) cream 0.1%|Fluocinonide (Vanos) cream 0.1% will be applied as currently approved by the FDA for treatment of corticosteroid responsive disorders of the skin. Treatment will continue for 4 months with a follow up at 6 and 12 months.
16646984|NCT02301494|Experimental|3.75% Imiquimod (Zyclara) Cream|3.75% Imiquimod (Zyclara) Cream will be used as currently labeled by the FDA for treatment of actinic keratoses. Treatment will continue for 4 months with follow up at 6 and 12 months.
16646985|NCT02301481|Experimental|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
16646986|NCT02301481|Active Comparator|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
16646987|NCT02301468|Experimental|Dry needling|Dry needling (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained
16647014|NCT02301286|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
16651129|NCT02273466|Experimental|Desipramine with Crobenetine|
16646988|NCT02301468|Experimental|Ischemic compression|Ischemic compression (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
16646989|NCT02301455|No Intervention|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
16646990|NCT02301455|Experimental|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
16646991|NCT02301455|No Intervention|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
16646992|NCT02301442|Experimental|Exercise + behaviour change intervention|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
16646993|NCT02301442|Active Comparator|Exercise + control education|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
16646994|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
16646995|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
16646996|NCT02301416|No Intervention|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
16646997|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
16646998|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
16646999|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
16647000|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
16647001|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
16647002|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
16647003|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
16647004|NCT02301351|Other|Graphic Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with FDA-approved graphic warning labels.
16647005|NCT02301351|Other|Text Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with standard text warning labels.
16647006|NCT02301338||Usual Care|"The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon
~The patient will answer questions on:
~Social support
~Quality of life"
16647007|NCT02301338||Phone Calls|"In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.
~The patient will answer questions on:
~Social support
~Quality of life"
16647008|NCT02301325|Other|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
16647009|NCT02301325|Other|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
16647010|NCT02301325|Other|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
16647011|NCT02301325|Other|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
16647012|NCT02301312|Experimental|POSS-PCU graft|POSS-PCU vascular graft will be used to create vascular access for dialysis.
16647013|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
16647015|NCT02301286|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
16647016|NCT02301273|Active Comparator|Usual Physiotherapy|Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
16647017|NCT02301273|Experimental|Enhanced Physiotherapy|Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
16647018|NCT02301260|Experimental|Speed of Processing Training (SPT)|SPT will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16647019|NCT02301260|Placebo Comparator|Placebo control group|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 sessions)
16647020|NCT02301247|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16647021|NCT02301247|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16647022|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
16647023|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
16647024|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
16647025|NCT02301221|Experimental|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
16647026|NCT02301208|Active Comparator|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
16647027|NCT02301208|Active Comparator|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
16647028|NCT02301208|Experimental|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
16647029|NCT02301208|Experimental|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
16647030|NCT02301195|Experimental|Therapeutic Horseback Riding|Ten-weekly one-hour manualized small group Therapeutic Horseback Riding intervention led by certified THR instructor.THR intervention taught riding and horsemanship skills.
16647031|NCT02301195|Active Comparator|Barn Activity Intervention|Ten-weekly one-hour manualized small group Barn Activity Intervention led by THR instructor, teaching horsemanship skills without horses present.
16647032|NCT02301182|Active Comparator|ADM X3-MoP Cup|THA: ADM dual-mobility hydroxyapatite coated cups with X3TM HXLPE liners on 28mm BIOLOX® delta femoral heads (Stryker) with femoral stems being 2nd generation Accolade stems of the taper lock type, proximal circumferential coated with a 50µm plasma-spray PureFix HA coating to aid the mechanical engagement in bone coating (Stryker)
16647033|NCT02301182|Active Comparator|CoC Cup|THA: CoC BIOLOX® delta-delta large-head single-mobility cementless fiber-mesh titanium coated acetabular system from Zimmer (Zimmer TrilogyIT cup/CLS spotorno stem) with a grit-blasted osteophilic titanium alloy CLS® Spotorno femoral stems (Zimmer) that has a three-dimensional wedge shape and sharpened ribs in the proximal region
16647034|NCT02301169|Active Comparator|T4P1001|
16647035|NCT02301169|Sham Comparator|Placebo|
16647038|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.
~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR
~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR
~Surgical intervention"
16647039|NCT02301130|Experimental|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.
~Part 1 (Dose Escalation Phase)
~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.
~Part 2 (Cohort Expansion Phase)
~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
16647040|NCT02301130|Experimental|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.
~Part 1 (Dose Escalation Phase)
~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.
~Part 2 (Cohort Expansion Phase)
~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
16647041|NCT02301117|Experimental|Mild Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
16647042|NCT02301117|Experimental|Moderate Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
16647043|NCT02301117|Experimental|Severe Renal Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
~The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts"
16647044|NCT02301117|Experimental|Normal Renal Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
16647045|NCT02301104|Experimental|Mild Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
16647046|NCT02301104|Experimental|Moderate Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
16647047|NCT02301104|Experimental|Severe Hepatic Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
~The dose level of severe cohort, if enrolled, will be determined based on the Interim Assessment of mild and moderate cohorts."
16647048|NCT02301104|Experimental|Normal Hepatic Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
16647049|NCT02301091|Experimental|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
16647050|NCT02301091|Active Comparator|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
16647051|NCT02301078||Percutaneous Needle Aponeurotomy|Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
16647052|NCT02301078||Xiaflex|Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
16647053|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
16647054|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
16647055|NCT02301052|Placebo Comparator|placebo|placebo topical cream 2 cc twice daily for 3 weeks
16647056|NCT02301052|Active Comparator|Anti-hemorrhoid topical cream drug|Anti hemorrhoid topical cream as a standard drug 2 cc twice daily for 3 week
16647057|NCT02301052|Active Comparator|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
16647058|NCT02301039|Experimental|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
16647059|NCT02301039|Experimental|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
16647060|NCT02301039|Experimental|Expansion|Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
16647061|NCT02301013|Experimental|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
16647062|NCT02301000|Experimental|Intestinal microbiota therapy|The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
16647063|NCT02301000|Active Comparator|Metronidazole|The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
16647064|NCT02300987|Active Comparator|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
16647065|NCT02300987|Placebo Comparator|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
16647066|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
16647067|NCT02300948|Experimental|PregVit-Folic 5®-5 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
16647068|NCT02300948|Active Comparator|PregVit®-1.1 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit® contains 1.1 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
16647069|NCT02300935|Experimental|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
16647070|NCT02300922|Experimental|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:
~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
16647071|NCT02300909|Experimental|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
16647072|NCT02300909|Other|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
16647073|NCT02300896|Experimental|Intervention|Group-based exercise training during hospitalization Procedure: Exercise training. Individual program training 5 days a week during hospitalization
16647074|NCT02300896|No Intervention|Control|Usual care including rehabilitation when necessary
16647075|NCT02300883||no treatment|no treatment
16647076|NCT02300870||Heart Transplant Rejection|Patients presenting with acute cellular rejection
16647077|NCT02300870||Heart Transplant Control|Patients presenting for routine office visit
16647078|NCT02300857|Active Comparator|Low carbohydrate diet|
16647083|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
16647084|NCT02300818|Active Comparator|Pulsed Electromagnetic Field Therapy|"Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
~PEMF has also proved to be beneficial in vision acuity of patients with low vision. In 50 per cent of the cases, values improved. Patients with vision acuity of 0.2 diopters showed improvement from 46 before treatment to 75 after treatment.
~Different studies on varied diseases have proved that Pulsed Electromagnetic Field Therapy (PEMF) treatment is a safe, non-invasive and effective option for curing ocular conditions."
16647085|NCT02300818|Active Comparator|Seawater eyedrops|instantly soothes and clears the eye irritation caused by pollution, pollen, smoke, etc. It is a very practical system for eye daily hygiene · enables efficient therapeutic help in basic eye conditions such as: · · internal and external stye blepharitis and keratoconjunctivitis · · Conjuntiviti Episcleritis and scleritis
16647086|NCT02300792|Active Comparator|honey|Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
16647087|NCT02300792|Placebo Comparator|molasses|Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
16647088|NCT02300779|Experimental|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
16647089|NCT02300779|Active Comparator|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
16647090|NCT02300766||Posterior fossa tumor patients|Children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th ventricle/brainstem ) requiring surgery or open biopsy at one of the participating centres.
16647091|NCT02300740|Experimental|low dose|500 mg nicotinamide riboside oral
16647092|NCT02300740|Experimental|high dose|1000 mg nicotinamide riboside oral
16647093|NCT02300727|Active Comparator|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.
~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
16647094|NCT02300727|Experimental|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
16647095|NCT02300727|Other|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).
~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
16647096|NCT02300714|Active Comparator|AP group|oblique view approach during transforaminal epidural block
16647097|NCT02300714|Active Comparator|OB group|oblique view approach during transforaminal epidural block
16647098|NCT02300701|Experimental|Xolair/Omalizumab|
16647099|NCT02300701|Placebo Comparator|Placebo|
16647100|NCT02300688|Experimental|Arm 1|Period 1 (Treatment A) - Wash out - Period 2 (Treatment B)
16647101|NCT02300688|Experimental|Arm 2|Period 1 (Treatment B) - Wash out - Period 2 (Treatment A)
16647102|NCT02300675|No Intervention|control arm|Patients follow the classic support prescription of hormonotherapy
16647103|NCT02300675|Experimental|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
16647104|NCT02300662|Experimental|Cycle Ergometer|Conventional physiotherapy and cycle ergometer 20 minutes, at 20 cycles per minute, once per day for as long as they remain on invasive mechanical ventilation
16647105|NCT02300662|Sham Comparator|Conventional Physiotherapy|Upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method and manual bronchial hygiene exercises.
16647106|NCT02300649|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
16647107|NCT02300649|Placebo Comparator|Control group|Saline will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
16647108|NCT02300636|Experimental|Training: open kinetic|"Co-contraction training in open kinetic chain position
~8 weeks, 3 days in a week"
16647109|NCT02300636|Experimental|Training: closed kinetic|"Co-contraction training in closed kinetic chain position
~8 weeks, 3 days in a week"
16647110|NCT02300636|Active Comparator|Training: Standard ACL rehabilitation|"Standard ACL rehabilitation
~8 weeks, 3 days in a week"
16647111|NCT02300623|Active Comparator|Control|Antiretroviral therapy alone
16647112|NCT02300623|Experimental|Treatment|Antiretroviral therapy plus Interleukin-2'
16647113|NCT02300610|Experimental|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
16647114|NCT02300610|Experimental|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
16647115|NCT02300597|Experimental|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
16647116|NCT02300597|No Intervention|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
16651130|NCT02273453|Experimental|Songha® Night|
16647117|NCT02300584|Experimental|Prototype Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
16647118|NCT02300584|Experimental|Field Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Based on the feedback from the prototype program, the videos may vary. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
16647119|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
16647120|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
16647121|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
16647122|NCT02300532||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
16647123|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
16647124|NCT02300506||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg, and enrolled in study GLI01S.
16647125|NCT02300493|Experimental|Experimental|weigh themselves daily
16647126|NCT02300493|Active Comparator|Control|Weigh themselves every six months
16647127|NCT02300480|Experimental|CTB group|Participants in this group will receive a single injection for calot's triangle block combined with PCIA post-operatively. CTB will be conducted by bile duct needle and 1.0% 10 ml ropivacaine will be injection in calot's triangle when before surgical dissection.Participants in this group will also receive PCIA after surgery,the regimens of PCIA are included tramadol 800 mg, flurbiprofenaxetil 100 mg with normal saline added up to a volume of 80 ml in total.
16647128|NCT02300480|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with normal saline added up to a volume of 80ml in total ) .The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
16647129|NCT02300467|Experimental|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
16647130|NCT02300454|Active Comparator|Non-slip element balloon (NSE)|Lacrosse® NSE dilatation before use of SeQuent® Please drug coated balloon (DCB)
16647131|NCT02300454|Placebo Comparator|Balloon|Non-compliant balloon dilatation before use of SeQuent® Please drug coated balloon (DCB)
16647132|NCT02300428||1-year cohort|"Patients with at least 1 prescription of any oral iron preparation in the last 2 years and who have at least 1 year of follow up data post-prescription.
~It is anticipated that ca. 123,000 patients in CPRD fulfil this criteria."
16647133|NCT02300428||10-year cohort|"All pre-menopausal women (18-45 years old) with at least 1 prescription of one ferrous iron salt (i.e. sulphate, fumarate and gluconate) since January 2000.
~It is anticipated that ca. 299,000 patients in CPRD fulfil this criteria."
16647134|NCT02300415||patient with sepsis|Patients admitted to the emergency department and with criteria of sepsis.
16647135|NCT02300389|Experimental|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
16647136|NCT02300389|Active Comparator|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
16647137|NCT02300376|Experimental|Calcium edetate de sodium versus inulin|The designing a Bayesian model of the plasma clearance of Calcium edetate de sodium is compared to the renal clearance of Inulin.
16647138|NCT02300363|Experimental|Treatment A|10 mg oral rosuvastatin administration
16647139|NCT02300363|Experimental|Treatment B|400 mg oral LX4211 qd administration
16647140|NCT02300363|Experimental|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
16647141|NCT02300350|Experimental|Treatment A|0.5 mg single-dose oral digoxin administration
16647142|NCT02300350|Experimental|Treatment B|400 mg oral LX4211 qd administration
16647143|NCT02300350|Experimental|Treatment C|0.5 mg single-dose oral digoxin administration + 400 mg oral LX4211 qd administration
16647144|NCT02300337|Experimental|Reduce Cuff Pressure|Cuff Pressure difference between inspiration and expiration is measured.
16647145|NCT02300324|Experimental|Standard v Beneforte v Beneforte Extra|This is a randomized, double-blinded, three-phase crossover trial investigating the bioavailability of SF following consumption of three types of broccoli + stilton soup containing different concentrations of glucoraphanin. The three types of soup are standard broccoli and stilton soup, beneforte broccoli and stilton soup, and beneforte extra broccoli and stilton soup.
16647146|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
16647147|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
16651131|NCT02273453|Active Comparator|Placebo + Oxazepam|
16647148|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
16647149|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
16647150|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
16647151|NCT02300272||Typically healthy older adults|Adults 65 years and older with only common late-life medical conditions who will complete a screening that includes a Polysomnograph and assessment that includes Actiwatch.
16647152|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
16647153|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
16647154|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
16647155|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
16647156|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
16647157|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
16647158|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
16647159|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
16647160|NCT02300246|Experimental|Test Group|Alveolar socket post-extraction covered with PRF
16647161|NCT02300246|No Intervention|Control Group|Only clot (spontaneous healing)
16647162|NCT02300233|Active Comparator|volanesorsen|
16647163|NCT02300233|Placebo Comparator|Placebo|
16647164|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
16647165|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
16647166|NCT02300207|No Intervention|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
16647167|NCT02300207|Experimental|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
16647168|NCT02300194|Active Comparator|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
16647169|NCT02300194|Placebo Comparator|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
16647170|NCT02300181|Placebo Comparator|Placebo (flour)|5 placebo capsules for each test (4.88 kcal/5 cap)
16647171|NCT02300181|Experimental|Bacillus subtilis var natto DC-15|5 experimental capsules for each test (4.96 kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
16647172|NCT02300155|Experimental|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
16647173|NCT02300155|Active Comparator|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
16647174|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
16647175|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
16647176|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
16647177|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
16647178|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
16647179|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
16647180|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:
~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)
~Period 2 (cross-over design):
~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
16647287|NCT02299492|Experimental|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
16647288|NCT02299492|No Intervention|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
16647743|NCT02296255|No Intervention|no HPV vaccine|No delivery of HPV vaccine
16647181|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:
~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
~Period 2 (cross-over design):
~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
16647182|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:
~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
~Period 2 (cross-over design):
~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
16647183|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:
~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
~Period 2 (cross-over design):
~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
16647184|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
16647185|NCT02300090||Intervention group|This group of patients (n=250) will receive the digital service (smart phone application and bluetooth inhaler device) in addition to current best care from their healthcare professional.
16647186|NCT02300090||Control group|This group of patients (n=250) will receive current best care alone. Control patients will not have access to the digital service.
16647187|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
16647188|NCT02300077|Active Comparator|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
16647189|NCT02300077|Active Comparator|Treatment methadone 0.15 mg/kg|
16647190|NCT02300064|Experimental|Healthy volunteers|Healthy volunteers will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
16647191|NCT02300064|Experimental|COPD patients|Patients with Chronic Obstructive Pulmonary Disease (COPD) will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
16647192|NCT02300051|Experimental|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
16647193|NCT02300051|Active Comparator|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
16647194|NCT02300051|Experimental|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
16647195|NCT02300038|Active Comparator|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
16647196|NCT02300038|Placebo Comparator|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
16647197|NCT02300025|Experimental|Cohort 1: Normal function|
16647198|NCT02300025|Experimental|Cohort 2: Mild Hepatic Impairment|
16647199|NCT02300025|Experimental|Cohort 3: Moderate Hepatic Impairment|
16647200|NCT02300025|Experimental|Cohort 4: Severe Hepatic Impairment|
16647201|NCT02300012|No Intervention|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
16647202|NCT02300012|Experimental|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
16647203|NCT02300012|No Intervention|Non-operation|Patients with ACL rupture not requiring operation
16647204|NCT02300012|No Intervention|Control|Healthy age matched volunteers - No operation
16647205|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
16647206|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
16647207|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
16647317|NCT02299245|Active Comparator|randomised to rosuvastatin (10mg/d)|randomised to rosuvastatin (10mg/d)
16647884|NCT02295137|Experimental|pre-procedure image guidance|
16647208|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
16647209|NCT02299986||Single arm Ultrasound measurement|Ultrasound measurement
16647210|NCT02299973|Placebo Comparator|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
16647211|NCT02299973|Experimental|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
16647212|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
16647213|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
16647214|NCT02299960||AH|patients with hypertension
16647215|NCT02299960||Nephropathy|patients with diabetic nephropathy
16647216|NCT02299947|Experimental|Haemocomplettan P|Study patients that receive Haemocomplettan P
16647217|NCT02299947|Placebo Comparator|NaCl 0.9%|Study patients that receive NaCl 0.9%
16647218|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
16647219|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
16647220|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
16647221|NCT02299908|Experimental|TAP block with Bupivacaine at 0.25%|Intervention: Injection of local anesthetics in the transverses abdominal plane
16647222|NCT02299908|Placebo Comparator|Placebo saline solution|Placebo: Injection of saline solution in the transverses abdominal plane
16647223|NCT02299882|Experimental|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
16647224|NCT02299882|No Intervention|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
16647225|NCT02299869|Other|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
16647226|NCT02299869|Other|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
16647227|NCT02299869|Other|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
16647228|NCT02299869|Other|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
16647229|NCT02299856||Myocarditis|Patients with strong clinical evidence for acute myocarditis (recent infection, elevated troponin and white blood cell count).
16647230|NCT02299856||Healthy Controls|Healthy volunteers without any signs of cardiac disease.
16647231|NCT02299843|Active Comparator|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
16647232|NCT02299843|Experimental|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
16647233|NCT02299830|Experimental|cryotherapy|give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
16647234|NCT02299830|Experimental|argon plasma coagulation|give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
16647235|NCT02299830|Experimental|stent|give the cases whose central airway stricture were caused by neoplasm compression stent placement
16647236|NCT02299830|Experimental|snare|give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
16647237|NCT02299817|Active Comparator|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
16647238|NCT02299817|Placebo Comparator|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
16647239|NCT02299804|Experimental|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
16647240|NCT02299804|Experimental|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
16647241|NCT02299804|Placebo Comparator|Placebo arm|Have no any active component
16647242|NCT02299791|Active Comparator|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
16647243|NCT02299791|Active Comparator|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
16647244|NCT02299778|Experimental|1mg of 13C6-p-aminobenzoic acid|
16647245|NCT02299765|Experimental|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.
~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
16647246|NCT02299765|Active Comparator|Arm B|Gefitinib 250mg/d until disease progression
16647247|NCT02299752|Experimental|Catheterization|Blood vessel Catheterization during resuscitation with single and double - gloving system. Catheterization was performed using simulation mannikin
16647248|NCT02299726|Experimental|Active|spironolactone
16647249|NCT02299726|Placebo Comparator|Placebo|matching placebo to active study drug
16647250|NCT02299713|Sham Comparator|placebo/sham acupuncture|There are different types of controls used in acupuncture trials. We used the control described as sham and by some as minimal acupuncture. This group had the same schedule as the electro-acupuncture group. Sham acupuncture was administered, with the same duration and frequency and by the same specialist who performed the non-sham acupuncture. Retractable needles were placed into small adhesive cylinders, so that the needles were supported but did not perforate the skin. The acupuncturist placed the needles at the same points as the non-sham group and used the same pairs of electrodes to simulate the electrical connection.
16647318|NCT02299232|Active Comparator|dexmedetomidine 3mcg/kg|dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
16647251|NCT02299713|Active Comparator|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat knee pain. The points selected were local points St 34, St 35, St 36,Liv 8, Sp 10. One distal point St 44.A total of six needles were inserted into each leg by the acupuncturist (the out come measures were not specifically targeted to whether the patient had one or both knees involved). All patients belonging to this group experienced a De Qi sensation, which is a tingling and numbness sensation upon needling of specific points.
16647252|NCT02299700||Autism Spectrum Disorder (ASD) Participants (6-9 years)|Participants with ASD aged 6 to 9 years will be observed for the usability of the Janssen Autism Knowledge Engine (JAKE) personal healthcare record (pHR) and biosensors in stage 1 and stage 2 (at laboratory sites).
16647253|NCT02299700||ASD Participants (13-17 years)|Participants with ASD aged 13 to 17 years will be observed for the usability of the JAKE pHR and biosensors in stage 1 and stage 2 (at laboratory sites).
16647254|NCT02299700||ASD Participants (3 or greater than 3 years)|Participants with ASD aged 3 or greater than 3 years will be observed for the usability of the JAKE pHR and biosensors in stage 2 (at clinical sites).
16647255|NCT02299687|Experimental|CYP2C19 EM|CYP2C19 EM
16647256|NCT02299687|Experimental|CYP2C19 IM|CYP2C19 IM
16647257|NCT02299687|Experimental|CYP2C19 PM|CYP2C19 PM
16647258|NCT02299674||Persons with unilateral transfemoral amputation|
16647259|NCT02299661|Experimental|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
16647260|NCT02299661|Experimental|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
16647261|NCT02299661|Experimental|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
16647262|NCT02299648|Other|Single arm|molecular profiling, patient derived cells
16647263|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
16647264|NCT02299609|Active Comparator|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
16647265|NCT02299609|Sham Comparator|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
16647266|NCT02299596|Experimental|Pre and postoperative exercise|"The intervention is prehabilitation preoperatively and physical training postoperatively. During the hospital stay both groups will be treated in the same manner.
~Preoperative intervention:
~One half hour of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.
~Inspiratory muscle training. Thirty breaths x two twice daily. Postoperative intervention is mainly the same as preoperatively."
16647267|NCT02299596|No Intervention|Control|Standard treatment with one exception, patients will fill in a physical activity diary
16647268|NCT02299583|Experimental|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
16647269|NCT02299583|No Intervention|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
16647270|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
16647271|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
16647272|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
16647273|NCT02299557|Experimental|Treatment|Intra-anal Oxymetazoline gel once daily
16647274|NCT02299557|Placebo Comparator|Placebo|Intra-anal Placebo gel once daily
16647275|NCT02299544|Experimental|OAB|"Patients with overactive bladder (OAB) with or without urge incontinence.
~Two patient populations will be enrolled in the study:
~Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) [de novo patient group] and Patients with a documented success on PTNS therapy [prior-PTNS group]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review.
~All patients will be treated with BlueWind Medical System."
16647276|NCT02299531|Experimental|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
16647277|NCT02299531|Experimental|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
16647278|NCT02299531|Experimental|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
16647279|NCT02299531|Experimental|High Energy Density, Small Portions|High meal energy density and small portion sizes
16647280|NCT02299531|Experimental|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
16647281|NCT02299531|Experimental|High Energy Density, Large Portions|High meal energy density and large portion sizes
16647282|NCT02299518|Experimental|Cohort A (mitoxantrone, etoposide, cytarabine, selinexor)|Patients receive mitoxantrone hydrochloride IV, etoposide IV, and cytarabine IV QD on days 1-6 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment continues for 1 course (28 days). Further treatment is based on disease response. Patients achieving CR/CRi are evaluated for stem cell transplant; patients who do not proceed to transplant may receive selinexor as monotherapy in the absence of disease progression or unacceptable toxicity.
16647283|NCT02299518|Experimental|Cohort B (etoposide, selinexor)|Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
16647284|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 450 mg (3×150 mg/capsule) administered in the morning immediately (within 30 minutes)following a low-fat meal.
16647285|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 600 mg (4×150 mg/capsule) administered in the morning immediately (within 30 minutes) following a low-fat meal.
16647286|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|Oral ceritinib QD (21 days/ cycle) at a dose of 750 mg (5×150 mg/capsule) administered in the morning on an empty stomach (i.e., fasted from food and drink except water)
16647289|NCT02299479|Experimental|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
16647290|NCT02299453|Experimental|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
16647291|NCT02299453|No Intervention|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
16647292|NCT02299440|Experimental|Ketamine|"Patients randomized to this group will be treated via Ketamine infusion.
~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions"
16647293|NCT02299440|Placebo Comparator|Placebo/Control|"Patients randomized to this group will be treated via saline solution infusion.
~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions"
16647294|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
16647295|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
16647296|NCT02299414|Experimental|Anti-hypertensive therapy to goal <140/90 mmHg|Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
16647297|NCT02299414|Active Comparator|No anti-hypertensive unless BP is severe (≥160/105 mmHg|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used
16647298|NCT02299401|Experimental|Buccal|Women randomized to receive three 800 mcg doses of misoprostol taken buccally in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
16647299|NCT02299401|Experimental|Sublingual|Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
16647300|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
16647301|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
16647302|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
16647303|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
16647304|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
16647305|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
16647306|NCT02299336|Other|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
16647307|NCT02299310|Experimental|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
16647308|NCT02299310|Active Comparator|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
16647309|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
16647310|NCT02299284|Experimental|Hand-Arm Bimanual Intensive Therapy (HABIT)|HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
16647311|NCT02299284|Experimental|Intensive Functional Lower-Limb Training|lower-limb function, strength training, balance, PT, OT, rehab
16647312|NCT02299271|Active Comparator|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
16647313|NCT02299271|Placebo Comparator|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
16647314|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
16647315|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
16647316|NCT02299245|Experimental|randomised to rosuvastatin (20mg/d)|randomised to rosuvastatin (20mg/d)
16651132|NCT02273453|Placebo Comparator|Placebo|
16647319|NCT02299232|Active Comparator|dexmedetomidine 4mcg/kg|dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI
16647320|NCT02299219|Experimental|Taking Charge Experimental Group|
16647321|NCT02299219|Active Comparator|Control Group|
16647322|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
16647323|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
16647324|NCT02299193|Experimental|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
16647325|NCT02299193|Sham Comparator|Healthy Sleep Habits|online sessions about healthy sleep practices
16647326|NCT02299180|No Intervention|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
16647327|NCT02299180|Experimental|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
16647328|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
16647329|NCT02299154|Experimental|Patient with memory disorders|psychological questionnaires
16647330|NCT02299154|Experimental|Accompanier|psychological questionnaires
16647331|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle
16647332|NCT02299128|Sham Comparator|Minimally Therapeutic Treatment|Non-differential, prescriptive protocol of physical therapy treatment with minimal to no therapeutic benefit.
16647333|NCT02299128|Experimental|Skilled Treatment|Differential treatment based on the results from the assessment. Physical Therapy treatment in this arm will be pragmatically designed and modified by the treating therapist. Treatments will include manual therapy to the cervical spine, neuromotor retraining (position sense and movement sense), habituation and adaptation exercises.
16647334|NCT02299115|Experimental|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
16647335|NCT02299115|Active Comparator|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
16647336|NCT02299102|Other|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
16647337|NCT02299102|Other|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
16647338|NCT02299089|Experimental|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
16647339|NCT02299089|Experimental|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
16647340|NCT02299089|Experimental|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
16647341|NCT02299089|Experimental|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
16647342|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
16647343|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
16647344|NCT02299063|Placebo Comparator|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
16647345|NCT02299063|Experimental|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
16647346|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day
~Other Names:
~Bromocriptine Mesylate Quick Release"
16647347|NCT02299024|No Intervention|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
16647348|NCT02299024|Experimental|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
16647349|NCT02299011|Experimental|Orsiro drug eluting stent|Orsiro drug eluting stent
16647350|NCT02299011|Active Comparator|Biomatrix drug eluting stent|Biomatrix drug eluting stent
16647351|NCT02298998||Intervention|The intervention group refers to surveillance based on the EAU guidelines.
16647352|NCT02298998||Control|The control group refers to surveillance based on the AUA guidelines.
16647353|NCT02298985|Active Comparator|curcumin|curcumin 3 g/day for 6 months
16647354|NCT02298985|Placebo Comparator|placebo|curcumin 3 g/day for 6 months
16647355|NCT02298972|No Intervention|Comparison group|The comparison group will receive standard care.
16647356|NCT02298972|Active Comparator|Intervention group|After completion of the comparison group, new patients starting chemotherapy treatment will be offered this study. Study participants will receive the nurse support and selfmanagement intervention.
16647486|NCT02298036|No Intervention|Treatment as Usual|Participants do not receive remote therapy and remain in usual care
16779870|NCT01407653|Other|usual care|
16647357|NCT02298959|Experimental|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab IV over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Cycles repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
16647358|NCT02298946|Experimental|DL1 - CTX, SBRTx1 day, & AMP-224|Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses
16647359|NCT02298946|Experimental|DL2 - CTX, SBRTx3 days, and AMP-224|Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
16647360|NCT02298933|Experimental|Eculizumab|1200 mg IV infusion over 30-40 min
16647361|NCT02298920|Experimental|Single Group|Open Label ADME Study
16647362|NCT02298881||Dry eye group|People with dry eye symptoms
16647363|NCT02298881||Non-dry eye group|People with no dry eye symptoms
16647364|NCT02298868|Experimental|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
16647365|NCT02298855|No Intervention|Conventional follow-up|Treatment as usual will involve: one post treatment appointment then 3 monthly appointments with a Dr. At appointments: medical history; investigations to monitor disease progression including CA125 tumour marker blood test if this were raised at diagnosis. A physical examination may be performed.
16647366|NCT02298855|Experimental|Individualised follow-up|Follow-up is delivered by a nurse and frequency and type (telephone or face-to-face) is negotiated to suit their individual situation. Assessment by holistic guide. The intervention is informed by a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to help patients manage symptoms and psychological discomfort.
16647367|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
16647368|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
16647369|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
16647370|NCT02298816||new B-Cell Hematologic Malignancy diagnosis|All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).
16647371|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
16647372|NCT02298790|Experimental|Early Meals|Meals are eaten early in the wake episode
16647373|NCT02298790|Experimental|Late Meals|Meals are eaten late in the wake episode
16647374|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)
~Biological samples (skin, urine and blood):
~1st point at patient's inclusion visit
~2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
16647375|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
16647376|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
16647377|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
16647378|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
16647379|NCT02298764|Active Comparator|standard + 10 psychotherapeutic sessions|- standard back pain treatment plus 10 psychotherapeutic sessions, that will include the shock-trauma method 'Somatic Experiencing'.
16647380|NCT02298764|Active Comparator|Standard back pain treatment|Standard back pain treatment
16647384|NCT02298738||New onset Atrial fibrillation|New-onset AF was defined as patients with hypertension and atrial fibrillation which was identified for the first time by an electrocardiogram or ambulatory holter monitoring.
16647385|NCT02298738||control|Hypertensive patients without atrial fibrillation.
16647386|NCT02298725|Experimental|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
16647387|NCT02298725|Experimental|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
16647388|NCT02298712||Observation|Patients with Hurler disease or high-grade suspicion for Hurler disease
16647389|NCT02298699||Observation|Patients with Sly disease or high-grade suspicion for Sly disease
16647390|NCT02298686||Observation|Patients with Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease
16647391|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
16647490|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
16647392|NCT02298660|Experimental|BOTOX|BOTOX® Total dose per patient: 200U Number of cycles:1 cycle Treatments will be conducted according to established protocol, 200 BOTOX® units with intradetrusor injections under cystoscopic guided injections into 20 sites, trigone sparing. One month later, urodynamics with continuous arterial blood pressure and electrocardiogram measurements will be repeated, as well as 24 hour ambulatory blood pressure monitoring. AD- HR QoL and I-QOL questionnaires will be administered to evaluate the effect of Botox on AD HR-QoL and bladder-related QoL.
16647393|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
16647394|NCT02298634||Observation|Patients with Farber disease or high-grade suspicion for Farber disease
16647395|NCT02298621|Experimental|pomegranate juice|pomegranate juice: 500 ml
16647396|NCT02298621|Placebo Comparator|placebo|sugar + aroma+ color: 500ml
16647397|NCT02298608|Experimental|Irreversible Electroporation|Percutaneous, CT guided, Irreversible Electroporation of renal mass
16647398|NCT02298595|Experimental|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
16647399|NCT02298595|Experimental|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
16647400|NCT02298595|Experimental|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
16647401|NCT02298582|Experimental|Intranasal fentanyl|
16647402|NCT02298569|No Intervention|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
16647403|NCT02298569|Experimental|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
16647404|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
16647405|NCT02298543||coronary spasm|
16647406|NCT02298530|Experimental|Combination of caffeine and theanine|250 mg caffeine + 200 mg theanine
16647407|NCT02298530|Placebo Comparator|Caffeine|250 mg caffeine
16647408|NCT02298517|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
16647409|NCT02298517|Experimental|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
16647410|NCT02298517|Experimental|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
16647411|NCT02298517|Experimental|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
16647412|NCT02298517|Experimental|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
16647413|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
16647414|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
16647415|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
16647416|NCT02298491|Experimental|H.P. Acthar Gel|
16647417|NCT02298478|Experimental|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
16647418|NCT02298478|Experimental|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
16647419|NCT02298478|Other|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.
~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
16647420|NCT02298465|Active Comparator|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
16647421|NCT02298465|Experimental|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
16647422|NCT02298452|Other|Hearing aid|172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.
16647423|NCT02298426|Experimental|health management and product|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
16647424|NCT02298426|Experimental|general management and product|"We provide general information about health. Information is provided through telephones and materials.
~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
16647425|NCT02298426|Experimental|health management and placebo|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
~Meanwhile, we use placebo to replace the dietary supplement products."
16647426|NCT02298426|Placebo Comparator|general management and placebo|"We provide general information about health. Information is provided through telephones and materials.
~Meanwhile, we use placebo to replace the dietary supplement products."
16647427|NCT02298400|Active Comparator|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
16647428|NCT02298400|Active Comparator|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
16647429|NCT02298400|Active Comparator|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
16647430|NCT02298387|Experimental|OMP-305B83|The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
16647431|NCT02298374|Experimental|Homecare reablement|Receives comprehensive assessment and individualized follow-up according to a plan with short and longterm goals.
16647432|NCT02298374|Active Comparator|Usual care|Receives normal care
16647433|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
16647434|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
16647435|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
16647436|NCT02298348|Other|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
16647437|NCT02298335|Experimental|prednisone|First,full-dose induction period, then protracted tapering period.
16647438|NCT02298322|Experimental|CoolSculpting Treatment|The intervention is the CoolSculpting System.
16647439|NCT02298309|No Intervention|Usual Care|Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa
16647440|NCT02298309|Active Comparator|Test-and-Treat Intervention|Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.
16647441|NCT02298296||No treatment|
16647442|NCT02298283|Experimental|study treatment|"induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks
~radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks
~Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
16647443|NCT02298270|Experimental|Relaxation Response Resiliency Program|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
16647444|NCT02298270|Placebo Comparator|Health Education|Participants will receive and 8-week general stress and health education program, with none of the active relaxation and resiliency-based components being tested in the experimental condition.
16647445|NCT02298257|Experimental|Treatment (BV + combination chemotherapy)|Patients receive doxorubicin hydrochloride given IV , vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16647446|NCT02298244|Active Comparator|PV isolation + GP Ablation|
16647447|NCT02298244|Active Comparator|PV isolation + GP ablation + Pulmonary GP ablation|
16647448|NCT02298231|Experimental|Group 1|Standard of Care Balance (SCB) Treatment
16647449|NCT02298231|Experimental|Group 2|Mystic Isle (MI) Balance Training
16647450|NCT02298231|Experimental|Group 3|Mystic Isle (MI) Dual Task Training
16647451|NCT02298218|Experimental|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
16647452|NCT02298218|No Intervention|No intervention|During 6 months, without meloxicam, the maintenance will be decided by the comparison of liver stiffness score comparing the intervention group.
16647453|NCT02298205|Other|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
16647454|NCT02298205|Active Comparator|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
16647455|NCT02298192|Experimental|Once weekly titration|
16647456|NCT02298192|Experimental|Twice weekly titration|
16647457|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
16647458|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
16647459|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
16647460|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
16647461|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
16647462|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
16647463|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
16647464|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
16647465|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
16647466|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
16647467|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
16647468|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
16647469|NCT02298166|Placebo Comparator|Standard arm|chemotherapy (MC) in combination with placebo
16647470|NCT02298166|Experimental|Experimental arm|chemotherapy (MC) in combination with crenolanib
16647471|NCT02298153|Experimental|atezolizumab (MPDL3280A) + epacadostat (INCB024360)|atezolizumab (MPDL3280A) 1200 mg given every 3 weeks + epacadostat (INCB024360) 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
16647472|NCT02298140|Experimental|SMS reminders|This arm will receive automated mobile phone text message reminders for health workers in outpatient departments of public and private health facilities on issues related to care of malaria patients and suspected patients.
16647473|NCT02298127|Experimental|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
16647474|NCT02298127|Experimental|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
16647475|NCT02298127|Sham Comparator|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
16647476|NCT02298114|Experimental|neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine. The electrodes will be placed over the motor points of the following muscles: pectoral muscles (fibres of the pectoralis major muscle) and rectus abdominis muscles (bilaterally) The first training session will have a duration of 30 minutes , which will then be extended by 1 minute for every 2 days of administration. The intensity will be increased until muscle contraction is visible or palpable or, intensity will be adjusted according to tolerance associated conventional physiotherapy. Neuromuscular electrical stimulation will be applied held until extubation end conventional respiratory and motor physiotherapy until discharge from the ICU.
16647477|NCT02298114|Sham Comparator|Conventional physiotherapy|Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
16647478|NCT02298101|Active Comparator|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
16647479|NCT02298101|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
16647480|NCT02298088|Active Comparator|Ticagrelor 180 mg|Patients assigned to Ticagrelor will receive oral Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
16647481|NCT02298088|Active Comparator|Clopidogrel|"Patients will take the 300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.
~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
16647482|NCT02298062|Experimental|Infliximab|For one group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them infliximab (5mg/kg) once.
16647483|NCT02298062|Active Comparator|IVIG|For the other group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them IVIG (2g/kg) once.
16647484|NCT02298049|Other|Scanning|"Repeated measures:
~Satiation scan + Pre-meal scan
~All participants undertook both scans"
16647485|NCT02298036|Experimental|Remote Therapy Offered|Participants randomised to this arm receive 6-10 sessions of remote CBT
16647491|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
16647492|NCT02297997|Experimental|1.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 1.5mg will be taken daily for two weeks.
16647493|NCT02297997|Experimental|3mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 3mg will be taken daily for two weeks.
16647494|NCT02297997|Experimental|4.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 4.5mg will be taken daily for two weeks.
16647495|NCT02297997|Experimental|6mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 6mg will be taken daily for two weeks.
16647496|NCT02297997|Placebo Comparator|Control|Placebo will be taken daily for two weeks.
16647497|NCT02297984||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
16647498|NCT02297945|Experimental|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
16647499|NCT02297932|Experimental|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
16647500|NCT02297932|Active Comparator|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
16647501|NCT02297919|Experimental|web based intervention|Web based intervention: Students will have access to the educational content through the learning management system on the web site (genc-e-saglik) created for this project.
16647502|NCT02297919|Active Comparator|classic preprepared lesson|Training at the control group,lectures will be presented on the basis of the classic preprepared lesson by educator and at the end of the training, will be answered student's questions.
16647503|NCT02297906|Experimental|Intranasal ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intranasal route using a mucosal atomization device.
16647504|NCT02297906|Active Comparator|Intravenous ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
16647505|NCT02297893|Experimental|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
16647506|NCT02297893|Active Comparator|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
16647507|NCT02297880|Experimental|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners (flavour)
16647508|NCT02297880|Active Comparator|Still water|Still water (no flavour)
16647509|NCT02297867|Experimental|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
16647510|NCT02297854|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
16647511|NCT02297854|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
16647512|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
16647513|NCT02297828|Experimental|Boussignac CPAP|"Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
16647514|NCT02297828|Active Comparator|Ventury face mask|"Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
16647515|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
16647516|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
16647517|NCT02297789|Experimental|Headgear 1|Full Face Mask with Headgear 1
16647518|NCT02297789|Experimental|Headgear 2|Full Face Mask with Headgear 2
16647519|NCT02297776||CPC score 1 to 2|The patients with CPC score 1 to 2 judged half a year after cardiac arrest
16647520|NCT02297776||CPC scores 3 to 5|The patients with CPC score 3 to 5 judged half a year after cardiac arrest
16647521|NCT02297763|Active Comparator|quetiapine|quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
16647522|NCT02297763|Placebo Comparator|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
16647523|NCT02297750|Active Comparator|single wire technique|single wire technique in patients undergoing ERCP with biliary cannulation
16647524|NCT02297750|Active Comparator|Double wire technique|double-wire technique in patients undergoing ERCP with biliary cannulation
16647578|NCT02297360|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
16647579|NCT02297334|Active Comparator|With CytoSorb device|Patients randomised to this arm are treated with the CytoSorb device during bypass.
16647525|NCT02297737|Experimental|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
16647526|NCT02297737|Active Comparator|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
16647527|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
16647528|NCT02297711|Experimental|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
16647529|NCT02297711|Active Comparator|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
16647530|NCT02297698|Experimental|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
16647531|NCT02297698|Active Comparator|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
16647532|NCT02297685|Sham Comparator|Sham Transcutaneous nerve stimulation|The group with sham TENS did not receive any current. Four surface electrodes (5×5 cm Prim-Trode®, Spain) were symmetrically placed over the L1 and L5 transverse processes with respect to the spine. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
16647533|NCT02297685|Experimental|Transcutaneous nerve stimulation|The group with TENS received current at a frequency of 80 Hz and with a pulse width of 150 μs with two channels, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
16647534|NCT02297685|Experimental|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
16647535|NCT02297672|Experimental|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
16647536|NCT02297659|Active Comparator|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
16647537|NCT02297659|Active Comparator|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
16647538|NCT02297646|Experimental|Carbohydrates|50 grams of carbohydrates 4 times a week for each training session
16647539|NCT02297646|Placebo Comparator|Control|no carbohydrate intake
16647540|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
16647541|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
16647542|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
16647543|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
16647544|NCT02297620||Suglat group|
16647545|NCT02297607|Experimental|Tube Feeding|Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
16647546|NCT02297607|No Intervention|Standard of Care|Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,
16647547|NCT02297594|Experimental|AK0529|Generic name: AK0529 Dosage Form: capsule
16647548|NCT02297594|Placebo Comparator|Placebo|Sugar placebo
16647580|NCT02297334|No Intervention|Withouot device|Patients randomised to this arm are treated without the CytoSorb device during bypass.
16647581|NCT02297321|Experimental|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
16647582|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
16647583|NCT02297295|Experimental|Physiotherapy|Comparing the patients to themselves (spontaneus evolution) before intervention.
16649153|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
16647549|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center
~A GFC is defined as follows:
~General geriatrician or ortho-geriatrician available in trauma/orthopaedic department
~Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)
~Local medical guidelines, consented by orthopedic surgeons and geriatrician
~Pre-defined order set for assessing laboratory values
~Pre-defined patient pathway to guarantee a fast track in the emergency room
~Daily communication among involved specialists
~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):
~Daily patient visit by geriatrician
~Daily patient visit by orthopedic surgeon in combination with nurse
~Daily therapy by physiotherapists, except for weekends
~Access to social workers, if required"
16647550|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center
~A UCC is defined as follows:
~No geriatrician available in trauma/orthopaedic department
~No pre-operative visit by a geriatrician as a standard
~No pre-defined medical guidelines for geriatric fracture patients
~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):
~No daily patient visits by a geriatrician as a standard"
16647551|NCT02297568|Active Comparator|Calciferol,1800 IU/d supplement|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to 1,800 IU/d .
16647552|NCT02297568|Placebo Comparator|Placebo|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to receive placebo.
16647553|NCT02297555|No Intervention|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
16647554|NCT02297555|Experimental|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
16647555|NCT02297542|Active Comparator|Flu Vaccine SD|Fluzone Standard Dose Influenza Vaccine
16647556|NCT02297542|Active Comparator|Flu Vaccine HD|Fluzone High Dose Influenza Vaccine
16647557|NCT02297516|Experimental|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
16647558|NCT02297516|Experimental|Filler as single treatment|Filler as single treatment at initial treatment
16647559|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
16647560|NCT02297503|Experimental|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
16647561|NCT02297490|Placebo Comparator|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
16647562|NCT02297490|Experimental|Allergovit 6-grasses immunotherapy|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
16647563|NCT02297477|Active Comparator|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
16647564|NCT02297477|Active Comparator|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
16647565|NCT02297464|Experimental|Eggs - 2 per day for breakfast|Participants will consume 2 eggs per day for breakfast for 4 weeks of the study.
16647566|NCT02297464|Experimental|Oatmeal - 1 packet per day for breakfast|Participants will consume 1 packet of oatmeal per day for breakfast for 4 weeks of the study.
16647567|NCT02297451|No Intervention|Brachial artery inflow|Elbow fistula created with brachial artery as inflow (ie. either brachiocephalic or brachiobasilic fistulas)
16647568|NCT02297451|Active Comparator|Proximal radial/ulnar artery as inflow|Elbow fistula created with either proximal radial or ulnar artery as inflow
16647569|NCT02297438|Experimental|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
16647570|NCT02297438|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
16647571|NCT02297425|Experimental|Single agent - study drug|The study will evaluate single-agent PF-06459988
16647572|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16647573|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16647574|NCT02297399|Experimental|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
16647575|NCT02297399|Active Comparator|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
16647576|NCT02297386|Experimental|[18F] DIHYDRO-TESTOSTERONE PET|"The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely quantitative, that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass)."
16647577|NCT02297360|Active Comparator|Viviscal Extra-Strength Supplement|Viviscal Extra-strength tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
16784845|NCT01372150|Experimental|Placebo|
16647584|NCT02297282|Experimental|Behavioural Activation|Originally a component of Cognitive Therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
16647585|NCT02297282|No Intervention|Wait List (Control Group)|The Control group (waitlist) will receive treatment as usual while they are waiting to start the BA intervention at the end of the Intervention Group Therapy time (28 sessions over an 18 week period). In addition to usual care, the control group will be assessed by clinical staff that offers treatment as usual for mood symptoms and quality of life measures during the waiting time.
16647586|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
16647587|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
16647588|NCT02297256|Active Comparator|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
16647589|NCT02297256|Active Comparator|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
16647590|NCT02297243|Experimental|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
16647591|NCT02297230|Experimental|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
16647592|NCT02297230|Experimental|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
16647593|NCT02297230|Experimental|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
16647594|NCT02297230|Experimental|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
16647595|NCT02297217|Experimental|Chemotherapy with Concurrent Radiation|Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
16647596|NCT02297204|Experimental|aflibercept|"2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.
~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.
~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
16647597|NCT02297191|Experimental|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.
~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
16647598|NCT02297178||Cystoscopy Alone|Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
16647599|NCT02297178||Cystoscopy & Urethral Dilatation|Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
16647600|NCT02297165|Experimental|Program|olfactory stimulation program
16647601|NCT02297165|No Intervention|Control|normal follow-up
16647602|NCT02297152|Other|FLIP HOLE|The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation
16647603|NCT02297139|Experimental|Dasatinib|This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
16647635|NCT02296918|Experimental|Double combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
16647636|NCT02296918|Experimental|Double combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
16647637|NCT02296918|Experimental|Triplet combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with rituximab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
16647604|NCT02297126|No Intervention|Control Arm|4,000 patients receiving a new prescription for targeted medication(s) randomized into the control arm receive standard care (no intervention affecting drug selection, dosage, dosage form, frequency and duration of therapy). Healthcare costs and adverse events data collected and analyzed for 12 months from time of entry into study. List of targeted medications: codeine, amitriptyline, aripiprazole, atazanavir, atomoxetine, azathioprine, citalopram, clopidogrel, cyclophosphamide, doxepin, efavirenz, escitalopram, esomeprazole, fluconazole, simvastatin, fluorouracil, phenytoin, quetiapine, glyburide, lansoprazole, mercaptopurine, methadone, methotrexate, nortriptyline, omeprazole, pantoprazole, rasburicase, tacrolimus, thioguanine, tramadol, venlafaxine, voriconazole and warfarin
16647605|NCT02297126|Experimental|Pharmacogenetic Intervention Arm|2,000 patients receiving new prescription for targeted medication(s) identified in the control arm will be randomized to the intervention arm, consented and a tests will be performed from a blood sample. The treating physicians will be provided with the pharmacogenetic information and will determine if intervention is appropriate. Physician may elect to stay the course of therapy or alter drug selection, dosage, dosage form, frequency or duration of therapy based on the pharmacogenetic test results and input from clinical pharmacology consultations (if requested). Patients in the intervention arm will have their overall healthcare costs and clinical outcomes (specifically adverse events) followed and analyzed for a 1 year period from the time that they are entered into the study
16647606|NCT02297113|Active Comparator|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
16647607|NCT02297113|Active Comparator|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
16647608|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
16647609|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
16647610|NCT02297087|Other|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
16647611|NCT02297074|Experimental|Ordinary White Bread|Ordinary white bread bread is characterised by a white crumb with regular soft alveoli and a slightly soft thin crust.
16647612|NCT02297074|Experimental|Precooked-Frozen White Bread|Precooked-Frozen white bread is characterized by white crumb with regular soft alveoli and bright crusty crust
16647613|NCT02297074|Experimental|Candeal-flour White Bread|Candeal-flour white bread has a thick crust of between one and two millimetres, which is smooth and crisp, golden to light brown in colour and which tastes of toasted cereal. The crumb of the bread is white and its texture is smooth, spongy and consistent, with little regular alveolus and with an intense cereal aroma with a pleasant and slightly sweet taste
16647614|NCT02297074|Experimental|Alfacar White Bread|Alfacar white bread is made according to its protected designation of origin and protected geographical indication (D.O. Alfacar, Granada, Spain). The bread has a creamy white, flexible and soft crumb, with many randomly scattered holes. The crust is medium-thick to thick, golden, slightly shiny and quite smooth
16647615|NCT02297074|Experimental|Organic Wholemeal Bread|The Organic wholemeal bread only includes organic whole grain flours as the unique difference compared with the Ordinary bread. The resulting dark brown bread is characterized by compact crumb free of alveoli and hard thin crust
16647616|NCT02297074|Active Comparator|Glucose|Glucose is used to calculate glycemic index, glycemic load and insulinemic index
16647617|NCT02297061||TEG group|200 consecutive hip fracture patients, Thrombelastography is performed on admission.
16647618|NCT02297048|Experimental|RU 486 (mifepristone)|Subjects will receive 400 mg once a day of RU486
16647619|NCT02297048|Placebo Comparator|Placebo|Subjects will receive placebo once a day
16647620|NCT02297035|Experimental|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
16647621|NCT02297035|Experimental|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
16647622|NCT02297022|Experimental|Deep Brain Stimulation|Patients with Prader-Willi syndrome to receive DBS.
16647623|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
16647624|NCT02296996|Experimental|Dabrafenib + trametinib|Single arm study with dabrafenib + trametinib combination therapy
16647625|NCT02296983|Experimental|Low dose arm|The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
16647626|NCT02296983|Experimental|Full dose arm|The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
16647627|NCT02296957|Experimental|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
16647628|NCT02296957|No Intervention|Control|Usual Care
16647629|NCT02296944||Children aged under 7 years old when tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
16647630|NCT02296944||Children aged 7 to 10 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
16647631|NCT02296944||Children aged 11 to 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
16647632|NCT02296944||Children aged over 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
16647633|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
16647634|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
16786669|NCT01359527||Total Hip Arthroplasty|
16647638|NCT02296918|Experimental|Triplet combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
16647639|NCT02296905|Experimental|Group I|Subjects with mild hepatic impairment
16647640|NCT02296905|Experimental|Group II|Subjects with moderate hepatic impairment
16647641|NCT02296905|Experimental|Group III|Subjects with severe hepatic impairment
16647642|NCT02296905|Experimental|Group IV|Subjects with normal hepatic function
16647643|NCT02296892|Experimental|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
16647644|NCT02296892|Placebo Comparator|Placebo|"Double-blind placebo arm as inactive control
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
16647645|NCT02296892|Active Comparator|Midazolam|"Open-label Midazolam arm: 1.75 mg* iv for sedation induction and 1.0 mg* iv for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
16647646|NCT02296879|Experimental|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.
~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
16647647|NCT02296853|Experimental|Severe Hepatic Impairment Group|Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
16647648|NCT02296853|Active Comparator|Matched Normal Hepatic Function Group|Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
16647649|NCT02296840|Experimental|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
16647650|NCT02296840|Active Comparator|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
16647651|NCT02296814|Active Comparator|Sinusitis Hevert SL Tablet|two weeks treatment
16647652|NCT02296814|Placebo Comparator|Placebo for Sinusitis Hevert SL Tablet|two weeks treatment
16647653|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
16647654|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
16647655|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
16647656|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
16647657|NCT02296788|No Intervention|No Exercise Control|Healthy Living Control Group
16647658|NCT02296788|Experimental|Aerobic Exercise Group|8 kcal/kg of body weight/week (KKW) (~900 kcal/wk)
16647659|NCT02296788|Experimental|Aerobic Exercise Group 2|20 KKW (~2250 kcal/wk)
16647660|NCT02296775|Experimental|DRL_RI|
16647661|NCT02296775|Active Comparator|Rituxan|
16647662|NCT02296775|Active Comparator|MabThera|
16647663|NCT02296762|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
16647664|NCT02296762|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
16647665|NCT02296749|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
16647666|NCT02296749|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
16647667|NCT02296736||Pancreatic malignancy|All patients who have undergone surgery for presumed pancreatic malignancy in Derriford Hospital between Jan 2006 and Jan 14 and had a Computerised tomography (CT) scan.
16647668|NCT02296723|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
16647669|NCT02296723|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
16647670|NCT02296710|Experimental|Echocardiographic and sleep apnea test|Echocardiographic Evaluation of systolic and diastolic function of both ventricles and evaluation of apnea-hypopnea index and type of apnea
16647671|NCT02296697|Active Comparator|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
16647672|NCT02296697|Active Comparator|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
16647673|NCT02296697|Placebo Comparator|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
16647706|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
16647707|NCT02296489||Healthy volunteers|
16647708|NCT02296489||Asthma patients|
16647709|NCT02296476|Experimental|Birabresib 80 mg|Participants received 80 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
16647710|NCT02296476|Experimental|Birabresib 120 mg|Participants received 120 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
16647674|NCT02296684|Experimental|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.
~Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:
~risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)
~optional image-guided radiation therapy
~risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course
~MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based on 's surgical pathology from standard of care surgery shows high risk features (positive margins or extracapsular extension). These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
16647675|NCT02296684|Experimental|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery
16647676|NCT02296671|Experimental|PEMOX|"Pemetrexed will be given intravenously (IV) on an outpatient basis on Day 1 of each 14-day cycle over 10 minutes. Oxaliplatin will be given (IV) on an outpatient basis on Day 1 of each 14-day cycle at a dose over 120 minutes. Drugs may be given in either order.
~-Oxaliplatin will be administered on Day 2 for Cycle 1 only. **"
16647677|NCT02296671|Experimental|FOLFOX|"The modified FOLFOX-6 regimen is the following drugs given every 14 days:
~Oxaliplatin on Day 1 of each cycle
~Leucovorin over 120 minutes on Day 1 of each cycle
~5-FU bolus and continuous infusion over 46 hours beginning on Day 1 of each cycle
~Oxaliplatin will be administered on Day 2 for Cycle 1 only and the 5-FU infusion will be interrupted at 20 hours so that the FLT-PET scan can be performed (only for FLT-PET scan eligible patients)."
16647678|NCT02296658|Experimental|S-1 based chemoradiotherapy|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy in a standard manner.
16647679|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
16647680|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
16647681|NCT02296619|Experimental|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
16647682|NCT02296619|Sham Comparator|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
16647683|NCT02296580|Experimental|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
16647684|NCT02296567|Active Comparator|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
16647685|NCT02296567|Active Comparator|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
16647686|NCT02296567|Active Comparator|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
16647687|NCT02296567|Active Comparator|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
16647688|NCT02296567|Active Comparator|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
16647689|NCT02296567|Active Comparator|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
16647690|NCT02296567|Active Comparator|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
16647691|NCT02296567|Active Comparator|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
16647692|NCT02296567|Active Comparator|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
16647693|NCT02296567|Active Comparator|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
16647694|NCT02296554|Experimental|SLAP Repair|Patient will receive SLAP repair for their SLAP tear.
16647695|NCT02296554|Experimental|Biceps Tenodesis Repair|Patient will receive biceps tenodesis repair for their SLAP tear.
16647696|NCT02296541|Experimental|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
16647697|NCT02296541|Placebo Comparator|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
16647698|NCT02296541|Experimental|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
16647699|NCT02296541|Placebo Comparator|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
16647700|NCT02296541|Experimental|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
16647701|NCT02296541|Placebo Comparator|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
16647702|NCT02296528|Other|Swallowing Expansion Device|Titanium swallowing expansion device
16647703|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
16647704|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
16647705|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
16651133|NCT02273440|Experimental|BIIL 284 BS with theophylline|
16647711|NCT02296476|Experimental|Birabresib 160 mg|Participants received 160 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
16647712|NCT02296463|Experimental|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
16647713|NCT02296463|Experimental|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
16647714|NCT02296463|Experimental|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
16647715|NCT02296463|Experimental|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
16647716|NCT02296463|Placebo Comparator|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
16647717|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
16647718|NCT02296437|Experimental|tDCS + CT|
16647719|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
16647720|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
16647721|NCT02296411|Experimental|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
16647722|NCT02296411|Placebo Comparator|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
16647723|NCT02296398||Romidepsin therapy|Patients who received romidepsin per standard of care practice or included in other clinical trials (when receiving romidepsin therapy).
16647724|NCT02296385|Experimental|Supplementation|Supplementation
16647725|NCT02296372|Other|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score < 7 at first day of measurement.
~Intervention: Measuring continuous glucose monitoring."
16647726|NCT02296372|Other|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score > 7 at first day of measurement.
~Intervention: Measuring continuous glucose monitoring."
16647727|NCT02296359||Asthma Discordant Monozygotic Twins|This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
16647728|NCT02296359||Non-Asthma Concordant Monozygotic Twins|This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.
16647729|NCT02296346|Active Comparator|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
16647730|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:
~ECP will be administered according to the following schedule:
~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
16647731|NCT02296333|Active Comparator|ondansetron|ondansetron iv, 8 mg, skin closure time
16647732|NCT02296333|Placebo Comparator|isotonic|isotonic 2ml, once, skin closure time
16647733|NCT02296320|Active Comparator|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
16647734|NCT02296320|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
16647735|NCT02296320|Active Comparator|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
16647737|NCT02296294|Active Comparator|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.
~Body Composition Monitoring every 10 minutes for 6hours."
16647738|NCT02296294|Placebo Comparator|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
16647739|NCT02296281|Experimental|treatment group|
16647740|NCT02296268||Pre-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
16647741|NCT02296268||Post-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
16647742|NCT02296268||Stroke Rehabilitation Physiotherapists|Physiotherapists whose current practice involves working full-time or part-time on in- or out-patient stroke service at the NSRC. Their self-efficacy regarding the clinical utilization of aerobic exercise post-stroke will be conducted prior to, and after, implementation of the Aerobics Clinic.
16788526|NCT01346917|Experimental|Lidocaine|
16647744|NCT02296255|Experimental|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
16647745|NCT02296242|Experimental|BVD-523|
16647746|NCT02296229|Experimental|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
16647747|NCT02296216|Active Comparator|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
16647748|NCT02296216|Placebo Comparator|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
16647749|NCT02296203|Experimental|cetuximab and irinotecan|
16647750|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
16647751|NCT02296190|Placebo Comparator|Placebo|1 dose of placebo via 4 intranasal applications at time 0
16647752|NCT02296177|No Intervention|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
16647753|NCT02296177|Active Comparator|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
16647754|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
16647755|NCT02296151|Placebo Comparator|Group A|Four iliotibial band stretches; to be completed 3 days per week.
16647756|NCT02296151|Active Comparator|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
16647757|NCT02296151|Experimental|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
16647758|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
16647759|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
16647760|NCT02296125|Experimental|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
16647761|NCT02296125|Active Comparator|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
16647762|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16647763|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
16647764|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
16647765|NCT02296086||Group I|"Study sites in which patients perform early mobilization as per local standard of care, which is as follows:
~2 days (at the latest) after surgery: Transfer from the bed to a sitting chair for the first time
~4 (± 2) days after surgery: Stand up and put both feet on the ground for the first time (walking aids allowed)
~5 (± 2) days after surgery: Walking (at least partial weight bearing, walking aids allowed)
~The patients are instructed by the investigator at the hospital about a standardized mobilization program to be followed at home"
16647766|NCT02296086||Group II|Study sites in which patients start walking (i.e. partial weight bearing, walking aids allowed) more than 7 days after surgery as per local standard of care
16647767|NCT02296073|Experimental|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
16647768|NCT02296073|Experimental|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
16647769|NCT02296073|Experimental|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
16647770|NCT02296073|Experimental|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
16647771|NCT02296060|Experimental|6 minutes walking test|
16647772|NCT02296047|Experimental|Group A|The medication order: subjects inhaled placebo,ipratropium bromide 80μg, salbutamol 400μg in sequence.
16647773|NCT02296047|Experimental|Group B|The medication order: subjects inhaled placebo, salbutamol 400μg, ipratropium 80μg in sequence.
16647774|NCT02296021|Experimental|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
16648083|NCT02293876|Sham Comparator|Eye drop|Eye drop LACRIBELL® - two drops each eye, three times a day, after eye cleansing.
16647775|NCT02296021|Active Comparator|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
16647776|NCT02296008|Other|surgery for Hirschsprung's disease|children after surgery for Hirschsprung's disease will undergo 3D high resolution anorectal manometry procedure
16647777|NCT02296008|Other|surgery for anorectal malformation|children after surgery for anorectal malformation will undergo 3D high resolution anorectal manometry procedure
16647778|NCT02296008|Other|surgery for other disorders|children after surgery for other disorders will undergo 3D high resolution anorectal manometry procedure
16647779|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
16647780|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
16647781|NCT02295982|Placebo Comparator|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
16647782|NCT02295982|Active Comparator|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
16647783|NCT02295956|Experimental|Home Based Exercise and Nutrition Program|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete. Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Exercise instructional booklet given to all participants describing all exercises. Participants to walk 20-30 minutes at least 3 times a week. Nutrition program discussed with participants. Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
16647784|NCT02295943|Other|Positioning measuring device|The supine time during the first postoperative day is measured
16647785|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:
~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
~l-LV 200 mg/sqm IV over 2-h, day 1 followed by
~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
~Surgical revaluation will be performed after the induction phase (8 cycles).
~Patients deemed unsuitable for surgery will received maintenance treatment as follows:
~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
16647786|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:
~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
~l-LV 200 mg/sqm IV over 2-h, day 1 followed by
~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
~Surgical revaluation will be performed after the induction phase (8 cycles).
~Patients deemed unsuitable for surgery will received maintenance treatment as follows:
~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
16647787|NCT02295891|Experimental|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.
~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
16647788|NCT02295878|Active Comparator|Treatment|400mg capsule containing seaweed extract (treatment)
16647789|NCT02295878|Placebo Comparator|Placebo|400mg capsule containing maltodextrin (placebo)
16647790|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
16647791|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
16647792|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
16647793|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
16647794|NCT02295852|Experimental|Group A: LOW-SODIUM LOW LIPID CALCIUM RICH DIET|Experimental Group A: patients will change their diet in a diet similar for total daily calories, sodium and macronutrients but enriched in calcium (1200 mg/daily) and will be followed up to 1 year with an intermediate control after the first 3 months;
16647795|NCT02295852|Active Comparator|Group B: LOW-SODIUM LOW LIPID DIET|Experimental Group B: patients will continue the low-lipid, low-sodium diet up to 1 year with an intermediate control after the first 3 months.
16647796|NCT02295839|No Intervention|Usual care|
16647797|NCT02295839|Experimental|Sleep Hygiene and Relaxation Education|
16647798|NCT02295826|Experimental|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients >80 years of age and/or an eGFR of 30-50 ml/min)
16647799|NCT02295826|Active Comparator|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
16647800|NCT02295813|Experimental|FBF001|"FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.
~FBF001 is administered once during 1 day or once per day during 5 days."
16647801|NCT02295813|Placebo Comparator|Placebo|The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
16647802|NCT02295800||Mothers|HIV Infected mothers
16647803|NCT02295800||Infants|HIV exposed infants
16647804|NCT02295800||Healthcare workers|Facility based healthcare workers
16647805|NCT02295787|Experimental|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
16647806|NCT02295787|Placebo Comparator|Placebo|Intranasal saline solution administered six times over three weeks.
16647807|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
16647808|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
16647809|NCT02295761|Active Comparator|Lifestyle counseling|12-weeks
16647810|NCT02295761|Active Comparator|Lifestyle counseling + activity watch|12-weeks
16647811|NCT02295748|Experimental|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
16647812|NCT02295735|Experimental|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
16647813|NCT02295735|No Intervention|Control|Standard pressure ulcer prevention according to hospital standard
16647814|NCT02295722|Experimental|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -
~IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.
~immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.
~Day 0
~•Stem cell infusion
~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
16647815|NCT02295709|Experimental|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
16647816|NCT02295709|Experimental|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
16647817|NCT02295709|Experimental|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
16647818|NCT02295696|Experimental|Intervention group|Intervention arm : EMMA consultations
16647819|NCT02295696|No Intervention|Control group|Control arm: Usual care/consultations
16647820|NCT02295670|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
16647821|NCT02295670|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16647822|NCT02295657|Experimental|ETI intubation|endotracheal intubation in manikin
16647823|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
16647824|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
16647825|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
16647826|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
16647827|NCT02295631|Experimental|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
16647828|NCT02295631|Experimental|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
16647829|NCT02295618|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16647830|NCT02295618|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
16647831|NCT02295605|Experimental|Land-based exercises|Land-based muscle strengthening exercises protocol
16647832|NCT02295605|Experimental|Water-based exercises|Water-based muscle strengthening exercises protocol
16647833|NCT02295592|Experimental|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
16647834|NCT02295592|Active Comparator|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
16647835|NCT02295566|Active Comparator|Nitric Oxide Group|Inhaled Nitric Oxide delivered via nasal canulae at 10ppm for 8 hours a night for 7 nights.
16647836|NCT02295566|Placebo Comparator|Control Group|Air/oxygen mix (according to clinical need) delivered via nasal canulae for 8 hours a night for 7 nights.
16647837|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
16647838|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
16647839|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
16647840|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
16647841|NCT02295540|Experimental|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
16647842|NCT02295527|Experimental|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
16647843|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
16647844|NCT02295514|Experimental|PTP1B dosage|PTP1B dosage during sepsis
16647845|NCT02295501|Experimental|EBOV convalescent donors|EBOV convalescent donors for passive immune therapy in subjects with acute EVD
16647846|NCT02295488|Experimental|Desensitization|Blood intake for biological sampling during validated desensitization protocol (Alyostall®)
16647847|NCT02295475|Experimental|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
16647848|NCT02295475|Active Comparator|Warfarin|Subjects will receive warfarin for the duration of the study, with the dose and frequency adjusted per clinician discretion to achieve an INR (International Normalized Ratio) between 2 and 4.
16647849|NCT02295462|Experimental|Person-centered Care|Medication Review + Person-centered Care
16647850|NCT02295462|Active Comparator|Optimised Treatment|Medication Review
16647851|NCT02295449|Experimental|1|
16647852|NCT02295436|Experimental|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
16647853|NCT02295436|Experimental|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
16647854|NCT02295436|Experimental|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
16647855|NCT02295436|Experimental|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
16647856|NCT02295410||Engaged in Home-Based CPT|Home-Based Telemental Health-Patients undergoing Home-Based CPT for PTSD
16647857|NCT02295410||Comparison|Treatment as Usual (TAU) Patients NOT receiving regular CPT or other evidence-based therapy for PTSD.
16647858|NCT02295397|Experimental|food provocation|open and placebo-controlled food challenges
16647859|NCT02295384||Audit Group|"Patients attending HHMP in Darlinghurst, Sydney, New South Wales with documented HIV-1 infection from 1st January 2005 to 31st July 2014, who were considered linked to care (Attendance during the study period for at least 2 visits >3 months and <12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site))."
16647860|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
16647861|NCT02295345|Experimental|CBT for Insomnia|Participants attend 5 weekly sessions of Cognitive Behavioural Therapy for Insomnia for pregnant women, administered by licensed clinical psychologist.
16647862|NCT02295332|Experimental|Cohort A|
16647863|NCT02295332|Experimental|Cohort B|
16647864|NCT02295319|Experimental|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
16647865|NCT02295319|No Intervention|Control|Usual discharge procedures
16647866|NCT02295293|Experimental|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
16647867|NCT02295293|Placebo Comparator|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
16647868|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
16647869|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
16647870|NCT02295267|Experimental|walnut allergy provocation|inclusion of walnut allergic patients, food provocation with walnut
16647871|NCT02295254||Research group|The study contain only one group: travelers who intended to travel to tropical destinations. The participants will give a feces sample before and after the travel.
16647872|NCT02295228||Adults undergoing total hip arthroplasty|No intervention will be administered, this is an observational trial. The study population includes adults 50+ who are undergoing elective total hip arthroplasty for osteoarthritis.
16647873|NCT02295215|No Intervention|Sedentary Group|The patients will not do exercise training
16647874|NCT02295215|Experimental|Trained Group|The patients will do exercise training for sixteen weeks.
16647875|NCT02295202|Experimental|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
16647876|NCT02295202|Placebo Comparator|Placebo|Nasal Strips
16647877|NCT02295189|Active Comparator|Visual analogue scale|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
16647878|NCT02295189|Active Comparator|Treatment|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
16647879|NCT02295176|Experimental|Armolipid Plus|Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
16647880|NCT02295176|Placebo Comparator|Placebo|1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
16647881|NCT02295163|Sham Comparator|Sham procedure|injection of NACL 0,9% in the stellate ganglion
16647882|NCT02295163|Experimental|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
16647883|NCT02295150|Experimental|Nadroparin|patients above 140 kg will receive a dose of 2850 IU nadroparine pre-operatively, anti-Xa factor will be determined 3 days after nadroparin use. After surgery patients receive 5700 IU nadroparin (our standard treatment). Three days after surgery and 4 weeks after surgery anti-Xa factor will be measured again.
16647885|NCT02295124|Active Comparator|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
16647886|NCT02295124|Active Comparator|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
16647887|NCT02295111|Active Comparator|EA treatment and TCM health consult|Participants randomized to the EA treatment will receive 2 EA +TCM health consult once a week x 4 weeks (8 total)
16647888|NCT02295111|Experimental|TCM health consult|Participants randomized to TCM health consult will receive 2 TCM health consult once a week x 4 weeks ( 8 total)
16647889|NCT02295111|Active Comparator|Usual care|Participants randomized to usual care will continue with their usual care
16647890|NCT02295098|Active Comparator|Thoracic epidural catheter|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
16647891|NCT02295098|Active Comparator|Paracostal catheter|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
16647892|NCT02295072|No Intervention|Control group|2 Usual Physical Education sessions/week
16647893|NCT02295072|Experimental|Intervention Group|A 5-months physical exercise-based program (3-5 Physical Education after school sessions/week + 2 Usual Physical Education sessions/week)
16647894|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
16647895|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
16647896|NCT02295046|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
16647897|NCT02295046|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
16647898|NCT02295033|Experimental|Boost irradiation|
16647899|NCT02295033|No Intervention|No boost irradiation|
16647900|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
16647901|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
16647902|NCT02295007|Other|text message|all families will receive text messages to which they can respond to report symptoms
16647903|NCT02294994|Experimental|half dose tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.075 µg per kilogram per minute for 24 to 36 hours.UFH heparin was administered as a bolus of 100 U/kg before PCI.
16647904|NCT02294994|Active Comparator|recommended-dose Tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours. UFH heparin was administered as a bolus of 100 U/kg before PCI.
16647905|NCT02294994|Placebo Comparator|none tirofiban|Tirofiban was not administered ,UFH heparin was administered as a bolus of 100 U/kg before PCI.
16647906|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
16647907|NCT02294981|Experimental|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
16647908|NCT02294968|Experimental|Family Startup|Family Startup plus usual pre- and postnatal care
16647909|NCT02294968|No Intervention|Control|Usual pre- and postnatal care
16647910|NCT02294955|Active Comparator|Catheterablation|Pulmonary vein isolation with Cryo-energy using a Arctic Front™ Cardiac CryoAblation Catheter or an irrigated radiofrequency ablation catheter, with an optional roof line.
16647911|NCT02294955|Active Comparator|Antiarrhythmic drug Class IC or III.|Serial testing of oral antiarrhythmic drugs; amiodarone 600 mg once daily 7-10 days, then 100-200 mg once daily; sotalol: 80-160 mg twice daily; flecainide 100 to 150 mg twice daily or entire dose as slow-release formula once daily; propafenone 300 mg twice daily; disopyramide 250-375mg twice daily, or dronedarone 400 mg twice Daily.
16647912|NCT02294942|Experimental|RANCAD 500mg|RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.
16647913|NCT02294942|Experimental|RANCAD 1000mg|RANCAD 2 tabs (500 mg), twice daily
16647914|NCT02294942|Active Comparator|Placebo|2 tabs, twice daily
16647915|NCT02294929|Other|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
16647916|NCT02294916|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16647917|NCT02294916|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16647918|NCT02294903|Experimental|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
16647919|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.
~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
16647951|NCT02294656|Active Comparator|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
16647952|NCT02294643|Active Comparator|aspirin, clopidogrel & sarpogrelate|the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (Anplag®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily
16647920|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.
~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
16647921|NCT02294864|Experimental|Pulsed Radiofrequency|Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
16647922|NCT02294864|Active Comparator|Physical Therapy|This group will receive standard of care outpatient physical therapy weekly for 3-4 weeks with therapist instructions to reduce knee pain.
16647923|NCT02294851|Experimental|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
16647924|NCT02294851|Placebo Comparator|Placebo|BMS-986168 Placebo
16647925|NCT02294838|Experimental|MRI with parotid gland stimulation|All participants will have MRI imaging of the parotid gland with IV Gadovist pre and post parotid stimulation with lemon juice. 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered. Approximately three minutes after scan commencement, the salivary glands will be stimulated by orally administering a small portion (≈5 ml) of Citric acid.
16647926|NCT02294812|Active Comparator|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
16647927|NCT02294812|Experimental|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
16647928|NCT02294812|Active Comparator|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
16647929|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
16647930|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
16647931|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
16647932|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
16647933|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
16647934|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
16647935|NCT02294760|Active Comparator|Subsensory, OFF, subsensory|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then turned OFF for the next 4 weeks and finally set subsensory for the last 4 weeks.
16647936|NCT02294760|Active Comparator|Subsensory, subsensory, OFF|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then set subsensory for another 4 weeks and finally turned OFF for the last 4 weeks.
16647937|NCT02294747|Active Comparator|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
16647938|NCT02294747|Active Comparator|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
16647939|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
16647940|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
16647941|NCT02294721|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
16647942|NCT02294721|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
16647943|NCT02294708|Experimental|supine|postoperative postures: patients in this arm are assigned to adopt supine position for 24 hours after the surgery
16647944|NCT02294708|Experimental|temporal lateral|postoperative postures: patients in this arm are assigned to adopt temporal lateral position for 24 hours after the surgery
16647945|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
16647946|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
16647947|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
16647948|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
16647949|NCT02294669|Experimental|Turris Facet Fuser|
16647950|NCT02294656|Experimental|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
16793375|NCT01312662||maculopathy|
16647953|NCT02294643|Placebo Comparator|aspirin, clopidogrel & placebo|the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily
16647954|NCT02294630|Active Comparator|Dose Schedule I|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
16647955|NCT02294630|Active Comparator|Dose Schedule II|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
16647956|NCT02294630|Active Comparator|Dose Schedule III|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
16647957|NCT02294630|Active Comparator|Dose Schedule IV|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2
16647958|NCT02294617|Active Comparator|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
16647959|NCT02294617|Active Comparator|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
16647960|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
16647961|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
16647962|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
16647963|NCT02294591|Active Comparator|NAC group|Receiving N-acetylcysteine as add-on treatment
16647964|NCT02294591|Placebo Comparator|Placebo group|Receiving placebo as add-on treatment
16647965|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
16647966|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
16647967|NCT02294565|Other|VST-1001 & 99mTc-labeled sulfur colloid|"VST-1001 (with medical devices) and 99mTc-labeled sulfur colloid are used together during a SLNB procedure in a single subject. Both drugs are evaluated for lymphatic mapping and localization of lymph nodes. The current standard of care for lymphatic mapping and lymph node localization during a SLNB procedure is a combined-modality technique that employs both a radiotracer (99mTc-labeled sulfur colloid is the radiotracer used in this study) and a vital blue dye (a patient receives both drugs). In this study, the vital blue dye is replaced with VST-1001 and companion medical devices.
~VST-1001 is excited by a medical device (blue-light LED illuminator) to fluoresce; the surgeon is wearing blue-light filtering eyewear to improve visualization of the relevant tissue structures."
16647968|NCT02294552|Experimental|Matched bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv
16647969|NCT02294552|Experimental|Matched peripheral blood stem cells graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
16647970|NCT02294552|Experimental|Mismatched peripheral blood stem cells or bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
16647971|NCT02294539|Experimental|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
16647972|NCT02294539|Experimental|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
16647973|NCT02294539|Active Comparator|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
16647974|NCT02294539|Active Comparator|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
16647975|NCT02294526|Experimental|Sardine diet|Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
16647976|NCT02294526|No Intervention|Control diet|Subjects only follow general dietary recommendations for diabetes.
16647977|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
16647978|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
16647979|NCT02294487||Subjects|Individuals over 50 who are going to get the seasonal flu vaccine, pneumococcal, HIB, and/or meningococcal vaccination and either have multiple myeloma or do not have multiple myeloma.
16647980|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
16647981|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
16647984|NCT02294448|Experimental|cohort 1|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)
16647985|NCT02294448|Experimental|cohort 2|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
16647986|NCT02294448|Experimental|cohort 3|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)
16651134|NCT02273440|Placebo Comparator|Placebo with theophylline|
16647987|NCT02294435|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
16647988|NCT02294435|Experimental|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
16647989|NCT02294422|Experimental|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
16647990|NCT02294422|Placebo Comparator|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
16647991|NCT02294409|Experimental|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
16647992|NCT02294409|Active Comparator|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
16647993|NCT02294396|Experimental|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
16647994|NCT02294396|Experimental|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
16647995|NCT02294396|Experimental|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
16647996|NCT02294396|Experimental|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
16647997|NCT02294383||Pre/post surgery pelvic floor assessment|
16647998|NCT02294383||Conservative treatmen monitoring|
16647999|NCT02294383||Pelvic floor muscle contrictions|
16648000|NCT02294383||Imaging reproducibility|
16648001|NCT02294370||subjects at the early stages of diabetes|Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test >7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose > 7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (<3 years)
16648002|NCT02294357|Experimental|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
16648003|NCT02294357|Experimental|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
16648004|NCT02294357|Experimental|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
16648005|NCT02294357|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
16648006|NCT02294357|Experimental|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
16648007|NCT02294344|Experimental|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)
16648008|NCT02294344|Active Comparator|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
16648009|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
16648010|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
16648044|NCT02294123|Experimental|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
16648045|NCT02294110||diabetes mellitus|spinal anesthesia
16648046|NCT02294097|No Intervention|Non-biopsy|Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
16650202|NCT02279875|Experimental|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
16648011|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
16648012|NCT02294305|Experimental|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
16648013|NCT02294305|Placebo Comparator|Placebo|Placebo PO QD for 12 weeks.
16648014|NCT02294292|Experimental|Carvedilol + Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
~if carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
16648015|NCT02294292|Active Comparator|Endoscopic Variceal Ligation (EVL)|
16648016|NCT02294279|Experimental|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
16648017|NCT02294279|No Intervention|Placebo|Blinded placebo inhaler
16648018|NCT02294266|Experimental|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration
~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
16648019|NCT02294266|Active Comparator|Mephedrone|"Mephedrone 200 mg, single dose, oral administration
~Lemon-flavoured water (350 ml), single dose, oral administration"
16648020|NCT02294266|Active Comparator|Alcohol|"Lactose 200 mg, single dose, oral administration
~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
16648021|NCT02294266|Placebo Comparator|Placebo|"Lactose 200 mg, single dose, oral administration
~Lemon-flavoured water (350 ml), single dose, oral administration"
16648022|NCT02294253|Experimental|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
16648023|NCT02294240|Experimental|Arm One|Energy dense biscuits will be provided throughout pregnancy after enrolment
16648024|NCT02294240|Placebo Comparator|Arm Two|Wheat Flour,oil, iron and folic acid will be provided fortnightly throughout pregnancy after enrolment
16648025|NCT02294227|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
16648026|NCT02294227|Experimental|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
16648027|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
16648028|NCT02294214|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
16648029|NCT02294214|Active Comparator|Intervention|Spatial Repellent product with active ingredient
16648030|NCT02294201|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
16648031|NCT02294201|Active Comparator|Intervention|Spatial Repellent product with active ingredient
16648032|NCT02294188|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
16648033|NCT02294188|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
16648034|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
16648035|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
16648036|NCT02294162|Experimental|0.5 mg/kg body weight Ketamin|Patients allocated to this arm will receive an iv dose of 0.5 mg/kg body weight ketamine.
16648037|NCT02294162|Placebo Comparator|5 ml normal saline as placebo|Patients allocated to this arm will receive an iv dose of 5ml saline as placebo.
16648038|NCT02294149|Placebo Comparator|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
16648039|NCT02294149|Experimental|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
16648040|NCT02294136|Experimental|Prep-C|Four session nurse administered behavioral intervention.
16648041|NCT02294136|Active Comparator|Educational Control|Attention Control
16648042|NCT02294123|Experimental|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
16648043|NCT02294123|Experimental|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
16648047|NCT02294097|Experimental|Protocol biopsy|Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
16793376|NCT01312662||optic neuropathy|
16648048|NCT02294084|Experimental|Sitagliptin|Subjects will receive Sitagliptin in a dosage of 100 mg/day p.o. for 12 weeks. The dosage corresponds to 1 gift/day.
16648049|NCT02294084|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks. Placebo will be given in 1 gift/day
16648050|NCT02294071|Experimental|acetaminophen|acetaminophen 15mg/kg (max 975mg)
16648051|NCT02294071|Experimental|ibuprofen|ibuprofen 10mg/kg (max 600mg)
16648052|NCT02294071|Experimental|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
16648053|NCT02294058|Active Comparator|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
16648054|NCT02294058|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
16648055|NCT02294058|Experimental|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
16648056|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
16648057|NCT02294019|Experimental|Ibuprofen caplet arm|
16648058|NCT02294006|Experimental|everolimus+octreotide LAR+metformin|everolimus+octreotide LAR+metformin
16648059|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
16648060|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
16648061|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
16648062|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
16648063|NCT02293980|Experimental|Part 1: PT2385 Tablets|PART 1: Multiple Dose/Dose-Escalation
16648064|NCT02293980|Experimental|Part 2: PT2385 Tablets and nivolumab|PART 2: PT2385 Tablets in combination with nivolumab
16648065|NCT02293980|Experimental|Part 3: PT2385 and cabozantinib tablets|PART 3: PT2385 Tablets in combination with cabozantinib tablets
16648066|NCT02293967|Experimental|MT-1303|[14C] MT-1303 after a single oral dose
16648067|NCT02293954|Experimental|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
16648068|NCT02293941|Experimental|JKB-122 5mg|5mg, oral, once daily
16648069|NCT02293941|Experimental|JKB-122 15 mg|15mg, oral, once daily
16648070|NCT02293941|Experimental|JKB-122 35 mg|35mg, oral, once daily
16648071|NCT02293941|Placebo Comparator|placebo|comparable capsule, oral, once daily
16648072|NCT02293928||Elective hybrid coronary revascularization|All patients are treated with non-enteric coated aspirin 75 mg once daily prior to study participation. Aspirin treatment is discontinued 8-10 days prior to surgery and resumed 6-9 hours after surgery. Left internal mammary grafting of the left descendent coronary artery is performed off-pump through an inferior J-hemisternotomy (JOPCAB). All patients receive an oral loading dose of aspirin 300 mg 6-9 hours after surgery followed by daily maintenance doses of 75 mg aspirin. An oral loading dose of clopidogrel 300 mg 12 hours prior to PCI is followed by daily maintenance doses of 75 mg for 12 months. Patients are followed for 1 year.
16648073|NCT02293915|Experimental|sodium oligo-mannurarate 900mg|
16648074|NCT02293915|Placebo Comparator|Placebo|
16648075|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
16648076|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
16648077|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
16648078|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
16648079|NCT02293889|Experimental|Vitamin D|Vitamin D3 2000IU/daily 3 months
16648080|NCT02293889|Experimental|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
16648081|NCT02293889|Experimental|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
16648084|NCT02293876|Sham Comparator|Ocular gel|Ocular gel LIPOSIC® applied three times a day at the lower palpebra from medium line to the lateral border.
16648085|NCT02293876|Sham Comparator|Glad wrap|Occlusion of the orbital area with a Glad wrap, turning the area into a moisture chamber.
16648086|NCT02293876|No Intervention|Control group|Ocular cleansing three times a day.
16648087|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
16648088|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
16648089|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
16648090|NCT02293850|Experimental|single intra-tumoral injection|OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
16648091|NCT02293837|Experimental|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
16648092|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
16648093|NCT02293824||Premature infants|Premature infants <29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.
16648094|NCT02293811|Other|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )
~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:
~healthy patients;
~patients with colonic Crohn disease in acute phase;
~patients with colonic Crohn disease in chronic phase;
~patients with ulcerative colitis in acute phase;
~patients with ulcerative colitis in chronic phase;
~patients with colon cancer"
16648095|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
16648096|NCT02293772|Active Comparator|Hypoxic ambulatory|Ambulatory in normobaric hypoxia
16648097|NCT02293772|Experimental|Hypoxic Bedrest|Bedrest in normobaric hypoxia
16648098|NCT02293772|Active Comparator|Normoxic bedrest|Bedrest in normobaric normoxia
16648099|NCT02293759|Active Comparator|HoLEP|Holmium laser enucleation of the prostate
16648100|NCT02293759|Active Comparator|Greenlight laser PVP|Phtoselective vaporization of the prostate
16648101|NCT02293746|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
16648102|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
16648103|NCT02293720|Experimental|EndoBarrier Device|Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
16648104|NCT02293707|Experimental|GX301 Regimen A (8 administrations)|Administration time frame: Day 1 to Day 63.
16648105|NCT02293707|Experimental|GX301 Regimen B (4 administrations)|Administration time frame: Day 1 to Day 63.
16648106|NCT02293707|Experimental|GX301 Regimen C (2 administrations)|Administration time frame: Day 1 to Day 63.
16648107|NCT02293694|Active Comparator|self-injection|Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
16648108|NCT02293694|Active Comparator|provider injection|Women randomized to this arm will received Sayana press from a family planning provider every three months.
16648109|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
16648110|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
16648111|NCT02293668|Active Comparator|Combined 450|Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
16648112|NCT02293668|Active Comparator|Combined 300|Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
16648113|NCT02293668|Active Comparator|Letrozole and hMG|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
16648139|NCT02293512|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
16648141|NCT02293512|No Intervention|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
16651135|NCT02273427|Active Comparator|BIIL 284 BS fasted|
16648114|NCT02293655|Placebo Comparator|MPH Discontinuation|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.
~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.
~DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
16648115|NCT02293655|Active Comparator|Sustained MPH|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.
~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.
~DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
16648116|NCT02293629|Placebo Comparator|A1: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
16648117|NCT02293629|Placebo Comparator|A2: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
16648118|NCT02293629|Placebo Comparator|A3: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
16648119|NCT02293629|Active Comparator|B1: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
16648120|NCT02293629|Active Comparator|B2: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
16648121|NCT02293616|Experimental|Nitrate Rich|A nitrate rich beetroot juice supplement (Beet It Shot®, James White Drinks, UK) high in nitrates will be provided to the subjects. Subject's diet will be supplemented once daily while hospitalized up to 14 days with one 70 ml bottle containing 300 mg of dietary nitrate.
16648122|NCT02293616|Placebo Comparator|Nitrate Depleted|This group will consume a beetroot juice supplement (Beet It Shot®, James White Drinks, UK) that has had the nitrate removed from the beverage by the manufacturer. Patient's diet will be supplemented once daily with one 70 ml bottle while hospitalized up to 14 days.
16648123|NCT02293603|Experimental|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
16648124|NCT02293603|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
16648125|NCT02293590|Experimental|intensive, adapted treatment strategy|"Experimental: intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200mg every 2 weeks after loading d 400mg at Weeks 0, 2 and 4
~DMARD:
~Patients without sufficient treatment response will be taken to the next step according to the therapeutic algorithm or next drug, for example: 15=>25mg Metoject (R)/week => Leflunomide Gebro (R)20mg/d => Salazopyrine EN(R) 2000mg/d
~Glucocorticoids:
~At Week, 0 patients will be initiated on Spiricort (R) 20mg/d and tapered every 5 days
~Joint injections:
~Starting at Week 0 up to 5 joint injections may be conducted into synovitic joints at every visit of the study.
~The maximum cumulative Lederlon (R) dose is 100mg/visit. Joints are to be infiltrated with the following doses of triamcinolone and lidocaine"
16648126|NCT02293590|Active Comparator|fixed-dosed program|"Intervention:
~Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.
~DMARD:
~Patients are to continue to receive their stable weekly dose of DMARD as noted at study entry for the duration of the study (24 weeks)
~Glucocorticoids:
~Prednisolone (Spiricort (R)) daily dose of ≤ 10 mg
~Joint injections:
~None"
16648127|NCT02293564|Experimental|gevokizumab|
16648128|NCT02293551|Experimental|Part A: Lispro (A)|Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
16648129|NCT02293551|Experimental|Part A: Lispro (B)|Formulation B: Single dose of lispro administered SC in one of five periods.
16648130|NCT02293551|Experimental|Part A: Lispro (C)|Formulation C: Single dose of lispro administered SC in one of five periods.
16648131|NCT02293551|Experimental|Part A: Lispro (D)|Formulation D: Single dose of lispro administered SC in one of five periods.
16648132|NCT02293551|Experimental|Part A: Lispro (Reference)|Reference formulation: Single dose of lispro administered SC in one of five periods.
16648133|NCT02293551|Experimental|Part B: Lispro|Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
16648134|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
16648135|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
16648136|NCT02293525|Active Comparator|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
16648137|NCT02293525|Placebo Comparator|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
16648138|NCT02293512|Experimental|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
16648140|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
16648142|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
16648143|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
16648144|NCT02293486|No Intervention|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
16648145|NCT02293486|Experimental|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
16648146|NCT02293486|Experimental|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
16648147|NCT02293473|Experimental|Protocol Group|"Using multimodal monitoring to optimise the patients' haemodynamic status, namely, the use of LiDCO Rapid, BIS-Bispectral Index Monitor and INVOS-Cerebral Oxygenation Monitor monitors to assess and fine tune the patient, as described in the study protocol in detail."
16648148|NCT02293473|Active Comparator|Control Group|Using current standard of care
16648149|NCT02293460|Experimental|I10E Arm|
16648150|NCT02293447|No Intervention|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
16648151|NCT02293447|Experimental|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
16648152|NCT02293447|Experimental|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
16648153|NCT02293434||All Children (1 month to 18 years)|All children (1 month to 18 years) admitted to all PICUs in France during three one-week periods (February, June, October) in the course of a year
16648154|NCT02293421|Other|STOP BANG|STOP BANG screening questionnaire and a snore question
16648155|NCT02293408||Component 1|Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.
16648156|NCT02293408||Component 2|Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).
16648157|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
16648158|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
16648159|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
16648160|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
16648161|NCT02293369|Active Comparator|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
16648162|NCT02293369|Active Comparator|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
16648163|NCT02293356|Experimental|Nimotuzumab Injection|200mg,Once a week，Intravenous infusion over 60 minutes
16648164|NCT02293343||control group|healthy subjects
16648165|NCT02293343||IgE positive|patients with high IgE level in serum
16648166|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
16648167|NCT02293330|Experimental|C group|continuous infusion of levobupivacaine
16648168|NCT02293330|Experimental|B group|Intermittent bolus infusion of levobupivacaine
16648169|NCT02293317|Experimental|M-001 0.5mg & TIV|M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
16648170|NCT02293317|Experimental|M-001 1.0mg & TIV|M-001 (1.0mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
16648171|NCT02293317|Placebo Comparator|Placebo & TIV|0.3ml Saline administered Intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
16648172|NCT02293304|Experimental|Self-etch approach|Application of universal adhesive as self-etch mode
16648173|NCT02293304|Experimental|Etch-and-rinse approach|Application of universal adhesive as etch-and-rinse mode
16648199|NCT02293135|Experimental|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
16648174|NCT02293291|Active Comparator|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.
~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
16648175|NCT02293291|Placebo Comparator|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.
~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
16648176|NCT02293278|Experimental|Physical Activity Intervention|"The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention.
~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
16648177|NCT02293278|No Intervention|Control Group|"Day cares randomly assigned to the control group will continue with their existing programming. Day care providers will receive the PA intervention upon completion of their involvement in the 6 month trial, including: 2 three hour educational workshops, Healthy Opportunities for Preschoolers manual and program outlining the ideal implementation of activities from the manual.
~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
16648178|NCT02293265|Other|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
16648179|NCT02293252|Experimental|Interventional group|Remote patient monitoring system (Motiva)
16648180|NCT02293252|No Intervention|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
16648181|NCT02293239|No Intervention|Control Group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
16648182|NCT02293239|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
16648183|NCT02293226|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16648184|NCT02293226|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions
16648185|NCT02293213|Active Comparator|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
16648186|NCT02293213|Experimental|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
16648187|NCT02293200|Experimental|Traditional learning|chest compression group learning without CPR feedback device. After a month of quality control of chest compressions is made also without the device.
16648188|NCT02293200|Experimental|Experimental learning|Training is done using TrueCPR feedback device. After a month of quality control of chest compressions is made without the device. To do this will be indicated on the impact of the use of feedback devices for improving the effectiveness of training in CPR.
16648189|NCT02293187|Active Comparator|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
16648190|NCT02293187|Placebo Comparator|Placebo|Placebo, microcrystalline cellulose
16648191|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
16648192|NCT02293161|Experimental|Cohort A GSK2618960|Subjects will receive GSK2618960 0.6 milligram per kilogram (mg/kg)
16648193|NCT02293161|Placebo Comparator|Cohort A Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
16648194|NCT02293161|Experimental|Cohort B GSK2618960|Subjects will receive GSK2618960,planned dose being 2mg/kg. However, actual dose level for Cohort B may be adjusted based on the emerging data on safety, tolerability, PK and RO from Cohort A. The maximum dose will not exceed 2.4 mg/kg (i.e. a 4-fold dose escalation from 0.6 mg/kg)
16648195|NCT02293161|Placebo Comparator|Cohort B Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
16648196|NCT02293148|Experimental|GSK1278863 (Part A)|All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A
16648197|NCT02293148|Experimental|GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)|Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule
16648198|NCT02293135|Experimental|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
16648200|NCT02293122||Observational|Observational group exposure to three test devices and one comparative device. The test Konan Non-con Robo Pachy F&A Specular Microscope.
16648201|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16648202|NCT02293096|Experimental|Metoprolol succinate, CYP2D6 Genotyping, CYP2D6 Phenotyping|"The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol. The following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.
~metoprolol succinate
~Genotyping: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete.
~CYP2D6 Phenotyping: Phenotype can be discordant from what is predicted by genotype. CYP2D6 henotyping using dextromethorphan will be used. Investigators will be blind to the patient blood pressure outcome for this intervention."
16648203|NCT02293083|Experimental|Lidocaine|Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
16648204|NCT02293083|Experimental|Hyaluronidase|Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml
16648205|NCT02293070|Experimental|Repeat Cardiac MRI Post Cryoablation|All subjects in this study receive a follow up delayed enhanced cardiac MRI 2-6 weeks after they undergo a cryoablation procedure.
16648206|NCT02293057|Active Comparator|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
16648207|NCT02293057|Placebo Comparator|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
16648208|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
16648209|NCT02293031|Experimental|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
16648210|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
16648211|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
16648212|NCT02293018|Experimental|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
16648213|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
16648214|NCT02292992|Experimental|Nasal pillow CPAP|Nasal pillow CPAP
16648215|NCT02292979|Active Comparator|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
16648216|NCT02292979|Experimental|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
16648217|NCT02292966|Experimental|Hepatitis C treatment|12 weeks of DCV/ASV/BCV therapy.
16648218|NCT02292927|No Intervention|Pre-intervention|Patients treated as standard before intervention
16648219|NCT02292927|Active Comparator|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
16648220|NCT02292914|Experimental|Robot-Assisted Surgery|patients undergoing robot assisted surgery for the treatment of cancer
16648221|NCT02292914|Active Comparator|Conventional Surgery|patients undergoing conventional surgery for the treatment of cancer
16648222|NCT02292901|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
16648223|NCT02292901|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
16648224|NCT02292888|Active Comparator|patients with LVEF >40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
16648225|NCT02292888|Active Comparator|patients with LVEF < or equal to 40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
16648226|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
16648227|NCT02292862||MG Main Group|lymph node and blood sampling
16648228|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
16648229|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
16648230|NCT02292836||rosacea patients|Questionnaire testing on routine dermatologist patient population
16648231|NCT02292836||non-rosacea patients|Questionnaire testing on routine dermatologist patient population
16648232|NCT02292810|Experimental|Inspiratory muscle exercise|Patients will exercise the inspiratory muscle using a load of 60% of maximum inspiratory mouth pressure (MIP 60%).
16648233|NCT02292810|Placebo Comparator|Inspiratory muscle exercise placebo|Patients will exercise the inspiratory muscle using a load of 2% of maximum inspiratory mouth pressure (MIP 2%).
16648331|NCT02292134|No Intervention|control|
16651136|NCT02273427|Experimental|BIIL 284 BS with high fat meal|
16648234|NCT02292784|Placebo Comparator|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous [IV] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
16648235|NCT02292784|Experimental|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram [mg] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
16648236|NCT02292784|Active Comparator|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter [mL] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
16648237|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
16648238|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
16648239|NCT02292758|Experimental|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16648240|NCT02292758|Active Comparator|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16648241|NCT02292745|Experimental|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
16648242|NCT02292732|Experimental|Trametinib/ ORTHO-NOVUM® tablet|Subjects in treatment period 1will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 21 days (Days 1 through 21), followed by one placebo tablet once daily at approximately the same time each day for 7 days (Days 22 through 28). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for a total of 17 days (Days 12 through 28). Subjects in treatment period 2 will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 11 days (Days 1 through 11). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for 11 days (Days 1 through 11).
16648243|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
16648244|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
16648245|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
16648246|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
16648247|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
16648248|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
16648249|NCT02292693|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
16648250|NCT02292680||NICU Tooth Study Cohort|All study subjects will have been cared for in the Mount Sinai NICU and have had the same hospital environment exposure.
16648251|NCT02292667|Experimental|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.
~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).
~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
16648252|NCT02292667|Active Comparator|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.
~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
16648253|NCT02292654|Experimental|Olipudase alfa|Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.
16651137|NCT02273427|Experimental|BIIL 284 BS with low fat meal|
16648254|NCT02292641|Other|Patients with advanced or recurrent rectal cancer|Provide these patients with a compartmentalized radiology report which will provide surgeons with data on optimal exenterative surgery
16648255|NCT02292628|Experimental|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
16648256|NCT02292628|Placebo Comparator|Ringer lactate solution|Ringer lactate solution
16648257|NCT02292615||cervical cancer|Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
16648258|NCT02292615||endometrial cancer|Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
16648259|NCT02292615||ovarian cancer|Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
16648260|NCT02292602|Experimental|Family-Based Weight Control Intervention|Families will receive the FBWC
16648261|NCT02292602|No Intervention|Control|Families will continue with standard of care at WIC
16648262|NCT02292589|Experimental|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
16648263|NCT02292589|Experimental|Temporal Stimulation|Left temporal cortex stimulation
16648264|NCT02292589|Experimental|Sham Stimulation|Sham stimulation
16648265|NCT02292576|Experimental|Acute dose/Chronic dose|Acute dose/Chronic dose.
16648266|NCT02292576|Experimental|Chronic dose/Acute dose|Chronic dose/Acute dose.
16648267|NCT02292563|Experimental|endoscopist only|Single inspection by endoscopist during colonoscopy
16648268|NCT02292563|Experimental|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
16648269|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
16648270|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
16648271|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
16648272|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
16648273|NCT02292550|Experimental|Ribociclib 300 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
16648274|NCT02292537|Experimental|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
16648275|NCT02292537|Sham Comparator|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
16648276|NCT02292524|No Intervention|Arm I: Control|Men in this group consumed a tomato free diet for the duration of the study (less than or equal to 5 mg lycopene/day) and, thus, did not consume a tomato intervention product.
16648277|NCT02292524|Experimental|Arm II: Juice|Commercially-available tomato food product: men in this group consumed V8® juice (11-16.5 fl. oz./day).
16648278|NCT02292524|Experimental|Arm III: Soup|Commercially-available tomato food product: men in this group consumed Campbell's® Tomato Soup (2-2 ¾ cups/day).
16648279|NCT02292524|Experimental|Arm IV: Sauce|Commercially-available tomato food product: men in this group consumed Prego® spaghetti sauce (5-7 oz./day).
16648280|NCT02292511|Experimental|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
16648281|NCT02292511|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
16648282|NCT02292498|Experimental|FLIR ONE thermal camera|Thermal camera (FLIR ONE)
16648283|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
16648284|NCT02292472|Experimental|Medytoxin®|Botulinum toxin type A
16648285|NCT02292472|Placebo Comparator|Normal Saline|Normal Saline
16648286|NCT02292459|Experimental|PEG 3350|Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
16648287|NCT02292459|Active Comparator|PEG 4000|Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
16648288|NCT02292446|Experimental|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
16648289|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
16648290|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
16648291|NCT02292407|Experimental|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
16648292|NCT02292394|Experimental|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
16648293|NCT02292394|Experimental|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
16648294|NCT02292394|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
16648295|NCT02292381||Glaucoma Patients|Patients with primary open angle glaucoma
16648296|NCT02292381||Healthy controls|age- and sex matched controls
16648297|NCT02292368|Experimental|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
16648298|NCT02292368|Experimental|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
16648299|NCT02292355|Experimental|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
16648300|NCT02292355|No Intervention|Occlusal splint|Control group who receive conventional treatment with occlusal splint
16648301|NCT02292342|Active Comparator|0.1 mg/ kg BW pure (-)-epicatechin|0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
16648302|NCT02292342|Active Comparator|0.5 mg/ kg BW pure (-)-epicatechin|0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
16648303|NCT02292342|Active Comparator|1.0 mg/ kg BW pure (-)-epicatechin|1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
16648304|NCT02292342|Placebo Comparator|0.0 mg/ kg BW pure (-)-epicatechin|Water only (3 ml/kg BW)
16648305|NCT02292329|Active Comparator|150g of acai fruit|150g of acai fruit in fruit smoothie form
16648306|NCT02292329|Placebo Comparator|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
16648307|NCT02292316|Experimental|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
16648308|NCT02292316|Sham Comparator|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
16648309|NCT02292303|Experimental|zinc-enriched yeast|zinc-enriched yeast capsules
16648310|NCT02292303|Active Comparator|zinc oxide|zinc oxide capsules
16648311|NCT02292303|Active Comparator|zinc gluconate|zinc gluconate capsules
16648312|NCT02292290|Active Comparator|Monotherapy 2|addition of Sulfonylurea or Pioglitazone to Metformin
16648313|NCT02292290|Experimental|Dual Therapy 1|Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)
16648314|NCT02292290|Active Comparator|Dual therapy 2|Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)
16648315|NCT02292290|Experimental|Monotherapy|Addition of Liraglutide to Metformin
16648316|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
16648317|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
16648318|NCT02292264||Surgical treatment of ventral hernia|Adult patients who underwent a ventral hernia Repair at Zealand University hospital
16648319|NCT02292251|Active Comparator|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
16648320|NCT02292251|Active Comparator|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
16648321|NCT02292238|Experimental|Benfotiamine|The patients in this arm will be treated with benfotiamine
16648322|NCT02292238|Placebo Comparator|Placebo|The patients in this arm will be treated with placebo
16648323|NCT02292225|Experimental|IPI-145 in Combination with Obinutuzumab|
16648324|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
16648325|NCT02292199|Experimental|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
16648326|NCT02292199|Active Comparator|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
16648327|NCT02292199|Placebo Comparator|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
16648328|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
16648329|NCT02292173|Experimental|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.
~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.
~Sorafenib: Twice daily, according to dose level upon entry.
~Each cycle is repeated every 28 days."
16648330|NCT02292134|Experimental|earplug and sleep mask|
16648332|NCT02292121|Experimental|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
16648333|NCT02292121|Active Comparator|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
16648334|NCT02292121|No Intervention|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
16648335|NCT02292108|Experimental|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
16648336|NCT02292108|Other|dietetic counselling|Patient will only benefit of usual dietetic counselling
16648337|NCT02292095|Experimental|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
16648338|NCT02292095|Active Comparator|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
16648339|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively
~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
~Surgeon will perform the periarticular injections:
~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
~Intravenous sedation with midazolam and propofol."
16648340|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively
~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
~Adductor canal block technique:
~Supine position, after IV sedation
~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
~Local anesthetic will be delivered periarterial between 12 and 6 o'clock
~Intravenous sedation with midazolam and propofol.
~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
16648341|NCT02292069|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
16648342|NCT02292069|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
16648343|NCT02292056|Experimental|Counseling Group|Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
16648344|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
16648345|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
16648346|NCT02292030||cardioversion+HTEA|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion+HTEA.
16648347|NCT02292030||only cardioversion|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion, but not with HTEA.
16648348|NCT02292017|Experimental|Embolization of intracranial aneurysm|Embolization with Target Coils
16648349|NCT02292004|Experimental|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
16648350|NCT02292004|Active Comparator|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
16648351|NCT02291991|Experimental|Group A|"Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo
~(1 subject : GX-E2, 1 subject : Placebo)
~Subjects in group A will be injected drug, So we observe safety. After three days, Subject in group B will be injected drug."
16648352|NCT02291991|Experimental|Group B|Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo (7 subjects : GX-E2, 1 subject : Placebo)
16648353|NCT02291978|Experimental|ExAblate 2100 Treatment|The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
16648354|NCT02291952|Experimental|Experimental|During Forced Desynchrony sleep and wake will occur at different circadian phases, while meals are restricted to the biological day.
16648355|NCT02291952|Other|Control|During Forced Desynchrony sleep and wake, as well as meals, will occur at different circadian phases.
16648356|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
16648357|NCT02291926|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
16648358|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
16648359|NCT02291900|Active Comparator|medial femoral condyle|Patients in this arm receive core decompression followed by free vascularized medial femoral condyle graft
16648360|NCT02291900|Active Comparator|core decompression|Patients in this arm receive core decompression followed by osseous autograft from the iliac crest
16648361|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
16648362|NCT02291874|Experimental|Ipragliflozin group|Ipragliflozin treatment
16648363|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
16648364|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
16650203|NCT02279875|Experimental|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
16648365|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
16648366|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
16648367|NCT02291848|Experimental|Group A|Patients receiving TAA-specific CTLs as therapy for Myeloma
16648368|NCT02291848|Experimental|Group B|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma
16648369|NCT02291809|Experimental|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
16648370|NCT02291809|Placebo Comparator|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
16648371|NCT02291796|Experimental|Bezafibrate group|Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment
16648372|NCT02291796|No Intervention|Control group|Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment
16648373|NCT02291783|Experimental|HTL0009936|HTL0009936 single and multiple ascending oral doses.
16648374|NCT02291783|Placebo Comparator|HTL0009936 Placebo|HTL0009936 matching placebo
16648375|NCT02291770|Active Comparator|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:
~MSC+prednisone+cyclosporine;
~MSC+prednisone+tacrolimus;
~MSC+prednisone+mycophenolate mofetil."
16648376|NCT02291770|Placebo Comparator|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:
~Placebo+prednisone+cyclosporine;
~Placebo+prednisone+tacrolimus;
~Placebo+prednisone+mycophenolate mofetil."
16648377|NCT02291757|Active Comparator|NEM brand eggshell membrane|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits.
16648378|NCT02291757|Placebo Comparator|Placebo|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.
16648379|NCT02291744|Experimental|XELOX plus surgery|Eight cycles of XELOX chemotherapy plus surgery:Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle. After 4 cycles, the patients are randomized to surgery group. Then the rest four cycles are administrated.
16648380|NCT02291744|Active Comparator|XELOX|Eight cycles of XELOX chemotherapy: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
16648381|NCT02291731|Experimental|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
16648382|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
16648383|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
16648384|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
16648385|NCT02291705|Experimental|rectus sheath block|rectus sheath block
16648386|NCT02291705|Active Comparator|tramadol|tramadol control group
16648387|NCT02291692|Active Comparator|Paravertebral blockade|Paravertebral blockade
16648388|NCT02291692|No Intervention|Paracetamol|The patients was given 15 mg/kg of paracetamol.
16648389|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
16648390|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
16648391|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
16648392|NCT02291666|Experimental|T2D patients with A1C ≤7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
16648393|NCT02291666|Experimental|T2D patients with A1C>7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
16648394|NCT02291666|Active Comparator|Non T2D subjects|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
16648395|NCT02291653|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16648396|NCT02291653|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16648397|NCT02291640|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16648398|NCT02291640|Experimental|Child ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
16648399|NCT02291627|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
16648441|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
16651138|NCT02273414|Experimental|BIIL 284 BS - rising dose|
16648400|NCT02291614|Experimental|AMG 211 200 μg/day for 7/14 Days|In cycle 1 participants receive 200 µg/day AMG 211 administered as a continuous intravenous infusion (cIV) infusion at a constant flow rate for 7 days followed by a 3-week treatment-free interval. In cycle 2 and thereafter, participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648401|NCT02291614|Experimental|AMG 211 200 μg/day for 14 Days|Participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648402|NCT02291614|Experimental|AMG 211 400 μg/day for 14 Days|Participants receive 400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648403|NCT02291614|Experimental|AMG 211 800 μg/day for 14 Days|Participants receive 800 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648404|NCT02291614|Experimental|AMG 211 1600 μg/day for 14 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648405|NCT02291614|Experimental|AMG 211 1600 µg/day for 28 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
16648406|NCT02291614|Experimental|AMG 211 3200 µg/day for 14 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648407|NCT02291614|Experimental|AMG 211 3200 µg/day for 28 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
16648408|NCT02291614|Experimental|AMG 211 6400 µg/day for 14 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
16648409|NCT02291614|Experimental|AMG 211 6400 µg/day for 28 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
16648410|NCT02291614|Experimental|AMG 211 12,800 µg/day for 28 Days|Participants receive 12,800 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
16648411|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
16648412|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
16648413|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
16648414|NCT02291588|Experimental|AMG 811|AMG 811 administered as subcutaneous and intravenous doses
16648415|NCT02291588|Placebo Comparator|Placebo|No active drug
16648416|NCT02291575|Experimental|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
16648417|NCT02291575|Active Comparator|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
16648418|NCT02291562|Experimental|Tetrahydrocannabinol|10 mg of Tetrahydrocannabinol as capsule (once)
16648419|NCT02291562|Experimental|Cannabidiol|600 mg Cannabidiol capsule (once)
16648420|NCT02291562|Placebo Comparator|placebo|placebo capsule (once)
16648421|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
~Mometasone furoate nasal spray (200mcg) once daily"
16648422|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure
~Mometasone furoate nasal spray (200mcg) once daily"
16648423|NCT02291536|Experimental|tetrahydrocannabinol|oral administration of 10mg of tetrahydrocannabinol, once
16648424|NCT02291536|Experimental|cannabidiol|oral administration of cannabidiol, 600mg, once
16648425|NCT02291536|Placebo Comparator|placebo|oral administration of placebo, once
16648426|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
16648427|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
16648428|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
16648429|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
16648430|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
16648431|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
16648432|NCT02291484|Experimental|Comprehensive cardiac CT|"Tiered cardiac CT protocol:
~CT calcium scan
~CT angiography (if calcium scan positive or high pre-test probability)
~CT perfusion (if >50% stenosis on CTA, or cannot be ruled out)"
16648433|NCT02291484|No Intervention|Standard care|Standard diagnostic management of suspected CAD, using stress testing
16648434|NCT02291471|Experimental|T0001|
16648435|NCT02291458|Experimental|L-arginine|Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
16648436|NCT02291458|Placebo Comparator|Placebo|Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
16648437|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
16648438|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
16648440|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
16648442|NCT02291406|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
16648443|NCT02291406|Active Comparator|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
16648444|NCT02291393|Other|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
16648445|NCT02291393|Other|Healthy volunteers|Aged and gender matched healthy controls.
16648446|NCT02291380|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose, dextran and gelatin.
16648447|NCT02291380|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but includes sucrose, dextran and gelatin.
16648448|NCT02291367|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|
16648449|NCT02291367|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
16648450|NCT02291354|Placebo Comparator|FMT + Placebo|Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.
16648451|NCT02291354|Experimental|FMT + Pectin|Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.
16648452|NCT02291341|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
16648453|NCT02291341|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
16648454|NCT02291328|Experimental|High Brassica|Participants will be asked to consume 3x 84g portions of frozen broccoli, 3x 84g portions of frozen cauliflower, and 3x 300g portions of frozen broccoli and sweet potato soups a week for a total of 2 weeks.
16648455|NCT02291328|Experimental|Low Brassica|Participants will be asked to consume 1x 84g portion of either frozen broccoli or frozen cauliflower in week one, and the remaining 84g portion of Brassica in week two.
16648456|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
16648457|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
16648458|NCT02291302|Placebo Comparator|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
16648459|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
16648460|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
16648461|NCT02291289|Experimental|Cohort 1: 5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
16648462|NCT02291289|Experimental|Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
16648463|NCT02291289|Experimental|Cohort 3: capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
16648464|NCT02291289|Experimental|Cohort 4: Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
16648465|NCT02291289|Active Comparator|Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
16648466|NCT02291289|Active Comparator|Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
16648467|NCT02291289|Active Comparator|Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
16648468|NCT02291289|Active Comparator|Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
16648501|NCT02291055|Experimental|Arm A|ADXS11-001& Medi4736, IV Infusion
16648502|NCT02291055|Experimental|Arm B|Medi4736, IV Infusion vs. ADXS11-001 & Medi4736, IV Infusion
16648469|NCT02291289|Other|Cohort 1: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
16648470|NCT02291289|Other|Cohort 2: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
16648471|NCT02291289|Other|Cohort 3: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
16648472|NCT02291289|Other|Cohort 4: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
16648473|NCT02291276||Female cancer patients with ascites|Primary epithelial ovarian female cancer patients with ascites (> 500 ml ascites in the preoperative sonographic examination)
16648474|NCT02291276||Female cancer patients aged > 70 years|"Primary epithelial ovarian female cancer patients aged > 70 years with at least one of the following secondary diagnoses:
~Status Post stent placement due to coronary heart disease respectively Status Post-myocardial infarction
~existing arterial Hypertension for more than 5 years
~chronic heart failure (New York Heart Association (NYHA) class II-III)
~peripheral arterial disease"
16648475|NCT02291263|Active Comparator|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
16648476|NCT02291263|Active Comparator|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
16648477|NCT02291263|Active Comparator|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
16648478|NCT02291250|Experimental|Sugar matched water with polycal OGTT|"Control: sugar matched (matched to currant sugar content) water with polycal
~Blackcurrants (200grams) with polycal
~Blackcurrants (200grams) with glucose
~Greencurrants (200grams) with polycal Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load.
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
16648479|NCT02291250|Experimental|Blackcurrants with polycal OGTT|"Blackcurrants (200grams) with polycal
~Blackcurrants (200grams) with glucose
~Greencurrants ( 200grams) with polycal
~Control: sugar matched (matched to currant sugar content) water with polycal
~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
16648480|NCT02291250|Experimental|Blackcurrants with glucose OGTT|"Blackcurrants (200grams) with glucose
~Greencurrants (200grams) with polycal
~Control: sugar matched (matched to currant sugar content) water with polycal
~Blackcurrants (200grams) with polycal
~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
16648481|NCT02291250|Experimental|Greencurrants with polycal OGTT|"Greencurrants (200grams) with polycal
~Control: sugar matched (matched to currant sugar content) water with polycal
~Blackcurrants (200grams) with polycal
~Blackcurrants (200grams) with glucose
~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments."
16648482|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
16648483|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
16648484|NCT02291224|Other|Control|The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
16650204|NCT02279875|Experimental|Linezolid 600 mg once per day (A)|600mg (scored) tablet
16648485|NCT02291224|Experimental|Intervention|"Enrollment
~Interactive multimedia platform focused on DP strategies.
~Intervention arm counseling by a health care provider to select DP strategy.
~Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.
~Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.
~6 month visit
~Abbreviated version of the interactive multimedia platform on DP strategies and adherence.
~Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.
~Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care."
16648486|NCT02291211|Experimental|S-1 plus cisplatin HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after palliative operation gastric cancer of stage IV limited peritoneal metastasis. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
16648487|NCT02291172|Experimental|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry. The comprehensive communication intervention: (a) teaches foundational social communicative behaviors, (b) related skills that predict long term language outcomes, (c) a range of communicative functions, (d) spoken language skills, (e) provides children with an immediate mode of communication, (f) incorporates instructional methods, contexts, and partners that increase both the critical skills for spoken language and social use of language. Because parents are essential partners for young children with ASD who are learning to communicate, we (g) include parents
16648488|NCT02291172|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
16648489|NCT02291159|Experimental|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
16648490|NCT02291159|Sham Comparator|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
16648491|NCT02291146|Experimental|LA Sprouts intervention|"The intervention classes will be taught during a 90-minute session once a week for 12 weeks. Participants will receive a 45-minute gardening lesson, taught by a Master Gardener (supervised by Dr. Gatto). This lesson will include learning how to plant, maintain and harvest various fruits and vegetables. Supplementing the gardening lesson, a USC nutrition educator, with help from various graduate students (supervised by PI Dr. Davis), will lead a 45-minute cooking activity and nutrition education lesson. Every participant will participate in the cooking activity and sample the food. The program will include lessons on growing crops that have cultural significance to Latino youth such as nopales, beans, corn and squash (the latter three crops are commonly referred to as the three sisters)."
16648492|NCT02291146|No Intervention|control|Approximately 200 students in the second region who are enrolled in LA's Best will serve as control participants. After the 12-week intervention is conducted and all post-testing measures are collected on controls, a vegetable/fruit garden will be built at both control schools and the LA Sprouts program will be taught to all 3rd, 4th and 5th graders in LAs Best and their parents at the control school as a delayed intervention.
16648493|NCT02291133|Experimental|Electrochemotherapy treatment|
16648494|NCT02291120|Active Comparator|MTA|ProRoot® MTA is a root canal repair material that is a unique improvement over other materials used for root canal repair. Made up of fine hydrophilic particles that set in the presence of water, ProRoot® MTA seals off all pathways between the root canal system and surrounding tissues, significantly reducing bacterial migration. Its excellent compatibility with the dentinal wall allows for a predictable clinical healing response.
16648495|NCT02291120|Experimental|MedCem Portland Cement (PC)|MedCem PC is an excellent capping material for cariology on permanent teeth (direct and indirect capping) and in milk tooth endodontics (milk tooth amputation). Is characterized by excellent colour stability and neutrality and does not contain any additional ingredients
16648496|NCT02291107|Experimental|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
16648497|NCT02291107|Active Comparator|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
16648498|NCT02291094|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
16648499|NCT02291094|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
16648500|NCT02291068|Other|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy.
16648503|NCT02291042|Experimental|Suppository|Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
16648504|NCT02291042|No Intervention|Control|Patients will be provided with routine care.
16648505|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
16648506|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
16648507|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
16648508|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
16648509|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
16648510|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
16648511|NCT02291016|Active Comparator|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.
~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
16648512|NCT02291016|Active Comparator|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.
~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
16648513|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
16648514|NCT02290990|Experimental|Multiple Sclerosis patients|Patients with MS
16648515|NCT02290990|Experimental|Insomnia patients|Patients with insomnia
16648516|NCT02290990|Experimental|Health professionists|Health professionists as healthy volunteers
16648517|NCT02290990|Active Comparator|Waiting list MS|pw MS filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
16648518|NCT02290990|Active Comparator|Waiting list arm Insomnia|pw INS Insomnia Subject filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
16648519|NCT02290990|Active Comparator|Waiting list arm Health professionists|Health professionist filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated.
16648520|NCT02290977|Experimental|Scheduled TACE-RT|RT will be delivered at two weeks after TACE for HCC combined PVTT.
16648521|NCT02290964|No Intervention|Control group|After general anesthesia is applied, surgery is performed. Whenever transfusion is indicated, the patients will received allogenic blood transfusion
16648522|NCT02290964|Active Comparator|ANH group|After general anesthesia is applied, blood from patients in this group were withdrawn. the volume of blood withdrawn was determined based on Gross equation. The blood obtained was then stored in the operating room at temperature between 23 - 25 Celsius degree, and given back to the patient whenever transfusion is indicated.
16648525|NCT02290938|Active Comparator|Community Wellness Gatherings|All youth will attend a CWG, which is a monthly gathering focused on making healthy choices and learning about Native American culture
16648526|NCT02290938|Experimental|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
16648527|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
16648528|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
16648529|NCT02290912|Experimental|Treatment|Health education program; informational website, experiential classes in various help domains, custom smart phone application, and wearable technology
16648530|NCT02290912|No Intervention|Control|No intervention
16648531|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
16648532|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
16648533|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
16648534|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
16648535|NCT02290873|Experimental|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.
~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
16648536|NCT02290873|Placebo Comparator|Placebo|"Inactive control arm
~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
16648537|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill
~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
16648538|NCT02290860|Other|Intervention|Type 2 diabetes diagnosis test.
16648539|NCT02290847|Active Comparator|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
16648540|NCT02290847|Active Comparator|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
16651139|NCT02273414|Placebo Comparator|Placebo|
16648541|NCT02290847|Active Comparator|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
16648542|NCT02290834|Active Comparator|ARM 1|"Breast cancer patients treated with chemotherapy
~Cognitive, functional and subjective assessments (Pre and Post Treatment)
~Imaging (Pre and Post Treatment)
~Magnetic Resonance Imaging (MRI) Scan
~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
16648543|NCT02290834|Active Comparator|ARM 2|"Non-treated breast cancer patient control
~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later
~Imaging (Post Enrollment and at 8-14 months later)
~Magnetic Resonance Imaging (MRI) Scan
~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
16648544|NCT02290834|Active Comparator|ARM 3|"Healthy control subjects
~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later
~Imaging (Post Enrollment and at 8-14 months later)
~Magnetic Resonance Imaging (MRI) Scan
~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
16648545|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
16648546|NCT02290821|Placebo Comparator|Placebo|Placebo
16648547|NCT02290808|Experimental|Theory-based group|The theory-based intervention group will receive strategies based on the Theory of Planned Behaviour to help increase physical activity among couples. Parents will receive materials on how to work together.
16648548|NCT02290808|No Intervention|Information group|The information group will serve as the control group and will receive informational materials on the benefits of physical activity.
16648549|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
16648550|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
16648551|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
16648552|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
16648553|NCT02290782|Experimental|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor > 3.5 cm, lobular cancer, resection margin < 2 mm*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.
~* In case of positive margins (<2 mm resection margin) a re-resection should be done"
16648554|NCT02290769|Experimental|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
16648555|NCT02290769|Active Comparator|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
16648556|NCT02290756|Active Comparator|Parenting program and toolkit|The intervention arm of the study will have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy and the parenting program delivered to the newborn for 12 months.
16648557|NCT02290756|Other|Control- toolkit|The control arm of the study will only have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy.
16648558|NCT02290743|Experimental|Kinesio tape|Kinesio tape on quadriceps femoris
16648559|NCT02290743|No Intervention|Control|No intervention
16648560|NCT02290730|Experimental|Kinesio tape|Kinesio tape on lower trapezius
16648561|NCT02290730|No Intervention|Control|No intervention
16648562|NCT02290717|Experimental|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
16648563|NCT02290717|Experimental|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
16648564|NCT02290717|Active Comparator|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
16648565|NCT02290704||controls|People without eye disease
16648566|NCT02290704||GO patients|patients with Graves' ophthalmopathy
16648567|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
16648568|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
16648569|NCT02290678|Experimental|Intervention|Participate in a two day Adventure-based Programming retreat and team building exercises.
16648570|NCT02290665|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
16648571|NCT02290665|Experimental|Saline enema|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
16648572|NCT02290652||Prospective|Prospective - Factors affecting sexual function pre-THR
16648573|NCT02290652||Retrospective|Retrospective- Factors affecting sexual function post-THR
16648574|NCT02290639|Experimental|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
16648575|NCT02290639|Active Comparator|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
16648576|NCT02290626|Experimental|Elemental diet|"Study 1: Elemental diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.
~Study 2: Elemental diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
16648577|NCT02290626|Active Comparator|Semi-solid diet|"Study 1: Semi-solid diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.
~Study 2: Semi-solid diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
16648578|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
16648579|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
16648580|NCT02290600||type 1 diabetes|type 1 diabetes with continuous glucose monitor (CGM)
16649892|NCT02282046||non-diabetic group|patients without diagnosed type 2 diabetes, having an HbA1c level below 6.0%
16648581|NCT02290587|Experimental|Patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
16648582|NCT02290587|Experimental|Control|healthy subject
16648583|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
16648584|NCT02290548|Experimental|high flow nasal cannula|High flow nasal cannula immediately use after extubation
16648585|NCT02290548|Placebo Comparator|stanrd oxygen therapy|Oxygen cannula or mask after extubation
16648586|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
16648587|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
16648588|NCT02290522|Experimental|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
16648589|NCT02290509|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
16648590|NCT02290509|Active Comparator|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
16648591|NCT02290496|Experimental|CBT for Insomnia (CBT-I)|Cognitive behavior therapy to improve sleep and depression.
16648592|NCT02290496|Placebo Comparator|Sleep Hygiene (SH)|Attention control placebo comprising sleep hygiene therapy
16648593|NCT02290470|Experimental|olanzapine Days 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment
~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:
~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (16 mg intravenously on the day of chemotherapy), plus
~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
16648594|NCT02290470|Experimental|olanzapine+Dexamethasone d 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment
~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:
~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus
~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
16648595|NCT02290470|Active Comparator|dexamethasone days 1-3|"Dexamethasone + Chemotherapy + Antiemetic treatment
~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:
~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus
~Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy"
16648596|NCT02290457|Experimental|CSTS|core strength training performed on stable surfaces
16648597|NCT02290457|Experimental|CSTU|core strength training performed on unstable surfaces
16648598|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
16648599|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
16648600|NCT02290431|Experimental|LBH589 + bortezomib + dexamethasone|Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
16648601|NCT02290418|Active Comparator|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass and routine care.
16648602|NCT02290418|Active Comparator|Omega-Loop Gastric Bypass|Laparoscopic Omega-Loop Gastric Bypass and routine care.
16648603|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
16648604|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
16648605|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
16648606|NCT02290379|Experimental|TNX-201 35 mg|Drug: TNX-201 35 mg
16648607|NCT02290379|Experimental|TNX-201 70 mg|Drug: TNX-201 70 mg
16648608|NCT02290379|Experimental|TNX-201 140 mg|Drug: TNX-201 140 mg
16648609|NCT02290379|Active Comparator|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
16648610|NCT02290379|Placebo Comparator|Placebo|Drug: Placebo
16648611|NCT02290366|Experimental|Focal Therapy|
16648612|NCT02290353|Experimental|Adult (Stroke) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
16648613|NCT02290353|Experimental|Teenagers (Cerebral Palsy) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
16648614|NCT02290340|Placebo Comparator|Placebo|Participants will receive placebo intramuscularly.
16648615|NCT02290340|Experimental|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
16648616|NCT02290340|Experimental|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
16648617|NCT02290340|Experimental|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
16648618|NCT02290327|Placebo Comparator|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
16648619|NCT02290327|Active Comparator|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
16648724|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
16648620|NCT02290314|Other|minimally invasive MID-line Lumbar Fusion (MIDLF)|MIDLF surgery involves a minimally invasive midline laminectomy posterior approach to the lumbar spine. An incision that is smaller than the standard incision is made in the midline of the low back directly over the spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed as described in the PLIF procedure.
16648621|NCT02290314|Other|posterior lumbar interbody fusion (PLIF)|PLIF surgery involves a standard incision in the midline of the low back directly over the involved spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed in between the vertebral bodies where the disc usually lies. This will allow bone fusion (healing) to occur from one vertebral body to the other.
16648622|NCT02290301||Type 2 Diabetes Mellitus|
16648623|NCT02290288|Active Comparator|SSF|1. vaginal surgery arm (SSF)
16648624|NCT02290288|Active Comparator|LSC|laparoscopic surgery arm (LSC)
16648625|NCT02290275|Placebo Comparator|Placebo|The subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
16648626|NCT02290275|Experimental|Creatine|The subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
16648627|NCT02290275|Experimental|Walking Exercise|The subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
16648628|NCT02290262|Experimental|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education plus usual care.
16648629|NCT02290262|No Intervention|Usual care|The control group will receive usual care alone.
16648630|NCT02290249|Active Comparator|normal airway|İntubation with glidescope or airtraq in normal airway
16648631|NCT02290249|Active Comparator|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
16648632|NCT02290249|Active Comparator|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
16648633|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
16648634|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
16648635|NCT02290210|Placebo Comparator|Placebo|Placebo x 2weeks
16648636|NCT02290210|Placebo Comparator|URC102 0.25mg|0.25mg URC102 x 2weeks
16648637|NCT02290210|Experimental|URC102 0.5mg|0.5mg URC102 x 2weeks
16648638|NCT02290210|Placebo Comparator|URC102 1.0mg|1.0mg URC102 x 2weeks
16648639|NCT02290210|Placebo Comparator|URC102 2.0mg|2.0mg URC102 x 2weeks
16648640|NCT02290197|Experimental|Hinged External Fixator|Hinged external fixator allows early and aggressive joint mobility in the sagittal plane only. Flexion and extension are permitted, but rotational movements, translations in the anterior-posterior plane, lateral (varus) and medial (valgus) openings are not allowed. Thus protective stability is ensured for ligament reconstruction procedures. Simultaneously we allow immediate joint mobilization, reducing the risk of arthrofibrosis, joint stiffness and postoperative ligament laxity.
16648641|NCT02290197|Active Comparator|Cast Immobilization|In these patients we used cast postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
16648642|NCT02290184|Experimental|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
16648643|NCT02290184|Active Comparator|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
16648644|NCT02290171|Active Comparator|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
16648645|NCT02290171|No Intervention|Delayed intervention group|The control groups will start intervention with 6 months delay
16648646|NCT02290158|Active Comparator|Orthodontic finishing|Patients receiving a complete orthodontic finishing protocol according to the ABO-OGS
16648647|NCT02290158|No Intervention|No orthodontic finishing|Patients receiving orthodontic treatment without the finishing protocol according to the ABO-OGS
16648648|NCT02290145|Experimental|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
16648649|NCT02290145|Other|surgery group|surgery with post-operative radiotherapy
16648650|NCT02290132||highly aggressive T cell tumors|The study is to research the outcome of Rabbit Anti-human Thymocyte Globulin (ATG)based myeloablative conditioning regimen after allo-HSCT in patients with highly aggressive T-cell tumors.
16648651|NCT02290119|Sham Comparator|Control - Without the use of Verasense|Total Knee Replacement without the use of intraoperative sensors
16648652|NCT02290119|Active Comparator|Sensor-assisted TKR (Verasense)|Total Knee Replacement with the use of intraoperative sensors
16648653|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
16648654|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
16648655|NCT02290093|Active Comparator|Standard full-volume PEG|
16648656|NCT02290093|Experimental|Split-dose full-volume PEG|
16648657|NCT02290093|Experimental|Split-dose low-volume PEG|
16648658|NCT02290080|Experimental|Oxygen|"For patients randomized to oxygen therapy:
~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)
~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
16651140|NCT02273401|Experimental|BI 11054 CL|
16648659|NCT02290080|No Intervention|No oxygen|"For patients randomized to withholding oxygen treatment
~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)
~all patients receive standard acute coronary syndrome treatment including reperfusion strategies
~observation duration 12 hours"
16648660|NCT02290067|Active Comparator|Omnitest 3|Blood glucose monitoring system
16648661|NCT02290067|Experimental|Omnitest 5|Blood glucose monitoring system
16648662|NCT02290067|Experimental|Omnitest 5D|Blood glucose monitoring system
16648663|NCT02290054|Sham Comparator|Control|A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
16648664|NCT02290054|Experimental|Treated|"A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Auriculotherapy is performed while the patient is sleeping but before thoracic incision.
~Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles."
16648665|NCT02290041|Experimental|Mesenchymal stem cells|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
16648666|NCT02290041|Placebo Comparator|Placebo|Intravenous infusion of 4 doses of Placebo
16648667|NCT02290028|Other|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
16648668|NCT02290015|Experimental|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
16648669|NCT02290015|Sham Comparator|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
16648670|NCT02290002|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
16648671|NCT02290002|Active Comparator|group B|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
16648672|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
16648673|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
16648674|NCT02289976|Active Comparator|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
16648675|NCT02289976|Active Comparator|core decompression|Core decompression and nonvascularized autograft from the iliac crest
16648676|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
16648677|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
16648678|NCT02289950|Experimental|Farletuzumab|All participants will receive a loading dose for the first 2 weeks of 10 milligram per kilogram (mg/kg) farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV).
16648679|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
16648680|NCT02289937|Experimental|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
16648681|NCT02289937|Placebo Comparator|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
16648682|NCT02289924||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy
16648683|NCT02289911|Active Comparator|Class|Traditional learning form
16648684|NCT02289911|Active Comparator|Web|Didactic training using internet
16648685|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
16648686|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
16648687|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
16648688|NCT02289885|Experimental|normal model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
16648689|NCT02289885|Experimental|ascites positive model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
16648690|NCT02289872|Experimental|Scenario A|The control scenario, where neither chest compression nor cervical stabilization was applied during intubation.
16648691|NCT02289872|Experimental|Scenario B|The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.
16648885|NCT02288650|Sham Comparator|Control group|Refeeding in the day case ward (usual practice)
16648692|NCT02289872|Experimental|Scenario C|The chest compression with cervical stabilization scenario, where both chest compression using Lucas-2 and cervical stabilization were applied. A correctly fitting standard cervical immobilization collar (StifNeck Select, Laerdal, Stavanger, Norway) was applied to the manikin's neck to prevent movement of the cervical spine.
16648693|NCT02289859|Active Comparator|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
16648694|NCT02289859|Active Comparator|Wound Closure without Undermining|One side of the wound will remain un-undermined.
16648695|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
16648696|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
16648697|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
16648698|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
16648699|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
16648700|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
16648701|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
16648702|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
16648703|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
16648704|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
16648705|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
16648706|NCT02289807|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone
16648707|NCT02289807|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
16648708|NCT02289794|Active Comparator|E.coli bioconjugate vaccine|E.coli bioconjugate vaccine in saline buffer
16648709|NCT02289794|Placebo Comparator|Placebo|Saline buffer
16648710|NCT02289781||Zirconia posterior crowns|Monolithic zirconia crowns which are polished and non-glazed
16648711|NCT02289781||Metal-Ceramic posterior crowns|Metal-supported glass-ceramic veneered crowns which are polished and non-glazed
16648712|NCT02289768|Experimental|5-fluorouracil/salicylic acid|Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
16648713|NCT02289768|Placebo Comparator|Vehicle|Vehicle solution applied to the affected area once-daily for 12 weeks
16648714|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria
~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
16648715|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
16648716|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
16648717|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
16648718|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
16648719|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
16648720|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
16648721|NCT02289703|Experimental|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
16648722|NCT02289703|Experimental|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
16648723|NCT02289690|Experimental|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.
~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
16649893|NCT02282046||type 2 diabetes group|patients diagnosed with type 2 diabetes of over 1 year duration.
16648725|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
16648726|NCT02289690|Active Comparator|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
16648727|NCT02289677|Experimental|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
16648728|NCT02289664|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16648729|NCT02289664|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16648730|NCT02289651|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16648731|NCT02289651|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16648732|NCT02289638|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16648733|NCT02289638|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16648734|NCT02289625|Active Comparator|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
16648735|NCT02289625|Active Comparator|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.
~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
16648736|NCT02289612|Placebo Comparator|Tapioca Starch - Low-Fibre|Tapoica starch pudding without added fibre
16648737|NCT02289612|Placebo Comparator|High Maltose Corn Syrup - Low-Fibre|High maltose corn syrup pudding without added fibre
16648738|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#1)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at first treatment study visit.
16648739|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#2)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at final treatment study visit.
16648740|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - Tapioca Starch|Yellow mustard gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
16648741|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - High Maltose Corn Syrup|Yellow mustard gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
16648742|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - Tapioca Starch|Soluble flaxseed gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
16648743|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - High Maltose Corn Syrup|Soluble flaxseed gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
16648744|NCT02289612|Active Comparator|Fenugreek Gum Fibre - Tapioca Starch|Fenugreek gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
16648745|NCT02289612|Active Comparator|Fenugreek Gum Fibre - High Maltose Corn Syrup|Fenugreek gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
16648746|NCT02289599|Experimental|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
16648747|NCT02289599|Experimental|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
16648748|NCT02289599|Experimental|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
16648749|NCT02289599|Experimental|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
16648750|NCT02289599|Experimental|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
16648751|NCT02289599|Experimental|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
16648752|NCT02289599|Experimental|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
16648753|NCT02289599|Experimental|Part B: Elderly cohort|One dose level below MTD from Part A
16648754|NCT02289586|Active Comparator|hypoxemia, central airway stenosis.|"Inclusion Criteria:
~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;
~Exclusion Criteria:
~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
16649154|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
16648755|NCT02289586|Experimental|hypoxemia, central airway stenosis|"Inclusion Criteria:
~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;
~Exclusion Criteria:
~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
16648756|NCT02289573|Experimental|neurally adjusted ventilatory assist|
16648757|NCT02289573|Sham Comparator|pressure support ventilation|
16648758|NCT02289560|Experimental|Transcranial ExAblate|Transcranial ExAblate
16648759|NCT02289547|No Intervention|Group A|observational arm
16648760|NCT02289547|Experimental|Group B|arm of capecitabine maintenance treatment
16648761|NCT02289521|Active Comparator|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation
~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
16648762|NCT02289521|Sham Comparator|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation
~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).
~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
16648763|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
16648764|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
16648765|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
16648766|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
16648767|NCT02289495|Experimental|GSK2838232 without RTV|Subjects will receive 20 mg of GSK2838232/ placebo (3:1) in cohort 1 and 50 mg of GSK2838232/ placebo (3:1) in cohort 2, administered QD for 8 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
16648768|NCT02289495|Experimental|GSK2838232 with RTV|Subjects will receive 10 mg of GSK2838232/ placebo (3:1) in cohort 3, 20 mg of GSK2838232/ placebo (3:1) in cohort 4 and 50 mg of GSK2838232/ placebo (3:1) in cohort 5, co administered with RTV 100 mg, QD for 11 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
16648769|NCT02289482|Experimental|GSK2838232 Part A: Single Dose Escalation|During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
16648770|NCT02289482|Experimental|GSK2838232 Part B: Single Dose, 3-Period Crossover, Relative B|During Part B, subjects will receive GSK2838232/ placebo, in an open-label, unbalanced, 3-period, cross-over design; subjects will be randomized (1:1) to each sequence. The relative bioavailability of single 100 mg doses of powder in a bottle (PIB) Active Pharmaceutical Ingredient (API) of GSK2838232 versus PIB Spray-Dried Dispersion (SDD) will be assessed (Period 1: SDD GSK2838232 100 mg vs GSK2838232 API 100 mg; period 2: GSK2838232 API 100 mg Vs SDD GSK2838232 100 mg ). A single dose of GSK2838232 will be co-administered on the 10th day of RTV dosing (period 3:GSK2838232 10 mg + RTV 100 mg); RTV dosing will continue for an additional 4 days (total of 14 days).
16648771|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
16648772|NCT02289469|No Intervention|Usual care|Usual medication history process
16648773|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle
~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
16648774|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
16648775|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
16648776|NCT02289430|Experimental|Crestor+Ezetrol|rosuvastatin+ezetimibe
16648777|NCT02289430|Active Comparator|Ezetrol|ezetimibe
16648778|NCT02289430|Active Comparator|Crestor|rosuvastatin
16648779|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks
~After 12 weeks:
~Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)
~Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)
~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
16648886|NCT02288637|Experimental|Conventional Olyset LLIN|High coverage (>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
16648887|NCT02288637|Experimental|Olyset Plus LLIN|High coverage (>80% access) of Olyset Plus LLIN
16648780|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks
~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)
~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
16648781|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)
~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
16648782|NCT02289404|Experimental|NVP-1203(fed then fasting)|Subjects will receive a oral dose of NVP-1203 under fed conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fasting conditions in period 2
16648783|NCT02289404|Experimental|NVP-1203(fasting then fed)|Subjects will receive a oral dose of NVP-1203 under fasting conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fed conditions in period 2
16648784|NCT02289391|Placebo Comparator|non-asthma group|"Non-asthma history
~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of normal saline at 10 minutes before the end of surgery."
16648785|NCT02289391|Experimental|Dexmedetomidine A|"With a history of asthma
~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
16648786|NCT02289391|Experimental|Dexmedetomidine B|"With a history of asthma
~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
16648787|NCT02289391|Placebo Comparator|Control group|"With a history of asthma
~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of normal saline at 10 minutes before the end of surgery."
16648788|NCT02289378|Experimental|Docetaxel, Oxaliplatin and 5-Fu|Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks
16648789|NCT02289365|Placebo Comparator|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
16648790|NCT02289365|Experimental|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
16648791|NCT02289365|Experimental|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
16648792|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
16648793|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
16648794|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
16648795|NCT02289339||TAVI patients|all patients undergoing transcatheter aortic valve prostheses implantation
16648796|NCT02289313|Experimental|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
16648797|NCT02289300|Experimental|DCB-BO1202|
16648798|NCT02289300|Experimental|DCB-BO1202+Placebo|
16648799|NCT02289300|Placebo Comparator|Placebo|
16648800|NCT02289287|Experimental|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
16648801|NCT02289287|Active Comparator|Standard Care|Participants will receive Standard Care only
16648802|NCT02289274|Experimental|NVP-1203|NVP-1203
16648803|NCT02289274|Active Comparator|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
16648804|NCT02289261|Active Comparator|Control|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
16648805|NCT02289261|Active Comparator|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
16648806|NCT02289248|Experimental|Ketamine/CBT Group|Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
16648807|NCT02289235|Experimental|Ginger|Ginger powder capsule 500 mg
16648808|NCT02289235|Placebo Comparator|Placebo|Placebo powder capsule
16648809|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
16648810|NCT02289209|Experimental|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
16648811|NCT02289196|Experimental|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
16648812|NCT02289196|Experimental|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
16648813|NCT02289196|Experimental|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
16648814|NCT02289196|Experimental|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
16648815|NCT02289183|Experimental|Totally laparoscopic distal gastrectomy|The totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy will be performed for the treatment of patients with distal gastric cancer assigned to this group.
16648816|NCT02289183|Active Comparator|Laparoscopy-assisted distal gastrectomy|The laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis will be performed for the treatment of patients with distal gastric cancer assigned to this group.
16648888|NCT02288637|Experimental|Conventional Olyset LLIN and IRS|High coverage (>80% access) of conventional Olyset LLIN and high coverage IRS (>80% of the household sprayed) with pirimiphos methyl CS
16650205|NCT02279875|Experimental|Linezolid 600 mg once per day (B)|600mg (scored) tablet
16648817|NCT02289170|Experimental|Heating and cooling combination therapy|The patients in this group received heating and cooling combination therapy by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. Doctor press 8 acupuncture points which is treated in LBP patients and select the most painful 2 acupuncture points. Device's probe is attached to the acupuncture points in 15 minutes. Probe's temperature is changed 5 cycles from maximum 45℃ to minimum 15℃.
16648818|NCT02289170|Sham Comparator|Sham heating and cooling therapy|The patients in this group received sham heating and cooling combination therapy in same conditions of treatment group except the temperature. Before the treatment begin, caregiver measure the patient's skin temperature. Then probe's temperature is changed 5 cycles from 1℃ over the skin temperature to 1℃ under the skin temperature.
16648819|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
16648820|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
16648821|NCT02289144|Experimental|Ceritinib|
16648822|NCT02289131|Experimental|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
16648823|NCT02289131|Experimental|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
16648824|NCT02289131|Experimental|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
16648825|NCT02289118||Diagnostic Imaging|[18F]T807 imaging tracer.
16648826|NCT02289105|Experimental|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
16648827|NCT02289105|No Intervention|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
16648828|NCT02289092|Experimental|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
16648829|NCT02289092|No Intervention|Control|Control families will receive services as usual that are being provided to the families within their school
16648830|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
16648831|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
16648832|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
16648833|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
16648834|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
16648835|NCT02289027|Experimental|Deployed volunteers - Group 1|Low dose cAd3-EBOZ (2.5x10e10 vp)
16648836|NCT02289027|Experimental|Deployed volunteers - Group 2|High dose cAd3-EBOZ (5x10e10 vp)
16648837|NCT02289027|Experimental|Not deployed volunteers - Group 3|Low dose cAd3-EBOZ (2.5x10e10 vp)
16648838|NCT02289027|Experimental|Not deployed volunteers - Group 4|High dose cAd3-EBOZ (5x10e10 vp)
16648839|NCT02289027|Placebo Comparator|Not deployed volunteers - Group 5|
16648840|NCT02289014|No Intervention|Wait-list control group|Wait-list control group
16648841|NCT02289014|Experimental|Active treatment group|online stress Management program
16648842|NCT02289001|Experimental|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
16648843|NCT02289001|No Intervention|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
16648844|NCT02288988|Other|GERD patients with Short Esophagus|Patients with True Short Esophagus diagnosed intra-operatively: The length of the intra-abdominal portion of the esophagus < 2.5 cm measured intra-operatively using a combined endoscopic-laparoscopic method. Minimally invasive antireflux surgery was performed (Collis gastroplasty + Nissen fundoplication).
16648845|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
16648846|NCT02288975||Control|Patients with septic shock will get routine ICU care.
16648847|NCT02288962|Experimental|cabergoline|"Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.
~Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study"
16648848|NCT02288962|No Intervention|observation|visits and controls as usual
16648849|NCT02288949||Prospective cohort|Stratification of patients admitted into a network of Spanish ICUs.
16648850|NCT02288936|Experimental|Enzalutamide|Enzalutamide 160 mg/day
16648851|NCT02288923|Active Comparator|Femoral nerve block|Femoral nerve block with 20ml 0.375% Levobupivacaine
16648928|NCT02288442|Experimental|exercise|exercise intervention during 8 weeks
16651141|NCT02273401|Placebo Comparator|Placebo|
16648852|NCT02288923|Active Comparator|Local Infiltration Analgesia|Local infiltration of knee joint using 40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
16648853|NCT02288897|Experimental|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
16648854|NCT02288897|Active Comparator|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
16648855|NCT02288884|Active Comparator|Silver containing dressing|Subjects will have a silver containing dressing (Acticoat PostOp) applied at the time of elective cesarean section.
16648856|NCT02288884|Placebo Comparator|Standard dressing|Subjects will have a standard dressing (OpSite PostOp) applied at the time of elective cesarean section.
16648857|NCT02288871|Other|"Sutureless valve"|"Patients who underwent aortic valve replacement with a sutureless aortic valve.
~An echocardiogram and a cardiac CT-scan will be conducted."
16648858|NCT02288871|Other|"Sewed-in valve"|"Patients who underwent aortic valve replacement with a sewed-in aortic valve. An echocardiogram and a cardiac CT-scan will be conducted."
16648859|NCT02288858|Active Comparator|Test product|Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
16648860|NCT02288858|Placebo Comparator|Placebo|Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
16648861|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
16648862|NCT02288832|Experimental|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold > 105.copies per ml and/or G. vaginalis > 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
16648863|NCT02288832|Other|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
16648864|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
16648865|NCT02288780||Control|BPH patients with normal diastolic function
16648866|NCT02288780||Diastolic dysfunction|BPH patients with preoperative diastolic dysfunction
16648867|NCT02288767|Active Comparator|Control group|For the traditional method group, crystalloid and colloid (maximum 50 ml/kg) are provided through the traditional method of assessing the blood pressure, heart rate and urine volume.
16648868|NCT02288767|Experimental|SVV group|The method of fluid administration to be employed (traditional or SVV via a FloTrac/ EV1000™ monitor) is determined based on the group. Fluid administration is performed in accordance with the group; in general, about 10 ml/kg/h is administered although it may vary for each patient depending on the preoperative fasting, fluid loss during surgery (evaporation, emanation, urination, surgical area, etc.), and blood loss. Crystalloid is administered in the SVV-monitored group with a target below SVV 12%, and a 200-300 ml of colloid (maximum 50 ml/kg) is loaded when SVV is above 12%. If the patient shows hypertension even when SVV is below 12%, a vasoconstrictor should be administered intermittently or consistently.
16648869|NCT02288754||Stage II or III curative surgery (closed to accrual)|Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
16648870|NCT02288754||Stage II or III neoadjuvant therapy cohort (closed to accrual)|Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
16648871|NCT02288754||Metastatic disease|Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
16648872|NCT02288741|Experimental|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
16648873|NCT02288741|Active Comparator|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
16648874|NCT02288741|Other|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
16648875|NCT02288728|Experimental|Group B (double-track anastomosis)|Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
16648876|NCT02288728|Other|Group A (Gastric tube anastomosis)|Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.
16648877|NCT02288715||SAE|patient who develop encephalopathy in the progress of sepsis
16648878|NCT02288715||non-SAE|patient who do not develop encephalopathy in the progress of sepsis
16648879|NCT02288702||Normal|This is the group with no neurological problems or syndrome
16648880|NCT02288702||Down syndrome|This is the group with Down syndrome
16648883|NCT02288663|Other|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
16648884|NCT02288650|Experimental|Liberal group|Early refeeding
16648889|NCT02288637|Experimental|Olyset Plus LLIN and IRS|High coverage (>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (>80% of the household sprayed) with pirimiphos methyl CS
16648890|NCT02288624|Placebo Comparator|Control|Water control (240 ml)
16648891|NCT02288624|Experimental|Orange Juice|Orange juice, 240 ml. Commercial orange juice
16648892|NCT02288624|Experimental|Whole orange|Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
16648893|NCT02288624|Experimental|processed orange juice|Processed orange juice, 240 ml. Experimental orange juice processing
16648894|NCT02288611|Placebo Comparator|Maltodextrin/Dextrose mix|"Twenty-two healthy human individuals were randomly assigned to consume a control (maltodextrin-dextrose, 40.2g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
~P.S. placebo is called control in this study, where the bioactive comparator is a fruit."
16648895|NCT02288611|Active Comparator|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume date fruits (approx. 50g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
16648896|NCT02288598|Experimental|Anodal TDCS|Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
16648897|NCT02288598|Sham Comparator|Sham TDCS|Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
16648898|NCT02288585|Active Comparator|Plant sterols|Plant sterols
16648899|NCT02288585|Placebo Comparator|Placebo product|Placebo product
16648900|NCT02288572|Active Comparator|Lactobacillus plantarum PCS 26|Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
16648901|NCT02288572|Placebo Comparator|Placebo|Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
16648902|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
16648903|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
16648904|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
16648905|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
16648906|NCT02288546||Vegans|Vegans' data are compared with those of sex-and age-matched non vegetarians
16648907|NCT02288546||Non-vegans|Non-vegans are age and sex-matched controls
16648908|NCT02288533|Experimental|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
16648909|NCT02288507|Experimental|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
16648910|NCT02288494||hypoalbuminemia|The primary purpose was to describe the acid base balance of ICU patients with severe hypoalbuminemia using Stewart's approach for acid base disorders, before and after an human albumin perfusion
16648911|NCT02288481|Experimental|Cohort 1 10 mg TBA-354|
16648912|NCT02288481|Placebo Comparator|Cohort 1 placebo|Placebo Suspension
16648913|NCT02288481|Experimental|Cohort 2 25 mg TBA-354|
16648914|NCT02288481|Placebo Comparator|Cohort 2 placebo|Placebo Suspension
16648915|NCT02288481|Experimental|Cohort 3 60 mg TBA-354|
16648916|NCT02288481|Placebo Comparator|Cohort 3 placebo|Placebo Suspension
16648917|NCT02288481|Experimental|Cohort 4 150 mg TBA-354|
16648918|NCT02288481|Placebo Comparator|Cohort 4 placebo|Placebo Suspension
16648919|NCT02288481|Experimental|Cohort 5 400 mg TBA-354|
16648920|NCT02288481|Placebo Comparator|Cohort 5 placebo|Placebo Suspension
16648921|NCT02288481|Experimental|Cohort 6 1000 mg TBA-354|
16648922|NCT02288481|Placebo Comparator|Cohort 6 placebo|Placebo Suspension
16648923|NCT02288468|Experimental|STN|"Deep Brain Stimulation of Nucleus subthalamicus with Vercise™ Deep Brain Stimulation System.
~The STN will be typically reached with the most distal contacts of the DBS electrode (8 contact). Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located in the STN. We expect the STN to be typically covered by contacts 1-4 of the Vercise™ DBS lead. Typically, only the most superficial contacts (3,4) will be activated after a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction, reduction of rigidity and bradykinesia. Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
16648924|NCT02288468|Experimental|Vim/DRT|"Deep Brain Stimulation of Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.
~The thalamic target (Vim/DRT) will be typically reached with the proximal contacts. Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located the thalamic target. We expect the thalamic target to be typically covered by contacts 5-8 of the Vercise™ DBS lead. We will perform a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction and the occurrence of side effects (typically capsular e.g. facial contraction). Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
16648925|NCT02288468|Experimental|STN+Vim/DRT|"Combined Deep Brain Stimulation of Nucleus subthalamicus and Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.
~STN+Vim/DRT stimulation is essentially a combination of the previously described procedure."
16648926|NCT02288455|Experimental|RELIEF II - GTU AUS|Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU Artificial Urinary Sphincter device in males with stress urinary incontinence.
16648927|NCT02288442|No Intervention|control|
16648929|NCT02288429||Colistin|"Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection
~Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
16648930|NCT02288416|Active Comparator|Group I (standard of care)|Patients receive standard of care following LCS consisting of routine visits and telephone contact with the LCS program nurse practitioner and coordinator.
16648931|NCT02288416|Experimental|Group II (video-based intervention)|Patients undergo a video-based intervention prior to undergoing LCS. Patients watch a 5-minute video that focuses on preparing patients for LCS by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. Patients also receive an educational handbook. Patients with positive scans (a Lung-RADS 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results.
16648932|NCT02288403|Experimental|Aerobic interval training|"Interval exercise at an intensity between 90-95% of maximum heart rate (15x30 s), with recoveries at an equivalent speed to 50-55 % of maximal oxygen consumption at baseline (14x60 s).
~24 training sessions, 3x weekly (on alternate days)."
16648933|NCT02288403|Active Comparator|Continuous training|"40 minutes of continuous exercise at an intensity between 65-75% of maximum heart rate.
~24 training sessions, 3x weekly (on alternate days)."
16648934|NCT02288390|Active Comparator|Miswak (Sewak)|Miswak (sewak) oral care applied 4 hourly for oral care in mechanically ventilated patients.
16648935|NCT02288390|Active Comparator|Chlorhexidine/ toothbrush|Chlorhexidine 0.12 % plus toothbrushing oral care applied 4 hourly for oral care in mechanically ventilated patients.
16648936|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
16648937|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
16648938|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
16648939|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
16648940|NCT02288351|Other|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
16648941|NCT02288338|Experimental|1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)|"Three treatment
~atorvastatin calcium 40mg will be administration to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
16648942|NCT02288338|Experimental|2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)|"Three treatment
~ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
16648943|NCT02288338|Experimental|3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)|"Three treatment
~atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
16648944|NCT02288338|Experimental|4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)|"atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
16648945|NCT02288338|Experimental|5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)|"ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
16648946|NCT02288338|Experimental|6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)|"atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
16648947|NCT02288325|Experimental|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release [ER]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
16648948|NCT02288325|Placebo Comparator|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
16648949|NCT02288325|Experimental|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
16648950|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
16648951|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
16648952|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
16648953|NCT02288299|Experimental|non invasive mechanical ventilation|Patients suffering from neuromuscular disease with NIV indication and cough inefficiency
16648954|NCT02288286|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
16648955|NCT02288286|Experimental|2.5IU/ml in humans aged 21-50|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
16648956|NCT02288286|Experimental|2.5IU/ml in humans aged 51-60|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
16648957|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
16648958|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 21-50 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
16651142|NCT02273388|Experimental|Volasertib|
16648959|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 51-60 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
16648960|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
16648961|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
16648962|NCT02288260||Part A|PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST
16648963|NCT02288260||Part B|Patients on ticagrelor at the time of discharge from hospital
16648964|NCT02288247|Experimental|Enzalutamide with docetaxel + prednisolone|Continued treatment with enzalutamide after adding docetaxel and prednisolone
16648965|NCT02288247|Placebo Comparator|Placebo with docetaxel + prednisolone|Treatment with placebo after adding docetaxel and prednisolone
16648966|NCT02288234||Vibativ|This is an observational study for patients who were already prescribed Vibativ.
16648967|NCT02288221|Experimental|With non pharmacological therapeutic|Installation of ICT at patient's home
16648968|NCT02288221|Active Comparator|Without non pharmacological therapeutic|No change at patient's home
16648969|NCT02288208|Experimental|Antiviral Therapy & Birinapant|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.
16648970|NCT02288208|Placebo Comparator|Antiviral Therapy & Placebo|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.
16648971|NCT02288195|Experimental|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
16648972|NCT02288195|Experimental|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
16648973|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
16648974|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
16648975|NCT02288169|Experimental|COPE|The experimental group will receive usual care plus the COPE intervention. This group will receive 3 individual intervention sessions. During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom. Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home. Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms. In addition they will get 2 phone calls encouraging them to apply COPE.
16648976|NCT02288169|Sham Comparator|Support|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
16648977|NCT02288169|No Intervention|Control|The control group will receive usual care and no additional attention from our interventionists.
16648978|NCT02288156|Active Comparator|0.1mM|
16648979|NCT02288156|Experimental|0.01mM|
16648980|NCT02288156|Experimental|0.001mM|
16648981|NCT02288156|Placebo Comparator|Placebo|
16648982|NCT02288143|Experimental|COOL-COS|All women will receive the intervention: Letrozole, Clomiphene, and low-dose hMG for the controlled ovarian stimulation.
16648983|NCT02288130|Active Comparator|GnRHa and placebo tablets|11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily)
16648984|NCT02288130|Active Comparator|Ulipristal|Three months of Ulipristal 5 mg once daily combined with a single saline injection at the onset of pretreatment (produced as placebo of Leuproreline)
16648985|NCT02288130|No Intervention|Control|No pre-treatment prior to laparoscopic myomectomy
16648986|NCT02288104|Other|needle based confocal endomicroscopy|The patient, scheduled for a standard liver or kidney percutaneous biopsy or ablation will undergo a needle-based confocal laser endomicroscopy procedure during the procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
16648987|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
16648988|NCT02288078|Active Comparator|Treatment group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), test drug capsule (dexamethasone 2 mg) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.
~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.
~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medicatiob check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
16649051|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
16649184|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
16648989|NCT02288078|Placebo Comparator|Placebo group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), placebo capsule (lactose) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.
~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.
~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medication check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
16648990|NCT02288065||responders|amelioration of dyspnea radiological amelioration after sterile talc pleurodesis
16648991|NCT02288065||failed intervention|unchanged symptoms and radiology after sterile talc pleurodesis
16648992|NCT02288052|Experimental|Writing program|The program will train participants in maintaining writing amplitude, writing speed, writing fluently and automatization of writing.
16648993|NCT02288052|Placebo Comparator|Stretch & Relaxation program|The program will learn participants to alleviate tension in the upper limbs and will consist of exercises performed while lying down or sitting.
16648994|NCT02288039|Experimental|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
16648995|NCT02288039|No Intervention|Standard Care|Participants will receive usual standard treatment
16648996|NCT02288026||Arm I|Patients undergo lobectomy
16648997|NCT02288026||Arm II|Patients undergo a wedge resection or anatomical segmentectomy
16648998|NCT02288013|Other|Stratafix Tissue control device|Closure of Uterine incision at C section
16648999|NCT02288013|Other|Vicryl suture|Closure of uterine incision at C section
16649000|NCT02288000|Active Comparator|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
16649001|NCT02288000|Placebo Comparator|Placebo|The placebo will be presented as capsule comparable to memantine
16649002|NCT02287987|Active Comparator|Clamp|Laparoscopic robot-assisted partial nephrectomy with clamping the renal pedicle during the resection of the tumor
16649003|NCT02287987|Experimental|Off clamp|Laparoscopic robot-assisted partial nephrectomy without clamping the renal pedicle during the resection of the tumor
16649004|NCT02287974|Experimental|Autologous mononuclear stem cell from the bone marrow|Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
16649005|NCT02287974|Experimental|Autologous endothelial stem cell from the bone marrow|Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
16649006|NCT02287974|Experimental|Autologous mesenchymal stem cells from the adiposite tissue|Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
16649007|NCT02287974|Active Comparator|Current medication for the disease|Current medication for the disease
16649008|NCT02287961|Other|Subjects|"Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
~High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
~Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy
~High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
16649009|NCT02287948||MS subjects group|Multiple sclerosis subjects wiht mild-moderate gait disability with EDSS score not higher than 5.5
16649010|NCT02287948||Healthy subjects group|Healthy subjects age-matched with multiple sclerosis subjects.
16649011|NCT02287935|Active Comparator|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique
16649012|NCT02287935|Active Comparator|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis procedure
16649013|NCT02287922|Experimental|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
16649014|NCT02287922|Experimental|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
16649015|NCT02287922|Experimental|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
16649016|NCT02287922|Active Comparator|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
16649017|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
16649018|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
16649019|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
16649020|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
16649021|NCT02287896|Experimental|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.
~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.
~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.
~The postnatal dose must still be given even when antenatal prophylaxis has been administered.
~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
16649022|NCT02287896|Experimental|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.
~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.
~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.
~The postnatal dose must still be given even when antenatal prophylaxis has been administered.
~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
16649023|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.
~Observational: Patient Activation and Engagement (PAE)"
16649024|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.
~Observational: Patient Activation and Engagement (PAE)"
16649025|NCT02287870|Experimental|Chloroprocaine Group|Epidural anesthesia with 3% chloroprocaine.
16649026|NCT02287870|Active Comparator|Lidocaine Group|Epidural anesthesia with 2% lidocaine.
16649027|NCT02287857|Experimental|Domestic Tenofovir Disoproxil Fumarate Tablets|
16649028|NCT02287857|Active Comparator|Tenofovir Disoproxil Fumarate Tablets of Gilead|
16649029|NCT02287844|Experimental|XOS group|Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.
16649030|NCT02287844|Experimental|INU-XOS group|Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.
16649031|NCT02287844|Active Comparator|Placebo|Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.
16649032|NCT02287831|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
16649033|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
16649034|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
16649035|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
16649036|NCT02287805||qualitative survey|"parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery
~12 patients aged over 15 years, operated more than 10 years before"
16649037|NCT02287805||quantitative survey 2|"100 parents of patients 1 year after surgery
~100 parents of patients, 5 years after the operation
~100 patients aged over 15 years and operated over 10 years ago"
16649038|NCT02287792|Experimental|18-FDG PET/CT scan|All patients will undergo a whole body PET/CT scan
16649039|NCT02287779|Experimental|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
16649040|NCT02287779|Placebo Comparator|Placebo|Three subjects per cohort will take a matched placebo
16649041|NCT02287766||Control|Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
16649042|NCT02287766||Metabolic Syndrome Diagnosis Group|Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
16649043|NCT02287753|Experimental|Vascular occlusion test (VOT)|Pediatric patients aged under 8 years old are enrolled in this study. VOT is performed in 3 times : after induction of anesthesia, during cardiopulmonary bypass (CPB) for main surgical procedure and after weaning from CPB. The relationship between postoperative outcome variables and the dynamic parameters from VOT, such as desaturation and reoxygenation rate, and reactive hyperemic area, will be evaluated.
16649044|NCT02287740|Experimental|Tai Ji Quan: Moving for Better Balance|This protocol involves training 2 times a week for 6 months.
16649045|NCT02287740|Active Comparator|Multimodal Exercise|This protocol involves training 2 times a week for 6 months.
16649046|NCT02287740|Sham Comparator|Stretching|This protocol involves participation of 2 times a week for 6 months.
16649047|NCT02287727|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16649048|NCT02287714|Active Comparator|Instep without Gastrocnemius Recession|Patient will receive an instep plantar fascial release but not a gastrocnemius recession.
16649049|NCT02287714|Experimental|Instep with Gastrocnemius Recession|Patient will receive an instep plantar fascial release as well as a gastrocnemius recession.
16649050|NCT02287701|Experimental|PET/MRI|Patient receives MRI
16649052|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
16649053|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:
~In adults, to assist in the:
~localization of lymph nodes draining a primary tumor in patients with
~breast cancer or malignant melanoma when used with a hand-held gamma counter.
~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
16649054|NCT02287662|Experimental|Vancouver 3M Clinical Pathway|The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
16649055|NCT02287649|Other|patients with rituximab treatment|blood sample intake
16649056|NCT02287636|Experimental|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
16649057|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
16649058|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
16649059|NCT02287597||Cohort|
16649060|NCT02287584|Placebo Comparator|DSP-5423P Placebo|Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
16649061|NCT02287584|Experimental|DSP-5423P 40mg|Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
16649062|NCT02287584|Experimental|DSP-5423P 80mg|Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
16649063|NCT02287584|Experimental|DSP-5423P Placebo-to-Flex|Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
16649064|NCT02287584|Experimental|DSP-5423P Active-to-Flex|Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
16649065|NCT02287571|Active Comparator|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
16649066|NCT02287571|Experimental|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
16649067|NCT02287558|Experimental|Pomalidomide|Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.
16649068|NCT02287545||Glaucoma, primary|Glaucoma patients undergoing trabeculectomy
16649069|NCT02287532|Experimental|DIABEO software alone|Patient will have an introductory training session in the use of DIABEO by the investigating physician an will return for an on site consultation at 6 mounths (optional), 12 mounths and 24 mounths
16649070|NCT02287532|Experimental|DIABEO+paramedical telemonitoring|"Patient will have an on site introductory training session in the use of DIABEO, by his/her telemedicine nurse from his/her region. The nurse will then follow up the patient according to a delegated tasks protocol written by the investigating physician with the nurse. Patient will be asked to return to see the investigator at 6 mounths (optional), 12 mounths and 24 mounths"
16649071|NCT02287532|No Intervention|Usual Follow up|Patient will continue his/her usual follow up and return to see the investigator at 6 mounths (optional) and at the one year end of follow up for the study
16649072|NCT02287519|Experimental|Support Group|"One group educational session will include information on resources, self-help strategies, and relaxation techniques.
~One telephone coaching session after the group session Or
~Pilot webinar format of the educational session"
16649073|NCT02287506|Experimental|ODS from enrolment|Optimised Diagnostic Strategy used from enrolment to study
16649074|NCT02287506|No Intervention|ODS at end of study|ODS fed back at the end of the participants involvement with the study
16649075|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
16649076|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
16649077|NCT02287480|Experimental|VSV-ZEBOV lower dose|"One intramuscular (deltoid) injection of a lower dose (10^7 plaque-forming units) of VSV-ZEBOV.
~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10^5 plaque-forming units) of VSV-ZEBOV"
16649078|NCT02287480|Experimental|VSV-ZEBOV higher dose|"One intramuscular (deltoid) injection of a higher dose (5 x 10^7 pfu) of VSV-ZEBOV.
~Study amendment (01.2015) : interrupted"
16649079|NCT02287480|Placebo Comparator|Placebo|One intramuscular (deltoid) injection of normal saline (0.5 ml)
16649080|NCT02287467|Experimental|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
16649081|NCT02287467|Placebo Comparator|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
16649263|NCT02286336|Active Comparator|young group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
16649082|NCT02287454|Experimental|Cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
16649083|NCT02287454|No Intervention|Control group|No intervention was administered.
16649084|NCT02287441|Placebo Comparator|Raw Group|Vegetables Prepared Raw (raw)
16649085|NCT02287441|Experimental|Tomato Group|Tomato Products (tomato)
16649086|NCT02287428|Experimental|Coh 1 (Original Cohort): Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):
~~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.
~During that time, participant NeoAntigen Vaccine-Preparation is created (process takes ~ 12 weeks)
~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:
~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
16649087|NCT02287428|Experimental|Coh 1a: Pembrolizumab w Std RT Followed by NeoVax + Pembro|"RT: Standard RT (60Gy) over 6 weeks
~Pembrolizumab: Starts within 2 weeks of start of RT, and continues every 3 weeks for up to 2 years
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
16649088|NCT02287428|Experimental|Coh 1b: Std RT Followed by NeoVax + Pembrolizumab|"RT: Standard RT (60Gy) over 6 weeks
~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
16649089|NCT02287428|Experimental|Coh 1c: Std RT (+ 1 dose Pembro) Followed by NeoVax & Pembo|"RT: Standard RT (60Gy) over 6 weeks
~Pembrolizumab: Single dose of pembrolizumab administered within 2 weeks of start of RT; re-starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years.
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
16649090|NCT02287428|Experimental|Coh 1d: Std RT+TMZ Followed by 6 Cyc TMZ + NeoVax + Pembro|"• RT: Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks. Concurrent TMZ @ 75 mg/m2/day for 6 weeks.
~Followed by:
~6 cycles of Adjuvant temozolomide (TMZ): Starts 4-6 weeks after completion of RT. TMZ (150-200 mg/m2/day) on days 1-5 of each 28-day cycle for 6 cycles.
~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
16649091|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
16649092|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
16649093|NCT02287389|Experimental|balloon dilation|give the cases balloon dilation as the intervention
16649094|NCT02287389|Experimental|balloon dilation plus cryotherapy|give the cases balloon dilation plus cryotherapy as the intervention
16649095|NCT02287389|Experimental|BD plus spiculiform electrosurgery|give the cases balloon dilation plus spiculiform electrosurgery as the intervention
16649096|NCT02287389|Experimental|BD plus mitomycin C|give the cases Balloon dilation plus mitomycin C as the intervention
16649097|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
16649098|NCT02287363||TPP group|TPP patients(between episodes of paralysis), the inclusion criteria consisted of a certain history of acute limb muscle weakness, hypokalemia and decreased TSH with elevated free FT4, FT3. Subjects who suffered from hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease were excluded.
16649099|NCT02287363||hyperthyroidism group|Control group, we included subjects with evidence of aberrant thyroid function (decreased TSH, elevated FT4, FT3) without paralysis. Graves' disease(GD) was preferred which required information concerning either increased thyrotrophin receptor antibody(TRAb) level, ophthalmopathy or diffusively enlarged goiter. Individuals with pure thyroid associated ophthalmopathy, history of thyroidectomy due to malignancy or adenoma as well as subacute thyroiditis and pituitary hyperthyroidism were excluded.
16649100|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
16649101|NCT02287337|Experimental|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
16649102|NCT02287337|Other|Exercise|Patients will receive 5 visits of therapeutic exercises
16649103|NCT02287324|Active Comparator|Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine
16649104|NCT02287324|Placebo Comparator|Manual Contact|Manual contact to suboccipital region of the cervical spine for 5 minutes
16649105|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.
~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.
~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
16649106|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.
~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.
~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
16649150|NCT02286973|Active Comparator|Intravenous + Topical 2g Group|"Intravenous Injection During Operation, 10mg/kr
~After Capsule Closure, Tranexamic acid Topical Injection 2g"
16649151|NCT02286973|Active Comparator|No Intravenous, Only Topical 2g Group|Only Topical Injection 2g
16649152|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
16649107|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.
~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.
~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
16649108|NCT02287298||2006 TO 2010 PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
16649109|NCT02287298||CURRENT PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
16649110|NCT02287285|Experimental|Exendin9|Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
16649113|NCT02287259|Experimental|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
16649114|NCT02287259|Active Comparator|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
16649115|NCT02287246|Experimental|Extended-Release liposomal bupivacaine|20mL Extended-release liposomal bupivacaine injected into the posterior vaginal wall following surgery
16649116|NCT02287246|Active Comparator|Placebo (normal saline)|20mL normal saline injected into the posterior vaginal wall following surgery
16649117|NCT02287233|Experimental|Venetoclax + Low-Dose Cytarabine (LDC)|Participants will receive various doses of Venetoclax
16649118|NCT02287220||Newborn Infants|0-12 months old Male or female Any ethnicity
16649119|NCT02287207|Active Comparator|Anodal tDCS|20 minutes, 1.0 mA unilateral-anodal motor cortex (M1) tDCS stimulation
16649120|NCT02287207|Sham Comparator|Sham tDCS|20 minutes, sham tDCS stimulation
16649121|NCT02287194||SpyGlass Direct Visualization System|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of biliary tract diseases.
16649122|NCT02287181|Active Comparator|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
16649123|NCT02287181|Active Comparator|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
16649124|NCT02287168|Experimental|dissemination of cancer cells|conversion of negative result of pre-gastrectomy peritoneal washing cytology to positive cytology after gastrectomy
16649125|NCT02287168|Experimental|elimination of cancer cells|elimination of peritoneal cancer cells occurred before (pre-gastrectomy peritoneal washing cytology) or after gastrectomy (post-gastrectomy peritoneal washing cytology) by intra operative peritoneal lavage ('post-lavage peritoneal washing cytology)
16649126|NCT02287155|Experimental|occupation based health promotion|"The description of the health promotion intervention is provided in the detailed description of the study. It's a single arm study."
16649127|NCT02287142|Active Comparator|Interscalene|Single-shot Interscalene Nerve Block with ropivacaine 0.5%
16649128|NCT02287142|Active Comparator|Supraclavicular|Single-shot Supraclavicular Nerve Block with ropivacaine 0.5%
16649129|NCT02287142|Active Comparator|Suprascapular|Single-shot Suprascapular Nerve Block with ropivacaine 0.5%
16649130|NCT02287129|Experimental|Non-Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy
16649131|NCT02287129|Active Comparator|Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy
16649132|NCT02287116|No Intervention|nasal mask and nasal prongs|
16649133|NCT02287103|Experimental|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
16649134|NCT02287103|Active Comparator|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
16649135|NCT02287077|No Intervention|Immediate cord clamping|At birth, neonate will be held at the level of placenta and umbilical cord will be clamped immediately (standard of care for depressed neonates).
16649136|NCT02287077|Experimental|Umbilical cord milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
16649137|NCT02287064|Experimental|Intravenous Immune Globulin (IVIG)|
16649138|NCT02287051||colonoscopy population|
16649139|NCT02287038|Active Comparator|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
16649140|NCT02287038|Placebo Comparator|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
16649141|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
16649142|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
16649143|NCT02287012||Pre-Plerixafor era|The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
16649144|NCT02287012||Plerixafor era|The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
16649145|NCT02286999|Experimental|B.infantis|Infants in the experimental arm will have two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis) on Day 7 and Day 14 of life.
16649146|NCT02286999|Placebo Comparator|Placebo|Infants in the experimental arm will have two doses of placebo (powdered maltodextrin) on Day 7 and Day 14 of life.
16649147|NCT02286986|Other|Cannabidiol|open label administration
16649148|NCT02286973|Active Comparator|Only Intravenous Group|Only Intravenous Injection During Operation, 10mg/kr
16649149|NCT02286973|Active Comparator|Intravenous + Topical 1g Group|"Intravenous Injection During Operation, 10mg/kr
~After Capsule Closure, Tranexamic acid Topical Injection 1g"
16649155|NCT02286934|Experimental|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd
~Day 4 to 8 : Carvedilol 25 mg qd
~Day 9 to 11 : Carvedilol 12.5 mg qd
~Isoproterenol Sensitivity Test
~Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.
~Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.
~Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol."
16649156|NCT02286921|Experimental|Arm A: Testosterone cypionate or testosterone enanthate|Patients on BAT will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
16649157|NCT02286921|Experimental|Arm B: Enzalutamide|Patients randomized to enzalutamide will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
16649158|NCT02286895|Active Comparator|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
16649159|NCT02286895|Experimental|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
16649160|NCT02286882|Experimental|Cohort 1: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649161|NCT02286882|Experimental|Cohort 2: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649162|NCT02286882|Experimental|Cohort 3: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649163|NCT02286882|Experimental|Cohort 4: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649164|NCT02286882|Experimental|Cohort 5: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649165|NCT02286882|Experimental|Cohort 6: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649166|NCT02286882|Experimental|Cohort 7: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649167|NCT02286882|Experimental|Cohort 8: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649168|NCT02286882|Experimental|Cohort 9: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
16649169|NCT02286869|Experimental|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.
~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.
~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
16649170|NCT02286869|Experimental|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.
~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.
~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
16649171|NCT02286869|Experimental|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.
~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.
~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
16649172|NCT02286856|Other|control group|Usual care followed bij diet intervention after 6 months
16649173|NCT02286856|Active Comparator|intervention group|diet intervention
16649174|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
16649175|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
16649176|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
16649177|NCT02286817|Experimental|Single arm of 30 subjects|Subjects will be administered single dose of NFC-1 to assess safety, tolerability, and pharmacokinetics, then proceed to continuous, daily administration of NFC-1 for 4 weeks to assess safety, tolerability, and impact on ADHD severity.
16649178|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
16649179|NCT02286791|Experimental|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
16649180|NCT02286791|Active Comparator|Health Education Program|18 sessions of health education program focusing on healthy living topics
16649181|NCT02286778|Active Comparator|Acetogenins|Dietary Supplement: Acetogenins BID for 12 months
16649182|NCT02286778|Placebo Comparator|Placebo|Dietary Supplement: No Acetogenins BID for 12 months
16649183|NCT02286778|No Intervention|Control|Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
16649629|NCT02283931|Active Comparator|two handed uterine displacement|Uterine displacement using two hands
16649185|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
16649186|NCT02286752|Active Comparator|neostigmine|
16649187|NCT02286752|Active Comparator|sugammadex|
16649188|NCT02286739|Sham Comparator|Group A TKA without VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
16649189|NCT02286739|Active Comparator|Group B TKA with VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.
16649190|NCT02286726|Experimental|Arm I (lower-dose (50 units/m^2) CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
16649191|NCT02286726|Experimental|Arm II (intermediate-dose (75 units/m^2) CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
16649192|NCT02286726|Experimental|Arm III (standard-dose (100 units/m^2) CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
16649193|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
16649194|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
16649195|NCT02286700|Active Comparator|Desonide Group|Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
16649196|NCT02286700|Experimental|Amino Acid Group|Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
16649197|NCT02286687|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16649198|NCT02286674|Experimental|Tablet for watching movie|The study group will receive standard of care in addition to a tablet to watch movies and/or TV
16649199|NCT02286674|No Intervention|Standard of care - no tablet|The control group will receive standard of care only.
16649200|NCT02286661|Active Comparator|Short Arm Cast|Short arm cast below the elbow
16649201|NCT02286661|Active Comparator|Long Arm Cast|Long arm cast above the elbow
16649202|NCT02286648|Experimental|Mineral Trioxide Aggregate|pulpotomy with MTA
16649203|NCT02286648|Active Comparator|Formocresol|pulpotomy with FC
16649204|NCT02286635|Experimental|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
16649205|NCT02286635|Experimental|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
16649206|NCT02286622|Experimental|Renal Impairment|Eight (8) subjects with ESRD on HD will receive one 18 mg dose of deflazacort.
16649207|NCT02286622|Experimental|Healthy Volunteers|Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the ESRD cohort. Subjects will receive one 18 mg dose of deflazacort.
16649208|NCT02286609|Experimental|Hepatic Impairment|Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
16649209|NCT02286609|Experimental|Healthy Volunteer|Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
16649210|NCT02286596||heparin-induced extracorporeal LDL precipitation|Lipid apheresis treatment for 3 hours
16649211|NCT02286596||dextran sulfate adsorption|Lipid apheresis treatment for 3 hours
16649212|NCT02286583|No Intervention|Microwave Thermography RTM-01-RES|Microwave thermography with sensitive probe that can detect skin and up to 8 cm microwave radiation deep tissues
16649213|NCT02286570|Active Comparator|face-to-face intubation of Glidescope|patients were intubated using glidescope by face-to-face approach
16649214|NCT02286570|Active Comparator|face-to-face intubation with Airtraq|patients were intubated using the Airtraq by face-to-face approach
16649215|NCT02286570|Active Comparator|face-to-face intubation with fastrach|patients were intubated using the Fastrach by face-to-face approach
16649216|NCT02286557|Experimental|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
16649217|NCT02286557|Experimental|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
16649218|NCT02286544|Active Comparator|Salmonella typhi vaccine|0.5 mL Salmonella typhi vaccine
16649219|NCT02286544|Experimental|Salmonella typhi vaccine + oxygen|0.5 mL Salmonella typhi vaccine + 6l/min oxygen
16649220|NCT02286544|Experimental|S. typhi vaccine + oxygen + Atorvastatin|0.5 mL Salmonella typhi vaccine + 6l/min oxygen + 80mg Atorvastatin
16649221|NCT02286531|Experimental|FET imaging|FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2[18F]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
16649222|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
16649223|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
16649224|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
16649225|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
16649226|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
16649227|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
16649228|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
16649229|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
16649230|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
16649231|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
16649232|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
16649233|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
16649234|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
16649235|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
16649236|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
16649237|NCT02286505|Experimental|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
16649238|NCT02286505|Other|Standard radiological assessment.|Standard neuroradiological report of the structural MRI only.
16649239|NCT02286479|Active Comparator|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
16649240|NCT02286479|Experimental|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
16649241|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
16649242|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
16649243|NCT02286453|Experimental|1|Benjakul
16649244|NCT02286453|Active Comparator|2|diclofenac
16649245|NCT02286440|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on test results
16649246|NCT02286440|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
16649247|NCT02286427|Active Comparator|Standard Dressing|J0 to J42 : once a week, primary dressing with Mepitel®
16649248|NCT02286427|Experimental|Amniotic Membrane|J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
16649249|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
16649250|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
16649251|NCT02286388|Experimental|Partial excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
16649252|NCT02286388|Active Comparator|Complete excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
16649253|NCT02286388|Experimental|Antibacterial dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
16649254|NCT02286388|Active Comparator|Conventional dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
16649255|NCT02286375|Experimental|Intervention group|Interventions include providing comprehensive assessment from Omaha system, giving information regarding the self-care management, assisting and coordinating self-regulating skills and abilities, and providing social support from health-social care team to community-dwelling older adults for three months
16649256|NCT02286375|Placebo Comparator|customary care group|Customary care includes receiving community services from the community center in the district, providing monthly social call by a reserch assistant for three months
16649257|NCT02286362||Cohort|
16649258|NCT02286349|Experimental|Real rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 blocks of real stimulation intensity of 10 Hz, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average).
16649259|NCT02286349|Sham Comparator|Sham rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 stimulation sham blocks, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average)
16649260|NCT02286349|Experimental|Real tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of real anodal transcranial direct current stimulation with intensity of 1 mA + 20 minutes of neuropsychological reassessment (on average).
16649261|NCT02286349|Sham Comparator|Sham tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of sham transcranial direct current stimulation + 20 minutes of neuropsychological reassessment (on average)
16649262|NCT02286336|Experimental|middle aged group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
16649264|NCT02286323|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
16649265|NCT02286323|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16649266|NCT02286310|Experimental|Group A|Kinetic Chain Exercises
16649267|NCT02286310|Active Comparator|Group B|Traditional Exercises
16649268|NCT02286297|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
16649269|NCT02286297|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16649270|NCT02286284|Experimental|Apheresis arm|Apheresis for extracorporal removal of sFlt-1
16649271|NCT02286258|Experimental|Inuline - Calcium EDTA|Calcium EDTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
16649272|NCT02286258|Experimental|Inuline - Gd-DOTA|Gd-DOTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
16649273|NCT02286245|Experimental|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
16649274|NCT02286245|Active Comparator|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
16649275|NCT02286232|Experimental|Stretching exercise|A series of 12 standardized, weekly stretching exercise classes will be held at the Wilton Family YMCA, designed for people with chronic low back pain unaccustomed to stretching. Participants will be asked to practice the identical routine of that week's stretching exercise class on off days and will be given handouts and CD's to assist in this.
16649276|NCT02286232|Active Comparator|Self-care book|The Back Pain Helpbook (Moore JE, Lorig K, Von Korff M, Gonzalez VM, Laurent DD. The Back Pain Helpbook. Reading, MA: Perseus Books; 1999)provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
16649277|NCT02286219|Experimental|FS102|Dose escalation of either weekly or Q3W of FS102
16649278|NCT02286206|Experimental|Clozapine bid|"Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.
~Intervention: Days 1-14"
16649279|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
16649280|NCT02286167|Other|Single arm diet|Intermittent, modified Atkins diet
16649281|NCT02286154|Experimental|Hydroxyurea|"All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the New Cohort or Old Cohort New Cohort participants include those who are not receiving hydroxyurea therapy upon study entry. Old Cohort participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines."
16649282|NCT02286141||Intervention|Patients receiving care at primary care clinics randomized to receive the supplemental training on stratified care for back pain through the use of the StartBack Tool will be considered to be a part of the intervention group. Randomization is done at the clinic level and not at the individual patient level.
16649283|NCT02286141||Control|Patients receiving care at primary care clinics randomized to receive the standard Group Health training on the updated Guidelines for Back Pain Care will be considered to be a part of the control group. Randomization is done at the clinic level and not at the individual patient level.
16649284|NCT02286128||Non-diabetic controls|Age-matched non-diabetic subjects
16649285|NCT02286128||Type 2 diabetes|Type 2 diabetes with metformin monotherapy failure
16649286|NCT02286115|Experimental|Life-Stress Interview|The Life-Stress Interview is an experiential assessment technique
16649287|NCT02286115|No Intervention|Wait-list Control|Wait-list Control
16649288|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
16649289|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
16649290|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
16649291|NCT02286063|Active Comparator|ambulatory oxygen cylinders|Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
16649292|NCT02286063|No Intervention|no oxygen cylinders|Subjects randomised to be on air for the first two weeks of the treatment period.
16649293|NCT02286050|Experimental|CF Nursing Intervention|
16649294|NCT02286011|Experimental|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.
~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
16649295|NCT02286011|Placebo Comparator|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
16649296|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
16649297|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
16649298|NCT02285985|Experimental|Saxagliptin|Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
16649299|NCT02285985|Placebo Comparator|Placebo|Sugar pill
16649300|NCT02285972|Placebo Comparator|saline|
16649301|NCT02285972|Active Comparator|dexketoprofen|
16649302|NCT02285972|Active Comparator|tenoxicam|
16649303|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
16649304|NCT02285933|Experimental|VRT|sitting balance exercises delivered via virtual reality training
16649305|NCT02285933|Active Comparator|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
16649306|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
16649307|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
16649308|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
16649309|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
16649310|NCT02285907|Experimental|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
16649311|NCT02285907|Experimental|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
16649312|NCT02285907|Experimental|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
16649313|NCT02285907|Experimental|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
16649314|NCT02285894|Experimental|Inspiratory hold|Mechanical inspiratory pressure held for 10 seconds at a time.
16649315|NCT02285881|Experimental|shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
16649316|NCT02285881|No Intervention|control group|Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
16649317|NCT02285868||Arm, Shoulder and Hand injuries|Pre- and post-treatment outcomes of care as measured by the DASH (Disabilities of the Arm, Shoulder and Hand) via physical therapy
16649318|NCT02285868||Lumbar spine injuries|Pre- and post-treatment outcomes of care as measured by the Modified Oswestry (lumbar spine) via physical therapy
16649319|NCT02285868||Knee injuries|Pre- and post-treatment outcomes of care as measured by the Knee Outcome Survey via physical therapy
16649320|NCT02285868||Foot and ankle injuries|Pre- and post-treatment outcomes of care as measured by the Foot & Ankle Ability Measure via physical therapy
16649321|NCT02285868||Hip and lower extremity injuries|Pre- and post-treatment outcomes of care as measured by the Lower Extremity Functional Scale via physical therapy
16649322|NCT02285868||Neck injuries|Pre- and post-treatment outcomes of care as measured by the Neck Disability Index Questionnaire via physical therapy
16649323|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
16649324|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
16649325|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
16649630|NCT02283931|Active Comparator|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
16649326|NCT02285829||T4/T1=0.1-0.25|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
16649327|NCT02285829||T4/T1=0.25-0.50|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
16649328|NCT02285829||T4/T1=0.50-0.75|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
16649329|NCT02285829||T4/T1=0.75-0.90|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
16649330|NCT02285816|Experimental|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
16649331|NCT02285816|Experimental|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10^10 pfu administered IM on day (-14). No dose escalation is planned.
16649332|NCT02285816|Experimental|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 & 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
16649333|NCT02285803|Active Comparator|TRT and real tDCS|
16649334|NCT02285803|Sham Comparator|TRT and sham tDCS|
16649335|NCT02285790|Experimental|RCM-OSS procedure|The Vivascope 1500 will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed for intended use only and interpreted on the Vivascope workstation by two investigators independently at both study locations. The investigators will be blinded to the results of the reference standard. After RCM imaging subjects will receive OSS surgical excision according to subtype. Clinically suspected primary BCCs that are not confirmed by RCM will also receive surgical treatment with a margin of 3mm.
16649336|NCT02285790|Active Comparator|Standard of care procedure|Clinical suspected primary BCCs, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most elevated part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. HE stained sections of the punch biopsies will be evaluated by an experienced board certified pathologist. Subjects will receive surgical excision according to subtype within 6 weeks after punch biopsy has been performed. Clinically suspected new primary BCCs that are not confirmed by punch biopsy will also receive surgical treatment with a margin of 3mm.
16649337|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
16649338|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
16649339|NCT02285764|Experimental|Nutritional Supplement|One 237 ml oral supplement consumed two times a day; Not commercially available.
16649340|NCT02285764|Other|Standard of Care|As determined by the study site
16649341|NCT02285751|Experimental|200mg acetylsalicylic acid per os|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os"
16649342|NCT02285751|Experimental|100mg acetylsalicylic acid intravenous|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously."
16649343|NCT02285751|Experimental|81 mg chewable acetylsalicylic acid|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid"
16649344|NCT02285751|Active Comparator|75mg clopidogrel|"control group for patients with high on treatment platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day"
16649345|NCT02285751|Experimental|60mg prasugrel|"Loading dose of prasugrel for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel"
16649346|NCT02285751|Experimental|600mg clopidogrel|"additional loading dose for 24 patients tested with high on treatment platelet reactivity to clopidogrel"
16649347|NCT02285751|Experimental|180mg ticagrelor|"Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity after being treated with 10mg prasugrel daily"
16649348|NCT02285751|Active Comparator|prasugrel 10mg|patients treated with 10mg prasugrel daily
16649349|NCT02285738|Active Comparator|Aspirin+Asprin/Simvastatin+Observation (ASO)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation
16649350|NCT02285738|Experimental|Aspirin+Observation+Asprin/Simvastatin (AOS)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin
16649351|NCT02285738|Experimental|Aspirin/Simvastatin+Observation+Asprin (SOA)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day
16652280|NCT02265939|Active Comparator|0.2% NPO-13|Low dose
16649352|NCT02285738|Experimental|Aspirin/Simvastatin+Asprin+Observation (SAO)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.
16649353|NCT02285738|Experimental|Observation+Aspirin/Simvastatin+Asprin (OSA)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.
16649354|NCT02285738|Experimental|Observation+Aspirin+Asprin/Simvastatin (OAS)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.
16649355|NCT02285725|Experimental|Augmented Microdrilling Surgery|
16649356|NCT02285712|No Intervention|Classical method of peripheral venous catheterization|Classical method will be applied only on arm and forearm.
16649357|NCT02285712|Experimental|Ultrasound guided peripheral venous catheterization|Nurse will use a vascular ultrasound system to orient the catheter toward the peripheral vein. Ultrasound method will be applied only on arm and forearm.
16649358|NCT02285699|Other|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
16649359|NCT02285673|Experimental|Umbilical Cord Mesenchymal Stem Cell|
16649360|NCT02285660|Other|Routine CT scan plus 4D PET-CT scan|
16649361|NCT02285660|Other|Routine CT scan|
16649362|NCT02285647|Experimental|Rolapitant - Oral|Investigational Product: Rolapitant Dose: 200 mg (4 x 50mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
16649363|NCT02285647|Experimental|Rolapitant - IV|Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
16649364|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
16649365|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
16649366|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
16649367|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
16649368|NCT02285621|Experimental|Optimized brace|Test group: Patient will receive optimized brace (3D computer assisted design of the brace)
16649369|NCT02285621|Active Comparator|Standard brace|Control goup: Patient will receive the Boston Thoracolumbosacral orthosis (TLSO) (conventional design method)
16649370|NCT02285608|Experimental|PIMM/SAM|Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
16649371|NCT02285608|No Intervention|Standard Prescribing Practice(SPP)|Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
16649372|NCT02285595|Other|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
16649373|NCT02285556|No Intervention|general information|use cross-sectional study to collect 1000 ATS abuse or dependence patients' general information and 5 ml blood,get their blood plasma and DNA sample in order to explore the possible addict mechanism.
16649374|NCT02285556|No Intervention|ATS diagnosis and evaluation for abusers|Use cohort study design to establish ATS abuse induced craving experiment.Do the initial and follow-up assessment from start smoking to stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community . Thus compare with normal group to explore the possible psychological abuse mechanism.
16649375|NCT02285556|Active Comparator|psychological training intervention|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
16649376|NCT02285556|Active Comparator|brain stimulation intervention|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
16649377|NCT02285556|No Intervention|ATS diagnosis and evaluation for normal people|Do the same initial and follow-up assessment as ATS abusers who stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community .
16649378|NCT02285556|Active Comparator|physical and neurological rehabilitation|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
16649379|NCT02285556|Placebo Comparator|fake brain stimulation intervention|fake transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
16649380|NCT02285543|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.
~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
16649381|NCT02285543|Other|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
16649382|NCT02285530|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.
~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
16649383|NCT02285530|Other|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
16649384|NCT02285517|Active Comparator|modified Meek technique|Intervention: modified Meek skin grafting technique. Patients with third degree of burns without infected wounds are included and the modified Meek results are studied , measured and compared to other group which is operated lesions by mesh technique
16649385|NCT02285517|Active Comparator|mesh technique|Intervention: mesh skin grafting technique. patients with third degree of burns without infected wounds are included and the mesh skin grafting technique results are studied , measured and compared to other group which is operated lesions by modified Meek skin grafting technique
16649386|NCT02285504|Experimental|SAGE-547|
16649387|NCT02285491|Experimental|bupivacaine group|This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision
16649388|NCT02285491|Placebo Comparator|saline group|This group will receive saline injections as placebo into both angles of the rectus sheath incision
16649389|NCT02285491|Experimental|bupivacaine and saline group|This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle.
16649390|NCT02285465|Experimental|ASP3700 multiple ascending dose cohort|
16649391|NCT02285465|Placebo Comparator|Placebo cohort|
16649392|NCT02285452|Active Comparator|Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)|Thorax wrap with ginger flour, duration max. 20 minutes
16649393|NCT02285452|Active Comparator|Thorax wrap with mustard flour (Sinapis nigrea semen)|Thorax wrap with mustard flour, duration max 20 minutes
16649394|NCT02285452|Placebo Comparator|Thorax wrap with warm water (placebo)|Thorax wrap with warm water (placebo), duration: 20 minutes
16649395|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
16649396|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
16649397|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
16649398|NCT02285426||suspected lungcancer|"Patients will undergo a bronchoscopy with the Pentax EB1990i HD-bronchoscope investigating the entire bronchial tree. The HD+ bronchoscopy needs to be performed in a standardized way using 3 different imaging modes:
~HD+bronchoscopy
~HD+bronchoscopy + i-Scan 1
~HD+bronchoscopy + i-Scan 2"
16649399|NCT02285413|Experimental|DC vaccination|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase
16649400|NCT02285413|Experimental|DC vaccination with cisplatinum|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase. each DC vaccine will be preceded by cisplatin infusion: 50 mg/m2, 1-2h before DC injection.
16649401|NCT02285400|Experimental|Moderate COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
16649402|NCT02285400|Experimental|Severe COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
16649403|NCT02285387|Experimental|Rhythm control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
~Cardioversion after 1 month
~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
~If AF recur, RFCA"
16649404|NCT02285387|Active Comparator|Rate control group|"No AAD, just anticoagulation
~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
16649405|NCT02285374|Experimental|Arm 1|Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily
16649406|NCT02285374|Experimental|Arm 2|Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily
16649407|NCT02285361||GIOTRIF|
16649408|NCT02285348|Other|Ataxia Telangiectasia|20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
16649409|NCT02285348|Other|Healthy Control|20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
16649410|NCT02285335|Experimental|Low group|GINST15 3g/day
16649411|NCT02285335|Experimental|High group|GINST15 6g/day
16649412|NCT02285322||BP control reached|Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to <140/90mmHg if aged less than 60 years old, and <150/90mmHg for those of ≥60 years
16649413|NCT02285322||BP control not reached|Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
16649414|NCT02285309||Cardiac surgery|
16649415|NCT02285296|No Intervention|control arm|usual care
16649416|NCT02285296|Experimental|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
16649417|NCT02285283|Placebo Comparator|Placebo|2 capsules by mouth twice a day for 24 weeks
16649418|NCT02285283|Active Comparator|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
16649419|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
16649710|NCT02283346|Experimental|HDR Brachytherapy + EBRT|HDR brachytherapy + hypofractionated EBRT
16652281|NCT02265939|Active Comparator|0.4% NPO-13|Medium dose
16649420|NCT02285244|Experimental|Treatment (sotrastaurin acetate)|Patients receive sotrastaurin acetate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16649421|NCT02285231|Experimental|TEST|Arginyl-fructose Supplementation
16649422|NCT02285231|Experimental|Placebo|Placebo Supplementation
16649423|NCT02285218||1) Normal control|metabolically healthy with no obesity
16649424|NCT02285218||2) dyslipidemia|high triglyceride levels or LDL-C levels
16649425|NCT02285218||3) type 2 diabetes|defined in 'inclusion criteria'
16649426|NCT02285218||4) non-alcoholic fatty liver disease|defined in 'inclusion criteria'
16649427|NCT02285205|Experimental|Lobeglitazone|
16649428|NCT02285192|Experimental|intracervical 18F-FDG injection during a dynamic PET/CT|The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
16649431|NCT02285166||Oral administration of 2 g of omega-3-acid ethyl esters|Oral administration of 2 g of omega-3-acid ethyl esters once daily or twice daily immediately after meals
16649432|NCT02285166||Standard antihyperlipidemic therapy|Standard antihyperlipidemic therapy other than omega-3 fatty acid ethyl esters (Lotriga) administration.
16649433|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
16649434|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
16649435|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
16649436|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
16649437|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
16649438|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
16649439|NCT02285127|Active Comparator|Short nail implant|used to treat pertrochanteric fractures
16649440|NCT02285127|Active Comparator|Long nail implant|used to treat pertrochanteric fractures
16649441|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
16649442|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
16649443|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age and between 17 kg to < 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
16649444|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
16649445|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
16649446|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
16649447|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
16649448|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
16649449|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
16649450|NCT02285114|Experimental|FTC/TAF +3rd ARV agent (Extension Phase)|After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
16649711|NCT02283333|Experimental|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
16649451|NCT02285101|Experimental|Cohort 1|PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
16649452|NCT02285101|Experimental|Cohort 2|PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
16649453|NCT02285101|Experimental|Cohort 3|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
16649454|NCT02285101|Experimental|Cohort 4|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
16649455|NCT02285101|Experimental|Cohort 5|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
16649456|NCT02285101|Experimental|Cohort 6|PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
16649457|NCT02285088|Experimental|GBT440|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
16649458|NCT02285088|Placebo Comparator|Placebo|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
16649459|NCT02285075|Other|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
16649460|NCT02285062|Experimental|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
16649461|NCT02285062|Active Comparator|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
16649462|NCT02285049||Urticaria Control Test|"Evaluation by UAS28, PatGA-LS, PhyGA-LS
~Fill the UCT and DLQI questionnaire"
16649463|NCT02285036|Experimental|A newly PPV23|The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
16649464|NCT02285036|Active Comparator|PNEUMOVAX 23|PNEUMOVAX 23 is an established US-licensed vaccine and manufactured by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
16649465|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)
~Fill the DLQI and CU-Q2oL questionnaire"
16649466|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
16649467|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
16649468|NCT02284997|Experimental|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
16649469|NCT02284997|No Intervention|Control|No treatment
16649470|NCT02284984|Experimental|Rituximab with belimumab|Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.
16649471|NCT02284971|Experimental|Arm A: CDX1127 & SBRT Concurrent|"SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).
~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
16649712|NCT02283333|Active Comparator|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
16649472|NCT02284971|Experimental|Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).
~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
16649473|NCT02284971|Experimental|Arm C: CDX1127 & SBRT Sequential; SBRT upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).
~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
16649474|NCT02284958|Active Comparator|Standard/Control group|Each participant will receive a one-off individualized educational session regarding the management of chronic low back pain with a Physical Therapist: includes a physical examination, standardized advice & provision of the 'Back Book'.
16649475|NCT02284958|Experimental|Walking group|Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
16649476|NCT02284945|Experimental|Posterior percutaneous instrumentations|
16649477|NCT02284945|Other|Traditional open surgery with pedicle screw fixation|
16649478|NCT02284932||COPD patients|Group : COPD patients No specific intervention for this study
16649479|NCT02284932||Healthy controls|Group : healthy volunteers No specific intervention for this study
16649480|NCT02284919|Experimental|ISO-1 PET/CT|All subjects will receive an [18F]ISO-1 PET/CT scan
16649481|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
16649482|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
16649483|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
16649484|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
16649485|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
16649486|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
16649487|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
16649488|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
16649489|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
16649490|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
16649491|NCT02284841|Experimental|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
16649492|NCT02284841|No Intervention|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
16649493|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
16649494|NCT02284815|Active Comparator|Glutenfree diet|Self-chosen glutenfree diet
16649495|NCT02284815|Placebo Comparator|Normal diet|Those not following the glutenfree diet
16649496|NCT02284802|Experimental|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
16649497|NCT02284789|Other|CAJAS evaluation|
16649498|NCT02284776|No Intervention|Témoin|No treatment.
16649499|NCT02284776|Experimental|Action|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
16649500|NCT02284763|Experimental|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
16649501|NCT02284750|Experimental|Two-stenting technique|Percutaneous coronary intervention with DK crush, or culotte technique
16649502|NCT02284750|Active Comparator|Provisional stenting technique|Percutaneous coronary intervention with Provisional stenting technique. Stenting of the side branch was required if TIMI flow was <3, or ≥ type B dissection after kissing balloon inflation.
16649503|NCT02284737|Experimental|PADN + sildenafil|Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
16649504|NCT02284737|Sham Comparator|sham PADN + sildenafil|The radiofrequency ablation catheter placed, no ablations.
16649505|NCT02284724|Experimental|Needling|Insertion of solid mono-filament needle into lumbar multifidus muscle at both sides of L4/5 segment
16649713|NCT02283320|Experimental|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
16649506|NCT02284724|Other|Sham|The plastic tube containing the mono-filament needle will be pressed into the skin over the lumbar multifidus muscle at both sides of L4/5 segment - without insertion through the skin
16649507|NCT02284711|Active Comparator|Bipolar|Coagulation during salpingectomy using conventional bipolar electric energy
16649508|NCT02284711|Active Comparator|Ultrasound|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
16649509|NCT02284698||Study Group|Study Group will have the field workers and active health education with referral mechanism
16649510|NCT02284698||Control Group|Control group will not have field workers and active health education. They will follow routine health care
16649511|NCT02284685|Experimental|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
16649512|NCT02284685|Experimental|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
16649513|NCT02284685|Experimental|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
16649514|NCT02284685|Experimental|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
16649515|NCT02284685|Experimental|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
16649516|NCT02284685|Experimental|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
16649517|NCT02284685|Experimental|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
16649518|NCT02284685|Experimental|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
16649519|NCT02284672|Placebo Comparator|control|"After preoxygenation for 3 minutes, normal saline would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.
~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
16649520|NCT02284672|Experimental|dexmedetomidine|"After preoxygenation for 3 minutes, dexmedetomidine would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.
~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
16649521|NCT02284659|Sham Comparator|FES-sham|Functional Electro Stimulation (FES-sham)
16649522|NCT02284659|Active Comparator|Intervention (FES)|functional electro stimulation
16649523|NCT02284646|Experimental|Personalized physical training|9-week personalized physical training program (ergometric bicycle)
16649524|NCT02284646|No Intervention|Information about physical activity|2 sessions of information on physical activity
16649525|NCT02284620|Experimental|CFNB group|Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
16649714|NCT02283307|Experimental|Reduced contrast DECT scan|Reduced Contrast Dual Energy CT
16649526|NCT02284620|Active Comparator|LWI group|Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
16649527|NCT02284607|Experimental|MHAA4549A higher dose|
16649528|NCT02284607|Experimental|MHAA4549A lower dose|
16649529|NCT02284607|Placebo Comparator|Placebo|
16649530|NCT02284594|Experimental|text message|Receipt of series of text messages regarding influenza vaccination
16649531|NCT02284594|No Intervention|usual care|
16649532|NCT02284581||Retrospective cohort|All consecutive metastatic breast cancers patients treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from Feb 2014 retrospectively back until 2000.
16649533|NCT02284581||Prospective cohort|All new consecutive metastatic breast cancers patients will be treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from March 2014 to December 2016.
16649534|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
16649535|NCT02284568|Experimental|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
16649536|NCT02284568|Experimental|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
16649537|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
16649539|NCT02284529|Experimental|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8~12 cycles
16649540|NCT02284516|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
16649541|NCT02284516|Placebo Comparator|Placebo|Placebo to match active treatment, BID for 84 days
16649542|NCT02284503|Experimental|40mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.
16649543|NCT02284503|Experimental|20mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.
16649544|NCT02284503|Experimental|no statin group|The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.
16649545|NCT02284490|Experimental|Treatment Arm|Pemetrexed 900 mg/m² every 21 days until disease progression.
16649546|NCT02284477|Experimental|non- PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in glass bottle for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
16649547|NCT02284477|Experimental|PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
16649548|NCT02284477|No Intervention|Only lunch and dinner|Participant received food for lunch and dinner After 1 week, participant get over to each experimental arms.
16649549|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
16649550|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
16649551|NCT02284451|Active Comparator|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
16649552|NCT02284451|Active Comparator|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
16649553|NCT02284451|Active Comparator|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
16649554|NCT02284451|Active Comparator|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
16649555|NCT02284438|Other|Biofilm formation on ETT|Three different endotracheal tubes uses on intubated mechanical ventilated patients will after extubation be examined regarding biofilm, structure and presence of microbes on the ETTs The different tubes will be used during consecutive time periods The study does not include any interventions concerning the treatment of these critically ill patients
16649556|NCT02284425|Experimental|Part A|Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
16649557|NCT02284425|Experimental|Part B|Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
16649558|NCT02284412|Active Comparator|neostigmine|Neostigmine will be dosed as 60 μg/kg, and glycopyrrolate 12 μg/kg (commercially available 5:1 co-formulation), as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
16649559|NCT02284412|Experimental|Sugammadex|Sugammadex will be dosed 15 mg/kg, as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
16649560|NCT02284412|Placebo Comparator|Water for injection|Water will be dosed arbitrarily as a 1 mL single iv bolus administered over 10sec.
16652282|NCT02265939|Active Comparator|0.8% NPO-13|High dose
16649561|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
16649562|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
16649563|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
16649564|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
16649565|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
16649566|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
16649567|NCT02284360|Experimental|Group A: Low dose|"Each volunteer in group A will receive both Verum and Placebo.
~The Verum lyophilized APOSEC™ is derived from 12.5*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.
~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
16649568|NCT02284360|Experimental|Group B: High dose|"Each volunteer in group B will receive both Verum and Placebo.
~The Verum lyophilized APOSEC™ is derived from 25*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.
~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
16649569|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
16649570|NCT02284334||Low GI-High GI|"Two study visits are separate by around one month.
~For this arm, test meal (Visit 1): low-glycemic index; test meal (Visit 2): high-glycemic index"
16649571|NCT02284334||High GI-Low GI|"Two study visits are separate by around one month.
~For this arm, test meal (Visit 1): high-glycemic index; test meal (Visit 2): low-glycemic index"
16649572|NCT02284308|Active Comparator|Concurrent RCHT|"Etoposide (day 1, 2 and 3) and cisplatin (day 1) every 3 weeks, 3 cycles)
~Etoposide (day 1, 2 and 3) and carboplatin (every 3 weeks, 3 cycles)
~Cisplatin (daily)
~Pemetrexed/Alimta and cisplatin (day 1 every 3 weeks, 3 cycles)
~Pemetrexed/Alimta and carboplatin (day 1 every 3 weeks, 3 cycles)
~Radiation schedule:
~Radiotherapy in both arms is delivered to a minimal total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the mininimal TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
16649573|NCT02284308|Active Comparator|Sequential RCHT|"Pemetrexed/Alimta and cisplatin day 1 every 3 weeks, 3 cycles,
~Pemetrexed/Alimta and carboplatin (every 3 weeks, 3 cycles),
~Gemcitabine (day 1 and 8) and cisplatin (day 1) every 3 weeks, 3 cycles)
~Gemcitabine (day 1 and 8) and carboplatin, (day 1 every 3 weeks, 3 cycles)
~Radtiation schedule:
~Radiotherapy in both treatment arms is delivered to a minimum total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the minimum TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
16649574|NCT02284295||occupational COPD|"Consists of 2 subgroups
~COPD patients with history of exposure to respirable silica dust
~COPD patients with history of exposure to aromatic hydrocarbons"
16649575|NCT02284295||smokers with COPD and healthy control|"patients with COPD, history of tobacco smoke and no history of occupational exposure
~healthy subjects"
16649576|NCT02284282|Active Comparator|Spinal injection|Patients receive spinal injection Bupivacaine/Morphine
16649577|NCT02284282|Placebo Comparator|Subcutaneum injection|Placebo subcutaneum injections
16649578|NCT02284256|Experimental|Fibrocaps|"Human fibrinogen and thrombin powder. Single application during surgery
~Other Names:
~Raplixa
~PRO-0601
~Fibrin sealant
~Device: Gelatin sponge. Single application during surgery
~Other Name: Spongostan"
16649579|NCT02284256|Active Comparator|TachoSil|Human fibrinogen and thrombin powder. Single application during surgery
16649580|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
16649581|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
16649582|NCT02284230|Active Comparator|Liraglutide treatment|Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
16649583|NCT02284230|Placebo Comparator|Placebo treatment|Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
16649584|NCT02284217|Experimental|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
16649585|NCT02284204|Active Comparator|Midazolam and Ketamine|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
16649586|NCT02284204|Experimental|Midazolam, Ketamine and Sevoflurane|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.
16649587|NCT02284191|Active Comparator|CT Coronary Angiogram|CT Coronary Angiogram plus standard care
16649588|NCT02284191|No Intervention|Standard Care|Standard care only
16649589|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
16649590|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
16649591|NCT02284152|Experimental|Typical versus Infant-Led feeding|This is a within-subject study; all infants and mothers will be exposed to both conditions (typical feeding versus infant-led feeding conditions). Order of presentation will be counterbalanced across infant/mother dyads.
16649592|NCT02284139|Placebo Comparator|Placebo|Placebo ointment dose not contain EGF.
16649593|NCT02284139|Active Comparator|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
16649594|NCT02284139|Active Comparator|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
16649595|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
16649596|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
16649597|NCT02284113|Experimental|Treatment|Treatment with focused cold therapy.
16649598|NCT02284113|Sham Comparator|Sham|Sham treatment with focused cold therapy device
16649599|NCT02284100|Experimental|animal assisted therapy group|the dog was present during post-operative awakening (2 hours after surgery)
16649600|NCT02284100|No Intervention|standard group|children had standard post-operative medical care
16649601|NCT02284087||V_PAS|Visuomotor paired associative stimulation protocol
16649602|NCT02284087||Sham V_PAS|Placebo group of Visuomotor paired associative stimulation protocol
16649603|NCT02284087||CER_PAS|cerebellar-motor associative stimulation protocol
16649604|NCT02284087||Sham CER_PAS|Placebo group of cerebellar-motor associative stimulation protocol
16649605|NCT02284074|Experimental|Nasal LPS spray|"This is a 5-way crossover, randomised, placebo-controlled study.
~Arms consists of the following nasal challenges:
~placebo, 1, 10, 30 and 100µg LPS."
16649606|NCT02284061|Experimental|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
16649607|NCT02284061|Other|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
16649608|NCT02284048|Placebo Comparator|control|nitrate,beta blocker
16649609|NCT02284048|Active Comparator|ticagrelor|ticagrelor 90mg qd
16649610|NCT02284035|Experimental|Group 1 Raltegravir / 3TC (MK0518B|Raltegravir / 3TC (MK0518B ) (50 patients)
16649611|NCT02284035|Active Comparator|Group 2 standard combination therapy|"NNRTI-Based Regimen:
~• EFV/TDF/FTC
~PI-Based Regimens:
~ATV/r + TDF/FTC or DRV/r + TDF/FTC
~INSTI-Based Regimens:
~DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
~NNRTI-Based Regimens:
~EFV plus ABC/3TC or RPV/TDF/FTC
~PI-Based Regimen:
~ATV/r plus ABC/3TC
~PI-Based Regimens:
~DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
~INSTI-Based Regimen:
~RAL plus ABC/3TC
~And other ART regimens"
16649612|NCT02284022||Brain Computer Interface|Patients will test the brain computer interface system
16649613|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
16649614|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
16649617|NCT02283983|Active Comparator|Standard cryoprotection|Proposal helmet without mittens and booties
16649618|NCT02283983|Experimental|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
16649619|NCT02283970||BAV and aortic regurgitation|BAV Diagnosis, Aortic Regurgitation with surgical indication (according to current clinical guidelines or best clinical practice), normal ascending aorta
16649620|NCT02283970||BAV and Ascending aorta dilatation|BAV diagnosis, no or trivial Aortic Regurgitation, ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice)
16649621|NCT02283970||BAV, aortic regurgitation and dilatation|BAV diagnosis, Aortic Regurgitation and ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice).
16649622|NCT02283970||BAV with aortic stenosis in pts>60yrs|BAV diagnosis, Aortic stenosis with surgical indication (according to current clinical guidelines or best clinical practice). Normal ascending aorta
16649623|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
16649624|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
16649625|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
16649626|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
16649627|NCT02283944|Experimental|TMS electrochemotherapy|Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
16649628|NCT02283931|Active Comparator|One handed uterine displacement|Uterine displacement using one hand
16649631|NCT02283918||Participants with education less than bachelor's degree|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
16649632|NCT02283918||Participants with bachelor's degree or equivalent|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
16649633|NCT02283905|Other|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. ~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
16649634|NCT02283892|Experimental|Checklist|2 checklists available for consultation by the attending physician: (1) dyspnea evaluation checklist and (2) cough evaluation checklist. The checklists are available on computers and mobile devices (smartphone, PDA or tablet computer).
16649635|NCT02283892|Active Comparator|Conventional assessment|Evaluation of patients reporting dyspnea or cough made by the attending physician, without the use of the checklists for dyspnea or cough evaluation.
16649636|NCT02283879|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
16649637|NCT02283866|Experimental|Administering desflurane according to the patient's BIS value|The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
16649638|NCT02283866|Experimental|Administering desflurane at 1 MAC|The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
16649639|NCT02283853|Experimental|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
16649640|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
16649641|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
16649642|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
16649643|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
16649644|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
16649645|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
16649646|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
16649647|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
16649648|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
16649649|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A
~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;
~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days
~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
16649650|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;
~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;
~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
16649651|NCT02283801|Experimental|Group A|"Group A
~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;
~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
16649652|NCT02283801|Experimental|Group B|"Group B
~Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;
~Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
16649653|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
16649654|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
16649715|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
16649655|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
16649656|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
16649657|NCT02283775|Experimental|PomdeSAR|"Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression
~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression"
16649658|NCT02283762|Experimental|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
16649659|NCT02283762|Placebo Comparator|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
16649660|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
16649661|NCT02283736|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one tablet containing Lactobacillus rhamnosus SP1 per day during 3 months.
16649662|NCT02283736|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
16649663|NCT02283723|Experimental|Patient Group 1|This patient group will begin receiving the Health TAPESTRY intervention from time zero.
16649664|NCT02283723|Active Comparator|Patient Group 2|Using a step-wedge approach, this patient group will receive the intervention after a six month waiting period where they will be used as a comparable group. In the first six months, they will receive usual care.
16649665|NCT02283710|Experimental|Pentoxifylline + lifestyle modification|Pentoxifylline for 6 months plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
16649666|NCT02283710|Experimental|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity.
16649667|NCT02283697|Experimental|Dietary Counseling|Apart from standard care, an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
16649668|NCT02283697|Other|Control: Standard Care|A standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
16649669|NCT02283684|Active Comparator|Greenlight laser PVP|Greenlight (532-nm) laser Photoselective vaporization of the prostate using (XPS) 180W system
16649670|NCT02283684|Active Comparator|Bipolar TUVP|Bipolar transurethral vaporization of the prostate using bipolar system
16649671|NCT02283671|Experimental|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.
~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.
~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
16649672|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16649673|NCT02283645|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the chest.
16649674|NCT02283645|Placebo Comparator|Placebo|Placebo lotion is applied twice daily to the chest.
16649675|NCT02283632|Experimental|Jejunal Diversion|all subjects who receive jejunal diversion surgery
16649676|NCT02283619||Patients with LBBB being evaluated for ACS|Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.
16649677|NCT02283580|Experimental|Single limb resistance training|"Low load, high-repetitive resistance training.
~single limb at a time (e.g., one arm or one leg)
~elastic bands"
16649678|NCT02283580|Active Comparator|Two limb resistance training|"Low load, high-repetitive resistance training.
~two limbs at a time (e.g., both arms or both legs)
~elastic bands"
16649679|NCT02283554|Placebo Comparator|ARM1- open flap debridement (OFD)|open flap debridement done for 30 subjects. After debridement, Metformin or PRF was not added into the intrabony defect.
16649680|NCT02283554|Experimental|ARM2- open flap debridement plus PRF(Platelet rich fibrin)|"After open flap debridement, PRF( Platelet rich fibrin) was added into the intrabony defect.
~No. of subjects= 30"
16649681|NCT02283554|Experimental|ARM3- open flap debridement plus 1%Metformin|After open flap debridement, 1% metformin was added into the intrabony defect No. of subjects= 30
16649682|NCT02283554|Experimental|ARM4- open flap debridement plus PRF plus metformin|"After open flap debridement, PRF and 1% metformin was added into the intrabony defect.
~No. of subject- 30"
16649716|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
16649717|NCT02283281|Experimental|Cannabis oil high dose|Single-dose, before anesthetic induction: 21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic
16649718|NCT02283281|Experimental|Cannabis oil low dose|Single-dose, before anesthetic induction: 10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
16650206|NCT02279875|Experimental|Linezolid 600 mg twice per day|600mg (scored) tablet
16649683|NCT02283541|Experimental|ASTM|Participants in Automatic self-transcending meditation (ASTM) arm will complete a 12 week meditation training program in addition to their existing treatment plan. This involves participating in 120-minute sessions on each of four consecutive days of the first week. Participants will individually be given a mantra on day one, and then be instructed in use of the mantra according to specific criteria over the four session program. This will be followed by weekly 60-minute follow up sessions for the 11 subsequent weeks. In addition, participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12.
16649684|NCT02283541|No Intervention|TAU|Participants in TAU arm will continue with their existing treatment schedule as usual. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12. However, no assessments will be done or information collected on the TAU arm from week 12 onwards. After week 12, TAU arm participants will be offered the opportunity to learn ASTM and attend follow up meditation.
16649685|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
16649686|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
16649687|NCT02283515|Active Comparator|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
16649688|NCT02283515|Placebo Comparator|group II - placebo|placebo-placed locally in intrabony defects.
16649689|NCT02283502|Experimental|Intervention: MRgHIFU, Surgery|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
16649690|NCT02283489|Experimental|Combination therapy A|Recombinant human endostatin adenovirus (EDS01), 5.0 × 1011 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
16649691|NCT02283489|Experimental|Combination therapy B|Recombinant human endostatin adenovirus (EDS01), 1.0 × 1012 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
16649692|NCT02283489|Experimental|Chemotherapy|Paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
16649693|NCT02283476|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with Gemcitabine and Cisplatin
16649694|NCT02283476|Active Comparator|Endostar routine intravenous infusion|Endostar routine intravenous infusion in combination with Gemcitabine and Cisplatin
16649695|NCT02283463|Active Comparator|Standard Cervical Tenaculum|Single tooth tenaculum, pierces the tissue of the cervix to allow provider to stabilize and place traction on the cervical cal/uterus
16649696|NCT02283463|Experimental|Bioceptive Cervical Retraction Device|Suction based method for stabilizing the cervix and uterus. Achieves suction 360 degrees around cervical os creating a portal through which instruments can be passed into the cervical canal and uterus. Provider can still place traction on uterus with this device just as with tenaculum.
16649697|NCT02283450||the experimental group|The patients in experimental group received the relevant tests and inspections before the beginning of experiment，signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，we evaluated the symptoms，the function of heart，blood pressure，heart rate and keep blood specimens. Three and six month later，electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
16649698|NCT02283450||the placebo group|The placebo group was followed up in the same way.
16649699|NCT02283437|Experimental|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program (PSBPF) using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living' (p.11).
16649700|NCT02283437|Active Comparator|Behavioral Management and Education Program|The Behavioral Management and Education group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) psycho-education and McFarlane et al.'s (2003) family behavioral management programs for schizophrenia.
16649701|NCT02283437|No Intervention|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
16649702|NCT02283424|Active Comparator|chemotherapy|Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
16649703|NCT02283424|Experimental|Icotinib|Icotinib, 125mg,3/D,2years
16649704|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
16649705|NCT02283398|Experimental|with RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
16649706|NCT02283398|Sham Comparator|without RIPC|the cuff will be placed around the left arm without being inflated
16649707|NCT02283385|Experimental|PROTECT Intervention|Participants will receive a brief psychotherapy that builds on Problem Solving Therapy (PST)
16649708|NCT02283372|Experimental|nab-Paclitaxel + Gemcitabine + IMRT|"Prior to initiation of chemoradiation, patients will undergo 1 full cycle of gemcitabine and nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
~Both gemcitabine and nab-paclitaxel will be given intravenously on an outpatient basis during the one-month lead-in period and during Weeks 1 and 2 (and, if enrolled to Dose Level or 2, Weeks 4 and 5) of radiotherapy. There may be up to 21 days between the last dose of lead-in chemotherapy (given on Day 15) and initiation of chemoradiation (inclusive of the week following Day 15, the fourth week of the lead-in cycle (an off-week), and an additional week following that).
~Intensity modulated radiation (IMRT) - the prescribed dose will range from 40-67.5 Gy over 15 to 25 fractions."
16649709|NCT02283359|Experimental|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m^2; Level 1: 40 mg/m^2; Level 2: 50 mg/m^2; Level 3: 65 mg/m^2.
~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m^2."
16649719|NCT02283281|Placebo Comparator|Control|Single-dose, before anesthetic induction: Dummy oromucosal spray containing alcohol vehicle without Cannabis oil .
16649720|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
16649721|NCT02283255|Active Comparator|Physical Activity 1|Aerobic Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months.
16649722|NCT02283255|Active Comparator|Physical Activity 2|Respiratory Training: muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
16649723|NCT02283255|Active Comparator|Physical Activity 3|Aerobic and Respiratory Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months and respiratory muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
16649724|NCT02283255|No Intervention|Physical Activity 4|No Physical Activity: Control group (usual care)
16649725|NCT02283242|Experimental|Galantamine|"8 mg of Galantamine for 4 weeks
~16 mg Galantamine for 8 weeks"
16649726|NCT02283242|Placebo Comparator|Placebo|"8 mg of placebo for 4 weeks
~16 mg placebo for 8 weeks"
16649727|NCT02283229|Active Comparator|Active|Newborns with preventive caring advices
16649728|NCT02283229|Placebo Comparator|Surveillance|Newborns with normal caring advices
16649729|NCT02283216|Experimental|Acoustic, Body, Cortical|Acoustic corresponds to noise sound stimulation. Body corresponds to body electrical stimulation. Cortical corresponds to transcranial magnetic stimulation. Acoustic is presented together with body and cortical stimulation. Different body locations and timing among acoustic, body, and cortical stimulation are presented across testing sessions.
16649730|NCT02283203|Active Comparator|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
16649731|NCT02283203|Placebo Comparator|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
16649732|NCT02283190|Experimental|Ewwinase|Six doses of Erwinase given three times weekly (Monday-Wednesday-Friday) for two weeks. Possible dose levels used are 20.000 IU/m2/day, 25,000IU/m2/day, and 30,000IU/m2/day.
16649733|NCT02283177|Experimental|Cohort A|Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
16649734|NCT02283177|Experimental|Cohort B|Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
16649735|NCT02283164|Experimental|Treatment|Hazardous materials online education and study feedback
16649736|NCT02283164|Active Comparator|Control then treatment|Hazardous materials online education and study feedback
16649737|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
16649738|NCT02283151|Experimental|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
16649739|NCT02283099|Experimental|rVSVΔ-ZEBOV-GP (BPSC1001)|Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
16649740|NCT02283086|No Intervention|Control|
16649741|NCT02283086|Experimental|Intervention|The intervention consisted of quarterly performance feedback reports sent via e-mail.
16649742|NCT02283073||Idiopathic Parkinson's disease|Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.
16649743|NCT02283073||Differential Diagnosis Group|MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls
16649744|NCT02283060|Experimental|Stribild switch arm|Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
16649745|NCT02283060|Active Comparator|Atripla control arm|Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
16649746|NCT02283047|Active Comparator|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
16649747|NCT02283047|Experimental|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
16649748|NCT02283047|Experimental|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
16649749|NCT02283047|Experimental|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
16649750|NCT02283034|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
16649751|NCT02283034|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
16649752|NCT02283021||NSCLC Patients|Sample biopsies from normal and cancerous lung tissue.
16649753|NCT02283021||Patients without NSCLC|Sample biopsies from normal lung tissue.Control group.
16649754|NCT02283008|No Intervention|Standard care|This arm will receive standard care which involves informal education on how to use metered dose inhalers
16649755|NCT02283008|Active Comparator|Structured education|This arm will receive structured education on the use of inhalers. At 6 weeks post education inhaler technique will be re-assessed. Participants who fail to achieve a set level of competence may be chosen for semi structured interview.
16652283|NCT02265926|Experimental|N95|Intervention: N95 mask material
16649756|NCT02282995||•FDR-Relatives of FD patients|"Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.
~Up to 20 ml of fasting blood sample will be collected
~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
16649757|NCT02282995||•FDC-Healthy control|"Healthy control. Controls who are self-referred to this study will be recruited.
~Up to 20 ml of fasting blood sample will be collected
~Fasting glucose test will be performed for FD patients
~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
16649758|NCT02282995||•FD-Patients with FD|"Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.
~Up to 20 ml of fasting blood sample will be collected
~Fasting glucose test will be performed for FD patients"
16649759|NCT02282995||•FDCR-Relatives of healthy controls|"Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.
~Up to 20 ml of fasting blood sample will be collected
~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
16649760|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
16649761|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
16649762|NCT02282956|Experimental|study group|single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
16649763|NCT02282956|Other|controll Group|After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
16649764|NCT02282943|Active Comparator|Laser|vapourisation/excision of endometriosis using CO2 laser
16649765|NCT02282943|Experimental|Harmonic scalpel|excision of endometriosis using Harmonic scalpel
16649766|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
16649767|NCT02282917|Experimental|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
16649768|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
16649769|NCT02282891|Active Comparator|Propofol|Induction of general Anesthesia using propofol 2mg/kg
16649770|NCT02282891|Experimental|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
16649771|NCT02282878|Experimental|High/Low Sodium Diet|All MS patients will receive 2 weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
16649772|NCT02282878|Active Comparator|High/Low Sodium Diet Control|Age matched controls will receive two weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
16649773|NCT02282865||Visual analogue scale (VAS) >5|The degree of surgery-related anxiety assessment using VAS
16649774|NCT02282865||Visual analogue scale (VAS) ≤5|The degree of surgery-related anxiety assessment using VAS
16649775|NCT02282852|Experimental|Wireless Capsule Endoscopy|Wireless capsule endoscopy is the investigation modality of choice for suspected diseases of the small bowel. A small pill-sized capsule contianing a camera is swallowed by the patient. The procedure is safe and non-invasive. Normally, the pill camera travels through the gut an exits the bowel via natural means. In a small number of cases the capsule is maintained. If the capsule is still in the stomach, mobilisation is encouraged followed by an intramuscular pro-kinetic injection if this fails.
16649776|NCT02282852|Active Comparator|Magnetically steerable capsule endoscopy|A handheld magnet (manufactured by Intromedic Ltd.) has been developed to allow some control of the pill camera (that contains a small amount of magnetic material) in the upper GI tract. We propose that this could be used, alongside positional changes, to expedite capsule transit through the stomach thus improving completion rates and avoiding the risks of unnecessary medication.
16649777|NCT02282839|Active Comparator|Study group|Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy
16649778|NCT02282839|Placebo Comparator|Control group|Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy
16649779|NCT02282826|Experimental|Dose 1 IV|GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649780|NCT02282826|Experimental|Dose 2 IV|GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649781|NCT02282826|Experimental|Dose 3 IV|GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649782|NCT02282826|Experimental|Dose 3 SC|GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649783|NCT02282826|Experimental|Dose 4 SC|GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649784|NCT02282826|Experimental|Dose 5 SC|GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649785|NCT02282826|Placebo Comparator|Placebo SC|placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649786|NCT02282826|Placebo Comparator|Placebo IV|placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
16649787|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
16649788|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
16649789|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
16649790|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
16649791|NCT02282800||Case group|Case group include patients with generalized AgP were the tissue samples taken to analyse the number of vitamin D receptor present.
16649887|NCT02282085|Experimental|Aripiprazole Once-Monthly|Switch to 400 mg aripiprazole once-monthly injection
16649792|NCT02282800||Control group|Ethnically matched, systemically and periodontally healthy individuals were included in control group were also gingival tissue taken for analysis of number of receptors present in nucleus and cytoplasm
16649793|NCT02282787|Experimental|5 micron dex arm|
16649794|NCT02282787|Experimental|10 micron dex arm|
16649795|NCT02282774|Experimental|SB|receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture
16649796|NCT02282774|Sham Comparator|C|receive subtenon block of 4mL saline
16649797|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
16649798|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
16649799|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
16649800|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
16649801|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
16649802|NCT02282709|Experimental|Daclatasvir and asunaprevir|daclatasvir 60 mg once daily asunaprevir 100 mg BID
16649803|NCT02282696|Experimental|cancer patients|Questionnaire, focus group participation
16649804|NCT02282683|Experimental|Prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months.
16649805|NCT02282683|No Intervention|Control|Maximum tolerated guideline-directed medical therapy
16649806|NCT02282670|Experimental|DA-5204|DA-5204 administered two times daily for two weeks
16649807|NCT02282670|Active Comparator|Stillen tab.|Stillen tab. administered three times daily for two weeks
16649808|NCT02282657|Experimental|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
16649809|NCT02282644|Experimental|CellSearch|
16649810|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
16649811|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
16649812|NCT02282618||heart failure with HTEA|Heart failure patients are treated with the world-wide accepted medicine, plus HTEA for 4 weeks.
16649813|NCT02282618||heart failure with medicine|Heart failure patients are treated with the world-wide accepted medicine.
16649814|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
16649815|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
16649816|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
16649817|NCT02282592||Cases|newly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
16649818|NCT02282592||Controls|patients without any malignant disease, matched for age an menopausal status with cases.
16649819|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
16649820|NCT02282566|Placebo Comparator|Protein-nutrition beverage - Placebo|: 8 oz protein-nutrition beverage 1
16649821|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 2|8 oz protein-nutrition beverage 2
16649822|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 3|8 oz protein-nutrition beverage 3
16649823|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 4|8 oz protein-nutrition beverage 4
16649824|NCT02282553|Experimental|Magnetically steerable pill camera|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet. This technique will be compared to conventional gastroscopy which uses a flexible endoscope. Both techniques will be used to diagnose upper gastrointestinal pathology in patients with recurrent/refractory iron deficient anemia.
16649825|NCT02282540|Experimental|Iodixanol to the Eustachian tube|Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
16649826|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
16649827|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
16649888|NCT02282085|Active Comparator|Standard of Care|Continue current SOC oral antipsychotic medication
16649889|NCT02282072|Active Comparator|Deep Brain Stimulation|Stimulator is ON
16649890|NCT02282072|Sham Comparator|Placebo|Stimulator is OFF
16649828|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
16649829|NCT02282501|Active Comparator|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
16649830|NCT02282501|Active Comparator|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
16649831|NCT02282488|Experimental|Group 1: Low protein formula|Low protein formula
16649832|NCT02282488|Experimental|Group 2: high protein formula|High protein formula
16649833|NCT02282488|No Intervention|Group Breastfeeding|Breastfeeding
16649834|NCT02282475||Cohort study of pregnant women|"Participants will complete the following at 12-16 weeks gestation and again at 32-36 weeks gestation:
~Fasting glucose, insulin and insulin sensitivity testing;
~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;
~Measurements of body fat using air displacement technology and MRI;
~Ultrasound to measure placental blood flow, visceral fat thickness (12-16 weeks only) and to estimate fetal weight (32-36 weeks only);
~24 hour diet recalls
~Questionaires regarding activity level"
16649835|NCT02282475||Case-control study Gestational Diabetes|"Participants diagnosed with gestational diabetes (cases) and without gestational diabetes (controls) will complete the following at 32-36 weeks gestation:
~Fasting glucose, insulin and insulin sensitivity testing;
~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;
~Measurements of body fat by using air displacement technology and MRI;
~Ultrasound to measure placental blood flow and to estimate fetal weight;
~24 hour diet recalls
~Questionaires regarding activity level"
16649836|NCT02282462|Experimental|Reg pressure, Active suction (Dig)|Regulated pleural pressure with active suction
16649837|NCT02282462|Experimental|Reg pressure, Passive drainage (Dig)|Regulated pleural pressure with passive drainage
16649838|NCT02282462|Experimental|Unreg pressure, Active suction (Trad)|Unregulated pleural pressure with active suction
16649839|NCT02282462|Experimental|Unreg pressure, Passive drainage (Trad)|Unregulated pleural pressure with passive drainage
16649840|NCT02282449|Experimental|Power Injectable Port|The subjects randomized to this group will receive the newer, power injectable port.
16649841|NCT02282449|Active Comparator|Non-Power Injectable Port|The subjects randomized to this group will receive the older, non-power injectable port.
16649842|NCT02282436||COPD exacerbation|No specific intervention for this study
16649843|NCT02282423|Experimental|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
16649844|NCT02282423|Experimental|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
16649845|NCT02282423|Experimental|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
16649846|NCT02282423|Experimental|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
16649847|NCT02282410|Experimental|ADVATE standard prophylaxis|This study is a prospective, open-label, interventional, multicenter study in a total of 15 PTPs with hemophilia A (FVIII≤2 %).The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
16649848|NCT02282397|No Intervention|Phase 1: SMBG|Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management. No intervention to be administered
16649849|NCT02282397|Other|Phase 1: CGM|Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management. RT-CGM (Continuous Glucose Monitoring) is the intervention.
16649850|NCT02282397|No Intervention|Phase 2: CGM/MDI|Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
16649851|NCT02282397|No Intervention|Phase 2: CGM/CSII|Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
16649852|NCT02282384|Experimental|oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
16649853|NCT02282384|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
16649855|NCT02282358|Experimental|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
16649856|NCT02282345|Experimental|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.
~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
16649857|NCT02282332|Experimental|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
16649858|NCT02282319|Experimental|A chloro|spinal chloroprocaine 40 mg
16649859|NCT02282319|Experimental|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
16649860|NCT02282319|Experimental|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
16649861|NCT02282306|Other|TTIP-PRO|"Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the Personal Feedback Report, which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the Personal Risk Factors Report which is mailed to the participant with some other helpful information."
16649862|NCT02282293|Active Comparator|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
16649863|NCT02282293|Placebo Comparator|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
16649864|NCT02282280||Study Group|All patients included in the study
16649865|NCT02282267|Experimental|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
16649866|NCT02282254|Active Comparator|Single-hormone closed-loop strategy|
16649867|NCT02282254|Active Comparator|Dual-hormone closed-loop strategy|
16649868|NCT02282241|Placebo Comparator|Placebo|Patients given once daily placebo (cellulose) orally in the evening, for 14 days.
16649869|NCT02282241|Experimental|Melatonin|Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.
16649870|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
16649871|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
16649872|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
16649873|NCT02282215|Active Comparator|G-CSF|Randomized
16649874|NCT02282202|Other|Off/on for 3 weeks followed by on/off for 3 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device (Aerobika ®) or no device for three weeks, then crossover for the following three weeks.
16649875|NCT02282189|Other|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
16649876|NCT02282176|Experimental|Azithromycin|10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
16649877|NCT02282176|Placebo Comparator|Placebo|Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
16649878|NCT02282163|Experimental|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
16649879|NCT02282150|Other|Conventional vs modified hydrocortisone;|5 weeks of conventional hydrocortisone followed by 16 weeks of modified-release hydrocortisone (Plenadren)
16649880|NCT02282137|Experimental|68Ga-PSMA|Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.
16649881|NCT02282124|Experimental|Intervention|"The intensity of the intervention follows a defined algorithm during the first eight months after renal transplantation. Behaviours are classified in three groups:
~Group 1: Patients with optimal behaviour in all three behaviours.
~Group 2: Patients with slight deviation (defined) from optimal behaviour in one or more behaviours.
~Group 3: Patients with larger deviation (defined) from optimal behaviour in one or more behaviours.
~All patients (group 1-3) will receive an assessment, education and a monthly reassessment.
~Patients from group 2 und 3 will receive additionally behavioral education and peer involvement. Patients from group 3 will receive additionally a consilium of specialized healthcare professionals such as a nutritionist, physiotherapist, or psychologist."
16649882|NCT02282124|Other|Control|
16649883|NCT02282111|Active Comparator|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
16649884|NCT02282111|Active Comparator|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
16649885|NCT02282098|Experimental|Active Colchicine|The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months
16649886|NCT02282098|Placebo Comparator|Placebo Colchicine|The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.
16649894|NCT02282033|Experimental|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.
~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
16649895|NCT02282020|Experimental|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
16649896|NCT02282020|Active Comparator|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
16649897|NCT02282007|No Intervention|No Intervention:Control group|
16649898|NCT02282007|Experimental|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
16649901|NCT02281981|Experimental|Curcumin supplement|200 mg, curcuminoids, 7d of supplementation in capsular form
16649902|NCT02281981|Placebo Comparator|Placebo|sucrose, capsular
16649903|NCT02281968|Experimental|NSAID cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
16649904|NCT02281968|Placebo Comparator|Placebo cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
16649905|NCT02281955|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
16649906|NCT02281942|Experimental|Yoga|Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension.
16649907|NCT02281942|Placebo Comparator|Education|A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress).
16649908|NCT02281929|Active Comparator|amoxicillin+ prednisolone|Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
16649909|NCT02281929|Placebo Comparator|Placebo + prednisolone|Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
16649910|NCT02281916|Experimental|P28GST treatment|P28GST as a parasite enzyme
16649911|NCT02281903|Experimental|Chest compression of manikins chest|Compression of pediatric manikins chest according European Resuscitation Council 2010 guidelines for cardiopulmonary resuscitation.
16649912|NCT02281890||Proven sepsis|Children included in the INIS trial in whom pathogenic organisms (i.e. bacteria or fungi) were cultured from blood and/or cerebrospinal fluid during the sepsis period at the time of study inclusion
16649913|NCT02281890||Clinical sepsis|Children included in the INIS trial in whom no pathogenic organisms (i.e. bacteria or fungi) were cultured from blood or cerebrospinal fluid during the sepsis period at the time of study inclusion
16649914|NCT02281877|Experimental|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.
~Standard Rehabilitation Protocol"
16649915|NCT02281877|Active Comparator|Control|Standard Rehabilitation Protocol
16649916|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
16649917|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
16649918|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
16649919|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
16649920|NCT02281838|Experimental|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
16649921|NCT02281838|Active Comparator|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
16649922|NCT02281825||Control|Adolescents without any psychiatric disorder
16649923|NCT02281825||Study|Adolescents with psychiatric disorder of the following: Attention-Deficit and Hyperactivity Disorder, Conduct, Oppositional defiant Disorder, Anxiety, Depression, Disruptive Mood Dysregulation Disorder
16649924|NCT02281812|Experimental|RFA group|A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
16649925|NCT02281812|No Intervention|Control group|Normal excision of the tumor according to the protocol
16649970|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
16650207|NCT02279875|Experimental|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
16649926|NCT02281799|Experimental|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.
~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
16649927|NCT02281786|Experimental|Cohort 1|8 volunteers (6 active, 2 placebo)
16649928|NCT02281786|Experimental|Cohort 2|8 volunteers (6 active, 2 placebo)
16649929|NCT02281786|Experimental|Cohort 3|8 volunteers (6 active, 2 placebo)
16649930|NCT02281786|Experimental|Cohort 4|8 volunteers (6 active, 2 placebo)
16649931|NCT02281786|Experimental|Cohort 5|8 volunteers (6 active, 2 placebo)
16649932|NCT02281786|Experimental|Cohort 6|8 volunteers (6 active, 2 placebo)
16649933|NCT02281773|Experimental|dose 1|
16649934|NCT02281773|Experimental|dose 2|
16649935|NCT02281773|Experimental|dose 3|
16649936|NCT02281773|Experimental|dose 4|
16649937|NCT02281773|Placebo Comparator|placebo|
16649938|NCT02281760|Experimental|Combination therapy with dabrafenib and trametinib in patients with ECD|Patients with Erdheim Chester Disease (ECD) and BRAFV600E mutation received combination therapy with dabrafenib, a BRAFV600E inhibitor 150mg orally every twelve hours, and trametinib, an inhibitor of MEK, downstream of BRAF, 2mg orally daily.
16649941|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
16649942|NCT02281708|No Intervention|low risk|low risk; observation
16649943|NCT02281708|No Intervention|high risk; observation group|high risk: observation
16649944|NCT02281708|Experimental|high risk; adjuvant chemotherapy group|high risk. vinorelbine plus cisplatin
16649945|NCT02281695|Active Comparator|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.
~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
16649946|NCT02281695|Active Comparator|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
16649947|NCT02281682|Active Comparator|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
16649948|NCT02281682|Active Comparator|5-Fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
16649949|NCT02281682|Active Comparator|Ingenol mebutate 0.015%|during 3 (consecutive) days once daily. Prior to treatment: curettage
16649950|NCT02281682|Active Comparator|MAL-PDT|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
16649951|NCT02281669||Research group|The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery [as our current policy].
16649952|NCT02281656|Experimental|Reverse End-to-side|"Surgery: a reverse end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or babysitting these muscles during the time period until this occurs."
16649953|NCT02281656|Active Comparator|Surgery:standard care|Surgery: the anterior interosseous (AIN) to motor branch of the ulnar nerve transfer has been established as an effective means to reinnervate ulnar innervated intrinsic hand muscles (without loss of function from using the AIN) when nerve injury is too proximal for recovering axons to reach the hand by 18 months. . The procedure (surgery) is presently the standard of care
16649954|NCT02281643|Experimental|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
16649955|NCT02281643|Active Comparator|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
16649956|NCT02281630|Experimental|KWA-0711 High dose|
16649957|NCT02281630|Experimental|KWA-0711 Low dose|
16649958|NCT02281630|Placebo Comparator|Placebo|
16649959|NCT02281604||0.2/1.2 microliter filter|Use of 0.2/1.2 microliter filters for intravenous drug administration
16649960|NCT02281604||5 mircroliter filter|Use of 5 microliter filters for intravenous drug administration
16649961|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
16649962|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
16649963|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
16649964|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
16649965|NCT02281578|Experimental|Combination prevention|Community-based, combination HIV prevention intervention package
16649966|NCT02281578|Active Comparator|Standard of care|Locally run standard of care HIV prevention, treatment and care services
16649967|NCT02281552|Experimental|tofacitinib modified release tablet|
16649968|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
16649969|NCT02281539|Experimental|Treatment using myoelectric signals|Virtual- and augmented reality, are controlled by the patient's phantom limb using muscle (myoelectric) signals from the stump. The patient learns to reactivate areas in the brain related to motor control of the missing limb. The medical device is non-invasive and based on surface electromyography
16649971|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
16649972|NCT02281513|Other|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
16649973|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
16649974|NCT02281487|Active Comparator|Hysterectomy|standard hysterectomy
16649975|NCT02281487|Experimental|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
16649976|NCT02281474|Active Comparator|150mg dosing|This arm will take 150mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
16649977|NCT02281474|Active Comparator|300mg dosing|This arm will take 300mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
16649978|NCT02281461|Experimental|Early ifants|Intervention Male circumcision using a non-surgical device
16649979|NCT02281461|Experimental|Cildren|Intervention Male circumcision using a non-surgical device
16649980|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
16649981|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
16649982|NCT02281435|Experimental|PrePex with Incision|Adult male circumcision by the PrePex™ device using foreskin incision
16649983|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
16649984|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
16649985|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
16649986|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
16649987|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
16649988|NCT02281409|Experimental|Phase I: Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin.
16649989|NCT02281409|Experimental|Phase II: Mogamulizumab (KW-0761)|Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
16649990|NCT02281396|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
16649991|NCT02281396|Experimental|2.5IU/ml in humans aged 21-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
16649992|NCT02281396|Active Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
16649993|NCT02281396|Active Comparator|2.5IU/ml in humans(from 21-60 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
16649994|NCT02281383|Experimental|Bacillus Calmette-Guérin (BCG)|Patients will be treated with an induction course (6 intravesical instillations) of BCG followed by a second induction course (6 intravesical instillations), with a recovery period between the 2 treatment courses.
16649995|NCT02281370|Experimental|SEQUENCE D0, D1, D2|Participants will receive treatment D0 in treatment period 1, D1 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 milligram (mg), D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
16649996|NCT02281370|Experimental|SEQUENCE D1, D0, D2|Participants will receive treatment D1 in treatment period 1, D0 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
16649997|NCT02281370|Experimental|SEQUENCE D1, D2, D0|Participants will receive treatment D1 in treatment period 1, D2 in treatment period 2 and D0 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
16649998|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
16649999|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
16650000|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
16650001|NCT02281331|Active Comparator|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
16650002|NCT02281331|Placebo Comparator|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
16650003|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
16650004|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
16650005|NCT02281305|Experimental|Colchicine Active treatment group|Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
16650006|NCT02281305|Placebo Comparator|Control group|Drug: Placebo
16650007|NCT02281292|Experimental|LKA651 (Part 1)|LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
16650008|NCT02281292|Placebo Comparator|Sham injection (Part 1)|Sham injection in the study eye
16650102|NCT02280603|Active Comparator|5% minoxidil|5% minoxidil is administered
16650009|NCT02281292|Experimental|LKA651 and Lucentis (Part 2)|LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
16650010|NCT02281292|Placebo Comparator|Sham injection and Lucentis (Part 2)|Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
16650011|NCT02281279|Experimental|Treatment (rituximab, romidepsin, lenalidomide)|Patients receive rituximab IV over 90 minutes on day 1; romidepsin IV over 4 hours on either day 1, days 1 and 8, or days 1, 8, and 15; and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16650012|NCT02281266|Experimental|treatment (T)|"The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.
~Nucleoside analog plan to give to HBV DNA positive patients."
16650013|NCT02281266|Other|control (C)|"The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.
~Nucleoside analog plan to give to HBV DNA positive patients."
16650014|NCT02281253|Experimental|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
16650015|NCT02281253|Experimental|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
16650016|NCT02281240||With hemostatic complications|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
16650017|NCT02281227|Active Comparator|compression group|skin compression with an indicator for determination of needle entry point
16650018|NCT02281227|Active Comparator|non-compression group|non skin compression with an indicator for determination of needle entry point
16650019|NCT02281214|Experimental|blood sample, biopsy|
16650020|NCT02281201|Experimental|BE1116|Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
16650021|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
16650022|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
16650023|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
16650024|NCT02281162||Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
16650025|NCT02281162||No Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
16650026|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
16650027|NCT02281123||Patient suspected of being infected by chikungunya|Patient (>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
16650028|NCT02281110||iFR/FFR assessment|Patients enrolled into this prospective registry will be derived from Stable Coronary Artery disease or Acute Coronary Syndrome (ACS) population undergoing cardiac catheterization. Patients with ACS may be evaluated by functional assessment in the non-culprit stenosis during the index PCI revascularization or in a staged procedure. The registry will enroll patients in whom physiological assessment (iFR/FFR) is particularly helpful in identifying haemodynamically significant stenosis: MVD patients defined by patients with lesions > 40% and <100% in 2 or more vessels.
16650029|NCT02281097|Active Comparator|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.
~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
16650030|NCT02281097|Placebo Comparator|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.
~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
16650031|NCT02281084|Experimental|Monotherapy: Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
16650032|NCT02281084|Experimental|Combination Therapy: Oral Azacitidine and Durvalumab|Oral Azacitidine 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous (IV) infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
16650033|NCT02281071|Experimental|laterally moved coronally advanced flap microsurgical|For the test group (LMCAF-M), the surgical procedures were performed with the aid of a galilean loupe, under 2.5x magnification vision, microsurgical instruments and microsurgical suture material .
16650034|NCT02281071|Active Comparator|laterally moved coronally advanced flap macrosurgical|For the control group (LMCAF), LMCAF was performed with conventional instruments (detaylı) and materials (stur). Loupe magnification, microsurgical instruments and suture material were not used in the control group.
16650103|NCT02280590|Experimental|Cresnon®|Rosuvastatin 10mg, tablet, q.d.
16650035|NCT02281058|Experimental|intervention group|Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
16650036|NCT02281045|Experimental|EVODIAL dialyzer and Selectbag citrate|Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
16650037|NCT02281045|Active Comparator|Regional citrate anticoagulation|Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.
16650038|NCT02281032|Other|interRAI Palliative Care|"15 experimental nursing homes:
~Caregivers of 15 participating nursing homes receive a training about the interRAI PC and the BelRAI webapplication
~Caregivers of 15 experimental nursing homes fill out the interRAI PC multidisciplinary every three months during one year for all nursing home residents with palliative care needs. Based on the results (Client Assessment Protocols and Scales) of the interRAI PC instrument, care plans are being evaluated, adapted and designed."
16650039|NCT02281032|No Intervention|No interRAI Palliative Care|"15 control nursing homes:
~- Caregivers of control nursing homes do not receive the intervention and provide care as usual"
16650040|NCT02281019||Indeterminate strictures or undefined filling defects|
16650041|NCT02281019||Biliary stone cases|
16650042|NCT02281019||Other indications|
16650043|NCT02281006|Experimental|Treated ear|Trans-tympanic injection of a sodium thiosulfate gel
16650044|NCT02281006|No Intervention|Control ear|No intervention
16650045|NCT02280993|Experimental|DHAP-BV|Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation
16650046|NCT02280980|Experimental|Combined rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department is supplemented with a three weeks home protocol of oculomotor and gaze stability exercises.
16650047|NCT02280980|No Intervention|Usual rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department for patients after stroke.
16650048|NCT02280967|Experimental|Education about HPV by school nurse|The educational intervention consists of education about HPV and a special designed leaflet and self-reported questionnaires. The educational intervention is included in the regular health interview with the school nurse (scheduled for about one hour) and includes information about HPV; facts about the virus, transmission, what it can cause and prevention (i.e. safe sex with condom use and HPV vaccination), facts about HPV vaccine and the importance of attending future cervical cancer screening controls. Students complete questionnaires before the health interview at baseline and after three months. A follow-up with parts of the boys will be performed with qualitative interviews. Participants (n=40)
16650049|NCT02280967|No Intervention|Control group 1|Students allocated to control group 1 receives standard treatment, the regular health interview with the school nurse. Students complete questionnaires before the health interview at baseline and after three months (n=400).
16650050|NCT02280954|Experimental|ICG injection group|This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
16650051|NCT02280941|Experimental|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
16650052|NCT02280928|Experimental|Single-task motor training group|The participants will receive only balance training which will progress from stance activities, to stance activities plus hand manipulation, then gait activities, and finally gait activities plus hand manipulation.
16650053|NCT02280928|Experimental|Single-task cognitive training group|The participants will receive cognitive training that will involve executive function, attention, and working memory.
16650054|NCT02280928|Experimental|Dual-task motor-cognitive training group|The participants assigned to the dual-task motor-cognitive training group will receive the same exercises as single-task motor training while simultaneously performing secondary tasks as those in the single-task cognitive training group.
16650055|NCT02280928|Experimental|Dual-task cognitive-cognitive training group|The participants in the dual-task cognitive-cognitive trainings group will receive two cognitive tasks at the same time.
16650056|NCT02280915|Experimental|Fortified savoury food product 1|Savoury food product fortified with iron
16650057|NCT02280915|Experimental|Fortified savoury food product 2|Savoury food product fortified with iron
16650058|NCT02280915|Experimental|Fortified savoury food product 3|Savoury food product fortified with iron
16650059|NCT02280915|Experimental|Fortified savoury food product 4|Savoury food product fortified with iron
16650060|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
16650061|NCT02280876|Active Comparator|1 - Andrographis paniculata p/st extract|1 - Andrographis paniculata extract. Active comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the active test product (Andrographis paniculata p/st extract, oral lozenges, one BID, for 12 months), in addition to base medication (Interferon).
16650062|NCT02280876|Placebo Comparator|2 - Excipients|2 - Excipients. Placebo comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the placebo formulation (Only the excipients of the active test product, in oral lozenges of same shape, one BID, for 12 months), in addition to base medication (Interferon).
16650063|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
16650064|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
16650065|NCT02280850|Experimental|Guanxin Shutong Capsule|3 capsules once, tid, Oral Duration: 4 weeks
16650104|NCT02280590|Active Comparator|Crestor®|Rosuvastatin 10mg, tablet, q.d.
16650066|NCT02280850|Placebo Comparator|Placebo Capsule|"Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.
~3 capsules once, tid, Oral Duration: 4 weeks"
16650067|NCT02280837||Patients with suspected or diagnosed coronary artery disease|
16650068|NCT02280824|Experimental|A|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
16650069|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
16650070|NCT02280798||pilot study|"A total of 5 volunteers from our egg donation program were included in the study with 4 endometrial biopsies for each one after 4 diferente protocols
~Endometrial biopsy after Stimulated cycle
~Endometrial biopsy after Natural Cycle
~Endometrial biopsy after Natural modified cycle: the biopsy is taken seven days after the hCG
~Endometrial biopsy after Hormone Replacement Therapy Cycle"
16650071|NCT02280785|Experimental|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.
~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
16650072|NCT02280772|Experimental|Glucomannan|Glucomannan orally, 3g/day (in three divided doses), for 12 weeks
16650073|NCT02280772|Placebo Comparator|Maltodextrin|Maltodextrin orally, 3g/day (in three divided doses), for 12 weeks
16650074|NCT02280759|Active Comparator|Gelatin Tannate|"Gelatin Tannate:
~4 times 250 mg/daily for 5 days for children under 3. years old or 4 times 500mg/daily for 5 days for children older then 3. years and under 5 years."
16650075|NCT02280759|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
16650076|NCT02280746|Experimental|A - gluten challenge group|Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
16650077|NCT02280746|No Intervention|B - gluten-free diet|Continuation of GFD.
16650078|NCT02280720|Active Comparator|CoCr-BAS|Stenting using Optimax™ cobalt-chromium alloy platform with a titanium-nitride-oxide coating
16650079|NCT02280720|Active Comparator|PtCr-EES|Stenting using PROMUS Element™ Plus durable polymer everolimus-eluting stent built on a platinum-chromium platform.
16650080|NCT02280707|Experimental|Intervention|
16650081|NCT02280707|No Intervention|Control|
16650082|NCT02280694|Experimental|capecitabine, cyclophosphamide, methotrexate, celecoxib|"The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment
~Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal)
~Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals)
~Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal)
~Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)"
16650083|NCT02280681||Couples with ovarian failure|Heterosexual couples confronted with infertility due to ovarian failure between the age of 18 and 44 years old treated in the K.U.Leuven and
16650084|NCT02280681||Clinicians|Clinicians who indicated an interest in reproductive medicine in their membership of the Belgian Society for Reproductive Medicine (BSRM).
16650085|NCT02280668|Active Comparator|Control Group|Will perform the eccentric muscle damage exercise and will not perform any icing interventions post damage. These participants will be the control group.
16650086|NCT02280668|Experimental|Icing Protocol 1|Will perform the eccentric muscle damage exercise and will begin the icing intervention immediately after the muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
16650087|NCT02280668|Experimental|Icing Protocol 2|Will perform the eccentric muscle damage exercise and will begin the icing intervention 6 hours post muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
16650088|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
16650089|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
16650090|NCT02280642||Both doses on time|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
16650091|NCT02280642||Dose 2 delayed|A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
16650092|NCT02280642||Dose 3 delayed|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
16650093|NCT02280642||Both doses delayed|A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
16650094|NCT02280629|Experimental|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
16650095|NCT02280629|Placebo Comparator|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
16650096|NCT02280629|Active Comparator|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
16650097|NCT02280616|Experimental|Low dose budesonide tablet|
16650098|NCT02280616|Experimental|High dose budesonide tablet|
16650099|NCT02280616|Experimental|High dose budesonide suspension|
16650100|NCT02280616|Placebo Comparator|Placebo|
16650101|NCT02280603|Experimental|DA-4001C|DA-4001C is administered
16650106|NCT02280564|Experimental|Health coaching with technology support|Behavioral strategies including problem solving skills building, family communication counseling, technology support, motivational interviewing support.
16650107|NCT02280551||Adolescents|1927 Grade 7 high school students
16650108|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
16650109|NCT02280538|Experimental|Intra-Articular Hyaluronic Acid|"hylan G-F 20 (high molecular weight hyaluronic acid):
~intra-articular administration
~6 mL
~administered every 6 months
~for 2 years"
16650110|NCT02280538|Placebo Comparator|Placebo|"Saline solution:
~intra-articular administration
~6 mL
~administered every 6 months
~for 2 years"
16650111|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #1|"Preferred regimen for CLL and low grade lymphoma
~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Days -5 to -3. Cyclophosphamide 200 mg/m2 by vein over 3 hours on Days -5 to -3. Rituximab 375 mg/m2 by vein over 3-6 hours on Day -5 for participants with B-cell cancer.
~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.
~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
16650112|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #2|"For all malignancies if able to tolerate higher dose cyclophosphamide per the discretion of the treating physician
~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2. Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.
~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.
~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
16650113|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #3|"For myeloid malignancies
~Lenalidomide 2.5 mg by mouth once a day on Days -2 to Day +14. Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2. Cytarabine 2 mg/m2 by vein on Days -6 to -2.
~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.
~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
16650114|NCT02280512||elderly with fractures|patients more than 65 years old accepting surgeries for lower extremities fracture
16650115|NCT02280486|Active Comparator|Saxagliptin|The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
16650116|NCT02280486|Active Comparator|Glimepiride|Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
16650117|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
16650118|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
16650119|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
16650120|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
16650121|NCT02280447|Experimental|1/3 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL suspension for injection for intramuscular use"
16650122|NCT02280447|Experimental|1/5 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL suspension for injection for intramuscular use"
16650123|NCT02280447|Experimental|1/10 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL suspension for injection for intramuscular use"
16650124|NCT02280447|Active Comparator|IPV SSI|"Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL solution for injection for intramuscular use"
16650125|NCT02280434|Active Comparator|CBP-307|Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
16650126|NCT02280434|Placebo Comparator|Placebo|Participants will receive a single dose or once daily dose of matching placebo for 28 days.
16650127|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
16650128|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
16650129|NCT02280408|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0 and Day 28.
16650130|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0 and Day 28.
16650131|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0 and Day 28.
16650132|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
16650133|NCT02280395|Experimental|RUT058-60|
16650134|NCT02280395|Placebo Comparator|Sterile Saline for Irrigation|
16650135|NCT02280382|Other|Femmeze®|Femmeze® will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
16650136|NCT02280369||automated abdominal binder|automated abdominal binder with waist and thigh accelerometers, and ActivPAL
16650166|NCT02280122||periodontally healthy|"PPD ≤ 3 mm
~PAL-V ≤ 2 mm at < 30% of sites
~BOP < 20%
~No radiographically detectable bone loss: distance cemento-enamel junction to provided
~no Intervention but aMMP-8 test"
16650167|NCT02280109|Active Comparator|Tenofovir Gel|Women will receive a single dose of tenofovir gel (1%;equivalent to 40 mg in 4ml's of gel) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
16650168|NCT02280109|Active Comparator|Tenofovir Film|Women will receive a single dose of tenofovir film (1.3%;40 mg) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
16650208|NCT02279875|Experimental|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
16650137|NCT02280356|Experimental|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate & seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, & treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) & every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal & sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
16650138|NCT02280330|Active Comparator|MNP group|The MNP group will receive 60 sachets of MNP in a period of 6 months or 10 sachets per month equivalent to 3-4 sachets in a week.
16650139|NCT02280330|Placebo Comparator|Placebo group|The placebo group will receive 60 sachets of placebo (with same characteristics) as the MNP or 10 sachets per month equivalent to 3-4 sachets in a week.
16650140|NCT02280317|Experimental|VAL201: Laboratory & Clinical Assessment|VAL201-001 Sub-cutaneous injection.
16650141|NCT02280304|Experimental|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
16650142|NCT02280304|Active Comparator|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
16650143|NCT02280291|Active Comparator|Ankle Single Shot Block (SSB)|
16650144|NCT02280291|Experimental|Ankle OnQ (Continuos Sedation OnQ Pump)|
16650145|NCT02280291|Experimental|DR SSB|
16650146|NCT02280291|Experimental|DR OnQ|
16650147|NCT02280278|Experimental|CIK group|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.
16650148|NCT02280278|Active Comparator|Control group|Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.
16650149|NCT02280265|Experimental|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight every 48 ± 6 hours) with Recombinant Human Coagulation Factor VIII for injection(ADVATE) for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
16650150|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:
~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule
~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule
~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:
~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
16650151|NCT02280239|Placebo Comparator|Control Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
16650152|NCT02280239|Experimental|Acetaminophen Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
16650153|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
16650154|NCT02280213|Experimental|Intubation without chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) during resuscitation without chest compressions.
16650155|NCT02280213|Experimental|Intubation with chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
16650156|NCT02280200|Experimental|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
16650157|NCT02280200|No Intervention|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
16650158|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
16650159|NCT02280174|Experimental|Drug: linagliptin|linagliptin 5 mg/d for 12 weeks
16650160|NCT02280174|No Intervention|Drug: standard treatment|sulfonylurea treatment for 12 weeks
16650161|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
16650162|NCT02280148|Experimental|Endoscopy of Intravenous Anesthesia|20-70 year-old volunteers who hold legitimate licenses were recruited to have gastroscopy or colonoscopy under intravenous anesthesia with propofol
16650163|NCT02280135|Experimental|Intravitreal injection of Autologous bone marrow Stem Cell|"Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.
~The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline."
16650164|NCT02280135|Placebo Comparator|Subconjunctival injection of saline|Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.
16650165|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm
~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites
~no Intervention provided"
16650169|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
16650170|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
16650171|NCT02280083|Experimental|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
16650172|NCT02280083|Placebo Comparator|placebo|excipient
16650173|NCT02280070|Active Comparator|SOX (S-1 + L-OHP)|"S-1 (80 mg/m2, p.o.) (day1-14）, L-OHP (130 mg/m2)(day 1): repeated every 3 weeks until 4 courses or meet discontinuation criteria.
~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
16650174|NCT02280070|Active Comparator|mFOLFOX6|"L-OHP (85 mg/m2) and l-LV (200 mg/m2) by IV infusion drip for 2hr at day 1. 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards (day 1-2: repeated every 2 weeks until 6 courses or meet discontinuation criteria.
~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
16650175|NCT02280057|Active Comparator|Metformin|Metformin 850 mg x 2 in six months
16650176|NCT02280057|Placebo Comparator|Placebo|Placebo 2 tablets daily for six months
16650177|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
16650178|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
16650179|NCT02280031|Active Comparator|Experimental|Acetylsalicylic Acid 80mg administered daily at bedtime
16650180|NCT02280031|Placebo Comparator|Control|Identical placebo administered daily at bedtime
16650181|NCT02280018|Experimental|JNJ-49122944, 5 milligram (mg)|Single dose of 5 mg JNJ-49122944, administered as a 22.2 milliliter (mL) intravenous (IV) infusion over 45 minutes in the morning following an overnight fast.
16650182|NCT02280018|Placebo Comparator|Placebo|Placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes in the morning following an overnight fast.
16650183|NCT02280005|Experimental|WAK Treatment|Use of experimental device.
16650184|NCT02279992|Experimental|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
16650185|NCT02279992|Active Comparator|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
16650186|NCT02279979|Experimental|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
16650187|NCT02279966|Experimental|Vortioxetine 10 mg|daily, encapsulated, orally
16650188|NCT02279966|Other|Paroxetine 20 mg (active reference)|daily, encapsulated, orally
16650189|NCT02279966|Placebo Comparator|Placebo|capsules, orally
16650190|NCT02279953|Experimental|Vortioxetine 10-20 mg|daily, encapsulated, orally
16650191|NCT02279953|Experimental|Vortioxetine 10-20 mg + SSRI|daily, encapsulated, orally
16650192|NCT02279953|Experimental|SSRI|licensed doses, encapsulated, orally
16650193|NCT02279927|Experimental|Low energy high frequency|Ureteroscopy with laser settings of low energy & high frequency with aim of stone dusting
16650194|NCT02279927|Active Comparator|High energy low frequency|Ureteroscopy with laser settings of low energy high frequency with aim of stone fragmentation and basket extraction of fragments
16650195|NCT02279914|Experimental|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
16650196|NCT02279914|Experimental|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
16650197|NCT02279901|No Intervention|Traditional|Patients will attend a 1 hour OSA Class where OSA education is provided and home sleep testing is set up. These patients return the next day for individual appointments where study is scored and test results are discussed with patient. If study is consistent with OSA based on AHI4% at least 5/hour, patients undergo a 1 week autoCPAP trial. During this week, wireless remote monitoring is performed and troubleshooting is provided via telephone if problems with CPAP use are identified. The autoCPAP is returned during an individual visit, and CPAP is ordered for long-term use based on trial results and patient feedback. Patients are scheduled a 3 month follow-up appointment but are also instructed to call their sleep center case manager prior to that visit if there are problems with CPAP use.
16650198|NCT02279901|Experimental|Telemedicine Education Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are emailed a link to view the Emmi OSA program within 2 weeks prior to their initial OSA class. If the patient tests positive for OSA and agrees to an autoCPAP trial, the patient is emailed a link to view the Emmi CPAP program. These patients are also scheduled for a 3 month follow-up visit to check CPAP usage.
16650199|NCT02279901|Experimental|Telemedicine IVR Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. Additionally, if CPAP is ordered for long-term therapy, the patient is enrolled into an IVR protocol that automatically analyzes the patient's CPAP use. If specific provider-defined thresholds are met, the platform will automatically deliver feedback messages to the patient (phone call, text messaging, or email) with the intention of encouraging better CPAP use. Patients are instructed to contact the sleep center for any issues with their therapy. This platform also includes a method for patients to track their own usage online. Automated messaging mechanism will be active for 3 months after CPAP is ordered, after which the messaging will stop. These patients are also scheduled for a 3 month follow-up visit.
16650200|NCT02279901|Experimental|Telemedicine Both Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are provided both Emmi education programs and IVR follow-up as previously outlined. These patients are also scheduled for a 3 month follow-up.
16650201|NCT02279888||CardioMEMS HF System Group|Patients implanted with a CardioMEMS HF System.
16650209|NCT02279875|Active Comparator|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the
~Subject's weight as follows:
~30-37 kg: 2 tablets;
~38-54 kg: 3 tablets;
~55-70 kg: 4 tablets;
~71 kg and over: 5 tablets."
16650210|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
16650211|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
16650212|NCT02279849|Experimental|Communications|These 6 stores received the communications intervention. Communications materials were developed for each program phase; 1) Healthier Drinks, 2) Healthier Essentials, and 3) Healthier Snacks. Each phase's materials included posters, recipe cards, educational handouts, shelf talkers, price tags, door signs, educational displays, and promotional giveaways (i.e., drink tumblers, re-usable shopping bags) to encourage healthy food purchasing and consumption. Stores receiving the communications intervention also received either a small refrigerator or freezer to help provide the environmental supports needed to stock perishable fruits and vegetables.
16650213|NCT02279849|No Intervention|Control|These 6 stores received no intervention.
16650214|NCT02279849|Experimental|Pricing|These 6 stores received a pricing intervention. 10-30% with discounts for specific foods contingent on price elasticity of demand, initial wholesale price, and projected store-level sales. Items were given the minimum discount needed to increase store supply and consumer demand. For example, brand name frozen vegetables were discounted 30% at the wholesaler, in order to provide the storeowner with enough incentive to stock the item. The % discount passed from the storeowner to the consumer was ultimately a decision made by the storeowner, but was suggested to be at least 50% in order to increase consumer demand. Discounts were automatically applied at wholesaler registers to stores receiving the pricing intervention.
16650215|NCT02279849|Experimental|Combined (Communications & Pricing)|These 6 stores received communications materials as well as pricing incentives as intervention (see Communications & Pricing Arms Descriptions).
16650216|NCT02279836|Other|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
16650217|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
16650218|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
16650219|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
16650220|NCT02279810||Medical students, medical staff|Survey about Knowledge, Attitude and Practice About Organ Transplantation
16650221|NCT02279784|Experimental|Freeway|angioplasty with Freeway drug-eluting balloon
16650222|NCT02279784|Experimental|Lutonix|angioplasty with Lutonix drug-eluting balloon
16650223|NCT02279771|Active Comparator|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
16650224|NCT02279771|Active Comparator|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
16650225|NCT02279758|Experimental|METFORMIN|850mg of metformin every 12 hours.
16650226|NCT02279745|Experimental|Ralinepag|Ralinepag immediate release (IR) capsules of 0.01, 0.02, 0.03, 0.04 mg, and 0.10 mg per capsule or extended release (XR) tablets of 50, 250, and 400 mcg (0.05, 0.25 and 0.4 mg) for oral administration. The starting dose and titration schedule will be determined for each subject in accordance with the starting dose and titration schedule optimized from Study APD811-003.
16650227|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)
~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
16650228|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
16650229|NCT02279719|Experimental|BBI608 and Sorafenib|
16650230|NCT02279719|Experimental|BBI503 and Sorafenib|
16650231|NCT02279719|Active Comparator|Sorafenib|
16650232|NCT02279693|Other|CBCT|cone beam computed tomography (CBCT) repositioning
16650233|NCT02279693|Other|fiducial markers|kV imaging of fiducial marker repositioning
16650234|NCT02279680|Other|Patients|Adults between 18 and 30 years old right handing Patients with ASD
16650235|NCT02279680|Other|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
16650236|NCT02279667|Experimental|Group A|"st period - 16 mL oral suspension 50 mg/mL
~nd period - Four 200 mg tablets
~rd period - One 800 mg tablet"
16650237|NCT02279667|Experimental|Group B|"st period - One 800 mg tablet
~nd period - 16 mL oral suspension 50 mg/mL
~rd period - Four 200 mg tablets"
16650238|NCT02279667|Experimental|Group C|"st period - Four 200 mg tablets
~nd period - One 800 mg tablet
~rd period - 16 mL oral suspension 50 mg/mL"
16650239|NCT02279654||Lenalidomide Population|Patients with transfusion-dependent, low- or intermediate (int)-1risk MDS and isolated del (5q) who receive at least 1 dose of lenalidomide after 15th June 2007 and have been followed up for on the registry for 3 years or until death/consent withdrawal
16650240|NCT02279654||Background Population|All MDS patients who have been diagnosed on 15th June 2007 or later, have never been exposed to lenalidomide and have been followed up on the registry for 3 years or until death/consent withdrawal
16650241|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
16650242|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
16650281|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
16650243|NCT02279628|Experimental|Continuous wound infiltration alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 1 ml sodium chloride 0.9% (without morphine). Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
16650244|NCT02279628|Active Comparator|Intrathecal moprhine alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of sodium chloride 0.9% 8 ml/H via a preperitoneal catheter.
16650245|NCT02279628|Experimental|Intrathecal morphine&wound infiltration|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
16650246|NCT02279615|Active Comparator|Treatment Group|(Mirabegron + Tamsulosin)
16650247|NCT02279615|Placebo Comparator|Control Group|(Placebo + Tamsulosin)
16650248|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
16650249|NCT02279589|Active Comparator|Group A|"Description :
~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,1
~Route : Intramuscular vaccination schedule : M0, M2, M12"
16650250|NCT02279589|Active Comparator|Group B|"Description 15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,1
~Route : Intramuscular vaccination schedule : M0, M2, M12"
16650251|NCT02279589|Active Comparator|Group C|"Description :
~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,5
~Route : Intramuscular vaccination schedule : M0, M2, M12"
16650252|NCT02279589|Active Comparator|Group D|"Description:
~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,5
~Route : Intramuscular vaccination schedule : M0, M2, M12"
16650253|NCT02279576|Experimental|Pazopanib plus weekly paclitaxel|Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.
16650254|NCT02279563|Experimental|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.
~Batch Number KL1981, Expiry Date Mar 2015."
16650255|NCT02279563|Active Comparator|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.
~Batch Number G30349, Expiry Date Mar 2015."
16650256|NCT02279563|Placebo Comparator|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.
~Batch Number KL0781, Expiry Date Mar 2015."
16650257|NCT02279550||hip fracture|aged >65 with hip fracture
16650258|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
16650259|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
16650260|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
16650261|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
16650262|NCT02279511|Experimental|24 hours infusion of ATP|
16650263|NCT02279511|Experimental|6 hours infusion of ATP|
16650264|NCT02279511|Placebo Comparator|24 hours infusion of placebo|
16650265|NCT02279511|Placebo Comparator|6 hours infusion of placebo|
16650266|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
16650267|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
16650268|NCT02279485|Experimental|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.
~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.
~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
16650269|NCT02279485|Experimental|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.
~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.
~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
16650270|NCT02279472|Other|laser peripheral iridotomy|Laser peripheral iridotomy (LPI) is widely regarded as the first-line intervention for either acute or chronic types of angle-closure glaucoma in early stage ,which relieves pupil block and thus flattening the iris contour and widening the drainage angle,performd by Nd.YAG LASER
16650271|NCT02279459||Patient|Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
16650272|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
16650273|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
16650274|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
16650275|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
16650276|NCT02279433|Experimental|DS-6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
16650277|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
16650278|NCT02279407|Placebo Comparator|placebo|
16650279|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
16650280|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
16650282|NCT02279394|Experimental|Elo / Len / Dex|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
~Other Name: HuLuc63
~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24
~Other Name: REVLIMID
~•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
~Other Name: Decadron"
16650283|NCT02279394|Experimental|Elo / Len|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
~Other Name: HuLuc63
~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24
~Other Name: REVLIMID"
16650284|NCT02279381|Experimental|Intervention group A|"Essential Neonatal Care
~Kangaroo mother Care
~Application of 4% Chlorhexidine
~Education and counseling for mothers and care providers"
16650285|NCT02279381|Experimental|Intervention group B|"Essential Neonatal Care
~Application of 4% Chlorhexidine
~Education and counseling for mothers and care providers"
16650286|NCT02279381|Active Comparator|Control group|"Essential Neonatal Care
~Education and counseling for mothers and care providers"
16650287|NCT02279368|Experimental|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
16650288|NCT02279368|No Intervention|Control Group|Control group families were followed in usual care.
16650289|NCT02279355||pressure ulcer group|Patient who developing pressure ulcer categorized as stage more than II after surgery
16650290|NCT02279355||Control group|Patients has identical values on the matching factors such as age, sex and surgical procedures of control group
16650291|NCT02279342|No Intervention|Non febuxostat treatment group|No febuxostat treatment
16650292|NCT02279342|Experimental|Febuxostat treatment group|once daily after breakfast
16650293|NCT02279329|Other|COPD and Bronchiectasis Patients|All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at up to 8 visits over 2-3 years.
16650294|NCT02279316|Experimental|Jaques-Dalcroze eurhythmics|Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
16650295|NCT02279316|Experimental|Home exercise program|Home exercise strength program (3x30min/wk) + 800 IU vitamin D
16650296|NCT02279316|Other|Vitamin D only|800 IU Vi-De 3
16650297|NCT02279303|Experimental|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
16650298|NCT02279303|Active Comparator|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
16650299|NCT02279290|Experimental|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
16650300|NCT02279290|Active Comparator|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
16650301|NCT02279277|No Intervention|No physical therapy|No prescribed, supervised physical therapy prior to total knee replacement
16650302|NCT02279277|Active Comparator|Physical Therapy|Prescribed, supervised physical therapy prior to total knee replacement
16650303|NCT02279251|Active Comparator|Brief CBT (VÅG)|This is a brief five session CBT group intervention developed at Uni Research. The intervention include self-help material (Psychological First Aid) for the adolescents to use at home between sessions.
16650304|NCT02279251|Active Comparator|Established CBT program (Cool Kids)|An established, 10 session CBT group program (school version) developed by researchers at Macquarie University, Australia. The intervention has previously not been evaluated with Norwegian adolescents.
16650305|NCT02279251|No Intervention|Waitlist|Waiting period is ten weeks, then participants are randomized to one of the two active interventions
16650306|NCT02279225|Placebo Comparator|placebo (P)|Intervention without radiation
16650307|NCT02279225|Experimental|phototherapy (FT)|Intervention only with phototherapy radiation
16650308|NCT02279225|Experimental|phototherapy+Physical activity (FT+A)|Intervention associated
16650309|NCT02279225|Experimental|Physical activity (A)|Intervention with physical activity: the gold standard of treatment in fibromyalgia
16650310|NCT02279199||Control|Normative data from standardized assessment
16650311|NCT02279199||Hemophilia|Persons aged 4-21 with any severity of hemophilia A or B
16650312|NCT02279186|Active Comparator|group A|receiving tranexamic acid
16650313|NCT02279186|No Intervention|group B|does not receive tranexamic acid
16650314|NCT02279173|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
16650315|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
16650316|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
16650317|NCT02279147|Experimental|raceanisodamine & neostigmine|Patients receive immediately raceanisodamine（10mg）by intramuscular injection after operation.Then the patients will be receive 50mg raceanisodamine and 0.15mg neostigmine within 24hs by slow injection into vein for three consecutive days.
16650318|NCT02279147|No Intervention|blank|Patients do not receive special treatment after operation.
16650319|NCT02279134|No Intervention|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
16650320|NCT02279134|Experimental|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
16650321|NCT02279134|Active Comparator|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
16650322|NCT02279121|Experimental|TauroLock|solution of taurolidine-citrate
16650323|NCT02279121|Other|Control|saline solution
16650324|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
16650325|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
16652287|NCT02265900|Active Comparator|Exercise 1|One type of exercise
16650326|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
16650327|NCT02279095|Experimental|Palovarotene dose level 2|Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
16650328|NCT02279095|Experimental|Palovarotene dose level 3|Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
16650329|NCT02279095|Experimental|Palovarotene dose level 4|All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
16650330|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
16650331|NCT02279069|Active Comparator|4-point canne|Stroke patients walk with 4-point canne
16650332|NCT02279069|Experimental|4-roll canne|Stroke patients walk with 4-roll canne
16650333|NCT02279056|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
16650334|NCT02279056|Placebo Comparator|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
16650335|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
16650336|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
16650337|NCT02279043|No Intervention|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
16650338|NCT02279017|Other|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
16650339|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
16650340|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
16650341|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
16650342|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
16650343|NCT02278991||Lutonix Drug Coated Balloon|Paclitaxel coated balloon catheter
16650344|NCT02278978|Experimental|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
16650345|NCT02278978|Experimental|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
16650346|NCT02278978|Experimental|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
16650347|NCT02278965|Experimental|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
16650348|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
16650349|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
16650350|NCT02278926||Patients ultrasound lypo-hypertrophy identification|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
16650351|NCT02278926||Control group|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
16650352|NCT02278913|Experimental|Basal Bolus (Glargine and Glulisine)|Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.
16650353|NCT02278913|Active Comparator|Human Insulin|Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal
16650354|NCT02278900|Experimental|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
16650355|NCT02278900|No Intervention|Control group|No intervention.
16650356|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
16650357|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
16650358|NCT02278874||Multiple gestation high risk pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
16650359|NCT02278861|Active Comparator|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
16650360|NCT02278861|Active Comparator|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.
~If there were any clinical adverse events the drug could be reduced to twice a week."
16650361|NCT02278848|Experimental|Diagnosis of ICAH|"One arm: patients with chronic adult hydrocephalus.
~All patients have: Computerised gait analysis, Ultrasound measurement of cerebral pulsatility, MRI flow, Urinary incontinence scale"
16650362|NCT02278835|Other|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
16650363|NCT02278835|Other|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
16650364|NCT02278822|Experimental|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
16650365|NCT02278822|Experimental|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
16650366|NCT02278809|No Intervention|waitlist control group|The waitlist control group parents received the online videos when the intervention period was over.
16650367|NCT02278809|Experimental|intervention group|
16650368|NCT02278796|Experimental|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
16650369|NCT02278796|Active Comparator|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
16650370|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
16650371|NCT02278757|Placebo Comparator|Low protein diet (LPD)|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
16650372|NCT02278757|Experimental|High protein diet (HPD)|HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
16650373|NCT02278744|Experimental|single-fraction radiosurgery|
16650374|NCT02278731|No Intervention|Control Group|The elderly in Control Group suffered no intervention and continued with their daily activities.
16650375|NCT02278731|Active Comparator|Pilates Group|Pilates group (PG), which underwent one-month (three times per week) training program with the Pilates method. This protocol consisted of Pilates exercises on the ground.Stretches were performed on upper trunk and lower limbs before the exercises. Subsequently, exercises that included the range of motion and strength of the upper limbs, trunk and lower limbs were performed, always associated with breathing and contraction of transversus abdominis muscles, in different positions, increasing repetitions and resistance in the weeks of the study, using the Swiss ball, thera-band and the magic circle.
16650376|NCT02278731|Active Comparator|PNF Group|PNF group that underwent one-month (three times per week) training program using the propriocptive neuromuscular facilitation method.The selected PNF diagonal patterns were chosen with all the basic procedures to the facilitation and according to three specific principles of PNF: rhythmic initiation, sustain and relax and reversal of antagonists. During the first week, one set of ten repetitions for each diagonal was performed; in the second week, two sets of ten repetitions and in the third and fourth weeks, three sets of ten repetitions were performed.
16650377|NCT02278718|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.
16650378|NCT02278718|Active Comparator|Standard of Care|Non surgical and Surgical Debridement
16650379|NCT02278705||Weight-status improved|"Cases, termed, weight-status improved, are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile decreases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later)."
16650380|NCT02278705||Weight-status unchanged/worse|Controls are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile remains unchanged or increases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later).
16650381|NCT02278692|Active Comparator|Vitamin K|Vitamin K1 (phytonadione) 10 mg orally three times a week after dialysis for 12 weeks
16650382|NCT02278692|Placebo Comparator|Placebo|Identical appearing placebo orally three times a week after dialysis for 12 weeks
16650383|NCT02278679||Anesthitized patient|First, it will be validated on 120 anesthetized patients undergoing prostate surgery comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports.
16650453|NCT02278237|Experimental|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
16650384|NCT02278679||Standardized patients|During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.
16650385|NCT02278679||Clinic patient|The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.
16650386|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
16650387|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
16650388|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
16650389|NCT02278653||Study group|The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
16650390|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
16650391|NCT02278627|Experimental|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
16650392|NCT02278627|No Intervention|Usual treatment|
16650393|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
16650394|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
16650395|NCT02278601|Experimental|MPIB modified programmed intermittent bolus|Modified programmed intermittent bolus (MPIB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
16650396|NCT02278601|Experimental|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
16650397|NCT02278601|Active Comparator|patient controlled epidural analgesia with basal infusion|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
16650398|NCT02278588||PD-R|Parkinson's disease receiving rasagiline
16650399|NCT02278588||PD-NMAO|Parkinson's disease not receiving any MAO-B inhibitors
16650400|NCT02278588||HC|Healthy Controls
16650401|NCT02278575|Other|Consisting of treatment with Atenativ|During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin
16650402|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
16650403|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
16650404|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
16650405|NCT02278549||Asymptomatic|Individuals between 30 and 50 years old that have had no episode of low back pain in the last two years requiring medical attention
16650406|NCT02278549||Patients with Low Back Pain|Individuals between 30 and 50 years old that present with non-specific low back pain for more than 3 months
16650407|NCT02278536||Multiple high risk gestation pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
16650408|NCT02278536||Multiple low risk gestation pregnancies|women pregnant with twins or triplets at low risk for aneuploidy
16650409|NCT02278523|Experimental|Inspiratory muscle training group|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
16650410|NCT02278523|Active Comparator|control group|normal volunteers use Inspiratory muscle trainer(Threshold IMT®)
16650411|NCT02278510|Experimental|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
16650412|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
16650413|NCT02278484|Other|Balloon Sinus Dilation|
16650414|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
16650415|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
~Polypill will be taken once daily."
16650416|NCT02278458|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
16650417|NCT02278445|Experimental|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
16650418|NCT02278419|Experimental|Group A1|Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.
16650419|NCT02278419|Experimental|Group A2|Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
16650420|NCT02278419|Experimental|Group B|Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
16650421|NCT02278406|Experimental|Parkinson's patients with DBS|Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
16650422|NCT02278393|Active Comparator|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
16650423|NCT02278393|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
16651036|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
16650424|NCT02278380|Other|Arm 1|"To compare the Glycemic Index value of seven test foods:
~Low GI standard Breakfast Medium GI standard Breakfast Nutritional pregnant milk supplement Nutritional product for diabetics Pregnant and lactation women milk powder Nutritional drinks for diabetics Test product"
16650425|NCT02278367|Experimental|Flortaucipir PET Scans|
16650426|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
16650427|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
16650428|NCT02278341|Experimental|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
16650429|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
16650430|NCT02278328|Experimental|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.
~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
16650431|NCT02278328|Experimental|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.
~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
16650432|NCT02278328|Experimental|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.
~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
16650433|NCT02278315|Experimental|Single|I-131-CLR1404 with or without concurrent dexamethasone
16650434|NCT02278302|Experimental|Aggrenox®|treatment alone or in combination with Ethanol
16650435|NCT02278302|Placebo Comparator|Placebo|treatment alone or in combination with Ethanol
16650436|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
16650437|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
16650438|NCT02278276|Placebo Comparator|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
16650439|NCT02278276|Active Comparator|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
16650440|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
16650441|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
16650442|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
16650443|NCT02278250|Experimental|Part A: M4344 BIW|Dose escalation of M4344 administered BIW as a single agent.
16650444|NCT02278250|Experimental|Part A2: M4344 BID or once daily|Dose escalation of M4344 administered BID or once daily as a single agent.
16650445|NCT02278250|Experimental|Part A3: M4344 Drug holiday schedule|Dose escalation of M4344 administered in a drug holiday schedule (different schedule with either 3 days once daily (QD) or BID followed by 4 days of pausing, 5 days of QD or BID followed by 2 days of pausing, 7 days of QD or BID dosing followed by 7 days of pausing or 14 days of QD or BID dosing followed by 7 days of pausing may be explored. Other dosing holiday schedules may be explored if agreed by the sponsor and Investigators).
16650446|NCT02278250|Experimental|Part B1: M4344 + Carboplatin|Dose escalation of M4344 in combination with carboplatin.
16650447|NCT02278250|Experimental|Part C1: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
16650448|NCT02278250|Experimental|Part C2: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
16650449|NCT02278250|Experimental|Part C3: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
16650450|NCT02278250|Experimental|Part C4: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
16650451|NCT02278250|Experimental|Part C5: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
16650452|NCT02278250|Experimental|Part C6: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
16652293|NCT02265861|Experimental|Group 3|PCOS without HA
16650454|NCT02278224|Experimental|Rumination Focused CBT|11 sessions of manualised group based Rumination Focused CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
16650455|NCT02278224|Active Comparator|Cognitive Behavioral Therapy|11 sessions of manualised group based CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
16650456|NCT02278211||Study Cohort|Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease
16650457|NCT02278198|Experimental|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.
~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).
~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.
~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
16650458|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
16650459|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
16650460|NCT02278172|Active Comparator|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
16650461|NCT02278172|Placebo Comparator|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
16650462|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
16650463|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
16650464|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
16650465|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
16650466|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
16650467|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
16650468|NCT02278133|Experimental|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
16650469|NCT02278120|Experimental|Ribociclib (LEE011) + NSAI/tamoxifen + goserelin|LEE011 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
16650470|NCT02278120|Placebo Comparator|LEE011 placebo+NSAI/tamoxifen+goserelin|LEE011 Placebo 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
16650471|NCT02278107|Experimental|Tidal Assist Ventilator System|Lightweight, portable, positive pressure ventilator system with proprietary nasal interface. Ventilator is powered by compressed oxygen delivered by cylinder, concentrator, or wall source.
16650472|NCT02278107|Active Comparator|Nasal Cannula Oxygen|Nasal Cannula Oxygen Standard nasal cannula oxygen at 2-5 liters per minute (LPM) based on patient requirement. Oxygen sources includes cylinder, concentrator, or wall source.
16650473|NCT02278094|Experimental|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
16650474|NCT02278094|Active Comparator|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
16650475|NCT02278081|Experimental|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
16650476|NCT02278081|Placebo Comparator|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
16650477|NCT02278068|Experimental|Metabolic Neuromodulation System (MNS)|Hepatic sympathetic denervation therapy to aid in glycemic control
16650478|NCT02278055|Experimental|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
16650479|NCT02278042|Active Comparator|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
16650480|NCT02278042|Active Comparator|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
16650481|NCT02278042|Active Comparator|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
16650482|NCT02278042|Active Comparator|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
16650483|NCT02278042|Active Comparator|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
16650484|NCT02278029||Concussed|those subjects with a concussion
16650485|NCT02278029||Controls|those subjects without a concussion
16650517|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
16651037|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
16650486|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.
~measure the amnesic effects of propofol."
16650487|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
16650488|NCT02277990|Active Comparator|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
16650489|NCT02277990|No Intervention|Control|No TYRX™ envelope, bare CIED
16650490|NCT02277977|Experimental|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
16650491|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.
~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
16650492|NCT02277951||Participants|The Bonfils Intubation Fibrescope the Video Rigid Flexing Laryngoscope the C-MAC® S Video Laryngoscope the Macintosh Laryngoscope
16650493|NCT02277938||Amantadine|Lung cancer patients being prescribed chemotherapy
16650494|NCT02277925|Active Comparator|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
16650495|NCT02277925|Experimental|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
16650496|NCT02277912|Experimental|Transcranial Magnetic Stimulation I|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the motor cortex
16650497|NCT02277912|Experimental|Transcranial Magnetic Stimulation II|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the secondary somatosensory cortex
16650498|NCT02277912|Sham Comparator|Sham Stimulation|Intervention: Repetitive sham Transcranial Magnetic Stimulation with SHAM block of the motor cortex
16650499|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.
~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:
~Communication regarding child's high weight status
~Counseling regarding cardiovascular risk factor screening and assessment
~Behavioral counseling
~Interval follow-up to readdress weight, and
~Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
16650500|NCT02277886|Experimental|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
16650501|NCT02277886|Active Comparator|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
16650502|NCT02277873||No Treatment|Defined population (pregnant women) compared on a environmental moon luminosity influence
16650503|NCT02277860|Experimental|Exercise|Aerobic and strength training using the Wii Fit Plus for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
16650504|NCT02277847|Experimental|IDA 8mg/M2|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
16650505|NCT02277847|Active Comparator|IDA 10mg/M2|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
16650506|NCT02277834||pancreatic adenocarcinoma|15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
16650507|NCT02277834||chronic pancreatitis|15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
16650508|NCT02277834||non-pancreatic, non-neoplastic disorders|15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
16650509|NCT02277821|Experimental|Stendo pulsating suit System|One 20 minutes Stendo pulsating suit session will be applied to the patient.
16650510|NCT02277808|Active Comparator|Respirgard II|Determination of pulmonary deposition
16650511|NCT02277808|Active Comparator|Isoneb|Determination of pulmonary deposition
16650512|NCT02277795|Experimental|AccuCirc|"The AccuCirc procedure is performed according to manufacturer instructions: http://www.clinicalinnovations.com/site_files/files/AccuCirc_IFUs.pdf
~Before the surgery, the mother (and father, if available) will be counseled on benefits and risks of EIMC in their language of choice (English, Kiswahili, DhoLuo). At least one parent/guardian will provide documented informed consent using IRB-approved Consent Form. Providers will record demographic and locator information and EIMC eligibility criteria. If the infant is eligible for EIMC, the provider will perform the procedure and document the outcome of the surgery on a post-operative form. Information recorded will include: amount and type of anesthesia provided, intra-operative adverse event and outcome, and procedure start and end time."
16650513|NCT02277782|Active Comparator|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
16650514|NCT02277782|Experimental|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
16650515|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
16650516|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
16650518|NCT02277756|Experimental|high functioning Autism|Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
16650519|NCT02277756|Placebo Comparator|witness|Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness
16650520|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
16650521|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
16650522|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
16650523|NCT02277730|Experimental|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
16650524|NCT02277730|Active Comparator|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
16650525|NCT02277717|Experimental|SYD985 (trastuzumab vc-seco-DUBA)|HER2-targeting Antibody-Drug Conjugate
16650526|NCT02277704|Placebo Comparator|Treatment A|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
16650527|NCT02277704|Active Comparator|Treatment B|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
16650528|NCT02277704|Active Comparator|Treatment C|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
16650529|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.
~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
16650530|NCT02277678|Experimental|Oxycodone|Epidural oxycodone 3mg single dose as opioid administration
16650531|NCT02277678|Active Comparator|Morphine|Epidural morphine 3mg single dose as opioid administration
16650532|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
16650533|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
16650534|NCT02277652|Experimental|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
16650535|NCT02277652|Experimental|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
16650536|NCT02277652|Experimental|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
16650537|NCT02277652|Experimental|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
16650538|NCT02277652|Experimental|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
16650539|NCT02277652|Experimental|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
16650540|NCT02277639|Experimental|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
16650541|NCT02277639|Experimental|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
16650542|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
16650543|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
16650544|NCT02277613|Experimental|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
16650545|NCT02277613|Sham Comparator|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
16650546|NCT02277600|Experimental|Cohort 1, Treatment A, B|"Treatment A:
~BMS-663068 orally twice daily (BID) on Days 1 through 4
~Treatment B:
~BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14"
16650547|NCT02277600|Experimental|Cohort 2, Treatment C, D|"Treatment C:
~BMS-663068 orally BID on Days 1 through 4
~Treatment D:
~BMS-663068 orally BID plus COBI QD on Days 5 through 14"
16650548|NCT02277587|Experimental|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
16650549|NCT02277587|Active Comparator|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.
~The total daily dose and timing is not changed during the study period."
16650550|NCT02277587|No Intervention|Healthy volunteers|Healthy volunteers will be enrolled as control group
16650551|NCT02277574|Experimental|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
16650552|NCT02277574|Experimental|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
16650553|NCT02277561|Experimental|Diagnostic (VB-DTI, MRI)|Patients undergoing WBRT for a total of 10 fractions also undergo VB-DTI MRI at baseline, 1 week after WBRT initiation, and 7-11 days after completion of WBRT. Patients undergoing SRS without WBRT also undergo VB-DTI MRI at baseline and 7-11 days after completion of SRS.
16650554|NCT02277548|Experimental|Lyrica at 300 mg per day|
16650555|NCT02277548|Placebo Comparator|Placebo|
16650556|NCT02277535|Experimental|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.
~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
16650557|NCT02277535|No Intervention|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
16650558|NCT02277522|Experimental|RNA autologous T cells (anti CD19 CAR T cells)|
16650559|NCT02277509|Experimental|Chinese DPP|Our Chinese DPP intervention includes: 1) skills development core adapted from the DPP core curriculum, 2) stress reduction counseling and activities, 3) physical activity sessions, 4) self-monitoring tools for diet and physical activity, 5) barriers assessment linked to tool box, and 6) post-core support intervention.
16650560|NCT02277509|Active Comparator|Minimal Intervention Control|The minimal control intervention will consist of providing patients with publically available materials on diabetes prevention, which are produced in Chinese.
16650561|NCT02277496|Experimental|HC toolkit intervention students|HC students will receiveeExperimental wellness education via a toolkit approach to address the 2010 Dietary Guidelines for reducing obesity in youth. The specific recommendations include: 1) reducing intake of sugary beverages, 2) increasing intake of fruits and vegetables, 3) increasing frequency of eating breakfast, 4) decreasing fast and junk food choices, 5) increasing physical activity to 1 hour/day, and 6) decreasing screen time to 2 hours per day.
16650562|NCT02277496|No Intervention|Comparison Schools|During the 2014-2015 school year, control schools were utilized to compare outcomes.
16650563|NCT02277483|Active Comparator|active treatment|LAIS® Mites Sublingual tablets + rescue medication
16650564|NCT02277483|No Intervention|control|Rescue medication
16650565|NCT02277470||Golimumab|Patients who are eligible for golimumab therapy.
16650566|NCT02277457|Experimental|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
16650567|NCT02277457|Experimental|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
16650569|NCT02277431|Experimental|Probiotic dietary supplement|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:
~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])
~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)
~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
16650570|NCT02277431|Placebo Comparator|Placebo|The placebo capsules utilized in this study will be indistinguishable from the probiotic dietary supplement capsules as they will be identical in appearance, odor, weight, and taste. Furthermore, the same sunflower oil matrix will be in both the probiotic dietary supplement and placebo. The only difference between the dietary supplement and placebo capsules will be the probiotic bacteria.
16650571|NCT02277418|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16650572|NCT02277418|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16650573|NCT02277418|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
16650574|NCT02277418|Experimental|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
16650575|NCT02277405|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
16650576|NCT02277405|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
16650577|NCT02277366||Fluorescence/Narrow Band Bronchoscopy|All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
16650578|NCT02277366||Routine Bronchoscopy|All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
16650579|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
16650580|NCT02277340|Experimental|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
16650581|NCT02277327|Experimental|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
16650582|NCT02277327|Placebo Comparator|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
16650583|NCT02277314|Other|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
16650584|NCT02277301|Experimental|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
16650585|NCT02277301|No Intervention|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
16650586|NCT02277288|No Intervention|Emptied bladder arm|No instillation of fluid into bladder.
16650587|NCT02277288|Experimental|Filled bladder arm|Instilled bladder with fluid.
16650588|NCT02277275|Placebo Comparator|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
16650589|NCT02277275|Experimental|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
16650590|NCT02277275|Placebo Comparator|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
16650591|NCT02277262|Experimental|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
16650592|NCT02277262|Active Comparator|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
16650593|NCT02277249|Other|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
16650594|NCT02277249|Other|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
16650595|NCT02277236||Younger Veterans|Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
16650596|NCT02277236||Young-Old Veterans|Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
16650597|NCT02277223|Experimental|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<30kg: 500 milligram, twice daily, weight>30kg: 1 gram twice daily
16650598|NCT02277223|Placebo Comparator|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
16650599|NCT02277210|Placebo Comparator|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
16650600|NCT02277210|Active Comparator|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
16650601|NCT02277197|Experimental|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.
~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
16650602|NCT02277184|Experimental|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.
~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.
~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
16650603|NCT02277171|Experimental|Nitric oxide impregnated catheter|
16650604|NCT02277158|Experimental|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
16650605|NCT02277145|Experimental|treatment group|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
16650606|NCT02277132|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
16650607|NCT02277132|Placebo Comparator|Placebo|Placebo tablets three times daily orally from randomization until delivery
16650608|NCT02277119|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
16650609|NCT02277119|Experimental|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
16650610|NCT02277119|Experimental|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
16650611|NCT02277106|Experimental|SAGE-547|Intravenous
16650612|NCT02277106|Placebo Comparator|Placebo|Intravenous sterile saline
16650613|NCT02277093|Experimental|Pacritinib|"Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)
~Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
16650614|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
16650615|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
16650616|NCT02277067|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
16650617|NCT02277067|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
16650618|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
16650619|NCT02277041|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
16650620|NCT02277041|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
16650621|NCT02277028|Experimental|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension. The priming (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total priming for one day is 30 minutes. Total task specific training for one day is 90 minutes"
16650622|NCT02277028|Active Comparator|Health Education|The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as above. The health education (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total time on health education website for one day is 30 minutes. Total task specific training for one day is 90 minutes
16650623|NCT02277015|Experimental|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
16650624|NCT02277015|Experimental|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
16650625|NCT02277002|Placebo Comparator|Placebo|Participants are exposed to unfiltered cabin air
16650626|NCT02277002|Active Comparator|Cabin Air Filter|Participants are exposed to filtered cabin air
16650627|NCT02276989|Experimental|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
16650628|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
16650629|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
16650630|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
16650631|NCT02276937|Placebo Comparator|Placebo (0 ciu/limb)|Placebo control
16650632|NCT02276937|Active Comparator|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
16650633|NCT02276937|Active Comparator|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
16650634|NCT02276924|Experimental|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
16650635|NCT02276911|Active Comparator|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
16650636|NCT02276911|Placebo Comparator|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
16650637|NCT02276898|Active Comparator|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
16650638|NCT02276898|Placebo Comparator|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
16650641|NCT02276872|Experimental|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
16650642|NCT02276872|Experimental|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
16650643|NCT02276872|Experimental|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
16650701|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
16650702|NCT02276469|Experimental|peer support|peer support is delivered on individual basis for half a year, the frequency depends on the patients requirement, but at least 3 sessions has to occur
16652294|NCT02265861|Experimental|Group 4|Control
16650644|NCT02276859|Experimental|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.
~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
16650645|NCT02276859|Experimental|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.
~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
16650646|NCT02276833|Experimental|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
16650647|NCT02276820|Experimental|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-A/m2 as a single infusion.
~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
16650648|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
16650649|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
16650650|NCT02276794|Experimental|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.
~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.
~A single treatment will be provided."
16650651|NCT02276794|Experimental|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.
~A single treatment will be provided"
16650652|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
16650653|NCT02276768|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
16650654|NCT02276768|Experimental|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
16650655|NCT02276768|Active Comparator|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
16650656|NCT02276768|Active Comparator|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
16650657|NCT02276768|Placebo Comparator|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses
~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
16650658|NCT02276755|Active Comparator|Intervention: 1|Dietary Supplement: Cholecalciferol (vitamin D3)
16650659|NCT02276755|Placebo Comparator|Placebo Comparator: 2|Dietary Supplement: Placebo
16650660|NCT02276742|No Intervention|Usual Care (UC)|Participants randomized to UC will receive baseline advice about the value of losing weight, becoming more physically active, and limiting intake of sodium and inorganic phosphates followed by 12 mos of UC. We have elected not to use a control group in which we provide equivalent attention to both study arms. Behaviors are difficult to change and there is no reason to believe that simply giving participants attention would create behavioral changes sufficient to result in weight loss, reduce sodium excretion, or reduce serum phosphorus. Numerous weight loss studies, including Look AHEAD, have used attention control groups that did not demonstrate weight loss.
16650661|NCT02276742|Active Comparator|Social Cognitive Theory (SCT)|Participants will be exposed to a group behavioral intervention that is based on SCT, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Mastery experiences will include emphasizing past successes; setting incremental, easily achievable goals; identifying modifiable barriers to healthy behavior; receiving positive feedback on goal achievement; and practicing problem solving skills around barriers to adherence.
16650662|NCT02276742|Active Comparator|Monitoring|Participants will be taught how to use a lifestyle self-monitoring program to reduce information processing requirements, make readily available the information required to make good self-management decisions, deliver automated, real-time feedback about achievement of behavioral goals, and permit individualized guidance from an interventionist who uses the MyNetDiary® electronic log to provide targeted education and advice. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
16650663|NCT02276742|Active Comparator|Combined|Participants randomized to COMBINED will receive all aspects of the SCT and MONITORING intervention conditions. Social Cognitive Theory based behavioral intervention in complex patients is strengthened when technology is used to manage information complexity, and weakened in its absence. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
16650703|NCT02276469|No Intervention|usual care|usual care was delivered to the patients
16652896|NCT02262234|Experimental|Education Program Type 2|
16650664|NCT02276729|Experimental|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
16650665|NCT02276729|No Intervention|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
16650666|NCT02276716|Experimental|Phosphatidylserine|"Phosphatidylserine titration from 300, 600 and 800 mg/day
~duration: 6 months"
16650667|NCT02276690|Experimental|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
16650668|NCT02276690|Active Comparator|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
16650669|NCT02276677|Experimental|Oxytocin|Oxytocin 24 IU x 1
16650670|NCT02276677|Placebo Comparator|Placebo|Placebo 24 IU x 1
16650671|NCT02276664|No Intervention|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
16650672|NCT02276664|Experimental|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
16650673|NCT02276664|Active Comparator|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
16650674|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
16650675|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
16650676|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
16650677|NCT02276625|Experimental|A - ID|Intradermal administration. 20% dose in a single visit.
16650678|NCT02276625|Experimental|B - ID|Intradermal administration. 40% dose in a single visit.
16650679|NCT02276625|Experimental|C - ID|Intradermal administration. 60% dose in a single visit.
16650680|NCT02276625|Active Comparator|D - IM|1x IM
16650681|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.
~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
16650682|NCT02276599||Cardiac catheterization|Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.
16650683|NCT02276586|Active Comparator|Group 1|Horizontal Tooth preparation
16650684|NCT02276586|Experimental|Group 2|Vertical tooth preparation
16650685|NCT02276573|Experimental|Oral lichen planus disease|buccal cavity sample
16650686|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
16650687|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
16650688|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
16650689|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
16650690|NCT02276534|Experimental|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
16650691|NCT02276534|Experimental|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
16650692|NCT02276521||Zero dose group|Participants that did not received any HPV vaccine previously.
16650693|NCT02276521||One dose group|Participants that received one dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
16650694|NCT02276521||Two dose group|Participants that received two dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
16650695|NCT02276521||Three dose group|Participants that received three dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
16650696|NCT02276508|Experimental|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
16650697|NCT02276495|Experimental|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
16650698|NCT02276495|Experimental|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
16650699|NCT02276495|Experimental|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
16650700|NCT02276482|Experimental|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
16650928|NCT02274766|Placebo Comparator|Placebo|Placebo
16650704|NCT02276456|Experimental|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
16650705|NCT02276456|No Intervention|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
16650706|NCT02276443|Experimental|Treatment (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 courses, and after 4 courses of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
16650707|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
16650708|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
16650709|NCT02276417||Sepsis|Blood Collection. Urine collection. Bioimpedance analysis. Quality-of-life questionnaires, physical function tests and cognitive function tests.
16650710|NCT02276417||Healthy Controls|Blood Collection.
16650711|NCT02276404|Experimental|relaxation training|Each participant of the experimental group 1 receives 2 one-hour sessions of guided relaxation training prior to surgery.
16650712|NCT02276404|Experimental|acupuncture|Each participant of the experimental group 2 receives 3 acupuncture treatments with a semi-standardized acupoint scheme: once a week over 2 weeks and the day before surgery.
16650713|NCT02276404|Experimental|relaxation training and acupuncture|Each patient of the experimental group 3 receives 3 acupuncture treatments with a semi-standardized acupoint scheme and 2 one-hour sessions of guided relaxation training prior to surgery.
16650714|NCT02276404|No Intervention|usual care|Patients receive usual senological treatment
16650715|NCT02276391|Experimental|Telmisartan/HCTZ fixed-dose combination|
16650716|NCT02276391|Active Comparator|Telmisartan|
16650717|NCT02276378|Experimental|Telmisartan low / HCTZ fixed-dose combination, fed|
16650718|NCT02276378|Experimental|Telmisartan high / HCTZ fixed-dose combination, fed|
16650719|NCT02276378|Active Comparator|Telmisartan low /HCTZ fixed-dose combination, fasted|
16650720|NCT02276378|Active Comparator|Telmisartan high /HCTZ fixed-dose combination, fasted|
16650721|NCT02276365|Experimental|Sequence ABC|"Treatment A: 50 mg BI 10773 once daily from day 1 to 5
~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
~Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out"
16650722|NCT02276365|Experimental|Sequence CAB|"Treatment C: 45 mg pioglitazone once daily from day 1 to 7
~Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out
~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7"
16650723|NCT02276352|Experimental|Meloxicam low dose - one tablet|
16650724|NCT02276352|Experimental|Meloxicam high dose - two tablets|
16650725|NCT02276352|Active Comparator|Meloxicam high dose - one tablet|
16650726|NCT02276339|Experimental|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
16650727|NCT02276326|Experimental|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
16650728|NCT02276300|Experimental|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
16650729|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
16650730|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
16650731|NCT02276261|Experimental|Vertical|Vaginal cuff closure performed in a vertical manner.
16650732|NCT02276261|Active Comparator|Horizontal|Vaginal cuff closure performed in a horizontal manner.
16650733|NCT02276248|Experimental|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
16650734|NCT02276235|Experimental|catgut embedding group|Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks
16650735|NCT02276235|Sham Comparator|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.
~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)
~The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks"
16650736|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
16650737|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
16650738|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
16650739|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
16650740|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
16650741|NCT02276196|Experimental|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
16650742|NCT02276196|Active Comparator|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
16650743|NCT02276183|Experimental|Arm1, Nutrition intervention, test formula and activity|
16650744|NCT02276170||Aminophylline per standard of care|
16650745|NCT02276157||Direct peroral cholangioscopy|Patients with bile duct disease that is eligible to direct peroral cholangioscopy
16650746|NCT02276131|Experimental|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
16650747|NCT02276118|Experimental|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
16650748|NCT02276118|Active Comparator|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
16650749|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
16650750|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
16650751|NCT02276079|Experimental|mTBI Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily aerobic exercise intervention lasting 1-week.
16650752|NCT02276079|Experimental|mTBI Non-Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily non-aerobic exercise intervention lasting 1-week.
16650753|NCT02276079|No Intervention|Non-injured Reference Group|Non-injured, healthy participants will serve as a reference group for functional outcome measures.
16650754|NCT02276066|Active Comparator|Inhospital group at day 14|This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
16650755|NCT02276066|Other|Released from hosptial prior to day 14|This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
16650756|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
16650757|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
16650758|NCT02276027|Experimental|BYL719 350 mg QD|Patient's tumor must have molecular alteration of the PIK3CA gene.
16650759|NCT02276027|Experimental|INC280 400 mg BID tab/600 mg BID cap|Patient's tumor must have molecular alteration of the c-MET gene.
16650760|NCT02276027|Experimental|LDK378 750 mg QD|Patient's tumor must have ALK or ROS1 gene rearrangement.
16650761|NCT02276027|Experimental|MEK162 45 mg BID|Patient's tumor must have KRAS, NRAS or BRAF mutation.
16650762|NCT02276014|Other|Supplement A|Beta-carotene 7mg formulation A
16650763|NCT02276014|Other|Supplement B|Beta-carotene 7mg formulation B
16650764|NCT02276014|Other|Supplement C|Beta-carotene 7mg formulation C
16650765|NCT02276001|Experimental|K-877|K-877
16650766|NCT02276001|Experimental|K-877 with Cyclosporine|K-877 with Cyclosporine
16650767|NCT02275988|Experimental|K-877|K-877
16650768|NCT02275988|Experimental|K-877 with Clarithromycin|K-877 with Clarithromycin
16650769|NCT02275975|Experimental|K-877|K-877
16650770|NCT02275975|Experimental|K-877 with Fluconazole|K-877 with Fluconazole
16650771|NCT02275962|Experimental|K-877|K-877
16650772|NCT02275962|Experimental|K-877 with Rifampin|K-877 with Rifampin
16650773|NCT02275949|Experimental|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
16650774|NCT02275949|Sham Comparator|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
16650775|NCT02275936|Experimental|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
16650776|NCT02275936|Experimental|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
16650777|NCT02275936|Experimental|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
16650778|NCT02275936|Placebo Comparator|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
16650779|NCT02275923|Experimental|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
16650780|NCT02275910|Experimental|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
16650781|NCT02275897|Experimental|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
16650782|NCT02275897|Experimental|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
16650783|NCT02275884|Active Comparator|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
16650784|NCT02275884|Sham Comparator|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
16650785|NCT02275871|Experimental|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
16650786|NCT02275858|Experimental|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
16650787|NCT02275858|Placebo Comparator|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
16650997|NCT02274233|Experimental|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
16650788|NCT02275845|Experimental|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
16650789|NCT02275845|Active Comparator|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
16650790|NCT02275832|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
16650791|NCT02275832|Placebo Comparator|Placebo|Placebo is applied twice daily to beard.
16650792|NCT02275819|No Intervention|control|Will not receive intervention with exercise
16650793|NCT02275819|Active Comparator|Intervention group|2 groups will receive 2 different types of therapy (exercise or Inspiratory Muscle Therapy)
16650794|NCT02275806|Other|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8
~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
16650795|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
16650796|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
16650797|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
16650798|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
16650799|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
16650800|NCT02275767|Experimental|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
16650801|NCT02275767|Active Comparator|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
16650802|NCT02275767|Active Comparator|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
16650803|NCT02275754|Experimental|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
16650804|NCT02275754|Active Comparator|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
16650805|NCT02275728|Experimental|Pelvic Floor Muscle Training(PFMT)|The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
16650806|NCT02275728|Active Comparator|EMG Biofeedback treatment|In this group, the same protocol of the TMAP will be held, however, emg biofeedback is used during training for 20 minutes, 2 times a week, 8 sessions.
16650807|NCT02275728|No Intervention|no treatment|In this group, will be held only the initial assessment, you will not receive treatment for a month and will be reevaluated after being serviced this period.
16650808|NCT02275715|Experimental|Parent Training Program (PT-F)|Treatment group
16650809|NCT02275715|No Intervention|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
16650810|NCT02275702|Placebo Comparator|Group 1|saline solution IV, bolus
16650811|NCT02275702|Active Comparator|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
16650812|NCT02275689|Active Comparator|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
16650813|NCT02275689|Active Comparator|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
16650814|NCT02275689|No Intervention|Physical therapy|Muscle strength training, home trainings programme
16650815|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
16650816|NCT02275663|Experimental|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1
~G-CSF 5 mcg/kg subcut on days 0 to + 6
~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5
~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
16650817|NCT02275650|Experimental|nbUVB|2 SED dose of nbUVB will be given every other week for this intervention group.
16650818|NCT02275650|No Intervention|control|No nbUVB illumination will be given for the control group.
16650819|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
16650820|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
16650821|NCT02275598|Experimental|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
16650822|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
16650823|NCT02275572|Experimental|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
16650824|NCT02275572|No Intervention|Control|Usual procedure.
16650825|NCT02275559|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
16650826|NCT02275559|Active Comparator|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
16650827|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
16650828|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
16650829|NCT02275533|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity.
16650830|NCT02275533|Active Comparator|Arm II (observation)|Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I.
16650831|NCT02275520|Other|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
16650832|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
16650833|NCT02275494||shortening group|Shortening group where the operated leg was more than 5mm shorter compared with the contralateral side
16650834|NCT02275494||Restoration group|the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side
16650835|NCT02275494||Lengthening group|The lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.
16650836|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
16650837|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
16650838|NCT02275468|Placebo Comparator|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.
16650839|NCT02275468|Experimental|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
16650840|NCT02275455|Experimental|Participants with autism|
16650841|NCT02275455|Experimental|Aged-matched controls|
16650842|NCT02275429|Other|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
16650843|NCT02275416|Experimental|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
16650844|NCT02275403|Experimental|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
16650845|NCT02275403|Active Comparator|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
16650846|NCT02275390|Experimental|Nurse-led Psycho-education [SPBB: Self-learning program]|"The Nurse-led Psychoeducation Program is comprised of eight 2-hour sessions held at every two weeks (over 4 months). The program consists of five themes: (a) orientation and engaging and understanding of mental health/illness, its related behaviors and community support resources; (b) working collaboratively and empowering and minimizing resistance and challenges using motivational interviewing approach; (c) effective interpersonal and communication skills; (d) strategies in coping with mental illness, sleep hygiene and allaying anxiety; and (e) self-review and evaluation and establishing a realistic plan for future.
~[Note: The participants in the SPBB will complete the self-help and problem-solving manual (5 modules) for caregivers of people with psychotic disorders over 20 weeks, together with an orientation, understanding about psychosis and its care and 4 review sessions.]"
16650847|NCT02275390|Active Comparator|Usual Psychiatric Outpatient Care|"Routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study
~[Note: for SPBB trial, routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study]"
16650848|NCT02275377|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
16650849|NCT02275377|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
16651234|NCT02272764|Experimental|ALKS 5461|ALKS 5461 or placebo Sublingual tablet
16650850|NCT02275377|No Intervention|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
16650851|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
16650852|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
16650853|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
16650854|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
16650855|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
16650856|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
16650857|NCT02275325|Experimental|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
16650858|NCT02275325|No Intervention|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
16650859|NCT02275299|Experimental|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
16650860|NCT02275299|Active Comparator|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
16650861|NCT02275286|Experimental|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
16650862|NCT02275273||Patients with adnexal masses|Every patient that are at least 18 years old with a planned pelvic magnetic resonance imagery and an adnexectomy within the institution.
16650863|NCT02275260|Experimental|All patients|All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing
16650864|NCT02275247|Experimental|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
16650865|NCT02275247|No Intervention|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
16650866|NCT02275234||Retrospective|Patients who survived cardiac arrest >3 months prior to the start of the study and a close family/friend,will be invited to attend an outpatient clinic
16650867|NCT02275234||Prospective- psychological intervention|In patients who survived cardiac arrest and a close family/friend,will be invited to attend an outpatient clinic
16650868|NCT02275221||Hepatitis B and C|Hepatitis B and C
16650869|NCT02275182|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
16650870|NCT02275182|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
16650871|NCT02275169|Experimental|Treated|Urofollitropin 150 IU ampoules three times a week for three months
16650872|NCT02275169|Placebo Comparator|Controls|Placebo ampoules three times a week for three months
16650873|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
16650874|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
16650875|NCT02275130|Experimental|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
16650876|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
16650877|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
16650878|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
16650879|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
16650880|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
16650881|NCT02275104||Ventricular arrhythmias|
16650882|NCT02275104||Persistent atrial fibrillation|
16650883|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
16650884|NCT02275091||Healthy|Healthy children 12-21 years old
16650885|NCT02275078|Other|Interventional|The program consists of 3 components: 1) COPD self-management using an Action Plan; 2) Telesystem-Phone self-assessment/reporting system; and 3) Nurse case manager support.
16650886|NCT02275065|Experimental|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
16650887|NCT02275065|Experimental|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
16650888|NCT02275065|Experimental|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
16650889|NCT02275065|Experimental|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
16650890|NCT02275065|Placebo Comparator|Placebo|Placebo matched to bictegravir tablet for 10 days
16650891|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
16650892|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
16650893|NCT02275039|Experimental|Treatment (MVA-p53 vaccine and gemcitabine hydrochloride)|Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
16650894|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
16650895|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
16650896|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
16650897|NCT02275000|Experimental|Intervention|5 Day physiotherapy programme at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK.
16650898|NCT02275000|Active Comparator|Treatment as usual|Participants are referred to their local neuro-physiotherapy service and if appropriate placed on a waiting list for inpatient rehabilitation.
16650899|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
16650900|NCT02274974|Active Comparator|lidocaine|20 ml of 2% lidocaine.
16650901|NCT02274974|Experimental|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
16650902|NCT02274961|Experimental|S-pantoprazole 10mg|S-pantoprazole 10mg Tablet once daily for 4 weeks
16650903|NCT02274961|Placebo Comparator|Placebo|Placebo tablet for the test drug
16650904|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
16650905|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.
~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
16650906|NCT02274935|Experimental|Gait and balance exercise|Traditional exercises focusing on gait and balance
16650907|NCT02274935|Experimental|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
16650908|NCT02274909|No Intervention|control group|The subjects received no intervention and continued with their daily activities.
16650909|NCT02274909|Active Comparator|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
16650910|NCT02274909|Active Comparator|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
16650911|NCT02274896|Experimental|PD catheter group|All patients will receive the Bayston PD catheter
16650912|NCT02274883|Experimental|Enriched Protein Fractions|This group is given Infant formula with enriched protein fractions.
16650913|NCT02274883|Active Comparator|Protein Fractions|This group is given Infant formula with protein fractions.
16650914|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
16650915|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
16650916|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
16650917|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
16650918|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
16650919|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
16650920|NCT02274831|Experimental|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
16650921|NCT02274831|No Intervention|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
16650922|NCT02274818|No Intervention|Standard Duty Hour Schedule|IM programs randomized to the currently mandated duty 16 hour standards (maximum work duration of 16 hours for interns and 28 hours for PGY2-3); this schedule may involve night float.
16650923|NCT02274818|Experimental|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:
~No more than 80 hours of work per week (when averaged over 4 weeks)
~1 day off in 7 (when averaged over 4 weeks)
~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
16650924|NCT02274805||Adults presenting for surgery in the neck area|
16650925|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
16650926|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy
~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy
~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.
~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
16650927|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
16650929|NCT02274740|Experimental|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).
~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
16650930|NCT02274740|No Intervention|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
16650931|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
16650932|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
16650933|NCT02274701|Experimental|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
16650934|NCT02274701|No Intervention|Control|The control group entails standard care - routine consultation between the patient and clinician.
16650935|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
16650936|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
~Randomized and will be blindly assessed."
16650937|NCT02274675|Experimental|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
16650938|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
16650939|NCT02274649|Active Comparator|Control|Control group receiving general peer support
16650940|NCT02274636|No Intervention|Data collection|This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
16650941|NCT02274636|Active Comparator|Intervention|In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
16650942|NCT02274623|Experimental|CTAP101 Capsules|CTAP101 Capsules daily
16650943|NCT02274610|Experimental|Group A|Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
16650944|NCT02274610|Experimental|Group B|Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
16650945|NCT02274597||Environmental impact on epitympanic temperature measurment|volunteers exposed to different environmental factors to simulate field settings
16650946|NCT02274584|Experimental|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
16650947|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
16650948|NCT02274571|Placebo Comparator|Placebo|Non active comparator
16650949|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
16650950|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
16650951|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
16650952|NCT02274545|Experimental|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
16650953|NCT02274532|Experimental|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
16650954|NCT02274532|Other|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
16650955|NCT02274519|Experimental|Tai Chi|Group randomized to participate in Tai Chi intervention
16650956|NCT02274519|Active Comparator|Educational|Group randomized to participate in educational intervention
16650998|NCT02274220|Experimental|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
16651038|NCT02273947|Experimental|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16650957|NCT02274506|Experimental|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.
~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
16650958|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
16650959|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
16650960|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
16650961|NCT02274467|Active Comparator|Uniport catheter|19 gauge uniport epidural catheter
16650962|NCT02274467|Active Comparator|Multiport catheter|19 gauge multiorifice epidural catheter
16650963|NCT02274454|Active Comparator|1.25mM Calcium-NO oxytocin pretreatment|
16650964|NCT02274454|Active Comparator|2.5mM Calcium-NO oxytocin pretreatment|
16650965|NCT02274454|Active Comparator|5.0mM Calcium-NO oxytocin pretreatment|
16650966|NCT02274454|Active Comparator|1.25mM Calcium-WITH oxytocin pretreatment|
16650967|NCT02274454|Active Comparator|2.5mM Calcium-WITH oxytocin pretreatment|
16650968|NCT02274454|Active Comparator|5.0mM Calcium-WITH oxytocin pretreatment|
16650969|NCT02274428|Other|pneumostem group|single arm, pneumostem treated infants
16650970|NCT02274415|Experimental|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
16650971|NCT02274415|Active Comparator|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
16650972|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
16650973|NCT02274389||Bedaquiline Patient Registry (BPR)|
16650974|NCT02274376||Cohort|
16650975|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
16650976|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
16650977|NCT02274337|Experimental|AC0010|patients receiving avitinib treatment Qd, at different dose stages
16650978|NCT02274324|Active Comparator|PD patients- Diet B first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet B and then crossover to diet C.
16650979|NCT02274324|Active Comparator|PD patients- Diet C first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet C and then crossover to diet B.
16650980|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
16650981|NCT02274298|Active Comparator|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
16650982|NCT02274298|No Intervention|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
16650983|NCT02274285|Experimental|Group A (SP0204)|Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
16650984|NCT02274285|Active Comparator|Group B (control)|Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
16650985|NCT02274285|Experimental|Group C|Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly
16650986|NCT02274272|Placebo Comparator|Placebo Capsules|
16650987|NCT02274272|Experimental|ADR-1|Lactobacillus reuteri GMNL-89
16650988|NCT02274272|Experimental|GMNL-263|Lactobacillus reuteri GMNL-263
16650989|NCT02274259|Active Comparator|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
16650990|NCT02274259|Active Comparator|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
16650991|NCT02274246|Experimental|Gadobutrol|Gadobutrol in Healthy volunteers
16650992|NCT02274233|Experimental|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
16650993|NCT02274233|Experimental|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
16650994|NCT02274233|Experimental|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
16650995|NCT02274233|Experimental|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
16650996|NCT02274233|Experimental|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
16650999|NCT02274220|Experimental|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
16651000|NCT02274220|No Intervention|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
16651001|NCT02274207|Experimental|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
16651002|NCT02274207|Active Comparator|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
16651003|NCT02274194|Active Comparator|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
16651004|NCT02274194|Experimental|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
16651005|NCT02274181|Experimental|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
16651006|NCT02274168|Other|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
16651007|NCT02274168|Other|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
16651008|NCT02274155|Experimental|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
16651009|NCT02274155|Experimental|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
16651010|NCT02274155|Experimental|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
16651011|NCT02274142|Experimental|Restorations with Encapsulated material|Restorations performed with encapsulated glass ionomer cement (EQUIA - GC Corp). Capsules with glass ionomer will be activated and applied after selective carious tissue removal in primary molars.
16651012|NCT02274142|Active Comparator|Restorations with Hand-Mixed material|Restorations will be performed with hand-mixed glass ionomer cement (Fuji IX - GC Corp) after selective carious tissue removal in primary molars.
16651013|NCT02274129|Experimental|Use of Healing cap II|Single arm study using a new healing cap as intervention
16651014|NCT02274116|Active Comparator|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.
~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes"
16651015|NCT02274116|Sham Comparator|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.
~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes"
16651016|NCT02274103|Active Comparator|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
16651017|NCT02274103|Active Comparator|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
16651018|NCT02274090|Placebo Comparator|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
16651019|NCT02274090|Active Comparator|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
16651020|NCT02274077|Active Comparator|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
16651021|NCT02274077|Placebo Comparator|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
16651022|NCT02274064|Experimental|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
16651023|NCT02274064|No Intervention|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
16651024|NCT02274051|Experimental|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.
~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
16651025|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
16651026|NCT02274012|Experimental|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
16651027|NCT02273999|No Intervention|Control Group (no device)|No devices were delivered after third molar tooth extraction
16651028|NCT02273999|Placebo Comparator|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
16651029|NCT02273999|Experimental|Test (activated device)|Activated devices were delivered after third molar tooth extraction
16651030|NCT02273986|Experimental|Digoxin|Digoxin
16651031|NCT02273986|Experimental|Digoxin with K-877|Digoxin with K-877
16651032|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
16651033|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
16651034|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
16651035|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
16651039|NCT02273947|Experimental|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651040|NCT02273947|Experimental|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651041|NCT02273947|Experimental|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651042|NCT02273947|Experimental|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651043|NCT02273947|Experimental|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651044|NCT02273947|Experimental|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651045|NCT02273947|Experimental|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
16651046|NCT02273947|Experimental|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651047|NCT02273947|Experimental|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651048|NCT02273947|Experimental|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651049|NCT02273947|Experimental|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651050|NCT02273947|Experimental|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651051|NCT02273947|Experimental|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651052|NCT02273947|Experimental|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651053|NCT02273947|Experimental|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651054|NCT02273947|Experimental|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651055|NCT02273947|Experimental|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651056|NCT02273947|Experimental|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651057|NCT02273947|Experimental|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651058|NCT02273947|Experimental|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
16651059|NCT02273934|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to adults, and there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the person on a daily basis focusing on self-help.
16651060|NCT02273934|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
16651061|NCT02273921|No Intervention|EEG|A non-invasive EEG recording
16651062|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
16651063|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
16651064|NCT02273895|Active Comparator|Control|Scopolamine
16651065|NCT02273895|Active Comparator|MCI|Scopolamine
16651066|NCT02273895|Active Comparator|AD|Scopolamine
16651067|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation <12 months of age
16651068|NCT02273856||Treatment naïve patients with CLL|
16651069|NCT02273856||Treatment naïve patients with iNHL|
16651070|NCT02273856||Relapsed/refractory patients with CLL|
16651071|NCT02273856||Relapsed/refractory patients with iNHL|
16651072|NCT02273843|Experimental|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
16651073|NCT02273843|Active Comparator|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
16651074|NCT02273830|Active Comparator|oxygen adjusted|oxygen adjusted to get SpO2> 90% during the walking test
16651075|NCT02273830|Placebo Comparator|control group|oxygen at 3L/min
16651076|NCT02273817|Experimental|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray
~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.
~Strength: 50 μg per actuation.
~Batch/Lot number (Expiry date): JM6697 (May 2012)
~Manufacturer: Apotex, Inc."
16651077|NCT02273817|Active Comparator|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,
~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide
~Strength: 50 μg per actuation
~Batch/Lot number (Expiry date): 131657 (03/2012)
~Manufacturer: Sepracor, Inc."
16651078|NCT02273817|Placebo Comparator|Placebo|"Placebo
~Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.
~Batch/Lot number (Expiry date): JR3808 (Nov 2012)
~Manufacturer: Apotex, Inc."
16651079|NCT02273804|Experimental|topiramate|pill
16651080|NCT02273804|Placebo Comparator|placebo|Sugar pill
16651081|NCT02273791||HRT group|Women will be subjected to HRT using Estradiol valerate before FET
16651082|NCT02273791||MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
16651083|NCT02273778|Other|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
16651084|NCT02273778|Other|Routine radiotherapy treatment|
16651085|NCT02273765|Active Comparator|Raltegravir|Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID
16651086|NCT02273765|Experimental|Efavirenz|Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD
16651125|NCT02273492|Active Comparator|Asasantin ER at fasted state|
16651126|NCT02273479|Experimental|Asasantin®|
16651127|NCT02273479|Placebo Comparator|Placebo|
16651128|NCT02273466|Active Comparator|Desipramine alone|
16651087|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
16651088|NCT02273739|Experimental|Enasidenib|During the dose escalation phase, consented eligible participants will be enrolled into sequential cohorts of increasing doses of enasidenib.The starting dose for this study is 100 mg administered every 24 hours,
16651091|NCT02273713|Experimental|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
16651092|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.
~Intervention: Rivaroxaban"
16651093|NCT02273687|Experimental|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.
~Intervention: Diaphragmatic ultrasound"
16651094|NCT02273674|Experimental|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
16651095|NCT02273674|Experimental|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
16651096|NCT02273661|Placebo Comparator|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
16651097|NCT02273661|Experimental|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
16651098|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with
~Diabetes (all types) at least 300 subjects should be included and analyzed in this segment
~Small vessels (≤2.75 mm) approx. 150 subjects
~Chronic total occlusion (CTO) approx. 50 subjects
~Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects
~Multivessels approx. 250 subjects
~In stent restenosis approx. 100 subjects
~Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months"
16651099|NCT02273635|Experimental|andrographolides|Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.
16651100|NCT02273635|Placebo Comparator|sugar tablets|Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.
16651101|NCT02273622|Experimental|hydroxytyrosol 5 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
16651102|NCT02273622|Experimental|hydroxytyrosol 20 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
16651103|NCT02273622|Placebo Comparator|placebo|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
16651104|NCT02273596|Experimental|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.
~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period."
16651105|NCT02273583|Experimental|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
16651106|NCT02273583|No Intervention|Control|31 weeks of MAP.
16651107|NCT02273570|Active Comparator|control|Control group: standard care. The iPTH target in this group is 300-540 pg/ml
16651108|NCT02273570|Experimental|Optimal CKD-MBD control|Optimal CKD-MBD control: in this group the PTH target is150-300 pg/ml to be achieved with a therapeutic algorithm
16651109|NCT02273557|Experimental|Asasantin ER (new formulation I - low)|
16651110|NCT02273557|Experimental|Asasantin ER (new formulation III - medium)|
16651111|NCT02273557|Experimental|Asasantin ER (new formulation II - high)|
16651112|NCT02273557|Active Comparator|Asasantin ER (present commercial formulation)|
16651113|NCT02273544|Experimental|Asasantin ER (new formulation - low)|
16651114|NCT02273544|Experimental|Asasantin ER (new formulation - medium)|
16651115|NCT02273544|Experimental|Asasantin ER (new formulation- high)|
16651116|NCT02273544|Active Comparator|Asasantin ER - commercial formulation|
16651117|NCT02273531|Experimental|Asasantin ER, new formulation|
16651118|NCT02273531|Active Comparator|Asasantin ER, present commercial formulation|
16651119|NCT02273518|Experimental|Asasantin ER, new formulation I|
16651120|NCT02273518|Experimental|Asasantin ER, new formulation II|
16651121|NCT02273518|Active Comparator|Asasantin ER, present commercial formulation|
16651122|NCT02273505|Experimental|Asasantin (ER)|
16651123|NCT02273505|Active Comparator|Combination of Persantin and ASA|
16651124|NCT02273492|Experimental|Asasantin ER after a standardized breakfast|
16651143|NCT02273375|Experimental|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
16651144|NCT02273375|Placebo Comparator|Placebo|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
16651145|NCT02273362|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
16651146|NCT02273349|Experimental|Treatment|Patients with Alpha-1-Antitrypsin deficiency treated with endoscopic lung volume reduction using Lung Volume Reduction Coils (PneumRx Inc.)
16651147|NCT02273336||Ancillary-Correlative (comprehensive genomic analysis)|Tissue and blood samples are analyzed via next generation sequencing and whole exome sequencing.
16651148|NCT02273323|Experimental|Tea|Black tea
16651149|NCT02273323|Placebo Comparator|Placebo|Placebo
16651150|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
16651151|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
16651152|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
16651153|NCT02273284|Experimental|Buzzy|Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
16651154|NCT02273284|No Intervention|control - no Buzzy|Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy
16651155|NCT02273271|Experimental|Imaging arm|18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
16651156|NCT02273258|Experimental|Test (T)|SAR342434: single dose injection
16651157|NCT02273258|Active Comparator|Reference 1 (R1)|US-approved Humalog®: single dose injection
16651158|NCT02273258|Active Comparator|Reference 2 (R2)|EU-approved Humalog®: single dose injection
16651159|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age>18) patients presenting with symptoms of AAS.
16651160|NCT02273232|Active Comparator|Supervised Exercise Group|All PVD patients will get the standard advice regarding exercises but this group will have a constructed exercise program under supervision of Dr. Micheál Newell who is qualified Sports and Exercise Scientist with a Doctorate degree in Integrated Biology. This include six minute walk test, Chair Stand Test and symptoms free distance.
16651161|NCT02273232|Active Comparator|RIPC and supervised Exercise Group|This group will have structured intermitting periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be applied for 5 minutes alternatively with 5 minutes rest to the total of 4 cycles, which needs 40 minutes per day. The RIPC group will receive an exercise program identical to the first group. The total number of days for each participant will be 28 days.
16651162|NCT02273232|Active Comparator|RIPC with Standard Care Group|The patients in this group will receive standard care advice regarding exercise in addition to RIPC as in the 2nd group.
16651163|NCT02273232|Sham Comparator|Control Group (Standard Care)|This group will get the standard advice regarding exercise for PVD patients and all the information available in Out patients clinic settings.
16651164|NCT02273219|Experimental|AEB071 and BYL719|AEB071, oral, 100-400 mg twice daily BYL719, oral, 200-350 mg daily
16651165|NCT02273206|Active Comparator|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
16651166|NCT02273206|Experimental|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.
~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
16651167|NCT02273193||Pregnant Women|Pregnant Women in the first trimester (<13 weeks) of pregnancy and the second trimester of pregnancy.
16651168|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
16651169|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
16651170|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
16651171|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
16651172|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
16651173|NCT02273154|Experimental|paroxetine and buspirone group|receive paroxetine (20-60mg/d) and buspirone(30mg/d)
16651174|NCT02273154|Active Comparator|paroxetine group|receive paroxetine (20-60mg/d)
16651175|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
16651176|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
16651177|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD>-2.5) and Chronic Periodontitis (>3mm Pocket Probing Depth)
16651201|NCT02272959|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
16651202|NCT02272959|Placebo Comparator|Placebo Group|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
16651364|NCT02271958|Experimental|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
16651178|NCT02273115|Active Comparator|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
16651179|NCT02273115|Active Comparator|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
16651180|NCT02273115|Active Comparator|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
16651181|NCT02273115|Active Comparator|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
16651182|NCT02273102|Experimental|TCP Dose Level 1|20mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
16651183|NCT02273102|Experimental|TCP Dose Level 2|40mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
16651184|NCT02273102|Experimental|TCP Dose Level 3|60mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
16651185|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
16651186|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
16651187|NCT02273063|Experimental|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
16651188|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
16651189|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
16651190|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
16651191|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
16651192|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
16651193|NCT02273024|Experimental|Exercise|Individuals will participate in weekly supervised and unsupervised exercise sessions prior to HSCT, during hospitalization and till 100 days from HSCT. Exercise will consist of endurance and resistance exercise 3-5 days a week.
16651194|NCT02273024|No Intervention|Usual Care|Usual care will have continue with standard of care treatment without any specific exercise instruction or guidance other than what is provided by the patient education team at the cancer centre.
16651195|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
16651196|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
16651197|NCT02272998|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16651198|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
16651199|NCT02272972||Retrospective group|One x-ray image per patient is assessed by the surgeon. The surgeon undergoes an educational intervention (video/poster) and applies the achieved knowledge during the second assessment of the same image. The intervention is not administered to patients, only to an image.
16651200|NCT02272972||Prosp.group (Application of knowledge)|No direct intervention at the patient. The surgeon applies the achieved knowledge during the performance of the fluoroscopy in the operating room. This image is assessed.
16653072|NCT02261116|Experimental|Telmisartan|
16651203|NCT02272946|Other|Safety Arm|In Stage 1: all 10 subjects will receive 150 mg Canakinumab subcutaneous injection. This will be a preliminary safety study (before Stage II).
16651204|NCT02272946|Experimental|Canakinumab|In Stage II: About 67 subjects will receive 150mg Canakinumab subcutaneous injection.
16651205|NCT02272946|Placebo Comparator|Placebo|In Stage II: About 33 subjects will receive 150mg placebo subcutaneous injection
16651206|NCT02272933|Experimental|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
16651207|NCT02272920|Experimental|Renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation: Medtronic Symplicity Flex, Medtronic Symplicity Spyral or St Jude EnligHTN.
~Renal denervation is performed within seven days after PCI in patients with acute myocardial infarction and hypertension."
16651208|NCT02272920|No Intervention|Control: Standard of care|Standard-of-care follow-up after ACS. Including nurse and physician out-patient visits.
16651209|NCT02272907|Experimental|Non-buttressed, non-imbricated oversewing|Along the staple line, the surgical attending will oversew the length of the staple line using a 2-0 Vicryl suture in a continuous fashion.
16651210|NCT02272907|Experimental|Non-buttressed, imbricated suture line|Along the staple line, the surgical attending will oversew the staple line using a 2-0 Vicryl suture in a continuous, imbricating fashion.
16651211|NCT02272907|Experimental|Buttressed stapling|"The specimen will be stapled utilizing the same stapling device, with Seamguard applied as a buttress. We will use the standard methodology to apply Seamguard as illustrated in the company's Instructions for Use."
16651212|NCT02272907|Active Comparator|No reinforcement|Data will be collected on staple lines without any reinforcement as a baseline for leak pressure.
16651213|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
16651214|NCT02272894||Group B|D2 Radical Gastrectomy
16651215|NCT02272881|Experimental|immediate surgical intervention|immediate surgical reconstruction of the pressure ulcer via flap closure or comparable procedure
16651216|NCT02272881|Other|wound care|conservative wound management directed by certified wound care experts
16651217|NCT02272868|Experimental|Fecal microbiome transplant|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Fecal Microbial Transplant
16651218|NCT02272868|Placebo Comparator|Normal saline|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Normal saline
16651219|NCT02272855|Experimental|HF10 plus ipilimumab|
16651220|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
16651221|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
16651222|NCT02272829|Active Comparator|Active|Participants in this arm will receive the study intervention (sessions with the BHC and the PCP).
16651223|NCT02272829|Placebo Comparator|Health Education|Participants in this arm will receive study sessions about various health topics.
16651224|NCT02272816|Experimental|Carboplatin AUC-10|
16651225|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide
~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Drug: Dexamethasone
~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Biological: Elotuzumab (BMS-901608)
~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
16651226|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide
~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Drug: Dexamethasone
~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
16651227|NCT02272790|Experimental|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
16651228|NCT02272790|Experimental|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
16651229|NCT02272790|Experimental|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.
~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
16651230|NCT02272790|Experimental|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
16651231|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
16651232|NCT02272777|Experimental|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
16651233|NCT02272764|Other|Itraconazole|Itraconazole or placebo
16651235|NCT02272751|Experimental|Exercise Intervention|"Subjects allocated to the Exercise arm will aim to undertake a personal prescribed home exercise programme for half an hour three times a week.
~Exercises will be progressed at 6 weeks as subjects progress. All exercise sessions will be documented in the logbooks provided.
~Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
16651236|NCT02272751|Experimental|Relaxation Intervention|"Subjects allocated to the Relaxation arm will aim to undertake a guided relaxation programme on a CD for half an hour three times a week.
~All relaxation sessions will be documented in the logbooks provided. Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
16651237|NCT02272738|Experimental|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.
~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.
~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.
~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
16651238|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
16651239|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
16651240|NCT02272712|Experimental|Cognitive Behavioural Therapy|A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
16651241|NCT02272712|No Intervention|Control Condition|The online attention matched control arm will provide education about sleep without any focus on the active ingredients that constitute the intervention group.
16651242|NCT02272699|Experimental|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.
~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.
~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
16651243|NCT02272699|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
16651244|NCT02272699|Active Comparator|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
16651245|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
16651246|NCT02272660|Experimental|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
16651247|NCT02272660|Placebo Comparator|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
16651248|NCT02272647|Experimental|IM Plac - Oral Plac - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
16651249|NCT02272647|Experimental|IM Plac - Oral Prog - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
16651250|NCT02272647|Experimental|IM E2 - Oral Plac - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)
16651251|NCT02272647|Experimental|IM E2 - Oral Prog - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
16651252|NCT02272634|Experimental|Treatment A|Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
16651253|NCT02272634|Experimental|Treatment B|Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
16651254|NCT02272634|Placebo Comparator|Treatment C|Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
16651255|NCT02272621|Experimental|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
16651256|NCT02272621|Experimental|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
16651257|NCT02272608||control|patients WHO do not have sleep apnea
16651258|NCT02272608||mild OSAS|mild apnea patients (AHI: 5-15)
16651259|NCT02272608||moderate OSAS|moderate apnea patients (AHI: 16-30)
16651260|NCT02272608||severe OSAS|severe OSAS patients (AHI: more than 30)
16651261|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
16651262|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
16651263|NCT02272582|Experimental|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
16651365|NCT02271958|Experimental|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
16651264|NCT02272582|Active Comparator|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
16651265|NCT02272569|Experimental|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space
16651266|NCT02272556|Active Comparator|Subjects with Type 2 Diabetes|Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination
16651267|NCT02272556|Active Comparator|Non-Diabetic Obese|Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals
16651268|NCT02272556|Active Comparator|Lean, healthy control subjects|Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)
16651269|NCT02272543|Active Comparator|Fish surimi peptide powder|Fish surimi peptide powder
16651270|NCT02272543|Placebo Comparator|Placebo|Placebo
16651271|NCT02272530||Healthy|100 healthy volunteers in age of 20-75 years
16651272|NCT02272530||Patients|100 patients with stable coronary artery disease and accordingly endothelial dysfunction
16651273|NCT02272517|Active Comparator|Escitalopram 10-20 mg|Encapsulated tablets once daily for 8 weeks
16651274|NCT02272517|Experimental|Vortioxetine 10-20 mg|Encapsulated tablets once daily for 8 weeks
16651275|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
16651276|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
16651277|NCT02272491|Experimental|ZrO2|"Straumann CARES Variobase Abutment RN
~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
16651278|NCT02272491|Active Comparator|PFM crown|Straumann Gold Abutment RN Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
16651279|NCT02272478|Active Comparator|Arm A|"Patients not known adverse karyotype
~Randomise between
~Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy
~Versus
~CPX-351 100 units/m2 on days 1, 3 and 5"
16651280|NCT02272478|Active Comparator|Arm B|"Patients with known adverse karyotype
~5 cycles of Vosaroxin and Decitabine therapy"
16651281|NCT02272478|Active Comparator|Arm C|"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1
~Randomise between
~Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)
~Versus
~Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive
~Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive
~Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)
~And Randomisation to receive AC220 or not"
16651282|NCT02272478|Active Comparator|Arm D|"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1
~Randomisation to receive AC220 or not"
16651283|NCT02272478|Active Comparator|Arm E|"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1
~Randomisation between
~CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)"
16651284|NCT02272478|Active Comparator|Arm F|"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1
~Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)
~versus
~Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)"
16651285|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
16651286|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
16651287|NCT02272439||Unexplained (male)|Men of couples with a diagnosis of Unexplained infertility (n=15)
16651288|NCT02272439||Unexplained (female)|Women of couples with a diagnosis of Unexplained infertility (n=15)
16651289|NCT02272439||male factor (male)|Men of couples with a diagnosis of male factor infertility (n=15)
16651290|NCT02272439||male factor (female/control)|Women of couples with a diagnosis of male factor infertility (n=15)
16651291|NCT02272439||PCOS (female)|Women of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
16651292|NCT02272439||PCOS (male/control)|Men of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
16651293|NCT02272439||healthy volunteer (male/control)|Men with a history of no reproductive dysfunction and proven fertility (n=15)
16651294|NCT02272439||healthy volunteer (female/control)|Women with a history of no reproductive dysfunction and proven fertility (n=15)
16651295|NCT02272426|Experimental|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
16651296|NCT02272426|Sham Comparator|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
16651297|NCT02272413|Experimental|BI 695502|
16651298|NCT02272413|Active Comparator|Avastin|
16651366|NCT02271958|Experimental|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
16651299|NCT02272400|Experimental|IGRT of prone partial breast|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy.
16651300|NCT02272387|Active Comparator|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
16651301|NCT02272387|Placebo Comparator|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
16651302|NCT02272374|Experimental|e-AVF group|120 elderly with end stage renal disease will undergo AVF creation.
16651303|NCT02272374|Experimental|e-TCC group|120 elderly with end stage renal disease will undergo TCC placement.
16651304|NCT02272374|Experimental|e-AVG group|60 elderly with end stage renal disease will undergo AVG creation.
16651305|NCT02272374|Experimental|ve-AVF group|80 very elderly with end stage renal disease will undergo AVF creation.
16651306|NCT02272374|Experimental|ve-TCC group|80 very elderly with end stage renal disease will undergo TCC placement.
16651307|NCT02272374|Experimental|ve-AVG group|40 very elderly with end stage renal disease will undergo AVG creation.
16651308|NCT02272361|Other|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
16651309|NCT02272361|Other|vaginal mesh surgery|vaginal mesh surgery
16651310|NCT02272348|Experimental|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
16651311|NCT02272348|Other|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
16651312|NCT02272335|Experimental|CB Stress Management|The Cognitive-Behavioral Stress Management (CBSM) intervention arm is a closed, structured group intervention that offers 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the Cancer Wellness and Education (CW) condition as well. i.e. Group Sessions
16651313|NCT02272335|Active Comparator|Cancer Wellness (CW)|Enhanced Breast Cancer Wellness and Education (CW). The CW condition consists of 10 weekly sessions that are roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain (e.g., National Cancer Institute, Susan G. Komen Foundation, American Cancer Society).i.e. Group Sessions
16651314|NCT02272309|Experimental|Healthy volunteers|Healthy volunteers
16651315|NCT02272309|Experimental|Patients with LUTS|Patients with LUTS
16651316|NCT02272309|Experimental|Patients with LUTS and treatment|Patients with LUTS and treatment
16651317|NCT02272296|Active Comparator|Jet Injector_main study|Administration of insulin or placebo injection in main study
16651318|NCT02272296|Placebo Comparator|conventional pen, NovoPen IV|Administration of insulin or placebo injection in main study
16651319|NCT02272296|Active Comparator|jet injector_sub study|Administration of insulin or placebo injection in sub study
16651320|NCT02272283|Active Comparator|Angio-guided PCI|"Patients allocated to angio-guided PCI are having Percutaneous Coronary Intervention (PCI) with stent implantation guided by routine angiography alone.
~Documentary (comparator) intravascular imaging with Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) is performed. The PCI-operator is blinded to the image aquisitions, and the analysis is performed offline later."
16651321|NCT02272283|Experimental|OCT-guided PCI|"After obtaining an angiographic optimal result, patients allocated to OCT-guided PCI have guiding Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) performed. Online image interpretation is performed by a dedicated OCT-analyst and the PCI-operator. If the OCT reveals; 1) under expansion of the stent with a minimal stent area (MSA) <90% of the distal/proximal reference vessel lumen area and/or; 2) significant acute incomplete stent apposition (defined as more than or equal to 3 stent struts detached >140 microns from the underlying vessel wall), and/or; 3) edge dissection(s) causing significant reduction in minimal lumen area(s) (MLA <4 mm2) and/or, 4) significant residual stenosis (MLA <4 mm2) at the proximal and/or distal reference segment(s), additional intervention is encouraged. The degree of optimization based upon OCT findings is left to the judgement of the PCI-operator."
16651322|NCT02272270|Experimental|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID
~Followed by 28 day break followed by
~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles
~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:
~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
16651323|NCT02272257|Experimental|Early Direct Access Physical Therapy|All care will be administered by one or more physical therapists employed by Temple University. This arm will be early, direct access, physical therapy (immediately evaluation following contacting the front desk administrator or reporting a work injury). Intervention will include interventions matched to their stratified risk category incorporating biopsychosocially oriented education, therapeutic exercise, and manual therapy tailored to the patient's needs.
16651324|NCT02272257|Active Comparator|Physician management|All usual care by physician will be administered by one or more employee health physicians employed by Temple University. Recommendations may or may not include referral to physical therapy.
16651325|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
16651367|NCT02271958|Experimental|Group 4|Oral administration of mifepristone placebo daily for 3 months
16651812|NCT02269072|Placebo Comparator|Placebo|Identical placebo cream applied daily
16651326|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
16651327|NCT02272218|Other|LAGB|There is only one arm for this study, since this study involves a single cohort receiving the same intervention, laparoscopic gastric banding (LAGB) surgery.
16651328|NCT02272192|Experimental|ESDM15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
16651329|NCT02272192|Experimental|ESDM 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
16651330|NCT02272192|Experimental|EIBI 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using Early Intensive Behavioral Intervention (EIBI) and following the Manual A Work in Progress"
16651331|NCT02272192|Experimental|EIBI 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using EIBI and following the Manual A Work in Progress"
16651332|NCT02272179|Experimental|ASAP Treatment and Brite|Participants in the experimental arm received the ASAP treatment, during their transition from inpatient to outpatient care, as well as the Brite app for distress tolerance/emotion regulation and safety planning.
16651333|NCT02272179|Active Comparator|Treatment as Usual|Participants in this grouping were studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants completed paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
16651334|NCT02272166|Active Comparator|propofol|Hypnotic used in this arm is exclusively intra-venous propofol.
16651335|NCT02272166|Active Comparator|sevoflurane|Hypnotic used in this arm is exclusively inhaled sevoflurane.
16651336|NCT02272153|Active Comparator|Egg refined grain|Eggs with white toast
16651337|NCT02272153|Active Comparator|Egg whole grain|Eggs with whole grain toast
16651338|NCT02272153|Active Comparator|Cereal Refined grain|rice cereal with white toast
16651339|NCT02272127|Experimental|intercalated treatment|Patients will receive 4 cycles treatment: chemotherapy(day 1) plus intercalated icotinib(day 8-21) every 3 weeks, and then oral icotinib continuously for 2 years or until disease progression or unacceptable toxic effects
16651340|NCT02272101|Experimental|Vitamin D|Vitamin D 4,000 I.U. orally
16651341|NCT02272101|Placebo Comparator|Placebo|Placebo orally
16651342|NCT02272088|Experimental|physical activity-moderate|participants will be walking during 60 minutes in a moderate pace
16651343|NCT02272088|Experimental|intense physical activity|participants will be running during 60 minutes in na intense pace.
16651344|NCT02272075|No Intervention|mobile colposcope|
16651345|NCT02272062|No Intervention|Preferences Not Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, but these preferences will NOT be shared with the treating clinicians.
16651346|NCT02272062|Experimental|Preferences Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, and these preferences WILL be shared with the treating clinicians.
16651347|NCT02272049|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
16651348|NCT02272036|Active Comparator|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
16651349|NCT02272036|Active Comparator|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
16651350|NCT02272023|Experimental|9 sessions of Intensive Motivational Interviewing|Experimental condition will consist of 9 1-hour intensive motivational interviewing sessions.
16651351|NCT02272023|Active Comparator|1 Standard Motivational Interview plus 8 nutrition classes|The standard MI intervention will consist of a commonly used, single session of MI (50 minutes) plus 8 hours of nutrition education to achieve time and attention equivalence of study conditions.
16651352|NCT02272010|Experimental|Experimental diet|Altered n-6 and n-3 fatty acid intake.
16651353|NCT02272010|Active Comparator|Comparator Diet|Diet standardized to usual n-6 and n-3 intake.
16651354|NCT02271997|Active Comparator|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
16651355|NCT02271997|Active Comparator|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
16651356|NCT02271997|Active Comparator|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
16651357|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
16651358|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
16651359|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
16651360|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
16651361|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
16651362|NCT02271971|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
16651363|NCT02271971|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.
16653073|NCT02261116|Active Comparator|Candesartan|
16651368|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
16651369|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
16651370|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
16651371|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
16651372|NCT02271919|Experimental|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
16651373|NCT02271919|Placebo Comparator|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
16651374|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
16651375|NCT02271893|Experimental|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
16651376|NCT02271893|Placebo Comparator|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
16651377|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
16651378|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
16651379|NCT02271867|Active Comparator|Levobupivacaine 0,5%|Levobupivacaine 0,5% 15 ml once
16651380|NCT02271867|Active Comparator|Levobupivacaine 0,5% with epinephrine|Levobupivacaine 0,5% with 1/200000 epinephrine 15 ml once
16651381|NCT02271867|Active Comparator|Ropivacaine 0,75%|Ropivacaine 0,75% 15 ml once
16651382|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
16651383|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
16651384|NCT02271841||Before introduction of PVI|Physicians' practices
16651385|NCT02271841||After introduction of PVI|Physicians' practices
16651386|NCT02271828|Active Comparator|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
16651387|NCT02271828|No Intervention|No sentinel lymph node procedure|No sentinel lymph node procedure
16651388|NCT02271815||Oral Hygiene|Oral Hygiene
16651389|NCT02271802|Experimental|Butyrate|Enema containing sodium butyrate
16651390|NCT02271802|Placebo Comparator|Placebo|Enema containing NaCl
16651391|NCT02271776|Active Comparator|Galactooligosaccharide|5g 3x per day for 12 weeks
16651392|NCT02271776|Placebo Comparator|maltodextrin|3x per day for 12 weeks (isocaloric to intervention)
16651393|NCT02271763|Active Comparator|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
16651394|NCT02271763|Experimental|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
16651395|NCT02271750||Dementia|
16651396|NCT02271750||controls|
16651397|NCT02271737|Experimental|Experimental|Improve infection control in health centers; improve home hygiene; improve newborn danger signs recognition by the HC staff, VHSG, and mothers; and improve care coordination between community and health facilities. The above improvements will be through the training of health center staff and VHSG; HC staff and VHSG provide health education to mothers at the health centers and at home respectively; and provide supportive supervision to both HC and VHSG. VHSG will conduct three home visits to the mothers/newborns on the first 24 hours, the 3rd day, and the 7th day after delivery.
16651398|NCT02271737|No Intervention|No Intervention|We do not make any interventions.
16651399|NCT02271724||CIDP/MMN newly diagnosed (drug naive)|"Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients.
~Lumbar puncture Blood sample"
16651400|NCT02271724||CIDP/MMN treated|"All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital.
~We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital."
16651401|NCT02271724||Other peripheral neuropathies|Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
16651402|NCT02271724||Syptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls
16651470|NCT02271308|No Intervention|Control group|Residents in control group will receive regular activity in nursing homes.
16651403|NCT02271711|Experimental|Treatment (autologous ex vivo-expanded NK cells)|Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
16651404|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
16651405|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
16651406|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
16651407|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
16651408|NCT02271685|Experimental|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
16651409|NCT02271685|Experimental|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
16651410|NCT02271685|Experimental|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
16651411|NCT02271685|Experimental|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
16651412|NCT02271672|Experimental|XP1000 RF group|Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
16651413|NCT02271672|Sham Comparator|Sham group|Subjects in the Sham group will be treated with the sham XP1000 RF device.
16651414|NCT02271659|Experimental|Brachytherapy boost|Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique
16651415|NCT02271659|Active Comparator|Exclusive external beam irradiation|Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
16651416|NCT02271646|Experimental|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
16651417|NCT02271633|Active Comparator|Sodium nitrate|Dietary supplement: 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
16651418|NCT02271633|Active Comparator|Beetroot juice|Dietary supplement: 800 mg of nitrate in concentrated beetroot juice (Beet-IT)
16651419|NCT02271633|Active Comparator|Spinach|Dietary supplement: 800 mg of nitrate in a spinach based beverage
16651420|NCT02271633|Active Comparator|Rocket salad|Dietary supplement: 800 mg of nitrate in a rocket salad based beverage
16651421|NCT02271620|Other|nonallergic rhinitis|nonallergic rhinitis nasal allergen provocation test
16651422|NCT02271607|Experimental|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
16651423|NCT02271607|No Intervention|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
16651424|NCT02271594|Active Comparator|Intervention|Intensive education on injection technique
16651425|NCT02271594|Placebo Comparator|Control|Standard education on injection technique
16651426|NCT02271568||Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
16651427|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
16651428|NCT02271555|Active Comparator|sevoflurane-remifentanil (Group SR)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
16651429|NCT02271555|Placebo Comparator|sevoflurane-saline (Group SS)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.
16651430|NCT02271542|Experimental|between 1-10 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
16651431|NCT02271542|Experimental|under 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
16651432|NCT02271542|Experimental|upper 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
16651433|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
16651434|NCT02271516|Experimental|188Re-BMEDA-liposome|"Stage I:
~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose
~Stage II:
~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)
~0.42±0.04 mCi/kg
~0.63±0.06 mCi/kg
~0.84±0.08 mCi/kg
~1.05±0.11 mCi/kg
~1.26±0.13 mCi/kg
~1.47±0.15 mCi/kg"
16651435|NCT02271503|Other|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
16651436|NCT02271503|Other|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
16651437|NCT02271503|Other|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
16651438|NCT02271490|Active Comparator|micoinjection according to classical protocole|incubation of sperm in incubation medium
16651439|NCT02271490|Experimental|incubation in follicular fluid|incubation of sperm in follicular fluid prior to microinjection
16651440|NCT02271477|No Intervention|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
16651441|NCT02271477|Experimental|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
16651442|NCT02271464|Experimental|Maintenance:BEVACIZUMAB|Induction: FOLFOXIRI; Manteinance: Bevacizumab
16651443|NCT02271464|Experimental|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Induction: FOLFOXIRI; Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE(Metronomic Chemotherapy)
16651444|NCT02271451|Experimental|Q collar|subjects wearing the q collar
16651445|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
16651446|NCT02271438|Experimental|Part 1: Ibrutinib 840 milligram (mg)|Participants will receive ibrutinib 840 mg (6*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.
16651447|NCT02271438|Experimental|Part 1: Ibrutinib 1680 mg|Participants will receive ibrutinib 1680 mg (12*140 mg capsules) on Day 1 of Part 1, Period 2.
16651448|NCT02271438|Experimental|Part 2: Treatment A|Participants will receive ibrutinib, 1680 mg (12*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.
16651449|NCT02271438|Experimental|Part 2: Treatment B|Participants will receive ibrutinib, 840 mg (6*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.
16651450|NCT02271438|Experimental|Part 2: Treatment C|Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.
16651451|NCT02271438|Experimental|Part 2: Treatment D|Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.
16651452|NCT02271425|Experimental|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)[¹³C₈] evacetrapib administered over a 4 hour infusion.
16651453|NCT02271412|Experimental|LY03005|LY03005 40, 80, 120, or 160 mg
16651454|NCT02271412|Placebo Comparator|Placebo|Placebo at 40, 80, 120, or 160 mg
16651455|NCT02271399|Active Comparator|acetylsalicylic acid|aspirin 300mg tablet by mouth, every 24 hours for postoperatively 10 days
16651456|NCT02271399|Experimental|rivaroxaban|xarelto 10mg tablet by mouth, every 24 hours for postoperatively 10 days
16651457|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
16651458|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
16651459|NCT02271373|Experimental|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
16651460|NCT02271373|No Intervention|control group|The control school did not have any interventions.
16651461|NCT02271360|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
16651462|NCT02271360|Active Comparator|group B|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat day of HCG injection and for 8 days .
16651463|NCT02271347|Experimental|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
16651464|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
16651465|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
16651466|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
16651467|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
16651468|NCT02271321|No Intervention|control group|The control group will receive usual care
16651469|NCT02271321|Experimental|experimental group|The experimental group will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
16651471|NCT02271308|Experimental|Experimental group|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
16651472|NCT02271295|Experimental|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
16651473|NCT02271295|No Intervention|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
16651474|NCT02271282|Experimental|Oral Toremifene/Oral Placebo|"Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.
~After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
16651475|NCT02271282|Experimental|Oral Placebo/Oral Toremifene|"Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.
~After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
16651476|NCT02271269|No Intervention|Usual Care (UC)|"Patients receiving Usual Care for Glaucoma comprising:
~Education on effective glaucoma treatment
~Routine check-ups with an ophthalmologist and prescription of glaucoma eye drops
~Glaucoma counselling [Can be recommended by ophthalmologist for non-adherent patients] covering:
~Glaucoma risk factors and symptoms
~Management and treatment
~Medications and optimal dosage windows
~Risks of medication non-adherence
~Formulation of a dosing schedule that compliments each patient's lifestyle"
16651477|NCT02271269|Experimental|Value Pricing (VP)|Patient receiving Usual Care for Glaucoma and given the opportunity to receive Value Pricing Subsidies.
16651478|NCT02271256|Experimental|Functional intimate apparel|A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
16651479|NCT02271256|No Intervention|Control|Monitoring and observation will be provided during the 6-9 months wearing period.
16651480|NCT02271243||Subject with suspected MBI|
16651481|NCT02271243||Subjects without suspected MBI|
16651482|NCT02271230|Experimental|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
16651483|NCT02271230|Placebo Comparator|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
16651484|NCT02271230|Experimental|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
16651485|NCT02271230|Placebo Comparator|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
16651486|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
16651487|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
16651488|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
16651489|NCT02271191|Active Comparator|Nicardipine and Remifentanil|intravenous nicardipine and remifentanil during deliberate hypotension
16651490|NCT02271191|Placebo Comparator|Remifentanil|intravenous remifentanil during deliberate hypotension
16651491|NCT02271178|Experimental|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
16651492|NCT02271178|Other|Conventional treatment|Usual therapy
16651493|NCT02271165|Active Comparator|IVIg naive|Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
16651494|NCT02271165|Active Comparator|non-IVIg naive|Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
16651495|NCT02271152|Experimental|FAST ablation + PVI|FAST mapping and ablation will be performed in addition to PVI
16651496|NCT02271152|Active Comparator|PVI|Pulnonary vein isolation will be performed
16651497|NCT02271126|Experimental|TEG|TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG. Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
16651498|NCT02271126|Active Comparator|APTT|APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
16651499|NCT02271113|Experimental|GMI-1271|IV GMI-1271
16651500|NCT02271113|Placebo Comparator|Placebo|IV Placebo
16651501|NCT02271113|Active Comparator|Enoxaparin Sodium (Lovenox®)|SC Lovenox®
16651502|NCT02271100|Placebo Comparator|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
16651503|NCT02271100|Active Comparator|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
16651527|NCT02270957|Placebo Comparator|Placebo|Patients receive placebo instead of Abatacept in a double blind fashion. Otherwise participation is the same, including that at the time of treatment failure they may elect any standard of care treatment and/or to begin taking open label abatacept but this rescue will define non-response in the primary endpoint at six months.
16651504|NCT02271074|No Intervention|Standard of Care|The role of this arm is to provide a baseline measure that can be used to assess the effectiveness of the combination interventions in improving the proportion of individuals entering care within 3 months. Participants in this arm only receive standard post-test counselling after they are issued with a positive HIV result. They are counselled on possible emotional resources, and given information on how to reduce risk of HIV transmission, ongoing positive living, nutrition and healthy lifestyles. These clients are given referral letters and referred to health facilities of their choice that offer HIV care/treatment. They are then followed up at the designated study time points to ascertain entry into care.
16651505|NCT02271074|Experimental|Point of care CD4 testing|Participants in this arm will receive point of care (POC) cluster differentiation 4 (CD4) testing using the PIMA™ CD4 test system.
16651506|NCT02271074|Experimental|Care facilitation|Participants receive a combination of POC CD4 testing and care facilitation.
16651507|NCT02271074|Experimental|Transport support|Participants receive a combination of POC CD4 testing and transport support.
16651508|NCT02271061|Experimental|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
16651509|NCT02271061|Sham Comparator|Control tape|Apply tape in same technique without tension.
16651510|NCT02271048|Experimental|Group I|"The raters in this group one firstly review ultrasound images numbered from one to 50 using LCD monitor of ultrasound machine and after mandatory rests of 20 minutes, review the remaining ultrasound examinations numbered from 51 to 100 using iPhone display with CubeView at their first visit.(Remote ultrasonography interpretation using the smartphone)
~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
16651511|NCT02271048|Experimental|Group II|"The raters in this group II firstly review the ultrasound images numbered from one to 50 using iPhone with CubeView (Remote ultrasonography interpretation using the smartphone) and 51 to 100 with the LCD monitor.
~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
16651512|NCT02271035|Active Comparator|Deflux|In each patient, Deflux will be injected into one of the ureteral orifices using the the HIT technique.
16651513|NCT02271035|Active Comparator|Vantris|Vantris will be injected into the other ureteral orifice using the same technique and the same amount of implant.
16651514|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
16651515|NCT02271009|Placebo Comparator|Placebo without Al(OH)3|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
16651516|NCT02271009|Active Comparator|AllerT (10 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
16651517|NCT02271009|Active Comparator|AllerT (25 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
16651518|NCT02271009|Active Comparator|AllerT (50 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
16651519|NCT02270996||NO Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) BEFORE the implementation of the Antimicrobial Stewardship Program.
16651520|NCT02270996||WITH Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) WITH the implementation of the Antimicrobial Stewardship Program.
16651521|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
16651522|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
16651523|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
16651524|NCT02270970|Active Comparator|Responders to Belimumab|This Arm is defined as patients who complete 6 months of belimumab without and meet the primary endpoint
16651525|NCT02270970|Active Comparator|Non Responders to Belimumab|This Arm is defined as patients who complete 6 months of study and do not meet the primary endpoint
16651526|NCT02270957|Active Comparator|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
16653074|NCT02261116|Placebo Comparator|Placebo|
16651528|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
16651529|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
16651530|NCT02270918|Active Comparator|Apixaban with Kcentra|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
16651531|NCT02270918|Placebo Comparator|Apixaban with placebo|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline
16651532|NCT02270905|Experimental|dCELL® Meniscus|
16651533|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
16651534|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
16651535|NCT02270879||Main group|Patients having performed bilateral consecutive cataract surgery between 1st October 2012 and 24th April 2014 in a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal).
16651536|NCT02270866|Experimental|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
16651537|NCT02270853|Other|sleep apnea screening with ApneaLinkTM|This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
16651538|NCT02270840||CRT-D|Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.
16651539|NCT02270840||Only ICD|"In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.
~Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only)."
16651540|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:
~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by
~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by
~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle
~Cisplatin or carboplatin may be given at the discretion of the investigator.
~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:
~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle
~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
16651541|NCT02270801|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
16651542|NCT02270788|Experimental|Study Participants|"All participants who consent and are enrolled on the study.
~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
16651543|NCT02270775||Fibromyalgia Patients|"The central Sensitization questionnaire will be filled in by each patients included.
~After One week, patients will filled it the questionnaire again to study the reliability."
16651544|NCT02270775||Ankle sprain Patients|The central Sensitization questionnaire will be filled in by each patients included.
16651545|NCT02270775||Healthy Volunteers|"The central Sensitization questionnaire will be filled in by each volunteer included.
~After One week, volunteers will filled it the questionnaire again to study the reliability."
16651546|NCT02270762|Experimental|1) Rest in bed|First evaluation of EIT with patient in bed at 30º of head inclination during 5 minutes.
16651547|NCT02270762|Experimental|2) Passive Verticalization|Second evaluation of EIT with patient in tilt table at 60º of verticalization during 10 minutes.
16651548|NCT02270762|Experimental|3) Rest in bed|Last evaluation of EIT with patient in bed at 30º of head inclination during 20 minutes.
16651549|NCT02270749|Active Comparator|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
16651550|NCT02270749|Active Comparator|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
16651551|NCT02270736|Experimental|Double-blind MP: Placebo (Age 6 to 17 Years)|Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.
16651552|NCT02270736|Experimental|Double-blind, MP: NT 201 (Age 6 to 17 Years)|Participants will receive NT 201 (up to 2.5 Units per kilogram [U/kg] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
16651553|NCT02270736|Experimental|Open-label, MP: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
16651554|NCT02270736|Experimental|OLEX: NT 201 (Age 6 to 17 Years)|"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms Double-blind, MP: placebo (age 6 to 17 years) and Double-blind, MP: NT 201 (age 6 to 17 years)."
16651555|NCT02270736|Experimental|OLEX: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).
16651556|NCT02270723|Active Comparator|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
16651557|NCT02270723|Placebo Comparator|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
16651558|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
16651559|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
16651560|NCT02270697||Regular Diagnosis|Difficult in regular diagnosis specimens, assistance with array.
16651561|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
16651562|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
16651563|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
16651564|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
16651565|NCT02270658|Experimental|Continuous positive airway pressure|Continuous positive airway pressure therapy (CPAP)
16651566|NCT02270658|Placebo Comparator|Nasal strips|Nasal strips applied to the outside surface of the nose with adhesive.
16651567|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.
~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.
~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
16651568|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.
~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.
~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
16651569|NCT02270632|Placebo Comparator|Arm 1|Placebo
16651570|NCT02270632|Experimental|Arm 2|F8IL10, 30 μg/kg
16651571|NCT02270632|Experimental|Arm 3|F8IL10, 160 μg/kg
16651572|NCT02270619|Placebo Comparator|Uninterrupted sleep & placebo|Uninterrupted sleep followed by placebo
16651573|NCT02270619|Experimental|Uninterrupted sleep & endotoxin|Uninterrupted sleep followed by endotoxin 0.8 ng/kg of body weight IV bolus
16651574|NCT02270619|Experimental|Partial sleep deprivation & placebo|Partial sleep deprivation followed by placebo
16651575|NCT02270619|Experimental|Partial sleep deprivation & endotoxin|Partial sleep deprivation followed by endotoxin 0.8 ng/kg of body weight IV bolus
16651576|NCT02270606|Experimental|Treatment(IMRT,fluorouracil,chemotherapy,surgery)|"CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours.
~PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity.
~SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery.
~POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity."
16651577|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
16651578|NCT02270580|Experimental|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
16651579|NCT02270580|Active Comparator|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
16651580|NCT02270554|Experimental|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
16651581|NCT02270541|No Intervention|Control|Standard pre-hospital emergency care by the Paramedic Intervention Team, in accordance with their standing operating procedures.
16651582|NCT02270541|Experimental|Telemedicine|In-ambulance teleconsultation by a stroke expert aiming to support the Paramedic Intervention Team by focusing on patient identification, obtaining homeostasis (optimal control of blood pressure, blood oxygenation, temperature, heart rate and rhythm, glycemia), assessment of the patient's neurological status, stroke diagnosis, hospital notification, and patient selection for specific stroke treatment.
16651583|NCT02270528|Experimental|HIT1|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. The second attempt, prior to the WCST, this group will perform a warm-up and 5-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
16655516|NCT02245464||Patients with essential hypertension|
16651584|NCT02270528|Experimental|HIT2|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and a 5-minute stationary period. The second attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
16651585|NCT02270528|Other|CON|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt and second attempt, prior to the WCST, this group will participate in a 15-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
16651586|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
16651587|NCT02270502||Adult patients on the SICU|Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
16651588|NCT02270489|Experimental|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
16651589|NCT02270489|Experimental|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
16651590|NCT02270489|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks
~1 administration 36 weeks after first injection"
16651591|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
16651592|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
16651593|NCT02270463|Experimental|SL-401|
16651594|NCT02270450|Experimental|Arm I (randomized to surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician.
16651595|NCT02270450|Experimental|Arm II (randomized to non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician.
16651596|NCT02270450|Experimental|Arm III (no randomization, surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician as in Arm I.
16651597|NCT02270450|Experimental|Arm IV (no randomization, non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician as in Arm II.
16651598|NCT02270437|Experimental|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
16651599|NCT02270437|No Intervention|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
16651600|NCT02270424|Experimental|Conventional medicine+ placebo TCM|Patients in this group will be given conventional medicine, Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three placebo TCM treatment, which are which are placebo Bufeijianpi granule, placebo Bufeiyishen granule and placebo Yiqizishen granule corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
16651601|NCT02270424|Experimental|conventional medicine+ TCM|Patients in this group will receive Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three types of TCM treatment, which are Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule. A herbal extract twice daily for 52 weeks for lower dosage. The three granules are corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
16651602|NCT02270411||Healthy Subjects|Healthy subjects.
16651603|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
16651604|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
16651605|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
16651606|NCT02270411||Psoriasis|Patient has a history of psoriasis for at least 6 months.
16651607|NCT02270411||Hidradenitis Suppurativa (HS)|Patient has a history of HS for at least 6 months.
16651608|NCT02270398|Experimental|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
16651609|NCT02270398|Active Comparator|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
16651610|NCT02270398|Active Comparator|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
16651611|NCT02270385|Experimental|Experimental group|The experimental group will be implemented a 16-week PU prevention programme. The PU prevention programme includes an intensive training on knowledge and skills ono PU prevention and also a PU prevention protocol. The purpose of the programme is to equip care staff with PU knowledge and skills and to guide especially health workers and personal care workers in PU prevention.
16651612|NCT02270385|Other|control group|The control group will be provided with the usual PU prevention care
16651613|NCT02270372|Experimental|Drug Combination|The drug combination of ONT-10 and varilumab
16651614|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
16652116|NCT02267005|Experimental|Treatment|patients on this arm will be treated with creapure supplements
16651615|NCT02270346|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device.
16651616|NCT02270346|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
16651617|NCT02270333|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
16651618|NCT02270333|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
16651619|NCT02270320|No Intervention|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
16651620|NCT02270320|Active Comparator|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
16651621|NCT02270307|Experimental|MSC+CY|Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery
16651622|NCT02270294|Experimental|Thai traditional massage|
16651623|NCT02270294|Sham Comparator|No massage|
16651624|NCT02270281|Other|Dexmedetomidine|Before dexmedetomidine infusion
16651625|NCT02270268|Experimental|pectin|a kind of soluble dietary fiber
16651626|NCT02270268|Placebo Comparator|Placebo|maltodextrin
16651627|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
16651628|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
16651629|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
16651630|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
16651631|NCT02270229||Healthcare providers|
16651632|NCT02270229||PD patients|
16651633|NCT02270229||Primary caregivers of the PD patients|
16651634|NCT02270229||Laboratory personnel|
16651635|NCT02270216|Active Comparator|elderly with isolated systolic hypertension|over 60 years of age with essential isolated systolic hypertension (stage I-II base on recommendation of JNC-VII) for the hypertension group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
16651636|NCT02270216|Active Comparator|healthy elderly|over 60 years of age with normal blood pressure in the healthy group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
16651637|NCT02270190|Other|tenesmus patients|Percutaneous Tibial Nerve Stimulation (PTNS) will be applied to all patients in the study
16651638|NCT02270177|No Intervention|Regular consultation|Regular headache consultations
16651639|NCT02270177|Other|Videoconsultation|Headache consultations through telemedicine technology
16651640|NCT02270164|Experimental|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
16651641|NCT02270164|Placebo Comparator|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
16651642|NCT02270151|Active Comparator|MyDiagnostick|Everyone aged 65 years or over, who visits the GP practice will be screened for AF with the MyDiagnostick. When the device indicates a positive result, the single lead ECG will be assessed to confirm/reject the diagnosis. Every new case of diagnosed AF will be evaluated for further treatment by the general practitioner.
16651643|NCT02270151|No Intervention|Control|Control arm will perform care as usual with selective screening by feeling the pulse.
16651644|NCT02270138|Experimental|Movement-to-music|Three movement-to-music video programs will be used by the participants. First and second videos last about 10 minutes including two songs and their movement preparation. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
16651645|NCT02270138|No Intervention|No movement-to-music|Another group will not receive movement-to-music video during intervention. However, their physical activity will be objectively measured as well.
16651646|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
16651647|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
16651648|NCT02270112||Paroxysmal Af|No Intervention is planned. All patients receive a 5 Minute ECG and have their pulse recordes by an iPhone.
16651649|NCT02270099||Subjects with suspected HSV Lesions|
16651650|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
16651651|NCT02270073|Experimental|TAU + mindfulness intervention|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together the brief intervention with mindfulness elements. Participants sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The text is standardized and spoken by Dr. Thomas Heidenreich. During the exercise, participants are instructed to observe their breathing and body sensations. After completion of the mindfulness intervention, the regular therapy session begins.
~Intervention: Cognitive behavior therapy of trainee therapists"
16651652|NCT02270073|Active Comparator|TAU + progressive muscle relaxation|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together a short version of progressive muscle relaxation (PMR). Both patient and therapist sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The PMR text is standardized and spoken by Dr. Thomas Heidenreich. Wording is as similar as possible to the mindfulness interventions.During the exercise, participants are instructed to tense and relax arms, face, body and legs. After completion of PMR, the regular therapy session begins.
~Intervention: Cognitive behavior therapy of trainee therapists"
16651682|NCT02269852|Experimental|trivalent seasonal influenza vaccine|"Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine
~60 infants: two-dose regimen with a 28-day interval;
~60 adults: single-dose regimen;
~60 seniors: single-dose regimen;"
16651653|NCT02270073|Other|Treatment as usual|"No specific intervention is conducted at the beginning of therapy sessions. Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions.
~Intervention: Cognitive behavior therapy of trainee therapists"
16651654|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
16651655|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
16651656|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
16651657|NCT02270047|Active Comparator|A|Orange nectar with NAXUS fibre, 5g/100mL
16651658|NCT02270047|Placebo Comparator|B|Orange nectar
16651659|NCT02270034|Experimental|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
16651660|NCT02270021|Experimental|Provider Mobile Application (ProvAPP)|Mobile phone application for providers.
16651661|NCT02270021|Experimental|ProvAPP + Patient Educational Tool (Tab)|Patient educational tool; plus the Mobile phone application for providers.
16651662|NCT02270021|No Intervention|ProvAPP Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
16651663|NCT02270021|No Intervention|ProvAPP+Tab Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
16651664|NCT02270008|Active Comparator|Pelvic floor training|The intervention group will undergo an in-person standardized training session by a trained nurse practitioner. The intervention is the pelvic floor training session. They will then be asked to continue muscle training at home at regular intervals and asked to log their exercises on a standardized exercise diary that is provided to them.
16651665|NCT02270008|No Intervention|Literature-only group|The literature-only group will receive a pamphlet with instructions for pelvic floor muscle exercises; however, no in-person training will be administered.
16651666|NCT02269995||E7040|
16651667|NCT02269982||men with mCRPC prior to enzalutamide/abiraterone|
16651668|NCT02269969|Experimental|Once daily aminoglycoside|Once daily dosing of Tobramycin
16651669|NCT02269956|Active Comparator|Intervention|The 2 NH's not used in the focus groups will receive the intervention, a 12-week feasibility study. At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for 3 meals over 2 days at baseline and again at week 6 and 12, and a medical record review will be conducted. After baseline data is collected, the training program will be delivered in 5 weekly modules with group coaching sessions completed the same week.
16651670|NCT02269956|No Intervention|Focus Groups|Year 1 focus groups will aim to identify how nursing staff feel about usual interventions for feeding behaviors of PWD and staff responses when a PWD displays difficult eating behaviors. Year 2 focus groups will evaluate the revised dementia feeding skills training program, the coaching interventions, and case scenarios, and indicate how realistic and compatible the intervention is with their work environment.
16651671|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
16651672|NCT02269930|Experimental|Group 1|Treatment Sequence 1: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41 Treatment Sequence 2: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29
16651673|NCT02269930|Experimental|Group 2|Treatment Sequence 1: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29 Treatment Sequence 2: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41
16651674|NCT02269917|Experimental|Experimental Treatment Regimen|Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
16651675|NCT02269917|Active Comparator|Current Treatment Regimen|Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
16651676|NCT02269904|Active Comparator|Fluorouracil Implants and Xelox regimes|"Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
~Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished."
16651677|NCT02269904|Active Comparator|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
16651678|NCT02269891|Experimental|Nu Femme|Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
16651679|NCT02269891|Placebo Comparator|Placebo|Two capsules taken once daily in the morning after breakfast for 24 weeks
16651680|NCT02269878||people with MPM with Thymine/Thymine,Thymine/cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
16651681|NCT02269878||people with MPM, Cytosine/Cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
16651683|NCT02269839|Active Comparator|theta-burst rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
16651684|NCT02269839|Sham Comparator|Control arm|The control (sham) stimulation will consist of stimulating with the rTMS coil held at right angles to the participants' head. This will result in no active stimulation of brain tissue but would feel similar to the patient. Each treatment session will therefore last approximately 20 minutes.
16651685|NCT02269826|Experimental|Vagisan® Moisturising Cream|non-hormonal vaginal cream for the treatment of vulvovaginal dryness
16651686|NCT02269826|Active Comparator|Gynomunal® vaginal gel|non-hormonal gel
16651687|NCT02269813||ET/GOOD|Endocrine therapy only.
16651688|NCT02269813||CT/POOR|Chemoendocrine therapy according to national guidelines.
16651689|NCT02269800|Experimental|Benzalkonium chloride solution|Tid, for 7 days.
16651690|NCT02269800|Active Comparator|Normal saline|Tid, for 7 days.
16651691|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
16651692|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
16651693|NCT02269774|Other|Pulmonary vein isolation|Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index > 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
16651694|NCT02269774|No Intervention|No intevention|Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index < 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.
16651695|NCT02269748|Experimental|Root coverage with Tunnel (TT)|The tunnel technique with subepithelial connective tissue graft (TT+SeCTG) will be utilized to cover the denude root surface
16651696|NCT02269748|Active Comparator|Coronally advanced flap (CAF+SeCTG)|The Coronally advanced flap with subepithelial connective tissue graft (CAF+SeCTG) will be utilized to cover the denude root surface
16651697|NCT02269735|Experimental|Part I: MK-2640 (Panel A)|Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651698|NCT02269735|Experimental|Part I: MK-2640 (Panel B)|Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651699|NCT02269735|Experimental|Part I: MK-2640 (Panel C)|Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651700|NCT02269735|Experimental|Part I: MK-2640 (Panel D)|Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651701|NCT02269735|Experimental|Part I: MK-2640 (Panel E)|Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651702|NCT02269735|Experimental|Part I: MK-2640 (Panel F)|Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651703|NCT02269735|Experimental|Part I: MK-2640 (Panel G)|Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
16651704|NCT02269735|Experimental|Part II: MK-2640 followed by RHI|Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
16651705|NCT02269735|Experimental|Part II: RHI followed by MK-2640|Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
16651706|NCT02269735|Experimental|Part III: MK-2640 followed by RHI|Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
16651707|NCT02269735|Experimental|Part III: RHI followed by MK-2640|Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
16651708|NCT02269722|Experimental|Short Clamp time|Radial clamp applied at full pressure for 20 minutes. At the end of 20 minutes, the clamp will be loosened ¼ turn every 5 minutes over 20 minutes and then removed.
16651709|NCT02269722|Experimental|Long Clamp Time|Radial clamp applied at full pressure for 60 minutes. At the end of 60 minutes, the clamp is to be loosened and removed under the same instruction as those patients in arm one.
16651710|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
16651711|NCT02269696|Experimental|Metoprolol|Metoprolol infusion
16651712|NCT02269696|Placebo Comparator|Normal saline|Equal volume of saline.
16651713|NCT02269683|Experimental|Robot-assisted|Distal pancreatectomy via robot-assisted minimally-invasive approach
16651714|NCT02269683|Active Comparator|Laparoscopic|Distal pancreatectomy via a conventional laparoscopic approach
16651747|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
16652248|NCT02266186|No Intervention|Care as usual|Childbirth preparation according to local routine
16651715|NCT02269670|Experimental|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
16651716|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
16651717|NCT02269644|Experimental|Dalbavancin|Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
16651718|NCT02269644|Active Comparator|Linezolid|Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
16651719|NCT02269644|Other|Linezold Placebo IV and Oral Capsules|Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
16651720|NCT02269644|Other|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
16651721|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
16651722|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
16651723|NCT02269618|Active Comparator|Control group (Group A)|The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed
16651724|NCT02269618|Other|Intervention group (Group B)|"Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:
~Home-based telehealth program
~Home-based rehabilitation"
16651725|NCT02269605|Placebo Comparator|Group 1|Patients receiving placebo (sodium chloride) at single dose
16651726|NCT02269605|Active Comparator|Group 2|Patients receiving Bryostatin 1 (10ug/m2) at single dose
16651727|NCT02269605|Active Comparator|Group 3|Patients receiving Bryostatin 1 (20ug/m2) at single dose
16651728|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
16651729|NCT02269579|Experimental|CPX-351|Study Drug CPX-351 will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
16651730|NCT02269566|Active Comparator|Allergen extract|0.1 ml of allergen extracts
16651731|NCT02269566|Placebo Comparator|Placebo|Normal saline, 0.1 ml
16651732|NCT02269553|Active Comparator|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
16651733|NCT02269553|Active Comparator|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
16651734|NCT02269540|Experimental|Sertraline and n-acetylcysteine|Sertraline and n-acetylcysteine for seven weeks of treatment
16651735|NCT02269540|Experimental|Citalopram and n-acetylcysteine|Citalopram and n-acetylcysteine for seven weeks of treatment
16651736|NCT02269540|Experimental|Existing medication treatment & NAC|Existing depression medication treatment and n-acetylcysteine for seven weeks of treatment
16651737|NCT02269527|Other|Live music|1-hour live music 5 days/week
16651738|NCT02269514|Active Comparator|Own Brand Cigarette|Own Brand Cigarette
16651739|NCT02269514|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 14mg nicotine)
16651740|NCT02269514|Experimental|Electronic Cigarette #2|VUSE® (original flavor, 29mg nicotine)
16651741|NCT02269514|Experimental|Electronic Cigarette #3|VUSE® (original flavor, 36mg nicotine)
16651742|NCT02269514|Active Comparator|Leading U.S. Nicotine Gum|Leading U.S. Nicotine Gum
16651743|NCT02269501|Experimental|Exercise treatment|Exercise treatment
16651744|NCT02269501|No Intervention|No treatment|No treatment
16651745|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
16651746|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
16651748|NCT02269462||Pregnant women - efavirenz|Pregnant women taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health
16651749|NCT02269462||Nursing mothers - efavirenz|Nursing mothers taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
16651750|NCT02269462||Pregnant women - nevirapine|Pregnant women taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health
16651751|NCT02269462||Nursing mothers - nevirapine|Nursing mothers taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
16651752|NCT02269449|Experimental|6Fr Glidesheath Slender sheath|TRI will be performed using a new 6Fr sheath (Glidesheath slender: GSS).
16651753|NCT02269449|Active Comparator|5Fr contemporary sheath|TRI will be performed using a contemporary safety of 5Fr sheath.
16651754|NCT02269449|Experimental|Hemostasis with TR band|Hemostasis is achieved by randomization of using TR band (TERUMO) Patent hemostasis.
16651755|NCT02269449|Active Comparator|Any hemostasis procedure|Hemostasis is achieved by randomization of any hemostasis of each hospital's routine procedure.
16651756|NCT02269436|Experimental|sNN0029 infusion solution|
16651757|NCT02269423|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
16651758|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
16651759|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
16651760|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
16651761|NCT02269410|Active Comparator|GBP-SPS|GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day)
16651762|NCT02269410|Experimental|GBP-HPS|GBP High PRO-S (1.2g protein/ kg ideal body weight/ day)
16651763|NCT02269410|Active Comparator|VSG-SPS|VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day)
16651764|NCT02269410|Experimental|VSG-HPS|VSG High PRO-S (1.2g protein/ kg ideal body weight/ day)
16651765|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
16651766|NCT02269384|Sham Comparator|No History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
16651767|NCT02269384|Active Comparator|History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
16651768|NCT02269371|Experimental|Group 1|Group 1: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
16651769|NCT02269371|Sham Comparator|Group 2|Group 2: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
16651770|NCT02269358|Experimental|Addition of methotrexate|Addition SC methotrexate at 15 mg/m2, not to exceed 25 mg/m2 . Patients in remission after 4 weeks will reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
16651771|NCT02269345|Experimental|Battlefield Acupuncture|BFA at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
16651772|NCT02269345|Placebo Comparator|Standard Treatment|Standard Treatment alone
16651773|NCT02269332||Screening Colonoscopy|Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
16651774|NCT02269319|Experimental|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
16651775|NCT02269319|Active Comparator|Linezolid|Linezolid 600 mg given twice a day for 10 days
16651776|NCT02269306|Experimental|clomiphen citrate(cc)|Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles.
16651777|NCT02269293|Experimental|Regimen 1|Paclitaxel 175 mg/m^2 IV, Day 1 (administered over approximately 3 hours) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
16651778|NCT02269293|Experimental|Regimen 2|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
16651779|NCT02269293|Experimental|Regimen 3|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once weekly on days 1, 8, and 15 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
16651780|NCT02269293|Experimental|Regimen 4|Paclitaxel and carboplatin will be delivered intravenously (IV) on day 1 of each cycle. Selinexor will be taken orally once a week on days 1, 8 and 15 of each chemotherapy cycle.
16651781|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 3|Azacitidine (AZA) Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
16651782|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 5|Azacitidine (AZA) 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
16651783|NCT02269280|Experimental|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
16651784|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
16651785|NCT02269267||Discontinuation of TKI medication|Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years.
16655517|NCT02245451|Experimental|TPV/r with methadone|
16651786|NCT02269254|Experimental|Persona PS|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
16651787|NCT02269254|Active Comparator|NexGen PS|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
16651788|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
16651789|NCT02269228|Experimental|Asasantin ER|Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)
16651790|NCT02269228|Experimental|Asasantin ER, administered twice daily from day 1 to day 14|
16651791|NCT02269228|Placebo Comparator|Placebo|
16651792|NCT02269215|Experimental|BIII 890 CL single rising dose|
16651793|NCT02269215|Placebo Comparator|Placebo|
16651794|NCT02269202|Experimental|Midazolam and crobenetine|
16651795|NCT02269202|Placebo Comparator|Midazolam and placebo|
16651796|NCT02269189|Experimental|BIIL 284 BS, high dose in adult patients|
16651797|NCT02269189|Experimental|BIIL 284 BS, low dose in pediatric patients|
16651798|NCT02269189|Placebo Comparator|Placebo|
16651799|NCT02269176|Experimental|Telmisartan|Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
16651800|NCT02269176|Active Comparator|Losartan|Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
16651801|NCT02269163|Active Comparator|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
16651802|NCT02269163|Experimental|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
16651803|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
16651804|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
16651805|NCT02269124|No Intervention|Conventional Measures Only|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
16651806|NCT02269124|Experimental|Conventional Measures + Hearing Aid|In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
16651807|NCT02269111|Experimental|Diagnostic (hybrid MRI)|Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
16651808|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.
~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
16651809|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
16651810|NCT02269085|Experimental|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m^2, 20/36 mg/m^2, 20/45 mg/m^2 or 20/56 mg/m^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.
~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.
~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
16651811|NCT02269072|Active Comparator|Testosterone|Testosterone cream applied daily
16655518|NCT02245438|Experimental|TPV/RTV low dose|
16651813|NCT02269059|Experimental|GT1 Participants|Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
16651814|NCT02269059|Experimental|GT3 Participants|Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
16651815|NCT02269046|Experimental|Acupuncture and moxibustion|"therapeutic lifestyle change
~Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)
~Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
~Group I and II will change alternatively every other week .
~Once per day five days per week."
16651816|NCT02269046|Active Comparator|Simvastatin|"therapeutic lifestyle change
~simvastatin
~oral administration with 10mg per day
~seven days per week for 12 weeks."
16651817|NCT02269046|Other|waiting list|- therapeutic lifestyle change
16651818|NCT02269033|Experimental|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
16651819|NCT02269033|Active Comparator|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
16651820|NCT02269020|Experimental|3 patients cancer of the epi larynx|"3 patients with squamous cell carcinoma of the epi-larynx
~Intervention: Neck Dissection"
16651821|NCT02269007|Experimental|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
16651822|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
16651823|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
16651824|NCT02268981|Experimental|Oxymizer® compared to CNC|"From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.
~The intervention will be performed on consecutive days and twice during study period."
16651825|NCT02268968|Experimental|Lidocaine|Intervention: Topical lidocaine gel 2% (0.3 ml/kg) will be applied once only to the nostrils and nasal CPAP prong 5 minutes prior to the application of nasal CPAP
16651826|NCT02268968|No Intervention|Control|No topical lidocaine will be used prior to application of nasal CPAP
16651827|NCT02268955|Placebo Comparator|Control Group: Adults age 18-55 years|Saline-only control group
16651828|NCT02268955|Active Comparator|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
16651829|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
16651830|NCT02268929|Other|Control Group|Patients treated by usual customary medical practice (Usual Care)
16651831|NCT02268929|Other|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
16651832|NCT02268916|Experimental|Intervention|OT-led counseling based on home activity pattern
16651833|NCT02268916|Placebo Comparator|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
16651834|NCT02268903|Active Comparator|Diuretics|
16651835|NCT02268903|Placebo Comparator|Placebo|
16651836|NCT02268890|Experimental|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
16651837|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
16651838|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
16651839|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
16651840|NCT02268851|Experimental|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Each Cycle = 28 days
~TGR-1202 (oral): Starting on Day 1 administered daily.
~Ibrutinib (oral): Starting on Day 1 administered daily."
16651841|NCT02268851|Experimental|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Each Cycle = 28 days
~TGR-1202 (oral): Starting on Day 1 administered daily.
~Ibrutinib (oral): Starting on Day 1 administered daily."
16651842|NCT02268838|Experimental|50 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
16651843|NCT02268838|Experimental|100 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
16651844|NCT02268838|Experimental|200 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
16651845|NCT02268838|Experimental|400 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
16651846|NCT02268838|Experimental|200 mg E6007 fed condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
16651847|NCT02268825|Experimental|MK-3475 treatment arm, all patients|
16651848|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.
~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
16651849|NCT02268799||DC Cardioversion|Patients undergoing DC cardioversion
16651850|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
16651851|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
16651852|NCT02268773|Experimental|Acetylsalicylic acid low dose with Asasantin®|
16651853|NCT02268773|Active Comparator|Acetylsalicylic acid high dose|
16651854|NCT02268760|Experimental|BILN 2061 ZW single rising doses|
16651855|NCT02268760|Placebo Comparator|Placebo|
16651856|NCT02268760|Experimental|BILN 2061 ZW fixed dose fed|
16651857|NCT02268760|Active Comparator|BILN 2061 ZW fixed dose fasted|
16651858|NCT02268747|Experimental|Dacomitinib|"Patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).
~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
16651859|NCT02268734||Sporadic Medullary Thyroid Cancer|Patients with diagnosis of locally relapsed and or metastatic sporadic MTC surgically treated (total thyroidectomy)
16651860|NCT02268721|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records before discharge, and at six and twelve weeks, as the intervention group. The control group receives no special treatment or care after discharge.
16651861|NCT02268721|Other|App for food delivery|"Intervention: Tablet Computer
~Patients in the intervention group receives a tablet upon discharge from the hospital. The tablet contains an app, which the patients in the intervention group can use for ordering meals for delivery from the kitchen at the hospital three times a week. The app also ask the patients to register their own dietary intake, and give them feedback on their daily energy and protein intake.
~Baseline measurements and records are taken at prior to discharge from the hospital, and after six and twelve weeks."
16651862|NCT02268708||COPD|"Patients:
~>18 years old COPD: FEV/FEV1<80% in respiratory evaluation who have un oncological pulmonary resection in Cochin Hospital Paris France"
16651863|NCT02268695|Active Comparator|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).
~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.
~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
16651864|NCT02268695|Experimental|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).
~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.
~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.
~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
16651865|NCT02268682|No Intervention|Standard of Care (Control)|Patients randomized to the standard of care condition will not receive any educational materials from our program and will only participate in the survey portion of the investigation. Dialysis providers will be asked to continue their current practices throughout the study period without change. While Control patients will be free to ask additional questions or solicit more information from their dialysis educators at any point during the study period, no additional educational interventions will be added to what is currently being done.
16651866|NCT02268682|Experimental|Patient-Guided|Over an 8-month period, patients in the Patient-Guided intervention condition will receive four educational modules and twelve transplant education postcards in the mail. Modules will be mailed once every other month and consist of an introductory letter, a transplant video, and printed resources. Transplant education postcard will be mailed every two weeks following the mailing of each module, for a total of three postcards over the course of 6-weeks.
16651867|NCT02268682|Experimental|Educator-Guided|Patients in the Educator-Guided intervention condition will receive the same intervention components as those in the Patient-Guided condition; however, the key difference in this condition is that Educator-Guided patients will also receive telephonic support from an experienced clinical social worker in the role of a Transplant Educator to maximally facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 minutes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an educational text messaging service designed to supplement the ET education they are receiving in the mail.
16651868|NCT02268669|Active Comparator|Primary angioplasty|Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations
16651869|NCT02268669|Active Comparator|Post-thrombolysis angioplasty|Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering >50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization
16651870|NCT02268656|Other|concentration in male|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
16652288|NCT02265900|Placebo Comparator|Exercise 2|A different type of exercise
16651871|NCT02268656|Other|concentraion in female|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
16651872|NCT02268643||group 1|ultrasound plus clinical breast examination
16651873|NCT02268630||Group A|Patients treated with Warfarin for VTE
16651874|NCT02268630||Grup B|Patients treated with Rivaroxaban for VTE
16651875|NCT02268617|Experimental|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
16651876|NCT02268604|Experimental|BIIB 722 CL|
16651877|NCT02268604|Placebo Comparator|Placebo|
16651878|NCT02268591|Active Comparator|Transcranial Stimulator|We will apply oscillating current at a slow frequency of 0.5-1.5 Hz during early sleep, which is rich in slow waves [ie non-REM sleep]. The peak intensity of stimulation which allows for optimal phase entrainment will be determined in pilot studies. However, peak stimulation intensities will not exceed 2 mA (as discussed above). The current will be applied over the left and right prefrontal cortex (F3, F4), corresponding to the predominant region of slow oscillations, during the onset of deep sleep to the first REM episode (early non-REM-rich sleep).
16651879|NCT02268591|No Intervention|Sham Stimulation|The EEG and stimulation electrodes will be placed as in the stimulation sessions, but stimulation will not be administered.
16651880|NCT02268578|Active Comparator|Transcranial Direct Current Stimulation|Subjects will receive a total of 5 sessions on consecutive days. During each session, 2 mA of tDCS will be applied for 20 minutes over the left DLPFC (active or sham). The electrodes will have the size of 35cm2 each. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes and delivered b y a specially developed, battery driven, constant current stimulator with a maximum output of 2mA.
16651881|NCT02268578|Sham Comparator|Sham TDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
16651882|NCT02268565|Placebo Comparator|Insomnia symptom induction/placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
16651883|NCT02268565|Experimental|Insomnia symptom induction/aspirin|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
16651884|NCT02268552|Experimental|branaplam|branaplam Treatment
16651885|NCT02268539|Active Comparator|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
16651886|NCT02268539|Active Comparator|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
16651887|NCT02268539|Active Comparator|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
16651888|NCT02268539|Active Comparator|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
16651889|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
16651890|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
16651891|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
16651892|NCT02268513||MASALA study|"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study.
~Objective of MASALA study:
~The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers."
16651893|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
16651894|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
16651895|NCT02268487|Experimental|Sertraline|Patients using Sertraline with any dose will be evaluated about Early Improvement
16651896|NCT02268474|Experimental|532nm KTP Laser|Cutera® Excel V
16651897|NCT02268474|Active Comparator|595nm Pulse Dye Laser|Candela/Syneron Vbeam
16651898|NCT02268461|Active Comparator|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
16651899|NCT02268461|Sham Comparator|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
16651900|NCT02268448|Experimental|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
16651901|NCT02268448|Experimental|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
16651902|NCT02268435|Experimental|Dovitinib plus Imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
16651903|NCT02268422|Experimental|7 day patch|Buprenorphine transdermal system (BTDS) 2nd generation
16651904|NCT02268422|Active Comparator|7 Day Patch|1st Generation BTDS: Butrans
16651905|NCT02268409|Experimental|ACE-536 0.8 mg/kg once every 3 weeks SC|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
16651906|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
16651907|NCT02268383|Experimental|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
16651908|NCT02268370|Other|Dasatinib|"This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.
~Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.
~If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.
~If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib."
16651909|NCT02268357|Experimental|Propranolol|capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
16651910|NCT02268357|Placebo Comparator|Placebo|capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
16651911|NCT02268344|Active Comparator|Grass SD9 Stimulator|Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection.
16651912|NCT02268344|No Intervention|No Stimulation|No stimulation will be performed in this group, and patients will simply have the neck dissection as planned. No sham stimulation is required, as all outcome measures are performed by individuals not present in the operating room, and therefore, blinded to the treatment arm.
16651913|NCT02268331|Experimental|Active Surveillance|"For 60 consecutive pediatric visits, patients will be asked to complete a PRE & POST form to capture adverse events (AEs) that occur up to 1 week after treatment. The PRE-treatment form will be completed prior to the start of the visit. The POST-treatment form will be completed after the treatment visit and mailed directly to the investigative team.
~The providers will collect data on the treatment provided on the same 60 pediatric patients. The treatment provided is at the discretion of the doctors. If a moderate, serious, or severe AE occurs, the provider will complete the AE form with detailed information about potential risk factors and patient outcomes."
16651914|NCT02268331|Active Comparator|Passive Surveillance|"All doctors allocated to this arm will be provided with a username and password with an established chiropractic passive surveillance reporting and learning online system (CPiRLS) in the UK. If a patient safety incident occurs in their office or an adverse event (AE), the provider will complete a report on the CPiRLS website. The providers can record events that occur during the time period of 60 pediatric visits.
~Treatment provided during these treatments is at the doctor's discretion."
16651915|NCT02268318|Experimental|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols
16651916|NCT02268318|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 1 bottle of dairy product/day with no Phytosterols
16651917|NCT02268305|Experimental|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
16651918|NCT02268305|Placebo Comparator|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
16651919|NCT02268292|Experimental|Bicycle Exercise|Bicycle Exercise for 12 weeks
16651920|NCT02268279|Experimental|solithromycin|oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day
16651921|NCT02268266|Other|Single-arm study|Early mobilization of patients after stroke or spinal cord injury. Monitoring of vital parameters during mobilization of healthy subjects
16651922|NCT02268253|Experimental|Tagraxofusp (SL-401)|
16651923|NCT02268240|Experimental|Experimental|Stepped Care
16651924|NCT02268240|No Intervention|Control|Usual Care
16651925|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
16651926|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
16651927|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
16651928|NCT02268201|Experimental|ADV group|Once daily
16651929|NCT02268201|Experimental|PRG group|Twice daily
16651930|NCT02268188|Experimental|Supportive Care (Harvesting Health program)|Participants undergo a series of 10 education and training sessions over 1 hour every 2 weeks, comprising education on current research, evidence-based health guidelines, application techniques, reference materials specific to extended-stage cancer survivors, and recommendations and personal health goals for survivorship. The guidelines described in class are part of a nutrition intervention and an exercise intervention with personal and group goal setting over the course of the study.
16651931|NCT02268175|Experimental|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).
~Participants will receive the assigned study treatment per cycle
~Enzalutamide- Once daily at prespecified dose, orally
~Abiraterone Acetate- Once daily at prespecified dose, orally
~Prednisone-Once daily at prespecified dose, orally
~Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
16651932|NCT02268175|Experimental|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).
~Participants will receive the assigned study treatment per cycle.
~Enzalutamide- once daily at prespecified dose, orally
~Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
16651933|NCT02268162|No Intervention|Routine Bronchoscopy|Participants in the group will receive routine bronchoscopy.
16651934|NCT02268162|Experimental|Routine Bronchoscopy with a guiding equipment|Participants in the group will receive routine bronchoscopy combined with a guiding equipment. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
16651935|NCT02268162|Experimental|Routine Bronchoscopy with two or more guiding equipments|Participants in the group will receive routine bronchoscopy combined with two or more guiding equipments. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
16651936|NCT02268149|Experimental|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
16651937|NCT02268149|Placebo Comparator|Placebo|
16651938|NCT02268136|Experimental|BIII 890 CL|single increasing doses
16651939|NCT02268136|Placebo Comparator|Placebo|
16651940|NCT02268110|Experimental|Supervised exercise therapy|Participants will receive 12 sessions with a physiotherapist where they will receive instructions on body mechanics, and be given a progressive abdominal exercise program
16651941|NCT02268110|Experimental|Abdominal binding|Participants will be fitted for an abdominal binder and asked to wear it for a period of 12 weeks.
16651942|NCT02268110|Experimental|Exercise therapy and Abdominal Binding|Participants will attend 12 sessions with a physiotherapist, and receive an abdominal binder
16651943|NCT02268110|No Intervention|Control|Participants will not receive an intervention during the study period
16651944|NCT02268097|Experimental|Freehand|Patellar resurfacing with freehand technique:Using freehand technique for patella preparation during total knee arthroplasty.
16651945|NCT02268097|Active Comparator|Resection guide|Patellar resurfacing with resection guide technique: Using patellar resection guide technique for patella preparation during total knee arthroplasty.
16651946|NCT02268084|Sham Comparator|Sham Stimulation|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
16651947|NCT02268084|Active Comparator|Active sTMS|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.
16651948|NCT02268071|Experimental|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
16651949|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.
~Patient and family received standard education on concussion management in the Emergency department."
16651950|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.
~Patient and family received standard education on concussion management in the Emergency department."
16651951|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.
~Patient and family received standard education on concussion management in the Emergency Department."
16651952|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.
~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
16651953|NCT02268045|Experimental|RTXM83|Active Ingredient: Rituximab (Biosimilar)
16651954|NCT02268045|Active Comparator|MabThera|Active Ingredient: Rituximab
16651955|NCT02268032|Experimental|Vaginal ring 1 (VRD)|20 women using DHEA (VRD) for 2 menstrual cycles
16651956|NCT02268032|Experimental|Vaginal ring 2 (VRaA)|20 women using another androgenic agent (VRaA) for 2 menstrual cycles
16651957|NCT02268032|Experimental|Vaginal ring 3 (VR2A)|20 women using fixed combination of 2 androgenic agents (VR2A) for 2 menstrual cycles
16651958|NCT02268019|Experimental|Hypospadiasis repair|
16651959|NCT02268006|Other|IMRT-SIB|
16651960|NCT02267993|Experimental|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
16651961|NCT02267993|Experimental|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
16651962|NCT02267980|Active Comparator|Group SK|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
16651963|NCT02267980|Placebo Comparator|Group SS|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.
16651964|NCT02267967|Experimental|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
16651965|NCT02267954|Experimental|50% Prices/50% Calories|"The participant is exposed to the baseline menu, but the prices are edited to be at 50% of the actual price (e.g., a $1 coffee is listed as costing $.50) and the calorie labels are edited to be at 50% of the actual content (e.g., a 500 calorie Large Fries is listed as having 250 calories). In addition, the baseline mistakes are still included.
~This is the Menu edited intervention."
16651966|NCT02267941||case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. According to the Stanford classification system, type A aortic dissection was defined as any dissection that involves the ascending aorta and type B as any that does not. Acute stage was confined to initial 14 days after symptom onset. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
16651967|NCT02267941||control|As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period. Types of disease in the control group included congenital heart disease (632), coronary heart disease (467), adult valve disease (375), pulmonary artery hypertension (292), appendicitis (234), pneumonia (197), fracture (189), intestinal polyps (167), gallstone (156), esophagus cancer (51). Patients in the control group were derived from Department of Cardiovascular Surgery, Department of General Surgery, Department of Thoracic Surgery, and Department of Respiration, respectively.
16651968|NCT02267928|Experimental|Check/Experience|Participants are asked to check the symptoms that they have experienced in the last 6 weeks.
16651969|NCT02267928|Experimental|Un-check/Experience|Participants are asked to un-check the symptoms that they have experienced in the last 6 weeks.
16651970|NCT02267928|Experimental|Check/Not Experienced|Participants are asked to check the symptoms that they have NOT experienced in the last 6 weeks.
16651971|NCT02267928|Experimental|Un-check/Not Experienced|Participants are asked to un-check the symptoms that they have NOT experienced in the last 6 weeks.
16651972|NCT02267915|Experimental|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
16651973|NCT02267902|Experimental|Part 1|Single oral therapeutic dose of 5mg DA-1229 as a tablet + An IV dose of 20㎍ [14C]-DA-1229
16651974|NCT02267902|Experimental|Part 2|Single oral therapeutic dose of 5mg [14C]-DA-1229
16651975|NCT02267889|Experimental|Image guided GP ablation|Use of cardiac nuclear imaging data to guide GP ablation procedures.
16651976|NCT02267876||BD VIPER LT|
16651977|NCT02267863|Experimental|Dose Escalation and Expansion|APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.
16651978|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
16651979|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
16651980|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
16651981|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
16651982|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
16651983|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
16651984|NCT02267811|Experimental|Fixed Orthodontic Treatment with OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
16651985|NCT02267811|Experimental|Fixed Orthodontic Treatment|Subjects assigned to this group receive orthodontic treatment with no OrthoPulse™ treatment.
16651986|NCT02267798|Experimental|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes and will focus on repetitive tasks that incorporate multidirectional reaching actions. In this robot-assisted therapy a robot manipulator applies forces to the paretic arm during goal-directed movements.
~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists of a battery powered programmable stimulator and a forearm-wrist-hand orthosis containing 5 electrodes positioned to provide reliable activation of muscles. The intensity of stimulation will be set to a level that provided comfortable and consistent activation of the extensor and flexor muscles to achieve whole hand opening and functional grasping."
16651987|NCT02267798|Active Comparator|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence, Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques based on neuro-developmental treatment.
16651988|NCT02267785|Experimental|Skill-Based Exercise|Participants assigned to this arm will complete the Skill-Based Exercise Intervention
16651989|NCT02267785|Experimental|Aerobic Exercise|Participants assigned to this arm will complete the Aerobic Exercise Intervention
16651990|NCT02267785|Experimental|Social Contact Group|Participants assigned to this arm will complete the Social Contact Intervention
16651991|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
16651992|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
16651993|NCT02267759|Experimental|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
16651994|NCT02267759|Active Comparator|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
16651995|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
16651996|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
16651997|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
16651998|NCT02267733|Experimental|Early Disease|Patients not requiring anti-tumor therapy
16651999|NCT02267733|Experimental|Disease Requiring Anti-tumor therapy|Patients that have disease requiring anti-tumor therapy at any time
16652000|NCT02267720|Active Comparator|Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
16652001|NCT02267720|Experimental|Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
16652002|NCT02267707|Experimental|Cohort 1 - Bilirubin level > 1.5 x ULN to 3 x ULN|4 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
16652003|NCT02267707|Experimental|Cohort 2 - Bilirubin level > 3 x ULN to 5 x ULN|6 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2 nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
16652004|NCT02267694|Other|Black raspberry powder|Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
16652005|NCT02267681|Experimental|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
16652006|NCT02267681|Experimental|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
16652007|NCT02267681|Active Comparator|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
16652008|NCT02267668|Experimental|STEP arm|"The Baseline Evaluation Session will include formal neuropsychological evaluation, postural stability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).
~Intervention includes exercise tolerance evaluations, 3 times per week exercise by physical therapist. Self report of symptoms and exertion."
16652009|NCT02267668|Active Comparator|Control|"The Baseline Evaluation Session will include formal neuropsychological evaluation, posturalstability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).
~Control protocol includes instructions for stretching, instructions for restricting physically demanding activity during first 3 weeks of study; instructions for light, self-guided daily exercise in last 3 weeks of study. Self report of symptoms and exertion."
16652010|NCT02267655|Active Comparator|inhaled Nitric Oxide 30 mcg/kg IBW/hr|30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
16652011|NCT02267655|Active Comparator|inhaled nitric oxide 75 mcg/kg IBW/hr|Part 2: 75mcg/Kg IBW/hr
16652012|NCT02267655|Active Comparator|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
16652013|NCT02267655|Placebo Comparator|Placebo|Placebo for 75 mcg/kg IBW/hr
16652014|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
16652015|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
16652016|NCT02267616|Experimental|Continued Use Implant Group|Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.
16652017|NCT02267616|Active Comparator|New Implant Group|Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.
16652018|NCT02267616|No Intervention|Observational Continued Use Group|Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).
16652019|NCT02267603|Experimental|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.
~* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
16652020|NCT02267590||MCL: 80-100 samples from 60- 70 patients|Mantle Cell lymphoma patients
16652021|NCT02267590||CLL: 15-20 samples from 10-15 patients|Chronic lymphocytic leukaemia patients
16652022|NCT02267577|Experimental|Healthy Adults Volunteers|Men and women over the age of 18 will have their blood pressure measured with both the Sphygmo: Automatic Blood Pressure Monitor device and the GE Dinamap ProCare automatic blood pressure monitor.
16652023|NCT02267564|Experimental|MPFLR without tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction without tibial tubercle transfer.
16652024|NCT02267564|Active Comparator|MPFLR with tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction with tibial tubercle transfer.
16652025|NCT02267551|Other|Mimic dV-Trainer|
16652026|NCT02267551|Other|daVinci Skills Simulator|
16652027|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
16652028|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
16652029|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
16652030|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
16652031|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
16652032|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
16652033|NCT02267512|Experimental|ATG-F single dosing group|Intravenous (IV)
16652034|NCT02267512|Experimental|ATG-F continuous dosing group|Intravenous (IV)
16652035|NCT02267499|Experimental|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
16652036|NCT02267499|No Intervention|Passive Control|Participants do not receive an intervention serving as passive controls
16652037|NCT02267486||Alzheimer Dementia (AD)|Patients with dementia caused by Alzheimer's disease
16652038|NCT02267486||Non-dementia|Patients with cognitive concern without dementia
16652039|NCT02267460|Active Comparator|AA4500 with investigator modeling and vacuum therapy|AA4500 with investigator modeling and home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
16652040|NCT02267460|Active Comparator|AA4500 without investigator modeling/with vacuum therapy|AA4500 without investigator modeling but with home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
16652041|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
16652042|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
16652043|NCT02267434|Experimental|Low dose AFFITOPE® PD03A + Adjuvant|"4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
16652044|NCT02267434|Experimental|High dose AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
16652045|NCT02267434|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks
~1 administration 36 weeks after first injection"
16652046|NCT02267421|Experimental|Home based aerobic exercise|Home based aerobic exercise on cycle ergometer. Three times per week, 30-60 minutes per session.
16652047|NCT02267421|No Intervention|Usual Care group|These patients will continue with their normal activities of daily living and will not be provided with equipment or coaching for home based exercise during the study period .
16652048|NCT02267408|Experimental|Fearon algorithm dosing|Warfarin adjustment using the Fearon algorithm
16652049|NCT02267408|Active Comparator|Standard dosing|Warfarin adjustment using standard dosing
16652050|NCT02267395||(No-PRMSDs)|Group 1 : No Playing Related Musculoskeletal Injury
16652051|NCT02267395||(Yes-PRMSDs)|Group 2: Playing Related Musculoskeletal Injury
16652052|NCT02267382|Experimental|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
16652053|NCT02267382|Experimental|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
16652054|NCT02267382|Experimental|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
16652055|NCT02267382|Experimental|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
16652056|NCT02267382|Placebo Comparator|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
16652057|NCT02267369|Active Comparator|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
16652058|NCT02267369|Experimental|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
16652059|NCT02267369|Experimental|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
16652060|NCT02267356|Experimental|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
16652061|NCT02267356|Experimental|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
16652062|NCT02267356|Experimental|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
16652063|NCT02267356|Experimental|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
16652064|NCT02267356|Placebo Comparator|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
16652065|NCT02267343|Experimental|ONO-4538 Arm|ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
16652066|NCT02267343|Placebo Comparator|Placebo Arm|Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
16652067|NCT02267330||Standard of care, Exposure recording|Patient will undergo fracture surgery as per standard of care, and will have radiation exposure recording.
16652068|NCT02267317|Active Comparator|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
16652069|NCT02267317|Active Comparator|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
16652070|NCT02267317|Active Comparator|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
16652071|NCT02267317|Active Comparator|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
16652072|NCT02267304|Experimental|Morphine/placebo/naxolone|
16652073|NCT02267304|Experimental|Naxolone/morphine/placebo|
16652074|NCT02267304|Experimental|placebo/naxolone/morphine|
16652075|NCT02267291|Experimental|All patients|Ventilatory support to alter intrathoracic pressure
16652076|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.
~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
16652077|NCT02267265|Experimental|Treatment intervention|The treatment group will complete a demographics questionnaire and the knowledge survey before the intervention. Participants will then view the 10 minute TMW-Newborn Intervention video around the time of the newborn hearing screening. Participants whose newborn does not pass the hearing screen will view an additional 3 minute video detailing the importance of following up for an outpatient re-screening. The participant will complete the knowledge survey again before discharge, and after approximately four to six weeks.
16652078|NCT02267265|Active Comparator|Control intervention|The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
16652079|NCT02267239|Active Comparator|Essential Oils, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the essential oils antiseptic solution
16652080|NCT02267239|Active Comparator|Chlorhexidine, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the chlorhexidine antiseptic solution
16652081|NCT02267239|Other|baseline|Professional oral cleaning Plaster cast IDODS Disk in basal conditions.
16652082|NCT02267239|Active Comparator|Essential Oils, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the essential oils antiseptic solution
16652083|NCT02267239|Active Comparator|Chlorhexidine, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the chlorhexidine antiseptic solution
16652084|NCT02267226|Experimental|Octafibrin|
16652085|NCT02267213|Experimental|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
16652291|NCT02265861|Experimental|Group 1|typical PCOS
16652086|NCT02267200||reversible PAH group|reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
16652087|NCT02267200||irreversible PAH group|irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
16652088|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
16652089|NCT02267174|Other|Standardized OR to ICU handoff|A standardized handoff process for conducting OR to ICU handoffs will be implemented in two intensive care units without a standard process.
16652090|NCT02267161|Experimental|neuropsycological tests|Psychometric scales for infants at 3 years of age
16652091|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
16652092|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
16652093|NCT02267122|Experimental|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound.
16652094|NCT02267122|Experimental|Mupirocin ointment application|After placing the staples, a Mupirocin ointment application was placed covering the wound.
16652095|NCT02267122|No Intervention|Conventional dressing|After placing the staples, a conventional dressing, without application of any special gauze or ointment, was placed covering the wound
16652096|NCT02267109|Experimental|2.5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 2.5 x 10(10):
16652097|NCT02267109|Experimental|5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 5 x 10(10):
16652098|NCT02267109|Experimental|1.0 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(10):
16652099|NCT02267109|Experimental|1.0 x 10(11) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(11):
16652100|NCT02267109|Experimental|Booster-MVA-BN® Filo or saline placebo|MVA-BN® Filo or saline placebo
16652101|NCT02267096|Experimental|Telephone Counseling (TC)|The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.
16652102|NCT02267096|Active Comparator|Minimal Treatment|The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.
16652103|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
16652104|NCT02267070|Experimental|Cognitive Training and Exercise|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
16652105|NCT02267070|Active Comparator|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
16652106|NCT02267057|Active Comparator|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
16652107|NCT02267057|Placebo Comparator|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
16652108|NCT02267044|Active Comparator|Ropivacaine Single Shot Block|Single Shot Interscalene block patients will receive a single shot of 30ml of 0.5% Ropivacaine prior to surgery
16652109|NCT02267044|Active Comparator|Ropivacaine Continuous block|Continuous Interscalene block patients will receive a shot of up to 30ml of 0.5% Ropivacaine and then a catheter is placed. The catheter is secured with Dermabond and Tegaderm. Once surgery is complete, the catheter is connected to a pain ball system which holds 400ml of 0.2% Ropivacaine local anesthetic. The rate is locked in at 8ml/hr. Catheter is pulled once the pain ball is empty.
16652110|NCT02267031|Active Comparator|normoxia and normocapnia|Normoxia PaO2 of 70-140 mm Hg Normocapnia PaCO2 of 35-48 mmHg
16652111|NCT02267031|Active Comparator|hyperoxia and normocapnia|Hyperoxia 150-300 mm Hg Normocapnia PaCO2 of 35-48 mmHg
16652112|NCT02267031|Active Comparator|normoxia and hypocapnia|Normoxia PaO2 of 70-140 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
16652113|NCT02267031|Active Comparator|hyperoxia-hypocapnia|Hyperoxia 150-300 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
16652114|NCT02267018|Active Comparator|nCPAP|Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
16652115|NCT02267018|Active Comparator|NIHFV|Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality is has not been well studied to date.
16652292|NCT02265861|Experimental|Group 2|PCOS without PCO
16652117|NCT02267005|Placebo Comparator|Placebo|patients on this arm will be given a placebo glucose tablet supplement
16652118|NCT02266992|Experimental|Fluenz Tetra|Live attenuated influenza vaccine- Fluenz tetra. Intra-nasal administration of 0.2ml (0.1ml in each nostril).
16652119|NCT02266966|Experimental|F2695|Single dose - 2 capsules / Day on Day 1 and Day 8
16652120|NCT02266966|Placebo Comparator|placebo|Single dose - 2 capsules / Day on Day 1 and Day 8
16652121|NCT02266953|Experimental|Use of communication tool about diet|The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices. This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
16652122|NCT02266953|Active Comparator|Treatment as usual|The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet. The consultations are carried out when the child is 10-, 12- and 15-18 months old.
16652123|NCT02266940|Experimental|200mg DS-1971a oral suspension fasted|200 mg DS 1971a given as oral suspension in fasted condition
16652124|NCT02266940|Experimental|200 mg DS-1971a tablet fasted|single 200 mg DS 1971a oral tablet in fasted condition
16652125|NCT02266940|Experimental|200 mg DS-1971a tablet fed|single 200 mg DS 1971a oral tablet given in fed condition
16652126|NCT02266927|Active Comparator|Flovent® HFA 440µg|Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg
16652127|NCT02266927|Experimental|OPTINOSE™ FLUTICASONE 400µg intranasal|OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally
16652128|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
16652129|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
16652132|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).
~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
16652133|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).
~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
16652134|NCT02266862||Study Group|The purpose of this study is to evaluate the location within the renal artery of maximal angular displacement before and after fenestrated endovascular aortic repair (FEVAR) using CT with end-inspiration and end-expiration CT images before and after repair.
16652135|NCT02266849|Active Comparator|Loperamide|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
16652136|NCT02266849|Placebo Comparator|Placebo|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
16652137|NCT02266836|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
16652138|NCT02266823|Active Comparator|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.
~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
16652139|NCT02266823|Other|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.
~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
16652140|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
16652141|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
16652142|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
16652143|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
16652277|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
16652144|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
16652145|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
16652146|NCT02266784|Experimental|Contingency Management (CM)|ADHD (N=20) & CTRL (N=20). Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system. This level of compensation will increase by the same amount each visit based upon abstinence. In addition, escalating bonus payments will be available for evidence of continued abstinence. The first 10 visits will be daily weekdays. The following 9 visits will be over three weeks. The final 3 treatment visits will occur weekly. The 2nd & 3rd type visits CM payments will be based upon monitoring participants' cotinine levels. A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day. If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days. Also follow-up visits at 3 and 6 months.
16652147|NCT02266784|Other|Treatment as Usual|ADHD (N=20). Transdermal nicotine skin patches (i.e. Habitrol) will be used along with supportive counseling in the treatment as usual groups. Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8). A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d. Also follow-up visits at 3 and 6 months.
16652148|NCT02266771|Active Comparator|NPWT with Instillation|Negative Pressure Wound Therapy with Instillation.
16652149|NCT02266771|Placebo Comparator|NPWT without Instillation|Negative Pressure Wound Therapy without Instillation
16652150|NCT02266758|Other|GDM Screening Method 1|GDM Screening Methods
16652151|NCT02266758|Other|GDM Screening Method 2|GDM Screening Methods
16652152|NCT02266745|Experimental|PT-112 injection|PT-112 Injection, administered by intravenous infusion
16652153|NCT02266732|Other|Interscalene block|
16652154|NCT02266732|Other|Femoral block|
16652155|NCT02266719|Experimental|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
16652156|NCT02266719|Experimental|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
16652157|NCT02266719|Experimental|Arch cohort|Patients enrolled in this arm will be implanted with patient-specific stent-grafts with one to three inner branches or a scallop.
16652158|NCT02266706|Experimental|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to <18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
16652159|NCT02266706|Experimental|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to <12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
16652160|NCT02266706|Experimental|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to <7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
16652161|NCT02266706|Experimental|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to <2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
16652162|NCT02266706|Experimental|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (>32 weeks gestation, 7 days postnatal) to <3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
16652163|NCT02266706|Experimental|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to <3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.
16652164|NCT02266693|Experimental|ICBT Group|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
16652165|NCT02266693|No Intervention|Waitlist Group|Upon completion of the 8-week study wait-list period (i.e. their study participation), the opportunity to participate in iCBT, outside the study framework will be provided.
16652166|NCT02266680|Experimental|Yoga Treatment Group|BFY will be taught by a trained yoga instructor. Group sessions will be offered twice a week for 60 minutes each (i.e., a total of 2 hours per week), for 8 weeks.
16652167|NCT02266680|No Intervention|Waitlist Group|Waitlisted participants will receive BFY at the next available group after their waitlist period is completed
16652168|NCT02266667|Experimental|Progressive scoliosis|Children with progressive scoliosis
16652169|NCT02266667|Experimental|Neuromuscular scoliosis|Children with neuromuscular scoliosis
16652208|NCT02266420|Other|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size < or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
16652249|NCT02266173||Pertuzumab|Participants for whom the treating physician has decided to administer pertuzumab according to standard of care and in line with the current summary of product characteristics (SmPC)/local labeling, will be observed.
16652278|NCT02265952|Experimental|Open-label|Open-label REGN1500
16652170|NCT02266654|Experimental|Prehospital-directed therapy arm|Patients who are hypotensive or whose lactate is ≥ 2.5, prehospital providers will provide a notification to the receiving hospital (Hospital Notification), establish an IV, and provide 1 liter normal saline (NS) bolus of IV fluids. An additional 1 liter normal saline bolus will be given for systolic blood pressure less than 100. Patients who have a history of end-stage renal disease or congestive heart failure would receive only 20 milliliters/kilogram of fluid. If the patient remains hypotensive, Emergency Medical Services will continue providing fluids as is standard of care.
16652171|NCT02266654|Experimental|Control Arm|Prehospital providers will obtain a point of care lactate, establish an IV, and provide IV fluids as judged necessary.
16652172|NCT02266641|Active Comparator|healthy pregnant women|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
16652173|NCT02266641|Experimental|healthy pregnant women's lineal relative with cancer|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
16652174|NCT02266641|Experimental|pregnant women or lineal relative with overweight/obesity|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
16652175|NCT02266641|No Intervention|healthy pregnant women's lineal relative with diabetes|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
16652176|NCT02266628|Experimental|Treatmetn Group A|RSV-F vaccine (0.5mL Injection)
16652177|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
16652178|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
16652179|NCT02266602|Other|Treatment|Patients treated with intraoperative radiation therapy at the time of partial mastectomy.
16652180|NCT02266589|Experimental|Hydrocortisone|little doses of hydrocortisone
16652181|NCT02266589|No Intervention|Placebo|Placebo
16652182|NCT02266576|Active Comparator|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
16652183|NCT02266576|Experimental|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
16652184|NCT02266563||Traumatic Brain Injury (TBI) Group|TBI subjects will have a history of one or more concussions and have a memory complaint and objective decline that is considered to be worse than others of the same age (in the absence of an acute medical event). Severity classifications of the subjects selected for past history of TBI will be based upon established criteria used in TBI research (i.e., traumatically induced physiologic disruption of brain function as indicated by at least one of the following: any period of loss of consciousness, any loss of memory for events immediately before or after the accident, any alteration in mental state at the time of the accident, focal neurologic deficits that may or may not be transient). TBI cases will be those with mTBI (single or multiple concussion). Most recent injury must have occurred at least 1 year prior to study enrollment.
16652185|NCT02266563||Mild Cognitive Impairment (MCI) Group|MCI Subjects will have MMSE scores between 24-30 (inclusive), a CDR of 0.5, have no depression, no history of TBI, and no dementia.
16652186|NCT02266563||Healthy Control Group|Healthy control subjects will have no self or informant-reported problems with cognition, no depression, no history of TBI, and no dementia.
16652187|NCT02266537|Experimental|Tamsulosin|
16652188|NCT02266537|Experimental|Alfuzosin|
16652189|NCT02266537|Experimental|Doxazosin|
16652190|NCT02266537|Placebo Comparator|Placebo|
16652191|NCT02266524|Experimental|Tamsulosin hydrochloride, very low dose|
16652192|NCT02266524|Experimental|Tamsulosin hydrochloride, low dose|
16652193|NCT02266524|Experimental|Tamsulosin hydrochloride, medium dose|
16652194|NCT02266524|Experimental|Tamsulosin hydrochloride, high dose|
16652195|NCT02266511|Experimental|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
16652196|NCT02266511|Experimental|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
16652197|NCT02266498|Experimental|BIBB 515 BS after a standard breakfast|
16652198|NCT02266498|Active Comparator|BIBB 515 BS|
16652199|NCT02266485|Experimental|BIBB 515 BS|
16652200|NCT02266485|Active Comparator|Pravastatin|
16652201|NCT02266485|Placebo Comparator|Placebo|
16652202|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
16652203|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
16652204|NCT02266446|Experimental|Attention & Interpretation Modification|The final product will be web-delivered, so it may be completed at the clinic or home. Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session
16652205|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.
~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine
~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
16652206|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.
~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
16652207|NCT02266420|Other|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size < or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
16652209|NCT02266407|Active Comparator|ASEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
16652210|NCT02266407|Active Comparator|SEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
16652211|NCT02266394|Active Comparator|Mesenchymal stem cell delivery|To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
16652212|NCT02266394|Active Comparator|Mesenchymal stem cell delivery with stent placement|To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.
16652213|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
16652214|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
16652215|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
16652216|NCT02266368|No Intervention|Control group|This arm will include patients with non-coated stents
16652217|NCT02266368|Active Comparator|Antimicrobeal group|This arm will include patients with antimicrobeal coated stents
16652218|NCT02266355|Experimental|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
16652221|NCT02266316|Experimental|Mask|Using mask that warms air at the mouth by utilising body heat
16652222|NCT02266316|No Intervention|No mask|Not using any mask that warms air at the mouth by utilising body heat
16652223|NCT02266303|Experimental|With checklist|Doctors will initiate insulin with the aid of a checklist
16652224|NCT02266303|No Intervention|Without checklist|Doctors will initiate insulin without the use of the checklist
16652225|NCT02266290|Experimental|Kinesio-Tape group|In this study, Sport tex® kinesiotape over lateral ankle (6cm*2.5m) is used.
16652226|NCT02266290|Placebo Comparator|Placebo Tape Group|In the placebo group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used. With patient in the same position described above, horizontal strips were placed covering the sural region with no defined direction.
16652227|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
16652228|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
16652229|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
16652230|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
16652231|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
16652232|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
16652233|NCT02266264|Experimental|100 milligrams of hydrocortisone|100 milligrams per day of hydrocortisone is the starting dosage.
16652234|NCT02266264|Active Comparator|200 milligrams of hydrocortisone|200 milligrams per day of hydrocortisone is the starting dosage.
16652235|NCT02266251||Surgical AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the Transcatheter Valve Therapies (TVT) Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS Adult Cardiac Surgical DAtabase (ACSD) (Jan 2011-Dec 2013).
16652236|NCT02266251||Transcatheter AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the TVT Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS ACSD (Jan 2011-Dec 2013).
16652237|NCT02266238|Experimental|Group 1|DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
16652238|NCT02266238|Experimental|Group 2|Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
16652239|NCT02266238|Experimental|Group 3|Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula
16652240|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
16652241|NCT02266212|Active Comparator|Smoke|Fagerstrom test for nicotine dependence
16652242|NCT02266212|Active Comparator|Pain|pain during post-operation Day1 to Day4
16652243|NCT02266212|Active Comparator|Morphine|Morphine consumption during post-operation Day1 to Day4
16652244|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
16652245|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
16652246|NCT02266186|Experimental|Internet CBT|Intervention:Internet-based cognitive behavioural therapy.
16652247|NCT02266186|Active Comparator|Traditional CBT|Intervention:Traditional CBT given by a therapist following given modules.
16652250|NCT02266160|Experimental|1|"71 tinnitus patients treated with 2 gram EMLA 5% cream a day for 4 days, 4 hours a day.
~we will compare the questionnaires results before and after 4 days of treatment to see whether EMLA cream changes the degree of suffer from tinnitus"
16652251|NCT02266160|Sham Comparator|2|71 tinnitus patients using cetomacrogol cream (lotion cream, does not contain any drug) for 4 days. these patients will fulfill the questionnaires as the investigational group.
16652252|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1
~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1
~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29
~PART 2
~Cycle 1: Required
~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1
~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29
~Cycle 2: Optional
~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181
~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209
~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
16652253|NCT02266134|Experimental|Standardized Implementation|Sites randomized to the standardized condition will be expected to use the Patient Health Questionnaire prior to each session with a depressed client and they will work as a team to maximize fidelity. Sites in this arm will receive the standard implementation of measurement based care intervention.
16652254|NCT02266134|Experimental|Tailored Implementation|Sites randomized to the tailored condition will develop a site-specific protocol for use of the Patient Health Questionnaire and they will work as a team to maximize the fit of measurement based care to this clinic. Sites in this arm will receive the tailored implementation of measurement based care intervention.
16652255|NCT02266121|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.
~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
16652256|NCT02266121|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
16652257|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
16652258|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
16652259|NCT02266095|Active Comparator|Oval-8 Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.
~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee). Oval-8 splints are not commonly used for treatment of thumb CMC arthritis.
~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
16652260|NCT02266095|Active Comparator|Tee Pee Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.
~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).
~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
16652261|NCT02266095|Active Comparator|Forearm Based Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.
~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).
~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
16652262|NCT02266069|Other|Research cluster 1: Antwerp|The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
16652263|NCT02266069|Other|Research cluster 2: Mons|The first French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from November 2014.
16652264|NCT02266069|Other|Research cluster 3: Brussels|The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
16652265|NCT02266069|Other|Research cluster 4: Limburg|The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
16652266|NCT02266069|Other|Research cluster 5: ?|A second French-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2015.
16652267|NCT02266056|Experimental|Deep neuromuscular relaxation|
16652268|NCT02266056|Active Comparator|Moderate neuromuscular relaxation|
16652269|NCT02266030|Experimental|Cilostazol|Cilostazol 100-200 mg qd
16652270|NCT02266030|Active Comparator|Aspirin|Asprin 100mg qd for active comparator
16652271|NCT02266017|Experimental|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
16652272|NCT02266017|Active Comparator|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
16652273|NCT02266004|Experimental|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
16652274|NCT02265978|Experimental|CopeSmart|
16652275|NCT02265978|No Intervention|Control|
16652276|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
16652279|NCT02265939|Placebo Comparator|0% NPO-13|Placebo
16652295|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
16652296|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
16652297|NCT02265835||Cases of anastomotic airway complication|Cases of anastomotic airway complication
16652298|NCT02265835||Patients with normal anastomotic healing|Patients with normal anastomotic healing
16652299|NCT02265822|Experimental|melatonin|0.5 mg/kg (max 20 mg) oral melatonin premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding water in a syringe without needle.
16652300|NCT02265822|Active Comparator|midazolam|0.5 mg/kg (max 20 mg) oral midazolam premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding 5% dextrose in a syringe without needle.
16652301|NCT02265809|Experimental|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2.
16652302|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
16652303|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
16652304|NCT02265783|Other|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
16652305|NCT02265770|Experimental|Stratum 1 arm A|Conformal radiotherapy followed by 16 weeks of VEC + CDDP.
16652306|NCT02265770|Active Comparator|Stratum 1 arm B|Conformal radiotherapy.
16652307|NCT02265770|Experimental|Stratum 2 arm A|VEC + HD-MTX followed by conformal radiotherapy +/- boost
16652308|NCT02265770|Active Comparator|Stratum 2 arm B|VEC followed by conformal radiotherapy +/- boost
16652309|NCT02265770|Experimental|Stratum 3 arm A|Chemotherapy + Valproate.
16652310|NCT02265770|Active Comparator|Stratum 3 arm B|Chemotherapy
16652311|NCT02265757|Experimental|No Cognitive Rehabilitation|Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Support Group, Wellness Education and Physical Exercise.
16652312|NCT02265757|Experimental|No Computer Brain Fitness Training|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Support Group, Wellness Education and Physical Exercise
16652313|NCT02265757|Experimental|No Support Group|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Wellness Education and Physical Exercise
16652314|NCT02265757|Experimental|No Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Physical Exercise
16652315|NCT02265757|Experimental|No Physical Exercise|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Wellness Education
16652316|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
16652317|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
16652318|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
16652319|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
16652320|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
16652321|NCT02265731|Experimental|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
16652322|NCT02265731|Experimental|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
16652323|NCT02265731|Experimental|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
16652324|NCT02265731|Experimental|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
16652325|NCT02265718||(Amyloid Negative)|
16652326|NCT02265718||Amyloid Positive|
16652327|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.
~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
16652328|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.
~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
16652329|NCT02265679|Experimental|BIIL 284 BS, low dose in pediatric patients|
16652330|NCT02265679|Experimental|BIIL 284 BS, medium dose in pediatric patients|
16652331|NCT02265679|Experimental|BIIL 284 BS, high dose in pediatric patients|
16652332|NCT02265679|Experimental|BIIL 284 BS, low dose in adult patients|
16652333|NCT02265679|Experimental|BIIL 284 BS, medium dose in adult patients|
16652334|NCT02265679|Experimental|BIIL 284 BS, high dose in adult patients|
16652335|NCT02265679|Placebo Comparator|Placebo|
16652336|NCT02265666|Experimental|BIIL 284 BS Tablet FF|
16652337|NCT02265666|Active Comparator|BIIL 284 BS tablet C|
16652338|NCT02265653|Experimental|BIIL 284 BS tablet C|
16652339|NCT02265653|Experimental|BIIL 284 BS tablet D|
16652340|NCT02265653|Active Comparator|BIIL 284 BS WIF tablet|
16652341|NCT02265640|Experimental|BIIL 284 BS boli - fasted|
16652342|NCT02265640|Experimental|BIIL 284 BS boli - fed|
16652343|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fasted|
16652344|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fed|
16652345|NCT02265627|Experimental|BIIL 284 BS, normal hepatic function|
16652346|NCT02265627|Experimental|BIIL 284 BS, mild hepatic impairment|
16652347|NCT02265627|Experimental|BIIL 284 BS, moderate hepatic impairment|
16652348|NCT02265614|Experimental|PGS|blastocyst biopsy and chromosomal analysis
16652349|NCT02265614|No Intervention|control|regular IVF
16652350|NCT02265601|Experimental|computer-based decision aid|"Making Your Wishes Known: Planning Your Medical Future- Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team."
16652351|NCT02265601|Active Comparator|standard care|paper/pencil living will form
16652352|NCT02265588|No Intervention|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
16652353|NCT02265588|Experimental|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
16652354|NCT02265575|Experimental|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
16652355|NCT02265562|Experimental|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
16652356|NCT02265562|Placebo Comparator|Placebo|60 minutes before the surgery 2 tablets of placebo tablets inserted rectally
16652357|NCT02265536|Experimental|LY3022855 - 1.25 mg/kg Dose A|1.25 milligram per kilogram (mg/kg) LY3022855 administered intravenously (IV), once every two weeks. Treatment is 6 week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
16652358|NCT02265536|Experimental|LY3022855 - Dose B|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
16652359|NCT02265536|Experimental|LY3022855 - Dose C|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
16652360|NCT02265536|Experimental|LY3022855 - Dose D|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
16652361|NCT02265523|No Intervention|Standard Post-op Exercise Group|The standard post-operative exercises are already currently recommended to patients. Briefly, they include deep breathing and coughing, ankle pumping, buttock contractions, and static quadriceps strengthening. These are performed on a daily basis , 2-3 times per day, 30 repetitions.
16652362|NCT02265523|Experimental|Viscus Group|The Viscus (intervention) group will complete the standard post-operative exercises and will also have access to a Viscus V1.5 cycle ergometer 24 hours per day in their recovery room to use at their leisure.
16652363|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
16652364|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
16652365|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
16652366|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
16652367|NCT02265484|Experimental|Lactulose + Rifaximin + Bromocriptine|
16652368|NCT02265484|Active Comparator|Lactulose+Rifaximin+Placebo|
16652369|NCT02265471||university hospital|university hospital
16652370|NCT02265471||large or small public hospitals|large or small public hospitals
16652371|NCT02265471||private HCFs|private HCFs
16652372|NCT02265471||referral centers for cancer|referral centers for cancer
16652373|NCT02265471||chirurgical facilities, clinic|chirurgical facilities, clinic
16652374|NCT02265471||mixed group|local hospitals, long term care and post-op and rehabilitation facilities, and nursing homes
16652375|NCT02265458|Experimental|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
16652376|NCT02265458|Active Comparator|Sensory isolation|Sensory isolation
16652377|NCT02265458|No Intervention|Standard of care|Standard of care
16652378|NCT02265445|Active Comparator|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
16652379|NCT02265445|Active Comparator|Deescalation therapy|Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy
16652380|NCT02265432|Experimental|Mobile technology intervention|"General physical activity educational materials
~Wearable activity tracking devices to enable the intervention participants to self-monitor their physical activity behavior and receive real-time feedback
~Access to an online map of Singapore providing location based information about leisure time physical activity opportunities
~Personalized text messages which include, educational information, tailored theory-based motivational messages, as well as compliance enhancing reminders"
16652381|NCT02265432|Other|Control|1.General physical activity educational materials
16652382|NCT02265419|Experimental|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
16652383|NCT02265406|Experimental|Ceftriaxone|
16652384|NCT02265406|Placebo Comparator|Sodium Chloride|
16652385|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
16652386|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
16655519|NCT02245438|Experimental|TPV/RTV high dose|
16652387|NCT02265380|Experimental|Treatment with OptiVein|The patient will have an IV catheter placed with the use of OptiVein device.
16652388|NCT02265380|Active Comparator|Treatment with Vasofix Certo|The patient will have an IV catheter placed with the use of Vasofix Certo device.
16652389|NCT02265367|Experimental|Levomilnacipran|In this three week period, baseline measures are obtained during the first week, levomilnacipran will be started during the second week and effects on smoking behavior will be assessed during the third week
16652390|NCT02265367|Placebo Comparator|Placebo|In this three week period, baseline measures are obtained during the first week, placebo will be started during the second week and effects on smoking behavior will be assessed during the third week
16652391|NCT02265354|Experimental|Collective-Intelligence computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a collective intelligence recommender systems algorithm for up to 6 months
16652392|NCT02265354|Active Comparator|Rule-based computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a rule-based algorithm for up to 6 months
16652393|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16652394|NCT02265328|Experimental|Bovine colostrum + prednisolone|"Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
~Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. If Lilli score > 0.45 after 7 days, then GC would be stopped and patients will be counselled for liver transplantation.
~Oral Bovine colostrum (200 ml (20 gram) TDS × 2 months."
16652395|NCT02265315|Sham Comparator|LSVT +sham TMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS)
16652396|NCT02265315|Active Comparator|LSVT +left rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to left side of head
16652397|NCT02265315|Active Comparator|LSVT + right rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to right side of brain
16652398|NCT02265302|Experimental|BIIL 284 BS oral solution|
16652399|NCT02265302|Experimental|BIIL 284 BS WIF tablets|
16652400|NCT02265302|Placebo Comparator|Placebo|
16652401|NCT02265289|Experimental|Lefradafiban with clopidogrel|"All patients received the same treatment:
~Lefradafiban only (day 1-4)
~Lefradafiban in combination with Clopidogrel (day 5-8)
~Clopidogrel only (day 9-12)"
16652402|NCT02265276|Active Comparator|Saroglitazar Group|Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks
16652403|NCT02265276|Placebo Comparator|Pioglitazone Group|Tab Pioglitazone 30 mg daily fixed dose for 24 weeks
16652404|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck
~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within two years after initial hospital stay."
16652405|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at maximum n= 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 104 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 years in Berlin.
~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
16652406|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.
16652407|NCT02265263||Surgical patients - 7 Tesla MRI|A study Group of at maximum n= 80 should be collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
16652408|NCT02265250||Asymptomatic, CACS <300|"5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) <300
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)"
16652409|NCT02265250||Asymptomatic, CACS ≥300|"5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
16652410|NCT02265250||Stable angina|"5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
16652411|NCT02265250||Recent acute MI|"5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
16652412|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
16652413|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
16652414|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
16652415|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
16652416|NCT02265224|Experimental|NAC 600 mg uncoated tablet|single dose of one tablet
16652417|NCT02265224|Active Comparator|NAC 600 mg coated tablet|single dose of one tablet
16652418|NCT02265211|Experimental|Self-Help App|Smartphone app designed to teach cognitive defusion.
16652419|NCT02265198||PC Group|patients with Pulmonary Contusion on chest computed tomography (CT)
16652420|NCT02265198||Control Group 1|Uninjured patients undergoing elective surgical procedures that will require intubation and mechanical ventilation
16652421|NCT02265198||Control Group 2|Trauma patients without chest injury who are mechanically ventilated
16652422|NCT02265198||MICU group|Patients in the Medical ICU who are mechanically ventilated with acute respiratory failure
16652423|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
16652424|NCT02265172|Experimental|Physiotherapy screening|"Screening consisted of a 60-min appointment including assessment, diagnosis and management. The patients received advice regarding ergonomics, exercises and/or treatment when needed. Management options were;
~Referral for orthopaedic surgeon consultation.
~Referral back to the patient's General Practitioner.
~Referral for further investigation.
~Referral to the physiotherapy or the occupational therapy clinic."
16652425|NCT02265172|Active Comparator|Standard practice (orthopaedic surgeon)|"Appointment was 15 min, including assessment, diagnosis and management. The patients received advice, prescriptions or injections when needed. Management options were;
~Referral for orthopaedic intervention.
~Referral back to the patient's General Practitioner.
~Referral for further investigation.
~Referral to the physiotherapy or the occupational therapy clinic."
16652426|NCT02265159|Other|Focal Therapy Using High Intensity Focused Ultrasound|
16652427|NCT02265120|Experimental|primary care providers by region|A questionnaire will be given to a randomized sample of primary care providers who care for patients in the 194 federally designated regions of Primary Care provider shortage within California will be studied.
16652428|NCT02265107|Experimental|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
16652429|NCT02265094|Experimental|Patients|Electroencephalography and neuropsychological tests in children with autism
16652430|NCT02265094|Experimental|Control|Electroencephalography and neuropsychological tests in children without autism
16652431|NCT02265081|Active Comparator|nulliparous women|internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
16652432|NCT02265081|Experimental|parous women|those who had vaginal delivery in the past; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
16652433|NCT02265081|Experimental|parous women - VBAC|those with previous LSCS and no vaginal births; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
16652434|NCT02265055|Active Comparator|transfer early cleavage embryos (EC)|transfer early cleavage embryos
16652435|NCT02265055|Active Comparator|transfer non early cleavage embryo (NEC)|transfer non early cleavage embryos
16652436|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
16652437|NCT02265029|Active Comparator|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
16652438|NCT02265029|Sham Comparator|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
16652439|NCT02265016||Patients with CAD|Patients with stable coronary artery disease
16652440|NCT02265016||Patients with ACS|Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
16652441|NCT02265016||healthy control group|healthy control group without clinical apparent arteriosclerosis
16652442|NCT02265003||Healthy young age|Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
16652443|NCT02265003||Healthy middle age|Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
16652444|NCT02265003||Healthy old|Healthy subjects in age of >70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
16652445|NCT02265003||Patients|Patients with atherosclerosis
16652446|NCT02264990|Experimental|Veliparib + Carboplatin + Paclitaxel|"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.
~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
16652447|NCT02264990|Active Comparator|Investigator's Choice Chemotherapy|"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:
~Carboplatin AUC 6 mg/mL*min + paclitaxel 200 mg/m²
~Cisplatin 75 mg/m² + pemetrexed 500 mg/m²
~Carboplatin AUC 6 or AUC 5 mg/mL*min + pemetrexed 500 mg/m²
~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
16652448|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
16652449|NCT02264964|Experimental|internal jugular vein catheterization|900 patients will be received temporary central vena catheterization in right internal jugular vein with non-cuff GamCath® catheter.They will undergo AVF creation.
16652450|NCT02264964|Experimental|femoral vein catheterization|500 patients will be received temporary central vena catheterization in femoral vein with non-cuff GamCath® catheter, which are unsuitable for right internal jugular vein catheterization.They will undergo AVF creation.
16652451|NCT02264951|Active Comparator|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
16656619|NCT02238119|Active Comparator|tiotropium|
16652452|NCT02264951|Active Comparator|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
16652453|NCT02264951|Active Comparator|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
16652454|NCT02264951|Placebo Comparator|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
16652455|NCT02264938|No Intervention|Observation|Patients with AREDS category 2 and 3 AMD are observed during 1 year
16652456|NCT02264938|Active Comparator|Antioxidant|Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
16652457|NCT02264925|Experimental|Deep Brain Stimulation|All of included patients will receive a standard deep brain stimulation of the thalamus in order to reduce their essential tremor
16652458|NCT02264912||stent-PCI patients|Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
16652459|NCT02264899|Experimental|Alzheimer's disease and related disorders|
16652460|NCT02264886|Experimental|Arm 1: Stereotactic body radiation therapy|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
~All patients will undergo MRI simulation in positioning appropriate for the specific treatment site. When medically feasible and applicable, patients will be simulated with IV and small bowel contrast (for non-thorax cases)."
16652461|NCT02264873|Other|Decitabine|This is a 3+3 design of dose escalation
16652462|NCT02264860|Other|Nutritional Supplements Zinc and SAMe|All men subjects will be started on 30 mg/day and women will be started on 25mg of elemental zinc plus 1600 mg/day of SAMe.
16652463|NCT02264847|Active Comparator|Clomiphene citrate plus hCG|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response could be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size . Women will receive 5,000 IU human chorionic gonadotrophin trigger in the morning between 9 and 10 a.m. and the couple will be advised to have intercourse the following night, about 36 hours later.
16652464|NCT02264847|Active Comparator|Clomiphene Citrate alone|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response will be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size , the women will be advised to have intercourse frequently over the next few days.
16652465|NCT02264834|Active Comparator|Control group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
16652466|NCT02264834|Experimental|Ambulatory group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
16652467|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
16652468|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
16652469|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
16652470|NCT02264808||Developmental outcomes|A developmental assessment (Bayley-III) of children 18-20 months who already enrolled in Florida Neonatal Neurologic Network. As part of this previous study, these children were born with Hypoxic Ischemic Encephalopathy (HIE) and underwent therapeutic cooling after birth.
16652471|NCT02264795|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline.
16652472|NCT02264795|Active Comparator|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
16652473|NCT02264782|Experimental|Group I (PreView)|Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.
16652474|NCT02264782|Active Comparator|Group II (educational video)|Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.
16652475|NCT02264769|Active Comparator|Carbetocin 20mcg|Patient is given carbetocin 20 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16652476|NCT02264769|Active Comparator|Carbetocin 100mcg|Patient is given carbetocin 100 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
16652477|NCT02264756||Ward CAP|Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
16652478|NCT02264743|Experimental|Femoston Conti 0.5mg/2.5mg|"Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg & dydrogesterone 2.5 mg
~Once a day
~The duration is six months.
~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
16652479|NCT02264743|Active Comparator|EVOREL® CONTI transdermal patches|"EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .
~The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .
~The duration is six months.
~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
16652480|NCT02264730|Experimental|Clot Foam|Application of Clotfoam
16652481|NCT02264717|Active Comparator|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
16652482|NCT02264717|Active Comparator|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
16652555|NCT02264288|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
16652483|NCT02264704|Experimental|High intensity exercise|High intensity exercise Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks.
16652484|NCT02264704|Experimental|Moderate intensity exercise|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks.
16652485|NCT02264704|No Intervention|Usual Care|Participants receive usual medical care.
16652486|NCT02264691||Normal (healthy volunteers)|No Research Intervention. Clinically indicated interventions only.
16652487|NCT02264691||Mild Asthmatics|No Research Intervention. Clinically indicated interventions only.
16652488|NCT02264691||Mild to Moderate Asthmatics|No Research Intervention. Clinically indicated interventions only.
16652489|NCT02264691||Severe Asthmatics|No Research Intervention. Clinically indicated interventions only.
16652501|NCT02264665||Sunitinib|
16652502|NCT02264665||Afinitor|
16652503|NCT02264665||other treatment (chémotherapy, SSA..)|
16652504|NCT02264652|Experimental|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS approximately 2mA will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the central cathodal electrode placed over the identified target and surrounding return electrodes forming approximately a 5-cm radius ring.
16652505|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
16652506|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
16652507|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
16652508|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
16652509|NCT02264626|Experimental|acutely ill patients|administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.
16652510|NCT02264613|Experimental|Dose Regimen A (DR-A)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.
16652511|NCT02264613|Experimental|Dose Regimen B (DR-B)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle
16652512|NCT02264613|Experimental|Dose Regimen C (DR-C)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle
16652513|NCT02264613|Experimental|Combination with palbociclib|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle
16652514|NCT02264587|Experimental|mosapride|mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days
16652515|NCT02264587|Active Comparator|domperidone|domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days
16652516|NCT02264574|Experimental|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
16652556|NCT02264288|Placebo Comparator|Placebo|Identically matching placebo administered IM on Study Days 1 and 8
16652557|NCT02264275|Experimental|Aerobic Exercise Training|An 8-week Nintendo Wii at-home dancing exergame Intervention
16656620|NCT02238119|Active Comparator|formoterol|
16652517|NCT02264574|Experimental|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.
~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
16652518|NCT02264561|Placebo Comparator|Placebo|Mannitol administered at visit 1 and at visit 2
16652519|NCT02264561|Active Comparator|caffeine|caffeine administered at visit 1 and at visit 2
16652520|NCT02264548|Experimental|Arm 1|Radiation: Radio-Ablation
16652521|NCT02264535|Experimental|0.1mg/ml Ginkgolides Meglumine Injection|Injection, 0.1mg/ml.
16652522|NCT02264535|Experimental|1mg/ml Ginkgolides Meglumine Injection|Injection, 1mg/ml.
16652523|NCT02264535|Experimental|5mg/ml Ginkgolides Meglumine Injection|Injection, 5mg/ml.
16652524|NCT02264522|Experimental|Single Arm|"All patients will be enrolled in the same intervention arm. Interventions are implemented based in 1-4 event levels on the device. Interventions include: Place dialysis chair into position 3, Decrease dialysate temperature, Decrease ultrafiltration rate by 25%, and Decrease ultrafiltration rate by 50%."
16652525|NCT02264509||Arterial insufficiency and HIV|Of a cohort of 206 HIV patients will be randomly selected 206 for Ankle-brachial index to identify wich suffer symptomatic or asymptomatic arterial insufficiency
16652526|NCT02264496|No Intervention|Control|Standard pre-operative care
16652527|NCT02264496|Experimental|Exercise|A 2-4 week low volume, moderate intensity, supervised, one to one, individualised exercise programme. '
16652528|NCT02264483||COPD exacerbation|"No intervention.
~The subjects will be divided in 2 subgroups according to the image study:
~COPD exacerbation with pneumonia
~COPD exacerbation without pneumonia"
16652529|NCT02264483||COPD stable patients|
16652530|NCT02264470||Patients with clinical stroke|All patients with stroke, 18 years or older, are asked for participation.
16652531|NCT02264457|Other|First eye closed loop haptic|subjects implanted with the Closed loop haptic during first eye surgery and the plate haptics toric intraocular lens during second eye surgery
16652532|NCT02264457|Other|First eye plate haptic|subjects implanted with the plate haptic toric during first eye surgery and the closed loop haptic toric intraocular lens during second eye surgery
16652533|NCT02264444|Experimental|Cholecystectomy visualization|All patients will undergo a standard single site cholecystectomy and will have their operation recorded and scored for visualization.
16652534|NCT02264418|Experimental|ODM 203|Oral capsules given once daily dosage 50-800mg
16652535|NCT02264418|Experimental|ODM-203|Oral tablets given once daily 200-1600mg
16652536|NCT02264392|Active Comparator|Ultrasound Guided|Ultrasound Guided Incision and Drainage- Patients will undergo ultrasound guided drainage of the abscess using bedside ultrasound
16652537|NCT02264392|Active Comparator|Blind I&D|Blind Incision and Drainage- Patients will undergo drainage of the abscess using physical exam.
16652538|NCT02264379||normal fractionated irradiation|
16652539|NCT02264379||hypo fractionated irradiation|
16652540|NCT02264366|Experimental|At Risk Group: ACCELERATION program|"This At Risk Group will include ;People at risk of cancer referred from UHN partners and community practices. Also included in this group are; First Nations population of BC, Asians and South Asian populations from Greater Vancouver and the working population of the City of Richmond employees. At the Montreal site users of the YMCA with risk factors for, or family history of, cancer and other chronic diseases will be targeted. And finally, in Nova Scotia the At Risk Group will be identified as being at risk of cancer and other chronic diseases referred from community practices and from the workplace population of the Capital District Health Authority (CDHA).
~Intervention: Motivational Communication for Health Behavior management"
16652541|NCT02264366|Experimental|Friends & Family -ACCELERATION Program|This group includes family and friends of cancer survivors and family and friends of cardiac & COPD rehab patients. The intervention includes Motivational Communication for Health Behavior management
16652542|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
16652543|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
16652544|NCT02264340|Active Comparator|Control|Relaxation technique
16652545|NCT02264340|Experimental|Experimental|Combined treatment
16652546|NCT02264327|Experimental|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.
~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
16652547|NCT02264327|Active Comparator|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.
~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
16652548|NCT02264327|Active Comparator|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.
~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
16652549|NCT02264314|Experimental|Intervention|This group received an audiological rehabilitation program with a tele-educative intervention boost
16652550|NCT02264314|Placebo Comparator|Control|This group received no intervention
16652551|NCT02264301|Active Comparator|Puerarin injection 400 mg|Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks
16652552|NCT02264301|Experimental|Qingkailing injection 40 ml|Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks
16652553|NCT02264288|Experimental|3 x 10^6 cells|Human Placenta Derived cells (PDA-002) administered intramuscularly (IM) on Study Days 1 and 8
16652554|NCT02264288|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
16656659|NCT02237820|Experimental|Dexamethasone|
16652558|NCT02264262|Experimental|Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
16652559|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
16652560|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
16652561|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
16652562|NCT02264236|Experimental|P10s-PADRE vaccine|Subjects will be immunized by administration of either three or four doses of P10s-PADRE vaccine over a six-week period at a dose level of 500 micrograms (µg) per injection depending on the slandered of care therapy they receive for their lung cancer.
16652563|NCT02264223|Active Comparator|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.
~Fermented red clover isoflavones in aglycone form"
16652564|NCT02264223|Active Comparator|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.
~Fermented red clover isoflavones in aglycone form"
16652565|NCT02264223|Active Comparator|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt
~Fermented red clover isoflavones in aglycone form"
16652566|NCT02264223|Active Comparator|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid
~Fermented red clover isoflavones in aglycone form"
16652567|NCT02264223|Active Comparator|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones
~Unfermented glycosides (as aglycone equivalents)"
16652568|NCT02264210|Experimental|Intervention group|Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
16652569|NCT02264210|No Intervention|Observation group|Observation.
16652570|NCT02264197|Experimental|BIBX 245 CL - fed|after a light breakfast with 40 g fat
16652571|NCT02264197|Active Comparator|BIBX 245 CL - fasted|
16652572|NCT02264184|Experimental|Tamsulosin + Paroxetine|"Tamsulosin: q.d on day 1
~Paroxetine: higher dose q.d. on days -7 to 2 q.d., lower dose on days -10 to -8 and 3 to 5"
16652573|NCT02264184|Active Comparator|Tamsulosin|Tamsulosin: q.d on day 1
16652574|NCT02264171|Experimental|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
16652575|NCT02264171|Active Comparator|Tamsulosin HCl|Tamsulosin HCl given at day 1
16652576|NCT02264158|Experimental|Telmisartan high|
16652577|NCT02264158|Experimental|Telmisartan low|
16652578|NCT02264158|Active Comparator|Lacidipine high|
16652579|NCT02264158|Active Comparator|Lacidipine low|
16652580|NCT02264158|Experimental|Telmisartan+Lacidipine|
16652581|NCT02264158|Placebo Comparator|Placebo|
16652582|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - low|
16652583|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - medium|
16652584|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - high|
16652585|NCT02264145|Experimental|Ethanolic Solution From Respimat®|
16652586|NCT02264132|Experimental|Pramipexole ER tablet versus Pramipexole IR tablet|
16652587|NCT02264132|Experimental|Pramipexole IR tablet versus Pramipexole ER tablet|
16652588|NCT02264119|Experimental|Lefradafiban tablet with Pantoprazole|
16652589|NCT02264119|Active Comparator|Lefradafiban tablet without Pantoprazole|
16652590|NCT02264119|Experimental|Lefradafiban double chamber sachet with Pantoprazole|
16652591|NCT02264119|Active Comparator|Lefradafiban double chamber sachet without Pantoprazole|
16652592|NCT02264106|Experimental|Lefradafiban tablet with pantoprazole|
16652593|NCT02264106|Active Comparator|Lefradafiban tablet|
16652594|NCT02264106|Experimental|Lefradafiban double chamber sachet with pantoprazole|
16652595|NCT02264106|Active Comparator|Lefradafiban double chamber sachet|
16652596|NCT02264093|Experimental|Talsaclidine with Propranol|
16652597|NCT02264093|Active Comparator|Propranolol|
16652598|NCT02264093|Active Comparator|Talsaclidine|
16652599|NCT02264080|Experimental|WAL2014|
16652600|NCT02264080|Placebo Comparator|Placebo|
16652601|NCT02264067|Experimental|Talsaclidine|single rising doses
16652602|NCT02264067|Placebo Comparator|Placebo|
16652603|NCT02264054|Experimental|[14C]talsaclidine, oral|single dose of 20 mg oral solution
16652604|NCT02264054|Active Comparator|[14C]talsaclidine, iv|single dose of 20 mg intravenous (iv) infusion
16652605|NCT02264041|Experimental|Cilobradine, low dose plus itraconazole|Pre-study
16652606|NCT02264041|Active Comparator|Cilobradine, low dose|Pre-study
16652607|NCT02264041|Experimental|Cilobradine, high dose plus itraconazole|main study
16652608|NCT02264041|Active Comparator|Cilobradine, high dose|main study
16652609|NCT02264028|Active Comparator|[14C]-DK-AH 269 CL intravenous|
16652610|NCT02264028|Experimental|[14C]-DK-AH 269 CL oral|
16652611|NCT02264015|Experimental|Cilobradine low|
16652612|NCT02264015|Placebo Comparator|Placebo|
16652613|NCT02264015|Active Comparator|Moxifloxacin|
16652614|NCT02264015|Experimental|Cilobradine high|
16652615|NCT02264002|Experimental|Cilobradine low dose 1|
16652616|NCT02264002|Experimental|Cilobradine low dose 2|
16652617|NCT02264002|Experimental|Cilobradine medium dose|
16652618|NCT02264002|Experimental|Cilobradine high dose 1|
16652619|NCT02264002|Experimental|Cilobradine high dose 2|
16652620|NCT02264002|Active Comparator|Metoprolol succinate|1 tablet on day 1, day 2 followed by two tablets from day 3 to day 14
16652621|NCT02264002|Placebo Comparator|Placebo|
16652622|NCT02263989|Experimental|Telmisartan film coated tablet|
16652623|NCT02263989|Active Comparator|Telmisartan conventional tablet|
16652624|NCT02263976|Experimental|BEA 2180 BR|single rising doses
16652625|NCT02263976|Placebo Comparator|Placebo|
16652626|NCT02263976|Experimental|Sub-Study|
16652627|NCT02263963|Experimental|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
16652628|NCT02263963|No Intervention|No TAP Block|
16652629|NCT02263950|Experimental|LON002|(Artemether sublingual spray)
16652630|NCT02263937|Active Comparator|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
16652631|NCT02263937|Sham Comparator|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
16652632|NCT02263924|Experimental|Experimental: Tocotrienol|Mixed tocotrienol 200mg twice a day for 6 months
16652633|NCT02263924|Placebo Comparator|Placebo (for tocotrienol)|Placebo capsules, 1 capsule twice a day for 6 months
16652634|NCT02263911|Experimental|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
16652635|NCT02263911|Experimental|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
16652636|NCT02263911|Experimental|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
16652637|NCT02263911|Experimental|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
16652638|NCT02263911|Experimental|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
16652639|NCT02263898|Experimental|Treatment (LGX818, MEK162)|Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
16652640|NCT02263885|Experimental|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
16652641|NCT02263872|Experimental|Minocycline|Minocycline 200mg perday
16652642|NCT02263872|Placebo Comparator|comparison group with placebo|Placebo provide
16652643|NCT02263859|Experimental|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
16652644|NCT02263859|Other|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
16652645|NCT02263846||Postmenopausal group|Patients at the age ≥ 60 years with more than one year of menopause, or patients having undergone bilateral oophorectomy.
16652646|NCT02263846||Premenopausal group|Patients with regular menses during recent 3 months and having never received luteinizing hormone-releasing hormone analogue therapy.
16652647|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
16652648|NCT02263807|Experimental|MPFL group|Arthroscopy and MPFL reconstruction
16652649|NCT02263807|Active Comparator|Control|Arhroscopy and rehabilitation
16652650|NCT02263794|Experimental|Image guided bronchial thermoplasty|At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
16652651|NCT02263794|Active Comparator|Conventional bronchial thermoplasty|Patients in this group will undergo conventional 3 stage bronchial thermoplasty (during 3 separate bronchoscopies).
16652652|NCT02263781|Experimental|Control Blood|Patients on routine postinfectious control, blood draw
16652653|NCT02263781|Experimental|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
16652654|NCT02263781|Experimental|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
16652655|NCT02263781|Experimental|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
16652656|NCT02263781|Experimental|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
16652657|NCT02263781|Experimental|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
16652658|NCT02263768|Other|Group 1 - Recall Interval of 12 months|"Oral clinical conditions:
~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
16652659|NCT02263768|Other|Group 2 - Recall Interval of 18 months|"Oral clinical conditions:
~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
16652660|NCT02263755||chronic hepatitis B subjects|Subjects who have been diagnosed with chronic hepatitis B.
16652661|NCT02263742|Experimental|Peer whole health|Peer whole health intervention will be compared to the treatment as usual at Wellness Center to assess healthcare choice and outcomes
16652662|NCT02263742|Active Comparator|EBPs at Wellness Center|EBPs at Wellness Center will be the active comparative to measure healthcare choice and outcomes with the peer whole health intervention
16652663|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
16652664|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
16652665|NCT02263716||Accelerometer|Utilize accelerometers to measure activity in a diverse population of patients with medical or surgical critical illness.
16652666|NCT02263703|Experimental|HPV vaccine|Quadrivalent HPV vaccine
16652667|NCT02263690|Active Comparator|Group Drops|"proparacaine 0.5% drops (Group Drops)
~Patients from group Drops received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.
~Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%."
16652668|NCT02263690|Active Comparator|Group SC|"proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)
~Patients from group SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.
~For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe."
16652669|NCT02263690|Active Comparator|Group Gel|"Lidocaine gel 2% on the eye (Group Gel)
~Patients from Group Gel received 1 mL of 2% lidocaine gel on the eye before receiving the drop of povidone iodine 5%.
~For the patients from Group Gel, 1 mL of 2% lidocaine gel was applied on the eye before receiving the drop of povidone iodine 5%."
16652670|NCT02263677|Experimental|Sitagliptin|60 day supply of 100mg Sitagliptin
16652671|NCT02263651|Active Comparator|Closure with conventional technique with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
16652672|NCT02263651|Experimental|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.
16652673|NCT02263638|Experimental|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period
16652674|NCT02263612||Danish Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
16652675|NCT02263599||Conservatively treated ventral hernias|
16652676|NCT02263599||Surgically treated ventral hernias|
16652677|NCT02263573|Experimental|PEP'C-R|Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
16652678|NCT02263573|Active Comparator|Control group|Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.
16652679|NCT02263560||Post-stroke patients|Patients who experienced stroke and who already recover gait abilities.
16652680|NCT02263560||Control population|Participants matching the criterion (age and gender) of the patients' group.
16652681|NCT02263547|Other|teriflunomide elimination with colestipol|
16652682|NCT02263534|Experimental|minisling|patients in this arm will undergo single incision minisling
16652683|NCT02263534|Sham Comparator|tension free vaginal tape|patients in this arm will undergo tension free vaginal tape
16652684|NCT02263521||physicians|Nationally-representative sample of physicians in all specialties who have direct or indirect patient care responsibilities
16652685|NCT02263521||resident physicians|Nationally-representative of resident physicians in all specialties
16652686|NCT02263521||medical students|Nationally-representative sample of 4th year medical students in all US allopathic medical schools.
16652687|NCT02263508|Experimental|Phase 1b;|Phase 1b: talimogene laherparepvec and pembrolizumab (MK-3475)
16652688|NCT02263508|Experimental|Phase 3 Arm 1;|Phase 3 Arm 1: talimogene laherparepvec and pembrolizumab (MK-3475)
16652689|NCT02263508|Experimental|Phase 3 Arm 2;|Phase 3 Arm 2: placebo and pembrolizumab (MK-3475)
16652690|NCT02263495|Active Comparator|Paclitaxel & Gemcitabine(PG)|Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1& Day8 every 3weeks
16652691|NCT02263495|Experimental|Eribulin & Gemcitabine(EG)|Eribulin 1.0 mg/m2, 2-5min iv ,Day1& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1& Day8 every 3weeks
16652692|NCT02263482|Other|Control group|patients awaiting for evaluation to cardiac rehabilitation or transplantation
16652693|NCT02263482|Experimental|moderate-intensity group|Patients will be submitted to a 8-weeks training program, with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with upper and lower exercises (50% of the 1-maximum repetition test).
16652694|NCT02263482|Active Comparator|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 Kg each).
16652695|NCT02263469|Experimental|Replenine®-VF|
16652696|NCT02263456|Active Comparator|Current Factor IX|
16652697|NCT02263456|Experimental|Replenine®-VF|
16652698|NCT02263443|Experimental|Soap sus enema (S.S.E.)|Patients in S.S.E. group will receive bowel preparation by soap suds enema until clear at night before surgery.
16652699|NCT02263443|Experimental|sodium chloride enema|Patients in unison enema group will receive Unison enema 100 ml per rectal at night before surgery.
16652700|NCT02263443|Placebo Comparator|no enema|Patients will receive none of bowel preparation. NPO after midnight
16652701|NCT02263430|Experimental|Deep Brain Stimulation|Stimulation is on.
16652702|NCT02263430|Sham Comparator|Placebo|Stimulation is off.
16652703|NCT02263417|Active Comparator|Deep Brain Stimulation|Stimulation is on
16652704|NCT02263417|Sham Comparator|Placebo|Stimulation is off
16652705|NCT02263404|Experimental|Deep Brain Stimulation|DBS Implant and stimulation Intervention: Device: Deep Brain Stimulation
16652706|NCT02263391|Experimental|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
16652738|NCT02263196|Experimental|combination of alcohol and betadin|the efficacy of combination of alcohol and povidone iodine on infection related to vascular access
16652739|NCT02263183|Active Comparator|red palm olein(labelled A)|red palm olein (labelled A)
16652740|NCT02263183|Placebo Comparator|palm olein(labelled B)(control)|palm olein(labelled B)(control)
16652741|NCT02263170||All study participants|Healthy (m/f), normal weighted
16652742|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
16652743|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
16652707|NCT02263391|Experimental|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
16652708|NCT02263378|Experimental|supplement|
16652709|NCT02263378|Placebo Comparator|not intervention|
16652710|NCT02263365|No Intervention|Control|
16652711|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
16652712|NCT02263352|Experimental|Lycored soft gels , Scaling and Rootplaning.|Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline
16652713|NCT02263352|Experimental|Scaling and Rootplaning only.|Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.
16652714|NCT02263339|Experimental|Aerobic Exercise|
16652715|NCT02263339|Active Comparator|Stretching Program|
16652716|NCT02263339|Active Comparator|Aerobic Exercise, Healthy Subjects|
16652717|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
16652718|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
16652719|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
16652720|NCT02263300||Supine- Supine|Group A (supine-supine) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global rating scale and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the supine, then Upright position. At the end of one week,the same medical student will then perform the intubation with the mannequin in both positions.
16652721|NCT02263300||Upright-upright|Group B (upright-upright) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position.At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
16652722|NCT02263300||Supine -upright|Group C( supine -upright) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position. At the end of one week, The same medical student will then perform the intubation with the mannequin in both positions.
16652723|NCT02263300||Upright - supine|Group D( upright - supine) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright,then supine position. At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
16652724|NCT02263287|Other|Alzheimer disease (AD)|Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
16652725|NCT02263287|Other|Dementia with Lewy Bodies (DLB)|Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
16652726|NCT02263287|Other|Probable AD and possible DLB|Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale
16652727|NCT02263274|Experimental|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
16652728|NCT02263261|Other|Flex HD Pliable Perforated HADM|Single Arm
16652729|NCT02263248|Experimental|venlafaxine XR plus buprenorphine|Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.
16652730|NCT02263248|Placebo Comparator|venlafaxine XR plus placebo|Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks
16652731|NCT02263235|Experimental|Group 1|60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
16652732|NCT02263235|Experimental|Group 2A|20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
16652733|NCT02263235|Experimental|Group 2B|30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
16652734|NCT02263222|Experimental|MDT-10013|Subjects will receive MDT-10013.
16652735|NCT02263209|Experimental|Bioguard Group|Randomised study to either Bioguard or control stock
16652736|NCT02263209|Active Comparator|Control Group|Randomised study to either Bioguard or control stock
16652737|NCT02263196|Experimental|alcohol and povidone iodine|the efficacy of combination of alcohol and povidone iodine on inflammation related to vascular access
16652744|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
16652745|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
16652746|NCT02263144||histologically-verified <10mm polyps|histologically-verified <10mm polyps, analyzed by virtual chromo-endoscopy using FICE Fujifilm Technology
16652747|NCT02263131|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
16652748|NCT02263131|Active Comparator|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
16652749|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
16652750|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
16652751|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
16652752|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
16652753|NCT02263105|Experimental|CDDP plus Temozolomide|"Patients were treated with CDDP and TMZ. CDDP was administered iv from Day 1 to 3 with everyday dose of 30mg. TMZ was orally administered from Day 1 to 7 and Day 15 to 21, with everyday dose of 125mg/m2 (Level 2). The period of one chemotherapy cycle is 28 days. TMZ dose levels were listed in Table 1.
~Table 1 TMZ dose levels Dose levels Daily TMZ dose( mg/m2/d ) TMZ dose per cycle(mg/m2)
~150 2100
~125 1750
~100 1400
~75 1050"
16652754|NCT02263092|Experimental|15 minutes of physical exercise|the subjects will do physical exercise on a treadmill with 64 to 74% of maxHR
16652755|NCT02263092|Experimental|10 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 77 to 95% of maxHR.
16652756|NCT02263092|Experimental|30 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 57 to 63% of maxHR.
16652757|NCT02263092|Experimental|Rest/control|the subjects will be on 15 or 30 minutes seat without move the legs.
16652758|NCT02263092|Experimental|Anodal tDCS + physical exercise 1|the subjects will be undergo to anodal tDCS + physical exercise 1
16652759|NCT02263092|Experimental|Anodal tDCS + physical exercise 2|the subjects will be undergo to anodal tDCS + physical exercise 2
16652760|NCT02263092|Experimental|Cathodal tDCS + physical exercise 1|the subjects will be undergo to cathodal tDCS + physical exercise 1
16652761|NCT02263092|Experimental|Cathodal tDCS + physical exercise 2|- the subjects will be undergo to cathodal tDCS + physical exercise 2
16652762|NCT02263092|Experimental|Sham tDCS + physical exercise 1|the subjects will be undergo to sham tDCS + physical exercise 1
16652763|NCT02263092|Experimental|Sham tDCS + physical exercise 2|the subjects will be undergo to sham tDCS + physical exercise 2
16652764|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
16652765|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
16652766|NCT02263079|Experimental|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
16652767|NCT02263066||Group 1|Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013
16652768|NCT02263053|Active Comparator|Posterior Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
16652769|NCT02263053|Active Comparator|Caudal Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
16652770|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
16652771|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
16652772|NCT02263027|Experimental|Vaccine, then placebo|1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment followed by 1 injection of normal saline placebo, 0.5mL/dose, 28 days later
16652773|NCT02263027|Experimental|Placebo, then vaccine|1 injection of normal saline placebo, 0.5mL/dose followed by 1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment, 28 days later
16652774|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after the surgery is completed.
16652775|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after unilateral mastectomy or breast conserving surgery is completed.
16652776|NCT02263001|Experimental|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
16652777|NCT02263001|Active Comparator|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
16652778|NCT02262988|Experimental|Autologous cells and knee arthroplasty|Regenerative cells recovered from the patient's infrapatellar fat pad will be processed using the Transpose RTTM system (InGeneron, Inc., Houston, TX, USA). The processed cells are injected into the knee as adjuvant treatment for total knee arthroplasty (TKA).
16652779|NCT02262988|Placebo Comparator|Control|Standard total knee arthroplasty (no fat cells harvested).
16652780|NCT02262975||donepezil (Aricept)|
16652781|NCT02262962|No Intervention|Usual Well-Child Care|No change in Well-Child Visits.
16652782|NCT02262962|Experimental|Redesigned Well-Child Care|The Redesigned Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and text messaging services (HealthyTxt).
16652783|NCT02262949|Experimental|LifeStent Vascular Stent|This is a single arm study and all subjects receive PTA and implantation of one Life Stent Vascular Stent.
16652784|NCT02262936|Active Comparator|Desmopressin|Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
16652785|NCT02262936|Active Comparator|Fesoterodine|Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
16652786|NCT02262923|No Intervention|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.
~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
16652787|NCT02262923|Experimental|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.
~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
16652788|NCT02262910|Experimental|ES414|Cohorts 1-3 of the dose escalation stage of the study (Stage 1) will test weekly doses of 0.2 mcg/kg to 2 mcg/kg. Cohorts 4-9 of the dose escalation stage of the study (Stage 1) will test continuous infusion at flat doses of 25 mcg to 300 mcg per day delivered continuously over 24 hours. The maximum tolerated dose from Stage 1 of the study will be further examined in Stage 2. Patients in cohorts 1-3 will receive ES414 weekly via intravenous (IV) infusion during the first three 28-day cycles and then on Day 1 and 15 of each subsequent cycle until disease progression, intolerable toxicity occurs, or the patient withdraws consent. Patients in cohorts 4-9 will receive ES414 as a continuous IV infusion for 6 months until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
16652789|NCT02262897|Experimental|Nab-paclitaxel single agent|Nab-paclitaxel single agent, either in 130mg/m2 weekly regimen, d1,8,15 every 4 weeks or in 230mg/m2 d1 every 3 weeks
16652790|NCT02262884|Active Comparator|AIS @ 12mmHg pressure|SurgiQuest AirSeal Insufflation System (AIS) set at 12mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
16652791|NCT02262884|Active Comparator|AIS @ 15mmHg pressure|SurgiQuest AirSeal insufflation System (AIS) set at 15 mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
16652792|NCT02262884|Active Comparator|CIS @ 15mmHg pressure|Conventional Insufflation System (CIS) set at 15mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephectomy.
16652793|NCT02262871|Experimental|CF patients HFN|CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
16652794|NCT02262871|Experimental|CF patients NIV|CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
16652795|NCT02262858|Experimental|Telmisartan and HCTZ (fix dose combination)|
16652796|NCT02262858|Active Comparator|Telmisartan and HCTZ (monocomponent)|
16652797|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
16652798|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
16652799|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
16652800|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
16652801|NCT02262845||Group E: Other|In subjects with other indications
16652802|NCT02262832|Other|Leptin study drug|Administration of study drug SQ BID
16652803|NCT02262806|Other|Leptin therapy|leptin administered via SC injections BID
16652804|NCT02262793|Experimental|telmisartan and ASA/ER-DP (concomitant)|
16652805|NCT02262793|Active Comparator|ASA/ER-DP alone|
16652806|NCT02262793|Experimental|telmisartan and ASA/ER-DP (consecutively)|
16652807|NCT02262793|Active Comparator|telmisartan|
16652808|NCT02262780|Experimental|Single low dose Telmisartan with HCTZ|
16652809|NCT02262780|Experimental|Single high dose Telmisartan with HCTZ|
16652810|NCT02262780|Experimental|Multiple high dose Telmisartan with HCTZ|
16652861|NCT02262520|Experimental|Treatment B: Apixaban and Digoxin|Apixaban and Digoxin tablets by mouth on specified days
16652862|NCT02262507|Experimental|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study. Subjects will undergo repeat oto-acoustic measures both wearing the device and not wearing the device. The intervention will be the auto-acoustic measurement - taken while wearing the collar and then again when not wearing the collar.
16652811|NCT02262767|Experimental|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
16652812|NCT02262767|Experimental|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
16652813|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
16652814|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
16652815|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
16652816|NCT02262741|Experimental|MEDI4736 + tremelimumab|
16652817|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
16652818|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
16652819|NCT02262715|Experimental|Part 1|Participants will receive in random order Treatment A (VX-787, 600 mg tablet 2 times a day on Day 1 to 4, followed by VX 787, 600 mg tablet on Day 5); Treatment B (Oseltamivir, 75 mg capsule 2 times a day on Day 1 to 4, followed by oseltamivir 75 mg capsule in the morning on Day 5) or Treatment C (VX-787, 600 mg tablet, 2 times a day orally + oseltamivir, 75 mg capsule, 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + oseltamivir, 75 mg capsule on Day 5). Each participant will receive all three treatments (Treatment A, B and C) in a random sequence.
16652820|NCT02262715|Experimental|Part 2 VX-787|Participants will receive VX-787, 600 mg, tablet 2 times a day, orally on Day 1 to Day 9, followed by single dose of VX-787, 600 mg on Day 10.
16652821|NCT02262715|Experimental|Part 2 Placebo|Participants will receive placebo matching to VX-787, 2 times a day, orally on Day 1 to Day 9, followed by single dose of matching placebo on Day 10.
16652822|NCT02262702||Extended Release Paracetamol|Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
16652823|NCT02262702||Standard Paracetamol|Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
16652824|NCT02262689|Experimental|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
16652825|NCT02262689|Placebo Comparator|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
16652826|NCT02262676||Rivaroxaban|Patients with Atrial fibrillation treated with Rivaroxaban
16652827|NCT02262663|Experimental|Vilaprisan [0.5mg]|0.5 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
16652828|NCT02262663|Experimental|Vilaprisan [1mg]|1 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
16652829|NCT02262663|Experimental|Vilaprisan [2mg]|2 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
16652830|NCT02262663|Experimental|Vilaprisan [4mg]|4 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
16652831|NCT02262650|Active Comparator|Telmisartan alone|
16652832|NCT02262650|Experimental|Telmisartan + Clopidogrel (concomitantly)|
16652833|NCT02262650|Experimental|Telmisartan + Clopidogrel (consecutively)|
16652834|NCT02262650|Active Comparator|Clopidogrel alone|
16652835|NCT02262637||Hypertensive patients - Cardiologists|
16652836|NCT02262637||Hypertensive patients - Nephrologists|
16652837|NCT02262637||Hypertensive patients - Diabetologists|
16652838|NCT02262624|Experimental|Telmisartan/HCTZ fixed combination|
16652839|NCT02262624|Active Comparator|Telmisartan and HCTZ monocomponents|
16652840|NCT02262611||Hypertension patients - Pneumology|
16652841|NCT02262611||Hypertension patients - Cardiology|
16652842|NCT02262611||Hypertension patients - Nephrology|
16652843|NCT02262611||Hypertension patients - Diabetology|
16652844|NCT02262598|Experimental|Telmisartan/HCTZ fixed dose|
16652845|NCT02262598|Active Comparator|Telmisartan and HCTZ monocomponents|
16652846|NCT02262585|Experimental|BIBR 277 tablet|(Mannitol based)
16652847|NCT02262585|Active Comparator|BIBR 277 capsule|
16652848|NCT02262572|Experimental|Telmisartan /HCTZ - compression tablet (DC)|
16652849|NCT02262572|Experimental|Telmisartan /HCTZ - dry granulation tablet (DG)|
16652850|NCT02262572|Active Comparator|Telmisartan /HCTZ - present commercial formulation|
16652851|NCT02262559|Experimental|BIBR 277 tablet|
16652852|NCT02262559|Active Comparator|BIBR 277 capsule|
16652853|NCT02262546|Experimental|Pramipexole|
16652854|NCT02262546|Active Comparator|Moxifloxacin|
16652855|NCT02262546|Placebo Comparator|Pramipexole Placebo|
16652856|NCT02262546|Placebo Comparator|Moxifloxacin Placebo|
16652857|NCT02262533|Experimental|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
16652858|NCT02262533|Experimental|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
16652859|NCT02262533|Experimental|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
16652860|NCT02262520|Experimental|Treatment A: Digoxin|Digoxin tablet by mouth on specified days
16652895|NCT02262234|Experimental|Education Program Type 1|
16652863|NCT02262494|Other|Suspected first episode of DVT|"The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.
~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs"
16652864|NCT02262481|Active Comparator|Dydrogesterone|tocolytic + corticosteroids + Dydrogesterone 10 mg/tablet prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
16652865|NCT02262481|Placebo Comparator|Placebo|tocolytic + corticosteroids + Placebo prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
16652866|NCT02262468||MOM total hip replacements|all patients with MOM 36mm hip replacements
16652867|NCT02262455|Experimental|STM 434|
16652868|NCT02262455|Experimental|STM 434 and Liposomal Doxorubicin|
16652869|NCT02262442|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
16652870|NCT02262442|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
16652871|NCT02262429||ONS QIP|Two (2) hospitals will administer the new rapid, comprehensive oral nutritional supplementation (ONS) QIP.
16652872|NCT02262429||ONS Standard Feeding|"Two (2) hospitals will use their current standard ONS feeding protocol."
16652873|NCT02262416|Placebo Comparator|controls|Normal saline of equivalent volume
16652874|NCT02262416|Active Comparator|case|0.5mg Leuprolide acetate injection
16652875|NCT02262403|Experimental|Hookworm infected|The amount, phenotype and function of Treg will be explored at several time points. Cultures with environmental antigen will be subsequently performed.
16652876|NCT02262403|Active Comparator|Non infected (hookworms) healthy subjects|All the tests done in the experimental hookworm infected group will be also done in the comparator non infected group.
16652877|NCT02262390|Active Comparator|Standard of Care|Partner notification slip is given to the pregnant female participant on the day she receives her syphilis test results to give to their sexual partner encouraging them to come to the STI clinic and be screened for syphilis. The partner notification slip will have a code number, but no identifiable features (no names).
16652878|NCT02262390|Active Comparator|SMS reminders and notification slip for partner screening|Participants will receive weekly SMS reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and on the SMS reminders.
16652879|NCT02262390|Active Comparator|Phone call reminders and notification slip for partner scree|Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
16652880|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
16652881|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
16652882|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
16652883|NCT02262351|Experimental|Screening|"Subjects will undergo three screening methods for atrial fibrillation:
~30 Second Pulse Check Watch BP Home A HeartCheck Hand-held ECG device"
16652884|NCT02262338|Experimental|Treated subjects|AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
16652885|NCT02262325|Experimental|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
16652886|NCT02262312||Patients with myelodysplastic syndrome|Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable
16652887|NCT02262299|Placebo Comparator|Placebo|Receive placebo tablets
16652888|NCT02262299|Active Comparator|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
16652889|NCT02262286||Brain Injury|Brain Injury
16652890|NCT02262286||Control|Healthy, or Head Trauma, or Orthopedic Trauma, or Poly-Trauma
16652891|NCT02262273||Serous ovarian cancer:|Women with platinum-sensitive recurrent serous ovarian cancer
16652892|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
16652893|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
16652894|NCT02262247||Transoral Visualization & Access|Subjects ≥ 22 yrs requiring transoral procedures
16652897|NCT02262221|No Intervention|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
16652898|NCT02262221|Other|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
16652899|NCT02262208|Other|Patients with type 2 diabetes|
16652900|NCT02262208|Other|Healthy|
16652901|NCT02262195||Carboxyhemoglobin|Induced carboxyhemoglobin levels up tp 15 percent.
16652902|NCT02262195||Methemoglobin|Induced methemoglobin levels up to 15 percent.
16652903|NCT02262182|Experimental|KP group|PEP delivery by EzPAP® device with manual chest physiotherapy .
16652904|NCT02262182|Placebo Comparator|KM group|Manual chest physiotherapy only;
16652905|NCT02262169|Active Comparator|Treatment I|2 Omeprazole capsules 20 mg once daily and 1 placebo caplet of DLBS2411, twice daily
16652906|NCT02262169|Experimental|Treatment II|1 DLBS2411 caplet 250 mg twice daily and 2 placebo capsules of Omeprazole once daily
16652907|NCT02262156|Experimental|Cognitive behavioral Therapy|"CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.
~12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks."
16652908|NCT02262156|Active Comparator|Selective serotonin euptake inhibitor|Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.
16652909|NCT02262143|Experimental|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
16652910|NCT02262143|Active Comparator|Comparator|Rosuvastatin 10 mg
16652911|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
16652912|NCT02262117|Placebo Comparator|standard care|No specific treatment (standard care)
16652913|NCT02262117|Experimental|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
16652914|NCT02262104|Experimental|Intensive exercise|Intensive strengthening and balance exercises 1 hour twice a week 12 weeks. Lead by physiotherapists.
16652915|NCT02262104|Placebo Comparator|Control|Control group activities: Social activities one hour twice a week. Light physical activities, reading, conversation, games. Lead by occupational therapist or nursing staff
16652916|NCT02262091|Placebo Comparator|Placebo group|
16652917|NCT02262091|Experimental|Food fibers|
16652918|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
16652919|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
16652920|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
16652921|NCT02262065||Controls|Patients with well tolerated arthroplasties
16652922|NCT02262052|Other|Phase 4 cohort study|MRDTI
16652923|NCT02262039|Active Comparator|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
16652924|NCT02262039|Experimental|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
16652925|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
16652926|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
16652927|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
16652928|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
16652929|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
16652930|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
16652931|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
16652932|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
16652933|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
16652934|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
16652935|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
16652936|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
16652937|NCT02262013|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
16652938|NCT02262013|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program.
16652939|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
16652940|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
16652941|NCT02261987|Active Comparator|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
16652942|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
16652943|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
16652944|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
16652945|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
16652946|NCT02261961|Experimental|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
16652947|NCT02261961|Placebo Comparator|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
16652948|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
16652949|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
16652950|NCT02261935|Active Comparator|Existing Home Care Nursing Practice|Home care nurses provide care based on existing home care practice
16652951|NCT02261935|Experimental|Practice Support Tool Intervention|"The practice support tool intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.
~Update - December 22, 2016 - In some home care offices only, a study nurse will meet with family caregivers who are in the intervention group to deliver the CSNAT intervention. Information arising from the CSNAT about family caregivers' support needs will be communicated by the study nurse to the home care nurse, and incorporated by the home care nurse into the home care plan for the patient and patient's family."
16652952|NCT02261922|Experimental|ticagrelor|ticagrelor treatment
16652953|NCT02261922|Active Comparator|prasugrel|prasugrel treatment
16652954|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
16652955|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
16652956|NCT02261896|Experimental|Placebo|1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
16652957|NCT02261896|Active Comparator|Antibiotic|Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
16652958|NCT02261883|Active Comparator|IV Remodulin|IV Remodulin will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
16652959|NCT02261883|Placebo Comparator|Placebo|Placebo will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
16652960|NCT02261870|Experimental|ALL_patients|MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
16652961|NCT02261857|Experimental|Intervention Arm|Intervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
16652962|NCT02261857|No Intervention|Historical Control Arm|Pre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.
16652963|NCT02261844|Experimental|resveratrol|Resveratrol 1 g daily for 10 days
16652964|NCT02261844|Placebo Comparator|Placebo|Placebo 1 pill daily for 10 days
16652965|NCT02261831|Experimental|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
16652966|NCT02261831|Experimental|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
16652967|NCT02261831|Experimental|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
16652968|NCT02261831|Experimental|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
16652969|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
16652970|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
16652971|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
16652972|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
16652973|NCT02261792|Active Comparator|A : 24 hours bed rest|24 hours bed rest
16652974|NCT02261792|Experimental|B : 24 hours Trendelenburg position|24 hours Trendelenburg position
16652975|NCT02261779|Experimental|Tretinoin & Tranylcypromine|Tretinoin started with 45mg/m2 on day 7 for one year, administered orally as soft capsules, Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets
16652976|NCT02261753|Active Comparator|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
16652977|NCT02261753|No Intervention|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
16652978|NCT02261740|Experimental|Yoga Therapy Group|Participants will attend twice-weekly group yoga classes and be instructed to practice yoga at home one additional hour a week, using a written manual.
16652979|NCT02261727|Placebo Comparator|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
16652980|NCT02261727|Active Comparator|Low-dose theophylline arm|Theophylline 100 mg twice daily
16652981|NCT02261727|Active Comparator|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
16652982|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
16652983|NCT02261701|Experimental|Early mobilization|Intervention is early mobilization, four weeks immobilization postsurgery with collar´n cuff only.
16652984|NCT02261701|Other|Post surgery shoulder lock|Post surgery shoulder lock with abduction cushion 3 weeks and after this period collar´n cuff 3 weeks
16652985|NCT02261688|Other|Subjects in study|All subjects in study are in a cross-over study with 3 interventions sequentially (low salt diet, low salt diet + IV normal saline, liberal salt diet)
16652986|NCT02261675|No Intervention|control group|children undergoing selective lower abdominal surgery received saline before induction
16652987|NCT02261675|Experimental|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
16652988|NCT02261675|Experimental|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
16652989|NCT02261662|Experimental|Ribavirin and Betamethasone|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
~It will be used along with Topical steroids; Betamethasone"
16652990|NCT02261662|Experimental|Betamethasone alone|Topical steroids alone will be used; Betamethasone.
16652991|NCT02261649||Cerebellar Tumor Surgically Removed|"Quantitative Sensory Testing and Neuroimaging
~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)
~Cold water bath
~MRI scanner
~Questionnaires"
16652992|NCT02261649||Healthy Volunteer|"Quantitative Sensory Testing and Neuroimaging
~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)
~Cold water bath
~MRI scanner
~Questionnaires"
16652993|NCT02261636||Pentasa|Treatment according to standard clinical practice.
16652994|NCT02261623||Palliation|Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery
16652995|NCT02261623||Curative intent surgery|Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy
16652996|NCT02261623||Benign biliary strictures|Treatment of benign biliary strictures
16652997|NCT02261623||Other indication|Other indication
16652998|NCT02261610|Experimental|clinical group|In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
16656660|NCT02237820|Active Comparator|Prednisone|
16652999|NCT02261610|Other|PCT group|In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
16653000|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
16653001|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
16653002|NCT02261584|Experimental|Microwave Thermal Coagulation|MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
16653003|NCT02261584|Experimental|Partial Splenic Embolization Catheter|Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has been considered first-line therapy for hypersplenism in many institutions, and has been proposed as an effective alternative to splenectomy for improving peripheral blood cell counts. However, PSE is associated with many complications, including intermittent fever, abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic infarction rate needs to be greater than 50% (8). Thus, severe complications can ensue.
16653004|NCT02261571|Experimental|Moxibustion|A series of moxibustion sessions within six weeks from baseline with adjuvant chemotherapy.
16653005|NCT02261571|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 6 weeks while receiving adjuvant chemotherapy
16653006|NCT02261558|Experimental|Clinical Improvisation Instrumental Music Therapy|Clinical Music Therapy session, 20 minutes. Focus on instrumental improvisation
16653007|NCT02261558|Experimental|Clinical Vocal Improvisation|Clinical Music Therapy session, 20 minutes. Focus on vocal improvisation
16653008|NCT02261558|No Intervention|Control Group|Participants enrolled in control group will complete the same study design, without having a clinical music improvisation
16653009|NCT02261545|Active Comparator|n-3 Fatty Acid Supplemetation|patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
16653010|NCT02261545|Placebo Comparator|Placebo|patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
16653011|NCT02261532|Experimental|TAS-102|
16653012|NCT02261519|Experimental|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
16653013|NCT02261519|Placebo Comparator|Placebo|The control treatment is placebo.
16653014|NCT02261506|Active Comparator|7 days|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
16653015|NCT02261506|Active Comparator|14 days|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
16653016|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
16653017|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
16653018|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
16653019|NCT02261480||Group A: Documented Prior History|"Pediatric and adult participants with sickle cell disease (SCD) with a documented prior history of parvovirus B19 infection (aplastic crisis).
~Group A participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group A."
16653020|NCT02261480||Group B: No Prior History|"Pediatric and adult participants with SCD who have never had a documented parvovirus B19 infection (aplastic crisis).
~Group B participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group B."
16653021|NCT02261480||Group C: Suspected and/or Confirmed|"Sickle cell disease patients with suspected and/or confirmed acute parvovirus B19 infection, the latter defined as febrile illness with anemia without adequate compensatory reticulocytosis.
~Group C participants will have blood draw and nasopharyngeal wash on day 1, day 7±4 days, day 30±7 days, and day 120±14 days."
16653022|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
16653023|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
16653024|NCT02261454|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
16653025|NCT02261454|Active Comparator|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
16653026|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
16653027|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
16653028|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
16653075|NCT02261103|Active Comparator|Pramipexole IR, fasted|Pramipexole immediate release (IR) tablets
16653029|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
16653030|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
16653031|NCT02261402|Experimental|Medisinstart|Patients in this arm will receive the service; Medisinstart
16653032|NCT02261402|No Intervention|Current Practice|Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
16653033|NCT02261389|No Intervention|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
16653034|NCT02261389|Experimental|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
16653035|NCT02261376|Experimental|Caucasian men, aged 18-55 years|
16653036|NCT02261376|Experimental|Caucasian men, aged 65 years or older|
16653037|NCT02261376|Experimental|Japanese men, aged 18-55 years|
16653038|NCT02261376|Experimental|Caucasian women, aged 18-55 years|
16653039|NCT02261363||Ecig group 1|
16653040|NCT02261363||Ecig group 2|
16653041|NCT02261350|Experimental|Food Fortification|Food Fortification
16653042|NCT02261350|Experimental|Oral Nutritional Supplements|Oral Nutritional Supplements - Fortisip Compact
16653043|NCT02261350|No Intervention|Usual Care|
16653044|NCT02261311||Quality of Life, tissue collection|All participants will complete the GAD-7 and Cancer Locus of Control Scale - Course of Illness Subscale questionnaires and additional tissue will be collected at the time of the diagnostic biopsy.
16653045|NCT02261298|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle
16653046|NCT02261298|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle
16653047|NCT02261298|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle
16653048|NCT02261285|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
16653049|NCT02261285|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
16653050|NCT02261285|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
16653051|NCT02261272|Experimental|CBT for insomnia|Cognitive-behavioral therapy for insomnia
16653052|NCT02261272|Active Comparator|Sleep Hygiene|Psychoeducational intervention based on standard sleep hygiene advices
16653053|NCT02261259|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
16653054|NCT02261259|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
16653055|NCT02261259|No Intervention|Healthy control (no neck pain)|In this arm, healthy controls are tested at baseline.
16653056|NCT02261246|Experimental|Immediate treatment|This arm receives spinal manipulation treatment shortly after enrollment
16653057|NCT02261246|Experimental|Delayed treatment|This arm receives spinal manipulation treatment approximately 4 weeks after enrollment
16653058|NCT02261246|No Intervention|Healthy control (no low back pain)|In this arm, healthy controls are tested at baseline.
16653059|NCT02261233|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
16653060|NCT02261233|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
16653061|NCT02261220|Experimental|MEDI4736 + Tremelimumab|Subjects with multiple tumor types.
16653062|NCT02261207|Experimental|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
16653063|NCT02261194|Experimental|Self-Care Tools|The tool binder includes 3 core tools and 4 supplemental tools. The tools that will be provided include a variety of self-care approaches to manage depression including audio-visual, internet, and paper-based tools that might appeal to individuals with different learning styles. The 3 core tools consist of the Antidepressant Skills Workbook, a Mood Monitoring Tool, and a DVD on depression.
16653064|NCT02261194|No Intervention|Delayed Self-Care Tools|This group will receive the self-care tools at the conclusion of the study.
16653065|NCT02261181|Experimental|XONRID|"Patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients.
~Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines. The use of other topical medications for the treatment of dermatitis will be not permitted during the study."
16653066|NCT02261168|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
16653067|NCT02261155|Other|Hypnosis|hypnotic induction followed by relaxation and pleasant imagery
16653068|NCT02261142|Experimental|Multifocal TENS|Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient
16653069|NCT02261142|Sham Comparator|Sham treatment|Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient
16653070|NCT02261129|Experimental|Telmisartan, film-coated tablet|one tablet of telmisartan
16653071|NCT02261129|Active Comparator|Telmisartan, conventional tablet|Two tablets of telmisartan
16653076|NCT02261103|Experimental|Pramipexole ER, fasted|Pramipexole extended release (ER) tablets
16653077|NCT02261103|Experimental|Pramipexole ER, fed|Pramipexole extended release tablets with a high-fat meal 30 min before drug administration
16653078|NCT02261090|Experimental|Formulation B|Slow release (SR) tablet
16653079|NCT02261090|Experimental|Formulation C|SR tablet
16653080|NCT02261090|Experimental|Formulation D|SR tablet
16653081|NCT02261090|Experimental|Formulation E|SR tablet
16653082|NCT02261090|Experimental|Formulation F|SR tablet
16653083|NCT02261090|Experimental|Formulation G|SR tablet
16653084|NCT02261090|Experimental|Formulation H|SR tablet
16653085|NCT02261090|Active Comparator|immediate release (IR) formulation|
16653086|NCT02261077|Experimental|Buscopan, single rising doses|
16653087|NCT02261077|Experimental|Buscopan, multiple rising doses|
16653088|NCT02261077|Placebo Comparator|Placebo|
16653089|NCT02261064|Experimental|Telmisartan/Amlodipine low dose, fed|Telmisartan low dose/Amlodipine fixed-dose combination
16653090|NCT02261064|Active Comparator|Telmisartan/Amlodipine low dose, fasted|Telmisartan low dose/Amlodipine fixed-dose combination
16653091|NCT02261064|Experimental|Telmisartan/Amlodipine high dose, fed|Telmisartan high dose/Amlodipine fixed-dose combination
16653092|NCT02261064|Active Comparator|Telmisartan/Amlodipine high dose, fasted|Telmisartan high dose/Amlodipine fixed-dose combination
16653093|NCT02261051||Non-concurrent control group|"A group of advanced cancer patients who received care at our Center before implementation of the LCCM model. They will receive current standard of care.
~This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase)."
16653094|NCT02261038|Other|Kanekasu radiographs|No drugs or devices are used in this study. Commonly available radiological techniques such as radiographs and CT are used. All patients undergo a CT of the knee and a special radiograph (Kanekasu technique).
16653095|NCT02261025|Experimental|Aspirin group|Aspirin 75-100mg,per day，oral
16653096|NCT02261025|No Intervention|non-aspirin group|No interventions
16653097|NCT02261012||30 healthy probands|group without the condition of interest
16653098|NCT02261012||30 CRPS patients|group with condition of interest
16653099|NCT02261012||30 CTS patients|group with a different type of pain on the upper limbs
16653100|NCT02260999||healthy|> 18 years old sufficient language knowledge
16653101|NCT02260999||chronic pain patients|
16653102|NCT02260999||patients with injury at the upper etxremity|
16653103|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
16653104|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
16653105|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
16653106|NCT02260973|Active Comparator|Omega-3|re esterified TG omega-3
16653107|NCT02260973|Placebo Comparator|Safflower Oil|vegetable oil
16653108|NCT02260960|Experimental|Omega-3|Reesterified Triglyceride form omega 3
16653109|NCT02260960|Placebo Comparator|Placebo|safflower oil
16653110|NCT02260947|Experimental|1|
16653111|NCT02260947|Experimental|2|
16653112|NCT02260947|Active Comparator|3|
16653113|NCT02260947|Active Comparator|4|
16653114|NCT02260947|Placebo Comparator|5|
16653115|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
16653116|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.
~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
16653117|NCT02260921|Experimental|iovera° Treatment|Treatment with the iovera° device administered by a trained investigator to treat knee pain.
16653118|NCT02260921|Sham Comparator|Sham Treatment|Sham Treatment (similar device with no active therapeutic treatment) administered by a trained investigator to treat knee pain.
16653119|NCT02260908|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
16653120|NCT02260908|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo (normal saline) 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
16653121|NCT02260895|No Intervention|Control|Standard 2-hour 75-gram oral glucose tolerance test
16653122|NCT02260895|Experimental|Almond Pre-test snack|1/2 ounce (14 g) almond snack 30 minutes prior to a 2-hour 75-gram oral glucose tolerance test
16653123|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
16653124|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
16653148|NCT02260739|Other|myelofibrosis|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
16653149|NCT02260726|Experimental|Surgical group|Subjects already scheduled to undergo surgical correction of a symptomatic cam-type hip impingement deformity. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound investigation prior to surgery.
16653150|NCT02260726|Other|Control|Asymptomatic subjects with normal hip morphometry, as determined by MRI. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound imaging.
16658206|NCT02227017|Active Comparator|TPV/RTV solutions fasted|
16653125|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
16653126|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
16653127|NCT02260856|Active Comparator|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
16653128|NCT02260856|Experimental|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
16653129|NCT02260843|No Intervention|Control|Subjects in this group do not received any intervention.
16653130|NCT02260843|Active Comparator|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
16653131|NCT02260843|Placebo Comparator|Generic Fitness Intervention|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
16653132|NCT02260830|Experimental|Treatment Period A|1 reference treatment (2 mg Lu AF11167 immediate release hard capsule) + 5 different test prototype formulations of Lu AF11167
16653133|NCT02260830|Experimental|Treatment Period B|Food interaction and multiple dosing of Lu AF11167
16653134|NCT02260817|Experimental|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.
~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
16653135|NCT02260817|Experimental|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.
~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
16653136|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
16653137|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
16653138|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
16653139|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
16653140|NCT02260778|Experimental|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
16653141|NCT02260778|No Intervention|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
16653142|NCT02260765|Active Comparator|HCP dTMS|this arm will receive dTMS treatment
16653143|NCT02260765|No Intervention|HCP TAU|this arm will continue with the same drugs that they are using usually, which mean treatment as usual
16653144|NCT02260752||Medical|Patients who receive medical therapy only for treatment of their uterine fibroids
16653145|NCT02260752||Procedure|Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.
16653146|NCT02260739|Other|chronic myelomonocytic leukemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
16653147|NCT02260739|Other|essential thrombocytemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
16658785|NCT02223000|Active Comparator|BIBV 308 SE solution|
16653151|NCT02260713|No Intervention|Control|control subjects with acute complete spinal cord injury who would not receive any bone marrow transplantation.
16653152|NCT02260713|Experimental|Transplantation via intrathecal route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via lumber puncture
16653153|NCT02260713|Experimental|Transplantation via intralesional route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via durotomy and injection at the lesional site .
16653154|NCT02260700|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
16653155|NCT02260700|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
16653156|NCT02260700|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed by Treatment A (single oral dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
16653157|NCT02260700|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed byTreatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
16653158|NCT02260700|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
16653159|NCT02260700|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
16653160|NCT02260687||Group 1|Decision of treatment is made by attending investigator according to the Japanese Package Insert
16653161|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
16653162|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
16653163|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
16653164|NCT02260661|Experimental|Part A|AZD8835 single agent dose escalation
16653165|NCT02260661|Experimental|Part B|Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene.
16653166|NCT02260661|Experimental|Part C|AZD8835 in combination with fulvestrant dose escalation
16653167|NCT02260661|Experimental|Part D|Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D).
16653168|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
16653169|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
16653170|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
16653171|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
16653172|NCT02260635|Placebo Comparator|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
16653173|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
16653174|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
16653175|NCT02260609|Other|Open-Label|Grafix®: Cryopreserved Placental Membrane
16653176|NCT02260596||Cohort Population|Pediatric SOT/HSCT recipients
16653204|NCT02260401|Experimental|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
16653251|NCT02260102|Active Comparator|hepatic transplant|Children requiring antibiotic prophylaxis following a hepatic transplant. Intervention: blood sampling for assay of temocillin
16653177|NCT02260583|Experimental|extracorporeal CO2 removal device|"the patients will be enroll to start a one shot session of extracorporeal CO2 removal. The patient will be connected to the device via a double lumen catheter inserted in the femoral vein An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used. Blood flow is driven by a roller nonocclusive pump (0-450 mL/min) through a polypropylene oxygenator ; priming volume, 100 mL; contact surface area, 1.35 m2; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter."
16653178|NCT02260570|Experimental|Functional MRI Arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
16653179|NCT02260557|Experimental|Selexipag|Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.
16653180|NCT02260557|Experimental|Placebo|Placebo matching selexipag tablets is administered according to the same schedule as selexipag
16653181|NCT02260544|Experimental|Test Product - T|"doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )
~Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks."
16653182|NCT02260544|Active Comparator|Reference Product - R|"doxorubicin hydrochloride liposome ( Sun Pharma )
~Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks."
16653183|NCT02260531|Experimental|Cohort 1 - Cabozantinib, Trastuzumab for HER2+|"HER2-positive
~Cabozantinib- orally administered daily per treatment cycle, 60 mg per day
~Trastuzumab- IV administered once per cycle, 8 mg/kg IV loading dose followed by 6 mg/kg IV Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
16653184|NCT02260531|Experimental|Cohort 2 - Cabozantinib for ER+ and/or PR+|"Hormone receptor-positive (ER+ and/or PR+)
~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
16653185|NCT02260531|Experimental|Cohort 3 - Cabozantinib for ER-, PR-, HER2-|"Triple negative (ER-, PR-, HER2-)
~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
16653186|NCT02260518|Experimental|Lifestyle Intervention|The intervention will focus on women gaining the recommended amount of weight, increasing physical activity to 150 minutes per week, and meeting healthy eating guidelines.
16653187|NCT02260518|Other|Standard Care|Women in the standard care group will attend their regularly scheduled obstetric (OB) visits with their prenatal care providers and will receive monthly mailings and matched number of podcasts.
16653188|NCT02260505|Experimental|Imatinib maintenance|Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).
16653189|NCT02260505|No Intervention|Imatinib Interruption|Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
16653190|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
16653191|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
16653192|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
16653193|NCT02260479|Active Comparator|Preheated chlorhexidine|Preheated skin disinfection with 36ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
16653194|NCT02260479|No Intervention|Room temperature chorhexidine|Room temperature skin disinfection with 20ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
16653195|NCT02260466|Other|elderly patients with Aortic steNosis valvular replacement|
16653196|NCT02260453|Active Comparator|A - Coronary angiography|All the patients receive preoperative coronary angiography followed, if needed, by percutaneous intervention (PCI) or bypass (CABG)
16653197|NCT02260453|Active Comparator|B - standard cardiac workup|Standard cardiac workup
16653198|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles
~Pembrolizumab will be given at 200 mg every 21 days.
~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
16653199|NCT02260427|Experimental|the i-gel group|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
16653200|NCT02260427|Active Comparator|the Air-Q sp group|After induction of general anesthesia, the air-Q sp will be inserted according to randomly allocated group.
16653201|NCT02260414|Experimental|Patients with multiple myeloma|Patient with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
16653202|NCT02260414|Active Comparator|Patients with agressive lymphoma|Patient hospitalized for aggressive lymphoma treated with chemotherapy treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
16653203|NCT02260414|Active Comparator|Patients with acute medical condition|Patient older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
16653205|NCT02260401|No Intervention|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
16653206|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
16653207|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
16653208|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
16653209|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
16653210|NCT02260375|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.
16653211|NCT02260375|No Intervention|No treatment.|
16653212|NCT02260362||HTAP of Congenital Heart Disease|
16653213|NCT02260349|Experimental|patient with Indocyanine green infusion|Infusion of Indocyanine Green 0,25 mg/Kg 24h before prostatic surgery
16653214|NCT02260336|Experimental|Panax Notoginseng Powder 1g|Panax Notoginseng Powder 1g, daily
16653215|NCT02260336|Experimental|Panax Notoginseng Powder 5g|Panax Notoginseng Powder 5g,daily
16653216|NCT02260336|Experimental|Panax Notoginseng Powder 10g|Panax Notoginseng Powder 10g,daily
16653217|NCT02260336|Experimental|Panax Notoginseng Powder 15g|Panax Notoginseng Powder 15g,daily
16653218|NCT02260336|Active Comparator|Celecoxib Capsule 400 mg daily|Celecoxib Capsule 400 mg daily
16653219|NCT02260323|Experimental|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
16653220|NCT02260323|Active Comparator|patient-tailored DMARDs|Patients use tailored DMARDs
16653221|NCT02260310|Experimental|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
16653222|NCT02260310|Active Comparator|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
16653223|NCT02260284|Experimental|Yaotong points acupuncture|patients under the treatment of Yaotong ponts penetration mode
16653224|NCT02260284|Active Comparator|standardized acupuncture|patients under the treatment of standardized acupuncture
16653225|NCT02260284|Other|the usual care|In the usual care group, participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS)).
16653226|NCT02260271||Database Entry/Biospecimen Collection|Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected.
16653227|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous intravenous (IV) infusion as per standard intensive care unit practice.
~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
16653228|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
16653229|NCT02260245|Other|Team training|All participating affiliates will undergo team training using the TeamSTEPPS model
16653230|NCT02260232|Experimental|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
16653231|NCT02260232|No Intervention|control|
16653232|NCT02260219|Active Comparator|S2|Surgically Implant an Ahmed Glaucoma Drainage Device Model S2 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
16653233|NCT02260219|Active Comparator|M4|Surgically Implant an Ahmed Glaucoma Drainage Device Model M4 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
16653234|NCT02260206|Experimental|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
16653235|NCT02260206|No Intervention|No intervention|No intervention
16653236|NCT02260193|Experimental|AKB-6548, starting dose 1|
16653237|NCT02260193|Experimental|AKB-6548, starting dose 2|
16653238|NCT02260193|Experimental|AKB-6548, starting dose 3|
16653239|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
16653240|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
16653241|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
16653242|NCT02260167|Experimental|Treatment with MIND|
16653243|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
16653244|NCT02260141|Experimental|Treatment with d-ribose|Treatment with ribose 5 gm TID
16653245|NCT02260128|Experimental|Gum chewing|"This intervention group will receive chewing gum four times daily following surgery. Each of which they are encouraged to chew for 30 minutes.
~Gum chewing is terminated when one of the primary end points occurs."
16653246|NCT02260128|No Intervention|Control group|This group will receive the normal postoperative treatment. Occurence of primary end points are registrered.
16653247|NCT02260115|Experimental|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
16653248|NCT02260115|Sham Comparator|Surgical Control|Laproscopic Surgery Only
16653249|NCT02260102|Active Comparator|urinary tract infections|Children requiring antibiotic treatment for urinary tract infections. Intervention: blood sampling for assay of temocillin
16653250|NCT02260102|Active Comparator|cholangitis|"Cirrhotic children requiring antibiotic treatment due to suspicion of cholangitis.
~Intervention: blood sampling for assay of temocillin"
16653252|NCT02260089|Experimental|Low dose of telmisartan|4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
16653253|NCT02260089|Experimental|High dose of telmisartan|After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
16653254|NCT02260076|Experimental|PEG 400|multiple rising doses
16653255|NCT02260076|Placebo Comparator|Placebo|
16653256|NCT02260063|Experimental|Epinastine syrup|
16653257|NCT02260063|Active Comparator|Epinastine tablets|
16653258|NCT02260050|Experimental|WAL 801 CL new formulation|
16653259|NCT02260050|Active Comparator|WAL 801 CL conventional formulation|
16653260|NCT02260037|Experimental|Epinastine nasal|single rising doses
16653261|NCT02260037|Placebo Comparator|Placebo|
16653262|NCT02260024|Active Comparator|Pramipexole IR|
16653263|NCT02260024|Experimental|Pramipexole SR C2 in the fasted state|
16653264|NCT02260024|Experimental|Pramipexole SR C2A in the fasted state|
16653265|NCT02260024|Experimental|Pramipexole SR C2B in the fasted state|
16653266|NCT02260024|Experimental|Pramipexole SR C in the fasted state|
16653267|NCT02260024|Experimental|Pramipexole SR C2 in the fed state|
16653268|NCT02260011|Experimental|Ipratropium bromide HFA-134a low|
16653269|NCT02260011|Experimental|Ipratropium bromide HFA-134a high|
16653270|NCT02260011|Active Comparator|Atrovent® CFC low|
16653271|NCT02260011|Active Comparator|Atrovent® CFC high|
16653272|NCT02260011|Placebo Comparator|Placebo|
16653273|NCT02259998|Experimental|Persantin® new formulation|
16653274|NCT02259998|Active Comparator|Persantin® commercial formulation|
16653275|NCT02259985|Experimental|Itasetron tablet fed|
16653276|NCT02259985|Active Comparator|Itasetron tablet fasted|
16653277|NCT02259985|Active Comparator|Itasetron infusion fasted|
16653278|NCT02259972|Experimental|BI 113823 solution|single rising doses, dose group 5 twice (fed and fasted)
16653279|NCT02259972|Experimental|BI 113823 tablet|dose group 5 only
16653280|NCT02259972|Placebo Comparator|Placebo|
16653281|NCT02259959|Experimental|BI 1744 CL in combination with Tiotropium|
16653282|NCT02259959|Placebo Comparator|Placebo|
16653283|NCT02259946|Experimental|BI 1744 CL - single rising dose + Tiotropium|Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
16653284|NCT02259946|Placebo Comparator|Placebo|
16653285|NCT02259933|Experimental|KUC 7483 CL|increasing repeated oral doses
16653286|NCT02259933|Placebo Comparator|Placebo|
16653287|NCT02259920|Active Comparator|Treatment A|KUC 4783 CL, immediate release tablets
16653288|NCT02259920|Experimental|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
16653289|NCT02259920|Experimental|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
16653290|NCT02259920|Experimental|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
16653291|NCT02259920|Experimental|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
16653292|NCT02259907|Experimental|KUC 7483 CL|single rising doses
16653293|NCT02259907|Experimental|KUC 7483 CL, fed|dosing after high fat meal
16653294|NCT02259907|Placebo Comparator|Placebo|
16653295|NCT02259894|Experimental|BIRT 2584|single rising doses
16653296|NCT02259894|Placebo Comparator|Placebo|
16653297|NCT02259881|Experimental|Low dose of BIBT 986 CL|
16653298|NCT02259881|Experimental|Medium dose of BIBT 986 CL|
16653299|NCT02259881|Experimental|High dose of BIBT 986 CL|
16653300|NCT02259881|Placebo Comparator|Placebo|
16653301|NCT02259868|Experimental|Group A|randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout
16653302|NCT02259868|Experimental|Group B|randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout
16653303|NCT02259868|Experimental|Group C|randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout
16653304|NCT02259868|Experimental|Group D|randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout
16653305|NCT02259855|Experimental|Mild hepatic insufficiency|
16653306|NCT02259855|Experimental|Moderate hepatic insufficiency|
16653307|NCT02259855|Experimental|Healthy subjects|
16653308|NCT02259842|Experimental|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
16653309|NCT02259842|Experimental|BI 34021 FU2 tablet|dose group 4 only
16653310|NCT02259842|Placebo Comparator|Placebo|
16653311|NCT02259829|Experimental|Telmisartan/Amlodipine fixed dose combination|
16653312|NCT02259829|Active Comparator|Telmisartan and Amlodipine monocomponents|
16653313|NCT02259816|Active Comparator|Telmisartan|
16653314|NCT02259816|Experimental|Telmisartan and amlodipine|
16653315|NCT02259803|Experimental|Telmisartan/amlodipine fixed-dose combination|
16653316|NCT02259803|Active Comparator|Telmisartan and amlodipine mono-components|
16653317|NCT02259790|Experimental|Telmisartan/amlodipine fixed-dose combination|
16653318|NCT02259790|Active Comparator|Telmisartan tablet and amlodipine tablet|
16653319|NCT02259777|Experimental|Telmisartan/Amlodipine, fed|
16653320|NCT02259777|Active Comparator|Telmisartan/Amlodipine, fasted|
16653321|NCT02259764|Experimental|KUC 7483 CL - single rising dose|"Treatment 1: KUC 7483 CL - low dose
~Treatment 2: KUC 7483 CL - medium dose
~Treatment 3: KUC 7483 CL - high dose
~In treatment 3 the same subjects as in treatment 2 received drug immediately after the ingestion of a standardized high fat meal"
16653322|NCT02259764|Placebo Comparator|Placebo|
16653323|NCT02259751|Experimental|KUC 7483 CL|
16653324|NCT02259751|Placebo Comparator|Placebo|
16653325|NCT02259738|Experimental|Human urinary kallidinogenase and Shuxuening injection|Human urinary kallidinogenase 0.15PNA and Shuxuening injection 20mg, every day for 7 days.
16653326|NCT02259725|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16653327|NCT02259712|Active Comparator|Pelviperineal physiotherapy|"The treatment duration is 2 days per week during 8 weks (two months). The aproximate duration of the season is 45 minutes. The protocol consists in:
~Anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity).
~Hygienic and behavioral advises preventing pelvic floor dysfunctions.
~Awareness of the pelvic floor muscles.
~Strengthening the pelvic floor muscles and the entire abdominal pelvic cavity. Use of electrostimulation and biofeedback in different positions if deemed necessary.
~Treatment the abdominal-pelvic cavity pain if it requires."
16653328|NCT02259712|Experimental|Hiporessive and Pelviperineal PT|The treatment duration is 2 days per week, 8 weeks (two months). The session is about 45 minutes. All women are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle. The participants are also treated by doing Hipopressive exercises and by specific physicaltherapy for the strengthening the pelvic floor muscles.
16653329|NCT02259712|Experimental|Hipopressive exercises|The treatment is done 2 times per week for 8 weeks (2 months). The session duration is about 45 minutes. All participants are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity). The participants are also treated by doing Hipopressive exercises in standing, sitting, and supine fours.
16653330|NCT02259699|Experimental|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
16653331|NCT02259699|No Intervention|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
16653332|NCT02259686|Experimental|Protocol 1. Apelin 1mg doses|5 Healthy volunteers
16653333|NCT02259686|Experimental|Protocol 2. Apelin 5mg doses|5 Healthy volunteers
16653334|NCT02259686|Experimental|Protocol 3. Apelin 10mg single dose|5 Healthy volunteers
16653335|NCT02259673|Experimental|Fun exercise|effect of fun physical exercise on sarcopenia
16653336|NCT02259673|Experimental|fun exercise|effect of fun physical exercise on interest in exercise
16653337|NCT02259660|Active Comparator|Active Group|Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.
16653338|NCT02259660|Placebo Comparator|Sham Training|The intervention in the sham training arm will be identical in every way to that of the active arm with the exception of the trainer that is provided. Subjects in the sham training arm will have inspiratory and expiratory muscle strength trainers which have had the pressure threshold spring removed and are therefore unable to provide a load to the muscles being trained.
16653339|NCT02259647|Experimental|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
16653340|NCT02259647|Active Comparator|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
16653341|NCT02259634|Experimental|Patient Navigation|Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
16653342|NCT02259634|No Intervention|Treatment as Usual|Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic
16653343|NCT02259621|Experimental|Arm B- Nivolumab|"Nivolumab administration:
~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
16653344|NCT02259621|Experimental|Arm C- Nivolumab, Carboplatin, & Paclitaxel|Nivolumab 360 mg IV, Carboplatin AUC 5 or 6 IV, and Paclitaxel 175 or 200 mg/m2 IV every 21 days for 3 cycles prior to planned surgery on Day 0.
16653345|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
16653346|NCT02259595|Experimental|HPN-07 500 mg / Placebo|Single dose of 500mg HPN-07 plus placebo in oral capsules.
16653347|NCT02259595|Experimental|HPN-07 1000 mg / Placebo|Single dose of 1,000mg HPN-07 plus placebo in oral capsules
16653348|NCT02259595|Experimental|HPN-07 1500 mg / Placebo|Single dose of 1,500mg HPN-07 plus placebo in oral capsules
16653349|NCT02259595|Experimental|HPN-07 MTD plus NAC 1200mg|Single dose of maximum tolerated dose of HPN-07 plus 1,200 mg NAC in oral capsules. Dose selection will be determined from safety data of previous cohorts by Data Assessment Committee (DAC).
16653350|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
16653351|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
16653352|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
16653353|NCT02259569|Experimental|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
16653354|NCT02259569|Active Comparator|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
16653355|NCT02259556|Experimental|anti-CD30 CAR T cells|Patients receive CART30 cell infusions with an escalation dose.
16653356|NCT02259543|No Intervention|G0|Root decontamination performed by scaling and root planing followed by rinsing with saline solution during the treatment of recession defects by subepithelial connective tissue graft (SCTG). Control group.
16653357|NCT02259543|Active Comparator|G90|Root conditioning with citric acid+tetracycline solution (1:1) for 90 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
16653358|NCT02259543|Active Comparator|G180|Root conditioning with citric acid+tetracycline solution (1:1) for 180 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
16653359|NCT02259530|Experimental|Integrated Psychotherapeutic Intervention|Integrated treatment of khat use disorder and PTSD
16653360|NCT02259517|Experimental|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
16653361|NCT02259517|Experimental|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
16653362|NCT02259491|Experimental|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
16653363|NCT02259491|No Intervention|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
16653364|NCT02259465|Active Comparator|Oligofructose|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with oligofructose, 7grams twice daily
16653365|NCT02259465|Placebo Comparator|Maltodextrin|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with maltodextrin, 7grams twice daily
16653366|NCT02259426|Active Comparator|Dihydroartemisínin-piperaquine (Artekin)|Dihydroartemisínin-piperaquine combination alone
16653367|NCT02259426|Experimental|Dihydroartemisinin-piperaquine, Primaquine|Dihydroartemisinin-piperaquine with single-dose 0.25mg/kg Primaquine
16653368|NCT02259413|Experimental|Exercise Rehabilitation|"Participants will receive baseline exercise counseling as per Standard Care group. Participants will then participate in a 26-week exercise rehabilitation program incorporating 3 components:
~One-to-one self-management/resistance education once per week during the first 4 weeks of intervention. Participants will subsequently receive resistance training material to allow for home exercise for the remaining 22 weeks of the intervention.
~Intradialytic aerobic exercise on a cycle ergometer 3 times weekly for 26 weeks at their usual hemodialysis sessions.
~Four additional one-to-one standardized education sessions will be completed during the intervention period."
16653369|NCT02259413|No Intervention|Standard Care|Participants will receive one exercise counseling session as part of their baseline assessment. Participants in the control group will not undergo any other exercise counseling or formal exercise intervention, but will not be prohibited from participating in exercise outside of the study protocol.
16653370|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
16653371|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
16653372|NCT02259387||Cases|Children with migraines will be placed into this group.
16653373|NCT02259387||Controls|Children without migraines or headaches will be placed into this group.
16653374|NCT02259374|Active Comparator|TAP BLOCK 0.2% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy.
~Intervention: TAP block Dose: 20 ml 0.2% ropivacaine"
16653375|NCT02259374|Active Comparator|TAP BLOCK 0.4% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy.
~Intervention: TAP block Dose: 20 ml 0.4% ropivacaine"
16653376|NCT02259361|Active Comparator|Experimental|Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
16653377|NCT02259361|Placebo Comparator|Placebo|Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
16653378|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
16653379|NCT02259335|Experimental|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise>20% of baseline and/or a rapid shallow-breathing index >100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
16653380|NCT02259322|Active Comparator|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
16653381|NCT02259322|Experimental|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
16653382|NCT02259322|Experimental|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
16658786|NCT02223000|Experimental|BIBV 308 SE capsule 1|
16653383|NCT02259309|Experimental|Misoprostol administration - buccal then vaginal|Vaginal or buccal administration
16653384|NCT02259309|Experimental|Misoprostol administration - vaginal then buccal|Vaginal or buccal administration
16653385|NCT02259296|Experimental|Lower eGFR for AVF creation|
16653386|NCT02259296|Active Comparator|Higher eGFR for AVF creation|
16653387|NCT02259283|Experimental|Achalasia|Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.
16653388|NCT02259270||ASTRA-1|"All patients discharged from the participating hospitals between July 2012 and July 2013.
~Determination of long term use of AST before, during and after hospitalisation based on dispensing data, no record review."
16653389|NCT02259270||ASTRA-2|Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
16653390|NCT02259244|Experimental|Mediterranean diet+physical activity|Mediterranean diet based on 1573 kcal/day with the goal of consumption of 30 ml/day of olive oil, 56g/week of nuts, 3-4 servings/week of fish, 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat
16653391|NCT02259244|Active Comparator|Hypolipemic reduction diet+physical activity|Hypolipemic reduction diet based on 1287 kcal/day with the goal of consumption of 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat, non-fat or low-fat dairy products
16653392|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
16653393|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
16653394|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
16653395|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
16653396|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
16653397|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
16653398|NCT02259231|Experimental|Omaveloxolone 150 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
16653399|NCT02259218||Ancillary-Correlative|Prospectively collected blood, urine, and tissue samples are analyzed for potential predictive biomarkers via metabolomic and other molecular profiling.
16653400|NCT02259205|Experimental|Enriched Yogurt|150 g yogurt enriched with approximately 0.5 g bioactive lipids extract from olive oil mill provided daily for 8 weeks
16653401|NCT02259205|Placebo Comparator|Plain Yogurt|150 g not enriched yogurt provided daily for 8 weeks
16653402|NCT02259205|No Intervention|Control|No yogurt consumption
16653403|NCT02259192|Experimental|Open-label|Cochlear Implant
16653404|NCT02259179|Active Comparator|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
16653405|NCT02259179|Active Comparator|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
16653406|NCT02259166|Experimental|EHFP+|Group receiving the intervention EHFP+, in addition to MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
16653407|NCT02259166|No Intervention|Control|MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
16653408|NCT02259153|Active Comparator|Lean red meat diet|Participants were given 350 g per day of lean red meat to incorporate to their usual diet for ten days.
16653409|NCT02259153|Active Comparator|Fat red meat diet|Participants were given 350 g per day of fat red meat to incorporate to their usual diet for ten days.
16653410|NCT02259140|Active Comparator|Proximal Femoral Resection Arthroplasty|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The abductors of the hip are detached with sharp dissection. A capsulotomy is performed. The femur is exposed in a supra-periosteal manner (2 cm distal to the lesser trochanter) at the level of the ischium; transverse osteotomy will then be performed. The joint capsule will be sutured to itself. The iliopsoas tendon and the abductor tendons are attached to the capsule. The quadriceps will be brought around the proximal femoral stump and sutured to medial tissues.
16653411|NCT02259140|Experimental|Subtrochanteric Valgus Osteotomy|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The medial half of the abductors may be incised off the greater trochanter for repair. The femoral head is resected at the base of the neck. The ligamentum teres is incised off the head and preserved. A lateral closing wedge osteotomy is performed below the lesser trochanter. 3.5 or 4.5 5 hole locking/non-locking surgeon-contoured plate ( 45⁰) will be used to stabilize the osteotomy. Femoral torsion will be corrected. The psoas tendon will attach the ligamentum teres to the lesser trochanter. The anterior and posterior capsule is sutured together creating interposition tissue. If the ligamentum teres was sutured to the lesser trochanter, the capsule will not close, but will be covered by the psoas tendon.
16653412|NCT02259127|Active Comparator|SOC arm|SOC for ODYSSEY A is defined as a PI or non nucleoside transcriptase inhibitors + 2 or 3 nucleoside transcriptase inhibitor SOC for ODYSSEY B is defined as a PI or non nucleoside transcriptase inhibitor+ 2 nucleoside transcriptase inhibitors
16653413|NCT02259127|Experimental|DTG arm|DTG + 2 nucleoside transcriptase inhibitors
16653414|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
16653415|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
16653416|NCT02259101|Experimental|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
16653417|NCT02259101|Active Comparator|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
16653418|NCT02259088|Experimental|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
16653419|NCT02259088|Active Comparator|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
16653420|NCT02259075|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.
16653421|NCT02259062|Active Comparator|Music listening|
16653422|NCT02259062|Experimental|Music listening with brief mindfulness|
16653423|NCT02259062|Placebo Comparator|Audio book intervention|
16653424|NCT02259049|Active Comparator|L-Tyrosine|We will administer 1,000 mg of L-tyrosine BID for 24 hours and record BP and HR.
16653425|NCT02259049|Placebo Comparator|Sugar Pill|We will administer a sugar pill BID for 24 hours and record BP and HR.
16653426|NCT02259036|Other|SmartCAT Enhanced Treatment|Cognitive Behavioral Therapy enhanced with an ecological momentary treatment enhancement smartphone app called SmartCAT.
16653427|NCT02259023|Experimental|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
16653428|NCT02259023|Experimental|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
16653429|NCT02259010|Experimental|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
16653430|NCT02258997||HbSS|Subjects are homozygous for the sickle hemoglobin mutation (HbS).
16653431|NCT02258997||HbS-beta thalassemia|Subjects are heterozygous for the HbS mutation and beta thalassemia
16653432|NCT02258984|Other|Open physician access to Venus 1000 CVP data|
16653433|NCT02258984|Other|No open physician access to Venus 1000 CVP data|
16653434|NCT02258971|Experimental|BEA 2180 BR oral|
16653435|NCT02258971|Active Comparator|BEA 2180 BR infusion|
16653436|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
16653437|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
16653438|NCT02258932||Continuous subcutaneous insulin infusion|This group will consist of patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
16653439|NCT02258919|Experimental|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
16653440|NCT02258919|Active Comparator|Best medical treatment|Best medical treatment
16653441|NCT02258906|Experimental|Ulinastatin group|Patients in the ulinastatin group are given ulinastatin during operation.
16653442|NCT02258906|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
16653443|NCT02258893|Experimental|NO2 Scrubber, then HEPA filter, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
16653444|NCT02258893|Experimental|NO2 Scrubber, then Control, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
16653445|NCT02258893|Experimental|HEPA filter, then NO2 scrubber, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
16653446|NCT02258893|Experimental|HEPA filter, then Control, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
16653447|NCT02258893|Experimental|Control, then HEPA filter, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
16653448|NCT02258893|Experimental|Control, then NO2 scrubber, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
16653449|NCT02258880|Experimental|SUN13837|Drug: SUN13837 daily for 28 days.
16653450|NCT02258880|Placebo Comparator|Placebo|Placebo: Matching Placebo daily for 28 days
16653451|NCT02258867|Placebo Comparator|Placebo|
16653452|NCT02258867|Experimental|Gevokizumab|
16653453|NCT02258854|Experimental|Dose 2 gevokizumab|
16653454|NCT02258841|Experimental|Personalized online Safety Decision Aid|Setting priorities for safety; Danger Assessment; Personalized Action Plan
16653455|NCT02258841|Active Comparator|General Online Risk/Safety Information|General Risk and Safety Information; Basic Emergency Safety Plan
16653456|NCT02258828|Experimental|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
16653457|NCT02258828|Placebo Comparator|Placebo|Patient received matched placebo
16653496|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units
~Usual Care on four Oncology units"
16653563|NCT02258113|Other|LEA numbers, Pelli-Robson, Octopus|Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
16653564|NCT02258100||Paper|Patients receiving care documented via paper anesthesia record.
16653458|NCT02258815|Experimental|ch14.18|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.
~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
16653459|NCT02258802|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
16653460|NCT02258802|No Intervention|Usual food practices|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
16653461|NCT02258789|Experimental|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
16653462|NCT02258776|Active Comparator|Pomegranate Extract|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
16653463|NCT02258776|Active Comparator|Pomegranate Juice|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
16653464|NCT02258776|Placebo Comparator|Placebo|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
16653465|NCT02258763|Experimental|Amoxicillin-Potassium Clavulanate|Patient will be on amoxicillin-clavulanate 22.5mg/kg/dose bd for 10 days
16653466|NCT02258763|Active Comparator|Placebo|Patient will be on amoxicillin-clavulanate 22.5mg/kg/bd for 3 days followed by another 7 days of placebo medication given at the same dose and frequency
16653467|NCT02258750|Experimental|Polydextrose|Tomato soup enriched with added polydextrose
16653468|NCT02258750|Placebo Comparator|Control|Tomato soup without added polydextrose
16653469|NCT02258737|Experimental|transitional case management|
16653470|NCT02258737|Active Comparator|standard care|
16653471|NCT02258711|Experimental|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
16653472|NCT02258711|No Intervention|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
16653473|NCT02258698||Elective on-pump cardiac surgery|Observation of perioperative Insulin resistance in patients undergoing elective on-pump cardiac surgery (CABG and/or valve repair)
16653474|NCT02258685||Cohort A1|ART-treated HIV-infected individuals with lipodystrophy
16653475|NCT02258685||Cohort A2|ART-treated HIV-infected individuals without lipodystrophy
16653476|NCT02258685||Cohort A3|HIV-1 infected individuals naïve to ART
16653477|NCT02258685||Cohort A4|HIV-1 seronegative individuals who are at a high risk for infection
16653478|NCT02258685||Cohort B1|A subset of subjects from Cohort A: ART-treated HIV-infected individuals with HIV-associated dysbiosis
16653479|NCT02258685||Cohort B2|A subset of subjects from Cohort A: ART-treated HIV-infected individuals without HIV-associated dysbiosis
16653480|NCT02258672|Experimental|Prehabilitation program|Participants will be physically trained before undergoing surgery
16653481|NCT02258672|No Intervention|Control|Patients will follow the normal course of care provided by the hospital
16653482|NCT02258659|Experimental|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
16653483|NCT02258659|Experimental|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
16653484|NCT02258659|Experimental|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*
~*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
16653485|NCT02258646|Experimental|Telerehabilitation|Exercise training at home, telemonitoring, and education/self-management
16653486|NCT02258646|Experimental|Unsupervised exercise training at home|Unsupervised exercise training at home
16653487|NCT02258646|No Intervention|Usual care|Usual care
16653488|NCT02258633|Experimental|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
16653489|NCT02258633|No Intervention|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
16653490|NCT02258620|Experimental|dinitrate isosorbide (intra venous)|dinitrate isosorbide by continuous intra venous injection (1 à 5 mg/h)
16653491|NCT02258620|Experimental|dinitrate isosorbide (intra arterial)|dinitrate isosorbide 5 mg by direct administration intra arterial
16653492|NCT02258620|Experimental|nitroglycerine (transdermic)|nitroglycerine dermal patch15 mg/24h soit 67,2 mg/21 cm2
16653493|NCT02258607|Experimental|Momelotinib (MMB) dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.
16653494|NCT02258607|Experimental|Trametinib dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.
16653495|NCT02258607|Experimental|Momelotinib (MMB)+trametinib|Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.
16653497|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units
~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
16653498|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
16653499|NCT02258568|Experimental|Smoking abstinence counseling|Telephone motivational counseling sessions supporting smoking abstinence
16653500|NCT02258568|No Intervention|Control|Do not receive telephone motivational counseling sessions supporting smoking abstinence
16653501|NCT02258555|Experimental|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
16653502|NCT02258542|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
16653503|NCT02258542|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
16653504|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
16653505|NCT02258516|Experimental|behavioral intervention|"Patient education for self-management called CHIME 3-M will be delivered"
16653506|NCT02258516|Active Comparator|control|attention control arm received phone calls to discuss non-heart failure related health topics
16653507|NCT02258503||numerical scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and then taken care according to the usual practice of the emergency department.
16653508|NCT02258503||algoplus scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and by Algoplus® scale then taken care according to the usual practice of the emergency department.
16653509|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
16653510|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
16653511|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
16653512|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
16653513|NCT02258464|Experimental|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
16653514|NCT02258464|Placebo Comparator|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
16653517|NCT02258438|Experimental|Uninterrupted sitting|Patient will refrain from any structured activity and reduce any daily life activity. The patient will spend 24 hours in the calorimeter room. During the 24 hours the patient will remain sedentary for the 24 hours but will be able to watch TV, computer work or read.
16653518|NCT02258438|Experimental|Sitting + 1 bout of activity|The patient will be asked to perform the 45 minutes of moderate-exercise intervention in the morning once per day for two days in their daily life. This bout of exercise will be supervised by study staff on one of the treadmills On day 3 the patient will report at the Clinical and Translational Research Center (CTRC) of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, you will be asked to sit quietly in a chair, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity walking on a treadmill.
16653519|NCT02258438|Experimental|Sitting + microbursts of activity|The patient will be asked to refrain from any structured exercise running, swimming, lifting weights, yoga, dancing, etc.) for two days but to walk for the 5 minute intervention each hour between 1000 and 1800. On day 3, The patient will report at the CTRC of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, the patient will be asked to rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5 min moderate-intensity walking on a treadmill, which represents a total of 45 min.
16653520|NCT02258425|Experimental|FEM-CARE|Six specialized nurse case managed and health education sessions and coach-facilitated mentoring
16653521|NCT02258425|Active Comparator|Health Promotion|One brief basic health education session and coach-facilitated mentoring
16653522|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
16653523|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
16653524|NCT02258399|Active Comparator|Breakfast Rest|
16653525|NCT02258399|Active Comparator|Breakfast Exercise|
16653526|NCT02258399|Experimental|Fasted Exercise|
16653527|NCT02258373|Experimental|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.
~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
16653528|NCT02258373|Active Comparator|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
16653529|NCT02258360|Active Comparator|24 hours hypothermia|Therapeutic hypothermia for 24 hours after reaching target temperature
16653530|NCT02258360|Experimental|48 hours hypothermia|Therapeutic hypothermia for 48 hours after reaching target temperature
16653531|NCT02258347|Experimental|Single arm|
16653532|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
16653533|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
16653534|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
16653535|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
16653536|NCT02258321|Experimental|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
16653537|NCT02258321|Experimental|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
16653538|NCT02258308|Experimental|CHW intervention|"The CHW intervention is in-home education and support by a community health worker (CHW). At the first home visit, the CHW assesses the participant's knowledge and skills related to asthma self-management, current status of the child's asthma, and resources and support for asthma self-management using a baseline questionnaire. The CHW will inspect the home environment using an Environmental Home Checklist to identify environmental triggers that can cause asthma symptoms and affect asthma control. The CHW makes up to three follow-up visits and two telephone visits during the year the participant is in the study. Participants receive resources to help them control asthma: vacuum cleaner, dust covers for a pillow and mattress and a green cleaning kit with cleaning supplies."
16653539|NCT02258308|No Intervention|control|The control group receives standard asthma care, as provided by a primary health care provider. When the intervention period is over, the control group receives one visit with a CHW and the resources provided to the intervention group participants.
16653540|NCT02258295|Experimental|Intragel|Intragel (IBSA) has an average size of 800-1200 kDaltons. Intragel will give given with a concentration of 16mg/2cc. Each injection (2cc) injection will be given at baseline, then 2 weeks and 4 weeks from the baseline.
16653541|NCT02258295|Active Comparator|Saline|Saline injections will be given similar to the active hyaluronic injections. Each injection (2cc) will be given at baseline, then 2 weeks and 4 weeks from the baseline.
16653542|NCT02258282|Experimental|Etanercept|Patients under the treatment of 50 mg Etanercept
16653543|NCT02258282|Sham Comparator|Control|Patients under the treatment of traditional DMARDs
16653544|NCT02258269|Experimental|SQ|Patients with rheumatoid arthritis exercise square dance
16653545|NCT02258269|Sham Comparator|Control|Patients with rheumatoid arthritis listen to accompany music of square dance at home
16653546|NCT02258256|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
16653547|NCT02258230|Active Comparator|2D mode LSC|2D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
16653548|NCT02258230|Active Comparator|3D mode LSC|3D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
16653549|NCT02258230|Active Comparator|2D mode PVR|2D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
16653550|NCT02258230|Active Comparator|3D mode PVR|3D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
16653551|NCT02258217|Experimental|Single arm|Acthar 80 units subcutaneously for five consecutive days.
16653552|NCT02258204|Placebo Comparator|tPA-placebo|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.
~Saline infusion : 0.15 mL/kg IV bolus (maximum 15 mL) followed by an IV infusion of 0.15 mL/kg over 60 minutes (maximum 15 mL)."
16653553|NCT02258204|Experimental|tPA-ketamine|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.
~Ketamine infusion : 0.15 mg/kg IV bolus (maximum 15 mg) followed by an IV infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg)."
16653554|NCT02258191|Active Comparator|NIV treatment with telemonitoring|telemonitoring is used to manage NIV treatment
16653555|NCT02258191|Sham Comparator|NIV treatment with sham telemonitoring|sham telemonitoring (data not used for NIV management)
16653556|NCT02258178||1, Flucelvax|Flucelvax exposure in pregnancy
16653557|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
16653558|NCT02258152|Placebo Comparator|Placebo|
16653559|NCT02258152|Experimental|SYN120|
16653560|NCT02258139|Experimental|Study Group 1|1st overnight visit with no contact lens; 2nd overnight visit randomized to either left or right eye for B&L Investigational Contact Lens
16653561|NCT02258126|Active Comparator|Control group|healthy lifestyle education including healthy lifestyle education, supportive therapy and behavioral advice for both children and parents to improve nutrition and physical activity
16653562|NCT02258126|Experimental|Exercise group|multidisciplinary intervention program including healthy lifestyle education, supportive therapy and behavioral advice for for both children and parents to improve nutrition and physical activity and supervised exercise.
16653608|NCT02257814|No Intervention|Control Group|Control group
16653565|NCT02258100||AIMS|Patients receiving care documented via electronic anesthesia record.
16653566|NCT02258087|Active Comparator|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
16653567|NCT02258087|Experimental|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
16653568|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
16653569|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
16653570|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
16653571|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
16653572|NCT02258061|Experimental|DDD-80 pacing|To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).
16653573|NCT02258061|Sham Comparator|DDD-60 pacing|To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).
16653574|NCT02258048||Patients with cirrhosis|
16653575|NCT02258035||DBP/Gc1f-1f genotype|Human volunteers homozygous for the 1f-1f (fast) genotype of DBP.
16653576|NCT02258035||DBP/Gc1s-1s genotype|Human volunteers homozygous for the 1s-1s (slow) genotype of DBP.
16653577|NCT02258035||DBP/Gc 2-2 genotype|Human volunteers homozygous for the 2-2 genotype of DBP.
16653578|NCT02258009|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
16653579|NCT02258009|Experimental|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
16653580|NCT02257996|Experimental|Interventional Group|Online Systematic Brief Psychodynamic Psychotherapy
16653581|NCT02257996|No Intervention|Control Group|Waiting list
16653582|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
16653583|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
16653584|NCT02257970|Experimental|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally
~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
16653585|NCT02257970|Experimental|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally
~Open-label group: 75 mgs, three times daily, for four months"
16653586|NCT02257970|Placebo Comparator|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally
~Placebo: 1 capsule, three times daily, for four months"
16653587|NCT02257970|Active Comparator|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally
~Ketoprofen: 1 capsule, three times daily, for four months"
16653588|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
16653589|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
16653590|NCT02257944|Experimental|Motivational Interviewing|Receive brief hospital-based intervention
16653591|NCT02257944|Other|Treatment as Usual|Treatment as Usual
16653592|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
16653593|NCT02257918|Experimental|Group 1|N = 70 subjects receive single oral dose , 2000 mg of AZD0914
16653594|NCT02257918|Experimental|Group 2|N =70 subjects receive single oral dose , 3000 mg of AZD0914
16653595|NCT02257918|Active Comparator|Group 3|N = 40 subjects receive single intramuscular dose, 500 mg of ceftriaxone
16653596|NCT02257905||AL Amyloidosis patients who received allo HSCT|
16653597|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
16653598|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
16653599|NCT02257879||Sequence A|water - GFJ - supplement
16653600|NCT02257879||Sequence B|GFJ - supplement - water
16653601|NCT02257879||Sequence C|supplement - water - GFJ
16653602|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
16653603|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
16653604|NCT02257853|No Intervention|Control Group|No intervention group
16653605|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
16653606|NCT02257827|Experimental|IMRT- Hypofractionated schedule 70 Gy/25 fx|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
16653607|NCT02257827|Active Comparator|3DCRT-Hypofractionated schedule 70 Gy/25 fx|The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
16653609|NCT02257814|Experimental|Incredible Years|incredible years intervention
16653610|NCT02257814|Experimental|Preschool PATHS|Preschool PATHS (Promoting Alternative Thinking Strategies)
16653611|NCT02257814|Experimental|Tools of the Mind|Tools of the Mind
16653612|NCT02257801|Experimental|Nutritional beverage fortified with 6mg lutein/day|
16653613|NCT02257801|Experimental|Nutritional beverage fortified with 12mg lutein/day|
16653614|NCT02257801|Placebo Comparator|Nutritional beverage fortified with 0mg lutein/day|
16653615|NCT02257788|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
16653616|NCT02257788|Active Comparator|Treatment Arm 2|PRO 140: one SC loading dose, 700 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
16653617|NCT02257788|Active Comparator|Treatment Arm 3|PRO 140: one SC loading dose, 700 mg (day 1), followed by one single SC dose 350 mg (day 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
16653618|NCT02257788|Active Comparator|Treatment Arm 4|PRO 140: one SC dose, 700 mg (day 1) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
16653619|NCT02257762|Experimental|Lipid-based nutrient supplement (LNS)|LNS added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
16653620|NCT02257762|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge, eaten over 6 months, age 6-12 months to age 11-17 months
16653621|NCT02257762|Active Comparator|Sprinkles|Sprinkles added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
16653622|NCT02257762|No Intervention|Control|Plain borbor and thereafter family foods, eaten over 6 months, age 6-12 months to age 11-17 months
16653623|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
16653624|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
16653625|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
16653626|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
16653627|NCT02257710||Orsiro|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
16653628|NCT02257697|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
16653629|NCT02257697|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).
~All study subjects will receive standard steroid therapies during the study."
16653630|NCT02257684|Experimental|Pegcrisantaspase|
16653631|NCT02257671|Active Comparator|Oral contraceptive|oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks
16653632|NCT02257671|Placebo Comparator|Placebo|Oral placebo capsule daily during 11 weeks
16653633|NCT02257658|Experimental|Doxycycline|Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.
16653634|NCT02257658|Active Comparator|Incentive|Subjects in the incentive arm will receive escalating payments for remaining STI free at Weeks 12, 24 and 36.
16653635|NCT02257645||Euforvac-Hib vaccine|
16653636|NCT02257632|Experimental|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
16653637|NCT02257632|Experimental|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
16653638|NCT02257619|Experimental|Itacitinib plus docetaxel|
16653639|NCT02257606|No Intervention|Control group (persons with MS)|no training
16653640|NCT02257606|Experimental|Experimental group (persons with MS)|Robot-assisted training
16653641|NCT02257593|Experimental|10 % Protein|10% Dietary protein energy
16653642|NCT02257593|Experimental|15% Protein|15% Dietary protein energy
16653643|NCT02257593|Experimental|25% Protein|25% Dietary protein energy
16653644|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
16653645|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
16653646|NCT02257567|Experimental|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
16653647|NCT02257567|Active Comparator|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
16653648|NCT02257567|Experimental|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
16653649|NCT02257567|Active Comparator|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
16653650|NCT02257567|Experimental|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
16653651|NCT02257567|Experimental|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
16653652|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
16653653|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
16653654|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
16653655|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
16653656|NCT02257567|Experimental|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
16653657|NCT02257567|Experimental|Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
16653658|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
16653659|NCT02257528|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
16653660|NCT02257502|Experimental|aflibercept|intravitreal injection of aflibercept (EYLEA)
16653661|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
16653662|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
16653663|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
16653664|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
16653665|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
16653666|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
16653667|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
16653668|NCT02257476|Experimental|Carfilzomib|Patients will receive single agent carfilzomib on a weekly dosing schedule (days 1, 8, 15) in a 21 day cycle. The initial dose will be 20 mg/m² for cycle 1, day 1. Dose escalation will proceed in a standard 3+3 fashion with the requirement that dose escalation to the next level can only proceed if 0 of 3 or ≤ 1 of 6 patients experience a dose limiting toxicity (DLT). Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
16653669|NCT02257463|Active Comparator|Study group (group A)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training) inspiratory muscle training: (at intensity that progressively increased from 30% to 60% of patients' maximal inspiratory pressure)"
16653670|NCT02257463|Active Comparator|control positive group (group B)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training)"
16653671|NCT02257463|Active Comparator|control negative group (group C)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations"
16653672|NCT02257437|Experimental|LNS + borbor|Lipid-based nutrient supplement (LNS) added to borbor
16653673|NCT02257437|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge
16653674|NCT02257437|Active Comparator|Sprinkles|Sprinkles added to borbor
16653675|NCT02257437|Active Comparator|LNS snack|LNS eaten as snack
16653676|NCT02257424|Other|Phase 1/2|
16653677|NCT02257411|Active Comparator|Ear-sized based and weight based formula|the sizes of the PLMA determined with the ear-based compared with the sizes according to the manufacturer's weight-based formula
16653678|NCT02257398|Experimental|Sequence ABDC|Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
16653679|NCT02257398|Experimental|Sequence BCAD|Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
16653798|NCT02256722|Active Comparator|Treatment E|
16653799|NCT02256709|Experimental|single rising dose BIBP 5371 CL|
16653800|NCT02256709|Experimental|BIBP 5371 CL tablet high dose|to be compared with same daily dose level from single rising dose arm
16653680|NCT02257398|Experimental|Sequence CDBA|Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
16653681|NCT02257398|Experimental|Sequence DACB|Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
16653682|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
16653683|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
16653684|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
16653685|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
16653686|NCT02257359|Experimental|Epelsiban Cohort 1|Subjects will receive 300 mg of epelsiban administered orally twice (every 12 hr) on Day 1 (total daily dose of 600 mg)
16653687|NCT02257359|Experimental|Epelsiban Cohort 2|Epelsiban dose for Cohort 2 will be determined based on data from Cohort 1, but will not exceed a total daily dose of 900 mg, administered orally in divided doses (450 mg every 12 hrs or 300 mg every 8 hrs).
16653688|NCT02257359|Experimental|Additional Cohorts TBD (to be decided)|Subjects will be enrolled if determined necessary, based on data collected in Epelsiban Cohort 1 and Cohort 2
16653689|NCT02257346|Active Comparator|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
16653690|NCT02257346|Placebo Comparator|Normal Saline|Intravenous normal saline infusion
16653691|NCT02257320|Other|Feasibility|Assessing EMG activity with Bruxoff(TM) device
16653692|NCT02257294|Placebo Comparator|Control Arm|two placebo vials
16653693|NCT02257294|Active Comparator|Arm A|Alteplase 10mg and placebo vial
16653694|NCT02257294|Active Comparator|Arm B|Alteplase 10mg and alteplase 10mg
16653695|NCT02257281|Experimental|Active Therapeutic Ultrasound|The three inflammatory forearm spots on the same side induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with active therapeutic ultrasound .
16653696|NCT02257281|Placebo Comparator|Non-active Therapeutic Ultrasound|The contralateral three inflammatory forearm spots induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with non-active therapeutic ultrasound .
16653697|NCT02257268|Experimental|Change behavior group|Change behavior group = Group of change behavior including physical activity and healthy habits promotion.
16653698|NCT02257268|No Intervention|Control group|Control group = Group that will not receive the VAMOS program as intervention.
16653699|NCT02257255|Active Comparator|Pfannenstiel cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by Pfannenstiel technique. Pain assessment on postoperative hours 6, 12 and 24.
16653700|NCT02257255|Experimental|Misgav-Ladach cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by minimally invasive technique. Pain assessment on postoperative hours 6, 12 and 24.
16653701|NCT02257242|Experimental|Dose-escalation cohort|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
16653702|NCT02257229||Surgical|Corrective Surgery only
16653703|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
16653704|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
16653705|NCT02257216|Active Comparator|Sequence 1: Treatment/Treatment|Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®
16653706|NCT02257216|Active Comparator|Sequence 2: Placebo/Treatment|Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®
16653707|NCT02257216|Placebo Comparator|Sequence 3: Placebo/Placebo|Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo
16653708|NCT02257203|Experimental|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
16653709|NCT02257203|Active Comparator|Reading Education|Parents will receive an educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
16653710|NCT02257190|Experimental|Control (Con)|No exercise intervention.
16653711|NCT02257190|Experimental|Interval Walking - 3 min intervals (IW3)|One hour of classical interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking.
16653712|NCT02257190|Experimental|Interval Walking - 1 min intervals (IW1)|One hour of fast alternating interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking
16653801|NCT02256709|Experimental|BIBP 5371 CL tablet low dose|to be compared with same daily dose level from single rising dose arm
16653802|NCT02256709|Placebo Comparator|Placebo drinking solution|
16653803|NCT02256709|Experimental|BIBP 5371 CL drinking solution|
16653713|NCT02257177|Active Comparator|0.15 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 0.15mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653714|NCT02257177|Active Comparator|1.5 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 1.5mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653715|NCT02257177|Active Comparator|3 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 3mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653716|NCT02257177|Active Comparator|10 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 10mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653717|NCT02257177|Active Comparator|20 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 20mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653718|NCT02257177|Active Comparator|50 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 50mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653719|NCT02257177|Placebo Comparator|Placebo Part 1|12 Healthy Subjects are administered placebo inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
16653720|NCT02257177|Active Comparator|0.3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 0.3mg TD139 once daily for 14 days inhaled as a dry powder.
16653721|NCT02257177|Active Comparator|3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 3mg TD139 once daily for 14 days inhaled as a dry powder.
16653722|NCT02257177|Active Comparator|10 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 10mg TD139 once daily for 14 days inhaled as a dry powder.
16653723|NCT02257177|Placebo Comparator|Placebo Part 2|9 Patients with IPF are administered placebo inhaled as a dry powder.
16653724|NCT02257164|Active Comparator|femoral nerve block|20 ml injection of 2 mg/ml ropivacaine in femoral nerve
16653725|NCT02257164|Experimental|obturator nerve block and intraarticular injection|10 ml injection of 2 mg/ml ropivacaine in obturator nerve intraarticular injection : 10 ml of chlorhydrate ropivacaine (2 mg/ml) and 10ml of magnesium sulfate
16653726|NCT02257151|Experimental|Group 1: BMS-986142 or placebo|BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified
16653727|NCT02257151|Experimental|Group 2: BMS-986142 or placebo|BMS-986142 or placebo Multiple dose oral Solution as specified
16653728|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine)|Patients receive ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16653729|NCT02257125|Experimental|high incentive|game version including visual effects and monetary rewards
16653730|NCT02257125|Active Comparator|low incentive|game version without visual effects or monetary rewards
16653731|NCT02257112|Experimental|Multistage low-energy stimulation|Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
16653732|NCT02257073|Experimental|CBT|Cognitive-behavioral treatment
16653733|NCT02257073|Sham Comparator|WLT|Waiting in list
16653734|NCT02257060|Experimental|Endocardial Ablation|
16653735|NCT02257047|Experimental|RYR|Patients under the treatment of red yeast rice
16653736|NCT02257047|Sham Comparator|Control|Patients under the treatment of tea
16653737|NCT02257034|Experimental|Taichi|patients exercise with Tai chi
16653738|NCT02257034|Sham Comparator|Control|patients under exercise of dance
16653739|NCT02257021|Experimental|Tipranavir and high dose of ritonavir plus BILR 355 BS|
16653740|NCT02257021|Experimental|BILR 355 BS with low dose of ritonavir|
16653741|NCT02257008|Experimental|Single rising dose of BILR 355 BS with grapefruit juice|
16653742|NCT02257008|Experimental|Single rising dose of BILR 355 BS with nelfinavir|
16653743|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir|
16653744|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir, ritonavir|
16653745|NCT02256995||Pregnant Women (>22 weeks gestation)|Biomarkers tracked over 3 antenatal care visits via standard of care (dipstick, manually/visually assessed) and via uChek (automated assessment via computer application)
16653746|NCT02256982|Experimental|Resectable Disease|"Consent and Registration
~3 cycles of gemcitabine + cisplatin
~Evaluate for surgery* (weeks 10-15)
~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.
~Proceed to surgery
~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
16653747|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration
~3 cycles of gemcitabine + cisplatin
~Evaluate for surgery* (weeks 10-15)
~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.
~Proceed to radiation therapy with protons or photons, determined by available resources
~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
16653804|NCT02256709|Experimental|BIBP 5371 CL tablet high dose with food|
16653805|NCT02256709|Experimental|BIBP 5371 CL tablet low dose with food|
16653806|NCT02256709|Placebo Comparator|Placebo tablet|
16653843|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
16653748|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.
~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
16653749|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.
~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
16653750|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.
~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
16653751|NCT02256956|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
16653752|NCT02256956|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
16653753|NCT02256943|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
16653754|NCT02256943|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
16653755|NCT02256930|Experimental|M518101|M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
16653756|NCT02256930|Placebo Comparator|M518101 Vehicle|M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
16653757|NCT02256930|Active Comparator|Sodium lauryl sulfate|The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
16653758|NCT02256930|Sham Comparator|Saline|The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
16653759|NCT02256917|Experimental|Human-cl rhFVIII|
16653760|NCT02256904|Experimental|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
16653761|NCT02256904|Active Comparator|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
16653762|NCT02256891|Experimental|Double Row|Double Row
16653763|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
16653764|NCT02256878|Experimental|BIRT 2584 XX + Amitriptyline|"BIRT 2584 XX:
~Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)
~Amitriptyline:
~Single dose on day -8, day 1, and day 15"
16653765|NCT02256865|Placebo Comparator|Placebo and Drug Group 2|Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day.
16653766|NCT02256865|Active Comparator|Drug and Placebo Group 1|Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day
16653767|NCT02256852|Experimental|QBKPN SSI|Individualized maintenance dose administered subcutaneously for 12 weeks
16653768|NCT02256839||non TB infection|Group tested with CST_001
16653769|NCT02256839||low exposure risk|Group tested with CST_001
16653770|NCT02256826|Experimental|Group A|
16653771|NCT02256826|Experimental|Group B|
16653772|NCT02256813|Experimental|BIRT 2584 XX + PK-cocktail|
16653773|NCT02256800|Experimental|UGT1A1 genotyping (6,6)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
16653774|NCT02256800|Experimental|UGTA1T1 genotyping (6,7)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
16653775|NCT02256800|Experimental|UGTA1T1 genotyping (7,7)|The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
16653776|NCT02256800|Experimental|UGT1A1 non-genotyping|The investigators will maintain the dosage of irinotecan by 180mg/m2
16653777|NCT02256787|Experimental|BILB 1941 ZW - single rising dose|Single rising dose part
16653778|NCT02256787|Placebo Comparator|Placebo|Single rising dose part
16653779|NCT02256787|Experimental|BILB 1941 ZW - tablet - fasted|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
16653780|NCT02256787|Experimental|BILB 1941 ZW - solution|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
16653781|NCT02256787|Experimental|BILB 1941 ZW - tablet - fed|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
16653782|NCT02256774|Experimental|Combivir® plus BILR 355/Ritonavir|
16653783|NCT02256774|Experimental|BILR 355/Ritonavir|
16653784|NCT02256761|Experimental|BIRT 2584 XX - single dose|"Part 1 - bioavailability/food effect
~two single doses, 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served"
16653785|NCT02256761|Placebo Comparator|Placebo|Part 2
16653786|NCT02256761|Experimental|BIRT 2584 XX - multiple escalating dose|Part 2 - multiple escalating dose, 14 days and 28 days
16653787|NCT02256748|Experimental|BIRT 2584 XX + Midazolam|"BIRT 2584 XX: Multiple doses for 12 days (bid on days 1 and 2, qd from days 3 to 12)
~Midazolam: Administration on days -2, 1, 3, and 12"
16653788|NCT02256735|Experimental|Treatment A|
16653789|NCT02256735|Experimental|Treatment B|
16653790|NCT02256735|Experimental|Treatment C|
16653791|NCT02256735|Experimental|Treatment D|
16653792|NCT02256735|Placebo Comparator|Placebo|
16653793|NCT02256735|Active Comparator|Moxifloxacin|
16653794|NCT02256722|Experimental|Treatment A|
16653795|NCT02256722|Experimental|Treatment B|
16653796|NCT02256722|Experimental|Treatment C|
16653797|NCT02256722|Experimental|Treatment D|
16653807|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
16653808|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
16653809|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
16653810|NCT02256683|Experimental|Dabigatran|Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
16653811|NCT02256683|Active Comparator|Phenprocoumon|Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response
16653812|NCT02256670|Experimental|Text Message Application Intervention|The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
16653813|NCT02256657|Experimental|Step 1: Toolkit Implemented in Month 4|Quality Improvement Toolkit
16653814|NCT02256657|Experimental|Step 2: Toolkit Implemented in Month 8|Quality Improvement Toolkit
16653815|NCT02256657|Experimental|Step 3: Toolkit Implemented in Month 12|Quality Improvement Toolkit
16653816|NCT02256657|Experimental|Step 4: Toolkit Implemented in Month 16|Quality Improvement Toolkit
16653817|NCT02256657|Experimental|Step 5: Toolkit Implemented in Month 20|Quality Improvement Toolkit
16653818|NCT02256644||Million Veteran Program (MVP) participants|Veterans who are currently enrolled in the Million Veteran Program.
16653819|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
16653820|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
16653821|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
16653822|NCT02256631|Experimental|Dose Group 4, Cohort 1|Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
16653823|NCT02256631|Experimental|Dose Group 4, Cohort 2|Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
16653824|NCT02256631|Experimental|Dose Group 5, Cohort 1|Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
16653825|NCT02256631|Experimental|Dose Group 5, Cohort 2|Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.
16653826|NCT02256618|Experimental|Cell therapy|Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion
16653827|NCT02256605||Insufficient Group|D-3 Chewable Wafer - 14,000 IU/wafer weekly Vitamin D-3 Caps - 2,000 IU/Cap daily Vitamin D-3 Liquid - 5,000 IU/ml (0.4) ml daily
16653828|NCT02256605||Deficient Group|D-3 Chewable Wafer - 50,000 IU/wafer weekly Vitamin D-3 Liquid - 5,000 IU/ml daily
16653829|NCT02256592|Experimental|Fecal microbiota transplant (FMT)|Donor fecal suspension will be delivered during colonoscopy to HIV+ individuals.
16653830|NCT02256566|Experimental|emotional memory training exercise|study training exercise - Emotional Faces Memory Task (EFMT)
16653831|NCT02256566|Active Comparator|memory training exercise|an active control exercise (CT)
16653832|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
16653833|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
16653834|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
16653835|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
16653836|NCT02256527||Promus Premier|observational data
16653837|NCT02256514|Experimental|Daily oral dose of hepcortespenlisimut-L|Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
16653838|NCT02256501|Experimental|Mono Nunlear Cell (MNC)|The patients with idiopathic dilated cardiomyopathy who underwent intracoronary injection of autologous bone marrow-derived mononuclear cells .
16653839|NCT02256501|No Intervention|Control|The patients with cardiomyopathy that are under observe during the study.
16653840|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
16653841|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
16653842|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
16653872|NCT02256332|Placebo Comparator|Reference food format|Reference food without plant-based ingredient
16653844|NCT02256475|Experimental|Adolescents Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
16653845|NCT02256475|Experimental|Adolescents Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
16653846|NCT02256475|Experimental|Adolescents Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
16653847|NCT02256475|Experimental|Children Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
16653848|NCT02256475|Experimental|Children Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
16653849|NCT02256475|Experimental|Children Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
16653850|NCT02256462|Experimental|Interventional|Adalimumab levels and antibodies will be obtained with every laboratory examination (every 2 months, except for the first 2 visits). Dose or interval adjustment will be performed as followed:when trough levels results taken prior to ADA injection are above 5 µg/ml no change in dosing is required. Detectable levels below 5 µg/ml will result in interval decrease to every week. If levels are still below 5 µg/ml dose will be increased to 40 mg (in patients receiving less than 40 mg). Undetectable levels below 0.3µg/ml will be followed by antibodies (ATAs) measurement. If ATAs are persistently above 8 µg/ml the patient will discontinue the study. If ATAs are below 8 µg/ml ADA intervals will be decreased to every week.
16653851|NCT02256462|No Intervention|Clinical|"Adalimumab levels and antibodies will be requested based on physician judgment when there are signs of loss of response (LOR). Dose and interval adjustment will be performed according to clinical measures: Following physician decision trough levels and ATAs will be collected and further adjustment may be considered according to results. Interval adjustment will be performed as described for the interventional arm.
~LOR is defined as PCDAI equal or higher than 10 or CRP higher than 0.5 mg/dl (5mg/l) and/or Fecal calprotectin higher than 150 mcg/gr (If lower than 150 at randomization)."
16653852|NCT02256449||BVS patients|Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.
16653853|NCT02256436|Active Comparator|Control|Participants receive paclitaxel 175 mg/m^2 intravenously (IV) or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
16653854|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to approximately 1 additional year).
16653855|NCT02256423|Active Comparator|REFERENCE 1: Nurofen® 200 mg tablet|Single group 3-way crossover study
16653856|NCT02256423|Active Comparator|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|Single group 3-way crossover study
16653857|NCT02256423|Experimental|ibuprofen 200 mg soft gel capsule|single group, 3-way cross
16653858|NCT02256410|Experimental|Stimulation|Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
16653859|NCT02256410|Sham Comparator|sham stimulation|Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
16653860|NCT02256397|Active Comparator|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
16653861|NCT02256397|Experimental|Enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:
~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller
~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
16653862|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
16653863|NCT02256371|Experimental|Hypnotic analgesia|"Hypnosis sessions:
~Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist"
16653864|NCT02256371|Experimental|Relaxation|"Relaxation group:
~Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist."
16653865|NCT02256371|No Intervention|Routine care|The patients will receive their usual pain treatments throughout the study
16653866|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
16653867|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
16653868|NCT02256345|Active Comparator|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
16653869|NCT02256345|Placebo Comparator|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
16653870|NCT02256332|Active Comparator|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
16653871|NCT02256332|Active Comparator|High dose plant based ingredient|Reference food with high dose of plant based ingredient
16653873|NCT02256319|Experimental|Dexmedetomidine recording|Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.
16653874|NCT02256319|Active Comparator|Propofol recording|Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.
16653875|NCT02256319|No Intervention|Basal recording|Recording registered through the deep brain stimulation electrodes with no sedation .
16653876|NCT02256306|Experimental|Young Donor Plasma|Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
16653877|NCT02256293|Experimental|Group Therapy|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
16653878|NCT02256280|Experimental|S Group|Sugammadex 2 or 4 mg/kg iv once at the end of surgery
16653879|NCT02256280|Active Comparator|N Group|Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery
16653880|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
16653881|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
16653882|NCT02256254|Active Comparator|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
16653883|NCT02256254|Placebo Comparator|Placebo|2 placebo capsules every evening for 14 days
16653884|NCT02256241||The role of RING ubiquitin ligases in osteogenic progenitors|Bone marrow (BM) will be collected from healthy patients undergoing orthopedic surgery. BM will be collected from disposable tissue that is removed during the normal sequence of the surgery.
16653885|NCT02256241||The role of RING ubiquitin ligases in musculoskeletal cancer|Collection of connective tissue from patients with tumors of musculoskeletal origin - a part of the resected tumor specimens.
16653886|NCT02256228|Active Comparator|Group R|Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
16653887|NCT02256228|Placebo Comparator|Group P|Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
16653888|NCT02256215|Experimental|Vitamin D|• All patients will have their serum vitamin D levels measured at the baseline visit. Those assigned to the treatment arm (group A) will receive either 50,000 international units of vitamin D3 by mouth once or more per week for six to eight weeks, then 800 to 1000 (or more) international units of vitamin D3 daily thereafter, this is according to the recommendations of the Endocrine Society clinical practice guideline 2011. Group B patients will receive placebo supplements identical in appearance to the vitamin D supplements.
16653889|NCT02256215|Placebo Comparator|Placebo|
16653890|NCT02256189|Other|Sitagliptin first, then placebo|Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks
16653891|NCT02256189|Other|Placebo first, then sitagliptin|Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks
16653892|NCT02256150|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
16653893|NCT02256150|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).
~All study subjects will receive standard steroid therapies during the study."
16653894|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
16653895|NCT02256124|Experimental|Lamotrigine|"Lamotrigine during 28 consecutive weeks:
~8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily
~18 weeks target-dose phase: 100mg twice daily
~2 weeks decline-phase: 100mg once daily."
16653896|NCT02256124|Placebo Comparator|Placebo|Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.
16653897|NCT02256111|Experimental|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
16653898|NCT02256111|Experimental|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
16653899|NCT02256098|Experimental|ATTUNE™|Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy
16653900|NCT02256098|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
16653901|NCT02256085|Sham Comparator|Sham rTMS|"Daily rTMS with Sham coil
~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil"
16653902|NCT02256085|Experimental|Active rTMS|"Daily rTMS with Active coil
~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
16653903|NCT02256085|Experimental|Open Active rTMS|"Open Label Daily rTMS with Active coil
~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
16653904|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
16653905|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
16653906|NCT02256059||Plate osteosynthesis|Patients with fracture of the lateral clavicle and indication for surgical treatment
16653907|NCT02256046|Experimental|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
16653908|NCT02256033|Experimental|Istradefylline|One 40-mg tablet of istradefylline administered on Day 1.
16653909|NCT02256020|Other|Original lifestyle|Original lifestyle, watching TV 50 minutes, three times a week for 6 months.
16653910|NCT02256020|Experimental|Wheel-chair music aerobic exercise|Wheel-chair music aerobic exercise with 3 times of 50-minute session (10 minutes warm up, 30 minutes exercise and 10 minutes cool down) a week for 6 months.
16653911|NCT02256007|Active Comparator|Standardized Assessments|"Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:
~Line Bisection Test
~Patient Reported Outcomes
~Trial Making A and B
~Usability Questionnaire"
16653912|NCT02256007|Experimental|Videogame Assessments|"Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:
~Line Crossing
~Patient Reported Outcomes
~Trial Making A & B-Asteroid Adventure Game
~Usability Questionnaire"
16653913|NCT02255994|Experimental|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
16653914|NCT02255994|Active Comparator|No MESH|Patients in this arm had subvesical plication without reinforcement.
16653915|NCT02255981|Experimental|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months
~."
16653916|NCT02255968|Experimental|EDP-788|Multiple doses with dose escalation to continue in successive cohorts
16653917|NCT02255968|Placebo Comparator|Placebo|Multiple doses with dose escalation to continue in successive cohorts
16653918|NCT02255955|Experimental|550 mg naproxen sodium and 30mg codeine|Preoperatively patients received oral naproxen sodium codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
16653919|NCT02255955|Active Comparator|300 mg paracetamol and 30 mg codeine|Preoperatively patients received oral paracetamol codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
16653920|NCT02255955|Placebo Comparator|Placebo|Preoperatively patients received oral placebo tablet, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
16653921|NCT02255942|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
16653922|NCT02255929|Experimental|Gamma Knife Radiosurgery|Gamma Knife treatment is conducted in one day and takes approximately 70 to 90 minutes.
16653923|NCT02255916|No Intervention|Controll|No sound-bed intervention
16653924|NCT02255916|Experimental|Music|live sound-bed music intervention
16653925|NCT02255903||Group 1(Control Group):|ultrasound and Doppler examination: of 100 pregnant females with gestational age 37-40 weeks.
16653926|NCT02255903||Group 2 (post date Group)|ultrasound and Doppler examination:will be done for 100 pregnant females with gestational age 41 weeks or more
16653927|NCT02255877|Active Comparator|Zip Surgical Skin Closure|Subjects randomized to receive one knee (left or right) closed with ZipSurgical Skin Closure and the other knee closed with standard staples
16653928|NCT02255877|Active Comparator|Steel Staples|Subjects randomized to receive one knee (left or right) closed with Staples and the other knee closed with ZipSurgical Skin Closure
16653929|NCT02255864|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
16653930|NCT02255851||Treatment Group|TAVR + SENTINEL (Cerebral Protection System)
16653931|NCT02255838|Experimental|Bronchoscope disposable, aScope IV|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
16653932|NCT02255838|Active Comparator|Bronchoscope reusable Storz 8402 2x|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
16653933|NCT02255825|Active Comparator|Control Group|Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.
16653934|NCT02255825|Experimental|Intervention Group|Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.
16653935|NCT02255812|Placebo Comparator|200 mL tap water|Single intragastric instillation of 200 mL tap water via nasogastric tube
16653936|NCT02255812|Active Comparator|2 g citric acid|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
16653937|NCT02255812|Active Comparator|2 g salt|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
16653938|NCT02255812|Active Comparator|0.017 g quinine|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
16653939|NCT02255812|Active Comparator|1 g monosodium glutamate|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
16653940|NCT02255812|Active Comparator|25 g glucose|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
16653941|NCT02255799|Active Comparator|Donepezil|Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.
16653942|NCT02255799|Placebo Comparator|Placebo|Placebo capsules once daily for 70 days.
16653943|NCT02255786|Experimental|ACT Parent Group|Participants will complete a total of five Acceptance and Commitment Therapy - Parent Group Sessions First four are held weekly, last session held one month from 4th session.
16653944|NCT02255786|No Intervention|Treatment as Usual|Treatment as usual-Control
16653945|NCT02255773|Other|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
16653946|NCT02255773|Other|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
16653947|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
16653948|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
16653949|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
16653950|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
16653951|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
16653952|NCT02255747|Active Comparator|anal dilatation|
16653953|NCT02255747|Active Comparator|Oral Lactulose|
16653954|NCT02255734|Active Comparator|Zovirax|
16653955|NCT02255734|Experimental|Virless|
16653956|NCT02255721|Experimental|SHIP Intervention|SHIP is a health behavior change intervention to give parents the knowledge, motivation, and skills necessary to set goals, problem-solve, and improve their child's sleep.
16653957|NCT02255721|Active Comparator|SHIP Control Arm|The active control arm uses the same strategies as the SHIP intervention arm, but for child health topics unrelated to sleep or outcome measures.
16653958|NCT02255708|Other|Healthy group.|Group formed by healthy patients.
16653959|NCT02255708|Other|Group with demyelinating polyneuropathy|Group formed by patients with demyelinating polyneuropathy.
16653960|NCT02255695|No Intervention|Control group|Control group
16653961|NCT02255695|Experimental|School-based exercise program|School-based exercise program
16653962|NCT02255682|Placebo Comparator|Simvastatin and Q10-placebo|Simvastatin 40 mg orally administered daily and Q10-placebo for 8 weeks
16653963|NCT02255682|Active Comparator|Simvastatin and Q10|Simvastatin 40 mg orally administered daily for 8 weeks in combination with Q10 supplementation of 400 mg/daily
16653964|NCT02255669|Active Comparator|partially covered SEMS|Deployment of Partially covered biliary self expandable metal stent
16653965|NCT02255669|Active Comparator|fully covered SEMS|Deployment of Fully covered biliary self expandable metal stent
16653966|NCT02255656|Experimental|Alemtuzumab|All Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649).
16653967|NCT02255643|Experimental|-10% of effective PMT|Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
16653968|NCT02255643|Active Comparator|former setting (+/- 0% of PMT)|Patients are set to their original PMT at start of study, Changes in PMT settings
16653969|NCT02255643|Experimental|+10% of effective PMT|Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
16653970|NCT02255630|Experimental|Salbutamol inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
16653971|NCT02255630|Experimental|Placebo inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
16653972|NCT02255617|Experimental|Fecal Microbiota Transplant|Single arm open label FMT administered at Week 0 by colonoscopy and at Weeks 1-4 by enema
16653973|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.
~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
16653974|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.
~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
16653975|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.
~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
16653976|NCT02255591|Experimental|Shamrock|Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
16653977|NCT02255591|Active Comparator|Lumbar Ultrasound Trident|Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.
16653978|NCT02255578|Other|IVF treatment|Fertility, as determined by egg quality parameters, as well as metabolic parameters, will be assessed following Endobarrier treatment in PCOS during IVF treatment.
16653979|NCT02255578|Other|clomiphene citrate treatment|Ovulation rate in response to clomiphen citrate after Endobarrier treatment in PCOS.
16653980|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
16653981|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
16653982|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
16653983|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
16653984|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
16653985|NCT02255539|Experimental|CPAP Nasal Mask|Geelong Prototype Mask
16653986|NCT02255526||Healthy Volunteers|Healthy volunteers between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
16653987|NCT02255526||Heart Failure|Heart failure patients between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
16653988|NCT02255513|Experimental|HLD200|"HLD200 (methylphenidate hydrochloride) 20, 40, 60, 80, or 100 mg capsules
~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to continue their HLD200 treatment over an one week double-blind, placebo-controlled phase. HLD200 was administered orally, once daily each evening."
16653989|NCT02255513|Placebo Comparator|Placebo|"Placebo capsules (dose matched to HLD200 capsules)
~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to receive placebo treatment over a one week double-blind, placebo-controlled phase. Treatments were administered orally, once daily each evening."
16653990|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
16653991|NCT02255487|Experimental|IrriSept System|IrriSept device used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen
16653992|NCT02255487|Active Comparator|Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
16653993|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
16653994|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
16653995|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
16653996|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
16653997|NCT02255448|Other|SV1, SV2|SV1 intervention: stroke volume using transthoracic echo SV2 intervention: stroke volume measured using the esCCO device.
16653998|NCT02255435|Experimental|Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
16653999|NCT02255435|Experimental|Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks
16654000|NCT02255435|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
16654001|NCT02255435|Experimental|Omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks
16654002|NCT02255435|Experimental|Omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks
16654003|NCT02255435|Experimental|Omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks
16654004|NCT02255435|Experimental|Omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks
16654005|NCT02255435|Experimental|Omaveloxolone Capsules 300 mg|omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks
16654006|NCT02255435|Experimental|Omaveloxolone Capsules 150 mg|omaveloxolone (RTA 408) Capsules, 150 mg taken orally once daily for 24 weeks
16654007|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
16654008|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
16654009|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
16654010|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
16654011|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
16654012|NCT02255422|Experimental|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
16654013|NCT02255422|Experimental|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
16654014|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
16654015|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
16654017|NCT02255370|Experimental|CURCUMIN|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
16658787|NCT02223000|Experimental|BIBV 308 SE capsule 2|
16654018|NCT02255370|Placebo Comparator|PLACEBO|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
16654019|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
16654020|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
16654021|NCT02255344||ST-Elevation Myocardial Infarction|Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
16654022|NCT02255344||Non ST Segment Elevation|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
16654023|NCT02255331||Retrieval Analysis|"You qualify for this Retrieval Analysis study if you:
~Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation.
~Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or
~Have a metal-on-polyethylene total hip replacement greater than 1 year old, or
~Have an infected total hip replacement (any surface bearing)
~You do not qualify for this arm of the study if you:
~Have occupational exposure to cobalt or chromium
~Presence of a metal-on-metal (MOM) implant, or a recalled implant
~Have had a prior revision of your total hip
~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
16654024|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:
~Have a total hip replacement with a ceramic component
~Have a metal-on-polyethylene total hip replacement.
~Have your original or revised total hip replacement.
~You do not qualify for this arm of the study if you:
~Have occupational exposure to cobalt or chromium
~Have cemented components.
~Presence of a metal-on-metal (MOM) implant, or a recalled implant
~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
16654025|NCT02255318|Experimental|Taurolock|Patients received Taurolock lock for 3 months administration.
16654026|NCT02255318|Placebo Comparator|Placebo|Patients received placebo lock (physiological serum) for 3 months administration.
16654027|NCT02255305|Experimental|FMT Group (Intervention Arm)|Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
16654028|NCT02255305|Active Comparator|Antimicrobial Group (Control Arm)|Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.
16654029|NCT02255292|Experimental|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study.
16654030|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
16654031|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
16654032|NCT02255266||A|
16654033|NCT02255253|Experimental|Telmisartan|capsule,40mg per day,2 months
16654034|NCT02255253|Experimental|Hydrochlorothiazide|tablet, 25mg per day, 2 months
16654035|NCT02255240|Experimental|Physical activity intervention|This arm will receive the physical activity intervention, which consists of three individual meetings, weekly brief counseling phone calls for 6 weeks, and provision of a video game console with three active video games.
16654036|NCT02255227|Active Comparator|1 dose Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
16654037|NCT02255227|Experimental|2 doses Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
16654038|NCT02255214||Surgical Patient|These are the results from the blood samples taken from the study participants.
16654039|NCT02255201|Active Comparator|Beverage A|Single dose, Pre-Workout Master Performance Blend Dose 1
16654040|NCT02255201|Active Comparator|Beverage B|Single dose, Pre-Workout Master Performance Blend Dose 2
16654041|NCT02255201|Active Comparator|Beverage C|Single dose, Pre-Workout Performance Energy Blend
16654042|NCT02255201|Active Comparator|Beverage D|Single dose, Pre-Workout Energy Blend
16654043|NCT02255201|Placebo Comparator|Beverage E|Single dose, Pre-Workout Placebo
16654044|NCT02255188||Graft type - PCL|PCL - polycaprolactone
16654045|NCT02255188||Graft type - PCL/ gelatin|polycaprolactone/ gelatin/poorly permeable layer;
16654046|NCT02255188||Graft type - PLGA/PCL/gelatin|PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
16654047|NCT02255188||Graft type - nylon 6|
16654048|NCT02255175|Experimental|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
16654049|NCT02255175|Active Comparator|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
16654050|NCT02255162|Experimental|Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Participants will receive the following:
~Cytarabine-intravenous, fixed dosage, given 5 times during cycle
~HLA-mismatched stem-cell microtransplantation
~Lenalidomide-administered daily per cycle"
16654051|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
16654088|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
16654052|NCT02255136|Experimental|Individualized homeopathic medicines|Psorinum, Tuberculinum, Medorrhinum, Calcarea carbonica, Natrum sulphuricum etc. as indicated; Rescue medicines, e.g. Aralea racemosa, Arsenicum album, Histamine hydrochloride, House dust, Ipecacuanha, Antimonium tartaricum, Grindelia robusta etc. as indicated; 5 ml dose of indicated homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; administered twice daily for 1 year
16654053|NCT02255136|Placebo Comparator|Intervention placebo|5 ml dose made up of single drop of rectified spirit in 5 ml distilled water, identical in appearance of homeopathic medicine, to be administered twice daily for 1 year
16654054|NCT02255110|Experimental|TH-302 and doxorubicin|
16654055|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
16654056|NCT02255084|Experimental|Group 1|"Group 1 remove self sample kit at gp consulting room or perform pap smear :
~Study coordinators send mail inviting women to remove a kit for vaginal self-sampling at their general practitioner s consulting room.
~Either a pap smear is perform or, at home, women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
16654057|NCT02255084|Experimental|Group 2|"Group 2 perform self sample at home or pap smear :
~Kit for vaginal self-sampling sent at women home. Women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
16654058|NCT02255071|Experimental|Acupressure|Patients will band a acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
16654059|NCT02255071|Sham Comparator|Sham-Acupressure|Patients will band a sham wristband over wrist but no acupressure for seven days.
16654060|NCT02255045|Experimental|Dose 1 of meloxicam in vaginal ring|2.4 g of meloxicam in a vaginal ring
16654061|NCT02255045|Experimental|Dose 2 of meloxicam in vaginal ring|3.0 g of meloxicam in a vaginal ring
16654062|NCT02255045|Active Comparator|Oral non-steroidal anti-inflammatory drug|Diclofenac potassium
16654063|NCT02255045|Placebo Comparator|Placebo vaginal ring and oral pill|Placebo vaginal ring and placebo oral pill
16654064|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
16654065|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
16654066|NCT02255019||IBD, CD, UC|All patients should either have a known IBD diagnose or suspect of having IBD.
16654067|NCT02255006|Experimental|active acupuncture|The participants in this group receive real acupuncture treatment at first. Afterwards crossover study is scheduled to be performed.
16654068|NCT02255006|Sham Comparator|Sham acupuncture|The participants in this group receive sham acupuncture treatment at first. afterwards crossover study is scheduled to be performed
16654069|NCT02255006|Experimental|Euglycon|Glibenclamide (Euglucon, Roche Pharma) is administered 3 hours before FMD measurement.
16654070|NCT02255006|Experimental|Celebrex|Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.
16654071|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
16654072|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
16654073|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
16654074|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
16654075|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
16654076|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
16654077|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
16654078|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
16654079|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:
~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL
~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL
~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
16654080|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:
~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume
~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
16654081|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
16654082|NCT02254980|Experimental|Vitamin-E group|Vitamin-E diffused polyethylene
16654083|NCT02254980|Active Comparator|Control group|Standard polyethylene
16654084|NCT02254967|Experimental|Fidaxomicin Extended Pulsed Regimen (EPFX)|Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
16654085|NCT02254967|Experimental|Vancomycin|Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
16654086|NCT02254954|Experimental|Macitentan in combination with RT & TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
16654087|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
16654089|NCT02254928|Other|Group 1|First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)
16654090|NCT02254928|Other|Group 2|First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)
16654091|NCT02254915|Experimental|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
16654092|NCT02254915|Active Comparator|Bacillus Calmette-Guérin|Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
16654093|NCT02254902|Experimental|Physical Activity|Participants in the Physical Activity intervention arm of the study receive culturally-modified, materials through participation in 12 weekly 1-.5-hour sessions focused on increasing daily step counts and bouts of moderate intensity physical activity. The group sessions include participation in different forms of physical activity as well as group discussions on the barriers and opportunities for increasing physical activity in daily life.
16654094|NCT02254902|No Intervention|Wait List Control|Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
16654095|NCT02254889|Active Comparator|pre-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) before ESD.
16654096|NCT02254889|Placebo Comparator|post-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) after ESD.
16654097|NCT02254876|Active Comparator|Standard physical therapy program|Standard physical therapy program is delivered for four rehabilitation sessions for a period of about 45 minutes each.
16654098|NCT02254876|Experimental|NeuroMuscular Taping (NMT)|"NeuroMuscular Taping is delivered in addiction to the Standard Treatment for four rehabilitation sessions. The sessions were spaced apart about five days to ensure the optimum adhesion of the NMT."
16654099|NCT02254863|Experimental|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
16654100|NCT02254850|Experimental|Mesoglycan|"The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml and inactive ingredients: sodium chloride, chlorocresol, water for injections.
~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg and Inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
~Patients also performed Flow Mediated Dilation (FMD)."
16654101|NCT02254850|Placebo Comparator|Placebo|"The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
~Patients also performed Flow Mediated Dilation (FMD)."
16654102|NCT02254837|Experimental|Zilver PTX|
16654103|NCT02254824|Active Comparator|Normal-dose statin|Lifestyle modification with Normal-dose statin
16654104|NCT02254824|Active Comparator|Lifestyle modification + Xuezhikang|Lifestyle changes with Xuezhikang
16654105|NCT02254824|Active Comparator|Lifestyle modification|Lifestyle modification
16654106|NCT02254811|Experimental|Delivery via capsule|Fecal microbiota transplant is delivered by oral capsules
16654107|NCT02254811|Experimental|Delivery via colonoscopy|Fecal microbiota transplant delivered by colonoscopy
16654108|NCT02254798||Transplanted patients|No intervention Prospective registration of patients receiving an allogeneic hematopoietic stem cell transplant
16654109|NCT02254785|Experimental|Cabazitaxel|
16654110|NCT02254785|Active Comparator|Abiraterone or enzalutamide|
16654111|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
16654112|NCT02254759|Other|IV Midazolam Alone|A single 1 milligram (mg) dose of IV Midazolam on Day 1.
16654113|NCT02254759|Other|Oral Midazolam Alone|A single 5 mg oral dose of midazolam on Day 2.
16654114|NCT02254759|Experimental|RO5186582 Alone|RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.
16654115|NCT02254759|Experimental|RO5186582 Plus IV Midazolam|RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.
16654116|NCT02254759|Experimental|RO5186582 Plus Oral Midazolam|RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.
16654117|NCT02254746|Experimental|Phase I (dose escalation)/ Phase II|"Phase I
~Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.
~Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.
~Phase II
~Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study."
16654118|NCT02254733|Experimental|ACT + CBSST|Implementing Cognitive Behavioral Social Skills Training in an Assertive Community Treatment model
16654119|NCT02254733|Active Comparator|ACT only|Assertive Community Treatment only
16654120|NCT02254720|Experimental|BEA 2180 BR IV|Rising doses
16654121|NCT02254720|Placebo Comparator|Placebo|
16654122|NCT02254720|Experimental|BEA 2180 BR inhalation|
16654123|NCT02254707|Experimental|BILB 1941 ZW|Escalating Doses
16654124|NCT02254707|Placebo Comparator|Placebo|
16654125|NCT02254694|Experimental|high heeled shoes|see detailed description
16654126|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
16654127|NCT02254668|Experimental|Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
16654189|NCT02254317|Active Comparator|900 mg GSE|Containing 900 mg of GSE
16654128|NCT02254668|Active Comparator|Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
16654129|NCT02254655|Experimental|Puerarin injection 400 mg|Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
16654130|NCT02254655|Sham Comparator|Control|Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
16654131|NCT02254642|Experimental|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
16654132|NCT02254642|Other|Control patients|Usual surgery assigned to control patients
16654133|NCT02254629|Experimental|laxative-probiotic sequential|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
16654134|NCT02254629|Active Comparator|probiotic|Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
16654135|NCT02254629|Active Comparator|Laxative followed by Probiotic 2 weeks later|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.
16654136|NCT02254616|Experimental|Mirror therapy with tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
16654137|NCT02254616|Active Comparator|Mirror Therapy|The MT only group will receive a 60-minute MT per session followed by a 30-minute functional training. Participant will go through the same protocol as that for the MT+tDCS and MT+sham tDCS groups with no tDCS presented in setting. This group is for evaluating placebo effect of the present of tDCS application.
16654138|NCT02254616|Active Comparator|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training. During the 60-mimute conventional training, interventions will include passive range of movement and muscle tone normalization techniques of the affected arm, and gross motor training (e.g., shoulder ladder activity), fine motor training (e.g., grasping cones), and muscle strength training in a unilateral and bilateral manners. During the 30-minute functional training, the same principles to those in the MT groups will be applied.
16654139|NCT02254616|Active Comparator|Mirror Therapy with sham-tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
16654140|NCT02254603|Other|Acupuncture controls|Acupuncture group will receive 30-minutes treatment three times a week for 3 months.
16654141|NCT02254603|Experimental|acupuncture and yoga exercise|Subject will receive a combination of acupuncture and yoga exercise three times a week for 3 months.
16654142|NCT02254590|Experimental|IEDL|Endoscopic decompression of spinal stenosis
16654143|NCT02254577|Experimental|Endometrin® plus Progesterone in Oil (PIO)|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.
16654144|NCT02254577|Active Comparator|Progesterone in Oil (PIO) Alone|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.
16654145|NCT02254564||Positive Scrapings|Skin scrapings that are positive for scabies
16654146|NCT02254564||Negative Controls|collect negative controls from patients in whom tinea (superficial fungal infection) was clinically suspected. Samples from patients with demodex folliculitis (a mite that is commonly found in oil glands on the face) are also intended to be used as negative controls as well.
16654147|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.
~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.
~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
16654148|NCT02254538|Experimental|BILR 355 BS|escalating doses
16654149|NCT02254538|Placebo Comparator|Placebo|
16654150|NCT02254525|Experimental|800 mg intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.
16654151|NCT02254525|Placebo Comparator|200 ml of saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.
16654152|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
16654153|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
16654154|NCT02254473|Experimental|Wedge Insert|Patients will receive a wedge insert
16654155|NCT02254473|Placebo Comparator|Flat insert|Patients will receive a flat insert
16654156|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
16654157|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
16654158|NCT02254447|Experimental|Sequence ABC|Subjects in this arm will receive single dose of treatment A in period 1, treatment B in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
16654159|NCT02254447|Experimental|Sequence ACB|Subjects in this arm will receive single dose of treatment A in period 1, treatment C in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
16654160|NCT02254447|Experimental|Sequence BAC|Subjects in this arm will receive single dose of treatment B in period 1, treatment A in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
16654161|NCT02254447|Experimental|Sequence BCA|Subjects in this arm will receive single dose of treatment B in period 1, treatment C in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
16654162|NCT02254447|Experimental|Sequence CAB|Subjects in this arm will receive single dose of treatment C in period 1, treatment A in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
16654163|NCT02254447|Experimental|Sequence CBA|Subjects in this arm will receive single dose of treatment C in period 1, treatment B in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
16654164|NCT02254434|Experimental|Eltrombopag 50 mg|Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions
16654165|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
16654166|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
16654167|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
16654168|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
16654169|NCT02254395|Experimental|Deep Brain Stimulation|Stimulation is on.
16654170|NCT02254395|Sham Comparator|Placebo|Sham Stimulation: Stimulation is off.
16654171|NCT02254382|Experimental|Adaptive servo ventilation (ASV)|This group will receive ventilation therapy (AutoSet CS, ASV device)
16654172|NCT02254369|Experimental|Cohort 1- GC021109|single dose, 0.0014 mg/kg GC021109
16654173|NCT02254369|Experimental|Cohort 2- GC021109|single dose, 0.014 mg/kg GC021109
16654174|NCT02254369|Experimental|Cohort 3-GC021109|single dose, 0.14 mg/kg GC021109
16654175|NCT02254369|Experimental|Cohort 4- GC021109|single dose, 1.4 mg/kg GC021109 subjects will receive GC021109 under fasting then under fed conditions separated by a washout of 14 (± 1) days after the first dose.
16654176|NCT02254369|Experimental|Cohort 5- GC021109|single dose, 4.2 mg/kg GC021109
16654177|NCT02254369|Placebo Comparator|Cohort 1- placebo|single dose, 0.0014 mg/kg matching placebo
16654178|NCT02254369|Placebo Comparator|Cohort 2- placebo|single dose, 0.014 mg/kg matching placebo
16654179|NCT02254369|Placebo Comparator|Cohort 3- placebo|single dose, 0.14 mg/kg matching placebo
16654180|NCT02254369|Placebo Comparator|Cohort 4- placebo|single dose, 1.4 mg/kg subjects will receive matching placebo under fasting then under fed conditions separated by a washout of 14 (+/- 1) days after the first dose.
16654181|NCT02254369|Placebo Comparator|Cohort 5- placebo|single dose, 4.2 mg/kg matching placebo
16654182|NCT02254356|Experimental|Zilver|
16654183|NCT02254343|Experimental|proximal robot-assisted therapy|treatment programs will target to shoulder and elbow portions of upper extremity via the InMotion2 robotic system
16654184|NCT02254343|Experimental|distal robot-assisted therapy|the InMotion3 robot system will be used to execute treatment programs focus on wrist movements. It includes three degrees of freedom to allow wrist flexion/extension, abduction/adduction, and pronation/supination.
16654185|NCT02254343|Active Comparator|individualized intensive therapy|individualized occupational therapy which is dose-match to robot-assisted therapy, based on task-oriented principle.
16654186|NCT02254317|Placebo Comparator|0 mg placebo|Not containing GSE (Placebo)
16654187|NCT02254317|Active Comparator|300 mg GSE|Containing 300 mg of GSE
16654188|NCT02254317|Active Comparator|600 mg GSE|Containing 600 mg of GSE
16654190|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
16654191|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
16654192|NCT02254291|Experimental|Semaglutide 0.5 mg|
16654193|NCT02254291|Experimental|Semaglutide 1.0 mg|
16654194|NCT02254291|Active Comparator|Sitagliptin 100 mg|
16654197|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
16654198|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
16654199|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
16654200|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
16654201|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
16654202|NCT02254239|Experimental|Treatment (everolimus, brentuximab vedotin)|"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or QOD on days 1-21. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity. Patients then receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or every other day on days 1-84 for 1 course.
~MAINTENANCE THERAPY: Beginning on course 17, patients receive everolimus PO QD, QOD, twice weekly, or thrice weekly on days 1-84. Courses repeat every 84 days in the absence of disease progression and unacceptable toxicity."
16654203|NCT02254226|Experimental|Salmeterol MDI low|
16654204|NCT02254226|Active Comparator|Salmeterol MDI high|
16654205|NCT02254226|Experimental|Salmeterol Diskus low|
16654206|NCT02254226|Experimental|Salmeterol Diskus high|
16654207|NCT02254200|Experimental|Fatmax group|Group who performed a continuous training program at the intensity eliciting the maximal fat oxidation
16654208|NCT02254200|Experimental|HIIT group|Group who performed a continuous training program with high intensity interval
16654209|NCT02254187|Experimental|Salmeterol capsule via Handihaler - low|
16654210|NCT02254187|Experimental|Salmeterol capsule via Handihaler - high|
16654211|NCT02254187|Active Comparator|Salmeterol via Serevent® Diskus®|
16654212|NCT02254174|Experimental|Tiotropium/Salmeterol|
16654213|NCT02254174|Active Comparator|Serevent® Diskus®|
16654214|NCT02254174|Active Comparator|Spiriva®|
16654215|NCT02254174|Active Comparator|Spiriva® and Serevent® Diskus®|
16654216|NCT02254161|Experimental|BI 1181181 healthy young|Medium doses as tablets q.d. for 10 days
16654217|NCT02254161|Experimental|BI 1181181 healthy elderly|Medium doses as tablets q.d. for 10 days
16654218|NCT02254161|Placebo Comparator|Matching placebo in healthy young|Matching placebo for 10 days
16654219|NCT02254161|Placebo Comparator|Matching placebo in healthy elderly|Matching placebo for 10 days
16654220|NCT02254148|Experimental|Treatment|single dose of CYP 450 substrates and a P-gp substrate + multiple doses of BI 187004
16654221|NCT02254135|Experimental|BEA 2180 BR solution - rising dose|
16654222|NCT02254135|Placebo Comparator|Placebo|
16654223|NCT02254122|Experimental|BEA 2180 BR|
16654224|NCT02254122|Placebo Comparator|Placebo|
16654225|NCT02254109|Experimental|BEA 2180 BR - rising dose|
16654226|NCT02254109|Placebo Comparator|Placebo|
16654227|NCT02254096|Experimental|BIRT 1696 BS|single escalating dose phase
16654228|NCT02254096|Experimental|BIRT 1696 BS + GFJ|single dose grapefruit effect arm
16654229|NCT02254096|Experimental|BIRT 1696 BS + HFM|single dose food effect arm
16654230|NCT02254096|Placebo Comparator|Placebo|
16654231|NCT02254083|Experimental|BIBT 986 BS - low|
16654232|NCT02254083|Experimental|BIBT 986 BS - high|
16654233|NCT02254083|Placebo Comparator|Placebo|
16654234|NCT02254070|Experimental|BIBT 986 BS|
16654235|NCT02254057|Experimental|BIBT 986 BS - single rising dose|
16654236|NCT02254057|Placebo Comparator|Placebo|
16654237|NCT02254044|Experimental|bivatuzumab mertansine|dose escalation
16654238|NCT02254031|Experimental|bivatuzumab mertansine|dose escalation
16654239|NCT02254018|Experimental|bivatuzumab mertansine|single dose escalation
16654240|NCT02254005|Experimental|single dose escalation|
16654241|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab
~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
16654242|NCT02253979|Placebo Comparator|standard double lumen tube|Intervention: Standard double lumen tube
16654243|NCT02253979|Experimental|VivaSight double lumen tube|Intervention: VivaSight double lumen tube
16654244|NCT02253966|Active Comparator|Methylprednisoloneacetate|"Administration of:
~1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery."
16654245|NCT02253966|Placebo Comparator|Sodium chloride|"Administration of:
~5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery."
16654246|NCT02253953|Experimental|D1|
16654247|NCT02253953|Experimental|D2|
16654248|NCT02253953|Experimental|D3|
16654249|NCT02253953|Experimental|D4|
16654250|NCT02253953|Experimental|D5|
16654251|NCT02253953|Experimental|D6|
16654252|NCT02253953|Experimental|D7|
16654253|NCT02253953|Experimental|D8|
16654254|NCT02253953|Experimental|D10|
16654255|NCT02253953|Placebo Comparator|Placebo|for D3 - D10
16654256|NCT02253940|Experimental|Dose Group 1 - low dose|Treatment sequences ABC / CAB / BCA
16654257|NCT02253940|Experimental|Dose Group 2 - high dose|Treatment sequences DE / ED
16654325|NCT02253472|Experimental|Deep Brain Stimulation|Stimulation is on.
16654258|NCT02253927|Experimental|BILR 355 (dose escalation) + Ritonavir|escalating dose groups, for food effect evaluation lowest dose group (D1) with high fat meal breakfast after wash-out period
16654259|NCT02253914|Experimental|BILR 355 BS, solution|escalating doses
16654260|NCT02253914|Experimental|BILR 355 BS, tablet|escalating doses
16654261|NCT02253914|Placebo Comparator|Placebo|
16654262|NCT02253901|Experimental|TRUVADA with BILR 355 BS and ritonavir|
16654263|NCT02253901|Active Comparator|BILR 355 BS in combination with ritonavir|
16654264|NCT02253888|Experimental|TPV/r - Room condition|
16654265|NCT02253888|Experimental|TPV/r - Refrigerated conditions|
16654266|NCT02253875|Experimental|TPV + RTV + Omeprazole|
16654267|NCT02253862|Experimental|Sequential treatment|
16654268|NCT02253849|Experimental|CBZ - TPB/r+CBZ|"Days 1-14: carbamazepine (CBZ) twice daily
~Days 15-22: CBZ twice daily plus TPV/r twice daily"
16654269|NCT02253836|Experimental|TAZ/RTV - TPV/RTV - TPV/RTV+TAZ|"Days 1-9: single dose TAZ/RTV
~Days 16-23: morning and evening dose TPV/RTV
~Days 24-32: TPV/RTV + TAZ"
16654270|NCT02253823|Experimental|TPV+RTV - low dose|
16654271|NCT02253823|Experimental|TPV+RTV - high dose|
16654272|NCT02253810|Experimental|Tranexamic Acid|Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.
16654273|NCT02253810|Placebo Comparator|Placebo|Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.
16654274|NCT02253797|Experimental|TPV/r followed by 14C-radiolabeled TPV|Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir
16654275|NCT02253784|Active Comparator|Group I (ISB-P)|Four nerve blocks with perineural injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
16654276|NCT02253784|Active Comparator|Group II (ISB-S)|Four nerve blocks with systemic injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
16654277|NCT02253784|Active Comparator|Group III (ISB-C)|Four nerve blocks without dexamethasone
16654278|NCT02253771|Experimental|shockwave therapy|shockwave therapy
16654279|NCT02253771|Placebo Comparator|Placebo treatment|sham shockwave therapy by an identically looking device without any function
16654280|NCT02253758|Experimental|Sedation|Volunteers will be sedated to Ramsay score 4-5 with propofol, and data will be recorded during arousal
16654281|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
16654282|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
16654283|NCT02253732|Experimental|'3 months exercise intervention program'|all participants will be subjected to 3 months supervised exercise intervention programme
16654284|NCT02253719||HIV positive women|500 HIV women will be recruited from the hospital's current patient base as well as the community
16654285|NCT02253719||HIV negative women|500 HIV women will be recruited from the hospital's current patient base as well as the community
16654286|NCT02253706|Active Comparator|Low flow nasal oxygen supplementation|Low flow nasal oxygen supplementation as per routine standard of care(control arm)
16654287|NCT02253706|Experimental|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35
16654288|NCT02253693||Patients with haemophilia|Adult patients with haemophilia A presenting joint disease.
16654289|NCT02253680|No Intervention|Routine care|Wool and crepe bandage for 24 hours post-operatively
16654290|NCT02253680|Experimental|Compression bandage|Actico, inelastic, short-stretch compression bandage worn 24 hours post-operatively
16654291|NCT02253667|Experimental|HFONC|Patient will use HFONC with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
16654292|NCT02253667|Other|Conventional oxygen|Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
16654293|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
16654294|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
16654295|NCT02253641|Active Comparator|Standard Weight Loss Intervention|"Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program. Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention."
16654326|NCT02253472|Sham Comparator|Placebo|Stimulation is off.
16654431|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
16654296|NCT02253641|Experimental|Stress-Focused Weight Loss Intervention|Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al.. The participants in this arm will receive all of the content that the comparison group receives (just moderately condensed to allow time for additional components) plus a stress-reduction intervention woven into each of the sessions. The stress-reduction content aims to reduce stress by helping participants: (1) identifying and reducing exposure (to the degree possible) of current stressors, (2) change their perceptions of current stressors and (3) use healthier stress-coping techniques (e.g. yoga, meditation, etc.)
16654297|NCT02253628|Experimental|Trial 1|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
16654298|NCT02253628|Experimental|Trial 2|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
16654299|NCT02253628|Experimental|Trial 3|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
16654300|NCT02253628|Experimental|Trial 4|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
16654301|NCT02253615|Active Comparator|Machine resistance training (MRT)|The machine resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
16654302|NCT02253615|Experimental|Elastic resistance training (ERT)|The elastic resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
16654303|NCT02253602|Experimental|Ferumoxytol Dose optimization|"We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg).
~Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once"
16654304|NCT02253602|Experimental|Before Surgery|Twenty patients will be measured directly before surgery. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study. MR parameters will be correlated with pathology data.
16654305|NCT02253602|Experimental|Before Neoadjucant therapy|Ten patients will be measured before start of neoadjuvant chemoradiation. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study. MR parameters will be correlated with pathology data.
16654306|NCT02253589|No Intervention|Waiting list|Participants will assessment only during study, same intervention after posttest
16654307|NCT02253589|Experimental|Intervention|Participants assigned to this arm will receive the modified ASSIST-linked Brief Intervention
16654308|NCT02253576|Experimental|inhaled 7% hypertonic saline|Three consecutive 4ml doses of 7% NaCl solution with salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
16654309|NCT02253576|Active Comparator|inhaled nebulized normal saline|Three consecutive 4ml doses of 0.9 NaCl solution added to salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
16654310|NCT02253563|Experimental|Resistance Training|Group performing resistance training.
16654311|NCT02253563|Experimental|Balance Training|Group performing balance training.
16654312|NCT02253550|Experimental|Cirrhosis|Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
16654313|NCT02253550|Experimental|Non-Cirrhotic|Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
16654314|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
16654315|NCT02253524|Active Comparator|Dimenhydrinate|50 mg Dimenhydrinate with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
16654316|NCT02253524|Active Comparator|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
16654317|NCT02253511|Experimental|Cidan capsule|Patients who undergone operation and TACE were administered 1.35 g cidan capsules (Weida Pharmaceutical Co., Ltd., Beijing, China) three times a day for 3 months.
16654318|NCT02253511|No Intervention|Control group|Patients were only accepted operation and TACE.
16654319|NCT02253498|Experimental|Deep Brain Stimulation|Deep Brain Stimulation is on
16654320|NCT02253498|Sham Comparator|Sham Stimulation|placebo
16654321|NCT02253485||telbivudine treated entire pregnancy|mothers in this group were treated with antiviral therapy during entire pregnancy for hepatitis, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
16654322|NCT02253485||telbivudine treated in late pregnancy|mothers with high serum HBV DNA load were treated with antiviral therapy in late pregnancy, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
16654323|NCT02253485||HBV DNA positive control|infants in this group born to mother with high serum HBV DNA load and receive standard immunoprophylaxis or additional HBIG injection at 1 month after birth for preventing MTCT of HBV.
16654324|NCT02253485||HBV DNA negative control|infants in this group born to a HBsAg positive and serum HBV DNA negative mothers and receive standard immunoprophylaxis for preventing MTCT of HBV
16654327|NCT02253459|Experimental|UTD1 Injection plus capecitabine|"UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.
~Number of Cycles: until progression or unacceptable toxicity develops."
16654328|NCT02253459|Active Comparator|capecitabine|"Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.
~Number of Cycles: until progression or unacceptable toxicity develops."
16654329|NCT02253446|Experimental|Piroksikam|20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
16654330|NCT02253446|Experimental|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
16654331|NCT02253433|Experimental|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
16654332|NCT02253433|Experimental|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
16654333|NCT02253420|Experimental|Copanlisib with and without concomitant Itraconazole (Arm A)|"To evaluate the effect of Itraconazole on the pharmacokinetics of Copanlisib (BAY80-6946) and safety in patients with advanced solid tumor. Cycle 1 of the study will be conducted in 2 parts: Part 1 and part 2:
~Part 1 of Cycle 1: 6 patients will be enrolled and will receive 12 mg of copanlisib on Day 1 and Day 15. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.
~Part 2 of Cycle 1: 20 patients will be enrolled and receive copanlisib doses of either 12 mg, 30 mg or 60 mg on Days 1 and 15 with the same dose administered on both days. Copanlisib dose for Part 2 will be based on safety and copanlisib pharmacokinetics in Part 1. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.
~Cycle 2 and subsequent cycles: All patients will receive copanlisib doses of 60 mg on Days 1, 8 and 15."
16654334|NCT02253420|Experimental|Copanlisib with and without concomitant Rifampin (Arm B)|"To evaluate the effect of Rifampin on the pharmacokinetics of Copanlisib (BAY 80-6946) and safety in patients with advanced solid tumor or non-Hodgkin's lymphoma in Cycle 1. Approximately 30 subjects will receive 60mg of copanlisib on Cycle 1 Day 1 and Cycle 1 Day 15. Rifampin will be administered once a day from Cycle 1 Day 10 to Day 21. Holter monitoring will be performed on Cycle 1 Day -1 and Cycle 1 Day 1 to evaluate the effect of copanlisib on the QT/QTc assessment.
~Cycle 2 and subsequent cycles, all patients will receive copanlisib dose of 60 mg on Days 1, 8 and 15. Holter monitoring will be performed on Cycle 3 Day 1 and Cycle 6 Day 1."
16654335|NCT02253407|Experimental|Disposable syringe jet injector|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
16654336|NCT02253407|Active Comparator|Needle-Syringe|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe
16654337|NCT02253394|Active Comparator|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
16654338|NCT02253394|Placebo Comparator|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
16654339|NCT02253381|Active Comparator|Right lateral decubitus position|Right lateral decubitus position during spinal anesthesia
16654340|NCT02253381|Active Comparator|Left lateral decubitus position|Left lateral decubitus position during spinal anesthesia
16654341|NCT02253368|Active Comparator|Sleep Arm 1|Sleep Arm 1
16654342|NCT02253368|Active Comparator|Sleep Arm 2|Sleep Arm 2
16654343|NCT02253355|Experimental|Deep Brain Stimulation|Stimulation is on
16654344|NCT02253355|Sham Comparator|Placebo|Stimulation is off
16654345|NCT02253342|Experimental|WCK 2349|Subjects will receive oral doses of WCK 2349 administered twice-daily for five days starting on Day 1
16654346|NCT02253329|Active Comparator|Treatment during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
16654347|NCT02253329|Active Comparator|Treatment prior to sleep|Protein ingestion directly after one-legged NMES, directly prior to sleep
16654348|NCT02253316|Experimental|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, & dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 55 mg of lenalidomide will be administered on daily on Days 1-21.
16654349|NCT02253316|Experimental|Maintenance Arm 1: Ixazomib|"Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxicity.
~09/23/2019: Upon review of the interim analysis, there will be no further randomizations into the maintenance portion of the trial. All patients will be enrolled into the lenalidomide arm with the exception of those who discontinue lenalidomide during the consolidation phase due to toxicity. Patients who discontinue lenalidomide may be enrolled into the ixazomib arm following approval from the principal investigator."
16654350|NCT02253316|Experimental|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
16654351|NCT02253303|Experimental|Midline incision|The extraction-site incision in laparoscopic colectomy is middline
16654352|NCT02253303|Active Comparator|off-midline incision|The extraction-site incision in laparoscopic colectomy is off-middline
16654353|NCT02253290||Neuromuscular disease|Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
16654386|NCT02253082|Active Comparator|OctaplasLG®|replacement to bleeding
16654387|NCT02253082|Placebo Comparator|Standard fresh frozen plasma|replacement to bleeding
16654388|NCT02253069|Experimental|PHMB-based antiseptic|Applying Prontosan antiseptic solution to tie-over dressings
16654389|NCT02253069|Placebo Comparator|Control|Applying water to tie-over dressings
16654390|NCT02253056|Experimental|Fasting|Intermittent fasting over 8 weeks (one day per week)
16654391|NCT02253056|Active Comparator|Healthy diet|Regular healthy diet according to current German (DGE) guidelines for healthy nutrition.
16654392|NCT02253043|Experimental|Deep Brain Stimulation|DBS Implant and stimulation
16654660|NCT02251223|Experimental|TPV/r high dose|
16654354|NCT02253277|Experimental|Nilotinib and Ruxolitinib|The study included two strata, which were to be treated in parallel. The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
16654355|NCT02253264|Experimental|Intrathecal rituximab|25 mg of rituximab will be administered intrathecally by direct infusion over 10 minutes at two time points, two weeks apart.
16654356|NCT02253251||Family Registry|For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
16654357|NCT02253251||KRAS-variant BRCA negative Breast Cancer|Women with breast cancer who are BRCA negative will be tested for the KRAS-variant, to determine the associations as well as the prevalence.
16654358|NCT02253251||Double primary breast cancer|Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
16654359|NCT02253251||Autoimmunity|We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
16654360|NCT02253238|Other|Standard of Care Group|Surveys administered in person or by telephone interview and are audio-recorded.
16654361|NCT02253238|Experimental|CYCORE Group + Standard of Care|"Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer).
~Surveys administered in person or by telephone interview and are audio-recorded."
16654362|NCT02253225||Bipolar Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).
16654363|NCT02253225||Major Depressive Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).
16654364|NCT02253225||Healthy Control|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.
16654365|NCT02253212|Experimental|SonoCloud + carboplatin|SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
16654366|NCT02253199|Active Comparator|1-6 months (Group 1)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
16654367|NCT02253199|Active Comparator|7-12 months (Group 2)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
16654368|NCT02253199|Active Comparator|13-24 months (Group 3)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
16654369|NCT02253199|Active Comparator|25-36 months (Group 4)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
16654370|NCT02253186|Experimental|Group I|Patients wear, for 90 days, the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
16654371|NCT02253186|No Intervention|Group II|Patients wear, for 30 days, only a usual custom-made compressive armsleeve during Day-time and no garment during night-time. Then, for the next 60 days, patients wear the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
16654372|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
16654373|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
16654374|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
16654375|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
16654376|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
16654377|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
16654378|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
16654379|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
16654380|NCT02253121|Experimental|Dapagliflozin + sliding scale insulin.|Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
16654381|NCT02253121|Placebo Comparator|Placebo + sliding scale insulin|Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
16654382|NCT02253108|Experimental|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
16654383|NCT02253108|Experimental|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
16654384|NCT02253095|Experimental|Multiple Intervention Arm|single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
16654385|NCT02253095|Placebo Comparator|Placebo|three placebos
16654393|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
16654394|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
16654395|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
16654396|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
16654397|NCT02253017||Children operated on for cataract|
16654398|NCT02253004|Experimental|Active|Cilostazol 200 mg single dose
16654399|NCT02253004|Placebo Comparator|Placebo|Placebo capsule
16654400|NCT02252991|Other|Arm A with physical activity during the treatment|In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
16654401|NCT02252991|Other|Arm B with physical activity after the treatment|In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.
16654402|NCT02252978|Experimental|Arm I (ciprofloxacin)|Patients receive ciprofloxacin PO BID for 2 weeks.
16654403|NCT02252978|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 2 weeks.
16654404|NCT02252965|Active Comparator|Metformin IR|
16654405|NCT02252965|Experimental|Metformin XR|
16654406|NCT02252952|Experimental|Sugar Sweetened Beverages|Any beverage from a range of caffeine free, sugar sweetened drinks. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
16654407|NCT02252952|Experimental|Diet Beverage|Any beverage from a range of caffeine free drinks sweetened with non-caloric sweetener. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
16654408|NCT02252952|Active Comparator|Water|12 oz of water. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
16654409|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
16654410|NCT02252926|Active Comparator|Bupivacaine lozenge|The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
16654411|NCT02252926|Other|Standard treatment|The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.
16654412|NCT02252913|Experimental|Volitinib+docetaxel|"Dose escalation stage: oral administration, Volitinib 600mg/800 QD + docetaxel 75mg/m2.
~If the dose of docetaxel 75mg/m2 is not tolerable, docetaxel dose will be reduced to 60mg/m2 while keep volitinib at 600mg QD as the initial dose. Volitinib dose escalation will be re-started and end at the dose of 800mg QD.
~Dose expansion Stage:Volitinib with docetaxel. Use the prefer dose from escalation stage"
16654413|NCT02252900|Experimental|cerebral MRI during follow-up of IE|All patients will undergo the diagnostic test specific to the study (Magnetic resonance imaging)
16654414|NCT02252887|Experimental|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it < 6 weeks prior to Cycle 1 Day 1.
16654415|NCT02252874|Placebo Comparator|Control Group|Receive leisure activities (e.g. reading, web-surfing, playing chess/ Mahjong) Twenty hours (2-3 sessions per week, 1.5 hours per session)
16654416|NCT02252874|Active Comparator|Intervention Group 1|Receive slow motion Nintendo Wii video games Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
16654417|NCT02252874|Active Comparator|Intervention Group 2|Receive fast motion Nintendo Wii video games (e.g. shooting game) Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
16654418|NCT02252861||Left Atrial Appendage Closure|Patients with atrial fibrillation and counter-indication to anticoagulant therapy referred for percutaneous Left Atrial Appendage Closure in routine care
16654419|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
16654420|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
16654421|NCT02252822|Experimental|The Overcoming Bulimia Online Programme|This treatment incorporates a combination of cognitive-behavioral, motivational and education strategies. The program will be presented in 8 collaborative, multi-media, web based CBT sessions for BN.
16654422|NCT02252809|Active Comparator|adalimumab|adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
16654423|NCT02252809|Active Comparator|methylprednisolone|methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
16654424|NCT02252809|No Intervention|control|no intervention, 7 days before endotoxin inhalation
16654425|NCT02252796|Experimental|Sub-group 1|HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
16654426|NCT02252796|Experimental|Sub-group 2|Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
16654427|NCT02252783|Experimental|BFPET|BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
16654428|NCT02252770|Active Comparator|Nitric oxide supplement arm|During this arm, subjects will receive a lozenge with nitric oxide supplement
16654429|NCT02252770|Placebo Comparator|Placebo Arm|During this arm, subjects will receive placebo
16654430|NCT02252731|Experimental|warfarin and FG-4592|Single dose of warfarin and Multiple doses of FG-4592 in combination with a single dose of warfarin
16654661|NCT02251210|Experimental|BIIL 284 BS low dose|
16654432|NCT02252705||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
16654433|NCT02252705||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
16654434|NCT02252692|Active Comparator|Enalapril|Renitec® 2 x 5 mg tablets administered at once, to be entirely swallowed with 240 ml water
16654435|NCT02252692|Experimental|Enalapril ODMT|10 x 1mg of Enalapril ODMT, swallowed entirely with 240ml of water
16654436|NCT02252692|Experimental|Enalapril ODMT dispersed|10 x 1mg of Enalapril ODMT, dispersed on tongue
16654437|NCT02252679||Osteoporosis|Postmenopausal women, men > age 50 years, or other patients with well-established causes of secondary osteoporosis (incl. glucocorticoid-induced osteoporosis, transplantation-related osteoporosis, disuse osteoporosis, etc.) N=20 treated with antiresorptive drugs N=10 treated with osteoanabolic drugs (e.g. teriparatide, Forsteo)
16654438|NCT02252679||Calcium malabsorption|N=10 Patients with clinically obvious potential causes of calcium malabsorption (incl. severe vitamin D-deficiency, Scopinaro or other bariatric surgery, exocrine pancreatic insufficiency/steatorrhea, cystic fibrosis, inflammatory bowel disease, celiac disease, anorexia nervosa/eating disorders, malnutrition, etc.), with or without bone pains, muscle weakness and other typical osteomalacia symptoms. Confirmed by 24h urine collection showing calciuria <100 mg/24h.
16654439|NCT02252679||Various disorders|Exploratory, heterogeneous group of calcium-related disorders (incl.hypercalcemia, hypocalcemia, primary/secondary/tertiary hyperparathyroidism, hypoparathyroidism, vitamin D deficiency, X-linked/autosomal dominant hypophosphatemic rickets, familial hypocalciuric hypocalcemia,etc.) N=20
16654440|NCT02252679||Normal control subjects|N=40 Men and women ≤ 40 years recruited from the population
16654441|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
16654442|NCT02252653||Familial Amyloidotic Cardiomyopathy (FAC)|
16654443|NCT02252640|Active Comparator|Group 1|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
16654444|NCT02252640|Active Comparator|Group 2|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
16654445|NCT02252640|Active Comparator|Group 3|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
16654446|NCT02252640|Active Comparator|Group 4|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
16654447|NCT02252640|No Intervention|Group 5|Week 11: Controlled Human Malaria Infection
16654448|NCT02252640|No Intervention|Group 6|Week 31-39: Controlled Human Malaria Infection
16654449|NCT02252627||Group 1|Healthy volunteers
16654450|NCT02252614|Active Comparator|Naproxen sodium codein|Preoperative Naproxen sodium codein administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
16654451|NCT02252614|Experimental|Paracetamol codein|Preoperative paracetamol codein administrered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
16654452|NCT02252614|Placebo Comparator|Placebo tablet|Preoperative placebo tablet administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
16654453|NCT02252601|Experimental|Well patients aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
16654454|NCT02252601|Experimental|Acute exacerbation aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
16654455|NCT02252601|Experimental|Children with CF aged 5-10 years|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
16654456|NCT02252601|Active Comparator|Healthy Control Children age 5-10 years.|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
16654457|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
16654458|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
16654459|NCT02252575|Experimental|Electromagnetic field|Exposure to the elctromagnetic field of an electric motor
16654460|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
16654461|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
16654462|NCT02252549|Active Comparator|A|SPIES+WLI assisted TURB
16654463|NCT02252549|Active Comparator|B|WLI assisted TURB
16654464|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
16654465|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
16654466|NCT02252523|Experimental|DEXMEDETOMIDINE|
16654467|NCT02252497|Active Comparator|Tranexamic acid|"1g Intra Venous just before surgery
~Then infusion of 1g of Exacyl over eight hours."
16654468|NCT02252497|Placebo Comparator|Physiologic serum|"1g Intra Venous, just before surgery
~Then infusion of 1g of physiologic serum over eight hours."
16654469|NCT02252484|Experimental|Weight loss intervention Group|Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
16654470|NCT02252484|Active Comparator|Comparison Group|All patients who are unwilling or not ready to engage in a weight loss program will be offered entry into the comparison group arm.
16654471|NCT02252471|Experimental|Choices-Teen Intervention|A three session intervention with two counseling sessions with a master's level therapist and a counseling session with a physician. The counseling with the master's level therapist utilizes a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, smoking and HIV risk behaviors. This part of the intervention (a) provides norms-based-but personalized-feedback; (b) encourages participating in the smoking cessation program; (c) increases motivation to change each of the target behaviors; (d) decreases temptation to engage in risk behaviors; (e) increases confidence to avoid risk behaviors; and (f) develops a personalized, tailored change plan. The physician session provides individualized contraception and HIV risk reduction counseling.
16654472|NCT02252458|Experimental|Fentanyl high dose|Fentanyl 10mcg/kg of bodyweight
16654473|NCT02252458|Active Comparator|Fentanyl low dose|Fentanyl 1mcg/kg of bodyweight
16654474|NCT02252445|Active Comparator|Propofol|Propofol will be administered as the anesthetic maintenance agent.
16654475|NCT02252445|Experimental|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
16654476|NCT02252432|Active Comparator|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
16654477|NCT02252432|Active Comparator|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
16654478|NCT02252432|Experimental|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
16654479|NCT02252419|Active Comparator|Dexamethasone|Dexamethasone will be administered 30 minutes before the anesthetic induction.
16654480|NCT02252419|Experimental|Dexamethasone+ Paracetamol (DP)|Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
16654481|NCT02252406|Experimental|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
16654482|NCT02252406|Placebo Comparator|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
16654483|NCT02252393|Experimental|Arm I (RARC with IUD)|Patients undergo RARC with IUD.
16654484|NCT02252393|Experimental|Arm II (RARC with EUD)|Patients undergo RARC with EUD.
16654485|NCT02252380|Experimental|Transcranial ExAblate System|Transcranial ExAblate System (MRgFUS)
16654486|NCT02252367|Experimental|Tadalafil|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.
16654487|NCT02252367|Placebo Comparator|Placebo|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.
16654488|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
16654489|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
16654490|NCT02252341|Placebo Comparator|placebo|"Dietary Supplement: N-Acetyl-Cysteine Phase 4 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study
~Primary Outcome Measure:
~Hamilton Depression Rating Scale [Time Frame: baseline, 1, 2, 3 months] [Designated as safety issue: Yes]
~Secondary Outcome Measures:
~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]
~Other Pre-specified Outcome Measures:
~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers N-Acetyl-cysteine 1800 mg / day will be taken for 12 weeks versus placebo 12 weeks."
16654491|NCT02252341|Placebo Comparator|N-Acetyl-Cysteine|"Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study
~Official Title: Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder
~Primary Outcome Measure:
~Hamilton Depression Rating Scale [Time Frame: baseline] [Designated as safety issue: Yes]
~Secondary Outcome Measures:
~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]
~Other Pre-specified Outcome Measures:
~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers
~Placebo will be taken for 12 weeks."
16654492|NCT02252328|Experimental|Simvastatine|Group of patients receiving simvastatin 80mg once daily in addition to standard care
16654493|NCT02252328|Placebo Comparator|Placebo|Group of patients receiving placebo once daily in addition to standard care
16654494|NCT02252315|Active Comparator|Written Education|
16654495|NCT02252315|Active Comparator|Verbal Education|
16654496|NCT02252302|Active Comparator|Resting in diesel exhaust following salbutamol inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
16654497|NCT02252302|Placebo Comparator|Resting in diesel exhaust following placebo inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
16654498|NCT02252302|Active Comparator|Cycling in diesel exhaust following salbutamol inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
16654499|NCT02252302|Placebo Comparator|Cycling in diesel exhaust following placebo inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
16654500|NCT02252302|Sham Comparator|Resting in filtered air following salbutamol inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
16654501|NCT02252302|Placebo Comparator|Resting in filtered air following placebo inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
16654502|NCT02252302|Sham Comparator|Cycling in filtered air following salbutamol inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
16654503|NCT02252302|Placebo Comparator|Cycling in filtered air following placebo inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
16654504|NCT02252289||Problematic severe asthmatics|"Approximately 75 Children aged 5 to 17 years with problematic severe asthma (PSA). Two groups of PSA children will be recruited: those who have already been assessed as part of the Difficult Asthma protocol and classified as DA (difficult asthma)/ STRA (severe therapy resistant asthma) (training set) and those newly referred to the protocol (validation set).
~Previous enrolment or new referral to the Royal Brompton Hospital Difficult Asthma Protocol."
16654505|NCT02252289||Control group of moderate asthmatics|A control group of 30 children aged 5 to 17 years with mild to moderate asthma.
16654506|NCT02252276|Experimental|Experimental|performed the same exercises and manual therapy during 4 weeks
16654507|NCT02252276|Active Comparator|Control|performed proprioceptive and strengthening exercises during 4 weeks
16654508|NCT02252263|Experimental|Arm 1: Elotuzumab + Lirilumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Lirilumab every 4 wks Intravenous solution for Up to 2 yrs, depending on response
16654509|NCT02252263|Experimental|Arm 2: Elotuzumab + Urelumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Urelumab every 4 wks Intravenous solution for Up to 26 weeks, depending on response
16654510|NCT02252250|Active Comparator|conventional laparoscopic|conventional laparoscopic total mesentery excision surgery for rectal cancer.
16654511|NCT02252250|Experimental|Transanal hybrid-laparoscopic|Transanal hybrid-laparoscopic total mesentery excision surgery for rectal cancer.
16654512|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
16654513|NCT02252224||T2DM patients treated with Forxiga|Korean patients who are at least 18 years old, diagnosed with type2 diabetes and treated with Forxiga according to the approved lable
16654514|NCT02252211|Experimental|DS-8895a|Patients received infusions with DS-8895a on Days 1, 8, 22, and 36. Infusions on Days 1 and 36 were trace labelled with ^89Zr (^89Zr-Df-DS-8895a). The Day 1 dose was 0.2 mg/kg, followed by subsequent doses calculated based on individual patient body weight and dosing cohort assignment.
16654515|NCT02252198||Investigational|• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
16654516|NCT02252185|Experimental|China made spine fusion system|patents in this arm will be implanted with Johnson&Johnson Medical Suzhou made Spine Fusion System.
16654517|NCT02252185|Active Comparator|Imported spine fusion system|patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .
16654518|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
16654519|NCT02252172|Active Comparator|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
16654520|NCT02252159||Cohort A|"Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:
~Watchful waiting (with or without aspirin)*, or
~Phlebotomy (PHL) alone (with or without aspirin)* - or
~HU alone (without concomitant PHL, with or without aspirin).
~(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)"
16654521|NCT02252159||Cohort B|"Patients with clinically overt PV, with one or more of the following disease characteristics:
~Treatment with HU and PHL in combination or
~Treatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or
~A history of thrombosis (venous or arterial) or
~A history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or
~Presence of documented splenomegaly (clinically assessed by palpation) or
~Presence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)
~Tiredness
~Difficulty sleeping
~Itching
~Muscle aches and/or bone pain
~Night sweats
~Sweats while awake
~Other"
16654522|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
16654662|NCT02251210|Experimental|BIIL 284 BS medium dose|
16654523|NCT02252133|Other|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
16654524|NCT02252133|Other|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
16654525|NCT02252120|Active Comparator|Supreme|Supreme LMA
16654526|NCT02252120|Active Comparator|Laryngeal Tube|Laryngeal tube LTSII
16654527|NCT02252107|Experimental|Decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
16654528|NCT02252094|Active Comparator|Conventional lung protective ventilation|Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
16654529|NCT02252094|Experimental|Ultra-protective ventilation|Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
16654530|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
16654531|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
16654532|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
16654533|NCT02252068|Experimental|I-CBT randomized trial|I-CBT in randomized trial.
16654534|NCT02252068|Active Comparator|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
16654535|NCT02252055|Experimental|ATDC Treatment|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation.
~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below :
~Prednidolone :
~D 0: 500 mg IV
~D 1: 125 mg IV
~D 2 to 14: 20.0 mg/d
~Wk 3 to 4: 15.0 mg/d
~Wk 5 to 8: 10.0 mg/d
~Wk 9 to 12: 5.0 mg/d
~Wk 13 to 14: 2.5 mg/d
~Wk 15 to End:Cessation
~MMF (or biologic equiv.):
~D -7 to -2: 500 mg/d (250mg 2x/d)
~D -1 to 14: 2000 mg/d
~Wk 3 to 36: 1000 mg/d
~Wk 37 to 40: 750 mg/d
~Wk 41 to 44: 500 mg/d
~Wk 45 to 48: 250 mg/d
~Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction.
~Tacrolimus :
~≤ 48 h pre-Tx to D 14: 3-12 ng/ml
~Wk 3 to 12: 3-10 ng/ml
~Wk 13 to 36: 3-8 ng/ml
~Wk 37 to End: 3-6 ng/ml"
16654536|NCT02252042|Experimental|Pembroliziumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
16654537|NCT02252042|Active Comparator|Active Comparator|Participants receive methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
16654538|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
16654539|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
16654540|NCT02252003|Experimental|Pain scales testing|
16654541|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
16654542|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
16654543|NCT02251977|Experimental|Adjuvant Chemotherapy plus GM1|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
16654544|NCT02251977|Placebo Comparator|Adjuvant Chemotherapy plus placebo|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4).
16654545|NCT02251964|Other|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
16654546|NCT02251951|Experimental|nab-Paclitaxel|Abraxane
16654547|NCT02251938|Experimental|DE-109 Sirolimus|DE-109 440 μg
16654548|NCT02251925|Experimental|Natural cycle|In natural cycle without hCG, daily monitoring of urinary LH is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of LH surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos.
16654549|NCT02251925|Experimental|Natural cycle + hCG for ovulation induction|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
16654550|NCT02251925|Experimental|Hormonally controlled cycle with GnRH-a|In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
16654663|NCT02251210|Experimental|BIIL 284 BS high dose|
16654664|NCT02251210|Placebo Comparator|Placebo|
16654665|NCT02251197|Experimental|BIII 890 CL|escalating doses
16654666|NCT02251197|Placebo Comparator|Placebo|
16654551|NCT02251925|Experimental|Hormonally controlled cycle without GnRH-a|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
16654552|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
16654553|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
16654554|NCT02251899|Experimental|Disease-Management intervention|Behavioral: Disease-Management intervention The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
16654555|NCT02251899|No Intervention|No Intervention: Control arm|Control group not receiving any in
16654556|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
16654557|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
16654558|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
16654559|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
16654560|NCT02251873|Experimental|TPV + RTV (low dose)+ ddI|
16654561|NCT02251873|Experimental|TPV+ RTV (high dose)+ ddI|
16654562|NCT02251860||Participants with Rheumatoid Arthritis|Participants with active rheumatoid arthritis who are prescribed tocilizumab treatment according to the marketing authorization by their physician will be followed under routine conditions over an observation period of up to 2 years if baseline and disease characteristics data are available.
16654563|NCT02251847|Active Comparator|R5|Rosuvastatin 5mg
16654564|NCT02251847|Active Comparator|R10|Rosuvastatin 10mg
16654565|NCT02251847|Active Comparator|R20|Rosuvastatin 20mg
16654566|NCT02251847|Experimental|R5/E10|Rosuvastatin 5mg/ezetimibe 10mg
16654567|NCT02251847|Experimental|R10/E10|Rosuvastatin 10mg/ezetimibe 10mg
16654568|NCT02251847|Experimental|R20/E10|Rosuvastatin 20mg/ezetimibe 10mg
16654569|NCT02251834|Experimental|Community Health Worker|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .
16654570|NCT02251834|Other|Usual Care|usual care and health education brochures every 4 months.
16654571|NCT02251821|Experimental|Treatment (ruxolitinib, transplant)|Patients receive a ruxolitinib and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.
16654572|NCT02251795|Experimental|Tipranavir/Ritonavir|500 mg Tipranavir / 200 mg Ritonavir 10 days BID
16654573|NCT02251795|Active Comparator|Darunavir/Ritonavir|600 mg Darunavir /100 mg Ritonavir 10 days BID
16654574|NCT02251795|Active Comparator|Ritonavir|100 mg Ritonavir 10 days BID
16654575|NCT02251782||Epi proColon Group|Subjects assigned to the Epi proColon Group will be offered the Epi proColon test for colorectal cancer screening.
16654576|NCT02251782||FIT Group|Subjects in the FIT Group will be offered a fecal immunochemical test (FIT test) for colorectal cancer screening.
16654577|NCT02251782||Usual Care Group|For the purpose of comparison to usual care, participating health systems will build an anonymized group of patients meeting study eligibility criteria, who do not participate in the study. This group will serve as a passive control and their CRC screening activity will be monitored via Medical Record.
16654578|NCT02251769|Experimental|Sequential administration|
16654579|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 1application|Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
16654580|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 2 applications|Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
16654581|NCT02251756|Experimental|Actinica, 2 mg/cm2, 1 application|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
16654582|NCT02251756|Experimental|Actinica, 2 mg/cm2, 2 applications|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
16654583|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
16654584|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
16654585|NCT02251730|Experimental|Refer for smoking cessation|Refer for smoking cessation
16654586|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
16654587|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
16654588|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
16654589|NCT02251691|Experimental|Advagraf|Take Advagraf once daily
16654590|NCT02251691|Active Comparator|Prograf|Take tacrolimus twice daily
16654591|NCT02251678|Experimental|Elimune capsules|Elimune capsules 2 capsules BID (four total capsules per day)
16654592|NCT02251665||Acute ischemic stroke, acute ICH, TIA|Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
16654593|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
16654594|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
16654667|NCT02251184|Experimental|Aggrenox|extended release
16654668|NCT02251184|Active Comparator|dipyridamole+aspirin|immediate release
16654669|NCT02251171|Experimental|TPV/RTV - Rifabutin|"Day 1: single dose Rifabutin
~Days 8-20: morning and evening doses of Tipranavir/Ritonavir
~Day 15: single dose Rifabutin"
16654595|NCT02251639|Experimental|Oral Imaging and Cytology|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
16654596|NCT02251626|Experimental|Coenzyme Q10 (ubiquinol)|Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day
16654597|NCT02251626|Placebo Comparator|Placebo for CoQ10 (ubiquinol)|Placebo group will be given placebo only
16654598|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
16654599|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
16654600|NCT02251600|Experimental|Deflazacort|This is an open label and single period study , dosed with 0.9mg/kg Deflazacort.
16654601|NCT02251587|Active Comparator|Standard Weight Management Program|Participants will be given information on diet and exercise. Participants will attend meetings to discuss barriers to exercise and nutrition and ways to solve these problems. Participants will be given healthy snack ideas and planning tools.
16654602|NCT02251587|Experimental|$ensible Weigh Program|Participants will be given information on diet and exercise with an emphasis on food security. Participants will be provided with additional information on community resources such as those for food, transportation, and safe places to exercise. A weekly cooking demonstration will be provided using inexpensive ingredients and common food pantry items.
16654603|NCT02251574|Experimental|Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 1200-1500 calories per day.
16654604|NCT02251574|Experimental|Very Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 520-800 calories per day.
16654605|NCT02251574|Active Comparator|Standard Care|Participants will receive normal care.
16654606|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
16654607|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
16654608|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-
~Oral, daily during each cycle
~fludarabine-administered at standard dosing for up to 6 cycles
~cyclophosphamide-administered at standard dosing for up to 6 cycles
~rituximab-administered at standard dosing for up to 6 cycles"
16654609|NCT02251535|Experimental|test group 1|Retrospective test group 1 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining) with intraoperative high level rollback
16654610|NCT02251535|Experimental|test group 2|Retrospective test group 2 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining)with intraoperative low level rollback
16654611|NCT02251535|Experimental|control group|Control group (n=10, PFC® SIGMA® Knee System, rotatinq platform, cruciate retaininq)
16654612|NCT02251522||ConforMIS iTotal Knee Replacement System|Patients who have had an iTotal knee replacement at least 6 months prior to testing
16654613|NCT02251522||Off-the-Shelf Knee Replacement System|Patients who have had an off-the-shelf knee replacement at least 6 months prior to testing
16654614|NCT02251509|Experimental|Carvedilol|carvedilol BID for 2 weeks
16654615|NCT02251509|Experimental|Metoprolol tartrate|Metoprolol tartrate BID for 2 weeks
16654616|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
16654617|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
16654618|NCT02251483|Other|SBI|Group 1: SBI (N=30) - one packet daily
16654619|NCT02251483|Placebo Comparator|Placebo|Group 2: Placebo (N=30) - one packet daily
16654620|NCT02251470|Experimental|HBE Wii (EG)|Participants receive an introduction of using the Nintendo Wii by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (wii-fit balances games) at home (instruction: min. 3 times a week for each 30 minutes).
16654621|NCT02251470|Active Comparator|HBE Control (CG)|Participants receive an introduction for conventional/traditional balance exercise by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (exercises in standing and walking) at home (instruction: min. 3 times a week for each 30 minutes).
16654622|NCT02251457|Experimental|ranolazine|ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
16654623|NCT02251444|Experimental|outpatient rehabilitation program|whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
16654624|NCT02251444|Active Comparator|physical therapy|prescribed physical therapy
16654625|NCT02251431|Experimental|Exenatide-extended release|Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks
16654626|NCT02251431|Placebo Comparator|Placebo|Matching placebo subcutaneously once per week x 38 weeks
16654627|NCT02251418|Experimental|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
16654628|NCT02251418|No Intervention|Control|Standard care treatment
16654629|NCT02251405|Placebo Comparator|One big bag, no stainless container|No stainless container
16654630|NCT02251405|Active Comparator|One big bag with two stainless containers|Two stainless containers
16654631|NCT02251392|Experimental|Chamomila recutita Gel|Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
16654632|NCT02251392|Experimental|Chamomila recutita Infuse 2,5%|Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
16654633|NCT02251392|Active Comparator|Urea cream based|Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
16654634|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
16654635|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
16654636|NCT02251366|No Intervention|SOC Examination Based Cohort|Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
16654637|NCT02251366|Active Comparator|Physician-Guided Diagnostic|Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
16654638|NCT02251353||lung and/or hepatic metastasis|intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
16654639|NCT02251340|Experimental|Intervention|Families in the intervention group will receive an Eczema Care Plan
16654640|NCT02251340|No Intervention|Control|Families in the control group will not receive an Eczema Care Plan
16654641|NCT02251327||Case detection group|Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
16654642|NCT02251327||Drug resistance risk group|Confirmed pulmonary tuberculosis cases with documented rifampin resistance, who have received anti-tuberculosis drugs for 31 days or less and/or history of prior tuberculosis PLUS ongoing signs and/or cases with symptoms of pulmonary tuberculosis PLUS suspected drug resistance and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
16654643|NCT02251301|Active Comparator|Macronutrient isoenergetic control|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of macro nutrient matched isoenergetic control (whey/casein protein and dextrose/lactose) consumed immediately and 1 h after each training session
16654644|NCT02251301|Experimental|Skim Milk|Participants will also engage in twelve weeks of High intensity interval training with consumption of one serving (250 mL) of fat-free fluid milk immediately and 1 h after each training session
16654645|NCT02251301|Placebo Comparator|Placebo|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of placebo (water) consumed immediately and 1 h after each training session.
16654646|NCT02251288|Experimental|Group 1|12 patients receive Intramuscular (IM) A/H7N9 15 mcg on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of Intranasal (IN) sprayer 10^7 FFU H7 N9 pLAIV on Day 29
16654647|NCT02251288|Experimental|Group 2|12 patients receive A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer10^7 FFU H7 N9 pLAIV on Day 85
16654648|NCT02251288|Experimental|Group 3|12 patients receive S A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer 10^7 FFU H7 N9 pLAIV on Day 169
16654649|NCT02251288|Experimental|Group 4|8 patients receive A/H7N9 15 mcg IM on Day 1, 8 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1
16654650|NCT02251288|Experimental|Group 5|12 patients receive A/H7N9 15 mcg plus MF59 adjuvant on Day 1 and Day 29
16654651|NCT02251275|Experimental|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:
~Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.
~Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.
~Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
16654652|NCT02251262|Experimental|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
16654653|NCT02251249|Experimental|STEMI Group|
16654654|NCT02251249|Other|Stable patient Group|Patient referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI)
16654655|NCT02251236|Other|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
16654656|NCT02251236|Other|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
16654657|NCT02251236|Other|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
16654658|NCT02251223|Experimental|TPV/r low dose|
16654659|NCT02251223|Experimental|TPV/r medium dose|
16654670|NCT02251158|Experimental|TPV/r with food|Tipranavir/Ritonavir paediatric/oral solution
16654671|NCT02251158|Experimental|TPV/r|Tipranavir/Ritonavir paediatric/oral solution
16654672|NCT02251158|Active Comparator|TPV/r capsules|
16654673|NCT02251145|Experimental|tipranavir/ritonavir low dose|
16654674|NCT02251145|Experimental|tipranavir/ritonavir high dose|
16654675|NCT02251132|Experimental|TPV/RTV Low 1|
16654676|NCT02251132|Experimental|TPV/RTV Low 2|
16654677|NCT02251132|Experimental|TPV/RTV Low 3|
16654678|NCT02251132|Experimental|TPV/RTV Medium 1|
16654679|NCT02251132|Experimental|TPV/RTV Medium 2|
16654680|NCT02251132|Experimental|TPV/RTV High 1|
16654681|NCT02251132|Experimental|TPV/RTV High 2|
16654682|NCT02251132|Experimental|TPV/RTV High 3|
16654683|NCT02251119|Experimental|TPV|"Administration of LOP on days 1, 9 and 22
~Administration of TPV on days 4-9
~Administration of TPV/RTV on days 12-22"
16654684|NCT02251119|Experimental|RTV|"Administration of LOP on days 1, 9 and 22
~Administration of RTV on days 4-9
~Administration of TPV/RTV on days 12-22"
16654685|NCT02251106|No Intervention|-LBP/-Brace|Subjects in this arm did not have back pain nor did they wear brace (asymptomatic controls). Subjects had their spine function measured before and after a two week period.
16654686|NCT02251106|Active Comparator|-LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm did not have back pain but wore a brace for a two week period (asymptomatic intervention). Subjects had their spine function measured before and after a two week period.
16654687|NCT02251106|Experimental|+LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm had back pain and wore a brace for a two week period (symptomatic intervention). Subjects had their spine function measured before and after a two week period.
16654688|NCT02251093|Experimental|Lcr Regenerans|
16654689|NCT02251093|Placebo Comparator|Placebo|
16654690|NCT02251080||Internet-based Survey|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF); and responses to a weekly Internet-based questionnaire of adherence and disease severity.
16654691|NCT02251080||Standard-of-Care|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF);
16654692|NCT02251067|Active Comparator|VPI-2690B low dose|6 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
16654693|NCT02251067|Active Comparator|VPI-2690B medium dose|18 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
16654694|NCT02251067|Placebo Comparator|Placebo|6 or 18 mg Placebo, administered subcutaneously every 2 weeks for 48 weeks
16654695|NCT02251067|Active Comparator|VPI-2690B high dose|48 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
16654696|NCT02251054|Experimental|Avatar group|"Intervention group viewed two avatar coaches: a generic avatar coach (GAC) and a self-avatar, peer mentor (SAP)."
16654697|NCT02251054|Active Comparator|No Avatar group|The control group version (voice only) observed the identical program, including introductions, question asking, narration of animations, delivery of key points, and summary of each section with identical pre-recorded voices without the avatars.
16654698|NCT02251041|Active Comparator|cases|the group receives a combination of drugs
16654699|NCT02251041|Placebo Comparator|controles|the group do not receive a combination of drugs, but a placebo (sodium chloride solution)
16654700|NCT02251028|Active Comparator|Group A|Group A receives value-based cognitive behavior therapy after randomization.
16654701|NCT02251028|Active Comparator|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
16654702|NCT02251015|Active Comparator|therapeutic exercises|13 as control group - The control group got only orientation related to therapeutic exercises.The orientation for therapeutic exercises seek to correctly position the jaw in the resting position. Maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
16654703|NCT02251015|Experimental|occlusal plate group|36 getting occlusal splints - the splinted group was subjects that used occlusal plate under the occlusal stability criteria. The patients also received therapeutic exercises too. The plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
16654704|NCT02251002||Control|no history of TBI or neurologic disorder
16654705|NCT02251002||mTBI|documented past mild to moderate TBI
16654706|NCT02250989||Hyperinsulinemia/Euglycaemia|In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
16654707|NCT02250989||Hyperinsulinemia/Hyperglycemia|In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
16654708|NCT02250989||Hypoinsulinemia/Hyperglycemia group|In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
16654709|NCT02250976|Experimental|Livasupril Cap.160/2mg|"Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
~once a day"
16654710|NCT02250976|Active Comparator|Lipilfen cap.160mg, Livaro tab. 2mg|"Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg
~Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day"
16654711|NCT02250963||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
16654712|NCT02250963||CTCA|Computed tomography coronary angiography is going to perform with a 64-slice system (Brilliance 64, Philips Healthcare, Best, the Netherlands).
16654713|NCT02250950|Experimental|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
16654714|NCT02250950|Sham Comparator|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
16654715|NCT02250937|Experimental|Arm I (busulfan days -13 and -12 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
16654716|NCT02250937|Experimental|Arm II (busulfan days -20 and -13 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
16654717|NCT02250924|Placebo Comparator|Placebo|Subjects will wear a silicone bracelet for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
16654718|NCT02250924|Sham Comparator|Sugar-less Gum|Subjects will chew one stick of sugar-less gum for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
16654719|NCT02250924|Experimental|Caffeinated Gum|Subjects will chew one stick of caffeinated gum (100mg caffeine per stick) for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
16654720|NCT02250911|Experimental|This web-based CCC Workshop|The Care for the Cancer Caregivers (CCC) workshop is composed of six webcasts. The Introductory Webcast is based upon Sessions 1 and 2 of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and provides participants with an introduction to the CCC Workshop, an overview of the different meaning-centered modules (i.e., legacy, choice, creativity, and connectedness), and a discussion about identity and how caregivers' identities have or have not changed since taking on this role.
16654721|NCT02250911|Active Comparator|Waitlist Control|"Participants randomized to the waitlist control arm will be offered what is considered usual care at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop."
16654722|NCT02250898|Experimental|Experimental/Myofascial|The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
16654723|NCT02250898|Active Comparator|Control/Global Relaxation|The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
16654724|NCT02250885|Experimental|Selinexor (KPT-330)|Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.
16654725|NCT02250872|Active Comparator|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
16654726|NCT02250872|Placebo Comparator|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
16654727|NCT02250859|Experimental|FMX101 Minocycline 4% foam|FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
16654728|NCT02250846|Experimental|arm a|EGFR exon 19 mutation with EGFR-TKI
16654729|NCT02250846|Experimental|arm b|EGFR exon 21 mutation with EGFR-TKI
16654730|NCT02250833|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
16654731|NCT02250833|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
16654732|NCT02250820|Experimental|Nasal Dexmedetomidine and oral placebo|If the patient is assigned to the dexmedetomidine arm, they will receive dexmedetomidine through the nose. In order to keep the assignment blinded, the patient will also receive an oral placebo.
16654733|NCT02250820|Experimental|Nasal placebo and oral pentobarbital|If the patient is assigned to the pentobarbital arm, they will receive pentobarbital through the mouth. In order to keep the assignment blinded, the patient will also receive an nasal placebo.
16654734|NCT02250807|Experimental|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
16654735|NCT02250794|Active Comparator|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
16654736|NCT02250794|Experimental|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
16654737|NCT02250781|Experimental|Treatment (Oral ONC201)|Patients receive Oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16654738|NCT02250768|Experimental|GM-CSF|Injected oocytes were cultured in GM-CSF supplemented media until day of transfer
16654739|NCT02250755|Experimental|MRI T1 T2 sequences|comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
16658788|NCT02222987|Active Comparator|Terbogrel|
16654740|NCT02250742|Experimental|low back pain group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utielized. The needles will be left in situ for 10 minutes.
16654741|NCT02250742|Active Comparator|healthy group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utilized. The needles will be left in situ for 10 minutes.
16654742|NCT02250729|Experimental|cases with NMBA anaphylaxis|Patients who experienced NMBA anaphylaxis during anesthesia
16654743|NCT02250729|Other|controls|Patients who underwent anesthesia with NMBA injection but did not experience anaphylaxis
16654744|NCT02250716|Experimental|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
16654745|NCT02250716|No Intervention|Arm 2|12 month cytology and histology follow-up
16654746|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
16654747|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
16654748|NCT02250690|Experimental|experimental group - tDCS|The tDCS intervention occur at 10 sessions of intervention where electrodes are connected to head specifically in supplementary motor area placed at 2 cm in front of vertex. The clinical stimulator (NeuroConn, Germany) provided the direct current using two silicon-sponge electrodes with a surface area of 35 cm2 (5 × 7cm) embedded in a saline-soaked solution. Immediately after 13 minutes of tDCS application, patient was submitted to gait training three times a week during 4 weeks with visuals cues. The patients were asked to walk along at a 7 meters rubber carpet to at different speed, forward and backward gait, side walk during thirty minutes with three intervals of two minutes. The patient may be at on state of drug administration and the training is applied by another physiotherapist.
16654749|NCT02250690|Sham Comparator|Control group (tDCS sham)|The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
16654750|NCT02250677||Patients with myalgia|Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
16654751|NCT02250677||Patients without myalgia|Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
16654752|NCT02250677||Control group|Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
16654753|NCT02250664|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
16654754|NCT02250664|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
16654755|NCT02250664|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
16654756|NCT02250651|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
16654757|NCT02250651|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
16654758|NCT02250651|Active Comparator|Timolol 0.5%: Comparator|Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
16654759|NCT02250612|Experimental|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
16654760|NCT02250612|Experimental|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
16654761|NCT02250612|Experimental|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
16654762|NCT02250612|Experimental|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
16654763|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
16654764|NCT02250599|Active Comparator|carboplatin and paclitaxel|carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
16654765|NCT02250599|Experimental|AVASTIN and carboplatin and paclitaxel|AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
16654766|NCT02250586|Experimental|CBT-CSO|"The CBT-CSO program will be based on concepts from cognitive-behavioral therapy and motivational interviewing, and is specifically developed for use with CSOs of treatment refusing problem gamblers. The program resembles the community reinforcement and family training approach that has been successfully used with CSOs of substance abusers.
~The program will be given as guided self-help with guidance given via email and telephone. There are 8 modules, which all contain homework exercises and about 5-10 pages of text."
16654767|NCT02250586|No Intervention|Wait-list|The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options-in their area and web-based-for the problem gambler.
16654768|NCT02250573|Experimental|Replenine®-VF|
16654769|NCT02250560|Experimental|Replenine®-VF|
16654770|NCT02250534|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
16654771|NCT02250534|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
16654772|NCT02250534|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
16654773|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
16654774|NCT02250508|Experimental|Optivate®|
16654775|NCT02250508|Active Comparator|Haemate P®|
16654776|NCT02250495|Experimental|Sympara Therapeutic System|All subjects will wear for the Sympara device for 30 days
16654777|NCT02250482|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
16654778|NCT02250469|Active Comparator|Axium SCS System|Implantation with the Axium Neurostimulator
16654779|NCT02250469|Active Comparator|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
16654780|NCT02250456||Turner syndrome patients and vascular abnormalities|
16654781|NCT02250443|Experimental|BYM338|BYM338 Group
16654782|NCT02250430|Experimental|Topical SB204|Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
16654783|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
16654784|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
16654785|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
16654786|NCT02250391|Experimental|NPB-06|1,500 unit, 5 days continuous-infusion
16654787|NCT02250391|Placebo Comparator|Placebo|0 unit, 5 days continuous-infusion
16654788|NCT02250378|Experimental|Treatment (stereotactic radiosurgery, wedge resection)|Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.
16654789|NCT02250365|Experimental|Continuous, suprasensory ESS|
16654790|NCT02250365|Active Comparator|Intermittent, suprasensory ESS|
16654791|NCT02250352||Cohort I (newly diagnosed, surgery before systemic therapy)|Patients undergo baseline and, if applicable, follow-up core needle biopsies of breast cancer in the breast, regional nodes, and distant metastases. Patients who experience a recurrence or progression after therapy undergo additional core biopsies at the time of recurrence. Clinical and blood specimens will also be gathered.
16654792|NCT02250352||Cohort II (newly diagnosed, systemic therapy before surgery)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients also undergo biopsies at a specific time point following the initiation of standard systemic therapy.
16654793|NCT02250352||Cohort III (patients with suspicious breast mass)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
16654794|NCT02250352||Cohort IV (breast cancer recurrence or progression)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients may also undergo 1-3 extra core biopsies.
16654795|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
16654796|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
16654797|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
16654798|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
16654799|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
16654800|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
16654801|NCT02250313||Case|All patients will have the tissue from their previous negative biopsy tested with the assay. Cases are defined as those subjects who receive the ConfirmMDx assay results.
16654802|NCT02250313||Control|All patients will have the tissue from their previous negative biopsy tested with the assay. Controls are defined as subjects who will be blinded to the ConfirmMDx assay results.
16654803|NCT02250300|Experimental|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
16654912|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
16654804|NCT02250300|Experimental|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
16654805|NCT02250300|Experimental|MLN9708 Phase I|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
16654806|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
16654807|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
16654808|NCT02250261|Experimental|KÄPY group|Workplaces, which are supported to promote employees' ACW.
16654809|NCT02250261|No Intervention|Comparison group|Workplaces, which are not supported to promote employees' ACW but will be offered support to do so after the study.
16654810|NCT02250248|Active Comparator|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
16654811|NCT02250248|Active Comparator|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
16654812|NCT02250235|Experimental|Self-affirmation|In the self-affirmation arm, the patients completed a 10 item questionnaire about their past acts of kindness (self-affirmation) prior to reading the health risk information.
16654813|NCT02250235|No Intervention|Control|Control patients completed 10 matched control questions with no self-affirming properties, prior to reading the health risk information.
16654814|NCT02250222|Experimental|Part 1: LGD-6972 15 mg|15 mg LGD-6972 administered once daily (QD) for 14 days.
16654815|NCT02250222|Placebo Comparator|Part 1: Placebo (Captisol ®)|Placebo administered once daily (QD) for 14 days.
16654816|NCT02250222|Experimental|Part 2: LGD-6972 5 mg|5 mg LGD-6972 administered orally QD for 14 days.
16654817|NCT02250222|Experimental|Part 2: LGD-6972 10 mg|10 mg LGD-6972 administered orally QD for 14 days.
16654818|NCT02250222|Experimental|Part 2: LGD-6972 15 mg|15 mg LGD-6972 administered orally QD for 14 days.
16654819|NCT02250222|Placebo Comparator|Part 2: Placebo (Captisol ®)|Placebo administered orally QD for 14 days.
16654820|NCT02250209|Experimental|Trastuzumab,Capecitabine,Oxaliplatin|"Patients receive eight 3-week cycles of oral capecitabine (800-1000 mg/m2 twice daily on days 1-14 of each cycle) ,intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) plus intravenous Trastuzumab (440mg on day 0 of each cycle).
~Number of cycle:capecitabine and oxaliplatin --8 cycles; Trastuzumab--14-16 cycles."
16654821|NCT02250196|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
16654822|NCT02250196|Active Comparator|SPMC 2|group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
16654823|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
16654824|NCT02250170|Experimental|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
16654825|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
16654826|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
16654827|NCT02250144|Experimental|Morpho-specific foot orthoses|"Morpho-specific thermo-molded foot orthoses are designed according to the patient's morphotype.
~Orthoses are custom-molded from different materials such as BIOFLUX resin, Covercuir MF, EVA300/60, EVA400/70, PE255/55, ABSORB Dur and CAPITON PU."
16654828|NCT02250144|Placebo Comparator|Placebo foot orthoses|The placebo foot orthoses will be made with the same principle of molding and with the same materials as for the experimental group. The only difference is that they involve no active corrective insert element : they will be made without morphotype correction.
16654829|NCT02250131|No Intervention|Control|Routine cardiopulmonary bypass technique. Flow adjusted on BSA and temperature
16654830|NCT02250131|Active Comparator|Goal Directed Perfusion|Perfusion targeted at oxygen delivery
16654831|NCT02250118|Experimental|Bevacizumab|Intrapleural use: range 0.5 - 5 mg/kg
16654832|NCT02250105|Active Comparator|ARI-3037MO|ARI-3037MO 3g bid orally for 12 weeks
16654833|NCT02250105|Placebo Comparator|Placebo|Matching placebo 3g bid orally for 12 weeks
16654834|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
16654835|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
16654836|NCT02250079|Experimental|Polyethilene body bag group|The intervention group infants were provided the same care as control infants, but were dressed with the polyethylene body bag immediately after birth. The bag had an upper opening for the head and a seal at the bottom. The intervention group infants remained in the plastic bag for the first 10 minutes after birth. The same process was done in surgery room in case of cesarean. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process were done in surgery room in case of cesarean
16654913|NCT02249572|Experimental|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
16654914|NCT02249572|No Intervention|Expectation|No active treatment given for vestibular schwannoma
16654837|NCT02250079|Active Comparator|Conventional group|): Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
16654838|NCT02250066|Other|Study group 1|Received high monounsaturated fat diet
16654839|NCT02250066|Other|Study group 2|Received high carbohydrate diet
16654840|NCT02250066|No Intervention|Control Group|Control group was encouraged to follow the Food Guide Pyramid
16654841|NCT02250053|Experimental|exercise|aerobic exercise on soluble intercellular adhesion molecules
16654842|NCT02250040|Active Comparator|Control group|Conventional physiotherapy for stroke.
16654843|NCT02250040|Experimental|Target group|Techniques based on patients' functional level were added.
16654844|NCT02250027|Experimental|experimental A (0.6g/day)|HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days
16654845|NCT02250027|Experimental|experimental B (1.2g/day)|HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days
16654846|NCT02250027|Experimental|experimental C (1.8g/day)|HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days
16654847|NCT02250027|Placebo Comparator|Placebo|placebo: 2 capsules at once, 3 times a day, for 7 days
16654848|NCT02250014|Experimental|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
16654849|NCT02250014|Active Comparator|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
16654850|NCT02250001||Treatment with DCV/ASV|Patients who are beginning to receive the treatment with DCV/ASV under the approved indications, dosage, and administration will be included in this study
16654851|NCT02249988|Experimental|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
16654852|NCT02249988|No Intervention|Group 2 - Control arm|NUCs background therapy only
16654853|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
16654854|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
16654855|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
16654856|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
16654857|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
16654858|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16654859|NCT02249936|Experimental|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
16654860|NCT02249936|Experimental|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
16654861|NCT02249936|Experimental|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
16654862|NCT02249923||Pulmonary Arterial Hypertension|
16654863|NCT02249910|Experimental|Semaglutide|
16654864|NCT02249897|Placebo Comparator|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
16654865|NCT02249897|Active Comparator|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
16654866|NCT02249884|Experimental|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
16654867|NCT02249884|Experimental|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
16654868|NCT02249884|Experimental|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
16654869|NCT02249884|Experimental|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
16654870|NCT02249884|Experimental|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
16654871|NCT02249884|Experimental|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
16654872|NCT02249871|Experimental|Semaglutide|
16654873|NCT02249871|Experimental|Semaglutide + Omeprazole|
16654874|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
16654875|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
16654876|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
16654877|NCT02249832|Experimental|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (>0.8m/sec) functioning.
16654878|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
16654879|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
16654880|NCT02249806||PH target therapy|Patients receiving PH target therapy
16654881|NCT02249793||Study group|Healthy volunteers
16654882|NCT02249780|Experimental|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
16654883|NCT02249780|Active Comparator|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
16654884|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
16654885|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
16654886|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
16654887|NCT02249754|Active Comparator|Routine health education|Routine health education alone
16654888|NCT02249754|Experimental|Nutrition education package|Nutrition education package and routine health education
16654889|NCT02249741|Experimental|Patients with osteoporosis|Treated with Ibandronic acid as per protocol
16654890|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
16654891|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
16654892|NCT02249715|Experimental|rDTMS|
16654893|NCT02249702|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
16654894|NCT02249702|Active Comparator|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
16654895|NCT02249689|Experimental|Definitive 65|The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
16654896|NCT02249689|Active Comparator|Definitive 74|The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
16654897|NCT02249676|Experimental|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .
~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
16654898|NCT02249676|Placebo Comparator|Control group|Patients with progressive and refractory NMO treated with regular methods
16654899|NCT02249663|Experimental|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
16654900|NCT02249663|Active Comparator|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
16654901|NCT02249663|Placebo Comparator|Placebo|Placebo Nasal Spray
16654902|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
16654903|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
16654904|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
16654905|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
16654906|NCT02249611|Experimental|MT and life counseling|To improve physical activity, body composition, physiological parameters and quality of life by using MT (mobile physical activity promotion tool) and lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination will be conducted for 3 months in intervention periods.
16654907|NCT02249611|Active Comparator|Standard care|Lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination based on the booklet of metabolic syndrome prevention which is edited by Health Promotion Administration, Ministry of Health and Welfare in Taiwan only once in this period (3 months).
16654908|NCT02249598|Experimental|Univeristy of Sheffield|lactamica
16654909|NCT02249598|Placebo Comparator|Hallam University|Phosphate Buffered Saline (PBS)
16654910|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
16654911|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
16655080|NCT02248467||eugonadal|50 eugonadal subjects
16654915|NCT02249559||GK subthalamotomy|Evaluate the safety and efficacy of unilateral GK subthalamotomy for PD in patients deemed poor candidates for DBS.
16654916|NCT02249546|Experimental|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
16654917|NCT02249546|Active Comparator|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
16654918|NCT02249533|Experimental|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).
~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
16654919|NCT02249533|No Intervention|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
16654920|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
16654921|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
16654922|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
16654923|NCT02249507|No Intervention|Control|sited rest for 45 minutes
16654924|NCT02249507|Experimental|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
16654925|NCT02249507|Experimental|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
16654926|NCT02249494|Experimental|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
16654927|NCT02249494|Placebo Comparator|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
16654928|NCT02249481|Active Comparator|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
16654929|NCT02249481|Experimental|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
16654930|NCT02249468||Mild and Moderate Alzheimer's Disease|
16654931|NCT02249468||Cognitively intact healthy people|
16654932|NCT02249455|Experimental|Acapella|Acapella is given to the patients twice daily for 20 min.
16654933|NCT02249455|Experimental|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
16654934|NCT02249455|Active Comparator|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
16654935|NCT02249442|Experimental|Scheme A, mild hepatic subjects|multi-dose
16654936|NCT02249442|Experimental|Scheme B, moderate hepatic subjects|single dose
16654937|NCT02249429|Experimental|bimiralisib (PQR309)|
16654938|NCT02249416|Experimental|TPV/RTV low + ZDV|
16654939|NCT02249416|Experimental|TPV/RTV high + ZDV|
16654940|NCT02249403|Experimental|Talsaclidine, 6 mg tid|
16654941|NCT02249403|Experimental|Talsaclidine, 12 mg tid|
16654942|NCT02249403|Experimental|Talsaclidine, 24 mg tid|
16654943|NCT02249403|Experimental|Talsaclidine, 36 mg tid|
16654944|NCT02249403|Experimental|Talsaclidine, 36 mg bid|
16654945|NCT02249403|Placebo Comparator|Placebo|
16654946|NCT02249390||Anyone|Any individual may complete this survey
16654947|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
16654948|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
16655081|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
16654949|NCT02249364|Active Comparator|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
16654950|NCT02249364|Experimental|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
16654951|NCT02249351|Experimental|Talsaclidine|
16654952|NCT02249351|Placebo Comparator|Placebo|
16654953|NCT02249338|Experimental|BIIL 284 BS|
16654954|NCT02249338|Placebo Comparator|Placebo|
16654955|NCT02249325|Experimental|Probiotic dietary supplement|Florajen3 oral probiotic (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum) taken daily beginning at 28 weeks gestation.
16654956|NCT02249325|No Intervention|Placebo|Women in the comparison group did not take a placebo.
16654957|NCT02249312|Experimental|BIIIL|
16654958|NCT02249312|Placebo Comparator|Placebo|
16654959|NCT02249299|Active Comparator|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
16654960|NCT02249299|Placebo Comparator|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
16654961|NCT02249286|Experimental|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
16654962|NCT02249286|No Intervention|No intervention|
16654963|NCT02249260|Experimental|Behavioral|Group-based high intensity interval training and lifestyle counseling
16654964|NCT02249247|Experimental|Low dose of BIIL 284 BS|
16654965|NCT02249247|Experimental|Medium dose of BIIL 284 BS|
16654966|NCT02249247|Experimental|High dose of BIIL 284 BS|
16654967|NCT02249247|Placebo Comparator|Placebo|
16654968|NCT02249234|Experimental|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
16654969|NCT02249234|Placebo Comparator|Saline|Saline 10ml of normal saline for a one-time injection
16654970|NCT02249221|Experimental|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
16654971|NCT02249221|Active Comparator|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
16654972|NCT02249208|Active Comparator|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
16654973|NCT02249208|Experimental|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
16654974|NCT02249208|Experimental|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
16654975|NCT02249182|Experimental|12 to < 18 Years Old|"Participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).
~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.
~United Kingdom:
~HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks
~United States/Australia/New Zealand:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
16654976|NCT02249182|Experimental|6 to < 12 Years Old|"Participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).
~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.
~United Kingdom:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks
~United States/Australia/New Zealand:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
16654977|NCT02249182|Experimental|3 to < 6 Years Old|"Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing < 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).
~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.
~United Kingdom:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks
~United States/Australia/New Zealand:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
16654978|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
16654979|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
16654980|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
16654981|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
16654982|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
16654983|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
16654984|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
16654985|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
16654986|NCT02249130|Experimental|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
16654987|NCT02249117|Experimental|BIWH 3|single escalating dose
16654988|NCT02249117|Placebo Comparator|Placebo|
16654989|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily
~Cetaphil Acne Regimen:
~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application
~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
16654990|NCT02249091|Experimental|Cohort 1 / Selinexor 40 mg/m^2 in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.
~Selinexor is administered at a dose of 40 mg/m^2 twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
16654991|NCT02249091|Experimental|Cohort 2 / Selinexor 60 mg flat dose in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m^2 continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.
~Selinexor is administered at a flat dose of 60 mg twice weekly orally in weeks 1-3 of a 4-week cycle starting on day 2 (total of 6 doses per induction cycle)."
16654992|NCT02249078|Experimental|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
16654993|NCT02249078|Experimental|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
16654994|NCT02249078|Experimental|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
16654995|NCT02249078|Experimental|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
16654996|NCT02249078|Placebo Comparator|Placebo|Placebo 2-mL vial solution for injection
16654997|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
16654998|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
16654999|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
16655000|NCT02249039|Experimental|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
16655001|NCT02249026|Experimental|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
16655002|NCT02249026|Active Comparator|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
16655003|NCT02249013|Experimental|HIPEC|Neoadjuvant Chemotherapy (NACT) followed by Cytoreductive Surgery (CRS) under a Fast-track recovery strategy plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and thus, Adjuvant Chemotherapy
16655004|NCT02249000|Experimental|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
16655005|NCT02248987||Clozapine|stable patients treated with clozapine
16655006|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
16655007|NCT02248987||Healthy volunteer|healthy controls
16655008|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
16655009|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
16655010|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
16655011|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
16655012|NCT02248948|Placebo Comparator|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
16655013|NCT02248948|Experimental|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
16655014|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
16655015|NCT02248922|Experimental|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
16658789|NCT02222987|Experimental|Terbogrel with Clopidogrel|
16655016|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
16655017|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
16655018|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
16655019|NCT02248883|Experimental|low TPV/RTV|
16655020|NCT02248883|Experimental|high TPV/RTV|
16655021|NCT02248883|Experimental|Placebo/RTV|
16655022|NCT02248870|Placebo Comparator|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
16655023|NCT02248870|Experimental|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
16655024|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
16655025|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.
~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.
~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
16655026|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
16655027|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
16655028|NCT02248831|Experimental|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
16655029|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
16655030|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
16655031|NCT02248805|Experimental|Does Escalation Arm A|MGD007 treatment once weekly
16655032|NCT02248805|Experimental|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
16655033|NCT02248805|Experimental|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
16655034|NCT02248805|Experimental|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
16655035|NCT02248792|Experimental|Group A|Methotrexate 10mg orally once weekly
16655036|NCT02248792|Active Comparator|Group B|Methotrexate 25mg orally once weekly
16655037|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:
~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.
~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.
~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
16655038|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:
~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.
~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.
~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
16655039|NCT02248766|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
16655040|NCT02248766|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
16655041|NCT02248753|Active Comparator|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
16655042|NCT02248753|Experimental|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
16655043|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).
~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
16655044|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).
~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
16655045|NCT02248727|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
16655046|NCT02248727|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
16655047|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
16655048|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
16655049|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
16655050|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
16658790|NCT02222987|Active Comparator|Clopidogrel|
16655051|NCT02248688|Other|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
16655052|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
16655053|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
16655054|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
16655055|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
16655056|NCT02248649|Experimental|Physical Activity|Structured walking program
16655057|NCT02248649|Active Comparator|Control|Health education attention control
16655058|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
16655059|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
16655060|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
16655061|NCT02248597|Experimental|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2
~TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
16655062|NCT02248584|Experimental|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
16655063|NCT02248584|Placebo Comparator|Placebo|Capsule containing only lactose
16655064|NCT02248571|Experimental|Arm A|"Bevacizumab plus Capecitabine (1st treatment phase) followed by Everolimus plus Exemestane (2nd treatment phase)
~Dosing (treatment cycle: 21days):
~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)
~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet
~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
16655065|NCT02248571|Experimental|Arm B|"Everolimus plus Exemestane (1st treatment phase) followed by Bevacizumab plus Capecitabine (2nd treatment phase)
~Dosing (treatment cycle: 21days):
~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet
~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)
~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
16655066|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
16655067|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
16655068|NCT02248545||Non-celiac Wheat Sensitivity Patients|Consecutive adult patients with irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
16655069|NCT02248545||Celiac Disease Patients|Celiac disease adult patients, sex- and age-matched, diagnosed according to standard criteria, during the same study period, chosen at random and enrolled as first control group.
16655070|NCT02248545||Irritable Bowel Syndrome Patients|"Irritable Bowel Syndrome adult patients, sex- and age-matched, diagnosed according to Rome II criteria, and unrelated to NCWS or other food intolerance, during the same study period, chosen at random and enrolled as second control group."
16655071|NCT02248532|Active Comparator|Group A|Repetitive stem cell administration
16655072|NCT02248532|Active Comparator|Group B|Single stem cell administration
16655073|NCT02248519|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
16655074|NCT02248519|Experimental|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
16655075|NCT02248506|Other|Clotrimazole|Clotrimazole 500 mg
16655076|NCT02248493|Experimental|paracetamol and ketoprofen|"paracetamol 20 mg/kg (1% 2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.
~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
16655077|NCT02248493|Placebo Comparator|placebo and ketoprofen|"0.9% sodium chloride (2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.
~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
16655078|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
16655079|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
16655082|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
16655083|NCT02248454|Experimental|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
16655084|NCT02248441|Experimental|Daily RIC|Daily ischemic conditioning treatment
16655085|NCT02248428|Experimental|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.
~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.
~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
16655086|NCT02248428|Active Comparator|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.
~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.
~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.
~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
16655087|NCT02248415|Experimental|No pump group|Blood cardioplegia administration without roller pump
16655088|NCT02248415|Other|Pump group|Blood cardioplegia administration with roller pump
16655089|NCT02248402|Experimental|Vax-DC/MM|
16655090|NCT02248389|Experimental|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
16655091|NCT02248376|Experimental|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
16655092|NCT02248376|No Intervention|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
16655093|NCT02248350|Experimental|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
16655094|NCT02248350|Active Comparator|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
16655095|NCT02248337|Active Comparator|4 Liter PEG|Colon preparation for colonoscopy: PEG 4 Liter before endoscopy
16655096|NCT02248337|Experimental|2 Liter PEG plus bisacodil|Colon preparation for colonoscopy: PEG 2 L before endoscopy
16655097|NCT02248311||Patients/Control Group|Observational
16655098|NCT02248311||Patients/Group Control|Observational
16655099|NCT02248298|Experimental|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
16655100|NCT02248298|Active Comparator|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
16655101|NCT02248298|Active Comparator|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
16655102|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
16655103|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
16655104|NCT02248272|Experimental|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
16655105|NCT02248272|Experimental|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
16655106|NCT02248272|Experimental|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
16655107|NCT02248259|Experimental|Reference treatment|Single oral dose of BI 409306
16655108|NCT02248259|Experimental|Test treatment|Single oral dose of BI 409306 and Administration of Itraconazole
16655109|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
16655194|NCT02247557|Experimental|Group A: Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
16658791|NCT02222974|Experimental|BIIR 561 CL|
16655110|NCT02248233|Experimental|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
16655111|NCT02248233|Experimental|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.
~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
16655112|NCT02248220||Parkinson's disease patients|
16655113|NCT02248207||Parkinson Disease patients|
16655114|NCT02248194|Experimental|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
16655115|NCT02248194|Active Comparator|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
16655116|NCT02248181||Idiopathic PD patients|
16655117|NCT02248168||Idiopathic Parkinson's disease patients|
16655118|NCT02248155||RLS patients|
16655119|NCT02248142||RLS patients|
16655120|NCT02248129||Hypertensive patients|
16655121|NCT02248116|Experimental|Alzheimer|
16655122|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
16655123|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
16655124|NCT02248090|Experimental|AZD9496|AZD9496 dose escalation and expansion(s)
16655125|NCT02248077|Active Comparator|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
16655126|NCT02248077|Other|Usual and Customary Care (UCC)|Standard of care
16655127|NCT02248064|No Intervention|Fixed flow oxygen|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
16655128|NCT02248064|Experimental|Auto-titrating arm|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
16655129|NCT02248051|Experimental|CXA-10|
16655130|NCT02248038|Active Comparator|open surgery|Conventional procedure
16655131|NCT02248038|Experimental|laparoscopic surgery|Minimum invasive procedure
16655132|NCT02248012|Experimental|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
16655133|NCT02247999||Cohort|HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.
16655134|NCT02247973|Experimental|Mesenchymal stem cells|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
16655135|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
16655136|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
16655137|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
16655138|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
16655139|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
16655140|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
16655141|NCT02247921|Experimental|Rehabilitation|nurse-led caregiver-delivered rehabilitation
16655142|NCT02247921|No Intervention|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
16655143|NCT02247908|Experimental|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
16655144|NCT02247908|Active Comparator|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
16655145|NCT02247895|Sham Comparator|Sham Treatment|Sham stimulation twice daily
16655146|NCT02247895|Active Comparator|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
16655147|NCT02247882|Experimental|Patient Education|Health Education.
16655148|NCT02247882|Active Comparator|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
16655149|NCT02247869|Experimental|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
16655150|NCT02247856|Active Comparator|Control Group|Noninvasive ventilation+ jet nebulizer
16655151|NCT02247856|Experimental|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
16655152|NCT02247843|Experimental|βAS3-FB vector transduced peripheral blood CD34+ cells|This is a single arm study without randomization. All subjects will receive the intervention of BetaAS3 lentiviral vector-modified autologous peripheral blood stem cell transplant.
16655153|NCT02247830|Experimental|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
16655367|NCT02246543|Placebo Comparator|Treatment 1 - Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
16655154|NCT02247830|Experimental|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
16655155|NCT02247830|No Intervention|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
16655156|NCT02247817|Experimental|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
16655157|NCT02247804|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
16655158|NCT02247804|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
16655159|NCT02247804|Active Comparator|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
16655160|NCT02247791|Active Comparator|Cemented femoral stem|Patient undergoing total hip arthroplasty surgery
16655161|NCT02247791|Active Comparator|Uncemented femoral stem|Patients undergoing total hip arthroplasty
16655162|NCT02247778|Active Comparator|conventional plate osteosynthesis|Standard procedure
16655163|NCT02247778|Active Comparator|mini-incision-type osteosynthesis|mini-incision
16655164|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
16655165|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
16655166|NCT02247752|Other|Inactive carriers|
16655167|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
16655168|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
16655169|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
16655170|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
16655171|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
16655172|NCT02247713||Retrospective cohort|Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
16655173|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
16655174|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
16655175|NCT02247687|Other|Counseling arm|Counseling without antiretroviral treatment modification
16655176|NCT02247687|Active Comparator|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
16655177|NCT02247687|Active Comparator|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm
~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
16655178|NCT02247674|Placebo Comparator|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
16655179|NCT02247674|Experimental|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
16655180|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
16655181|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
16655182|NCT02247648|Experimental|treatment|treatment: tramadol group
16655183|NCT02247648|Placebo Comparator|control|control: placebo group
16655184|NCT02247635|No Intervention|Conventional medical treatment|Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
16655185|NCT02247635|Active Comparator|Healthy lifestyle and adherence|1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
16655186|NCT02247622||Healthy control|
16655187|NCT02247622||IBD|patients with inflammatory bowel disease, study group
16655188|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
16655189|NCT02247609|Experimental|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
16655190|NCT02247596|Placebo Comparator|Placebo|Sugar pill 1g tds for 2 weeks
16655191|NCT02247596|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
16655192|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
16655193|NCT02247570|Experimental|Vestibular Rehabilitation|Vestibular Rehabilitation
16655195|NCT02247557|Experimental|Group B: BoNT-A 200 U in Normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
16655196|NCT02247557|Placebo Comparator|Group C: Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
16655197|NCT02247544|Experimental|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).
~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
16655198|NCT02247531|Experimental|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
16655199|NCT02247531|Experimental|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
16655200|NCT02247531|Sham Comparator|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
16655201|NCT02247518|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg*1t/day for 5days, Treatment B : Tadarafil 5mg*1t/day and Tamsulosin 0.2mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
16655202|NCT02247518|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
16655203|NCT02247505|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
16655204|NCT02247505|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
16655205|NCT02247492||Orsiro|
16655206|NCT02247479|Experimental|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
16655207|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
16655208|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
16655209|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
16655210|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
16655211|NCT02247453|Experimental|Screening|Healthy heavy smokers aged 50-75 years
16655212|NCT02247440|Experimental|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week
~Ribavirin initial dosing in the morning and in the evening:
~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).
~For genotypes 1, 4, 5 and 6:
~800 mg/day, if bodyweight <65 kg,
~1000 mg/day, if bodyweight between 66-80 kg,
~1200 mg/day, if bodyweight between 81-105 kg,
~1400 mg/day, if bodyweight >105 kg.
~Duration: 48 weeks"
16655213|NCT02247427|Experimental|Off-pace group|Deactivated device group
16655214|NCT02247427|No Intervention|On-Pace group|Ongoing device activity group
16655215|NCT02247414|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
16655216|NCT02247414|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
16655217|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
16655218|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
16655219|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
16655220|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
16655221|NCT02247388|No Intervention|Standard Care|Standard Care
16655222|NCT02247375|Experimental|Low dose of BIIL 284 BS|
16655223|NCT02247375|Experimental|High dose of BIIL 284 BS|
16655224|NCT02247375|Placebo Comparator|Placebo|
16655225|NCT02247362|Experimental|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
16655226|NCT02247362|Experimental|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
16655227|NCT02247362|Experimental|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
16655228|NCT02247362|Placebo Comparator|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
16655229|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose -1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655230|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655231|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655232|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 3|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655233|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 4|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655234|NCT02247349|Experimental|Dose Expansion (Monotherapy)- Cohort A (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655235|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort B (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655236|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort C (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655237|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort D (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
16655238|NCT02247349|Experimental|Dose Escalation (Combination) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
16655239|NCT02247349|Experimental|Dose Escalation (Combination) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
16655240|NCT02247349|Experimental|Dose Expansion (Combination)- (Refractory and Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
16655241|NCT02247336|Experimental|Immediate|Patients will complete a family health history platform at enrollment
16655242|NCT02247336|Active Comparator|Delayed|Patients will complete a family health history platform 12 months following enrollment
16655243|NCT02247323||premenopausal women|premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
16655244|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
16655245|NCT02247297||Pregnant Women|Healthy pregnant women and women with preeclampsia, HELLP syndrom, amniotic infection syndrome, or preterm premature rupture of membranes
16655246|NCT02247284|Experimental|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
16655247|NCT02247271|Other|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
16655248|NCT02247258|Active Comparator|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
16655249|NCT02247258|Active Comparator|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
16655250|NCT02247245|Placebo Comparator|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
16655251|NCT02247245|Active Comparator|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
16655252|NCT02247245|Experimental|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
16655253|NCT02247232|Placebo Comparator|Placebo|
16655254|NCT02247232|Experimental|Z-100|
16655255|NCT02247219|Experimental|Intervention|'Counselling and education individually and in groups'
16655256|NCT02247219|Other|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
16655257|NCT02247206|Experimental|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
16655289|NCT02246985|Experimental|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
16655258|NCT02247206|No Intervention|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
16655259|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
16655260|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
16655261|NCT02247180|Experimental|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
16655262|NCT02247180|Active Comparator|Cognitive Training|standardized cognitive training in the domesticity
16655263|NCT02247167|Experimental|adenotonsillectomy (AT)|Children with SDB studied before and after before adenotonsillectomy.
16655264|NCT02247154|Experimental|Vigam® Liquid|
16655265|NCT02247141|Experimental|Subgam®|
16655266|NCT02247128|Active Comparator|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
16655267|NCT02247128|Active Comparator|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
16655268|NCT02247128|Active Comparator|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
16655269|NCT02247128|Active Comparator|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
16655270|NCT02247102|Experimental|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
16655271|NCT02247102|Active Comparator|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
16655272|NCT02247076|Placebo Comparator|Grazing|"Participants will eat meals spread over the course of the day (grazing)."
16655273|NCT02247076|Experimental|Time-restricted feeding (early eating)|Participants will eat meals only in the early part of the day (early lunch and very early dinner).
16655274|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
16655275|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
16655276|NCT02247050|Experimental|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
16655277|NCT02247050|Experimental|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
16655278|NCT02247050|Experimental|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
16655279|NCT02247050|Experimental|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
16655280|NCT02247050|Experimental|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
16655281|NCT02247050|Experimental|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
16655282|NCT02247037||Triple Negative Breast Cancers|All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
16655283|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
16655284|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
16655285|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
16655286|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
16655287|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
16655288|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
16655290|NCT02246985|Experimental|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
16655291|NCT02246985|Experimental|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
16655292|NCT02246985|Experimental|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
16655293|NCT02246972|Experimental|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
16655294|NCT02246972|Active Comparator|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
16655295|NCT02246959|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive electronic pill bottles for their statin medication but are not enrolled in the sweepstakes.
16655296|NCT02246959|Experimental|Process Arm|Arm 2 will be a Process incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
16655297|NCT02246959|Experimental|Outcome Arm|Arm 3 will be an Outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group may receive incentives if they lower their LDL.
16655298|NCT02246959|Experimental|Process Plus Outcome Arm|Arm 4 will be a process plus outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication and receive additional incentives for lowering their LDL cholesterol.
16655299|NCT02246946|Experimental|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
16655300|NCT02246946|Active Comparator|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.
~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
16655301|NCT02246946|Placebo Comparator|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.
~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
16655302|NCT02246933|Experimental|PUFA Diet|
16655303|NCT02246933|Placebo Comparator|Control Diet|
16655304|NCT02246920|Experimental|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
16655305|NCT02246920|Active Comparator|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
16655306|NCT02246920|Placebo Comparator|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
16655307|NCT02246907|No Intervention|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
16655308|NCT02246907|Other|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
16655309|NCT02246894|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
16655310|NCT02246881|Active Comparator|Current Factor VIII|Optivate® (Human Coagulation Factor VIII)
16655311|NCT02246881|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
16655312|NCT02246868|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
16655313|NCT02246855|Experimental|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
16655314|NCT02246855|Experimental|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
16655315|NCT02246855|Experimental|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
16655316|NCT02246842|Experimental|D-Gam®|D-Gam® (human anti-D immunoglobulin)
16655317|NCT02246842|Active Comparator|Rhophylac®|Human Anti-D Immunoglobulin
16655318|NCT02246829|Other|Aflibercept 2mg Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
16655319|NCT02246816|Experimental|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
16655320|NCT02246803|Active Comparator|CABG+pulmonary vein isolation|CABG+pulmonary vein isolation procedure
16655321|NCT02246803|Active Comparator|Isolated CABG|Isolated CABG procedure
16655322|NCT02246790|Active Comparator|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
16655323|NCT02246790|Active Comparator|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
16655324|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
16655325|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
16655326|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
16655327|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
16655328|NCT02246751|Experimental|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
16655329|NCT02246738||Cohort1|
16655330|NCT02246738||Cohort 2|
16655331|NCT02246738||Cohort 3|
16655332|NCT02246738||Cohort 4|
16655333|NCT02246738||Cohort 5|
16655334|NCT02246738||Cohort 6|
16655335|NCT02246738||Cohort 7|
16655336|NCT02246738||Cohort 8|
16655337|NCT02246738||Cohort 9|
16655338|NCT02246725||Contact with palliative care unit versus contact when needed.|
16655339|NCT02246712|Active Comparator|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G>T in CYP2B6 gene (CYP2B6 genotype).
16655340|NCT02246712|Experimental|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).
~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
16655341|NCT02246712|Experimental|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).
~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
16655342|NCT02246699|Experimental|KiOnutrime®-Cs|The product is presented as a capsule containing chitosan as ingredient supporting the activity.
16655343|NCT02246699|Placebo Comparator|Placebo|Placebo is presented as a capsule containing inactive ingredients.
16655344|NCT02246686|Experimental|STW5-II|Half of study population, assigned randomly
16655345|NCT02246686|Placebo Comparator|Placebo|Half of study population, assigned randomly
16655346|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
16655347|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
16655348|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
16655349|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
16655350|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
16655351|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
16655352|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
16655353|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
16655354|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
16655355|NCT02246634|Experimental|Diffusion Weighted MRI scan|Patients in the study will get a DW-MRI of the liver in addition to their standard treatment imaging prior to their surgery.
16655356|NCT02246621|Experimental|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
16655357|NCT02246621|Placebo Comparator|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
16655358|NCT02246608|Active Comparator|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
16655359|NCT02246608|Experimental|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
16655360|NCT02246595|Active Comparator|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
16655361|NCT02246595|Placebo Comparator|Placebo|dose escalation mimicing i.v. placebo treatment:
16655362|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
16655363|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
16655364|NCT02246556|Active Comparator|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
16655365|NCT02246556|Active Comparator|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
16655366|NCT02246556|Experimental|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
16655368|NCT02246543|Active Comparator|Treatment 2 - HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
16655369|NCT02246543|Active Comparator|Treatment 3 - LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
16655370|NCT02246543|Active Comparator|Treatment 4 - HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
16655371|NCT02246543|Active Comparator|Treatment 5 - LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
16655372|NCT02246530|Active Comparator|PRP injection into PTRCT|Treatment - PRP injection
16655373|NCT02246530|Active Comparator|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
16655374|NCT02246517|Experimental|N2O&Oxygen|70% N2O & 30% Oxygen by Aspiration for 5 min
16655375|NCT02246517|Placebo Comparator|Oxygen|100% Oxygen by Aspiration for 5 min
16655376|NCT02246504|Experimental|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
16655377|NCT02246491|Other|iPSCs without gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
16655378|NCT02246491|Other|iPSCs with gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
16655379|NCT02246478|Placebo Comparator|Placebo|
16655380|NCT02246478|Active Comparator|TAS-205 low dose|
16655381|NCT02246478|Active Comparator|TAS-205 middle dose|
16655382|NCT02246478|Active Comparator|TAS-205 high dose|
16655383|NCT02246465|Experimental|RXI-109|RXI-109 dosed at the site of the revised hypertrophic scar
16655384|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
16655385|NCT02246439|Placebo Comparator|Placebo|Placebo
16655386|NCT02246426|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
16655387|NCT02246426|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
16655388|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
16655389|NCT02246413|No Intervention|Usual Care|Usual Care.
16655390|NCT02246400|Active Comparator|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
16655391|NCT02246400|Experimental|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
16655392|NCT02246387||Manchester Operation|Manchester Operation: Native tissue repair
16655393|NCT02246374|Experimental|ExAblate Treated Arm|ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
16655394|NCT02246374|Sham Comparator|ExAblate Sham Treated Arm|ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
16655395|NCT02246361|No Intervention|Phase 1 (without PIL)|No particular intervention during consultation for the patient
16655396|NCT02246361|Experimental|Phase 2|Patient Information Leaflet is given to the patient during the consultation
16655397|NCT02246348|Experimental|Doppler ultrasound|
16655398|NCT02246335|Active Comparator|Control group|Hemiarthroplasty
16655399|NCT02246335|Active Comparator|Treatment group|Total hip arthroplasty
16655400|NCT02246322|Experimental|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
16655401|NCT02246322|Experimental|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
16655402|NCT02246309|Experimental|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
16655403|NCT02246309|Active Comparator|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
16655404|NCT02246296|Active Comparator|Standard F75 Milk|F75 with 63% of total energy from carbohydrates, including 10% of energy from lactose (standard F75).
16655405|NCT02246296|Experimental|Modified F75 Milk|F75 milk with 43% of total energy from carbohydrates, without any lactose, and providing the same amount of energy as standard F75 by increased lipid in the form of medium chain triglycerides.
16655406|NCT02246270|Experimental|Intravesical heparin|Recurrent UTI subject receives intravesical heparin once every week for 6 weeks
16655407|NCT02246270|Active Comparator|Placebo|Recurrent UTI subject receives intravesical saline once every week for 6 weeks
16655440|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
16655441|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
16655408|NCT02246257|Other|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.
~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
16655409|NCT02246257|Other|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.
~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
16655410|NCT02246244|Experimental|Escitalopram|10 mg once per day
16655411|NCT02246244|Placebo Comparator|Placebo|
16655412|NCT02246231|Experimental|NF2 who has an auditory implant|
16655413|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
16655414|NCT02246205|Experimental|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
16655415|NCT02246205|Active Comparator|DPC UN|Child reconstruction after pancreaticoduodenectomy
16655416|NCT02246192|Experimental|control group|sinus pilonidal excision and standard cares
16655417|NCT02246192|Experimental|PRGF group|sinus pilonidal excision+ PRGF
16655418|NCT02246179|Experimental|1: AFXL + AHES|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
16655419|NCT02246179|Experimental|2: AFXL + EMLA|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
16655420|NCT02246179|Sham Comparator|3: Sham AFXL + AHES|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will then be applied at this test region on the intact skin at t1. Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
16655421|NCT02246179|Sham Comparator|4: Sham AFXL + EMLA|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will then be applied at this test region on the intact skin at t1. Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
16655422|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
16655423|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
16655424|NCT02246153|Experimental|Laparoscopic gastrectomy|Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
16655425|NCT02246153|Active Comparator|Open gastrectomy|Open distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
16655426|NCT02246140|Experimental|Cannabis users|Cerebral MRI and MRA
16655427|NCT02246140|Active Comparator|healthy volunteers|Cerebral MRI and MRA
16655428|NCT02246127|Active Comparator|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
16655429|NCT02246127|Experimental|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
16655430|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
16655431|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
16655432|NCT02246101||WTC responders|WTC responders who were enrolled in the WTC-CHEST program.
16655433|NCT02246088|Experimental|MT + NE|A manual therapy (MT) intervention combined with neuroscience education (NE)
16655434|NCT02246088|Active Comparator|MT + E|Manual therapy (MT) intervention plus an educational program based on a traditional patho-anatomical or biomedical model (E)
16655435|NCT02246075|Experimental|EVP-6124, low dose|Low dose, Tablet, Once Daily, Day 1 through Day 168
16655436|NCT02246075|Experimental|EVP-6124, high dose|High dose, Tablet, Once Daily, Day 1 through Day 168
16655437|NCT02246075|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 168
16655438|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
16655439|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
16655442|NCT02246049|Experimental|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
16655443|NCT02246036|Experimental|APD probe|Placement of a duodenal probe during 24 hours.
16655444|NCT02246023|Active Comparator|Fractionated propofol administration|"Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response.
~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy"
16655445|NCT02246023|Experimental|Propofol-TCI|"Flexible bronchoscopy in moderate sedation with TCI propofol perfusor:
~Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation.
~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively."
16655446|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
16655447|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
16655448|NCT02245997|Experimental|patients with high-risk neuroblastoma|Patients undergo external beam radiation therapy using IMRT or proton beam RT twice daily for 5-6 weekdays (10-12 treatments). Patients will be evaluated by physical exams, CT scan or MRI of the primary site, and MIBG at, 6, 12, 18 and 24 months (+/- 6 weeks).
16655449|NCT02245984|Experimental|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
16655450|NCT02245984|Experimental|electronic nursing process|for two weeks students in this group will be implemented electronic nursing process for patients.
16655451|NCT02245971|Active Comparator|Whole precutting group|
16655452|NCT02245971|Active Comparator|Partial precutting group|
16655453|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
16655454|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
16655455|NCT02245945|Experimental|TFV 1% gel|"Participants will be instructed to use TFV 1% vaginal gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.
~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.
~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
16655456|NCT02245945|Placebo Comparator|hydroxyethylcellulose (HEC) placebo gel|"Participants will be instructed to use HEC placebo gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.
~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.
~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
16655457|NCT02245932|Experimental|Resveratrol supplementation|150 mg of resveratrol for 4 weeks (split over two doses of 75 mg/day)
16655458|NCT02245932|Placebo Comparator|Placebo supplementation|Placebo for 4 weeks (split over two doses per day)
16655459|NCT02245919|Experimental|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
16655460|NCT02245906|Placebo Comparator|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
16655461|NCT02245906|Experimental|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
16655462|NCT02245906|Placebo Comparator|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
16655463|NCT02245893|Active Comparator|Screw|"In the SCREW Group (standard surgery technique), surgical treatment will be by closed reduction utilizing intraoperative fluoroscopy to visualize the reduction and percutaneous syndesmosis screw insertion. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.
~'open reduction internal fixation (ORIF)"
16655464|NCT02245893|Active Comparator|Anatomic repair technique (ART)|"In the ART group (study group) surgical treatment will be by open reduction and internal fixation. In order to stabilize the syndesmosis, direct visual anatomic alignment will be conducted and a syndesmotic screw inserted. In addition, fixation of the anterior ligament will be performed with use of a 2.7 to 4.0 mm suture anchor. Repair of the intact portion of the ligament will be made using a modified Mason -Allen repair. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.
~'open reduction internal fixation (ORIF)"
16655465|NCT02245880|Active Comparator|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
16655466|NCT02245880|Active Comparator|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
16655467|NCT02245867|Experimental|Phase Ia|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:
~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks."
16655468|NCT02245867|Experimental|Phase Ib|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:
~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12."
16655469|NCT02245854|Experimental|Colonic polyps|Exacto™
16655470|NCT02245841|Experimental|H.P Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
16655471|NCT02245828|Placebo Comparator|Placebo|Placebo comparator
16655472|NCT02245828|Experimental|QCC374|Single and multiple ascending doses of QCC374
16655473|NCT02245815|Experimental|use probiotics boucardii|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
16655474|NCT02245815|Experimental|use probiotics Multi-species|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
16655475|NCT02245802||Low risk group|CU Prediction model < 3
16655476|NCT02245802||High risk group|CU Prediction model >=3
16655477|NCT02245789|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope. All patients will received propofol and remifentanil anesthesia.
16655478|NCT02245789|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope. All patients will received propofol and remifentanil anesthesia.
16655479|NCT02245776|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
16655480|NCT02245750|No Intervention|Routine Invistigations|ICSI with long luteal phase protocol
16655481|NCT02245750|Experimental|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
16655482|NCT02245737|Experimental|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
16655483|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
16655484|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
16655485|NCT02245724|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
16655486|NCT02245711|Experimental|Stem Cell|
16655487|NCT02245698|Experimental|Stem Cell|Bone marrow mononuclear cells
16655488|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
16655489|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
16655490|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
16655491|NCT02245659|Experimental|CPAP|
16655492|NCT02245659|Other|Nasal dilator strip|Control
16655493|NCT02245646||Control group|No indication for stapedotomy
16655494|NCT02245646||Distortion positive|Subjects after stapedotomy perceiving sound distortions
16655495|NCT02245646||Distortion negative|Subjects after stapedotomy not perceiving sound distortions.
16655496|NCT02245633||vitamin D levels deficient|Diabetic hemodialysis patients with vitamin D levels deficient
16655497|NCT02245633||vitamin D levels sufficient|Diabetic hemodialysis patients with vitamin D levels sufficient
16655498|NCT02245620|Experimental|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
16655499|NCT02245620|Placebo Comparator|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
16655500|NCT02245607|Experimental|Compensatory Cognitive Training|Compensatory Cognitive Training
16655501|NCT02245607|Active Comparator|Recreational Therapy|Recreational Therapy
16655502|NCT02245594||Gl motility and sleep pattern|
16655503|NCT02245581|Active Comparator|SVV-guided fluid management|SVV : Stoke volume variation
16655504|NCT02245581|Active Comparator|CVP-guided fluid management|CVP : Central venous pressure
16655505|NCT02245568|Experimental|LMTM|
16655506|NCT02245555||Patients with benign prostatic hyperplasia|
16655507|NCT02245542||BPH patients|
16655508|NCT02245529||Patients with benign prostatic hyperplasia (BPH)|
16655509|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
16655510|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
16655511|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
16655512|NCT02245490|Experimental|Tamsulosin|
16655513|NCT02245490|Placebo Comparator|Placebo|
16655514|NCT02245477||Obstetric Ultrasoud|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
16655515|NCT02245477||Serum Vascular Endothelial Growth Factor|Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
16655520|NCT02245425|Active Comparator|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
16655521|NCT02245425|Active Comparator|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
16655522|NCT02245412|Experimental|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
16655523|NCT02245412|Experimental|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
16655524|NCT02245412|Experimental|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
16655525|NCT02245399|Experimental|A canola oil enriched mediterranean diet|Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
16655526|NCT02245399|Active Comparator|A high wheat fiber diet|Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
16655527|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
16655528|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
16655529|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
16655530|NCT02245373||Antidepressants|Naturalistic assignment: Patients whose physician decides to indicate antidepressants.
16655531|NCT02245373||Active Monitoring|Naturalistic assignment: Patients whose physician considers starting an Active Monitoring intervention.
16655532|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
16655533|NCT02245360|Placebo Comparator|Placebo|Placebo
16655534|NCT02245347||Patients with expected MDR TB|
16655535|NCT02245334|Experimental|Povidone-iodine|povidone iodine pill
16655536|NCT02245334|No Intervention|no intervention|no intervention
16655537|NCT02245321|Placebo Comparator|Letter Group- No information|Receive a thank you letter after each blood donation.
16655538|NCT02245321|Experimental|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
16655539|NCT02245321|Placebo Comparator|Ferrous gluconate- 0 mg|Receive pills to take daily that contain no iron (a placebo or inert pill).
16655540|NCT02245321|Experimental|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
16655541|NCT02245321|Experimental|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
16655542|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
16655543|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
16655544|NCT02245295||EBUS-TBNA|EBUS-TBNA for enlarged mediastinal/hilar lymph nodes
16655545|NCT02245269|Experimental|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
16655546|NCT02245256|Placebo Comparator|Normal saline|same infusion rate as experimental group (dexmedetomidine)
16655547|NCT02245256|Experimental|dexmedetomidine|0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.
16655548|NCT02245243|Experimental|Delafloxacin|Single Dose 300 mg IV
16655549|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
16655550|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
16655551|NCT02245217|Experimental|PET/CT Imaging arm|
16656059|NCT02241928|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
16655552|NCT02245204|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
16655553|NCT02245191|Experimental|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
16655554|NCT02245191|Experimental|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
16655555|NCT02245191|Experimental|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
16655556|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
16655557|NCT02245165|Experimental|Nitric oxide synthase (NOS) inhibition|After a control period of 4 hours, intervention with L-NMMA (10 mg/kg IV) is done and recording continued for 4 hours.
16655558|NCT02245165|Sham Comparator|Saline|After a control period of 4 hours, intervention with saline is done and recording continued for 4 hours.
16655559|NCT02245152|Experimental|PROMIS intervention|"Small group behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly well-baby visits for children 0-17 months of age
~Caregivers with children 0-17 months of age that attend the well-baby visit will be provided with a monthly dose of LNS (20g/day)"
16655560|NCT02245152|Active Comparator|control|Monthly well-baby visits as prescribed by national policy This arm is the basic comparison arm. Caregivers are invited to frequent the health center once a month for well-baby visits. During these visits necessary vaccinations are administered, child growth and nutrition status is evaluated and preventive counseling on child nutrition and health is provided in large groups of caregivers.
16655561|NCT02245126|Experimental|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)
~3-3-4 mix was administered"
16655562|NCT02245126|Active Comparator|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
16655563|NCT02245113|Experimental|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
16655564|NCT02245113|Experimental|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
16655565|NCT02245113|Experimental|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
16655566|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
16655567|NCT02245087|Experimental|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
16655568|NCT02245087|No Intervention|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
16655569|NCT02245074|Other|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
16655570|NCT02245074|Other|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
16655571|NCT02245074|Other|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
16655572|NCT02245061|Experimental|paired pulses cortical electrical stimulation|
16655573|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
16655574|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
16655575|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
16655576|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
16655577|NCT02245022|Experimental|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
16655578|NCT02245022|Active Comparator|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
16655579|NCT02245009||Pacemaker patients|Patients with pacemaker, presenting for cardioversion.
16655580|NCT02245009||ICD patients|Patients with ICD, presenting for cardioversion.
16655581|NCT02245009||CRT patients|Patients with CRT device, presenting for cardioversion.
16655582|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
16655583|NCT02244996|Placebo Comparator|Placebo|Placebo
16655584|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
16655585|NCT02244970|Experimental|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
16655586|NCT02244970|Active Comparator|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
16655587|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
16655588|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
16655589|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
16655590|NCT02244931|Experimental|Phase 1: Performance evaluation on ergometer|"The 3 devices are experimented in random order to compare them on performance using an ergometer wheelchair:
~Servomatic™ assisting device
~E.Motion© assisting device
~Standard manual Wheelchair"
16655591|NCT02244931|Experimental|Phase 2: Comparison of maneuverability|"The 3 devices are experimented in random order to compare them on maneuverability:
~Servomatic™ assisting device
~E.Motion© assisting device
~Standard manual Wheelchair"
16655592|NCT02244931|Experimental|Phase 3: Comparison of the autonomy|"The 3 devices are experimented in random order to compare them on the autonomy they afford to patients:
~Servomatic™ assisting device
~E.Motion© assisting device
~Standard manual Wheelchair"
16655593|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
16655594|NCT02244918|Experimental|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
16655595|NCT02244905|Experimental|Positive Deviance Intervention Arm|Three hospital wards received Positive Deviance intervention.
16655596|NCT02244905|Other|Control Arm|Three hospital wards randomized to control arm received the Standard-of-Care Infection Control approach.
16655597|NCT02244879|Placebo Comparator|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
16655598|NCT02244879|Experimental|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
16655599|NCT02244879|Experimental|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
16655600|NCT02244866|Active Comparator|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
16655601|NCT02244866|Active Comparator|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
16655602|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
16655603|NCT02244827|Experimental|WCK 2349|Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.
16655604|NCT02244814|Experimental|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
16655605|NCT02244814|Active Comparator|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
16655606|NCT02244801|Other|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.
~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
16655607|NCT02244801|Other|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.
~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
16655608|NCT02244762|Experimental|Mild Renal Impairment|20 mg HC-ER
16655609|NCT02244762|Experimental|Moderate Renal Impairment|20 mg HC-ER
16655610|NCT02244762|Experimental|Severe Renal Impairment|20 mg HC-ER
16655611|NCT02244749||skin specimen|skin specimen
16655612|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
16655613|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
16655614|NCT02244736||Diabetics|Subjects with abnormal OGTT
16655615|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.
~For each patient a lung ultrasound examination will be performed."
16655616|NCT02244710|Experimental|Ticagrelor|180mg initial dose next day 90mg BID
16655617|NCT02244710|Active Comparator|Clopidogrel|600mg po initial dose and 75mg qd starting next day
16655618|NCT02244697||Experimental: laryngeal ultrasound stridor|Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre.
16655619|NCT02244697||Other: laryngeal ultrasound -control|Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx.
16655620|NCT02244684||Pregnant women|
16655621|NCT02244671|Experimental|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
16655622|NCT02244658|Experimental|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
16655623|NCT02244658|No Intervention|control|no thrombopoietic agents
16655624|NCT02244645|Other|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
16655625|NCT02244645|Experimental|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
16655626|NCT02244632|Experimental|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
16655627|NCT02244632|Experimental|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
16655628|NCT02244632|Experimental|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
16655629|NCT02244632|Experimental|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
16655630|NCT02244632|Experimental|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
16655631|NCT02244632|Experimental|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
16655632|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
16655820|NCT02243306|Experimental|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
16655633|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
16655634|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
16655635|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
16655636|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
16655637|NCT02244593|No Intervention|Mammography screening only|"This group will receive their standard of care mammogram only. Participants in this arm will not receive the FAST MRI.
~Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram."
16655638|NCT02244593|Experimental|FAST MRI and mammogram screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram. The intervention is the addition of the FAST Breast MRI.
16655639|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
16655640|NCT02244567|Active Comparator|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
16655641|NCT02244567|Active Comparator|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
16655642|NCT02244567|Active Comparator|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
16655643|NCT02244554|Experimental|enLighten Laser Picosecond Pulse|Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
16655644|NCT02244554|Experimental|enLighten Laser Nanosecond Pulse|Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
16655645|NCT02244541|Experimental|Anavex2-73 oral then the Anavex2-73 intravenous formulation|Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
16655646|NCT02244541|Experimental|Anavex2-73 intravenous then the Anavex2-73 oral formulation|Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
16655647|NCT02244541|Experimental|Anavex2-73 30 mg oral formulation|Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
16655648|NCT02244541|Experimental|Anavex2-73 50 mg oral formulation|Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
16655649|NCT02244528|Experimental|Treatment|sildenafil treatment
16655650|NCT02244515|Placebo Comparator|Group C|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered 10 ml NaCI 0.9%.
16655651|NCT02244515|Experimental|Group D|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
16655652|NCT02244502|Experimental|TTFields in combination with weekly paclitaxel|Patients will be treated continuously with the NovoTTF-100L(O) device, in addition to weekly paclitaxel.
16655653|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine|Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.
16655654|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine+oxaliplatin|Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.
16655655|NCT02244463|Experimental|MLN0128|Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
16655656|NCT02244450|Experimental|Screened patients|SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
16655657|NCT02244450|No Intervention|Control group|SCID children diagnosed without screening by pediatricians local referents DIP
16655658|NCT02244437|Active Comparator|Ibuprofen|Ibuprofen has been shown to prevent AMS from previous studies.
16655659|NCT02244437|Experimental|Acetaminophen|Acetaminophen has not been tested yet in AMS prevention.
16655660|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
16655661|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
16655706|NCT02244112|Experimental|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
16656060|NCT02241915|Active Comparator|Microbial Sealant|Integuseal (Kimberly Clark)
16656061|NCT02241915|Sham Comparator|Control|No microbial sealant
16655662|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
16655663|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
16655664|NCT02244398|Experimental|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
16655665|NCT02244398|Active Comparator|FP services|VHTs in the control arm only provide family planning services.
16655666|NCT02244385||Observation|No intervention
16655667|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
16655668|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
16655669|NCT02244372|Placebo Comparator|Placebo|Placebo
16655670|NCT02244359|Experimental|Training|Online tutorial, decision aid and interactive workshop
16655671|NCT02244359|Other|Usual care|Usual care
16655672|NCT02244346||Benign prostatic hyperplasia patients|
16655673|NCT02244333||Patients with symptomatic BPS|
16655674|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
16655675|NCT02244307||Patients with BPH treated with alpha-andrenergic blockade|
16655676|NCT02244294|Experimental|FLOMAX®|
16655677|NCT02244294|Placebo Comparator|Placebo|
16655678|NCT02244281|Experimental|FLOMAX®|
16655679|NCT02244281|Placebo Comparator|Placebo|
16655680|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
16655681|NCT02244255|Experimental|FLOMAX®|
16655682|NCT02244255|Active Comparator|HYTRIN®|
16655683|NCT02244242|Experimental|Tamsulosin hydrochloride|modified release capsules
16655684|NCT02244229|Experimental|Tamsulosin|
16655685|NCT02244229|Active Comparator|Finasteride|
16655686|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
16655687|NCT02244203|Experimental|Single rising doses of BI 60732|
16655688|NCT02244203|Placebo Comparator|Placebo|
16655689|NCT02244190|Experimental|new Tipranavir + Ritonavir|
16655690|NCT02244190|Active Comparator|current Tipranavir + Ritonavir|
16655691|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
16655692|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
16655693|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.
~Until 11,March, 2015, 59 cases are collected."
16655694|NCT02244164|Active Comparator|Sulfonylurea|Patient will received metformine with sulfonylurea
16655695|NCT02244164|Active Comparator|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
16655696|NCT02244164|Active Comparator|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
16655697|NCT02244151|Experimental|DECAPEPTYL® diario|Group 1: DECAPEPTYL® diario,OPU 24 hours after GnRHa administration.
16655698|NCT02244151|Experimental|Decapeptyl® diaro|Group 2:Decapeptyl® diario OPU 30 hours after GnRHa administration.
16655699|NCT02244151|Experimental|Decapeptyl® diario.|Group 3: Decapeptyl® diario, OPU 40 hours after GnRHa administration.
16655700|NCT02244151|Active Comparator|Decapeptyl® daily|Group 4: Decapeptyl® daily OPU 36 hrs after GnRH administration
16655701|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
16655702|NCT02244125|Other|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:
~The treatment phase:
~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The consolidation phase:
~Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)
~2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The maintenance phase: Until progression or discontinuation for any other reason
~Pomalidomide and Dexamethasone"
16655703|NCT02244125|Other|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:
~The treatment phase:
~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The consolidation phase:
~5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The maintenance phase: Until progression or discontinuation for any oher reason
~Pomalidomide and Dexamethasone"
16655704|NCT02244112|Experimental|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:
~Diet A: Fasted conditions
~Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat
~Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
16655705|NCT02244112|Experimental|Part II: Drug-Drug Interaction (DDI)|"Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4
~Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
16655777|NCT02243631|Experimental|Probenecid|These patients will receive 5 days of probenecid.
16655778|NCT02243631|No Intervention|No intervention|These patients will receive no intervention.
16655707|NCT02244099|Experimental|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
16655708|NCT02244086|No Intervention|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
16655709|NCT02244086|Experimental|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
16655710|NCT02244073|Experimental|Individualized blood glucose target|Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
16655711|NCT02244073|Active Comparator|Conventional blood glucose target|Maintain blood glucose bellow 10 mmol/l.
16655712|NCT02244060|Experimental|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
16655713|NCT02244060|No Intervention|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
16655714|NCT02244047|Active Comparator|Bifidobacterium breve|Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
16655715|NCT02244047|Active Comparator|Placebo|Placebo in the same powder packages as Bifidobacterium breve
16655716|NCT02244034||1250 patients who had cardiac surgery wit|
16655717|NCT02244021|Experimental|BRENTUXIMAB VEDOTIN|1 arm for all patients
16655718|NCT02244008|Experimental|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
16655719|NCT02244008|Placebo Comparator|manual contact|
16655720|NCT02243995|Experimental|Physical training|
16655721|NCT02243982|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile. Radiopharmaceutical tracer
16655722|NCT02243969|Experimental|flaxseed oil (rich in α-linolenic acid )|
16655723|NCT02243969|Placebo Comparator|high oleic sunflower oil|
16655724|NCT02243956|Experimental|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
16655725|NCT02243956|Placebo Comparator|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
16655726|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
16655727|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
16655728|NCT02243930|Experimental|Cap|Sigmoidoscopy with cap
16655729|NCT02243930|No Intervention|No cap|Sigmoidoscopy without cap
16655730|NCT02243917|Experimental|Dose Escalation Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles; subjects who have completed at least one cycle may optionally participate in a food effect week, wherein CB-5083 will be orally administered once daily, on days 1 and 4, and thereafter return to the original dosing schedule
16655731|NCT02243917|Experimental|Dose Expansion Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles
16655732|NCT02243917|Experimental|Food Effect Stage - CB-5083|CB-5083 will be orally administered once daily, on days 1 and 4 of week 1, cycle 1, and orally administered daily, 4 days on and 3 days off, for the remaining 3 weeks of cycle 1; for subsequent 28 day cycles, CB-5083 will be orally administered daily, 4 days on and 3 days off
16655733|NCT02243904||Lead exposure|
16655734|NCT02243891|Active Comparator|Control|Atrial fibrillation ablation only
16655735|NCT02243891|Experimental|ROX Coupler|Atrial fibrillation ablation with concurrent ROX Coupler insertion
16655736|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.
~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
16655737|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.
~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
16655738|NCT02243865|Experimental|Chordate System S200 + CT100 (active treatment)|
16655739|NCT02243865|Placebo Comparator|Chordate System S200 + CT100 (placebo treatment)|
16655740|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
16655741|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
16655779|NCT02243618|Active Comparator|Rebamipide group|
16655780|NCT02243618|Active Comparator|Polaprezinc group|
16655781|NCT02243605|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16655821|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
16656062|NCT02241902||No pyuria|
16655742|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.
~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
16655743|NCT02243839|Active Comparator|Thrombolytic therapy|In the first arm, thrombolytic therapy (TT) is performed to the patients with obstructive prosthetic valve thrombosis. The TT regimen depends on the functional status of the patient. In patients with NYHA class III-IV dyspnea low dose, relatively faster TT regimen (25 mg tPA/6 hours) is performed. In patients with NYHA class I-II dyspnea TT with low dose and ultra-slow infusion of tPA (25 mg tPA/25 hours) is performed. During TT, patients are followed up with transesophageal echocardiography in every 24 hours.
16655744|NCT02243839|Active Comparator|Surgery|In the second arm, redo valve surgery is performed for obstructive valve thrombosis. Intraoperative and postoperative results are recorded
16655745|NCT02243826|Experimental|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
16655746|NCT02243826|Other|compressed air|The second group will inhale compressed air during the same period of time
16655747|NCT02243813|Experimental|Delayed Participation|Participants will begin the psilocybin intervention 6 months after study enrollment.
16655748|NCT02243813|Experimental|Immediate Participation|Participants will begin psilocybin intervention immediately after study enrollment.
16655749|NCT02243800|Experimental|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
16655750|NCT02243800|Placebo Comparator|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
16655751|NCT02243787|Experimental|COVA322|single i.v. infusion
16655752|NCT02243787|Placebo Comparator|Placebo|single i.v. infusion
16655753|NCT02243774|No Intervention|No letter|Individuals randomized to the control group who will not receive any of the four letters
16655754|NCT02243774|Experimental|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
16655755|NCT02243774|Experimental|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
16655756|NCT02243774|Experimental|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
16655757|NCT02243774|Experimental|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
16655758|NCT02243761|Experimental|DBT Based Skills Groups for Families|Family members of youth with concurrent disorder participate in a 12-week DBT based skills group led by therapists and/or peer facilitators.
16655759|NCT02243748|Active Comparator|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
16655760|NCT02243748|Experimental|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
16655761|NCT02243735|Active Comparator|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
16655762|NCT02243735|Active Comparator|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
16655763|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
16655764|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
16655765|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
16655766|NCT02243683|Experimental|Cohort A|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
16655767|NCT02243683|Experimental|Cohort B|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
16655768|NCT02243670|Experimental|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
16655769|NCT02243657|Placebo Comparator|1: Placebo dose level|
16655770|NCT02243657|Experimental|2: ASP3652 lowest dose level twice daily|
16655771|NCT02243657|Experimental|3:ASP3652 low dose level twice daily|
16655772|NCT02243657|Experimental|4: ASP3652 medium dose level twice daily|
16655773|NCT02243657|Experimental|5: ASP3652 high dose level twice daily|
16655774|NCT02243657|Experimental|6: ASP3652 highest dose level once daily|
16655775|NCT02243644|Active Comparator|Group A|7 days of albendazole 15 mg/kg/day
16655776|NCT02243644|Active Comparator|Group B|28 days of albendazole 15 mg/kg/day
16655782|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
16655783|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
16655784|NCT02243566||Essential hypertension|
16655785|NCT02243553|Experimental|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
16655786|NCT02243553|Experimental|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
16655787|NCT02243553|Experimental|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
16655788|NCT02243553|Experimental|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
16655789|NCT02243527|Experimental|Inspiratory Muscle Training|
16655790|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
16655791|NCT02243514||Resistant hypertension|
16655792|NCT02243514||Essential hypertension|
16655793|NCT02243514||Chronic heart failure|
16655794|NCT02243514||Control|
16655795|NCT02243501|Experimental|Intervention Group|The Intervention Group receives access to the BNBD intervention, and can access alternative resources while enrolled in the study. The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
16655796|NCT02243501|No Intervention|Usual Care Group|The Usual Care Group will receive no treatment until after the 8 month follow-up assessment. The Usual Care Group can access alternative resources and additional programs and services while enrolled in the study.
16655797|NCT02243488|Experimental|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
16655798|NCT02243488|Experimental|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
16655799|NCT02243462|Other|No pre-op warming|No pre-warming in bay before surgery.
16655800|NCT02243462|Active Comparator|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
16655801|NCT02243449|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
16655802|NCT02243449|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
16655803|NCT02243436|Experimental|BV-ESHAP|"- 3 cycles every 21 days:
~Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)
~Etoposide 40 mg/m2/day, on days 1 to 4
~Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4
~Cisplatin 25 mg/m2/day, on days 1 to 4
~Ara C (cytarabine) 2 g/m2, on day 5
~- A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.
~- Autologous peripheral blood stem cell transplant
~- A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
16655804|NCT02243423|Experimental|SUPINE group|The surgical table will remain horizontal after intrathecal (spinal) anesthesia injection for cesarean section. Choosing to position the patient supine is the intervention.
16655805|NCT02243423|Active Comparator|TILT group|The surgical table will be turned to 15° of left lateral tilt after patients are laid supine after spinal anesthesia injection. The tilted group is the control group.
16655806|NCT02243384|Experimental|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
16655807|NCT02243384|Active Comparator|Radiofrequency Ablation|Radiofrequency Ablation
16655808|NCT02243371|Experimental|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
16655809|NCT02243371|Experimental|Arm B: CY/ GVAX/ CRS-207|
16655810|NCT02243345||Delayed|Time from surfacing to recompression >=48 hours
16655811|NCT02243345||Early|Time from surfacing to recompression <48 hours
16655812|NCT02243332|Experimental|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
16655813|NCT02243319|Experimental|Group 1|"A → B → C
~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
16655814|NCT02243319|Experimental|Group 2|C → A → B
16655815|NCT02243319|Experimental|Group 3|B → C → A
16655816|NCT02243319|Experimental|Group 4|C → B → A
16655817|NCT02243319|Experimental|Group 5|B → A → C
16655818|NCT02243319|Experimental|Group 6|A → C → B
16655819|NCT02243306|Experimental|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
16656063|NCT02241902||Persistent pyuria|
16655822|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655823|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655824|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
16655825|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655826|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655827|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655828|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655829|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655830|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655831|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
16655832|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
16655833|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
16655834|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
16655835|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
16655836|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
16655837|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
16655838|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
16655839|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
16655840|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
16655841|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
16655842|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
16655843|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
16655844|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
16655845|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
16655846|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
16655847|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
16655848|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
16655849|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
16655850|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
16655851|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
16655852|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
16655853|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
16655854|NCT02243254|Placebo Comparator|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
16655855|NCT02243254|Placebo Comparator|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
16655856|NCT02243254|Active Comparator|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
16655857|NCT02243254|Active Comparator|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
16655858|NCT02243241|Experimental|HYD|
16655859|NCT02243241|Other|Moxifloxacin|Moxifloxacin is the positive control.
16655860|NCT02243241|Placebo Comparator|Placebo|Placebo for HYD and placebo for moxifloxacin
16655861|NCT02243228|Experimental|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
16655862|NCT02243215|Experimental|Offsite training|Access to a portable trainer for laparoscopic skills
16655863|NCT02243215|No Intervention|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
16655864|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
16655865|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
16655866|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
16655867|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
16655868|NCT02243189|Experimental|JNJ-43260295 (Healthy Participants)|Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
16655869|NCT02243189|Placebo Comparator|Placebo (Healthy Participants)|Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
16655870|NCT02243189|Experimental|JNJ-43260295 (Asthmatic Participants)|Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.
16655871|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
16655872|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
16655873|NCT02243163|Experimental|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
16655874|NCT02243150|Experimental|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
16655875|NCT02243150|Experimental|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
16655876|NCT02243150|Experimental|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
16655877|NCT02243150|Experimental|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
16655878|NCT02243150|Experimental|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
16655879|NCT02243150|Experimental|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
16655880|NCT02243150|Experimental|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
16655881|NCT02243137|Active Comparator|prasugrel and acetylsalicylic|single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
16655882|NCT02243137|Experimental|lysine acetylsalicylate and prasugrel|single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous
16655883|NCT02243124|Active Comparator|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
16655884|NCT02243124|Active Comparator|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
16655885|NCT02243124|Active Comparator|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
16655886|NCT02243111|Experimental|Doppler ultrasound|Recording Doppler signals from the lungs
16655887|NCT02243098|Experimental|Semaglutide|
16655888|NCT02243085||photoselective vaporization|
16658792|NCT02222974|Placebo Comparator|Placebo|
16655889|NCT02243072|Experimental|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
16655890|NCT02243072|No Intervention|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
16655891|NCT02243059|Experimental|GDF-MRI|"In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.
~Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset)."
16655892|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
16655893|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
16655894|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
16655895|NCT02243033||Visualase|MR-guided laser focal therapy
16655896|NCT02243020|Experimental|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
16655897|NCT02243020|Active Comparator|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
16655898|NCT02243007|Experimental|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel
~Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.
~After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.
~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
16655899|NCT02243007|Experimental|Gemcitabine/nab-Paclitaxel- Arm B|"Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).
~Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.
~After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine
~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
16655900|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
16655901|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
16655903|NCT02242955|Active Comparator|"AD = as-usual diazepam"|Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
16655904|NCT02242955|Experimental|"PD = prolonged diazepam"|Diazepam will be slowly tapered to be stopped at day 30
16655905|NCT02242942|Experimental|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
16655906|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
16655907|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
16655908|NCT02242929|Active Comparator|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
16655909|NCT02242929|Experimental|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
16655910|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
16655911|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
16655912|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
16655913|NCT02242890|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
16655914|NCT02242877||Isolated systolic hypertension|
16655915|NCT02242877||Systolic and diastolic hypertension|
16655916|NCT02242864||Patients with hypertension and diabetes mellitus|
16655917|NCT02242851||Hypertensive patients|
16655918|NCT02242838||Hypertensive patients|
16655919|NCT02242825||Patients with hypertension and diabetes mellitus|
16655920|NCT02242812|Experimental|Telmisartan|MICARDIS®
16655921|NCT02242812|Active Comparator|Metoprolol succinate|BELOC ZOK®
16655922|NCT02242799|Experimental|Study A Sequence 1|Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
16655923|NCT02242799|Experimental|Study A Sequence 2|Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
16655924|NCT02242799|Experimental|Study B Sequence 1|Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
16655925|NCT02242799|Experimental|Study B Sequence 2|Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
16655926|NCT02242786|Experimental|EBRT|
16655927|NCT02242773|Experimental|Active Surveillance|Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.
16655928|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
16655929|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
16655930|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
16655931|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
16655932|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
16655933|NCT02242747|Other|ingenol mebutate|Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area
16655934|NCT02242747|Other|5% 5-FU|Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area
16655935|NCT02242734|Experimental|Mild Hepatic Impairment|20 mg HC-ER
16655936|NCT02242734|Experimental|Moderate Hepatic Impairment|20 mg HC-ER
16655937|NCT02242734|Experimental|No Hepatic Impairment|20 mg HC-ER
16655938|NCT02242721||Intensive care unit patients needing renal replacement therapy|Male and female patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs.
16655939|NCT02242708|No Intervention|Normal breathing|The control group will do normal breathing.
16655940|NCT02242708|Experimental|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
16655941|NCT02242695|Experimental|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
16655942|NCT02242695|Active Comparator|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
16655943|NCT02242682|No Intervention|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
16655944|NCT02242682|Experimental|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
16655945|NCT02242669||AIM 1|200 current DBSA participants.
16655946|NCT02242669||AIM 2|60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
16655947|NCT02242669||AIM 3|100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
16655948|NCT02242656|Experimental|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
16655949|NCT02242656|Experimental|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
16655950|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.
~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
16655951|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.
~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
16655952|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
16655953|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
16655954|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
16655955|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
16655956|NCT02242617|Active Comparator|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
16655957|NCT02242617|Active Comparator|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
16655958|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
16655959|NCT02242591|Active Comparator|ACB_active/placebo|"Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0).
~The measurements for baseline and outcome will be made in following order:
~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
16656016|NCT02242227|Experimental|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
16656017|NCT02242227|Active Comparator|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
16656018|NCT02242227|Placebo Comparator|Placebo|
16656019|NCT02242214||Misoprostol 200 µg VDS|At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
16655960|NCT02242591|Placebo Comparator|ACB_placebo/active|"Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0).
~The measurements for baseline and outcome will be made in following order:
~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
16655961|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
16655962|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
16655963|NCT02242565|Other|Control: all-sizes of ShangRing|All-sizes of ShangRings will be available.
16655964|NCT02242565|Active Comparator|Reduced-sizes|7 adult sizes of ShangRings will be available
16655965|NCT02242539|Experimental|Height measurement poster|
16655966|NCT02242539|Experimental|Community-based monitoring|
16655967|NCT02242539|No Intervention|Control|
16655968|NCT02242526|Active Comparator|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
16655969|NCT02242526|Active Comparator|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
16655970|NCT02242513|Active Comparator|pulsed mode radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. One dose of PRF was given in tibial nerve behine the medial ankle in intervention group.
16655971|NCT02242513|Placebo Comparator|Xylocaine|2 c.c xylocaine was given in tibial nerve behind the medial ankle in control group.
16655972|NCT02242500|Experimental|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
16655973|NCT02242500|Other|Coronally advanced flap|Coronally advanced flap procedure alone
16655974|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
16655975|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
16655976|NCT02242474|Active Comparator|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
16655977|NCT02242474|Experimental|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
16655978|NCT02242461|Placebo Comparator|Rhodiola placebo capsules|starch
16655979|NCT02242461|Experimental|Rhodiola Crenulata|Rhodiola Crenulata
16655980|NCT02242435|Experimental|Ampion 4ml|4 mL intra-articular injection of Ampion
16655981|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
16655982|NCT02242422||transobturator tape|
16655983|NCT02242409|Experimental|Gemcitabine/abraxane|Gemcitabine and Abraxane
16655984|NCT02242396||Hypertensive patients|
16655985|NCT02242383||Essential hypertension|
16655986|NCT02242370|Experimental|Telmisartan low dose|
16655987|NCT02242370|Experimental|Telmisartan high dose|
16655988|NCT02242357||Patients with hypertension|
16655989|NCT02242344|Experimental|telmisartan - low dose|
16655990|NCT02242344|Experimental|telmisartan - high dose|
16655991|NCT02242344|Placebo Comparator|Placebo|
16655992|NCT02242331||essential hypertension patients|
16655993|NCT02242318|Experimental|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
16655994|NCT02242318|Active Comparator|Valsartan|low dose for two weeks, then up titration to high dose, once daily
16655995|NCT02242318|Placebo Comparator|Placebo|
16655996|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
16655997|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
16655998|NCT02242292|Experimental|Hyoscine butylbromide|"5 tablets taken in a 24-hour period/each episode:
~for up to 7 episodes, or
~over a period of up to 6 weeks"
16655999|NCT02242292|Placebo Comparator|Placebo|
16656000|NCT02242279|Experimental|BEA 2180 - low dose|
16656001|NCT02242279|Experimental|BEA 2180 - medium dose|
16656002|NCT02242279|Experimental|BEA 2180 - high dose|
16656003|NCT02242279|Active Comparator|Tiotropium|
16656004|NCT02242279|Placebo Comparator|Placebo|
16656005|NCT02242266|Experimental|Tiotropium low dose|oral inhalation via the blue HandiHaler®
16656006|NCT02242266|Experimental|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
16656007|NCT02242266|Active Comparator|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
16656008|NCT02242266|Placebo Comparator|Placebo|
16656009|NCT02242253|Experimental|Tiotropium+salmeterol QD|free combination of tiotropium and salmeterol
16656010|NCT02242253|Active Comparator|Tiotropium+salmeterol BID|free combination of tiotropium and salmeterol
16656011|NCT02242253|Active Comparator|Tiotropium QD|
16656012|NCT02242253|Active Comparator|Salmeterol BID|
16656013|NCT02242240|Experimental|Tiotropium with single dose of formoterol|
16656014|NCT02242240|Experimental|Tiotropium with double dose of formoterol|
16656015|NCT02242240|Experimental|Tiotropium with Placebo|
16656020|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
16656021|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
16656022|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
16656023|NCT02242188|Experimental|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.
~The intervention will last from 4 months to 9 months of age."
16656024|NCT02242188|Placebo Comparator|Placebo|"Maltodextrin prepared in sachets. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.
~The intervention will last from 4 months to 9 months of age."
16656025|NCT02242175|Other|normal group|
16656026|NCT02242175|Other|irritable bowel syndrome group|
16656027|NCT02242162||neuromuscular diseases|
16656028|NCT02242149|Placebo Comparator|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
16656029|NCT02242149|Experimental|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
16656030|NCT02242136|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1,5 and 2 hrs depending on the needs of the participant.
16656031|NCT02242136|No Intervention|Waiting list|
16656032|NCT02242123||Study group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of mild intestinal histology damage (grade 1-2) at first evaluation.
16656033|NCT02242123||Control group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of intestinal villous atrophy (intestinal histology damage grade 3) at first evaluation.
16656034|NCT02242110|Experimental|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
16656035|NCT02242097|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
16656036|NCT02242084|Experimental|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
16656037|NCT02242071|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
16656038|NCT02242058||High frequency pain group|39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
16656039|NCT02242058||Low Pain Frequency group|39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
16656040|NCT02242058||Healthy control group|39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
16656041|NCT02242058||Pain Crisis group|30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
16656042|NCT02242058||Pain Service group|10 patients without sickle cell disease admitted to the pain service.
16656043|NCT02242045|Experimental|Idelalisib|Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
16656044|NCT02242032|Experimental|P-321|P-321 Ophthalmic Solution
16656045|NCT02242032|Placebo Comparator|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
16656046|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
16656047|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
16656048|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
16656049|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
16656050|NCT02241993||Type 1 diabetic|
16656051|NCT02241980||Medicare Part D patients|Survey
16656052|NCT02241980||Physician Providers|Survey
16656053|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
16656054|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
16656055|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
16656056|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
16656057|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
16656058|NCT02241941|Experimental|Daptomycin|
16656064|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
16656065|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
16656066|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
16656067|NCT02241876|Placebo Comparator|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
16656068|NCT02241876|Experimental|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
16656069|NCT02241863|Experimental|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
16656070|NCT02241863|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
16656071|NCT02241850|Other|High intensity training|9 weeks of supervised training
16656072|NCT02241824|Active Comparator|Elastic abdominal binder|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an elastic abdominal binder.
16656073|NCT02241824|No Intervention|No brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen with no brace (control).
16656074|NCT02241824|Experimental|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
16656075|NCT02241811|Placebo Comparator|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
16656076|NCT02241811|Experimental|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
16656077|NCT02241798|Experimental|Pre-oxygenation first|"st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated
~nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
16656078|NCT02241798|Experimental|Standard practice first|"st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).
~nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
16656079|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
16656080|NCT02241772|Experimental|10mg TA-8995|10mg TA-8995 once daily
16656081|NCT02241772|Experimental|2.5mg TA-8995|2.5mg TA-8995 once daily
16656082|NCT02241772|Placebo Comparator|Placebo to TA-8995|Placebo to TA-8995 once daily.
16656083|NCT02241759|Experimental|TA-8995|Single oral dose of 150mg TA-8995
16656084|NCT02241759|Experimental|Placebo|Single oral dose of placebo to TA-8995
16656085|NCT02241759|Active Comparator|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
16656086|NCT02241746||malnutrition|
16656087|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
16656088|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
16656089|NCT02241720|Experimental|Regorafenib treatment|
16656090|NCT02241694||survey|
16656091|NCT02241681|Other|Peptamen 1.5|500 mL of Peptamen 1.5
16656092|NCT02241668|Experimental|FLT PET Scan + 3'-Deoxy-3'-18f-Fluorothymidine|After a magnetic resonance imaging (MRI) scan of brain performed, an FLT PET scan using 3'-Deoxy-3'-18f-Fluorothymidine solution performed. After solution is injected into a vein, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. The entire procedure should last about 60-70 minutes.
16656093|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
16656094|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
16656095|NCT02241642|Experimental|Treatment|VIVASURE CLOSURE DEVICE™
16656096|NCT02241629|Experimental|levo phencynonate hydrochloride 1mg|levo phencynonate hydrochloride tablet 1mg
16656097|NCT02241629|Placebo Comparator|placebo|Placebo
16656098|NCT02241629|Experimental|levo phencynonate hydrochloride 2mg|levo phencynonate hydrochloride 2mg
16656099|NCT02241616|Experimental|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
16656100|NCT02241603|Experimental|Weight loss|Obese Veterans will aim to lose 5-10% body weight
16656101|NCT02241603|No Intervention|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
16656102|NCT02241590|Placebo Comparator|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
16656103|NCT02241590|Experimental|Entecavir + Fuzheng Huayu Tablet|Tablet with Entrcavir+ Tablet with Fuzheng Huayu
16656104|NCT02241577|Experimental|Surgical treatment|Surgical access for scaling and disinfection of dental implant
16656105|NCT02241577|Experimental|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of dental implant
16656106|NCT02241564||Malignancy post transplantation|
16656107|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
16656108|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
16656210|NCT02240875|Experimental|Group 1c|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
16656109|NCT02241538|Experimental|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
16656110|NCT02241538|Experimental|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
16656111|NCT02241538|Experimental|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
16656112|NCT02241538|Active Comparator|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group will not receive additional exercise.
16656113|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
16656114|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
16656115|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
16656116|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
16656117|NCT02241499|Experimental|Radiotherapy and chemotherapy (oxaliplatin and fluorouracil).|Radiotherapy (5 x 4 Gy) will be given. After completion of radiotherapy, 4 cycles of chemotherapy will be administered, cycle length 14 days. Each patient will receive oxaliplatin as infusion at a dose of 85 mg/m2, followed by a bolus injection of fluorouracil at a dose of 400 mg/m2, and a long time infusion (44 hours) of fluorouracil at a dose of 2 400 mg/m2.
16656118|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
16656119|NCT02241473|Experimental|CH training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion.
16656120|NCT02241473|Active Comparator|CN training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) condition in a single-blind fashion.
16656121|NCT02241460|Active Comparator|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
16656122|NCT02241460|Placebo Comparator|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
16656123|NCT02241447||Observation|the nurse identifies cases with severe AS and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
16656124|NCT02241447||Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
16656125|NCT02241434|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
16656126|NCT02241421|Placebo Comparator|Placebo|No intervention: Placebo 3x2 capsules per day during 7 consecutive days.
16656127|NCT02241421|Experimental|Treatment Antibiotics: Amoxicillin|Experimental: Amoxicillin (broad spectrum antibiotics) 1500 mg/day (3x2 capsules of 250 mg) during 7 consecutive days.
16656128|NCT02241421|Experimental|Treatment Antibiotics: Vancomycin|Experimental: Vancomycin (small spectrum antibiotics) 1500mg/day (3x2 capsules of 250 mg) during 7 consecutive days
16656129|NCT02241395|Experimental|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
16656130|NCT02241382|Active Comparator|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a > 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
16656131|NCT02241382|Experimental|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
16656132|NCT02241369|Experimental|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
16656133|NCT02241369|Experimental|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
16656134|NCT02241356|Active Comparator|single vision glasses|single vision glasses
16656135|NCT02241356|Experimental|bifocals|bifocal glasses
16656136|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
16656137|NCT02241330|Placebo Comparator|Control|Control wheat used for meal, level of zinc is usual
16656138|NCT02241330|Active Comparator|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
16656139|NCT02241330|Active Comparator|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
16656140|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
16656141|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
16656142|NCT02241278|Placebo Comparator|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
16656352|NCT02239978||Control|Age-matched healthy adults
16656143|NCT02241278|Experimental|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
16656144|NCT02241265||Past Bronchial Thermoplasty data|Data will be collected from records of patients who, in the past, have undergone bronchial thermoplasty.
16656145|NCT02241252|Other|iPhone ECG QT recording|iPhone ECG
16656146|NCT02241239||participants|healthy adults without stroke and coronary heart disease
16656147|NCT02241226|Experimental|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
16656148|NCT02241226|No Intervention|Resort group|Resort group at the La Costa resort
16656149|NCT02241213|Active Comparator|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (> 1 Hz), low frequency (<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency <1 Hz with repetitive pulses.
16656150|NCT02241213|Placebo Comparator|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
16656151|NCT02241200|Experimental|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
16656152|NCT02241200|Experimental|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
16656153|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
16656154|NCT02241174|Experimental|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
16656155|NCT02241174|Placebo Comparator|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
16656156|NCT02241161|Active Comparator|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
16656157|NCT02241161|Active Comparator|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
16656158|NCT02241161|Active Comparator|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
16656159|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream +rejuvenating serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
16656160|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream + antioxidant serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
16656161|NCT02241148|Active Comparator|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
16656162|NCT02241148|Experimental|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
16656163|NCT02241135|Experimental|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
16656164|NCT02241135|Experimental|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
16656165|NCT02241135|Experimental|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
16656166|NCT02241135|Experimental|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
16656167|NCT02241135|Experimental|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
16656168|NCT02241135|Experimental|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
16656169|NCT02241135|Experimental|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
16656170|NCT02241135|Experimental|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
16656171|NCT02241122|Experimental|MRI guided prostate biopsy|prostate biopsy after MR-imaging
16656172|NCT02241109|Other|All patients|Compare patients with high calcification propensity do have faster valve-stenosis progression
16656173|NCT02241096|Experimental|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
16656174|NCT02241083|Active Comparator|dopamine group|vasopressor dosage individually titred according to the mean arterial pressure
16656175|NCT02241083|Active Comparator|norepinephrine group|vasopressor dosage individually titred according to the mean arterial pressure
16656176|NCT02241083|Active Comparator|control group|no medication
16656177|NCT02241070|Experimental|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
16656178|NCT02241070|No Intervention|waiting-list control|passive control group
16656179|NCT02241057|Experimental|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
16656180|NCT02241057|Experimental|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
16656181|NCT02241044|Active Comparator|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
16656182|NCT02241044|Placebo Comparator|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
16656183|NCT02241031|Experimental|MPs|MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
16656184|NCT02241031|Active Comparator|Non-MPs|Patients can receive platelet infusion but can not receive platelet stimulating factors.
16656185|NCT02241018|Experimental|Mesenchymal stem cells|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.
16656186|NCT02241018|Experimental|CD25 Mc Ab & calcineurin inhibitors|CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given.
16656187|NCT02241005|Active Comparator|Theraworx™|Participants are randomized to use the Theraworx™ bath wipes.
16656188|NCT02241005|Active Comparator|Standard|Participants are randomized to use standard bath wipes.
16656189|NCT02240992|Experimental|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
16656190|NCT02240992|Experimental|MSCs|MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
16656191|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
16656192|NCT02240953|Active Comparator|Warfarin|In the first arm only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
16656193|NCT02240953|Active Comparator|Warfarin + ASA 100 mg + PPI|In the second arm 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
16656194|NCT02240953|Active Comparator|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
16656195|NCT02240953|Active Comparator|Observational Warfarin|This arm is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
16656196|NCT02240940|Experimental|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
16656197|NCT02240927|Active Comparator|Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
16656198|NCT02240927|Active Comparator|Enoxaparine and 2.5 mg warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1.0). Full dose warfarin is continued after first trimester and dose is regulated according to INR (between 2.5-4)
16656199|NCT02240927|Active Comparator|Enoxaparine and 4 mg warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
16656200|NCT02240927|Active Comparator|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
16656201|NCT02240914||Vascular USG and IVUS imaging diagnosis|
16656202|NCT02240901|Experimental|Laryngeal mask airway|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
16656203|NCT02240901|Experimental|Endotracheal intubation group（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
16656204|NCT02240888|Active Comparator|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
16656205|NCT02240888|Active Comparator|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
16656206|NCT02240888|Active Comparator|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
16656207|NCT02240888|Active Comparator|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
16656208|NCT02240875|Experimental|Group 1|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly
16656209|NCT02240875|Experimental|Group 1b|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
16658793|NCT02222961|Experimental|BIIR 561 CL|
16656211|NCT02240875|Experimental|Group 2|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly
16656212|NCT02240875|Experimental|Group 2b|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
16656213|NCT02240875|Experimental|Group 2c|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
16656214|NCT02240875|Experimental|Group 3|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly
16656215|NCT02240875|Experimental|Group 3b|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
16656216|NCT02240875|Experimental|Group 3c|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
16656217|NCT02240875|Experimental|Group 4|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 7
16656218|NCT02240875|Experimental|Group 5|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 14
16656219|NCT02240875|Experimental|Group 6|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 7
16656220|NCT02240875|Experimental|Group 7|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 14
16656221|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
16656222|NCT02240849|Experimental|Functional pillow|cervical pillow, designed functionally to decrease neck pain and help to ensure the right support of the cervical curve, was applied to patients' posterior neck area.
16656223|NCT02240849|Placebo Comparator|General pillow|Applicants Randomly allocated to this group were issued by placebo-general pillow. There is not any specific intervention for their neck discomfort except for that.
16656224|NCT02240836|Experimental|Intervention. Exercise|The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
16656225|NCT02240836|No Intervention|Control group|Control group, standard treatment regimen
16656226|NCT02240823|Experimental|adipose derived stem cells|
16656227|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
16656228|NCT02240797||Anorexia Nervosa - Recovered (AN-REC)|Anorexia Nervosa - Recovered (AN-REC)
16656229|NCT02240797||Healthy Control (HC)|Healthy Control (HC)
16656230|NCT02240784||Acute Hepatic Porphyria|
16656231|NCT02240771|Active Comparator|Transarterial chemotherapy|Doxorubicin 50mg, Cisplatin 100mg
16656232|NCT02240771|Placebo Comparator|Oral chemotherapy|Thalidomide---50-300mg once a day Capecitabine---- 500-1500mg once a day
16656233|NCT02240758|Experimental|surgical removal of the tumors+stereotaxic biopsy|
16656234|NCT02240745||All patients|Patients with a suspicion of coronary heart disease
16656235|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.
~Observational with imaging."
16656236|NCT02240719|Experimental|Everolimus + Bendamustine|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16656237|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
16656238|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
16656239|NCT02240693|Experimental|BI 409306 dose 1|
16656240|NCT02240693|Experimental|BI 409306 dose 2|
16656241|NCT02240693|Experimental|BI 409306 dose 3|
16656242|NCT02240693|Experimental|BI 409306 dose 4|
16656243|NCT02240693|Placebo Comparator|Placebo|
16656244|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
16656245|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
16656246|NCT02240667||Subjects with atrial fibrillation|
16656247|NCT02240654||Dabigatran etexilate|
16656248|NCT02240641||hypertension treatment strategies|
16656249|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
16656250|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
16656251|NCT02240615|Experimental|Sinopsys Lacrimal Stent|All enrolled patients will receive a Sinopsys Lacrimal Stent inserted from the caruncle to the ethmoid sinus. Discharge instructions will include administration of sterile saline and ophthalmic drops as well as assessments for device patency.
16656252|NCT02240602|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
16656253|NCT02240602|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
16656254|NCT02240602|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
16656255|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
16656256|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
16656353|NCT02239965||Anaesthesia personnel|Anaesthesiologists and nurse anaesthetists
16656354|NCT02239952|Experimental|sunitinib|
16656257|NCT02240563|Experimental|Low-level laser therapy|This group of patients was treated with a continuous wave diode laser device (830 nanometer, infrared) with a beam area of 0.002827 cm2 using the punctual method on the continuous emission mode at an output power of 50 milliwatts and a fluence of 707 Joules/cm2 six years before.
16656258|NCT02240563|Placebo Comparator|Non laser ordinary red light|This group of patients was treated using the same method and equipment, except that a non laser ordinary red light, an output power of 0.1 Watt and a fluence of 1.41 Joules/cm2 and an irradiance value of 0.0002827 Watts/cm2 (the placebo), indistinguishable from the laser beam, was used. Therefore, the patients were blinded to which treatment they received.
16656259|NCT02240550|Active Comparator|ProFlor Hernia Repair System|A 3-D hernia mesh
16656260|NCT02240550|Active Comparator|Lichtenstein Hernia Repair|Using flat polypropylene mesh
16656261|NCT02240537|Experimental|Open Label Treatment Arm|BB-MPI-03 peptides plus montanide plus sargramostim
16656262|NCT02240524|Experimental|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.
~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.
~Systemic chemotherapy (XELOX):
~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
16656263|NCT02240524|Placebo Comparator|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.
~Systemic chemotherapy (XELOX):
~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
16656264|NCT02240511|Active Comparator|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
16656265|NCT02240511|Experimental|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator
~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
16656266|NCT02240498|Experimental|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
16656267|NCT02240498|Experimental|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 10 minutes.
16656268|NCT02240498|Experimental|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 15 minutes.
16656269|NCT02240498|Experimental|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 20 minutes.
16656270|NCT02240498|Experimental|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 25 minutes.
16656271|NCT02240498|Experimental|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 30 minutes.
16656272|NCT02240485|Experimental|Behavioral Couple Therapy|"Already described in the Intervention Description section"
16656273|NCT02240485|Active Comparator|Usual individual/group treatment|Well described in the Intervention section
16656274|NCT02240472|No Intervention|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
16656275|NCT02240472|Experimental|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
16656276|NCT02240459|Experimental|Fesoterodine 4mg daily|fesoterodine 4mg oral
16656277|NCT02240459|Experimental|Fesoterodine 8mg|Fesoterodine 8mg in form of 2, 4mg tablets
16656278|NCT02240459|Active Comparator|oxybutynin|oxybutynin immediate release, encapsulated 2, 5mg capsules daily
16656279|NCT02240459|Placebo Comparator|placebo capsule|placebo capsule, 2 per day
16656280|NCT02240446|Experimental|Active tDCS|Active tDCS
16656281|NCT02240446|Placebo Comparator|Sham tDCS|Sham tDCS
16656282|NCT02240433|Experimental|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
16656283|NCT02240420|Active Comparator|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
16656284|NCT02240420|No Intervention|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
16656285|NCT02240407|Experimental|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
16656355|NCT02239952|Experimental|vandetanib|
16656356|NCT02239952|Experimental|Erlotinib|
16656286|NCT02240407|Sham Comparator|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
16656287|NCT02240381|Experimental|Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)|Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
16656288|NCT02240368||Group 1|Children age between 1 month to 12 months
16656289|NCT02240368||Group 2|Children age between 13 months and 36 months
16656290|NCT02240368||Group 3|Children age between 37 months to 144 months
16656291|NCT02240355|Experimental|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
16656292|NCT02240355|Experimental|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
16656293|NCT02240355|Experimental|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
16656294|NCT02240342|Experimental|Poor ovarian reserve women|
16656295|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
16656296|NCT02240316||Follicular NHL Cohort|
16656297|NCT02240316||DLBCL Cohort|
16656298|NCT02240303||Chronic Pain Group|Participants that experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
16656299|NCT02240303||No Chronic Pain Group|Participants that do not experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
16656300|NCT02240290|Experimental|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
16656301|NCT02240264|Active Comparator|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.
~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
16656302|NCT02240264|Placebo Comparator|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
16656303|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
16656304|NCT02240238|Experimental|NC-6004 and Gemcitabine|
16656305|NCT02240212|Experimental|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
16656306|NCT02240212|Experimental|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
16656307|NCT02240212|Experimental|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
16656308|NCT02240199|Experimental|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
16656309|NCT02240199|Active Comparator|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
16656310|NCT02240199|Active Comparator|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
16656311|NCT02240199|Placebo Comparator|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
16656312|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
16656313|NCT02240173|Experimental|Jobelyn + Haloperidol|Combination of the conventional drugs and Jobelyn
16656314|NCT02240173|Active Comparator|Haloperidol + Placebo|Combination of the conventional drug + Placebo
16656612|NCT02238184||Chronic Obstructive Pulmonary Disease|patients receiving Atrovent®
16656613|NCT02238184||Cronic Obstructive Pulmonary Disease|patients receiving Ventilat®
16656315|NCT02240160|Experimental|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
16656316|NCT02240160|Experimental|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
16656317|NCT02240160|Experimental|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
16656318|NCT02240147|Experimental|home-based exercise training|
16656319|NCT02240147|No Intervention|Control group|
16656320|NCT02240134|Experimental|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
16656321|NCT02240134|Active Comparator|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
16656322|NCT02240134|Sham Comparator|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
16656323|NCT02240121|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
16656324|NCT02240121|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
16656325|NCT02240108|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
16656326|NCT02240108|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
16656327|NCT02240095|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, students will be offered all 3 online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
16656328|NCT02240095|Experimental|Interventions A + B|"See Interventions Description. In this arm, students will be offered the 2 following interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach"
16656329|NCT02240095|Experimental|Interventions A + C|"In this arm, students will be offered the 2 following online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention C - Online Audit and Feedback"
16656330|NCT02240095|Experimental|Interventions B + C|"See Interventions Description. In this arm, students will be offered the 2 following online interventions combined:
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
16656331|NCT02240095|Experimental|Intervention A alone|"See Interventions Description. In this arm, students will be offered only the following intervention:
~* Intervention A - Online Clinical Questions Recorder"
16656332|NCT02240095|Experimental|Intervention B alone|"See Interventions Description. In this arm, students will be offered only the following intervention:
~* Intervention B - Online Evidence Retrieval Coach"
16656333|NCT02240095|Experimental|Intervention C alone|"See Interventions Description. In this arm, students will be offered only the following intervention:
~* Intervention C - Online Audit and Feedback"
16656334|NCT02240095|No Intervention|No intervention|In this arm, students will be offered none of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
16656335|NCT02240082|Experimental|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
16656336|NCT02240082|No Intervention|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
16656337|NCT02240069|Experimental|Education (Tx1)|Education on best burn practices
16656338|NCT02240069|Active Comparator|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
16656339|NCT02240069|Sham Comparator|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
16656340|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
16656341|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
16656342|NCT02240056||healthy subjects|healthy postmenopausal women without coronary artery disease
16656343|NCT02240043|Other|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
16656344|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
16656345|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
16656346|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
16656347|NCT02240017|Active Comparator|Carboplatin/Gemcitabine|
16656348|NCT02240017|Experimental|Fractionated Cisplatin/Gemcitabine|
16656349|NCT02239991|No Intervention|Historical control|Group of patients that had their coagulopathy secondary to the liver transplant treated based on conventional laboratory tests. Before the implementation of thromboelastometry.
16656350|NCT02239991|Experimental|Intervention|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
16656351|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
16656357|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
16656358|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
16656359|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
16656360|NCT02239926|Placebo Comparator|Placebo|Placebo
16656361|NCT02239913|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16656362|NCT02239913|Experimental|Topiramate Dose 1|Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16656363|NCT02239913|Experimental|Topiramate Dose 2|Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16656364|NCT02239900|Experimental|Group 1 Liver: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 1: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
16656365|NCT02239900|Experimental|Group 2 Liver: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 2: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
16656366|NCT02239900|Experimental|Group 3 Lung: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
16656367|NCT02239900|Experimental|Group 4 Lung: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 29 - 33 of each 21 day cycle.
16656368|NCT02239900|Experimental|Group 5 Liver/Lung Metastasis: (late) Ipilimumab and SBRT|Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
16656369|NCT02239900|Experimental|Thyroid Expansion Cohort|"Participants enrolled in this arm treated to a total dose of 50 Gy in 4 fractions, 60 Gy in 10 fractions, or 20 Gy in 5 fractions with stereotactic radiotherapy to a liver or lung lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.
~Participants receive Ipilimumab every 21 days for a total of 4 doses."
16656370|NCT02239887||WaveCrest LAA occlusion device|Left Atrial Occlusion
16656371|NCT02239874|Placebo Comparator|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
16656372|NCT02239874|Active Comparator|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
16656373|NCT02239874|Active Comparator|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
16656374|NCT02239874|Active Comparator|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
16656376|NCT02239835|Experimental|TPV low dose + RTV low dose|
16656377|NCT02239835|Experimental|TPV high dose + RTV low dose|
16656378|NCT02239835|Active Comparator|SQV + RTV high dose|
16656379|NCT02239822|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
16656380|NCT02239822|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
16656381|NCT02239809|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
16656382|NCT02239809|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
16656383|NCT02239796|Experimental|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.
~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
16656614|NCT02238171||Chronic Obstructive Pulmonary Disease|
16656384|NCT02239796|Sham Comparator|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.
~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.
~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
16656385|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
16656386|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
16656387|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
16656388|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
16656389|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
16656390|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
16656391|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
16656392|NCT02239757|Experimental|Right radial approach|Primary PCI performed through right radial approach.
16656393|NCT02239757|Experimental|Left radial approach|Primary PCI performed through left radial approach.
16656394|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
16656395|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
16656396|NCT02239731|Experimental|FDX104 (4% Doxycycline)|Active ingredient: Doxycycline Concentration: 4% Route: Topical Dosage schedule: Twice daily, morning and evening. Prophylactic treatment to prevent the rash associated with EGFRI treatment. patients will apply a thin layer of the drug twice daily for five weeks to one half of face
16656397|NCT02239731|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Twice daily, morning and evening. Patients will apply a thin layer of the placebo twice daily for five weeks to the opposite half of the face of which they received active treatment.
16656398|NCT02239718|Experimental|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
16656399|NCT02239718|Active Comparator|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
16656400|NCT02239705||Fluid challenge|Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output
16656401|NCT02239705||Inotropic infusion|Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output
16656402|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
16656403|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
16656404|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
16656405|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
16656406|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
16656407|NCT02239666||Moderate to Severe Plaque Psoriasis|Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
16656408|NCT02239653|Experimental|Physician communication|"The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption."
16656409|NCT02239653|No Intervention|Usual care|
16656410|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
16656411|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
16656412|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
16656413|NCT02239614|Experimental|Group 1: LAV (T=0), PIV (T=28)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.
~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study."
16656414|NCT02239614|Experimental|Group 2: PIV (T=0), LAV (T=28)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.
~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study."
16656415|NCT02239614|Experimental|Group 3: LAV (T=0), PIV (T=180)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.
~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study."
16656615|NCT02238158||Chronic Obstructive Pulmonary Disease|
16656416|NCT02239614|Experimental|Group 4: PIV (T=0), LAV (T=180)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.
~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study."
16656417|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
16656418|NCT02239588|Experimental|Pure Canterbury milk powder|Oral consumption of infant formula (0-6 months) milk powder
16656419|NCT02239588|Active Comparator|Other infant formula milk powder|"Oral consumption of milk powder (other than the experimental product) selected by subjects' parents. The products including:
~Yashili Ambery Infant Formula Milk Powder (Stage 1: 0-6 months)
~Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)
~Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)
~Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)
~Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)
~Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
16656420|NCT02239588|Placebo Comparator|Breast milk|Oral consumption of breast milk
16656421|NCT02239562|Experimental|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
16656422|NCT02239562|Experimental|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
16656423|NCT02239562|Experimental|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
16656424|NCT02239562|Experimental|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
16656425|NCT02239562|Experimental|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
16656426|NCT02239562|Experimental|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
16656427|NCT02239549|Experimental|Jumbo cold forceps polypectomy group|Polypectomy conducted with jumbo cold forceps
16656428|NCT02239549|Experimental|Cold snare polypectomy group|Polypectomy conducted with cold snare
16656429|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
16656430|NCT02239536|Experimental|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
16656431|NCT02239523|Active Comparator|Letter Group|Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.
16656432|NCT02239523|Experimental|Intervention Group|Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.
16656433|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
16656434|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
16656435|NCT02239497|Experimental|femoral block by US and NE and intravenous analgesia|preincisional femoral block by ultrasound and neurostimulation, with 20 ml bupivacaine 0,5% and epinephrine. ketoprofen, dipyrone and dexamethasone IV. Morphine IV to rescue analgesia
16656436|NCT02239497|Experimental|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and morphine. IV morphine to rescue analgesia
16656437|NCT02239484|Experimental|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
16656438|NCT02239484|Experimental|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
16656439|NCT02239484|Experimental|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
16656440|NCT02239458|Placebo Comparator|Placebo|Placebo intake during 3 months
16656441|NCT02239458|Active Comparator|Saxagliptin 5mg|Saxagliptin dose of 5mg for 3 months
16656442|NCT02239445|Active Comparator|chloral hydrate group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
16656443|NCT02239445|Experimental|low dose dexmedetomidine Group|"Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
16656444|NCT02239445|Experimental|high dose dexmedetomidine group|"Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
16656445|NCT02239432||Suspected Adenocarcinoma of the Lung|Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
16656446|NCT02239432||Healthy Control|Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
16656447|NCT02239432||Age-matched controls with proven solid lung malignancy|Patients with biopsy-proven advanced solid malignancy of the lung
16656448|NCT02239419|Experimental|CO2-Enriched Tap Water (Carbothera)|CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C. Tap water will be enriched with CO2 by the investigational Carbothera device.
16656449|NCT02239419|Placebo Comparator|Non-CO2-Enriched Tap Water|Non-CO2-enriched tap water (i.e. normal tap water) maintained at a temperature of 37˚C.
16656450|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
16656451|NCT02239393|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
16656452|NCT02239393|Experimental|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
16656453|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
16656454|NCT02239367|Experimental|Depression Decision Aid protocol|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
16656455|NCT02239354|Experimental|Cohort 1|2 VC-01™ Combination Product implants
16656456|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01™ Combination Product implants
16656457|NCT02239341|Active Comparator|Music Intervention (M)|The M intervention will be 30 minutes (same amount of time as E group), but the participants will simply be listening to the same music in bed with no exercise component. They will be wearing the heart rate monitor as in the E group. The M group will act as a control group for the E group.
16656458|NCT02239341|Experimental|Muscle Conditioning Intervention (E)|E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.
16656459|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
16656460|NCT02239315|Experimental|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
16656461|NCT02239289|Experimental|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
16656462|NCT02239263|Experimental|N6 Input Processing Features|
16656463|NCT02239250|Experimental|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
16656464|NCT02239250|No Intervention|Control|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
16656465|NCT02239237||Compound Kuh-seng Injection|Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
16656466|NCT02239224|Experimental|Cohort 1: ATYR1940 0.3 mg/kg|Participants will receive ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion once weekly for 4 weeks.
16656467|NCT02239224|Experimental|Cohort 2: ATYR1940 1.0 mg/kg|Participants will receive ATYR1940 1.0 mg/kg IV infusion once weekly for 4 weeks.
16656468|NCT02239224|Experimental|Cohort 3: ATYR1940 3.0 mg/kg|Participants will receive ATYR1940 3.0 mg/kg IV infusion once weekly for 12 weeks.
16656469|NCT02239224|Placebo Comparator|Placebo|Participants will receive placebo matched to ATYR1940 IV infusion once weekly for 4 weeks in Cohorts 1 and 2 and for 12 weeks in Cohort 3.
16656470|NCT02239211|Experimental|BTT1023|BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
16656471|NCT02239198|Experimental|C|Nutrition bar without omega-3 fatty acids
16656472|NCT02239198|Experimental|B|Nutrition bar without added minerals and vitamins
16656473|NCT02239198|Active Comparator|A|Complete nutrition bar
16656474|NCT02239185|Other|Hernial sac ligation in continuity|laparoscopic closure of hernia sac in continuity using 3 - 0 non-absorbable purse-string suture. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying.
16656475|NCT02239185|Other|Hernial sac disconnection|circumferential incision on the peritoneum at internal inguinal ring (IIR) with separation of hernia sac from the peritoneum. The proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
16656476|NCT02239172|Experimental|12.5 µg + Alhydrogel|vaccine
16656477|NCT02239172|Experimental|25 µg + Alhydrogel|vaccine
16656478|NCT02239172|Experimental|50 µg + Alhydrogel|vaccine
16656479|NCT02239172|Experimental|100 µg + Alhydrogel|vaccine
16656480|NCT02239159|No Intervention|Control|Electrodes will be attached, but stimulation will not be given
16656481|NCT02239159|Sham Comparator|Non-acupoint TES|TES is for transcutaneous electric stimulation.Stimulation will be given through electrodes attached to non-acupoints
16656482|NCT02239159|Experimental|Acupoint TES|Transcutaneous stimulation will be given through acupoints
16656483|NCT02239146|Experimental|rFXIII|
16656484|NCT02239146|Placebo Comparator|Placebo|
16656485|NCT02239133|Experimental|ProVATE vaginal pessary|"The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse (POP). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only."
16656486|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
16656487|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
16656488|NCT02239107|Experimental|N-Acetyl cysteine|Laparoscopic ovarian drilling followed by NAC 1200mg daily in two divided doses for five days starting cycle day 2 for 6 month
16656489|NCT02239107|Active Comparator|laparoscopic drilling group|laparoscopic drilling only will be done
16656490|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
16656491|NCT02239081|Experimental|CTP-730, 5 mg|oral suspension, once daily.
16656492|NCT02239081|Experimental|CTP-730, 10 mg|Oral Suspension, once daily.
16656493|NCT02239081|Experimental|CTP-730, 20 mg|Oral Suspension, once daily.
16656494|NCT02239081|Experimental|CTP-730, 30 mg|Oral Suspension, once daily.
16656495|NCT02239081|Experimental|CTP-730, 40 mg|Oral Suspension, once daily.
16656496|NCT02239081|Experimental|CTP-730, 50 mg|Oral Suspension, once daily.
16656497|NCT02239081|Experimental|CTP-730, 60 mg|Oral Suspension, once daily.
16656498|NCT02239055||Focus Group 1|Staff Perceptions
16656499|NCT02239055||Focus Group 2|Staff Perceptions
16656500|NCT02239042|Sham Comparator|Low-level laser therapy (LLLT) Sham|LLLT Sham on the palatal donor site of connective tissue graft
16656501|NCT02239042|Experimental|Low-level laser therapy (LLLT)|LLLT on the palatal donor site of connective tissue graft
16656502|NCT02239029|Active Comparator|Platelet rich plasma|"Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side."
16656503|NCT02239029|Placebo Comparator|normal saline|Normal saline was injected into the other side of knee as the control group.
16656504|NCT02239003|Experimental|DAOIB|250-1500 mg/day, oral, for 24 weeks
16656505|NCT02239003|Placebo Comparator|Placebo|placebo, oral, for 24 weeks
16656506|NCT02238977|Active Comparator|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
16656507|NCT02238977|Experimental|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
16656508|NCT02238964|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
16656509|NCT02238964|Active Comparator|Standard closure|"Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures.
~Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon."
16656510|NCT02238951|Experimental|Mobile Health (mHealth)|Care coordination using mHealth technology enhancements
16656511|NCT02238951|Active Comparator|No mHealth|Care coordination without mHealth enhancements
16656512|NCT02238938|Experimental|en-bloc resection|En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
16656513|NCT02238938|Active Comparator|piecemeal resection|"Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.
~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy."
16656514|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):
~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.
~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.
~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
16656515|NCT02238912|Experimental|Kandhaga Rasayanam- single arm|Kandhaga Rasayanam- 2grams twice a day for 45 days
16656516|NCT02238886|Experimental|Parenteral nutrition|Patients receives a goal-directed nutritional intervention combining oral intake and parenteral nutrition
16656517|NCT02238886|No Intervention|Standard treatment|patients receives a standard nutritional strategy of resting the bowel till clear signs of bowel recovery and feeding orally after bowel recovery
16656518|NCT02238873|Active Comparator|Pegfilgrastim +1|Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
16656519|NCT02238873|Experimental|Pegfilgrastim +3|Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
16656520|NCT02238860|Active Comparator|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
16656521|NCT02238860|Active Comparator|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
16656522|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)
~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
16656523|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).
~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
16656524|NCT02238834|Experimental|SAD Cohorts 1-8 Experimental Arm|
16656525|NCT02238834|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
16656616|NCT02238145||Chronic Obstructive Airways Disease|
16656526|NCT02238834|Experimental|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
16656527|NCT02238834|Placebo Comparator|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
16656528|NCT02238821||resectable colorectal cancer|
16656529|NCT02238808|Experimental|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
16656530|NCT02238795||Purpura fulminans|Patients diagnosed with Purpura fulminans in association with sepsis
16656531|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
16656532|NCT02238769||Hepatocellular Carcinoma|18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue
16656533|NCT02238756|Experimental|CV8102|
16656534|NCT02238756|Active Comparator|Rabipur|
16656535|NCT02238756|Experimental|CV8102 + Rabipur|
16656536|NCT02238730|Active Comparator|Ultrabrief Right Unilateral|Ultrabrief (0.25 ms) Right Unilateral Electroconvulsive Therapy
16656537|NCT02238730|Active Comparator|Brief Pulse Bitemporal|Brief Pulse (0.5 ms) Bitemporal Electroconvulsive Therapy
16656538|NCT02238717|Experimental|PF-06372865 (65mg)|
16656539|NCT02238717|Experimental|PF-06372865 (15mg)|
16656540|NCT02238717|Active Comparator|Pregabalin|
16656541|NCT02238717|Placebo Comparator|Placebo|
16656542|NCT02238704|Experimental|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
16656543|NCT02238704|Active Comparator|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
16656544|NCT02238691|Experimental|Mask ventilation with PEEP|15 subjects will undergo anesthetic induction with application of PEEP of 10 cm H2O during mask ventilation.
16656545|NCT02238691|No Intervention|Mask ventilation without PEEP|15 subjects will undergo anesthetic induction without PEEP during mask ventilation.
16656546|NCT02238678||Deep endometriosis patients|
16656547|NCT02238665||Ulcerative colitis|
16656548|NCT02238665||Crohn's disease|
16656549|NCT02238652|No Intervention|Control|
16656550|NCT02238652|Active Comparator|Intervention|Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety
16656551|NCT02238639|Experimental|Active search for pulmonary embolism|All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.
16656552|NCT02238639|No Intervention|Standard management|All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.
16656553|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
16656554|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
16656555|NCT02238613|Experimental|radioactive stent|The radioactive stent carrying seeds iodine 125 is made of Polytetrafluoroethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the irradiation group patients.
16656556|NCT02238613|Other|plastic stent|The plastic stent is made of polyethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the conventional group patients.
16656557|NCT02238587|Placebo Comparator|Placebo/Ganoderma|In control group, oral placebos for 6 weeks. Then the patients in control groups are switched, Ganoderma Spores Powder Capsules are given for 6 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
16656558|NCT02238587|Experimental|Ganoderma|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
16656559|NCT02238574|Experimental|follow up & surgery|CIN positive with surgery and intensified follow up
16656560|NCT02238574|Active Comparator|follow up|CIN positive, only intensified outpatient follow up
16656561|NCT02238561||Elective major abdominal surgery|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth Hospitals National Health Service (NHS) Trust (PHNT)
16656562|NCT02238548|Placebo Comparator|Control group|Regular cholera vaccination
16656563|NCT02238548|Experimental|Milk bolus|Cholera vaccination - raw milk - bolus
16656564|NCT02238548|Experimental|Milk controlled|Cholera vaccination - raw milk - controlled intake
16656565|NCT02238535|Active Comparator|Ventavis + Warfarin|Patients in this group will receive drug treatment - ventavis (2,0 ml - 6 time per day - during 5 days). Warfarin - INR=2,0-3,0
16656566|NCT02238535|Active Comparator|Warfarin|Patients in this group will receive drug treatment according to up-to-date guidelines (Warfarin - INR=2,0-3,0)
16656567|NCT02238522|Experimental|Dose Escalation Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
16656568|NCT02238522|Experimental|Dose Expansion Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
16656569|NCT02238509|Experimental|lapatinib and trastuzumab|ARM A: Lapatinib and trastuzumab (experimental arm). Patients with hormone receptor (HR) positive breast cancer will also receive endocrine therapy at the physician's discretion (preferred choice with fulvestrant).
16656570|NCT02238509|Experimental|trastuzumab plus chemotherapy|ARM B: Trastuzumab plus chemotherapy (control arm). Any type of chemotherapy in combination with trastuzumab will be allowed at the physician's discretion.
16656617|NCT02238132||Chronic Obstructive Airways Disease|
16656618|NCT02238119|Experimental|tiotropium + formoterol|
16656571|NCT02238496|Other|Surgical Cohort - cytoreductive surgery|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
16656572|NCT02238496|Other|Medical Cohort - no cytoreductive surgery|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
16656573|NCT02238483|Experimental|AZD7624|Active treatment
16656574|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
16656575|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
16656576|NCT02238457|Active Comparator|Low dose losartan|Low dose losartan
16656577|NCT02238457|Active Comparator|High dose losartan|High dose losartan
16656578|NCT02238444|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
16656579|NCT02238444|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
16656580|NCT02238431|Experimental|Lucrin depot, artificial cycle start|intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval
16656581|NCT02238431|Active Comparator|OCP active, artificial cycle start|to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days
16656582|NCT02238431|Experimental|Natural, menstrual period|to wait for the second bleed to commence the artificial FET cycle
16656583|NCT02238418|Experimental|Usual vitamin D supplementation|
16656584|NCT02238405|Experimental|Counseling|Intensive anti-smoking counseling
16656585|NCT02238405|No Intervention|Standard Care|Control group will receive current standard of care.
16656586|NCT02238392|Active Comparator|Group A|Adenosine testing after PVI and elimination of dormant conduction
16656587|NCT02238392|Active Comparator|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
16656588|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
16656589|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
16656590|NCT02238366||Prostate cancer patients|Patients recently diagnosed with prostate cancer requiring ADT.
16656591|NCT02238353|Experimental|azelastine + fluticasone|azelastine 137 µg + fluticasone 50 µg combined applied twice daily one puff in each nostril duration: 4 weeks
16656592|NCT02238353|Placebo Comparator|placebo|twice daily one puff in each nostril duration: 4 weeks
16656593|NCT02238340|Experimental|Extended-release oxycodone 10mgr|Extended-release oxycodone 10 mgrs , started 12 hours before orthopaedic surgery
16656594|NCT02238340|Experimental|Extended-release oxycodone 20 mgr|Extended-release oxycodone 20 mgr , started 12 hours before orthopaedic surgery
16656595|NCT02238327||HIV positive normal pulmonary function|HIV positive DLCO percent predicted >=.80 FEV1/FVC percent predicted >=0.70
16656596|NCT02238327||HIV positive with pulmonary dysfuntion|HIV positive DLco percent predicted <=0.80% FEV1/FVC percent predicted<=0.70%
16656597|NCT02238314|Experimental|Tipranavir low dose|
16656598|NCT02238314|Experimental|Tipranavir high dose|
16656599|NCT02238301|Other|"Patients test (pregnant women with a eutrophic fetus)"|Test the type of mask, oxygen flow and duration of oxygenation, adjustment of MRI machine Adjustment of MRI machine (choice of antenna calibration, verifying Settings of each sequence, adaptation of the number of cuts for the duration of each sequence, checking the correct execution of the succession of sequences, settings of total examination time)
16656600|NCT02238301|Active Comparator|Pregnant women with a diagnosis of IUGR fetuses|Measure of the BOLD effect in the feto-placental units of IUGR fetuses
16656601|NCT02238301|Active Comparator|Pregnant women with eutrophic fetuses|Measure of BOLD effects of fetal-placental unit eutrophic fetuses
16656602|NCT02238288|Active Comparator|aminocaproic acid|Crushed tablets inserted in the dental socket post-extraction
16656603|NCT02238288|Other|Routine care after dental extraction|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
16656604|NCT02238275||Patients with hypertension|
16656605|NCT02238262||essential hypertension patients|
16656606|NCT02238249||paediatric patients with urticaria|
16656607|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
16656608|NCT02238223||Patients without experience in treatment with epinastine|
16656609|NCT02238210|Experimental|Atrovent® - common cold group|Treatment duration for common cold group - three time daily for 4 days
16656610|NCT02238210|Experimental|Experimental: Atrovent® - allergy group|Treatment duration for allergy group - three time daily for 14 days
16656611|NCT02238197||Chronic Obstructive Pulmonary Disease|
16656621|NCT02238106|Experimental|Salmeterol inhalation powder, medium dose|administered via HandiHaler®
16656622|NCT02238106|Active Comparator|Salmeterol inhalation powder, low dose|administered via HandiHaler®
16656623|NCT02238106|Active Comparator|Salmeterol inhalation powder, high dose|administered via HandiHaler®
16656624|NCT02238106|Active Comparator|Serevent® Diskus®|administered via Diskus®
16656625|NCT02238106|Placebo Comparator|Placebo|administered via Diskus® or HandiHaler®
16656626|NCT02238093||Dialysis Patients|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.
16656627|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
16656628|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
16656629|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
16656630|NCT02238041||GlucoClear System|
16656631|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
16656632|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
16656633|NCT02238015||surgery group|patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
16656634|NCT02238015||control group|patients' other eye that did not have surgery
16656635|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
16656636|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
16656637|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
16656638|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
16656639|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
16656640|NCT02237976|Active Comparator|Routine practice|No specific intervention
16656641|NCT02237963||Posterolateral thoracotomy|Surgeons perform a posterolateral thoracotomy
16656642|NCT02237963||Axillary thoracotomy|Surgeons perform an axillary thoracotomy
16656643|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
16656644|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
16656645|NCT02237937|Experimental|Normal dosage|"Selected antidepressants that are substrates of the P-glycoprotein:
~Dosage:
~paroxetine < 40 mg/d
~sertraline < 100 mg/d
~citalopram < 40 mg/d
~escitalopram < 20 mg/d
~venlafaxine < 225 mg/d
~amitriptyline < 150 mg/d
~amitriptylinoxide < 150 mg/d
~nortriptyline < 150 mg/d
~trimipramine < 150 mg/d"
16656646|NCT02237937|Experimental|High dosage|"Selected antidepressants that are substrates of the P-glycoprotein:
~Dosage:
~paroxetine < 80 mg/d
~sertraline < 200 mg/d
~citalopram < 80 mg/d
~escitalopram < 40 mg/d
~venlafaxine < 450 mg/d
~amitriptyline < 300 mg/d
~amitriptylinoxide < 300 mg/d
~nortriptyline < 300 mg/d
~trimipramine < 300 mg/d"
16656647|NCT02237924|Experimental|endostar + IMRT|
16656648|NCT02237924|Active Comparator|DDP + IMRT|
16656649|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
16656650|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
16656651|NCT02237911|No Intervention|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
16656652|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
16656653|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
16656654|NCT02237885|Experimental|Neurofeedback|
16656655|NCT02237859|Experimental|Vancomycin|Vancomycin 125 mg PO QD vs Placebo
16656656|NCT02237846|Active Comparator|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
16656657|NCT02237846|Active Comparator|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
16656658|NCT02237833||Septic shock and vasopressor|Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.
16656661|NCT02237807|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
16656662|NCT02237807|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
16656663|NCT02237794||Patients Without Acute Heart Conditions|Patients without acute heart conditions who were hospitalized for other medical indications.
16656664|NCT02237781|Experimental|AMH levels|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.
16656665|NCT02237768|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
16656666|NCT02237768|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
16656667|NCT02237755|Active Comparator|Clomiphene citrate|Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
16656668|NCT02237755|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
16656669|NCT02237742|Experimental|PF-06427878|
16656670|NCT02237729|Experimental|PF-06410293|
16656671|NCT02237729|Active Comparator|Adalimumab-US|
16656672|NCT02237729|Active Comparator|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
16656673|NCT02237703||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
16656674|NCT02237703||Trauma Control (TC)|Trauma Control (TC)
16656675|NCT02237703||Healthy Control (HC)|Healthy Control (HC)
16656676|NCT02237690|Experimental|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
16656677|NCT02237690|Active Comparator|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
16656678|NCT02237677||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
16656679|NCT02237677||Healthy Controls (HC)|Healthy Controls (HC)
16656680|NCT02237664|Active Comparator|Patient-controlled paravertebral analgesia (PC-PVB)|Patient-controlled paravertebral analgesia
16656681|NCT02237664|Placebo Comparator|Continuous paravertebral analgesia (C-PVB)|Continuous paravertebral analgesia
16656682|NCT02237651||topical anesthesia multi-use device|anesthesia with multi-use device (Laryngeal atomizer, Karl Storz, Tuttlingen, Germany
16656683|NCT02237651||topical anesthesia Intranasal Mucosal Atomization|single-use product (LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Teleflex medical, Kernen Germany) for topical anesthesia
16656684|NCT02237638|Experimental|hVEGF26-104/RFASE vaccination|hVEGF26-104/RFASE is investigated in dose escalation in which hVEGF26-104 is escalated from 62.5 ug to 500 ug and RFASE is given in a fixed dose of 20 mg. Three patients are treated at each dose level. If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort. If 1 of the 3 patients shows DLT, 3 additional patients are treated at that dose level. If none of these show DLT, the dose level is escalated for the next cohort; otherwise, the prior dose level is defined as the MTD. At the highest dose level 6 patients will be treated. The recommended dose for a phase II trial will be the lowest dose that results in the most effective VEGF neutralization, together with acceptable safety and toxicity.
16656685|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
16656686|NCT02237612|Experimental|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
16656687|NCT02237586|Experimental|Group IA|"Adults with naturally acquired immunity and HbAA (Group IA, n=10)
~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
16656688|NCT02237586|Experimental|Group IS|"Adults with naturally acquired immunity and HbAS (Group IS, n=10)
~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
16656689|NCT02237586|Experimental|Group NI|"Adults without previous exposure to malaria and HbAA (Group NI, n=5)
~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
16656690|NCT02237573|Experimental|Intervention|Written medical report and standardized medical advices
16656691|NCT02237573|Active Comparator|Control|Standardized medical advice only
16656692|NCT02237560|Experimental|Cybercycle-Game|Combined aerobic & cognitive exercise for 6 months, 3-5x/week.
16658794|NCT02222961|Placebo Comparator|Placebo|
16656693|NCT02237560|Active Comparator|Cybercyle-Tour|Aerobic exercise only for 6 months, 3-5x/week.
16656694|NCT02237560|Active Comparator|Game Only|Cognitive exercise only 6 months, 3-5x/week.
16656695|NCT02237547|Experimental|IV and IT UC-MSC and BMMC|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
16656696|NCT02237534|Active Comparator|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.
16656697|NCT02237534|Experimental|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
16656698|NCT02237521||End-stage renal disease|Patients with normal glucose tolerance and end-stage renal disease
16656699|NCT02237521||Controls|Healthy controls with normal kidney function and normal glucose tolerance
16656700|NCT02237508|Experimental|Z7200|single dose (two inhalations)
16656701|NCT02237508|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
16656702|NCT02237508|Experimental|Z7200 with charcoal|single dose (two inhalations)
16656703|NCT02237508|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
16656704|NCT02237508|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
16656705|NCT02237495|Placebo Comparator|Saline|Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
16656706|NCT02237495|Experimental|dexmedetomidine|dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
16656707|NCT02237482|Experimental|Small periacetabular bone defects|Patients with cup loosening and small periacetabular bone defects
16656708|NCT02237482|Experimental|Large periacetabular bone defects|Patients with cup loosening and large periacetabular bone defects
16656709|NCT02237469||Prone and supine simulation|Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
16656710|NCT02237443|Other|Post-induction|Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
16656711|NCT02237430|Active Comparator|Manuel compression|Conventional manual compression
16656712|NCT02237430|Experimental|MynxGrip closure device|Closure device for femoral artery access closure
16656713|NCT02237417|Other|Healthy Control|
16656714|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
16656715|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
16656716|NCT02237404|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
16656717|NCT02237404|Experimental|Remote monitoring of pacemakers|"Telemedicine System:
~Patients have not to go to the hospital to be monitorized"
16656718|NCT02237391|Experimental|CIPAP Program|Complex Interdisciplinary Pain Assessment Program
16656719|NCT02237391|Other|Treatment as Usual (TAU)|Treatment as usual control group
16656720|NCT02237378|Experimental|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
16656721|NCT02237365|Experimental|81mg aspirin|Aspirin 81mg daily for 60 days
16656722|NCT02237365|Experimental|1000mg aspirin|Aspirin 1000mg daily for 60 days
16656723|NCT02237365|Placebo Comparator|Placebo|Visually matched placebo daily for 60 days
16656724|NCT02237352||Control|Subjects without diabetic nephropathy
16656725|NCT02237352||Diabetic nephropathy|Subjects with diabetic nephropathy
16656726|NCT02237339|Active Comparator|Allopurinol|Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.
16656727|NCT02237339|Placebo Comparator|Placebo tablet|Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.
16656728|NCT02237326|Active Comparator|Visual Inspection with Lugol's Iodine|Participants underwent colposcopic exam, followed by Visual Inspection with Lugol's Iodine (VILI) by a second, blinded clinician (the order of exams was reversed to eliminate potential interference with exam results due to iodine staining). Biopsy was done after the VILI.
16656729|NCT02237326|Active Comparator|Visual Inspection with Acetic Acid|Participants underwent Visual Inspection with Acetic Acid followed by colposcopy by a second clinician who was blinded to the screening test result.
16656730|NCT02237313|Experimental|prevalent cases|"40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.
~8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program"
16656731|NCT02237300|Experimental|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
16656732|NCT02237300|Active Comparator|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
16656733|NCT02237287|Sham Comparator|wound dressing with VAC|After wound debridement wounds are treated for 2 weeks with VAC dressing alone
16656734|NCT02237287|Other|wound dressing with VAC and sNAG under Antiaggregation|In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
16656735|NCT02237287|Experimental|wound dressing with VAC and sNAG without antiaggregation|In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG
16656736|NCT02237274|Experimental|Patients with Fontan circulation|High altitude exposition
16656737|NCT02237274|Other|Age and gender-matched healthy volunteers|High altitude exposition
16656738|NCT02237261|Experimental|Bendamustine, Bortezomib, Prednisone|Induction: Bortezomib: 1.3 mg/m2 subcutaneous for 7 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison: : 60 mg/m2 per os for 4 days Consolidation: Bortezomib: 1.3 mg/m2 subcutaneous for 4 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison 60 mg/m2 per os for 4 days
16656739|NCT02237235|Experimental|MMFS-202 -302|"MMFS-202: evening dose
~MMFS-302: morning dose"
16656740|NCT02237235|Placebo Comparator|Placebo|Placebo
16656741|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.
~Frequency and intensity are individually assigned."
16656742|NCT02237209|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
16656743|NCT02237209|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
16656744|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.
~Cat immunotherapy will be administered weekly."
16656745|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.
~Cat immunotherapy will be administered weekly."
16656746|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.
~Placebo for Cat immunotherapy will be administered weekly."
16656747|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.
~Placebo for cat immunotherapy will be administered weekly."
16656748|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
16656749|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
16656750|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
16656751|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
16656752|NCT02237170||Castration Resistant Metastatic Prostate Cancer|Castration Resistant Metastatic Prostate Cancer with no history of prior systemic chemotherapy
16656753|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 1)|Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
16656754|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 2)|Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
16656755|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 3)|Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
16656756|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 4)|Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
16656757|NCT02237144|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
16656758|NCT02237144|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
16656759|NCT02237144|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
16656760|NCT02237144|Experimental|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
16656761|NCT02237144|Experimental|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
16656762|NCT02237131|Experimental|Oral contraceptives cyclic|Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free. The regimen will be repeated for the duration of the trial.
16656763|NCT02237131|Active Comparator|Oral contraceptives continuous|Oral contraceptives containing 0.030 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for the duration of the trial.
16656764|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
16656765|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
16656766|NCT02237105|Experimental|Cognitive Behavioral Therapy Group|This group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery
16656767|NCT02237105|No Intervention|control group|This group will not undergo any psychological intervention before the spinal surgery.
16656768|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
16656769|NCT02237079|Experimental|Bazedoxifene/Conjugated Estrogens (BZA/CE)|"Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications."
16656770|NCT02237079|Placebo Comparator|Placebo|"Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind."
16656771|NCT02237066|Experimental|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
16656772|NCT02237066|Active Comparator|Standard PTA Balloon|Standard PTA Balloon Angioplasty
16656773|NCT02237053|Active Comparator|Glucagon with Octreotide and insulin|Overnight (10 hours) infusion of glucagon, then 3 hours infusion of glucagon with concurrent infusions of Octreotide and insulin.
16656774|NCT02237053|Placebo Comparator|Placebo, Glucagon with Octreotide and Insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of glucagon with concurrent infusions of Octreotide and insulin.
16656775|NCT02237053|Placebo Comparator|Placebo, with Octreotide and insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of saline with concurrent infusions of Octreotide and insulin.
16656776|NCT02237040|Experimental|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
16656777|NCT02237027|Experimental|TasP group|HIV positive female sex workers receiving TasP using ART regimen as per Benin guidelines
16656778|NCT02237027|Experimental|PrEP group|HIV negative female sex workers receiving PrEP using Truvada
16656779|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
16656780|NCT02236988|Experimental|Group 1|"Participants received the following 4 treatments, given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB) with 7 to 10 days between each treatment:
~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) B) A single oral dose 75 mg apremilast tablet prototype MR 1 C) A single oral dose 75 mg apremilast tablet prototype MR 2 D) A single oral dose 75 mg apremilast capsule prototype MR 3"
16656781|NCT02236988|Experimental|Group 2|"Participants received the following 4 treatments, given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE) with 7 to 10 days between each treatment:
~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) E) A single oral dose 75 mg apremilast capsule prototype MR 4 F) A single oral dose 75 mg apremilast capsule prototype MR 5 G) A single oral dose 75 mg apremilast capsule prototype MR 6"
16656782|NCT02236988|Experimental|Group 3|"Participants received the following 3 treatments, given in 6 possible sequences (AIJ, IJA, JAI, AJI, IAJ, or JIA) with 7 to 10 days between each treatment:
~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) I) A single oral dose 80 mg apremilast capsule prototype MR 8 J) A single oral dose 80 mg apremilast capsule prototype MR 9"
16656783|NCT02236988|Experimental|Group 4|"Participants received the following 5 treatments, given in 10 possible sequences (ALOMN, LMANO, MNLOA, NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, or MLNAO) with 7 to 10 days between each treatment:
~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) L) A single oral dose 80 mg apremilast capsule prototype MR 11 M) A single oral dose 80 mg apremilast capsule prototype MR 12 N) A single oral dose 80 mg apremilast capsule prototype MR 13 O) A single oral dose 80 mg apremilast capsule prototype MR 14"
16656784|NCT02236975|Experimental|BuMA Supreme Biodegradable drug coating coronary stent system|Implant BuMA Supreme stent only
16656785|NCT02236975|Active Comparator|Resolute Integrity durable polymer stent system|Implant Resolute stent
16656786|NCT02236962|Placebo Comparator|Placebo|lactose powder in equivalent capsule
16656787|NCT02236962|Experimental|Drug treatment|sympathetic agonist and thiazolidinedione
16656788|NCT02236949|Experimental|Pain Practice Change Booster|Pain Practice Change Booster Intervention: 12 months after the EPIQ intervention, and every 4 months for 2 years, a 30-60 minute standardized booster session was delivered to a small group of champions in each hospital unit randomized to the intervention group. Two co-facilitators familiar with the EPIQ intervention conducted all booster sessions via teleconference. Booster sessions included reviewing the effectiveness knowledge translation strategies champions implemented over the past four months to sustain and improve targeted pain practices; determining the sustainability of the pain practice changes, developing a commitment to change plan of action for the next four months.
16656789|NCT02236949|No Intervention|Usual Care Group|No interventions associated with the study were conducted on these units.
16656790|NCT02236936|Active Comparator|Arm A - Standard of care|"Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.
~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
16656791|NCT02236936|Experimental|Arm B - Parenteral over night nutrition|"Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss >5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.
~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
16656792|NCT02236923||Group A: Single procedure|Group A consists of patients recorded as having only had an ascending aortic dissection repair procedure.
16656793|NCT02236923||Group B: Multiple procedures|Group B consists of patients who had an ascending aortic dissection repair procedure together with any other surgical intervention.
16656794|NCT02236910|Experimental|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
16656795|NCT02236910|Experimental|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
16656796|NCT02236897|Experimental|PET Scanning|Imaging of mGluR5 using PET scanning
16656797|NCT02236884|Experimental|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
16656798|NCT02236871|No Intervention|Control|Maintain current milk and milk product intakes.
16656799|NCT02236871|Active Comparator|2 servings|Participants will be asked to consume 1 milk (250 ml) plus a yogurt (100-175 g) or cheese (up to 50 g) to reach an average of 2 servings of milk or milk products/d.
16656800|NCT02236871|Active Comparator|4 servings|Participants will be asked to consume recommended servings of milk or milk products/d for their age, so they will receive 1 milk (250 ml), a yogurt (175 g) and cheese (50 g) or more. This would provide ≥ 3 servings/d.
16658917|NCT02222324|Active Comparator|Treatment D|Moxifloxacin
16656801|NCT02236858|Sham Comparator|Sham HEPA Air Cleaner|Sham HEPA Air Cleaner and Delayed Intervention. Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
16656802|NCT02236858|Active Comparator|HEPA Air Cleaner|HEPA Air Cleaner also containing carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time. These air cleaners are suitably sized to provide clean air delivery rates for the rooms in which they will be placed. Participants will be instructed to run the air cleaners continually during the course of the study and the units will be modified to prevent them from being turned off by the participants.
16656803|NCT02236845|Experimental|Lacrima medical active device|
16656804|NCT02236845|Sham Comparator|Lacrima medical sham device|
16656805|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
16656806|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
16656807|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
16656808|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
16656809|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
16656810|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
16656811|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
16656812|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
16656813|NCT02236806|Placebo Comparator|Arm 4|Placebo
16656814|NCT02236793|Experimental|BioChaperone PDGF-BB|BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
16656815|NCT02236793|Placebo Comparator|Standard of Care|Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
16656816|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
16656817|NCT02236754|Other|Healthy Controls|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
16656818|NCT02236754|Other|Patients with T1D|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
16656819|NCT02236741||users of anti-parkinsonian drugs|
16656820|NCT02236728||Parkinson's disease patients|
16656821|NCT02236715||Chronic Obstructive Airways Disease|
16656822|NCT02236702||Asymptomatic control|Asymptomatic control
16656823|NCT02236702||Mildly symptomatic with depressive symptoms|Mildly symptomatic with depressive symptoms
16656824|NCT02236702||Moderately symptomatic with depressive symptoms|Moderately symptomatic with depressive symptoms
16656825|NCT02236702||Severely symptomatic with depressive symptoms|Severely symptomatic with depressive symptoms
16656826|NCT02236689|Active Comparator|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
16656827|NCT02236689|Placebo Comparator|Non Operative|control group will not undergo a second portal or muscle release.
16656828|NCT02236676|Active Comparator|Nap after rehearsal trials|A 30-minute daytime nap after training
16656829|NCT02236676|Placebo Comparator|Resting while awake|Placebo condition of 30 minutes between training and retesting in which the half hour is spent resting awake in bed.
16656830|NCT02236663|Experimental|App Based Safety Decision Aid|Personalized App-Based Safety Decision Aid
16656831|NCT02236663|Active Comparator|Control App|Usual Care Safety Plan
16656832|NCT02236650|Experimental|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
16656833|NCT02236650|Active Comparator|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
16656834|NCT02236637||mCRPC patients|Patients with metastatic castration-resistant prostate cancer treated according to routine clinical practice
16656835|NCT02236624|Experimental|Aerobic Exercise|
16656836|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
16656837|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
16656838|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
16656839|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months
~Subjects will be instructed to take the pills"
16656840|NCT02236585|Active Comparator|Patient-controlled epidural analgesia|Patient-controlled epidural analgesia
16656841|NCT02236585|Placebo Comparator|Continuous epidural analgesia|Continuous epidural analgesia
16656842|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
16656871|NCT02236403|Placebo Comparator|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
16656872|NCT02236390|Active Comparator|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
16656843|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.
~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
16656844|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.
~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
16656845|NCT02236546|Experimental|FDG-PET/CT|Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
16656846|NCT02236533|Placebo Comparator|Control pasta|Volunteers were fed with control pasta, without B-glucans and spores of B. coagulans once a day for 12 weeks.
16656847|NCT02236533|Experimental|Probiotic Whole Grain Pasta|Volunteers were fed with probiotic fortified pasta, including B-glucans and spores of B. coagulans once a day for 12 weeks.
16656848|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
16656849|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
16656850|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
16656851|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
16656852|NCT02236507|Other|children without anorectal disorders|All children will be investigated by 3D high resolution anorectal manometry procedure
16656853|NCT02236494|Active Comparator|General Health Information Pamphlet|This group will not receive a brief intervention in the ED. They will receive a pamphlet with general health information for older adults, as well as contact information for an outpatient alcohol treatment center where they have the option to follow-up for alcohol treatment at their discretion. The patient's readiness to change their alcohol habits will be measured using a 1-10 scale with a visual cue.
16656854|NCT02236494|Experimental|Brief Negotiated Interview|The BNI will follow standard steps (7, 63): 1. The research assistant (RA) will ask permission to discuss the patient's alcohol use with them. 2. They will provide feedback regarding the patient's alcohol use, and will review guidelines drinking in older adults. Where relevant, the RA will discuss how the patient's current visit may relate to their alcohol use. 3. The RA will assess the patient's readiness to change using a 1-10 scale, and will enhance motivation. 4. The RA will negotiate a goal for the patient's drinking and give advice. The patient will be asked to sign a drinking agreement.
16656855|NCT02236481|Experimental|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
16656856|NCT02236481|Active Comparator|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
16656857|NCT02236468|Experimental|new EHFP|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
16656858|NCT02236468|Experimental|old EHFP+WASH|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication since 2014
16656859|NCT02236468|Other|new EHFP+WASH|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014 + WASH/malaria behavior change communication since 2014
16656860|NCT02236468|Other|old EHFP+WASH+LNS distribution|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication and distribution of LNS since 2014
16656861|NCT02236455|Experimental|Audio Relaxation technique|Relaxation is a process that decreases the effects of stress on your mind and body. Relaxation techniques can help you cope with everyday stress and with stress related to various health problems, such as cancer and pain.
16656862|NCT02236455|Experimental|Medical Music Intervention|Music intervention is use to assist with relaxation and reduce stress levels in patients.
16656863|NCT02236455|Experimental|Nature Therapy without Music|Ecotherapy is the use of nature to reduce stress and to increase levels of well-being in patients.
16656864|NCT02236455|Experimental|Nature Therapy with Music|Nature therapy videos were produced with and without music for surgical patients.
16656865|NCT02236442|No Intervention|Usual care|First arm : Passive recording head pain, linked symptoms, treatment used and diagnosis.
16656866|NCT02236442|Experimental|After protocol recommendation care|Recording head pain, linked symptoms, treatment used and diagnosis after intervention that is recommendation to use global headache treatment protocol
16656867|NCT02236429|Experimental|recurrent bacterial vaginitis|
16656868|NCT02236416|Experimental|Intervention group|Physical exercise
16656869|NCT02236416|Other|Control group|Posture Education/Unchanged condition
16656870|NCT02236403|Experimental|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
16660083|NCT02214901|Placebo Comparator|Placebo|
16656873|NCT02236390|Active Comparator|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
16656874|NCT02236390|Active Comparator|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
16656875|NCT02236377|Active Comparator|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
16656876|NCT02236377|Active Comparator|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
16656877|NCT02236377|Active Comparator|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
16656878|NCT02236377|Active Comparator|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
16656879|NCT02236364|Experimental|New device for OPTICAL determination of blood glucose level|
16656880|NCT02236351|Placebo Comparator|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
16656881|NCT02236351|Experimental|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
16656882|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).
~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
16656883|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).
~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
16656884|NCT02236325|Experimental|DBT Brief Suicide Intervention|
16656885|NCT02236325|Active Comparator|Relaxation Training|
16656886|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
16656887|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
16656888|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
16656889|NCT02236312|Placebo Comparator|Placebo|I.M. injection
16656890|NCT02236299|Placebo Comparator|saline placebo infusion|30 minute infusion of a saline placebo Right coronary artery percutaneous coronary intervention
16656891|NCT02236299|Experimental|GLP-1 infusion|30 minute infusion of GLP-1 Right coronary artery percutaneous coronary intervention
16656892|NCT02236286|Experimental|Exercise|Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions). The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD. The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
16656893|NCT02236286|Active Comparator|Chronic Disease Management Education|Subjects will also receive (cross-over) six weeks of educational classes. The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism. Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks. Subject will do an additional 120 minutes of relaxation at home/week.
16656894|NCT02236273|Experimental|Conventional Text Message|Conventional text message reminder
16656895|NCT02236273|Experimental|Enhanced reminders|Enhanced text message reminders
16656896|NCT02236260|Active Comparator|Local anesthesia alone|
16656897|NCT02236260|Experimental|Local Anesthesia + Electroacupuncture|
16656898|NCT02236247|Experimental|ivabradine|I(f) inhibitor, heart rate controller
16656899|NCT02236247|Placebo Comparator|placebo|placebo pill will be administered orally twice daily
16656900|NCT02236234|Experimental|Vaccine|one group with HPV vaccine
16656901|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
16656902|NCT02236182|Experimental|Ipratropium Bromide low|delivered via RESPIMAT®
16656903|NCT02236182|Experimental|Ipratropium Bromide high|delivered via RESPIMAT®
16656904|NCT02236182|Placebo Comparator|Placebo|delivered via RESPIMAT®
16656905|NCT02236169|Experimental|Ipratropium bromide|
16656906|NCT02236169|Active Comparator|ATROVENT|
16656907|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
16656908|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
16656909|NCT02236143||MRI|Subjects undergoing MRI
16656910|NCT02236130|Active Comparator|General|General Anesthesia only
16656911|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
16656912|NCT02236117|Experimental|Intervention: Aerobic Training|The children included in the experimental group will make 10 weeks of aerobic training. The intensity of the race will be based on individual speed obtained in the last stage completed the progressive test, known as the maximal aerobic speed (MAV) in km/h. The running speed of the exercise protocol will be minimum 80% of the MAV in the protocol of continuous training. The intermittent progressive training is n * (10*15 s) to 100% MAV, and n from 2 to 6 series between the first and tenth week. The training protocol was adapted from previously described (Mandigout et al, 2002, Gamelin et al, 2009.). Acceptance of the exercise in a pediatric population has been previously observed by pilot study.
16656913|NCT02236117|No Intervention|physical education classes|
16656914|NCT02236104|Experimental|cough assist session|Mechanical insufflation-exsufflation contains 15 cycles durea 2-3 seconds. pressure level fixed +/-30 cm H2O.
16656915|NCT02236091||Inpatients|
16656916|NCT02236078|Experimental|High dose isoniazid|INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing <45 kg)
16656917|NCT02236065|Experimental|UCB + G-CSF|UCB + G-CSF
16656918|NCT02236052|Experimental|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
16656919|NCT02236052|Experimental|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
16656920|NCT02236052|Experimental|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
16656921|NCT02236052|Experimental|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
16656922|NCT02236052|Experimental|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
16656923|NCT02236052|Placebo Comparator|Placebo|A single dose of Placebo
16656924|NCT02236039|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by a bronchoscopy 24 hours post exposure.
16656925|NCT02236039|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by a bronchoscopy 24 hours post exposure.
16656926|NCT02236026|Experimental|Supratherapeutic dose of Nestorone|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
16656927|NCT02236026|Placebo Comparator|Placebo|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
16656928|NCT02236026|Experimental|Moxifloxacin|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
16656929|NCT02236013|Experimental|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
16656930|NCT02236013|Experimental|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
16656931|NCT02236013|Experimental|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
16656932|NCT02236013|Experimental|Continuous ASP2215 Exposure during Consolidation (Part 4)|During Consolidation, ASP2215 will be given daily on day 1 up to day 56.
16656933|NCT02236000|Experimental|Neratinib and T-DM1|
16656934|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
16656935|NCT02235974|Experimental|Acute/Early|Intervention: A 20-hour dose of early intensive upper extremity motor training therapy will be initiated within 30 days post-stroke.
16656936|NCT02235974|Experimental|Sub-acute/Outpatient|Intervention: A 20-hour dose of sub-acute intensive upper extremity motor training therapy will be initiated within 2 to 3 months post-stroke.
16656937|NCT02235974|Experimental|Chronic|Intervention: A 20-hour dose of chronic intensive upper extremity motor training therapy will be initiated 6 to 9 months post-stroke
16656938|NCT02235974|Placebo Comparator|Control|Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
16656939|NCT02235961|Experimental|Part 1|
16656940|NCT02235961|Experimental|Part 2|
16656941|NCT02235948|Experimental|folic acid|folic acid supplementation placebo controlled
16656942|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
16656943|NCT02235922|Experimental|Dual task training|Dual task training
16656944|NCT02235922|Experimental|Conventional training|Conventional training
16656945|NCT02235909|Experimental|Double blind phase: Azilsartan Medoxomil|Double blind phase; Randomized 1:1:1:1. Once a day dosing. Azilsartan medoxomil at 10 mg, or 20 mg, or 40 mg force-titrated to 80 mg
16656946|NCT02235909|Active Comparator|Double blind phase: Losartan 25 or 50 mg|Double blind phase: Double blind phase; Randomized 1:1:1:1. Once a day dosing
16656947|NCT02235909|Active Comparator|Withdrawal Phase: Azilsartan medoxomil dose taken in Double blind phase|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
16656948|NCT02235909|Placebo Comparator|Withdrawal Phase: Placebo to match azilsartan medoxomil|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
16656949|NCT02235909|Experimental|Open Label Phase: Azilsartan Medoxomil|Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)
16656950|NCT02235909|Other|"Open Label Phase: Other"|Additional antihypertension medication, as needed. Name and dose as determined by PI
16656951|NCT02235909|Active Comparator|Withdrawal Phase: Losartan 25 or 50 mg|Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
16656952|NCT02235909|Placebo Comparator|Withdrawal Phase: Placebo to Losartan|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
16656953|NCT02235896|Other|Education/Behavior Modification|Education/Behavior modification program
16656954|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
16656955|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
16656956|NCT02235857|Experimental|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
16656957|NCT02235844|Experimental|Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells
16656958|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
16657044|NCT02235207|Experimental|Neuromuscular exercise|The exercise group will participate in Fustra20 Neck & Back neuromuscular exercise program.
16656959|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
16656960|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
16656961|NCT02235818|Active Comparator|Kinesiotape (KT)|Kinesiotape was used only on the affected side as per the manufacturer instructions. With the elbow extended, wrist fully flexed and fingers pointed down 24, KT was applied with slight stretch (10-15%) and paper off tension to the lateral arm beginning just above the bony portion of lateral epicondyle. Once the top strand was anchored, KT was applied along the side of elbow such that hole in the tape was over lateral epicondyle of the elbow. Two strands of tape followed the lateral forearm and ended at around beginning of the distal one third of forearm. Once the support was applied, KT was gently rubbed to activate the glue.
16656962|NCT02235818|Active Comparator|Counterforce elbow brace|The counterforce brace was approximately 5cm wide with velcro attachment for adjustable girth. It had gel pack for extra support on extensor muscle mass. With the elbow extended, brace was applied 2.5cms below the lateral epicondyle. A feeling of comfortable compression, as reported by the patients was used to adjust the brace.
16656963|NCT02235805|Experimental|Magnesium Citrate|
16656964|NCT02235805|Placebo Comparator|Placebo|
16656965|NCT02235792|Experimental|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
16656966|NCT02235779|Other|Cryobiopsy|
16656967|NCT02235766||CRT candidates patients|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.
16656968|NCT02235753|Experimental|High-intensity interval training, HIT-S|High-intensity aerobic interval training, short interval (HIT-S)
16656969|NCT02235753|Experimental|High-intensity interval training, HIT-L|High-intensity aerobic interval training, long interval (HIT-L)
16656970|NCT02235753|No Intervention|Usual care|control group
16656971|NCT02235740|Experimental|Afuresertib 125 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive Afuresertib 125 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg (increased dosage of 27 mg/meter (m)^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
16656972|NCT02235740|Experimental|Afuresertib 150 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive oral Afuresertib 150 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
16656973|NCT02235740|Experimental|Afuresertib 100 mg+ Carfilzomib (Part 1)|An additional arm with 100 mg of afuresertib may be evaluated if the other 2 arms are not tolerated. Approximately 8 subjects will receive Afuresertib 100 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
16656974|NCT02235740|Experimental|Afuresertib/carfilzomib (Part 2)|Approximately 50 subjects will receive Afuresertib Recommended Phase 2 Dose (RP2D) daily starting Cycle 1 Day 1 + Carfilzomib 20 mg/m^2 Cycle 1, Day 1, 2. Carfilzomib 27 mg (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15 and 16; Cycle Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9 and 15 and 16 of each cycle.
16656975|NCT02235740|Active Comparator|Carfilzomib (Part 2)|Approximately 50 subjects will receive Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9 15, and 16; Cycle 2, Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9, 15 and 16 of each cycle.
16656976|NCT02235727|Experimental|GBR 900|Test treatment GBR 900
16656977|NCT02235727|Placebo Comparator|Placebo|Placebo Treatment
16656978|NCT02235714||Tetraplegia|Individuals with chronic tetraplegia
16656979|NCT02235714||Asthma|Individuals with mild asthma
16656980|NCT02235714||Able-bodied controls|Age matched able-bodied (AB) controls with no history of lung disease
16656981|NCT02235701|Experimental|aldoxorubicin|
16656982|NCT02235688|Experimental|aldoxorubicin|
16656983|NCT02235675|Experimental|Tack-It|Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
16656984|NCT02235662|Experimental|TFV IVR|TFV IVR is an intravaginal ring 55.0 mm in diameter, consisting of single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. Used for one month, the IVR delivers 8-10 mg/day TFV.
16656985|NCT02235662|Experimental|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm: a longer segment containing white TFV paste and a shorter one (20 mm) with a white LNG core. Used for one month, the IVR delivers 8-10 mg/day TFV and 20 μg/day LNG.
16656986|NCT02235662|Placebo Comparator|Placebo Intravaginal Ring|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month.
16656987|NCT02235649|No Intervention|TAU|Treatment as usual
16656988|NCT02235649|Active Comparator|SOC+TAU|Social Cognition intervention + Treatment as Usual
16656989|NCT02235636||Laparoscopic group|
16656990|NCT02235636||Robotic group|
16656991|NCT02235623|Other|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
16656992|NCT02235623|Other|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
16660084|NCT02214888|Experimental|BIRB 796 BS, low dose|
16656993|NCT02235610|No Intervention|Standard Group|"Recipients receive standard donor lungs as per current clinical practice.
~No experimental procedures will be carried out."
16656994|NCT02235610|Experimental|EVLP Group|Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.
16656995|NCT02235597||Patients and Staff of Community Clinics|Patients and Staff of Community Clinics who shared strategies and solutions to overcome barriers to accessing health care
16656996|NCT02235584|Experimental|Dexamethasone|This is a before-after study. All subjects are administered dexamethasone 2mg BID for 5 days.
16656997|NCT02235571|No Intervention|Control|These subjects are receiving standard patient education
16656998|NCT02235571|Experimental|iChoose Kidney Decision Aid|These subjects receive iChoose Kidney Decision Aid along with standard patient education
16656999|NCT02235558|Experimental|Verapamil|Super-selective intra-arterial administration of 10 mg verapamil immediately following successful intra-arterial thrombolysis
16657000|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
16657001|NCT02235532|Experimental|Foramen Herbal Aloe toothpaste|test group was asked to brush the teeth with Foramen Herbal Aloe toothpaste for 30 days once a day.
16657002|NCT02235532|Active Comparator|use of fluoride toothpaste (signal)|use of a fluoride toothpaste (signal) in control group once a day for 30 days .
16657003|NCT02235519|Active Comparator|Azilsartan low dosage|Patients will take azilsartan 40 mg during 12 weeks
16657004|NCT02235519|Active Comparator|Azilsartan high dosage|Patients will take azilsartan 80 mg during 12 weeks
16657005|NCT02235506|Experimental|epidural infusion|In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation,
16657006|NCT02235506|Experimental|femoral sciatic|In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr.
16657007|NCT02235493||Retrospective Case Only|
16657008|NCT02235480|Experimental|Tazarotene Gel|once daily
16657009|NCT02235480|Placebo Comparator|Placebo Gel|once daily
16657010|NCT02235467|Active Comparator|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
16657011|NCT02235467|No Intervention|ABA parent training control|
16657012|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
16657013|NCT02235441|Experimental|Cardiopulmonary Fitness|All eligible subjects will participate in treadmill exercise to measure cardiopulmonary fitness during chemoradiation therapy.
16657014|NCT02235428|Experimental|Ipratropium bromide|
16657015|NCT02235428|Active Comparator|Salbutamol|
16657016|NCT02235415||Motens|
16657017|NCT02235402|Experimental|Lacidipine|
16657018|NCT02235402|Active Comparator|Bendrofluazide|
16657019|NCT02235402|Placebo Comparator|Placebo|
16657020|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
16657021|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
16657022|NCT02235376||critical care|
16657023|NCT02235363|Experimental|facelift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
16657024|NCT02235350|Experimental|Action Observation Treatment (AOT)|Conventional physiotherapy + Action Observation Treatment
16657025|NCT02235350|Sham Comparator|Observation of videos with no motor content (MNO)|Conventional physiotherapy + Observation of videos with no motor content (MNO)
16657026|NCT02235337|Experimental|Riboflavin|
16657027|NCT02235324|Experimental|Treatment (ziv-aflibercept, leucovorin calcium, fluorouracil)|"PHASE I:
~Patients receive ziv-aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients proceed to Phase II.
~PHASE II:
~Patients receive ziv-aflibercept IV over 1 hour, leucovorin calcium IV over 1 minute, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
16657028|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
16657029|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
16657030|NCT02235298|Experimental|Dapagliflozin and Metformin Group|Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.
16657031|NCT02235298|Active Comparator|Metformin and Placebo Group|Participants in this group will receive Metformin and Placebo for 6 months.
16657032|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
16657033|NCT02235272|Experimental|XG-102|
16657034|NCT02235272|Placebo Comparator|Placebo|
16657035|NCT02235259|Experimental|XG-104 low dose|
16657036|NCT02235259|Experimental|XG-104 intermediate dose|
16657037|NCT02235259|Experimental|XG-104 high dose|
16657038|NCT02235259|Placebo Comparator|Placebo|Placebo
16657039|NCT02235246|Experimental|normal saline|
16657040|NCT02235246|Active Comparator|magnesium sulfate|
16657041|NCT02235233|Experimental|Patients with NASH|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
16657042|NCT02235233|Active Comparator|Healthy Normal Volunteers|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
16657043|NCT02235220|Experimental|Composite resin restoration|A canine guidance is reestablished by additive composite resin restorations of the canine cusp.
16657045|NCT02235207|No Intervention|Control group|Participants are encouraged to continue there usual physical activity and exercise
16657046|NCT02235194|Active Comparator|Amino Acids, Chromium - Picolinate|Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
16657047|NCT02235194|Placebo Comparator|Placebo Drink|Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
16657048|NCT02235181|No Intervention|Standard Treatment|Women will be allocated to standard treatment, currently this is no treatment.
16657049|NCT02235181|Active Comparator|Arabin pessary|The Arabin cervical pessary will be inserted between 18 and 20+6 days gestation and removed between 35 and 36+6 weeks gestation unless Labour occurs sooner.
16657050|NCT02235168|Experimental|With rollator|Six minutes walking test with rollator
16657051|NCT02235168|Active Comparator|Without rolator|Six minutes walking test without rollator
16657052|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
16657053|NCT02235142|Experimental|Localised prostat cancer and androgen deficiency|
16657054|NCT02235129|Experimental|6 minutes walking test|
16657055|NCT02235116||Patients who responded to the survey|
16657056|NCT02235103||Clinical Pregnancy|Patients who are clinically pregnant after first treatment cycle with intra-uterine insemination.
16657057|NCT02235103||No Clinical Pregnancy|Patients who are not clinically pregnant after first treatment cycle with intra-uterine insemination.
16657058|NCT02235090|Sham Comparator|Zero-strength of direct current stimulation|Sham transdermal direct current stimulation of cervical spinal cord
16657059|NCT02235090|Experimental|100 microamperes direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
16657060|NCT02235090|Experimental|1 milliampere direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
16657061|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
16657062|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
16657063|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
16657064|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
16657065|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
16657066|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
16657067|NCT02235038|Active Comparator|Low carbohydrate diet|
16657068|NCT02235038|Active Comparator|Moderate carbohydrate diet|
16657069|NCT02235038|Active Comparator|High carbohydrate diet|
16657070|NCT02235025|Other|Asymptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score equal to zero and are free of respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze.
16657071|NCT02235025|Other|Symptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score > 0.
16657072|NCT02235025|Other|Healthy controls|Healthy controls have normal baseline spirometry (FEV1 > 80% predicted, FEV1/FVC > 0.7). They don't have any health problems, including cardiovascular, metabolic, neuromuscular, musculoskeletal, or respiratory diseases that could contribute to breathlessness or exercise limitation. They have a mMRC score equal to zero and do not complain any respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze and/or chronic respiratory related medication.
16657073|NCT02235012|Experimental|Ketamine then placebo|Infusion of low dose Ketamine then infusion of a saline solution
16657074|NCT02235012|Experimental|Placebo then ketamin|Infusion of a saline solution then infusion of low dose Ketamine
16657075|NCT02234999|Experimental|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg [14C]-CC-122. given as a suspension under fasting conditions on Day 1
16657076|NCT02234986|Experimental|ENMD-2076|ENMD-2076, oral capsule Once daily dose 250 mg/day
16657077|NCT02234973||11 First Nations Community and Clinical Teams|11 Community & Clinical Teams in each First Nation community participated in the intervention.
16657078|NCT02234960||Cohort of RA Participants|Participants with RA treated with tocilizumab at a dose and duration at the discretion of physician in accordance with the summary of product characteristics as per routine clinical practice were observed for a period of 6 months with the length of entire study for 24 months.
16657079|NCT02234947||New onset of Type 1 Diabetes|The subjects with new onset of Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
16657080|NCT02234947||Antibody Positive Risk for Diabetes|The subjects with single or double antibody positive risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
16657081|NCT02234947||Antibody Negative Risk for Diabetes|The subjects with antibody negative risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
16657082|NCT02234947||Healthy Control|The subjects has no family history for Type 1 Diabetes. They will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
16657293|NCT02233452|Active Comparator|Ketamine|Group treated with ketamine solution
16657083|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part A|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
16657084|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part B|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after modified myeloreductive conditioning including increased monitoring and rescue treatment
16657085|NCT02234921|Experimental|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
16657086|NCT02234908|Experimental|Contacts|Contacts are the household contacts of confirmed TB and drug-resistant TB patients.
16657087|NCT02234908|Other|Index|Index subjects are confirmed TB and drug-resistant TB patients who distribute referral cards to their household contacts.
16657088|NCT02234895|Experimental|Lateral wedge plus medial arch support|The lateral wedge plus medial support orthotic will be custom-made and designed using a 3D volumetric cast of the foot with the participant's foot in a subtalar joint neutral position. The cast will be balanced so that it rests in a neutral position then smoothed to address any irregularities and to allow for soft tissue splay. Polypropylene sheets of 3mm or 4mm thickness will be vacuum formed or milled directly to produce a ¾ length shell. An ethyl-vinyl-acetone (EVA) lateral post in the heel and forefoot of 5 degrees will be incorporated into the orthotic. The orthotic will be finished with a neoprene cover for improved comfort and patient compliance.
16657089|NCT02234895|Experimental|Lateral wedge|The lateral wedge only orthotic will be constructed of EVA, made to full length of the subject's footwear and incorporate a 5 degree posting. The wedge will be finished with a neoprene cover for improved comfort and patient compliance.
16657090|NCT02234882|Experimental|Rosuvastatin and BMS-663068|Treatment A: Rosuvastatin, single dose (SD) Treatment B: BMS-663068 administered on specified days Treatment C: Combination BMS-663068 and Rosuvastatin administered on specified days
16657091|NCT02234869|Experimental|Peginterferon beta-1a|Participants will receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks during the 6-month comparator period of the study and during the 12-month extension period.
16657092|NCT02234869|Active Comparator|Interferon-β|Participants will continue to receive their standard-of-care interferon beta treatment for the first six months. During the 12-month extension period participants will switch to receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks.
16657093|NCT02234856|No Intervention|conventional residency training|no intervention
16657094|NCT02234856|Experimental|Laparoscopic Hysterectomy trainer|Intervention: An educational video and web-based e-module will be created. The final product will be reviewed by the expert contributors. Once approved, these tools will be showcased to a voluntary focus group of Obstetrics and Gynecology residents at the University of Toronto. A quantitative assessment of effectiveness of this tool will be performed through the use of pre- and post-tests of knowledge. A qualitative needs assessment will also be performed using post-viewing surveys. If found to be effective, this educational tool will be incorporated in the University of Toronto Obstetrics and Gynecology residency curriculum.
16657095|NCT02234843|Experimental|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
16657096|NCT02234843|Experimental|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
16657097|NCT02234830|Experimental|Exoseal closure device|Closure device for femoral artery access closure
16657098|NCT02234830|Active Comparator|Angio-Seal closure device|Closure device for femoral artery access closure
16657099|NCT02234804|Experimental|Medtronic Resolute Integrity stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
16657100|NCT02234804|Experimental|OCT|OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
16657101|NCT02234804|Active Comparator|Angiography|Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
16657102|NCT02234804|Active Comparator|Xience Prime stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
16657103|NCT02234791||gene mutation|
16657104|NCT02234778|Experimental|Study Treatment|Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
16657105|NCT02234765|Active Comparator|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
16657106|NCT02234765|Experimental|Primary Care|Patients diagnosed and followed up in the Primary Care.
16657107|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
16657108|NCT02234739|Experimental|active treatment|Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
16657109|NCT02234726|Experimental|Early Childhood Development Program|"Treatment clusters will be assigned a trained Child Development Agent (CDA) who will have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases including malaria, diarrhea, and pneumonia and referral for diagnosis and treatment; and 4) organization and mentoring of biweekly caregiver meetings to discuss parenting and promote early childhood cognitive stimulation.
~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
16657110|NCT02234726|No Intervention|Control|Children residing in comparison health zones will only receive baseline and end line evaluations of their health and developmental status. There will be no active intervention in the comparison areas during the course of the study.
16657208|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
16657111|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
16657112|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
16657113|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
16657114|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
16657115|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
16657116|NCT02234674|Active Comparator|Standard intensive CDP|This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit.
16657117|NCT02234674|Experimental|Stendo group|This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions.
16657118|NCT02234661|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
16657119|NCT02234661|No Intervention|Control Standard of CAP|Control participants access to CAP array of service
16657120|NCT02234648|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
16657121|NCT02234648|Active Comparator|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
16657122|NCT02234635|Other|monofocal IOLs group|monofocal IOLs group were implantation with Tecnis® ZCB00
16657123|NCT02234635|Active Comparator|Diffractive multifocal IOLs group|Diffractive multifocal IOLs group were implantation with Tecnis® ZMB00
16657124|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
16657125|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
16657126|NCT02234609|Other|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
16657127|NCT02234596|Experimental|Nintedanib|
16657128|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
16657129|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
16657130|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
16657131|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
16657132|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
16657133|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
16657134|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
16657135|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
16657136|NCT02234557|Experimental|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
16657137|NCT02234544|Placebo Comparator|Placebo + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
16657138|NCT02234544|Active Comparator|Ezetimibe + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
16657139|NCT02234531|Experimental|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
16657140|NCT02234531|Other|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
16657141|NCT02234518|Experimental|High quantity fiber food product|
16657142|NCT02234518|Experimental|Low quantity fiber food product|
16657143|NCT02234518|Placebo Comparator|Placebo|
16657144|NCT02234505|Experimental|Trans-tibial prosthesis users|prosthetic alignment perturbation
16657145|NCT02234492|Active Comparator|Rosuvastatin|Rosuvastatin 10mg once daily for 6 months.
16657146|NCT02234492|No Intervention|No rosuvastatin|No rosuvastatin- this group will continue with their current medical therapy for 6 months.
16657209|NCT02234050|Experimental|Trabectedin|Patient will be treated with trabectedin
16657210|NCT02234050|Other|Local standard of care|Treatment in the control arm is left to the discretion of the investigator, according to the local standard of care.
16657147|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
16657148|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
16657149|NCT02234466|Active Comparator|Oral Dexamethasone|"Oral dexamethasone- two 4mg tabs and one 2mg tab contained within a gelatin capsule Administered a single time, 2 hours pre-induction
~Ondansetron 6mg IV will be administered at skin closure"
16657150|NCT02234466|Placebo Comparator|Gelatin pill|"Gelatin capsule contained within second gelatin capsule. Administered a single time, 2 hours pre-induction
~Ondansetron 6mg IV will be administered at skin closure"
16657151|NCT02234453|Experimental|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
16657152|NCT02234440|Experimental|Metformin|Metformin- 500 mg once daily as a starting dose, can be escalated to 2 g/day to control diabetes
16657153|NCT02234440|Active Comparator|Insulin|
16657154|NCT02234427|Experimental|Aspirin|
16657155|NCT02234401|Experimental|Non invasive ventilation (NIV)|Non invasive ventilation used for the first 7 days of study
16657156|NCT02234401|Active Comparator|Standard Care|High Flow Controlled Oxygen Therapy
16657157|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
16657158|NCT02234375|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
16657159|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
16657160|NCT02234349|Experimental|pancreas kidney transplant|Patients with pancreas kidney transplantation
16657161|NCT02234349|Experimental|kidney transplant subjects|Patients with kidney transplantation
16657162|NCT02234349|No Intervention|Control|
16657163|NCT02234336||Subjects with HCM|All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
16657164|NCT02234323|Experimental|rFVIIIFc|Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (>=) 50 exposure days (ED: 24-hour period in which >=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (>=5.00 Bethesda Units per milliliter [BU/mL]) or positive low titer inhibitor (>=0.60 and <5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.
16657165|NCT02234310|Experimental|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
16657166|NCT02234297|Experimental|BLZ-100|
16657167|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
16657168|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
16657169|NCT02234271|Active Comparator|Health Educator Arm|Health Educator for contraception information
16657170|NCT02234271|Experimental|Mobile Health Application Arm|Plan A Birth Control - iPad based application for contraception information
16657171|NCT02234258|Experimental|Cognitive behavioral social skills|In Cognitive behavioral social skills training (CBSST), skills-based CBT is used to teach individuals how to correct inaccurate dysfunctional thoughts that interfere with goal-directed activities, including defeatist expectancies, low self-efficacy beliefs, and anomalous beliefs. SST focuses on behaviorally-based instruction of interpersonal social skills, utilizing role-modeling, rehearsal, corrective feedback, and positive reinforcement to facilitate learning. In the modified version of CBSST used in this project: 1) we will strengthen the focus on corrective feedback from successful social interactions; 2) focus on normalization and destigmatization of attenuated psychotic symptoms; 3) add motivational interviewing techniques to promote treatment engagement; and 4) use examples and role plays. CBSST will be delivered in three 6-session modules (i.e., Cognitive Skills, Social Skills, and Problem Solving Skills), a total of 18 90-minute group sessions.
16657172|NCT02234258|Active Comparator|Psychoeducation|The purpose of this alternative treatment is to match CBSST for the nonspecific effects of therapist contact and interest, social interaction and support. Common factors include client expectancy, providing a rationale for change, therapist factors and therapeutic alliance. The psychoeducation group will meet weekly, for a total of 18 90-minute sessions. Therapists will follow brief guidelines as to what they can and cannot do. In each session the therapists will ask how the previous week had been. Any crises will be dealt with, and advice will be offered to help with any immediate problems. No active CBT or SST techniques will be taught or used. Psychoeducational information about high risk for psychosis will be offered. There will be a focus on listening, reflecting and empathizing, and demonstrating uncritical acceptance and genuineness. Social exchanges amongst participants will be encouraged.
16657173|NCT02234245|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
16657174|NCT02234245|Experimental|Remote monitoring of pacemakers|"Telemedicine System:
~Patients have not to go to the hospital to be monitorized"
16657175|NCT02234232|Experimental|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
16657176|NCT02234232|Experimental|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
16657177|NCT02234232|Experimental|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
16657178|NCT02234232|Active Comparator|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
16657179|NCT02234219|Active Comparator|Circular Anastomosis|
16657180|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
16657181|NCT02234206|Experimental|Chandrakanthi choornam|"Chandrakanthi Choornam (CKC) - 12gm in milk
~OD dose; Oral route
~3 Months - duration
~Intervention Drug: Chandrakanthi Choornam (CKC)"
16657182|NCT02234193|Active Comparator|Micro biopsies 2mm x control|2 mm diameter micro biopsies will be performed on all subjects.
16657183|NCT02234193|Active Comparator|Micro biopsies 1mm x control|1 mm diameter micro biopsies will be performed on all subjects.
16657184|NCT02234193|Active Comparator|Micro biopsies 0.8 mm x control|0.8 mm diameter micro biopsies will be performed on all subjects.
16657185|NCT02234193|Active Comparator|Micro biopsies 0.6 mm x control|0.6 mm diameter micro biopsies will be performed on all subjects.
16657186|NCT02234193|Active Comparator|Micro biopsies 0.5 mm x control|0.5 mm diameter micro biopsies will be performed on all subjects.
16657187|NCT02234193|Active Comparator|Micro biopsies 0.40 mm x control|0.4 mm diameter micro biopsies will be performed on all subjects.
16657188|NCT02234193|Active Comparator|Micro biopsies 0.20 mm x control|0.2 mm diameter micro biopsies will be performed on all subjects.
16657189|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16657190|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16657191|NCT02234167|Other|Risk behaviour and infectious diseases|.(among IDU)
16657192|NCT02234154|Other|TOPS System|Post Marketing Study
16657193|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
16657194|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
16657195|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
16657196|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
16657197|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
16657198|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
16657199|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
16657200|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
16657201|NCT02234102|Active Comparator|Paroxysmal Atrial Fibrillation (PAF)|Endoscopically guided laser ablation
16657202|NCT02234102|Active Comparator|Persistent Atrial Fibrillation|Endoscopically guided laser ablation
16657203|NCT02234089||Degarelix|
16657204|NCT02234089||LHRH agonist|
16657205|NCT02234076|Experimental|VRET|"Virtual Reality Exposure Therapy (VRET)
~The experimental treatment VRET is offered with the Multi-Modal Memory Restructuring System (3MR system) and a therapy manual. Participants can use this system at home. Note: The 3MR system is offered via a computer screen, no head-mounted display (HMD) equipment is used in this study."
16657206|NCT02234076|Active Comparator|TAU|Treatment As Usual
16657207|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
16657248|NCT02233751|Experimental|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
16660085|NCT02214888|Experimental|BIRB 796 BS, high dose|
16657211|NCT02234037|Experimental|Decitabine and Exercise|8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.
16657212|NCT02234024|Experimental|Supplementation of gangliosides|Supplementation of dairy-derived concentrated gangliosides
16657213|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
16657214|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
16657215|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
16657216|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
16657217|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
16657218|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
16657219|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
16657220|NCT02233972|Experimental|Midazolam and Ginkgolides Meglumine Injection|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Ginkgolides Meglumine Injection: 25mg, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
16657221|NCT02233972|Placebo Comparator|Midazolam and placebo|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Placebo: Sodium Chloride Injection, 250 ml, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
16657222|NCT02233959||Healthy Adults|
16657223|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
16657224|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
16657225|NCT02233933|Active Comparator|argon plasma coagulation|argon plasma coagulation of radiation proctitis
16657226|NCT02233933|Experimental|argon plasma coagulator and hemospray|treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
16657227|NCT02233920||Chronic obstructive bronchitis patients|
16657228|NCT02233907||Chronic obstructive pulmonary disease patients|
16657229|NCT02233894||Chronic obstructive pulmonary disease patients|
16657230|NCT02233881||Chronic obstructive pulmonary disease patients|
16657233|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
16657236|NCT02233816|Experimental|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
16657237|NCT02233816|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
16657238|NCT02233816|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
16657239|NCT02233816|Placebo Comparator|Placebo|A single dose of Placebo
16657240|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
16657241|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
16657242|NCT02233790|Experimental|Ticagrelor|
16657243|NCT02233790|Active Comparator|Clopidogrel|
16657244|NCT02233777|Experimental|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg pregabalin.
16657245|NCT02233777|Active Comparator|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg pregabalin.
16657246|NCT02233764|Experimental|FeZnPM|The FeZnPM arm will consume iron- and zinc-biofortified pearl millet (ICTP8203-Fe).
16657247|NCT02233764|Active Comparator|CtrlPM|The CtrlPM arm will consume conventional pearl millet three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
16657249|NCT02233751|Experimental|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
16657250|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
16657251|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
16657252|NCT02233725|Active Comparator|Definity Perflutren Suspension|Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.
16657253|NCT02233712|Experimental|Group 1|G17DT; 250 µg dose administered at 0, 1, and 3 weeks.
16657254|NCT02233712|Experimental|Group 2|G17DT; 100 µg dose administered at 0, 1, and 3 weeks.
16657255|NCT02233712|Experimental|Group 3|G17DT; 500 µg dose administered at 0, 1, and 3 weeks.
16657256|NCT02233712|Experimental|Group 4|G17DT; 500 µg dose administered at 0, 2, and 6 weeks.
16657257|NCT02233699|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
16657258|NCT02233699|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
16657259|NCT02233686|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
16657260|NCT02233686|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
16657261|NCT02233673|Experimental|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
16657262|NCT02233673|No Intervention|Standard care|Participants receive standard obstetrical care from their provider
16657263|NCT02233660|Experimental|Physical Therapy Group.|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
16657264|NCT02233660|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
16657265|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
16657266|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.
~Placebo will be administered acutely during low dose phendimetrazine maintenance."
16657267|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.
~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
16657268|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.
~Placebo will be administered acutely during high dose phendimetrazine maintenance."
16657269|NCT02233634|Active Comparator|CAD Patients|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
16657270|NCT02233634|Active Comparator|Healthy Volunteers (Control Group)|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
16657271|NCT02233621|Experimental|PET with [18F]-FES|PET with [18F]-FES compared to histological analysis performed at least on one biopsy done during coelioscopy.
16657272|NCT02233608|No Intervention|Usual Care|The usual care group will receive generic pelvic floor muscle exercise (PMFX) instructions and demonstrations by the research coordinator at the initial post-operative time point. This will include instruction on how to engage the pelvic floor and specific PFMX prescription. Repetition volume will start at 20 repetitions per day during weeks 1-2; 60/day during weeks 3-4; and 90/day during weeks 5-6, and 100+/day for weeks 7-26. The total number of repetitions will be divided equally between rhythmic (contract and relaxed over one second) and sustained contractions (contract and hold for up to 10 seconds).
16657273|NCT02233608|Experimental|Advanced Pelvic Floor Exercise (APFX)|Participants in this group will receive detailed week-by-week description of the program. The program progresses participants through stages of training every two weeks, starting the introduction of basic PFMX, and slowly incorporates Pfilates and Hypopressives exercises until week 8, where patients will maintain the final stage of training until week 26 or urinary incontinence is completely resolved.
16657274|NCT02233595||Adjuvant chemotherapy|
16657275|NCT02233582|Experimental|ibuprofen plus ascent to high altitude|subjects randomized to this arm will take ibuprofen 200 mg 3 times daily during ascent and at altitude.
16657276|NCT02233582|Placebo Comparator|sugar pill plus ascent to high altitude|subjects randomized to this arm will receive the placebo
16657277|NCT02233569|Active Comparator|PH|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
16657278|NCT02233569|Active Comparator|VS|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
16657279|NCT02233556|Experimental|Memantine|This study has only one arm. i.e. Single dose of memantine 20mg
16657292|NCT02233452|Active Comparator|Methadone|Group treated with methadone solution.
16657280|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
16657281|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
16657282|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.
~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
16657283|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
16657284|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
16657285|NCT02233491|Placebo Comparator|Control|This group will be counselled in clinic by clinicians about the risks of glucose intolerance and will receive leaflets outlining lifestyle modification advice. The leaflets include advice on healthy eating, exercise and the importance of weight loss. However there will be no dietician referral, psychosocial intervention or focused exercise and weight loss monitoring programme. Follow up will be at routine clinic visits only where lifestyle modification advice will be reinforced as per usual clinical practise.
16657286|NCT02233491|Active Comparator|Active intervention|This group will receive active lifestyle modification intervention and will consist of dietician referral, graded exercise programme and weight loss advice. The dietician will be supported by Clinical Psychology services and our collaboration with a recognised expert in behavioural change therapy. The dietician will be trained with motivational interviewing skills and psychological tools will be utilised to support the active lifestyle intervention.
16657287|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
16657288|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
16657289|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
16657290|NCT02233465|Experimental|IPOM Mesh-repair parastomal hernia|Mesh-repair of para-stomal hernia. Patients with para-stomal hernia requiring surgery are offererd enrollment in the study. Preoperatively a CT-scan of the abdomen and or a 3D ultrasonography of the stoma is performed. All patients in the stydy are operated with IPOM-mesh designed for treatment of parastomal hernia.
16657291|NCT02233465|No Intervention|No mesh-repair|Patients not attending the study
16657294|NCT02233452|Active Comparator|Methadone plus ketamine|Group treated with methadone plus ketamine solution
16657295|NCT02233439|Placebo Comparator|Placebo|a placebo identical in appearance to the galactagogue product
16657296|NCT02233439|No Intervention|No treatment|Usual care and breastfeeding support
16657297|NCT02233439|Experimental|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
16657298|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
16657299|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
16657300|NCT02233400|Experimental|Treatment|Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
16657301|NCT02233400|No Intervention|Control|Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
16657302|NCT02233387|Experimental|[18F] HX4 PET imaging|injection with [18F] HX4 and PET imaging at baseline and after 20 Gy radiotherapy
16657303|NCT02233374|Experimental|Assessing response with MRI + PET.|"Pre-operative chemo/RT as per standard treatment. Intensity Modulated Radiotherapy (IMRT) / Volumetric Arc Therapy (VMAT) 45Gray/25 fractions with simultaneous integrated Boost of 50Gray/25 fractions + concurrent capecitabine chemotherapy.
~Intervention 1 'Early MRI and PET/CT - 2 weeks after commencing chemo/RT' involves additional Multiparametric MRI + PET/CT 2 weeks into chemo/RT Intervention 2 :\'Late MRI and PET/CT 6 weeks post chemo/RT' involves additional Multiparametric MRI + PET/CT 6 weeks post chemo/RT"
16657304|NCT02233361|Experimental|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
16657305|NCT02233361|No Intervention|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
16657306|NCT02233348||ASD group|Subjects with DSM-IV ASD diagnosis
16657307|NCT02233348||Control group|Controls without lifetime ASD or a family history of ASD
16657308|NCT02233322|Experimental|iron supplements|all subjects will receive iron supplementation based on iron levels in blood
16657309|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.
~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
16657310|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
16657311|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
16657312|NCT02233283|Active Comparator|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
16657313|NCT02233283|Experimental|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
16657314|NCT02233283|Active Comparator|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
16657315|NCT02233283|Experimental|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
16657316|NCT02233244|Other|CTX-4430 and midazolam|Midazolam 2 mg solution once, CTX-4430 100 mg tablet once per day for 7 days, Midazolam 2 mg solution once
16657317|NCT02233231|Active Comparator|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
16657318|NCT02233231|Placebo Comparator|Placebo|Placebo tablets equivalent to IMP.
16657319|NCT02233218|Experimental|telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 40 subjects. Telmisartan80mg + Amlodipine 10mg 9 days, Telmisartan80mg + Amlodipine 10mg , Rosuvastatin 20mg 5days Total 14days administration of investigational products to healthy male volunteers
16657320|NCT02233218|Experimental|Telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 20 subjects. Rosuvastatin 20mg 5 days, Rosuvastatin 20mg , Telmisartan80mg + Amlodipine 10mg 9days, Total 14days administration of investigational products to healthy male volunteers
16657321|NCT02233205|Experimental|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
16657322|NCT02233179|Experimental|Removable Cast Walker|An offloading device that can be removed by the patients
16657323|NCT02233179|Active Comparator|Irremovable Cast Walker|A removable cast rendered irremovable using instant total contact cast, so patients cannot remove offloading device.
16657324|NCT02233153||Pre-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
16657325|NCT02233153||Post-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
16657326|NCT02233153||Pre-Elder Friendly Surgical Control Group|Elder Acute Care and Emergency Surgery patients
16657327|NCT02233153||Post-Elder Friendly Surgical Control Group|
16657328|NCT02233140|Experimental|Shockwave with manual manipulation|A shockwave (EPAT) therapy with two supervised manual manipulation per week
16657329|NCT02233140|Active Comparator|Manual manipulation|A Placebo (no) shockwave with two supervised manual manipulations per week
16657330|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
16657331|NCT02233114|Experimental|Yogic exercises|Yogic exercises for lung disorders
16657332|NCT02233114|Active Comparator|physiotherapy|Physiotherapy during the yogic exercises
16657333|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
16657334|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
16657335|NCT02233088|Experimental|ELM Group|A 6-month group lifestyle intervention, consisting of 12 weekly and 6 bi-weekly 2-hour sessions. The sessions consist of 30-min physical activity, 30-min meal demonstration, and 60-min group behavioral intervention, with a focus on experiential learning in naturalistic setting. Sessions are facilitated by dietitian/personal trainer and behavioral specialist.
16657336|NCT02233088|Other|ELM Classes|A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
16657337|NCT02233088|Active Comparator|ELM Individual|A 6-month intervention, that consists of educational manuals on physical activity, diet and stress reduction and recommended 3 medical visits every 3 months for medical counseling and feedback using 5A (Ask, Advise, Assess, Assist, and Arrange) framework . These Metabolic syndrome care materials and provider documentation will be embedded in electronic medical record system, and will be accessible to medical providers by usual means. This enhanced usual care by participant's usual health care provider focuses on metabolic syndrome and lifestyle modifications to reduce the risk of chronic disease.
16657338|NCT02233075|Experimental|REP 2139-Ca + Pegasys (TM)|REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.
16657339|NCT02233062|Experimental|Semen quality|
16657340|NCT02233049|Experimental|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
16657341|NCT02233049|Experimental|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
16657342|NCT02233049|Experimental|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
16657343|NCT02233049|Experimental|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
16657344|NCT02233023|Experimental|Pramixpexole|
16657345|NCT02233023|Active Comparator|Bromocriptine and other dopamine agonists|
16657346|NCT02233010||kidney function normal group|kidney function normal group : defined by the normal level of NGAL after post operation 4hrs
16657347|NCT02233010||kidney function decreased group|kidney function decreased group : defined by the increased level of NGAL after post operation 4hrs
16657348|NCT02232997|Active Comparator|Long Hydration|Long term hydration at routine speed(12h before and after procedure)
16657349|NCT02232997|Active Comparator|Short Hydration|Short term hydration at high speed(1h before and 4h after procedure)
16657350|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
16657351|NCT02232971|Placebo Comparator|Placebo|Isotonic Saline
16657352|NCT02232971|Experimental|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
16657353|NCT02232971|Experimental|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
16657354|NCT02232971|Experimental|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
16657355|NCT02232958|Experimental|Hyperbaric Oxygen treatment|administration of 100% Oxygen at 2 Atmospheres Absolute for 1 hour 1 daily, 5 days a week for 2 weeks
16657356|NCT02232945|Placebo Comparator|placebo|placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.
16657357|NCT02232945|Experimental|Banlangen granules & placebo|Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate
16657358|NCT02232945|Active Comparator|oseltamivir phosphate & placebo|oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules
16657359|NCT02232932|Experimental|CAPECITABINE-Radiotherapy -Liver Transplantation|Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)
16657360|NCT02232932|Active Comparator|RESECTION|Liver resection
16657361|NCT02232919|Experimental|Deep Brain Stimulation|The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index [BMI] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
16657362|NCT02232906|Experimental|intravenous ferric carboxymaltose|
16657363|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
16657364|NCT02232893|Placebo Comparator|Placebo|Placebo TID
16657365|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.
~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
16657418|NCT02232464||ADHD group|Adults with clinical diagnosis of ADHD according to the DSM-IV criteria
16657419|NCT02232464||Control group|Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD
16657366|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.
~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
16657367|NCT02232867|Experimental|Arm and Leg Cycling Exercise Program|Multiple baseline test sessions will be used for the same participant to establish a meaningful baseline thus confirming consistency of all outcome measures prior to the intervention.
16657368|NCT02232854|Experimental|Depression training/supervision program|"A complex intervention, which will include:
~Primary Health Care team training in depression
~A focus group, after training
~Telephone monitoring of patients
~Web-based supervision of clinicians"
16657369|NCT02232854|No Intervention|Usual Care|Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.
16657370|NCT02232841||Mechanical ventilation|Hospitalized adult patients with lung injury receiving mechanical ventilation and who also have received or will receive a CT scan as part of their standard care
16657371|NCT02232828|Experimental|Selective removal|
16657372|NCT02232828|Active Comparator|Stepwise removal|
16657373|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
16657374|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
16657375|NCT02232789|Experimental|Mephedrone|Mephedrone 200 mg, single dose, oral administration
16657376|NCT02232789|Active Comparator|3,4-methylenedioxymethamphetamine|3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
16657377|NCT02232789|Placebo Comparator|Lactose|Placebo, single dose, oral administration
16657378|NCT02232776|Experimental|Losartan treatement|All patients had received losartan treatment for 24 weeks.
16657379|NCT02232763|Experimental|Losartan|12 weeks of losartan or placebo with crossover to the other
16657380|NCT02232763|Experimental|Placebo|12 weeks of losartan or placebo with crossover to the other
16657381|NCT02232737|Experimental|0.8 mg nicotine|0.8 mg nicotine cigarettes
16657382|NCT02232737|Experimental|0.12 mg nicotine|0.12 mg nicotine cigarettes
16657383|NCT02232737|Experimental|0.03 mg nicotine|0.03 mg nicotine cigarettes
16657384|NCT02232724|Experimental|Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
16657385|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
16657386|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
16657387|NCT02232685|Experimental|Choline PET/CT|18F-Choline PET/CT
16657388|NCT02232672|Experimental|MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
16657389|NCT02232659|Experimental|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
16657390|NCT02232659|Experimental|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
16657391|NCT02232646|Experimental|BBI503|
16657392|NCT02232633|Experimental|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
16657393|NCT02232620|Experimental|BBI503|
16657394|NCT02232607|Experimental|Lacidipine, low dose|
16657395|NCT02232607|Experimental|Lacidipine, medium dose|
16657396|NCT02232607|Experimental|Lacidipine, high dose|
16657397|NCT02232607|Active Comparator|Placebo|
16657398|NCT02232594||chronic obstructive respiratory tract disease patients|
16657399|NCT02232581|Experimental|Alovudine - low|
16657400|NCT02232581|Experimental|Alovudine - medium|
16657401|NCT02232581|Experimental|Alovudine - high|
16657402|NCT02232581|Placebo Comparator|Placebo|
16657403|NCT02232568|Experimental|Feedback Arm|Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb <8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
16657404|NCT02232568|No Intervention|Control Arm|Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.
16657405|NCT02232555|Experimental|Duloxetine|
16657406|NCT02232555|Placebo Comparator|Placebo|
16657407|NCT02232542|Experimental|Duloxetine - low dose|
16657408|NCT02232542|Experimental|Duloxetine - high dose|
16657409|NCT02232542|Placebo Comparator|Placebo|
16657410|NCT02232529|Experimental|Part 1: MIN-101|"MIN-101
~modified release formulation (MR),single oral dose between 16 and 64 mg"
16657411|NCT02232529|Experimental|Part 2: MIN-101 low dose|"MIN-101
~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
16657412|NCT02232529|Placebo Comparator|Part 2: placebo|"placebo MIN-101
~daily oral dose from Day 1 to Day 7"
16657413|NCT02232529|Experimental|Part 2: MIN-101 high dose|"MIN-101
~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
16657414|NCT02232516|Experimental|Treatment (romidepsin, lenalidomide)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16657415|NCT02232490|Experimental|hepcortespenlisimut-L|Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
16657416|NCT02232490|Placebo Comparator|placebo|placebo
16657417|NCT02232477|Experimental|Open-label treatment|laronidase 1.74 mg IT q 3 months for five years
16657490|NCT02231996||gene mutation|
16657420|NCT02232451|Experimental|ERCP with loop tip wire|ERCP with loop tip wire is an endoscopic procedure to treat biliary disease. Wire guide cannulation with loop-tip is a new procedure to improve rate of biliary cannulation and reduce complication, as post-procedure pancreatitis.
16657421|NCT02232451|Active Comparator|ERCP for cannulation|ERCP for cannulation of CBD with traditional technique
16657422|NCT02232438|Experimental|Behavioral activation therapy|Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.
16657423|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
16657424|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
16657425|NCT02232399|Active Comparator|Milrinone|In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg
16657426|NCT02232399|Experimental|Levosimendan|In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg
16657427|NCT02232386|Experimental|Treatment|"Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Treatment duration with Ibrutinib will be based on what comes first of the following three options:
~Treatment until progression or toxicity
~Treatment until MRD negativity for 6 months
~Treatment for 6 years. Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1."
16657428|NCT02232373|Sham Comparator|Normal FODMAP arm|Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
16657429|NCT02232373|Experimental|Low FODMAP arm|Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
16657430|NCT02232360|Experimental|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
16657431|NCT02232360|Active Comparator|Rosuvastatin alone|Rosuvastatin 10 mg per day
16657432|NCT02232347|Experimental|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
16657433|NCT02232347|Active Comparator|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
16657434|NCT02232334|Experimental|Osteopathic manual treatment|Global Osteopathic Manual treatment: each subject will be treated according to what restrictions or areas of poor mobility are found individually. No two subjects will receive the same overall treatment.
16657435|NCT02232334|No Intervention|Control--no change in current treatment of subject|The population will act as their own control prior to intervention of osteopathy, their will be a control period where the subject maintains current treatment of their gastroparesis. During that period they will fill out the GCSI measuring tool at the beginning of the control period and at the end. Those measurements will be compared to the GSCI results during the intervention period.
16657436|NCT02232321|Other|PsA MDA|
16657437|NCT02232308|Experimental|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
16657438|NCT02232308|Experimental|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
16657439|NCT02232308|Experimental|Nizatidine plus Lisinopril|Nizatidine (150 mg) and Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
16657440|NCT02232308|Placebo Comparator|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
16657441|NCT02232295|Active Comparator|Conventional group|Conventional group consist of Upper extremity task oriented functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities.
16657442|NCT02232295|Experimental|Graded Motor imagery group and Conventional group|"Graded Motor imagery is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:
~Left Right discrimination training (Implicit Motor Imagery) - 2 weeks
~Explicit Motor Imagery (Imagined movements) - 2 weeks
~Mirror Therapy - 2 weeks"
16657443|NCT02232282|Sham Comparator|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
16657444|NCT02232282|Active Comparator|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
16657445|NCT02232269|Placebo Comparator|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
16657446|NCT02232269|Active Comparator|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
16657447|NCT02232269|Experimental|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour
~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
16657448|NCT02232269|Active Comparator|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour
~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
16657449|NCT02232256|Experimental|CALPXT96|"1st treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)
~2 week wash out period
~2nd treatment period: 4 weeks placebo (two capsules hs at bedtime)"
16657450|NCT02232256|Placebo Comparator|Placebo|"1st treatment period: 4 weeks placebo (two capsules hs at bedtime)
~2 week wash 'out' period
~2nd treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)"
16657451|NCT02232243|Experimental|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
16657452|NCT02232243|Experimental|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
16657453|NCT02232243|Experimental|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
16657454|NCT02232217|Experimental|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
16657455|NCT02232217|Active Comparator|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
16657456|NCT02232204|Active Comparator|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
16657457|NCT02232204|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
16657458|NCT02232191|Active Comparator|Nonoperative|Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
16657459|NCT02232191|Active Comparator|Angioembolization|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
16657460|NCT02232191|Active Comparator|Splenectomy|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
16657461|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
16657462|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
16657463|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
16657464|NCT02232165|Experimental|Hypotension avoidance (MAP >= 65 mmHg)|Mean arterial blood pressure is maintained >= 65 mmHg for 7 days following acute SCI.
16657465|NCT02232165|Active Comparator|Induced hypertension (MAP >= 85 mmHg)|Induced hypertension with mean arterial blood pressure >= 85 mmHg for 7 days following acute SCI.
16657466|NCT02232152|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
16657467|NCT02232139|No Intervention|Standard therapy group|Participant who will not receive midazolam for pharmacological anxiolytic premedication before general surgery
16657468|NCT02232139|Experimental|Midazolam group|Participant who will receive midazolam for pharmacological anxiolytic premedication before general surgery
16657469|NCT02232126|No Intervention|Usual Care|
16657470|NCT02232126|Experimental|Intervention|
16657471|NCT02232113|Experimental|CERA|We included HD patients with stable hematocrit (between 30~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
16657472|NCT02232100|Experimental|10AMG|Attentional bias modification group - 10 training sessions
16657473|NCT02232100|Placebo Comparator|10ACG|Attentional control group - 10 placebo sessions
16657474|NCT02232100|Experimental|18AMG|Attentional bias modification group - 18 training sessions
16657475|NCT02232100|Placebo Comparator|18ACG|Attentional control group - 18 placebo sessions
16657476|NCT02232087|Experimental|test product A|salmeterol and fluticasone propionate, 2 puffs
16657477|NCT02232087|Active Comparator|reference product D|salmeterol and fluticasone propionate, 2 puffs
16657478|NCT02232087|Experimental|test product B|salmeterol and fluticasone propionate, 6 puffs
16657479|NCT02232087|Active Comparator|reference product E|salmeterol and fluticasone propionate, 6 puffs
16657480|NCT02232087|Experimental|test product C|salmeterol and fluticasone propionate, 12 puffs
16657481|NCT02232087|Active Comparator|reference product F|salmeterol and fluticasone propionate, 12 puffs
16657482|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
16657483|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
16657484|NCT02232061|Experimental|Fingolimod|Fingolimod 0.5mg/day tablets taken orally.
16657485|NCT02232048||Corticosteroid Treatment|Patients in the internal medicine department who are being treated with corticosteroids will undergo Transthoracic Echocardiogram to determine change in heart function.
16657486|NCT02232035|Placebo Comparator|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
16657487|NCT02232035|Experimental|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
16657488|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
16657489|NCT02232009|Other|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
16657491|NCT02231983||Severe Combined Immunodeficiency|Case histories were analyzed to grasp important characteristics of the diseases. Distribution of lymphocyte subsets from peripheral blood were examined by flow cytometry. Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
16657492|NCT02231970|Experimental|Endoscopic sleeve gastroplasty|The intervention is an endoscopic procedure: to perform endoscopic sleeve gastroplasty we used a cap-based flexible endoscopic suturing system (OverStitch™, Apollo, Inc. Austin, Texas) mounted on a double-channel endoscope (GIF-2T160; Olympus Medical Systems Corporation, Tokyo, Japan) to achieve full-thickness, running sutures through the gastric wall from antrum to fundus.
16657493|NCT02231957|Experimental|educational text message reminders|receipt of education-embedded text message vaccine reminders
16657494|NCT02231957|Active Comparator|conventional text message reminders|receipt of conventional text message vaccine reminders
16657495|NCT02231944|Experimental|Replenine®-VF|
16657496|NCT02231931|Experimental|A (Reference 1) Digoxin|1 tablet as single dose, fasted
16657497|NCT02231931|Experimental|B (Reference 2) Furosemide|oral solution, as single dose, fasted
16657498|NCT02231931|Experimental|C (Reference 3) Metformin hydrochloride|1 film-coated tablet as single dose, fasted
16657499|NCT02231931|Experimental|D (Reference 4) Rosuvastatin|1 film-coated tablet as single dose, fasted
16657500|NCT02231931|Experimental|E (Test) 1|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
16657501|NCT02231931|Experimental|F (Test 2)|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted
16657502|NCT02231931|Experimental|G (Test 3)|Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
16657503|NCT02231918|Experimental|MIRAPEX® - low|
16657504|NCT02231918|Experimental|MIRAPEX® - medium|
16657505|NCT02231918|Experimental|MIRAPEX® - high|
16657506|NCT02231905|Experimental|BI-Sifrol®|Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.
16657507|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
16657508|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
16657509|NCT02231879|Active Comparator|Year 1 crossover|G-CSF or plerixafor, blinded
16657510|NCT02231879|Active Comparator|Year 2 crossover|G-CSF or plerixafor, blinded
16657511|NCT02231866|Experimental|Group 1|cAd3-EBO at 2x10(10)PU IM
16657512|NCT02231866|Experimental|Group 2|cAd3-EBO at 2x10(11)PU IM
16657513|NCT02231866|Experimental|Group 3|cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
16657514|NCT02231866|Experimental|Group 4A|cAd3-EBOZ at 1x10(10)PU IM
16657515|NCT02231866|Experimental|Group 4B|cAd3-EBOZ at 1x10(11)PU IM
16657516|NCT02231866|Experimental|Group 5|cAd3-EBO at 2x10(11)PU IM
16657517|NCT02231853|Experimental|-1|1x10e4 MVST/kg infusion
16657518|NCT02231853|Experimental|1|1x10e5 MVST/kg infusion
16657519|NCT02231853|Experimental|2|5x10e5 MVST/kg infusion
16657520|NCT02231853|Experimental|3|1x10e6 MVST/kg infusion
16657521|NCT02231853|Experimental|3B|1x10e6 MVSTr/kg infusion
16657522|NCT02231853|Experimental|4|5x10e6 MVSTr/kg infusion
16657526|NCT02231827|Experimental|Gait analysis|
16657527|NCT02231814|Experimental|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
16657528|NCT02231814|Experimental|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
16657529|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
16657530|NCT02231788|Experimental|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
16657531|NCT02231788|Active Comparator|Telmitrend®Tab. 80mg|Telmitrend®Tab.(Telmisartan) 80mg
16657532|NCT02231775|Experimental|Treatment (dabrafenib, trametinib, surgery)|Patients receive dabrafenib PO BID and trametinib PO QD for 8 weeks. After completion of 8 weeks of dabrafenib and trametinib, patients undergo surgery. Approximately 1 week after surgery, patients receive dabrafenib PO BID and trametinib PO QD for 44 additional weeks in the absence of disease progression or unacceptable toxicity.
16657533|NCT02231762|Experimental|Lanreotide Autogel 120mg & Temozolomide|"Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.
~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment."
16657536|NCT02231736||Type 2 diabetes, HbA1c>7.5|
16657537|NCT02231736||Type 2 diabetes, HbA1c<7.5|
16657538|NCT02231723|Experimental|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
16657539|NCT02231723|Experimental|B: BBI608 in combination with modified FOLFIRINOX|
16657540|NCT02231723|Experimental|C: BBI608 in combination with FOLFIRI|
16657541|NCT02231723|Experimental|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
16657542|NCT02231710|Experimental|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
16657543|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
16657544|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
16657545|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
16657546|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
16657547|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
16657548|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
16657549|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
16657550|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
16657551|NCT02231684|Experimental|i.v. 0.25 mg (1 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
16657552|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by i.v. 0.25 mg (1 mg/ml)|
16657553|NCT02231671|Experimental|Part 1: Absolute Bioavilability|Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg [14C]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
16657554|NCT02231671|Experimental|Part 2: Mass Balance|Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg [14C]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range.
16657555|NCT02231658|Experimental|Liraglutide|The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
16657556|NCT02231658|Experimental|Lixisenatide|The highest injected once daily dose will be 20µg s.c. for lixisenatide.
16657557|NCT02231645|Experimental|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
16657558|NCT02231645|No Intervention|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
16657559|NCT02231632|Experimental|Live attenuated Poliomyelitis vaccine (human diploid cell)|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
16657560|NCT02231632|Experimental|Poliomyelitis（Live）Vaccine(Monkey Kidney Cell),Oral|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
16657561|NCT02231619|No Intervention|Demonstration of LSUPT at baseline|This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker.
16657562|NCT02231619|Active Comparator|Baseline verbal instruction of LSUPT|Verbal instruction on how to do LSUPT at baseline
16657563|NCT02231606|No Intervention|Group 1: Pure Control|Provision of glasses prescription only
16657564|NCT02231606|Experimental|Group 2: Free Glasses|Free glasses for all, no upgrade glasses offered
16657565|NCT02231606|Experimental|Group 3: Free + Upgrade Glasses 1|Free glasses for all, optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
16657566|NCT02231606|Experimental|Group 4: Free + Upgrade Glasses 2|Free glasses for all, optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
16657567|NCT02231593||Acromegalic patients|
16657568|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
16657569|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
16657570|NCT02231567|Experimental|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
16657571|NCT02231567|Active Comparator|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
16657572|NCT02231554|Experimental|Feldenkrais|The Feldenkrais method is a self education method that uses the somatic sensory-motor learning to enhance the functions of people in daily life activities through the awareness of their motor habits and the experience of more efficient alternatives.
16657573|NCT02231554|Active Comparator|Back School|The Back School teaches the patient, with theoretical and practical knowledge, how to defend his own back from the pain and how to prevent their disease, considering awareness and education as important parts of the therapeutic process .
16657574|NCT02231541|Experimental|Very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
16657575|NCT02231541|Placebo Comparator|Turned off very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
16657576|NCT02231528|Experimental|Use of ultrasound with active GPS|
16657577|NCT02231528|Active Comparator|Use of ultrasound with inactive GPS|
16657578|NCT02231515|Experimental|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty
16657579|NCT02231515|Active Comparator|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty (SLT)
16657580|NCT02231502|Experimental|Vegetable-based convenience food|"One time ingestion of a vegetable-based convenience product. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).
~At least 7 days wash-out between each assessment visit."
16657620|NCT02231177|Active Comparator|Tiotropium|
16657621|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
16657622|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
16657581|NCT02231502|Active Comparator|Vegetable meal|"One time ingestion of a minimally processed vegetable meal. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).
~At least 7 days wash-out between each assessment visit."
16657582|NCT02231489|Experimental|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram [mg] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
16657583|NCT02231489|Experimental|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
16657584|NCT02231463||ultrasound measurement|"measuring subclavian vein Diameter in six Groups:
~neutral positioning, PEEP 0 cm H2O, neutral positioning, PEEP 5cm H2O, neutral positioning, PEEP 10cm H2O, Trendelenburg positioning -20°, PEEP 0 cmH2O, Trendelenburg positioning -20°, PEEP 5 cmH2O, Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure."
16657585|NCT02231450|Experimental|Patients with mild hepatic impairment (Group1)|8 patients with mild hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054
16657586|NCT02231450|Experimental|Patients with moderate hepatic impairment (Group 2)|8 patients with moderate hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054.
16657587|NCT02231450|Experimental|Healthy subjects (Group 3)|8 healthy subjects will be administered a single oral dose of 60 mg Lu AE58054.
16657588|NCT02231437||chronic obstructive respiratory tract disease patients|
16657589|NCT02231424||chronic obstructive respiratory tract disease patients|
16657590|NCT02231411|Active Comparator|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
16657591|NCT02231411|Active Comparator|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
16657592|NCT02231398||Women who participated in nuMoM2b|
16657593|NCT02231385|Experimental|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.
~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
16657594|NCT02231385|No Intervention|Control Group|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.
~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
16657595|NCT02231372||chronic obstructive airways disease patients|
16657596|NCT02231359||chronic obstructive airways disease patients|
16657597|NCT02231346||chronic obstructive pulmonary disease patients|
16657598|NCT02231333|Experimental|S-adenosylmethionine (SAMe)|
16657599|NCT02231333|Active Comparator|pentoxiphylline (PTX)|
16657600|NCT02231320||Chronic Obstructive Pulmonary Disease patients|
16657601|NCT02231307|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
16657602|NCT02231307|Experimental|SUBLIVAC FIX Birch 40,000 AUN/ml|
16657603|NCT02231294||Idiopathic Parkinson's Disease Patients|
16657604|NCT02231281|Experimental|cART(TDF/AZT+3TC+LPV/r)|cART(TDF/AZT+3TC+LPV/r)
16657605|NCT02231281|Experimental|CTL infusion|cART plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
16657606|NCT02231268||Depressive patients|
16657607|NCT02231255||Idiopathic Parkinson's disease patients|
16657608|NCT02231242|Experimental|Intrathecal Autologous Bone Marrow TNC|Procedure/Surgery: Intrathecal Autologous Bone Marrow TNC. Other Names: Autologous Stem Cell Transplantation Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) (10mcgr/kg of body weight) for 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the autologous TNC concentrate of 10 mL will be infused intrathecally.
16657609|NCT02231242|No Intervention|Control group|"Patients will be evaluated with the Gross Motor Functional Classification System initially, at one, three and six months, and then cross to the intervention arm."
16657610|NCT02231229|Experimental|PCR-based strategy|PCR-based strategy: after testing for isoniazid and rifampin resistance using a molecular testing with PCR (GenoType ®MTB DR plus), patients will receive HRZ combination therapy (INH , RIF, PZA) if no resistance is detected
16657611|NCT02231229|Active Comparator|conventional therapy|Conventional therapy: based on the standard of care in France: initiation of the standard 4 drug regimen INH, RIF, PZA, and EMB, until drug susceptibility testing (DST) results are available.
16657612|NCT02231216|Experimental|Rhinoseptoplasty and turbinectomy|Patients submitted to rhinoseptoplasty associated to Endoscopic partial turbinectomy.
16657613|NCT02231216|Active Comparator|Rhinoseptoplasty|Patients submitted only to rhinoseptoplasty, without turbinectomy procedure.
16657614|NCT02231203|Placebo Comparator|Placebo|2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
16657615|NCT02231203|Active Comparator|Omegaven|2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
16657616|NCT02231190|Experimental|GSK1278863|Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
16657617|NCT02231190|Placebo Comparator|Placebo|Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
16657618|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
16657619|NCT02231177|Active Comparator|BI 1744 CL|
16657623|NCT02231151|Experimental|Pediatric Acute Care Professionals|Individuals must work in ER or ICU setting regularly or rotate through this setting with up to date BLS/PALS/ACLS certification. The participants will be required to rate the CPR based on accuracy for each video shown. The type of CPR error(s) shown to the individuals will be randomized.
16657624|NCT02231138|Experimental|Abelmoschus manihot (AM)|"age above 12 years old (including 12)：huangkui capsule are given orally at 2.5 g three times per day
~age between 6-12 years old(including 6):huangkui capsule are given orally at 1.5 g three times per day
~age under 6 years old：huangkui capsule are given orally at 1.0 g three times per day"
16657625|NCT02231125|Experimental|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huangkui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
16657626|NCT02231125|Experimental|Losartan|Losartan potassium (Hangzhou MSD Pharmaceutical Co., Ltd.), 100 mg × 7 capsules/box.
16657627|NCT02231112|Experimental|Prone position whole breast RT|
16657628|NCT02231099|Experimental|prolift + m|surgery with mesh (prolift+M)
16657629|NCT02231099|Active Comparator|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
16657630|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
16657631|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
16657632|NCT02231073|Experimental|Exercise: Agility Boot Camp-Cognitive|Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
16657633|NCT02231073|Active Comparator|Education: Living with Parkinson's disease|The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
16657634|NCT02231060||AIE after Cardiac Arrest|Male and female patients with AIE following CA.
16657635|NCT02231047|Experimental|64N Nutraceutical|Powdered 64N Nutraceutical 40 mg/kg/day mixed in 12 ounces of a culturally appropriate warm drink for 1 week (7 days).
16657636|NCT02231047|Sham Comparator|No 64N Nutraceutical|Culturally appropriate 12 ounce warm drink daily for 1 week (7 days).
16657637|NCT02231021|Experimental|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
16657638|NCT02231021|Active Comparator|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
16657639|NCT02231021|Active Comparator|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
16657640|NCT02231008|Experimental|Tasimelteon|Single dose oral capsule, daily dosage, for 21 weeks
16657641|NCT02231008|Placebo Comparator|Placebo|Placebo comparator
16657642|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
16657643|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
16657644|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
16657645|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
16657646|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
16657647|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
16657648|NCT02230930|Active Comparator|Massage with a spiky ball|Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
16657649|NCT02230930|Active Comparator|Hydrocortisone cream 1%|Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
16657650|NCT02230930|Active Comparator|Subcutaneous hydrocortisone 10mg|Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
16657695|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
16657696|NCT02230631||Part 2 (prospective observational evaluation)|
16657651|NCT02230930|Active Comparator|Apomorphine 0.25% (2.5mg/ml)|Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.
16657652|NCT02230917|Experimental|Sotatercept|Sotatercept 0.2 mg/kg will be administered every 21 days for 12 doses subcutaneously into the upper arm, abdomen or thigh.
16657653|NCT02230917|Placebo Comparator|Placebo|0.2 mg/kg of normal saline will be administered subcutaneously in the upper arm, abdomen or thigh for 21 days for 12 doses.
16657654|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
16657655|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
16657656|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
16657657|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
16657658|NCT02230891|No Intervention|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
16657659|NCT02230878|Experimental|JNJ-42847922, 5 milligram (mg) and Placebo|Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
16657660|NCT02230878|Experimental|JNJ-42847922, 10 mg and Placebo|Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
16657661|NCT02230878|Experimental|JNJ-42847922, 20 mg and Placebo|Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
16657662|NCT02230878|Experimental|JNJ-42847922, 40 mg and Placebo|Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
16657663|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
16657664|NCT02230839|Experimental|Exercise training protocol|
16657665|NCT02230839|Experimental|Energy restriction-induced weight loss|
16657666|NCT02230839|No Intervention|Health Education|
16657667|NCT02230826||Patients with Hip arthroplasty|Patients with Hip implants.
16657668|NCT02230813||Oral antibiotic therapy|Consecutive adult patients attending the study Emergency Departments with cellulitis will be considered eligible for recruitment to the study. Only those patients deemed suitable for oral antibiotic therapy and planned for discharge will be recruited to the study. Oral antibiotic therapy prescribed will be dependent on local institutional prescribing guidelines. For the purposes of the sites enrolling participants, the antibiotic of choice is oral flucloxacillin 500 milligrams four times daily for seven days. We will be assessing the treatment failure rate for this cohort of patients; namely, the number of patients requiring the primary outcome (change from oral to intravenous antibiotic therapy). We will also assess this group of patient for the secondary outcomes listed above.
16657669|NCT02230800|Experimental|Tocovid SupraBio plus pentoxifylline (PTX)|Tocovid SupraBio* 200mg po bd plus pentoxifylline (PTX) 400mg po bd for 12 months.
16657670|NCT02230800|Placebo Comparator|Matching placebos|Matching placebos bd for 12 months.
16657671|NCT02230787|Active Comparator|Recession coverage without Emdogain|
16657672|NCT02230787|Experimental|Recession coverage with Emdogain|
16657673|NCT02230774||medical staff|Nurses and doctors oncall
16657674|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
16657675|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
16657676|NCT02230735|Experimental|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
16657677|NCT02230735|Placebo Comparator|Normal Saline|Total of 14 ml of normal saline, 7ml into the right uterosacral ligament and 7ml into the left uterosacral ligament
16657678|NCT02230722|Active Comparator|Attention Control|The neutral 10-15 minute visit with the Care Manager will consist of a brief review of ATHENA-OT safety education and the patient's Pain Care Plan. The CM will answer patient questions, but will avoid using Motivational Interviewing communication. The Care Manager will review upcoming telephone check-in and assessment sessions.
16657679|NCT02230722|Experimental|Collaborative Care|Collaborative Care intervention in which one of two Care Managers delivering both interventions will assist primary care providers (PCPs) by using Motivational Interviewing to communicate computer-based ATHENA-OT (opioid therapy) decision support guidelines to veterans with chronic pain.
16657680|NCT02230709|Experimental|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
16657681|NCT02230709|Active Comparator|"TENS and dry needling"|Application of TENS current after dry needling treatment.
16657685|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
16657686|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
16657687|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
16657688|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
16657689|NCT02230670|Placebo Comparator|Placebo|Placebo BID
16657690|NCT02230657|Active Comparator|Same day Discharge|
16657691|NCT02230657|Active Comparator|Next day discharge|
16657692|NCT02230644|Experimental|Audio enhanced|Enhanced Clinical Environment: participants wait for their operation in the enhanced audio-visual booth.
16657693|NCT02230644|Active Comparator|Other distraction method|Participants wait for their operation in a booth with another distraction such as the news on television
16657694|NCT02230644|No Intervention|Ordinary|Participants wait for their operation in an ordinary, unenhanced booth
16657698|NCT02230605|Experimental|Cognitive Exercise|The cognitive exercises will consist of a series of computer games focusing on five categories: memory, speed, attention, flexibility and problem-solving. Participants will be expected to complete 1 hour of Lumosity exercise daily for a minimum of 8 days prior to surgery. Participants will be instructed to complete no less than 15 minutes of exercise at a time throughout each day. Each hour of exercise, participants will work through at least 1 game under each category. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
16657699|NCT02230605|Placebo Comparator|Normal Activity|Participants randomized into the Normal Activity group will be encouraged to maintain their normal activity level prior to surgery. These participants are asked not to alter their normal daily routine of mental exertion (i.e. watching television, reading, puzzles, etc.) and not permitted to subscribe to Lumosity while in the research study. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
16657700|NCT02230579|Experimental|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
16657701|NCT02230579|Experimental|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
16657702|NCT02230579|Experimental|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
16657703|NCT02230579|Experimental|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
16657704|NCT02230579|Experimental|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
16657705|NCT02230579|Experimental|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
16657706|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
16657707|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
16657708|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
16657709|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
16657710|NCT02230553|Experimental|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
16657711|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.
~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
16657712|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.
~Catheterization with SelfCath (comparator) followed by measurement of residual urine.
~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
16657713|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
16657714|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
16657715|NCT02230514|Experimental|XCEL-MT-OSTEO-ALPHA and surgery|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue"
16657716|NCT02230514|Other|Autologous iliac crest and surgery|Standard treatment
16657717|NCT02230501|Experimental|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner
~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
16657718|NCT02230501|Experimental|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner
~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
16657719|NCT02230488|Active Comparator|Intensive Diabetes Case Management|Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
16657720|NCT02230488|No Intervention|Control :Standard/ usual care|
16657721|NCT02230462|Experimental|Viewing of cancer excision defect|Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
16657722|NCT02230462|No Intervention|No viewing of cancer excision defect|Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.
16657723|NCT02230436|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 72)
16657724|NCT02230436|Experimental|Late drain removal|Removing drain(s) on postoperative day 4 or later (n = 72)
16657725|NCT02230423|Experimental|Patients receiving nose surgery|"Patients in need of nose surgery, before and after surgery; or only after successful surgery, then with or without Empty Nose Syndrome."
16657727|NCT02230397|Other|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
16657728|NCT02230397|Other|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
16657729|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
16657730|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
16657731|NCT02230371|Experimental|Granisetron|Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
16657732|NCT02230371|Placebo Comparator|Control (placebo)|Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.
16657733|NCT02230358|Other|Regional anesthesia (RA)|Regional anesthesia (RA) for a carotid endarterectomy Interventions: Regional anesthesia (RA), blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, Near-infrared spectroscopy (NIRS) monitoring, oxygen supply (not invasive 'Vigileo')
16657734|NCT02230358|Other|General anesthesia (GA)|General anesthesia (GA) for a carotid endarterectomy Interventions: General anesthesia, blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, NIRS monitoring, oxygen supply (not invasive 'Vigileo')
16657735|NCT02230345|Experimental|Probiotic yogurt|Daily administration, during two weeks, of two probiotic yogurts (200 mL each)
16657736|NCT02230345|Active Comparator|Acidified milk|Daily administration, over two consecutive weeks, of an isocaloric dose (compared to probiotics) of unfermented acidified milk
16657737|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
16657738|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
16657739|NCT02230319|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
16657740|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.
~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
16657741|NCT02230293|Active Comparator|Conventional Group|Conventional treatment and follow up
16657742|NCT02230293|Experimental|Multidisciplinary Group|Multidisciplinary assistance
16657743|NCT02230280|Other|The intervention cohort.|A community transition and rehabilitation intervention that includes a mobile health solution
16657744|NCT02230267|Experimental|High intensity boot camp|Each of the two HIBCs will have 10 participants (20 total) with a 1:5 physical therapist-to-patient ratio. Each HIBC session will last 1.5 hours and will be held on 4 days of the week. Participants will be required to attend 3 of those 4 days but may attend all. Because this is a pragmatic trial, therapists will have some leeway to control the intensity and the modality of the exercise. However, the basic format of the HIBC will consist of the following exercise components: A. 30 minutes of moderate-high intensity aerobic exercise at 70%+ of estimated maximum heart rate; B. 15 minutes of strengthening the major muscle groups of the trunk and upper/lower extremities; C. 15 minutes of balance training; and, D. 15 minutes of rest and stretching. Participants will rotate through these four different exercise components in a circuit fashion.
16657745|NCT02230267|Active Comparator|Usual care arm|The low intensity exercise group will participate in the Fitness Counts Exercise Program (FCEP) which is a basic low intensity, sitting and standing exercise program (10 minutes of stretching, 10 minutes of aerobic exercise (60% of heart rate maximum), and 10 minutes of strengthening). This exercise program was developed by the National Parkinson Foundation and is commonly used in PD exercise classes. The physical therapist-to-patient ratio will be 1:5. As there are two clinical sites, there will be 10 participants in each of the two boot camps (20 total). The FCEP will be 1 hour daily on four days of the week. Participants will be required to attend 3 days per week but may attend more if they are able.
16657746|NCT02230254|Experimental|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
16657747|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
16657748|NCT02230228|Experimental|ALK-001 capsules|
16657749|NCT02230215|Experimental|Patient-Specific Instrumentation|Patients to have a total knee replacement surgery completed using Patient-Specific Instrumentation
16657750|NCT02230215|No Intervention|Traditional Instrumentation|Patients to have a total knee replacement surgery done using traditional instrumentation.
16657751|NCT02230202||Healthy control|Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
16657752|NCT02230202||Stage III or IV CKD patients|Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
16657753|NCT02230202||Post-transplant patients|Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
16657754|NCT02230189|Experimental|Non-allergic/Non-asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with neither asthma nor allergy (as established by skin prick testing)
16657755|NCT02230189|Experimental|Allergic/Non-asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with allergy (as established by skin prick testing) but without asthma
16657756|NCT02230189|Experimental|Allergic/Asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with both asthma and allergy (as established by skin prick testing)
16657757|NCT02230176|Experimental|177Lu-DOTA0-Tyr3-Octreotate or OCLU|7.4 GBq per injection (max: 4 injections)
16657758|NCT02230176|Active Comparator|Sunitinib|37.5 mg/day
16657759|NCT02230137|Experimental|Text message arm|
16657760|NCT02230137|No Intervention|No text message arm|
16657761|NCT02230124|Experimental|MRE|
16657762|NCT02230111|Experimental|Energy restriction plus CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. They will be told that they are on a low-calorie diet and strategies to increase CDR will be used.
16657763|NCT02230111|Experimental|Energy restriction without CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
16657764|NCT02230098|Experimental|Remote Ischemic Conditioning|By use of short-term obstruction of the blood supply to the arm
16657765|NCT02230098|No Intervention|Before Remote Ischemic Conditioning|
16657766|NCT02230085||CPAP therapy|
16657767|NCT02230072|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
16657768|NCT02230059||Metastatic Castration-resistant Prostate Cancer|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
16657769|NCT02230046|Experimental|Sequence 1 (ABC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
16657770|NCT02230046|Experimental|Sequence 2 (BCA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
16657771|NCT02230046|Experimental|Sequence 3 (CAB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
16657772|NCT02230046|Experimental|Sequence 4 (ACB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
16657773|NCT02230046|Experimental|Sequence 5 (BAC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
16657774|NCT02230046|Experimental|Sequence 6 (CBA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
16657775|NCT02230033|Experimental|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1.
16657776|NCT02230033|Experimental|Treatment B|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
16657777|NCT02230033|Experimental|Treatment C|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
16657778|NCT02230020||Nasal High Flow|All subjects are in this group
16657779|NCT02230007|Experimental|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
16657780|NCT02230007|No Intervention|Without MEOPA|Physiotherapit care without MEOPA
16657781|NCT02229994||Adults patients with chronic respiratory diseases|"- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.
~Sample 1 (n=110 patients) with COPD
~Sample 2 (n=30 patients) with Diffuse interstitial lung diseases
~Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).
~Sample 4 (n=30 patients) Adult with Cystic fibrosis"
16657782|NCT02229981|Experimental|ABC294640|Patients will receive ABC294640 orally in gelatin capsules BID.
16657783|NCT02229968|Experimental|Amicar (ε-aminocaproic acid)|Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.
16657784|NCT02229968|Placebo Comparator|normal saline|Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.
16657785|NCT02229955|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
16657786|NCT02229955|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
16657787|NCT02229942|Experimental|Rituximab|Rituximab induction (two infusions two weeks apart) and maintenance (infusions at 3, 6, 9 and 12 months)
16657788|NCT02229942|Placebo Comparator|Placebo|Saline (with added albumin), two infusions two weeks apart, followed by infusions at 3, 6, 9 and 12 months.
16657789|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
16657790|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
16657791|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
16657792|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
16657793|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
16657794|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
16657795|NCT02229903|Active Comparator|Active DTMS Treatment|Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
16657796|NCT02229903|Sham Comparator|Sham Treatment|The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
16657797|NCT02229890||Acute ischemic stroke within three hours after symptom onset|
16657798|NCT02229877|Experimental|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days
~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
16657799|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
16657800|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
16657801|NCT02229851|Active Comparator|Daily hGH|
16657802|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
16657803|NCT02229838|Experimental|BIBB 1464 MS single rising dose fed|
16657804|NCT02229838|Experimental|BIBB 1464 MS tablet fasted|
16657805|NCT02229838|Active Comparator|BIBB 1464 MS solution fasted|
16657806|NCT02229838|Placebo Comparator|BIBB 1464 MS placebo|
16657807|NCT02229825|Experimental|Duloxetine low|
16657808|NCT02229825|Experimental|Duloxetine high|
16657809|NCT02229812||thrombolytic therapy in stroke|
16657810|NCT02229799||Stroke patients|
16657811|NCT02229786|Experimental|Buscopan® plus|
16657812|NCT02229786|Active Comparator|Buscopan®|
16657813|NCT02229786|Active Comparator|Paracetamol|
16657814|NCT02229786|Placebo Comparator|Placebo|
16657815|NCT02229773|Experimental|BIBB 1464 MS low dose|
16657816|NCT02229773|Placebo Comparator|Placebo|
16657817|NCT02229773|Active Comparator|Pravastatin|
16657818|NCT02229773|Experimental|BIBB 1464 MS medium dose|
16657819|NCT02229773|Experimental|BIBB 1464 MS high dose|
16657820|NCT02229760|Experimental|TPV/r (Tipranavir co-administered with low dose ritonavir)|
16657821|NCT02229747|Experimental|Meloxicam suspension|
16657822|NCT02229747|Active Comparator|Diclofenac suspension|
16657823|NCT02229747|Active Comparator|Nimesulide suspension|
16657824|NCT02229734|Experimental|Radiation plus Androgen Supression|Radiation plus Androgen Suppression give as stereotactic radiation 7gray (Gy) per week x 5 weeks and leuprolide 45mg every 6 months for 18 months
16657825|NCT02229721|Active Comparator|Syntocinon Nasalspray 32 IU|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
16657826|NCT02229721|Placebo Comparator|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
16657827|NCT02229708|No Intervention|Usual Care|The Usual Obstetric Care group will receive usual advice about nutrition and activity during pregnancy from their obstetrician along with some additional information about pregnancy and childbirth through readings from The American College of Obstetricians and Gynecologists. In addition, participants will receive weekly text messages to maintain contact and ensure follow-up.
16657828|NCT02229708|Experimental|Healthy Lifestlye Group|The Healthy Lifestyle Group will take part in an individual, technology-based behavioral intervention program which will include specific information about nutrition and physical activity, and strategies for helping them make changes to their diet, physical activity, and weight-related behaviors during pregnancy. Participants will receive information through print materials, text messages, a private Facebook group, and in-person visits and phone calls from a health coach who is part of our research team.
16657829|NCT02229682|Experimental|Mild-dose IMRT|"Experimental: Mild-dose of 46Gy with IMRT
~Drug:
~gemcitabine：1250mg/m2 (iv drip) on days 1, oxaliplatin: 85 mg/m2 (iv drip) on day 1, and pegaspargase: 2500 IU/m2 (intramuscular injection) on day 1. Cycle is repeated every 14 days
~IMRT： IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions."
16657830|NCT02229669|Experimental|Horizontal incisions|Coronally advanced flap was performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted extending beyond the mucogingival junction, to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed.
16657858|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
16657892|NCT02229240|Placebo Comparator|Matching albiglutide placebo|Subjects will receive once-weekly subcutaneous injections of matching albiglutide placebo in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms
16657831|NCT02229669|Experimental|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
16657832|NCT02229656|Experimental|radiotherapy and olaparib|Radiotherapy will be given with accelerated fractionation following the DAHANCA schedule Olaparib: dose escalation
16657833|NCT02229643||Traumatic brain injury|Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
16657834|NCT02229630|Experimental|Pregnant women|Foetuses with intra-uterine growth restriction, between 28 and 32 weeks of gestation, with an estimated foetal weight < 5th percentile (Hadlock calculator)
16657835|NCT02229617|Active Comparator|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
16657836|NCT02229604|Experimental|EA group|Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
16657837|NCT02229604|Active Comparator|drug group|Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.
16657838|NCT02229591||EFL patients|Patients with Expiratory Flow Limitation undergoing surgery
16657839|NCT02229591||Control group|Patients withouth Expiratory Flow Limitation undergoing surgery
16657840|NCT02229578||Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
16657841|NCT02229578||Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
16657842|NCT02229565||Caucasian|Caucasian subjects having a biopsy or prostatectomy.
16657843|NCT02229565||African American|African American subjects having a biopsy or prostatectomy.
16657844|NCT02229552|Other|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
16657845|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.
~Patients will complete the Oral Symptoms booklet per the protocol."
16657846|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.
~Patients will complete the Oral Symptoms booklet per the protocol."
16657847|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.
~Patients will complete the Oral Symptoms booklet per the protocol."
16657848|NCT02229526|Active Comparator|Low dose fish oil|
16657849|NCT02229526|Placebo Comparator|Low dose olive oil|
16657850|NCT02229526|Experimental|High dose fish oil|
16657851|NCT02229526|Placebo Comparator|High dose olive oil|
16657852|NCT02229513|No Intervention|Control|Normal cesarean technique.
16657853|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
16657854|NCT02229500|Active Comparator|Control|Inulin control, 10g/d for 7 days. Isotope and appetite measurements on day 7
16657855|NCT02229500|Experimental|Delivery system 1|Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
16657856|NCT02229500|Experimental|Delivery system 2|Delivery system, 54% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
16657857|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
16657859|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
16657860|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
16657861|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
16657862|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
16657863|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
16657864|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
16657865|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
16657866|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
16657867|NCT02229448||IgG4 UKN diagnosis|who ever been found with IgG4 sub class in blood sample or in his byposy
16657868|NCT02229435||eGFR <60ml/min|Patients with CKD with eGFR <60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.
16657869|NCT02229422|Experimental|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.
~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.
~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.
~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.
~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
16657870|NCT02229409|No Intervention|Control|Observation only, no behavioral intervention
16657871|NCT02229409|Experimental|Intervention|Intervention Walkadoo.
16657872|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
16657873|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
16657874|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
16657875|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
16657876|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
16657877|NCT02229370||ECAA|all patients diagnosed with an extracranial carotid artery aneurysm
16657878|NCT02229357|Experimental|OrniFlu® inactivated vaccine|
16657880|NCT02229331||gait analysis|gait analysis
16657881|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
16657882|NCT02229305|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
16657883|NCT02229305|Experimental|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
16657884|NCT02229292|Active Comparator|Tranexamic acid|The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
16657885|NCT02229292|Placebo Comparator|Saline|The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
16657886|NCT02229279|Active Comparator|Teleconsulting|Teleconsulting
16657887|NCT02229279|No Intervention|No Teleconsulting|
16657888|NCT02229266|Experimental|NK cells|Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
16657889|NCT02229266|Active Comparator|Control Intervention|1 cycle of consolidation chemotherapy with high-dose cytarabine
16657890|NCT02229253||Degarelix|Treatment according to standard clinical practice.
16657891|NCT02229240|Experimental|Albiglutide|Subjects will receive once-weekly subcutaneous injections of albiglutide 30 mg (with forced uptitration to albiglutide 50 mg at Week 4) in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms.
16660086|NCT02214888|Placebo Comparator|Placebo|
16657893|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
16657894|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
16657895|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
16657896|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
16657897|NCT02229201|Experimental|Propofol|intravenous anaesthetic
16657898|NCT02229201|Active Comparator|Sevoflurane|volatile anaesthetic
16657899|NCT02229188|Active Comparator|Problem Solving Therapy|Problem Solving Therapy is an evidence-based behavioral treatment for late life depression proven effective with different geriatric groups including ambulatory; medically ill; older adults with executive dysfunctions; and more recently, low-income, disabled older adults.
16657900|NCT02229188|Experimental|Evolution|Evolution is a plasticity intervention in the form of a video driving game that targets the cognitive conflict network.
16657901|NCT02229188|Placebo Comparator|Words|Words is a challenging crosswords type of game that will serve as the placebo comparator to Evo.
16657902|NCT02229175|Experimental|IVB + laser|Intravitreal bevacizumab (IVB) will be administered at baseline, month 1, and month 2, consistent with previous DME trials. Subvisible laser treatment will be administered at baseline. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB and laser therapy every 3 months if defined retreatment criteria are met, as described below.
16657903|NCT02229175|Active Comparator|IVB only|IVB monthly at baseline, month 1, and month 2. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB if defined retreatment criteria are met, as described below. Patients will also undergo sham laser treatment (patient will be placed in front of laser but no laser will be activated) to mask the patient to the treatment.
16657904|NCT02229162||90 seconds DCC|the initial 15-20 subjects (15 enrolled subjects who complete study) will have cord clamped at 90 seconds. Then data will be analyzed and evaluated by DSMB
16657905|NCT02229162||Two minutes DCC|If Data Safety Monitoring Board (DSMB) concurs, DCC will then be practiced for 2 minutes for second group, which is the minimum amount of time recommended to be defined as DCC.
16657906|NCT02229149|Experimental|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab
~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND
~physician's choice of chemotherapy:
~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
~Docetaxel 75 mg/m2 IV every 3 weeks; OR
~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
~AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
16657907|NCT02229149|Active Comparator|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab
~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND
~physician's choice of chemotherapy:
~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
~Docetaxel 75 mg/m2 IV every 3 weeks; OR
~Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
16657908|NCT02229136|Experimental|Miracle Mouthwash plus Hydrocortisone|Miracle Mouthwash plus Hydrocortisone, swish and expectorate 10cc (10 mLs) 4 times per day, every day for 12 weeks.
16657909|NCT02229136|Active Comparator|Prednisolone|Prednisolone oral solution 15 mg/5 ml; swish and expectorate 10cc (10 mL) 4 times per day, every day for 12 weeks.
16657910|NCT02229123|Experimental|Intravenous levetiracetam|1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.
16657911|NCT02229110|Active Comparator|Signal|In addition to usual care, there will be an automatic signal in the electronic medical record (EMR) upon opening that will show the reader that the patient is currently not treated in the correct treatment setting and it simultaneously will give advice to which treatment allocation this patient should be transferred to.
16657912|NCT02229110|No Intervention|No signal|Patients receive usual care, consisting of 4 office visits yearly
16657913|NCT02229097|Experimental|Normal then Coordinated|normal bolus during 2 weeks then coordinated bolus during 2 weeks
16657914|NCT02229097|Experimental|Coordinated then Normal|coordinated bolus during 2 weeks then normal bolus during 2 weeks
16657915|NCT02229084|Experimental|Part 1 - Chemovax Schedule A|Feasibility - Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
16657916|NCT02229084|Experimental|Part 1 - Chemovax Schedule B|Feasibility - Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
16657990|NCT02228538||Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers
16657917|NCT02229084|Experimental|Part 1 - Chemovax Schedule C|Feasibility - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
16657918|NCT02229084|Experimental|Part 1 - Chemovax Schedule D|Feasibility - Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
16657919|NCT02229084|Experimental|Part 1 - Chemovax Schedule E|Feasibility - Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
16657920|NCT02229084|Experimental|Part 2 - Chemovax Schedule C|Primary Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
16657921|NCT02229084|Experimental|Part 3 - Chemovax Schedule C|Expanded Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
16657922|NCT02229071|Experimental|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
16657923|NCT02229071|Active Comparator|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
16657924|NCT02229058|Experimental|Albumin Bound Paclitaxel plus S-1|Abraxane 120 mg/m2, D1,D8;S-1 40~60mg QD D1-D14,every 3 weeks until disease progress or intolerable toxicity.
16657925|NCT02229045|Experimental|Albumin Bound Paclitaxel With 5-FU/CF|Albumin Bound Paclitaxel 150 mg/m2 (on day 1),5FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
16657926|NCT02229032||Dravet Sydrome|Patients with Dravet Syndrome who are self-seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy
16657927|NCT02229019|Experimental|Volunteer mealtime assistance|Trained volunteers will provide mealtime assistance to older hospital inpatients at one mealtime each weekday.
16657928|NCT02229006||Aneurysm surveillance|Radiation: 18F-NaF PET-CT
16657929|NCT02229006||Control patients|Radiation: 18F-NaF PET-CT
16657930|NCT02228993||Awake Craniotomy|
16657931|NCT02228993||General Anesthesia Craniotomy|
16657932|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
16657933|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
16657934|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
16657935|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
16657936|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
16657937|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:
~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.
~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.
~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
16657938|NCT02228954||Renal Cell Cancer|
16657939|NCT02228941||gene mutation|
16657940|NCT02228928|Experimental|CAPNP, 50 ug/cm2 capsaicin patch|50 ug/cm2 capsaicin patch, 49cm2, 1patch/4days
16657941|NCT02228928|Experimental|CAPNP, 100 ug/cm2 capsaicin patch|100ug/cm2 capsaicin patch, 49cm2, 1patch/4days
16657942|NCT02228928|Active Comparator|0.075% capsaicin cream|capsaicin cream qc/day
16657943|NCT02228928|Placebo Comparator|Placebo patch|
16657944|NCT02228902|Active Comparator|ferrous fumarate|12 patients receive ferrous fumarate, 12 patients receive ferrous gluconate
16657945|NCT02228902|Active Comparator|ferrous gluconate|12 patients receive ferrous fumarate and 12 patients receive ferrous gluconate
16657946|NCT02228889|Experimental|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
16657985|NCT02228603|Active Comparator|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
16657986|NCT02228603|Other|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
16657987|NCT02228590|Other|APL-130277|open label baseline comparison
16657988|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
16657989|NCT02228551|Other|ARC PPS|Augmented renal clearance Point prevalence study
16657947|NCT02228889|Experimental|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
16657948|NCT02228863|Experimental|Early Inmotion and Botox|Concomitant use of Inmotion and botulinum toxin from the baseline
16657949|NCT02228863|Active Comparator|Botox, then Inmotion|Inmotion training 4 weeks after botulinum toxin injection
16657950|NCT02228863|Active Comparator|Inmotion, then Botox|From the baseline Inmotion, then Botox injection at 4 weeks after baseline
16657951|NCT02228863|Active Comparator|Late Inmotion and Botox|No intervention, then Inmotion and Botox injection at 4 weeks from the baseline
16657952|NCT02228850|Experimental|Alprostadil Cream (300mcg)|300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
16657953|NCT02228850|Experimental|Alprostadil Cream (1000mcg)|1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
16657954|NCT02228850|Experimental|Alprostadil Cream (3000mcg)|3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration
16657955|NCT02228837|Placebo Comparator|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
16657956|NCT02228837|Experimental|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
16657957|NCT02228824|Experimental|Very low nicotine content cigarettes|
16657958|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
16657959|NCT02228811|Experimental|DCC-2701 tablet|DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16657960|NCT02228798||Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require surgery or a procedure.
16657961|NCT02228798||Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require surgery or a procedure.
16657962|NCT02228798||Apixaban|Patients currently taking apixaban that have atrial fibrillation and require surgery or a procedure.
16657963|NCT02228785|Experimental|100µg dose of G17DT|Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
16657964|NCT02228785|Experimental|200µg dose of G17DT|Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
16657965|NCT02228785|Experimental|500µg dose of G17DT|Patients in this arm received a 500µg dose of G17DT via intramuscular injection.
16657966|NCT02228772|Experimental|MLN 9708|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~MLN 9708 will be given with standard multi-drug regimen for ALL . MLN 9708 will be administered on determined days during Induction therapy cycle and Consolidation cycle. If remission occurs and if eligible, the next stage with be either Stem Cell or Bone Marrow Transplant.
~If not eligible to receive a transplant, the participant will continue on this study for the next 3 stages.
~CNS Therapy
~Consolidation 2
~Continuation Therapy
~No further MLN9708, the investigational drug, will be given after Consolidation 1 Standard chemotherapy -Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate"
16657967|NCT02228759|Experimental|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
16657968|NCT02228746|Experimental|Alpha-galacto-oliosaccharides|
16657969|NCT02228746|Placebo Comparator|Placebo|
16657970|NCT02228733|Experimental|KBP-5074: Cohort 1|Healthy Volunteers will receive one dose of KBP-5074
16657971|NCT02228733|Experimental|KBP-5074: Cohort 2|Healthy Volunteers will receive one dose of KBP-5074
16657972|NCT02228733|Experimental|KBP-5074: Cohort 3|Healthy Volunteers will receive one dose of KBP-5074
16657973|NCT02228733|Experimental|KBP-5074: Cohort 4|Healthy Volunteers will receive one dose of KBP-5074
16657974|NCT02228733|Experimental|KBP-5074: Cohort 5|Healthy Volunteers will receive one dose of KBP-5074
16657975|NCT02228733|Experimental|KBP-5074: Fed Group|Healthy Volunteers will receive one dose of KBP-5074
16657976|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
16657977|NCT02228707|Experimental|BIIB061|Participants receive BIIB061
16657978|NCT02228707|Placebo Comparator|Placebo|Participants receive matched placebo
16657979|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
16657980|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
16657981|NCT02228655|Other|FMX-8|FMX-8 for injection, 15mg/kg, twice weekly, 29 days
16657982|NCT02228629|Experimental|Typical house shoe|Subject's typical shoes worn in and around home
16657983|NCT02228616|Experimental|Prucalopride plus Polyethylene glycol or lactulose|
16657984|NCT02228603|Experimental|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
16658024|NCT02228278|Experimental|Group A|Group A will receive the typical clinic visits plus daily text messages
16657991|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
16657992|NCT02228512|Active Comparator|1|Treatment naive PEL (main cohort)
16657993|NCT02228512|Active Comparator|2|Treatment na(SqrRoot) ve large cell lymphoma arising in KSHV-MCD
16657994|NCT02228512|Active Comparator|3|Previously treated KSHV-NHL
16657995|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
16657996|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
16657997|NCT02228486|Active Comparator|Cue Exposure Therapy and verum tDCS|During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
16657998|NCT02228486|Placebo Comparator|Cue Exposure Therapy and sham tDCS|During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
16657999|NCT02228486|No Intervention|Waiting list control group|The Cue-Reactivity of patients assigned to this arm will be measured twice with an interval of 5 weeks. Afterwards, patients will take part in the cue exposure therapy like subjects assigned to the active arms of the study
16658000|NCT02228473|Experimental|Glycopyrrolate|Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
16658001|NCT02228473|Active Comparator|Atropine|Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
16658002|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
16658003|NCT02228447|No Intervention|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
16658004|NCT02228447|Experimental|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
16658005|NCT02228434|Experimental|Tailored intervention group|"For the monitoring session, physical activity was assessed by accelerometer and dietary was assessed by diary. Based on the monitoring information, the individual tailored prescription, including the normative feedback and process feedback, were formed and delivered to children and parents. Children were encouraged to modify the behaviors according to the prescription.
~Then, next monitoring circle was followed. In total, 7 monitoring round were completed."
16658006|NCT02228434|Experimental|Happy 10 exercise group|All the schools participating in this group were encouraged to take two Happy 10 sessions on each school day.
16658007|NCT02228434|Experimental|Nutrition education group|The nutrition intervention was mainly conducted based on the nutrition knowledge through health education lectures given by researchers. The lectures were given for eight times to students and twice to parents. Each lecture session lasted no less than 40 min.
16658008|NCT02228434|No Intervention|Control group|Receive no intervention
16658009|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
~Allowable Dosage Forms:
~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
16658010|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
16658011|NCT02228395|Experimental|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
16658012|NCT02228395|Experimental|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
16658013|NCT02228395|Experimental|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
16658014|NCT02228382|Experimental|Bosutinib|
16658015|NCT02228369|Experimental|Daily dose of AZD3759|Daily oral dose of AZD3759
16658016|NCT02228369|Experimental|Daily Dose of AZD9291|Daily oral dose of AZD9291
16658017|NCT02228343|Experimental|Ayurveda|Ayurvedic therapy
16658018|NCT02228330|Experimental|uni-lateral obturator nerve block|"Patients scheduled for TUR for bladder tumor Intervention: uni-lateral obturator nerve block.
~non-blocked obtorator side of each patient will be used as control"
16658019|NCT02228317|Experimental|Telemedicine consultation|EMTs will systematically establish teleconsultation by either telephone or video with the EMDC-physician in all cases of non-critical illness
16658020|NCT02228304|Experimental|NT-503-3 ECT implantation|
16658021|NCT02228304|Active Comparator|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
16658022|NCT02228291|Placebo Comparator|Placebo|Cellulose
16658023|NCT02228291|Experimental|Citric flavonoid|Citric flavonoid
16658203|NCT02227017|Experimental|TPV/RTV capsules fed|
16658025|NCT02228278|Other|Group B|Group B will act as the control and will receive the typical clinic visits.
16658026|NCT02228265||Ancillary-Correlative (genetic analysis)|Patients undergo collection of blood and tissue samples at baseline, during administration of enzalutamide and after the time of disease progression for analysis via immunohistochemistry, comparative genome hybridization, and sequencing.
16658027|NCT02228252|Experimental|20 g whey protein (-15 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
16658028|NCT02228252|Experimental|20 g whey protein (-30 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 30 min prior to the main meal.
16658029|NCT02228252|Experimental|20 g casein|20 g casein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
16658030|NCT02228252|Experimental|20 g gluten protein|21.5 g gluten protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
16658031|NCT02228239|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
16658032|NCT02228239|Experimental|Sequence 2 (BCA)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
16658033|NCT02228239|Experimental|Sequence 3 (CAB)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
16658034|NCT02228239|Experimental|Sequence 4 (CBA)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
16658035|NCT02228239|Experimental|Sequence 5 (ACB)|Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
16658036|NCT02228239|Experimental|Sequence 6 (BAC)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
16658037|NCT02228226||MG-1treated group|MG-1treated group: Patients those who underwent arthroscopic Bankart repair for glenohumeral instability using MG-1
16658038|NCT02228213|Experimental|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
16658039|NCT02228213|Placebo Comparator|Saline|Saline administered i.v. once weekly for 52 weeks
16658040|NCT02228200|Experimental|Nurse-led care|Subjects in the nurse-led care arm received nurse-led care and routine care.
16658041|NCT02228200|Active Comparator|Routine care|Subjects in the routine care arm received routine care provided by the study hospital.
16658042|NCT02228187|Active Comparator|BCI Intervention|Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
16658043|NCT02228187|No Intervention|Waitlist Control Group|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
16658044|NCT02228174|Experimental|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
16658045|NCT02228161|Experimental|Yoga exercise|Participatants will receive regular 60-minutes yoga classes twice a week for 3 months.
16658046|NCT02228161|No Intervention|Regular schedule of daily living|Participants will maintain regular schedule as usual.
16658047|NCT02228148|Experimental|NFS|Cochlear Nucleus Fitting Software
16658048|NCT02228148|Active Comparator|CSS|Cochlear Nucleus Custom SoundTM Suite
16658049|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
16658050|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
16658051|NCT02228122|Experimental|Aquacel® Ag+ Extra|
16658052|NCT02228109|Experimental|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
16658053|NCT02228109|Experimental|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
16658054|NCT02228109|Experimental|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
16658055|NCT02228096|Experimental|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
16658056|NCT02228083|Active Comparator|Safety of dental anesthesia|Application of local dental anesthesia with two cartridges (5,6 mL) of the lidocaine 2% with epinephrine 1:100.000 in heart failure patients in functional class III or IV.
16658057|NCT02228083|Other|Oral health profile|An oral health profile of patients with heart failure will be described based in oral clinical examination.
16658058|NCT02228070|Experimental|strabismus video goggles|
16658059|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
16658060|NCT02228044|Experimental|Prevention Program|This is a cognitive-behavioral substance abuse, suicide, and HIV prevention program delivered in a workshop format to adolescent participants and their parents/legal guardians.
16658061|NCT02228044|No Intervention|Assessment Only|
16658204|NCT02227017|Experimental|TPV/RTV capsules fasted|
16658205|NCT02227017|Active Comparator|TPV/RTV solutions fed|
16658062|NCT02228031|Experimental|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.
16658063|NCT02228031|Placebo Comparator|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
16658064|NCT02228018|Experimental|CALSA and FRI repeatability|CT-Scan No medication used
16658065|NCT02228005|Experimental|Depression|Sertraline 50- 200mg
16658066|NCT02228005|No Intervention|Comparison group (non-depressed)|No intervention
16658067|NCT02227992|Experimental|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
16658068|NCT02227992|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
16658069|NCT02227979|Experimental|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
16658070|NCT02227979|Active Comparator|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
16658071|NCT02227966|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
16658072|NCT02227966|Sham Comparator|sham-YBand (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
16658073|NCT02227953|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
16658074|NCT02227953|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
16658075|NCT02227940|Experimental|Arm 1 (ceritinib MTD then with gemcitabine alone)|"Dose Escalation Cohort 1: Patients with advanced solid tumors for whom gemcitabine hydrochloride-based therapy is clinically appropriate receive ceritinib PO (QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Expansion Cohort 1E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors who previously progressed on gemcitabine hydrochloride-based therapy receive ceritinib and gemcitabine hydrochloride as in the dose escalation cohort 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16658076|NCT02227940|Experimental|Arm 2 (ceritinib MTD then with gemcitabine and nab-paclitaxel)|"Dose Escalation Cohort 2: Patients with advanced pancreatic cancer receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Expansion Cohort 2E: Once the MTD of ceritinib has been determined, patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation as in the dose escalation cohort 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16658077|NCT02227940|Experimental|Arm 3 (ceritinib MTD then with gemcitabine and cisplatin)|"Dose Escalation Cohort 3: Patients with advanced solid tumors for whom gemcitabine hydrochloride and cisplatin-based therapy is clinically appropriate receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Expansion Cohort 3E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and cisplatin as in the dose escalation cohort 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
16658078|NCT02227914|Experimental|Oprozomib with Sorafenib|"Phase 1b:
~Oprozomib doses will be escalated in sequential groups of at least 2 subjects. Study subjects will receive oprozomib at dose levels of 90, 120, 150, 180, 210, or 240 mg + sorafenib to reach the dose levels of 600 or 800 mg total daily dose until the maximum tolerated dose (MTD) is reached.
~Phase 2:
~Study subjects who meet the entry criteria will receive oprozomib + sorafenib at the RP2D (recommended Phase 2 dose) established in the Phase 1b portion of the study."
16658079|NCT02227914|Active Comparator|Sorafenib|"Phase 2:
~Study subjects who meet the entry criteria will receive sorafenib 400 mg twice a day (800 mg total daily dose)."
16658080|NCT02227901|Experimental|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.
~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
16658081|NCT02227888|Experimental|N91115|Every 12 hour oral dosing of 50 mg N91115 for 14 days
16658082|NCT02227875|Experimental|Mylan's insulin Glargine|receive Mylan's insulin Glargine
16658083|NCT02227875|Active Comparator|Lantus®|receive Lantus®
16658084|NCT02227862|Experimental|Mylan's Insulin Glargine|Receive Mylan's Insulin Glargine plus insulin lispro.
16658085|NCT02227862|Active Comparator|Lantus®|Receive Lantus® plus insulin lispro
16658086|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
16658087|NCT02227836|Experimental|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:
~2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.
~Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits
~The patches will be removed at 48 hours, and results read at 72 and 120 hours after application
~Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
16658088|NCT02227823|Experimental|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
16658089|NCT02227823|No Intervention|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
16658090|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
16658091|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
16658092|NCT02227797|Experimental|Voriconazole|
16658093|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
16658094|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
16658095|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
16658096|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
16658097|NCT02227771||Patient with chronic total occlusion|
16658098|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
16658099|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
16658100|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
16658101|NCT02227732|Other|New Indwelling Pleural Catheter|
16658102|NCT02227719|Experimental|Test: CTI|CTI is titanium mesh
16658103|NCT02227719|Active Comparator|Control: Collagen membrane|Collagen membrane is used for ridge augmentation
16658104|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
16658105|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
16658106|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
16658107|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
16658108|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
16658109|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
16658110|NCT02227680|Active Comparator|Music Therapy|Patients randomized to the music therapy group will receive 1-3 10-40 minute music therapy sessions during each of the days of their stay on the inpatient unit. Each participant randomized to the music therapy intervention will be given a personalized CD and one portable CD player with headphones which they may keep after the study has ended.
16658111|NCT02227680|Active Comparator|Massage Therapy|Patients randomized to the massage therapy group will receive 1-3 10-40 minute massage treatments during each of the days of their stay on the inpatient unit.
16658112|NCT02227680|No Intervention|Usual Care|The control group will continue to receive usual care while on the Family Medicine Inpatient Unit.
16658113|NCT02227667|Experimental|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
16658114|NCT02227654|Experimental|Abnormal Ovarian Ultrasound|Abnormal Ovarian Ultrasound
16658115|NCT02227641|Experimental|Adoptive transfer of CMV/EBV specific T-cells|Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.
16658116|NCT02227641|No Intervention|Control|Observation only.
16658117|NCT02227628|Placebo Comparator|Sugary Beverage|Sugary Beverage
16658118|NCT02227628|Experimental|Acai beverage|Acai Polyphenolics
16658119|NCT02227615|Placebo Comparator|Sugary beverage|Sugary beverage
16658120|NCT02227615|Experimental|Mango beverage|Mango polyphenolics
16658121|NCT02227602|Experimental|Mango|Mango polyphenolics
16658122|NCT02227589|Experimental|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
16658123|NCT02227589|Active Comparator|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
16658124|NCT02227589|Active Comparator|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
16658125|NCT02227576|Experimental|Romiplostim|Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.
16658126|NCT02227563|Experimental|Active tDCS|active tDCS
16658127|NCT02227563|Sham Comparator|control|sham (placebo) tDCS condition
16658128|NCT02227550|Experimental|Apixaban|Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)
16658129|NCT02227550|Active Comparator|Vitamin K antagonist|VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine
16658130|NCT02227537||Adolescence idiopathic scoliosis|Patients must be at least 10 years of age with a risser score of 0, 1, or 2
16658131|NCT02227524|Experimental|No Device|Assistive device conditions
16658132|NCT02227524|Experimental|Single Point Cane|Assistive device condition
16658133|NCT02227524|Experimental|Four-Point Cane|Assistive device condition
16658134|NCT02227524|Experimental|Trekking Pole|Assistive device condition
16658135|NCT02227511|Active Comparator|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
16658136|NCT02227511|Active Comparator|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
16658137|NCT02227498|Experimental|Effect of Argus II on Functional Vision|All subjects enrolled in the study will be implanted with the Argus II Retinal Prosthesis. To evaluate safety and effectiveness of Argus II on visual function.
16658138|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
16658139|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
16658140|NCT02227472||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study will complete evaluation of cognitive and pre-academic skills, and parent questionnaires.
16658141|NCT02227459|Experimental|Experimental: Arm A|Once a week dosing
16658142|NCT02227459|Experimental|Experimental: Arm B|Twice a week dosing
16658143|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.
~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
16658144|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
16658145|NCT02227433|Experimental|brentuximab vedotin (BV)|
16658146|NCT02227420|Experimental|Anakinra|Anakinra 100mg s.c. x 5
16658147|NCT02227407|Experimental|Energy expenditure, gait pattern, RGOs|using motion capture system and forceplates to monitor gait pattern while wearing reciprocating gait orthoses to calculate the mechanical energy cost
16658148|NCT02227394|Experimental|Z7200|"Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.
~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
16658149|NCT02227394|Active Comparator|Symbicort® Turbohaler|Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).
16658150|NCT02227381||Microarray / NGS test|
16658151|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
16658152|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
16658153|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) <70 years of age.
16658154|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
16658155|NCT02227342|Experimental|Fecal Microbiota Transplantation|serial Fecal Microbiota Transplantation
16658156|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
16658157|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
16658158|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
16658159|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
16658160|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
16658161|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
16658162|NCT02227303|Other|Lifestyle counseling|
16658163|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
16658164|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
16658165|NCT02227277|Experimental|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
16658166|NCT02227277|Experimental|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
16658167|NCT02227277|No Intervention|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
16658168|NCT02227264|Experimental|Cinacalcet|"Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.
~Second intervention: Parathyroid adenomectomy."
16658174|NCT02227225||Postoperative Delirium|
16658175|NCT02227212|Experimental|Insulin glargine U300|Once daily subcutaneous injection for 4 weeks
16658176|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 1 (brentuximab 1.2mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.2mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
16658177|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 2 (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
16658178|NCT02227199|Experimental|Phase II: Dose Expansion (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
16658179|NCT02227186|No Intervention|Control arm|No school-located influenza vaccination clinic
16658180|NCT02227186|Experimental|School-located influenza vaccination clinics|School-located influenza vaccination clinics
16658181|NCT02227173|Experimental|Single-Sequence, A B C|"Treatment A:
~Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1
~Treatment B:
~BMS-986020 orally twice daily (BID) on Day 8 through Day 10
~Treatment C:
~BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17"
16658182|NCT02227160|Experimental|Psychosocial group intervention|Subjects will seek outpatient counseling, support groups, in addition to 10 weekly group meetings
16658183|NCT02227160|Active Comparator|Control|Subjects will seek outpatient counseling and support groups only
16658184|NCT02227147|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
16658185|NCT02227147|Placebo Comparator|Placebo|Vehicle: formulation containing anti-oxidant
16658186|NCT02227134|Other|Difficult Airway|Children with a history of difficult airway intubation.
16658187|NCT02227134|Other|Obstructive Sleep Apnea|Children with a history of obstructive sleep apnea.
16658188|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
16658189|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
16658190|NCT02227095|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
16658191|NCT02227095|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
16658192|NCT02227082|Experimental|radiotherapy and olaparib|radiotherapy: 61.18 Gy olaparib: dose escalating
16658193|NCT02227069|Experimental|M518101|M518101 is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
16658194|NCT02227069|Placebo Comparator|M518101 Vehicle|M518101 vehicle is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
16658195|NCT02227069|Active Comparator|sodium lauryl sulfate|A solution of 0.2% sodium lauryl sulfate is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
16658196|NCT02227069|Sham Comparator|Saline|A solution of 0.9% saline is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
16658197|NCT02227056|Experimental|Methylphenidate treatment|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
16658198|NCT02227056|No Intervention|Control|On three different days each participant will be re-evaluated without recieveing Methylphenidate.
16658199|NCT02227030|Experimental|BIIB 722 CL single rising dose|
16658200|NCT02227030|Experimental|BIIB 722 CL cross over|
16658201|NCT02227030|Placebo Comparator|Placebo solution|
16658202|NCT02227030|Placebo Comparator|Placebo tablet|
16658207|NCT02227004||MRI in patients with Pacemaker or ICD|Perform MRI in patients with pacemaker or ICD and evaluate patient and device safety
16658208|NCT02226991|Experimental|TPV/RTV/EFV|tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23
16658209|NCT02226978|Experimental|TPV/r with valaciclovir|VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)
16658210|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
16658211|NCT02226952|Experimental|Group 1|BILN 2061 W, medium dose, in patients with genotype 1, minimal fibrosis
16658212|NCT02226952|Experimental|Group 2|BILN 2061 W, high dose, in patients with genotype 1, minimal fibrosis
16658213|NCT02226952|Experimental|Group 3|BILN 2061 W, high dose, in non-genotype 1 patients, minimal fibrosis
16658214|NCT02226952|Experimental|Group 4|BILN 2061 W, low dose, in patients with genotype 1, minimal fibrosis
16658215|NCT02226952|Experimental|Group 5|BILN 2061 W, medium dose, in patients with genotype 1, advanced fibrosis
16658216|NCT02226952|Placebo Comparator|Placebo|
16658217|NCT02226939|Experimental|BILN 2061 ZW|
16658218|NCT02226939|Placebo Comparator|Placebo|
16658219|NCT02226926|Experimental|Aggrenox|Dipyridamole extended release / Acetylsalicylic acid
16658220|NCT02226926|Active Comparator|Persantin Retard|Dipyridamole extended release
16658221|NCT02226926|Active Comparator|Acetylsalicylic acid|
16658222|NCT02226913|Experimental|lidocaine & sodium bicarbonate|2% lidocaine with 1: 80,000 epinephrine buffered with 0.18 mL of 8.4% sodium bicarbonate
16658223|NCT02226913|Active Comparator|lidocaine & placebo|2% lidocaine with 1:80,000 epinephrine with 0.18 mL of sterile distilled water
16658224|NCT02226900|Experimental|Hybrid Revascularization|The hybrid myocardial revascularization group will be accomplished by a two-step scheme, comprised by off-pump LIMA-to-left anterior descending grafting, followed by percutaneous coronary interventions with Promus Element (everolimus second generation drug eluting stent) for the remaining coronary lesions.
16658225|NCT02226900|Other|Conventional Surgical Coronary Bypass Grafting|Conventional Coronary Artery Bypass Grafts with in pump technique.
16658226|NCT02226887|Experimental|MESH|
16658227|NCT02226887|Active Comparator|NO MESH|
16658228|NCT02226861|Experimental|1|Subjects will receive CD34-selected stem cells followed by fixed dose ULG IL-2 (100,000 IU/m2) given subcutaneously for 12 weeks+Sirolimus until Day +60
16658229|NCT02226822||Adult patients with documented T2DM|Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
16658230|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
16658231|NCT02226796|Active Comparator|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes to the dorsolateral prefrontal cortex prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
16658232|NCT02226796|Active Comparator|Non-Prime Condition/Control|The non-primed (NON-PRIME) condition, or sham controlled, is an intervention that will consist of presentation of sham tDCS to the dorsolateral prefrontal cortex for 20 minutes prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
16658233|NCT02226783|Experimental|Treatment A AZD1722 salt tablet (fasted)|Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner
16658234|NCT02226783|Experimental|Treatment B AZD1722 salt tablet (fed)|Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner
16658235|NCT02226783|Experimental|Treatment C AZD1722 salt tablet (fasted)|Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption
16658236|NCT02226783|Experimental|Treat D AZD1722 free-base tablet (fast)|Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner
16658237|NCT02226783|Experimental|Treat E AZD1722 free-base+Omeprazole|Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
16658238|NCT02226770|Other|ICD|Implantation of an Implantable Cardioverter Defibrillator (ICD) in patients with heart failure
16658239|NCT02226757|Experimental|Paclitaxel-trastuzumab|Paclitaxel-trastuzumab weekly
16658240|NCT02226744|Active Comparator|Focused breathing|Focused deep breathing techniques used to produce specific physiological and psychological states
16658241|NCT02226744|Active Comparator|Focused breathing 2|Focused deep breathing techniques used to produce specific physiological and psychological states
16658242|NCT02226731|Experimental|Early Belfort-Dildy balloon device|
16658243|NCT02226731|Other|Late Belfort-Dildy balloon device|
16658244|NCT02226718||questionnaire|
16658245|NCT02226705|Experimental|Multiple Surgeries|Patients undergoing transnasal endoscopic surgery
16658246|NCT02226692||nonspecific chronic low back pain|Physical examination and follow-up assessment by questionnaires at 2, 4, 6, and 12 months
16658247|NCT02226679|Experimental|Algisyl-LVR device implantation|Algisyl-LVR™ employed as a method of left ventricular augmentation and restoration in patients with dilated cardiomyopathy. Algisyl-LVR™ will be injected into the myocardium under direct visualization during the surgical procedure.
16660108|NCT02214745||Mentally retarded Israeli Arab children|
16658248|NCT02226666||Patients having MRI with Eovist|Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
16658249|NCT02226666||Patients having MRI with Multihance|Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
16658250|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
16658251|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
16658252|NCT02226640||Non-Diabetic Lean Athletes|Athletes with a Body Mass Index (BMI) less than or equal to 25 kg/m2.
16658253|NCT02226640||Non-Diabetic Lean No Diabetes History|Adults with a BMI < 25 kg/m2 and no family history of diabetes
16658254|NCT02226640||Non-Diabetic Lean Yes Diabetes History|Adults with a BMI < 25 kg/m2 and family history of diabetes
16658255|NCT02226640||Non-Diabetic Obese|Adults with BMI greater than or equal to 30 kg/m2.
16658256|NCT02226640||Non-Diabetic Obese Female PCOS|Female adults with BMI > 30 kg/m2 and Polycystic Ovarian Syndrome (PCOS).
16658257|NCT02226640||Diabetic No Medication|Have diabetes and currently receiving no medication or early treatment with one medication. Some participants receiving insulin may also be included in this study
16658258|NCT02226640||Diabetic GAD Ab+|Have diabetes with Latent Autoimmune Diabetes in Adults (LADA).
16658259|NCT02226640||Diabetic With NASH|Have diabetes with Nonalcoholic Steatohepatitis (NASH), which is chronic liver disease with fat in the liver, inflammation, and damage not associated with drinking alcohol.
16658260|NCT02226614|Experimental|head cooling|head cooling
16658261|NCT02226601|Active Comparator|Aprepitant|"Aprepitant
~40 mg IV pre-operatively
~40 mg PO post-op day #1
~40 mg PO post-op day #2"
16658262|NCT02226601|Placebo Comparator|Placebo|"electrolyte (0.9% NaCl) infusion) pre-operatively
~capsule without medication on post-op day #1
~capsule without medication on post-op day #2"
16658263|NCT02226588|Experimental|Secondary prevention|Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
16658264|NCT02226588|Active Comparator|Universal prophylaxis|Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby
16658265|NCT02226575|Experimental|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
16658266|NCT02226575|No Intervention|Control|Controls only dilivery standard care
16658267|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
16658268|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
16658269|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
16658270|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
16658271|NCT02226536|Placebo Comparator|control|Diet group Control group
16658272|NCT02226536|Active Comparator|fractioned diet without glucose|Fractioned diet without glucose
16658273|NCT02226523||ACS|subjects with final diagnosis of ACS, or non-ACS
16658274|NCT02226510|Placebo Comparator|Placebo|Placebo capsules (with an identical appearance to the active drug) and containing only microcrystalline cellulose PhEur
16658275|NCT02226510|Active Comparator|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day (metformin XL 500mg x2/day). They will continue on Metformin XL 500mg x2/day for two weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day (and stopped if this cannot be tolerated).
16658276|NCT02226497|Active Comparator|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
16658277|NCT02226497|Experimental|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
16658278|NCT02226484|Experimental|Quercetin|Two 250 mg capsules of oral quercetin (Q) twice-a-day (BID) one hour before meals with a glass of water for 6 weeks.
16658279|NCT02226471||NW-NBP group|normal weight and blood pressure subjects
16658280|NCT02226471||NW-HTN group|Normal weight with hypertension subjects
16658281|NCT02226471||OB-NBP group|obese-normal blood pressure subjects
16658282|NCT02226471||OB-HTN group|Obese-hypertension subjects
16658283|NCT02226458|Experimental|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
16658284|NCT02226445||ADHD medication and psychosocial counseling|
16658285|NCT02226432|Sham Comparator|Kinesics|- Classic Rehabilitation and Kinesic Therapy
16658286|NCT02226432|Sham Comparator|surgery|"- Surgery:
~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
16658287|NCT02226432|Active Comparator|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
16658288|NCT02226419|Experimental|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
16658289|NCT02226406|Experimental|Legs Cycloergometer Group (A)|Patients randomized in this group will do 10 minutes of legs cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
16658290|NCT02226406|Experimental|Hands Cycloergometer Group (B)|Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
16658291|NCT02226406|Experimental|Walk in place (C)|Patients randomized in this group will do 10 minutes of active walk in place. Continuously evaluated with electric impedance tomography.
16658292|NCT02226393|Experimental|Prolonged exposure|See intervention description
16658293|NCT02226393|Active Comparator|Child-parent Play Therapy|see intervention description
16658294|NCT02226380|Experimental|mFOLFOX6,chemotherapy regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
16658295|NCT02226367|Active Comparator|prazosin hydrochloride|Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.
16658296|NCT02226367|Placebo Comparator|placebo|Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.
16658297|NCT02226354|Active Comparator|Flaxseed oil|9.73ml Flaxseed oil once daily, for 28 days
16658298|NCT02226354|Experimental|Ahiflower oil|9.73ml Ahiflower oil once daily, for 28 days
16658299|NCT02226341|Active Comparator|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
16658300|NCT02226341|Active Comparator|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
16658301|NCT02226328|Experimental|Propofol sedation|"Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.
~Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.
~Maintenance with 10-20 mg of propofol in case of discomfort."
16658302|NCT02226328|Active Comparator|Midazolam and Fentanyl sedation|"1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.
~Maintenance with 1 mg Midazolam in case of discomfort."
16658303|NCT02226315||Multiple gestations|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have passed their Estimated Date of Delivery (EDD).
16658304|NCT02226302||Female Group 2|Females with BMI >30 kg/m2 who are having a hysterectomy for benign conditions
16658305|NCT02226302||Females Group 1|Females with BMI <30 kg/m2 who are having a hysterectomy for benign conditions
16658306|NCT02226302||Males|2 males with BMI <30 kg/m2 and 2 males with BMI >30 kg/m2
16658307|NCT02226289|Experimental|bevacizumab-containing|bevacizumab with the latest received cytotoxic regimen
16658308|NCT02226276|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
16658309|NCT02226263|Experimental|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
16658310|NCT02226250|Experimental|3 Placebo Beverages|Sugar beverage 2 hr before meal and with meal and 2 hr after meal
16658311|NCT02226237|No Intervention|Control Group|in which patients received no specific treatment, only the usual general guidelines
16658312|NCT02226237|Experimental|group of pelvic floor exercises|in which patients were instructed to perform home exercises daily
16658313|NCT02226237|Experimental|anal electrostimulation group|in which patients, and are instructed to perform the exercises mentioned in the group of pelvic floor exercises, also underwent anal electrostimulation
16658314|NCT02226224||early gastric cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
16658315|NCT02226224||Locally Advanced Gastric Cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
16658316|NCT02226224||early esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
16658317|NCT02226224||locally advanced esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
16658318|NCT02226211|Experimental|air-Q group|
16658319|NCT02226211|Experimental|aura-i group|
16658320|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
16658321|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
16658322|NCT02226185|Experimental|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
16658323|NCT02226185|Placebo Comparator|placebo|identical-appearing placebo supplements for 2-3 years
16658324|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
16658325|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
16658326|NCT02226159|Active Comparator|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
16658327|NCT02226159|Experimental|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
16658328|NCT02226146|Experimental|Bertilimumab|Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
16658329|NCT02226133|Experimental|Exclusion of Left Atrial Appendage|Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,
16658330|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
16658331|NCT02226107|Experimental|Peer-PN|Peer Patient Navigation
16658332|NCT02226107|Active Comparator|Pro-PN|Professional Patient Navigation
16658333|NCT02226094|Experimental|DWT device dose A|Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments).
16658334|NCT02226094|Active Comparator|Ellex Tango SLT machine|Selective Laser Trabeculoplasty (SLT)
16658335|NCT02226094|Sham Comparator|DWT Sham|Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface.
16658336|NCT02226094|Experimental|DWT device dose B|Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments).
16658337|NCT02226068|Other|CsA-ECP|Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given
16658338|NCT02226068|Other|ECP-CsA|Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given
16658339|NCT02226055||Arterial stiffness: CKDu patients|Cohort of 50 patients with CKD of unknown aetiology Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
16658340|NCT02226055||Arterial stiffness: CKD known cause|Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
16658341|NCT02226055||Arterial Stiffness: Healthy Sri Lankan volunteers|Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
16658342|NCT02226055||2nd aim: 250 CKDu patients for investigation of aetiology|"To recruit a cohort of up to 250 CKDu patients from specific CKDu clinics in Anuradhapura and Padavi-Sri Pura for detailed history, basic anthropometric tests, and further analysis of serum, and urine. Analysis for biomarkers of kidney damage, proteomics, exosomes, and DNA adducts will be used to seek information that may complement already collected data and help refine aetiological hypotheses.
~Inclusion and Exclusion criteria as per CKDu cases in cohort 1"
16658343|NCT02226042|Experimental|Mindfulness-based Cognitive Therapy|Individuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
16658344|NCT02226042|No Intervention|Non-MBCT arm|Individuals currently in remission from depression will choose not to undergo the 8 week MBCT group programme
16658345|NCT02226042|No Intervention|Healthy volunteers|Individuals who have never experienced major depression
16658346|NCT02226029|Experimental|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
16658347|NCT02226029|Experimental|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
16658348|NCT02226016|Experimental|Ptosis|Device (measurement of levator strength in patients with upper lid ptosis)
16658349|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
16658350|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
16658351|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
16658352|NCT02225990|Active Comparator|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
16658353|NCT02225990|Active Comparator|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
16658354|NCT02225990|Experimental|Experimental Group, Sub-Acute|This group consists of sub-acute stroke patients who are between three weeks and six months post-stroke and will receive the QualPro protocol. If the participant is an inpatient at Shands Rehabilitation Hospital at the beginning of the study, his/her first three weeks of research therapy sessions will take place at the Shands Rehabilitation Hospital. After being discharged, the remainder of the study sessions will take place at either UF Health Rehab Center- Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
16658355|NCT02225990|Experimental|Experimental Group, Chronic|This group consists of chronic stroke patients who are greater than six months post-stroke and will receive the QualPro protocol. The study sessions will take place at either UF Health Rehab Center-Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
16658356|NCT02225977||Gilenya treated - 1 month|Patient's taking continuous oral Gilenya at prescribed dose for 1 month.
16658357|NCT02225977||Gilenya treated - 3 months|Patient's taking continuous oral Gilenya at prescribed dose for 3 months.
16658358|NCT02225977||Gilenya treated - 6 months|Patient's taking continuous oral Gilenya at prescribed dose for 6 months.
16658359|NCT02225977||Gilenya treated - 12 months|Patient's taking continuous oral Gilenya at prescribed dose for 12 months.
16658486|NCT02224950|Active Comparator|Sleeve 2|Non-medicated Emollient plus Lyocell/Chitosan Sleeve
16658360|NCT02225977||Gilenya qualified - untreated|Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.
16658361|NCT02225964||aMCIp,aMCIs|progressive aMCI,stable aMCI
16658362|NCT02225951|Active Comparator|Test group|Nutritional product as breakfast.
16658363|NCT02225951|Other|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
16658364|NCT02225938||Intensive care survivors|Patients surviving an admission to an intensive care unit
16658365|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
16658366|NCT02225912|Experimental|PrevinC|PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.
16658367|NCT02225912|Placebo Comparator|Control solution|The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.
16658368|NCT02225899||Subjects with Cystic Fibrosis|Cross-sectional, observational study
16658369|NCT02225899||healthy volunteers|Cross-sectional, observational study
16658370|NCT02225899||Subjects with CF in a vitamin D study|This is a longitudinal observational study in subjects enrolled in a high-dose vitamin D study. The investigator (Jessica Alvarez) does not assign the intervention to the subjects of the study.
16658371|NCT02225886|Experimental|Ascorbic acid|Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.
16658372|NCT02225886|Placebo Comparator|Control group|Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.
16658373|NCT02225873|Experimental|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
16658374|NCT02225873|Placebo Comparator|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
16658375|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
16658376|NCT02225860|No Intervention|Control|Continue with usual diet
16658377|NCT02225847|Active Comparator|Control|Members of this group will continue with their daily life activities and will not receive gardening intervention. The control group will be given a set of psychometric assessments for health and quality of life evaluations and undergo a Functional Magnetic Resonance Imaging (fMRI) brain scan, followed by a second round of psychometric assessments and a fMRI brain scan administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
16658378|NCT02225847|Experimental|Gardening|Members of this group will be given a set of psychometric assessments for health and quality of life evaluations and a Functional Magnetic Resonance Imaging (fMRI) brain scan prior to receiving the gardening activities intervention. The gardening intervention will consist of twice weekly group sessions lasting 60 minutes in duration that will take place in a greenhouse. The duration of the experimental intervention will be six weeks for a total of 12 individual gardening activity sessions. Following the completion of the gardening intervention, a second round of psychometric assessments and a fMRI brain scan will be administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
16658379|NCT02225834|Experimental|early Atorvastatin treatment|Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
16658380|NCT02225834|No Intervention|no early treatment with atorvastatin|Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge
16658381|NCT02225821|Active Comparator|antibiotic prophylaxis|a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
16658382|NCT02225821|Placebo Comparator|No antibiotic prophylaxis|a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
16658383|NCT02225808|Experimental|CBT for anxiety in autism|Cognitive-behavioral therapy (CBT) teaches skills for coping with anxiety and consist of 12 weekly sessions. CBT is conducted with child and parent.
16658384|NCT02225795|Experimental|Single Arm: All subjects|Hematopoietic stem cell transplantation
16658385|NCT02225782|Active Comparator|1.0 mg alteplase (tPA)|1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
16658386|NCT02225782|Experimental|2.0 mg alteplase (tPA)|2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
16658387|NCT02225769|Experimental|e-POCT|Febrile children managed using the e-POCT tool. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
16658388|NCT02225769|Active Comparator|ALMANACH|Febrile children managed using the ALMANACH algorithm. ALMANACH is an improved Integrated Management of childhood Illness (IMCI) algorithm based on mobile phones and tablets that has already been assessed for safety and efficacy.
16658389|NCT02225769|No Intervention|Routine practice|Febrile children managed according to routine care such as provided by routine health facility health workers.
16658390|NCT02225756|Experimental|Cyclosporine A dose 1|
16658391|NCT02225756|Experimental|Cyclosporine A dose 2|
16658392|NCT02225756|Placebo Comparator|Placebo|
16658393|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
16658394|NCT02225717|Experimental|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
16658395|NCT02225717|Experimental|Preterm Labor|Pregnant women admitted for preterm labor
16658396|NCT02225717|Experimental|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
16658397|NCT02225704|Experimental|Radium-223 and enzalutamide|Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
16658398|NCT02225691|Experimental|paired testing of blood glucose|Patient will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Paired testing arm will undergo paired testing of blood glucose.
16658485|NCT02224950|Placebo Comparator|Control|"Non-medicated Emollient with no Clothing Covering Upper Limb - Baseline/Control Cells"
16658399|NCT02225691|No Intervention|control arm|Non-insulin patients will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Patients in the control arms will not undergo paired testing and will be managed as before.
16658400|NCT02225665|Experimental|Cohort 1|
16658401|NCT02225665|Experimental|Cohort 2|
16658402|NCT02225652|Experimental|FEC + filgrastim x 3 cycles q 14-21 days and Weekly Paclitaxel|"FEC (FLUOROURACIL 500 mg/m2 IV infusion of 30 minutes + EPIRUBICIN 60 mg/m2 IV infusion of 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion of 30 minutes).
~From day 7 until hematological recovery = Filgrastim 300 microg s.c. After 21 days from the last FEC cycle = Paclitaxel 100 mg/m2 IV infusion of 1hour (weekly for 8 cycles, at day 1)."
16658403|NCT02225639|Active Comparator|PRC-063|
16658404|NCT02225639|Placebo Comparator|Placebo|
16658405|NCT02225626|Experimental|BI 1060469 fed|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
16658406|NCT02225626|Experimental|BI 1060469 fasted|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
16658407|NCT02225613|Active Comparator|Usual protocol|2 weeks conventional rehabilitation 3 weeks conventional rehabilitation
16658408|NCT02225613|Active Comparator|Spa protocol|2 weeks conventional rehabilitation 3 weeks aquatic rehabilitation
16658409|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
16658410|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
16658411|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
16658412|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
16658413|NCT02225574|Experimental|Advanced CML + Philadelphia positive Acute Leukemia-Group 1|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.
~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
~Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.
~Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle."
16658414|NCT02225574|Experimental|Chronic Phase CML - Group 2|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.
~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
~Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.
~Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
16658415|NCT02225561|Experimental|Intervention arm|Pharmaco- mechanical optimization
16658416|NCT02225561|Active Comparator|Mechanical optimization only|Mechanical optimization only
16658417|NCT02225548|Experimental|Selegiline and Tadalafil|Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
16658418|NCT02225535|Placebo Comparator|Usual Care (NP)|Rural NP with client in-person, usual care
16658419|NCT02225535|Active Comparator|PT in-person|Urban PT travels to rural area to manage patient's back pain in-person.
16658420|NCT02225535|Active Comparator|PT/NP Telehealth|Intervention: Rural NP is joined by PT via Telehealth for interprofessional videoconference with patient
16658421|NCT02225522|No Intervention|Standard Care|Patients in this arm receive standard genetic evaluation without the addition of next generation sequencing for the diagnosis of their presumed genetic condition
16658422|NCT02225522|Experimental|Rapid whole genome sequencing (StatSeq)|Patients in this arm will receive standard of care genetic evaluation and next generation sequencing of their genome to achieve rapid diagnosis of genetic conditions.
16658423|NCT02225509|Other|Patients with thyroid nodules|Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.
16658424|NCT02225496|Experimental|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow [MBS] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.
16658425|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
16658426|NCT02225470|Experimental|Arm A, E7389 (Eribulin Mesylate)|The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
16658427|NCT02225470|Active Comparator|Arm B, Vinorelbine injection|The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
16658428|NCT02225457|Experimental|Hypercaloric diet and polyphenols|"polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
~Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
16658429|NCT02225457|Active Comparator|Hypercaloric diet and placebo|"Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
~Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
16658430|NCT02225444||OsteoAMP treatment group|The OsteoAMP treatment group contains patients randomized to receive their own bone (retrieved from the surgical site) augmented with the OsteoAMP growth factor to assist with posterolateral arthrodesis at 1 or 2 adjacent levels between L1-S1.
16658539|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
16658431|NCT02225431|Active Comparator|Standard saline infusion|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
16658432|NCT02225431|Experimental|Double saline infusion|All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)
16658433|NCT02225418|Sham Comparator|Placebo TQL block|30 ml single shot TQL block with saline 0,9%
16658434|NCT02225418|Active Comparator|Active TQL block|30 ml single shot TQL block with ropivacaine 0,75%
16658435|NCT02225405|Experimental|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
16658436|NCT02225392|Active Comparator|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.
~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
16658437|NCT02225392|Experimental|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.
~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
16658438|NCT02225379|Experimental|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference method and data generated by the non- invasive study device (Hypo Sense) during approximately 4 hours, in which a hypoglycemic event will be induced.
16658439|NCT02225366|Experimental|Intra-Tumoral Injection of LL37|LL37 administered intratumorally in cutaneous or subcutaneous tumors at least 1 cm in diameter. Patients will receive weekly intratumoral injections of LL37 for up to 8 weeks. The injections will be given every 7 days (+/- 48 hours). Starting dose 250 µg/tumor.
16658440|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
16658441|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
16658442|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
16658443|NCT02225340||Controls|
16658444|NCT02225340||Familial hypercholesterolemia|
16658445|NCT02225327|Active Comparator|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
16658446|NCT02225327|Active Comparator|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
16658447|NCT02225327|Active Comparator|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
16658448|NCT02225327|Active Comparator|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
16658449|NCT02225314|Experimental|Brain Fitness|Brain Fitness is a computer-based cognitive training programs designed to augment auditory processing speed and accuracy over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
16658450|NCT02225314|Experimental|InSight|InSight is a computer-based cognitive training programs designed to augment visual processing and working memory over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
16658451|NCT02225314|Active Comparator|Active Control|An active control arm is necessary to model practice effects in an untreated group. Participants in this group will view and complete quizzes on a computerized learning program designed to improve knowledge about literature, art, and history.
16658452|NCT02225301|Experimental|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
16658453|NCT02225288|Experimental|Group A|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group A: 48 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
16658454|NCT02225288|Experimental|Group B|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group B: 72 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
16658455|NCT02225288|Experimental|Group C|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group C: 96 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
16658540|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
16658456|NCT02225288|Experimental|Group D|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group D: 120 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
16658457|NCT02225275|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
16658458|NCT02225262|Experimental|CyberKnife Radiosurgery|
16658459|NCT02225236|Experimental|Classroom Intervention|The intervention focuses on training executive functioning (e.g., working memory and inhibition) and metacognition (i.e., the ability to predict, check, monitor, coordinate and control cognitive operations) using play activities and structured language and reinforcement.
16658460|NCT02225236|No Intervention|No treatment control|No intervention
16658461|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
16658462|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
16658463|NCT02225210|Experimental|Group dexmedetomidine ,dexmedetomidine|Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
16658464|NCT02225210|Active Comparator|Group midazolam,midazolam,fentanyl|Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05~0.1mg.kg-1.h-1 and fentanyl 0.5~1μg.kg-1.h-1 separately.
16658465|NCT02225197|Experimental|CyberKnife Radiosurgery|
16658466|NCT02225171||Physicians|15 physicians each will be interviewed from the specialties of reproductive endocrinology and obstetrics/gynecology.
16658467|NCT02225132|Experimental|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
16658470|NCT02225106|Experimental|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
16658471|NCT02225093|Experimental|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
16658472|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
16658473|NCT02225067|Experimental|C13-CAC|
16658474|NCT02225054|Placebo Comparator|Ropivacaine,Normal Saline,Saline Bolus|Ropivacaine 15 mL 0.5% Normal Saline mL 0.9% Saline Bolus
16658475|NCT02225054|Experimental|Ropivacaine,Dexmedetomidine,Saline Bolus|Ropivacaine15 mL 0.5% Dexmedetomidine0.5 u/kg Saline Bolus
16658476|NCT02225054|Active Comparator|Ropivacaine,Saline,Dexmedetomidine|Ropivacaine 15 mL 0.5% Normal Saline 1 mL 0.9% Dexmedetomidine single IV bolus 0.5 u/kg over 30 minutes
16658477|NCT02225028|Active Comparator|Physical Activity Counseling|Participants who are randomized to the physical activity counseling intervention group will work with a physical activity coach over the course of 6 months to come up with a physical activity program that works for each individual. Participants will have 16 phone calls and discuss goals and values, track physical activity, troubleshoot barriers, and work on keeping exercise interesting and motivating. Participants will also learn strategies for managing stress and battling unhelpful thoughts that may get in the way of activity. By the end of the intervention, the goal is to be regularly doing 150 minutes of physical activity each week. The physical activity coach will work with participants to ensure that they are increasing activity safely in order to prevent injuries.
16658478|NCT02225028|No Intervention|Usual Care|Participants randomized to the usual care control group will receive a packet of exercise related-information at the end of the baseline assessment as well as a letter from study staff informing them of their randomization status and their test results. The letter will provide information on biological markers that are in the at-risk range, advice to seek medical advice regarding lifestyle changes such as diet and exercise and information on how to contact study staff regarding test results. We will offer to forward test results to their health care provider provided they furnish written release of information We will emphasize our interest in providing them with a follow-up assessment in 6 months.
16658479|NCT02225015|Active Comparator|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
16658480|NCT02225015|No Intervention|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
16658481|NCT02224989|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
16658482|NCT02224976|Experimental|Intensified training|Volunteers will increase exercise training by 30% from baseline
16658483|NCT02224963|Experimental|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
16658484|NCT02224963|Active Comparator|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
16658487|NCT02224950|Placebo Comparator|Placebo Sleeve|Non-medicated Emollient plus Cotton Sleeve
16658488|NCT02224937|Experimental|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
16658489|NCT02224937|Placebo Comparator|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
16658490|NCT02224924|Active Comparator|autologous blood patch injection (ABPI)|
16658491|NCT02224924|Experimental|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
16658492|NCT02224911||Laser Interstitial Thermal Therapy|This is a minimally invasive procedure for focal treatment of prostate cancer.
16658493|NCT02224898||Definite/Suspected Chronic Pancreatitis|Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
16658494|NCT02224898||Healthy Control Group|Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
16658495|NCT02224885|Other|addition of nCLE to help target biopsy|The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
16658496|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
16658497|NCT02224859|Other|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place
~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
16658498|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
16658499|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
16658500|NCT02224833|Experimental|Intervention|
16658501|NCT02224833|No Intervention|Control|
16658502|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
16658503|NCT02224807|Active Comparator|Progressive Resistance Training (PRT) and a healthy diet|PRT will be done with resistance bands; participants will receive instruction on three resistance band exercises (triceps, biceps, and shoulder overhead) from an American College of Sports Medicine (ACSM) certified exercise specialist. Participants also will receive dietary counseling from a registered dietitian on correcting nutrient deficiencies that are detected during analysis of their 2-day dietary recalls.
16658504|NCT02224807|Experimental|PRT and a healthy diet, plus weight loss|This arm will receive all components of the active comparator arm, plus counseling to achieve a weight loss of 1.5-2 pounds/week. Participants will be trained on how to achieve this caloric deficit through both dietary restriction and increased physical activity. Weight loss will be promoted via a healthy, nutritionally adequate diet consistent with American Cancer Society guidelines. Protein levels will be based on 0.8 g/kg body weight. The distribution of food groups will be customized for preferences. An exercise program will be tailored taking into account kcal expenditure for various activities at a specific body weight; expenditures of 200-400 kcal/day will serve as a goal. Aerobic training of large muscles (legs) will be emphasized to achieve a greater kcal deficit; ramping of intensity and volume over time will be pursued as per the ACSM guidelines. Participants will train once weekly while supervised by an exercise physiologist and daily at home.
16658505|NCT02224794||Fast-Track Group|includes subjects who complete the Fast-Track EVAR protocol
16658506|NCT02224794||Standard P-EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access
16658507|NCT02224794||Standard EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair)
16658508|NCT02224781|Experimental|Arm A (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C."
16658509|NCT02224781|Experimental|Arm B (BRAF inhibitor therapy)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.
16658510|NCT02224781|Experimental|Arm C (BRAF inhibitor therapy)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16658541|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
16658542|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
16658543|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
16658511|NCT02224781|Experimental|Arm D (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
16658512|NCT02224768||HCP and Patient inclusion|"HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools
~Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials"
16658513|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
16658514|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
16658515|NCT02224742|Experimental|LeucoPatch|Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
16658516|NCT02224742|Active Comparator|Usual care|Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
16658517|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
16658518|NCT02224716||Pre-intervention All patients admitted with a diagnosis of CAP|
16658519|NCT02224716||Post intervention All patient admitted with a diagnosis of CAP|
16658520|NCT02224703|Experimental|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter [mL] cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
16658521|NCT02224703|Experimental|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
16658522|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
16658523|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
16658524|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
16658525|NCT02224677||Children with Craniofacial Microsomia|125 children with craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for children at the first visit include: assessment of development, video, photographs, and a hearing evaluation. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, saliva sample, hearing evaluation, speech assessment.
16658526|NCT02224677||Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 children without craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for the first visit include: assessment of development, video, and photographs. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, and speech assessment.
16658527|NCT02224677||Parents of Children with Craniofacial Microsomia|125-250 parents of children with craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete more questionnaires, have their picture taken, and donate saliva.
16658528|NCT02224677||Parents of Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
16658529|NCT02224677||Teacher/Day Care Provider|When the children participants are around 36 months old, we will ask parents for permission to contact their child's teacher/day care provider. We would like the teacher/day care provider to fill out a questionnaire.
16658530|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
16658531|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
16658532|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
16658533|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
16658534|NCT02224651|Experimental|(1-1000mg) Immediate Release formulation|
16658535|NCT02224651|Placebo Comparator|Immediate Release Placebo arm|
16658536|NCT02224651|Experimental|(10-500) mg Modified Release formulation|
16658537|NCT02224651|Placebo Comparator|Modified Release Placebo arm|
16658538|NCT02224638|Active Comparator|TheraHoney HD|Honey product
16658544|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
16658545|NCT02224612|Active Comparator|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask
~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
16658546|NCT02224612|Active Comparator|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask
~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
16658547|NCT02224612|Active Comparator|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask
~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
16658548|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
16658549|NCT02224586||light treatment|clinical routine treatment according to the doctor's advice
16658550|NCT02224573|Experimental|GWP42003-P|
16658551|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
16658552|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
16658553|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
16658554|NCT02224547|Experimental|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
16658555|NCT02224534|Experimental|Ticagrelor and Clopidogrel.|The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
16658556|NCT02224534|Active Comparator|Clopidogrel|The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
16658557|NCT02224521|Experimental|Cohort 1|Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
16658558|NCT02224521|Experimental|Cohort 2|The selected formulation will be dosed with GSK2190915 capsule formulation at 20mg (fasted), 100mg (fasted), 100mg (fed) and 200mg (fasted).
16658559|NCT02224521|Experimental|Cohort 3|Cohort 3 will be a 4-way complete crossover study with single doses of 20mg and 200mg of up to two capsule formulations taken forward from cohort 2 in 10 healthy adult subjects in the fasted state.
16658560|NCT02224521|Experimental|Cohort 4|The regimen for Cohort 4 will be either the highest dose (200mg) of the capsule formulation (A, B or C) taken forward from the previous cohorts or the solution formulation (200mg).
16658561|NCT02224521|Experimental|Cohort 5|Subjects will take milled and micronised tablet formulations of GSK2190915 in the fasted state in periods 1 and 2, and will take milled and micronised tablet formulations of GS2190915 in the fed state in periods 3 and 4.
16658562|NCT02224521|Experimental|Cohort 6|Tablet formulations (milled and micronised, different to the Cohort 5 formulations) of GSK2190915 will be dosed in the fasted and fed (after a light breakfast) states.
16658563|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
16658564|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
16658565|NCT02224495|Placebo Comparator|Control|Standard of care
16658566|NCT02224495|Experimental|Structured exercise training|8-week outpatient exercise-training program, encompassing 3 sessions per week, including endurance and resistance training
16658567|NCT02224482|No Intervention|Control|Print materials
16658568|NCT02224482|Active Comparator|Intervention Group|PROGRESS
16658569|NCT02224469|Experimental|ECoG (electrocorticography) sensing|Use ECoG-based Brain Computer interface to control assistive technology
16658570|NCT02224456|Experimental|Tenofovir|Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
16658571|NCT02224443|Experimental|Group A, dexmedetomidine , 0.3µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
16658572|NCT02224443|Experimental|Group B,dexmedetomidine , 0.5µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
16658573|NCT02224443|Placebo Comparator|Group C ,normal saline|Normal saline infusion will be given with the same infusion volume as group A and B
16658574|NCT02224430||schizophrenia/schizoaffective disorder|Participants with schizophrenia/schizoaffective disorder.
16658575|NCT02224417|Other|Diabetes Educational Program (DEP) only|Participants will receive the Diabetes Educational Program, as required, which is part of usual care at the Polyclinic. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one).
16658576|NCT02224417|Other|DEP + Process Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified process goals.
16658577|NCT02224417|Other|DEP + Outcome Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified outcome goals.
16658578|NCT02224404|Experimental|Fast Gelling Dressing|
16658579|NCT02224391|Experimental|Arm I (ABM training)|Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
16658580|NCT02224391|Sham Comparator|Arm II (sham training)|Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
16658581|NCT02224378|Experimental|peep induced CVP|
16658582|NCT02224378|Active Comparator|passive leg raising(PLR)|
16658583|NCT02224365|Experimental|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
16658584|NCT02224365|Placebo Comparator|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
16658585|NCT02224352|Experimental|Single-Arm Study|Functional neuromuscular electrical stimulation of abdominal-wall muscles triggered by an airway pressure signal
16658586|NCT02224339||plaque neovascular and stress echo|After the SE and CEUS examination, patients will be grouped per the result of SE and CEUS as follows: group I: plaque neovascularization and normal wall motion; group II: plaque neovascularization and abnormal wall motion; group III: no plaque neovascularization and abnormal wall motion; group IV: no plaque neovascularization and normal wall motion.
16658587|NCT02224313|No Intervention|1.Premenopausal women|No treatment
16658588|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
16658589|NCT02224300|Experimental|Education|"Intervention group will receive the ELC for six weeks (15.9. - 26.10.2014) and comparison group will not receive it.
~Members of the intervention group in will work in teams of 10 nurses with weekly questions (released in Mondays) based on patient-description existing in Moodle. One member of the team will send the solutions to questions once a week (in Thursdays) Moodle. Researcher will download the model-answer to Moodle once a week (in Fridays) and nurses will compare their answer to model answer (self-evaluation)."
16658590|NCT02224287|Other|Fluoroscopy|Technologist control of fluoroscopy Surgeon control of fluoroscopy
16658591|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
16658592|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
16658593|NCT02224261|Experimental|Physical Therapy|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords and patient education."
16658594|NCT02224261|Active Comparator|Control|Control protocol includes standard progressive active and action-assisted arm exercises & patient education.
16658595|NCT02224248|Experimental|Health checks with fitness testing|
16658596|NCT02224248|Active Comparator|Health checks without fitness testing|
16658597|NCT02224235|Experimental|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
16658598|NCT02224235|Active Comparator|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
16658599|NCT02224235|Experimental|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
16658600|NCT02224222||Patients undergoing vascular procedures|Including all non-interventional surgical procedures, excluding varix surgery
16658601|NCT02224222||Patients undergoing cardiac procedures|Including all non-interventional surgical procedures, excluding HTX
16658602|NCT02224209|Experimental|Staged angioplasty|"Using Abbott EPD systems (Accunet/Emboshield), a balloon, stent
~Method of stage-1 angioplasty
~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device; Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.
~Method of stage-2:
~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
16658603|NCT02224209|Active Comparator|Routine single-stage CAS|"Using a balloon, stent
~Routine stenting procedure:
~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
16658604|NCT02224196|Experimental|manual ventilation|
16658605|NCT02224196|Active Comparator|pressure-controlled ventilation|
16658606|NCT02224183|Active Comparator|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
16658644|NCT02223988|Experimental|subglottic secretion drainage|
16660109|NCT02214745||Israeli Arab children with cerebral palsy|
16658607|NCT02224183|Active Comparator|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
16658608|NCT02224170|Experimental|Lidocaine group|
16658609|NCT02224170|Active Comparator|Dexamethasone group|
16658610|NCT02224157|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
16658611|NCT02224157|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
16658612|NCT02224144|Experimental|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months
~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
16658613|NCT02224144|Placebo Comparator|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months
~1 pill of placebo (sugar pill) per day for 12 months"
16658614|NCT02224131|Experimental|Monitoring Arm|dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay(TEG)
16658615|NCT02224131|Active Comparator|Conventional Arm|fixed dose regiment of both aspirin and clopidogrel in all patients following stent deployment according to international guidelines
16658616|NCT02224118|Experimental|CNTO 3649 10 mcg/kg (single dose)|A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
16658617|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (single dose)|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
16658618|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (single dose)|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
16658619|NCT02224118|Experimental|CNTO 3649 300 mcg/kg (single dose)|A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
16658620|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
16658621|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
16658622|NCT02224118|Placebo Comparator|Placebo|Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
16658623|NCT02224105|Experimental|BI 653048 BS|escalating doses
16658624|NCT02224105|Active Comparator|Prednisolone low|
16658625|NCT02224105|Active Comparator|Prednisolone high|
16658626|NCT02224105|Placebo Comparator|Placebo|
16658627|NCT02224092|Active Comparator|Active|Active is a multivitamin multimineral with phytonutrient product.
16658628|NCT02224092|Placebo Comparator|Placebo|Placebo is a sugar pill.
16658629|NCT02224079|Experimental|BIIB 722 CL|
16658630|NCT02224079|Placebo Comparator|Placebo|
16658631|NCT02224066|Experimental|Ticagrelor|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
16658632|NCT02224066|Active Comparator|Aspirin/Clopidogrel|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
16658633|NCT02224066|No Intervention|Registry arm|Patients with normal-on-treatment platelet reactivity (PRU < 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.
16658634|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
16658635|NCT02224040|Experimental|Ceftriaxone I.V|The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
16658636|NCT02224040|Experimental|Ceftriaxone I.V+Azithromycin P.O|The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
16658637|NCT02224040|Experimental|Azithromycin P.O|The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
16658638|NCT02224040|Experimental|Azithromycin P.O+Cefixime P.O|The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
16658639|NCT02224027|Active Comparator|i-gel|Each novice performs i-gel insertion in difficult laryngoscopy scenario.
16658640|NCT02224027|Active Comparator|proceal laryngeal mask airway|Each novice performs proceal laryngeal mask airway insertion in difficult laryngoscopy scenario.
16658641|NCT02224027|Active Comparator|tracheal tube|Each novice performs tracheal intubation in difficult laryngoscopy scenario.
16658642|NCT02224014||Lendormin D tablets|
16658643|NCT02224001|Experimental|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts
~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
16658683|NCT02223715||CDI|
16658645|NCT02223975||Vulval Disease|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.
16658646|NCT02223962|Experimental|Physical activity|The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
16658647|NCT02223962|Placebo Comparator|Usual Care|During the hospital stay, the patients in the control group will be informed about the beneficial effects of being physically inactive.They will not receive feedback about their activities performed and will not be stimulated to become more active.
16658648|NCT02223949|Experimental|Cook double balloon catheter|Insertion of the Cook double balloon catheter to the cervix until both balloons are properly located in the cervical canal. After properly located it is inflated with 20 ml of saline. Then both balloons are additionally inflated to a total of 80 ml each balloon. Twelve hours later the balloons are deflated and the device is removed.
16658649|NCT02223949|Active Comparator|PGE1 tablet insertion|Insertion of 25 mg PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix. The patient woll the be instructed to stay in bed for the next 60 minutes. After six hours a repeated dose will be administered. Total of 4 PGE1 doses within 24 hours.
16658650|NCT02223936|Other|children with Prenatal enlarged nuchal transluce|
16658651|NCT02223936|Other|Control|
16658652|NCT02223923|Experimental|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
16658653|NCT02223923|Experimental|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
16658654|NCT02223923|Experimental|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
16658655|NCT02223923|Experimental|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
16658656|NCT02223910|Active Comparator|Motor Cortex|Feedback training of functional connectivity between motor cortex and the rest of the brain
16658657|NCT02223910|Placebo Comparator|Control region|Feedback training of functional connectivity between medial prefrontal cortex of healthy hemisphere and the rest of the brain
16658658|NCT02223897|Experimental|Conventional treatment, huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
16658659|NCT02223897|Placebo Comparator|Conventional plus placebo|Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).
16658660|NCT02223884|Experimental|weekly docetaxel and carboplatin|
16658661|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
16658662|NCT02223858|Experimental|Positive Activities (PA)|Positive Activities (PA) Program
16658663|NCT02223858|Active Comparator|Attention Control (AC)|Attention Control (AC) Program
16658664|NCT02223845|Experimental|Music|Played music during embryo transfer
16658665|NCT02223845|No Intervention|Control|No music played during embryo transfer
16658666|NCT02223832|Experimental|ACT-128800|"A single oral dose of 40 mg ACT-128800 will be administered as
~1 capsule given in the fasted state in the morning"
16658667|NCT02223819|Experimental|Crizotinib|Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
16658668|NCT02223806|Active Comparator|Self-assessment of uterine tonus|Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
16658669|NCT02223806|Experimental|Midwife uterine tonus assessment|Uterine tonus assessment every 15 minutes for 2 hours by midwive.
16658670|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
16658671|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
16658672|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
16658673|NCT02223780|Placebo Comparator|control|standard management
16658674|NCT02223780|Active Comparator|early palliative care|early palliative care
16658675|NCT02223767|Experimental|Verum TMS|10 Hz TMS over medial prefrontal cortex
16658676|NCT02223767|Experimental|Sham TMS|10 Hz sham TMS over medial prefrontal cortex
16658677|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
16658678|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
16658679|NCT02223741||Korean medicine conjugate rehabilitation|those with more than 30 days of herbal drugs or more than 12 times of acupuncture (Korean medical treatment) within six months in addition to conventional rehabilitation
16658680|NCT02223741||Conventional rehabilitation|those with one of the treatments; physical, occupational, speech-language or cognitive-behavioral therapies
16658681|NCT02223728|Experimental|Treatment Condition|Telehealth Lifestyle Program
16658682|NCT02223728|Sham Comparator|Attention Control Condition|Health Education Program
16658684|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
16658685|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
16658686|NCT02223689|Experimental|Skin Affix|Surgical adhesive
16658687|NCT02223676|Experimental|Intervention|Clinical pharmacists conduct medication history
16658688|NCT02223676|No Intervention|Control|standard procedures for admission is followed
16658689|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
16658690|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
16658691|NCT02223637||Exposure group|"Pregnant women who were exposed to
~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
16658692|NCT02223624|Experimental|eccentric aerobic exercise group|Eccentric aerobic exercise group: Participants in this group will participate in an eccentric aerobic exercise rehabilitation program for a total of eight weeks, two sessions per week. Outcome measurements will be taken post exercise program and also after a 3 month follow-up period. Each session will be approximately 60 minutes in duration and include approximately 10 minutes of warm up (stretches), eccentric stepper aiming for 20 minutes, walking and light weights, followed by a five minute cool-down period.
16658693|NCT02223624|Active Comparator|Concentric aerobic exercise group|"Concentric aerobic exercise group (usual care): The length of the concentric aerobic exercise based rehabilitation program will be the same as the study group- twice weekly exercise sessions for 8 weeks. Outcome measurements will also be taken after a 3-month follow-up period.
~Participants in the concentric aerobic exercise group will participate in the same warm-up and cool down period as the eccentric group. They will also complete walking and light weights. To replace the 20 minutes of eccentric exercise, concentric participants will complete approximately 20 minutes of exercise bike, stair climbing and rowing as able with required rests."
16658694|NCT02223624|No Intervention|Waiting list control|Waiting list (no exercise): Participants assigned to this group will not receive any intervention during the study period. They will be assessed like other participants at baseline and after eight weeks, but not at three-month follow-up due to ethical concerns around withholding care known to be effective. Given that there is a waiting list for the current exercise program of 4-12 weeks, it is felt that delaying care for a set period of eight weeks is not of ethical concern. Following the completion of assessments, waiting list participants will be able to complete the traditional exercise program as usual but not as participants of the study's experimental groups.
16658695|NCT02223611|Experimental|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)<1.25 m2, 50mg; bid when 1.25 m2≤BSA<1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.
~3 weeks/4cycles"
16658696|NCT02223611|Active Comparator|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.
~3 weeks/4cycles"
16658697|NCT02223598|Experimental|Dose Escalation - CB-5083|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies
16658698|NCT02223598|Experimental|Dose Expansion - CB-5083, Dexamethasone|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)
16658699|NCT02223598|Experimental|Dose Expansion - CB-5083|CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor
16658700|NCT02223585|Experimental|Cross-over single arm|
16658701|NCT02223572|Experimental|osteoporotic hip fracture|
16658702|NCT02223559||right heart catheterization patients|
16658703|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
16658704|NCT02223533|Experimental|Wound catheter|analgesia with wound catheter after colon surgery
16658705|NCT02223533|Active Comparator|morphine|analgesia with morphine after colon surgery
16658706|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
16658707|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
16658708|NCT02223507|Experimental|BIIR 561 CL|
16658709|NCT02223507|Placebo Comparator|Placebo|
16658710|NCT02223494|Experimental|Terbogrel|
16658711|NCT02223481|Experimental|Terbogrel low dose|
16658712|NCT02223481|Experimental|Terbogrel high dose|
16658713|NCT02223481|Placebo Comparator|Placebo|
16658714|NCT02223468||CASE-CONTROL|CASE: Liver transplant recipients (n=20) CONTROL: A healthy person with a similar age (±10 years) to the control selected from the same family setting (n=20)
16658715|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
16658716|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
16658717|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
16658718|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
16658746|NCT02223234|Active Comparator|Control|Control- monthly mailed information on children's health
16658719|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
16658720|NCT02223416|Experimental|RGB-10|
16658721|NCT02223416|Active Comparator|Forsteo|
16658722|NCT02223403|Experimental|submaximal steady state exercise|90 minutes after respective beetroot juice ingestion, subjects walked on treadmill at a pre-determined steady state workload for a total of 15 minutes with oxygen consumption recorded for the last 10 minutes
16658723|NCT02223403|Experimental|six minute walk test|subjects performed six-minute walk at self-determined pace 30 minutes after treadmill exercise was performed
16658724|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
16658725|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
16658726|NCT02223377|Active Comparator|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).
~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
16658727|NCT02223377|Active Comparator|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).
~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
16658728|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
16658729|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
16658730|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
16658731|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
16658732|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
16658733|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:
~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
16658734|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:
~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
16658735|NCT02223325||Elderly, acute pancreatitis|No intervention
16658736|NCT02223325||Adults <65 y, acute pancreatitis|No intervention
16658737|NCT02223312|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
16658738|NCT02223299|Experimental|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
16658739|NCT02223299|Placebo Comparator|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
16658740|NCT02223286||ASGES (Treatment Group)|Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
16658741|NCT02223286||Non-ASGES (Control Group)|Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
16658742|NCT02223273|Experimental|Multifaceted Strategy|"Multifaceted Intervention
~Simulation Based Team Training
~Case Manager
~Check lists
~Reminders
~Educational Materials"
16658743|NCT02223273|No Intervention|Usual Care|Hospital Standard Treatment
16658744|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
16658745|NCT02223247|Experimental|TVB-2640|Oral TVB-2640 capsules or tablets of various dose strengths administered QD for 21 - 28 day dosing cycles, alone or in combination with certain standard chemotherapy agents
16658784|NCT02223013|Experimental|BIBV 308 SE capsule S|
16658747|NCT02223234|Experimental|Email and 4 Home Visits|Weekly emails and 4 home visits with a health educator
16658748|NCT02223234|Experimental|Email and 2 Home Visits|Weekly emails and 2 home visits
16658749|NCT02223221|Experimental|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.
~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
16658750|NCT02223221|Active Comparator|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.
~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
16658751|NCT02223208|Experimental|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
16658752|NCT02223182|Experimental|Viaskin Milk 150 mcg|
16658753|NCT02223182|Experimental|Viaskin Milk 300 mcg|
16658754|NCT02223182|Experimental|Viaskin Milk 500 mcg|
16658755|NCT02223182|Placebo Comparator|Viaskin Placebo|
16658756|NCT02223169|Experimental|Egg albumin-derived peptide|Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.
16658757|NCT02223169|Placebo Comparator|Placebo|Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.
16658758|NCT02223156||MediYoga|
16658759|NCT02223156||Music relaxation|
16658760|NCT02223156||No treatment|
16658761|NCT02223130|Experimental|Intervention Group|Participants will attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys. After their baseline interview and before their first follow-up interview, participants attend the Intervention Group, which consist of 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who uses Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions, and behaviors in response to stressful/discrimination experiences.
16658762|NCT02223130|No Intervention|Waitlist Control|"Participants are not given the Intervention Group while they are enrolled in the study. Instead, they only attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys.
~After they have completed the study, participants from the first two cohorts are offered the option of attending an intervention group that is identical in content to the intervention group being studied.The third cohort is offered the intervention group after they have completed the first follow-up but before they complete the final follow-up due to timing and budgetary restraints. No data is collected and no incentives are given during these intervention groups."
16658763|NCT02223117|Experimental|Intervention|Thrombosomes
16658764|NCT02223117|Placebo Comparator|Placebo|Buffer/placebo Control
16658765|NCT02223104|Active Comparator|Sensura|Ostomy pouch
16658766|NCT02223104|Experimental|Flexima Active|Ostomy pouch
16658767|NCT02223091|Experimental|Consultation by a trained physician|The physicians of this group receive a free consultation training program on skills regarding consultations on complementary medicine for breast-cancer patients. The training was developed by a multi-professional team and is comprised of three parts: (1) online-training, (2) on-site-training, and (3) consultation manual. Each of the physicians will counsel 10 patients. The patients in this group therefore receive a consultation by a trained physician.
16658768|NCT02223091|Active Comparator|Consultation by an untrained physician|The physicians of the control arm receive no training. Each will counsel 10 patients. The patients in this group therefore receive a consultation by an untrained physician.
16658769|NCT02223078|Experimental|G17DT|Three 250 µg injections over a six week period (weeks 0,2 and 6)
16658770|NCT02223078|Placebo Comparator|Placebo|Three 250 µg injections of a placebo over a six week period (weeks 0,2 and 6)
16658771|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
16658772|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
16658773|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1|Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
16658774|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1|One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
16658775|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
16658776|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
16658777|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
16658778|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
16658779|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
16658780|NCT02223026|Experimental|Linagliptin/metformin fed|
16658781|NCT02223026|Active Comparator|Linagliptin/metformin fasted|
16658782|NCT02223013|Active Comparator|BIBV 308 SE solution|
16658783|NCT02223013|Experimental|BIBV 308 SE capsule L|
16658795|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
16658796|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
16658797|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
16658798|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
16658799|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
16658800|NCT02222935|Experimental|Balance exercise training|Balance exercise training - thrice week, 2 weeks, 10 repetition Maximum/ set, 2 sets
16658801|NCT02222935|Active Comparator|Routine Back exercise Program|Routine Back exercise Program - 10 Repetition Maximum / set, 2 sets, three times weekly, 2 weeks
16658802|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
16658803|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
16658804|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
16658805|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
16658806|NCT02222909|Experimental|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
16658807|NCT02222909|No Intervention|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
16658808|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
16658809|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
16658810|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
16658811|NCT02222883||patients with primary diagnosis|patients with primary diagnosis of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
16658812|NCT02222883||patients with platinum-sensitive recurrence|patients with platinum-sensitive recurrence of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
16658813|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
16658814|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
16658815|NCT02222844|No Intervention|Preoperative CT scan|CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
16658816|NCT02222844|Experimental|Preoperative MRI scan|Standard treatment plus an additional MRI scan before surgery
16658817|NCT02222844|No Intervention|Observational|Observational only
16658818|NCT02222831|Experimental|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:
~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).
~The embryo culture media will be collected at day 2-5."
16658819|NCT02222831|No Intervention|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.
~The embryo culture media will be collected at day 2-5."
16658820|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
16658821|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
16658822|NCT02222805|Other|Early cord clamping (ECC)|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
16658823|NCT02222805|Other|Delayed cord clamping (DCC)|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
16658824|NCT02222792||Septic patient group|The septic patient group will be comprised of patients presenting with bone and joint prosthetic device infection confirmed by intraoperative microbiological culture (at least 2 deep positive samples for the same bacterial strain).
16658825|NCT02222792||Non-septic patient group|The non-septic patient group will be comprised of prosthetic patients presenting with symptoms of mechanical loosening, and whose deep intraoperative samples have all proved negative
16658826|NCT02222792||Intermediate group|An intermediate group will be comprised of patients with only one deep positive sample.
16658827|NCT02222779||Patients with Parkinson´s Disease|
16658828|NCT02222779||Patient´s with Alzheimer´s Disease|
16658829|NCT02222779||Patients with Multiple Sclerosis|
16658830|NCT02222779||Patients with any other neurodegenerative diseases|
16658831|NCT02222766|Experimental|Parents and Tots Together Program|9-week group-based parenting program
16658832|NCT02222766|Active Comparator|Control|Minimal attention control- weekly mailed information on general child development for 9 weeks
16658833|NCT02222740|Experimental|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
16658834|NCT02222740|Experimental|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
16658835|NCT02222727|Active Comparator|Donepezil|Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
16658836|NCT02222727|No Intervention|Control|Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.
16658837|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
16658838|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
16658839|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
16658840|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
16658841|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
16658842|NCT02222701||Replacement|Composite resins with Alpha values for the marginal adaptation criteria were used as the positive control and were made with resin composite (Filtek Supreme, 3M ESPE), eith rubber dam isolation and the adhesive system L-Pop Prompt (3M-ESPE)
16658843|NCT02222701||No treatment|Composite resin restorations (Z100, 3M ESPE) in general clinically acceptable, did not receive treatment.
16658844|NCT02222701||Refurbishing|For this group, The dentists finished the occlusal, lingual or facial surfaces of defective RBC restorations with the medium series of aluminum oxide disks (Sof-Lex,3M ESPE) or carbide burs (12 and 30 blades,Brasseler USA, Dental Instrumentation,Savannah, Ga.) and then polished them with afine series of aluminum oxide disks (Sof-Lex, 3M ESPE) and diamond-impregnated composite polisher (ComposiPro Diacomp, Brasseler). For restorations in which proximal surface areas were affected, the clinicians smoothed them with interproximal aluminum oxide finishing strips (Sof-Lex Finishing Strips, 3M ESPE).
16658845|NCT02222688|Experimental|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
16658846|NCT02222688|Experimental|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
16658847|NCT02222688|Experimental|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
16658848|NCT02222688|Experimental|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
16658849|NCT02222688|Experimental|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
16658850|NCT02222688|Experimental|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
16658851|NCT02222688|Experimental|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
16658852|NCT02222675|Experimental|Sonographically assisted breast surgery|Sonographically assisted breast surgery
16658853|NCT02222675|Active Comparator|Conventional breast surgery|Conventional breast surgery
16658854|NCT02222662|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
16658855|NCT02222662|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
16658856|NCT02222649|Experimental|Vitamin D3|Group supplemented with high single dose of 200,000 IU of vitamin D3 (cholecalciferol)
16658857|NCT02222649|Placebo Comparator|placebo group|Placebo capsules with starch
16658858|NCT02222636|Placebo Comparator|Group 1,Normal saline,1 milliliter|Patients will be assigned to receive intranasal normal saline 1 milliliter
16658859|NCT02222636|Experimental|Group 2,dexmedetomidine 1μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter
16658860|NCT02222636|Experimental|Group 3,dexmedetomidine 2μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter
16658861|NCT02222623|Active Comparator|glargine insulin|Basal glargine given once daily in the morning before breakfast plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
16658862|NCT02222623|Active Comparator|NPH insulin|Basal NPH given twice daily before breakfast and at bedtime plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
16658863|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.
~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on spectral domain (SD)-optical coherence tomography (OCT). The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
16658864|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.
~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
16658865|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.
~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
16658866|NCT02222597||positive infrascanner finding|
16658867|NCT02222584||IBD group|patients with with inflammatory bowel disease who are visiting the out-patient clinic of severance hospital from July 2014 to February 2015
16658868|NCT02222571|Active Comparator|Control|9-week parenting group focused on safety
16658869|NCT02222571|Experimental|Parents and Tots Together Program|Parents and Tots Together Program is a 9-week, group-based parenting intervention
16658870|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
16658871|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
16658872|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
16658873|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
16658874|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
16658875|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
16658876|NCT02222545|Experimental|OMS721 low dose|Administration of OMS721 at a low dose
16658877|NCT02222545|Experimental|OMS721 medium dose|Administration of OMS721 at a medium dose
16658878|NCT02222545|Experimental|OMS721 high dose|Administration of OMS721 at a high dose
16658879|NCT02222532|Experimental|Tetronine|Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
16658880|NCT02222532|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
16658881|NCT02222519||Statin use group|patients taking statins for at least 3 months
16658882|NCT02222519||non statin use|no history of taking statin
16658883|NCT02222506|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.
16658884|NCT02222493|Experimental|PF-06438179|
16658885|NCT02222493|Active Comparator|Infliximab|
16658886|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg
16658887|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 60/25mg
16658888|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg
16658889|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 120/25mg
16658890|NCT02222480|Placebo Comparator|Placebo|placebo
16658891|NCT02222467|Experimental|Klox BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for venous leg ulcers.
16658892|NCT02222454|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.
16658893|NCT02222441|Experimental|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
16658894|NCT02222441|Experimental|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
16658895|NCT02222428|Experimental|BI 1744 CL/BI 54903 XX FDC|
16658896|NCT02222428|Active Comparator|BI 54903 XX|
16658897|NCT02222428|Active Comparator|BI 1744 CL|
16658898|NCT02222415|Placebo Comparator|Training + placebo drink|Exercise + non-caloric placebo drink
16658899|NCT02222415|Experimental|Exercise + Protein drink|exercise + Drink containing Protein, Carbohydrates and Fat
16658900|NCT02222402|Experimental|INTRA-DIALYTIC EXERCISE TRAINING|"Using a modified cycle ergometer, aerobic exercise will be performed in a semi-recumbent position, 3 times per week during the first two hours of haemodialysis. The initial prescription will be set in the moderate intensity range of 40-60% of peak aerobic capacity, progressing to 75% level by the end of the intervention.
~Twice per week patients will also complete lower extremity muscular conditioning exercise, using ankle weights, after the aerobic cycling exercise."
16658901|NCT02222402|No Intervention|HAEMODIALYSIS RENAL REPLACEMENT THERAPY|"Haemodialysis is the most common dialysis (renal replacement) treatment for kidney failure.
~They may also receive dietary advice, counselling, input from social workers, and other forms of educational support."
16658902|NCT02222389|Experimental|CM for alcohol|CM for alcohol
16658903|NCT02222389|Experimental|CM for drugs|CM for drugs
16658904|NCT02222389|Experimental|CM for both substances|CM for both substances
16658905|NCT02222389|Other|Non-Contingent group|No CM for either substance, the Non-Contingent (NC) group
16658906|NCT02222376|Active Comparator|Conventional treatment|Weekly ulcer debridement and daily cleansing
16658907|NCT02222376|Experimental|Pirfenidone|Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
16658908|NCT02222363|Experimental|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
16658909|NCT02222350|Experimental|DS-8500a 10mg once daily|10mg DS-8500a tablet given orally once daily
16658910|NCT02222350|Experimental|DS8500a 75 mg once daily|75mg DS-8500a tablet given orally once daily
16658911|NCT02222350|Placebo Comparator|placebo to match DS-8500a tablet|placebo matching DS-8500a tablet
16658912|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
16658913|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
16658914|NCT02222324|Placebo Comparator|Treatment A|Placebo
16658915|NCT02222324|Experimental|Treatment B|E2609 Low dose
16658916|NCT02222324|Experimental|Treatment C|E2609 High dose
16658918|NCT02222311||Autistic Children|Children diagnosed with autism spectrum disorder according to the criteria of the Diagnostic Statistical Manual-V will have blood samples taken for laboratory analysis.
16658919|NCT02222311||Healthy Children|Children with no developmental or physical diseases will have blood samples taken for laboratory analysis.
16658920|NCT02222311||Children with Attention Deficit Disorder|Blood samples from children with Attention Deficit Disorder will be measured for Vitamin D and oxidative stress markers.
16658921|NCT02222298|Experimental|VAAPS group|patients undergoing video assisted ablation of pilonidal sinus
16658922|NCT02222298|Active Comparator|conventional treatment group|patients undergoing conventional off-midline Bascom cleft lift procedure
16658923|NCT02222285|Placebo Comparator|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
16658924|NCT02222285|Active Comparator|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
16658925|NCT02222285|Active Comparator|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
16658926|NCT02222259|Experimental|GA and Integrated Care Plan|Participants allocated to the intervention group will be seen in the geriatric oncology clinic where they will be assessed using a geriatric assessment. Based on the issues identified in the geriatric assessment, a care plan will be developed with the participant to address the issues.
16658927|NCT02222259|No Intervention|Standard oncology care|Participants randomized to standard oncology care will receive usual care from their oncology team.
16658928|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
16658929|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
16658930|NCT02222233|Experimental|BI 671800 HEA delayed release (enteric coated) tablet|
16658931|NCT02222233|Experimental|BI 671800 HEA solution released in jejunum|BI 671800 HEA solution in the Enterion® capsule released in the jejunum
16658932|NCT02222233|Experimental|BI 671800 HEA solution released in ascending colon|BI 671800 HEA solution in the Enterion® capsule released in the ascending colon
16658933|NCT02222233|Experimental|BI 671800 HEA solution released in descending colon|BI 671800 HEA solution in the Enterion® capsule released in the descending colon
16658934|NCT02222233|Experimental|BI 671800 HEA particulate released in ascending colon|BI 671800 HEA as particulate in the Enterion® capsule released in the ascending colon
16658935|NCT02222220|Placebo Comparator|metoclopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
16658936|NCT02222220|Experimental|metocliopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
16658937|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
16658938|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
16658939|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
16658940|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
16658941|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
16658942|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
16658943|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
16658944|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
16658945|NCT02222194||VAM|"Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.
~Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice."
16658946|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
16658947|NCT02222168|Experimental|1 BI 409306|tablet, fasted, oral administration with 240 ml water
16658948|NCT02222168|Experimental|2 BI 409306|tablet, fed, oral administration with 240 ml water
16658949|NCT02222168|Experimental|3 BI 409306|tablet, oral administration with 240 ml water at bed time
16658950|NCT02222155|Active Comparator|CCX168 low dose plus standard of care|Capsule, 10mg, twice daily, 12 weeks
16658951|NCT02222155|Active Comparator|CCX168 high dose plus standard of care|Capsule, 30 mg, twice daily, 12 weeks
16658952|NCT02222155|Placebo Comparator|Placebo BID plus standard of care|Capsule, placebo, twice daily, 12 weeks
16658953|NCT02222142||Isoflurane group|Isoflurane inhalational anesthesia during OPCAB
16658954|NCT02222142||Propofol group|Total intravenous anesthesia with propofol during OPCAB
16658955|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
16658956|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
16658957|NCT02222116|Experimental|MGuard Prime|MGuard Prime
16658958|NCT02222116|Active Comparator|Control|BMS or DES
16658959|NCT02222103||Suspected obstructive sleep apnea in adults|Already scheduled in-lab sleep study
16658960|NCT02222090||patients who have been prescribed warfarin|
16658961|NCT02222090||patients who have been prescribed apixaba|
16658962|NCT02222064|Experimental|Mindfulness|8 week self-managed mindfulness based intervention
16658963|NCT02222051|Experimental|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
16658964|NCT02222051|Active Comparator|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
16658965|NCT02222051|No Intervention|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
16658966|NCT02222038|Other|skin biopsy|4mm punch biopsy
16658967|NCT02222025|Experimental|Injury Prevention Programme|see intervention prescription
16658968|NCT02222025|No Intervention|Control|The coaches of the control group will receive the instruction to regularly perform a common warm-up consisting of running and ball-based exercises (sham treatment, no neuromuscular and stability exercises).
16658969|NCT02222012|Active Comparator|single channel|
16658970|NCT02222012|Experimental|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|
16658971|NCT02221999|Active Comparator|Chemotherapy only|Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles
16658972|NCT02221999|Experimental|GnRHa|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously
16658973|NCT02221999|Experimental|letrozole|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day
16658974|NCT02221986|Experimental|Interdisciplinary rehabilitation|"The intervention consists of 6 weeks intensive outpatient physiotherapy in conjunction with 0-6 weeks of occupational therapy if need is indicated. The physical intervention contains supervised group exercise of 90 minutes three times a week in groups up to four patients included continuously.
~The occupational therapy intervention consists of individual training 60 minutes twice a week for patients having deficits in activity or participation levels measured by the Assessment of Motor and Process Skills (AMPS)."
16658975|NCT02221986|No Intervention|Care as usual|The control group receives usual standard of care (e.g. no training, individual training or group training in the municipality). The amount of training in this group is based on a questionnaire at the follow-up trials.
16658976|NCT02221973|Experimental|milk with 1.2g/d sterols and 8g/d hawthorn powder|
16658977|NCT02221973|Experimental|milk with 1.8g/d sterols and 8g/d hawthorn powder|
16658978|NCT02221973|Active Comparator|milk without sterols and hawthorn powder|
16658979|NCT02221960|Experimental|Monotherapy Arm|MEDI6383
16658980|NCT02221960|Experimental|Combination Arm|MEDI6383 and MEDI4736
16658981|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
16658982|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
16658983|NCT02221934|Experimental|Signal more likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
16658984|NCT02221934|Active Comparator|Signal less likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
16658985|NCT02221921|Experimental|MicroPort's Transcatheter Aortic Valve and Delivery System|single arm with intervention that percutaneous implantation of the MicroPort's Transcatheter Aortic Valve and Delivery System
16658986|NCT02221908||Patients brought to Hahnemann Hospital ED|
16658987|NCT02221895|Experimental|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
16658988|NCT02221895|Active Comparator|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
16658989|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16658990|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
16658991|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
16658992|NCT02221856|Experimental|Motion View|
16658993|NCT02221856|Active Comparator|Conventional Orthodontic Treatment|
16658994|NCT02221830|Placebo Comparator|Placebo|Normal Saline (standard of care)
16658995|NCT02221830|Experimental|Treatment|normal saline + oxytocin
16658998|NCT02221804|Experimental|COPD - reduced activity levels|COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
16658999|NCT02221804|Experimental|Healthy - reduced activity levels|Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
16659000|NCT02221804|No Intervention|COPD - unchanged activity levels|
16659001|NCT02221791|Active Comparator|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
16659002|NCT02221791|Active Comparator|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
16659003|NCT02221791|Placebo Comparator|Placebo|Participants will consume 70g white chocolate + placebo capsules
16659004|NCT02221778|Experimental|SBRT|SBRT according to the intervention description
16659005|NCT02221765|Experimental|Arm 1|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.
~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.
~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg."
16659006|NCT02221765|Experimental|Arm 2|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.
~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously."
16660110|NCT02214745||Israeli Jewish children with cerebral palsy|
16659007|NCT02221752|Experimental|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
16659008|NCT02221752|Experimental|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
16659009|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
16659010|NCT02221726|Experimental|JNJ-35684-AAA-023: 5.5 cm^2 Patch|
16659011|NCT02221726|Experimental|JNJ-35684-AAA-023: 44 cm^2 Patch|
16659012|NCT02221713||Group A: perforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with perforated diverticulitis (i.e., Hinchey III or IV).
16659013|NCT02221713||Group B: unperforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with unperforated diverticulitis (Hinchey I or II).
16659014|NCT02221713||Group C: asymptomatic diverticulosis|Patients with asymptomatic diverticulosis will be recruited from the 2-week wait (2ww) colorectal cancer pathway. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
16659015|NCT02221713||Group D: normal controls|Patients with or without haemorrhoids, and no other colonic pathology will be recruited from the 2ww colorectal cancer pathway. These will be the normal controls. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
16659016|NCT02221700|Experimental|Group I (leg massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
16659017|NCT02221700|Experimental|Group II (leg massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
16659018|NCT02221700|Experimental|Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
16659019|NCT02221700|Experimental|Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
16659020|NCT02221687|Experimental|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain
~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.
~Route : oral, ad libitum
~Duration of product intake:
~Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)
~Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
16659021|NCT02221687|Placebo Comparator|Control formula|"Control formula : standard formula without pre and probiotic
~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.
~Route: oral, ad libitum
~Duration of product intake:
~Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)
~Control FoF : 6 months of consumption (from 6 to 12 months of age)"
16659022|NCT02221687|No Intervention|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.
~Dose:
~Breast milk : on demand
~Route : oral, ad libitum
~Duration of product intake:
~Breast milk : at least 4 month (from birth until at least 4 months of age)"
16659023|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
16659024|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
16659025|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
16659026|NCT02221635||rTMS+Risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.At the same time,risperidone (2-4mg) was took orally.
16659027|NCT02221635||Risperidone|Risperidone (2-4mg) was took orally.
16659028|NCT02221622|Experimental|Allopregnanolone 2 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
16659029|NCT02221622|Experimental|Allopregnanolone 4 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
16659030|NCT02221622|Experimental|Allopregnanolone 6-18 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
16659031|NCT02221622|Placebo Comparator|Placebo|Drug: Placebo injection (intravenous solution) once per week for 12 weeks
16659032|NCT02221609|Experimental|Treatment based on Movement System Impairment based model|Treatment based on Movement System Impairment based classification model is composed by patient education, analysis and modification of daily living activities and prescription of specific exercises
16659033|NCT02221609|Active Comparator|General exercise|The general exercise program consists of stretching exercises of the trunk and lower limbs muscles and strengthening exercises of the trunk muscles (Hayden et al., 2005; Rainville et al., 2004).
16659034|NCT02221596|Experimental|vitamin D + aerobic training|vitamin D capsules every weekday (10,000IU/day) and exercise
16659035|NCT02221596|Active Comparator|vitamin D + no aerobic training|vitamin D capsules every weekday (10,000IU/day) and no exercise
16659036|NCT02221596|Active Comparator|placebo + aerobic training|placebo capsule every weekday and exercise
16659037|NCT02221596|No Intervention|placebo + no aerobic training|placebo capsule every weekday and no exercise
16659038|NCT02221583|Experimental|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
16659039|NCT02221583|Experimental|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
16659040|NCT02221570|Active Comparator|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
16659041|NCT02221570|Placebo Comparator|Placebo|placebo of baclofen
16659042|NCT02221557|Experimental|New alloplastic bone graft material|
16659043|NCT02221544|Experimental|rTMS treatment followed by Sham|A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment
16659044|NCT02221544|Experimental|Sham treatment followed by rTMS|A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS
16659045|NCT02221531|Experimental|Short infusion|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
16659046|NCT02221531|Other|Bolus application|Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds
16659047|NCT02221518|Experimental|Patients with OCD|Behavioral: Exposure & Response Prevention (EX/RP)
16659048|NCT02221505|Experimental|LOP628 - Solid Tumor|with LOP628
16659049|NCT02221505|Experimental|LOP628 - AML|With LOP628
16659050|NCT02221505|Experimental|LOP628 - Solid Tumor Expansion|With LOP628
16659051|NCT02221492|Active Comparator|granulocyte colony-stimulating factor alone|G-CSF administered up to 8 days
16659052|NCT02221492|Experimental|granulocyte colony-stimulating factor plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
16659053|NCT02221479|Active Comparator|Granulocyte colony-stimulating factor (G-CSF) alone|G-CSF administered up to 8 days
16659054|NCT02221479|Experimental|G-CSF plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
16659055|NCT02221466||diabetic patients|Diabetic patients given HBOT
16659056|NCT02221466||None diabetic patients|None diabetic patients given HBOT
16659057|NCT02221453|Other|Triamcinolone Acetonide Treatment|Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection
16659058|NCT02221440|Placebo Comparator|air, second stage of labor|"Patients randomized to the group will receive sham administered by nasal catheter.
~The therapy will continue until after delivery"
16659059|NCT02221440|Experimental|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by low flow nasal oxygen at a flow rate of 2 L/min.
~The therapy will continue until after delivery"
16659060|NCT02221427|Active Comparator|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
16659061|NCT02221427|Experimental|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
16659062|NCT02221414|Experimental|Treatment A (FDC)|
16659063|NCT02221414|Active Comparator|Treatment B (single agents)|
16659064|NCT02221401|Experimental|Treatment A (FDC)|
16659065|NCT02221401|Active Comparator|Treatment B (single agents)|
16659066|NCT02221388|Active Comparator|BI 671800 ED capsules|
16659067|NCT02221388|Experimental|BI 671800 HEA tablet in fasted state|
16659068|NCT02221388|Experimental|BI 671800 HEA EC tablet in fasted state|
16659069|NCT02221388|Experimental|BI 671800 HEA tablet in fed state|
16659070|NCT02221388|Experimental|BI 671800 HEA EC tablet in fed state|
16659071|NCT02221388|Experimental|BI 671800 HEA, 50 mg tablet in fasted state|
16659072|NCT02221375|Experimental|BHT low|
16659073|NCT02221375|Experimental|BHT medium|
16659074|NCT02221375|Experimental|BHT high|
16659075|NCT02221375|Experimental|BI 54903 XX low|
16659076|NCT02221375|Experimental|BI 54903 XX medium 1|
16659077|NCT02221375|Experimental|BI 54903 XX medium 2|
16659078|NCT02221375|Experimental|BI 54903 XX high|
16659079|NCT02221375|Experimental|BI 54903 XX medium single dose|
16659080|NCT02221375|Active Comparator|Ciclesonide|
16659081|NCT02221362||Observational|No interventions
16660111|NCT02214745||Mentally retarded Israeli Jewish children|
16659082|NCT02221349|Other|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
16659083|NCT02221349|Other|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
16659084|NCT02221336|Placebo Comparator|Non-MONARCA II system|Use of smartphone for normal communicative purposes only. No self-monitoring and no feedback loop.
16659085|NCT02221336|Experimental|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
16659086|NCT02221323|Experimental|Insulin lispro|
16659087|NCT02221310|Experimental|Gemtuzumab Ozogamicin|Conditioning therapy with Gemtuzumab Ozogamicin in combination with busulfan and cyclophosphamide chemotherapy followed by allogeneic stem cell transplantation.
16659088|NCT02221297|Experimental|Supplement product with plant stanol ester|
16659089|NCT02221297|Placebo Comparator|Placebo supplement product|
16659090|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
16659091|NCT02221271|Experimental|NPB-01|
16659092|NCT02221258|Experimental|FURESTEM-RA Inj.+DMARDs|FURESTEM-RA Inj. 1. 2.5x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 2. 5.0x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 3. 1.0x10^8 stem cells+DMARDs after registration
16659093|NCT02221245||Patients with Esophageal Cancer|Tumor Biopsy via Ultrasound Endoscopy
16659094|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
16659095|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
16659096|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
16659097|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
16659098|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
16659099|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
16659100|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
16659101|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
16659102|NCT02221206|Active Comparator|Treatment|mini-screw implant anchorage-assisted retraction of maxillary incisors
16659103|NCT02221206|No Intervention|Control|regular maximum anchorage
16659104|NCT02221193|Experimental|site specific vs panoral disinfection|
16659105|NCT02221180|Experimental|Treatment Sequence ABDC|Treatment A (1 immediate release (IR) fixed dose combination [FDC] tablet containing canagliflozin 150 milligram [mg] and metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659106|NCT02221180|Experimental|Treatment Sequence BCAD|Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659107|NCT02221180|Experimental|Treatment Sequence CDBA|Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659108|NCT02221180|Experimental|Treatment Sequence DACB|Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659109|NCT02221167|No Intervention|Exclusive breastfeeding|Infants in the exclusive breastfeeding group will continue to breastfeed.
16660518|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
16659110|NCT02221167|Active Comparator|Donor Milk|"Infants in this arm will continue to breastfeed and will be given 10 ml of donor breast milk by syringe after each breastfeeding until their mother's milk comes in. (until the onset of lactogenesis II)"
16659111|NCT02221154|Experimental|Inofolic®|standard ovarian stimulation and Inofolic®
16659112|NCT02221154|Active Comparator|Gonadotropins;Folic Acid|standard ovarian stimulation without Inofolic®
16659113|NCT02221115|Other|Google Glass|Investigators using Google Glass during clinic visit
16659114|NCT02221115|No Intervention|No Google Glass|Investigator will not be using Google Glass during clinic visit
16659115|NCT02221102|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
16659116|NCT02221102|Experimental|edoxaban 30mg|Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
16659117|NCT02221102|Experimental|edoxaban 60mg|Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
16659118|NCT02221089|Experimental|Retaron|
16659119|NCT02221089|Placebo Comparator|Placebo|
16659120|NCT02221076|Experimental|Confocal Laser Endomicroscopy (CLE)|The patient will undergo a 10 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs.
16659121|NCT02221063|Active Comparator|low [thiamin] fortified fish sauce|Fish sauce will contain 2 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
16659122|NCT02221063|Active Comparator|higher [thiamin] fortified fish sauce|Fish sauce will contain 8 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
16659123|NCT02221063|Placebo Comparator|Placebo fish sauce|Fish sauce will contain only iron (as NaFeEDTA), no thiamin
16659124|NCT02221037|Experimental|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
16659125|NCT02221037|Placebo Comparator|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
16659126|NCT02221024|Experimental|Flushing every 24 hours|Flushing with positive pressure with normal saline every 24 hours
16659127|NCT02221024|Active Comparator|Flushing every 12 hours|Flushing with positive pressure with normal saline every 12 hours
16659128|NCT02221011|Experimental|shock wave (three times)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks
16659129|NCT02221011|Sham Comparator|Sham shock wave|E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle
16659130|NCT02221011|Experimental|Shock wave (one time)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose
16659131|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
16659132|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
16659133|NCT02220985|Experimental|Arm A (MRD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
16659134|NCT02220985|Experimental|Arm B (MRD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
16659135|NCT02220985|Experimental|Arm C (MUD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
16659136|NCT02220985|Experimental|Arm D (MUD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
16659137|NCT02220972|Experimental|Arm A: First on Perampanel with a crossover to Placebo|Treatment Arm A will initially receive perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD with a crossover to placebo.
16659138|NCT02220972|Experimental|Arm B: First on Placebo with a crossover to Perampanel|Treatment Arm B will initially receive placebo with a crossover to perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD.
16659272|NCT02220010|No Intervention|Drain only|If POPF grade B or C is detected on post operative day 3 or more, only the per-operatively placed drain is used as treatment
16659139|NCT02220959|Experimental|walk test|morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
16659140|NCT02220946|Active Comparator|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. Each patient received a 20 minute session once a week for total 8 sessions
16659141|NCT02220946|Placebo Comparator|plasebo|sham electrical stimulation
16659142|NCT02220933|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
16659143|NCT02220933|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
16659144|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
16659145|NCT02220920|Placebo Comparator|Placebo＋insulin|
16659146|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
16659147|NCT02220894|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
16659148|NCT02220894|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
16659149|NCT02220881|Experimental|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
16659150|NCT02220881|Other|Observation|This group will follow the physician instruction of care for the hallux valgus
16659151|NCT02220868|Other|Sofossbuvir, Riabvirin, Stribild|Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild
16659152|NCT02220855|Experimental|BKM120|BKM120, 100mg capsule for oral use, taken once daily for two or more months for a maximum of one year. Each cycle is 28 days.
16659153|NCT02220842|Experimental|Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab|Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression.
16659154|NCT02220842|Experimental|Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
16659155|NCT02220842|Experimental|Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
16659156|NCT02220842|Experimental|Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression.
16659157|NCT02220842|Experimental|Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
16659158|NCT02220829|Active Comparator|Preventive administration of Rapaflo|Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
16659159|NCT02220829|Other|Standard care|Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
16659160|NCT02220816|Experimental|Competitive Training|The patients will receive only competitive activities designed to restore attention abilities. These include pencil-and-paper tasks completed under competitive circumstances and competitive virtual games specifically designed to treat different aspects of attention (divided, selective, sustained, etc).
16659161|NCT02220816|Active Comparator|Non-Competitive Training|The patients will receive conventional attentional training. Pencil and paper tasks focused on different aspects of attention (divided, selective, sustained, etc.) will be completed by all participant under individual or group-therapy sessions. No competitive training will be allowed.
16659162|NCT02220803|Active Comparator|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.
~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
16659163|NCT02220803|Active Comparator|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
16659273|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
16660519|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
16659164|NCT02220803|Experimental|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
16659165|NCT02220777|Experimental|1. ASP8477 and placebo|Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
16659166|NCT02220777|Experimental|2. ASP8477 alone|Part 3, fasted or fed
16659167|NCT02220777|Experimental|3. omeprazole alone|Part 4, Drug-Drug Interaction
16659168|NCT02220777|Experimental|4. ASP8477 + omeprazole|Part 4: Drug-Drug Interaction
16659169|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
16659170|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
16659171|NCT02220751|Placebo Comparator|chronic periodontitis|Non-surgical periodontal therapy.
16659172|NCT02220751|Active Comparator|Chronic periodontitis + type 2 diabetes|Non-surgical periodontal therapy + systemic doxycycline non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before first scaling and root planning session.
16659173|NCT02220751|No Intervention|Control|Periodontal- and systemically healthy patients were included as control group.
16659174|NCT02220738|Experimental|ABT-957|ABT-957 administered twice-daily for 7 days
16659175|NCT02220738|Placebo Comparator|Placebo|Placebo administered twice-daily for 7 days
16659176|NCT02220725|Experimental|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
16659177|NCT02220725|Experimental|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
16659178|NCT02220712|Experimental|Drug: OPC-14597 IMD|
16659179|NCT02220686|Experimental|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
16659180|NCT02220686|No Intervention|Usual Care|Physician will follow their institution's standard of care for smoking cessation.
16659181|NCT02220673|Experimental|BHT 0.1%|
16659182|NCT02220673|Experimental|BHT 0.5%|
16659183|NCT02220673|Placebo Comparator|Placebo for RMT-B|
16659184|NCT02220673|Placebo Comparator|Placebo for HFA-MDI|
16659185|NCT02220660|Active Comparator|Free dose combination|
16659186|NCT02220660|Experimental|Fixed dose combination|
16659187|NCT02220647|Experimental|Treatment A (FDC)|
16659188|NCT02220647|Active Comparator|Treatment B (single agents)|
16659189|NCT02220634|Experimental|Regadenoson|Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.
16659190|NCT02220621|Experimental|Treatment|After the hysteroscopic adhesiolysis, crosslinked hyaluronic acid gel is applied into the uterine cavity, then a Foleys balloon catheter is inserted into the uterine cavity.
16659191|NCT02220621|Active Comparator|Control|After hysteroscopic adhesiolysis, a Foleys balloon catheter is inserted into the unterine cavity.
16659192|NCT02220608|Experimental|Arm 1: Dose Level 1 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
16659193|NCT02220608|Experimental|Arm 2: Dose Level 2 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
16659194|NCT02220595|Experimental|Carotid stenting|Carotid artery stenting for treatment of carotid artery stenosis
16659195|NCT02220595|Active Comparator|Carotid endarterectomy|Carotid artery endarterectomy for treatment of carotid artery stenosis
16659196|NCT02220543|Experimental|Back on Track intervention|Back on Track intervention is a biopsychosocial primary care intervention
16659197|NCT02220543|Active Comparator|Primary care as usual|Primary care as usual comprises maximally 12 individual regular physical therapy sessions for a maximum of 8 weeks.
16659198|NCT02220530||Sedation group|Colonoscopies performed with conscious sedation with iv midazolam and fentanyl
16659199|NCT02220530||Control group|Colonoscopies performed without sedation.
16659200|NCT02220517|Experimental|A: MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
16659201|NCT02220517|Experimental|B: MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
16659202|NCT02220504|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
16659203|NCT02220504|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
16659204|NCT02220491|Active Comparator|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.
~The Brain contour will be generated using the segmentation wizard and edits as required.
~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
16659274|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
16659275|NCT02219984||patients anticoagulated|
16659205|NCT02220491|Experimental|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of < 0.7 mm (CT field of view < 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
16659206|NCT02220478|Active Comparator|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
16659207|NCT02220478|Active Comparator|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
16659208|NCT02220465|Experimental|PA+ Smoking Cessation (LMPA)|This intervention integrates low-to-moderate physical activity (PA) with evidence based smoking cessation programming. Over the 4-week treatment period, the intervention (1 in-person and 3 phone counseling sessions) focuses on (a) gradually increasing routine PA during the pre-quit period and maintaining PA post quit day (b) increasing daily PA (steps/day) using a weekly tailored algorithm with the goal of achieving 10,000 steps by Week 4 (quit day) and (c) training participants to use PA as a primary urge management strategy, thereby embedding PA within evidence-based smoking cessation counseling. Other components include additional smoking urge management skills, increasing motivation to quit, overcoming barriers and maintaining PA for quitting and staying smoke-free .
16659209|NCT02220465|Active Comparator|Standard Care Smoking Counseling (SCC)|The control intervention parallels the format of the LMPA intervention with focus only on behavioral and cognitive urge management strategies (avoiding/escaping high-risk situations, stimulus control) and minimizing the probability that participants in the control group would increase increase/use PA during the intervention period. Participants are provided a pedometer without any instructions or encouragement around increasing walking/steps during the 8-week intervention period.
16659210|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
16659211|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
16659212|NCT02220439||Case: non-rotavirus seroconverters|Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti-RV Immunoglobulin A < 20 U/ml
16659213|NCT02220439||Control: rotavirus seroconverters|Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti-rotavirus Immunoglobulin A > 20 U/ml
16659214|NCT02220426|Other|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
16659215|NCT02220400|Experimental|Ketamine|Ketamine infusion group
16659216|NCT02220400|Placebo Comparator|Placebo|Normal saline infusion
16659217|NCT02220387||occupational COPD|"Consists of 2 subgroups
~COPD patients with history of exposure to respirable silica dust
~COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust"
16659218|NCT02220387||smokers with COPD and healthy control|"Consists of 2 subgroups
~patients with COPD, history of tobacco smoke and no history of occupational exposure
~healthy subjects"
16659219|NCT02220374|Experimental|Supportive Finger Tape|Participants will be randomised to either placebo or supportive taping
16659220|NCT02220361|Placebo Comparator|placebo group|received 20 ml intravenous physiological saline
16659221|NCT02220361|Experimental|low dose dexmedetomidine group|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
16659222|NCT02220361|Experimental|hemabate+high dose dexmedetomidine group|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
16659223|NCT02220348|Experimental|linaclotide|Linaclotide 72μg, 145 μg, or 290 μg capsules, once daily for 3 days, oral administration
16659224|NCT02220335|Experimental|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
16659225|NCT02220335|Active Comparator|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
16659226|NCT02220309||Anxiety and mood disorders|
16659227|NCT02220296|Experimental|Part 1 insulin 338|
16659228|NCT02220296|Placebo Comparator|Part 1 placebo|
16659229|NCT02220296|Experimental|Part 2 insulin 338|
16659230|NCT02220296|Active Comparator|Part 2 insulin glargine|
16659231|NCT02220270||patient with PDA or ASD|
16659232|NCT02220257||Newly diagnosed type 1 diabetes|
16659233|NCT02220244|Experimental|MD1003|MD1003 100mg capsule, 1 capsule TID for 12 months
16659234|NCT02220244|Placebo Comparator|Placebo|Placebo capsule, 1 capsule TID for 6 months, then switch to MD1003 100mg capsule, 1 capsule TID for 6 months
16659235|NCT02220231|Experimental|capnothorax group|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
16659236|NCT02220218|Experimental|Treatment Sequence ABDC|Treatment A (canagliflozin and metformin immediate release [IR] fixed dose combination [FDC] tablet 50 milligram [mg]/500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659370|NCT02219373|Experimental|Gabapentin|
16659237|NCT02220218|Experimental|Treatment Sequence BCAD|Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659238|NCT02220218|Experimental|Treatment Sequence CDBA|Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659239|NCT02220218|Experimental|Treatment Sequence DACB|Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
16659240|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
16659241|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
16659242|NCT02220192|Experimental|Focal LEEP|All patients will undergo focal treatment of high-grade cervical intraepithelial neoplasia using LEEP. A two-week follow-up assessment will evaluate the side effects of the treatment and any unusual symptoms. This will be done through a phone survey. At six months a clinic visit is required to assess whether there are any precancerous cells of the patient's cervix.
16659243|NCT02220179|No Intervention|control|service as usual
16659244|NCT02220179|Experimental|Intervention group 1|Participants are offered access to the web based resilience program
16659245|NCT02220179|Experimental|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
16659246|NCT02220166|Experimental|Triticum monococcum|60 days of daily administration of 100 grams of water biscuits of Triticum monococcum
16659247|NCT02220153|Experimental|UCB7665 Intravenous 1|Single dose calculated based on body weight for 60 minutes intravenous infusion.
16659248|NCT02220153|Experimental|UCB7665 Intravenous 2|Single dose calculated based on body weight for 60 minutes intravenous infusion.
16659249|NCT02220153|Experimental|UCB7665 Intravenous 3|Single dose calculated based on body weight for 60 minutes intravenous infusion.
16659250|NCT02220153|Experimental|UCB7665 Intravenous 4|Single dose calculated based on body weight for 60 minutes intravenous infusion.
16659251|NCT02220153|Experimental|UCB7665 Intravenous 5|Single dose calculated based on body weight for 60 minutes intravenous infusion.
16659252|NCT02220153|Experimental|UCB7665 Subcutaneous 1|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
16659253|NCT02220153|Experimental|UCB7665 Subcutaneous 2|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
16659254|NCT02220153|Placebo Comparator|Intravenous Placebo|Single dose placebo comparator for each active arm of intravenous infusion.
16659255|NCT02220153|Placebo Comparator|Subcutaneous Placebo|Single dose placebo comparator for each active arm of subcutaneous infusion.
16659256|NCT02220140|No Intervention|Control|Service as usual
16659257|NCT02220140|Experimental|Intervention group|Participants are offered access to the web based resilience program and are invited to join a short introduction course.
16659258|NCT02220127|Experimental|8 mm collimator|GKR with a single shot of the 8 mm collimator
16659259|NCT02220127|Experimental|4 mm collimator|GKR with a single shot of the 4 mm collimator
16659260|NCT02220114|Other|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days.
~Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks."
16659261|NCT02220088|Experimental|TAI of FOLFOX|Retreatment With Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin
16659262|NCT02220088|Active Comparator|Sorafenib|treatment with sorafenib
16659263|NCT02220075||spontaneous group|maintain spontaneous breathing during the operation, and recording tidal volume, ET CO2, respiratory rate, peak airway pressure, SpO2
16659264|NCT02220075||controlled group|controlled ventilation(tidal volume 8ml/kg, ET CO2 35~40mmHg) during the operation, recording peak airway pressure, SpO2
16659265|NCT02220062|Active Comparator|EUS-CPN group|Group that be performed by Endoscopic ultrasound guided bilateral celiac plexus neurolysis
16659266|NCT02220062|Experimental|EUS-CGN group|Group that be performed by Endoscopic ultrasound guided celiac ganglia neurolysis
16659267|NCT02220049|Experimental|Velcade|Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
16659268|NCT02220036|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
16659269|NCT02220036|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
16659270|NCT02220023|Experimental|Nitric Oxide|40 ppm, one time administration, inhaled.
16659271|NCT02220010|Experimental|Pancreatic stent|If POPF grade B or C is detected on post operative day 3 or more, a pancreatic stent is endoscopically positioned in the pancreatic duct.
16659371|NCT02219373|Experimental|Oxcarbazepine|
16659276|NCT02219971|Experimental|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
16659277|NCT02219971|Experimental|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
16659278|NCT02219971|Experimental|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
16659279|NCT02219971|Experimental|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
16659280|NCT02219971|Experimental|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
16659281|NCT02219971|Experimental|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
16659282|NCT02219971|Experimental|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
16659283|NCT02219958||RAMP-HT and Non-RAMP-HT|
16659284|NCT02219945|Experimental|Group 1 - 20 PTB patients aged >18yrs|Group 1 - 20 TB patients aged > 18 yrs 5 min exhaled breath sampling with nose clamp
16659285|NCT02219945|Experimental|Group 2 - 20 TB suspects > 18 yrs|Group 2 - 20 non-TB patients > 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp
16659286|NCT02219945|Experimental|group 3 - 20 lung patients, non-TB|Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp
16659287|NCT02219945|Experimental|Group 4 - 20 healthy controls|Group 4 - 20 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp
16659288|NCT02219945|Experimental|Group 5 - 7 newly diagnosedMDR PTB pts|Group 5 - 7 newly diagnosed MDRTB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp
16659289|NCT02219945|Experimental|group 6 - cohort of TB suspects|300 more individuals, suspected to have TB - final diagnosis by standard procedures plus sputum culture plus follow-up for >2 years 5 min exhaled breath sampling with nose clamp
16659290|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
16659291|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
16659292|NCT02219919|Experimental|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
16659293|NCT02219919|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
16659294|NCT02219906|Placebo Comparator|Placebo|Placebo capsule given three times daily X 3 weeks
16659295|NCT02219906|Experimental|Resveratrol|Resveratrol 1 gram three times daily X 3 weeks
16659296|NCT02219893|Experimental|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
16659297|NCT02219880|Placebo Comparator|Placebo|Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
16659298|NCT02219880|Experimental|Kava - standardised 240mg kavalactones|Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day
16659299|NCT02219867|Experimental|Ketamine|Active Comparator
16659300|NCT02219854|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
16659301|NCT02219854|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
16659302|NCT02219841||No intervention group|Receive general life-style advice and information on heart healthy diet Undergo catheter ablation for AFib
16659303|NCT02219841||Life-style intervention|patients will receive personilized low-calorie diet menu and undergo supervised exercise in the cardiac rehabilitation facility for 3 months before ablation with an aim of loosing >10% of body weight. They will continue diet and exercise for 1 year following ablation procedure Will receive catheter ablation for AFib
16659304|NCT02219828|Placebo Comparator|Placebo|placebo sc
16659305|NCT02219828|Active Comparator|Anakinra|Anakinra 2mg/Kg up to 100mg (maximum dose)
16659308|NCT02219802|Active Comparator|Drug-eluting stent|Treatment of infarct related laesion with a drug-eluting stent
16659309|NCT02219802|Experimental|Drug-coated balloon|After treatment of the infarct related artery with a drug-coated ballon, an additional BMS is advised to be used in case of residual stenosis > 50% or coronary artery dissection type > B.
16659310|NCT02219789|Experimental|Treatment (alisertib, fulvestrant)|Patients receive fulvestrant IM on day 1 (days 1 and 15 of course 1 only) and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16659311|NCT02219776|Active Comparator|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
16659312|NCT02219776|Experimental|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
16659313|NCT02219750|Active Comparator|Preprandial premix therapy|switch twice-daily insulin Preprandial premix therapy mean that transition of advance insulin based on the basal insulin daily total dose at study entry divided into two equal dose of preprandial NovoMix 30. Patient discontinued all pre-study oral antidiabetic drug(OAD), including sulfonylureas, glinides, Thiazolidinedione(TZD) and Dipeptidyl peptidase-4(DPP-4) inhibitor but left metformin alone
16659314|NCT02219750|Active Comparator|Basal-plus insulin|switch twice-daily insulin Basal-plus insulin consisted of continued previous basal insulin and add-on once-daily insulin aspart(NovoRapid) before breakfast. The starting dose of insulin aspart was 4 unit(U) before breakfast and continued under previous basal insulin dose.
16659315|NCT02219737|Experimental|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16659316|NCT02219724|Experimental|MOXR0916: Dose Escalation Stage|Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days.
16659317|NCT02219724|Experimental|MOXR0916: Expansion Stage|Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years).
16659318|NCT02219711|Experimental|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
16659319|NCT02219698|Experimental|Symptomatic treatment|
16659320|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
16659321|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
16659322|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
16659323|NCT02219672|Experimental|Triptolide group|cART for 6 months, and the experimental group will take Triplitode 2 tabs tid po for another 12 months
16659324|NCT02219672|Active Comparator|Comparator group|combined antiretroviral therapy (cART): TDF+3TC+LPV/r+RAL for 18 months
16659325|NCT02219659|Active Comparator|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
16659326|NCT02219659|Active Comparator|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
16659327|NCT02219659|Active Comparator|Fentanyl push first|This arm attempts to manage patient's pain and agitation with analgesia first. Fentanyl intravenous (IV) pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and titrated to target RASS score up to 6 hours.
16659328|NCT02219646|Experimental|Vardenafil|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Study Group were treated with vardenafil 10 mg twice/daily.
16659329|NCT02219646|Placebo Comparator|Control|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Control Group were treated with tablets twice/daily identical to the Study Group, but containing placebo.
16659330|NCT02219633|Experimental|LEO 39652 cream|Topical application
16659331|NCT02219633|Placebo Comparator|LEO 39652 cream vehicle|Topical application
16659332|NCT02219620|Experimental|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
16659333|NCT02219620|Active Comparator|Social Control|social control/interaction group
16659334|NCT02219607||epidural|
16659335|NCT02219607||general anesthesia|
16660652|NCT02211170|Placebo Comparator|Placebo|
16659336|NCT02219594|Experimental|Gemstone CT|Gemstone CT ：Discovery CT750 HD（high definition） ，GE（General Electric Co.） Healthcare, Milwaukee； CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient
16659337|NCT02219594|Active Comparator|320-detector row spiral CT|320-detector row spiral CT：Aquilion One, Toshiba, Nasu, Japan. CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient .
16659338|NCT02219581|Placebo Comparator|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
16659339|NCT02219581|Experimental|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
16659340|NCT02219581|Experimental|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
16659341|NCT02219568|Experimental|obscure gastrointestinal bleeding|Those patients who developed obscure gastrointestinal bleeding either overt or occult bleeding who will then undergo video capsule endoscopy and CT enterography.
16659342|NCT02219555||Non-surgical treatment|When clinically indicated, subjects will receive a standard of care carpal tunnel injection whose volume and specific steroid drug will be based on the recommendation of the treating clinician
16659343|NCT02219555||Surgical treatment|When clinically indicated, subjects will receive standard of care carpel tunnel release surgery as recommended by treating clinician
16659344|NCT02219542|Placebo Comparator|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
16659345|NCT02219542|Experimental|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
16659346|NCT02219529|Experimental|MCE|patients were assigned to swallow MCE first, followed by the gastroscopy
16659347|NCT02219529|Active Comparator|Standard gastroscopy|patients were assigned to swallow MCE first, followed by the gastroscopy
16659348|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
16659349|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
16659350|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
16659351|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
16659352|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
16659353|NCT02219490|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
16659354|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
16659355|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
16659356|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
16659357|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
16659358|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
16659359|NCT02219451|Experimental|exercise training|We studied twenty-six chronic heart failure outpatients and they were assigned to 2 groups: Untrained (n=13) and trained (n=13).
16659360|NCT02219438|Experimental|RIGHT side BOLUS and left side basal|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours
16659361|NCT02219438|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours. For the left catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours.
16659362|NCT02219425|Other|endometrial biopsy|
16659363|NCT02219412|Experimental|ticagrelor mono-therapy|Take ticagrelor 90 mg Bid for 2 weeks.
16659364|NCT02219412|Active Comparator|aspirin/ticagrelor dual-therapy|Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
16659365|NCT02219399|Experimental|300 mg DHA|300 mg DHA
16659366|NCT02219399|Placebo Comparator|Placebo|olive oil or high oleic acid sunflower oil placebo
16659367|NCT02219399|Experimental|600 mg DHA|600 mg DHA
16659368|NCT02219386|Active Comparator|Deep dry needling|The group of DDN receive this treatment and stretch
16659369|NCT02219386|Other|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
16659372|NCT02219373|Placebo Comparator|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
16659373|NCT02219347|Other|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of < 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
16659374|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
16659375|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
16659376|NCT02219321|Active Comparator|Lidocaine infusion|A continuous intravenous infusion of lidocaine
16659377|NCT02219321|Placebo Comparator|Saline infusion|A continuous intravenous infusion of saline
16659378|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.
~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
16659379|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.
~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
16659380|NCT02219295|Experimental|sweet -block|application of different sugars, artificial sweeteners and sweet-taste antagonists in a single dose in 300 ml tap water every week up to 7 times and collection of blood samples over 3 hours
16659381|NCT02219295|Experimental|bitter block|application of purified bitter tasting ingredients of vegetables and hop in 300 ml tap water , collection of blood samples for 3h (-15,0,15,30,60,120,180 min)
16659382|NCT02219295|Experimental|umami-block|"application of glutamate and glutamate +IMP
~same procedure as above"
16659383|NCT02219295|Other|gastroscopy|gastroscopy with and without oral intervention with artificial sweetener saccharin to take tissue samples from the upper bowel for the investigation of taste receptor cells in the upper bowel in human beings
16659384|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
16659385|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
16659386|NCT02219269||Medically complex contraception users|Cohort includes women of reproductive age with diverse medical conditions (listed in inclusion criteria) who are referred to Family Planning felowship-trained physicians, seeking contraception counseling and administration.
16659387|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
16659388|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
16659389|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
16659390|NCT02219243|No Intervention|Waitlist Control|This is a 1-month waitlist control to be compared with the active online interpretation training interventions. This is a no intervention control group
16659391|NCT02219243|Experimental|Active Interpretation Training|Online Interpretation Training Condition 2 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
16659392|NCT02219243|Experimental|Placebo Interpretation Training|Online Interpretation Training Condition 1 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
16659393|NCT02219230|Experimental|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
16659394|NCT02219217|Experimental|No arms|All participants will be administered Tivicay® (dolutegravir 50 mg once daily) for 10 days, then will undergo a nine-day wash out period and then take Stribild® (245 mg of tenofovir disoproxil, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.
16659395|NCT02219204|Active Comparator|Acupuncture treatment|"This will be performed twice weekly for 30 days. There will be 8 sessions of acupuncture treatments in total.
~The needles to be use around the eyes will have the dimensions of 0.25 (diameter) x 13mm (length), while 0.25 x 25mm needles will be used behind the ear (feng chi) and 0.30 X 25mm needles on the upper and lower limbs. These needles will remain in the points for 20 minutes. The depth of penetration will be about 1-2 mm."
16659396|NCT02219204|Active Comparator|Herbal treatment|"This formulation is called qi ju gan lu yin or Lycium berry, a chrysanthemum beverage. This is a modified version of qi ju di huang wan published previously. The senior TCM collaborator, Prof Wei QP has made this modification in order to treat the dry eye patients with lung-kidney yin deficiency."
16659397|NCT02219204|No Intervention|Eye drops|
16659398|NCT02219191|Experimental|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
16659399|NCT02219191|Active Comparator|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
16659400|NCT02219178|Experimental|RsqVD|Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
16659436|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
16659401|NCT02219165|Experimental|IVIG 2 g/kg|Intravenous human immunoglobulin Day 1: As soon as there is suspicion of TSS, randomisation will be performed in order for the study treatment to be administered within the 12h following PICU admission (or following the manifestation of the first signs of shock). Concurrently, the TSS antibiotherapy following Surviving Sepsis Campaign recommendations is given
16659402|NCT02219165|Placebo Comparator|Albumin 4%|Same study scheduling as the first arm. Only the study treatment given is different (albumin instead of IGIV)
16659403|NCT02219152|Experimental|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
16659404|NCT02219152|Placebo Comparator|saline|the saline will be administrated using an infusion during the biopsy.
16659405|NCT02219139|Other|ESTA abutment Roxolid|"One study abutment per patient will be placed. After healing for 6 to 7 weeks, patients will be asked to stop oral hygiene at the study site for 2 weeks.
~Sulcus fluid and plaque samples will be taken at the abutment site at several visits before and during abdication of oral hygiene.
~The study finishes with biopsy visit. Afterwards a regular abutment will be placed and the patients will be treated according to the standard protocol of the clinic to obtain their final restoration."
16659406|NCT02219126|Experimental|Homogenized and pasteurized milk|Milk that has undergone homogenization ans pasteurization treatment
16659407|NCT02219126|Experimental|Nonhomogenized and nonpasteurized milk|Unhomogenized and unpasteurized milk (raw milk)
16659408|NCT02219113|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
16659409|NCT02219100|Experimental|Home administration of mifepristone|This arm consisted of women who chose home administration of 200 mg mifepristone.
16659410|NCT02219100|No Intervention|Clinic administration of mifepristone|This arm consisted of women who underwent clinic administration of 200 mg mifepristone.
16659411|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
16659412|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
16659413|NCT02219074|Experimental|Sebacia microparticle and laser treatment|
16659414|NCT02219074|Sham Comparator|Vehicle and laser treatment|
16659415|NCT02219061||GMT|
16659416|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
16659417|NCT02219048|Experimental|PF-03715455|PF-03715455
16659418|NCT02219035||stroke-ischaemic|no interventions
16659419|NCT02219035||stroke -haemorrhagic|no intervention
16659420|NCT02219035||stroke: not confirmed|no intervention
16659421|NCT02219022|Active Comparator|Control group|Patient remain with their usual clinical treatment.
16659422|NCT02219022|Experimental|Experimental group|"Patients in experimental group participated in a 12-week progressive resistance training using a maximum repetition exercise in which patients performed 1 Maximum Repetition with the maximum bearable weight. Once the 1 Maximum Repetitionwas determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1 Maximum Repetition.
~The exercises were knee extension and flexion and hip abduction and adduction, elbow extension and flexion, wrist extension and flexion and shoulder abduction and adduction and spine extension and flexion all performed in machines. The 1 Maximum Repetition load was reevaluated every 6 weeks.
~Patient remain with their usual clinical treatment."
16659423|NCT02219009|Experimental|MIND1 System|
16659425|NCT02218983|Experimental|Limited transthoracic echocardiogram (LTTE)|LTTE (SonoSite Ultrasound), which will be performed every 10 - 30 minutes, after each fluid challenge or transfusion, until two consecutive equivalent measurements are reached without fluid challenge or transfusion
16659426|NCT02218983|Active Comparator|Usual care|measurements on :blood pressure, heart rate, urine output, lactate, lactate clearance (after 6 hrs), base deficit, creatinine
16659427|NCT02218970|Experimental|strength training|Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
16659428|NCT02218970|Other|control|patients treated for substance-related disorder but not participating in strength training intervention (no training control group)
16659429|NCT02218957|Active Comparator|Standard RYGB|Standard RYGB
16659430|NCT02218957|Experimental|Extended Pouch RYGB|Restrictive/extended pouch RYGB
16659431|NCT02218944|Experimental|Response Inhibition Training: A|In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
16659432|NCT02218944|Active Comparator|Response Inhibition Training: B|In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
16659433|NCT02218944|Placebo Comparator|Benign|A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
16659434|NCT02218931|Experimental|Targeted ESTEEM diet|"The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia.
~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
16659435|NCT02218931|No Intervention|Current clinical practice|The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
16659555|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
16659437|NCT02218918|Active Comparator|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
16659438|NCT02218918|Experimental|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
16659439|NCT02218905|Experimental|Sit to stand test|One minute sit to stand in 40 inches armless chair. Fatigue, breathlessness and failure to maintain tempo will lead to decease the test
16659440|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
16659441|NCT02218879||Patients with relapsing MS|
16659442|NCT02218866||Group 1|All participants will be examined by a neurologist to test sensation, reflexes, and strength and complete a few questionnaires. Tests will be performed to measure nerve function and small punch skin biopsies will be taken to assess nerve fiber density. Blood and urine tests will measure various markers of interest. Participants will be seen before and after their bariatric surgery.
16659443|NCT02218866||Group 2|"In addition to the procedures described for Group 1, participants in Group 2 will have the following procedures:
~During bariatric surgery, a small biopsy from the liver and abdominal fat will be taken to examine how fat is processed within the body.
~At the first visit, after a skin biopsy is taken, a small capsaicin patch will be placed on the lower thigh. The patch will remain in place for 48 hours and will cause the nerves in the immediate area to pull back from the skin. A biopsy will be taken from the patch area 48 hours, 1 month, and 3 months after the initial biopsy. This procedure will be repeated after surgery.
~MRIs may be performed before and after bariatic surgery.
~Participants may be asked to complete additional tests to evaluate nerve function"
16659444|NCT02218866||Group 3|Group 3 will comprise of individuals who are not overweight. Participants in this group will undergo a similar evaluation to Group 2.
16659445|NCT02218853||Bipolar I disorder, with psychosis|Individuals diagnosed with Bipolar I disorder, with psychotic features
16659446|NCT02218853||Bipolar I disorder, without psychosis|Individuals diagnosed with Bipolar I disorder, without psychotic features
16659447|NCT02218853||Healthy Controls|Must have no personal history of any psychotic or mood disorder, or a family history of psychotic or recurrent mood disorder among their first-degree relatives
16659448|NCT02218840||Behavioral|Evaluation of cigar smoking topography
16659449|NCT02218827|Experimental|dry eye patients|Loteprednol Etabonate (FML) topical treatment 1 drop 4 times daily for 1 month then Loteprednol Etabonate (FML) 1 drop 2 times daily for 1 month
16659450|NCT02218814|Experimental|Adductor Canal Block:|Adductor Canal Nerve Block: The patient is placed in a supine position with the extremity to be blocked slightly externally rotated. On the medial thigh, at the midpoint between the inguinal crease and the medial condyle, 13-6-MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) is placed in a transverse orientation to visualize the femoral artery in short axis deep to the sartorius muscle. Sterile field and patient sedation achieved. A 21-gauge,100 mm, short-bevel needle (Stimuplex; B Braun) is inserted under ultrasound guidance in in-plane technique to position the needle tip anterolateral to the artery and just deep to the posterior fascia of the sartorius muscle. Once in position, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
16659451|NCT02218814|Active Comparator|Femoral Nerve Block|Femoral Nerve Block. The procedure is conducted with the patient in a supine position with a 13-6 MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) applied to the skin at the level of the inguinal crease. The femoral artery, fascia iliac, and femoral nerve are visualized. Sterile field and patient sedation achieved. A 22-gauge, 50-mm, short-bevel stimulating needle (Stimuplex; B Braun, Bethlehem, Pennsylvania) connected to twitch monitor B/Braun Stimuplex DIG RC is inserted under ultrasound guidance using an in-plane technique from lateral to medial until a quadriceps motor response is elicited at a current between 0.5 and 0.2 mA with a pulse width of 0.1millisecond from a twitch monitor . After negative aspiration, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral nerve and deep to the fascia iliac, with intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
16659452|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
16659453|NCT02218775|Experimental|LY2456302|LY2456302 dosed orally at 10 mg daily for 2 weeks in healthy volunteers
16659454|NCT02218762|Experimental|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
16659455|NCT02218762|Experimental|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
16659456|NCT02218749|Experimental|Initially triaged to physiotherapist|Initially triaged to physiotherapist
16659457|NCT02218749|Active Comparator|Initially triaged to physician|Initially triaged to physician
16659458|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
16659459|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
16659460|NCT02218723|Active Comparator|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF [100 microgram (mcg) per blister from 0.6% blend] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659556|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
16659461|NCT02218723|Active Comparator|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659462|NCT02218723|Active Comparator|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659463|NCT02218723|Active Comparator|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659464|NCT02218723|Active Comparator|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659465|NCT02218723|Active Comparator|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659466|NCT02218723|Active Comparator|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659467|NCT02218723|Active Comparator|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659468|NCT02218723|Active Comparator|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659469|NCT02218723|Active Comparator|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
16659470|NCT02218710||Growth hormone deficiency|
16659471|NCT02218710||healthy controls|
16659472|NCT02218697|Experimental|Co-Ad Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
16659473|NCT02218697|Experimental|Control Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
16659474|NCT02218684|Experimental|Telmisartan + Lacidipine - low dose|
16659475|NCT02218684|Experimental|Telmisartan + Lacidipine - medium dose|
16659476|NCT02218684|Experimental|Telmisartan + Lacidipine - high dose|
16659477|NCT02218684|Placebo Comparator|Placebo|
16659478|NCT02218671|Experimental|WE 941 OD under deglutition|
16659479|NCT02218671|Experimental|WE 941 OD under non-deglutition|
16659480|NCT02218658|Experimental|WE 941 OD|
16659481|NCT02218658|Active Comparator|Brotizolam|
16659482|NCT02218645|Experimental|WE 941 OD|
16659483|NCT02218645|Active Comparator|Brotizolam|
16659484|NCT02218632|Active Comparator|lactose-free diet|lactose-free diet (standard therapy) vs. lactose-free diet plus temporary oral galactose supplements
16659485|NCT02218632|Active Comparator|lactose free diet|lactose-free diet (standard therapy)
16659486|NCT02218619|Experimental|Taurourodeoxycholic Acid (TUDCA)|TUDCA 1750 mg/day x 12 months
16659487|NCT02218619|Placebo Comparator|Sugar pill (placebo)|Placebo at same dose, frequency, and duration as experimental treatment
16659488|NCT02218606|Experimental|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
16659489|NCT02218606|Experimental|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
16659490|NCT02218593|Experimental|WREX orthosis|WREX Orthosis
16659491|NCT02218580|Experimental|Massage therapy & standard care|"Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.
~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen."
16659492|NCT02218580|Active Comparator|Standard care|Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
16659493|NCT02218567|Other|Patients|
16659494|NCT02218567|Other|Caregivers|
16659495|NCT02218554|Experimental|Study Group|Subject has been diagnosed with BRONJ
16659496|NCT02218554|No Intervention|Control Group|Subject has not developed any signs or symptoms of BRONJ
16659497|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
16659498|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
16659499|NCT02218528|Placebo Comparator|Starchy meal|No Plant-based ingredient added to a starchy meal
16659500|NCT02218528|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
16659501|NCT02218528|Placebo Comparator|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
16659502|NCT02218528|Active Comparator|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
16659503|NCT02218528|Active Comparator|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
16659504|NCT02218528|Active Comparator|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
16659505|NCT02218515|Other|Open Flap Debridement|Open Flap Debridement (Control Group)
16659506|NCT02218515|Experimental|Enamel Matrix Derivative|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)
16659507|NCT02218515|Experimental|Enamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
16659508|NCT02218502|Other|If simple rules are conclusive|All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
16659509|NCT02218502|Other|If simple rules are inconclusive|If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
16659510|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
16659511|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
16659512|NCT02218476|Other|APS Patient|
16659513|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
16659514|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
16659515|NCT02218437|Experimental|MSC+ATG|The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.
16659516|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
16659517|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
16659518|NCT02218411|Experimental|Exercise|Exercises routine based on the Otago exercise programme
16659519|NCT02218398|Experimental|Bronchodilator|Albuterol 3-4 times per day, steroids when necessary.
16659520|NCT02218398|No Intervention|No drug|No drug
16660653|NCT02211157|Experimental|BIBR 796 BS, fasted|dose escalation
16659521|NCT02218385||ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
16659522|NCT02218372|Experimental|Fidaxomicin|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
16659523|NCT02218372|Active Comparator|Vancomycin|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
16659524|NCT02218359|Experimental|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.
16659525|NCT02218359|Placebo Comparator|Aerosolized Placebo|Aerosolized placebo to be administered by aerosol using the AFIS Inline System.
16659526|NCT02218346|Active Comparator|Treatment A (unfed)|Treatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
16659527|NCT02218346|Active Comparator|Treatment B (fed)|Treatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
16659528|NCT02218333|Placebo Comparator|Control drink|An isocaloric drink to milk
16659529|NCT02218333|Experimental|Milk|Protein enriched milk (Styrk)
16659530|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
16659531|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
16659532|NCT02218307|Active Comparator|Mupirocin|topical antibiotic
16659533|NCT02218307|Placebo Comparator|Placebo|Placebo control for mupirocin
16659534|NCT02218294|Experimental|[14C] BCX4161|Includes a radiolabelled dose of [14C] BCX4161 and unlabelled BCX4161
16659535|NCT02218281|Experimental|C2Q-Teen app|Smoking cessation treatment delivered through a smartphone app via mindfulness training.
16659536|NCT02218281|Active Comparator|NCI's QuitSTART app|Smoking cessation treatment delivered through a smartphone app by NCI, without mindfulness training.
16659537|NCT02218281|Active Comparator|Written smoking cessation materials only|Receipt of written smoking cessation materials.
16659538|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.
~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
16659539|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.
~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
16659540|NCT02218255|Active Comparator|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
16659541|NCT02218255|Active Comparator|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
16659542|NCT02218255|No Intervention|Day 5 eSET with Traditonal Morphology|
16659543|NCT02218242|Experimental|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
16659544|NCT02218229|Experimental|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
16659545|NCT02218229|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
16659546|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
16659547|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
16659548|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
16659549|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
16659550|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
16659551|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
16659552|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
16659553|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
16659554|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
16659557|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
16659558|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
16659559|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
16659560|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
16659561|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
16659562|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
16659563|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
16659564|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
16659565|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
16659566|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
16659567|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
16659568|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
16659570|NCT02218151|Experimental|Patient-Centered Medical Home (PCMH)|"Day-to-Day Care:
~Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
16659571|NCT02218151|Active Comparator|Standard Care|"These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self.
~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
16659572|NCT02218138|Experimental|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
16659573|NCT02218138|Experimental|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
16659574|NCT02218125|Experimental|Group 1- MVA Mosaic|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
16659575|NCT02218125|Placebo Comparator|Group 2 - Placebo|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
16659576|NCT02218125|Experimental|Group 3 - MVA Mosaic|Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
16659577|NCT02218125|Placebo Comparator|Group 4- Placebo|Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
16659578|NCT02218112||OB - Bariatric surgery (gastric bypass)|Obese patients who will undergo a bariatric surgery (gastric bypass)
16659579|NCT02218112||OB- Control group|Obese patients who will not undergo surgery - Control group
16659580|NCT02218099|Experimental|1: Single dose of ASP8232|Subjects receive a single oral dose of ASP8232
16659581|NCT02218099|Experimental|2: Multiple doses of ASP8232 or placebo|Subjects receive multiple oral doses of ASP8232 or placebo
16659582|NCT02218086|Experimental|professionals|balancing on the slackline / wobbling board 3 times by 30 seconds balancing on the slackline with a fix visual anchor / moving visual anchor 3 times by 30 seconds
16659583|NCT02218086|Experimental|beginners|balancing on the slackline / wobbling board 3 times by 30 seconds pre-training compared to post-training
16659584|NCT02218073|Experimental|Treatment Sequence AB|Participants will receive 10 milligram (mg) JNJ-42756493 tablet orally on Day 1 of Period 1 and 100 microgram (mcg) of JNJ-61818549 as intravenous injection 2 hours after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 2.
16659585|NCT02218073|Experimental|Treatment Sequence BA|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 1 and JNJ-42756493 10 mg tablet orally on Day 1 of Period 2.
16659586|NCT02218060|Experimental|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
16659587|NCT02218060|Other|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
16659588|NCT02218047|Active Comparator|Best available therapy (BAT)|Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study
16659589|NCT02218047|Experimental|Pegylated-Proline-interferon alpha-2b|AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study
16660181|NCT02214342|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
16659590|NCT02218034|Experimental|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
16659591|NCT02218034|Experimental|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
16659592|NCT02218034|Active Comparator|TAZORAC® Gel 0.1%|TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
16659593|NCT02218034|Active Comparator|TAZORAC® Cream 0.1%|TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
16659594|NCT02218021|Experimental|Samidorphan Dose 1|
16659595|NCT02218021|Experimental|Samidorphan Dose 2|
16659596|NCT02218021|Experimental|Samidorphan Dose 3|
16659597|NCT02218021|Placebo Comparator|Placebo|
16659598|NCT02218021|Active Comparator|Oxycodone Dose 1|
16659599|NCT02218021|Active Comparator|Oxycodone Dose 2|
16659600|NCT02218008|Experimental|High Dose|
16659601|NCT02218008|Experimental|Low Dose|
16659602|NCT02218008|Placebo Comparator|Placebo|
16659603|NCT02217995|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in ten 2.5 hour group sessions with 15 participants per group.
16659604|NCT02217995|No Intervention|Waitlist|Wait list as per usual.
16659605|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
16659606|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
16659607|NCT02217969|Experimental|Electronic alert to SLUScore increase|Patients whose anesthesia care team members are receiving alerts to increments in their SLUScore (progressive hypotensive exposures) are anticipated to be given interventions aimed at minimizing further hypotensive exposures. The decision of whether or not to intervene as well as the type(s) of interventions will be at the sole discretion of the patient's anesthesia care team
16659608|NCT02217969|No Intervention|Control (no alert)|Routine anesthesia care at the discretion of the anesthesia care team
16659609|NCT02217956|Experimental|HCIP + bevacizumab|"4 dose level of cisplatin are planned: Level 1 : 50 mg/m2 (start level) Level 2 : 60 mg/m2 Level 3 : 70 mg/m2 Level 4 : 80 mg/m2 Level -1: 40 mg/m2 (in case of DLT at level 1)
~bevacizumab: Treatment starts between week 10 and 14 after HCIP. Dosage: 15 mg/kg for a total of 22 injections every 3 weeks for 15 months"
16659610|NCT02217943|Active Comparator|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
16659611|NCT02217943|Active Comparator|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
16659612|NCT02217930|Placebo Comparator|Placebo|"Placebo matched to WCK 2349, oral tablet(s)
~Placebo matched to moxifloxacin overencapsulated tablet"
16659613|NCT02217930|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg positive control (overencapsulated tablet)
16659614|NCT02217930|Experimental|WCK 2349|WCK 2349 supratherapeutic dose determined in Part 1, oral tablet(s)
16659615|NCT02217917|Experimental|Cohort 1|Single ascending dose in 3 period cross-over design (with optional 4th period)
16659616|NCT02217917|Experimental|Cohort 2|Multiple ascending dose
16659617|NCT02217917|Experimental|Cohort 3|Multiple ascending dose
16659618|NCT02217904|Experimental|Islatravir 1 mg|Single oral dose of islatravir 1 mg
16659619|NCT02217904|Experimental|Islatravir 2 mg|Single oral dose of islatravir 2 mg
16659620|NCT02217904|Experimental|Islatravir 10 mg|Single oral dose of islatravir 10 mg
16659621|NCT02217904|Experimental|Islatravir 30 mg|Single oral dose of islatravir 30 mg
16659622|NCT02217904|Experimental|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
16659623|NCT02217904|Experimental|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
16659624|NCT02217904|Experimental|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
16659625|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.
~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
16659626|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
16659627|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
16659628|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
16659629|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
16659630|NCT02217852|Experimental|A1 nitrendipine|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and nitrendipine will be added (dose range 10mg-20mg bid).
16659631|NCT02217852|Experimental|A2 hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and hydrochlorothiazide will be added (dose range 12.5mg-25mg)
16659632|NCT02217852|Experimental|B1 captopril plus Hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and captopril plus Hydrochlorothiazide will be added (dose range：captopril 25mg-50mg tid, Hydrochlorothiazide 12.5mg-25mg qd).
16659633|NCT02217852|Experimental|B2 Beijing hypotensive No.0|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and Beijing hypotensive will be added (dose range：Beijing hypotensive No.0 one pile qd or less ).
16659634|NCT02217839|Experimental|DG3173|
16659635|NCT02217839|Experimental|DG3173+Octreotide|
16659636|NCT02217826|Experimental|DG3173|
16659637|NCT02217826|Placebo Comparator|Saline|
16659638|NCT02217826|Active Comparator|Octreotide|
16659639|NCT02217813|Experimental|1. Tafamidis|
16659640|NCT02217813|Experimental|2. Tafamidis|
16659641|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
16659642|NCT02217787|Other|fasted condition|
16659643|NCT02217787|Other|fed condition|
16659644|NCT02217774|Experimental|MGUIDE assisted implant placement|Implant placement, using MGUIDE MORE system for implant planning and placement
16659645|NCT02217748|Experimental|Survey questionnaire version 1|Name generator order: leisure, money, support
16659646|NCT02217748|Experimental|Survey questionnaire version 2|Name generator order: leisure, support, money
16659647|NCT02217748|Experimental|Survey questionnaire version 3|Name generator order: money, leisure, support
16659648|NCT02217748|Experimental|Survey questionnaire version 4|Name generator order: money, support, leisure
16659649|NCT02217748|Experimental|Survey questionnaire version 5|Name generator order: support, leisure, money
16659650|NCT02217748|Experimental|Survey questionnaire version 6|Name generator order: support, money, leisure
16659651|NCT02217735|Experimental|Writing Intervention - Expressive Arm|Participants are asked to write about the most traumatic or stressful experience of their entire lives in three, 20 minute writing sessions.
16659652|NCT02217735|Active Comparator|Writing Intervention - Neutral Arm|Participants are asked to write about what they did the day before, refraining from including emotional details.
16659653|NCT02217722|Experimental|Ulcerative Colitis Diet counseling|Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
16659654|NCT02217722|Experimental|Antibiotic Treatment|Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
16659655|NCT02217709|Experimental|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade < or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
16659656|NCT02217696|Experimental|Computerized reading training first|Cross-over design: group first receives the intervention
16659657|NCT02217696|Experimental|Waiting Control First|Cross-over design: group first serves as waiting control
16659658|NCT02217683|No Intervention|Young blood transfusion|The first group of patients (n=30) will be randomized to receive leukoreduced blood transfusion stored for less than 10 days
16659659|NCT02217683|No Intervention|Old blood transfusion|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days
16659660|NCT02217683|Active Comparator|Old blood transfusion and Nitric Oxide|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days while breathing nitric oxide (80 part per million) and oxygen
16659661|NCT02217670|Experimental|Metformin (test)|single oral dose of Metformin 1000 mg granules
16659662|NCT02217670|Active Comparator|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
16659663|NCT02217657|Active Comparator|operator informed to contact force|Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)
16659664|NCT02217657|Experimental|operator blinded to contact force|Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)
16659665|NCT02217644|Experimental|BI 653048 H3PO4 solution|single rising doses
16659666|NCT02217644|Experimental|BI 653048 H3PO4 low dose capsule|
16659667|NCT02217644|Experimental|BI 653048 H3PO4 high dose capsule|
16659668|NCT02217644|Placebo Comparator|Placebo|
16659669|NCT02217631|Experimental|BI 653048 BS H3PO4|dose escalation
16659670|NCT02217631|Active Comparator|Prednisolone low dose|
16659671|NCT02217631|Active Comparator|Prednisolone high dose|
16659672|NCT02217631|Placebo Comparator|Placebo|
16659673|NCT02217618|Experimental|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
16659674|NCT02217605|Experimental|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) followed by 75 minutes 31P MRS
16659675|NCT02217579|Placebo Comparator|Control|Isocaloric food without the test protein and prebiotic fiber.
16659676|NCT02217579|Experimental|Protein|Dietary protein consumed as two daily servings of 5 grams protein/serving.
16659677|NCT02217579|Experimental|Fiber|Prebiotic fiber consumed as two daily servings of 8 grams protein/serving.
16659678|NCT02217579|Experimental|Protein plus prebiotic fiber|Protein and prebiotic fiber consumed as two daily servings of 5 grams protein/serving plus 8 grams fiber/serving.
16659679|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
16660655|NCT02211157|Placebo Comparator|Placebo|
16659680|NCT02217553|Experimental|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
16659681|NCT02217540|Experimental|Experimental Group|Experimental Group consist of the physiotherapy standard protocol and active movement plus accessory mobilizations of the humeral head using Mulligan Concept Mobilisation with Movement.
16659682|NCT02217540|Active Comparator|Control Group|Standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
16659683|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
16659684|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
16659685|NCT02217514|Experimental|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
16659686|NCT02217514|Experimental|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
16659687|NCT02217514|Experimental|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
16659688|NCT02217514|Experimental|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
16659689|NCT02217514|Experimental|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
16659690|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
16659691|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
16659692|NCT02217488|Experimental|DG3173|
16659693|NCT02217488|Placebo Comparator|Vehicle|
16659694|NCT02217475|Experimental|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
16659695|NCT02217475|Experimental|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
16659696|NCT02217475|Placebo Comparator|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
16659697|NCT02217462||Pregnant women|
16659698|NCT02217449||HD|Prediction of histology
16659699|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
16659700|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
16659701|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
16659702|NCT02217423|Experimental|Obstructive increased AC|"Patient with obstructive respiratory disease with increased abdominal circumference.
~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
16659703|NCT02217423|Experimental|Obstructive disfunction with normal AC|"Patients with obstructive respiratory disease with normal abdominal circumference.
~Patient with obstructive respiratory disease with increased abdominal circumference.
~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
16659704|NCT02217423|Experimental|Restrictive increased AC|"Patients with restrictive respiratory disease with increased abdominal circumference. chest physiotherapy chest wall expansion.
~The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
16659705|NCT02217423|Experimental|Restrictive disfunction with normal AC|"Patients with restrictive respiratory disease with normal abdominal circumference.
~Chest physiotherapy chest wall expansion. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
16659706|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
16659707|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
16659708|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction]
16659709|NCT02217397|Experimental|OA, CPAPm, combination therapy|
16659710|NCT02217371|Experimental|ADHD patient|
16659711|NCT02217371|Active Comparator|Healthy volunteers|
16659712|NCT02217358|Experimental|NBI endoscopy|150 patients with suspected lesion in larynx and hypopharynx on standard ENT white light endoscopy examination will undergo NBI endoscopy in order to compare the outcomes of these two examination methods
16659713|NCT02217345|Experimental|Growth hormone|Growth hormone (somatropin) administered by daily injection at 0.3 mg daily for women and 0.2 mg daily for men given for the duration of the 6 month study
16659714|NCT02217345|Placebo Comparator|Placebo|Placebo will be administered by daily injection in this double blind study design.
16659715|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
16659716|NCT02217319|Active Comparator|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
16659717|NCT02217319|Placebo Comparator|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
16659718|NCT02217306||Contrast Sensitivity|Determine changes in contrast sensitivity frequences and visual function (visual acuity) after one month of treatment photocoagulation in macular edema
16659719|NCT02217293|Active Comparator|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
16659720|NCT02217293|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
16659721|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
16659722|NCT02217267|Placebo Comparator|Placebo group|Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times
16659723|NCT02217267|Active Comparator|Lidocaine group|Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times
16659724|NCT02217254|Active Comparator|two 3-minute cryoablations|two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure
16659725|NCT02217254|Active Comparator|One 3-minute cryoablation|One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure
16659726|NCT02217241|Experimental|Intervention|Students in the intervention group participated in a one-hour interactive, small-group handoff workshop facilitated by a study investigator. The workshop focused on the importance of specific handoff skills to patient safety.
16659727|NCT02217241|No Intervention|Control|
16659728|NCT02217228|Experimental|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
16659729|NCT02217228|Experimental|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
16659730|NCT02217228|Experimental|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
16659731|NCT02217215||Negative and Referral Cytology Results|CNDS Advanced Cervical Scan Colposcopy
16659732|NCT02217202|Experimental|ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
16659733|NCT02217189|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
16659734|NCT02217189|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
16659735|NCT02217176||endotracheal intubation|
16659736|NCT02217176||laryngeal mask airway|
16659737|NCT02217163|Experimental|Single Arm|The combination therapy of Carfilzomib, cyclophosphamide and dexamethasone (KCyd) will be used to treat eligible patients for up to 6 cycles.This will be followed by an autologous bone marrow transplantation and 2 further consolidation cycles of KCyd. Depending on their disease response, patients will be managed expectantly or be started on maintenance.
16659738|NCT02217150||Metastatic Lesions to the spine|Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
16659739|NCT02217124|Experimental|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
16659740|NCT02217124|Placebo Comparator|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
16659741|NCT02217111|Experimental|voice therapy|
16659742|NCT02217098|Active Comparator|GIC Restorations|Restorations using Glass Ionomer Cement
16659743|NCT02217098|Experimental|Compomer Restorations|Restorations using Compomer
16659744|NCT02217098|Experimental|Carbomer Restorations|Restorations using Glass Carbomer
16659745|NCT02217072|No Intervention|Control|Control
16659746|NCT02217072|Experimental|Parents as Tutors|Educational support intervention
16659747|NCT02217072|Experimental|school intervention|Educational support intervention
16659748|NCT02217059||Prehypertension|Using the JNC7 definition
16659749|NCT02217059||Stage I Hypertension|Using the JNC7 definition
16659750|NCT02217059||Stage II Hypertension|Using the JNC7 definition
16659751|NCT02217046|Experimental|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
16659752|NCT02217046|No Intervention|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
16659753|NCT02217033|Placebo Comparator|Purified Water|"In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.
~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days."
16659754|NCT02217033|Experimental|'R' (Electro-kinetically altered beverage)|"Patients randomized to this arm will begin to consume R (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.
~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days."
16659755|NCT02217020|Experimental|FOLFOXIRI|patients received FOLFOXIRI alone for 4 cycles before surgery.
16659756|NCT02217007|Experimental|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
16659789|NCT02216760|Active Comparator|Ripple Mapping guided VT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to identify conduction channels within the ventricular scar substrate to guide ablation lesions in patients with monomorphic VT.
16659757|NCT02216994|Other|surgery treatment|The patients with a predicting score of more than 5 are diagnosed with HD, and are performed surgery to remove the aganglionic bowel. The patients with a score less than 5 are mostly indicative of HAD, and receive conservative treatments that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments. one stage pull through procedure to remove the dysganglionic bowel segments.
16659758|NCT02216981|Experimental|Intensive Cognitive Behavioural Therapy|Intensive CBT (an average of 12-18 hours of CBT offered in an intensive format, delivered on 2-3 days per week over a period of 3 weeks)
16659759|NCT02216981|Active Comparator|Weekly Cognitive Behavioural Therapy|Weekly CBT (an average of 12-18 hours of CBT delivered in 60-90 minute sessions on a weekly basis)
16659760|NCT02216981|No Intervention|Wait list|Wait list (3 months). Participants randomized to wait list will commence treatment after 3 months, in the treatment condition to which they are re-randomized (either Intensive or Weekly CBT).
16659761|NCT02216968|Experimental|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.
~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
16659762|NCT02216968|Experimental|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.
~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
16659763|NCT02216942|Active Comparator|Vitapex|Endodontic treatment using Vitapex
16659764|NCT02216942|Experimental|Guedes Pinto Paste|Endodontic treatment using Guedes Pinto
16659765|NCT02216916|Experimental|HM781-36B|
16659766|NCT02216903||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
16659767|NCT02216890|Experimental|SGN-CD70A|
16659768|NCT02216877|Placebo Comparator|Placebo|Oral placebo twice daily for 8 weeks. 12 subjects.
16659769|NCT02216877|Experimental|Mablet 360 mg once daily|Oral Mablet 360 mg once daily and oral placebo once daily for 8 weeks. 12 subjects.
16659770|NCT02216877|Experimental|Mablet 360 mg twice daily|Oral Mablet 360 mg twice daily for 8 weeks. 12 subjects.
16659771|NCT02216864|Experimental|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
16659772|NCT02216864|No Intervention|Control|Subjects will receive no intervention control on the other side of the face.
16659773|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
16659774|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
16659775|NCT02216838|Experimental|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
16659776|NCT02216838|Placebo Comparator|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
16659777|NCT02216825|Experimental|Delayed release capsule, L. reuteri NCIMB 30242|
16659778|NCT02216825|Experimental|Standard vegetarian capsule, L. reuteri NCIMB 30242|
16659779|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
16659780|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
16659781|NCT02216799|Active Comparator|Regular Insulin incorporated in parenteral nutrition|Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk, will be added to parenteral nutrition to run over 24 hours as 80% of the total insulin requirement of the preceding day administered via subcutaneous sliding scale
16659782|NCT02216799|Active Comparator|Insulin glargine|Insulin glargine adminstred at daily night, calculated as 80% of the total insulin requirement of the preceding day from the insulin administered via subcutaneous sliding scale
16659783|NCT02216786|Experimental|Fulvestrant and AZD2014 (continuous)|Experimental arm
16659784|NCT02216786|Active Comparator|Everolimus and Fulvestrant|Comparator arm
16659785|NCT02216786|Active Comparator|Fulvestrant|Control 1
16659786|NCT02216786|Experimental|Fulvestrant +AZD2014 (intermittent)|Experimental arm
16659787|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.
~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
16659788|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.
~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
16659790|NCT02216760|Active Comparator|Conventional VT Ablation|Standard substrate ablation as per local operator preference will be used to guide ablation in the ventricular scar in patients with monomorphic VT.
16659791|NCT02216747|Active Comparator|prednisone 60 mg/meter square Body Surface Aera|A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.
16659792|NCT02216747|Active Comparator|prednisone 45 mg/meter square BSA|B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.
16659793|NCT02216747|Active Comparator|prednisone 30 mg/meter squer BSA|C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.
16659794|NCT02216734|Experimental|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
16659795|NCT02216734|No Intervention|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
16659796|NCT02216721||Non primary aldosteronism|Non primary aldosteronism patients undergoing usual anti hypertensive treatment
16659797|NCT02216721||Primary Aldosteronism|Patients with confirmed primary aldosteronism undergoing treatment
16659798|NCT02216708|Experimental|intravenous fluid for rehydration rapidly over 6 hours|intravenous fluid for rehydration rapidly over 6 hours
16659799|NCT02216708|Experimental|receive slow rehydration recommended by WHO (12 hours)|receive intravenous fluid followed by ORS (slow rehydration recommended by WHO) over 12 hours
16659800|NCT02216669|Experimental|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
16659801|NCT02216656|Placebo Comparator|Plascebo|
16659802|NCT02216656|Experimental|KHK7580 low dose|
16659803|NCT02216656|Experimental|KHK7580 middle dose|
16659804|NCT02216656|Experimental|KHK7580 high dose|
16659805|NCT02216656|Active Comparator|KRN1493|
16659806|NCT02216643|Experimental|thrombectomy|mechanical thrombectomy with stentriever Solitaire FR® and/or thromboaspiration with Penumbra System® in patients with large vessel occlusion in cerebral anterior circulation vessels
16659807|NCT02216643|No Intervention|best medical treatment|best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion
16659808|NCT02216630|Experimental|Adipose-Derived Stem Cell (ADSC) Therapy|This arm, as the sole arm, will consist of the ADSC treatment procedure. Intervention will consist of Adipose Derived Stem Cell (ADSC) Therapy
16659809|NCT02216617|Experimental|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)
~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)
~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
16659810|NCT02216604|Experimental|Intervention group|Multimodal Exercise intervention (console-based training, age-specific resistance training and body awareness)
16659811|NCT02216604|No Intervention|Control|age, disease and gender matched
16659812|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
16659813|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
16659814|NCT02216578|Experimental|cabozantinib|cabozantinib 60 mg oral daily
16659815|NCT02216565|Other|Medical treatment|Conventional medical non-interventional treatment
16659816|NCT02216565|Other|Endovascular treatment|Conventional medical treatment plus endovascular treatment
16659817|NCT02216552|Experimental|Resveratrol|Intervention: Resveratrol Oral supplementation of resveratrol (ResVida) 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days.
16659818|NCT02216552|Placebo Comparator|Placebo|Intervention: Placebo Control Oral supplementation of placebo twice daily (with breakfast and dinner) for a total duration of 30 days.
16659819|NCT02216539|Experimental|Self-hypnosis|Patients trained to self-hypnosis before surgery
16659820|NCT02216539|Active Comparator|Usual pain management|Patients receiving the usual post-operative pain management protocols
16659821|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
16659822|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
16659823|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
16659824|NCT02216513|Active Comparator|Desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
16659825|NCT02216513|Placebo Comparator|placebo|normal saline IV for 4 hours for 5 consecutive days
16659826|NCT02216500|Experimental|Ketogenic Therapy|Ketogenic Therapy will be administered.
16659827|NCT02216487|Experimental|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
16659828|NCT02216474|Sham Comparator|Sham transcranial direct current stimulation (frontal cortex)|Transcranial direct current stimulation will be ramped up over 60 seconds and then ramped down gradually to encourage blinding to condition.
16659829|NCT02216474|Experimental|Anodal transcranial DC stimulation (frontal cortex)|Anodal transcranial direct current stimulation to prefrontal cortex for approximately 15 minutes plus ramp up and down time
16659830|NCT02216461|Experimental|Low dose of BIBW 2948 BS|
16659831|NCT02216461|Experimental|Medium dose of BIBW 2948 BS|
16659832|NCT02216461|Experimental|High dose of BIBW 2948 BS|
16659833|NCT02216461|Placebo Comparator|Placebo|
16659834|NCT02216448|Other|simulator training|Training knee simulator in Lab
16659835|NCT02216448|Other|OR training|Training in the OR - 2 knee arthroscopies.
16659836|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
16659837|NCT02216409|Experimental|Treatment (Hu5F9-G4)|Hu5F9-G4 monotherapy
16659838|NCT02216383|Experimental|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
16659839|NCT02216383|Active Comparator|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
16659840|NCT02216383|Active Comparator|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
16659841|NCT02216370||Cryptogenic Stroke or TIA|
16659842|NCT02216370||Healthy Volunteers|Healthy Volunteers as comparative group adjusted to investigated group by age and gender
16659843|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
16659844|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
16659845|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
16659846|NCT02216331|Experimental|Group 1 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
16659847|NCT02216331|Experimental|Group 1 TMC207 and rifapentine|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifapentine administered as 4 tablets of 150 mg per tablet on each of Study Days 20-41.
16659848|NCT02216331|Experimental|Group 2 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
16659849|NCT02216331|Experimental|Group 2 TMC207 and rifampicin|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifampicin administered as 4 capsules of 150 mg per capsule on each of Study Days 20-41.
16659850|NCT02216318|Placebo Comparator|red light|red light during the whole day
16659851|NCT02216318|Active Comparator|Blue light|Blue light during early day
16659852|NCT02216305|Active Comparator|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
16659853|NCT02216305|Active Comparator|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
16659854|NCT02216292||Preterm Single Donor Milk Group|The prospective study group = preterm single donor milk group (PSDM-Group) from June 2012 - April 2013
16659855|NCT02216292||Control Group|Retrospective control group receiving no donor milk = control group from March 2011 - May 2012
16659856|NCT02216279|Experimental|Pulmonary Hypertension Patients|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
16659857|NCT02216279|Active Comparator|Control Non-Smoking Participants|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
16659858|NCT02216266|Active Comparator|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
16659859|NCT02216266|Placebo Comparator|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
16659860|NCT02216253|Active Comparator|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|The combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract will be administered in tablet twice a day 7 days before and after surgery
16659861|NCT02216253|Placebo Comparator|Placebo|Placebo tablet twice a day 7 days before and after surgery
16659862|NCT02216240|Active Comparator|Accident and emergency|Patients randomised to A&E were treated as per standard care and given no information other than that pertaining to the study.
16659863|NCT02216240|Experimental|Paramedic|Treatment at the scene by a paramedic. Valsalva manoeuvre with subsequent administration of 6mg and 12mg of adenosine unless the supraventricular tachycardia terminated. Patients were taken to accident and emergency if the tachycardia did not terminate, restarted, or the patient had continuing symptoms, a persistently abnormal ECG (other than T wave inversion) or was heamodynamically unstable. Prior to discharge from the ambulance patients received an information pack and a referral letter for their GP to refer them to an arrhythmia clinic.
16660002|NCT02215343|Experimental|High fibre diet (wheat bran extract)|
16660003|NCT02215343|Experimental|High PUFA diet (fish oil supplement)|
16660247|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
16659864|NCT02216227|Experimental|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):
~ecolonize with intranasal Mupirocin ointment BID x 5 days
~hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)
~efazolin plus Vancomycin (no Vanco for MSSA positive)
~Patient has a known negative Staph aureus pre-op screening result:
~HG bathing (night before & morning of surgery using wipes or liquid)
~efazolin
~Patient was not screened or results are unknown at time of surgery:
~ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)
~HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before & morning of surgery using wipes or liquid)
~efazolin plus Vancomycin"
16659865|NCT02216214|Placebo Comparator|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
16659866|NCT02216214|Experimental|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
16659867|NCT02216188|Experimental|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
16659868|NCT02216188|Experimental|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
16659869|NCT02216188|Other|Control|Untreated control group
16659870|NCT02216175|Experimental|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
16659871|NCT02216175|Active Comparator|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
16659872|NCT02216175|Placebo Comparator|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
16659873|NCT02216162|Experimental|A: Interventional adapted physical activity + enhanced geriatr|Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment. Weekly Taï-Chi exercises.
16659874|NCT02216162|Other|Arm B: control|Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
16659875|NCT02216149|Experimental|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
16659876|NCT02216149|Active Comparator|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
16659877|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
16659878|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
16659879|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
16659880|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
16659881|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
16659882|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
16659883|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
16659884|NCT02216097|Experimental|Treatment|
16659885|NCT02216097|Placebo Comparator|Placebo|
16659886|NCT02216084|Experimental|Recombinant ADAMTS13|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
16659887|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
16659888|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
16659889|NCT02216058|Experimental|NOYA|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
16659890|NCT02216045|Active Comparator|Peginterferon ,Ribavirin|drug :Peginterferon, Ribavirin,
16659891|NCT02216045|Experimental|Peginterferon, Ribavirin, camel milk|drug :Peginterferon, Ribavirin, camel milk
16660072|NCT02214953|Experimental|BI 11634 ER formulation M|
16660073|NCT02214953|Experimental|BI 11634 ER formulation C|
16660074|NCT02214953|Active Comparator|BI 11634 IR tablet|
16659892|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
16659893|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
16659894|NCT02216019||study cohort|Patient undergoing planned heart surgery with cardiopulmonary bypass
16659895|NCT02216006|Active Comparator|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.
~Initial ventilatory settings are also done in a conventional manner."
16659896|NCT02216006|Active Comparator|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.
~Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver."
16659897|NCT02215993|Active Comparator|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
16659898|NCT02215993|Active Comparator|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
16659899|NCT02215980|Experimental|A|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.
~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
16659900|NCT02215980|Experimental|B|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21
~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.
~Maintenance until progression or intolerance:
~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
16659901|NCT02215967|Experimental|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
16659902|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
16659903|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
16659904|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
16659905|NCT02215941|Experimental|TV-45070 7%|twice daily topical application to 7% body surface area for 7.5 days (15 applications)
16659906|NCT02215941|Experimental|TV-45070 21%|twice daily topical application to 21% body surface area for 7.5 days (15 applications)
16659907|NCT02215941|Experimental|TV-45070 53%|twice daily topical application to 53% body surface area for 7.5 days (15 applications)
16659908|NCT02215941|Placebo Comparator|Placebo|
16659909|NCT02215928||Ancillary-correlative (tumor genomic profiling)|Tissue samples are collected at baseline and blood for liquid biopsy is collected at baseline and every 6-8 weeks during active treatment. Tissue samples are analyzed via sequencing for tumor genomic profiling.
16659910|NCT02215915|Experimental|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
16659911|NCT02215915|Active Comparator|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
16659912|NCT02215902|Experimental|Hemopurifier|Affinity plasmapheresis
16659913|NCT02215889|Experimental|Surgery|
16659914|NCT02215876|Experimental|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
16659915|NCT02215863|Active Comparator|PCV13 and Fluad|437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
16659916|NCT02215863|Active Comparator|Fluad alone|437 Fluad recipients: one vaccine injection administered on Day 0
16659917|NCT02215863|Active Comparator|PCV13 alone|437 PCV13 recipients: one vaccine injection administered on Day 0
16659918|NCT02215850|Experimental|SLC-0111|
16659919|NCT02215837|Sham Comparator|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
16659920|NCT02215837|Experimental|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
16659921|NCT02215824|Experimental|BIWH 3|in escalating doses
16659922|NCT02215824|Placebo Comparator|Placebo|
16659923|NCT02215811|Experimental|Mesenchymal stromal cells|
16659924|NCT02215798||Cymbalta|
16659925|NCT02215785|Experimental|kiwifruit cohort|Patients that presented at Primary Care Centres with registered -Roma III criteria based- constipation and who accepted to participate in the study were followed-up for two weeks before intervention and three weeks under 3-daily kiwifruit intake.
16659926|NCT02215772|Experimental|BI 44370 BS|200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity
16659927|NCT02215759|Experimental|BI 44370 TA|
16659928|NCT02215759|Placebo Comparator|Placebo|
16659929|NCT02215746|Experimental|Treatment A|BI 44370 TA drinking solution 100 mg fasted
16659930|NCT02215746|Experimental|Treatment B|BI 44370 TA drinking solution 100 mg fed
16659931|NCT02215746|Experimental|Treatment C|BI 44370 TA drinking solution 200 mg fasted
16659932|NCT02215746|Experimental|Treatment D|BI 44370 TA drinking solution 200 mg fed
16659933|NCT02215746|Experimental|Treatment E|100 mg BI 44370 BS as two tablets 50 mg fasted
16659934|NCT02215746|Experimental|Treatment F|100 mg BI 44370 BS as two tablets 50 mg fed
16659935|NCT02215733||Patients prescribed antihypertensives|
16659936|NCT02215720|Experimental|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
16660075|NCT02214940|Experimental|BI 11634|multiple rising dose
16659937|NCT02215707|Experimental|Group 1|"Group 1: 5 doses of 2.7x10^5 PfSPZ Vaccine; homologous 3D7 CHMI
~Grp 1 (n=15) gets 5 doses of 270,000 PfSPZ per dose (4 doses at 4 wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 and 2 start immunizations together.
~1 subj in each of Grps 1 and 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/Grp 2 pilot subjects: 1st subject will be immunized, observed on site for minimum 1 hr; the 2nd subject may be immunized, will also be observed for minimum 1 hr. If no safety concerns are identified after 24 hrs that trigger the stopping rules, then rest of subjects in Grps 1 and 2 will be immunized.
~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (Pf3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
16659938|NCT02215707|Experimental|Group 2|"Grp 2: 5 doses of 2.7x10^5 PfSPZ Vaccine; heterologous 7G8 CHMI
~Grp 2 (n=15) gets 5 doses of 270,000 PfSPZ/dose (4 doses at 4wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 / 2 start immunizations together.
~1 subj in each of Grps 1 / 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/ 2 pilot subj: 1st subj will be immunized, observed on site for min 1 hr; 2nd subj may be immunized, will also be observed for min 1 hr. If no safety concerns after 24 hrs that trigger stopping rules, then rest of Grps 1 / 2 will be immunized.
~Approx 3 wks after final dose, Grps 1/3 have homologous CHMI; 2-3 days later, Grp 2 will undergo heterologous CHMI (Pf7G8) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1/3 have 2nd homologous CHMI; 2-3 days later, Grp 2 will undergo 2nd heterologous CHMI (7G8 strain) with 6 Infectivity Controls. Subj will be followed for 8 wks after last CHMI for safety purposes."
16659939|NCT02215707|Experimental|Group 3|"Grp 3 (n=15) will receive 3 doses by DVI of 450,000 PfSPZ/dose (of PfSPZ Vaccine) at 8 wk intervals (starting approx. 4 wks after Grps 1 and 2 get 1st immunization).
~3 subjects in Grp 3 will be immunized approx 24 hrs prior to rest of grp (pilot subjects). The 3 subjects will be immunized sequentially with min 2 hr observation period between subjects (and a 2 hr observation of 3rd subject as well). If no safety concerns identified in pilot subjects after 24 hours that trigger the stopping rules, the rest of subjects in Grp 3 will be immunized as scheduled.
~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
16659940|NCT02215707|No Intervention|CHMI Controls.1|n = 6, infectivity controls for 1st homologous CHMI (3D7) occurring approximately 3 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
16659941|NCT02215707|No Intervention|CHMI Controls.2|n = 6, infectivity controls for 1st heterologous CHMI (7G8) occurring approximately 3 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
16659942|NCT02215707|No Intervention|CHMI Controls.3|n = 6, infectivity controls for 2nd homologous CHMI (3D7) occurring approximately 24 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
16659943|NCT02215707|No Intervention|CHMI Controls.4|n = 6, infectivity controls for 2nd heterologous CHMI (7G8) occurring approximately 24 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
16659944|NCT02215694|Experimental|probiotic group|consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
16659945|NCT02215694|Placebo Comparator|placebo group|consumed 2g of powder daily without probiotics
16659946|NCT02215681|Experimental|acupuncture|acupuncture treatment
16659947|NCT02215681|No Intervention|standard treament|watchful waiting
16659948|NCT02215668|No Intervention|No physical exercise|Women are never subjected to any exercise prior to mammography.
16659949|NCT02215668|Experimental|Physical exercise (Upper limb)|Women will be subjected to physical exercise on upper limb prior to mammography.
16659950|NCT02215668|Active Comparator|Group 2|Women are subjected to physical exercise in the lower limbs prior to mammography
16659951|NCT02215655|Active Comparator|Motivational interviewing|Motivational interviewing counselling will be administered to the subjects
16659952|NCT02215655|No Intervention|No intervention: control group|No motivational interviewing counselling will be administered to the subjects
16659953|NCT02215629|Experimental|Experimental VS4718|Oral VS-4718 administered BID during a 28 day cycle.
16659954|NCT02215616|Placebo Comparator|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
16659955|NCT02215616|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
16659956|NCT02215616|Experimental|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
16659957|NCT02215616|Experimental|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.
~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
16659958|NCT02215603|No Intervention|Prolonged sitting|9 h of prolonged sitting
16659959|NCT02215603|Experimental|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
16659960|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
16659961|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
16659962|NCT02215590|Experimental|Re-Step|"The system consists of a pair of special shoes which sole height and angles change in a specific given order, thereby facilitating motor learning and problem solving in real time.
~This unpredictable change will introduce a situation of necessary adaptation to keep balance."
16659963|NCT02215577|Experimental|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
16659964|NCT02215577|Active Comparator|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
16659965|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
16660076|NCT02214940|Placebo Comparator|Placebo|
16660077|NCT02214927|Experimental|BI 11634 single rising dose|tablet
16659966|NCT02215551||Study Group|"Younger than 90 years old. no communication barriers (e.g., English speaking, household telephone) Affirmative response to each of the three following questions: a) Do patients have pain, weakness, numbness, or tingling in their legs when walking standing? b) Does this pain, weakness, numbness or tingling in their legs interfere with their daily activities? c) Have patients tried at least one non-surgical treatment for their leg symptoms (e.g., physical therapy, pain medications, spinal injection)? Have been scheduled for surgery on lower back for a condition called lumbar spinal stenosis.
~Whom have non degenerative causes of LSS such as tumor, infection, trauma, hemorrhage, or epidural lipomatosis, Prior lumbar spinal surgery, spondylolisthesis with spinal instability, significant cognitive impairment."
16659967|NCT02215538|Experimental|OROS methylphenidate|This was a 4-week double-blind arm. Medication was initiated at 18 mg/day and increased every 2 or 3 days by 9 mg based on treatment response and side effects. Maximum dose - 90 mg/day. Patients were seen weekly. Generally a stable dose was seen in 2 weeks and maintained the last 2 weeks of the arm. Side effects were assessed at each visit.
16659968|NCT02215538|Placebo Comparator|placebo|This arm was identical to the active medication arm except that placebo replaced the active medication.
16659969|NCT02215525|Experimental|UVA and Herbal|Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
16659970|NCT02215525|Experimental|Herbal|Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
16659971|NCT02215512|Experimental|RRx-001 + WBRT|RRx-001 administered intravenously twice a week (10, 17, 33, 55 mg) in subjects with brain metastases receiving whole brain radiation therapy (WBRT).
16659972|NCT02215499|Active Comparator|Xyrem®|Oral suspension
16659973|NCT02215499|Experimental|JZP-386|Oral suspension
16659974|NCT02215499|Placebo Comparator|Placebo|Oral suspension
16659975|NCT02215473|Experimental|gingivitis mouth rinse|
16659976|NCT02215473|Experimental|periodontitis mouth rinse|
16659977|NCT02215473|Active Comparator|gingivitis no mouth rinse|
16659978|NCT02215473|Active Comparator|periodontitis no mouth rinse|
16659979|NCT02215460|Experimental|Full-mouth scaling (FMS)|
16659980|NCT02215460|Experimental|FMS chlorhexidine rinse|
16659981|NCT02215460|Experimental|FMS azithromycin tablets|
16659982|NCT02215460|Placebo Comparator|FMS placebo rinse|
16659983|NCT02215460|Experimental|Quadrant scaling (QS)|
16659984|NCT02215460|Experimental|QS chlorhexidine rinse|
16659985|NCT02215460|Experimental|QS azithromycin tablets|
16659986|NCT02215460|Placebo Comparator|QS placebo tablets|
16659987|NCT02215460|Placebo Comparator|FMS placebo tablets|
16659988|NCT02215460|Placebo Comparator|QS placebo rinse|
16659989|NCT02215447|Experimental|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
16659990|NCT02215434|Placebo Comparator|Biolipid B2 (blanked/placebo)|"The study is a single-center, single-blind, placebo-controlled, parallel group trial.
~It consists of a 4-week screening period plus a 12-week treatment phase. At the screening visit, all participants underwent a physical examination including vital signs and breast and pelvic examination.
~They were randomly assigned in a 1:1 ratio to receive a transdermal vehicle biolipid B2 (identical placebo) provided by Evidence Pharmaceuticals Inc, SP,BRAZIL.
~The testosterone and placebo emulsion were alcohol-free matrixes that were applied topically to the forearm daily for the period of 12 weeks."
16659991|NCT02215434|Active Comparator|Testosterone, Transdermal, Behavior|Testosterone 0.5%, daily, 3 months
16659992|NCT02215421|Experimental|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
16659993|NCT02215421|No Intervention|No game play|No intervention control.
16659994|NCT02215408|No Intervention|Control|Patient received usual care from the provider in the local clinic.
16659995|NCT02215408|Experimental|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
16659996|NCT02215395|Experimental|CVR treatment cycle|Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
16659997|NCT02215382|Active Comparator|sugammadex|
16659998|NCT02215382|Active Comparator|neostigmine + atropine|
16659999|NCT02215369|Experimental|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
16660000|NCT02215356|Active Comparator|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5, cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles, while chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times). Progressive patients will be administered oral icotinib 125 mg three times daily.
16660001|NCT02215356|Experimental|Icotinib with concurrent radiotherapy|Chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times), while icotinib 125mg three times daily (375 mg per day) by mouth. Maintenance icotinib will be administered after radiotherapy. Progressive patients will receive chemotherapy, using the platinum-based two-drug chemotherapy regimen.
16660004|NCT02215330|Placebo Comparator|Sugar pill|"Maltodextrin filled into capsules.
~1 Pill starting dosage
~Follow-up visits (every two weeks, beginning at week 4):
~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.
~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.
~If no subretinal fluid is present and the patient takes no medication everything stays the same.
~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
16660005|NCT02215330|Experimental|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.
~1 Pill starting dosage
~Follow-up visits (every two weeks, beginning at week 4):
~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.
~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.
~If no subretinal fluid is present and the patient takes no medication everything stays the same.
~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
16660006|NCT02215317||OSA group|Patients found to have OSA based on an overnight sleep study
16660007|NCT02215317||Non-OSA group|Patients found not to have OSA based on an overnight sleep study
16660008|NCT02215304|Active Comparator|Bifidobacterium longum R0033|Bifidobacterium longum ssp infantis R0033, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
16660009|NCT02215304|Active Comparator|Lactobacillus helveticus R0052|Lactobacillus helveticus R0052, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
16660010|NCT02215304|Active Comparator|Bifidobacterium bifidum R0071|Bifidobacterium bifidum R0071, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
16660011|NCT02215304|Placebo Comparator|Placebo|potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
16660012|NCT02215291||Patients undergoing EGD or esophagoscopy|The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance
16660013|NCT02215278|Experimental|low phytic acid bean (lpa variety)|
16660014|NCT02215278|Experimental|high iron biofortified bean variety|
16660015|NCT02215278|Experimental|normal iron, normal phytic acid bean|
16660016|NCT02215265|No Intervention|A: No adjuvant treatment|Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.
16660017|NCT02215265|Active Comparator|B1: Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.
~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
16660018|NCT02215265|Experimental|B2: Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.
~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
16660019|NCT02215265|Active Comparator|C1: Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.
~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
16660020|NCT02215265|Experimental|C2: Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).
~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
16660021|NCT02215252|Experimental|PF-05089771|
16660022|NCT02215252|Experimental|Placebo|
16660023|NCT02215252|Experimental|Pregabalin|
16660024|NCT02215252|Experimental|PF-05089771 + Pregabalin|
16660025|NCT02215239|Experimental|Working type A & Workplace intervention|Participants: Workers tend to be seated during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
16660026|NCT02215239|No Intervention|Working type A & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
16660027|NCT02215239|Experimental|Working type B & Workplace intervention|Participants: Workers tend to be standing during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
16660028|NCT02215239|No Intervention|Working type B & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
16660029|NCT02215213|Active Comparator|Intervention Group|Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
16660030|NCT02215213|Active Comparator|Arm 2 intervention group|Arm 2 is receiving vitamin D supplementation in 4000/IU per day
16660031|NCT02215213|Active Comparator|Arm 3 control group|Arm 3 is receiving vitamin D supplementation in 400 IU/day
16660078|NCT02214927|Experimental|BI 11634 cross-over|sequence: 1. tablet 2. drinking solution
16660079|NCT02214914|Experimental|BI 11634 drinking solution|single rising dose
16660080|NCT02214914|Placebo Comparator|Placebo|
16660081|NCT02214914|Experimental|BI 11634 tablet|
16660082|NCT02214901|Experimental|BIBW 2948 BS in single rising doses|
16660032|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.
~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
16660033|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.
~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
16660034|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
16660035|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
16660036|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
16660037|NCT02215174|Experimental|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
16660038|NCT02215174|Experimental|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
16660039|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16660040|NCT02215148||Brain injured patients with hyponatremia|Patients with acute brain injury who develop hyponatremia and are administered tolvaptan via the nasogastric tube, deemed necessary by the primary medical team.
16660041|NCT02215135|Experimental|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
16660042|NCT02215122|Experimental|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
16660043|NCT02215122|Experimental|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
16660044|NCT02215122|Experimental|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
16660045|NCT02215109||BRVO, Retinal vessel diameter|The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
16660046|NCT02215096|Experimental|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
16660047|NCT02215096|Experimental|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
16660048|NCT02215083|Experimental|L-Glutamine|All patients will receive 20-30 grams of l-glutamine daily for 9 weeks (+/- 1 week)
16660049|NCT02215070|Experimental|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
16660050|NCT02215057|Experimental|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
16660051|NCT02215057|Experimental|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
16660052|NCT02215044|Experimental|BI 2536 in combination with gemcitabine|
16660053|NCT02215031|Experimental|BI 44370|
16660054|NCT02215031|Placebo Comparator|Placebo|
16660055|NCT02215018|Experimental|BI 44370 TA solution|
16660056|NCT02215018|Experimental|BI 44370 TA tablet|
16660057|NCT02215018|Placebo Comparator|Placebo solution|
16660058|NCT02215018|Placebo Comparator|Placebo tablet|
16660059|NCT02215005|Experimental|Telmisartan + Ramipril|5 days qd
16660060|NCT02215005|Active Comparator|Telmisartan|5 days qd
16660061|NCT02215005|Active Comparator|Ramipril|5 days qd
16660062|NCT02214992|Experimental|Telmisartan/Ramipril|Fixed dose combination tablet
16660063|NCT02214992|Active Comparator|Telmisartan + Ramipril capsule|
16660064|NCT02214992|Active Comparator|Telmisartan + Ramipril tablet|
16660065|NCT02214979|Experimental|Telmisartan/Ramipril|
16660066|NCT02214979|Active Comparator|Telmisartan + Ramipril capsule|
16660067|NCT02214979|Active Comparator|Telmisartam + Ramipril tablet|
16660068|NCT02214966|Experimental|Telmisartan/Ramipril, fed|
16660069|NCT02214966|Active Comparator|Telmisartan/Ramipril, fasted|
16660070|NCT02214953|Experimental|BI 11634 ER formulation A|
16660071|NCT02214953|Experimental|BI 11634 ER formulation B|
16660087|NCT02214875|Experimental|CQI/BTS|"Experimental: CQI/BTS
~CQI/BTS interventions will be applied through rapid structured cycles of data collection, testing of solutions and review of changes will be done. At each site, Quality Improvement Teams (QIT) will be established among facility staff. Local Government/State QI teams will provide oversight function of facility based QI initiatives. Break Through Collaborative Series (BTS) will hold quarterly in each study state at a central location with participants from intervention sites. Sessions will provide opportunity for teams to learn from each other; adapt and implement changes using the Plan-Do-Study-Act (PDSA) model. Process indicators will be used to measure quality improvement from the intervention sites and collaboratives."
16660088|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
16660089|NCT02214862|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
16660090|NCT02214849|Experimental|LATCH Intervention|Women enrolled in the WIC program and receiving breastfeeding peer counseling services will receive text messages to support them with their breastfeeding intentions. They will start receiving automated text messages starting in pregnancy and continuing throughout the first 6 months after giving birth. Messaging during pregnancy will emphasize what to expect in the hospital, the onset of lactation, skin-to-skin contact with baby, early and often breastfeeding in post-partum period, milk transfer (suck & swallow), positioning (with links), common breastfeeding problems and how to seek help. Throughout the study, participants will be able to respond to automated text messages with specific questions that will be received and answered by their WIC program peer counselors. Texting will also have prompts to respond occasionally (at minimum once every two weeks) to ensure that phone is still in service and that the participant in the intervention arm are receiving intervention.
16660091|NCT02214836|Experimental|Kidney stones|"Device: Verasonics Data Acquisition System (VDAS)
~Other Names:
~Verasonics Data Acquisition System (VDAS) Verasonics Ultrasound Engine Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified.
~Subjects in this arm will be imaged by ultrasound by the VDAS. Stone location and size will be determined and compared to clinical determination of stone location and size."
16660092|NCT02214823|Experimental|FES-Cycling|"Timeframe: Within 72 hours of ICU admission. Program: Standard care physiotherapy AND up to one hour of supine cycling daily using a cycle ergometer (RT300 supine model Restorative Therapies, Ltd or Letto 300.) attached to a six channel stimulator (SAGE) and 2 additional RT50 wireless stimulator channels.
~One leg will undergo cycling alone without the electrodes turned on (sham) and the other leg will undergo cycling and muscle stimulation. Electrodes will be placed on all major lower limb muscles. Intervention will be provided individually and supervised by a physiotherapist in ICU only. Duration /Intensity: Up to 1 hour at least 5 times a week for 28 days or ICU discharge, if 20 sessions have not occurred at this time, intervention will continue until this is achieved. Intensity of muscle stimulation will be delivered at a level able to cause visible muscle contractions, confirmed by palpation.
~A subgroup of 10 individuals will be involved in biomarker analyses."
16660093|NCT02214823|Active Comparator|Standard Care|"Both groups will receive usual medical and nursing care in the ICU and ward. Both groups (control and intervention) will receive standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
~A subgroup of 10 individuals will be involved in biomarker analyses. This will involve collection of muscle biopsy, blood and urine analyses at baseline and ICU discharge."
16660094|NCT02214810|Active Comparator|Control- Marcain|Group 1 will receive non-liposomal bupivacaine introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
16660095|NCT02214810|Experimental|Experimental- Exparel|Group 2 will receive a mixture of non-liposomal bupivacaine and Exparel introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
16660096|NCT02214797|Other|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D
~Control lens : Lotrafilcon B and Senofilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
16660097|NCT02214797|Other|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D
~Control lens : Lotrafilcon B and Senofilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
16660098|NCT02214797|Other|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D
~Control lens : Lotrafilcon B and Senofilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
16660099|NCT02214797|Other|Non-presbyopic group|"18 to 39 years old No Add
~Control lens : Lotrafilcon B and Etafilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
16660100|NCT02214784|Active Comparator|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
16660101|NCT02214784|Placebo Comparator|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
16660102|NCT02214771||1: CDI in patients treated with fidaxomicin|Diagnosed with a CDI and treated with fidaxomicin
16660103|NCT02214771||2: CDI in patients receiving treatment other than fidaxomicin|Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)
16660104|NCT02214758|Other|Dietary counseling|
16660105|NCT02214758|Other|Oral health counseling|
16660106|NCT02214758|No Intervention|nutrition no counseling|
16660107|NCT02214758|No Intervention|oral health no counseling|
16660112|NCT02214732|Experimental|MBCT + Treatment as Usual (TAU)|"Behavioural: Mindfulness Based Cognitive Therapy
~Participants in the MBCT group attend an 8 week course of a modified MBCT program for pregnant women, delivered by a licensed clinical psychologist."
16660113|NCT02214732|No Intervention|Treatment as Usual (TAU)|Participants in the TAU group access community resources for pregnant women experiencing psychological distress.
16660114|NCT02214719|Experimental|Baseline observation for EASI-IDM use|Baseline observation period to gather information on current practice about diabetes care
16660115|NCT02214706|Experimental|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
16660116|NCT02214706|Experimental|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
16660117|NCT02214706|Experimental|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
16660118|NCT02214706|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
16660119|NCT02214693|Experimental|Group 1(Severe decrease in GFR)|Severe decrease in GFR
16660120|NCT02214693|Experimental|Group 2(Moderate decrease in GFR)|Moderate decrease in GFR
16660121|NCT02214693|Experimental|Group 3(Mild decrease in GFR)|Mild decrease in GFR
16660122|NCT02214693|Experimental|Group 4(Normal GFR)|Normal GFR
16660123|NCT02214680|Experimental|Combination of Brimonidine and Timolol|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
16660124|NCT02214667|Experimental|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
16660125|NCT02214667|Active Comparator|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
16660126|NCT02214654||ticagrelor，clopidogrel，antiplatelet drugs|
16660127|NCT02214641|Experimental|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
16660128|NCT02214641|Active Comparator|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
16660129|NCT02214628|Experimental|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
16660130|NCT02214628|Experimental|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
16660131|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
16660132|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
16660133|NCT02214602|Experimental|Study group(Epirubicin)|in this arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
16660134|NCT02214602|No Intervention|Control group|in this arm -control group- : patients will not receive immediate intravesical instillation of of epirubicin after compete transurethral resection of bladder tumor.
16660135|NCT02214589|Active Comparator|Oral glucose and NNS|Oral glucose and NNS
16660136|NCT02214589|Active Comparator|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
16660137|NCT02214589|Active Comparator|Facilitated Tucking and NNS|Facilitated tucking and NNS
16660138|NCT02214563|Active Comparator|Thrice-weekly cholecalciferol|Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
16660139|NCT02214563|Active Comparator|Monthly cholecalciferol|Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
16660140|NCT02214563|Placebo Comparator|Thrice-weekly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
16660141|NCT02214563|Placebo Comparator|Monthly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
16660142|NCT02214550|No Intervention|Pain Discovery Aim|"255 Reproductive age women (18-45) will be identified and divided into 5 groups
~Healthy Controls
~Chronic Pain (Positive Controls)
~Dysmenorrhea (D)
~Dysmenorrhea with Cross Organ Sensitization (D+COS)
~Painful bladder syndrome (PBS)/interstitial cystitis (IC)
~After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
16660143|NCT02214550|No Intervention|D+COS-no OC|For Aim #2, ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
16660144|NCT02214550|Active Comparator|D+COS-cyclic microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
16660145|NCT02214550|Active Comparator|D+COS-continuous microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
16660656|NCT02211144|Experimental|BIRB 796 BS|in escalating doses
16660146|NCT02214550|Active Comparator|PBS-continuous microgestin 1/20|For Aim #2, 26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
16660147|NCT02214537|Experimental|MACS|Patients with MACS Selection
16660148|NCT02214524|Experimental|Bair hugger forced air warming therapy|Use of Bair Hugger forced-air warming system perioperatively to keep patient normothermia
16660149|NCT02214524|No Intervention|conventional warming care|conventional warming care
16660150|NCT02214511||MDD patients|emotional facial stimuli cyberball game
16660151|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
16660152|NCT02214498|Active Comparator|Enalapril/hydrochlorothiazide|This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
16660153|NCT02214498|Placebo Comparator|Placebo|This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
16660154|NCT02214485|Experimental|integrated care (IC)|Subjects will receive such care twice weekly for 12 weeks.
16660155|NCT02214485|Experimental|lower extremity strength training (LEST)|Subjects will receive training twice weekly for 12 weeks
16660156|NCT02214472|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
16660157|NCT02214472|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
16660158|NCT02214459|Experimental|mhealth counseling|DASH Mobile mhealth enhanced coaching
16660159|NCT02214446||primary caregivers of children newly diagnosed with cancer|Explore Factors related to Truth Telling in Primary Caregivers of Children Newly Diagnosed with Cancer
16660160|NCT02214433|Experimental|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
16660161|NCT02214433|Experimental|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
16660162|NCT02214433|Experimental|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
16660163|NCT02214433|Experimental|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
16660164|NCT02214433|Placebo Comparator|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
16660165|NCT02214433|Experimental|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
16660166|NCT02214433|Experimental|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
16660167|NCT02214433|Experimental|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
16660168|NCT02214433|Experimental|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
16660169|NCT02214433|Experimental|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
16660170|NCT02214433|Experimental|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
16660171|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
16660172|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
16660173|NCT02214407|Experimental|ARM A: DECITABINE (DACOGEN)|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.
~Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.
~Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L."
16660174|NCT02214407|Experimental|ARM B: HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.
~Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 109/L (if initially below 100 X 109L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation."
16660175|NCT02214394|Experimental|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
16660176|NCT02214381|Active Comparator|Mycet/Cyclophosphamid|4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile.
16660177|NCT02214381|Active Comparator|Myocet/Cyclophosphamide/Paclitaxel|2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile.
16660178|NCT02214368|Experimental|NIV bundle group|early use of NIV, and combination fiberoptic bronchoscopy and sedation
16660179|NCT02214368|Other|Conventional treatment group|standard supplemental oxygen, and conventional application of noninvasive ventilation.
16660180|NCT02214342|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
16660182|NCT02214329|Experimental|Sensor-based exercise training|The intervention group receives sensor-based balance training with real-time joint feedback through an interactive interface on LC monitor screen.
16660183|NCT02214329|Active Comparator|In-home balance training|The control group performs similar exercise as intervention group at home without use of sensor or any joint feedback from sensor data.
16660184|NCT02214316|Experimental|Interventional 1|Interventional experimental arm with hypertonic saline
16660185|NCT02214303||Allergic asthma|Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
16660186|NCT02214303||Allergic rhinitis|allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
16660187|NCT02214303||Control group|Healthy subjects
16660188|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
16660189|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
16660190|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 mg) provided by NOW FOODS
16660191|NCT02214277|Experimental|Test Arm|
16660192|NCT02214277|Active Comparator|Control Arm|
16660193|NCT02214277|Other|Safety Arm|
16660194|NCT02214264|Experimental|Loving-Kindness training|Participants receive Loving-Kindness meditation training for approximately 12 minutes.
16660195|NCT02214264|Experimental|Breath Awareness training|Participants receive Breath Awareness meditation training for approximately 12 minutes.
16660196|NCT02214264|Experimental|Gratitude training|Participants will receive Gratitude training for approximately 12 minutes.
16660197|NCT02214264|Other|Control|Participants write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
16660198|NCT02214251|Experimental|PK-16CH EXG system|PK-16CH EXG is a wireless physiological signal acquisition system for monitoring the bio-signals, such as EEG, ECG, and EMG. The system can concomitant EEG and EMG recording during ambulation.
16660199|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
16660200|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
16660201|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
16660202|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
16660203|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
16660204|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:
~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
16660205|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:
~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
16660206|NCT02214199|Active Comparator|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
16660207|NCT02214199|Experimental|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
16660208|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
16660209|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
16660210|NCT02214173|Experimental|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
16660211|NCT02214173|Placebo Comparator|placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
16660212|NCT02214160|Experimental|UX007|Participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
16660213|NCT02214147|Experimental|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN.
16660214|NCT02214147|Experimental|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin > 1.5-3 x ULN and any ALT level.
16660246|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
16660215|NCT02214147|Experimental|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin > 3 x ULN and any ALT level.
16660216|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
16660217|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
16660218|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
16660219|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
16660220|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
16660221|NCT02214108|Experimental|Phisical activity with Nintendo Wii|3 hours of weekly of physical activity, divided in 1 hour interday with Nintendo WII. games applied: Wii Boxing, Wii Tennis; Wii Bowling
16660222|NCT02214108|No Intervention|phisical activity with phisiotherapist|3 hours of weekly physical activity, divided in 1 hour interday. applying cardiovascular and muscular endurance static exercises.
16660223|NCT02214095|Active Comparator|glucosamine sulphate capsules|500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
16660224|NCT02214095|Placebo Comparator|lactose capsules|lactose capsules three times daily for 3 months
16660225|NCT02214082|No Intervention|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
16660226|NCT02214082|Experimental|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
16660227|NCT02214069||Patients with Atrial Fibrillation|Patients with Atrial Fibrillation admitted to the hospital for drug loading with Dofetilide or Sotalol willing to record and transmit heart rhythm using AliveCor.
16660228|NCT02214056||The study population|"There is only one group in this study. Please see the inclusion/exclusion criteria.
~Intervention: Patient recruitment Intervention: Mobile team exam"
16660229|NCT02214043||Group 2|
16660230|NCT02214043||group 1|
16660231|NCT02214030|Active Comparator|Assiut Femoral Compression Device|the sheaths were removed 2 hours after PCI instead of conventional 6hours. To standardize compression times, AFCD were applied to patient and complete femoral artery compression were applied for 5 minutes, followed by a gradual release of pressure over the ensuing 8 minutes. Therefore each patient received a minimum of 13 minutes of compression, with further compression applied only if full hemostasis had not been achieved at that point with maximum of 30 minutes.
16660232|NCT02214030|Placebo Comparator|Manual compression|The intra-arterial sheaths were removed 6 hours after PCI in the MC group according to the standard local protocols.
16660233|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
16660234|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
16660235|NCT02214004|Experimental|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
16660236|NCT02213991|Experimental|Intraoperative Radiotherapy|"Intervention:
~Intraoperative Radiotherapy
~* Operation day
~Breast conservative surgery + Intraoperative radiotherapy 20 Gy
~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done.
~* Postoperative period
~± Chemotherapy
~WBRT (46 Gy) for 4~5 weeks
~± Endocrine therapy or target therapy"
16660237|NCT02213965||Vasofix® Safety|Peripheral IV catheter Vasofix® Safety
16660238|NCT02213965||Introcan Safety®|Peripheral IV catheter Introcan Safety® IV catheter
16660239|NCT02213952|Experimental|Platelet-Rich Plasma|Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
16660240|NCT02213952|Active Comparator|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
16660241|NCT02213939||CPB + Cytosorb|On pump myocardial revascularization with the use of the cytokine adsorbing circuit (Cytosorb)
16660242|NCT02213939||CPB / Control|Controll group; on pump myocardial revascularization
16660243|NCT02213939||OPCAB / Control|Controll Group; off-pump myocardial revascularization
16660244|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
16660245|NCT02213913|Experimental|Treatment (lenalidomide, DA-EPOCH-R)|"INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months."
16660657|NCT02211144|Placebo Comparator|Placebo|
16660248|NCT02213887|Experimental|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.
~Intervention: Days 2-8"
16660249|NCT02213887|Experimental|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.
~Intervention: Days 2-8"
16660250|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
16660251|NCT02213861|Experimental|1.0% SHAPE Gelled Solution once daily|
16660252|NCT02213861|Experimental|0.5% SHAPE Gelled Solution twice daily|
16660253|NCT02213861|Experimental|1.0% SHAPE Gelled Solution twice daily|
16660254|NCT02213848|Experimental|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
16660255|NCT02213848|Placebo Comparator|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
16660256|NCT02213835|Experimental|Specific Carbohydrate diet (SCD)|"The treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include Breaking the Vicious Cycle by Elaine Gottschall and Recipes for the Specific Carbohydrate Diet by Raman Prasad."
16660257|NCT02213822||Pts with Solid Tumors/ Hematological Cancer|Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.
16660258|NCT02213809|Experimental|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
16660259|NCT02213809|Active Comparator|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
16660260|NCT02213796|Other|1h infusion of 1 g meropenem|
16660261|NCT02213783|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 2-5 days
16660262|NCT02213783|Experimental|Extended infusion arm|Infusion of 0.5 g of imipenem for 4 hr every 6 hr for 2-5 days
16660263|NCT02213770||Intervention group|Group that followed high- intensity interval training program in TEX study.
16660264|NCT02213770||Control group|Followed up on a regular basis for HTx recipients in Norway.
16660265|NCT02213757|Experimental|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
16660266|NCT02213757|Placebo Comparator|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
16660267|NCT02213744|Experimental|MM-302 + trastuzumab|MM-302 + trastuzumab
16660268|NCT02213744|Active Comparator|Chemotherapy of Physician's Choice plus trastuzumab|Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine
16660269|NCT02213731|Other|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
16660270|NCT02213718|Experimental|Desflurane|desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
16660271|NCT02213718|Active Comparator|propofol|intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
16660272|NCT02213705|Experimental|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide
16660273|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
16660274|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
16660275|NCT02213679|Experimental|Guanidinoacetic acid|Supplementation with dietary guanidinoacetic acid
16660276|NCT02213679|Placebo Comparator|Placebo|Supplementation with cellulose
16660277|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
16660278|NCT02213653|Experimental|Concomitant iron and I.V. epoietin zeta|
16660279|NCT02213653|Experimental|Iron and I.V. epoietin zeta sequential|
16660280|NCT02213653|Active Comparator|Epoietin zeta|
16662381|NCT02199899|Placebo Comparator|Placebo|
16660281|NCT02213640|Experimental|Arm A Anodal tDCS and prismatic adaptation|anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
16660282|NCT02213640|Placebo Comparator|Arm B: control|Prismatic adaptation with placebo stimulation
16660283|NCT02213627|Experimental|Corifollitropin alfa|From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
16660284|NCT02213627|Experimental|Recombinant FSH|From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
16660285|NCT02213627|Experimental|HP-hMG|From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
16660286|NCT02213614|Experimental|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.
~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
16660287|NCT02213614|Experimental|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
16660288|NCT02213601|Experimental|Yoga|8-week Gentle Vinyasa Flow yoga intervention
16660289|NCT02213601|No Intervention|Wait-list Control Group|
16660290|NCT02213588|Active Comparator|AOX blend|Rosemary:Quercetin:Turmeric (300 mg total)
16660291|NCT02213588|Placebo Comparator|Placebo|Maltodextrin
16660292|NCT02213575|Other|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
16660293|NCT02213562|Experimental|200 mg CFO|200 mg of chrysanthemum flower oil
16660294|NCT02213562|Experimental|300 mg CFO|300 mg of chrysanthemum flower oil
16660295|NCT02213562|Experimental|400 mg CFO|400 mg of chrysanthemum flower oil
16660296|NCT02213549|Placebo Comparator|Placebo|3 placebo capsules/day for 12 weeks
16660297|NCT02213549|Experimental|Ume paste and ginger powder|3 experimental capsules/day for 12 weeks.
16660298|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
16660299|NCT02213523|Experimental|Plant concentrate A|Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
16660300|NCT02213523|Experimental|Plant concentrate B|Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
16660301|NCT02213523|Experimental|Plant concentrate C|Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
16660302|NCT02213523|Experimental|Plant concentrate D|Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
16660303|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
16660304|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
16660305|NCT02213484||Marfan syndrome|Individuals with a clinical diagnosis of Marfan syndrome
16660306|NCT02213484||Aortopathy syndrome|Individuals with one of the following clinical diagnoses: Loeys-Dietz syndrome, Turner syndrome, Ehlers-Danlos type IV syndrome, Thoracic Aortic Aneurysm and Dissection syndromes.
16660307|NCT02213471||Elevated risk for melanoma|Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
16660308|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
16660309|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
16660310|NCT02213432|Experimental|Day 1 vaccination|"Different timing of influenza vaccination: Day 1
~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts."
16660311|NCT02213432|Active Comparator|Day 11 vaccination|"Different timing of influenza vaccination: Day 11
~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts"
16660312|NCT02213419|Experimental|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
16660313|NCT02213406|Experimental|intervention group|Fat detection threshold test, intake of high and low fat yogurt, fMRI-measurements
16660314|NCT02213393|Experimental|Protein enriched products|The intervention group receives protein enriched products (CwC products) in the hospital and receives these also after discharge during 12 weeks.
16660315|NCT02213393|Active Comparator|Usual menu|The control group receives the usual protein and energy rich menu in the hospital and receives regular products, no protein enrichment, after discharge during 12 weeks.
16660316|NCT02213380|Other|group GA|General anesthesia
16660317|NCT02213380|Other|group RA|Regional anesthesia
16660318|NCT02213367|Active Comparator|20 mg Bilastin|20mg Bilastine once daily
16660319|NCT02213367|Active Comparator|Bilastin 40mg|40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
16660320|NCT02213367|Active Comparator|Bilastin 80mg|80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
16660321|NCT02213354|Experimental|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
16662384|NCT02199873|Placebo Comparator|Placebo|
16660322|NCT02213354|Experimental|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
16660323|NCT02213354|Experimental|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
16660324|NCT02213354|Experimental|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
16660325|NCT02213354|Experimental|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
16660326|NCT02213354|Experimental|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
16660327|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
16660328|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
16660329|NCT02213328|Experimental|Truvada|All participants will take Truvada, once daily by mouth for the first 12 weeks of the study. After Week 12 of the study, only participants who indicate a willingness to use Truvada PrEP and who do not have any medical reasons not to do so will continue to receive the Truvada tablets through Week 52.
16660330|NCT02213315|Experimental|100mg arm|100mg dose
16660331|NCT02213315|Experimental|150mg arm|150mg dose
16660332|NCT02213315|Placebo Comparator|Placebo|Placebo
16660333|NCT02213302|Placebo Comparator|Isotonic serum|placebo administration
16660334|NCT02213302|Active Comparator|Midazolam|midazolam intravenous administration 0.02mg/kg
16660335|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)|"For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:
~Immuno-oncology included PD-L1 IHC combined positivity score >10, high microsatellite instability, tumor mutation burden >15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab."
16660336|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (HER2 amplified)|HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
16660337|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EFGR amplified)|EGFR amplified. These patients received ABT-806.
16660338|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)|FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
16660339|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)|MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
16660340|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EGFR expressing)|EGFR expressing. These patients received standard cytotherapy plus ABT 806.
16660341|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (All negative)|All negative. These patients received standard cytotherapy plus Ramucirumab.
16660342|NCT02213289|Other|Non-ITT: Standard Therapy|Patients without monoclonal antibodies available received standard cytotherapy.
16660343|NCT02213276|Experimental|Healthy males|Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
16660344|NCT02213263|Experimental|PF-05280586|
16660345|NCT02213263|Active Comparator|MabThera®|
16660346|NCT02213250|Experimental|BeneFIX|
16660347|NCT02213224|Experimental|Perindopril|Perindopril 4mg qd taken in the morning;
16660348|NCT02213224|Experimental|Telmisartan|Telmisartan 80mg qd taken in the morning;
16660349|NCT02213224|Placebo Comparator|Amlodipine|Amlodipine；5mg qd taken in the morning.
16660350|NCT02213211|Experimental|Diagnosis and treatment of malaria|"School-based diagnosis and treatment of uncomplicated malaria using malaria RDTs and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers.
~Drug: Artemether lumefantrine (artemisinin-based combination therapy [ACT], Coartem). Three-day doses of 20mg/120mg, 40mg/240mg, 60mg/360mg and 80mg/480mg Coartem are provided, according to weight, upon a positive rapid diagnostic test (RDT) result."
16660351|NCT02213211|No Intervention|No intervention|No intervention provided
16660352|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
16660353|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
16660354|NCT02213185|Experimental|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
16660355|NCT02213185|Active Comparator|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
16660356|NCT02213185|Placebo Comparator|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
16660357|NCT02213185|Placebo Comparator|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
16660358|NCT02213172|Experimental|Bifidobacterium longum R0175|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
16660359|NCT02213172|Experimental|Lactobacillus paracasei HA-196|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
16660360|NCT02213172|Placebo Comparator|Placebo|1 capsule daily for 8 weeks
16660361|NCT02213159|Active Comparator|Dexmedetomidine|prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes
16660362|NCT02213159|Active Comparator|Morphine|prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
16660363|NCT02213146|Experimental|BioChaperone human insulin|BioChaperone Human Insulin
16660364|NCT02213146|Active Comparator|Human insulin|Huminsulin® Normal
16660365|NCT02213146|Active Comparator|Insulin lispro|Humalog®
16660480|NCT02212353||Site 3 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 3 in delivering to care to neck of femur patients.
16660481|NCT02212340|Experimental|TIVA group|Anesthesia is maintained with fresofol and remifentanil
16660482|NCT02212340|Active Comparator|Des group|Anesthesia is maintained with desflurane and remifentanil
16660483|NCT02212327||PD subjects|
16660366|NCT02213133|Experimental|Cohort 1: Head and Neck-SCC|Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than [<] 100*10^9 per litre [/L]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
16660367|NCT02213133|Experimental|Cohort 2: Lungs-SCC|Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
16660368|NCT02213133|Experimental|Cohort 3: Esophagus-SCC|Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
16660369|NCT02213120||Dizziness|Patients with Dizziness
16660370|NCT02213107|Experimental|Enzalutamide and dutasteride|Two oral drugs.
16660371|NCT02213094|Experimental|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
16660372|NCT02213094|Experimental|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
16660373|NCT02213081|Experimental|Ulipristal|25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
16660374|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:
~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.
~Tacrolimus tapered over one month as follows:
~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue
~MPA: administered according to SOC"
16660375|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.
~Tacrolimus tapered over one month as follows:
~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
16660376|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:
~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.
~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
16660377|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
16660378|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
16660379|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
16660380|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
16660381|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
16660416|NCT02212808|Experimental|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
16660484|NCT02212327||Controls|
16660654|NCT02211157|Experimental|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
16660382|NCT02213029|Experimental|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
16660383|NCT02213029|Experimental|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges.
16660384|NCT02213029|Experimental|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
16660385|NCT02213016|Sham Comparator|Transcranial magnetic stimulation|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
16660386|NCT02213016|Active Comparator|Transcraneal magnetic stimulation|Active repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
16660387|NCT02213016|Sham Comparator|Sham Comparator|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
16660388|NCT02213016|Active Comparator|Active Comparator|Active repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
16660389|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
16660390|NCT02212990|Active Comparator|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
16660391|NCT02212990|Placebo Comparator|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
16660392|NCT02212990|Active Comparator|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
16660393|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
16660394|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
16660395|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
16660396|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
16660397|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
16660398|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
16660399|NCT02212938|Experimental|BI 14332 CL fasted|
16660400|NCT02212938|Experimental|BI 14332 CL fed|
16660401|NCT02212925|Experimental|BI 14332 CL|
16660402|NCT02212925|Placebo Comparator|Placebo|
16660403|NCT02212912|Other|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
16660404|NCT02212912|Other|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
16660405|NCT02212886|Experimental|GA Depot 80mg|Monthly IM injection
16660406|NCT02212886|Experimental|GA Depot 40mg|Monthly IM injection
16660407|NCT02212873|No Intervention|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
16660408|NCT02212873|Experimental|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
16660409|NCT02212860|Experimental|Single Fraction|Stereotactic neoadjuvant ablative radiation give in one single dose of 21 Gy. Lumpectomy to follow within 14-20 from radiation treatment date.
16660410|NCT02212860|Experimental|Three Fractions|Stereotactic neoadjuvant ablative radiation give in three doses of 10 Gy (30 Gy given in 3 fractions, one treatment every second business day). Lumpectomy to follow within 14-20 days from last radiation treatment.
16660411|NCT02212847|Experimental|vestibular stimulation|
16660412|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
16660413|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
16660414|NCT02212821|Placebo Comparator|Placebo|intravenous infusion
16660415|NCT02212821|Experimental|Erythromycin|intravenous infusion
16660474|NCT02212392|Experimental|Antibiotics|this arm was given IV antibiotics, prophylactically, right from the day of admission. They were given intravenous broad spectrum (MEROPENEM) twice daily at 12 hours interval for 7-10 days
16660475|NCT02212379|Experimental|raltegravir and etravirine|
16660476|NCT02212366|Experimental|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
16660417|NCT02212808|Experimental|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
16660418|NCT02212795|Experimental|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
16660419|NCT02212795|Experimental|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
16660420|NCT02212795|Experimental|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
16660421|NCT02212782|Experimental|A Group|1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg
16660422|NCT02212782|Experimental|B Group|1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
16660423|NCT02212769|Experimental|A Group|1st oral administration of Losartan 50mg and 2nd oral administration of Losartan 50mg and DW1029M 1200mg
16660424|NCT02212769|Experimental|B Group|1st oral administration of DW1029M 1200mg and Losartan 50mg and 2nd oral administration of Losartan 50mg
16660425|NCT02212756|Experimental|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
16660426|NCT02212756|Experimental|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
16660427|NCT02212730|Experimental|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
16660428|NCT02212730|Experimental|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
16660429|NCT02212717|Active Comparator|EUS-guided gallbladder drainage|
16660430|NCT02212717|Active Comparator|Percutaneous cholecystomy|
16660431|NCT02212704|Experimental|Vestibular stimulation|This is the experimental paradigm applied in all participants
16660432|NCT02212691||Sickle cell disease|Patients diagnosed with sickle cell disease
16660433|NCT02212691||Healthy control|Healthy individuals recruited through fliers and have no history of cognitive disorders
16660434|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
16660435|NCT02212665|Experimental|High intense interval training (HIIT)|3 x 20 sec, 3 x week
16660436|NCT02212665|Experimental|Increased daily activity detected by the pedometer|10.000 steps a day
16660437|NCT02212665|Experimental|Increased daily activity detected by te pedometer+HIIT|10.000 steps + 3 x 20 sec, 3 x week
16660438|NCT02212665|Experimental|Increased daily activity (pedometer)+group intervention|10.000 steps + group intervention
16660439|NCT02212665|No Intervention|Control group|
16660440|NCT02212652|Active Comparator|Standard of Care plus Vitamin D|If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
16660441|NCT02212652|Placebo Comparator|Standard of Care plus Placebo|If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
16660442|NCT02212639|Experimental|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
16660443|NCT02212626|Experimental|Rotarex|After assessment of the lesion by angiography the occlusion is intraluminally crossed with the wire according to physician's discretion. The device is introduced and the catheter is activated while its tip is still proximal to the occlusion to allow lubrication of the spiral inside the catheter with the aspirated blood. The catheter is advanced into the occlusion with occasional retraction into the already recanalized lumen. Care must be taken to achieve sufficient cooling of the catheter tip and evacuation of the debris to get an appropriate blood flow along the catheter. In order to minimize peripheral embolization of clot the distal end of the occlusion should not be passed too fast before all loose material has been sucked back into the catheter. Several passages of the occlusion may be needed to clean out all wall-adherent thrombotic material. If residual underlying stenosis of >30% persist further endovascular treatment can be performed according to the physician's discretion.
16660444|NCT02212613|Experimental|Brexpiprazole|Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally
16660445|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
16660446|NCT02212587|Experimental|TOBI Podhaler|
16660477|NCT02212366|Sham Comparator|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
16660478|NCT02212353||Site 1 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 1 in delivering to care to neck of femur patients.
16660479|NCT02212353||Site 2 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 2 in delivering to care to neck of femur patients.
16660447|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.
~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
16660448|NCT02212561|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
16660449|NCT02212548|Experimental|Hydrogel|The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.
16660450|NCT02212535|Experimental|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
16660451|NCT02212522||Isis-Diab patients|French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
16660452|NCT02212522||Isis-Diab controls|French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
16660453|NCT02212496||Cancer-associated stroke|Cryptogenic embolic stroke with active cancer
16660454|NCT02212496||Cryptogenic embolic stroke|Cryptogenic embolic stroke without active cancer
16660455|NCT02212483|Experimental|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
16660456|NCT02212483|Active Comparator|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.
~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
16660457|NCT02212483|Other|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
16660458|NCT02212470|Active Comparator|Drug Eluting Balloon|Admiral In.Pact Drug Eluting Balloon
16660459|NCT02212470|Active Comparator|Nitinol Stent|Complete SE Self-expandible Nitinol stent
16660460|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
16660461|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
16660462|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
16660463|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
16660464|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
16660465|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
16660466|NCT02212444|Experimental|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
16660467|NCT02212444|Active Comparator|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
16660468|NCT02212431|Experimental|Cysteamine|"Dosing will be in accordance with licensed use of cysteamine for cystinosis, i.e. 450mg qds.
~Dose will be escalated:
~450mg od for one week 450mg bd for one week 450mg tds for one week 450mg qds for two weeks"
16660469|NCT02212418|Experimental|Abdominal hypopressive technique|
16660470|NCT02212405|Sham Comparator|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
16660471|NCT02212405|Experimental|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
16660472|NCT02212405|Experimental|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
16660473|NCT02212392|No Intervention|control|This arm was not given any prophylactic antibiotics. Patients were managed in the surgical ward by post graduate residents under the supervision of consultants
16660485|NCT02212314|Experimental|Response Inhibition Training|Treatment group will receive immediate treatment after pre-test.
16660486|NCT02212314|No Intervention|Waitlist Crossover|Waitlist group will not receive intervention while treatment group is active, but waitlist group will be offered treatment after post-test is completed.
16660487|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
16660488|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
16660489|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
16660490|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
16660491|NCT02212275|Experimental|Dextromethorphan in ASD|8-12 years old: > 30 boys will be recruited who have a known or suspected diagnosis of ASD confirmed by DSM-5 checklist and the ADOS-2 at screening. They will have the cortical metric measured 20 min prior to receiving DXM and 2 hours after receiving a single age and weight appropriate dose of DXM. The outcome reported is the difference in the cortical metric after the DXM dose and before the DXM dose.
16660492|NCT02212275|Active Comparator|Dextromethorphan in controls|30 typically developing boys 8-12 years old who have the cortical metric measured 20 min before receiving a single age and weight appropriate dose of DXM and 2 hours after the single dose of DXM. The reported value will be the difference between the cortical metric 2hrs after the single dose of DXM and the cortical metric 20 minutes prior to the single dose of DXM.
16660493|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
16660494|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
16660495|NCT02212249|Active Comparator|Systemic sclerosis|patients with systemic sclerosis
16660496|NCT02212249|Sham Comparator|primary raynaud disease|patients with primary raynaud disease
16660497|NCT02212236|Experimental|Psychological preparation + TAU|TAU=treatment as usual
16660498|NCT02212236|No Intervention|Treatment as usual|Usual care including medication, nursing, and psychologist support.
16660499|NCT02212223|Experimental|Group 1: Somali immigrant group, 10 µg (400 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months
16660500|NCT02212223|Experimental|Group 2: Somali immigrant group, 20 µg (800 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months
16660501|NCT02212223|Placebo Comparator|Group 3: Somali immigrant group, 0 µg vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months
16660502|NCT02212223|Experimental|Group 4: Original Finnish group, 10 µg (400 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months.
16660503|NCT02212223|Experimental|Group 5: Original Finnish group, 20 µg (800 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months.
16660504|NCT02212223|Placebo Comparator|Group 6: Original Finnish group, 0 µg vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months.
16660505|NCT02212210|Active Comparator|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
16660506|NCT02212210|Placebo Comparator|Normal saline|2cc preservative free normal saline
16660507|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
16660508|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
16660509|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
16660510|NCT02212184|Sham Comparator|Control Group|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
16660511|NCT02212184|Experimental|Intevention Group|"All patients will receive the Manual Diaphragm Release Technique, during 6 days of treatment. They will undertake four evaluations throughout treatment: before and immediately after the Day 1 (Baseline 1 and Post 1) and before and after Day 6 (Baseline 6 and Post 6).
~In the other Days (2nd to 5th) patients will only receive the intervention and won't be evaluated."
16660512|NCT02212171|Experimental|TRIAP intervention|
16660513|NCT02212171|No Intervention|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
16660514|NCT02212158|Experimental|motivational interviewing group|"Motivational Group Intervention:
~Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies."
16660515|NCT02212145||Screened group|Screened group is defined as those individuals who were willing to participate in the cardiovascular prevention program and all the individuals who lived in Sollentuna during the intervention.
16660516|NCT02212145||Relatives to the screened group|Relatives to individuals included in the screened group, who lived in Stockholm County at least during one year at the time of the intervention.
16660517|NCT02212145||Control group|"Matched controls is going to be selected randomly from the population of Stockholm County minus Sollentuna Municipality with relevant background factors. The whole population will be used as a comparison group when evaluating the result from all the municipality of Sollentuna during 1988-1993."
16660520|NCT02212119|Placebo Comparator|Saline|Saline injection up to 5 cc in arm with paratonia (one time injection)
16660521|NCT02212119|Active Comparator|Botulinum Toxin|Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
16660522|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
16660523|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
16660524|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
16660525|NCT02212080|Experimental|BAY1214784|Dose 1 to 7 of BAY1214784
16660526|NCT02212080|Placebo Comparator|Placebo|Placebo Dose 1 to 7 of BAY1214784
16660527|NCT02212067|Experimental|Semaglutide|Total of 12 visits
16660528|NCT02212067|Placebo Comparator|Placebo|Total of 12 visits
16660529|NCT02212067|No Intervention|Healthy subjects|Total of 2 visits
16660530|NCT02212054|Experimental|conservative & operative treatment|anal dilation; colon lavage; probiotics
16660531|NCT02212054|Active Comparator|operative treatment|one stage pull- through radical colectomy
16660532|NCT02212041|Experimental|Electronic cigarettes|Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
16660533|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
16660534|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
16660535|NCT02212015|Experimental|Pazopanib + Paclitaxel|
16660536|NCT02212002||Control|Control group: infants born to GBS-negative mothers, who thus did not receive any antibiotic treatment before/at delivery.
16660537|NCT02212002||IAP|IAP group: infants born to GBS-positive mothers who have received adequate intrapartum antibiotic prophylaxis (IAP). According to the Institutional treatment protocol for GBS prophylaxis (derived from CDC guidelines), intravenous ampicillin is given every 4 hours until delivery (first dose 2 g, following doses 1 g each). IAP is considered adequate when the mother received at least two doses of ampicillin before delivery.
16660538|NCT02211989|Experimental|BI 14332 CL|single rising dose
16660539|NCT02211989|Placebo Comparator|Placebo|
16660540|NCT02211976|Experimental|Bisacodyl|
16660541|NCT02211976|Experimental|Simeticone|
16660542|NCT02211976|Experimental|Bisacodyl and simeticone|
16660543|NCT02211963|Experimental|BI 44847|
16660544|NCT02211963|Placebo Comparator|Placebo|
16660545|NCT02211950|Experimental|Treatment A|single dose BI 44847 administered to white subjects
16660546|NCT02211950|Experimental|Treatment B|100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
16660547|NCT02211950|Experimental|Treatment C|single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
16660548|NCT02211950|Experimental|Treatment D|single dose BI 44847 administered to asian subjects
16660549|NCT02211950|Experimental|Treatment E|single dose BI 44847 administered to african subjects
16660550|NCT02211937|Active Comparator|Treatment A|BI 44847 suspension high dose, fasted
16660551|NCT02211937|Experimental|Treatment B|BI 44847 tablet high dose, fasted
16660552|NCT02211937|Experimental|Treatment C|BI 44847 tablet high dose, fed
16660553|NCT02211937|Active Comparator|Treatment D|BI 44847 solution low dose, fasted
16660554|NCT02211937|Experimental|Treatment E|BI 44847 tablet low dose, fasted
16660555|NCT02211924|Experimental|BI 44847|single rising dose
16660556|NCT02211924|Placebo Comparator|Placebo|
16660557|NCT02211911|Experimental|Bisacodyl|
16660558|NCT02211911|Experimental|Sodium picosulfate|
16660559|NCT02211898|Experimental|BNS003|
16660560|NCT02211872|Experimental|Treatment A|BI 2536 BS single rising dose
16660561|NCT02211872|Experimental|Treatment B|BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
16660562|NCT02211859|Experimental|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
16660563|NCT02211846|Experimental|Mirabegron|Administered under fed and fasted conditions
16660564|NCT02211833|Experimental|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
16660565|NCT02211807||Patients initiating an Efavirenz|Patients initiating an Efavirenz-containing antiretroviral regimen
16660566|NCT02211807||Patients initiating an Efavirenz-free regimen|
16660567|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
16660570|NCT02211755|Experimental|1|Starting doses are clofarabine at 1 mg/m(2) IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
16660571|NCT02211742|Active Comparator|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
16660572|NCT02211742|Placebo Comparator|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
16660573|NCT02211729|Active Comparator|Seasonal malaria chemoprevention|Sulphadoxine-Pyrimethamine Amodiaquine Placebo Azithromycin
16660574|NCT02211729|Experimental|seasonal malaria chemoprevention plus AZ|Sulphadoxine-Pyrimethamine+ Amodiaquine + Azithromycin 4 rounds during malaria transmission season
16660575|NCT02211716|Experimental|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
16660611|NCT02211469|Experimental|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
16660612|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
16660576|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
16660577|NCT02211690|Experimental|dolutegravir 50mg with co-formulated emtricitabine-tenofovir|One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days
16660578|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
16660579|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
16660580|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
16660581|NCT02211664|Experimental|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:
~pre-dilation of the lesion with a Passeo-18 balloon (mandatory)
~dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)
~stenting of the lesion with a Pulsar-18 stent (mandatory)
~post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
16660582|NCT02211651||ObeseDYS|Obese subjects with dysfunctional vascularization and inflammation of placenta.
16660583|NCT02211651||ObeseNL|Obese subjects with normal vascularization and inflammation of placenta
16660584|NCT02211651||LeanNL|Lean subjects with normal vascularization and inflammation of placenta.
16660585|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
16660586|NCT02211625|Experimental|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
16660587|NCT02211625|Active Comparator|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
16660588|NCT02211612|Experimental|Saturated fatty acids (SFA)-group|Weight gain created by addition of muffins baked on saturated fat
16660589|NCT02211612|Experimental|Polyunsaturated fatty acids (PUFA)-group|Weight gain created by addition of muffins baked on polyunsaturated fat
16660590|NCT02211599|Experimental|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
16660591|NCT02211599|Experimental|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
16660592|NCT02211573|No Intervention|Control group|Patients of this group don't performed physical training
16660593|NCT02211573|Experimental|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
16660594|NCT02211560|Placebo Comparator|Placebo|Identical looking cellulose capsules
16660595|NCT02211560|Experimental|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
16660596|NCT02211547|No Intervention|Control|No treatment to be rendered following separator placement.
16660597|NCT02211547|Placebo Comparator|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
16660598|NCT02211547|Experimental|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
16660599|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
16660600|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
16660601|NCT02211521|Experimental|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
16660602|NCT02211521|Active Comparator|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
16660603|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
16660604|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
16660605|NCT02211495|Active Comparator|No device|Treated with best medical therapy
16660606|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
16660607|NCT02211482|Other|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
16660608|NCT02211469|Experimental|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
16660609|NCT02211469|Experimental|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
16660610|NCT02211469|Experimental|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
16660651|NCT02211170|Experimental|BIBR 796 BS, high dose|
16660613|NCT02211443|Experimental|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:
~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg
~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
16660614|NCT02211430|Experimental|Cognitive-Behavioral Counseling (CBC)|Cognitive-Behavioral Counseling (CBC) consists of two 45-minute on-site intervention sessions (session 1 and 3), one 15 minute on-site session (session 2), and one 15-minutes phone session (booster session).
16660615|NCT02211430|Active Comparator|Best Practice (BP) Control|Best Practice (BP) Control Condition consists of two 10-15 min, on-site intervention sessions (session 1 and 3), one brochure pick-up (session 2), and receipt of a newsletter by mail (booster session).
16660616|NCT02211417|Experimental|DS107G|DS107G 2g capsules taken by mouth daily for 56 days.
16660617|NCT02211417|Placebo Comparator|Placebo|Placebo capsules 2g taken by mouth daily for 56 days.
16660618|NCT02211391|Experimental|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
16660619|NCT02211391|Placebo Comparator|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
16660620|NCT02211378|Experimental|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
16660621|NCT02211378|Active Comparator|Hotseat|Trainees are in the 'hotseat' actively participating during all 3 simulation sessions
16660622|NCT02211352|Active Comparator|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
16660623|NCT02211352|Placebo Comparator|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
16660624|NCT02211339|Experimental|Peer-led intervention group|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
16660625|NCT02211339|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
16660626|NCT02211326|Experimental|genotype-guided group|Interventions：on day1~day3, patients received dose according to IWPC formula (PGx-1) included clinical variables and genotype data for VKORC1, CYP2C9*1, CYP2C9*2, and CYP2C9*3; on day4~day7, patients received dose according to Lenzini formula consisted of clinical variables, VKORC1, CYP2C9*2, CYP2C9*3 and previous INR and dosing information (PGx-2); and on day8, the clinicians adjusted the dose according to observed INR.The overall follow-up period is 12 weeks.
16660627|NCT02211326|Active Comparator|control group|Interventions：on day1~day3, patients were given initial dose (2.25mg); and starting from day4, the clinicians began to adjust the dose for patients according to observed INR.The overall follow-up period is 12 weeks.
16660628|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
16660629|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
16660630|NCT02211300|Experimental|Optiscanner values vs YSI|Matched samples up to 12 times per 24 hour period
16660631|NCT02211287|Experimental|Intervention|The intervention will include five key elements: a Project Nurse - ACP facilitator; family education on comfort care at the end of life for individuals with dementia using the 'Comfort Care at the end of life for persons with dementia' booklet; a family meeting with follow-up telephone call; documentation of ACP decisions, and orientation and education directed towards General Practitioners (GPs) and nursing home staff about the intervention.
16660632|NCT02211287|No Intervention|Usual care|Care will continue as usual for the nursing home residents
16660633|NCT02211274|Experimental|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
16660634|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
16660635|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
16660636|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
16660637|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
16660638|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
16660639|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
16660640|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
16660641|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
16660642|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
16660643|NCT02211248|Active Comparator|Conventional Group|Conventional treatment and follow up
16660644|NCT02211248|Experimental|Multidisciplinary Group|Multidisciplinary assistance
16660645|NCT02211209|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
16660646|NCT02211209|Experimental|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
16660647|NCT02211196|Experimental|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
16660648|NCT02211183|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
16660649|NCT02211183|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
16660650|NCT02211170|Experimental|BIBR 796 BS, low dose|
16660658|NCT02211131|Other|Surgery|Surgical resection of melanoma tumor lesion(s)
16660659|NCT02211131|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).
16660660|NCT02211118|Experimental|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
16660661|NCT02211105||Laparoscopic Nissen Fundoplication|Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
16660662|NCT02211105||Transoral Incisionless Fundoplication|Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
16660663|NCT02211092|Experimental|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
16660664|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
16660665|NCT02211079|Experimental|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2*50 mg tablets), midazolam 2 mg (1 milliliter [mL], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
16660666|NCT02211066|Active Comparator|Clopidogrel|Clopidogrel 75 mg will be administered daily for 1 year
16660667|NCT02211066|Experimental|Ticagrelor|Ticagrelor 90 mg will be administered daily for 1 year
16660668|NCT02211053|Active Comparator|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
16660669|NCT02211053|Placebo Comparator|Placebo|Infusion matched to intervention arm
16660670|NCT02211040|Experimental|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
16660671|NCT02211040|Experimental|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
16660672|NCT02211027|Experimental|Vaccine|The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
16660673|NCT02211014|Experimental|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
16660674|NCT02211014|Experimental|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
16660675|NCT02211001|Experimental|Pilates Group|The individuals were treated with Mat Pilates Method.
16660676|NCT02211001|Experimental|Segmented Dynamic Exercises Group|The individual were treated with ball exercises.
16660677|NCT02211001|Experimental|Global Postural Reeducation Group|The individuals were treated with postures of Souchard Method.
16660678|NCT02210988|Experimental|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
16660679|NCT02210975|Experimental|Electrical Stimulation Therapy|
16660680|NCT02210962|Experimental|essential fatty acids|The experimental treatment is a food supplement containing fish oil. The daily dose of 4 capsules provides 1320 mg of eicosapentaenoic acid and 880 mg of docosahexaenoic acid, 26 weeks intervention
16660681|NCT02210962|Placebo Comparator|olive oil|Placebo capsules contain olive oil and trace amount of fish oil to assure comparable taste, 26 weeks intervention
16660682|NCT02210949|Other|Erythropoietin Iron|"Erythropoietin and iron:
~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .
~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once."
16660683|NCT02210936|Other|PDMP Data|
16660684|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:
~20 Hz, 3 Volts, 480 microseconds
~20 Hz, 6 Volts, 480 microseconds
~50 Hz, 3 Volts, 480 microseconds
~50 Hz, 6 Volts, 480 microseconds
~90 Hz, 3 Volts, 480 microseconds
~90 Hz, 6 Volts, 480 microseconds"
16660685|NCT02210910|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
16660686|NCT02210910|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair, and placement of the InSpace™ system.
16660687|NCT02210884|Experimental|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
16660688|NCT02210884|Placebo Comparator|Placebo|Placebo capsule containing no vitamin D
16660689|NCT02210871|Experimental|Normal hepatic function|
16660690|NCT02210871|Experimental|Mild hepatic impairment|
16660691|NCT02210871|Experimental|Moderate hepatic impairment|
16660692|NCT02210871|Experimental|Severe hepatic impairment|
16660693|NCT02210858|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16660694|NCT02210845|Active Comparator|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
16660695|NCT02210845|Placebo Comparator|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
16660696|NCT02210845|Active Comparator|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
16660697|NCT02210832|Experimental|Best practices for pregnant smokers|Five As plus referral to pregnancy-specific tobacco quit line
16660698|NCT02210832|Experimental|Best practices plus financial incentives|Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
16660699|NCT02210832|No Intervention|Never-smoker comparison condition|We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum
16660700|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
16660701|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
16660702|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
16660703|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
16660704|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
16660705|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
16660706|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
16660707|NCT02210793|Active Comparator|Transepithelial PRK|20 eyes to undergo a no touch , all-laser advanced surface ablation technique termed transepithelial PRK using the Amaris laser platform (Schwind eye-tech solutions Gmbh, Germany)
16660708|NCT02210793|Active Comparator|Conventional LASIK|20 eyes to undergo LASIK using a mechanical microkeratome (M2, Moria Surgical, Antony, France) and the Mel 80 excimer laser system(Carl Zeiss Meditec)
16660709|NCT02210780|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
16660710|NCT02210780|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
16660711|NCT02210767|Experimental|Walnut Diet|Provides ~2 oz. walnuts/day (2-3% of total calories from alpha-linolenic acid [ALA])
16660712|NCT02210767|Active Comparator|Walnut Control Diet|Provides same fatty acid profile (<7% SFA, 9% MUFA, 14-15% PUFA, 2-3% ALA) as Walnut Diet, but is devoid of walnuts and their bioactives
16660713|NCT02210767|Placebo Comparator|Low ALA Diet|Provides similar macronutrient and linoleic acid profile but replaces ALA with oleic acid (<7% SFA, 12% MUFA, 12% PUFA, 0.5% ALA)
16660714|NCT02210754|Experimental|E-cigarette 1|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
16660715|NCT02210754|Experimental|E-cigarette 2|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/propylene glycol (PG) vehicle)
16660716|NCT02210754|Experimental|E-cigarette 3|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
16660717|NCT02210754|Experimental|E-cigarette 4|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
16660718|NCT02210754|Experimental|E-cigarette 5|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
16660719|NCT02210754|Active Comparator|Combustible Cigarette|Marlboro Cigarette
16660720|NCT02210728|Active Comparator|Medication only|Stimulant medication (methylphenidate or amphetamine product approved for clinical use in Canada), with dose optimized for each patient based on report of efficacy and side effects.
16660721|NCT02210728|Active Comparator|Cognitive behavioral therapy + medication|Patients are first titrated to an optimal dose of stimulant medication. They then undergo the 12 weeks of group cognitive behavioral therapy.
16660722|NCT02210728|Experimental|Cognitive behavioral therapy alone|12 weeks of structured group cognitive behavioral therapy, focusing on acquisition of skills in organization, time management, goal attainment, cognitive restructuring, stress management, anger management, impulse control, self-esteem, and relationship management.
16660723|NCT02210715|Experimental|switch to Isentress|28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
16660724|NCT02210715|Active Comparator|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
16660725|NCT02210702|Experimental|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
16660726|NCT02210702|Experimental|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
16660727|NCT02210702|No Intervention|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
16660728|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
16660729|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
16660730|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
16660731|NCT02210676|Experimental|Patients with Mallet Finger|All enrolled patients
16660732|NCT02210663|Experimental|veliparib (ABT-888)|
16660733|NCT02210650|Other|Ureteral stone removal|Group 1 will receive the standard treatment of having only the ureteral stone removed
16660734|NCT02210650|Other|Asymptomatic kidney stones and ureteral stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the ureteral stone
16660735|NCT02210637||Retrospective Cohort|Retrospective Cohort of scheduled outpatient appointment
16660736|NCT02210624|Experimental|Single arm|"Experimental: HYNR-CS inj.
~Treatment group with HYNR-CS inj."
16660737|NCT02210611|Active Comparator|36 hours|Intrauterine insemination 36 hours after ovulation induction
16660738|NCT02210611|Active Comparator|42 hours|Intrauterine insemination 42 hours after ovulation induction
16660739|NCT02210598|Active Comparator|inpatient Foley balloon induction|"Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley blindly by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded."
16660825|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
16660740|NCT02210598|Experimental|outpatient Foley balloon induction|Patients randomized to the experimental group will undergo outpatient Foley induction of labor. Either of the above two described methods will be used to place an 18 French Foley catheter transcervically and its balloon filled with 60mL of sterile saline. The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours. When the patient returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
16660741|NCT02210585|Active Comparator|Kneehab|5 sessions per week
16660742|NCT02210585|Placebo Comparator|Placebo|5 sessions per week
16660743|NCT02210572|Experimental|Bimuno Galacto-oligosaccharide|Dietary intervention
16660744|NCT02210572|Placebo Comparator|Low- FODMAPs diet|Dietary intervention
16660745|NCT02210559|Experimental|Arm A|FG-3019 + Gemcitabine + Nab-paclitaxel
16660746|NCT02210559|Other|Arm B|Gemcitabine + Nab-paclitaxel
16660747|NCT02210546|Experimental|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
16660748|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
16660749|NCT02210520|Experimental|laser|3 J/cm², 2 minutes in 6 points around the back spine
16660750|NCT02210520|Experimental|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine
16660751|NCT02210520|Experimental|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
16660752|NCT02210520|No Intervention|control|no treatment.
16660753|NCT02210507|Experimental|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
16660754|NCT02210507|Experimental|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
16660755|NCT02210507|Experimental|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
16660756|NCT02210494|Experimental|Secretrol|
16660757|NCT02210481||GLUC-MAC-COHORT|post vitrectomy for retinal detachment or epimacular membrane patients
16660758|NCT02210468|Experimental|APIC-CF 4cc,|APIC-CF 4cc, once at first day
16660759|NCT02210468|Experimental|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
16660760|NCT02210468|Placebo Comparator|Saline|
16660761|NCT02210455|Experimental|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
16660762|NCT02210455|Active Comparator|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
16660763|NCT02210442|Experimental|Educaguia intervention|Implementation of practice clinical guidelines with educational games
16660764|NCT02210442|Active Comparator|Control group|Implementation of clinical practice guidelines with standard practice care
16660765|NCT02210429|Active Comparator|IV Opioids|
16660766|NCT02210429|Active Comparator|Supraclavicular Single-Shot Block|
16660767|NCT02210429|Active Comparator|Supraclavicular Catheter|
16660768|NCT02210429|Active Comparator|Supraclavicular Angiocath|
16660769|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
16660770|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
16660771|NCT02210403|Active Comparator|Upper limb motor function training + tDCS|Bi-hemispheric tDCS with motor function training
16660772|NCT02210403|Sham Comparator|upper limb motor function training + sham tDCS|sham tDCS with motor function training
16660773|NCT02210390|Experimental|Intervention|Psycho-education Sessions will be offered weekly basis
16660774|NCT02210390|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
16660775|NCT02210377|Experimental|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
16660776|NCT02210377|Placebo Comparator|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
16660777|NCT02210364|Experimental|lurbinectedin (PM01183) and capecitabine|
16660778|NCT02210351|Experimental|MRI test|
16660779|NCT02210338|Experimental|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
16660780|NCT02210338|Experimental|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
16660781|NCT02210325|Active Comparator|Ceftriaxone plus Azithromycin|A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin
16660782|NCT02210325|Experimental|Solithromycin|A single oral dose of 1000 mg solithromycin
16660783|NCT02210312||elective non-cardiac surgery and non-neurosurgical procedures|300 Patients aged 60 years and older undergoing elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia with a duration of operation of 120 minutes or longer. 80 age-, gender- and education-matched healthy controls.
16660784|NCT02210299|Other|Exposure study|2-6 months-old children and 12-18 months-old children
16660785|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
16660786|NCT02210273|Experimental|Treatment|Subjects undergoing treatment with the Solace Bladder Control (Vesair) Balloon on day 0
16660787|NCT02210273|Sham Comparator|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control (Vesair) Balloon at 3 months
16660788|NCT02210260|Active Comparator|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
16660789|NCT02210260|Experimental|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
16660790|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
16660791|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
16660792|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
16660793|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
16660794|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
16660795|NCT02210234|Active Comparator|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat brand cereal during the day for 3 weeks.
16660796|NCT02210234|Active Comparator|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat brand cereal the day for 3 weeks.
16660797|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
16660798|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
16660799|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
16660800|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
16660801|NCT02210182|Experimental|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
16660802|NCT02210182|Placebo Comparator|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
16660803|NCT02210169|No Intervention|Intermittent infusion of vancomycin|Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
16660804|NCT02210169|Active Comparator|Continuous infusion of vancomycin|A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.
16660805|NCT02210156|Placebo Comparator|Placebo|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
16660806|NCT02210156|Experimental|Omniplus Supreme|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
16660807|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
16660808|NCT02210143||AERSA-II gingival recession|AERSA > 15 mm2 named as AERSA-II (high risk group).
16660809|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
16660810|NCT02210130||patients HIV+ CSVD+|patients with HIV and cerebral small vessel disease
16660811|NCT02210130||control HIV+ CSVD-|patients with HIV and without cerebral small vessel disease
16660812|NCT02210117|Experimental|Arm A (nivolumab, surgery)|"Patients receive nivolumab IV over 60 minutes on day 1 every 2 weeks for 6 weeks. Approximately 4 weeks later, patients undergo nephrectomy, metastasectomy or biopsy.
~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
16660813|NCT02210117|Experimental|Arm B (nivolumab, bevacizumab, surgery)|"Patients receive nivolumab IV over 60 minutes and bevacizumab IV over 90 minutes on day 1 every 2 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.
~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
16660814|NCT02210117|Experimental|Arm C (nivolumab, ipilimumab, surgery)|"Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1 every 3 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.
~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
16660815|NCT02210104|Experimental|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10^10 cells/m^2.
16660816|NCT02210091|Experimental|<6 years old|
16660817|NCT02210091|Experimental|≥6 to <12 years|
16660818|NCT02210078|Experimental|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
16660819|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
16660820|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
16660821|NCT02210039|Experimental|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
16660822|NCT02210026|Experimental|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
16660823|NCT02210013||Caucasian women|200 Caucasian infertile women undergoing their first or second IVF cycle
16660824|NCT02210013||Indian women|200 Indian women undergoing their first or second IVF cycle.
16660826|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
16660827|NCT02209987|Experimental|GS-5745 SC|Participants will receive a single dose of GS-5745 by SC injection.
16660828|NCT02209987|Experimental|GS-5745 IV|Participants will receive a single dose of GS-5745 by IV infusion.
16660829|NCT02209974|Placebo Comparator|Inhaled Placebo|Inhaled placebo administered to healthy (n=7) and to a half (n=8) of COPD patients
16660830|NCT02209974|Experimental|Inhaled corticosteroids (Fluticasone, 0.5 mg)|Inhaled corticosteroids administered to the other half (n=8) of COPD patients
16660831|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
16660832|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
16660833|NCT02209948|No Intervention|Without treatment|
16660834|NCT02209935|Active Comparator|Usual Care|Typically, usual care is when therapies are not initiated until the treating team places an order for each element of care (physical, occupational, speech, and emotional therapy consultation).
16660835|NCT02209935|Experimental|Early Rehabilitation Protocol|Physical, occupational, speech, and emotional evaluation and support personalized to the subject's severity of illness and developmental status.
16660836|NCT02209922|Active Comparator|Transcranial direct current stimulation|"ARM1: Transcranial direct current stimulation (tDCS) intervention and simultaneous balance training.
~Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week."
16660837|NCT02209922|Sham Comparator|ARM 2|ARM2: Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
16660838|NCT02209909|Experimental|aspirin continuation|Intervention : Low-dose aspirin (< 100mg/day) is used before OPCAB surgery in the aspirin continuation group.
16660839|NCT02209909|Experimental|aspirin discontinuation|Intervention: Low-dose aspirin is stopped more than 4 days before OPCAB surgery in the aspirin discontinuation group.
16660840|NCT02209896|Experimental|BlueWind Reprieve System|The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.
16660841|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
16660842|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
16660843|NCT02209870||E-checklist group|The patients after CPR team using E-checklist system
16660844|NCT02209844|Experimental|BI 44847 powder|single rising dose reconstituted with natrosol solution
16660845|NCT02209844|Placebo Comparator|Placebo|reconstituted with natrosol solution
16660846|NCT02209831|Experimental|BIBR 796 BS + pantoprazole|
16660847|NCT02209831|Active Comparator|BIBR 796 BS without pantoprazole|
16660848|NCT02209818|Experimental|Laser Irradiation One Dose|Laser irradiation will be applied in one dose for patients in this group, but only on one side of the jaw. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
16660849|NCT02209818|Experimental|Laser Irradiation Two doses|Laser irradiation will be applied in two doses for patients in this group, but only on one side of the jaw. The second dose will be given after 24 hour of the first one. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
16660850|NCT02209805|Experimental|BIRB 796 BS, low dose|
16660851|NCT02209805|Experimental|BIRB 796 BS, high dose|
16660852|NCT02209805|Placebo Comparator|Placebo|
16660853|NCT02209805|Experimental|BIRB 796 BS, medium dose|
16660854|NCT02209792|Placebo Comparator|Placebo|
16660855|NCT02209792|Experimental|BIRB 796 BS, low dose|2 x 5 mg b.i.d.
16660856|NCT02209792|Experimental|BIRB 796 BS, medium dose 1|20 mg b.i.d.
16660857|NCT02209792|Experimental|BIRB 796 BS, medium dose 2|2 x 5 mg + 20 mg b.i.d.
16660858|NCT02209792|Experimental|BIRB 796 BS, high dose|3 x 20 mg b.i.d.
16660859|NCT02209779|Experimental|BIBR 796 BS, low dose|twice daily doses of 5 mg for 4 weeks
16660860|NCT02209779|Experimental|BIBR 796 BS, medium dose 1|twice daily doses of 10 mg for 4 weeks
16660861|NCT02209779|Experimental|BIBR 796 BS, medium dose 2|twice daily doses of 20 mg for 4 weeks
16660862|NCT02209779|Experimental|BIBR 796 BS, high dose|twice daily doses of 30 mg for 4 weeks
16660863|NCT02209779|Active Comparator|Placebo|
16660864|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
16660865|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
16660866|NCT02209753|Experimental|BIRB 796 BS, low dose|
16660867|NCT02209753|Experimental|BIRB 796 BS, medium dose 1|
16660868|NCT02209753|Experimental|BIRB 796 BS, medium dose 2|
16660869|NCT02209753|Experimental|BIRB 796 BS, high dose|
16660870|NCT02209753|Placebo Comparator|Placebo|
16660871|NCT02209740||Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
16660872|NCT02209727|Experimental|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
16660873|NCT02209714|Experimental|BIIF 1149 BS|
16660874|NCT02209714|Placebo Comparator|Placebo|
16660875|NCT02209701|Experimental|Porfiromycin|
16660876|NCT02209688|Experimental|ESR 1150 CL dose escalation fasted|
16660877|NCT02209688|Experimental|ESR 1150 CL fed|
16660878|NCT02209688|Placebo Comparator|Placebo|
16660879|NCT02209675|Other|patients with elevated liver enzymes|Patients with elevated liver enzymes and/or hyperbilirubinemia post transplantation for hepatitis C virus related disease will have liver biopsy
16660880|NCT02209662|Experimental|APIC-PRP and Standard of Care|APIC-PRP
16660881|NCT02209662|Placebo Comparator|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
16660882|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation A|
16660883|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation B|
16660884|NCT02209649|Active Comparator|Lacidipine and Telmisartan, mono|
16660946|NCT02209233|No Intervention|Control|If randomized to the control group, patients will not be receiving massage therapy.
16660885|NCT02209636|Experimental|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
16660886|NCT02209636|Placebo Comparator|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
16660887|NCT02209623||Pregnant Women receiving TDAP|
16660888|NCT02209610|Other|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
16660889|NCT02209610|Other|Health Control Subjects and Neuromuscular Function|Health Control Subjects
16660890|NCT02209597|Experimental|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a
~Subjects will be studied in 4 phases for a total of approximately 28 weeks:
~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
16660891|NCT02209571|Experimental|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
16660892|NCT02209571|Active Comparator|Control|Breath test and venous blood markers in healthy subjects
16660893|NCT02209558|No Intervention|Standard Written Sternal Precautions|"Patients will receive education that is the standard of care at North Shore Long Island Jewish Health Systems in their post-operative sternal precautions."
16660894|NCT02209558|Experimental|Visual Sternal Precautions|"Patients will receive both standard of care written sternal precautions, as well as visual sternal precautions."
16660895|NCT02209545|Experimental|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
16660896|NCT02209545|Placebo Comparator|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
16660897|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
16660898|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
16660899|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
16660900|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
16660901|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
16660902|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
16660903|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
16660904|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
16660905|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
16660906|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
16660907|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
16660908|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
16660909|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
16660910|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
16660911|NCT02209493|Experimental|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
16660912|NCT02209493|Sham Comparator|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
16662385|NCT02199860|Experimental|SD I - single rising doses|
16660913|NCT02209480|Experimental|Alexander Technique|5 lessons of AT, each lasting up to 45 minutes, weekly intervals The lessons aimed at sensory awareness of everyday movements and movement sequences, such as sitting, walking, lying, or lifting in order to replace habitual patterns using conscious control; and different techniques were applied, such as demonstration, verbal instructions, hands on techniques and others
16660914|NCT02209480|Active Comparator|Heat pad application|5 treatments by means of a heat pad, 15-0 minutes, sitting or lying position, quiet room Heat pad: Zapp-Sack® contained certain grains and a ginger extract, and could be heated up in the microwave.
16660915|NCT02209480|Active Comparator|guided imagery|guided imagery relaxation technique , 45 minutes, 5 sessions in weekly rhythm including body scan, breathing relaxation, visualization
16660916|NCT02209467|No Intervention|Group balance training late start|Participants randomized to late start act as No intervention group during the study period.
16660917|NCT02209467|Experimental|Group balance training early start|Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
16660918|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
16660919|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
16660920|NCT02209428|Active Comparator|IDH wild type|Patients with IDH wild type, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
16660921|NCT02209428|Experimental|IDH mutation|Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
16660922|NCT02209415|Active Comparator|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
16660923|NCT02209415|Experimental|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
16660924|NCT02209402|No Intervention|Usual Care|
16660925|NCT02209402|Experimental|Exercise Training|
16660926|NCT02209389||Positive OctavaPink|Following a positive OctavaPink result, an MRI is performed and any additional testing (required by the MRI).
16660927|NCT02209389||Negative OctavaPink - control|"For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and recalled for an MRI and any additional testing (required by the MRI).
~MRI won't be performed to all negative OctavaPink results. Only one negative control will be assigned to each OctavaPink positive result."
16660928|NCT02209376|Experimental|Arm 1|
16660929|NCT02209363|Experimental|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
16660930|NCT02209363|Sham Comparator|nasal dilator strips|Sham treatment
16660931|NCT02209350|Active Comparator|Group 1|Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
16660932|NCT02209350|Active Comparator|Group 2|Standard endovascular treatment (stenting) in patients with the iliac segment occlusive disease. Medication: after stenting all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
16660933|NCT02209337|Experimental|SRS-I|Implantation of SRS-I
16660934|NCT02209324|Experimental|ASP2151|
16660935|NCT02209311|Experimental|Tissue engineered construction implantation|
16660936|NCT02209298||CoreValve Transcatheter Valve|Medtronic CoreValve SystemTM is designed to replace the native or surgical bioprosthetic aortic heart valve without open heart surgery and without concomitant surgical removal of the failing valve. The support frame is manufactured by Nitinol, which has multi-level, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from a single layer of porcine pericardium into a tri-leaflet configuration. The bioprosthesis is processed with alpha-amino oleic acid (AOA™), which is a compound derived from oleic acid, a naturally occurring long-chain fatty acid. AOA™ is an antimineralization treatment shown to reduce both early and late valvular calcification.
16660937|NCT02209285|No Intervention|Control group|The control group will receive usual care, which is provided by the community care access centre (CCAC). Usual care may include in-home visits by regulated health care providers, personal support workers, and care coordination through the community care access centre. Case conferences may occur on an as-needed basis.
16660938|NCT02209285|Active Comparator|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month self-management intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
16660939|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
16660940|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
16660941|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
16660942|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
16660943|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
16660944|NCT02209246|Experimental|Intervention|The intervention group will be comprised of patients who will complete the PROMIS- CAT for pain interference, pain behavior and physical function prior to the encounter with the physician and then will complete the MISS-21 after the encounter.
16660945|NCT02209246|Experimental|Control|The control group will complete the PROMIS- CAT for pain interference, pain behavior and physical function after the encounter and after completing a satisfaction questionnaire (MISS-21).
16660947|NCT02209233|Experimental|Massage Therapy|If randomized to the intervention group, patients will receive massage therapy of the hand, arm, shoulder, and neck by the licensed massage therapist on duty. The massage will be given in a manner that is congruent with standard of care practices by the Heart and Surgical Hospital and the licensed massage therapist.
16660948|NCT02209220|Active Comparator|Automatic positive airway pressure|Automatic positive airway pressure treatment of obstructive sleep apnea
16660949|NCT02209220|Active Comparator|Continuous positive airway pressure|Continuous positive airway pressure for the treatment of obstructive sleep apnea
16660950|NCT02209207|Active Comparator|Continuous walking training|n=10 patients with COPD Walking intensity 60 percent of 6-minute walking test speed
16660951|NCT02209207|Active Comparator|Interval walking training|n=10 patients with COPD Walking intensity 120 percent of 6-minute walking test speed for 1 minute alternating with 1 minute of rest
16660952|NCT02209194||Aortoiliac Aneurysms Iliac Aneurysms|Endovascular repair of aortoiliac or iliac aneurysms
16660953|NCT02209181|Experimental|JNJ-10450232 250 mg|
16660954|NCT02209181|Experimental|JNJ-10450232 1000 mg|
16660955|NCT02209181|Placebo Comparator|Placebo|
16660956|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
16660957|NCT02209168||Infertile Indian Population|200 Infertile Indian population
16660958|NCT02209168||Infertile arabian population|200 Infertile Arabian population
16660959|NCT02209168||Infertile caucasian population|200 Infertile Caucasian population
16660960|NCT02209155|Active Comparator|R-verapamil 75 mg tablet|375 mg/day; one in the morning, two in the afternoon and two at bedtime daily
16660961|NCT02209155|Placebo Comparator|Placebo|one in the morning, two in the afternoon and two at bedtime daily
16660962|NCT02209142|Experimental|pan-genomic screen|A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,
16660963|NCT02209142|Sham Comparator|control|a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject
16660964|NCT02209129||women at high risk for breast cancer|
16660965|NCT02209116|Active Comparator|QB Open|Participants and their clinician will receive results of the Qb Test
16660966|NCT02209116|Other|Qb Blind|Participants and their clinician will be blind to the results of the Qb test
16660967|NCT02209103|Experimental|Citrus flavonoid|Citrus flavonoid
16660968|NCT02209103|Experimental|Citrus flavonoid formulation|Citrus flavonoid formulation
16660969|NCT02209103|Placebo Comparator|Placebo|Placebo
16660970|NCT02209090|Experimental|maternal modified sims position|"Women in this group will adopt the modified Sims position, lying on the side of the foetal back.
~This position is maintained for the greater part of labour, at least 40 minutes, every hour. The mother can use other positions during resting time of no more than 20 minutes each hour, but never use a lateral position against the side of the foetal back."
16660971|NCT02209090|Sham Comparator|maternal free positions|Women can adopt the position they wish and which is most comfortable, except for lateral positions which can only be used for a maximum of 20 minutes each hour to avoid confounding factors.
16660972|NCT02209077|Experimental|Healthy Volunteers|OCT performed to collect data from the back of the eye
16660973|NCT02209077|Experimental|Glaucoma group|OCT performed to collect data from the back of the eye
16660974|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
16660975|NCT02209051|Active Comparator|AMNIOEXCEL|Human Amniotic Membrane Allograft
16660976|NCT02209051|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading of wound.
16660977|NCT02209038|Experimental|Expanded AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?
~4 answer choices:
~Yes, I would like to complete a comprehensive version of an advance directive.
~Yes, I would like to complete an expanded version of an advance directive.
~Yes, I would like to complete a brief version of an advance directive.
~No, I do not wish to complete an advance directive."
16660978|NCT02209038|No Intervention|Standard AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?
~2 answer choices:
~Yes, I would like to complete an AD.
~No, I do not wish to complete an advance directive."
16660979|NCT02209038|Experimental|Expanded Life-sustaining therapy Choice|"For each hypothetical illness state described in the living will:
~4 answer choices:
~No, I would not want life support.
~Yes, I would want life support.
~I would want life support if my doctor believes it could help, but I want to stop receiving life support if at any time my doctor believes it is only delaying the moment of my death.
~I do not wish to specify a preference at this time."
16660980|NCT02209038|No Intervention|Standard Life-sustaining Therapy Choice|"For each hypothetical illness state described in the living will:
~3 answer choices:
~No, I would not want life support.
~Yes, I would want life support.
~I do not wish to specify a preference at this time."
16660981|NCT02209025|Placebo Comparator|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
16660982|NCT02209025|Experimental|Theobromine|500mg theobromine in a drink
16660983|NCT02209012||ALA|Subjects who received ALA in CP0108
16660984|NCT02209012||Vehicle|Subjects who received Vehicle in CP0108
16660985|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
16660986|NCT02208986|Active Comparator|0.2mg Triptorelin|Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
16660987|NCT02208986|Active Comparator|0.3mg Triptorelin|Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
16660988|NCT02208986|Active Comparator|Active Comparator: 0.4mg Triptorelin|Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
16660989|NCT02208973|Experimental|PBF-680 (5 mg)|5 mg of PBF-680
16660990|NCT02208973|Experimental|PBF-680 (10 mg)|10 mg of PBF-680
16660991|NCT02208973|Experimental|PBF-680 (20 mg)|20 mg of PBF-680
16660992|NCT02208973|Experimental|PBF-680 (40 mg)|40 mg of PBF-680
16660993|NCT02208973|Experimental|PBF-680 (60 mg)|60 mg of PBF-680
16661421|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
16660994|NCT02208973|Placebo Comparator|Placebo|Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo
16660995|NCT02208960|Experimental|Neonatal Kit|Mothers in the neonatal kit clusters will receive a neonatal kit and training on how to use the kit components during their third trimester of pregnancy. The kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Community Health Workers will be equipped with a hand-held battery operated scale to identify low birth weight newborns.
16660996|NCT02208960|Experimental|Neonatal Stimulation|During home visits in the 3rd trimester, mothers in the neonatal stimulation clusters will be taught 3 core messages pertaining to neonatal stimulation. First, mothers will be taught how to make eye contact and talk to their child. This type of interaction encourages social inclusion, attachment, and development of social-communication skills. Second, mothers will be taught techniques to foster responsive feeding and caregiving. Finally, mothers will be encouraged to sing songs and nursery rhymes, including those with gentle touch in order to support the development of communication skills, and introduce a tactile component to caregiving. These messages will be reiterated at subsequent home visits by the CHW after the baby is born.
16660997|NCT02208960|Experimental|Neonatal Kit and Neonatal Stimulation|Participants in this arm of the study will receive both a neonatal kit (described in Arm 1) and neonatal stimulation (described in Arm 2).
16660998|NCT02208960|No Intervention|Control (Standard Care)|"In control clusters, CHWs will visit the home according to the regular schedule (same as in the intervention clusters) and deliver the standard CHW post-natal care that consists of talking to mothers about:
~Exclusive breastfeeding and proper nutrition for both the mother and the baby.
~Ensuring warmth to the baby.
~Full immunization and growth monitoring of newborn.
~Hygiene and sanitation practices.
~Family Planning and promote the proper use of Insecticides Treated Nets.
~Identifying any danger sign/complication for both mothers and new-borns and refer for prompt treatment (within 24 hours) for management and treatment.
~Promoting the use of services such as birth registration.
~Giving advice on proper care of the umbilical cord."
16660999|NCT02208947|Active Comparator|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
16661000|NCT02208947|Experimental|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
16661001|NCT02208934|Experimental|PBF-999 (5 mg)|5 mg of PBF-999
16661002|NCT02208934|Experimental|PBF-999 (10 mg)|10 mg of PBF-999
16661003|NCT02208934|Experimental|PBF-999 (20 mg)|20 mg of PBF-999
16661004|NCT02208934|Experimental|PBF-999 (40 mg)|40 mg of PBF-999
16661005|NCT02208934|Placebo Comparator|Placebo|Placebo for the 5, 10, 20 and 40 mg dose
16661006|NCT02208921||T2DM patients with Chronic Kidney Disease|T2DM patients with Chronic Kidney Disease
16661007|NCT02208908||Patient with cancer hospitalize inpalliative situation|"An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
~An assessment of the traceability of clinical assessment and appropriate treatment prescribed or will be conducted on day 3 and repeated the day of the release of hospitalization (or day 15) from information recorded in the patient record"
16661008|NCT02208895||iSTAT Study Group|Measure glucose of pleural fluid via glucometer, in the laboratory, and using the iSTAT device to see if the three methods give a similar reading or not.
16661009|NCT02208882|Experimental|Panel 1: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
16661010|NCT02208882|Experimental|Panel 2: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
16661011|NCT02208882|Experimental|Panel 3: BMS-986120 or Placebo + Midazolam|BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
16661012|NCT02208882|Experimental|Panel 4: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
16661013|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.
~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
16661014|NCT02208856|Placebo Comparator|Placebo|
16661015|NCT02208856|Experimental|BIBR 796 BS food effect|
16661016|NCT02208856|Experimental|BIBR 796 BS|
16661017|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
16661018|NCT02208830|Experimental|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
16661019|NCT02208830|Experimental|pulmonary rehabilitation|Duration of 8 week, twice weekly exercise program with: lower limb strength training and aerobic training per 30 minutes.
16661020|NCT02208817||Ill patients|Ill patients who require Paediatric Intensive Care or Paediatric High Dependency Care
16661021|NCT02208817||Well Controls|Matched controls who are well (PEWS<3)
16661022|NCT02208817||Parent feedback|Feedback from parents/carers of children recruited into the PRefill study
16661023|NCT02208817||Healthcare professionals feedback|Feedback from healthcare professionals who have cared for a child with the device on
16661024|NCT02208804|Experimental|Surefire Infusion System|Hepatic arterial administrations using the Surefire Infusion System
16661025|NCT02208804|Active Comparator|Standard End-hole Microcatheter|Hepatic arterial administrations using the standard end-hole microcatheter
16661026|NCT02208791|Active Comparator|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
16661027|NCT02208791|Experimental|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
16661028|NCT02208778|Experimental|Duloxetine|Duloxetine 30 mg a day (2 weeks), then 60 mg a day (4weeks), taken by mouth
16661029|NCT02208778|Placebo Comparator|Placebo (for Duloxetine)|Sugar pill: 1 capsule a day (2 weeks), then 2 capsules a day (4 weeks) taken by mouth
16661030|NCT02208778|Experimental|Remifentanil|Intravenous infusion with maximum estimated plasma target of 1.0 ng/ml, during less than 20 minutes
16661031|NCT02208778|Placebo Comparator|Placebo (for Remifentanil)|Intravenous infusion of normal saline, during less than 20 min
16661032|NCT02208765|Other|Study cohort|Any patient referred to the Nuclear Cardiology Laboratory of the University Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis evaluation of suspected or know coronary artery disease
16661033|NCT02208752|Active Comparator|Exercises|exericises on motor control and strengthening exercises on the Rotator Cuff
16661034|NCT02208752|Placebo Comparator|Control group- No exercises|No exercises
16661035|NCT02208739|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy was given to all patients at baseline
16661036|NCT02208739|Active Comparator|Oral hygiene instructions|Oral hygiene instructions were given to all patients at baseline
16661037|NCT02208726|Placebo Comparator|Sucrose pillules|Unmedicated sucrose pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
16661038|NCT02208726|Experimental|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH. Pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
16661039|NCT02208713|Experimental|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
16661040|NCT02208700|Experimental|Oxepa|Other: Therapeutic nutrition with EPA, GLA and antioxidants.
16661041|NCT02208700|Active Comparator|Jevity 1.5|Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .
16661042|NCT02208687|Experimental|Energetic|Self management group program aimed at reconditioning and social participation
16661043|NCT02208687|Other|Control group|Usual care
16661044|NCT02208674|No Intervention|Usual Care|Primary care provider-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per usual care.
16661045|NCT02208674|Experimental|Protocolized, pharmacist-delivered CKD Action Plan|Protocolized, pharmacist-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per KDIGO and JNC-8 recommendations.
16661046|NCT02208648||Deceased|"Peri-operative mortality (within 90 days). Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
16661047|NCT02208648||Matched control|"Patients who survived beyond 90 days peri-operatively. Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
16661048|NCT02208635|Experimental|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (~30 µg Zn/g).
16661049|NCT02208635|Experimental|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
16661050|NCT02208635|Active Comparator|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
16661051|NCT02208622|Experimental|Study 1: Whey Supplement Day 1|Children in this arm received the whey supplement as part if their diet on day 1.
16661052|NCT02208622|Experimental|Study 1: Whey Supplement Day 2|Children in this arm received whey supplement as part of their diet on day 2.
16661053|NCT02208622|Experimental|Study 2: Whey Supplement|Children in this arm received a whey supplement as part of their diet.
16661054|NCT02208622|No Intervention|Study 2: Control|Children in this arm did not receive a whey supplement as part of their diet.
16661055|NCT02208609|Experimental|Maize Tortillas with 20% Amaranth|Children in this arm were fed maize tortillas fortified with 20% amaranth
16661056|NCT02208609|Experimental|Maize Tortillas without 20% Amaranth|Children in this arm were fed maize tortillas without amaranth
16661057|NCT02208596|Experimental|Group A|In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
16661058|NCT02208596|Experimental|Group B|In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
16661059|NCT02208596|Experimental|Group C|In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
16661237|NCT02207387|Experimental|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
16661060|NCT02208583|Active Comparator|AR dependent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:
~CRPC patients without druggable gene mutations: Docetaxel & Prednisone; CRPC patients with druggable gene mutations: DP & Targeted drugs"
16661061|NCT02208583|Active Comparator|AR independent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:
~CRPC patients without druggable gene mutations: cisplatin & Etoposide; CRPC patients with druggable gene mutations: EP & Targeted drugs"
16661062|NCT02208570|Experimental|P(+)V(+)|PPV>14% before anesthesia induction, HES 6ml/kg infused
16661063|NCT02208570|Experimental|P(+)V(-)|PPV>14% before anesthesia induction, no additional volume infused
16661064|NCT02208570|Experimental|P(-)V(+)|PPV<14% before anesthesia induction, HES 6ml/kg infused
16661065|NCT02208570|Experimental|P(-)V(-)|PPV<14% before anesthesia induction, no additional volume infused
16661066|NCT02208557|Active Comparator|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
16661067|NCT02208557|Experimental|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
16661068|NCT02208544|Experimental|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:
~negative: watchful waiting including confirmatory ultrasound
~positive: diagnostic thyroid surgery as planned"
16661069|NCT02208544|Other|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
16661070|NCT02208531|No Intervention|Control|
16661071|NCT02208531|Experimental|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
16661072|NCT02208518||Elastography analysis|Consecutive patients undergoing for upper endoscopy ultrasound
16661073|NCT02208505|Experimental|Dexmedetomidine|we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).
16661074|NCT02208505|Active Comparator|Remifentanil|we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.
16661075|NCT02208492|Experimental|Levetiracetam|
16661076|NCT02208492|Active Comparator|Carabamazepine|
16661077|NCT02208479||cardiac surgery|
16661078|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
16661079|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
16661080|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
16661081|NCT02208453|Experimental|InSpace implantation|InSpace device implantation
16661082|NCT02208440|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
16661083|NCT02208440|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
16661084|NCT02208427|Experimental|3M_RH|Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
16661085|NCT02208427|Active Comparator|9M_INH|Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
16661086|NCT02208414|Experimental|Crab or shrimp|Intervention: treated with crab and shrimp energy signature vial using NAET
16661087|NCT02208414|Placebo Comparator|Placebo|Treated with water vial
16661088|NCT02208401|Active Comparator|conventional cold snare polypectomy|conventional cold snare polypectomy
16661089|NCT02208401|Experimental|Cold snare polypectomy with suction|Cold snare polypectomy with suction
16661090|NCT02208388|Experimental|Computed tomography perfusion|Patients with Computed tomography perfusion
16661091|NCT02208388|Active Comparator|Fractional flow reserve|Patients with Fractional flow reserve
16661092|NCT02208375|Experimental|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
16661093|NCT02208375|Experimental|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
16661094|NCT02208375|Experimental|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
16661095|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018.
~Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
16662386|NCT02199860|Experimental|SD II - single rising doses|
16661096|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions
16661097|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
16661098|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
16661099|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
16661100|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
16661101|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
16661102|NCT02208336||Observational (electronic medical record review)|Patients' electronic medical records are reviewed for adherence, severe myelosuppression, and patient morbidity retrospectively and prospectively.
16661103|NCT02208323|Experimental|Bubble CPAP|Bubble CPAP for 28 days
16661104|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
16661105|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
16661106|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
16661107|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
16661108|NCT02208284|Experimental|Cohort 1-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
16661109|NCT02208284|Experimental|Cohort 2-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
16661110|NCT02208284|Experimental|Cohort 3-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
16661111|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
16661112|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
16661113|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
16661114|NCT02208245|Active Comparator|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
16661115|NCT02208245|Active Comparator|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
16661116|NCT02208232||MC 6125 AS IOL|cataract surgery with implantation of intraocular lens MC 6125 AS in one eye
16661117|NCT02208219|Experimental|Music-supported Therapy (n=40)|Participants in this group will receive a Music-supported Therapy training at the Hospital during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
16661118|NCT02208219|Experimental|home-based Music-supported Therapy(n=40)|Participants in this group will receive a Music-supported Therapy training at home during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
16662387|NCT02199860|Experimental|SD II - single rising doses + Placebo|
16661119|NCT02208219|Active Comparator|Conventional treatment (n=40)|Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
16661120|NCT02208193|Experimental|healthy controls group|Healthy volunteers
16661121|NCT02208193|Experimental|Alzheimer subjects group|"Group A Alzheimer group: patients with mild to severe stages of Alzheimer's disease: subgroup A1 Alzheimer group hospitalized at the Paul Spillmann Centre (Centre Paul Spillmann, CPS) (CHU de Nancy, France); subgroup A2 Alzheimer group monitored at the Resource and Research Memory Centre (Centre Mémoire de Ressources et de Recherche, CMRR) (CHU de Nancy, France)"
16661122|NCT02208180|Experimental|Return of genomic results on cardiovascular disease risk|Participants will receive genomic cardiovascular disease risk information.
16661123|NCT02208180|Active Comparator|Return of lifestyle results on cardiovascular disease risk|Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
16661124|NCT02208167|Other|Chronic HIV infection|HXTC infusion
16661125|NCT02208167|Other|Acute HIV infection|HXTC infusion
16661126|NCT02208154|Active Comparator|Standard care|"Standard infection prevention measurements will be implemented before the baseline period and carried out throughout the entire trial. They consist of:
~Chlorhexidine 2% body washings (CHX-BW) for all ICU patients. The face and neck of the patient will not be cleansed with Chlorhexidine to prevent irritation of the eyes and face.
~A hand hygiene improvement program (HHIP) based on the program designed by the World Health organisation (WHO).
~Standard oropharyngeal care consists of oral washing with sterile water (3-4 times daily) and tooth brush twice daily."
16661127|NCT02208154|Experimental|Chlorhexidine oral care (CHX-Oro)|Chlorhexidine digluconate oromucosal gel 1%, 2cm, to be administered 4 times daily, during invasive mechanical ventilation.
16661128|NCT02208154|Experimental|Selective oropharyngeal decontamination|Selective oropharyngeal decontamination (SOD) mouth paste containing colistin and tobramycin in a 2% concentration and nystatin 1 x 10^5 units, dosage 0.5g , to be administered 4 times daily during the entire period of invasive mechanical ventilation.
16661129|NCT02208154|Experimental|Selective digestive decontamination|Selective digestive decontamination (SDD), suspension via the nasogastric tube containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u., dosage 10ml, to be administered together with SOD (see above) 4 times daily during entire period of mechanical ventilation.
16661130|NCT02208141||lean and obese children and adolescents|study cohort may be stratified for lean (definded as BMI <1.28 SDS) and overweight/obese (definded as BMI>= 1.28 SDS) children for posthoc analyses no intervention
16661131|NCT02208128|No Intervention|Receptor-Tyrosinkinase-Inhibitor|Guidelines-oriented therapy with approved systemic medications for renal cell carcinoma individually for each patient (Receptor-Tyrosinkinase-Inhibitor) (e.g.Sunitinib, Pazopanib, Bevacizumab, Everolimus, Axitinib, Temsirolimus). With 1.progression turning to second line treatment with one of the upper mentioned medications. Third line therapy due to the individual molecular modifications for each patient.
16661132|NCT02208115|Experimental|Meal composition - High GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
16661133|NCT02208115|Experimental|Meal composition - Low GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
16661134|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
16661135|NCT02208089|Active Comparator|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
16661136|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
16661137|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
16661138|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
16661139|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
16661140|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
16661141|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
16661142|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
16661143|NCT02208024|Experimental|Stereotactic Body Radiation Therapy|5 fractions of 6.6 Gy delivered twice weekly with each fraction separated by greater than 48 hours over 15 days
16661144|NCT02207998|Experimental|Homeopathic complex and physiotherapy|"Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.
~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist."
16661145|NCT02207998|Placebo Comparator|Placebo and physiotherapy|"Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.
~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist ."
16662388|NCT02199860|Placebo Comparator|Placebo|
16661146|NCT02207985|Experimental|Hematopoetic stem cell transplantation|Patients with pancreatic adenocarcinoma that have undergone Whipple surgery and show no sign of disease recurrence can be treated with hematopoietic stem cell transplantation to achieve an immunological anti-tumor effect.
16661147|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
16661148|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
16661149|NCT02207959|Experimental|Surveillance Endoscopy|White light examination, vital-dye enhanced fluorescence examination (VFI), High Resolution Microendoscope (HRME)
16661150|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
16661151|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
16661152|NCT02207933|Experimental|AP shifting group|
16661153|NCT02207933|Active Comparator|gait training group|
16661154|NCT02207920|Experimental|Group 1|"At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid."
16661155|NCT02207920|Experimental|Group 2|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
~At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
16661156|NCT02207920|Experimental|Group 3|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
16661157|NCT02207920|Experimental|Group 4|At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
16661158|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
16661159|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
16661160|NCT02207881|Placebo Comparator|placebo|placebo gel, 25mg, 3 times up to 10 days
16661161|NCT02207881|Experimental|VDO gel|VDO gel 25mg, 3 times a day up to 10 days
16661162|NCT02207868||no treatment|
16661163|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
16661164|NCT02207842||Volatile anesthesia exposure|
16661165|NCT02207842||No volatile anesthesia exposure|
16661166|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
16661167|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
16661168|NCT02207816|Experimental|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
16661169|NCT02207816|Active Comparator|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
16661170|NCT02207816|Active Comparator|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
16661171|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
16661172|NCT02207803|No Intervention|Control|Control
16661173|NCT02207790|Experimental|E2609 low-dose and placebo in healthy Japanese subjects|Cohort 1 will consist of Japanese subjects randomized to a low-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
16661174|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy Japanese subjects|Cohort 2 will consist of Japanese subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
16661238|NCT02207387|Experimental|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
16661487|NCT02205710|Placebo Comparator|Computerized game training|Series of gamified tasks.
16661175|NCT02207790|Experimental|E2609 high-dose and placebo in healthy Japanese subjects|Cohort 3 will consist of Japanese subjects randomized to a high-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
16661176|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy White subjects|Cohort 4 will consist of White subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
16661177|NCT02207777|Experimental|Roux-en-Y gastric bypass (RYGB)|Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain approximately 16-18% (with a range of 16-25%) weight loss.
16661178|NCT02207777|Active Comparator|Low-calorie diet|Subjects in this group will participate in a low-calorie diet intervention to obtain approximately 16-18% (with a range of 16-25%) weight loss.
16661179|NCT02207764|Experimental|Reiki Intervention|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
16661180|NCT02207764|No Intervention|nursing presence control|Each patient in the control group will receive usual care including the study nurse presence for the 15-minute period.
16661181|NCT02207738|Experimental|microneedling radiofrequency device|microneedling radiofrequency
16661182|NCT02207738|Active Comparator|bipolar radiofrequency device|bipolar radiofrequency treatment
16661183|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
16661184|NCT02207725|Placebo Comparator|Placebo|Placebo
16661185|NCT02207712|Active Comparator|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
16661186|NCT02207712|Experimental|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
16661187|NCT02207699|Experimental|Benzonatate 200 mg|
16661188|NCT02207699|Experimental|Benzonatate 800 mg|
16661189|NCT02207699|Active Comparator|Moxifloxacin 400 mg|
16661190|NCT02207699|Placebo Comparator|Placebo|
16661191|NCT02207686||von Hippel-Lindau disease|Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
16661192|NCT02207673|Active Comparator|Spikes as biomarker|"In arm  spikes the resection of epileptogenic tissue is guided by epileptiform spikes in the aECoG (current standard). (Independent of the randomisation ictiform spike patterns will always be resected.)"
16661193|NCT02207673|Experimental|HFOs as biomarker|"In arm HFOs resection of epileptogenic tissue is guided by HFOs in the aECoG (new). (Independent of the randomisation ictiform spike patterns will always be resected.)"
16661194|NCT02207660||Cisplatin,P-HDFL|The general principles for patients schedule for P-HDFL regimen treatment were as followings: patients must have had white cell count > 3000/mm3, platelet count > 100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance ([urine creatinine level (mg/dL) X 24-hr urine amount (mL)]/[serum creatinine level (mg/dL) X 1,440 min]) of ≧ 40 mL/min [12,15], total bilirubin ≦ 2 mg/dL, and transaminase (≦3X the upper normal limits). Also, patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
16661195|NCT02207647||Patients with syndromes requiring lumbar puncture|
16661196|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
16661197|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
16661198|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
16661199|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
16661200|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
16661201|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
16661202|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
16661203|NCT02207595|Experimental|UCB5857 Cohort 1|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
16661204|NCT02207595|Experimental|UCB5857 Cohort 2|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
16661205|NCT02207595|Experimental|UCB5857 Cohort 3|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
16661206|NCT02207595|Experimental|UCB5857 Cohort 4|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
16661207|NCT02207595|Experimental|UCB5857 Cohort 5|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
16661208|NCT02207582|Experimental|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
16661209|NCT02207582|Placebo Comparator|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
16661210|NCT02207569|Experimental|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:
~Evolut R Transcatheter Aortic Valve (TAV)
~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
~EnVeo R Loading System (LS)"
16661211|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
16661212|NCT02207543|Experimental|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
16661213|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
16661214|NCT02207517|Experimental|Office-based verg/accomm therapy (OBVAT)|OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
16661215|NCT02207517|Placebo Comparator|Office-based placebo therapy (OBPT)|"Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures.
~The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT"
16661216|NCT02207504|Experimental|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.
~Crizotinib- given orally daily-28 day cycle
~Enzalutamide- given orally daily-28 day cycle"
16661217|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
16661218|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
16661219|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
16661220|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
16661221|NCT02207465|Experimental|Single Arm|
16661222|NCT02207452|Other|Salbutamol + Ipratropium|Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose.
16661223|NCT02207452|Other|Ipratropium + Salbutamol|Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose.
16661224|NCT02207439|Experimental|Single Arm Phase 2|
16661225|NCT02207426|Experimental|TobrAir® 6.0|Tobramycin 75mg inhalation solution
16661226|NCT02207426|Experimental|TOBI® / PARI LC® PLUS Nebulizer|Tobramycin 300mg nebulizer solution
16661227|NCT02207426|Experimental|TOBI® Podhaler™|Tobramycin 112mg (4x28mg) inhalation powder
16661228|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
16661229|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
16661230|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
16661231|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
16661232|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
16661233|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
16661234|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
16661235|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
16661236|NCT02207387|Experimental|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
16661239|NCT02207387|Experimental|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.
~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
16661240|NCT02207387|Experimental|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.
~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
16661241|NCT02207374|Experimental|Semaglutide 0.5 mg|
16661242|NCT02207374|Experimental|Semaglutide 1.0 mg|
16661243|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
16661244|NCT02207361|Experimental|Paclitaxel, Carboplatin，injection|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
16661245|NCT02207361|Active Comparator|Paclitaxel, Epirubicin，injection|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
16661246|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with FlexPen®|
16661247|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with the PDS290 pen-injector|
16661248|NCT02207335|Experimental|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
16661249|NCT02207335|Active Comparator|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
16661250|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)
~-- Complete baseline data collection, and registration
~Patient Randomization
~Standard transplant oncology care
~-- Palliative care consults only upon request
~Longitudinal Data Collection (patient & family caregivers)
~Week-2 of hospitalization
~3-months, and 6-months post HSCT"
16661251|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care
~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)
~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits
~Longitudinal Data Collection (patient & family caregivers)
~Week-2 of hospitalization
~3-months, and 6-months post HSCT"
16661252|NCT02207309|Active Comparator|Pazopanib|800mg, oral, 24 months
16661253|NCT02207309|Placebo Comparator|Placebo|800mg, oral, 24 months
16661254|NCT02207296|Other|PVI group|Fluid optimisation using PVI
16661255|NCT02207296|No Intervention|Control group|Standard care using a hemodynamic protocol during general anesthesia
16661256|NCT02207270|Experimental|Same day discharge|Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
16661257|NCT02207270|Other|Overnight stay standard care|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.
16661258|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
16661259|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
16661260|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
16661261|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
16661262|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
16661263|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
16661264|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
16661265|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
16661298|NCT02206984|Active Comparator|Anastrozole|1mg given orally daily for 21 days
16661266|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
16661267|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
16661268|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
16661269|NCT02207218||NovoEight®|
16661270|NCT02207205|Other|Catheter vs venipuncture blood samples|Evaluation of whether there is any difference in results of whole blood clotting time in blood samples drawn from an indwelling catheter versus direct venipuncture
16661271|NCT02207192||Morbidly obese|Consecutive morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric surgery were prospectively recruited.Subjects with respiratory and cardiac history (asthma, Chronic obstructive pulmonary disease, heart failure) were excluded.
16661272|NCT02207179|No Intervention|Single Arm|LumaScan Image Guided Surgery
16661273|NCT02207166||user group|volunteers who are willing to receive 40 minutes video monitoring and questionnaires while operation a electronic blood pressure measuring machines.
16661274|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
16661275|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
16661276|NCT02207140|Experimental|probiotic|HOWARU Restore
16661277|NCT02207140|Placebo Comparator|placebo|microcrystalline cellulose
16661278|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
16661279|NCT02207114|No Intervention|Observational|9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
16661280|NCT02207114|Experimental|Biomarker Algorithm Intervention|"The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics.
~The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs."
16661281|NCT02207101|Active Comparator|E-OJ-01 (OXYJUN)|E-OJ-01 (OXYJUN). Dose: 01 capsule to be taken orally daily after lunch.
16661282|NCT02207101|Placebo Comparator|Placebo|Matching placebo capsules [for E-OJ-01 (OXYJUN)] composed of microcrystalline cellulose. Dose: 01 capsule to be taken orally daily after lunch.
16661283|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
16661284|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.
~SPMS subjects will have two baseline [11C]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
16661285|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline [C11]PK-1195 PET scans and 1 MRI.
16661286|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
16661287|NCT02207049|Active Comparator|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
16661288|NCT02207049|Active Comparator|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
16661289|NCT02207049|Active Comparator|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
16661290|NCT02207036|Experimental|Facebook intervention|Assignment to private group on Facebook with 3 months of content delivered to the group.
16661291|NCT02207036|Active Comparator|Referral|Referral to smokefree.gov website
16661292|NCT02207023|No Intervention|Memory Training Program|Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
16661293|NCT02207023|Experimental|Healthy Lifestyle Training Program|Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
16661294|NCT02207010|Experimental|AZD1775|Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
16661295|NCT02206997||Passive Insulation standard treatment|no active warming before start of anesthesia and no active warming at PACU
16661296|NCT02206997||Active prewarming treatment|active warming before start of anesthesia and active warming at PACU following recommendations of S3-guideline
16661297|NCT02206984|Active Comparator|tamoxifen|Tamoxifen is administered orally, at a dose of 20 mg,daily, for 21 days
16661299|NCT02206984|Active Comparator|fulvestrant|500 mg, administered as two 250 mg IM injections, given on days 1 and 14
16661300|NCT02206971|Active Comparator|Feedback Group|receive a Smoking Cessation Manual, the opportunity for smoking cessation counseling on the phone, and urine analyses feedback via the mail plus a phone call to discuss the information
16661301|NCT02206971|No Intervention|Standard Care|receive a Smoking Cessation Manual and the opportunity for smoking cessation counseling on the phone
16661302|NCT02206958|Other|No treatment control group|No treatment control group
16661303|NCT02206958|Experimental|Behavioral Urinary Incontinence Treatment|12 week program combining behavioral treatments for urinary incontinence and physical activity
16661304|NCT02206945|Experimental|neurofeedback|Two imaging sessions of neurofeedback.
16661305|NCT02206945|Placebo Comparator|control feedback|Two imaging sessions of feedback
16661306|NCT02206932|Other|Sofosbuvir + Simeprevir|Subjects will be enrolled and treated with simeprevir 150 mg and sofosbuvir 400 mg once daily for 12 weeks
16661307|NCT02206906||Study Participants|All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
16661308|NCT02206893|Experimental|Mobile: Professional and peer support|A mobile app that provides both professional support and peer support
16661309|NCT02206893|Experimental|Mobile: Peer support|A mobile app that provides peer support, but not professional support
16661310|NCT02206893|Experimental|Mobile: Professional Support|A mobile app that provides professional support, but no peer support
16661311|NCT02206893|Active Comparator|Mobile: No Support|A mobile app that provides neither peer support nor professional support
16661312|NCT02206893|Active Comparator|Web: No Support|A web app that provides neither peer support, nor professional support
16661313|NCT02206867|Experimental|LBAL|Developed by LG Life Sciences
16661314|NCT02206867|Active Comparator|Humira®|Abbvie
16661315|NCT02206854|Experimental|R-flurbiprofen|200 mg R-flurbiprofen in gelatine capsules once
16661316|NCT02206841||NAFLD|Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as targeted SNP arrays, super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, metabolomics, fecal microbiome, metabolite, metagenome/metatranscriptome analyses.
16661317|NCT02206828||1 GROUP|Only 1 group not predetermined
16661318|NCT02206815|Active Comparator|Ticagrelor+Warfarin|Ticagrelor:Plain, round, yellow, film-coated tablet, 90mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
16661319|NCT02206815|Active Comparator|Clopidogrel+Aspirin+Warfarin|Clopidogrel:Light red bisulfate tablets, containing one 75mg; Aspirin:Plain, round, white, film-coated tablet, 100mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
16661320|NCT02206802||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
16661321|NCT02206802||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
16661322|NCT02206789|Active Comparator|penetrating keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators.
~3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years
~."
16661323|NCT02206789|Active Comparator|therapeutic keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators. (For all patients with fungal keratitis topical steroids will be administered only after 2 weeks post keratoplasty.) Until then diclofenac sodium0.1% may be used 3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years
~."
16661324|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
16661325|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
16661326|NCT02206763|Experimental|Momelotinib (MMB)+erlotinib|Participants will receive momelotinib (MMB) plus erlotinib.
16661327|NCT02206750|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16661328|NCT02206750|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16661329|NCT02206737|Experimental|E-Cigarette|3 doses of e-cigarette to be given No nicotine Low dose nicotine High dose nicotine
16661330|NCT02206724|Experimental|STEREOTACTIC BODY RADIOTHERAPY|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
16661331|NCT02206711|Experimental|Single oral dose of [14C] BMS 955176|A single 180 mg oral dose of [14C] BMS-955176 containing approximately 80 microcurie of total radioactivity.
16661332|NCT02206711|Experimental|Nasoduodenal (ND) Tube Cohort|A single dose of [14C] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.
16661333|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
16661334|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
16661335|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
16662389|NCT02199847|Experimental|Pharmaton® Caplets|
16661336|NCT02206659|Experimental|Telmisartan|2-week placebo run-in period followed by 6 weeks of treatment with telmisartan
16661337|NCT02206646||Metalyse|weight-adjusted dose
16661338|NCT02206633||Elderly, assisted living residents|Hydration Monitor ultrasound measurements
16661339|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
16661340|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
16661341|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
16661342|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
16661343|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
16661344|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
16661345|NCT02206594|Experimental|Descemetorhexis|
16661346|NCT02206581||young healthy adult athletes|Hydration Monitor measurement of the ultrasound velocity and measures of hydration status including urine specific gravity, plasma and urine osmolality in male and female young adults after undergoing 3% acute dehydration and a 2-hr rehydration period
16661347|NCT02206568|Experimental|URAL vs. Insulin lispro|Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.
16661348|NCT02206555|Experimental|Treatment group (TRUVADA)|Homosexual men and heterosexual men and women at high risk of HIV infection
16661349|NCT02206542|Experimental|Robot-assisted group|Electroacupuncture, physical therapy and upper limb rehabilitation robot
16661350|NCT02206542|Active Comparator|Control group|Electroacupuncture and physical therapy
16661351|NCT02206529|Active Comparator|Social Network Engagement+Std Treatment|"Social Network Engagement = content and activities to help the parent engage his/her social network in supporting healthy lifestyle behaviors.
~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
16661352|NCT02206529|Other|Standard Treatment|"This comparator arm consists of historical controls, participants in the FOCUS trial who received standard treatment.
~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
16661353|NCT02206516|Experimental|patients|Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
16661354|NCT02206503|Experimental|Cyclophosphamide; Lenalidomide; Dexamethasone|"MM Patients who experienced biochemical progression during Rd treatment without CRAB (signs of organ damage, multiple myeloma-related, as renal impairment and/or anemia and/or new bone lesions and/or hypercalcemia), will continue:
~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days.
~Dexamethasone orally at the dose of 40 mg once a week.
~Adding:
~· Cyclophosphamide orally at the dose of 50 mg/day on days 1-21 every 28 days. CRd combination will be continued for 9-4week cycles. Patients will not receive any maintenance therapy."
16661355|NCT02206490|Active Comparator|Naltrexone Study Drug|Subjects will take naltrexone 4.5 mg daily for three months.
16661356|NCT02206490|Placebo Comparator|Naltrexone placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
16661357|NCT02206490|Active Comparator|dextromethrophan study drug|subjects will take a sustained release dextromethorphan pill twice a day.
16661358|NCT02206490|Placebo Comparator|dextromethoprhan placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
16661359|NCT02206477|Experimental|DMSO treatment group|The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
16661360|NCT02206477|Placebo Comparator|the control group|The control group will be treated with the same post-operative protocol, but with 0.9% saline instead of DMSO. On the seventh post-operative day, the patient will be guided to set 10 cc 0.9% saline soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
16661361|NCT02206464|Experimental|Group 1|H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
16661362|NCT02206464|Experimental|Group 2|H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
16661363|NCT02206464|Experimental|Group 3|H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
16661364|NCT02206438|Experimental|1)C-LMA group|
16661365|NCT02206438|Active Comparator|2)Air-Q group|
16661366|NCT02206425|Experimental|bortezomib + melphalan + prednisone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661367|NCT02206425|Experimental|bortezomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661417|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
16661418|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
16661368|NCT02206425|Experimental|carfilzomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661369|NCT02206425|Experimental|bortezomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661370|NCT02206425|Experimental|carfilzomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661371|NCT02206425|Experimental|bortezomib + cyclophosphamide + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661372|NCT02206425|Experimental|bortezomib + cyclophosphamide + ascorbic acid|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.
16661373|NCT02206425|Experimental|bortezomib + PLD + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661374|NCT02206425|Experimental|bortezomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661375|NCT02206425|Experimental|carfilzomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
16661376|NCT02206412||HMGB1 group|
16661377|NCT02206386|Experimental|MentalHealthTraining-Net|MHTraining-Net is an implementation strategy that uses a web-based platform with several long distance tools (e.g. e-learning modules, consultation, telephone calls, toolkits, and discussion boards) to deliver four types of implementation activities: infrastructure development, training and education, quality improvement, and social networking.
16661378|NCT02206386|Active Comparator|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded trainings in the use of the protocol and depression screening posted by Brightree.
16661379|NCT02206360||Individuals at elevated risk for pancreatic cancer|Individuals with an elevated risk of developing pancreatic cancer as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk.
16661380|NCT02206347|Other|attention focus|
16661381|NCT02206334|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.
16661382|NCT02206321||Navigation total knee arthroplasty|Navigation total knee arthroplasty
16661383|NCT02206321||Conventional total knee arthroplasty|Conventional total knee arthroplasty
16661384|NCT02206308|Experimental|single arm|Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;
16661419|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
16661420|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
16661385|NCT02206295|Experimental|Treatment Sequence AB|"Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.
~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.
~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
16661386|NCT02206295|Experimental|Treatment Sequence BA|"Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.
~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.
~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
16661387|NCT02206269||Alair System|This is a single arm study with Alair system used.
16661388|NCT02206256|Active Comparator|Low calorie diet|Low calorie diet 2 weeks pre-operatively
16661389|NCT02206256|Active Comparator|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
16661390|NCT02206243||Embozene|Patients receiving Embozene microspheres
16661391|NCT02206230|Experimental|Hypofractionated radiation therapy|Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
16661392|NCT02206230|Active Comparator|Standard radiation therapy|Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
16661393|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
16661394|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
16661395|NCT02206204|Experimental|Group A|Subjects in Group A receive selexipag on Days 3 to 23 and moxifloxacin-matching placebo on Days 2 and 24. Selexipag administered orally, twice a day, for 21 days according to the following multiple dose up-titration regimen: 400 μg on Days 3-5, 600 μg on Days 6-8, 800 μg on Days 9-11, 1000 μg on Days 12-14, 1200 μg on Days 15-17, 1400 μg on Days 18-20, and 1600 μg on Days 21-23 (only morning dose on Day 23).
16661396|NCT02206204|Experimental|Group B1|Subjects in Group B1 receive 400 mg moxifloxacin, orally on Day 2 and moxifloxacin-matching placebo, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
16661397|NCT02206204|Experimental|Group B2|Subjects in Group B2 receive moxifloxacin-matching placebo, orally on Day 2 and 400 mg moxifloxacin, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
16661398|NCT02206191||Mothers of 6-11 year olds|
16661399|NCT02206178|Experimental|acetaminophen|"The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.
~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine
~- decrease the antinociceptive effect of acetaminophen in comparison to a group control
~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
16661400|NCT02206178|Placebo Comparator|placebo|"- decrease the antinociceptive effect of acetaminophen in comparison to a group control
~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
16661401|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 5mg|Candesartan 8mg + Amlodipine 5mg, po, q.d.
16661402|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 10mg|Candesartan 8mg + Amlodipine 10mg, po, q.d.
16661403|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
16661404|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
16661405|NCT02206165|Active Comparator|Candesartan 8mg|Candesartan 8mg, po, q.d.
16661406|NCT02206165|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
16661407|NCT02206165|Active Comparator|Amlodipine 5mg|Amlodipine 5mg, po, q.d.
16661408|NCT02206165|Active Comparator|Amlodipine 10mg|Amlodipine 10mg, po, q.d.
16661409|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
16661410|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
16661411|NCT02206126|Experimental|Energy restriction group|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
16661412|NCT02206126|No Intervention|Control group|The control group was advised not to change their food intake.
16661413|NCT02206113|Experimental|Standing workstation - 16 weeks|This arm, Standing workstation - 16 weeks, received the intervention of a standing workstation for 16 weeks. For the first 8 weeks, the participants were instructed how long to stand per hour for an 8 hour shift. The second 8 weeks their use was monitored for sustainability.
16661414|NCT02206113|Active Comparator|Standing workstation - second 8 weeks|This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
16661415|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
16661416|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
16662390|NCT02199847|Placebo Comparator|Placebo|
16661422|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
16661423|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
16661424|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
16661425|NCT02206074|Active Comparator|T2DM|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
16661426|NCT02206074|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
16661427|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.
~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
16661428|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
16661429|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
16661430|NCT02206048|Experimental|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
16661431|NCT02206035|Experimental|Tacrolimus, Methotrexate and Tocilizumab (Tac/MTX/Toc)|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant. Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
16661432|NCT02206022|Experimental|Remifentanil|Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
16661433|NCT02206022|Placebo Comparator|Placebo|Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion
16661434|NCT02206009|Experimental|Collagen membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
16661435|NCT02205996|Active Comparator|Controls|Weight-matched healthy controls. Euglycaemic Hypoglycaemic insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
16661436|NCT02205996|Active Comparator|Type 2 diabetes|People with a known diagnosis of type 2 diabetes. Euglycaemic Hypoglycaemic Insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
16661437|NCT02205983|Experimental|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
16661438|NCT02205983|Experimental|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
16661439|NCT02205983|Experimental|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
16661440|NCT02205983|Placebo Comparator|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
16661441|NCT02205970|Active Comparator|TENS active|TENS (interactive): frequency (90 and 150 pps) and pulse duration (300 and 400μs)
16661442|NCT02205970|Sham Comparator|TENS sham|Placebo lasting 35 minutes.
16661443|NCT02205957||Training quality|Tunisian residents in anesthesiology and intensive care
16661444|NCT02205944|No Intervention|Control Group|The control group will receive routine vascular access pre-op teaching and care.
16661445|NCT02205944|Experimental|Normal Exercise Group|"Group 1 (Normal Exercise Group): progressive handgrip exercise
~Group 2 (Restricted Blood Flow Exercise Group): progressive handgrip exercise with controlled tourniquet"
16661446|NCT02205931|Experimental|Ketogenic diet|8 week trial of the ketogenic diet (KD) therapy. Children allocated to KD therapy will have their diets individually calculated by a paediatric dietitian with consideration of daily calorie requirements, adequate protein intake for growth and vitamin and mineral supplementation. All diets will be implemented according to a classical KD protocol, i.e. based on a ratio of fat to carbohydrate and protein that will usually be between 2:1 and 4:1.
16662886|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
16661447|NCT02205931|Active Comparator|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug (AED) for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy according to a standardised manual (consensus document) written following the initial workshop of the paediatric neurologists from all the trial centres.
16661448|NCT02205918||Sham TMS|"Participants in this group will receive one, 30 minute session of inactive (sham) TMS."
16661449|NCT02205918||Active TMS|Participants in this group will receive one, 30 minute session of 1hz TMS.
16661450|NCT02205905|Experimental|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
16661451|NCT02205892|Active Comparator|Lupeol|
16661452|NCT02205892|Placebo Comparator|Vehicle|
16661453|NCT02205879|Experimental|pregabalin|
16661454|NCT02205879|Placebo Comparator|Placebo|
16661455|NCT02205866|Active Comparator|Group A|Non Obese patients
16661456|NCT02205866|Experimental|Group B|Obese patients
16661457|NCT02205853|Other|The patient-directed (PD) strategy|A single-faceted patient-directed (PD) strategy that will embed the change at patient level.
16661458|NCT02205853|Other|The multi-faceted (MF) strategy|A multi-faceted (MF) strategy that will embed the change at the patient, professional and organizational levels.
16661459|NCT02205840|Experimental|SI-614|
16661460|NCT02205840|Placebo Comparator|Placebo Vehicle|
16661461|NCT02205827|No Intervention|Single-arm|healthy volunteers
16661462|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
16661463|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
16661464|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
16661465|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
16661466|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
16661467|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
16661468|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
16661469|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
16661470|NCT02205775|Placebo Comparator|twice placebo before PCI|
16661471|NCT02205775|Experimental|atorvastatin 80 + 40 mg pre PCI|
16661472|NCT02205775|Experimental|rosuvastatin 40 + 40 mg before PCI|
16661473|NCT02205775|Experimental|rosuvastatin 5 + ezetimibe 10 mg twice before PCI|
16661474|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).
~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
16661475|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
16661476|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.
~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
16661477|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
16661478|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH
~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
16661479|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.
~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.
~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.
~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
16661480|NCT02205749|Other|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
16661481|NCT02205749|Other|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
16661482|NCT02205749|Other|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
16661483|NCT02205736|Other|Living Room Visit participants|Latino women who received breast health education while attending a Living Room Visit.
16661484|NCT02205723|Experimental|Smartphone Asthma Control|Smartphone Asthma Control
16661485|NCT02205723|Active Comparator|Control|Control group
16661486|NCT02205710|Experimental|Computerized cognitive training|Series of gamified tasks.
16661488|NCT02205697|Experimental|Implementation intention|The entire cohort will be asked to create an implementation intention to increase their intake of fruit and vegetables over the study period.
16661489|NCT02205684|Experimental|Physical activity|Aerobic High Intensity Training (HIT)
16661490|NCT02205684|Active Comparator|Computer game skills training|Playing Nintendo Wii Sports
16661491|NCT02205671|Experimental|Intervention|Building Better Caregivers Small-group Workshop
16661492|NCT02205658||Autism|Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder.
16661493|NCT02205658||Sensory Processing|Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder
16661494|NCT02205658||Typical|Typically functioning individuals aged 13-95 years
16661495|NCT02205645|Experimental|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
16661496|NCT02205632|Other|High myopic patients with lacker craks|
16661497|NCT02205632|Other|High myopic patients without lacker cracks|
16661498|NCT02205619|Experimental|Ultrasonic instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic instrumentation (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) treatment group
16661499|NCT02205619|Experimental|Hand instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into hand curette (Gracey curettes, American Eagle, Missoula, MT, USA) treatment group hand instrumentation (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA)
16661500|NCT02205619|Experimental|subgingival airpolishing with glycine|"Prior to extraction, the teeth (N = 12) were randomly included into air-polishing (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) with the glycine powder (Air-flow® Powder Perio, EMS) treatment group.
~subgingival airpolishing with glycine(Air-flow® Powder Perio, EMS SA, Nyon, Swiss)"
16661501|NCT02205619|Experimental|ultrasonic following airpolishing|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic following airpolishing ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) with the glycine powder treatment group
16661502|NCT02205606|Active Comparator|HGP0816 5mg|
16661503|NCT02205606|Active Comparator|HGP0816 10mg|
16661504|NCT02205606|Active Comparator|HGP0816 20mg|
16661505|NCT02205606|Experimental|HCP1306 5/10mg|
16661506|NCT02205606|Experimental|HCP1306 10/10mg|
16661507|NCT02205606|Experimental|HCP1306 20/10mg|
16661508|NCT02205593|Placebo Comparator|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
16661509|NCT02205593|Active Comparator|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
16661510|NCT02205580|Experimental|Sufentanil infusion rate 0.02μg•kg-1•h-1|Sufentanil infusion rate 0.02μg•kg-1•h-1 lasted for 48 hours
16661511|NCT02205580|Experimental|Sufentanil infusion rate 0.03μg•kg-1•h-1|Sufentanil infusion rate 0.03μg•kg-1•h-1 lasted for 48 hours
16661512|NCT02205580|Experimental|Sufentanil infusion rate 0.04μg•kg-1•h-1|Sufentanil infusion rate 0.04μg•kg-1•h-1 lasted for 48 hours
16661513|NCT02205567||Group 2|1000 mg/day of Bergamot-derived product
16661514|NCT02205567||Group 1|500 mg/day of Bergamot-derived product
16661515|NCT02205554|Active Comparator|Omnitram-Tramadol-Placebo|Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.
16661516|NCT02205554|Active Comparator|Tramadol-Placebo-Omnitram|Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.
16661517|NCT02205554|Active Comparator|Placebo-Omnitram-Tramadol|Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.
16661518|NCT02205541|Experimental|Eculizumab|"300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.
~Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection."
16661519|NCT02205541|Placebo Comparator|Placebo|"Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.
~Placebo will be administrated intravenously as a 30-minute injection."
16661520|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
16661521|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
16661522|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
16661523|NCT02205515|Other|Radiotherapy|SBRT or EBRT
16661524|NCT02205502|Experimental|Lidocaine|"Proper amount of lidocaine will be injected lacerated wound.
~dosage form: fluid
~dosage: not exceeding 1mg/kg
~frequency: once
~duration: n/a"
16661525|NCT02205502|Placebo Comparator|Normal saline|Normal saline will be used as a placebo for lidocaine
16661526|NCT02205489|Experimental|GZ402673 LEMTRADA|First course: Intravenous infusion for 5 consecutive days. Second course (will occur 12 months after the first course of treatment): Intravenous infusion for 3 consecutive days.
16661527|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
16661528|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
16661561|NCT02205320|Experimental|Treatment Sequence IV (A, B, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
16661775|NCT02203734|Experimental|Moderate Pressure Massage|Moderate Pressure Massage Therapy
16661529|NCT02205463|Experimental|KD019|Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
16661530|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
16661531|NCT02205437||Controls|Healthy subjects without psychotic disorder.
16661532|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
16661533|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
16661534|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
16661535|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
16661536|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
16661537|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
16661538|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
16661539|NCT02205411|Experimental|HeartAssist 5® VAD System|Implant of the HeartAssist 5® VAD System
16661540|NCT02205411|Active Comparator|Control VAD|
16661541|NCT02205398|Experimental|c-MET positive mCRC and HNSCC|c-MET positive and K/NRAS WT mCRC and c-MET positive HNSCC patients
16661542|NCT02205385|Active Comparator|Traditional Traction Neurectomy|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the current standard of care surgical treatment.
~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). In the active comparator arm, gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally. It may be buried in healthy muscle to further pad the nerve ending. The intention is to place the inevitable recurrent end-neuroma away from superficial locations in which it is likely to become mechanically irritated."
16661543|NCT02205385|Experimental|Targeted Muscle Reinnervation|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the experimental surgical treatment.
~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle."
16661544|NCT02205372|Experimental|MT-3995|
16661545|NCT02205372|Placebo Comparator|Placebo|
16661546|NCT02205359|Experimental|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
16661547|NCT02205359|Active Comparator|aCRT OFF|Standard CRT
16661548|NCT02205346||no treatment|no treatment
16661549|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
16661550|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
16661551|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
16661552|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
16661553|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
16661554|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
16661555|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
16661556|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
16661557|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
16661558|NCT02205320|Experimental|Treatment Sequence I (DRL, A, B)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
16661559|NCT02205320|Experimental|Treatment Sequence II (DRL, B, A)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
16661560|NCT02205320|Experimental|Treatment Sequence III (A, DRL, B)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
16661562|NCT02205320|Experimental|Treatment Sequence V (B, A, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
16661563|NCT02205320|Experimental|Treatment Sequence VI (B, DRL, A)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
16661564|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
16661565|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
16661566|NCT02205294|No Intervention|Assessment Only|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
16661567|NCT02205294|Active Comparator|Assessment and Treatment|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
16661568|NCT02205281|No Intervention|Standard Care|
16661569|NCT02205281|Experimental|Lifestyle Intervention|
16661570|NCT02205268|Experimental|Neurofeedback training|20 sessions of near infrared spectroscopy neurofeedback training to increase activation to bilateral prefrontal cortex. Two sessions per week.
16661571|NCT02205255|Experimental|Azithromycin|N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
16661572|NCT02205255|Placebo Comparator|Placebo|N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
16661573|NCT02205242|Experimental|Azithromycin|"N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
16661574|NCT02205242|Placebo Comparator|Placebo|"N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
16661575|NCT02205229||Patients receiving a topical compounded medication|
16661576|NCT02205216|Active Comparator|Active tDCS|Active tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
16661577|NCT02205216|Sham Comparator|Sham tDCS|Sham tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
16661578|NCT02205203|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
16661579|NCT02205203|Experimental|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
16661580|NCT02205190|Other|Treatment AB|"Treatment A (1 day) → wash-out(7days) → Treatment B (1 day)
~Treatment A : Fimasartan and Rosuvastatin
~Treatment B : Fimasartan/Rosuvastatin combination"
16661581|NCT02205190|Other|Treatment BA|"Treatment B (1 day) → wash-out(7days) → Treatment A (1 day)
~Treatment A : Fimasartan and Rosuvastatin
~Treatment B : Fimasartan/Rosuvastatin combination"
16661582|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
16661583|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
16661584|NCT02205164|Experimental|Palonosetron + Aprepitant|Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
16661585|NCT02205164|Active Comparator|Palonosetron|multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
16661586|NCT02205151|Other|Treatment AB|"Treatment A (1 day) → wash-out(14days) → Treatment B (1 day)
~Treatment A : Fimasartanm and Amlodipine
~Treatment B : Fimasartan/Amlodipine combination"
16661774|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
16661587|NCT02205151|Other|Treatment BA|"Treatment B (1 day) → wash-out(14days) → Treatment A (1 day)
~Treatment A : Fimasartanm and Amlodipine
~Treatment B : Fimasartan/Amlodipine combination"
16661588|NCT02205138|Experimental|ALLOB® cells with ceramic scaffold|ALLOB® cells with ceramic scaffold Implantation
16661591|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
16661592|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
16661593|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
16661594|NCT02205099|Placebo Comparator|Placebo|Placebo
16661595|NCT02205086|Other|Diagnosis|Test diagnostic decision support software
16661596|NCT02205073|Placebo Comparator|Dosing Period 1|
16661597|NCT02205073|Active Comparator|Dosing Period 2|
16661598|NCT02205073|Experimental|Dosing Period 3|
16661599|NCT02205060|Experimental|virtual reality exposure therapy (VRET)|
16661600|NCT02205060|Experimental|cognitive and behavioral approaches therapy without VRET|
16661601|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
16661602|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
16661603|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
16661604|NCT02205034|Active Comparator|first arm|4IU of oxytocin every other day
16661605|NCT02205034|Active Comparator|second arm|4 IU of oxytocin daily
16661606|NCT02205034|Active Comparator|third arm|4 IU of oxytocin twice daily
16661607|NCT02205021||All subjects|
16661608|NCT02205008|Active Comparator|Arm A|curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1
16661609|NCT02205008|Placebo Comparator|Arm B|curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1
16661610|NCT02204995|Active Comparator|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
16661611|NCT02204995|Active Comparator|Trapeziectomy|Trapeziectomy
16661612|NCT02204982|Experimental|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
16661613|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.
~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
16661614|NCT02204969|Sham Comparator|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
16661615|NCT02204969|Placebo Comparator|lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water
~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
16661616|NCT02204956|Experimental|Sustained Care|A 40-minute, in-hospital motivational counseling session about smoking cessation, 8 Interactive Voice Response (IVR) phone calls and/or texts over 90 days, including the possibility of a warm transfer to a telephone tobacco quit line and up to 8-weeks of free transdermal nicotine patches.
16661617|NCT02204956|Active Comparator|Usual Care|A brief 5-10 minute tobacco education session that all hospitalized smokers will receive, delivered by a hospital nurse. During this session, they will be provided with written handouts describing the stages of readiness for change in quitting, self-monitoring of smoking, self-management of smoking situations, relapse prevention, managing stress, other quitting tips and use of nicotine replacement therapy.
16661618|NCT02204943|Experimental|Bone Biopsy and Circulating Tumor Cell Samples|
16661619|NCT02204930|Experimental|Haemostat|PeproStat
16661620|NCT02204917|Experimental|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
16661621|NCT02204904||Allo-HSCT prospective|Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
16661622|NCT02204904||Allo-HSCT partial prospective/retrospective|Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
16661623|NCT02204904||Allo-HSCT retrospective|Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.
16661624|NCT02204891|Experimental|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
16661625|NCT02204891|Active Comparator|Probiotics|Administration of probiotics in patients with IBS without SIBO
16661626|NCT02204878|Placebo Comparator|A|1ml of saline was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. 1ml saline Q12h will be given within 72 hours after surgery
16661711|NCT02204202||Grade A0|Double-lung transplant recipients with no evidence of rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
16661627|NCT02204878|Experimental|AT|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
16661628|NCT02204865||Pacemaker/ICD with ApneaScan|Patients with HFREF due to receive a pacemaker or ICD with ApneaScan function
16661629|NCT02204852|Experimental|Iloprost+eptifibatide|Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
16661630|NCT02204852|Placebo Comparator|Saline|Double dummy 0.9% saline as 48h continuous i.v infusion
16661631|NCT02204839|Experimental|Basal dose reduction|Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.
16661632|NCT02204826|Experimental|V + KRG group (n = 20)|three capsules of KRG (500 mg/dose) daily and varicocelectomy.
16661633|NCT02204826|Active Comparator|non-V + KRG group|three capsules of KRG (500 mg/dose) daily
16661634|NCT02204826|Active Comparator|V + P group (n = 20)|placebo capsules and varicocelectomy
16661635|NCT02204826|Placebo Comparator|non-V + P group|non-V + P group (n = 20) placebo capsules
16661636|NCT02204813|Experimental|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
16661637|NCT02204800||Small clear cell renal tumors (Wild Type)|No specific chromatin remodeling gene (CRG) alteration
16661638|NCT02204800||Small clear cell renal tumors (Mutant)|Specific chromatin remodeling gene (CRG) alteration
16661639|NCT02204787|Experimental|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
16661640|NCT02204787|Sham Comparator|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
16661641|NCT02204774||Dilatated or aneurysmatic Aorta|Complete cohort, which will be followed over 3 years
16661642|NCT02204761|Experimental|Treatment|Proton beam radiation therapy
16661643|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
16661644|NCT02204735|Experimental|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
16661645|NCT02204735|Experimental|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
16661646|NCT02204722|Experimental|Group B|the group who has more than 10% of the BCR-ABL(IS) level for three months will receive 600mg/day of Imatinib after three months.
16661647|NCT02204722|Experimental|Group A|the group who has more than 10% of the BCR-ABL(IS) level for three months will maintain the dose, 400mg/day of Imatinib, after three months.
16661648|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
16661649|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
16661650|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
16661651|NCT02204696||Tonsillectomy|All participants will undergo baseline sleep study, a second preoperative sleep study after a period of watchful waiting, and a postoperative sleep study.
16661652|NCT02204683|Other|Aflibercept|Subjects who have had a vitrectomy previously
16661653|NCT02204683|Other|Aflibercept in Non-Vitrectomized eyes|Patients who have not had vitrectomy.
16661654|NCT02204670||Overweight Adolescents Performing Resistance Training|Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period. Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training. This will be the primary exposure variable. After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks. During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
16661655|NCT02204657|Active Comparator|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
16661656|NCT02204657|No Intervention|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
16661657|NCT02204644|Experimental|Flumatinib mesylate tablets|Flumatinib mesylate tablets 600mg qd for 12 months
16661658|NCT02204644|Active Comparator|Imatinib mesylate tablets|Imatinib mesylate tablets 400mg qd for 12months
16661659|NCT02204631|Experimental|Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).
~After enrollment and baseline data collection, the participant will be given the handbook. The clinician giving out the handbook will give an overview of the handbook and flip through the important sections. The clinician will encourage the participant to bring it back and forth.
~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception)."
16661712|NCT02204202||Grades A2-3|Double-lung transplant recipients with mild to moderate rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
16661660|NCT02204631|No Intervention|Non Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).
~The first group of participants will not receive the handbook but will receive the current standard care in the head and neck disease center.
~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception).
~At completion of Phase I, all 30 participants will also be given a copy of the handbook and an accompanying questionnaire."
16661661|NCT02204618|Experimental|cochlear implantation|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
16661662|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
16661663|NCT02204605|No Intervention|Control|Visits are not videotaped
16661664|NCT02204605|Experimental|Videoed Patients|Patients will have their visit videotaped.
16661665|NCT02204579|Experimental|NPSP795|intravenous
16661666|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
16661667|NCT02204540|Experimental|Monitoring by webcam|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming food) while being recorded and monitored by webcam.
16661668|NCT02204540|Active Comparator|In-person monitoring|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming good) while being monitored in-person.
16661669|NCT02204527|Experimental|vitamin D3|supplementation of 100.000 IU of vitamin D3
16661670|NCT02204527|Placebo Comparator|Placebo pill|Placebo
16661671|NCT02204514||Surgery for external snapping hip|
16661672|NCT02204501|Experimental|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
16661673|NCT02204501|Experimental|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
16661674|NCT02204488|Active Comparator|Total Joint Arthroplasty|Total Joint Arthroplasty
16661675|NCT02204488|Active Comparator|Trapeziectomy|Trapeziectomy
16661676|NCT02204475|Active Comparator|BOC/PR|All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
16661677|NCT02204475|Experimental|Grazoprevir/Elbasvir|Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
16661678|NCT02204462|Experimental|Newly diagnosed breast cancer|Patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e. index cancer). Patients will undergo FBnTP PET imaging for detection of malignant breast cancer.
16661679|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
16661680|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
16661681|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
16661682|NCT02204423|Experimental|Trans-Radial PCI|
16661683|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
16661684|NCT02204397|Experimental|INGAP Peptide, Ustekinumab|INGAP Peptide, Ustekinumab subcutaneous
16661685|NCT02204384|Experimental|HFD Meal: high fiber from food|HFD Meal: high amount of fiber from diet food sources (total fiber 9.7g; soluble fiber 5.4g)
16661686|NCT02204384|Experimental|HFS Meal: High fiber from supplement|HFS Meal: high amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - Fiber Mais, Nestlé
16661687|NCT02204384|Experimental|UF Meal: usual amount of fiber|UF Meal: usual amount of fiber (total fiber 2.4g; soluble fiber 0.8g)
16661713|NCT02204189|Experimental|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
16661771|NCT02203760|Experimental|Pazopanib plus Gemcitabine|Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
16661772|NCT02203760|Active Comparator|Pazopanib|Pazopanib 800 mg orally once daily
16661773|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
16661688|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
16661689|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
16661690|NCT02204358|Experimental|autologous bone marrow stem cells|Using collagen scaffold loaded with autologous bone marrow stem cells to treat severe intrauterine adhesions or endometrial dysplasia.
16661691|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
16661692|NCT02204332|Experimental|Cabazitaxel|"Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).
~Besides, patient will be treated with BSC."
16661693|NCT02204332|Other|Best Supportive Care|Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
16661694|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
16661695|NCT02204306|Other|TSER *2/*2 *2/*3|Patients with TSER *2/*2 *2/*3 genotypes will be assigned to this group and receive standard chemotherapy contains fluorouracil. (FOLFOX 6/XELOX/SOX)
16661696|NCT02204306|Other|TSER*3/*3 (fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
16661697|NCT02204306|Other|TSER*3/*3 (non-fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
16661698|NCT02204293|Experimental|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
16661699|NCT02204293|Placebo Comparator|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
16661700|NCT02204280||Type 2 Diabetic|Patiens with type 2 diabetic which conform to the WHO in 1999 diabetes diagnostic criteria.
16661701|NCT02204280||Diabetic With macro-or Microalbuminuria|Patients with diabetic with macro-or microalbuminuria.
16661702|NCT02204280||proteinuria,nondiabetic renal disease|Patients with proteinuria due to nondiabetic renal disease,such as IgA nephropathy,FSGS,Hypertensive renal damage and MN.
16661703|NCT02204280||healthy controls|Healthy person.
16661704|NCT02204267|Experimental|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
16661705|NCT02204267|No Intervention|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
16661706|NCT02204254|Experimental|Radiofrequence|3 sessions of radiofrequency at 3 weeks intervals V1, V2 (W3 or W4) and V3 (between W6 and W8), with clinical examination, evaluation of tolerance, adverse events report, photos, surface biopsy (SSSB), and confocal microscopy (V1 and V3). Follow up visit V4 (M6) with clinical evaluation, photos, SSSB, confocal microscopy, adverse events report and treatment satisfaction.
16661707|NCT02204254|Placebo Comparator|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
16661708|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:
~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.
~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).
~Treatment schedule for maintenance until progression or intolerance:
~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
16661709|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
16661710|NCT02204215|Experimental|electric acupuncture & conservative|Electric acupuncture therapy on four limbs 30 min each time, twice per day; or conservative treatment without electric acupuncture.
16661714|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
16661715|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
16661716|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
16661717|NCT02204163|Experimental|Eutropin|Eutropin 0.24mg/kg/week
16661718|NCT02204163|Active Comparator|Genotropin|Genotropin 0.24mg/kg/week
16661719|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
16661720|NCT02204137||Completion of Questionnaires|"Participants will complete an assessment consisting of the Falls Risk Questionnaire, a primarily self-administered geriatric assessment (GA) developed by the Cancer and Aging Research Group, a quality of life scale (FACT GOG/NTX) and the Falls Efficacy Scale-International.
~Each questionnaire contains approximately 150 questions and will take between 30 minutes and one hour to complete."
16661721|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
16661722|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
16661723|NCT02204111||Control Cluster|Care as usual
16661724|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
16661725|NCT02204098|Active Comparator|Cohort 1:Neoadjuvant endocrine therapy alone|"Will be treated with standard of care adjuvant endocrine therapy as determined by their treating physician
~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy"
16661726|NCT02204098|Experimental|Cohort 2:Neoadjuvant endocrine + mammaglobin-A DNA vaccine|"Will be treated with standard of care adjuvant endocrine therapy
~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy
~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)
~All study injections will be administered using a TriGrid electroporation device"
16661727|NCT02204098|Active Comparator|Cohort 3: Neoadjuvant chemotherapy alone|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician
~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28
~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in cohort 3"
16661728|NCT02204098|Experimental|Cohort 4: Neoadjuvant chemotherapy + mammoglobin-A DNA vaccine|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician
~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28
~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)
~All study injections will be administered using a TriGrid electroporation device
~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in either cohort 4"
16661729|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
16661730|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
16661731|NCT02204072|Experimental|BI 836845 & Enzalutamide|
16661732|NCT02204072|Active Comparator|Enzalutamide|
16661733|NCT02204059|Experimental|hMAb BIWA 4|Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4
16661734|NCT02204046|Experimental|BIWA 4|"Generic Name: Bivatuzumab
~186Re-labelled humanised monoclonal antibody BIWA 4"
16661735|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - low dose|
16661736|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - medium dose|
16661737|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - high dose|
16661738|NCT02204033|Experimental|186 Re - labelled hMAb BIWA 4 - escalating dose|
16661739|NCT02204020|Experimental|5-azacytidine|5-aza SC or IV 32mg/m2 - 75mg/m2 (based on dose escalation)
16661740|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
16661741|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
16661742|NCT02203994|Experimental|extracorporeal shock wave therapy (ESWT)|"one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 T-Top (Storz Medical AG, Tägerwilen, Switzerland))"
16661743|NCT02203968|Placebo Comparator|Normal saline|Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
16661744|NCT02203968|Active Comparator|Fibrinogen concentrate|Fibrinogen concentrate (RiaSTAP™) is a freeze-dried lyophilised plasma product presented in powdered form. The powder is reconstituted with water for intravenous injection at a concentration of 20 mg fibrinogen per ml. The concentrate is formulated with human albumin, L-arginine, sodium citrate and sodium chloride. RiaSTAP™ is supplied as a purified lyophilisate in a 1g dosage form and is reconstituted in 50 ml of sterile water. The final volume of RiaSTAP™ to be infused in this study will therefore be 300 ml.
16661745|NCT02203955|Active Comparator|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
16661746|NCT02203955|Placebo Comparator|Maltodextrin|4 chews (maltodextrin) daily for 12 months
16661747|NCT02203942||Vaginal Infections (BV, VVC, trich)|NAAT testing Amsel criteria Nugent score yeast culture TV culture
16661748|NCT02203929||Phakic eyes|Phakic eyes will be monitored with 4 preoperative optical coherence tomography scans as these patients will undergo phacoemulsification and intraocular lens implantation prior to their macular hole surgery
16661749|NCT02203929||Pseudophakic eyes|Phakic eyes will be monitored with 2 preoperative optical coherence tomography scans as there is no surgical intervention prior to the macular hole treatment.
16661750|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
16661751|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
16661752|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
16661753|NCT02203903|Experimental|Tumor associated antigen lymphocytes (TAA-T)|"For Arm A Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first.
~For Arm B Patients (pre-HSCT): TAA-T will be infused any time > 7 days after previous therapy for relapsed disease.
~For Arm C Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT.
~Five different dosing levels will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.
~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2 Dose Level Five: 1 x 108 cells/m2 (ONLY applicable to Arm A patients)
~Arm C patients will ONLY be enrolled at: Dose Level Four (4 x 107 cells/m2)"
16661754|NCT02203890||Apparently Healthy|Apparently healthy preschool children who attend 3 daycare centers of the Secretariat of Beneficials Works of the First Lady in Guatemalan Western Highlands
16661755|NCT02203877|Placebo Comparator|Maltodextrin|1 capsule/day for 16 weeks
16661756|NCT02203877|Experimental|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
16661757|NCT02203864|Experimental|BIBW2 with IL-2 secreting cell line|
16661758|NCT02203864|Experimental|BIBW2 without IL-2 secreting cell line|
16661759|NCT02203851|Experimental|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
16661760|NCT02203851|Experimental|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved <90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
16661761|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
16661762|NCT02203825|Experimental|CM-CS1 T-cell infusion|"The treatment will consist of a single infusion of CM-CS1 cells.
~The following dose levels will be evaluated:
~Cohort 1: 1x 10^6 CM-CS1 T-cells Cohort 2: 3x 10^6 CM-CS1 T-cells Cohort 3: 1x 10^7 CM-CS1 T-cells Cohort 4: 3x 10^7 CM-CS1 T-cells"
16661763|NCT02203812|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
16661764|NCT02203812|Placebo Comparator|Placebo Arm|Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
16661765|NCT02203799|Experimental|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
16661766|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).
~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules
~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.
~Response measured to 15 min session of a commercial slot machine game."
16661767|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).
~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules
~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.
~Response measured to 15 min session of a commercial slot machine game."
16661768|NCT02203773|Experimental|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
16661769|NCT02203773|Experimental|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
16661770|NCT02203773|Experimental|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
16661776|NCT02203734|Sham Comparator|Light Pressure Massage|Light Pressure Massage Therapy
16661777|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
16661778|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
16661779|NCT02203708|Active Comparator|BPD prevention|Supportive Program for Mother with BPD (SuPMother-B) : BPD mothers participate to prevention program in groups or/and house calls.
16661780|NCT02203708|No Intervention|Usual care of BPD mothers|BPD mothers don't participate to Supportive Program (SuPMother-B).
16661781|NCT02203695|Experimental|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT [Intensity-modulated radiation therapy]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
16661782|NCT02203695|Placebo Comparator|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
16661785|NCT02203669|Active Comparator|Structured In-Office Therapy|Structured In-Office Therapy: Study subjects will receive structured, therapist-supervised occupational/physical therapy twice per week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Patients in this arm will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These patients will also receive exercise and stretching handouts to use at home between therapy visits. Will complete the DASH at week 1 and week 4.
16661786|NCT02203669|No Intervention|No therapy|Study subjects in this arm will not receive post-operative occupational /physical therapy. Will complete the DASH at week 1 and week 4.
16661787|NCT02203669|Active Comparator|Home Therapy|Home Therapy: Study subjects will receive a handout of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist to complete independently at home for four (4) weeks. Will complete the DASH at week 1 and week 4.
16661788|NCT02203656|Placebo Comparator|Placebo Supplement|Daily placebo supplement for 30 days after discharge.
16661789|NCT02203656|Experimental|Nutritional Supplement|Daily nutritional supplement for 30 days after discharge.
16661790|NCT02203656|Experimental|In-home exercise + placebo|in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
16661791|NCT02203656|Experimental|In-home exercise + nutrition|in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
16661792|NCT02203656|Experimental|Testosterone|Single testosterone injection within 24 hours of hospital discharge.
16661793|NCT02203643|Experimental|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.
~After the end of consolidation all patients will be randomized to receive:
~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
16661794|NCT02203643|Experimental|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.
~After the end of consolidation all patients will be randomized to receive:
~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
16661795|NCT02203643|Experimental|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.
~After that all patients will be randomized to receive:
~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
16661796|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
16661797|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
16661798|NCT02203617|Experimental|educational baby books|books embedded with educational information (pediatric anticipatory guidance)
16661799|NCT02203617|Active Comparator|non-educational baby books|baby books given with same illustrations but no educational information
16661800|NCT02203617|No Intervention|no books|not given any baby books
16661801|NCT02203604|Experimental|Treatment (aldesleukin, ipilimumab)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.
~MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity."
16661802|NCT02203591|Experimental|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16661803|NCT02203591|Experimental|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16661804|NCT02203591|Active Comparator|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16661805|NCT02203591|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16661806|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16661807|NCT02203565|Experimental|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
16661856|NCT02203305|Experimental|Cochlear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
16661808|NCT02203552|Experimental|Arm I (minocycline hydrochloride)|Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
16661809|NCT02203552|Placebo Comparator|Arm II (placebo)|Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
16661810|NCT02203539|Experimental|bright light|Intervention: exposure to bright light
16661811|NCT02203539|Experimental|blue-enriched light|Intervention: exposure to blue-enriched light
16661812|NCT02203539|Experimental|normal light|Intervention: exposure to normal light
16661818|NCT02203513|Experimental|1-prexasertib|Prexasertib monotherapy treatment
16661819|NCT02203500|Experimental|Lacidipine|
16661820|NCT02203500|Experimental|Telmisartan|
16661821|NCT02203500|Experimental|Lacidipine + Telmisartan|
16661822|NCT02203487|Experimental|BIIF 1149 BS - single rising dose|
16661823|NCT02203487|Placebo Comparator|Placebo|
16661824|NCT02203474|Experimental|Tiotropium HFA BAI 5 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
16661825|NCT02203474|Experimental|Tiotropium HFA BAI 10 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
16661826|NCT02203474|Experimental|Tiotropium HFA BAI 15 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
16661827|NCT02203474|Active Comparator|SPIRIVA HandiHaler|2 inhalations from one 18 mcg capsule daily
16661828|NCT02203474|Placebo Comparator|Placebo|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
16661829|NCT02203461|Experimental|Group I|STRIBILD® Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
16661830|NCT02203461|Active Comparator|Group II|Truvada®/Kaletra® Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
16661831|NCT02203461|Experimental|Group III|Truvada®/Prezista®/Norvir® Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
16661832|NCT02203448||FACET WEDGE spinal system|The FACET WEDGE spinal system provides additional stability to a spinal segment to enhance fusion conditions.
16661833|NCT02203422|Experimental|combination treatment group|60 enrolled patients are randomly picked up to take cyclosporin A in combination with rhTPO at the indicated dose.
16661834|NCT02203422|Active Comparator|single treatment group|60 enrolled patients are randomly picked up to take cyclosporin A at the indicated dose.
16661835|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
16661836|NCT02203396|Experimental|Severe Aplastic Anemia|Drug: rabbit ATG, Cyclosporine, Levamisole
16661837|NCT02203383||Pts with CSA for CRT implantation|Patients with heart failure (EF<40%) and moderate to severe CSA (>15 events per hour, >50% Central)
16661838|NCT02203383||No Sleep Apnoea for CRT implantation|Heart failure (EF < 40%) but no significant sleep apnoea (<5 events per hour).
16661839|NCT02203370||all patients|All patients will be measured throughout the procedure with both devices. There no further separation into groups as both sensors can be placed on the same patient.
16661840|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
16661841|NCT02203357|Experimental|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
16661842|NCT02203357|Experimental|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
16661843|NCT02203344||Light sedation|Light sedation is defined as RASS of +1 to -2.
16661844|NCT02203344||Deep sedation|Deep sedation is defined as RASS of -3 to -5
16661845|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
16661846|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
16661847|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
16661848|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
16661849|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
16661850|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
16661851|NCT02203318||control|healthy children with normal bilateral testis
16661852|NCT02203318||undescended palpable testis|patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area
16661853|NCT02203318||non-paplpable testis|patient whose affected testis is not palpable during the physical examination
16661854|NCT02203305|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
16661855|NCT02203305|Other|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
16662382|NCT02199886|Experimental|BIBH 1|dose escalation: 0.5, 2, 10 or 20mg/m**2, 7 days prior to surgery
16661857|NCT02203292|Active Comparator|Liberal|Liberal transfusion strategy. Patients will have red blood cells transfused only if Hb < 9.0 g/dL
16661858|NCT02203292|Experimental|Restrictive|Restrictive transfusion strategy. Patients will have red blood cells transfused only if Hb < 7.0 g/dL
16661859|NCT02203279|Experimental|Rebase II Fast|The direct chair-side relining materiel 'Rebase II Fast' will be used.
16661860|NCT02203279|Experimental|Flexacryl|The direct chair-side relining material Flexacryl will be used
16661861|NCT02203279|Experimental|Vertex|Vertex is a heat-cured resin material which is going to be used for indirect relining
16661862|NCT02203266|Experimental|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
16661863|NCT02203266|Active Comparator|Demonstration|Current best practice - inhaler technique education
16661864|NCT02203266|No Intervention|Control|Usual care in the community pharmacy setting
16661865|NCT02203253|Active Comparator|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
16661866|NCT02203253|Placebo Comparator|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
16661867|NCT02203240|Experimental|Cocoa|3 servings of polyphenol-rich cocoa beverage consumed per day.
16661868|NCT02203240|Placebo Comparator|Placebo|3 servings of non-cocoa beverage consumed per day.
16661869|NCT02203227|Placebo Comparator|Placebo|Capsule containing 250 mg of placebo, two times a day
16661870|NCT02203227|Experimental|BioTurmin|Capsule containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
16661871|NCT02203227|Experimental|BioTurmin-WD|Capsule containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
16661872|NCT02203227|Experimental|MaQxan|Capsule containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
16661873|NCT02203214||Ligamys|All patients treated with Ligamys can be included in the study. Patients must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled.
16661874|NCT02203201||Study group|NCWS patients who had showed a negative celiac disease serology and a Marsh 0-1 duodenal histology, but who had displayed a positive EmA assay in the culture medium of the duodenal biopsies (EmA-biopsy).
16661875|NCT02203201||Control group|NCWS patients with negative EmA-biopsy.
16661876|NCT02203188|Experimental|Lid debridgement scaling|Perform lid debridgement scaling
16661877|NCT02203188|No Intervention|Control|No Treatment
16661878|NCT02203175|Placebo Comparator|Group C (plasebo): no pretreatment|saline injection
16661879|NCT02203175|Active Comparator|propofol and fentanyl|propofol 50 mg with fentanyl 50 mcgr iv during anesthesia induction ones time
16661880|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
16661881|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
16661882|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
16661883|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
16661884|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
16661885|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
16661886|NCT02203136||Muscle Invasive Bladder Cancer (MIBC)|During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
16661887|NCT02203123|Other|Ultrasound, inferior vena cava, aorta, normal saline|
16661888|NCT02203097|Experimental|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
16661889|NCT02203084||Children with Chronic Medical Conditions|The Social Determinants Questionnaire will be administered to the three groups of children with chronic diseases (cystic fibrosis, diabetes mellitus type I, or chronic renal insufficiency). The questionnaire questions will be asked by a research assistant. Each participant will have the same general and background information questions then will have questions specific to their chronic medical condition.
16661890|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
16661891|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
16661892|NCT02203058|Experimental|Pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) with pursed-lips breathing.
16661893|NCT02203058|Placebo Comparator|No pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) without pursed-lips breathing.
16661926|NCT02202915|Experimental|Fidelity Checklist Arm|Therapists are receiving training using the fidelity Checklist
16661927|NCT02202902|Experimental|Group 1 : 1H magnetic resonance spectroscopy and CMRI|Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance
16661894|NCT02203045|Active Comparator|Tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
16661895|NCT02203045|Experimental|Non- tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
16661896|NCT02203032|Experimental|Open-label ustekinumab|
16661897|NCT02203032|Experimental|Double-blind guselkumab|
16661898|NCT02203032|Experimental|Double-blind ustekinumab|
16661899|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
16661900|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
16661901|NCT02203006|Other|OVIHD|Cohort and a blood sample collection will be done with data and blood of HIV infected patients
16661902|NCT02202993|Experimental|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.
~This will be given concurrently with hypofractionated radiation therapy."
16661903|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
16661904|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
16661905|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
16661906|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
16661907|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
16661908|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
16661909|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
16661910|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
16661911|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
16661912|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
16661913|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
16661914|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
16661915|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
16661916|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
16661917|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
16661918|NCT02202967|Active Comparator|Misoprostol|Misoprostol
16661919|NCT02202967|Placebo Comparator|Placebo|Placebo
16661920|NCT02202954|Active Comparator|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.
~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
16661921|NCT02202954|No Intervention|Conventional rehabilitation|conventional therapy in the community
16661922|NCT02202941|Experimental|Procalcitonin guided treatment|Patients who will be randomized to this arm will receive antibiotics therapy based on procalcitonin-guided algorithm.
16661923|NCT02202941|Active Comparator|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
16661924|NCT02202928|Sham Comparator|Chemo-radiotherapy|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.
16661925|NCT02202928|Experimental|DC-CIK|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.
16662383|NCT02199873|Experimental|BIIX 1 XX - single rising dose|
16661928|NCT02202902|Experimental|Group 2 : 1H magnetic resonance spectroscopy and CMRI|Group 2: Cushing's syndrome patients with normal glucose intolerance
16661929|NCT02202902|Experimental|Group 3 : 1H magnetic resonance spectroscopy and CMRI|age-, sex- and BMI-matched healthy volunteers
16661930|NCT02202876|Active Comparator|Aim 1: Children with Cystic Fibrosis|Cystic Fibrosis children aged 1 to 9 years with normal glucose tolerance receiving Oral Glucose Tolerance Test
16661931|NCT02202876|Active Comparator|Aim 1: Control Children|Children with out Cystic Fibrosis aged 1 to 9 years controls with normal glucose tolerance receiving Oral Glucose Tolerance Test
16661932|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - High Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating High Glycemic Index Meal
16661933|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - Low Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating Low Glycemic Index Meal
16661934|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Test Soda|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of a test soda. A week later these participants will have an Oral Glucose Tolerance Test.
16661935|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Fruit Juice|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of fruit juice. A week later these participants will have an Oral Glucose Tolerance Test.
16661936|NCT02202863|Experimental|Red Wine Grape Pomace Flour (WGPF)|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
16661937|NCT02202863|No Intervention|Control|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks.
16661938|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
16661939|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
16661940|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
16661941|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
16661942|NCT02202824|Experimental|Survey questionnaire version 1|Study participants will receive version 1 of the survey questionnaire
16661943|NCT02202824|Experimental|Survey questionnaire version 2|Study participants will receive version 2 of the survey questionnaire
16661944|NCT02202824|Experimental|Survey questionnaire version 3|Study participants will receive version 3 of the survey questionnaire
16661945|NCT02202811|Experimental|Obstructive Sleep Apnea|Forced Desynchrony, OSA
16661946|NCT02202811|Placebo Comparator|Control|Forced Desynchrony, Control
16661947|NCT02202798||Syringe device|Endotracheal tube cuff pressure measured by 2 new syringe devices.
16661948|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
16661949|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
16661950|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
16661951|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
16661952|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
16661953|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
16661954|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
16661955|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
16661956|NCT02202746|Experimental|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
16661957|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
16661958|NCT02202733|Other|Cooking|A skill-based cooking intervention for caretakers of an overweight/obese child aged 3-10 years.
16661959|NCT02202720|Experimental|sevoflurane|
16661960|NCT02202707|Other|Gabapentin|Open label single arm study. All participants will receive Gabapentin.
16661961|NCT02202694|Experimental|Intervention|Culturally Adapted Cognitive Behavior Therapy
16661962|NCT02202694|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
16661963|NCT02202681|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
16661964|NCT02202668|Experimental|TRS|
16662007|NCT02202434|Active Comparator|CoreValve TAVR System - Randomized|Transcatheter aortic valve replacement (TAVR) with CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
16661965|NCT02202642|Experimental|limbal stem cells|"Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of limbal stem cells need special cell-cell contact and cell-extracellular matrix interaction to support their survival"
16661966|NCT02202629|Placebo Comparator|Cherry flavoured beverage 1|10floz cherry flavoured test article
16661967|NCT02202629|Experimental|Cherry flavoured beverage 2|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
16661968|NCT02202629|Experimental|Cherry flavoured beverage 3|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
16661969|NCT02202629|Experimental|Cherry flavoured beverage 4|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
16661970|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
16661971|NCT02202603|Active Comparator|Teriparatide group 1|Subcutaneous injection of Teriparatide
16661972|NCT02202603|Placebo Comparator|excipients|Oral pill without API
16661973|NCT02202603|Experimental|API|Oral administration of pill with API
16661974|NCT02202603|Experimental|API optimization 1|Oral administration of pill with API, for PK optimization #1
16661975|NCT02202603|Experimental|API optimization 2|Oral administration of pill with API, for PK optimization #2
16661976|NCT02202603|Experimental|API optimization 3|Oral administration of pill with API, for PK optimization #3
16661977|NCT02202603|Experimental|API optimization 4|Oral administration of pill with API, for PK optimization #4
16661978|NCT02202603|Experimental|API optimization 5|Oral administration of pill with API, for PK optimization #5
16661979|NCT02202603|Experimental|API optimization 6|Oral administration of pill with API, for PK optimization #6
16661980|NCT02202603|Experimental|API optimization 7|Oral administration of pill with API, for PK optimization #7
16661981|NCT02202603|Active Comparator|Teriparatide group 2|Subcutaneous injection of Teriparatide
16661982|NCT02202603|Experimental|Excipients|Oral pill without API
16661983|NCT02202603|Experimental|API Optimized|expanded group size with API in optimized dosage and administration form.
16661984|NCT02202590|Experimental|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
16661985|NCT02202577|Experimental|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
16661986|NCT02202577|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
16661987|NCT02202564|Experimental|LT+ADV-TK|Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.
16661988|NCT02202564|Active Comparator|LT|Orthotopic liver transplantation
16661989|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
16661990|NCT02202538|Experimental|Indego|Indego
16661991|NCT02202525||Essential arterial hypertension|Patients with essential arterial hypertension needing a new antihypertensive therapy
16661992|NCT02202512|Experimental|BI 1060469 low dose|Low-Dose,Tablet,oral administration with 240 ml water,over 10 days
16661993|NCT02202512|Experimental|BI 1060469 high dose|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
16661994|NCT02202512|Active Comparator|Cimetidine|
16661995|NCT02202512|Active Comparator|Naproxen|
16661996|NCT02202512|Experimental|BI 1021958|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
16661997|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
16661998|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
16661999|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
16662000|NCT02202486||Migraine with aura|Brain MRI
16662001|NCT02202486||Migraine without aura|Brain MRI
16662002|NCT02202486||Chronic migraine|Brain MRI
16662003|NCT02202473|Active Comparator|Lamivudine|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd
16662004|NCT02202473|Experimental|Lamivudine+Oxymatrine Capsules|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.
16662005|NCT02202447|Experimental|EC1169|"PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
~PART A: EC1169 given as IV bolus QW on Weeks 1 and 2 of a 3 week cycle. Dose based on dose escalation plan starting with 0.2 mg/m2
~PART B: EC1169 cohort 1 - taxane naive mCRPC patients that have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible).
~PART B: EC1169 cohort 2 - taxane exposed mCRPC patients who have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and who have progressed subsequent to receiving > 2 cycles of a taxane-based regimen for mCRPC."
16662006|NCT02202434|Experimental|Lotus Valve System - Randomized|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
16662008|NCT02202434|Experimental|Lotus Valve Sytem - Single-arm 21mm Cohort|Transcatheter aortic valve replacement (TAVR) with 21mm Lotus Valve System
16662009|NCT02202434|Experimental|Lotus Valve System - Single-arm Continued Access Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
16662010|NCT02202434|Experimental|Lotus Valve System - Single-arm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
16662011|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm Edge Nested Registry|Transcatheter aortic valve replacement (TAVR) with 23mm, 25mm and 27mm LOTUS Edge Valve System.
16662012|NCT02202421|Active Comparator|T-ABA Parent Training Only|Participants in the T-ABA Parent Training Only group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
16662013|NCT02202421|Experimental|T-ABA Parent Group + Individual Therapy|Participants in the T-ABA Parent Group plus Individual Therapy group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions.
16662014|NCT02202408|Experimental|SKI2670|"Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group
~-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4"
16662015|NCT02202408|Placebo Comparator|Placebo|Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)
16662016|NCT02202395|Active Comparator|0.25mg|LTS 0.25mg,qd MTX qw
16662017|NCT02202395|Active Comparator|0.5mg|LTS 0.5mg, qd MTX qw
16662018|NCT02202395|Active Comparator|1.0mg|LTS 1.0mg,qd MTX qw
16662019|NCT02202395|Placebo Comparator|Placebo|Placebo qd MTX qw
16662020|NCT02202382|Placebo Comparator|non-V + P group|no surgery and placebo (12 weeks)
16662021|NCT02202382|Active Comparator|V + P group|Surgery with placebo (12 weeks)
16662022|NCT02202382|Active Comparator|non-V + KRG group|no surgery with KRG (korean red ginseng, 1.5 gm daily 12weeks)
16662023|NCT02202382|Experimental|V + KRG group|Surgery with KRG (1.5 gm daily 12weeks)
16662024|NCT02202369|Experimental|Multimodal Analgesia (MMA) Treatment|
16662025|NCT02202369|Active Comparator|Standard of Care Pain Managment Protocol|
16662026|NCT02202356|Experimental|ALS-008176 Single Dose|Single dose of ALS-008176 administered orally as a suspension
16662027|NCT02202356|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally as a suspension
16662028|NCT02202356|Experimental|ALS-008176 Multiple Doses|Multiple doses of ALS-008176 administered orally as a suspension
16662029|NCT02202356|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo administered orally as a suspension
16662030|NCT02202343|Experimental|School-based health and nutrition education|
16662031|NCT02202330|Placebo Comparator|Standard Care, Organized Discharge|Stroke patients are given instructions before discharge regarding diet, need for rehabilitation, possible complications, medication use and information booklets are also handed out. This information is imparted by a multidisciplinary team consisting of a neuro physician, a stroke nurse, a dietitian and a physiotherapist. These are verbal instructions and handouts are written in English. On the day of discharge, or 24 hours prior to discharge, a discharge coordinator details the skills learnt . A detailed written discharge summary is given out detailing all aspects of care, follow-up, medications and test results.
16662032|NCT02202330|Experimental|Video Arm, Standard Discharge|"Intervention is as follows:
~5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)
~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.
~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
16662033|NCT02202317|Experimental|Y90 Based PET/CT Scan|
16662034|NCT02202304|Experimental|Chlorhexidine/Thymol varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by painting it over the surfaces of these teeth."
16662035|NCT02202304|Placebo Comparator|Placebo varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush and painting it on all the surfaces of these teeth.."
16662036|NCT02202291|Experimental|Patient with Raynaud's phenomenon|
16662037|NCT02202278||ovarian hyperstimulation patients|Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit >45%, weight gain >2 kg, white blood cell count >15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of >50 ml/min, liver dysfunction.
16662038|NCT02202278||without ovarian hiperstimulation|Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS
16662039|NCT02202265|Active Comparator|Control diet (standard dietary)|Patients will receive a control diet based on standard dietary guidelines
16662040|NCT02202265|Experimental|Olive oil (30ml a day)|Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day
16662041|NCT02202265|Experimental|Nuts (30g a day)|Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day
16662042|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.
~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
16662043|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.
~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
16662044|NCT02202239|Experimental|Group E|Etomidate was used in both induction and maintenance of anesthesia.
16662045|NCT02202239|Active Comparator|Group P|Propofol was used in both induction and maintenance of anesthesia.
16662046|NCT02202226|Experimental|Lu AF35700 oral solution (1 mg/mL)|Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
16662047|NCT02202226|Placebo Comparator|Matching placebo|Oral solution
16662048|NCT02202213|Experimental|Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg|"Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone
~Three times daily oral dosing for 14 days."
16662049|NCT02202213|Placebo Comparator|Matching placebo|Daily oral dosing matching the experimental arm.
16662050|NCT02202200|Experimental|PD-0332991|
16662051|NCT02202187|Experimental|GSK2140944|Dose range 100mg to 3000mg single dose
16662052|NCT02202187|Placebo Comparator|Matching Placebo|Placebo
16662053|NCT02202174||Supraglottic Airway Device|Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
16662054|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
16662055|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
16662056|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
16662057|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
16662058|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
16662059|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
16662060|NCT02202148||alcohol withdrawal|
16662061|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
16662062|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
16662063|NCT02202122||Study Group|OSA Scoring
16662064|NCT02202109|Active Comparator|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
16662065|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
16662066|NCT02202096|Experimental|Intervention (plus usual care)|Patient education: One-on-one visit Discharge planning: Assessment of barriers to discharge Medication reconciliation: Patient medication review Appointment before discharge: Additional measure to ensure awareness of next clinic visit Transition coach Patient-centered discharge instructions: Enhanced Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology Timely follow-up: Barriers to clinic follow-up visits will be discussed Timely PCP communication Follow-up telephone call Patient hotline: 24 hour follow-up following call to Ask My Nurse number
16662067|NCT02202096|No Intervention|Usual Care|Usual care-Standard of care that all colorectal cancer patients normally receive
16662068|NCT02202083|Experimental|oxytocin|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.
~This group is term gestaion,with bishop score less than 6."
16662069|NCT02202070|Experimental|Botox injection first, followed by placebo|50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
16662070|NCT02202070|Experimental|Placebo injection first, followed Botox|Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
16662071|NCT02202057||Parkinson's disease|Men and women with Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation and Fluoroscopic swallowing evaluation.
16662072|NCT02202057||Healthy adults|Men and women without Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation.
16662073|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
16662074|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
16662075|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
16662076|NCT02202018|Experimental|Active KT Intervention|CKD clinics receiving the active knowledge translation intervention.
16662077|NCT02202018|No Intervention|Usual standard of care|Clinics will continue their standard of care education and approach to use of home dialysis.
16662078|NCT02202005|Experimental|Nevirapine|
16662079|NCT02202005|Active Comparator|Viramune®|
16662126|NCT02201719||Hysterectomy Adenomyosis|Adenomyosis present
16662127|NCT02201719||Hysterectomy no adenomyosis|Adenomyosis not present
16662080|NCT02201992|Experimental|Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16662081|NCT02201992|Active Comparator|Arm B (observation)|Patients undergo observation.
16662082|NCT02201979||Breast lift in combination with implants.|Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
16662083|NCT02201966||Female gymnasts with low back pain|Subset of competitive female gymnasts who report significant low back pain that affects their ability to perform gymnastics.
16662084|NCT02201966||Female gymnasts without low back pain|Subset of competitive female gymnasts who deny significant low back pain that affects their ability to perform gymnastics.
16662085|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
16662086|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
16662087|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
16662088|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
16662089|NCT02201927|Experimental|patient with right parietal lobe lesion|Patient with right parietal lobe lesion
16662090|NCT02201927|Experimental|patient stroke|patient with cerebral vascular accident
16662091|NCT02201927|Experimental|healthy volunteers|healthy volunteers
16662092|NCT02201914|Experimental|Clomiphene citrate|
16662093|NCT02201914|Experimental|Daily FSH and LH plus Cetrorelix|
16662094|NCT02201914|Experimental|Triptorelin plus daily FSH and LH|
16662095|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
16662096|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
16662097|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
16662098|NCT02201888|Experimental|Computer-assisted cognitive training|Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
16662099|NCT02201888|Active Comparator|Computerized active condition|Patients allocated to this condition completed the same number of sessions as the cognitive training group but followed a computerized typing program (www.rapidtyping.com). This had similar design characteristics to the CRT condition, in that it was hierarchically organized with exercise level of difficulty being adjusted to the individual's level of performance and feedback being given at the end of each exercise. Additionally, patients in this condition played computerized games requiring typing (crosswords, word puzzles, etc) and were taught basic internet navigation by a supervisor. Exposure to the computer was of equivalent duration to the CRT condition.
16662100|NCT02201888|Placebo Comparator|Treatment as usual|Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities
16662101|NCT02201875||Healthy subjects|male, aged 18-65 moderately trained healthy, no treatment
16662102|NCT02201875||obstructive sleep apneas|patients with apnea/hypopnea index > 15 BMI < 30 Age < 50 yrs
16662103|NCT02201875||cardiac failure|NYHA class I to III ejection fraction < 40% age < 65 yrs BMI < 30
16662104|NCT02201862||Euploid Subjects|Subject's with fetal euploidy confirmed by chromosome analysis
16662105|NCT02201862||Aneuploid Subjects|Subject's with fetal aneuploidy confirmed by chromosome analysis
16662106|NCT02201849|Experimental|Study Drug|Oral capsules
16662107|NCT02201849|Active Comparator|Active Control|Oral capsules
16662108|NCT02201849|Placebo Comparator|Placebo|Oral capsules
16662109|NCT02201836|Active Comparator|One time music therapy session|One time music therapy session which consists of music meditation, including as assessment/evaluation of confined body breathing function as expressed through drawing and coloring post music imagery session. This is followed by an entrainment wind playing/breath expansion music therapy intervention. At the end of the session, the subjects are given a donated wind instrument for play at home.
16662110|NCT02201836|Active Comparator|Weekly group music therapy intervention|The weekly group music therapy intervention consists of children and teens using guided visualization and expressing their fears and or fantasies related to breathing with one another. This is followed by creative music improvisations with part-playing on flutes, slide whistles, recorders and melodicas.
16662111|NCT02201836|No Intervention|Control|
16662112|NCT02201823|Experimental|ABTL0812|ABTL0812 oral
16662113|NCT02201810|Experimental|2nd level intervention: Rate Reduction|Rate reduction intervention
16662114|NCT02201810|Experimental|2nd level intervention: Recycling|Recycling Group
16662115|NCT02201810|Experimental|2nd level intervention: Choice|Choice Group
16662116|NCT02201797|Experimental|DCE and DWI MRI|MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
16662117|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
16662118|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
16662119|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
16662120|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
16662121|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
16662122|NCT02201758|Placebo Comparator|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
16662123|NCT02201758|Experimental|flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
16662124|NCT02201732|Experimental|Arm A : Operative hysteroscopy|operative hysteroscopy with direct visualization
16662125|NCT02201732|Active Comparator|Arm B : Aspirative curettage|curettage is the standard surgical treatment in most centers
16662128|NCT02201706|Experimental|Multi-electrocoagulation retinectomy|Retinal re-detachment in eyes with silicone oil filled,a modified surgery named Multi-electrocoagulation retinectomy will be used to re-attach the retina.
16662129|NCT02201693|Experimental|Cyclic exclusive MODULEN IBD|Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
16662130|NCT02201693|Experimental|MODULEN IBD supplementation (25% of caloric requirements)|MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
16662131|NCT02201680||parents and children|Anxiety tests
16662132|NCT02201667|Experimental|Ticagrelor group|Patients wil be given 180 mg loading dose of ticagrelor and 300mg loading dose of aspirin followed by PCI, then will receive 90 mg ticagrelor twice daily with aspirin maintenance dose to 30 days after randomization.
16662133|NCT02201667|Active Comparator|Clopidogrel group|Patients will be given clopidogrel 300mg loading dose and 300mg loading dose of aspirin followed by PCI, then will receive 75mg clopidogrel once with aspirin maintenance dose to 30 days after randomization.
16662134|NCT02201654|Other|EBUS patients|All patients in our study are in the same arm, as each patient serves as their own internal control. More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
16662135|NCT02201641|Experimental|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
16662136|NCT02201641|Experimental|Cone Beam computed tomography (CBCT)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
16662137|NCT02201641|Active Comparator|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
16662138|NCT02201641|Active Comparator|Glass ionomer cement ( Fuji IX™)|Glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
16662139|NCT02201628|Experimental|Nasopharyngeal and oesophageal temperatures|An oesophageal and nasopharyngeal temperature probe will be placed and temperature will be measured at these site
16662140|NCT02201615|Experimental|Perineal Massage & Control|"Perineal Massage every 30 min, a 10 min 4 times in the first stage of labour, 1 times in the second stage of labour.
~Control routine care procedure at the clinic."
16662141|NCT02201602|Experimental|Gliclazide|Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
16662142|NCT02201602|Active Comparator|Glibenclamide|Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks
16662143|NCT02201589|Experimental|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
16662144|NCT02201576|Experimental|Bortezomib|Five plasma exchanges, two cycles of bortezomib + dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
16662145|NCT02201576|Active Comparator|Control|Five plasma exchanges, dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
16662146|NCT02201563|Experimental|Minocycline|oral Minocycline 100 mg twice a day for 3 months.
16662147|NCT02201550||Liraglutide|Patients with type 2 diabetes undertaking treatment with liraglutide
16662148|NCT02201537|Other|Imag-NCT|"The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant.
~The functional imaging examinations will be held as follows:
~1st stage - the conventional Doppler ultrasound:
~2nd stage - the elastography:.
~Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound.
~Renal biopsy will be performed after the functional ultrasound at 3 and 12 months."
16662149|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
16662150|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
16662151|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
16662152|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
16662153|NCT02201511|Experimental|Arm 1|
16662154|NCT02201511|Experimental|2|
16662155|NCT02201511|Experimental|3|
16662156|NCT02201511|Experimental|4|
16662157|NCT02201498|Active Comparator|Formocresol/OZE|Conventional pulpotomy technique, with formocresol and zinc oxide eugenol
16662158|NCT02201498|Active Comparator|Biodentine|New technique, with biodentine
16662159|NCT02201485|Active Comparator|PTA in combination with stent-placement|In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
16662160|NCT02201485|Active Comparator|PTA alone|In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
16662161|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
16662162|NCT02201459|Active Comparator|Nilotinib|Control arm, this compound been licensed in this indication.
16662163|NCT02201459|Experimental|Peg-IFN alfa 2a (Pegasys®) and Nilotinib|Arm testing the efficacy of a combination of nilotinib and Peg-IFN alfa 2a as frontline therapy for first line chronic phase CML patients.
16662164|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
16662165|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
16662166|NCT02201433||medical staff and member of an association|"members of medical staff and member of an association of parents of premature infants.
~This cohort is necessary to build protocol interview for part 2 of the study"
16662167|NCT02201433||fathers|fathers of preterm newborns
16662168|NCT02201433||fathers or médical staff|This cohort is build for data validation. We will include fathers who have experienced this situation. Caregivers of NICU who are not participating in the first part
16662169|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
16662170|NCT02201407||CHB Participants Treated With Peginterferon alfa-2a|As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with local labeling and not directed by the protocol. Participants with CHB who are receiving peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics, and in line with the local labeling will be followed for the duration of treatment with peginterferon alfa-2a (48 weeks) and up to 24 weeks after peginterferon alfa-2a treatment (72 weeks in total).
16662171|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
16662172|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
16662173|NCT02201381|Experimental|Metabolic Treatment|"Subjects will take the following treatments and have their data collected from their medical records every 3 months.
~Oral atorvastatin up to 80mg uid, for study duration.
~Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.
~Oral doxycycline 100mg uid, for study duration.
~Oral Mebendazole 100mg uid, for study duration."
16662174|NCT02201368|Experimental|Triheptanoin|
16662175|NCT02201368|Active Comparator|MCT (Medium-Chain Triglycerides)|
16662176|NCT02201355|Experimental|chemoradiation|Hypofractionated, PET-directed, Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy
16662177|NCT02201342|Experimental|Udenafil Dose Level 1 qd|Udenafil tablet dose Level 1 daily for 5 days
16662178|NCT02201342|Experimental|Udenafil Dose Level 1 bid|Udenafil Dose Level 1 twice daily for 5 days.
16662179|NCT02201342|Experimental|Udenafil Dose Level 2 qd|Udenafil tablet dose level 2 once daily for 5 days.
16662180|NCT02201342|Experimental|Udenafil Dose Level 2 bid|Udenafil tablet dose level 2 twice daily for 5 days
16662181|NCT02201342|Experimental|Udenafil Dose Level 3 qd|Udenafil tablet dose level 3 daily for 5 days
16662182|NCT02201342|No Intervention|No Drug|No drug
16662183|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
16662184|NCT02201316|Experimental|Sequence 1 (ABC)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
16662185|NCT02201316|Experimental|Sequence 2 (ACB)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
16662186|NCT02201316|Experimental|Sequence 3 (BAC)|Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
16662187|NCT02201316|Experimental|Sequence 4 (BCA)|Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
16662188|NCT02201316|Experimental|Sequence 5 (CAB)|Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
16662189|NCT02201316|Experimental|Sequence 6 (CBA)|Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
16662190|NCT02201303|Experimental|Part 1|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
16662191|NCT02201303|Experimental|Part 2|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
16662192|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
16662193|NCT02201277|Experimental|Denali|Denali IVC Filter
16662194|NCT02201277|Experimental|Option|Option Elite IVC Filter
16662195|NCT02201264||Primary PCI for STEMI patients|Primary PCI for patients presenting with ST elevation MIs
16662196|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
16662197|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
16662308|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
16662198|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in tube)|1% diclofenac sodium plus 3% menthol gel (in 30g aluminium tube). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
16662199|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in roll-on device)|1% diclofenac sodium plus 3% menthol gel (in roll-on applicator device supplied in 30g plastic bottles). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
16662200|NCT02201238|Active Comparator|Diclofenac sodium tablets|50mg diclofenac sodium tablets administered orally, three times daily for three consecutive days with 6h between adjacent doses on the same day
16662201|NCT02201238|Active Comparator|Voltaren gel|Voltaren gel supplied in 100g aluminium tube. Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
16662202|NCT02201225|Active Comparator|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
16662203|NCT02201225|Sham Comparator|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
16662204|NCT02201212|Experimental|Everolimus|"Everolimus
~Fixed doses orally once a day per each 28 day cycle
~Participants will stay on study as long as they do not progress for a maximum of 24 months.
~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
16662205|NCT02201199|Active Comparator|insulin glargine U100|1 single dose
16662206|NCT02201199|Experimental|insulin glargine U200|1 single dose
16662207|NCT02201199|Experimental|insulin glargine U500|1 single dose
16662208|NCT02201186|Experimental|manuka honey enema treatment|Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.
16662209|NCT02201173|Experimental|Locomotor Training|
16662210|NCT02201160|Active Comparator|omega 3|The subjects will take 4 capsules/day during 6 months. Each capsule of the active n-3 PUFA supplement contained 500 mg of fish oil (each capsule provides 300 mg of n-3 PUFA (EPA+DHA) with 3.75 U vitamin E to prevent peroxidation).
16662211|NCT02201160|Placebo Comparator|Sun Flower|The subjects will take 4 capsules/day during 6 months. The placebo capsule contained 500 mg of sunflower oil with 3.75 U vitamin E.
16662212|NCT02201147|Experimental|cold biopsy polypectomy|
16662213|NCT02201147|Experimental|Cold snare polypectomy|
16662214|NCT02201134|Other|sevoflurane|
16662215|NCT02201121|Experimental|phenylephrine group, dopamine group, ephedrine group|"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.
~dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level."
16662218|NCT02201095|No Intervention|Normal care|Normal care - no active warming
16662219|NCT02201095|Active Comparator|Forced air warming|Underbody forced air warming blanket
16662220|NCT02201095|Active Comparator|Conduction warming mattress|Underbody conduction warming mattress
16662221|NCT02201082|Experimental|Nebulization and airway clearance technique|nebulization combined to airway clearance
16662222|NCT02201082|Active Comparator|Nebulization|nebulization
16662223|NCT02201069|Experimental|health coaching|12 weeks of health coaching using weekly contact in the first month and biweekly contacts in months 2-3.
16662224|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
16662225|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
16662226|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
16662227|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
16662228|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
16662229|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
16662230|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
16662231|NCT02201043|Active Comparator|Thalidomide 150mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd.po.to the end
16662232|NCT02201043|Active Comparator|Thalidomide 100mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end
16662233|NCT02201043|Placebo Comparator|Placebo|Placebo po.
16662234|NCT02201030|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
16662235|NCT02201030|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
16662236|NCT02201004|Experimental|tofogliflozin|Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
16662237|NCT02201004|Placebo Comparator|placebo|Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
16662238|NCT02200991|Experimental|Lixisenatide|"Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.
~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
16662239|NCT02200991|Active Comparator|Sitagliptin - Januvia|"50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.
~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
16662309|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
16662344|NCT02200185|Placebo Comparator|IV titrated morphine|"patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).
~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS > 50%, 30 minutes after the beginning of the protocol."
16662240|NCT02200978|Active Comparator|ATO and chemotherapy|"Induction:
~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).
~Consolidation 1:
~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20 mg (1-3 years), or 30 mg ( > 3 years), dexamethasone 2mg.
~Consolidation 2:
~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Consolidation 3:
~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Maintenance:
~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance."
16662241|NCT02200978|Experimental|RIF and chemotherapy|"Induction:
~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).
~Consolidation 1:
~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20mg (age 1-3 years), or 30mg (age > 3 years), dexamethasone 2mg.
~Consolidation 2:
~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Consolidation 3:
~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Maintenance:
~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment."
16662242|NCT02200965|Active Comparator|Received a letter on 3 occasions|"My Diabetes, My Information, My Plan Document:
~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.
~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
16662243|NCT02200965|Active Comparator|Received letter on 1 occasion|"My Diabetes, My Information, My Plan Document:
~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.
~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
16662244|NCT02200952||Patients at risk of OHSS|Patients at risk of OHSS on the oocytes triggering day with an oestradiol > 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm
16662245|NCT02200939|Experimental|Partial-thickness tear|Medium or large partial-thickness tear or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
16662246|NCT02200939|Experimental|Full-thickness tear|Medium or large full-thickness tear of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
16662247|NCT02200926|Experimental|Placebo|The breathing was performed normally in this groups.
16662248|NCT02200926|Experimental|Loaded breathing training|subjects will trained to inspire deeply against the resistance setting by using BreathMAX® at the loaded of 18 cmH2O with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
16662249|NCT02200926|Experimental|Unloaded breathing training|subjects will trained to inspire deeply (no resistance) with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
16662250|NCT02200913|Experimental|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
16662251|NCT02200913|Experimental|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
16662252|NCT02200900|Active Comparator|Group 1 ( CPAP followed by HFNC)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.
16662253|NCT02200900|Active Comparator|Group 2 (HFNC followed by CPAP)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.
16662254|NCT02200887||Advanced Parkinsons Disease|Polysomnogram
16662255|NCT02200887||Parkinsons Disease with Dyskinesia|Polysomnogram
16662256|NCT02200887||De novo Parkinsons Disease|Polysomnogram
16662257|NCT02200887||Healthy Volunteers|Polysomnogram
16662258|NCT02200874||before NST-implementation (group A)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: Before implementation of Nutrition Support Team (NST).
16662259|NCT02200874||After NST-implementation (group B)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: After implementation of Nutrition Support Team (NST).
16662260|NCT02200848|Experimental|Lenalidomide, Ibrutinib, Rituximab|Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.
16662261|NCT02200822|No Intervention|non-intervention arm|continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)
16662262|NCT02200822|Active Comparator|withdrawal of beta blockers|"Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.
~(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:
~bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop
~metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop
~nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop
~carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop"
16662379|NCT02199912|Experimental|Patients with colorectal surgery|
16662263|NCT02200822|Active Comparator|withdrawal of RAAS blockers|"intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)
~first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop
~after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:
~captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop
~enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop
~lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop
~ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop
~candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop
~valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop"
16662264|NCT02200822|Active Comparator|withdrawal of RAAS - and beta blockers|"intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)
~First: spironolactone/eplerenone cfr reduction schedule supra
~After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra
~After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra"
16662265|NCT02200809|Experimental|MR-guided focal laser ablation|
16662266|NCT02200796|Experimental|Low Protein Meal|Low Protein Test Meal (15 g)
16662267|NCT02200796|Experimental|Moderate Protein Meal|Moderate Protein Meal (30 g)
16662268|NCT02200796|Experimental|High Protein Meal|High Protein Meal (45g)
16662269|NCT02200796|Experimental|Control Meal|High Carbohydrate Control Meal (7 g of protein)
16662270|NCT02200783|Active Comparator|Radial|Cardiac catheterization and coronary angioplasty performed via standard radial artery technique.
16662271|NCT02200783|Active Comparator|Femoral|Cardiac catheterization and coronary angioplasty performed via standard femoral artery technique.
16662272|NCT02200783|Experimental|TripTable|Cardiac catheterization and coronary angioplasty performed with standard transradial technique plus using the TRIPTable device.
16662273|NCT02200770|Placebo Comparator|Total Placebo|Aquaporin-4-antibody (AQP4- IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15 in OLP and will be followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP.
16662274|NCT02200770|Experimental|Total Inebilizumab|AQP4-IgG sero positive and sero negative participants will receive IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who entered OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15 of OLP and will be followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP.
16662275|NCT02200757|Experimental|Aldoxorubicin|
16662276|NCT02200757|Active Comparator|Topotecan|
16662277|NCT02200744||Dislocation reduction using propofol|
16662278|NCT02200731|Experimental|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience.
16662279|NCT02200731|No Intervention|Control|In Denmark, standard care after treatment does not include systematic psychosocial support. Families are able to seek support on their own or contact a support group offered by the Danish Cancer Society. However support specializing the families with childhood cancer survivors and their siblings after ending medial treatment is limited.
16662280|NCT02200718|Experimental|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant
16662281|NCT02200718|Placebo Comparator|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion
16662282|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
16662283|NCT02200692||plasma transfusion|Patients receiving plasma transfusion.
16662284|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
16662285|NCT02200653|Experimental|Low dose of MICARDIS®|
16662286|NCT02200653|Experimental|High dose of MICARDIS®|
16662287|NCT02200653|Active Comparator|Low dose of COZAAR® / LORZAAR®|
16662288|NCT02200653|Active Comparator|High dose of COZAAR® / LORZAAR®|
16662289|NCT02200640|Experimental|Low dose of Micardis®|
16662290|NCT02200640|Experimental|High dose of Micardis®|
16662291|NCT02200640|Active Comparator|Low dose of COZAAR®|
16662292|NCT02200640|Active Comparator|High dose of COZAAR®|
16662293|NCT02200614|Experimental|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
16662294|NCT02200614|Placebo Comparator|Placebo|Participants received matching placebo 2 tablets twice daily with food.
16662295|NCT02200601|Experimental|Seipher Wellness|
16662296|NCT02200588||Patients|Patients followed in the First Episode Psychosis Clinical Program (PAFIP) with psychotic disorder
16662297|NCT02200588||Controls|Healthy subjects without psychotic disorder
16662298|NCT02200575||Patients with non-secondary, essential hypertension|
16662299|NCT02200562|Experimental|Ipilimumab and Dabrafenib|
16662300|NCT02200549|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
16662301|NCT02200549|Experimental|Cycle training group|A 30-minute cycling training session is performed 3 days a week using calibrated cycle ergometer.
16662302|NCT02200549|Experimental|Combined group|A 30-minute Combined training session is performed 3 days a week using calibrated cycle ergometer and threshold loading device.
16662303|NCT02200536|Experimental|Test|Infant oral health promotion package
16662304|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
16662305|NCT02200536|No Intervention|Control 2|
16662306|NCT02200523|Experimental|SARA electrode|new electrode
16662307|NCT02200523|Active Comparator|Gold cup|gold standard
16662310|NCT02200484|Experimental|Parent Training/Obesity Prevention|Mother-child dyads randomized to the active intervention in the pilot study will be administered 8 weeks of a combined parenting training and obesity prevention program that was adapted through analysis of formative research interviews with adolescent mothers with feedback from an expert panel of multidisciplinary research team members and community members.
16662311|NCT02200484|Active Comparator|8-week Wellness Program (Control)|Participants randomized to control condition during intervention piloting will receive print-based health and wellness materials once weekly for 8-weeks + 2 follow up telephone calls at the beginning and conclusion of the 8-week program.
16662312|NCT02200471|Experimental|VeinViewer|VeinViewer will be used in conjunction with routine cosmetic dermatology procedures. Patients and physicians will complete questionnaires.
16662313|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
16662314|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).
~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.
~The dose levels will be as follows:
~Cohort 1: 0.3x10^6 IU/m^2/day.
~Cohort 2: 1.0x10^6 IU/m^2/day.
~Cohort 3: 1.5x10^6 IU/m^2/day.
~Up to 6 subjects will be recruited to each dose cohort.
~Once the maximum tolerated dose has been identified, a further 10 subjects will receive IL-2 at the maximum tolerated dose."
16662315|NCT02200432|No Intervention|Control|The study's current rule-based CTHC system is embedded within the Decide2Quit.org web service. Control smokers will receive the current Decide2Quit.org system, including informational web pages, an interactive quit plan, plus pushed email messages. The messages will be selected using the current rule-based CTHC system. The CTHC selects messages based on decision rules (e.g: readiness to quit, gender) using information from a smoker's baseline profile. Participants will receive one message per day for 30 days
16662316|NCT02200432|Experimental|Intervention|The PERSPeCT intervention smokers will receive all components of the Decide2Quit.org web service, but persuasive email messages will be selected by the PERSPeCT recommender system developed in Aim 2. PERSPeCT will use data (see Figure 1) to predict messages that would be most influential to the participant. Intervention smokers will receive one PERSPeCT-generated message per day for 30 days. With each message rating, the PERSPeCT system will further adapt to patient preferences.
16662317|NCT02200419|Other|Transfusion Algorithm|Hospitals will be randomized to the intervention arm of the study in a stratified manner.
16662318|NCT02200406|Other|Desvenlafaxine|"Open-label pilot study
~Desvenlafaxine will be administered during 56 consecutive days
~Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks."
16662319|NCT02200393|Experimental|Abdominal FES|Participants in the Abdominal Functional Electrical Stimulation (AFES) group will receive AFES 5 times per week (20 to 40 mins per day), on four alternate weeks.
16662320|NCT02200380|Experimental|CDX-301|
16662321|NCT02200380|Experimental|CDX-301 and plerixafor|
16662322|NCT02200367|Experimental|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
16662323|NCT02200367|Other|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
16662324|NCT02200354|Experimental|pemetrexed with bevacizumab|pemetrexed rechallenge with bevacizumab pemetrexed (500mg/m2 day1) bevacizumab (15mg/kg day1)
16662325|NCT02200341|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) 8-week intervention
16662326|NCT02200341|Active Comparator|Progressive Relaxation Training - Psychoeducation|Progressive Relaxation Training and Psychoeducation (PRT-PsyEd) 8-week intervention
16662327|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
16662328|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
16662329|NCT02200315|Experimental|No Antimicrobial prophylaxis|No use of antimicrobial prophylaxis during surgery
16662330|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
16662331|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
16662332|NCT02200263|Experimental|Lutein plus Zeaxanthin|Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
16662333|NCT02200263|Placebo Comparator|Placebo softgels|Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
16662334|NCT02200250||Post Barretts Excision|Patients who have undergone an EMR for Barretts Oesophagus
16662335|NCT02200237|Placebo Comparator|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
16662336|NCT02200237|Experimental|EV71 with adjuvant aluminium phosphate|Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 μg/0.5ml
16662337|NCT02200224|Experimental|Rapid Testing/Treatment Group|All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED.
16662338|NCT02200224|No Intervention|Control|All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED.
16662339|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
16662340|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
16662341|NCT02200198|Active Comparator|Inspiratory group|Inspiratory muscle training
16662342|NCT02200198|Sham Comparator|Sham group|Sham training
16662343|NCT02200198|Experimental|Expiratory group|Expiratory muscle training
16662380|NCT02199899|Experimental|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
16662345|NCT02200185|Experimental|Low dose nebulised morphine|"patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.
~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo"
16662346|NCT02200185|Experimental|High dose nebulised morphine|"patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.
~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo."
16662347|NCT02200172|Active Comparator|Melatonin|A single daily sublingually administered tablet of 3mg non-animal synthetic source melatonin (immediate-release) at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
16662348|NCT02200172|Placebo Comparator|Placebo|A single daily sublingually administered tablet of placebo at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
16662349|NCT02200159||dexmedetomidine|
16662350|NCT02200146|Active Comparator|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
16662351|NCT02200146|Experimental|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
16662352|NCT02200133|Experimental|Individualized Survivorship Care Plan (SCP)|"Participant information sheet and instructions on how to use the SCP
~Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)
~Newest Vital Sign nutrition label to measure health literacy and its instructions
~Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
16662353|NCT02200133|No Intervention|Usual care (no SCP)|"Materials that their transplant center routinely provides to patients for follow-up care
~Newest Vital Sign nutrition label to measure health literacy and its instructions
~Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
16662354|NCT02200107|Experimental|self management education|self management education program delivered by family doctor in primary care clinics and during and physical therapy design
16662355|NCT02200107|No Intervention|control|Routine follow up according to standard practice
16662356|NCT02200094||Outpatients with essential hypertension|
16662357|NCT02200081|Experimental|MGN1703|MGN1703, solution in Dulbecco's Phosphate-Buffered Saline (DPBS), 2 mL of 60 mg/4 mL (15 mg/mL), administered SC at 2 application sites twice weekly
16662358|NCT02200081|Other|Standard of care|Continous first line therapy
16662359|NCT02200068|Active Comparator|PHR Group|This group will have access to a personal health record website SANOIA in addition to all resources they use or find online
16662360|NCT02200068|No Intervention|Non-PHR Group|This group will not be informed of the Personal Health Record Website and will use Internet as they usually do.
16662361|NCT02200055|Experimental|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.
~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.
~Bioimpedance Assessment"
16662362|NCT02200042|Experimental|Radiation therapy|Liver-directed radiation therapy
16662363|NCT02200042|No Intervention|Observation|No radiation therapy
16662364|NCT02200029|Experimental|Ademetionine IV|
16662365|NCT02200029|Experimental|Ademetionine oral|
16662366|NCT02200016|Experimental|SAX|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
16662367|NCT02200016|Active Comparator|LAX|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
16662368|NCT02200003|Experimental|Attention Bias Modification|640 Trials (20 minutes) four times over four weeks
16662369|NCT02200003|Sham Comparator|Sham Attention bias modification|640 Trials (20 minutes) four times over four weeks
16662370|NCT02199977|Other|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
16662371|NCT02199977|Other|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
16662372|NCT02199977|Other|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
16662373|NCT02199977|Other|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
16662374|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
16662375|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
16662376|NCT02199951||Dihydroartemisinin and piperaquine|The patients will take Eurartesim® (DHA/PQP) with a dose regimen of one administration every 24 hours over a period of three days, i.e. at Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3) from the first administration. The dose will be based on body weight. Two strengths of Eurartesim® will be provided for dosing in children and adults: 20/160mg and 40/320mg of DHA and PQP respectively. Body weight (kg) Daily dose (mg) Number of tablets per dose 20/160mg DHA/PQ 40/320mg DHA/PQ 5 to <7 10 mg DHA and 80 mg PQP ½ tablet 7 to <13 20 mg DHA and 160 mg PQP 1 tablet 13 to < 24 40 mg DHA and 320 mg PQP 1 tablet 24 to < 36 80 mg DHA and 640 mg PQP 2 tablets 36 to < 75 120 mg DHA and 960 mg PQP 3 tablets 75 to < 100 160 mg DHA and 1280 mg PQP 4 tablets > 100.
16662377|NCT02199938||musculoskeletal tumors|Patients with suspected or confirmed bone or soft tissue tumors undergoing biopsy or surgery
16662378|NCT02199925|Experimental|Gammaplex 5% IGIV|Gammaplex 5% IGIV administered intravenously
16662391|NCT02199834|Experimental|Peer group|24 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support to this group under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
16662392|NCT02199834|Other|Refused peer group|Patients who fit the criteria of peers but refuse to be contacted by peer supporters will be signed as refused group. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
16662393|NCT02199834|Experimental|Report group|Patients in this group will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values twice a year through mails.
16662394|NCT02199834|No Intervention|Usual care|Patients will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
16662395|NCT02199821|Active Comparator|Soybean oil formula commonly used in the hospita|
16662396|NCT02199821|Experimental|Formula with soybean oil, medium-chain triglyce|
16662397|NCT02199808||7-9 year olds|These are children who are between 7 and 9 years old when they are tested.
16662398|NCT02199808||10-12 year olds|These are children who are between 10 and 12 years old when they are tested.
16662399|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
16662400|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
16662401|NCT02199782|Active Comparator|Welsh|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
16662402|NCT02199782|Active Comparator|English|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
16662403|NCT02199769|Experimental|Clinical Decision Support|Visit-based, EMR-enabled case identification and real-time decision support to identify patients without diabetes who have a RBG>= 125mg/dL and no resulted diabetes screening.
16662404|NCT02199769|No Intervention|Usual care|Diabetes screening/testing and diagnosis per usual care at the discretion of the treating physician.
16662405|NCT02199756||Cesarean section|Women with cesarean section
16662406|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
16662407|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
16662408|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
16662409|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
16662410|NCT02199704|Other|No control or comparison arm.|This case series study has no control or comparison arm. There is only one arm being evaluated (the self directed parenting intervention).
16662411|NCT02199691|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
16662412|NCT02199691|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
16662413|NCT02199691|Experimental|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
16662414|NCT02199691|Active Comparator|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
16662415|NCT02199678|Placebo Comparator|Placebo|Placebo
16662416|NCT02199678|Active Comparator|ketamine 25 mg|ketamine
16662417|NCT02199678|Active Comparator|ketamine 35 mg|ketamine
16662418|NCT02199678|Active Comparator|ketamine 50 mg|ketamine
16662419|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16662420|NCT02199652|Placebo Comparator|placebo|placebo pill
16662421|NCT02199652|Experimental|prazosin|prazosin pill
16662422|NCT02199639||Spain|Group of patients with hemophilia recruited in the Region of Murcia (Spain) and evaluated in the Universidad Católica San Antonio between June and July 2014.
16662423|NCT02199639||El Salvador|"Group of patients with hemophilia recruited in the city of San Salvador (El Salvador) and evaluated in the Hospital Nacional Rosales and the Hospital Nacional de niños Benjamín Bloom from San Salvador in April 2014."
16662424|NCT02199639||Bolivia|Group of patients with hemophilia recruited in the city of Santa Cruz (Bolivia) and evaluated at the Hospital Nacional de niños in Santa Cruz August 2014.
16662425|NCT02199626|Experimental|CCE-2|Second generation of Colon capsule endoscopy in pediatric Crohn's disease
16662426|NCT02199613|Experimental|Treatment simplification|Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food
16662427|NCT02199600|Other|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
16662428|NCT02199587|Active Comparator|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
16662429|NCT02199587|No Intervention|Endocrine test without medical clown|
16662430|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
16662431|NCT02199561|Experimental|Fecal Microbiota Transplant|Open label single arm delivering fecal transplant to each participant
16662432|NCT02199548||Study Participants|All enrolled participants will take part in a face-to-face interview.
16662433|NCT02199522|Experimental|titration induction of propofol|titration induction of propofol by Fresenius pump at the speed of 1 mg•kg-1•min-1
16662434|NCT02199522|No Intervention|convention induction of propofol|propofol 2mg•kg-1 intravenously by Fresenius pump at the speed of 250mg•min-1
16662435|NCT02199496|Experimental|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
16662436|NCT02199496|Experimental|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
16662437|NCT02199470||C-peptide minimal detectable|C-peptide level between 0,01-0,08 ng/mL
16662438|NCT02199470||C-peptide sustained|C-peptide level between higher or equal to 0,08 ng/mL
16662439|NCT02199470||C-peptide not detectable|C- peptide level equal to or lower than 0,01 ng/mL
16662440|NCT02199457|Other|SVSS and reference devices|Vital signs will be measured on the same subject with the reference devices and with the SVSS. The subject will have blood pressure, pulse, blood oxygen, body temperature and respiration rate measured using standard equipment. The same subject will then use the investigational device which measures all vital signs at the same time, by placing the index finger on a sensor.
16662441|NCT02199444|Experimental|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
16662442|NCT02199444|Placebo Comparator|Placebo|The patients received placebo three times a day
16662443|NCT02199431|Experimental|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
16662444|NCT02199431|Experimental|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
16662445|NCT02199418|Experimental|Paclitaxel and Cisplatin|"Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
~Trastuzumab (only for human epidermal growth factor receptor-2(HER2)-positive patients): Loading dose: 4 mg/kg, Maintenance dose: 2 mg/kg, day 1 q day 8 for 16 weeks. Post-surgery: up to a total duration of 1 year"
16662446|NCT02199405|Experimental|massage and Sishi Daoyin|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
16662447|NCT02199405|Active Comparator|conventional massage and cervical traction|Conventional massage , 15 minutes, three times one week for 4 weeks Cervical traction , 15 minutes, three times one week for 4 weeks
16662448|NCT02199392|Experimental|Lenvatinib 24 mg|The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
16662449|NCT02199379|Experimental|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
16662450|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
16662451|NCT02199353|Experimental|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.
~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.
~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
16662452|NCT02199353|Active Comparator|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.
~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
16662453|NCT02199340|Experimental|Cystic fibrosis|"iStep exercise test
~CPET exercise test"
16662454|NCT02199340|Active Comparator|Healthy control|- iStep exercise test
16662455|NCT02199327|Active Comparator|Mitomycin C|Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
16662456|NCT02199327|Active Comparator|Interferon alfa 2b|Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
16662457|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
16663269|NCT02193919||South Beach Diet + UVB|South Beach DIet + UVB
16662458|NCT02199301|Experimental|BMTKT|Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)
16662459|NCT02199288||Cohort|
16662460|NCT02199262|Experimental|control groupe|agitation diagnosis and management according to implemented guidelines= reminder implementation
16662461|NCT02199262|Experimental|music intervention + reminder|agitation diagnosis and management according to implemented guidelines+ music intervention
16662462|NCT02199262|Experimental|reflexology + reminder|agitation diagnosis and management according to implemented guidelines + reflexology
16662463|NCT02199249|Active Comparator|Open Reduction Tightrope fixation (OT)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
16662464|NCT02199249|Active Comparator|Open Reduction screw fixation (OS)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
16662465|NCT02199236|Experimental|endorectal brachytherapy, concurrent chemo and questionnaires|This is a phase I, dose-escalation study to evaluate the safety of endorectal brachytherapy with concurrent capecitabine or 5-fluoruracil (5-FU) in the management of locally recurrent/residual rectal or anal cancer in patients who have received pelvic external beam radiation therapy (EBRT) +/- chemotherapy. We will use magnetic resonance imaging (MRI) with dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI) series to contribute to the assessment of tumor response.
16662466|NCT02199223|Experimental|panitumumab + regorafenib|
16662467|NCT02199210|Experimental|Prompting forethought|"A demographic questionnaire will be filled out by each participant. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:
~participants forethought will be prompted and each participant will be asked to report his/her forethought,
~participants then will be asked to manage a simulated massive transfusion scenario,
~at completion of the scenario, each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
16662468|NCT02199210|No Intervention|No prompting|"A demographic questionnaire will be filled out by each participants. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:
~participants will sit and wait for a predetermined time before entering into the simulator,
~participants then will be asked to manage a simulated massive transfusion scenario,
~at completion of the scenario, each participant will be interviewed about their thought process before entering to the simulation room,
~each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
16662469|NCT02199197|Experimental|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
16662470|NCT02199197|Active Comparator|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
16662471|NCT02199184|Experimental|Treatment (DA-EPOCH and ofatumumab or rituximab)|Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
16662472|NCT02199171|Experimental|HIPEC carboplatin|"Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.
~Doses as appropriate for assigned dose level in 500 cubic centimeters (cc)"
16662473|NCT02199158|Experimental|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
16662474|NCT02199145|Other|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria /creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
16662475|NCT02199132||Nasopharyngeal Carcinoma|
16662476|NCT02199119|Experimental|Control|Sitting quietly for 30 min No TV No exercise
16662477|NCT02199119|Experimental|TV viewing only|watching TV for 30 min
16662478|NCT02199119|Experimental|Exercise only|exercising for 30 min
16662479|NCT02199119|Experimental|TV viewing and Exercise|30 min of moderate exercise on a treadmill while watching TV
16662480|NCT02199106|Experimental|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)
~Intervention: Left temporal verum cTBS"
16662481|NCT02199106|Experimental|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings
~Intervention: Left temporal placebo cTBS"
16662482|NCT02199093|Experimental|Functional Rehabilitation of apraxia|The participants will be randomly assigned to an experimental group, to receive intervention in upper limb apraxia at home since two approaches, a rehabilitative and another compensatory (providing adaptive strategies at home). The treatment will be performed three times a week, 30 minutes a day, during a 4-week period.
16663006|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
16662483|NCT02199093|Active Comparator|Traditional health educative protocol|Control group will receive treatment with a traditional health educative protocol to improve his functionality in activities of daily living. The treatment will be performed twice in two month.
16662484|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
16662485|NCT02199054|Placebo Comparator|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
16662486|NCT02199054|Active Comparator|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
16662487|NCT02199054|Active Comparator|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
16662488|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.
~Cells for infusion are prepared using the CliniMACS System."
16662489|NCT02199028|Experimental|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.
~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
16662490|NCT02199028|Experimental|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.
~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.
~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
16662491|NCT02199015|Experimental|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
16662492|NCT02199002|Other|healthy volunteers|healthy volunteers (no gastric complains)
16662493|NCT02199002|Other|PPI responders|proven reflux, good symptom relief upon PPI therapy
16662494|NCT02199002|Other|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
16662495|NCT02199002|Other|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
16662496|NCT02199002|Other|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
16662497|NCT02198989|Experimental|peer support and yoga music therapy|"Patients in the group will receive peer support and yoga music therapy before bed.
~Patients in the group will received the group education courses and clinical medical therapy."
16662498|NCT02198989|No Intervention|Control group|Patients in the group will received the group education courses and clinical medical therapy.
16662499|NCT02198976||Barrett's Oesophagus|Patients with Barrett's Oesophagus with either high grade dysplasia (HGD) or intramucosal cancer (IMC)
16662500|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
16662501|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
16662502|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
16662503|NCT02198950||ICU patients|all patients admitted into the ICU
16662504|NCT02198937||Smokers|Healthy smokers
16662505|NCT02198937||Non-Smokers|Healthy non-smokers
16662506|NCT02198924|Experimental|Parecoxib and Celecoxib|"Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3."
16662507|NCT02198924|Placebo Comparator|placebo|"Patients in the control group are supplied with the corresponding placebo with the same instructions.
~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3."
16662508|NCT02198911|Active Comparator|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
16662509|NCT02198911|Active Comparator|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
16662510|NCT02198911|Active Comparator|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
16662511|NCT02198898|No Intervention|GUARDIX|no guadix
16662512|NCT02198898|Experimental|guadix|guadix treatment
16663270|NCT02193919||Ornish Diet + UVB|Ornish Diet + UVB
16662513|NCT02198885||Control|This group receives the standard prehospital care en route to hospital, and they do not receive the FAST ultrasound en route.
16662514|NCT02198885||FAST|This group receives the FAST ultrasound en route to hospital.
16662515|NCT02198872|Experimental|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
16662516|NCT02198872|Active Comparator|Land Group|Patients of this group perform physical training on bicycle.
16662517|NCT02198859|Experimental|Lithium|Oral lithium carbonate dose escalation: Level 1 of 600 mg/day, then escalating to Level 2 of 900 mg/day, then the final Level 3 of 1200 mg/day.
16662518|NCT02198846|Experimental|Insulin pump|insulin pump
16662519|NCT02198846|Active Comparator|conventional treatment|intensification of conventional treatment
16662520|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
16662521|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
16662522|NCT02198820||General|All patients included who underwent surgery with general anesthesia
16662523|NCT02198820||Loco Regional|All patients included who underwent surgery with loco regional anesthesia
16662524|NCT02198807|Experimental|Fosmidomycin-Piperaquine|Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days
16662525|NCT02198794|Experimental|Part A: SD-809|Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
16662526|NCT02198794|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
16662527|NCT02198794|Active Comparator|Part B: SD-809|Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
16662528|NCT02198781||Cohort|Basic science study
16662529|NCT02198768||Ankle Fracture|Patients with isolated ankle fractures.
16662530|NCT02198768||Ankle Fracture-Dislocation|Patients with ankle fracture-dislocations.
16662531|NCT02198755|Active Comparator|High Resolution Ultrasound|High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner
16662532|NCT02198755|Active Comparator|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI)
16662533|NCT02198742|Active Comparator|Miller blade|Subjects must have >500 intubations in order to participate in this study. There is no placebo group, and each subject wil be his or her own control.
16662534|NCT02198742|Active Comparator|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable. There is no placebo group, and each subject wil be his or her own control.
16662535|NCT02198742|Active Comparator|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacterer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
16662536|NCT02198729|Active Comparator|Endoscopic Mucosal Resection|Participants randomised to this arm will receive standard of care Endoscopic Mucosal Resection for removal of their lesions.
16662537|NCT02198729|Experimental|Endoscopic Submucosal Dissection|Participants randomised to this arm will receive Endoscopic Mucosal Dissection to remove their lesion.
16662538|NCT02198716|Other|Drug eluting stent|Percutaneous coronary intervention
16662539|NCT02198716|Other|Bare Metal Stent|Percutaneous Coronary Intervention
16662540|NCT02198703|Experimental|AB-Life|1 capsule of AB-Life daily during 12 weeks consumed immediately before, after or during the breakfast. The daily dose corresponds to the intake of 1.8E+10 CFU. According to the product's stability and the duration of the experiment, all participants receive at least 1.2E+09 CFU/capsule/day by the end of the study.
16662541|NCT02198703|Placebo Comparator|Placebo|1 capsule of placebo daily during 12 weeks consumed immediately before, after or during the breakfast.
16662542|NCT02198690|Experimental|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women >75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
16662543|NCT02198690|Placebo Comparator|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
16662544|NCT02198677|Experimental|AP|Anterior to posterior pressures 5x10 seconds per set with 10 seconds rest between each set
16662545|NCT02198677|Experimental|Lateral glides|Lateral glides 5x10 seconds per set with 10 seconds rest between each set
16662546|NCT02198664|Experimental|Peanut Protein Capsule|Biological: Capsules containing peanut flour, oral immunotherapy, will be used for dose escalation build-up, and maintenance phase
16662547|NCT02198651|Experimental|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
16662548|NCT02198651|Active Comparator|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
16662549|NCT02198651|Placebo Comparator|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
16662550|NCT02198651|Experimental|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
16662551|NCT02198638|Other|Patients or healthcare workers|
16662552|NCT02198625|No Intervention|FiO2 80%,Nonprotective Lung Ventilation|
16662553|NCT02198625|Experimental|FiO2 30%,Nonprotective Lung Ventilation|FiO2 30%,Nonprotective Lung Ventilation
16662554|NCT02198625|Experimental|FiO2 80%,protective Lung Ventilation|FiO2 80% and protective Lung Ventilation
16662555|NCT02198625|Experimental|FiO2 30%,protective Lung Ventilation|FiO2 30% and protective Lung Ventilation
16662556|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
16662557|NCT02198599|Experimental|Mobility-enhancing-nursing intervention|A 30 day mobility enhancing-nursing intervention for patients with Multiple Scerosis and stroke to expand kinaesthetic competence in order to increase compensation of limitations, improve functionality, and quality of life
16662558|NCT02198599|No Intervention|Standard usual rehabilitation care|Participants in the control group will receive usual care, which is based on the principles of rehabilitation nursing. Based on patients functional ability (EBI data) the nursing process is used to determine objectives and interventions. The main focus is on providing a therapeutic environment and supporting and advancing abilities to perform the Activities of Daily Living, support mobility and kinesthetic perception.
16662559|NCT02198586||No treatment|The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
16662560|NCT02198560||Normal (Eyes without pathology)|
16662561|NCT02198547|Experimental|Ropivacaine Magnesium sulfate|"Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg.
~Sciatic block at popliteal level."
16662562|NCT02198547|Active Comparator|Ropivacaine|Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG
16662563|NCT02198534||ophthalomogically normal subjects|
16662564|NCT02198521||Bilateral Carpal Tunnel Syndrome (CTS)|
16662565|NCT02198508|Active Comparator|DFX single treatment|a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
16662566|NCT02198508|Active Comparator|DFP single treatment|single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
16662567|NCT02198508|Experimental|combination treatment|sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
16662568|NCT02198495|Active Comparator|Ferric carboxymaltose|Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30
16662569|NCT02198495|Active Comparator|Iron sucrose|Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38
16662570|NCT02198482|Active Comparator|Daunorubicin, Cytarabine (DA)|"DA
~Induction I:
~Daunorubicin 60 mg/m² i.v., d 1-3
~Cytarabine 100 mg/m² cont. i.v., d 1-7
~Induction II:
~Daunorubicin 50 mg/m² i.v. d 1-3
~Cytarabine 100 mg/m² cont. i.v., d 1-5
~Consolidation therapy:
~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).
~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. infusion on day 1.
~Intermediate-dose cytarabine:
~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT."
16662571|NCT02198482|Experimental|Volasertib, Daunorubicin, Cytarabine|"VDA
~Induction I
~Volasertib i.v., d1
~Daunorubicin 60 mg/m² i.v., d 2-4
~Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II
~Volasertib i.v., d1
~Daunorubicin 50 mg/m² i.v. d 2-4
~Cytarabine 100 mg/m² cont. i.v., d 2-6
~Consolidation therapy:
~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).
~Volasertib i.v., d1
~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 2.
~Intermediate-dose cytarabine:
~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT."
16662572|NCT02198482|Experimental|Daunorubicin, Cytarabine, Volasertib|"DAV
~Induction I
~Volasertib i.v., d7
~Daunorubicin 60 mg/m² i.v., d 1-3
~Cytarabine 100 mg/m² i.v., d 1-7 Induction II
~Volasertib i.v., d5
~Daunorubicin 50 mg/m² i.v. d 1-3
~Cytarabine 100 mg/m² cont. i.v., d 1-5
~Consolidation therapy:
~Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).
~Volasertib i.v., d4
~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 1.
~Intermediate-dose cytarabine:
~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT."
16662573|NCT02198469|Experimental|Er:YAG AFL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
16662574|NCT02198469|Active Comparator|MAL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
16662575|NCT02198456||3D echocardiography|
16662576|NCT02198443|Active Comparator|Tenofovir+emtricitabine|
16662577|NCT02198443|Experimental|Elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|
16663007|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
16662578|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
16662579|NCT02198430||Control group|Children without hemophilia
16662580|NCT02198417|Experimental|Metformin|Metformin ER 1500 mg per day treatment for 12 weeks
16662581|NCT02198404|Experimental|sedation with propofol|propofol injection: induction with propofol at 20 mg/kg/h. When patient is sleeping, the dosage is deceased to 6 mg/kg/h
16662582|NCT02198391||3 x 1 tablet per day|Echinaforce Junior tablets (low dose)
16662583|NCT02198391||5 x 1 tablet per day|Echinaforce Junior tablets (high dose)
16662584|NCT02198378|Active Comparator|Morphine|Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
16662585|NCT02198378|Experimental|MEOPA and paracetamol|"The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.
~During the same time, an intravenous injection of 1 g paracetamol will be administered."
16662586|NCT02198365||Group 2|Group 1: normal pap smear Group 2: cervical neoplasia
16662587|NCT02198352|Experimental|BIBN 4096 BS - in single rising doses|
16662588|NCT02198352|Placebo Comparator|Placebo|
16662589|NCT02198339|Experimental|BIBN 4096 BS - ranging dose|"sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance
~IV infusion over 10 minutes"
16662590|NCT02198339|Placebo Comparator|Placebo|IV infusion over 10 minutes
16662591|NCT02198326|Experimental|BIBN 4096 BS - in single rising doses|
16662592|NCT02198326|Placebo Comparator|Placebo|
16662593|NCT02198313|Experimental|BIIX 1 XX - D1|
16662594|NCT02198313|Experimental|BIIX 1 XX - D2|
16662595|NCT02198313|Experimental|BIIX 1 XX - D3|
16662596|NCT02198313|Placebo Comparator|Placebo|
16662597|NCT02198300|Active Comparator|rDES Group|regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
16662598|NCT02198300|Experimental|BiOSS LIM Group|BiOSS LIM® stent implantation into coronary lesion within bifurcation.
16662599|NCT02198287|Experimental|BIIX 1 XX, rising doses|
16662600|NCT02198287|Placebo Comparator|Placebo|
16662601|NCT02198274|Experimental|BIBH 1|
16662602|NCT02198261||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
16662603|NCT02198261||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
16662604|NCT02198248|Experimental|Low-dose glucocorticoid|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).
~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy."
16662605|NCT02198248|Active Comparator|High-dose glucocorticoid|"Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).
~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering."
16662606|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
16662607|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
16662608|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
16662609|NCT02198209|Other|single arm|"Liraglutide (Victoza)
~acute study: one injection of 0.6 mg s.c. before IVGTT
~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
16662610|NCT02198196|Experimental|Weight Talk-Mindfulness|WT-M retain the evidence-based elements of WT-S (control condition), including the DASH diet, physical activity components, and an emphasis on self-monitoring. However, each call in WT-M will include an emphasis on mindfulness and stress management that will not be included in the control condition.
16662611|NCT02198196|No Intervention|Weight Talk-Standard|Weight Talk-Standard is a phone and web-based weight loss intervention offered by employers as a benefit to their employees. Weight Talk is based on the NIH Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in Adults and utilizes the curriculum developed for the Diabetes Prevention Program. Weight Talk-S contains no additional stress management techniques.
16662612|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
16662613|NCT02198170|Experimental|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period
16662614|NCT02198170|Experimental|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
16662615|NCT02198157|Active Comparator|intermittent urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will receive intermittent catheterization
16662616|NCT02198157|Active Comparator|continuous urinary catheter|nullipara women with epidural anaesthesia who pose urination difficulty will receive continuous catheterization
16662617|NCT02198144|Other|barbershop-based BP measurement|BP monitoring by barbershop based Barbers and BP lowering medication(s)
16662618|NCT02198131|Experimental|Supportive Care (pulsed dye laser)|Patients undergo pulsed dye laser monthly for three months.
16662619|NCT02198118|No Intervention|Control Group|Control group (CG) subjected only to evaluations and to no exercises.
16662620|NCT02198118|Experimental|Study Group|Study group (SG) instructed to perform domiciliary exercises for the upper limbs
16662621|NCT02198105||Femoropopliteal stenosis|"Consecutive patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis/occlusion.
~Intervention with Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon-PTA."
16662622|NCT02198092||Patient Group FAP|"Clinical diagnosis of familial adenomatous polyposis (FAP).
~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.
~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
16662623|NCT02198092||Patient Group Lynch Syndrome|"Clinical diagnosis of Lynch Syndrome, also known as HNPCC.
~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.
~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
16662624|NCT02198092||Patient Group MAP / MYH|"Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.
~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.
~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
16662625|NCT02198092||Control Group (FAP Genetically-Related)|"Genetically related family member of enrolled FAP patient.
~Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.
~The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.
~If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.
~Blood draws in FAP patients should always be accompanied by blood draws in their family member controls."
16662626|NCT02198079||Cystic Fibrosis|Children with Cystic Fibrosis
16662627|NCT02198066|Other|Dry Sterile Dressing|Subjects in this study arm received a dry sterile dressing (Primapore®, Smith & Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
16662628|NCT02198066|Active Comparator|Metallic Silver Dressing|Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith & Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
16662629|NCT02198066|Active Comparator|Ionic Silver Dressing|Subjects in this arm received an ionic silver dressing (Dermanet Ag®, DeRoyal), a semi-transparent dressing that includes silver, alginate, and maltodextrin. The dressing was cut to fit the incision and then covered with a transparent dressing (Transseal®, DeRoyal). This dressing should not be used on patients with known sensitivity to alginates (a seaweed based component).
16662630|NCT02198053||Ticagrelor2|Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
16662631|NCT02198053||Ticagrelor1|Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
16662632|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
16662633|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
16662634|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
16662635|NCT02198027|Experimental|Bupivacaine infiltration|10 ml of 0.25 % Bupivacaine
16662636|NCT02198027|Placebo Comparator|Normal saline infiltration|10 ml of normal saline
16662637|NCT02198014|Experimental|Manual Therapy group|We employed joint traction, passive muscle stretching and isometric exercises, active resisted and proprioception exercises. The treatment in this group consisted of two sessions per week for one hour each.
16662638|NCT02198014|Experimental|Educational gruop|"This group received educational sessions and home exercises. The exercises are aimed at improving quadriceps strength, flexibility, range of motion and knee proprioception.
~Each educational session of 90 minute every two weeks, with exercises daily home"
16662639|NCT02198014|No Intervention|Control group|The control group (group C) did not receive any treatment. The patients of this group were assessed by the same reviewers and under the same conditions as the subjects of the two intervention groups.
16662640|NCT02198001|Active Comparator|tooth extraction and insertion of PRF|Experimental: Atraumatic tooth extraction with antibiotics( amoxicillin clavulanate combination) .Insertion of PRF membrane in tooth-extraction site.
16662641|NCT02198001|Placebo Comparator|No PRF|Atraumatic extraction with antibiotic without PRF insertion
16662642|NCT02197988|Active Comparator|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block Exparel 1.33% (20ml Volume)
16662643|NCT02197988|Active Comparator|Thoracic Epidural Anesthesia|Thoracic Epidural Anesthesia 0.125% bupivicaine with 2 mcg/ml Fentanyl
16662644|NCT02197975|Experimental|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
16662645|NCT02197975|Experimental|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
16662646|NCT02197975|Placebo Comparator|Placebo MDI|Placebo MDI. Administered as 2 inhalations
16662647|NCT02197962|Experimental|Extracorporeal radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
16662648|NCT02197962|Placebo Comparator|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
16662649|NCT02197949||Breast cancer patients with infiltrated axillary l|
16662650|NCT02197936||Peristalsis adenomyosis|with adenomyosis
16662651|NCT02197936||Peristalsis control|No adenomyosis
16662652|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
16662653|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
16662654|NCT02197910|Active Comparator|High content of wheat bioactive peptides|100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
16662655|NCT02197910|Placebo Comparator|Low dose of wheat bioactive peptides|100 gr pasta/day, containing around 3 mg bioactive peptides
16662656|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
16662657|NCT02197884|Experimental|Itraconazole + JNJ-54861911 (Part 1)|Single dose of JNJ-54861911, 25 milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
16662658|NCT02197884|Experimental|Clarithromycin + JNJ-54861911 (Part 2)|Single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
16662659|NCT02197871|No Intervention|blank control|usual diet
16662660|NCT02197871|Experimental|nutrition supplementation|In addition to usual diet,the patients will be given enteral nutrition emulsion, which is a oral nutrition liquid composed of proteins,omega-3 fatty acids,carbohydrate,vitamins.Every package contains 200ml and provides 260 kcal energy.
16662661|NCT02197845|Experimental|Phase I: Recruitment into Specialty Care|Participants in the Phase I Experimental Arm are enrolled into SCD specialty care. PN's will contact patient up to 3 times to assure patients have had an initial visit by 3 months time.
16662662|NCT02197845|Experimental|Phase II: Patient Navigator Arm|Participants in the Phase II Experimental Arm follow routine clinical care and are assigned a Patient Navigator. A specially trained (SCD specefic)PN will work with participants for one year. Participants will be contacted by their Navigator weekly for the first 6 months, then biweekly for the second 6 months.
16662663|NCT02197845|No Intervention|Phase II: Passenger Arm|No Intervention. Participants in the Phase II Passenger Arm follow routine clinical care.
16662664|NCT02197832|Experimental|EA|in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
16662665|NCT02197832|Placebo Comparator|Control|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.
16662666|NCT02197819|Experimental|External Rotation Brace|Shoulder placed in an external rotation brace for 4 weeks
16662667|NCT02197819|Active Comparator|Traditional Sling|Patient placed in traditional sling
16662668|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
16662669|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
16662670|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
16662671|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
16662672|NCT02197793|Experimental|Community Mobilization Program|Intervention activities will map onto six mobilization domains identified as key components for communities to mobilize for change around testing, linkage and retention in care (Treatment as Prevention (TasP)).
16662673|NCT02197793|No Intervention|Control Arm|The control arm does not receive the Community Mobilization Intervention.
16662674|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
16662675|NCT02197754|Experimental|Polyphenol Diet|After 2 weeks of adaptation to a controlled diet, polyphenol-rich fruits (berries and apple) and beverages (tea) will be fed (8 wks) as part of a controlled diet (10 wks total).
16662676|NCT02197741||opiate without bolus|continuous opiate administration without bolus application
16662677|NCT02197741||opiate with bolus|continuous opiate administration with additional bolus application
16662678|NCT02197728|Active Comparator|Hohl uterine manipulator ®|Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®
16662679|NCT02197728|Active Comparator|Colpo-Probe™ Vaginal Fornix Delineator|Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator
16662717|NCT02197403|Active Comparator|Non-alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
16662718|NCT02197403|Active Comparator|Non-alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
16663271|NCT02193906|Experimental|Intervention group|Cognitive training.
16662680|NCT02197715|Experimental|computer-adaptive SAFE|Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
16662681|NCT02197715|Experimental|Face-to-face SAFE|Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques. Each session will be led by an experienced counselor. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods. Session 4 will focus on effective strategies to communicate with a sexual partner.
16662682|NCT02197715|Active Comparator|Usual Care|Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
16662683|NCT02197702|Placebo Comparator|Placebo|2 ml identical placebo taken by mouth at baseline and 3.5 months.
16662684|NCT02197702|Active Comparator|Vitamin D|Vitamin D (100,000IU) given in a 2 ml oral dose at baseline and 3.5months.
16662685|NCT02197689|Experimental|SMS Medication Reminder|763 patients were assigned to experimental group
16662686|NCT02197689|No Intervention|No SMS Reminder|435 patients were assigned to control group as no SMS reminder
16662687|NCT02197676|Experimental|SGI-110|
16662688|NCT02197663|Experimental|Acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
16662689|NCT02197663|Sham Comparator|sham acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
16662690|NCT02197637|Experimental|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle
16662691|NCT02197611||Validation group|Group of patients who we will consult the characteristics of the scale designed and will be made the statistical calculations of validity, reliability and reproducibility
16662692|NCT02197598|Experimental|Selincro® (nalmefene) 18 mg, tablets|One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.
16662693|NCT02197585|Experimental|Glue|Mesh fixation with glue
16662694|NCT02197585|Active Comparator|Suture|Mesh fixation with suture
16662695|NCT02197572|Experimental|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
16662696|NCT02197559||BMS group, DES group|All the participants in this group will be performed with bare-metal stents or drug -eluting stents
16662697|NCT02197546|Other|acupuncture plus local anesthesia|Bilateral acupuncture with 1.5 mm long indwelling fixed needles
16662698|NCT02197546|No Intervention|Local anesthesia alone|Standard therapy - local anesthesia alone without acupuncture
16662699|NCT02197533|Experimental|Written list|Patients in the intervention group will receive both verbal information and a written supplement (Appendix 1), produced during the discussion by CM or a fellow (not the individual who obtained consent), on treatment recommendations for OAB. They will leave clinic with this written list of recommendations and will be able to take it home with them.
16662700|NCT02197533|No Intervention|Control|Patients in the control group will receive the same verbal information on the treatment recommendations for OAB, however, these patients will not receive the written list of management strategies for their condition.
16662701|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
16662702|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
16662703|NCT02197507|Experimental|RA patients|
16662704|NCT02197494|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
16662705|NCT02197494|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
16662706|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
16662707|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
16662708|NCT02197468||Probiotics|"Preterm infants given probiotics: GA 24-27 weeks/Birth weight < 1000 g
~Preterm infants not given probiotics: GA 28-31 weeks/Birth weight 1000-1500 g
~Full-term infants not given probiotics (control)"
16662709|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
16662710|NCT02197442|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
16662711|NCT02197442|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
16662712|NCT02197429|Experimental|Acupuncture|Acupuncture
16662713|NCT02197429|No Intervention|Wait-list Control|Wait-list Control
16662714|NCT02197416|Experimental|dabigatran etexilate|
16662715|NCT02197403|Experimental|alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
16662716|NCT02197403|Active Comparator|alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
16662719|NCT02197390|Experimental|Health Care plus Public Health|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs). The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
16662720|NCT02197390|Experimental|Health Care|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs).
16662721|NCT02197390|Experimental|Public Health|The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
16662722|NCT02197390|Experimental|Control|No intervention.
16662723|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
16662724|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
16662725|NCT02197364||ILD, Other respiratory diseases, Healthy control group|"ILD: those with interstitial lung disease.
~Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.
~Healthy control group: those who is healthy."
16662726|NCT02197351|Experimental|Gastric Symptoms|Patients with gastric symptoms including dyspepsia undergoing upper endoscopy will undergo white light biopsy narrow band imaging guided biopsy protocolled biopsy
16662727|NCT02197338|Experimental|Short Wire, Small Tome|Short wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
16662728|NCT02197338|Active Comparator|Short Wire, Standard Tome|Short wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
16662729|NCT02197338|Active Comparator|Long Wire, Small Tome|Long wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
16662730|NCT02197338|Active Comparator|Long Wire, Standard Tome|Long wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
16662731|NCT02197325|Active Comparator|PICSO|Participants enrolled in the PICSO treatment Group will be treated with PICSO concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction
16662732|NCT02197325|No Intervention|Parallel control|Participants enrolled in will receive treatment based on the standard guidelines for treatment of a myocardial infarction.
16662733|NCT02197312|Other|NobelProcera Bridge Shaded Zirconia|posterior region
16662734|NCT02197299|Experimental|Carnitine|Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks
16662735|NCT02197299|Placebo Comparator|Sugar pill|Oral administration of placebo sugar pill
16662736|NCT02197286|Experimental|Vitamin D (cholecalciferol)|Intervention: Capsules containing the active ingredient, cholecalciferol @ 4,000 international units (IU). One capsule daily, oral administration for 10 weeks.
16662737|NCT02197286|Placebo Comparator|Placebo|"Daily matching placebo gelatin capsule (also contains microcrystalline cellulose).
~Capsules are identical in size, color and taste to experimental drug."
16662738|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):
~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine
~Injection into capsular tissue after placement of the acetabular component:
~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline
~Total Knee Arthroplasty (TKA):
~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc
~Injection into posterior capsule of the knee:
~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline
~Total Shoulder Arthroplasty (TSA):
~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
16662739|NCT02197273|Experimental|Liposomal bupivacaine|"THA:
~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue
~TKA:
~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue
~TSA:
~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.
~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
16662740|NCT02197260|Experimental|Protocol A|Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
16662741|NCT02197260|Active Comparator|Protocol B|Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)
16662742|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
16662743|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
16663131|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
16662744|NCT02197221|Experimental|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
16662745|NCT02197221|Active Comparator|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
16662746|NCT02197208|Active Comparator|Spontaneous NC|Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
16662747|NCT02197208|Experimental|hCG induced NC|Timing by giving hCG when the dominant follicle reaches >=17mm in diameter on ultrasound monitoring
16662748|NCT02197195|Experimental|Chocolate Milk Beverage|Chocolate milk beverage and sitting quietly
16662749|NCT02197195|Experimental|Chocolate Milk Beverage and Exercise|Chocolate milk beverage and exercising
16662750|NCT02197195|Experimental|Fruit Drink Beverage|Fruit drink beverage and sitting quietly
16662751|NCT02197195|Experimental|Fruit Drink Beverage and Exercise|Fruit drink beverage and exercising
16662752|NCT02197182|Experimental|LUXSOL Cream|LUXSOL Cream is a copper containing cream to be administered intravaginally before bedtime for 10 consecutive nights.
16662753|NCT02197182|Active Comparator|Metronidazole cream|Metronidazole cream is the active comparator drug to be self-administered intravaginally each night before bedtime for 10 consecutive nights. Dosage is per package insert.
16662754|NCT02197169|Experimental|DNX-2401 alone|Single intratumoral injection of DNX-2401
16662755|NCT02197169|Experimental|DNX-2401 + Interferon gamma (IFN-γ)|Interferon gamma (IFN-γ) beginning at Day 14
16662756|NCT02197156|Experimental|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
16662757|NCT02197156|Experimental|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
16662758|NCT02197156|Experimental|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
16662759|NCT02197156|Experimental|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
16662760|NCT02197156|Active Comparator|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
16662761|NCT02197156|Placebo Comparator|Placebo|Matching placebo
16662762|NCT02197143|Experimental|Esomeprazole|40 mg Esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
16662763|NCT02197143|Experimental|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
16662764|NCT02197143|Experimental|placebo|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
16662765|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
16662766|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
16662767|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
16662768|NCT02197117|Active Comparator|Remote ischemic conditioning|Standard blood pressure cuff placed on upper arm and inflated to 200 mmHg. The cuff is left inflated at this level for 5 minutes and then rapidly deflated to 0 mmHg left deflated for 5 minutes0 this cycle is repeated 4 times in total.
16662769|NCT02197117|Sham Comparator|Control|Standard blood pressure cuff placed on upper arm and left un-inflated for 40 minutes, and then cuff is removed.
16662770|NCT02197104|Experimental|Citocoline|
16662771|NCT02197091||Observational (communication in oncology treatment)|Patients complete questionnaires, including the FACIT-TS-G, the FACIT-Sp12, the MOS-SSS, and the DT. Doctors also complete a questionnaire. Patients' medical records may be reviewed, if necessary.
16662772|NCT02197078||Glitazones|
16662773|NCT02197078||Linagliptin|
16662774|NCT02197078||Sulfonylurea|
16662775|NCT02197078||Within-class comparators|
16662776|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
16662777|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
16662778|NCT02197052||Computer Based Survey Arm|Participants randomized to the computer based self-completed survey arm were issued a tablet computer to answer survey questions. All participants were encouraged to ask for technical assistance if needed at any point, and like in the face-to-face interviews, electronic survey could be re-initiated at the point of discontinuation after any interruption. Those in the tablet survey arm also could complete the survey in their preferred language and all were additionally given headsets so they could use audio assist with identical, pre-recorded questions in the selected language.
16662779|NCT02197052||Face-to-face interview arm|Participants randomized to this condition were interviewed in-person by a fully bilingual (English-Spanish), bi-cultural research assistant trained in cultural humility, standard research protocols and interviewing practices. Interviews were conducted in clinical rooms in respondent's preferred language, were easily interrupted for medical care, and the survey could be re-initiated at the point of discontinuation after any interruption. Participant responses during face-to-face interviews were recorded by the research assistant on paper and later recorded electronically.
16662780|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.
~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.
~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
16662839|NCT02196623|Experimental|Hypoxic Exercise|Supervised, progressive aerobic exercise for 8 weeks under hypoxic conditions
16662840|NCT02196623|Sham Comparator|Normoxic exercise|Supervised, progressive aerobic exercise for 8 weeks under normoxic conditions
16662842|NCT02196610||END-STAGE RENAL DISEASE (ESRD) group|A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate <15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
16662781|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.
~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.
~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
16662782|NCT02197026|Experimental|Synvisc group|injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments
16662783|NCT02197026|Active Comparator|Osteoarthritis standard treatment group|Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product
16662784|NCT02197013||Introcan Safety 3|Closed IV Catheter
16662785|NCT02197013||Introcan Safety|IV catheter
16662786|NCT02197000|Experimental|DIM-Avail 100mg|women will receive DIM 100mg*1/d, a nutritional supplement for 24 months.
16662787|NCT02196987||Urination, urethral catheterisation|Act of urination during urethral catheterisation in males
16662788|NCT02196987||Lie, catheterisation, urethra|Urethral catheterisation without medical professional guidance
16662789|NCT02196974|Experimental|cryobiopsy|
16662790|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
16662791|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
16662792|NCT02196948|Experimental|Electrolysis Percutaneous Therapeutic (EPTE)|Electrolysis Percutaneous Therapeutic (EPTE) consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon, to initiate a local inflammatory process allowing phagocytosis and repair of the affected tissue. The technique is pain-free since the electrical intensity is adapted to each patient. In addition, patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
16662793|NCT02196948|Experimental|Eccentric exercise|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
16662794|NCT02196935||ERCP/EUS|All patients who undergo ERCP and EUS for clinical indications will undergo a detailed prospective assessment of clinical course.
16662795|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
16662796|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
16662797|NCT02196909|Active Comparator|HIBM patient|motor function, muscle strength, NMR, 24h urine and serum collections at baseline, then annually
16662798|NCT02196909|Active Comparator|Controls|motor function, muscle strength, 24h urine and serum collections at baseline only
16662799|NCT02196896|Experimental|deprexis®|Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
16662800|NCT02196896|Placebo Comparator|Information|Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
16662801|NCT02196883|Active Comparator|MRI Pathology|
16662802|NCT02196883|Active Comparator|Physical Exam Pathology|
16662803|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
16662804|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
16662805|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
16662841|NCT02196610||HEALTHY SUBJECTS group|A group of 20 healthy staff volunteers identified from the Division of Nephrology, Dept. of Medicine and the Kidney Research Centre at the Ottawa Hospital Research Institute will be invited to participate. Measurements of arterial stiffness will be performed by Applanation tonometry. Healthy status will be defined by a self-reporting questionnaire obtained over the phone prior to enrolment and 2 subsequent non-invasive measurements of arterial blood pressure (BP) prior to testing. Subjects will be included if diastolic BP is ≤ 90 mm Hg and systolic BP ≤ 140 mm Hg on 2 consecutive measurements.
16662843|NCT02196597||resection with RCT|rectal resection in the case of rectal carcinoma with preoperative radiochemotherapy
16662844|NCT02196597||resection without RCT|patients with rectal resection without preoperative radiochemotherapy
16662806|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.
~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.
~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
16662807|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
16662808|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
16662809|NCT02196818||Mpact Acetabular Shell|Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
16662810|NCT02196805|Experimental|1|
16662811|NCT02196805|Experimental|2|
16662812|NCT02196792|Active Comparator|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
16662813|NCT02196792|Active Comparator|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
16662814|NCT02196792|Active Comparator|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
16662815|NCT02196792|Active Comparator|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
16662816|NCT02196779||Patients undergoing abdominoplasty|Skin circulation to abdominal flap is evaluated during surgery using laser fluorescent imaging.
16662817|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
16662818|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
16662819|NCT02196753||CIED related infection|"All patients will undergo standard diagnostic process that will consist of: medical interview, physical examination, laboratory tests, blood cultures (3 sets, 1 hour apart, repeated after 24 hours and -if applicable - with fever peak above 38°C); imaging studies (echocardiography: transthoracic, and if there are no contraindications transesophageal, in case of negative or equivocal result repeated after 7-10 days, or in series if necessary, computed tomography scan for pulmonary embolism if indicated); if there are abnormalities in other systems, decisions concerning further diagnostics will be made by the physician in charge.
~Apart from standard diagnostic procedures patients will undergo whole body PET CT scan to localize infection or inflammation.
~Then the investigators team will make a decision concerning further treatment (antibiotics and complete device removal vs conservative treatment)."
16662820|NCT02196753||Non-infective|Control group consisting of 20 pts with implanted CIEDs who underwent PET CT due to non infectious indications and have no data for infectious process in follow-up
16662821|NCT02196740|Active Comparator|creosote|Creosote ，once，three weeks Triple Antibiotic Paste ，none
16662822|NCT02196740|Experimental|Triple Antibiotic Paste|Triple Antibiotic Paste,once,three weeks creosote,none
16662823|NCT02196727||Patients undergoing Bascom operation|
16662824|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
16662825|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
16662826|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
16662827|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
16662828|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
16662829|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
16662830|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
16662831|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
16662832|NCT02196662|Experimental|Treatment A|IBD98-M: mesalamine-sodium hyaluronate 200mg-28.75mg X2
16662833|NCT02196662|Experimental|Treatment B|IBD98-M without HA: Mesalamine 200mg X2
16662834|NCT02196662|Experimental|Treatment C|Delzicol 200 mg X2
16662835|NCT02196649|Experimental|Endoscopic Clipping|Participants randomised to the arm will receive endoscopic clips to their defect following EMR.
16662836|NCT02196649|No Intervention|No Endoscopic Clipping|These participants will receive standard of care practice only.
16662837|NCT02196636|Experimental|Part 1: Single Ascending Dose (SAD)|Adaptive model per protocol
16662838|NCT02196636|Experimental|Part 2: Food Effect (FE)|Fasted versus Fed
16662885|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
16662845|NCT02196571|Experimental|Exercise and lifestyle change|Women in the experimental group will be included in structured exercise programme two times per week with duration of 50 minutes.Participants will start with training sessions right after they are diagnosed with GDM and they will exercise until the end of the pregnancy or occurence of contraindications. Programme will consist of aerobic exercises (20 minutes), resistance exercises (20 minutes), plevic floor, stretching and relaxation exercises (10 minutes). Women in control group will receive standard antenatal care.
16662846|NCT02196571|No Intervention|Control|Standard antenatal care
16662847|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
16662848|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
16662849|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
16662850|NCT02196545|Experimental|Exercise|Exercise, patients train on a specifically programmed movement trainer three times a week for 30 minutes (total duration 12 weeks)
16662851|NCT02196545|No Intervention|Treatment as usual|Treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without movement trainer exercise
16662852|NCT02196532||migraine group|Patients with migraine
16662853|NCT02196532||healthy control|Sex- and agematched healthy subjects
16662854|NCT02196519|Experimental|Test|All test arm subjects received Sylys Surgical sealant around anastomotic junction after closure.
16662855|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
16662856|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
16662857|NCT02196493|Experimental|Azithromycin|250mg azithromycin three times weekly for 12 weeks
16662858|NCT02196480|No Intervention|Methotrexate|JIA patients on stable dose of methotrexate vaccinated with PPV23
16662859|NCT02196480|Experimental|anti-TNF|JIA patients refractory to methotrexate immediately before the association of anti-TNF vaccinated with PPV23
16662860|NCT02196467|Experimental|Myoblast transplantation & strength|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
16662861|NCT02196467|Sham Comparator|Saline injection & strength|The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
16662862|NCT02196454|No Intervention|Vaccine Information Statement|Study participants will receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
16662863|NCT02196454|Experimental|Video & Vaccine Information Statement|Participants will view an educational video about the HPV vaccine with a male or female narrator. Participants will also receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
16662864|NCT02196441|Experimental|Group 2|0.5% bupivacaine Deep topical fornix nerve block anaesthesia (DTFNB)
16662865|NCT02196441|Experimental|Group 1|2% tetracaine local anaesthetic drops
16662866|NCT02196428|Other|Telemonitoring and Teleconsultation|
16662867|NCT02196402||study population|"Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications (screening, symptoms, surveillance).
~Exclusion criteria:
~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer
~patients with inadequate bowel preparation
~patients in which cecal intubation was not achieved or scheduled for partial examinations
~polyps could not be resected due to ongoing anticoagulation or could not be retrieved for pathologic assessment"
16662868|NCT02196389|Active Comparator|Nozovent|Nasal Dilator
16662869|NCT02196389|Active Comparator|Nasanita|Nasal Dilator
16662870|NCT02196389|Active Comparator|Breath Right|Nasal Dilator
16662871|NCT02196389|Active Comparator|Airmax|Nasal Dilator
16662872|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
16662873|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
16662874|NCT02196363||Pregnant mothers|No intervention
16662875|NCT02196350|Experimental|Intervention A: Diet|Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).
16662876|NCT02196350|Experimental|Intervention B: Exercise|"Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes).
~Healthy isocaloric diet."
16662877|NCT02196350|Experimental|Intervention C: Diet and Exercise|"Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet.
~One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)"
16662878|NCT02196350|No Intervention|Control - Historical data|Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.
16662879|NCT02196337||Women of reproductive age|Age: 18-44 years
16662880|NCT02196337||Pregnant women|Age: 18-44 years
16662881|NCT02196337||Lactating women|Age: 18-44 years
16662882|NCT02196337||Young infants|Age: younger than 6 months
16662883|NCT02196337||Toddlers|Age: between 6 and 24 months
16662884|NCT02196337||School-aged children|Age: 6-12 years
16662887|NCT02196311||Supracondylar humerus fractures|We are looking to compare open reduction internal fixation versus circular external fixation for supracondylar humerus fractures.
16662888|NCT02196298|Experimental|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
16662889|NCT02196298|Active Comparator|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
16662890|NCT02196285|Experimental|Double viral vaccine (MR)|Measles and rubella vaccine
16662891|NCT02196272|Experimental|Nurse-led email program through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse care manager (NCM).
16662892|NCT02196272|No Intervention|Management of diabetic patients|Usual care, educational program and usual management of Diabetic patients
16662893|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
16662894|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
16662895|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
16662896|NCT02196207|Experimental|Eloctate Prophylaxis|Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
16662897|NCT02196207|Experimental|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
16662898|NCT02196207|Experimental|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
16662899|NCT02196207|Active Comparator|Eloctate ITI Alone|Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
16662900|NCT02196194||tiotropium|
16662901|NCT02196181|Experimental|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
16662902|NCT02196181|Experimental|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
16662903|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
16662904|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
16662905|NCT02196155|Active Comparator|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
16662906|NCT02196155|Active Comparator|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
16662907|NCT02196155|Placebo Comparator|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
16662908|NCT02196142|Active Comparator|Cortisol first, Placebo second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
16662909|NCT02196142|Active Comparator|Placebo first, Cortisol second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
16662910|NCT02196129|Experimental|Sinbaro-3|1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions
16662911|NCT02196129|Placebo Comparator|Hwangryun(distillation)|1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention
16662912|NCT02196116|Active Comparator|Group 1|Controls
16662913|NCT02196116|Experimental|Group 2|Cognitively-impaired subjects without dementia and without memory
16662914|NCT02196116|Experimental|Group 3|Cognitively-impaired subjects without dementia and with memory
16662915|NCT02196103|Experimental|Expectant management|
16662916|NCT02196090|Experimental|Single arm|Study uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
16662917|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
16662918|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
16662919|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
16662920|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
16662921|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
16662922|NCT02196064||Safety of the three-drug combination TDF/FTC/RPV|A total of 176 patients will be included in this study, as well as 352 patients naive for RPV who initiated any ART that does not include RPV, who will serve as control group.
16663132|NCT02194686|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
16662923|NCT02196051|Experimental|Exercise Training|Participants will engage in a single bout of elliptical exercise for 45 minutes (3X15 spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Participants will then take part in six weeks of exercise training on an elliptical trainer 3 times per week each time for 45 minutes. Hepatic de novo lipogenesis will be compared pre and post to examine wether improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
16662924|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
16662925|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
16662926|NCT02196025|Experimental|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
16662927|NCT02196012|Experimental|Lifestyle counseling|The intervention condition will contain multiple components: nutrition education, physical activity, social support, social media (Pinterest and Facebook), and smartphone applications for self-monitoring. Students in this condition will have access to the private study website, which will be the central platform for delivery of the program materials and social support. The website, developed using Wordpress.com, will include nutrition materials, exercise videos, a forum, and links to the study's Facebook and Pinterest pages
16662928|NCT02196012|Active Comparator|attention control condition|Students randomized to the attention control condition will receive educational emails three times per week. Nutrition materials will be sent once a week, and links to the YouTube exercise videos will be sent twice a week. At the start of the program, students will be emailed a link to the Pandora workout station. The materials sent to the control group will be the same materials posted on the website for the intervention group. Participants will access the emailed lessons and videos each week at their own convenience. Individuals in the attention control condition will not have access to the study website or social media pages.
16662929|NCT02195999||Individuals with DMD|"Magnetic Resonance Imaging is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
~Pulmonary Function testing (PFT) are a series of non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
~Metabolic exercise testing using stationary bicycle (exercise capacity and MVO2) evaluates global cardiopulmonary functional status.
~Echocardiogram with multiple-echo Dixon method helps to assess cross-sectional and longitudinal variations in myocardial structure."
16662930|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
16662931|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
16662932|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
16662933|NCT02195973|Experimental|Paclitaxel + LDE225|Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
16662934|NCT02195960|Placebo Comparator|placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
16662935|NCT02195960|Active Comparator|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
16662936|NCT02195947|Experimental|Antagonist and Growth hormone|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
16662937|NCT02195947|No Intervention|Antagonist|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
16662938|NCT02195934|Other|Standard orange juice (OJ) followed by blood OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
16662939|NCT02195934|Other|Blood orange juice followed by standard OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
16662940|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
16662941|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
16662974|NCT02195739||Smoking cessation advice cohort|Cohort (control patients) defined as patients whose first recorded smoking cessation intervention involved smoking cessation advice leading to a quit attempt unassisted by pharmacological smoking cessation aids, at the index smoking cessation attempt.
16662942|NCT02195921|Experimental|ST36+CV12 acupoints|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
16662943|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
16662944|NCT02195908|Experimental|Single point PC6|"choose single point: Neiguan(PC6).Neiguan(PC6): On the anterior aspect of the forearm,between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
16662945|NCT02195908|Experimental|Single point CV12|"choose another single point Zhongwan（CV12）. Zhongwan(CV12): On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line. Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
16662946|NCT02195908|Experimental|Matching points PC6+CV12|"Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
16662947|NCT02195908|Active Comparator|only antiemetic|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.
16662948|NCT02195895|Experimental|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months
~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
16662949|NCT02195882|Experimental|Exercise program|
16662950|NCT02195869|Experimental|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
16662951|NCT02195869|Experimental|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
16662952|NCT02195869|Experimental|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
16662953|NCT02195869|Experimental|Phase 2|Subjects receive daily dose of recommended phase 2 dose
16662954|NCT02195856|Active Comparator|Diseased condition|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
16662955|NCT02195856|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
16662956|NCT02195843|Active Comparator|Emperical|Anatomical optimization of device and leads
16662957|NCT02195843|Active Comparator|Electrical|Electrical optimization by RVLV Conduction Time with VectSelect
16662958|NCT02195830|Other|Single arm - Ultrasound|All participants will have an Ultrasound measurement of their inferior vena cava at enrolment as described in the intervention
16662959|NCT02195817|Other|Selincro® 18 mg with continuous psychosocial support: Cohort A|Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support
16662960|NCT02195817|Other|Initial psychosocial support: Cohort B|Initial psychosocial support followed by usual care practice, 12-week Observational Period
16662961|NCT02195804|Experimental|Ranitidine HCL ODT Vanilla-Mint|
16662962|NCT02195804|Experimental|Ranitidine HCL ODT RM Vanilla-Mint|
16662963|NCT02195804|Active Comparator|Ranitidine HCL|Maximum Strength ZANTAC 150®
16662964|NCT02195791|Active Comparator|Pioglitazone|
16662965|NCT02195791|Placebo Comparator|Placebo|
16662966|NCT02195778||Young, 18 to 30|
16662967|NCT02195778||Middle, 31 to 50|
16662968|NCT02195778||Older, 51 to 70|
16662969|NCT02195765|Experimental|enamel matrix derivative|Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
16662970|NCT02195765|Active Comparator|Open flap debridment|Open flap debridement
16662971|NCT02195752||Prescribed Compounded Pain Cream|The study is limited to patients who have been prescribed treatment with a topical compounded pain cream as a component of their ordinary care by a qualified physician.
16662972|NCT02195739||Nicotine replacement therapy cohort|Cohort defined as patients in whom nicotine replacement therapy (in any preparation) was initiated at the index smoking cessation attempt as the first recorded smoking cessation intervention.
16662973|NCT02195739||Other smoking cessation therapy|Cohort defined as patients in whom other (non-nicotine replacement therapy) smoking cessation pharmacotherapy's were initiated at the index smoking cessation attempt (e.g. bupropion, varenicline) as the first recorded smoking cessation intervention
16662975|NCT02195726|Sham Comparator|Sham remote ischemic preconditioning'|In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline
16662976|NCT02195726|Experimental|Remote ischemic preconditioning|"In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion.
~In subjects presenting with BMI > 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation"
16662977|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
16662978|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
16662979|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
16662980|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
16662981|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
16662982|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
16662983|NCT02195661|Active Comparator|Melatonin sleep EEG induced group|"All children who were referred to the neurophysiology department who were either unable to keep still for their EEG, or required a sleep EEG as part of their epilepsy work-up and whose caregivers agreed to the administering of sedation with melatonin. Melatonin by mouth (3mg for children < 15kg, 6mg for those > 15kg) 1 hour before the scheduled EEG by the unit nurse. Children who can swallow the capsules directly, those who cannot are given the contents of the powder in the capsule mixed in a few millilitres of water. If the child fails to fall asleep within one hour of administration of the melatonin then a second dose 3mg is given) ."
16662984|NCT02195661|Other|Comparison group for children sedated using previous practice|Since the choral hydrate had been withdrawn a direct comparison group was not possible. However a study performed the previous year in the department measured a several parallel useful outcomes. This study had addressed the usefulness of electroencephalograms in a South African population. A proportion of this group screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). These patients were drawn from the same regional pool, with the same disease demographics, and the same sleep deprivation and procedural techniques to the current group. This group was screened for several common denominators to the current study themes, and comparison will be made between these, namely the proportion of patients with successful attainment of sleep studies, the proportion of studies with excessive artifact (precluding interpretation) and the usefulness of the data attained detailing whether the studies were able to assist or alter patient management.
16662985|NCT02195648|Experimental|Suboccipital inhibition|The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
16662986|NCT02195648|No Intervention|Control|No intervention will be done to the participants during the study. After study completion, the participants will be offered to receive the therapy.
16662987|NCT02195635|Experimental|Period 1|Single oral dose of 500 mg telotristat etiprate on Day 1
16662988|NCT02195635|Other|Period 2|Subcutaneous injections of 200 µg octreotide acetate three times daily with a single oral dose of 500 mg telotristat etiprate on Day 6
16662989|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
16662990|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
16662991|NCT02195609|Other|Omega-3|600 mg (EPA, DHA and Omega-3) twice a day
16662992|NCT02195609|Other|Soy Isoflavones|54.4mg oral twice a day
16662993|NCT02195596|Experimental|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient."
16662994|NCT02195596|Active Comparator|Low intensity aerobic exercise+strength|The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
16662995|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
16662996|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
16662997|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
16662998|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
16662999|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
16663000|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
16663001|NCT02195570|Experimental|QSN with CM (QSN-CM).|Women will receive standard of care Quit Smoking Now tobacco education and support plus prize-based contingency management. Their smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Women will earn chances to win prizes each time they test negative for smoking according to biochemical measures.
16663002|NCT02195570|Active Comparator|QSN Only|Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
16663003|NCT02195557||Synvisc®|
16663004|NCT02195544||Synvisc®|
16663005|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
16663008|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
16663009|NCT02195505||Synvisc®|
16663010|NCT02195505||Usual treatment of knee|nonsteroidal antiinflammatory drugs, antalgics
16663011|NCT02195492||Synvisc®|
16663014|NCT02195466|Experimental|TPV + RTV + FCZ|
16663015|NCT02195453|Experimental|Yangzhengxiaoji Capsule|"Gemcitabine or Pemetrexed
~Cisplatin
~Yangzhengxiaoji Capsule four granules t.i.d po"
16663016|NCT02195453|Placebo Comparator|Placebo Capsule|"Gemcitabine or Pemetrexed
~Cisplatin
~Placebo Capsule four granules t.i.d po"
16663017|NCT02195440|Experimental|PRI-724|
16663018|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
16663019|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
16663020|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
16663021|NCT02195401||Sleeping in a cleanroom|Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
16663022|NCT02195388||CR with AH|Patients after ACS with arterial hypertension treat with comprehensive cardiac rehabilitation
16663023|NCT02195388||N-CR with AH|Patients after ACS with arterial hypertension don't treat with comprehensive cardiac rehabilitation.
16663024|NCT02195388||CR without AH|Patients after ACS without arterial hypertension treat with comprehensive cardiac rehabilitation
16663025|NCT02195375|Experimental|Flutiform 500/20 µg BID|Flutiform 250/10 (2 puffs BID)
16663026|NCT02195375|Experimental|Flutiform 250/10 µg BID|Flutiform 125/5 (2 puffs BID)
16663027|NCT02195375|Active Comparator|Seretide Accuhaler 50/500 µg BID|Seretide Accuhaler 50/500 (BID)
16663028|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
16663029|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
16663030|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
16663031|NCT02195336|Experimental|dMRT, Bevacizumab, Chemotherapy|"dMRT: Magnetic Resonance Tomograph, Baseline, day 8, day 28, day 92, progression/relapse.
~Bevacizumab: 7.5mg/kg every 3 weeks for 3 cycles. Standard of care NSCLC first-line chemotherapy, doublets containing paclitaxel and carboplatin are preferred, every 3 weeks for 3 cycles.
~Thereafter Bevacizumab 7.5mg/kg every 3 weeks until progression/relapse or unacceptable toxicity."
16663032|NCT02195323|Experimental|MSC recipient|The patients with CKD who underwent intravenous injection of MSC.
16663033|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
16663034|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
16663035|NCT02195297|Active Comparator|ANTICELLULITE GMG GIULIANI|Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
16663036|NCT02195297|Active Comparator|SOMATOLINE|Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
16663037|NCT02195284|Experimental|Sub-study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler
16663038|NCT02195284|Experimental|Sub-study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI (metered-dose inhaler) or use MDI first and then ELLIPTA inahler
16663039|NCT02195284|Experimental|Sub-study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA inhaler
16663040|NCT02195271|Active Comparator|Melatonin|0,25mg/Kg sl before tDCS
16663041|NCT02195271|Experimental|tDCS|Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
16663042|NCT02195258||salbutamol|
16663043|NCT02195245|No Intervention|Control|Control - Observational (non interventional) data is collected from current state of the art absorber devices.
16663044|NCT02195245|Experimental|memsorb|New CO2 filter - data is collected using the new CO2 absorber.
16663045|NCT02195232|Experimental|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days
~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
16663046|NCT02195232|Experimental|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days
~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
16663047|NCT02195219|Experimental|open reduction internal fixation|open reduction internal fixation
16663048|NCT02195219|Active Comparator|non operative treatment|'sling rest and early functional recovery
16663049|NCT02195206||Healthy|Adult
16663050|NCT02195193|No Intervention|Usual Care (UC)|"The standard interventions from Clinical Pathway for Acute Coronary Syndromes in China-Phase 3 (CPACS-3) study that are limited to in-patient ACS care (refer to Usual Care [UC]), will be implemented in the participating hospitals, and hence will be received by all patients in both intervention (IC) and control (UC) groups; standardized cardiovascular disease education also will be provided to all participants.CPACS-3 registration number is NCT01398228"
16663051|NCT02195193|Experimental|Intervention Care (IC)|Besides of the UC, an nurse-coordinated integrated care model for Acute Coronary Syndromes(ACS) and depression will be delivered to intervention group, including ACS secondary prevention therapies at and after discharge, screening and treatment of depression during hospitalization and after discharge.
16663052|NCT02195180|Experimental|standard of care combined with ERY001|standard of care = Gemcitabine or folfox
16663053|NCT02195180|Sham Comparator|standard of care alone|standard of care = Gemcitabine or folfox
16663054|NCT02195167|Experimental|Dasotraline|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
16663055|NCT02195154|Experimental|18F-DTBZ for Vascular Parkinsonism|This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
16663056|NCT02195141|Active Comparator|conventional fraction|Radiotherapy (25x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily
16663057|NCT02195141|Experimental|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
16663058|NCT02195115|Active Comparator|Laparoscopic cholecystectomy|surgical removal of gallbladder
16663059|NCT02195115|Active Comparator|Non-operative treatment|Administration of amitriptyline 25mg daily, Low Fat-Low Cholesterol Diet
16663060|NCT02195102||transcatheter aortic valve Replacement|Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses.
16663061|NCT02195089|Experimental|BLS_ILB_E710c 500mg|"Drug: BLS_ILB_E710c 500mg
~Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 & 8)"
16663062|NCT02195089|Experimental|BLS_ILS_E710c 1000mg|"Drug: BLS_ILS_E710c 1000mg
~Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 & 8)"
16663063|NCT02195089|Experimental|BLS_ILS_E710c 1500mg|"Drug: BLS_ILS_E710c 1500mg
~Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 & 8)"
16663064|NCT02195076||Breast Cancer patients|
16663065|NCT02195076||Lung cancer patients|
16663066|NCT02195076||Healthy controls|
16663067|NCT02195063||Pain management|patients undergoing transdermal treatment for pain
16663068|NCT02195063||Scar care|patients undergoing transdermal treatment for scars
16663069|NCT02195063||Wound care|patients undergoing transdermal treatment for wounds
16663070|NCT02195063||UDT|patients receiving urinary drug tests
16663071|NCT02195050||Therapeutic target arm|Statin treated patients with and without raised triglycerides who do not have diabetes or dysglycemia. Statin treated patients with type 2 diabetes.Statin treated patients with CKD stages 4 and 5 (eGFR ≤30mL/min).
16663072|NCT02195050||Nerve function arm|Patients with severe hypertriglyceridaemia (fasting TG > 5.5mmol/l.) are recruited for nerve function assessment and corneal confocal microscopy.
16663073|NCT02195050||Genetic screening arm|For LAL deficiency screening, patients will be recruited over a 5 year period with a documented triglyceride level of more than 10 mmol/l at any time, low HDLC, raised ALT, combined hyperlipidaemia, or non-alcoholic fatty liver disease. Patients recruited from Manchester will be offered additional genetic testing for familial hypercholesterolaemia.
16663074|NCT02195024|Active Comparator|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
16663075|NCT02195024|No Intervention|No MRI group|Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
16663076|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.
~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
16663077|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.
~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
16663078|NCT02194998|Experimental|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
16663079|NCT02194998|Experimental|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
16663080|NCT02194998|Experimental|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
16663081|NCT02194998|Experimental|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
16663082|NCT02194985|Experimental|Migalastat HCl 150 mg|Migalastat HCl 150 milligram (mg).
16663083|NCT02194972|Experimental|soluble dietary fiber|pectin, a kind of soluble dietary fiber
16663084|NCT02194972|No Intervention|Placebo|Placebo
16663085|NCT02194959|Experimental|Peer PN|A scheduling phone call will be made to all patients within 14 days of their initial referral to the study. Following the scheduling of their appointment, each patient will be mailed an informational pamphlet with written instructions for the colonoscopy once they have scheduled the procedure. The first reminder PPN phone call will be made two weeks before a patient's scheduled colonoscopy. The second reminder PPN call will be made three days before the scheduled colonoscopy. For all calls, at least three attempts (at different times of the day and different days of the week) will be made to reach patients. All telephone calls will be audio-recorded to facilitate fidelity monitoring. All colonoscopy appointments will be made within the Division of Gastroenterology at each of the hospital sites. The Project Coordinator will be responsible for confirming completion (and no-shows) for all colonoscopy appointments.
16663086|NCT02194959|Active Comparator|Pro PN|Participants randomized to standard patient navigation received care that they would normally receive if they were not participating in the study with navigation from the GI staff, and three phone calls that involved scheduling and reminding the participant about their colonoscopy appointment.
16663087|NCT02194946|Active Comparator|CKD-related management group|"Patients in basic care group are provided with basic western medicine treatment according to Kidney Disease: Improving Global Outcomes(KDIGO) and The National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guidelines but not prescribed any Chinese herbal medicine.
~The basic western medicine treatment mainly includes dietary protein restriction(0.6g/kg·d, for Chinese), Blood pressure control, treating anemia with erythropoietin,treatment of abnormal calcium-phosphate metabolism, and treatment of fluid, electrolyte and acid-base disorders."
16663088|NCT02194946|Experimental|CM therapies group|Participants will receive CM therapies and CKD-related management concurrently. One or several the following CM patterns will be allowed: a. Chinese herbal formula via oral administration; b. Chinese patent medicine via oral administration; c. Chinese herbal formula via colonic administration; d. Chinese patent medicine via colonic administration.
16663089|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
16663090|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
16663091|NCT02194920||Parathyroid reimplantation|
16663092|NCT02194907|Active Comparator|Anterior insula cortex activation|Participants will receive training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain, while thinking of and viewing emotional faces, scenes, and text.
16663093|NCT02194907|Active Comparator|Primary auditory cortex activation|Participants will have training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain while thinking of and viewing emotional faces, scenes, and text.
16663094|NCT02194894|Active Comparator|NAFLD patients|Twenty patients with NAFLD will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
16663095|NCT02194894|Active Comparator|Healthy controls|Twenty healthy controls will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
16663096|NCT02194881||Ivacaftor 1|patients with CF who are homozygous or heterozygous for the G551D mutation and treated with Ivacaftor
16663097|NCT02194868||donors of hematopoietic stem|Adult and minor donors of hematopoietic stem
16663098|NCT02194868||patients requiring allogeneic hema|Adult and minor patients (recipients) requiring allogeneic hema
16663099|NCT02194855|Experimental|laparoscopic operation on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
16663133|NCT02194686|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
16663272|NCT02193906|Placebo Comparator|Placebo group|Placebo task.
16663100|NCT02194855|Experimental|laparoscopic operation on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
16663101|NCT02194855|Experimental|conventional open surgery on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
16663102|NCT02194855|Experimental|conventional open surgery on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
16663103|NCT02194842|Active Comparator|Enzalutamide|Enzalutamide will be given at a dose of 160 mg daily
16663104|NCT02194842|Experimental|Enzalutamide and Ra223|Ra223 will be administered 50kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.
16663105|NCT02194829|Experimental|Arm A (phase I, dose level 1)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 PO daily on days 1, 2, 8, 9, 15, and 16.
16663106|NCT02194829|Experimental|Arm B (phase I, dose level 2)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.
16663107|NCT02194829|Active Comparator|Arm C (phase II, placebo)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily on days 1, 2, 8, 9, 15, and 16.
16663108|NCT02194829|Experimental|Arm D (phase II, WEE1 inhibitor MK-1775)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 (recommended phase II dose) as in Arm A.
16663109|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
16663110|NCT02194803||Cohort with routine OCT monitoring|
16663111|NCT02194803||Cohort without routine OCT monitoring|
16663112|NCT02194790|Experimental|community-based Integrated CKD care|Standard CKD care + multidisciplinary team and home visit by community care team
16663113|NCT02194790|No Intervention|Conventional CKD care|standard CKD care
16663114|NCT02194777|Experimental|BIBN 4096 BS - in single rising doses|
16663115|NCT02194777|Placebo Comparator|Placebo|
16663116|NCT02194764|Experimental|Expirimental Formulation|Participants will be administered a single encapsulated dose of the test formulation (Model Naltrexone 50mg containing 2-butanol). Breath samples will be taken over 90 minutes (-5, 0, 5, 10, 20, 40, 60, 90). Subjects will then be randomly crossed over to the four interventions (Formulation 1, Formulation 2, Formulation 3, Formulation-free positive control) three formulations from the first part of the study and a control administration (a capsule-in-capsule design).
16663117|NCT02194751|Experimental|Oncoquest-L vaccine|Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
16663129|NCT02194712||travellers|travellers with recent (<12 weeks) high risk water contact are included in the study and asked to provide samples for CAA testing
16663130|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
16664911|NCT02183415|Placebo Comparator|Placebo|
16663134|NCT02194673|Experimental|Trans free palm margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
16663135|NCT02194673|Experimental|Interesterified palm based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
16663136|NCT02194673|Experimental|IE soybean oil-based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
16663137|NCT02194660||M- main hospital|Patient enrolled in the main hospital
16663138|NCT02194660||B- Beihu branch|Patients enrolled in the Beihu branch
16663139|NCT02194634|Experimental|Conbercept treatment group|Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the subjects need to get repeated treatment according to monthly assessment.
16663140|NCT02194634|Active Comparator|Laser treatment group|Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months.
16663141|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
16663142|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
16663143|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
16663144|NCT02194608|Experimental|Telemedicine system|Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits.
16663145|NCT02194608|No Intervention|Usual care|Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits.
16663146|NCT02194595|Experimental|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
16663147|NCT02194595|Active Comparator|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
16663148|NCT02194595|Active Comparator|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
16663149|NCT02194569|Experimental|High citrate group|Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
16663150|NCT02194569|Experimental|Low citrate group|Blood flow according to weight. Target citrate concentration is 2.5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 1.3-1.6 mg/dL.
16663151|NCT02194556|Experimental|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
16663152|NCT02194556|Active Comparator|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib (125 mg three times per day) as maintenance treatment until disease progression or intolerable toxicity.
16663153|NCT02194543||HD 3D|The patients received surgeries with HD 3D on their left eyes.
16663154|NCT02194543||Conventional|The patients received surgeries with conventional method on the other eye.
16663155|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
16663156|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
16663157|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
16663158|NCT02194517|No Intervention|control (B)|Patients performing CHO and FP exchanges calculation with standard method.
16663159|NCT02194517|Experimental|ELKa (A)|Patients counting CHO and FP exchanges with ELKa toolset.
16663160|NCT02194504|No Intervention|No dietary advice|No dietary intervention
16663161|NCT02194504|Experimental|Dietary advice, Targeted|12-wk dietary advice
16663162|NCT02194504|Experimental|Dietary advice, Western|12-wk dietary advice
16663163|NCT02194491|Experimental|[11C]AS2471907 administration (Part 1)|Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.
16663164|NCT02194491|Experimental|ASP3662 administration (Part 2)|The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.
16663165|NCT02194478|Other|8 Week Meditation|Allina Health employees undergoing 8 week meditation intervention
16663166|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
16663167|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
16663168|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
16663169|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
16663170|NCT02194465|Experimental|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
16663171|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
16663172|NCT02194465|Placebo Comparator|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
16663173|NCT02194452|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|"Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.
~Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis"
16663174|NCT02194439||hematopoietic stem cell transplant|procedure
16663175|NCT02194426|Experimental|MP0250|"see section intervention description below"
16663176|NCT02194413|Experimental|Arm 1 (healing touch)|"Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital (therapeutic touch).
~Interventions: therapeutic touch, quality-of-life assessment, and questionnaire administration"
16663177|NCT02194413|Active Comparator|Arm II (usual care)|"Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital.
~Interventions: quality-of-life assessment, and questionnaire administration"
16663178|NCT02194400|Placebo Comparator|Placebo|Saline infusion
16663179|NCT02194400|Experimental|RSLV-132|0.3 - 10 mg/kg experimental drug
16663180|NCT02194387|Experimental|Supportive care (energy balance interventions)|"TELEPHONE COACHING VS EMAIL COACHING: Participants receive telephone coaching once per week for 16 weeks or 1 email per week for 16 weeks (with follow-up responses if the participant responds) from a coach trained in motivational interviewing.
~TEXT MESSAGES: Participants receive daily text messages promoting adherence to diet and exercise recommendations daily 1-3 times per day or no text messages.
~SOCIAL NETWORKING: Participants are invited to an online forum for study participants available for 16 weeks or do not receive an invitation for social networking.
~SELF-MONITORING: Participants are asked to record their dietary intake 4-7 days per week or 1 day per week on a website or smartphone app."
16663181|NCT02194374|Experimental|ROR1R-CAR-T Cells|"Peripheral blood mononuclear cells (PBMC) collected via venipuncture and/or steady state leukapheresis at discretion of PI. Participants receive a cycle of lympho-depleting chemotherapy as chosen by treating physician 4 to 5 days before ROR1R-CAR-T cell infusion : Fludarabine, Cyclophosphamide, and Rituximab (FCR), Bendamustine and Rituximab (BR), or Fludarabine, Bendamustine, and Rituximab (FBR).
~Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.
~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
16663182|NCT02194361|Experimental|Anthocyan capsules|
16663183|NCT02194361|Placebo Comparator|Placebo|
16663184|NCT02194348|Experimental|BIBN 4096 BS - in single rising doses|
16663185|NCT02194348|Placebo Comparator|Placebo|
16663186|NCT02194335|Experimental|BIBN 4096 BS - in single rising doses|
16663187|NCT02194335|Placebo Comparator|Placebo|
16663188|NCT02194322|Experimental|BIBN 4096 BS - in single rising doses|
16663189|NCT02194322|Placebo Comparator|Placebo|
16663190|NCT02194309|Experimental|Telmisartan low + amlodipine|
16663191|NCT02194309|Experimental|Telmisartan high + amlodipine|
16663192|NCT02194296|Experimental|Ambroxol hydrochloride - lozenge|
16663193|NCT02194296|Active Comparator|Ambroxol hydrochloride - syrup|Mucosolvan®
16663194|NCT02194283|Experimental|Ambroxol - in single rising doses|
16663195|NCT02194283|Placebo Comparator|Placebo|
16663196|NCT02194270|Experimental|Ambroxol hydrochloride - soft pastille|
16663197|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - low dose|
16663198|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - high dose|
16663199|NCT02194257|Experimental|[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge|
16663200|NCT02194257|Experimental|[14C]-benzyl ambroxol oral solution + ambroxol lozenge|
16663201|NCT02194244|Experimental|Granules Fasted|
16663202|NCT02194244|Experimental|Granules Fed|
16663203|NCT02194244|Active Comparator|Tablet Fasted|
16663204|NCT02194244|Active Comparator|Tablet Fed|
16663205|NCT02194231|Experimental|Trabectedin|Patients will receive trabectedin treatment
16663206|NCT02194218|Experimental|Nevirapine XR 4 doses|
16663207|NCT02194218|Active Comparator|Nevirapine XR 2 doses|
16663208|NCT02194205|Experimental|COMBIVENT HFA|
16663209|NCT02194205|Placebo Comparator|Placebo HFA|
16663210|NCT02194205|Active Comparator|COMBIVENT (CFC)|
16663211|NCT02194205|Placebo Comparator|Placebo CFC|
16663212|NCT02194192|Experimental|Group E|Ephedrine 10 mg in Normal Saline 10 ml
16663213|NCT02194192|Active Comparator|Group O|Ondansetron 8 mg in Normal saline 10 ml
16663214|NCT02194192|Placebo Comparator|Group P|Normal saline 10 ml
16663215|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fasted|
16663216|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fed|
16663217|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fasted|
16663218|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fed|
16663219|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fasted|
16663220|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fed|
16663221|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fasted|
16663222|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fed|
16663223|NCT02194179|Active Comparator|NVP IR 200 mg (Viramune®)|
16663224|NCT02194166|Experimental|Pre-Randomization (Trastuzumab IV)|Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
16663267|NCT02193932|Experimental|EEG Triggered fMRI using Micro Maglink|EEG Triggered fMRI to be performed using the Micro Maglink
16663268|NCT02193919||cohort 1 placebo + UVB|cohort 1 placebo + UVB
16663225|NCT02194166|Experimental|Group A: Trastuzumab SC (First Vial Formulation, then SID)|Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
16663226|NCT02194166|Experimental|Group B: Trastuzumab SC (First SID, then Vial Formulation)|Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
16663227|NCT02194153||Metalyse|Metalyse weight-adjusted
16663228|NCT02194140|Other|oral contrast|oral iodinated contrast material
16663229|NCT02194127|Experimental|Anthocyan capsules|capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)
16663230|NCT02194127|Placebo Comparator|Placebo|
16663231|NCT02194114|Experimental|Dietary Protein Intake|One treatment Arm; Protein Diet: All patients will be fed the following five diets, in random order, each for 17-19 days: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
16663232|NCT02194101||Supernormal oxygen delivery goal therapy|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.
16663233|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
16663234|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
16663235|NCT02194075|Active Comparator|Fluvoxamine+Methylphenidate Hydrochloride|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.
~Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks."
16663236|NCT02194075|Placebo Comparator|Fluvoxamine+sugar pill|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.
~sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks."
16663237|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
16663238|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
16663239|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
16663240|NCT02194049|Experimental|BKM 120, cisplatin, etoposide|Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16663241|NCT02194036|Experimental|Learning oriented physiotherapy|Learning oriented physiotherapy is a treatment approach based on knowledge from neuroscience and particularly aimed to curb physical symptoms and ailments, but also to regain a sense of better physical balance and mental control. Therapy sessions are normally given every 2 weeks with individual homework lessons between. The therapy will last between 6 to 12 months depending on learning process and individual needs.
16663242|NCT02194036|Active Comparator|Widely Recognized Psychiatric Treatment|Standard Outpatient Treatment within the Psychiatric clinic
16663243|NCT02194023|Placebo Comparator|Placebo (PCB)|Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)
16663244|NCT02194023|Experimental|0.12%NF|0.12% Chlorhexidine digluconate new formulation
16663245|NCT02194023|Experimental|0.03%NF|0.03% Chlorhexidine digluconate new formulation
16663246|NCT02194023|Active Comparator|PAT (Perio-Aid Treatment)|Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)
16663247|NCT02194010||Participants evaluated at INC sites|Participants being evaluated at the INC sites will participate in both the DSI and HMSN-R-ODS by completing these PROs during their visit.
16663248|NCT02194010||INC Contact Registry|INC Contact Registry completes the HMSN-R-ODS on web http://rarediseasesnetwork.epi.usf.edu/INC/
16663249|NCT02193997|Experimental|Fiber 1|Fiber bar containing inulin as fiber soucre taken once daily for 4 weeks
16663250|NCT02193997|Experimental|Fiber 2|Fiber bar containing soluble corn as fiber soucre taken once daily for 4 weeks
16663251|NCT02193997|Placebo Comparator|Placebo|Bar with low fiber content (placebo) once daily for 4 weeks
16663252|NCT02193984|Experimental|Peer support|Study participants are assigned a volunteer peer supporter who has been trained to offer support on diabetes management.
16663253|NCT02193984|No Intervention|Control|No intervention
16663254|NCT02193971|Active Comparator|BS-DES with prasugrel 10mg daily|BS-DES with prasugrel 10mg daily
16663255|NCT02193971|Active Comparator|BS-DES with prasugrel 5mg daily|BS-DES with prasugrel 5mg daily
16663256|NCT02193971|Experimental|BD-DES with prasugrel 10mg daily|BD-DES with prasugrel 10mg daily
16663257|NCT02193971|Experimental|BD-DES with prasugrel 5mg daily|BD-DES with prasugrel 5mg daily
16663258|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
16663259|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
16663260|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
16663261|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
16663262|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
16663263|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
16663264|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
16663265|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
16663266|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
16663273|NCT02193893|Active Comparator|Stem/progenitor cells transplantation.|Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.
16663274|NCT02193893|Sham Comparator|Standard treatment of ALS|Symptomatic treatment of ALS without biologic cell-based treatment
16663275|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
16663276|NCT02193867|Experimental|Open-Label Sebelipase Alfa|All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (United Kingdom only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.
16663277|NCT02193854|Experimental|Mobile phone|"General practitioners (GPs) received TD consultation through Sana system.
~Mobile phones with Sana system installed were provided to 10 rural GPs from three different districts of Mongolia."
16663278|NCT02193841|Active Comparator|C & P|Curettage with puncture (C & P) will be performed alone
16663279|NCT02193841|Active Comparator|C & P with Vitoss|A predetermined amount of Vitoss morsels will be injected following the curettage and puncture (C & P)
16663280|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
16663281|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
16663282|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
16663283|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
16663284|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
16663285|NCT02193802|Other|Endoscopy|"CHANCE is a single arm study: all patients will undergo one capsule endoscopy ( PillCam® COLON 2 capsule and PillCam Crohn's) of the whole intestine AND one ileocolonoscopy.
~The patients will be then treated according to the preference of their physician and a second capsule endoscopy AND an ileoconoscopy will be performed 6 at 12 months later.
~Both exams will be evaluated locally by two independent investigators and all the recorded films will be evaluated and compared by four central readers."
16663286|NCT02193789|Experimental|Anastomosis site stricture|anastomosis site stricture after subtotal gastrectomy with Billroth-I anastomosis
16663287|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
16663288|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
16663289|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
16663290|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
16663291|NCT02193763|Experimental|90 days and under--Interventional|Neonates aged 90 days and under randomized to ultrasound assisted lumbar puncture
16663292|NCT02193763|No Intervention|90 days and under--control|Neonates aged 90 days and under randomized to lumbar puncture using the anatomical landmark approach
16663293|NCT02193763|Experimental|Over 90 days--Interventional|Neonates aged over 90 days randomized to ultrasound assisted lumbar puncture
16663294|NCT02193763|No Intervention|Over 90 days--Control|Neonates aged over 90 days randomized to lumbar puncture using the anatomical landmark approach
16663295|NCT02193750|Placebo Comparator|Placebo|1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
16663296|NCT02193750|Experimental|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
16663297|NCT02193750|Experimental|High Oligosaccharide Group|1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)
16663298|NCT02193737|Experimental|Early oral fluid recovery.|
16663299|NCT02193737|Active Comparator|Delayed oral fluid recovery.|
16663300|NCT02193724||Retinoblastoma|Participants identified with heritable retinoblastoma will undergo a skin biopsy or blood draw to collect cells for processing and analysis.
16663301|NCT02193711|Experimental|Topical Arthritis Cream|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
16663302|NCT02193711|Placebo Comparator|Placebo|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
16663303|NCT02193698|Experimental|Lenalidomide+Dexamethasone|Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
16663304|NCT02193685||Subjects with HAEC|There is no intervention involvement. The clinical data and biologic specimens collected during the study will serve as an invaluable resource for a wide spectrum of clinical and translational ancillary studies directly related to the aims and goals of the study.
16663305|NCT02193685||Subjects without HAEC|A subgroup of children who have Hirschsprung Disease may or may not develop enterocolitis; therefore we will be identifying the bio-markers in children with or without associated enterocolitis.
16663351|NCT02193334|Active Comparator|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
16664912|NCT02183402|Experimental|Digoxin with BI 1356|
16663306|NCT02193672|Experimental|PET/CT + [18F]Fluciclatide|"At baseline: Participants have PET/CT imaging within 7 days prior to initiation of chemotherapy treatment. Participants monitored at 24 hours post scan via telephone.
~On treatment: Participants have PET/CT imaging at end of the first cycle and prior to the initiation of the second cycle of chemotherapy. Participants assessed at 24 hours post scan via telephone call.
~Baseline and on treatment PET/CT imaging performed with agent [18F] Fluciclatide."
16663307|NCT02193659|Experimental|Cereals|For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet. The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
16663308|NCT02193633|Experimental|AZD2014 3 on/4 off & weekly paclitaxel|3 days on, 4 days off AZD2014 BD administered orally Days 1-3 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
16663309|NCT02193633|Experimental|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 BD administered orally Days 1-2 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
16663310|NCT02193620|Placebo Comparator|Placebo group|Placebo soft capsules
16663311|NCT02193620|Experimental|Study group|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
16663312|NCT02193607|Active Comparator|No TVT-O|Improved reconstruction pelvic surgery
16663313|NCT02193607|Experimental|Combined surgery group|Improved reconstruction pelvic surgery TVT-O procedure
16663314|NCT02193594|Experimental|CCRT group|The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.
16663315|NCT02193594|Active Comparator|CT group|The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.
16663316|NCT02193581||Suspicious skin lesions.|Patients with a suspicious skin lesion referred for a biopsy are tested using MDS
16663317|NCT02193568|Experimental|Arm I (light sedation)|Patients receive light sedation (awake) and undergo craniotomy.
16663318|NCT02193568|Active Comparator|Arm II (intubated general anesthesia)|Patients receive intubated general anesthesia and undergo craniotomy.
16663319|NCT02193555|Other|Non-presbyopic group|"Non-presbyopic group: age ranging from 7 to 39 years
~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.
~For each fitting visit, lenses will be fitted bilaterally."
16663320|NCT02193555|Other|Presbyopic group|"Presbyopic group: age 40 and above
~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.
~For each fitting visit, lenses will be fitted bilaterally."
16663321|NCT02193542||Pregnant patient|Pregnant woman presenting for vaginal or cesarean delivery
16663322|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
16663323|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
16663324|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
16663325|NCT02193477|No Intervention|Control|Patients were given no TEAS.
16663326|NCT02193477|Experimental|TEAS Treatment|Patients were given 30min of TEAS before general anesthesia induction, 1th day and 2nd day after surgery.
16663327|NCT02193477|Sham Comparator|Sham TEAS|Patients were given 30min of sham TEAS before general anesthesia induction,1th day and 2nd day after surgery.
16663328|NCT02193464||inflammatory bowel disease|
16663329|NCT02193451|Experimental|Urodynamics|Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
16663330|NCT02193451|Active Comparator|Usual care|Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
16663331|NCT02193438|Active Comparator|Spice 1|Red chili pepper extract
16663332|NCT02193438|Active Comparator|Spice 2|Cinnamon extract
16663333|NCT02193438|Active Comparator|Spice 3|Refreshing agent
16663334|NCT02193438|Placebo Comparator|Placebo|Tomato juice
16663336|NCT02193412|Experimental|patients|"noxious stimulus
~change in operating table slope: head-down tilt position
~change in operating table slope: head-up tilt position"
16663337|NCT02193399|Experimental|Physiotherapy exercises|Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
16663338|NCT02193399|No Intervention|Control group|Patients undergoing allogeneic transplantation without treatment of physiotherapy
16663339|NCT02193386|Active Comparator|Usual Care|No intervention, no follow-up, only registration of usual therapy
16663340|NCT02193386|Experimental|Intervention period|Predefined, evidence-based program and support
16663341|NCT02193373|Active Comparator|Sub-Occipital Release|Osteopathic Manual Medicine
16663342|NCT02193373|Active Comparator|Rib-Raising|Osteopathic Manual Medicine
16663343|NCT02193373|Active Comparator|Stellate Ganglion Release|Osteopathic Manual Medicine
16663344|NCT02193373|Active Comparator|All techniques|Osteopathic Manual Medicine
16663345|NCT02193373|Sham Comparator|All Techniques-S|Sham Osteopathic Manual Medicine
16663346|NCT02193373|Sham Comparator|Sub-Occipital Release-S|Sham Osteopathic Manual Medicine
16663347|NCT02193373|Sham Comparator|Rib-Raising-S|Sham Osteopathic Manual Medicine
16663348|NCT02193373|Sham Comparator|Stellate Ganglion Release -S|Sham Osteopathic Manual Medicine
16663349|NCT02193360|Experimental|Single arm Dose Escalation|
16663350|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
16664913|NCT02183402|Active Comparator|Digoxin|
16663352|NCT02193334|Placebo Comparator|Placebo|Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
16663353|NCT02193321|Experimental|Amniotic membrane patch placement|One amniotic membrane patch will be placed on the epicardial surface of the heart immediately following a CABG procedure prior to wound closure.
16663354|NCT02193321|No Intervention|Control|Amniotic membrane patch will not be placed after CABG procedure prior to wound closure.
16663355|NCT02193308|Experimental|Telmisartan/Amlodipine FDC|
16663356|NCT02193308|Active Comparator|Telmisartan + Amlodipine mono|
16663357|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction.
16663358|NCT02193295|Experimental|NAFLD|Placebo or ACC inhibitor treatment for 12 weeks.
16663359|NCT02193295|Experimental|NAFLD Extension|A 48-week open-label extension arm with following either completion of either both arms or one arm of the 12-week double-blind crossover study.
16663360|NCT02193282|Experimental|Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
16663361|NCT02193282|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
16663362|NCT02193282|Experimental|Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16663363|NCT02193282|Active Comparator|Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
16663364|NCT02193269|Placebo Comparator|sugar pill|0.0mg
16663365|NCT02193269|Active Comparator|Minocycline|200mg
16663366|NCT02193256|Active Comparator|Varenicline plus Prazosin|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
16663367|NCT02193256|Placebo Comparator|Varenicline plus Placebo|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Placebo: placebo will be given instead of prazosin (Weeks 1-3)
16663368|NCT02193217|Experimental|MT-1303-Low|MT-1303-Low dose
16663369|NCT02193217|Experimental|MT-1303-High|MT-1303-High dose
16663370|NCT02193217|Active Comparator|Fingolimod|Fingolimod
16663371|NCT02193217|Placebo Comparator|Placebo|Placebo
16663372|NCT02193204|Experimental|Social Drinkers Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers with depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
16663373|NCT02193204|Experimental|Social Drinkers No Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers without depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
16663374|NCT02193204|Experimental|Alcohol Dependent, Non-Depressive|30 treatment-engaged 28-day abstinent, alcohol dependent (AD) smokers, without Depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
16663375|NCT02193204|Experimental|Alchohol Dependent Depressive Symptoms|30 treatment-engaged 28-day abstinent, alcohol dependent smokers with depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
16663376|NCT02193191|Experimental|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
16663377|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
16663378|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
16663379|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
16663380|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
16663381|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.
~One cycle of pazopanib is 28 days."
16663382|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
16663383|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
16663384|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
16663385|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
16663386|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
16663387|NCT02193126|Experimental|Treatment|
16663388|NCT02193126|No Intervention|Comparison|
16663389|NCT02193113|Experimental|KVD001 Injection Dose 1|Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
16663390|NCT02193113|Experimental|KVD001 Injection Dose 2|Single 100uL intravitreal injection KVD001 injection Dose 2
16663391|NCT02193113|Experimental|KVD001 Injection Dose 3|Single 100uL intravitreal injection of KVD001 injection Dose 3
16663392|NCT02193100||13C-glucose|experimental (13C-glucose)
16663393|NCT02193100||No glucose|control (no glucose)
16663431|NCT02192892|Placebo Comparator|RSB - α-amylase|RSB - α-amylase: Porridge from Rice Soy Blend without α-amylase
16663394|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
16663395|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
16663396|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
16663397|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
16663398|NCT02193074|Experimental|nusinersen|
16663399|NCT02193074|Sham Comparator|Sham procedure|
16663400|NCT02193061|Active Comparator|ROTA 1|two doses of monovalent vaccine Rotarix followed by one dose of sterile water
16663401|NCT02193061|Active Comparator|ROTA 2|three doses of pentavalent vaccine RotaTeq
16663402|NCT02193061|Active Comparator|ROTA 3|one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
16663403|NCT02193061|Active Comparator|ROTA 4|one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
16663404|NCT02193061|Active Comparator|ROTA 5|two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
16663405|NCT02193061|Active Comparator|ROTA 6|one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
16663406|NCT02193061|Active Comparator|ROTA 7|a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix
16663408|NCT02193035|Experimental|Single group|Patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Microparticle levels will be measured before and after TAVR.
16663409|NCT02193022|Experimental|Miltefosine|
16663410|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
16663411|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
16663412|NCT02192996|Other|Probiotics supplementation|"Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight < 1300 g and gestational age < 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of Bifidobacterium breve and Lactobacillus salivarius , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10^9 colony forming units (CFU) per doses of each one of the probiotic bacteria."
16663413|NCT02192983||chemotherapy regimen|those with XELOX regimen and those with EOX regimen
16663414|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
16663415|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
16663416|NCT02192957|Other|Ottawa AF Cardioversion|elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
16663417|NCT02192944|Active Comparator|Chloroquine|Chloroquine base 600 mg single dose
16663418|NCT02192944|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose
16663419|NCT02192931|Active Comparator|Creatine monohydrate|5 grams of daily creatine monohydrate for 8 weeks
16663420|NCT02192931|Placebo Comparator|Placebo|5 g of placebo for 8 weeks
16663421|NCT02192931|No Intervention|Healthy Control|
16663422|NCT02192918|Experimental|Airbrush|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Participants will receive access to one of each of the following after the 6-month assessment at no cost: massage, pedicure, yoga class, and dance class. Participants will schedule these activities on their own and the study staff will arrange for payment for the appointment.
16663423|NCT02192918|Experimental|Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class. These activities are being given as healthy alternatives to the relaxation sensation of indoor tanning.
16663424|NCT02192918|Active Comparator|Delayed Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
16663425|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
16663426|NCT02192892|Experimental|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from Corn Soy Blend drum dried with α-amylase
16663427|NCT02192892|Placebo Comparator|CSB drum dried - α-amylase|CSB drum dried - α-amylase: Porridge from Corn Soy Blend drum dried without α-amylase
16663428|NCT02192892|Experimental|CSB + α-amylase|CSB + α-amylase: Porridge from Corn Soy Blend with α-amylase
16663429|NCT02192892|Placebo Comparator|CSB - α-amylase|CSB - α-amylase: Porridge from Corn Soy Blend without α-amylase
16663430|NCT02192892|Experimental|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
16663432|NCT02192892|Active Comparator|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
16663433|NCT02192892|Active Comparator|Commercial porridge flour|Porridge from commercial porridge flour
16663434|NCT02192892|Active Comparator|Commercial porridge bar|Porridge from commercial porridge bar
16663435|NCT02192892|Experimental|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from Corn Soy Blend PLUS drum dried with α-amylase
16663436|NCT02192892|Placebo Comparator|CSB PLUS drum dried - α-amylase|CSB PLUS drum dried - α-amylase: Porridge from Corn Soy Blend PLUS drum dried without α-amylase
16663437|NCT02192892|Experimental|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
16663438|NCT02192892|Placebo Comparator|CSB PLUS - α-amylase|CSB PLUS - α-amylase: Porridge from Corn Soy Blend PLUS without α-amylase
16663439|NCT02192892|Experimental|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
16663440|NCT02192892|Placebo Comparator|RSB PLUS - α-amylase|RSB PLUS - α-amylase: Porridge from Rice Soy Blend PLUS without α-amylase
16663441|NCT02192892|Experimental|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
16663442|NCT02192892|Placebo Comparator|WSB PLUS - α-amylase|WSB PLUS - α-amylase: Porridge from Wheat Soy Blend PLUS without α-amylase
16663443|NCT02192892|Active Comparator|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
16663444|NCT02192879|Active Comparator|Thoracic Epidural|
16663445|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
16663446|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
16663447|NCT02192866||Peanut allergic|No intervention(s) to be administered.
16663448|NCT02192866||Other food allergic|No intervention(s) to be administered.
16663449|NCT02192866||Controls|No intervention(s) to be administered.
16663450|NCT02192853|Experimental|Sitagliptin|Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.
16663451|NCT02192853|Placebo Comparator|placebo|
16663452|NCT02192840|Active Comparator|rDES Group|"Regular drug-eluting stent implantation, one of the following:
~Device: LucChopin (Balton, Poland) Device: Prolim (Balton, Poland) Device: Xience Pro (Abott Vascular) Device: Biomatrix (Biosensors) Device: Promus (Boston Scientific) Device: Cypher (Cordis) Device: Taxus (Boston Scientific) Device: Coroflex Please (BBraun) Device: Resolute Integrity (Medtronic)"
16663453|NCT02192840|Experimental|BiOSS Group|New dedicated bifurcation stent BiOSS Expert (Balton, Warsaw, Poland) implantation
16663454|NCT02192827|Experimental|Single Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once
16663455|NCT02192827|Experimental|Two Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.
16663456|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.
~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.
~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
16663457|NCT02192788|Experimental|SBRT|Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
16663458|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
16663459|NCT02192762|Experimental|Withdrawal regulation training|Withdrawal coping skills
16663460|NCT02192762|Active Comparator|Relaxation training|Relaxation skills instruction
16663461|NCT02192749|Experimental|Umbilical cord mesenchymal stem cells|
16663462|NCT02192736|Other|Intra-nasal infusion of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally
16663463|NCT02192723|Experimental|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day) for 8 weeks.
16663464|NCT02192723|Active Comparator|Risperidone|Risperidone, 2~6mg/day, twice day, 8 weeks
16663465|NCT02192723|Active Comparator|Olanzapine|5~20mg/day
16663466|NCT02192723|Active Comparator|Quetiapine|400~750mg/day
16663467|NCT02192723|Active Comparator|Aripiprazole|Aripiprazole, 10~30mg/day, twice per day, 8 weeks
16663468|NCT02192723|Active Comparator|Ziprasidone|Ziprasidone, 80~160mg/day, twice per day, 8 weeks
16663469|NCT02192710|Active Comparator|Hypnovel® (midazolam)|Midazolam oral intake before anesthesia
16663470|NCT02192710|Experimental|Electronic tab|
16663471|NCT02192697|Experimental|Phase I dose-escalation group|Oral administration
16663472|NCT02192697|Experimental|Phase I EGFR-T790M mutation group|Oral administration
16663473|NCT02192697|Experimental|Phase II group|Oral administration
16663474|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
16663475|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
16663476|NCT02192671|Experimental|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
16663477|NCT02192671|Active Comparator|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
16663478|NCT02192658||People with Disability (PWD) (N= 850)|"PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).
~A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria."
16663479|NCT02192658||Non-Disabled People (control group) (N= 850)|For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
16663480|NCT02192645|Experimental|Sanfujiu|"Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time.
~Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time."
16663481|NCT02192645|Placebo Comparator|placebo|"Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint .
~Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time."
16663482|NCT02192645|No Intervention|waiting list|No intervention in the first year. Accept Sanfujiu in the second and the third years.
16663483|NCT02192632|Experimental|Epiduo- dermatologist's detailed instruction|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist
16663484|NCT02192632|Experimental|Epiduo- drug insert only gruop|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group
16663485|NCT02192632|Placebo Comparator|BPO group|After randomly assigned to side of BPO application, patients apply BPO during 12 week
16663486|NCT02192619||observational|
16663487|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
16663488|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
16663489|NCT02192593|Experimental|Computer CBT|A 10-session computerized cognitive-behavioral therapy intervention
16663490|NCT02192593|No Intervention|Usual Care|
16663491|NCT02192580|Active Comparator|Omega-3|omega-3 (DHA+EPA) in divided 3 times/day in addition to standard regimens: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
16663492|NCT02192580|No Intervention|Control|control group received just standard regimens without omega-3
16663493|NCT02192567|Experimental|DS-5573a does escalation (step 1) and expansion (step 2)|"Step 1 of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg.
~Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg Step 2: 30 subjects will be enrolled and treated at the dose determined in Step 1."
16663494|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
16663495|NCT02192528||cardiac surgical patients|patients undergoing a cardiac surgical procedure
16663496|NCT02192515|Experimental|APD356 10 mg|Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
16663497|NCT02192515|Experimental|APD356 20 mg|Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
16663498|NCT02192515|Experimental|APD356 XR-20 mg|Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
16663499|NCT02192515|Experimental|APD356 10 mg and APD356 XR-20mg (orange tablet)|"Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.
~Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed)
~Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted)"
16663500|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
16663501|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
16663502|NCT02192489|Experimental|CC-220 0.3mg|CC-220 0.3 mg capsules by mouth (PO) daily for 12 weeks
16663503|NCT02192489|Experimental|CC-220 0.6mg|CC-220 0.6mg capsules by PO daily for 12 weeks
16663504|NCT02192489|Placebo Comparator|Placebo|Identically matching placebo PO daily for 12 weeks
16663505|NCT02192476|Active Comparator|conventional|15 participants are allotted in this arm and each participants received conventional neuro rehabilitation programme 5 days a week for 6 weeks.
16663506|NCT02192476|Experimental|intervention|15 participants allotted in this arm and each participants received California tri-pull taping method along with conventional neuro rehabilitation was given 5 days a week for 6 weeks
16663507|NCT02192463|Experimental|Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release|
16663508|NCT02192463|Experimental|NVP ER 300 mg (KCR 25%) Medium Release|
16663509|NCT02192463|Experimental|NVP ER 300 mg (KCR 30%) Slow Release|
16663510|NCT02192463|Experimental|NVP ER 400 mg (KCR 25%) Medium Release|
16663511|NCT02192463|Experimental|NVP ER 300 mg (KCR 40%) Slow Release|
16663512|NCT02192463|Experimental|NVP ER 300 mg (ECR 20%) Fast Release|
16663513|NCT02192463|Experimental|NVP ER 400 mg (KCR 20%) Medium Release|
16663514|NCT02192463|Experimental|NVP ER 400 mg (KCR 30%) Slow Release|
16663515|NCT02192463|Experimental|NVP ER 400 mg (KCR 40%) Slow Release|
16663516|NCT02192463|Experimental|NVP ER 400 mg (ECR 20%) Fast Release|
16663517|NCT02192463|Active Comparator|Nevirapine IR 1 tablet|
16663518|NCT02192463|Active Comparator|Nevirapine IR 2 tablets|
16663549|NCT02192281|Experimental|Playworks|Playworks was implemented during the entire school year, and outcome measures were collected in spring of the school year.
16663550|NCT02192281|No Intervention|Control|Playworks was not implemented at these schools.
16663870|NCT02190123||ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
16663519|NCT02192450|Active Comparator|Insulin glargine|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.
~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.
~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.
~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
16663520|NCT02192450|Experimental|Insulin degludec|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.
~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.
~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.
~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
16663521|NCT02192437|Experimental|Methionine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine). Control diet for 4 weeks followed by a washout for 3-4 weeks, then a methionine restricted diet (70%) for 4 weeks, followed by 3-4 weeks washout period and then a methionine restricted diet (90%) for 4 weeks.
16663522|NCT02192437|Experimental|Methionine and cysteine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine and cysteine). Control diet for 4 weeks followed by a washout for 3-4 weeks then a methionine and cysteine restricted diet (50%) followed by 3-4 weeks washout period and then a methionine and cysteine restricted diet (65%) for 4 weeks.
16663523|NCT02192424|Active Comparator|Metformin alone|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
16663524|NCT02192424|Experimental|Metformin + Intermittent Insulin Therapy|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.
16663525|NCT02192411|Active Comparator|Standard Lidocaine|50mL 1% lidocaine in 450mL normal saline
16663526|NCT02192411|Experimental|1/4 dose lidocaine|12.5mL 1% lidocaine in 487.5mL normal saline
16663527|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:
~guanfacine (2mg)
~guanfacine (1mg)
~placebo
~Subjects will be instructed to take one capsule in the evening for 4 weeks."
16663528|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:
~guanfacine (2mg)
~guanfacine (1mg)
~placebo
~Subjects will be instructed to take one capsule in the evening for 4 weeks."
16663529|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:
~guanfacine (2mg)
~guanfacine (1mg)
~placebo
~Subjects will be instructed to take one capsule in the evening for 4 weeks."
16663530|NCT02192372||metabolic syndrome|Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference > 102 cm in men and > 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (<40 mg/dl in men and <50 mg/dl in women).
16663531|NCT02192372||control|Age and sex adjusted control subjects
16663532|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16663533|NCT02192346|Experimental|2.4 mg/kg α-TEA|Patients will receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
16663534|NCT02192346|Experimental|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
16663535|NCT02192346|Experimental|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
16663536|NCT02192346|Experimental|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
16663537|NCT02192346|Experimental|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
16663538|NCT02192346|Experimental|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
16663539|NCT02192346|Experimental|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
16663540|NCT02192346|Experimental|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
16663541|NCT02192346|Experimental|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
16663542|NCT02192333|No Intervention|Arm I (usual care)|Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.
16663543|NCT02192333|Experimental|Arm II (survivorship care)|Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
16663544|NCT02192320|Experimental|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;
~Dexamethasone: 0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
16663545|NCT02192320|Active Comparator|Atorvastatin|Atorvastatin: 20 mg (every evening orally) for 5 weeks
16663546|NCT02192307|Experimental|potassium oxalate gel|Professional application
16663547|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
16663548|NCT02192294|Experimental|Bosutinib|
16663551|NCT02192268|Active Comparator|HFOO|Children of the HFOO group will be subjected to two daily sessions of this resource which should be the same throughout her hospitalization with Shaker equipment.
16663552|NCT02192268|Active Comparator|Assisted Coughing|The children in the control group will be subjected to two daily sessions of assisted coughing.
16663553|NCT02192268|Active Comparator|PEP|The children will be subjected to PEP group two daily sessions of this resource which should be the same throughout her hospitalization with facial mask and valve Spring load with expiratory pressure of 10cmH2O.
16663554|NCT02192255|Experimental|Intervention phone call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
16663555|NCT02192255|No Intervention|Control arm - usual care|Those in the control arm received usual care.
16663556|NCT02192242|Experimental|Acute ischemic pain|acute ischemic pain was induced by treadmill testing in all patients investigated
16663557|NCT02192229|Active Comparator|intervention group|The intervention group will be supplemented with 50.000 IU vitamin D3 every week for 12 consecutive weeks
16663558|NCT02192229|Placebo Comparator|Placebo group|The placebo group will receive placebo Tablet which will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
16663559|NCT02192216|Experimental|Exercise & Chemotherapy|Following a control period during active chemotherapy the patients undergo ten weeks of supervised exercise comprised of resistance and aerobic training in combination with protein supplementation during ongoing chemotherapy.
16663560|NCT02192203|Experimental|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
16663561|NCT02192203|Active Comparator|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
16663562|NCT02192203|Active Comparator|Menthol Only Gel|3% menthol
16663563|NCT02192203|Placebo Comparator|Placebo Only Gel|0.09% menthol
16663564|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
16663565|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
16663566|NCT02192190|Experimental|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
16663567|NCT02192190|Experimental|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
16663568|NCT02192190|Experimental|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
16663569|NCT02192190|Experimental|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
16663570|NCT02192177||Group 1|Pregnant subjects diagnosed with obstetric cholestasis who didn't have any foreknown systemic disease.
16663571|NCT02192177||Group 2|entirely healthy pregnant subjects, the control group.
16663572|NCT02192138|Experimental|Therapeutic thoracentesis|Patients with pleural effusion who require therapeutic thoracentesis will be enrolled into the study
16663573|NCT02192125|Experimental|REWIRE-System|The training system consists of a so-called Tymoplate® (Tyromotion, Austria), a medical device class 1 with CE certification and approval by the FDA for use in neurorehabilitation after stroke. The Tymoplate® is connected to a computer and allows by means of a base plate with integrated pressure sensors and custom-developed training software different postural biofeedback exercise.
16663574|NCT02192099|Experimental|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
16663575|NCT02192086|Experimental|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).
~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
16663576|NCT02192086|Active Comparator|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).
~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
16663577|NCT02192073|Active Comparator|Suprapectoral Biceps Tenodesis|Suprapectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the superior border of the pectoralis major insertion
16663578|NCT02192073|Active Comparator|Subpectoral Biceps Tenodesis|Subpectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the inferior border of the pectoralis major insertion
16663579|NCT02192060|Experimental|Test|Using of a suspension containing Triclosan
16663580|NCT02192060|Placebo Comparator|Control|Using of a suspension without Triclosan or other active ingredient
16663581|NCT02192047|Experimental|palm olein margarine|8 weeks
16663582|NCT02192047|Experimental|IE palm olein margarine|8 weeks
16663583|NCT02192047|Experimental|IE soybean oil-based margarine|8 weeks
16663584|NCT02192034|Experimental|Navigation Group|This group will receive standard clinic instructions for the colonoscopy and two additional phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure.
16663585|NCT02192034|Placebo Comparator|Control|This group will receive only clinic instructions without intervention from the patient navigator.
16663586|NCT02192021|Experimental|Micro needle array-Doxorubicin (MNA-D)|MNA-D application for all subjects
16663587|NCT02192008|Active Comparator|Part A|Cohort naive to typhoidal Salmonella challenged with either S. Typhi or S. Paratyphi
16663588|NCT02192008|Active Comparator|Part B|Cohort previously challenged with S. Typhi or Paratyphi re-challenged with either S. Typhi or S. Paratyphi.
16663589|NCT02191995|Experimental|body awareness yoga|body awareness yoga session prior to breakfast meal
16663590|NCT02191995|No Intervention|Control Arm|No intervention
16663591|NCT02191982|Experimental|Intervention|This arm will begin the Walk With Ease program after the completion of chemotherapy.
16663592|NCT02191982|Active Comparator|Wait List Control|The arm will begin the Walk With Ease program three months after completion of chemotherapy.
16663593|NCT02191969|No Intervention|Control|This group will be receiving adjuvant chemotherapy for colorectal cancer. They will not participate in the Walk With Ease program. They will be followed up using standard of care.
16663594|NCT02191969|Experimental|Intervention|"This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day.
~Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy."
16663595|NCT02191956|Active Comparator|Behavioral Parent Training|Standard of care intervention
16663596|NCT02191956|Experimental|Behavioral Parent Training - Enhanced|Standard of Care Behavioral Parent Training plus new delivery methods
16663597|NCT02191943|Active Comparator|Control (fluoride varnish)|
16663598|NCT02191943|Experimental|resin infiltration (Icon)|
16663599|NCT02191930|Experimental|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
16663600|NCT02191930|Experimental|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
16663601|NCT02191917|Experimental|Measurement of Respiratory Muscle Strength|
16663602|NCT02191904|Active Comparator|Truview EVO2®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively.
16663603|NCT02191904|Active Comparator|Airtraq®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
16663604|NCT02191904|Active Comparator|Direct laryngoscopy|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
16663605|NCT02191891|Experimental|BI 836845 + afatinib|BI 836845 low or high dose (weekly IV infusion), afatinib 30mg or 40mg (once daily oral dosing)
16663606|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.
~Phase 2 - dose expansion at the MTD."
16663607|NCT02191865|Experimental|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
16663608|NCT02191865|Experimental|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
16663609|NCT02191865|Experimental|Healthy volunteers|Healthy control subjects
16663610|NCT02191852|Experimental|Seresis®|2 capsules per day for a period of 16 consecutive weeks
16663611|NCT02191839|Active Comparator|alpha 1 antitrypsin|patients receive 4 grams of IV alpha 1 antitrypsin preoperatively
16663612|NCT02191839|Placebo Comparator|placebo|10 patients will randomely receive placebo
16663613|NCT02191826|Experimental|SOM0226 single dose|
16663614|NCT02191826|Experimental|SOM0226 multiple doses|
16663615|NCT02191813|Experimental|Seresis®|
16663616|NCT02191813|Placebo Comparator|Placebo|
16663617|NCT02191787|Experimental|Seresis® + Placebo|"2 capsules Seresis® o.d. for 5 days
~2 capsules Placebo o.d. the day before treatment with Seresis®"
16663618|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
16663824|NCT02190500|No Intervention|Standard Management|Acute ischemic stroke patients receiving standard management
16663619|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
16663620|NCT02191761|Experimental|SM04755|
16663621|NCT02191748|Active Comparator|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site.
16663622|NCT02191748|Experimental|Needling and Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site.
16663623|NCT02191748|No Intervention|No treatment|No treatment will be done to these vitiligo patches as a control.
16663624|NCT02191735||Troponin I|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
16663625|NCT02191735||Myoglobin|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP Myoglobin test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
16663626|NCT02191735||CK-MB|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP CK-MB test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
16663627|NCT02191735||NT-proBNP|Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
16663628|NCT02191722|Experimental|JIA patients|All participants will be evaluated before and after reading the comics booklet
16663629|NCT02191709|Experimental|Dextromethorphan syrup|Bisoltussin® Syrup
16663630|NCT02191709|Active Comparator|Dextromethorphan soft pastilles|Silomat® DMP soft pastilles
16663631|NCT02191683||Health of women before conception|Tanzanian women aged 18-40 years focusing on prevalence of anaemia, infections, nutritional status, and NCDs.
16663632|NCT02191683||480 women during pregnancy|"Describe how 1st and 2nd trimester anaemia compared to 3rd trimester anaemia alters foetal growth and newborns' body composition.
~Evaluate anaemia's effect on villous branching in placenta, and uterine and umbilical artery blood flow.
~Evaluate effect on vascular endothelial growth factor A/placental growth factor balance and insulin-like growth factor axis.
~Determine which markers for foetal programming such as methylation of regulatory genes related to metabolism and haematopoiesis may be discovered early after exposure to anaemia."
16663633|NCT02191670||METALYSE®|
16663634|NCT02191657|Experimental|Cohort 1|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
16663635|NCT02191657|Experimental|Cohort 2|Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
16663636|NCT02191657|Experimental|Cohort 3|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.
16663637|NCT02191644|Placebo Comparator|Refined rice|
16663638|NCT02191644|Experimental|Whole grains and legumes|
16663639|NCT02191631|Experimental|Internet-delivered CBT|Participants will receive 12 weeks of internet-delivered cognitive behavior therapy with psychologist support.
16663640|NCT02191631|No Intervention|Wait list|Participants will receive no treatment for 12 weeks. After that period participants will receive Internet-delivered Cognitive Behavior Therapy.
16663641|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
16663642|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
16663643|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
16663644|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
16663645|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
16663646|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
16663647|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
16663648|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
16663825|NCT02190487||TAS group|patients who had thoracic aortic surgery due to dissection
16663649|NCT02191566|Experimental|S-1/Oxaliplatin|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
16663650|NCT02191553|Active Comparator|Control Group: Relaxation Techniques|Relaxation techniques which do not involve either formal or informal mindfulness training. Subjects in this group practice Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
16663651|NCT02191553|Experimental|Loving Kindness Meditation (Metta)|Loving-kindness meditation following Kristin Neff protocol
16663652|NCT02191553|Experimental|Body Scan|Body scan as described in standard MBSR protocol
16663653|NCT02191553|Experimental|Sitting Practice|Sitting practice as mindfulness meditation described in standard MBSR protocols.
16663654|NCT02191540|Experimental|Abnoba Viscum F 20mg|
16663655|NCT02191527|Experimental|Point of Care Testing|The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.
16663656|NCT02191527|No Intervention|Laboratory Testing - Standard of care|Samples sent to the laboratory for analysis, (standard of care)
16663657|NCT02191501|Experimental|Pyloric restriction|Endoscopic method of pyloric restriction in order to decrease gastric emptying. The hypothesis is that this will cause and early and prolonged satiety which will inturn lead to decreased food consumption and lead to weight loss.
16663658|NCT02191488|Experimental|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
16663659|NCT02191475|Active Comparator|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.
16663660|NCT02191475|Experimental|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.
16663661|NCT02191462|Experimental|Niagen 100mg|1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
16663662|NCT02191462|Experimental|Niagen 300mg|3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
16663663|NCT02191462|Experimental|1000mg Niagen|10 Niagen capsules (10 x 100mg capsule)
16663664|NCT02191436||Patients with haemophilia|Hemophilia patients (children, youth and adults) and parents of children with hemophilia under 18
16663665|NCT02191423|Experimental|postpartum depression|"Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy
~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).
~All women in this group participate in 8-weeks of dyadic psychotherapy (DP) at the outpatient Psychiatric Department, Tel-Aviv Medical Center.
~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
16663666|NCT02191423|Other|normal controls|"Normal control women not suffering from postpartum depression assessed by fMRI
~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).
~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
16663667|NCT02191410|Active Comparator|High Frequency Positive Pressure Ventilation|
16663668|NCT02191410|Placebo Comparator|Continuous Positive Airway Pressure|
16663669|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
16663670|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
16663671|NCT02191384|Experimental|Orcinoside 25mg per day|
16663672|NCT02191384|Experimental|Orcinoside 50mg per day|
16663673|NCT02191384|Experimental|Orcinoside 100mg per day|
16663674|NCT02191384|Experimental|Orcinoside 200mg per day|
16663675|NCT02191384|Experimental|Orcinoside 400mg per day|
16663676|NCT02191384|Experimental|Orcinoside 600mg per day|
16663677|NCT02191384|Placebo Comparator|placebo|
16663867|NCT02190136|Active Comparator|Protein whole foods|Ingestion of 20-25 grams per serving consumed 4-6 times per day; 1 within an hour of waking in the morning and the other 2.5-3 hours apart during the day.
16663678|NCT02191371|Experimental|propofol|Propofol is used as a maintenance anesthetic to patients in the propofol group. Intervention: propofol infusion by target-controlled infusion for maintaining anesthesia propofol (Fresofol MCT 2%) target effect site concentration: 4~5 mcg/ml, during general anesthesia
16663679|NCT02191371|Experimental|desflurane|"Desflurane is used as a maintenance anesthetic to patients in the desflurane group.
~Intervention: Desflurane administration for maintaining anesthesia desflurane (Suprane) inhalation as 6~8 vol% during general anesthesia"
16663680|NCT02191358||"Tested patients (prospective)"|Patients whose providers decide to have them undergo testing via the YouScript Personalized Prescribing System will be recruited for the study. Data will be gathered at baseline and 120 days later. The decision to utilize YouScript and all treatment decisions will be made at the discretion of the provider in accordance with their usual care practice, and will be made prior to the decision to participate in the study.
16663681|NCT02191358||"Untested patients (retrospective)"|Patients for comparison to the prospectively followed patients will be derived from Inovalon's MORE2 healthcare database. Patients meeting the same enrollment criteria (excluding the YouScript testing) will be matched on key characteristics to the tested patients. Outcomes will be compared between the prospectively enrolled patients undergoing pharmacogenetic testing with the YouScript Personalized Prescribing System at the discretion of their treating physician.
16663682|NCT02191345|No Intervention|10 minute break|Participants asked to take a 10 minute break as usual 3 times per week for 4 weeks
16663683|NCT02191345|Experimental|Guided Imagery|Participants listen to one of 6 pre-recorded guided imagery tracks 3 times per week for 4 weeks
16663684|NCT02191332||Viramune|
16663685|NCT02191319||Viramune®|Patients switching from protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) containing antiretroviral regimen to Viramune®
16663686|NCT02191306||HIV Positive Patients (Study Group)|
16663687|NCT02191306||Non HIV Positive Patients (Control)|
16663688|NCT02191293||Viramune®|
16663689|NCT02191280|Experimental|Antistax®, low dose|
16663690|NCT02191280|Experimental|Antistax®, high dose|
16663691|NCT02191280|Placebo Comparator|Placebo|
16663692|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
16663693|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
16663694|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
16663695|NCT02191254|Experimental|Antistax®|1 tablet per day for 12 weeks
16663696|NCT02191254|Placebo Comparator|Placebo|
16663697|NCT02191241|Experimental|Red Vine Leaf Extract|
16663698|NCT02191228|Experimental|Group 1|Linagliptin in subjects with normal renal function
16663699|NCT02191228|Experimental|Group 2|Linagliptin in patients with mild renal insufficiency (RI)
16663700|NCT02191228|Experimental|Group 3|Linagliptin in patients with moderate RI
16663701|NCT02191228|Experimental|Group 4|Linagliptin in patients with severe RI
16663702|NCT02191228|Experimental|Group 5|Linagliptin in patients with end-stage renal disease (ESRD)
16663703|NCT02191228|Experimental|Group 6|Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
16663704|NCT02191228|Experimental|Group 7|Linagliptin in patients with normal renal function and T2DM
16663705|NCT02191215||Nevirapine (Viramune®)|
16663706|NCT02191202||Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
16663707|NCT02191189|Active Comparator|Treatment A, p.o.|50 mg Nevirapine administered orally in 100 mL water
16663708|NCT02191189|Experimental|Treatment B, ascending colon|50 mg Nevirapine administered to the ascending colon via Enterion™ capsule
16663709|NCT02191189|Experimental|Treatment C, jejunum|50 mg Nevirapine administered to the jejunum via Enterion™ capsule
16663710|NCT02191189|Experimental|Treatment D, ileum|50 mg Nevirapine administered to the ileum via Enterion™ capsule
16663711|NCT02191189|Experimental|Treatment E, descending colon|50 mg Nevirapine administered to the descending colon via Enterion™ capsule
16663712|NCT02191176|Experimental|Dextromethorphan syrup - low dose|
16663713|NCT02191176|Experimental|Dextromethorphan syrup - high dose|
16663714|NCT02191176|Placebo Comparator|Placebo|
16663715|NCT02191163|Experimental|Antistax®|1 x 360 mg for 42 days
16663716|NCT02191163|Placebo Comparator|Placebo|
16663717|NCT02191150||Cohort 1|Patients with CKD
16663718|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
16663719|NCT02191124|Experimental|measurement-based care|MBC allows psychiatrists to individualize treatment decisions for each patient based on the change of psychopathology and tolerance toward antidepressants. Treatment decisions were made by treating psychiatrists according to ratings of self-report scales obtained at each treatment visit. Paroxetine was started at 20mg/day and then raised to 30mg/day by week 4, 40mg/day by week 6, 50mg/day by week 8 and 60mg/day by week 10. Mirtazapine was started at 15mg/day and raised to 30mg/day by week 1 and 45mg/day by week 4. Dose adjustments were dependent on how long a patient had received a particular dose, symptom changes and side effects.
16663720|NCT02191124|Active Comparator|Standard treatment|Patients in the ST group are treated by their psychiatrists according to their clinical needs as judged at each outpatient visit, receiving either open-label paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) within the therapeutic dose range.
16663721|NCT02191111|Experimental|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
16663722|NCT02191111|No Intervention|Control|These sites will continue practice as usual, with no contact from study staff.
16663723|NCT02191098|Experimental|ALT-803|ALT-803
16663868|NCT02190136|Experimental|Protein Resistance Exercise Training|Ingestion of 4-6 protein-rich meals per day and 3 times per week of resistance functional training.
16664020|NCT02189226|Active Comparator|chromoendoscopy (CE) group|
16663724|NCT02191085|No Intervention|Standard Management|"Patients in the Standard Management arm will be assessed without any interventions.Patients will be assessed by a sleep respirologist and follow a management plan that is determined by the sleep physician and patient. This plan may involve polysomnography or the initiation of PAP therapy. If further testing is ordered, follow-up may occur with the physician or with an ACP, at the physician's discretion. For patients initiating PAP therapy, the decision to delegate follow-up to an ACP will be left up to the physician, as the intent of this study is to observe real-world practice and not to change the management of individual patients."
16663725|NCT02191085|Active Comparator|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient."
16663726|NCT02191072|Experimental|omalizumab|omalizumab 300mg subcutaneously once
16663727|NCT02191059|Experimental|Intermittent High Dose of Icotinib|"Intermittent High Dose of Icotinib in Combination With Docetaxel:
~Icotinib 625mg tablet b ymouth three times per day for day1-2, Docetaxel 75mg/m2 injection intravenous drip for day 3, 3 weeks as 1 cycle"
16663728|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
16663729|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
16663730|NCT02191033|Experimental|Text messaging|Smoking counseling, nicotine patch, text messaging
16663731|NCT02191033|Active Comparator|Standard of care|Smoking counseling, nicotine patch
16663732|NCT02191020|Experimental|Total glucosides of paeony & Acitretin Capsules|During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d
16663733|NCT02191020|Active Comparator|Acitretin Capsules|20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.
16663734|NCT02191007|Experimental|Calcipotriol/Betamethasone and Calcipotriol|Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;
16663735|NCT02191007|Sham Comparator|Calcipotriol/Betamethasone and urea cream|alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period
16663736|NCT02191007|Active Comparator|Calcipotriol/Betamethasone|Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period
16663737|NCT02190994|No Intervention|A. Normal function, non-GC replacement|No glucocorticoid replacement will be given perioperatively.
16663738|NCT02190994|Active Comparator|B. Normal function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
16663739|NCT02190994|Active Comparator|C. Impaired function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
16663740|NCT02190994|Active Comparator|D. Impaired function, high-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3.
16663741|NCT02190981||Ultrasound for Small Bowel Obstruction|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected small bowel obstruction
16663742|NCT02190968|Experimental|Mindful Mood Balance|An 8 session internet intervention targeting residual depressive symptoms.
16663743|NCT02190968|Active Comparator|Usual Depression Care|Usual Depression Care through Kaiser Permanente Colorado
16663744|NCT02190955||NEPTUNE contact registry patients|Patients and caregivers will be recruited from the Nephrotic Syndrome Study Network (NEPTUNE) Patient Contact Registry. Over 1000 patients and caregivers are members of the registry and have already provided permission to be contacted for future research studies. Analysis of the one-time online questionnaire will be done in collaboration with investigators from the NEPTUNE Consortium.
16663745|NCT02190942||Vasculitis Contact Registry Patients|Consent will be obtained from at least 20 randomly selected patients with each of the following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care providers to request that the providers complete an online version of this questionnaire (or print copy, if they prefer), and request specific chart items from their office to further verify the data.
16663746|NCT02190929||Vasculitis Contact Registry Patients|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.
16663747|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
16663748|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
16663749|NCT02190890|Experimental|Dry needling: 4 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 4 local twitch responses were elicited.
16663750|NCT02190890|Experimental|Dry needling: 6 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 6 local twitch responses were elicited.
16663751|NCT02190890|Experimental|Dry needling: Until no more local twitch responses elicited|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until no more local twitch responses were elicited.
16663752|NCT02190890|Active Comparator|Control|The needle was inserted 1.5 cm away from the trigger point in the trapezius muscle and withdrawn without any consecutive insertion.
16663753|NCT02190877||Cohort 1: Subjects taking diuretic medication|All subjects will be in the same group, Cohort 1
16663754|NCT02190851|Experimental|electrical nerve stimulation (TENS)|"Two electrodes are attached around the internal malleolus and connected to the TENS unit, by UROSTIM 2.
~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
16663755|NCT02190851|Placebo Comparator|Control group|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
16663756|NCT02190838|Experimental|Dacarbazine with Metformin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Metformin 850 mg BID.
16663757|NCT02190838|Experimental|Dacarbazine and Melatonin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Melatonin 3 mg before sleep daily.
16663758|NCT02190838|Active Comparator|Dacarbazine|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days
16663759|NCT02190812|Experimental|Forearm supporter|This study measured the effect of proper forearm supporter to alleviate pain and improve the wrist and grip strength in the subjects with tennis elbow.
16663760|NCT02190812|Experimental|Grip ball|In this study a portable grip ball training system is developed. This study use the grip ball to train the wrist muscle. It's expected to reduce the risk of injury of the elderly in their daily lives.
16663761|NCT02190799|Experimental|Convalescent plasma|Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria
16663762|NCT02190786|Experimental|KUX-1151, Low dose|
16663763|NCT02190786|Experimental|KUX-1151, Middle dose|
16663764|NCT02190786|Experimental|KUX-1151, High dose|
16663765|NCT02190773||Chronic periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment
16663766|NCT02190773||Agressive periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment.
16663767|NCT02190773||Control group|Periodontally healthy individuals
16663768|NCT02190760|Active Comparator|Group I (ISB-P)|Interscalene block with perineural injection of dexamethasone 0.1 mg/kg
16663769|NCT02190760|Active Comparator|Group II (ISB-S)|Interscalene block with systemically injection of dexamethasone 0.1 mg/kg.
16663770|NCT02190760|Active Comparator|Group III - ISB-C|Interscalene block without adjuvant.
16663771|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
16663772|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
16663773|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
16663774|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
16663775|NCT02190734|Other|wheelchair, walking on treadmill, walking overground|Sitting in wheel chair Gait training on treadmill Gait training overground
16663776|NCT02190721|Experimental|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
16663777|NCT02190708|Experimental|PQ912 & Midazolam & Omeprazole|day2 - day6 800mg PQ912 twice per day po day1 / day6 2.5 mg Midazolam once per day day1 / day6 20 mg Omeprazole once per day
16663778|NCT02190695|Active Comparator|Decitabine|Decitabine 20mg/m2 IV over 1hour daily times 5 days every 28 days
16663779|NCT02190695|Experimental|Decitabine and Carboplatin|Decitabine 20mg/m2 IV over 1hour daily times 5 days, plus Carboplatin AUC 5 IV over 1hour on day 8. repeat every 28 days.
16663780|NCT02190695|Experimental|Decitabine and Arsenic|Decitabine 20mg/m2 IV over 1 hour daily for 5 days plus Arsenic Trioxide 0.15mg/kg IV daily for 5 days. repeat every 28 days
16663781|NCT02190669||exercise in individuals without diabetes|exercise in individuals without diabetes
16663782|NCT02190669||exercise in type 1 diabetes|exercise in type 1 diabetes
16663783|NCT02190669||exercise in type 2 diabetes|exercise in type 2 diabetes
16663784|NCT02190656||Anterior resection|Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery
16663785|NCT02190643|Experimental|Adherence condition|Brief smoking cessation counseling session (based on 5 A's approach) that includes a module focused on improving adherence to using the nicotine patch, plus 8-week supply of nicotine patches.
16663786|NCT02190643|Active Comparator|Standard condition|Brief smoking cessation counseling session (based on 5 A's approach) that does not include a module focused on improving nicotine patch adherence, plus 8-week supply of nicotine patches.
16663787|NCT02190630|Active Comparator|Part time (12hour) wear|the' Modified Clark Twin Block' will be worn part time
16663788|NCT02190630|Active Comparator|Full time (24hour) wear|the ' Modified Clark Twin Block' will be worn full time
16663789|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Management Plan|"Patients in study arm will receive:
~Enhanced Clinic Intervention
~Enhanced Health Plan
~Unified Management Plan"
16663790|NCT02190617|Active Comparator|CHW Home Visit Only|"Patients in study arm will receive:
~CHW Home Visit
~Usual clinic care with enhanced health plan"
16663791|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Plan+ CHW|"Patients in study arm will receive:
~CHW Home Visit
~Enhanced Clinic intervention
~Enhanced health plan
~Unified asthma management plan"
16663792|NCT02190617|No Intervention|Usual Care|-Usual clinic care with enhanced healthplan
16663793|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663794|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663869|NCT02190136|Experimental|Protein Stretching/Yoga Training|Ingestion of Protein-rich diet 4-6 meals/day and stretching/yoga training 3 times per week
16663795|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663796|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663797|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663798|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663799|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663800|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663801|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663802|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
16663803|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
16663804|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
16663805|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
16663806|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
16663807|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
16663808|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
16663809|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
16663810|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
16663811|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
16663812|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
16663813|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
16663814|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
16663815|NCT02190578|Experimental|Diagnostic: Reveal G4|Subjects tested with investigational devices and approved comparator assay algorithms for HIV
16663816|NCT02190565|Placebo Comparator|Placebo|Placebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
16663817|NCT02190565|Active Comparator|Food supplement|Food supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
16663818|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
16663819|NCT02190539|Experimental|Homeopathic treatment|A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
16663820|NCT02190526|Experimental|Mesalazine(asacol 800 mg)|patients receive asacol (800 mg/TDS) and a placebo agent similar to amitriptyline (10 mg/HS) for 8 weeks
16663821|NCT02190526|Experimental|Amitriptyline|patients receive amitriptyline (10 mg/HS) and a placebo like asacol (800 mg/ TDS) for 8 weeks
16663822|NCT02190526|Placebo Comparator|placebo group|patients receive placebo like asacol (800 mg/TDS) and placebo similar to amitriptyline (10 mg/HS) for 8 weeks
16663823|NCT02190500|Active Comparator|Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
16663826|NCT02190474|Experimental|Mindfulness Group|These adolescents will be invited to participate in a group mindfulness meditation program based on a protocol refined by the investigative team. The weekly group meetings will be taught by an MBSR teacher at the Yale School of Medicine, with experience teaching mindfulness interventions to adults, children, and adolescents.
16663827|NCT02190461|Experimental|Early Respiratory Rehabilitation|Starting the Early Respiratory Rehabilitation programme during the admission and continues it at home immediately after discharge for a period of 3 months.
16663828|NCT02190461|Active Comparator|Conventional Respiratory Rehabilitation|Started a conventional Respiratory Rehabilitation programme at home one month after discharge from hospital and continues for 3 months.
16663829|NCT02190448|Experimental|study herbal tea|Supplementation of 3-5, 8 oz cups of study tea daily for 4 weeks.
16663830|NCT02190448|Placebo Comparator|herbal placebo tea|Supplementation of 3-5, 8oz cups of tea daily for 4 weeks.
16663831|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
16663832|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
16663833|NCT02190409|Experimental|Test, Control|Test: Minimum two tapered implants (Ankylosis, Dentsply Friadent) were placed to each patient. After surgical preparation of implant sockets, PRF that was prepared preoperatively was placed randomly to one of the sockets (PRF+). Acellular plasma portion of PRF was used to wet the implant placed into the PRF-coated socket Control: Other socket was selected as a control group (No Platelet Rich Fibrin used): In the control group no extra intervention used and the conventional procedure was done. Thus the readings of the experimental arm compared with this control.
16663834|NCT02190396||Group 1|Placental calcification of Grade 3
16663835|NCT02190396||Group 2|No placental calcification noted, the control group.
16663836|NCT02190383|Experimental|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
16663837|NCT02190370|Experimental|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
16663838|NCT02190357|Experimental|rifaximin|400 mg bid,orally
16663839|NCT02190357|No Intervention|controlled group|no intervention
16663840|NCT02190344|Experimental|Functionality of 8-channel paddle coil system|
16663841|NCT02190331|Experimental|Interventional program|The training protocol is constituted by 4 strengthening exercises (Side Lying External Rotation, Prone Horizontal Abduction with External Rotation, Y to I exercise and Chin Tuck) and 3 stretching exercises(one- Sided Unilateral Self Stretch Exercise, one-sided Unilateral Self Stretch Exercise, Static Sternocleidomastoid Stretch and Static Levator Scapulae Stretch
16663842|NCT02190331|Active Comparator|Control group|The control group will only participate in the Physical Education classes
16663843|NCT02190318|Experimental|Losartan|Losartan is taken orally 100mg/d
16663844|NCT02190318|Experimental|spirolactone|spirolactone is taken orally 20mg/d
16663845|NCT02190318|Experimental|losartan in combination with spirolactone|Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d
16663846|NCT02190318|Sham Comparator|blank control|patients with antihypertensives besides ACEI/ARBs and spirolactone.
16663847|NCT02190305|Experimental|Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg|Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
16663848|NCT02190292||PANS group|All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.
16663849|NCT02190292||Psychiatric controls|60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.
16663850|NCT02190292||Healthy controls|25 age and sex matched children to the PANS group will be recruited.
16663851|NCT02190279|Experimental|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
16663852|NCT02190279|Experimental|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
16663853|NCT02190279|Experimental|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
16663855|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
16663856|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
16663857|NCT02190227|Other|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
16663858|NCT02190201|Experimental|videolaryngoscope|DLT intubation with McGrath videolaryngoscope
16663859|NCT02190201|Active Comparator|Direct laryngoscope|DLT intubation with Macintosh laryngoscope
16663860|NCT02190188|No Intervention|No specific treatment|No specific treatment after partial meniscectomy
16663861|NCT02190188|Other|Wedge Insole with 5mm wedge angel|Participants wear a wedge insole after partial meniscectomy
16663862|NCT02190188|Other|Knee Brace|Participants wear a knee brace after partial meniscectomy
16663863|NCT02190162|Active Comparator|Tantum Verde® mouthwash|solution of Tantum Verde
16663864|NCT02190162|Placebo Comparator|placebo mouthwash|saline with mint flavor
16663865|NCT02190149||ADVATE (Factor VIII)|Participants will remain on their current (pre-study) treatment regimen of ADVATE throughout the study period
16663866|NCT02190149||RIXUBIS (Factor IX)|Participants will remain on their current (pre-study) treatment regimen of RIXUBIS throughout the study period
16663871|NCT02190110||Suspected pulmonary embolism patients|Adult patients (more than 18 years old) suspected of PE will be recruited at the time of the medical evaluation and before a final diagnosis is established
16663872|NCT02190097|Experimental|paleolithic diet|subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
16663873|NCT02190097|Active Comparator|American Diabetes Association diet|subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
16663874|NCT02190084|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
16663875|NCT02190084|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.
16663876|NCT02190058|Experimental|DS-1971a|DS-1971a suspension, up to 4650mg/day
16663877|NCT02190058|Placebo Comparator|placebo|matching DS-1971a suspension
16663878|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
16663879|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
16663880|NCT02190032|Active Comparator|Control group|"Intubating a manufacturer-provided-angled double-lumen tube (=Conventional-angled group,MallinckrodtTM endotracheal tube, Covidien)"
16663881|NCT02190032|Experimental|Tube angle modification|The angle of the double lumen tube(MallinckrodeTM endotracheal tube) is modified individually.At sniffing position, the distal tip of the tube is placed at the patient's cricoid cartilage level and the tube is bent at the intersection point of the two airway axes (oropharyngeal axis and tracheal axis) with an angle between the two axes.
16663882|NCT02190019|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
16663883|NCT02190019|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 10 treatments identical in duration will be administered over a two week period.
16663884|NCT02190006||Polycystic ovarian syndrome|Women with polycystic ovarian syndrome undergoing ICSI
16663885|NCT02189993||Total Parenteral Nutrition Use|The cohort investigated consisted of patients with intestinal failure requiring total parenteral nutrition use.
16663886|NCT02189980|Placebo Comparator|Saline & nasal clip|Saline and nasal clip inhaled post-operatively
16663887|NCT02189980|Experimental|Aromatherapy blend & nasal clip|Aromatherapy blend and nasal clip inhaled post-operatively
16663888|NCT02189967|Active Comparator|conventional fractionation|radiotherapy with conventional fractionation (5 x 2Gy per week)
16663889|NCT02189967|Active Comparator|accelerated fraction|radiotherapy with accelerated fraction (7 x 2 Gy per week)
16663890|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
16663891|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
16663892|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
16663893|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
16663894|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
16663895|NCT02189928|Experimental|With per-CID protocol|Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
16663896|NCT02189928|Other|Without per-CID protocol|Usual care patients (thrombolysis or not).
16663897|NCT02189915|Experimental|Creatine monohydrate|
16663898|NCT02189902|Active Comparator|4000 IU/d of D3 by mouth for 12 weeks|4000 IU/d of D3 by mouth for 12 weeks
16663899|NCT02189902|Experimental|7000IU/d of D3 by mouth for 12 weeks|7000IU/d of D3 by mouth for 12 weeks
16663900|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
16663901|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
16663902|NCT02189876|Experimental|FemAALES|Females of African American Legacy Empowering Self Intervention. A nine session, theoretically grounded small group intervention.
16663903|NCT02189876|Active Comparator|Standard of Care|A one-time STD/family planning testing and counseling session provided to all study participants.
16663904|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
16663905|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
16663906|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
16663907|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
16663908|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
16663909|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
16663910|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
16663911|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
16663912|NCT02189824|Experimental|Infusion of partially matched unrelated donor cells|
16663913|NCT02189811|Experimental|IPV|IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
16663914|NCT02189811|Experimental|bOPV|bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
16663915|NCT02189811|Experimental|bOPV and IPV|bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
16663916|NCT02189811|Experimental|bOPV and IPV and IPV2|bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
16663917|NCT02189811|Active Comparator|tOPV|tOPV at birth, 6, 10, 14, 18 and 22 weeks of age
16663918|NCT02189798|Experimental|Newly Implanted Group|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness. Patients retaining considerable low frequency acoustic hearing after the surgery, will be fitted with the EAS sound processor.
16663919|NCT02189798|Experimental|Existing Implanted Group|Adults unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness will be fitted with the EAS sound processor.
16663920|NCT02189798|Experimental|EAS Extended Use Arm|Adults who are unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness and completed the 12 Month visit using the EAS sound processor in either the Newly Implanted Group or Existing Implanted Group.
16663921|NCT02189785||Healthy Controls|Healthy men and women ages 18-25 years
16663922|NCT02189772|Experimental|MDX (metadoxine extended release)|"Route of administration: oral
~The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:
~40-49 kg 700 mg consisting of a 700 mg tablet
~50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet
~65-100 kg 1400 mg consisting of two 700 mg tablets"
16663923|NCT02189772|Placebo Comparator|placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
16663924|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
16663925|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
16663926|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
16663927|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
16663928|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to 1 hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
16663929|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
16663930|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
16663931|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
16663932|NCT02189733|Experimental|Caplacizumab - Treatment A|Single s.c. dose of reconstituted lyophilized solution of caplacizumab followed by single s.c. dose of liquid formulation of caplacizumab
16663933|NCT02189733|Experimental|Caplacizumab - Treatment B|Single s.c. dose of liquid formulation of caplacizumab followed by single s.c. dose of reconstituted lyophilized solution of caplacizumab
16663934|NCT02189707|Experimental|Probiotic Bifidobacterium 1x1010 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
16663935|NCT02189707|Experimental|Probiotic Bifidobacterium 1x109 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
16663936|NCT02189707|Placebo Comparator|Placebo powder in capsules|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
16663937|NCT02189694|Active Comparator|Insulin pump therapy|Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
16663938|NCT02189694|Active Comparator|Single-hormone closed-loop strategy|Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
16663939|NCT02189694|Active Comparator|Dual-hormone closed-loop strategy|Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
16663940|NCT02189681|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthesia.
16663941|NCT02189681|Experimental|Group P|This group had pre-procedure ultrasound guided L5S1 paramedian spinal anaesthesia performed
16663942|NCT02189668|Experimental|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
16663943|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
16663944|NCT02189655|No Intervention|Group Control|Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
16663945|NCT02189655|Experimental|Group Diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
16663946|NCT02189642||Genito-Urinary/Urology Surgical Procedure Types|Pediatric patients undergoing circumcision, orchidopexy, hypospadias repair, hernia repair, cystoscopy, pyeloplasty, and ureteral reimplants or ureteral stents.
16663947|NCT02189642||Otolaryngology Surgical Procedure Types|Pediatric patients undergoing tonsil and/or adenoid removal, tympanostomy, tympanoplasty, and mastoidectomy.
16663948|NCT02189642||Orthopaedics Surgical Procedure Types|Patients undergoing hip and knee arthroscopies, hardware removal, and tendon lengthening.
16663949|NCT02189642||Plastic Surgery Surgical Procedure Type|Pediatric patients undergoing alveolar cleft repair.
16663950|NCT02189629|Experimental|CD5789 (trifarotene) cream|
16663951|NCT02189616|Other|regular care group|receive regular care which contains filling a paper asthma diary daily.
16663952|NCT02189616|Experimental|SMS reminder group|receive weekly mobile phone short message reminders for 3 months
16663953|NCT02189616|Experimental|SMS reminder and SMS consultation group|receive weekly mobile phone short message reminders and can consult asthma nurse by mobile phone short message when needed for 3 months
16663954|NCT02189603|Experimental|Senior group(over 65 years old)-HE|Anti-HEV IgG seronegative participants over 65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
16663955|NCT02189603|Active Comparator|Younger groups(16-65 years old)|Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
16663956|NCT02189603|No Intervention|Senior group(over 65 years old)-Cont|Anti-HEV IgG seropositive participants over 65 years old were enrolled. This is the safety control group, without any intervention.
16663957|NCT02189590|Experimental|air-Q|Patients will receive the air-Q with size based on manufacturer recommendations of body weight
16663958|NCT02189590|Experimental|i-gel|Patients will receive the i-gel with size based on manufacturer recommendations of body weight
16663961|NCT02189564|Active Comparator|Intrinsic reward|Feedback about good performance
16663962|NCT02189564|Experimental|Intrinsic and extrinsic reward|Feedback about good performance + money
16663963|NCT02189564|Experimental|Intrinsic reward (average performance)|Feedback about random selection of trials
16663964|NCT02189551|Active Comparator|Lokomat Pro|gait robot established on the market
16663965|NCT02189551|Experimental|Lokomat Pro FreeD|gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market
16663966|NCT02189538|Experimental|ω-3 PUFA|Modular low fat diet (18%) including 9% as ω-3 PUFA
16663967|NCT02189538|Active Comparator|Low fat enteral diet|Modular low fat (18%)
16663968|NCT02189525||Sports induced concussion|Exposure to sports induced concussion
16663969|NCT02189525||Routine Athletic Exertion|Exposure to routine athletic exertion without sports-induced concussion (non-concussion control)
16663970|NCT02189512|Other|brain death organ donors|cases - blood sampling
16663971|NCT02189512|Other|abdominal aortic aneurysm repair|controls - blood sampling
16663972|NCT02189499|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
16663973|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
16663974|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
16663975|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
16663976|NCT02189460||Healthy adults|20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.
16663977|NCT02189447|Experimental|Refractive surgery|Patients with keratoconus treated with simultaneous photorefractive keratectomy and Corneal collagen cross-linking.
16664916|NCT02183376|Experimental|BI 1356 - healthy subjects|
16663978|NCT02189434||Cytoreductive surgery|Patients having undergone cytoreductive surgery with or without HIPEC will have serum procalcitonin lab draws
16663979|NCT02189421|Other|Direct peroral cholangioscopy|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
16663980|NCT02189408|Experimental|PRP|one intraoperative application of PRP in the interventional group
16663981|NCT02189408|No Intervention|Control|No application of any substance during knee arthroscopy
16663982|NCT02189395|Experimental|NPH and regular insuline group|For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
16663983|NCT02189395|Active Comparator|glargine and humalog group|Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.
16663984|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
16663985|NCT02189382|Other|Water|Self Applied
16663986|NCT02189369|Experimental|Day 3 embryo-Own-above cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
16663987|NCT02189369|Experimental|Day 5 embryo-Own-above cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
16663988|NCT02189369|Experimental|Day 3 embryo-Donor-above cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
16663989|NCT02189369|Experimental|Day 5 embryo-Donor- above cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
16663990|NCT02189369|Experimental|Day 3 embryo-Donor-lower cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
16663991|NCT02189369|Experimental|Day 5 embryo-Donor-lower cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
16663992|NCT02189369|Experimental|Day 3 embryo-own-lower cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
16663993|NCT02189369|Experimental|Day 5 embryo-own-lower cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
16663994|NCT02189356|Experimental|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
16663995|NCT02189356|Other|contol group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
16663996|NCT02189343|Experimental|Dose Escalation Cohort|Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
16663997|NCT02189330|Experimental|Tafamidis|
16663998|NCT02189330|Experimental|Tafamudus Free Acid|
16663999|NCT02189330|Experimental|20 mg new soft gelatin capsule|
16664000|NCT02189330|Experimental|4 capsules of 20 mg tafamidis of commercial formulation|
16664001|NCT02189330|Experimental|4 capsules of 12.2 mg tafamidis of free acid tablet|
16664002|NCT02189317|Experimental|Exparel|This arm will receive Exparel
16664003|NCT02189317|No Intervention|Control|
16664004|NCT02189304|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
16664005|NCT02189304|Experimental|PT009|PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
16664006|NCT02189304|Active Comparator|Symbicort Turbohaler|Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations
16664007|NCT02189291|Experimental|Immediate catheter removal|The indwelling Foley catheter will be removed prior to exiting the operating room.
16664008|NCT02189291|Active Comparator|Post op day 1 catheter removal|Patients assigned to this group will follow the standard of care at present, with removal of indwelling catheter on the morning of postoperative day 1.
16664009|NCT02189278|Experimental|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
16664010|NCT02189278|No Intervention|Treatment as usual|Treatment as usual control.
16664011|NCT02189265||Full cohort|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
16664012|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
16664013|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
16664014|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
16664015|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
16664016|NCT02189239|Active Comparator|Zeller Entspannung film coated tablets|Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.
16664017|NCT02189239|Placebo Comparator|Placebo tablets|Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.
16664018|NCT02189239|Sham Comparator|No Treatment|No medication intake.
16664019|NCT02189226|Experimental|probe-based confocal laser endomicroscopy (pCLE) group|
16664021|NCT02189213|Active Comparator|Sertraline|Sertraline will be administered PO to treat anxiety disorders in children and adolescents. he following dosing schedules will be used: Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks. The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration.
16664022|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
16664023|NCT02189200|Active Comparator|Oat bran group|oat bran (40g per day)
16664024|NCT02189200|Placebo Comparator|Placebo group|refined rice flour (40g per day)
16664025|NCT02189187|Experimental|Mindfulness Based Stress Reduction (MBSR) program|Mindfulness Based Stress Reduction (MBSR) is an 8-week program that consists of training in mindfulness practices, the application of mindfulness to daily life, and information about healthy living and the role played by thoughts and emotions in health.
16664026|NCT02189187|Active Comparator|Healthy Living Course (HLC)|Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
16664027|NCT02189174|Experimental|CLR457|
16664028|NCT02189161|Experimental|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
16664029|NCT02189148||Cohort|"Each participant will :
~give consent
~provide a blood sample (10 ml)
~be measured (weight and height for BMI calculation)
~undergo a blood pressure measurement
~have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)
~answer to a short questionnaire (5 pages)"
16664030|NCT02189135|No Intervention|Usual care|Usual care from physician/ doctor
16664031|NCT02189135|Experimental|Telemedicine|Mobile wireless glucometer with feedback from physicians
16664032|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
16664033|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
16664034|NCT02189109|Experimental|Dose Escalation|NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.
16664035|NCT02189096||No change from current practice|"Phase 1 (4 months)
~No change from current practice. Each Paramedic crew routinely documents patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be electronically captured. The data will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria [signs of systemic inflammation] and suspicion of infection) by the study investigators. An estimate will be made of the time of completion of the ePRF in relation to patient transport."
16664036|NCT02189096||NEWS and Sepsis Screening|"Phase 2 (4 months)
~The ten crews will undertake implementation of NEWS and Sepsis Screening. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, the patients transfer will be as per normal protocol but receiving ED staff will receive the information about NEWS score and Sepsis screening as part of a structured handover."
16664037|NCT02189096||Point of care lactate measurement|"Phase 3 ( 4 months)
~The ten crews will undertake Point of Care Lactate measurement when NEWS ≥ 4 or when the patient screens positive for Sepsis. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection).
~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge. The lactate level, along with the NEWS score and sepsis screening, will be given to the receiving ED staff as part of a structured handover."
16664038|NCT02189083|Experimental|High dose TSD|Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
16664039|NCT02189083|Active Comparator|Low dose TSD|Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
16664040|NCT02189070||Responders|Responding participants
16664041|NCT02189070||Non-responders|Non-responding participants
16664042|NCT02189057|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
16664043|NCT02189057|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
16664044|NCT02189044|Other|exercises; muscle strength|Evaluate the effects of Pilates exercises on respiratory muscle strength in elderly women before and after eleven weeks of training
16664045|NCT02189031||Upper Extremity Amputee|Robust custom tactor to facilitate embodiment and proprioception
16664046|NCT02189031||Able Bodied|Bypass tactor
16664047|NCT02189018|Active Comparator|Control|Ad lib activity at home
16664048|NCT02189018|Experimental|Active Exercise|Active exercise on treadmill
16664049|NCT02189018|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
16664050|NCT02189018|Experimental|Weight loss and active exercise|Weight loss plus active exercise on treadmill
16664051|NCT02189005|Experimental|PreCrea|Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.
16664052|NCT02189005|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
16664053|NCT02188992||Cohort 1|Patients with sepsis syndrome, without criteria for severe sepsis/septic shock. These patients are recruited from the emergency department.
16664054|NCT02188992||Cohort 2|Patients with community acquired sepsis syndrome REQUIRING critical care admission due to severity of sepsis. These patients are recruited from the critical care areas (ICU/HDU).
16664917|NCT02183376|Experimental|BI 1356 - mild liver impairment|
16664055|NCT02188992||Cohort 3|Patients without sepsis syndrome. Age and gender matched to cohort 1, and recruited from Emergency Department.
16664056|NCT02188966|Experimental|Geographical Information System|Availability of Geographical Information System data from ambulances destined for the Emergency Department of Regional Hospital Horsens.
16664057|NCT02188953|Experimental|ACCS100|Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
16664058|NCT02188953|Placebo Comparator|Calcium carbonate|Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.
16664059|NCT02188940|Active Comparator|Exercise, dietary and behavioral therapy|The interventions of active comparator will be education program, dietary and behavioral therapy and exercise training.
16664060|NCT02188940|Sham Comparator|Dietary and behavioral therapy|The intervention in sham comparator will be education program, dietary and behavioral therapy and stretching and breathing exercise.
16664061|NCT02188927|Experimental|Implementation of ANL|"Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure
~Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)"
16664062|NCT02188927|Active Comparator|No included ANL|Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy
16664063|NCT02188914||Inhalant use disorder group|Subjects must have a diagnosis of inhalant use disorder, according to the DSM-5, who are under a treatment program for addictive disorders.
16664064|NCT02188914||Normal control group|Normal control without a history of drug abuse or dependency.
16664065|NCT02188901|Other|single arm|
16664066|NCT02188888||Tachycardic patients|Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
16664067|NCT02188875|Experimental|SMS Text Messages & Fitbit One|All study participants were provided a Fitbit One to facilitate self-monitoring of PA. Those who were randomly assigned to the intervention group were asked to indicate 3 preferred times of the day to receive text message prompts to do PA throughout the 6-week study period.
16664068|NCT02188875|Active Comparator|Fitbit One Only|An active control group was also provided the Fitbit One to facilitate self-monitoring of PA throughout the 6-week study period.
16664069|NCT02188862||Rheumatic heart disease cases|Patients with rheumatic heart disease as defined in the case criteria
16664070|NCT02188862||Population controls|Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)
16664071|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
16664072|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
16664073|NCT02188836|Experimental|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
16664074|NCT02188836|Placebo Comparator|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
16664075|NCT02188823|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.
~Participants will also be taught information about exercise, sleep, mindfulness, and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
16664076|NCT02188810|Active Comparator|Group 1|Single dose of control vaccine (a single dose of 0.5 mL TIV).
16664077|NCT02188810|Experimental|Group 2|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
16664078|NCT02188810|Experimental|Group 3|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 1x PAL, i.e. 60 μg).
16664079|NCT02188810|Experimental|Group 4|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 2x PAL (i.e., 120 μg).
16664080|NCT02188810|Experimental|Group 5|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 4x PAL (i.e., 240 μg).
16664081|NCT02188810|Experimental|Group 6|Single dose of the test article (0.125 mL of TIV with 4x PAL i.e., 240 μg).
16664082|NCT02188797|Experimental|Group MI risk reduction program|Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
16664083|NCT02188797|No Intervention|Usual care control|Participant receive HIV information brochure and Community Resource Guide.
16664084|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
16664085|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
16664086|NCT02188771|Experimental|RegenoGel SP 2ml|"RegenoGel-SP is a new viscosupplement intended for the intra-articular treatment of OA.
~Following signing the Informed Consent form (Visit 1), subjects who conform to the inclusion criteria will be evaluated for vital signs, blood hematology, chemistry, INR, aPTT and ECG, and will be subjected to a 30-40ml blood withdrawal that will be used for the production of autologous RegenoGel-SP. Subjects randomized to receive RegenoGel-SP will receive a single, intra-articular injection (Visit 2)."
16664087|NCT02188758||Adults - CFPE Treatment|Other: CF Pulmonary Exacerbation (CFPE) Treatment
16664117|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.
~A lower dose of TXa will be given as follows:
~10 mg/kg loading dose and 5 mg/kg/h infusion"
16664089|NCT02188732|Experimental|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):
~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
16664090|NCT02188732|Active Comparator|CBHH+SMT|"CBHH+SMT Community-Based Health Home (CBHH) PLUS Self-Management Training (SMT) of I-IMR
~I-IMR integrates psychiatric illness self-management with strategies for medical illness self-management . The psychiatric component includes psychoeducation about illness and treatment, cognitive behavioral approaches to increase medication adherence, training and relapse prevention, teaching coping skills to manage persistent symptoms, and social skills training. The medical illness component consists of an individually tailored curriculum focused on managing physical illnesses using parallel skills and strategies taught for psychiatric illness self-management, as well as a nurse health care manager to facilitate coordination of necessary preventive and ongoing health care. The I-IMR curriculum consists of 10 modules delivered by an I-IMR specialist through eight months of weekly sessions customized to the specific needs and disorders of each client."
16664091|NCT02188732|Active Comparator|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
16664092|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
16664093|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
16664094|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
16664095|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
16664096|NCT02188693||Gemcitabine, Experimental|Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause
16664097|NCT02188693||Observational|Observation for every 12 weeks until disease progression or the date of first documented death from any cause
16664098|NCT02188680|Active Comparator|Low FODMAPS diet and positive breath testing for fructose|Patients with breath testing positive have a low FODMAPS diet. The test will be considered as positive if we observe an increase of more than 20 ppm of H2 and/or CH4 on a sample with regard to the basal concentration
16664099|NCT02188680|Sham Comparator|negative breath testing for fructose|patients with negative breath test have a low FODMAPS diet
16664100|NCT02188667|Active Comparator|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
16664101|NCT02188667|Sham Comparator|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
16664102|NCT02188654|Experimental|Metformin|500 mg metformin
16664103|NCT02188654|Placebo Comparator|Placebo|500 mg of placebo tablets
16664104|NCT02188641|Other|Diet|Low-fat diet
16664105|NCT02188641|Other|Exercise|3-day/week exercise programme
16664106|NCT02188641|Other|Diet and exercise|healthy low fat diet and 3day/week exercise programme
16664107|NCT02188641|Other|Healthy lifestyle (Control) group|Control group was provided with health education using videotaped presentation
16664108|NCT02188628|Experimental|H-Man|H-Man is a novel, portable, inexpensive end-effector upper limb robot.
16664109|NCT02188628|Active Comparator|Additional Conventional Therapy|Repetitive goals based arm therapy
16664110|NCT02188615|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
16664111|NCT02188615|Active Comparator|Radical Chemoradiotherapy|only Radical Chemoradiotherapy
16664112|NCT02188615|Active Comparator|Mckeown MIE|only Mckeown MIE
16664113|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
16664114|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
16664115|NCT02188589|Experimental|Nasal implant group|Bilateral or unilateral INEX nasal implants
16664116|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.
~A higher dose of tranexamic acid will be given to this arm as follows:
~50 mg/kg loading dose and 5 mg/kg/h infusion"
16664329|NCT02187250|Active Comparator|roflumilast|In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.
16664118|NCT02188563|Experimental|Comprehensive intervention|New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
16664119|NCT02188563|Active Comparator|Enhanced usual care|Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
16664120|NCT02188550|Experimental|Single|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
16664121|NCT02188537|Experimental|Nelfinavir, Bortezomib, Dexamethasone|"The trial is designed as an add-on therapy, where nelfinavir is added to the approved bortezomib-containing therapy. Bortezomib and dexamethasone background treatment will be given in the Swissmedic-approved dose and schedule and according to international therapeutic standard."
16664122|NCT02188524|No Intervention|Control Group|No exercise program
16664123|NCT02188524|Experimental|Exercise Group|exercise program
16664124|NCT02188511|Experimental|Group A|Electronic cigarette (nicotine/placebo) - Day 8 Intervention: Electronic cigarette exposure will be limited to one day.
16664125|NCT02188511|Experimental|Group B|Electronic cigarette (nicotine/placebo) - Days 7 through 8 Electronic cigarette exposure will be limited to two days
16664126|NCT02188511|Experimental|Group C|Electronic cigarette (nicotine/placebo) - Days 6 through 8 Electronic cigarette exposure will be limited to 3 days
16664127|NCT02188511|Experimental|Group D|Electronic cigarette (nicotine/placebo) - Days 5 through 8 Electronic cigarette exposure will be limited to 4 days
16664128|NCT02188511|Experimental|Group E|Electronic cigarette (nicotine/placebo) - Days 4 through 8 Electronic cigarette exposure will be limited to 5 days.
16664129|NCT02188498||Polysomnography with Holter monitoring|Patients will undergo resting electrocardiogram (ECG) test at the beginning of the night and be monitored by a Holter device for the duration of the sleep study.
16664130|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
16664131|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
16664132|NCT02188472|Active Comparator|Penicillin V|Penicillin V 2 tablets of 330 mg twice dayly for 7 days
16664133|NCT02188472|Active Comparator|Trimethoprim|2 Tablet Trimethoprim of 100 mg twice daily for 7 days
16664134|NCT02188472|Placebo Comparator|Placebo|2 Placebo Tablets twice daily for 7 days
16664135|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
16664136|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
16664137|NCT02188446|Experimental|Smoking and alcohol cessation education|
16664138|NCT02188446|No Intervention|Standard treatment|Standard treatment is information about benefits of stopping drinking and smoking before surgery and if wanted, advice about who to contact to get support.
16664139|NCT02188433|Experimental|Cut down to quit (CDTQ)|"For those subjects who claim that they cannot quit smoking ≤7 days, they will receive a leaflet (i.e. include a roadmap of smoking reduction strategy) plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit as quitting can greatly reduce risks, and participants will be advised to cut down cigarette consumption at their own pace, but the process should not exceed 3 months. (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention and encourage smokers who fail to quit or relapse to reduce again during each telephone follow-up.
~For the subjects have intention to quit smoking ≤7 days, the investigator will follow-up them after a week. For those who report quitted, they will be followed up as other participants. However, if they report failed to quit, they will receive the same interventions and will be followed-up as other participants in the experimental group."
16664140|NCT02188433|Active Comparator|Quit Immediately (QI)|QI group subjects will receive a smoking cessation booklet (provided by COSH) plus brief intervention using AWARD model similar to CDTQ group. For the subsequent telephone follow-up repeat the health warning that 'one in two smokers will be killed by smoking' and encourage smokers who fail to quit or relapse to try again.
16664141|NCT02188420|Experimental|Latency minus 3ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
16664142|NCT02188420|Experimental|Latency minus 5ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
16664143|NCT02188420|Experimental|Latency minus 7ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
16664144|NCT02188420|Active Comparator|Latency plus 100ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency + 100ms), known to have no effect, where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
16664145|NCT02188407|Experimental|Sevoflurane|Sevoflurane group (S group)- The group anaesthesied with sevoflurane
16664146|NCT02188407|Active Comparator|Propofol|Propofol 4-6 mg/kg/h iv
16664147|NCT02188394|Experimental|Anesthetic blockades with bupivacaine|Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
16664148|NCT02188394|Placebo Comparator|Isotonic saline injection|Patients will receive a bilateral occipital injection with isotonic saline
16664149|NCT02188381||Normal controls without hypertension|Control subjects will have a systolic BP <140mmHg with no cardiovascular disease. These subjects will provide a one time stool sample and a blood sample.
16664150|NCT02188381||Controlled hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
16664330|NCT02187237|Experimental|Laser therapy|
16664151|NCT02188381||Resistant hypertension|Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg despite ≥3 anti-hypertensive medications of different classes. These subjects will provide a one time stool sample and a blood sample.
16664152|NCT02188381||Prior enrolled in NCT 02133872|These subject will be asked to provide two stool samples and two blood samples. One at baseline and one after 3 months of therapy.
16664153|NCT02188381||Remodeled Resistent Hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
16664154|NCT02188368|Experimental|A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)|"POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
16664155|NCT02188368|Experimental|B: POM 3mg+PLD with or without steroids|"POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
16664156|NCT02188368|Experimental|C: POM MTD + other drugs|"Phase 1:
~POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed
~Phase 2:
~POM at the MTD All other agents, at the same dose and on the same days as phase 1"
16664157|NCT02188342|Experimental|HIT exercise training|
16664158|NCT02188329||Households with children under 13|Interviews were conducted with the parent or guardian of a child or children under age 13.
16664159|NCT02188329||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own.
16664160|NCT02188329||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
16664161|NCT02188329||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
16664162|NCT02188316|Active Comparator|Jumbo forceps polypectomy|89 patients were randomized to jumbo forceps arm and 120 diminutive colorectal polyps were removed by jumbo forceps polypectomy.
16664163|NCT02188316|Active Comparator|Hot biopsy electrocauterization|90 patients were randomized to hot biopsy forceps arm and 117 diminutive colorectal polyps were removed by hot biopsy electrocauterization.
16664164|NCT02188303|Placebo Comparator|Placebo (Single Dose, Cohorts 1-3)|Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1
16664165|NCT02188303|Experimental|LY2944876 (Single Dose, Cohorts 1-3)|Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1
16664166|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1-7
16664167|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|40 mg LY2944876 administered once daily SC on Days 1-7
16664168|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
16664169|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC
16664170|NCT02188290||HAPLO group|Control group of all eligible patients who received an HSCT from a haploidentical donor without ATIR administration between 1 January 2006 and 30 June 2013
16664171|NCT02188290||MUD group|Control group of eligible patients who received an HSCT from a fully matched unrelated donor between 1 January 2010 and 31 December 2012
16664172|NCT02188290||MMUD group|Control group of eligible patients who received an HSCT from a 1-locus mismatched unrelated donor between 1 January 2010 and 31 December 2012
16664173|NCT02188290||UCB group|Control group of eligible patients who received a double umbilical cord blood transplantation between 1 January 2010 and 31 December 2012
16664174|NCT02188277|Experimental|Xeomin®|4-8 Units per kg body weight. Single injection cycle.
16664175|NCT02188277|Active Comparator|Botox®|4-6(8) Units per kg body weight. Single injection cycle.
16664177|NCT02188251|Experimental|Activamp|Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks
16664178|NCT02188251|Placebo Comparator|Placebo|1 capsule taken twice daily for 12 weeks
16664179|NCT02188238||Saliva Sample Collection|Collection of stimulated whole mouth saliva . Whole mouth saliva is collected through stimulation by inert gum, and collecting saliva in a sterile tube.
16664180|NCT02188225|Experimental|Acupuncture|12 sessions of acupuncture / 3 sessions weekly/ 20 minutes each session
16664181|NCT02188225|Active Comparator|fluoxetine|10 mg daily
16664182|NCT02188212|Other|NobelProcera Crown Shaded Zirconia|NobelProcera Crown Shaded Zirconia molar
16664183|NCT02188199||Knee Replacement|Patients undergoing knee replacement surgery
16664184|NCT02188199||Hip Replacement|Patients undergoing hip replacement
16664185|NCT02188186|Active Comparator|Conventional treatment|"Initial dual combination therapy with sulfonylurea and metfomin. Dose of sulfonylurea (glimepride 2-8 mg) and metfomin (500-2550 mg) can be ecalated at investigator's discreition at every visit.
~Insulin therpy can be added as a rescue therapy at investigator's discreition."
16664186|NCT02188186|Experimental|Initial triple combination treatment|"Initial dual combination therapy with metformin, sitagliptin (Januvia 100 mg), and lobeglitazone (Duvie 0.5 mg).
~Insulin therpy can be added as a rescue therapy at investigator's discreition."
16664220|NCT02187887|No Intervention|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
16664187|NCT02188173||dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
16664188|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
16664189|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
16664190|NCT02188147|Experimental|SWD 1000|Short Term Wearable Defibrillator
16664191|NCT02188134||65 and older|No intervention will be administered
16664192|NCT02188121|Experimental|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
16664193|NCT02188121|No Intervention|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
16664194|NCT02188108|Experimental|Survey|Wisconsin Stone-QOL survey. Patients with kidney stones or a history thereof will complete a kidney stone-specific health-related survey at enrollment and post-enrollment at 3 months, 12 months, 24 months, and 36 months.
16664195|NCT02188095||Excia T®|
16664196|NCT02188082|Experimental|IvabRadine hemisulfate Sustained-release Tablets|5-15mg qd
16664197|NCT02188082|Placebo Comparator|placebo|5-15mg qd
16664198|NCT02188043|Other|Relay Model|"AUDIT score 8+: Brief Motivational Intervention with alcohol therapist. AUDITscore16+:Brief Motivational Intervention and appointment at Alcohol Treatment Clinic
~-"
16664199|NCT02188043|No Intervention|Usual Referral Procedure|Hospital staff refer patient to Alcohol Treatment Clinic according to usual procedure
16664200|NCT02188030|Active Comparator|Group Exercise Training (GET).|Group Exercise Program. The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum 12. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
16664201|NCT02188030|Active Comparator|Individual Exercise Training|Individual Exercise Program. The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al. and Sundstrup et al . During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
16664202|NCT02188017|Active Comparator|80 units|80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading
16664203|NCT02188017|Active Comparator|40 units|40 units of ACTHAR gel will be given twice a week for 22 weeks after loading
16664204|NCT02187991|Active Comparator|ER+/HER2- Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
16664205|NCT02187991|Experimental|ER+/HER2- Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
16664206|NCT02187991|Active Comparator|Triple Negative Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
16664207|NCT02187991|Experimental|Triple Negative Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
16664208|NCT02187978|Experimental|Early total enteral feeding (ETEF)|"Feeding will be initiated on D1 with 80ml/kg/day of expressed breast milk or LBW formula milk.
~No intravenous fluid will be provided. Feeds will be advanced till 150ml/kg/day is attained."
16664209|NCT02187978|Active Comparator|Conventional enteral feeding (CEF)|"Feeding will be initiated on D1of life with 20ml/kg of expressed breast milk or LBW formula milk.
~Remaining requirement as intravenous fluids. Feeds advanced by 20ml/kg/day for next 2 days and then 30ml/kg/day for the next three days until 150ml/kg/day is reached."
16664210|NCT02187952|Experimental|Behavioral feeding intervention|Behavioral feeding intervention will be conducted as usual. The intervention will not be altered for purposes of the study.
16664211|NCT02187952|No Intervention|Waitlist control|
16664212|NCT02187939|Active Comparator|Summer wellness program - nutrition & physical activity|The GROOVE condition uses conventional means to address health-related activities and content within the context of a science museum summer enrichment program. The emphasis is on nutrition, physical activity, and healthy lifestyle.
16664213|NCT02187939|Experimental|Summer program plus virtual world technology|The GROOVE+ condition enhances the conventional approach to address health-related activities and content within the context of a science museum summer enrichment program by employing technology and a 3-D virtual world as a key educational strategy. The emphasis is on nutrition, physical activity, and healthy lifestyle.
16664214|NCT02187926||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved label in Greece.
16664215|NCT02187913|Experimental|Resistant starch|The test snack bar consumed has the resistant starch
16664216|NCT02187913|Experimental|Control|The control bar uses maltodextrin rather than the resistant starch.
16664217|NCT02187900|Experimental|TWH for the treatment of IgAN|Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
16664218|NCT02187900|Active Comparator|MMF for IgAN|MMF for the treatment of IgAN for 6 months
16664219|NCT02187887|Experimental|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
16664331|NCT02187224|Experimental|Progesterone|For the three days prior to each test day every participant in this arm will receive progesterone.
16664221|NCT02187874|Active Comparator|early umbilical cord occlusion|Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.
16664222|NCT02187874|Experimental|delayed umbilical cord occlusion|"One of the paediatricians will hold the newborn ( in vaginal deliveries between 20-30 cm under the mother, in C-sections between the legs of the mother) until clamping of the umbilical cord is indicated by a second paediatrician who will be controlling the time and overall state of the baby. The baby will be wrapped during this time in a thermal blanket in a flexed lateral decubitus position to minimise stress and heat loss. Time of clamping: after 30 to 60 seconds( preferably 60). If loss of the baby's wellbeing is suspected, the paediatrician will assess the newborn's heart rate , stopping the procedureif this falls under 100ppm, initiating at that moment the necessary reanimation procedures.
~60 second after the delivery of the new born 10 IU of oxytocin will be administered intramuscularly."
16664223|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
16664224|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
16664225|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
16664226|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
16664227|NCT02187848|Experimental|SAR408701 Main Dose Escalation Cohort|Dose escalation administered intravenously, once every two weeks
16664228|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC)|Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
16664229|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
16664230|NCT02187848|Experimental|SAR408701 Expansion Cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
16664231|NCT02187848|Experimental|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
16664232|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
16664233|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
16664234|NCT02187848|Experimental|SAR408701 Expansion Cohort small cell lung cancer (SCLC)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
16664235|NCT02187848|Experimental|SAR408701 Dose Escalation every 3 weeks cohort|Dose escalation administered intravenously, once every three weeks
16664236|NCT02187835||schizophrenia|patients with a diagnosis of schizohrenia
16664237|NCT02187835||control|healthy control group
16664238|NCT02187822|Experimental|Dose Escalation + Dose Expansion|"Dose Escalation followed by Dose Expansion.
~Dose Escalation Phase: The maximum tolerated dose (MTD) for TPI 287 given concurrently with Fractionated Stereotactic Radiotherapy (FSRT) will be determined using the standard 3+3 study design.
~Dose Expansion Phase: Participants will be treated with TPI 287 at MTD given concurrently with FSRT to further assess toxicity and tumor response."
16664239|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
16664240|NCT02187796||Normal Cognition|HIV+ individuals with no detectable neurocognitive impairment
16664241|NCT02187796||ANI (asymptomatic neurocognitive impairment)|"HIV+ individuals where impairment involves at least two cognitive domains, and results in neuropsychological testing performance at least 1 Standard Deviation (SD) below the appropriate mean age/education norm for:
~Information processing speed
~Sensory/motor skills
~Short-term and long-term memory
~Ability to learn new skills and solve problems
~Attention, concentration, and distractibility
~Logical and abstract reasoning functions
~Ability to understand and express language
~Visual-spatial organization Visual-motor coordination
~Planning, synthesizing and organizing abilities"
16664242|NCT02187796||MCD (Mild Cognitive Disorder)|HIV+ individuals with cognitive impairment same as ANI but patient or caregivers report that cognitive deficit interferes with mental acuity, work efficiency, home making or social activity
16664243|NCT02187796||HAD (HIV-associated dementia)|"HIV+ individuals where impairment involves at least two cognitive domains and results in neuropsychological testing at least 2 SD below the appropriate mean age/education norm for:
~Information processing speed
~Short-term and long-term memory
~Ability to learn new skills and solve problems
~Attention, concentration, and distractibility
~Logical and abstract reasoning functions
~Ability to understand and express language
~Visual-spatial organization Visual-motor coordination
~Planning, synthesizing and organizing abilities Cognitive impairment significantly interferes with work, home life, social activities or ADL's."
16664286|NCT02187510|Experimental|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
16664918|NCT02183376|Experimental|BI 1356 - moderate liver impairment|
16664244|NCT02187796||Healthy Controls (HIV-)|Our P300 COGNISION apparatus has been used only in subjects over the age of 60, whereas our participants in the HAND study will all be younger than 60. So, we cannot use COGNISION normative data base for comparison. We will add 10 HIV- healthy controls to our planned 40 HIV+ subjects. These HIV- participants will be age- and gender-matched to the HIV- Asymptomatic Neurocognitive Impairment (ANI) patients, and will undergo all the same assessments
16664245|NCT02187783|Experimental|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
16664246|NCT02187757|Experimental|PreLipid|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.
16664247|NCT02187757|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
16664248|NCT02187744|Experimental|PF-05280014|
16664249|NCT02187744|Active Comparator|Herceptin®|
16664250|NCT02187718|Other|SNPGA|Sentinel Node Procedure under General Anaesthesia
16664251|NCT02187718|Other|SNPLA|Sentinel Node Procedure under Local Anaesthesia
16664252|NCT02187705||Patients with normotension at baseline|
16664253|NCT02187705||Patients with essential hypertension at baseline|
16664254|NCT02187705||Patients with isolated hypertension at baseline|
16664255|NCT02187692|No Intervention|TAU|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
16664256|NCT02187692|Experimental|MCT|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
16664257|NCT02187679|Experimental|Abobotulinum toxin A|Abobotulinum toxin A Injection
16664258|NCT02187666||Lumbar|Patients undergoing lumbar spinal surgery
16664259|NCT02187666||Cervical|Patients undergoing cervical spine surgery
16664260|NCT02187653||Lumbar|Patients undergoing lumbar surgery
16664261|NCT02187653||Cervical|Patients undergoing cervical surgery
16664262|NCT02187640|Experimental|Self-administered acupressure|A 10-day self-administered acupressure program was implemented by the participants who were adult psychiatric in-patients and randomly assigned into this treatment group. The patients would receive a 3-session training of this therapy conducted by a qualified acupressure therapist and each session lasted about an hour. They would be assessed by the trainer to ensure that they are able to identify the five acupoints and applied a constant and an appropriate pressure on each acupoint before actual implementation.
16664263|NCT02187640|Sham Comparator|Sham control group|Sham control group: Patients would receive 3-session training and be assessed by the trainer. However, they would be trained to locate five non-acupoints adjacent to the actual acupoints and with minimal pressure applied.
16664264|NCT02187627|Experimental|Part 1: Tracer Selection|Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2.
16664265|NCT02187627|Experimental|Part 2A: Test-Retest|Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
16664266|NCT02187627|Experimental|Part 2B: Dosimetry|Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry.
16664267|NCT02187614|Experimental|Diclofenac and Placebos|Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
16664268|NCT02187614|Active Comparator|Morphine and Placebos|Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
16664269|NCT02187614|Active Comparator|Paracetamol and Placebos|participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.
16664270|NCT02187601|Experimental|CLD with MPBA and BID|Chronic Liver Disease (CLD) patients of all degrees will be offered to be tested on the MPBA (multi purpose breath analyzer) and BID (BreathID) on a walk- in basis with , proving they meet inclusion/exclusion criteria.
16664271|NCT02187601|Experimental|HV with MPBA and BID|Healthy volunteers (HV) with no known liver disease will undergo the breath test with the MPBA and the BID before and after substrate ingestion.
16664272|NCT02187588|Experimental|Eschscholtzia Californica - low dose|
16664273|NCT02187588|Experimental|Eschscholtzia Californica - high dose|
16664274|NCT02187588|Active Comparator|Ibuprofen|
16664275|NCT02187588|Placebo Comparator|Placebo|
16664276|NCT02187575|Experimental|UHAC 62 XX tablet|
16664277|NCT02187575|Active Comparator|UHAC 62 XX capsule|
16664278|NCT02187562|Experimental|Meloxicam/Aspirin|Meloxicam days 1-10 / Aspirin days 5-10
16664279|NCT02187562|Active Comparator|Aspirin|Aspirin 2 days
16664280|NCT02187549|Experimental|HYMOVIS|HYADD(TM) 4 Hydrogel Intra-Articular Injection
16664281|NCT02187549|Placebo Comparator|Placebo|Saline Intra-Articular Injection
16664282|NCT02187536|Experimental|Telmisartan combined with Simvastatin|Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)
16664283|NCT02187536|Active Comparator|Simvastatin and telmisartan placebo|Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)
16664284|NCT02187523|Experimental|Telmisartan/HCTZ FDC|
16664285|NCT02187523|Active Comparator|Telmisartan and HCTZ individual tablets|
16664287|NCT02187510|Active Comparator|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
16664288|NCT02187497|Experimental|Low dose of BIBR 277|
16664289|NCT02187497|Experimental|Medium dose of BIBR 277|
16664290|NCT02187497|Experimental|High dose of BIBR 277|
16664291|NCT02187484|Experimental|Single rising doses of BIBR 277|
16664292|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
16664293|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
16664294|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
16664295|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
16664296|NCT02187445|Experimental|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
16664297|NCT02187432||ADPKD|EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).
16664298|NCT02187419|Active Comparator|5 Therapist-Delivered Hypnosis Session|Participants will complete five therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
16664299|NCT02187419|Active Comparator|3 Therapist-Delivered Hypnosis Session|Participants will complete three therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
16664300|NCT02187419|Active Comparator|5 Phone Calls; Hypnosis Recordings Only|Participants will complete five phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
16664301|NCT02187419|Active Comparator|3 Phone Calls; Hypnosis Recordings Only|Participants will complete three phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
16664302|NCT02187406|No Intervention|Control|
16664303|NCT02187406|Experimental|Traditional ankle athletic taping|Described by Purcell and Schuckman (2009)
16664304|NCT02187406|Experimental|modified ankle athletic taping|Described by Montag and Asmussen (1992)
16664305|NCT02187380||Control group|Pharmacists received no depression training, delivered usual care to patients starting a new treatment with depression.
16664306|NCT02187380||Intervention group|Pharmacists received a depression training day and provided structured medication counselling to patients starting a new treatment with antidepressants
16664307|NCT02187367|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
16664308|NCT02187367|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
16664309|NCT02187341|Experimental|5-HTP|200 mg 5-HTP capsule will be ingested 2h prior to reporting to the laboratory.
16664310|NCT02187341|Placebo Comparator|Placebo|For these visit subjects will ingest placebo (Sugar pill) capsule 2 hours before reporting to the laboratory.
16664311|NCT02187328|Experimental|Grapefruit juice|12.5 OZ Grapefruit juice: Subject will ingest grapefruit juice 12.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon prior to their evening visit
16664312|NCT02187328|Placebo Comparator|Apple juice|10.5 OZ Apple juice: Subject will ingest apple juice 10.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon 3 hours prior to their evening visit.
16664313|NCT02187315|Experimental|Melodie group|Induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
16664314|NCT02187315|Other|Routine-chemotherapy group|Induction chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
16664315|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:
~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;
~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
16664316|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
16664317|NCT02187289|Active Comparator|Standard care|Weeks 1-12, Standard Care only (Compression Sleeve, daytime wear)
16664318|NCT02187289|Experimental|Standard Care plus Night-time Compression Bandages|Weeks 1 - 12, Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered Compression Bandages.
16664319|NCT02187289|Experimental|Standard Care Plus Night-time Compression System Garment|Weeks 1 - 12, Standard care (day-time sleeve) plus night-time use of a custom-made Night-time Compression System Garment
16664320|NCT02187276||Alzheimer disease or mixed dementia|Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
16664321|NCT02187263||hereditary DCM|
16664322|NCT02187263||inflammatory DCM|
16664323|NCT02187263||LVNC|
16664324|NCT02187263||HCM|
16664325|NCT02187263||ARVC|
16664326|NCT02187263||acute myocarditis|
16664327|NCT02187250|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
16664328|NCT02187250|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
16664919|NCT02183376|Experimental|BI 1356 - severe liver impairment|
16664332|NCT02187224|Placebo Comparator|Placebo|For the three days prior to each test day every participant in this arm will receive placebo.
16664333|NCT02187211|Experimental|Minocycline Low Dose|Participants in this arm will receive a low dose (200mg/day) of Minocycline for 10 days
16664334|NCT02187211|Experimental|Minocycline High Dose|Participants in this arm will receive a high dose (400mg/day) of Minocycline for 10 days
16664335|NCT02187211|Placebo Comparator|Placebo|Participants in this arm will receive the Placebo for 10 days
16664336|NCT02187198|Experimental|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
16664337|NCT02187198|Experimental|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
16664338|NCT02187185|Active Comparator|Sonicare Elite-Flexcare|Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
16664339|NCT02187185|Active Comparator|Manual Toothbrush|Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
16664340|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
16664341|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
16664342|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
16664343|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
16664344|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
16664345|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
16664346|NCT02187146||ART population|Patients undergoing IVF/ICSI/FET treatment at the Birmingham Womens Fertility Centre 2013-2014
16664347|NCT02187133|Experimental|Treatment|Patients receive carfilzomib IV over 30 minutes twice weekly on days 1, 2, 8, 9, 15, and 16 or weekly on days 2, 9, and 16; bendamustine hydrochloride IV over 60 minutes on days 1 and 2; and rituximab IV over 30-90 minutes on day 9 (course 1 only) and day 1 (subsequent courses). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16664348|NCT02187120|Experimental|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.
~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
16664349|NCT02187120|Placebo Comparator|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).
~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
16664350|NCT02187107|Experimental|TMC114 + rtv|Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours
16664351|NCT02187094|Placebo Comparator|Placebo|One capsule of placebo administered as a single dose.
16664352|NCT02187094|Experimental|2 mg TC-6499|One capsule of 2 mg TC-6499 administered as a single dose.
16664353|NCT02187094|Experimental|5 mg TC-6499|One capsule of 5 mg TC-6499 administered as a single dose.
16664354|NCT02187094|Experimental|10 mg TC-6499|One capsule of 10 mg TC-6499 administered as a single dose.
16664355|NCT02187081|Experimental|Sorafenib+RFA|We give radiofrequency ablation plus Sorafenib for the treatment of HCC
16664356|NCT02187081|Active Comparator|RFA alone|We give Radiofrequency ablation alone for the treatment of HCC
16664357|NCT02187068|Experimental|Dexmedetomidine obese 1|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
16664396|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
16664358|NCT02187068|Experimental|Dexmedetomidine obese 2|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
16664359|NCT02187068|Experimental|Dexmedetomidine non-obese 1|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
16664360|NCT02187068|Experimental|Dexmedetomidine non obese 2|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
16664361|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
16664362|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
16664363|NCT02187055|Active Comparator|Adalimumab with methotrexate|
16664364|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
16664365|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
16664366|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
16664367|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
16664368|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
16664369|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
16664370|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
16664371|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
16664372|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
16664373|NCT02187003|Experimental|Rivipansel Treatment Arm|
16664374|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
16664375|NCT02186990|Active Comparator|propofol|
16664376|NCT02186990|Active Comparator|etomidate|
16664377|NCT02186990|Active Comparator|propofol-etomidate|
16664378|NCT02186977|Active Comparator|Intramuscular group|These subjects will receive one intramuscular injection of 1.0cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur-MSD) with syringe and needle in the deltoid region.
16664379|NCT02186977|Experimental|Intradermal group (Mantoux)|These subjects will receive one intradermal injection with mantoux technique in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur-MSD) will be injected.
16664380|NCT02186977|Experimental|Intradermal group (VAX-ID) A|These subjects will receive one intradermal injection with the newly developed intradermal injection device VAX-ID in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
16664381|NCT02186977|Experimental|Intradermal group (VAX-ID) B|These subjects will receive two intradermal injections with two newly developed intradermal injection devices VAX-ID in both forearms each 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
16664382|NCT02186964|Experimental|tension free primary closure|patients treated by tension free primary closure
16664383|NCT02186964|Experimental|karydakis|patients treated by Karydakis method
16664384|NCT02186964|Experimental|Limberg flap|patients treated by Limberg flap procedure
16664385|NCT02186951|Experimental|Amoxicillin clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
16664386|NCT02186951|Placebo Comparator|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
16664387|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
16664388|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
16664389|NCT02186925||Bladder, Kidney and Prostate Cancer Patients|
16664390|NCT02186912|Experimental|mandible|Nobel Active Nobel Procera IBO
16664391|NCT02186912|Experimental|maxilla|Nobel Active Nobel Procera IBO
16664392|NCT02186899|Active Comparator|General Anesthesia Femoral continuous|General anesthesia plus continuous femoral nerve block
16664393|NCT02186899|Active Comparator|General anesthesia Femoral bolus|General anesthesia plus single shot femoral nerve block
16664394|NCT02186899|Active Comparator|Femoral Sciatic Obturator Nerve block|Ultrasound guided femoral plus sciatic plus obturator nerve block
16664395|NCT02186886|Other|Golimumab|Golimumab: Patients with body weight less than 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter // Patients with body weight greater than or equal to 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter
16664920|NCT02183363|Experimental|BI 1356 - Tablet TFII|
16664397|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
16664398|NCT02186860|Experimental|CAR-T cells|Targeting CD19
16664399|NCT02186847|Active Comparator|Chemoradiation|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
16664400|NCT02186847|Experimental|Metformin + Chemoradiation|Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
16664401|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).
~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
16664402|NCT02186821|Experimental|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
16664403|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
16664404|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
16664405|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
16664406|NCT02186782|Active Comparator|Clomiphene citrate-Estradiol group|Women will receive clomiphene citrate and estradiol
16664407|NCT02186782|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate and placebo
16664408|NCT02186769|Active Comparator|Risperdal® Consta®|25 Mg or 50 mg
16664409|NCT02186769|Experimental|L03004|25 mg or 50 mg
16664410|NCT02186756|Experimental|EMG-Biofeedback and Usual Care|"Patients in the intervention group started EMG-biofeedback training within three days after inclusion. In total 14 sessions of EMG-biofeedback training were applied. They started with three sessions of therapy in week 1-3 and had one session per week in week 4-8.
~Patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 minutes per day. Additionally, they should try to apply the techniques in stressful situations, for example appointments at the dentist's."
16664411|NCT02186756|No Intervention|Usual care|The patients in the control group had only two encounters with the therapist in the eight week interval. At these encounters pain was assessed by a visual analogue scale and their trapezius muscle activity was measured during 5 minutes analogously to the intervention group. However, afterwards they did not continue with muscle straining and relaxation.
16664412|NCT02186743|Experimental|Intervention Diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
16664413|NCT02186743|Active Comparator|Active control diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
16664414|NCT02186730|Experimental|Stressbsuters|"Computerised Cognitive Behaviour package consisting of eight 30-45 minute sessions of CBT designed for 12-18 year olds. Each Stressbusters session is an interactive presentation featuring narration synchronised with videos, animations, graphics and printouts.
~The programme has a narrator guiding individuals through each of the eight sessions in a linear progression. Each session builds on the knowledge gained in previous sessions and on tasks carried out at home. Sessions contain flexible add-ons such as written fact sheets (for example about bullying, sleep problems) which can be printed out and taken away together with home practice related handouts from the programme (for example mood diary sheets). Session topics include getting activated, relapse prevention, challenging negative thoughts and problem solving"
16664415|NCT02186730|Active Comparator|Websites|Any individuals randomised to arm 2 of the trial will spend the equivalent time accessing currently available self help websites that provide information about low mood/depression. These four websites will be the same as those used in our initial feasibility study of which, based on our preliminary data, there is evidence for their usefulness.
16664416|NCT02186717|Experimental|Chewing gum|Chewing gum
16664417|NCT02186717|No Intervention|No Chewing Gum|No Chewing Gum
16664418|NCT02186704||ICD with DX system|Implantable cardioverter-defibrillator recipients with DX system
16664419|NCT02186704||Dual chamber ICD|Dual chamber implantable-cardioverter-defibrillator recipients (retrospective cohort from IMPACT study)
16664420|NCT02186704||Single chamber ICD|Single chamber implantable cardioverter-defibrillator recipients (retrospective cohort from Cornell registry)
16664421|NCT02186691|Experimental|RV and LV ejection fraction assesment|assesment RV and LV ejection fraction after PVR measured by MRI
16664422|NCT02186678|Experimental|assesment by 68Ga-DOTATATE PET-CT|
16664423|NCT02186665|Experimental|calcitriol ointment|calcitriol 3 mcg/g ointment
16664424|NCT02186665|Placebo Comparator|placebo|placebo comparator
16664425|NCT02186652|Other|Pantoprazole|
16664426|NCT02186639||COPD|40 COPD patients (20 non-frequent and 20 frequent-exacerbators). No intervention.
16664427|NCT02186639||Controls|"Subjects with no apparent lung disease and normal lung function testing. Matched for age, gender and smoking history (pack years).
~No intervention."
16664428|NCT02186626|Experimental|WN/DEN4Δ30 Vaccine|Participants will receive one dose of the WN/DEN4Δ30 vaccine at study entry and one dose at Day 180.
16664429|NCT02186626|Placebo Comparator|Placebo|Participants will receive one dose of the placebo at study entry and one dose at Day 180.
16664430|NCT02186613|Experimental|Experimental|These mothers and their babies will receive Primary Care standard care (office visits at 1, 2, 4 and 6 months) plus the telephone support
16664431|NCT02186613|No Intervention|No intervention|Standard care (office visits at 1, 2, 4 and 6 months)
16664432|NCT02186600|Active Comparator|Control|Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have ~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
16664433|NCT02186600|Experimental|Risedronate|"Subjects in the risedronate group will take 35 mg of the bisphosphonate risedronate weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes."
16664434|NCT02186600|Experimental|Exercise|Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.
16664435|NCT02186587|Other|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
16664436|NCT02186574|Active Comparator|Pre-emptive tenofovir|Tenofovir disoproxil
16664437|NCT02186574|Placebo Comparator|Placebo|Placebo
16664438|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
16664439|NCT02186548|Active Comparator|Closed surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo closed surgical exposure, which is an intervention to correct the position of PDC:s.
16664440|NCT02186548|Active Comparator|Open surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo open surgical exposure, which is an intervention to correct the position of PDC:s.
16664441|NCT02186535|Other|Daily dosing|Daily oral capsule of Vitamin D in 4000 IU/day with daily oral capsules of 1000mg of calcium
16664442|NCT02186535|Other|weekly dosing|Oral capsule Vitamin D 50,000 IU/week with a oral capsule of 1000mg of calcium, daily
16664443|NCT02186522||Critical Care Patients|Patients staying in the ICU for at least 48 hours, requiring external support of one or more organs (invasive ventilation, inotropes/vasopressors or renal replacement therapy) and who are not expected to die within 48 hours of study entry.
16664444|NCT02186509|Experimental|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
16664445|NCT02186496|Experimental|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
16664446|NCT02186496|Experimental|CKD-330|CKD-330 8/5mg, PO, 1days or 22days
16664447|NCT02186483|Experimental|Metformin|Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration
16664448|NCT02186483|Experimental|Rosuvastatin|Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin
16664449|NCT02186483|Experimental|Co-administration|Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin
16664450|NCT02186470|Experimental|Treatment (image-guided intensity-modulated APBI)|Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
16664451|NCT02186457|Experimental|Polymyxin B in Normal Saline|Polymyxin B (500,000 U) in 1 liter of 0.9% Normal Saline
16664452|NCT02186457|Placebo Comparator|Placebo: Normal Saline|0.9 % Normal Saline
16664453|NCT02186444||PHI Navigator|Personalized Health Information Navigator (PHIN).
16664454|NCT02186444||NCI Information Booklets (IB)|National Cancer Institute (NCI) Information Booklets (IB).
16664455|NCT02186431|Experimental|history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events
16664456|NCT02186431|Active Comparator|without a history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers without a history of corneal infiltrative events.
16664457|NCT02186418|Experimental|ARU-1801|Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
16664458|NCT02186405|Experimental|LEVOTHYROXINE|administration of levothyroxine
16664459|NCT02186392|No Intervention|Control department|The control department where the conventional light is installed.
16664460|NCT02186392|Experimental|Circadian Light luminaries|The department where the special circadian light is installed. The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
16664461|NCT02186379|Experimental|RePace Intervention Group|"Re-Pace intervention-five weekly intervention sessions lasting about 1 hour each.
~Lab Test Meal-2 test meals 6-8 weeks apart."
16664462|NCT02186379|Active Comparator|Usual Care Control Group|One 25 minute education session (week 6) 2 lab test meals 6-8 weeks apart (baseline and week 6)
16664463|NCT02186366|Experimental|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
16664464|NCT02186366|Active Comparator|Buspirone|Buspirone by mouth 5mg three times per day for 6week
16664465|NCT02186353|Experimental|Intact/minimally processed whole grains|Partial feeding study
16664466|NCT02186353|Experimental|Highly processed whole grains|Partial feeding study
16664467|NCT02186353|Active Comparator|Refined grains|Partial feeding study
16664468|NCT02186340|Experimental|Inspiratory muscle training|
16664469|NCT02186327|No Intervention|Standard care|The control arm will continue to receive standard care as they did prior to enrollment.
16664470|NCT02186327|Experimental|Integrative health coaching|Subjects in this arm will receive 6 sessions of integrative health coaching over a 3 month period, in addition to standard care.
16664471|NCT02186314|Active Comparator|Apical stimulation|Pacemaker Biotronik: apical stimulation
16664472|NCT02186314|Active Comparator|Bifocal stimulation|Pacemaker Biotronik: bifocal stimulation
16664473|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
16664474|NCT02186301|Experimental|Rociletinib Mono-Therapy|
16664475|NCT02186288||Adult ICU patients|
16664476|NCT02186275|Experimental|Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day|"3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UIday as maintenance therapy for 48 weeks.
~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
16664477|NCT02186275|Active Comparator|Vitamin D3 800 UI/day then 800 UI/day|800 UI/day as induction therapy for 4 weeks, then 800 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).
16664478|NCT02186262||Primary gliomas, Recurrent gliomas|
16664479|NCT02186236||Lung and Colorectal cancer patients|Eligible people who consent to participation will provide urine (both in lung cancer and colorectal cancer) and blood (in lung cancer only) samples at pre-specified times.
16664480|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
16664481|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
16664482|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
16664483|NCT02186197||Shock and/or Respiratory Failure|
16664484|NCT02186184|Experimental|Orthokeratology in the first year|The participants would wear orthokeratology in the first year and then switch to spectacle in the second year
16664485|NCT02186184|Active Comparator|Spectacle in the first year|The participants would wear spectacle in the first year and then changed to orthokeratology in the second year
16664486|NCT02186171|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
16664487|NCT02186171|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
16664488|NCT02186158|Experimental|Vitamin C|Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime.
16664489|NCT02186158|Placebo Comparator|Placebo|Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime.
16664490|NCT02186145|Experimental|Association of metronidazole; nystatin and dexamethasone|Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
16664491|NCT02186145|Active Comparator|Flagyl|Vaginal cream of metronidazole 500 mg, nystatin 100.000 UI - once a day. Period: 10 days
16664492|NCT02186132|Experimental|Atropine 0.6 mg|Atropine 0.6 mg intravenous
16664493|NCT02186132|Active Comparator|Atropine 1.2 mg intravenous|Atropine 1.2 mg intravenous
16664494|NCT02186119|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, and 20, followed by a sham procedure at weeks 12, 16, and 24.
16664495|NCT02186119|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
16664496|NCT02186119|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
16664497|NCT02186119|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
16664498|NCT02186106|Experimental|Loading dose substitution|Substituted with a highdose of cholecalciferol at study start
16664499|NCT02186106|No Intervention|Historic controls|Control subjects from journal archive
16664500|NCT02186093||Korea|patients in South of Korea
16664501|NCT02186093||United Kingdom|patients in England
16664502|NCT02186093||Spain|patients in Spain
16664503|NCT02186093||United State of America|patients in USA
16664504|NCT02186080|Experimental|Gemigliptin|Gemigliptin 50mg qd added to subjects current diabetes treatment
16664505|NCT02186080|Placebo Comparator|Placebo|Placebo (identical in appearance to gemigliptin)
16664506|NCT02186067|Experimental|Referral System|"Referral System:
~Primary Level Secondary Level Tertiary Level"
16664507|NCT02186067|No Intervention|Control|Usual/routine care will be provided to the patients
16664508|NCT02186054|Other|Imaging- MRI examinations|Liver MRI imaging will be performed on 50 patients.
16664509|NCT02186041||De-Novo patients|Patients tested and de novo implanted with Interstim®. These patients will be followed-up for 5 years after the implant visit.
16664510|NCT02186041||Device replacement|Patients implanted with Interstim® for a device replacement. These patients will be followed-up for 5 years after the implant visit.
16664511|NCT02186041||Not-implanted patients|Patients who are tested and are not implanted with the Interstim® system. The data of the follow up of the test will be captured up to one year after the end-test visit
16664512|NCT02186028|Experimental|Vitamin D 400 IU|"Vitamin D-400IU/ml- 1ml daily
~Neonates will be administered Vitamin D 400 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
16664558|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
16664513|NCT02186028|Active Comparator|Vitamin D 200IU|"Vitamin D 400IU/ml : 0.5ml daily
~Neonates will be administered Vitamin D 200 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
16664514|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
16664515|NCT02186015|No Intervention|Vitamin D sufficient|All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.
16664516|NCT02186002|Experimental|Group 1|A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
16664517|NCT02186002|Experimental|Group 2|A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
16664518|NCT02186002|Experimental|Group 3|A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
16664519|NCT02186002|Experimental|Group 4|A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
16664520|NCT02186002|Experimental|Group 5|A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
16664521|NCT02186002|Experimental|Group 6|A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
16664522|NCT02185989|Active Comparator|Electrical muscle stimulation and bicycling|Patients will undergo early electrical stimulation of the quadriceps and early leg bicycling in addition to routine care (which comprises early standard mobilization)
16664523|NCT02185989|No Intervention|Standard early passive/active rehabilitation|In this control group, patients will undergo routine care that comprises standard early passive/active rehabilitation delivered by physiotherapist with the assistance of ICU nurses
16664524|NCT02185976|Active Comparator|cartoon|paediatric patients undergoing general anesthesia. This group will choose a cartoon movie to watch throughout the preparation until the induction of anesthesia
16664525|NCT02185976|No Intervention|routine|paediatric patients undergoing general anesthesia
16664526|NCT02185963|Experimental|Rosuvastatin|Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors
16664527|NCT02185950|Experimental|Ultrasound group|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm, and the application parameters with a matched control side of the patient, in a region with contralateral uninjured skin.
16664528|NCT02185950|Experimental|Group paraffin|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.
16664529|NCT02185950|Experimental|Ultrasound group + endermotherapy|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm. The application of endermotherapy will be held shortly after the therapeutic ultrasound in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
16664559|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
16664560|NCT02185794|Placebo Comparator|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
16664561|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
16664627|NCT02185417|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study
16664530|NCT02185950|Experimental|Group paraffin + endermotherapy|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.The application of endermotherapy will be held shortly after the paraffin therapy in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
16664531|NCT02185937|No Intervention|water|imatinib intake with water
16664532|NCT02185937|Active Comparator|cola|imatinib intake with cola
16664533|NCT02185924|Experimental|CONTINUOUS FEMORAL BLOCK AND PARECOXIB|Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib
16664534|NCT02185924|Placebo Comparator|CONTINUOUS FEMORAL BLOCK AND PLACEBO|Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%
16664535|NCT02185911||Cohort 1|Patients with CKD
16664536|NCT02185898|Active Comparator|Leading U.S. tobacco-burning non-menthol cigarette|Leading U.S. non-menthol cigarette
16664537|NCT02185898|Active Comparator|Leading U.S. tobacco-burning menthol cigarette|Leading U.S. menthol cigarette
16664538|NCT02185898|Experimental|Electronic cigarette #1|VUSE® (menthol flavor, 29 mg nicotine)
16664539|NCT02185898|Experimental|Electronic cigarette #2|VUSE® (original flavor, 29 mg nicotine)
16664540|NCT02185898|Experimental|Electronic cigarette #3|VUSE® (original flavor, 14 mg nicotine)
16664541|NCT02185898|Experimental|U.S. Market-sample electronic cigarettes (two brands)|blu™ (any variety) and NJOY® (any variety)
16664542|NCT02185885|Experimental|Increased bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted according to department guidelines with the modification that MAP is kept between 70 and 80 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
16664543|NCT02185885|No Intervention|Regular bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted in accordance with departmental guidelines, where MAP is sought to be ≥ 45 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
16664544|NCT02185872|Active Comparator|Aerobic and Resistance Training|Participants completed 24 exercise sessions based on current guidelines. Aerobic exercise (50 min) was performed on machines every session and resistance training (20 min) was performed on machines two sessions per week. Aerobic intensity was prescribed at 40-50% of heart rate reserve (HRR) Weeks 1-4 and 50-60% HRR Weeks 5-8. Resistance training was supervised by an ACE certified personal trainer. One-repetition maximums (1-RM) were assessed Week 1 (i.e., seated bicep curl, military press, seated lat pulldown, seated leg extension, triceps pulldown, bench press, reverse leg curl, seated leg press). For Weeks 2-3 participants completed, 3 sets of 15 reps at 50% 1-RM; Weeks 4-5, 3 sets of 12 reps at 60% 1-RM; Weeks 6-7, 3 sets of 10 reps at 70% 1-RM; Week 8, 3 sets of 8 reps at 75% 1-RM. Three sets of 15 unweighted crunches were completed each day. One minute of rest was taken between each set and each exercise.
16664545|NCT02185872|Experimental|High-intensity functional training|Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
16664546|NCT02185859|Experimental|Perioperative lidocaine infusion|
16664547|NCT02185859|Experimental|Perioperative magnesium infusion|
16664548|NCT02185859|Active Comparator|Noraml saline infusion|
16664549|NCT02185846|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
16664550|NCT02185846|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.Ve Tic. A. Ş., Turkey, one tablet, once
16664551|NCT02185833|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
16664552|NCT02185833|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
16664553|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:
~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).
~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.
~Treatment schedule for maintenance until progression or intolerance:
~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.
~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
16664554|NCT02185807|Active Comparator|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians, and receive face- to face discussion with their physicians as well.
16664555|NCT02185807|Placebo Comparator|control group|The control patients receive verbal information and discussion from their physicians.
16664556|NCT02185794|Placebo Comparator|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
16664557|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
16664921|NCT02183363|Experimental|BI 1356 - Tablet iFF|
16664562|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
16664563|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
16664564|NCT02185794|Placebo Comparator|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
16664565|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
16664566|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
16664567|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
16664568|NCT02185794|Experimental|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
16664569|NCT02185794|Experimental|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
16664570|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
16664571|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
16664572|NCT02185781|Experimental|Autologous NK Cells infusions|
16664573|NCT02185768|Experimental|DC-BEADS + Idarubicin|Chemoembolization with DC BEAD loaded with idarubicin
16664574|NCT02185755|Active Comparator|Internet-Based Glucose Monitoring System|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
16664575|NCT02185755|Other|Normal Medication Positive Control|The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
16664576|NCT02185742|Experimental|Strength Based Case Management|Strength Based Case Management
16664577|NCT02185742|No Intervention|Contemporary, HIV+ Jail Detainees|No intervention
16664578|NCT02185729|Active Comparator|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
16664579|NCT02185716|Active Comparator|local infiltration|Group L (n=25) will be given total 30 ml 0.25 % levobupivacaine infiltration around trocar-site with injector in sterilized conditions without administering TAP block at the end of the operation
16664580|NCT02185716|No Intervention|Control|Only routine general anesthesia will be applied
16664581|NCT02185716|Experimental|TAP|Group T (n=25) will be given bilateral total 30 ml 0.25 % levobupivacaine administering TAP block under the guidance of ultrasound at the preoperative period.
16664582|NCT02185703|Experimental|Chordate System S020 in treatment mode|
16664583|NCT02185703|Sham Comparator|Chordate System S020 in placebo mode|
16664584|NCT02185690|Other|Binimetinib efficacy/safety|"This is a Phase I/Ib, open-label, dose-escalation, multi-center, non-randomized study designed to evaluate the safety and tolerability of oral Binimetinib in combination with carboplatin and pemetrexed.
~Phase I part A standard 3+3 dose-escalation will be used to determine the maximum administered dose (MAD) and the RP2D for the combination in subjects with advanced non-squamous lung carcinoma.
~Phase Ib part Once RP2D has been identified, an expansion cohort will be accrued; these patients will be stratified by KRAS genotype.
~The RP2D will be expanded by enrolling additional patients, stratified by KRAS genotype, to a total of 30 patients eligible for the safety set (including those treated at the same dose combination in the dose-escalation phase of the study who are eligible for the safety set) to be evaluated for safety, tolerability, pharmacokinetics and biologic activity of MEK162."
16664585|NCT02185677||MSA-P|
16664586|NCT02185677||MSA-C|
16664587|NCT02185664|Active Comparator|Landmark technique|The landmark technique is the standard technique used for internal jugular vein cannulation.
16664588|NCT02185664|Experimental|Static Ultrasound technique|Static ultrasound technique was used to assist internal jugular vein cannulation.
16664589|NCT02185651|Active Comparator|Zavesca® 100 mg|"3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.
~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
16664590|NCT02185651|Active Comparator|Zavesca® 300 mg|"3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.
~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
16664623|NCT02185456|Experimental|B2 BV Remission to conversion|A subgroup of B1 patients who convert to consistently poor qPCR scores during the study (conversion) will be randomized into Arm B2 and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days. These patients will continue monthly visits and daily self swabs. B2 patients who recur with symptomatic BV will be dropped from the study and given other options for therapy.
16664624|NCT02185443|Experimental|SBRT|
16664591|NCT02185638|Experimental|A20-50|"A20-50 (2 capsules). Each capsule contains:
~Yerba Mate (Ilex paraguariensis), Guarana seed (Paullinia cupana), Magnesium Oxide , Caffeine , Damiana (Turnera microphylla), Green tea (Camellia sinensis), Ginger (Zingiber Officinale), Kola nut (Cola acuminate or nitida), Pyridoxine Hydrochloride, Tibetan Ginseng root (Rhodiola crenulata), Schisandra (Schisandra Chinensis), Jujube (Ziziphus Jujuba) , Cocoa nut (Theobroma cacao), Chinese Skullcap (Scutellaria Baicalensis), Black tea leaf (Thea sinensis), Rice flour (to fill)
~Dose = 2 capsules have a total of 200 mg of caffeine"
16664592|NCT02185638|Active Comparator|YGD|"YGD blend (2 capsules). Each capsule contains:
~Yerba Maté (leaf) , Guarana (seed) , Damiana (leaf) , Rice flour: to fill ,
~The 2 capsules of the YGD blend contain about 40 mg xanthines (caffeine and caffeine-like stimulants)."
16664593|NCT02185638|Placebo Comparator|Placebo|"Placebo (2 capsules). Each capsule contains:
~Rice Flour"
16664594|NCT02185625|Experimental|Safe Delivery smartphone application|
16664595|NCT02185625|No Intervention|Control|
16664596|NCT02185612|No Intervention|Control|Participants will be randomized to a 1 year wait list. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
16664597|NCT02185612|Experimental|Savings program|Participants will be randomized to the EARN.org online savings program for 6 months. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
16664598|NCT02185599||Colposcopy with DySIS|The prospective arm will recruit patients referred for colposcopy and will be examined using DySIS.
16664599|NCT02185599||Standard colposcopy|The retrospective arm will collect historical data from colposcopy examinations performed using a standard colposcope.
16664600|NCT02185586|Experimental|LALC|lower abdominal laparoscopic cholecystectomy
16664601|NCT02185586|Experimental|SLC|single laparoscopic cholecystectomy
16664602|NCT02185586|Placebo Comparator|UALC|upper abdominal laparoscopic cholecystectomy
16664603|NCT02185573|No Intervention|Conventional Technique|Multi-layer filling technique
16664604|NCT02185573|Active Comparator|Bulk fill technique|Bulk fill technique
16664605|NCT02185573|Experimental|SonicFill technique|SonicFill technique
16664606|NCT02185560||BAY43-9006|NEXAVAR treatment group
16664607|NCT02185547|Experimental|ICBT in combination with sertraline treatment|Internet cognitive behavioral therapy in combination with sertraline treatment
16664608|NCT02185547|Active Comparator|ICBT|Only Internet cognitive behavioral treatment, no additional depression treatment
16664609|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
16664610|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
16664611|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
16664612|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.
~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
16664613|NCT02185508||Lumbar spine surgery with IONM|Patients diagnosed with 1 or 2 level lumbar disk disease and radicular symptoms who underwent decompressive surgery, and for whom IONM records exist.
16664614|NCT02185495|Experimental|High-risk individuals|"The elder and heavy smokers, which are high-risk individuals for early lung cancer. These subjects will be examined using Observer nodule detection and  Computer-aided nodule detection."
16664615|NCT02185482|Experimental|Physician Supported Care|The intervention is an individualized, stepped-care depression treatment program provided by a depression clinical specialist primary care physician.
16664616|NCT02185482|Other|Usual care|Usual care patients will be advised to consult with their primary care physician regarding depression. Primary care physicians prescribe antidepressant medication and can refer patients to the Mental Health Services.
16664617|NCT02185469|Active Comparator|pneumatic retinopexy group|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
16664618|NCT02185469|Active Comparator|vitrectomy group|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
16664619|NCT02185456|No Intervention|Healthy|Patients with no history of bacterial vaginosis. These women will be monitored monthly and with daily self swabs.
16664620|NCT02185456|Active Comparator|G1 BV in clinical & molecular remission|Patients will receive standard of care intervention, oral metronidazole 500 mg twice a day for 7 days. They will then be monitored to confirm that initial BV treatment was effective by Nugent and Amsel, and by the qPCR test (LbRC). These will be monitored with monthly visits and daily self swabs. Those who recur with symptomatic BV may enroll in the B2 arm for more aggressive treatment.
16664621|NCT02185456|Experimental|G2. Molecular conversion subarm|Half of G1 patients who convert to poor qPCR test results while remaining asymptomatic will be randomized into this G2 arm and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days, with continued monthly visits and daily swabs.
16664622|NCT02185456|Active Comparator|B1 Initially poor qPCR responders|The B1 arm are patients who enter remission after standard of care treatment, oral metronidazole 500 mg twice a day for 7 days, but who have poor initial qPCR scores. Half of such patients will be randomized into B1, half into B2. B1 patients will be monitored with monthly visits and via daily swabs, but will receive no further treatment while BV negative. Patients who recur with BV may enroll as B2 patients for more aggressive treatment.
16664625|NCT02185430|Placebo Comparator|Control group|saline solution
16664626|NCT02185430|Active Comparator|dexmedetomidine group|dexmedetomidine
16664628|NCT02185417|Active Comparator|Chlorthalidone|Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study
16664629|NCT02185404|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
16664630|NCT02185391|Experimental|fact-finding group|Intervention: Audience Response System and motivational telephone interview
16664631|NCT02185391|No Intervention|control group|
16664632|NCT02185378|Active Comparator|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
16664633|NCT02185378|Active Comparator|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
16664634|NCT02185365||Developmental dysplasia of the hip (DDH)|Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
16664635|NCT02185352|Experimental|Inductional BEEP regimen|"Induction BEEP regimen:
~Every 3 weeks a cycle for a total of 3 cycles (around 2 months)
~Bevacizumab 15mg/kg IVF on D1
~Etoposide 70 mg/m2 IVF QD, D2-4
~Cisplatin 70 mg/m2 IVF on D2
~WBRT:
~3000cGy in 10 fractions"
16664636|NCT02185352|No Intervention|WBRT alone|"standard WBRT:
~3000cGy in 10 fractions"
16664637|NCT02185339|Experimental|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is > or < than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
16664638|NCT02185339|Active Comparator|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count >2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is > or < than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
16664639|NCT02185326|Experimental|Microflare and growth hormone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
16664640|NCT02185326|No Intervention|Microflare protocol alone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later
16664641|NCT02185313|Experimental|gaze holding|
16664642|NCT02185300|Experimental|Sequence ABCDE|Subject will be administered treatments in the sequence ABCDE where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 minutes(mins), re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 minutes, re-dispersed, and then taken by subject
16664643|NCT02185300|Experimental|Sequence BCDEA|Subject will be administered treatments in the sequence BCDEA where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
16664644|NCT02185300|Experimental|Sequence CDEAB|Subject will be administered treatments in the sequence CDEAB where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
16664645|NCT02185300|Experimental|Sequence DEABC|Subject will be administered treatments in the sequence DEABC where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
16664646|NCT02185300|Experimental|Sequence EABCD|Subject will be administered treatments in the sequence EABCD where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
16664647|NCT02185287||Lower urinary tract dysfunction, female, age: 18-40 years|
16664648|NCT02185287||Healthy female subjects, age: 18-40 years|
16664649|NCT02185261|Experimental|interferon Alfa-2b group|Acute leukemia patients who are minimal residual disease positive after hematopoietic stem cell transplantation receive interferon Alfa-2b
16664650|NCT02185248|No Intervention|Control Group|General clinical counseling in regards to child's BMI category and necessary changes to diet and activity regimen.
16664651|NCT02185248|Experimental|Wellness Plan|Received a wellness action plan. The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
16664652|NCT02185235|Experimental|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
16664653|NCT02185235|Active Comparator|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
16664654|NCT02185222|Experimental|Cholecalciferol 100 000 UI (Unité Internationale)|Oral solution in single-dose : 100 000 UI per month
16664655|NCT02185222|Placebo Comparator|Placebo|Oral solution in single-dose per month
16664656|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
16664657|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
16664658|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
16664659|NCT02185196|Active Comparator|Vitamin D3|Vitamin D3, Doses form: 20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
16664660|NCT02185196|Placebo Comparator|Miglyol-oil|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
16664661|NCT02185183|Experimental|AlequelTM|AlequelTM
16664662|NCT02185170|Experimental|Fluorescence assesment|"All patients undergo a transurethral resection.
~There are four different steps in the study:
~the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,
~the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,
~the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,
~the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner."
16664663|NCT02185157|Experimental|Experimental: Dual Task exercises|Dual-task training, includes 18 sessions model of cognitive and 12 motor dual-task exercises model, were administered in groups of four participants in a comfortable environment, without distraction effects. The 50-minute sessions included 30 minutes of motor dual-task exercises, and then, the participants were divided into pairs. The first pair performed free walks during 10 minutes at their maximal speeds, while the other received individual cognitive dual-task training for the same time, and these activities will be exchanged, so that all pairs could walk and receive cognitive training.
16664664|NCT02185157|Other|Control intervention: Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
16664665|NCT02185144|Experimental|PATH for Triples (PFT)|The Nurse Health Navigator (NHN) meets at least weekly with the experimental participants to implement the adherence component of PFT using approaches tailored to the communication and comprehension of the person that includes memory aids, education regarding side effects and other treatment aspects, engagement with participants' social networks and treatment providers, and active community outreach. PFT will be implemented for 6 months and participants will be followed for an additional 3 months to allow examination of potential decay of the intervention after it is withdrawn.
16664666|NCT02185144|Placebo Comparator|Treatment as Usual (TAU)|Participants in the the Treatment as Usual (TAU) group receive usual treatment after inpatient care.
16664667|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
16664668|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
16664669|NCT02185118|Experimental|oxygen plus isoflurane/sevoflurane|"All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.
~The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients."
16664670|NCT02185105|Experimental|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
16664671|NCT02185105|Active Comparator|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
16664672|NCT02185092|Placebo Comparator|Sugar Pill|1 pill orally daily
16664673|NCT02185092|Active Comparator|Lactobacillus GG|1 pill (2 x 10x 9 CFU) daily orally
16664674|NCT02185079|Active Comparator|Group C|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
16664675|NCT02185079|Experimental|Group M|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be subjected to training to proficiency based on the metrics developed for labor epidural catheter placement in a epidural simulator.
16664676|NCT02185066|Experimental|Group 1|"Single-dose crossover
~Reference: Atorvastatin 20mg and Metformin XR 500mg
~Test: CJ-30056 20/500mg
~Once daily Oral administration with 7days of washout period"
16664677|NCT02185066|Experimental|Group 2|"Single-dose crossover
~Test: CJ-30056 20/500mg
~Reference: Atorvastatin 20mg and Metformin XR 500mg
~Once daily Oral administration with 7days of washout period"
16664678|NCT02185053|Experimental|CPC-201|
16664679|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
16664680|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)
~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
16664681|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days
~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
16664682|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
16664683|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
16664684|NCT02185027||complications and compliance with GIHP recommendations|Description at 1 month post-intervention of an potential event
16664685|NCT02185014|Other|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
16664686|NCT02185001|Active Comparator|Surgical Treatment Group|Direct Medial Patellofemoral Ligament (MPFL) Repair
16664687|NCT02185001|Active Comparator|Conservative Treatment Group|Immobilization, stabilization bracing, and physical therapy
16664688|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
16664689|NCT02184975|Experimental|Stitches|Cold Knife Conization with stitches
16664690|NCT02184975|Active Comparator|No stitches|Cold Knife Conization without stitches
16664691|NCT02184949||Primary Sample|All percutaneous coronary intervention patients who meet the primary eligibility criteria for this study.
16664692|NCT02184949||Subsample|Patients drawn from the main sample who specifically underwent a primary percutaneous coronary intervention procedure.
16664693|NCT02184936||acute ischemic stroke|
16664694|NCT02184923|Experimental|verticality measurements|
16664695|NCT02184910||gastritis and pepsinogen|
16664696|NCT02184897|Active Comparator|AM group|Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
16664697|NCT02184897|Experimental|PM group|Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
16664698|NCT02184884||MACE group|the patients with MACE after OPCAB
16664699|NCT02184884||no MACE group|the patients without MACE after OPCAB
16664700|NCT02184871||intrahepatic cholangiocarcinoma|Patients committed to surgery and stratified according to exposure to different risk factors for ICC, basing on modified ReNaM questionnaire.
16664701|NCT02184858|Experimental|lisinopril|dose titration of investigational product (lisinopril) dependant on blood pressure, levels of renin and aldosterone and on adverse events.
16664702|NCT02184845|Experimental|NobelActive 3.0|
16664703|NCT02184832|Experimental|Low tryptophan diet|2 days of a low tryptophan diet
16664704|NCT02184832|Experimental|High tryptophan diet|2 days of a high tryptophan diet
16664705|NCT02184819|Active Comparator|levosimendan|study drug
16664706|NCT02184819|Placebo Comparator|placebo|placebo group
16664707|NCT02184806|Experimental|1- orthotopic graft|
16664708|NCT02184806|Experimental|2- heterotopic graft|
16664709|NCT02184793|Other|EMD (Inclinomax) then usual care|"EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.
~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h."
16664710|NCT02184793|Other|usual care then EMD (Inclinomax)|"Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.
~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h."
16664711|NCT02184780||GUSTO Neurocognitive Cohort|This study involves retrospective analysis of data from an existing cohort of 600 infants who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in Singapore, where subjects were followed up from in-utero up to 36 months of age and beyond. The infants have already undergone a rigorous battery of neurocognitive tests at 6, 18, 24 and 36 months of age and their detailed demographic and medical information are available.
16664712|NCT02184767|Experimental|ADASUVE®|oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
16664713|NCT02184754||MEI|
16664714|NCT02184741|Placebo Comparator|Placebo|Infusion of normal saline
16664715|NCT02184741|Experimental|GB-0998|Infusion of GB-0998 (Immunoglobulin)
16664716|NCT02184728|No Intervention|EMMA(TM)|"A small capnograph for measuring ET-CO2 - the EMMA capnometer
~1"
16664717|NCT02184715|Active Comparator|Virtual reality video game|Participants received rehabilitation treatment and additional virtual reality system (30 minutes of interactive virtual reality system play, two times per week, in eight sessions over a 4-week span) for 1 month, followed by rehabilitation treatment for 1 month
16664718|NCT02184715|Placebo Comparator|Virtual reality system|received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system (30 minutes of interactive video game play, two times per week, in eight sessions over a 4-week span) during the one month of intervention period.
16664719|NCT02184702||shoulder arthroscopy|
16664720|NCT02184689|Experimental|Fexinidazole|
16664721|NCT02184676|Other|Children born to mother/father with type 1 diabetes|
16664722|NCT02184663|Active Comparator|Standard care without APA program|
16664723|NCT02184663|Experimental|standard care with APA program|
16664724|NCT02184650||Premature infants|Premature infants with a GA < 32 weeks
16664725|NCT02184637|Experimental|Cohort 1- TQ w/DHA+PQP|Tafenoquine (TQ) will be co-administered with Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) on Day 1. DHA+PQP alone will be administered at 24 hours (h) (Day 2) and 48 h (Day 3) post first dose administration.
16664726|NCT02184637|Experimental|Cohort 2 - TQ w/AL|Tafenoquine co-administered with Artemether + Lumefantrine (AL) on Day 1. AL alone will be administered at 8h (Day 1), 24h and 36h (Day 2), 48h and 60 h (Day 3) post first dose administration.
16664727|NCT02184637|Experimental|Cohort 3 - DHA+PQP alone|Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration
16664914|NCT02183389|Experimental|Treatment B: BI 1356 and Warfarin|BI 1356 for 12 days combined with a single dose of warfarin on day 6
16664728|NCT02184637|Experimental|Cohort 4 - AL alone|Artemether + Lumefantrine will be administered on Day 1 and 8h, 24 and 36h (Day 2), 48h and 60 h(Day 3) post first dose administration
16664729|NCT02184637|Experimental|Cohort 5 - TQ alone|A single dose of Tafenoquine will be administered on Day 1
16664730|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
16664731|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
16664732|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
16664733|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
16664734|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
16664735|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
16664736|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
16664737|NCT02184598|Placebo Comparator|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
16664738|NCT02184598|Experimental|Cognitive training|Cognitive training with 6 different games each of which gets progressively more difficult as children obtain proficiency.
16664739|NCT02184585|Experimental|Cohort 1: Fasted state|Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
16664740|NCT02184585|Experimental|Cohort 2 : Fed state|Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
16664741|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
16664742|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
16664743|NCT02184559|Experimental|TAP block|
16664744|NCT02184559|Active Comparator|infiltration continues|
16664745|NCT02184533|Experimental|Treatment (sodium selenite and radiation therapy)|Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
16664746|NCT02184520|Active Comparator|TRANSITION|Stabilization System
16664747|NCT02184520|Active Comparator|REVERE|Stabilization System
16664748|NCT02184507|Experimental|Supplement pre CABG|Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
16664749|NCT02184507|Experimental|Supplement post CABG|Consumption of placebo 7 days before surgery and supplement 30 days post surgery
16664750|NCT02184507|Experimental|Supplement pre and post CABG|Consumption of the supplement 7 days before and 30 days post surgery
16664751|NCT02184507|Placebo Comparator|Placebo|Consumption of placebo 7 days before and 30 days post surgery
16664752|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
16664753|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
16664754|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
16664755|NCT02184481|Experimental|Working memory training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level adapted to the working memory capacity of the participant.
16664756|NCT02184481|Placebo Comparator|Placebo training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level in the placebo condition was easy and did not adapt to the working memory capacity of the participant.
16664757|NCT02184468|Other|Dual dispatch|Simultaneously dispatching of EMS, firefighters and/or police in OHCA
16664758|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
16664759|NCT02184442|Experimental|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
16664760|NCT02184442|Active Comparator|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
16664761|NCT02184429|Experimental|Single Ascending Dose-1|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
16664762|NCT02184429|Experimental|Single Ascending Dose-2|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
16664763|NCT02184429|Experimental|Multiple Ascending Dose-1|Daily dose of PF-06669571 in healthy volunteers
16664764|NCT02184429|Experimental|Multiple Ascending Dose-2|Daily dose of PF-06669571 in healthy volunteers
16664765|NCT02184429|Experimental|Multiple Ascending Dose-3|Daily dose of PF-06669571 in healthy volunteers
16664766|NCT02184429|Experimental|Multiple Ascending Dose-4|Daily dose of PF-06669571 in healthy volunteers
16664767|NCT02184429|Experimental|Multiple Ascending Dose-5|Daily dose of PF-06669571 in healthy volunteers
16664768|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:
~Sutent (prospective) - Inlyta
~Sutent (retrospective) - Inlyta
~Sutent - not further active treatment (supportive care)
~Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
16664769|NCT02184390|Experimental|tutorial|Parents who receive access to the tutorial immediately
16664770|NCT02184390|No Intervention|wait list control|Parents who are assessed at the same time points as the intervention arm, but do no receive access to the tutorial
16664771|NCT02184377||RLN+SLN paralysis|unilateral recurrent laryngeal and superior laryngeal nerve paralysis
16664772|NCT02184377||RLN paralysis|unilateral recurrent laryngeal nerve paralysis
16664773|NCT02184364|Experimental|Low dose of Klimadynon®|
16664774|NCT02184364|Experimental|Medium dose of Klimadynon®|
16664775|NCT02184364|Experimental|High dose of Klimadynon®|
16664776|NCT02184364|Active Comparator|Oestrofeminal®|
16664777|NCT02184364|Placebo Comparator|Placebo|
16664778|NCT02184351|Experimental|Roxanes's clotrimazole troches|
16664779|NCT02184351|Active Comparator|Mycelex® troches|
16664780|NCT02184338|Experimental|BIRB 1017 BS in single rising doses|
16664781|NCT02184338|Placebo Comparator|Placebo|
16664782|NCT02184325|Experimental|Kiddi® Pharmaton Fizz, effervescent tablets|with reduced amount of minerals
16664783|NCT02184325|Active Comparator|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
16664784|NCT02184325|Active Comparator|Comparator product|in the form of a product that is a market leader
16664785|NCT02184312|Experimental|Nevirapine XR low dose|
16664786|NCT02184312|Experimental|Nevirapine XR medium dose|
16664787|NCT02184312|Active Comparator|Nevirapine XR high dose|
16664788|NCT02184312|Active Comparator|Nevirapine (VIRAMUNE®)|commercial product
16664789|NCT02184299|Experimental|Nevirapine + Prednisone|"week 1-2: Nevirapine + Prednisone
~week 3-24: Nevirapine alone"
16664790|NCT02184299|Active Comparator|Nevirapine|week 1-24: Nevirapine
16664791|NCT02184286|Experimental|Nevirapine + Saquinavir-sgc|
16664792|NCT02184273|Experimental|Magnesium metamizol|
16664793|NCT02184273|Placebo Comparator|Placebo|
16664794|NCT02184260|Experimental|Metamizole|
16664795|NCT02184260|Placebo Comparator|Placebo|
16664796|NCT02184247|Experimental|anhydrous theophylline, 350 mg|
16664797|NCT02184247|Active Comparator|anhydrous theophylline, 300 mg|
16664798|NCT02184234|Experimental|Antistax film coated tablets|
16664799|NCT02184221|Experimental|High frequency stimulation|alpha burst, 8~12Hz, run 2 seconds, rest 8 seconds, lasts 20 minutes each time
16664800|NCT02184221|Active Comparator|Low frequency stimulation|0.5Hz, run 0.5 seconds, rest 1.5 seconds, lasts 20 minutes each time
16664801|NCT02184208||Device utlization following extubation|
16664802|NCT02184208||Pulmonary mechanics|
16664803|NCT02184195|Experimental|Olaparib|Olaparib tablets po. 300 mg twice daily
16664804|NCT02184195|Placebo Comparator|Placebo|Placebo tablets twice daily
16664805|NCT02184182|Experimental|VLS ablation/portal ligation/hepatectomy|"Step1:
~exploratory laparoscopy to exclude extrahepatic disease
~right portal vein ligation if surgically feasible
~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)
~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1
~Step 2: only if FRL/body weight > 0.5
~- laparoscopic/laparotomic right trisectionectomy"
16664806|NCT02184169|Experimental|HLHS|Patients undergoing palliative repair.
16664807|NCT02184169|Active Comparator|TGA|Surgical repair of TGA.
16664808|NCT02184156|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL intra-articular injection of Ampion
16664809|NCT02184156|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
16664810|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
16664811|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
16664812|NCT02184130|Experimental|TMS|
16664813|NCT02184117||All patients|Entire cohort undergoes paired testing
16664814|NCT02184104|Active Comparator|Aeroshot|A single 100 mg caffeine dose administered using the Aeroshot device.
16664815|NCT02184104|Active Comparator|Energy Drink|A single 100 mg caffeine dose administered as an oral solution.
16664816|NCT02184091|Experimental|Nevirapine|Single dose administration
16664817|NCT02184078|Experimental|single group|"Nevirapine:
~Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)
~Rifabutin:
~Study Days 0 to 42"
16664818|NCT02184065||Meloxicam|
16664819|NCT02184052||Meloxicam|
16664915|NCT02183389|Active Comparator|Treatment A: Warfarin|Warfarin as single dose
16664820|NCT02184026|Experimental|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
16664821|NCT02184000||1. the control group healthy adult volunteers|
16664822|NCT02184000||2. patients with chronic hepatitis B or C|
16664823|NCT02184000||3. pacients with liver cirrhosis type B or C|
16664824|NCT02183987|Experimental|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
16664825|NCT02183987|No Intervention|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
16664826|NCT02183974|Experimental|Peptest|44 children at the age between 1 to 7 years diagnosed with bilateral or unilateral OME who underwent adenoidectomy and myringotomy with insertion of ventilation tube. Effusion was collected and analysed using Peptest, which contains monoclonal antibodies targeted against pepsin. Result of the Peptest was stated as positive (2 lines), negative (1 line) and invalid (no line).
16664827|NCT02183961|Experimental|Laryngopharyngeal reflux|EER was detected using three methods: oropharyngeal pH was monitored for 24 hours using the Restech system; detection of pepsin in middle ear fluid obtained during myringotomy was done using Peptest, and detection of pepsin in adenoid specimen was done immunohistochemically using antibody P3635Rb-h.
16664828|NCT02183948|Experimental|oxytocin|nasal spray
16664829|NCT02183948|Placebo Comparator|Placebo|nasal spray
16664830|NCT02183935|No Intervention|Lifestyle counseling, metformin|Age, gender and BMI matched controls will be managed by lifestyle counseling and metformin if indicated.
16664831|NCT02183935|Active Comparator|Duodeno - jejunal liner|Duodeno-jejunal liner (Endobarrier) will be implanted for the duration of 12 months. During this time subjects will be regularly monitored for investigated parameters. In addition, subjects will be carefully monitored upon device removal for additional 12 months.
16664832|NCT02183922|Placebo Comparator|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
16664833|NCT02183922|Experimental|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
16664834|NCT02183922|Experimental|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid group received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
16664835|NCT02183909|Experimental|Study intervention|
16664836|NCT02183896|Experimental|Platelet-rich plasma (PRP)|Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.
16664837|NCT02183896|Placebo Comparator|Saline|Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.
16664838|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
16664839|NCT02183870|Experimental|Crizotinib|Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
16664840|NCT02183857|Other|Ultrasound|Patients in group Ultrasound will have their femoral arterial lines inserted under the guidance of US. The Ultrasound equipment used is a SonoSite 180 PLUS with an L25/10- to 5-MHz linear array transducer (SonoSite, Inc., Bothell, WA)
16664841|NCT02183857|Other|Landmark|No Device is used. Patients in group Landmark will have their femoral line inserted using the blinded, external landmark-guided technique. After localization of the femoral artery by identifying the pulse in the femoral triangle immediately distal to the inguinal ligament.
16664842|NCT02183844|Experimental|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
16664843|NCT02183831||Capsular tension ring non insertion group|The patients who had same cataract surgery procedure without CTR insertion
16664844|NCT02183831||Capsular tension ring insertion group|The patients who underwent capsular tension ring insertion just before IOL implantation during cataract surgery
16664845|NCT02183818||Healthy nonsmokers|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
16664846|NCT02183818||Smokers with COPD|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
16664847|NCT02183805|Experimental|Metastatic triple negative breast cancer|Abraxane,Cyclophosphamide,Carboplatin
16664848|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
16664849|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
16664850|NCT02183779|Experimental|Reynaud|patients with reynaud phenomena
16664851|NCT02183779|Experimental|Healthy|Healthy volunteers
16664852|NCT02183766|Placebo Comparator|Maltodextrin|6 mL once a day diluted in juice during 30 days.
16664853|NCT02183766|Active Comparator|Galactooligosaccharide prebiotic|6 mL once a day diluted in juice during 30 days.
16664854|NCT02183753|Active Comparator|Wood smoke|The dose of WSP to be used (500 µg/m3 for 2 hours) is based on prior studies which indicate the exposure is well tolerated, and is similar to that found in some indoor exposures in homes heated by wood burning (24-26). The route of administration (breathing air containing WSP at rest, nasally) is intended to mimic natural exposures.
16664855|NCT02183753|Placebo Comparator|clean air|Chapel Hill air which has been filtered to remove ambient air pollutants.
16664907|NCT02183428|Active Comparator|Glyburide|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
~Treatment B: 1 day of combined treatment of BI1356 and glyburide
~Treatment C: 1 day of treatment with glyburide alone"
16664908|NCT02183415|Experimental|BI 1356 BS, low dose|
16664909|NCT02183415|Experimental|BI 1356 BS, medium dose|
16664910|NCT02183415|Experimental|BI 1356 BS, high dose|
16664856|NCT02183740|Experimental|Multifaceted educational program|"A multifaceted educational program for nursing home staff consisting of:
~One seven hours educational meeting (interactive workshop) conducted in the nursing home. Theoretical input and case-base discussions considering guidelines for nurse led assessment og interventions of patients fecal incontinence.The content will be made available as educational material.
~Recruitment of one local opinion leader per nursing home unit.
~Seven educational outreach meetings (1 hour 30 minutes per meeting) during the three months intervention period."
16664857|NCT02183740|No Intervention|Control|The control arm will not receive any educational program and will continue with usual care. Data with information about ordinary care will be gathered as part of the data collection procedure in the study.
16664858|NCT02183727|Experimental|L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
16664859|NCT02183727|Active Comparator|Hamstring Autograft|Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.
16664860|NCT02183714|Experimental|Songha Night ®|
16664861|NCT02183714|Placebo Comparator|Placebo|
16664862|NCT02183701|Experimental|Telmisartan|4 weeks placebo run-in, 6-weeks fixed dose period
16664863|NCT02183701|Active Comparator|Losartan + Hydrochlorothiazide|4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
16664864|NCT02183688|Experimental|ASA + paracetamol + caffeine|
16664865|NCT02183688|Active Comparator|ASA + paracetamol|
16664866|NCT02183688|Active Comparator|ASA|
16664867|NCT02183688|Active Comparator|Paracetamol|
16664868|NCT02183688|Active Comparator|Caffeine|
16664869|NCT02183688|Placebo Comparator|Placebo|
16664870|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
16664871|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
16664872|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
16664873|NCT02183662|Experimental|BI 224436|
16664874|NCT02183662|Placebo Comparator|Placebo|
16664875|NCT02183649|Experimental|pentoxyverine citrate vs. placebo|All subjects were allocated to receive both verum and placebo in randomised order
16664876|NCT02183636|Experimental|Treatment 1 (T1)|Linagliptin/pioglitazone, FDC formulation C5
16664877|NCT02183636|Experimental|Treatment 2 (T2)|Linagliptin/pioglitazone, FDC formulation C8
16664878|NCT02183636|Active Comparator|Reference (R)|Linagliptin tablet and pioglitazone tablet (Actos®)
16664879|NCT02183623|Experimental|BI 1356 BS and Simvastatin|
16664880|NCT02183610|Experimental|[14C] BI 1356 as oral (p.o.) solution|
16664881|NCT02183610|Experimental|[14C] BI 1356 solution for i.v. infusion|
16664882|NCT02183597||Advanced breast cancer|Women with advanced breast cancer
16664883|NCT02183584|Experimental|Rifampicin and Linagliptin|
16664884|NCT02183571|Experimental|Glucophage® high dose|Part I: Treatment A + B
16664885|NCT02183571|Experimental|Glucophage® low dose|Part II: Treatment C+ D
16664886|NCT02183558|Experimental|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
16664887|NCT02183558|Experimental|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
16664888|NCT02183545|Experimental|BI 1060469|single rising doses given as tablet
16664889|NCT02183545|Placebo Comparator|Placebo|given as tablet (matching placebo of BI 1060469)
16664890|NCT02183532|Experimental|BI 1356 BS|
16664891|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
16664892|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
16664893|NCT02183506|Active Comparator|Metformin|
16664894|NCT02183506|Experimental|BI 1356 BS and metformin|Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
16664895|NCT02183493|Experimental|Fed administration of BI 1356|
16664896|NCT02183493|Active Comparator|Fasted administration of BI 1356|
16664897|NCT02183480|Experimental|Linagliptin, low dose|
16664898|NCT02183480|Experimental|Linagliptin, medium dose|
16664899|NCT02183480|Active Comparator|Linagliptin, high dose|
16664900|NCT02183467|Experimental|BI 1356, low dose|
16664901|NCT02183467|Experimental|BI 1356, high dose|
16664902|NCT02183467|Placebo Comparator|Placebo|
16664903|NCT02183467|Active Comparator|Moxifloxacin|
16664904|NCT02183441|Experimental|BI 1356 plus ritonavir|Treatment A: 3 days of ritonavir, 1 day BI 1356
16664905|NCT02183441|Active Comparator|BI 1356|Treatment B: BI 1356 alone
16664906|NCT02183428|Experimental|BI 1356|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
~Treatment B: 1 day of combined treatment of BI1356 and glyburide
~Treatment C: 1 day of treatment with glyburide alone"
16664922|NCT02183363|Active Comparator|BI 1356 - Tablet TFIIb|
16664923|NCT02183350|Experimental|BI 1356 BS - single rising dose|
16664924|NCT02183350|Placebo Comparator|Placebo|
16664925|NCT02183337|Experimental|BI 1356|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days BI 1356 until steady state followed by
~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days
~Treatment C: 7 days of treatment with Pioglitazone alone"
16664926|NCT02183337|Active Comparator|Pioglitazone|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days BI 1356 until steady state followed by
~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days
~Treatment C: 7 days of treatment with Pioglitazone alone"
16664927|NCT02183324|Experimental|Low dose of BI 1356 BS|
16664928|NCT02183324|Experimental|Medium dose of BI 1356 BS|
16664929|NCT02183324|Experimental|High dose of BI 1356 BS|
16664930|NCT02183324|Placebo Comparator|Placebo|
16664931|NCT02183311|Experimental|BI 1356 BS - single rising dose|
16664932|NCT02183311|Experimental|BI 1356 BS - multiple rising dose|
16664933|NCT02183311|Active Comparator|Placebo|
16664934|NCT02183298|Experimental|BI 1356 BS - single rising dose|
16664935|NCT02183298|Placebo Comparator|Placebo|
16664936|NCT02183285|Experimental|PHL 00747 capsules|
16664937|NCT02183285|Experimental|PHL 00747 tablets|
16664938|NCT02183285|Placebo Comparator|Placebo|
16664939|NCT02183272|Active Comparator|Intranasal Ketamine|0.2 mg / kg dose of intranasal ketamine for treatment of suicidality will be given in two separate doses on the day of admission to the hospital.
16664940|NCT02183272|Placebo Comparator|Intranasal Saline Placebo|0.2 mg / kg dose saline intranasal will be given in two separate doses on the day of hospital admission.
16664941|NCT02183259|Experimental|ESR 1150 CL capsule|
16664942|NCT02183259|Experimental|ESR 1150 CL ampoule|
16664943|NCT02183246|Experimental|Porfiromycin + Radiotherapy|
16664944|NCT02183246|Placebo Comparator|Placebo + Radiotherapy|
16664945|NCT02183233|Experimental|Eschscholtzia Californica|
16664946|NCT02183233|Placebo Comparator|Eschscholtzia Californica Placebo|
16664947|NCT02183220|Experimental|Metamizol high & Placebo|
16664948|NCT02183220|Experimental|Metamizol low & Placebo|
16664949|NCT02183220|Active Comparator|Acetylsalicylic acid & Placebo|
16664950|NCT02183220|Placebo Comparator|Placebo|
16664951|NCT02183207|Experimental|PEG insertion arm via EG Scan|Percutaneous endoscopic insertion of gastrostomy via visualization through E.G. ScanTM
16664952|NCT02183194|Experimental|Lutonix Paclitaxel Drug Coated Balloon|
16664953|NCT02183181|Experimental|Meloxicam capsule|Capsules 15 mg
16664954|NCT02183181|Active Comparator|Meloxicam tablet|Tablets 15 mg
16664955|NCT02183168|Experimental|Meloxicam suppository|
16664956|NCT02183168|Experimental|Meloxicam tablet|
16664957|NCT02183168|Active Comparator|Indomethacin suppository|
16664958|NCT02183155|Experimental|Meloxicam - low|
16664959|NCT02183155|Experimental|Meloxicam - medium|
16664960|NCT02183155|Experimental|Meloxicam - high|
16664961|NCT02183155|Placebo Comparator|Placebo|
16664962|NCT02183155|Active Comparator|Extended-release indomethacin|
16664963|NCT02183142|Active Comparator|Mobic Germany|
16664964|NCT02183142|Experimental|Mobic China|
16664965|NCT02183129|Experimental|Meloxicam|
16664966|NCT02183129|Active Comparator|Diclofenac|
16664967|NCT02183116|Experimental|Meloxicam|
16664968|NCT02183103|Active Comparator|meloxicam rapid release tablet after an overnight fast|
16664969|NCT02183103|Experimental|meloxicam rapid release tablet after high fat breakfast|
16664970|NCT02183090|Experimental|Meloxicam ampoule|
16664971|NCT02183090|Active Comparator|Meloxicam tablet|
16664972|NCT02183077|Experimental|Meloxicam gel|
16664973|NCT02183077|Active Comparator|Meloxicam tablet|
16664974|NCT02183064|Experimental|Meloxicam|
16664975|NCT02183064|Active Comparator|Usual care prescription NSAID|
16664976|NCT02183051|Experimental|Meloxicam 15 mg|
16664977|NCT02183051|Experimental|Meloxicam 7.5 mg|
16664978|NCT02183051|Experimental|Meloxicam 3.75 mg|
16664979|NCT02183051|Experimental|Meloxicam 1.875 mg|
16664980|NCT02183051|Active Comparator|Ibuprofen 400 mg|
16664981|NCT02183051|Active Comparator|Ibuprofen 200 mg|
16664982|NCT02183051|Placebo Comparator|Placebo|
16664983|NCT02183038|Experimental|Meloxicam low & Placebo|
16664984|NCT02183038|Experimental|Meloxicam high & Placebo|
16664985|NCT02183038|Active Comparator|Naproxen sodium & Placebo|
16664986|NCT02183025|Experimental|Meloxicam 7.5 mg|
16664987|NCT02183025|Experimental|Meloxicam 15 mg|
16664988|NCT02183025|Active Comparator|Mefenamic acid 1500 mg|500 mg three times daily
16664989|NCT02183012|Experimental|A: Ibuprofen extrudate, fed state|
16664990|NCT02183012|Experimental|B: Ibuprofen extrudate, fasted state|
16664991|NCT02183012|Active Comparator|C: Ibuprofen lysinate tablet, fed state|
16664992|NCT02183012|Active Comparator|D: Ibuprofen lysinate tablet, fasted state|
16664993|NCT02183012|Active Comparator|E: Ibuprofen tablet, fed state|
16664994|NCT02183012|Active Comparator|F: Ibuprofen tablet, fasted state|
16664995|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
16664996|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
16664997|NCT02182986||Subjects Enrolled Pre-Transplant|"Subjects (N=approximately 357) Enrolled Pre-Transplant
~Subjects with evidence of EBV infection prior to transplant
~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
16665055|NCT02182531|Experimental|Epinastine and Pseudoephedrine combination|
16665056|NCT02182531|Active Comparator|Epinastine|
16664998|NCT02182986||Subjects Enrolled Post-Transplant|"Subjects (N=approximately 588) Enrolled 3 Yrs Post-Transplant
~Subjects with evidence of EBV infection prior to transplant
~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
16664999|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
16665000|NCT02182960|Experimental|Ibuprofen|
16665001|NCT02182960|Active Comparator|Brufen|
16665002|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
16665003|NCT02182934|Experimental|Ginsana|
16665004|NCT02182934|Placebo Comparator|Placebo|
16665005|NCT02182908|Other|Non surgical aneurysm of abdominal aorta|PET-Scan
16665006|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
16665007|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
16665008|NCT02182882|Experimental|GINSANA|
16665009|NCT02182882|Placebo Comparator|Placebo|
16665010|NCT02182869|Experimental|Combivent® HFA|
16665011|NCT02182869|Active Comparator|Combivent® CFC|
16665012|NCT02182856|Experimental|Ipratropium bromide/salbutamol sulphate|"Randomised sequence of four different treatments
~Ipratropium bromide 500 µg/salbutamol sulphate 3 mg
~Ipratropium 500 µg
~Salbutamol sulphate 3 mg
~Salbutamol sulphate 6 mg"
16665013|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
16665014|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
16665015|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
16665016|NCT02182817||GA-Exposed Group|Exposure to general anaesthesia below 15 months of age
16665017|NCT02182817||Unexposed Group|Children not exposed to general anaesthesia or surgery from GUSTO cohort. (GUSTO: Growing Up Towards Healthy Outcomes in Singapore: a prospective longitudinal study providing normative data from the local population)
16665018|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
16665019|NCT02182791|Experimental|Nevirapine tablets|"once a day (q.d.) Day 2-15,
~twice a day (b.i.d.) Study day 16-30"
16665020|NCT02182791|Active Comparator|EE/NET tablets|Single dose on Study Day 0 and 30
16665021|NCT02182778|Experimental|Gemcitabine/Cisplatin group|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
16665022|NCT02182778|Experimental|Gemcitabine/Cisplatin /S-1 group|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
16665023|NCT02182765|Experimental|Nevirapine|"Part I: Study days 15-43
~Part II: Study day 44 to end of trial"
16665024|NCT02182765|Active Comparator|Amprenavir|"Part I: Study days 0 to 43
~Part II: Study day 44 to end of trial"
16665025|NCT02182765|Active Comparator|Abacavir|"Part I: Study days 0 to 43
~Part II Study day 44 to end of trial"
16665026|NCT02182752|Active Comparator|Ropivacaine - Tramadol|
16665027|NCT02182752|Active Comparator|Ropivacaine|
16665028|NCT02182739||Meloxicam|
16665029|NCT02182726||MOBEC|
16665030|NCT02182713|Experimental|Arm 1 - CombiventTM followed by Salbutamol|
16665031|NCT02182713|Active Comparator|Arm 2 - Salbutamol followed by CombiventTM|
16665032|NCT02182700|Experimental|Combivent® aerosol|
16665033|NCT02182687|Other|Arm A|Stereotactic Body Radiation Therapy (SBRT)
16665034|NCT02182687|Other|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
16665035|NCT02182674|Experimental|Combivent HFA|
16665036|NCT02182674|Active Comparator|Combivent (CFC)|
16665037|NCT02182661|Experimental|Ba253BINEB|
16665038|NCT02182648|Experimental|etomidate group|infusion of etomidate at 2 minutes before anesthesia induction
16665039|NCT02182648|Active Comparator|propofol group|infusion of propofol at 2 minutes before anesthesia induction
16665040|NCT02182648|Active Comparator|sevoflurane group|inhale sevoflurane for anesthesia induction and maintenance
16665041|NCT02182635|Experimental|Ba253BINEB|
16665042|NCT02182622|Experimental|Dose Level -1|Docetaxel 60mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 200mg oral daily
16665043|NCT02182622|Experimental|Dose Level 1|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice a day LDE225 200mg oral daily
16665044|NCT02182622|Experimental|Dose Level 2|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 400mg oral daily
16665045|NCT02182622|Experimental|Dose Level 3|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 800mg oral daily
16665046|NCT02182609|Experimental|99mTc-rhAnnexin V-128|
16665047|NCT02182596|Experimental|DAUNORUBICINE - ARACYTINE - MYLOTARG -|"Adaptive Bayesian method for dose-finding in phase I/II clinical trials based on treatment efficacy and toxicity (Thall, Russel, 1998), with successive patients cohorts and three combined dose levels:
~DNR 45 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.
~DNR 60 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.
~DNR 60 mg/m2 IV days 1 to 3 + AraC 200 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.
~Two consolidation courses for CR patients:
~Amsacrine: 90 mg/m2 IV Day 1 Cytarabine: 1g/m2 twice a day IV Days 1 to 4 Mylotarg: 3 mg/m2 IV Day 1."
16665048|NCT02182583|Experimental|Ba253BINEB|
16665049|NCT02182583|Active Comparator|Ba253MDI|
16665050|NCT02182570|Experimental|WAL 801 CL|
16665051|NCT02182557|Experimental|WAL 801 CL Dry Syrup + Placebo|
16665052|NCT02182557|Active Comparator|Ketotifen Fumarate Dry Syrup + Placebo|
16665053|NCT02182544|Experimental|WAL801CL dry syrup + Placebo|
16665054|NCT02182544|Active Comparator|Ketotifen fumarate dry syrup + Placebo|
16665057|NCT02182531|Active Comparator|Pseudoephedrine|
16665058|NCT02182518|Experimental|Epinastine + Pseudoephedrine|
16665059|NCT02182518|Experimental|Epinastine|
16665060|NCT02182505|Experimental|Berodual® Respimat®, low dose|
16665061|NCT02182505|Experimental|Berodual® Respimat®, high dose|
16665062|NCT02182505|Active Comparator|Berodual® MDI Aerochamber®|
16665063|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
16665064|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
16665065|NCT02182479|Experimental|Berodual® via Respimat®, high dose|
16665066|NCT02182479|Experimental|Berodual® via Respimat®, low dose|
16665067|NCT02182479|Active Comparator|Berodual® via MDI, high dose|
16665068|NCT02182479|Placebo Comparator|Placebo via Respimat®|
16665069|NCT02182479|Placebo Comparator|Placebo via MDI|
16665070|NCT02182466||Colonic endoscopy indicated|
16665071|NCT02182453|Experimental|BI 10773 - single rising dose|
16665072|NCT02182453|Placebo Comparator|Placebo|
16665073|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
16665074|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
16665075|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
16665076|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
16665077|NCT02182414|Active Comparator|BI 207127 NA (TF-I)|trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
16665078|NCT02182414|Experimental|BI 207127 NA (TF-II)|trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
16665079|NCT02182414|Experimental|BI 207127 NA delayed release|trial part 1: 800 mg BI 207127 NA TF-II, delayed release
16665080|NCT02182414|Experimental|BI 207127 NA extended release (10% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
16665081|NCT02182414|Experimental|BI 207127 NA extended release (15% PEO)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
16665082|NCT02182414|Experimental|BI 207127 NA extended release (20% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
16665083|NCT02182414|Experimental|BI 207127 (TF-II), fed|trial part 2
16665084|NCT02182414|Experimental|BI 207127 (TF-II), fasted|trial part 2
16665085|NCT02182401|Experimental|BI 207127 NA|fixed sequence
16665086|NCT02182388|Experimental|BI 207127 NA|single rising dose part
16665087|NCT02182388|Placebo Comparator|Placebo|
16665088|NCT02182388|Experimental|BI 207127 NA, fasted or fed|
16665089|NCT02182375|Experimental|BI 201335 NA|"400 mg raltegravir (bid) from day 1-14 and once on day 15;
~240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15"
16665090|NCT02182362|Experimental|BI 201335 NA in rising doses|single dose of BI 201335 NA on day 1, multiple dosing days 4-24
16665091|NCT02182362|Placebo Comparator|Placebo|
16665092|NCT02182362|Experimental|BI 201335 NA|highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
16665093|NCT02182349|Experimental|BI 201335 NA|multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of [14C]-BI 201335 NA radiolabelled drug on day 9
16665094|NCT02182336|Experimental|BI 201335 NA|
16665095|NCT02182323|Experimental|BI 201335 in single rising doses|
16665096|NCT02182323|Placebo Comparator|Placebo|
16665097|NCT02182323|Experimental|BI 201335 NA fasted or fed|"two randomized sequences:
~BI 201335 NA or placebo fasted
~BI 201335 NA or placebo after high-fat breakfast"
16665098|NCT02182310|Placebo Comparator|BI 201335 placebo|crossover part
16665099|NCT02182310|Experimental|BI 201335 low dose|crossover part
16665100|NCT02182310|Experimental|BI 201335 high dose|crossover part
16665101|NCT02182310|Active Comparator|Moxifloxacin|crossover part
16665102|NCT02182310|Experimental|BI 201335 or Placebo|tolerability part in female subjects
16665103|NCT02182297|Experimental|BI 201335 NA in single rising doses|
16665104|NCT02182297|Placebo Comparator|Placebo|
16665105|NCT02182284|Experimental|BI 201335 NA - low dose|
16665106|NCT02182284|Experimental|BI 201335 NA - high dose|
16665107|NCT02182271|Experimental|BI 201335 ZW - single rising dose|
16665108|NCT02182271|Placebo Comparator|Placebo|
16665109|NCT02182258|Placebo Comparator|Placebo|
16665110|NCT02182258|Active Comparator|BIBF 1120 intravenous|
16665111|NCT02182258|Experimental|BIBF 1120 capsule|
16665112|NCT02182245|Experimental|Combination Therapy|
16665113|NCT02182245|Experimental|Monotherapy|
16665114|NCT02182232|Experimental|BIBF 1120 with paclitaxel and carboplatin|
16665115|NCT02182232|Experimental|BIBF 1120 monotherapy|
16665116|NCT02182219|Experimental|BIBF 1120|
16665117|NCT02182206|Experimental|BIBF 1120|
16665118|NCT02182193|Experimental|BIBF 1120 capsules charge 1|
16665119|NCT02182193|Experimental|BIBF 1120 capsules charge 2|
16665120|NCT02182193|Active Comparator|BIBF 1120 drinking solution|
16665121|NCT02182180||Protocol participants|All participants enrolled on the protocol
16665122|NCT02182167|Experimental|IV NAC|"Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .
~Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours."
16665123|NCT02182167|Placebo Comparator|Placebo|Water
16665124|NCT02182154|Experimental|BIBF 1120 ES|
16665125|NCT02182141|Experimental|BIBF 1120|
16665126|NCT02182128|Experimental|BIBF 1120|
16665127|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
16665178|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
16665128|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.
~Chlorhexidine gluconate soap applied for bathing daily.
~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.
~Nasal mupirocin to applied inside nostrils twice daily."
16665129|NCT02182102|Experimental|BIBF 1120 + Pemetrexed|
16665130|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:
~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
16665131|NCT02182089||Patients with less than 10% IDH|"Study Population:
~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
16665132|NCT02182076|Active Comparator|fasted administration of BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules in fasting state
16665133|NCT02182076|Experimental|fed administration of BIBF 1120|three 50 mg BIBF 1120 soft gelatine capsule immediately after a high fat, high caloric meal
16665134|NCT02182063|Experimental|BIBF 1120 low dose|
16665135|NCT02182063|Experimental|BIBF 1120 high dose|
16665136|NCT02182050|Experimental|BIBF 1120 ES low dose|
16665137|NCT02182050|Experimental|BIBF 1120 ES high dose|
16665138|NCT02182050|Placebo Comparator|Placebo|
16665139|NCT02182037|Experimental|BIBT 1011 BS|
16665140|NCT02182037|Placebo Comparator|BIBT 1011 BS placebo|
16665141|NCT02182024|Experimental|Dabigatran high dose in healthy subjects|healthy subjects with a creatinine clearance of >80 mL/m
16665142|NCT02182024|Experimental|Dabigatran high dose in mild renal impairment|patients with a creatinine clearance of >50 up to 80 mL/min
16665143|NCT02182024|Experimental|Dabigatran high dose in moderate renal impairment|patients with a creatinine clearance of >30 up to 50 mL/min
16665144|NCT02182024|Experimental|Dabigatran high dose in severe renal impairment|patients with a creatinine clearance of up to 30 mL/min
16665145|NCT02182024|Experimental|Dabigatran low dose in haemodialysis patients|patients requiring haemodialysis
16665146|NCT02182011|Experimental|Tenecteplase|Single i.v. bolus followed by infusion, weight adjusted
16665147|NCT02182011|Active Comparator|Alteplase|Single i.v. bolus followed by infusion
16665148|NCT02182011|Active Comparator|Streptokinase|I.V. infusion
16665149|NCT02181998|Active Comparator|tenecteplase + unfractioned heparin|
16665150|NCT02181998|Experimental|tenecteplase + enoxaparin|
16665151|NCT02181985|Active Comparator|TNK-tPA + heparin|
16665152|NCT02181985|Experimental|TNK-tPA + enoxaparin|
16665153|NCT02181985|Experimental|TNK-tPA + abciximab + heparin|
16665154|NCT02181972|Experimental|Gingko biloba|
16665155|NCT02181972|Placebo Comparator|Placebo|
16665156|NCT02181959|Experimental|Pharmaton® with DMAE|
16665157|NCT02181959|Active Comparator|Pharmaton® without DMAE|
16665158|NCT02181959|Placebo Comparator|Placebo|
16665159|NCT02181946|Experimental|Fluconazole with and without Nevirapine|
16665160|NCT02181933|Experimental|Nevirapine|Mother: two doses, Infant: one dose
16665161|NCT02181933|Active Comparator|Zidovudine (ZDV) + Lamivudine (3TC)|
16665162|NCT02181920|Experimental|Metamizole - Diclofenac|metamizole followed by diclofenac
16665163|NCT02181920|Experimental|Diclofenac - Metamizole|diclofenac followed by metamizole
16665164|NCT02181920|Experimental|Metamizole - Placebo|metamizole followed by placebo
16665165|NCT02181920|Experimental|Placebo - Metamizole|placebo followed by metamizole
16665166|NCT02181907|Experimental|UH-AC 62 XX tablet|
16665167|NCT02181907|Active Comparator|UH-AC 62 XX capsule|
16665168|NCT02181894||Orally intubated infants|Subjects will be <72 hours of age and orally intubated. Following consent, four measures will be reported (i.e. body weight, nasal to tragus length, suprasternal notch to xyphoid process and shoulder to elbow length). Measures will be compared against a chest x-ray and placement of ETT at the subjects lip to identify the most accurate method to place endotracheal tubes in the newborn.
16665169|NCT02181881|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
16665170|NCT02181881|Active Comparator|Life Steps|A 3-session HIV medication adherence support program for individuals.
16665171|NCT02181881|No Intervention|Treatment as usual (TAU)|HIV positive individuals will continue to follow their current HIV treatment plan.
16665172|NCT02181855|Other|Atypical GERD syptoms treated with GERD-X|Patients treated by means of full-thickness gastroplication
16665173|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
16665174|NCT02181829|Experimental|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
16665175|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
16665176|NCT02181803|Experimental|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
16665177|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
16665299|NCT02180997|Experimental|Tamsulosin 1|Volunteers will be taken Tamsulosin and solifenacin
16665543|NCT02179411|Active Comparator|healthy volunteers|healthy volunteers
16665179|NCT02181803|Experimental|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
16665180|NCT02181803|Placebo Comparator|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
16665181|NCT02181803|Placebo Comparator|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
16665182|NCT02181803|Placebo Comparator|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
16665183|NCT02181790|Experimental|First Group|excimer laser treatment to one palm and/or one sole
16665184|NCT02181790|Experimental|Second Group|excimer laser treatment to both palms and/or soles
16665185|NCT02181777|Experimental|GRASP|GRoup trAining for Social skills in Psychosis
16665186|NCT02181777|Active Comparator|Standard care|Treatment as usual as provided by care team
16665187|NCT02181764|Experimental|KRN23|Single SC administration on day 1
16665188|NCT02181751|Experimental|Treatment Group|Children in the Treatment Group will receive treatment between 0 and 4 months from the study start date. The intervention will be a Trauma Focused Cognitive Behavioural Therapy Group.
16665189|NCT02181751|Other|Waitlist Group|Children in the wait-list group will receive treatment from 5-8 months of the studies start date. The intervention once this group receives treatment will be a Trauma Focused Cognitive Behavioural Therapy Group
16665190|NCT02181738|Experimental|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: Specified dose on specified days
~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days"
16665191|NCT02181725|Experimental|Multimodal Rehabilitation Program|Multimodal Rehabilitation Program, consisting of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM)
16665192|NCT02181725|Active Comparator|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
16665193|NCT02181712|Experimental|Mesenchymal Stem cells|Subjects who have never received Mesenchymal Stem Cells
16665194|NCT02181712|Experimental|Booster Mesenchymal Stem Cells|Subjects who have previously received Mesenchymal Stem Cells
16665195|NCT02181699|Experimental|KHK2823|single agent KHK2823 administered at selected dose levels
16665196|NCT02181686||Sentus QP group|Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.
16665197|NCT02181686||VR-T/DR-T group|Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family
16665198|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
16665199|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
16665200|NCT02181660|Experimental|Dose Escalation Cohort|ASP2215
16665201|NCT02181647|Experimental|Intervention|Safe Touches Personal Safety Training for Children
16665202|NCT02181647|Other|Comparison|Received Safe Touches after week-1 assessment completed (delayed intervention).
16665203|NCT02181634|Experimental|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
16665204|NCT02181621|Placebo Comparator|Solosite gel|Hydrogel with preservatives, used to create a moist wound environment.
16665205|NCT02181621|Active Comparator|Iodosorb|Cadexomer iodine gel
16665206|NCT02181582|Experimental|Emapunil Administration|Single Arm Study
16665208|NCT02181556|Experimental|FOLFIRI + Aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
16665209|NCT02181543|Experimental|Clonidine|Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
16665210|NCT02181543|No Intervention|No Clonidine|Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.
16665211|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
16665212|NCT02181517|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
16665213|NCT02181517|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
16665214|NCT02181517|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
16665215|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
16665216|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
16665217|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
16665218|NCT02181491|Experimental|P943 PET Scan|
16665274|NCT02181166|Experimental|kineshioterapy + isquemic compression|The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
16665300|NCT02180997|Experimental|Solifenacin 1|Volunteers will be taken Tamsulosin and solifenacin
16665219|NCT02181478|Experimental|Treatment (intra-osseous UCB with hMSC co-transplant)|"REDUCED INTENSITY CONDITIONING (RIC):
~Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.
~Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.
~GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.
~TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
16665220|NCT02181465|Experimental|Group 1|One injection of G17DT followed by up to three booster injections depending on antibody response over 16 week period
16665221|NCT02181465|Experimental|Group 2|Three injections of G17DT with option of one booster after 16 weeks
16665222|NCT02181439|Other|Right irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the right maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.
~The same procedure will be applied to the left non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
16665223|NCT02181439|Other|Left irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the left maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.
~The same procedure will be applied to the right non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
16665224|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
16665225|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
16665226|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
16665227|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
16665228|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
16665229|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
16665230|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
16665231|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
16665232|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
16665233|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
16665234|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
16665235|NCT02181361||hirudin plus aspirin|14 days after stroke onset, patients in the hirudin plus aspirin group received natural hirudin 0.75g, three times a day and aspirin 100mg, once daily.
16665236|NCT02181361||Warfarin|14 days after stroke onset, patients in warfarin group were given an initial dose of 1.25mg of warfarin,once daily. 3 days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
16665237|NCT02181348|Active Comparator|Intervention (Vitamin E supplementation)|Vitamin E 400 mg once daily for 3 months
16665238|NCT02181348|Placebo Comparator|placebo (edible oil)|
16665239|NCT02181335|Experimental|Respimat ® Budesonide low dose + Turbohaler® Placebo|
16665240|NCT02181335|Experimental|Respimat ® Budesonide high dose + Turbohaler® Placebo|
16665241|NCT02181335|Active Comparator|Turbohaler® Budesonide + Respimat Placebo®|
16665242|NCT02181322|Experimental|Meloxicam - low dose, fasted|
16665243|NCT02181322|Experimental|Meloxicam - medium dose, fasted|
16665244|NCT02181322|Experimental|Meloxicam - high dose, fasted|
16665245|NCT02181322|Experimental|Meloxicam - high dose, fed|
16665246|NCT02181309|Experimental|Meloxicam low dose, fasted|
16665247|NCT02181309|Experimental|Meloxicam medium dose, fasted|
16665248|NCT02181309|Experimental|Meloxicam high dose, fed|
16665249|NCT02181309|Active Comparator|Meloxicam high dose, fasted|
16665250|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
16665251|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
16665252|NCT02181283|Active Comparator|W+W|Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
16665253|NCT02181283|Active Comparator|W+P|Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
16665254|NCT02181283|No Intervention|Enhanced Usual Care|Enhanced usual care.
16665255|NCT02181270|Experimental|high intensity exercise|High-intensity interval exercise (HIIE): Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
16665256|NCT02181270|Experimental|Continuous moderate exercise group|Continuous moderate exercise group (CME): Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
16665257|NCT02181257|Other|Newly Diagnosed Bronchiolitis Obliterans (NEW BOS)|"Participants with NEW BOS will be randomized to Early Photopheresis Intervention (EPI) or Control (Standard of Care). EPI patients will receive 24 treatments in a 6-month period and may continue maintenance treatments.
~The Control group will receive local Standard of Care for the management of BOS. Therapy will involve changes in immunosuppressive agents."
16665258|NCT02181257|Other|Refractory Bronchiolitis Obliterans Syndrome (REFRACTORY BOS)|Participants with REFRACTORY BOS will be electronically assigned to either ECP treatment or Observation based on the participant's pre-enrollment Forced Expiratory Volume in 1 second (FEV1). Values from pulmonary function tests from the preceding 12 months will be entered into a web-based treatment allocation which will perform an automated calculation. Patients who have a statistically significant rate of decline within the preceding 6 months, and a derived protocol defined slope, will be assigned to the ECP Treatment arm. If a patient does not meet these criteria, the participant will be assigned to the Observation arm.
16665259|NCT02181244|Experimental|Egg, one a day, for breakfast|The intervention consists in feeding the subjects egg, one a day for breakfast during 5 weeks. At the end of the intervention, blood will be obtained to measure plasma lipids, glucose, insulin and inflammatory markers. All measurements will be finished 24 weeks after the intervention is finished. All data will be reported 1 year after completion of the study.
16665260|NCT02181244|Experimental|Oatmeal, one cup a day|In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
16665261|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
16665262|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
16665263|NCT02181218|Experimental|Dose Level 0 (starting dose) (8 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;
~Gemcitabine IV over 30 minutes on Day 1
~Oxaliplatin IV over 2 hours on Day 1
~Dexamethasone orally on Days 1-4
~Pegfilgrastim subcutaneously on Day 3
~Drugs may be administered in any order on Day 1.
~Each cycle is 21 days.
~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
16665264|NCT02181218|Experimental|Dose Level 1 (10 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;
~Gemcitabine IV over 30 minutes on Day 1
~Oxaliplatin IV over 2 hours on Day 1
~Dexamethasone orally on Days 1-4
~Pegfilgrastim subcutaneously on Day 3
~Drugs may be administered in any order on Day 1.
~Each cycle is 21 days.
~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
16665265|NCT02181218|Experimental|Dose Level 2 (12 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;
~Gemcitabine IV over 30 minutes on Day 1
~Oxaliplatin IV over 2 hours on Day 1
~Dexamethasone orally on Days 1-4
~Pegfilgrastim subcutaneously on Day 3
~Drugs may be administered in any order on Day 1.
~Each cycle is 21 days.
~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
16665266|NCT02181205|Experimental|placebo|sphenopalatine ganglion block performed with normal saline as the placebo
16665267|NCT02181205|Active Comparator|bupivacaine|sphenopalatine ganglion block performed with bupivacaine
16665268|NCT02181192|Experimental|delayed radiotherapy|PET/CT and Radiotherapy after achievement of PSA marginal value Additive imaging
16665269|NCT02181192|Active Comparator|instant radiotherapy|Instant Radiotherapy according to guidelines
16665270|NCT02181179|Active Comparator|Yoga|This will involve participating in at least two 60-minute Vinyasa yoga sessions each week for eight weeks (weeks 1-8). This will begin the week following a baseline laboratory appointment. These sessions will be conducted at a local Austin studio that has numerous locations in the area.
16665271|NCT02181179|No Intervention|Waitlist|If randomized to this group, participants will complete weekly assessments only and not yoga during their time in the study. Following full completion of the study (i.e., after week 10), participants will be compensated with a voucher for 2 free months of yoga.
16665272|NCT02181166|Experimental|kinesiotherapy + High voltage electrical stimulation|Same protocol group kinesiotherapy + high voltage electrial stimulation with two rectangular electrodes (3x5 cm) active silicon-carbon and an electrode rectangular dispersive (10x18cm) aluminum wrapped with a damp felt in water. The active electrodes are positioned in central myofascial trigger point of the upper trapezius muscle after application of water soluble gel. The dispersive electrode was placed in the lumbar region. The following parameters will be use: frequency of 10 Hz, twin pulses of 20μs to 100ms between pulses and the maximum voltage tolerated by voluntary until the motor threshold (visible muscle contraction) to increase every five minutes, totaling 30 minutes of stimulation. The negative polarity will be use.
16665273|NCT02181166|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: These exercises involve stretching of the cervical, anterior and posterior chain of the upper trunk and active mobilization of the cervical, shoulder movements of flexion, extension, abduction and adduction of the shoulder and upper limb. The exercises lasted 50 minutes, with 10 minutes of walking, and stretching was performed with two repetitions of 20 seconds, and active mobilization exercises of three sets of eight repetitions and final relaxation of 10 minutes were performed.
16665275|NCT02181153|Other|siblings of patients with IBD|Blood and fecal samples from 100 siblings of children affected with IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form.
16665276|NCT02181153|Other|patients without family history of IBD|Blood and fecal samples of 100 healthy children without a family history of IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form
16665277|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
16665278|NCT02181127|Active Comparator|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
16665279|NCT02181127|Placebo Comparator|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
16665280|NCT02181114|Experimental|Expert System Coaching|Patients in the intervention group will receive coaching based off the answers provided in the computer-based Expert System that is designed to track their readiness level to pursue a living donor kidney transplant.
16665281|NCT02181114|No Intervention|Control|Patients in the control group will only receive the standard of care education that is offered at the UCLA Kidney and Pancreas Transplant Center which consists of a powerpoint presentation on their Evaluation Day appointment.
16665282|NCT02181101|Experimental|AA-BA|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years
16665283|NCT02181101|Experimental|AB-BA|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years
16665284|NCT02181101|Experimental|AA-BB|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years
16665285|NCT02181101|Active Comparator|AB-BB|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years
16665286|NCT02181088|Experimental|Group 1 (ChAd63 RH5 low dose)|1 dose of ChAd63 RH5 5 x 10^9 vp intramuscularly
16665287|NCT02181088|Experimental|Group 2A (ChAd63 RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly
16665288|NCT02181088|Experimental|Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later intramuscularly
16665289|NCT02181088|Experimental|Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later intramuscularly
16665290|NCT02181075|Experimental|Part I|"All participants in Part I received:
~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour
~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
16665291|NCT02181075|Experimental|Part II|"All participants in Part II received:
~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour
~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
16665292|NCT02181062|Experimental|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.
~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.
~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.
~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
16665293|NCT02181062|No Intervention|Wait-list control|After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
16665294|NCT02181036|Experimental|family work shop|2 to 3 hours per session, one session per week, for a total of 6 weeks of family work shop
16665295|NCT02181023|Experimental|Aclidinium - Glycopyrronium|Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
16665296|NCT02181023|Experimental|Glycopyrronium - Aclidinium|Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).
16665297|NCT02181010|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in low-income, urban, minority neighborhoods. Intervention components will occur at the policy level; food wholesaler level; small food retail outlet level; neighborhood level; household level.
16665298|NCT02181010|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
16665301|NCT02180997|Experimental|Co-administration 1|Volunteers will be taken Tamsulosin and solifenacin
16665302|NCT02180997|Experimental|Tamsulosin 2|Volunteers will be taken Tamsulosin and solifenacin
16665303|NCT02180997|Experimental|Solifenacin 2|Volunteers will be taken Tamsulosin and solifenacin
16665304|NCT02180997|Experimental|Co-administration 2|Volunteers will be taken Tamsulosin and solifenacin
16665305|NCT02180984|Active Comparator|BED randomized to rTMS|"30 obese individuals currently diagnosed with BED and meeting criteria for the study will be randomized to active rTMS treatment.
~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).
~Proposed schedule of treatment:
~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. For the real treatment condition, stimulation will target the left DLPFC at 110% of the resting motor threshold. Each session of 10 Hz stimulation will apply 1000 pulses to the left hemisphere, with a duty cycle of 5s on and 55s off, for a total stimulation time of 20 min."
16665306|NCT02180984|Sham Comparator|Sham BED TMS|"30 obese individuals currently diagnosed with BED will be randomized to receive sham TMS treatment. Blinded to participants and study staff, except to the doctor applying the TMS treatment.
~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).
~Proposed schedule of treatment:
~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. Sham treatment condition, will follow the same protocol however no real TMS will be delivered."
16665307|NCT02180984|No Intervention|Control (obese non BED)|15 controls, obese but without a current or past diagnosis of BED will complete the baseline measurements only.
16665308|NCT02180984|No Intervention|Controls (normal weight)|15 controls, normal weight and without a current or past diagnosis of BED will complete baseline measures only.
16665309|NCT02180971|Experimental|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
16665310|NCT02180971|Experimental|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
16665311|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
16665312|NCT02180945||Intracranial Dural Arteriovenous Fistula|Adult patients requiring endovascular treatment of Intracranial Dural Arteriovenous Fistulae.
16665313|NCT02180932|Experimental|periodontal disease|Saliva samples
16665314|NCT02180919|No Intervention|Control period|All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
16665315|NCT02180919|Experimental|Telemonitoring|telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
16665316|NCT02180906||Patients with NSTI|Definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and are spreading along tissue structures.
16665317|NCT02180893|Experimental|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
16665318|NCT02180893|Placebo Comparator|No block|Patients who did not receive PVB
16665319|NCT02180880|Experimental|Pregabalin and Oxcarbazpepine|Pregabalin and Oxcarbazepine
16665320|NCT02180867|Experimental|Regimen A (pazopanib, chemoradiation)|See Regimen A Detailed Description.
16665321|NCT02180867|Experimental|Regimen B (chemoradiation)|See Regimen B Detailed Description.
16665322|NCT02180867|Experimental|Regimen C (pazopanib, radiation therapy)|"INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.
~SURGERY: Patients undergo surgery on week 10.
~CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13."
16665323|NCT02180867|Experimental|Regimen D (radiation therapy)|"INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.
~SURGERY: Patients undergo surgery on week 10.
~CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13."
16665324|NCT02180854|Experimental|Intervention (8 hours)|EWS every 8 hours
16665325|NCT02180854|Active Comparator|Control (12 hours)|EWS every 12 hours
16665326|NCT02180841|Experimental|Soy 25g|Soy protein powder (25g/day)
16665327|NCT02180841|Experimental|Soy 50g|Soy protein powder 50 g/day
16665328|NCT02180841|Placebo Comparator|Control|Control powder
16665329|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
16665330|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
16665331|NCT02180815||ReVENT implanted group|
16665332|NCT02180802|Experimental|motivational intervieing group|The behavioral intervention targets were improved eating and physical activity behavior in order to reduce obesity levels. Each adolescent was encouraged to eat a variety of foods from each of the four major food groups and low-fat alternatives . Moreover, each adolescent was encouraged to achieve at least 60 minutes of moderate-to-vigorous intensity physical activity daily as recommended by the World Health Organization
16665333|NCT02180802|Experimental|motivational interviewi group with parental involvement|an additional single session with parents or guardians over 60 minutes in the clinic
16665334|NCT02180802|Active Comparator|Control|The patients received routine care
16665335|NCT02180789|Experimental|Harnalidge® OCAS®|
16665336|NCT02180776|Active Comparator|Group A|Patients assigned to group A wore the Summit 456 TLSO (intervention) for four weeks in phase 1 of the study, followed by four weeks of observation (control) in phase 2.
16665337|NCT02180776|Placebo Comparator|Group B|Patients assigned to group B started four weeks of observation (control) in phase 1, followed by four weeks of summit 456 TLSO (intervention) in phase 2 of the study.
16665338|NCT02180763|Experimental|Gammanorm® 165 mg/mL|
16665339|NCT02180750|Experimental|Intervention: Memory Work Therapy|Residential week intervention consisting of memory box, memory book, tree of life, Active Citizen book, all activities facilitated.
16665340|NCT02180750|Active Comparator|Control: standard care|Usual care services.
16665341|NCT02180737|Experimental|Dexmeditomedine|Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
16665342|NCT02180724|Experimental|Previously Treated/Naive|Previously treated, N=92 Treatment Naïve, N=14
16665343|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1
16665344|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects
16665345|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
16665346|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
16665347|NCT02180711|Experimental|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
16665348|NCT02180698|Experimental|Treatment (TLR4 agonist GLA-SE, radiation therapy)|Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
16665349|NCT02180685|Other|Anchor fixation|Medial fixation of the reconstruction at the medial femural condyle with suture anchors.
16665350|NCT02180685|Other|Screw fixation|Medial fixation of the reconstruction at the medial femural condyle with a screw.
16665351|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
16665352|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
16665353|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
16665354|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
16665355|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
16665356|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
16665357|NCT02180633||Fellow Eyes|Patients that suffer from unilateral idiopathic macular hole, and whose fellow eyes don't show any sign of retinal pathology.
16665358|NCT02180633||Controls|Healthy subjects age-matched to the other group, with no visible retinal pathologies.
16665359|NCT02180620|Experimental|No exercise|participants will remain sedentary during testing
16665360|NCT02180620|Experimental|Meal then exercise|45 min of resistance training will be performed after a standard meal
16665361|NCT02180620|Experimental|exercise then meal|45 min of resistance training will be performed prior to a standard meal
16665362|NCT02180607||Healthy Controls|Response to social feedback, monetary incentive delay, and go/no-go tasks
16665363|NCT02180607||MDD patients|Response to social feedback, monetary incentive delay, and go/no-go tasks
16665364|NCT02180581|Experimental|Probiotic (2 * 10^9 cfu/d)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12) and Lactobacillus Rhamnosus GG (LGG) in a dosage of 10^9 cfu/day of each strain. The probiotics are provided as powder in a sachet, and can be added to food or drink
16665365|NCT02180581|Placebo Comparator|Placebo|provided as powder in a sachet, and can be added to food or drink
16665366|NCT02180568|Experimental|Lipiodol|Lipiodol-guided lung localization technique
16665367|NCT02180568|Active Comparator|Hookwire|Hookwire-guided lung localization technique
16665368|NCT02180555||ICU patients|
16665369|NCT02180542||Ischemic stroke patients|Patients admitted with ischemic stroke from march 2012 to april 2014
16665370|NCT02180529|Experimental|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
16665371|NCT02180529|Placebo Comparator|Placebo|Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
16665372|NCT02180516||Meloxicam|
16665373|NCT02180516||Other NSAIDs|
16665374|NCT02180503|Experimental|BI 1356 BS - low dose|
16665375|NCT02180503|Experimental|BI 1356 BS - high dose|
16665376|NCT02180490|Experimental|UHAC 62 XX tablet|
16665377|NCT02180490|Active Comparator|UHAC 62 XX capsule|
16665378|NCT02180477|Experimental|UHAC 62 XX TF1 tablet|
16665379|NCT02180477|Experimental|UHAC 62 XX TF2 tablet|
16665380|NCT02180477|Active Comparator|UHAC 62 XX capsule|
16665381|NCT02180464|Experimental|LAS41004|Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily
16665382|NCT02180464|Active Comparator|control|Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily
16665383|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
16665384|NCT02180425||Healthy Group|The subjects in this group do not have a history of acne.
16665385|NCT02180425||Acne Group, Topical Retinoid|These subjects have been prescribed a topical retinoid for their acne. They will participate in the study for a period of 1 month.
16665386|NCT02180425||Acne Group, Isotretinoin|These subjects have been prescribed isotretinoin for their acne. They will participate in the study for a period of 5-6 months.
16665387|NCT02180412|Experimental|Panhematin|Panhematin plus glucose
16665388|NCT02180412|Placebo Comparator|Placebo|Placebo (saline) plus glucose
16665389|NCT02180386|Experimental|Experimental group|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
16665390|NCT02180373||vein graft bypass|patients who have had peripheral bypass
16665391|NCT02180373||SFA stent|Patients who have had SFA stenting
16665392|NCT02180360|Experimental|Capoeira training group|"The Capoeira training was performed during eight weeks, twice a week with duration of 60min each session, divided in 1) initial part: 10min warm-up with activities of low intensity or the ginga used in Capoeira; 2) main part: from the Basic Programmed Lesson (40min) and ; 3) final part: Capoeira presentation of 10min. In this last moment, the participants remained in a circle and, in pairs, executed the movements practiced earlier in the sessions. In order to perform the Basic Programmed Lesson, the activities were divided in four stages, composed by ginga and other movements: dodging, unbalancing, traumatizing and acrobatic. The volunteers would perform the initial part of the basic lesson (ex. 1st stage) and afterwards, when performing the subsequent part (ex. 2nd stage), would first repeat the 1st basic lesson, with the purpose of continuing the learning process and improving the previous lesson."
16665393|NCT02180360|No Intervention|Control group|The Control group did not perform any physical exercise during the intervention period (eight weeks).
16665394|NCT02180347||Multifocal contact lenses|Coopervision Proclear Multifocal
16665395|NCT02180347||Single vision contact lenses|Coopervision Proclear Sphere
16665396|NCT02180334|Experimental|Mosapride|"Mosapride citrate 5 mg (Gasmotin®): 1 tablet (5 mg) will be administered 1 hour before MMTT.
~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.
~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
16665397|NCT02180334|Placebo Comparator|Control|"Placebo drug: 1 tablet will be administered 1 hour before MMTT.
~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.
~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
16665398|NCT02180321|Active Comparator|Control|
16665399|NCT02180321|Experimental|Tranexamic acid|
16665400|NCT02180308||PET/MRI|Patient receives PET/MRI
16665401|NCT02180295|Experimental|V212 Lot 1|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
16665402|NCT02180295|Experimental|V212 Lot 2|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
16665403|NCT02180295|Experimental|V212 Lot 3|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
16665404|NCT02180282|Experimental|Acne Treatment|Acne treatment using the M22-IPL acne filter
16665405|NCT02180269|Experimental|Cohort A|Single oral dose of either JNJ-54861911, 25 milligram (mg) tablet or matched placebo tablet on Day 1.
16665406|NCT02180269|Experimental|Cohort B|Single oral dose of either JNJ-54861911, 50 mg (2*25 mg tablets) or matched placebo tablets on Day 1.
16665407|NCT02180269|Experimental|Cohort C|Single oral dose of either JNJ-54861911, 100 mg (4*25 mg tablets) or matched placebo tablets on Day 1.
16665408|NCT02180256|Experimental|Endoscratching, non-RIF|Endometrial scratching. Women with no more than 1 previous unsuccessful embryo transfer. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
16665409|NCT02180256|No Intervention|Control, non-RIF|No intervention. Women with no more than 1 previous unsuccessful embryo transfer.
16665410|NCT02180256|Experimental|Endoscratching, RIF|Endometrial scratching. Women with 2 or more previous unsuccessful embryo transfers. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
16665411|NCT02180256|No Intervention|Control, RIF|No intervention. Women with 2 or more previous unsuccessful embryo transfers.
16665412|NCT02180243|Experimental|Yoga/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
16665413|NCT02180243|Active Comparator|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
16665414|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
16665415|NCT02180217|Experimental|osilodrostat (LCI699)|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then osilodrostat during a double-blind, placebo controlled RW Period.
16665416|NCT02180217|Placebo Comparator|LCI699 Placebo|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then placebo during a double-blind, placebo controlled RW Period.
16665417|NCT02180204|Experimental|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg
16665418|NCT02180204|Active Comparator|Alteplase|Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg
16665419|NCT02180191||Obesity|27 obese individuals (20 men and 7 women with mean BMI: 39.98±5.56 kg/m2)
16665420|NCT02180191||Diabetes|26 patients with newly diagnosed type 2 diabetes (18 men and 8 women with mean BMI: 28.63±5.08 kg/m2)
16665421|NCT02180191||Control|Healthy control subjects (22 men and 6 women with mean BMI: 23.02±1.70 kg/m2)
16665422|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
16665539|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
16665423|NCT02180165|Experimental|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
16665424|NCT02180165|Active Comparator|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
16665425|NCT02180165|Experimental|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
16665426|NCT02180165|Active Comparator|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
16665427|NCT02180152|Experimental|Postprandial walk|
16665428|NCT02180152|No Intervention|sedentary pregnant women|
16665429|NCT02180139|Experimental|Primary motor cortex (M1) stimulation|Treatment by transcranial direct current stimulation will be targeted to the motor cortex for all treatment sessions with Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral M1, 15 minutes (Goal: decrease contralateral M1 excitability)
16665430|NCT02180139|Experimental|Cerebellum stimulation|Treatment with transcranial direct current stimulation will be targeted to the cerebellum at every session with anode to ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits)
16665431|NCT02180139|Experimental|Combined M1 and Cerebellum stimulation|Treatment with transcranial direct current stimulation will be placed with M1 anode contralateral + cerebellum anode. M1 will first be 'primed' with anode on contralateral M1, cathode on face, for 10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the contralateral M1 with increased excitability to engage a potentially larger effect from the following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect on the motor circuits including M1)
16665432|NCT02180139|Placebo Comparator|Sham stimulation|transcranial direct current stimulation will be given in placebo form. Sham stimulation: electrode placement will be same as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds following standard practice for sham tDCS.
16665433|NCT02180126||Positive ANCA|Patients with borderline positive ANCA results.
16665434|NCT02180113|Other|Fibroscan®|Fibroscan® is an active non implantable medical device using ultrasound. It has been designed to measure liver stiffness in a painless, rapid and non invasive manner. It is a diagnostic aid tool. In this study, Spleen Stiffness Measurement will be assessed using a dedicated FibroScan® device which has been developed specifically to assess spleen stiffness.
16665435|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
16665436|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
16665437|NCT02180087|Placebo Comparator|placebo group|Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours
16665438|NCT02180087|Other|ketopofen quarter dose|"Group 2 : Ketoprofen quarter dose (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours."
16665439|NCT02180087|Other|ketoprofen half-dose|"Group 3 : Ketoprofen half-dose (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours."
16665440|NCT02180087|Other|Ketoprofen full dose|"Group 4 : Ketoprofen full dose (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours"
16665441|NCT02180074||I|Women without PAD (ABI >1.0 and <1.4) or CAD, and < 2 risk factors for cardiovascular disease (to serve as healthy controls)
16665442|NCT02180074||II|Women without PAD (ABI>1.0 and <1.4) or CAD and > 2 risk factors for cardiovascular disease
16665443|NCT02180074||III|Women with PAD as defined by ABI <0.9 and a coronary angiogram without any significant coronary artery disease.
16665444|NCT02180074||IV|Women with CAD without PAD, as defined by >50% stenosis by coronary angiography and ABI >1.0 and <1.4.
16665445|NCT02180074||V|Women with both CAD and PAD.
16665446|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
16665447|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
16665448|NCT02180048|Active Comparator|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
16665449|NCT02180048|Active Comparator|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
16665450|NCT02180048|Placebo Comparator|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
16665451|NCT02180035|Experimental|Symbiotic & Nutritional intervention|Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
16665452|NCT02180035|Placebo Comparator|Maltodextrin & Nutritional intervention|Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
16665453|NCT02180022|Placebo Comparator|Placebo|Patients treated with placebo for 12 weeks
16665454|NCT02180022|Experimental|Onion peel extract|Patients treated with onion peel extract for 14 days
16665455|NCT02180009||normal control|healthy people
16665456|NCT02180009||sepsis|mild response to infection
16665457|NCT02180009||severe sepsis|infection with at least one organ dysfunction
16665458|NCT02180009||septic shock|patients with septic shock
16665459|NCT02179996|Active Comparator|Three vaccine injections|Infants in this study arm will receive three vaccine injections at two, three and four months after birth (vaccine: DTP-pertussis-Hib).
16665460|NCT02179996|Experimental|Two vaccine injections|Infants in this study arm will receive two vaccine injections at two and four months after birth (vaccine: DTP-pertussis-Hib).
16665461|NCT02179983|No Intervention|Standard care|Standard care for exacerbation and follow-up without rehabilitation
16665462|NCT02179983|Experimental|Pulmonary rehabilitation|6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)
16665463|NCT02179970|Other|Plerixafor (Mozobil)|Plerixafor (Mozobil), continuous 7 day IV infusion. Starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
16665464|NCT02179957||CT and FFR|Coronary stenoses which have been analysed with both CT and FFR
16665465|NCT02179944||Participants|
16665466|NCT02179931|Experimental|Flupentixol/melitracen film-coated tablet|test treatment - 0.5 mg/10 mg; oral as a single dose
16665467|NCT02179931|Other|Flupentixol/melitracen coated tablet (Deanxit®)|reference treatment - 0.5 mg/10 mg, oral as a single dose
16665468|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
16665469|NCT02179905||Irritable bowel syndrome, Control|
16665470|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
16665471|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
16665472|NCT02179879||Video validation group|This will include video taping of experts (defined as one who has performed more than 500 labor epidurals in preceding 5 year period) and novices (defined as one who has done less than 50 epidurals in preceeding 2 years) perfoming labor epidural
16665473|NCT02179866|Experimental|[14C]-labeled RO5285119|Single oral dose - drinking solution
16665474|NCT02179853|Experimental|Anakinra|This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).
16665475|NCT02179840|Active Comparator|Intravenous|Anesthesia is maintained via intravenous agents. Mechanical ventilation adjustment will be performed.
16665476|NCT02179840|Active Comparator|Inhalational|Anesthesia is maintained via inhalational agents. Mechanical ventilation adjustment will be performed.
16665477|NCT02179814|Experimental|AMPT|"Experimental:
~alpha-methyl-paratyrosine (AMPT, trade name: Demser), body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 time points over 24 hours"
16665478|NCT02179814|Sham Comparator|Diphenhydramine & placebo|Diphenhydramine (25mg, trade name in Switzerland: Benocten) at the first medication intake time point, placebo at the second to fourth intake time point (medication intake over 24 hours)
16665479|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
16665480|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:
~Days 1-7, take 1 capsule with evening meal
~Days 8-14, take 3 capsules with evening meal
~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal
~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
16665481|NCT02179775|Active Comparator|propranolol|
16665482|NCT02179775|Active Comparator|Quince's oxymel|
16665483|NCT02179775|Placebo Comparator|placebo|
16665484|NCT02179762|Experimental|Arm I (moderate intensity exercise)|Patients perform moderate intensity exercise on a stationary bike for 20-50 minutes, three days a week for 16 weeks.
16665485|NCT02179762|Experimental|Arm II (HIIT exercise on a standard stationary bike)|Patients perform HIIT exercise on a standard stationary bike, three days a week for 16 weeks.
16665486|NCT02179762|Experimental|Arm III (HIIT exercise on a cybercycle)|Patients perform HIIT exercise on a cybercycle using racing or other games, three days a week for 16 weeks.
16665487|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
16665488|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
16665489|NCT02179736|Experimental|Active treatment|
16665490|NCT02179723|Experimental|Leukosan Adhesive|Leukosan Adhesive applied to one wound (left or right)
16665491|NCT02179723|Active Comparator|Transcutaneous suture|Transcutaneous suture applied to second wound (left or right)
16665492|NCT02179710||Motivational Interviewing|Review of adherence dashboard by the investigator with the patient to facilitate and engage intrinsic motivation within the client in order to change behavior.
16665493|NCT02179697|Active Comparator|Surgery + Bracing vs. Bracing Alone|"Randomize between 2 treatments:
~Treatment 1: Surgery + Bracing Treatment 2: Bracing alone"
16665494|NCT02179697|Other|Patient's choice|Patient will decide which group is best for him/her. The patient will be followed at the same points as Group 1.
16665495|NCT02179684|Experimental|Early surgery|Patienst with Bell´s Palsy with an early surgical intervention (< 3month), according to 'baby-sitter' method
16665496|NCT02179684|Active Comparator|Conventional treatment and follow-up|Patienst with Bell´s Palsy treated with conventional treatment and standardized physiotherapy according to Jaqueline Diels model.
16665497|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
16665498|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
16665499|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
16665500|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
16665501|NCT02179658|Experimental|OPT-80 group|Oral
16665502|NCT02179658|Active Comparator|Vancomycin group|Oral
16665503|NCT02179645|Experimental|GRC 27864|Test Treatment GRC 27864
16665504|NCT02179645|Active Comparator|Celecoxib|Active Comparator Treatment
16665505|NCT02179645|Placebo Comparator|Placebo|Placebo Treatment
16665540|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
16665541|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
16665542|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
16665506|NCT02179632|Experimental|Disclosure intervention zero|Treatment Group 1: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. A. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. A, according to manufacturer, in 2012. Dr. A will be a physician the researchers have chosen who does not appear on the website and therefore did not receive any payments in 2012. Participants should report $0/not listed as the response. Following this stage, participants will be told that Dr. A does not appear on the website and therefore did not receive any payments.
16665507|NCT02179632|Experimental|Disclosure intervention low|"Treatment Group 2: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. B. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. B, according to manufacturer, in 2012. Dr. B will be a physician the researchers have chosen who received an aggregate amount that is a low payment (below $100) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. B in 2012."
16665508|NCT02179632|Experimental|Disclosure intervention high|"Treatment Group 3: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. C. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. C, according to manufacturer, in 2012. Dr. C will be a physician the researchers have chosen who received an aggregate amount that is a high payment (above $250) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. C in 2012."
16665509|NCT02179632|No Intervention|Control group|Control Group: The control group will not be exposed to the disclosure website, but will participate in another online information-seeking task. These participants will visit the Farmer's Almanac website and be asked to search for temperature reports.
16665510|NCT02179619|Experimental|Dermalax(Deep)|subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
16665511|NCT02179619|Active Comparator|Restylane|Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
16665512|NCT02179606|Experimental|Dermalax Implant Plus|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
16665513|NCT02179606|Active Comparator|Restylane Sub-Q|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
16665514|NCT02179593|Other|2-Segment SARPE|Maxilla expansion using one sagittal section of the maxilla.
16665515|NCT02179593|Other|3-Segment SARPE|Maxilla Expansion using two parasagittal section of the maxilla.
16665516|NCT02179580|Experimental|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days
16665517|NCT02179580|Placebo Comparator|Placebo|Placebo at a rate of 3.0 g three times per day for 28 days
16665518|NCT02179567|Experimental|Doc/Bev|Docetaxel/Bevacizumab
16665519|NCT02179554||cardiopulmonary bypass|Patients undergoing elective surgery requiring cardiopulmonary bypass
16665520|NCT02179541||Group 1|All Group 1 patients were diagnosed with OME, diagnoses made by endoscopic-otoscopic examination findings and type-B tympanograms. They were all scheduled for ventilation tube insertion. Diagnosis of OME was confirmed during this surgery. All patients were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements. Viscosity was measured by the Brookfield DV-II+ProCP Viscometer.
16665521|NCT02179541||Group 2|Children in Group 2 had totally normal tympanic membranes and type A tympanograms. They had no hearing loss, Eustachian tube dysfunction, or any other ear-related problem, and were included in the study as healthy controls. Excluded from the study were patients presenting with acute otitis media, tympanosclerotic plaques, mental retardation, and children who were difficult to cooperate with. All subjects were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements.
16665522|NCT02179541||Group 1a|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion below the mean viscosity value of 450 cP (centipoise) were assigned to Group 1a.
16665523|NCT02179541||Group 1b|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion above the mean viscosity value of 450 cP (centipoise) were assigned to Group 1b.
16665524|NCT02179528|Active Comparator|etoposide,maintenance therapy|etoposide,25mg qd d1-20，repeat every 28 days
16665525|NCT02179528|No Intervention|blank control|blank control
16665526|NCT02179515|Experimental|modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine|Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
16665527|NCT02179502|Experimental|GLPG1690 single dose|Single oral dose of GLPG1690 suspension or solid formulation - ascending doses
16665528|NCT02179502|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension or solid formulation
16665529|NCT02179502|Experimental|GLPG1690 multiple doses|Multiple oral doses of GLPG1690 suspension - ascending doses
16665530|NCT02179502|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
16665531|NCT02179489|No Intervention|Control|surgery alone
16665532|NCT02179489|Experimental|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
16665533|NCT02179476|Experimental|Glyder|Glyder Facet Restoration Device
16665534|NCT02179463||Neoadjuvant Chemotherapy|undergo neoadjuvant chemotherapy before surgery
16665535|NCT02179450||Blepharospasm|Patients suffering from Blepharospasm
16665536|NCT02179450||Cervical Dystonia|Patients suffering from cervical dystonia
16665537|NCT02179450||Bilateral facial palsy|Patients suffering from bilateral facial palsy of inflammatory origin
16665538|NCT02179450||Healthy Control|Control subjects
16665544|NCT02179411|Active Comparator|renal transplant recipients|renal transplant recipients
16665545|NCT02179411|Active Comparator|renal transplant recipients grave|renal transplant recipients grave
16665546|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.
~(WBC and band counts blinded to the physician in charge of the patient)"
16665547|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.
~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
16665548|NCT02179385|Experimental|Health coaching|Patients receive health coaching via the phone, face to face or group support, according to patients' choice
16665549|NCT02179385|Placebo Comparator|Standard of Care|
16665550|NCT02179372|Experimental|Eicosapentaenoic acid|Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months
16665551|NCT02179372|Placebo Comparator|Medium chain fatty acid (placebo)|Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months
16665552|NCT02179359|Experimental|Reduced Toxicity Ablative Regimen|For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are <12 years and/or have mild/moderate iron exposure.
16665553|NCT02179359|Experimental|Reduced Intensity Preparative Regimen|For use in patients with unrelated donor bone marrow and for DBA patients who are >12 years and/or have significant iron exposure.
16665554|NCT02179359|Experimental|Myeloablative Preparative Regimen|For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
16665555|NCT02179346||Cartilage defects in the hip joint|NOVOCART® Inject Autologous Chondrocyte Implantation
16665556|NCT02179333||Subjects with Ataxia|Patients with a diagnosis of ataxia (Friedreich's ataxia or Spinocerebellar ataxia type 1-30) aged 18-80 years old will be recruited for the study.
16665557|NCT02179320|Active Comparator|Dry needling|Dry needling for myofascial pain syndrome, in the trapezius muscle.
16665558|NCT02179320|Sham Comparator|Sham needling|Superficial dry needling in the trapezius muscle
16665559|NCT02179307|Experimental|Arm label 1-Set, 3-Set|12-week progressive strength training protocol of different volumes
16665560|NCT02179294|Active Comparator|Pethidine|Pethidine is pain relief in labour
16665561|NCT02179294|Active Comparator|Remifentanil|Remifentanil intravenous patient controlled analgesia
16665562|NCT02179281|Experimental|Suspend Before Low feature turned ON|"MiniMed™ 640G system with the Suspend Before Low feature turned ON; continuously set on at 3,6 mmol/L (65 mg/dL). Suspend On Low Alert and Resume Basal Alert for the SmartGuard group should be set OFF.
~Administered intervention: Medtronic MiniMed™ 640G system"
16665563|NCT02179281|Active Comparator|Suspend Before Low feature turned OFF|"MiniMed™ 640G system with the Suspend Before Low and Suspend On Low features are both turned OFF; Alert On Low is set at 65 mg/dL (3,6 mmol/L). Resume Basal Alert should be set OFF as well.
~Administered intervention: Medtronic MiniMed™ 640G system"
16665564|NCT02179268|Active Comparator|sertraline & control|sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
16665565|NCT02179268|Active Comparator|citalopram & Control|citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
16665566|NCT02179268|Active Comparator|venlafaxine & control|venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
16665567|NCT02179268|Active Comparator|reboxetine & control|reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
16665568|NCT02179255|Experimental|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) plus FSH 450 to 600 units per day administered subcutaneous (SQ) daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
16665569|NCT02179255|Active Comparator|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
16665570|NCT02179242|No Intervention|Control arm|This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
16665571|NCT02179242|Experimental|Cardiac rehab|This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.
16665572|NCT02179229|Placebo Comparator|CONTROL|Patient in the CONTROL arm will receive a powder containing only tapioca-resistant starch comparable in colour, texture and taste to the synbiotic.
16665573|NCT02179229|Experimental|SYNBIOTIC|Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
16665574|NCT02179216|Active Comparator|Hydration|•Group 1: First day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl). Second day, Orthostatic Hypotension test with venous contention in the morning.
16665575|NCT02179216|Active Comparator|Venous contention|•Group 2: First day, Orthostatic Hypotension test after implementation of venous contention in the morning. Second day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl).
16665576|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
16665577|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
16665578|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
16665579|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
16665580|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
16665581|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
16665582|NCT02179138|Other|TFV 1% Gel|TFV 1% gel with the user-filled paper applicator
16665583|NCT02179125|Experimental|Bronchoscopic LVR-coil treatment|Bronchoscopic lung volume reduction with coil treatment
16665584|NCT02179099|Experimental|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
16665585|NCT02179086|Active Comparator|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16665586|NCT02179086|Experimental|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16665587|NCT02179086|Active Comparator|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16665588|NCT02179086|Experimental|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
16665589|NCT02179073||neurogenic bladder dysfunction|
16665590|NCT02179060||Cooling group|The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation
16665591|NCT02179060||Control group|Standard care, no cooling during pre-hospital care
16665592|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
16665593|NCT02179047||placebo|healthy subject
16665594|NCT02179034|Placebo Comparator|Tobacco Flavor|In this arm, subjects will receive tobacco flavor- without nicotine (placebo). Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
16665595|NCT02179034|Active Comparator|Low Dose Nicotine|In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
16665596|NCT02179034|Active Comparator|High Dose Nicotine|In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
16665597|NCT02179008|Experimental|DE-117 Low Dose ophthalmic solution|One drop Low Dose DE-117 in each eye QD for 90 days
16665598|NCT02179008|Experimental|DE-117 Low/Middle Dose ophthalmic solution|One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days
16665599|NCT02179008|Experimental|DE-117 Middle Dose ophthalmic solution|One drop Middle Dose DE-117 in each eye QD for 90 days
16665600|NCT02179008|Experimental|DE-117 Middle/High Dose ophthalmic solution|One drop Middle/High Dose DE-117 in each eye QD for 90 days
16665601|NCT02179008|Experimental|DE-117 High Dose ophthalmic solution|One drop High Dose DE-117 in each eye QD for 90 days
16665602|NCT02179008|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop latanaprost in each eye QD for 90 days
16665603|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.
~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
16665604|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
16665605|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
16665606|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
16665635|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
16665607|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
16665608|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
16665609|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
16665610|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
16665611|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
16665612|NCT02178982||standard treatments of ARDS|
16665613|NCT02178982||protocol treatment of ARDS|
16665614|NCT02178956|Experimental|BBI608 plus Paclitaxel|
16665615|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
16665616|NCT02178943||Heart Transplant Recipients|Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.
16665617|NCT02178930|Other|Integrated self management support|The intervention involves the introduction of an interactive chronic disease support platform into doctor-patient consultations, in addition to a self-management support program. Specifically, the intervention comprises the following interlinked components: within consultation engagement; at home exploration; phone and web-based health coaching.
16665618|NCT02178930|No Intervention|Usual care|The control group will receive usual care from study sites until all study participants have completed 12 months of follow up from their Baseline Visits. At this point access to the study intervention will be expanded to include control sites.
16665619|NCT02178917|Experimental|patients with central neuropathic pain|Randomised to 20 neurofeedback therapy sessions
16665620|NCT02178917|Other|Control: patients with central neuropathic pain|Randomised to no neurofeedback treatment
16665621|NCT02178917|No Intervention|patients with no central neuropathic pain|Observed for development of central neuropathic pain
16665622|NCT02178904||Suspected Coronary Artery Disease|Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test
16665623|NCT02178891|Other|short implants|
16665624|NCT02178878||Progress, Pain|Progress, Pain
16665625|NCT02178865||translocation carrier|balanced translocation carriers who have undergone IVF
16665626|NCT02178852|Experimental|TNS-active|TRIGEMINAL NERVE STIMULATION (TNS)
16665627|NCT02178852|Placebo Comparator|TNS-sham|TRIGEMINAL NERVE STIMULATION (TNS) - sham
16665628|NCT02178839|Experimental|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
16665629|NCT02178839|Placebo Comparator|Maltodextrin|8.5 g/d Maltodextrin
16665630|NCT02178826|Experimental|Rapid Maxillary Expansion|A Rapid Maxillary Expander will be fitted and the palate will be expanded approximately 5mm.
16665631|NCT02178826|Placebo Comparator|Placebo group|A Sham appliance is fitted and activated for 10-14 days. The patients in this group will after it has been revealed they were randomized into the placebo group have a true Rapid Maxillary Expander fitted and the palate will be expanded approximately 5 mm.
16665632|NCT02178813|Experimental|Administration of minocycline|"All patients in the study will receive minocycline periprocedurally with the following schedule:
~Day prior to procedure: 800mg p.o., 700mg p.o.
~Day of procedure: 600mg i.v., 500mg p.o.
~Day after procedure: 400mg p.o., 400mg p.o."
16665636|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
16665637|NCT02178774||parturients|tissue oxymetry
16665638|NCT02178761|Active Comparator|Angioplasty alone|plain old balloon angioplasty alone
16665639|NCT02178761|Active Comparator|Stenting|Balloon angioplasty plus stenting
16665640|NCT02178761|Active Comparator|drug-eluting balloon|Balloon angioplasty with drug-eluting balloon
16665641|NCT02178761|Active Comparator|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stent
16665642|NCT02178748|Experimental|Group 1|Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
16665643|NCT02178748|Experimental|Group 2|Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
16665644|NCT02178735|Experimental|Anterior compartment prolapse|Woman with cystocele who underwent anterior vaginal tailored mesh surgery
16665645|NCT02178735|Experimental|Posterior compartment prolapse|Woman with rectocele, enterocele, uterine prolapse, vaginal stump prolpase who underwent posterior vaginal tailored mesh surgery
16665646|NCT02178735|Experimental|anterior and posterior prolapse|Woman with cystocele and rectocele/uterine prolapse/vaginal vault prolapse/enterocele who underwent anterior and posterior vaginal tailored mesh surgery
16665647|NCT02178722|Experimental|Phase 1: MK-3475 + INCB024360|Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
16665648|NCT02178722|Experimental|Phase 2: MK-3475 + INCB024360|(recommended phase 2 dose)
16665649|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:
~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle
~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle
~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle
~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.
~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
16665650|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
16665651|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
16665652|NCT02178683|No Intervention|Tacrolimus and Mycophenolate Mofetil|Non-myeloablative allogeneic SCT from an HLA-Identical or non-identical family onor or unrelated donors, with fludarabine and low-dose TBI, with immunosuppression utilizing tacrolimus and MMF.
16665653|NCT02178670|Placebo Comparator|non-cancer stem cell vaccine|There is no cancer stem cell vaccine in this group
16665654|NCT02178670|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16665655|NCT02178670|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16665656|NCT02178670|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16665657|NCT02178657|Experimental|Bone marrow transplantation low dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10^6 per kilogram)
16665658|NCT02178657|Experimental|Bone marrow transplantation high dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10^6 per kilogram)
16665659|NCT02178657|No Intervention|Control|
16665660|NCT02178644|Experimental|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
16665661|NCT02178631|Experimental|Deprexis|Online self-help
16665662|NCT02178631|Active Comparator|CAU|Care as usual
16665663|NCT02178618|Active Comparator|Partially covered biliary self expandable metal stent|
16665664|NCT02178618|Active Comparator|Uncovered biliary self expandable metal stent|
16665665|NCT02178605||Cervical arthrodesis candidates|Patients scheduled to undergo cervical arthrodesis to treat their spinal pathology will undergo cervical arthrodesis with rhBMP-2
16665666|NCT02178592|Experimental|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
16665667|NCT02178592|Active Comparator|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
16665668|NCT02178579||Multiple Myeloma (MM) treatment with bortezomib|No intervention planned.
16665669|NCT02178579||Multiple Myeloma (MM) treatment with carfilzomib|No intervention planned.
16665670|NCT02178566|Placebo Comparator|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
16665748|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
16665671|NCT02178566|Active Comparator|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
16665672|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
16665673|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
16665674|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
16665675|NCT02178527|Experimental|Mulitfaceted podiatry Intervention|Foot and ankle exercises, foot orthoses, footwear provision
16665676|NCT02178527|Placebo Comparator|Usual podiatry care|Continued provision of usual NHS (National Health Service) podiatry care
16665677|NCT02178514|Experimental|Formula Feeding group by BabyNes Nutrition System|In this arm, all infants will be fed with BabyNes Nutrition System since enrollment until 12 month of age
16665678|NCT02178514|No Intervention|Breastfeeding group|used as reference to compare with formula feeding group
16665679|NCT02178501|Experimental|Omega-3 PUFA|OMEGA-3 PUFA 2000 mg once daily (1000 mg EPA and 1000 mg DHA)
16665680|NCT02178501|Placebo Comparator|Placebo|Placebo once daily
16665681|NCT02178488|Active Comparator|Cholecalciferol|150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month
16665682|NCT02178488|Placebo Comparator|Sugarpill|150 patients with MRSA resistent Placebo daily 12 month
16665683|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
16665684|NCT02178462||Primary ovarian cancer patients|Intervention will not be administered.
16665685|NCT02178462||Primary endometrial cancer patients|Intervention will not be administered.
16665686|NCT02178462||Benign gynecological disease patients|Intervention will not be administered.
16665687|NCT02178462||Healthy controls|Intervention will not be administered.
16665688|NCT02178449|Experimental|Verum|Dexamethasone and Ropivacaine
16665689|NCT02178449|Active Comparator|Placebo|Ropivacaine and Saline
16665690|NCT02178436|Experimental|Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)|Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16665691|NCT02178436|Experimental|Group II: Phase II Group I (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
16665692|NCT02178436|Experimental|GroupIII: Phase II Group II (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16665693|NCT02178423|Experimental|Ultrasound|Ultrasound for diagnosis of CVC position in children
16665694|NCT02178410|Active Comparator|Vitamin D + fish oil|
16665695|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
16665696|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
16665697|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
16665698|NCT02178397|Experimental|EXPERIMENTAL ARM B|"INDUCTION chemotherapy: 4 cycles of
~pemetrexed with cisplatin or carboplatin
~or gemcitabine with cisplatin or carboplatin in combination with erlotinib
~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib"
16665699|NCT02178397|Active Comparator|STANDARD ARM A|"INDUCTION chemotherapy: 4 cycles of
~pemetrexed with cisplatin or carboplatin
~or gemcitabine with cisplatin or carboplatin
~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed"
16665700|NCT02178384|Experimental|Altered-cast technique|Removable partial dentures will be made using altered-cast technique for free saddles.
16665701|NCT02178384|Active Comparator|Precision attachments|Removable partial dentures will be made using precision attachments which will be located on the distal abutment teeth.
16665702|NCT02178384|Active Comparator|Resilient layer|Removable partial dentures will be made using a resilient-layer on the distal extension of each appliance.
16665703|NCT02178371|Experimental|UTWC (control group)|the control group performs the same tasks than the experimental group, but without healthy hand constraint/containment.
16665704|NCT02178371|Experimental|mCIMT|"The study is conducted over a period of 5 weeks of treatment, using a movement restriction time healthy upper extremity of 2 hours daily.
~The restriction applied in the study is performed with the closed hand position and thumb inside the fist through a transparent film that reaches the wrist joint.
~In periods mCIMT, monitored the activities designed to enhance their functionality, based on motivation, avoiding frustrations are made."
16665705|NCT02178358|Experimental|150 milligram (mg) Galunisertib Monotherapy|150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
16665706|NCT02178358|Experimental|150 mg Galunisertib + 400 mg Sorafenib Therapy|"150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle).
~400 mg sorafenib administered orally BID for 28 days."
16665749|NCT02178046||Gingivitis|optical measurements
16665878|NCT02177188|Experimental|Haemorrhage simulation|
16665707|NCT02178358|Placebo Comparator|400 mg Sorafenib + Placebo Therapy|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle).
~400 mg sorafenib administered orally BID for 28 days."
16665708|NCT02178345||Surgical patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
16665709|NCT02178345||surveillance management patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
16665710|NCT02178332|Experimental|Yhteispeli, whole school programme|Yhteispeli-programme aims to support children's socio-emotional skills and well being at schools. Schools receive the Yhteispeli manual and teachers receive 3 and head masters 2 lecture days about use of Yhteispeli methods including group discussions and exercises. In addition every school is visited 4 times to support the use of Yhteispeli methods. (Lectures for the head masters March 2013 - November 2013, teachers August 2013 - January 2014)
16665711|NCT02178332|Active Comparator|Two theoretical lectures|Teachers receive two theoretical lectures on development of children's socio-emotional skills (3 hours in November 2013 and 3 hours in March 2014 ).
16665712|NCT02178319|Active Comparator|open group|the patients under go the open esophagogastric devascularization and splenectomy
16665713|NCT02178319|Experimental|laparoscopic group|the patients under go the laparoscopic esophagogastric devascularization and splenectomy
16665714|NCT02178306|Experimental|Telmisartan|
16665715|NCT02178293|Active Comparator|Benzidamine hydrochloride|
16665716|NCT02178293|Experimental|Ketoprofen lysine salt|
16665717|NCT02178280|No Intervention|unresectable hilar cholangiocarcinoma|control group
16665718|NCT02178280|Experimental|liver transplantation|liver transplantation combined with neoadjuvant radiochemotherapy
16665719|NCT02178267|Experimental|Lactobacillus reuteri|The study was performed by two groups. And these groups were constituted from the newborn preterm infants who are received probiotics (Lactobacillus reuteri) and no probiotics.
16665720|NCT02178254|Experimental|Sequence 3|N=10 subjects receive 3grams oral sachet of Monurol in Period 1; 1.0gram of Intravenous (IV) ZTI-01 for Period 2 (1-hour infusion); and 8.0 grams IV ZTI-01 for Period 3.
16665721|NCT02178254|Experimental|Sequence 1|N=10 subjects receive 1.0gram of Intravenous (IV) ZTI-01 for Period 1 (1-hour infusion); 8.0 grams IV ZTI-01 for Period 2 (1-hour infusion); and 3grams oral sachet of Monurol in Period 3.
16665722|NCT02178254|Experimental|Sequence 2|N=10 subjects receive 8.0 grams IV ZTI-01 for Period 1(1-hour infusion); 3grams oral sachet of Monurol in Period 2 and 1.0gram of IV ZTI-01 for Period 3 (1-hour infusion)
16665723|NCT02178241|Experimental|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16665724|NCT02178228||Subjects over age 18|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are over the age of 18
16665725|NCT02178228||Subjects age 15-17|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are age 15-17 with one permission of one parent.
16665726|NCT02178215|Placebo Comparator|Placebo shower gel|•Wash forearm by prepared placebo shower gel twice a day
16665727|NCT02178215|Active Comparator|Holly Mangrove Shower Gel|•Wash forearm by Holly Mangrove Showver gel twice a day
16665728|NCT02178189|Active Comparator|Standard-calorie infant formula|Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
16665729|NCT02178189|Experimental|High-calorie infant formula|Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
16665730|NCT02178176|Experimental|Education, encouragement, card sort|
16665731|NCT02178176|Active Comparator|Education, encouragement|
16665732|NCT02178163|Experimental|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
16665733|NCT02178150|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 8 weeks, every day 1 tablet
16665734|NCT02178150|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 8 weeks, one tablet every day
16665735|NCT02178137|Active Comparator|Glucosamine/Chondroitin|"Glucosamine/Chondroitin twice a day for a daily total dose of 1500 mg of Glucosamine and 1200 mg of Chondroitin.
~Tablets will have 750 mg Glucosamine Sulphate and 600 mg of Chondroitin Sulphate. These will be taken twice a day after breakfast and dinner."
16665736|NCT02178137|Active Comparator|Diacerien|Diacerien 50 mg twice a day in capsule form. To be taken twice a day after breakfast and dinner
16665737|NCT02178137|Placebo Comparator|Placebo pill|Placebo tablets with Zinc sulfate twice a day. These will contain pharamacologically non active ingredients (Usually expedients).
16665738|NCT02178124|Experimental|dosage 1|drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)
16665739|NCT02178124|Experimental|dosage 2|"dosage2 period 1 : oral administration drug : 12 people(10mg)
~dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)"
16665740|NCT02178111|Experimental|Never perform episiotomy|In this group the birth attendant will sought to avoid the use of episiotomy, and try not to carry out the procedure unless considered absolutely needed
16665741|NCT02178111|Active Comparator|Selective episiotomy|Patients will be subjected to the usual routine (selective episiotomy, ie, in the presence of indications described in the literature, according to the discretion of the physician or nurse assisting the birth)
16665742|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
16665743|NCT02178098|Placebo Comparator|Placebo|Placebo control
16665744|NCT02178085|Experimental|Flow imaging|Glaucoma patients and healthy subjects who will undergo ocular flow imaging
16665745|NCT02178072|Other|HPV positive|HPV positive patients
16665746|NCT02178072|Other|HPV negative|HPV negative patients
16665747|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
16665750|NCT02178033|Other|low-volume (2L) PEG|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, both doses are taken the day before colonoscopy, starting on the evening at about 18:00. Solution intake should be completed before 22.00 h.
16665751|NCT02178033|Active Comparator|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, the first dose is taken on the evening before colonoscopy (at about 20:00 h), the second one is taken early in the morning on the day of the procedure, starting about 4 h before the scheduled procedure time.
16665752|NCT02178020||knee arthroplasty, standard polyethylene|total knee arthroplasty with Standard Compression Molded tibial Polyethylene Liner
16665753|NCT02178020||knee arthroplasty, Highly Cross-Linked (XLP) polyethylene|knee arthroplasty with Highly Cross-Linked tibial Polyethylene Liner
16665754|NCT02177994|Experimental|Group A ceftriaxone after cord clamping|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive
~1 gm. ceftriaxone via l intravenous infusion single dose after cord clamping."
16665755|NCT02177994|Active Comparator|Group B ceftriaxone before skin incision|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive
~1 gm. ceftriaxone vial intravenous infusion single dose 30-60 minutes before skin incision."
16665756|NCT02177981|Active Comparator|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
16665757|NCT02177981|Sham Comparator|Control|The cuff will be placed around the arm but not inflated.
16665758|NCT02177968||Elderly fallers or non-fallers|characteristics of these groups
16665759|NCT02177955|Placebo Comparator|midazolan|7.5 mg midazolan 45 minutes before the surgery
16665760|NCT02177955|Placebo Comparator|diazepam|10 mg diazepam 45 minutes before the surgery
16665761|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
16665762|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
16665763|NCT02177929|Experimental|adapted canoeing, handbike, conventional physiotherapy|Individuals are divided into three groups: one group adapted canoeing, one group of handbike and one grup of conventional physiotherapy.
16665764|NCT02177916|Experimental|Traditional teaching|
16665765|NCT02177916|Experimental|DVD|
16665766|NCT02177903|Other|Bair PawsPatient Adjustable Warming System|Bair PawsPatient Adjustable Warming System for active pre-warming
16665767|NCT02177903|Other|Passive pre-warming|Passive pre-warming
16665768|NCT02177890|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve
16665769|NCT02177890|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.
16665770|NCT02177864|Experimental|Fiber|
16665771|NCT02177864|Placebo Comparator|Placebo|
16665772|NCT02177851|Experimental|Single oral iron supplement per day (120 mg)|Single oral iron dose of 120 mg per day for 3 consecutive days
16665773|NCT02177851|Active Comparator|B.i.d. oral iron supplement (2x 60 mg)|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
16665774|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
16665775|NCT02177825|Experimental|Imatinib Mesylate|Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
16665776|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
16665777|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
16665778|NCT02177799||gastroenteritis|
16665779|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
16665780|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
16665781|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
16665782|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
16665783|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
16665784|NCT02177760|Experimental|Sirolimus|Sirolimus (0.05 mg/kg/day) day -5 for aGVHD prophylaxis through day +100 or until T-regulatory cells >9% of CD4 effector cells; whichever comes first.
16665785|NCT02177747|Experimental|Diabet patients|Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy
16665786|NCT02177734|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 1 at a 21 day interval
16665787|NCT02177734|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 2 at a 21 day interval
16665788|NCT02177734|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 3 at a 21 day interval
16665789|NCT02177734|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 4 at a 21 day interval
16665790|NCT02177734|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3277509A H7N9 vaccine formulation 5 at a 21 day interval
16665791|NCT02177734|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
16665792|NCT02177721|Experimental|Raxibacumab arm|"This is an open-label, single arm study. The study will be implemented for subjects who receive FDA-approved raxibacumab as part of medical treatment of anthrax or for post-exposure prophylaxis.
~Intervention: Sampling of subjects or use of subjects salvaged standard of care samples may be considered for the following assessments (if available/applicable): pregnancy test, pharmacokinetics (PK) sampling, protective antigen, toxin neutralizing antibody (TNA), anti-raxibacumab antibodies."
16665793|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
16665794|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
16665795|NCT02177682|Experimental|Afuresertib|"Three subjects will be enrolled and given afuresertib 125 mg orally and monitored for toxicity. After completion of PK sampling in 3 days (Cycle 0), daily repeated dose of 125 mg will be given for 21 days (Cycle 1). If no DLT event is found after 21 days of repeated dosing, up to 6 subjects will be enrolled and given afuresertib 150 mg. If afuresertib 150 mg is assessed to be tolerable, up to 6 subjects can be enrolled and given afuresertib 200 mg. If afuresertib 200 mg is assessed to be intolerable, up to 6 subjects will be enrolled and given afuresertib 150mg or 175 mg. In any Dose levels, if DLT occurs in more than 2 subjects, that Dose level will be considered as intolerable."
16665796|NCT02177669||Normals without ocular disease|
16665797|NCT02177656|No Intervention|Usual care|Patients in the usual care group received six patient educational materials in the hospital, a baseline and follow-up phone call by blinded research assistants.
16665798|NCT02177656|Experimental|MI tailored intervention|The MI intervention was provided by a heart failure specialist nurse. The nurse conducted a home-based motivational interviewing intervention followed up by three phone calls over the course of 90 days. The intervention began with a conversation about the participant's self-identified goals. In the home intervention, the nurse focused on self-care areas that the participant identified as high priority. During the home-based intervention, the participant also set specific goals, which the nurse followed up with and reinforced over the follow-up phone calls.
16665799|NCT02177643|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.
16665800|NCT02177643|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
16665801|NCT02177630||Magnetic resonance imaging and endomyocardial biopsy|Magnetic resonance imaging and endomyocardial biopsy
16665802|NCT02177617|Active Comparator|Botox only|Participants randomized to receive Botox injections alone.
16665803|NCT02177617|Active Comparator|Botox plus Physical Therapy|Participants randomized to receive Botox injection combined with Physical Therapy
16665804|NCT02177604|Experimental|Wingate HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction 3 supervised sessions of Wingate High-intensity Interval Training.
16665805|NCT02177604|Experimental|Modified HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction with 3 supervised sessions of Modified High-Intensity Interval Training
16665806|NCT02177604|Active Comparator|No Exercise Control|7 days of high-fat overfeeding (50% excess calories) with no supervised exercise
16665807|NCT02177591||CAD and MI|Patients with a history of coronary artery disease who have had a myocardial infarction in the past.
16665808|NCT02177591||CAD, no MI|Patients who have a history of coronary artery disease and have not had a myocardial infarction in the past.
16665809|NCT02177591||no CAD|Patients with no documented history of coronary artery disease.
16665810|NCT02177578|Experimental|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions
~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
16665811|NCT02177578|Active Comparator|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.
~Will be prescribed to 46 Gy in 2 Gy fractions
~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.
~Will be prescribed to 14 Gy in 2 Gy fractions"
16665812|NCT02177565|Experimental|carrier plus BMSCs|carrier plus in vitro expanded autologous BMSCs
16665813|NCT02177565|Placebo Comparator|carrier alone (control).|Carrier alone
16665877|NCT02177201|Active Comparator|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
16665814|NCT02177552|Experimental|Experimental chemotherapy|Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.
16665815|NCT02177552|Other|Standard chemotherapy|Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks
16665816|NCT02177539|Active Comparator|Cyclopentolate|
16665817|NCT02177539|Experimental|Cyclopentolate+tropicamide+phenylephrine|
16665818|NCT02177526|Other|Imaging - CT and MRI examinations|Abdominal and pelvic CT and pelvic MRI imaging will be performed in 30 patients.
16665819|NCT02177513|Active Comparator|1|
16665820|NCT02177513|Active Comparator|2|
16665821|NCT02177513|Active Comparator|3|
16665822|NCT02177513|Placebo Comparator|4|
16665823|NCT02177513|Active Comparator|5|
16665824|NCT02177500|Experimental|Telmisartan + hydrochlorothiazide and matching placebo|
16665825|NCT02177500|Experimental|Telmisartan and matching placebo|
16665826|NCT02177487|Experimental|Telmisartan + Hydrochlorothiazide|
16665827|NCT02177474|Experimental|Telephone based peer support|The telephone based peer support was delivered by 11 women with chd aged 54 to 73 years, living all over Germany. Participants could call according to their needs during scheduled times on workdays.
16665828|NCT02177474|Other|Waitlist Group|Waitlist condition with delayed telephone based peer support starting at 5 months
16665829|NCT02177461|Experimental|Telmisartan|
16665830|NCT02177461|Active Comparator|Enalapril|
16665831|NCT02177461|Experimental|Telmisartan + clonidine TTS1|
16665832|NCT02177461|Active Comparator|Enalapril + clonidine TTS1|
16665833|NCT02177448|Experimental|BIBR277 and placebo matching enalapril|
16665834|NCT02177448|Active Comparator|Enalapril and placebo matching BIBR277|
16665835|NCT02177435|Experimental|Telmisartan plus Hydrochlorothiazide|
16665836|NCT02177435|Experimental|Telmisartan|
16665837|NCT02177422|Experimental|Telmisartan|
16665838|NCT02177409|Experimental|Telmisartan|4-week placebo run-in, 8-week fixed dose period
16665839|NCT02177409|Active Comparator|Amlodipine|4-week placebo run-in, 8-week fixed dose period
16665840|NCT02177396|Experimental|Telmisartan|
16665841|NCT02177396|Active Comparator|Valsartan|
16665842|NCT02177383|Experimental|Docosahexaenoic acid|1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek) provides 1.14 g DHA/daily
16665843|NCT02177383|Placebo Comparator|Olive oil|1 liter/day of placebo beverage (containing 0.8% olive oil)
16665844|NCT02177370|Experimental|Fenoterol metered dose inhaler (MDI)|
16665845|NCT02177370|Active Comparator|DSCG MDI|
16665846|NCT02177357|Experimental|Pramipexole - escalation dose|
16665847|NCT02177357|Placebo Comparator|Placebo|
16665848|NCT02177344|Experimental|Low dose of ipratropium bromide|
16665849|NCT02177344|Experimental|High dose of Ipratopium bromide|
16665850|NCT02177344|Active Comparator|Atrovent|
16665851|NCT02177344|Placebo Comparator|Placebo|
16665852|NCT02177331|Experimental|Lacidipine|
16665853|NCT02177318||Patients with COPD|
16665854|NCT02177305|Experimental|Tiotropium dose group 1|0.02 mcg tiotropium solution
16665855|NCT02177305|Experimental|Tiotropium dose group 2|0.04 mcg tiotropium solution
16665856|NCT02177305|Experimental|Tiotropium dose group 3|0.08 mcg tiotropium solution
16665857|NCT02177305|Experimental|Tiotropium dose group 4|0.16 mcg tiotropium solution
16665858|NCT02177305|Experimental|Tiotropium dose group 5|0.28 mcg tiotropium solution
16665859|NCT02177305|Experimental|Tiotropium dose group 6|0.40 mcg tiotropium solution
16665860|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
16665861|NCT02177279|Other|Visit A- 120g wheat bran cereals|A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
16665862|NCT02177279|Other|Visit B-40g wheat bran cereals|A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
16665863|NCT02177279|Other|Follow up-40g (8days), 120g (1day) wheat bran cereals|Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
16665864|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
16665865|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
16665866|NCT02177253|Experimental|Ipratropium bromide / Salbutamol Inhalation solution|
16665867|NCT02177253|Placebo Comparator|Placebo Inhalation solution|
16665868|NCT02177253|Experimental|Ipratropium bromide Inhalation solution|
16665869|NCT02177253|Active Comparator|COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)|
16665870|NCT02177253|Placebo Comparator|Placebo Inhalation Aerosol|
16665871|NCT02177240|Active Comparator|GRS (GlideRite®)|GlideScope® intubation with GRS® stylet of a simulated difficult airway
16665872|NCT02177240|Active Comparator|FIS (Flex-it® )|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
16665873|NCT02177227|Experimental|Total Knee Arthroplasty with PSI|Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation
16665874|NCT02177227|No Intervention|Total Knee Replacement|Total Knee Replacement, as per Standard of Care
16665875|NCT02177214||ventral hernia|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with inclusion of primary and incisional hernias. Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
16665876|NCT02177201|Sham Comparator|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
16665879|NCT02177175|Experimental|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
16665880|NCT02177175|Placebo Comparator|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
16665881|NCT02177149|Active Comparator|Standard of Care|DBS using standard of care.
16665882|NCT02177149|Experimental|DBS Clinical Support System|DBS using Clinical Support System.
16665883|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Participants randomized to 1.5 mg OCA took 1.5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 3 mg OCA daily for an additional 12 weeks.
16665884|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
16665885|NCT02177136|Experimental|Placebo|Participants randomized to placebo took placebo for 24 weeks during the DB phase.
16665886|NCT02177136|Experimental|LTSE OCA Total|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
16665887|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)
16665888|NCT02177110||Study|Patients who have fresh frozen and FFPE tissue taken prior to treatment
16665889|NCT02177110||Control|Fresh frozen tissue and FFPE tissue is available
16665890|NCT02177097||40 patients (uTHA)|Patients undergoing primary uncemented total hip arthroplasty surgery.
16665891|NCT02177097||40 patients (hTHA)|40 patients undergoing primary hybrid total hip replacement surgery.
16665892|NCT02177097||40 patients (TKA)|40 patients undergoing total knee replacement surgery.
16665893|NCT02177084|Experimental|PTNS + conservative treatment|"PTNS consists in the insertion of a small electrode above the medial malleolus adjacent to the posterior tibial nerve. An adhesive surface electrode is placed under th arch of the foot. Both electrodes are connected to the neurostimulator that generates electricity. A neuromodulation session lasts 30 minutes.
~The treatment plan includes 12 weekly sessions, followed by two sessions at 2-week intervals and the last one after one month. Two additional sessions of reinforcement (top-up) are provided at intervals of 6 months or earlier in case of worsening of symptoms"
16665894|NCT02177084|No Intervention|conservative treatment|
16665895|NCT02177071|No Intervention|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
16665896|NCT02177071|Other|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
16665897|NCT02177071|Other|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
16665898|NCT02177058|Experimental|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
16665899|NCT02177058|Active Comparator|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
16665900|NCT02177058|No Intervention|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
16665901|NCT02177045|Experimental|Microbubbles contrast media for US|Sonovue, Bracco, microbubbles contrast media
16665902|NCT02177032|Experimental|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
16665903|NCT02177032|Experimental|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
16665904|NCT02177032|Active Comparator|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
16665905|NCT02177032|Active Comparator|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
16665906|NCT02177019|Experimental|Development of personal health plan|Personal Health Plan
16665907|NCT02177006||Caregivers|Caregivers of children 2-6 years of age
16665908|NCT02177006||Pediatric clinicians|Pediatricians and nurse practitioners at Lake Forest Pediatric Associates
16665909|NCT02176993||Application of surface cooling|Surface cooling during 60 minutes.
16665910|NCT02176980|Active Comparator|Medical provider (MP) brief alcohol counseling & referral|"Screening of HCV-infected patients for alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT).
~Patients self-administer the AUDIT.
~HCV providers review the AUDIT with the patient.
~If the patient is using any alcohol, the HCV provider conducts brief alcohol counseling using the FRAMES model, based on the evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) method.
~Medical provider will explain the importance of alcohol abstinence in the presence of HCV infection.
~Patient is referred to an alcohol treatment programs outside the liver clinic. Typical counseling will take the form of individual and group therapy."
16665911|NCT02176980|Experimental|Brief alcohol counseling & 6 months of HCV-alcohol treatment|"Steps 1 through 5 as described in comparator arm above.
~6 months of group therapy, offered weekly.
~6 months of individual therapy, in person or by phone, offered every two weeks.
~Therapy content emphasizes interplay between alcohol use and liver health/HCV.
~Informal collaboration between HCV providers and addictions therapists.
~Shared EMR charting.
~Referral to study-provided psychiatry as needed."
16665941|NCT02176824|Sham Comparator|Sham Triple Chronotherapy|Total sleep deprivation, Three day fixed wake schedule, and sham light therapy.
16665942|NCT02176824|Active Comparator|Treatment As Usual|Normal inpatient care including pharmacotherapy, psychotherapy, milieu therapy, and social work interventions.
16665943|NCT02176811||Non-alcoholic Fatty Liver Disese|no treatment
16665944|NCT02176811||healthy controls|no treatment
16665945|NCT02176785|Sham Comparator|Sham tDCS|tDCS will be applied, but then turned off after 30 seconds.
16665915|NCT02176954|Experimental|Test A, Test B, Comparator|The subjects first test Coloplast Test A followed by Coloplast Test B and finally Comparator.
16665916|NCT02176954|Experimental|Test A, Comparator, Test B|The subjects first test Coloplast Test A followed by Comparator and finally Coloplast Test B.
16665917|NCT02176954|Experimental|Test B, Test A, Comparator|The subjects first test Coloplast Test B followed by Coloplast Test A and finally Comparator.
16665918|NCT02176954|Experimental|Test B, Comparator, Test A|The subjects first test Coloplast Test B followed by Comparator and finally Coloplast Test B.
16665919|NCT02176954|Experimental|Comparator, Test A, Test B|The subjects first test Comparator followed by Coloplast Test A and then Coloplast Test B
16665920|NCT02176954|Experimental|Comparator, Test B, Test A|The subjects first test Comparator followed by Coloplast Test B and then Coloplast Test A.
16665921|NCT02176941||ATHEROMA group|"ATHEROMA group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease"
16665922|NCT02176941||Control Surgery group|"Control Surgery group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease."
16665923|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
16665924|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
16665925|NCT02176915|Experimental|Group program|8-session group weight loss program and 4 follow-up phone counseling sessions
16665926|NCT02176915|Active Comparator|Print Materials|8 weekly mailings of print materials covering weight loss topics through US mail.
16665927|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
16665928|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.
16665929|NCT02176889|Experimental|Lactospore|One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days
16665930|NCT02176889|Placebo Comparator|Placebo|One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.
16665931|NCT02176876|Experimental|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
16665932|NCT02176876|Placebo Comparator|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
16665933|NCT02176863|Experimental|Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 2 g/kg of body weight administered via intravenous infusion over 2 consecutive days (Flebogamma 5% DIF 1 g/kg infused on Day 1 and Flebogamma 5% DIF 1 g/kg infused on Day 2) every 4 weeks for 52 weeks.
16665934|NCT02176863|Experimental|Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 1 g/kg of body weight administered via intravenous infusion on Day 1 and 20 mL/kg of body weight of normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will also be administered on a separate day, for a total dosing period of 2 consecutive days. every 4 weeks for 52 weeks. The order of 1 g/kg of body weight of Flebogamma® 5% DIF or 20 mL/kg of body weight normal saline solution infused on 2 consecutive days will be randomly determined for each participant by the Interactive Web Response System (IWRS), which will remain the same for the participant for all infusion visits during the treatment period.
16665935|NCT02176863|Placebo Comparator|Stage 1 Arm 3: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight Normal Saline Solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight. Normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
16665936|NCT02176863|Experimental|Stage 2 Arm 1: Flebogamma 5% DIF|The dose of Flebogamma® 5% DIF selected from Stage 1 will be administered over 2 consecutive days every 4 weeks for 52 weeks.
16665937|NCT02176863|Placebo Comparator|Stage 2 Arm 1: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
16665938|NCT02176850||Micardis®|
16665939|NCT02176837|Experimental|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
16665940|NCT02176824|Experimental|Triple Chronotherapy|Total Sleep Deprivation, Sleep phase advance, and Bright Light Therapy. Carex Health Brands Day-Light Classic 10,000 Lux
16665946|NCT02176785|Experimental|Anodal tDCS 2mA 10 Minutes|Anodal tDCS will be applied bi-frontally for 10 minutes at 2mA
16665947|NCT02176785|Experimental|Cathodal tDCS 2mA 10 Minutes|Cathodal tDCS will be applied Bi-Frontally for 10 minutes at 2mA
16665948|NCT02176772||Tuberculosis, no HIV and severe anemia|
16665949|NCT02176759|Experimental|Regular FePP|Rice (50g dry weight) fortified with 4mg regular FePP
16665950|NCT02176759|Experimental|Regular FePP with citrate added during extrusion|Rice (50g dry weight) fortified with 4mg regular FePP and citrate added during the extrusion process
16665951|NCT02176759|Experimental|Regular FePP with citrated added at consumption|Rice (50g dry weight) fortified with 4mg regular FePP and citrate shortly added before consumption
16665952|NCT02176759|Active Comparator|Ferrous sulphate|Rice (50g dry weight) fortified with 4mg ferrous sulphate
16665953|NCT02176746|Placebo Comparator|non-cancer stem cell vaccine|This is no cancer stem cells vaccine in this group
16665954|NCT02176746|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16665955|NCT02176746|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16665956|NCT02176746|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16665957|NCT02176733|Experimental|cyclosporine|
16665958|NCT02176720|No Intervention|Standard diagnostics without PET|Standard of care brain imaging modalities, predominantly MRI
16665959|NCT02176720|Experimental|FDOPA PET-CT|PET-CT with administration of FDOPA as an experimental radiopharmaceutical. This arm includes standard of care imaging plus FDOPA PET-CT
16665960|NCT02176707||Idiopathic pulmonary fibrosis sufferers|
16665961|NCT02176694|No Intervention|Standard Care|Aside from the asthma education provided at enrollment and placement of the SmartInhaler (i.e.,electronic monitoring device), adolescents will continue to receive usual care through their primary care providers.
16665962|NCT02176694|Experimental|Text Messaging|A technology based system which allows adolescents to compose, schedule and send one-time or recurring text messages to their own cell phones.
16665963|NCT02176681|Active Comparator|Insulin alone|Use the usual frequency and dose
16665964|NCT02176681|Experimental|Insulin and Vildagliptin|vildagliptin 50 mg/day during 3 months
16665965|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
16665966|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal,
16665967|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
16665968|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
16665969|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
16665970|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg before meal
16665971|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
16665972|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
16665973|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
16665974|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
16665975|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
16665976|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
16665977|NCT02176629|Experimental|Condition virtual reality (VR)|The subject is placed in front of a Barcotm screen capable of displaying high quality images.
16665978|NCT02176629|Active Comparator|Condition classic cognitive stimulation (CSC)|It is proposed about using the test dam Zazzo suitable for elderly. This classic test measures sustained attention.
16665979|NCT02176616|Active Comparator|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
16665980|NCT02176616|Experimental|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
16665981|NCT02176603||Patients with Phenylketonuria|Patients with Phenylketonuria due to phenylalanine hydroxylase deficiency
16665982|NCT02176603||Control group|Control group of healthy volunteers
16665983|NCT02176590|Experimental|Power PATH|Classroom PATHS Social Emotional Learning Curriculum (for preschool classrooms) plus Coping Power parent intervention (teaches parents what children are learning in the classroom PATHS program and also provides parents with mental health intervention and parenting topics to promote family well-being)
16665984|NCT02176590|Active Comparator|Head Start as usual|Head Start as usual (will measure the effects of Head Start programming as usual on the primary outcomes)
16665985|NCT02176577|Experimental|Product 0405|Topically Active Investigational Product 0405
16665986|NCT02176564||Chronic obstructive pulmonary disease|Patients with COPD treated with inhaled bronchodilators
16665987|NCT02176551|Experimental|Product 0405|Topical active investigational Product 0405
16665988|NCT02176551|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
16665989|NCT02176538|Experimental|Product 0405|Topical active investigational Product 0405
16665990|NCT02176538|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
16665991|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
16665992|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
16665993|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
16665994|NCT02176512|Experimental|Sequence 1|"four treatment periods:
~Treatment A
~Treatment B
~Treatment B
~Treatment A"
16665995|NCT02176512|Active Comparator|Sequence 2|"four treatment periods:
~Treatment B
~Treatment A
~Treatment A
~Treatment B"
16665996|NCT02176499|Experimental|Telmisartan, low dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
16665997|NCT02176499|Experimental|Telmisartan, high dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
16665998|NCT02176499|Placebo Comparator|Placebo|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
16665999|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
16666000|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
16666001|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
16666002|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
16666003|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
16666004|NCT02176473|Experimental|Computerized Cognitive Behavioral Therapy|A computerized version of CBT has been developed in an effort to more widely disseminate the powerful effects of this psychotherapy modality, with studies showing efficacy comparable to that of traditional CBT.8 The present study aims to further investigate the feasibility of combining ECT and computerized CBT (c-CBT).
16666005|NCT02176460|Experimental|colchicine|0.5mg twice daily for 16 weeks
16666006|NCT02176460|Placebo Comparator|placebo tablet|1 tablet twice daily for 16 weeks
16666007|NCT02176434|Experimental|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
16666008|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
16666009|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment
~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
16666010|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment
~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
16666011|NCT02176395|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
16666012|NCT02176395|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
16666013|NCT02176395|No Intervention|healthy volunteer|
16666014|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
16666015|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
16666016|NCT02176369|Experimental|vinorelbine|50 mg three times a week for a three weeks cycle
16666017|NCT02176369|No Intervention|Close observation/Best Supportive Care|Close observation/Best Supportive Care (BSC)
16666018|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
16666019|NCT02176343|Experimental|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
16666020|NCT02176330|Active Comparator|Usual care|ePAQ-PF followed by a face to face consultation.
16666021|NCT02176330|Experimental|Virtual Clinic|ePAQ-PF followed by a telephone consultation.
16666022|NCT02176317|Experimental|Autologous Umbilical Cord Blood (UCB)|All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
16666023|NCT02176304|Active Comparator|Suprapatellar Knee Injection Site|Patients will be injected specified dose of lidocaine and depomedrol through suprapatellar-lateral knee entry site.
16666024|NCT02176304|Active Comparator|Anterolateral knee injection|Patients will be injected specified dose of lidocaine and depomedrol through anterolateral knee entry site.
16666025|NCT02176291|Experimental|Buprenorphine|Buprenorphine
16666026|NCT02176291|Placebo Comparator|Placebo|Placebo
16666027|NCT02176278|No Intervention|Usual Care Group|"Usual care (UC) group:
~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
16666066|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy
~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks
~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
16666717|NCT02171715|Active Comparator|BIBW 2992 MA 2 drinking solution|
16666028|NCT02176278|Experimental|Empowered Care Group|"Empowered care (EC) group:
~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
16666029|NCT02176278|Experimental|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:
~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
16666030|NCT02176265|Experimental|Qvanteq bioactive coronary stent system|Open-label, single arm, non-randomized study
16666031|NCT02176252|Experimental|AZD1722|Dose escalation from 5 mg to 90 mg BID
16666032|NCT02176239||Gammaplex® IVIg|
16666033|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
16666034|NCT02176213|Experimental|Pomalidomide, Cyclophosphamide, Dexamethasone|Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)
16666035|NCT02176200|Experimental|Berodual® Respimat®|
16666036|NCT02176200|Active Comparator|Berodual® HFA-MDI|
16666037|NCT02176187|Experimental|natural technique, without instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
16666038|NCT02176187|Experimental|optimal technique, with instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
16666039|NCT02176174||White|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
16666040|NCT02176174||Black|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
16666041|NCT02176174||South Asian|Self-reported ethnic group of South Asian, using the United Kingdom Census categories, as recorded in electronic health records.
16666042|NCT02176174||Mixed/Other|Self-reported ethnic group of Mixed or other, using the United Kingdom Census categories, as recorded in electronic health records.
16666043|NCT02176161|Experimental|Surgical Prostate Cancer Patients|"Radical Prostatectomy patients with:
~High risk surgical pathology (Gleason 8 or higher, positive surgical margins, evidence of extra capsular extension or seminal vesicle invasion)
~Prior Radiation Therapy OR
~Prior Radiation Therapy with rising PSA.
~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
16666044|NCT02176161|Experimental|Radiation Patients|"Radiation Patients with Biochemical Recurrence (rising PSA).
~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
16666045|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
16666046|NCT02176135|Experimental|Dose escalation|Auranofin 3 to 6 mg/day oral administration for 12 weeks
16666047|NCT02176122|Active Comparator|Meropenem|Meropenem 1g adm every 8 hours IV up to study day 4.
16666048|NCT02176122|Experimental|Piperacillin-tazobactam combination product|Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
16666049|NCT02176096|Experimental|Glycosade|
16666050|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
16666051|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
16666052|NCT02176057|Experimental|Antibiotic|Azithromycin, suspension (liquid), 1 gram, one-time dose
16666053|NCT02176057|No Intervention|Observation|
16666054|NCT02176044|Placebo Comparator|Glucose infusion|Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
16666055|NCT02176044|Active Comparator|Sodium Nitroprusside infusion|Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
16666056|NCT02176031|Experimental|Natalizumab|"Natalizumab-
~(Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion
~At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.
~If participants have no response after one dose, they will be not be given a second dose.
~Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.
~Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.
~Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
16666057|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
16666058|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
16666059|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
16666060|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
16666061|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
16666062|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
16666063|NCT02175979|Placebo Comparator|standard|standard of care
16666064|NCT02175979|Experimental|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
16666065|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:
~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks
~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
16666067|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks
~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks
~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
16666068|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks
~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks
~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
16666069|NCT02175953|Experimental|Interventiongroup|Psychotherapy
16666070|NCT02175953|No Intervention|Waitling list group|waiting list
16666071|NCT02175940||Myopic Choroidal Neovascularization patients|
16666072|NCT02175940||Control patients undergoing cataract surgery|
16666073|NCT02175927|Experimental|High Dose Amoxicillin|High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid
16666074|NCT02175927|Active Comparator|Tetracycline|Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
16666075|NCT02175914|Experimental|Erythromycin|Oral treatment with Erythromycin 500mg twice daily.
16666076|NCT02175901|Experimental|Amoxicillin/metronidazole|Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
16666077|NCT02175901|Active Comparator|Amoxicillin/clarithromycin|Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
16666078|NCT02175888|Experimental|Oral iron supplement every day for 14 days|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days
16666079|NCT02175888|Active Comparator|Oral iron supplement every second day for 28 days|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
16666080|NCT02175875||comatose patients|180 mg ticagrelor followed by 90 mg BID for comatose patients after cardiac arrest
16666081|NCT02175862||Trauma patients before PS-HEMS|"The before period was between december 1 2009 to april 30 2010 (five months)."
16666082|NCT02175862||Traume patients after PS-HEMS|"The after period was between may 1 2010 to april 30 2011 (12 months)."
16666083|NCT02175849||Drug resistant TB patients|Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
16666084|NCT02175849||Contacts|Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
16666085|NCT02175836||SCD possitive versus SCD negative group|The total Heart Failure patients subgroup experiencing Sudden Cardiac Death surrogate end-points during follow up versus the patients subgroup that is free from Sudden Cardiac Death surrogate end-points.
16666086|NCT02175797|Other|Pacemaker + leads|all patients must have a MRI exam after pacemaker implantation
16666087|NCT02175784|Experimental|ipragliflozin group|oral
16666088|NCT02175784|Experimental|placebo group|oral
16666089|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666090|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666091|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666092|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666093|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666094|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666095|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666130|NCT02175524||Control|Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing.
16666131|NCT02175511|Experimental|Cloud-based home BP monitoring|170 were assigned to the experimental group
16666096|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16666097|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to < 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
16666098|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to < 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
16666099|NCT02175758|Experimental|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to < 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
16666100|NCT02175758|Experimental|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to < 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
16666101|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
16666102|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
16666103|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
16666104|NCT02175732|Experimental|KnowIt|Please see the 'KnowIt' intervention description below. Diabetes education, behavioral management
16666105|NCT02175732|Experimental|OnTrack|Please see the 'OnTrack' intervention description below. Diabetes Distress Reduction, Problem Solving Therapy
16666106|NCT02175719||E2014|
16666107|NCT02175706|Active Comparator|Resolute Integrity®|The coating of Resolute Integrity consists of zotarolimus as antiproliferative agent and the BioLinx® polymer system. This polymer system consists of a blend of three different polymers: (1) the hydrophobic C10 polymer, which aids in the control of drug release; (2) the hydrophilic C19 polymer, which supports biocompatibility; and (3) polyvinyl pyrro-lidinone, which increases the initial drug burst and enhances the elution rate.
16666108|NCT02175706|Active Comparator|Promus Element®|"Promus Element utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation.
~Promus Element is composed of the Element platform, a thin fluoropolymer coating, and Everolimus."
16666109|NCT02175693||E2014|
16666110|NCT02175680|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
16666111|NCT02175667|Experimental|Global Postural Reeducation|Participants receiving GPR treatment during 45 minutes to stretch muscular chains
16666112|NCT02175667|No Intervention|Control|Participants not receiving GPR treatment
16666113|NCT02175654|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks, followed by one week of rest, according to the 3/1 regimen
16666114|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
16666115|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
16666116|NCT02175628|Experimental|Acoustic Angiography|All breast patients will be included in the experimental group.
16666117|NCT02175628|Experimental|Healthy Volunteers|A volunteer group was added to the study to perfect the image acquisition techniques.
16666118|NCT02175602|Experimental|Cohort 2|Sertraline (50 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Sertraline (50 milligrams each morning) days 23-29
16666119|NCT02175602|Experimental|Cohort 1|Escitalopram (10 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Escitalopram (10 milligrams each morning) days 23-29
16666120|NCT02175589|Other|Study group|Colchicine Cessation in FMF patients with one MEFV mutation
16666121|NCT02175589|No Intervention|Control group|The control group includes FMF patients that will be kept on a daily colchicine treatment
16666122|NCT02175576|Experimental|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
16666123|NCT02175576|Active Comparator|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
16666124|NCT02175563|No Intervention|Without feedback|Participants compress the chest of the manikin without smartphone based feedback app.
16666125|NCT02175563|Experimental|With feedback|Participants compress the chest of the manikin with a smartphone based feedback app.
16666126|NCT02175550|Experimental|NR CC|
16666127|NCT02175537|Experimental|Microclinic social induction training|BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
16666128|NCT02175537|No Intervention|Controls|Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
16666129|NCT02175524||Case|Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing.
16666718|NCT02171702|Experimental|BIBW 2992|dose escalation
16666132|NCT02175511|No Intervention|Traditional Care|212 patients were assigned to the traditional care group (paper-based data)
16666133|NCT02175498|Experimental|Homoeopathic medicines|4 pills once a week of the indicated similium for a period of one year
16666134|NCT02175485|Experimental|Fexofenadine HCl|2 tablets of Dellegra Combination Tablets (Fexofenadine Hydrochloride 30 mg+Pseudoephedrine Hydrochloride 60 mg/tablet), oral, administrated 2 hours after start of exposure with 8,000 grains/cubic meter of Japanese cedar pollen
16666135|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
16666136|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
16666137|NCT02175446|Experimental|Experimental1|"Bevacizumab and eribulin
~In this study all patients will receive:
~Eribulin 1.23 mg/m2 on days 1, 8 every 3 weeks intravenously
~Bevacizumab 15 mg/kg every 3 weeks intravenously or Bevacizumab 10 mg/kg every 2 weeks intravenously"
16666138|NCT02175433|Experimental|Dose Escalation of AGS67E 0.05 mg/kg Without GF|Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.
16666139|NCT02175433|Experimental|Dose Escalation of AGS67E 0.1 mg/kg Without GF|Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
16666140|NCT02175433|Experimental|Dose Escalation of AGS67E 0.3 mg/kg Without GF|Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
16666141|NCT02175433|Experimental|Dose Escalation of AGS67E 0.6 mg/kg Without GF|Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
16666142|NCT02175433|Experimental|Dose Escalation of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
16666143|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg Without GF|Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
16666144|NCT02175433|Experimental|Dose Expansion of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
16666145|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg With GF|Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
16666146|NCT02175433|Experimental|Dose Escalation of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
16666147|NCT02175433|Experimental|Dose Escalation of AGS67E 1.8 mg/kg With GF|Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
16666148|NCT02175433|Experimental|Dose Expansion of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
16666149|NCT02175420|Active Comparator|TFV alone|Typhim Vi
16666150|NCT02175420|Experimental|BCG+TFV|BCG (SSI, Denmark) followed after 14 days by Typhim Vi
16666151|NCT02175407|Experimental|ASP1707 alone|
16666152|NCT02175407|Experimental|ASP1707 + itraconazole|
16666153|NCT02175394|Active Comparator|Microgynon®|Microgynon® once daily during period 1 (day 1 to day 14)
16666154|NCT02175394|Experimental|Microgynon® and BI 1356|Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)
16666155|NCT02175381|Experimental|Carbo/GEM|
16666156|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
16666157|NCT02175355|Experimental|Low dose of Micardis®|
16666158|NCT02175355|Experimental|Medium dose of Micardis®|
16666159|NCT02175355|Experimental|High dose of Micardis®|
16666160|NCT02175355|Active Comparator|Hydrochlorothiazide|
16666161|NCT02175355|Placebo Comparator|Placebo|
16666162|NCT02175342|Experimental|Tiotropium-1.25 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff
16666163|NCT02175342|Experimental|Tiotropium-2.5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff
16666164|NCT02175342|Experimental|Tiotropium-5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff
16666165|NCT02175342|Experimental|Tiotropium-10 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff
16666166|NCT02175342|Experimental|Tiotropium-20 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff
16666167|NCT02175342|Placebo Comparator|Placebo Respimat|
16666168|NCT02175342|Active Comparator|Tiotropium-18 lactose powder Handihaler|
16666169|NCT02175342|Placebo Comparator|Placebo lactose powder Handihaler|
16666170|NCT02175329|Experimental|CAD/CAM veneering|CAD/CAM manufactured e.max CAD veneers on zirconia framework
16666171|NCT02175329|Active Comparator|manually layered|Manually layered veneering on CAD/CAM fabricated zirconia bridge framework
16666172|NCT02175316|Experimental|Experimental: EECP for DOMS|All enrolled subjects will receive EECP treatment Delayed Onset Muscle Soreness.
16666173|NCT02175303|Experimental|Decidual stromal cell therapy for toxicity and inflammation|Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
16666174|NCT02175290||Spinocerebellar Ataxia 3 Yemenite Jews patients|
16666175|NCT02175277|Experimental|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
16666176|NCT02175264||Patients and Families with isolated non syndromic CDH cases|
16666177|NCT02175251|Active Comparator|low frequency (1Hz)|low frequency
16666178|NCT02175251|Sham Comparator|Sham Comparator|Sham Comparator
16666179|NCT02175251|Experimental|high frequency (20Hz)|high frequency
16666180|NCT02175238|Experimental|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
16666181|NCT02175238|Active Comparator|BI 691751 fasted|single dose BI 691751 in fasted state
16666182|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
16666183|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
16666184|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
~Bicalutamide 50 mg tablet every day for 2 months
~High dose conformal radiotherapy
~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
16666185|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
~Bicalutamide 50 mg tablet every day for 2 months
~High dose conformal radiotherapy"
16666186|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
16666187|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
16666188|NCT02175186|Experimental|ALBIS|Albis Tab 2 tab twice a day 12weeks
16666189|NCT02175186|Placebo Comparator|Placebo|placebo Tab 2 tab twice a day 12weeks
16666190|NCT02175173||E2080|Children ages >= 4 years: Patients weighing 15.0-30.0 kg: oral daily dose of 200 mg in two divided doses after meals for the first 2 days. The dose will be increased by up to 200 mg/day every two days. The maintenance dose should be 1000 mg/day in two divided doses after meals. The dose can be increased or decreased within a range not exceeding 1000 mg/day, and should be increased by up to 200 mg/day at intervals not less than 2 days. Patients weighing >= 30.1 kg: Adults: oral daily dose of 400 mg in two divided doses after meals for the first 2 days, then increased by up to 400 mg/day every two days. The maintenance dose should be 1800 mg/day for patients weighing 30.1-50.0 kg, 2400 mg/day for patients weighing 50.1-70.0 kg, and 3200 mg/day for patients weighing 70.1 kg or over in two divided doses after meals. Dose can be increased or decreased within a range not exceeding the above maintenance dose, and should be increased by up to 400 mg/day at intervals not less than 2 days.
16666191|NCT02175160|Experimental|Braking and functionality with right knee osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right knee osteoarthritis
16666192|NCT02175160|Experimental|Braking and functionality with right knee arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right total knee arthroplasty
16666193|NCT02175134|No Intervention|conventional diagnostic flow arm|Perform the laparoscopic biopsy as a discretion of attending physician's decision
16666194|NCT02175134|Experimental|two-step algorithm-based approach|"Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.
~Blood ELISPOT >= 6 spots or ascites adenosine deaminase > 20 IU/L, and
~Ascites ELISPOT/Blood ELISPOT rato > 3"
16666195|NCT02175121|Placebo Comparator|Treatment A- Placebo|
16666196|NCT02175121|Experimental|Treatment B- PF-06291874|
16666197|NCT02175121|Experimental|Treatment C- PF-06291874|
16666198|NCT02175121|Experimental|Treatment D- PF-06291874|
16666199|NCT02175121|Experimental|Treatment E- PF-06291874|
16666200|NCT02175095|Experimental|Regorafenib and FLT-PET|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional [18F]FDG-PET will be performed before treatment and at 8 weeks (just once at the point of first response evaluation).
16666201|NCT02175082|Active Comparator|Forced exercise cycling|Cycling exercise at approximately 90 rpm
16666202|NCT02175082|Active Comparator|Self-selected pace cycling|Cycling at self selected rate, with same aerobic level as forced cycling group
16666203|NCT02175069|Experimental|Interscalene Nerve Block - 5ml|"ultrasound guided interscalene plexus block (UISB)
~Ropivacaine 0.75%, 20ml Gadopentetate-Dimeglumine 0.05 mmol Shoulder Surgery"
16666204|NCT02175069|Active Comparator|Interscalene Nerve Block - 20ml|"ultrasound guided interscalene plexus block (UISB)
~Ropivacaine 0.75%, 5ml Gadopentetate-Dimeglumine 0.0125 mmol Shoulder Surgery"
16666205|NCT02175056|Experimental|HL2351|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
16666206|NCT02175056|Placebo Comparator|Placebo|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
16666207|NCT02175056|Active Comparator|Kineret(Anakinra)|100 mg (SC) / Single-Dose
16666208|NCT02175043|Experimental|the operation to add in CFAE to conventional liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
16666209|NCT02175043|Active Comparator|only doing conventional liner ablation|The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
16666210|NCT02175030|Active Comparator|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
16666211|NCT02175030|Active Comparator|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
16666212|NCT02175017|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
16666213|NCT02175004|Experimental|IONIS-TTR Rx|
16666214|NCT02174991|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
16666254|NCT02174783|Experimental|Mediterranean diet|Mediterranean diet for 6 months
16666255|NCT02174783|Experimental|Protein-Sparing Modified Fast (PSMF)|PSMF for 6 months
16666215|NCT02174991|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
16666216|NCT02174978|Experimental|Group 1: 10 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
16666217|NCT02174978|Experimental|Group 2: 30 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
16666218|NCT02174978|Other|Infectivity control|Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
16666219|NCT02174965|Experimental|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
16666220|NCT02174965|Active Comparator|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
16666221|NCT02174952|Experimental|TAU+SH|Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician. They will also receive an introductory DVD aimed at highlighting key components of the intervention.
16666222|NCT02174952|No Intervention|TAU|Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child & Adolescent Mental Health Services (CAMHS) during the trial phase. Families in the TAU condition will be offered the self-help manual at the end of the trial.
16666223|NCT02174939|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
16666224|NCT02174939|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
16666225|NCT02174926|Active Comparator|Conservative treatment|Written lifestyle guidance and fiber supplements
16666226|NCT02174926|Experimental|Elective laparoscopic sigmoid resection|
16666227|NCT02174913|Active Comparator|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
16666228|NCT02174913|Placebo Comparator|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
16666229|NCT02174900|Experimental|G6PD deficient 0.25 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
16666230|NCT02174900|Active Comparator|G6PD deficient receiving AL only|G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
16666231|NCT02174900|Active Comparator|G6PD normal 0.25 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
16666232|NCT02174900|Active Comparator|G6PD normal 0.4 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
16666233|NCT02174900|Experimental|G6PD-deficient 0.4 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
16666234|NCT02174887|Experimental|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days The patients will receive 2 cycles of treatment every 28 days
16666235|NCT02174874||Oral Ondansetron|Arm that receive oral solution .8 mgms per ml ondansetron - Apotex Brand DIN 02291967
16666236|NCT02174874||Oral disintegrating tablets|Arm that receives the disintegrating tablets either 4mg or 8 mgs Glaxo Brand 4 mg DIN 02239372, 8 mg DIN 02239373
16666237|NCT02174861|Experimental|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
16666238|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
16666239|NCT02174835|Experimental|Cohort A - Period 1|Twice daily dosing orally for 7 days
16666240|NCT02174835|Active Comparator|Cohort A - Period 2|Twice daily dosing orally for 7 days
16666241|NCT02174835|Experimental|Cohort A - Period 3|Twice daily dosing orally for 7 days
16666242|NCT02174835|Experimental|Cohort B - Period 1|Twice daily dosing orally for 7 days
16666243|NCT02174835|Active Comparator|Cohort B - Period 2|Twice daily dosing orally for 7 days
16666244|NCT02174835|Experimental|Cohort B - Period 3|Twice daily dosing orally for 7 days
16666245|NCT02174822|Experimental|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
16666246|NCT02174822|Experimental|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
16666247|NCT02174822|Experimental|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
16666248|NCT02174822|Experimental|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
16666249|NCT02174809|Experimental|5As|Physicians' use of the 5As tool to discuss gestational weight gain with their pregnant patients
16666250|NCT02174809|Active Comparator|Usual care|Usual care by physicians in addressing gestational weight gain with their pregnant patients
16666251|NCT02174796|Experimental|Surgical treatment group|"patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
~intervention: surgical correction (Ravitch or Nuss type intervention)."
16666252|NCT02174796|Experimental|Orthopedic treatment group|patients who chose an orthopedic treatment by vacuum bell. intervention : orthopedic treatment by vacuum bell.
16666253|NCT02174783|Active Comparator|Control group|Standard of care group
16666256|NCT02174770|Experimental|ACL BFR group|This group is patients with post-op from ACL reconstruction who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
16666257|NCT02174770|Active Comparator|ACL Standard Therapy|This group is patients with post-op from ACL reconstruction who are randomized into the standard therapy arm. They will receive ACSM guided-strength training as part of their post-operative physical therapy program.
16666258|NCT02174770|Other|Chronic Muscle Weakness|This is a crossover group where all subjects will be randomized to begin with either standard or blood flow restriction therapy for 4 weeks. After completion of the initial training, each subject will be switched to the opposite in an AB/BA crossover design.
16666259|NCT02174770|Experimental|Knee Arthroscopy BFR|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
16666260|NCT02174770|Active Comparator|Knee Arthroscopy Standard|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the standard physical therapy arm. They will receive ACSM-guided strength training as part of their post-operative physical therapy program during normal post-op rehab.
16666261|NCT02174757|Experimental|Inersan|Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2.
16666262|NCT02174757|Experimental|Inersan and Doxycycline together|"Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
~Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2."
16666263|NCT02174757|Active Comparator|Doxycycline|Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
16666264|NCT02174744||numerical scale|
16666265|NCT02174731|Experimental|Roxadustat|
16666266|NCT02174731|Active Comparator|Epoetin alfa|
16666267|NCT02174718|Experimental|Daily 4000IU transdermal D patch|Only in the stage 2, Efficacy Study
16666268|NCT02174718|Active Comparator|Daily placebo patch plus oral placebo|Only in the stage 3, non-inferiority Study
16666269|NCT02174718|Active Comparator|Daily placebo patch plus oral vitamin D|Only in the stage 3 Non-inferiority Study
16666270|NCT02174718|Active Comparator|Daily 4000IU topical patch plus oral placebo|Only for the 3rd Stage of the study, Non-inferiority Study
16666271|NCT02174718|Placebo Comparator|Daily transdermal placebo patch|Only in the stage 2, Efficacy Study
16666272|NCT02174705|Experimental|Sucrose|Sucrose prior to vaccine injections
16666273|NCT02174705|Active Comparator|Rotavirus|Rotavirus prior to vaccine injections
16666274|NCT02174692|Experimental|Elderly|"Exercise One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum
~2 minutes rest between sets"
16666275|NCT02174692|Experimental|Young|"Exercise
~One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum
~2 minutes rest between sets"
16666276|NCT02174666|Active Comparator|Red clover extract|Group recieving daily red clover extract containing isoflavones (80 mg/d), along with calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
16666277|NCT02174666|Placebo Comparator|Placebo group|Group recieving daily placebo extract (with no isoflavone content), calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
16666278|NCT02174653|Active Comparator|EPs® 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet
~During the common cold free period: One film-coated tablet (20 mg) three times a day
~During a common cold episode: Two film-coated tablets (1 x 20 mg and 1x placebo) three times a day (in the morning, midday and evening; total daily dose 60 mg) over the individual treatment duration of 14 consecutive days."
16666279|NCT02174653|Active Comparator|EPs(R) 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet
~During the common cold free period: One film-coated tablet (20 mg) three times a day
~During a common cold episode: Two film-coated tablets (2 x 20 mg = 40 mg) three times a day (in the morning, midday and evening; total daily dose 120 mg) over the individual treatment duration of 14 consecutive days."
16666280|NCT02174653|Placebo Comparator|Placebo|"During the common cold free period: One film-coated tablet (placebo) three times a day
~During a common cold episode: Two film-coated tablet (placebo) three times a day (in the morning, midday and evening) over the individual treatment duration of 14 consecutive days."
16666281|NCT02174640|Active Comparator|Coffee|Coffee Beverage
16666282|NCT02174640|Placebo Comparator|Water|Water
16666283|NCT02174627|Experimental|Roxadustat|
16666284|NCT02174627|Placebo Comparator|Placebo|
16666285|NCT02174614|Active Comparator|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
16666286|NCT02174614|Experimental|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment
16666287|NCT02174614|Experimental|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized games 3 times per week for the first 4 weeks.
16666288|NCT02174601||colonoscopy group|
16666289|NCT02174588|Experimental|balanced propofol group|
16666290|NCT02174588|Active Comparator|propofol alone group|
16666291|NCT02174575|Active Comparator|Sevoflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
16666292|NCT02174575|Active Comparator|Desflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
16666719|NCT02171702|Experimental|BIBW 2992, fasted|food effect part: maximum tolerated dose of BIBW 2992
16666293|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
16666294|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
16666295|NCT02174549|Experimental|Tirapazamine|Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.
16666296|NCT02174536|Active Comparator|Decidual Stromal cell therapy|Decidual stromal cell therapy (approximately 1x10^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.
16666297|NCT02174536|Placebo Comparator|Placebo|Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).
16666298|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
16666299|NCT02174523|Placebo Comparator|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
16666300|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
16666301|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
16666302|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
16666303|NCT02174497||Control|Three day Bowel Preparation
16666304|NCT02174497||Study Arm|One day Bowel Preparation
16666305|NCT02174484||Pacemaker recipients|Patients implanted with a single or dual pacemaker and with Home-Monitoring system activated and periodic IEGM activated
16666306|NCT02174458||Bariatric Surgery only|Patients after Bariatric Surgery but no secondary reconstructive procedures
16666307|NCT02174458||Body Contouring surgery|Post-bariatric patients and patients with no history of bariatric surgery but after natural weight loss
16666308|NCT02174445|Experimental|Imatinib|Imatinib 400-800mg, daily, maximum 6 years
16666309|NCT02174445|Active Comparator|Nilotinib|Nilotinib, 300mg, twice daily, maximum 6 years
16666310|NCT02174432|Experimental|nalbuphine HCl ER|nalbuphine HCl ER
16666311|NCT02174419|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
16666312|NCT02174419|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
16666313|NCT02174419|Placebo Comparator|Sugar pill|Placebo tablets BID
16666314|NCT02174406||women scheduled for breast screening|"Each patient will have the following:
~Screening whole breast ultrasound
~DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
16666315|NCT02174393|Experimental|Microneedling Plus Universal Peel|"(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each.
~Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11."
16666316|NCT02174380|No Intervention|Passive Household Contact Evaluation|Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
16666317|NCT02174380|Experimental|Active Household Contact Evaluation|The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district. During the home visit health staff will evaluate all household contacts for symptoms of active TB. Any person reporting cough for >14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation. All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required. Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
16666318|NCT02174367||Psoriasis|Patients with moderate to sever psoriasis attending a tertiary referral center. patients will be evaluated with a questionnaire, measurement of height,weight, waist circumference, fasting bloods, abdominal ultrasound and transient elastography.
16666319|NCT02174354||Psoriasis|Patients with psoriasis taking methotrexate
16666320|NCT02174328|Experimental|acetylsalicylic acid|This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
16666321|NCT02174328|Placebo Comparator|Placebo|This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36
16666322|NCT02174315|Experimental|Contingency Management|
16666323|NCT02174315|No Intervention|Non-Contingent Control Group|
16666324|NCT02174289|Active Comparator|Active Bi-ventricular Pacing|
16666325|NCT02174289|Placebo Comparator|No Biventricular pacing|
16666326|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
16666327|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
16666366|NCT02174029||Ventilation- mandatory mode only|those patient ventilator days during which they had only received a mandatory mode of ventilation
16666720|NCT02171702|Experimental|BIBW 2992, fed|food effect part: maximum tolerated dose of BIBW 2992
16666328|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
16666329|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
16666330|NCT02174263|Experimental|Supportive care (tocilizumab)|Patients receive tocilizumab IV over 1 hour every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11) and then every 4 weeks for 12 weeks (weeks 13, 17, and 21).
16666331|NCT02174250|Experimental|Istradefylline 40mg|Period 1: Day 1, istradefylline 40mg then crossover to Period 2
16666332|NCT02174250|Experimental|Rifampin 300mg BID + istradefylline 40mg|Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only
16666333|NCT02174237|Experimental|LNP1892|Dosage Form: Tablet Two Parts. Part A: Single Ascending Dose (SAD) starting with 25 mg (Maximum 5 cohorts). Part B: Multiple Ascending Dose (MAD), 10 days dosing, Maximum 3 cohorts. Six subjects in each cohort will receive LNP1892
16666334|NCT02174237|Placebo Comparator|Placebo|Two subjects in each cohort will receive matching placebo.
16666335|NCT02174224|Experimental|SMC + BI + Case Management|This arm will include all interventions in Standard Medical Care + Brief Intervention Arm. Case management will also be given to this arm. General needs based assessments will be conducted by the outreach worker. These assessments will be done at the hospital or at the youth's home, whichever they prefer. This assessment tool addresses education, vocational training, employment, housing, medical insurance, follow-up care and pro-social activities. Although each youth in this arm will receive the same needs-based assessment, individual youth will have variable needs, which will guide each unique and individualized case management plan.
16666336|NCT02174211|Active Comparator|Arm A: Ranibizumab (Lucentis)|Previous Vitrectomy
16666337|NCT02174211|Active Comparator|Arm B: Ranibizumab (Lucentis)|Non-vitrectomised, PVD / no PVD
16666338|NCT02174211|Active Comparator|Arm C: Aflibercept (Eylea)|Non-vitrectomised, PVD / no PVD
16666339|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
16666340|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
16666341|NCT02174185||bladder cancer, conduit diversion|new patients with bladder cancer scheduled for radical cystectomy and subsequent conduit diversion
16666342|NCT02174185||bladder cancer, orthotopic neobladder|new patients with bladder cancer scheduled for radical cystectomy and subsequent orthotopic neobladder
16666343|NCT02174172|Experimental|Arm A: Atezolizumab with Ipilimumab|Participants will receive atezolizumab along with ipilimumab.
16666344|NCT02174172|Experimental|Arm B: Atezolizumab with Interferon alfa-2b|Participants will receive atezolizumab along with Interferon alfa-2b.
16666345|NCT02174172|Experimental|Arm C: Atezolizumab with PEG- interferon alfa-2a|Participants will receive atezolizumab along with PEG- interferon alfa-2a.
16666346|NCT02174172|Experimental|Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab|Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.
16666347|NCT02174172|Experimental|Arm E: Atezolizumab with Obinutuzumab|Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.
16666348|NCT02174159|Experimental|Panel A: MK-8507 600 mg|Single oral dose of MK-8507 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
16666349|NCT02174159|Experimental|Panel B: MK-8507 150 mg|Single oral dose of MK-8507 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
16666350|NCT02174159|Experimental|Panel C: MK-8507 <=600 mg|Single oral dose of MK-8507 <=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
16666351|NCT02174146|Other|non-surgical therapy|non-surgical periodontal therapy with ultrasonic scalers and periodontal curettes
16666352|NCT02174133||patients after HTX|
16666353|NCT02174133||patients after LVAD implantation|
16666354|NCT02174133||patients with coronary heart disease|
16666355|NCT02174133||healthy volunteers|
16666356|NCT02174120|Experimental|Group A|During maintenance of anesthesia, etomidate was give by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml to keep bispectral index between 40 to 60.
16666357|NCT02174120|Experimental|Group B|During maintenance of anesthesia, Propofol was give by target controlled infusion, the effect-site concentration is 2 to 4 micrograms/ml to keep bispectral index between 40 to 60.
16666358|NCT02174120|Experimental|Group C|During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
16666359|NCT02174107|Experimental|Arm A|Percutaneous vertebroplasty
16666360|NCT02174107|Experimental|Arm B|External radiotherapy
16666361|NCT02174094|Experimental|Clobazam|Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
16666362|NCT02174094|Placebo Comparator|Placebo|Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
16666363|NCT02174068|Experimental|paracetamol|drug interaction between paracetamol and nefopam in healthy volunteers.
16666364|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. The study is divided in three phases. In Phase 1, approximately 15 depressed patients (as determined clinically) and approximately 15 non-depressed patients will undergo individual interviews. In Phase 2, the team will use the themes and subthemes obtained in Phase 1 to write a set of indicators into questionnaire form. In Phase 3, the newly developed questionnaire will be given to a sample of approximately 150 cancer patients who meet the eligibility criteria. Survey results obtained from this sample of 150 patients will be used to assess internal consistency, conduct item analysis, and determine the unique content of the proposed instrument.
16666365|NCT02174042|Experimental|Tangning Tongluo Capsule|Type 2 diabetes
16666367|NCT02174029||Ventilation- voluntary mode only|Those patient days on a mechanical ventilator who have not received prior mandatory ventilation during this episode of mechanical ventilation.
16666368|NCT02174029||voluntary with preceding mandatory|Those patient ventilator days where the patient had at least one prior day of mandatory mechanical ventilation during this episode of respiratory support.
16666369|NCT02174016|Experimental|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
16666370|NCT02174003||Open Treatment Group|The Open Treatment Group (all participants in this study) will receive the active / WBH treatment in an open fashion.
16666372|NCT02173977|Active Comparator|ARM A- Agonist/Antagonist protocol|The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
16666373|NCT02173977|Active Comparator|ARM B- Antagonist protocol|The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
16666374|NCT02173964|Experimental|pinaverium bromide|pinaverium bromide 50 mg tablet per oral administration one time
16666375|NCT02173964|Placebo Comparator|water|water ~100mL
16666376|NCT02173951|Active Comparator|arm 1 iron chelation|Active Comparator arm : iron chelation Included 32 thalassemia major patients with low serum ferritin (≥500) . They will receive low dose Deferiprone( DFP )on 50 mg/kg/d.
16666377|NCT02173951|Placebo Comparator|arm 2 blood transfusion|Placebo Comparator arm: blood transfusion only Included 32 thalassemia patients with low serum ferritin (≥500). They receive blood transfusion with no chelation. Patients will start deferiprone 75 mg/kg/d when reaching Primary end point which is elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6
16666378|NCT02173938||Treatment seekers|
16666379|NCT02173925||Functional dyspepsia group|Patients who had epigastric pain or discomfort with normal upper endoscopy and no organic evidence for explaining these symptoms
16666380|NCT02173925||Control group|Subjects with normal endoscopic finding who do not have any gastrointestinal symptoms
16666381|NCT02173912|Experimental|Sequence 1|"Single-dose crossover
~Test: CJ-30059
~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg
~Once daily Oral administration with at least 14 days of washout period"
16666382|NCT02173912|Experimental|Sequence 2|"Single-dose crossover
~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg
~Test: CJ-30059
~Once daily Oral administration with at least 14 days of washout period"
16666383|NCT02173899|Experimental|varicella-1|The second varicella vaccine and 1 year of the interval time between 2 doses
16666384|NCT02173899|Experimental|varicella-3|The second varicella vaccine and 3 years of the interval time between 2 doses
16666385|NCT02173899|Experimental|varicella-5|The second varicella vaccine and 5 years of the interval time between 2 doses
16666386|NCT02173886|Experimental|Bupropion|Bupropion SR and XL, single dosages of each separated by a wash-out period
16666387|NCT02173873|Experimental|one injection of ziv aflibercept intravitreal route|Intervention: Inject 0.05 ml of zaltrap into the vitreous of blind eyes with various diseases (AMD, CRVO) and monitor vision and OCT 1 day and 1 week after injection
16666388|NCT02173860|Active Comparator|FFR-guided revascularization|Patients with valvular heart disease scheduled for elective cardiac surgery and concomitant significant coronary artery disease will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions in vessels pre-specified as suitable for surgical revascularization. If the FFR is ≤0.80, then CABG will be performed. If the FFR is >0.80 then no graft will be placed in that particular vessel. Patients in whom FFR of a particular lesion is not possible can be included if at least one additional lesion is suitable for FFR measurement and grafting.
16666389|NCT02173860|Active Comparator|Angio-guided revascularization|Concomitant CABG will be performed as per clinical routine in all vessels with at least one stenosis > 50%. The vessel should be pre-specified as suitable for surgical revascularization before randomization. An internal mammary graft to the LAD should be attempted in all cases, if possible. Further revascularization strategy is left to the discretion of each center.
16666390|NCT02173847|Experimental|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Diode laser welding of the flap in its final position. 12 months follow up study
16666391|NCT02173834|Other|Lean subjects|Lean, young, healthy, Caucasian, male subjects
16666392|NCT02173834|Other|Obese subjects|Obese, Young, Healthy, Caucasian, male subjects
16666393|NCT02173808|Experimental|Contraceptive|
16666394|NCT02173795|Experimental|Berodual® Respimat® - Berodual® MA HFA|"randomized sequence
~Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)
~Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)"
16666395|NCT02173782|Experimental|Berodual® Respimat ® high dose|
16666396|NCT02173782|Active Comparator|Berodual® MDI|
16666397|NCT02173782|Experimental|Berodual® Respimat® low dose|
16666398|NCT02173782|Placebo Comparator|Placebo|
16666399|NCT02173769||Adults with COPD|
16666400|NCT02173756|Experimental|oral morphine gel|1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
16666401|NCT02173756|Placebo Comparator|placebo gel|1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
16666402|NCT02173743|Experimental|PRP group|PRP during barbotage
16666403|NCT02173743|Other|Control group|Regular barbotage
16666404|NCT02173730|Experimental|BIBR 1048 MS without Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day
16666405|NCT02173730|Experimental|BIBR 1048 MS with Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.
16666721|NCT02171689|Experimental|BIBW 2992 MA2|
16666722|NCT02171676|Experimental|Docetaxel + BIBW 2992|Dose escalation
16666406|NCT02173717|Experimental|Dabigatran etexilate|"Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.
~Single oral administration of dabigatran etexilate on Day 1;
~Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;
~Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;
~Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout"
16666407|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
16666408|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
16666409|NCT02173691|Experimental|Tiotropium|
16666410|NCT02173691|Active Comparator|Salmeterol|
16666411|NCT02173691|Placebo Comparator|Placebo|
16666412|NCT02173678|Experimental|COMBIVENT® HFA|
16666413|NCT02173678|Active Comparator|COMBIVENT® CFC|
16666414|NCT02173678|Placebo Comparator|Placebo HFA-MDI (metered dose inhaler)|
16666415|NCT02173665|Experimental|BI 1356 BS - Powder in bottle (PIB)|
16666416|NCT02173665|Experimental|BI 1356 BS - Tablet|
16666417|NCT02173665|Active Comparator|Placebo|
16666418|NCT02173652|Experimental|BI 1356, high dose|Treatment A: 7 days of BI 1356 treatment given once daily
16666419|NCT02173652|Active Comparator|BI 1356, low dose|Treatment B: 7 days of BI 1356 treatment given twice daily
16666420|NCT02173639|Experimental|BI 1356/metformin|
16666421|NCT02173639|Experimental|BI 1356 + Metformin|
16666422|NCT02173626|Other|GSH Medical Staff|Volunteers from the Good Samaritan Hospital medical staff were included on a first come first serve basis
16666423|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
16666424|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
16666425|NCT02173600|Experimental|Group-level Intensive Dietary Counselling|Active learning through 4-6 60-minute sessions workshop, enrolling 8-12 people each time.
16666426|NCT02173600|Active Comparator|Individual-level Intensive Dietary Counselling|Individualised dietary counselling delivered at the health-care point
16666427|NCT02173587|Experimental|Mussel oil capsules|Four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) per day for first two months and two mussel oil capsules (containing 400mg mussel oil and 400mg corn oil) per day thereafter for four months.
16666428|NCT02173587|Placebo Comparator|Corn oil capsuels|Four corn oil capsules (containing 1600mg corn oil) for first two months and two mussel oil capsules (containing 800mg corn oil) per day thereafter for four months.
16666429|NCT02173574|Experimental|Open-Label Single Arm Cohort|
16666430|NCT02173561|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
16666431|NCT02173561|Experimental|Individual Cognitive Processing Therapy-Cognitive Only|
16666432|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
16666433|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
16666434|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
16666435|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
16666436|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
16666437|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
16666438|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
16666439|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
16666440|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
16666441|NCT02173509|Experimental|Educational multifaceted intervention|Multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense, in physicians and pharmacists.
16666442|NCT02173496||Colour contrast sensitivity|Colour contrast sensitivity
16666443|NCT02173483|Other|Quadriceps graft|Proximally from patella the Quadriceps graft is harvested and used as a knew anterior cruciate ligament after rupture.
16666444|NCT02173483|Other|Hamstrings Graft|The Hamstrings graft is harvested and used as a knew anterior cruciate ligament after rupture.
16666445|NCT02173470|No Intervention|Control|Routine clinical care (which includes a conventional chest X-ray).
16666446|NCT02173470|Experimental|CT scan|Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).
16666447|NCT02173457|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 24 weeks
16666448|NCT02173457|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 24 weeks
16666449|NCT02173457|Active Comparator|Arm 3|Patients administrate Sitagliptin 100mg once daily for 24 weeks
16666450|NCT02173431||BMI 20 to 24.99|30 patients
16666451|NCT02173431||BMI 25 to 29.99|30 patients
16666452|NCT02173431||BMI 30 to 34.99|30 patients
16666453|NCT02173431||BMI 35 to 39.99|30 patients
16666454|NCT02173431||BMI 40 to 44.99|30 patients
16666455|NCT02173431||BMI 45 to 49.99|30 patients
16666456|NCT02173431||BMI more than 50|30 patients
16666457|NCT02173418|Experimental|Ropivacaine|Phrenic nerve block with Ropivacaine
16666458|NCT02173418|Placebo Comparator|Placebo|Phrenic nerve block with Sodium chloride
16666494|NCT02173145|Active Comparator|Azithromycin first, Placebo second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo.
16666459|NCT02173405|Active Comparator|Treatment Group|20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.
16666460|NCT02173405|Placebo Comparator|Placebo group|20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.
16666461|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
16666462|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
16666463|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
16666464|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
16666465|NCT02173366|Experimental|Change Club Intervention|
16666466|NCT02173353|Experimental|Pancreas cancer|Develope a stand, cradle or robotic arm to hold the ultrasound probe, to obtain an ultrasound just before a standard radiation therapy treatment is given.
16666467|NCT02173327|Other|Continuously Helm CPAP|Continuously helm CPAP for 6 hours
16666468|NCT02173327|Other|Intermittent Mask CPAP|Intermittent Mask CPAP for 10minuttes every 2 hours in a 18 hours period postoperative.
16666469|NCT02173314|Experimental|Treatment|
16666470|NCT02173314|No Intervention|Comparison|
16666471|NCT02173301|Experimental|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
16666472|NCT02173301|Experimental|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
16666473|NCT02173301|Experimental|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
16666474|NCT02173301|Placebo Comparator|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
16666475|NCT02173288|Active Comparator|Standard medical therapy|Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
16666476|NCT02173288|Active Comparator|Midodrine group|Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
16666477|NCT02173288|Active Comparator|Tolvaptan group|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
16666478|NCT02173288|Experimental|Tolvaptan plus midodrine arm|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day
16666479|NCT02173275||derivation cohort|n = 309
16666480|NCT02173275||validation cohort|n = 309
16666481|NCT02173262|Other|G-CSF|Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.
16666482|NCT02173262|Other|Ciprofloxacin|Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.
16666483|NCT02173249|Experimental|AC 170 0.24%|
16666484|NCT02173236|Experimental|platform-switched implants|platform-switched implants vs. platform-matched implants
16666485|NCT02173236|Active Comparator|platform-matched implants|platform-switched implants vs. platform-matched implants
16666486|NCT02173223|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
16666487|NCT02173223|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
16666488|NCT02173210||Prior preterm birth|Pregnant women with a prior preterm birth, eligible to receive 17 hydroxyprogesterone caproate (17OHPC)
16666489|NCT02173197||OT arm|"Through the initial evaluation of the complex patients' needs, the OT will propose a targeted intervention to the needs emerged and decide which approach will use to achieve the goal (i.e. compensatory or restorative).
~We will describe the characteristics of the population included and identify common needs and problems of the complex patients through the COPM.
~The needs and problems identified will be grouped into macro-areas, and the OT will propose the appropriate treatment on the basis of the area identified, the patient's needs and the available resources regardless of the origin of the disease."
16666490|NCT02173184|Placebo Comparator|Placebo|Placebo vehicle (0.9% NaCl solution)
16666491|NCT02173184|Experimental|Gynevac|Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution
16666492|NCT02173171||Previously treated with T-VEC|Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
16666493|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
16666709|NCT02171780|Placebo Comparator|Placebo|
16666710|NCT02171767|Experimental|BIBW 2992 MA2 - single rising dose|
16666495|NCT02173145|Active Comparator|Placebo first, Azithromycin second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo. Placebo will be capsulated similar to verum and given 3 times a week.
16666496|NCT02173132|Active Comparator|acetyl-L-carnitine|2 g acetyl-L carnitine twice a day for 90 days
16666497|NCT02173132|Placebo Comparator|sugar pill|Placebo twice a day for 90 days
16666498|NCT02173119||HCC patients having MRI post-TACE|HCC patients who have undergone conventional lipiodol based chemoembolization.
16666499|NCT02173106|Experimental|Group A: steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.
16666500|NCT02173106|No Intervention|Group B: no steroid & Cyclosporin|no steroid and cyclosporin and waiting for spontaneous remission for 6 months
16666501|NCT02173093|Experimental|Treatment (IL-2, GM-CSF, GD2Bi-aATC)|Patients receive IL-2 SC daily on days -2 to 35, GM-CSF SC twice weekly x 5 weeks, and GD2Bi-aATC IV over 30 minutes twice weekly x 4 weeks for a total of 8 infusions. Laboratory evaluations of immune responses are obtained prior and after immunotherapy.
16666507|NCT02173067||2% lidocaine|35 patients received 5.4 mL of 2% lidocaine.
16666508|NCT02173067||2% lidocaine with epinephrine|35 patients recieved 5.4 mL of 2% lidocaine with 1:100,000 epinephrine.
16666509|NCT02173054|Placebo Comparator|Adapalene gel|"Evening
~Wash face by prepared facial foam and dry your face
~Apply adapalene gel all over the face"
16666510|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning
~Wash face by prepared facial foam and dry their face
~Apply placebo cream all over the face
~Evening
~Wash face by prepared facial foam and dry your face
~Apply adapalene gel all over the face
~Apply placebo cream all over the face"
16666511|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning
~Wash face by prepared facial foam and dry their face
~Apply Eucerin cream all over the face
~Evening
~Wash face by prepared facial foam and dry your face
~Apply adapalene gel all over the face
~Apply Eucerin cream all over the face"
16666512|NCT02173041|Other|Standard Usual Care|Community program which follows with referral services
16666513|NCT02173041|Experimental|Prevention Awareness Groups (PAG)|Prevention Awareness Groups (PAG) is a community based integrated substance abuse prevention program targeting vulnerable populations. It comprises of community programs, physician led counseling followed by treatment follow up in community based clinic.
16666514|NCT02173028||Optimal beta blocker titration|We will compare the efficacy of two management strategies for beta-blocker up-titration: Standard in-office visits vs. Remote follow-up.
16666515|NCT02173028||Without optimal titration of beta blocker|This analysis will be conducted within the Cardiac Resynchronization Therapy observational study Modular Registry (CRT MORE - ClinicalTrials.gov Identifier: NCT01573091).
16666516|NCT02173015|No Intervention|Low Fall Risk|"Individuals who have a functional reach greater than 8 and a unipedal stance time greater than 5 s."
16666517|NCT02173015|No Intervention|High Fall Risk, No Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, but do not qualify for compensatory step training due to health concerns."
16666518|NCT02173015|Experimental|High Fall Risk, Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, and qualify for compensatory step training."
16666519|NCT02173002|Active Comparator|Standard care|Standard care
16666520|NCT02173002|Experimental|myIBDcoach|myIBDcoach
16666521|NCT02172976|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery
16666522|NCT02172976|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery
16666523|NCT02172963|Experimental|Decidual Stromal Cell therapy for Hemorrhagic Cystitis|
16666526|NCT02172937|Experimental|Decidual Stromal Cells as last line treatment|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.
16666527|NCT02172937|Active Comparator|Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.
16666528|NCT02172924|Active Comparator|Early Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.
16666529|NCT02172924|Active Comparator|Late Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.
16666530|NCT02172911|Experimental|Cohort I: INO-3112: Curative Intent|Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
16666711|NCT02171754|Experimental|BIBW 2992 + Ritonavir|
16666531|NCT02172911|Experimental|Cohort II: INO-3112: Salvage Therapy|Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
16666532|NCT02172898||Heavily Drinking Controls|Heavy alcohol drinking will be defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment. Heavy drinkers, who have just become abstinent within prior 2 weeks, including those we convince to seek treatment as part of the recruiting process, are eligible for enrollment. Control subjects must meet the following criteria: (1) AST, ALT, and total bilirubin levels must be within normal range; (2) no prior history of known alcoholic liver disease; and (3) absence of hepatosplenomegaly (from physical examination or radiographic imaging) or stigmata of liver disease.
16666533|NCT02172898||Subjects with AH|Diagnosis of AH will be established on published criteria based on history of heavy alcohol consumption (defined as > 40 grams per day on average in women and > 60 grams per day on average for men for a minimum of 6 months and within the 6 weeks prior to study enrollment), clinical evaluation and appropriate laboratory testing (as defined as total bilirubin > 2 mg/dL and AST > 50 U/L). When diagnosis of AH remains in question, a liver biopsy (if clinically feasible and subject has no contraindications) will be required. We plan to enroll patients with AH in special population infected with hepatitis B (HBV), hepatitis C (HCV), or HIV.
16666534|NCT02172885|Experimental|Mesenchymal stem cells|Five Mesenchymal Stem Cell infusions
16666535|NCT02172872|Active Comparator|standard combination chemotherapy|
16666536|NCT02172872|Experimental|decitabine|
16666537|NCT02172859|Active Comparator|lumiVida™|lumiVida™ (2 x 0.5 g sachets to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days.
16666538|NCT02172859|Placebo Comparator|Placebo|Placebo (2 x 0.5 g sachets of casein hydrolysate to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days
16666539|NCT02172846|Experimental|Treatment (PBT, paclitaxel, and carboplatin)|"CHEMORADIATION THERAPY:
~PBT daily 5 days a week over 3 weeks for a total of 15 fractions
~Paclitaxel intravenously (IV) over 1 hour weekly for 3 weeks
~Carboplatin intravenously (IV) over 30 minutes weekly for 3 weeks.
~CONSOLIDATION CHEMOTHERAPY (B=beginning 4-6 weeks after completion of radiation therapy, patients may receive):
~Paclitaxel IV over 1 hour on day 1
~Carboplatin IV over 30 minutes on day 1
~At the discretion of the treating physician
~Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
16666540|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
16666541|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
16666542|NCT02172807|Experimental|Tiotropium low & Placebo|Tiotropium 18 µg inhalation capsule and Placebo MDI
16666543|NCT02172807|Experimental|Tiotropium high & Placebo|Tiotropium 36 µg inhalation capsule and Placebo MDI
16666544|NCT02172807|Active Comparator|Oxitropium & Placebo|Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules
16666545|NCT02172794|Experimental|tiotropium|
16666546|NCT02172794|Active Comparator|salmeterol|
16666547|NCT02172781|Experimental|Ipratropium - unit dose vial|
16666548|NCT02172781|Experimental|Tiotropium - inhalation capsule - low dose|
16666549|NCT02172781|Placebo Comparator|Placebo matching tiotropium - inhalation capsule|
16666550|NCT02172781|Placebo Comparator|Placebo matching to ipratropium - unit dose vial|
16666551|NCT02172781|Experimental|Tiotropium - inhalation capsule - high dose|
16666552|NCT02172768|Experimental|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
16666553|NCT02172768|Active Comparator|daily dosing|micafungin daily for 8 days
16666554|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
16666555|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
16666556|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate
~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
16666557|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo
~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
16666558|NCT02172729|Experimental|ACB with lidocaine 5 mg/ml|Adductor canal block (ACB) with 20 ml lidocaine 5 mg/ml, single bolus
16666559|NCT02172729|Experimental|ACB with lidocaine 15 mg/ml|Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
16666560|NCT02172716|Experimental|Nonsurgical periodontal treatment|Nonsurgical periodontal treatment will be conducted following a full-mouth approach; no antibiotics or chemical plaque control will be provided.
16666561|NCT02172703|Other|Non-invasive ICP measurement|non-invasive ICP measurement with NON-INVASIVE ICP ABSOLUTE VALUE METER (carried out simultainusly with standard invasive ICP measurement catheter and probes)
16666562|NCT02172690|Experimental|Laparoscopic Staging|For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
16666563|NCT02172677|Experimental|Healthy participants|Structural and functional MRI and memory assessment
16666564|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
16666565|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
16666712|NCT02171754|Active Comparator|BIBW 2992|
16666713|NCT02171741|Experimental|Docetaxel + BIBW 2992|
16666566|NCT02172651|Experimental|Vitamin D3 - Blinded Registration|One capsule of vitamin D3 10,000 IU orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative vitamin D3 for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
16666567|NCT02172651|Placebo Comparator|Placebo - Blinded Registration|One placebo capsule orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative placebo for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
16666568|NCT02172638|Experimental|FAST-TRACK Group|Patients in this group will be managed according to an specifically designed FAST-TRACK protocol which will include: Preoperatory nutritional management and coaching by surgeon, anesthetist, nutritionist and specifically trained nurse personnel, reduced preoperatory fasting, avoiding use of intraabdominal drainages, specific anesthetic management to reduce intraoperative stress, avoiding use of Nasogastric tube, avoiding the need for major opioid in postoperatory analgesia and use of an standardized postoperatory management protocol directed to obtain an early oral intake and mobilization with a the goal of normal diet and deambulation in the 3rd day after surgery.
16666569|NCT02172638|Active Comparator|Classical management group|Patients assigned to this group will receive the standard management preformed in our center until now. This management includes a preoperatory control exclusively by the surgeon and anesthetist, minimum of 8h fasting previous to surgery, loose use of intraabdominal drainage , systematic use of nasogastric tube whenever rectum resection or omentectomy is performed, Postoperative analgesia following standing Vall d'Hebron protocols for Moderate-severe postoperative pain, which include use of combined analgesia with non opioids drugs and major Opioids, and usual flexible, non standardized postoperatory management with mobilization and oral intake progression depending on perceived evolution by attending surgeon.
16666570|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
16666571|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
16666572|NCT02172612|Experimental|Arm 1 - Intervention|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
16666573|NCT02172612|No Intervention|Arm 2 - Control|Those included in the control group will receive a generic brochure about medication safety and inappropriate medication use in the elderly.
16666574|NCT02172599|Experimental|multi-component intervention|"Sit-stand workstation provision
~The multi-component intervention will align with the World Health Authority's promotion of a healthy workplace model, which emphasises that best-practice workplace health interventions should involve an integrated approach involving organisation and individual level approaches to behaviour change (WHO, 2010). Thus, participants will receive a sit-stand workstation with additional support to use the sit-stand workstation."
16666575|NCT02172599|Experimental|Sit-stand workstation only|"Sit-stand workstation provision
~Participants in this arm will receive a sit-stand workstation. They will not receive any support to use the sit-stand workstation, except some health and safety advice upon installation."
16666576|NCT02172599|No Intervention|Usual practice (seated workstation)|This arm is the control group. They will continue to use their usual seated workstation for the duration of the study.
16666577|NCT02172586|Experimental|Telmisartan|
16666578|NCT02172586|Experimental|Telmisartan + Hydrochlorothiazide|
16666579|NCT02172586|Active Comparator|Losartan|
16666580|NCT02172586|Active Comparator|Losartan + Hydrochlorothiazide|
16666581|NCT02172573|Experimental|Pramipexole|
16666582|NCT02172573|Experimental|Bromocriptine|
16666583|NCT02172573|Placebo Comparator|Placebo|
16666584|NCT02172560||Premature withdrawal from tiotropium|
16666585|NCT02172547||COPD patients who stopped smoking during treatment|
16666586|NCT02172534|Experimental|Tiotropium bromide low|Single dose: 2.5 µg Tiotropium
16666587|NCT02172534|Experimental|Tiotropium bromide medium|Single dose: 5 µg Tiotropium
16666588|NCT02172534|Experimental|Tiotropium bromide high|Single dose: 10 µg Tiotropium
16666589|NCT02172534|Experimental|Tiotropium bromide low (28 days)|multiple dose: 2.5 µg Tiotropium
16666590|NCT02172534|Experimental|Tiotropium bromide medium (28 days)|Multiple dose: 5 µg Tiotropium
16666591|NCT02172534|Placebo Comparator|Placebo|single or multiple dose of Placebo
16666592|NCT02172521||COPD and proven hyperinflation|Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram
16666593|NCT02172508|Experimental|Tiotropium|
16666594|NCT02172508|Placebo Comparator|Placebo|
16666595|NCT02172495||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
16666596|NCT02172482||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
16666597|NCT02172469|Experimental|Tiotropium & Placebo|
16666598|NCT02172469|Active Comparator|Atrovent & Placebo|
16666599|NCT02172456|Experimental|Tiotropium|
16666600|NCT02172443|Experimental|tiotropium inhalation capsules|
16666601|NCT02172443|Active Comparator|Atrovent MDI|
16666602|NCT02172430|Experimental|Tiotropium|
16666603|NCT02172430|Active Comparator|Oxitropium bromide|
16666604|NCT02172417|Experimental|Cimetidine + Tiotropium followed by Tiotropium|
16666605|NCT02172417|Experimental|Ranitidine + Tiotropium followed by Tiotropium|
16666606|NCT02172404|Experimental|HandiHaler® vs. MDI|sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
16666607|NCT02172404|Experimental|MDI vs. HandiHaler®|sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
16666608|NCT02172391|Experimental|Tiotropium|Tiotropium inhalation powder capsules 18 mcg, one capsule once daily for 28 days
16666609|NCT02172391|Placebo Comparator|Placebo|Placebo inhalation powder capsules, one capsule once daily for 28 days
16666610|NCT02172378|Experimental|Tiotropium inhalation capsules|
16666611|NCT02172378|Placebo Comparator|Placebo inhalation capsules|
16666612|NCT02172352|Experimental|Ba 679 BR low dose|
16666613|NCT02172352|Placebo Comparator|Placebo inhalation powder|
16666614|NCT02172352|Experimental|Ba 679 BR middle dose|
16666615|NCT02172352|Experimental|Ba 679 BR high dose|
16666616|NCT02172339|Experimental|Tiotropium|group comparison (healthy, renal impairment)
16666617|NCT02172326|Experimental|Tiotropium inhalation capsules|
16666618|NCT02172313|Experimental|Fed conditions|Fasting for 10 hours overnight followed by a high-fat, high-calorie meal, after the meal dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
16666619|NCT02172313|Experimental|Fasting conditions|Fasting for 10 hours overnight followed by dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
16666620|NCT02172313|Experimental|Reference dosing condition|Fasting for 6 hours overnight followed by dosing of the tablet with 120 mL of water and a post-dose fasting period of 30 min
16666621|NCT02172300|Experimental|Tiotropium|Tiotropium inhalation capsules via HandiHaler
16666622|NCT02172300|Placebo Comparator|Placebo|Placebo inhalation capsules via HandiHaler
16666623|NCT02172287|Experimental|Tiotropium (Ba679 BR)|Tiotropium capsule once daily by oral inhalation
16666624|NCT02172287|Active Comparator|Salmeterol|Salmeterol inhalation aerosol twice daily
16666625|NCT02172287|Placebo Comparator|Placebo|"Tiotropium (Ba679 BR)- placebo one capsule once daily by inhalation
~Salmeterol- placebo, inhalation aerosol twice daily"
16666626|NCT02172274|Experimental|[14C]-BI 10773 - oral solution|
16666627|NCT02172261|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and glimepiride once on day 1
~Treatment C: Glimepiride once on day 1"
16666628|NCT02172261|Experimental|Sequence CAB|"Treatment C: Glimepiride once on day 1
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and glimepiride once on day 1"
16666629|NCT02172248|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4
~Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4"
16666630|NCT02172248|Experimental|Sequence CAB|"Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4"
16666631|NCT02172235|Active Comparator|Pioglitazone|
16666632|NCT02172235|Experimental|Pioglitazone + BI 10773 low|
16666633|NCT02172235|Experimental|Pioglitazone + BI 10773 medium|
16666634|NCT02172235|Experimental|Pioglitazone + BI 10773 high|
16666635|NCT02172235|Experimental|Pioglitazone low + BI 10773 medium|
16666636|NCT02172235|Experimental|Pioglitazone + BI 10773 1 hour after Pioglitazone|
16666637|NCT02172222|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI10773 and linagliptin once daily from day 1 to 7
~Treatment C: Linagliptin once daily from day 1 to 7"
16666638|NCT02172222|Experimental|Sequence CAB|"Treatment C: Linagliptin once daily from day 1 to 7
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI10773 and linagliptin once daily from day 1 to 7"
16666639|NCT02172209|Experimental|BI 10773 tablet administered with food|50 mg BI 10773 after a standardised high fat breakfast
16666640|NCT02172209|Active Comparator|BI 10773 tablet administered to fasted subjects|50 mg BI 10773 p.o. after an overnight fast of at least 10 hours
16666641|NCT02172196|Experimental|Treatment sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
~Treatment C: Sitagliptin once daily from day 1 to 5"
16666642|NCT02172196|Experimental|Treatment sequence CAB|"Treatment C: Sitagliptin once daily from day 1 to 5
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5"
16666643|NCT02172183|Experimental|CBT group|This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
16666644|NCT02172183|Active Comparator|Psychopharmacological treatment|Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
16666645|NCT02172170|Experimental|BI 10773 single rising dose|
16666646|NCT02172170|Placebo Comparator|Placebo|
16666647|NCT02172157|Experimental|BI 1744 CL i.v. (intravenous) infusion|
16666648|NCT02172157|Active Comparator|BI 1744 CL Oral solution|
16666649|NCT02172144|Experimental|BI 1744 CL|
16666650|NCT02172144|Placebo Comparator|Placebo|
16666651|NCT02172144|Active Comparator|Moxifloxacin (Avalox®)|
16666652|NCT02172131|Experimental|BI 1744 CL|Single rising dose of BI 1744 CL as intravenous (i.v.) infusion
16666653|NCT02172131|Placebo Comparator|Placebo|
16666654|NCT02172118|Experimental|severely renally impaired patients|
16666655|NCT02172118|Experimental|healthy volunteers|
16666656|NCT02172105|Experimental|BI 1744 CL|
16666657|NCT02172105|Placebo Comparator|Placebo|
16666658|NCT02172092|Experimental|Ketoacidosis|Patients treated for diabetic ketoacidosis at the Intensive care unit, Vrinnevi Hospital, Norrköping.
16666714|NCT02171728|Experimental|BIBW 2992|dose escalation
16666715|NCT02171715|Experimental|BIBW 2992 MA2, final formulation|
16666716|NCT02171715|Experimental|BIBW 2992 MA2, trial formulation II|
16666659|NCT02172079|Experimental|Real mobilization-with-movement (MWM)|For the MWM group, an accessory posterior-lateral gliding movement in the humeral head combined with a movement of active shoulder flexion will be applied. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior aspect of the head of the humerus
16666660|NCT02172079|Sham Comparator|Sham mobilization-with-movement (MWM)|The sham condition will replicate the treatment condition except for the hand positioning. The therapist locates one hand over the belly of the pectoralis major muscle and the other over scapula without applying any pressure. The patient will be asked to move the arm in a similar manner as in the MWM group
16666661|NCT02172066|Experimental|Narrative Exposure Therapy (NET)|During NET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for emotions, cognitions, sensory information, and physiological reactions to link the traumatic events to an autobiographical context, namely time and place. In total the Individuals receive 6 sessions of NET, every session lasting between 1,5 and 2 hr depending on the needs of the participant.
16666662|NCT02172066|No Intervention|No treatment control|
16666663|NCT02172053|Active Comparator|Compensatory Workplace Exercise (CWE)|Comparative Group will receive a light training protocol including warming up, stretching and resisted exercise using elastic bands.
16666664|NCT02172053|Experimental|Individual Resistance Exercise (IRE)|Intervention group will receive training protocol including warming up, stretching a specific resistance training with increase progressive load.
16666665|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
16666666|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
16666667|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
16666668|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
16666669|NCT02172027||Lung Cancer, Pleural effusion|
16666670|NCT02172014|Experimental|Fentanyl|midazolam and fentanyl citrate infusion
16666671|NCT02172014|Placebo Comparator|Control|midazolam and normal saline infusion
16666672|NCT02172001|Experimental|Iron isomaltoside 1000|Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
16666673|NCT02172001|Placebo Comparator|Placebo (NaCl 0,9%)|Sodium Chloride. Dose: 100 ml or 5 ml
16666674|NCT02171988|Active Comparator|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
16666675|NCT02171988|Active Comparator|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
16666676|NCT02171988|Active Comparator|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
16666677|NCT02171988|Active Comparator|Bisoprolol+pyridostgmine|start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
16666678|NCT02171975|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthetic.
16666679|NCT02171975|Experimental|Group P|This group had their spinal anaesthetic done based on pre-procedure ultrasound guided paramedian spinal
16666680|NCT02171962|Experimental|Zilver® PTX® VI|
16666681|NCT02171949|No Intervention|Control group|
16666682|NCT02171949|Active Comparator|Bone marrow mononuclear cell therapy|
16666683|NCT02171936||chronic pain|
16666684|NCT02171923||Remitted depressed patients|Formerly depressed patients in remission for 6 months or more
16666685|NCT02171923||healthy controls|healthy subjects with no history of mental disorders
16666686|NCT02171910|Active Comparator|Doxapram|Propofol sedation with a doxapram 1mg/kg i.v. bolus at induction and an i.v. infusion 1mg/kg/h) during the procedure
16666687|NCT02171910|Placebo Comparator|Placebo|Propofol sedation with a placebo i.v. bolus at induction and a placebo i.v. infusion during the procedure
16666688|NCT02171897|Experimental|Patients treated with osteosynthesis|
16666689|NCT02171897|Experimental|Patients treated with total hip replacement|
16666690|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
16666691|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
16666692|NCT02171884||Group T1|Singletons conceived naturally
16666693|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
16666694|NCT02171871|Experimental|CONTROL GROUP|"Healthy non-smoking volunteers (18-40 years old) will be subject, after giving their brief medical history, to IOS and to the nitrogen washout test. The IOS will be conducted in four positions (standing, sitting, right and left lateral decubitus), whereas the nitrogen washout test in two (sitting and decubitus).
~Then the subjects will be exposed to a smoking environment for 20 minutes."
16666695|NCT02171858||stroke|Patients admitted to hospital who are diagnosed with stroke will be treated as usually a our center by observation, venous or arterial thrombolysis depending on extension, condition, thrombolysis feasibility.
16666696|NCT02171845||Foetus|
16666697|NCT02171832|Experimental|Mildly liver impaired patients|
16666698|NCT02171832|Experimental|Moderately liver impaired patients|
16666699|NCT02171832|Experimental|Healthy volunteers|
16666700|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
16666701|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
16666702|NCT02171819|Placebo Comparator|Placebo|Phosphate buffered saline
16666703|NCT02171806|Experimental|BI 1744 CL multiple rising doses|
16666704|NCT02171806|Placebo Comparator|Placebo|
16666705|NCT02171806|Experimental|BI 1744 CL medium dose, females|
16666706|NCT02171793|Experimental|BI 1744 CL|
16666707|NCT02171793|Placebo Comparator|Placebo|
16666708|NCT02171780|Experimental|BI 1744 CL single rising doses|
16666726|NCT02171624|Experimental|dabigatran etexilate|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
16666727|NCT02171624|Experimental|quinidine|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
16666728|NCT02171611|Experimental|Dabigatran etexilate pellets|
16666729|NCT02171611|Experimental|Dabigatran etexilate powder|
16666730|NCT02171611|Active Comparator|Dabigatran etexilate capsule|
16666731|NCT02171598|Experimental|Fixed sequence 1|multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
16666732|NCT02171598|Experimental|Crossover|clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
16666733|NCT02171598|Experimental|Fixed sequence 2|intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
16666734|NCT02171585|Experimental|Dabigatran without Clarithromycin|
16666735|NCT02171585|Experimental|Dabigatran with Clarithromycin|
16666736|NCT02171572|Experimental|Dabigatran etexilate low|
16666737|NCT02171572|Experimental|Dabigatran etexilate high|
16666738|NCT02171559|Experimental|Dabigatran etexilate capsules after enoxaparin ampoules|
16666739|NCT02171559|Active Comparator|Dabigatran etexilate capsules without enoxaparin|
16666740|NCT02171546|Active Comparator|Dabigatran etexilate capsules|
16666741|NCT02171546|Experimental|Dabigatran etexilate capsules and quinidine sulfate tablets|
16666742|NCT02171546|Active Comparator|Fexofenadine tablets|
16666743|NCT02171546|Experimental|Fexofenadine and quinidine sulfate tablets|
16666744|NCT02171533|Experimental|Fixed sequence|Treatments will be given in a fixed sequence
16666745|NCT02171533|Experimental|Crossover|Treatments will be given in randomized sequences
16666746|NCT02171520|Experimental|Dabigatran etexilate generation I|
16666747|NCT02171520|Active Comparator|Dabigatran etexilate generation II|
16666748|NCT02171507|Active Comparator|Dabigatran etexilate|
16666749|NCT02171507|Active Comparator|Diclofenac|
16666750|NCT02171507|Experimental|Dabigatran etexilate + diclofenac|
16666751|NCT02171494|Experimental|IVAX warfarin|Treatment A: IVAX warfarin
16666752|NCT02171494|Active Comparator|BMS coumadin|Treatment B: BMS coumadin tablets
16666753|NCT02171481|Experimental|Dabigatran etexilate polymorph II|
16666754|NCT02171481|Active Comparator|Dabigatran etexilate polymorph I|
16666755|NCT02171468|Experimental|Dabigatran high dose|
16666756|NCT02171468|Experimental|Dabigatran low dose|
16666757|NCT02171455|Experimental|Dabigatran etexilate low dose|
16666758|NCT02171455|Experimental|Dabigatran etexilate medium dose|
16666759|NCT02171455|Experimental|Dabigatran etexilate high dose|
16666760|NCT02171442|Experimental|BIBR 953 ZW Intravenously|
16666761|NCT02171442|Active Comparator|BIBR 1048 Oral Solution|
16666762|NCT02171429|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
16666763|NCT02171429|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
16666764|NCT02171429|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
16666765|NCT02171416|Placebo Comparator|Placebo|Placebo s.c every 7 days
16666766|NCT02171416|Experimental|Rilonacept 160mg|Rilonacept s.c every 7 days
16666767|NCT02171403||Lactose intolerance|Patients with a positive lactose-breath test and complaints during the test
16666768|NCT02171403||Lactose malabsorption|Patients with a positive lactose-breath test and no complaints during the test
16666769|NCT02171403||Healthy controls|Subjects with a negative lactose-breath test
16666770|NCT02171390|Active Comparator|Daily testosterone transdermal gel|
16666771|NCT02171390|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
16666772|NCT02171377|Experimental|Group 2 : quadricipital electrical stimulation|stimulation in addition to rehabilitation (30 min bilateral quadricipital electrical stimulation pd, 5 days per week, 8 weeks)
16666773|NCT02171377|Active Comparator|Group 1 : Pulmonary rehabilitation|Pulmonary rehabilitation 3 to 5 times per week, 8 weeks
16666774|NCT02171364|Experimental|virtual simulation|This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape.
16666775|NCT02171364|Active Comparator|conventional ablation|The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation.
16666776|NCT02171351|Experimental|effect of neuromuscular electrostimulation (NMES)|
16666777|NCT02171351|Experimental|effect of neuro electrostimulation (NES)|
16666778|NCT02171351|Experimental|effect of voluntary contractions (VC)|
16666779|NCT02171338|Other|Antibiotic treatment based on PCT-level|"Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).
~With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started."
16666780|NCT02171338|No Intervention|Control|"Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.
~PCT-level will be measured but the treating doctor has no access to the result."
16666781|NCT02171325|Experimental|irinotecan|irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
16666782|NCT02171312||Concussion Cohort|Participants with possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
16666783|NCT02171312||Healthy Controls|Participants without possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
16666784|NCT02171299|Experimental|intervetional group (local anaesthetic)|intraoperative wound infiltration with ropivacaine 10%.
16666839|NCT02171000|Experimental|BIBR 1048|BIBR 1048 MS
16666785|NCT02171299|No Intervention|control (no local anesthetic)|no infiltration of the wound with local anaesthetic
16666786|NCT02171286||No Treatment|
16666787|NCT02171273|Experimental|Chronic circadian disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
16666788|NCT02171273|Experimental|Chronic sleep restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
16666789|NCT02171273|Active Comparator|Control (sleep extension)|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
16666790|NCT02171260|Experimental|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m^2.
16666791|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
16666792|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
16666793|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
16666794|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
16666795|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
16666796|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
16666797|NCT02171221|Experimental|Oral DFP-11207|DFP-11207: daily oral dosing, 28 day treatment cycle
16666798|NCT02171208|Active Comparator|Reference, Test, Reference (RTR)|Doses will be separated by a washout period
16666799|NCT02171208|Active Comparator|Test, Reference, Reference (TRR)|Doses will be separated by a washout period
16666800|NCT02171195|Experimental|Group 1 (20 mg)|
16666801|NCT02171195|Experimental|Group 2 (50 mg)|
16666802|NCT02171195|Experimental|Group 3 (100 mg)|
16666803|NCT02171195|Experimental|Group 4 (200 mg)|
16666804|NCT02171195|Experimental|Group 5 (400 mg)|
16666805|NCT02171195|Experimental|Group 6 (600 mg)|
16666806|NCT02171195|Experimental|Group 7 (900 mg)|
16666807|NCT02171195|Experimental|Group 8 (1200 mg)|
16666808|NCT02171182||Qutenza patients w/ post-operative peripheral neuropathic pain|
16666809|NCT02171169||Transsacral lumbar interbody fusion|
16666810|NCT02171169||Transforaminal lumbar interbody fusion|
16666811|NCT02171143|Experimental|ASP2409 Dose Escalation|
16666812|NCT02171143|Placebo Comparator|Placebo Dose Escalation|
16666813|NCT02171130|Experimental|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
16666814|NCT02171117|No Intervention|CT-group|standard induction and consolidation chemotherapy only, without microtransplantation
16666815|NCT02171117|Experimental|MST-group|standard induction and consolidation chemotherapy with microtransplantation
16666816|NCT02171104|Experimental|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical
~See intervention descriptions."
16666817|NCT02171104|Experimental|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical
~See intervention descriptions."
16666818|NCT02171104|Experimental|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)
~-Haplo-Identical Only
~See intervention descriptions."
16666819|NCT02171104|Experimental|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
16666820|NCT02171104|Experimental|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
16666821|NCT02171104|Experimental|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
16666822|NCT02171104|Experimental|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
16666823|NCT02171091||study arm|One tracheal sample will be obtained using sterile (5 ml) sterile saline solution using irrigation and wall suction from each patient every day for 72 hours, total sampling time is approximately 10 seconds per specimen. Lung samples or fiberoptic obtained samples will be collected at same time intervals as the tracheal samples when possible and if they are done as standard of care. Samples will not be collected for research only and the time for this procedure will not be extended to collect extra tissue. A blood sample (10ml) will be collected simultaneously with the airway samples and also will be used for baseline control measurements.
16666824|NCT02171078||Alliance for Clinical Trials Database|Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
16666825|NCT02171078||National Cancer Database|Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
16666826|NCT02171078||Stakeholder Engagement|Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.
16666827|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
16666828|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
16666829|NCT02171052|Experimental|Dabigatran etexilate plus digoxin|
16666830|NCT02171052|Active Comparator|Dabigatran etexilate|
16666831|NCT02171052|Active Comparator|Digoxin|
16666832|NCT02171039|Experimental|dabigatran plus atorvastatin|
16666833|NCT02171039|Active Comparator|dabigatran|
16666834|NCT02171039|Active Comparator|atorvastatin|
16666835|NCT02171026|Experimental|Dabigatran etexilate + Amiodarone|
16666836|NCT02171026|Active Comparator|Amiodarone|
16666837|NCT02171013|Experimental|Dabigatran etexilate batch A|
16666838|NCT02171013|Experimental|Dabigatran etexilate batch B|
16666840|NCT02170987|Experimental|Dabigatran etexilate low|
16666841|NCT02170987|Experimental|Dabigatran etexilate high|
16666842|NCT02170987|Placebo Comparator|Placebo to dabigatran etexilate|
16666843|NCT02170987|Active Comparator|Moxifloxacin|
16666844|NCT02170974|Experimental|BIBR 1048 MS polymorph II|
16666845|NCT02170974|Active Comparator|BIBR 1048 MS polymorph I|
16666846|NCT02170961||acute heart failure (AHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
16666847|NCT02170961||Non acute heart failure (NAHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
16666848|NCT02170948|Experimental|Dex 0.5|Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
16666849|NCT02170948|Experimental|Dex 1.0|Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline
16666850|NCT02170935|Experimental|BIBR 1048 capsule|
16666851|NCT02170922|Experimental|Sequence 1|BIBR 1048 MS tablet (fasted) - BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet after high fat meal
16666852|NCT02170922|Experimental|Sequence 2|BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet (fasted) - BIBR 1048 MS tablet after high fat meal
16666853|NCT02170909|Experimental|BIBR 1048 MS low dose|
16666854|NCT02170909|Experimental|BIBR 1048 MS medium dose|
16666855|NCT02170909|Experimental|BIBR 1048 MS high dose|
16666856|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule A+Pantoprazole|
16666857|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule B+Pantoprazole|
16666858|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule C+Pantoprazole|
16666859|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule D+Pantoprazole|
16666860|NCT02170896|Active Comparator|Period 1: BIBR1048 MS solution+Pantoprazole|
16666861|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule C|
16666862|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule D|
16666863|NCT02170896|Active Comparator|Period 2: BIBR1048 MS solution|
16666864|NCT02170883|Experimental|Interactive SMS|"Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement I follow my asthma medication plan and pharmacist follow-up"
16666865|NCT02170883|Active Comparator|Usual care|Pharmacist conducted patient education, counseling and action-plan
16666866|NCT02170870|Experimental|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
16666867|NCT02170870|Placebo Comparator|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
16666868|NCT02170870|Experimental|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
16666869|NCT02170870|Placebo Comparator|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
16666870|NCT02170870|Experimental|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
16666871|NCT02170870|Placebo Comparator|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
16666872|NCT02170857|No Intervention|Open Curettage Only|patients will be treated by the conventional surgical method, i.e. open curettage without injecting any material.
16666873|NCT02170857|Experimental|Open Curettage with Hyaluronic Acid|Hyaluronic Acid injection will be employed in conjunction with the ordinary surgical procedure.
16666874|NCT02170844|Experimental|BIBR 1048 MS (Japanese)|Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
16666875|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Japanese)|Japanese subjects will receive placebo of BIBR 1048 MS
16666876|NCT02170844|Experimental|BIBR 1048 MS (Caucasian)|Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
16666877|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Caucasian)|Japanese subjects will receive placebo of BIBR 1048 MS
16666878|NCT02170831|Experimental|BIBR 1048 MS low dose|
16666879|NCT02170831|Experimental|BIBR 1048 MS medium dose 1|
16666880|NCT02170831|Experimental|BIBR 1048 MS medium dose 2|
16666881|NCT02170831|Experimental|BIBR 1048 MS high dose|
16666882|NCT02170831|Placebo Comparator|BIBR 1048 Placebo|
16666883|NCT02170818|Experimental|Educational Workshop on Speaking-Up|Educational Workshop on Speaking-Up Before Simulated Case
16666884|NCT02170818|Sham Comparator|Unrelated Education|Unrelated Education (CPR) before simulated case (Educational Workshop on Speaking-up after case and debriefing)
16666885|NCT02170805|Experimental|Substudy 1|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence
~BIBR 1048 MS capsule formulation A without pantoprazole;
~BIBR 1048 MS capsule formulation A with coadministration of 40 mg pantoprazole (bid);
~BIBR 1048 MS powder plus solution without pantoprazole"
16666886|NCT02170805|Experimental|Substudy 2|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence
~BIBR 1048 MS capsule formulation B without pantoprazole;
~BIBR 1048 MS capsule formulation B with coadministration of 40 mg pantoprazole (bid);
~BIBR 1048 MS powder plus solution without pantoprazole"
16666887|NCT02170792|Experimental|BIBR 1048 MS with ranitidine|Low, medium or high dose in combination with ranitidine
16666888|NCT02170792|Experimental|BIBR 1048 MS without ranitidine|Low, medium or high dose
16666889|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
16666890|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
16666953|NCT02170337|Experimental|AMG 282|AMG 282 administered as subcutaneous and intravenous doses.
16666954|NCT02170337|Placebo Comparator|Placebo|No active drug
16666891|NCT02170766|Experimental|BIBR 1048 low1|"Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole
~BIBR 1048 12.5 mg without Pantoprazole
~BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)"
16666892|NCT02170766|Experimental|BIBR 1048 low2|"Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole
~BIBR 1048 25 mg without Pantoprazole
~BIBR 1048 25 mg with 40 mg Pantoprazole (bid)"
16666893|NCT02170766|Experimental|BIBR 1048 medium|"Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole
~BIBR 1048 50 mg without Pantoprazole
~BIBR 1048 50 mg with 40 mg Pantoprazole (bid)"
16666894|NCT02170766|Experimental|BIBR 1048 high|"Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole
~BIBR 1048 100 mg without Pantoprazole
~BIBR 1048 100 mg with 40 mg Pantoprazole (bid)"
16666895|NCT02170753|Experimental|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy
16666896|NCT02170753|Active Comparator|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
16666897|NCT02170740|Experimental|BIBR 1048 MS|
16666898|NCT02170740|Experimental|BIBR 1048 MS + Pantoprazole|
16666899|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
16666900|NCT02170714||ASC|Consecutive children hospitalized for an episode of acute ASC, defined as a PUCAI > 65. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms. A follow-up of 2 years for the colectomy risk was evaluated for all patients.
16666901|NCT02170701|Experimental|BIBR 1048|Ascending doses (in mg) given twice daily
16666902|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
16666903|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
16666904|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.
~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
16666905|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.
~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
16666906|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
16666907|NCT02170675|Experimental|Dabigatran etexilate + Ketoconazole|"Period 1 - Dabigatran etexilate
~Period 2 - Dabigatran etexilate and single dose of 400 mg Ketoconazole on Day 8 and 9
~Period 3 - Dabigatran etexilate and multiple doses of 400 mg Ketoconazole on Day 10 to 16"
16666908|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
16666909|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
16666910|NCT02170649|Experimental|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
16666911|NCT02170636|Experimental|Period 1: BIBR 1048 MS + Pantoprazole|"Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence.
~BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole"
16666912|NCT02170636|Experimental|Period 2: BIBR 1048 MS|"Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).
~BIBR 1048 MS Capsule E without pantoprazole;
~BIBR 1048 MS Tablet H without pantoprazole;
~BIBR 1048 MS Drinking solution without pantoprazole"
16666913|NCT02170623|Experimental|Period 1: BIBR 1048 MS with Pantoprazole|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.
~BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);
~BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);
~BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)"
16667188|NCT02168920|Placebo Comparator|Placebo|
16666914|NCT02170623|Experimental|Period 2: BIBR 1048 MS|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.
~BIBR 1048 MS Capsule K (bid for 3 days);
~BIBR 1048 MS Drinking solution (bid for 3 days)"
16666915|NCT02170610|Experimental|BIBR 1048 MS capsule|
16666916|NCT02170610|Experimental|BIBR 1048 capsule with pantoprazole|
16666917|NCT02170610|Experimental|BIBR 1048 capsule with food|
16666918|NCT02170597|Experimental|BIBR 1018 MS HPMC capsule fasted|
16666919|NCT02170597|Experimental|BIBR 1048 MS HPMC capsule after high fat meal|
16666920|NCT02170597|Active Comparator|BIBR 1048 MS gelatine capsule fasted|
16666921|NCT02170584|Experimental|BIBR 953 ZW IV|
16666922|NCT02170584|Active Comparator|BIBR 1048 MS oral solution|
16666923|NCT02170584|Experimental|BIBR 1048 MS tablet|
16666924|NCT02170584|Placebo Comparator|BIBR 953 ZW IV Placebo|
16666925|NCT02170571|Experimental|Dabigatran etexilate|
16666926|NCT02170558||Patients implanted w/TM-Ardis|Patients who are receiving a TM-Ardis implant for degenerative disc disease will have a CT scan immediate post op (2 weeks) and again at 6 months to determine if fusion can be assessed with the study metal reduction software. Will utilize TM- Ardis implant and Metal Reduction CT software
16666927|NCT02170545||Multi-Part Proximal Humerus Fracture|All participants that meet the entry criteria will be included in the study cohort.
16666928|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
16666929|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
16666930|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
16666931|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
16666932|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
16666933|NCT02170519|Experimental|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.
~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
16666934|NCT02170519|Experimental|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.
~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
16666935|NCT02170506|Experimental|submental sensitive transcutaneous electrical stimulation.|Each Healthy subjects will be his own witness. Urostim 2 stimulation Arm
16666936|NCT02170467|Experimental|Control|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in controls and camparison with pateints with anorexia nervosa.
16666937|NCT02170467|Experimental|patients with anorexia nervosa|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in patients with anorexia nervosa before and after re-feeding.
16666938|NCT02170454|Active Comparator|rTMS|rTMS on pharyngeal cortical area in healthy subjects
16666939|NCT02170454|Placebo Comparator|Placebo|Sham rTMS on pharyngeal cortical area in healthy subjects
16666940|NCT02170441||Patients at risk for drug-resistant TB|No intervention
16666941|NCT02170428||growth and development|Growth and development of a random sample of healthy Danish infants
16666942|NCT02170415|Active Comparator|Intervention limb|"Medical review and analgesic optimisation.
~Pain education (in the form of leaflet and website recommendations)
~Psychological input for patients with evidence of psychological morbidity.
~Protective analgesia - one pre-procedure dose of 150mg oral pregabalin.
~Five days post-procedure oral pregablin twice daily at a dose of 75mg twice a day.
~Patients offered a paravertebral block, local anaesthetic infiltrated around the wound by the surgeon.
~Daily, focused visits from the hospital pain team.
~Any patient displaying concerning pain symptoms, behaviour or who underwent prolonged (>3 hours surgery) may be booked for early 'preemptive' review in pain clinic."
16666943|NCT02170415|No Intervention|Usual care|These partcipants will receive usual care before, during and after their breast surgery
16666944|NCT02170402|Experimental|Previously Treated Patients (PTPs)|"PTPs will participate sequentially with:
~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:
~12 adults (>12 years of age)
~12 children (≤12 years of age)
~Part 2: On-demand treatment with ADVATE for 6 months
~Part 3: Prophylaxis regimen with ADVATE for 6 months"
16666945|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
16666946|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
16666947|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
16666948|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
16666949|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
16666950|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
16666951|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
16666952|NCT02170350|Experimental|Brief mindful meditation practice|Patients use brief mindful meditation practice (sitting meditation in which the mind is guided to focus in the present, thinking of your existence, and allowing sensations to arise with an openness and curiosity) over 12 minutes daily for 14 days during radiation therapy.
16666955|NCT02170324|Experimental|GLP-1 agonism group|Exenatide injection 10 ug twice daily for 10 days subcutaneously.
16666956|NCT02170324|Placebo Comparator|Placebo group|0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
16666957|NCT02170311|Experimental|Z-213 100mg|Group/Cohort Label: 100 mg iron Z-213 will be administered by intravenous infusion.
16666958|NCT02170311|Experimental|Z-213 500mg|Group/Cohort Label: 500 mg iron Z-213 will be administered by intravenous infusion.
16666959|NCT02170311|Experimental|Z-213 800mg|Group/Cohort Label: 800 mg iron Z-213 will be administered by intravenous infusion.
16666960|NCT02170311|Experimental|Z-213 1000mg|Group/Cohort Label: 1000 mg iron Z-213 will be administered by intravenous infusion.
16666961|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.
~Drug: Placebo"
16666962|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.
~Drug: Lisdexamfetamine"
16666963|NCT02170285|Experimental|Interventional tDCS|The primary intervention will be cathodal (inhibitory) tDCS (see below).
16666964|NCT02170285|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
16666965|NCT02170272|Experimental|Home-based Lymphedema Care Program|Home-based Lymphedema Care Program (HBLCP): Participants will undergo one training session with a lymphedema therapist, and then receive a self-care video and educational manual to review at home. After completion of training session, follow-up measures occur at 1, 2, and 3 months.
16666966|NCT02170259|Experimental|suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region.
16666967|NCT02170259|Experimental|The articulatory technique|- The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases.
16666968|NCT02170259|Experimental|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT.
16666969|NCT02170259|No Intervention|Control group|Control group. The control group was not applied a treatment technique
16666970|NCT02170246|No Intervention|Antiretroviral Therapy (ART) only|Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
16666971|NCT02170246|Experimental|ART + Telmisartan|Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).
16666972|NCT02170233||Sepsis|This group will contain patients meeting criteria for sepsis for enrollment in the study (target population).
16666973|NCT02170233||Normals|This group will be healthy patients who will have data points recorded for controls for the study to assess the reliability of these measures on healthy patients.
16666974|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
16666975|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
16666976|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
16666977|NCT02170194|Experimental|Resilience Enhancement Group|The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
16666978|NCT02170194|Placebo Comparator|Control Group|"The control group will be provided with an initial informational session providing them with details of where they can get help if they have worsened symptoms over time. In addition, the psychologist will briefly review the apps, but not provide the same pscyhoeducational detail given to the resilience enhancement group. They will receive daily texts with inspirational aphorisms (e.g., Early to bed and early to rise makes a man healthy, wealthy, and wise.) for 6 weeks."
16666979|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
16666980|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
16666981|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
16666982|NCT02170181||RE-IRRADIATION ARM|
16666983|NCT02170168||Orkdal region patients|cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
16666984|NCT02170168||Romsdal county patients|control palliative care cancer patients in standard care, i.e. a local hospital in the county of Møre and Romsdal, Molde Hospital, and nine districts
16667510|NCT02166684|Experimental|Do-it-yourself devices|All subjects will use do-it-yourself devices for self-monitoring health parameters
16666985|NCT02170168||Orkdal region carers|carers of cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
16666986|NCT02170168||Romsdal county carers|carers of cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
16666987|NCT02170168||Orkdal region health care providers|Health care providers for cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
16666988|NCT02170168||Romsdal county health care providers|Health care providers for cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
16666989|NCT02170155||Patients with CSM|
16666990|NCT02170155||Patients with spinal injury (SCI)|
16666991|NCT02170155||Healthy controls|
16666992|NCT02170142||No treatment|All subjects studied are normal healthy neonates without a condition. MRI will be used to assess normal brain development.
16666993|NCT02170129|Active Comparator|100% AAB|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 100% AAB (Bio-Oss) followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
16666994|NCT02170129|Active Comparator|50% AAB plus 50% autologous bone|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 50% AAB (Bio-Oss) plus 50% autologous bone harvested locally with a bone scraper followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
16666995|NCT02170116|Experimental|BIBR 1048 MS dose 1|
16666996|NCT02170116|Experimental|BIBR 1048 MS dose 2|
16666997|NCT02170116|Experimental|BIBR 1048 MS dose 3|
16666998|NCT02170116|Experimental|BIBR 1048 MS dose 4|
16666999|NCT02170116|Experimental|BIBR 1048 MS dose 5|
16667000|NCT02170116|Placebo Comparator|Placebo|
16667001|NCT02170103|Experimental|Ultrasound and microbubbles|Patients who provide emergent consent will be randomized to either conventional therapy for a heart attack, or conventional therapy and ultrasound with microbubbles. The ultrasound will be applied both before and after emergent heart catheterization, in order to break up the blood clots that are not only in the artery supplying the heart muscle, but also in the small branches (capillaries) that are fed by this artery.
16667002|NCT02170103|Other|Standard of care|Emergent PCI/antithrombotic/antiplatelet therapy with Echocardiogram to assess LVEF (Left Ventricular Ejection Fraction) and Aspirin, Plavix, or Direct Thrombin Inhibitor.
16667003|NCT02170090|Experimental|Gemcitabine plus Cisplatin|"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles)
~and Observation
~Second randomisation for R1 resected patients: 8 cycles Cisplatin and Gemcitabin or 6 cycles Cisplatin and Gemcitabin followed by IMRT with capecitabine"
16667004|NCT02170090|Active Comparator|Capecitabine|"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles)
~and Observation
~Second randomisation for R1 resected patients: 8 cycles capecitabine or 6 cycles capecitabine followed by IMRT with capecitabine"
16667005|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
16667006|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
16667007|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
16667008|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
16667009|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
16667066|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
16667010|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
16667011|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
16667012|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
16667013|NCT02170038|Experimental|Arm 1|Healthy premenopausal subjects will receive multiple oral doses of Microgynon for 21days
16667014|NCT02170038|Experimental|Arm 2|Healthy premenopausal subjects will receive a single intramuscular dose of Noristerat
16667015|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
16667016|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
16667017|NCT02170012|Experimental|Cohort 1-PF-06743649 or placebo|
16667018|NCT02170012|Experimental|Cohort 2-PF-06743649 or placebo|
16667019|NCT02170012|Experimental|Cohort 3-PF-06743649 or placebo|
16667020|NCT02170012|Experimental|Cohort 4-PF-06743649 or placebo|
16667021|NCT02170012|Experimental|Cohort 5-PF-06743649 or placebo|
16667022|NCT02169999|Experimental|Personalized Diabetes Care Website|Subjects are exposed to Personalized Diabetes Care website.
16667023|NCT02169999|No Intervention|No Exposure To Website|Subjects are not exposed to Personalized Diabetes Care website
16667024|NCT02169986|No Intervention|control group|Parents/caregivers will receive the standard of care.
16667025|NCT02169986|Experimental|electronic reminders|In this group, the parents/caregivers will receive two daily electronic reminders in addition to the standard of care.
16667026|NCT02169973|Experimental|Part A|3 to 5 participants will undergo Positron Emission Tomography (PET)/computed tomography scan after administration of 11C-MK-3168 on Day 1.
16667027|NCT02169973|Experimental|Part B|3 to 12 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive 2 single doses of JNJ-42165279: 100 mg on Days 1 and up to 250 mg on Day 8. Participants will undergo PET scans after 1 hour of each administration of JNJ-42165279 on Days 1 and 8, with 11C-MK-3168 administration.
16667028|NCT02169973|Experimental|Part C|4 to 8 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive once daily dose of JNJ-42165279 (up to 100 mg) from Day 1 to Day 7. Participants will undergo PET scans after 24 hour of administration of JNJ-42165279 on Days 1 and 7, with 11C-MK-3168 administration.
16667029|NCT02169960|Active Comparator|Middle School, General|OVK Resiliency Training Program - Cognitive Behavioral Therapy designed to modify negative thoughts and feelings. This program also includes a social problem-solving component.
16667030|NCT02169960|No Intervention|High School, General|No intervention - no Resiliency training, no online intervention for high school students who do not score at risk for development of mental health issues
16667031|NCT02169960|Active Comparator|Middle School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues. OVK Resiliency Training is also provided.
16667032|NCT02169960|Active Comparator|High School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues.
16667033|NCT02169947|Active Comparator|Weight loss core|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program.
16667034|NCT02169947|Experimental|Weight loss core plus maintenance|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program PLUS 12 maintenance sessions.
16667035|NCT02169934|Experimental|Radiolabeled TRV130|
16667036|NCT02169921|Experimental|TurboHawk|This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk
16667037|NCT02169908|Other|Occurrence of painful neuropathy|Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.
16667038|NCT02169895|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~Every period with concomitant single oral administration of Prolopa® 100-25"
16667039|NCT02169895|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~Every period with concomitant single oral administration of Prolopa® 100-25"
16667040|NCT02169895|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~Every period with concomitant single oral administration of Prolopa® 100-25"
16667041|NCT02169895|Active Comparator|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~Every period with concomitant single oral administration of Prolopa® 100-25"
16667042|NCT02169882|Active Comparator|Rifampicin 450 mg (standard dose)|"Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).
~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.
~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
16667185|NCT02168920|Experimental|Aripiprazole, 2 mg/day|
16667043|NCT02169882|Experimental|Rifampicin 900 mg per oral|"Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.
~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
16667044|NCT02169882|Experimental|Rifampicin 1350 mg per oral|"Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.
~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
16667045|NCT02169869|Experimental|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
16667046|NCT02169869|Active Comparator|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
16667047|NCT02169856|Other|control group|"control group was not given any EFTs (emotional freedom techniques) therapy for postoperative nausea and vomiting.
~Following medications were given to both groups. details are in respective interventions.
~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
16667048|NCT02169856|Experimental|EFTs study group|"EFTs (emotional freedom techniques) was applied to the patietns. one session of 5 to 10 min at 6 hours postoperatively.
~Following medications were given to both groups. details are in respective interventions.
~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
16667049|NCT02169843|Experimental|Sevoflurane & Dexmedetomidine|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Dexmedetomidine 0.2µg/kg/h.
16667050|NCT02169843|Active Comparator|Sevoflurane & Placebo|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Placebo(for Dexmedetomidine )0.05ml/kg/h.
16667051|NCT02169830|Active Comparator|nortriptyline|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
16667052|NCT02169830|Active Comparator|topiramate|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
16667053|NCT02169830|Other|diet modification|Participants will begin with diet modification for four (4) weeks.
16667054|NCT02169817|Experimental|Enterogermina + Enterolyte|2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation
16667055|NCT02169804|Experimental|70 years or older|Non-smoking healthy adult males >or equal to 70 years of age.
16667056|NCT02169804|Experimental|Under 60 years of age|Non-smoking healthy adult males<60 years of age.
16667057|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
16667058|NCT02169778|Experimental|Intermittent energy restricted diet|The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
16667059|NCT02169778|Experimental|Continuous energy restricted diet|The continuous energy restricted group will be prescribed a low calorie diet (LCD) with 33% energy restriction, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. The diets' macronutrient composition of the two groups will be matched (50% carbohydrates, 20% protein and 30% fat).
16667060|NCT02169765|Active Comparator|Hepatic resection|Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
16667061|NCT02169765|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
16667062|NCT02169752|Active Comparator|Ambrisentan|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
16667063|NCT02169752|Placebo Comparator|Placebo|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
16667064|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
16667065|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
16667186|NCT02168920|Experimental|Aripiprazole, 3 mg/day|
16667187|NCT02168920|Experimental|Aripiprazole, 6 mg/day|
16667067|NCT02169713|Experimental|Treatment Sequence 1|Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
16667068|NCT02169713|Experimental|Treatment Sequence 2|Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
16667069|NCT02169700|Experimental|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling.
16667070|NCT02169700|Sham Comparator|Sham Ischemic compression. Dry Needling|Sham Ischemic compression was carried out after dry needling.
16667071|NCT02169700|No Intervention|Control group|No intervention. Control group
16667072|NCT02169687|Experimental|Hifu|
16667073|NCT02169674|Active Comparator|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
16667074|NCT02169674|Active Comparator|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
16667075|NCT02169661|Experimental|Burger and Beetroot Study|
16667076|NCT02169648|Experimental|ranibizumab|Experimental: Intravitreal injection of Ranibizumab
16667077|NCT02169635|Experimental|Macula buckle|Macular buckle: perform episcleral macular buckle surgery using a three-armed silicone capsule to support the posterior staphyloma in high myopia.
16667078|NCT02169609|Experimental|Dinutuximab. Immunotherapy|"Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours.
~Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward).
~Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if < 12kg) PO divided into 2 doses daily x 14 days.
~Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3"
16667079|NCT02169596|Other|Coronary Artery Disease|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
16667080|NCT02169596|Other|Healthy Normals|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
16667081|NCT02169583|Experimental|Part A (Cohort 1)|Approximately 8 subjects (6 Active, 2 Placebo) will be randomized to receive single escalating IV doses i.e.10 milligrams (mg), 25 mg and 100 mg, plus one oral 100 mg dose (on the last occasion) of GSK1325756 or matching placebo, with a 7-days washout between doses. Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 100 mg. Additional subjects/Cohorts may be enrolled.
16667082|NCT02169583|Experimental|Part B (Cohorts 2 and 3)|Approximately 8 subjects (6 Active, 2 Placebo) per cohort will be randomized to receive escalating repeated IV doses of GSK1325756 or matching placebo (Cohort 2: 25 mg, Cohort 3: 50 mg) for 5 days. Repeated (BID) doses of GSK1325756 will begin the morning of Day 1 and continue through the morning of Day 5 (9 total doses). Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 50 mg BID. Additional subjects/Cohorts may be enrolled.
16667083|NCT02169570|Active Comparator|Vitamin D|Vitamin D supplementation Anti Tuberculosis Treatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks and color and taste matched placebo for calcium for 3 months
16667084|NCT02169570|Placebo Comparator|Placebo|Anti Tuberculosis Treatment with placebo color matched for vitamin D and color and taste matched placebo for calcium
16667085|NCT02169570|Experimental|Vitamin D and Calcium|Vitamin D and Calcium supplementation Anti TuberculosisTreatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks with daily 1000 mg calcium carbonate for 3 months
16667086|NCT02169557|Experimental|Fexinidazole|
16667087|NCT02169544||RA patients who are prescribed Abatacept|Abatacept
16667088|NCT02169544||Patients who are prescribed other RA treatments|
16667089|NCT02169531|Experimental|ex vivo activated immune cells|Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
16667090|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
16667091|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
16667092|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).
~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
16667093|NCT02169479|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
16667094|NCT02169479|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
16667095|NCT02169479|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
16667096|NCT02169479|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
16667097|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
16667098|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
16667099|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
16667100|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
16667101|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
16667102|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
16667103|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
16667104|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
16667105|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
16667106|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
16667107|NCT02169427|Experimental|Opicapone (OPC)|100 mg OPC
16667108|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
16667109|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
16667110|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
16667111|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
16667112|NCT02169401||Treated subjects|All subjects recruited and treated with the Axium Neurostimulator
16667113|NCT02169388|Experimental|Probiotic|Microbial composition using Probiotic，3 capsules / times, 2 times / day for 4 weeks
16667114|NCT02169388|Placebo Comparator|placebo|Microbiota modulation using placebo，3 capsules / times, 2 times / day for 4 weeks
16667115|NCT02169375|Experimental|Mu Rhythm with adaptation|
16667116|NCT02169375|Experimental|Mu Rhythm without adaptation|
16667117|NCT02169362|Experimental|Platelet Rich Plasma - Bio-Bandage™|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
16667118|NCT02169362|Sham Comparator|Saline Spray, Standard of Care|
16667119|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
16667120|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
16667121|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
16667122|NCT02169323|Experimental|Step-down|Step-down of the inhaled corticosteroid (ICS) dose
16667125|NCT02169297|Experimental|Ultrasound-Guided Sub-Paraspinal Block|Patients allocated to the treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location and an intravenous PCA post-operatively
16667126|NCT02169297|Placebo Comparator|PCA only|Patients allocated to the control group had two sham multi-perforated soaker catheters taped to their back and received intravenous PCA post-operatively
16667127|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
16667128|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
16667129|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
16667130|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
16667131|NCT02169258|Placebo Comparator|Selective Strategy|non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia
16667132|NCT02169258|No Intervention|Registry|Clinical decisions are reached by consensus of operators, patients and family as usual care
16667133|NCT02169258|Active Comparator|Systemic Strategy|Routine coronary angiography before PTA without a previous non-invasive stress test
16667134|NCT02169245|Experimental|Average Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and fiber for this age group for 2 weeks.
16667135|NCT02169245|Experimental|Average Protein and High Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and higher than average amount of fiber for this age group for 2 weeks.
16667136|NCT02169245|Experimental|High Protein and Average Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of fiber and higher than average amount of protein for this age group for 2 weeks.
16667137|NCT02169245|Experimental|Higher Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with a higher than average amount of protein and fiber for this age group for 2 weeks.
16667138|NCT02169232|Active Comparator|Videolaryngoscope|Intubation by videolaryngoscope
16667139|NCT02169232|Active Comparator|Fiberoptic|Intubation by fibroscope
16667140|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
16667141|NCT02169206|Other|shoulder radiography|Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
16667142|NCT02169193|Experimental|99mTc-Rhenium Sulfide Nanocolloid|99mTc-Rhenium Sulfide Nanocolloid
16667143|NCT02169180|Experimental|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
16667144|NCT02169167|Experimental|Resin salve treatment|The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
16667145|NCT02169167|Active Comparator|Octenidine treatment|Octenidine treatment is implemented with the similar manner as resin salve treatment by using sterile gauze that is impregnated with the octenidine dihydrochloride.
16667146|NCT02169154|Experimental|Diclofenac Sodium/Menthol Gel|1% diclofenac sodium + 3% menthol
16667147|NCT02169154|Active Comparator|Diclofenac Gel|1% diclofenac sodium + 0.09% menthol
16667148|NCT02169154|Active Comparator|Menthol Gel|3% menthol
16667149|NCT02169154|Placebo Comparator|Placebo Gel|0.09% menthol
16667150|NCT02169154|Active Comparator|Voltaren Gel|1% diclofenac sodium
16667151|NCT02169154|Placebo Comparator|Sodium lauryl sulfate|0.2% Sodium lauryl sulfate
16667152|NCT02169154|Placebo Comparator|Saline|0.9% saline
16667153|NCT02169141||PK of Levofloxacin-Capreomycin|Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
16667154|NCT02169128||Patients and their significant others|Patients affected by necrotizing fasciitis and their significant others
16667155|NCT02169115|Experimental|Omalizumab 150mg|
16667156|NCT02169115|Experimental|Omalizumab 300mg|
16667157|NCT02169115|Placebo Comparator|Placebo|
16667158|NCT02169102|Other|Control|
16667159|NCT02169102|Sham Comparator|Sham Laser|
16667160|NCT02169102|Experimental|Laser 1|Low Power Laser applied at 0.16 Joules/point. 2 points of laser irradiation
16667161|NCT02169102|Experimental|Laser 2|Low Power Laser applied at 16 Joules/point. 2 points of laser irradiation
16667162|NCT02169089|Experimental|Spironolactone|Spironolactone
16667163|NCT02169089|Placebo Comparator|Placebo|Placebo
16667164|NCT02169076|Active Comparator|CRT-On|Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device
16667165|NCT02169076|Sham Comparator|CRT-Off|Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device
16667166|NCT02169063|Experimental|Diagnostic (11C-acetate, 18F-fluoride, PET)|Patients receive carbon-11 acetate IV and fluorine F 18 sodium fluoride IV over 1 minute and undergo PET at baseline and at 6-12 weeks after systemic therapy starts.
16667167|NCT02169050||No intervention|There is no intervention to subjects in this study. All subjects are morbidly women seeking bariatric surgeries.
16667168|NCT02169037|Experimental|FIRM ablation|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM) alone.
16667169|NCT02169037|Active Comparator|Conventional AF ablation with PVI|These patients will treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
16667170|NCT02169024|Experimental|Expect With Me group prenatal care|receiving prenatal care through an Expect With Me group
16667171|NCT02169024|Active Comparator|Individual Care Only|Standard of Care- individual prenatal care
16667172|NCT02169011|Active Comparator|Latissimus Dorsi Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the Latissimus Dorsi flap and if needed an implant.
16667173|NCT02169011|Active Comparator|TAP Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the TAP-flap and if needed an implant in combination with an acellular dermal matrix.
16667174|NCT02168998|No Intervention|No clown|Routine venipuncture without distraction
16667175|NCT02168998|Active Comparator|Clown|A medical clown is present in the procedure room during venipuncture
16667176|NCT02168985|Experimental|Attend TFH Program|Couples attend the three-day Faithful House Training program immediately
16667177|NCT02168985|No Intervention|Wait-listed for TFH Program|Couples attend The Faithful House program three-months after the initial group
16667178|NCT02168972|Experimental|Global mapping and ablation device|
16667179|NCT02168959|Active Comparator|Femoral nerve block|bupivacaine
16667180|NCT02168959|No Intervention|No femoral nerve block|No block
16667181|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
16667182|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
16667183|NCT02168933|Experimental|active excimer laser|308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.
16667184|NCT02168933|Sham Comparator|Sham excimer laser|Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.
16667189|NCT02168907|Experimental|Treatment (CPI-613, bendamustine hydrochloride, rituximab)|Patients receive 6,8-bis(benzylthio)octanoic acid intravenously IV over 2 hours on days 1-4 (week 1) and days 1 and 4 (weeks 2 and 3). Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 and rituximab on day 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16667190|NCT02168894|Experimental|Group 1 - Acupuncture With Electrical Stimulation|Participants in Group 1 have acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
16667191|NCT02168894|Experimental|Group 2 - Acupuncture Sessions Without Electrical Stimulation|Participants in Group 2 have acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
16667192|NCT02168894|Active Comparator|Group 3 - Waitlist Group|Participants in Group 3 have acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
16667193|NCT02168881|Active Comparator|misoprostol|oral misoprostol in solution 25 microgram every 2 hours
16667194|NCT02168881|Active Comparator|dinoprostone|3 mgs dinoprostone vaginally every six hours
16667195|NCT02168868||Control Group of Children|2-12 years old age & sex-matched controls (age-matched within ±12 months) - typically developing (TD) children and their mothers.
16667196|NCT02168868||Children-Autism Spectrum Disorder|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00), and their mothers. 4:1 case:control ratio.
16667197|NCT02168855|Active Comparator|Active nicotine gum|
16667198|NCT02168855|Placebo Comparator|Inactive gum|
16667199|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
16667200|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
16667201|NCT02168829|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg daily
16667202|NCT02168829|Active Comparator|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
16667203|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
16667204|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
16667205|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
16667206|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
16667207|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
16667208|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
16667209|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
16667210|NCT02168790|Experimental|Amniotic membrane ring|Application of amniotic membrane device for 6-7 days.
16667211|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
16667212|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
16667213|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
16667214|NCT02168764|Experimental|Treatment|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
16667215|NCT02168764|Active Comparator|Control|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
16667216|NCT02168751|Active Comparator|propofol|propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
16667217|NCT02168751|Experimental|sevoflurane|Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
16667218|NCT02168738|Active Comparator|13-C labeled PC-DHA|
16667219|NCT02168738|Active Comparator|13-C labeled TG-DHA|
16667220|NCT02168738|Experimental|13-C labeled AceDoPC-DHA|
16667262|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
16667511|NCT02166671|Experimental|HBV booster vaccination|
16667221|NCT02168725|Experimental|briciclib|The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.
16667222|NCT02168712|Active Comparator|Moderate continuous exercise training|Moderate intensity continuous exercise training
16667223|NCT02168712|Experimental|Interval exercise training|High intensity interval exercise training
16667224|NCT02168699|Other|Ultrasound examination|Ultrasound examination of the axillary region in children
16667225|NCT02168686|Experimental|Part A: Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
16667226|NCT02168686|Experimental|Part A: Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
16667227|NCT02168686|Experimental|Part A: Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
16667228|NCT02168686|Experimental|Part A: Dose 4|ADVM-043 administered at a dose that will be determined
16667229|NCT02168686|Experimental|Part B (optional): Intrapleural administration|ADVM-043 administered intrapleurally at a dose that will be determined
16667230|NCT02168673||Group 1|Healthy non-smokers
16667231|NCT02168673||Group 2|Healthy non-smokers
16667232|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
16667233|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
16667234|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
16667235|NCT02168647|Experimental|Behavioral Lifestyle counseling|Intervention group participants will take part in behavioral lifestyle counseling provided by a Registered Dietitian Nutritionist from week 14 of gestation through childbirth.
16667236|NCT02168647|Active Comparator|Control|Participants in the control arm will receive no form of lifestyle intervention.
16667237|NCT02168634|Experimental|Botulinum toxin|5U Botulinum toxin in 1cc normal saline, administered in one of the two itchy points
16667238|NCT02168634|Placebo Comparator|Normal Saline|1cc normal saline, administered in the other itchy point
16667239|NCT02168621|Active Comparator|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
16667240|NCT02168621|Active Comparator|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval. Follow-up 2-4 weeks after the last session of SRP for oral hygiene control and re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
16667241|NCT02168608|Experimental|Remote ischemia precondition|patients in this arm accepted RIPC procedure after induction of anesthesia
16667242|NCT02168608|Experimental|None remote ischemia precondition|patients in this arm didn't accept RIPC procedure after induction of anesthesia
16667243|NCT02168595|Experimental|Cohort 1|2 mg/kg GMI-1271 or matching placebo
16667244|NCT02168595|Experimental|Cohort 2|5 mg/kg GMI-1271 or matching placebo
16667245|NCT02168595|Experimental|Cohort 3|10 mg/kg GMI-1271 or matching placebo
16667246|NCT02168582||low back pain|
16667247|NCT02168569|Active Comparator|Cohort 1|5 sites, namely Manhiça, Dondo, Montepuez, Tete and Chokwe
16667248|NCT02168569|Active Comparator|Cohort 2|3 sites, namely Montepuez, Dondo and Chokwe
16667249|NCT02168556|Placebo Comparator|Standard of Care|Patient underwent urodynamic testing by receiving only standard of care with mailed information and during test teaching.
16667250|NCT02168556|Active Comparator|Music|Patient underwent urodynamic testing while listening to music that was 60 beats per minute and received standard of care information and teaching.
16667251|NCT02168556|Active Comparator|Video|Patient watched an informational video prior to urodynamic testing.
16667252|NCT02168543|Experimental|Alendronate|1% Alendronate gel once in periodontal pocket (Gums)
16667253|NCT02168543|Placebo Comparator|Placebo|Placebo gel once in periodontal pocket (Gums)
16667254|NCT02168530|Placebo Comparator|Placebo|
16667255|NCT02168530|Experimental|Vismodegib|
16667256|NCT02168517||Group I|Overweight osteoarthritis patients
16667257|NCT02168517||Group II|Normal weight osteoarthritis patients.
16667258|NCT02168517||Group III|Overweight healthy men.
16667259|NCT02168517||Group IV|Normal weight healthy men.
16667260|NCT02168504||Healthy controls|Healthy male and female subjects older than 18 years of age without the symptoms of Parkinson's disease. The ages of subjects in this group will be matching to the ages of subjects in Parkinson's disease group
16667261|NCT02168504||Parkinson's disease patients|male and female subjects older than 18 years of age at the early stage the disease
16667409|NCT02167412||Syncope without POTS|Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
16667263|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.
~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
16667264|NCT02168465|Other|teaching self-management of intermittent catheter|Single group pre-post test of feasibility, teaching self-management
16667265|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
16667266|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
16667267|NCT02168426|Active Comparator|Guardix|6g per body
16667268|NCT02168426|Active Comparator|Seprafilm|1 sheet per body
16667269|NCT02168400|Experimental|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
16667270|NCT02168400|Sham Comparator|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
16667271|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
16667272|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
16667273|NCT02168374|Experimental|Chlorhexidine - CHX|Deciduous teeth were filled with GIC containing 1.25% chlorhexidine.
16667274|NCT02168374|Experimental|Doxycycline - DOX|Deciduous teeth were filled with GIC containing 4.5% doxycycline.
16667275|NCT02168374|Placebo Comparator|Glass ionomer cement - GIC|Deciduous teeth were filled with GIC without chlorhexidine or doxycycline.
16667276|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
16667277|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
16667278|NCT02168348||Diabetic patients with a lesion on the foot|
16667279|NCT02168335|Experimental|Treatment group|"OrasaltsTM
~1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
16667280|NCT02168335|Placebo Comparator|Control group|"Sea salt
~1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
16667281|NCT02168322|Experimental|collagen membranes|collagen barrier that help in isolating unwanted tissues in periodontal regneration
16667282|NCT02168309|Other|Labetalol|Labetalol 200mg PO BID starting dose
16667283|NCT02168309|Other|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
16667284|NCT02168296|Placebo Comparator|No added Plant-based ingredient|No Plant-based ingredient added to starchy meal
16667285|NCT02168296|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
16667286|NCT02168296|Active Comparator|High dose added to starchy meal|Plant-based ingredient in high dose added to starchy meal
16667287|NCT02168296|Active Comparator|Low dose added to liquid|Plant-based ingredient in low dose added to liquid
16667288|NCT02168296|Active Comparator|High dose added to liquid|Plant-based ingredient in high dose added to liquid
16667289|NCT02168283|Experimental|treatment arm|active fluid management includes 3 components: dietary counseling, diuretics, and intensive dialysis regimen
16667290|NCT02168283|Active Comparator|control arm|dietary counseling alone
16667291|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16667292|NCT02168257|Experimental|RAM Cannula CPAP|CPAP provided by RAM Cannula
16667293|NCT02168257|Active Comparator|Binasal Prong CPAP|CPAP provided by binasal prong
16667294|NCT02168244|Active Comparator|Ice pack|Pre-treatment with ice - Ice applied to the skin 2-3 minutes before injecting biologic drug injection
16667295|NCT02168244|Active Comparator|Heating Pack|Pre-treatment with heat - Heat applied to the skin 2-3 minutes before injecting biologic drug injection
16667296|NCT02168244|No Intervention|No treatment before injection|No treatment applied to the skin 2-3 minutes before injecting biologic drug injection
16667297|NCT02168231||Complex abdominal wall repair Strattice|Complex abdominal wall repair Strattice
16667298|NCT02168218|Experimental|high protein|20% protein diet
16667299|NCT02168218|Active Comparator|low protein|7.5% protein diet
16667300|NCT02168205|Experimental|4 mg Pomalidomide - Fed|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
16667301|NCT02168205|Experimental|4 mg Pomalidomide - Fasted|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
16667302|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Non-smoking|Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
16667303|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Smoking|Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
16667304|NCT02168192|Placebo Comparator|Traditional Lecture|These subjects received a 10 minute power point lecture on BBN skills.
16667305|NCT02168192|Experimental|Simulation-Debrief|These subjects received a formal debrief process, reviewing their prior baseline simulation.
16667306|NCT02168179|Experimental|Supportive Care (KeraStat Skin Therapy)|Patients apply KeraStat Skin Therapy topically BID during radiation therapy.
16667307|NCT02168166|Active Comparator|Executive Function Training|"Two weeks of training of cognitive domain of executive functioning
~Using online program (Scientific Brain Training Pro)
~Four exercises"
16667512|NCT02166658|Experimental|Single Arm|Patients receive Cabazitaxel 25 mg/m2 i.v. infusion. This trial is a single arm trial.
16667308|NCT02168166|Placebo Comparator|Placebo Training|"Two weeks of training with exercises not affecting working memory, information processing speed, or cognitive load
~Exercises maintain other traditional progressive aspects to preserve appearance of dynamic titration of difficulty levels
~Using online program (Scientific Brain Training Pro)
~Four exercises"
16667309|NCT02168153|Active Comparator|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
16667310|NCT02168153|Placebo Comparator|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
16667312|NCT02168127|Experimental|Active drug group|PRC-063 - Active methylphenidate hydrochloride extended-release capsules drug group
16667313|NCT02168114|Experimental|Duchenne Muscular Dystrophy|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
16667314|NCT02168114|Experimental|Non-affected Subjects|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
16667315|NCT02168101|Experimental|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
16667316|NCT02168101|Experimental|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
16667317|NCT02168101|Experimental|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
16667318|NCT02168088||Index case|Subjects who have died of sudden unexplained death
16667319|NCT02168088||Biologically related family member|Biologically related family member of the deceased individual
16667320|NCT02168075|Experimental|Group 1|0.25g/kgof 20% mannitol administered at drilling of skull.
16667321|NCT02168075|Experimental|Group 2|0.5g/kg of 20% mannitol administered at drilling of skull.
16667322|NCT02168075|Experimental|Group 3|1.0 g/kg of 20% mannitol administered at drilling of skull.
16667323|NCT02168075|Experimental|Group 4|1.5g/kg of 20% mannitol administered at drilling of skull.
16667324|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
16667325|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
16667326|NCT02168049|Experimental|Heart and Lung Function Monitioring|
16667327|NCT02168036||Patients with lung disease|General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
16667328|NCT02168023|Experimental|DACC impregnated dressing|Patients undergoing elective or emergency caesarean section with DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
16667329|NCT02168023|Active Comparator|Standard surgical dressing|Patients undergoing elective or emergency caesarean section with standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
16667330|NCT02168010|Experimental|Experiment|Test Drug Group: 2 times a day; 4 tablets per time (2 tablets of Analgecine and 2 tab. of placebo)
16667331|NCT02168010|Active Comparator|PosCtrl|PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
16667332|NCT02168010|Placebo Comparator|Placebo|Placebo Group: 2 times a day; 4 tablets / time (4 placebo tablets).
16667333|NCT02167984||at term newborns|Infant with GE >=37w
16667334|NCT02167984||preterm newborns|Infant with GE <37w
16667335|NCT02167971|Experimental|Active Coil|The patients assigned to this group will undergo repetitive Transcranial Magnetic Stimulation over 10 sessions (each one with 2,000 pulses) on left dorsolateral prefrontal cortex.
16667336|NCT02167971|Sham Comparator|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
16667337|NCT02167958|Experimental|Treatment|"Day -6, -5 Fludarabine 30 mg/M2 IV over 30-60 minutes Cyclophosphamide 14.5 mg/kg IV over 1-2 hours*, Mesna 14.5 mg/kg IV in 4 divided doses
~Day -4 through -2 Fludarabine 30 mg/M2 IV over 30-60 minutes
~Day -1 Total Body Irradiation 200 cGy, donor apheresis
~Day 0 T cell replete PBSC
~Days 3, 4 Cyclophosphamide 50 mg/kg IV Mesna 50 mg/kg IV in 4 divided doses
~Day 5 Begin tacrolimus ,mycophenolate, and G-CSF"
16667338|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
16667339|NCT02167932||Breast Cancer Patients|Breast Cancer patients undergoing chemotherapy will participate in the Walk with Ease program during their treatment.
16667340|NCT02167919|Experimental|Prostatic artery embolization|Microspheres measuring 100-300 microns will be injected under fluoroscopic guidance into the left and right prostatic arteries for embolization.
16667341|NCT02167906|Experimental|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
16667342|NCT02167906|Active Comparator|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
16667343|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
16667344|NCT02167867|Experimental|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
16667345|NCT02167867|Experimental|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
16667346|NCT02167854|Experimental|LJM716, BYL719 AND TRASTUZUMAB|A treatment cycle will consist of 28 days. Treatment doses for trastuzumab and LJM716 will be fixed at trastuzumab 2mg/kg weekly, and LJM716 20mg/kg weekly. The exception to this is if dose de-escalation results in treatment of patients at dose level 1, where LJM will be dosed at 10mg/kg weekly. On Arm A, BYL719 was administered orally once daily continuously at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. On Arm B, BYL719 will be administered orally once daily during 4 of 7 days in a week, at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. This means BYL719 will be given to patients on Arm B during days 1-4, 8-11, 15-18, and 22-25 of each cycle. The dose-finding phase will follow a Continuous Reassessment Methods (CRM) phase I biostatistical design.
16667347|NCT02167841|Experimental|Knee-Chest position|In this arm, the women will perform daily the Knee-Chest position between weeks 32-37. In week 37 the investigators will check via ultra sound if there was a successful version (if not, the woman would go to External Cephalic Version)
16667348|NCT02167841|No Intervention|External Cephalic Version|In this group the women will perform External Cephalic Version without doing maternal Knee-Chest position before.
16667349|NCT02167828|Experimental|Social Support|Participants will be trained to give one another ongoing, theory-based but personally-tailored advice, recommendations, and support to encourage entry to HIV medical care, remaining in care, and adhering to medication regimens when they are prescribed. The intervention's intent is to increase mutual support, positive attitudes, intentions, plans, and collective self-efficacy for care engagement.
16667350|NCT02167828|No Intervention|No Intervention|Participants in this arm will not receive an intervention.
16667351|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
16667352|NCT02167815|Experimental|Intervention ( Mepilex XT)|
16667353|NCT02167789|No Intervention|PhD|
16667354|NCT02167776|Experimental|Church-based teaching|Teaching about male circumcision provided to church leaders in addition to standard teaching available from Ministry of Health.
16667355|NCT02167776|No Intervention|No church-based teaching|Standard of care. Teaching about male circumcision provided by Ministry of Health.
16667356|NCT02167763|Experimental|VeraCept Intrauterine Contraceptive|The VeraCept low-dose Intrauterine Copper Contraceptive
16667357|NCT02167763|Active Comparator|TCu380|A commercial standard T-shaped copper IUD (TCu380)
16667358|NCT02167750|Placebo Comparator|Cherry flavored beverage - Mix 1|Mix 1 flavored still beverage
16667359|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 2|Mix 2 flavored still beverage with phytochmicals and caffeine
16667360|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 3|Mix 3 flavored still beverage with phytochemicals and caffeine
16667361|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 4|Mix 4 flavored still beverage with phytochemicals and caffeine
16667362|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 5|Mix 5 flavored still beverage with phytochemicals and caffeine
16667363|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 6|Mix 6 flavored still beverage with caffeine
16667364|NCT02167737|Experimental|Bedside Decision Aid Group|This arm will include study participants who are randomized to the group utilizing the bedside decision aid, which has hospital staff arrange fall-risk reduction interventions (e.g., home safety checks, exercise programs, vision checks, etc.).
16667365|NCT02167737|Active Comparator|Control Arm|"Participants in the control/comparator arm will experience the same study procedures with the exception of not using the Bedside Decision Aid and instead being given the Centers for Disease Control (CDC) brochure, What You Can Do to Prevent Falls, and arranging for their own fall prevention strategies."
16667366|NCT02167724|Experimental|Patients with schizophrenia|
16667367|NCT02167711|Experimental|SIRT|
16667368|NCT02167698|Experimental|Airway pressure release ventilation arm|"This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.
~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups."
16667369|NCT02167698|Active Comparator|Low-tidal volume ventilation arm|Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
16667370|NCT02167685||CMX001|Subjects who have previously participated in CMX001-301 or other CMX001 study.
16667371|NCT02167672||Consumers|Women who have had a Hysterectomy in the previous 2 years
16667372|NCT02167672||Doctors|Obstetricians and Gynaecologists
16667432|NCT02167243|Experimental|Reinforcement for performing BG testing|Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
16667433|NCT02167243|Active Comparator|No reinforcement for BG testing|Subjects will receive standard of care without reinforcement for Self Monitoring Blood Glucose
16667373|NCT02167659|Experimental|BIS Assessment|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include L-Dex, skin assessment and self-report forms. Patients with < 6.5 L-Dex units change will continue follow-up for 36 months. Patients with an L-Dex value change ≥ 6.5 will undergo circumference measurement and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.
~*At discretion of the site PI or attending physicians."
16667374|NCT02167659|Active Comparator|Tape Measure|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include arm volume (tape measure), skin assessment and self-report forms. Patients with no volume increase will continue follow-up for 36 months. Patients with a volume change of between ≥ 5% and < 10% in the at-risk limb will undergo L-Dex testing and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.
~*At discretion of the site PI or attending physicians."
16667375|NCT02167646|Other|Bilaterally innervated flap|Two nerve branches attached with the flap for sensory reconstruction.
16667376|NCT02167633|Active Comparator|Decompression surgery plus fractionated radiotherapy|
16667377|NCT02167633|Experimental|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in one fraction to cover as large a fraction as possible the defined target volume
16667378|NCT02167620|Placebo Comparator|Metformin|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
16667379|NCT02167620|Placebo Comparator|Placebo|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
16667380|NCT02167607|Active Comparator|Purple Potato|Active Comparator
16667381|NCT02167607|Placebo Comparator|White Potato|Placebo Comparator
16667382|NCT02167594|Experimental|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
16667383|NCT02167594|Experimental|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
16667384|NCT02167594|Experimental|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
16667385|NCT02167581||epithelial odontogenic tumours|
16667386|NCT02167568||Corpus callosum agenesis/dysgenesis|patients with Corpus callosum agenesis/dysgenesis
16667387|NCT02167568||parents|parents of patients with corpus callosum agenesis/dysgenesis
16667388|NCT02167555|Active Comparator|Wild Bluberries|Active Comparator
16667389|NCT02167555|Placebo Comparator|Placebo|Placebo Comparator
16667390|NCT02167542|Experimental|NPPV group|Patients assigned to noninvasive positive pressure ventilation (NPPV) are connected to the ventilator through a face mask (VBM Endoscopy Mask) that is secured to the patient's face by the investigator.
16667391|NCT02167542|Active Comparator|CPAP valve group|Patients assigned to CPAP valve (Boussignac valve, Vygon, Inc) are connected to this device through a standard face mask that is secured to the patient's face with elastic straps.
16667392|NCT02167516|Experimental|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
16667393|NCT02167516|Active Comparator|glucosamine sulfate capsule|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
16667394|NCT02167490|Active Comparator|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
16667395|NCT02167490|No Intervention|Arm 2: observation|No axillary staging
16667396|NCT02167477|Active Comparator|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
16667397|NCT02167477|Active Comparator|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
16667398|NCT02167464|Active Comparator|Aldosterone Antagonist|Prescribe an aldosterone antagonist such as Spironolactone 12.5-25 mg daily as a starting dose with a maximum recommended dose of 50 mg daily.
16667399|NCT02167464|Active Comparator|Referral Hypertension specialist|Referral to a hypertension specialist
16667400|NCT02167464|Active Comparator|Renin treatment-guided therapeutics|Renin treatment-guided therapeutics. A treatment algorithm is provided to guide treatment based upon renin levels.
16667401|NCT02167464|Active Comparator|Renin-guided therapeutics and referral|Renin treatment-guided therapeutics and referral to hypertension specialist. Treatment based upon algorithm for treatment related to renin level in addition to referral to a hypertension specialist.
16667402|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
16667403|NCT02167438|Experimental|Investigational|Application of the Hem-Avert device.
16667404|NCT02167438|No Intervention|Control|No Application of the Hem-Avert device.
16667405|NCT02167425||Late Post-IMAT Cohort|Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
16667406|NCT02167425||Early Post-IMAT Cohort|Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
16667407|NCT02167425||Late Pre-IMAT Cohort|Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
16667408|NCT02167425||Early Pre-IMAT Cohort|Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
16667410|NCT02167399||smart phone inclinometer|For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
16667411|NCT02167399||2-D video analysis|two dimensional video analysis by first placing markers on the subject at the midpoint of the femoral condyles, midpoint of the ankle malleoli, and the proximal thigh along a line from the anterior superior iliac spine (ASIS) to the knee marker. Testing will take place in front of a digital video camera with tape on the floor to give a reference point for the subject being tested. Participants will be tested twice on day 1 and then again 5-9 days later. Subjects will be allowed 2-3 practice trials prior to each test in order to allow the subject to feel comfortable with each test. Following the practice trials the subject will perform 3 trials of each test on bilateral lower extremities. This set up was consistent with the set up by Munro et al.
16667412|NCT02167386|Experimental|Enhanced PrEP Adherence|Enhanced PrEP Adherence: peer navigators, PrEP support group, on-line support group, text message reminders
16667413|NCT02167386|Active Comparator|Standard PrEP Adherence|Standard PrEP Adherence: support groups, case management
16667414|NCT02167373|No Intervention|Control|
16667415|NCT02167373|Experimental|Intervention|Cogito Companion Intervention. Participants will be provided with a mobile phone application that provides feedback on their mental health. The participants' clinicians will be provided with a desktop application to review their patients' results.
16667416|NCT02167360|Experimental|Single Arm|
16667417|NCT02167347|Experimental|Family Intervention|Culturally Adapted Family intervention for Psychosis Sessions will be offered weekly basis
16667418|NCT02167347|No Intervention|Control|"Caregiver ' s Patients who will be randomized to the treatment as usual arm will receive routine care"
16667419|NCT02167334|Experimental|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
16667420|NCT02167334|Active Comparator|Oxygenation with simple breathing mask|spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
16667421|NCT02167321|Active Comparator|Arm A|"Arm A; standard neoadjuvant chemoradiotherapy group
~fluoropyrimidine based concurrent chemoradiotherapy-> TME -> adjuvant chemotherapy (Low risk: fluoropyrimidine-based chemotherapy, High risk: FOLFOX)"
16667422|NCT02167321|Experimental|Arm B|"Arm B : adjuvant FOLFOX group
~Total mesorectal excision (TME) --> 12 cycles of FOLFOX every 2 weeks (or Total mesorectal excision (TME) --> Concurrent chemoradiotherapy + 12 cycles of FOLFOX every 2 weeks)"
16667423|NCT02167308|Active Comparator|Laser acupuncture group|Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
16667424|NCT02167308|Sham Comparator|Control group|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. Acupuncture points, application duration, and total number of treatments will be identical to the Laser acupuncture group.
16667425|NCT02167295||Focus group|The focus groups will consist of 6 to 8 persons each (N = 32). The focus group discussions will last for about 60 to 90 minutes. The discussion topics will be based on previous literature and experience and will include reasons for betel quid chewing or for quitting, pros and cons of betel quid chewing, barriers to and facilitators of abstinence, health beliefs and experiences about betel quid chewing and other issues.
16667426|NCT02167295||In-depth interviews.|We will conduct 15 one-to-one interviews, each lasts for about 45 to 60 minutes. Participants will be interviewed by a trained interviewer using a structured interview. The interview will be designed to collect information on socio-demographic background, current and/or former betel quid use, other substance use (smoking and/or alcohol consumption), as well as other variables including usage parameters, psychosocial and environmental influences on betel quid chewing, barriers to and interest in quitting, and knowledge of adverse effects on health.
16667427|NCT02167295||Self-report questionnaire|This study is expected to enroll 30 participants who have smoking and betel nut chewing behaviors.Participants will complete 4 separate visits to CMUH, during which they will complete the same self-report questionnaire designed to measure withdrawal symptoms relating to betel quid chewing. To better measure betel quid withdrawal symptoms and to distinguish the 6 symptoms from those of smoking withdrawal, Participants will be required to attend one visit regular cigarette smoking and betel nut chewing behavior without restriction (as control), one visit after 12 hours of overnight betel quid deprivation (no cigarette deprivation), one visit after 12 hours of overnight cigarette deprivation (no betel quid deprivation), and one visit after 12 hours of both overnight betel quid and cigarette deprivation.
16667428|NCT02167269|Active Comparator|Baby EAR-JR|The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
16667429|NCT02167269|Active Comparator|JR-Baby EAR|The subjects receive Jackson-Rees (JR) circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Baby EAR circuit and the procedure will be repeated.
16667430|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
16667431|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
16667434|NCT02167230|Experimental|Jailed-balloon technique|Apply jailed-balloon technique to protect the side branch during coronary bifurcation PCI
16667435|NCT02167230|Active Comparator|Jailed-wire technique|Apply jailed-wire technique to protect the side branch during coronary bifurcation PCI
16667436|NCT02167217|Experimental|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
16667437|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
16667438|NCT02167191|Experimental|HIT|High intensity interval training sessions on an cycle ergometer
16667439|NCT02167178||Volunteers receiving 0.9% NaCl|Volunteers receiving 0.9% NaCl to optimise stroke volume
16667440|NCT02167178||Volunteers receiving gelofusine|Volunteers receiving gelofusine to optimise stroke volume
16667441|NCT02167165||Digoxin and AF|Patients consulting the emergency deprtment (ED) for AF and receiving Digoxin treatment
16667442|NCT02167152|Experimental|Ischemic Preconditioning Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
16667443|NCT02167152|Active Comparator|Control Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
16667444|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
16667445|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
16667446|NCT02167126|Experimental|Kinesio Taping|Kinesio Taping was applied as experimental group.
16667447|NCT02167126|Placebo Comparator|Micropore|Micropore Tape was used as placebo tape
16667448|NCT02167113||study population|
16667449|NCT02167100||Retained in Care|Each patient who had at least 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring until 31st of March 2014.
16667450|NCT02167100||Lost to follow-up (LTFU)|Each patient who had at 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring but did not maintain regular attendance at HHMP until 31st March, 2014.
16667451|NCT02167087|Experimental|Sentinel node mapping|Sentinel node mapping with indocyanine green injected orally and anally to the tumor.
16667452|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
16667453|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
16667454|NCT02167061|Experimental|(Part 1) DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
16667455|NCT02167061|Experimental|(Part 1) E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
16667456|NCT02167061|Experimental|(Part 2) DA-1229_01 fast → fed|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
16667457|NCT02167061|Experimental|DA-1229_01 fed → fast|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
16667458|NCT02167048|Experimental|Normal-dose Psychostimulant, Low-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
16667459|NCT02167048|Active Comparator|Low-dose Psychostimulants, Normal-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
16667460|NCT02167048|No Intervention|No intervention, No intervention|This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).
16667461|NCT02167035|Active Comparator|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
16667462|NCT02167035|Active Comparator|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
16667463|NCT02167022|Experimental|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
16667464|NCT02167022|Experimental|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
16667465|NCT02167009|Experimental|Prostate Artery Embolization|Embospheres microspheres
16667466|NCT02166996|Active Comparator|A|Suture removal time 7 days.
16667467|NCT02166996|Experimental|B|Suture removal time 14 days.
16667468|NCT02166983|Experimental|Arm IA (Lumosity, relaxation, compensatory strategies)|Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
16667508|NCT02166710|Placebo Comparator|Simulated nerve blockade|Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
16667509|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
16667469|NCT02166983|Experimental|Arm IB (Active Journaling, relaxation, compensatory strategy)|Participants complete Active Journal cognitive exercises. Active Journaling requires participants to keep a written diary or journal where she discusses what her thoughts and feelings about various events with a focus on describing the meaning of the activities and experiences, particularly new things that were learned. Active Journaling is a method of practicing various cognitive skills including communication, organization, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises and compensatory strategies as in Arm IA.
16667470|NCT02166983|Experimental|Arm II (Lumosity only)|Participants complete Lumosity exercises as in Arm IA.
16667471|NCT02166970|Experimental|Single stent deployment|Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
16667472|NCT02166970|Active Comparator|Multiple stent deployment|Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
16667473|NCT02166957||Long disruption > 5cm +/- loss of SES|
16667474|NCT02166957||Short disruption < 5cm|
16667475|NCT02166944|Experimental|tamoxifen|tamoxifen 40 mg daily for one year
16667476|NCT02166944|Placebo Comparator|placebo|placebo drugs
16667477|NCT02166931|Placebo Comparator|placebo|placebo with the same color, order, taste as BRAND'S® Essence of Chicken , 70cc daily for 2weeks
16667478|NCT02166931|Experimental|Chicken Essence|BRAND'S® Chicken Essence 70cc, daily for 2 weeks
16667479|NCT02166918||patients with schizophrenia|320 patients with a diagnosis of schizophrenia according to Diagnostic and Statistical Manual IV edition (DSM-IV) criteria, confirmed by the Structured Clinical Interview for DSM-IV - Patient Version (SCID -IP), will be included in the study.
16667480|NCT02166918||unaffected first-degree relatives|240 unaffected first-degree relatives of the recruited patients (120 unaffected parents and 120 unaffected siblings)
16667481|NCT02166918||healthy control|320 healthy control subjects.
16667482|NCT02166905|Experimental|Arm I (CDX-1401, poly ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC as in Phase I.
16667483|NCT02166905|Experimental|Arm II (CDX-1401, poly ICLC, IDO1 inhibitor INCB024360)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 as in Phase I.
16667484|NCT02166892|Active Comparator|Normal weight|Normal weight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
16667485|NCT02166892|Active Comparator|Overweight children|Overweight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
16667486|NCT02166879||Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Chart review from patients undergoing elective surgery.
16667487|NCT02166866||Experimental arm|
16667488|NCT02166853|Experimental|conventional group|"a conventional group, in which intravenous sedation with midazolam will be administered"
16667489|NCT02166853|Experimental|sevoflurane group|"a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices"
16667490|NCT02166840|Experimental|Self expanding metal stent|Patients with self expanding metal stent inserted into bile duct.
16667491|NCT02166840|Active Comparator|Plastic stent|Patients with obstructive jaundice who got a plastic stent inserted into bile duct.
16667492|NCT02166827|Active Comparator|NeuroAD|NeuroAd Treatment, synchronized TMS and cognitive training stimulation
16667493|NCT02166827|Sham Comparator|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
16667494|NCT02166814|Experimental|Fimasartan and Rosuvastatin|Combination of Fimasartan and Rosuvastatin
16667495|NCT02166814|Active Comparator|Fimasartan|Fimasartan monotherapy
16667496|NCT02166814|Active Comparator|Rosuvastatin|Rosuvastatin monotherapy
16667497|NCT02166801|Active Comparator|Early intervention for infants|A 30w intensive intervention according to the small step program, with daily practice sections conducted by parents at home, with weekly support by therapists.
16667498|NCT02166801|Active Comparator|Usual care|Usual care means that the Children in this arm of the study participate in the established follow up program that is established at the Astrid Lindgrens Children's Hospital and offered to all Children that displays a delayed early gross and fine motor development.
16667499|NCT02166788|Other|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
16667500|NCT02166788|Other|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
16667501|NCT02166762|Experimental|QLV interval measurement|QLV measurements collected during implantation of CRT-D device
16667502|NCT02166749||Subtotal abdominal hysterectomy|107 women
16667503|NCT02166749||Total abdominal hysterectomy|105 women
16667504|NCT02166736|Experimental|Instantaneous wave-free ratio (iFR)|
16667505|NCT02166736|Active Comparator|Fractional Flow Reserve (FFR)|
16667506|NCT02166723||CRYOABLATION|Cryoballoon ablation will be applied to all patients with persistent atrial fibrillation. It consists on applying the Arctic Front Cryoballoon to the pulmonary veins and freezing the antrum. In addition debulking of the atrial roof will be performed by a single application of the cryoballoon to the left and right roof, the septal wall and the lateral ridge wall.
16667507|NCT02166710|Experimental|Adductor canal femoral nerve blockade|Patients will receive continuous adductor canal femoral nerve blockade for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
16667513|NCT02166645|Experimental|Prone position|Prone position per 48 hours after extubation
16667514|NCT02166645|Active Comparator|Supine position|Supine position per 48 hours after extubation
16667515|NCT02166632|Experimental|Intracapsular Injection|Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
16667516|NCT02166632|Active Comparator|Periarticular Injection|Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.
16667517|NCT02166619|Experimental|tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
16667518|NCT02166619|Sham Comparator|Sham tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric sham tDCS will be applied. Anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds. After bihemispheric sham tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
16667519|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
16667520|NCT02166593|Experimental|Pravastatin 40mg/Fenofibrate160mg|Pravastatin (40mg/day) Fenofibrate (160mg/day)
16667521|NCT02166593|Active Comparator|Atorvastatin Sodium|Atorvastatin Sodium (10mg/day)
16667522|NCT02166567|Experimental|YoPro and FACS|Spermatozoa to be used for ICSI will be stained with the YoPro Dye and then be sorted with FACS to select non-YoPro stained spermatozoa, known to have significantly less fragmented DNA.
16667523|NCT02166567|Active Comparator|Swim-up|Spermatozoa will be processed using the conventional swim-up me
16667524|NCT02166554|Placebo Comparator|Control Arm|Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery
16667525|NCT02166554|Experimental|Cross-linked Hyaluronan Hydrogel Arm|HyaRegen
16667526|NCT02166541|Experimental|INRS with BCSK|"Intensive Neurophysiological Rehabilitation System (INRS) including the Biomechanical correction of the spine according to Kozyavkin (BCSK).
~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
16667527|NCT02166541|Sham Comparator|INRS, traditional spinal manipulation|"Intensive Neurophysiological Rehabilitation System (INRS) including spinal manipulation by the traditional technique.
~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
16667528|NCT02166528||experiment group|patients with FPFD
16667529|NCT02166528||control group|patients without FPFD
16667530|NCT02166515||experiment group|patients with cervical cancer, endometrial cancers or ovary cancer
16667531|NCT02166515||control group|postmenopausal women with benign tumor
16667532|NCT02166502||Nevirapine|The patients in this study are newborn infants clinically prescribed combination antiretroviral treatment with nevirapine for prevention of mother-to-child HIV transmission.
16667533|NCT02166489|Experimental|mesenchymal stem cell transplantation|Intravenous injection of mesenchymal stem cell in patients with PKD
16667534|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
16667535|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
16667536|NCT02166463|Active Comparator|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over 1-15 minutes on days 1-2, bleomycin sulfate IV over 10 minutes or SC on days 1 and 8, vincristine sulfate IV over 1 minute on days 1 and 8, etoposide IV over 60-120 minutes on days 1-3, prednisone PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV over 30-60 minutes on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
16667537|NCT02166463|Experimental|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV over 1 minute on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
16667538|NCT02166450||Control group|Denture wearers without clinical signs of denture-related stomatitis confirmed with negative Candida swabs.
16667539|NCT02166450||Denture-related stomatitis group|"Denture wearers with clinical signs of denture-related stomatitis, confirmed with positive Candida swabs.
~Treated for fungal infection, with nystatin [100 000 IU every 6 h for 3 weeks, applied on the infected area of the mucous membrane of the palate and cheeks]."
16667540|NCT02166437||Alendronate|Patients treated with alendronate
16667541|NCT02166437||Minodronate|Patients treated with minodronate
16667542|NCT02166437||Denosmab|Patients treated with denosmab
16667543|NCT02166424|Active Comparator|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
16667544|NCT02166424|Placebo Comparator|olive oil|2880mg olive oil daily
16667545|NCT02166411|Experimental|myomectomy using barbed sutures|.Myoma bed is sutured with barbed sutures
16667546|NCT02166411|Active Comparator|myomectomy using conventional sutures|Myoma bed is sutured with conventional sutures
16667547|NCT02166398|Active Comparator|Amosartan 5/50 tab|Amosartan 5/50 tab given by oral administration
16667548|NCT02166398|Experimental|UI15AML055MT tab|UI15AML055MT tab given by oral administration
16667549|NCT02166372||Obese diabetic patients|Diabetic patients with BMI over 25 Age 20 to 67 Diabetes medically controlled at our center for at least six months
16667550|NCT02166359|Active Comparator|Glucose group|Glucose use of 2.5% or 4.25% dextrose solution at least 4 hours
16667551|NCT02166359|Experimental|Extraneal (Icodextrin) group|Extraneal (Icodextrin) use at least 8 hours
16667552|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
16667553|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
16667554|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
16667555|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
16667556|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
16667557|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
16667558|NCT02166320|Active Comparator|Partially covered SEMS|Boston Scientific Ultraflex SEMS
16667559|NCT02166320|Experimental|Fully covered SEMS|Boston Scientific Wallflex Esophageal SEMS.
16667560|NCT02166294|Experimental|NEOX® CORD 1K|Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
16667561|NCT02166294|Active Comparator|Pressure bandage|Standard of Care Pressure bandage with off-loading instructions
16667562|NCT02166294|Experimental|Standard of Care Cross over to NEOX|Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
16667563|NCT02166268|Active Comparator|Avanz Phleum pratense|Avanz Phleum pratense 15,000 SQ+ (standardised quality), suspension for subcutaneous injection.
16667564|NCT02166268|Placebo Comparator|Placebo|Placebo, suspension for subcutaneous injection.
16667565|NCT02166255|Experimental|Treatment (APN401)|Patients receive autologous siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes.
16667566|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
16667567|NCT02166229|Experimental|Divalproex sodium|Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.
16667568|NCT02166216||Healty subjects|Healthy subjects that participate in a high intensity, endurance bicycle race.
16667569|NCT02166190|Experimental|Radiofrequency Ablation (EndoHbp probe)|Radiofrequency Ablation using EndoHPB Probe
16667570|NCT02166190|Active Comparator|Stenting only|Stenting only
16667571|NCT02166177|Experimental|Autologous Regulatory T cell therapy|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)
16667572|NCT02166164|Experimental|Experiemental pain models|all study participants will be tested with the same experimental pain models: Brief thermal sensitization, Long thermal stimulation, and Heat-pain-detection threshold.
16667573|NCT02166151|Experimental|Omalizumab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
16667574|NCT02166138|Experimental|Laser treated Group|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits. Thus, patients in this group will be getting the Non-Abilative laser treatment.
16667575|NCT02166138|Placebo Comparator|Not Laser treated Group|Patients in this group will be given the laser treatment with the 1540 non-abilative laser device, but the device will not be set to provide treatment. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
16667576|NCT02166125||Endoscopic suturing|Any patient who has undergone clinically indicated and/or standard of care endoscopic suturing within the Gastrointestinal tract.
16667577|NCT02166112||Permacol mesh placement|No intervention performed
16667659|NCT02165540|No Intervention|Routine care/No Doula|Patients will have routine care with clinical staff only.
16667578|NCT02166099||SpyGlass Choledochoscopy procedure|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of a pancreatico-biliary disorder
16667579|NCT02166086||Endoscopic imaging|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment of a pancreatico-biliary disorder.
16667580|NCT02166060|Experimental|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
16667581|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
16667582|NCT02166047|Experimental|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
16667583|NCT02166047|Experimental|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
16667584|NCT02166047|Experimental|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
16667585|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
16667586|NCT02166047|Experimental|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
16667587|NCT02166047|Experimental|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
16667588|NCT02166047|Experimental|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
16667589|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
16667590|NCT02166047|Experimental|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
16667591|NCT02166047|Experimental|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
16667592|NCT02166047|Experimental|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
16667593|NCT02166034|Experimental|garden intervention|Schools assigned to the garden intervention receive raised bed garden kits and access to a toolkit of garden-based curriculum
16667594|NCT02166034|No Intervention|Control|Wait-list control (no garden intervention + lessons) until end of the study.
16667595|NCT02166021|Experimental|IT- Treated|Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
16667596|NCT02166021|Experimental|IV - Treated|Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
16667597|NCT02166021|Placebo Comparator|Placebo|Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.
16667598|NCT02166008|Active Comparator|Repamipide|Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
16667599|NCT02166008|Placebo Comparator|placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.
16667600|NCT02165995|Experimental|Navigated Transcranial Magnetic Stimulation (nTMS)|Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
16667601|NCT02165982||Patients controles|Inpatients suffering from anorexia nervosa at Institut Mutualiste Montsouris
16667602|NCT02165982||Individus sains témoins|Healthy controls selected from the general population
16667603|NCT02165969|Experimental|endoscopic endonasal surgery with UPSIT|endoscopic endonasal surgery with UPSIT prior to surgery and at months 1, 3, 6, and 12 after surgery.
16667604|NCT02165956|Experimental|New Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
16667605|NCT02165956|Active Comparator|Standard Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
16667606|NCT02165943||Vitoss Bone Graft with BMA|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage age was recommended and who received Vitoss bone graft with BMA to fill the cavity.
16667607|NCT02165943||Vitoss bone graft|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage was recommended and who received Vitoss bone graft to fill the cavity.
16667608|NCT02165930|Experimental|Treatment A|
16667609|NCT02165930|Experimental|Treatment B|
16667610|NCT02165917|Placebo Comparator|Excision only|Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration
16667611|NCT02165917|Active Comparator|Excision plus hyaluronic acid gel|Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration
16667612|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
16667613|NCT02165891|Other|Urokinase|insertion of a chest drain with urokinase instillation
16667614|NCT02165891|Other|VATS|primary video-assisted thorascopic surgery Other interventions except drainage procedure are the same in both arms
16667615|NCT02165878||Children and adolescent|children and adolescent CKD patients of any etiology
16667616|NCT02165865|Experimental|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
16667617|NCT02165852|Experimental|Papillectomy without injection|Conventional snaring mucoal resection without submucosal injection
16667618|NCT02165852|Active Comparator|Papillectomy with injection|Conventional mucosal resction method following injeciton of diluted epinephrine mixture.
16667619|NCT02165839|Active Comparator|Healthy Eating Education Learning (HEAL)|Control group.
16667620|NCT02165839|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|
16667621|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
16667660|NCT02165527|Experimental|x-ray with iXDA scan|Tota body scan taken by the Lunar iXDA. During the scan, subject will be asked to lay on their back. Following the Lunar iDXA scan, the computer of the Luna iXDA will calculate bone length. The calculation of bone length will be compared to a calculation from the subject's conventional x-ray to determine accuracy.
16667622|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
16667623|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
16667624|NCT02165813|Active Comparator|Nitazoxanide|oral nitazoxanide suspension twice daily for 3 days
16667625|NCT02165813|Placebo Comparator|Placebo|oral placebo suspension twice daily for 3 days
16667626|NCT02165800|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
16667627|NCT02165800|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
16667628|NCT02165787||patients|
16667629|NCT02165787||healthy control subjects|
16667630|NCT02165774|Active Comparator|sacral neuromodulation ON|active sacral neuromodulation (neuromodulator ON)
16667631|NCT02165774|Placebo Comparator|sacral neuromodulation OFF|placebo sacral neuromodulation (neuromodulator OFF)
16667632|NCT02165761|Active Comparator|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
16667633|NCT02165761|Other|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
16667634|NCT02165735|Experimental|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
16667635|NCT02165735|Experimental|Usual Care|Usual care for HIV
16667636|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
16667637|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
16667638|NCT02165709|Experimental|Salpingectomy|Participants will be offered a risk-reducing salpingectomy, and if they choose this options the surgeon will proceed with a salpingectomy.
16667639|NCT02165709|Active Comparator|Traditional sterilization|Participants will be offered a risk-reducing salpingectomy, and those that choose a traditional sterilization will be in this treatment arm.
16667640|NCT02165696|Experimental|Manual lymphatic drainage and compression bandaging|Experimental group: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
16667641|NCT02165696|Active Comparator|Manual lymphatic drainage|Control group: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
16667642|NCT02165670||Ischemic heart disease|Patients undergoing percutaneous coronary intervention (PCI)
16667643|NCT02165657|Experimental|Excimer laser|Excimer laser treatment
16667644|NCT02165644|Experimental|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with current standard of care which is Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
16667645|NCT02165644|Active Comparator|Standard of care|Subjects will receive only standard of care for subarachnoid hemorrhage which will include Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
16667646|NCT02165631||Group A-Simbinza|Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
16667647|NCT02165631||Group B-Timolol|Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
16667648|NCT02165618|No Intervention|GCT|In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
16667649|NCT02165618|Active Comparator|GCT-RASP|Medication review, based on but not limited to the RASP list
16667650|NCT02165605|Experimental|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
16667651|NCT02165605|Placebo Comparator|Placebo|The patient is her own control.
16667652|NCT02165592||Patients with hemophilia|Patients with hemophilia who meet the inclusion criteria
16667653|NCT02165579||Age > 21, diabetes, osteomyelitis|1 Cohort, standard care, observational patients are: Diagnosis of diabetes mellitus Age ≥ 21 years Infectious Disease Society of America stage 3 infection
16667654|NCT02165566|Experimental|Regular-insulin,|regular-insulin or lispro-insulin at 0.04 units/kg/hour continuous infusion crossover and random assignement
16667655|NCT02165566|Experimental|Lispro insulin|patients randomly assigned in a crossover way to one of the 2 treatments
16667656|NCT02165553|Experimental|Hibiscus sabdariffa calyces extract as a cold drink|Subjects are asked to consume 250 ml of Hibiscus calyces drink after a high fat breakfast
16667657|NCT02165553|Placebo Comparator|Water|Subjects are asked to consume 250 ml of water after a high fat breakfast
16667658|NCT02165540|Experimental|Doula|Patients will have a doula support person during their procedure.
16667661|NCT02165514|Experimental|Lunar iDXA (DEXA) scan|Spinal scans taken by DEXA scanner
16667662|NCT02165475|Experimental|Biofeedback|
16667663|NCT02165475|Experimental|medical treatment|
16667664|NCT02165475|Experimental|combination of the two treatments|
16667665|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
16667666|NCT02165449|Experimental|Ketamine|
16667667|NCT02165436|Placebo Comparator|Control|No gum
16667668|NCT02165436|Active Comparator|Chewing Gum|Bubble gum-flavored sugar-free gum - chew for 15-30 minutes 5 times/day
16667669|NCT02165423|Experimental|Control|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
16667670|NCT02165423|Experimental|Intervention|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
16667671|NCT02165410|Experimental|Eye tracking and RMI|
16667672|NCT02165397|Experimental|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
16667673|NCT02165397|Experimental|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
16667674|NCT02165397|Experimental|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
16667675|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
16667676|NCT02165371|Experimental|Sinovuyo Caring Families Programme|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly 3 hour sessions. Program is manualized.
16667677|NCT02165371|No Intervention|No intervention|Control group receives not intervention
16667678|NCT02165358||Patients|Patients verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
16667679|NCT02165358||Controls|Healthy controls matched for age and gender.
16667680|NCT02165345|Experimental|Tocilizumab|Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.
16667681|NCT02165332|Placebo Comparator|Part 1: Placebo|Saline solution, given as a minimum of a 2 hour infusion
16667682|NCT02165332|Experimental|Part 1: RO7033877|Single ascending dose
16667683|NCT02165332|Experimental|Part 2: RO7033877|Single-dose 4-way crossover
16667684|NCT02165319|Active Comparator|Barrel|Endotracheal tube with barrel-shaped cuff will be used during general anesthesia.
16667685|NCT02165319|Active Comparator|Tapered|Endotracheal tube with tapered-shaped cuff will be used during general anesthesia.
16667686|NCT02165306|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
16667687|NCT02165306|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the neurologist/neurosurgeon and nurses.
16667688|NCT02165293|Experimental|RO7033877|
16667689|NCT02165280|Active Comparator|Guided IMagery (GIM)|If randomized to GIM, they will then be given an audio Compact Disc. Patients will be instructed to listen to the recording least once per day in a calm location during the week leading up to surgery. They will then be seen prior to surgery in the surgical waiting area where they will evaluated for anxiety, preparedness and study compliance.
16667690|NCT02165280|No Intervention|Standard of Care (SOC)|"Each participant will complete a baseline set of questionnaires. The Pelvic Floor Distress Inventory (PFDI) is a 20 question self-administered questionnaire on the presence and both of pelvic floor symptoms .
~The Pelvic Organ Prolapse Quantification System (POPQ) measures the topography of the vagina and is considered to be gold standard for quantifying prolapse .
~The State-Trait Anxiety Inventory (STAI) has been used extensively in research and clinical practice since its introduction in 1966 and is the most widely cited measure of anxiety.
~New measurements at the 6-week follow-up appointment will include the Patient Global Impression of Improvement (PGII), and a postoperative questionnaire eliciting overall satisfaction and development of new pelvic symptoms."
16667691|NCT02165267|Experimental|Arm 1: VRC01 (6 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0, followed by IV infusions of 20 mg/kg of VRC01 administered in 100 mL of normal saline over at least 30 minutes to 1 hour at Days 28, 56, 84, 112, and 140.
16667692|NCT02165267|Experimental|Arm 2: VRC01 (3 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0 and over at least 30 minutes to 1 hour at Days 56 and 112.
16667693|NCT02165267|Experimental|Arm 3a: VRC01 (1 IV infusion plus multiple SC injections)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of 5 mg/kg of VRC01 administered every 2 weeks for 20 weeks.
16667694|NCT02165267|Placebo Comparator|Arm 3b: Placebo for VRC01 (infusion plus injections)|Participants will receive an IV infusion of sodium chloride placebo administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of placebo for VRC01 administered every 2 weeks for 20 weeks.
16667695|NCT02165267|Experimental|Arm 4: 10 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 10 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
16667696|NCT02165267|Experimental|Arm 5: 30 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 30 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
16667697|NCT02165254|Other|high dose tai chi intervention|
16667698|NCT02165254|Other|standard dose tai chi intervention|
16667699|NCT02165228|Experimental|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
16667700|NCT02165228|Active Comparator|Nutrition Enhancement|Nutrition education class and behavioral intervention
16667701|NCT02165228|No Intervention|Control|No class or behavioral intervention
16668979|NCT02156375|Experimental|Ustekinumab 5 mg/mL|
16667702|NCT02165215|Experimental|Open-Label Induction Phase: Etrolizumab|All participants will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) up to Week 10.
16667703|NCT02165215|Experimental|Double-Blind Maintenance Phase: Etrolizumab|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive etrolizumab 105 mg SC injection Q4W from Week 12 up to Week 62.
16667704|NCT02165215|Placebo Comparator|Double-Blind Maintenance Phase: Placebo|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive placebo (matched to etrolizumab) SC injection Q4W from Week 12 up to Week 62.
16667705|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
16667706|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
16667707|NCT02165189|Experimental|Simeprevir plus Sofosbuvir plus Ribavirin (Arm 1)|Participants will be administered simeprevir capsule 150 milligram (mg), sofosbuvir 400 mg tablet, and ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram [kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg weight), orally once daily up to 12 weeks.
16667708|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 2)|Participants will be administered simeprevir capsule 150 mg and sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
16667709|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 3)|Participants will be administered simeprevir 150 mg capsule and sofosbuvir 400 mg tablet orally once daily 24 weeks.
16667710|NCT02165176|Experimental|10mg acute oral cannabis|10mg acute oral cannabis
16667711|NCT02165176|Experimental|25mg acute oral cannabis|25mg acute oral cannabis
16667712|NCT02165176|Experimental|50mg acute oral cannabis|50mg acute oral cannabis
16667713|NCT02165163|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
16667714|NCT02165163|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
16667715|NCT02165150|Experimental|Wheelchair-bound Senior Elastic Band|WSEB interventions three times per week, 40 minutes per practice
16667716|NCT02165150|No Intervention|Control|routine care
16667717|NCT02165137||trauma patients|type and severity of patients, circumstances and trauma pre- and post-injury / -quality initiative
16667718|NCT02165124|Experimental|Intervention/Bariatric Embolization|
16667719|NCT02165111|Experimental|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).
~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
16667720|NCT02165111|Placebo Comparator|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).
~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
16667721|NCT02165098|Experimental|Cariprazine PR tablet B|Cariprazine prolonged release tablet B - fed
16667722|NCT02165098|Experimental|Cariprazine PR tablet A|Cariprazine prolonged release tablet A - fed
16667723|NCT02165098|Experimental|Cariprazine capsule|Cariprazine capsule - fasted
16667724|NCT02165098|Experimental|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
16667725|NCT02165098|Experimental|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
16667726|NCT02165085||Vascular-Ehlers Danlos syndrome|N=50 patients with vascular Ehlers-Danlos syndrome
16667727|NCT02165085||Spontaneous arterial dissection(s)|N=50 patients
16667728|NCT02165085||Healthy volunteers|n=100 Healthy volunteers
16667729|NCT02165059||Study Group|Patients undergoing surgical full thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder.
16667730|NCT02165059||Control Group|"Patient undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, Whipple surgery, transplant surgery.
~Patients who are organ donors and undergoing surgery are also part of the control group."
16667731|NCT02165046|Experimental|SYN006 HFA MDI, 180/10 mcg/dose|SYN006 HFA MDI(Budesonide/Procaterol Hydrochloride, 180/10mcg), Single dose, 4 puffs
16667732|NCT02165046|Active Comparator|Pulmicort pMDI|Budesonide 200mcg, single dose, 4 puffs
16667733|NCT02165046|Active Comparator|Meptin Air 10mcg|Procaterol hydrochloride 10mcg, single dose, 4 puffs
16667734|NCT02165033|Experimental|Budesonide/Procaterol 180/10 X 4 puffs|Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days
16667735|NCT02165020|Experimental|Rectal toxicities after prostate hypofractionated radiotherapy|Rectal toxicities after prostate hypofractionated radiotherapy with hyaluronic acid
16667768|NCT02164747||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
16667849|NCT02164175||HeRO Graft|End stage renal disease patients who receive HeRO Graft implant for dialysis access
16667736|NCT02165007|Experimental|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
16667737|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
16667738|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
16667739|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
16667740|NCT02164968||Obstructive bronchitis|1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
16667741|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
16667742|NCT02164942||Single Arm|Specimen Collection
16667743|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
16667744|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
16667745|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
16667746|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
16667747|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
16667748|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16667749|NCT02164903||Imatinib|Patients in first line treatment with imatinib for no more than 3 years.
16667750|NCT02164903||Dasatinib|Patients in first line treatment with dasatinib for no more than 3 years.
16667751|NCT02164890|Other|Pharmacokinetics of micafungin|
16667752|NCT02164877|Experimental|pectin|Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
16667753|NCT02164877|Placebo Comparator|control|Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks
16667754|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
16667755|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
16667756|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
16667757|NCT02164838|Experimental|Axitinib|
16667758|NCT02164825|Experimental|Single-shot nerve block|Efficacy compared to epidural
16667759|NCT02164825|Active Comparator|Continuous epidural|Continuous epidural perfusion
16667760|NCT02164812|Experimental|Moxifloxacin, Placebo, Efavirenz|Moxifloxacin, Placebo, Efavirenz single dose as specified
16667761|NCT02164799||Shock|Patients found to have persistent hypotension after resuscitation or vasopressor requirement
16667762|NCT02164799||Pre-shock|Patients with markedly abnormal vital signs (Heart Rate (HR)>130, Respiratory Rate (RR)>24, Shock Index >1, Lactate > 4.0mmol/L, or Systolic Blood Pressure (SBP) <90mm/hg) without shock, as defined previously.
16667763|NCT02164786||Acute severe disease|
16667764|NCT02164773|Active Comparator|magnesium sulfate|magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.
16667765|NCT02164773|Placebo Comparator|o.9%normal saline|0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.
16667766|NCT02164760|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
16667767|NCT02164760|No Intervention|STSG alone|STSG alone
16667769|NCT02164747||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
16667770|NCT02164747||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
16667771|NCT02164747||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
16667772|NCT02164734|Active Comparator|Endotracheal intubation|Endotracheal intubation for surfactant administration, following remifentanil and atropine pre-medication
16667773|NCT02164734|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
16667774|NCT02164721|Other|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
16667775|NCT02164708|Experimental|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
16667776|NCT02164695|Active Comparator|PPCI plus RIPC|The patients randomized to PPCI plus RIPC group will receive RIPC during PPCI.
16667777|NCT02164695|Sham Comparator|PPCI only|The patients randomized to PPCI only group will receive PPCI only but the sham procedure of RIPC.
16667778|NCT02164682||IV PCA group|
16667779|NCT02164682||IV PCA+ caudal block group|
16667780|NCT02164656|Experimental|mindfulness training|8 week course in mindfulness for smokers
16667781|NCT02164643|Experimental|Florbetapir (18F)|
16667782|NCT02164643|Experimental|Flutemetamol (18F)|
16667783|NCT02164630|Experimental|Hope Therapy|Patients assigned to this arm will receive Hope Therapy in three individual intervention sessions. Intervention will be administered by an experienced therapist.Training focuses on effective goal setting and augmenting hopeful thinking.
16667784|NCT02164630|Other|Pain Education|Patients assigned to this arm will receive Pain Education in three individual intervention sessions. Intervention will be administered by an experienced therapist. Training will focus on understanding TMD-related pain and learning pain management techniques.
16667785|NCT02164617|Experimental|Wheelchair-bound Senior Elastic Band|Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
16667786|NCT02164617|No Intervention|control|routine care
16667787|NCT02164604|Experimental|Ranibizumab|All eyes receive one intravitreal injection with 0.03ml ranibizumab
16667788|NCT02164578|Experimental|Rivaroxaban|"Patients receive IMP in 5mg b.i.d. for 20 weeks
~+ addidional 32 weeks (extension study for 80 patients)"
16667789|NCT02164578|Active Comparator|Aspirin|Patients receive IMP in a dosage of 100mg once daily for 20 weeks. Thereof 80 patients receive treatment for addidional 32 weeks (extension study)
16667790|NCT02164565|Experimental|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
16667791|NCT02164565|Experimental|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
16667792|NCT02164552||Vitamin D3 pills|Vitamin D3 (cholecalciferol) supplementation (50,000 IU/week for 8 weeks) followed by 1000 IU/day for 16 weeks
16667793|NCT02164552||Placebo pill|Placebo pills will be given 1 per week for 8 weeks followed by 1 per day for 16 weeks
16667794|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
16667795|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
16667796|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
16667797|NCT02164526||No treatment|
16667798|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
16667799|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
16667800|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
16667801|NCT02164500|Experimental|Ruxolitinib|
16667802|NCT02164487||B1 blood levels|
16667803|NCT02164474|Experimental|High-Intensity Interval Training (HIIT)|Participants will perform a series of high-intensity intervals with an interval length of 60-seconds at 90% of peak aerobic capacity workload, and a rest length of 60-seconds.
16667804|NCT02164474|Active Comparator|Moderate-Intensity Continuous Exercise|Participants will engage in exercise at 45% of peak aerobic capacity workload.
16667805|NCT02164461|Experimental|ADXS11-001|
16667806|NCT02164448|Experimental|dexmedetomidine group|
16667807|NCT02164448|Placebo Comparator|control group|
16667808|NCT02164435|Other|Renal Denervation|
16667809|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
16667810|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
16667811|NCT02164422|Placebo Comparator|Placebo|Placebo
16668980|NCT02156362|Other|follow up|
16667812|NCT02164409||Patient|Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
16667813|NCT02164409||Control|A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
16667814|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
16667815|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
16667816|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
16667817|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
16667818|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:
~How effective is the following intervention:
~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
16667819|NCT02164370||non-pregnant controls|Acid-base in healthy non-pregnant women in childbearing age
16667820|NCT02164370||healthy pregnant control group|healthy pregnant volunteers matched in gestational age to cases
16667821|NCT02164370||severe pre-eclampsia|Acid-base in severe pre-eclampsia
16667822|NCT02164357||EVT|Patients receiving endovascular treatment (EVT) within 4.5 hours after onset because intravenous thrombolytic therapy (IVT) is contraindicated
16667823|NCT02164357||IVT + EVT|Patients receiving intravenous thrombolytic therapy (IVT) followed by endovascular treatment (EVT) within 4.5 hours after onset
16667824|NCT02164357||IVT (intravenous thrombolytic therapy)|Patients that will received IVT only within 4.5 hours after onset
16667825|NCT02164344|Experimental|Probiotics|HIV-1 infected patients take daily dietary supplement with probiotics for at least 3 months
16667826|NCT02164331|Experimental|JNC guideline training|Providers will receive current JNC guideline training for treating patients with uncontrolled hypertension.
16667827|NCT02164331|No Intervention|Control|Provider patient panels will be assessed for number of uncontrolled hypertensives before receiving the JNC guidelines training. These baseline characteristics will serve as their control conditions.
16667828|NCT02164318|No Intervention|Control group|Standard of care
16667829|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
16667830|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
16667831|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
16667832|NCT02164305|Experimental|Strengthening group|4-week exercise training, 3 times a week, 30 minutes per visit.
16667833|NCT02164305|Experimental|Neuromuscular group|4-week exercise training, 3 times a week, 30 minutes per visit
16667834|NCT02164305|Sham Comparator|Control|Only have 2 assessments.
16667835|NCT02164292||ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
16667836|NCT02164279||Progressor (ND)|Group of patients with an albuminuria > 100mg/L, by Urinary sample collection
16667837|NCT02164279||Non-Progressor (non-ND)|Group of patients without an albuminuria > 100mg/L, by Urinary sample collection
16667838|NCT02164266|Experimental|Part 1: Healthy Volunteers|
16667839|NCT02164266|Experimental|Part 2: Patients with T2D, Group A|Low dose daily oral administration of RO6799477
16667840|NCT02164266|Experimental|Part 2: Patients with T2D, Group B|High dose daily oral administration of RO6799477
16667841|NCT02164253|Experimental|Deferiprone|Deferiprone, 25 to 30 mg/kg per day, oral use
16667842|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
16667843|NCT02164227|Experimental|respiratory pattern|Deep and slow inspiration is used in the initial and active stages, at which time the contractions vary from uncomfortable to strong, lumbosacral pain and cervical dilation may occur between 3 and 8 cm in this case the mother is driven to inspire slowly and the level of inspiratory reserve volume followed by slow exhalation to functional residual capacity; Sigh with post-expiratory pause that corresponds to a small spontaneous exhalation to relax occurs in tidal volume; Expiratory delay that corresponds to a prolonged propelled with the lips during the lull and expiration in the expiration time that corresponds to a slow inspiration followed by two or three puffs with the short lips will be used propelled.
16667844|NCT02164227|No Intervention|Control|Follows the service routine
16667845|NCT02164214|Experimental|patients PSORIATIC ARTHRITIS|etanercept Treatment
16667846|NCT02164214|Active Comparator|patients RHEUMATOID ARTHRITIS|etanercept Treatment
16667847|NCT02164188|No Intervention|control|Initially this control group will not receive an intervention (wait list). After 8 weeks this goup will receive the Flourishing protocol (cross over).
16667848|NCT02164188|Experimental|Flourishing protocol|This group will receive the intervention Flourishing protocol and after that it will not receive any other intervention (cross over).
16667850|NCT02164162|Experimental|Experimental group|"Participants received 12 sessions of robotic assisted body weight-supported treadmill training on the Lokomat. Training occurred approximately 3 days/ week for 4 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support.
~Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session."
16667851|NCT02164162|Active Comparator|Control group|Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
16667852|NCT02164149||Quality of colon cancer surgery|Patients with primary colon cancer
16667853|NCT02164136|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
16667854|NCT02164136|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
16667855|NCT02164123|Experimental|Spinal mobilization|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute. The subject will be comfortable prone lying.
16667856|NCT02164123|Active Comparator|Spinal Mobilization II|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
16667857|NCT02164123|Placebo Comparator|Placebo|20 subjects will be randomized to this arm. Only manual contact will be applied, without any oscillation. The subject will be comfortable prone lying. The intervention time is the same of the other arms.
16667858|NCT02164110|Experimental|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2
~Method of administration: oral administration
~Dose of drug to be administered: 1.5 mL/dose"
16667859|NCT02164110|Active Comparator|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2
~Method of administration: oral administration
~Dose of drug to be administered: 1.5 mL/dose"
16667860|NCT02164097|Experimental|ODSH and ICE Chemotherapy|"Patients will receive standard doses of ICE Chemotherapy:
~Ifosfamide 1800 mg/m2 mixed with Mesna 360 mg/m2 IV over 2 hours on days 1, 2, 3, 4, and 5
~Carboplatin 400 mg/m2 IV over 1 hour on days 1 and 2
~Etoposide 100 mg/m2 IV over 1 hour on days 1, 2, 3, 4, and 5
~ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first ifosfamide dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for five consecutive days, on days 1-5, for a total of 120 hours of continuous ODSH infusion."
16667861|NCT02164084|Experimental|SB204|SB204 8% topically twice daily for 4 days and once on Day 5
16667862|NCT02164084|Placebo Comparator|Vehicle Gel|Vehicle Gel topically twice daily for 4 days and once on Day 5
16667863|NCT02164071||Multiple Myeloma (MM)|Patients with Myltiple Myeloma, symptomatic or asymptomatic
16667864|NCT02164071||Myelodysplastic Syndromes or Acute Myeloid Leukemia|Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
16667865|NCT02164071||Chronic Lymphocytic Leukemia (CLL)|Patients with Chronic Lymphocytic Leukemia
16667866|NCT02164058|Experimental|TandemHeart System + PCI|TandemHeart System prior to percutaneous coronary intervention
16667867|NCT02164058|Active Comparator|PCI|Percutaneous coronary intervention
16667868|NCT02164045|Experimental|BMS-663068- Fasted|BMS-663068 tablet twice a day by mouth on specified days
16667869|NCT02164045|Experimental|BMS-663068- Fed|BMS-663068 tablet twice a day by mouth on specified days
16667870|NCT02164032|Placebo Comparator|Insulin dilution buffer|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.
~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
16667871|NCT02164032|Active Comparator|Intranasal Insulin administration|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.
~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
16667872|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
16668966|NCT02156414||Clinically Localized Prostatic Neoplasm|Radical Prostatectomy Extended Lymphadenectomy
16667873|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
16667874|NCT02164006|Experimental|TGR-1202 + brentuximab vedotin|TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
16667875|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
16667876|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
16667877|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
16667878|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
16667879|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
16667880|NCT02163980|Placebo Comparator|Caudal ropivacaine + normal saline|1.5ml kg-1 ropivacaine 0.15% with normal saline (Control group, n=40).
16667881|NCT02163980|Experimental|Caudal ropivacaine + dexmedetomidine|1.5ml kg-1 ropivacaine 0.15% with dexmedetomidine 1 μg kg-1 (DEX group, n=40)
16667882|NCT02163967|Other|Dose sequence: Sham, Low, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
16667883|NCT02163967|Other|Dose sequence: Sham, High, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
16667884|NCT02163967|Other|Dose sequence: Low, Sham, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
16667885|NCT02163967|Other|Dose sequence: Low, High, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
16667886|NCT02163967|Other|Dose sequence: High, Sham, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
16667887|NCT02163967|Other|Dose sequence: High, Low, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation
16667888|NCT02163954|Active Comparator|Clopidogrel|Patients treated with clopidogrel for 14 days
16667889|NCT02163954|Experimental|Ticagrelor|Patients treated with ticagrelor for 14 days
16667890|NCT02163941|Experimental|Compassion Training|8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
16667891|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
16667892|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
16667893|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
16667894|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
16667895|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
16667896|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
16667897|NCT02163902|Experimental|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
16667898|NCT02163902|Placebo Comparator|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
16667899|NCT02163889||Candida Positive Patients|Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida
16667900|NCT02163876|Experimental|HuCNS-SC cells|Intramedullary transplantation of HuCNS-SC cells in the cervical spine
16667901|NCT02163876|No Intervention|non-surgery arm|non-surgery arm
16667902|NCT02163863|Experimental|BioMimics 3D|The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
16667903|NCT02163863|Active Comparator|Control|CR Bard LifeStent System, delivering a self-expanding Nitinol stent
16667904|NCT02163850|Experimental|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
16667905|NCT02163850|Active Comparator|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
16667906|NCT02163837|Experimental|rifaximine|
16667907|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
16667908|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
16667909|NCT02163824|Placebo Comparator|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
16667910|NCT02163824|Placebo Comparator|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
16667911|NCT02163811|Experimental|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
16667912|NCT02163811|Active Comparator|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
16667913|NCT02163798|Experimental|Tai Chi Group|Participants in this group received a 12-week instructor-led Tai Chi training program.
16667914|NCT02163798|Experimental|Walking Group|Participants in this group received a 12-week instructor-led brisk walking training program.
16667915|NCT02163798|No Intervention|Control Group|Participants in the control group did not receive intervention during the 12 weeks, and were told that they would be provided two sessions of free health and fitness evaluation with an interval of three months (12 weeks).
16667916|NCT02163785|Active Comparator|Supine position|Abdominoperineal resection - perineal time- in supine position
16667917|NCT02163785|Experimental|Prone position|Abdominoperineal resection - perineal time- in prone position
16667918|NCT02163772|Experimental|Intracordal hyaluronate injection (HI)|The intervention of Intracordal hyaluronate (Restylane) injection is given in this group No other therapies are given
16667919|NCT02163772|No Intervention|Conservative management (CM)|In this arm, only observation is arranged. No therapy is given.
16667920|NCT02163759|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
16667921|NCT02163759|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
16667922|NCT02163759|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
16667923|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
16667924|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
16667925|NCT02163733|Other|Fasted|AZD9291 tablets following a period of fasting
16667926|NCT02163733|Other|High-fat meal|AZD9291 tablets following a high-fat meal.
16667927|NCT02163720||Yondelis®-Caelyx®-relapse ovarian cancer|Yondelis®-Caelyx®-relapse ovarian cancer
16667928|NCT02163707|Other|Psilocybin Dose 1|0.3 mg/kg (approximately 20mg/70kg)
16667929|NCT02163707|Other|Psilocybin Dose 2|0.45 mg/kg (approximately 30 mg/70 kg)
16667930|NCT02163707|Other|Psilocybin Dose 3|0.6 mg/kg (approximately 40 mg/70 kg)
16667931|NCT02163694|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Veliparib Placebo on Day -2 through 5 of a 21-day cycle. Carboplatin on Day 1 of a 21-day cycle and paclitaxel on Day 1, 8, and 15 of a 21-day cycle.
16667932|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib on Day -2 through 5 of a 21-day cycle. Carboplatin on Day 1 of a 21-day cycle and paclitaxel on Day 1, 8, and 15 of a 21-day cycle.
16667933|NCT02163681|Experimental|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
16667934|NCT02163668|Experimental|Yoga group|8 months of progressive Yoga training
16667935|NCT02163668|No Intervention|Control group|No training, just pre and post testing
16667936|NCT02163655|Placebo Comparator|PLACEBO|PLACEBO: placebo, oral, every 24 hours for maximum 5 days
16667937|NCT02163655|Experimental|FUROSEMIDE|FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
16667938|NCT02163642||Non-CF Bronchiectasis|Cyranose® 320
16667939|NCT02163629|Experimental|psychotherapeutic intervention|"The psychotherapeutic intervention stress management is based on therapeutic, behavioral and cognitive strategies. They are active and put the patient actor of his adaptation of the heart transplantation entire process. The approached components are emotional, cognitive and behavioral (techniques of communication and problem solving)."
16667940|NCT02163629|No Intervention|Usual medical care|
16667941|NCT02163616|Experimental|PPH Treatment|800mcg sublingual misoprostol
16667942|NCT02163603||Pelvic osteotomy|
16667943|NCT02163590|Experimental|2Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 2Hz frequency.
16667944|NCT02163590|Experimental|0,5Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 0,5Hz frequency.
16667945|NCT02163590|Placebo Comparator|Placebo|A simulation technique, that mimic the other groups, in this case only manual contact will be applied, without any oscillation.
16667946|NCT02163577|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W). Dose was determined by the participant's weight and prescribed dose by their study doctor.
16667947|NCT02163577|Experimental|Burosumab Q4W Then Q2W|Burosumab SC injections every 4 weeks (Q4W). Dose was determined by the participant's weight and prescribed dose by their study doctor. Participants in Q4W were to switch to Q2W beginning with Week 64 dosing.
16667948|NCT02163564|No Intervention|Focus groups|The first part of the study is to conduct focus groups of adolescents with insomnia and depression. The treatment arm is informed by responses provided by teens in the focus group portion.
16667949|NCT02163564|Active Comparator|Treatment|A modified cognitive behavioral therapy for insomnia is the treatment intervention in this treatment arm.
16667950|NCT02163551||Spinal Cord Injury|Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
16667951|NCT02163551||Controls|Twenty healthy age-matched adults will also participate.
16667952|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
16667953|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
16667954|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
16667955|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
16667956|NCT02163512||Non-refractory ascites|
16667957|NCT02163512||Refractory ascites|
16667958|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
16667959|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
16667960|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
16667961|NCT02163473||Septic patients|Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
16667962|NCT02163473||Healthy Control|The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
16667963|NCT02163460|Experimental|Drain|In group 1(Drain), a 4.8 mm diameter continuous closed-suction tubular drain : was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
16667964|NCT02163460|Experimental|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
16667965|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
16667966|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
16667967|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
16667968|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
16667969|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
16667970|NCT02163434|Experimental|gabapentin|1800-2400mg/day divided tid or qid, orally.
16667971|NCT02163434|Experimental|metoclopramide|45-60mg/day divided tid or qid, orally
16667972|NCT02163421|Experimental|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
16667973|NCT02163421|Experimental|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
16667974|NCT02163421|Experimental|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
16667975|NCT02163421|Active Comparator|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
16667976|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
16667977|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
16668123|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
16667978|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
16667979|NCT02163382|Experimental|Neurovent Monitor XIII|1 hour Ventilation with NAVA
16667980|NCT02163369|Experimental|Peppermint and Lavender Essential Oils|
16667981|NCT02163356|Experimental|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
16667982|NCT02163343||No treatment|
16667983|NCT02163330|Active Comparator|Acetazolamide|active comparator group will receives 500 mg azetazolamide daily
16667984|NCT02163330|Placebo Comparator|sugar pill|placebo comparator group will receives placebo daily.
16667985|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
16667986|NCT02163304|Active Comparator|Artificial Sweetner|Artificial Sweetener
16667987|NCT02163304|Placebo Comparator|Tasteless Solution|12 oz tasteless solution
16667988|NCT02163304|Active Comparator|Sucrose|12 oz 75 g sucrose beverage
16667989|NCT02163291|Experimental|paclitaxel liposome|S-1 plus paclitaxel liposome
16667990|NCT02163278|Experimental|DBPR108|
16667991|NCT02163278|Placebo Comparator|matching placebo|
16667992|NCT02163265|Experimental|Surgery|Patients suffering from Pectus excavatum and Pectus carinatum will be surgically treated
16667993|NCT02163252|Active Comparator|Standard|A 12-week internet-based weight loss program that involves weekly video lessons, a self-monitoring platform where participants submit their weight, calorie, and activity information, and weekly automated feedback.
16667994|NCT02163252|Experimental|Early intervention|Participants randomized to Early Intervention will receive the same internet-based weight loss program compared to the Standard group. In addition, Early Intervention participants achieving less than optimal weight loss following several weeks of treatment will be given the opportunity to come to the Weight Control and Diabetes Research Center for an individual visit. At this visit, an interventionist will discuss with the participant any barriers that he or she may be experiencing and recommend alternate strategies to assist in their weight loss. One such strategy would be to recommend the use of meal replacement products or portion controlled meals. In addition to this one-time visit, the interventionist will follow up with the participant via phone weekly, for 2 weeks following this in-person visit.
16667995|NCT02163239||10mm Cannula|Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator
16667996|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
16667997|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
16667998|NCT02163213|Other|Serum Bovine Immunoglobulin|"Serum-Derived Bovine Immunoglobulin (SBI) 5.0 g by mouth twice daily;
~Effects of SBI will be compared with observations and measurements performed at baseline PRIOR to starting the SBI treatment"
16667999|NCT02163200||pressure of total hip replacement|Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA
16668000|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
16668001|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
16668002|NCT02163174|Active Comparator|Pentoxyfilline arm|Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
16668003|NCT02163174|Placebo Comparator|Placebo arm|Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
16668004|NCT02163161|Experimental|Treatment A|
16668005|NCT02163161|Experimental|Treatment B|
16668006|NCT02163161|Experimental|Treatment C|
16668007|NCT02163148||Public Speaking Anxiety|Intervention to be administered: One speech exposure session.
16668008|NCT02163122|Experimental|NAC Followed by EEC|This arm will undergo allergy assessment first by NAC. After a rest and washout period, the same individuals will undergo assessment in an EEC.
16668009|NCT02163122|Experimental|EEC Followed by NAC|This arm will undergo allergy assessment first in an EEC. After a rest and washout period, the same individuals will undergo assessment by NAC.
16668010|NCT02163122|Experimental|Dose-finding Phase|An initial group of 6 to 12 participants with cat allergy as defined by the eligibility criteria will undergo a single-visit, stepwise dose-escalating nasal allergen challenge only, with the aim of estimating the most appropriate single dose of allergen to use in the randomized phase. Eligible participants who participate in the dose-finding phase may proceed to the randomized phase of the trial after a minimum 28-day washout period.
16668011|NCT02163109||Critically-ill patients|Adult patients requiring intubation and mechanical ventilation on an intensive care unit, predicted to require a further 48 hours of artificial ventilation
16668012|NCT02163096||History of Wheezing, Benign Joint Hypermobility Syndrome|
16668013|NCT02163096||Asthma, Benign Joint Hypermobility Syndrome|
16668014|NCT02163083|No Intervention|Lymphadenectomy using standard Methods|Lymphadenectomy will be performed as a standard procedure
16668015|NCT02163083|Experimental|Lymphadenectomy using ICG|A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.
16668016|NCT02163070|Experimental|whey drink|consumption of 220 milliliters of whey drink three times a week,
16668017|NCT02163070|Experimental|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
16668018|NCT02163070|Experimental|vitaminE|consumption of 400 milligrams of vitamin E three times a week,
16668019|NCT02163070|No Intervention|D- control|control group: no intervention,
16668020|NCT02163057|Other|Cohort 1: Surgery Cohort|Participants received up to two doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart before surgery and up to three doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart after surgery for a total of no more than four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device.
16668021|NCT02163057|Other|Cohort 2: Chemoradiation|Participants received four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device 3 weeks (± 3 days) apart beginning approximately 2 to 6 months after chemoradiation therapy.
16668022|NCT02163044||Statin|Patients on statin treatment
16668023|NCT02163031|Active Comparator|right radial approach|devices used in the coronary angiography by right radial approach
16668024|NCT02163031|Active Comparator|left radial approach|devices used in the coronary angiography by left radial approach
16668025|NCT02163018|Experimental|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1.
16668026|NCT02163018|Placebo Comparator|Placebo|Subcutaneous administration of placebo
16668027|NCT02163005|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
16668028|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
16668029|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
16668030|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
16668031|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
16668032|NCT02162966|Experimental|High Dose Colistin|High dose colistin protocol
16668033|NCT02162966|Active Comparator|Standard Dose Colistin|Standard dose of colistin
16668034|NCT02162940||patients taking statins|Visual anlogue score vas used to evaluate pain. The SF 36 test was used to evaluate quality of life.
16668035|NCT02162940||patients not taking statins|Visual anlogue score vas used to evaluate pain.The SF 36 test was used to evaluate quality of life.
16668036|NCT02162927|Experimental|Potassium Nitrate (N)|This involves 1 serving (2 pills) of potassium nitrate KNO3- (N) (8 mmols NO3-). The supplementation period is six days. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
16668037|NCT02162927|Placebo Comparator|Potassium Chloride|This involves 1 serving (2 pills) of the nitrate-free placebo (PL) potassium chloride (8 mmol KCl) for a six-day supplementation period. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
16668038|NCT02162914|Active Comparator|Regorafenib/active|Subjects randomized to be treated with Regorafenib (active product) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
16668039|NCT02162914|Placebo Comparator|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib (placebo) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
16668040|NCT02162901|Experimental|Choice-Class with IVR Calls|Participants enrolled in this arm of the study will have chosen to attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months.
16668041|NCT02162901|Experimental|Choice-DVD with IVR calls|Participants enrolled in this arm of the study will have chosen to watch a DVD at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
16668042|NCT02162901|Experimental|Random-Class with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
16668043|NCT02162901|Experimental|Random-DVD with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will be given a DVD to watch at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
16668044|NCT02162901|Active Comparator|Random-Class only|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the intervention and will receive a workbook to use at home.
16668045|NCT02162888|Other|Eagle-BDM; Teva-BDM; Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
16668046|NCT02162888|Other|Teva-BDM; Eagle-BDM;Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
16668047|NCT02162888|Other|Teva-BDM, Teva-BDM, Eagle-BDM|Eagle-BDM: IV Teva-BDM: IV
16668048|NCT02162875|Experimental|MDA once a year|Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
16668049|NCT02162875|Experimental|MDA 2nd year CWT follwed by 2 years SBT|Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
16668050|NCT02162875|Experimental|Praziquantel every second year CWT|Treatment with praziquantel given every second year as CWT
16668051|NCT02162875|Experimental|MDA once a year SBT|Treatment with praziquantel as above given as 4 years of SBT
16668052|NCT02162875|Experimental|MDA given for 2 years as SBT|Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
16668053|NCT02162875|Experimental|MDA as SBT 1year and 1 year without MDA|Treatment with praziquantel given as one years of SBT alternating with one year without treatment
16668054|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
16668055|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
16668056|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
16668057|NCT02162849|Experimental|Varenicline + Placebo Patch|"Varenicline dosing follows the recommended 12 week course: 0.5 milligram mg/day by mouth for Days 1-3, 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter. Participant takes Varenicline 1-10 days after Visit 1.
~Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day.
~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.
~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo. Some of the counseling sessions may be recorded by video and/or audio tape.
~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
16668058|NCT02162849|Experimental|Nicotine Patch + Placebo Tablet|"Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
~Starting on Day 8, and then every day after that, participant applies 1 nicotine patch.
~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.
~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo.
~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
16668059|NCT02162836|Experimental|Cohort 1|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
16668060|NCT02162823||Pancreatic cancer|Patients with pancreatic cancer and age&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
16668061|NCT02162810|Active Comparator|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
16668062|NCT02162810|Placebo Comparator|placebo-controlled|Simple Syrup will be used as the placebo
16668063|NCT02162797|Experimental|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
16668064|NCT02162797|Experimental|zinc supplementation|Intervention group A. Patients who will orally receive zinc for 3 months.
16668065|NCT02162784|Experimental|Budesonide/procaterol 180/10mcg X1|HFA MDI, oral inhalation, 180/10mcg, one puff
16668066|NCT02162784|Experimental|Budesonide/Procaterol, 180/10mcg X2|HFA MDI, oral inhalation, two puffs
16668067|NCT02162784|Active Comparator|Albuterol HFA MDI 100 mcg X2|HFA MDI, oral inhalation, 100mcg, two puffs
16668068|NCT02162771|Experimental|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.
~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
16668069|NCT02162771|Active Comparator|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.
~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
16668070|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
16668071|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
16668072|NCT02162745|Experimental|Isotonic solution (NaCl 0.9%)|Single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril
16668073|NCT02162745|Experimental|Hypertonic solution (NaCl 3%)|Single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril
16668074|NCT02162745|No Intervention|Supportive care|Wiping the nose, positioning the child, changing a wet diaper, feeding.
16668075|NCT02162732|Experimental|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
16668076|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
16668190|NCT02161887||Complementary Medicine Group|Patients receiving chiropractic care, acupuncture, or meditation for chronic pain
16668077|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
16668078|NCT02162693|Experimental|Mesenchymal progenitor cells|Administrated for intra-articular use of Mesenchymal progenitor cells
16668079|NCT02162693|Active Comparator|Sodium Hyaluronate|Administrated for intra-articular use of Sodium Hyaluronate.
16668080|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
16668081|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
16668082|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
16668083|NCT02162667|Experimental|CT-P6|
16668084|NCT02162667|Active Comparator|Trastuzumab|
16668085|NCT02162654|Active Comparator|Remote ischemic preconditioning|Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
16668086|NCT02162654|Sham Comparator|Sham preconditioning|Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
16668087|NCT02162641||SCC of the anus|
16668088|NCT02162628||Exair for Total Repair|Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair
16668089|NCT02162628||Total Native Tissue Repair|Total repair with native tissue only
16668090|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
16668091|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
16668092|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
16668093|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
16668094|NCT02162589||POEM for Achalasia|Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia.
16668095|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
16668096|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.
~Intervention: FOLFOXIRI with bevacizumab"
16668097|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.
~Intervention: FOLFOX/FOLFIRI with bevacizumab"
16668098|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.
~Intervention: FOLFOX/FOLFIRI with panitumumab"
16668099|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.
~Intervention: FOLFOX/FOLFIRI with bevacizumab"
16668100|NCT02162550|Experimental|Bydureon|injectable medication Bydureon
16668101|NCT02162550|Placebo Comparator|Placebo|a similar looking injectable
16668102|NCT02162537|Other|Arm A (standard arm)|Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)
16668103|NCT02162537|Other|Arm B (experimental arm)|Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain
16668104|NCT02162524|No Intervention|No Exercise Control|Healthy Living Group
16668105|NCT02162524|Active Comparator|Aerobic Exercise Group|Persons are aerobically exercising.
16668106|NCT02162511|Experimental|ARM A Malignant TBI|Malignant diseases Conditioning including total body irradiation and chemotherapy
16668107|NCT02162511|Experimental|ARM B Malignant Non-TBI|Malignant diseases chemotherapy based conditioning
16668108|NCT02162511|Experimental|ARM C Non-malignant|Non-malignant diseases Chemotherapy based conditioning
16668109|NCT02162498|Experimental|Feeding buddies intervention|Sites receiving a comprehensive feeding buddy program implemented by the Window of Opportunity program.
16668110|NCT02162498|No Intervention|Standard of care|Sites from Window of Opportunity program who are not yet receiving the comprehensive feeding buddies program and are only receiving standard of care PMTCT support.
16668111|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler|Single dose of Salmeterol/fluticasone Easyhaler
16668112|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)
16668113|NCT02162485|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
16668114|NCT02162485|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)
16668115|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
16668116|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
16668117|NCT02162459||whey beverage|consumption of 52 grams of whey protein supplement following resistance exercise
16668118|NCT02162459||chocolate milk beverage|consumption of chocolate flavored milk following resistance exercise
16668119|NCT02162446|Experimental|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
16668120|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
16668121|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
16668122|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
16668124|NCT02162420|Experimental|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
16668125|NCT02162420|Experimental|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
16668126|NCT02162407|Experimental|Insulin detemir 60 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
16668127|NCT02162407|Experimental|Insulin detemir 120 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
16668128|NCT02162407|Active Comparator|Human insulin 6 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
16668129|NCT02162394||Referred for Holter monitoring|
16668130|NCT02162381|Experimental|methylphenidate provided|the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
16668131|NCT02162381|Active Comparator|control|control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation
16668132|NCT02162355|Experimental|GLPG0634 in Japanese subjects|Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days
16668133|NCT02162355|Placebo Comparator|Placebo in Japanese healthy subjects|Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days
16668134|NCT02162355|Experimental|GLPG0634 in Caucasian subjects|In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days
16668135|NCT02162355|Placebo Comparator|Placebo in Caucasian healthy subjects|In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days
16668136|NCT02162342||Rehabilitative intervention|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
16668137|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
16668138|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
16668139|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.
~After 8 week follow up visit, Wait-List Group offered meditation program."
16668140|NCT02162316|Active Comparator|H.Pylori eradication therapy|A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
16668141|NCT02162316|Experimental|Motilitone®|30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
16668142|NCT02162303|Experimental|Colchicine|Colchicine 0.6 mg tablets,once daily, for 6 months
16668143|NCT02162303|Placebo Comparator|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment.
16668144|NCT02162290|Experimental|Interval exercise|Exercise bouts in low and high intensities
16668145|NCT02162290|Experimental|Continuous exercise|Exercise continuously with moderate intensity
16668146|NCT02162277||Osteoporosis diagnostic kit|
16668147|NCT02162264||E2020|
16668148|NCT02162251||E2020|
16668149|NCT02162238|Placebo Comparator|purified water|Filtered water Pump water purified by the LSF-filtering device Intervention: Device: LSF-filtering device
16668150|NCT02162238|Experimental|zinc enriched purified water|Zinc water water purified and zinc-enriched by the LSF-filtering device Intervention: Device: LSF-filtering device
16668151|NCT02162225|Experimental|Beet Juice|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.
~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
16668152|NCT02162212|Active Comparator|ADA guideline Instructed|The control intervention will be instruction in basic wellness activities according to the American Diabetes Association guidelines
16668153|NCT02162212|Experimental|Optimized Shoulder Movement Program|"The experimental intervention is the Optimized Shoulder Movement Program. Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation, and active shoulder motion based on the participant's baseline activity count ."
16668154|NCT02162199|Experimental|Debio 1450|Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions
16668155|NCT02162199|Placebo Comparator|Placebo|Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions
16668156|NCT02162173|Experimental|Endoscopy|All patients underwent the same endoscopy.
16668157|NCT02162160|Experimental|Probiotic creme|Women receing probiotic creme
16668158|NCT02162160|Placebo Comparator|placebo|Women receiving a moisturizer
16668159|NCT02162134|Other|no chewing gum.|the no chewing gum group was control and receive no chewing gum postoperatively. While they received all other medications like anesthesia, antibiotics etc
16668160|NCT02162134|Experimental|sugar free chewing gum|sugar free chewing was given to patients 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started.
16668161|NCT02162134|Experimental|sugared chewing gum|sugared chewing gum will be given 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started
16668162|NCT02162121|Experimental|Stimulating catheter|"After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
16668163|NCT02162121|Active Comparator|Non-stimulating catheter|"After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
16668164|NCT02162095||Chronic obstructive pulmonary disease|Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
16668165|NCT02162095||Control|Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
16668166|NCT02162082|Experimental|stent or scaffold|implantation of stents or scaffolds after recanalization of coronary chronic total occlusions
16668167|NCT02162069|Experimental|transcatheter aortic valve replacement|Patients receive transcatheter aortic valve replacement.
16668168|NCT02162056|Experimental|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffold for coronary artery disease.
16668169|NCT02162043||Usability assessment|Patients without any experience with visual field testing will be recruited and tested with different versions of the developed self-test. This will help identify usability features that will make the test user-friendly.
16668170|NCT02162043||Hospital-based clinical trial|The new test will be evaluated on patients attending Manchester Royal Eye Hospital to provide an estimate of its diagnostic performance.
16668171|NCT02162043||Community-based trial|Patients attending Manchester Royal Eye Hospital's outpatient clinics will be recruited to trial the new test on their friends and family in order to evaluate the uptake and performance of the new test in a home environment without any researchers/clinicians presence.
16668172|NCT02162030|Other|Full ACT|Acceptance and Commitment Therapy
16668173|NCT02162030|Other|Modified ACT|Acceptance and Commitment Therapy
16668174|NCT02162017|Experimental|The lying flat intervention|Patients in lying flat intervention to be nursed lying flat (0°) immediately after diagnosis of acute stroke is made and to remain in this position for 24 hours
16668175|NCT02162017|Active Comparator|The sitting-up intervention|Patients in the sitting up intervention to be nursed with their head elevated (≥30°) by raising the head of the bed (or with extra pillows or wedge) immediately after the diagnosis of acute stroke is made, and to remain in this position for the next 24 hours
16668176|NCT02162004|Experimental|Continuous correction|The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
16668177|NCT02162004|No Intervention|Control|Regular sensor-augmented pump therapy.
16668178|NCT02161991|Experimental|aprepitant group|Patients assigned to aprepitant group should receive aprepitant for the control of CINV, aprepitant 125 mg for day1, 80mg for day2 and day3.
16668179|NCT02161991|Placebo Comparator|placebo|Patients assigned to placebo group should receive placebo for the control of CINV compared with aprepitant group.
16668180|NCT02161965|Experimental|Rivaroxaban|"Rivaroxaban (oral tablet) for patients with atrial fibrillation:
~20 mg once daily for patients with GFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml.
~Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
16668181|NCT02161965|Active Comparator|vitamin K antagonists|Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
16668182|NCT02161952|Experimental|Pirfenidone|Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
16668183|NCT02161952|Placebo Comparator|Matched equivalent placebo|Matched equivalent placebo
16668184|NCT02161926|Experimental|obese men from 60 to 70 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
16668185|NCT02161926|Active Comparator|obese men from 30 to 40 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
16668186|NCT02161913|Active Comparator|SCI Education Control Group|The SCIEC condition is a 16-session, highly structured educational intervention that provides information on how SCI affects the body; methods for maximizing function, coping, and living with SCI; and staying healthy with SCI. It also includes general guidelines for improving health behavior. Each SCIEC session follows the same structure, beginning with a presentation of the objectives for the current session and a brief review of material from the previous session before introducing the session's topic and presenting information on one or two key problem areas. SCIEC utilizes a traditional didactic model with information delivered by an expert SCI educator in a classroom or lecture setting.
16668187|NCT02161913|Experimental|Multi-family Group Treatment|The MFG Program uses a structured problem-solving and skills training program to provide participants with SCI and their caregivers with tools and information to improve coping and help family members to connect through positive behavioral exchanges. MFG educators are health professionals with experience in management of SCI, such as physical therapists, recreational therapists, occupational therapists, and psychologists. MFG will last for 16 sessions across 9 months.
16668188|NCT02161900|Active Comparator|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
16668189|NCT02161900|Experimental|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
16668316|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
16668191|NCT02161887||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management) for chronic pain.
16668192|NCT02161874|Experimental|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
16668193|NCT02161874|Active Comparator|Nanotite certain tapered implant|Nanotite Certain tapered implant
16668194|NCT02161861|Experimental|group cFEE|"The group cFEE will be similarly inseminated with 100000/ml motile spermatozoa and will be supplemented with cFEE 100µM during 18 hours.
~The cFEE will increase the fusiogenic capacities of a gamete,"
16668195|NCT02161861|No Intervention|untreated group|control group
16668196|NCT02161848||Patients|Patients with verified singe large-scale mtDNA deletions and chronic progressive external ophthalmoplegia.
16668197|NCT02161848||Controls|Healthy controls matched for age and gender.
16668198|NCT02161848||Patient group as Controls|Patients with mitochondrial DNA 3243A>G mutations
16668199|NCT02161835|Experimental|Training|Participants exercise 3 times a week, 30 minute, on an ergometer bike.
16668200|NCT02161835|No Intervention|Control|Participants is tested with the 4 objective myotonia test and measurements of self-assessed myotonia by the Myotonia Behavior Scale is collected.
16668201|NCT02161822|Experimental|Simvastatin|single arm : Simvastatin
16668202|NCT02161809|Experimental|Physical Activity Intervention|This arm (10 summer day camps) will receive the Physical Activity intervention the first year and both healthy eating and physical activity the second and thrid years.
16668203|NCT02161809|Other|Healthy EAting Intervention|This arm (10 summer day camps) will receive the Healthy Eating intervention the first year and both healthy eating and physical activity the second and thrid years.
16668204|NCT02161796|Experimental|1: young male subjects|3x single dose of FG-4592 and a placebo
16668205|NCT02161796|Experimental|2: young female subjects|3x single dose of FG-4592 and a placebo
16668206|NCT02161796|Experimental|3: elderly male subjects|3x single dose of FG-4592 and a placebo
16668207|NCT02161796|Experimental|4: elderly female subjects|3x single dose of FG-4592 and a placebo
16668208|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
16668209|NCT02161770|Other|Normal hepatic function|Patients without a history or presence of hepatic disease
16668210|NCT02161770|Other|Mild hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh A
16668211|NCT02161770|Other|Moderate hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh B
16668212|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
16668213|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
16668214|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
16668215|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
16668216|NCT02161744|Experimental|ADSCs administration|Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
16668217|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
16668218|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
16668219|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
16668220|NCT02161718|Placebo Comparator|Placebo + olanzapine|
16668221|NCT02161705|Experimental|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
16668222|NCT02161705|Placebo Comparator|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
16668223|NCT02161692|Experimental|High dose chemotherapy|"Characterized by the following sequence:
~High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin
~1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue"
16668224|NCT02161692|Active Comparator|Conventional dose chemotherapy|Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles
16668225|NCT02161679|Experimental|IMMU-132|IMMU-132 infusion is administered
16668226|NCT02161679|Active Comparator|IMMU-132 plus Carboplatin|IMMU-132 infusion and Carboplatin infusion are administered to the participants in this arm of study.
16668227|NCT02161666||Patients|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
16668228|NCT02161666||Controls|Age, sex and BMI-matched healthy controls
16668229|NCT02161653|No Intervention|Prednisone|Prednisone 40 mg daily by mouth during 30 days.
16668230|NCT02161653|No Intervention|Pentoxifylline|Pentoxifylline 400 mg thrice in day by mouth during 30 days
16668231|NCT02161653|Experimental|Prednisone plus metadoxine|Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
16668232|NCT02161653|Experimental|Pentoxifylline plus metadoxine|Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
16668233|NCT02161640||Control|Age/sex matched control participants, not suffering from inflammatory bowel disease or any other chronic inflammatory disease
16668234|NCT02161640||Inflammatory Bowel Disease|Patients with active or remissive inflammatory bowel disease
16668235|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
16668236|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
16668237|NCT02161614|Placebo Comparator|Placebo|Patients will use placebo for 30 days
16668238|NCT02161614|Experimental|Estradiol Valerate|patients will use estradiol valerate 1mg/day during 30 days
16668239|NCT02161601|Experimental|Correctly and incorrectly applied cricoid pressure|
16668240|NCT02161588|Experimental|Semaglutide|
16668241|NCT02161588|Placebo Comparator|Placebo|
16668242|NCT02161575|Experimental|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
16668243|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
16668244|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
16668245|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
16668246|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
16668247|NCT02161536|Experimental|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
16668248|NCT02161536|Experimental|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
16668249|NCT02161536|Experimental|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
16668250|NCT02161510|Experimental|Part I: MK-2248 200 mg (Panel A)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
16668251|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel B)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668252|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel C)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.
16668253|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel D)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668254|NCT02161510|Experimental|Part II: MK-2248 200 mg (Panel E)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
16668255|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel F)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668256|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel G)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668257|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel H)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668258|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel I)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668259|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel J)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
16668260|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
16668261|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
16668262|NCT02161471||Aortic coarctation|Patients after repair of coarctation of the aorta
16668263|NCT02161471||Tetralogy of Fallot|Patients after repair of tetralogy of Fallot
16668264|NCT02161471||TGA atrial switch|Patients with transposition of the great arteries after atrial switch (Senning procedure)
16668265|NCT02161471||TGA arterial switch|Patients with transposition of the great arteries after arterial switch operation
16668266|NCT02161471||Normal|Normal controls
16668267|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
16668268|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
16668269|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
16668270|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
16668271|NCT02161445||AHF group|patients with AHF diagnosed based on clinical, biological and echocardiographic findings. Two sub-groups of patients were identified within HF group: Patients with reduced (<45%) LVEF (HFrEF) and those with preserved (≥45%) LVEF (HFpEF).
16668272|NCT02161445||non AHF group|we included patients with acute dyspnea and for whom acute heart failure was excluded
16668273|NCT02161432|Experimental|Treatment A|single dose of BI 187004 in fasted state
16668274|NCT02161432|Experimental|Treatment B|single dose of BI 187004
16668275|NCT02161432|Experimental|Treatment C|single dose of BI 187004 in fed state
16668276|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
16668277|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
16668278|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
16668279|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
16668280|NCT02161393|Experimental|Physical Activity Intervention|12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
16668281|NCT02161393|Active Comparator|Pulmonary Rehabilitation Programme|6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
16668282|NCT02161380|Experimental|1 Chronic Bilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
16668283|NCT02161380|Experimental|2 Acute Bilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
16668284|NCT02161380|Experimental|3 Acute Unilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
16668285|NCT02161367|Experimental|Simethicone, OVOL|Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
16668286|NCT02161367|Placebo Comparator|Oral Suspending Vehicle, Ora-Plus|Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
16668287|NCT02161354|Experimental|2mg dose of NTC-510 or placebo|Subjects will be dosed with 2 mg of NTC-510 or placebo.
16668288|NCT02161354|Experimental|4 mg dose of NTC-510 or placebo|Subjects will be dosed as a split dose of 2 mg followed by 2 mg an hour later of NTC-510 or placebo.
16668289|NCT02161354|Experimental|6 mg dose of NTC-510 or placebo|Subjects will be dosed with 6 mg of NTC-510 or placebo.
16668290|NCT02161354|Experimental|2 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 2mg of NTC-510A or placebo
16668291|NCT02161354|Experimental|4 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 4 mg of NTC-510A or placebo
16668292|NCT02161354|Experimental|6 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 6 mg of NTC-510A or placebo
16668293|NCT02161328||ICU patients undergoing a dilatative tracheotomy.|
16668294|NCT02161315||Observation group|Steroid Aromatase Inhibitors
16668295|NCT02161315||Control group|Non-Steroid Aromatase Inhibitor
16668296|NCT02161302|Experimental|Active tDCS|tDCS will be applied in the head of the patients in 20 minute sessions, daily from Monday to Friday for 2 weeks (10 sessions total). The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current.
16668297|NCT02161302|Sham Comparator|tDCS Sham|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
16668298|NCT02161276|Experimental|TNTL capsule and Placebo|3-4 capsules 3 times a day Used before meals
16668299|NCT02161263||Quality of Vision after LASIK surgery|Questionnaire
16668300|NCT02161250|Experimental|Resistant starch|The test beverage consumed has the resistant starch.
16668301|NCT02161250|Experimental|Control|The control beverage uses maltodextrin rather than the resistant starch.
16668302|NCT02161237|Experimental|standard dose group|Oral
16668303|NCT02161237|Experimental|optimized dose group|Oral
16668304|NCT02161224|Experimental|1: FG-4592 in subjects with moderate hepatic impairment|
16668305|NCT02161224|Experimental|2: FG-4592 in healthy subjects|
16668306|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
16668307|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
16668308|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
16668309|NCT02161198|Experimental|Y-75|volunteers receive 3 packages twice a day up to 14 weeks
16668310|NCT02161198|Placebo Comparator|Placebo|volunteers receive 3 packages twice a day up to 14 weeks
16668311|NCT02161185|Other|USL261|
16668312|NCT02161172||Mild traumatic brain injury|Traumatic brain injury patients with Glasgow coma score (GCS) of 13-15.
16668313|NCT02161159||Patients With Urinary Incontinence Due to iOAB|Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
16668314|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
16668315|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
16668317|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
16668318|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
16668319|NCT02161133|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
16668320|NCT02161133|Active Comparator|Health Education|Health education provides didactic information about Gulf War Illness
16668321|NCT02161120|Active Comparator|Traditional rye bread|As part of habitual diet participants are expected to consume 100-200 grams of traditional Finnish rye bread daily
16668322|NCT02161120|Experimental|Low-FODMAP rye bread|As part of habitual diet participants are expected to consume 100-200 grams of low-FODMAP rye bread daily
16668323|NCT02161107|Experimental|Grass-SPIRE 1|Grass-SPIRE regimen 1 given 2 weeks apart
16668324|NCT02161107|Experimental|Grass-SPIRE 2|Grass-SPIRE regimen 2 given 2 weeks apart
16668325|NCT02161107|Placebo Comparator|Placebo|Placebo given 2 weeks apart
16668326|NCT02161094|Experimental|Group 1: Physicians|Give incentives to physicians based on their patient's HbA1c improvement
16668327|NCT02161094|Experimental|Group 2: Diabetic patients|Give incentives to patients based on their own HbA1c improvement
16668328|NCT02161094|Experimental|Group 3: Both Physicians and Patients|Give incentives to both based on the HbA1c improvements from the physicians' patients
16668329|NCT02161094|No Intervention|Group 4: Control group|Receive no incentive but will be provided diabetes education booklet and group education courses for DM control as usual
16668330|NCT02161081|Experimental|Myocardial CT perfusion (21-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 21-second scan duration.
16668331|NCT02161081|Active Comparator|Myocardial CT perfusion (30-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 30-second scan duration.
16668332|NCT02161055|Experimental|Strict control group|"Intensive insulin therapy: Keep Target blood glucose levels between 4.4-7.0 mmol/L;
~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
16668333|NCT02161055|Experimental|Moderate control group|"Intensive insulin therapy: Keep target blood glucose levels between 7.1 and 10.0 mmol/L.
~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours"
16668334|NCT02161055|Experimental|Slight control group|"Intensive insulin therapy: Keep target blood glucose levels between 10.1 and 13.0 mmol/L.
~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
16668335|NCT02161055|Active Comparator|Non-intensive insulin therapy|Rapid blood glucose levels were measured once every 2 hours. When blood glucose levels were ≤ 13.0 mmol/L, no intervention was performed; When blood glucose levels were > 13.0 mmol/L, regular insulin was subcutaneously injected separately. During fasting, insulin was injected once every 8 hours. During venous or enteral nutrition infusion, insulin was infused at 30 minutes before nutrition infusion. When blood glucose levels were ≤ 13.0 mmol/L, insulin infusion was terminated.
16668336|NCT02161042||fresh blood Transfusion|
16668337|NCT02161042||Old blood transfusion|
16668338|NCT02161029|Active Comparator|New drill biopsy instrument|To take biopsies from gastric submucosal tumors with a new drill biopsy instrument used with flexible endoscopes.
16668339|NCT02161029|Active Comparator|Conventional biopsy instrument|To take biopsies from gastric submucosal tumors with conventional biopsy forceps used with flexible endoscopes
16668340|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
16668341|NCT02161003|Experimental|Stem Cells Isolation|"Stem cell isolation technique and Stem Cells Injection Technique The method of isolation of MSC from bone marrow will be carried out using the Ficoll-Paque technique for the isolation of mononucleated cells followed by the separation of MSC by adherence to plastic. Finally, the cells will be resuspended and counted using a hemocytometer.
~Mononucleated cells will be cultured and incubated at 37°C in an atmosphere of 95% relative humidity and 5% CO2."
16668342|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
16668343|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
16668344|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
16668345|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
16668346|NCT02160951|Experimental|LGH447|LGH447, QD
16668347|NCT02160938||3 year follow-up cohort|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.
~At as close to the age of 3 as possible, the following exams will be performed and are described below:
~The Vineland-II Adaptive Behavior Scale (VABS)
~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)
~Children will also be photographed (for review by the study dysmorphologist)"
16668348|NCT02160938||Limited follow-up cohort|Women with children who will not reach the age of 2 years 6 months by the end of our study but have a prenatally diagnosed CNV will be recruited into the limited follow-up study. Each center will describe the study to eligible women and will verbally obtain their permission to be contacted by the Study Follow-up Specialist. The Study Follow-Up Specialist will contact the patient, explain the study, and obtain full written informed consent.
16668349|NCT02160925|Experimental|Preoperative 99mTc-Sestamibi SPECT/CT|
16668350|NCT02160912||Ectoin Mund- & Rachenspray|treatment with Ectoin Mund- & Rachenspray 1%
16668351|NCT02160912||Emser Pastillen|treatment with Emser Pastillen
16668352|NCT02160899|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
16668353|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
16668354|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
16668355|NCT02160899|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
16668356|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
16668357|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
16668358|NCT02160886|Experimental|Child-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the children themselves, using the Swedish version of the Perceived Efficacy and Goal Setting System (PEGS).
~A PEGS interview will be performed with the children. The children identifies tasks they find difficult to perform and prioritize three tasks, they want to perform better, as goals for intervention."
16668359|NCT02160886|Experimental|Parent-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the parents using the Canadian Occupational Performance Measure (COPM).
~Using the COPM interview technique, the parents are encouraged to talk about an ordinary day to identify occupational performance issues their child is not able to perform. Identified performance issues are rated for importance and the parents selects the three most important issues as goals for intervention."
16668360|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
16668361|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
16668362|NCT02160860||Children|Children
16668363|NCT02160847|Experimental|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
16668364|NCT02160847|No Intervention|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
16668365|NCT02160834|Experimental|B-MOBILE smartphone-based intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
16668366|NCT02160834|Experimental|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
16668367|NCT02160834|No Intervention|Control|
16668368|NCT02160821|Experimental|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block TAPB Ultrasound guided TAPB
16668369|NCT02160821|Experimental|Caudal Epidural Block|Caudal Epidural Block Caudal Block Neuraxial Block Ultrasound Guided Caudal Block
16668370|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
16668371|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
16668372|NCT02160782|Experimental|LUM001 (Maralixibat)|"LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.
~Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat."
16668373|NCT02160782|Placebo Comparator|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
16668374|NCT02160756|Active Comparator|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) softgel capsule on Day 1.
16668375|NCT02160756|Experimental|Treatment B|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
16668376|NCT02160756|Experimental|Treatment C|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
16668377|NCT02160756|Experimental|Treatment D|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
16668378|NCT02160743|Experimental|CJ-30056 20mg/500mg|fasting, fed
16668379|NCT02160743|Experimental|group 2|fed, fasting
16668381|NCT02160717||Turner Syndrome|Female with Turner Syndrome
16668382|NCT02160717||Healthy Controls|Healthy Female
16668383|NCT02160704|Experimental|Arm 1(IP)|Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks
16668384|NCT02160704|Placebo Comparator|Arm 2 (Placebo)|Placebo capsule 1x daily for 16 weeks
16668387|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
16668388|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
16668389|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
16668390|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
16668391|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
16668392|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
16668393|NCT02160652||Patients|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
16668394|NCT02160639|No Intervention|usual care|usual care includes diabetes self management education
16668395|NCT02160639|Active Comparator|diabetes self management support|diabetes self management support in addition to usual care, which includes diabetes self management education
16668396|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
16668397|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
16668398|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
16668399|NCT02160613|Other|Open flap for periodontitis patients|Open flap debridement
16668400|NCT02160600|Experimental|split bolus|Patients will undergo diagnostic Split bolus DECT scan
16668401|NCT02160600|Experimental|Standard|Patients will undergo routine multiphase diagnostic CT
16668402|NCT02160587|Active Comparator|ZuraPrep|Irritation scores of the following applied to test sites will be compared: ZuraPrep, ZuraPrep without IPA, ChloraPrep, and 0.9% Physiological Saline.
16668403|NCT02160574|Active Comparator|ZuraPrep|ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.
16668404|NCT02160561|Experimental|Intervention Arm|Experimental - Intervention Arm patients who are in critical illness with acute respiratory failure and are mechanically ventilated will be placed in an upright reverse trendelenburg position
16668405|NCT02160548|Placebo Comparator|'Standard care'|Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.
16668406|NCT02160548|Experimental|'Standard care+ 2.5 mg Salbutamol'|Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care
16668407|NCT02160548|Experimental|'Standard care+ 5 mg Salbutamol'|Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care
16668408|NCT02160535|Experimental|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
16668409|NCT02160522||Cuffed ETT|Patients that are intubated with a cuffed endotracheal tube.
16668410|NCT02160509||- The patients who undergo ultrasonography in the ED|
16668411|NCT02160496|Active Comparator|20% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
16668412|NCT02160496|Active Comparator|27% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 27% protein, 30% fat and 43% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
16668413|NCT02160496|Active Comparator|35% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 35% protein, 30% fat and 35% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
16668414|NCT02160483|Experimental|Magnetic resonance imaging|Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis
16668415|NCT02160470|Experimental|Exposure with Retrieval|Exposure Therapy with Retrieval
16668416|NCT02160470|Experimental|Exposure with Compounding|Exposure Therapy with Compound Extinction
16668417|NCT02160470|Experimental|Exposure with Retrieval and Compounding|Exposure Therapy with Retrieval and Compound Extinction
16668418|NCT02160470|Active Comparator|Therapist-Guided Exposure Therapy|Therapist-guided Exposure Therapy
16668419|NCT02160457|Experimental|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis (IGA)
16668420|NCT02160457|No Intervention|Intervention without IGA|'Care as usual' - Individually tailored interdisciplinary interventions based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations BUT NOT (IGA).
16668421|NCT02160444|Experimental|CBT plus Parent as CBT Coach Training|CBT plus Parent as CBT Coach Training
16668422|NCT02160431|Experimental|CBT for pediatric OCD|Participants complete standard CBT for OCD
16668423|NCT02160418|No Intervention|Control|36 Participants will be sent a new toothbrush and will be asked to use it in place of their current brush. They also receive twice daily reminders via sms to brush their teeth.
16668424|NCT02160418|Experimental|Financial Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. They will also be offered financial incentives twice a day to brush their teeth.
16668425|NCT02160418|Experimental|Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
16668426|NCT02160418|Experimental|Financial and Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice daily they receive financial incentives to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
16668427|NCT02160405|Experimental|Normal diet|
16668428|NCT02160392||Endometrial biopsy|HIV + and HIV negative women underwent lower and upper genital tract sampling.
16668429|NCT02160379||post Roux-en-Y-gastric bypass|Formerly obese females 1-5 years after gastric bypass
16668967|NCT02156401||Cohort 1: Suspect of Pulmonary Embolism (PE)|
16668430|NCT02160379||matched controls|non-operated females age-and weight-matched to post Roux-en-Y-gastric bypass subjects
16668431|NCT02160379||healthy young controls|non overweight (BMI between 19 and 25 kg/m2) healthy females
16668432|NCT02160366||Biomarker/Molecular Data Collection and Analyzation|Advanced cancer participants
16668433|NCT02160353|Experimental|Combined hormonal therapy|Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days Prednisolone; 5mg/day (1 tablet orally once a day, concomitant to abiraterone acetate) for 126 days GnRh agonist for 4 injections (at 28 day intervals)
16668434|NCT02160340||Vitreomacular adhesion|Male or female subjects aged over 40 years with vitreomacular adhesion
16668435|NCT02160314|Placebo Comparator|pad|absorbent pad control
16668436|NCT02160314|Experimental|pessary|disposable, single-use pessary
16668437|NCT02160301|Experimental|Multimodal pain control|Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.
16668438|NCT02160301|Active Comparator|Standard pain control|Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.
16668439|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
16668440|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
16668441|NCT02160275|Active Comparator|Open Loop|4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring
16668442|NCT02160275|Experimental|Closed Loop|4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)
16668443|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
16668444|NCT02160249|Experimental|Community-based rehabilitation and facility based care|"Community-based rehabilitation is delivered to participants and their caregivers at their home by a specialist CBR worker. It comprises psychoeducation, adherence support, rehabilitation (including self-care and social skills), family support groups and accessing existing community organisations. It also involves community awareness raising and education and mobilisation of community leaders.
~Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education."
16668445|NCT02160249|Active Comparator|Facility-based care|Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education.
16668446|NCT02160236|Active Comparator|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
16668447|NCT02160236|Active Comparator|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
16668448|NCT02160236|Placebo Comparator|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
16668449|NCT02160223|Experimental|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at the end of surgery
16668450|NCT02160223|Active Comparator|Neostigmine|Group N patients will receive 50 µg kg-1 neostigmine and 05 mg atropin at the end of surgery
16668451|NCT02160210|Experimental|Ultrafine Endoscope|The ultrafine endoscope for colonoscopy with water method is performed in screening the colorectal diseases.
16668452|NCT02160197|No Intervention|No Immobilisation|No immobilisation post op, allowing patients to weight bear as tolerated.
16668453|NCT02160197|Active Comparator|Functional Bracing|Immobilise patients in Functional brace, allowing patients to weight bear as tolerated.
16668454|NCT02160197|Active Comparator|Plaster Immobilisation|Immobilise patients in plaster, allowing patients to weight bear as tolerated.
16668455|NCT02160171||Term neonates|Term neonates who are undergoing continuous video amplified Electroencephalogram (aEEG)/Electroencephalogram (EEG) monitoring for clinical purposes (e.g. because seizures were suspected, or the neonate is being treated with therapeutic hypothermia). EEGs will be analysed off line by 'Algorithm for Neonatal Seizure Recognition'
16668456|NCT02160158|Experimental|Cohort 1|
16668457|NCT02160158|Experimental|Cohort 2|
16668458|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
16668459|NCT02160145|Placebo Comparator|Placebo|Placebo
16668460|NCT02160132|Experimental|A 1-2-3Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
16668461|NCT02160132|Active Comparator|B 1-3-5Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
16668462|NCT02160119||Healthy Controls|
16668463|NCT02160119||Autism Spectrum Disorders|
16668464|NCT02160106|Experimental|TEW-7197|Dose Escalation of TEW-7197: TEW 7191 tablets will be given once daily (QD) or twice daily (BID) for 5 days followed by 2 days without treatment in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
16668465|NCT02160080|Experimental|Boc+Peg-int alfa+Rbv|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
16668466|NCT02160067|Experimental|Treatment A|Second generation patch BTDS 12.6mg
16668467|NCT02160067|Experimental|Treatment B|Second generation patch BTDS 3.15mg
16668468|NCT02160067|Active Comparator|Treatment C|First generation patch BuTrans 20mg
16668469|NCT02160067|Active Comparator|Treatment D|First generation patch BuTrans 5mg
16668470|NCT02160054||Group 1|patients with kidney transplantation who converted the immunosuppressant from cyclosporine to Graceptor ®
16668471|NCT02160041|Experimental|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
16668472|NCT02160028|Active Comparator|Standard information|This group is given anesthetics and standard information before dental treatment about the anesthetics.
16668473|NCT02160028|Experimental|Extended information|This group is given anesthetics and extended information before dental treatment about the anesthetics.
16668474|NCT02160015|Experimental|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16668475|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
16668476|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
16668477|NCT02159989|Experimental|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16668478|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
16668479|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
16668480|NCT02159963|Experimental|Supervised training|8 weeks of high intensity training three times a week, once supervised. Followed by 8 weeks home based, unsupervised optional training.
16668481|NCT02159963|Experimental|Unsupervised training|"Participants have 8 weeks of non-intervention Control period, followed by 8 weeks of home based, unsupervised high intensity interval training."
16668482|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
16668483|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
16668484|NCT02159937||Patients with metastatic cancer|Blood sampling by vena punction.
16668485|NCT02159924||Asymptomatic|
16668486|NCT02159911||200 mcg misoprostol|Misoprostol administered orally one hour before surgery
16668487|NCT02159911||400 mcg misoprostol|Misoprostol administered orally one hour before surgery
16668488|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
16668489|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
16668490|NCT02159885|Experimental|Telemonitoring|In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment.
16668491|NCT02159885|No Intervention|Usual Care|"Subjects in this arm will receive usual care for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure."
16668492|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
16668493|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
16668494|NCT02159846||Test Group and Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
16668495|NCT02159846||Test Group & Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
16668496|NCT02159833|Experimental|Intervention|Intranasal challenge with food protein or vehicle control
16668497|NCT02159820|Active Comparator|DTC Arm|Patients are randomly assigned to receive lower-dose decitabine treatment followed by TC regimen (ie, DTC arm).
16668498|NCT02159820|Active Comparator|TC regimen|Patients were randomly assigned to receive carboplatin plus paclitaxel (ie, TC arm).
16668499|NCT02159807|Active Comparator|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
16668500|NCT02159807|Active Comparator|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
16668501|NCT02159807|Active Comparator|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
16668502|NCT02159794|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
16668503|NCT02159781|Experimental|periodontal treatmnent|
16668504|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
16668506|NCT02159742||Cohort 1|
16668507|NCT02159729|Placebo Comparator|Placebo|Participants treated with placebo in previous ATX-101 studies
16668508|NCT02159729|Experimental|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm^2) in previous phase 2 studies
16668509|NCT02159729|Experimental|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm^2) in previous phase 2 studies
16668510|NCT02159729|Experimental|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm^2) in previous phase 2 studies
16668511|NCT02159716|Experimental|Metastatic Pancreatic (ductal) adenocarcinoma (PDA)|
16668512|NCT02159716|Experimental|Serious Epithelial Ovarian Cancer|
16668513|NCT02159716|Experimental|Malignant Epithelial Pleaural Mesothelioma|
16668514|NCT02159703|Experimental|Single Arm Phase 2|
16668515|NCT02159677||Healthy Subjects|Healthy subjects aged 21-80 years with no history of present or past disabling back or neck pain, sciatica, cervical radiculopathy, or any generalized neuromuscular condition except for mild polyneuropathy or common mononeuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy at the elbow.) Additionally, subjects cannot have any history of any moderate-to-severe ongoing medical condition producing generalized disability, such as advanced cardiac or renal disease, or metal spine implants of any type.
16668516|NCT02159677||Radiculopathy Subjects|Subjects aged 21-80 years with a history consistent with radiculopathy based on clinical, radiologic, and standard electrophysiological criteria, as determined by spine expert.
16668517|NCT02159677||Musculoskeletal Back Pain Subjects|Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.
16668518|NCT02159677||Undiagnosed Lower Back or Neck Pain Subjects|Subjects aged 21-80 years with a major complaint of lower back or neck pain.
16668519|NCT02159664|Experimental|didgeridoo practice|
16668520|NCT02159651||1: Dermatomyositis group|patients with interstitial pneumonia associated with dermatomyositis
16668521|NCT02159651||2: Polymyositis group|patients with interstitial pneumonia associated with polymyositis
16668522|NCT02159638|Other|comparisson CGM accuracy|Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose
16668523|NCT02159625|Experimental|Abdominal Compression Elastic Support|To compress the abdomen at 15 mmHg for 3 hours during the course of hemodialysis treatment.
16668524|NCT02159612||FSHD|A cohort of adult danish patients with facioscapulohumeral muscular dystrophy is invited to perform a MRI scan.
16668525|NCT02159599|Active Comparator|Darunavir/Ritonavir + 2 nucleos(t)idos|Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
16668526|NCT02159599|Experimental|Darunavir/ritonavir + Lamivudine|Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
16668527|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
16668528|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
16668529|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
16668530|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
16668531|NCT02159534|Experimental|Primebrain|"' Stimulation ' Infants group will receive Primebrain stimulation whose items were selected according to a Delphi process and discussed at the European Academy of Childhood Disability (2013).
~This sensorimotor stimulation programme is administered at home by parents (trained and monitored by a physical therapist), once a day between term-age and 6 months of corrected age.
~In addition, these infants undergo systematic monitoring for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
16668532|NCT02159534|Other|usual care|"Infants in the comparison group receive usual care for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
16668533|NCT02159521|Experimental|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
16668534|NCT02159508|No Intervention|Individualised on-demand counselling|Individualized on-demand counselling group was assigned to receive baseline nutritional counselling, that consisted of one dietetic consultation before (chemo)radiotherapy. During (chemo)radiotherapy on-demand counselling group patients received further counselling only on demand.
16668535|NCT02159508|Experimental|Intensive nutritional counselling|Intensive nutritional counselling consisted of protocolled counselling given by a dietitian once at baseline and on the 2nd and 4th week of treatment and at the end of chemoradiotherapy.
16668536|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
16668537|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
16668538|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
16668539|NCT02159456|Experimental|Continuous enteral feeding|Continuous enteral feeding via infusion pump is applied for at least 7 days after the start of enteral feeding
16668540|NCT02159456|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via gravity-based infusion is applied for at least 7 days after the start of enteral feeding.
16668541|NCT02159443||Study Participants|Those who meet eligibility criteria and consent to participate in the study.
16668542|NCT02159430||HereditaryAngioEdema|Patients from the Eastern Sicily HAE register
16668543|NCT02159417|Experimental|Therapeutic Education|Intensive training individual or collective teaching
16668544|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
16668545|NCT02159404||Healthy controls|
16668546|NCT02159391|No Intervention|Usual Intervention|A standard intervention will be performed by nursing staff during hospital admission. Written information about the consequences of driving under the influence of alcohol and/or drugs will be provided. No psychological intervention.
16668547|NCT02159391|Experimental|Brief Motivational Interview|A Brief Motivational Interviewing will be performed during hospital admission by a psychologist experienced with this intervention.
16668548|NCT02159378|Other|GD with Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
16668549|NCT02159378|Other|GD without Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
16668550|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
16668551|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days
~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
16668552|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days
~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
16668553|NCT02159339||gene-methylation|"gene-low-level of methylation: patients with early stage gastric carcinoma containing low-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.
~gene-middle-level of methylation: patients with early stage gastric carcinoma containing middle-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.
~gene-high-level of methylation: patients with early stage gastric carcinoma containing high-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.
~gene-without of methylation: patients with early stage gastric carcinoma NOT containing methylated E-cadherin,GFRA1,p16,SRF or ZNF382 CpG island."
16668554|NCT02159326|Experimental|Arm1|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
16668555|NCT02159326|Experimental|Arm2|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
16668556|NCT02159313|Experimental|BAY63-2521 with Non sparkling water|Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature
16668557|NCT02159313|Experimental|BAY63-2521 with applesauce|Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)
16668558|NCT02159313|Experimental|BAY63-2521 with water|Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)
16668559|NCT02159313|Experimental|BAY63-2521 after breakfast|Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature
16668560|NCT02159300||Patients|Patients with fibromyalgia pain Intervention: experience brain activity recording
16668561|NCT02159300||Healthy Controls|Healthy controls without chronic pain of any type.
16668562|NCT02159287|Experimental|Low molecular-weight heparin|these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.
16668563|NCT02159287|Active Comparator|unfractionated heparin|This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).
16668564|NCT02159274||BCS without oncoplastic techniques|BCS without oncoplastic techniques
16668565|NCT02159274||BCS with oncoplastic techniques|BCS with oncoplastic techniques.
16668566|NCT02159261||Cohort 1|Female patients ≥ 18 years old requiring contraception.
16668567|NCT02159248|Experimental|Tolfenamic acid + gemcitabine + radiation|
16668568|NCT02159235||AIHD-patients (ICD-10 I21)|Patients suffering from acute ischemic heart disease according to ICD-10 I21
16668569|NCT02159235||CIHD-patients (ICD-10 I25)|patients suffering from chronic ischemic heart disease according to ICD-10 I25
16668570|NCT02159222|Experimental|Additional physical therapy|
16668571|NCT02159209||Drug Induced Renal Injury (DIRI)|This is a prospective observational cohort study of patients who have developed acute kidney injury Stage 2 or a glomerular disorder following exposure to specific drugs that have been associated with DIRI.
16668572|NCT02159196|Active Comparator|acetylcysteine and salbutamol|Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
16668573|NCT02159196|Experimental|acetylcysteine or salbutamol|"Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.
~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm."
16668574|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
16668575|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
16668576|NCT02159170|Experimental|NGF|injection of 50 µl NGF, once into the left volar forearm and injection of 50 µl NaCl (sodium chloride) once into the right volar forearm
16668577|NCT02159157|No Intervention|Arm A|"Physical Therapy consult for post op care and general physical activity recommendation 1-4 weeks prior to starting chemotherapy.
~Phone calls designed to support the patient to maintain current activity level."
16668578|NCT02159157|Placebo Comparator|Arm B|"Physical Therapy consult for post-op care 1-4 weeks prior to starting chemotherapy.
~Exercise prescription aimed at increasing physical activity by a minimum of 10 MET hours/week.
~Motivational phone calls aimed at encouraging the patient to adhere to their exercise prescription."
16668579|NCT02159144|Experimental|healthy adults|
16668968|NCT02156401||Cohort 2: Suspect of Deep Vein Thrombosis (DVT)|
16668580|NCT02159131|Experimental|OC containing levonorgestrel and ethinyl estradiol + GSK126574|Eligible subjects will enter a run-in-period of 21 days (may extend to 49 days) to stabilize on OC containing levonorgestrel and ethinyl estradiol in order to synchronize the menstrual cycles of multiple subjects. Subjects completing run-in-period will enter Treatment period 1 and will be dosed OC once daily on Days 1 to 10. At day 11 subjects will enter Treatment period 2 and will be dosed with OC containing levonorgestrel and ethinyl estradiol + 744 once daily on Day 12 to 19. Subjects completing Treatment period 2 will have 7 OC free days (Day 22 to 28) during which withdrawal menses should occur. Subjects will then be followed up for 7 to 14 days (Day 28 to 35/49).
16668581|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
16668582|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
16668583|NCT02159105||Women undergoing cesarean delivery|"FAST scan and non-invasive hemoglobin measurement
~Women undergoing cesarean delivery will undergo a non-invasive hemoglobin measurement both before and after surgery. An abdominal ultrasound will be performed to establish normal levels of intra-abdominal fluid after cesarean delivery."
16668584|NCT02159092|Experimental|Contingency Management|Monetary incentives are given for submitting negative saliva cotinine tests.
16668585|NCT02159092|No Intervention|Fixed Rate Control|Fixed amounts of payments are provided for submitting saliva samples
16668586|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
16668587|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
16668588|NCT02159066|Experimental|LGX818 + MEK162|
16668589|NCT02159066|Experimental|LGX818 + MEK162 + LEE011|
16668590|NCT02159066|Experimental|LGX818 + MEK162 + BGJ398|
16668591|NCT02159066|Experimental|LGX818 + MEK162 + BKM120|
16668592|NCT02159066|Experimental|LGX818 + MEK162 + INC280|
16668593|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
16668594|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
16668595|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
16668596|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
16668597|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
16668598|NCT02159027|Placebo Comparator|placebo|placebo identical in appearance to maraviroc 150 and 300 mg tablets will be added to each subjects antiretroviral regimen at doses as recommended by the package insert
16668599|NCT02159027|Experimental|maraviroc|Maraviroc Tablets are available as 150 mg and 300 mg tablets. Each subject will add maraviroc to their current antiretroviral regimen with dosage based on recommendations as per maraviroc package insert
16668600|NCT02159014|Experimental|Phase 1|Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).
16668601|NCT02159014|Active Comparator|Phase 2|Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.
16668602|NCT02159001|Active Comparator|ECT treatment right after recruitment|This group receives electroconvulsive therapy treatment right after they are recruited.
16668603|NCT02159001|Placebo Comparator|ECT after 4 weeks period.|This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
16668604|NCT02158988|No Intervention|without HIPEC|"Preoperative chemotherapy 3 cycles, each cycle 21 days. Patients with negative or unknown HER-2 status receive Epirubicin 50 mg/m² infusion (maximum 100mg/d). Oxaliplatin 130 mg/m² infusion (maximum 260 mg/d) and capecitabine oral 625 mg/m² two times a day (maximum 2500 mg/d).
~Patients with positive HER-2 status receive:
~Cisplatin : 80 mg/m² infusion (maximum of 160 mg/d). Capecitabine: oral 1000 mg/m2 (two times a day maximum of 4000 mg/d), on day 1-14.
~Trastuzumab: 8 mg/kg infusion (on cycle 1 and 6 mg/kg on cycle 2 and 3). CRS is performed and 4-12 weeks after CRS 3 cycles of postoperative chemotherapy have to be applied. In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
16668605|NCT02158988|Experimental|With HIPEC|"Patients will be treated with a preoperative chemotherapy as described for the control group. EOX or CCT depending on the HER-2 status.
~CRS will be performed 2 to 3 weeks after end of last chemotherapy cycle. HIPEC with mitomycin C and cisplatin either at the time of CRS or a delayed HIPEC within 5-7 days.
~HIPEC:
~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.
~Patients may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs can be excluded.
~In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
16668606|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
16668607|NCT02158962|Experimental|Behavioral - Education|"3 Educational Sessions
~Session 1 - Reducing Risk for Intimate Partner Violence (IPV); Session 2 - Reducing risk for Sexually Transmitted Infections including HIV (STI/HIV) Session 3 - A group session which reinforces skills for reducing IPV and STI/ HIV risk reduction."
16668608|NCT02158962|Active Comparator|Behavioral - Education|"3 Educational Sessions
~Session 1 - Breast Health Education and Developing A Breast Cancer Risk Reduction Plan Session 2 - Reducing risk for overweight and obesity and Developing a Healthy Eating and Activity Plan Session 3 - A group session which integrates and reinforces skills from Sessions 1 and 2."
16668609|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
16668610|NCT02158949|No Intervention|Usual Care|Usual care in ED
16668611|NCT02158936|Experimental|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
16668612|NCT02158936|Placebo Comparator|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
16668613|NCT02158923|Experimental|Individualized ventilation|Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
16668614|NCT02158923|Experimental|Individualized vent. + postop. CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed. Postoperatively a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
16668615|NCT02158923|No Intervention|Standard ventilation|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed.
16668616|NCT02158923|Active Comparator|Standard vent. + postoperative CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed. Postoperatively, a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
16668617|NCT02158910||Aricept Group 1|Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
16668618|NCT02158910||Aricept Group 2|Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
16668619|NCT02158897|No Intervention|Control|Participants will consume their normal diet. Body weight and physiological change at two time points (approximately 2-3 months apart) will be examined. The participants will be crossed over to the diet group.
16668620|NCT02158897|Experimental|Prolon Diet|Participants will be provided with a 5-day supply of fasting-mimicking diet, including energy bars, soups, drink packets and dietary supplements. Participants will diet for 3 cycles. Each one-month cycle consists of 5 days of dieting with a calorie intake estimated at 600-1200 calories per day. The rest of the month participants will eat normally. After 3 cycles, participants will be examined again after consuming their normal diet after 2-3 months.
16668621|NCT02158884|Other|IDEO brace|IDEO brace
16668622|NCT02158871|Experimental|Contact-based mental health education|"The Beyond Silence' program is 12 hours in length: six 1.5-2 hour in-person group sessions every other week, plus five online sessions between each of the in-person sessions."
16668623|NCT02158871|Active Comparator|Mental health literacy training|"Mental Health First Aid training consists of twelve hours of standardized, module-based mental health literacy training offered in a group format. It will be offered as 2 full-day training sessions (or four half-day sessions)."
16668624|NCT02158858|Experimental|Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm|"Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi.(CPI-0610 alone)
~Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)"
16668625|NCT02158858|Experimental|Arm 2: Prior JAKi Combination Arm|"Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)
~Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)"
16668626|NCT02158858|Experimental|Arm 3: JAKi Naïve Combination Arm|Open to patients with MF who have not previously received a JAKi. (CPI-0610 + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
16668627|NCT02158858|Experimental|Arm 4: Essential Thrombocytopenia (ET) Monotherapy Arm|Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)
16668628|NCT02158845|Active Comparator|LNG-IUS|LNG-IUS: levonorgestrel intrauterine system
16668629|NCT02158845|Active Comparator|GnRHa|GnRHa: leuprolide
16668630|NCT02158832|Experimental|Acupuncture + Electrical Stimulation|Acupuncture needles are inserted beneath the skin and electrical stimulation applied for 20 minutes.
16668631|NCT02158832|No Intervention|Control|Participants who are randomized to receive no intervention will still receive physical assessment.
16668632|NCT02158819|No Intervention|TKA with standard instrumentation|This arm consists of the Genesis II Total knee implant system or the Legion Primary total knee system with standard instrumentation
16668969|NCT02156401||Cohort 3: Incidental Venous Thromboembolism (VTE)|
16668633|NCT02158819|Active Comparator|Total knee arthroplasty with Visionaire|This arm will consist of the Genesis II Total Knee Implant System or Legion Primary Total Knee System with the Visionaire patient-matched instrumentation
16668634|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
16668635|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
16668636|NCT02158793|Experimental|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
16668637|NCT02158780|Experimental|Scrotal Orchidopexy|Single incision
16668638|NCT02158780|Other|Inguinal Orchidopexy|Double Incision (Standard)
16668639|NCT02158754||Corus CAD (ASGES)|Subjects receiving CorusCAD (ASGES) gene expression test as part of their diagnostic workup for typical and/or atypical symptoms of obstructive coronary artery disease.
16668640|NCT02158754||Control|Matched subjects in the same practice that did NOT receive Corus CAD (ASGES) as part of their diagnostic workup.
16668641|NCT02158741|No Intervention|Usual Primary Care|Usual Primary Care will be received by half the participants during the course of the Study
16668642|NCT02158741|Active Comparator|Home Visits and educational support|Intervention comprised of Home Visits and group educational sessions. Home Visits and will be conducted by Diabetes Education staff in lieu of usual care conducted at the Diabetes clinic. Lifestyle support and educational will be offered in the form of monthly Diabetes Wellness Days offered in the community where nutrition, exercise and support will be given to help improve self-management of diabetes.
16668643|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).
~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
16668644|NCT02158715||Smartphone positioning during Chest compression|
16668645|NCT02158702|Experimental|Pomalidomide and Dexamethasone|"PO pomalidomide 4mg from D1-21 and PO dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.
~PO or IV cyclophosphamide 300mg/m2 on D1, 8 and 15 can be added at the discretion of the treating physician to induce added response under the following circumstances: 1) If there is less than a MR after 3 cycles in the absence of disease progression, or 2) If there is disease progression within the first 3 cycles of Pomalidomide and Dexamethasone treatment.
~Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
16668646|NCT02158689|Active Comparator|human menopausal gonadotropin (hMG)|hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
16668647|NCT02158689|Active Comparator|Letrozole|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
16668648|NCT02158676|Experimental|Prebiotic|6 g/day of prebiotic (fructooligosaccharides) for 15 days.
16668649|NCT02158676|Experimental|Synbiotic|6 g/day of synbiotic (fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019) for 15 days.
16668650|NCT02158676|Placebo Comparator|Placebo|6 g/day of placebo (maltodextrin) for 15 days.
16668651|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
16668652|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
16668653|NCT02158650|Experimental|Video Group|Patients randomized to Group II will be emailed the educational video, pre- and post- knowledge assessments, and patient satisfaction survey with instructions on what order to fill them out. Group II patients will report to the treatment visit and undergo discussion of options and treatment as per standard of care. An additional knowledge assessment survey will be administered to Group II patients after discussion with treating physician.
16668654|NCT02158650|No Intervention|Control Group|Patients randomized to Group I will be come to the clinic for the treatment visit and discuss options and treatment as per standard of care. Pre- and post- discussion knowledge assessments and satisfaction surveys will be administered at the time of the treatment visit.
16668655|NCT02158637||Cancer patients receiving treatment|Patients receiving active treatment for cancer or initiating treatment for cancer in the next 7 days
16668656|NCT02158624|Experimental|Ranibizumab|
16668657|NCT02158611|Other|Lifestyle counseling|
16668658|NCT02158598|No Intervention|wash-out|2 months
16668659|NCT02158598|Experimental|Vitamin D chewable tablet supplementation|A chewable vitamin D tablet containing 1000 IU to be taken once a day for 2 months.
16668660|NCT02158598|Experimental|Vitamin D pill supplementation|A vitamin D pill containing 1000 IU to be taken once a day for 2 months.
16668661|NCT02158585|Placebo Comparator|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
16668662|NCT02158585|Active Comparator|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day, or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
16668970|NCT02156388|Experimental|Ia-GW003 50μg/kg|2-3 subjects
16668663|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
16668664|NCT02158559|Experimental|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
16668665|NCT02158559|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
16668666|NCT02158546|Experimental|ALKS 5461|
16668667|NCT02158546|Placebo Comparator|Placebo|
16668668|NCT02158533|Experimental|High Dose|
16668669|NCT02158533|Experimental|Low Dose|
16668670|NCT02158533|Placebo Comparator|Placebo|
16668671|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
16668672|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
16668673|NCT02158507|Experimental|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
16668674|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
16668675|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
16668676|NCT02158481|Active Comparator|Dietary ingredients: polyphenols and carotenoids|Dietary ingredients: polyphenols and carotenoids
16668677|NCT02158481|Placebo Comparator|Placebo product|Placebo product
16668678|NCT02158468|Active Comparator|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
16668679|NCT02158468|Active Comparator|Postconditioning|4 cycles of postconditioning (30s ischemia, 30s reperfusion) after primary PCI/stenting
16668680|NCT02158468|No Intervention|Control group|Standard infarction treatment without conditioning intervention
16668681|NCT02158455|Experimental|NT SVG grafts|NT SVG randomized for revascularization of left or right coronary territory
16668682|NCT02158455|Active Comparator|RA grafts|RA grafts randomized for revascularization of left or right coronary territory
16668683|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
16668684|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
16668685|NCT02158429|Active Comparator|3 Dimensional ultrasound|an additional 5-10 minutes of ultrasound using three dimensional technique
16668686|NCT02158429|Active Comparator|2 dimensional|an additional 5-10 minutes of ultrasound using standard two-dimensional technique
16668687|NCT02158416||Hematology-oncology|hematology-oncology outpatients requiring platelet transfusion
16668688|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
16668689|NCT02158390|Experimental|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC
~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
16668690|NCT02158390|No Intervention|Community treatment as usual|Children access educational and speech-language interventions available to them through schools and community resources.
16668691|NCT02158377|Active Comparator|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
16668692|NCT02158377|Experimental|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
16668693|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
16668694|NCT02158351||Simple steatosis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
16668695|NCT02158351||Non-alcoholic steato-hepatitis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
16668696|NCT02158338||Asthma|Mothers of children thought to have asthma
16668697|NCT02158338||Non-asthma|Mothers of children without diagnosed respiratory problems
16668971|NCT02156388|Experimental|Ia-GW003 150μg/kg|2-3 subjects
16668698|NCT02158325|Active Comparator|3.0-3.9 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0-3.9 mm in diameter)
16668699|NCT02158325|Experimental|4.0-5.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (4.0-5.0 mm in diameter)
16668700|NCT02158325|Active Comparator|5.1-6.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (5.1-6.0 mm in diameter)
16668701|NCT02158312|Experimental|transcranial direct current stimulation|bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, for 20 minutes
16668702|NCT02158312|Placebo Comparator|sham stimulation|same as the experimental stimulation condition but only for 2 minutes
16668703|NCT02158299|Experimental|Avitene,Drainaging,reexamine|
16668704|NCT02158299|Experimental|Sapylin,Drainaging,reexamine|
16668705|NCT02158299|Active Comparator|Drainaging,reexamine|
16668706|NCT02158286||Esophagectomy, Emptying from gastric tube|Validate paracetamol clearance technique to scintigraphy for measuring emptying rate from the gastric tube.
16668707|NCT02158273|Active Comparator|TRICOR (fenofibrate)|
16668708|NCT02158273|Placebo Comparator|Sugar Pill|
16668709|NCT02158260|Experimental|position changing|During the examination, subjects changed position in the following sequence: left lateral head-down position, supine position, prone head-down position, right lateral head-down position, supine position, left lateral position, prone position, prone hip-high position, right lateral position and sitting position.
16668710|NCT02158260|No Intervention|free position|
16668711|NCT02158247||Conventional group, Touch and Read group|
16668712|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
16668713|NCT02158221|Active Comparator|Migraine patients with high genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
16668714|NCT02158221|Active Comparator|Migraine patients with low genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
16668715|NCT02158208||Patients with HD|
16668716|NCT02158208||Controls|
16668717|NCT02158195||Patients|
16668718|NCT02158195||controls|
16668719|NCT02158182|Experimental|lactulose|
16668720|NCT02158182|Experimental|L-ornithine L-aspartate|
16668721|NCT02158182|Experimental|Rifaximin|
16668722|NCT02158182|Placebo Comparator|Placebo|
16668723|NCT02158156|Experimental|Excercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
16668724|NCT02158143|Experimental|vitamin D3|
16668725|NCT02158130||Healthy Living|non exercise healthy living control group
16668726|NCT02158130||General Health|Exercise Group (8 KKW) One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. We will recruit 1 year post study intervention.
16668727|NCT02158130||Weight Loss|Exercise Group (20 KKW) Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session. We will recruit 1 year post study intervention.
16668728|NCT02158117|Experimental|nasal naloxone|8 and 16 mg/ml, comparator 1 mg/ml. Three daily occasions with at least 3 days washout between treatment (min 8 days).
16668729|NCT02158104||Latent trigger point in the upper trapezius muscle|
16668730|NCT02158091|Experimental|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.
~Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.
~Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
16668731|NCT02158065|No Intervention|Usual care|Patients will receive information (leaflet) and guidance on the benefits associated with increased physical activity in COPD patients and their health status
16668732|NCT02158065|Experimental|Coaching program|In addition to usual care, patients will receive the coaching program
16668733|NCT02158052|Experimental|Transplantation|Single arm combined bone marrow and kidney transplantation
16668734|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
16668735|NCT02158026||infertility without polycystic ovarian syndrome|1000 women with infertility without polycystic ovarian syndrome who are already decided to be treated with ICSI will be recruited
16668736|NCT02158013|Active Comparator|Diltiazem, calcium channel blocker|Diltiazem gel 2% applied twice daily for 8 weeks
16668737|NCT02158013|Experimental|Levorag, Hibiscus plant extract|Levorag Emulgel applied twice daily for 8 weeks
16668738|NCT02158000|Active Comparator|Group A|In group A , 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles are allocated to receive one tab / 8 hs of Diosmin ( 500mg) beginning from the day of ovum retrieval and for 3 days (till the day of embro trasfer) in addition to aspiration of the fluid by an IUI catheter.
16668739|NCT02158000|No Intervention|Group B|In group B (control group) 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles, no thing will be done
16668740|NCT02157987|Experimental|bevacizumab|bevacizumab spray
16668741|NCT02157974|Experimental|PCOS, medication naive + Byetta|PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
16668742|NCT02157974|No Intervention|Control|Up to 25 girls without PCOS
16668743|NCT02157974|No Intervention|PCOS medication naive|Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
16668972|NCT02156388|Experimental|Ia-GW003 300μg/kg|3-6 subjects
16668744|NCT02157974|No Intervention|PCOS on COCPs|Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
16668745|NCT02157974|No Intervention|PCOS on metformin|Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
16668746|NCT02157961||General Practitioner / Family Physician in German Primary care|
16668747|NCT02157961||Medical Specialists|Working in the ambulatory setting
16668748|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
16668749|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
16668750|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
16668751|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
16668752|NCT02157922|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
16668753|NCT02157922|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
16668754|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
16668755|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
16668756|NCT02157896||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
16668757|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
16668758|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
16668759|NCT02157844||COPD|Subjects with diagnosis of COPD
16668760|NCT02157844||OSA|Subjects with diagnosis of OSA
16668761|NCT02157844||controls|Gender, age, BMI matched controls
16668762|NCT02157831|Experimental|Subjects from UPCC 10903|
16668763|NCT02157818|Active Comparator|midazolam|midazolam IV bolus 0.05ml/kg bolus in 1minute. rescue drug(Midazolam) 1 mg, IV boluses for double blinding setting, we use saline, 0.4 mcg/kg IV bolus in 10 minutes and 0.5 mcg/kg/h, as placebo.
16668764|NCT02157818|Experimental|Dexmedetomidine|"Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.25-0.75 mcg/kg/h for RSS 3-5. Midazolam 1mg bolus IV pro re nata (PRN).
~for double blinding setting, IV bolus 0.05ml/kg bolus in 1minute."
16668765|NCT02157805|Active Comparator|rare beef meat|beef meat cooked during 5 minutes at 55°C
16668766|NCT02157805|Active Comparator|well cook beef meat|beef meat cooked during 30 minutes à 90°C
16668767|NCT02157792|Experimental|Part A|This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.
16668768|NCT02157792|Experimental|Part B|This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.
16668769|NCT02157792|Experimental|Part B2|This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.
16668770|NCT02157792|Experimental|Part C1|This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.
16668771|NCT02157792|Experimental|Part C2|This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.
16668772|NCT02157792|Experimental|Part C3|This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.
16668773|NCT02157779|Experimental|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
16668774|NCT02157779|Active Comparator|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
16668775|NCT02157766|Active Comparator|MNP with Asthma: Mindfulness Based Stress Reduction|
16668776|NCT02157766|No Intervention|MNP w/ Asthma: Wait List Control|
16668777|NCT02157766|Active Comparator|MNP, no asthma - Mindfulness Based Stress Reduction|
16668778|NCT02157766|Active Comparator|MNP, no asthma: Health Enhancement Program|
16668779|NCT02157766|No Intervention|MNP, no asthma - Wait List Control|
16668780|NCT02157766|Active Comparator|Long Term Meditator|
16668781|NCT02157740||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
16668782|NCT02157740||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
16668783|NCT02157740||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
16668784|NCT02157740||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
16668785|NCT02157727||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
16668786|NCT02157727||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
16668787|NCT02157727||Control group, Prior Tele-expertise|
16668788|NCT02157727||Control group, during Tele-expertise|Infants hospitalized in health facilities not performing Tele-expertise while the exposed group use Tele-expertise
16668789|NCT02157714|Experimental|PRX002|PRX002
16668790|NCT02157714|Placebo Comparator|Placebo|Placebo
16668791|NCT02157701|Experimental|Polyherbal capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
16668973|NCT02156388|Experimental|Ia-GW003 400μg/kg|3-6 subjects
16668792|NCT02157701|Placebo Comparator|Placebo capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
16668793|NCT02157688||case|Patient with a folliculitis Decalvans
16668794|NCT02157688||control|Control without folliculitis decalvans
16668795|NCT02157675|Experimental|Polyherbal capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
16668796|NCT02157675|Placebo Comparator|Placebo capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
16668797|NCT02157662||No coronary disease and risk factors >=3|
16668798|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
16668799|NCT02157662||No coronary disease and risk factors 0-1|
16668800|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
16668801|NCT02157649|Experimental|ER Tablet under Fasted Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, to subjects under fasted conditions.
16668802|NCT02157649|Active Comparator|IR Tablet under Fasted conditions|IR Tablet combination tablet of Codeine/Guaifenesin 20mg/400mg administered under fasted conditions as a single tablet every 4 hours during a 12 hour study [three doses]
16668803|NCT02157649|Experimental|ER Tablet under Fed Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, following a standard high-fat breakfast.
16668804|NCT02157636|Experimental|CPI-0610|
16668805|NCT02157623|Experimental|Red Light PDT and Blue Light PDT|The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.
16668806|NCT02157610|Experimental|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
16668807|NCT02157610|Experimental|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
16668808|NCT02157597|Active Comparator|Control Arm|"The control patients will have open display of the NIRS monitor in the OR, but recording without display in the CICU, along with a request to the surgical and intensive teams to react to the data in their usual way. The disparity between the OR and CICU reflect the current opinions of the clinicians in these different environments regarding the necessity of NIRS monitoring within their sphere of practice.
~In this way, continuous recording of cerebral and somatic oximetry will be made in all patients. However for control patients the monitor display will be switched off in the CICU using a pre-programmed research mode, which permits both ongoing recording and also the display of technical error messages (such as inadvertent disconnections or probe displacement)."
16668809|NCT02157597|Experimental|NIRS based management|The trial interventions of NIRS based management consists of provision to the cardiac surgical and intensive care teams of a protocol to guide their interpretation of cerebral and somatic NIRS monitoring and interventions to try in the event of monitored desaturation during the pre- and post-bypass periods (when the circulation is perfused by the beating of the native heart). The investigators believe that there is insufficient data to inform an evidence-based protocol for the bypass phase of surgery, particularly regarding the interpretation of NIRS data under conditions of hypothermia.
16668810|NCT02157584|Experimental|Treatment A|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
16668811|NCT02157584|Experimental|Treatment B|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
16668812|NCT02157571|Experimental|Prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.
~Placebo of levofloxacin hydrochloride tablet, without active components."
16668813|NCT02157571|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.
~Placebo of prulifloxacin film-coated tablet without active components."
16668814|NCT02157558|Experimental|All subjects|All subjects will receive a single oral dose of fexofenadine on Day 1 while fasting. Days 2 to 5 will be Washout days. On Day 6, subjects will begin a 5 day telotristat etiprate regimen. On Day 10 subjects will be given the morning telotristat etiprate dose concomitantly with a single dose of fexofenadine while fasting.
16668815|NCT02157545||pyridostigmine|administration of rocuronium to determine its potency.
16668816|NCT02157545||control arm (no pyridostigmine)|determination of potency of rocuronium in patients not taking pyridostigmine
16668817|NCT02157532|Active Comparator|Best standard treatment|intravenous r-tPA or any other medical management
16668818|NCT02157532|Active Comparator|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
16668974|NCT02156388|Experimental|Ia-GW003 500μg/kg|3-6 subjects
16668819|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
16668820|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
16668821|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
16668822|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
16668823|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
16668824|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
16668825|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
16668826|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
16668827|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
16668828|NCT02157493|Experimental|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
16668829|NCT02157493|Active Comparator|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
16668830|NCT02157480|No Intervention|control|usual follow-up for 6 weeks
16668831|NCT02157480|Experimental|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
16668832|NCT02157480|Experimental|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
16668833|NCT02157467|Experimental|Arm 1: NGMN/EE + BMS-955176|"Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28
~Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)"
16668834|NCT02157454|Experimental|Website access|Two-week access to the colorectal cancer module of the website www.krankheitserfahrungen.de
16668835|NCT02157454|No Intervention|Control|Participants who are randomized to the control group don't have access to the website until they have finished the last questionnaire at 6 weeks follow up.
16668836|NCT02157441|Experimental|all patients|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
16668837|NCT02157428|Placebo Comparator|saline|patients received 20 ml of saline during 1 minute, after end of surgery.
16668838|NCT02157428|Active Comparator|flumazenil|patients received 1 mg of flumazenil, after end of surgery
16668839|NCT02157415|Experimental|Long-term catherized patients|Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
16668840|NCT02157402|Experimental|Intervention Group|The intervention group will received activities and social events designed according 8 social marketing Benchmark criteria to promote healthy lifestyles.
16668841|NCT02157402|No Intervention|Control Group|The control group will not received any intervention activities and social events to promote healthy lifestyles.
16668842|NCT02157389|Experimental|placebo|Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect
16668843|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
16668844|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
16668845|NCT02157363|Active Comparator|Repositioning Group|The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
16668881|NCT02157051|Experimental|Arm 2 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/M2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
16668975|NCT02156388|Experimental|Ia-GW003 600μg/kg|3-6 subjects
16668976|NCT02156388|Experimental|Ib-GW003 150μg/kg|6-8 subjects
16668846|NCT02157363|Experimental|Single positioning|The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.
16668847|NCT02157350|Experimental|Panretinal Laser Photocoagulation|See interventional description.
16668848|NCT02157337|Experimental|atrovastatin|
16668849|NCT02157337|Placebo Comparator|placebo|
16668850|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
16668851|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
16668852|NCT02157311|Experimental|Four consecutive days on treatment and 3 days off|All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
16668853|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
16668854|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
16668855|NCT02157285|No Intervention|Routine Counseling|Subjects randomized to receive routine counseling before selecting a method of contraception
16668856|NCT02157285|Experimental|Peer Mentor counseling|Subjects randomized to receive peer counseling before selecting a method of contraception
16668857|NCT02157272|Experimental|Rivaroxaban|Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
16668858|NCT02157272|Active Comparator|Warfarin|To Keep an INR between 2.0 and 3.0
16668859|NCT02157246|Other|Group A, pimonidazole, no CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole
16668860|NCT02157246|Other|Group B, CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI
16668861|NCT02157233|Experimental|Hot environment|Subjects will perform the intervention in a hot environment (33°C)
16668862|NCT02157233|Sham Comparator|Neutral environment|Subjects will perform the intervention in a neutral environment (22°C)
16668863|NCT02157220|Experimental|Randomised group 1|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
16668864|NCT02157220|Experimental|Randomised group 2|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
16668865|NCT02157207|Placebo Comparator|Placebo|Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
16668866|NCT02157207|Experimental|Antioxidant|"Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.
~of vitamin E."
16668867|NCT02157181|Experimental|HCL, 2CdA +/- Rituximab|"Risk stratification
~HCL variant will be treated with cladribine plus rituximab, independent of previous therapy
~Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is < 3 years.
~All repeated relapses (> 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.
~Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion
~Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is > 3 years.
~Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection"
16668868|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
16668869|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.
~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
16668870|NCT02157155|Experimental|Intervention|Insulin reduction and mimic infection with LPS
16668871|NCT02157155|No Intervention|Control|Normal insulin and no LPS
16668872|NCT02157142|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
16668873|NCT02157129|Experimental|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
16668874|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
16668875|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
16668876|NCT02157103|Experimental|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
16668877|NCT02157090|Active Comparator|Herpes Patch SOS (Hansaplast®)|
16668878|NCT02157090|Active Comparator|Herpes vesicle patch of Compeed®|
16668879|NCT02157077|Experimental|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
16668880|NCT02157051|Experimental|Arm 1 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 1 injection ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
16668977|NCT02156388|Experimental|Ib-GW003 300μg/kg|6-8 subjects
16668882|NCT02157051|Experimental|Arm 3 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 3 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
16668883|NCT02157051|Experimental|Arm 4 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 1 additional STEMVAC vaccine at 3 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
16668884|NCT02157038|Experimental|Procedures|RNA/DNA blood sample will be collected. Participant will complete questionnaires, MRI and strength and reflex testing.
16668885|NCT02157025|Experimental|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
16668886|NCT02157025|Active Comparator|Usual Care|Usual care procedures for Humphrey perimetry in young children
16668887|NCT02157012|Experimental|The condition of rheumatoid arthritis|
16668888|NCT02156999|Experimental|Osteoporosis|
16668889|NCT02156986||9 month old infant|
16668890|NCT02156986||12 month old infant|
16668891|NCT02156986||18 month old toddler|
16668892|NCT02156986||24 month old toddler|
16668893|NCT02156986||36 month old toddler|
16668894|NCT02156973|No Intervention|Group One Usual care|Patients attending for CT coronary angiography all receive an information leaflet with their appointment letter, and a brief verbal description of the scan by the radiographer immediately before it is undertaken, as standard care. All patients attending will be offered the opportunity to complete a short questionnaire (until all patients are recruited - anticipated to be 4 weeks). The Speilberger State-Trait Anxiety Index has been abbreviated and validated for use in outpatient settings to gauge levels of pre-procedural anxiety. This will be undertaken on arrival and repeated immediately before the scan, to see if patients feel better prepared after the standard interaction with staff.
16668895|NCT02156973|Experimental|Group Two Video information|The patient video will be introduced to Group Two once Group One has been completed. In addition to the information sheet these patients (again, for four weeks or until recruitment is complete) will be sent an internet hyperlink to its presence on YouTube (video-sharing website) and the Hospital website with their appointment letter. Patients who do not have internet access will be offered the opportunity to see the video in the preparation room while waiting for their scan. Questionnaires will be administered as before, again done twice to examine any late impact of the information on patient anxiety, and the patient will undergo their test.
16668896|NCT02156960|Experimental|Denosumab and/or teriparatide treatment|Denosumab and/or teriparatide treatment in osteoporotic patients
16668897|NCT02156947||Chronic cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
16668898|NCT02156947||Acute cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
16668899|NCT02156934|Experimental|Muscle derived stem cell|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
16668900|NCT02156921|No Intervention|Control group|Self-guided training without app-based training (written hand-outs)
16668901|NCT02156921|Active Comparator|Intervention group|Self-guided training with app-based training
16668902|NCT02156908|Experimental|D-serine|D-serine
16668903|NCT02156882||TB patients and Tb suspects|Patients with confirmed tuberculosis who are treated by the National TB Programme
16668904|NCT02156869|Experimental|Intervention arm|The intervention was the use of a decision aid.
16668905|NCT02156869|No Intervention|Control arm|Usual care
16668906|NCT02156856||Hemodynamic optimisation|
16668907|NCT02156856||No hemodynamic optimisation|
16668908|NCT02156843|Experimental|Pyridorin|Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
16668909|NCT02156843|Placebo Comparator|Placebo|Placebo Oral Capsule taken BID (twice daily, every 12 hours)
16668910|NCT02156817||Late Preterm Infants (LPT)|34 weeks and 0-6 days gestational age
16668911|NCT02156817||Moderate preterm infants (MPT)|32 weeks and 0-6 days gestational age
16668912|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
16668913|NCT02156791|Experimental|gpASIT+TM|
16668914|NCT02156778|Active Comparator|Extended Standard Care (Stroke Card)|
16668915|NCT02156778|Active Comparator|Standard Care|
16668916|NCT02156752|Experimental|ACT|Behavioral weight loss plus techniques from Acceptance and Commitment Therapy
16668917|NCT02156752|Active Comparator|SR|Behavioral weight loss plus self-regulation techniques
16668918|NCT02156752|Active Comparator|WLO|Behavioral weight loss plus cooking tips and demonstrations
16668919|NCT02156739|Experimental|Diagnostic (contrast-enhanced MRI)|Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.
16668920|NCT02156726||Low dose FCR in Elderly/Comorbid CLL|low dose FCR
16668921|NCT02156713|Experimental|CIMT Camp|Members of this study will participate in the group CIMT camp.
16668922|NCT02156700||Liver tumors|Measurement of tumor stiffness by Shear wave elastography - SWE™
16668923|NCT02156687|Active Comparator|Cololast, Inc. Restorell Y mesh|Y mesh
16668924|NCT02156687|Active Comparator|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
16668925|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
16668926|NCT02156661|Active Comparator|Oxytocin|"Oxytocin: Syntocinon-Spray, Novartis
~intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT"
16668927|NCT02156661|Placebo Comparator|Placebo|Placebo nasal spray
16668965|NCT02156427|Placebo Comparator|PLACEBO|In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
16668928|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
16668929|NCT02156635|Experimental|Active tdcs / CIMT|Participants in the acute post-stroke stage will receive active tDCS associate to rehabilitation (CIMT)
16668930|NCT02156635|Sham Comparator|Sham stimulation / CIMT|Participants in the acute post-stroke stage will receive sham stimulation associate to rehabilitation (CIMT)
16668931|NCT02156622||Depression Care Manager|All enrolled in AIM 3 received decision support from Depression Care Manager
16668932|NCT02156609|Experimental|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
16668933|NCT02156596|Active Comparator|Intravenous NSAI|patients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
16668934|NCT02156596|Experimental|Nebulised Morphine|patients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
16668935|NCT02156583||Older, left ventricular assist device|Older heart failure patients undergoing left ventricular assist device implantation
16668936|NCT02156570|Experimental|Sofosbuvir and ribavirin|"Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily
~Treatment will be for 6 weeks in all participants."
16668937|NCT02156557|Experimental|peptide application|"Investigational Agent Administration
~KCCFPAQ-GGGSK-(5-FITC)-NH2
~1.2 mg lyophilized powder per single-use amber vial
~Lyophilized powder reconstituted with 10 mL of 0.9% NaCl
~Final concentration of 76.4 μM for single, one-time topical application
~The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)"
16668938|NCT02156544|Experimental|CKD-519 25mg|CKD-519 25mg or placebo
16668939|NCT02156544|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
16668940|NCT02156544|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
16668941|NCT02156544|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
16668942|NCT02156544|Experimental|CKD-519 400mg|CKD-519 400mg or placebo
16668943|NCT02156531|Placebo Comparator|Attention Control Condition|3.c.14.5. Arm 1: Attention Control Condition. The minimally effective attention-control group procedure is identical to the active CBM procedure except that during the presentation of the trials where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. Thus, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active versions of CBM in Arms 2 and 3.
16668944|NCT02156531|Experimental|Arm 2: Self-administered CBM only|3.c.14.6. Arm 2: Self-Administered CBM Only. Youth assigned to this arm will receive the self-administered active CBM intervention. As described above in detail, in the 80% of CBM trials where a neutral and disgust face are both presented, the probe always replaces the neutral face. Thus, participants are trained to disengage their attention from threat. These youth do not receive Adherence Promotion telephone calls.
16668945|NCT02156531|Experimental|Arm 3: Self-administered CBM + Adherence Promotion|3.c.14.7. Arm 3: Self-Administered CBM + Adherence Promotion. Youth assigned to this arm will receive both the self-administered active CBM intervention and the telephone coach calls to deliver the Adherence Promotion (AP) procedures. AP procedures are intended to compensate for the important nonspecific 'scaffolding' provided by research staff when CBM has been traditionally delivered in laboratories. This includes technical assistance with use of the program, support/encouragement, motivational enhancement, and brainstorming solutions to barriers to regular sessions. The addition of AP to the 3rd arm of this trial attempts to recreate much of this nonspecific, yet likely important, support of in-person interventions, which we hypothesize will lead to greater participant adherence to the program and therefore better clinical outcomes.
16668946|NCT02156518|Experimental|Vocal Function Exercises|Vocal Function Exercises
16668947|NCT02156518|Active Comparator|Vocal hygiene|Vocal hygiene
16668948|NCT02156505|Experimental|DoubleBare stent|Placement of double bare stent
16668949|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
16668950|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
16668951|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
16668952|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
16668953|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
16668954|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
16668955|NCT02156479||Allo-HSCT recipients|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive
16668956|NCT02156466|Experimental|MSB0010841 30 mg|
16668957|NCT02156466|Experimental|MSB0010841 60 mg|
16668958|NCT02156466|Experimental|MSB0010841 120 mg|
16668959|NCT02156466|Experimental|MSB0010841 240 mg|
16668960|NCT02156466|Placebo Comparator|Placebo|
16668961|NCT02156453||Total knee arthroplasty|Patients undergoing uncomplicated total knee replacement
16668962|NCT02156440|Placebo Comparator|Placebo|Placebo capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
16668963|NCT02156440|Experimental|SierraSil Joint Formula 14|SierraSil Joint Formula 14 capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
16668964|NCT02156427|Experimental|VITICELL|In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
16668978|NCT02156375|Experimental|Ustekinumab 90 mg/mL|
16668981|NCT02156349|Other|Control Group|Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
16668982|NCT02156349|Other|Intervention group|"Patients are treated according to the concept Integrated personalized diabetes management."
16668983|NCT02156336|Placebo Comparator|PLACEBO|"500 mg PLACEBO PO 2 times a day for 1 week (Week 1)
~1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
16668984|NCT02156336|Active Comparator|RANOLAZINE|"500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)
~1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
16668985|NCT02156323|Experimental|Treatment Sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
16668986|NCT02156323|Experimental|Treatment Sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
16668987|NCT02156297||Induction Group|
16668988|NCT02156297||Consolidation Group|
16668989|NCT02156297||Salvage Group|
16668990|NCT02156297||Maintenance Group|
16668991|NCT02156297||Alleviatitive Group|
16668992|NCT02156284|Experimental|Empathic behaviour by nurses|Patients who received empathic behaviour was performed by a trained nurse.
16668993|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
16668994|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
16668995|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
16668996|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
16668997|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
16668998|NCT02156245|Experimental|"Conventional group"|
16668999|NCT02156245|Experimental|"Combined group"|
16669000|NCT02156232|Active Comparator|TIPS,Emboliaztion|The covered stents were used for TIPS The SPSS will be embolized during the procedure of TIPS
16669001|NCT02156232|Active Comparator|TIPS alone|The covered stents were used for TIPS No embolization of SPSS will be performed during TIPS
16669002|NCT02156219||Under separation|Exposure to the separation of women and men in the metro of Mexico City.
16669003|NCT02156219||No treatment|Non exposure to the separation of women and men in the metro of Mexico City.
16669004|NCT02156206||123 women line|Women who call the 123 emergency line and have also immediate services from the 123 women emergency line
16669005|NCT02156206||No treatment|Women who call the 123 emergency line and do not have immediate services from the 123 women emergency line
16669006|NCT02156193|Experimental|Prophylactic clip|Before conventional snare polypectomy, hemoclips will be applied on the base of stalk.
16669007|NCT02156193|Active Comparator|No prophylactic management|Conventional snare polypectomy will be performed without any preventive management.
16669008|NCT02156180||Early stage oral cavity / oropharyngeal cancer|Exhaled breath
16669009|NCT02156167|Experimental|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
16669010|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
16669011|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
16669012|NCT02156141|Experimental|Supervised high intensity training|"8 weeks of supervised high intensity training, 10 minutes, 3 times a week (once a week supervised) on a cycle ergometer followed by 8 weeks of unsupervised optional training.
~Participants: Patients with Kennedy's disease or healthy control subjects (individually matched with patients).
~Participants: Patients with Kennedys disease and healthy control subjects."
16669013|NCT02156141|Experimental|Unsupervised High intensity training|"8 week control period with no training followed by 8 weeks of unsupervised high intensity training on a cycle ergometer.
~Participants: Patients with Kennedy's disease."
16669014|NCT02156128|Experimental|Cogmed|Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
16669015|NCT02156128|Active Comparator|Control group|These subjects will participate in the vocational rehabilitation program for 3,5 weeks. The program includes cognitive therapy (ACT) and physical activity, but no working memory training.
16669016|NCT02156115||healthy volunteers|healthy volunteers
16669017|NCT02156115||lymphatic patients|lymphatic patients
16669018|NCT02156115||relatives|relatives
16669022|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
16669023|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
16669024|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
16669025|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
16669026|NCT02156063|Experimental|NT100|NT100 Dose 1
16669027|NCT02156063|Placebo Comparator|Placebo|Placebo
16669028|NCT02156050|Active Comparator|OBLOO device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
16669029|NCT02156050|Experimental|BBLOO Device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
16669030|NCT02156037|Experimental|dashboard team care intervention|Dashboard team
16669031|NCT02156037|Active Comparator|usual diabetes team control|usual clinical diabetes team with no access to the diabetes dashboard
16669032|NCT02156024|Placebo Comparator|placebo|placebo drink, 1 dose at a time, twice a day, duration: 4 weeks
16669033|NCT02156024|Active Comparator|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
16669034|NCT02156011||Instrumented knee implant|"4-6 subjects with an instrumented TKA, that has been implanted within the study Kniemessprothese: Belastungsmessung bei Patienten mittels einer instrumentierten Knie-Endoprothese (EA4/069/06) approved and conducted at the Charité- Universitätsmedizin in Berlin, Germany, will be involved in this project."
16669035|NCT02155998||PREVENT study patients|Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation.
16669036|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
16669037|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
16669038|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
16669039|NCT02155972|Active Comparator|Bifidobacterium infantis|Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily
16669040|NCT02155972|Placebo Comparator|Placebo|Placebo capsule once daily
16669041|NCT02155959||one group|one group receiving a toric intraocular lens during cataract surgery.
16669042|NCT02155946|Experimental|Arm 1|Group receives active brain stimulation plus memory rehabilitation
16669043|NCT02155946|Sham Comparator|Arm 2|Group receives sham brain stimulation plus memory rehabilitation
16669044|NCT02155946|Active Comparator|Arm 3|Group receives active brain stimulation plus reminiscence training
16669045|NCT02155946|Active Comparator|Arm 4|Group receives sham brain stimulation plus reminiscence training
16669046|NCT02155933||Hyperandrogenemia|Peripubertal girls with hyperandrogenemia
16669047|NCT02155933||Controls|Peripubertal girls without hyperandrogenemia
16669048|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
16669049|NCT02155907||Rtest, Atrial fibrillation|Patients with ischemic stroke or TIA within the last week. Sinus rhythm on the surface ECG. Age ≥ 60 years. Given written informed consent
16669050|NCT02155894|Experimental|Disease control, Telemedicine, doctor|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a doctor at week 13, 26, 39.
16669051|NCT02155894|Experimental|Disease control, Telemedicine, nurse|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a nurse at week 13, 26, 39.
16669052|NCT02155894|No Intervention|Usual care|Usual care: control of disease activity with consultations in the outpatient clinic.
16669053|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
16669054|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
16669055|NCT02155868|Experimental|Intervention|"Cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C.
~Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it."
16669056|NCT02155868|Placebo Comparator|Control|Only cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C during cardiac surgery and the first six hours after it.
16669057|NCT02155855|Experimental|Telemedicine|"Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit."
16669058|NCT02155855|Active Comparator|Control|Control Subjects will continue routine care which requires blood glucose testing at least 4 times a day. Parents will use customary ways to communicate (pager, email, fax or phone) with the Diabetes team, if they are concerned about glycemic control..
16669059|NCT02155842|Experimental|High intensity endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume high intensity endurance exercise, followed by 6 months non-supervised endurance exercise
16669060|NCT02155842|Active Comparator|Moderate continuous endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume moderate intensity endurance exercise, followed by 6 months non-supervised endurance exercise
16669131|NCT02155426||Treatment|Treatment: Chemotherapy or targeted therapy
16669061|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks
~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
16669062|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks
~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
16669063|NCT02155816|Placebo Comparator|Placebo|MCT (medium chain triglyceride)
16669064|NCT02155816|Experimental|Omega 3|Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.
16669065|NCT02155816|Experimental|Omega 7 + 3|210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3
16669066|NCT02155803|Experimental|Sarcoidosis related Calcium Dysregulation|Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
16669067|NCT02155790|Experimental|Renal Denervation by Neurolysis|Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
16669068|NCT02155777|No Intervention|No intervention|No intervention.
16669069|NCT02155777|Active Comparator|OrthoNovum 1/35|OrthoNovum 1/35
16669070|NCT02155764|Experimental|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
16669071|NCT02155764|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
16669072|NCT02155764|Active Comparator|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
16669073|NCT02155751|Experimental|Full NELIP group|"These women (n=10) will receive the full NELIP intervention and will be introduced to both the dietary program and the exercise program as described above under detailed description."
16669074|NCT02155751|Experimental|Exercise program only/ELIP|These women (n=10) will only be given the exercise component (ELIP) of NELIP, as outlined below in interventions. Once dietary intake has been assessed, this group will not be given any dietary intervention but will be encouraged to eat a healthy, balanced diet. Access to the nutritionist in the clinic is available and encouraged.
16669075|NCT02155751|Experimental|Nutrition program only/NLIP|These women (n=10) will only be given the nutrition program (NLIP) of NELIP as outlined below in intervention. They will be encouraged to be more active but will not be given an exercise intervention.
16669076|NCT02155751|No Intervention|Control|A control group (n=30) of obese pregnant women will also be recruited and will be matched by pre-pregnancy BMI, maternal age and parity, with no intervention, but will attend the clinic for standard obstetric care and follow-up.
16669077|NCT02155738|Placebo Comparator|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
16669078|NCT02155738|Experimental|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
16669079|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
16669080|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
16669083|NCT02155699|Experimental|Exercise 1|65% of V02 Max, 3x per week, 3 months
16669084|NCT02155699|Experimental|Exercise 2|85% of VO2 Max, 2x per week, 3 months
16669085|NCT02155699|No Intervention|Waitlist|Waitlist (three months)
16669086|NCT02155686|Experimental|Biosensors|Participants in this arm are equipped both with home telecare/automation and with biometric sensors
16669087|NCT02155686|Active Comparator|Automation|Participants in this arm are equiepd with home automation only
16669088|NCT02155673|Experimental|Low Dose GCS-100|Low dose of GCS-100
16669089|NCT02155673|Experimental|High Dose GCS-100|GCS-100 High dose
16669090|NCT02155660|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
16669091|NCT02155660|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
16669092|NCT02155660|Experimental|Benralizumab Arm C|Benralizumab administered subcutaneously
16669093|NCT02155660|Placebo Comparator|Placebo|Placebo administered subcutaneously
16669094|NCT02155647|Experimental|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
16669095|NCT02155647|Experimental|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
16669096|NCT02155634|Experimental|Lenalidomide|Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
16669097|NCT02155634|No Intervention|Observation|Observation until disease progression. Long term follow-up 5 years post last patient randomized.
16669098|NCT02155621|Experimental|Genome Sequencing|There is only one arm to this study.
16669173|NCT02155179||bad prognosis|Sperm samples <5mill/ml <5% progresive sperms
16669099|NCT02155608|Experimental|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
16669100|NCT02155608|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
16669101|NCT02155595||500 with BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
16669102|NCT02155595||500 without BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed
16669103|NCT02155582|Experimental|Arm 1|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients
16669104|NCT02155582|Experimental|Arm 2|45 mg and 60 mg for the diabetic patients
16669105|NCT02155569|Active Comparator|Transperitoneal Cesarean|
16669106|NCT02155569|Active Comparator|Extraperitoneal Cesarean|
16669107|NCT02155556||Healthy volunteers|
16669108|NCT02155543|Experimental|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
16669109|NCT02155543|Experimental|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
16669110|NCT02155543|Experimental|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
16669111|NCT02155543|Experimental|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
16669112|NCT02155543|Placebo Comparator|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
16669113|NCT02155543|Experimental|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
16669114|NCT02155543|Placebo Comparator|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
16669115|NCT02155530|Experimental|High efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
16669116|NCT02155530|Active Comparator|Low efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
16669117|NCT02155517|Experimental|Propofol Infusion|"Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..
~The study will make in two stages:
~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
~STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
16669118|NCT02155504|Experimental|ASP3700 single ascending dose cohort|Part 1
16669119|NCT02155504|Placebo Comparator|Placebo single ascending dose cohort|Part 1
16669120|NCT02155504|Experimental|ASP3700 alone|Part 2
16669121|NCT02155504|Active Comparator|ASP3700 and itraconazole|Part 2
16669122|NCT02155491||Prospective cohort 1|In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
16669123|NCT02155491||Prospective cohort 2|In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
16669124|NCT02155478|Other|AMO ZCB00|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
16669125|NCT02155478|Active Comparator|ISERT 250|ISERT 250 (HOYA, Japan): a standard IOL
16669126|NCT02155465|Experimental|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.
~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
16669127|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
16669128|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
16669129|NCT02155439|Active Comparator|Triamcinolone|kortikosteroid
16669130|NCT02155439|Active Comparator|5-fluorouracil|antimitotic drug
16669132|NCT02155400|Experimental|Prototype development|10 patients (this phase will be terminated once prototype is confirmed ready) Intervention: prototype device
16669133|NCT02155400|Active Comparator|Treatment arm - Prototype|- 18 patients Intervention: Prototype device (heating both sole of foot and popliteal fossa with compression)
16669134|NCT02155400|Active Comparator|Control arm - Forced Air Warming Blanket|18 patients Intervention: Forced air warming blanket (Bair hugger)
16669135|NCT02155400|Active Comparator|Comparison - Sole of foot only|9 patients heating sole of foot only Intervention: prototype device
16669136|NCT02155400|Active Comparator|Comparison - Popliteal fossa only|9 patients heating popliteal fossa only Intervention: prototype device
16669137|NCT02155387||Coronary artery bypass graft surgery|with cardiopulmonary bypass
16669138|NCT02155387||Pulmonary metastasectomy by thoracotomy|with one lung ventilation
16669139|NCT02155387||Minimal invasive mitral valve surgery|with cardiopulmonary bypass and one lung ventilation
16669140|NCT02155374|Active Comparator|Sliding scale insulin|Sliding scale insulin Glucose 7.8-12 mmol/l --> 2 IU insulin, glucose 12.1-17 mmol/l --> 4 IU insulin, glucose ≥17.1 mmol/l --> 6 IU insulin. In case of insufficient control, insulin doses will be increased
16669141|NCT02155374|Experimental|Intermediate acting insulin|Intermediate acting insulin, 0.01 IU / mg prednison / kg body weight with a maximum of 0.5 unit insulin per kg body weight. In case of age > 70 years or diminished renal function (GFR <30ml/min)
16669142|NCT02155361|Active Comparator|Topical Citrullus colocynthis fruit oil|Topical Citrullus colocynthis fruit oil (1%) 1 cc twice daily
16669143|NCT02155361|Placebo Comparator|Placebo (Vehicle)|Topical vehicle oil 1 cc twice daily
16669144|NCT02155348|Active Comparator|Multifocal group|Bilateral cataract surgery with implantation of multifocal IOLs
16669145|NCT02155348|Active Comparator|Monovision|Bilateral cataract surgery with monovision
16669146|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
16669147|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
16669148|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
16669149|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
16669150|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
16669151|NCT02155296|Experimental|Schools receiving RPI|"This arm contains schools receiving RPI. RPI offers a continuum of practices that range from informal (e.g., using affective statements that communicate feelings) to formal (e.g., hosting a restorative circle where participants are encouraged to express emotions and form emotional bonds). The circles or group meetings that are designed to take place between school staff and students, are the crux of RPI. School staff are encouraged to use the restorative practices to build relationships and resolve staff issues (restorative staff community), as well as when interacting with parents (restorative approach with families). All restorative practices encourage acting with youth and setting high expectations. When a school becomes proficient in all 11 essential practices it is officially recognized as a Restorative Practices School."
16669152|NCT02155296|Experimental|Schools not receiving RPI|This arm is the control arm and consists of schools that are not receiving RPI.
16669153|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
16669154|NCT02155270|Active Comparator|Precut|A corneal precut of 600µm will be performed.
16669155|NCT02155270|Active Comparator|Stab incision|A stab incision without corneal precut will be performed.
16669156|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
16669157|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
16669158|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
16669159|NCT02155244||Common bile duct stones|Common bile duct stones traeted with ERCP
16669160|NCT02155244||CBDS|treated with ERCP combined with surgery
16669161|NCT02155231||previous enrolled|
16669162|NCT02155231||New Enrolled|
16669163|NCT02155218|Active Comparator|Standard Injection Rate|Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size, given at an injection rate of 2 - 2.5 cc/second.
16669164|NCT02155218|Experimental|Patient Tailored Injection Rate|"Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the contrast - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves. The injection rate will vary from 1 to 3 cc/second."
16669165|NCT02155205|Experimental|Telotristat etiprate|Single dose of telotristat etiprate followed by a 7-day washout.
16669166|NCT02155205|Active Comparator|Moxifloxacin|Single dose of moxifloxacin followed by a 7-day washout.
16669167|NCT02155205|Placebo Comparator|Placebo|Single dose of placebo with a 7-day washout to follow.
16669168|NCT02155192||Cohort 1|Participants who participated in NCT01483599 (X-PLORE) study.
16669169|NCT02155192||Cohort 2|Participants who participated in NCT00267969 (PHOENIX 1) study.
16669170|NCT02155192||Cohort 3|Participants who participated in NCT00307437 (PHOENIX-2) study.
16669171|NCT02155192||Cohort 4|Participants who participated in NCT00454584 (ACCEPT) study.
16669172|NCT02155179||Good prognosis|Sperm samples >15mill/ml >30% progresive sperms
16669174|NCT02155166|Active Comparator|intracervical anesthesia|Intracervical anesthesia with lidocaine 2%
16669175|NCT02155166|Active Comparator|ibuprofen|ibuprofen 400 mg
16669176|NCT02155153|Experimental|Sugar Free Chewing Gum|All patients receiving sugar free gum
16669177|NCT02155153|No Intervention|Control|Patients receiving no intervention
16669178|NCT02155140|Active Comparator|Jejunal feeding|Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
16669179|NCT02155140|No Intervention|No jejunal feeding|No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks
16669180|NCT02155127|Experimental|walking intervention|Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
16669181|NCT02155127|No Intervention|usual care|these subjects receive information on walking program, however do not receive any coaching over 12 weeks
16669182|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
16669183|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
16669184|NCT02155088|Experimental|Combination Therapy: BYL719, Gemcitabine, (Nab)-Paciltaxel|Dose escalation, followed by expansion, of BYL719 in combination with Gemcitabine and (Nab)-Paclitaxel. BYL719: once daily. Gemcitabine: Days 1,8, 15 of 28-day cycle. (Nab)-Paclitaxel: Days 1,8, 15 of 28-day cycle.
16669185|NCT02155075|Experimental|Arm 1|"Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant.
~All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI."
16669186|NCT02155075|Experimental|Arm 2|Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
16669187|NCT02155062|Experimental|Whole grain rye|3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
16669188|NCT02155062|Experimental|Whole grain wheat|3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
16669189|NCT02155062|Placebo Comparator|Refined cereal|No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
16669190|NCT02155049|Experimental|Prostaglandin Analogues|The patients will receive a single daily drop of bimatoprost for six months.
16669191|NCT02155036|No Intervention|Usual care|Usual care
16669192|NCT02155036|Active Comparator|Exercise|exercise intervention
16669193|NCT02155023|Experimental|Insulin dosing and glucose sensors|To test the glucose sensors different levels of glycemia are needed. To provoke different glycemic levels the following intervention will be performed: Lunch (with fast glucose absorption characteristics) will be served. Up to 30 minutes after the usual insulin dosing time, the subjects will take his/her lunch dose of insulin adjusted to the chosen lunch plus additional approximately 25% (in the range of 0-50% according to the discretion of the Investigator) of insulin - in order to provoke moderate postprandial hypoglycaemia with glucose values < 70 mg/dl.
16669194|NCT02155010|Experimental|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
16669195|NCT02155010|Active Comparator|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
16669196|NCT02154997||Type 1 and Type 2 Diabetes|pregnant women which have a known condition of type 1 or type 2 diabetes
16669197|NCT02154997||Gestational diabetes|pregnant women which have developed Gestational diabetes
16669198|NCT02154997||Control group|Pregnant women whom do not suffer from any altered glucose metabolism
16669199|NCT02154984|Experimental|Behavioral (time restricted diet)|Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
16669200|NCT02154971||Patients|HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
16669201|NCT02154971||Control|non-HIV (matched for age and gender)
16669202|NCT02154958||Unexplained infertility|
16669203|NCT02154932|Active Comparator|double dose misoprostol|2 doses, 3 and 1 hours, prior surgery (group B, 35 cases).
16669204|NCT02154932|Active Comparator|single dose Misoprostol|intra-vaginal single dose of 400 microgram Misoprostol 1 hour pre-operatively (group A, 34 cases)
16669205|NCT02154919||complete revascularization group|this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
16669206|NCT02154919||conservative pharmacotherapy group|patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
16669207|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
16669208|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
16669209|NCT02154893|Experimental|Device and exercise|Device with ultrasound and laser associated with therapeutic exercise
16669210|NCT02154893|Experimental|Device|Device with ultrasound and laser
16669211|NCT02154893|Placebo Comparator|Placebo|Without any treatment
16669212|NCT02154880||HIV positive under 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
16669213|NCT02154880||HIV negative under 50 yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
16669214|NCT02154880||HIV positive over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
16669215|NCT02154880||HIV negative over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
16669216|NCT02154867|Experimental|Fecal transplantation|Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
16669217|NCT02154867|Placebo Comparator|Placebo fecal transplantation|Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.
16669218|NCT02154854|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.
~Drug: Tacrolimus targeted half-dose"
16669219|NCT02154854|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
16669220|NCT02154841|Experimental|Questionnaire, taste test, visual food test|The participants will complete a questionnaire that asks them about their taste preferences. They will also will be shown photos of various food stuffs and asked to choose their preferred meal. They will also be asked to put five sponge sticks (a single use item commonly used for mouth care) dipped in one of a five different liquids into their mouths and give their comments what each taste was and on how much they enjoyed it. These five liquids represent the four well-described tastes (sweet, sour, salty, bitter) and a more recently proposed taste, savoury. The intention of this part of the trial is to assess the patient's ability to detect alteration in pure taste and to identify if any of these tastes are preferred.
16669221|NCT02154828||Integrative practices|"Children included in this project are children 3 to 6 years with diagnosis F84.0 F84.1 according to CIM-10.
~these children must be supported in care units that meet the criteria defined integrative practices."
16669222|NCT02154815||PPT|Patients with a pre-emptive kidney transplantation from deceased or living donors
16669223|NCT02154815||PDT|Patients who have experienced a pre-transplant dialysis period of less than 36 months
16669224|NCT02154802|Experimental|video: community member|Participant watches video of a community member
16669225|NCT02154802|Experimental|video: physician|Participant watches video of a physician
16669226|NCT02154802|Experimental|video: choice of video|Participant can choose to watch video of either the community member of the physician
16669227|NCT02154802|No Intervention|no video|
16669228|NCT02154789|Experimental|polidocanol|
16669229|NCT02154789|Active Comparator|cryotherapy|
16669230|NCT02154789|Active Comparator|infra-red coagulation|
16669231|NCT02154776|Experimental|LEE011 + buparlisib + letrozole|open label, dose escalation evaluating max tolerated dose of the triple combination
16669232|NCT02154763|Placebo Comparator|Intraperitoneal Normal Saline|Intraperitoneal Normal Saline: 100mL (Milliliter) normal saline administered as in intervention arm
16669233|NCT02154763|Experimental|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (Milliliter) (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL (Milliliter) of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
16669234|NCT02154750|Active Comparator|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
16669235|NCT02154750|Experimental|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled
16669236|NCT02154737|Experimental|erlotinib and gemcitabine|"Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg
~Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle."
16669237|NCT02154724|Other|aDBS|The aDBS (adaptive Deep Brain Stimulation) device is applied both in aDBS and in DBS modality, for two hours in random order for two days. The aDBS can be programmed to deliver aDBS controlled by local fields potential or conventional DBS.
16669238|NCT02154711||Mitochondrial Disease|Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease
16669239|NCT02154711||Unaffected|Healthy individuals, without mitochondrial disease
16669240|NCT02154698|Active Comparator|22-gauge Standard Needle|Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)
16669241|NCT02154698|Active Comparator|22-gauge ProCore Needle|Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)
16669242|NCT02154685|Other|Retrieval-Extinction: Smoking Cues|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
16669243|NCT02154685|Other|Non-Retrieval Extinction: Neutral Cues|This is the group that will not receive retrieval-extinction training and will be exposed to neutral cues.
16669244|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
16669245|NCT02154659|Other|postprandial reflux group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
16669246|NCT02154659|Other|normal group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
16669295|NCT02154464|Active Comparator|Paracetamol|
16669296|NCT02154464|Placebo Comparator|Placebo|
16669247|NCT02154646|Experimental|LY2157299 + Gemcitabine|150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days without study drug (28 day cycle.) Gemcitabine 1000 milligram per square meter will be administered intravenously (IV) on Days 8, 15, and 22 in each cycle (28 day cycle). Participants may continue to receive treatment until discontinuation criteria are met.
16669248|NCT02154633|Experimental|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
16669249|NCT02154633|Active Comparator|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
16669250|NCT02154620|No Intervention|Plaster cast|The patient will be treated in a dorsal plaster cast for 4 weeks following the injury to the wrist
16669251|NCT02154620|Experimental|Volar plate|The patient will undergo surgery to the injured wrist with a Synthes Two-column plate (TCP) with a volar approach. Cast will be worn 2 weeks after surgery.
16669252|NCT02154607|No Intervention|Symptomatic treatment|Symptomatic analgetic Treatment only was performed without any Manipulation of OLP lesions.
16669253|NCT02154607|Active Comparator|CO2-Laser Treatment|CO2-Laser Vaporisation was performed of OLP lesions under local anaesthesia.
16669254|NCT02154594|Experimental|Acacia|Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days
16669255|NCT02154594|Active Comparator|Chlorhexidine gluconate|Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days
16669256|NCT02154594|Placebo Comparator|Distilled water|Rinse with 10 ml distilled water twice daily for 15 days.
16669257|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
16669258|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
16669259|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
16669260|NCT02154555|No Intervention|no debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During all three postoperative visits, no debridement will be performed.
16669261|NCT02154555|Experimental|debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During the one week postoperative visit, the randomized unilateral debridement will be performed. Debridement includes removing any crust or mucous in the nose. During the one month and three month visit, the PI will only examine the nose.
16669262|NCT02154542|Active Comparator|Experimental A|NAVA then standard mode
16669263|NCT02154542|Active Comparator|Experimental B|Standard mode then NAVA
16669264|NCT02154529|Experimental|Phase 1b, Arm 1|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 150mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
16669265|NCT02154529|Experimental|Phase 1b, Arm 2|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 250mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
16669266|NCT02154529|Experimental|Phase 1b, Arm 3|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 300mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
16669267|NCT02154529|Experimental|Phase 1b, Arm 4|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 350mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
16669268|NCT02154529|Experimental|Phase 1b, Arm 5|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 400mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
16669269|NCT02154529|Experimental|Phase 2a, Group 1|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive breast cancer and brain metastases that have progressed after radiation therapy.
16669270|NCT02154529|Experimental|Phase 2a, Group 2|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive metastatic breast cancer who do not have brain metastases, or who have asymptomatic brain metastases, or who have minimally symptomatic brain metastases that do not require immediate radiation therapy or neurosurgery.
16669271|NCT02154529|Experimental|Phase 2a, Group 3|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will be limited to those with HER2-positive metastatic breast cancer with pathologically confirmed leptomeningeal metastases with or without brain metastases. Brain metastases do not have to have progressed after radiation therapy in this group.
16669272|NCT02154516|Active Comparator|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:
~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem
~OXINIUM heads on polyethylene liners or
~Ceramic heads on ceramic liners (all uncemented components)"
16669273|NCT02154516|Experimental|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:
~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem
~R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)
~R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)
~Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
16669297|NCT02154438|Experimental|ketamine|ketamine 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
16669298|NCT02154438|Placebo Comparator|Placebo|normal saline 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
16669324|NCT02154256|No Intervention|Usual care control|The investigators will offer incentives that are identical to the incentives normally offered by the investigators' partner company.
16669274|NCT02154503|Experimental|Microneedling|"By randomization, the side for treatment will be determined. Topical anaesthetic will be then placed onto the treatment area under occlusion for thirty minutes to one hour. This will then be removed with 70% alcohol. The area will be rolled with microneedles in two planes: coronally and sagitally. In each plane, five passes will be made. Patients will restart application of Minoxidil the following day to both sides of the lesion.
~The same half of the scalp will be treated for the rest of the sessions, with topical anaesthetic applied by patient 30 minutes to an hour prior to start of treatment session. Patients will undergo microneedling on alternate weeks for a total of six treatments in 12 weeks. If there is >30% growth seen after six weeks, then the entire area will be treated."
16669275|NCT02154490||S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
16669276|NCT02154490||S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
16669277|NCT02154490||S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
16669278|NCT02154490||S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669279|NCT02154490||S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
16669280|NCT02154490||S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669281|NCT02154490||S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16669282|NCT02154490||S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
16669283|NCT02154490||S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16669284|NCT02154490||S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669285|NCT02154490||S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
16669286|NCT02154490||S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669287|NCT02154490||S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
16669288|NCT02154490||S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
16669289|NCT02154490||S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
16669290|NCT02154490||S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669291|NCT02154490||S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16669292|NCT02154490||S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16669293|NCT02154477|Active Comparator|diabetes|All patient will receive insulin at one visit and saline at another visit
16669294|NCT02154477|Active Comparator|control|All patient will receive insulin at one visit and saline at another visit
16669299|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
16669300|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
16669301|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
16669302|NCT02154399|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection.
16669303|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
16669304|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
16669305|NCT02154360|Experimental|Aprepitant|"Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days.
~6 participants will be receiving an antiretroviral regimen containing atazanavir/ritonavir (300/100 mg) daily plus two other antiretrovirals.
~6 participants will be receiving an antiretroviral regimen containing darunavir/ritonavir (800/100 mg) daily plus two other antiretrovirals."
16669306|NCT02154347|Experimental|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
16669307|NCT02154347|Other|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
16669308|NCT02154334|Experimental|Cohort 1|One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
16669309|NCT02154334|Experimental|Cohort 2: Sequence 1|One Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A) and pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 2 (Treatment C).
16669310|NCT02154334|Experimental|Cohort 2: Sequence 2|Pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1 (Treatment C) and 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 2 (Treatment A).
16669311|NCT02154321||Attention Deficit Hyperactivity Disorder|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
16669312|NCT02154321||Healthy Control|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
16669313|NCT02154308|Experimental|IL-YANG influenza vaccine|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
16669314|NCT02154295|Active Comparator|Eagle Eye Platinum|Eagle Eye Platinum Catheter as the comparator.
16669315|NCT02154295|Active Comparator|Revolution|Revolution Catheter as the comparator
16669316|NCT02154295|Active Comparator|TVC Insight 40MHz|TVC Insight as comparative catheter.
16669317|NCT02154295|Active Comparator|Atlantis Pro|Atlantis Pro catheter as comparator
16669318|NCT02154282|Experimental|ipod games|Administered ipod games with cognitive testing before and after
16669319|NCT02154269|Experimental|G-CSF|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
16669320|NCT02154269|Placebo Comparator|Saline|Subjects will be randomly assigned to receive saline for five days, during 4 cicles.
16669321|NCT02154256|Experimental|Increasing incentives|The investigators will offer incentives to users that begin low, and get higher over time.
16669322|NCT02154256|Experimental|Decreasing incentives|The investigators will offer incentives to users that start high, and decrease over time.
16669323|NCT02154256|Experimental|Stable incentives|The investigators will offer incentives that stay stable over time.
16669527|NCT02152917|Active Comparator|Floseal®|Floseal® will be applied in regions of potential bleeding before the release of the pneumatic tourniquet.
16669325|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
16669326|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
16669327|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
16669328|NCT02154230|Experimental|sulphate-bicarbonate-calcium water and low-calorie diet (SW-D)|"Experimental arm: Those patients assigned to this interventional arm of the study will be asked to follow a low-calorie diet. For the first 12 weeks, the diet will cover only basal metabolism expenditure ± 10%. At the end of this 12 weeks, for the following 12 weeks, patients will follow a maintenance diet which will cover both basal metabolism and physical activity expenditure. Patients will be invited to maintain the same level of physical activity preceding enrollment throughout the entire study period. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
16669329|NCT02154230|Active Comparator|tap water and low-calorie diet (TW-D)|Active comparator: Those patients assigned to this interventional arm of the study will be asked to follow the same low-calorie diet of the experimental arm. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Rome tap water at room temperature.
16669330|NCT02154217|Experimental|Bimatoprost|once daily
16669331|NCT02154217|Experimental|Latanoprost/Timolol|once daily
16669332|NCT02154191|Experimental|Surgical Intervention Group|The Surgical Intervention Group will undergo the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
16669333|NCT02154191|No Intervention|Non-Intervention Group (Control)|No Intervention.This group will consist of patients wait listed for surgery but further back in the queue.
16669334|NCT02154178|Experimental|Biomarker group|"Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.
~Biomarker group"
16669335|NCT02154178|No Intervention|Control group|Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).
16669336|NCT02154165|Active Comparator|Blue light wavelenght 460 nm|
16669337|NCT02154165|Active Comparator|Turquoise light wavelength 499 nm|
16669338|NCT02154152|Experimental|Homoeopathic Medicine Causticum|The drug namely Causticum 200C potency shall be administered as 4 globules, prescribed once a week for 3 months with placebo to follow for the remaining period.
16669339|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
16669340|NCT02154126|Other|Accuracy assessment|
16669341|NCT02154113|Active Comparator|Velashape II device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
16669342|NCT02154113|Active Comparator|Ultrashape|The UltraShape Contour I V3 uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
16669343|NCT02154100|Experimental|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
16669344|NCT02154100|Placebo Comparator|Placebo|12 weeks tart cherry juice taken in two doses of 240 ml per day.
16669345|NCT02154087|Experimental|HP802-247|
16669346|NCT02154074|Active Comparator|N1 group: Isoflurane & saline|for normal patients: inhale Isoflurane + the same volume of saline during operation
16669347|NCT02154074|Experimental|N2 group: Isoflurane & Dexmedetomidine|for normal patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
16669348|NCT02154074|Active Comparator|D1 group: Isoflurane & saline|for diabetes patients: inhale Isoflurane + the same volume of saline during operation
16669349|NCT02154074|Experimental|D2 group: Isoflurane & Dexmedetomidi|for diabetes patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
16669350|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
16669351|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
16669352|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
16669353|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
16669354|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
16669357|NCT02154022||1|Patients with cancer who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
16669358|NCT02154009||Healthy Volunteers|Volunteers will be studied for Fellows to practice and gain normative values for pupillometric function.
16669359|NCT02154009||Patients|Referred patients with known or suspected abnormalities of one or more components of the autonomic nervous system
16669360|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Placebo|Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation
16669361|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Colchicine|Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation
16669528|NCT02152917|No Intervention|Control group|
16669529|NCT02152904||Peptic ulcer bleeding patients|Endoscopy
16669362|NCT02153983|Experimental|Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine|Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.
16669363|NCT02153983|No Intervention|Evaluation Only Non-obese Adults|Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
16669364|NCT02153983|No Intervention|Evaluation Only Obese Adults Not Randomized|Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.
16669365|NCT02153983|No Intervention|Evaluation Only Adults with Type 2 Diabetes|Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
16669368|NCT02153944|Experimental|1|Methylphenidate
16669369|NCT02153944|Placebo Comparator|2|Placebo
16669370|NCT02153931||Volunteers|Parents of children with NF1
16669371|NCT02153918|Experimental|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
16669372|NCT02153905|Experimental|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
16669373|NCT02153905|Experimental|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
16669374|NCT02153892|Other|Multi-center, prospective, single-arm study|To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
16669375|NCT02153879|Experimental|Fenofibrate|Fenofibrate 145 mg/day for 12 weeks
16669376|NCT02153879|Experimental|Niacin plus Laropiprant|Niacin 2g/day plus Laropiprant for 12 weeks
16669377|NCT02153866|Placebo Comparator|rotavirus|vaccinate one dose rotavirus vaccine for each of 700 participants aged 8~9months
16669378|NCT02153866|Placebo Comparator|measles-rubella|vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8~9 months.
16669379|NCT02153866|Placebo Comparator|measles-mumps-rubella|vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8~9 months.
16669380|NCT02153866|Experimental|rotavirus, measles-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8~9 months.
16669381|NCT02153866|Experimental|rotavirus, measles-mumps-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8~9 months.
16669382|NCT02153853||Rectal cancer|Patients undergoing laparoscopic surgery for rectal cancer at the Department of Gastrointestinal Surgery, Hvidovre Hospital, Copenhagen, Denmark.
16669383|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule|PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
16669384|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule low dose group|PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
16669385|NCT02153840|Placebo Comparator|placebo|Placebo granule 1.1g os once a day for 12weeks.
16669386|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
16669387|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
16669388|NCT02153814|Sham Comparator|Control|Will undergo sham procedure twice
16669389|NCT02153814|Experimental|One Endometrial Scratch Procedure|Will undergo one sham procedure and one endometrial scratch procedure
16669390|NCT02153814|Experimental|Two Endometrial Scratch Procedures|Will undergo endometrial scratch procedure twice
16669391|NCT02153801|Active Comparator|Low Inferior Mesenterci Artery Ligation|The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
16669392|NCT02153801|Other|High Inferior Mesenterci Artery Ligation|"For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.
~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
16669393|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
16669394|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
16669395|NCT02153775|Experimental|Progressive muscle relaxation|Progressive muscle relaxation: single 20-minutes session
16669396|NCT02153775|No Intervention|Reading newspaper of the day|Reading newspaper of the day : single 20-minutes session
16669397|NCT02153762|Experimental|Right side|Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.
16669885|NCT02150616|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
16669398|NCT02153762|Active Comparator|Left first|Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.
16669399|NCT02153749|Experimental|Cognitive Regulation of Craving|Training in craving regulation component of Cognitive Behavioral Therapy(CBT) for addictions.
16669400|NCT02153749|Experimental|Mindfulness-Based Regulation of Craving|Training in craving regulation component of Mindfulness Based Therapy(MBT) for addiction.
16669401|NCT02153749|No Intervention|No training control|No training sessions will be provided in this arm.
16669402|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
16669403|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
16669404|NCT02153723|Experimental|Copaxone|"Dose escalation:
~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
16669405|NCT02153710|Experimental|Phonomotor therapy|Experimental group
16669406|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
16669407|NCT02153697|Experimental|Pigmanorm Cream, Q-switched Ruby laser,solar lentigines|Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.
16669408|NCT02153684||Mild COPD, symptomatic|Smokers fitting GOLD 1B criteria for COPD
16669409|NCT02153684||Mild COPD, asymptomatic|Smokers fitting GOLD 1A criteria for COPD
16669410|NCT02153684||Symptomatic smokers, at risk for COPD|Smokers who do not meet spirometric criteria for COPD
16669411|NCT02153684||Healthy, non-smoking controls|Non-smokers, matched to smoking groups for age (>40 yrs of age) and gender
16669412|NCT02153671|Experimental|Primed with H5N2|Subjects who received A(H5N1) inactivated influenza vaccine as well as primed with H5N2 live attenuated influenza vaccine approximately 1.5 years before
16669413|NCT02153671|Active Comparator|Did not receive A(H5N2)|Subjects who received A(H5N1) inactivated influenza vaccine and did not receive A(H5N2) live attenuated influenza vaccine in a previous study.
16669414|NCT02153658|No Intervention|Arm 1|Subjects followed the current hygiene instructions, standard washing in a shower with soap.
16669415|NCT02153658|Active Comparator|Arm 2|Subjects cleaned the foreskin with soapy water using a syringe once a day.
16669416|NCT02153658|Active Comparator|Arm 3|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
16669417|NCT02153645|Experimental|240mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 240mg daily for 12 weeks post two week titration phase.
16669418|NCT02153645|Experimental|320mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 320mg daily for 12 weeks post a two week dose titration phase.
16669419|NCT02153645|Placebo Comparator|Placebo tablets|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 16 weeks.
16669420|NCT02153632|Experimental|240mg amantadine HCl ER tablets|amantadine HCl ER, 240 mg tablets, once daily, 22 weeks
16669421|NCT02153632|Experimental|320mg amantadine HCl ER tablets|amantadine HCl ER, 320 mg tablets, once daily, 22 weeks
16669422|NCT02153632|Placebo Comparator|Placebo Tablets for Amantadine|Placebo, tablets, once daily, 26 weeks.
16669423|NCT02153619|Experimental|Meaning-Centered Grief Therapy (MCGT)|Part 1: Open Trials. Participants (n = 5 for Step 1 & n = 5 for Step 2) will receive 16 1-hour (approx) weekly sessions MCGT, & all therapy sessions will be audio recorded. Will make every effort to complete 16 sessions in 16 weeks, due to normal life activities, this is considered an approximation (i.e. there may be weeks where sessions don't take place &/or weeks where more than 1 session takes place in a week). If participant provides us with permission, we will also video record the sessions. Assessments will be administered at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). They will provide their feedback about MCGT & the measures. PI will review the open trial sessions to help refine the MCGT manual & treatment integrity forms. Sessions for Step 1 participants in Part 1 will be held at the MSK Counseling Center. Sessions for Step 2 participants in Part 1 will be conducted via videoconferencing.
16669424|NCT02153619|Experimental|MCGT or Supportive Psychotherapy|Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation & therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, & d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
16669425|NCT02153606|Active Comparator|Glycerin Suppository|
16669426|NCT02153606|Sham Comparator|Sham Suppository|
16669427|NCT02153593|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
16669428|NCT02153593|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
16669429|NCT02153593|Active Comparator|Usual hemostasia|Electrocauterization
16669430|NCT02153580|Experimental|Group I (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.
~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.
~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
16669530|NCT02152891|Experimental|CHAP-EMS/CP@clinic Program Intervention|12 month implementation of the intervention
16669431|NCT02153580|Experimental|Group II (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.
~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.
~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
16669432|NCT02153567|Placebo Comparator|Control (Placebo) group|"Identical looking placebo (once daily)
~Double blinding of study medication is achieved by repacking Escitalopram 5mg and 10mg as blue and green capsules respectively.. Identical appearing placebos packed in blue and green capsules will be used for the control group."
16669433|NCT02153567|Experimental|Escitalopram|Escitalopram 5mg & 10mg daily
16669434|NCT02153554|Experimental|Trained|Training civil servants in Medellin (Colombia) on attention to violence against women.
16669435|NCT02153554|No Intervention|Non trained|
16669436|NCT02153541|Placebo Comparator|Mineral oil|For those participants who receive mineral oil placebo, we do not anticipate any change in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
16669437|NCT02153541|Active Comparator|Antipyrine-benzocaine otic solution|Will be used on 50% of participants.
16669438|NCT02153528|Active Comparator|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
16669439|NCT02153528|Experimental|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
16669440|NCT02153515|Experimental|Fingerprick of autologous blood (FAB)|Fingerprick of autologous blood (FAB) four times a day for 2 months
16669441|NCT02153502|Experimental|AVP-786|
16669442|NCT02153502|Placebo Comparator|Placebo|
16669443|NCT02153489|Experimental|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
16669444|NCT02153489|Placebo Comparator|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
16669445|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
16669446|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
16669447|NCT02153463|Experimental|Activity Counselling|Physical Activity Counselling weekly for 8 weeks
16669448|NCT02153463|No Intervention|Standard Care|Standard care with no change in medications for 8 weeks
16669449|NCT02153450|Experimental|Treatment (stereotactic radiosurgery, metformin hydrochloride)|"Patients receive metformin hydrochloride PO daily or BID on days -11 to -1. Patients then undergo stereotactic radiosurgery 5 days a week for 5 weeks and receive concurrent metformin hydrochloride* PO BID for 5 weeks. Patients undergo laparotomy on week 6 (or weeks 5-7). Systemic therapy continues as soon as it is considered feasible by the treating physicians.
~*NOTE: Metformin hydrochloride should be stopped 2 days before laparotomy."
16669450|NCT02153437|Experimental|Arm A: BMS-919373|BMS-919373 oral Solution/tablet single dose for one day
16669451|NCT02153437|Active Comparator|Arm B: Sotalol|Sotalol oral Tablet single dose for one day
16669452|NCT02153437|Placebo Comparator|Arm C: Placebo for BMS-919373|Oral solution/tablet one single dose for one day
16669453|NCT02153424||NVAF patients in Mexico treated with Apixaban|All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
16669454|NCT02153411||8645 asthmatic patients|Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
16669455|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
16669456|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
16669457|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
16669458|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
16669459|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
16669460|NCT02153385|Experimental|Yoga group|Two yoga sessions per week for 8 weeks
16669461|NCT02153385|No Intervention|Control group|Usual level of physical activity; no involvement in any yoga practice during the course of the study
16669462|NCT02153372|Experimental|BMC2012|The large bone defect was then be bridged as per clinical standard, filled with a clinically established scaffold (ß-TCP), and 1.3 x106/ml BMC were loaded per 1 ml ß-TCP in situ.
16669463|NCT02153359|Experimental|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
16669493|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
16669494|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
16669464|NCT02153359|Sham Comparator|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
16669465|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
16669466|NCT02153333||HRV Group|Subjects who had received 2 doses of HRV vaccine in previous studies.
16669467|NCT02153333||Placebo Group|Subjects who had received 2 doses of placebo in previous studies.
16669468|NCT02153320|Experimental|HBsAg + adjuvant 1 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).
16669469|NCT02153320|Experimental|HBsAg + adjuvant 2 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).
16669470|NCT02153320|Experimental|HBsAg + adjuvant 3 Group|Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).
16669471|NCT02153307|Experimental|Implantable loop recorders Reveal ICM LINQ®,|
16669472|NCT02153294|Experimental|Ventilation with lower tidal volumes|Use of low tidal volume (4 to 6 ml/kg PBW) after intubation and during all mechanical ventilation
16669473|NCT02153294|Other|Ventilation with higher tidal volumes|Use of high tidal volume (8 to 10 ml/kg PBW) after intubation and during all mechanical ventilation
16669474|NCT02153281|Experimental|Phenelzine treatment|Subjects will undergo a PET and MRI scan before and after the treatment.
16669475|NCT02153268|Experimental|single arm, Liposuction, BonoFill Transplantation|"Liposuction - will be performed on Visit 2 for all eligible subjects
~BonoFill Transplantation - will be performed on Visit 6 for all eligible subjects"
16669476|NCT02153255||Children With Mucopolysaccharidosis Type IVa|
16669477|NCT02153242||Supra Ventricular Tachycardia (SVT)|Patients undergoing SVT studies
16669478|NCT02153229|Experimental|patients who undergo RP plus photofrin-based PDT|
16669479|NCT02153229|Experimental|patients who undergo RP alone|
16669480|NCT02153203|Experimental|Behavioral approach|The Prevent-Teach-Reinforce Model will be implemented with families in their home settings.
16669481|NCT02153203|Active Comparator|Educational approach|Each child's parent will participate in one 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior in children with autism spectrum disorders.
16669482|NCT02153190|Experimental|HYBRID-OPEN|"Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
~During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
16669483|NCT02153190|Experimental|OPEN-HYBRID|"Patients are randomized on the schedule: open period and after hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
~During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
16669484|NCT02153177|Active Comparator|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
16669485|NCT02153177|Active Comparator|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
16669486|NCT02153151||In vitro effect of AMP-514|Patients undergo blood sample collection at baseline, during the second week of RT, at the end of RT, and at 1 month after the end of RT
16669487|NCT02153125|Experimental|Eplerenone|25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment
16669488|NCT02153125|Placebo Comparator|Placebo|
16669489|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
16669490|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
16669491|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
16669492|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
16669495|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
16669496|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
16669497|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
16669498|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
16669499|NCT02153099|Experimental|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
16669500|NCT02153099|Experimental|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
16669501|NCT02153099|Experimental|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
16669502|NCT02153099|Experimental|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
16669503|NCT02153099|Experimental|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
16669504|NCT02153099|Experimental|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
16669505|NCT02153099|Placebo Comparator|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
16669506|NCT02153086||Ramelteon 8 mg Tablets|
16669507|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
16669508|NCT02153060|Experimental|20mg dexamethasone group|Dexamethasone 20 mg per day, 4 consecutive days
16669509|NCT02153060|Experimental|40mg dexamethasone group|Dexamethasone 40 mg per day, 4 consecutive days
16669510|NCT02153047|Experimental|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
16669511|NCT02153047|No Intervention|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
16669512|NCT02153034||Buruli ulcer patients, no intervention|Buruli ulcer patients administered standard standard care by the attending physician
16669513|NCT02153034||Healthy contacts, no intervention|Healthy volunteers who will be contacts of patients recruited or non-endemic controls. No intervention will be administered
16669514|NCT02153021|Placebo Comparator|Lifestyle counseling|alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.
16669515|NCT02153021|Active Comparator|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.
~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
16669516|NCT02153008||Symptomatic population for GAS|This study is a diagnostic study to aid in the detection of Strep throat. No intervention or medication is a part of this study.
16669517|NCT02152995|Experimental|Treatment (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
16669520|NCT02152969|Other|Part B|Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
16669521|NCT02152969|Other|Part A|Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
16669522|NCT02152956|Experimental|Flotetuzumab|CD123 x CD3 bispecific DART® antibody
16669523|NCT02152943|Experimental|Treatment (everolimus, letrozole, trastuzumab)|Patients receive everolimus PO QD and letrozole PO QD. Patients also receive trastuzumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669524|NCT02152930|Active Comparator|Supervised Exercise Therapy|Standard treatment: Supervised Exercise Therapy during 12 weeks
16669525|NCT02152930|No Intervention|Controlled group|
16669526|NCT02152917|Active Comparator|Tranexamic acid|A dose of tranexamic acid (10mg/Kg) will be administered 20 minutes before inflating the pneumatic tourniquet and another dose 15 minutes after the tourniquet release.
16669965|NCT02150070|Experimental|Subcutaneous ASP2408 low dose|
16669531|NCT02152891|No Intervention|Control|Will complete a survey at baseline and at 1 year, no program or intervention provided
16669532|NCT02152878|Active Comparator|Active stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
16669533|NCT02152878|Placebo Comparator|Sham stimulation|For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
16669534|NCT02152865|Active Comparator|Lupeol|Patients are supposed to apply lupeol on one side of face two times per day for 8 weeks
16669535|NCT02152865|Placebo Comparator|Control vehicle|Patients are supposed to apply vehicle control to another side of face two times per day for 8 weeks
16669536|NCT02152852|Experimental|Community Health Worker Intervention|Community Health Worker Intervention-home visits from community health workers providing education and support for self-management of type 2 diabetes, resources for diabetes control, and assistance in effective communication with medical providers
16669537|NCT02152852|No Intervention|Usual Care Control Group|Usual Care Control Group- Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support diabetes self-management (such as classes and support groups) and educational pamphlets.
16669538|NCT02152839|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
16669539|NCT02152839|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
16669540|NCT02152826|Experimental|potassium oxalate gel|Professional application
16669541|NCT02152826|Active Comparator|Potassium oxalate liquid|Professional application
16669542|NCT02152813|Active Comparator|1. Bilateral TENS (Bi-TENS) group|Subjects having bilateral electrical stimulation and task-orientated exercises
16669543|NCT02152813|Placebo Comparator|Unilateral TENS (Uni-TENS) group|Subjects having unilateral TENS over their affected lower limb only, and task-oriented exercises
16669544|NCT02152800|Experimental|Vacyless® 1000 mg|one Vacyless® 1000 mg tablets, 3 times daily for 7days
16669545|NCT02152800|Experimental|Vacyless® 500mg|Two Vacyless® 500mg tablets, 3 times daily for 7 days
16669546|NCT02152800|Active Comparator|Valtrex® 500 mg|Two Valtrex® 500 mg tablets, 3 times daily for 7days
16669547|NCT02152787|Experimental|1) propofol 1.0mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
16669548|NCT02152787|Experimental|2) propofol 0.5mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
16669549|NCT02152787|Placebo Comparator|3) normal saline group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
16669550|NCT02152774|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
16669551|NCT02152774|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
16669552|NCT02152761|Experimental|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
16669553|NCT02152761|Experimental|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
16669554|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
16669555|NCT02152761|Experimental|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
16669556|NCT02152748||Glioblastoma|The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
16669557|NCT02152735|Active Comparator|Cleaning the uterine cavity|Cleaning the uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
16669558|NCT02152735|No Intervention|Not cleaning the uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
16669559|NCT02152722||Total Body Irradiation Subjects|Subjects undergoing total body irradiation prior to chemotherapy. It is expected that all of these subjects will be receiving ablative radiation prior to bone marrow transplant. Breath will be collected before and after the first radiation exposure on each day of total body irradiation.
16669560|NCT02152709|Experimental|10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
16669561|NCT02152709|Active Comparator|5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.
16669562|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
16669563|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
16669564|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
16669565|NCT02152683|Experimental|long protocol|Renova
16669566|NCT02152683|Experimental|short protocol|Renova
16669567|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
16669568|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
16669569|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
16669570|NCT02152657|Experimental|Mesenchymal stem cell transplantation|
16669571|NCT02152644||amyloid|unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
16669572|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
16669573|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
16669574|NCT02152618|Experimental|Treatment|
16669575|NCT02152618|No Intervention|Comparison|
16669576|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
16669577|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
16669578|NCT02152592|No Intervention|PCM/NAPR group|paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
16669579|NCT02152592|Active Comparator|PCM/Oxy1 group|Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
16669580|NCT02152592|Active Comparator|PCM/Oxy2 group|CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
16669581|NCT02152579|Experimental|Isosorbide-5-mononitrate, tablet|Single treatment arm.
16669582|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
16669583|NCT02152553|Active Comparator|Hydrocortisone|Near-physiologic doses of Hydrocortisone are being given to subjects. The first day between 09.00 and 12.00 0,024 mg Hydrocortisone/kg per hour. The first day between 12.00 and 20.00 0,012 mg Hydrocortisone/kg per hour. The first day between 20.00 and 24.00 0,008 mg Hydrocortisone/kg per hour. The second day between 00.00 and 11.00 0,030 mg Hydrocortisone/kg per hour. Hydrocortisone infusion: 0,4 ml Solu Cortef 100 mg (50 mg/ml) added in 999,6 ml sodium chloride 0,9% solution (1 mg Solu Cortef/ 50 ml total solution volume).
16669584|NCT02152553|Placebo Comparator|Placebo|The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
16669585|NCT02152540|Experimental|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
16669586|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
16669587|NCT02152527||Trimetazidine|Patients for coronary artery bypass grafting surgery who had preoperative trimetazidine usage in standard ischemic coronary disease therapy.
16669588|NCT02152527||Control|Patients for coronary artery bypass grafting surgery who had standard therapy for ischemic coronary disease without trimetazidine.
16669589|NCT02152514|Active Comparator|Intrathecal Morphine/Sufentanil and PCA|Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
16669590|NCT02152514|Placebo Comparator|PCA alone|Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.
16669591|NCT02152501|Experimental|Exercise Energy Expenditure 300 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 300 kcal/day.
16669592|NCT02152501|Experimental|Exercise Energy Expenditure 600 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 600 kcal/day.
16669593|NCT02152475|Experimental|PDT with blue light and curcumin|PDT treatment was performed with light and curcumin.The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence. The curcumin concentration of 30 mg/L was used.
16669594|NCT02152475|Active Comparator|Curcumin|The curcumin concentration of 30 mg/L was used.
16669966|NCT02150070|Experimental|Subcutaneous ASP2408 middle dose|
16669595|NCT02152475|Active Comparator|Blue light|The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence.
16669596|NCT02152462|Other|Exergaming|Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
16669597|NCT02152462|No Intervention|Control|Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
16669598|NCT02152449|No Intervention|Control group|"Control group: systematic advice on swallowing, plus:
~If no weight loss compared to usual weight: no intervention
~if weight loss <5%: advice on a fat- and protein-enriched diet
~if weight loss ≥5%: advice on a fat- and protein-enriched diet + 1 unit of ONS/day per os"
16669599|NCT02152449|Experimental|oral nutritional supplementation|"Experimental ONS Group: systematic advice on swallowing + systematic advice on a fat- and protein-enriched diet, plus:
~if no weight loss compared to usual weight: 1 ONS/day per os
~if weight loss <5% compared to usual weight: 2 ONS/day per os
~if weight loss ≥5% compared to usual weight: 3 ONS/day per os"
16669600|NCT02152436||Before simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured before simulation-based curriculum
16669601|NCT02152436||After simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured after simulation-based curriculum
16669602|NCT02152423|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
16669603|NCT02152423|Active Comparator|ENOXAMED|patients are given a curative dose of Enoxaparin (ENOXAMED)
16669604|NCT02152410|Experimental|acupuncture group|The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
16669605|NCT02152410|Active Comparator|Morphine group|Each patient must receive a bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement (VAS> 30).
16669606|NCT02152397|Active Comparator|Therapist-led brief intervention (TBI)|"Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
16669607|NCT02152397|No Intervention|Enhanced usual care|Participants will receive therapist-led, computer-assisted control sessions with a therapist.
16669608|NCT02152384|Experimental|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
16669609|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
16669610|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
16669611|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
16669612|NCT02152358|Active Comparator|Ganciclovir|Patients with a positive CMV PCR
16669613|NCT02152358|Placebo Comparator|Ganciclovir placebo|Patients with a positive CMV PCR
16669614|NCT02152358|Active Comparator|Aciclovir|Patients with a PCR positive for HSV
16669615|NCT02152358|Placebo Comparator|Aciclovir placebo|Patients with a positive PCR for HSV
16669616|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
16669617|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
16669618|NCT02152332|Experimental|Treatment Sequence Group ADBC|Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
16669619|NCT02152332|Experimental|Treatment Sequence Group BACD|Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).
16669658|NCT02152085|Experimental|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
16669620|NCT02152332|Experimental|Treatment Sequence Group CBDA|Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
16669621|NCT02152332|Experimental|Treatment Sequence Group DCAB|Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).
16669622|NCT02152319|Experimental|KHV reporting|Clinicians will view the motor symptom severity reports and videoconference to titrate medications.
16669623|NCT02152319|Active Comparator|Standard care|Subjects in this group will still use KHV at home to minimize any placebo effects that could be attributed to using the system; however, clinicians will view the motor symptom severity reports and videoconference to titrate medications solely for the experimental subjects.
16669624|NCT02152306|Experimental|Fimasartan and Amlodipine|Combination of Fimasartan and Amlodipine
16669625|NCT02152306|Active Comparator|Fimasartan|Fimasartan Monotherapy
16669626|NCT02152280|Experimental|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
16669627|NCT02152280|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
16669628|NCT02152267|Experimental|tDCS 1mA|the parameters used in the TDCS will be 1mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
16669629|NCT02152267|Experimental|tDCS 2mA|the parameters used in the TDCS will be 2mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
16669630|NCT02152267|Sham Comparator|tDCS Sham|the parameters used in the TDCS will be sham, cathodal over right DLPFC and anodal over supraorbital contralateral area.
16669631|NCT02152254|Active Comparator|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
16669632|NCT02152254|Experimental|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
16669633|NCT02152241||Patients with IBD|Adult patients with IBD diagnosed during childhood
16669634|NCT02152228|Experimental|Oral Parathyroid Hormone (1-34)|Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)
16669635|NCT02152215|Active Comparator|Acellular dermal matrix membrane|An acellular dermal matrix membrane will be used as a barrier between the osseous graft and the soft tissue flap.
16669636|NCT02152215|Experimental|Polylactic acid membrane|A polylactic acid membrane will be used as a barrier between the osseous graft and the soft tissue flap.
16669637|NCT02152202|Experimental|Semi-upright position|Semi-upright position defined as 45 degrees incline from horizontal of the patients bed during nocturnal sleep, for two postoperative nights. Daytime naps will be excluded. A regular pillow may be used by the patients based upon the level of comfort and also to support the head in a neutral position.
16669638|NCT02152202|Other|Control group (Supine position)|In this group patients' bed will be set into Supine/0 degree angle during sleep in the night time. Patient will be managed according to routine care
16669639|NCT02152189||Screening population|
16669640|NCT02152176|Experimental|Patient Controlled Analgesy group|Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
16669641|NCT02152176|No Intervention|Control group|titration will be perform in the usual manner in accordance with the recommendations : a nurse will assess pain using a visual analog scale in the control group to assess the need for a new bolus of morphine
16669642|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
16669643|NCT02152163|Placebo Comparator|IV Saline|IV Saline
16669644|NCT02152150|Experimental|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content)
16669645|NCT02152150|Active Comparator|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content)
16669646|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16669647|NCT02152124||Controlled on LA-SMSA|Patients with controlled acromegaly on long-acting somatostatin analogs
16669648|NCT02152124||Controlled on LA-SMSA and pegvisomant|Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant
16669649|NCT02152124||Controlled after surgery|Controlled acromegaly patients without need for medical therapy after surgery
16669650|NCT02152124||Healhy controls|Healthy volunteers
16669651|NCT02152124||Uncontrolled on LA-SMSA|Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage
16669652|NCT02152111|Experimental|Dietary Supplement: Coconut flour|Diet hipoernergetic plus 26g/day coconut flour during three months (12weeks).
16669653|NCT02152111|Active Comparator|Nutritional Treatment|All patients received an individualized diet plan and balanced. The diet was calculated to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of total energy value
16669654|NCT02152098|Experimental|Chronic Exercise|Chronic Exercise
16669655|NCT02152098|Experimental|Acute Early onset of rehabilitation|Acute Early onset of rehabilitation
16669656|NCT02152098|Experimental|Chronic control|Chronic control
16669657|NCT02152098|Experimental|Acute Delayed onset of rehabilitation|Acute Delayed onset of rehabilitation
16669785|NCT02151214|No Intervention|Normal per os nutrition|The patients will eat orally
16669659|NCT02152085|Experimental|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
16669660|NCT02152072||medical students|
16669661|NCT02152059|Experimental|BIBF1120|BIBF1120 200 mg twice daily continuously
16669662|NCT02152046||Spring loaded retractor|The Alfonso Eyelid Speculum, newborn size
16669663|NCT02152046||Screw retractor|Cook Eyelid Speculum, infant size
16669664|NCT02152033|Experimental|Home-based Continuing Care|The components of Home-based Continuing Care (HCC) include brief parent training, brief Young Adult (YA) orientation and recovery planning, telephone-based continuing care (TCC) and home-based contingency management. Both parent and YA participants will attend sessions with a family specialist.
16669665|NCT02152033|Other|Services as Usual|YAs completing residential care usually are referred to continuing outpatient services and/or self-help groups.
16669666|NCT02152020||Cancer survivors|
16669667|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
16669668|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
16669669|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
16669670|NCT02151981|Experimental|Osimertinib|Osimertinib 80 mg, orally, once daily
16669671|NCT02151981|Active Comparator|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
16669672|NCT02151968|Active Comparator|Traditional blind peribulbar block|
16669673|NCT02151968|Experimental|Ultrasound-guided peribulbar block|
16669674|NCT02151955|Experimental|Individual parent infant intervention|Children and parents will be offered an assessment and then a tailored individual 10 to 15 week based attachment and parent intervention to promote parent child relationship.
16669675|NCT02151942||Control group|Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal
16669676|NCT02151942||Rehearsal group|Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal
16669677|NCT02151929|Experimental|Bioresorbable Vascular Scaffold|Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI
16669678|NCT02151929|Active Comparator|Everolimus Eluting stent|Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI
16669679|NCT02151916|Experimental|Dental care, AG, MI & fluoride varnish|The intervention comprises four components; provision of dental care to the mother during pregnancy (2nd trimester), preventive treatment with fluoride varnish to the teeth of children, and two behavioral interventions, namely oral health anticipatory guidance and motivational interviewing with the caregiver/mother.
16669680|NCT02151916|Other|Delayed intervention|Three fluoride varnish applications to the teeth of children and oral health anticipatory guidance and motivational interviewing for the caregiver when the child is aged 24, 30 and 36 months. Dental care also will be offered to the mothers/caregivers in the delayed intervention group when their children are aged 2 to 3 years old. Before the children are aged 2 years, standard dental care will be the comparator, which usually involves provision of dental care only if the participant is in pain.
16669681|NCT02151903|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
16669682|NCT02151903|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
16669683|NCT02151890|Experimental|Laparoscopic Stem Cell Transplantation.|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS)Laparoscopic injected of stem cell Sample in the ovaries.. Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.
16669684|NCT02151877|Experimental|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
16669685|NCT02151877|Placebo Comparator|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
16669686|NCT02151864|Experimental|LDE225|LDE225 200mg-800mg oral daily
16669687|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.
~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
16669688|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.
~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
16669689|NCT02151825|Experimental|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
16669690|NCT02151825|Placebo Comparator|Placebo|3 capsules of Maltodextrin per day
16669691|NCT02151812|Experimental|Agent Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
16669692|NCT02151812|Active Comparator|SeQuent Please Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
16669693|NCT02151799|Experimental|Body contouring surgery|
16669694|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
16669695|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
16669696|NCT02151760|Experimental|18F-DCFPyL|
16669697|NCT02151747||Sanger|BRCA 1/2 test results by Sanger sequencing
16669698|NCT02151747||NGS|BRCA 1/2 test results by NGS
16669699|NCT02151734|Experimental|KALOMIN™ Tab.|KALOMIN™ Tab./Placebo to Umckamin syrup
16669700|NCT02151734|Active Comparator|Umckamin syrup|Umckamin syrup/Placebo to KALOMIN™ Tab.
16669701|NCT02151721|Experimental|vorinostat, gefitinib, combination|single arm vorinostat plus gefitinib
16669702|NCT02151708|Active Comparator|motilitone 90mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
16669703|NCT02151708|Active Comparator|motilitone 180mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
16669704|NCT02151708|Placebo Comparator|placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
16669705|NCT02151695|Active Comparator|Panretinal photocoagulation|
16669706|NCT02151695|Experimental|Aflibercept intravitreal injections|
16669707|NCT02151682|Active Comparator|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.
~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
16669708|NCT02151682|Experimental|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.
~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
16669709|NCT02151682|Experimental|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
16669710|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
16669711|NCT02151682|No Intervention|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
16669712|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
16669713|NCT02151669|Experimental|Mediterranean Diet Group|Nutritional intervention to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
16669714|NCT02151669|No Intervention|Control group|Participants of control group will be referred to your doctor or nurse with reference to a report on specific according to your personal situation dietary recommendations.
16669715|NCT02151656|Experimental|F17464|Oral administration - During 6 weeks - 4 capsules daily
16669716|NCT02151656|Placebo Comparator|Placebo|Oral administration - During 6 weeks - 4 capsules daily
16669717|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
16669718|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
16669719|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
16669720|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
16669721|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
16669786|NCT02151201|Experimental|Influenza vaccination video education|Influenza vaccination video education
16669787|NCT02151201|Placebo Comparator|Hand Washing video education|Hand Washing vaccination video education
16669722|NCT02151630|Active Comparator|Pyruvic acid|Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
16669723|NCT02151630|Active Comparator|Salicylic acid|Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
16669724|NCT02151617|Experimental|Cohort 1-PF-06743649 or placebo|Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
16669725|NCT02151617|Experimental|Cohort 2-PF-06743649 or placebo|
16669726|NCT02151617|Experimental|Cohort 3-PF-06743649 or placebo|
16669727|NCT02151617|Experimental|Cohort 4-PF-06743649 or placebo|
16669728|NCT02151617|Experimental|Cohort 5-PF-06743649 or placebo|
16669729|NCT02151604|Experimental|129 Xenon MR Imaging|Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
16669730|NCT02151591|Experimental|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
16669731|NCT02151591|Other|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
16669732|NCT02151578|No Intervention|nothing at home level|No intervention at community level. The study drugs (arthemeter/Lumefantrine and Cotrimoxazole) available at the health facility drug stores level and prescribed exclusively to sick children attending to the health facility for care seeking. No Community Heath Worker /Key Opinion leader (CHWs/KOLs) selected in those clusters
16669733|NCT02151578|Experimental|Home management of malaria|"At the community level, the Community health workers/ keay opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc"
16669734|NCT02151578|Experimental|Home management of malaria and pneumonia|"At the community level, the Community health workers/ key opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) or antibiotic (Cotrimoxazole) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc. The treatment decision making for the CHWs/KOLs based on the algorithm"
16669735|NCT02151565|Experimental|HTEMS|High-tone external muscle stimulation 5 times within 10 days
16669736|NCT02151565|Active Comparator|TENS|Transcutaneous electrical nerve stimulation 5 times within 10 days
16669737|NCT02151552|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
16669738|NCT02151539||Observational (medical chart review)|Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.
16669739|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
16669740|NCT02151513||Cancer Pain|Placement of an intrathecal pump
16669741|NCT02151500|Experimental|Stress and Health Interview|Stress and Health Interview is an experiential assessment technique
16669742|NCT02151500|No Intervention|Wait-list Control|Standard medical care until the 6-week follow-up is completed
16669743|NCT02151487||Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
16669744|NCT02151487||Ropivacaine and dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
16669745|NCT02151487||Ropivacaine and clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
16669746|NCT02151487||Ropivacaine, dexamethasone and clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
16669747|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
16669748|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
16669749|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
16669750|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
16669751|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
16669752|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
16669753|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
16669754|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
16669788|NCT02151188|Other|Bread and water|co-ingestion control session
16669789|NCT02151188|Experimental|bread with cow milk co-ingestion|co-ingestion bread with cow milk
16669790|NCT02151188|Experimental|bread with soy milk co-ingestion|co-ingestion bread with soy milk
16669791|NCT02151188|Experimental|preload cow milk|preload cow milk 30 min, then bread
16669792|NCT02151188|Experimental|preload soy milk|preload soy milk 30 min, then bread
16669793|NCT02151175|Experimental|LIFUP|
16669794|NCT02151162|Experimental|Stress management plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
16669967|NCT02150070|Experimental|Subcutaneous ASP2408 high dose|
16669755|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before & after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days & CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed & Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
16669756|NCT02151435||Patients with IPF|Observation of longitudinal biomarkers in IPF patients
16669757|NCT02151422|Experimental|Breathing exercises|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
16669758|NCT02151409|Experimental|NNC 0151-0000-0000 i.v.|Dose escalation trial
16669759|NCT02151409|Experimental|NNC 0151-0000-0000 s.c.|Dose escalation trial
16669760|NCT02151409|Placebo Comparator|Placebo|
16669761|NCT02151396|Experimental|Cogmed Working Memory Training|Cogmed (TM) working memory training following standard, recommended administration procedures
16669762|NCT02151383|Experimental|Serelaxin|Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.
16669763|NCT02151370||Cohort|
16669764|NCT02151357|Experimental|DCBCI0901|DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20
16669765|NCT02151344|Experimental|Cohort 1|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
16669766|NCT02151344|Experimental|Cohort 2|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
16669767|NCT02151344|Experimental|Cohort 3|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
16669768|NCT02151344|Experimental|Cohort 4|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
16669769|NCT02151344|Experimental|Cohort 5|Participants will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28.
16669770|NCT02151331|Experimental|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
16669771|NCT02151331|Experimental|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
16669772|NCT02151305|Experimental|Total intravenous anesthesia group|This group received propofol and remifentanil for the maintenance of general anesthesia.
16669773|NCT02151305|Experimental|Inhalation anesthesia group|This group received sevoflurane for the maintenance of general anesthesia.
16669774|NCT02151279|Placebo Comparator|control group|Chitosan as wine fining agent
16669775|NCT02151279|Active Comparator|Shrimp allergic patients|Chitosan as wine fining agent
16669776|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
16669777|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
16669778|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
16669779|NCT02151253|Experimental|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.
~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
16669780|NCT02151253|Placebo Comparator|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.
~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
16669781|NCT02151240|Experimental|Arm I|Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV
16669782|NCT02151240|Active Comparator|Arm II|First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV
16669783|NCT02151227||magnesium intake categories|comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake
16669784|NCT02151214|Experimental|Parenteral nutrition|Parenteral nutrition will be administered to the patients
16669883|NCT02150629||Healthy subjects|
16669795|NCT02151162|Active Comparator|Stress management plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
16669796|NCT02151162|Active Comparator|Psychoeducation leaflet plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
16669797|NCT02151162|Active Comparator|Psychoeducation leaflet plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
16669798|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
16669799|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
16669800|NCT02151136|Experimental|24% sucrose + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml 24% sucrose will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
16669801|NCT02151136|Placebo Comparator|Sterile water + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml sterile water will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
16669802|NCT02151123||Diagnosed colon cancer patients|Patients undergoing colectomy for colonic adenocarcinoma.
16669803|NCT02151110|Placebo Comparator|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
16669804|NCT02151110|Experimental|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
16669805|NCT02151110|Experimental|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
16669806|NCT02151110|Experimental|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
16669807|NCT02151110|Experimental|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
16669808|NCT02151110|Experimental|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
16669809|NCT02151110|Experimental|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
16669810|NCT02151110|Experimental|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
16669811|NCT02151097||High risk prostate cancer|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage ≥T2c, or Prostate Specific Antigen (PSA)>20 ng/ml, or Gleason Score 8-10, scheduled to have radical prostatectomy.
16669812|NCT02151084|Experimental|Arm A (Continuous Dosing)|"Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)
~On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
16669813|NCT02151084|Experimental|Arm B (Sequential Dosing)|"Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout
~On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.
~Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
16669814|NCT02151084|Experimental|Arm C (Standard Care)|Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.
16669815|NCT02151071|Other|Breast conserving surgery|Females ≥ 30 years of age with a diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS), scheduled for BCS +/- SLNB or ALND
16669816|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
16669817|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
16669818|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
16669819|NCT02151045|Active Comparator|Non target epidural infiltration at L3-L4 stage|"In this control arm, there are patients with a non target posterior epidural space infiltration of corticoids done at L3-L4 stage on scan control.
~These patients must have a discal hernia confirmed by scanner or RMI"
16669820|NCT02151045|Experimental|Epidural infiltration on contact of disco radicular conflict|"In this experimental arm, there are patients with an epidural infiltration of corticoids done in lateral on contact of disco radicular conflict on scan control.
~These patients must have a discal hernia confirmed by scanner or RMI"
16669821|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
16669822|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
16669823|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
16669824|NCT02151019|Experimental|Experimental Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
16669825|NCT02151019|No Intervention|Control Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique
16669826|NCT02151006|Active Comparator|DHEA|women will receive DHEA 6 weeks before starting IVF/ICSI
16669827|NCT02151006|No Intervention|Control|
16669828|NCT02150993|Experimental|Arm A : TDF + FTC (or 3TC) + ZDV|Tenofovir + Emtricitabine or Lamivudine + Zidovudine
16669829|NCT02150993|Experimental|TDF+FTC (or 3TC) +LPV/r|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
16669830|NCT02150993|Experimental|Arm C : TDF +FTC (or 3TC) + RAL|Tenofovir + Emtricitabine or Lamivudine + Raltegravir
16669831|NCT02150967|Experimental|BGJ398 (infigratinib)|To estimate anti-tumor activity of BGJ398
16669884|NCT02150616|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
16669832|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
16669833|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
16669834|NCT02150941|Experimental|BioVac Direct Suction Device|Experimental arm
16669835|NCT02150941|Active Comparator|Standard Endoscopy Suction|Control arm
16669836|NCT02150928|Experimental|Erwinaze / Erwinase|
16669837|NCT02150915|Experimental|new acupoint|Subjets in this arm receive acupuncture therapy in a new acupoint (leopard spot needling technique)
16669838|NCT02150915|Active Comparator|classical acupoint|Subjects in this arm receive acupuncture therapy in a classical acupoint in the pericardial conduit (leopard spot needling technique)
16669839|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
16669840|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
16669841|NCT02150889|No Intervention|Lean Trained|Metabolic control
16669842|NCT02150889|Experimental|Obese or Overweight|Running Program Yoga Program
16669843|NCT02150863|Active Comparator|Ultrapulse laser alone|
16669844|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
16669845|NCT02150863|No Intervention|Control|
16669846|NCT02150850||Registry|Patients who have who have sustained an AFF that consent to participating in the registry only.
16669847|NCT02150850||Cases|Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.
16669848|NCT02150850||Controls|For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.
16669849|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 & 2 & 2 Meal Replacement Plan for weight loss.
16669850|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 & 2 & 1 Meal Replacement Plan for weight loss.
16669851|NCT02150824|Experimental|BI 187004 low dose mono QD|patient to receive one tablet containing low dose of BI 187004 or matching placebo
16669852|NCT02150824|Experimental|BI 187004 medium dose mono QD|patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
16669853|NCT02150824|Experimental|BI 187004 high dose mono QD|patient to receive one tablet containing high dose of BI 187004 or matching placebo
16669854|NCT02150824|Experimental|BI 187004 high dose QD add on|patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
16669855|NCT02150811||Hunner's ulcer|
16669856|NCT02150798|Experimental|High fat and low carbohydrate diet|High fat low carbohydrate diet composition was 40 % of carbohydrates, 40 % of lipids (12 % saturated, 18 % monounsaturated and 10% polyunsaturated, ) and 20 % of protein for two months
16669857|NCT02150798|Active Comparator|Control diet|the standard diet composition was 50 % of carbohydrates, 30 % of lipids (10 % saturated, 10 % polyunsaturated, and 10 % monounsaturated) and 20 % of protein for two months
16669858|NCT02150785|Experimental|Adminstering Streptokinase|treatment with 15,000 units/Kg of streptokinase in ischemic stroke patients with symptoms onset for less than 3 hours
16669859|NCT02150772|Other|Shear Wave Elastography|All included patients have SWE performed
16669860|NCT02150759|Experimental|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
16669861|NCT02150759|Active Comparator|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
16669862|NCT02150746||Pancreatic Cancer CTC|Peripheral/Central Venous Blood Draw Peritoneal Wash
16669863|NCT02150733|Experimental|Group 1 - Normal hepatic function|Subjects with normal hepatic function
16669864|NCT02150733|Experimental|Group 2 - Mild hepatic impairment|Subjects with mild hepatic impairment by Child-Pugh classification scores
16669865|NCT02150733|Experimental|Group 3 - Moderate hepatic impairment|Subjects with moderate hepatic impairment by Child-Pugh classification scores
16669866|NCT02150733|Experimental|Group 4 - Severe hepatic impairment|Subjects with severe hepatic impairment by Child-Pugh classification scores
16669867|NCT02150720|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
16669868|NCT02150720|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,
16669869|NCT02150720|Active Comparator|Usual hemostasia|Electrocauterization
16669870|NCT02150707||Dipeptidyl-Peptidase IV Inhibitors|Newly started on DPP4 inhibitor for hyperglycaemia
16669871|NCT02150707||Glucagon-Like Peptide 1|Newly started on GLP-1 for hyperglycaemia or obesity
16669872|NCT02150694|Experimental|Apelin agonist infusion|Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.
16669873|NCT02150694|Experimental|Apelin receptor antagonist infusion|Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent
16669874|NCT02150694|Experimental|Apelin agonist/antagonist co-infusion|Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.
16669875|NCT02150681|Experimental|Mindfulness-based cognitive therapy|8 class sessions of mindfulness therapy given in a group setting, with one 2-hr session per week for 8 weeks.
16669876|NCT02150668|Experimental|HOPS Intervention|School counselors deliver HOPS intervention to students during the school day. This includes 16, 20-minute sessions with the student and two joint family meetings.
16669877|NCT02150668|Active Comparator|HSI Intervention|School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
16669878|NCT02150655|Experimental|Probiotic|Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 oral capsules
16669879|NCT02150655|Placebo Comparator|Placebo|Sugar pill
16669880|NCT02150642||Neurological Injury|
16669881|NCT02150642||No Neurological Injury|
16669882|NCT02150629||SCI patients|
16669886|NCT02150616|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
16669887|NCT02150616|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
16669888|NCT02150603||Adults with congenital heart disease|
16669889|NCT02150590|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
16669890|NCT02150590|Placebo Comparator|Sham oxygen|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
16669891|NCT02150577|Experimental|Implementation|Evidence Based Quality Improvement
16669892|NCT02150577|No Intervention|Control|Usual Quality Improvement
16669893|NCT02150564|Other|Navigation only group|Sonowand system will be used for navigation control arm as well as sononavigation experimental arm.Navigation will be used to plan the craniotomy and throughout the procedure as desired by the operating surgeon. At no point of time however will the Ultrasound be used.
16669894|NCT02150564|Experimental|SonoRCT Test group|Surgery to resect the tumor with the aid of sononavigation. In addition to the navigation function, the Ultrasound will be available at all times. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue.
16669895|NCT02150551|Experimental|Mesenchymal Stromal Cells (MSCs)|A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
16669896|NCT02150538|Active Comparator|Right ventricular stimulation|patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
16669897|NCT02150538|Experimental|Biventricular Stimulation|Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
16669898|NCT02150525|Experimental|Arm I (oral omega-3 fatty acid)|Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
16669899|NCT02150525|Placebo Comparator|Arm II (placebo)|Patients received equivalent, matched oral placebo (seven capsules) daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
16669900|NCT02150512|Experimental|Transpulmonary thermodilution (TPTD)|The intervention group (TPTD guided therapy) follows a fluid resuscitation protocol based on stroke volume variation (SVV) and extravascular lung water (EVLW). Initial trigger for fluid loading when circulatory insufficiency is present will be SVV.
16669901|NCT02150512|Active Comparator|Surviving Sepsis Guidelines (SSG)|The standard group (SSG guided therapy) follows a fluid resuscitation protocol based on the Surviving Sepsis Campaign recommendations. Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg).
16669902|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
16669903|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
16669904|NCT02150473|Experimental|Adalimumab|receive adalimumab 40 mg eow injections in combination with MTX for 24 weeks
16669905|NCT02150473|Placebo Comparator|Placebo|receive placebo injections in combination with MTX for 24 weeks
16669906|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
16669907|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
16669908|NCT02150447|Active Comparator|Intervention group|Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
16669909|NCT02150447|Placebo Comparator|Placebo group|Placebo for the prevention of gastric cancer bleeding
16669910|NCT02150434|Sham Comparator|Compressed Air|compressed air delivered at a fixed flow of 2 L/min
16669911|NCT02150434|Active Comparator|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
16669912|NCT02150434|Experimental|Automated oxygen titration|oxygen at a variable flows delivered by the FreeO2
16669913|NCT02150421||e-book|study the course materials by using e-book
16669914|NCT02150408|Experimental|assesment by 68Ga-DOTATATE PET-CT|
16669915|NCT02150395|Experimental|music therapy|pt received a protocolized music therapy intervention that included altered state induction, music driven guided visualiztion, and psychoeducation on relaxation techniques to be used during simulation for radiation therapy. Prescribed pre-recorded music program provided to be used during simulation.
16669916|NCT02150395|No Intervention|control|no intervention
16669917|NCT02150369||Patient, care partner, primary nurse case|In Phase I of this pilot, a case is comprised of the metastatic RCC patient receiving IL-2, their care partner, and their primary nurse. In Phase II, the IL-2 patient can either have MM or metastatic RCC. The care partner for this study will be the family member or friend staying with the IL-2 patient throughout treatment.
16669918|NCT02150356|Experimental|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
16669919|NCT02150356|Placebo Comparator|Control|Diet based on refined cereal products for a period of 8 weeks.
16669920|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
16669921|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
16669922|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
16669923|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
16669924|NCT02150330|Active Comparator|DHEAS in DOR Group|Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
16669925|NCT02150330|Active Comparator|Normal Control|Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
16669926|NCT02150330|Active Comparator|Shame DOR Group|Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.
16669927|NCT02150317|Active Comparator|TACE+Sorafenib|TACE followed by Sorafenib
16669928|NCT02150317|Experimental|TACE|TACE alone
16669929|NCT02150304||intravenous aminophylline|intravenous aminophylline use during spinal anesthesia
16669930|NCT02150304||no intravenous aminophylline|no use of intravenous aminophylline during spinal anesthesia
16669931|NCT02150291|Active Comparator|Group A|one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
16669932|NCT02150291|Active Comparator|Group B|Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
16669933|NCT02150291|Active Comparator|Group C|Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
16669934|NCT02150291|Placebo Comparator|Group D|Patients will receive matching placebo capsule to take during hepatitis C treatment
16669935|NCT02150278|Experimental|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
16669936|NCT02150265|No Intervention|Waiting list control group|6 week waiting list
16669937|NCT02150265|Experimental|Individual cognitive behavioral therapy with SMART|SMART manual cognitive behavioral therapy individual weekly sessions for 6 weeks
16669938|NCT02150252|Experimental|BY HWT，placebo-BY HWT ， Gait parameter|
16669939|NCT02150239||postoperative pain|
16669940|NCT02150226|Experimental|Experimental: Zirconia monolithic crowns and bridges|Evaluation of Lava Plus zirconia dental crowns and bridges
16669941|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
16669942|NCT02150200|Other|A group : Conventional hospitalization|Patients discharged after 3 days hospital stay after laparoscopic hysterectomy
16669943|NCT02150200|Experimental|B group : shorter stay|Patients going home within 24 hours discharged the first day after laparoscopic hysterectomy.
16669944|NCT02150187|Experimental|HCap Formula|Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.
16669945|NCT02150187|Placebo Comparator|Placebo|Same as treatment with placebo pills
16669946|NCT02150174|Experimental|Patients with schizophrenia|
16669947|NCT02150174|Active Comparator|Healthy subjects|
16669948|NCT02150161|Experimental|lidocaine/ ketamine infusion|lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
16669949|NCT02150161|Active Comparator|fentanyl|iv fentanyl, 3ug/kg bolus
16669950|NCT02150148|Experimental|Mentored Gardening Intervention|Participants in this arm will be provided with either a raised bed garden or 4 earthboxes, gardening supplies, and plants and seeds. A master gardener from the Cooperative Extension will mentor them over the course of a year to plant three gardens (spring, summer and fall).
16669951|NCT02150148|Other|Wait-List|Participants in this arm will be provided with the same gardening supplies as the other group, but will receive them one year after enrollment in the study. They also will receive instruction from a master gardener from the Cooperative Extension at this time as well.
16669952|NCT02150135|Experimental|Oncothermia group|Patients were treated with oncothermia 2 or 3 times a week. Treatment was performed for about 1 hours per each visits.
16669953|NCT02150122|Experimental|10 micrograms (400 IU) vitamin D3|Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.
16669954|NCT02150122|Experimental|20 micrograms (800 IU) vitamin D3|Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.
16669955|NCT02150122|No Intervention|Placebo|Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.
16669956|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
16669957|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
16669958|NCT02150096|Active Comparator|Continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
16669959|NCT02150096|Active Comparator|Pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
16669960|NCT02150096|Active Comparator|low level laser therapy group|the group will be treated with 3J during 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
16669961|NCT02150096|No Intervention|control group|group of women no treated, only evaluated in two moments and this group will be compared with orthers: laser, pulsed ultrasound and continuous ultrasound.
16669962|NCT02150083|Experimental|OR retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is NOT replaced for the duration of the surgery. The surgery is completed and the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will be instructed to void. The voided volume and residual volume will be recorded.
16669963|NCT02150083|No Intervention|PACU retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is replaced for the duration of the surgery and when complete the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will undergo a retrograde bladder fill with 300 mL of normal saline. The foley catheter will be removed and she will be instructed to void. The voided volume and residual volume will be recorded.
16669964|NCT02150070|Experimental|Intravenous ASP2408|
16669968|NCT02150070|Placebo Comparator|Intravenous Placebo|
16669969|NCT02150070|Placebo Comparator|Subcutaneous Placebo|
16669970|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
16669971|NCT02150057|Active Comparator|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
16669972|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
16669973|NCT02150031|Other|Control|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).
~No prophylactic Chlorhexidine regimen.
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
16669974|NCT02150031|Active Comparator|CHX-Mouthwash|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).
~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
16669975|NCT02150031|Active Comparator|CHX-MW/SUB_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).
~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
16669976|NCT02150031|Active Comparator|CHX-MW/SUPRA_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).
~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
16669977|NCT02150018||non invasive ventilation (NIV)|
16669978|NCT02150005|Experimental|Periodontal treatment|The test group received oral hygiene instructions, supragingival and subgingival scaling and root planning using curettes and an ultrasonic appliance.
16669979|NCT02150005|No Intervention|Control|
16669980|NCT02149992|Experimental|Myo-inositol, folic acid|"myo-inositol, oral, 2g, two times per day for 5 total days
~folic acid, oral 200 micrograms, two times per day for 7 days
~Continuous Glucose Monitoring Surveillance device for 7 days during study period
~Capillary glucose monitoring 4 times per day"
16669981|NCT02149979|Experimental|Temperature Controlled Laser Soldering|Efficacy and safety of Temperature Controlled Laser Soldered wound incisions closure
16669982|NCT02149966|Experimental|AG-348|Multiple oral doses of AG-348
16669983|NCT02149966|Placebo Comparator|Placebo|Multiple oral doses of placebo.
16669984|NCT02149953|Experimental|Glycine intake|Dietary supplement: Glycine intake
16669985|NCT02149940|Experimental|clinical pharmacy intervention|
16669986|NCT02149927|Experimental|Sevoflurane|Single arm: dose escalation of study medication
16669987|NCT02149914|Experimental|PPI treatment|Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
16669988|NCT02149901|Experimental|Pseudoephedrine + 480 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 480 ml
16669989|NCT02149901|Placebo Comparator|Pseudoephedrine + 50 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 50 ml
16669990|NCT02149901|Experimental|Placebo + 480 ml water (optional)|Placebo PO 45 minutes before water 480 ml
16669991|NCT02149901|Placebo Comparator|Placebo + 50 ml water (optional)|Placebo PO 45 minutes before water 50 ml
16669992|NCT02149888|Experimental|Tenofovir/emtricitabine|MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis
16669993|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
16669994|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
16669995|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
16669996|NCT02149862|Experimental|cancer|patients with an indication of partial or total bladder resection will have urine infrared analysis
16669997|NCT02149862|Placebo Comparator|control group|"Lithiasic patients should be operated a urinary calculation, without catheter double J, will have urine infrared analysis"
16669998|NCT02149849|No Intervention|Standard lateral positioning|
16669999|NCT02149849|Experimental|Modified lateral positioning|Modified lateral positioning. This will ensure less pressure and stretch on shoulder than standard lateral positioning.
16670000|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
16670006|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
16670087|NCT02149238|Active Comparator|methylxanthine rich drink intervention|methylxanthine rich drink
16670007|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
16670008|NCT02149797|Active Comparator|Four port laparoscopic cholecystectomy|This group of patients undergone classical four port laparoscopic cholecystectomy
16670009|NCT02149797|Active Comparator|SILC-Pick'n roll-Beginning (group I)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's beginning arm."
16670010|NCT02149797|Active Comparator|SILC-Pick'n roll-Experienced (group II)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's experienced arm."
16670011|NCT02149784|Experimental|Surgical treatment group|Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.
16670012|NCT02149784|No Intervention|Chemotherapy group|Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.
16670013|NCT02149771|Experimental|TACE&Stents|chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
16670014|NCT02149771|Active Comparator|TACE|Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
16670015|NCT02149758|Experimental|Etoricoxib|Etoricoxib 60 mg once daily
16670016|NCT02149758|Placebo Comparator|matching placebo|matching placebo once daily
16670017|NCT02149745|Experimental|Calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by calling the patient's name
16670018|NCT02149745|Experimental|Not calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by giving verbal stimulus other than the patient's name
16670019|NCT02149719|Experimental|Desensitisation to peanut|Desensitisation using boiled peanut
16670020|NCT02149719|Experimental|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
16670021|NCT02149706|Experimental|NeuroVax|NeuroVax
16670022|NCT02149706|Placebo Comparator|IFA Incomplete Freund's Adjuvant|Incomplete Freund's Adjuvant IFA
16670023|NCT02149693|Experimental|high-fidelity simulation and teamwork training|high-fidelity simulation and teamwork training
16670024|NCT02149693|Active Comparator|traditional resuscitation training|traditional resuscitation training
16670025|NCT02149680||Experimental group|Patient who has had an epidural blood patch following accidental dura puncture during pregnancy
16670026|NCT02149680||Control Group|Women in the same group, equal numbers of those with or without epidurals, without accidental dural puncture, similar parity would constitute the control group. They would be chose at random, 10 times the number in the experimental group (n = 600).
16670027|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
16670028|NCT02149641||Nasopharyngeal cancers|Intensitiy modulated radiotherapy with chemotherapy
16670029|NCT02149628|Active Comparator|desflurane|use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)
16670030|NCT02149628|Experimental|propofol|propofol infusion with target-controlled infusion(TCI) device guided by BIS
16670031|NCT02149615|Experimental|isotretinoin|Retinal nerve fibre layer measurement in patients under isotretinoin treatment
16670032|NCT02149615|Active Comparator|lymecycline|Retinal nerve fibre layer measurement in patients under lymecycline treatment
16670033|NCT02149615|Active Comparator|minocycline|Retinal nerve fibre layer measurement in patients under minocycline treatment
16670034|NCT02149615|Active Comparator|doxycycline|Retinal nerve fibre layer measurement in patients under doxycycline treatment
16670035|NCT02149602||oropharyngeal and hypopharyngeal HNSCC|Intensity Modulated Radiotherapy HPV positive and HPV negative
16670036|NCT02149589|Experimental|Focal ARDS|In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt.
16670037|NCT02149589|Other|non focal ARDS|In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used
16670038|NCT02149576|Active Comparator|LDCT Surveillance Program Group|This cohort will follow a strict schedule of Low Dose Computed Tomography Imaging scans and clinical visits 3, 6, and 12 months after surgery. At each encounter, a history, physical examination, and review of the LDCT results will be performed. Patients with normal clinical and imaging findings will proceed to the next scheduled clinical encounter. Patients with abnormal findings will be managed according to predetermined algorithms.
16670039|NCT02149576|Other|Historical Control Group|The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
16670040|NCT02149563|Active Comparator|Treatment|One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.
16670041|NCT02149563|Placebo Comparator|Placebo|100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month
16670042|NCT02149550|Active Comparator|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
16670043|NCT02149550|Experimental|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
16670044|NCT02149550|Experimental|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
16670045|NCT02149550|Active Comparator|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
16670046|NCT02149550|Experimental|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
16670047|NCT02149550|Experimental|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
16670048|NCT02149537|Experimental|hydroxyurea|500mg of hydroxyurea/day during 6 months
16670049|NCT02149537|No Intervention|No treatment|No hydroxyurea treatment during 6 months
16670050|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
16670051|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
16670052|NCT02149511||SCI subjects|
16670053|NCT02149511||healthy control subjects|
16670054|NCT02149498||Parkinson Disease (PD)|Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)
16670055|NCT02149498||Healthy Controls|Healthy individuals
16670056|NCT02149472||Pregnant women with PPH|All pregnant women in participating hospitals are asked for their informed consent (n = 9.500). All women will complete a bleeding score generating questionnaire during their pregnancy. Only from women developing postpartum haemorrhage > 1000 cc blood samples will be drawn (n = 600).
16670057|NCT02149459|Experimental|treatment arm|Partial brain re-irradiation combined with metabolic intervention (low carbohydrate diet and/or metformin treatment)
16670058|NCT02149446|Experimental|Surgisis reinforcement of staple line|The stapler used to divide the pancreas is reinforced with Surgisis (COOK Medical).
16670059|NCT02149446|No Intervention|No reinforcement of staple line|The stapler used to divide the pancreas is not reinforced with any material
16670060|NCT02149433|Experimental|Prednisone versus placebo|Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days
16670061|NCT02149420|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
16670062|NCT02149420|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
16670063|NCT02149420|Placebo Comparator|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
16670064|NCT02149407|Active Comparator|Glycerin group (GG)|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
16670065|NCT02149407|Active Comparator|Rectal stimulation group (SG)|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
16670066|NCT02149407|Sham Comparator|Control group (CG)|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
16670067|NCT02149394|Experimental|Ice|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale.The experimental group received an ice popsicle made of 10 mL mineral water.The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice was supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
16670068|NCT02149394|Active Comparator|Water|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
16670069|NCT02149381|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy is a manual-based group intervention for chr depression (20 weeks).
16670070|NCT02149381|Active Comparator|Befriending|Befriending is a social support intervention
16670071|NCT02149381|Active Comparator|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
16670072|NCT02149355||controls|teeth molding in subjects without congenital fourth nerve palsy
16670073|NCT02149355||congenital fourth nerve palsy|teeth molding in patients suffering from congenital fourth nerve palsy
16670074|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
16670075|NCT02149329|Experimental|Short treatment|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
16670076|NCT02149329|No Intervention|Extended treatment|Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature <38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC > 0,5 x10^9/L), whichever comes first.
16670077|NCT02149316|Experimental|RIPC+RIPostC|
16670078|NCT02149316|Sham Comparator|control|
16670079|NCT02149303||Dabigatran|
16670080|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
16670081|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
16670082|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
16670083|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
16670084|NCT02149251||Pre-genetic diagnosis|Women in this group had ICSI and PGD to exclude genetically affected children or for sex selection
16670085|NCT02149251||Control group|This group will include women who had IVF without PGD
16670086|NCT02149238|Active Comparator|flavanol rich drink intervention|flavanol rich drink
16670088|NCT02149238|Active Comparator|flavanol + methylxanthine rich drink intervention|flavanol + methylxanthine rich drink
16670089|NCT02149225|Experimental|APVAC1 and 2 vaccine plus polyICLC and GMCSF concurrent to TMZ|
16670090|NCT02149212|Active Comparator|Clinical Treatment|Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
16670091|NCT02149212|Active Comparator|Iliac vein stenting|Wallstent
16670092|NCT02149199|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
16670093|NCT02149199|Active Comparator|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
16670094|NCT02149199|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
16670095|NCT02149186|Experimental|Rehabilitation|
16670096|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
16670097|NCT02149160|Experimental|FRM-0334; Arm 1|low dose, Capsule, Once Daily, Day 1 through Day 28
16670098|NCT02149160|Experimental|FRM-0334; Arm 2|high dose, Capsule, Once Daily, Day 1 through Day 28
16670099|NCT02149160|Placebo Comparator|Placebo Comparator; Arm 3|Placebo, Capsule, Once Daily, Day 1 through Day 28
16670100|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
16670101|NCT02149134|Experimental|New extensively hydrolyzed casein formula|Subjects with cow's milk allergy treated with a new formula
16670102|NCT02149121|Experimental|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
16670103|NCT02149121|Active Comparator|Rituxan|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
16670104|NCT02149121|Active Comparator|MabThera|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
16670105|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
16670106|NCT02149108|Placebo Comparator|Placebo + BSC|
16670107|NCT02149095|Experimental|TransCon PEG treprostinil|Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
16670108|NCT02149082||Infrascanner exam|Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
16670109|NCT02149056||Impaired Glucose Tolerance|
16670110|NCT02149043||Ulcerative Colitis patients|30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
16670111|NCT02149043||Healthy volunteers|30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
16670112|NCT02149030|Active Comparator|A1|A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
16670113|NCT02149030|No Intervention|A2|A2) infrequent information of screening results, only at the age 30 years.
16670114|NCT02149030|Other|A3|A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
16670115|NCT02149017|Experimental|SNUBH-NM-333(18F), Safety, Efficacy|10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients
16670116|NCT02149004||Site Bonn|
16670117|NCT02149004||Site Heidelberg|
16670118|NCT02149004||Site Munich|
16670119|NCT02149004||Site Hamburg|
16670120|NCT02149004||Site Hannover|
16670121|NCT02149004||Site Cologne|
16670122|NCT02149004||Site Freiburg|
16670123|NCT02149004||Site Frankfurt|
16670124|NCT02149004||Site Essen|
16670125|NCT02148991||Irbesartan|Patients on irbesartan treatment
16670126|NCT02148978|Experimental|Saxagliptin administration|Saxagliptin Administration- The participants in this study will undergo an OGTT (Oral Glucose Tolerance Test) at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin. After 6 weeks of treatment the participants will return to perform a second OGTT.
16670127|NCT02148965|Experimental|Lifestyle intervention|Physical Exercise / Physical Activity. Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
16670128|NCT02148965|No Intervention|Control Group|A group of eligible women, twice as large as the intervention group, will not receive the exercise intervention but will be followed-up equally to compare outcomes in the future.
16670129|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
16670130|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
16670131|NCT02148913|Active Comparator|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
16670132|NCT02148913|Active Comparator|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
16670133|NCT02148913|Active Comparator|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
16670134|NCT02148913|Active Comparator|Cohort 3: Carfilzomib 27mgm2|Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
16670135|NCT02148900||Marfan|Diagnosis of Marfan syndrome, according to Ghent criteria.
16670136|NCT02148900||Marfan Related Disorders|Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.
16670137|NCT02148900||Control Subjects|Unaffected by Marfan or Marfan related disorders.
16670138|NCT02148887||SCI patients with upper limb impairment - Upper limb training|
16670139|NCT02148887||SCI patients with lower limb impairment - Lower limb training|
16670140|NCT02148887||Healthy controls - Upper limb training|
16670141|NCT02148887||Healthy controls - Lower limb training|
16670142|NCT02148887||Healthy controls - No intervention|
16670143|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
16670144|NCT02148861|Experimental|Insulin 287 + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
16670145|NCT02148861|Active Comparator|Insulin degludec + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
16670146|NCT02148848|Active Comparator|Early bisphosphonate use|"Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients.
~Risedronate (35 mg) 1 tablet orally once a week"
16670147|NCT02148848|No Intervention|Late bisphosphonate use|"Give only calcium and vitamin D supplementation during the first 3 months after the surgery.
~Bisphosphonate, risedronate (Actonel), will be given at 3 months after surgery for an osteoporotic femoral neck fracture."
16670148|NCT02148835|Active Comparator|Triomeg|Sausage: Triomeg
16670149|NCT02148835|Placebo Comparator|Control sausage|Sausage: Control
16670150|NCT02148822||Malnourished|Children with either height for age z score or body mass index for age z score below 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
16670151|NCT02148822||Not malnourished|Children with either height for age z score or body mass index for age z score equal or higher than 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
16670152|NCT02148809|Experimental|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
16670153|NCT02148796|Active Comparator|Broncho-Vaxom (BV)|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
16670154|NCT02148796|Placebo Comparator|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
16670155|NCT02148783|Experimental|methylphenidate administration|All participants will receive oral methylphenidate 60 mg before the second TMS study. The participants will receive oral methylphenidate 60 mg before the second PET scan. Subjects will then be treated with oral methylphenidate, using a forced titration. Dose titration will be incremental within 6 days (dose-escalation phase) , starting at 5 mg orally twice daily for 3 days, and 10 mg twice daily for the next 3 days. Then the dose will be increased to 30 mg twice daily starting from day 7 given twice daily for additional 3 weeks.
16670156|NCT02148770|Experimental|Neurofeedback|Neurofeedback training: Up-regulation of DLPFC.
16670157|NCT02148770|Sham Comparator|Neurofeedback SHAM|Neurofeedback training: Sham-regulation of DLPFC.
16670158|NCT02148757|Other|DVT|Doppler Ultrasound
16670159|NCT02148744|Experimental|XmAb7195 or Placebo|
16670160|NCT02148731||Comprehensive Geriatric Assessment (CGA)|Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
16670161|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
16670162|NCT02148705|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (~ surface of an adult palm) for four hours.
16670163|NCT02148705|Placebo Comparator|Gel Vehicle|Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (~ surface of an adult palm) for four hours.
16670164|NCT02148705|Active Comparator|Standard of Care (SOC)|Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.
16670165|NCT02148692|Experimental|Higher PEEP|PEEP of 12 cmH2O or higher and lung recruitment maneuvers
16670166|NCT02148692|Active Comparator|Lower PEEP|PEEP of 4 cmH2O without lung recruitment maneuvers
16670167|NCT02148679|Experimental|DASH/SRD|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge
~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions
~Intervention: pre-prepared, home delivered DASH/SRD-compliant meals for 4 weeks after hospital discharge"
16670168|NCT02148679|Placebo Comparator|Attention Control|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge
~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions"
16670169|NCT02148666||experimental : intracoronary stem cells|intracoronary stem cells will be injected in infarct related artery.
16670984|NCT02143531|Active Comparator|Group I|Patients will receive 4 mg of Ondansetron IV upon occurrence of nausea or vomiting
16670170|NCT02148653|Experimental|Multifunctional diet (MFD)|Subjects eat a diet designed according to the Nordic Nutrition Recommendations with the addition of important amounts of various functional food concepts: Low GI and GI-modulating food items; Natural antioxidant-rich items, Long chain omega-3 fatty acid-rich fish; Betaglucan-rich barley and oat food/drinks; Cholesterol-modulating foods.
16670171|NCT02148653|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Nutrition Recommendations but lacking the functional items included in the MFD.
16670172|NCT02148640|Experimental|CT-P13|Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
16670173|NCT02148640|Active Comparator|INX|Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion
16670174|NCT02148627|Experimental|LY3041658 (IV)|Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.
16670175|NCT02148627|Experimental|LY3041658 (SC)|Single dose of LY3041658 administered subcutaneously (SC).
16670176|NCT02148627|Placebo Comparator|Placebo|Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.
16670177|NCT02148614|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
16670178|NCT02148614|Active Comparator|Libramed|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
16670179|NCT02148601|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation from healthy donors will be infused by colonoscopy
16670180|NCT02148601|Active Comparator|Standard Antibiotic Therapy|Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients
16670181|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire
~Sensory mapping of the affected limb
~Quantitative Sensory Testing
~Patients will have a peripheral nerve blockade"
16670182|NCT02148575|Experimental|Self-Management Group|"Managing Cancer Care: A Personal Guide (MCC) is a set of magazine-format, printed modules that includes information about key self-management topics, worksheets, conversation starters, and targeted links to local and internet resources, among other features."
16670183|NCT02148575|Active Comparator|Symptom Management Group|Participants in the Symptom Management Group will be given a symptom management toolkit that provides information on the most commonly experienced symptoms and side effects of cancer treatment, including fatigue, nausea, and sleep problems, among others. Each chapter includes information on when and why the symptom may occur, how the symptom can be managed, and when to call a provider.
16670184|NCT02148562||Chronic Hepatitis B|Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
16670185|NCT02148562||End stage liver disease|Diagnosis of advanced liver disease related to Hepatitis B
16670186|NCT02148549|Experimental|Optimal chemotherapy courses|Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients
16670187|NCT02148536||HPS-TIPS group|
16670188|NCT02148523|Experimental|Weekly Adherence Report|Adherence report to subject every 7 days.
16670189|NCT02148523|Experimental|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
16670190|NCT02148523|Other|Usual Care|Usual care with GlowCap.
16670191|NCT02148510|Experimental|Monobloc|Treatment with an appliance that holds the lower jaw in a fixed protruded position
16670192|NCT02148510|Active Comparator|Bibloc|Bibloc device where a maxillary splint is connected to a mandibular splint by a connector allowing a slight opening of the jaw without compromizing the protrusion (Narval)
16670193|NCT02148497|Other|Dry Eye Disease or Sjogren's Disease|Capturing images of the tear surface using the multi-colored Placido disk
16670194|NCT02148497|Other|Control|Capturing images of the tear surface using the multi-colored Placido disk
16670195|NCT02148484|Experimental|1|Prolonged exposure for adolescents
16670196|NCT02148484|Active Comparator|2|Client centered therapy
16670197|NCT02148471||Healthy controls|Healthy living liver donors with healthy liver on imaging and/or liver histology
16670198|NCT02148471||Simple steatosis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
16670199|NCT02148471||Nonalcoholic steatohepatitis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
16670200|NCT02148471||Minimal findings|Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.
16670201|NCT02148458|Other|Control group|Western diet for 8 weeks, followed by 8 weeks of Western diet with intermittent fasting.
16670202|NCT02148458|Experimental|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting.
16670203|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
16670204|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
16670205|NCT02148432|Experimental|dexmedetomidine 0.5 mcg/kg/hr|
16670206|NCT02148432|Active Comparator|dexmedetomidine 1.0 mcg/kg/hr|
16670232|NCT02148263|Experimental|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
16670233|NCT02148263|Experimental|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
16670234|NCT02148250|Experimental|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
16671197|NCT02142101||GFR 15-60|5 patients with polycystic kidney disease with eGFR between 15-60 ml/min.
16670207|NCT02148406|Experimental|Arm I (YST intervention)|Patients undergo YST intervention comprising four individualized, 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation during outpatient chemotherapy sessions in weeks 2, 4, 6, and 8. Patients practice awareness - noticing the current state and establishing relaxed breathing for 5 minutes; movement - 7 minutes of gentle movements coordinated with the breath (such as raising and lowering the arms); breathing practice - 3 minutes of inhaling cool air as if through a straw; and meditation - 5 minutes of focus on letting go of physical and mental tension. Patients review a handout describing the YST and to encourage patients to practice daily with strategies to increase adherence to home practice. Patients also receive an audio recording of the YST and devices to play the recording and are asked to keep a home practice log.
16670208|NCT02148406|Active Comparator|Arm II (attention control)|Patients attend four 30-minute sessions with an interventionist in weeks 2, 4, 6, and 8. During these sessions, patients are encouraged to discuss their experiences while receiving chemotherapy and do not receive instruction of movement, meditation or breathing practices. Patients will also be asked to write brief diary entries daily at home.
16670209|NCT02148393|Active Comparator|Control|In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.
16670210|NCT02148393|Experimental|Intervention|"Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.
~On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible."
16670211|NCT02148380|Experimental|chemotherapy group(B)|pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
16670212|NCT02148380|Experimental|combination therapy group(A)|pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
16670213|NCT02148380|Experimental|gefitinib group (group C)|received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death
16670214|NCT02148367|Active Comparator|Erythropoietin (EPO)|Participants (n=20) will receive EPO with a dose of 40,000 IU EPO subcutaneously (s.c.) once weekly for 4 weeks.
16670215|NCT02148367|Placebo Comparator|placebo|Participants (n=10) will receive placebo s.c. once weekly for 4 weeks
16670216|NCT02148354|Experimental|Group with support by the therapist.|Intervention group that do the Smiling is Fun program and receives support by the therapist (a brief weekly two-minute call without clinical content).
16670217|NCT02148354|Experimental|Group without support by the therapist|Intervention group that do the Smiling is Fun program and does not receive support by the therapist.
16670218|NCT02148354|Other|Waiting list control group|"Control group that could access the Smiling is Fun program after waiting for 12 weeks.
~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
16670219|NCT02148341|Experimental|Community of Practice Facilitation|Medical Centers assigned to this arm will recieive the communtiy of practice facilitation. In this process we will contact existing members of the community of practice (called the Heart Failure Network) at the facility as well as attempt to identify new providers and other staff at the facility with an interest in improving heart failure care. The facilitation includes: describing the national H2H program, providing talking points and strategies for local providers to obtain support from their local facility to initiate local projects related to H2H, providing a forum for successful sites to describe how they initiated projects to sites yet to initiate projects.
16670220|NCT02148341|Experimental|Usual Care|Medical centers in this arm will hear of H2H through usual routs (calls with facilty Directors and Chiefs of staff).
16670221|NCT02148328|Experimental|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants.
16670222|NCT02148328|Active Comparator|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
16670223|NCT02148328|Experimental|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
16670224|NCT02148328|Active Comparator|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
16670225|NCT02148315|Experimental|garden intervention|garden kit and access to garden-based lessons
16670226|NCT02148315|No Intervention|no garden|control - receives garden and lessons at end of study
16670227|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.
~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.
~A run-in period of two weeks followed by twelve weeks of active treatment"
16670228|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
16670229|NCT02148289|Active Comparator|Nitrate rich beverage|Nitrate rich beverage will contain 140ml nitrate rich beetroot juice + 200ml blackcurrant juice containing 12.7mmol nitrate
16670230|NCT02148289|Placebo Comparator|Nitrate free beverage|Nitrate free beverage will 140ml water + 200ml blackcurrant juice containing <0.5mmol nitrate
16670231|NCT02148276||Research Participants|All participants will complete two measures of social harm at monthly research appointments for a three month period. The social harms assessments will be (1) the ACASI-SHQ that was developed in Phase 1 and (2) the HIV Vaccine Trials Network (HVTN) Social Impact Assessment.
16670272|NCT02148029|Experimental|Exercise|Standard care + Interventional Exercise therapy
16670235|NCT02148250|Experimental|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
16670236|NCT02148237|No Intervention|Treatment as Usual|Participants in Treatment as Usual (TAU) will receive standard breastfeeding (BF) services from the WIC program and participate in research assessments. Standard services include an on-site and home-visiting lactation consultant, occasional one-on-one peer counseling, and an enhanced food package for BF women.
16670237|NCT02148237|Experimental|Contingency Management|These participants will receive usual WIC care. The frequency, duration, content, and size of the meetings and participation requirements will be the same as for the TAU group, except that this group will also receive contingency management (CM). Members will demonstrate breastfeeding and receive cash incentives weekly if they breastfeed.
16670238|NCT02148224||healthy without diabetes|
16670239|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
16670240|NCT02148198|Active Comparator|1g NWT-03, then placebo|7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
16670241|NCT02148198|Placebo Comparator|placebo, then 1g NWT-03|7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period
16670242|NCT02148198|Active Comparator|2g NWT-03, then placebo|7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
16670243|NCT02148198|Placebo Comparator|placebo, then 2g NWT-03|7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period
16670244|NCT02148198|Active Comparator|5g NWT-03, then placebo|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
16670245|NCT02148198|Placebo Comparator|placebo, then 5g NWT-03|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
16670246|NCT02148185|Experimental|MT-1303|
16670247|NCT02148172|Active Comparator|Standard Plyometric Training|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice delivered at a standard dosage of sets and repetitions.
16670248|NCT02148172|Experimental|Plyometric Training with BWS|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
16670249|NCT02148159|Experimental|Cachexia Acupuncture-A|"Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period.
~Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture"
16670250|NCT02148159|Sham Comparator|General Acupuncture-B|"General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted.
~Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture"
16670251|NCT02148133|Experimental|Eltrombopag|Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
16670252|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6, 1 puff|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
16670253|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6 µg, 4 puffs|Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg
16670254|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 1 puff|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
16670255|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 4 puffs|Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg
16670256|NCT02148120|Placebo Comparator|Placebo NEXThaler|Placebo
16670257|NCT02148107|Experimental|BI 691751 Dose 1|multiple dose given over 14 days
16670258|NCT02148107|Experimental|BI 691751 Dose 2|multiple dose given over 14 days
16670259|NCT02148107|Experimental|BI 691751 Dose 3|multiple dose given over 14 days
16670260|NCT02148107|Experimental|BI 691751 Dose 4|multiple dose given over 14 days
16670261|NCT02148107|Experimental|BI 691751 Dose 5|multiple dose given over 14 days
16670262|NCT02148107|Experimental|BI 691751 Dose 6|multiple dose given over 14 days
16670263|NCT02148107|Placebo Comparator|Placebo|Placebo
16670264|NCT02148094|Experimental|Truvada|Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP.
16670265|NCT02148081||Critically ill children|
16670266|NCT02148068||Bariatric Surgery - Gastric Bypass|This population will undergo a laparoscopic roux-en-y gastric bypass
16670267|NCT02148068||Bariatric Surgery - Sleeve Gastrectomy|This group will undergo a laparoscopic sleeve gastrectomy
16670268|NCT02148055|Other|A group of 20 pregnant patients.|20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.
16670269|NCT02148042||Anorexics|
16670270|NCT02148042||Controls|
16670271|NCT02148029|Active Comparator|Control|Standard care: anticoagulation, compression & ad-lib ambulation
16670273|NCT02148016|Experimental|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.
~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
16670274|NCT02148016|Active Comparator|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
16670275|NCT02148016|Experimental|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.
~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
16670276|NCT02148016|Active Comparator|PRK only (Traditional Technique)|PRK alone will be performed.
16670277|NCT02148003|Active Comparator|RFA at 90 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 90 degrees Celsius
16670278|NCT02148003|Active Comparator|RFA at 80 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 80 degrees Celsius
16670279|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
16670280|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
16670281|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
16670282|NCT02147977|Active Comparator|dietary supplement: n-3 PUFA|"n-3 polyunsaturated fatty acids from fish oil
~capsules of 500 mg. 2 g a day."
16670283|NCT02147977|Placebo Comparator|olive oil|Capsules of 500 mg. 2 g a day.
16670284|NCT02147964|Experimental|Acyline; T Gel; placebo dutasteride, placebo ketoconazole|"All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
16670285|NCT02147964|Experimental|Acyline; T gel; Ketoconazole; placebo|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
16670286|NCT02147964|Experimental|Acyline; Tgel; Ketoconazole; Dutasteride|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
16670287|NCT02147964|Experimental|Acyline; Tgel; HCG|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
16670288|NCT02147938||1: early conversion from Prograf® to Advagraf®|patients converted during the first 6 months post-transplantation
16670289|NCT02147938||2: late conversion from Prograf® to Advagraf®|patients converted between 6 and 12 months post-transplantation
16670290|NCT02147925|Active Comparator|Liraglutide|Liraglutide combined with metformin
16670291|NCT02147925|Active Comparator|Insulin glargine|Insulin glargine combined with metformin
16670292|NCT02147925|Active Comparator|Sitagliptin|Sitagliptin combined with metformin
16670293|NCT02147912|Active Comparator|Aerobic exercise|A six week aerobic exercise intervention in COPD depressed population.
16670294|NCT02147912|No Intervention|Control sample|"Only participants randomized in the arm named Aerobic exercise will receive a six weeks aerobic exercise intervention."
16670295|NCT02147899|Experimental|SYM-1219 Low Dose|Administered orally
16670296|NCT02147899|Experimental|SYM-1219 High Dose|Administered orally
16670297|NCT02147899|Placebo Comparator|Placebo|Administered orally
16670298|NCT02147886|Experimental|Cabaletta 15gr|Cabaletta 15gr
16670299|NCT02147886|Experimental|Cabaletta 30gr|Cabaletta 30gr
16670300|NCT02147873|Active Comparator|azacitidine with birinapant|Azacitidine 75 mg/m2 IV on days 1-5, 8 & 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 & 4) for 3 out of 4 weeks
16670301|NCT02147873|Placebo Comparator|Azacitidine and placebo|Azacitidine 75mg/m2 IV days 1-5, 8 & 9 OR days 1-7 and placebo IV twice a week (days 1 & 4) for 3 out of 4 weeks
16670302|NCT02147860|Placebo Comparator|Sensor Augmented Pump Therapy|Each camp participant will be randomized to full day and night CLC or sensor augmented pump therapy for up to 7 days/6 nights. The subject will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
16670303|NCT02147860|Experimental|Diabetes Assistant (DiAs) with USS Virginia|"With the use of the UVA Artificial Pancreas (DiAs), the study will assess safety and feasibility and are not powered for statistical significance. These studies are intended to train staff on system function and obtain data regarding safe and feasible system use.
~Camp participants will be randomized to either closed-loop control using the DiAs or sensor-augmented pump therapy only. These studies would generate up to 120 days of closed-loop data and 120 comparable days of open-loop data."
16670304|NCT02147847|Experimental|Video game based training 1|Video Game play with training strategy 1
16670305|NCT02147847|Experimental|Video game based training 2|Video Game play with training strategy 2
16670306|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
16670307|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
16670308|NCT02147821|No Intervention|Standard|Standard treatment will be defined as current practice whereby two mediastinal chest tubes are used for drainage, as well as an additional pleural tube if the pleura is opened during surgery. As part of current standard practice, the pleural and mediastinal spaces will be suctioned during the achievement of hemostasis prior to the insertion of chest tubes.
16670309|NCT02147821|Experimental|Intervention|The treatment arm of the study will involve standard placement of the mediastinal tubes with the exclusion of the pleural tube.
16670310|NCT02147808|Experimental|All subjects|All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
16670311|NCT02147795||Control cohort|Standard care before implementation (pre-implementation)
16670312|NCT02147795||PBM cohort|After implementation of PBM program (post-implementation)
16670313|NCT02147782||control|Healthy people from physical examination centers are recruited as controls.
16670314|NCT02147782||CKD1|"with clinical one or more symptoms and signs of kidney injury listed as below：
~Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)
~urinary sediments abnormality
~renal tubular lesions
~renal histological abnormalities
~abnormal structure showed by imaging
~history of renal transplantation
~GFR≥90（ml/min/1.73m²)"
16670315|NCT02147782||CKD2|with clinical symptoms and signs of kidney injury, and 60<=GFR<=89（ml/min/1.73m²)
16670316|NCT02147782||CKD3|with clinical symptoms and signs of kidney injury, and 30<=GFR<=59（ml/min/1.73m²)
16670317|NCT02147782||CKD4|with clinical symptoms and signs of kidney injury, and 15<=GFR<=29（ml/min/1.73m²)
16670318|NCT02147782||CKD5|with clinical symptoms and signs of kidney injury, and GFR<15（ml/min/1.73m²)
16670319|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
16670320|NCT02147756|Active Comparator|CO2RE|Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
16670321|NCT02147756|Active Comparator|RePair|Fractional CO2 system that comprises an infrared laser controlled by an embedded processor and a handpiece that directs the laser treatment. The device laser has a wavelength of 10.6μm and its tissue chromophore is water. It delivers multiple low energy pulses in microscopic spots as the handpiece glides over the skin surface. The selected energy determines the depth and width for each microscopic treatment zone (MTZs).
16670322|NCT02147743|Experimental|CCP+MDFT|Multidimensional Family Therapy (MDFT) is a multisystemic, flexible intervention system (Liddle, 2002). It is a strengths-based approach promoting protective factors and reducing risk factors for delinquency, substance use, and school problems. MDFT organizes interventions in key areas of the teen's life: self of the adolescent (includes HIV-STD risk behaviors), parenting, family environment, and school/vocational functioning.
16670323|NCT02147743|Other|CCP+SAU|Services as Usual (SAU) are determined on a case-by-case basis by the CCP Case Manager. SAU includes a variety of services offered by a number of community partners.
16670324|NCT02147730||surgical patients|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, hallux valgus surgery, hernia repair, saphenectomy, cesarean section,colectomy, hysterectomy, nephrectomy mastectomy during study period
16670325|NCT02147717|Experimental|Laser stimulation|"Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.
~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
16670326|NCT02147717|Placebo Comparator|fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
16670327|NCT02147704|Other|Goup I|Group I: Fimasartan 60 mg in a low-sodium intake period --> Fimasartan 60 mg in a high-sodium intake period
16670328|NCT02147704|Other|Group II|Group II: Fimasartan 60 mg in a high-sodium intake period --> Fimasartan 60 mg in a low-sodium intake period
16670329|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%
~Azelaic acid 15% to the face each PM"
16670330|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
16670331|NCT02147678|Experimental|Group E|Etomidate/remifentanil group. Patients in group E will be given etomidate and remifentanil during the operation, the speeds are 10~15 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
16670332|NCT02147678|Experimental|Group P|Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50~75 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
16670333|NCT02147665|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after Hookah smoking.
16670334|NCT02147652|Experimental|Personalized music|
16670335|NCT02147639|Experimental|Sodium Nitrate|Patients will ingest a single oral dose of sodium nitrate (~8.4 mmol)
16670336|NCT02147639|No Intervention|Baseline|This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
16670337|NCT02147639|Experimental|Dose-escalation trial|This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (~16.8 mmol).
16670338|NCT02147639|Placebo Comparator|Placebo-control trial|This is an optional study visit, where patients will ingest a placebo.
16670339|NCT02147639|Experimental|Increased exercise intensity|This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
16670340|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the American Heart Association (AHA) Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) Dietary Approaches to Stop Hypertension (DASH) website, and the NIH smoking cessation website
16670341|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
16670342|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
16670343|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
16670344|NCT02147600||Chronic plaque psoriasis|Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
16670345|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
16670346|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
16670347|NCT02147574|Experimental|antiperistaltic ileosigmoid anastomosis|To assess the operative results after laparoscope subtotal colectomy with antiperistaltic ileosigmoid anastomosis for the slow-transit constipation.
16670348|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
16670349|NCT02147548|Experimental|etifoxine (Anxiolytic)|etifoxine, 100 mg, a single oral intake
16670350|NCT02147548|Active Comparator|lorazepam|lorazepam, 2 mg, a single oral intake
16670351|NCT02147548|Placebo Comparator|Placebo|2 capsules of Placebo, a single oral intake
16670352|NCT02147535|Experimental|Methylphenidate|
16670353|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
16670354|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.
~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
16670355|NCT02147509|Experimental|Severe dry eye|"0.02% Fm, SH
~0.02% Fm, SH, AS
~0.02% Fm, SH, 0.05% CsA
~0.02% Fm, SH, tBCL (0.05% CsA: 0.05% cyclosporin A; tBCL: therapeutic bandage contact lenses; 0.02% Fm: 0.02% Fluorometholone; AS: Autologous Serum; SH: Sodium Hyaluronate)"
16670356|NCT02147496|Experimental|2% M.F. Milk|Dietary treatment: 2% m.f. milk
16670357|NCT02147496|Experimental|1% M.F. Chocolate Milk|Dietary treatment: 1% m.f. chocolate milk
16670358|NCT02147496|Experimental|1.5% M.F. Drinkable Yogurt|Dietary treatment: 1.5% m.f. drinkable yogurt
16670359|NCT02147496|Experimental|Tropical Punch|Dietary treatment: fruit-flavoured beverage
16670360|NCT02147496|Experimental|Water|Dietary treatment: calorie-free control
16670361|NCT02147483|Active Comparator|Treatment as usual|Treatment as usual as prescribed by clinician.
16670362|NCT02147483|Experimental|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
16670363|NCT02147470|Other|prerenal AKi, acute tubular necrosis and hepatorenal syndrome|All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.
16670364|NCT02147457||ELBW (CASES)|Extremely low birth weights, born in 2000-2005, birth weight below 1000 grams, who were initially admitted (2000-2005) at the Neonatal Intensive Care Unit, UZ Leuven Belgium and have been well characterized and documented in the postnatal period.
16670365|NCT02147457||CONTROLS|Survivors (CASES) (n = 140) will be matched with two healthy controls. One control will be matched to sex, birth year and residential area and will be suggested by the index patient (e.g. school friend, neighbor), the second control will be age and sex matched from the area of the field.
16670366|NCT02147444||Non-valvular atrial fibrillation|"Patients diagnosed with non-valvular atrial fibrillation
~Patients who are treated or will be treated with rivaroxaban"
16670367|NCT02147431|Experimental|Semaglutide|
16670368|NCT02147431|Placebo Comparator|Placebo|
16670369|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
16670370|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
16670371|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
16670372|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
16670373|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
16670374|NCT02147379|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
16670375|NCT02147379|No Intervention|Treatment as usual|Patients randomized to this arm will continue their usual treatment.
16670493|NCT02146651|Experimental|BioChaperone insulin lispro 0.4U/Kg|BioChaperone insulin lispro 0.4U/Kg
16670376|NCT02147366|Experimental|Behavioral (Lifestyle)|Only standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
16670377|NCT02147366|Experimental|Behavioral (Music & lifestyle changes)|Experimental: Music along with standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
16670378|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
16670379|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
16670380|NCT02147340||Heart failure patients with ICD|Heart failure patients with ICD and RPM system equipped with sensors for the measurement of weight and pressure
16670381|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):
~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
16670382|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
16670383|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
16670384|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
16670385|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
16670386|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
16670387|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
16670388|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
16670389|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
16670390|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
16670391|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
16670392|NCT02147275||hypertension disease|patients have hypertension disease, whether well-controlled or uncontrolled, more than 3 year
16670393|NCT02147262|Active Comparator|ACA-doxy 14 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
16670394|NCT02147262|Active Comparator|ACA-doxy 28 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
16670395|NCT02147249|Experimental|erythema migrans patients treated with antibiotics|adult patients with erythema migrans will be treated with oral antibiotics
16670396|NCT02147223|Active Comparator|Flavanol rich product A|250 mg flavanols
16670397|NCT02147223|Active Comparator|Flavanol rich product B|500 mg flavanols
16670398|NCT02147223|Active Comparator|Flavanol rich product C|750 mg flavanols
16670399|NCT02147223|Placebo Comparator|Flavanol free product|flavanol free
16670400|NCT02147210||1-Case|patients who developed CTG secondary to antibody-mediated kidney rejection (AMR), diagnosed by microscopic analysis.
16670401|NCT02147210||2-Control|patients with antibody-mediated kidney rejection (AMR) but without CTG
16670402|NCT02147197|Experimental|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
16670403|NCT02147197|Experimental|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
16670404|NCT02147197|Placebo Comparator|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
16670405|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
16670406|NCT02147184||Unmedicated Group|No treatment with SSRIs
16670407|NCT02147171|Active Comparator|Active lutein group|44 participants taking VisionAce daily for a period of 1 year
16670408|NCT02147171|Placebo Comparator|Placebo group|44 participants taking placebo daily for a period of 1 year
16670409|NCT02147158|Experimental|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
16670410|NCT02147158|Experimental|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
16670411|NCT02147158|Experimental|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
16670412|NCT02147158|Experimental|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
16670413|NCT02147158|Experimental|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
16670494|NCT02146651|Active Comparator|Humalog® 0.2U/Kg|Humalog® 0.2U/Kg
16670414|NCT02147158|Experimental|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
16670415|NCT02147145||Observation Cohort|
16670416|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
16670417|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
16670418|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
16670419|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
16670420|NCT02147119||Patients post- cardiac catheterisation|
16670421|NCT02147106||Videoconsultation|Performing two videoconsulations with the treating medical oncologist
16670422|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
16670423|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
16670424|NCT02147080|Experimental|Tailored Intervention|Subject has access to the tailored web intervention
16670425|NCT02147080|Active Comparator|Skin Cancer Foundation Website|Subject has access to the pre-existing Skin Cancer Foundation website
16670426|NCT02147080|No Intervention|Assessment Only Condition|Subjects will only complete assessments
16670427|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
16670428|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
16670429|NCT02147054|Active Comparator|Rocuronium with >95% inhibition|"IV Rocuronium to be given:
~Bolus dose of Rocuronium 0.3 mg/kg to achieve >95% inhibition as indicated by Train of Four monitoring
~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition
~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
16670430|NCT02147054|Active Comparator|Rocuronium with 50% inhibition|"IV Rocuronium to be given:
~Bolus dose of Rocuronium 0.3 mg/kg to achieve 50% inhibition as indicated by Train of Four monitoring
~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition
~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
16670431|NCT02147054|No Intervention|No Rocuronium|No Rocuronium will be given
16670432|NCT02147041|Experimental|EGCG(Epigallocatechin Gallate)|EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
16670433|NCT02147041|Placebo Comparator|placebo|cellulose (500mg, three times a day, 12 weeks)
16670434|NCT02147028|Experimental|Hippocampal sparing whole brain RT|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
16670435|NCT02147028|Active Comparator|Control: Conventional whole brain RT|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
16670436|NCT02147015|Experimental|Personalized variable dose of glucocorticoids arm|Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
16670437|NCT02147015|Other|Fixed dose of glucocorticoids arm|Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
16670438|NCT02147002|Active Comparator|omega 3 acids 1|Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)
16670439|NCT02147002|Active Comparator|omega 3 acids 2|Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)
16670440|NCT02147002|Active Comparator|omega 3 acids 3|Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)
16670441|NCT02147002|Active Comparator|omega 3 acids 4|Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum
16670442|NCT02146989||Cerebral Palsy|Children and adolescents with spastic unilateral Cerebral Palsy (with perinatal acquired hypoxic ischemic incidents), aged 7 to 18 years, MACS levels I-III.
16670443|NCT02146989||Healthy controls|Children and adolescents without Cerebral Palsy
16670444|NCT02146976|Experimental|Propofol|introvenious infusion of propofol
16670445|NCT02146976|Experimental|Inhaled anaesthetic (Sevoflurane)|sevoflurane (1.0-1.3% Minimum Alveolar Concentration)
16670446|NCT02146963||alcohol withdrawal|
16670447|NCT02146950||LCS12|New users of LCS12
16670448|NCT02146950||Mirena|New users of Mirena
16670449|NCT02146950||Copper IUD|New users of copper IUDs
16670450|NCT02146950||Kyleena|New users of Kyleena
16670451|NCT02146950||Other hormonal IUD (OHIUD)|New users of other hormonal IUDs (e.g. Levosert, Fibroplant)
16670452|NCT02146937|Experimental|Combination therapy- bicalutamide and finasteride|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
16670453|NCT02146924|Experimental|Arm I (cellular immunotherapy closed to accrual January 2019)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
16670495|NCT02146638|Active Comparator|Morphine|Patients received morphine 0.02 mg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
16671880|NCT02137824|Experimental|sinus floor elevation|
16670454|NCT02146924|Active Comparator|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells after 28 days.
16670455|NCT02146911|Experimental|Bupropion|Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
16670456|NCT02146911|Experimental|Varenicline|Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
16670457|NCT02146898|Active Comparator|Lateral|patient placed in the lateral postion for spinal anesthesia
16670458|NCT02146898|Active Comparator|Sitting|patient placed in the sitting position for spinal anestheisa, then supine
16670459|NCT02146898|Active Comparator|Recline|patient placed in the sitting position for spinal anesthesia administration. After spinal placed, the patient turned to a 30-degree upperbody tilt, followed by a slow recline to supine over 5 minutes
16670460|NCT02146885||Weight Control|Weight Control
16670461|NCT02146872||Very Premature CAD|Patients who have received a coronary intervention procedure on the basis of atherosclerosis before the age of 40
16670462|NCT02146872||Healthy middle-aged 1st degree relatives|Healthy 1st degree relatives aged 30-65 years of patients with very premature CAD.
16670463|NCT02146872||PCAD families|Families severely affected by premature CAD
16670464|NCT02146859||general anesthesia|Patient having general anesthesia
16670465|NCT02146846||Imatinib, CML|Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
16670466|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
16670467|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
16670468|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
16670469|NCT02146820|Experimental|Picosecond Laser System|
16670470|NCT02146807|Experimental|Picosecond Laser System|
16670471|NCT02146794|Experimental|Renal denervation|renal denervation
16670472|NCT02146781|Placebo Comparator|0.80 mL Saline Placebo Cohort 1|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan and are skin test positive or negative at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens.
~Cohort # 1: Subjects will receive four 0.200 mL volume intradermal injections of saline control as a placebo control using the Biojector device.
~Intervention: Saline Control via Intradermal route."
16670473|NCT02146781|Experimental|2.16 mg of CryJ2-DNA-LAMP plasmid vaccine Cohort 2|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.
~Cohort # 2: Subjects receive four (4) injections of 0.200 mL volumes (2.7 mg/mL) for a single dose of 2.16 mg of CryJ2-DNA-LAMP plasmid vaccine; intradermally (ID) administered using the Biojector device (each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B
~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
16670474|NCT02146781|Experimental|1.08 mg CryJ2-DNA-LAMP plasmid vaccine Cohort 3|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.
~Cohort # 3: Subjects will receive two (2) injections of 0.200 mL (2.7 mg/mL) for a single dose intradermally (ID) for a single dose of 1.08 mg CryJ2-DNA-LAMP plasmid vaccine administered using the Biojector device, each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B
~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
16670475|NCT02146742|Experimental|1. ASP1707 lowest dose|
16670476|NCT02146742|Experimental|2 ASP1707 higher dose|
16670477|NCT02146742|Experimental|3. ASP1707 Highest dose|
16670478|NCT02146729|Experimental|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
16670479|NCT02146729|Active Comparator|Open Treatment|Midline posterior incision with instrumentation.
16670480|NCT02146716|No Intervention|Control|
16670481|NCT02146716|Experimental|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
16670482|NCT02146703|Experimental|gemcitabine and S-1|
16670483|NCT02146690|Other|osteopathic manipulative treatment|newborns will receive osteopathic manipulative evaluation and treatment during the entire period of hospitalization plus usual care
16670484|NCT02146690|Other|sham|newborns will receive sham treatment for the entire period of hospitalization plus usual care
16670485|NCT02146690|Other|usual care|newborns allocated in the usual care arm will receive standard care only
16670486|NCT02146677|Other|Sham|newborns will be osteopathically evaluated and softly touched
16670487|NCT02146677|Other|Usual care|newborns will be undergone usual routine neonatology care
16670488|NCT02146677|Other|OMT|newborns will receive osteopathic evaluation and treatment according to international guidelines. Osteopathic treatment use will be indirect techniques.
16670489|NCT02146664|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for eight weeks of study period
16670490|NCT02146664|Placebo Comparator|Placebo|Placebo is administered one tablet three times daily, everyday for eight weeks of study period
16670491|NCT02146651|Experimental|BioChaperone insulin lispro 0.2U/Kg|BioChaperone insulin lispro 0.2U/Kg
16670492|NCT02146651|Experimental|BioChaperone insulin lispro 0.1U/Kg|BioChaperone insulin lispro 0.1U/Kg
16671954|NCT02137330|No Intervention|Dietary and lifestyle changes Arm|
16670496|NCT02146638|Experimental|Fentanyl|Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
16670497|NCT02146625|Experimental|Dose level 1 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
16670498|NCT02146625|Experimental|Dose level 2 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
16670499|NCT02146625|Experimental|Dose level 3 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
16670500|NCT02146625|Experimental|Dose level 4 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
16670501|NCT02146625|Experimental|Dose level 5 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
16670502|NCT02146612||Group Receiving Supplement|Amino acid supplement group
16670503|NCT02146599||Pseudophakic|
16670504|NCT02146586||Dystrophinopathies|
16670505|NCT02146586||Gold Standard Clinical Evaluators (GS-CEs)|
16670506|NCT02146586||Sites Clinical Evaluators (CEs)|
16670507|NCT02146573|Experimental|CCI Provider for Parent-patient dyad|Parents and patients are randomly assigned to a Continuity Care Intensivist (CCI) Provider who has received specialized communication training. The parent-patient dyad will receive standardized care from the CCI throughout their time in the PICU in addition to being assigned a rotating physician of record.
16670508|NCT02146573|No Intervention|Usual Care for Parent-patient dyad|Patients and parents randomly assigned to usual care in the PICU which includes the rotation of the physician of record approximately every 7 days. There is no standardized process by which patients may be assigned a primary attending who would follow them throughout their stay. In the usual care arm it may never happen that they are assigned a primary intensivist, regardless of the length of their hospitalization.
16670509|NCT02146547|Active Comparator|aripiprazole oral|the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.
16670510|NCT02146547|Active Comparator|Aripiprazole depot|"The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).
~After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.
~If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered."
16670511|NCT02146547|Active Comparator|Paliperidone|The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
16670512|NCT02146547|Active Comparator|Paliperidone palmitate|The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.
16670513|NCT02146534|Experimental|fampridine|extended release fampridine 10mg BID PO for 14 weeks
16670514|NCT02146534|Placebo Comparator|placebo|placebo pill BID PO for 14 weeks
16670515|NCT02146521||patients undergoing CT|Emergency department's patients undergoing CT scanning for evaluation of acute abdominal pain and tenderness
16670516|NCT02146508|Experimental|Endoscopic treatment|Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
16670517|NCT02146495|Active Comparator|Amygdala EEG-NF|Amygdala activity based EEG-NF
16670518|NCT02146495|Placebo Comparator|Sham EEG-NF|Sham EEG-NF
16670519|NCT02146495|No Intervention|Change in drug therapy|Pain and sleep quality measured after a change in drug therapy performed by the treating physician irrespective of the study - an observational arm
16670520|NCT02146495|Active Comparator|A/T EEG-NF|EEG-NF based on alpha/Theta ratio
16670521|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
16670522|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
16670523|NCT02146469|Experimental|None varicella vaccine history|2 doses with an 3 months interval
16670524|NCT02146469|Experimental|1 year after first dose|A second dose with an 1 year interval
16670525|NCT02146469|Experimental|3 years after first dose|A second dose with an 3 year interval
16670526|NCT02146469|Experimental|5 years after first dose|A second dose with an 5 year interval
16670527|NCT02146469|Experimental|Testing group for conbined immunization|1 dose Varicella vaccine and 1 dose MMR given at the same time
16670528|NCT02146469|Placebo Comparator|Control group for conbined immunization|1 dose MMR
16670529|NCT02146456|No Intervention|Colloid|During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
16670530|NCT02146456|Experimental|Tranexamic acid|"During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
~In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion."
16670985|NCT02143531|Active Comparator|Group II|Patients will receive 1mg of Haloperidol IV upon occurrence of nausea or vomiting
16670531|NCT02146443|Active Comparator|Baseline|Completion of the star shaped manual dexterity test, five rounds clockwise and five rounds counter clockwise without any intervention. Time and number of errors are recorded. Measurement of static arm strength with the stretched arm test. test subject is asked to hold a 2.5 kg weight in stretched arm for as long as possible. Maximum endurance time is recorded.
16670532|NCT02146443|Active Comparator|Fatigue|Prior to completion of the star shaped manual dexterity test, the test subject is asked to stand up still and hold a 2.5-kg weight with the dominant arm fully extended as long as possible without moving. Maximum endurance time is recorded. After this, the test subject completes the the star shaped manual dexterity test and time and number of errors are recorded.
16670533|NCT02146443|Active Comparator|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test. Completion time and number of errors are recorded.
16670534|NCT02146443|Active Comparator|Fatigue and Stress|The test subject will be fatigued prior to the test (as detailed in the fatigue arm), and asked to identify cards during completion of the star shaped manual dexterity test (as detailed in the stress arm). Completion time and number of errors are recorded.
16670535|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
16670536|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
16670537|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
16670538|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
16670539|NCT02146417|Active Comparator|Normal pressure pneumoperitoneum & deep neuromuscular block|Normal pressure pneumoperitoneum
16670540|NCT02146417|Experimental|Low pressure pneumoperitoneum & deep neuromuscular block|Low pressure pneumoperitoneum
16670541|NCT02146404|Active Comparator|Euglycemia|Plasma glucose levels will be clamped at a constant value of ~5.0 mmol/l
16670542|NCT02146404|Experimental|Hypoglycemia|Plasma glucose levels will be clamped at a stable value of ~3.0 mmol/l
16670543|NCT02146391|Experimental|Androxal 25 mg|
16670544|NCT02146378||Vyndaqel|
16670545|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
16670546|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
16670547|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
16670548|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
16670549|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
16670550|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
16670551|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
16670552|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
16670553|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
16670554|NCT02146339|Experimental|Unfortified-3g-5g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
16670555|NCT02146339|Experimental|Unfortified-5g-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
16670556|NCT02146339|Experimental|3g-5g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
16670557|NCT02146339|Other|3g-Unfortified-5g milk polar lipid fortified cheese product|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.
~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
16670558|NCT02146339|Experimental|5g-unfortified-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
16670559|NCT02146339|Other|5g-3g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
16670560|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
16670561|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
16670562|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
16670563|NCT02146326|Active Comparator|BREATHE-Clients|
16670564|NCT02146313|Experimental|Dose-escalation Cohort|DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
16670565|NCT02146313|Experimental|Platinum-resistant Ovarian Cancer Dose-expansion Cohort|Platinum-resistant Ovarian Cancer participants will be administered with the identified RP2D during the Dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
16670566|NCT02146313|Experimental|Unresectable Pancreatic Cancer Dose-expansion Cohort|Unresectable pancreatic cancer participants will be administered with the identified RP2D during the dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
16670567|NCT02146300|Experimental|Allergen and xylometatsolin|Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
16670568|NCT02146287|Active Comparator|Early Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 28 weeks PMA
16670569|NCT02146287|Active Comparator|Late Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 36 weeks PMA
16670570|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
16670571|NCT02146261|Experimental|1|Subcutaneous administration of E6011 50 mg
16670572|NCT02146261|Experimental|2|Subcutaneous administration of E6011 100 mg
16670573|NCT02146261|Experimental|3|Subcutaneous administration of E6011 200 mg
16670574|NCT02146261|Experimental|4|Subcutaneous administration of E6011 400 mg
16670575|NCT02146261|Placebo Comparator|5|Subcutaneous administration of placebo
16670576|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).
~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
16670577|NCT02146235|Experimental|Treatment Group - Music Therapy|The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
16670578|NCT02146235|No Intervention|Standard Pulmonary Rehabilitation|"Pulmonary rehabilitation is a program to people with chronic lung diseases like COPD, emphysema, and chronic bronchitis lead full, satisfying lives and restore them to their highest functional capacity. Pulmonary rehab is aimed to improve quality of life by:
~Decreasing respiratory symptoms and complications Encouraging self-management and control over daily functioning Improving physical conditioning and exercise performance Improving emotional well-being Reducing hospitalizations
~Pulmonary rehab programs include:
~Medical management Exercise Breathing retraining Education Emotional support Nutrition counseling"
16670579|NCT02146222|Experimental|Arm I (high dose X-82, docetaxel)|Patients receive high dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15. Beginning course 2, patients also receive docetaxel IV over 60 minutes on day 1.
16670580|NCT02146222|Experimental|Arm II (low dose X-82, docetaxel)|Patients receive low dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15 and docetaxel IV as in Arm I.
16670581|NCT02146209|Experimental|Test Product Formula A|Metronidazole benzoate
16670582|NCT02146209|Active Comparator|Reference Product Formula B|Flagyl 125 mg/5 ml oral suspension
16670583|NCT02146209|Active Comparator|Reference Product Formula C|Flagyl 400 mg Tablets
16670584|NCT02146196|Experimental|Heart failure, robotic assisted training|4 weeks robotic assisted training with the Lokomat®
16670585|NCT02146196|Experimental|Post cardiac surgery|One week robotic assisted gait training with the Lokomat®
16670586|NCT02146183|Placebo Comparator|placebo / Corn starch|Carbohydrate-containing composition that comprises 2 g carbohydrate per kg of body weight. This composition will be 500 mg placebo starch corn.
16670587|NCT02146183|Active Comparator|Carbohydrate steviol glycosides|500 mg steviol glycosides.
16670589|NCT02146157|Active Comparator|herb and mineral combination product|Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
16670590|NCT02146157|Placebo Comparator|placebo|Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
16670591|NCT02146144|No Intervention|no peeling|where the ILM peeling will not be made
16670592|NCT02146144|Active Comparator|active peeling|where the ILM peeling will be made
16670593|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
16670594|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.
~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
16670595|NCT02146118|Experimental|Erlotinib and Silibin|
16670596|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
16670649|NCT02145689|Experimental|onabotulinumtoxinA Dose 1|Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.
16670597|NCT02146092|Active Comparator|Standard physiotherapy|Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
16670598|NCT02146092|Experimental|Incentive Spirometry|"Patients in the Incentive Spirometry arm will receive standard physiotherapy care in addition to training and use of an incentive spirometer. The physiotherapy care includes routine care as per current institutional standards.
~They will also receive an incentive spirometer on the first postoperative day and will be taught how to use it with an accompanying instructional sheet for later reference. Teaching will emphasize slow deep breathing, sustained vacuum pressure, and gradual increase in difficulty. Patients will be instructed to use the spirometer 10 times every hour until 30 days after surgery."
16670599|NCT02146079|Experimental|Semaglutide 0.5 mg|Dose-escalation trial
16670600|NCT02146079|Placebo Comparator|Semaglutide placebo 0.5 mg|
16670601|NCT02146079|Experimental|Semaglutide 1.0 mg|Dose-escalation trial
16670602|NCT02146079|Placebo Comparator|Semaglutide placebo 1.0 mg|
16670603|NCT02146053|Active Comparator|Ferrous sulfate|ferrous sulfate taken at mealtimes twice daily during 1 week of the treatment period.
16670604|NCT02146053|Placebo Comparator|Placebo|placebo taken at mealtimes twice daily during 1 week of the treatment period.
16670605|NCT02146027|Experimental|Fermented Milk Drink Yakult 40|"Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40
~Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks."
16670606|NCT02146027|Placebo Comparator|Placebo|"The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.
~Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and"
16670607|NCT02146014|Experimental|Transcranial Direct Current Stimulation|These subjects will receive real transcranial direct current stimulation.
16670608|NCT02146014|Placebo Comparator|Sham tDCS|These subjects will receive sham transcranial direct current stimulation (placebo)
16670609|NCT02146001|Active Comparator|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
16670610|NCT02146001|Experimental|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
16670611|NCT02145988|Experimental|DLBS1033|DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
16670612|NCT02145988|Placebo Comparator|Placebo|Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period
16670613|NCT02145975|Experimental|Fentanyl|"Procedure: Fentanyl for rescue of acute postoperative pain in the postanesthesia care unit
~Intervention:
~The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
16670614|NCT02145975|Active Comparator|Morphine|"Procedure: Morphine for rescue of acute postoperative pain in the postanesthesia care unit
~Intervention:
~The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
16670615|NCT02145962|Active Comparator|Forearm tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the medical services site of the Autonomous University of Nuevo Leon, Monterrey, Mexico. These study patients should receive treatment in the forearm region.
16670616|NCT02145962|Active Comparator|Thorax tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
16670617|NCT02145949|Experimental|Essential Amino Acids (EAA)|"Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.
~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).
~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.
~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%)."
16670618|NCT02145949|Placebo Comparator|Placebo (Alanine)|"Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.
~The placebo supplement consists of 20 g (100%) alanine.
~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.
~The placebo supplement consists of 23 g (100%) alanine."
16670619|NCT02145936|Experimental|oleic acid diet|Participants are provided with meals enriched in oleic acid (18:1)
16670620|NCT02145936|Experimental|palmitic acid diet|Participants are provided with meals enriched in palmitic acid (18:0)
16670621|NCT02145936|Experimental|stearic acid diet|Participants are provided with meals enriched in stearic acid (18:0)
16670650|NCT02145689|Experimental|onabotulinumtoxinA Dose 2|Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.
16670622|NCT02145923|Other|allogeneic MMSCs infusion|Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion.
16670623|NCT02145910|Experimental|WBRT + Vemurafenib|Patients undergo WBRT once daily (QD) for 10 doses
16670624|NCT02145910|Experimental|SRS + Vemurafenib|Patients undergo SRS (gamma knife, tomotherapy, cyberknife, or megavoltage LINAC radiation therapy) on day 1
16670625|NCT02145897|Experimental|Autologous Stromal Vascular Fraction|single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
16670626|NCT02145897|Experimental|Autologous Adipose Derived MSCs|One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
16670627|NCT02145897|Active Comparator|Control|
16670628|NCT02145884|Experimental|timolol maleate 0.5% gel|timolol gel 1 to 2 drops twice a day to lesions for 4 months
16670629|NCT02145871|Active Comparator|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
16670630|NCT02145871|Experimental|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
16670631|NCT02145845|Experimental|Treatment|Injectable SIS
16670632|NCT02145832|Experimental|Fluconazole|"Fluconazole Kabi, Fresenius 2mg/ml
~Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg once daily, depending of corrected gestational age (GA) at the beginning of treatment:
~12 mg/kg/day for neonates corrected GA (GA + postnatal age) < 30 weeks
~20 mg/kg/day for neonates corrected GA (GA + postnatal age) ≥ 30 weeks
~The infusion will last two hours."
16670633|NCT02145832|Experimental|Micafungin|"Mycamine 50mg - 10 mg/mL of micafungin
~Micafungin will be administered as a loading dose of 15 mg/kg on the first day of treatment and followed by a maintenance dose of 10 mg/kg once daily.
~The infusion will last two hours."
16670634|NCT02145819|Placebo Comparator|A: spontaneous LH peak|In group A, embryos are thawed 4 days after LH surge, with a re-evaluation and transfer 5 days after LH surge.
16670635|NCT02145819|Active Comparator|B: hCG|In group B, embryos are thawed 5 days after hCG administration, with a re-evaluation and transfer 6 days after hCG.
16670636|NCT02145793|Active Comparator|ADHD Group Curriculum|Participants assigned to the group visit intervention agree to participate in 5 group visits every 3 months rather than individual ADHD follow-up visits to the clinic. Parents and children participate in separate but simultaneously run groups. Group portion is 60 minutes and then parent-child dyads complete individual visits for medication titration and physical exam.
16670637|NCT02145793|No Intervention|Control|Participants continue to go to the clinic for 5 routine ADHD follow-up visits to the clinic every 3 months as usual clinical protocol.
16670638|NCT02145780|Experimental|2g of grape polyphenol extract supplement|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
16670639|NCT02145780|Placebo Comparator|2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
16670640|NCT02145767|Experimental|Progesterone|Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.
16670641|NCT02145767|Placebo Comparator|Placebo|Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.
16670642|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
16670643|NCT02145741|Experimental|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
16670644|NCT02145728|Experimental|Individual Cognitive Functional Therapy|The intervention being tested has four main components: (1) a cognitive component, for each patient, their vicious cycle of pain will outlined in a diagram based on their findings from the examination and the Orebro Musculoskeletal Pain Screening Questionnaire; (2) specific movement exercises designed to normalize maladaptive movement behaviours; (3) targeted functional integration of activities in their daily life previously, reported to be avoided or provocative by the patient; and (4) a physical activity and lifestyle programme.
16670645|NCT02145728|Active Comparator|Group Exercise Classes|6 classes will take place in total. The class has 3 components each week. First, a 30 minute talk and discussion on chronic pain, and some tips for participants. Second, a 40 minute exercise circuit, involving aerobic exercise, and gentle stretching and strengthening exercises. Finally, a 5 minute relaxation/mindfulness session will take place at the end. The total time involved is approximately 1 hour and 15 minutes.
16670646|NCT02145715|Experimental|Velcade, Thalidomide, Dexamethasone (VTD) + Panobinostat|"Up to 16 cycles of VTD+Panobinostat followed by panobinostat maintenance for 1 year or until disease progression.
~Induction - Cycles 1-16 (21-day cycle)
~Velcade: 1.3mg/m2 (subcutaneous) on days 1 and 8
~Thalidomide: 100mg (PO)on days 1 -21
~Dexamethasone: 20 mg (PO) on days 1, 2, 8 and 9
~Panobinostat: 10mg, 15mg or 20mg days 1, 3, 5, 8, 10 and 12 Dose depends on cohort entry at registration during the dose escalation phase. The recommended dose will be used during the expansion phase.
~Panobinostat monotherapy maintenance for 1 year. Panobinostat will be given at the same dose as the recommended dose during expansion phase"
16670647|NCT02145702|Experimental|Exercise Group|Subjects randomized to this group will start 12 weeks of supervised aerobic exercise after baseline testing.
16670648|NCT02145702|Experimental|Control Group|Subjects randomized to this group will continue with 12 weeks of Standard Care. After 12 weeks, the subjects will cross over to the exercise arm and undergo baseline testing again and then start 12 weeks of exercise intervention.
16670986|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel|High Dose Na-GST-1/Alhydrogel® Only
16670651|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
16670652|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
16670653|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
16670654|NCT02145650||All Participants|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study.
16670655|NCT02145637|Experimental|Afatinib plus Ruxolitinib combination (single arm)|
16670656|NCT02145624|Active Comparator|Repevax|Repevax in pregnancy
16670657|NCT02145624|Active Comparator|Boostrix-IPV|Boostrix-IPV in pregnancy
16670658|NCT02145624|No Intervention|unvaccinated|unvaccinated mothers
16670659|NCT02145611|Active Comparator|vildagliptin|Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks
16670660|NCT02145611|Active Comparator|glibenclamide|Glibenclamide: Dosage: 5 mg to 20 mg; Duration: 12 weeks
16670661|NCT02145598|Experimental|Lenalidomide|Lenalidomide 10mg/day
16670662|NCT02145598|Placebo Comparator|Placebo|Placebo
16670663|NCT02145585||Robotic pharmacological system|Robotic pharmacological system/Automated anesthesia delivery system
16670664|NCT02145572||Obese adolescents with type 2 diabetes|No intervention
16670665|NCT02145572||Obese adolescents without diabetes|No intervention
16670666|NCT02145572||Healthy non-obese adolescents|No intervention
16670667|NCT02145559|Experimental|Metformin XR|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will recieve metformin XR (500 mg daily with the evening meal)(through day 21). On day 15, patients randomized to metformin XR will have their dose increased to 1000 mg daily if there is no grade ≥ 2 toxicity due to metformin XR. Patients who develop grade 2 toxicity due to metformin will be maintained on metformin XR 500 mg daily for the rest of the study, while patients who develop > grade 2 toxicity will be taken off study. From day 22 onwards, all patients will be on combination of sirolimus and metformin.
16670668|NCT02145559|Active Comparator|Delayed Metformin|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
16670669|NCT02145546|Experimental|Amiodarone|Patient will take Amiodarone orally
16670670|NCT02145546|Experimental|Sotalol|Patients will take sotalol orally
16670671|NCT02145546|Experimental|Propafenone|Patients will take propafenone orally
16670672|NCT02145546|No Intervention|Control|Patients will take no antiarrhythmic drugs except β-blocker
16670673|NCT02145533||Group I|patient with ruptured aneurysms
16670674|NCT02145533||Group II|patients with non-ruptured aneurysms
16670675|NCT02145533||Group III|Healthy volunteers
16670676|NCT02145520|Experimental|Magnesium sulfate|Magnesium sulfate. Single dose intravenous over one hour.
16670677|NCT02145520|Placebo Comparator|placebo|"Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).
~•All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.•Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
16670678|NCT02145507|Other|Arm 1: Room Temperature Storage/Filtration|In vitro whole blood storage, leukoreduction and processing of donated whole blood.
16670679|NCT02145507|Other|Arm 2 : Cold storage|In vitro analysis of whole blood following refrigerated storage for > 66 hours prior to leukoreduction and subsequent processing of packed red blood cells.
16670680|NCT02145494|Experimental|Treatment|Radiotherapy
16670681|NCT02145481|No Intervention|Survey development|Patients with coronary artery disease will be given a survey to complete assessing their knowledge, communication with physicians, involvement, and treatment preferences after completing the treatment decision-making process.
16670682|NCT02145481|Experimental|Decision Aid|Patients with stable coronary artery disease will be given a decision aid to review prior to making a treatment decision.
16670683|NCT02145481|Active Comparator|CAD Education|Patient with coronary artery disease will be given a general educational handout on coronary artery disease.
16670684|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
16670685|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
16670686|NCT02145455|Active Comparator|Mechanical alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes mechanical alignment via measured resection to establish knee alignment.
16670687|NCT02145455|Active Comparator|Anatomic alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes anatomic alignment via ligament balancing with the tibial cut perpendicular to the tibial anatomic axis.
16670688|NCT02145442|Experimental|Obex|Obex®, two oral sachets daily during three months.
16670689|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
16670690|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
16670691|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
16670720|NCT02145234|Experimental|MAD Panel 1:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 multiple subcutaneous administrations weekly"
16670721|NCT02145234|Experimental|MAD Panel 2:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
16670722|NCT02145234|Experimental|MAD Panel 3:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
16670692|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);
~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;
~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;
~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;
~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);
~International Prostate Symptom Score (IPSS)."
16670693|NCT02145377|Experimental|PXVX0200 10E8 then placebo|PXVX0200 10E8 on day 0; Placebo on day 14
16670694|NCT02145377|Experimental|Placebo, then PXVX0200 10E8|Placebo on day 0; PXVX0200 10E8 on day 14
16670695|NCT02145377|Experimental|PXVX0200 10E9 then Placebo|PXVX0200 10E9 on day 0; Placebo on day 14
16670696|NCT02145377|Experimental|Placebo then PXVX0200 10E9|Placebo on day 0; PXVX0200 10E9 on day 14
16670697|NCT02145377|Active Comparator|Shanchol|Two doses of Shanchol, on day 0 and day 14
16670698|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
16670699|NCT02145351|Active Comparator|Pacing off|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
16670700|NCT02145351|Experimental|Pacing on|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
16670701|NCT02145338|Experimental|Antibiotic prophylaxis|Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
16670702|NCT02145338|Other|No prophylaxis|The control arm will be a strategy of no prophylaxis. Participants will self-monitor their symptoms as usual and report to their General Practitioner if they develop symptoms and signs suggestive of UTI requiring treatment.
16670703|NCT02145325|Experimental|Expanded Tregs|Immune cells in the blood will be removed by leukopheresis procedure and stored for later manufacture of subject's Expanded Tregs cellular product. Two months following subject's kidney transplantation, subject will be given an Expanded Tregs infusion intravenously in the Northwestern Clinical Research Unit.
16670704|NCT02145312|Experimental|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
16670705|NCT02145299|Experimental|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
16670706|NCT02145299|Active Comparator|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
16670707|NCT02145286|Experimental|Radiation Therapy|Stereotactic Body Radiation Therapy
16670708|NCT02145273|Experimental|Intervention|Subjects screen positive for depression and are offered a group Therapy intervention for depression: Interpersonal Psychotherapy for Depression Group.
16670709|NCT02145273|No Intervention|Control|Subjects screen positive for depression and are offered Treatment as usual: External referral.
16670710|NCT02145273|No Intervention|comparison|Subjects screen negative for depression: no referral or intervention.
16670711|NCT02145260|Active Comparator|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
16670712|NCT02145260|Experimental|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
16670713|NCT02145247|Active Comparator|Normal adult women|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.
~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.
~Blood samples will be obtained at T = -0.5, 0, and +24 hours.
~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.
~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
16670714|NCT02145247|Active Comparator|Women with PCOS|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.
~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.
~Blood samples will be obtained at T = -0.5, 0, and +24 hours.
~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.
~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
16670715|NCT02145234|Experimental|SAD Panel 1:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
16670716|NCT02145234|Experimental|SAD Panel 2:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
16670717|NCT02145234|Experimental|SAD Panel 3:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
16670718|NCT02145234|Experimental|SAD Panel 4:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
16670719|NCT02145234|Experimental|SAD Panel 5:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
16670723|NCT02145234|Experimental|MAD Panel 4:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
16670724|NCT02145234|Experimental|MAD Panel 5:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administration every 2 weeks
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
16670725|NCT02145234|Experimental|MAD Panel 6:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
16670726|NCT02145234|Experimental|MAD Panel 7:BMS-986089/Placebo|"BMS-986089 a single subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks"
16670727|NCT02145221|Experimental|Music therapy|Music therapy post surgery
16670728|NCT02145221|No Intervention|No intervention|
16670729|NCT02145208|Experimental|Medi-Tate iTind|TIND System
16670730|NCT02145195|Experimental|Vitamin D (10 microgram/day)|Tablets with 10 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
16670731|NCT02145195|Experimental|Vitamin D (20 microgram/day)|Tablets with 20 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
16670732|NCT02145195|Placebo Comparator|Placebo control|Tablets with 0 microgram vitamin D daily for 20 weeks.
16670733|NCT02145182|Experimental|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
16670734|NCT02145182|Placebo Comparator|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
16670735|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
16670736|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
16670737|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
16670738|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
16670739|NCT02145143|Experimental|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that > or = 2000 cGy can be achieved in at least one tumor with < 300 mCi of 131I, Thyrogen-stimulated standard dosimetry & therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued & tumor assessments will be conducted with serial radiologic scan(s) & thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, & 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, & the patient will be taken off the study.
16670740|NCT02145130|Experimental|denovoDerm|Autologous tissue-engineered dermal substitute
16670741|NCT02145130|Experimental|denovoSkin|Autologous tissue-engineered dermo-epidermal skin substitute
16670742|NCT02145117|Other|MBSR Training|Mindfulness Based Stress Reduction (MBSR) Training
16670743|NCT02145104|Experimental|Arm A|cilinidpine 10mg + valsartan 160mg
16670744|NCT02145104|Experimental|Arm B|cilnidipine 5mg + valsartan 160mg
16670745|NCT02145104|Active Comparator|Arm C|valsartan 160mg
16670746|NCT02145091|Experimental|One all-day session|"Participants will complete on all-day study session with a moderately-high dose of psilocybin.
~Preparation will include two days of screening, and an additional 8 hours of session preparation over at least 2 days. Follow-up will consist of an interview and MRI scan one day after the all-day session, a questionnaire follow-up 2 months after the all-day session, and a final follow-up 12-18 months after the all-day session."
16670747|NCT02145091|Experimental|Two all-day sessions|"Participants will complete two all-day study sessions, the first with placebo and the second with a moderately-high dose of psilocybin.
~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the second all-day session."
16670748|NCT02145091|Experimental|Three all-day sessions|"Participants will complete three all-day study sessions, the first two with placebo and the third with a moderately-high dose of psilocybin. The majority of participants (over 90%) will be assigned to either one or two all-day sessions. A small minority of participants (less than 10%) will be assigned to three all-day sessions.
~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the third all-day session."
16670749|NCT02145091|Experimental|MRI of the acute effects of psilocybin|This is an optional arm consisting of two sessions where either placebo, a very-low dose of psilocybin, or a moderately-low dose of psilocybin will be administered. During each session, participants will undergo MRI scanning shortly after the administration of each dose. Study sessions may occur over one or two days. Participants who have previously completed an all-day session with psilocybin in this study will be eligible to volunteer for this arm.
16670750|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
16670751|NCT02145065|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty
16670752|NCT02145065|Experimental|microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation
16671198|NCT02142101||GFR <15|5 patients with polycystic kidney disease with eGFR <15 ml/min.
16670753|NCT02145052|Active Comparator|Continuous suture|0 non-looped PDS using a tapered needle starting at the superior and the inferior portions of the wound. Fascia is then approximated with at least 1cm distance from the edge of the fascia and 1cm advancement. The two sutures are then knotted in the center with 8 square knots.
16670754|NCT02145052|Active Comparator|Interrupted Suture|Using a tapered needle, 0 non-looped PDS interrupted figure of eight suture 1cm from the edge and advancing 1cm between each suture.
16670755|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
16670756|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
16670757|NCT02145013||Portal hypertension|Hepatectomy
16670758|NCT02145013||No portal hypertension|Hepatectomy
16670759|NCT02145000|Experimental|Rotavirus vaccine (BRV-PV)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
16670760|NCT02145000|Placebo Comparator|Placebo|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
16670761|NCT02144974||Patients undergoing total pelvic exenteration|Patients undergoing total pelvic exenteration for gynecological malignancies and reconstruction of the pelvic floor with a TMG flap.
16670762|NCT02144961||Ultrasound|Breast ultrasound in female patients who are post-mastectomy pursuing autologous tissue breast reconstruction surgery.
16670763|NCT02144948|Experimental|E.-coli-Nissle|10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd
16670764|NCT02144935||myelitis, transverse or acute flaccid myelitis|Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
16670765|NCT02144922|Placebo Comparator|Control|Patients continue taking their antihypertensive medication alone.
16670766|NCT02144922|Active Comparator|Pitavastatin|Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
16670767|NCT02144909|Experimental|Partners in Care with Semi-Structured Support Group|Partners in Care with Semi-Structured Support Group: participants will receive the Partners in Care intervention followed by 6 semi-structured support groups, conducted every other week for 3 months. Half of the support groups will be conducted by professionals with diabetes specific knowledge, e.g., pharmacists, physicians, nutritionists. While the other half will be conducted by the trained diabetes self-management facilitator.
16670768|NCT02144909|No Intervention|Partners in Care Standard Follow-up|Participants will receive the Partners in Care intervention followed by monthly healthy lifestyle tips related to diabetes self-management
16670769|NCT02144896|Experimental|Ankle splinting|Older adults will have one leg randomly assigned to ankle splinting for 4 weeks. The non-splinted leg will serve as the control.
16670770|NCT02144896|No Intervention|No Ankle Splinting|The non splinted leg will serve as the control
16670771|NCT02144883|Active Comparator|Materials|Self-help materials mailed to subjects home.
16670772|NCT02144883|Experimental|Telephone Counseling and Materials|Subjects received up to 9 telephone counseling calls plus self-help quit kit and 5 additional mailings
16670773|NCT02144870|Active Comparator|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
16670774|NCT02144870|Active Comparator|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
16670775|NCT02144857|Active Comparator|Anti-TNFa regimen|Etanercept 50 mg
16670776|NCT02144857|Active Comparator|Anti IL12/23 regimen|ustekinumab 45 mg
16670777|NCT02144857|Active Comparator|Cyclosporine regimen|Cyclosporine 2.5-3 mg/kg
16670778|NCT02144857|Active Comparator|anti-interleukin 17 A regimen|secukinumab 300 mg
16670779|NCT02144857|Active Comparator|inhibitor of phosphodiesterase-4|apremilast 30mg
16670780|NCT02144844|Experimental|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
16670781|NCT02144844|No Intervention|Treatment as Usual (TAU)|Treatment as Usual (TAU) Control
16670782|NCT02144831|Active Comparator|anti-thrombotic treatment|10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
16670783|NCT02144831|Active Comparator|anti-thrombotic|30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
16670784|NCT02144818|Active Comparator|GnRH agonist|
16670785|NCT02144818|Active Comparator|hCG|
16670786|NCT02144818|Active Comparator|dual triggering: GnRH agonist and hCG|
16670787|NCT02144805|Active Comparator|Suturing in a single layer|The technique used for single layer to close the uterine incision following cesarean sectio
16672324|NCT02135029|Placebo Comparator|Placebo|
16670788|NCT02144805|Active Comparator|Suturing in two layer|The technique used for two layer technie to close the uterine incision following cesarean sectio
16670789|NCT02144792|Active Comparator|Control group (healthy persons)|Normal controls take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
16670790|NCT02144792|Active Comparator|Patients with drug-resistant epilesy|Patients with drug-resistant epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
16670791|NCT02144792|Active Comparator|Patients with drug-sensitive epilepsy|Patients with drug-sensitive epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
16670792|NCT02144779|Active Comparator|Usual care|No treatment for this group
16670793|NCT02144779|Experimental|Assigned to palliative care team|The intervention group will be assigned to a palliative care team member that will facilitate communication and meetings between families and the medical team
16670794|NCT02144766|Experimental|Ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
16670795|NCT02144766|Placebo Comparator|saline|caudal block with 1 ml/kg of saline
16670796|NCT02144753|Experimental|NTX-1|NTX-1 (18 g)
16670797|NCT02144753|Active Comparator|Psyllium|psyllium (15 g)
16670798|NCT02144740|Other|NWT-03, then placebo|4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period
16670799|NCT02144740|Other|Placebo, then NWT-03|4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period
16670800|NCT02144727|Active Comparator|D2 distal subtotal gastrectomy|D2 distal subtotal gastrectomy D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
16670801|NCT02144727|Experimental|D1+ distal subtotal gastrectomy|D1+ distal subtotal gastrectomy D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
16670802|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
16670803|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
16670804|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
16670805|NCT02144701|Experimental|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
16670806|NCT02144701|No Intervention|No intervention|Patients receive no intervention.
16670807|NCT02144688|Experimental|Change in ARVs to improve cognition|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
16670808|NCT02144675|Experimental|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
16670809|NCT02144675|Active Comparator|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
16670810|NCT02144662|Experimental|Ranibizumab|Ranibizumab
16670811|NCT02144649|No Intervention|Group I (control, no juice)|Patients consume no tomato juice.
16670812|NCT02144649|Experimental|Group II (tangerine tomato juice)|Patients will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks)
16670813|NCT02144649|Experimental|Group III (red tomato juice)|Patients consume two cans of red tomato juice daily until their scheduled surgery (approximately 4 weeks).
16670814|NCT02144636|Experimental|treament|herbalife protein shake along with exercise
16670815|NCT02144636|No Intervention|control|diet and exercise only
16670816|NCT02144623|Experimental|Valproate|
16670817|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
16670818|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
16670819|NCT02144597|Active Comparator|2-week LCD and Roux-en-Y gastric bypass (RYGB)|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
16670820|NCT02144597|Active Comparator|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
16670821|NCT02144597|Other|Control diet|1000 calorie diet
16670822|NCT02144584|Placebo Comparator|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
16670823|NCT02144584|Active Comparator|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
16670824|NCT02144571|Experimental|Lifestyle|Diet and physical activity intervention group. Measurements taken at baseline, 12 weeks and 1 year.
16670825|NCT02144571|No Intervention|Wait-list control|No-treatment control group. Measurements taken at baseline, 12 weeks and 1 year. People in the control condition can elect to take the intervention after 1 year.
16672847|NCT02131545|Experimental|Quetiapine|Quetiapine 25 mg
16670826|NCT02144558|Experimental|Spinal cord injured (SCI) men, para or tetraplegic|SCI men will have 4 medical visits associated to sperm retrieval (penile vibratory stimulation (PVS) or masturbation)
16670827|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 33Fr bougie size and 2 cm distance from the pylorus.
16670828|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 33Fr bougie size and 5 cm distance from the pylorus
16670829|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
16670830|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
16670831|NCT02144532|Experimental|Patients with EDS hypermobility type|Patients with EDS hypermobility type wearing compression garment then compression garment removal
16670832|NCT02144519|Experimental|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
16670833|NCT02144519|Experimental|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
16670834|NCT02144506|Experimental|T&E|"Home-based exercises program T&E.This exercise program proposes 50 exercises with a booklet, cards and an electronic tablet. The participants choose their exercises on the basis of a rating scale of perception of exercise difficulty."
16670835|NCT02144506|Active Comparator|OTAGO|"Programm OTAGO is a home-based exercises program."
16670836|NCT02144493||Patients with recurrent CBD stone|
16670837|NCT02144493||Patients without recurrent CBD stone|
16670838|NCT02144480|Experimental|Intensive training|intensive aerobic training in moderate intensity day5 postoperatively. 30 minutes per sessions, 2 sessions per day, 10 sessions per week. There will be 20 sessions in total.
16670839|NCT02144480|Sham Comparator|traditional training|traditional rehabilitation
16670840|NCT02144467||Large-sample healthy participants|MRI scanning.
16670841|NCT02144454|Active Comparator|Meal rich in saturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in saturated fats
16670842|NCT02144454|Experimental|Meal rich in monounsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in monounsaturated fats
16670843|NCT02144454|Experimental|Meal rich in n-6 polyunsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in n-6 polyunsaturated fats
16670844|NCT02144441|Experimental|Patient self-administered insulin|The study's only arm
16670845|NCT02144428||Cow's milk allergy|Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet
16670846|NCT02144415|Experimental|EB-1020 400 mg|EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
16670847|NCT02144415|Experimental|EB-1020 800 mg|EB-1020 800 mg, administered as eight 100-mg IR capsules
16670848|NCT02144415|Active Comparator|lisdexamfetamine 150 mg|lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
16670849|NCT02144415|Active Comparator|d-amphetamine 40 mg|d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
16670850|NCT02144415|Placebo Comparator|Placebo|Placebo, administered as 8 matching placebo capsules
16670851|NCT02144402|Active Comparator|infant formula with DHASCO|standard infant formula with docosahexaenoic acid (DHA)
16670852|NCT02144402|Experimental|infant formula with DHASCO-B|standard infant formula with DHA-B
16670853|NCT02144389|Active Comparator|Praziquantel (PZQ)|A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
16670854|NCT02144389|Experimental|Arachidonic acid (ARA)|A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
16670855|NCT02144389|Experimental|PZQ + ARA|A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.
16670856|NCT02144376|Placebo Comparator|Maltodextrin|7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
16670857|NCT02144376|Active Comparator|Ispaghula|7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
16670858|NCT02144350|Experimental|Intervention|patients will undergo daily hyperbaric oxygen sessions in addition to IV steroids for 10 days.
16670859|NCT02144350|Sham Comparator|Sham|Patients will undergo sham hyperbaric air sessions in addition to IV steroids for 10 days
16670860|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
16670861|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
16670862|NCT02144324|Experimental|Tandem Appliance|This group of patients will receive the new appliance which is called the Tandem Appliance
16670863|NCT02144324|No Intervention|Traditional Treatment|Patients in this group will be treated by the traditional Face Mask appliance.
16670864|NCT02144311|Experimental|MRI with DW-MRI & DCE-MRI & FDG PET/CT|Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
16670987|NCT02143518|Experimental|30 µg Na-GST-1/Alhydrogel + CpG 10104|Low Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
16670865|NCT02144298||cold blood cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cold blood cardioplegia.
16670866|NCT02144298||cristalloid cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cristalloid cardioplegia.
16670867|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
16670868|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
16670869|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
16670870|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
16670871|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
16670872|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
16670873|NCT02144272|Experimental|LY3114062 (SC)|LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.
16670874|NCT02144272|Experimental|LY3114062 (IV)|LY3114062 given once intravenous (IV).
16670875|NCT02144272|Placebo Comparator|Placebo|Placebo (sodium chloride injection) given as a single SC dose.
16670876|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
16670877|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
16670878|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
16670879|NCT02144246|Other|Pre-intervention|Patients will act as their own controls. Will have no hormones for 3 months
16670880|NCT02144246|Experimental|Post-intervention|Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
16670881|NCT02144233|Experimental|Occlusal adjustment therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
16670882|NCT02144233|Placebo Comparator|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
16670883|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
16670884|NCT02144207|Active Comparator|Glidescope: Unrestricted View|Unrestricted view of the larynx.
16670885|NCT02144207|Active Comparator|Glidescope: Restricted View|Restricted view of the larynx.
16670886|NCT02144194|Experimental|Maintenance treatment|"Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles
~Followed by:
~Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
16670887|NCT02144194|Experimental|Observation arm|"Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles
~Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
16670888|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
16670889|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
16670890|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
16670891|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
16670892|NCT02144168|Active Comparator|prebiotics-free enteral formula|Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal
16670893|NCT02144168|Experimental|prebiotics containing enteral formula|Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days
16670894|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
16670895|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
16670896|NCT02144142|Experimental|Moisturizer with each subject's own antimicrobial bacteria|Each subject will have a moisturizer containing their own antimicrobial bacteria species spread over their arms in the clinic
16670897|NCT02144129|Experimental|active WB-EMS|2 sessions/week with 20 min of active WB-EMS application
16670898|NCT02144129|Experimental|Passive WB-EMS|2 sessions/week with 20 min of passive WB-EMS application in a resting supine position
16670899|NCT02144129|No Intervention|Inactive Control Group|sedentary non-training control group
16670900|NCT02144116|Experimental|Experimental group|Patients with fibromyalgia included in a dance-movement therapy programme
16670901|NCT02144116|Active Comparator|Control group|Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
16670902|NCT02144103|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
16670903|NCT02144090|Experimental|Fractional flow reserve|Fractional flow reserve measurement
16670904|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
16670905|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
16670906|NCT02144064|Active Comparator|Group A(heparin group)|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
16670907|NCT02144064|No Intervention|Group B|group B (n = 100) receive no thing
16670908|NCT02144051|Experimental|AZD5312|"AZD5312 will be given intravenously (IV) as an infusion, over one hour. For the purpose of planning, each 4 week period (28 days) will be called a Cycle. AZD5312 will initially be administered 4 times within the first 11 days, (on Days [1, 4, 8 and 11]± 2), with no dosing on sequential days. Patients will receive weekly treatments on Days 15 and 22 to complete Cycle
~1. During the subsequent cycles, patients will receive weekly treatment on Days 1, 8, 15 and 22 (±2)."
16670909|NCT02144038|Experimental|Phase Ib: LGH447 + BYL719|Dose-escalation, LGH447 in combinatinon with BYL719
16670910|NCT02144038|Experimental|Phase II: LGH447 + BYL719|LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
16670911|NCT02144038|Experimental|Phase II: LGH447 alone|LGH447 alone (dosing according to single-agent RDE)
16670912|NCT02144025|Experimental|Topical cyclosporine|This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen. In this arm, patients who are candidates to this trial, will receive topical cyclosporine twice a day for 12 months to prevent ocular graft versus host disease.
16670913|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
16670914|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
16670915|NCT02143999||Cohort|
16670916|NCT02143986||Macrophagic activation syndrome|
16670917|NCT02143986||Still's disease|
16670918|NCT02143986||Hyperferritinemia|
16670919|NCT02143986||Sepsis|
16670920|NCT02143973|Experimental|nalbuphine HCl ER|nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
16670921|NCT02143960|Active Comparator|Velashape III device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
16670922|NCT02143960|Active Comparator|Noninvasive Cryolipolysis Device|A noninvasive device that reduces fat by freezing fat cells
16670923|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
16670924|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
16670925|NCT02143934|Active Comparator|Primaquine|Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
16670926|NCT02143934|Placebo Comparator|Placebo|Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
16670927|NCT02143921|Experimental|Training Intervention|One service provider group received training
16670928|NCT02143921|No Intervention|Control|Control group service providers did not received intervention training
16670929|NCT02143908|Placebo Comparator|placebo supplementation|2000 mg placebo tablets/day
16670930|NCT02143908|Active Comparator|Supplementation|lysine 2000 mg tablets/day supplementation
16670931|NCT02143882|Experimental|LAIV|All children will receive LAIV, currently available as the marketed product Fluenz
16670932|NCT02143856|Experimental|100 mg GLPG1205 fasted|Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast
16670933|NCT02143856|Experimental|100 mg GLPG1205 fed|Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast
16670934|NCT02143843|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
16670935|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
16670936|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
~The maximum number of patients enrolled in this arm will be 10."
16670981|NCT02143557|Active Comparator|MCT-formula group|Infants in this arm of the study were fed a MCT-containing medical food which is the current standard of care.
16670982|NCT02143544|Active Comparator|Preoperative intra-aortic balloon pump.|Intervention: Preoperative placement of the intra-aortic balloon pump.
16670983|NCT02143544|No Intervention|Control|No preoperative placement of the intra-aortic balloon pump.
16671073|NCT02142881|Experimental|Antihypertensive medication intensification|
16670937|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
16670938|NCT02143817|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
16670939|NCT02143817|Experimental|Whole body vibration training plus L-citrulline|Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)
16670940|NCT02143817|Experimental|Whole body vibration training & placebo|Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)
16670941|NCT02143817|Experimental|L-citrulline supplementation|(6g per day)containing L-citrulline
16670942|NCT02143804|Experimental|CG0070|oncolytic virus genetically modified to express GM-CSF
16670943|NCT02143791||Burst stimulation|At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation
16670944|NCT02143778|Experimental|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
16670945|NCT02143765|Experimental|Mitiglinide|Mitiglinide 10 mg three times a day, orally, for 12 weeks
16670946|NCT02143765|Active Comparator|Acarbose|Acarbose 50 mg three times a day, orally, for 12 weeks
16670947|NCT02143752||Mindfulness|Smokers enter a Mindfulness Training for Smokers course
16670948|NCT02143752||Quit Line|Smokers attempt smoking cessation with the help of the Wisconsin Tobacco Quit Line
16670949|NCT02143739||Newly diagnosed asthma patients|The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.
16670950|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16670951|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16670952|NCT02143713|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
16670953|NCT02143713|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
16670954|NCT02143700||Stable and exacerbated patients|Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation. Cognitive assessment of these patients will be performed.
16670955|NCT02143687|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
16670956|NCT02143687|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
16670957|NCT02143687|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
16670958|NCT02143687|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
16670959|NCT02143674|Experimental|INTERVENTION|Muscle stretching and Strength Training
16670960|NCT02143674|Experimental|Educated about physical exercises|
16670961|NCT02143661||Critically ill patients in the newly designed ICU rooms|Critically ill patients treated in one of the newly designed ICU rooms.
16670962|NCT02143661||Critically ill patients in the conventional ICU rooms|Critically ill patients treated in one of the conventional rooms on the same ICU.
16670963|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
16670964|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
16670965|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
16670966|NCT02143635|Experimental|Arm A|
16670967|NCT02143635|Experimental|Arm B|
16670968|NCT02143635|Experimental|Arm C|
16670969|NCT02143635|Experimental|Arm D|
16670970|NCT02143622|Experimental|LJM716+cetuximab|
16670971|NCT02143609|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
16670972|NCT02143609|Placebo Comparator|Sham oxygen|sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
16670973|NCT02143596|Active Comparator|Bun/Cr based hydration|receive intravenous normal saline infusion and adjust infusion rate by Bun/Cr followed in the first 72 hours
16670974|NCT02143596|No Intervention|control|receive intravenous normal saline infusion as clinician's adjustment
16670975|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
16670976|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
16670977|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
16670978|NCT02143570|Experimental|Darifenacin + Physiotherapy|Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms.
16670979|NCT02143570|Active Comparator|Physiotherapy|Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill.
16670980|NCT02143557|Experimental|Fat-Modified Breast Milk|Infants in this arm of the study were fed their own mother's breast milk where the fat layer was removed by centrifugation. Prior to feeding, extra energy and nutrients were added to the defatted breast milk.
16670988|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel + CpG 10104|High Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
16670989|NCT02143505|Experimental|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements for 3 years
16670990|NCT02143505|Placebo Comparator|placebo|identical-appearing placebo supplements for 3 years
16670991|NCT02143479||1:early conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
16670992|NCT02143479||2:late conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation
16670993|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
16670994|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
16670995|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
16670996|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
16670997|NCT02143453|Experimental|High intensity interval training|
16670998|NCT02143453|Experimental|Endurance training|
16670999|NCT02143440|Other|Newly diagnosed type 2 patients|The initial assessment of daily insulin dose.
16671000|NCT02143427|Experimental|Social Skills Training|Social Skills Training child-focused and subsequent social competence training which combines patient- and parent-/teacher and peer-focused interventions
16671001|NCT02143427|Active Comparator|Treatment Program with techniques to activate resources|Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training child-focused
16671004|NCT02143401|Experimental|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 cycle of 1 only) and sorafenib tosylate PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16671005|NCT02143388|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
16671006|NCT02143388|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
16671007|NCT02143375|Experimental|810 Diode Laser|810 nm Diode Laser, contact, continuous wave,320micron,
16671008|NCT02143362|Experimental|Dexmedetomidine group|"Infusion of dexmedetomidine(0.8μg/kg) at10 minutes before anesthesia induction.
~Infusion of dexmedetomidine at 0.4 μg•kg-1•h-1during anesthesia maintenance.
~The infusion rate of dexmedetomidine was reduced to 0.1 μg•kg-1•h-1 for awaken test."
16671009|NCT02143362|Placebo Comparator|Control group|"Infusion normal saline(0.8μg/kg) at 10 minutes before anesthesia induction.
~Infusion normal saline at 0.4 μg•kg-1•h-1 during anesthesia maintenance.
~The infusion rate of normal saline was reduced to 0.1 μg•kg-1•h-1 for awaken test."
16671010|NCT02143349|Experimental|Coleus forskohlii extract|Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks
16671011|NCT02143349|Placebo Comparator|Placebo|Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks
16671012|NCT02143336|Experimental|Subcuticular suture|Subcuticular suture (absorbable) for skin closure
16671013|NCT02143336|Active Comparator|Skin staples|Standard skin staples for wound closure
16671014|NCT02143323|Active Comparator|Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild|Augmentin tablet
16671015|NCT02143323|Active Comparator|GSTT1/GSTM1 wild/null type|Augmentin tablet
16671016|NCT02143323|Active Comparator|GSTT1/GSTM1 null/wild type|Augmentin tablet
16671017|NCT02143323|Active Comparator|GSTT1/GSTM1 null/null type|Augmentin tablet
16671018|NCT02143310|Experimental|EVP|Subject who use the EVP for up to 2 years
16671019|NCT02143297||SAHS negative|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
16671020|NCT02143297||SAHS positive|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
16671021|NCT02143284|Experimental|Endoscopy exploratory single arm|Exploratory single arm, the system will be used in otherwise standard procedures, and will be reviewed in terms of performance, usability, ease of use and safety.
16671022|NCT02143271|Experimental|KHK7580|
16671023|NCT02143258|Experimental|Neurointerventional|Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
16671074|NCT02142881|Other|Usual care|
16671075|NCT02142855|No Intervention|Old Control|Older individuals (65-75 y) with no exercise intervention
16671024|NCT02143245|Other|Revision Population|"The study population is both men and women who have had previous shoulder surgery with symptoms suggestive of deep infection. These include the presence of pain, stiffness, and radiologic signs of infection including implant lucencies or migration.
~Patients in this population will undergo a synovial biopsy, in addition to undergoing an open tissue biopsy at the time of their procedure. Diagnostic accuracy will be compared, and all participants will be tracked over time."
16671025|NCT02143232|Experimental|Remote patient monitoring (Telus RPM)|The remote monitoring device (Telus RPM) is used by every patient in the study post operatively at home.
16671026|NCT02143219|Other|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
16671027|NCT02143206||Exercise Method|Patients attend exercise 80 minute exercise sessions of which 30 minutes includes aerobic exercise on a NuStep and Biodex elliptical machine. Patients pain levels are scored when using the NuStep then when using the Biodex and these scores are compared to determine which machine give the best outcome for pain management
16671028|NCT02143193|Experimental|Skin to Skin Contact|implement mother-baby Skin-to-Skin contact immediately after vaginal birth
16671029|NCT02143193|No Intervention|Standard of Care|standard care for newborn and mother immediately after vaginal birth
16671030|NCT02143167|Experimental|SR-fampridine/placebo|24 weeks of SR-fampridine followed by four weeks of inactive placebo.
16671031|NCT02143167|Experimental|Placebo/SR-fampridine|24 weeks of inactive placebo followed by four weeks of SR-fampridine
16671032|NCT02143154||GBS positive women|Women wih GBS positive bacteruria with plan for treatment with vancomycin in labor, or women with positive GBS screening cultures with a plan to receive vancomycin in labor
16671033|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
16671034|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
16671035|NCT02143128||ESScore reliability|Same patients evaluated by two or more health professionals
16671036|NCT02143128||ESScore|Tool used for evaluation of patients after surgery
16671037|NCT02143128||ESScore without evaluation|Scored by tool, but not evaluated by it
16671038|NCT02143128||No ESScore|Regular ward routines
16671039|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
16671040|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
16671041|NCT02143089|Active Comparator|Group 1|Use of urinary catheterization in Cesarean section
16671042|NCT02143089|No Intervention|Group 2|NO urinary catheterization during Cesarean section
16671043|NCT02143076||Sickle Cell Disease|Participants will complete three questionnaires during the course of the study: Demographic Questionnaire, Medical Adherence Measure Questionnaire, and Acceptability Questionnaire. All questionnaires will be completed in a private clinic room.
16671044|NCT02143063|Active Comparator|standard care|standard care
16671045|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
16671046|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
16671048|NCT02143037|Active Comparator|Control Group|usual care
16671049|NCT02143037|Experimental|Experimental Group|usual care plus prize contingency management for attending treatment
16671050|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
16671051|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
16671052|NCT02143011|Other|orange juice|no sugar
16671053|NCT02143011|Other|sugar beverage|no sugar
16671054|NCT02142998|Active Comparator|GERD Symptoms|
16671055|NCT02142998|Active Comparator|No GERD Symptoms|
16671056|NCT02142985|Experimental|crystalloid solution|vascular filling with 500 ml of crystalloid solution within 10 minutes
16671057|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
16671058|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
16671059|NCT02142959|Placebo Comparator|Lotion vehicle/Placebo|Lotion vehicle/placebo will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
16671060|NCT02142946||RIS MS patients|Radiologically Isolated Syndrome (RIS) MS patients
16671061|NCT02142946||CIS MS patients|Clinically Isolated Syndrome (CIS) patients during a stable phase
16671062|NCT02142946||RRMS patients|Relapsing-remitting (RR) MS patients during a stable phase
16671063|NCT02142946||SPMS Patients|Secondary progressive MS patients (SPMS)
16671064|NCT02142946||PPMS Patients|Primary progressive MS patients (PPMS)
16671065|NCT02142946||Controls|Age and gender matched controls
16671066|NCT02142946||CI Patients|Cochlear Implant patients pre- and post-operatively
16671067|NCT02142946||UVL Patients|Unilateral vestibular loss patients in acute and compensated state
16671068|NCT02142946||Chronic UVL|Chronic unilateral vestibular loss patients
16671069|NCT02142946||Phobic|Phobic vertigo patients
16671070|NCT02142933|Other|rectal swab and vagino-perineal swab|single-arm
16671071|NCT02142920|Experimental|[14C] PF 05212384|Receive PF-05212384 89 mg Dose
16671072|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
16671076|NCT02142855|Experimental|Old Concentric|Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training
16671077|NCT02142855|Experimental|Old Eccentric|Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training
16671078|NCT02142855|No Intervention|Young Control|Young individuals (18-30 y) with no exercise intervention
16671079|NCT02142855|Experimental|Young Concentric|Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training
16671080|NCT02142855|Experimental|Young Eccentric|Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training
16671081|NCT02142842|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3 radiographic OA severity with 16 patients as control.
16671082|NCT02142829|Active Comparator|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
16671083|NCT02142829|Active Comparator|On-Q Pain Ball|Device for delivering bupivacaine.
16671084|NCT02142816|Active Comparator|Doppler|Fluid directed by oesophageal doppler
16671085|NCT02142816|Active Comparator|PVI|Fluid therapy directed by Pleth Variability Index
16671086|NCT02142803|Experimental|Treatment (TORC1/2 inhibitor INK128, bevacizumab)|Patients receive TORC1/2 inhibitor INK128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16671087|NCT02142790|Experimental|paclitaxel liposome injection weekly|paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable
16671088|NCT02142790|Experimental|paclitaxel liposome injection every 3 weeks|paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable
16671089|NCT02142777|Experimental|Investigational|All study subjects will take a 10mg pill by mouth twice daily over a 6 week period. Subjects will receive either placebo or S -Equol. They will not know which they are receiving.
16671090|NCT02142764|Experimental|Multiple Sclerosis|Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed
16671091|NCT02142764|Other|Control|HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
16671092|NCT02142764|Experimental|Multiple Sclerosis patients treated|HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
16671093|NCT02142751|Experimental|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
16671094|NCT02142751|Active Comparator|Meropenem intravenous|1g every 8 hours (15-30 min infusion)
16671095|NCT02142751|Other|Ceftriaxone intravenous|1g every 24h (2-4 min)
16671096|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
16671097|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
16671098|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
16671099|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
16671100|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
16671101|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
16671102|NCT02142725|Experimental|LT-02|LT-02 0.8g four times daily
16671103|NCT02142725|Experimental|B: LT-02|LT-02 1.6g twice daily
16671104|NCT02142725|Placebo Comparator|Placebo|LT-02 Placebo
16671105|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
16671106|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
16671107|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.
~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
16671108|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
16671109|NCT02142699|Active Comparator|Heme arginate 1mg/kg|"This is the lower of the 2 doses of Heme arginate (HA). This will be given as a single dose of 1mg/kg on the first study visit.
~This is given over 1 hour intravenously."
16671110|NCT02142699|Active Comparator|Heme arginate 3mg/kg|"This is the larger dose, Heme arginate 3mg/kg (up to a maximum dose of 250mg)
~This will be given intravenously, as a single dose on the first study visit, over one hour."
16671111|NCT02142686|Active Comparator|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm.
16671112|NCT02142686|Active Comparator|Filling pressure 50.|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg in this group
16671113|NCT02142686|Active Comparator|illing pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm Hg.
16671114|NCT02142673|Active Comparator|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
16671115|NCT02142673|Active Comparator|Filling pressure 60|The hysteroscope filling pressure will be to 50mm Hg
16671116|NCT02142673|Active Comparator|Filling pressure 40|The hysteroscope filling pressure will be to 40mm Hg
16671117|NCT02142660||Sprayshield|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie
16671118|NCT02142647|Active Comparator|meat group|Infants in this group will receive complementary foods with high protein content mainly from meat
16671119|NCT02142647|Active Comparator|dairy group|infants in this group will receive complementary foods mainly from dairy
16671120|NCT02142634|Experimental|A|Budesonide granules 9 mg
16671121|NCT02142634|Placebo Comparator|B|Placebo granules
16671122|NCT02142621|Active Comparator|transpyloric tube feeds|Continuous transpyloric tube feeds administered through an oral/nasal feeding tube.
16671123|NCT02142621|Active Comparator|gastric tube feeds|Continuous gastric tube feeds administered through an oral/nasal feeding tube.
16671124|NCT02142608|Experimental|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
16671125|NCT02142595|Experimental|dexmeditomidine group D|The sedative solution was prepared as a 10µg /ml dexmedetomidine in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
16671126|NCT02142595|Experimental|Midazolam group M|The sedative solution was prepared as a 0.375mg/ml midazolam or normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
16671127|NCT02142595|No Intervention|group control|normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
16671128|NCT02142582|Active Comparator|WHO ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
16671129|NCT02142582|Active Comparator|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
16671130|NCT02142569|Active Comparator|Chinese Red Yeast Rice (CRYR)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 Sugar Pill/Placebo capsules for 12 weeks.
16671131|NCT02142569|Active Comparator|Tocotrienol-enriched Fraction of Palm Oil (TRF)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 TRF and 2 Sugar Pill/Placebo capsules for 12 weeks.
16671132|NCT02142569|Active Comparator|CRYR + TRF|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF + CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 TRF capsules for 12 weeks.
16671133|NCT02142569|Placebo Comparator|Sugar Pill|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the placebo (sugar pill) arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 4 placebo tablets for 12 weeks. Additionally during a two-week run-in period, subjects will be asked to follow the American Heart Association Step 1 dietary regimen and to take a placebo capsule daily to determine their ability to comply with the diet and a pill regimen.
16671134|NCT02142556|Experimental|Quetiapine XR|Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
16671135|NCT02142543|Placebo Comparator|placebo|placebo powder containing zinc oxide, karaya gum, and yellow dye, which was added to imitate the color of the original powder, applied twice a day until the ulcer had resolved, an expected average of 3-5 days
16671136|NCT02142543|Experimental|2-DeNT powder|2-DeNT powder containing dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum, applied twice a day until the ulcer had resolved, applied twice a day until the ulcer had resolved, in an expected average of 3 to 5 days
16671137|NCT02142530|Experimental|Carfilzomib/ Belinostat|"Carfilzomib and Belinostat will be administered on a 28-day schedule.
~Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).
~Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.
~Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2
~A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2."
16671165|NCT02142296|Other|Eylea|The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
16671166|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
16671167|NCT02142283|Active Comparator|Medical Management|Medical Management
16671168|NCT02142270||Victims of cardiac arrest, either SCD or aborted SCA|
16671138|NCT02142517|Active Comparator|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
16671139|NCT02142517|Active Comparator|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
16671140|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
16671141|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
16671142|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
16671143|NCT02142478||Adapted scheme|Participants referred by their GP practices to Centre A will take part in the Adapted Exercise for Health (EFH) scheme.
16671144|NCT02142478||Standard scheme|Participants referred by their GP practices to Centre B will take part in the Standard Exercise for Health (EFH) scheme.
16671145|NCT02142452|Experimental|mobile health intervention|Behavioral intervention. Women with excessive weight gain in pregnancy will be recruited in their 3rd trimester. They will begin with a 5 week group session on weight management. After they deliver the baby, they will begin receiving text messages supporting behavior change they learned in their 3rd trimester. They will follow up at 6 weeks postpartum and 4 months postpartum.
16671146|NCT02142452|Placebo Comparator|Control Group|Women will receive usual prenatal care from their OB. Postpartum, they will receive a monthly newsletter relevant to the new mother on her nutrition and physical activity. They will be followed at 6 weeks postpartum and 4 months postpartum.
16671147|NCT02142439|Experimental|Intervention group 1|Exercise counseling 1 time/week, Strength training 3 times/week, dose: 5 RM x 3 sets.
16671148|NCT02142439|Experimental|Intervention group 2|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
16671149|NCT02142439|Experimental|Intervention group 3|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 30 RM x 3 sets
16671150|NCT02142439|No Intervention|Control group|Exercise counseling 1 time/week
16671151|NCT02142413||Acute Ischemic Stroke|Patients older than 18 years with an acute ischemic stroke (according to WHO criteria), stroke onset within 2 days, language: German, MRI compatibility, admission to the stroke unit at the Charité, Campus Benjamin Franklin.
16671152|NCT02142400|Experimental|DS-1093|Group 1 will receive 10mg, group 2 will receive 25mg of DS-1093
16671153|NCT02142400|Placebo Comparator|placebo|placebo to match DS-1093 dosage
16671154|NCT02142387|Active Comparator|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
16671155|NCT02142387|No Intervention|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000&bid=0021&tag=&act=view&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
16671156|NCT02142361|Active Comparator|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
16671157|NCT02142361|Active Comparator|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
16671158|NCT02142361|Active Comparator|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
16671159|NCT02142348||osteoprosis research|
16671160|NCT02142335|Experimental|Rituxan/Abraxane|This is a single arm study. All patients recieve treatment.
16671161|NCT02142309|Experimental|Glimepiride|up to 4 mg/day
16671162|NCT02142309|Experimental|Vildagliptin|50 mg bid
16671163|NCT02142309|Experimental|Pioglitazone|up to 30 mg/day
16671164|NCT02142309|Experimental|Canagliflozin|300 mg/day
16673564|NCT02126774||focal epilepsy|observational study
16671169|NCT02142270||Premature death|"All residents of districts of interest will be surveyed during 3 years. premature deaths occurring in residents of districts of interest will be checked for past medical history, circumstances of death, and autopsy report (if possible). Investigators will also analyze the employment of resuscitation attempts during the timeframe of sudden cardiac arrest (SCA) in various patient populations throughout African countries.
~The arm group of the study is every resident of the district of interest"
16671170|NCT02142257||Gastric Bypass|Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
16671171|NCT02142257||AspireAssist Aspiration Therapy|Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
16671172|NCT02142244|Experimental|Near infra red sentinel node biopsy|Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.
16671173|NCT02142231|Placebo Comparator|Laser Acupuncture|Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
16671174|NCT02142231|Active Comparator|Acupuncture|Acupuncture at the acupoint Heart 7, on both wrists, each for 1 minute, eliciting a deqi-response, additional stimulation and total needle-in time of 20 minutes (2 minutes treatment and 18 minutes of resting time)
16671175|NCT02142205|Experimental|BG00002 (natalizumab)|300 mg IV infusion every 4 weeks
16671176|NCT02142192|Experimental|natalizumab|natalizumab 300mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)
16671177|NCT02142179|Experimental|KARE Intervention|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
16671178|NCT02142179|No Intervention|A traditional curriculum education.|The control group will receive a traditional curriculum education.
16671179|NCT02142166|Experimental|SAB analysis|"Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture
~Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
16671180|NCT02142166|Experimental|Control|"Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology
~Single analysis of Biomarker in serum and liquor"
16671181|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
16671182|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
16671183|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
16671184|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
16671185|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
16671186|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
16671187|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
16671188|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
16671189|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
16671190|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
16671191|NCT02142140|Experimental|Medication Monitoring & Case Management|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning. Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher).
16671192|NCT02142140|Active Comparator|Community Follow-up Group|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
16671193|NCT02142127|Experimental|14C-labelled GFT505 120 mg|
16671194|NCT02142114|Active Comparator|Eye injection by 30 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection). When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
16671195|NCT02142114|Active Comparator|Eye injection by 32 gauge needle|
16671196|NCT02142101||GFR >60|5 patients with polycystic kidney disease with eGFR > 60 ml/min.
16671199|NCT02142088|Other|Glucose Monitoring|Each patient will undergo simultaneous Glucose monitoring with 2 devices. One is GlySure's intervascular continuous measurement sensor (test device) introduced through a CVC, and the other measures glucose intermittently from repeated venous blood samples drawn through an indwelling ventflon style catheter
16671200|NCT02142075|Experimental|Daptomycin, IV|"Patients with creatinine clearance ≥30 ml/min will receive 10 mg/kg of daptomycin (Cubicin®) once daily,
~Patients with creatinine clearance <30 ml/min will receive the same daptomycin dose (10 mg/kg) but less frequently, every 48h instead of every day"
16671201|NCT02142062||Venography and IVUS imaging guiding treatment|
16671202|NCT02142049|Experimental|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
16671203|NCT02142049|Experimental|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
16671204|NCT02142049|Experimental|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
16671205|NCT02142049|Experimental|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
16671206|NCT02142049|Experimental|Part 2: RP2D|Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
16671207|NCT02142036|Experimental|ATI based targeted therapy.|EMA-approved ATI based targeted therapy. Patients will receive therapy based on molecular aberrations identified in the metastatic lesion.
16671208|NCT02142010|Other|paclitaxel liposome injection plus cisplatin|
16671209|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
16671210|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
16671211|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
16671212|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
16671213|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
16671214|NCT02141971||Non-demented; Ages 30-40|Four non-demented Down syndrome patients between the ages of 30-40 years old
16671215|NCT02141971||Non-demented; Ages 40-50|Four non-demented Down syndrome patients between the ages of 40-50 years old
16671216|NCT02141971||Demented; Ages 50-60|Four demented Down syndrome patients between the ages of 50-60 years old
16671217|NCT02141958|Experimental|Fenretinide|Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
16671218|NCT02141958|Placebo Comparator|Placebo|Four (4) patients will be on Placebo.
16671219|NCT02141932|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries and the heart. All participants will then be examined by reference imaging in specific ultrasound laboratories and when appropriate computer tomography or magnetic resonance imaging.
16671221|NCT02141906|Experimental|Oncozene-DEB-TACE|"Screening Visit (procedures should be done within 28 days of treatment day):
~Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw).
~Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day
~Follow up after completion of treatment every 4-6 weeks:"
16671222|NCT02141893|Active Comparator|CALMA|Participants only received a family education intervention (previously tested) known as CALMA
16671223|NCT02141893|Experimental|Calma plus|Participants in Arm 2 received the CALMA family education intervention and physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs.
16671224|NCT02141880||Treatment|All subjects will be under the same protocol which is eating and drinking on one afternoon.
16671225|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
16671226|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
16671227|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
16671228|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
16671229|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
16671230|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
16671231|NCT02141828|Experimental|EPZ-5676|EPZ-5676 Dose escalation and expansion cohorts
16671232|NCT02141815|Experimental|Arabinoxylan-oligosaccharides|Arabinoxylan-oligosaccharides 10g BID
16671233|NCT02141815|Placebo Comparator|Maltodextrine|Maltodextrine BID
16671234|NCT02141802|Active Comparator|Control|Normal standing time
16671235|NCT02141802|Experimental|Doubling standing time|Doubled standing time calculated by doubling baseline standing time
16671236|NCT02141789|Experimental|Outpatient Cognitive Behavioral Psychotherapy|Outpatient Cognitive Behavioral Therapy is a well-known and frequently applied psychotherapy approach that does not need further description.
16671237|NCT02141776|Sham Comparator|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
16671238|NCT02141776|Active Comparator|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
16671239|NCT02141763|Experimental|240/160/160 mg of UCB4940|240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
16672026|NCT02136823|Experimental|riluzole|50mg tablet, single oral dose, one day (single dose)
16671240|NCT02141763|Experimental|160/80/80 mg of UCB4940|160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
16671241|NCT02141763|Experimental|80/40/40 mg of UCB4940|80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
16671242|NCT02141763|Experimental|560/320/320 mg of UCB4940|560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
16671243|NCT02141763|Placebo Comparator|Placebo|0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial
16671244|NCT02141737|Placebo Comparator|Group C|Induction protocol: patients will be given 2 ml normal saline solution, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
16671245|NCT02141737|Experimental|Group L1|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 20 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
16671246|NCT02141737|Experimental|Group L2|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 30 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
16671247|NCT02141737|Experimental|group L3|Induction protocol: patients will be given 2 ml lidocaine injection in which 40 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
16671248|NCT02141724||neuromuscular patients|neuromuscular patients using wheelchair
16671249|NCT02141711|Experimental|Cohort 1: TAK-438 10 mg|TAK-438 10 mg tablets, orally, once, daily, for 7 days.
16671250|NCT02141711|Experimental|Cohort 2: TAK-438 20 mg|TAK-438 20 mg tablets, orally, once, daily, for 7 days.
16671251|NCT02141711|Experimental|Cohort 3: TAK-438 40 mg|TAK-438 40 mg tablets, orally, once, daily, for 7 days.
16671252|NCT02141711|Experimental|Cohort 4: TAK-438 30 mg|TAK-438 30 mg tablets, orally, once, daily, for 7 days.
16671253|NCT02141711|Placebo Comparator|Cohorts 1-4: Placebo|TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
16671254|NCT02141698|Experimental|Cohort 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
16671255|NCT02141698|Experimental|Cohort 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
16671256|NCT02141698|Experimental|Cohort 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
16671257|NCT02141698|Experimental|Cohort 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
16671258|NCT02141698|Experimental|Cohort 5: TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once on Day 1.
16671259|NCT02141698|Experimental|Cohort 6: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
16671260|NCT02141698|Experimental|Cohort 7: TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once on Day 1.
16671261|NCT02141698|Experimental|Cohort 8A: Food-effect|TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
16671262|NCT02141698|Experimental|Cohort 8B: Food-effect|TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.
16671263|NCT02141698|Experimental|Cohort 9: TAK-438 Multiple Dose 1|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
16671264|NCT02141698|Experimental|Cohort 10: TAK-438 Multiple Dose 2|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
16671265|NCT02141698|Experimental|Cohort 11: TAK-438 Multiple Dose 3|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
16671266|NCT02141698|Experimental|Cohort 12: Ethnic Bridging|TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.
16671267|NCT02141698|Placebo Comparator|Cohorts 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1
16671268|NCT02141698|Placebo Comparator|Cohorts 9-11: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.
16671269|NCT02141685||IVF patients undergoing aCGH Testing|Women undergoing fresh IVF treatment and array-comparative genomic hybridization testing (aCGH), as recommended based on medical need by the clinical site reproductive endocrinologist.
16671270|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
16671271|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
16671272|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID
~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
16671273|NCT02141659|Experimental|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
16671274|NCT02141659|Experimental|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
16671275|NCT02141659|Experimental|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
16671276|NCT02141659|Experimental|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
16671277|NCT02141659|Experimental|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
16671393|NCT02140892|Experimental|respiratory physical therapy manual technique|respiratory physical therapy manual technique- Autogenic Drainage
16671278|NCT02141659|Experimental|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
16671279|NCT02141646|Experimental|Motivational interviewing|
16671280|NCT02141646|Experimental|Behavioral skills training|
16671281|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
16671282|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
16671283|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
16671284|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
16671285|NCT02141607||Hemorrhagic Shock|"Hypovolemic shock characterized by:
~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.
~Rapid loss of significant amount of blood
~Lactate levels ≥ 2 mmol/L"
16671286|NCT02141607||Cardiogenic shock|"State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:
~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.
~Need for a continuous infusion of inotropic drugs
~Cardiac Index <2.2 L/min/m2 or use of inotropic drugs (dobutamine/isoprenaline/phosphodiesterase inhibitors or levosimendan)
~Signs of reduced heart function
~Cardiac overload or altered left/right ventricular function"
16671287|NCT02141607||Septic shock|"Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.
~Only community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).
~Lactate levels ≥ 2mmol/L."
16671288|NCT02141607||control group|"The control group will consist on:
~5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis
~a cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
16671289|NCT02141594||Early glaucoma|The study group consisted of consecutive unilateral glaucoma patients, categorized as early stage by Hodapp-Anderson-Parrish classification.
16671290|NCT02141594||Normal subjects|Normal control subjects had a normal ocular examination, Intraocular pressure (IOP) <22 mmHg, no past history of high IOP, no family history of glaucoma, normal optic disc morphology and visual field in both eyes. One eye of control subject was randomly selected.
16671291|NCT02141581|Experimental|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)
~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
16671292|NCT02141581|Experimental|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)
~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
16671293|NCT02141581|Experimental|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.
~FluMist was only used in the first year of study."
16671294|NCT02141568|Experimental|Intervention Group for Prospective Study|"Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis."
16671295|NCT02141568|No Intervention|No Intervention|Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur
16671296|NCT02141555|Active Comparator|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
16671297|NCT02141555|Experimental|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
16671298|NCT02141542|Experimental|Tremelimumab and MEDI3617|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Tremelimumab-Fixed doses of Tremelimumab are given once per cycle
~MEDI3617-MEDI3617 is administered twice per cycle"
16671299|NCT02141529|Active Comparator|Unipolar PRF|Unipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
16671300|NCT02141529|Experimental|Bipolar PRF|Bipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
16671301|NCT02141516|Experimental|Group A|Complement deficiency
16671302|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
16671303|NCT02141516|Active Comparator|Group C|age-matched healthy controls
16671304|NCT02141490|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
16671305|NCT02141477|Experimental|Omacetaxine + Decitabine|"Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.
~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
16671306|NCT02141451|Experimental|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
16671341|NCT02141256|Experimental|Protein enriched products|Protein enriched products will be given to elderly residents of a care home for 10 days. Does this lead to an increased protein intake or do elderly compensate for the extra amount of protein?
16671307|NCT02141451|Experimental|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
16671308|NCT02141451|Experimental|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
16671309|NCT02141451|Experimental|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
16671311|NCT02141425|Experimental|ASP015K low dose|
16671312|NCT02141425|Experimental|ASP015K medium dose|
16671313|NCT02141425|Experimental|ASP015K high dose|Optional, depending on safety review and regulatory authority input
16671314|NCT02141425|Placebo Comparator|Placebo|
16671315|NCT02141412|Active Comparator|Group I|Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane
16671316|NCT02141412|Active Comparator|Group II|Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane
16671317|NCT02141412|Active Comparator|Group III|Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane
16671318|NCT02141412|Placebo Comparator|Group IV|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
16671319|NCT02141399|Experimental|ALKS 5461|
16671320|NCT02141386|Experimental|Treatment A|plasticity-based, adaptive, computerized cognitive remediation (PACR)
16671321|NCT02141386|Active Comparator|Treatment B|"Ordinary Computer Games (an active control condition)"
16671322|NCT02141373|Experimental|Glubran 2|Glubran 2 will be used at end of surgery
16671323|NCT02141373|No Intervention|Standard Surgery|
16671324|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
16671325|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
16671326|NCT02141347|Other|Part A|Dose escalation of tremelimumab mono therapy for advanced solid malignancies
16671327|NCT02141347|Other|Part B|Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies
16671328|NCT02141347|Other|Part C|Fixed dose of tremelimumab for malignant mesothelioma
16671329|NCT02141321|Experimental|Misoprostol|Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
16671330|NCT02141321|Placebo Comparator|Placebo|Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
16671331|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
16671332|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
16671333|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
16671334|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
16671335|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
16671336|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
16671337|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
16671338|NCT02141282|Experimental|ABT-199 after ibrutinib therapy|Single daily doses increasing weekly as tolerated
16671339|NCT02141282|Experimental|ABT-199 after ibrutinib or idelalisib therapy|Single daily doses increasing weekly as tolerated
16671340|NCT02141282|Experimental|ABT-199 after idelalisib therapy|Single daily doses increasing weekly as tolerated
16671342|NCT02141243|Experimental|Group A|"All participants will receive both the lingual frenotomy and sham procedure. Group A infants will receive lingual frenotomy for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.
~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.
~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).
~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and a laser, (iLaseTM 940 ± 15 nm) or scissors, will be used to release its attachment to the level of the periosteum."
16671343|NCT02141243|Experimental|Group B|"All participating infants will receive both the lingual frenotomy and sham procedure. Group B infants will receive the sham procedure for intervention #1 and a lingual frenotomy for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.
~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).
~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.
~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and an iLaseTM 940 ± 15 nm laser used to release its attachment to the level of the periosteum."
16671344|NCT02141230|Experimental|Alli® 60 mg|Participants purchasing Alli®
16671345|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
16671346|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
16671347|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
16671348|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
16671349|NCT02141191|Experimental|HS/sham|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
16671350|NCT02141191|Experimental|sham/HS|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
16671351|NCT02141178|Active Comparator|Bupivacaine|Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
16671352|NCT02141178|Experimental|Exparel|Patients will received Exparel subcutaneously for local anesthesia during surgery
16671353|NCT02141165|Experimental|Primary.|Diagnosis, autoCPAP, follow up.
16671354|NCT02141165|Active Comparator|Hospital|Diagnosis, autoCPAP, follow up
16671355|NCT02141152||gastric cancer|This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
16671356|NCT02141152||colorectal cancer|This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
16671357|NCT02141152||biliary tract cancer/pancreatic cancer|This study will recruit a total of 78 biliary tract cancer/pancreatic cancer patients. It is expected to recruit about 100 biliary tract cancer/pancreatic cancer patients per year. About 20% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 35% for the targeted group and about 5% for the untargeted group. With N=78 biliary tract cancer/pancreatic cancer patients, about 16 patients will belong to the targeted group and about 62 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
16671358|NCT02141152||Rare cancer|Rare cancer is hepatocellular carcinoma, melanoma and neuroendocrine tumor. This study will recruit a total of 87 hepatocellular carcinoma/rare cancer patients. It is expected to recruit about 150 biliary tract cancer/pancreatic cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 30% for the targeted group and about 5% for the untargeted group. With N=87 biliary tract cancer/pancreatic cancer patients, about 22 patients will belong to the targeted group and about 65 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 86% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
16671359|NCT02141152||genitourinary cancer|
16671360|NCT02141139|No Intervention|Control arm|no medication or acetaminophen
16671361|NCT02141139|Experimental|NSAIDS (ketorolac intravenous, ibuprofen)|ketorolac IV (just before surgery) and ibuprofen for 1 weeks
16671362|NCT02141126|Experimental|Resistance training|Usual care and resistance exercises.
16671363|NCT02141126|Other|Usual care|Usual inpatient physiotherapy
16672027|NCT02136823|Experimental|isradipine|5mg capsule, single oral dose, one day (single dose)
16671364|NCT02141113|Active Comparator|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)"
16671365|NCT02141113|Placebo Comparator|Sugar Pill Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)"
16671366|NCT02141100|Experimental|6-thioguanine, 6-mercaptopurine and methotrexate|"This is the only treatment arm; all eligible patients will receive standard methotrexate/6-mercaptopurine (6MP/MTX) maintenance therapy supplemented with 6-thioguanine (6TG).
~Patients are enrolled when they have 12 to 3.5 months remaining of their maintenance therapy. After dose reduction in 6MP to 2/3 of the current dose 6TG therapy is initiated with a starting dose of 2.5 mg/m2/day. The 6TG dose will hereafter be increased at 2.5 mg/m2/day every 14 days until a max. of 12.5 mg/m2/day is reached or until the thiopurine metabolite profile (Ery-TGN/Ery-MeMP) has been increased by at least a factor 5."
16671368|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation A (Treatment A)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
16671369|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation B (Treatment B)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
16671370|NCT02141048|Experimental|Positive Parenting Skills Training|Participants assigned to the intervention group will receive the Positive Parenting Skills Training.
16671371|NCT02141048|No Intervention|Wait-list control|Participants assigned to the wait-list control group will receive no intervention for the duration of this trial. Only after the one-year follow-up assessment has been completed will they receive the Positive Parenting Skills Training.
16671372|NCT02141035|Experimental|Acetyl-l-carnitine|Acetyl-l-carnitine will be administered for 2 months duration at a dosage of 3000 mg/d starting at the time of decompression surgery.
16671373|NCT02141035|Placebo Comparator|Placebo|Placebo will be given for 2 months starting at the time of decompression surgery
16671374|NCT02141022|Experimental|PACR Program: Plasticity based, Adaptive Cognitve Remediation|PACR Program Use: To use PACR, the participant navigates to the PACR study web site. The participant then logs into the PACR (using a study provided screen name and study identification number). A game-like experience begins, where the participant is presented with games in a set order. Each game consists of targeted exercises that contain the core science stimuli and tasks. The scheduling mechanism ensures that a participant progresses through the exercises in a defined order, generally moving from more simple (early sensory processing) exercises to more complex (multimodal, cognitive control) exercises over the course of the three-month experience.
16671375|NCT02141022|Active Comparator|Ordinary Computer Games|Active Control Program Use (Ordinary Computer Games): The active control program is composed of 13 ordinary computer games matched to the PACR condition overall. This condition is designed to be a face-valid approach to cognitive remediation. The control condition is also designed to account for nonspecific treatment effects, including placebo response, interactions with research personnel, and experience with computers and computer-related activities, and any halo or expectation effect on study assessments.
16671376|NCT02141009|Other|Prevnar 13|Prevnar 13, 1 administration of 1 single dose (0.5mL)
16671377|NCT02140996|Experimental|Ad-sig-hMUC-1/ecdCD40L vector vaccine|Experimental: Ad-sig-hMUC-1/ecdCD40L vector vaccine This trial has six cohorts with 3 subjects planned for each cohort. Subjects in the 1st cohort will receive 1 dose of vaccine injection at the lowest planned dose of the vector, 1 x 10^9 VP. If none of the patients in the 1st cohort experience Dose limiting toxicity (DLT), a 2nd cohort will receive 1 dose of 1x10^10 VP. If none of the patients in the 2nd cohort experience DLT, the dose escalation will continue with the 3rd cohort receiving 1 doses of 5 x 10^10 VP per injection. The patients in the 4th cohort will receive 1 injection of 1x10^11 if no DLT occurs in the preceding cohort. Additional patients will be added to cohort 5 or 6 if DLTs are encountered in the first 3 patients tested in each of these cohorts.
16671378|NCT02140983|Active Comparator|Liraglutide|90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
16671379|NCT02140983|Placebo Comparator|Placebo|90 days of placebo pen, up to 1.8mg/day.
16671380|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
16671381|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
16671382|NCT02140957|Experimental|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
16671383|NCT02140957|Placebo Comparator|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
16671384|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
16671385|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
16671386|NCT02140931|Active Comparator|Angiogenic Cell Precursors|Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg
16671387|NCT02140931|Placebo Comparator|Cell culture medium|Intra-muscular injections of cell culture medium in the ischemic leg
16671388|NCT02140918|Experimental|Fludrocortisone 100 μg|"100 μg/day (25 µg four times daily) of fludrocortisone during 5 days
~Investigations the sixth day"
16671389|NCT02140918|Experimental|Fludrocortisone 200 μg|"200 μg/day (50 µg four times daily) of fludrocortisone during 5 days
~Investigations the sixth day"
16671390|NCT02140918|Experimental|Fludrocortisone 400 μg|"400 μg/day (100 µg four times daily) of fludrocortisone during 5 days
~Investigations the sixth day"
16671391|NCT02140918|Placebo Comparator|Placebo|"Placebo (four times daily) during 5 days
~Investigations the sixth day"
16671392|NCT02140905||Patients undergoing hemodialysis.|Subjects participating in the study
16671394|NCT02140892|Experimental|respiratory physical therapy technique- IPV|respiratory physical therapy technique- Intrapulmonary Percussive Ventilation
16671395|NCT02140892|No Intervention|standart medical care|standard medical care
16671396|NCT02140879|Placebo Comparator|Capsule 1|Placebo is a mixture of corn and soy oils.
16671397|NCT02140879|Active Comparator|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
16671398|NCT02140866|Experimental|Hand Exercise|The intervention group will receive an exercise program for the hand/arm in combination with a compensatory intervention program (CIP).
16671399|NCT02140866|Active Comparator|Compensatory Intervention Program (CIP)|The control group will receive the Compensatory Intervention Program (CIP) only.
16671400|NCT02140853||MDR group|patients of MDR pathogen infection
16671401|NCT02140853||non-MDR group|patients of non-MDR pathogen infection
16671402|NCT02140827|Experimental|IMP education|patients in this group are educated about bowel preparation by instant messaging program and meanwhile a booklet was also sent to them.
16671403|NCT02140827|No Intervention|normal education|patients in this group are educated about bowel preparation on the day of reservation by nurse for about 15 minutes and meanwhile a booklet was also sent to them.
16671404|NCT02140814|Experimental|Niacinamide|All subjects in this study will take niacinamide at a dose of 30 mg per kilogram of body weight by mouth daily, in two divided daily doses, for 12 months.
16671405|NCT02140801|Experimental|Ticagrelor|Ticagrelor 90mg tablet, twice daily
16671406|NCT02140801|Experimental|Clopidogrel|Clopidogrel 75mg tablet, daily
16671407|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
16671408|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
16671409|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
16671410|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
16671411|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
16671412|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
16671413|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
16671414|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
16671415|NCT02140749|Experimental|sc-FOS 2g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)
16671416|NCT02140749|Experimental|sc-FOS 4g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)
16671417|NCT02140749|Experimental|sc-FOS 8g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)
16671418|NCT02140736||Patients with chemo-induced symptomatic anemia|
16671419|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
16671420|NCT02140710|Active Comparator|Osteopathic treatment group|visceral osteopathic treatment algorithm
16671421|NCT02140710|No Intervention|Control group|no intervention
16671422|NCT02140697|Experimental|Hippophae rhamnoides L. Leaf Extract|Hippophae rhamnoides L. Leaf Extract 3g/day
16671423|NCT02140697|Placebo Comparator|Placebo|Placebo 3g/day
16671424|NCT02140684||eNO monitoring|Patients undergoing eNO monitoring at the index prescription date
16671425|NCT02140684||No eNO monitoring|
16671426|NCT02140671||Patients with an asthma diagnosis|
16671427|NCT02140671||Patients where there is diagnostic doubt|
16671428|NCT02140658|Active Comparator|multiple health education interventions|The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
16671429|NCT02140658|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
16671430|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
16671431|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
16671432|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
16671433|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
16671434|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
16671435|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
16671436|NCT02140632|Experimental|Local steroid injection|"The local injection of steroid is performed by the same investigator after the randomization. Using a sterile technique, 20mg methylprednisolone acetate premixed with lidnocaine is injected using a 25-gauge x 5/8 needle. The needle is inserted medially to the palmaris longus tendon at the distal palmar crease in the wrist at an angle of 45-degree to the forearm. The steroid is injected at approximately 1cm below the skin. The needle will be repositioned if there is any resistance to injection, or any pain or paraesthesia in the median nerve territory."
16671437|NCT02140632|Active Comparator|Wrist splinting|After randomization, the hands of the patients in the splinting group are splinted in neutral position with standard cotton-polyester splint. Patients are encouraged to use the splints during nighttime whenever possible for one month.
16671438|NCT02140619|Active Comparator|multiple health education interventions|The group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 1 year after discharge.
16671439|NCT02140619|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
16671440|NCT02140606|Experimental|Cafusertib Hydrochloride + Cytarabine|Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
16671441|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
16671442|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
16671443|NCT02140580|Active Comparator|Minimally invasive surfactant therapy|Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.
16671444|NCT02140580|Sham Comparator|Continuation on CPAP|Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.
16671445|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
16671446|NCT02140554|Experimental|Group A|"Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
~*No Longer Recruiting"
16671447|NCT02140554|Experimental|Group B|"Group B1:
~Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
~*No Longer Recruiting
~Group B2:
~Plerixafor mobilization and apheresis will be used for collection of rescue cells and exploratory manufacturing development. Subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
~*No Longer Recruiting"
16671448|NCT02140554|Experimental|Group C|Plerixafor mobilization and apheresis will be used for collection of rescue cells, and subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by plerixafor mobilization and apheresis transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
16671449|NCT02140541||Blood eosinophil count ≤ 400/µl|
16671450|NCT02140541||Blood eosinophil count > 400/µl|
16671451|NCT02140528|Experimental|Mesenchymal stem cell receipients|Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.
16671452|NCT02140528|Placebo Comparator|Placebo|Placebo injection in the site of fracture in patients with tibia fracture.
16671453|NCT02140515|Active Comparator|Luveris|Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
16671454|NCT02140515|Active Comparator|Gonal-F& Luveris|Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
16671455|NCT02140502||Men undergoing prostate biopsy|
16671456|NCT02140489|Experimental|Sequence 1|amosartan → rosuvastatin → amosartan and rosuvastatin
16671457|NCT02140489|Experimental|Sequence 2|rosuvastatin → amosartan and rosuvastatin → amosartan
16671458|NCT02140489|Experimental|Sequence 3|amosartan and rosuvastatin → amosartan → rosuvastatin
16671459|NCT02140476|Experimental|Thyroid Goiter|Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
16671460|NCT02140476|Active Comparator|Papillary Thyroid Cancer|Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.
16671461|NCT02140463||metastatic cancer|metastatic gastrointestinal cancer metastatic genitourinary cancer other rare cancer lung cancer
16671462|NCT02140450|Active Comparator|Timolol|Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
16671463|NCT02140450|Active Comparator|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
16671464|NCT02140450|Active Comparator|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
16671465|NCT02140450|Active Comparator|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
16671466|NCT02140450|Sham Comparator|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
16671467|NCT02140437|Experimental|Fulvestrant and anastrozole|Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
16671468|NCT02140437|Active Comparator|Anastrozole|Anastrozole 1 mg PO QD
16671469|NCT02140424||youth with type 1 diabetes|
16671470|NCT02140424||healthy controls|
16671471|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
16671472|NCT02140398|Experimental|Currettage|Endometrial Currettage (endometrial scrapping) will be performed at the time of laparoscopic ovarian drilling
16671473|NCT02140398|No Intervention|Nothing|No endometrial curettage at time of Laparoscopic ovarian drilling
16672028|NCT02136823|Experimental|memantine|5mg tablet, single oral dose, one day (single oral dose)
16671474|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia preservation|Scarpa's fascia preservation Lymphoscintigraphy 3D imaging Abdominal ultrasound
16671475|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia ablation|Scarpa's fascia ablation Lymphoscintigraphy 3D imaging Abdominal ultrasound
16671476|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
16671477|NCT02140359|No Intervention|Control Group: Usual Care|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet with case managers according to the usual procedures for new residents and will be given a standard case manager interaction.
16671478|NCT02140359|Experimental|Motivational Network Interview Recipients|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
16671479|NCT02140346|Experimental|28 day repeat dose (low dose)|
16671480|NCT02140346|Experimental|28 day repeat dose (high dose)|
16671481|NCT02140333|Experimental|Erlotinib 100mg|Erlotinib 100mg
16671482|NCT02140333|Active Comparator|Erlotinib 150mg|Erlotinib 150mg
16671483|NCT02140320|Experimental|Single dose (healthy volunteers)|
16671484|NCT02140320|Experimental|14 day repeat dose (healthy volunteers)|
16671485|NCT02140320|Experimental|14 day repeat dose (asthma patients)|
16671486|NCT02140320|Experimental|28 day repeat dose (healthy volunteers)|
16671487|NCT02140307|Experimental|Meditation training, group format|"The course Relaxation Response-based Mental Health Promotion (publicly referred to as Open and Calm) is given in group format.
~The intervention entails 9 courses (1 per week of 2.5 hrs), a course book (120 pages), audio support (6 guided meditative practices), access to a webpage with additional information, and the possibility of two personal sessions with the intervention instructor (a certified psychologist)."
16671488|NCT02140307|Active Comparator|Meditation training, individual format|"The course Relaxation Response-based Mental Health Promotion (Open and Calm) is given by the same instructor as for group formats using precisely the same material and methods, but in about 6-9 (as to each persons' individual needs and preferences) face-to-face meetings."
16671489|NCT02140307|No Intervention|Wait-list control|This arm is an inactive wait-list control.
16671490|NCT02140294|Experimental|Polymeric nutritional supplement|
16671491|NCT02140294|Active Comparator|Standard Nutritional Treatment|
16671492|NCT02140281|Experimental|Sequence 1 (Treatment A/B)|Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2
16671493|NCT02140281|Experimental|Sequence 2 (Treatment B/A)|Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2
16671494|NCT02140268|Active Comparator|Midazolam 7.5 mg|Volunteers will receive Midazolam 7.5 mg administered by mouth as a syrup
16671495|NCT02140268|Experimental|AZD1722 15 mg|Volunteers will received AZD1722 15 mg administered by mouth, as a tablet
16671496|NCT02140268|Experimental|AZD1722 15 mg and Midazolam 7.5 mg|Volunteers will receive AZD1722 15 mg tablet and Midazolam 7.5 mg syrup, by mouth
16671497|NCT02140255|Experimental|Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
16671498|NCT02140255|Experimental|Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
16671499|NCT02140255|Experimental|Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
16671500|NCT02140255|Experimental|Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
16671501|NCT02140255|Experimental|Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01|Participants will receive 2 NRTIs + NVP + RAL + VRC01.
16671502|NCT02140242|Active Comparator|daunorubicin 60 mg/m2|study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5
16671503|NCT02140242|Active Comparator|Double induction|study part 2: induction cycles double induction (only patients with good response)
16671504|NCT02140242|Experimental|Single induction|study part 2: induction cycles single induction (only patients with good response)
16671505|NCT02140229|Active Comparator|Usual care|Usual care and follow-up every 3 months
16671506|NCT02140229|Experimental|US-driven therapy|Clinical evaluation according to DAS28 + US every 3 months
16671507|NCT02140229|Active Comparator|ACR/EULAR remission criteria-driven therapy|Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months
16671508|NCT02140216||Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
16671509|NCT02140216||Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
16671510|NCT02140216||No blood transfusion|Patients undergoing elective spine surgery receiving no blood transfusion.
16671511|NCT02140203|Active Comparator|Young Yoga Group|People who are younger than 60 year-old They have received Yoga training in one-year experimental period
16671512|NCT02140203|No Intervention|Young Control Group|People who are younger than 60 year-old No Yoga training through out the one-year experimental period
16671513|NCT02140203|No Intervention|Aged Control Group|People who are equal or older than 60 year-old They have not received any yoga training during the one-year experimental period
16671514|NCT02140203|Active Comparator|Aged Yoga Group|People who are equal or older than 60 year-old They have received any yoga training during the one-year experimental period
16671515|NCT02140177||Adult Medical Inpatients|Adult medical inpatients; We will enroll adult patients, ages 18 years and older, admitted to identified inpatient medical units during designated data collections days.
16671516|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
16671517|NCT02140151|No Intervention|Sham|Sham Injection
16671518|NCT02140151|Active Comparator|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
16671519|NCT02140138|Experimental|Arm A (i.d. vaccinations with needle free injection device)|"Duration: Patients in Arm A will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.
~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).
~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.
~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
16671520|NCT02140138|Experimental|Arm B (i.d. vaccination by conventional injection)|"Duration: Patients in Arm B will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.
~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).
~Administration site: Skin of the medial part of the upper arms and thigh
~Dose: 2 x 160 μg mRNA per injection (2 x 200 μL), equals 320 μg mRNA per RNActive® drug product component"
16671521|NCT02140138|Other|Arm C (i.d. vaccination with needle free injection device)|"Duration: Patients in Arm C will receive no vaccination before radical prostatectomy. After surgery high risk or very high risk patients will be offered to receive 6 vaccinations with CV9104 at week 8, 9, 10, 12, 14 and 16 after surgery.
~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).
~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.
~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
16671522|NCT02140125|Experimental|ASP2408 low dose group|
16671523|NCT02140125|Experimental|ASP2408 middle dose group|
16671524|NCT02140125|Experimental|ASP2408 high dose group|
16671525|NCT02140125|Placebo Comparator|Placebo group|
16671526|NCT02140112|Active Comparator|Trichuris suis ova|TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
16671527|NCT02140112|Placebo Comparator|Placebo|Placebo 8 doses every 2 weeks
16671528|NCT02140099|Experimental|Healthy Relationships Education/Skills|The experimental intervention is the group-based, 15-session Healthy Relationships Plus Program (HRPP). In this study, the HRPP will be offered in a condensed 8-day format (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the program for 2 hours, and on day 8, participants will attend the program for 1 hour. The program will be facilitated by high school teachers. Eight HRPP groups will run concurrently during the study period.
16671529|NCT02140099|Other|Classroom Activities|The control condition is a group-based, 15-session program focusing on typical Classroom Activities. The primary activity is to create a school welcome packet for incoming Grade 9 students, with other activities including reading and physical exercise. The control condition will be offered on 8 consecutive weekdays (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the control program for 2 hours, and on day 8, participants will attend the control program for 1 hour. The control group will be facilitated by bachelor's level research assistants and pre-service teachers. Eight control groups will run concurrently during the study period.
16671530|NCT02140086|Experimental|Buteyko based Remedial Breathing Therapy|Buteyko based Remedial Breathing Therapy
16671531|NCT02140086|No Intervention|Waiting List|Training in the course of the study
16671532|NCT02140073|Experimental|omeprazole+domperidone SR|patients with GERD receive omeprazole 20mg + domperidone SR 30mg , 2 capsules in the morning
16671533|NCT02140073|Active Comparator|omeprazole|omeprazole 40mg in the morning
16671534|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
16671535|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
16671536|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
16671537|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
16671538|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
16671539|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
16671540|NCT02140047|Experimental|MT-2301-Low|
16671541|NCT02140047|Experimental|MT-2301-High|
16671542|NCT02140047|Active Comparator|ActHib|
16671543|NCT02140034|Experimental|Study Arm: Extensive Peritoneal Lavage|The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
16671544|NCT02140034|No Intervention|Control Arm: Standard Treatment|The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
16671545|NCT02140021|Experimental|Screening (biospecimen collection)|Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
16671546|NCT02140008|Experimental|I-gel group|
16671547|NCT02140008|Active Comparator|Air-Q group|
16671548|NCT02139995|Experimental|Transfusion trigger based on WCTS-CP|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP
16671549|NCT02139995|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience
16671550|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
16671551|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
16671552|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
16671553|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
16671554|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
16671555|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
16671556|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
16671557|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
16671558|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
16671559|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
16671560|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
16671561|NCT02139956||stress urinary incontinence|group 1 women with stress urinary incontinence by ultrasonography
16671562|NCT02139956||continent group|group 2 women without stress urinary incontinence by ultrasonography
16671563|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
16671564|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
16671565|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
16671566|NCT02139930|Active Comparator|Normal Nicotine Control Group|These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
16671567|NCT02139930|Experimental|Immediate Nicotine Reduction Group|This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
16671568|NCT02139930|Experimental|Gradual Nicotine Reduction Group|This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
16671569|NCT02139917|Experimental|Transitional Palliative Care|"Transitional palliative care include:-
~telephone follow up for early identification of signs and symptoms
~home visit for spiritual support"
16671570|NCT02139917|No Intervention|Customary care|"Customary care receive care :-
~hospital based medical follow up
~general nursing assessment and advice"
16671571|NCT02139904|Placebo Comparator|Active Symptom Control|Active symptom control includes palliative care and standard care methods used to manage symptoms
16671572|NCT02139904|Active Comparator|Vinorelbine|Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
16671573|NCT02139891|Experimental|"MultiPoint Pacing On"|Patients will be randomized to the MPP-ON Arm vs MPP-OFF in in crossover fashion with 3 months in each period.
16671574|NCT02139891|Active Comparator|"MultiPoint Pacing Off"|Patients will be randomized to the MPP-OFF arm vs MPP-ON in crossover fashion with 3 months in each period.
16671575|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
16671576|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
16671577|NCT02139865|Experimental|30%|Training at 30% 1RM
16671578|NCT02139865|Experimental|80%|Training at 80% 1RM
16671579|NCT02139852|Experimental|capsaicin|Capsaicin
16671580|NCT02139852|Placebo Comparator|Placebo|
16671581|NCT02139839|Placebo Comparator|Gelatin pill first|
16671582|NCT02139839|Experimental|Lactobacillus capsules first|
16671583|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
16671584|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
16671585|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
16671586|NCT02139813|Experimental|Laparoscopic Omega Loop Bypass|Laparoscopic Mini-gastric bypass
16671587|NCT02139813|Active Comparator|Laparoscopic Roux-en-Y Gastric ByPass|Procedure of reference in bariatric surgery
16671588|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
16671589|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
16671590|NCT02139787|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing hypertension or obesity through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
16671591|NCT02139787|Active Comparator|Control -listened to a brochure|Participants received an audio version of a standard brochure about hypertension or obesity prevention.
16671592|NCT02139774||Active Survelliance|Men age 65 and older who are undergoing active surveillance as primary treatment for their prostate cancer.
16671593|NCT02139774||Radiation|Men age 65 and older who are undergoing radiation only as primary treatment for their prostate cancer.
16671594|NCT02139774||Endocrine Therapy|Men age 65 and older who are undergoing endocrine therapy as primary treatment for their prostate cancer.
16671595|NCT02139774||Surgery|Men age 65 and older who are undergoing surgery as primary treatment for their prostate cancer.
16673565|NCT02126761|Active Comparator|Group 1|aTIV
16671596|NCT02139761|Active Comparator|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
16671597|NCT02139761|Placebo Comparator|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
16671598|NCT02139748|Active Comparator|Dental Implant & ADM|Dental implant placement plus simultaneous grafting use one layer of ADM.
16671599|NCT02139748|Experimental|Dental Implant & ADM & bone xenograft|Dental implant placement plus simultaneous grafting use one layer of ADM with bovine xenograft.
16671600|NCT02139735|Experimental|Ultrasound|3 MHz (Mega Hertz) ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ (Temporomandibular joint) and masseter muscles bilaterally
16671601|NCT02139735|Experimental|Ultrasound associated with stretchting|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally.
~Active stretching of the masseter muscles with mouth opening and closed lips"
16671602|NCT02139735|Experimental|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
16671603|NCT02139722|No Intervention|Provider Panel Notification (PPN) Alone|The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
16671604|NCT02139722|Experimental|Video Doctor, PA + PPN|Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
16671605|NCT02139709|Experimental|Ganglioside|1.0 gram ZETA dairy lipid powder (Fonterra NZ)
16671606|NCT02139709|Placebo Comparator|Placebo|1.0 gram milk fat fraction void of ganglioside
16671607|NCT02139696||MS patients initiating fingolimod|Patients will be imaged using PET and MRI at baseline, and twice during treatment.
16671608|NCT02139683|Experimental|HIFU treatment|HIFU treatment in patient diagnosed with fibroadenoma
16671609|NCT02139670||pregnant womens|
16671610|NCT02139657|Experimental|RIG-C|Single 20 IU/kg dose of RIG-C by intramuscular injection
16671611|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16671612|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16671613|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16671614|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16671615|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
16671616|NCT02139631|Experimental|Healthy volunteers|The volunteers initially underwent a clinical examination, spirometry and echocardiography to prove the health state. Then, different levels of positive end expiratory pressure (PEEP) is applied by the noninvasive ventilation in all individuals and the hemodynamic repercussions are evaluated by the doppler echocardiography
16671617|NCT02139618|Experimental|Methyl Aminolevulinate (MAL)|1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
16671618|NCT02139618|Placebo Comparator|Placebo|1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
16671619|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
16671620|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
16671621|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
16671622|NCT02139579|Experimental|Avastin|bevacizumab 7.5mg/kg+paclitaxel 200mg/m2＋carboplatin area under curve(AUC)=6, every 3 weeks，maximum 4 cycles
16671623|NCT02139566|Experimental|Hi-tech video consent|This group will be shown a professionally animated video that presents the major components of the informed consent document. Intervention is Video Consent (high-tech) PDF informed consent document.
16671624|NCT02139566|Experimental|Low-tech video consent|"Participants in this arm will be provided with informed consent information through viewing a talking head video produced by a non-professional presenter, with widely available and inexpensive video equipment. Intervention is video consent (low-tech), PDF informed consent document."
16671625|NCT02139566|Experimental|FAQ consent|"Participants in this arm will be provided with informed consent content through an interactive frequently asked questions format, in which the participant will click on a question and be shown text that provides an answer to that question. Major informed consent topics will have one or more question and answer pairs. Intervention is FAQ format consent, PDF informed consent document"
16671626|NCT02139566|Active Comparator|Standard consent process|Participants in this arm will be provided with informed consent content by being shown a standard informed consent document in a scrolling window within the browser window, PDF informed consent document
16671627|NCT02139553|Experimental|Rhythmic rehabilitation|Patients undergo a first evaluation, and a second evaluation one month later to determine their natural evolution. The following month, patients get 12 sessions of rhythmic therapy. A third evaluation is organized straight after this month and a fourth evaluation, 3 months after to assess the after-effects of the therapy.
16671628|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
16671629|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
16671630|NCT02139514|Active Comparator|Virtual Reality Social Cognition Training|Virtual Reality Social Cognition Training
16671631|NCT02139514|No Intervention|Control|Participants in the Control condition will be offered treatment following the Control condition.
16671632|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 14 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days
16671633|NCT02139501|Experimental|rhTPO, 300Units/kg ,one times every other day for 7 times|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times.
16671634|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 7 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days.
16671635|NCT02139488||neoadjuvant or definitive chemoradiation|Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
16671636|NCT02139475||Colonoscopy|patients undergoing colonoscopy after colorectal cancer surgery
16671637|NCT02139462|Experimental|Standard training|Therapists will receive standard training in FBT.
16671638|NCT02139462|Experimental|Novel training|Therapists will receive a novel, more efficient training in FBT
16671639|NCT02139449||ICD/CRT registry|ICD / CRTregistry in Severance or Ewha Womans University Medical Center
16671640|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
16671641|NCT02139436|Other|Wait-list time control|Subjects will wait for 6 months before performing 6 months of FES-row-training.
16671642|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training followed by 6 months of FES-row-training
16671643|NCT02139423|Experimental|All newborns who fail universal newborn|CMV PCR
16671644|NCT02139410||IGF-1 1st and 2nd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
16671645|NCT02139410||IGF-1 3rd and 4rd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
16671646|NCT02139397|Experimental|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
16671647|NCT02139371|Experimental|64Cu-DOTA-AE105 PET|One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection
16671648|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
16671649|NCT02139345|Experimental|TC-A PS|Subject will be implanted with the TC-A PS Total Knee Replacement System
16671650|NCT02139345|Active Comparator|TC-PLUS Solution PS|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
16671651|NCT02139332|Active Comparator|Resource & Referral group|Individuals randomized to the control group will receive a resource & Referral service immediately after their baseline research visit.
16671652|NCT02139332|Experimental|PFR Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
16671653|NCT02139319|Experimental|Botulinum toxin|Single intra-articular injection
16671654|NCT02139319|Placebo Comparator|Placebo|Single intra-articular injection
16671655|NCT02139306|Experimental|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
16671656|NCT02139306|Placebo Comparator|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
16671657|NCT02139293|Experimental|auricular vagus nerve stimulation|"Study participants (healthy) are treated with auricular vagus nerve stimulation using five needle electrodes connected to an electrical stimulation device (PrimeStim). After acclimatization the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and 10 minutes paused stimulation. This intervention is repeated on four consecutive days, whereas at each intervention only one of the four stimulation points (and one fixed reference point) is stimulated. Needle electrodes are applied at each study visit.
~Stimulation points in the auricle are stimulated in random order. One stimulation pattern is tested. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.
~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
16671658|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
16671761|NCT02138617|Experimental|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
16672029|NCT02136823|Experimental|therapeutic stretching|Manual therapeutic stretching of tested muscle by licensed clinician
16671659|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
16671660|NCT02139267|Experimental|1mg of GX-188E per dose|1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
16671661|NCT02139267|Experimental|4mg of GX-188E per dose|4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
16671662|NCT02139254||Low risk|Pregnant women with a low risk for metabolic diseases
16671663|NCT02139254||High risk|Pregnant women with a high risk for metabolic diseases
16671664|NCT02139241|Experimental|Ramosetron|Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia
16671665|NCT02139241|Placebo Comparator|Control|Intravenous administration of 2ml normal saline before the induction of general anesthesia
16671666|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).
~No vaccine was administered during this trial"
16671667|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).
~No vaccine was administered during this trial"
16671668|NCT02139202|Other|Full Program|"The intervention will (1) use the GlowCaps, a remote monitoring and reminder pill bottle; (2) be assigned an engagement advisor from the study team; (3) be asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence for the first three months; and (5) will determine their preferences for Way to Health platform communication methods during the study.
~The group receiving the program intervention will also have their claims data analyzed for the 1 months post-enrollment."
16671669|NCT02139189|Experimental|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
16671670|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
16671671|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
16671672|NCT02139163||patients with pneumonia|
16671673|NCT02139150|Experimental|Serial FLT PET Imaging|"Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma)."
16671674|NCT02139137|Experimental|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
16671675|NCT02139137|Active Comparator|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
16671676|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
16671677|NCT02139124|Experimental|PRC-063 25 mg|PRC-063 25 mg
16671678|NCT02139124|Active Comparator|PRC-063 45 mg|PRC-063 45 mg
16671679|NCT02139124|Active Comparator|PRC-063 70 mg|PRC-063 70 mg
16671680|NCT02139124|Active Comparator|PRC-063 100 mg|PRC-063 100 mg
16671681|NCT02139111|Placebo Comparator|Placebo|Placebo Arm
16671682|NCT02139111|Active Comparator|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
16671683|NCT02139111|Active Comparator|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
16671684|NCT02139111|Active Comparator|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
16671685|NCT02139111|Active Comparator|PRC-063 85 mg and Placebo|PRC-063 85 mg and placebo capsule by mouth once daily
16671686|NCT02139098|Experimental|Amitriptyline flexible dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
16671687|NCT02139098|Experimental|Zolpidem flexible dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
16671688|NCT02139098|Active Comparator|Amitriptyline fixed dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
16671689|NCT02139098|Active Comparator|Zolpidem fixed dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
16671690|NCT02139098|Active Comparator|Amitriptyline continuous dosing|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
16671691|NCT02139085|Active Comparator|GSV Electrocoagulation|GSV Electrocoagulation Source: Electrosurgical Generator(FX-Valley Lab; USA) Energy: 60 Watts x 10 seconds
16671692|NCT02139085|Active Comparator|GSV Radiofrequency|GSV Radiofrequency Source: Closure FAST(Covidien, USA) Energy: 60 Joules / cm
16671693|NCT02139072||CoaguChek XS|INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
16671694|NCT02139072||Standard Lab Draw|INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
16671695|NCT02139059|Active Comparator|initial urinary drainage|initial urinary drainage to stabilize renal functions before ureteroscopy
16671696|NCT02139059|Active Comparator|direct ureteroscopy|direct ureteroscopy without initial urinary drainage
16671839|NCT02138097||Linagliptin|
16671697|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16671698|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16671699|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16671700|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16671701|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16671702|NCT02139033|Experimental|Arm 1|Retain 1-2 drops, bilaterally, BID
16671703|NCT02139020||No treatment|"Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples:
~Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al [11]
~Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. [10]
~Group 3 = patients treated with a molecular targeted agent as a part of a clinical study"
16671704|NCT02139007|Active Comparator|Continuation Arm|Alendronate continuation arm
16671705|NCT02139007|Active Comparator|Discontinuation Arm|Alendronate discontinuation arm
16671706|NCT02138994|Active Comparator|Triple Antibiotic Ointment Neosporin|Daily direct application to the wound, covered with conventional dressing. Dressing should be changed daily or as directed by the health care provider.
16671707|NCT02138994|Experimental|Next Science Wound Gel|Daily direct application to the wound, covered with a conventional non-alginate dressing. Dressing should be changed daily or as directed by the health care provider.
16671708|NCT02138981|Active Comparator|Immediate Resection|patients received immediate surgical hepatic resection
16671709|NCT02138981|Experimental|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
16671710|NCT02138968|Experimental|Multidimensional intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
16671711|NCT02138968|No Intervention|Usual care|Usual care
16671712|NCT02138955|Experimental|Liposomeal curcumin ascending dose phase 1b|
16671713|NCT02138942|Experimental|The study population|"See inclusion/exclusion criteria.
~Intervention: LIR"
16671714|NCT02138929|Experimental|Everolimus + LDE 225|"Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.
~Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days."
16671715|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
16671716|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
16671717|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
16671718|NCT02138903||ZEEP and tubing-spontaneous ventilation|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
16671719|NCT02138903||trans-thoracic echocardiography|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
16671720|NCT02138890|Experimental|APS injection|Autologous Protein Solution
16671721|NCT02138890|Placebo Comparator|Control|Saline
16671722|NCT02138877|Active Comparator|After coming stent|Dismembered pyeloplasty with insertion of an after coming stent
16671723|NCT02138877|Active Comparator|Stentless|Stentless dismembered pyeloplasty
16671724|NCT02138864|Experimental|18F-FP-(+)-DTBZ only|PET tracer: 18F-FP-(+)-DTBZ
16671725|NCT02138851|Experimental|Ficus Carica|Ficus Carica 300g/day
16671726|NCT02138851|Placebo Comparator|Placebo|Placebo 300g/day
16671727|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
16671728|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
16671729|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
16671840|NCT02138097||Meglitinides|
16671841|NCT02138097||Metformin|
16671730|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
16671731|NCT02138812|Experimental|BAY1161909 + Paclitaxel|Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.
16671732|NCT02138799|Experimental|1: single dose of enzalutamide|
16671733|NCT02138799|Experimental|2: multiple doses of rifampin and single dose of enzalutamide|
16671734|NCT02138786|Experimental|selinexor|"oral tablets
~10 mg & 25 mg (bottled); or
~20 mg (blister pack)"
16671735|NCT02138773|Experimental|Fed, formulation-A|drug administered at 0.5h after the start of a standard breakfast
16671736|NCT02138773|Experimental|Fed, formulation-B|drug administered at 0.5h after the start of a standard breakfast
16671737|NCT02138773|Experimental|Fasted, formulation-A|drug administered under fasted condition (fasting for at least 10 hours)
16671738|NCT02138773|Experimental|Fasted, formulation-B|drug administered under fasted condition (fasting for at least 10 hours)
16671739|NCT02138760|No Intervention|MRI guided cognitive fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional cognitive (freehand) biopsies of MRI suspicious targets
16671740|NCT02138760|Experimental|UroNav fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional UroNav fusion biopsy of MRI suspicious targets
16671741|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
16671742|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
16671743|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
16671744|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
16671745|NCT02138734|Experimental|N-803+BCG|(Phase Ib and IIb) for BCG-naive patients
16671746|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
16671747|NCT02138721|No Intervention|No local treatment|Routine care in metastatic prostate cancer.
16671748|NCT02138721|Experimental|Local treatment|Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
16671749|NCT02138708|Experimental|Shunt closed|patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
16671750|NCT02138695||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
16671751|NCT02138682||l-123 Ioflupane|Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.
16671752|NCT02138669|Other|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
16671753|NCT02138656|Active Comparator|Best standard care only - not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.
~Parents aware that infant is not receiving chiropractic treatment"
16671754|NCT02138656|Sham Comparator|Best Standard Care and Sham - Blind|Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
16671755|NCT02138656|Experimental|BSC & Chiropractic - Not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.
~Parents aware that infant is receiving chiropractic treatment."
16671756|NCT02138656|Experimental|BSC & Chiropractic - Blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.
~Parents not aware that infant is receiving chiropractic treatment."
16671757|NCT02138643|Active Comparator|Endoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
16671758|NCT02138643|Sham Comparator|Laparoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
16671759|NCT02138630|Placebo Comparator|Placebo|
16671760|NCT02138630|Experimental|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
16671842|NCT02138097||Non-insulin injectables|
16671843|NCT02138097||Saxagliptin|
16671844|NCT02138097||Sitagliptin|
16671762|NCT02138617|Experimental|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
16671763|NCT02138617|Experimental|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
16671764|NCT02138591|Experimental|Vitamin D3|"Vitamin D3 (cholecalciferol) 50,000 IU by mouth daily for each of the five days prior to surgery.
~Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2"
16671765|NCT02138591|Placebo Comparator|Placebo pill|Placebo pill by mouth daily for each of the five days prior to surgery. Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2
16671766|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
16671767|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
16671768|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
16671769|NCT02138565|Experimental|Bariatric surgery|
16671770|NCT02138552|Active Comparator|OCT 0.1% vs. Placebo|0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
16671771|NCT02138552|Active Comparator|OCT 0.15% vs. Placebo|0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
16671772|NCT02138552|Active Comparator|OCT 2.0% vs. Placebo|0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
16671773|NCT02138539|Active Comparator|4% Hydroquinone|4% hydroquinone applied to one side of the face.
16671774|NCT02138539|Experimental|Herbal depigmenting agent|Herbal depigmenting agent applied on the other side of the face.
16671775|NCT02138526|Active Comparator|fasted|Intake of pazopanib in agreement with drug label - fasted state
16671776|NCT02138526|Experimental|Continental breakfast|Intake of a reduced equivalent pazopanib dose with a continental breakfast
16671777|NCT02138513|Experimental|Online MBCT|
16671778|NCT02138513|Experimental|group MBCT|
16671779|NCT02138513|No Intervention|Treatment as usual|3 months waiting list, subsequent assignment to group or online MBCT
16671780|NCT02138500|Experimental|Cohort 1: PF-06372865 10 mg|
16671781|NCT02138500|Experimental|Cohort 2: PF-06372865 TBD dose|
16671782|NCT02138500|Experimental|Cohort 3: PF-06372865 TBD dose|
16671783|NCT02138487|Active Comparator|Restricted postoperative activity|"Women in the restricted postoperative activity group must abstain from exercise and heavy lifting for 3 months postoperatively"
16671784|NCT02138487|Experimental|Liberal postoperative activity|"Women in the liberal postoperative activity group will be allowed to resume their normal activities without restriction."
16671785|NCT02138474|Experimental|Lacticum acidum homaccord|Lacticum acidum homaccord 30 mL bottle of medicated sucrose pillules take 5 pillules of the medication in the morning and in the evening for 4 weeks
16671786|NCT02138474|Placebo Comparator|Placebo|Unmedicated sucrose pillules, take 5 pillules twice daily for 4 weeks
16671787|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
16671788|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
16671789|NCT02138448|Experimental|Intervention practices|Intervention practices will implement an interactive preventive health record in addition to their standard personal health record functionality.
16671790|NCT02138448|No Intervention|Control practices|Control practices will continue to field their existing personal health record
16671791|NCT02138435||VSD-patients|Patients who had VSD closure between 1990 and 1995. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
16671792|NCT02138435||Control|A group of healthy control subjects. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
16671793|NCT02138422|Placebo Comparator|Placebo|Placebo administered intravenously every 2 weeks
16671794|NCT02138422|Active Comparator|Xilonix|Xilonix administered intravenously every 2 weeks
16671795|NCT02138409|Experimental|ON FSS 100 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 100 µg
16671796|NCT02138409|Experimental|ON FSS 200 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 200 µg
16671797|NCT02138409|Experimental|OE FSS 400 µg|Participants classified as opioid-experienced (OE), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, at a dose of 400 µg
16671798|NCT02138409|Placebo Comparator|ON PSS|Participants classified as opioid-naïve (ON) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
16671799|NCT02138409|Placebo Comparator|OE PSS|Participants classified as opioid-experienced (OE) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
16671800|NCT02138396|Experimental|FSS first, then FCI|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit. After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit.
16671845|NCT02138097||Sulfonylurea|
16671846|NCT02138084|Experimental|Cohort 1: BMS-663068 + Rifabutin|"Regimen A: BMS-663068 tablet by mouth as specified
~Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified"
16671801|NCT02138396|Experimental|FCI first, then FSS|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit. After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit.
16671802|NCT02138383|Experimental|Dose Escalation and Dose Expansion|"Dose Escalation: To find the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
~Dose Expansion: To find the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel."
16671803|NCT02138370||stage II and III colorectal cancer|
16671804|NCT02138357|Placebo Comparator|Placebo Patch|"The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.
~Each subject will participate in this arm of the study for four weeks."
16671805|NCT02138357|Experimental|buprenorphine transdermal delivery system (BTDS)|"buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.
~Each subject will participate in this arm of the study for four weeks."
16671806|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
16671807|NCT02138344||Healthy control subjects|
16671808|NCT02138344||Subjects with peripheral nerve diseases|
16671809|NCT02138331|Experimental|Exosomes|The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nm. Some of these RNAs are microRNAs that are predominantly pre-microRNAs..Additionally, CB-SC displayed very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.
16671810|NCT02138318|Other|chromoendoscopy|
16671811|NCT02138318|Other|High definition (HD) endoscopy|
16671812|NCT02138305|Other|Patients referred for CABG|"Patients who after undergoing standard of care diagnostic coronary angiography will be referred for CABG
~ComboMap XT Guidewire
~'SPY' NIRF During CABG"
16671813|NCT02138292|Experimental|Trametinib (2mg)/Digoxin (0.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.
~Digoxin (0.25mg) will be administered orally on a daily basis.
~On a 8-week cycle, duration of treatment can last from 8 to 104 weeks."
16671814|NCT02138279||Male and female adults 18+ years of age|
16671815|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
16671816|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
16671817|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
16671818|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
16671819|NCT02138253|Placebo Comparator|Placebo|Placebo BID
16671820|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
16671821|NCT02138227|Active Comparator|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
16671822|NCT02138227|Active Comparator|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
16671823|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
16671824|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
16671825|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
16671826|NCT02138201||control|individuals with normal bladder function
16671827|NCT02138201||neurogenic bladder|individuals suffering from neurogenic lower urinary tract dysfunction
16671828|NCT02138188||T1D patients on CSII|Patients affected by Type 1 Diabetes on insulin pump therapy
16671829|NCT02138175||Patients at risk for bleeding|Patients at risk for bleeding
16671830|NCT02138162|Experimental|1:Single dose of enzalutamide in hepatically impaired subjects|Single dose of enzalutamide
16671831|NCT02138162|Experimental|2:Single dose of enzalutamide in healthy subjects|Single dose of enzalutamide
16671832|NCT02138149||spinal cord injury|individuals with neurogenic lower urinary tract dysfunction
16671833|NCT02138149||control group|individuals with physiologic bladder function
16671834|NCT02138136|Experimental|Lubiprostone|"Participants receive lubiprostone twice daily
~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
16671835|NCT02138123|Experimental|IOL-shell technique|In this group, before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
16671836|NCT02138123|Active Comparator|Conventional procedure|In this group, a Sensar IOL (AMO Laboratories) was implanted in the capsular bag with the injector system after the lens material was completely removed. The nuclear fragmentation was performed using the Phaco-chop technique, which was then followed by ultrasound emulsification of the nuclear fragments piece by piece. Due to lack of cortical shell within the capsular bag, special care was taken to carry out the emulsification of the last nuclear fragment at a relatively more anterior anatomical position between the iris plan and the anterior chamber.
16671837|NCT02138110|Experimental|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
16671838|NCT02138097||Glitazones|
16671847|NCT02138084|Experimental|Cohort 2: BMS-663068 + Rifabutin + Ritonavir|"Regimen A: BMS-663068 tablet by mouth as specified
~Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified"
16671848|NCT02138071||Individual|Treatment in the 'Individual group therapy' will include physiotherapy protocols usually used by physiotherapist working at Maccabi Healthcare Services (Exercises, Modalities, Maual therapy and Back Care education)
16671849|NCT02138071||group|Participants in group therapy will receive 6-8 group treatments (6-12 pateints per group) which will also include exercises and back-care education. No intervention will be done by the investigator.Therapists will use protocols commonly used in Maccabi Healthcate Services.
16671850|NCT02138058|Placebo Comparator|Placebo|a 12 week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention
16671851|NCT02138058|Experimental|topiramate|a 12 week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention
16671852|NCT02138045|Placebo Comparator|Placebo treatment|"Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:
~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
16671853|NCT02138045|Active Comparator|Liraglutide treatment|"Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:
~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
16671854|NCT02138032|Experimental|Gains Framed Message|gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
16671855|NCT02138032|Experimental|Loss Framed Message|loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
16671856|NCT02138019|Experimental|Fibrin glue|In ophthalmic field, the use of organic glues has provided good results for the repair of leaking blebs and perforated corneal ulcers, conjunctival closure in strabismus surgery, surgery for retinal detachment, cataract surgery, trabeculectomy, and mucous membrane grafting to repair lesions of the conjunctival fornix. In this study, the investigators try to evaluate the effect of Fibrin Glue assisted external eye surgery.
16671857|NCT02138006|Experimental|Intensive insulin treatment|Intensive insulin treatment
16671858|NCT02138006|Active Comparator|Standard insulin treatment|Standard insulin treatment
16671859|NCT02137993|Experimental|A-prexa|A-prexa 5, 10mg
16671860|NCT02137993|Active Comparator|Zyprexa|Zyprexa 5, 10mg
16671861|NCT02137967|Experimental|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medication
16671862|NCT02137967|Active Comparator|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament
16671863|NCT02137954|Active Comparator|lidocaine|Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day
16671864|NCT02137954|Placebo Comparator|placebo|
16671865|NCT02137941|Active Comparator|techniques to optimize potential (TOP)|
16671866|NCT02137941|Active Comparator|heart coherence (HC)|
16671867|NCT02137941|Placebo Comparator|controls|
16671868|NCT02137928|Experimental|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)
16671869|NCT02137928|Active Comparator|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months
16671870|NCT02137902|Experimental|Tobacco/Physical Activity Intervention|Includes a psychosocial component that utilizes a counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy, and self-monitoring with a pedometer-based walking program. The intervention will provide 12 weeks of nicotine replacement therapy for participants.
16671871|NCT02137902|Experimental|Diet plus BP/CHOL Intervention|Consists of a psychosocial component that includes counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing hypertension and hypercholesterolemia, and adherence with antihypertensives and statins with supportive dietary changes. The intervention provides a cookbook of heart healthy regional recipes and medication bag for storing medications.
16671872|NCT02137889|Experimental|Arm 1- relapsed/refractory CLL patients|Patients with relapsed/refractory CLL with two or three prior treatment regimens
16671873|NCT02137889|Experimental|Arm 2 - rituximab or ofatumumab refractory CLL patients|Patients with relapsed/refractory CLL with four or more prior treatment regimens
16671874|NCT02137863|Placebo Comparator|Control|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
~100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.
~1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
16671875|NCT02137863|Active Comparator|Dexmedetomidine|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
~Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.
~1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
16671877|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
16671878|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
16671879|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
16671881|NCT02137811||Patients that received MICK assay|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
16671882|NCT02137798|Experimental|CARTOUNIVU|Radiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
16671883|NCT02137798|Active Comparator|CARTO3|Radiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
16671884|NCT02137785|Experimental|ALA|
16671885|NCT02137785|Placebo Comparator|Vehicle|
16671886|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
16671887|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
16671888|NCT02137759|Active Comparator|Std RT/TMZ (Cohort 1)|"Standard radiation therapy
~Standard temozolomide"
16671889|NCT02137759|Experimental|Std RT/TMZ + belinostat (Cohorts 2a, 2b)|"Standard radiation therapy
~Standard temozolomide
~Belinostat"
16671890|NCT02137746|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCa Experimental therapy
16671891|NCT02137733|Active Comparator|Bisoprolol group|Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
16671892|NCT02137733|Active Comparator|Carvedilol group|Daily oral administration of carvedilol 1.25 mg, 1 tablet twice a day (after breakfast and supper) should be given (Step 1). If tolerability is confirmed by an investigator after administering 2.5 mg/day of carvedilol, the dose should be increased to 5 mg (carvedilol 2.5 mg, 1 tablet twice daily) (Step 2). In the same manner, the dose should be increased to 10 mg (carvedilol 2.5 mg, 2 tablets twice daily, Step 3), to 15 mg (carvedilol 2.5 mg, 3 tablets twice daily, Step 4), and to 20 mg (carvedilol 10 mg, 1 tablet twice daily, Step 5).
16671893|NCT02137720|Experimental|Telephonic Diabetes Self-Management Support|This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support. Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
16671894|NCT02137720|Active Comparator|Educational Print Materials|Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
16671895|NCT02137707||Gilenya treatment|Gilenya oral form once a day
16671896|NCT02137694|Other|PapU-APV|No drug and no placebo will be used in this study. For the study participants, only their medical history data and vaginal auto-takings ( APV) and urinary will be collected.
16671897|NCT02137681|Experimental|2 cycles|2 cycles RTX
16671898|NCT02137681|Active Comparator|standard 4 cycles|standard 4 cycles RTX
16671899|NCT02137668|Experimental|Oral Vancomycin|Every participant with PSC or BA will received the same Arm of Oral Vancomycin
16671900|NCT02137642|Active Comparator|RM-131|
16671901|NCT02137642|Placebo Comparator|Placebo|
16671902|NCT02137629||Korean patients|All Korean patients intended to be treated with Vidaza® according to the approved package insert
16671903|NCT02137616|Active Comparator|risperidone|low dosage of antipsychotic drug
16671904|NCT02137616|Active Comparator|olanzapine|low doseage of antipsychotic
16671905|NCT02137616|Active Comparator|quetiapine|low doseage of antipsychotic
16671906|NCT02137616|Active Comparator|aripiprazole|low doseage of antipsychotic
16671907|NCT02137603|Experimental|Fast track|Patients discharged home the same day following appendectomy
16671908|NCT02137603|No Intervention|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
16671909|NCT02137590|Experimental|Spanish Black Radish|Spanish Black Radish product
16671910|NCT02137577|Experimental|DEB catheter|use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
16671911|NCT02137577|Active Comparator|common PTA balloon catheter|use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
16671912|NCT02137564|Experimental|Treatment (gamma secretase inhibitor PF-03084014)|Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.
16671913|NCT02137551|Experimental|ABM Intervention in FQHC|Pharmacy technicians within El Rio will implement the ABM
16671914|NCT02137551|Experimental|ABM Intervention in a Supermarket Pharmacy|Pharmacists within Fry's will implement the ABM
16671915|NCT02137551|No Intervention|Usual care|Patients will refill prescriptions at their usual pharmacy in the customary way.
16671916|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
16671917|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
16671918|NCT02137525|Active Comparator|Morphine 6 mg|Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg
16671986|NCT02137096|Experimental|High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
16671919|NCT02137525|Experimental|Fentanyl 100 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg
16671920|NCT02137525|Experimental|Fentanyl 200 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg
16671921|NCT02137525|Experimental|Fentanyl 400 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg
16671922|NCT02137512|Experimental|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
16671923|NCT02137512|Active Comparator|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
16671924|NCT02137499|Active Comparator|Healthy subjects|Healthy subjects, free from vascular disease
16671925|NCT02137499|Experimental|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
16671926|NCT02137499|Experimental|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
16671927|NCT02137499|Experimental|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
16671928|NCT02137486||sequential ballooning|include BMS or DES
16671929|NCT02137486||final kissing ballooning|include BMS or DES
16671930|NCT02137473|Active Comparator|Bovine protein-based fortifier|
16671931|NCT02137473|Experimental|Human milk-based fortifier|
16671936|NCT02137447|Experimental|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.
~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
16671937|NCT02137434|Placebo Comparator|Low calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 40 mg of calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
16671938|NCT02137434|Experimental|High dietary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of skimmed milk containing 540 mg of dietary calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
16671939|NCT02137434|Experimental|High supplementary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 540 mg of supplementary calcium from calcium carbonate, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
16671940|NCT02137421|Experimental|CAD, Metabolic syndrome .|"Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .
~Each experiment repeats three times ."
16671941|NCT02137421|Experimental|Healthy subjects .|"Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .
~Each experiment repeats three times ."
16671942|NCT02137408|Active Comparator|200 mg docosahexaenoic acid|Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily (1-200mg capsule of DHA). This is a standard dose used in prenatal vitamins. Participants will be supplemented by mouth daily between 18-20 weeks gestation through 6 weeks post-partum.
16671943|NCT02137408|Active Comparator|1000 mg docosahexaenoic acid|Participants will be randomized to 1000 mg of docosahexaenoic acid (DHA) administered PO daily (5- 200mg capsules of DHA). Participants will be supplemented daily PO between 18-20 weeks gestation through 6 weeks post-partum.
16671944|NCT02137395|Experimental|Dexamethasone|Patients are received dexamethasone via intravenous (iv) route of 0.5 mg.kg-1 (maximum dose of 8 mg) in group D at the induction of anesthesia.
16671945|NCT02137395|Placebo Comparator|Placebo|An equal volume of saline iv in group S at the induction of anesthesia.
16671946|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
16671947|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
16671948|NCT02137369|Active Comparator|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
16671949|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
16671950|NCT02137356|Experimental|treatment arm|standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
16671951|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
16671952|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
16671953|NCT02137330|Experimental|Obalon Arm|Children swalowed up to 3 intragastric balloons
16671955|NCT02137317|Experimental|LAPPE/DP|In the LAPPE experiment the farmer will work as usual (mixing/loading/application/cleaning). wearing the LAPPE solution and carrying a new hand pressured backpack sprayer with a standardized nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the DP solution.
16671956|NCT02137317|Active Comparator|DP/LAPPE|In the DP experiment the farmer will work as usual (mixing/loading/application/cleaning) wearing the DP solution and carrying his usual backpack sprayer with his usual nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the LAPPE solution.
16671957|NCT02137304|Experimental|neuromuscular patients|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
16671958|NCT02137291||Left-sided double-lumen tube|Lung isolation with a left-sided double-lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland)
16671959|NCT02137291||Modified right-sided double-lumen tube|Right-sided double-lumen tube modified in accordance with Bussières et al. in Can J Anesth 2007
16671960|NCT02137278|Active Comparator|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment
16671961|NCT02137278|Experimental|Vasoactive drug therapy|Continue current vasoactive therapy
16671962|NCT02137265|Active Comparator|Clomiphene citrate|Clomiphene citrate 50 mg daily during 4-6 months
16671963|NCT02137265|Placebo Comparator|Placebo|Placebo (1 pill daily) during 4-6 months
16671964|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of double-blinded naltrexone vs. placebo for 5 weeks. Treatment will be initiated at 25 mg/day (or equivalent placebo) during the first week to improve tolerability. The dose will be escalated to 50 mg/day (or equivalent placebo) after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
16671965|NCT02137252|No Intervention|Monitoring Phase|Brief self-report questionnaire (Functional Assessment of Chronic Illness Therapy-Fatigue Subscale; FACIT-F)
16671966|NCT02137252|Placebo Comparator|Sugar Pill|daily dose placebo for 5 week treatment period
16671967|NCT02137239|Experimental|Belatacept + Everolimus|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
16671968|NCT02137239|Experimental|Tacrolimus + Mycophenolate mofetil|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
16671969|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
16671970|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
16671971|NCT02137213|Experimental|Arm A: Naloxone then placebo|Subjects assigned to Arm A will receive methadone with naloxone for one week and then methadone with placebo for one week
16671972|NCT02137213|Experimental|Arm B: Placebo then naloxone|Subjects assigned to Arm B will receive methadone with placebo for one week and then methadone with naloxone for one week
16671973|NCT02137200|Active Comparator|Delayed pushing|
16671974|NCT02137200|Experimental|Immediate pushing|
16671975|NCT02137187|Experimental|Drug therapy|Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)
16671976|NCT02137187|Active Comparator|Device: AV junction ablation & CRT|AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy
16671977|NCT02137174|Active Comparator|Home and school visits|
16671978|NCT02137174|No Intervention|Control|
16671979|NCT02137161|Active Comparator|Dexamethasone+Tobramycin eye drop|An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
16671980|NCT02137161|Experimental|Bromfenac|Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
16671981|NCT02137135|Experimental|follicular phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
16671982|NCT02137135|Active Comparator|luteal phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
16671983|NCT02137122|Experimental|Cognitive Training|Participants will undergo 60 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The training control will be the same tasks set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
16671984|NCT02137122|Placebo Comparator|Training Control|Participants will undergo 60 hours of training control. Training control will involve the same computerized games as in the cognitive training condition but are set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
16671985|NCT02137109||natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab per the local label specifications.
16672025|NCT02136823|Placebo Comparator|sugar pill|sugar pill, oral administration, placebo capsule
16671987|NCT02137083|Experimental|Docetaxel Plus Fulvestrant|"Docetaxel:75mg/m2 D2 every 21 days
~Fulvestrant:500mg D1, D15, D29, D57, every 28 days later"
16671988|NCT02137083|Active Comparator|Docetaxel|Docetaxel:75mg/m2 D2 every 21 days
16671989|NCT02137070||Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH & Shands Hospital.
16671990|NCT02137070||Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
16671991|NCT02137057||control ( patients without diabetes)|patients without diabetes
16671992|NCT02137057||DM ( patients with diabetes)|patients with diabetes
16671993|NCT02137044|Experimental|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
16671994|NCT02137044|No Intervention|Usual Care|Subjects assigned to usual care were informed by the CCM of their depressive and pain symptoms and that they should consult with their MS or primary care provider about possible care for these conditions. Study personnel did not make any further attempts to influence usual care participants' depression or pain management unless a psychiatric emergency arose (e.g., suicidal ideation was detected at baseline or any of the outcome assessments).
16671995|NCT02137031|Experimental|Mini Link REAL-Time Transmitter|
16671996|NCT02137018|Active Comparator|laparotomy with PPL mesh implantation|control group: laparotomy with PPL mesh implantation (traditional method)
16671997|NCT02137018|Experimental|laparotomy with PPL fixation by BP|laparotomic surgery with PPL mesh fixation by BP (new fixing method)
16671998|NCT02137018|Active Comparator|laparoscopy with PPL mesh implantation|control group: laparoscopy with PPL mesh implantation (traditional method)
16671999|NCT02137018|Experimental|laparoscopy with PPL fixation by BP|laparoscopic surgery with PPL mesh fixation by BP (new fixing method)
16672000|NCT02137005||Cerebral Palsy|Patients with cerebral palsy who were seen at the Center for Gait and Movement Analysis (CGMA) at Children's Hospital Colorado as children.
16672001|NCT02136992|Placebo Comparator|Placebo (without active ingredient)|placebo will be taken two tablets 3 times a day during the whole study process.
16672002|NCT02136992|Experimental|Pirfenidone（200mg）|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
16672003|NCT02136979|Active Comparator|Propofol group|patients with propofol-based anesthesia
16672004|NCT02136979|Active Comparator|Sevoflurane group|patients with sevoflurane-based anesthesia
16672005|NCT02136966|Experimental|Programme|"Distribution of Micronutrients powders (MNP)
~Intensive counseling on Infant and Young Child Nutrition
~Cooking demonstrations"
16672006|NCT02136966|No Intervention|Controle|"Usual Infant growth monitoring and promotion activities
~No distribution of micronutrients powders
~No Intensive counseling
~No cooking demonstrations"
16672007|NCT02136953|Experimental|Exercise|12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.
16672008|NCT02136953|Active Comparator|Cognitive Behavioural Therapy (CBT)|12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.
16672009|NCT02136953|Experimental|Exercise and CBT|Combined 12-week Exercise program and CBT.
16672010|NCT02136953|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
16672011|NCT02136940|Experimental|AMA0076 0.1%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
16672012|NCT02136940|Experimental|AMA0076 0.25%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
16672013|NCT02136940|Experimental|AMA0076 0.50%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
16672014|NCT02136940|Placebo Comparator|Placebo|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
16672015|NCT02136927|Experimental|SPARC1210|Intravenous administration of SPARC1210
16672016|NCT02136927|Active Comparator|Reference1210|Intravenous administration of Reference1210
16672017|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
16672018|NCT02136914|Placebo Comparator|Placebo|Placebo
16672019|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
16672020|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
16672021|NCT02136888|Experimental|Group A|"Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).
~Placebo matched for ponesimod will be given on Day -1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24."
16672022|NCT02136888|Experimental|Group B|Placebo matched for ponesimod will be administered orally, once daily on Day -1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
16672023|NCT02136875|Experimental|Double dose of Advair for AECOPD|Double dose of Salmeterol + Fluticasone Propionate (Advair) Self-administered prescription Self-management education on the use of a self-administered prescription
16672024|NCT02136836||gastric adenocarcinoma|
16672030|NCT02136797|Experimental|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
16672031|NCT02136784|Experimental|morphine sulfate|30mg, single dose,
16672032|NCT02136784|Experimental|hydrocodone|10mg single dose
16672033|NCT02136784|Experimental|hydromorphone HCI|4mg single dose
16672034|NCT02136784|Experimental|oxycodone|10 mg single dose
16672035|NCT02136784|Experimental|buprenorphine|4 mg single dose
16672036|NCT02136784|Placebo Comparator|oral tablet placebo|single dose
16672037|NCT02136784|Placebo Comparator|sublingual tablet placebo|single dose
16672038|NCT02136771|Active Comparator|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
16672039|NCT02136771|Placebo Comparator|Placebo|Oily drops as placebo
16672040|NCT02136758|Experimental|Lifestyle modification|The intervention group participated in individualized therapeutic lifestyle plans to reduce cardiovascular risk. Participants were introduced to factors contributing to cardiovascular disease and met individually with a registered dietitian, exercise physiologist, stress management instructor, and psychologist to learn effective strategies for integrating healthy changes into their current lifestyle.
16672041|NCT02136758|No Intervention|Usual care controls|Control group received standard care from their primary physicians, but did not participate in any component of the lifestyle program or receive any information, advice, or counseling regarding healthy lifestyle behaviors.
16672042|NCT02136745|Experimental|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
16672043|NCT02136732|Experimental|Active self-management intervention|Participants will receive home visits and phone calls from a registered nurse and social worker. The registered nurse and social worker will provide participants one on one coaching, education, support and referrals to community resources to help them manage their chronic conditions.
16672044|NCT02136732|Active Comparator|Attention control phone calls|Participants will receive an initial visit and then a phone call every other month from a social services aide who can provide information about community resources that might be helpful.
16672045|NCT02136719|Active Comparator|Group A|bimanual uterine compression immediately after delivery of placenta for 5 minutes in 260 women
16672046|NCT02136719|No Intervention|Group B|no intervention (260 women).
16672047|NCT02136706|No Intervention|10/30 min rest/stress|Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
16672048|NCT02136693|Placebo Comparator|Placebo|3.5 g /day of inert compound for 180 days after STARR
16672049|NCT02136693|Experimental|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
16672050|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
16672051|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
16672052|NCT02136667||Exposed|Women with a history of preeclampsia 10 years ago
16672053|NCT02136667||Unexposed|Women with a history of uncomplicated pregnancy 10 years ago
16672054|NCT02136654|Experimental|Culturally tailored diabetes program|"Culturally tailored diabetes program
~culturally tailored diabetes education
~lifestyle counselling
~medication adherence counseling
~peer supporter
~communication training
~family member involvement"
16672055|NCT02136654|No Intervention|Usual Care|Usual Care includes continuing to visit primary care physician for ongoing diabetes management Printed diabetes education materials.
16672056|NCT02136641|Active Comparator|Midazolam|1. Sedation with Midazolam 0.03 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
16672057|NCT02136641|Experimental|Midazolam+Fentanyl Combination|2. Sedation with Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
16672058|NCT02136641|Experimental|Midazolam+Ketamine Combination|3. Sedation with Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
16672059|NCT02136628|Experimental|RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.
~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
16672097|NCT02136381|Experimental|LEAP intervention|A newly developed internet-based lifestyle programme (Living, Eating, Activity and Planning through retirement (LEAP)) will promote three key health and social behaviours; healthy eating following a Mediterranean diet, increasing physical activity and improve social connectedness.
16672143|NCT02136147||Atomoxetine medication|Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
16672060|NCT02136628|No Intervention|Control|Conventional midline mass closure technique. Upon completion of the surgical procedure was the closure of abdominal wall which will be made with the number 0 monofilament PDS, starting with knot at one end of the wound, continuous with continuous súrgete, moving each point to a centimeter away from the other. Each point will be a distance of one centimeter from the edge of the fascia. At the opposite end of the wound the same procedure was initiated and found the two suture lines at the midpoint of the wound will proceed to tying the two sutures with 4 square knots.
16672061|NCT02136615||overweight and obese male volunteers|BMI between 23-40 kg/m2
16672062|NCT02136589|Experimental|Dicrofenac|
16672063|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
16672064|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
16672065|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
16672066|NCT02136563||Darbepoetin alfa|
16672067|NCT02136550|Experimental|Smoking cessation|36 smokers will participate in the study and will be evaluated at baseline, 6 months e 12 months of the smoking cessation program. If they quit the program, they will be asked to continue the study.
16672068|NCT02136537|Active Comparator|Best medical therapy|Claudicants treated according to local protocol - no added treatment
16672069|NCT02136537|Experimental|Best medical therapy plus NMES|In addition to best medical therapy, subjects will receive bilateral neuromuscular stimulation of their legs, 4 hours per day.
16672070|NCT02136524|Experimental|Capsule formulation|
16672071|NCT02136524|Experimental|Tablet formulation|
16672072|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
16672073|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
16672074|NCT02136485|Experimental|MBSR|8 weekly sessions each lasting 2.5 hours
16672075|NCT02136485|Other|Control|Control arm - waiting list control, once the intervention group has completed MBSR the control group will be invited to participate in MBSR
16672076|NCT02136472||Subfertile women|"Women who visit the fertility clinic of the Maastricht University Medical Centre who start with a basic fertility work-up. Women diagnosed with an unexplained subfertility or with (signs of) a decreased ovarian reserve are asked for further participation in the study of the cardiovascular profile.
~As a control group parous women with an uncomplicated pregnancy more than 6 months ago will be asked for participation."
16672077|NCT02136459|Experimental|Small tube size|Size 6.5 ETT for female, size 7.0 ETT for male
16672078|NCT02136459|Active Comparator|Large tube size|Normal tube size, size 7.5 for female, size 8 for male
16672079|NCT02136446|Experimental|EchoGlo™ Peripheral Nerve Block Catheter|Echogenic nerve block catheter (test)
16672080|NCT02136446|Active Comparator|Pajunk® EpiLong Catheter|Non-echogenic nerve block catheter (control)
16672081|NCT02136433|Experimental|Tablet - self exercise|"Existing tablet Apps that encourage finger movement in a fun manner while playing a game will be used. The apps will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).
~The intervention will include 15-20 sessions of 60 minutes of self-training using a tablet."
16672082|NCT02136433|Active Comparator|GRASP self exercise|"GRASP (Graded Repetitive Arm Supplementary Program)(Harris et al., 2009)is an arm and hand exercise program developed for individuals with stroke with upper extremity impairments GRASP provides a method for patients to undertake a self-directed arm and hand exercise program.
~The exercises will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).
~The intervention will include 15-20 sessions of 60 minutes of self-training"
16672083|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
16672084|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
16672085|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
16672086|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
16672087|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
16672088|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
16672089|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
16672090|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
16672091|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.
~This arm corresponds to results published in Diaz-Artiles et al 2017."
16672092|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.
~This arm corresponds to results published in Diaz-Artiles et al 2017."
16672093|NCT02136407||Blood donors|N=540
16672094|NCT02136407||Thrombocyte donors|N=75
16672095|NCT02136394||Severe/moderate acid reflux|
16672096|NCT02136394||Mild/absent acid reflux|
16672212|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
16672098|NCT02136381|Other|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).
~This website contains general information on improving life style and health."
16672099|NCT02136368|Experimental|Multi-Modal, Mind Motor Exercise (M4)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of mind-motor exercise.
16672100|NCT02136368|Active Comparator|Multi-Modal Exercise (M2)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of balance and range of motion exercises.
16672101|NCT02136355|Experimental|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
16672102|NCT02136342|Experimental|chlorogenic acid|
16672103|NCT02136329|Experimental|Sildenafil|All subjects in groups 1-6 will receive SIldenafil but in escalating doses.
16672104|NCT02136316|Experimental|ASP7962 low dose|
16672105|NCT02136316|Experimental|ASP7962 medium dose|
16672106|NCT02136316|Experimental|ASP7962 high dose|
16672107|NCT02136316|Placebo Comparator|Placebo|
16672108|NCT02136303|Placebo Comparator|S1-Placebo|placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
16672109|NCT02136303|Experimental|S1-1L|capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
16672110|NCT02136303|Experimental|S1-2L|capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
16672111|NCT02136303|Experimental|S1-5L|capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
16672112|NCT02136303|Experimental|S2-Kale_extract|
16672113|NCT02136303|Experimental|S2-Kale_purée|
16672114|NCT02136303|Placebo Comparator|S3-Placebo|
16672115|NCT02136303|Experimental|S3-AMD-Patients|
16672116|NCT02136303|Experimental|S3-non-AMD|
16672117|NCT02136303|Placebo Comparator|S1-Placebo-Tagetes|capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
16672118|NCT02136303|Experimental|S1-1L-Tagetes|capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
16672119|NCT02136303|Experimental|S1-2L-Tagetes|capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
16672120|NCT02136303|Experimental|S1-5L-Tagetes|capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
16672121|NCT02136303|Experimental|S1-10L-Tagetes|capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
16672122|NCT02136290|Other|Usual Care|Weight loss counseling
16672123|NCT02136290|Experimental|Prepackaged meal|Prepackaged meals
16672124|NCT02136277||Colorectal patients|Subjects undergoing colorectal surgery
16672125|NCT02136264|Active Comparator|PCFA interventional dietary counselling|personalized categorical food avoidance dietary counselling
16672126|NCT02136264|Sham Comparator|conventional DASH diet counselling|"DASH = conventional dietary approach to stop hypertension"
16672127|NCT02136251||shoulder replacement|Subjects who had shoulder replacement surgery at The University of Nebraska and The Nebraska Medical Center at least 5 or more years ago and autologous bone graft around the anchor-peg glenoid prosthesis was used.
16672128|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
16672129|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
16672130|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
16672131|NCT02136225|Experimental|Counseling|Intervention: Means restriction counseling. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun in the home where youth are present.
16672132|NCT02136225|Experimental|Counseling and locking devices|Intervention: Means restriction counseling and locking devices. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present. Parents will also receive locking devices to store their guns securely.
16672133|NCT02136225|No Intervention|Control group|Youth in the control group will receive usual care.
16672134|NCT02136212|Experimental|Approach-positive AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure designed to increase automatic approach responses for positive social cues.
16672135|NCT02136212|Placebo Comparator|Control AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
16672136|NCT02136199|Other|Active Implementation of Share EBM Toolkit|Investigators led implementation of tailored activities and tactics (Shared EBM Toolkit) designed to promote the use of the decision aids in clinical encounters (i.e. journal clubs, value map streaming).
16672137|NCT02136199|Other|Passive Implementation of Share EBM Toolkit|Locally supported dissemination of Shared EBM Toolkit designed to promote the use of the decision aids in clinical encounters.
16672138|NCT02136186|No Intervention|Standard of care|patients will receive standard of care discharge instructions
16672139|NCT02136186|Active Comparator|Philips Telehealth|patients will be discharged with a telemonitoring device for 30 days
16672140|NCT02136173|Experimental|sequential balloons|effect of weight loss by applying sequential balloons
16672141|NCT02136147||Children with ADHD medication|Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
16672142|NCT02136147||Lisdexamphetamine medication|Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
16672213|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
16673566|NCT02126761|Experimental|Group 2|aTIV + 1X MF59
16672144|NCT02136147||Methylphenidate medication|Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
16672145|NCT02136147||Guanfacine medication|Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
16672146|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
16672147|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone.
16672148|NCT02136121|Experimental|da Vinci Sp Surgical System|da Vinci Sp Surgical System - Robotic - assisted single-port surgery
16672149|NCT02136108|Experimental|OPENtext|OPENtext will target cognitive, affective, and behavioral strategies through a single, brief in-person assessment, followed by 12 weeks of theoretically-informed text messages, a core set of information organized in a 'frequently asked questions' structure, interactive peer support, static resources on key patient-identified topics, and a library of peer stories accessible throughout the study period.
16672150|NCT02136108|Active Comparator|OPENnav|Peer Navigation is currently offered to some individuals in this Medicaid population but not all. Peer navigators interact with patients by phone/text and at home visits. Efforts focus on drivers of a patient's ED use, and may include providing or identifying patient support, improving health literacy, assisting with transportation vouchers, health education, family support, accessing housing services, and orienting to other community support services.
16672151|NCT02136095|Experimental|IFC-group|The investigators included patients undergoing laparoscopic cholecystectomy by a single surgeon between September and December 2013 at a single centre university department with unrestricted referral of patients. The included patients represented all patients undergoing laparoscopic cholecystectomy by one surgeon during the study period. All patients underwent intra-operative fluorescent cholangiography (IFC) with concomitant angiography, according to a standardized protocol, during their laparoscopic cholecystectomy.
16672152|NCT02136082|Experimental|Asha Support + Training|Asha Support + Training: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
16672153|NCT02136082|Experimental|Asha Support + Food|Asha Support + Food 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; and c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
16672154|NCT02136082|Experimental|Asha Support + Training + Food|Asha Support + Training + Food: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
16672155|NCT02136082|Active Comparator|Asha Support Only|Asha Support Only 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
16672156|NCT02136069|Experimental|Etrolizumab + Placebo (IV)|Participants will receive ertolizumab (SC) Q4W until Week 52 along with placebo matched to infliximab as IV infusion until Week 46.
16672157|NCT02136069|Active Comparator|Infliximab + Placebo (Injection)|Participants will receive IV infusion of infliximab at Weeks 0,2, and 6, then every 8 weeks until Week 46 partnered with placebo matched to etrolizumab by SC injection Q4W until Week 52.
16672158|NCT02136056|Experimental|Self-management program (SMP)|Participants in the experimental group receive six weekly group-sessions of self-management and patient education; specifically targeting self-management of the return to work process and disease symptoms.
16672159|NCT02136056|No Intervention|Treatment as usual|Participants in the control-group receive standard rehabilitation care and follow-up in the job-center.
16672160|NCT02136043|Experimental|Group 1|Insertion of catheter into nasal cavity carried out by patient. Fixation of catheter during treatment with patient´s hand.
16672161|NCT02136043|Experimental|Group 2|Insertion of catheter into nasal cavity carried out by health professional. Fixation of catheter during treatment with helmet.
16672162|NCT02136030|Experimental|Lipo-AB|
16672163|NCT02136030|Active Comparator|Amphotericin B|
16672164|NCT02136017||Changchun biologial's vaccine|Changchun Biological's vaccine group is the population injected with this vaccine.
16672165|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
16672166|NCT02135991|Experimental|Project CHOICE + Getting To Outcomes|Boys and Girls Club sites will receive a) training and materials for Project CHOICE and b) training, ongoing technical assistance for two years, and materials for Getting To Outcomes
16672167|NCT02135991|Active Comparator|Project CHOICE only|Boys and Girls Club sites will receive a) training and materials for Project CHOICE
16672168|NCT02135978|Experimental|One-to-one training group for shoulder home exercise program|Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
16672214|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
16672321|NCT02135042|Experimental|Arm IV (chemoradiation, observation)|Patients undergo clinical observation.
16672169|NCT02135978|Active Comparator|Enhanced training group for shoulder home exercise program|Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
16672170|NCT02135978|No Intervention|Historical control group|Historical control group has received no intervention. Eligibility criteria, outcome measures and study duration for historical control group is matched for the experimental group and active comparator.
16672171|NCT02135965|Experimental|Albuterol 2mg|2 mg of Albuterol is in a pill form or placebo
16672172|NCT02135965|Experimental|Albuterol 4mg|4mg of Albuterol or placebo is given in pill form
16672173|NCT02135965|Experimental|Caffeine 100mg|100mg of Caffeine or placebo is given in a pill form.
16672174|NCT02135965|Experimental|Caffeine 200mg|200mg of Caffeine or placebo is given in a pill form
16672175|NCT02135965|Experimental|Albuterol 2mg & Caffeine 100mg|100mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
16672176|NCT02135965|Experimental|Albuterol 2mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
16672177|NCT02135965|Experimental|Albuterol 4mg and Caffeine 100mg|100mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
16672178|NCT02135965|Experimental|Albuterol 4mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
16672179|NCT02135952|Active Comparator|SRP+MTZ+AMX|Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day [TID] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)
16672180|NCT02135952|Placebo Comparator|SRP+placebo|Scaling and root planing + placebo
16672181|NCT02135939|Active Comparator|American Heart Association diet|Participants randomized into this arm will follow an American Heart Association diet plan for 8 weeks.
16672182|NCT02135939|Experimental|Whole-food plant-based vegan diet|Participants randomized into this arm will be asked to follow a whole-food plant-based vegan diet plan for 8 weeks.
16672183|NCT02135926|Active Comparator|Best medical care|Best clinical care in dedicated stroke unit
16672184|NCT02135926|Active Comparator|Thrombectomy|All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
16672185|NCT02135913|Experimental|Viatamin D|All children enrolled into the study will be prescribed standard of care vitamin D.
16672186|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
16672187|NCT02135887||MB-6+FOLFOX chemotherapy|MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
16672188|NCT02135887||Placebo+FOLFOX chemotherapy|Placebo, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
16672190|NCT02135861|Experimental|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
16672191|NCT02135861|Experimental|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
16672192|NCT02135861|Experimental|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
16672193|NCT02135848|Experimental|GSK1278863|Study Drug
16672194|NCT02135848|Placebo Comparator|Placebo|Placebo
16672195|NCT02135835|Experimental|Shenfu Zhusheye|80 ml Shenfu Zhusheye + 70 ml 5% glucose injection, ivdrip, once a day for 7 days.
16672196|NCT02135835|Placebo Comparator|5% glucose injection|150 ml 5% glucose injection, ivdrip, once a day for 7 days.
16672197|NCT02135822|Experimental|nanoparticle albumin-bound paclitaxel, gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8, in combination with gemcitabine which is given at 1000 mg/m2, on day 1 and 8, each 21-day cycle. Number of cycle: 6 cycles.
16672198|NCT02135809|Experimental|FCSEMS|Patients will receive the WallFlex Pancreatic Stent.
16672199|NCT02135796||Sepsis/Septic Shock|Individuals who are admitted to the Intensive Care Unit (ICU) with an infection called Sepsis or Septic Shock. This group will receive transthoracic echocardiography as part of the study.
16672200|NCT02135783|Experimental|Decompressive Craniectomy|Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
16672201|NCT02135783|Active Comparator|non-Decompressive Craniectomy|non-Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
16672202|NCT02135770|Experimental|Unfractionated Heparin|Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion
16672203|NCT02135770|Placebo Comparator|Placebo|Normal saline packed in same form with trial drugs.
16672204|NCT02135744|No Intervention|Control|Group of patients undergo standard care as determined by the primary inpatient team
16672205|NCT02135744|Experimental|Bundle|Group of patients that receive the screening and educational tool
16672206|NCT02135731|No Intervention|Paper|Usual care -medication review on paper
16672207|NCT02135731|Experimental|Computer|Medication review software with pictures
16672208|NCT02135718||Group 1|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the MDI inhaler twice daily for 5 to 9 days during the second period.
16672209|NCT02135718||Group 2|Subjects will use the MDI inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
16672210|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
16672211|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
16672215|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
16672216|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
16672217|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
16672218|NCT02135666|Experimental|2-dose Primed Group|Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084).
16672219|NCT02135666|Experimental|3-dose Primed Group|Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084).
16672220|NCT02135653||Feasibility Phase: Eischens Yoga Group|
16672221|NCT02135653||Phase II: Eischens Yoga Group|
16672222|NCT02135640|Experimental|denosumab 60 mg|solution
16672223|NCT02135640|Experimental|denosumab 120 mg|solution
16672224|NCT02135640|Placebo Comparator|placebo|solution
16672225|NCT02135627|Experimental|Control group|Current standard endoscopic therapy such as epinephrine injection, sclerotherapy, mechanical (endoclip). contact electrocautery/thermal, and non-contact electrocalcautery (APC) ± radiation therapy, angioembolization, and/or surgery.
16672226|NCT02135627|Active Comparator|TC-325|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
16672227|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
16672228|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
16672229|NCT02135601|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
16672230|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
16672231|NCT02135588|Experimental|Active Treatment|Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)
16672232|NCT02135575|Experimental|Premenopausal women|The Premenopausal women are randomized to exercise by spinning (cycle)
16672233|NCT02135575|Experimental|Postmenopausal women|The Postmenopausal women are randomized to exercise by spinning (cycle)
16672234|NCT02135562|Experimental|Supportive Care (PSMF)|Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
16672235|NCT02135549|Experimental|SugarDown 4 grams|SugarDown 4 gram dose in tablet form, before meals, daily for one week
16672236|NCT02135549|Experimental|SugarDown 8 grams|SugarDown 8 gram dose in tablet form, before meals, daily for one week
16672237|NCT02135549|Placebo Comparator|Placebo|Placebo dose in tablet form, before meals, daily for one week
16672238|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
16672239|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
16672240|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
16672241|NCT02135523|Experimental|single arm: involved-field radiation therapy group|
16672242|NCT02135510|Active Comparator|metoclopramide|
16672243|NCT02135510|Active Comparator|dexamethason|
16672244|NCT02135510|Active Comparator|palonosetron|
16672245|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
16672246|NCT02135471|Experimental|acellular dermal matrix graft|
16672247|NCT02135471|Experimental|enamel matrix derivative|
16672248|NCT02135458|Experimental|Telemonitoring|Home-based patient management using AUTONOM@DOM telemonitoring system to record and transmit heart rate, blood pressure and weight; along side conventional care (patient therapeutic education or personalised care program)
16672249|NCT02135458|Active Comparator|Conventional care|Conventional care including patient therapeutic education or personalised care program
16672250|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
16672251|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
16672252|NCT02135432|Experimental|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
16672253|NCT02135432|Placebo Comparator|Placebo|matching placebo
16672322|NCT02135029|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
16672256|NCT02135406|Experimental|Multiple Myeloma Patients|Adult subjects (18 years or older) with multiple myeloma and with poor prognosis by virtue of having relapsed/progressive disease within one year of first autologous stem cell transplantation.
16672257|NCT02135393|Experimental|13C5-folic acid or 13C5-6S-5-FormylTHF|Physiological 500 nmol (220 µg folic acid equivalent) dose of dietary supplement 13C5-folic acid or 13C5-6S-5-FormylTHF given to subjects with in situ transjugular intrahepatic portosystemic stent at the time of routine venography patency check followed by regular portal venous sampling for 85 minutes at pre determined intervals and then physiological 500 nmol dose of 13C-6S-5-FormylTHF or 13C5-folic acid respectively at the next annual routine venography patency check followed by portal venous sampling for 85 minutes
16672258|NCT02135380|Other|Autologous Stromal Vascular Fraction|Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
16672259|NCT02135380|Other|Autologous Adipose Derived MSCs|3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
16672260|NCT02135380|Active Comparator|Control|"corticosteroids i.e. Prednisolone ≤10mg/day or ≤20 mg every alternate day
~Immunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day
~Antioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.
~Pirfenidone at dose upto 1200 to 1800 mg/day"
16672261|NCT02135367|Experimental|PRP|This group of patients will be treated by three weekly Platelet rich Plasma intra-articular injections in the knee.
16672262|NCT02135367|Active Comparator|HA|"This group of patients will be treated by three weekly hyaluronic acid (HA) intra-articular injections in the knee.
~The HA used is Hyalubrix 30 mg/2ml (Fidia Farmaceutici Spa, Padova, Italy)"
16672263|NCT02135354|Experimental|Azithromycin|"N = 250
~From day 1 up to and including day 3: 500 mg azithromycin PO once a day
~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
16672264|NCT02135354|Placebo Comparator|Placebo|"N = 250
~From day 1 up to and including day 3: 500 mg placebo PO once a day
~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
16672265|NCT02135341|Experimental|Group A: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
16672266|NCT02135341|Experimental|Group B: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
16672267|NCT02135328|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing type 2 diabetes through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
16672268|NCT02135328|Active Comparator|Audio brochure|Participants received an audio version of a standard brochure about type 2 diabetes prevention and management.
16672269|NCT02135315|Experimental|intensive controle group|the end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous Isosorbide Dinitrate (RISORDON) perfusion associated, if needed, with Labetalol (TRANDATE) continuous perfusion.
16672270|NCT02135315|Active Comparator|standard control group|the end point in these group was to maintain the systolic blood pressure between 120 and 140 mmHg using a continuous perfusion of Isosorbide Dinitrate (RISORDON) or other drugs depending on the physician choice.
16672271|NCT02135302|Experimental|Impaired hepatic function|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.
16672272|NCT02135302|Experimental|Healthy subjects|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.
16672273|NCT02135289||IMID patients|Patients with IMID
16672274|NCT02135289||Control - subjects without IBD|Patients without IBD
16672275|NCT02135276|Experimental|End stage renal disease (ESRD) subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
16672276|NCT02135276|Experimental|Normal healthy subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
16672277|NCT02135263|Experimental|Methylphenidate|
16672278|NCT02135263|Experimental|Enalapril|
16672279|NCT02135250|Experimental|placebo|the placebo is not drug
16672280|NCT02135250|Experimental|Xinkeshu tablet|4 Xinkeshu tablets are given three times per day
16672281|NCT02135237|Active Comparator|Control Group|Standard Care
16672282|NCT02135237|Experimental|Experimental Group|Standard Care plus Prize Contingency Management for Alcohol Abstinence
16672283|NCT02135224|Active Comparator|Fentanyl|20 microgram per hour
16672284|NCT02135224|Placebo Comparator|Normal saline|0.4 ml per hour
16672285|NCT02135211|Experimental|Lifestyle counseling|This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.
16672286|NCT02135198|Experimental|2 mg AZD7325|2 mg AZD7325 in orange capsule, Size 0, single oral dose
16672287|NCT02135198|Experimental|10 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, singe oral dose
16672288|NCT02135198|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose
16672289|NCT02135185|Experimental|Rehabilitation effort|custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment
16672290|NCT02135185|Active Comparator|Control|Control with dietary management adapted to the nutritional status
16672291|NCT02135172|Experimental|Sitting|During the sitting treatment condition, walking and standing will be restricted. Participants will be in a designated room with access to a computer, books/magazines throughout the day. Participants will have a cannula fitted and the first of the half-hourly blood samples will be taken (time point: -1hr). Participants will then be asked to sit quietly for 60 minutes to achieve a steady state. Following this, participants will have another blood sample taken and then be provided with a standardised mixed meal breakfast (09:00am) (time point: 0h). Blood sampling will continue at 30 minutes intervals for 3 hours following breakfast. A second, lunch meal (12:00pm), will be then be consumed over 15 minutes. Blood sampling will then continue at 30 minute intervals for 3 hours following lunch.
16672323|NCT02135029|Active Comparator|Atorvastatin|
16672292|NCT02135172|Experimental|Standing|This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
16672293|NCT02135172|Experimental|Walking|This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
16672294|NCT02135159|Experimental|TDM1 concommitant with RT|T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
16672295|NCT02135159|Experimental|TDM1 during and after RT|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
16672296|NCT02135159|Experimental|RT before TDM1|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
16672297|NCT02135159|Experimental|TDM1 before RT|T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
16672298|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
16672299|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
16672300|NCT02135133|Experimental|Idelalisib & Ofatumumab|Idelalisib will be given orally continuously at 150 mg BID. On day 57, ofatumumab will begin with the 300 mg dose, given after idelalisib is taken. Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8). The overall induction treatment period will then be 8 months, comprised of two months of single agent idelalisib followed by 6 months of ofatumumab with idelalisib. After the completion of the induction treatment, idelalisib will continue indefinitely in arbitrarily defined 28 day cycles in all participants who have not had excessive toxicity and do not have progressive disease.
16672301|NCT02135120|Active Comparator|Morphine group|Patients will receive a combined spinal epidural anesthesia technique with intrathecal morphine
16672302|NCT02135120|Active Comparator|Morphine-femoral group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
16672303|NCT02135120|Active Comparator|Morphine-femoral-sciatic group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
16672304|NCT02135107|Experimental|Arm A|
16672305|NCT02135107|Experimental|Arm B|
16672306|NCT02135107|Experimental|Arm C|
16672307|NCT02135107|Experimental|Arm D|
16672308|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
16672309|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
16672310|NCT02135081||Single Ventricle|"Subjects will be single ventricle patients who will be prospectively recruited when they are at the first stage of Fontan reconstruction; they will be followed throughout all 3 stages with cerebral blood flow measurements and brain MRIs.
~Additional single ventricle patients who will not participate in the study for all 3 stages but who may participate for one of two. For example, patients who completed their Stage I and hemi Fontan/bidirectional Glenn operations before this study began will be recruited before Fontan stage completion. Also, patients whose Stage I and hemi Fontan/bidirectional Glenn surgeries will be completed during the study, but who will not complete all 3 surgical stages before this project ends. Cerebral blood flow measurements and brain MRIs will be completed after each surgical stage which occurs during study participation."
16672311|NCT02135081||Normal Control Group|Children likely to have a normal brain MRI will be asked to participate. After the brain MRI is obtained as part of routine clinical care, and a normal brain scan is confirmed, measurement of cerebral blood flow using velocity mapping in the jugular veins and the aorta will be performed. This will add approximately 10 minutes to the scan but no extra sedation medications will be administered to obtain this data.
16672312|NCT02135068|Experimental|CL and exercise with proactive snacking|Subject will consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
16672313|NCT02135068|Active Comparator|CL and exercise without proactive snacking|Subject will not consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
16672314|NCT02135055|Experimental|Normal immune function|The value of monocyte human leukocyte antigen-DR (mHLA-DR) is equal to or more than 15000 monoclonal antibody.
16672315|NCT02135055|Experimental|Moderate immunosuppression|The value of mHLA-DR is equal to or more than 10000 and less than 15000 monoclonal antibody.
16672316|NCT02135055|Experimental|Sever immunosuppression|The value of mHLA-DR is equal to or more than 5000 and less than 10000 monoclonal antibody.
16672317|NCT02135055|Experimental|Immune paralysis|The value of mHLA-DR is less than 5000 monoclonal antibody.
16672318|NCT02135042|Active Comparator|Arm I (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
16672319|NCT02135042|Experimental|Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)|Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
16672320|NCT02135042|Active Comparator|Arm III (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen as in Arm I of Phase II.
16672325|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
16672326|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
16672327|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
16672328|NCT02135003|Experimental|Buddy arm, Standard of care arm|"Standard of care: Patients enrolled for pre-ART care received general health education, clinical monitoring, CD4 testing and other clinically indicated investigations, treatment of opportunistic infections, and cotrimoxazole prophylaxis.
~Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. buddies attended at least two HIV health education. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments"
16672329|NCT02134990|Experimental|Oshadi D and Oshadi R with Docetaxel|Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy
16672330|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
16672331|NCT02134964|Experimental|OLT1177 Capsules|"A total of 5 patients in each cohort will receive OLT1177 Capsules:
~Cohort 1 will receive a single 100 mg dose of OLT1177
~Cohort 2 will receive a single 300 mg dose of OLT1177
~Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart)
~Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days
~Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days
~Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days"
16672332|NCT02134964|Placebo Comparator|Placebo Capsules|"A total of 1 patient in each cohort will receive Placebo Capsules:
~Cohort 1 will receive a single placebo capsule
~Cohort 2 will receive three placebo capsules
~Cohort 3 will receive ten placebo capsules (seven days apart)
~Cohort 4 will receive a single placebo capsule QD for 8 days
~Cohort 5 will receive three placebo capsules QD for 8 days
~Cohort 6 will receive ten placebo capsules QD for 8 days"
16672333|NCT02134951|Experimental|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
16672334|NCT02134951|Placebo Comparator|Placebo|Placebo group will receive normal saline
16672335|NCT02134938|Experimental|Konjac Glucomannan|650g KJM-G
16672336|NCT02134938|Experimental|Half Control/Half Konjac Glucomannan|325g KJM-G
16672337|NCT02134938|No Intervention|Control|0g KJM-G
16672338|NCT02134925|Experimental|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
16672339|NCT02134925|Placebo Comparator|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
16672340|NCT02134912|Experimental|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
16672341|NCT02134912|Experimental|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
16672342|NCT02134899|Experimental|Everolimus|everolimus based immunosuppression
16672343|NCT02134899|Active Comparator|Calcineurin|Calcineurin inhibitors maintenance
16672344|NCT02134886|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16672345|NCT02134873|Active Comparator|0.1ml 24% sucrose concurrent opioids|0.1ml 24% sucrose concurrent opioids
16672346|NCT02134873|Active Comparator|0.5ml 24% sucrose concurrent opioids|0.5ml 24% sucrose concurrent opioids
16672347|NCT02134873|Active Comparator|1.0ml 24% sucrose concurrent opioids|1.0ml 24% sucrose concurrent opioids
16672348|NCT02134873|Active Comparator|0.1ml 24% sucrose no opioids|0.1ml 24% sucrose no opioids
16672349|NCT02134873|Active Comparator|0.5ml 24% sucrose no opioids|0.5ml 24% sucrose no opioids
16672350|NCT02134873|Active Comparator|1.0ml 24% sucrose no opioids|1.0ml 24% sucrose no opioids
16672351|NCT02134860|Active Comparator|Isocaloric diet|3 daily meals
16672352|NCT02134860|Active Comparator|Alternate daily fasting|One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
16672353|NCT02134847|Experimental|Intervention cohort|This cohort will work on the SCS intervention schedule
16672354|NCT02134847|No Intervention|Control cohort|This group will work on a traditional schedule
16672355|NCT02134834|Experimental|Ascending single dose of OP0595|
16672356|NCT02134834|Placebo Comparator|Normal Saline|
16672357|NCT02134821||Low pain sensitivity group|total Pain Sensitivity Questionnaire score <6.5
16672358|NCT02134821||High pain sensitivity group|total pain sensitivity questionnaire score ≥ 6.5
16672359|NCT02134808|Active Comparator|Creatine|Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
16672360|NCT02134808|Placebo Comparator|Placebo|Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
16672361|NCT02134795|Experimental|TNM (trade name), a form of brainstem stimulation|ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for ~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
16672362|NCT02134782|Experimental|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (5 days per week or 15 days in total). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
16672433|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
16672363|NCT02134782|Active Comparator|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily (5 days per week) for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
16672364|NCT02134769|No Intervention|Control|No use of Bionecteur; handling according to institutional guideline
16672365|NCT02134769|Active Comparator|Bionecteur|Use of Bionecteur; handling according to institutional guideline
16672366|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
16672367|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
16672368|NCT02134743|Experimental|Experimental Group|At this group the patients will receive dental implants which have a modified SLA surface. These surface have wettability, which could improve and accelerate the osseointegration.Intervention: implant placement.
16672369|NCT02134743|Active Comparator|Control Group|The patient of this group will receive implant with conventional surface, SLA (Sandblasted and Acid-Etched Surface).Intervention: implant placement.
16672370|NCT02134730|No Intervention|Wait list|Schools in waitlist condition will be offered the intervention after the 12-months follow up. Waitlist means that the schools work as usual with issues of mental health.
16672371|NCT02134730|Experimental|FRIENDS for life|The intervention is delivered for 10 consecutive weeks, 60 minutes per session.
16672372|NCT02134717|Experimental|sarcoidosis stage II|All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.
16672373|NCT02134704|Experimental|Scoliosis Group|
16672374|NCT02134704|Experimental|Healthy Volunteers Group|
16672375|NCT02134691|Experimental|Prolonged Exposure|Behavioral: Prolonged Exposure (PE) PE is a 16 week, 90 minute culturally informed treatment program.
16672376|NCT02134691|Active Comparator|Applied Relaxation|Behavioral: Applied Relaxation (AR) AR is a 16 week, 90 minute treatment program.
16672377|NCT02134678|Experimental|self-system therapy|self-system therapy for depression
16672378|NCT02134678|Active Comparator|cognitive therapy|cognitive therapy for depression
16672379|NCT02134665||severe acute pancreatitis|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.
16672380|NCT02134665||Pneumonia|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.
16672381|NCT02134652||Suspected Dengue|Children with an acute febrile illness, and two of the following: headache, retro-orbital pain, myalgias, arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath, abdominal distention/pain) will all receive a diagnostic bedside ultrasound.
16672382|NCT02134639||Patient who is suspected of endocrine tumors|According to symptomatology, biology or imaging or pathological context
16672383|NCT02134626|Experimental|Simvastatin|Arm 1: Simvastatin 40mg / pill, one pill once a day for three months
16672384|NCT02134626|Placebo Comparator|Placebo pill|Arm 2: Placebo one pill once a day for three months
16672385|NCT02134613|Experimental|anti-TNF-alpha scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
16672386|NCT02134600|Experimental|Omega-3 enriched fruit juice|Single arm study: Omega-3 enriched fruit juice in increasing dosage
16672387|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
16672388|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
16672389|NCT02134561|Other|All subjects|psychological interview, MRI, neurological tests, cognitive tests
16672390|NCT02134535||laboratory specimens|cervical biopsies vaginal biopsies blood
16672391|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
16672392|NCT02134509|Experimental|Experimental App|This is a 3-week smartphone-based training program that trains behavioral strategies for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
16672393|NCT02134509|Active Comparator|Active comparator app|This is a 3-week smartphone application for smoking cessation in which smokers self-monitor their smoking habits, mood, and experience, to quit smoking with a target quit date of 3 weeks.
16672394|NCT02134496|No Intervention|no assessment of motorfunction in PACU|no assessment of motorfunction after spinal anesthesia in PACU
16672395|NCT02134496|Active Comparator|motorfunction assessment in PACU|Assesment of motorfunction after spinal anesthesia
16672396|NCT02134483|Experimental|Parathyroid allo-transplantation|patients who have permanent hypoparatyroidism
16672397|NCT02134470|Experimental|Testosterone|Chemical testing of saliva is an objective method to quantify steroid hormones. Recent studies indicate that salivary testosterone is significantly higher than in other body fluids. Therefore, saliva may serve as pre-screening parameter to select suspicious cases for further target evaluation. The aim of the present project is to detect administered testosterone in saliva and compare these levels to those in blood and urine. Therefore, each participant represents its own control.
16672398|NCT02134457|Experimental|Ranibizumab 0.12 mg|"20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.
~A maximum number of 3 regular re-injections can be applied."
16672434|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
16673567|NCT02126761|Experimental|Group 3|aTIV + TIV
16672399|NCT02134457|Experimental|Ranibizumab 0.20 mg|"20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.
~A maximum number of 3 re-injections can be applied."
16672400|NCT02134444|Experimental|Experimental Group|Experimental group will receive the assigned intervention which is a game-based rehabilitation program delivered at home.
16672401|NCT02134444|Active Comparator|Control group|Control group will receive a vestibular rehabilitation program which will include the Herdman gaze stabilization exercises and balance training program.
16672402|NCT02134431||HIV positive|HIV-positive subjects ages 10-14 years old and 18-21 years old taking tenofovir in their antiretroviral regimen.HIV positive subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. HIV-1 levels and tenofovir levels in tissue will be measured.
16672403|NCT02134431||HIV negative|HIV-negative subjects ages 10-14 years old and 18-21 years old. HIV negative subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. These tissue samples will be pretreated with tenofovir and challenged with laboratory HIV-1.
16672404|NCT02134418|Experimental|Irony CBT training|CBT of irony comprehension
16672405|NCT02134418|No Intervention|No Intervention|No Intervention
16672406|NCT02134405|Experimental|Rebamipide and Esomeprazole|Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
16672407|NCT02134405|Active Comparator|Rebamipide and placebo|Placebo drug with Rebamipide 100mg tid
16672408|NCT02134392|Experimental|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
16672409|NCT02134379||Heart Failure|Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction
16672410|NCT02134366|Experimental|Clobazam|Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
16672411|NCT02134366|Active Comparator|Clonazepam|Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
16672412|NCT02134366|Active Comparator|Lorazepam|Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
16672413|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
16672414|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
16672415|NCT02134340|Experimental|[I-124]-CPD-1028 PET/CT|"Administration of [I-124]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.
~A pre-targeting dose of CPD-1061 may be given prior to injection of [I-124]-CPD-1028."
16672416|NCT02134327|Experimental|Premedication with Midazolam|
16672417|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
16672418|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
16672419|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
16672420|NCT02134288|Active Comparator|Belatacept|Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
16672421|NCT02134288|Active Comparator|Everolimus|Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.
16672422|NCT02134275|Experimental|Whole body vibration training|Whole body vibration training (timed stand on vibration platform) 3 20-minute sessions per week for 6 months
16672423|NCT02134275|Placebo Comparator|Control group|No significant changes to diet, exercise and lifestyle.
16672424|NCT02134262|Experimental|Dose Level -1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
16672425|NCT02134262|Experimental|Dose Level 1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
16672426|NCT02134262|Experimental|Dose Level 2|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
16672427|NCT02134262|Experimental|Dose Level 3|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
16672428|NCT02134249|Active Comparator|Group A (Diosmin group)|In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.
16672429|NCT02134249|Active Comparator|Group B(Cabergoline group)|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .
16672430|NCT02134223|Experimental|dialectical behavior therapy|Primary intervention group: receiving one year of dialectical behavior therapy
16672431|NCT02134223|Placebo Comparator|treatment as usual|Comparison group: receiving one year of treatment as usual
16672432|NCT02134223|No Intervention|Receiving no treatment at all|Healthy control group
16672435|NCT02134197|Experimental|Lupartumab Amadotin (BAY1129980)|Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980.
16672439|NCT02134171|Experimental|Biological investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
16672440|NCT02134158|Experimental|sham and then anodal|visit 2 sham stimulation (120 seconds) and visit 3 anodal stimulation (30 minutes)
16672441|NCT02134158|Experimental|anodal and then sham|visit 2 anodal stimulation (30 minutes) and visit 3 sham stimulation (120 seconds)
16672442|NCT02134145||Self Selected Investors|A self selected crowdfunding backers from teh Scanadu Scout Crowdfunding campaign.
16672443|NCT02134132|Active Comparator|platelet rich plasma|The patients with diabetic foot ulcer who receive PG treatment.
16672444|NCT02134132|Placebo Comparator|Placebo|The patients with diabetic foot ulcer who receive placebo.
16672445|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
16672446|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
16672447|NCT02134106|Active Comparator|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
16672448|NCT02134106|Experimental|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
16672449|NCT02134093|Placebo Comparator|Normal saline|Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery
16672450|NCT02134093|Experimental|High dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery
16672451|NCT02134093|Experimental|Low dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery
16672452|NCT02134080|Active Comparator|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
16672453|NCT02134080|Placebo Comparator|Placebo|Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.
16672454|NCT02134067|Experimental|TAS-119|"TAS-119 tablets, oral, dose-escalating, 28-day cycle.
~Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms."
16672455|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
16672456|NCT02134041||traumatic brain injury|mild traumatic brain injury
16672457|NCT02134041||without TBI|without TBI
16672458|NCT02134028|Experimental|dupilumab treatment|"For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1* Dose every 2 weeks added to current controller medications.
~For participants coming from other studies: dupilumab 1 * Dose SC every 2 weeks added to current controller medications."
16672459|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
16672460|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
16672461|NCT02134002|Experimental|Disulfiram|disulfiram 250 mg/day
16672462|NCT02134002|Placebo Comparator|Placebo|Placebo
16672463|NCT02133989|Experimental|Ticlopidine+Ginko biloba|Switch to ticlopidine + ginko biloba
16672464|NCT02133989|Active Comparator|Clopidogrel|Keep clopidogrel
16672465|NCT02133976|Active Comparator|cognitive therapy|Cognitive therapy will be delivered to decrease pain interference
16672466|NCT02133976|Active Comparator|mindfulness training|Mindfulness training will be delivered to decrease pain interference
16672467|NCT02133976|Active Comparator|behavior therapy|Behavior therapy will be delivered to decrease pain interference
16672468|NCT02133976|Active Comparator|treatment as usual|Subjects will engage in their usual care for low back pain.
16672469|NCT02133963||women with no history of depression|Non-Probability Sample of women with no history of depression
16672470|NCT02133963||women with a past depression history|Non-Probability Sample of women with a past history of depression
16672471|NCT02133950|Experimental|freeze all embryos following PGD|no fresh embryo transfer; elective cryopreservation of all embryos after PGD
16672472|NCT02133950|Active Comparator|elective fresh embryo transfer|
16672473|NCT02133937|Experimental|High Concentration Liquid Formulation (HCLF)|
16672474|NCT02133937|Active Comparator|Lyophilized formulation|
16672476|NCT02133911|No Intervention|Controls|
16672477|NCT02133911|Experimental|Ranolazine|Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
16672478|NCT02133898|Other|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
16673229|NCT02128971|Active Comparator|Ferrochel® 90 mg|Ferrochel® capsule 90 mg OD for 30 days
16672479|NCT02133885|Active Comparator|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
16672480|NCT02133885|Placebo Comparator|Placebo Group|These subjects will start with placebo (this will look like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive a minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
16672481|NCT02133872|Other|Minocycline Dose Escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/> 5mm Hg BP subjects will receive minocycline 200 mg.
16672482|NCT02133859||Chronic Heart Failure patients using ASV|Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period
16672483|NCT02133846|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
16672484|NCT02133846|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions).
16672485|NCT02133846|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
16672486|NCT02133846|Placebo Comparator|Placebo|0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
16672487|NCT02133833|Experimental|Quantum Spectrum Radiation Emitter|five pieces of Quantum Spectrum Radiation Emitter will be placed on the affected shoulder daily for three weeks.
16672488|NCT02133820|Active Comparator|12 hourly capsule fasted|4 mg 12 hourly capsule - strong pain killer fasted
16672489|NCT02133820|Active Comparator|12 hourly capsule fed|4 mg 12 hourly capsule - strong pain killer fed
16672490|NCT02133820|Experimental|12 hourly capsule with antagonist fasted|4 mg 12 hourly capsule strong painkiller with antagonist fasted
16672491|NCT02133820|Experimental|12 hourly capsule with antagonist fed|4 mg 12 hourly capsule strong painkiller with antagonist fed
16672492|NCT02133807|Experimental|Specific Lp(a) apheresis & Atorvastatin|"Specific Lp(a) apheresis was performed with Lp(a) Lipopak immunosorbent columns (POCARD Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
16672493|NCT02133807|No Intervention|Atorvastatin|Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
16672494|NCT02133794|Experimental|Tomosynthesis|
16672495|NCT02133781|Experimental|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
16672496|NCT02133781|Experimental|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
16672497|NCT02133781|Experimental|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
16672498|NCT02133755|Other|Bromocriptine mesylate (Cycloset)|Cycloset 1.6 to 3.2 mg daily for 3 months
16672499|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
16672500|NCT02133729|Experimental|Gestational diabete|
16672501|NCT02133716|Experimental|expressed breast milk|"A single dose of expressed breast milk was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.
~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
16672502|NCT02133716|Active Comparator|sucrose 24% oral|"A single dose of sucrose was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.
~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
16672503|NCT02133703|Experimental|Mutation Carrier: Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
16672504|NCT02133703|Experimental|Mutation Carrier: Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
16672505|NCT02133703|Active Comparator|Mutation Carrier: Enhanced Print DA|BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
16672506|NCT02133703|Active Comparator|Mutation Carrier: Print DA|BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
16672507|NCT02133703|Experimental|Inconclusive Results: DA|Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
16672508|NCT02133703|No Intervention|Inconclusive Results: Usual care|Participants who receive inconclusive/uninformative results who are randomized to this arm will receive usual care but no additional decision support intervention
16672509|NCT02133690|Experimental|Vaccine Arm|3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
16672510|NCT02133690|Placebo Comparator|Placebo group|3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
16672511|NCT02133677|Experimental|temozolomide+WBRT|temozolomide: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks WBRT:30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week)
16672512|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
16672513|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
16672514|NCT02133638|Active Comparator|Sevoflurane|Sevoflurane Based Volatile Induction and Maintenance of Anaesthesia
16672515|NCT02133638|Active Comparator|Propofol|Propofol Based Total Intravenous Anesthesia
16672516|NCT02133625|Experimental|Pioglitazone and Carboplatin|"MTD Determination
~Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21
~Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1"
16672517|NCT02133625|Experimental|MTD Expansion Carboplatin and Pioglitazone|"MTD Expansion:
~Carboplatin alone on cycle 1, day 1.
~Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.
~On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks"
16672518|NCT02133612|Experimental|single arm paclitaxel and cisplatin|
16672519|NCT02133599|Other|Iohexol|All patients will receive two Iohexol clearance tests, 5 mL each time before cycle 1 and 4 of HDMTX
16672520|NCT02133586|Placebo Comparator|Clean Air - O3|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
16672521|NCT02133586|Experimental|NO2-O3|"Day #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise.
~Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
16672522|NCT02133586|Placebo Comparator|Clean Air - NO2|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
16672523|NCT02133586|Experimental|O3 - NO2|"Day #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
16672524|NCT02133573|Experimental|Progesterone|Vaginal gel, 90mg twice a day (BID)
16672525|NCT02133573|Placebo Comparator|Vaginal Lubricant|Vaginal twice a day (BID)
16672526|NCT02133560|Other|Medication Administration + Education|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip during months 1-3 and completing the medication administration log during months 1-6. During months 1-6 subjects will meet with study staff and receive educational materials on a monthly basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
16672527|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
16672528|NCT02133521|Placebo Comparator|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
16672529|NCT02133521|Experimental|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
16672530|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
16672531|NCT02133495|Experimental|open label|Non Cadaveric human BellaDerm Acellular dermal tissue
16672532|NCT02133482|Experimental|BI 639667|single rising doses given as oral solution
16672533|NCT02133482|Placebo Comparator|Placebo|placebo solution
16672534|NCT02133469|Experimental|PCV7 (Vaccine)|Randomized group of 1634 subjects to be administered a single dose of PCV7 (Hib vaccine offered at end of study).
16672535|NCT02133469|Active Comparator|Hib vaccine|Randomized group of 1634 subjects to be administered a single dose of Hib Vaccine(PCV7 vaccine offered at end of study).
16672536|NCT02133456||SIBP's vaccine|SIBP's vaccine group is the population injected with this vaccine.
16672537|NCT02133443|Active Comparator|Pressure Support Ventilation|Device: PSV - pressure support ventilation
16672538|NCT02133443|Active Comparator|Neurally Adjusted Ventilatory Assist|Device: Partial ventilator support with partial ventilation mode (NAVA)
16672539|NCT02133430|Experimental|Bispectral index (BIS) group|Bispectral index as measured by a BIS Processor is used to guide doses of anesthetic for maintaining the BIS values of 40-60
16672540|NCT02133430|No Intervention|Control group|Clinical signs is used to guide doses of anestheitics.
16672541|NCT02133417||Women|Women with mammographically-detected breast lesions
16672542|NCT02133404|Experimental|ASP7991 group|receiving ASP7991 and Cinacalcet-placebo
16672543|NCT02133404|Active Comparator|Cinacalcet group|receiving Cinacalcet and ASP7991-placebo
16672544|NCT02133391|Active Comparator|Practice-based reminder/recall or Usual care arm|"Practices participating in state immunization registry invited to reminder/recall (R/R) webinar trainings and provided educational materials to encourage immunization within their practices (child and adolescent trials only)
~Patients not randomized to the collaborative centralized R/R arm will receive usual care from their provider, which does not include R/R (adult trials only)"
16672545|NCT02133391|Experimental|Collaborative centralized R/R|Collaborative centralized reminder/recall (R/R) effort will be conducted by state immunization registry in collaboration with accountable care organizations and practices
16672546|NCT02133378|Experimental|Hemopatch|Use of Hemopatch on bleeding spot
16672547|NCT02133378|Sham Comparator|Control|Traditional techniques hemostasis (dry or wet gauze compression or similar)
16672548|NCT02133365|Active Comparator|Mindfulness and Interoceptive Exposure|Atrial fibrillation patients will receive 4-5 manualized, individualized sessions of Mindfulness and Interoceptive Exposure.
16672549|NCT02133365|No Intervention|Medical care as usual|Atrial fibrillation patients will receive medical and cardiac care as usual.
16672550|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
16672551|NCT02133339|Experimental|TRN-157|
16672552|NCT02133339|Placebo Comparator|Placebo|
16672553|NCT02133326|Experimental|Caldolor|800 mg of Caldolor® will be infused at the rate of 5-7 minutes as per the manufacturer's guidelines or
16672554|NCT02133326|Experimental|Ofirmev|1000 mg of Ofirmev® will be infused at the rate of 15 minutes as per the manufacturer's guidelines.
16672555|NCT02133313||Peritoneal Dialysis Patients|Patients on Peritoneal Dialysis
16672556|NCT02133300|Experimental|electrical stimulation|Compex 3 professional NMES for 60' per day
16672557|NCT02133300|No Intervention|control|
16672558|NCT02133287|Experimental|AVI® Arsenic trioxide drug eluting stent|Study group: Arsenic trioxide drug eluting stent delivery system (AVI®)
16672559|NCT02133287|Active Comparator|Firebird2® sirolimus eluting stent system|Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2®)
16672560|NCT02133274|No Intervention|Standard oncologic care|Standard oncologic care
16672561|NCT02133274|Experimental|Early Palliative Care|A first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
16672562|NCT02133274|Experimental|Psychosocial plus early Palliative Care|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy plus early palliative care. Regarding the early Palliative Care, a first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
16672563|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
16672564|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
16672565|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
16672566|NCT02133235|Active Comparator|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
16672567|NCT02133235|Experimental|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
16672568|NCT02133222|Experimental|Metastatic (stage IV) melanoma|
16672569|NCT02133209|Active Comparator|Stress Management for Headaches|This intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills for managing migraine headaches.
16672570|NCT02133209|Active Comparator|Mindfulness Based Stress Reduction|Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. The intervention also included an extended period of training in addition to the usual 8 weeks.
16672573|NCT02133183|Experimental|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16672574|NCT02133183|Experimental|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16672575|NCT02133170|Active Comparator|Psychopharmacological + MBCT|psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT)
16672576|NCT02133170|Active Comparator|psychopharmacological + psychoeducation|psychopharmacological treatment plus structured group psychoeducation;
16672577|NCT02133170|Other|Psychopharmacological treatment.|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
16672578|NCT02133157|Experimental|Sulfatinib capsule|cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.
16672579|NCT02133144|Experimental|High fat diet|Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
16672580|NCT02133144|Experimental|High carbohydrate diet|Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
16672581|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
16672582|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
16672583|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
16672584|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
16672585|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
16672586|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
16672587|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
16672588|NCT02133118||Patients on metformin mono-therapy who receive add-on|
16672589|NCT02133105|Active Comparator|Levosimendan|Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
16672590|NCT02133105|Active Comparator|Dobutamine|Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
16672591|NCT02133092||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
16672592|NCT02133079|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
16672593|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
16672594|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
16672595|NCT02133053||Ectoin Group|Ectoin Allergy Nasal Spray (Medical Device, drug-like)
16672596|NCT02133053||Beclomethasone Group|Beclomethasone nasal spray
16672597|NCT02133040||T3 > 4 nmol/l|Acute hyperthyroidism with a T3 > 4 nmol/l
16672598|NCT02133027|Experimental|Rouviere's Sulcus|Rouviere's sulcus is a 2 to 5 cm sulcus running to the right of the liver hilum anterior to the caudate process and usually containing the right portal triad or its branches.Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
16672599|NCT02133027|Other|traditional anatomy method|Ratcheted grasper is inserted through the lateral 5-mm port to retract the gallbladder fundus in cephalad fashion. An atraumatic grasper is inserted through the middle 5-mm port to retract the gallbladder infundibulum laterally, exposing the anteromedial aspect of the triangle of Calot.
16672600|NCT02133014|Experimental|surgical operation therapy|Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.
16672601|NCT02133014|No Intervention|conventional therapy|using the method of conventional conservative therapy without surgical management.
16672602|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
16672603|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
16672604|NCT02132988|Experimental|OPT-822/OPT-821|
16672605|NCT02132975|Experimental|With motorised probe handler|The surgeon use the motorised probe handler to do the biopsy
16672606|NCT02132975|Experimental|Without motorised probe handler|The surgeon do the biopsy as he usually do.
16672607|NCT02132962|Active Comparator|Healthy controls|Amino acid infusion
16672608|NCT02132962|Active Comparator|Cirrhosis|Amino acid infusion
16672609|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams [mg] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram [mg/kg] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
16672610|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m^2 intravenously (IV) q3w, epirubicin 100mg/m^2 IV q3w, and cyclophosphamide 600mg/m^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m^2 in Cycle 5, then 100mg/m^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
16672611|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
16672612|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
16672613|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
16672614|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
16672615|NCT02132923||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
16672616|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.
~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.
~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.
~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.
~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
16672617|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.
~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.
~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.
~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
16673568|NCT02126761|Experimental|Group 4|aTIV + aTIV
16672618|NCT02132897|Other|TR (Test - Reference)|Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
16672619|NCT02132897|Other|RT (Reference - Test)|Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
16672620|NCT02132884|Active Comparator|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
16672621|NCT02132884|Experimental|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
16672622|NCT02132871||1|
16672623|NCT02132858||Ancillary-Correlative (genetic mutation analysis)|Patients undergo collection of blood and tissue samples for analysis via sequencing.
16672624|NCT02132845|Active Comparator|Arm A (standard of care therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Patients receive standard of care therapy based on the discretion of the treating physician.
16672625|NCT02132845|Experimental|Arm B (target-directed therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Based on the results of the next generation sequencing, patients receive target-directed therapy.
16672626|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
16672627|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
16672628|NCT02132819|Placebo Comparator|Feeding During Transfusion|The feeding process will be continued during the transfusion
16672629|NCT02132819|Active Comparator|witholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
16672630|NCT02132806|Experimental|OFD with piezosurgery|Open flap debridement with Piezosurgery
16672631|NCT02132806|Experimental|OFD with piezosurgery+biomaterial|Open flap debridement with Piezosurgery with biomaterial mp3
16672632|NCT02132806|Experimental|OFD with piezosurgery+mp3+bracket|Open flap debridement with Piezosurgery with biomaterial mp3 + bracket
16672633|NCT02132793|Active Comparator|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
16672634|NCT02132793|Experimental|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
16672635|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF
~Amiodarone and/or DC-cardioversion
~Amiodarone Initial Dose
~Oral: 400 mg po TID for 3 days is recommended
~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
~Oral: at least 200 mg/day to be continued until 60 days after randomization
~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
16672636|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF
~Beta-blocker and/or Calcium channel blockers and/or Digoxin
~Dose, frequency and duration determined by medical professional as medically needed"
16672637|NCT02132754|Experimental|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672638|NCT02132754|Experimental|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672639|NCT02132754|Experimental|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672640|NCT02132754|Experimental|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672641|NCT02132754|Experimental|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672642|NCT02132754|Experimental|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672643|NCT02132754|Experimental|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672644|NCT02132754|Experimental|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672645|NCT02132754|Experimental|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672646|NCT02132754|Experimental|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672647|NCT02132754|Experimental|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672648|NCT02132754|Experimental|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672649|NCT02132754|Experimental|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672650|NCT02132754|Experimental|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672651|NCT02132754|Experimental|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672652|NCT02132754|Experimental|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672653|NCT02132754|Experimental|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672654|NCT02132754|Experimental|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672655|NCT02132754|Experimental|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672656|NCT02132754|Experimental|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
16672657|NCT02132754|Experimental|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672658|NCT02132754|Experimental|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672659|NCT02132754|Experimental|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672660|NCT02132754|Experimental|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672661|NCT02132754|Experimental|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672662|NCT02132754|Experimental|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672663|NCT02132754|Experimental|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672664|NCT02132754|Experimental|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672665|NCT02132754|Experimental|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672666|NCT02132754|Experimental|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672667|NCT02132754|Experimental|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672668|NCT02132754|Experimental|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672669|NCT02132754|Experimental|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672670|NCT02132754|Experimental|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
16672671|NCT02132741||Treated hypertension|Patients on treatment for hypertension
16672672|NCT02132741||CKD-ESRD|Pre- & post haemodialysis
16672673|NCT02132741||Healthy individuals|Healthy volunteers
16672674|NCT02132741||CKD|Pre-dialysis CKD & those with a functional renal transplant
16672675|NCT02132741||Hypertension|Untreated
16672676|NCT02132728|No Intervention|Control group|In the group with 11 volunteers, the control group did no change in normal food intake.
16672677|NCT02132728|Experimental|Flaxseed group|In this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
16672678|NCT02132728|Experimental|Rice and low carb group|In this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
16672679|NCT02132728|Experimental|Flaxssed and low carb group|In this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
16672680|NCT02132715|Active Comparator|Resistance exercise|Traditional isotonic lower-extremity resistance training
16672681|NCT02132715|Experimental|KAATSU exercise|Lower-extremity exercise with blood flow mildly restricted
16672682|NCT02132702|Experimental|Ekso treatment|
16672683|NCT02132689|Active Comparator|Actilyse|Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).
16672684|NCT02132689|Active Comparator|UHF/LMWH|Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).
16672685|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
16672686|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
16672687|NCT02132663|Experimental|Infant formula containing an alternate source of DHA|
16672688|NCT02132663|Active Comparator|Marketed routine infant formula|
16672689|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
16672690|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
16672691|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
16672692|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
16672693|NCT02132624|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
16672694|NCT02132611|Experimental|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
16672695|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.
~Treatment cycles are 4 weeks in duration"
16672696|NCT02132585||Sjogren|Sjogren Patients evaluated with Speckle tracking echocardiography
16672697|NCT02132585||Control|Controls Speckle tracking echocardiography
16672698|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
16672699|NCT02132559||DHEA administration,no treatment|The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
16672700|NCT02132546|Experimental|Chlorhexidine 0,2%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX.
16672701|NCT02132546|Experimental|Chlorhexidine 0,2% with ADS|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX with ADS.
16672702|NCT02132546|Experimental|Chlorhexidine 0,12%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.12% CHX.
16672703|NCT02132533|Experimental|Nifedipine|Women with preterm labor will receive nifedipine.
16672704|NCT02132533|Experimental|Placebo|Women with preterm labor will receive placebo.
16672705|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
16672706|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
16672707|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
16672708|NCT02132494|Experimental|Physical activity|60 minutes of daily physical activity during one school year
16672709|NCT02132494|No Intervention|Control|
16672710|NCT02132481|Experimental|EMA Only|See intervention
16672711|NCT02132481|Experimental|EMI Only|See intervention
16672712|NCT02132481|Experimental|EMA+EMI|See intervention
16672713|NCT02132481|Active Comparator|Neither - RSAU|See intervention
16672714|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
16672715|NCT02132455|Experimental|3 minutes in the right side colon|Colonoscopy, at least 3 minutes in the right side colon from the total withdrawal time
16672716|NCT02132455|Experimental|4 minutes in the right side colon|Colonoscopy, at least 4 minutes in the right side colon from the total withdrawal time
16672717|NCT02132455|No Intervention|6 minutes whole withdrawal time|Colonoscopy, at least 6 minutes whole withdrawal time regardless of time spent in any segment
16672718|NCT02132455|Experimental|8 minutes whole withdrawal time|Colonoscopy, at least 8 minutes whole withdrawal time regardless of time spent in any segment
16672719|NCT02132442|Experimental|Vitamin D supplementation|Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
16672720|NCT02132442|Placebo Comparator|Placebo|Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
16672721|NCT02132429|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 daily for 14 days.
16672722|NCT02132429|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo daily for 14 days.
16672723|NCT02132416|Active Comparator|Surgical management|Operative fixation of unstable thoracic cage injuries and chest wall deformity. Thoracic Epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
16672724|NCT02132416|Active Comparator|Conservative management|Conservative management of unstable thoracic cage injuries and chest wall deformity. Thoracic epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
16672725|NCT02132403|Experimental|IMPRIME PGG, BTH1704, & Gemcitabine|Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.
16672726|NCT02132390|Experimental|Arm I|Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity
16672727|NCT02132390|Experimental|Arm II|Patients who had CIA receive toremifene as in arm I
16672728|NCT02132390|Experimental|Arm III|Patients without CIA receive oral toremifene and goserelin for ovarian function suppression
16672729|NCT02132390|Experimental|Arm IV|Patients with CIA receive oral toremifene and goserelin for ovarian function suppression.
16672730|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
16672731|NCT02132364|No Intervention|typical follow-up|no intervention
16672732|NCT02132351||Hepatologists|Doctors working as hepatologists
16672733|NCT02132338|Experimental|The Education Health Program|Intervention forth knowledge and attitudes necessary for self-care
16672734|NCT02132325|Experimental|Dignity Therapy|
16672735|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
16672736|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
16672737|NCT02132299|Experimental|Group 1|Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
16672759|NCT02132195|Active Comparator|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
16672760|NCT02132182||Patients newly diagnosed with osteosarcoma|Blood draw
16672761|NCT02132169|Experimental|AC-170 0.24%|
16672762|NCT02132169|Placebo Comparator|AC-170 0%|
16672814|NCT02131818|Placebo Comparator|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
16673230|NCT02128971|Active Comparator|Sumalate® 90 mg|Sumalate® capsule 90 mg OD for 30 days
16672738|NCT02132299|Experimental|Group 2(A)|Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
16672739|NCT02132299|Placebo Comparator|Group 2(B)|Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
16672740|NCT02132299|Experimental|Group 3(A)|Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
16672741|NCT02132299|Placebo Comparator|Group 3(B)|Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
16672742|NCT02132299|Experimental|Group 4|The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
16672743|NCT02132299|Placebo Comparator|Group 5|The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
16672744|NCT02132286|Experimental|Quetiapine -XR (extended release)|Quetiapine-XR (extended release) 150-300mg- treatment in MDD patients with S/Lg alleles in MDD
16672745|NCT02132286|Active Comparator|Citalopram|Citalopram 10-20 mgm/day treatment for 8 weeks in MDD with S/Lg alleles
16672746|NCT02132273|Experimental|Educational Story|Participants receiving this intervention will have access to the educational story as they prepare for the overnight sleep study.
16672747|NCT02132273|No Intervention|Typical Preparation|Participants will receive traditional materials, directions, what to bring list, only. They will not recieve access to educational story
16672748|NCT02132260|Experimental|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)
16672749|NCT02132260|Active Comparator|Naftin® Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2%
16672750|NCT02132260|Placebo Comparator|Placebo Topical Cream|Placebo Topical Cream
16672751|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
16672752|NCT02132234|Experimental|Biological treatment|"Patients with high disease activity receiving biological treatment according to rheumatologic indication:
~etanercept 50 mg s.c. every week
~adalimumab 40 mg s.c. every 2 weeks
~certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks
~infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
16672753|NCT02132234|Placebo Comparator|control group|Patients with high disease activity receiving other than biological treatment and receiving placebo.
16672754|NCT02132221|Experimental|Cognitive Behavioral Therapy (CBT)|cognitive therapy (10 weekly sessions)
16672755|NCT02132221|No Intervention|no CBT- wait list|no cognitive therapy
16672756|NCT02132208||Trauma|Severe trauma patients admitted in the resuscitation room of our emergency department.
16672757|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2
~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
16672758|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
16672763|NCT02132143|Experimental|Progression-free survival&Concurrent chemoradiotherapy|"The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy, 21 days as a cycle.
~Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W."
16672764|NCT02132143|Active Comparator|Progression-free survival&sequential chemoradiotherapy|Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, 21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.
16672765|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
16672766|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
16672767|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
16672768|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
16672769|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
16672770|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
16672771|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
16672772|NCT02132104|Experimental|amnion graft in severe IUA|patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
16672773|NCT02132104|Sham Comparator|non-amnion graft in severe IUA|patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
16672774|NCT02132091|Experimental|Intermittent Fasting|Intermittent Fasting
16672775|NCT02132091|Experimental|Intermittent Fasting + Antioxidants|Intermittent Fasting; 400 IU Vitamin E; 1000 mg Vitamin C
16672776|NCT02132078||Lung transplant recipients with uncomplicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
16672777|NCT02132078||Lung transplant recipients with complicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
16672778|NCT02132065|No Intervention|Standard pain keller|
16672779|NCT02132065|Experimental|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
16672780|NCT02132039|Active Comparator|12-step sitting Tai Chi Chuan|The intervention is a simplified Tai Chi Chuan exercise, which consists of 12 steps, including weight shifting in different sitting positions, trunk and upper limb movements, and alternate thigh lift in a smooth and coordinated manner.
16672781|NCT02132039|Placebo Comparator|Control|We provide participants in the control group with a level of social contact equivalent to the intervention group, which comprises structured conversations on topic other than physical activity.
16672782|NCT02132026|Active Comparator|Alendronic Acid|50 patients will receive once weekly Alendronic Acid tablets (70mg).
16672783|NCT02132026|Placebo Comparator|Alendronic Acid placebo|25 patients will receive alendronic acid placebo tablets.
16672784|NCT02132026|Active Comparator|Denosumab|50 patients will receive 6 monthly denosumab injections
16672785|NCT02132026|Placebo Comparator|Denosumab Placebo|25 patients will receive a 6 monthly placebo injection.
16672786|NCT02132013|Experimental|Intervention SUBLIME|Intervention group
16672787|NCT02132013|No Intervention|Control|Regular care
16672788|NCT02132000|Active Comparator|tamoxifen|tamoxifen,20mg/day
16672789|NCT02132000|Experimental|toremifene|toremifene,60mg/day
16672790|NCT02131987||Dislocation|Patients operated with hip hemiarthroplasty for a femoral neck fracture with a postoperative dislocation of the prosthesis
16672791|NCT02131987||Non-dislocated|Patents without dislocation of a hemiarthroplasty for a femoral neck fracture
16672792|NCT02131961|Experimental|Study arm|Collagenase ointment topical application, once daily for 14 days, modified Contact Cast System, applied at days 0,3, and 7.
16672793|NCT02131948|Experimental|Intranasal insulin|40 IU of intranasal insulin
16672794|NCT02131948|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
16672795|NCT02131935||ISR Group|Patients Group Experienced In-Stent Restenosis (ISR)
16672796|NCT02131935||Non-ISR|Patients Group Without in-stent restenosis (ISR)
16672797|NCT02131922|Placebo Comparator|Hygenization Treatment|Basic oral hygiene instructions Supragingival plaque removal
16672798|NCT02131922|Experimental|Intensive Treatment|One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
16672799|NCT02131909|Experimental|mirror therapy|5 sessions mirror therapy 15 minutes per week for 5 weeks
16672800|NCT02131909|Placebo Comparator|bimanual rehabilitation exercises|5 sessions control therapy 15 minutes per week for 5 weeks
16672801|NCT02131896|Experimental|Mediterranean Diet|Mediterranean Diet
16672802|NCT02131896|Active Comparator|Regular nutritional instructions|Regular nutritional instructions
16672803|NCT02131883|Experimental|Group-Cognitive Behavioral Therapy|Group-Cognitive Behavioral Therapy for 7 patients and 2 therapists, 3 hours sessions a week in 12 weeks and a 3 hours booster session 12 weeks after
16672804|NCT02131883|Other|Wait-List with treatment as usual|Wait-List with treatment as usual waiting in 9 months for the intervention with group-CBT
16672805|NCT02131870|Active Comparator|L plantarum DSM 9843|
16672806|NCT02131870|Placebo Comparator|Placebo|
16672807|NCT02131857|Experimental|Staff|active interventional program based on Mindfulness training
16672808|NCT02131857|Experimental|Parents|active interventional program based on Mindfulness training
16672809|NCT02131857|Experimental|Patients with CF|active interventional program based on Mindfulness training
16672810|NCT02131844|Experimental|Facilitated early mobilization|Early mobilization facilitated by a dedicated health professional
16672811|NCT02131844|Active Comparator|Usual care|Instructions about early mobilization covered in a preoperative education session
16672812|NCT02131831||cirrhosis|
16672813|NCT02131818|Experimental|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
16672815|NCT02131805|Experimental|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
16672816|NCT02131792|Experimental|Lateral Rectus Muscle Slanted Recession|Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness
16672817|NCT02131779|Experimental|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
16672818|NCT02131779|Active Comparator|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
16672819|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.
~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
16672820|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
16672821|NCT02131753|Other|Cladribine s.c. injection, HCL treatment|Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
16672822|NCT02131740|Experimental|Eye rubbing intervention|eye rubbing performed for 1 minute in horizontal direction, clockwise rest for 5 seconds eye rubbing for a further 1 minute
16672823|NCT02131740|Active Comparator|No eye rubbing|no eye rubbing - comparator
16672824|NCT02131727|Experimental|Hand Hygiene Improvement Intervention|Hand Hygiene Improvement Intervention: Participants receive a 4 minute training video about actions to take to reduce risk of respiratory and GI infections that includes hand hygiene practices, along with educational posters and hand hygiene supplies.
16672825|NCT02131727|Placebo Comparator|Ask Me 3|Participants in the control group received a 4 minute training video about the Ask Me 3 program for clearer communication with health care providers, a brochure, and a key chain containing principles for clear communication with health care providers.
16672826|NCT02131714|Active Comparator|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
16672827|NCT02131714|Placebo Comparator|lifestyle counseling|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character.
16672828|NCT02131701|Active Comparator|Training group|The training group received individualized information about moderate training and was also offered training in group twice a week during 12 months. The training included both endurance training (nordic walking, water gymnastics) and training in gym.
16672829|NCT02131701|Active Comparator|Prescription of exercise|Individualized sessions for exercise prescription aiming at moderate exercise of 30 minutes at least 5 days a week
16672830|NCT02131688|Experimental|Mitoxantrone Hydrochloride Liposome|
16672831|NCT02131675||Boost shake|children that have had type 1 diabetes for more than 1 year
16672832|NCT02131662|Experimental|VPR 4 mg|
16672833|NCT02131662|Experimental|VPR 2 mg|
16672834|NCT02131662|Experimental|VPR 1 mg|
16672835|NCT02131662|Experimental|VPR 0.5 mg|
16672836|NCT02131662|Placebo Comparator|Placebo|
16672837|NCT02131649|Experimental|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
16672838|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
16672839|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
16672840|NCT02131623||Validation Group|Subjects with ALGS or PFIC and/or their caregivers
16672841|NCT02131610||Obstructive slep apnea patients|Patients with OSA
16672842|NCT02131610||Control group|Subjects without OSA
16672843|NCT02131597|Experimental|Treatment (guadecitabine)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
16672845|NCT02131571||HIV patients older than 50 years|HIV infected patients older than 50 years in current follow up
16672846|NCT02131558|Experimental|ICG Dye|Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
16672848|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.
~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
16672849|NCT02131519||internal jugular vein catheter|pediatric patients required internal jugular vein catheter
16672850|NCT02131506|Experimental|Lapatinib, Caelyx|"Lapatinib is given at escalating doses orally and continuously on days 1-21.
~Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1."
16672851|NCT02131493|Active Comparator|Gemcitabine|Gemcitabine：1000mg/m2，iv 30min，d1, d8,d15 q4w, 6 cycles
16672852|NCT02131493|Experimental|S-1+ Gemcitabine|S-1：40~60mg bid，d1~14; (S-1 dosage：BSA <1.25m2，40mg bid，1.25m2≤BSA≤1.5m2，50mg bid，BSA>1.5m2， 60mg bid) Gemcitabine：1000mg/m2，iv 30min，d1, d8 q3w, 8 cycles
16672853|NCT02131480|Experimental|Soft tissue|
16672854|NCT02131480|Experimental|Uterus|
16672855|NCT02131467|Experimental|Perampanel|Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.
16672856|NCT02131454|Experimental|Education and Inhalation technique training|Training in technique of drug inhalation in asthma and COPD patients and education about the role of inhalation therapy in the course of the disease.
16672857|NCT02131454|No Intervention|Education|Basic education about asthma and COPD.
16672858|NCT02131441|Other|laparoscopic hepatectomy|laparoscopic hepatectomy
16672859|NCT02131441|Other|open liver resection|open liver resection
16672860|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
16672861|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
16672862|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
16672863|NCT02131389|Other|Iconacy Hip System|Iconacy hip system prosthesis components
16672864|NCT02131376|Active Comparator|Cortical renorrhaphy|Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
16672865|NCT02131376|Experimental|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
16672866|NCT02131363|Experimental|Ingrowing Toenail Treatment Kit|"Ingrowing Toenail Treatment Kit consists of 3 components:
~Toe nail clip: one clip to be applied each week, for 6 weeks.
~Aerosol spray: to be applied up to 5 times a day, no more than one spray per hour.
~Nail adhesive: used to attach the clip to the nail."
16672867|NCT02131350|Experimental|Ranibizumab with Photocoagulation|
16672868|NCT02131337|Other|Contact force lesions|
16672869|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
16672870|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
16672871|NCT02131311|Experimental|pessary|disposable, single-use pessary
16672872|NCT02131298|Other|Fixed sequence|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B (palbociclib with itraconazole)
16672873|NCT02131285|Experimental|Sensory training|Experimental group received balance rehabilitation aimed at improving motor strategies and sensory strategies. Subjects in this group were treated to improve recovery of sensory impairment and were given exercises in the impaired sensory conditions, inhibiting the reliable sensory systems and forcing the Central Nervous System to use the impaired ones.
16672874|NCT02131285|No Intervention|No sensory strategy|Control group received usual care rehabilitation which did not include training of sensory strategies.
16672875|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
16672876|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
16672877|NCT02131259||Afatinib|
16672878|NCT02131246|Experimental|Faster-acting insulin aspart|Each subject will be allocated to two treatments (in random sequence).
16672879|NCT02131246|Active Comparator|NovoRapid®|Each subject will be allocated to two treatments (in random sequence).
16672880|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
16672881|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
16672882|NCT02131220|Experimental|Prourokinase|Intracoronary bolus infusion of 20mg prourokinase using selective catheter
16672883|NCT02131220|Active Comparator|Tirofiban|Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)
16672884|NCT02131220|Placebo Comparator|Normal saline|Intracoronary saline bolus infusion using selective catheter (20ml)
16673093|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
16672885|NCT02131207||Diagnostic (MRI and biopsy)|Participants undergo pelvic magnetic resonance imaging (MRI). Within 1-2 weeks, patients undergo scheduled prostate biopsy.
16672886|NCT02131194|Experimental|Lenstatin|Lenstatin (2) capsules orally per day for (6) months
16672887|NCT02131194|Placebo Comparator|Sugar Pill|Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months
16672888|NCT02131181||Delirium|Patients with delirium and patients without delirium
16672889|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
16672890|NCT02131155|Placebo Comparator|Placebo|Once daily
16672891|NCT02131142|Experimental|BioFreedom|
16672892|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
16672893|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
16672894|NCT02131116|Experimental|IMT|Integrated Metacognitive Therapy
16672895|NCT02131116|No Intervention|TAU|No intervention group/Treatment as Usual
16672896|NCT02131103|Active Comparator|Early ( < 24hr)|Early percutaneous coronary intervention means performed coronary intervention between 3-24 hours after successful fibrinolytic therapy.
16672897|NCT02131103|Active Comparator|Delay ( > 24 hours)|Delay percutaneous coronary intervention means received coronary intervention >24 hours to 2 weeks after successfully fibrinolytic therapy.
16672898|NCT02131103|Active Comparator|Early|"We randomized the patients into two groups early (≤ 24 hours) and delay group (> 24 hours) All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.
~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
16672899|NCT02131090|Experimental|Tegaderm TM|Participants in this arm of the study will receive the Tegaderm dressing to secure the epidural catheter
16672900|NCT02131090|Experimental|Lock-it Plus|Participants in this arm of the study will receive the Lock-it Plus dressing to secure the epidural catheter
16672901|NCT02131090|Experimental|Epifix|Participants in this arm of the study will receive the Epifix dressing to secure the epidural catheter
16672902|NCT02131077|Experimental|treatment|ALLO-ASC-TI injection
16672903|NCT02131077|Placebo Comparator|Placebo|Saline injection
16672904|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
16672905|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
16672906|NCT02131051||Azelastine group|Azelastine nasal spray Azelastine eye drops
16672907|NCT02131051||Ectoin group|Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
16672908|NCT02131038||Ectoin group|Ectoin Allergy Nasal Spray
16672909|NCT02131038||Cromolyn group|Cromolyn sodium
16672910|NCT02131012|Experimental|Celecoxib|1-4 mg intravitreal injection ofCelecoxib
16672911|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1
~Single I.V. dose of tasimelteon 2 mg on Day 6"
16672912|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1
~Single oral dose of tasimelteon 20 mg on Day 6"
16672913|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
16672914|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
16672915|NCT02130973|Active Comparator|Standard Clinical Practice Regimen|Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).
16672916|NCT02130973|Experimental|Experimental (cyclic) regimen|Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).
16672917|NCT02130947|Experimental|Exercise Intervention Arm|The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting ~1.5 hours.
16672918|NCT02130947|No Intervention|Non-Exercise Control Arm|Participants in the Non-Exercise Control Arm will not exercise for 12 weeks.
16672919|NCT02130934||childhood cancer survivors|Cardiac 3D MRI
16673094|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
16675159|NCT02116062|Other|Penetrating keratoplasty|
16672920|NCT02130921|No Intervention|Control|Community Health Workers (CHWs) in the control group will be invited to one group lecture didactically reviewing medical ethics, and the attending CHWs will be requested to pay a home visit to participating IDUs and FMs after the lecture.
16672921|NCT02130921|Experimental|Intervention|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.
~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.
~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
16672922|NCT02130908|Experimental|Lean fish|
16672923|NCT02130908|Experimental|Fatty fish|
16672924|NCT02130908|Experimental|Lean meat|
16672925|NCT02130895|Experimental|Intervention|STOPP Criteria Decision Support Content Intervention arm will receive CDS suggestions based on the STOPP criteria.
16672926|NCT02130895|No Intervention|Control|Control arm will provide care as usual during the intervention period.
16672927|NCT02130882|Active Comparator|Drug|Benralizumab (30mg) will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
16672928|NCT02130882|Placebo Comparator|Placebo|Placebo will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
16672929|NCT02130869|Experimental|Group A: Neuroblastoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group A participants receive busulfan, melphalan, CD133+ selected autologous stem cell infusion, hu14.18K322A, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.
~Cells for infusion are prepared using the CliniMACS System."
16672930|NCT02130869|Experimental|Group B: Lymphoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group B participants receive bendamustine, etoposide (or etoposide phosphate), cytarabine, melphalan, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.
~Cells for infusion are prepared using the CliniMACS System."
16672931|NCT02130869|Experimental|Group C: High-Risk Tumors|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group C participants receive melphalan, etoposide (or etoposide phosphate), carboplatin, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.
~Cells for infusion are prepared using the CliniMACS System."
16672932|NCT02130856|Experimental|Neonatal Kit|The neonatal kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Lady Health Workers will be equipped with a hand held electric scale to identify low birth weight newborns.
16672933|NCT02130856|No Intervention|Control (Standard care)|"In the control arm, Lady Health Workers will visit the home according to the regular schedule (same as in the intervention clusters) and will deliver the standard post-natal care consisting of:
~be present at delivery (though not conduct the delivery) and thorough examination of newborn and mother post delivery
~check mother for vaginal bleeding and abnormal blood pressure and make referral to nearest health facility as appropriate
~refer any newborn with congenital anomaly or evidence of asphyxia
~if unable to attend delivery for any reason, visit within first 24 hours post delivery
~assess newborn in first month of life during visits and provide basic treatment for acute respiratory infections, pneumonia, and diarrhea in the home
~encourage breastfeeding"
16672934|NCT02130843||MALE PATIENTS BEFORE UDS|MALE PATIENTS BEFORE UDS WITH DIFFICULT CATHETERIZATION
16672935|NCT02130830|Experimental|Topical anesthesia|Application of topical 2,5% lidocaine + 2,5% prilocaine gel to the anal canal before the procedure
16672936|NCT02130830|Placebo Comparator|Placebo|Application of placebo gel into the anal canal before the procedure
16672937|NCT02130817|Experimental|Belatacept|"Belatacept (nujolix):
~Tacrolimus withdrawal
~Standard of care(SOC) treatment:
~Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy
~Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.
~Maintenance immunosuppression:
~Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
~Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30."
16672938|NCT02130804|Experimental|Salsalate|Salsalate (4 g/day)
16672939|NCT02130804|Placebo Comparator|Placebo|Placebo (4 g/day)
16672940|NCT02130791|Experimental|PSD then TSD|baseline sleep, five nights sleep restriction, four nights recovery sleep, one night total sleep deprivation, one night recovery sleep
16672941|NCT02130791|Experimental|TSD then PSD|baseline sleep, one night total sleep deprivation, four nights recovery sleep, five nights sleep restriction, one night recovery sleep
16672942|NCT02130778|Active Comparator|Saline infusion|infusion of saline
16672943|NCT02130778|Active Comparator|Saline infusion with GLP1|infusion of saline with GLP1
16672944|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
16672945|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
16672946|NCT02130752|Experimental|Ultrasonic scalpel surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
16672947|NCT02130752|Experimental|Monopolar electrocautery surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
16672948|NCT02130739||thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
16676331|NCT02108327|Active Comparator|Unipolar electrocautery|
16672949|NCT02130726|Experimental|Minimally-invasive Gastrectomy|Patients allocated to the 'Minimally-invasive Gastrectomy' group will undergo minimally-invasive/laparoscopic total gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
16672950|NCT02130726|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive total resection of the stomach via laparotomy. This group is considered the control group
16672951|NCT02130713|Active Comparator|Group A, antibiotics|Prulifloxacin 600 mg
16672952|NCT02130713|Active Comparator|Group B, antibiotics plus nutraceuticals|Prulifoxacin plus Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg
16672953|NCT02130700|Experimental|Chemotherapy-Naive Patients|VT-464: given orally twice daily in 28-day cycles
16672954|NCT02130700|Experimental|Previous Chemotherapy Patients|VT-464: given orally twice daily in 28-day cycles
16672955|NCT02130700|Experimental|AR Positive 1 - 9% TNBC|VT-464: given orally once daily in 28-day cycles
16672956|NCT02130700|Experimental|Male ER Positive|VT-464: given orally once daily in 28-day cycles
16672957|NCT02130700|Experimental|AR Positive >10% TNBC|VT-464: given orally once daily in 28-day cycles
16672958|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
16672959|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
16672960|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
16672961|NCT02130674|Experimental|Dipeptiven|0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion
16672962|NCT02130661|Experimental|Part A|Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)
16672963|NCT02130661|Experimental|Part B|Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)
16672964|NCT02130648||Prenatal diagnosis|Prenatal diagnosis witch A sampling of blood de 14 ml
16672965|NCT02130635|Experimental|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
16672966|NCT02130635|Placebo Comparator|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
16672967|NCT02130635|Experimental|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
16672968|NCT02130635|Experimental|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
16672969|NCT02130635|Experimental|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
16672970|NCT02130635|Experimental|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
16672971|NCT02130635|Experimental|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
16672972|NCT02130635|Experimental|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
16672973|NCT02130635|Placebo Comparator|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
16672974|NCT02130622|Experimental|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
16672975|NCT02130622|Placebo Comparator|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
16672976|NCT02130609|Experimental|Skintel|
16672977|NCT02130596|Experimental|Acceptance-Based Behavioral Intervention|
16672978|NCT02130596|Active Comparator|Nutritional Counselling|
16672979|NCT02130583|Experimental|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
16672980|NCT02130583|Active Comparator|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
16672981|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
16672982|NCT02130570|No Intervention|Usual Care|Usual Care
16672983|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
16672984|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
16672985|NCT02130531|Experimental|Cohort 1|"Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):
~Emixustat HCl Tablet Strength B (mid dose); 1 tablet once daily & 1 placebo tablet once daily for 7 days
~Emixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
16672986|NCT02130531|Experimental|Cohort 2|"Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):
~Emixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days
~Emixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days
~Emixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
16672987|NCT02130518|Experimental|Auriclosene (AIS)|Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks
16672988|NCT02130518|Placebo Comparator|Auriclosene Vehicle Solution|Auriclosene Vehicle Solution, 8 treatments over 4 weeks
16672989|NCT02130505|Active Comparator|T2DM|Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
16672990|NCT02130505|Active Comparator|FCH|Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
16672991|NCT02130505|Active Comparator|FH|Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
16672992|NCT02130505|Active Comparator|Healthy controls|Healthy controls
16672993|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
16672994|NCT02130479|Experimental|Contingency Management-Family Engagement|The Contingency Management-Family Engagement or CM-FAM model integrates behavioral (e.g., drug testing linked with consequences) and cognitive behavioral (e.g., functional analyses of drug use, self-management and drug refusal skills training) strategies based on the Community Reinforcement Approach with effective family engagement strategies used in Multisystemic Therapy.
16672995|NCT02130479|Active Comparator|Treatment as Usual|Standard community-based substance abuse treatment services.
16672996|NCT02130466|Experimental|Pembro+D+T (Parts 1, 2 & 3)|Participants receive pembrolizumab intravenously (IV) on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose (twice per day, or BID) starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, once daily (QD) starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
16672997|NCT02130466|Placebo Comparator|Placebo+D+T (Part 3)|Participants receive placebo IV on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
16672998|NCT02130466|Experimental|Pembro+T (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
16672999|NCT02130466|Experimental|Pembro+D (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
16673000|NCT02130466|Experimental|Pembro+T Concurrent Dosing (Parts 4 & 5)|Participants receive trametinib tablets, 1.5 mg monotherapy, orally, QD for 4 weeks. Starting with Week 5, participants receive pembrolizumab IV on Day 1 of each 3-week cycle and a concurrent dosing schedule for trametinib tablets, 1.5 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
16673001|NCT02130466|Experimental|Pembro+T Intermittent Dosing (Parts 4 & 5)|Participants receive trametinib 1.5 mg monotherapy, orally QD for 2 weeks. Starting with Week 3, participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle and an intermittent dose schedule for trametinib tablets, 1.5 mg, orally, QD with 1 week OFF trametinib and 2 weeks ON trametinib through completion of 2 years of treatment or through study treatment discontinuation.
16673002|NCT02130453|Experimental|ReSTE Cardiac Imaging|Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
16673003|NCT02130453|Other|SPECT Cardiac Imaging|After resting strain measurement done, first set of nuclear images taken. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving Regadenoson, measurements repeated. These measurements take about 2 minutes to complete. At about 30 minutes after Regadenoson given, participant will have final images for the nuclear portion of the testing.
16673004|NCT02130440|Active Comparator|Resveratrol nasal spray|2 sprays per nostril 3 times a day for a period of two months
16673005|NCT02130440|Placebo Comparator|Placebo|2 sprays per nostril 3 times a day for a period of two months
16673006|NCT02130427|Other|Lung Imaging|Weekly 3D/4D CT scans during radiation therapy. MRI may be used in addition to or instead of CT depending on the location of the tumor and the decision of the treating physician.
16673007|NCT02130414|Active Comparator|Sandimmun® IV|Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
16673008|NCT02130414|Experimental|CyCol® capsules|CyCol®: 75 mg OD & BID for 7 days
16673009|NCT02130414|Experimental|CyCol® capsules 37.5 mg|CyCol®: 37.5 mg OD or BID for 7 days
16673010|NCT02130414|Experimental|CyCol® capsules, 150 mg|CyCol®: 150 mg OD or BID for 7 days
16673011|NCT02130401|Experimental|TNM (thermoneuromodulation device)|A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
16673012|NCT02130388|Other|Renal Insufficiency|Based on creatinine clearance
16673013|NCT02130388|Other|Renal Sufficiency|Based on creatinine clearance
16673014|NCT02130375|Experimental|stress urinary incontinence|Women with stress urinary incontinence
16673015|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
16673016|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
16673017|NCT02130349||Crohns Disease|IBD patients diagnosed with Crohn's disease
16673018|NCT02130349||Ulcerative colitis|IBD patients diagnosed with ulcerative colitis
16673019|NCT02130349||IBD-Undefined|IBD patients with undefined IBD
16673231|NCT02128971|Active Comparator|Ferrous Fumarate 90 mg|Ferrous Fumarate capsule 90 mg OD for 30 days
16673020|NCT02130336|Experimental|Aerobic interval training|"Frequency: Exercise 3 times a week. Twice under supervision and home exercise once a week.
~Duration: Totally 40 minutes in one session. Intensity: 10-minute warm-up and 5-minute cool-down at 40% maximal heart rate (HRmax), participants and exercise 4-minute high-intensity training at 85-90% HRmax and 4 times separated by 3-minute active recovery at 70% HRmax.
~Type: Using treadmill while under supervision."
16673021|NCT02130336|Experimental|Continuous moderate-intensity exercise|"Frequency: 5 times a week. Twice under supervision and home exercise 3 times a week.
~Duration: Totally 45 minutes per session. Intensity: 10-minute warm-up at 40% maximal heart rate (HRmax), 30-minute moderate intensity exercise at 50-70% HRmax and 5-minute cool-down at 40% HRmax Type: Using treadmill under supervision."
16673022|NCT02130336|No Intervention|Control group|Subjects in control group will receive general exercise knowledge and counseling.
16673023|NCT02130323|Active Comparator|Loop Electrosurgical Excision Procedure|Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
16673024|NCT02130323|Experimental|Imiquimod|Imiquimod 12.5mg intravaginally once weekly for 16 weeks
16673025|NCT02130310|Experimental|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first.
16673026|NCT02130310|Placebo Comparator|Placebo injection|The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed.
16673027|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
16673028|NCT02130297|Active Comparator|Group 2 - day 14|Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.
16673029|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
16673030|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
16673031|NCT02130271||Healthy|"Healthy subjects with no pain.
~Radioactive dye
~PET/MRI
~Blood draw"
16673032|NCT02130271||Sciatica|"Subjects with sciatica and scheduled for an epidural steroid injection (ESI).
~Radioactive dye
~PET/MRI
~Blood draw"
16673033|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
16673034|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
16673035|NCT02130245|Active Comparator|Early cholecystectomy|Laparoscopic cholecystectomy well be done after the immediate admission
16673036|NCT02130245|Active Comparator|Delayed cholecystectomy|Laparoscopic cholecystectomy after a period of conservative treatment
16673037|NCT02130232|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
16673038|NCT02130232|Active Comparator|Usual Care|Usual Medical Care
16673039|NCT02130219|Experimental|Chronic daily headache group|"Patients with chronic daily headache with suspicion of intracranial hypertension selected. Selection based on clinical symptoms (headache description, leading symptoms)and para-clinical pathological findings (optical nerve papilla edema). Not enough evidence to diagnose any other headache type. Simultaneous CSF pressure measurements and non-invasive ICP measurement will be performed.
~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT."
16673040|NCT02130219|Experimental|Multiple sclerosis group|"Multiple sclerosis (MS) group patients selected based on clinical symptoms and brain MRI changes typical for the disease. Diagnosis based on McDonalds criteria. CSF test for oligoclonal bands required as supporting diagnostic criteria. Patients selected with disease relapse symptoms. Simultaneous noninvasive ICP and CSF pressure measured.
~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
16673041|NCT02130219|Experimental|Stroke group|"Patients selected for this group have stroke/intracranial hemorrhage that might be complicated with intracranial hypertension. Stroke/intracranial hemorrhage diagnosed based on clinical findings and changes on brain CT/MRI. Patients with stroke less than 33% of middle cerebral artery territory included. Patients with intracranial hemorrhage 20-40 ml volume included. Patients unable to cooperate or sign informed consent excluded.
~Bilateral non-invasive ICP measurements performed. Results compared with brain MRI/CT lesion volume, mid-line shift.
~Interventions: non-invasive intracranial pressure measurement; brain MRI/CT"
16673042|NCT02130219|Experimental|Normal pressure hydrocephalus group|"Patients meeting normal pressure hydrocephalus diagnosis criteria selected to compare invasive CSF pressure versus non-invasive ICP.
~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
16673043|NCT02130206|Active Comparator|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
16673044|NCT02130206|Placebo Comparator|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
16673045|NCT02130206|Active Comparator|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
16673046|NCT02130206|Placebo Comparator|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
16676365|NCT02108106|Experimental|AG-348|Single oral dose of AG-348
16673047|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
16673048|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
16673049|NCT02130180||ED T1DM and hyperglycemia without criteria for DKA|
16673050|NCT02130180||Well controlled T1DM|
16673051|NCT02130180||ED DKA|
16673052|NCT02130167|Experimental|0.01% Atropine|
16673053|NCT02130167|Active Comparator|0.05% Atropine|
16673054|NCT02130154||Young males|Healthy, Lean, Caucasian, Young males
16673055|NCT02130154||Old males|Healthy, Lean, Caucasian, Older males
16673056|NCT02130141|Experimental|Dark chocolate, dietary counselling|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
16673057|NCT02130141|Active Comparator|Dietary counselling|Usual snacks are limited.
16673058|NCT02130128|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System
16673059|NCT02130102||Users of ModuLAAr|A group of volunteers (aged 60+), living in assisted living homes, will be provided with module based technical solutions to improve their independency and quality of life.
16673060|NCT02130089|Other|All patients|Intensive tailored education
16673061|NCT02130076||Stop|Patients with stable RA stopping TNF inhibition
16673062|NCT02130076||Continue|Patients with stable RA continuing TNFi therapy
16673063|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
16673064|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
16673065|NCT02130050||OSA Patient|•male patients aged 30 to 65 yr who are newly diagnosed as severe OSA (AHI >=30/hr)
16673066|NCT02130050||Control subjects:|•male control subjects are recruited from Heath Check-up Center. Subjects who are matched with OSA patients at age (+/-2 yrs), body height (+/-3cm) and body weight (<100 kg: +/-3kg, >100 kg: +/-4kg) are screened. Only subjects who are not sleepy (ESS<10) and have no OSA (AHI<5/hr PSG)
16673067|NCT02130037|Active Comparator|psychotherapy only|
16673068|NCT02130037|Experimental|application|
16673069|NCT02130024|Experimental|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
16673070|NCT02130024|Active Comparator|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
16673071|NCT02130011|No Intervention|without feeding/fluid instructicon|Ten patients treated with preoperative chemoradiotherapy without feeding/fluid instructions
16673072|NCT02130011|Experimental|with feeding/fluid instructions|Ten patients treated with preoperative chemoradiotherapy with feeding/fluid instructions
16673073|NCT02129998||Standard IVF/ICSI treatment|
16673074|NCT02129985|Experimental|Exenatide|patients were all received a short-term intensive insulin therapy,then randomised to Exenatide group(10 ug two times a day for three months)
16673075|NCT02129985|Active Comparator|Metformin|patients were all received a short-term intensive insulin therapy,then randomised to metformin group(850mg two times a day for three months)
16673076|NCT02129972|Experimental|video capsule endoscopy|
16673077|NCT02129959||laparoscopy|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
16673078|NCT02129946|Active Comparator|Resistant Starch Bagels|Bagels made from high-resistant starch flour (provides 24g resistant starch per day)
16673079|NCT02129946|Placebo Comparator|Control Bagels|Bagels made from wheat flour
16673080|NCT02129933|Experimental|Tracer bevacizumab-IRDye800CW|"Two days prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform), all patients will receive the fluorescent tracer bevacizumab-IRDye800CW intravenously.
~*amendement June 2015: topical administration of bevacizumab-800CW"
16673081|NCT02129920||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and treated with rivaroxaban
16673082|NCT02129894|Active Comparator|abdominal binder|Post cesarean section patients will get a abdominal binder placed
16673083|NCT02129894|No Intervention|No Abdominal Binder|Post cesarean section patients will not have abdominal binder
16673084|NCT02129881|Experimental|Autologous regulatory T Cell Product|"Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:
~Prednisolone Day 0: 500 mg IV (250mg pre-op, 250mg intra-op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day -7 to -2: 500 mg/day oral Day -1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day -4 to 14: 3-12 ng/ml oral Week 3 to 12: 3-10 ng/ml oral Week 13 to 36: 3-8 ng/ml oral Week 37 to End: 3-6 ng/ml oral"
16673085|NCT02129868|Experimental|Closed-loop on day 1 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 1 after CGM sensor insertion.
16673086|NCT02129868|Active Comparator|Closed-loop on day 3 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 3 or 4 after CGM sensor insertion.
16673087|NCT02129842||Atrial Fibrillation|
16673088|NCT02129829||Observational Group|Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly
16673089|NCT02129829||Treatment Group (Tenofovir disoproxil)|Patients who meet EASL treatment criteria who receive Tenofovir disoproxil
16673090|NCT02129816|Active Comparator|Bryophyllum|50% in 350mg Lactose, 2-2-2
16673091|NCT02129816|Placebo Comparator|Placebo|Lactose 350mg, 2-2-2
16673092|NCT02129816|Experimental|Solifenacin|10mg in 350mg Lactose, 2-2-2
16673095|NCT02129790|Experimental|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A will include psychoeducation and coping strategies.
16673096|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
16673097|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
16673098|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
16673099|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
16673100|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
16673101|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
16673102|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
16673103|NCT02129764|Experimental|Prednisone|Prednisone will be given 30mg/day for 2 weeks and then tapered off.
16673104|NCT02129764|Active Comparator|Allopurinol|Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.
16673105|NCT02129751|Experimental|bupropion hydrobromide|study drug
16673106|NCT02129751|Placebo Comparator|placebo|placebo
16673107|NCT02129738|Experimental|LoFric|LoFric catheters
16673108|NCT02129725|Experimental|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
16673109|NCT02129725|Placebo Comparator|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
16673110|NCT02129712|Placebo Comparator|Non-adaptive cognitive training|Non-adaptive cognitive training
16673111|NCT02129712|Experimental|Adaptive cognitive triaining|Adaptive cognitive training
16673112|NCT02129699|Other|None, standard chemotherapy only|"4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.
~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
16673113|NCT02129699|Experimental|Standard chemotherapy + Denosumab|"4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.
~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
16673114|NCT02129686|Experimental|Immediate Acupuncture Group|"Immediate acupuncture arm will receive acupuncture 3 times per week during week 1 and week 2, then 2 times per week from week 2 to week 8 for a total of 18 sessions. The crossover will take place after 8th week.
~The immediate acupuncture arm will enter a follow-up phase without acupuncture for 8 weeks from week 9 to week 16, while the standard usual care will be provided."
16673115|NCT02129686|Active Comparator|Delayed Acupuncture Group|The patients on the usual care/delayed acupuncture arm will continue their standard usual care with their physicians and care team. The crossover will take place after 8th week. After crossover, the patients initially on the usual care/delayed acupuncture arm will receive the identical acupuncture protocol but a less frequent schedule from week 9 to week 16: 2 times per week at week 9, then 1 time per week from week 10 to week 16 for a total of 9 sessions
16673116|NCT02129673|Experimental|VS101 Insert Dose A|VS101 Insert Dose A placed under the conjunctiva
16673117|NCT02129673|Experimental|VS101 Insert Dose B|VS101 Insert Dose B placed under the conjunctiva
16673118|NCT02129673|Experimental|VS101 Insert Dose C|VS101 Insert Dose C placed under the conjunctiva
16673119|NCT02129673|Active Comparator|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
16673120|NCT02129660|Experimental|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
16673121|NCT02129660|Experimental|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
16673122|NCT02129660|Active Comparator|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
16673123|NCT02129660|Active Comparator|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
16673124|NCT02129660|Placebo Comparator|Vehicle|Vehicle Topical Wipes
16673125|NCT02129647|Experimental|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
16673126|NCT02129634|Active Comparator|CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
16673155|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
16673156|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
16673157|NCT02129413|Experimental|Delta system treatment|
16673158|NCT02129400|Experimental|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
16673159|NCT02129400|Experimental|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
16673160|NCT02129400|Experimental|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
16673127|NCT02129634|Experimental|DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
16673128|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
16673129|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
16673130|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
16673131|NCT02129595|Active Comparator|resveratrol|resveratrol will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
16673132|NCT02129595|Placebo Comparator|placebo|A placebo will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
16673133|NCT02129582|Experimental|Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)|"CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.
~TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11."
16673134|NCT02129569|Experimental|Arm I (psychoeducational and behavioral interventions)|Participants meet with a nurse in-person for approximately 30 minutes to receive information about strategies for cognitive self-management of distress and an individualized walking prescription to gradually increase their walking to 30 minutes per day, 5 times per week. Participants wear a pedometer for at least 3 consecutive days during weeks 1, 6, and 12. Participants are also contacted by the nurse via telephone at 1 and 3 weeks for supplemental counseling support.
16673135|NCT02129569|Active Comparator|Arm II (control)|Participants meet with a nurse in-person for approximately 20 minutes to receive NCI educational booklets and a link to the ACS website. Participants are also contacted by the nurse via telephone at 1 and 3 weeks but the calls are primarily social in nature and do not include counseling support.
16673136|NCT02129556|Experimental|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.
~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.
~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
16673137|NCT02129543||Arm A: Treatment for Malignancy/Failure Group|Participants in this group will be those who are undergoing treatment for hematologic malignancy or bone marrow failure state.
16673138|NCT02129543||Arm B: Standard-of-Care SCT Group|Participants in this group will be cancer participants being treated with standard of care stem cell therapy
16673139|NCT02129543||Arm C: Adoptive T Cell Therapy Group|Participants in this group will be participants being treated with adoptive T cell therapy.
16673140|NCT02129543||Arm D: Control Group|Participants without cancer for studies of immunophenotype and immunologic function.
16673141|NCT02129530|Experimental|Community Social Mobilization Program|A manualized intervention developed with Sonke Gender Justice Network using a workshop intervention manual and a community mobilization toolkit will be used.
16673142|NCT02129530|No Intervention|Control Arm|The Control Arm does not receive the Community Mobilization Intervention
16673143|NCT02129517|Experimental|Arm I (IMPACT Intervention)|Oncology nurses watch tailored, web-based informational video clips addressing knowledge, attitudes, subjective norms, and perceived behavioral control (barriers of discussing clinical trials with patients). They also watch role-play video clips to help improve perceived behavioral control and address attitudinal barriers.
16673144|NCT02129517|Active Comparator|Arm II (online educational materials)|Oncology nurses view online clinical trials educational materials developed based upon NCI clinical trials educational materials for health care providers. The educational materials contain text and tables as presented on the NCI Website.
16673145|NCT02129504|Experimental|coronal advanced technique|root coverage with the porcine collagen matrix using the coronal advanced technique (standard technique)
16673146|NCT02129504|Experimental|extended flap technique|root coverage with the porcine collagen matrix using the extended flap technique (new surgical technique)
16673147|NCT02129491||Pediatric Stroke and Hemiplegia|Any infant or child with acute stroke or hemiplegia
16673148|NCT02129478|Experimental|Olanzapine|
16673149|NCT02129452||CDR (Clinical dementia rating) 0|10 participants complaining subjective memory problem and acquiring CDR 0
16673150|NCT02129452||CDR 0.5|10 participants complaining subjective memory problem and acquiring CDR 0.5
16673151|NCT02129452||CDR 1|10 participants with mild cognitive impairment and acquiring CDR 1
16673152|NCT02129452||CDR 2|10 participants with moderate to severe cognitive impairment and acquiring CDR 2
16673153|NCT02129439|Experimental|SB012|"SB012 will be available in this clinical trial in a concentration of 7.5 mg/ml hgd40 in 30ml PBS. The maximum daily dose will not exceed 225mg.
~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 12 of the 18 subjects will receive verum SB012 (in a 2:1 randomization SB012:Placebo)"
16673154|NCT02129439|Placebo Comparator|Placebo|"Placebo will be administered with an identical volume of 30ml PBS.
~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 6 of the 18 subjects will receive placebo (in a 2:1 randomization SB012:Placebo)"
16673227|NCT02128984|Experimental|Vitafos Junior|Symbiotic Formula with DHA and antioxidants
16673161|NCT02129400|Experimental|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
16673162|NCT02129400|Experimental|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
16673163|NCT02129400|Experimental|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
16673164|NCT02129400|Experimental|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
16673165|NCT02129400|Experimental|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
16673166|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
16673167|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
16673168|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
16673169|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
16673170|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
16673171|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
16673172|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
16673173|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
16673174|NCT02129374|Experimental|Direct repair of pars defect|The pars defect was repaired with 4.5mm cortical screw.
16673175|NCT02129374|No Intervention|Conservative treatment|The pars defect of spondylolysis was not repaired with cortical screw.
16673178|NCT02129348|Active Comparator|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).
~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
16673179|NCT02129348|Placebo Comparator|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).
~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
16673180|NCT02129335||stress|patient with glioblastoma diagnosis and partners
16673181|NCT02129322|Active Comparator|Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
16673182|NCT02129322|Experimental|S-1 and Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
16673183|NCT02129309|Experimental|Systemic Apelin infusion|"Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers
~Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures"
16673184|NCT02129309|Experimental|Apelin infusion - forearm|"Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.
~Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures."
16673185|NCT02129296|Active Comparator|hemiosphere® BALLOON|Balloon filled with air according to the manufacturing company orders 600 or 720 ml air
16673186|NCT02129296|Active Comparator|Fluid filled balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
16673187|NCT02129283|Experimental|Simulation training|End-of-life simulation training of critical care physicians and nurses using standardized patients to improve communication and interpersonal skills.
16673188|NCT02129283|No Intervention|Control|No simulation training
16673189|NCT02129270|Active Comparator|Lidocaine HCl 2%|Lidocaine HCl 2% (200mg/10ml) 10 ml.
16673190|NCT02129270|Experimental|Lidocaine HCl 1%|Lidocaine HCl 1% (100mg/10ml) 15-20 ml.
16673191|NCT02129257|Experimental|FOLFIRI-AFLIBERCEPT|Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen. Treatment will be repeated every 2 weeks. FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours. FOLFIRI administration will immediately follow the aflibercept one. In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
16673192|NCT02129244|Active Comparator|NCM Plus Intervention|The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
16673228|NCT02128984|Active Comparator|Standard Formula|Standard isocaloric and isonitrogenous formula.
16676366|NCT02108106|Placebo Comparator|Placebo|Single oral dose of placebo
16673193|NCT02129244|No Intervention|Standard/Usual Care|Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
16673194|NCT02129231|Placebo Comparator|placebo|calcined magnesia 100 mg tablets once a day for 16 weeks
16673195|NCT02129231|Active Comparator|ezetimibe/simvastatin|ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
16673196|NCT02129231|Active Comparator|rosuvastatin|rosuvastatin 20 mg tablets once a day for 16 weeks
16673197|NCT02129218|Experimental|Cohort 1: Low glycemic load with standard diet|Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.
16673198|NCT02129218|Experimental|Cohort 2: Low glycemic load with intensified diet|Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.
16673199|NCT02129218|Active Comparator|Cohort 3: Medium glycemic load with standard diet|Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.
16673200|NCT02129218|Active Comparator|Cohort 4: Medium glycemic load with intensified diet|Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.
16673201|NCT02129205|Experimental|PF-06650808|
16673202|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
16673203|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
16673204|NCT02129179|Experimental|GLP-1|
16673205|NCT02129166|Placebo Comparator|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
16673206|NCT02129166|Active Comparator|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.
~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
16673207|NCT02129153|Experimental|LIFT (Parent information)|"LIFT (Parent information): during their child's 7th and 8th grade years research staff will 1. communicate with parents about their child's academic and behavioral performance in school, roughly twice-monthly 2. invite parents to participate in a 2-hour parent support session to help teach parents to communicate better with their child and support better academic and behavioral performance in school
~students take a baseline survey then 3 surveys (one/year)
~parents take a baseline survey then 2 surveys (one/year)"
16673208|NCT02129153|No Intervention|Usual care group|"Usual care control group/No Intervention consists of neither communication of academic information to parents nor invitation to parent support sessions.
~students take a baseline survey then 3 surveys (one/year)
~parents take a baseline survey then 2 surveys (one/year)"
16673209|NCT02129140||Hernia graft/mesh|Hernia repair patients implanted with biologic hernia graft during surgery
16673210|NCT02129127|Experimental|Drug Coated Chocolate|Paclitaxel Coated Chocolate Balloon Angioplasty
16673211|NCT02129114|Experimental|ReDura Onlay|The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
16673212|NCT02129114|Active Comparator|DuraGen|Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
16673213|NCT02129101|Experimental|Treatment (azacitidine, sonidegib, decitabine)|"Patients receive azacitidine SC or IV on days 1-7, sonidegib PO QD on days 1-28 or 1-7* or decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: Sonidegib PO QD is given on days 1-7 if in combination with azacitidine or on days 1-28 is given if in combination with decitabine."
16673214|NCT02129088|Experimental|Cohort 1|Participants will receive esketamine 14 milligram (mg) as intranasal spray into each nostril on Day 1.
16673215|NCT02129088|Experimental|Cohort 2|All participants will receive esketamine 14 mg as intranasal spray into each nostril on Day 1 of Period 1 as Treatment A and esketamine 14 mg as intranasal spray followed by intranasal administration of placebo solution after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Period 2 as Treatment B in a fixed sequence.
16673216|NCT02129075|Experimental|Arm I (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
16673217|NCT02129075|Active Comparator|Arm II (CDX-1401 and poly-ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
16673218|NCT02129075|Experimental|Arm III (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -3 and 22-26 of course 1 only and DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
16673219|NCT02129075|Experimental|Arm IV (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -3 of course 1 only, and DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
16673220|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16673221|NCT02129049|Experimental|Supportive care (Enhancing Connections Telephone Program)|See Detailed Description.
16673222|NCT02129023|Experimental|exergame|Participants were asked to use exergame (Xbox 360) half hour for three times per week in the 12-week study period.
16673223|NCT02129023|No Intervention|control|Participants were not asked to use exergames.
16673224|NCT02129010||Subarachnoid hemorrhage with and without Terson syndrome|Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome
16673225|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
16673226|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
16673232|NCT02128971|Active Comparator|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg OD for 30 days
16673233|NCT02128971|Active Comparator|Ferric glycinate 90 mg|Ferric glycinate capsule 90 mg OD for 30 days
16673234|NCT02128971|Active Comparator|Placebo|Placebo capsule OD for 30 days
16673235|NCT02128958|Experimental|CF102|orally q12h
16673236|NCT02128958|Placebo Comparator|Placebo tablets of CF102|orally q12h
16673237|NCT02128945|Experimental|FLUDATEP|[18F] - Fludarabine PET/CT
16673238|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
16673239|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
16673240|NCT02128932|Active Comparator|Insulin glargine|
16673241|NCT02128919|Experimental|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
16673242|NCT02128919|Sham Comparator|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
16673243|NCT02128906|Active Comparator|Cisplatin-IMRT|Cisplatin 40 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
16673244|NCT02128906|Active Comparator|Docetaxel-Cetuximab-IMRT|Docetaxel 15 mg/m2 weekly x 7; Cetuximab 400 mg/m2 load, one week prior to IMRT; Cetuximab 250 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
16673245|NCT02128893|Experimental|Isavuconazole alone|Isavuconazole three times a day on Days 1 and 2 and once a day on Days 3, 4, and 5
16673246|NCT02128893|Experimental|Isavuconazole and Esomeprazole|Esomeprazole daily for 10 days starting on Day 1 and isavuconazole three times a day on Days 6 and 7 and once a day on Days 8, 9, and 10
16673247|NCT02128880|Experimental|CARRII|CARRII: This is a highly interactive Internet intervention consisting of 6 Cores of Intervention material, including Core 1, Overview, Core 2: Your Risk for AEP, Core 3: Drinking, Core 4: Contraception, Core 5: Thoughts and Decisions, and Core 6: Commit to It.
16673248|NCT02128880|Active Comparator|Patient Education|CARRII Education: This is a static website containing educational information on the following topics: What is Alcohol Exposed Pregnancy (AEP)?, Fetal Alcohol Spectrum Disorders, Impact of AEP, Prevalence of AEP, Causes and Prevention of AEP, Treatment for AEP, and Links to related information.
16673249|NCT02128867|Experimental|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
16673250|NCT02128867|Experimental|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
16673251|NCT02128867|Experimental|bouncing|bouncing . intervention to relax the infant
16673252|NCT02128854|Experimental|Tablets Intervention|Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
16673253|NCT02128854|No Intervention|Usual Care|Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician. The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care. Between scheduled office encounters, contact will be initiated by the individual.
16673254|NCT02128841|Experimental|All patients|CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
16673255|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
16673256|NCT02128815|Experimental|Coaching|diabetes health coaching + usual diabetes self-management education
16673257|NCT02128815|No Intervention|Usual Care|Usual care or self-management education
16673258|NCT02128802|Experimental|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
16673259|NCT02128802|Experimental|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
16673260|NCT02128789|No Intervention|Control Condition|Subjects receive usual care and support. No study intervention provided
16673261|NCT02128789|Experimental|Elder Tree Condition|Elder Tree website. Subjects receive usual care, support and access to the study intervention website.
16673262|NCT02128776|Active Comparator|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
16673263|NCT02128776|Active Comparator|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
16673264|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
16673265|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
16673266|NCT02128750|Experimental|revascularization group|Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.
16673267|NCT02128737|No Intervention|Control|10 hours time-in-bed all nights of study
16673268|NCT02128737|Experimental|1 Recovery Night|2 baseline nights, five nights sleep restriction, 1 recovery night, five nights sleep restriction, 4 recovery nights
16673269|NCT02128737|Experimental|3 Recovery Nights|2 baseline nights, five nights sleep restriction, 3 recovery nights, five nights sleep restriction, 2 recovery nights
16673270|NCT02128737|Experimental|5 Recovery Nights|2 baseline nights, five nights sleep restriction, 5 recovery nights, five nights sleep restriction, 1 recovery nights
16673271|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
16673272|NCT02128698|Experimental|Protein and computer-assisted exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
16673298|NCT02128568|Experimental|YRI only|Immediately following assessment and collection of biomarkers, participants will be offered the YRI sessions.
16673273|NCT02128698|Placebo Comparator|Placebo and computer-assisted exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
16673274|NCT02128698|Active Comparator|Protein and usual exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
16673275|NCT02128698|Active Comparator|Placebo and usual exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
16673276|NCT02128685|Active Comparator|Dydrogesterone|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
16673277|NCT02128685|Placebo Comparator|Placebo pill|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
16673278|NCT02128672|Active Comparator|Conventional SCS lead|Conventional Thoracic-lumbar SCS lead placement
16673279|NCT02128672|Experimental|SCS Experimental Lead Placement|Experimental SCS lead placement in a novel position
16673280|NCT02128659|Experimental|SHE Project|Receives SHE Project Intervention during Week 1 of enrollment
16673281|NCT02128659|Active Comparator|Wait-List Control|Receive SHE Project intervention during Week 2 of Enrollment
16673282|NCT02128646|Experimental|Treatment Group 1|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 1 will have an open surgery for abdominal hernia repair.
16673283|NCT02128646|Experimental|Treatment Group 2|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 2 will have a laparoscopic abdominal hernia repair.
16673284|NCT02128646|Active Comparator|Control Group 1|Patients scheduled in Control Group 1 will have an open surgery for abdominal hernia repair. The Control Group patients will receive traditional treatment.
16673285|NCT02128646|Active Comparator|Control Group 2|Patients scheduled in Control Group 2 will have laparoscopic abdominal hernia repair. The Control Group patients will receive traditional treatment.
16673286|NCT02128633|Placebo Comparator|placebo|"Individuals that were randomized for treatment  A  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  A  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Placebo gel)."
16673287|NCT02128633|Experimental|Experimental gel|"Individuals that were randomized for treatment  B  - The product was delivered in a transparent plastic syringe with 10 mls identified by the letter  B . The syringes were given to individuals in an opaque plastic envelope sealed and with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% ) ."
16673288|NCT02128633|Active Comparator|Positive control|"Individuals that were randomized for treatment  C  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  C  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Fluoride neutral NaF gel 2 %)."
16673289|NCT02128620|No Intervention|Control Group|Users randomized to the www.sjekkdeg.no A version, consisting en the educative web app, not including the Game-Based Appointment System
16673290|NCT02128620|Experimental|Intervention Group|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
16673291|NCT02128607|Active Comparator|Real SNAG|A real sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
16673292|NCT02128607|Placebo Comparator|Sham SNAG|A sham (placebo) sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
16673293|NCT02128594|Experimental|Standard of Care|Standard of care
16673294|NCT02128581|Placebo Comparator|Saline|a saline infusion will be started and maintained till the end of the study at 1300 (300 minutes).
16673295|NCT02128581|Active Comparator|Exendin-9,39 @ 300|Exendin-9,39 @ 300pmol/kg/min
16673296|NCT02128581|Active Comparator|Exendin-9,39 @ 750|Exendin-9,39 @ 750pmol/kg/min
16673297|NCT02128568|Active Comparator|Waitlist + YRI only|Participants will complete the assessment and collection of biomarkers and be placed on a waitlist. Once the trial of the first arm has been concluded, participants complete another round of assessments and are offered the YRI sessions. The epigenetic biomarkers collected will be compared with the experimental arm.
16673299|NCT02128555|Active Comparator|Arthrodesis|Ankle arthrodesis (fusion)
16673300|NCT02128555|Experimental|Total Ankle Replacement|Total Ankle Replacement
16673301|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
16673302|NCT02128529||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
16673303|NCT02128516|Active Comparator|whey protein|whey protein
16673304|NCT02128516|Placebo Comparator|placebo|placebo
16673305|NCT02128516|Experimental|pea protein|pea protein
16673306|NCT02128503|Other|HBV DNA level monitoring|Group with HBV DNV level being monitored regularly
16673307|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16673308|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16673309|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16673310|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16673311|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
16673312|NCT02128464|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
16673313|NCT02128464|Active Comparator|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
16673314|NCT02128451|Active Comparator|Meperdine group|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
16673315|NCT02128451|Active Comparator|Fentanyl group|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
16673316|NCT02128425|Experimental|FOLFOXIRI|FOLFOXIRI
16673317|NCT02128425|Active Comparator|FOLFOX|FOLFOX
16673318|NCT02128412|Active Comparator|Stent oversize group|"Oversized stent deployed at low pressure:
~A stent premounted on a balloon with a nominal diameter halfway between the lumen diameter and the true vessel diameter (approximated by external elastic lamina) as assessed by IVUS. This will be based on the smallest of the vessel reference diameters proximal and distal to the lesion. In addition the vessel diameter must be greater than this diameter throughout the length of the lesion. This stent will be implanted at an inflation pressure of 10 atmospheres or less for at least 15 seconds and a second IVUS will be performed to assess the end point."
16673319|NCT02128412|Active Comparator|High pressure group|"Stent deployed at high pressure:
~A stent premounted on a balloon with a nominal diameter approximately equal to the vessel segment lumen reference diameter as previously assessed by IVUS will be used. This stent will be implanted at an inflation pressure of 14 atmospheres or more for at least 15 seconds and a second IVUS will be performed to assess the end point"
16673320|NCT02128399||patients before and after intervetion|
16673321|NCT02128386||Renal sympathetic denervation|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus renal sympathetic denervation
16673322|NCT02128386||Intensified antihypertensive treatment|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus second-line antihypertensive agents (e.g. mineralocorticoid receptor antagonists or alpha-1-blockers)
16673323|NCT02128373|Active Comparator|Arm I (usual care)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
16673324|NCT02128373|Experimental|Arm II (usual care with CLOSER intervention)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention
16673325|NCT02128360|Active Comparator|Minimal stimulation protocol|Low dose Letrozole 2.5 mg over 5 days, starting from cycle day 2, overlapping with low dose gonadotropins, starting from day 3 of the Letrozole at 150 units per day. GnRH antagonist to avoid premature LH surge will be introduced when one or more of the growing follicles reached approximately 14 mm in size
16673326|NCT02128360|Active Comparator|High dose protocol|High dose of gonadotropins (≥300 IU/day) starting from cycle day 3. GnRH antagonist will be introduced to avoid premature LH surge when one or more of the growing follicles will reach approximately 14 mm in size
16673327|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and healthcare workers to communicate through a secure, password protected online portal with data transfer capabilities. Effectiveness of the portal in improving several health outcomes from baseline-12 months will be assessed in this study.
16673328|NCT02128334||Patients with advanced prostate carcinoma|
16673399|NCT02127840|Experimental|Synacthen|Synacthen infusion during adrenal venous sampling
16673329|NCT02128321|Experimental|Isavuconazole + Repaglinide + Caffeine|Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16
16673330|NCT02128308|Experimental|Levofloxacin and Streptomycin added|Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
16673331|NCT02128308|Experimental|Moxifloxacin and Kanamycin added|Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
16673332|NCT02128295|Experimental|Primiparous mothers|Mother who are primiparous
16673333|NCT02128295|Experimental|Multiparous mothers|Mothers who are multiparous
16673338|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
16673339|NCT02128256|Experimental|Cerament G injection|Cerament G is injected to fill a bone defect after debridement of the infected bone.
16673340|NCT02128243|Experimental|Arm A: De-escalation therapy|Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated.
16673341|NCT02128243|Experimental|Arm B: Chemotherapy by Investigator's choice|Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first.
16673342|NCT02128230|Experimental|Total Therapy 5b|Induction, optional bridging, first transplant, optional bridging, inter-therapy, optional bridging, second transplant, optional bridging, consolidation, maintenance
16673343|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
16673344|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
16673345|NCT02128204|Experimental|HYADERMIS LA Facial Dermal Implant|Subjects will be randomly assigned to receive experiment treatment, lidocaine contained hyaluronate facial dermal filler, in one side of the face.
16673346|NCT02128204|Active Comparator|Hya-Dermis Facial Dermal Implant|Subjects will be randomly assigned to receive control treatment, hyaluronate facial dermal filler, in one side of the face.
16673347|NCT02128191|Active Comparator|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later
16673348|NCT02128191|Placebo Comparator|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
16673349|NCT02128178|Active Comparator|ENOXAPARIN 2 HOURS BEFORE|Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
16673350|NCT02128178|Active Comparator|Enoxaparin 40 mg 12 hours before|Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
16673351|NCT02128165|Active Comparator|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
16673352|NCT02128165|Active Comparator|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere)those BMI below 45
16673353|NCT02128152|Experimental|Ekso Training Safety and Efficacy|
16673354|NCT02128126|Experimental|ISA101/ISA101b|The maximum total treatment duration for a patient is six cycles (1 cycle is 21 days) for a total of 18 weeks. On day 15 of cycles 2, 3 and 4 patients are to receive the vaccination scheme of ISA101/ISA101b. Patients will be vaccinated with a fixed dose of ISA101/ISA101b every three weeks for a total of three rounds of vaccination. Four dose levels of ISA101 have been tested. ISA101b will be tested in bridging cohorts.
16673355|NCT02128113|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days
16673356|NCT02128113|Experimental|0.5% omaveloxolone (RTA 408) opthalmic suspension|0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
16673357|NCT02128113|Experimental|1% omaveloxolone (RTA 408) opthalmic suspension|1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
16673358|NCT02128100|Experimental|Folririnox with SBRT|"Folfirinox
~Oxaliplatin 85 mg/m² for over 2 hours,
~Leucovorin 400n mg/m² for over 2 hours,
~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion
~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes
~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
~SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment."
16673359|NCT02128087|No Intervention|Control group|This study arm will receive care as usual.
16673360|NCT02128087|Experimental|Two-way SMS intervention group|"Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages (We hope you are feeling well today. Reply 1 if well, 2 if unwell) to request a follow-up call from the clinic."
16673361|NCT02128087|Experimental|One-way SMS intervention group|"Clients will receive a weekly one-way SMS with the message We hope you are feeling well today. There will be no prompt for response."
16673362|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
16673363|NCT02128061|Active Comparator|R-miniCHOP|"All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² Day 1 (D1) DOXORUBICINE IV : 25 mg/m² D1 VINCRISTINE IV : 1 mg Total Dose (TD) D1 PREDNISONE PO : 40 mg/m² D1 to D5 RITUXIMAB SC* : 1400 mg TD D1
~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
16673364|NCT02128061|Experimental|R2-miniCHOP|"All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14
~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
16673365|NCT02128048||Heavy smokers|Assessment of body composition and muscle function
16673366|NCT02128035|No Intervention|Without Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.
~The LEAD SHIELD will not be used in this group.
~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
16673367|NCT02128035|Experimental|With Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.
~In this group, a LEAD SHIELD will be used. The Pelvic lead shield will be draped on patient from umbilicus to knees.
~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
16673368|NCT02128022|Experimental|GLP-1 (7-36) amide and Glibenclamide|Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
16673369|NCT02128022|Experimental|Glibenclamide alone|Glibenclamide 5 mg orally prior to PCI
16673370|NCT02128022|Active Comparator|GLP-1 (7-36) amide|GLP-1 (7-36) amide
16673371|NCT02128022|No Intervention|Saline control|0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)
16673372|NCT02128009||osteoporosis,non-osteoporosis|
16673373|NCT02127996|Placebo Comparator|Normal Saline|Infusion of Normal Saline during Percutaneous Coronary Intervention
16673374|NCT02127996|Experimental|GLP-1|Infusion of GLP-1 (7-36) amide during elective percutaneous coronary intervention
16673375|NCT02127983|Experimental|Early intervention|Early intervention arm engaging informal providers Received the intervention early in the first 12 months
16673376|NCT02127983|Active Comparator|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
16673377|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
16673378|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
16673379|NCT02127957|Other|Exercise|Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
16673380|NCT02127957|No Intervention|Control|Control group will have 4 visit and 3 phone call. They will receive standard counselling for exercise in cystic fibrosis, but no prescribed exercice will be given.
16673381|NCT02127944||FERTILE GROUP|WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD
16673382|NCT02127944||UNEXPLAINED INFERTILE GROUP|WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN
16673383|NCT02127931|Experimental|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
16673384|NCT02127931|Active Comparator|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
16673385|NCT02127918||ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
16673386|NCT02127905|Other|CD34+ selected cells|use of unrelated bone marrow or peripheral blood for hematopoietic stem cell transplantation with CD34+ selected cells
16673387|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
16673388|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
16673389|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
16673390|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
16673391|NCT02127879|Experimental|Transcranial Magnetic Stimulation|Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
16673392|NCT02127879|Sham Comparator|Transcranial Magnetic Stimulation with sham coil|Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
16673393|NCT02127866|Experimental|CHF 5259 25 µg plus Foster 100/6 µg|
16673394|NCT02127866|Experimental|CHF 5259 50 µg plus Foster 100/6 µg|
16673395|NCT02127866|Experimental|CHF 5259 100 µg plus Foster 100/6 µg|
16673396|NCT02127866|Active Comparator|Foster 100/6 µg|
16673397|NCT02127853|Experimental|Gabapentin|gabapentin pretreatment
16673398|NCT02127853|Placebo Comparator|Placebo|placebo drug pretreatment
16673400|NCT02127840|No Intervention|Without Synacthen|Adrenal venous sampling without Synacthen
16673401|NCT02127827|Experimental|investigational device off|
16673402|NCT02127814|Experimental|L. reuteri|
16673403|NCT02127814|Placebo Comparator|Identical Placebo|
16673404|NCT02127801|Experimental|Group A|Participants in group A will receive REGN1908-1909
16673405|NCT02127801|Experimental|Group B|Participants in group B will receive placebo
16673406|NCT02127788||Micafungin|Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.
16673407|NCT02127775|Experimental|Sequence B|Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)
16673408|NCT02127775|Experimental|Sequence A|Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)
16673409|NCT02127762|Experimental|Mindfulness Based Stress Reduction|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
16673410|NCT02127762|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
16673411|NCT02127749|Experimental|Control|Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
16673412|NCT02127749|Experimental|Antibiotics|Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
16673413|NCT02127736|Experimental|Experimental group|
16673414|NCT02127736|Placebo Comparator|Control group|
16673415|NCT02127723|Experimental|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
16673416|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
16673417|NCT02127697|Experimental|NVA237|Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
16673418|NCT02127697|Placebo Comparator|Placebo|Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
16673419|NCT02127684|Active Comparator|Standard Dosing Group|Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6). After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score <83
16673420|NCT02127684|Experimental|Frequent dosing group|Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab. Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity
16673421|NCT02127671|Experimental|IDEAL intervention|Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
16673422|NCT02127671|Other|Control|All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
16673423|NCT02127658|Active Comparator|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
16673424|NCT02127658|Active Comparator|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
16673425|NCT02127645|Experimental|Early Rectal Cancer|patients with T1 - T2, N0, G1-2 rectal cancer
16673426|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
16673427|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
16673428|NCT02127606|Experimental|Vibration with tilt-table standing|Participants in this arm will undergo alternating side-to-side, whole body vibration while standing on a tilt table for multiple treatments for a total of approximately 14 minutes for 3 sessions over 3 different days
16673429|NCT02127593|Experimental|First NGM/EE (Wet Process), then NGM/EE (Dry Process)|Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
16673430|NCT02127593|Experimental|First NGM/EE (Dry Process), then NGM/EE (Wet Process)|Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
16673431|NCT02127580||with BAV|Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
16673432|NCT02127580||without BAV|Patients undergoing TA-TAVI WITHOUT predilation of the AV
16673433|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
16673563|NCT02126787|No Intervention|Wait-list control group|
16673434|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
16673435|NCT02127554||Electric coagulation|Patients with anterior epistaxis, treated with electric coagulation
16673436|NCT02127554||Chemical coagulation|Patients with anterior epistaxis, treated with chemical coagulation
16673437|NCT02127554||Outpatient tamponade|Patients with posterior epistaxis, treated with tamponade as an outpatient
16673438|NCT02127554||Inpatient tamponade|Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
16673439|NCT02127554||Surgery|Patients with posterior epistaxis, treated with surgery as inpatients
16673440|NCT02127554||Foley balloon catheter|Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
16673441|NCT02127554||Combined treatment|Patients with posterior epistaxis, treated as inpatients with a combination of methods
16673442|NCT02127541|Experimental|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.
16673443|NCT02127515|Experimental|Non Invasive Prenatal Testing|Blood sample
16673444|NCT02127515|Active Comparator|Invasive Prenatal Testing|CVS or amniocentesis
16673445|NCT02127502||Critically ill patients sepsis suspected|
16673446|NCT02127489|Active Comparator|Midazolam|1 mL/kg bupivacaine 0.25%.
16673447|NCT02127489|Placebo Comparator|saline|5mL rectal saline
16673448|NCT02127476|Experimental|KHK6640|KHK6640
16673449|NCT02127476|Placebo Comparator|Placebo|Placebo
16673450|NCT02127463|Experimental|MC-1101 active|Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
16673451|NCT02127463|Placebo Comparator|MC-1101 Vehicle Control|"Topical Drug:
~Ophthalmic Solution Topically, two times per day; morning and bedtime"
16673452|NCT02127450||Case: NS-CARB positive|Patient with a clinical sample positive for a NS-CARB Enterobacteriaceae
16673453|NCT02127450||Control 1: non-NS-CARB positive|Patient with clinical sample positive for a non-NS-CARB Enterobacteriaceae
16673454|NCT02127450||Control 2 : negative sample|Patient having had clinical sample(s) being stayed negative since the beginning of his admission and up to 3 days after the detection of the case
16673455|NCT02127437|Experimental|A - treated group|
16673456|NCT02127437|Placebo Comparator|B - control group|
16673457|NCT02127424|Experimental|Combination of the nurse-driven HIV targeted screening and the|Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
16673458|NCT02127424|Active Comparator|Current practice (no intervention)|Physician-directed HIV diagnostic testing
16673459|NCT02127411|Experimental|Mindfulness-based relapse prevention|Mindfulness-Based Relapse Prevention
16673460|NCT02127411|No Intervention|Waitlist|this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
16673461|NCT02127398|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
16673462|NCT02127385||IUGR|
16673463|NCT02127359||Lung/Colon Adenocarcinomas|Metastatic lung and colon adenocarcinomas
16673464|NCT02127346||Chronic Periodontitis|"Male patients
~Patients are suffering from chronic periodontitis
~Patients do not have any systemic diseases
~Subjects should have 20 teeth at least
~Age: 30 years or greater"
16673465|NCT02127346||Healthy Volunteers|"Males
~Healthy with no systemic diseases or periodontitis
~30 years old at least
~20 teeth are present at least"
16673466|NCT02127333||CAD patients with COPD|
16673467|NCT02127333||CAD patients without COPD|
16673468|NCT02127333||healthy volunteers|
16673469|NCT02127320|Experimental|Sequence 1|Rosuvastatin 20mg → Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg
16673470|NCT02127320|Experimental|Sequence 2|Rosuvastatin 20mg and Ezetimibe 10mg→ Rosuvastatin 20mg → Ezetimibe 10mg
16673471|NCT02127320|Experimental|Sequence 3|Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg → Rosuvastatin 20mg
16673472|NCT02127320|Experimental|Sequence 4|Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg → Rosuvastatin 20mg
16673473|NCT02127320|Experimental|Sequence 5|Ezetimibe 10mg → Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg
16673474|NCT02127320|Experimental|Sequence 6|Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg
16673475|NCT02127294|Experimental|Transcatheter closure group|Migraine patients with patent foreman ovale (PFO)，who meet the criteria and agree to conduct closure of patent foramen ovale will be selected to this group.
16673476|NCT02127294|No Intervention|Contrast group|Migraine patients with PFO，who meet the criteria but don't agree to conduct closure of patent foramen ovale will be selected to this group.
16673477|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
16673478|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
16673479|NCT02127268|Active Comparator|Arm T|Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
16673480|NCT02127268|No Intervention|Arm B|With best support according to NCCN Guideline
16673481|NCT02127255|Active Comparator|A (Acupuncturist 1)|Manual acupuncture implemented by acupuncturist 1 (clinical experience >15 years)
16673482|NCT02127255|Active Comparator|B (Acupuncturist 2)|Manual acupuncture implemented by acupuncturist 2 (clinical experience < 5 years)
16673483|NCT02127242|Experimental|air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
16673484|NCT02127242|No Intervention|hepatectomy group|Hepatic resection using an open approach is performed for all segments affected by biliary stenosis and the affected bile duct drainage area.Hepaticojejunostomy is performed in patients with common bile duct stenosis and in those considered to be at high risk for recurrence.
16673485|NCT02127229|No Intervention|Blinded observation of ERCP|Blind observation of disposable accessories use.
16673486|NCT02127229|Experimental|Endoscopist informed of cost per procedure|Endoscopists informed following each ERCP.
16673487|NCT02127216|No Intervention|Standard of Care Group - A|The control group
16673488|NCT02127216|Active Comparator|MOSES - Group B|Individual patients using application and pedometer without healthcare provider support
16673489|NCT02127216|Active Comparator|MOSES - Group C|Individual patients using application and pedometer with healthcare provider support
16673490|NCT02127216|Active Comparator|MOSES - Group D|Peer patient teams using application and pedometer without healthcare provider support
16673491|NCT02127216|Active Comparator|MOSES - Group E|Peer patient teams using application and pedometer with healthcare provider support
16673492|NCT02127203||Chronic Periodontitis group (ChP)|20 patients aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
16673493|NCT02127203||Resistant Control group (R)|20 age-sex matched patients who are > 45 years exhibit no signs of periodontal disease as determined by the absence of the evidence of interproximal (CAL ≤ 1mm), PD > 3 mm at any site, whole-mouth bleeding scores <10% and have no clinical signs of gingival inflammation .
16673494|NCT02127203||Aggressive Periodontitis group (AgP)|20 patients who are aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
16673495|NCT02127203||Young Control group (YC)|20 age- and sex matched patients who are < 35 years and exhibit no signs of periodontal disease.
16673496|NCT02127190|Placebo Comparator|CXA-10 placebo emulsion|single intravenous dose of CXA 10 placebo emulsion
16673497|NCT02127190|Experimental|CXA-10 Emulsion|single ascending intravenous doses of CXA-10 emulsion
16673498|NCT02127177|Experimental|Cpap|
16673499|NCT02127177|No Intervention|No Cpap|
16673500|NCT02127164|Experimental|"Veraflo device, Dakin's solution"|
16673501|NCT02127151|Experimental|BMN 673|BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
16673502|NCT02127138|Experimental|ATP technique|This arm plan to enroll 158 subjects，Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of unprotected distal left main bifurcation lesions.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
16673503|NCT02127138|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects.Sirolimus-eluting Drug stent implantation via Provisional T Stenting technique in the treatment of unprotected distal left main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
16673504|NCT02127125|Placebo Comparator|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
16673505|NCT02127125|Placebo Comparator|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
16673506|NCT02127125|Placebo Comparator|Lean with NGT -Placebo|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
16673507|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
16673508|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
16673509|NCT02127125|Active Comparator|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
16673510|NCT02127125|Active Comparator|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
16673511|NCT02127125|Active Comparator|Lean with NGT - Synbiotic|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
16673512|NCT02127125|Active Comparator|Lean with NGT - Sevelamer|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
16673513|NCT02127112|Active Comparator|Block Allograft plus Matrix Allograft|The positive control treatment will include a block allograft plus a demineralized bone matrix moldable allograft.
16673514|NCT02127112|Experimental|Moldable Matrix Allograft|In the test arm of the study the treatment will include a demineralized bone matrix moldable allograft.
16673515|NCT02127099||Patients with OSA|Post operative patients with OSA
16673516|NCT02127099||Post-operative Patients without OSA|All post operative patients without OSA
16673517|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
16673518|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
16673519|NCT02127073|Experimental|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
16673520|NCT02127060|Experimental|Vitamin C|in postoperative time, vitamin C administered orally with other pain analgesics.
16673521|NCT02127060|Placebo Comparator|Placebo drug|in postoperative time, vitamin C do not administered.
16673522|NCT02127047|Experimental|Sitagliptin|Patients receive Sitagliptin (100mg/d) without further intervention
16673523|NCT02127047|Experimental|Sitagliptin and exercise|Patients receive sitagliptin (100mg/d) and follow a physical training intervention program
16673524|NCT02127034|Experimental|Digoxin / digoxin + solifenacin and mirabegron|Digoxin alone then followed by digoxin with solifenacin and mirabegron
16673525|NCT02127034|Experimental|Digoxin + solifenacin and mirabegron / digoxin|Digoxin with solifenacin and mirabegron then followed by digoxin alone
16673526|NCT02127021|Experimental|Norzyme® 40000 IU|Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
16673527|NCT02127021|Placebo Comparator|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount
16673528|NCT02127008|Experimental|Resection of epidural fat|During surgical procedure, epidural fat was resected fully.
16673529|NCT02127008|Active Comparator|No resection of epidural fat|During surgical procedure, the epidural fat was not resected.
16673530|NCT02126995|Experimental|Metadoxine Immediate/Slow-release|Flexed and fixed-dose Metadoxine Immediate/Slow-release 700 mg and 1400 mg administered orally once daily
16673531|NCT02126995|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product. Administered orally once daily
16673532|NCT02126982||Clopidogrel hydrogen sulfate (CHS)|Clopidogrel hydrogen sulfate, 75 mg / day
16673533|NCT02126982||Clopidogrel Besylate (CB)|Clopidogrel Besylate , 75 mg / day
16673534|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
16673535|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
16673536|NCT02126956|Experimental|ACT-128800|Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)
16673537|NCT02126943||Opsumit (macitentan)|10 mg tablets
16673538|NCT02126930|Active Comparator|Routine care|"The patients in this receive routine care.
~Intervention: Routine care"
16673539|NCT02126930|Experimental|Pharma consult|"The patients in this arm will have a pharmaceutical consult upon hospital discharge.
~Intervention: Pharma consult"
16673540|NCT02126917|Experimental|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
16673541|NCT02126917|Experimental|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
16673542|NCT02126917|Experimental|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
16673543|NCT02126904||IVR group|
16673544|NCT02126891|Experimental|Canoeists|13 canoeists from a training center of the French canoeing team
16673545|NCT02126891|Experimental|Military|10 young recruits in military school of officers in ground forces of the French army
16673549|NCT02126865|Experimental|BI 1060469 Healthy|Multiple rising dose qd for 15 days
16673550|NCT02126865|Placebo Comparator|Placebo to BI 1060469|Matching placebo as tablet for 15 days
16673551|NCT02126865|Experimental|BI 1060469 asthmatics|Multiple rising dose qd for 29 days
16673552|NCT02126865|Placebo Comparator|Placebo to BI 1060469 asthmatics|Matching placebo as tablet for 29 days
16673553|NCT02126852|Experimental|AMG (one-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
16673554|NCT02126852|Experimental|AMG (three-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
16673555|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
16673556|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
16673557|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
16673558|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
16673559|NCT02126813|Active Comparator|500 ml.|A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
16673560|NCT02126813|Experimental|800 ml|A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
16673561|NCT02126787|Experimental|Intensive Group Analytic Psychotherapy|Intensive Group Analytic Psychotherapy in a day clinic setting
16673562|NCT02126787|Experimental|Intensive GCBT|Intensive transdiagnostic cognitive-behavioral group therapy in a day clinic setting
16673569|NCT02126761|Active Comparator|Group 5|aTIV (Left deltoid) Saline (Right deltoid)
16673570|NCT02126761|Experimental|Group 6|aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)
16673571|NCT02126761|Experimental|Group 7|aTIV (Left deltoid) aTIV (Right deltoid)
16673572|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
16673573|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
16673574|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
16673575|NCT02126722||Patients with dyspepsia on PPI|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
16673576|NCT02126722||Patients with dyspepsia not on PPI|Fifty patients not on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
16673577|NCT02126709|Experimental|Treatment Arm|"Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%
~Application of study cream twice a day during the 8 week study period
~It will be applied once in the morning and once in the night
~We recommend the application to occur after the face is washed
~One Finger Tip Unit is required per application to the entire face
~The gel should be left on and not washed of for at least15 -30 minutes"
16673578|NCT02126709|Placebo Comparator|Placebo Arm|"Name: Neutrogena hydroboost gel Active ingredient: NA Strength: NA Dosage form: Water gel Administration route: Topical
~Application of placebo cream twice a day during the 8 week study period
~It will be applied once in the morning and once in the night
~We recommend the application to occur after the face is washed
~One Finger Tip Unit is required per application to the entire face
~The gel should be left on and not washed of for at least15 -30 minutes"
16673579|NCT02126696||Patients on anti-retroviral therapy|The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study.
16673580|NCT02126683|Experimental|Plaquenil first|Start Plaquenil 200mg BID orally since enrollment Duration: 6 months
16673581|NCT02126683|Experimental|Plaquenil later|Start Plaquenil 200mg BID orally since the 25th week after enrollment Duration: 6 months
16673582|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
16673583|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
16673584|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
16673585|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
16673586|NCT02126657|Other|Single Arm|Single arm study - pre and post peel assessment
16673587|NCT02126644|Other|Single Arm|Single arm of 10 patients - efficacy and safety assessed pre and post peel
16673588|NCT02126618||women with lower urinary tract symptoms|
16673589|NCT02126592||PCOS cohort|Women with PCOS
16673590|NCT02126592||Control cohort|Women without PCOS
16673591|NCT02126579|Experimental|Arm A (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673592|NCT02126579|Experimental|Arm B (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673593|NCT02126579|Experimental|Arm C (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after the vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673594|NCT02126579|Experimental|Arm D (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673595|NCT02126579|Experimental|Arm E (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673596|NCT02126579|Experimental|Arm F (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673597|NCT02126579|Experimental|Arm G(Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673598|NCT02126579|Experimental|Arm E2|"Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
16673599|NCT02126566|Experimental|Single Arm|Administration of light therapy - measurement of results before and after therapy
16673600|NCT02126553|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
16673601|NCT02126540|Experimental|Primary Cohort|Main cohort; treatment Arm with Pantheris Atherectomy System
16673602|NCT02126527|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16673603|NCT02126514|Experimental|AZD3293|7 subjects will receive AZD3293
16673604|NCT02126501|No Intervention|Sudden wean|When ready Nasal Continuous Positive Airway Pressure (NCPAP) will be removed from the neonate
16673605|NCT02126501|Active Comparator|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
16673606|NCT02126488|Experimental|treadmill perturbation|treadmill slip perturbation
16673607|NCT02126488|Placebo Comparator|treadmill placebo|treadmill training placebo
16673608|NCT02126488|Sham Comparator|observation|observation training
16673609|NCT02126475||Healthy volunteers|
16673610|NCT02126475||Park patients|
16673611|NCT02126462|Experimental|30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)|30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
16673612|NCT02126462|Active Comparator|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
16673613|NCT02126462|Experimental|100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)|100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
16673614|NCT02126449|Experimental|Fasting mimicking diet|Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC>T)
16673615|NCT02126449|No Intervention|regular diet|Standard neoadjuvant chemotherapy (AC>T)
16673616|NCT02126436|Active Comparator|Acupuncture|"Eight treatments of acupuncture will be given to participants twice weekly over four weeks. A combination of body and auricular acupuncture will be given and treatment will be pragmatic.
~In addition the group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff)."
16673617|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
16673618|NCT02126423||1st intravitreal injection|Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection
16673619|NCT02126423||>20 intravitreal injections|Conjunctival and nasopharyngeal swabs are obtained from each patient with >20 intravitreal injection therapies.
16673620|NCT02126397|Active Comparator|polyps resection with Laser Diode|application of the laser diode by hysteroscopy to remove the endometrial polyp
16673621|NCT02126397|Active Comparator|polyps resection with bipolar electrode|application of the bipolar electrode Versapoint by hysteroscopy to remove the endometrial polyp
16673622|NCT02126384|Experimental|pneumovax|Single arm, open label pneumovax vaccination of healthy subjects
16673623|NCT02126371|Other|Active|LEO32731
16673624|NCT02126358|Placebo Comparator|Gemigliptin|only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)
16673625|NCT02126358|Placebo Comparator|Rosuvastatin|only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)
16673626|NCT02126358|Experimental|FDC|Gemigliptin & Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)
16673627|NCT02126345||MASTER SL|
16673628|NCT02126332|Other|Conventional group|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
16673629|NCT02126332|Experimental|EA group (Epidural anesthesia )|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
16673630|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
16673631|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
16673632|NCT02126306|Placebo Comparator|Placebo|Normal saline administered orally daily as a placebo
16673633|NCT02126306|Active Comparator|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
16673634|NCT02126293|Experimental|Zinc deficient patients|If the patient is found to be zinc deficient (serum zinc < 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
16673635|NCT02126293|Active Comparator|Zinc sufficient patients|Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.
16673636|NCT02126280||Subclinical atherosclerosis|In vitro estimation of individual reactivity of monocytes in study participants with asymptomatic atherosclerotic plaques found in carotid arteries by ultrasound examination
16673637|NCT02126280||Healthy subjects|In vitro estimation of individual reactivity of monocytes in study participants without ultrasound signs of subclinical carotid atherosclerosis
16673638|NCT02126280||Diffuse intimal thickening|In vitro estimation of individual reactivity of monocytes in study participants with diffuse intima-media thickening of carotid arteries found at ultrasound examination
16673639|NCT02126267|Experimental|Full mouth disinfection - FMD|n = 10: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
16673640|NCT02126267|Experimental|FMD + chlorhexidine (FMD-CX)|n = 15: Same as FMD with the inclusion of chlorhexidine in office (application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)). In addition, use was made of homemade CX 0.2% for 60 days after the scaling in a single phase.
16673641|NCT02126267|Experimental|FMD + azithromycin (FMD-AZ)|n = 15: Same as with the FMD include the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the scaling.
16673642|NCT02126267|Experimental|Scaling and root planing (SRP)|(n = 13): scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
16673643|NCT02126267|Experimental|SRP + azithromycin (SRP-AZ)|n = 11: Same as scaling and root planing group (SRP) with inclusion of the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the last scaling hemi-arch;
16673644|NCT02126267|Experimental|SRP + chlorhexidine (SRP-CX)|n = 13 : Same as group scaling and root planing (SRP) with the inclusion of home use of CX 0.2% for 60 consecutive days after the end of the first session of scaling
16673645|NCT02126254|No Intervention|Control group|Control group will be treated in the cardiology and internal medicine departments according to the guidelines for the management of Heart Failure
16673646|NCT02126254|Active Comparator|Hemodynamic group|Hemodynamic group patients will be examined in the cardiology and internal medicine departments and treated according to the NICaS system in addition to current guidelines. Patients in this group will be tested within 12 hours from hospitalization and thereafter on an everyday basis until discharge
16673647|NCT02126241|Experimental|NICaS guided CRT optimization|For each subject, we will determine a set of AV and VV delays values, for which the NICaS measured CO will be maximum. In each patient, the CRT device will then be programmed according to these values.
16673648|NCT02126215||Study group - MRI CO2 and O2 stress test|This is a pilot study to assess feasibility of using MRI CO2 and O2 stress testing to predict POD.
16673649|NCT02126202|No Intervention|Conservative therapy|Optimized medical therapy
16673650|NCT02126202|Experimental|Invasive therapy|Coronary angiography and revascularization if feasible
16673651|NCT02126189||Head and neck cancer|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra Hospital, Brisbane, Australia are invited to participate.
16673652|NCT02126163|Experimental|Treatment Group|The treatment group will receive three interactive Computer Tailored Intervention (CTI) sessions during the course of six months, which will include tailored feedback based on the user's responses, and two assessment only follow-up sessions at twelve and eighteen months.
16673653|NCT02126163|No Intervention|Control Group|The control group will receive four assessment only sessions during 18 months.
16673654|NCT02126150||Ethnicity|
16673655|NCT02126137|Experimental|Ezetimibe|Ezetimibe administered by mouth 10 mg BID for 12 weeks
16673656|NCT02126124|Active Comparator|Active dTMS Treatment|Brainsway Deep TMS Treatment
16673657|NCT02126124|Sham Comparator|Sham Treatment|Brainsway Sham Treatment
16673658|NCT02126111|Active Comparator|DEPIGOID phleum|The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
16673659|NCT02126111|Placebo Comparator|DEPIGOID Placebo & DEPIGOID Phleum|"This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.
~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
16673660|NCT02126098||Adults who diagosed ANCA-vasculitis|"Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had
~Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA
~manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
16673661|NCT02126085|Active Comparator|Intubation|Intubation and invasive mechanical ventilation + endovascular recanalisation
16673662|NCT02126085|Experimental|No Intubation|Conscious sedation and non-invasive ventilatory support + endovascular recanalisation
16673663|NCT02126072|Experimental|Alcohol|The study is a randomized single blinded trial in cross over design. Subjects are randomized to drink alcohol in one session and water in another session.
16673664|NCT02126072|Active Comparator|Water|Water in the same volume as the volunteer would have to drink in wine according to the protocol.
16673665|NCT02126059|Experimental|Cognitive stimulation|One cognitive stimulation session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to cognitive stimulation.
16673666|NCT02126059|Experimental|Aroma-massage|One hand and shoulder massage session per week for a continuous 10 weeks, each session contains 30 minutes, totally 10 session massage.
16673667|NCT02126059|Experimental|reminiscence|One reminiscence session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to reminiscence.
16673668|NCT02126059|No Intervention|Control|Control group remain regular activities
16673669|NCT02126046|Other|Hi-HSC-CBT|
16673670|NCT02126033|Experimental|celiac disease|
16673671|NCT02126020|Experimental|topical infliximab|topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months
16673672|NCT02126007|Experimental|Sleep and Rhythm Intervention|This arm receives a 4-week behavioral intervention aimed at improving sleep and circadian rhythms, and thereby reducing fatigue.
16673673|NCT02126007|Placebo Comparator|Dietary Modifications|This arm receives a 4-week placebo intervention focused on dietary modifications for reducing fatigue.
16673674|NCT02125994|Active Comparator|Ropivacaine 0.5%|Ultrasound guided Intercalene nerve block with ropivacaine 0.5 %
16673675|NCT02125994|Active Comparator|Ropivacaine 0.375 %|Ultrasound guided Intercalene nerve block with ropivacaine 0.375 %
16673676|NCT02125981|Experimental|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
16673677|NCT02125981|Placebo Comparator|Control|taking placebo drug
16673745|NCT02125552|Placebo Comparator|Traditional intravenous access|The patients randomized to traditional IV access will have their IVs placed by standard technique.
16673678|NCT02125968|Active Comparator|interactive video game|"Participants in interactive video game group receive six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min interactive video game intervention, for 3 times per week for a 2-week duration.
~Short- and medium-term therapeutic effects of interactive video game intervention for patients with chronic low back pain will be assessed."
16673679|NCT02125968|Sham Comparator|therapeutic exercise|"Participants received six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min supervised therapeutic exercise,for 3 times per week for a 2-week duration.
~short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain will be evaluated."
16673680|NCT02125955|Experimental|Prebiotic fiber|The intervention group will consume an 8 gram dose of prebiotic fiber one time per day approximately 30 minutes prior to their evening meal.
16673681|NCT02125955|Placebo Comparator|Placebo|The placebo group will consume an isocaloric dose of placebo (maltodextrin; 3.3 grams) one time per day approximately 30 minutes prior to their evening meal.
16673682|NCT02125942|Experimental|meditation|Central Meditation and Imagery Therapy
16673683|NCT02125942|No Intervention|wait list|waiting list
16673684|NCT02125929|Experimental|robotic arm|robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
16673685|NCT02125929|Experimental|Laparoscopic surgery|laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
16673686|NCT02125929|Experimental|Open surgery|Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100
16673687|NCT02125916|Experimental|COLD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
16673688|NCT02125916|Experimental|COLD with long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
16673689|NCT02125916|Experimental|ILD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
16673690|NCT02125916|No Intervention|Controls|Driving in the simulator one time without oxygen therapy
16673691|NCT02125903|Active Comparator|Continuous Adductor Canal Block (CACB)|"Continuous Adductor Canal block performed with:
~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h
~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
16673692|NCT02125903|Active Comparator|Continuous Femoral Nerve Block (CFNB)|"Continuous Femoral Nerve Block performed with:
~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h
~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
16673693|NCT02125890|Experimental|Tranexamic Acid|We will be administering Tranexamic Acid in patients with ruptured abdominal aortic aneurysms to determine if this has an effect on primary outcome measures as significant bleeding, blood transfusion requirements.
16673694|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
16673695|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
16673696|NCT02125864|Experimental|Aflibercept|
16673697|NCT02125851|Experimental|Xanthan Gum|"A total of 12 subject will be administered sucralose slurry and the xanthan gum slurry. Six will get sucralose first (then an hour later the xanthan gum) and 6 will receive the xanthan gum first (then an hour later the sucralose slurry).
~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.
~The xanthan gum-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 1ml of xanthan gum gel, crystallized orange flavoring agent, and 1mCi of Tc99-Sulfur colloid."
16673698|NCT02125851|Experimental|Honey|"A total of 12 subject will be administered sucralose slurry and the honey slurry. Six will get sucralose first (then an hour later the honey) and 6 will receive the honey first (then an hour later the sucralose slurry).
~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.
~The honey-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 6ml of honey and 1mCi of Tc99-Sulfur Colloid."
16673699|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
16673700|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
16673701|NCT02125825||Parkinson's disease on levodopa|Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms
16673702|NCT02125812|Placebo Comparator|scaling and root planing|scaling and root planing
16673703|NCT02125812|Experimental|scaling and systemic moxifloxacin|scaling and root planing combined with systemic moxifloxacin
16673704|NCT02125799|Experimental|Accelerated HF-rTMS|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
16673746|NCT02125539|Experimental|Navigating my Journey program|Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
16673709|NCT02125773|Experimental|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator.
16673710|NCT02125773|No Intervention|Control|Subjects in the control arm will not be provided with the results of the risk calculators.
16673711|NCT02125760|Sham Comparator|Inspiratory Muscle Training (IMT)|Patients with subacute stroke in a neurorehabilitation setting.
16673712|NCT02125760|Experimental|High-intensity IMT|Patients with subacute stroke in a neurorehabilitation setting.
16673713|NCT02125747|Other|No Respiratory Therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.
16673714|NCT02125747|Experimental|Respiratory therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy
16673715|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
16673716|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
16673717|NCT02125721|Experimental|CBTD Patients|Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period
16673718|NCT02125708|Other|OvulaRing®|Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
16673719|NCT02125695||Healthy Volunteers|Skin taping; blood sampling; optional biopsy
16673720|NCT02125695||Cutaneous lupus erythematosus|This group consists of participants affected with lupus (DLE, SCLE). Skin taping; blood sampling; optional skin biopsy (DLE participants); required skin biopsy (SCLE participants)
16673721|NCT02125695||Atopic dermatitis|Skin taping; blood sampling; optional skin biopsy
16673722|NCT02125682|Active Comparator|low dose|patients receiving 10 mg of atorvastatin daily
16673723|NCT02125682|Active Comparator|High dose|Patients receiving 80 mg of atorvastatin daily
16673724|NCT02125669|Active Comparator|Laser Treatment|Pulsed dye laser 595nm
16673725|NCT02125669|Sham Comparator|SHAM Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
16673726|NCT02125656|No Intervention|Regular Sleep|A single night of regular sleep
16673727|NCT02125656|No Intervention|Sleep Deprivation|A single night of sleep deprivation
16673728|NCT02125656|Experimental|HIIT + Regular Sleep|2 weeks of HIIT and after a single night of regular sleep.
16673729|NCT02125656|Experimental|HIIT + Sleep Deprivation|2 weeks of HIIT and after a single night of sleep deprivation
16673730|NCT02125643|Active Comparator|Caffeine Pill|The caffeine will be administered.
16673731|NCT02125643|Placebo Comparator|Placebo/Flour Pill|The flour will be administered.
16673732|NCT02125630||Systemic therapy|Standart chemotherapy
16673733|NCT02125630||Primary surgery|Standart surgery
16673734|NCT02125630||Neoadjuvant chemotherapy|Standart chemotherapy followed by surgery
16673735|NCT02125617||Castration-resistant prostate cancer, Progression after taxane|Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day
16673736|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
16673737|NCT02125591|Experimental|Active PoNS CN-NINM|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
16673738|NCT02125591|Sham Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
16673739|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a)|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks.
16673740|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a) and Placebo|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
16673741|NCT02125578|Placebo Comparator|Placebo|Placebo dose will be administered SC every other week for a total of 6 weeks.
16673742|NCT02125565|Experimental|Local Anaesthesia|These subjects received an injection of lidocaine 1% 2ml subcutaneously prior to arterial puncture
16673743|NCT02125565|No Intervention|No Local Anaesthesia|Patients underwent arterial puncture directly with NO prior anaesthesia
16673744|NCT02125552|Experimental|Ultrasound guided intravenous access|This group will have their IV placed by ultrasound guidance.
16676664|NCT02106247|Experimental|Placebo|tablet
16673747|NCT02125539|Active Comparator|Attention Control|Client participants of counselors who were randomized to the control condition will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
16673748|NCT02125526|Active Comparator|IABP group|After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia
16673749|NCT02125526|No Intervention|Control group|After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines
16673750|NCT02125513|Active Comparator|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
16673751|NCT02125513|Experimental|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
16673752|NCT02125500|Experimental|Sofosbuvir/Ledipasvir|"Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks.
~Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
16673753|NCT02125487|Active Comparator|Low-Fidelity Simulation|Teaching using traditional method
16673754|NCT02125487|Experimental|Hybrid Simulation|Teaching using Hybrid Simulation of breast examination
16673755|NCT02125474|Experimental|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
16673756|NCT02125461|Experimental|MEDI4736|MEDI4736 (intravenous infusion)
16673757|NCT02125461|Placebo Comparator|PLACEBO|Placebo (matching placebo for intravenous infusion)
16673758|NCT02125448||Resectable esophageal cancer|Neoadjuvant chemoradiotherapy. MRI and PET-CT.
16673759|NCT02125435|Experimental|ASP2408 dose escalation cohort|
16673760|NCT02125435|Placebo Comparator|Placebo dose escalation cohort|
16673761|NCT02125422|Experimental|Cefaly tDCS|"Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC.
~2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV"
16673762|NCT02125409|Experimental|Group 1|Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.
16673763|NCT02125409|Experimental|Group 2|Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.
16673764|NCT02125396|Experimental|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
16673765|NCT02125396|Active Comparator|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
16673766|NCT02125383|Experimental|Active tDCS|Receives 20 minutes of anodal tDCS three times while sleeping during the night.
16673767|NCT02125383|Sham Comparator|Sham tDCS|Receives 20 minutes of sham tDCS three times while sleeping during the night.
16673768|NCT02125370||Nicotine Replacement Therapy|
16673769|NCT02125357|Other|A - Abiraterone Acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care, or until PSA progression then cross-over to Arm B.
16673770|NCT02125357|Other|B - Enzalutamide|160mg PO OD as per standard of care, or until PSA progression then cross-over to Arm A.
16673771|NCT02125344|Experimental|PM(Cb)|"PM(Cb):
~paclitaxel 80mg/m² 18 times weekly simultaneously with NPLD (Myocet®)20mg/m² 18 times weekly simultaneously with carboplatin AUC 1.5 18 times weekly (only in patients with TNBC) Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all cycles."
16673772|NCT02125344|Active Comparator|ETC|"ETC:
~epirubicin 150mg/m² every 2 weeks for 3 cycles followed by paclitaxel 225 mg/m² every 2 weeks for 3 cycles followed cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles. Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all T and C cycles."
16673773|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
16673774|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
16673775|NCT02125318|Experimental|Anagrelide CR (GALE-401)|
16673776|NCT02125305|Experimental|Metformin|Metformin 750mg(D1), Metformin 500mg(D2)
16673777|NCT02125292|Experimental|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
16673778|NCT02125292|Experimental|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
16673779|NCT02125292|Experimental|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
16673780|NCT02125279|Experimental|Calcitriol ointment|
16673781|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
16673782|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
16673783|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
16673784|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
16673785|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
16673786|NCT02125240|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
16673787|NCT02125240|Active Comparator|Placebo|1 tablet three times daily by mouth
16673788|NCT02125227|Experimental|Group 1 of Study A|single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755
16673789|NCT02125227|Experimental|Group 2 of Study A|single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin
16673790|NCT02125227|Experimental|Group 1 of Study B|single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast
16673791|NCT02125227|Experimental|Group 2 of Study B|single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state
16673792|NCT02125214|Experimental|ASA 1-2|ASA 1-2 patients 20-40 yr
16673793|NCT02125201|Experimental|intranasal fentanyl|Intranasal Fentanyl 1.5-2 mcg/kg
16673794|NCT02125201|Active Comparator|intravenous fentanyl|Intravenous Fentanyl 1-1.5 mcg/kg
16673795|NCT02125188|Experimental|Desmopressin|Desmopressin 3ug/kg in saline 100ml ivdrip before surgery
16673796|NCT02125188|Placebo Comparator|saline|saline 100ml ivdrip before surgery
16673797|NCT02125175|Experimental|Hypofractionated IMRT boost Radiotherapy|
16673798|NCT02125162|Experimental|Treatment A|BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1
16673799|NCT02125162|Experimental|Treatment B|BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1
16673800|NCT02125162|Experimental|Treatment C|BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1
16673801|NCT02125149|No Intervention|Control|Standard of care
16673802|NCT02125149|Experimental|Intervention|Exercise intervention from 12 week gestation until delivery
16673803|NCT02125136|Experimental|Gem/nab-Pac|2 further cycles Gem/nab-Pac (duration of each cycle 28 days)
16673804|NCT02125136|Experimental|FOLFIFINOX|4 cycles combination therapy with 5-fluorouracil/folinic acid, irinotecan, oxaliplatin (FOLFIFINOX) - duration of each cycle 14 days
16673805|NCT02125123|Experimental|Nutritional Supplement and Counseling|Two servings a day; ready-to-feed nutritional supplement plus dietary counseling
16673806|NCT02125123|Active Comparator|Counseling|Dietary Counseling
16673807|NCT02125110|Experimental|study group (cohort PELAGIE)|100 children included in the cohort PELAGIE
16673808|NCT02125110|Experimental|pilot group (no cohort PELAGIE)|10 children not included in the PELAGIE cohort to optimise MRI
16673809|NCT02125097|Experimental|Intracranial Aneurysm Treatment|Barrel™ Vascular Reconstruction Device (VRD) is Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
16673810|NCT02125084|Experimental|Everolimus and Enzalutamide|"Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined.
~Everolimus: Orally (PO) once daily (dose to be determined;
~Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing.
~Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase."
16673811|NCT02125071||Hepabig|Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation
16673812|NCT02125058|Other|Transcutaneous sutures|Transcutaneous sutures
16673813|NCT02125058|Other|Intracutaneous sutures|Intracutaneous sutures
16673814|NCT02125045|Experimental|L-GSH|Glutathione 100 mg tablets twice a day
16673815|NCT02125045|Placebo Comparator|Placebo|Matching placebo will be administered for 4 weeks in a double blind fashion.
16673816|NCT02125032|Active Comparator|Transcranial pulsed electromagnetic fields (T-PEMF)|One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
16673817|NCT02125032|Placebo Comparator|Trancranial electromagnetic pulsed fields (T-PEMF)|8 weeks of T-PEMF treatment placebo.
16673818|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
16673819|NCT02125006|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
16673820|NCT02125006|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
16673821|NCT02124993||Sleeve gastrectomy surgery Participants|Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger.
16673822|NCT02124980|Experimental|Recovery Line plus Treatment-as-Usual (RL+TAU)|The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
16673823|NCT02124980|No Intervention|Treatment-as-Usual|Treatment-as Usual involves daily methadone and associated psychosocial services. Patients are required to attend 1 group session per month and are encouraged to attend open drop-in groups available daily covering a range of topics.
16673824|NCT02124967|Experimental|Exercise|A one hour exercise session which includes both aerobic activity and resistance training
16673825|NCT02124954|Experimental|Digoxin with/without TA-8995|Digoxin with/without TA-8995
16673826|NCT02124954|Experimental|Midazolam with/without TA-8995|Midazolam with/without TA-8995
16673827|NCT02124941|Experimental|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
16673828|NCT02124941|Experimental|[18F]-FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
16673829|NCT02124941|Experimental|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
16673830|NCT02124941|Active Comparator|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
16673831|NCT02124928||carotid artery stenosis|Patients with symptomatic or asymptomatic carotid artery stenosis indicated for carotid endarterectomy, who provide written informed consent, will be included in this study. The investigators will compare patients ultrasonographic data, serum laboratory analyses and histomorphological preferances to look for biomarkers for the plaque instability.
16673832|NCT02124915||Transtibial amputees|
16673833|NCT02124902|Experimental|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.
16673834|NCT02124902|Experimental|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
16673835|NCT02124889|Experimental|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
16673836|NCT02124889|No Intervention|No Survey|Subjects will take the multivitamin.
16673837|NCT02124876||Transtibial amputees|
16673838|NCT02124863|Experimental|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
16673839|NCT02124850|Experimental|Motolimod plus cetuximab|Cohort 1: motolimod plus cetuximab
16673840|NCT02124850|Experimental|Motolimod, cetuximab, and nivolumab|Cohort 2: motolimod, cetuximab, and nivolumab
16673841|NCT02124837|No Intervention|Control group|Participants continue their normal lunch routine.
16673842|NCT02124837|Experimental|Relaxation exercise during lunch break|Participants perform relaxation exercises during each lunch break during work for a period of 2 working weeks.
16673843|NCT02124837|Experimental|Park walk during lunch break|Participants go for a walk in the closest park nearby each lunch break during work for a period of 2 working weeks.
16673844|NCT02124824|Experimental|Arm 1: Control|Control
16673845|NCT02124824|Experimental|Arm 2: Heart Failure|Heart Failure
16673846|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
16673847|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
16673848|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
16673849|NCT02124785|Experimental|HAV Group|Subjects who were previously vaccinated with Havrix in primary studies.
16673850|NCT02124772|Experimental|Part A - TMT 0.0125 mg/kg/day|Participants treated with trametinib 0.0125 mg/kg/day
16673851|NCT02124772|Experimental|Part A - TMT 0.025 mg/kg/day|Participants treated with trametinib 0.025 mg/kg/day
16673852|NCT02124772|Experimental|Part A - TMT 0.032 mg/kg/day|Participants under 6 years of age treated with trametinib 0.032 mg/kg/day
16673853|NCT02124772|Experimental|Part A - TMT 0.04 mg/kg/day|Participants treated with trametinib 0.04 mg/kg/day
16673854|NCT02124772|Experimental|Part B - Neuroblastoma|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
16673855|NCT02124772|Experimental|Part B - LGG fusion|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
16673856|NCT02124772|Experimental|Part B - NF-1 with PN|Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day
16673857|NCT02124772|Experimental|Part B - BRAF V600 mutant solid tumor|Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day
16673858|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 50% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for <12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)
16673859|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 100% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
16673860|NCT02124772|Experimental|Part C - TMT 0.032 mg/kg/day + 100% DRB RP2D|Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)
16673861|NCT02124772|Experimental|Part D - LGG|Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
16673862|NCT02124772|Experimental|Part D - LCH|Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
16673863|NCT02124759|Placebo Comparator|Placebo|Placebo: maltodextrin, 6 g three times a day
16673864|NCT02124759|Active Comparator|Sevelamer|Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
16673865|NCT02124759|Active Comparator|Synbiotic|Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
16673866|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
16673867|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
16673868|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.
~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
16673869|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
16673870|NCT02124733|Active Comparator|Group 1: 30 minutes|The first 4 patients enrolled will be considered Group 1, and will receive 30 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated in terms of erythema immediately post-PDT (Day 1) and on Day 4 . If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 2
16673871|NCT02124733|Active Comparator|Group 2: 45 minutes|Patients in this group will receive 45 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema response immediately post-PDT and at Day 4. If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 3.
16673872|NCT02124733|Active Comparator|Group 3: 60 minutes|Patients in this group will receive 60 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema responses immediately post-PDT and at Day 4. If the post-PDT reaction on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of patients, then the protocol will terminate after 15 patients (total for all groups) have been treated.
16673873|NCT02124720|Experimental|Mobile application|Use of the iSTIM mobile application 2 to 4 times per week over approximately 8 to 16 weeks
16673874|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
16673875|NCT02124694|Experimental|HTUG and IPT|This arm includes the Historical Trauma and Unresolved Grief intervention (HUTG) combined with group Interpersonal Psychotherapy (IPT).The HTUG/IPT arm is 12 two-hour sessions delivered weekly on average, except for weather delays, over 16 weeks. HTUG/IPT includes sessions on identifying relationship issues which may trigger depressive symptoms, using group support, and connecting the impact of collective tribal trauma and losses with personal lifespan and current losses. HTUG/IPT is aimed at reducing depressive symptoms related to interpersonal conflicts and grief. HTUG is a Tribal Best Practice which may serve to engage AI in IPT, an empirically supported treatment for depression.
16673876|NCT02124694|No Intervention|IPT Only|IPT is a standard empirically supported treatment. This IPT Only group is not receiving the experimental HTUG component and is being compared to the combined HTUG with IPT.
16673877|NCT02124681|Placebo Comparator|Placebo|Placebo PO
16673878|NCT02124681|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO QD
16673879|NCT02124668|Experimental|Enzalutamide|Enzalutamide
16673880|NCT02124655|Experimental|Essential oils/0.2% chlorhexidine/Sterile water|A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
16673881|NCT02124642|Active Comparator|Folic acid, 400 mcg/day|A daily 400 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 400 mcg dose approximates the current Recommended Dietary Allowance (RDA) for pregnant women of 600 mcg Dietary Folate Equivalents (400 mcg folic acid ≈ 600 mcg DFEs; conversion factor based on higher bioavailability of folic acid is: 1 mcg folic acid = 1.7 mcg DFE).
16673882|NCT02124642|Experimental|Folic acid, 800 mcg/day|A daily 800 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 800 microgram dose, which is considerably higher than the current RDA, represents an amount commonly found in over-the-counter prenatal vitamin formulations.
16673883|NCT02124616||Neuromuscular diseases|Prospective cohort of children with inherited or acquired neuromuscular diseases.
16673884|NCT02124603||single group|Patients undergone cataract surgery
16673885|NCT02124590|Experimental|Acute Exercise|Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.
16673886|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
16673887|NCT02124525|Placebo Comparator|N-acetylcysteine|"Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.
~Duration: 12 weeks"
16673888|NCT02124525|Placebo Comparator|Placebo|Placebo will be taken for 12 weeks
16673889|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
16673890|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
16673891|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
16673892|NCT02124486|Active Comparator|Dietetic Intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers diet programme.
16673893|NCT02124486|Experimental|Bariatric surgery|Patients randomised to the bariatric surgery arm will be referred to the bariatric surgery pathway and, if judged suitable according to the bariatric surgery clinic's screening processes, undergo bariatric surgery.
16673894|NCT02124486|No Intervention|Matched obese control group|To evaluate the baseline difference in ICP between IIH patients and a matched obese control cohort we will recruit 20 obese but otherwise healthy participants who will undergo the same baseline visit as the main trial participants and then exit the study.
16673895|NCT02124486|No Intervention|MRI Test run|5 patients will undergo double baseline MR scans to validate the novel MR sequences being used in the main trial.
16673896|NCT02124473|Experimental|Homeopathy|A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
16673897|NCT02124473|Placebo Comparator|Placebo|Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
16673898|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
16673899|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
16673900|NCT02124447|Active Comparator|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
16673901|NCT02124447|Active Comparator|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
16673902|NCT02124447|Active Comparator|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
16673903|NCT02124447|Active Comparator|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
16673904|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
16673905|NCT02124421|Active Comparator|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
16673906|NCT02124421|Experimental|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
16673907|NCT02124408|Experimental|Intervention group|Personalized Behavioral Intervention
16673908|NCT02124408|No Intervention|Control group|
16673909|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
16673910|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
16673911|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
16673912|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
16673913|NCT02124369|Other|Abraxane & gemictabine|Abraxane, IV, 125mg/m2 and gemcitabine, IV, 1000mg/m2, on days 1,8 & 15 per 28 day cycle, up to a maximum of 6 cycles.
16673914|NCT02124356||Emergency High-risk Abdominal Surgery|
16673915|NCT02124343|Experimental|Interval Exercise|"Subjects will undertake an interval exercise session (on a harnessed treadmill) (HP Cosmos Mercury 4.0, HP Cosmos Sports and Medical Gmbh, Nussdorf-Traustein,Germany) based on the average speed calculated from the 6 minute walk test (6MWT).
~Intervals are based on the work previously done by Mador et al., 2009 who used intervals of 150% (for 1 minute) followed by intervals of 75% (for 2 minutes) based on 80% average speed from the 6 minute walk test.
~This study repeated these intervals 7 times with a duration of 23 minutes in total for the exercise intervention with the 75% intervals at the start and at the end of the exercise session. No warm up was undertaken for this method as it was a walking exercise test and the risk of injury was minimised with use of the harnessed treadmill."
16673916|NCT02124330|Experimental|montmorillonite 5 g|5g Montmorillonite + 15 g protein (ratio 1:3)
16673917|NCT02124330|Experimental|Montmorillonite 3 g|3g Montmorillonite + 15 g protein (ratio 1:5)
16673918|NCT02124330|Experimental|Montmorillonite 1 g|1g Montmorillonite + 15 g protein (ratio 1:15)
16673919|NCT02124330|No Intervention|Control|A control goup will intake 15 g of protein alone
16673920|NCT02124317|Experimental|nanoparticle albumin-bound paclitaxel, S-1|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycle: 6 cycles.
16673921|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
16673922|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
16673923|NCT02124291|No Intervention|No Assisted Hatching|No Assisted Hatching
16673924|NCT02124291|Active Comparator|Assisted Hatching|Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.
16673925|NCT02124278|Experimental|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
16673926|NCT02124278|Placebo Comparator|Sterile water for injection|Sterile water for injection administered by nebulization
16673927|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
16673928|NCT02124252|No Intervention|Control|Women will be offered HPV testing within the health facilities in the communities randomized to this arm. Women who test HPV positive will be referred to care at the sub-district and district hospitals (current standard of care).
16673929|NCT02124252|Active Comparator|Standard Intervention|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
16673930|NCT02124252|Active Comparator|Enhanced Intervention|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
16673931|NCT02124239|Experimental|Scalp|Treatment of scalp with 0.027% ingenol mebutate once daily for 3 days
16673932|NCT02124239|Experimental|Arm|Treatment of arm with 0.06% ingenol mebutate once daily for 4 days
16673933|NCT02124239|Experimental|Face|Treatment of face with 0.027% ingenol mebutate once daily for 3 days
16673934|NCT02124226|Experimental|Methotrexate|Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks
16673935|NCT02124226|Placebo Comparator|Matched placebo|Placebo pills
16673936|NCT02124213|Experimental|Cohor 1 - 30 mg|Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
16673937|NCT02124213|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
16673938|NCT02124213|Experimental|Cohort 3 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
16673939|NCT02124200|Other|EGO/CE4, 9mg nicotine|
16673940|NCT02124187|Experimental|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
16673941|NCT02124187|Sham Comparator|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
16673942|NCT02124187|Placebo Comparator|Nicotine free inhalator|nicotine free inhalator for 12 weeks
16673943|NCT02124174|Experimental|Vidaza and Valproic Acid|Vidaza and Valproic Acid
16673944|NCT02124161|Other|13vPnC+SIIV/Placebo|
16673945|NCT02124161|Other|Placebo+SIIV/13vPnC|
16673946|NCT02124148|Experimental|Prexasertib + Cisplatin (Part A)|"Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days.
~Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days.
~Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days.
~Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose.
~Participants may remain on treatment until discontinuation criteria are met."
16673947|NCT02124148|Experimental|Prexasertib + Cetuximab (Part B)|"Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days.
~Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days.
~Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days.
~Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose.
~Participants may remain on treatment until discontinuation criteria are met."
16673948|NCT02124148|Experimental|Prexasertib + Pemetrexed (Part C)|"Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days.
~Participants may remain on treatment until discontinuation criteria are met."
16673949|NCT02124148|Experimental|Prexasertib + 5-FU (Part D)|"Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days.
~Participants may remain on treatment until discontinuation criteria are met."
16673950|NCT02124148|Experimental|Prexasertib + LY3023414 (Part E)|"Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days.
~Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion).
~Participants may remain on treatment until discontinuation criteria are met."
16673951|NCT02124135|Active Comparator|Clinic-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in the clinic setting.
16673989|NCT02123927|Experimental|Step 8 B: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
16673952|NCT02124135|Experimental|Restaurant-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in a restaurant, while dining.
16673953|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
16673954|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
16673955|NCT02124109||Control|Control group
16673956|NCT02124109||rheumatic heart disease|Patients with rheumatic heart disease
16673957|NCT02124083|Experimental|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
16673958|NCT02124057||Healthy female control|Age-matched healthy control women
16673959|NCT02124057||Healthy male control|Age-matched healthy control men
16673960|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
16673961|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
16673962|NCT02124057||SMBA|SBMA carrier women
16673963|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
16673964|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
16673965|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.
~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
16673966|NCT02124005|Experimental|Femoral block, ultrasound, bupivacaine|
16673967|NCT02123992|Active Comparator|Elevate Apical and Posterior|The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
16673968|NCT02123992|Active Comparator|Native Tissue Repair|The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
16673969|NCT02123979|Placebo Comparator|placebo patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
16673970|NCT02123979|Experimental|Neupro® transdermal patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
16673971|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
16673972|NCT02123953|Experimental|TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.
16673973|NCT02123953|Experimental|TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.
16673974|NCT02123953|Experimental|TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.
16673975|NCT02123953|Experimental|TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.
16673976|NCT02123953|Experimental|TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.
16673977|NCT02123953|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.
16673978|NCT02123940|Experimental|nasal humidified high flow therapy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
16673979|NCT02123940|Other|standard strategy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
16673980|NCT02123927|Experimental|Step 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
16673981|NCT02123927|Experimental|Step 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
16673982|NCT02123927|Experimental|Step 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
16673983|NCT02123927|Experimental|Step 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
16673984|NCT02123927|Experimental|Step 5: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
16673985|NCT02123927|Experimental|Step 6: TAK-438 80 mg|TAK-438 80 mg, tablets, orally, once on Day 1.
16673986|NCT02123927|Experimental|Step 7: TAK-438 120 mg|TAK-438 120 mg, tablets, orally, once on Day 1.
16673987|NCT02123927|Placebo Comparator|Steps 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1.
16673988|NCT02123927|Experimental|Step 8A: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
16674137|NCT02123043|No Intervention|Control|The control group will not experience any wheelchair training or 'practice' with a manual wheelchair.
16673990|NCT02123927|Experimental|Step 9A: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
16673991|NCT02123927|Experimental|Step 9B: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
16673992|NCT02123927|Placebo Comparator|Steps 8 (A & B) and 9 (A & B): Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.
16673993|NCT02123914|Experimental|Aerobic exercise with Vit. C & Aerobic exercise|
16673994|NCT02123914|Active Comparator|exercise without vit. c supplement & no exercise|
16673995|NCT02123901|Experimental|Walking meditation & Walking|
16673996|NCT02123901|Active Comparator|Walking meditation & No exercise|
16673997|NCT02123888|Experimental|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
16673998|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
16673999|NCT02123875|Other|Physiotherapy intervention arm|Caregiver delivered, home based physiotherapy
16674000|NCT02123862||Prostate Cancer|
16674001|NCT02123862||Breast Cancer|
16674002|NCT02123862||Colorectal Cancer|
16674003|NCT02123862||Solid Tumor|
16674004|NCT02123862||Benign Condition|
16674005|NCT02123849|Experimental|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
16674006|NCT02123849|Experimental|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
16674007|NCT02123836|Experimental|NK cells|Peripheral blood cell will be collected by apheresis from donors. Peripheral blood mononucleated cells will be cultured with irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 for 10 days. After T-cell depletion, expanded activated NK cells will be infused. Before infusion, patients will receive immunosuppressive therapy to promote temporary engraftment of NK cells. After infusion, they will receive IL-2 to support NK cell viability and expansion in vivo. The effects of NK cell infusion will be determine by comparing MRD levels before and after treatment.
16674008|NCT02123823|Active Comparator|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
16674009|NCT02123823|Experimental|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
16674010|NCT02123823|Experimental|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
16674011|NCT02123810|Other|Control|The investigators measure quality of chest compressions before nightshift. Control group
16674012|NCT02123810|Other|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
16674013|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
16674014|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
16674015|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
16674016|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
16674017|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
16674018|NCT02123784||Rotator cuff tear|Patients which demonstrate a full-thickness tear of the rotator cuff tendon and meet the inclusion criteria.
16674019|NCT02123771||Helicobactor Pylori Infection|Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects. Rapid urease test result from the respective patients will be used as the golden standard. Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
16674020|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
16674021|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
16674022|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
16674023|NCT02123732|Experimental|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
16674171|NCT02122848|Experimental|Bilevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
16674024|NCT02123732|Placebo Comparator|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
16674025|NCT02123719||Patients post liver transplantation|Patients after liver transplantation
16674026|NCT02123719||Control group|Patients with an abdominal incisional hernia without a history of immunosuppresion
16674027|NCT02123693|Experimental|Osteopathic Manipulative Treatment|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on indirect techniques
16674028|NCT02123693|Sham Comparator|Sham therapy|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on specific parameters set out previously based on a predetermined protocol
16674029|NCT02123693|Other|No intervention|Patients in this group will not receive any type of intervention, both therapeutic than fictitious, and will not be evaluated by any operator
16674030|NCT02123667||Asthmatic patients|asthmatic patients 18 to 65
16674031|NCT02123667||Healthy volunteers|Volunteers 18 to 65
16674032|NCT02123654|Experimental|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
16674033|NCT02123654|Active Comparator|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
16674034|NCT02123654|Experimental|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
16674035|NCT02123641|Active Comparator|Heavy resistance training|Heavy resistance training of the lower and upper extremities three times weekly for 52 weeks.
16674036|NCT02123641|Experimental|Moderate intensity training|Home-based moderate intensity training of the lower and upper extremities three times weekly for 52 weeks.
16674037|NCT02123641|Experimental|Control|No training
16674038|NCT02123628|Active Comparator|antibiotic therapy|"patients are treated with a 6 week-duration of antibiotic therapy :
~Rifampin IP and PO twice daily, 10mg/kg /12H
~Levofloxacin IV and PO 500-750mg once daily
~Doxycycline PO 200mg once daily
~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily
~Fusidic acid PO 500mg twice daily
~Linezolid IV and PO 600mg twice daily
~Ciprofloxacin IV and PO 750to 1000mg/12h
~Cefotaxime IV 100mg/kg in three IV infusions daily
~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily
~Cefepime IV ou intra-muscularly 2g /8-12h"
16674039|NCT02123628|Active Comparator|12 week-duration of antibiotic therapy|"patients are treated with a 12 week-duration of antibiotic therapy :
~Rifampin IP and PO twice daily, 10mg/kg /12H
~Levofloxacin IV and PO 500-750mg once daily
~Doxycycline PO 200mg once daily
~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily
~Fusidic acid PO 500mg twice daily
~Linezolid IV and PO 600mg twice daily
~Ciprofloxacin IV and PO 750to 1000mg/12h
~Cefotaxime IV 100mg/kg in three IV infusions daily
~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily
~Cefepime IV ou intra-muscularly 2g /8-12h"
16674040|NCT02123615|Experimental|Gadolinium For abdomen|"Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
16674041|NCT02123615|Experimental|Gadolinium For lower back|"1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
~Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score."
16674042|NCT02123615|Experimental|subjects (%) of any infections|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674043|NCT02123615|Experimental|Annual rate of any infections|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674044|NCT02123615|Experimental|subjects (%) with Antibiotic use|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674045|NCT02123615|Experimental|Annual rate with Antibiotic use|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674046|NCT02123615|Experimental|subjects (%) with Days out of work|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674047|NCT02123615|Experimental|Annual rate with Days out of work|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674048|NCT02123615|Experimental|(%) with hospitalized infections|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674172|NCT02122835|Other|heart failure|aerobic exercise training
16674049|NCT02123615|Experimental|Annual rate hospitalized infections|Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
16674050|NCT02123615|Experimental|Adverse Injection Local Reactions|Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674051|NCT02123615|Experimental|Adverse Reactions Headache|Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674052|NCT02123615|Experimental|Adverse Reactions Fever|Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674053|NCT02123615|Experimental|Adverse Reactions Nausea|Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674054|NCT02123615|Experimental|Adverse Reactions Vomiting|Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674055|NCT02123615|Experimental|Adverse Reactions Fatigue|Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674056|NCT02123615|Experimental|Adverse Reactions Diarrhea|Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674057|NCT02123615|Experimental|Adverse Reactions Asthma|Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674058|NCT02123615|Experimental|Adverse Reactions Oropharyngeal|Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674059|NCT02123615|Experimental|Adverse Reactions Abdominal Pain|Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
16674060|NCT02123602|Experimental|Core stabilization|This arm will receive 3 weeks of core stabilization training followed by 3 weeks of lower extremity stretching and strengthening as appropriate to address impairments noted in the examination and to progress function.
16674061|NCT02123602|Active Comparator|Lower extremity training only|This arm with receive 6 weeks of impairment based stretching and strengthening to restore function.
16674062|NCT02123589|Experimental|Deep sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3
16674063|NCT02123589|Experimental|Deep and daily interruption of sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3.and from the second day after subject was admitted in ICU, daily interruption of sedation will be taken .
16674064|NCT02123589|Experimental|Light sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -2 and +1.
16674065|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
16674066|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
16674067|NCT02123563|Experimental|Ultrason Essential oils rinse|Ultrasonic debridement followed by twice daily home use of an essential-oils mouth rinse (20mL, 30 seconds for each rinse) for 3 months
16674068|NCT02123563|Placebo Comparator|Ultrason Placebo rinse|Ultrasonic debridement followed by twice daily home use of a placebo rinse (20mL, 30 seconds for each rinse) for 3 months
16674069|NCT02123537|Experimental|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System for walking daily during the 12 weeks of the study.
16674070|NCT02123524|Experimental|Rivaroxaban|Rivaroxaban 10mg tablet daily for 45 days
16674071|NCT02123524|Placebo Comparator|Control|Placebo tablet daily for 45 days
16674072|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
16674073|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
16674074|NCT02123498|Experimental|Single Arm|
16674075|NCT02123485|Experimental|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
16674076|NCT02123485|Sham Comparator|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
16674077|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
16674078|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
16674079|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
16674080|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
16674081|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
16674082|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
16674083|NCT02123433|Experimental|13-valent vaccine|
16674084|NCT02123420|Other|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.
~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
16674085|NCT02123420|Other|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.
~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
16674086|NCT02123407|Experimental|Carbon Nanoparticles|Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.
16674087|NCT02123407|Active Comparator|Gastrectomy with D2 dissection|Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used
16674088|NCT02123394|Placebo Comparator|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
16674089|NCT02123394|Experimental|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
16674090|NCT02123381|Experimental|Arm A|All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy，patients receive right thoracotomy with three incisions radical surgery.
16674091|NCT02123368|Active Comparator|Hialuronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
16674092|NCT02123368|Active Comparator|Hyaluronic acid and MSC 10|Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
16674093|NCT02123368|Active Comparator|Hyaluronic acid AND MSC 100|Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
16674094|NCT02123355|Experimental|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
16674095|NCT02123355|Sham Comparator|Normal saline|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
16674096|NCT02123342|No Intervention|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
16674097|NCT02123342|Experimental|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
16674098|NCT02123329|Active Comparator|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
16674099|NCT02123329|Experimental|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
16674100|NCT02123316|Active Comparator|Pangramin Plus D. pteronyssinus|Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
16674101|NCT02123316|Placebo Comparator|Placebo|Placebo for subcutaneous injection
16674102|NCT02123303||Veterans|
16674103|NCT02123290|Experimental|Plasmodium falciparum|Patients with Plasmodium falciparum malaria
16674104|NCT02123290|Experimental|Plasmodium vivax|Patients with Plasmodium vivax malaria
16674105|NCT02123277|Experimental|concept proof|Balloon catheter for the Eustachian tube
16674106|NCT02123264|Active Comparator|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
16674107|NCT02123264|No Intervention|No intervention|No intervention
16674138|NCT02123043|Experimental|Motor learning-based training|The motor learning-based training, like the 'practice' condition, will consist of six visits over three weeks. Each visit will involve two 5-minute wheeling trials with 10-minutes of rest between trials. The motor learning-based training will focus on variable practice and sporadic feedback.
16674108|NCT02123251|Experimental|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
16674109|NCT02123251|No Intervention|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
16674110|NCT02123238|Other|Control|standard of care positioning (0 degree)
16674111|NCT02123238|Other|30 degree|30 degree bed positioning
16674112|NCT02123238|Other|60 degree|60 degree bed positioning
16674113|NCT02123212|Experimental|Mt. Sinai|Cluster randomization with EHR Alert intervention
16674114|NCT02123212|Experimental|Henry Ford Health System|Simple randomization with mailer intervention
16674115|NCT02123212|Experimental|University of Alabama, Birmingham|Crossover randomization with in-person recruitment intervention
16674116|NCT02123199||Indacaterol/QAB149|Patients treated with Indacaterol for COPD prior to enrollment in study
16674117|NCT02123186||newborns testing for SMA|
16674118|NCT02123173||non-intubated|VATS, non-intubated
16674119|NCT02123173||intubated|VATS, intubated
16674120|NCT02123160|Experimental|Child Parent Psychotherapy (CPP)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads will be randomly assigned to either Child Parent Psychotherapy (CPP) treatment or control (usual treatment) group. CPP treatment will be conducted by a CPP study clinician over approximately six months (24 weekly sessions). CPP includes developmental guidance and fostering affect regulation , continuity in daily living, reciprocity between mother and child, and helping the mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma.
16674121|NCT02123160|Active Comparator|Usual Treatment|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred for usual treatment via referral to therapists in the community and at Columbia University Medical Center, for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Additionally, control patient dyads will be monitored through regular contact with the study research assistant. If the research assistant detects worsening of depressive symptoms or the presentation of new symptoms, a licensed study clinician will follow up to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
16674122|NCT02123147||Sjogren's syndrome|Patients who are diagnosed with Sjogren's syndrome. Blood will be collected once every 3-6 months for up to 3 years.
16674123|NCT02123147||Healthy Control|Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
16674124|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
16674125|NCT02123134|Experimental|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
16674126|NCT02123121|Placebo Comparator|Vegetable cellulose|Participants will orally consume one capsule of vegetable cellulose following each of their main meals (i.e. breakfast, lunch, and dinner) for 90 days.
16674127|NCT02123121|Active Comparator|Resveratrol 1000 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1000 mg/day for 90 days.
16674128|NCT02123121|Active Comparator|Resveratrol 1500 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1500 mg/day for 90 days.
16674129|NCT02123108|Active Comparator|Basiliximab|"Basiliximab
~Basiliximab Peri-transplant
~• 40mg IV infusion within 4 hours of transplant x1
~Basiliximab Post-transplant • 20mg IV infusion Post Operative Day #4 (POD 4) x1
~Tacrolimus (with basiliximab induction)
~• Post Operative Day #7 (POD 7) or subclinical acute rejection (SCr) < 1.8 mg/dl to one year: 0.03-0.1mg/kg q12h
~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1: 720 mg po bid will be administered once the patient is able to tolerate PO medication.
~Corticosteroids • Intraoperative: hydrocortisone 1000mg intravenous push (IVP)
~Followed by:
~• Standard steroid taper:"
16674130|NCT02123108|No Intervention|Tacrolimus Group|"Tacrolimus (without basiliximab induction); standard of care group
~Beginning Post Operative Day #1 to six months: 0.03-0.1 mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL
~Six months to one year: maintain whole blood trough concentration of 5-8ng/mL
~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1. Immediately post transplant, while subjects have nasogastric (ng) tube; this will be delivered as CellCept (mycophenolate mofetil) oral suspension 1,000 mg BID administered via the ng tube. Enteric coated mycophenolic acid (Myfortic) - 720 mg po bid will be administered once the patient is able to tolerate PO medication.
~Corticosteroids • Intraoperative: hydrocortisone IVP
~Followed by:
~• Standard steroid taper"
16674131|NCT02123082|Other|Single-Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
16674132|NCT02123082|Experimental|Dual Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
16674133|NCT02123069||Women with uterine fibroids|"Brachial artery catheter
~Acetylcholine
~Nitroprusside
~Norepinephrine
~Nitroprusside and phenylephrine"
16674134|NCT02123069||Women without uterine fibroids|"Brachial artery catheter
~Acetylcholine
~Nitroprusside
~Norepinephrine
~Nitroprusside and phenylephrine"
16674135|NCT02123056|Active Comparator|Metoprolol|Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
16674136|NCT02123056|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
16674173|NCT02122835|Other|heart failure plus type 2 diabetes|aerobic exercise training
16674139|NCT02123043|Active Comparator|Practice wheeling|To provide a comparable amount of exposure to wheelchair propulsion, the practice group will participate in the same number of visits and wheeling time as the motor-learning based training group. This will allow us to determine whether the motor-learning based training is superior to exposure through practice. The practice group will come to the lab six times over three weeks and wheel for two 5-minute trials with a 10-minute rest break in between. Participants randomized to this group will receive no feedback.
16674140|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
16674141|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
16674142|NCT02123017|Experimental|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
16674143|NCT02123017|Experimental|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
16674144|NCT02123017|Experimental|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
16674145|NCT02123004|Experimental|Ticagrelor|"Investigational product/Dosage form and strength/Manufacturer:
~ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks"
16674146|NCT02123004|Active Comparator|Clopidogrel|"Investigational product/Dosage form and strength/Manufacturer:
~clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks"
16674147|NCT02122991||Able-Bodied Controls|Subjects must be between the ages of 30 and 64 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
16674148|NCT02122991||Spinal Cord Injury|Subjects must be between the age of 30 and 64 years old, be English-literate and able to provide informed consent. They must be at least 1 year from the date of their spinal cord injury. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
16674149|NCT02122978|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
16674150|NCT02122978|Experimental|MBSCT 8 week course|Mindfulness Based Self Compassion Therapy
16674151|NCT02122978|Active Comparator|Mindfulness Based Self-Compassion - Audio guided|MBSC - minimal contact
16674152|NCT02122965|Experimental|Pharmacist-led medication review|Pharmacist-led medication review in the ED
16674153|NCT02122965|No Intervention|Usual care|Usual care includes nurse-led medication reconciliation.
16674154|NCT02122952|Experimental|Cohort 1|6.7 X 10^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
16674155|NCT02122952|Experimental|Cohort 2|2.0 X 10^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
16674156|NCT02122939|Experimental|Escitalopram|
16674157|NCT02122926|Experimental|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:
~Inpatient protocol for adjusting the discharge diabetes regimen;
~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;
~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);
~Visiting nurse intervention after discharge;
~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;
~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and
~Follow-up with PCP or endocrinologist within 1 week of discharge."
16674158|NCT02122926|No Intervention|Usual Care|Patients in the control arm of this study receive usual care.
16674159|NCT02122913|Experimental|Tumor patients_Dose 1|Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
16674160|NCT02122913|Experimental|Tumor patients_Dose 2|Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
16674161|NCT02122913|Experimental|Tumor patients_Dose 3|Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
16674162|NCT02122913|Experimental|Tumor patients_Dose 4|Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
16674163|NCT02122913|Experimental|Tumor patients_Dose 5|Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
16674164|NCT02122913|Experimental|Tumor patients_Dose 6|Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
16674165|NCT02122913|Experimental|Tumor patients_Expansion|"Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).
~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part."
16674166|NCT02122887|No Intervention|control group|no intervention for 3 months
16674167|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
16674168|NCT02122874|Active Comparator|Diet|The patients follow only a 1200 Kcal diet
16674169|NCT02122874|Experimental|Diet +PENS dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
16674170|NCT02122861|Experimental|ID-LV305|Dose escalation and expansion cohort including treatment of melanoma
16674174|NCT02122822|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
16674175|NCT02122809|Experimental|Chiauranib|Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
16674176|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
16674177|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
16674178|NCT02122783|Experimental|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
16674179|NCT02122783|Experimental|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
16674180|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.
~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
16674181|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.
~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.
~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.
~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
16674182|NCT02122757|Placebo Comparator|Sham Anodal Cefaly tDCS|2 mA placebo anodal tDCS (the direct current is delivered just for 30 seconds) is applied over the visual cortex for 20 minutes, everyday for 2 months, in 15 patients
16674183|NCT02122757|Active Comparator|Anodal Cefaly tDCS|2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, everyday for 2 months, in 15 patients.
16674184|NCT02122744|Active Comparator|Super Rapid Magstim Stimulator rTMS QP|rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
16674185|NCT02122744|Placebo Comparator|Placebo|rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
16674186|NCT02122731|Experimental|Amiloride|This is a non-randomized and non-controlled study with only one treatment arm with amiloride.
16674187|NCT02122718|Experimental|Allopurinol|
16674188|NCT02122718|Placebo Comparator|Placebo|
16674189|NCT02122705||VPIA remifentanil|VPIA remifentanil labour analgesia
16674190|NCT02122692|Experimental|Lu AE58054 30 mg + itraconazole 200 mg|
16674191|NCT02122679|Active Comparator|Study group|Receive tranexamic acid in operating room.
16674192|NCT02122679|Placebo Comparator|Placebo group|Receive placebo in the operating room
16674193|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
16674194|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
16674195|NCT02122653|Experimental|Older WT|Older people with weight training
16674196|NCT02122653|Experimental|Older WT and ES|Older people with weight training combined electrical stimulation.
16674197|NCT02122653|No Intervention|Young control group|Young people with control group
16674198|NCT02122627|Experimental|Vitamin D|colecalciferol 16.800 IU per week
16674199|NCT02122627|Placebo Comparator|Placebo|placebo
16674200|NCT02122614|Experimental|Experimental group|
16674201|NCT02122614|Active Comparator|Control group|
16674202|NCT02122601|Other|LBSA0103|single arm , LBSA0103 only
16674203|NCT02122588||OVATAR study patients|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18 years and older, diagnosed 3 months before enrolment into the study or later, consented to participate in this non-interventional study, who are being treated for OC, FTC (Fallopian Tube Cancer) and PC (Peritoneal Cancer) in the oncology hospitals/departments in the Russian Federation.
16674204|NCT02122575||1|Males and females between the ages of 21 and 37
16674205|NCT02122549|Experimental|HWD1000|Subjects using HWD1000
16674206|NCT02122536|Active Comparator|Xeomin right side; Xeomin to left side of face|Patients were randomized as to which side of the face was treated with Xeomin.
16674207|NCT02122536|Active Comparator|Botox right side; Botox to left side|Patients were randomized as to which side of the face was treated with Botox.
16674208|NCT02122523|Experimental|SLN identification with NIR-dye-subserosa injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
16674209|NCT02122523|Active Comparator|SLN identification with NIR-dye-submucosal injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
16674210|NCT02122510|Active Comparator|dexmetomedine group|dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.
16674211|NCT02122510|Active Comparator|Bupivacaine group|Bupivacaine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.
16674212|NCT02122497||abdominal aortic aneurysm (AAA) endovascular|endovascular aortic repair
16674213|NCT02122497||abdominal aortic aneurysm (AAA) open|open surgical repair
16674214|NCT02122497||abdominal aortic occlusive disease (AOD)|open surgical repair
16674215|NCT02122484|Placebo Comparator|Control group|Patients taking placebo
16674216|NCT02122484|Experimental|Colchicine|Active treatment group
16674217|NCT02122471|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
16674218|NCT02122471|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
16674219|NCT02122471|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
16674220|NCT02122458|Active Comparator|hearing impaired vs hearing impaired + PTSD|The investigators will have two treatment groups fitted with mild-gain open-fit hearing aids and will be monitored across 6 months.
16674221|NCT02122458|Other|delayed treatment|A third group will consist of a delayed treatment group. This group will be monitored over 12 months with hearing aids fitted at 6 months.
16674222|NCT02122458|No Intervention|Diagnostic Testing|Battery of auditory and auditory related assessment tasks.
16674223|NCT02122445|Experimental|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
16674224|NCT02122432|Experimental|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association and sends them to the dermatologist using a secured email server.
~Dermatologist answer is standardized."
16674225|NCT02122432|No Intervention|Usual care|Usual care for dermatologic conditions requiring an expertise from a dermatologist involves the general practitioner 1) giving the patient a paper letter containing at least the following information: date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes) and 2) telling him to see the dermatologist of his choice (patient manages his appointments alone).
16674226|NCT02122419||lateral|spinal anesthesia performed during lateral position
16674227|NCT02122419||sitting|spinal anesthesia performed during sitting position
16674228|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
16674229|NCT02122393|Active Comparator|Sertraline|
16674230|NCT02122393|Active Comparator|Cognitive Behavioural Therapy|
16674231|NCT02122393|Active Comparator|Combined Therapy|
16674232|NCT02122380|Experimental|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
16674233|NCT02122380|Experimental|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
16674234|NCT02122367|Experimental|stroke volume variation, pleth variability index|"stroke volume variation: recorded using the FloTrac/Vigileo system (Edwards Lifesciences)
~pleth variability index: recorded using the Masimo Radical-7 monitor (Masimo Corporation, Irvine, CA, USA)"
16674235|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
16674236|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
16674237|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
16674238|NCT02122328|Active Comparator|Selective procedure|Selective laser photocoagulation of communicating vessels.
16674239|NCT02122328|Experimental|Sequential procedure|Sequential laser photocoagulation of communicating vessels
16674240|NCT02122315|Experimental|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles.
16674241|NCT02122315|Active Comparator|Physical therapy|Best-evidence physical therapy intervention
16674242|NCT02122302|Experimental|Web-based health assessment|
16674243|NCT02122289|Experimental|Application of Smartphone|Weekly questionnaire on Smartphone
16674244|NCT02122289|Placebo Comparator|No application Smartphone|No Weekly questionnaire on Smartphone
16674245|NCT02122276|Experimental|SCI|SCI participated in a 4-month robot-assisted passive ankle exercise regimen.
16674246|NCT02122263||NAFLD after sleeve gastrectomy surgery|
16674247|NCT02122250|Experimental|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
16674248|NCT02122250|Active Comparator|Static web-based materials|Static version of the interactive web-based materials
16674249|NCT02122237|Experimental|Cathodal Cefaly tDCS|Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
16674250|NCT02122224|Experimental|Group 1|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
16674251|NCT02122224|Experimental|Group 2|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
16674252|NCT02122224|Experimental|Group 3|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
16674253|NCT02122224|Experimental|Group 4|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
16674254|NCT02122211|Experimental|Betaine supplement|Will use powdered betaine (BetaPower, Dupont Nutrition) that is commercially available for food uses. This powder will be delivered as capsules containing 0.5 gram of powdered betaine which will be administered as eleven capsules twice per day (6 in the morning, 5 in the evening) for a daily total of 6 grams of betaine.
16674255|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
16674256|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.
~Weekly application of estradiol patch 0.075mg/d months 6-9.
~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
16677141|NCT02103153|Experimental|Picosure Laser System|
16674257|NCT02122185|Experimental|Metformin plus chemotherapy|Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
16674258|NCT02122185|Placebo Comparator|Placebo plus chemotherapy|Patients receive placebo PO BID and standard chemotherapy for 6 -8 cycles. Treatment with placebo continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
16674259|NCT02122172|Experimental|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16674260|NCT02122159|Experimental|MA09-hRPE Cellular Therapy|MA09-hRPE cells for transplantation will be provided by Ocata Therapeutics as a suspension frozen to the temperature of liquid nitrogen (approximately -196 °C). They will be processed at UCLA under GMPs according to protocol. Following vitrectomy performed under general anesthesia or waking sedation at the surgeon's discretion, hRPE cells will be introduced into a subretinal bleb formed by the injection of balanced salt solution (BSS). Direct viewing will guide the implantation of thawed and washed MA09-hRPE cells, resuspended in BSS, into the created bleb over a period of one minute. To avoid cell reflux, the cannula used to introduce the cells will be held in position for an additional minute. A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
16674261|NCT02122146|Experimental|PF-06664178|Experimental
16674262|NCT02122133||PC 400|Patients treated with the PC 400 according to the IFU
16674263|NCT02122133||Conventional Embolic Coils|These are any approved embolic coils on the market used as part of the standard of care for treating intracranial aneurysms.
16674264|NCT02122120||Before HEN|Patients with tube feeding with kitchen diet for at least twelve months
16674265|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
16674266|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
16674267|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
16674268|NCT02122094|Experimental|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
16674269|NCT02122081|Experimental|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.
~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
16674270|NCT02122068|Experimental|Mentalizing Imagery Therapy|Meditation and mindfulness 4 week program
16674271|NCT02122068|Active Comparator|Relaxation cd|Listening to a relaxation cd
16674272|NCT02122055|Experimental|Propofol/Dexmedetomidine|"Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
16674273|NCT02122055|Experimental|Midazolam/Dexmedetomidine|"Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
16674274|NCT02122042|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
16674275|NCT02122042|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
16674276|NCT02122029|Experimental|Bariatric Surgery|
16674277|NCT02122029|Experimental|Lifestyle counselling|
16674278|NCT02122016|Experimental|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
16674279|NCT02122016|Active Comparator|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
16674280|NCT02122003|Experimental|sorafenib|Sorafenib 400 mg bid
16674324|NCT02121665|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
16674281|NCT02121990|Experimental|Cisplatin, Paclitaxel, bevacizumab & olaparib|All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
16674282|NCT02121977|Active Comparator|Elevate Anterior and Apical|Prolapse repair with mesh
16674283|NCT02121977|Active Comparator|Native Tissue Repair|Prolapse repair with sutures
16674284|NCT02121964|Other|Capsulectomy|Capsulectomy in Direct Anterior Total Hip Arthroplasty
16674285|NCT02121964|Other|Capsulotomy|Capsulotomy in Direct Anterior Total Hip Arthroplasty
16674286|NCT02121951|Active Comparator|Local Anesthetic infiltration and MAC|"Local Anesthetic infiltration with 1% lignocaine
~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
16674287|NCT02121951|Experimental|Quadratus Lumborum block and MAC|"QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine
~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
16674288|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
16674289|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
16674290|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
16674291|NCT02121886|Experimental|Parietal peritoneum|
16674292|NCT02121873||Women with and without breast cancer|Nipple aspirator, ductal lavage microcatheter, blood draw
16674293|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
16674294|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
16674295|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
16674296|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
16674297|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
16674298|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
16674299|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
16674300|NCT02121821|No Intervention|Control|A control group of pregnant women receiving no intervention (i.e. no SMS reminders).
16674301|NCT02121821|Experimental|SMS reminder messages|The intervention group will be composed of pregnant women receiving SMS reminder messages via the SMS Mother Reminder system.
16674302|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
16674303|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
16674304|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
16674305|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
16674306|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
16674307|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
16674308|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
16674309|NCT02121782|Active Comparator|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
16674310|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
16674311|NCT02121756|Active Comparator|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
16674312|NCT02121743|Experimental|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
16674313|NCT02121743|Placebo Comparator|No strattice|the colostomy is not reinforced with a mesh
16674314|NCT02121730||Kidney Transplantation|Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
16674315|NCT02121717|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 52 weeks
16674316|NCT02121717|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 52 weeks
16674317|NCT02121717|Placebo Comparator|Arm 3|Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
16674318|NCT02121704|No Intervention|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
16674319|NCT02121704|Active Comparator|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
16674320|NCT02121691|Experimental|Walk by Faith|Intervention arm
16674321|NCT02121691|No Intervention|Comparison|Non-intervention arm
16674322|NCT02121678|Experimental|Run-in - Aerobic - Resistance|"Week -12 to 0: Run-in period with no training
~Week 0 to 12: Aerobic training on ergometer bicycle
~Week 12 to 24: Resistance training with dumbbells"
16674323|NCT02121678|Experimental|Run-in - Resistance - Aerobic|"Week -12 to 0: Run-in period with no training
~Week 0 to 12: Resistance training with dumbbells
~Week 12 to 24: Aerobic training on ergometer bicycle"
16674325|NCT02121665|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
16674326|NCT02121652|Active Comparator|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
16674327|NCT02121652|Experimental|Cognitve behaviroal therapy|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
16674328|NCT02121639|Experimental|AZD5363|AZD5363
16674329|NCT02121639|Placebo Comparator|Placebo|Placebo
16674330|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
16674331|NCT02121613|Experimental|Permixon® 160 mg & Placebo|
16674332|NCT02121613|Placebo Comparator|Placebo|
16674333|NCT02121613|Other|Tamsulosine LP & Placebo|Active control arm
16674334|NCT02121600|Other|Docetaxel|Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan
16674335|NCT02121600|Other|Abiraterone|Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan.
16674336|NCT02121587||Pain self-management course|This is a single group observational cohort study. Participants are adults with persistent musculoskeletal pain who choose to participate in an optional, six week pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment for individual patients.
16674337|NCT02121574||Zero-flux and ingestible thermometer|Ingestion of a capsule thermometer pre-operatively Attachment of a zero flux temperature electrode intraoperatively Standard oesophageal thermometer
16674338|NCT02121561|Experimental|Self-Acceptance Group Therapy|Participants receive Self-Acceptance Group Therapy
16674339|NCT02121548|Placebo Comparator|Outreach|Gets outreach materials and info on where to get screened by CHW.
16674340|NCT02121548|Active Comparator|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
16674341|NCT02121548|Active Comparator|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
16674342|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
16674343|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
16674344|NCT02121522|Experimental|BI 144807|twice daily
16674345|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
16674346|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
16674347|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
16674348|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
16674349|NCT02121496|Experimental|Resources for Postpartum Parenting|Behavioral intervention will include techniques to help mothers get their infants to cry/fuss less and sleep more to determine if this has an effect on prevalence of postpartum depression in low SES women and if it improves the quality of mother-infant interaction and subsequent child development.
16674350|NCT02121496|No Intervention|Control Group|This group will not receive the coaching tips to help babies cry less and sleep more.
16674351|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
16674352|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
16674353|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
16674354|NCT02121457|No Intervention|Control Group|This group did not receive any intervention.
16674355|NCT02121457|Experimental|Treatment Group|This group took one Brazil nut daily during 6 months.
16674356|NCT02121444||Cohort 1|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
16674357|NCT02121431|Experimental|Online-Delivered Parenting Intervention|The Online-Delivered Parenting Intervention, which is based on the Triple P--Positive Parenting Program system of interventions, is an interactive website designed to engage and activate the participant through sequenced, personalized, interactive, and video-based content. The intervention emphasizes a self-regulatory process, parent specification of goals, practical and straightforward parenting strategies, modeling, and action activation.
16674358|NCT02121431|Active Comparator|Staff-Delivered Parenting Intervention|The Staff-Delivered Parenting Intervention is based on the Triple P--Positive Parenting Program system and involves 10 face-to-face sessions with each family. This intervention is the well-established Level 4 Standard Triple P program.
16674359|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
16674394|NCT02121158|Other|1|ICD implantation in addition to Optimal Medical Therapy
16674395|NCT02121158|Active Comparator|2|Optimal Medical Therapy
16674396|NCT02121145|Experimental|Vivotif + Typherix primary immunization|Vivotif + Typherix primary immunization
16674827|NCT02118259|Other|The study population|"See inclusion and exclusion criteria.
~Intervention: Before-after study"
16674360|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
16674361|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine adjuvant chemotherapy.
16674362|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
16674363|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
16674364|NCT02121379|No Intervention|control|stretching exercise
16674365|NCT02121379|Experimental|pulmonary rehablitation|warming up exercise strengthening exercise aerobic exercise cool down
16674366|NCT02121366|Experimental|Insulinoma|Patients with Insulinomas will received EUS-guided ethanol ablation therapy
16674367|NCT02121353|Experimental|PF582|PF582 is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
16674368|NCT02121353|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
16674369|NCT02121340|Experimental|Behavioral Activation|CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
16674370|NCT02121340|No Intervention|Usual Care|Usual Care
16674371|NCT02121327|Active Comparator|usual care|usual care group receive regular outpatient treatment
16674372|NCT02121327|Experimental|disease management|desease management program include self management education by nurse on 6months.
16674373|NCT02121314|Active Comparator|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
16674374|NCT02121314|Active Comparator|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
16674375|NCT02121301|Experimental|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
16674376|NCT02121301|Experimental|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
16674377|NCT02121301|Placebo Comparator|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
16674378|NCT02121288|Experimental|Ticagrelor|oral ticagrelor 90 mg (yellow) tablet
16674379|NCT02121288|Active Comparator|Clopidogrel|oral clopidogrel 75 mg (pink) tablet
16674380|NCT02121275||Laparoscopic surgery|Patients undergoing laparoscopic surgery under general anaesthesia, patients undergo ultrasound of the lungs and electric impedance tomography at 4 times during anaesthesia
16674381|NCT02121262|Other|Laser Photocoagulation|Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
16674382|NCT02121262|Experimental|Dexamethasone|Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.
16674383|NCT02121249|Experimental|Robot assisted pedicle screw fixation|posterior lumbar interbody fusion using Robot assisted pedicle screw fixation (Renaissance, Mazor Robotics Ltd, Caesare, Israel)
16674384|NCT02121249|Active Comparator|Free hand technique|using Free hand technique, posterior lumbar interbody fusion (No specific device)
16674385|NCT02121236||Patients with benign radiolucent lesions|
16674386|NCT02121223|Active Comparator|Control|Patients in control group will receive current standard therapy for STEMI: manual thrombus aspiration + Promus Element stent implantation ( with a pressure less than 12 atm), but not post-dilatation
16674387|NCT02121223|Experimental|Post-dilatation|Patients in this group will receive high pressure post-dilatation with a Quantum Maverick balloon after manual thrombus aspiration + Promus Element stent implantation
16674388|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
16674389|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
16674390|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
16674391|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
16674392|NCT02121171|Experimental|Ologen Collagen Matrix Intervention|Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
16674393|NCT02121171|Active Comparator|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
16674397|NCT02121145|Experimental|Vivotif booster|Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization
16674398|NCT02121145|Experimental|Typherix booster|Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization
16674399|NCT02121145|Experimental|Vivotif + Typherix booster|Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization
16674400|NCT02121132||No treatment|
16674401|NCT02121119|Active Comparator|Lidocaine|0.5% lidocaine infusion hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
16674402|NCT02121119|Placebo Comparator|Bupivacaine|Infusion of 0.1% bupivacaine hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
16674403|NCT02121106|Experimental|Cognitive Remediation|Participants in this group will receive active cognitive remediation.
16674404|NCT02121106|Sham Comparator|Sham Cognitive Remediation|Participants in this group will receive a sham comparison, which is a computerized exposure to the same exercises as the active intervention, but with cognitively complex elements removed and no titration of the difficulty of tasks.
16674405|NCT02121093|No Intervention|alpha band of the EEG and electromyographic activity|- 20 will be in the evaluation group (EG); then review the alpha band of EEG and EMG activity.
16674406|NCT02121093|Experimental|Vibration|"• 20 vai participar no grupo de baixa freqüência de vibração estimulação (LFVS);
~20 no grupo de estimulação da vibração de média freqüência (MFVS);
~20 vai participar no grupo de alta freqüência de vibração estimulação (HFVS). then review the alpha band of EEG and EMG activity."
16674407|NCT02121080|Experimental|Cohort 1|Dosing regimen 1
16674408|NCT02121080|Experimental|Cohort 2|Dosing regimen 2
16674409|NCT02121080|Experimental|Cohort 3|Dosing regimen 3
16674410|NCT02121080|Experimental|Cohort 4|Dosing regimen 4
16674411|NCT02121080|Experimental|Cohort 5|Dosing regimen 5
16674412|NCT02121067|Experimental|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
16674413|NCT02121041|No Intervention|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
16674414|NCT02121041|Active Comparator|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
16674415|NCT02121028||Intracranial Atherosclerotic Disease, Stroke/TIA|Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
16674416|NCT02121015|Active Comparator|Self-Directed|Access to the e-health intervention (an interactive website with didactic material and interactive tools) for participants to use at their own pace for 8 weeks (Self-Directed)
16674417|NCT02121015|Experimental|Share|Access to the same e-health intervention + an internet social networking component consisting of up to 12 other pregnant women (Share).
16674418|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
16674419|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
16674420|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
16674421|NCT02120976|Experimental|Dose 1 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674422|NCT02120976|Experimental|Dose 2 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674423|NCT02120976|Experimental|Dose 3 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674424|NCT02120976|Experimental|Dose 4 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674425|NCT02120976|Experimental|Dose 5 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674426|NCT02120976|Experimental|Dose 6 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674427|NCT02120976|Experimental|Dose 7 JTT-252 or Placebo|Tablets, single dose in fasted condition
16674428|NCT02120976|Experimental|Dose 8 JTT-252|Tablets, single dose in fed condition
16674429|NCT02120976|Experimental|Dose 9 JTT-252|Tablets, single dose in fasted condition
16674430|NCT02120963|Experimental|intervention program|Person-centered physical therapy intervention program
16674431|NCT02120963|No Intervention|Control group|Health care as usual
16674432|NCT02120950|Experimental|Aflibercept + Sham PDT|Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
16674433|NCT02120950|Experimental|Aflibercept + Active PDT|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
16674434|NCT02120937|Experimental|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
16674435|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
16674436|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
16674437|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
16674438|NCT02120911|Experimental|Pertuzumab, trastuzumab|Pertuzumab, trastuzumab
16674439|NCT02120898|Experimental|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
16674581|NCT02119949|Placebo Comparator|Placebo training|
16674862|NCT02118012|Active Comparator|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
16674440|NCT02120898|Active Comparator|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
16674441|NCT02120898|Placebo Comparator|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
16674442|NCT02120885|Experimental|Exercise group|physical activity intervention
16674443|NCT02120885|No Intervention|Control group|
16674444|NCT02120872|Active Comparator|PRF and SMV Group|sites treated with Open Flap Debridement with Platelet Rich Fibrin along with Simvastatin
16674445|NCT02120872|Sham Comparator|PRF Group|sites treated with Open Flap Debridement with autologous Platelet Rich Fibrin
16674446|NCT02120872|Other|OFD Group|sites treated with Open Flap Debridement i.e. conventional flap surgery
16674447|NCT02120859|Experimental|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
16674448|NCT02120859|Other|DEB angioplasty with provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
16674449|NCT02120846|Experimental|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
16674450|NCT02120846|No Intervention|Control|Daily routines
16674451|NCT02120833|Active Comparator|EPI|
16674452|NCT02120833|Experimental|NEE|
16674453|NCT02120820|Active Comparator|Multisensory environment|Multisensory environment (MSE): 30 minutes/session, twice a week for 10 weeks
16674454|NCT02120820|Active Comparator|Massage therapy|Massage therapy (MT): 15 minutes/session, twice a week for 10 weeks
16674455|NCT02120820|Other|Control group|Control group: usual care for 10 weeks, with attention and interactions with the caregivers only.
16674456|NCT02120820|Active Comparator|Massage in multisensory environment|Participants receive 15 minutes massage therapy in multisensory environment (MT-MSE), twice a week for 10 weeks.
16674457|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
16674458|NCT02120794|Experimental|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
16674459|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
16674460|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
16674461|NCT02120768|Experimental|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
16674462|NCT02120768|Active Comparator|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
16674463|NCT02120755|Active Comparator|AmnioClear™|AmnioClear™ Human Allograft Amniotic Membrane
16674464|NCT02120755|No Intervention|Standard of Care|Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)
16674465|NCT02120742|Experimental|Social Norming|"The first group will receive SMS message reminders framed as social norming (ie Most of your peers wear helmets)."
16674466|NCT02120742|Experimental|Fear Appeal|"The second group will receive SMS message reminders framed as fear appeals (ie Not wearing your helmet increases your chance of dying in an accident)."
16674467|NCT02120742|Placebo Comparator|Control|The third group will act as the control and receive texts that relate to general road safety, but not helmet use.
16674468|NCT02120729|No Intervention|Standard of Care|Patients assigned to standard-of-care pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription and psychotropic therapy follows the institutional norm.
16674469|NCT02120729|Active Comparator|Genotype-guided Care|Patients assigned to genetically-guided pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription as part of psychotropic therapy.
16674470|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
16674471|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
16674472|NCT02120703|Active Comparator|gabapentin|
16674473|NCT02120703|Active Comparator|Pregabalin|
16674474|NCT02120690|Experimental|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
16674475|NCT02120690|Sham Comparator|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
16674476|NCT02120677|Experimental|Itraconazole ointment|Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
16674477|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
16674478|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
16674479|NCT02120651|Active Comparator|Fibrin monomer|40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
16674480|NCT02120651|Placebo Comparator|Hemostatic sponge|40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.
16674481|NCT02120638|Active Comparator|Pyrazinamide Sensitive Comparator|"Pyrazinamide containing regimen: Regimen B1 - 6ZAmkLfxClrPto\6ZlfxClrPto
~Six months of chemotherapy with Pyrazinamide,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by
~Six months of Pyrazinamide,Levofloxacin,Clarithromycin,plus Prothionamide"
16674482|NCT02120638|Experimental|Pyrazinamide Resistant Comparator|"Regimen without Pyrazinamide: Regimen B2 - 6HAmkLfxClrPto\18HlfxClrPto
~Six months of chemotherapy with Isoniazid,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by
~Eighteen months of Isoniazid,Levofloxacin,Clarithromycin,plus Prothionamide"
16674483|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
16674484|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
16674485|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
16674486|NCT02120599|Active Comparator|corn-soy-blend|This is the control group for the study, which will receive the Malawi standard of care. The treatment provided to women randomized to this arm of the study includes daily iron (60 mg) and folic acid (400 mcg) supplementation, along with 4 kg/2 weeks corn-soy blend (~357 gm/d CSB).
16674487|NCT02120599|Experimental|corn-soy-blend + multiple micronutrients|The treatment provided to women randomized to this arm of the study includes 200gm/d CSB along with a standard maternal multiple micronutrient tablet, which together provide a comparable amount of energy, protein and micronutrients to the ready-to-use supplemental food. The micronutrient supplement known as the United Nations Children's Emergency Fund (UNICEF) / World Health Organization (WHO) / United Nations University (UNU) international multiple micronutrient preparation (UNIMMAP) is widely available and has been used in many settings worldwide in pregnant women.
16674488|NCT02120599|Experimental|ready-to-use supplementary food|RUSF-P (ready-to-use supplementary food) provides 750 kcal/d, 20 g protein/d, and 200% of RDA/d for most micronutrients during pregnancy (except for vitamins A, B3, folic acid, minerals iodine, magnesium, and calcium which will remain near 100%)
16674489|NCT02120586|No Intervention|Control group|Usual care
16674490|NCT02120586|Experimental|Respiratory training group|"Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
~Intervention: Inspiratory Muscle training (12-weeks)"
16674491|NCT02120586|Experimental|Peripheral training group|"Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
~Intervention: Peripheral muscle training (12-weeks)"
16674492|NCT02120573|Active Comparator|medical students|medical students took part in workshop
16674493|NCT02120573|Active Comparator|general population|general population took part in workshop
16674494|NCT02120573|Active Comparator|nonmedical students|all students from different subjects, non medical and paramedical
16674495|NCT02120560|Active Comparator|Interrupted Anticoagulation|Patients randomized to undergo atrial fibrillation ablation with interrupted anticoagulation with apixaban (5mg twice daily; 2.5mg twice daily >80 years old, Cr > 1.5, wt < 60kg), rivaroxaban (20mg daily; 15mg daily CrCl < 50 mL/minute), dabigatran (150mg twice daily; 75mg twice daily CrCl < 30mL/minute), or warfarin (dosed case-by-case).
16674496|NCT02120560|Active Comparator|Uninterrupted anticoagulation with warfarin|Patients randomized to undergo atrial fibrillation ablation with uninterrupted anticoagulation with warfarin (dosed case-by-case).
16674497|NCT02120547|Experimental|Cenicriviroc in mild liver impaired|Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
16674619|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
16674498|NCT02120547|Experimental|Cenicriviroc in moderate liver impaired|Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
16674499|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
16674500|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
16674501|NCT02120521||Sepsis group|Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
16674502|NCT02120521||SIRS group|Sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
16674503|NCT02120508|Experimental|1 Hz rTMS, real|1 Hz rTMS over unaffected hemisphere for 15 minutes
16674504|NCT02120508|Sham Comparator|1Hz rTMS, sham|1Hz sham rTMS, over unaffected hemisphere for 15 minutes
16674505|NCT02120495|Experimental|intraoral condylectomy via coronoid process resction|This procedure has no facial nerve injury and skin scar,little injury to TMJ anatomy and function.
16674506|NCT02120482|Experimental|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
16674507|NCT02120469|Experimental|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16674508|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
16674509|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
16674510|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
16674511|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
16674512|NCT02120443|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
16674513|NCT02120430|Active Comparator|Early administration of the video|Video delivered at one month of child's life
16674514|NCT02120430|Experimental|Late administration of the video|Video delivered at seven months of child's life
16674515|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
16674516|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
16674517|NCT02120404|No Intervention|Control group (GC)|Control group: no esmolol administration
16674518|NCT02120404|Experimental|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
16674519|NCT02120404|Experimental|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
16674520|NCT02120391|Sham Comparator|Control (Arm A)|"Patients randomized to Arm A(control group) will receive an iPhone application without any of the adherence intervention turned on. The control phone application will allow patients to record their medications and how many refills they have remaining. The application will also provide patients with links about their medication.
~No adherence intervention will be done to these patients."
16674521|NCT02120391|Experimental|Cases (Arm B)|"Patients randomized to Arm B will receive an iPhone application with the adherence intervention turned on. The study coordinator will help with the installation of the iPhone application.
~Participants in this group will not need to pay for the iPhone application."
16674522|NCT02120365|Experimental|Perampanel 6mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg days prior to each test day, and then observed dosing moderate 6mg dose perampanel in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
16674523|NCT02120365|Placebo Comparator|Placebo|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with placebo 7 days prior to each test day, and then observed dosing of placebo in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
16674620|NCT02119676|Active Comparator|Placebo plus regorafenib|
16674621|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
16674622|NCT02119663|Active Comparator|Placebo plus capecitabine|
16674524|NCT02120365|Experimental|Perampanel 10 mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose perampanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
16674525|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
16674526|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
16674527|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
16674528|NCT02120339|Experimental|Carvedilol|Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day
16674529|NCT02120326|Experimental|active tDCS|
16674530|NCT02120326|Placebo Comparator|simulated tDCS|
16674531|NCT02120313|Active Comparator|inpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in a rehabilitation hospital.
16674532|NCT02120313|Experimental|outpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in an outpatient rehabilitation center.
16674533|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
16674534|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
16674535|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
16674536|NCT02120287|Experimental|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.
~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
16674537|NCT02120274|No Intervention|Control|Pegylated Interferon-Alfa plus ribavirin for 48 weeks
16674538|NCT02120274|Experimental|Vitamins|Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
16674539|NCT02120261|Experimental|TPI with Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
16674540|NCT02120261|Active Comparator|TPI with Lidocaine & Triamcinolone Acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
16674541|NCT02120248|No Intervention|Control|Participants receive standard WIC breastfeeding support but do not have contact with a breastfeeding peer counselor
16674542|NCT02120248|Other|Low Intensity|Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
16674543|NCT02120248|Active Comparator|High Intensity|Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
16674544|NCT02120222|Experimental|Treatment (selinexor)|Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
16674545|NCT02120196|Experimental|rifaximin|Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.
16674546|NCT02120196|Active Comparator|norfloxacin|Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.
16674547|NCT02120183|Experimental|Psycho-educational support group therapy|4 week psycho-educational support group focusing on topics specific to psychosocial and emotional aspects of the cancer caregiving role
16674548|NCT02120170|Active Comparator|Hemoclipping during colon polypectomy for all lesion|The enrolled patients of group 1 will be performed hemoclipping for all polypectomy lesion irrespective of the presence of immediate bleeding.
16674549|NCT02120170|No Intervention|No hemoclipping if there were no bleeding during polypectomy|The patients of group 2 will be performed hemoclipping only for the immediate bleeding during colon polypectomy
16674623|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
16674624|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
16677208|NCT02102633|Experimental|Dabigatran|Dabigatran 150 mg orally
16674550|NCT02120157|Experimental|1: Acute Lymphoblastic Leukemia/Lymphoma|"Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*
~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+
~Day 0: Infuse unmanipulated bone marrow
~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg Ideal body weight (IBW)/day IV#
~Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day
~Day +30 Assess chimerism and disease status in bone marrow
~Day +35 Discontinue MMF
~Day +60 Assess chimerism and disease status in bone marrow
~Day 180 Discontinue tacrolimus"
16674551|NCT02120157|Experimental|2: Acute Lymphocytic Leukemia/Lymphoma|"Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+
~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days
~Day 0: Infuse unmanipulated bone marrow
~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV
~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day
~Day +30 Assess chimerism and disease status in bone marrow
~Day +35: Discontinue MMF
~Day +60: Assess chimerism and disease status in bone marrow
~Day 180 Discontinue tacrolimus"
16674552|NCT02120144|Experimental|Intervention|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
16674553|NCT02120144|Active Comparator|Reading|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to a reading phase on a computer for 10 minutes.
16674554|NCT02120131||test envelope|envelope flap
16674555|NCT02120131||control, trapezodal|standard incision
16674556|NCT02120118|Experimental|Radiation; Hyperthermia; Chemotherapy|Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will cisplatin 30mg/m2 and taxotere 20mg/m2 per week for 6 weekly cycles.
16674557|NCT02120105||Cystinuria|
16674558|NCT02120092|Active Comparator|Clopidogrel + ASA|
16674559|NCT02120092|Placebo Comparator|Clopidogrel + Placebo|
16674560|NCT02120092|Active Comparator|Ticagrelor + ASA|
16674561|NCT02120092|Placebo Comparator|Ticagrelor + Placebo|
16674562|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
16674563|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
16674564|NCT02120066|Other|Vitrectomy|
16674565|NCT02120053|Experimental|Bone substitute material group|Immediate denture placement following extractions and alveolar sockets filling with bone substitute material
16674566|NCT02120053|Active Comparator|Conventional protocol|Immediate denture placement following the conventional protocol
16674567|NCT02120040|Other|Hemangioblastoma (HB) of the Central nervous system (CNS)|
16674568|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
16674569|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
16674570|NCT02120014|Experimental|Heart Failure Reduced EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.
~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.
~Measurements form the right heart catheterization will be recorded for analysis."
16674571|NCT02120014|Experimental|Heart Failure Preserved EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.
~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.
~Measurements form the right heart catheterization will be recorded for analysis."
16674572|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
16674573|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
16674574|NCT02119988|Experimental|TIPS combined with embolization|"The covered stents were used for TIPS
~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
16674575|NCT02119988|Active Comparator|TIPS alone|"The covered stents were used for TIPS
~No embolization of any collateral will be performed during TIPS"
16674576|NCT02119975|Placebo Comparator|Placebo working memory training|
16674577|NCT02119975|Experimental|Working memory training|
16674578|NCT02119962|Experimental|Working memory training|
16674579|NCT02119962|Placebo Comparator|Placebo training|
16674580|NCT02119949|Experimental|Working memory training|
16674582|NCT02119936|Experimental|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
16674583|NCT02119923|Experimental|Working memory training|
16674584|NCT02119923|Placebo Comparator|Placebo training|
16674585|NCT02119910|Experimental|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
16674586|NCT02119910|No Intervention|Waitlist|Participants will serve as the control condition.
16674587|NCT02119897|Experimental|Low Level Light Therapy (LLLT)|"LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck
~Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2
~Route: Extraoral
~Total Treatment Time (all sites): 6 min
~Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.
~Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment."
16674588|NCT02119884|Experimental|Terlipressin group|Patients receive terlipressin 2 mg IV bolus
16674589|NCT02119884|Active Comparator|High Dose Octreotide group|Patients receive Octreotide 50 μg/h with an initial bolus of 100 μg
16674590|NCT02119871|Experimental|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
16674591|NCT02119871|Active Comparator|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
16674592|NCT02119858|Experimental|Diagnostic (ICG, diffuse optical imaging, surgery)|Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.
16674593|NCT02119845|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
16674594|NCT02119832|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
16674595|NCT02119819|Experimental|10 mg LY2944876|"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.
~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
16674596|NCT02119819|Experimental|15 mg LY2944876|15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
16674597|NCT02119819|Experimental|30 mg LY2944876|30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
16674598|NCT02119819|Experimental|50 mg LY2944876|50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
16674599|NCT02119819|Experimental|Exenatide extended-release|2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
16674600|NCT02119819|Placebo Comparator|Placebo|"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.
~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
16674601|NCT02119806|Active Comparator|Benzodiazepine group|"Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ;
~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;
~Postoperative 10-100mcg/kg/min of propofol"
16674602|NCT02119806|Active Comparator|Non-benzodiazepine group|"Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;
~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;
~Postoperative 10-100mcg/kg/min of propofol"
16674603|NCT02119793|Experimental|YVOIRE contour|
16674604|NCT02119780|Experimental|YVOIRE® contour|
16674605|NCT02119780|Active Comparator|Restylane SubQ™|
16674606|NCT02119767||Natural gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have natural gradients sampled using the LBS
16674607|NCT02119767||Induced gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have induced gradients sampled using the LBS
16674608|NCT02119754|Experimental|Plurogel PN|Plurogel PN
16674609|NCT02119741||Affected Interdental Papillae Group|This is the only group in which the material will be used
16674610|NCT02119728|Active Comparator|Arm I (standard of care surgery)|Patients undergo standard of care surgery on day 1.
16674611|NCT02119728|Experimental|Arm II (HPPH, photodynamic therapy)|Patients receive HPPH IV over 1 hour on day 0. Approximately 24 hours later, patients undergo photodynamic therapy on day 1.
16674612|NCT02119715|Experimental|Pegylated rhG-CSF 100μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4
16674613|NCT02119715|Experimental|Pegylated rhG-CSF 150μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4
16674614|NCT02119715|Active Comparator|G-CSF 5 μg/kg/d|Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4
16674615|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment, engaged in care with ART treatment history available.
16674616|NCT02119702||Uninfected Cohort|Perinatally HIV-exposed, perinatally-uninfected participant at or beyond their 18th birthday at enrollment. Must have been previously or currently enrolled in PHACS AMP or PHACS SMARTT, and may have horizontally-acquired HIV infection.
16674617|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
16674618|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
16674625|NCT02119637||Study 1 TMS to S1|Cohort of healthy participants received screening, brain MRI, TMS to S1 and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
16674626|NCT02119637||Study 2 TMS targeting S2/insula|Cohort of healthy participants received screening, brain MRI before and after TMS, TMS to S2/insula and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
16674627|NCT02119624||1|Healthy non-treatment-seeking heavy drinkers
16674628|NCT02119624||2|Healthy light drinkers
16674629|NCT02119611|Other|Single-arm|Therapy
16674630|NCT02119585||Patients undergoing OLT|insertion of nasogastric tube for measurements of chest wall mechanics
16674631|NCT02119572|Experimental|peer support|Patients are divided into small groups and assigned with peer leaders for twelve months according to their residence. Besides the same training and follow-ups as the control arm, patients from intervention groups are suggested and encouraged to take part in the group activities with the peer leaders per month. And if possible, casual activities (such as phone call, chatting, short message; physical exercise, group member family visiting，going to supermarket together, etc.)are also recommended
16674632|NCT02119572|Active Comparator|usual education|Patients attend the usual self-management education and communicate with the professionals every two months, getting the information on diabetes diet, exercise, glucose monitor, etc. besides that the group members should attend three follow ups at baseline,6 and 12 months.
16674633|NCT02119559|Other|CTC assay, Cetuximab|Detection & characterization of viable CTC in the peripheral blood.
16674634|NCT02119546|Experimental|Exercise intervention|Aerobic exercise and dual-task training
16674635|NCT02119546|Active Comparator|Stretch exercise|Stretch exercise & sitting balance
16674636|NCT02119520|Active Comparator|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
16674637|NCT02119520|Sham Comparator|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
16674638|NCT02119520|Other|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
16674639|NCT02119507|Experimental|Curodont Repair|Single application on Day 0.
16674640|NCT02119507|Other|No treatment - control|"No treatment as control - wait and see."
16674641|NCT02119481|Experimental|Mindfulness-based stress reduction|Mindfulness-based stress reduction training
16674642|NCT02119481|Active Comparator|Expressive writing condition|Expressive writing
16674643|NCT02119481|No Intervention|Waiting-list control condition|Waiting list
16674644|NCT02119468|Experimental|Treatment (3mg MLN9708)|Patients receive 3mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16674645|NCT02119468|Experimental|Treatment (4mg MLN9708)|Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16674646|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
16674647|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
16674648|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
16674649|NCT02119429|Placebo Comparator|Wheat Germ Oil|Participants will be instructed to consume 2 wheat germ oil capsules ,2g, per day for 12 weeks.
16674650|NCT02119429|Experimental|Pumpkin Seed Oil|Participants will be instructed to consume 2 pumpkin seed oil capsules ,2g, per day for 12 weeks
16674651|NCT02119416|Experimental|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
16674652|NCT02119416|Experimental|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
16674653|NCT02119416|Experimental|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
16674654|NCT02119403|Experimental|Hand Held NitrousTM|There are no other interventions to this device
16674655|NCT02119390|Other|Standard Care|Participants in the Standard Care group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care.
16674656|NCT02119390|Experimental|Pill Trial+|Participants in the Pill Trial+ group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care plus three 25-minute individualized, behavioral, staff-delivered intervention sessions at HAART initiation, and 1-, and 3-month follow-up visits. Two brief booster sessions will also be provided following sessions 1 (in clinic) and 2 (by phone).
16674657|NCT02119377||Transgender and Transsexual People|Transgender and transsexual (trans) people aged 18 years or older living in Australia were invited to complete a questionnaire assessing a range of mental and physical health domains.
16674658|NCT02119364|Active Comparator|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
16674659|NCT02119364|No Intervention|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
16674660|NCT02119351|Active Comparator|ViaValve™ Safety IV Catheter|Insertion of the ViaValve™ Safety IV Catheter
16674661|NCT02119351|Active Comparator|ProtectIV® Plus Safety IV Catheter|Insertion of the ProtectIV® Plus Safety IV Catheter
16674662|NCT02119338|Experimental|5-ala preoperatively|A dose of 5-ala will be taken by mouth approximately 3 hours before going to surgery.
16674663|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
16674863|NCT02118012|Active Comparator|Chlorcyclizine HCl only|Chlorcyclizine HCl only
16674664|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
16674665|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
16674666|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
16674667|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
16674668|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
16674669|NCT02119273|Experimental|Steroid|The steroid arm will take prednisone 10mg tabs starting 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
16674670|NCT02119273|Placebo Comparator|Placebo|The placebo arm will receive placebo pills identical in appearance to prednisone 10mg pills. They will start taking them 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
16674671|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
16674672|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
16674673|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
16674674|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
16674675|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
16674676|NCT02119247|Experimental|CHF6001 dry powder for inhalation via NEXThaler®|4 inhalations of CHF 6001 NEXThaler®
16674677|NCT02119247|Active Comparator|CHF 6001 DPI capsules for inhalation via Aerolizer|3 inhalations of CHF 6001 capsules via Aerolizer®
16674681|NCT02119221|Experimental|[14C]Copanlisib|
16674682|NCT02119208|Experimental|Lifestyle counseling|
16674683|NCT02119195|No Intervention|No treatment|The composite resin restorations had marginal defects, but were clinically acceptable, did not receive treatment
16674684|NCT02119195|No Intervention|Positive control|Composite resins with alpha value in marginal adaptation criteria
16674685|NCT02119195|Experimental|Intervention|For this group, defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3M ESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure
16674686|NCT02119182||Comprehensive Assessment with MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.
~Phone Outcome Assessment at 3 months.
~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.
~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
16674687|NCT02119182||Comprehensive Assessment without MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.
~Phone Outcome Assessment at 3 months.
~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
16674688|NCT02119182||Brief Assessment|• Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.
16674689|NCT02119169|Experimental|pigtail catheter|Pigtail catheter for pleural drainage of recurrent hepatic hydrothorax
16674690|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
16674691|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
16674692|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
16674693|NCT02119143|Active Comparator|Vitamines and minerals|41 middel aged subjects receive vitamin and mineral supplementation
16674694|NCT02119143|Placebo Comparator|cellulose|41 middle aged subjects get the placebo
16674695|NCT02119130|No Intervention|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
16674696|NCT02119130|Experimental|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
16674697|NCT02119117|Placebo Comparator|sugar pill|Group 2 will receive a placebo of CoQ10
16674698|NCT02119117|Experimental|CoQ10|Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).
16674699|NCT02119104||Prevenar (13v)|
16674700|NCT02119091|Experimental|Moxifloxacin|Single oral dose 400 mg
16674701|NCT02119091|Placebo Comparator|Placebo|Single oral dose
16674702|NCT02119078|Active Comparator|ACE Service|Admission to the Acute Care for Elders (General Medicine Team 1) service. (See Intervention, below)
16674703|NCT02119078|No Intervention|Standard care (other General Medicine teams)|Admission to one of the 4 non-ACE general medicine teaching teams at OHSU.
16674704|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
16674705|NCT02119052|Experimental|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
16674706|NCT02119052|Placebo Comparator|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
16674707|NCT02119039|Experimental|RGTA OTR 4120 (CACICOL20)|
16674708|NCT02119039|Active Comparator|Genteal HA|
16674709|NCT02119026|Active Comparator|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)
~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance
~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
16674710|NCT02119026|Active Comparator|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)
~Arm B:
~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance
~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
16674711|NCT02119013|Experimental|OCTEOTRIDE|Octeotride, 20 mg monthly intramuscular injection for 3 years
16674712|NCT02119013|Placebo Comparator|PLACEBO|Placebo (salin soluction), intramuscular injection monthly for 3 years
16674713|NCT02119000|Experimental|PEG electrolytes 2L/2L split dose|
16674714|NCT02119000|Active Comparator|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|
16674715|NCT02118987|Experimental|Omalizumab|300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. During this treatment period, patients will continue receiving their regularly scheduled chemotherapy desensitizations per the prescribed treatment schedule from the patient's oncologist.
16674716|NCT02118974|Experimental|Robot-assisted|Robot-assisted hysterectomy
16674717|NCT02118974|Experimental|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
16674718|NCT02118961|Experimental|BK1301|
16674719|NCT02118961|Active Comparator|DT toxoid|
16674720|NCT02118948|Experimental|Abuse-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on the psychological consequences of abuse, current sexual risk behavior, and the link between the two.
16674721|NCT02118948|Active Comparator|Sexual behavior-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on current sexual risk behavior.
16674722|NCT02118935|Active Comparator|Previously marketed cow's milk-based infant formula|
16674723|NCT02118935|Experimental|Marketed cow's milk-based infant formula with prebiotics|
16674724|NCT02118922||Healthy volunteers|Volunteers with normal corneas
16674725|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
16674726|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
16674727|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
16674728|NCT02118922||Volunteers to receive PRK surgery|This group includes patients who have been diagnosed with myopia and have been scheduled to undergo PRK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen or artificial tears will be excluded.
16674729|NCT02118922||Volunteers to receive LASIK Surgery|This group includes myopic patients who are scheduled to receive LASIK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen and artificial tears will be excluded.
16674824|NCT02118298||Demographically matched controls|Ages 18 - 66, No known neurological disorder, no learning disorder, and no psychiatric disturbance that is actually interfering with life.
16674730|NCT02118922||Patients with Fuch's Endothelial Corneal Dystrophy|This group includes subjects who are diagnosed with Fuch's corneal dystrophy, at early, mild and advanced stages. The inclusion also extends to subjects with, and without keratoconus. But this exclude patients with any other corneal disorders other than keratoconus, and/or history of ophthalmological surgeries that may affect endothelium cell status, e.g. cataract surgeries.
16674731|NCT02118909|Experimental|Part 1 (Pracinostat + Itraconazole)|Single-dose pracinostat and itraconazole dosing every day for 8 days
16674732|NCT02118909|Experimental|Part 2 (Pracinostat + Ciprofloxacin)|Single dose pracinostat and ciprofloxacin 2 times a day for 7 days
16674733|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
16674734|NCT02118883|Other|Essentia Water|Essentia Water, electrolyzed high-pH water
16674735|NCT02118883|Other|Bottled Water|Purified bottle water
16674736|NCT02118870|Active Comparator|DAPT 360 days|Treatment 360 days DAPT
16674737|NCT02118870|Active Comparator|DAPT 90 days|Treatment 90 days DAPT
16674738|NCT02118857||Omnivore, vegetarian and vegan subjects.|These subjecs followed the diet from at least two years.
16674739|NCT02118844|Active Comparator|Moderate rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain moderate neuromuscular blockade (TOF-count 2-4) during gastrojejunal anastomosis
16674740|NCT02118844|Experimental|deep rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain deep neuromuscular blockade (here defined as a Posttetanic Count 1 - 5) during gastrojejunal anastomosis
16674741|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
16674742|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
16674743|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
16674744|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
16674745|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
16674746|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
16674747|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
16674748|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
16674749|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
16674750|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
16674751|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
16674752|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
16674753|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
16674754|NCT02118779|Experimental|Behavioural change intervention|Cognitive behavioural therapy (CBT) combined with exercise
16674755|NCT02118779|No Intervention|Standard Patient Management|Standard care like usual (i.e. annual checks with neurologist, checks with cardiologist, if needed physical therapy)
16674756|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
16674757|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
16674758|NCT02118753|No Intervention|ischemic preconditioning|"After baseline recordings of contractile function, the investigators will assign 2 trabeculae of each patient to either a stimulus for (1) ischemic preconditioning (IP) or (2) no IP. Subsequently, the trabeculae will be exposed to 90 min of ischemia, followed by 120 minutes of recovery. The investigators will measure the recovery of contractile function in both trabeculae.
~This experiment serves as a positive control, to ensure that our model is still working properly."
16674759|NCT02118753|Experimental|eplerenone|In the next patients, a similar ischemia-reperfusion experiment will be performed, but now the 2 trabeculae will be randomized to pretreatment with eplerenone or DMSO. The percentage recovery (compared to baseline) of contractile force of the trabeculae at the end of reperfusion will serve as the primary endpoint.
16674760|NCT02118727|Active Comparator|Memantine|20mg taken by mouth every day BID for 32 weeks
16674761|NCT02118727|Placebo Comparator|Placebo|Placebo (for Memantine) taken by mouth everyday BID for 32 weeks
16674762|NCT02118714|Experimental|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
16674763|NCT02118701|Experimental|SDM care planning|
16674764|NCT02118688|Placebo Comparator|Placebo|"Drug: Placebo
~Placebo suspension administered PO/NG/FT q12h to mimic risperidone
~Placebo suspension administered PO/NG/FT q8h to mimic trazodone"
16674765|NCT02118688|Active Comparator|Risperidone alone|"Drug: Risperidone
~Initiate risperidone at 1 mg PO/NG/FT q12h
~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose
~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
16674766|NCT02118688|Active Comparator|Trazodone alone|"Drug: Trazodone
~Initiate trazodone dosing at 50 mg PO/NG/FT q8h
~Trazodone dose can be titrated upwards every 24 hours by 25 mg per dose
~Maximum trazodone daily dose 600 mg per day (200 mg every 8 hours)"
16674767|NCT02118688|Active Comparator|Risperidone and Trazodone combination|"Drug: Risperidone
~Initiate risperidone at 1 mg PO/NG/FT q12h
~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose
~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)
~Drug: Trazodone
~Initiate risperidone at 1 mg PO/NG/FT q12h
~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose
~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
16674768|NCT02118675||Age 5-17 years|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
16674769|NCT02118675||Age 18-80 years|Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
16674770|NCT02118662|Experimental|Male Cohort|"Eight Male participants per cohort will complete the following:
~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
16674771|NCT02118662|Experimental|Female Cohort|"Eight femalel participants per cohort will complete the following:
~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
16674772|NCT02118649|Experimental|Game|Participants will play a video game directing their gaze to on-screen targets.
16674773|NCT02118636||Aromatase inhibitor therapy|Subjects who are starting treatment with any of the three aromatase inhibitor (AI) medications
16674774|NCT02118623|Active Comparator|Level 1|Moderated discussion board only
16674775|NCT02118623|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
16674776|NCT02118623|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools.
16674777|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
16674778|NCT02118610|Placebo Comparator|Sugar Pill|
16674779|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
16674780|NCT02118584|Experimental|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
16674781|NCT02118584|No Intervention|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
16674782|NCT02118558|Experimental|Negative Pressure Wound Therapy (NPWT)|
16674783|NCT02118558|Active Comparator|standard prophylactic therapy|
16674784|NCT02118545||vWF and postoperative Outcome|An independent prospective validation cohorts will be obtained from 4 different Institutions: 2 in Vienna , 1 in Salzburg and 1 in Bern
16674785|NCT02118532|Experimental|IN.PACT Admiral|
16674786|NCT02118519|Active Comparator|mesenchymal stem cells|Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
16674787|NCT02118519|Active Comparator|mesenchymal cells&platelet lysate|Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury
16674788|NCT02118506|Active Comparator|Physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.
~Physical practice: is the execution of the motor action."
16674789|NCT02118506|Experimental|Mental and physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.
~Mental practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.
~Physical practice: is the execution of the motor action."
16674790|NCT02118493|Experimental|Benign Biliary Stenosis, Laser|Subjects that undergo the experimental intervention, that being single use of a laser excision catheter.
16674791|NCT02118480|Experimental|cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
16674792|NCT02118480|Active Comparator|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
16674793|NCT02118467|Active Comparator|Norepinephrine and epinephrine|"Patients will receive norepinephrine infusion per standard protocol. Dose range will be 0.03-0.3 mcg/kg/minute. Norepinephrine concentration will be 16 mg/250 mL. If a second vasopressor is required, epinephrine will be added. Dose range of epinephrine will be 0.03-0.3 mcg/kg/minute. Epinephrine concentration will be 16 mg/250 mL. The drugs norepinephrine and epinephrine will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.
~If the patient's shock is not adequately treated with the highest doses of both norepinephrine and epinephrine, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
16674825|NCT02118285|Experimental|Treatment|Haploidentical donor NK cells and IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion and continues twice daily for 90 days.
16674826|NCT02118272|Other|Physica KR|
16675045|NCT02116829|Experimental|Danish butter, dairy|
16674794|NCT02118467|Active Comparator|Phenylephrine and vasopressin|"Patients will receive phenylephrine infusion per standard protocol. Dose range will be 0.3 to 3.0 mcg/kg/minute. Phenylephrine concentration will be 160 mg/250 mL. If a second vasopressor is required, vasopressin will be added. Dose range of vasopressin will be 0.1 to 0.6 milliunits/kg/minute. Vasopressin concentration will be 40 units/250 mL. The drugs phenylephrine and vasopressin will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.
~If the patient's shock is not adequately treated with the highest doses of both phenylephrine and vasopressin, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
16674795|NCT02118454|Experimental|Daily IVR calls|"The Daily IVR Calls Intervention: consisting of two (2) automated voice calls (intervention messages) each day for six months, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months"
16674796|NCT02118454|Active Comparator|Weekly IVR Survey Only|The Weekly IVR Survey Only control condition: consisting of standard care, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months.
16674797|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
16674798|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.
~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
16674799|NCT02118428|Experimental|Mirasol|Transfusions with Mirasol-treated whole blood
16674800|NCT02118428|Active Comparator|Control|Transfusions with untreated whole blood
16674801|NCT02118415|Experimental|Interventional|Interventional group: activated autologous NK cell treatment
16674802|NCT02118415|No Intervention|Control group|Control group: BSC
16674803|NCT02118402|Active Comparator|Fortified maize porridge (MNP)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, maltodextrin carrier (added up to 11g)
16674804|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
16674805|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe+GOS)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA plus 7.5 g of galactooligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
16674806|NCT02118389|Experimental|Glucerna,Meal Replacement|Glucerna 52g instead of night meal 5weeks
16674807|NCT02118376|Experimental|exenatide|exenatide, 5ug, bid, 3months
16674808|NCT02118350|Experimental|Mat Pilates training|Mat Pilates training performed two times at week for 16 weeks.
16674809|NCT02118350|No Intervention|Control|
16674810|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 3 mg/kg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.
16674811|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
16674812|NCT02118337|Experimental|MEDI0680 0.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
16674813|NCT02118337|Experimental|MEDI0680 2.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
16674814|NCT02118337|Experimental|MEDI0680 10 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
16674815|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
16674816|NCT02118337|Experimental|MEDI0680 20 mg/kg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
16674817|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 750 mg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
16674818|NCT02118337|Active Comparator|Nivolumab 240 mg|Participants in dose-expansion phase will receive IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
16674819|NCT02118324|Experimental|Exercise treatment|Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.
16674820|NCT02118324|No Intervention|Control group|No intervention is provided.
16674821|NCT02118311|Experimental|TREG|T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
16674822|NCT02118311|Experimental|Non-Myeloablative Only|Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
16674823|NCT02118298||Multiple Sclerosis|Ages 18 - 66, 10 years or less of MS,
16675046|NCT02116829|Active Comparator|Olive oil, refined|
16674828|NCT02118246|Experimental|Dry Needling|The taut band of trigger point in vastus lateralis muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
16674829|NCT02118246|Experimental|Kinesio Tape|Y technique with 25% tension on the tails was applied. Direction of the technique was insertion to origin of the muscle and zone of the trigger point was placed at the center of Y strip.
16674830|NCT02118233||Carotid Endarterectomy (CEA)|Surgical Revascularization- Carotid Endarterectomy (CEA)
16674831|NCT02118233||Carotid Angioplasty and Stenting (CAS)|Surgical Revascularization- Carotid Angioplasty and Stenting (CAS)
16674832|NCT02118233||Control Group- Medical Management|Control Group- Medical Management
16674833|NCT02118220|Other|Concussion Questionnaire|"The questionnaire is specifically designed to elicit occurrence and symptoms of a concussion. If the patient answers yes to question 2a, which asks At the time of the injury do you recall a blow to the head, neck, face or body that resulted in sustained symptoms of concussion (e.g., headache, dizziness, confusion, nausea, vomiting, etc.)?, the research team will administer the 22 item self-reporting symptom scale in the above mentioned SCAT3. The responses obtained from the questionnaire will be used to determine the incidence of symptomatic concussions, either known or unrecognized, in pediatric patients sustaining an orthopedic injury requiring surgical repair."
16674834|NCT02118207|Experimental|Control dives 1st|Subjects in this group complete the first 3 dives as control dives and the second 3 dives preceded by aerobic exercise
16674835|NCT02118207|Experimental|Predive exercise 1st|Subjects complete the first 3 dives preceded by the intervention of aerobic exercise and the second 3 with no exercise as control dives
16674836|NCT02118194||Paraplegia, spinal cord injury|An exoskeleton-assisted walking system for people with paralysis from spinal cord injury at thoracic level 1 and below (paraplegia) will be used.
16674837|NCT02118181|No Intervention|Control|
16674838|NCT02118181|Experimental|HMB|Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate
16674839|NCT02118168||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-002 and that received at least 3 immunizations and reached 48-weeks of follow-up."
16674840|NCT02118155|Sham Comparator|Connective tissue graft (CTG)|The gingival recession defects were treated by connective tissue graft surgical procedure and received the sham application os low-intensity laser therapy.
16674841|NCT02118155|Experimental|Connective tissue graft plus laser (CTG+L)|The gingival recession defects were treated by connective tissue graft associated with the application of a LILT protocol
16674842|NCT02118142|Active Comparator|Betaine|6 gram dose of betaine delivered in encapsulated form
16674843|NCT02118142|Placebo Comparator|Dextrose|6 gram dose of dextrose delivered in encapsulated form
16674844|NCT02118129|Experimental|Behavioural intervention|Behavioural intervention consisting of an educational video component and use of a handheld mobile app to track vitamin D intake.
16674845|NCT02118129|Placebo Comparator|Control group|Wait-list control group
16674846|NCT02118116|No Intervention|Wait-list Control|No training, wait-listed for ASIST at a later date
16674847|NCT02118116|Experimental|ASIST|Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
16674848|NCT02118116|Experimental|ASIST uncontrolled arm|The ASIST workshop will be offered to participants who refuse to be part of the waitlist control arm. This is due to the reality in gathering data in these communities. Many times it is not possible for participants to be waitlisted, and therefore we would still want to gather data on those that refuse to participate in the RCT design and will collect uncontrolled data on these participants only.
16674849|NCT02118103|Experimental|Spinal Manipulation|bilateral lumbar spine manipulation
16674850|NCT02118103|No Intervention|No Intervention - control|no intervention
16674851|NCT02118090|Experimental|Chloroquine|Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days
16674852|NCT02118090|Active Comparator|DHA-PP|Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP
16674853|NCT02118077|Experimental|G17DT|250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.
16674854|NCT02118077|Placebo Comparator|Placebo|Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.
16674855|NCT02118064|Experimental|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
16674856|NCT02118051|Experimental|CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.|"Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.
~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
16674857|NCT02118051|Active Comparator|hMG ,Ganirelix,choriogonadotropin alfa,progesterone|"Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.
~Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.
~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
16674858|NCT02118038||HELPMOM1|corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
16674859|NCT02118038||HELPMOM2|corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring
16674860|NCT02118025||Off-pump coronary artery bypass graft|Patients operated on with off-pump coronary artery bypass graft, beating heart surgery.
16674861|NCT02118025||Mini extracorporeal circulation bypass|Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
16674864|NCT02117999|Experimental|Cross-linking with iontophoresis|Transepithelial cross-linking by using iontophoresis to administer riboflavin into the corneal stroma
16674865|NCT02117999|Active Comparator|Standard corneal cross-linking|Standard corneal cross-linking includes de-epithelialization and stromal soaking by applying drops of riboflavin
16674866|NCT02117986|Experimental|loading dose of colistin|Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous
16674867|NCT02117986|Active Comparator|without loading dose of colistin|Patients will receive 3 million international units of colistin every 8 hours intravenous
16674868|NCT02117973|Active Comparator|Conventional Technique using Persona prosthesis|The surgeon will realize the implantation of the Persona prosthesis according to the surgical technique. Potential variables such as methodology for determining tibial rotation, measuring of bone cuts, and any intra-operative adjustments will be captured on the operative case report form.
16674869|NCT02117973|Experimental|iAssist Technique using Persona prosthesis|iAssist is an electronic displacement sensor based instrumentation system that provides intra-operative verification at each surgical step (bone cuts alignment and resection level); in order to help reduce bone cuts errors. iAssist features simple and intuitive instrumentation that is based on conventional total knee arthroplasty instrumentation. iAssist should take less than 2-3 minutes (on average) to setup
16674870|NCT02117960|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
16674871|NCT02117960|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
16674872|NCT02117947|Experimental|Behavioral Counseling|Behavioral counseling used evidence-based smoking cessation intervention components as well as a theoretically-framed focus on behavioral shaping to promote the adoption of smoke-free homes and cars. Sessions included two, 1-hour in-home counseling and seven, 5-15 minute telephone follow-up sessions over 16 weeks. Content included health ed around the benefits of eliminating children's exposure to secondhand smoke; skills training around adoption and maintenance of smoke-free environments; goal setting, problem solving, and positive reinforcement for progress toward goals; coping skills training for smoking urge and mood management; and home support for maternal smoking behavior change achieve through family contracts and home detailing promoting pro-smoke-free home norms.
16674873|NCT02117947|Active Comparator|Self-help control|The self-help control group received a comprehensive self-help manual that outlined all of the goals and strategies covered in counseling, however, counseling was not provided to this group.
16674874|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
16674875|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
16674876|NCT02117921|Experimental|MBS therapy education|
16674877|NCT02117908|Experimental|CPAP +4 cm H2O|CPAP +4 cm H2O pressure using ResMedTM face mask
16674878|NCT02117908|Sham Comparator|ShamCPAP|shamCPAP using ResMedTM CPAP face mask modified for technical sham
16674879|NCT02117895|Experimental|Pancreatectomy & celiac plexus resection|Left celiac plexus resection will be performed besides standard distal pancreatectomy. Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
16674880|NCT02117895|Active Comparator|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
16674881|NCT02117882||minimally invasive approach test|minimally invasive lateral approach
16674882|NCT02117882||control lateral traditional approach|standard surgical approach
16674883|NCT02117869|Experimental|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin hybrid grapefruit juice plus midazolam 5mg orally on the third day.
16674884|NCT02117869|Active Comparator|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
16674885|NCT02117869|Other|water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
16674886|NCT02117856|Active Comparator|1 implant|"Participants receive the following:
~1 implant placed surgically in the mandibular midline; Soft reline of the existing complete lower denture; 2.25mm ball patrix placed on 1 healed implant; and Reline with 1 retentive matrix in the lower denture."
16674887|NCT02117856|Active Comparator|2 implants|"Participants receive the following:
~2 implants placed surgically in the mandibular canine sites; Soft reline of the existing complete lower denture; 2.25mm ball patrices placed on 2 healed implants; and Reline with 2 retentive matrices in the lower denture."
16674888|NCT02117843|Experimental|AVI® Arsenic trioxide drug eluting stent|The Arsenic trioxide as AVI eluting drug, biodegradable polylactic acid as drug carrier.
16674889|NCT02117830|Experimental|Androxal 25 mg|
16674890|NCT02117830|Experimental|Androxal 250 mg|supratherapeutic dose
16674891|NCT02117830|Placebo Comparator|Placebo|
16674892|NCT02117830|Other|Moxifloxacin 400 mg|positive control
16674893|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
16674894|NCT02117804||High ESDP Score|Patients with 10 or greater score on the Early Screen for Discharge Planning at the time of admission.
16674895|NCT02117804||Low ESDP Score|Patients with 9 or lower score on the Early Screen for Discharge Planning at the time of admission.
16674896|NCT02117791||Group 1|Riociguat treatment group
16674897|NCT02117778|Active Comparator|Interscalene|Continuous Interscalene Nerve Block
16674898|NCT02117778|Active Comparator|Supraclavicular|Continuous Supraclavicular Nerve Block
16674899|NCT02117778|Active Comparator|Suprascapular|Continuous Suprascapular Nerve Block
16675047|NCT02116816|Experimental|Polyphenol|Polyphenol preparations
16675051|NCT02116790|Active Comparator|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
16674900|NCT02117765|Experimental|Treatment|"Four cohorts of 5 subjects will be recruited:
~Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks.
~Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks.
~Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks.
~Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks."
16674901|NCT02117752|Experimental|Dapsone Gel Subset 1|Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
16674902|NCT02117752|Experimental|Dapsone Gel Subset 2|Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
16674903|NCT02117739|Experimental|All Participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches twice a week for 21 days followed by a 10 to 17 day rest period then another application of dapsone gel and dapsone gel vehicle by patch.
16674904|NCT02117726|Experimental|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
16674905|NCT02117726|Active Comparator|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
16674906|NCT02117713|Experimental|LUM001 (Maralixibat)|Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
16674907|NCT02117700|Experimental|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
16674908|NCT02117700|Experimental|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
16674909|NCT02117700|Placebo Comparator|Placebo|Placebo twice/day for 16 weeks
16674910|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
16674911|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
16674912|NCT02117674|Active Comparator|standard forward-viewing colonoscopy|polyp detection with standard forward-viewing colonoscopy polyp detection in the right colon with scope retroflexion
16674913|NCT02117674|Active Comparator|full-spectrum colonoscopy|polyp detection with full-spectrum colonoscopy polyp detection in the right colon with scope retroflexion
16674914|NCT02117661|Experimental|L-carnitine capsules|2000 mg daily (2x 500 mg capsules twice a day - BID) for six months
16674915|NCT02117661|Placebo Comparator|Cellulose capsules|2x capsules twice a day - BID (4 total per day) for six months
16674916|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
16674917|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
16674918|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
16674919|NCT02117635|Experimental|allogeneic human neural stem cell|"CTX DP
~human neural stem cell product, single dose once only injection"
16674920|NCT02117622||Patients with diabetes mellitus requiring insulin therapy|
16674921|NCT02117609|Experimental|New DELICAL formula|New high-protein oral nutrient supplement
16674922|NCT02117609|Active Comparator|Standard DELICAL formula|Standard isoenergetic isoprotein formula
16674923|NCT02117596|Other|Sirolimus|Single arm
16674924|NCT02117583|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16674925|NCT02117583|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16674926|NCT02117583|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16674927|NCT02117583|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16674928|NCT02117570|Experimental|High dose of C. difficile vaccine|
16674929|NCT02117570|Experimental|Low dose of C. difficile vaccine|
16674930|NCT02117570|Placebo Comparator|Placebo|
16674931|NCT02117557|Experimental|Single incision laparoscopic surgery|Transumbilical single incision laparoscopic surgery will be performed for patients in this group.And addition of only one trocar through the stoma for drainage tube is allowed.
16674932|NCT02117557|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
16674933|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
16674934|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
16674935|NCT02117518||no treatment|T1D patients at ages 0-25
16675119|NCT02116335|Experimental|Bosentan|Sub-Chronic (3 days) Bosentan 250mg/day.
16674936|NCT02117505|Experimental|Group 1 (Formulation 2 Then Formulation 1)|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in first treatment period; followed by JNJ-54781532 formulation 1 as 150 mg orally (5*30 mg tablet=150 mg) in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16674937|NCT02117505|Experimental|Group 2 (Formulation 1 Then Formulation 2)|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 mg oral tablet (5*30 mg tablet=150 mg) in first treatment period; followed by JNJ-54781532 formulation 2 as 150 mg oral tablet in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
16674938|NCT02117492|Experimental|Vertical Cuff|Vaginal cuff closure will be done vertically.
16674939|NCT02117492|Experimental|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
16674940|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
16674941|NCT02117479|Active Comparator|Placebo plus capecitabine|
16674942|NCT02117466|Other|Standard dose cetuximab|Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
16674943|NCT02117466|Experimental|Dose escalation cetuximab|No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
16674944|NCT02117453|Experimental|Group I|Rosuvastatin 20 mg/day
16674945|NCT02117453|Placebo Comparator|Group II|Placebo
16674946|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
16674947|NCT02117427|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
16674948|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
16674949|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
16674950|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
16674951|NCT02117401|Experimental|group 1|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s
16674952|NCT02117401|Experimental|group 2|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s
16674953|NCT02117401|Experimental|group 3|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
16674954|NCT02117401|Experimental|group 4|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
16674955|NCT02117401|Experimental|group 5|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
16674956|NCT02117401|Experimental|group 6|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
16674957|NCT02117401|Experimental|group 7|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
16674958|NCT02117401|Experimental|group 8|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
16674959|NCT02117401|Experimental|group 9|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
16674960|NCT02117401|Experimental|group 10|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
16674961|NCT02117401|Experimental|group 11|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
16674962|NCT02117401|Experimental|group 12|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
16674963|NCT02117401|Experimental|group 13|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
16674964|NCT02117401|Experimental|group 14|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
16674965|NCT02117401|Experimental|group 15|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
16674966|NCT02117401|Experimental|group 16|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
16674967|NCT02117388|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
16674968|NCT02117388|Experimental|Sleep Restriction|Sleep Restriction therapy will limit the time participants spend in bed in order to make sure they are sleepy enough to fall asleep quickly.
16674969|NCT02117388|Experimental|Combined Therapy Treatment for Insomnia|Combined Therapy involves combining Sleep Restriction and Cognitive Therapy so that the two therapies reinforce each other.
16674970|NCT02117375|Experimental|Patients with multiple sclerosis|80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60
16674971|NCT02117375|Experimental|Healthy volunteers|20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24
16674972|NCT02117362|Experimental|Cohort 1|1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
16674973|NCT02117362|Experimental|Cohort 2|2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
16674974|NCT02117362|Experimental|Cohort 3|4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
16674975|NCT02117362|Experimental|Cohort 4|8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
16675048|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
16675120|NCT02116335|Placebo Comparator|Placebo|Stress response and endothelial function will be determined following a three day treatment of placebo
16674976|NCT02117349|Experimental|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:
~A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.
~A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.
~Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.
~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.
~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
16674977|NCT02117349|Other|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.
~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
16674978|NCT02117336|Experimental|P1446A-05|
16674979|NCT02117310|Experimental|ICG|Angiography with administered ICG
16674980|NCT02117297|Experimental|Gemtuzumab Ozogamicin|Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is >1000/mm3 and platelet count is >40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.
16674981|NCT02117284||Coronary artery disease|All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.
16674982|NCT02117271|Placebo Comparator|nasal dilator strip|Breathe Right ® nasal dilator strip used during sleep
16674983|NCT02117271|Experimental|continuous positive airway pressure|nasal continuous positive airway pressure used during sleep
16674984|NCT02117258|Experimental|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
16674985|NCT02117258|Experimental|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
16674986|NCT02117258|Experimental|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
16674987|NCT02117258|Placebo Comparator|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
16674988|NCT02117232|Experimental|Visualization balloon|"Colonoscopy performed with the use of Visualization balloon"
16674989|NCT02117232|Active Comparator|Traditional CO2-insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
16674990|NCT02117219|Experimental|MEDI4736 Evaluate MEDI4736 in MDS|Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS
16674991|NCT02117219|Experimental|MEDI4736 + tremelimumab|Evaluate MEDI4736 in combination with tremelimumab
16674992|NCT02117219|Experimental|MEDI4736 + tremelimumab + azacitidine|Evaluate MEDI4736 in combination with tremelimumab and azacitidine
16674993|NCT02117206|Active Comparator|L-Arginine|Femoral arterial infusion of 2 g L-Arginine for 30 min
16674994|NCT02117206|Placebo Comparator|Nacl|Femoral arterial infusion of Nacl for 30 min
16674995|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
16674996|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
16674997|NCT02117180|Other|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
16674998|NCT02117167|Experimental|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, olaparib tablet per os 300 mg bd continuous dosing savolitinib tablet per os 600 mg od continuous dosing
16674999|NCT02117167|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
16675000|NCT02117167|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with durvalumab for patient without actionable genomic alterations or non eligible to Targeted substudy 1, durvalumab Intra-venous 10 mg/kg, Q2W
16675001|NCT02117167|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
16675002|NCT02117154||HbA1c, 6-day Professional CGM|6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
16675003|NCT02117141|Experimental|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
16675004|NCT02117141|Experimental|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
16675005|NCT02117128|Experimental|Tranexamic acid, IA group|Tranexamic acid 1g, intra-articular injection, post-operationally
16675006|NCT02117128|Active Comparator|Tranexamic acid, IV group|Tranexamic acid, 1g, intravenous injection, post-operationally
16675007|NCT02117128|Experimental|Tranexamic acid, IV+IA group|Tranexamic acid, 1g, intravenous injection, post-operationally; Tranexamic acid, 1g, intra-articular injection, post-operationally
16675008|NCT02117115|Experimental|CT scan with contrast|
16675009|NCT02117102|Experimental|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
16675010|NCT02117102|No Intervention|Control group|Ordinary pediatric urine collection bag
16675011|NCT02117089|Experimental|Device-assisted rehabilitation|
16675049|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
16675050|NCT02116790|Placebo Comparator|Control Group|10 participants will be given two pills: both will be placebos
16675012|NCT02117076|Active Comparator|gabapentin immediate release|Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
16675013|NCT02117076|Active Comparator|gabapentin enacarbil extended release|Horizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
16675014|NCT02117063|Experimental|Go Girls! Fitness Support Group|
16675015|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
16675016|NCT02117037|Other|study of PEC markers and chemokines/ chemokine recep|blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
16675017|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
16675018|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
16675019|NCT02117011|Other|Physical activity|An 8-week structured, moderate-intensity aerobic training exercise regimen concurrent with their radiation therapy (N=15),
16675020|NCT02117011|No Intervention|Control|Patients will continue with usual care, which includes radiation treatment.
16675021|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
16675022|NCT02116998|Placebo Comparator|Placebo|
16675023|NCT02116985|Experimental|Dual-Loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
16675024|NCT02116985|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
16675025|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
16675026|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
16675027|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
16675028|NCT02116959|Experimental|Cohort 1|"Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy.
~Bilateral retinoblastoma patients will be in Cohort 1.
~For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy."
16675029|NCT02116959|Experimental|Cohort 2|Patients will receive only intra-arterial (IA) therapy for more limited disease.
16675030|NCT02116946|Experimental|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
16675031|NCT02116946|Experimental|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
16675032|NCT02116946|Placebo Comparator|Saline + exercise|Saline injection and a 12 week exercise program.
16675033|NCT02116933|Active Comparator|Level I|A small, level I study will compare autologous fat grafting alone to stromal vascular fraction SVF enriched autologous fat grafting int he same patient. One breast will be treated with AFG alone and act as the control, and the other breast will be treated with SVF enriched AFG adn act as the experimental side exploring the efficacy of adipose derived stem cells.
16675034|NCT02116933|Active Comparator|Level II|A larger, level II study comparing Autologous Fat Grafting to SVF enriched AFG in different patients. In this study, patients can choose to have AFG in both breasts or SVF enriched AFG in both breasts. The two patient groups will be compared. Here the group with the AFG in both breasts will be the control and the SVF enriched AFG in both breasts will be the experimental group exploring the efficacy of adipose derived stem cells.
16675035|NCT02116920||VIA Positive|Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid
16675036|NCT02116907|Experimental|Perampanel|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
16675037|NCT02116894|Experimental|PF-03446962 plus regorafenib|
16675038|NCT02116881||Open colorectal surgery|Patients scheduled to undergo open colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
16675039|NCT02116881||Laparoscopic colorectal surgery|Patients scheduled to undergo laparoscopic colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
16675040|NCT02116868|Experimental|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
16675041|NCT02116868|No Intervention|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
16675042|NCT02116855|Experimental|tertiary prophylaxis prophy on Hemophilia A patiets|A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.
16675043|NCT02116842|Experimental|0.075% bupivacaine|Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
16675044|NCT02116842|Experimental|0.1% bupivacaine|Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
16675052|NCT02116790|Active Comparator|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
16675053|NCT02116790|Active Comparator|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
16675054|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 1|(Part A): Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16675055|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 2|(Part B): Relapse/Refractory EWS or PNET Patients receive MTD from Phase 1 portion of study. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
16675056|NCT02116764||Cross Sectional|3 years after Transplant
16675057|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
16675058|NCT02116764||Prospective|Prior to Transplant Conditioning
16675059|NCT02116764||Retrospective|1 year after Transplant
16675060|NCT02116738|Experimental|Flap Transposition Technique|Flap Transposition Technique
16675061|NCT02116725|Experimental|Shower gel with zinc|Zinc gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
16675062|NCT02116725|Placebo Comparator|Plain shower gel|Plain shower gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
16675063|NCT02116725|Sham Comparator|Distilled water|Distilled Water is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
16675064|NCT02116712|Experimental|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.
~More regarding dose escalation is included in intervention below."
16675065|NCT02116699|Experimental|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
16675066|NCT02116699|Placebo Comparator|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
16675067|NCT02116686||Heart failure patients with sleep apnea syndrom|For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
16675068|NCT02116673|Other|Control|The control arm receives usual care discharge instructions.
16675069|NCT02116673|Experimental|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
16675070|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
16675071|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
16675072|NCT02116647|Experimental|Psychoanalytic therapy|manualized psychoanalytic psychotherapy
16675073|NCT02116647|No Intervention|Control Group|Standard care
16675074|NCT02116634|Experimental|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
16675075|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
16675076|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
16675077|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
16675078|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
16675079|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
16675080|NCT02116595|Experimental|feeding a high acid diet x 24 hrs|2 diets, one low and one high net acid loads
16675081|NCT02116595|Active Comparator|low acid diet|
16675082|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
16675083|NCT02116569|Experimental|Daratumumab 8 milligram per kilogram (mg/kg)|Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
16675084|NCT02116569|Experimental|Daratumumab 16 mg/kg|Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
16675085|NCT02116556|Active Comparator|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
16675086|NCT02116556|Experimental|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
16675087|NCT02116543|Experimental|TD-6450|TD-6450 capsules
16675088|NCT02116543|Placebo Comparator|Placebo|Placebo capsules
16675121|NCT02116322|Experimental|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
16679475|NCT02087397|Experimental|AD-SVF Cell Injection|
16675089|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:
~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus
~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus
~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
16675090|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:
~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus
~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus
~placebo"
16675091|NCT02116517|Experimental|green tea extract first|green tea extract (EGCG) 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally cellulose 500mg tid for 6 weeks total 14 weeks
16675092|NCT02116517|Placebo Comparator|Placebo first|cellulose 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally EGCG 500mg tid for 6 weeks total 14 weeks
16675093|NCT02116504|Other|Global population|"All included patients :
~Sampling of blood"
16675094|NCT02116491|No Intervention|Closed suction system|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Cloesd suction system was performed which the patient remained connected to the ventilator. The catheter was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
16675095|NCT02116491|Experimental|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
16675096|NCT02116478|Experimental|gastrocnemius recession|gastrocnemius recession
16675097|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 1|single oral dose of levodopa carbidopa immediate release tablets
16675098|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 1|single oral dose of levodopa carbidopa immediate release tablets
16675099|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 2|single oral dose of levodopa carbidopa immediate release tablets
16675100|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 2|single oral dose of levodopa carbidopa immediate release tablets
16675101|NCT02116452|No Intervention|Breast Milk|Breast FED newborns
16675102|NCT02116452|Placebo Comparator|Standard Formula|Standard Formula FED newborns
16675103|NCT02116452|Active Comparator|Supplemented Formula|GOS/PDX Formula FED newborns
16675104|NCT02116439||Violent events|People in this group were observed to manifest violence.
16675105|NCT02116439||Victims|People in this group are the victims of the other group.
16675106|NCT02116426||The study population|"The study population includes all adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected Acute Coronary Syndrome (ACS) without ST segment elevation.
~Intervention: Blood work in the ambulance Intervention: Blood work upon arrival in the emergency room Intervention: Blood work at 3 hours post-arrival in the emergency room"
16675107|NCT02116413||The study population|"The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:
~oliguria <0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate > 2 mmol / l SvcO2 <70% or SvO2 <65% Patient on noradrenaline.
~Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate> 4 mmol / l or organ dysfunction.
~Intervention: Fluid challenge Intervention: Cardiac ultrasound"
16675108|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.
~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
16675109|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.
~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
16675110|NCT02116387|Active Comparator|Routine Physical Therapy|"Patients randomized to this arm will follow a classic, routine, physical therapy program.
~Intervention: Routine Physical Therapy"
16675111|NCT02116387|Experimental|I-Moove Physical Therapy|"Patients randomized to this arm will follow a physical therapy program using the I-Moove device.
~Intervention: I-Moove Physical Therapy"
16675112|NCT02116374||HIV-1 patients|
16675113|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
16675114|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
16675115|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
16675116|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
16675117|NCT02116348|Experimental|Cerebrolysin|Nerve growth factor Cerebrolysin will be given to the intervention group
16675118|NCT02116348|No Intervention|Conventional|These children will receive conventional treatment for cerebral palsy
16675158|NCT02116062|Other|Pterygium surgery|
16675122|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
16675123|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
16675124|NCT02116296|Other|LIfestyle counseling|
16675125|NCT02116270|Other|Control group|Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
16675126|NCT02116270|Experimental|Severe renal failure|Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
16675127|NCT02116270|Experimental|Peritoneal dialysis|Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
16675128|NCT02116270|Experimental|Hemodialysis|Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
16675129|NCT02116257|Experimental|Propacetamol|
16675130|NCT02116257|Placebo Comparator|PCA regimen|routine PCA drug
16675131|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
16675132|NCT02116231|Experimental|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy: IMRT was given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy.
16675133|NCT02116231|Active Comparator|IMRT alone|IMRT is given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume.
16675134|NCT02116218|Experimental|acupuncture|Experimental group would receive acupuncture at specific acupoints for 15 minutes.
16675135|NCT02116218|Sham Comparator|seed|Control group would receive another intervention that we would put Vaccaria seeds near the acupoints but without acupressure for the same period.
16675136|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
16675137|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
16675138|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
16675139|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
16675140|NCT02116192|Active Comparator|General Healthy Diet|Control: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
16675141|NCT02116192|Experimental|Low-fructose, reduced carbohydrate diet|"Intervention: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)
~● Aim for less than 25g fructose daily."
16675142|NCT02116179|Experimental|DVD Intervention|DVD Intervention presented at one 90 minute group session
16675143|NCT02116179|No Intervention|Wait list Control Group|Group will get no intervention until after 90 day follow up
16675144|NCT02116166||Young|Young (20-35 years old)
16675145|NCT02116166||Old|Older (70-99 years old)
16675146|NCT02116140|Experimental|[C11]Acetate HED PET|"AMEND is a single centre substudy of the ADVENT-HF trial. This substudy is a clinical physiologic proposal designed to determine the effects of long-term (6 months) ASV on cardiac energetics and SN function in patients with chronic stable HF and sleep apnea extending our previous evaluation of short-term CPAP in patients with OSA and HF.
~All subjects consenting to the ADVENT primary trial will be eligible to participate in the substudy.
~Substudy consenting patients will have [11C]acetate and [11C]HED PET imaging; HR variability; plasma norepinephrine (NE) levels, urine normetanephrine levels within 2 weeks of the sleep study. Baseline measurements will be repeated after 6 months in all patients."
16675147|NCT02116127|Experimental|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
16675148|NCT02116127|Sham Comparator|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
16675149|NCT02116114|Experimental|Aquatic exercises|"3 times a week
~heating
~aerobic training
~slowdown"
16675150|NCT02116114|No Intervention|control group|The control group participated in the study only to usual care , conventional medical treatment orientation about the disease , methods of energy conservation and evaluation.
16675151|NCT02116101|Active Comparator|Bright Momchilovtsi yogurt|Bright Momchilovtsi yogurt Contains 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
16675152|NCT02116101|Placebo Comparator|Bright Dairy Beverage|Dairy beverage product without prebiotics
16675153|NCT02116088|Active Comparator|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
16675154|NCT02116088|No Intervention|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
16675155|NCT02116075|Experimental|Epidural Steroid|80mg depo-medrol 9mL 1% lidocaine
16675156|NCT02116075|Active Comparator|Epidural Prolotherapy|10ml of 5% generic dextrose
16675157|NCT02116062|Other|Amniotic membrane transplantation|
16675160|NCT02116049|Active Comparator|Attention Control Case Management|"Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients. This project's case management will mimic the experimental condition with a meeting schedule reflective of the experimental arm plus a booster session at 3 months."
16675161|NCT02116049|Experimental|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
16675162|NCT02116036|Experimental|Rivaroxaban|Rivaroxaban 20mg po daily
16675163|NCT02116023|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
16675164|NCT02116023|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
16675165|NCT02116023|Placebo Comparator|Orange flavored beverage - Placebo|240ml orange beverage
16675166|NCT02116010|Active Comparator|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
16675167|NCT02116010|Experimental|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
16675168|NCT02116010|Active Comparator|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
16675169|NCT02116010|Experimental|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
16675170|NCT02115997|Experimental|Rituximab|Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
16675171|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
16675172|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
16675173|NCT02115971|Experimental|Jumping exercise|"Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.
~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme."
16675174|NCT02115971|Active Comparator|Strength exercise|"Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.
~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored."
16675175|NCT02115958|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16675176|NCT02115958|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16675177|NCT02115958|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16675178|NCT02115958|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16675179|NCT02115945|Experimental|epidural block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
16675180|NCT02115945|Active Comparator|femoral block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
16675181|NCT02115932|Experimental|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
16675182|NCT02115932|No Intervention|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
16675183|NCT02115919|Experimental|Cohort A|Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
16675184|NCT02115919|Experimental|Cohort B|Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
16675185|NCT02115906||Acromegalic patients|Acromegalic patients before and after initiation of individual therapy will be investigated by 1H/31P magnetic resonance spectroscopy, thyroid sonography and oral glucose tolerance testing
16675186|NCT02115906||Healthy control subjects|Age and Body mass index matched control subjects will be investigated by 1H/31P magnetic resonance spectroscopy and oral glucose tolerance testing
16675187|NCT02115893|Active Comparator|Sodium Nitrate|Dietary Supplement: Sodium nitrate 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
16675188|NCT02115893|Placebo Comparator|Sodium Cloride|Dietary Supplement: Sodium chloride 800 mg of sodium chloride added with water to get a 140 mL solution (Frisia Zout BV, Harlingen, The Netherlands)
16675189|NCT02115880|Experimental|Prevention programme|
16675190|NCT02115880|No Intervention|Control (treatment as usual)|
16675191|NCT02115867|Active Comparator|Probiotic|"Probiotic arm Liquid broth
~1 mL/kg every morning for 90 days"
16675192|NCT02115867|Placebo Comparator|Placebo|"Placebo arm Liquid broth
~1 mL/kg each morning for 90 days"
16675193|NCT02115854||bacteriologically confirmed tuberculosis|
16675194|NCT02115841|Experimental|E1|Experiment 1 will measure the cortical excitability change after TENS intervention.
16675195|NCT02115841|Experimental|E2|Experiment 2 will measures implicit sequential motor task performance and cortical hemodynamic response using near infrared spectroscopy (NIRS) during motor execution. Cortical excitability will also be measured contemporary
16675196|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
16675197|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
16675198|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
16675199|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
16675200|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
16675201|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
16675202|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
16675203|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
16675204|NCT02115802|Experimental|Activa PC+S|Specific features of LFP recorded from the deep brain nuclei will be examined for possible correlation with different natural behaviors, such as movement, walking, or speech.
16675205|NCT02115789||Survey Group|Adult male or female volunteers.
16675206|NCT02115776|No Intervention|Control|Receiving no prophylaxis
16675207|NCT02115776|Active Comparator|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
16675208|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
16675209|NCT02115776|Active Comparator|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
16675210|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
16675211|NCT02115763|Experimental|Caffeine|There is only one arm, it receives both caffeine and placebo.
16675212|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
16675213|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
16675214|NCT02115737|Experimental|Dialectical Behavior Therapy Skills Group|Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
16675215|NCT02115737|Experimental|Psychoeducation group treatment|The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh
16675216|NCT02115724|Experimental|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
16675217|NCT02115724|Other|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
16675218|NCT02115711|Experimental|Community health worker|Home visits by community health worker to deliver the multi-component behavioural intervention targeted at the individual's hypertension, diabetes or smoking.
16675219|NCT02115711|No Intervention|Usual care|Patients will receive usual care in the community
16675220|NCT02115698|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
16675327|NCT02115035|Experimental|Vermurafenib|Vermurafenib dosing will be given twice daily by oral administration in cycles of 28 days
16675221|NCT02115698|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
16675222|NCT02115698|Active Comparator|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
16675223|NCT02115698|Active Comparator|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
16675224|NCT02115698|Placebo Comparator|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
16675225|NCT02115685|No Intervention|One day testing|Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
16675226|NCT02115685|Experimental|Effects of long term training|Aim 3 will then look at changes in bloodflow during exercise after training. Three different eight week exercise training programs will be tested including 1) treadmill training at high intensity as defined by 70-80% of HRR or 15-17 RPE 2) treadmill training at low intensity as defined by 30-40% of HRR or <13 RPE
16675227|NCT02115672|Experimental|BL-8040|Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
16675228|NCT02115659|Placebo Comparator|Placebo|Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
16675229|NCT02115659|Experimental|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.
16675230|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
16675231|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
16675232|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
16675233|NCT02115620|Experimental|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
16675234|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
16675235|NCT02115594|Experimental|Fulvestrant + Entinostat|Arm A: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus entinostat (5 mg PO once weekly)
16675236|NCT02115594|Active Comparator|Fulvestrant + Placebo|Arm B: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus placebo (5 mg PO once weekly)
16675237|NCT02115581|Experimental|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.
~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
16675238|NCT02115581|Placebo Comparator|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
16675239|NCT02115568||Long-term safety follow-up|To be eligible, subjects must have actively participated in a Juventas (JVS-100) sponsored trial under IND 14203.
16675240|NCT02115555|Experimental|HIT-aided approach|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the Self Monitored Blood glucose tests.
16675241|NCT02115555|Experimental|Contracted conflict management system|Adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent.
16675242|NCT02115555|Experimental|HIT plus contracted conflict management|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the tests. In addition, adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent. This arm combines arms 1 and 2.
16675243|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
16675244|NCT02115529|Active Comparator|Cesamet (nabilone)|0.5 mg capsule containing Cesamet (single dose) given preoperatively
16675245|NCT02115529|Placebo Comparator|Placebo|identical capsule containing placebo (single dose) given preoperatively
16675246|NCT02115516|Experimental|Stage A: Grp A1 - 3,200 PfSPZ Challenge|Group A1 (PfSPZ Challenge) (n=9) receives three injections of 3,200 PfSPZ Challenge intravenous (IV) at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
16675328|NCT02115022||Potentially resectable pancreatic cancer|Patients with a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery with a curative (R0) intent.
16675329|NCT02114983||first episode of suspected DVT of the lower limbs|patients with first suspected episode of DVT of the lower limbs
16675247|NCT02115516|Experimental|Stage A: Grp A2 - 12,800 PfSPZ Challenge|Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
16675248|NCT02115516|Experimental|Stage A: Grp A3 - 51,200 PfSPZ Challenge|Group A3 (PfSPZ Challenge) (n=9) starts when Group A2 receives the second immunization. Group A3 receives three injections of 51,200 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A Week on 27.
16675249|NCT02115516|Placebo Comparator|Stage A: Grp A1 - 0.9% Sodium Chloride|Group A1 (placebo) (n=5) receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
16675250|NCT02115516|Placebo Comparator|Stage A: Grp A2 - 0.9% Sodium Chloride|Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
16675251|NCT02115516|Placebo Comparator|Stage A: Grp A3 - 0.9% Sodium Chloride|Group A3 (placebo) (n=5) starts when Group A2 receives the second immunization. Group A3 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A on Week 27.
16675252|NCT02115516|Experimental|Stage B: Grp B1 - 51,200 PfSPZ Challenge|Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
16675253|NCT02115516|Placebo Comparator|Stage B: Group B1 - 0.9% Sodium Chloride|Group B1 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28. This group will follow the the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
16675254|NCT02115516|Experimental|Stage B: Grp B2 - 51,200 PfSPZ Challenge|Group B2 (n=5) will receive 3 injections of 51,200 PfSPZ Challenge on days 0, 14 and 28, using same std chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive extended-release azithromycin (ER-AZ, 2g) on the day of 1st PfSPZ Challenge and monitored for parasitemia by quantitative real time polymerase reaction (qPCR). In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following first PfSPZ Challenge injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will continue and ER-AZ will not be administered for the 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge, 10 weeks after the last immunization.
16675255|NCT02115516|Placebo Comparator|Stage B: Group B2 - 0.9% Sodium Chloride|Group B2 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28, using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive ER-AZ, 2g on the day of 1st placebo injection and monitored for parasitemia by qPCR. In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following 1st injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to the development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will be continued and ER-AZ will not be administered for 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after last immunization.
16675256|NCT02115516|Experimental|Stage B: Grp B3 - 51,200 PfSPZ Challenge|Group B3 (n=9) volunteers will receive CQ and PfSPZ Challenge simultaneously every five days with one additional dose of CQ five days after the third PfSPZ Challenge injection. A 10 mg/kg CQ base loading dose is given at the time of first PfSPZ Challenge inoculation, followed by 5 mg/kg CQ base on the day of second and third inoculation and five days after the last PfSPZ Challenge inoculation. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
16675761|NCT02112123|Active Comparator|Icariin - 1680 mg/day|Icariin given at 1680 mg/day (qd po) for 5 days
16675257|NCT02115516|Placebo Comparator|Stage B: Group B3 - 0.9% Sodium Chloride|Group B3 (placebo) (n=2) volunteers will receive CQ and 0.9% Sodium Chloride simultaneously every five days with one additional dose of CQ five days after the third placebo injection. A 10 mg/kg CQ base loading dose is given at the time of first placebo injection, followed by 5 mg/kg CQ base on the day of second and third injections and five days after the last placebo injection. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
16675258|NCT02115503||Cohort 1|Cohort 1 will consist of those having primarily Class I antibody development post-transplant
16675259|NCT02115503||Cohort 2|Cohort 2 will include those having primarily Class II antibody development post-transplant
16675260|NCT02115503||Cohort 3|Cohort 3 will consist of the remaining subjects that have a mix of Class I and II antibodies.
16675261|NCT02115490||Osteoporosis_with_Bisphosphonates|This group of patients are taking Bisphosphonates orally in their treatment
16675262|NCT02115490||Osteoporosis-without-Bisphosphonates|This group of patients has not taken Bisphosphonates in the course of treatment
16675263|NCT02115477||Group with lymphadenectomy|The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery
16675264|NCT02115477||Group without lymphadenectomy|The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery
16675265|NCT02115464|Experimental|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
16675266|NCT02115464|Active Comparator|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
16675267|NCT02115451||Surgical treatment|Patients who undergo rehabilitation and anterior cruciate ligament reconstruction, other surgical interventions may be performed
16675268|NCT02115451||Nonsurgical treatment|Patients who undergo rehabilitation without anterior cruciate ligament reconstruction, other surgical interventions may be performed
16675269|NCT02115438||Occupational Stress|
16675270|NCT02115425||Age 10-17|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
16675271|NCT02115425||Age 18-80|Age 18-80 years Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
16675272|NCT02115412||medication non-adherence|
16675273|NCT02115399||ADStaph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
16675274|NCT02115399||ADStaph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
16675275|NCT02115399||NAStaph-|Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
16675276|NCT02115399||NAStaph+|Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
16675277|NCT02115386|Experimental|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
16675278|NCT02115373|Experimental|Phase 1b: Tepotinib 300 mg|
16675279|NCT02115373|Experimental|Phase 1b: Tepotinib 500 mg|
16675280|NCT02115373|Experimental|Phase 2: Tepotinib 500 mg|
16675281|NCT02115360|Active Comparator|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,
16675282|NCT02115360|Active Comparator|fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
16675283|NCT02115347|Experimental|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
16675284|NCT02115347|Other|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
16675285|NCT02115347|Experimental|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
16675286|NCT02115334|Experimental|professional-based group|professional therapists delivering the PHPA
16675287|NCT02115334|Experimental|parents-based group|parents executing the PHPA
16675288|NCT02115334|Active Comparator|control group|health education only
16675289|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
16675290|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
16675291|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
16675292|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
16675293|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
16675433|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
16675294|NCT02115295|Experimental|Treatment (cladribine, cytarabine, idarubicin)|"INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity."
16675295|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
16675296|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
16675297|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
16675298|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
16675299|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
16675300|NCT02115243|Other|Ipi/ILI|Patients will receive ipilimumab followed by ILI.
16675301|NCT02115230|Experimental|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
16675302|NCT02115230|No Intervention|Medical therapy|Standard optimized medical therapy for diastolic heart failure
16675303|NCT02115217|Experimental|Leukotape K, basketball training|Use of Leukotape K to ensure stability of the ankle in basketball players
16675304|NCT02115217|Placebo Comparator|Sham, basketball training|Use of sham tape
16675305|NCT02115204|Experimental|EC-Doc|4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
16675306|NCT02115204|Active Comparator|CMF/CEF|6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks
16675307|NCT02115191|Experimental|2-octylcyanoacrylate|Application of 2-octylcyanoacrylate
16675308|NCT02115191|Active Comparator|Surgical reintervention|Surgical reintervention for urethrocutaneous fistula repair
16675309|NCT02115178||Lithotomy or Prone position|
16675310|NCT02115165|Experimental|Cabazitaxel|
16675311|NCT02115152|Active Comparator|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
16675312|NCT02115152|Experimental|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
16675313|NCT02115139|Experimental|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
16675314|NCT02115126|Active Comparator|LMP2A-loaded conventional DC vaccine|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine
16675315|NCT02115126|Experimental|LMP2A-loaded DC vaccine + DUK-CPG-001|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001
16675316|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
16675317|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
16675318|NCT02115100|Active Comparator|pulmonary vein+renal artery denervation|Procedure: pulmonary vein and renal artery denervation
16675319|NCT02115100|Active Comparator|Pulmonary vein isolation|Procedure: Pulmonary vein isolation
16675320|NCT02115087|Experimental|ultrasound guided rectus sheath block|Ultrasound guided rectus sheath block
16675321|NCT02115087|Active Comparator|iv morphine|0.1 mg.kg-1 loading dose of morphine by intravenous route in intraoperative period
16675322|NCT02115074|Experimental|Fluvastatine Celebrex|dose escalation for Fluvastatine
16675323|NCT02115061|Active Comparator|Cyanoacrylate|"This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
~Treatment: cyanoacrylate"
16675324|NCT02115061|Sham Comparator|Coil + cyanocrylate|"This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
~Treatment: coil + cyanoacrylate"
16675325|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
16675326|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
16675434|NCT02114281|Experimental|Care|Patient with dental care
16675330|NCT02114970|Other|Focus Group- paper and tablet consent|Participation in a focus group of other older adults, lasting 120 minutes. Participants will answer semi-structured questions in a group format, describing their impressions of both a prototype tablet-delivered and a paper consent.
16675331|NCT02114970|Active Comparator|Randomized- paper consent|Participants will review a mock paper consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the paper informed consent form.
16675332|NCT02114970|Active Comparator|Randomized- Tablet-delivered consent|Participants will review a mock tablet-delivered consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the tablet-delivered informed consent.
16675333|NCT02114957|Experimental|study herb|
16675334|NCT02114944||NIV|Patients with acute respiratory failure or dyspnea and DNI order treated with noninvasive ventilation
16675335|NCT02114944||CPAP|Patients with dyspnea or acute respiratory failure and DNI order treated with continuous positive airways pressure (CPAP)
16675336|NCT02114944||Standard oxygen|Patients with dyspnea and/or acute respiratory failure and DNI order, treated with standard oxygen therapy either via face mask or nasal cannula
16675337|NCT02114944||HFNC|Patients with dyspnea and/or acute respiratory failure and DNI order treated with high-flow nasal cannula (HFNC).
16675338|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
16675339|NCT02114918|Experimental|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
16675340|NCT02114918|Placebo Comparator|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
16675341|NCT02114905|Experimental|OTs Trained and Deliver CBIT|CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
16675342|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
16675343|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
16675344|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
16675345|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
16675346|NCT02114840|Experimental|Pronator quadratus preservation|Pronator quadratus preservation
16675347|NCT02114840|Active Comparator|Pronator quadratus non repair|
16675348|NCT02114840|Active Comparator|Pronator quadratus repair after disruption|
16675349|NCT02114827|Experimental|Video|"Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience"
16675350|NCT02114827|Active Comparator|FAQ Sheet|Patients will receive HSCT FAQ sheet developed by the NCI at the NIH
16675351|NCT02114814|Experimental|Intervention group|Diabetes self-management and family support
16675352|NCT02114814|Active Comparator|Attention control group|General health information
16675353|NCT02114801|Experimental|manual brushing|manual brushing; Oral-B®, Stages 4, Rio de Janeiro, Rio de Janeiro;
16675354|NCT02114801|Experimental|electric toothbrush linked|electric toothbrush linked; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
16675355|NCT02114801|Experimental|off electric toothbrush|off electric toothbrush; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
16675356|NCT02114788||group 1|No intervention
16675357|NCT02114788||Group 2|Intervention with interactive website
16675358|NCT02114775|Active Comparator|Recombinant Growth Hormone|Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
16675359|NCT02114775|Active Comparator|Sildenafil|Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
16675360|NCT02114762|Experimental|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
16675361|NCT02114749|Experimental|volunteers in daily life activities|a set of wearable respiration and cardiac monitoring devices
16675362|NCT02114736|Experimental|Rectus femoris tenotomy|Surgical release of the proximal tendon of the rectus femoris
16675363|NCT02114736|Active Comparator|Botulinum toxin in the rectus femoris muscle|Botulinum toxin (200U Botox) injection in the rectus femoris muscle
16675364|NCT02114723|Active Comparator|Medical Taping Concept|"3 band of a special and hypoallergenic tape, called Cure Tape ® (2 strips of 12 x 5 cm and 1 strip of 20 cm x 5 cm) are attached to the abdominal and lower back. One piece of 12 cm in length is applied right from below the navel and reached to where the pubic hair below, and another piece of 12 cm in length is applied to make a cross shape with the first piece (inside 11-12 dermatomes area). The piece of 20cm in length is placed horizontally to the lower back.
~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
16675365|NCT02114723|Placebo Comparator|Cross tape|Two pieces of special and squared tape of 2.5 x 2 cm called Cross Tape ® are attached to the external side of the thigh at the hip joint area (outside 11-12 dermatomes area)
16675366|NCT02114710|Experimental|Hydrocortisone|little doses of hydrocortisone
16675367|NCT02114710|No Intervention|Placebo|Placebo
16675368|NCT02114697|Active Comparator|Lifestyle modification|Lifestyle modification is tailored to each participant and includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.
16675369|NCT02114697|Experimental|Statin therapy|Participants will receive statin medication along with instruction about regular exercise.
16675370|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.
~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks
~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
16675371|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.
~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.
~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
16675372|NCT02114671|Experimental|Faldaprevir QD high dose|capsules, oral administration with 240 ml water, fed conditions
16675373|NCT02114671|Experimental|Faldaprevir QD low dose|tablets/capsules, oral administration with 240 ml water, fed conditions
16675374|NCT02114671|Placebo Comparator|Placebo|capsules, oral administration with 240 ml water, fed conditions
16675375|NCT02114671|Active Comparator|Ciprofloxacin|tablets, oral administration with 240 ml water, fed conditions
16675376|NCT02114658|Experimental|Arm 1|Sorafenib 400 mg bid continuous dose
16675377|NCT02114645|Active Comparator|LongGnRH agonist protocol(controlgroup)|Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
16675378|NCT02114645|Experimental|Long protocol-leuprolide acetate|Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
16675379|NCT02114645|Active Comparator|GnRHantagonist protocol(control group)|GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
16675380|NCT02114645|Experimental|antagonist protocol-leuprolide acetate|GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
16675381|NCT02114632|Active Comparator|Polyunsaturated fatty acids|"6 capsules of food supplement Eye q per day divided in two daily doses (558 mg EPA, 174 mg DHA, 60 mg GLA per day)"
16675382|NCT02114632|Placebo Comparator|placebo|6 capsules of olive oil per day divided in two daily doses.
16675383|NCT02114619|Active Comparator|Low dose of I-131|Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
16675384|NCT02114619|Active Comparator|Intermediate dose|Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
16675385|NCT02114619|Active Comparator|High dose|Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
16675386|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.
16675387|NCT02114593|Experimental|Parent support program|Parent support program
16675388|NCT02114593|No Intervention|Standard activities|Standard activities
16675389|NCT02114580|Experimental|Aerobic exercise|
16675390|NCT02114580|Active Comparator|stretching exercise|
16675391|NCT02114567|Experimental|PSV ventilation|AECOPD Patients who were ventilated wiht PSV, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. Pressure support was set to get the tidal volume of 6ml/kg.
16675392|NCT02114567|Experimental|NAVA ventilation|AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
16675393|NCT02114528|Active Comparator|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
16675394|NCT02114528|Active Comparator|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
16675395|NCT02114515|Other|Usual Care|"Hospital usual care
~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
16675396|NCT02114515|Experimental|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)
~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.
~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team
~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
16675397|NCT02114502|Experimental|Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT|Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
16675398|NCT02114489|Experimental|Ibandronate|Unique perfusion of ibandronate 3 mg IV
16675399|NCT02114489|Placebo Comparator|Placebo|Unique perfusion of NaCl 3mg IV
16675400|NCT02114476|Placebo Comparator|nonhormonal contraception|nonhormonal intrauterine device tubal sterilization
16675401|NCT02114476|Experimental|progestin implant|Jadelle
16675402|NCT02114463|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
16675403|NCT02114463|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
16675404|NCT02114450|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
16675405|NCT02114450|Active Comparator|Supervised motor practice|Participants in this group will perform walking and other lower limb exercises (as applicable) under the supervision of a research physical therapist. Training will be for 3 sessions per week for 4 weeks, each session lasting about 1.5 hours.
16675406|NCT02114437|Experimental|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
16675407|NCT02114437|Placebo Comparator|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
16675408|NCT02114424|Active Comparator|Positional vibrator belt|Positional belt to avoid supine sleep.
16675409|NCT02114424|No Intervention|No Night balance|the first 2 months without Night Balance
16675410|NCT02114411||Dyspeptic patients|Patients (45 years and older, both genders) with dyspepsia referred for the GastroPanel test and gastroscopy with multiple bisopies at Homerton University Hospital (London, United Kingdom).
16675411|NCT02114398|Experimental|usual treatment|usual treatment
16675412|NCT02114398|Experimental|usual treatment + sophrology|usual treatment + sophrology
16675413|NCT02114385|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
16675414|NCT02114385|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
16675419|NCT02114359|Experimental|Platinum/fluoropyrimidine combination chemotherapy|
16675420|NCT02114359|Active Comparator|Fluoropyrimidine monochemotherapy|
16675421|NCT02114346|Experimental|Atorvastatin|Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material.
16675422|NCT02114346|Placebo Comparator|Placebo|Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material.
16675423|NCT02114333|Active Comparator|A - Live zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85
~First dose live vaccine, Zostavax (0.65ml, subcutaneous)
~Second dose placebo, normal saline (0.65ml. subcutaneous)"
16675424|NCT02114333|Active Comparator|B - recombinant zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85
~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
16675425|NCT02114333|Active Comparator|C - Live zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85
~First dose live vaccine, Zostavax (0.65ml, subcutaneous)
~Second dose placebo, normal saline (0.65ml. subcutaneous)"
16675426|NCT02114333|Active Comparator|D - recombinant zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85
~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
16675427|NCT02114320|Experimental|EUS-BD-1|EUS-BD-1 inserts a partially covered self-expanding metallic (hybrid) stent with a dedicated introducer for EUS-BD
16675428|NCT02114320|Experimental|EUS-BD-2|EUS-BD-2 inserts a fully covered self-expanding metallic stent
16675429|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
16675430|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
16675431|NCT02114294|Experimental|Isolated hip strengthening|Isolated hip strengthening (abduction, external rotation, extension)
16675432|NCT02114294|Active Comparator|Quadriceps based training|Quadriceps based training (mini-squat, straight leg raising, terminal extensions)
16675435|NCT02114281|Active Comparator|Not care|Patient with not dental care
16679476|NCT02087384|Experimental|Gardasil|Gardasil
16675436|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
16675437|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
16675438|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
16675439|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
16675440|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
16675441|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
16675442|NCT02114255|Experimental|BCG vaccination|BCG vaccination
16675443|NCT02114255|Placebo Comparator|NaCl 0.9%|administration of NaCl 0.9%.
16675444|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
16675445|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age > 30"
16675446|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age > 40
16675447|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).
~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
16675448|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.
~Interventions:
~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.
~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
16675449|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.
~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.
~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
16675450|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
16675451|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
16675452|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
16675453|NCT02114203|Experimental|cohort 1 PF-04447943|
16675454|NCT02114203|Experimental|cohort 2 PF-04447943|
16675455|NCT02114203|Placebo Comparator|placebo comparator|
16675456|NCT02114203|Experimental|optional cohort of PF-04447943|
16675457|NCT02114190|Experimental|Adolescent Mindful Eating Group|Adolescents will participate in a 8 week mindful eating programs tailored for adolescents.
16675458|NCT02114190|Experimental|Parent Intergrated Group|This intervention incorporates a family systems perspective into mindful eating interventions for adolescents. This intervention will consist of 11 sessions in an 8 week period, with sessions 2,7, and 11 incorporating family sessions. The purpose of the family sessions are to increase overall family motivation for behavior change, involve family members in identifying specific targets of change and establishing agreed upon strategies.
16675459|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
16675460|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
16675461|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
16675462|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
16675463|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
16675464|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
16675465|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
16675466|NCT02114125|No Intervention|Usual Care Group:|Usual care consists of standard institutionalized services provided by physicians, nurses, and support staff (e.g., nurse assistants, social workers) in long-term care facilities.
16675467|NCT02114125|Experimental|High-intensity physical activity (5PA)|The intervention conducts the group-based physical activity, 5 days per- week for 8 weeks.
16675468|NCT02114125|Experimental|Low-intensity PA and CT(3PA+2CT)|The intervention conducts 3 days per-week physical activity and 2 days per-week cognitive training for 8 weeks.
16675469|NCT02114125|Experimental|High-intensity PA and CT (5PA+5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5days per- week and group-based physical activity, 5 days per- week and for 8 weeks.
16675470|NCT02114125|Experimental|Low-intensity cognitive training (2CT)|The intervention conducts the individual-based, multi-domains cognitive training, 2 days per- week for 8 weeks.
16675471|NCT02114125|Experimental|High-intensity cognitive training (5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5 days per- week for 8 weeks.
16675472|NCT02114112|Experimental|Group A-NCPAP Cycling group|Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
16675473|NCT02114112|Active Comparator|Group B-Continuous NCPAP|Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.
16675474|NCT02114099|Experimental|Atorvastatin|prescribe Atorvastatin to see its effect
16675475|NCT02114086||breast cancer|observation of intraoperative radiotherapy
16675476|NCT02114073|Experimental|Cyclosporine|In the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
16675477|NCT02114073|Active Comparator|Betamethasone|In the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
16675478|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
16675479|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
16675480|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
16675481|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
16675482|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
16675483|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
16675484|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
16675485|NCT02114034||Non-severe asthma|"Children Controlled without treatment or with low doses of inhaled corticosteroids (<500 mg / day beclometasone equivalent) asthma
~and Children with normal EFR
~and Children who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year
~and Children not admitted in the previous year for asthma"
16675486|NCT02114034||Severe asthma|"Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene (inhaler technique and compliance verified) presents one of the 3 criteria following:
~Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months
~exacerbations in the previous year:
~at least one care unit admission or continued resuscitation
~at least two hospitalizations for acute severe asthma requiring IV therapy
~at least 2 courses of oral corticosteroids for exacerbations
~post BD FEV <80% or UARS post BD> 150% predicted"
16675487|NCT02114021|Experimental|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
16675488|NCT02114021|Experimental|lidocaine jelly|lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
16675489|NCT02114021|Placebo Comparator|distilled water|betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
16675490|NCT02114008|Active Comparator|Abbreviated fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin).
16675491|NCT02114008|Active Comparator|Traditional fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test).
16675492|NCT02113995|Active Comparator|ACERTO|"Patients received 400 ml of a beverage containing water and 50 g of maltodextrin 6 hours before the operation. They received orally extra 200 ml of this beverage containing water and 25 g of maltodextrin 3 hours before the operation. Regarding the intravenous fluids, they received 1 to 1.5 liter of crystalloid fluids (ringer lactate) in the intraoperative. In the immediate postoperative they were programmed to receive 2 liters of crystalloid fluids (ringer lactate) and 1 to 2 liters in the first day of the postoperative period. The venous hydration was suspended as soon as they started to drink liquids.
~Prophylaxis of nausea and vomiting with dexamethasone 8 mg at the beginning of the anesthesia and ondansetron 4-8 mg after the surgery. In the postoperative period we utilized analgesics such as dipyrone and ketorolac and, if necessary, low doses of morphine and antiemetics like ondansetron."
16675493|NCT02113995|Active Comparator|Traditional care|"The analgesia in the postoperative period of the group control was performed with dipyrone, tramadol hydrochloride, and morphine. The prophylaxis of nausea and vomiting with dexamethasone 8 mg in the beginning of the anesthesia and the metoclopramide at the end of the surgery. During the anesthetic induction antibiotic prophylaxis (cefazolin 3 grams/day for 2 days) was administrated.
~The control group were submitted to the protocol of traditional fasting with at least 8 hours. Patients in this group received 1 to 2 liters of crystalloid fluid (ringer lactate) in the intraoperative, and they received 3 to 4 liters of crystalloid fluids (ringer lactate, saline 0.9% and/or dextrose 5%). In the immediate postoperative, 2 to 3 liters in the first day of postoperative and, finally, 1 to 2 liters in the second day of the postoperative."
16675494|NCT02113982|Experimental|Relapse/Refractory Acute Myeloid Leukemia|Intervention: SL-401
16675495|NCT02113982|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: SL-401
16675496|NCT02113969|Experimental|Vaginal Pessary|Pessary users for at least 12 months
16675497|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
16675498|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
16675499|NCT02113930||Idiopathic CD4 lymphocytopenia|Constitution of a biobank of frozen cells, plasma and serum samples
16675500|NCT02113930||Genetic Study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
16675501|NCT02113917||hemophagocytic syndrome|patient with hemophagocytic syndrome
16675502|NCT02113904|Experimental|Adalimumab|
16675503|NCT02113891|Experimental|Eculizumab|Eculizumab will be given in addition to standard immunosuppression regimen (tacrolimus, mycophenalte mofeti, prednisone)
16675504|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.
~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.
~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).
~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
16675505|NCT02113865||Grupo 0|Null or mild fibrosis
16675506|NCT02113865||Grupo 1|Cirrhosis
16675507|NCT02113865||Grupo 2|HCC diagnosis
16675508|NCT02113839|Active Comparator|No frequent exacerbators|"Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.
~Interventions:
~Spirometry
~Emogas analysis
~Modified Borg Dyspnea Scale
~CO Exhaled breath
~P01
~FeNO"
16675509|NCT02113839|Active Comparator|Frequent exacerbators|"Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.
~Interventions:
~Spirometry
~Emogas analysis
~Modified Borg Dyspnea Scale
~CO Exhaled breath
~P01
~FeNO"
16675510|NCT02113826|Experimental|Pazopanib|Pazopanib 800mg po qd until disease progression
16675511|NCT02113813|Experimental|ASP8273 Dose Escalation cohort (part 1)|oral
16675512|NCT02113813|Experimental|ASP8273 Response Expansion cohort (part 1)|oral
16675513|NCT02113813|Experimental|ASP8273 and Midazolam RP2D Expansion cohort (part 2)|oral
16675514|NCT02113813|Experimental|Food Effect Fasted cohort (part 2)|oral
16675515|NCT02113813|Experimental|Food Effect Fed cohort (part 2)|oral
16675516|NCT02113813|Experimental|Exon 20 Cohort (part 2)|oral
16675517|NCT02113800|Experimental|Single Arm|"Patients receive Everolimus orally, 10 mg/day.
~The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study."
16675518|NCT02113787|Active Comparator|Pharmacokinetic study, topamed|"For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in first visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in second visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day."
16675519|NCT02113787|Active Comparator|Pharmacokinetic study, topamax|"For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in first visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in second visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day."
16675520|NCT02113774|No Intervention|no therapy|
16675521|NCT02113774|Active Comparator|antimicrobial treatment according to in-vitro susceptibility|
16675522|NCT02113748|Experimental|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
16675523|NCT02113748|Active Comparator|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
16675524|NCT02113735|Experimental|Group 1|H.P. Acthar® Gel , 64 U, 0.8 mL daily
16675525|NCT02113735|Placebo Comparator|Group 2|Placebo, 0.8 mL, daily
16675526|NCT02113735|Experimental|Group 3|H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily
16675527|NCT02113735|Placebo Comparator|Group 4|Placebo, 0.4 mL, 2x daily
16675528|NCT02113735|Experimental|Group 5|H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily
16675529|NCT02113735|Placebo Comparator|Group 6|Placebo, 0.2 mL, 2x daily
16675530|NCT02113722|Active Comparator|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation
16675531|NCT02113722|Placebo Comparator|Standard of care|Continuing medical therapy
16675532|NCT02113709|Experimental|Visual improvement|To see how efficiently visual improvement occurs by Full-time Occlusion therapy with an eye patch in severe amblyopia.
16675533|NCT02113696|Experimental|Placebo group|Placebo Capsules
16675534|NCT02113696|Experimental|Omega 3 intake|Omega 3 intake, morbid obesity
16675535|NCT02113683||MMS test|therapy monitoring of patients with colo-rectal or stomach disease or with melanoma
16675536|NCT02113670|Experimental|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
16675537|NCT02113657|Experimental|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
16675573|NCT02113384||Observational study|Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
16675538|NCT02113644||Overweight or obese children|Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare
16675539|NCT02113644||Lean children|Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears
16675540|NCT02113631|Active Comparator|Telaprevir|Telapravir was administer with Peg-IFN and Ribavirin as per package insert Dose Telaprevir : PO, tablet 1125 mg BID for 12 weeks
16675541|NCT02113631|Active Comparator|Boceprevir|Boceprevir was administer with Peg-IFN and Ribavirin as per package insert Dose Boceprevir PO capsule, 800mg TID for up to 44 weeks
16675542|NCT02113618|Active Comparator|Cogmed Training|Cogmed® working memory training is a computer program that will be administered online. The program consists of 7 verbal and non-verbal working memory tasks and gives immediate performance feedback to the subject undergoing training.
16675543|NCT02113618|Placebo Comparator|Standard training|Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
16675544|NCT02113605|Experimental|Cognitive behavior therapy|All included children are treated with a face-to-face exposure-based cognitive behaviour therapy for 10 weeks. There will be no comparison arm.
16675545|NCT02113592|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
16675546|NCT02113592|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
16675547|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
16675548|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
16675549|NCT02113566|Placebo Comparator|Placebo|2 capsules identical to comparator, 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
16675550|NCT02113566|Active Comparator|Ibuprofen|2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
16675551|NCT02113553|Experimental|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
16675552|NCT02113540|Placebo Comparator|placebo group|taking atorvastatin like placebo 12 hours before the procedure
16675553|NCT02113540|No Intervention|long term statin group|taking atorvastatin for a long time before entering the study (their routine treatment)
16675554|NCT02113540|Experimental|preoperation statin group|taking atorvastatin 12 hours before the procedure
16675555|NCT02113527||Epigastric pain syndrome (EPS)|Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
16675556|NCT02113527||Postprandial distress syndrome (PDS)|Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
16675557|NCT02113527||Healthy subjects|Healthy subjects as control group
16675558|NCT02113514||Normal Pap smear|Women with normal pap test.
16675559|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
16675560|NCT02113501||HGT1a|HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).
16675561|NCT02113501||HGT1b|HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
16675562|NCT02113488||Control: P|Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
16675563|NCT02113488||Case: A|Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
16675564|NCT02113488||Control: C|Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
16675565|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
16675566|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
16675567|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
16675568|NCT02113423|Experimental|recurrent T1-2 NPC,no treatment|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
16675569|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
16675570|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
16675571|NCT02113397||Continuous Therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
16675572|NCT02113397||Cyclic therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.
16680175|NCT02082418|Experimental|Healthy|healthy control subjects
16675574|NCT02113371|Experimental|Intervention|The intervention consists of monthly scripted, peer-led social support sessions covering health and safety topics.
16675575|NCT02113371|No Intervention|Control|Usual practices with regard to health and work conditions.
16675576|NCT02113358|Experimental|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.
~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.
~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
16675577|NCT02113358|Active Comparator|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.
~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.
~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
16675578|NCT02113345|Experimental|lifestyle counseling|Metamemory Cognitive Intervention
16675579|NCT02113332|Experimental|Liraglutide|Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
16675580|NCT02113332|Placebo Comparator|Placebo|Placebo injected once per day for 24 weeks. Dose is 1,8 or highest tolerable dose.
16675581|NCT02113319|Experimental|dasatinib|
16675582|NCT02113306|Experimental|t-VNS|"electrical stimulation of the concha of the ear
~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
16675583|NCT02113306|Sham Comparator|sham t-VNS|"Sham stimulation of the earlobe will be conducted by positioning the electrode upside down
~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
16675584|NCT02113293|Experimental|CyclASol®|CyclASol®
16675585|NCT02113293|Placebo Comparator|Placebo|Placebo (vehicle)
16675586|NCT02113280|Active Comparator|Physiotherapy|Physiotherapy
16675587|NCT02113280|Experimental|Arthroscopy|Arthroscopy
16675588|NCT02113267|Experimental|Mometasone furoat|Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
16675589|NCT02113267|Placebo Comparator|Placebo spray|Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
16675590|NCT02113254|Experimental|Healthy volunteer|
16675591|NCT02113241|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
16675592|NCT02113241|Placebo Comparator|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
16675593|NCT02113228||Short Bowel Syndrome|Verify the total energy expenditure in patients with short bowel syndrome using the doubly labeled water method.
16675594|NCT02113228||Control Group|Verify the total energy expenditure in patients without short bowel syndrome using the doubly labeled water method.
16675595|NCT02113215||Young Males|Males, age 18-35 years. 9-hour Stable isotope infusion
16675596|NCT02113215||Young Females|Females, age 18-35 years. 9-hour Stable isotope infusion
16675597|NCT02113215||Older Males|Males, age 60-75. 9-hour Stable isotope infusion
16675598|NCT02113215||Older Females|Females, age 60-75. 9-hour Stable isotope infusion
16675599|NCT02113202|Experimental|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
16675600|NCT02113202|Experimental|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
16675601|NCT02113202|Experimental|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
16675602|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
16675603|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
16675604|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
16675605|NCT02113176|Experimental|Minocycline|"200 mg IV/placebo
~Followed by 100 mg IV BID x 7days
~Followed by 200 mg tablet QD x 14days"
16675606|NCT02113176|Placebo Comparator|Placebo|
16675607|NCT02113163|Active Comparator|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
16675608|NCT02113163|Active Comparator|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
16675609|NCT02113150|Active Comparator|remifentanil|remifentanil, short acting opioid
16675610|NCT02113150|Active Comparator|ketamine|ketamine, intravenous anesthetic
16675611|NCT02113137|Experimental|group 1: drug|Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
16675612|NCT02113137|Experimental|group 2: device:|group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning
16675613|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
16675614|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
16675615|NCT02113111||Fasting|Patients being admitted to an internal integrative medicine hospital and referred to therapeutic fasting therapy
16675616|NCT02113098|Experimental|Treadmill, ankle load|The experimental group will perform gait training on a treadmill with added load to the non-paretic lower limb
16675617|NCT02113098|Active Comparator|Treadmill|The control group (active comparator) will perform gait training on a treadmill
16675618|NCT02113085|Experimental|Self-determination enhancement|Self-determination enhancement through one-on-one coaching and mentoring workshops
16675619|NCT02113072|Experimental|Probiotics & Beclomethasone|"It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
~Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months."
16675620|NCT02113072|Active Comparator|Beclomethasone & Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
16675621|NCT02113059||Liver resection|Patients undergoing a hemihepatectomy.
16675622|NCT02113046|Active Comparator|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
16675623|NCT02113046|Active Comparator|traditional anastomosis|pancreatic resections with traditional stump closure
16675624|NCT02113033|Experimental|Treated with Equilia system|Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
16675625|NCT02113020|Experimental|TAK-233|Oral administration
16675626|NCT02113020|Placebo Comparator|Placebo|Oral administration
16675627|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
16675628|NCT02112994|Experimental|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
16675629|NCT02112981|Experimental|Sirolimus Eluting Coronary Stent|BioMime Sirolimus Eluting Stent of Meril Life Sciences
16675630|NCT02112981|Active Comparator|Everolimus-eluting Coronary stent|XIENCE family (V, Xpedition or Prime) of Everolimus-eluting stent system of Abbott Vascular Inc.
16675631|NCT02112968|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes.
16675632|NCT02112968|Experimental|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
16675633|NCT02112968|Experimental|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
16675634|NCT02112955|Experimental|Stroke self-management program|The program is aimed at enhancing community-dwelling stroke survivors' post-stroke recovery.
16675635|NCT02112955|Active Comparator|Usual care|Usual care provided to stroke survivors discharged to their home.
16675636|NCT02112942|Experimental|Group A|Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days
16675637|NCT02112942|Experimental|Group B|HCV subjects genotype 1, IDX21459 capsules, once for 1 day
16675638|NCT02112942|Experimental|Group C|HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days
16675639|NCT02112929|Experimental|Inhalation of hyperpolarized xenon|One litre of hyperpolarized xenon to be inhaled during MRI scan of the lungs
16675640|NCT02112916|Active Comparator|Arm A (combination chemotherapy)|Patients receive combination chemotherapy without bortezomib. See Detailed Description.
16675641|NCT02112916|Experimental|Arm B (combination chemotherapy, bortezomib)|Patients receive combination chemotherapy with bortezomib. See Detailed Description.
16675642|NCT02112903|Experimental|Encapsulated vortioxetine IR tablet, 20 mg|Single oral dose
16675643|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 5.5)|Single oral dose
16675644|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 6.0)|Single oral dose
16675645|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 7.0)|Single oral dose
16675646|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
16675647|NCT02112877|Experimental|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
16675648|NCT02112877|Experimental|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
16675649|NCT02112864|Experimental|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
16675650|NCT02112864|Placebo Comparator|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
16675651|NCT02112851|Placebo Comparator|Orange flavored beverage|240ml orange beverage
16675652|NCT02112851|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
16675653|NCT02112851|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
16675654|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
16675655|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
16675656|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
16675657|NCT02112825|Experimental|Exercise|12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes
16675658|NCT02112825|No Intervention|control|Control group asked to continue usual activities
16675659|NCT02112812|Experimental|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
16675660|NCT02112799|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
16675661|NCT02112799|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
16675856|NCT02111499|Experimental|formulation 2|topical treatment, once daily for 4 weeks
16675662|NCT02112799|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
16675663|NCT02112799|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
16675664|NCT02112786|Active Comparator|Intermittent then Continuous|This group will be set to intermittent stimulation first, then after the wash out period they will be switched to continuous stimulation.
16675665|NCT02112786|Active Comparator|Continuous Then Intermitent|This group will be set to continuous stimulation first, then switch to intermittent after the wash out time period.
16675666|NCT02112760|Experimental|Patient|To evaluate the effect of specific stabilization intervention in recurrent low back pain participants
16675667|NCT02112747|No Intervention|Arm 1: website access only|There is no intervention with this arm. Completion of the website is part of enrollment.
16675668|NCT02112747|Experimental|Arm 2: patient navigator|"The intervention consists of participants receiving the services of a patient navigator to address individual barriers to adhering to the personal prescription for colon and rectal cancer screening."
16675669|NCT02112747|No Intervention|Arm 3: genetic counseling|There is no intervention in this arm. Patients diagnosed as positive for Lynch Syndrome use genetic counseling to discuss medical and family history and genetic risk of CRC, including genetic factors such as DNA mismatch repair genes, autosomal dominant inheritance, cancer risks associated with LS, screening recommendations, and genetic testing. There is no intervention. This is standard care.
16675670|NCT02112747|Experimental|Arm 4:Gen. counselor & patient navigator|Participants diagnosed positive for Lynch syndrome use genetic counseling as in Arm 3 and in addition receive the services of a patient navigator to address individual barriers to adhering to the CRC screening recommendations.
16675671|NCT02112734|Active Comparator|vitamin D|400 IU /daily cholecalciferol/vitamin D
16675672|NCT02112734|Placebo Comparator|placebo|carrier formulation minus vitamin D
16675673|NCT02112721|Experimental|Vitamin D Group|Each participant will be given an initial stat dose of 2500 μg (100,000 IU) of Ostelin (Reckitt Benckiser). Thereafter, participants will take 100 μg/day (4,000 IU, 4 tablets) Ostelin daily for a period of 16 weeks.
16675674|NCT02112721|Placebo Comparator|Placebo group|Each participant will be given an equivalent number of placebo tablets
16675675|NCT02112708|Experimental|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
16675676|NCT02112708|Active Comparator|Control Group|The control group (GC) will take the usual medical care for dysthimia, according with up-dated guidelines.
16675677|NCT02112695|Experimental|sportswomen|3 micrograms [11C]diprenorphine
16675678|NCT02112695|Experimental|control subjects|3 micrgrams [11C]diprenorphine
16675679|NCT02112682|Active Comparator|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
16675680|NCT02112682|No Intervention|No completion axillary treatment|
16675681|NCT02112669|Experimental|AV fistula with VasQ|Implant VasQ over AV fistula
16675682|NCT02112669|No Intervention|AV fistula|AV fistula without any adjunct device
16675683|NCT02112656|Experimental|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
16675684|NCT02112656|Placebo Comparator|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
16675685|NCT02112643|Active Comparator|Selenium|100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.
16675686|NCT02112643|Placebo Comparator|Sugar pill|A placebo pill will be taken orally twice daily for 6 months.
16675687|NCT02112630|Experimental|Group 1 - Response Guided Therapy|"Treatment naive and documented relapsers : Subjects who have never been previously treated with P-IFN +/- ribavirin therapy and those who have documented relapse after P-IFN +/- ribavirin therapy.
~Subjects in group 1 will receive P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24 treatment with be continued for a total duration of 28 to 48 weeks.Subjects will be followed through treatment and up to 24 weeks post treatment."
16675688|NCT02112630|Experimental|Group 2 - Fixed Duration Therapy|"Partial/Null Responders /Undefined Previous Response, Compensated cirrhosis: Subjects who have compensated cirrhosis, and/or were previously treated with P-IFN +/- ribavirin without SVR (including partial responders, null responders, and those previously treated without adequate documentation of response).
~Subjects in Group 2 will all be assigned to fixed duration therapy.Patients will be treated with P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir for a total of 48 weeks of therapy. Subjects will be followed through treatment and up to 24 weeks post treatment."
16675689|NCT02112617|Experimental|Proton Beam Radiation Therapy (PBRT)|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
16675690|NCT02112604||Ventilated patients|Patients who have been extubated within 24 hours and have been mechanically ventilated for at least 24 hours. Alice PDx, pulmonary function tests, muscle strength tests, grip strength measurements, ventilator, Sedatives and muscle relaxants given in the ICU
16675691|NCT02112591|Active Comparator|Transobturator suburethral tape (TOT)|transobturator approaches for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide
16675692|NCT02112591|Experimental|S-TOT|transobturator subtrigonal tape: S-TOT
16675693|NCT02112578|Experimental|Meclizine|Meclizine 25 mg, tablets
16675694|NCT02112578|Active Comparator|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
16675695|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16675729|NCT02112292|Experimental|T-C-P|Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
16675730|NCT02112292|Experimental|T-P-C|Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
16675696|NCT02112552|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.
~RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23)."
16675697|NCT02112539||ADP Blockers|platelet aggregation in response to antiplatelet drugs
16675698|NCT02112526|Experimental|Acalabrutinib|
16675699|NCT02112513||salivary estriol measurement|Serum Estriol measurement via different assays is complex, expensive, labor intensive, time consuming, and generally performed at specific reference labs. Salivary Estriol level is an ideal potential surrogate for serum Estriol. It is convenient, non-invasive, and expedient. It may not, however, be as sensitive as serum estriol concentrations at detecting the association with glucocorticoid response. This study will collect both samples to determine which one is better suited for clinical use in this condition.
16675700|NCT02112513||serum estriol measure|we will determine if changes in maternal serum estriol represent a biomarker of response to antenatal corticosteroids as evidenced by neonatal development of RDS
16675701|NCT02112513||Betamethasone pharmacokinetic|we will determine if pharmacokinetic parameters and neonatal outcomes after antenatal corticosteroid use are associated with genetic polymorphisms in drug metabolizing enzymes, transporters, and steroid pathway genes
16675702|NCT02112513||betamethasone concentration and genetics|we will determine if maternal betamethasone concentrations and genetics are associated with maternal estriol changes or RDS development
16675703|NCT02112500|Experimental|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
16675704|NCT02112487|Experimental|Macitentan|10 mg once daily
16675705|NCT02112474|Experimental|Spinal Cord Stimulation Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
16675706|NCT02112474|Experimental|Spinal Cord Stimulation Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
16675707|NCT02112461|Experimental|Intervention Group|SCP-Hospice Alert
16675708|NCT02112461|No Intervention|Usual Care|Caregiver calls into monitoring system to report the patient's end of life symptoms but does not receive feedback about the symptoms and the hospice nurse does not receive the information.
16675709|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
16675710|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
16675711|NCT02112435|Active Comparator|Narval ORM ® or SomnoDent ®|Mandibular advancement splint (Narval ORM ® or SomnoDent ®)
16675712|NCT02112435|Experimental|Somnyx ®|Active mandibular advancement splint (Somnyx ®)
16675713|NCT02112422|Active Comparator|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
16675714|NCT02112422|Experimental|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
16675715|NCT02112409|Experimental|cell salvage and hemodilution technique|cell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
16675716|NCT02112409|Active Comparator|cell salvage|cell salvage technique throughout scoliosis corrective surgery
16675717|NCT02112396|Experimental|Immediate Intervention|Subjects receive 12 sessions of Community Reinforcement and Family Training (CRAFT) immediately after study inclusion
16675718|NCT02112396|Other|Waiting list group|Waiting list group members receive the Community Reinforcement and Family Training CRAFT intervention after the first follow-up (3 months post study inclusion)
16675719|NCT02112383|Experimental|Internet-based cognitive behavior therapy|
16675720|NCT02112383|Experimental|Cognitive behavior group therapy|
16675721|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
16675722|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
16675723|NCT02112357||Targeted genetic sequencing of tumour specimen|
16675724|NCT02112344|Experimental|Total mucosal irradiation|
16675725|NCT02112331|Experimental|Raw human milk / pasteurized human milk|"Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk.
~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :
~one before the meal,
~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
16675726|NCT02112331|Experimental|Pasteurized human milk / pasteurized-homogenized human milk|"Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk.
~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :
~one before the meal,
~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
16675727|NCT02112305|Experimental|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval
16675728|NCT02112305|Active Comparator|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
16675731|NCT02112292|Experimental|C - T - P|Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
16675732|NCT02112292|Experimental|C - P - T|Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
16675733|NCT02112292|Experimental|P - T - C|Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
16675734|NCT02112292|Experimental|P - C - T|Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
16675735|NCT02112279|Experimental|Microbiota Transplant|Close relative or purchased donor microbiota transplant will be administered via colonoscopy; Donor microbiota applied via colonoscopy
16675736|NCT02112266|Other|no mail support|no mail support during follow-up
16675737|NCT02112266|Other|mail support|
16675738|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 2 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
16675739|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 3 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
16675740|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 2 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
16675741|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 3 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
16675742|NCT02112253|Active Comparator|Deep brain stimulator empirical programming|Any of the four electrode contacts on each of the two deep brain stimulation leads can be activated in any combination with any amplitude, frequency or pulse width settings to achieve optimized clinical control of motor tics whilst minimizing side effects. Both programmer and patient may be unblinded. The assessors are blinded to stimulation settings.
16675743|NCT02112240|Experimental|Surgery with pre- and intra-op imaging|Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
16675744|NCT02112227|Active Comparator|Discharge planning services|Proven effective discharge-planning services will be grouped into 'patient-centered care transitions in heart failure' patients. This will be known as the PACT-HF model.
16675745|NCT02112227|No Intervention|Standard Care|Standard of care will be provided to HF patients at discharge.
16675746|NCT02112214|Active Comparator|Intervention group|10-day bismuth-based quadruple therapy for H. pylori positive subjects
16675747|NCT02112214|Placebo Comparator|Placebo group|Placebo for H. pylori positive subjects
16675748|NCT02112201|Experimental|Integrated intervention for parents and adolescent girls|Twelve session parent education and support group; twelve session one-on-one adolescent skills training intervention
16675749|NCT02112201|No Intervention|Treatment as usual|Treatment as usual
16675750|NCT02112188||Chinese patients with advanced cancer|IMCP intervention to be culturally & linguistically tailored for Chinese cancer patients. This study will be carried out in 3 phases: 1) formative research & 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process & session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, & Applebaum), Drs. Leng, Gany, & Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process & content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline & Treatment Integrity Coding Manual. PHASE 3: Conduct feasibility study of IMCP-Ch for Chinese cancer patients
16675751|NCT02112175|Experimental|Lenalidomide|Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.
16675752|NCT02112162|Experimental|Diagnostic (FDG PET/MRI, gene expression)|FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
16675753|NCT02112149|Experimental|LIVESTRONG Program|Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
16675754|NCT02112149|No Intervention|Wait-List Control|Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.
16675755|NCT02112136|Other|GeneQuest|"No drug will be administrated in this study
~Blood collection"
16675756|NCT02112123|Placebo Comparator|Placebo|Matching placebo given for 5 days (qd po)
16675757|NCT02112123|Active Comparator|Icariin - 100 mg/day|Icariin given at 100 mg/day (qd po) for 5 days
16675758|NCT02112123|Active Comparator|Icariin - 200 mg/day|Icariin given at 200 mg/day (qd po) for 5 days
16675759|NCT02112123|Active Comparator|Icariin - 400 mg/day|Icariin given at 400 mg/day (qd po) for 5 days
16675760|NCT02112123|Active Comparator|Icariin - 840 mg/day|Icariin given at 840 mg/day (qd po) for 5 days
16680176|NCT02082418|Experimental|MCI|mild cognitive impariments
16675762|NCT02112110|Experimental|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days
16675763|NCT02112097|Experimental|For Left Upper Arm|"For Left Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
16675764|NCT02112097|Experimental|For Right Upper Arm|"For Right Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
16675765|NCT02112097|Experimental|sPGA 50 n(%)|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, and Efficacy of Enbrel subcutaneously at Week 36 vs. Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, and Efficacy of Enbrel subdermally at Week 36. sPGA 50 n(%) clear or minimal is the % of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and % of patients with a reduction of PASI of at least 50% from baseline."
16675766|NCT02112097|Experimental|PASI 75 n(%)|"PASI 75 n(%)
~Response to treatment defined as the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI, as PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, and PASI 75 n(%) subcutaneously at Week 36 vs. PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, and PASI 75 n(%) subdermally at Week 36."
16675767|NCT02112097|Experimental|Adverse Injection site reactions|Injection site reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675768|NCT02112097|Experimental|Adverse Reactions with Heart failure|Heart failure as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675769|NCT02112097|Experimental|Adverse Reactions Allergic Reactions|Allergic Reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675770|NCT02112097|Experimental|Adverse Reactions Blood/low blood counts|Blood problems/low blood counts as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675771|NCT02112097|Experimental|Adverse Reactions with Nervous system|Nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675772|NCT02112097|Experimental|Adverse Reactions with Infections|Infections (upper respiratory infection, pyelonephritis, bronchitis, septic osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675773|NCT02112097|Experimental|Adverse Reactions with Malignancies|Malignancies (lymphoma, basal & squamous skin cancer, non-cutaneous solid tumor, & Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675774|NCT02112097|Experimental|Adverse Reactions with Immunogenicity|Immunogenicity as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675775|NCT02112097|Experimental|Adverse Reactions with Autoantibodies|Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
16675776|NCT02112084|No Intervention|Usual Care|Usual care participants do not receive an intervention.
16675777|NCT02112084|Experimental|Individualized DPM|Individualized DPM
16675778|NCT02112071|Experimental|Exercise|blended supervised-hombased exercise training 3-4 times/week for 12 weeks
16675779|NCT02112071|No Intervention|control|control group asked to continue usual activities
16675780|NCT02112058|Experimental|Program|A series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program. Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula. The third component was family support services.
16675781|NCT02112058|No Intervention|Control|Business as usual
16675782|NCT02112045|Experimental|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.
~HDM intravenously (IV) on Day -2.
~Autologous stem cell transplantation on Day 0"
16675783|NCT02112045|Active Comparator|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.
~Autologous stem cell transplantation on Day 0."
16675784|NCT02112032|Experimental|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
16675785|NCT02112032|Experimental|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
16675786|NCT02112032|Experimental|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
16675787|NCT02112019|Experimental|Sialoendoscopy with saline|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and possible strictures are dilated
16675788|NCT02112019|Active Comparator|Sialoendoscopy: saline and hydrocortisone|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and hydrocortisone and possible strictures are dilated
16675789|NCT02112019|No Intervention|Control: no treatment|
16675790|NCT02112006|Experimental|distal injection|0.5% bupivacaine injected in the forearm
16675791|NCT02112006|Active Comparator|proximal injection|20-30ml of 0.5% bupivacaine
16675792|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
16675793|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
16675794|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
16675795|NCT02111967||Diabetes mellitus type 2, Metformin|The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.
16675796|NCT02111967||Diabetes mellitus type 2|The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment
16675797|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
16675798|NCT02111941|Experimental|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
16675799|NCT02111928||NovaTears®|
16675800|NCT02111915|Other|Enhanced Usual Care (EUC)|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services
16675801|NCT02111915|Experimental|THPP-P|Trial participant s who are in the THPP group will receive, in addition to EUC, 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
16675802|NCT02111889|Experimental|one|
16675803|NCT02111876||AHRF follow-up|
16675804|NCT02111863|Experimental|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
16675805|NCT02111850|Experimental|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
16675806|NCT02111850|Experimental|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
16675807|NCT02111837|Placebo Comparator|Standard infant formula|Standard infant formula fed ad libitum
16675808|NCT02111837|Experimental|Standard infant formula with PL1|Standard infant formula enriched with PL1 lipid fraction fed ad libitum
16675809|NCT02111837|Experimental|Standard infant formula with PL2|Standard infant formula enriched with PL2 lipid fraction fed ad libitum
16675810|NCT02111824|Experimental|Group 2|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
16675811|NCT02111824|Experimental|Group 3|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
16675812|NCT02111824|No Intervention|Group 1|Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
16675813|NCT02111811|Experimental|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
16675814|NCT02111811|No Intervention|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
16675815|NCT02111798|Placebo Comparator|Placebo/Abstinence Initiation|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
16675816|NCT02111798|Active Comparator|Bupropion XL/Abstinence Initiation|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
16675817|NCT02111798|Placebo Comparator|Placebo/Relapse Prevention|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
16675818|NCT02111798|Active Comparator|Bupropion XL/Relapse Prevention|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
16675819|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
16675820|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
16675821|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
16675822|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
16675823|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
16675824|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
16675825|NCT02111759|Other|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
16675826|NCT02111759|Other|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
16675857|NCT02111499|Experimental|formulation 3|topical treatment, once daily for 4 weeks
16675858|NCT02111499|Experimental|formulation 4|topical treatment,once daily for 4 weeks
16675827|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
16675828|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
16675829|NCT02111733|Experimental|Hs-TnT|Hs-TNT dosage
16675830|NCT02111720|Experimental|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
16675831|NCT02111720|Active Comparator|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
16675832|NCT02111707|Active Comparator|Rectal Indomethacin pre-ERCP|Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
16675833|NCT02111707|Active Comparator|Rectal Indomethacin post-ERCP|Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)
16675834|NCT02111694|Experimental|Clear versus Opaque Bottle|This is a within-subject study; all infants will be exposed to both conditions. Order of presentation will be counterbalanced across infants.
16675835|NCT02111681|Experimental|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.
~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
16675836|NCT02111655|Other|Clasical Surveillance of AVF|"Classical evaluation of AVF includes:
~Vital sings and predialysis physical examination of AVF every dialysis session.
~Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session.
~Weekly ktv test using biosensors or monthly if using monocompartimental Daugirdas equation.
~Quarterly recirculation with urea method.
~Following Spanish Nephrology VA guidelines will be consider as alarm criteria:
~1.25% Increased venous pressure. 2.25% Decreased pump blood flow. 3.0,2 ktv decreased compared with previous measurement. 4.> 10% recirculation using urea method. 5.Prolonged coagulation time or cannulation difficulties in 3 consecutive dialysis sessions.
~6.Pathologic physical examination with any other criteria."
16675837|NCT02111655|Experimental|Second generation surveillance of AVF|"In addition to the classical surveillance and monitoring methods, in the experimental group Doppler ultrasound and transonic dilution method will be performed on a quarterly basis.
~In addition to the classical alarm criteria and derived from the results in Doppler ultrasound an transonic dilution method the following alarm criteria would also be considered in the experimental group:
~25% or higher decreased in QA compared with previous measurement.
~QA lower than 500 ml/min.
~Stenotic area with a higher than 50% reduction of blood vessel lumen would be considered as alarm criteria only if it comes with a haemodynamic repercussion criteria defined as Peak systolic velocity (PSV) higher than 400 cm/sc, aliasing, or PSV ratio stenosis/pre-stenosis higher than 3."
16675838|NCT02111642|Experimental|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
16675839|NCT02111642|Placebo Comparator|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
16675840|NCT02111629|Experimental|Fluconazole and Secnidazole|
16675841|NCT02111616|Active Comparator|Standard of Care (SCP)|Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
16675842|NCT02111616|Experimental|Intervention Arm (SCP + PCP visit)|"Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
~SCP plus Coordinated PCP Visit: Care coordinators will schedule patient appointment with PCP within 4 weeks of treatment."
16675843|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
16675844|NCT02111590||IVIG to SCIG|Patients with CIDP or MMN in maintenance therapy with IVIG every 3rd to 6th week are shifted to weekly SCIG treatment in unaltered dose.
16675845|NCT02111590||SCIG to SCIG|Patients with CIDP or MMN in maintenance therapy with SCIG (Subcuvia(R) or Hizentra(R)) are shifted to treatment with Gammanorm(R) in unaltered weekly dose.
16675846|NCT02111577|Experimental|DCVAC/PCa with standard of care chemotherapy|Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
16675847|NCT02111577|Placebo Comparator|Placebo with standard of care chemotherapy|Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
16675848|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
16675849|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
16675850|NCT02111551|Experimental|DMXB-A 75 mg|DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level
16675851|NCT02111551|Experimental|DMXB-A 150 mg|DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level
16675852|NCT02111551|Placebo Comparator|Sugar Pill|placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind
16675853|NCT02111538||Amyloidosis|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
16675854|NCT02111512|Other|Egg allergic children|Children with a physician diagnosis of egg allergy will be recruited to receive the intranasal LAIV as part of a safety surveillance study
16675855|NCT02111499|Experimental|formulation 1|topical treatment, once daily for 4 weeks
16675859|NCT02111499|Placebo Comparator|formulation 5|topical treatment, once daily for 4 weeks
16675860|NCT02111499|Active Comparator|formulation 6|topical treatment, once daily for 4 weeks
16675861|NCT02111486|Experimental|breakfast #1|breakfast food containing high viscosity fibre
16675862|NCT02111486|Experimental|breakfast #2|breakfast food containing low viscosity fibre
16675863|NCT02111486|Placebo Comparator|Control|breakfast food without viscous fibre
16675864|NCT02111473|Other|testosterone|testosterone 250 mg injection per 3-4 weeks for 6 months
16675865|NCT02111460|Experimental|Radiotherapy|Systemic Chemotherapy Combined with Loco-regional Radiotherapy
16675866|NCT02111460|Active Comparator|Chemotherapy|Chemotherapy alone without Loco-regional Radiotherapy
16675867|NCT02111447|Active Comparator|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
16675868|NCT02111447|Active Comparator|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
16675869|NCT02111447|Active Comparator|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
16675870|NCT02111447|Active Comparator|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
16675871|NCT02111434|Experimental|testosterone|testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
16675872|NCT02111421|Experimental|parturients|Parturients after the umbilical cord was clapped in cesarean section were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
16675873|NCT02111421|Experimental|nonpregnant women|Nonpregnant women were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
16675874|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
16675875|NCT02111382|Experimental|CV4 (4th ventricle technique) technique|Will be conduced a real cranial osteopathic medicine technique.
16675876|NCT02111382|Sham Comparator|CV4 sham|This group will received only a sham manual therapy technique.
16675877|NCT02111382|No Intervention|Control|The participants will be in supine position for 5 minutes without any visual or verbal contact.
16675878|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
16675879|NCT02111356|Experimental|Pinhole glasses|All subjects perform ophthalmic examinations before and after the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
16675880|NCT02111343|Experimental|Computer-based auditory training (CBAT)|The CBAT programmes in the current study were specifically designed to improve speech-in-noise and dichotic listening skills of children diagnosed with CAPD. All the training programmes were designed to be installed on home-user's computer, and they were visually attractive and appealing to children. The development of the software (non commercial) for the speech-in-noise and dichotic listening training was done by two different teams in the United Kingdom and Singapore, respectively.
16675881|NCT02111343|No Intervention|Control|No intervention other than participants' regular school activities
16675882|NCT02111330|Experimental|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
16675883|NCT02111330|Placebo Comparator|Dose I - Placebo|one Placebo capsule
16675884|NCT02111330|Experimental|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
16675885|NCT02111330|Placebo Comparator|Dose II - Placebo|Two Placebo capsule
16675886|NCT02111330|Experimental|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
16675887|NCT02111330|Placebo Comparator|Dose III - Placebo|Three Placebo capsule
16675888|NCT02111317|Experimental|ASP015K and verapamil|Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
16675889|NCT02111304|Active Comparator|Part A (Adults)|In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
16675890|NCT02111304|Active Comparator|Part B (Pediatric)|"Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.
~Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen."
16675891|NCT02111291|Experimental|SANTYL®|
16675892|NCT02111291|Sham Comparator|Supportive Care|
16680177|NCT02082418|Experimental|Dementia|established diagnosis of dementia
16675893|NCT02111278|Experimental|lumbar Manipulation|Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
16675894|NCT02111278|Placebo Comparator|Sham Manipulation|Patients randomized to this treatment group will receive a sham manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
16675895|NCT02111265|Experimental|Propofol|Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.
16675896|NCT02111265|Experimental|Etomidate|Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.
16675897|NCT02111252|Experimental|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
16675898|NCT02111239|No Intervention|No imaging|No preoperative imaging is performed for this group
16675899|NCT02111239|Experimental|CTA|Patients randomized to this group will undergo a preoperative CTA scan.
16675900|NCT02111239|Experimental|MRA|Patients randomized to this group will undergo a preoperative MRA scan.
16675901|NCT02111226|Active Comparator|Passive SMS Group|Passive SMS messages focused on lifestyle adjustment
16675902|NCT02111226|Experimental|Active SMS Group|Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
16675903|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
16675904|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
16675905|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
16675906|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
16675907|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
16675908|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
16675909|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
16675910|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
16675911|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
16675912|NCT02111161|Active Comparator|IVIG (Privigen)|Intravenous polyspecific immunoglobulin G (Privigen). Dosage: 25 g/day (250 ml) for three consecutive days
16675913|NCT02111161|Placebo Comparator|Saline 0.9%|0.9% saline for Intravenous administration. Dosage: 250 ml for three consecutive days.
16675914|NCT02111148|Active Comparator|urea and creatinine|urea and creatinine detected in vaginal fluid wash after injecting of 5 ml saline intavaginally
16675915|NCT02111148|Active Comparator|Nitrazine|Biochemical description of Nitrazine in the vaginal wash
16675916|NCT02111148|Active Comparator|saline|5ml saline will be injected in vagina of each patient in both groups within 24 hours of membrane rupture.
16675917|NCT02111135|Experimental|Group 1|b-OPV, m-IPV HD and m-OPV2
16675918|NCT02111135|Active Comparator|Group 2|b-OPV, t-IPV and m-OPV2
16675919|NCT02111122|Experimental|Sodium Oxybate|"Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
16675920|NCT02111122|Placebo Comparator|Placebo|"Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
16675921|NCT02111109||Traumatic injury|
16675922|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
16675923|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
16675924|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
16675925|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
16675926|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
16675927|NCT02111070|Experimental|ILYANG Inactivated split influenza vaccine|IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection
16681570|NCT02073461|Placebo Comparator|Vehicle|Vehicle
16675928|NCT02111057||Perioperative RA|Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 90.
16675929|NCT02111044|Active Comparator|Octreotide|Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks
16675930|NCT02111044|Experimental|ITF2984 500 mcg|ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks
16675931|NCT02111044|Experimental|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
16675932|NCT02111044|Experimental|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
16675933|NCT02111031||Case|Patients with documented (histologically/pathologically confirmed) mBC diagnosis, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions).
16675934|NCT02111018|Active Comparator|CVVH|
16675935|NCT02111018|Experimental|CytoSorb Device|
16675936|NCT02111005||Smoking Aggressive Periodontitis group|This group comprises 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
16675937|NCT02111005||Smoking Chronic Periodontitis group|This group comprises 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
16675938|NCT02111005||Non-smoking Aggressive Periodontitis grp|This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
16675939|NCT02111005||Non-smoking Chronic periodontitis grp|This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.
16675940|NCT02110992|Experimental|Docetaxel + Stereotactic Radiation|Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by > 48 hours.
16675941|NCT02110979|Experimental|PDA|Subjects receive an internet-based patient decision aid video. The PDA is viewed outside of the doctor's office via a personal computer in preparation for regularly scheduled face to face interaction between patients and clinicians.
16675942|NCT02110979|No Intervention|Usual care|Patients receive usual care as determined by their clinician.
16675943|NCT02110966|Experimental|Mepivacaine plus Tramadol|1.3 ml of Mepivacaine 2% epinephrine 1:100000 mixed with 0.5 ml of Tramadol (50mg/ml) will be used for the anesthetic blockade in the experimental group
16675944|NCT02110966|Active Comparator|Mepivacaine|The control group will receive the inferior alveolar nerve block using 1.8 ml of Mepivacaine 2% epinephrine 1: 100000.
16675945|NCT02110953|Experimental|Treatment (irinotecan-eluting beads)|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for a total of 2 treatments in the absence of disease progression or unacceptable toxicity. Patients with bi-lobular disease and no evidence of progression in the treated lobe may repeat treatment at the discretion of the treating physician.
16675946|NCT02110940|Active Comparator|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
16675947|NCT02110940|Experimental|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.
~Subjects will be instructed to practice everyday, each action repeat for 10 times."
16675948|NCT02110927|Experimental|Transcutaneous microcurrent|This group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 milliampere (mA). Every 20 minutes changed from 25 hertz (Hz) to 10 Hz
16675949|NCT02110927|Placebo Comparator|Control group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
16675950|NCT02110914|Experimental|Coaching|10 coaching sessions over a period of 6 - 9 months. The intervention is life coaching based on principles of the co-active coaching model.
16675951|NCT02110914|No Intervention|Control|Standard care
16675952|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
16675953|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
16675956|NCT02110875||CONTROLS|Age- and Gender-Matched Controls
16675957|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
16675958|NCT02110849||Prostate Cancer Patients|Prostate cancer patients who received proton radiation therapy
16675959|NCT02110836|Active Comparator|Glucose ingestion|Glucose ingestion during exercise at a rate of 1.8 g/min.
16675960|NCT02110836|Experimental|Sucrose ingestion|Sucrose ingestion during exercise at a rate of 1.8 g/min.
16675961|NCT02110810|Experimental|Indomethacin|100 mg of Indomethacin suppository immediately afterwards while still under sedation
16675962|NCT02110810|Placebo Comparator|2.6-g suppository of glycerin|suppository of 2.4 g of glycerin immediately afterwards while still under sedation
16675963|NCT02110797|Other|RETT patients|
16675964|NCT02110784|Experimental|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
16675992|NCT02110602|Experimental|Initial Diet - low in amino acid levels|"Visit 1 (Day 1): Screening Visit
~Visit 2 (14-21 days after Visit 1): Begin low amino acid diet
~Visit 3 (4 days after Visit 2): Completion of low amino acid diet
~Visit 4 (3 days after Visit 3): Begin high amino acid diet
~Visit 5 (4 days after Visit 4): Completion of high amino acid diet, completion of study"
16681630|NCT02073084|Other|Sequence B|Sequence B
16675965|NCT02110771|Experimental|GAÏA - facial affect recognition targeted|"GAÏA:20hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment cognitive remediation targeted on facial affects recognition. exercises were designed by Gaudelus and Franck (2012) and tutoractiv'company. It includes photos, computer and role games exercises.Computer based exercises have 5 difficulty levels.
~2 sessions of one hour per week with therapist.
~Tasks at home are given once a week and targeting functional outcomes associated with facial affects recognition impairment."
16675966|NCT02110771|Active Comparator|RECOS - attentional process targeted|"RECOS (Cognitive REmediation for Schizophrenia): 20 hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment.
~RECOS is a validated cognitive remediation program, developed by P. Vianin and SBT company. It includes paper and pen and computer based exercises. The original program proposes 5 modules targeting 5 cognitive functions, each patient participated in the module corresponding to his/her most altered cognitive function. In this study, all patients randomized in this arm are allocated in the attentional module.Every computer exercises have 10 difficulty levels.
~2 sessions of one hour per week with therapist.
~Tasks at home are given once a week and targeting functional outcome"
16675967|NCT02110758||Pilot Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
16675968|NCT02110758||Comparison Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
16675969|NCT02110758||Pilot Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
16675970|NCT02110758||Comparison Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
16675971|NCT02110758||Pilot Practices Quality Measures Cohort|Patients with a new diagnosis of cancer in the past two years
16675972|NCT02110745|Experimental|Sevofluorane|Sevofluorane 8% in induction
16675973|NCT02110745|Experimental|Propofol|Propofol 2.5 mg/kg intravenous in induction
16675974|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
16675975|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
16675976|NCT02110719|Active Comparator|Standard|"Patients will be given the following:
~no preoperative medications
~intraoperative medications per anesthesia
~postoperatively, patients will receive ibuprofen, tylenol and narcotics as needed"
16675977|NCT02110719|Active Comparator|Multimodal|"Patients in the multimodal arm will receive the following:
~preoperative celebrex and gabapentin
~intraoperative IV acetaminophen, dexamethasone, zofran
~postoperative scheduled IV acetaminophen, PO celebrex and gabapentin, and as needed PO narcotics
~patient will be discharged on scheduled ibuprofen and acetaminophen for 3 days followed by as needed use as well as as needed narcotics"
16675978|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
16675979|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
16675980|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
16675981|NCT02110680|Active Comparator|TENS 1|TENS at posterior tibial nerve area
16675982|NCT02110680|Sham Comparator|TENS 2|TENS at shoulder area
16675983|NCT02110667||Prostate cancer, post-prostatectomy|
16675984|NCT02110654|Active Comparator|mometasone furoate nasal spray|mometasone furoate nasal spray,200ug qd, 6 months
16675985|NCT02110654|Experimental|mometasone furoate nasal spray combined with montelukast|montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months
16675986|NCT02110641|Active Comparator|In-Person or Telephone-Based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs.
16675987|NCT02110641|No Intervention|Usual Care/Wait List|At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
16675988|NCT02110628|Experimental|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
16675989|NCT02110628|Experimental|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
16675990|NCT02110615|Experimental|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
16675991|NCT02110602|Experimental|Initial Diet - high in amino acid levels|"Visit 1 (Day 1): Screening Visit
~Visit 2 (14-21 days after Visit 1): Begin high amino acid diet
~Visit 3 (4 days after Visit 2): Completion of high amino acid diet
~Visit 4 (3 days after Visit 3): Begin low amino acid diet
~Visit 5 (4 days after Visit 4): Completion of low amino acid diet, completion of study"
16675993|NCT02110589|Experimental|Patient Group 1|"Testing of Epidetect:
~Adult Patients with difficult to control tonic-clonic (convulsant) epilepsy undergoing hospitalised video telemetry monitoring. Patients will be hospitalised as part of their normal investigation of the epilepsy and patients will be consented 1 week before hospitalisation. Epidetect will be used in conjunction with the normal EEG monotoring and video telemetry. The patient will be fitted with the topical sensors at the start of monotoring and then depending on the seizure activity will wear the sensors until enough data is gathered. Hospitalisation under these circumstances typically lasts no more than five days, so monitoring with the topical sensor will be no longer than this."
16675994|NCT02110589|Experimental|Patient Group 2|"Testing of Epidetect:
~Paediatric patients (over 7 years) where parental consent will enable the epilepsy monitor to be used at home for 1 week and brought back in for analysis along with video evidence. This will not constitute any change in normal care or treatments, and the video evidence provided represents enhanced care through accurate seizure diary reporting. Suitable families and children will be selected and consented through scheduled clinics in paediatric neurology."
16675995|NCT02110589|Experimental|Patient group 3|"Testing of Epidetect:
~Patients where the epilepsy is suspected to be psychogenic (pseudo-seizures) rather than organic epilepsy. We will test whether the epilepsy monitor will be able to differentiate between epilepsy and psychogenic seizures in the medical setting when patients are hospitlised for seizure investigation. Suitable patients will be selected and consented through scheduled clinics in paediatric neurology (under 16) and adult neurology."
16675996|NCT02110589|Experimental|Patient Group 4|"Testing of Epidetect:
~Internal negative Controls. Juveniles or adults with other forms of epilepsy that do not have a hypertonic (increased muscle stiffening) phenotype e.g. absence seizures."
16675997|NCT02110589|Other|Control Group 1|"Testing of Epidetect:
~Volunteers who do not have a history of seizures / epielsy, head trauma, migraine, neurological or muscular-skeletal disorders. This is to produce the baseline data for the Monitor."
16675998|NCT02110576||Healthy Controls|Healthy controls in general good health, without chronic disease/illness, including but not limited to: cancer, diabetes mellitus, renal disease, cardiac disease, hypertension, lung disease, liver disease, complications of morbid obesity, autoimmune/inflammatory disease, or any condition of sufficient severity that it requires daily medication to manage
16675999|NCT02110563|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
16676000|NCT02110550|No Intervention|IPS.emmax crown|
16676001|NCT02110550|Experimental|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
16676002|NCT02110537|Experimental|Active Acupuncture + flecainide|The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
16676003|NCT02110537|Sham Comparator|Sham acupuncture + flecainide|The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
16676004|NCT02110524|Experimental|CVI Drug Coated Balloon|
16676005|NCT02110511|Experimental|alpha-gal & blended lentils|3 capsules of alpha-gal taken with blended lentils
16676006|NCT02110511|Experimental|alpha-gal & whole lentils|3 calpsules of alpha-gal taken with whole lentils
16676007|NCT02110511|Experimental|alpha-gal & no lentils|3 capsules of alpha-gal taken with no lentils control
16676008|NCT02110511|Placebo Comparator|Placebo & blended lentils|3 capsules of placebo taken with blended lentils
16676009|NCT02110511|Placebo Comparator|Placebo & whole lentils|3 capsules of placebo taken with whole lentils
16676010|NCT02110511|Placebo Comparator|Placebo & no lentils|3 capsules of placebo taken with no lentils control
16676011|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
16676012|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
16676013|NCT02110472|Other|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
16676014|NCT02110459|Experimental|Mild renal impairment|3h IV POL7080 infusion
16676015|NCT02110459|Experimental|Moderate renal impairment|3h IV POL7080 infusion
16676016|NCT02110459|Experimental|Severe renal impairment|3h IV POL7080 infusion
16676017|NCT02110459|Experimental|End stage renal disease arm 1|3h IV POL7080 infusion
16676018|NCT02110459|Experimental|End stage renal disease arm 2|3h IV POL7080 infusion
16676019|NCT02110459|Experimental|Normal Renal function|3h IV POL7080 infusion
16676020|NCT02110446|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
16676021|NCT02110446|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
16676022|NCT02110433|Other|Placebo group|Patients will be managed per consensus guidelines Clinicians could see the patients as many times as necessary in order to optimize their therapy and could make BNP measurement (but not using Home BNP monitoring)
16676023|NCT02110433|Experimental|Cordiva System (R)|Patient will see their cardiologist every three months and benefit from telemonitoring of their weight and general well being through a specific communicant device.
16676024|NCT02110433|Active Comparator|BNP and Cordiva (R) monitoring system|In this group, patients and doctors have access to the platform detailed above (Cordiva (R) monitoring system) and had also access to BNP home monitoring (BNP heartcheck).
16676025|NCT02110420|Experimental|CC-90001 10mg (Single Dose)|
16676026|NCT02110420|Experimental|CC-90001 30mg (Single Dose)|
16676027|NCT02110420|Experimental|CC-90001 60mg (Single Dose)|
16676028|NCT02110420|Experimental|CC-90001 120mg (Single Dose)|
16676029|NCT02110420|Experimental|CC-90001 240mg (Single Dose)|
16676030|NCT02110420|Experimental|CC-90001 10mg (Multiple Doses)|
16676031|NCT02110420|Experimental|CC-90001 30mg (Multiple Doses)|
16676032|NCT02110420|Experimental|CC-90001 60mg (Multiple Doses)|
16676033|NCT02110420|Experimental|CC-90001 120mg (Multiple Doses)|
16676034|NCT02110420|Experimental|CC-90001 240mg (Multiple Doses)|
16676036|NCT02110420|Experimental|CC-90001 480mg (single dose)|CC-90001 480mg will be administered as a single oral dose
16676037|NCT02110420|Experimental|CC-90001 720mg (single dose)|CC-90001 720mg will be administered as a single oral dose
16676038|NCT02110420|Experimental|CC-90001 480mg (multiple doses)|CC-90001 480mg will be administered daily for 14 days
16676039|NCT02110407|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
16676040|NCT02110407|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
16676041|NCT02110394||bendamustine and rituximab|
16676042|NCT02110381|Active Comparator|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
16676043|NCT02110381|Active Comparator|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
16676044|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
16676045|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
16676046|NCT02110355|Experimental|AMG 232 with Trametinib and Dabrabenib|Arm 1 of Part 1 and 2 and Part 3
16676047|NCT02110355|Experimental|AMG 232 with Trametinib|Arm 2 of Part 1 and 2
16676048|NCT02110355|Active Comparator|Trametinib and Dabrafenib|Part 3
16676049|NCT02110342|Experimental|Treatment|
16676050|NCT02110329|No Intervention|stage II-III colon cancer treated with surgery|stage II-III colon cancer treated with surgery
16676051|NCT02110316|Other|Bioavailability|1 arm, different dosage form
16676052|NCT02110303|Experimental|18F-F Positive - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
16676053|NCT02110303|Placebo Comparator|18F-F Positive - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
16676054|NCT02110303|Experimental|18F-F Negative - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
16676055|NCT02110303|Placebo Comparator|18F-F Negative - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
16676056|NCT02110290||Children with Physical Disabilities|This group includes children 8-18 years old participating in an adapted ski/snowboarding program with any type of physical disability, including cerebral palsy, traumatic brain injury, spinal cord injury, and amputation.
16676057|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
16676058|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
16676059|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
16676060|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
16676061|NCT02110251|Experimental|Supervised exercise therapy|Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
16676062|NCT02110251|No Intervention|Walking advice|Standard care and a oral walking advice.
16676063|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
16676064|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
16676065|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
16676066|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
16676067|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
16676068|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
16676069|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
16676070|NCT02110186|Experimental|Discectomy and dynamic stabilization|Discectomy with posterior dynamic stabilization
16676071|NCT02110186|Active Comparator|Discectomy alone|Discectomy
16676072|NCT02110186|Active Comparator|Discectomy and fusion|Discectomy with internal fixation and fusion
16676073|NCT02110147|Experimental|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
16676074|NCT02110134|Experimental|Revlite Laser System with Topical|Revlite Laser System for the Treatment of Melasma and hydroquinone skin care regimen
16676075|NCT02110134|Active Comparator|Topical|Hydroquinone skin care regimen
16676076|NCT02110121|Experimental|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
16676077|NCT02110121|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
16676078|NCT02110108|Experimental|Revlite Laser System- Single Wavelength|Revlite Laser System- 1064nm wavelength will be used on half of the face.
16676079|NCT02110108|Experimental|Revlite Laser System- Dual Wavelength|Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
16676080|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
16676081|NCT02110082|Experimental|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
16676082|NCT02110082|Experimental|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
16676083|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.
~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
16676084|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.
~Sirolimus trough levels will be maintained between 10-15 ng/ml."
16676085|NCT02110056|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
16676086|NCT02110056|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
16676087|NCT02110043|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with anodal transcranial direct current stimulation (tDCS)
16676088|NCT02110043|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
16676089|NCT02110030|Experimental|Transcutaneous nerve stimulation|"The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 15 sessions at a frequency of 80 Hz and with a pulse width of 150 ns.
~The group with TENS received electrical stimulation by using an approved electrotherapy device (Endomed 182, Enraf-nonius, Germany). The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2)."
16676090|NCT02110030|Active Comparator|Interferential Currents|The group with Interferential Currents (IC) received a base frequency of 4000 Hz by using the same approved electrotherapy device than the TENS group (Endomed 182, Enraf-nonius, Germany).
16676091|NCT02110017|Other|Patients with schizophrenia|"Twenty patients suffering from schizophrenia (DSM-IV-R), with medication and medical care. No recent relapse of the psychotic disease, nor change in medications.
~No neurological comorbidity.
~After anatomic scans, each subject will go through the fMRI social cognition task."
16676092|NCT02110017|Other|Healthy subjects|"Twenty healthy subjects (no mental or neurological disease)
~After anatomic scans, each subject will go through the fMRI social cognition task."
16676093|NCT02110004|Other|Ablation procedure|Collect intra-cardiac signals
16676094|NCT02109991|Experimental|CG-100 device|
16676095|NCT02109978||Responders|Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.
16676096|NCT02109978||Progressors|Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment >10 years from diagnosis.
16676097|NCT02109965|Active Comparator|Control|Use midazolam or propofol for sedation
16676098|NCT02109965|Experimental|Dexmedetomidine|Use dexmedetomidine for sedation
16676099|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
16676100|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
16676101|NCT02109926||Cases: testicular cancer patients|
16676102|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
16676103|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
16676104|NCT02109913|Other|Everolimus plus exemestane|Biomarker study in patients receiving standard treatment
16676105|NCT02109900||Serum Progesteron Levels|
16676106|NCT02109887||PCP with true CMV co-infection|
16676107|NCT02109887||PCP with innocent bystander CMV|
16676108|NCT02109887||PCP without any evidence of CMV|
16676109|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 5/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
16676110|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 15/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
16676111|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 50/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
16676112|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 150/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
16676113|NCT02109874|Placebo Comparator|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|Placebo: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl. This is the identical buffer solution in which IC31 is formulated.
16676114|NCT02109861|Experimental|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
16676115|NCT02109861|Experimental|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
16676116|NCT02109861|Experimental|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
16676117|NCT02109848||keratoconus|
16676118|NCT02109848||post-keratoplasty|
16676119|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
16676120|NCT02109835||Asymptomatic type 2 diabetes|Patients without previous history of coronary artery disease
16676121|NCT02109822||CF patients with pulmonary exacerbations|Patients with CF who are hospitalized with a pulmonary exacerbation treated with intravenous antibiotics.
16676122|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
16676123|NCT02109796|Experimental|hemiplegic patient|anodal transcranial direct current stimulation
16676124|NCT02109796|Sham Comparator|patient control|Sham transcranial direct current stimulation
16676125|NCT02109783|Active Comparator|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
16676126|NCT02109783|Active Comparator|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
16676127|NCT02109783|Placebo Comparator|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
16676128|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
16676129|NCT02109757|Experimental|Software intervention and education|This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.
16676130|NCT02109757|Active Comparator|Education only|This group will not receive software intervention prior to and after one-on-one education, only afterwards.
16676131|NCT02109744|Experimental|Decitabine followed by rapamycin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
16676132|NCT02109744|Experimental|Decitabine followed by ribavirin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
16676133|NCT02109731|Experimental|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
16676134|NCT02109718|Experimental|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
16676135|NCT02109718|Active Comparator|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.
16676136|NCT02109705||Alzheimer's Disease|
16676137|NCT02109705||other Dementia|
16676138|NCT02109705||cognitive healthy|
16676139|NCT02109692|Other|cohort|blood sample : doage of miRNA
16676140|NCT02109679|Experimental|Treatment A|multiple doses BI 187004
16676141|NCT02109679|Experimental|Treatment B|multiple doses BI 187004 + multiple doses metformin
16676142|NCT02109679|Experimental|Treatment C|multiple doses metformin
16676143|NCT02109666||RA patients treated with Abatacept|RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
16676144|NCT02109653|Experimental|LGX818|Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.
16676145|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
16676146|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
16676147|NCT02109627|Experimental|Ficlatuzumab, Cytarabine|"Ficlatuzumab 5-20 mg/kg; intravenous; Days 0, 14, 28, 42; Number of cycles: until progression or unacceptable toxicity develops.
~Cytarabine 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops."
16676148|NCT02109614|Experimental|Extended release Niacin|Taking 1500-2000mg niacin daily
16676149|NCT02109614|Placebo Comparator|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
16676150|NCT02109601|Active Comparator|Control|Control patients receive iPad tablets during their hospital stay with only LIMITED bedside training from a research assistant on how to access and effectively use their patient portal.
16676151|NCT02109601|Experimental|Intervention|Intervention patient receive iPad tablets during their hospital stay with EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
16676152|NCT02109588|No Intervention|Control|Sedentary pregnant women
16676153|NCT02109588|Experimental|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training
~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
16676154|NCT02109575||Heart Transplant Recipients|Up to 10 cc of blood will be drawn from heart transplant recipients at various time points prior to and after transplant. Blood draw is the only research activity that study participants will undergo. In addition to blood draw, data will be collected from clinical records representing the participant's transplant course such as the medical record, imaging, and biopsy slides with pathology reports.
16676155|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
16676408|NCT02107846|Experimental|100 Units|PRX-112 100 Units daily for 5 days
16676156|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
16676157|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
16676158|NCT02109549||Diabetes and metformin|Patients with diabetes mellitus treated with metformin only.
16676159|NCT02109549||Insulin-diabetes without metformin|Patients with insulin-dependent diabetes mellitus not treated with metformin
16676160|NCT02109549||Controlgroup|The remaining patients serve as control group.
16676161|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
16676162|NCT02109523|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
16676163|NCT02109523|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
16676164|NCT02109510|Experimental|Nonintubated sedation anesthesia|nonintubated single port thoracoscopic bullectomy using local anesthesia under sedation Drug: Dexmedetomidine IV loading dose of 1ug/kg for 10 minutes and maintain dosage of 0.3-1 ug/kg/hr, ketamine IV 2-4 mg/kg/hr and intercostal nerve block with 2% lidocaine 2cc Device: facial O2 Mask
16676165|NCT02109510|Active Comparator|Intubated general anesthesia|intubated single port thoracoscopic bullectomy under general anesthesia Drug: propofol 2mg/kg IV , rocuronium 0.6mg/kg IV,1.2-2.4% sevoflurane, N20 50% 02 at fresh gas flow of 4L/min Device: double lumen endotracheal tube intubation
16676166|NCT02109497|Other|Caffeine Dosing|Single dose of caffeine 100 mg administered
16676167|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
16676168|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
16676169|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
16676170|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
16676171|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
16676172|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
16676173|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
16676174|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
16676175|NCT02109471||corneal opacities|
16676176|NCT02109458|Experimental|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
16676177|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
16676178|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
16676179|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
16676180|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:
~Self-directed Pedal Desk
~Facilitated Pedal Desk
~Facilitated Pedal Desk with Pedometer"
16676181|NCT02109419||All participants|All participants, including control, mild cognitive impairment, and dementia.
16676182|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
16676183|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
16676184|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
16676185|NCT02109393|Experimental|MIRT group|"This group underwent a 4-weeks MIRT exploiting the use of a treadmill-plus (treadmill associated with visual cues and auditory feedbacks).
~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
16676186|NCT02109393|Experimental|MIRT+Lokomat group|"This group underwent a 4-weeks MIRT involving the use of Lokomat® for 5 days per week in spite of treadmill-plus.
~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
16676187|NCT02109380|Experimental|Bed rest|One week of bed rest.
16676188|NCT02109367||Pelvic mass|Women who present to the Gynecologic Oncology clinic with a pelvic mass who are scheduled to undergo surgical excision.
16676189|NCT02109354|Active Comparator|HIV Regimen + Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
16676190|NCT02109354|Active Comparator|HIV Vaccine Regimen|Participants will receive a placebo for tetanus vaccine by injection (placebo tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a placebo for hepatitis B vaccine series (months 7.5, 8.5, 13)
16676228|NCT02109081|Experimental|Dexamethasone|Patients will be administered dexamethasone 10 mg at induction of anesthesia
16676229|NCT02109081|Placebo Comparator|Placebo-2.5 cc of saline|Patients will be administed placebo at induction of anesthesia
16681631|NCT02073084|Other|Sequence C|Sequence C
16676191|NCT02109354|Placebo Comparator|Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of a placebo for the experimental canarypox HIV vaccine (placebo for ALVAC-HIV; months 1, 2), than 2 injection of a placebo protein HIV vaccine boost (placebo for AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
16676192|NCT02109341|Experimental|Nab-FOLFIRI|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.
~Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence."
16676193|NCT02109341|Experimental|Nab-FOLFOX|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks.
~Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.
~Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence"
16676194|NCT02109328|Experimental|Alisertib + Paclitaxel|After the first single arm phase with Alisertib monotherapy (20 patients, primary endpoint: response-rate), 110 patients will be randomized 1:1 in the second part of the trial.
16676195|NCT02109328|Placebo Comparator|Paclitaxel + Placebo|Weekly paclitaxel + oral Placebo
16676196|NCT02109315|Experimental|Liraglutide endovenous 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
16676197|NCT02109315|Experimental|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
16676198|NCT02109289|Experimental|Methotrexate and Etanercept|Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks
16676199|NCT02109276|Active Comparator|Spheric Sensar(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive a Spheric Sensar(R) 3-piece IOL
16676200|NCT02109276|Experimental|Aspheric Tecnis(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive an Aspheric Tecnis(R) 3-piece IOL
16676201|NCT02109263|Experimental|saccharose|20% saccharose
16676202|NCT02109263|Placebo Comparator|breast-feeding|breast-feeding
16676203|NCT02109250||all Belgian patients treated with Caprelsa® (vandetanib)|It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
16676204|NCT02109237|Experimental|Bronchiolitis Obliterans 2 & 3|Assessment of sleep disorders and treatment if required
16676205|NCT02109237|Active Comparator|Bronchiolitis Obliterans 0|Assessment of sleep disorders and treatment if required
16676206|NCT02109224|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
16676207|NCT02109211|Other|Standard care - Magill forceps|Patients will be intubated, as per standard care, with Magill forceps.
16676208|NCT02109211|Experimental|Altered Magill forceps|Patients will be intubated with modified Magill forceps.
16676209|NCT02109198|Experimental|Active CN-NINM PoNS|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
16676210|NCT02109198|Placebo Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
16676211|NCT02109185|Active Comparator|Mometasone Furoate Monohydrate Nasal Spray,50 μg/act.|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
16676212|NCT02109185|Active Comparator|Nasonex® Nasal Spray, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
16676213|NCT02109185|Active Comparator|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray Suspension per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
16676214|NCT02109185|Placebo Comparator|Placebo Nasal Spray, 50 μL/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays of placebo nasal spray per nostril once daily.
16676215|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
16676216|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
16676217|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
16676218|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
16676219|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
16676220|NCT02109146|Experimental|TACE|Patients after surgery receive Transcatheter Arterial Chemoembolization (TACE)
16676221|NCT02109146|Active Comparator|Control|Patients after surgery do not receive TACE
16676222|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
16676223|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
16676224|NCT02109120||carotid endarterectomy (CEA)|CEA patients with vein blood collection
16676225|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
16676230|NCT02109068|Active Comparator|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
16676231|NCT02109068|Active Comparator|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
16676232|NCT02109068|No Intervention|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
16676233|NCT02109055|Experimental|Pilates|Regarding upper limb exercises the limit of flexion and abduction less than 90°, with the exercises involving only the movement of flexion and extension of elbow shoulder will be respected. Along with patient data will be an exercise protocol based on the Pilates method that will be performed by a trained team of physiotherapists. Before and after the exercises the data of heart rate, blood pressure, oxygen saturation and subjective feeling of perceived exertion using the Modified Borg scale will be listed.
16676234|NCT02109055|Active Comparator|Convencional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy.
16676235|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
16676236|NCT02109029|Experimental|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
16676237|NCT02109029|Active Comparator|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute [pmol/kg/min]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
16676238|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
16676239|NCT02109003|Experimental|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Pressure easy® device for 24h, followed by discontinuous control (every 4 hours) with a manual manometer for 24 h.
16676240|NCT02109003|Active Comparator|Manual control of Pcuff followed by continuous control.|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
16676241|NCT02108990|Experimental|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
16676242|NCT02108990|Experimental|Acetaminophen 500mg|500mg Acetaminophen orally three times a day
16676243|NCT02108977|Experimental|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
16676244|NCT02108977|Active Comparator|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
16676245|NCT02108964|Experimental|Phase I part|Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
16676246|NCT02108964|Experimental|Phase II part|Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations will be administered with EGF816 at RP2D during Phase II part of the study.
16676247|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
16676248|NCT02108938||Case|Subject's with Crohn's disease at least 18 years of age
16676249|NCT02108938||Control|"Findings from this study will be compared to controls. These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
16676250|NCT02108925|Experimental|Supplementary oxygen|Study subjects receive, in randomized order, either supplementary 30% oxygen or air (21% Oxygen) from a gas tight bag
16676251|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
16676252|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
16676253|NCT02108899|Experimental|Patients with schizophrenia|
16676254|NCT02108899|Active Comparator|Healthy subjects|
16676255|NCT02108886|Experimental|Montelukast|Intervention group
16676256|NCT02108886|Placebo Comparator|Placebo|Placebo
16676257|NCT02108873||Retrospective Cohort|Adult patients who had scheduled an appointment for outpatient primary care. Patients were divided into two groups, including those who attended their scheduled appointment and those who missed it.
16676258|NCT02108860|Experimental|Blinded abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
16676259|NCT02108860|Placebo Comparator|blinded placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
16676260|NCT02108847|Experimental|Fascia Iliaca Block - Ropivacaine|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of 0.2% ropivacaine.
16676261|NCT02108847|Sham Comparator|Fascia Iliaca Block - Saline|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of Saline.
16676262|NCT02108834|Active Comparator|nerve block|cervical plexus block with ropivacaine
16676263|NCT02108834|Placebo Comparator|Placebo|placebo saline
16676264|NCT02108821|Experimental|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
16676265|NCT02108808|Active Comparator|Prasugrel or Clopidogrel|Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated
16676266|NCT02108808|Experimental|Ticagrelor|Ticagrelor 180mg loading dose
16676267|NCT02108795|Experimental|remifentanil group|Remifentanil 0.05 ug/kg/min is infused to the patients.
16676268|NCT02108795|Placebo Comparator|control|Normal saline 0.2 ml/kg/hour is infused to the patients
16676269|NCT02108782|Experimental|Treatment (dovitinib lactate)|Patients receive dovitinib lactate PO on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16676270|NCT02108769|Experimental|Yogic Breathing|"Chanting Om
~Sharp deep inhalation through nostrils
~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.
~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.
~Yogic Breathing:
~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.
~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.
~Hold breath in this position for about 16 seconds.
~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.
~Go to step a)."
16676271|NCT02108769|Active Comparator|Attention Control|The participants will read a text of their choice for 20 minutes.
16676272|NCT02108756|Experimental|L-pantoprazole sodium|
16676273|NCT02108756|Active Comparator|Panmeilu|
16676274|NCT02108743|Active Comparator|Albuterol|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
16676275|NCT02108743|Placebo Comparator|Placebo|Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
16676276|NCT02108730||non-focal congenital hyperinsulinism|13 children and one adult with non-focal congenital hyperinsulinism
16676277|NCT02108717|Experimental|Group I|"The raters in this group one firstly reviewed the CT scans numbered from one to 60 using LCD monitor and after mandatory rests of 20 minutes, reviewed the remaining CT examinations numbered from 61 to 120 using iPhone with TeamViewer at their first visit.
~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
16676278|NCT02108717|Experimental|Group II|"The raters in this group II firstly reviewed the CT scans numbered from one to 60 using iPhone with TeamViewer and 61 to 120 with the LCD monitor.
~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
16676279|NCT02108704|Active Comparator|Helicobacter pylori eradication therapy|Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD
16676280|NCT02108704|Placebo Comparator|Placebo|Maltodextrin
16676281|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
16676282|NCT02108691|Placebo Comparator|Placebo|
16676283|NCT02108678|Experimental|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
16676284|NCT02108678|Experimental|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
16676285|NCT02108665|Other|Radiographic hysterosalpingography|Realisation in first: radiographic hysterosalpingographyresonance then imaging hysterosalpingography
16676286|NCT02108665|Other|Magnetic resonance imaging hysterosalpingography|Realisation in first : magnetic resonance imaging hysterosalpingography then a radiographic hysterosalpingography
16676288|NCT02108639|Experimental|DCV 3DAA FDC + BMS-791325|"Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days
~Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
16676289|NCT02108626|Active Comparator|E-Cigarette with nicotine|Electronic cigarette with cartridge fluid containing nicotine
16676290|NCT02108626|Placebo Comparator|E-Cigarette without nicotine|Electronic cigarette with cartridge fluid containing no nicotine (placebo)
16676291|NCT02108613|Experimental|Intervention|The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.
16676292|NCT02108613|No Intervention|Control|The control group will receive sexual health counseling.
16676293|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
16676294|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
16676295|NCT02108587|Experimental|optical coherence tomography for diagnosis|Patients undergo optical coherence tomography over 10-15 minutes.
16676296|NCT02108574|Placebo Comparator|Placebo Filter|Placebo device
16676297|NCT02108574|Active Comparator|Rhinix Nasal Filter|Actual Rhinix Nasal Filter
16676298|NCT02108561||Breast Cancer|Post Surgical Her2 testing
16676299|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose|
16676300|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose - Food Effect|
16676301|NCT02108548|Placebo Comparator|Part 1: Placebo|
16676302|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose|
16676303|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose Elderly|
16676304|NCT02108548|Placebo Comparator|Part 2: Placebo|
16676305|NCT02108548|Active Comparator|Part 2: Naproxen|
16676306|NCT02108535|Experimental|Nanocrystalline silver|Flexible polyester low-grip coated nanocrystalline silver dressing. The dressing was applied to the lesion after being soaked in sterile distilled water. About this compresses to bandage movements will have been added and comes to avoid tourniquet bandage on-site maintenance, temperature of the affected area, cushioning and absorption of wound exudate when present. Is finished with the application of crepe bandages in the form of flakes containment curative and maintenance of pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, avoiding tourniquet. The exchanges were performed every three days.
16676307|NCT02108535|Active Comparator|Silver sulfadiazine|Ranges for rayon containing cream 1% silver sulfadiazine were used. Involving this layer, bandages for dressings were added in movements back and forth to avoid the tourniquet, providing maintenance of the temperature of the affected area, cushioning and absorption of wound exudate when present. This application was completed with crepe bandages to contain the dressing and maintain pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, scales, avoiding the tourniquet. Dressing changes were performed daily.
16676308|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.
~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also thought to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
16676309|NCT02108496|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
16676310|NCT02108496|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
16676311|NCT02108483|Experimental|All participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches on Day 1.
16676312|NCT02108470|No Intervention|Dental consultation without OHQoL assessment|Dentist performs consultation in the traditional method
16676313|NCT02108470|Experimental|Dental consultation using OHIP|Dental consultation using OHIP incorporating OHRQoL issues.
16676314|NCT02108457||Proton subjects|
16676315|NCT02108457||IMRT subjects|
16676316|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
16676317|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
16676318|NCT02108431|Experimental|balloon catheter for transurethral bladder-drainage|intraoperatively placement of transurethral catheter after robot-assisted radical prostatectomy
16676319|NCT02108431|Active Comparator|balloon catheter for suprapubic bladder-drainage|intraoperatively placement of suprapubic catheter after robot-assisted radical prostatectomy
16676320|NCT02108418|Experimental|TG-2349 as the original formulation|400 mg, 2 syringes
16676321|NCT02108418|Experimental|TG-2349 as a new capsule formulation|400 mg, 4 capsules
16676322|NCT02108405||Sepsis|Sepsis Forty eight patients developed septic complication during ICU stay (sepsis group).
16676323|NCT02108405||SIRS group|SIRS group Forty seven patients were critically ill without evidence of infectious organism (SIRS group).
16676324|NCT02108379|Experimental|Rhinix Nasal Filters|All included will receive rhinix nasal filters
16676325|NCT02108366|Placebo Comparator|Placebo|Placebo + oseltamivir 75mg bid for 5 days
16676326|NCT02108366|Experimental|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
16676327|NCT02108353|Active Comparator|Melatonin 2mg|The study medication will be compared to placebo control.
16676328|NCT02108353|Placebo Comparator|Placebo|The study medication will be compared to placebo control.
16676329|NCT02108340|Experimental|Microwave radiometry|Patients diagnosed with acute appendicitis will undergo a measurement of the temperature of the appendix with the use of microwave radiometry in a room temperature of 20 -24 degrees celsius.
16676330|NCT02108327|Experimental|surgical blade|
16676332|NCT02108314|No Intervention|Control Group|Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
16676333|NCT02108314|Active Comparator|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
16676334|NCT02108301|Experimental|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
16676335|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
16676336|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
16676337|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
16676338|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
16676339|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
16676340|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
16676341|NCT02108249||Annex Group|Patients prospectively treated with Annex™ Adjacent Level System
16676342|NCT02108249||Retrospective Control|Patients previously treated for adjacent level disease using other systems
16676343|NCT02108236|No Intervention|Blank control group|A control group of patients is put on a waiting list for no intervention and remaining unchanged lifestyle.
16676344|NCT02108236|Active Comparator|intervention group|An intervention group of patients is put on a waiting list for acupuncture treatment.
16676345|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
16676346|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
16676347|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
16676348|NCT02108210|Experimental|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
16676349|NCT02108210|Placebo Comparator|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.
~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
16676350|NCT02108197|Experimental|CPAP Intervention|Continuous positive airway pressure (S9, ResMed)
16676351|NCT02108197|No Intervention|Wait-list|Wait list controls
16676352|NCT02108184|Experimental|Sequential therapy 10 days|1.(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 5 days
16676353|NCT02108184|Active Comparator|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days
16676354|NCT02108184|Active Comparator|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 10 days
16676355|NCT02108184|Active Comparator|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days
16676356|NCT02108171|Active Comparator|dexmedetomidine|intranasal dexmedetomidine
16676357|NCT02108171|Placebo Comparator|placebo|intranasal saline
16676358|NCT02108158|Experimental|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
16676359|NCT02108158|Active Comparator|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
16676360|NCT02108145|Active Comparator|unilateral metal stent insertion|unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more liver volume
16676361|NCT02108145|Experimental|bilateral metal stent insertion|percutaneous transhepatic biliary drainage plus bilateral metal stent.The bare stents were used for PTBS
16676362|NCT02108132|Experimental|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
16676363|NCT02108119|Active Comparator|Probiotics|
16676364|NCT02108119|Placebo Comparator|Control placebo|
16676367|NCT02108093|Experimental|RAP (retrograde autologous priming) group|In the RAP (retrograde autologous priming) group, the priming solution is partially replaced by the patient's own circulating blood, before initiation of CPB. After initiation of cardiopulmonary bypass the priming volume is approximately 900 ml.
16676368|NCT02108093|No Intervention|Control group|In the control group, the priming volume of the arterial and venous line will not be replaced by patient's own blood. The priming volume of cardiopulmonary bypass is 1300 ml in the control group.
16676371|NCT02108054|Experimental|1|People with alcohol use disorder
16676372|NCT02108054|Experimental|2|People without alcohol use disorder
16676373|NCT02108041||Physicians that interact with the black/High SES avatar patien|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American.
16676374|NCT02108041||Physicians that interact with the black/Low SES avatar patient|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American.
16676375|NCT02108041||Physicians that interact with the white race/high SES avatar|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian.
16676376|NCT02108041||Physicians that interact with the white race/low SES avatar p|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian.
16676386|NCT02107976||Diabetics|Type II diabetics
16676387|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
16676388|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
16676389|NCT02107950|Experimental|DCVAC/OvCa in parallel with chemotherapy|Combination therapy with DCVAC/OvCa and Standard of Care
16676390|NCT02107950|Active Comparator|Standard of Care|Standard of Care carboplatin and gemcitabine
16676391|NCT02107937|Experimental|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
16676392|NCT02107937|Experimental|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
16676393|NCT02107937|Active Comparator|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
16676394|NCT02107924||APPI of TKR-Stimulan|Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin
16676395|NCT02107924||APPI of TKR-historical|Surgery 2.4 G Tobramycin 2.0 G Vancomycin
16676396|NCT02107911||men who have sex with men|MSM who seek voluntary HIV counseling and testing service at the Anonymous Clinic, TRC-ARC, including those who describe risky sexual exposure to HIV within the preceding 72 hours and meet nPEP criteria.
16676397|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
16676398|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.
~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)
~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
16676399|NCT02107885|Experimental|DS-1971|single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.
16676400|NCT02107885|Placebo Comparator|placebo|placebo matching each of the DS-1971 dosages.
16676401|NCT02107872|Experimental|dosing cohort 1|Patients will receive REGN1500 or placebo in dosing cohort 1
16676402|NCT02107872|Experimental|dosing cohort 2|Patients will receive REGN1500 or placebo in dosing cohort 2
16676403|NCT02107872|Experimental|dosing cohort 3|Patients will receive REGN1500 or placebo in dosing cohort 3
16676404|NCT02107872|Experimental|dosing cohort 4|Patients will receive REGN1500 or placebo in dosing cohort 4
16676405|NCT02107872|Experimental|dosing cohort 5|Patients will receive REGN1500 or placebo in dosing cohort 5
16676406|NCT02107859|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
16676407|NCT02107846|Experimental|50 Units|PRX-112 50 Units daily for 5 days
16676409|NCT02107846|Experimental|200 Units|PRX-112 200 Units daily for 5 days
16676410|NCT02107846|Experimental|400 Units|PRX-112 400 Units daily for 5 days
16676411|NCT02107833|Experimental|2 mg|OPRX-106 2 mg oral once daily for 5 days
16676412|NCT02107833|Experimental|8 mg|OPRX-106 8 mg oral once daily for 5 days
16676413|NCT02107833|Experimental|16 mg|OPRX-106 16 mg oral once daily for 5 days
16676414|NCT02107820|Active Comparator|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
16676415|NCT02107820|Experimental|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
16676416|NCT02107807|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
16676417|NCT02107807|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
16676418|NCT02107807|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
16676419|NCT02107807|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
16676420|NCT02107794|Active Comparator|Decision Aid|Observation of clinical encounter using the decision aid, via video, audio or written notes.
16676421|NCT02107794|No Intervention|Usual Care|Observations in clinical encounters, either video, audio, or observational notes.
16676422|NCT02107781||Patients with open abdomen|Patients in a critical care unit with abdomen that was not closed during initial operation & will have intra-abdominal pressure monitoring using the AbViser abdominal compartment pressure measuring device.
16676423|NCT02107768|Experimental|Exercise recommendation|Patients randomized to the control group receive general advice for physical training and activity but no specific training or other rehabilitation efforts
16676424|NCT02107768|Experimental|Aerobic exercise|"The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added. The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20, Rate of Perceived Exertion (Borg 's RPE scale)
~Two fitness goals was to be achieved during the training session:
~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.
~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) .Which corresponds to 85% of maximum heart rate."
16676425|NCT02107755|Experimental|Treatment (ipilimumab, stereotactic radiosurgery)|Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
16676426|NCT02107742|Experimental|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
16676427|NCT02107729|Experimental|Needle gauge small|injection needle 23 G
16676428|NCT02107729|Experimental|Needle gauge normal|injection needle 25 G
16676429|NCT02107729|Experimental|Needle gauge large|injection needle 27 G
16676430|NCT02107716|Experimental|Bicarbonate|Each participant will receive two lidocaine injections on the abdomen with different pH
16676431|NCT02107703|Experimental|Abemaciclib + Fulvestrant|150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
16676432|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
16676433|NCT02107703|Experimental|Abemaciclib + Fulvestrant (Endocrine Naïve Cohort)|150 milligrams mg Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
16676434|NCT02107690|Experimental|low temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
16676435|NCT02107690|Experimental|room temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
16676436|NCT02107690|Experimental|body temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
16676437|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
16676438|NCT02107651||NOAC|Patients admitted for GI bleeding while in treatment with NOAC
16676439|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
16676440|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
16676547|NCT02106897|Experimental|Part 1, Cohort 7: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Once on Day 1
16676441|NCT02107625|Experimental|Diet A i.e. Low FODMAP diet|The patients are thoroughly informed verbally and in writing how to eat according to the low FODMAP diet. The diet imply restrictions in carbohydrate intake and the patients need to follow a list with yes/no-foods for 4 weeks.
16676442|NCT02107625|Experimental|Diet B, i.e. Traditional IBS diet|The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
16676443|NCT02107612|Experimental|Integrated system to insert two splinted (bar) miniimplants|Participants were randomly assigned to experimental group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
16676444|NCT02107612|Active Comparator|Denture|Participants were randomly assigned to comparator group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
16676445|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
16676446|NCT02107586|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
16676447|NCT02107586|Active Comparator|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
16676448|NCT02107573|Active Comparator|Rotator cuff repair without Suprascapular Nerve decompression|approximately 17 subjects in the study will receive traditional rotator cuff repair surgical intervention with no suprascapular nerve decompression surgical intervention
16676449|NCT02107573|Active Comparator|Rotator Cuff Repair with Suprascapular Nerve decompression|approximately 17 subjects in the study will undergo rotator cuff repair with arthroscopic suprascapular nerve decompression surgical intervention
16676450|NCT02107547|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
16676451|NCT02107547|Active Comparator|Labral repair|32 subjects in the study will receive labral repair as a surgical intervention
16676452|NCT02107534|Experimental|parent training (dyslexia)|Participants take part in parent training, five two-hour sessions held biweekly.
16676453|NCT02107534|No Intervention|wait list control group|Participants of the waiting list control group had the possibility to take part in the parent training after the follow-up was completed.
16676454|NCT02107521|Active Comparator|ICSI group|In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
16676455|NCT02107521|Experimental|IMSI group|In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
16676456|NCT02107495||CHF-confirmed subjects|Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.
16676457|NCT02107495||Subjects with potentially co-morbidities|non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).
16676458|NCT02107495||Apparently healthy subjects|Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.
16676459|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
16676460|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
16676461|NCT02107469|Experimental|Ancient herbal treatment|"Phyllanthus niruri 3g fine dry powder 3 times a day with warm water before meals for 8 weeks
~Sida cordifolia 7g coarse dry powder 2 times a day prepared as traditional decoction before meals for 8 weeks. Decoction: Take provided measurement cup full of water (112ml) and soak one portion (pe-packed) of the powder for 12 hours, then boil it until the upper level has been reduced to 1/4, filter, cool down to room temperature, drink"
16676462|NCT02107469|Experimental|Modern extract herbal treatment|"Phyllanthus niruri extract 2 capsules 3 times a day with warm water before meals for 8 weeks
~Sida cordifolia roots extract 2 capsules 2 times a day with warm water before meals for 8 weeks"
16676463|NCT02107469|Placebo Comparator|Placebo|"Phyllanthus niruri placebo 2 capsules 3 times a day with warm water before meals for 3 weeks
~Sida cordifolia placebo 2 capsules 2 times a day with warm water before meals for 3 weeks"
16676464|NCT02107456|Experimental|Dry Needling|The taut band of trigger point in upper trapezius muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
16676465|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
16676466|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
16676467|NCT02107430|Experimental|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
16676468|NCT02107430|Active Comparator|Standard radiotherapy|Standard care
16676504|NCT02107183|Experimental|Nasal high-flow oxygen therapy|High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher & Paykel Healthcare) after extubation up to ICU discharge
16676505|NCT02107183|Active Comparator|Venturi mask oxygen therapy|Oxygen delivered through standard Venturi mask after extubation up to ICU discharge
16676469|NCT02107417|Experimental|Experimental Group (EG) - TENS active|Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
16676470|NCT02107417|Sham Comparator|Control Group (CG)- Placebo TENS|Control Group (CG) who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, . It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted.
16676471|NCT02107404|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCA Experimental therapy
16676472|NCT02107404|No Intervention|Standard Therapy|No Intervention
16676473|NCT02107391|Experimental|DCVAC/PCA added Standard Hormone Therapy|Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy
16676474|NCT02107391|Active Comparator|Standard of Care Hormone Therapy|Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate
16676475|NCT02107378|Experimental|DCVAC/OvCa in parallel with chemo (SoC)|Combination therapy with DCVAC/OvCa and Standard of Care (SoC)
16676476|NCT02107378|Active Comparator|Standard of Care (Chemotherapy)|Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)
16676477|NCT02107365|Experimental|Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a|Quadritherapy from Day 0 to Week 24
16676478|NCT02107352||Naltrexone|50mg/day
16676479|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
16676480|NCT02107352||Baclofen|30 mg/day
16676481|NCT02107352||Placebo|
16676482|NCT02107339|Experimental|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
16676483|NCT02107339|Active Comparator|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
16676484|NCT02107326|Experimental|Webdia Software use|Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.
16676485|NCT02107326|No Intervention|Observation|No use of the software. No intervention.
16676486|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
16676487|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
16676488|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
16676489|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
16676490|NCT02107287|Experimental|IMRT Hypofractionated|Neo-adjuvant hormone therapy for three months followed by IMRT combined with a 24-month hormonal therapy.
16676491|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
16676492|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
16676493|NCT02107261|Active Comparator|Naive to botulinum toxin|Individuals with musicians dystonia who have not been treated previously with botulinum toxin.
16676494|NCT02107261|Active Comparator|Prior treatment with botulinum toxin|Individuals with musician's dystonia who have been previously treated with botulinum toxin.
16676495|NCT02107248|Active Comparator|Sleep position: supine|Subjects will be instructed to sleep in a supine position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
16676496|NCT02107248|Experimental|Sleep position: no restrictions|Patients do not have any restrictions in sleeping position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
16676497|NCT02107235|Experimental|Rigosertib + Cisplatin + Radiation|"Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.
~Cisplatin will be administered intravenously at a dose of 40 mg/m^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.
~The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week."
16676498|NCT02107222|No Intervention|mechanical ventilation (MV)|mechanical ventilation according to guidelines
16676499|NCT02107222|Experimental|MV + ECCO2-R(PALP-Device/MaquetCP)|MV according to the guidelines plus CO2-Removal with PALP
16676500|NCT02107209|Experimental|Bronchoscopic Lung volume reduction using Autologous blood.|Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope
16676501|NCT02107209|Active Comparator|Bronchoscopic Lung volume reduction using Fibrin glue|injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy
16676502|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
16676503|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
16676546|NCT02106897|Experimental|Part 1, Cohort 6: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
16676506|NCT02107170|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
16676507|NCT02107170|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
16676508|NCT02107157|Experimental|755nm Alexandrite laser with cap array|
16676509|NCT02107144|Experimental|trimetazidin|Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI- Paients that are TMZ naïve and randomized to TMZ group will be given oral loading of 70mg TMZ.
16676510|NCT02107144|No Intervention|Control|Patients, who are TMZ naïve, will be randomly assigned to receive just previous cardiac medication (Control group).
16676511|NCT02107131|Active Comparator|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
16676512|NCT02107131|Active Comparator|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
16676513|NCT02107118|Active Comparator|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
16676514|NCT02107118|Placebo Comparator|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
16676515|NCT02107105||Observational (questionnaire)|Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
16676516|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
16676517|NCT02107079|Active Comparator|melatonin 1 mg immediate release tablet|
16676518|NCT02107079|Active Comparator|melatonin 2,5mg immediate release capsule|
16676519|NCT02107079|Active Comparator|melatonin 0.1 mg oromucosal tablet|
16676520|NCT02107066|Active Comparator|attention control|Women randomized to attention control will receive the same attention as women randomized to exercise intervention, i.e., weekly phone calls for 6 months. Each call is about 15 min. Women in the attention control will receive information on ovarian cancer health education topics.
16676521|NCT02107066|Experimental|exercise|Women randomized to exercise will receive telephone-counseling weekly for 6 months to increase their exercise
16676522|NCT02107053|Experimental|IV iron + PJ|Each patient will serve as a self control
16676523|NCT02107053|Experimental|No IV iron + PJ|Each patient will serve as a self control
16676524|NCT02107053|Experimental|IV iron no PJ|Each patient will serve as a self control
16676525|NCT02107027|Active Comparator|nMARQ catheter (circular catheter)|Group treated with the circular ablation catheter for atrial fibrillation ablation
16676526|NCT02107027|Active Comparator|Navistar catheter (conventional catheter)|Group treated with the conventional ablation catheter for atrial fibrillation ablation
16676527|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
16676528|NCT02107001||Patients with pleuritic chest pain|Study investigators will perform lung ultrasound in each patient with pleuritic chest pain at inclusion
16676529|NCT02106988|Experimental|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.
~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
16676530|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
16676531|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
16676532|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
16676533|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
16676534|NCT02106949|Experimental|SMS|The patients of the test group receive a first SMS 48 hours after their discharge from the hospital then a total of 10 messages distributed over six months: 48 hours, S1, S2, M1, M2, M3, M4, M5, M6 and M13.
16676535|NCT02106949|No Intervention|Without SMS|The patients of the group benefit from the usual care.
16676536|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
16676537|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
16676538|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
16676539|NCT02106910|Experimental|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
16676540|NCT02106910|Experimental|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
16676541|NCT02106897|Experimental|Part 1, Cohort 1: BIIB059 0.05 mg/kg IV|BIIB059 0.05 mg/kg IV dose, Once on Day 1
16676542|NCT02106897|Experimental|Part 1, Cohort 2: BIIB059 0.3 mg/kg IV|BIIB059 0.3 mg/kg IV dose, Once on Day 1
16676543|NCT02106897|Experimental|Part 1, Cohort 3: BIIB059 1 mg/kg IV|BIIB059 1 mg/kg IV dose, Once on Day 1
16676544|NCT02106897|Experimental|Part 1, Cohort 4: BIIB059 3 mg/kg IV|BIIB059 3 mg/kg IV dose, Once on Day 1
16676545|NCT02106897|Experimental|Part 1, Cohort 5: BIIB059 10 mg/kg IV|BIIB059 10 mg/kg IV dose, Once on Day 1
16676548|NCT02106897|Placebo Comparator|Part 1, Cohort 1-6: Placebo IV|Matching placebo IV dose, Once on Day 1
16676549|NCT02106897|Placebo Comparator|Part 1, Cohort 7: Placebo SC|Matching placebo SC dose, Once on Day 1
16676550|NCT02106897|Experimental|Part 2, Cohort 8: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
16676551|NCT02106897|Placebo Comparator|Part 2, Cohort 8: Placebo IV|Matching placebo IV dose, Once on Day 1
16676552|NCT02106897|Experimental|Part 3a, Cohort 9: BIIB059 20 mg SC|BIIB059 20 mg SC dose, Every 4 weeks for 2 doses
16676553|NCT02106897|Experimental|Part 3a, Cohort 10: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
16676554|NCT02106897|Experimental|Part 3a, Cohort 11: BIIB059 150 mg SC|BIIB059 150 mg SC dose, Every 4 weeks for 2 doses
16676555|NCT02106897|Experimental|Part 3a, Cohort 12: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
16676556|NCT02106897|Placebo Comparator|Part 3a, Cohort 9-12: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
16676557|NCT02106897|Experimental|Part 3b, Cohort 13: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
16676558|NCT02106897|Experimental|Part 3b, Cohort 14: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
16676559|NCT02106897|Placebo Comparator|Part 3b, Cohort 13-14: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
16676560|NCT02106884|Experimental|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
16676561|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
16676562|NCT02106871|Placebo Comparator|Placebo|Placebo daily for 4 weeks
16676563|NCT02106871|Active Comparator|Sildenafil|50mg sildenafil daily for 4 weeks
16676564|NCT02106858||Group 1|Patients treated by Physician with Stivarga under approved local prescriptions
16676565|NCT02106845|Experimental|P-gp probe substrate(digoxin)+regorafenib|
16676566|NCT02106845|Experimental|Group B: BCRP probe substrate (rosuvastatin) + regorafenib|
16676567|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
16676568|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
16676569|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
16676570|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
16676571|NCT02106819||Cerebellar Ataxia subjects|40 individuals with either hereditary or sporadic ataxia will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
16676572|NCT02106819||Healthy Control subjects|40 age matched controls will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
16676573|NCT02106806|Experimental|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
16676574|NCT02106806|Placebo Comparator|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
16676575|NCT02106806|Other|Zinc Control|Healthy volunteers supplemented with zinc
16676576|NCT02106806|Other|Placebo Control|Volunteers received placebo
16676577|NCT02106793|Experimental|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
16676578|NCT02106793|Placebo Comparator|Placebo|Identical placebo solution
16676579|NCT02106780|Experimental|1: ASP1707|
16676580|NCT02106767|Active Comparator|Rosuvastatin|
16676581|NCT02106767|Experimental|Rifampin plus rosuvastatin|
16676582|NCT02106754|Experimental|Brief Intervention|Youth may receive brief intervention from their provider based on randomization.
16676583|NCT02106754|Active Comparator|Treatment As Usual|Youth may receive treatment as usual from their provider based on randomization.
16676584|NCT02106754|Experimental|Brief Intervention with Coaching|Youth may receive brief intervention with coaching from their provider based on randomization.
16676585|NCT02106741|Experimental|Relaxation acupressure|
16676586|NCT02106741|Active Comparator|Stimulating acupressure|
16676587|NCT02106741|No Intervention|Wait-list control|
16676588|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
16676589|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
16676590|NCT02106715|Active Comparator|Training|Two exercises for training of core stability and mobility.
16676591|NCT02106715|No Intervention|Control|Control group without training
16676592|NCT02106702|Active Comparator|FAP counseling|Control arm utilizing the standard of care: access to services provided by the Forensic AIDS Project for up to 90 days after release
16676593|NCT02106702|Experimental|Navigator enhanced case-management|Experimental arm: access to Navigator enhanced case-management services for one year after release
16676662|NCT02106247|Experimental|1 BI 1181181 low dose|tablet
16676663|NCT02106247|Experimental|BI 1181181 high dose|tablet
16676594|NCT02106689|Experimental|Needle free system|"Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle"
16676595|NCT02106689|Active Comparator|Standard needle injection system|Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections
16676596|NCT02106676||Pregnant women with PCOS and offspring|Exposures of interest: Polycystic ovary Syndrome (PCOS) according to Rotterdam
16676597|NCT02106676||Pregnant women without PCOS and offspring|Exposures of interest: Pregnant women without polycystic ovary Syndrome (PCOS) according to Rotterdam
16676598|NCT02106663|Active Comparator|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs), guided by 3D electroanatomic mapping (Carto, Biosense Webster, Inc. or ESI NavX, St. Jude, Inc.) with a 3D LA geometry created either by using the roving mapping catheter or by importing a pre-recorded 3D CT image of the left atrium. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed (entrance block at a minimum).
16676599|NCT02106663|Active Comparator|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing myocardial connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter around the PV ostium or antrum, until mapping demonstrates elimination of all PV potentials (entrance block at a minimum).
16676600|NCT02106650|Experimental|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).
~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.
~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
16676601|NCT02106637|Active Comparator|study groups|study groups will receive Varenicline
16676602|NCT02106637|Placebo Comparator|control group|Participants allocated to the control group will receive placebo
16676603|NCT02106624|Experimental|High Nitrogen|In this arm, daily nitrogen supply is as much as 2.5-3.0 g per kilogram (lean mass weight)
16676604|NCT02106624|Active Comparator|conventional nitrogen|In this arm, daily nitrogen supply is 1.2-1.5g per kilogram (lean mass weight) as recommended by ESPEN guideline
16676605|NCT02106611||Hodgkin Lymphoma Survivor|This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
16676606|NCT02106598|Experimental|Phase 2 - Head and Neck Cancer|Patients with early oral cavity squamous cell carcinoma, and prior to standard of care wide local resection of the primary tumor and elective neck dissection, will receive a locally-administered, peritumoral injection of fluorescent cRGDY-PEG-Cy5.5-C dots (0.25 - 1 ml) around the primary lesion while under standard-of-care anesthesia for identification of optically-avid SLNs and to assess for metastatic disease. After completion of the neck dissection, nodal specimens will be examined ex vivo for fluorescence signal. Any fluorescent and non-fluorescent nodes will be compared to determine the true positive and false positive rates for cancer detection in this pilot study. No change in standard of care surgical practice will occur.
16676607|NCT02106585|Experimental|Dose 1 JTT-251 or Placebo|Tablets, single dose in fed condition
16676608|NCT02106585|Experimental|Dose 2 JTT-251 or Placebo|Tablets, single dose in fed condition
16676609|NCT02106585|Experimental|Dose 3 JTT-251 or Placebo|Tablets, single dose in fed condition
16676610|NCT02106585|Experimental|Dose 4 JTT-251 or Placebo|Tablets, single dose in fed condition
16676611|NCT02106585|Experimental|Dose 5 JTT-251 or Placebo|Tablets, single dose in fed condition
16676612|NCT02106585|Experimental|Dose 6 JTT-251 or Placebo|Tablets, single dose in fed condition
16676613|NCT02106585|Experimental|Dose 7 JTT-251 or Placebo|Tablets, single dose in fed condition
16676614|NCT02106585|Experimental|Dose 8 JTT-251 or Placebo|Tablets, single dose in fed condition
16676615|NCT02106585|Experimental|Dose 9 JTT-251 or Placebo|Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
16676616|NCT02106572|Experimental|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
16676617|NCT02106572|Active Comparator|Mitomycin C|intravesical instillation of Mitomycin C
16676618|NCT02106559|Experimental|Treatment (surgery, porfimer sodium, PDT)|Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.
16676619|NCT02106546|Experimental|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
16676620|NCT02106546|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
16676621|NCT02106533|Experimental|Group 1 peak VO2 <17.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP.
16676622|NCT02106533|Experimental|Group 2 peak VO2 > 17.5 < 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
16676623|NCT02106533|Experimental|Group 3 peak VO2 > 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill . Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
16676624|NCT02106520|Experimental|Bevacizumab 25mg|Three administrations of 25 mg of Bevacizumab spaced of 14 days
16676625|NCT02106520|Experimental|Bevacizumab 50mg|Three administrations of 50 mg of Bevacizumab spaced of 14 days
16676626|NCT02106520|Experimental|Bevacizumab 75mg|Three administrations of 75 mg of Bevacizumab spaced of 14 days
16676627|NCT02106520|Placebo Comparator|Placebo|Three administrations of placebo spaced of 14 days
16676628|NCT02106507|Experimental|Progressive Metastatic Castration-Resistant Prostate Cancer|This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of apalutamide in combination with everolimus.
16676629|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
16676630|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
16676631|NCT02106481|Active Comparator|Femoral Nerve Catheters|Patients will receive a Single Shot Femoral Nerve Block along with a conventional continuous femoral nerve catheter
16676632|NCT02106481|Active Comparator|Single Shot Femoral Nerve Blocks|Patients will receive a Single Shot Femoral Nerve Block and a sham catheter post op.
16676633|NCT02106468|Active Comparator|prednisone 50 mg tablet|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
16676634|NCT02106468|Active Comparator|Omega-3 capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
16676635|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
16676636|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
16676637|NCT02106429||PAD and CLI patients|Subjects undergoing non emergent lower extremity revascularization
16676638|NCT02106416|Experimental|PET/MRI|Patient receives PET/MRI
16676639|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
16676640|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
16676641|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
16676642|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
16676643|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
16676644|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
16676645|NCT02106364|Experimental|LY2605541|LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator. Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician.
16676646|NCT02106364|Active Comparator|Insulin Glargine|Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician.
16676647|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
16676648|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
16676649|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).
~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
16676650|NCT02106338|Experimental|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
16676651|NCT02106338|Experimental|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
16676652|NCT02106338|Experimental|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
16676653|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
16676654|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
16676655|NCT02106312|Other|Radiation|Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.
16676656|NCT02106299|Experimental|Regen Sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen Sling (medprin).
16676657|NCT02106299|Active Comparator|tension-free vaginal tape-obturator|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
16676658|NCT02106286|Active Comparator|Bisoprolol|Patients not betablocked at baseline receive an acute 72hr dose of beta blocker therapy before CPET
16676659|NCT02106286|No Intervention|No Bisoprolol|No beta blocker given
16676660|NCT02106273||Bronchial blocker|Pilot study to enroll ASA class I-III patients age between 18-70 years who undergoes thoracic surgery which require one-lung ventilation.
16676661|NCT02106260|Experimental|CLS003|
16676665|NCT02106234|Active Comparator|Control: NO prophylactic iv hydration|"Control group:
~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed."
16676666|NCT02106234|No Intervention|Standard care: prophylactic iv hydration|"Standard care group:
~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will receive the standard intravenous prophylactic hydration treatment with normal saline as prescribed."
16676667|NCT02106221|Experimental|Intervention|Financial incentives will be provided based on performance in areas determined to be of high-value.
16676668|NCT02106221|Active Comparator|Control|Financial incentives are a flat rate which can be reduced if an appropriate amount of effort or improvement is not met
16676669|NCT02106208|Experimental|Cheese diet|A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
16676670|NCT02106208|Experimental|Butter diet|A 4-week experimental diet with all meals and foods be provided to participants, the diet will contain 13% of SFA mostly from butter. The diet will contain 14% of MUFA, 5% of PUFA and 53% of CHO.
16676671|NCT02106208|Experimental|CHO diet|A 4-week experimental diet with all meals and foods will provided to participants. The diet will contain 60% of CHO, 6% of SFA, 14% of MUFA and 5% of PUFA.
16676672|NCT02106208|Experimental|MUFA diet|A 4-week experimental diet with all meals and foods be provided to participants. The diet will contain 21% of MUFA, 6% of SFA, 5% of PUFA and 53% of CHO.
16676673|NCT02106208|Experimental|PUFA diet|A 4-week experimental diet with all meals and foods will be provided to participants. The diet will contain 12% of PUFA, 14% of MUFA, 6% of SFA and 53% of CHO.
16676674|NCT02106195|Experimental|Belumosudil 200 mg|Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
16676675|NCT02106182|Experimental|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
16676676|NCT02106169|Experimental|Therapeutic education group|"At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.
~The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours)."
16676677|NCT02106169|No Intervention|Control group|At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
16676678|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
16676679|NCT02106143|Experimental|RejuvenAir™ Radial Spray Cryotherapy|Subjects will receive Rejuvenair Radial SCT prior to lobectomy.
16676680|NCT02106130|Experimental|R - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
16676681|NCT02106130|Experimental|R+M - R|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
16676682|NCT02106130|Experimental|M - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
16676683|NCT02106130|Experimental|R+M - M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
16676684|NCT02106117||neutropenic patients|Patients receiving treatment for hematological malignancies expected to result in prolonged neutropenia (neutrophil counts <0.5 x 10 ^9/L for more than seven days).
16676685|NCT02106104|Experimental|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
16676686|NCT02106104|Active Comparator|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
16676687|NCT02106091|Experimental|AFM11|IV (intravenous) infusion, dose escalation
16676688|NCT02106078|Active Comparator|Level 1|Moderated discussion board only
16676689|NCT02106078|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
16676690|NCT02106078|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools
16676691|NCT02106065|Experimental|In-person Education and Skill-Building Rehabilitation (ESBR-i) Condition|Education and Skill-Building Rehabilitation delivered in clinic
16676692|NCT02106065|Experimental|Education and Skill-Building Rehabilitation over Video (ESBR-V) Condition|Education and Skill-Building Rehabilitation delivered via video telehealth.
16676693|NCT02106065|Active Comparator|Usual Care Condition|Usual Care plus supplemental paper education materials
16676694|NCT02106052|Active Comparator|Aerobic exercise|
16676695|NCT02106052|Other|Stretching and toning exercise|
16676696|NCT02106039|Experimental|intensive monitoring|more intensive monitoring strategy of blood glucose and clinical review
16676697|NCT02106039|No Intervention|standard monitoring|glucose monitoring followed the prevailing practice at each site
16676698|NCT02106026|No Intervention|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
16676699|NCT02106026|Experimental|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
16681632|NCT02073084|Other|Sequence D|Sequence D
16676700|NCT02106013||Low HDL-C|Study participants with HDL-C levels below the 10th percentile (HDL-C ≤32 mg/dL)
16676701|NCT02106013||Intermediate HDL-C|Study participants with HDL-C levels between 40th and 60th percentiles (40≤HDL-C≤67 mg/dL)
16676702|NCT02106013||High HDL-C|Study participants with HDL-C levels above the 90th percentile (HDL-C ≥78mg/dL)
16676703|NCT02106000||Arm 1: Non-pregnant females|Inhalation profiles will be recorded for non-pregnant females
16676704|NCT02106000||Arm 2: Pregnant females|Inhalation profiles will be recorded for the women in the 3rd stage of labour
16676705|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
16676706|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
16676707|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
16676708|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
16676709|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
16676710|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
16676711|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
16676712|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
16676713|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
16676714|NCT02105935||Normative study|male and female athletes, ages 8-14.
16676715|NCT02105935||Baseline|male and female athletes, ages 8-18.
16676716|NCT02105922|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
16676717|NCT02105922|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
16676718|NCT02105922|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
16676719|NCT02105909|Experimental|obese subjects|DNA analysis
16676720|NCT02105909|Placebo Comparator|lean subjects|DNA analysis
16676721|NCT02105883|No Intervention|Scenario C (control)|no badge
16676722|NCT02105883|Active Comparator|Scenario B (badge)|Use of Identification badge during scenarios (roles and places)
16676723|NCT02105870|Experimental|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
16676724|NCT02105870|Placebo Comparator|Control group|Intracoronary Reopro
16676725|NCT02105857|No Intervention|Standard care|Patients receiving the standard rehabilitation protocol
16676726|NCT02105857|Experimental|grade A+ knee mobilization|Patients receiving the standard rehabilitation protocol plus grade A+ knee mobilization
16676727|NCT02105844||Atrial Fibrillation|Cohort Study on patients with atrial fibrillation in Switzerland
16676728|NCT02105831||CEU skeletal muscle perfusion imaging|Heart failure with LVAD Contrast ultrasound skeletal muscle perfusion imaging
16676729|NCT02105818||Systemic sclerosis|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).
16676730|NCT02105805|Experimental|low energy diet|low energy diet treatment
16676731|NCT02105805|Active Comparator|Nordic recommendation|Nordic recommendation, no restrictions on energy
16676732|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
16676733|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment >10 years from diagnosis.
16676734|NCT02105779|Experimental|Targeted Cognitive Training|40 hours of BFP auditory training
16676735|NCT02105779|Experimental|Social Cognitive Training|40 hours of auditory training and 10 hours social exercises
16676736|NCT02105766|Experimental|male donor - female recipient|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody)
16676737|NCT02105766|Experimental|patients with preexisting antibodies|patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort. It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
16676738|NCT02105753|Experimental|1210nm axillary laser treatments|two laser treatments right axilla and one treatment left axilla
16676739|NCT02105753|Experimental|1210nm laser treatments to the axilla|two laser treatments left axilla and one treatment right axilla
16676740|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
16676741|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
16676742|NCT02105727|Experimental|Salt reduction|Community-based salt reduction
16682035|NCT02070354||Group 3|6 months after bariatric surgery
16676743|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
16676744|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
16676745|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
16676746|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
16676747|NCT02105688|Experimental|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
16676748|NCT02105688|Placebo Comparator|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
16676749|NCT02105675|Experimental|DCVAC/PCa add on to Standard of Care|Combination therapy with Dendritic Cells DCVAC/PCa and Standard of Care
16676750|NCT02105675|Active Comparator|Standard of Care|Docetaxel as an Active Comparator
16676751|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
16676752|NCT02105649|Experimental|calf muscle strengthenig group|"experimental group
~will receive the same selected physical therapy program in addition to manual and mechanical strengthening exercises and electrical stimulation program for calf muscles of both lower limbs."
16676753|NCT02105649|Other|No calf muscle strengthening group|"control group
~will receive only the selected physical therapy program"
16676754|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
16676755|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression
~OR
~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression
~OR
~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
16676756|NCT02105623|Active Comparator|Standard Therapy|Risk factor control Diet Exercise
16676757|NCT02105623|Experimental|Rosuvastatin therapy|Risk factor control Rosuvastatin
16676758|NCT02105610|Experimental|volatile anesthetics (desflurane, isoflurane, sevoflurane)|
16676759|NCT02105610|Active Comparator|total intravenous anesthesia|
16676760|NCT02105597|Experimental|Mobile application|
16676761|NCT02105597|No Intervention|Standard care|
16676762|NCT02105584|Experimental|LAA closure device|Implantation of LAA closure device
16676763|NCT02105571|Experimental|Intervention|Intervention activities take place over a 6-month period for each participant, and include a weight loss competition with self-monitoring and feedback; computer-based training units on healthy weight loss, healthy eating, exercise, and sleep; and up to four motivational interviews with a health coach by cell phone.
16676764|NCT02105571|No Intervention|Control|"Continued work conditions and Usual Practices in that workplace"
16676765|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
16676766|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
16676767|NCT02105545|Experimental|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
16676768|NCT02105532|Active Comparator|Restrictive Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
16676769|NCT02105532|Active Comparator|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
16676770|NCT02105519|No Intervention|The group receiving no influenza vaccine|Participants in this group will not receive any influenza vaccine (negative control group).
16676771|NCT02105519|Experimental|One dose of AdimFlu-S group|Participants in this group will receive one dose of the seasonal trivalent influenza vaccine (one dose of AdimFlu-S group), formulation 2013-2014, at the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
16676821|NCT02105246|Experimental|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
16677449|NCT02100956|Experimental|oxytocin|oxytocin 100 micrograms administered intrathecally (IT)
16676772|NCT02105519|Experimental|Two dose of AdimFlu-S group|Participants in this group (Two dose of AdimFlu-S group)will receive the seasonal trivalent influenza vaccine, formulation 2013-2014, at the week 0 and 4 weeks after the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
16676773|NCT02105506|Experimental|Tachosil patch|Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
16676774|NCT02105493|Active Comparator|500 microgram of Nitroglycerin|500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure
16676775|NCT02105493|Placebo Comparator|Saline 5 mL|0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure
16676776|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
16676777|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
16676778|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
16676779|NCT02105441||cochlear implant|How well patients with cochlear implants understand speech in noise with implant on, compared to implant off.
16676780|NCT02105428|No Intervention|Sedentary Control|Participants will be randomized to an exercise training program or sedentary control group. The sedentary will not perform any structured physical activity or exercise. Participants will be encouraged to maintain their sedentary lifestyle and will be monitored by an accelerometer to track physical activity.
16676781|NCT02105428|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of aerobic exercise training
16676782|NCT02105415|Active Comparator|Etomidate|weight based dose of 0.15mg/kg
16676783|NCT02105415|Experimental|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
16676784|NCT02105402|Experimental|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
16676785|NCT02105402|No Intervention|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
16676786|NCT02105389|Experimental|Individualized Yoga Intervention|Individualized Yoga Intervention sessions will be administered by a trained yoga instructor three times weekly (or up to a maximum of five times per week) for three consecutive weeks. There will be a common structure for all sessions that will include relaxation and breathing exercises as well as a series of poses focused on strengthening, flexibility, and balance. There will be low, moderate and high intensity regimens prescribed depending on the wishes and abilities of the child and parent and the judgment of the yoga instructor.
16676787|NCT02105376|Experimental|Trigeminal Nerve Stimulation (TNS)|"TNS active group
~TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally."
16676788|NCT02105376|Placebo Comparator|Sham|"TNS sham
~The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia."
16676789|NCT02105363||Age 11-15|
16676790|NCT02105363||Age 16-20|
16676791|NCT02105363||Age 21-25|
16676792|NCT02105363||Age 26-30|
16676793|NCT02105363||Age 31-35|
16676794|NCT02105363||Age 36-40|
16676795|NCT02105363||Age 41-45|
16676796|NCT02105363||Age 46-50|
16676797|NCT02105363||Age 51-55|
16676798|NCT02105363||Age 56-60|
16676799|NCT02105363||age 61-65|
16676800|NCT02105363||Age 66-70|
16676801|NCT02105363||Age 71-75|
16676802|NCT02105363||Age 76-80|
16676803|NCT02105363||Age 81-85|
16676804|NCT02105363||Age 86-90|
16676805|NCT02105363||Age 91-95|
16676806|NCT02105363||Age 96-100|
16676807|NCT02105363||Age 0-5|
16676808|NCT02105363||Age 6-10|
16676809|NCT02105350|Experimental|MEK 162, gemcitabine, and oxaliplatin|MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
16676810|NCT02105337||tegaderm placement|all pts will have tegaderm placed prior to goggles for VEP
16676811|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
16676812|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
16676813|NCT02105311|Experimental|Selective laser trabeculoplasty|Treating with the selective laser trabeculoplasty
16676814|NCT02105311|Active Comparator|Travoprost|Using eye drop: travoprost
16676815|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
16676816|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
16676817|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
16676818|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
16676819|NCT02105259|Experimental|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for social anxiety disorder during 10 weeks and guided by a psychologist
16676820|NCT02105259|Active Comparator|Waiting list with support|Behavioral: supportive check-ups via the Internet during 10 weeks
16676822|NCT02105246|Active Comparator|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
16676823|NCT02105233|Experimental|BMG|brain mimicking fluid
16676824|NCT02105220||Obese|"We will enroll patients with BMI≥40 kg/m2 to describe the impact of obesity on chest wall compliance and respiratory mechanics.
~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
16676825|NCT02105220||Intraabdominal Hypertension|"We will enroll patients with IAP≥12 mmHg to describe the impact of intraabdominal hypertension on chest wall compliance and respiratory mechanics.
~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
16676826|NCT02105207|Experimental|Lung Ultrasound|In Patients allocated to this arm Lung ultrasound for detection of interstitial syndrome will be performed before chest radiography.
16676827|NCT02105207|Experimental|Chest Radiography|In Patients allocated to this arm chest radiography will be performed for the detection of indirect signs of pulmonary congestion/ADHF without ultrasound evaluation.
16676828|NCT02105194|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
16676829|NCT02105181|Other|Fully covered metal stent (FCMS)|There is one arm in the study : the intervention consists on placing a device which is a fully covered metal stent in the biliary tract of all patients
16676830|NCT02105168|Experimental|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
16676831|NCT02105155|Experimental|Conversion at day 7 ± 3|Conversion from Prograf to Advagraf at D7 ± 3
16676832|NCT02105155|Active Comparator|Conversion at day 90±5|Conversion from Prograf to Advagraf at 90±5
16676833|NCT02105142|Active Comparator|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
16676834|NCT02105142|Active Comparator|ADHD Group visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
16676835|NCT02105142|Active Comparator|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Online discussion portal access granted to parent participants and will allow parents to communicate with each other in between in-person group visits
16676836|NCT02105129|Experimental|HMPL-523|Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A
16676837|NCT02105129|Placebo Comparator|Placebo|Placebo: oral administration
16676838|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
16676839|NCT02105103|Other|Accu-Chek® Insight Insulin Pump|
16676840|NCT02105090|Placebo Comparator|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
16676841|NCT02105090|Experimental|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
16676842|NCT02105090|Experimental|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
16676843|NCT02105077||Xenon|Patients undergoing surgery with xenon-based general anesthesia
16676844|NCT02105064|Active Comparator|Active rTMS|rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions.
16676845|NCT02105064|Sham Comparator|Sham|Sham stimulation, 20 minutes per session, total 20 sessions
16676846|NCT02105038|Experimental|Knob|Steering in a driving simulator using a steering wheel spinner knob.
16676847|NCT02105038|Active Comparator|No Knob|Steering in a driving simulator immediately following surgical treatment of hip fractures.
16676848|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
16676849|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
16676850|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
16676851|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
16676852|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
16676853|NCT02104999|Other|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
16676854|NCT02104986|Experimental|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
16676855|NCT02104986|Experimental|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
16676856|NCT02104986|Experimental|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
16676857|NCT02104986|Experimental|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
16676885|NCT02104791||plasma of blood|-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
16676960|NCT02104440|Experimental|Patients with cytopenia after allo-HSCT|Patients with cytopenia after allo-HSCT
16677029|NCT02103881|Experimental|Ketamine|Patients enrolled in this arm will be given 500 mg of intramuscular ketamine for their severe agitation they experience in the prehospital environment.
16676858|NCT02104973|Experimental|Lifestyle counseling|After obtaining the approval of schools and parents, will be established in schools, units in which individual attention is given to children, parents and teachers that request: the advice is aimed at training users on healthy diet and constant physical activity. Workshops with children, in which selected topics will be discussed based on the analysis of depth interviews with children, parents and teachers, and information on habits and resources gathered through questionnaires will be conducted. The intervention included the provision of information and feedback with the population through a website. The work will include participation in the selection of foods sold in schools.
16676859|NCT02104973|No Intervention|Control|Usual care
16676860|NCT02104960||PROOF|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date. (NCT00759304)
16676861|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
16676862|NCT02104934|No Intervention|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
16676863|NCT02104934|Active Comparator|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
16676864|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
16676865|NCT02104921||Healthy volunteers|
16676866|NCT02104908|Experimental|paravertebral nerve|Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)
16676867|NCT02104908|Other|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
16676868|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
16676869|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
16676870|NCT02104882|Experimental|Intraoperative Radiotherapy|Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.
16676871|NCT02104869|Active Comparator|Recommended dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: single 0.5 mL dose."
16676872|NCT02104869|Active Comparator|Healthy adults|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: single 0.5 mL dose."
16676873|NCT02104869|Experimental|Single double dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: single 1.0 mL dose."
16676874|NCT02104869|Experimental|Two sequential doses (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: two 0.5 mL doses 21 days apart."
16676875|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
16676876|NCT02104843|Experimental|Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin|"Treatment A: Rosuvastatin tablet orally on specified days
~Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days
~Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
16676877|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
16676878|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
16676879|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
16676880|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
16676881|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
16676882|NCT02104804|Experimental|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
16676883|NCT02104804|Placebo Comparator|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
16676884|NCT02104791||procalcitonin in blood|-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
16676886|NCT02104791||procalcitonin,prematureruptureofmembrane in blood|"Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).
~Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.
~The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.
~They will be asked for their permission and consent."
16676887|NCT02104778|Experimental|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
16676888|NCT02104778|Placebo Comparator|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
16676889|NCT02104778|Experimental|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
16676890|NCT02104765|Experimental|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
16676891|NCT02104765|Experimental|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
16676892|NCT02104765|Experimental|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
16676893|NCT02104765|Experimental|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
16676894|NCT02104765|Experimental|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
16676895|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
16676896|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
16676897|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
16676898|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
16676899|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
16676900|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
16676901|NCT02104739|Placebo Comparator|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
16676902|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
16676903|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
16676904|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
16676905|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
16676906|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
16676907|NCT02104739|Experimental|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
16676908|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
16676909|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
16676910|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
16676911|NCT02104726|Active Comparator|Blind Steroid Injection|Blind Steroid Injection for patients with OA deemed qualified for it clinically
16676912|NCT02104726|Active Comparator|Fluoroscopy guided steroid injection|Fluoroscopy guided Steroid Injection for patients with OA deemed qualified for it clinically. We want to see which one is better.
16676913|NCT02104713|Experimental|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.
~Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
16676914|NCT02104700|Active Comparator|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
16676915|NCT02104700|Active Comparator|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
16676957|NCT02104453|Experimental|E-C clamp mask holding technique|"the airway maneuver that press the mask against the patient's face (using the C of our thumb and forefinger) while pulling the jaw forward (using the E of our other fingers behind the mandible), and leaves one hand free to squeeze the bag."
16676958|NCT02104453|Experimental|two-handed ventilation with jaw thrust|the airway maneuver performed with thumbs point toward feet, palms press down and other fingers perform jaw thrust
16682036|NCT02070354||Group 4|12 months after bariatric surgery
16676916|NCT02104687|Active Comparator|Flow|The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value >2.5 l/m/m2 (FTc - flow time <330 ms was chosen as variable defining preload; PV, peak velocity <70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
16676917|NCT02104687|Active Comparator|Press|The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
16676918|NCT02104674|Placebo Comparator|Placebo|
16676919|NCT02104674|Active Comparator|Singulair (montelukast)|
16676920|NCT02104674|Experimental|lebrikizumab|
16676921|NCT02104661|Experimental|OxCarbazepine Treatment|Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
16676922|NCT02104661|Placebo Comparator|OxCarbazepine Placebo|Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
16676923|NCT02104648|Placebo Comparator|Part A: Placebo|
16676924|NCT02104648|Experimental|Part A: RO4602522|
16676925|NCT02104648|Experimental|Part B: RO4602522 Multiple Doses|
16676926|NCT02104648|Experimental|Part B: RO4602522 Single Dose|
16676927|NCT02104648|Experimental|Part B: moxifloxacin Single Dose|
16676928|NCT02104635|No Intervention|Control group|The control group receives standard of care from Jacaranda clinic and does not receive any additional post-partum check-in from a community health worker.
16676929|NCT02104635|Experimental|CHW-Visit|The CHW-Visit group will receive a visit at their home from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
16676930|NCT02104635|Experimental|CHW-Phone|The CHW-Visit group will receive a phone call from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
16676931|NCT02104622|Experimental|ReWalk training|
16676932|NCT02104609||Normal weight women|Levonorgestrel 1.5mg by mouth once
16676933|NCT02104609||Obese women|Levonorgestrel 1.5mg by mouth once
16676934|NCT02104609||Extremely obese women|Levonorgestrel 1.5mg by mouth once
16676935|NCT02104596|Experimental|Xylitol injection|Intraarticular injection of Xylitol
16676936|NCT02104596|Placebo Comparator|Control|
16676937|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
16676938|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
16676939|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
16676940|NCT02104570|Other|Control|In this session, participants will be evaluated before and after a muscle fatigue protocol, with no intervention.
16676941|NCT02104570|Experimental|Kinesio taping with tension|A kinesio taping technique for the deltoid muscle will be applied before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
16676942|NCT02104570|Sham Comparator|Kinesio taping without tension|A kinesio taping technique will be applied on the deltoid muscle without tension (tension is considered to be the therapeutic effect) before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
16676943|NCT02104557||prevention of pregnancy|Non intervention
16676944|NCT02104557||management of endometriosis-associated pain|Non intervention
16676945|NCT02104531||Shoulder Pain|No intervention. Subjects will have a standard static MRI taken of their shoulder, and also complete a series of shoulder motions using video fluoroscopy.
16676946|NCT02104531||Healthy Subjects|No intervention. Subjects will receive a standard shoulder MRI and perform shoulder motions while being measured with video fluoroscopy.
16676947|NCT02104518||G6PD testing|Blood samples will be tested for G6PD activity levels
16676948|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
16676949|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
16676950|NCT02104492|Experimental|Intervention group|a 12-week respiratory muscles training program (RMTP) with ORYGEN Dual® device and peripheric resistive muscle training program
16676951|NCT02104492|Active Comparator|Control Group|Peripheric resistive muscle training program and Health Education Program.
16676952|NCT02104479||Immunocompromised Patients|Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population
16676953|NCT02104479||Control Group|Patients without Immunosuppression with pleural effusions
16676954|NCT02104466|No Intervention|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
16676955|NCT02104466|Experimental|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
16676956|NCT02104466|Experimental|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
16676959|NCT02104453|Experimental|triple airway maneuver|the airway maneuver performed with two-handed mask ventilation, jaw thrust and head-tilt chin-lift technique
16682037|NCT02070354||Group 5|24 months after bariatric surgery
16676961|NCT02104427|Experimental|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
16676962|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
16676963|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
16676964|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
16676965|NCT02104401|Experimental|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
16676966|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
16676967|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
16676968|NCT02104375|Experimental|L-citrulline|L-citrulline (6 g/day for 2 weeks)
16676969|NCT02104375|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
16676970|NCT02104362|Other|exclusive single-fraction irradiation|
16676971|NCT02104349|Experimental|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
16676972|NCT02104349|No Intervention|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
16676973|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
16676974|NCT02104323|Experimental|Endostatin，treatment effect evaluation|Patients receive continuous intravenous Endostatin drug pumping during the course of treatment. The drug dosage is 7.5mg/m2/d. Every course of treatment lasts three months. Patients are designed to receive total three courses of treatment if there is no disease progression. The interval between two courses is one month.
16676975|NCT02104310|Experimental|Fluorine-18-L-dihydroxyphenylalanine|18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure
16676976|NCT02104297|Active Comparator|Deksmedetomidine infusion|To prevent agitation deksmedetomidine infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
16676977|NCT02104297|Experimental|Remifentanil infusion|To prevent agitation remifentanil infused during operation at the end of surgery agitation scor measured by Riker sedation agitation scale.
16676978|NCT02104297|Placebo Comparator|Saline infusion|Saline infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
16676979|NCT02104284|Other|Normal controls, methacholine positive|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls
16676980|NCT02104284|Other|Normal controls, mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.
16676981|NCT02104284|Active Comparator|Asthma, Methacholine|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics
16676982|NCT02104284|Active Comparator|Asthma, Mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics
16676983|NCT02104271|Experimental|Argon Plasma Coagulation|"Argon Plasma Coagulation (APC) treatment will be delivered using a spray-painting technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
16676984|NCT02104271|Active Comparator|Historical control|"Argon Plasma Coagulation (APC) treatment was delivered using a spray-painting technique, with short applications at 40-50W power and argon gas flow of 2.0 - 2.5 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
16676985|NCT02104258|Active Comparator|Physiotherapy ASPETAR|"The patients will follow the ASPETAR Hamstring Rehabilitation Protocol, which is a standardised physiotherapy protocol, including range of motion exercises, progressive strengthening exercises, core stability training and agility exercises [10].
~The ASPETAR protocol consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.
~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
16676986|NCT02104258|Active Comparator|Physiotherapy ASPETAR+|"The patients will follow the ASPETAR+ Hamstring Rehabilitation Protocol. ASPETAR+ is similar to ASPETAR, but consists of additional lengthening exercises which will be initiated early in the rehabilitation phase.
~ASPETAR+ consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.
~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
16676987|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
16676988|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
16677099|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative dialysis cohort|4 placebo IM injections
16676989|NCT02104232|Experimental|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
16676990|NCT02104232|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
16676991|NCT02104193|Experimental|simvastatin|they will receive simvastatin in addition to radiation therapy
16676992|NCT02104193|Active Comparator|control|they will receive radiation therapy only
16676993|NCT02104180|Active Comparator|TulleGras M.S.|
16676994|NCT02104180|Active Comparator|Urgotul|
16676995|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
16676996|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
16676997|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
16676998|NCT02104128|Experimental|Depressed patient given bupropion|All depressed patients will be given open label bupropion
16676999|NCT02104128|No Intervention|Control pts given no intervention|Control participants will be assessed at the same time points as the depressed group, but will be given no drug
16677000|NCT02104115|Other|Gluten free white bread|Sliced loaf of gluten free white bread
16677001|NCT02104115|Other|Normal gluten content white wheat bread|Sliced loaf of normal gluten content white wheat bread
16677002|NCT02104115|Other|High gluten content white wheat bread|Sliced loaf of high gluten content white wheat bread
16677003|NCT02104102|Experimental|Mirror group|Composed of 30 volunteers who carry out the mirror therapy, whose name shall Mirror Group (MG).
16677004|NCT02104102|Experimental|Control Group - kinesiotherapy|Called by Control Group (CG), composed of 30 volunteers who will carry out the kinesiotherapy with the same sequence of movements for the Mirror Therapy that the MG, but without the view in the mirror, since it will be blocked.
16677005|NCT02104089||Endovascular treatment|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
16677006|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
16677007|NCT02104063||MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
16677008|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
16677009|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
16677010|NCT02104037|Experimental|Liraglutide treated patients|
16677011|NCT02104024||Kidney transplant recipients|CEUS in Kidney Transplant recipients
16677012|NCT02104024||Pancreas transplant recipients|CEUS in pancreas transplant recipients
16677013|NCT02104011|Experimental|Patient|
16677014|NCT02103998|Experimental|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
16677015|NCT02103998|Placebo Comparator|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
16677016|NCT02103985|Experimental|Treatment A|Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition.
16677017|NCT02103985|Experimental|Treatment B|Participants will receive 100 mg JNJ-39823277 under fasted condition.
16677018|NCT02103972|Placebo Comparator|Maltodextrin|Maltodextrin
16677019|NCT02103972|Active Comparator|GM080|GM080
16677020|NCT02103959|Experimental|CMX-2043 2.4 mg/Kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
16677021|NCT02103959|Experimental|CMX-2043 3.6 mg/kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
16677022|NCT02103959|Experimental|CMX-2043 2.4 mg/kg given twice|Bolus injection of investigational product given prior to the cardiac catheterization and again 24 hours after the first dose.
16677023|NCT02103959|Placebo Comparator|Placebo comparator|Placebo comparator (PBS) given prior to cardiac catheterization and again 24 hours after the first dose.
16677024|NCT02103946|Active Comparator|Serratus anterior muscle plane block|Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
16677025|NCT02103946|Active Comparator|Paravertebral block|Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
16677026|NCT02103907|No Intervention|Wait list|Wait list control group. Participants will be placed on the wait list and asked to maintain their current routine and level of activity during the 10 week period. Control group participants will receive the dynamic balance training program in a single training session after the followup (second testing session at 10 weeks).
16677027|NCT02103907|Experimental|Treatment (balance training)|Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
16677028|NCT02103894|Experimental|[18F]T807 ([18F]MNI-777)|At the [18F]MNI-777 PET imaging visit, subjects will be injected with no more than 10 mCi (370 MBq) of [18F]MNI-777).
16677140|NCT02103166|Placebo Comparator|Physiological serum|100 ml of physiological serum (0.9% NaCl).
16677030|NCT02103881|Experimental|Haloperidol|Patients enrolled in this arm will be given 10 mg of intramuscular haloperidol for their severe agitation they experience in the prehospital environment.
16677031|NCT02103868|No Intervention|Control|No active intervention will be given for tobacco cessation.
16677032|NCT02103868|Experimental|Medium Intervention|Tobacco Cessation Counseling : Medium intervention in the form of 3 contact sessions will be given for tobacco cessation.
16677033|NCT02103868|Experimental|Low intensity intervention|Tobacco Cessation Counseling: Only a single contact session will be done for tobacco cessation.
16677034|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.
~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
16677035|NCT02103842|Experimental|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
16677036|NCT02103829|Active Comparator|Condition #1|Condition #1 will consist of Brief Intervention #1, a brief online suggestion that takes less than 1 minute to complete.
16677037|NCT02103829|Experimental|Condition #2|Condition #2 will consist of Brief Intervention #1 and Brief Intervention #2 that together take less than a minute to complete.
16677038|NCT02103829|Experimental|Condition #3|Condition #3 will consist of Brief Intervention #1 and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
16677039|NCT02103829|Experimental|Condition #4|Condition #4 will consist of Brief Intervention #1, Brief Intervention #2, and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
16677040|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
16677041|NCT02103790|Experimental|Home NIV installation|
16677042|NCT02103777|Active Comparator|High dose caffeine|High dose (loading 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base)
16677043|NCT02103777|Active Comparator|Low dose caffeine|Low dose (loading 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base and maintenance of 10 mg/kg/day equivalent to 5 mg /kg/day of caffeine base) caffeine.
16677044|NCT02103764|Experimental|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
16677045|NCT02103764|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
16677046|NCT02103738||Arm 1 (Monthly)|0.5 mg intravitreal injections of Ranibizumab monthly for the duration of the study.
16677047|NCT02103738||Arm 2 (Treat and Extend)|Three consecutive months of 0.5 mg Ranibizumab intravitreal injections (Day 1, Month 1, and Month 2). Monthly injections will continue until evidence of disease stability is observed. Specifically, monthly treatment will continue until visual acuity is deemed stable as indicated by a gain in visual acuity of ≤ 3 ETDRS letters from the prior month, no clinical evidence of lesion growth, fluid or blood, and no intraretinal or subretinal fluid on OCT. When this is achieved, the intervals between each subsequent injection will be extended by 2 weeks (intervals of 6 weeks, 8 weeks, 10 weeks, to a maximum of 12 weeks) until clinical or diagnostic evidence of disease instability is observed based on OCT findings and/or BCVA ETDRS.
16677048|NCT02103725|Experimental|pimecrolimus 10 mg/g cream|Active drug
16677049|NCT02103725|Placebo Comparator|Vehicle cream|Placebo drug
16677050|NCT02103712||Hypospadias|
16677051|NCT02103699||Hepatitis C virus infected patients receiving simeprevir|
16677052|NCT02103686|Active Comparator|Immediate release capsule|Immediate release capsule treatment under fasted condition
16677053|NCT02103686|Experimental|sustained release tablet|sustained release tablet treatment under fasted condition
16677054|NCT02103686|Experimental|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
16677055|NCT02103673|Experimental|DAOIB|Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks
16677056|NCT02103673|Placebo Comparator|Placebo|Placebo by mouth per day for 6 weeks
16677057|NCT02103660|Active Comparator|Depo-Medroxyprogesterone Acetate|Half of women will be randomized to receive Depo-Medroxyprogesterone Acetate injections every 13 weeks
16677058|NCT02103660|Active Comparator|Progestin Implant (Jadelle)|Half of women will be randomized to receive progestin implant.
16677059|NCT02103647|Active Comparator|Immediate release capsule(lyrica capsule 150mg)|Immediate release capsule repeat treatment for 3days under fasted condition
16677060|NCT02103647|Experimental|sustained release tablet|sustained release tablet repeat treatment for 3days under fasted condition
16677061|NCT02103634||Lesion Imaging|Image patients with the standard of care of a FDG PET/CT and the experimental method of the NaF PET/MRI and compare the number of images found within and between patients to determine the most effective way of looking at breast cancers metastasized to bone
16677062|NCT02103621|Experimental|Unifed Protocol (UP) for Discontinuation|Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
16677063|NCT02103621|Active Comparator|Taper and Monitoring (TAP-M)|Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter. TAP-M consists of assessment and monitoring. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
16677064|NCT02103608|Experimental|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
16677065|NCT02103595|Other|Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink|
16677066|NCT02103595|Other|Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus|
16677067|NCT02103582|Placebo Comparator|control|Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
16677068|NCT02103582|Experimental|intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
16677069|NCT02103569|Experimental|Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325|"Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days
~Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
16677070|NCT02103556|Active Comparator|Mineral oil|4ml daily (adjusted as needed), for 4 weeks
16677071|NCT02103556|Active Comparator|Olive oil|4ml daily (adjusted as needed), for 4 weeks
16677072|NCT02103556|Active Comparator|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
16677073|NCT02103543|Active Comparator|Physical Therapy first|patients will undergo physical therapy 3-4 sessions followed by lumbar interlaminar epidural steroid injection
16677074|NCT02103543|Active Comparator|lumbar epidural steroid first|lumbar interlaminar epidural steroid injection followed by patients will undergo physical therapy 3-4 sessions
16677075|NCT02103530|Experimental|FLT PET/CT|Patients who had FLT PET/CT
16677076|NCT02103517|Experimental|Omega-3 fatty acid capsules|Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
16677077|NCT02103517|Placebo Comparator|corn oil|Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.
16677078|NCT02103504|Other|DePuy Attune TKA|DePuy Attune posterior stabilized fixed bearing total knee replacement
16677079|NCT02103491|Active Comparator|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol).
16677080|NCT02103491|Placebo Comparator|Placebo administration|In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose).
16677081|NCT02103478|Experimental|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
16677082|NCT02103478|Experimental|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
16677083|NCT02103478|Experimental|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
16677084|NCT02103465|Experimental|Rotigotine|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
16677085|NCT02103465|Placebo Comparator|Placebo|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
16677086|NCT02103452|Experimental|ovarian endometrioma|Ovarian and endometrial samples
16677087|NCT02103452|Experimental|normal ovary|Ovarian and endometrial samples
16677088|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
16677089|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
16677090|NCT02103426|Experimental|Part 1: ASP0113 CMV-seropositive healthy cohort|5 mg single dose IM injection
16677091|NCT02103426|Experimental|Part 1: ASP0113 CMV-seronegative healthy cohort|5 mg single dose IM injection
16677092|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seropositive healthy cohort|single dose IM injection
16677093|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seronegative healthy cohort|single dose IM injection
16677094|NCT02103426|Experimental|Part 2: ASP0113 CMV-seropositive healthy cohort|4 IM injections of ASP0113
16677095|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative healthy cohort|4 IM injections of ASP0113
16677096|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative dialysis cohort|4 IM injections of ASP0113
16677097|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seropositive healthy cohort|4 placebo IM injections
16677098|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative healthy cohort|4 placebo IM injections
16677100|NCT02103413|Experimental|EUS-BD|EUS-BD using a fully or partially covered self-expanding metallic stent will be performed by EUS guided 19 G needle puncture.
16677101|NCT02103413|Experimental|PTBD|PTBD with 8.5F catheter will be inserted under fluoroscopic and/or ultrasonography guidance by experienced interventional radiologists.
16677102|NCT02103400|Experimental|Experimental group|Patients hospitalized for community-acquired pneumonia
16677103|NCT02103400|Active Comparator|Control group|Patients hospitalized for community-acquired pneumonia
16677104|NCT02103387|Experimental|Cognitive Behavioral Training|Cognitive Behavioral Training 5 weekly 1.5-hour sessions of group-based cognitive behavioral training
16677105|NCT02103387|Experimental|Relaxation Training|Relaxation Training 5 weekly 1.5-hour sessions of group-based relaxation training
16677106|NCT02103387|Active Comparator|Health Education Control|Health Education Control 5 weekly 1.5 sessions of group-based health education training
16677107|NCT02103374|Experimental|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
16677108|NCT02103374|Placebo Comparator|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
16677109|NCT02103361||Stelara (ustekinumab) exposed|Stelara (ustekinumab)-exposed pregnant women
16677110|NCT02103361||Tremfya (guselkumab) exposed|Tremfya (guselkumab-exposed pregnant women
16677111|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
16677112|NCT02103348||Severe Asthma|"Major Criteria: (1 required)
~Treatment with oral corticosteroids for at least 6 of the previous 12 months
~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months
~Minor Criteria: (2 required)
~Daily treatment with an asthma controller medication in addition to inhaled, or
~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or
~Persistent airway obstruction with baseline FEV1 <80% predicted, or
~≥ 1 urgent visits for asthma in the previous 12 months, or
~≥ 3 systemic corticosteroid bursts in the previous 12 months, or
~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or
~A near-fatal asthma event (i.e., intubation) in the past."
16677113|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
16677114|NCT02103335|Experimental|Single Group Assignment|Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
16677115|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
16677116|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
16677117|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
16677118|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
16677119|NCT02103296|Active Comparator|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
16677120|NCT02103296|Experimental|Cord Blood|Admission labs to be drawn from the infant's cord blood
16677121|NCT02103283|Experimental|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
16677122|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
16677123|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
16677124|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
16677125|NCT02103257|Experimental|Sequential icotinib plus chemotherapy|Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
16677126|NCT02103257|Active Comparator|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
16677127|NCT02103244|Experimental|carboplatin|An adjusted dosing algorithm will be applied to calculate the dose of carboplatin. in 24 patients blood will be obtained in order to determine the pharmacokinetics of carboplatin after adjusted dosing
16677128|NCT02103231||Full Term Birth|History of full term birth (>37 weeks gestation) including sub-group with diagnosis of hypertension
16677129|NCT02103231||Preterm Birth|History of preterm birth (<37 weeks gestation) including subgroup with diagnosis of hypertension
16677130|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
16677131|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
16677132|NCT02103205|Active Comparator|Low iron, with lactoferrin|Low iron, with lactoferrin
16677133|NCT02103205|Active Comparator|Low iron, no lactoferrin|Low iron, no lactoferrin
16677134|NCT02103205|Placebo Comparator|Normal iron, no lactoferrin|Normal iron, no lactoferrin
16677135|NCT02103192|Experimental|Control plus low level nutrient fortification|Control plus low level nutrient fortification
16677136|NCT02103192|Experimental|Control plus increasing level nutrient fortification|Control plus increasing level nutrient fortification
16677137|NCT02103192|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
16677138|NCT02103179||ECC patients|Extrahepatic cholangiocarcinoma patients treated by surgical treatment
16677139|NCT02103166|Experimental|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
16677142|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
16677143|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
16677144|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
16677145|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
16677146|NCT02103114|Experimental|Anti-thrombin III|
16677147|NCT02103114|Placebo Comparator|Placebo|
16677148|NCT02103101|Other|Study cohort|"Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp
~All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated."
16677149|NCT02103088|Experimental|Sexual and urological intervention|Standard care and the PROCAN intervention consisting of i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
16677150|NCT02103088|No Intervention|Control|Standard care consists of:systematic offer of medical treatment for erectile dysfunction, if not contra indicated. The medical treatment will consist of either daily treatment with Cialis 5 mg or phosphodiesterase type 5 inhibitor on demand before sexual activity. Alternatively use of alprostadil as either urethral pin or penile injection. Furthermore standard treatments include preoperative instruction in pelvic floor muscle training, regular outpatient visits and possible referral to rehabilitation in accordance with the rules that apply to the Danish Health legislations. In case of prolonged incontinence the patients may on request be referred to a private practicing physiotherapist.
16677151|NCT02103075|Experimental|The SCA|
16677152|NCT02103075|Experimental|The age-matched control|
16677153|NCT02103075|Experimental|The young control|
16677154|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
16677155|NCT02103049|Other|Ezetimibe, dyslipidemia, kidney transplant|
16677156|NCT02103036|Experimental|Core Stability Exercises|"Core Stability Exercises:
~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Core Stability Exercises (25-30 minutes)."
16677157|NCT02103036|Experimental|Traditional Back School|"Traditional Back School:
~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Traditional Back School (25-30 minutes)."
16677158|NCT02103023|Experimental|ID TIV + imiquimod|imiquimod ointment followed by intradermal influenza vaccine
16677159|NCT02103023|Sham Comparator|ID sham + imiquimod|imiquimod ointment followed by sham intradermal influenza vaccine
16677160|NCT02103023|Active Comparator|IM TIV + aq|aqueous cream followed by intramuscular influenza vaccine
16677161|NCT02103023|Active Comparator|ID TIV + aq|aqueous cream followed by intradermal influenza vaccine
16677162|NCT02103010||HNC patients|head and neck cancer patients
16677163|NCT02102984|Active Comparator|covered stents|endoscopic placement of covered biliary stents
16677164|NCT02102984|Active Comparator|uncovered biliary stents|endoscopic placement of uncovered biliary stents
16677165|NCT02102971||Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
16677166|NCT02102958|Experimental|Experimental|DSME with Nonvisual Foot Examination
16677167|NCT02102958|Active Comparator|Comparison|DSME with Usual Foot Examination Instruction
16677168|NCT02102945|Other|Computed tomography perfusion|Participants will undergo CT perfusion of the head after cooling following cardiac arrest.
16677169|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
16677170|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
16677209|NCT02102633|Experimental|Dabigatran + Bosutinib|Dabigatran 150 mg co-administered with Bosutinib 500 mg orally
16677171|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
16677172|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
16677173|NCT02102919|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & virtual games) - T2
16677174|NCT02102919|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
16677175|NCT02102906|Experimental|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
16677176|NCT02102880|Other|Healthy Subjects|
16677177|NCT02102854|Active Comparator|Standard dose rATG|Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
16677178|NCT02102854|Experimental|Single dose rATG|Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration
16677179|NCT02102841|Experimental|Skin biopsy|5mm skin punch biopsy on forearm
16677180|NCT02102841|Experimental|Skin suction blister|Skin suction blister induced on forearm
16677181|NCT02102841|Experimental|Mantoux, skin biopsy, suction blister|0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
16677182|NCT02102828|Placebo Comparator|Aspirin only|Patients receive aspirin therapy
16677183|NCT02102828|Experimental|extended compression|aspirin and extended compression therapy in combination
16677184|NCT02102815|Experimental|Dexamethasone|Preoperative dexamethasone 0.15mg/Kg mixed with NSS to 50 mL IV slowly push over 5 minutes
16677185|NCT02102815|Placebo Comparator|Placebo|Preoperative intravenous normal saline 50 mL slowly push over 5 minutes
16677186|NCT02102802||Full dose MDMA|Participants will receive 125 mg MDMA possibly followed 1.5 to 2 h later by 62.5 mg MDMA
16677187|NCT02102789|Experimental|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
16677188|NCT02102789|Experimental|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
16677189|NCT02102776|Active Comparator|MMC after pterygium excision|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision. The conjunctival defect will be left bare without graft.
16677190|NCT02102776|Active Comparator|AMT after Pterygium Excision|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
16677191|NCT02102776|Active Comparator|CAG after Pterygium Excision|A conjunctival autograft will be harvested from the superior side of the operating eye's bulbar conjunctiva. Then the graft will be sutured to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
16677192|NCT02102750|Experimental|tafluprost|
16677193|NCT02102737|Experimental|6-DIG and clamp|injection of 6-DIG and hyperinsulinemic euglycemic clamp
16677194|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
16677195|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
16677196|NCT02102711|Experimental|vitaminA drops|3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
16677197|NCT02102711|No Intervention|control|Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
16677198|NCT02102698|Experimental|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
16677199|NCT02102698|Placebo Comparator|Placebo|Placebo is the inactive comparator
16677200|NCT02102685|Active Comparator|VAC Therapy|active comparator: 14 patients within the first three days the VAC therapy was placed , proceeding as follows : organize the material , bandage removal , cleaning of the wound with irrigation solution , cut the sponge and placement on the wound , use of polyvinyl alcohol and / or silver foam, insertion of the tube seal and connection to the containing recipient.
16677201|NCT02102685|Placebo Comparator|Traditional Therapy|14 patients: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
16677202|NCT02102672|Placebo Comparator|Sugar pill|Placebo 1 pill bid, 3 months
16677203|NCT02102672|Experimental|Trimetazidine|Trimetazidine 35 mg bid for 3 months
16677204|NCT02102659|Experimental|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium."
16677205|NCT02102659|Active Comparator|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
16677206|NCT02102646|Active Comparator|Triptorelin|Triptorelin 22,5mg/24th week intramuscularly
16677207|NCT02102646|Active Comparator|orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
16677210|NCT02102620|Experimental|IAI triamcinolone hexacetonide|"Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).
~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day)."
16677211|NCT02102620|Placebo Comparator|IAI lidocaine|Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
16677212|NCT02102607||age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
16677213|NCT02102594|Experimental|Bortezomib (Velcade)|
16677214|NCT02102581||short time tourniquet|60 patients were randomly divided into 2 groups (30 cases/group): group A using the tourniquet throughout the operation, and group B using the tourniquet starting from the implantation of prosthesis to the completion of the operation(short time).
16677215|NCT02102555|Active Comparator|IV acetaminophen|Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
16677216|NCT02102555|Placebo Comparator|Placebo|Patients in the placebo arm will receive normal saline in the pre-operative area.
16677217|NCT02102542||Antisialagouge|A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
16677218|NCT02102542||Bradycardia|A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
16677219|NCT02102542||For reversal of neuromuscular blocking agents|Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
16677220|NCT02102529||bowel endometriosis|laparoscopic colonic resection
16677221|NCT02102516|Experimental|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
16677222|NCT02102503|Experimental|MI and Medication review|The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.
16677223|NCT02102503|Active Comparator|Standard treatment|Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.
16677224|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
16677225|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
16677226|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
16677227|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
16677228|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
16677229|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
16677230|NCT02102438|Experimental|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
16677231|NCT02102425||Chronic kidney disease, PD|Patients with or without bandage over exit site
16677232|NCT02102412|Experimental|single arm|single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.
16677233|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
16677234|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
16677235|NCT02102386||CerOx|Patients will be monitored using the CerOx monitor. Probes will be attached bi-laterally in the OR to the forehead.
16677236|NCT02102373|Active Comparator|low-fiber diet|Patients received low-fiber diet for 24 hours before colonoscopy
16677237|NCT02102373|Active Comparator|clear liquid diet|Patients received clear liquid diet for 24 hours before colonoscopy
16677238|NCT02102360|Experimental|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
16677239|NCT02102360|Experimental|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
16677450|NCT02100956|Placebo Comparator|normal saline|preservative free normal saline: 3 milliliters administered intrathecally (IT)
16677240|NCT02102347|Experimental|exercise group|An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
16677241|NCT02102347|Experimental|phototherapy group|And, Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant.with one 905-nm diode (mean power: 1 milliwatt ; peak power: 10 megawatt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 17.5 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 15 mW; spot size: 1 cm2); frequency: 1000 Hz; 300-second irradiation time in each quadrant; total energy: 39.3 Joules per quadrant. Phototherapy will be included in the exercises group.
16677242|NCT02102347|Placebo Comparator|Phototherapy placebo|Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
16677243|NCT02102334||Unilateral osteoarthritis|Patients operated with a total hip replacement due to unilateral osteoarthritis of the hip. Radiographic measurements of the postoperative radiographs.
16677244|NCT02102321|Experimental|albendazole|albendazole 400 mg
16677245|NCT02102321|Active Comparator|placebo|placebo
16677246|NCT02102308|Experimental|Exercise|Multicomponent exercise
16677247|NCT02102308|Placebo Comparator|Education classes|Education classes
16677248|NCT02102295|Active Comparator|Experimental toothpaste|L-ascorbic acid 2-phosphate magnesium salt / fluoride
16677249|NCT02102295|Placebo Comparator|Control toothpaste|fluoride
16677250|NCT02102282||Subject study|Patients with breast cancer during pregnancy
16677251|NCT02102269|Active Comparator|actimove sling|standard orthosis: actimove sling
16677252|NCT02102269|Experimental|shoulderlift|newly developed orthosis: shoulderlift
16677253|NCT02102269|No Intervention|controle group|no orthosis
16677254|NCT02102256|Experimental|Experimental|Device Implantation
16677255|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:
~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
16677256|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:
~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
16677257|NCT02102230|Experimental|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
16677258|NCT02102230|Active Comparator|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
16677259|NCT02102230|Placebo Comparator|PC|Desensitization Treatment for Insomnia (DTI)
16677260|NCT02102217|Experimental|Precious arm|Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted.
16677261|NCT02102217|No Intervention|Control|Standard postoperative controls. Additional testing will only be conducted on demand.
16677262|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
16677263|NCT02102191|Active Comparator|cigarette|common cigarette sold in the stores
16677264|NCT02102191|Active Comparator|e-cigarette|e-cigarette (Ovale Elips)
16677265|NCT02102178|Experimental|Group 1 (Intensive occupational therapy)|"All patients received pharmacological treatment for pain in accordance with the World Health Organization (WHO)'s analgesic ladder and occupational therapy follow-up, with guidance regarding activities of daily living (ADLs).
~They also carried out therapeutic activities such as embroidery onto gauze (tapestry), weaving a scarf on a nail frame and playing dominos."
16677266|NCT02102178|Active Comparator|Group 2 (Regular occupation therapy)|All patients received pharmacological treatment for pain in according to WHO's analgesic ladder and only guidance regarding ADLs from the occupational therapist.
16677267|NCT02102165|Experimental|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
16677268|NCT02102152|Active Comparator|TOBI / Placebo|TOBI / Placebo.
16677269|NCT02102152|Active Comparator|Placebo / TOBI|Placebo / TOBI
16677270|NCT02102139|Experimental|DXM + Propofol|"DXM (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During DXM loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.
~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.
~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
16682038|NCT02070354||Group 6|≥ 36 months after bariatric surgery
16677271|NCT02102139|Placebo Comparator|Saline + Propofol|"Saline (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During saline loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.
~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.
~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
16677272|NCT02102126|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
16677273|NCT02102126|No Intervention|Control group|Subjects are maintained on baseline anti-hypertensive medications.
16677274|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
16677275|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
16677276|NCT02102100|Experimental|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
16677277|NCT02102100|Experimental|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
16677278|NCT02102087|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used in conjunction with standard blood culture bottles.
16677279|NCT02102087|Active Comparator|Lab standard practice (LSP)|A standard blood culture kit will be used.
16677280|NCT02102061|Experimental|multidisciplinary intervention|
16677281|NCT02102061|No Intervention|control|
16677282|NCT02102048|Active Comparator|Atazanavir|patients that switch cART to boosted or unboosted ATV
16677283|NCT02102048|No Intervention|other Protease Inibithors|patients that continue the previous cART without changes.
16677284|NCT02102035|Other|Dorsal digital island flap|The flap is used to cover the soft-tissue defects of the fingers.
16677285|NCT02102022|Experimental|ADI-PEG 20 plus modified FOLFOX6|"Dose: 36 mg/m2 given weekly
~Route of Administration: Intramuscular (IM)
~In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus"
16677286|NCT02102009|Experimental|Vitafos|Complete enteral formula
16677287|NCT02102009|Active Comparator|Dietary Advise|Dietary advise according to the hospital routine clinical practice.
16677288|NCT02101996||Healthy|Not insulin resistant
16677289|NCT02101996||Insulin resistant|Insulin resistant by an insulin clamp
16677290|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
16677291|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
16677292|NCT02101970|Experimental|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
16677293|NCT02101970|Active Comparator|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
16677294|NCT02101957|Experimental|RP103|RP103 capsule, 16 capsules per day
16677295|NCT02101957|Placebo Comparator|placebo|placebo capsule, 16 capsules per day
16677296|NCT02101944|Experimental|Treatment (dexamethasone, carfilzomib, Reolysin)|Patients receive dexamethasone intravenously (IV), carfilzomib IV over 30 minutes, and Reolysin IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16677297|NCT02101931|Experimental|Urine spectral analysis|The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking Amino levulinic Acid and the samples will be analyzed by photodynamic diagnostic procedure. Amino levulinic Acid gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).The above samples is taken in a four side polished quartz cuvette of 1cmx1cmx4cm and put into the table top spectral scan. This consists of a 5 mw, blue diode laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid.
16677298|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
16677415|NCT02101151|Experimental|Vitamin D3 group|supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months
16677301|NCT02101892|Active Comparator|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
16677302|NCT02101892|Placebo Comparator|placebo|sugar pills
16677303|NCT02101879||Breast cancer Her2 positive|Trastuzumab & Pertuzumab & Taxanes
16677304|NCT02101866|Experimental|Vapendavir 300 mg tablet|Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose
16677305|NCT02101866|Experimental|Two Vapendavir 132 mg capsules|Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose
16677306|NCT02101853|Active Comparator|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT. Closed effective September 18, 2019.
16677307|NCT02101853|Experimental|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
16677308|NCT02101853|Active Comparator|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
16677309|NCT02101853|Experimental|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance.
16677310|NCT02101840|Active Comparator|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
16677311|NCT02101840|Active Comparator|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
16677312|NCT02101840|Placebo Comparator|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
16677313|NCT02101827||Hysteroscopic surgery|Women who received hysteroscopic surgeries or examinations
16677314|NCT02101814|Other|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
16677315|NCT02101801|Other|freshwater|receives vegetables from freshwater farms
16677316|NCT02101801|Active Comparator|recycled wastewater|receives vegetables from farms using recycled wastewater irrigation
16677317|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
16677318|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16677319|NCT02101775|Experimental|Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)|Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16677320|NCT02101775|Active Comparator|Arm II (placebo, gemcitabine hydrochloride)|Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16677321|NCT02101762||Silver Coated Catheters|Subjects that had previously received silver coated Foley catheters.
16677322|NCT02101762||ERASE CAUTI Non-Silver Coated Catheters|Subjects that received non-silver catheters from an ERASE CAUTI tray.
16677323|NCT02101749|Active Comparator|trivalent inactivated influenza (INTANZA)|Intradermal injection
16677324|NCT02101749|Active Comparator|trivalent inactivated influenza (VAXIGRIP)|Intramuscle injection
16677325|NCT02101736|Experimental|Experimental Agent XL184 (Cabozantinib)|"Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.
~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose
~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort."
16677326|NCT02101723|Active Comparator|Micronutrient Powder (MNP) + Zn/Fe|Micronutrient Powder with 5 mg Zn and 12 mg Fe
16677327|NCT02101723|Active Comparator|MNP + Zn|Micronutrient Powder with 5 mg Zn
16677328|NCT02101723|Placebo Comparator|Control|Placebo sachets without micronutrients
16677329|NCT02101710|Experimental|Elantan SR 60 mg fed|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 2 and on Day 1 of treatment period 2 for Fed group 1.
16677330|NCT02101710|Experimental|Imdur SR 60 mg fed|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 1 and on Day 1 of treatment period 2 for Fed group 2.
16677331|NCT02101710|Experimental|Elantan SR 60 mg fasted|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 2 and on Day 1 of treatment period 2 for Fasted group 1.
16677332|NCT02101710|Experimental|Imdur SR 60 mg fasted|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 1 and on Day 1 of treatment period 2 for Fasted group 2.
16677333|NCT02101697|Experimental|HIV Stigma Reduction Intervention|The HIV stigma reduction arm group will participate in a promising intervention designed to reduce HIV stigma among health professionals. The intervention builds on results of our previous research, identifying prevalence and drivers of stigma and discrimination in Indian healthcare settings among PLHIV, health care providers, and uninfected patients.The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
16677416|NCT02101151|Placebo Comparator|Placebo group|Placebo (starch) capsules identical to vitamin D capsules in appearance
16677334|NCT02101697|Placebo Comparator|Time Matched Control Group|The time-matched control group will also receive three sessions; two administered by computers and one in small group format to control for attention effects. However, rather than AIDS stigma, the content will be focused on diabetes management (a disease not considered to be stigmatized).
16677335|NCT02101684|Experimental|Orteronel 300mg b.i.d.|Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.
16677336|NCT02101671||trendelemburg positioning|Patients undergone laparoscopic surgery in trendelemburg position
16677337|NCT02101671||Not trendelemburg positioning|Patients undergone laparoscopic surgery not in trendelemburg position
16677338|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
16677339|NCT02101645|Experimental|LIDC treatment and bioimpedance monitoring of venous ulcers.|Lower extremity venous ulcers will be treated using periodical LIDC stimulation. Wound healing and edema reduction efforts will be monitored using bioimpedance based monitoring.
16677340|NCT02101632|Experimental|Bee Venom|Bee Venom Ointment 0,0005%
16677341|NCT02101632|Placebo Comparator|Vaseline|Vaseline ointment
16677342|NCT02101619||Moderate aortic stenosis.|
16677343|NCT02101619||Severe aortic stenosis.|
16677344|NCT02101606|Experimental|Tenecteplase|
16677345|NCT02101593|Experimental|ADI-PEG 20|
16677346|NCT02101580|Experimental|ADI-PEG 20|
16677347|NCT02101567|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
16677348|NCT02101567|Active Comparator|Oxytocin and Methergine (methyl ergometrine)|The second group of patients included in the study will be given Oxytocin 5 IU ampoule by intravenous infusion and Methergine 0.2 mg IV after delivery of fetal head.
16677349|NCT02101554|Experimental|Embeda|One arm, open label, active
16677350|NCT02101541|Experimental|FIRM ablation|"The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.
~The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme."
16677351|NCT02101528||PD Patients|"PD patients with a diagnosis of clinically probable idiopathic PD in Hoehn-Yahr stage 2-3, with the ability to walk without any assistance, with mini-mental state examination score ≥26, without any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance."
16677352|NCT02101528||Controls|age and sex matched healthy volunteers
16677353|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
16677354|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural
~Intervention: one additional hour for the second stage of labor
~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
16677355|NCT02101502|Active Comparator|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
16677356|NCT02101502|Active Comparator|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
16677357|NCT02101502|Active Comparator|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
16677358|NCT02101489|Active Comparator|Intraop Foley catheter measurement|20 women will have intraoperative Foley catheter measurement of the urethral length
16677359|NCT02101489|No Intervention|Without intraop Foley cath measurement|20 women without intraoperative Foley catheter measurement of the urethral length
16677360|NCT02101476|Active Comparator|Percocet|Oxycodone/APAP (acetaminophen)
16677361|NCT02101476|Active Comparator|Xartemis|
16677362|NCT02101463|Other|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
16677363|NCT02101450|No Intervention|Intra-abdominal removal of the placenta|The uterus will be left in the abdominal cavity and the placenta will be manually removed with uterine massage as soon as possible. After removal of the placenta, the uterus will be dragged out of the abdominal cavity. The cesarean incision will be sutured with no. 1 Vicryl ®. Uterus will be replaced in the abdominal cavity. Intra-abdominal cavity will be cleaned by aspirator and mounted-gauze tampon. The weight of the placenta will be measured. The weight of the gauze tampons will be measured with gravimetric method before and after use.
16677364|NCT02101450|Experimental|Extra-abdominal removal of the placenta|"No drug or device is used. The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
~The placenta will be manually removed with uterine massage as soon as possible. The cesarean section will be completed as described in No intervention group."
16677365|NCT02101437|Placebo Comparator|control|normal subjects.
16677366|NCT02101437|Active Comparator|clopidogrel|subjects received clopidogrel 75mg qd.
16677367|NCT02101437|Active Comparator|ticagrelor|subjects received ticagrelor 90mg qd.
16677368|NCT02101437|Active Comparator|cilostazol|subjects received cilostazol 100mg bid.
16677369|NCT02101424||Overdose|
16677370|NCT02101411||clopidogrel|treated with cloopidogrel
16677371|NCT02101411||ticagrelor|treated with ticagrelor
16677372|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
16677373|NCT02101398|Experimental|F7A|Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
16677374|NCT02101398|Experimental|F7C|Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
16677375|NCT02101398|Experimental|T5A|Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
16677376|NCT02101398|Experimental|T5C|Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
16677377|NCT02101398|Sham Comparator|Sham|Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
16677417|NCT02101138|Experimental|Dexpramipexole|Dexpramipexole treatment
16677451|NCT02100943||OSA in Pregnancy|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation
16677378|NCT02101385|Experimental|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
16677379|NCT02101385|Other|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
16677380|NCT02101372|Active Comparator|treatment as usual|
16677381|NCT02101372|Experimental|Psychoeducation Group|
16677382|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.
~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
16677383|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.
~Topical Mydriatic treatments were instilled three times before surgery."
16677384|NCT02101346|Experimental|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
16677385|NCT02101346|Experimental|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.
~Saturated fat Triolein 13C"
16677386|NCT02101333|Experimental|TOCILIZUMAB MONTHLY DURING 6|intravenous injection, 8 mg/kg, monthly during 6 months
16677387|NCT02101320|No Intervention|Group 1|Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
16677388|NCT02101320|Experimental|Group 2|Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
16677389|NCT02101307||RA Patients on RoActemra/Actemra treatment|
16677390|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
16677391|NCT02101281|Experimental|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
16677392|NCT02101281|Experimental|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
16677393|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
16677394|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
16677395|NCT02101255|Experimental|Curodont Repair|Application on Day 0 and Day 360
16677396|NCT02101255|Active Comparator|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
16677397|NCT02101242||Orthopedic surgery of the shoulder|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
16677398|NCT02101242||Gynecological, urological or general surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
16677399|NCT02101242||Cardiac surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).
16677400|NCT02101229|No Intervention|unsual treatment|The patient will have his usual treatment in this arm
16677401|NCT02101229|Experimental|The Diabeloop algorithm|In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
16677402|NCT02101216|Experimental|Pharmacokinetics of low dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
16677403|NCT02101216|Experimental|Pharmacokinetics medium dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
16677404|NCT02101216|Experimental|Pharmacokinetics of high dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
16677405|NCT02101216|Experimental|Bioequivalence of Prurisol (350 mg)|Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
16677406|NCT02101216|Active Comparator|Bioequivalence of Ziagen (300 mg)|Single dose of Ziagen 300 mg (1 x 300mg tablet)
16677407|NCT02101203|Experimental|Placebo|40 subjects administered placebo
16677408|NCT02101203|Experimental|Testosterone + Buspirone|40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride
16677409|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
16677410|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
16677411|NCT02101177||Patients under Dual therapy|- 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A).
16677412|NCT02101177||Early Defaulters|- 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).
16677413|NCT02101164|Active Comparator|Treatment Group A|1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.
16677414|NCT02101164|Active Comparator|Treatment Group B|1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.
16682987|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
16677418|NCT02101125|Experimental|BMS-986020 + Rosuvastatin (Treatment A, B and C)|"Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days
~Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
16677419|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
16677420|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
16677421|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
16677422|NCT02101099||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
16677423|NCT02101086|Experimental|Autologous Cord Blood Transfusion|Autologous cord blood transfusion 10 mL per kg for anemia
16677424|NCT02101086|Active Comparator|Allogeneic blood transfusion|Allogeneic blood transfusion 10 mL per kg for anemia
16677425|NCT02101073|Experimental|ALX-0061 low dose i.v.|
16677426|NCT02101073|Experimental|ALX-0061 high dose i.v.|
16677427|NCT02101073|Experimental|ALX-0061 low dose s.c.|
16677428|NCT02101073|Experimental|ALX-0061 middle dose s.c.|
16677429|NCT02101073|Experimental|ALX-0061 high dose s.c.|
16677430|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
16677431|NCT02101060|No Intervention|control|usual care controls
16677432|NCT02101047|Experimental|phenylephrine 50mcg bolus|Phenylephrine 50 mcg bolus dosing with continuous placebo infusion
16677433|NCT02101047|Experimental|Phenylephrine 100 mcg bolus|Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.
16677434|NCT02101047|Experimental|Phenylephrine continuous infusion 100mcg/min|Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.
16677435|NCT02101034|Experimental|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
16677436|NCT02101034|Experimental|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
16677437|NCT02101034|Experimental|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
16677438|NCT02101034|Experimental|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
16677439|NCT02101034|Experimental|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
16677440|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
16677441|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
16677442|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
16677443|NCT02100995|Experimental|STOP Intervention|The STOP treatment includes content designed to simultaneously and explicitly target both chronic pain and obesity. Treatment components are drawn from evidence-based interventions for chronic pain and obesity, separately.
16677444|NCT02100995|Active Comparator|Standard Care Weight (SCW)|The weight loss intervention includes content focused around nutrition and eating habits, stimulus control and behavioral change, and physical activity. This content has been chosen because of its demonstrated effectiveness and importance in behavioral interventions to reduce weight.
16677445|NCT02100995|Active Comparator|Standard Care Pain (SCP)|The chronic pain intervention is focused around reconceptualization of pain, decreasing catastrophizing, and increasing self-efficacy for pain. This content has been chosen because of its demonstrated effectiveness and importance in non-pharmacological interventions to improve pain management.
16677446|NCT02100982|Other|Care As Usual|Before the office visit with the PCP, patient participants in the Care As Usual arm will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
16677447|NCT02100982|Experimental|Customized Care|Before the office visit with the PCP, patient participants in the intervention group will interact with the computer based components of the customized care intervention while in the waiting room. The research staff will help the participant use an iPad in the waiting room and direct them to the Discussion Prioritization tool (DPT). After participants use the DPT, the program automatically generates a customized questions prompt list (QPL) which will be printed out in the office. Study staff will hand the QPL to intervention patients to bring to their office visit with the PCP. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
16677448|NCT02100969|Experimental|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
16677452|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
16677453|NCT02100917|Experimental|DMB-3111|6 mg/kg is once given in intravenous drip infusion taking 90 min
16677454|NCT02100917|Active Comparator|trastuzumab|6 mg/kg is once given in intravenous drip infusion taking 90 min
16677455|NCT02100904||Women undergoing radiofrequency ablation.|Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
16677456|NCT02100904||Women undergoing myomectomy|About 25% of women in the trial will be in the group who receive treatment with myomectomy.
16677457|NCT02100891|Experimental|Allogeneic HCT + Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
16677458|NCT02100878||Lean adolescents|
16677459|NCT02100878||Obese adolescents|
16677460|NCT02100865|Experimental|Solar powered oxygen|Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
16677461|NCT02100865|Active Comparator|Oxygen from cylinders|Conventional oxygen delivery from compressed gas cylinders
16677462|NCT02100852|Experimental|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days.
16677463|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL
~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
16677464|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.
~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
16677465|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
16677466|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
16677467|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
16677468|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
16677469|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
16677470|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
16677471|NCT02100800|Experimental|COPD Group|30 patients with diagnosis of COPD
16677472|NCT02100800|Sham Comparator|Control Group|10 volunteers with extrapulmonary neoplasia
16677473|NCT02100787|Experimental|TheraTears lubricating drops|TheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
16677474|NCT02100774||healthy male adults|no added micronutrient, tomato puree, lutein supplement, vitamin E supplement, vitamin D supplement
16677475|NCT02100761||invasive pulmonary aspergillosis|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole according to their physician decision in five hospital, Jinan, China
16677476|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
16677477|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
16677478|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
16677479|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
16677480|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
16677481|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
16677482|NCT02100735|Experimental|Sedation protocol|Sedation protocol is a document that will be used to guide the adjustment of sedation in the ICU.
16677483|NCT02100735|Active Comparator|Standard of care|Current practices
16677484|NCT02100722|Active Comparator|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
16677485|NCT02100722|Active Comparator|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
16677486|NCT02100709|No Intervention|Control Arm|This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
16677487|NCT02100709|Active Comparator|Intervention Arm|This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.
16677488|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
16677489|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
16677490|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
16677491|NCT02100696|Placebo Comparator|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
16677527|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
16677492|NCT02100696|Placebo Comparator|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
16677493|NCT02100696|Experimental|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
16677494|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA with a minimum diameter of < 4 mm.
16677495|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
16677496|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
16677497|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
16677498|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
16677499|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).
~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.
~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
16677500|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
16677501|NCT02100631|Experimental|PXVX0200 in Older Adults|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
16677502|NCT02100631|Placebo Comparator|Placebo in Older Adults|Placebo physiological saline
16677503|NCT02100631|Other|Historical Control: Adults Aged 18-45|This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
16677504|NCT02100618|Experimental|HPV Group 1|Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970).
16677505|NCT02100618|Active Comparator|HPV Group 2|Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970).
16677506|NCT02100605|Active Comparator|Phytosun, decongestant, nasal spray|"Phytosun, decongestant, nasal spray
~Nasal spray 20 ml contains:
~22g/l hypertonic seawater Essential oils of Eucalyptus, Niaouli and Wild menthol
~Instructions for use:
~Shake the bottle before use
~Tilt the bottle to one side; press the nozzle firmly for at least one second, repeat until obtaining the 1st spray.
~Spray in each nostril with the head upright"
16677507|NCT02100605|Placebo Comparator|Isotonic saline, nasal spray|"Isotonic saline, nasal spray
~20 ml nasal spray contains Isotonic water solution 0.9% sodium chloride"
16677508|NCT02100592|Experimental|Erigo treated|Early rehabilitation treatment on Erigo Hocoma, a tilt table with integrated stepping device within 3 - 30 days from injury
16677509|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
16677510|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
16677511|NCT02100566|Experimental|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
16677512|NCT02100566|No Intervention|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
16677513|NCT02100553|Other|Non-Obese|BMI <30 kg/m^2
16677514|NCT02100553|Other|Obese|BMI >= 30 kg/m^2
16677515|NCT02100540|Placebo Comparator|I placebo capsule|I placebo capsule
16677516|NCT02100540|Experimental|II RDC 0.3mg capsule|II RDC 0.3mg capsule
16677517|NCT02100540|Experimental|III RDC 0.6mg capsule|III RDC 0.6mg capsule
16677518|NCT02100527|Experimental|PF-05175157|
16677519|NCT02100527|Placebo Comparator|Placebo|
16677520|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
16677521|NCT02100514|Placebo Comparator|placebo|
16677522|NCT02100501||Atkins diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 53. enrolled patients are assigned to randomly in one of KD group or Atkins group.
16677523|NCT02100501||Ketogenic diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 51. enrolled patients are assigned to randomly in one of KD group or Atkins group.
16677524|NCT02100488|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
16677525|NCT02100488|Experimental|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
16677526|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
16677528|NCT02100462|Experimental|Chlorthalidone 12.5 mg|Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
16677529|NCT02100462|Experimental|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
16677530|NCT02100462|Active Comparator|Aspirin 81 mg|Aspirin 81 mg by mouth once daily for 2 weeks
16677531|NCT02100449|Other|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
16677532|NCT02100449|Other|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
16677533|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
16677534|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
16677535|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
16677536|NCT02100423|Experimental|Treatment (curcumin, cholecalciferol)|Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years.
16677537|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
16677538|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
16677539|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
16677540|NCT02100397|Experimental|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
16677541|NCT02100384|Active Comparator|Ultrasonics|Ultrasonic instrumentation for peri-implant maintenance
16677542|NCT02100384|Active Comparator|Scalers|Titanium Scalers instrumentation for peri-implant maintenance
16677543|NCT02100371|Experimental|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
16677544|NCT02100358||acute cholecystitis|acute cholecystitis
16677545|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
16677546|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
16677547|NCT02100306|Experimental|Patients|"Patients will receive:
~Auditory Feedback 100% Auditory Feedback 50% alternate"
16677548|NCT02100293|Active Comparator|standard dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.6 mg/kg
16677549|NCT02100293|Active Comparator|low dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.45 mg/kg
16677550|NCT02100293|Active Comparator|low dose rocuronium plus magnesium group|pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg
16677551|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
16677552|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
16677553|NCT02100267|Experimental|Asthma patients|
16677554|NCT02100267|Experimental|Healthy volunteers|
16677555|NCT02100254|Experimental|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
16677556|NCT02100254|Active Comparator|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
16677557|NCT02100241|Experimental|Active stretching with currents|Active stretching performed while currents are applied on hamstring muscles.
16677558|NCT02100241|Experimental|Active stretching|Active stretching are performed.
16677559|NCT02100241|No Intervention|Control group|Routine clinical practice
16677560|NCT02100228|Experimental|Apixaban|
16677561|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
16677562|NCT02100215|Experimental|Expert Modeling|Participants will have access to 70 minutes of expert modeling videos available over 5 weeks on an online learning management system. The investigator will be the expert model in the videos. Expert modeling videos will address content related to seven concepts: Taking report with a graphic organizer worksheet, prioritizing patient care, delegating to unlicensed assistive personnel, safety checks in patient rooms, focused physical assessments, safe medication administration, and using a standardized healthcare provider communication tool on the telephone.
16677600|NCT02099955|Experimental|Endocrine Arm|"Vitamin D3 Supplementation and Endocrine Function:
~To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR."
16677563|NCT02100215|Active Comparator|Voice Over PowerPoint|Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
16677564|NCT02100215|Placebo Comparator|Reading|Participants will have access to articles, policies, and procedures on an online learning management system. The estimated time required for participants to review these materials is 45 minutes
16677565|NCT02100202|Placebo Comparator|Placebo|Capsules containing 250 mg of placebo, two times a day
16677566|NCT02100202|Experimental|BioTurmin|Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
16677567|NCT02100202|Experimental|BioTurmin-WD|Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
16677568|NCT02100202|Experimental|MaQxan|Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
16677569|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
16677570|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
16677571|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H&Y stages 1,5-2)
16677572|NCT02100163|Experimental|Virtual Reality Hypnosis|The patient receives VRH daily.
16677573|NCT02100163|Experimental|Audio Hypnosis|The patient receives Audio Hypnosis daily.
16677574|NCT02100163|Experimental|Standard Treatment|The patient receives the standard treatment. This is a control group and there are no interventions.
16677575|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
16677576|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
16677577|NCT02100137||Women with endometrial hyperplasia|
16677578|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
16677579|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
16677580|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
16677581|NCT02100111||Participants with advanced or metastatic BCC|Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.
16677582|NCT02100085||Observational group|Subjects in the period less than 48 weeks after the final administration of GX-188E
16677583|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
16677584|NCT02100059|Experimental|Electrical Stimulation (TENS)|The TENS (transcutaneous electrical nerve stimulation) electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
16677585|NCT02100046|Experimental|ethosuximide|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
16677586|NCT02100046|Other|control group|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
16677587|NCT02100033|Experimental|acupuncture|acupuncture manipulation
16677588|NCT02100020|Experimental|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
16677589|NCT02100020|No Intervention|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
16677590|NCT02100007|Experimental|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
16677591|NCT02099994|Experimental|A - AM|Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.
16677592|NCT02099994|Experimental|B - DDDAM|pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
16677593|NCT02099994|Experimental|C - DeDeDeAM|"Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.
~Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20."
16677594|NCT02099981|Experimental|Control Group|Control subjects will receive AG.
16677595|NCT02099981|Experimental|Type 1 diabetes|Type 1 diabetic subjects will receive AG.
16677596|NCT02099968|Experimental|Comprehensive Lifestyle Modification|
16677597|NCT02099968|Active Comparator|Standard Lifestyle Modification / modified DASH|
16677598|NCT02099955|No Intervention|Screening Study|To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
16677599|NCT02099955|Experimental|Pulmonary Arm|"Vitamin D3 Supplementation and Pulmonary Function:
~To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).
~To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels)."
16677601|NCT02099929|Experimental|Coffee with Sugar|300mL of Coffee with 30g of Sugar
16677602|NCT02099929|Experimental|Coffee without Sugar|300mL of Coffee without Sugar
16677603|NCT02099929|Experimental|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
16677604|NCT02099929|Sham Comparator|Water with Sugar|300mL of Water with 30g of Sugar
16677605|NCT02099929|Sham Comparator|Water without Sugar|300mL of Water without Sugar
16677606|NCT02099916|Active Comparator|gonadotropins plus DHEA|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks.
16677607|NCT02099916|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
16677608|NCT02099903|No Intervention|Medical therapy for heart failure|Standard optimized medical therapy for heart failure.
16677609|NCT02099903|Experimental|Renal denervation + medical therapy.|Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.
16677610|NCT02099890|Experimental|Anti-inflammatory Supplementation|Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
16677611|NCT02099877||Nulliparous requesting epidural|"Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated course of singleton vertex pregnancy requesting epidural analgesia for pain relief will be included.
~When the patient requests analgesia, cervical dilatation will be verified by the obstetric resident/attending. Then epidural analgesia will be initiated with a test dose of 3mL of 2% lidocaine and epinephrine 15 µg and a dose of fentanyl 100 µg diluted to a total volume of 10 mL with preservative- free normal saline. Before placement of the epidural, venous blood (2 mL) will be drawn into special tubes. Genotyping of OPRM1: p.118A/G will be also performed."
16677612|NCT02099864|Experimental|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
16677613|NCT02099851|Experimental|Carotid body ablation|Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
16677614|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
16677615|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
16677616|NCT02099825|Experimental|Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
16677617|NCT02099825|Active Comparator|Non-Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
16677618|NCT02099812||Obese|Obese individuals
16677619|NCT02099812||Non-obese|Non-obese individuals
16677620|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
16677621|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
16677622|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
16677623|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
16677624|NCT02099773||support workers & AAC users|Support workers who use KeyWordSigning in the communication with their client who has an intellectual disability
16677625|NCT02099773||support workers & KWS users|Support workers who use aided AAC in the communication with their client who has an intellectual disability
16677626|NCT02099760||STD testing (GC/Ct/trich)|
16677627|NCT02099747|Active Comparator|hATG + CsA|Control Arm
16677628|NCT02099747|Experimental|hATG + CsA + Eltrombopag|Experimental
16677629|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
16677630|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
16677631|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
16677632|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.
~These subjects receive an ICD/CRT-D implant."
16677633|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.
~These subjects choose not to receive an ICD/CRT-D implant."
16677634|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).
~These subjects receive an ICD/CRT-D implant."
16677635|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).
~These subjects choose not to receive an ICD/CRT-D implant."
16677703|NCT02099201|Experimental|Group B2|Ten subjects will receive ACT-389949 (provisionally 200 mg) and 3 subjects will receive placebo, every 2 days for 9 days (a total of 5 doses), administered orally, in the morning following an overnight fast. The actual dose will depend on the emerging data from Group B1.
16677636|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.
~These subjects receive an ICD/CRT-D implant."
16677637|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.
~These subjects choose not to receive an ICD/CRT-D implant."
16677638|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
16677639|NCT02099695|Active Comparator|Oxybutynin Chloride|"Tablet
~Dose 5,0 or 10 mg/ day"
16677640|NCT02099695|Placebo Comparator|Placebo|- Tablet
16677641|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
16677642|NCT02099669|Experimental|Liberal transfusion strategy|"Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is < 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L.
~Transfusions administered more frequently."
16677643|NCT02099669|Active Comparator|Restrictive transfusion strategy|Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is < 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration
16677644|NCT02099656|Experimental|Lebrikizumab|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.
16677645|NCT02099656|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.
16677646|NCT02099617|Experimental|Drug Eluting Stent|Synergy II
16677647|NCT02099617|Active Comparator|Bare Metal Stent|Omega or Rebel
16677648|NCT02099604|Experimental|Vitamin D|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
16677649|NCT02099604|No Intervention|Standard of Care|Pegylated Interferon Alpha 2b + Ribavirin
16677650|NCT02099591|Experimental|Age group: > = 12y to < 18y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
16677651|NCT02099591|Experimental|Age group: > = 12y to < 18y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
16677652|NCT02099591|Experimental|Age group: > = 6y to < 12y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
16677653|NCT02099591|Experimental|Age group: > = 6y to < 12y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
16677654|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
16677655|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
16677656|NCT02099578|Placebo Comparator|Control Group|Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
16677657|NCT02099578|Active Comparator|25 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
16677658|NCT02099578|Experimental|50 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
16677659|NCT02099565||OPTIMA study patients|The study population will consist of OPTIMA study patients who have not been lost for follow-up and have given a written informed consent.
16677660|NCT02099552||XLHED|Those with the condition of XLHED
16677661|NCT02099539|Experimental|ALT-803|
16677662|NCT02099500|Experimental|Stem Cell Injection|Non-Randomized
16677663|NCT02099487|Experimental|Radiation|To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
16677664|NCT02099474|Experimental|Raltegravir|All women have been prescribed raltegravir before study participation.
16677665|NCT02099461|Other|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
16677666|NCT02099461|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
16677667|NCT02099461|Experimental|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
16677668|NCT02099448||Elective Cardiac Catheterization|
16677669|NCT02099435||Hemospray to treat lower GI bleeds|
16677670|NCT02099409|Experimental|Starting with FLORENCED2 followed by open loop|Start 2 Overnight periods with closed loop through FLORENCED2 Device , followed by 2 overnight periods with open loop.
16677671|NCT02099409|Experimental|Start open loop followed by FLORENCED2|Start with 2 overnight periods with open loop , followed by 2 overnight with closed loop FLORENCED2
16677672|NCT02099396|Experimental|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.
~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
16677762|NCT02098889|Active Comparator|hyoscine-N-butyl bromide|A single dose intravenously(IV) 20ml hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose 20ml IV NaCl) on the active phase of labor
16677673|NCT02099396|Experimental|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.
~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
16677674|NCT02099383|Active Comparator|normal saline, bolus|Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
16677675|NCT02099383|No Intervention|normal saline, control|Patients of control group will receive intravenous normal saline 60 cc per hour.
16677676|NCT02099357|Placebo Comparator|Placebo|Daily supplementation with 3g of dextrose during eight weeks and placebo ampoules each two weeks.
16677677|NCT02099357|Experimental|Creatine|Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
16677678|NCT02099357|Active Comparator|Vitamin D|Daily supplementation with 3g of dextrose during eight weeks. Vitamin D supplementation, 25000 IU each two weeks.
16677679|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
16677680|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
16677681|NCT02099331|Experimental|Melatonin|The investigators will administer melatonin at 40mg by mouth (two 20 mg tablets), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
16677682|NCT02099331|Placebo Comparator|Placebo|The investigators will administer matching Placebo by mouth (two tablets to match Melatonin), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
16677683|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
16677684|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
16677685|NCT02099305|Experimental|Intervention|Receive Adolescent Depression Awareness Program (ADAP) intervention
16677686|NCT02099305|No Intervention|Wait list control|no intervention
16677687|NCT02099292|Experimental|Rituximab and DexaBEAM|Rituximab and DexaBEAM
16677688|NCT02099279||echocardiography examination|
16677689|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
16677690|NCT02099253|Experimental|Youth Group|People in this group, aged 18~39,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
16677691|NCT02099253|Experimental|Middle-aged Group|People in this group, aged 40~64,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
16677692|NCT02099253|Experimental|Older Group|People in this group, aged 65~80,were accepted an initial dose of 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
16677693|NCT02099240|Active Comparator|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
16677694|NCT02099240|Active Comparator|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
16677695|NCT02099227||Ultrasound|those who received point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
16677696|NCT02099227||No Ultrasound|those who did not receive point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
16677697|NCT02099214|Experimental|Patients with HFE hereditary haemochromatosis|"The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.
~Then will be performed :
~An electrocardiogram
~Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank
~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)
~A 3Tesla abdominal MRI
~An echocardiography at rest."
16677698|NCT02099214|Experimental|Healthy volunteers|"The healthy volunteers (10 men and 10 women) will undergo :
~A urinary pregnancy test (if applicable)
~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)
~An echocardiography at rest."
16677699|NCT02099201|Experimental|Group A1|Ten subjects will receive ACT-389949 40 mg and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
16677700|NCT02099201|Experimental|Group A2|Ten subjects will receive ACT-389949 (Predicted to be 200 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
16677701|NCT02099201|Experimental|Group A3|Ten subjects will receive ACT-389949 (Predicted to be 800 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
16677702|NCT02099201|Experimental|Group B1|Ten subjects will receive ACT-389949 200 mg and 3 subjects will receive placebo, every 3 days for 13 days (a total of 5 doses), administered orally, in the morning, following an overnight fast.
16677763|NCT02098889|Placebo Comparator|Saline(0,9NaCl)|Placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
16677704|NCT02099201|Experimental|Group C1|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
16677705|NCT02099201|Experimental|Group C2|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
16677706|NCT02099188|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:
~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w
~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w
~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.
~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.
~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle
~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.
~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.
~Intestinal Type Adenocarcinoma with functional p53.
~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.
~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w
~Followed by radiotherapy"
16677707|NCT02099175|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:
~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w
~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w
~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:
~First Cycle and every other cycle:
~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Second Cycle and every other cycle:
~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Intestinal Type Adenocarcinoma with functional p53:
~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w
~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w
~Followed by Radiotherapy"
16677708|NCT02099149||Controls|Infants born to GBS colonized mother who do not develop GBS disease
16677709|NCT02099149||Cases|Infants with culture confirmed GBS disease
16677710|NCT02099136|Experimental|Group I (placebo)|Patients receive placebo PO BID for 14 days.
16677711|NCT02099136|Experimental|Group II (low-dose celecoxib)|Patients receive low-dose celecoxib PO BID for 14 days.
16677712|NCT02099136|Experimental|Group III (higher dose celecoxib BID)|Patients receive higher dose celecoxib PO BID for 14 days.
16677713|NCT02099136|Experimental|Group IV (higher dose celecoxib QD)|Patients receive same dose of celecoxib PO as Group III QD for 14 days.
16677714|NCT02099136|Experimental|Group V (high-dose celecoxib)|Patients receive high-dose celecoxib PO QD for 14 days.
16677715|NCT02099123|Experimental|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
16677716|NCT02099123|Placebo Comparator|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
16677717|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
16677718|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
16677719|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
16677720|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
16677721|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
16677722|NCT02099097|Active Comparator|Standard Care|"usual care, which consists of four (face-to-face or telephone) counseling sessions with a trained nurse who has expertise in helping cancer patients quit smoking. This is the same as the treatment an MSK patient who enrolls in the MSK smoking cessation program would receive.
~To collect further data to improve the game intervention, the investigators will conduct semi-structured telephone interviews with patients who were randomized to the treatment arm but did not play the game during the one month intervention period. The purpose of the interviews is to elicit qualitative feedback on any barriers that may have prevented participants from playing. At the completion of the intervention period, patients will be asked if they would like to participate in a telephone interview. Telephone interviews will take about twenty minutes and will be held at a time that is convenient for the patient."
16677723|NCT02099097|Experimental|Smoking Cues Coping Skills Game (SC+SCCS/Quit IT).|Smokers randomly assigned to SC+SCCS/Quit IT will receive all the components of Standard Care. The patient will be oriented and trained face-to-face (during their hospitalization) on use of the game by study staff using an iPad. The orientation and training session will comprise: 1) Overview of the game and its objectives; 2) discussion of the rules of the game; 3) watching a 10 minute tutorial given by the game narrator (avatar); 4) answering all patient questions; and 5) evaluation of the patient's comprehension of game play via a 17 question survey. Once patients have access to QuitIT, they will also receive a set of Coping Cards
16677724|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
16677725|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
16677726|NCT02099071|Experimental|Group 1|Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677727|NCT02099071|Experimental|Group 2|Six subjects will receive a single oral dose of ACT-389949 5 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677728|NCT02099071|Experimental|Group 3|Six subjects will receive a single oral dose of ACT-389949 20 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677764|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
16677765|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
16677729|NCT02099071|Experimental|Group 4|"Subjects will participate in two different treatment periods separated by a washout of 7-10 days between the study drug administrations.
~In the first treatment period six subjects will receive a single oral dose of ACT-389949 50 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
~In the second treatment period, subjects randomized to ACT-389949 will receive a single oral dose of ACT-389949 50 mg in fed condition, 30 minutes after the start of a high fat and high calorie breakfast."
16677730|NCT02099071|Experimental|Group 5|Six subjects will receive a single oral dose of ACT-389949 100 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677731|NCT02099071|Experimental|Group 6|Six subjects will receive a single oral dose of ACT-389949 200 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677732|NCT02099071|Experimental|Group 7|Six subjects will receive a single oral dose of ACT-389949 500 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677733|NCT02099071|Experimental|Group 8|Six subjects will receive a single oral dose of ACT-389949 1000 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
16677739|NCT02099045||Ultrasound examination|All patients over the age of 18 presenting in the emergency department.
16677740|NCT02099032|Experimental|3g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
16677741|NCT02099032|Experimental|5 g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
16677742|NCT02099032|Placebo Comparator|Unfortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks
16677743|NCT02099006|Experimental|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
16677744|NCT02099006|Placebo Comparator|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
16677745|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.
~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
16677746|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
16677747|NCT02098980|Active Comparator|Dietary Supplement: Vitamin D|Vitamin D supplement 4000 IU/day for 6 months
16677748|NCT02098980|Placebo Comparator|Placebo|Placebo for 6 months
16677749|NCT02098967|Experimental|Acute myeloid leukemia patients|
16677750|NCT02098967|Experimental|Cohort 0|
16677751|NCT02098967|Experimental|Solid tumor patients|
16677752|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
16677753|NCT02098941||Topiramate|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.
16677754|NCT02098941||Levetiracetam|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.
16677755|NCT02098941||Oxcarbazepine|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.
16677756|NCT02098928|Active Comparator|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
16677757|NCT02098928|Placebo Comparator|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
16677758|NCT02098915|Experimental|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide
16677759|NCT02098915|Placebo Comparator|control arm|the control arm will receive placebo
16677760|NCT02098902|Experimental|Smart Moms Intervention|This arm will receive the Smart Moms intervention immediately following randomization.
16677761|NCT02098902|No Intervention|Waitlist control group|This arm will receive a modified version of the Smart Moms intervention after the 6-month assessment.
16677766|NCT02098837|Active Comparator|Immediate switch|Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
16677767|NCT02098837|Active Comparator|Deferred switch|Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
16677768|NCT02098824|Active Comparator|Galantamine|Single administration of capsule containing 16 mg Galantamine
16677769|NCT02098824|Placebo Comparator|Placebo|Single oral administration of capsule containing placebo
16677770|NCT02098824|Active Comparator|Methylphenidate|Single administration of capsule containing 10 mg Methylphenidate
16677771|NCT02098811|Experimental|1064nm laser Treatment Before Abdominoplasty|Patient will be treated with 1064nm Laser prior to abdominoplasty
16677772|NCT02098811|Experimental|940nm Laser Treatment Before Abdominoplasty|Patient will be treated with 940nm Laser prior to abdominoplasty
16677773|NCT02098798||HD|High Definition Colonoscopy alone
16677774|NCT02098798||HD + iSCAN|HD colonoscopy + iSCAN
16677775|NCT02098798||HD + Dye|High definition colonoscopy + dye spraying chromoendoscopy
16677776|NCT02098785|Experimental|Caffeine citrate (Peyona) 400mg|Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)
16677777|NCT02098772|Experimental|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
16677778|NCT02098772|Active Comparator|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
16677779|NCT02098759|Experimental|epilepsy early diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
16677780|NCT02098759|Experimental|standard epilepsy diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
16677781|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
16677782|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
16677783|NCT02098720|Experimental|Conbercept|Subjects will receive Conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 3 months, the investigator will decide whether repeat injections are needed based on the monthly assessment results.
16677784|NCT02098707||30 Parkinson disease patients|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen&Yahr (mean Unified Parkinson Disease Rating Scale [UPDRS] III 18.8±10.5) will undergo a balance training using a stabilometric platform.
16677785|NCT02098694|Experimental|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
16677786|NCT02098694|No Intervention|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
16677787|NCT02098668||Normal, pathological cycle, infertility|healthy women PCOS Endometriosis hyperprolactinemia fertility treatment
16677788|NCT02098655||30 patients with PD|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) with PD in stage 3 of H&Y will undergo training of balance using a stabilometric platform
16677789|NCT02098655||12 healthy volunteers|12 healthy volunteers (3 M, 9 F, mean age 66,5 ± 6,0) served as controls will undergo training of balance using a stabilometric platform
16677790|NCT02098642||Patients with passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT), including the mobilization of the metatarsophalangeal joint of the hallux
16677791|NCT02098642||No passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT)
16677792|NCT02098629|Active Comparator|Milrinone+Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.
~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
16677793|NCT02098629|Placebo Comparator|Saline infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion.
16677794|NCT02098616|Experimental|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
16677795|NCT02098616|Experimental|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
16677796|NCT02098616|Experimental|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
16677797|NCT02098616|Experimental|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
16677798|NCT02098616|Experimental|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
16677799|NCT02098616|Experimental|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
16677800|NCT02098603|No Intervention|Testing Only|
16677801|NCT02098603|Experimental|Testing & Intervention|
16677826|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
16677802|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF135.C10|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
16677803|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF166.C8|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
16677804|NCT02098590|Other|NF54 CPS-immunization challenged by NF54|[Negative control group, to assess effectiveness of CPS-immunization.] Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a homologous malaria challenge infection by exposure to the bites of 5 NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
16677805|NCT02098590|Other|Control group challenged by NF135.C10|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
16677806|NCT02098590|Other|Control group challenged by NF166.C8|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
16677807|NCT02098590|Other|Control group challenged by NF54|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
16677808|NCT02098577||PD patients cross-over treatment|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent cross-over treatment with the ability to walk without any assistance with mini-mental state examination score >26.
16677809|NCT02098577||PD patients stabilometric platform|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent stabilometric platform treatment, with the ability to walk without any assistance with mini-mental state examination score >26.
16677810|NCT02098564|Active Comparator|strong sense of coherence control group|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
16677811|NCT02098564|Experimental|strong sense of coherence intervention|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
16677812|NCT02098564|Active Comparator|weak sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
16677813|NCT02098564|Experimental|weak sense of coherence intervention|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
16677814|NCT02098564|Experimental|medium sense of coherence intervention|Patients with a medium sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
16677815|NCT02098564|Active Comparator|medium sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
16677816|NCT02098551||Four (4)|"Group 1: Birch pollen-related atopic dermatitis (AD) (n=15) Group 2: Birch pollen allergic patients without AD (n=5) Group 3: Allergic individuals without birch pollen allergy (n=5) Group 4: Non-allergic individuals (n=5)
~Patients will be tested by SPT and APT:
~SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, and equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.
~APT: birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, equimolar mix of rBet v 1 fragments (160 μg/application); negative control with vaseline"
16677817|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
16677818|NCT02098525||HIV associated CM patients|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital.
16677819|NCT02098512|Experimental|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
16677820|NCT02098499|Active Comparator|Haloperidol and Diphenhydramine|Haloperidol 5mg IV X1 and Diphenhydramine 25mg IV X1
16677821|NCT02098499|Active Comparator|Metoclopramide and Diphenhydramine|Metoclopramide 10mg IV X1 and Diphenhydramine 25mg IV X1
16677822|NCT02098486|Active Comparator|Ceftraxone|ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)
16677823|NCT02098486|Active Comparator|Moxifloxacin|Intravenous moxifloxacin (400 mg/day, infused more than 60 min)
16677824|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
16677825|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
16677827|NCT02098460|Placebo Comparator|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
16677828|NCT02098460|Placebo Comparator|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
16677829|NCT02098460|Active Comparator|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
16677830|NCT02098447|Experimental|auricular vagal nerve stimulation|"Study participants (healthy and diabetics) are treated with auricular vagal nerve stimulation using four needle electrodes connected to an electrical stimulation device (PrimeStim). After an acclimatization phase the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and another 10 minutes paused stimulation. This intervention is repeated on four consecutive days. Needle electrodes stay fixed over the whole study period.
~Two different stimulation schemes are tested, each being assessed twice in random order. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.
~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
16677831|NCT02098434|Experimental|Montreal Imaging Stress Task|Math task to induce stress response
16677832|NCT02098421|No Intervention|Control|No oxytocin while the Foley bulb is in place
16677833|NCT02098421|Experimental|Oxytocin|Use of oxytocin while the Foley bulb is in place
16677834|NCT02098421|Experimental|PROMS Foley and oxytocin|Subjects who are induced due to premature rupture of membranes randomized to use of Foley bulb and oxytocin once the bulb is removed.
16677835|NCT02098421|No Intervention|PROMS no Foley bulb|Subjects who are induced due to premature rupture of membranes randomized to no Foley bulb.
16677836|NCT02098408|Experimental|Standard treatment + cognitive remediation|The cognitive remediation therapy targets neurocognition as well as social cognition.
16677837|NCT02098408|Active Comparator|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling
16677838|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
16677839|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
16677840|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
16677841|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
16677842|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
16677843|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
16677844|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
16677845|NCT02098369|Other|Usual care|Written education material (basic)
16677846|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
16677847|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
16677848|NCT02098356|Experimental|Low bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
16677849|NCT02098343|Experimental|Phase Ib. APR-246 + Carboplatin/PLD.|Dose escalation of APR-246.
16677850|NCT02098343|Experimental|Phase II: Arm A. APR-246 + Carboplatin/PLD.|Experimental
16677851|NCT02098343|Active Comparator|Phase II: Arm B. Carboplatin/PLD.|Active Comparator
16677852|NCT02098330|Active Comparator|: Ginkgo biloba & methylprednisolone|Patients receive Ginkgo biloba & methylprednisolone per oral.
16677853|NCT02098330|Placebo Comparator|Ginkgo biloba|Patients receive Ginkgo biloba per oral.
16677854|NCT02098317|Experimental|TREATED GROUP|this group will treated with pearls containing DHA plus Vitamin D3 (500 mg and 800 IU, respectively) given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
16677855|NCT02098317|Placebo Comparator|PLACEBO GROUP|this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
16677856|NCT02098304|Other|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
16677857|NCT02098291|Experimental|G17DT|
16677858|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
16677859|NCT02098265|Experimental|Experimental Group - Immediate BCI Therapy|EEG - BCI training (closed loop)
16677860|NCT02098265|Experimental|Experimental Group - Delayed BCI Therapy|Scanned and tested 4 times over a 10-week period before EEG-BCI training
16677861|NCT02098265|Experimental|Experimental Group - RecoveriX|Recruited from participants who have completed the study intervention
16677862|NCT02098265|Active Comparator|Control Group 1|48 stroke patients, 48 participants with risk factors for stroke, 48 healthy controls receiving 4-6 training sessions on the EEG-BCI, pre- and post- behavioral testing, and MRI
16677863|NCT02098265|Active Comparator|Control Group 2|24 Stroke Patients with UE impairment receiving standard FES only therapy
16677864|NCT02098252|Active Comparator|Interventional therapy|"Interventional therapies include:
~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).
~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
16677900|NCT02097992|Experimental|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
16682988|NCT02063997|Active Comparator|Allopurinol 300 mg|
16677865|NCT02098252|No Intervention|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
16677866|NCT02098239|Active Comparator|Group A|Jaundiced patients with bilirubin value >80 μmol/L. Received G17DT immediately prior to biliary stenting.
16677867|NCT02098239|Active Comparator|Group B|Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was <40 μmol/L.
16677868|NCT02098213|Active Comparator|Immediate Spa treatment|Three week course of spa treatment soon after randomization
16677869|NCT02098213|Sham Comparator|Late Spa treatment|Three week course of spa treatment soon after 4,5 months visit
16677870|NCT02098200|Experimental|Percutaneous treatment of TR by TriCinch|Percutaneous treatment of Tricuspid Regurgitation with TriCinch System
16677871|NCT02098187|Active Comparator|Below target dose MP-3180|0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
16677872|NCT02098187|Active Comparator|2 times above target dose MP-3180|2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
16677873|NCT02098187|Active Comparator|4 times above target dose MP-3180|4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
16677874|NCT02098187|Active Comparator|At target dose MP-3180|1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
16677875|NCT02098174|Experimental|Healthy participants|MP-3180 (1 µmol/kg or 0.372 mg/kg) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol comparator (Omnipaque 300, 5 mL) was then administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
16677876|NCT02098161|Experimental|Treatment (SMAC mimetic LCL161)|Patients receive SMAC mimetic LCL161 PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16677877|NCT02098148|Experimental|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
16677878|NCT02098148|Experimental|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
16677879|NCT02098135|Experimental|ArmeoSenso|The ArmeoSenso system is an easy to set up and use upper limb rehabilitation system for the home environment. It consists of a motion capture system based on wearable sensors in combination with a personal computer as well as a therapy software that provides an ergonomic user interface, therapy games and automated assessments.
16677880|NCT02098122||Tetraplegia|
16677881|NCT02098122||Paraplegia|
16677882|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)
~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)
~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)
~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
16677883|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)
~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)
~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)
~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
16677884|NCT02098096|Experimental|Negative Work|Negative work exercise via isokinetic knee extension/flexion will be performed twice per week for 12 weeks.
16677885|NCT02098096|Placebo Comparator|Stretching|A home exercise program consisting of stretches for the major lower extremity muscles groups will be performed twice per week for 12 weeks.
16677886|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
16677887|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
16677888|NCT02098057|Placebo Comparator|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
16677889|NCT02098057|Active Comparator|Gluten|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
16677890|NCT02098044||Professional footballers|Retired professional footballers
16677891|NCT02098044||Control Population|members of the general public recruited from the east midlands region
16677892|NCT02098031|No Intervention|control|
16677893|NCT02098031|Experimental|intervention|Nutritional intervention (nutrition education)
16677894|NCT02098018|Active Comparator|Program 1|Program 1
16677895|NCT02098018|Active Comparator|Program 2|Program 2
16677896|NCT02098005|Active Comparator|Usual care|usual care evidence-based physiotherapy
16677897|NCT02098005|Experimental|modern neuroscience approach|modern neuroscience approach
16677898|NCT02097992|Experimental|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
16677899|NCT02097992|Experimental|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
16677901|NCT02097992|Experimental|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
16677902|NCT02097979|Experimental|Glaucoma Educational Intervention|
16677903|NCT02097979|No Intervention|Delayed Intervention|
16677904|NCT02097953|Experimental|Daptomycin and Rifampin|Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on the first study day Drug: Rifampin Rifampin 600 mg capsules will be given orally once daily for 14 days starting on study day 2 Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on study day 15
16677905|NCT02097940|Active Comparator|treatment|The treatment group performed of proprioceptive exercises with shifts and one-leg jumps.
16677906|NCT02097940|No Intervention|control|The control group remained in soccer training
16677907|NCT02097927|Experimental|High energy, low sensory|Mango-flavour beverage
16677908|NCT02097927|Experimental|Low energy, high sensory|Mango-flavour beverage
16677909|NCT02097927|Experimental|High energy, high sensory beverage|Mango-flavour beverage
16677910|NCT02097914|No Intervention|Control|Participant receives usual care.
16677911|NCT02097914|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
16677912|NCT02097901|Experimental|Microfracture|Rotator Cuff Repair AND Microfracture at rotatorcuff footprint
16677913|NCT02097901|Active Comparator|NO microfracture|Rotator cuff reinsertion without microfracture
16677914|NCT02097875|Experimental|BLZ-100|A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.
16677915|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:
~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
16677916|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:
~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
16677917|NCT02097836|Experimental|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
16677918|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.
~Olanzapine dosing:
~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses
~Aprepitant dosing:
~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
16677919|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.
~Olanzapine dosing:
~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses
~Aprepitant dosing:
~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
16677920|NCT02097810|Experimental|Entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)
16677921|NCT02097797|Experimental|Fecal Transplantation|patients receiving the fecal transplant (fecal microbiota from a healthy donor)
16677922|NCT02097797|Sham Comparator|Sham Transplantation|patients receiving the vehicle (Physiological serum)
16677923|NCT02097784|Other|cirrhosis with portal hypertension,ascite and acute kidney|
16677924|NCT02097771|Active Comparator|LMA SupremeTM|
16677925|NCT02097771|Sham Comparator|Ambu AuraOnce|
16677926|NCT02097758|Experimental|transcatheter device closure|Choosing device size using three dimensional image and the formula without sizing balloon
16677927|NCT02097745|Experimental|MabThera/Rituxan|
16677928|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
16677929|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
16677930|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
16677931|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
16677932|NCT02097706|Active Comparator|NMDA receptor antagonist|20mg/daily for 8 weeks (56 days)
16677933|NCT02097706|Placebo Comparator|Placebo tablet|1 capsule/daily for 8 weeks (56 days)
16677934|NCT02097693||dyston-dyskinetic cerebral palsy|Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi
16677935|NCT02097680|Experimental|Letrozole|
16677936|NCT02097680|Placebo Comparator|Placebo comparator|
16677937|NCT02097654|Experimental|SENATOR|Physicians attending multi-morbid older patients i.e. with 3 or more chronic medical conditions receive a SENATOR software-generated report with advice details on potentially inappropriate pharmacotherapy and/or potentially inappropriate prescribing omissions.
16677938|NCT02097654|No Intervention|Control|Standard pharmaceutical care as per local practice.
16677939|NCT02097641|Experimental|Human Mesenchymal Stromal Cells (hMSCs)|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
16677940|NCT02097641|Placebo Comparator|Plasma-Lyte A (placebo)|A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.
16678053|NCT02096978|Experimental|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
16677941|NCT02097628|Active Comparator|pressure-controlled ventilation|pressure-controlled ventilation: a peak airway pressure that provided a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column, respiratory rate 12-16 times per minute.
16677942|NCT02097628|Experimental|volume-controlled ventilation|volume-controlled ventilation: tidal volume 8-12ml/kg, respiratory rate 12-16 times per minute.
16677943|NCT02097615|Experimental|chlorhexidine gluconate|application every 24 hours, six weeks
16677944|NCT02097615|Other|Other: deionized water|application every 24 hours, six weeks
16677945|NCT02097589|Experimental|Pneumovax-Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
16677946|NCT02097589|Placebo Comparator|Pneumovax-Placebo|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
16677947|NCT02097576|Active Comparator|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
16677948|NCT02097576|Active Comparator|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
16677949|NCT02097563|Experimental|High Intensity Training|High intensity training: clinician attends a 6-hr live workshop in family-focused treatment techniques, and then, after taking on a case, gets weekly technical consultation sessions (by telephone) in FFT from an expert after every session;
16677950|NCT02097563|Active Comparator|Low Intensity Training|Low Intensity Training: clinician completes online workshop in FFT and then, after taking on a case, gets telephone consultation sessions after every third session.
16677951|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
16677952|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
16677953|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
16677954|NCT02097524|Experimental|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
16677955|NCT02097524|Experimental|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
16677956|NCT02097524|Active Comparator|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
16677957|NCT02097524|Active Comparator|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
16677958|NCT02097511|Experimental|Sarpogrelate pretreatment and Metoprolol|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
16677959|NCT02097511|Active Comparator|Sarpogrelate and Metoprolol|Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
16677960|NCT02097511|Active Comparator|Metoprolol only|Metoprolol Tartrate 100 mg once a day
16677961|NCT02097498|No Intervention|Simulation only|One group will be randomized to receive simulation training similar to that required for certification. Paramedics in this group will then complete a second simulation scenario
16677962|NCT02097498|Experimental|Directed feedback|One group will review their baseline simulation scenario with a member of the research staff while providing specific feedback for errors made during the first simulation. Paramedics in this group will then complete a second simulation scenario.
16677963|NCT02097498|Experimental|Basic Videolaryngoscopy|One group will review a series of instructional videos related to common airway management errors. Paramedics in this group will then complete a second simulation scenario.
16677964|NCT02097485|Active Comparator|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
16677965|NCT02097485|Placebo Comparator|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
16677966|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
16677967|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
16677968|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
16677969|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
16677970|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
16677971|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
16677972|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
16679181|NCT02089165|Active Comparator|Fish oil|The interventions are administered in the randomized order.
16677973|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
16677974|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
16677975|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
16677976|NCT02097459|Experimental|Failed group|Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy.
16677977|NCT02097459|Experimental|Succeeded group|Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy.
16677978|NCT02097459|Active Comparator|No chang group|Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy.
16677979|NCT02097446|Experimental|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
16677980|NCT02097446|Active Comparator|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
16677981|NCT02097433|Experimental|Dacomitinib|
16677982|NCT02097420|Other|Single device arm|Mitral valve replacement
16677983|NCT02097407|Experimental|Group D : Dexmedetomidine + propofol group|In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
16677984|NCT02097407|Placebo Comparator|Group C : Saline + propofol group|In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.
16677985|NCT02097394|Active Comparator|Combizym-treated group|The patients who received polypectomy of colon polyps take the digestion enzyme (Combizym) regularly.
16677986|NCT02097394|Active Comparator|Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take Bifidobacteri regularly
16677987|NCT02097394|Active Comparator|Combizym + Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take drugs (Combizym + Bifidobacteri) regularly
16677988|NCT02097394|No Intervention|control|The patients who received polypectomy of colon polyps take no drugs
16677989|NCT02097381|Other|naïve for cART that met the criteria to start treatment|"patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.
~These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy."
16677990|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
16677991|NCT02097355|Experimental|TriVox Active|Provider using TriVox for clinical care
16677992|NCT02097355|No Intervention|TriVox Delayed-start|Providers not using TriVox for clinical care
16677993|NCT02097342|Experimental|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
16677994|NCT02097342|Placebo Comparator|Placebo|Tablet Placebo per oral, once daily will be given to 10 patients for 6 months
16677995|NCT02097342|Active Comparator|Voglibose|Tablet Voglibose (0.2mg) per oral, thrice daily (with meals) will be given to 10 patients for 6 months
16677996|NCT02097329|Experimental|Cohort 1: Palbociclib under fed conditions|
16677997|NCT02097329|Experimental|Cohort 2: Palbociclib under fed conditions|
16677998|NCT02097316|Experimental|JewelPump|JewelPump for the first treatment period followed by the usual pump for the second treatment period
16677999|NCT02097316|Active Comparator|Usual insulin pump|Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.
16678000|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
16678001|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
16678002|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
16678003|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
16678004|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
16678005|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
16678006|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks
~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
16678007|NCT02097264|Experimental|NNC0109-0012|
16678008|NCT02097264|Active Comparator|Adalimumab|
16678009|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
16678010|NCT02097225|Experimental|Treatment (dabrafenib, trametinib, onalespib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16678011|NCT02097199||Sports group|The cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
16678054|NCT02096978|Active Comparator|Drill preparation|Preparing the osteotomy to accept a standard implant device
16678012|NCT02097186|Experimental|Remote ischaemic preconditioning|Remote ischaemic preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
16678013|NCT02097186|No Intervention|Control to remote preconditioning group|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
16678014|NCT02097173|Other|SC MTX followed by IM MTX|1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week
16678015|NCT02097173|Other|IM MTX followed by SC MTX|1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL) after a wash-out phase of 1 week
16678016|NCT02097160|Active Comparator|Control Group 1|regular fortified milk + regular cheese/yogurt
16678017|NCT02097160|Experimental|Intervention Group 2|Vitamin D fortified yogurt and cheese; vitamin D dose increment of 252 IU vs grp 1
16678018|NCT02097160|Experimental|Intervention Group 3|Vitamin D fortified yogurt and cheese, vitamin D dose increment of 420 IU vs grp 1
16678019|NCT02097147|Experimental|Vilazodone 20 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.
16678020|NCT02097147|Experimental|Vilazodone 40 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days, followed by vilazodone 40 mg once daily for 21 days
16678021|NCT02097147|Active Comparator|Paroxetine 20 mg|Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days
16678022|NCT02097147|Placebo Comparator|Placebo|Placebo once daily for 35 days
16678023|NCT02097134|Experimental|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16678024|NCT02097121|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
16678025|NCT02097121|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
16678026|NCT02097121|Experimental|OnabotulinumtoxinA Dose C|OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
16678027|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
16678028|NCT02097095||Vaccine group|TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
16678029|NCT02097095||Placebo Comparator|Placebo administered on study TB-018
16678030|NCT02097082|Experimental|STANZA Drug-eluting Resorbable Scaffold|Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold
16678031|NCT02097069|Other|Subgroup A|folic acid 400 mcg/day
16678032|NCT02097069|Experimental|Subgroup B|myo-inositol 2000 mg twice a day
16678033|NCT02097069|Experimental|Subgroup C|D-chiro-inositol 250 mg twice a day
16678034|NCT02097069|Experimental|Subgroup D|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
16678035|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
16678036|NCT02097043|Experimental|[Group 1] DA-7218|200mg, By mouth or orally (PO) & intravenous(IV) administration
16678037|NCT02097043|Placebo Comparator|[Group 1] Placebo|Placebo, By mouth or orally (PO) & intravenous(IV) administration
16678038|NCT02097043|Experimental|[Group 2] DA-7218|400mg, By mouth or orally (PO) administration
16678039|NCT02097043|Placebo Comparator|[Group 2] Placebo|Placebo, By mouth or orally (PO) administration
16678040|NCT02097043|Experimental|[Group 3] DA-7218|600mg, By mouth or orally (PO) administration
16678041|NCT02097043|Placebo Comparator|[Group 3] Placebo|Placebo, By mouth or orally (PO) administration
16678042|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
16678043|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
16678044|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
16678045|NCT02097017|Active Comparator|lidocaine spray group|
16678046|NCT02097017|Placebo Comparator|placebo arm|
16678047|NCT02097004|Experimental|Concomitant:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks
~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
16678048|NCT02097004|Experimental|Sequential:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks
~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks
~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
16678049|NCT02097004|Active Comparator|Control Group|"Continue Entecavir(0.5mg) for 100 weeks(once daily)
~After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks"
16678050|NCT02096991|Active Comparator|Glass|consume beverage in glass first and cross over to other interventions
16678051|NCT02096991|Experimental|Can 1|consume one canned beverage and a glass bottled beverage first and cross over to other interventions
16678052|NCT02096991|Experimental|Can 2|Consume two canned beverage first and cross over to other interventions
16678055|NCT02096965|Experimental|Tolvaptan first, then Placebo|Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)
16678056|NCT02096965|Experimental|Placebo first, then Tolvaptan|Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)
16678057|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
16678058|NCT02096939||Primary aldosteronism|Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists
16678059|NCT02096939||Essential hypertension|Patients with essential hypertension who will be started on antihypertensive medication
16678060|NCT02096926|Placebo Comparator|Placebo|placebo
16678061|NCT02096926|Active Comparator|Ibuprofen|400 mg PO
16678062|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 4 weeks|
16678063|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 12 weeks|
16678064|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
16678065|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
16678066|NCT02096887|Other|Patient Education|Patient Education
16678067|NCT02096874|Other|Bevacizumab|Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.
16678068|NCT02096861|Experimental|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
16678069|NCT02096861|Active Comparator|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
16678070|NCT02096861|Active Comparator|Remicade - Remicade|Remicade followed by Remicade from Week 30
16678071|NCT02096861|Experimental|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
16678072|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
16678073|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
16678074|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
16678075|NCT02096822|Active Comparator|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
16678076|NCT02096822|Experimental|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
16678077|NCT02096809|Experimental|One week loading of Bone Anchored Hearing Aid (BAHA)|Bone Anchored Hearing Aid (BAHA) loading after one week
16678078|NCT02096796||persons without arm pump|
16678079|NCT02096796||persons with arm pump|
16678080|NCT02096783|Active Comparator|Arm I (standard counseling)|Patients receive standard counseling at both the pre-operative and 2-4 week post-operative visit.
16678081|NCT02096783|Experimental|Arm II (standard counseling, scripted intervention)|Patients receive standard counseling at the pre-operative visit and the scripted sexual health intervention at the 2-4 week post-operative visit.
16678082|NCT02096783|Experimental|Arm III (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at the pre-operative visit and standard counseling at the 2-4 week post-operative visit.
16678083|NCT02096783|Experimental|Arm IV (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at both the pre-operative and 2-4 week post-operative visit.
16678084|NCT02096757|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
16678085|NCT02096757|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
16678086|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
16678087|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
16678088|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
16678089|NCT02096731||LABA + tiotropium|
16678090|NCT02096731||LABA mono|
16678091|NCT02096731||neither tiotropium nor LABA|
16678092|NCT02096731||tiotropium + LABA|
16678093|NCT02096731||tiotropium mono|
16678094|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
16678095|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
16678096|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
16678097|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
16678098|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
16678099|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
16678100|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
16678101|NCT02096666|Experimental|Single arm|
16678102|NCT02096653|Experimental|X-ray guided intra-articular injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
16678103|NCT02096653|Active Comparator|Landmark-guided SI joint injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
16678173|NCT02096224|Active Comparator|Desflurane|Desflurane will be administered as the maintenance agent of general anesthesia.
16678104|NCT02096640|Active Comparator|Percutaneous dilatation tracheostomy: Smiths Medical|Type of surgical teqnique for tracheostomy: Percutaneous dilatation tracheostomy. The set for the tracheostomy is bought from Smiths Medical TM.
16678105|NCT02096640|Active Comparator|Open surgery tracheostomy|Type of surgical teqnique for tracheostomy: Open surgical tracheostomy
16678106|NCT02096627||conventional|Patients who undergo routine cataract surgery using conventional phacoemulsification technique
16678107|NCT02096627||FLACS|Patients who undergo femtosecond laser assisted cataract surgery
16678108|NCT02096614|Experimental|Low dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
16678109|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
16678110|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 2|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
16678111|NCT02096614|Experimental|TBI-1201 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
16678112|NCT02096601|Experimental|ND0612|Levodopa and carbidopa SC solution
16678113|NCT02096601|Active Comparator|Oral levodopa and carbidopa|Oral levodopa and carbidopa
16678114|NCT02096588|Experimental|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
16678115|NCT02096588|Active Comparator|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
16678116|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.
~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
16678117|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.
~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
16678118|NCT02096562|Placebo Comparator|B - No compression stockings|normal therapy - no compression stockings
16678119|NCT02096562|Active Comparator|A - Use of compression stockings|Patients use compression stockings for 10 days after surgery
16678120|NCT02096536|Other|Vancomycin|All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.
16678121|NCT02096523|Experimental|platelet disease|patients with inherited platelet disorders
16678122|NCT02096523|Experimental|Healthy|Healthy family members of patients with inherited platelet disorders
16678123|NCT02096510|Experimental|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
16678124|NCT02096510|Active Comparator|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
16678125|NCT02096510|Experimental|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
16678126|NCT02096497||Vascular pattern 1|
16678127|NCT02096497||Vascular pattern 2|
16678128|NCT02096497||Vascular pattern 3|
16678129|NCT02096497||Vascular pattern 4|
16678130|NCT02096497||Vascular pattern 5|
16678131|NCT02096497||Vascular pattern 6|
16678132|NCT02096497||Vascular pattern 7|
16678133|NCT02096497||Vascular pattern 8|
16678134|NCT02096497||Vascular pattern 9|
16678135|NCT02096497||Vascular pattern 10|
16678136|NCT02096497||Vascular pattern 11|
16678137|NCT02096484|Experimental|Metacognitive Therapy|Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
16678138|NCT02096484|Experimental|Mindfulness Meditation Therapy|Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
16678139|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
16678140|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
16678141|NCT02096445|Experimental|Robot group|"Receive robot-assisted neurocognitive therapy instead of conventional neurocognitive therapy.
~(4 x 45 min/week)"
16678142|NCT02096445|Active Comparator|Control group|Receive dose-matched conventional neurocognitive therapy
16678143|NCT02096432|Experimental|Behavioral: Behavioral Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
16678144|NCT02096432|Other|Usual Community Care|Community standard care as usual
16678145|NCT02096419|No Intervention|control group|Patients in this group will receive standard clopidogrel dose
16678146|NCT02096419|Experimental|interventional group|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).
~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.
~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
16678147|NCT02096406|Other|ACE/ARB Continuation|ACE/ARB will be continued up to and including the morning of surgery.
16678148|NCT02096406|Other|ACE/ARB withdrawal|ACE/ARB will be discontinued medication 48 hours prior to surgery
16678149|NCT02096393|Experimental|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
16678150|NCT02096393|Active Comparator|Standard instrumentation|The patient will undergo surgery using standard instrumentation
16678151|NCT02096380||one cycle induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil
~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
~Other Names:
~docetaxel, cisplatin and fluorouracil"
16678152|NCT02096380||three cycles induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil
~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
~Other Names:
~docetaxel, cisplatin and fluorouracil"
16678153|NCT02096367|Experimental|Hemiplegia after vascular stroke|"Muscle vibration stimulation
~Gait analysis with Gait Rite : quantitative and spatio-temporal gait parameters
~Kinematic gait analysis in lower limb measured by optoelectronic system (Optitrack).
~Analysis of static posture on force platform
~Evaluation of the gait on treadmill during 2 minutes"
16678154|NCT02096354|Experimental|RRx-001 followed by irinotecan|Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
16678155|NCT02096354|Active Comparator|Regorafenib followed by irinotecan|Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
16678156|NCT02096341|Experimental|RRx-001|RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses-16 and 27 mg/m2- will be tested.
16678157|NCT02096328|Experimental|POL7080, Anti-pseudomonal antibiotics|POL7080 daily co-administered with standard of care treatment
16678158|NCT02096315|Experimental|POL7080|POL7080 administered daily
16678159|NCT02096302|Experimental|Experimental Formula|Infant formula with a novel probiotic CECT7210
16678160|NCT02096302|Active Comparator|Standard Formula|Standard infant formula without probiotics
16678161|NCT02096289|Experimental|Thioridazine|Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study).
16678162|NCT02096276||Exposure Group_Prospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and prospective (i.e., registration to registry is done before the outcome of the pregnancy is known)
16678163|NCT02096276||Exposure Group_Retrospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and retrospective (i.e., pregnancy outcome is already known at the time of registration to Registry)
16678164|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
16678165|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
16678166|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
16678167|NCT02096250|Experimental|NaFeEDTA|NaFeEDTA
16678168|NCT02096250|Experimental|Ferrous fumarate|Ferrous fumarate
16678169|NCT02096250|Experimental|NaFeEDTA + ferrous fumarate|NaFeEDTA + ferrous fumarate
16678170|NCT02096237|Experimental|apheresis, IgE adsorber|9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
16678171|NCT02096237|No Intervention|Conventional drug treatment|Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
16678172|NCT02096224|Experimental|Sevoflurane|Sevoflurane will be administered as the maintenance agent of general anesthesia.
16678174|NCT02096211||CERAMAX COC 36mm Acetabular Cup|The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
16678175|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
16678176|NCT02096185|Experimental|3 dimensional tomosynthesis imaging|Breast specimen to be x-rayed using both conditions 3 dimensional tomosynthesis imaging 2 dimensional conventional digital imaging
16678177|NCT02096185|Experimental|2 dimensional digital imaging|Breast specimens to be x-rayed under both conditions 3 dimensional tomosynthesis imaging 2 dimensional digital imaging
16678178|NCT02096159|Experimental|Antibiotics|trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days
16678179|NCT02096159|Placebo Comparator|Placebo|placebo oral suspension, 0.5 mL/kg twice daily for 10 days
16678180|NCT02096146|Other|TMT Fusion Plate|Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
16678181|NCT02096146|Other|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .
16678182|NCT02096133|Experimental|Cholecalciferol|Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
16678183|NCT02096133|Placebo Comparator|Placebo comparator|placebo drops during 16 weeks
16678184|NCT02096120||All patients|
16678185|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
16678186|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
16678187|NCT02096094|Experimental|Chlorhexidine bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes impregnated with 2% chlorhexidine and with shampoo with 0.15% chlorhexidine.
16678188|NCT02096094|Placebo Comparator|Control bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes and shampoo without chlorhexidine.
16678189|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
16678190|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
16678191|NCT02096068|Experimental|Study group|"Application of Dexmedetomidine (Dexdor®) perioperatively for a maximum of 48 hours
~Dosing Scheme:
~during operation and mechanical ventilation: 0,7μg/kgABW/h; recovery time until extubation: 0,4μg/kgABW/h; after extubation: 0,2-1,4μg/kgABW/h"
16678192|NCT02096068|Placebo Comparator|Control group|Application of placebo for a maximum of 48 hours
16678193|NCT02096068|No Intervention|POCD control group|A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
16678194|NCT02096055|Experimental|Arm I (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine as in Induction therapy. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
16678195|NCT02096055|Experimental|Arm II (CLOSED) (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-10. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 (days 1-10 of courses 1 and 2). Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
16678196|NCT02096055|Experimental|Arm III (guadecitabine, idarubicin)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on days 1-2. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on day 1. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
16678197|NCT02096055|Experimental|Arm IV (CLOSED) (guadecitabine, cladribine)|"INDUCTION THERPAY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
16678198|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
16678199|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
16678200|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
16678201|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
16678202|NCT02096016||Human Papilloma Virus test|"Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.
~It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study"
16678203|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
16678204|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
16678205|NCT02095990|Experimental|Hydroquinone|"Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.
~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.
~It will be applied daily, at night, during 8 weeks."
16678206|NCT02095990|Placebo Comparator|Placebo|"Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.
~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.
~It will be applied daily, at night, during 8 weeks."
16678207|NCT02095977|Other|participants|all subjects meeting inclusion and none of exclusion criteria
16678208|NCT02095964||Cardiac Syndrome X|
16678209|NCT02095964||Control Group|
16678210|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
16678211|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
16678212|NCT02095938|Experimental|Solian|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
16678213|NCT02095925||cancer patients|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
16678214|NCT02095899|Experimental|Rufinamide|- oral Rufinamide administration as ad-on to Oxycodone
16678215|NCT02095899|Placebo Comparator|Manitol|- oral Placebo administration - as ad-on to Oxycodone
16678216|NCT02095886|Experimental|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
16678217|NCT02095886|Experimental|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
16678218|NCT02095886|Experimental|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
16678219|NCT02095886|Experimental|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
16678220|NCT02095886|Experimental|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
16678221|NCT02095886|Experimental|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
16678222|NCT02095886|Experimental|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
16678223|NCT02095886|Experimental|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
16678224|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
16678225|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
16678226|NCT02095860|Experimental|Treatment A: DCV 3DAA FDC fasted state|DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state
16678227|NCT02095860|Experimental|Treatment B: DCV 3DAA FDC with high-fat meal|DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal
16678228|NCT02095860|Experimental|Treatment C: DCV 3DAA FDC with light meal|DCV 3DAA FDC tablet by mouth once on specified days with light meal
16678229|NCT02095847|Experimental|Hysteroscope Imaging|All patients entered in study will undergo cervical dilation after induction of general anesthesia. Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the High-Resolution Microendoscopy (HRME) camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera. The resectoscope will then be used to remove all tumor as guided through HRME images. The entire imaging and tumor resection process is estimated to take 45 minutes or less.
16678230|NCT02095834|Experimental|Treatment (dexamethasone, bendamustine, carfilzomib)|Patients receive dexamethasone PO or IV over 20 minutes on days 1, 2, 8, 9, 15, 16, 22, and 23 of courses 1-3; on days 1, 2, 15, and 16 of courses 4-12; and on days 1 and 2 of all subsequent courses. Patients also receive bendamustine hydrochloride IV over 10 minutes on days 1 and 2 of courses 1-3 and on day 1 of all subsequent courses and carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of courses 1-12 and on days 1, 2, 15, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16678231|NCT02095821||Humoral rejection, TPE|
16678232|NCT02095808|Experimental|Surgery|"The 13C-glucose solution will be given intravenously. It will be started at about the same time as the start of surgery, according to the study guidelines.
~The 13C-glucose IV solution will be stopped once the surgeon has removed the tumor tissue."
16678279|NCT02095470|Placebo Comparator|traditional laryngoscope|comparison to active group with routine laryngoscope
16678597|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
16678233|NCT02095795|Experimental|Technological Rehabilitation|Patients in the experimental group received a multimodal treatment intervention consisting of 60 minutes of conventional treatment according to the Bobath approach (Bobath B. Adult hemiplegia: evaluation and treatment. Oxford: Butterworth-Heineman, 1990) followed by 30 minutes of robotic gait training on the Lokomat robotic system with the supervision of an expert rehabilitator. Patients started the first session with 50% weight unload and 1.5 Km/h gait speed, performances increments are allowed only in the following sessions. Each patient received 20 sessions over a period of 4 weeks (5 sessions per week).
16678234|NCT02095795|Active Comparator|Control Rehabilitation|Patients in the control group received the same number of treatment sessions of a similar duration as those in the experimental group but they received activities of overground walking exercises targeted to improve walking in substitution of the robotic gait trainer.
16678235|NCT02095782|Experimental|chemotherapy and erlotinib|Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation
16678236|NCT02095756|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of melasma
16678237|NCT02095743|Experimental|PICC line|Use of a PICC line for chemo administration (PowerPICC SOLO²)
16678238|NCT02095743|Active Comparator|Implanted Port|Use of an implanted port for chemo administration
16678239|NCT02095730|Active Comparator|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
16678240|NCT02095730|Active Comparator|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
16678241|NCT02095730|Active Comparator|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
16678242|NCT02095730|Active Comparator|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
16678243|NCT02095717|Experimental|Curcumin|curcumine capsule
16678244|NCT02095717|Placebo Comparator|Placebo|placebo capsule
16678245|NCT02095704|Experimental|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
16678246|NCT02095704|Experimental|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
16678247|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
16678248|NCT02095678|Experimental|HCC or metastatic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
16678249|NCT02095678|Active Comparator|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
16678250|NCT02095665|Active Comparator|Narcotic analegesic only|"Drug:
~Tylenol #3 1 tablet every six hours as necessary"
16678251|NCT02095665|Active Comparator|Mirabegron and narcotic analgesia|"Drug :
~Mirabegron 50 mg oral daily
~Drug:
~Tylenol #3 1 tablet every six hours as necessary"
16678252|NCT02095665|Active Comparator|Tamsulosin and narcotic analgesia|"Drug:
~Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary"
16678253|NCT02095665|Experimental|Mirabegron, Tamsulosin and narcotic|"Drug:
~Mirabegron 50 mg oral daily
~Drug:
~Tamsulosin 0.4mg oral daily
~Drug:
~Tylenol #3 1 tablet every six hours as necessary"
16678254|NCT02095639||ECT and Treatment Resistant Depression|Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two [18F]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.
16678255|NCT02095626|Experimental|AP301|Treatment group
16678256|NCT02095626|Placebo Comparator|Saline solution|
16678257|NCT02095613|Active Comparator|Corn-soy-blend plus|food A type of ground meal called corn-soy-blend plus
16678258|NCT02095613|Active Comparator|Ready-to-use-supplementary food|food A nutrient dense food comprised of peanuts, oil, multivitamins.
16678259|NCT02095600|Experimental|Radiosurgical thalamotomy|
16678260|NCT02095587|Experimental|Mild Hepatic Impairment|
16678261|NCT02095587|Experimental|Moderate Hepatic Impairment|
16678262|NCT02095587|Experimental|Healthy Subjects|
16678263|NCT02095587|Experimental|Severe Hepatic Impairment|Optional arm based on results from Arms 1, 2, and 3
16678264|NCT02095574|Experimental|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
16678265|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
16678266|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
16678267|NCT02095548|Experimental|SM04690, 0.03mg/2mL|Single, intra-articular injection of SM04690, 0.03mg/2mL
16678268|NCT02095548|Experimental|SM04690, 0.07mg/2mL|Single, intra-articular injection of SM04690, 0.07mg/2mL
16678269|NCT02095548|Experimental|SM04690, 0.23mg/2mL|Single, intra-articular injection of SM04690, 0.23mg/2mL
16678270|NCT02095548|Placebo Comparator|Placebo|Single, intra-articular injection of placebo
16678271|NCT02095535||Study group|All study participants
16678272|NCT02095522|Experimental|Colchicine|Colchicine 1mg per day for one month
16678273|NCT02095522|Placebo Comparator|Placebo|Placebo 1mg per day
16678274|NCT02095509|Active Comparator|Subcutaneous Enoxaparin|Subcutaneous enoxaparin 40 mg every 24 hours for three days
16678275|NCT02095509|Active Comparator|Intravenous Enoxaparin|40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)
16678276|NCT02095496|Experimental|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
16678277|NCT02095496|Active Comparator|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
16678278|NCT02095470|Experimental|videolaryngoscope group|video laryngoscopy was done for them
16682989|NCT02063997|Placebo Comparator|Placebo|
16678280|NCT02095457|Active Comparator|Frequent Monitoring and Feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
16678281|NCT02095457|Sham Comparator|Infrequent monitoring without feedback|In the control arm, patients will infrequently fill short monitoring questionnaires, the results of which are not fed back to their therapists and staff. The frequency of monitoring is between about once a year
16678282|NCT02095444|Experimental|Menstrual blood stem cells|1x10*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.
16678283|NCT02095431||with AKI and without AKI|development of AKI by sCr and by novel biomarkers
16678284|NCT02095418|Experimental|Mycophenolate mofetil, Corticosteroids|"Mycophenolate mofetil: 500-1500mg/day, bid, PO
~Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
16678285|NCT02095418|Active Comparator|Corticosteroids, Mycophenolate mofetil|"Mycophenolate mofetil: 500-1000mg/day, bid, PO
~Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
16678286|NCT02095405|Active Comparator|Caffeine arm|"SVT group: Caffeine tablets, 5 mg/kg.
~AF group: Caffeinated substances and Dark Chocolate"
16678287|NCT02095405|Placebo Comparator|Placebo arm|"SVT group: Placebo
~AF group: Decaffeinated substances and White Chocolate"
16678288|NCT02095392|Experimental|P1000/Ca0|
16678289|NCT02095392|Experimental|P1000/Ca500|
16678290|NCT02095392|Experimental|P1000/Ca1000|
16678291|NCT02095392|Placebo Comparator|Placebo|
16678292|NCT02095379||oligosecretary|Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
16678293|NCT02095366|Experimental|IN Sufentanil AND IV Placebo|Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
16678294|NCT02095366|Active Comparator|IV Morphine AND IN Placebo|Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray
16678295|NCT02095340|Experimental|Positive Training|
16678296|NCT02095340|Sham Comparator|Neutral Training|
16678297|NCT02095314|Experimental|Pentavalen|Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly
16678298|NCT02095301|Experimental|Control plus herbal extract|Control plus herbal extract
16678299|NCT02095301|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
16678300|NCT02095288||Healthy volunteers|Blood draw
16678301|NCT02095275||Acute kidney injury|ICU patients with Acute kidney injury
16678302|NCT02095262|Active Comparator|STAR2|Reactive auditory training
16678303|NCT02095262|Experimental|Treasure Hunter|Interactive auditory training
16678304|NCT02095262|Experimental|Submarine|Interactive auditory training
16678305|NCT02095249|Other|Pimonidazole|
16678306|NCT02095236|Experimental|experimental|Radioopaque fiducial markers or electro-magnetic transponders will be implanted into or in close proximity of the tumor. During a radiotherapy treatment session image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors The data will help to characterize tumor and organ motion during one treatment session which may in fact have impact on dose distribution
16678307|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
16678308|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
16678309|NCT02095210|Experimental|[68Ga]ABY-025 PET imaging|Radiolabeled [68Ga]ABY-025
16678310|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
~No Catheter Delivery will be used to deliver the medication."
16678311|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
~Catheter targeted delivery will be used to deliver the medication."
16678312|NCT02095184|Active Comparator|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
16678313|NCT02095184|Active Comparator|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
16678314|NCT02095184|Active Comparator|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
16678315|NCT02095184|Active Comparator|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
16678316|NCT02095184|Active Comparator|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
16678317|NCT02095184|Active Comparator|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
16678318|NCT02095171|Experimental|PRX002|
16678319|NCT02095171|Placebo Comparator|Placebo|
16678320|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
16678321|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
16678322|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
16678323|NCT02095132|Experimental|Treatment (irinotecan hydrochloride, adavosertib)|Patients receive irinotecan hydrochloride PO and adavosertib PO on days 1-5. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
16678324|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
16678325|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
16678326|NCT02095093|Experimental|Intellijoint HIP|Patient's will have their leg length and hip offset determined intraoperatively using Intellijoint HIP.
16678327|NCT02095093|Active Comparator|Outrigger|Control patients will have their leg length and hip offset determined intra-operatively using the standard at Mount Sinai Hospital, which is a pin and outrigger system.
16678328|NCT02095080|Experimental|Leucine intake|Dietary supplement: Leucine intake
16678329|NCT02095067|Experimental|Video consultation|Patients in this arm receive video consultation from physician at the emergency medical dispatch center
16678330|NCT02095067|No Intervention|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician at the emergency medical dispatch center.
16678331|NCT02095054|Experimental|Regorafenib + Cetuximab|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle. Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.
~Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle. Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.
~Symptom questionnaire completed at each study visit."
16678332|NCT02095041||Healthy Term infants|
16678333|NCT02095028|Experimental|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
16678334|NCT02095028|No Intervention|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
16678335|NCT02095015||Analysis population|All subjects enrolled in the study who meet the eligibility criteria
16678336|NCT02094989||diagnostic|
16678337|NCT02094976|Active Comparator|Group C|Group C means active comparator group which use chest rolls intraoperatively for prone position.
16678338|NCT02094976|Active Comparator|Group W|Group W means experimental group which use Wilson frame intraoperatively for prone position.
16678339|NCT02094976|Experimental|Group J|Group J means experimental group which use Jackson surgical table intraoperatively for prone position.
16678340|NCT02094963|Experimental|Ticagrelor|
16678341|NCT02094963|Active Comparator|Clopidogrel|
16678342|NCT02094950|Experimental|Lung Cancer Patient with Dyspnea|
16678343|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
16678344|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
16678345|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
16678346|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
16678347|NCT02094924|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1 and treatment B in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
16678348|NCT02094924|Experimental|Sequence 2|Participants in this arm will receive treatment B in period 1 and treatment A in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
16678349|NCT02094911|Experimental|Combined lifestyle intervention|Lifestyle counselling (nutrition and physical activity) by dietician and physiotherapist during 10-month intervention period
16678350|NCT02094911|Other|Usual care group|Subjects receive brochures on healthy lifestyle at baseline, and during the 10-month intervention period only usual care as provided by their own general practitioner.
16678351|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
16678352|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
16678353|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
16678354|NCT02094872|Experimental|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
16678355|NCT02094859||GlucoClear System|
16678356|NCT02094846|Active Comparator|Voice messages|This group receive voice messages to reinforce given information about diet, physical activity, glycemic index
16678357|NCT02094846|Placebo Comparator|Messages|This group received voice messages with fun facts.
16678358|NCT02094833|Experimental|Group A|Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age
16678359|NCT02094833|Active Comparator|Group B|Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim™) at age 2, 4, and 6 months
16678360|NCT02094820||Single Group Study|Questionnaires
16678361|NCT02094807|Other|Conservative management|Not operated. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
16678362|NCT02094807|Active Comparator|Operative management|Operative fixation of rib fractures. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
16678363|NCT02094794|Experimental|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
16678364|NCT02094781|Experimental|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
16678365|NCT02094781|Active Comparator|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
16678366|NCT02094781|Placebo Comparator|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
16678367|NCT02094768|Experimental|Reduced Fat Milk|20 oz. reduced fat (2%) milk per day
16678368|NCT02094768|Experimental|Sugar Sweetened Soda|24oz. soda per day
16678369|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
16678370|NCT02094742|Other|all-commers|All patients will undergo a biopsy of their metastatic lesion and have a blood sample taken for molecular screening purposes. No drugs are administered or other interventions are performed.
16678371|NCT02094729|Experimental|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
16678372|NCT02094729|Experimental|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
16678373|NCT02094729|Experimental|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
16678374|NCT02094729|Placebo Comparator|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
16678375|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
16678376|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
16678377|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
16678378|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
16678379|NCT02094703|Experimental|levofloxacin and solifenacin succinate|Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days
16678380|NCT02094703|Active Comparator|levofloxacin and placebo|Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days
16678381|NCT02094690|Active Comparator|Device Hyperboloid|"5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy (RT) and kept until the end of RT.
~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
16678382|NCT02094690|Active Comparator|Device Therabite|"10 repetitions holding the device Therabite for 30 seconds
~5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT.
~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
16678383|NCT02094690|No Intervention|Control|The control group (GEC) will not receive any of the protocols tested in the study, but together with the other groups, will receive the regular treatment offered by the institution, which is made up of guidance and advice given by the hospital´s nursing team about the radiotherapy treatment. Currently, patients do not receive any information as far as trismus is concerned.
16678384|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
16678385|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
16678386|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
16678387|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
16678388|NCT02094651|Experimental|divalproex sodium|divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks
16678389|NCT02094651|Placebo Comparator|Placebo|Blue and white capsules with equivalent amount of lactose spheres/beads inside Placebo will be formulated to look identical to the active medication
16678390|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
16678431|NCT02094339|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
16678432|NCT02094339|Active Comparator|Nerve Block|People in this group will receive a postoperative pain management by continuous lumbar plexus block with 0.2% ropivacaine.
16678552|NCT02093481|Experimental|+ ind. CHO + prim|Test meal: ate intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
16678391|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.
~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
16678392|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
16678393|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
16678394|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
16678395|NCT02094599|Experimental|All Enrolled Participants|Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
16678396|NCT02094586|Experimental|PXVX0200 Lot A|PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
16678397|NCT02094586|Experimental|PXVX0200 Lot B|PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
16678398|NCT02094586|Experimental|PXVX0200 Lot C|PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
16678399|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
16678400|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
16678401|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
16678402|NCT02094560|Experimental|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
16678403|NCT02094560|Experimental|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
16678404|NCT02094560|Experimental|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
16678405|NCT02094547|Experimental|New infant formula|New infant formula with key ingredients.
16678406|NCT02094547|Active Comparator|Standard infant formula|Standard infant formula
16678407|NCT02094547|Other|Breastfeeding|Control
16678408|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
16678409|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
16678410|NCT02094521|Experimental|NNC0113-0987|
16678411|NCT02094495||breast cancer group|Taking tamoxifen
16678412|NCT02094482|Other|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
16678413|NCT02094469|Other|Cilostazol|Cilostazol 50mg and 100mg
16678414|NCT02094456|Experimental|Endoscopic clipping of diverticula|Endoscopic clipping of diverticula Follow-up colonoscopy
16678415|NCT02094443|Experimental|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
16678416|NCT02094443|Experimental|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
16678417|NCT02094430|Experimental|FGTW|
16678418|NCT02094417|Experimental|AMG531 (Dose 1)|
16678419|NCT02094417|Experimental|AMG531 (Dose 2)|
16678420|NCT02094417|Experimental|AMG531 (Dose 3)|
16678421|NCT02094417|Experimental|AMG531 (Dose 4)|
16678422|NCT02094404||Children at the ED<18yr|
16678423|NCT02094391|Experimental|Ipilimumab|
16678424|NCT02094391|No Intervention|No Ipilimumab|
16678425|NCT02094378|Experimental|Esketamine-Placebo|Participants assigned to treatment sequence 1 will receive 84 mg esketamine intranasally on Day 1 of Period 1 and then receive placebo intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
16678426|NCT02094378|Placebo Comparator|Placebo-Esketamine|Participants assigned to treatment sequence 2 will receive placebo intranasally on Day 1 of Period 1 and then receive 84 mg esketamine intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
16678427|NCT02094365|Experimental|ALS-008176|ALS-008176 drug substance for oral suspension
16678428|NCT02094365|Placebo Comparator|vehicle alone|Vehicle alone
16678429|NCT02094352|Experimental|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.
~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
16678430|NCT02094352|Placebo Comparator|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.
~Outpatient: Patients will receive three saline booster infusions over the course of three months."
16678595|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
16678433|NCT02094339|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
16678434|NCT02094313|Experimental|atovastatin|
16678435|NCT02094300|Experimental|Endovascular|
16678436|NCT02094287|Experimental|verum, instruction, conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.
16678437|NCT02094287|Experimental|verum, instruction, no conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied
16678438|NCT02094287|Experimental|placebo, instruction, conditioning|This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.
16678439|NCT02094287|Experimental|verum, no instruction, no conditioning|Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.
16678440|NCT02094274|Experimental|LAS40468|Single dose, administered via Genuair® dry powder inhaler (DPI)
16678441|NCT02094274|Active Comparator|Salmeterol/fluticasone propionate|Single dose, Seretide® (salmeterol fluticasone propionate) administered via Accuhaler™
16678442|NCT02094274|Placebo Comparator|Placebo|Single dose administered via Genuair® or Accuhaler™ dry powder inhaler (DPI)
16678443|NCT02094261|Experimental|AZD9291|Once daily tablet 80 mg
16678444|NCT02094248|Experimental|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
16678445|NCT02094248|Placebo Comparator|control|Normal saline，1ml/day, s.c injection
16678446|NCT02094235|Experimental|1|E6005 0.2% ointment applied twice a day to eczema areas
16678447|NCT02094235|Experimental|2|E6005 0.05% ointment applied twice a day to eczema areas
16678448|NCT02094235|Placebo Comparator|3|Placebo ointment applied twice a day to eczema areas
16678449|NCT02094196||Controls, highrisk for AD|Community-based ad-hoc participants, high risk for alcohol dependence, matched to inpatients by sociodemographics
16678450|NCT02094196||Controls, low risk for AD|Community-based ad-hoc participants, low risk for alcohol dependence, matched to inpatients by sociodemographics
16678451|NCT02094196||Alcohol detoxification|Inpatients with alcohol dependence from local psychiatric hospital wards (18-65 years old)
16678452|NCT02094183|Experimental|GLP-1|GLP-1 and low calorie diet
16678453|NCT02094183|Experimental|Control|low calorie diet
16678454|NCT02094157|Active Comparator|Bridged regimen|Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
16678455|NCT02094157|Experimental|Tapered warfarin regimen|Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.
16678456|NCT02094144|Other|exercise group (brisk walking program)|The intervention is named brisk walking program. It consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
16678457|NCT02094144|Other|control group (physical activity habits)|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
16678458|NCT02094131|Experimental|Cliniflo group (CG)|Training using flow-oriented incentive spirometry Cliniflo
16678459|NCT02094131|Experimental|Voldyne group (VG)|Training using volume-oriented incentive spirometry Voldyne
16678460|NCT02094131|No Intervention|Control group (CONG)|No intervention. Assessment and reassessment after 5 weeks.
16678461|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
16678462|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
16678463|NCT02094105|Experimental|screening|endoscopy examination with iodine staining
16678464|NCT02094105|No Intervention|control|1/10 sampling questionnaire interview for control group.
16678465|NCT02094092|Placebo Comparator|ProTectis drops|Arm A.
16678466|NCT02094092|Placebo Comparator|Placebo drops|Arm B
16678467|NCT02094079||L-T4 treated hypothyroid pregnant women|L-T4 treated pregnant women
16678468|NCT02094066|Active Comparator|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
16678469|NCT02094066|Sham Comparator|serum physiologic|preoperative 100 cc serum physiologic
16678470|NCT02094053|Experimental|E2020 3 mg|3 mg of E2020 (oral) once daily, for 24 weeks
16678471|NCT02094053|Experimental|E2020 5 mg|5 mg of E2020 (oral) once daily, for 24 weeks
16678472|NCT02094053|Placebo Comparator|Placebo|placebo (oral) once daily, for 24 weeks
16678473|NCT02094040|Experimental|Follow-up visit|Receive municipality-based follow-up visit including primary physician.
16678474|NCT02094040|No Intervention|Usual care|Does not receive follow-up visit
16678475|NCT02094027|Experimental|Guided Self Help|Guided Self Help intervention to reduce binge eating
16678476|NCT02094027|Placebo Comparator|Treatment As Usual|No intervention for binge eating (treatment as usual in the form of bariatric surgery)
16678477|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).
~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
16678478|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.
~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
16678596|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
16678479|NCT02094001|Experimental|Riociguat therapy|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
16678480|NCT02093988|Experimental|Topical and Intravenous TXA|
16678481|NCT02093988|Active Comparator|Intravenous TXA only|
16678482|NCT02093975|Experimental|Video consultation|Patients in this arm receive video consultation from physician in doctor manned rapid response vehicle.
16678483|NCT02093975|Active Comparator|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician in rapid response vehicle.
16678484|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
16678485|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
16678486|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
16678487|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
16678488|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
16678489|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
16678490|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
16678491|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
16678492|NCT02093923|Experimental|DX-2930, Cohort 1|Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
16678493|NCT02093923|Experimental|DX-2930, Cohort 2|Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
16678494|NCT02093923|Experimental|DX-2930, Cohort 3|Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
16678495|NCT02093923|Experimental|DX-2930, Cohort 4|Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
16678496|NCT02093923|Placebo Comparator|Placebo|Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
16678497|NCT02093910|Experimental|Monosialotetrahexosylganglioside|each patient in this arm received velcade+dexamethasone (VD) regimen（bortezomib,1.3mg/㎡，subcutaneously injection，d1,8,15,22；dexamethasone,20mg d1-2, 8-9,15-16,22-23）every 4 weeks; and monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.
16678498|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
16678499|NCT02093884|Experimental|Text Messaging Intervention|Patients in the text messaging group will receive educational and motivational text messages.
16678500|NCT02093884|Active Comparator|Standard Referral|Patients in the standard referral arm will receive paper based information about the Family Planning Clinic.
16678501|NCT02093871|Experimental|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
16678502|NCT02093858||olanzapine|15-25mg/day for 24 weeks
16678503|NCT02093845|Active Comparator|SYNERGY|Coronary implantatation of the SYNERGY everolimus-eluting stent
16678504|NCT02093845|Active Comparator|Biomatrix Neoflex|Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent
16678505|NCT02093832||Total hip arthroplasty|
16678506|NCT02093819|Experimental|BI 416970 single rising dose part|single rising dose given as tablet
16678507|NCT02093806||CT of the temporal bone|
16678508|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
16678509|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
16678510|NCT02093780|Experimental|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
16678511|NCT02093780|Active Comparator|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:
~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
16678512|NCT02093767|Active Comparator|7.5g dose Synergy1|7.5 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 3.75 g each which are consumed at breakfast and dinner
16678513|NCT02093767|Active Comparator|15g Synergy1|15 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 7.5 g each which are consumed at breakfast and dinner
16678514|NCT02093741||ADVATE - 2mL|
16678515|NCT02093728|Experimental|selumetinib; itraconazole; selumetinib + itraconazole|Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule
16683054|NCT02063581|Experimental|Sequence 2: Capsule followed by Tablet|
16678516|NCT02093728|Experimental|selumetinib; fluconazole; selumetinib + fluconazole|Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.
16678517|NCT02093715||RSV|Infant with acute bronchiolitis due to RSV
16678518|NCT02093715||Co- Infection|Infant with acute bronchiolitis due to RSV and other respiratory virus
16678519|NCT02093715||Other|Infant with acute bronchiolitis due to non-RSV respiratory virus
16678520|NCT02093715||Unknown|Infant with acute bronchiolitis with negative PCR results for respiratory viruses
16678521|NCT02093715||Control|Healthy infants
16678522|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
16678523|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
16678524|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
16678525|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
16678526|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
16678527|NCT02093676|Experimental|parents counseling|parents counseling guided by the experiment protocol
16678528|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
16678529|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
16678530|NCT02093650|Active Comparator|Black cohosh extract|black cohosh extract 80 mg daily
16678531|NCT02093650|Placebo Comparator|Placebo|Matching placebo
16678532|NCT02093637|Placebo Comparator|Placebo acupuncture|Placebo acupuncture up to 5 acupuncture needles* in each ear (up to 10 needles total) at points identified by point-finder to have no electrical conductance) plus usual operative and post-operative care (narcotic and non-narcotic pain medication).
16678533|NCT02093637|Experimental|Battlefield Acupuncture|Usual operative and post-operative care (narcotic and non-narcotic pain medication) plus Battlefield Acupuncture (up to 5 acupuncture needles* in each ear (up to 10 needles total), identified by a point-finder.
16678534|NCT02093637|No Intervention|standard therapy|standard therapy
16678535|NCT02093611|Placebo Comparator|Placebo|This arm will serve as the placebo supplementation.
16678536|NCT02093611|Active Comparator|ATP|This arm will serve as the treatment intervention, ATP
16678537|NCT02093598|Experimental|Temsirolimus|25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses).
16678538|NCT02093585|Experimental|Tenofovir to abacavir|Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
16678539|NCT02093585|Experimental|Abacavir to tenofovir|Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
16678540|NCT02093572|Experimental|Control|Subjects randomized to this group will consume 3 standard meals/day during the 2 week intervention period of the study.
16678541|NCT02093572|Experimental|Breakfast skipping|Subjects randomized to this group will consume 2 meals/day (omit breakfast - with caloric intake equal to consuming 3 meals/day) during the 2 week intervention period of the study.
16678542|NCT02093559|Experimental|Brief Counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
16678543|NCT02093559|No Intervention|Control Group|The control group will have access to brochures and be offered referral to services requested. SFDPH Community Behavioral Health Services (CBHS) provides immediate access to substance abuse treatment in San Francisco, including office- and clinic-based methadone and buprenorphine treatment. Given the pilot nature of this study, the control group will not be a full attention control; we will account for an attention effect due to assessment alone.
16678544|NCT02093546||Ancillary-correlative (Biospecimen collection)|Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28.
16678545|NCT02093533|Experimental|Eculizumab|Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
16678546|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
16678547|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
16678548|NCT02093507|Experimental|parents manipulation|parents manipulation
16678549|NCT02093507|No Intervention|no manipulation|no manipulation
16678550|NCT02093494|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used to collect the blood culture.
16678551|NCT02093494|Active Comparator|Lab standard practice (LSP)|The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.
16678553|NCT02093481|Experimental|- ind. CHO + prim|Reference:ate no intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
16678554|NCT02093481|Experimental|+ ind. CHO - prim|Test meal: ate intrinsic indigestible carbohydrates 1 day prior to measurements of variables (no priming)
16678555|NCT02093481|Experimental|- ind. CHO - prim|Reference: ate no indigestible carbohydrates the day prior to measurements of variables (no priming).
16678556|NCT02093468|Placebo Comparator|Saline|Saline administered IV for 12 hours
16678557|NCT02093468|Experimental|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
16678558|NCT02093468|Experimental|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
16678559|NCT02093455|Active Comparator|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
16678560|NCT02093455|Placebo Comparator|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
16678561|NCT02093442|Experimental|Endometrial injury|Women allocated to this group will be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
16678562|NCT02093442|No Intervention|Control|Women allocated to this group will NOT be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
16678563|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
16678564|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
16678565|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
16678566|NCT02093416||Group 1: Control Group|BMI <30 There are 20 controls in this group
16678567|NCT02093416||Group 2|BMI 30-35 There were 12 controls in this class
16678568|NCT02093416||Group 3|BMI 35-40 There were 9 controls in this clas
16678569|NCT02093416||Group 4|BMI >40 There were 9 controls in this class
16678570|NCT02093403|Experimental|Treatment (decitabine and selinexor)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity."
16678571|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
16678572|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
16678573|NCT02093377|No Intervention|Control|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone
16678574|NCT02093377|Active Comparator|Adaptive servo-ventilation|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.
16678575|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
16678576|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
16678577|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
16678578|NCT02093338|Experimental|fermentum 3x|Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day
16678579|NCT02093338|Experimental|fermentum 6x|Lactobacillus fermentum CECT5716 at 6x10e9cfu/day
16678580|NCT02093338|Experimental|fermentum 9x|Lactobacillus fermentum CECT5716 at 9x10e9cfu/day
16678581|NCT02093338|Placebo Comparator|maltodextrin|maltodextrin
16678582|NCT02093325|Experimental|eltrombpag|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days.
16678583|NCT02093325|Placebo Comparator|Eltrombopag/placebo|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days
16678584|NCT02093312|No Intervention|Control group|The control group is not offered any home food-delivery service, but continues with their habitual diet
16678585|NCT02093312|Experimental|Intervention group|The intervention group is offered home food-delivery service
16678586|NCT02093299||Stroke|clopidogrel 75 mg
16678587|NCT02093286||Pentabio Vaccine|1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly
16678588|NCT02093273|Active Comparator|tOPV commercial batch (Bio Farma)|tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)
16678589|NCT02093273|Experimental|tOPV pilot batch|tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)
16678590|NCT02093260|Experimental|Vaccine|"Vaccine
~Flubio (Influenza HA) vaccine
~2 doses for infants and children (6 months - 8 years old)
~1 doses for children (9-11 years old)
~The vaccine will be given intramuscularly"
16678591|NCT02093234|Active Comparator|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
16678592|NCT02093234|Active Comparator|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
16678593|NCT02093234|Experimental|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
16678594|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
16678598|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
16678599|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
16678600|NCT02093195|Experimental|Bosentan|Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.
16678601|NCT02093195|Active Comparator|Control|Inhaled Symbicort turbuhaler, 320/9μg, bid.
16678602|NCT02093169|Experimental|Part A: Lu AF35700|
16678603|NCT02093169|Experimental|Part B: Lu AF35700|
16678604|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
16678605|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
16678606|NCT02093143|Experimental|Remifentanil|"The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group.
~The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient.
~Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe."
16678607|NCT02093143|Placebo Comparator|Placebo|"The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group.
~The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil."
16678608|NCT02093130|Experimental|Pomegranate Juice|Eight ounces of 100% Pomegranate Juice daily
16678609|NCT02093130|Placebo Comparator|Placebo|Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.
16678610|NCT02093117|Experimental|Recruitment maneuver|The recruitment maneuver will involve application of continuous positive airway pressure of 30 cm of water for 30 seconds.
16678611|NCT02093117|Sham Comparator|Sham recruitment maneuver|The sham recruitment maneuver will involve application of continuous positive airway pressure of 5 cm of water for 30 seconds.
16678612|NCT02093091|Sham Comparator|Vitremer|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer (n = 30). The right molars was always filled by Vitremer. A split-mouth design was used in the present clinical trial. Twenty nine children were involved in the present study and every one had one bilateral identical pair of carious molars except one child that had two identical pairs. This design was performed to enhance the accuracy of the present study.
16678613|NCT02093091|Active Comparator|Ketac Nano|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano (n=30). The left molars was always restored with Ketac Nano filling material.
16678614|NCT02093078||CARD|"Intervention: CARD
~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
16678615|NCT02093078||Control Arm|
16678616|NCT02093052|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up - 10 session intervention to enhance nurturance and following the lead
16678617|NCT02093052|Active Comparator|Developmental Education for Families|Developmental Education for Families - 10 session intervention that targets cognitive development
16678618|NCT02093052|No Intervention|Low-risk|Low-risk comparison group
16678619|NCT02093039|Experimental|Decision aid group|Women allocated to the decision aid group received an invitation to participate in the national breast cancer screening program and the specially-designed decision aid (a leaflet), by mail.
16678620|NCT02093039|No Intervention|Control group|Women in the control group received an invitation and the usual standard information by mail.
16678621|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
16678622|NCT02093013|Experimental|Integrated care program|
16678623|NCT02093013|No Intervention|Control group|This group kept receiving usual care from their health care professionals.
16678624|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
16678625|NCT02092987|Experimental|NYU Caregiver Intervention|The New York University (NYU) caregiver intervention arm received the NYU caregiver intervention in addition to social work support and educational materials.
16678626|NCT02092987|Active Comparator|REACH OUT|The Resources for Enhancing Caregiver Health Offering Useful Treatments (REACH OUT) intervention arm received the REACH OUT caregiver intervention in addition to social work support and educational materials.
16678627|NCT02092974|Experimental|tDCS + SSRI|
16678628|NCT02092974|Placebo Comparator|tDCS + placebo|
16678629|NCT02092974|Sham Comparator|sham-tDCS + SSRI|
16678630|NCT02092974|Placebo Comparator|sham-DCS + placebo|
16678631|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
16678632|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
16684808|NCT02051985|Active Comparator|Standard physical therapy|
16678633|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
16678634|NCT02092948|Experimental|All patients|Patients will receive one intravenous dose of 4 mg, 20mg or 40 mg of A11 minibody labeled with 5 mCi (185 MBq) of 124I, followed by [124I] PSCA-Minibody PET/CT imaging of the whole body.
16678635|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
16678636|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
16678637|NCT02092922|Experimental|Filanesib|
16678638|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
16678639|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 2|Study 2: Cognitive performance test
16678640|NCT02092896|Experimental|Liraglutide + Insulin + Study 2|Study 2: Cognitive performance test
16678641|NCT02092896|Experimental|Liraglutide + Insulin + Study 1|Study 1: Gastric emptying test
16678642|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 1|Study 1: Gastric emptying test
16678643|NCT02092883|Experimental|Infantile Spasms|
16678644|NCT02092870|Experimental|Treatment of Chronic Wound|Patients will receive a single treatment with ASCs in the form of multiple injections of cells within and immediately surrounding the wound. Cells will be delivered using a 1 cc syringe with an appropriate gauge and length needle. Each injection will have a volume less than 250 micro-liters. The number of injections will be determined by the surgeon as a function of total wound volume.
16678645|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
16678646|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
16678647|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
16678648|NCT02092844|Experimental|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
16678649|NCT02092844|Placebo Comparator|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
16678650|NCT02092831|Experimental|Crossover sequence 1|
16678651|NCT02092831|Experimental|Crossover sequence 2|
16678652|NCT02092831|Experimental|Crossover sequence 3|
16678653|NCT02092831|Experimental|Crossover sequence 4|
16678654|NCT02092818||Group 1|Patients who have been prescribed Adempas for a medically appropriate use
16678655|NCT02092805|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce some of subjective sensation of rTMS.
16678656|NCT02092805|Active Comparator|Real rTMS|The active group recieved real-rTMS over the motor cortical area corresponding to the hand of painful side. Each train consist of 2000 pulses at 20 Hz and 80% RMT (total duration 10s). The treatment was repeated every day for 5 consecutive days in week for two weeks (the total number of sessions had be given was 10 sessions).
16678657|NCT02092792|Experimental|Dose-Escalation Phase|
16678658|NCT02092792|Experimental|Dose-expansion cohort|
16678659|NCT02092779||Obese patients, no treatment|
16678660|NCT02092766|Experimental|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
16678661|NCT02092766|Active Comparator|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
16678662|NCT02092753|Placebo Comparator|Standard diet|Standard diet (SD): Nutrition following the standard recommendations of the German society for nutrition
16678663|NCT02092753|Experimental|Ketogenic diet|"Nutritional intervention: Ketogenic diet (KD).
~Intervention: Nutritional support (hospital) + self support (outpatient phase) with KD"
16678664|NCT02092753|Experimental|Logi diet|"Nutritional intervention: low glycämic and insulinemic diet (LOGI)
~Intervention: Nutritional support (hospital) + self support (outpatient phase) with LOGI"
16678665|NCT02092740||Seminoma|Seminoma
16678666|NCT02092740||Non-Seminoma|Non-Seminoma
16678667|NCT02092727|No Intervention|Control|Standard of care arm will receive no specific interventions, but will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
16678668|NCT02092727|Experimental|Behavioral Intervention|A variety of dialysis facility-level, behavioral interventions will be examined.
16678669|NCT02092714||Ancillary-correlative (molecular analysis)|Previously collected tissue samples are analyzed via mutational sequencing and immunohistochemistry.
16678670|NCT02092701|Experimental|cholecalciferol|
16678671|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
16678672|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
16678673|NCT02092675||COPD patients - frequent exacerbator|COPD patients with 2 and more exacerbation in one year
16678674|NCT02092675||COPD patients - non frequent exacerbator|COPD patients with less than 2 exacerbation during one year
16678675|NCT02092675||control group - healthy smokers|healthy smokers, they do not have COPD
16678676|NCT02092662||Stroke|Stroke patients at the subacute phase
16678677|NCT02092662||Healthy controls|healthy age-matched voluntiers
16678678|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
16678679|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
16678680|NCT02092636|Experimental|NIR/US Diagnostic Group|These patients will include women who have breast lumps/lesions visible by ultrasound and are prescribed follow up with an ultrasound-guided biopsy at the UCHC Cancer Center for evaluation and diagnosis of actual/suspected breast abnormalities.
16678681|NCT02092636|Experimental|NIR/US Neoadjuvant Chemotherapy Group|These patients will include women who have breast lumps/lesions visible by ultrasound and have been diagnosed with breast cancers and will undergo neoadjuvant chemotherapy. These patients may be identified from the diagnostic group or after initial diagnosis. Patients will only be enrolled to one of the two groups.
16678682|NCT02092636|Other|NIR/US Process Validation Group|This group will contain data from about five women who did not have ultrasound visible lumps on the day of the planned biopsy. Data from the NIR/US scan will be used to validate instrument measurements.
16678683|NCT02092623|Other|Transvaginal posterior mesh surgery|All study patients undergo transvaginal mesh operation.
16678684|NCT02092610|Active Comparator|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
16678685|NCT02092610|Experimental|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
16678686|NCT02092597|Active Comparator|GLP-1 agonist|Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months
16678687|NCT02092597|Active Comparator|DPP-4 inhibitor|Linagliptin 5 mg tbl qd for 3 months
16678688|NCT02092597|Active Comparator|Sulfonylurea derivate|Gliclazid 30 mg tbl qd for 3 months
16678689|NCT02092584|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
16678690|NCT02092584|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
16678691|NCT02092571|Experimental|Treatment A|1 ring intravaginal for 7 days, produced from the new process
16678692|NCT02092571|Experimental|Treatment B|1 ring intravaginal for 7 days, produced from the legacy process
16678693|NCT02092558||Female 1|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
16678694|NCT02092558||Male 2|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
16678695|NCT02092545|Other|Ketogenic diet|Weight management on a male population of retired NFL athletes.
16678696|NCT02092532|Other|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
16678697|NCT02092519|Active Comparator|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport (NA-220H-8022)
16678698|NCT02092519|Active Comparator|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport (NA-230H-8020)
16678699|NCT02092506|Active Comparator|triple therapy|10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
16678700|NCT02092506|Active Comparator|Concomitant therapy|10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
16678701|NCT02092506|Active Comparator|sequential therapy|10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)
16678702|NCT02092493|No Intervention|Non-ScopeGuide|This arm will have patients undertaking the procedure without ScopeGuide. All outcome measures will be recorded as usual
16678703|NCT02092493|Experimental|ScopeGuide|Patients have their colonoscopy done with ScopeGuide
16678704|NCT02092480|Experimental|Intervention|After baseline data collection, four schools will be randomly assigned to the intervention arm, those receiving the If I Were Jack programme. RSE teachers will deliver the intervention to all participating Year 11 pupils during four weekly lessons of the 'Learning for Life and Work' strand of the Key Stage 4 curriculum.
16678705|NCT02092480|No Intervention|Control|After baseline data collection, three schools will be randomly assigned to the control arm. Participating pupils will not receive the If I Were Jack intervention and will continue with normal RSE practice.
16678706|NCT02092467|Experimental|Treatment Arm 1|
16678707|NCT02092467|Experimental|Treatment Arm 2|
16678708|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
16678709|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
16678710|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
16678711|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
16678712|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
16678713|NCT02092428|Experimental|Image Quality|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to compare image quality between contrast and non-contrast scans.
16678714|NCT02092428|Experimental|Diagnostic Accuracy|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to assess the diagnostic accuracy of coronary MRI in detecting CAD as compared to conventional x-ray angiography
16678715|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
16678716|NCT02092402|Placebo Comparator|Fecal transplantation of own stool|Autologous fecal transplantation (own stool)
16678717|NCT02092402|Experimental|Fecal transplantation (stool from donor)|Allogeneic fecal transplantation (from donor)
16678783|NCT02091908|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
16678784|NCT02091908|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
16678718|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
16678719|NCT02092376|Active Comparator|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
16678720|NCT02092376|Placebo Comparator|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
16678721|NCT02092363|Experimental|Drug: OMP-54F28, Paclitaxel and Carboplatin|
16678722|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
16678723|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
16678724|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
16678725|NCT02092337|Experimental|computer assisted speech training|computer assisted speech training
16678726|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
16678727|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
16678728|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
16678729|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
16678730|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
16678731|NCT02092272|Experimental|instructional exercise video source|instructional exercise video source
16678732|NCT02092272|No Intervention|Standard Therapy|Standard Therapy
16678733|NCT02092246|Active Comparator|Ultrasound Machine Guided Injection|Use of ultrasound machine guidance in needle placement into the knee joint
16678734|NCT02092246|Active Comparator|Unguided Injection|Needle placement performed without ultrasound machine guidance
16678735|NCT02092233||Blinded, Prospective Arm|The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.
16678736|NCT02092233||Blinded, Pre-selected Arm|For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.
16678737|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
16678738|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
16678739|NCT02092207|Experimental|KL7016 900mg|
16678740|NCT02092207|Placebo Comparator|Placebo|
16678741|NCT02092207|Experimental|KL7016 600mg|
16678742|NCT02092194|Active Comparator|Standard Dose online HDF|Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
16678743|NCT02092194|Experimental|High Dose online HDF|Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
16678744|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 mg daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or, for those in the placebo arm, two placebo tablets.
16678745|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
16678746|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
16678747|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
16678748|NCT02092155||Indwelling tunneled pleural catheter|
16678785|NCT02091908|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
16678786|NCT02091908|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
16678749|NCT02092142|Experimental|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
16678750|NCT02092129||Acromegaly|Patients with acromegaly who have received surgical treatment
16678751|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.
~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
16678752|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).
~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.
~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
16678753|NCT02092103|No Intervention|Delayed Clamping|"The American Congress of Obstetricians and Gynecologists (ACOG) recommends delayed cord clamping for preterm infants. Infants randomized to this group will follow the protocol below:
~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)
~Once infant is delivered designated RN starts timer
~Infant warming bag on delivery table
~Infant placed into warming bag then wrapped in a towel
~Assistant to deliver preps cord clamps
~Registered Nurse (RN) notifies provider at 30 seconds
~Cord clamped and cut
~Infant handed off to waiting staff
~Exceptions: Placental separation, cord stops pulsating, need for immediate resuscitation, all would result in clamping prior to 30 seconds"
16678754|NCT02092103|Experimental|Cord Milking|"Infants randomized to the cord milking group will follow the protocol below:
~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)
~Infant held and the cord is milked from perineum to infant four times
~Assistant to deliver preps cord clamps
~Cord clamped and cut
~Infant handed off to waiting staff"
16678755|NCT02092090|No Intervention|Control|Dietary advice at baseline only
16678756|NCT02092090|Experimental|Dietary sodium reduction|Dietary advice and reduced-sodium added-potassium salt substitute
16678757|NCT02092077|Experimental|TV-1106 0.554 mg|
16678758|NCT02092077|Experimental|TV-1106 0.924 mg/kg|
16678759|NCT02092077|Experimental|TV-1106 1.20 mg/kg|
16678760|NCT02092077|Active Comparator|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
16678761|NCT02092051|Experimental|Continuous glucose monitoring|Continuous glucose monitoring with DexCom G4 platina during 6 months
16678762|NCT02092051|No Intervention|Conventional therapy|Conventional therapy during 6 months using only SMBG for glucose monitoring
16678763|NCT02092038|Experimental|Preoperative chemoradiation|Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide
16678764|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
16678765|NCT02092012|Active Comparator|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anesthesia induction
16678766|NCT02092012|Active Comparator|dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
16678767|NCT02091999|Experimental|Part A enfortumab vedotin Dose Escalation (Dose Levels 1-4)|All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
16678768|NCT02091999|Experimental|Part B enfortumab vedotin Renal Insufficiency Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at a dose level below and escalated up to the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
16678769|NCT02091999|Experimental|Part B enfortumab vedotin NSCLC Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
16678770|NCT02091999|Experimental|Part B enfortumab vedotin Ovarian Cancer Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
16678771|NCT02091999|Experimental|Part C enfortumab vedotin CPI Treated Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15). A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of enfortumab vedotin, Investigator decision or consent withdrawal.
16678772|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
16678773|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
16678774|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
16678775|NCT02091973|Experimental|Everolimus|everolimus dosing to tough level 6-10 ng/ml
16678776|NCT02091973|Experimental|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
16678777|NCT02091960|Experimental|Enzalutamide + Trastuzumab|Participants received 160 mg enzalutamide orally once daily and 6 mg/kg trastuzumab administered by intravenous infusion or subcutaneous injection every 21 days. Participants continued on treatment until disease progression, unacceptable toxicity or any other discontinuation criteria were met.
16678778|NCT02091947|Experimental|experimental group|Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.
16678779|NCT02091947|Sham Comparator|sham group|sham FMS, 5 Hz, 20 min per day, for 10 weekdays.
16678780|NCT02091934|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
16678781|NCT02091934|Active Comparator|Wavefront-optimized PRK|Wavefront-optimized PRK
16678782|NCT02091921|Experimental|Experimental|All subjects will receive Ticagrelor.
16678787|NCT02091895|Experimental|endo group|colon polyp, early colon cancer, colorectal submucosal tumor, ileocecal ulcers
16678789|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
16678790|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
16678791|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
16678792|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
16678793|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
16678794|NCT02091843|Experimental|DBS of the Amygdala-30 days|Deep brain stimulation of the amygdala BLn starting at 30 days post-operatively.
16678795|NCT02091843|Experimental|DBS of the Amygdala-90 days|Deep brain stimulation of the amygdala BLn starting at 90 days post-operatively.
16678796|NCT02091830||Non-surgical treatment|
16678797|NCT02091817|Other|Control group|Control group will be administered oxytocin and placebo, in a double-blind randomized order.
16678798|NCT02091817|Experimental|congenital prosopagnosia|Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
16678799|NCT02091804|Active Comparator|Wait-List group|Individuals randomized to the control group will receive the intervention program immediately after their 3-month research visit.
16678800|NCT02091804|Experimental|Immediate Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
16678801|NCT02091791|Experimental|LT10|"Long duration (30 minutes) traction sessions of low force (10% of body weight) for 2 weeks (5 sessions/week)."
16678802|NCT02091791|Experimental|LT50|"Long duration (30 minutes) traction sessions of high force (50% of body weight) for 2 weeks (5 sessions/week)."
16678803|NCT02091778|Experimental|Fast Gelling Dressing|
16678804|NCT02091765|No Intervention|Minimal intervention control group|Women who are assigned to the control group will be contacted by telephone by a member of the study staff to inform them about this allocation. They will receive a booklet per mail that addresses 80 questions about sexuality and cancer. Six weeks later, they will receive an empathetic phone call from one of the sexologists, during which there is also time available to discuss further questions the participants may have concerning sexuality and cancer. The purpose of keeping in contact with the control group, as opposed to a pure waiting list control group, is creating the opportunity to provide some control for a possible attention placebo-effect. The final questionnaire will be completed twenty weeks post study entry, after which women will be given the opportunity to undergo the internet-based cognitive behavioral program.
16678805|NCT02091765|Experimental|Internet-based cognitive behavioral therapy|"Each woman who is allocated to the intervention group is assigned a personal sexologist (therapist) who guides her through the internet-based cognitive behavioral therapy (CBT) program and provides feedback on the homework assignments. The CBT program comprises a maximum of ten treatment modules that can be used in varying order. Each module contains three interventions and a personal evaluation form to report on the intervention. Each intervention comprises the following elements: 1) introduction, 2) psycho-education about symptoms, 3) homework assignments (e.g. relaxation techniques (pelvis); discuss intimacy with partner; sensate focus) and 4) reporting back to the therapist and receiving feedback on the homework assignments. Each week there are two practice sessions of 30 minutes each and one hour per week to report on/evaluate the intervention. The therapy has a mean duration of 20 weeks."
16678806|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
16678807|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.
~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.
~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
16678808|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.
~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.
~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
16678809|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.
~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.
~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
16678810|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
16678811|NCT02091713||Experimental/Functional movement screen|300 subjects from three different combat units will undergo functional movement screening
16678812|NCT02091700||Normals|Subjects with normal visual and retinal function will be enrolled
16678813|NCT02091674|Experimental|Hyaluronic acid|All subjects administered hyaluronic acid
16678814|NCT02091661|Active Comparator|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh.surgery started with dissection of the pelvic lymph nodes. If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing.The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
16678815|NCT02091661|Active Comparator|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
16678816|NCT02091648|Experimental|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
16678817|NCT02091648|Active Comparator|Standard Education Intervention|"this group will receive the standard American Lung Association Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute recommendations for asthma education."
16678818|NCT02091648|No Intervention|No treatment control|"This group will receive no treatment during the course of the study and will have the option to receive the Open Airways program after their participation in the study is complete."
16678819|NCT02091635|Active Comparator|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
16678820|NCT02091635|Placebo Comparator|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
16678821|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
16678822|NCT02091622|No Intervention|No intervention|No intervention.
16678823|NCT02091609|Experimental|group : implants and oral hygiene|dental floss
16678824|NCT02091609|Experimental|implants and oral hygiene|dental interproximal brush
16678825|NCT02091596|Placebo Comparator|PluroGel|PluroGel
16678826|NCT02091596|Experimental|PluroGel N|PluroGel N
16678827|NCT02091583|Placebo Comparator|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
16678828|NCT02091583|Active Comparator|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
16678829|NCT02091583|Active Comparator|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
16678830|NCT02091583|Active Comparator|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
16678831|NCT02091570|Placebo Comparator|Nutrition bar|50 g nutrition bar
16678832|NCT02091570|Experimental|Nutrition Bar 1|50 g nutrition bar with additional 2 g of milk-based nutrient
16678833|NCT02091570|Experimental|Nutrition bar 2|50 g nutrition bar with additional 3 g of milk-based nutrient
16678834|NCT02091557||GnRH-analogue|CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients
16678835|NCT02091544||Lifestyle intervention|lifestyle intervention
16678836|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
16678837|NCT02091518|Experimental|MRI|"Add-On Research Patients will include patients who are scheduled for a routine clinical MRI who meet the eligibility requirements for this protocol. Protocol participation will consist of an add-on research. MRI scan, which will be performed any point during of the routine clinical MRI scan.
~Volunteers will be subjects expressing interest in participation and who meet the eligibility requirements for this protocol. No contrast enhanced research MRIs including gadolinium-based or other contrast agents will be performed in volunteers."
16678838|NCT02091505|Experimental|Intravitreal injection of Ranibizumab|
16678839|NCT02091492|Active Comparator|Teriparatide|Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
16678840|NCT02091492|Placebo Comparator|Placebo-Teriparatide|Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
16678841|NCT02091479|Experimental|UFH Early group|anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
16678842|NCT02091479|Active Comparator|UFH Late group|anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage
16678843|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
16678844|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
16678845|NCT02091453|Experimental|attention training acute|20 hours of attention training, APT training, or multiprofessional rehabilitation
16678846|NCT02091453|Experimental|attention training subacute|20 hours of attention training, APT training, or multiprofessional rehabilitation
16678847|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
16678848|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
16678849|NCT02091401|Active Comparator|IV|Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IV maintenance regimen.
16678850|NCT02091401|Experimental|Springfusor|Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor® pump).
16678851|NCT02091388|Experimental|LY03004 25 mg|5 intramuscular injections 25 mg over 113 days
16678852|NCT02091388|Active Comparator|Risperdal® Consta® 25 mg|5 intramuscular injections 25 mg over 113 days
16678960|NCT02090647|Active Comparator|zirconia 2|zirconia abutment type 2
16678853|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
16678854|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
16678855|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
16678856|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
16678857|NCT02091349|Placebo Comparator|Group A- placebo|control- snack bar or muffin containing no fiber
16678858|NCT02091349|Experimental|Group B- polydextrose|polydextrose- randomly bonded polysaccharide of glucose which is poorly digested in small intestine
16678859|NCT02091349|Experimental|Group C- soluble corn fiber|Soluble corn fiber made from corn starch and contains oligosaccharides with random glyucosyl bonds and may contain minor amounts of monosaccharides
16678860|NCT02091336|Active Comparator|Glyburide|Glyburide 2,5 mg
16678861|NCT02091336|Active Comparator|Metformin|Metformin 500mg bid
16678862|NCT02091323|Experimental|BMI<28kg/m2|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI<28kg/m2 group.
16678863|NCT02091323|Other|control|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI>28kg/m2 group as well.
16678864|NCT02091310|Placebo Comparator|Placebo (Study Part I)|Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water
16678865|NCT02091310|Experimental|GFT505 300 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water
16678866|NCT02091310|Experimental|GFT505 360 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water
16678867|NCT02091310|Placebo Comparator|Placebo (Study Part II)|Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
16678868|NCT02091310|Experimental|GFT505 120 mg (Study Part II)|Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water
16678869|NCT02091310|Experimental|GFT505 xx mg (Study Part II)|Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
16678870|NCT02091310|Active Comparator|Moxifloxacin 400 mg (Study Part II)|On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14
16678871|NCT02091297|Active Comparator|TAP BLOCK|One unique regional technique for lower abdominal surgery, that has been shown effective for Cesarean Section in particular, is the transversus abdominis plane (TAP) block, which blocks T6-L1 sensory nerve branches and provides anesthesia to the anterior abdominal wall. The TAP block has been recommended and shown in case reports, but not clinically studied with trials, for patients on methadone or buprenorphine, to improve post-operative pain control. A long active local anesthetic, called ropivacaine, will be used to provide this anesthesia.
16678872|NCT02091297|Active Comparator|Common Care|Common care refers to the common way pain is treated after Cesarean Section: a long-acting spinal or epidural opioid such as morphine, plus oral and IV opioids and non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
16678873|NCT02091297|Active Comparator|Patient Controlled Epidural Analgesia|For post-Cesarean analgesia, another regional technique that has been employed for superior pain control is continued epidural analgesia with local anesthesia and an opioid, either in addition or instead of long acting neuraxial opioids (Cohen). One study revealed equal analgesic efficiency, higher patient satisfaction scores, and less side effects with patient controlled epidural ropivacaine compared to epidural morphine (Chen). This is an especially attractive option for opioid dependent patients, but like the TAP block, has been not studied whether or not it lessens acute or chronic postoperative cesarean section, in the setting or in the absence of neuraxial opioids.
16678874|NCT02091284|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
16678875|NCT02091284|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
16678876|NCT02091245|Experimental|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
16678877|NCT02091219|Experimental|25(OH)D3|20 micrograms/day by mouth for 16 weeks
16678878|NCT02091219|Experimental|Vitamin D3|2,400 IU/day by mouth for 16 weeks
16678879|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
16678880|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
16678881|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
16678882|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
16678883|NCT02091193||Placebo to Krill Oil|Group 2 receives supplement B for four weeks, undergoes a two week washout period, and then receives supplement A for another four weeks. Measurements are taken at baseline, after supplement B completion and after supplement A completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 2 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
16678884|NCT02091193||Krill Oil to Placebo|Group 1 receives supplement A for four weeks, undergoes a two week washout period, and then receives supplement B for another four weeks. Measurements are taken at baseline, after supplement A completion and after supplement B completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 1 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
16678885|NCT02091180|Experimental|Mannitol|Patients will receive 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
16678886|NCT02091180|Placebo Comparator|Control|Patients will receive normal saline
16678887|NCT02091167|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
16678888|NCT02091167|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
16678889|NCT02091154|Experimental|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
16678890|NCT02091154|Experimental|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
16678891|NCT02091154|Experimental|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
16678892|NCT02091154|No Intervention|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
16678893|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks. This treatment arm is now closed for screening and enrollment.
16678894|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
16678895|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
16678896|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
16678897|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
16678898|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
16678899|NCT02091128||Females with classic galactosemia and POI|
16678900|NCT02091115|Placebo Comparator|Dairy drink|Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
16678901|NCT02091115|Active Comparator|Dairy drink with probiotic culture|Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
16678902|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
16678903|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
16678904|NCT02091076|Experimental|Silk with bioactive coated dressing|Silk fibroin coated with bioactive layer, apply once only
16678905|NCT02091076|Active Comparator|Control|Bactigras wound dressing, apply once only
16678906|NCT02091063|Experimental|Phase Ib: Arm A: ACY-1215 QD|Phase Ib: ACY-1215 160mg PO QD
16678907|NCT02091063|Experimental|Phase Ib: Arm B: ACY-1215 BID|Phase Ib: ACY-1215 160mg PO BID
16678908|NCT02091063|Experimental|Phase II: ACY-1215|Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.
16678909|NCT02091050|Other|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
16678910|NCT02091024|Experimental|ECG (Ecklonia cava extract)|ECE 200mg, twice a day
16678911|NCT02091024|Placebo Comparator|Placebo|Placebo 200mg, twice a day
16678912|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
16678913|NCT02090998|Active Comparator|SPG Nerve Block with Lidocaine 5% gel|Sphenopalatine Ganglion Nerve Block (SPG Nerve Block) will be administed weekly for 4 weeks using 5% Lidocaine gel This intervention (a nerve block) will treat the headache for the time period investigated
16678961|NCT02090647|Active Comparator|titanium nitrate|titanium nitrate abutment
16678914|NCT02090998|Active Comparator|Amitriptyline / Elavil|Amitriptyline / Elavil 10 mg once a day for one week then Amitriotyline 20 mg once a day for three weeks This intervention will treat the headache for the time period investigated
16678915|NCT02090985|Experimental|Lipomodelling|Lipomodelling of peri-stomal skin contour abnormalities
16678916|NCT02090972||Patients with fracture|"fracture within the last 14 days
~no other fractures within the last 6 month
~patients >60 years"
16678917|NCT02090972||Control Patients|"patients hospitalized for an internal reason
~no other fractures within the last 6 month
~patients >60 years"
16678918|NCT02090959|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
16678919|NCT02090946||parental experiences|interviews
16678920|NCT02090933|Experimental|Treatment (celecoxib)|Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
16678921|NCT02090920||Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
16678922|NCT02090907|Experimental|Levothyroxin|In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.
16678923|NCT02090907|Placebo Comparator|Placebo|In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.
16678924|NCT02090894|Experimental|UV Light|
16678925|NCT02090881|Experimental|ultrasound scan in ages 2-16 years|Children aged 2-16 years of age with Sickle Cell Disease and under the care of consultant haematologist as part of the NHS screening programme.
16678926|NCT02090868||Pre Introduction|Pre tool introduction cohort 22 patient participants who will receive standard care (no patients were recruited)
16678927|NCT02090868||Nurses|12 nurse participants who will take part in 2 focus group interviews and a teaching session (6 nurse participants were recruited)
16678928|NCT02090868||Post Introduction|Pre tool introduction cohort 22 patient participants who's ability to eat and drink orally will be assessed using the Oral Intake Screening Tool (no patient participants were recruited)
16678929|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
16678930|NCT02090842|Experimental|Whey protein isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks.
16678931|NCT02090842|Experimental|Ca-caseinate|Subjects are asked to supplement their habitual diet with 56 g of Ca-caseinate a day for 8 weeks.
16678932|NCT02090842|Other|Maltodextrin|Subjects are asked to supplement their habitual diet with 54 g of maltodextrin a day for 8 weeks.
16678933|NCT02090829|Placebo Comparator|Placebo Group|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.
~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.
~One dose equals 6 spray puffs (3 puffs in each nostril)."
16678934|NCT02090829|Active Comparator|Experimental Group|"Intranasal oxytocin (Trade name: Syntocinon) Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.
~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.
~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril). Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
16678935|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
16678936|NCT02090803||Graft of autologous hematopoietic stem cells|
16678937|NCT02090790|Active Comparator|iv dexamethasone|perioperative 2ml 8 mg ıv dexamethasone
16678938|NCT02090790|Active Comparator|femoral dexamethasone|femoral block was performed postoperative 30 ml 0,5 % bupivacaine added 2 ml 8 mg dexamethasone
16678939|NCT02090790|Placebo Comparator|serum physiologic|
16678940|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
16678941|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
16678942|NCT02090764|Placebo Comparator|Placebo|Placebo cream
16678943|NCT02090751||No Maculopathy|Aged 50 to 80 with no macular disease
16678944|NCT02090751||Early Maculopathy|Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
16678945|NCT02090738|Experimental|Arm1|Treatment group
16678946|NCT02090738|Active Comparator|Arm2|Control group
16678947|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
16678948|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
16678949|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
16678950|NCT02090699||Myocardial Iron Overload|chronic blood transfusion related myocardial iron overload
16678951|NCT02090699||Healthy Volunteers|age matched healthy volunteers
16678952|NCT02090686|Active Comparator|Pulsatile Cupping|
16678953|NCT02090686|Active Comparator|Minimal Cupping|
16678954|NCT02090686|No Intervention|No Intervention|Waiting list
16678955|NCT02090673||Group1:Type 2 diabetic patients treated with Exenatide therapy|Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label
16678956|NCT02090660|Experimental|VATS wedge lung resection|
16678957|NCT02090647|Active Comparator|titanium 1|titanium abutment type 1
16678958|NCT02090647|Active Comparator|titanium 2|titanium abutment type 2
16678959|NCT02090647|Active Comparator|zirconia 1|zirconia abutment type 1
16678962|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
16678963|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
16678964|NCT02090621|Experimental|Extracorporeal Photopheresis|Extracorporeal Photopheresis
16678965|NCT02090608|Experimental|Paricalcitol|In patients identified by the inclusion criteria, data will be collected at baseline , during administration of oral Paricalcitol (PCT) (after 1, 3 and 6 months), and three months after PCT withdrawal. PCT will administered at dosage of 1 mcg/day; this dosage was chosen as it is not associated with excessive decline of parathyroid hormone (PTH) levels in most patients
16678966|NCT02090595|Experimental|MBCT-C|Mindfulness-Based Cognitive Therapy for Anxious Children (MBCT-C) is a 12-week manualized group therapy program for children with anxiety disorders. The program involves teaching children to pay attention to anxiety-related thoughts, emotions, and physical sensations with openness and non-judgment.
16678967|NCT02090595|Other|Waitlist Control|Education and Therapy
16678968|NCT02090582|Other|Structured Palliative Care|
16678969|NCT02090582|Other|Usual Care|
16678970|NCT02090569|Experimental|Functional micro-Doppler sonography|
16678971|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
16678972|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
16678973|NCT02090543||Group 1|300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
16678974|NCT02090543||Group 2|300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
16678975|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
16678976|NCT02090517|Active Comparator|Pulsed Dye Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser.
16678977|NCT02090517|Active Comparator|Long Pulsed Alexandrite Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with long pulsed alexandrite laser.
16678978|NCT02090517|Active Comparator|Pulsed Dye Laser Plus Nd:YAG Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser plus Nd:YAG laser.
16678979|NCT02090517|Active Comparator|Electrodesiccation|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.
16678980|NCT02090517|No Intervention|No Treatment|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will receive no treatment.
16678981|NCT02090504|Experimental|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:
~SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);
~placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
16678982|NCT02090504|Active Comparator|Oxazepam|"Patients randomized to the second arm of the study will receive:
~OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;
~placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
16678983|NCT02090478|Sham Comparator|No change in dietary sugar levels|Group met with a dietician as often as the control group to discuss diet, but the dietician gave them advice geared toward no change in dietary sugar levels
16678984|NCT02090478|Experimental|Low sugar group|Subjects met with a dietician who discussed diet records. After the first month (baseline, regular diet), the dietician made suggestions geared toward reducing calories from simple sugars by 40%. This will be achieved by replacing sugar calories with complex carbohydrates and fats, while maintaining energy balance (same number of calories as the baseline month).
16678985|NCT02090465||all eligible patients|Treatment with Picato according to Summary of Product Characteristics (SmPC)
16678986|NCT02090452|Experimental|Transmission of vital signs, ecg, chat|Data from patients transported in ambulances with equipment which enables real time transmission of vital signs, ecg and chat from ambulances to the emergency department.
16678987|NCT02090452|No Intervention|No transmission of data|Patient transported with conventional ambulances without the possibility to transmit real time patient related data.
16678988|NCT02090439|Experimental|standard treatment with Silodosin|Silodosin
16678989|NCT02090439|No Intervention|standard treatment|
16678990|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
16679065|NCT02089919|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679066|NCT02089906||Chinese Elderly|multi-center cross-sectional study
16679067|NCT02089893||Healthy subjects|Healthy subjects
16679068|NCT02089880|Experimental|C-brace then stance control orthosis|
16678991|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
16678992|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.
~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
16678993|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.
~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
16678994|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.
~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
16678995|NCT02090400|Other|Bazedoxifene & Calcium/Vit D|Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)
16678996|NCT02090400|Other|Calcium/Vit D|Calcium 500mg and 400 IU vitamin D (OSTINE )daily.
16678997|NCT02090387|Active Comparator|Control ONS|ONS without AN777
16678998|NCT02090387|Experimental|Investigational ONS|ONS containing AN777
16678999|NCT02090374|Experimental|TLR agonist nasal challenge in non-atopic patients|
16679000|NCT02090374|Experimental|TLR agonist nasal challenge in atopic patients|
16679001|NCT02090374|Experimental|Tuberculin nasal challenge in subjects with latent TB|
16679002|NCT02090374|Experimental|Tuberculin nasal challenge healthy subjects|
16679003|NCT02090374|Experimental|Timothy grass pollen nasal challenge in hay fever subjects|
16679004|NCT02090374|Experimental|Timothy grass pollen nasal challenge in asthmatic subjects|
16679005|NCT02090374|Experimental|Timothy grass pollen nasal challenge in non-atopic subjects|
16679006|NCT02090374|Experimental|Resiquimod nasal challenge in allergic asthma|
16679007|NCT02090361|Experimental|skin graft with dermal matrix|Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
16679008|NCT02090361|Placebo Comparator|skin graft - classic procedure|Epidermization of the defect by applying a thin layer of autologous epidermis
16679009|NCT02090348|Experimental|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
16679010|NCT02090335|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
16679011|NCT02090335|Active Comparator|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
16679012|NCT02090322|Experimental|Bevacizumab|"The treatment for Retinopathy of prematurity is Intravitreal bevacizumab. We want to compare two dosages (0.500 and 0.625mg) and demonstrate that 0.500mg there isn't lower in efficacy than 0.625mg.
~When the baby have the diagnosis or Retinopathy of prematurity we are going to inyect the eye that have te problem, then we are going to explore until this illness disappear. It is only one intervention"
16679013|NCT02090309|Active Comparator|Hydrocortisone injection|I.V Hydrocortisone 100 mg single bolus.
16679014|NCT02090309|Placebo Comparator|normal saline|I.V normal saline 0.9% a single bolus of 5 ml.
16679015|NCT02090296|Placebo Comparator|Sugar water|Placebo arm
16679016|NCT02090296|Active Comparator|Hydroxyurea|Treatment Arm
16679017|NCT02090283|Experimental|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
16679018|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
16679019|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
16679020|NCT02090257|Experimental|TRANSIT, behavioral|The intervention group will receive more guidance during their transition from a pediatric center to the adult center
16679021|NCT02090257|No Intervention|Usual Care Group|The usual care group will receive a standard transfer of care from a pediatric center to an adult center.
16679022|NCT02090244|No Intervention|Control|Standard care postoperatively.
16679023|NCT02090244|Experimental|Teriparatide|One injection daily for 4 weeks
16679024|NCT02090231|Experimental|Real 5 Hz rTMS|real 5 Hz rTMS, 10 minutes per day, for 10 weekdays.
16679025|NCT02090231|Sham Comparator|sham 5 Hz rTMS|sham 5Hz rTMS, 10 minutes per day, for 10 weekdays.
16679026|NCT02090218|Active Comparator|I-Gel|I-Gel supraglottic airway device
16679027|NCT02090218|Active Comparator|LTS, ETI or other airway practice|Laryngeal tube, endotracheal tube or other current airway management practice
16679028|NCT02090205|Placebo Comparator|Non-ventilation during CPB|This group of patients will not be ventilated during the cardio-pulmonary bypass. They will be disconnected from the respirator.
16679029|NCT02090205|Experimental|Ventilation with CPAP|This group will receive a ventilation with CPAP (at least 5 cmH2O) and FiO2 50%-80%
16679030|NCT02090205|Experimental|Ventilation with 5 act/minute|This group will receive 5 respiratory acts/minute. Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
16679069|NCT02089880|Experimental|Stance control orthosis then C-brace|
16679070|NCT02089867|Experimental|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
16679071|NCT02089867|Experimental|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
16679072|NCT02089867|No Intervention|Control group|No additional therapy, statin maintenance
16679031|NCT02090192|Experimental|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
16679032|NCT02090192|Experimental|WBV+ PRT training|
16679033|NCT02090192|Active Comparator|PRT training|
16679034|NCT02090192|Placebo Comparator|Control group|
16679035|NCT02090179||MPS IIIB|Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
16679036|NCT02090166|Other|lung cancer diagnosis|"4 arms will be included in the study:
~The groups sample size is as follows:
~Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects
~A blood test will be taken from each patient."
16679037|NCT02090153|Experimental|S-1 plus LV|All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.
16679038|NCT02090140|Experimental|ADSC Application|Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.
16679039|NCT02090140|Active Comparator|Microfracture Arm|Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.
16679040|NCT02090114|Experimental|Post-abiraterone or post-enzalutamide or post-castration only|Men with castration-resistant prostate cancer who have progressed on either abiraterone or enzalutamide or castration-only therapy will be enrolled to this arm. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with either abiraterone 1000 mg by mouth daily or enzalutamide 160 mg by mouth daily, depending on which drug they previously received or remain on LHRH agonist alone for one month to re-establish a castrate level of testosterone (<50 ng/dL).
16679041|NCT02090101|Experimental|ANAKINRA|LV5FU2 + bevacizumab + anakinra
16679042|NCT02090088||All Subjects|All Subjects
16679043|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
16679044|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
16679045|NCT02090049|Experimental|Puravita Breakfast|Puravita Breakfast is a high protein and high fiber soft bread that contains 22% fruit (figs, apricots, raisins and prunes), a selection of cereals: wheat, oat and spelt and no added sugar.
16679046|NCT02090049|Placebo Comparator|Control breakfast|White bread (85g) with jam (10g) and margarine (2g) adjusted for energy, fat, and sugar levels and for energy density.
16679047|NCT02090036|Active Comparator|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
16679048|NCT02090036|Experimental|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
16679049|NCT02090023||NHIRD obstructive sleep apnea|Secondary database from community-based National Health Insurance Research Database
16679050|NCT02090023||NTUH obstructive sleep apnea cohort|Primary database from enrollment of retrospective NTUH hospital-based cohort
16679051|NCT02090010|Active Comparator|GroupC|Group C means Control group which use Seldinger technique for subclavian catheterization. The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed. After that catheter is passed over the guidewire into the vessel.
16679052|NCT02090010|Experimental|Group MS|Group MS means experimental group which use modified Seldinger technique for subclavian catheterization. The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instatntly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
16679053|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
16679054|NCT02089984|Experimental|Internet-Based Training|On-line tutorial followed by live remote training via videoconferencing
16679055|NCT02089971||Young Chinese adults|cross-sectional, observational study of community dwelling young Chinese adults
16679056|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
16679057|NCT02089945||transcatheter aortic valve implantation|This study recruits individuals that are undergoing transcatheter aortic valve implantation.
16679058|NCT02089932|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
16679059|NCT02089932|Experimental|Group B-DEX 25 : Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
16679060|NCT02089932|Experimental|Group B-DEX 50:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
16679061|NCT02089932|Experimental|Group B-DEX 75:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
16679062|NCT02089919|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679063|NCT02089919|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679064|NCT02089919|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679073|NCT02089867|Experimental|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
16679074|NCT02089854|Experimental|endocrine therapy|toremifene 60mg PO. per day for premenopausal and perimenopausal patients; anastrozole 1mg PO. per day for postmenopausal patients
16679075|NCT02089854|No Intervention|observation|
16679076|NCT02089841|Experimental|Artemether/lumefantrine|In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
16679077|NCT02089828|Experimental|autologous purified CD34+ cell|transplantation of autologous purified CD34+ cell
16679078|NCT02089828|Active Comparator|autologous PB-MNC|transplantation of autologous peripheral blood mononuclear cells
16679079|NCT02089815|Experimental|Home based exercise|simple designed home based exercise program
16679080|NCT02089815|Active Comparator|fall prevention education and counseling|fall prevention education & counseling : home modification, vision screening, avoid sedative drugs use, proper shoes, report dizziness and fall to doctors
16679081|NCT02089802|Experimental|Normal plasma level patients and low plasma level patients.|"Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).
~Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
16679082|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
16679083|NCT02089763|Experimental|PEG-BCT-100|pegylated recombinant human arginase 1
16679084|NCT02089750|Active Comparator|Orthotics|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
16679085|NCT02089750|Active Comparator|Orthotics Plus Chiropractic Care|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period in addition to receiving Chiropractic Care 1-4 times per week during the first 6 weeks of the 12 week study period.
16679086|NCT02089750|Other|Wait List|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last six weeks they are fitted for the custom-made shoe orthotics.
16679087|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
16679088|NCT02089724||vemurafenib/other BRAF inhibitors|
16679089|NCT02089711||Japanese healthy subjects|subjects with healthy eyes
16679090|NCT02089698|Active Comparator|Reversed tip|Reversed Kelman tip
16679091|NCT02089698|Experimental|Mini-flared|Mini-flared Kelman tip
16679092|NCT02089685|Experimental|Pembrolizumab + PegIFN-2b|Participants in Part A receive pembrolizumab intravenously (IV) at assigned dose every 3 weeks + PegIFN-2b subcutaneously (SC) at assigned dose once a week in each 6-week cycle.
16679093|NCT02089685|Experimental|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 1 mg/kg every 3 weeks (Q3W) for a total of two 6-week cycles.
16679094|NCT02089685|Experimental|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 50 mg every 6 weeks (Q6W) for a maximum of four 6-week cycles.
16679095|NCT02089685|Experimental|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 100 mg every 12 weeks (Q12W) for a maximum of eight 6-week cycles.
16679096|NCT02089672||Atrial flutter patients|Atrial flutter patients undergoing catheter ablation
16679097|NCT02089659|Experimental|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
16679098|NCT02089659|Experimental|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
16679099|NCT02089659|Experimental|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
16679100|NCT02089633|Experimental|PACOX|Pegylated human arginase (PA) in combination with Capecitabine (C) and Oxaliplatin (OX)
16679101|NCT02089620|Active Comparator|Yasmin|Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
16679102|NCT02089620|Active Comparator|Calver|Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
16679103|NCT02089620|Placebo Comparator|Placebo|A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
16679104|NCT02089607|Experimental|Thoracoabdominal Aortic Aneurysm Arm|The TAAA study arm will include patients treated by endovascular aortic repair of thoracoabdominal aortic aneurysms (Extent I to IV) using either an off-the-shelf Zenith t-Branch or patient-specific stent-graft with a combination of fenestrations and/or branches. The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
16679105|NCT02089607|Experimental|Aortic Arch Aneurysm Arm|Aortic Arch study arm will include patients with aortic arch aneurysms treated by Patient-specific stent-grafts with one to three inner branches or a scallop. The study will include patients with thoracoabdominal and/or aortic arch aneurysms due to degenerative aneurysms or chronic aortic dissections. The stent-graft design for this study will be individually selected based on anatomy at the discretion of the principal investigator, including an off-the-shelf stent-graft (t-Branch stent-graft) or patient-specific stent-graft with a combination of fenestrations and/or branches.
16679180|NCT02089165|Experimental|Krill meal|The interventions are administered in the randomized order.
16679106|NCT02089594|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
16679107|NCT02089594|Experimental|No Hyperbaric Oxygen Treatment (HBOT)|Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
16679108|NCT02089581|Active Comparator|Drug|MR2XXX
16679109|NCT02089581|Experimental|MRXXX|MRXXX capsule 12 hourly
16679110|NCT02089581|Experimental|MR1XXX|MR1XXX capsule, 12 hourly
16679111|NCT02089581|Experimental|Experimental|Experimental Fed
16679112|NCT02089568|Experimental|Drug: co-amoxiclav|experimental
16679113|NCT02089568|Placebo Comparator|Control|comparator
16679114|NCT02089555||African Americans|This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
16679115|NCT02089555||Non-Hispanic Whites|This group consists of Non-Hispanic White (NHW) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)). African American (AA) and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
16679116|NCT02089542|Experimental|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
16679117|NCT02089529|Active Comparator|Ibuprofen/Ibumetin|Ibumetin is administrated. Intervention: No information about the effect.
16679118|NCT02089529|Placebo Comparator|Placebo|Placebo is administrated. Intervention: No information about the effect.
16679119|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+positive information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
16679120|NCT02089529|Placebo Comparator|Placebo+positive information|Placebo is administrated. Intervention:The patient receive written information that the capsule is Ibumetin.
16679121|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+neutral information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
16679122|NCT02089529|Placebo Comparator|Placebo+neutral information|Placebo is administrated. Intervention:The patients receive information that the capsule is placebo.
16679123|NCT02089529|No Intervention|Control|Control condition
16679124|NCT02089516||Frail elderly|Measuring movement activity in frail elderly (GFI score ≥ 4) of 75 years and older using DynaPort.
16679125|NCT02089503||induction phase + intravitreal inj.|Group of patients who received Lucentis ® with induction phase
16679126|NCT02089503||intravitreal inj. without induction|Group of patients who received Lucentis ® without induction phase
16679127|NCT02089503||intravitreal inj. + monthly follow-up|group of patients who were monthly monitored (+/- 1 week)
16679128|NCT02089503||intravitreal inj. + follow-up :> 1 month|group of patients with Follow up visits intervals> 1 month (+/- 1 week)
16679129|NCT02089503||intravitreal inj +induction+ month. FU|Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)
16679130|NCT02089503||date Lucentis® 1st intravitreal Inj.|Group of patients selected in accordance with the date of Lucentis® treatment start.
16679131|NCT02089490|Experimental|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
16679132|NCT02089477|Experimental|Support|"The participants in the intervention group receives the intervention and support consisting of:
~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.
~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
16679133|NCT02089477|No Intervention|Control group|Patient's in the control group receives the intervention with interval Walking and no other support.
16679134|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
16679135|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
16679136|NCT02089451|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 5 treatment periods
16679137|NCT02089438|Experimental|Saxagliptin|Ssaxagliptin is given before breakfast
16679138|NCT02089438|Experimental|´Sitagliptin|Sitagliptin is given before breakfast
16679139|NCT02089438|Experimental|Vildagliptin|Vildagliptin is given before breakfast
16679140|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
16679141|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
16679142|NCT02089412|Experimental|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
16679143|NCT02089412|Experimental|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
16679144|NCT02089399|Experimental|Treatment AB|S->S+C
16679145|NCT02089399|Experimental|Treatment C|C
16679146|NCT02089386|Experimental|Tamoxifen|Tamoxifen 20 mg daily for 12 weeks
16679147|NCT02089373|Experimental|Probe-based confocal laser endomicroscopy|
16679148|NCT02089373|Active Comparator|White light endoscopy|
16679149|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
16679150|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
16679151|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
16679152|NCT02089321||Patients with Low Back Pain|"n= 19
~Inclusion Criteria:
~Between the ages of 18 and 70 years Currently seeking, but not yet initiated, treatment from a health care professional (PT, MD, DO, DC) for a chief complaint of pain between the level of the twelfth thoracic vertebrae and the coccyx Able to transition between standing, sitting, supine, prone and sidelying independently
~Exclusion Criteria:
~Signs of neurological impairment including diminished myotatic reflex, sensory impairment or strength deficits in a myotomal pattern No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
16679153|NCT02089321||Healthy Controls|"n= 19
~Inclusion Criteria:
~Between the ages of 18 and 70 years No LBP episodes requiring clinical care by a health professional and/or greater than 3 days absence from work/school/recreation within the previous 5 years Able to transition between standing, sitting, supine, prone and sidelying independently
~Exclusion Criteria:
~No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
16679154|NCT02089308|Other|Treatment-Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.
~Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)
~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
16679155|NCT02089308|Other|Treatment-Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.
~Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)
~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
16679156|NCT02089295|Experimental|Treatment A|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16679157|NCT02089295|Experimental|Treatment B|Single dose of 20 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16679158|NCT02089295|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16679159|NCT02089282||Clavicle fractures|
16679160|NCT02089269||Cohort 1|1,625 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
16679161|NCT02089269||Cohort 2|100 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
16679162|NCT02089256|Experimental|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
16679163|NCT02089243|Experimental|Vagus nerve stimulation therapy|Surgical follow-up typically occurred 2 weeks postoperatively and, subsequently, on a variable schedule as indicated. The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes. Retrospective chart review was performed to collect follow-up and outcome data. At the time of last available clinical follow-up, the following data were collected: mean weekly seizure frequency (from seizure logs kept by caretakers or patient or caretaker report averaged of the last 3 months prior to ﬁnal follow-up), complications of VNS therapy, duration of VNS therapy, timing and all subsequent surgical procedures.
16679164|NCT02089243|Experimental|Resective surgery|The type of surgery performed consisted of standard anterior temporal lobectomy, electrocorticography tailored temporal lobectomy, anteromedial temporal lobectomy, transcortical or transsylvian or subtemporal selective amygdalohippocampectomy, temporal lobe disconnection and hippocampal transection.
16679165|NCT02089230|Experimental|Phase I Cohort 1 - MEK 162|Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.
16679166|NCT02089230|Experimental|Phase I Cohort 2 - MEK 162|Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
16679167|NCT02089230|Experimental|Phase II Cohort 3 - MDK 162|Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
16679168|NCT02089217|Active Comparator|Carotid Endarterectomy (CEA)|Carotid Endarterectomy
16679169|NCT02089217|Active Comparator|Carotid Stenting (CAS)|Carotid Stenting
16679170|NCT02089217|Experimental|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
16679171|NCT02089217|Experimental|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
16679172|NCT02089204||FMISO-PET/CT|18F-MISO PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
16679173|NCT02089204||FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
16679174|NCT02089204||contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy . GTVs were delineated based on fusing diagnostic CT images with simulation CT images.All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
16679175|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
16679176|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
16679177|NCT02089178|Experimental|intravenous|the total intravenous anesthesia group
16679178|NCT02089178|Active Comparator|inhalation|the inhalation anesthesia group
16679179|NCT02089165|Experimental|Krill oil|The interventions are administered in the randomized order.
16679182|NCT02089152|Other|Cluster A|General education for prevention of diabetic complications in year 1, Melioidosis prevention education in years 2, 3 and 4.
16679183|NCT02089152|Other|Cluster B|General education for prevention of diabetic complications in year 1 and 2, Melioidosis prevention education in year 3 and 4.
16679184|NCT02089152|Other|Cluster C|General education for prevention of diabetic complications in year 1, 2 and 3, Melioidosis prevention education in year 4.
16679185|NCT02089139|Experimental|DISCOGEL|Percutaneous intradiscal injection of Discogel
16679186|NCT02089139|Active Comparator|conventional treatment|conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks
16679187|NCT02089126|Experimental|Gemigliptin/Glimepiride combination|Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination & Placebo for Glimepiride.
16679188|NCT02089126|Placebo Comparator|Placebo|The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination & Glimepiride.
16679189|NCT02089113|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
16679190|NCT02089113|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
16679191|NCT02089100|Experimental|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
16679192|NCT02089100|Active Comparator|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
16679193|NCT02089087|Experimental|CFZ533 in healthy volunteers|CFZ533 single dose in healthy volunteers
16679194|NCT02089087|Experimental|CFZ533 in rheumatoid arthritis patients|CFZ533 single dose in rheumatoid arthritis patients
16679195|NCT02089087|Placebo Comparator|Placebo|Placebo single dose
16679196|NCT02089074|Experimental|drug use counselling|Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
16679197|NCT02089074|No Intervention|Control group|The patients in the control group receive no intervention just treatment and follow up according to national standards
16679198|NCT02089061|Experimental|Cohort 1: Rosuvastatin + BMS-919373|"Rosuvastatin 10 mg tablet orally once for Day 1 and 5
~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
16679199|NCT02089061|Experimental|Cohort 2: Atorvastatin + BMS-919373|"Atorvastatin 40 mg tablet once for Days 1 and 5
~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
16679200|NCT02089048|Experimental|Cohort 1|15 subjects receive 6mg of auranofin once every 24 hours for 7 days
16679201|NCT02089035|Experimental|MUFA-rich dairy products|"Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period.
~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
16679202|NCT02089035|Experimental|Conventional dairy products|"Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks.
~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
16679203|NCT02089022|Experimental|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
16679204|NCT02089009|Other|Group 1 Standard Population|Retinal Imaging, vessel measurements, vessel changes of a population of a female health hospital
16679205|NCT02089009|Other|Group 2 Pregnant Population|Change in vessel diameter at perinatal visits with retinal imaging (Retinal Imaging, vessel measurements, vessel changes)
16679206|NCT02088996|Active Comparator|IT and LWD on high power|IT and LWD on high power
16679207|NCT02088996|Placebo Comparator|LWD on low power|LWD on low power
16679208|NCT02088983|Experimental|CDP-Choline|Single dose of 500 mg, 1000 mg, or 2000 mg given in one of 4 test sessions
16679209|NCT02088983|Placebo Comparator|Placebo (cellulose)|Given randomly in one of the 4 testing sessions as a comparison
16679210|NCT02088970|Active Comparator|antibiotic treatment alone|
16679211|NCT02088970|Experimental|Crosslinking + Antibiotic|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.
~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
16679212|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.
~Subjects should transition to oral medication as soon as they are able to swallow tablets."
16679213|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.
~Subjects should transition to oral medication as soon as they are able to swallow tablets."
16679214|NCT02088944||exposed to IFX|
16679285|NCT02088463|Other|Ultrasound and infrared therapy|ultrasound and infrared are a traditional treatment for low back painThe treatment duration for the three groups was 3 times/week for 4 weeks.
16679215|NCT02088931|Experimental|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.
~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
16679216|NCT02088918|Active Comparator|Nateglinide+Metformin|coadministration of nateglinide and metformin
16679217|NCT02088918|Experimental|Nateglinide/Metformin|Nateglinide/Metformin tablet
16679218|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
16679219|NCT02088905|No Intervention|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
16679220|NCT02088892|Experimental|Group A|10 BCG-naïve subjects receiving intradermal BCG SSI at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
16679221|NCT02088892|Experimental|Group B|10 BCG-naïve subjects receiving BCG Tice at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
16679222|NCT02088892|Experimental|Group C|10 BCG-naïve subjects receiving intradermal BCG SSI at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
16679223|NCT02088892|Experimental|Group D|10 BCG-naïve subjects receiving intradermal BCG Tice at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
16679224|NCT02088892|Experimental|Group E|8-12 BCG-naïve subjects receiving the optimal strain and dose of intradermal BCG identified from preliminary results obtained from Group A, B, C and D, followed by a punch biopsy at the challenge site 14 days later.
16679225|NCT02088879|Experimental|Group1|"first : chest compression with kneeling position
~second : chst compression with standing position"
16679226|NCT02088879|Experimental|Group2|"first : chest compression with standing position
~second : chst compression with kneeling position"
16679227|NCT02088866|Experimental|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
16679230|NCT02088840||stem cell tranplant|All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease
16679231|NCT02088827|Other|Activity|During a 4 hour Meal Test subjects will cycle for 2 minutes every 20 minutes
16679232|NCT02088827|Other|Inactivity|During a 4 hour Meal Test study subjects will remain inactive (remain lying on a bed)
16679233|NCT02088814|Experimental|'EPICAP'|Secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
16679234|NCT02088814|No Intervention|Medical treatment as usual|Medical treatment of burn injuries as usual
16679235|NCT02088801|Experimental|Airtraq, blade without channel for tracheal tube|intubation
16679236|NCT02088801|Experimental|KingVision , blade without channel for tracheal tube|intubation
16679237|NCT02088801|Experimental|A.P. Advance, blade without channel for tracheal tube|intubation
16679238|NCT02088801|Experimental|Macintosh|intubation
16679239|NCT02088788|Experimental|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
16679240|NCT02088788|Active Comparator|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
16679241|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
16679242|NCT02088762||1 cm safety margin|1 cm safety margin
16679243|NCT02088762||2 cm safety margin|2 cm safety margin
16679244|NCT02088749|Experimental|small group treatment|lifestyle intervention for obesity delivered to small groups of approximately 12 participants/group
16679245|NCT02088749|Active Comparator|large group treatment|lifestyle intervention for obesity delivered to a large group of approximately 30 participants
16679246|NCT02088736|Active Comparator|Intravenous and Intraosseous|'IV + IO' Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If IV is unsuccessful, IO will attempt at the Primary site (proximal tibia). If IO is unsuccessful at scene, 2nd attempt can be done in the ambulance. Adrenaline will be delivered as according to protocol.
16679247|NCT02088736|Experimental|Intravenous|Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
16679248|NCT02088723|Experimental|head of bed elevation|Compare the apnea hypopnea index with the patient in standard polysomnography and in elevated polysomnography (head of bed elevation)
16679249|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
16679250|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
16679251|NCT02088684|Experimental|LEE011 + BKM120 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
16679252|NCT02088684|Experimental|LEE011 + BYL719 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
16679253|NCT02088684|Experimental|LEE011 + fulvestrant|LEE011 - 28 day cycles (3 weeks on, 1 week off) or (continuous daily dosing - dose escalating) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
16679254|NCT02088671||Anesthesia|"A single study group undergoing general anesthesia procedure to observe post-hoc the effect on the NeuroSENSE monitor readings.
~Interventions of interest:
~Drug: Propofol induction followed by randomized doses of desflurane; Emergence by stepping down the desflurane ET - See intervention descriptions.
~Device: Recording of EEG using NeuroSENSE (blinded to clinicians) - See intervention descriptions.
~Other: Data Collection - See intervention descriptions"
16679473|NCT02087410||study|patients with polycystic ovary syndrome
16679255|NCT02088658|Experimental|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes.
16679256|NCT02088658|No Intervention|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
16679257|NCT02088645|Experimental|Phase 0: One arm; Phase I: One arm|"Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)
~Phase I: expected 12 - 18 patients, intravenous application of max. 6 x 7-8 GBq 177Lu-PP-F11N (increasing number of applications by one in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study."
16679258|NCT02088632|Active Comparator|Incobotulinumtoxina|Xeomin 25-100 units injected to chosen area one time.
16679259|NCT02088632|Placebo Comparator|Placebo Comparator|Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.
16679260|NCT02088619|Experimental|Quality of Life Therapy (QOLT)|Positive emotion-focused cognitive behavioral psychotherapy
16679261|NCT02088619|Active Comparator|Heart Healthy Education (HHE)|Heart healthy education program
16679262|NCT02088593|Experimental|DAWN simulation|Simulated Dawn Light box
16679263|NCT02088593|Active Comparator|Sleep hygiene instructions read aloud|Standard sleep hygiene instructions were read aloud.
16679264|NCT02088580|Experimental|Triple Chronotherapy|Total sleep deprivation, Sleep phase advance, and Bright light therapy.
16679265|NCT02088567|Experimental|dHACM|Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
16679266|NCT02088567|Other|Control|Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
16679268|NCT02088541|Experimental|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m^2 (milligrams per square meter) (60 to 120 mg based on body surface area [BSA]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
16679269|NCT02088541|Experimental|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
16679270|NCT02088541|Experimental|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
16679271|NCT02088541|Active Comparator|Physician's Choice 1 (PV <5)|Participants under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
16679272|NCT02088541|Active Comparator|Physician's Choice 2 (PV >=5)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
16679273|NCT02088528|Active Comparator|Aurolab glaucoma drainage device|
16679274|NCT02088528|Active Comparator|Trabeculectomy with mitomycin-c|
16679275|NCT02088515|Experimental|experimental group|experimental group: Nedaplatin(（80 mg/m2, i.v Day1）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total.
16679276|NCT02088515|Active Comparator|comparative group|comparative group:Cisplatin (（75 mg/m2, i.v Day1 or 25 mg/m2 Day1-3）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total
16679277|NCT02088502|Active Comparator|N-acetylcysteine|Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
16679278|NCT02088502|Active Comparator|Theophylline|Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
16679279|NCT02088502|Active Comparator|Theophylline plus N-acetylcysteine|Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.
16679280|NCT02088489|Active Comparator|Atrial flutter, irrigated catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® (Biosense Webster, Diamond Bar, CA) irrigated catheter
16679281|NCT02088489|Experimental|Atrial flutter, porous tip catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® SF(Biosense Webster, Diamond Bar, CA) irrigated catheter
16679282|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
16679283|NCT02088463|Experimental|Mobilization (manual therapy)|Mobilization (manual therapy) posterior- anterior at the L3 for 2 minutes in addition to the traditional treatment in the form of infra-red and ultrasound. The treatment duration for the three groups was 3 times/week for 4 weeks.
16679284|NCT02088463|Placebo Comparator|placebo mobilization|placebo mobilization applied without force application. The treatment duration for the three groups was 3 times/week for 4 weeks
16679286|NCT02088450|Active Comparator|Active treatment|Active treatment with nitrendipine (10-40 mg/day). If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
16679287|NCT02088450|Placebo Comparator|Placebo|Placebo tablets were identical to the study drugs with a similar schedule.
16679288|NCT02088437|Active Comparator|Usual care|usual care physiotherapy - once daily treatment whilst inpatient in acute hospital
16679289|NCT02088437|Experimental|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention
16679290|NCT02088424||group A|cases with recurrent abortion with insulin resisance
16679291|NCT02088424||GROUP B|cases that are pregnant with no history of recurrent abortion with no insulin resistance
16679292|NCT02088411|Active Comparator|Diclofenac|Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
16679293|NCT02088411|Active Comparator|Wobenzym|Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.
16679294|NCT02088411|Placebo Comparator|Placebo|Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
16679295|NCT02088398|Experimental|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
16679296|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
16679297|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
16679298|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
16679299|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
16679301|NCT02088359||Cycled light|Approximately 12 hours of light on and 12 hours of light off.
16679302|NCT02088359||Near darkness|Continue near darkness
16679303|NCT02088346||Teleconsultation|Intravenous thrombolysis guided by telemedicine consultation system based on portable hardwares
16679304|NCT02088346||Historical control|Usual stroke care without the guidance from hub hospital
16679305|NCT02088333|Experimental|mCRC intervention|intervention arm
16679306|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
16679307|NCT02088307|No Intervention|Control|Subjects in the control arm will not receive an intervention.
16679308|NCT02088307|Experimental|CardioLife|The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.
16679309|NCT02088294|No Intervention|Non-intervention control|No intervention will be delivered.
16679310|NCT02088294|Experimental|Lifestyle Education (LS)|"The lifestyle curriculum will be taught in twice weekly after-school sessions of ~1.25 hours, one physical activity and one nutrition-related, delivered over 12-weeks during the course of a single academic semester. The lifestyle program will utilize the Shape Up curriculum of SOSMentor, a community non-profit collaborator, modified to seamlessly integrate key concepts of the non-diet philosophy of Intuitive Eating. The curriculum fully encompasses health-promoting nutrition and physical activity practices consistent with consensus recommendations ."
16679311|NCT02088294|Experimental|LS + Stress Reduction Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided Imagery (IGI) consisting of standard stress reduction imagery practices, delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures."
16679312|NCT02088294|Experimental|LS + Activity/Eating Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating."
16679313|NCT02088281|Experimental|Indigo naturalis extract in oil ointment|Indigo naturalis extract in oil ointment: each gram of ointment contains 200 μg±20 μg of indirubin.
16679314|NCT02088268|Experimental|platelet-rich plasma|wound healing
16679315|NCT02088255|Active Comparator|Static surface|The subjects will do the walking training with partial body weight support on static surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
16679316|NCT02088255|Active Comparator|dynamic surface|The subjects will do the walking training with partial body weight support on dynamic surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
16679317|NCT02088242|Placebo Comparator|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
16679318|NCT02088242|Experimental|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
16679319|NCT02088216|Active Comparator|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
16679320|NCT02088216|Other|Control group|Participants received as-needed therapy.
16679321|NCT02088203|Experimental|Single Dose Sequence 1|Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.
16679322|NCT02088203|Experimental|Single Dose Sequence 2|Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.
16679323|NCT02088203|Experimental|Single Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.
16679324|NCT02088203|Experimental|Single Dose Sequence 4|Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.
16679325|NCT02088203|Experimental|Single Dose Sequence 5|Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.
16679326|NCT02088203|Experimental|Single Dose Sequence 6|Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.
16679327|NCT02088203|Experimental|Single Dose Sequence 7|Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.
16679328|NCT02088203|Experimental|Single Dose Sequence 8|Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.
16679329|NCT02088203|Experimental|Single Dose Sequence 9|Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.
16679330|NCT02088203|Experimental|Multiple Dose Sequence 1|Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679331|NCT02088203|Experimental|Multiple Dose Sequence 2|Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679332|NCT02088203|Experimental|Multiple Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679333|NCT02088203|Experimental|Multiple Dose Sequence 4|Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679334|NCT02088203|Experimental|Multiple Dose Sequence 5|Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679335|NCT02088203|Experimental|Multiple Dose Sequence 6|Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679336|NCT02088203|Experimental|Multiple Dose Sequence 7|Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679337|NCT02088203|Experimental|Multiple Dose Sequence 8|Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679338|NCT02088203|Experimental|Multiple Dose Sequence 9|Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
16679339|NCT02088190||Age group 1|Age > 60 years old
16679340|NCT02088190||Age group 2|Age < 60 years old
16679341|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
16679342|NCT02088164||Healthy men|Healthy men who received PSA screening
16679343|NCT02088151|Experimental|Treatment|Patients receive selective retinal pigment epithelium laser treatment
16679344|NCT02088138|Experimental|Functional Electrical Stimulation|"Functional Electrical Stimulation
~In the intervention group the FES was applied in the medial and lateral vastus of both thighs targeting the movement of knee extension. The application frequency was 15 Hz, lasting 40 minutes, pulse width of 0.5 ms, time ON 5s, time OFF 10s, ramp-up of 0 or 1s, descent ramp 2s and intensity as tolerance patient."
16679345|NCT02088138|Experimental|FES placebo|"Functional Electrical Stimulation placebo
~The placebo group received functional electrical stimulation with the same parameters in the intervention group, except that the intensity of stimulation did not lead to visible or palpable contraction."
16679346|NCT02088125|Active Comparator|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
16679347|NCT02088125|Active Comparator|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
16679348|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
16679349|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
16679350|NCT02088099|Experimental|Complex clinical intervention|
16679351|NCT02088099|Active Comparator|Treatment as usual|
16679352|NCT02088086|Experimental|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
16679353|NCT02088086|Active Comparator|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
16679354|NCT02088086|No Intervention|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
16679355|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
16679356|NCT02088073|Placebo Comparator|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
16679357|NCT02088073|Experimental|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
16679358|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
16679359|NCT02088073|Experimental|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
16679360|NCT02088060|Experimental|Cannabidiol|Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks
16679474|NCT02087410||control|healthy patients serves as control group
16679361|NCT02088060|Active Comparator|Olanzapine|Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks
16679362|NCT02088060|Placebo Comparator|Placebo|Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks
16679363|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
16679364|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
16679365|NCT02088034|Experimental|Promotora-led Intervention|The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
16679366|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
16679367|NCT02088034|Active Comparator|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
16679368|NCT02088021|Experimental|Portico Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a ALC delivery system
16679369|NCT02088008|Experimental|cilnidipine/valsartan|cilnidipine/valsartan tablet
16679370|NCT02088008|Active Comparator|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
16679371|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
16679372|NCT02087982||Seniors|"The study will be based on a 6-months assessment period, with two consecutive monitoring visits on enrollment.
~Patient follow-up after 3 months will be conducted by telephone and monitoring after 6 months will be carried out as part of a routine consultation.
~Each subject will have a BGA (Brief Geriatric assesment)."
16679373|NCT02087969|Experimental|Dry Needling|Dry Needling to Triceps Surae
16679374|NCT02087969|Experimental|Stretching|Subjects will be given a home exercise program of stretches which are commonly prescribed to improve ankle dorsiflexion.
16679375|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
16679376|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
16679377|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
16679378|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
16679379|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
16679380|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
16679381|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
16679382|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
16679383|NCT02087930||healthy control|healthy infants
16679384|NCT02087917|Placebo Comparator|Placebo|
16679385|NCT02087917|Active Comparator|HS-25 5 MG|
16679386|NCT02087917|Active Comparator|HS-25 10 MG|
16679387|NCT02087917|Active Comparator|HS-25 20 MG|
16679388|NCT02087917|Active Comparator|HS-25 30 MG|
16679389|NCT02087904|Experimental|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
16679390|NCT02087904|Experimental|ABT-981 medium dose|100 mg ABT-981 SC E2W
16679391|NCT02087904|Experimental|ABT-981 high dose|200 mg ABT-981 SC E2W
16679392|NCT02087904|Placebo Comparator|Placebo|Placebo
16679393|NCT02087891|No Intervention|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
16679394|NCT02087891|Experimental|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
16679395|NCT02087891|Experimental|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
16679396|NCT02087891|Experimental|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
16679397|NCT02087878||Group 1|To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL.
16679398|NCT02087865|Active Comparator|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
16679399|NCT02087865|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks.
16679400|NCT02087865|No Intervention|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
16679401|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
16679402|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
16679403|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
16679404|NCT02087852||high risk|Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation
16679405|NCT02087826|Active Comparator|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test
~Day 3-7: 500mg metformin, twice daily
~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
16679406|NCT02087826|Placebo Comparator|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test
~Day 3-7: 500mg metformin, twice daily
~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
16679407|NCT02087813|Experimental|A1AT|Alpha1-antitrypsin 120mg/kg once weekly for a total of 4 doses, to be given intravenously. This will be given in addition to standard of care 3-5 days of 1000mg IV methylprednisolone.
16679408|NCT02087813|Active Comparator|Standard of care|Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
16679409|NCT02087800||F Phase Lab session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the F phase lab session will be first. Followed by the L phase lab session.
16679410|NCT02087800||L Phase Lab Session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the L phase lab session will be first. Followed by the F phase lab session.
16679411|NCT02087787|No Intervention|Control|The control group will be provided the standard method, which is providing the Cancer Legal Line (CALL) brochure with a short explanation of the resource.
16679412|NCT02087787|Experimental|Intervention|The intervention group will be provided with a 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
16679413|NCT02087774|No Intervention|Control School|Control School received no intervention.
16679414|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
16679415|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
16679416|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
16679417|NCT02087735|Experimental|cranberry extract 1|One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
16679418|NCT02087735|Experimental|cranberry extract 2.|Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
16679419|NCT02087735|Placebo Comparator|cranberry extract 3.|Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
16679420|NCT02087722|Experimental|KI1001|
16679421|NCT02087722|Placebo Comparator|Placebo|
16679422|NCT02087709|Experimental|Low-calorie diet|The subjects were prescribed a daily energy intake 500 kcal lower than the estimated energy requirement.
16679423|NCT02087696|Other|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.
~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
16679424|NCT02087696|Other|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.
~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
16679425|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months.
16679426|NCT02087683|Placebo Comparator|Control Group (Placebo)|Participants in this group will receive a placebo containing gelatin and corn oil per day for 12 months
16679427|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
16679428|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
16679429|NCT02087657|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
16679430|NCT02087644|Experimental|CYT003|Injections of CYT003
16679431|NCT02087644|Placebo Comparator|Placebo|Injections of placebo
16679432|NCT02087631|Experimental|Quetiapine|Extended-release quetiapine fumarate up to 300mg once daily for 4 weeks
16679433|NCT02087618|Active Comparator|Kodro+|Will begin Kodro program at baseline
16679434|NCT02087618|Placebo Comparator|Kodro+D|Will begin Kodro program 12-weeks post baseline
16679435|NCT02087592|No Intervention|Control|Usual standard of care
16679436|NCT02087592|Experimental|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
16679437|NCT02087579|Experimental|Cohort A: Aripiprazole|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
16679438|NCT02087579|Experimental|Cohort B: Olanzapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
16679439|NCT02087579|Experimental|Cohort C: Paliperidone|Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
16679440|NCT02087579|Experimental|Cohort D: Quetiapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
16679441|NCT02087579|Experimental|Cohort E: Risperidone|Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
16679442|NCT02087566|Other|Administration of linezolid to 6 healthy volunteers|Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
16679443|NCT02087566|Other|Administration of linezolid to 6 acute renal failure patients|Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
16679444|NCT02087566|Other|Administration of linezolid to 6 ESRD patients|Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of >60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).
16679445|NCT02087553||Transfused pediatric patients|Children who might receive packed red blood cell (PRBC) transfusion will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Transfusion of red blood cells will be done according to standard of care.
16679446|NCT02087553||Saline/Albumin infusion|Children who might receive albumin or saline for volume resuscitation will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Infusion will be done according to standard of care.
16679447|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
16679448|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
16679449|NCT02087540|Active Comparator|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
16679450|NCT02087540|Active Comparator|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
16679451|NCT02087540|Active Comparator|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
16679452|NCT02087540|Placebo Comparator|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
16679453|NCT02087527|Experimental|CORTICOSTEROID|In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
16679454|NCT02087527|Placebo Comparator|NORMAL SALINE|In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours
16679455|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
16679456|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
16679457|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
16679458|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
16679459|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
16679460|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
16679461|NCT02087501|Other|HORIZON AAA Stent Graft|All patients will received the HORIZON AAA Stent Graft
16679462|NCT02087488|Experimental|auricular acupuncture(AA) & Eszopiclone|The disposable Seirin Pyonex Needle will be chosen as AA material to attach every 3 days for 4 weeks, meanwhile, oral Eszopiclone 1 piece (3mg) will be applied 15 minutes before going to sleep everyday for 4 weeks. The manufacturer of disposable Seirin Pyonex Needles is Seirin Corporation, a Japanese company.
16679463|NCT02087488|Placebo Comparator|placebo AA & Eszopiclone|The disposable Pyonex Zero Needle, a non-invasive material will be chosen as placebo AA, with auricular acupoints have no certain effect on PI. Additionally, 1 piece (3mg) Eszopiclone will be administrated to participants 15 minutes before going to sleep everyday for 4 weeks.
16679464|NCT02087475|Experimental|Neoadjuvant therapy arm|FOLFIRI * 6 cycles +/- radiotherapy -> surgery -> FOLFIRI * 6 cycles
16679465|NCT02087475|Active Comparator|Adjuvant therapy arm|Surgery -> FOLFIRI * 12 cycles +/- radiotherapy
16679466|NCT02087462|Experimental|Electroacupuncture (EA)|Use Electroacupuncture only
16679467|NCT02087462|Other|EA + Traction|Use electroacupuncture and traction together
16679468|NCT02087462|Other|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
16679470|NCT02087436|Active Comparator|Taperloc Complete Standard|Group one will receive a total hip replacement with Taperloc Complete Standard. Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
16679471|NCT02087436|Active Comparator|Taperloc Complete Microplasty|Group one will receive a total hip replacement with Taperloc Complete Microplasty.Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
16679472|NCT02087423|Experimental|MEDI4736|see below
16679477|NCT02087384|Placebo Comparator|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
16679478|NCT02087371||Included patients|Patients with end-stage liver failure and registered on transplantation list.
16679479|NCT02087358||Stress and craving|This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
16679480|NCT02087345||Dental erosions|
16679481|NCT02087332|Experimental|Prolonged release Torasemide (Britomar)|"Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose.
~Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect."
16679482|NCT02087332|Active Comparator|Torasemide (Diuver)|Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate. Dosage scheme: per os, once a day, after meals. Therapeutic dose - 5 mg a day. If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
16679483|NCT02087319|Experimental|platelet-rich plasma|hair loss, baldness
16679484|NCT02087306|Experimental|Brincidofovir|"Subjects who weighed <50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension.
~Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine)."
16679485|NCT02087293|Experimental|Intervention group, IVR call, RPh counseling|Group receives interactive voice response automated call asking about side effects of newly prescribed medications; has opportunity to speak with study pharmacist via phone about medication
16679486|NCT02087293|No Intervention|Control|Intervention patients are matched with control patients; control patients have only chart review completed.
16679487|NCT02087280||Anorexia Nervosa|
16679488|NCT02087280||Healthy controls|
16679489|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
16679490|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
16679491|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
16679492|NCT02087228|Experimental|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
16679493|NCT02087228|Active Comparator|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
16679494|NCT02087215|Active Comparator|boron gel|diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
16679495|NCT02087215|Placebo Comparator|control gel|placebo gel containing polymer of carbopol ultrex (1%)
16679496|NCT02087202|Experimental|magnesium|magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.
16679497|NCT02087202|Experimental|ketamine|ketamine is administered to those patients undergoing stated TKA and other operations.
16679498|NCT02087202|Placebo Comparator|control|normal saline (placebo) is administered to the patients.
16679499|NCT02087189||ICD/ CRT-D therapy|
16679500|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
16679501|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
16679502|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
16679503|NCT02087150|No Intervention|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
16679504|NCT02087150|Experimental|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
16679505|NCT02087137|Active Comparator|Memory and Aging Program|The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
16679506|NCT02087137|No Intervention|Wait-list Control|Participants randomized to the wait-list control group will receive no intervention following randomization. They will be offered the intervention immediately following completion of the week 14 outcome testing session.
16679507|NCT02087124|Experimental|0g whey protein|0g whey protein dissolved in 200 milliliter (mL) water.
16679508|NCT02087124|Experimental|10g whey protein|10g whey protein dissolved in 200 milliliter (mL) water.
16679509|NCT02087124|Experimental|20g whey protein|20g whey protein dissolved in 200 milliliter (mL) water.
16679510|NCT02087111|Experimental|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
16679511|NCT02087098||Patients with residual OAB symptoms|Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics
16679512|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
16679612|NCT02086344|Active Comparator|TLH _adnexal preservation|Standard TLH without PBS
16680478|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
16679513|NCT02087085|Sham Comparator|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
16679514|NCT02087072||Recently discharged homebound patients|
16679515|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
16679516|NCT02087046|Other|Stimulation|ANS Totally Implantable Deep Brain Stimulation System
16679517|NCT02087033|Placebo Comparator|ritmonutra and placebo|ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks
16679518|NCT02087020||Periprosthetic joint infection|Patient treated with 'Debridement, antibiotics and implant retention' for early postoperative periprosthetic joint infection at Danderyd Hospital between 2007-01-01 and 2012-12-01
16679519|NCT02087007|Experimental|group 1|Cilostazol 50mg, Cilostzaol 100mg
16679520|NCT02087007|Placebo Comparator|group 2|placebo
16679521|NCT02086994|Active Comparator|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
16679522|NCT02086994|Active Comparator|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
16679523|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
16679524|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
16679525|NCT02086955|No Intervention|Standard care|All participants receive three specially-developed brochures with information regarding the diabetic foot condition. The brochures containes explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home.
16679526|NCT02086955|Experimental|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention go on for five weeks. During a period of five weeks, the participants are provided with weekly education, skill training, and counseling sessions on foot care.
16679527|NCT02086942|Experimental|modified VCD regimen1|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen1 for 5 cycles.
~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.
~Interventions:
~Drug: Bortezomib 1.6mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
16679528|NCT02086942|Experimental|modified VCD regimen2|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen 2 for 5 cycles.
~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.
~Interventions:
~Drug: Bortezomib 1.3mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
16679529|NCT02086929|Experimental|Trazodone|"300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.
~Dosage form: capsule."
16679530|NCT02086929|Active Comparator|Venlafaxine XR|"75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.
~Dosage form: capsule."
16679531|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
16679532|NCT02086903|Experimental|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
16679533|NCT02086903|Experimental|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
16679534|NCT02086890|Experimental|Electro-acupuncture|Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
16679535|NCT02086890|Sham Comparator|Sham Electro-acupuncture|No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
16679536|NCT02086890|Experimental|Laser acupuncture|Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
16679537|NCT02086890|Sham Comparator|Sham Laser acupuncture|An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
16679538|NCT02086890|Experimental|Transcorneal Electrical Stimulation|Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
16679539|NCT02086890|Sham Comparator|Sham Transcorneal Electrical Stimulation|Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
16679540|NCT02086877||ICU Survivors who required > 72 hrs mechanical ventilation|No intervention
16679541|NCT02086864|No Intervention|Usual care|
16680215|NCT02082171|Experimental|Intervention group|Comprehensive geriatric assessment followed by multi-domain preventive intervention
16679542|NCT02086864|Active Comparator|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
16679543|NCT02086864|Placebo Comparator|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
16679544|NCT02086851|Experimental|Lifestyle Intervention plus Parent Motivational Interviewing|Lifestyle intervention + Parent MI
16679545|NCT02086851|Active Comparator|Lifestyle Intervention alone|lifestyle intervention alone
16679546|NCT02086838|Active Comparator|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
16679547|NCT02086838|Active Comparator|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
16679548|NCT02086825|Experimental|Rifaximin|
16679549|NCT02086825|Experimental|Lactulose|
16679550|NCT02086799|Experimental|IV thyroxin|IV thyroxin
16679551|NCT02086799|Placebo Comparator|control IV saline|Placebo
16679552|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
16679553|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
16679554|NCT02086773|Experimental|Low transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 7 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
16679555|NCT02086773|Active Comparator|High transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 8 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
16679556|NCT02086760|Experimental|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
16679557|NCT02086747|Active Comparator|Acetaminophen|Postoperative 72 hours acetaminophen 1 g iv 4 times a day for 72 hours iv
16679558|NCT02086747|Placebo Comparator|isotonic|1 g intravenous %0.9 NaCl four times Daily for 72 hours
16679559|NCT02086734||mRCC patients assessed with Perfusion CT|Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT
16679560|NCT02086721|Experimental|Oligometastatic cancer patients; N=18|
16679561|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
16679562|NCT02086695||Cancer Group|All subjects with cancer who will be treated with anyone of the following chemotherapy drugs; Pazopanib, Sutent or Bevacizumab
16679563|NCT02086682||General Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.
16679564|NCT02086682||Critical Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.
16679565|NCT02086669|Experimental|Pneumatic dilatation|Repetitive pneumatic dilatation as the initial treatment followed by repetitive dilatation in case of dysphagia recurrence.
16679566|NCT02086669|Active Comparator|Surgical myotomy|Laparoscopic myotomy and subsequent follow up.
16679567|NCT02086656|Experimental|open label|Single arm, open label
16679568|NCT02086643|Experimental|Retroclavicular block|Retroclavicular block
16679569|NCT02086630|Experimental|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
16679570|NCT02086630|No Intervention|Control|Treatment as usual
16679571|NCT02086617|Other|ultrasound of aorta|
16679572|NCT02086604|Experimental|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.
~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
16679573|NCT02086604|Experimental|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.
~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
16679574|NCT02086604|Experimental|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.
~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
16679575|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
16679576|NCT02086578|Experimental|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
16679609|NCT02086370|Experimental|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
16679610|NCT02086357||SWUE|
16679577|NCT02086578|Experimental|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
16679578|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
16679579|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
16679580|NCT02086552|Experimental|Treatment (sonidegib, lenalidomide)|Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.
16679581|NCT02086539|No Intervention|Normal Letter|This arm will receive the recruitment letter in a business sized envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
16679582|NCT02086539|Experimental|Large Envelope|This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
16679583|NCT02086539|Experimental|Priority Mail|Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
16679584|NCT02086539|Experimental|Amazon|This arm will receive a recruitment letter with the image of an Amazon gift card and told they will receive the $25 gift card if they enroll in the study.
16679585|NCT02086526|Experimental|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
16679586|NCT02086526|Other|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
16679587|NCT02086513|Experimental|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose of 200 mg, 400 mg, 600 mg, or 800 mg depending on the specific cohort. Starting dose 200 mg daily for a 28 day cycle. The DLT period will be for the first 2 cycles of therapy. Each cycle is 28 days in length, making the DLT period of minimum of 56 days.
16679588|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
16679589|NCT02086500|Placebo Comparator|Control|Identical volume of saline during emergency medical transport
16679590|NCT02086487|Experimental|Nilotinib 300 mg|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely.
~In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones:
~BCR-ABL1 transcript level ≤ 10% at 3 months;
~CCyR at 6 months,
~BCR/ABL1 ≤ 1% at 6 months
~MMR at 12 months, or
~if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose."
16679591|NCT02086474|Experimental|Hyaluronan|Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection
16679592|NCT02086474|Placebo Comparator|Bupivacaine|one Marcain extra-capsular injection
16679593|NCT02086461|Sham Comparator|15 mm Pyloric balloon dilatation.|During fluoroscopic control the pneumatic balloon is positioned of the pyloric sphincter and maintained there during the entire dilatation.
16679594|NCT02086461|Active Comparator|Pneumatic pyloric dilatation.|Endoscopy and 15 mm balloon dilatation is completed according to the same principle as active comparator arm.
16679595|NCT02086448|No Intervention|Obese, SDB negative|No intervention, observational comparison group
16679596|NCT02086448|Active Comparator|Obese, SDB postive, CPAP|Therapeutic CPAP
16679597|NCT02086448|Sham Comparator|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
16679598|NCT02086448|Other|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
16679599|NCT02086435|Experimental|Extracorporeal morcellation|"Extracorporeal morcellation in which patients are treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
16679600|NCT02086435|Active Comparator|Intracorporeal morcellation|Intracorporeal morcellation patients treated with standard intracorporeal morcellation, using reusable electronic device
16679601|NCT02086422|Active Comparator|ivabradine|Exercise with ivabradine
16679602|NCT02086422|Placebo Comparator|Placebo|Exercise with placebo
16679603|NCT02086409|Experimental|Yogurt supplemented with vitamin D and calcium|20 participants take yogurt supplemented with vitamin D and calcium during 12 weeks
16679604|NCT02086409|Active Comparator|Yogurt not supplemented with vitamin D and calcium|20 participants take yogurt not supplemented with vitamin D and calcium during 12 weeks
16679605|NCT02086396|Experimental|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
16679606|NCT02086396|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
16679607|NCT02086383||Patients with COPD|This is an observational study of patients with chronic obstructive pulmonary disease (COPD) who attend pulmonary rehabilitation, which is the routine standard of care in Guy's and St. Thomas' Hospital, London. It lasts for 14 sessions, twice a week and primarily consists of a supervised exercise program and educational sessions.
16679608|NCT02086370|Active Comparator|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
16679611|NCT02086344|Experimental|TLH_plus_PBS|TLH plus PBS
16679613|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
16679614|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
16679615|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
16679616|NCT02086318||OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
16679617|NCT02086305|Experimental|Usual Care + Transitional Care Model|Transitional Care, Evidence-based symptom management, Protocol-driven home visit and telephone follow-up, Trained nurse case manager and volunteer partnership
16679618|NCT02086305|Active Comparator|Usual Care|Usual care
16679619|NCT02086292|Experimental|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
16679620|NCT02086292|Experimental|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
16679621|NCT02086279|No Intervention|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for surgery are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.
~Patients enrolled will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between 1 and 4 days of the menstrual cycle will be measured at study entry and at 1, 3 and 6 months after the administration of the first vial of GnRH-a"
16679622|NCT02086266|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
16679623|NCT02086266|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation associated with Pelvic Floor Muscle Training, supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
16679624|NCT02086253|Experimental|BQ-788|Effect of BQ-788 on the magnitude of sustained flow-mediated dilatation
16679625|NCT02086253|Experimental|BQ-123|Effect of BQ-123 on the magnitude of sustained flow-mediated dilatation
16679626|NCT02086253|Experimental|BQ-788 + BQ-123|Effect of BQ-788+BQ-123 on the magnitude of sustained flow-mediated dilatation
16679627|NCT02086240|Experimental|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity. In a previous study (approved by NRES Committee London-West London, REC ref No. 12/LO/0735), we administered an oral dose of XBD173 (up to 90mg) in 12 subjects. No adverse events due to XBD173 occurred and it was well tolerated.
16679628|NCT02086227|Experimental|A Glucagon for Injection, Fresenius Kabi USA|The subjects will be administered the test (A) (Glucagon for Injection, Fresenius Kabi USA)or reference (B) product (GlucaGen® for Injection, Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
16679629|NCT02086227|Active Comparator|B GlucaGen® (Bedford Laboratories)|The subjects will be administered the test (A) Glucagon for Injection, Fresenius Kabi USA; or reference (B) product, GlucaGen® (Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
16679630|NCT02086214|Experimental|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
16679631|NCT02086214|Placebo Comparator|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
16679632|NCT02086201|Active Comparator|Problem Solving Therapy|Problem solving therapy is an evidence based psychotherapy for depression, with 30 years of research supporting its efficacy. PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment.
16679633|NCT02086201|Experimental|Engage|"Engage utilizes reward exposure consisting of the reintroduction of activities that patients once found rewarding and enjoyed, but have abandoned after they developed depression. Engage uses basic problem solving through which patients learn how to form action plans for pursuing rewarding activities of their choice."
16679634|NCT02086188|Experimental|Mirabegron|Mirabegron - 25mg (one tablet) taken by mouth daily with option to up-titrate to 50mg daily (two tablets) taken by mouth daily
16679635|NCT02086188|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth daily and two tablets taken by mouth daily if subject chooses up-titration
16679637|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
16679638|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
16679639|NCT02086149|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
16679640|NCT02086149|Active Comparator|Health Education|12-week health education control
16679641|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
16679642|NCT02086123|Active Comparator|Epidural Analgesia|Subjects randomized to this arm will receive Bupivacaine + Fentanyl Epidural Analgesia. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
16679643|NCT02086123|Active Comparator|Parenteral Analgesia (Intravenous)|Subjects randomized to this arm will receive Analgesia with Dilaudid 0.2 -0.4 mg Intravenously (IV) every 3 hours. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
16680605|NCT02079571|Experimental|ginger tea +water|
16679644|NCT02086110|Active Comparator|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
16679645|NCT02086110|Active Comparator|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
16679646|NCT02086097|Experimental|dexketoprofen trometamol|Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
16679647|NCT02086097|Active Comparator|IBUPROFEN|Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
16679648|NCT02086097|Placebo Comparator|PLACEBO|4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
16679649|NCT02086084|Active Comparator|NIV|Standard application of NIV in hypercapnic respiratory failure as per usual standard of care
16679650|NCT02086084|Experimental|ECCO2R|Addition of ECCO2R to NIV in AECOPD
16679651|NCT02086071|Other|Re biopsies feasibility|the Interest of the study is to evaluate the feasibility of the re biopsy; the re biopsy is done if the patient agrees to perform it.
16679652|NCT02086045|Other|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|DESolve Scaffold
16679653|NCT02086032|Experimental|micronized progesterone|1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
16679654|NCT02086032|Experimental|dydrogesterone|1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.
16679655|NCT02086019|Other|Conservative Arm- Medical therapy|Medical therapy
16679656|NCT02086019|Other|Invasive Arm-angiogram with PCI or CABG|same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate
16679657|NCT02086006|Other|DESolve scaffold|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold. test arm, intervention
16679658|NCT02085993||single arm|single arm study
16679659|NCT02085980|Experimental|Laser Treatment|Laser Treatment
16679660|NCT02085967|Experimental|E2006 Part A|E2006 10-mg tablets alone and in combination with rifampin 600 mg or itraconazole 200 mg
16679661|NCT02085967|Experimental|E2006 Part B|E2006 10-mg tablets alone and in combination with midazolam 2 mg plus bupropion 75 mg
16679662|NCT02085941|Experimental|Image-guided cryoablation +/- biopsy|"MRI/PET/CT imaging in the Advanced Multimodality Image Guided Operating (AMIGO) suite used to place cryoablation needle(s) into target lesion (Mean: 3 cryoprobes, Range: 1-10).
~MR/PET/CT imaging in the AMIGO suite will monitor two 15-minute freeze cycles separated by a 10 minute thaw period."
16679663|NCT02085928||Lateral epicondylitis|Patients with lateral epicondylitis with persistent pain for at least 3 months
16679664|NCT02085915|Other|strip Peri Screen|
16679665|NCT02085902|No Intervention|standard anesthesia|
16679666|NCT02085902|Experimental|standard anesthesia with ropivacaine|ropivacaine
16679667|NCT02085889||food intolerance|lactose intolerance fructose intolerance neither intolerance
16679668|NCT02085876||Patients requiring a liver biopsy|
16679669|NCT02085863|Experimental|Laquinimod|once daily oral doses of laquinimod (with combination oral contraceptives)
16679670|NCT02085863|Placebo Comparator|Placebo|Matching placebo (with combination oral contraceptives)
16679671|NCT02085850||Subjects identified in the Tema Eye Survey|Subjects identified in the Tema Eye Survey
16679672|NCT02085837|Experimental|Healthy Transitions Group|"Additional nursing services will be provided to this group in addition to a usual care by Nephrologist.
~Daily weight measurement and monitoring
~Medication review
~Universal dietary education
~Focused advanced directive program
~Countdown to fistula program"
16679673|NCT02085837|No Intervention|Usual Care Group|Usual care by nephrologist. No additional nursing support services will be provide to this group.
16679674|NCT02085824|Experimental|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
16679675|NCT02085824|Experimental|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
16679676|NCT02085824|Experimental|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
16679677|NCT02085811||Patients|
16679678|NCT02085798||Group 1|Low or intermediate-1 risk MDS patients according to IPSS
16679679|NCT02085798||Group 2|Intermediate-2 risk MDS patients according to IPSS
16679680|NCT02085798||Group 3|Any risk CMML patients according to CPSS
16679681|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
16679682|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
16679683|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
16679684|NCT02085772|Experimental|Patients with pre-conceptional obesity|
16679685|NCT02085759||Normal BMI|Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.
16679686|NCT02085759||Overweight BMI|Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.
16679687|NCT02085759||Obese BMI|Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.
16679688|NCT02085733||Possible Septic Arhtritis Patients|
16679689|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
16679690|NCT02085707|Active Comparator|Total hip replacement arthroplasty|59 off 118 patients will be randomized to total hip replacement arthroplasty
16679691|NCT02085707|Active Comparator|Closed reduction and internal fixation|"59 off 118 patients will be randomized to closed reduction and internal fixation.
~2 cancellous parallel hip pins"
16679692|NCT02085694|Experimental|Lactobacillus brevis CD2 lozenges|
16679693|NCT02085681|Experimental|Tele-medicine|Tele-medicine aided retinal imaging and referral to eye hospital
16679694|NCT02085681|Other|Conventional Referral|Patients will be counselled on the importance of eye examination and will be referred to the eye hospital in the conventional manner.
16679695|NCT02085668|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
16679696|NCT02085668|No Intervention|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
16679697|NCT02085655|Experimental|PEG-ASP+Gemox regimen group|PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21
16679698|NCT02085655|Active Comparator|AspaMetDex regimen group|Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD
16679699|NCT02085642|Experimental|Acupuncture|True acupuncture
16679700|NCT02085642|Sham Comparator|Sham needle|Retractable acupuncture needles will be used. No true transcutaneous needling through the skin
16679701|NCT02085629|Experimental|M reg treatment|"Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:
~Prednisolone
~D 0: 500 mg IV
~D 1: 125 mg IV
~D 2 - 14: 20.0 mg/d (oral)
~Wk 3 - 4: 15.0 mg/d
~Wk 5 - 8: 10.0 mg/d
~Wk 9 - 12: 5.0 mg/d
~Wk 13 - 14: 2.5 mg/d
~Wk 15 - End: Cessation
~MMF (or biologic equiv.)
~D -7 to -2: 500 mg/d (250mg 2x/d)
~D -1 to 14: 2000 mg/d
~Wk 3 - 36: 1000 mg/d
~Wk 37 - 40: 750 mg/d
~Wk 41 - 44: 500 mg/d
~Wk 45 - 48: 250 mg/d
~Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.
~Tacrolimus (or biologic equiv.)
~≤ 48 h pre-Tx to D 14: 3-12 ng/ml
~Wk 3 - 12: 3-10 ng/ml
~Wk 13 - 36: 3-8 ng/ml
~Wk 37 - End: 3-6 ng/ml"
16679702|NCT02085616|Experimental|Proactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
16679703|NCT02085616|Active Comparator|Reactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
16679704|NCT02085603|Active Comparator|Saracatinib|Saracatinib at a dose of 125mg orally will be administered daily for four weeks.
16679705|NCT02085603|Placebo Comparator|Placebo|Placebo tablet to be orally administered daily for four weeks.
16679706|NCT02085590|Active Comparator|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
16679707|NCT02085590|Placebo Comparator|NaCl 0.9%|injection 0.1 cc intradermal
16679708|NCT02085577|Experimental|Ketamine|"(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/h terminated at last suture to the skin.
~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.
~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.
~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed
~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.
~The patients usual daily opioids"
16679709|NCT02085577|Placebo Comparator|Placebo|"Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/h terminated at last suture to the skin.
~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.
~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.
~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed
~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.
~The patients usual daily opioids"
16679710|NCT02085564||GEJ-cancer patients consideres resectable|All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
16679711|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
16679712|NCT02085538|Experimental|Normal Renal Function|
16679713|NCT02085538|Experimental|Mild Renal Impairment|
16679714|NCT02085538|Experimental|Moderate Renal Impairment|
16679715|NCT02085538|Experimental|Severe Renal Impairment|
16679716|NCT02085525|Other|Weekly NP Visits|100 HNC (Head and Neck Cancer) patients seen weekly in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
16679717|NCT02085525|Other|Every Other Week NP Visits|100 HNC (Head and Neck Cancer) patients seen every other week in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
16679755|NCT02085291|Experimental|Resp-FL|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one. The target MAP was maintain MAP within 10% of the reference value.
16679718|NCT02085512|Experimental|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
16679719|NCT02085512|Placebo Comparator|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
16679720|NCT02085499|Other|NIMV followed by S-NIMV|During the study infants assigned to this arm will undergo a 2-hour period of non-synchronized NIMV followed by a 2-hour period of Synchronized-NIMV.
16679721|NCT02085499|Other|S-NIMV followed by NIMV|During the study infants assigned to this arm will undergo a 2-hour period of synchronized NIMV followed by a 2-hour period of non-synchronized NIMV.
16679722|NCT02085486|Experimental|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
16679723|NCT02085486|Other|Standard|Classical method wtih inspection and palpation
16679724|NCT02085473|Active Comparator|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
16679725|NCT02085473|Experimental|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
16679726|NCT02085473|Experimental|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
16679727|NCT02085473|Experimental|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
16679731|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
16679732|NCT02085434|Experimental|FITLINE practice-based referral program|
16679733|NCT02085434|No Intervention|Contemporaneous control|
16679734|NCT02085421|Active Comparator|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
16679735|NCT02085421|Sham Comparator|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
16679736|NCT02085408|Active Comparator|Arm I (daunorubicin hydrochloride and cytarabine)|See Detailed Description
16679737|NCT02085408|Experimental|Arm II (clofarabine)|See Detailed Description
16679738|NCT02085395|Experimental|SR-T100 ® Gel|Topical gel containing 2.3% of solamargine in Solanum undatum extract is used once daily with occlusive dressing for 16 weeks.
16679739|NCT02085382|Other|Kangaroo Mother Care Group|"Mothers in the KMC group were oriented in detail about KMC procedure. The mothers provided skin to skin contact using a specially tailored kangaroo tube made of soft flannel cloth. The mothers were encouraged to keep the baby in KMC as long as possible during the day and night for an accumulated time of at least 6 hours per day. The duration of the kangaroo care by each of the mother were recorded and tallied accordingly."
16679740|NCT02085382|Other|Conventional Mother Care|Conventional method of care was the routine care offered in the neonatal unit to low birth weight infants.
16679741|NCT02085356|Experimental|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
16679742|NCT02085356|Experimental|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
16679743|NCT02085356|No Intervention|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
16679744|NCT02085356|No Intervention|Control women alone|Women will enroll alone and will attend time-matched video sessions
16679745|NCT02085343|Experimental|EXP + SBF + AA|Exposure therapy (EXP) with safety behavior fading (SBF) and anti-phobic action (AA)
16679746|NCT02085343|Active Comparator|EXP + SBF|Exposure therapy (EXP) with safety behavior fading (SBF)
16679747|NCT02085343|Active Comparator|EXP|Standard therapist-guided in vivo exposure therapy (EXP)
16679748|NCT02085343|No Intervention|Wait-list control|Subjects assigned to this arm will undergo assessments at Weeks 0, Week 1, and Week 5, but will not receive any interventions.
16679749|NCT02085330|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
16679750|NCT02085330|No Intervention|Standard follow up|
16679751|NCT02085317|Other|Lepromatous Patients|Composed of patients with lepromatous Leprosy acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
16679752|NCT02085317|Other|Healthy Patients|Composed of patients without any disease acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
16679753|NCT02085304|Experimental|GammaKnife(R) stereotactic radiosurgery|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
16679754|NCT02085304|Active Comparator|Standard fractionated radiation therapy|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.
16679756|NCT02085291|Experimental|Resp-NE|In Resp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
16680606|NCT02079558|Experimental|Oxytocin|A single 100 microgram IV dose of carbetocin after operation
16679757|NCT02085291|Experimental|Nonresp-NE|In Nonresp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
16679758|NCT02085278|Experimental|Apollo Group|Apollo Micro catheter device
16679759|NCT02085265|Experimental|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
16679760|NCT02085265|Active Comparator|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
16679761|NCT02085252|Experimental|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
16679762|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
16679763|NCT02085239|Active Comparator|Lidocaine alone|Lidocaine: 8-10 ml of Lidocaine by subcutaneous injection
16679764|NCT02085239|Experimental|Lidocaine Ropivacaine|"Lidocaine Ropivacaine
~8-10 ml of Lidocaine given by subcutaneous injection
~8-10 ml of Ropivacaine given by subcutaneous injection"
16679765|NCT02085226|Experimental|Creative Engagement Intervention|Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
16679766|NCT02085226|Placebo Comparator|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
16679767|NCT02085213|Experimental|Glyceryl Trinitrate|"Nitrolingual Pump Spray [Coro-Nitro] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.
~Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.
~The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given."
16679768|NCT02085213|Placebo Comparator|Placebo|Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
16679769|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
16679770|NCT02085200|Other|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
16679771|NCT02085187|Experimental|Telemedicine training and counselling|
16679772|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
16679773|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
16679774|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
16679775|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
16679776|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
16679777|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
16679778|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
16679779|NCT02085135|Experimental|Titration Schedule 1|
16679780|NCT02085135|Experimental|Titration Schedule 2|
16679781|NCT02085122|Experimental|noninvasive ventilation|
16679782|NCT02085122|No Intervention|Control Group|
16679783|NCT02085109|Experimental|High fat meal|A high fat milkshake containing 60.6 grams of fat
16679784|NCT02085109|Placebo Comparator|Low fat meal|A Low fat milkshake containing 10.5 gram of fat
16679785|NCT02085109|Experimental|A Low fat meal containing theobromine|A low fat milkshake containing 10.5 grams of fat supplemented with 850 mg of theobromine
16679786|NCT02085096|Experimental|Problem-Solving Therapy|A problem-solving therapy training program will be provided to the spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
16679787|NCT02085096|Placebo Comparator|Standard Supportive Care|Participants who are randomized to this arm will be encouraged to use whatever supporting care is recommended to them by their health provider.
16679822|NCT02084849||Group 1|Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.
16680671|NCT02079155|Active Comparator|Arm I (RALP)|Patients undergo standard RALP.
16679788|NCT02085083|Experimental|Regular telephone and email access to an IBD Nurse|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the intervention arm each month. The email will include the following: Brief Questionnaire;The Option For Direct Nurse Contact; Educational modules; MyHealth Passport and a Comprehensive Study Questionnaire.
16679789|NCT02085083|Active Comparator|Minimal Intervention|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the control arm every 3 months. The email will include the following: MyHealth Passport and Study Questionnaire. This intervention is not expected to significantly improve outcomes.
16679790|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
16679791|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
16679792|NCT02085057||anorexia nervosa|Diagnosis of anorexia nervosa
16679793|NCT02085057||obsessive-compulsive disorder|Diagnosis of obsessive-compulsive disorder
16679794|NCT02085057||healthy control|No psychiatric diagnoses
16679795|NCT02085057||sisters|Sisters of those enrolled with a diagnosis of anorexia nervosa
16679796|NCT02085044|Experimental|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
16679797|NCT02085044|Active Comparator|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
16679798|NCT02085031|Experimental|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed for the patients assigned to this arm.
16679799|NCT02085031|Active Comparator|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed for the patients assigned to this arm.
16679800|NCT02085018|Experimental|Omeprazole|Omeprazole 20 milligrams twice a day taken for 90 days
16679801|NCT02085018|Placebo Comparator|Matched placebo|Matched placebo twice a day taken for 90 days
16679802|NCT02085005|Experimental|Aflibercept|Intravenous (IV) infusion on Day 1 every 3 weeks, followed by CAPOX (capecitabine by oral administration on Day 1 to Day 14 and oxaliplatin intravenous (IV) infusion on Day 1 every 3 weeks) for the induction treatment period (6 cycles) after which the patient may enter the maintenance period during which the treatment is Aflibercept + Capecitabine
16679803|NCT02084992|Experimental|Expanded technology disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.
16679804|NCT02084992|Active Comparator|telephonic disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.
16679805|NCT02084979|Experimental|Asynchronous telepsychiatry|Experimental Arm: Asynchronous telepsychiatry evaluation and consultation
16679806|NCT02084979|Active Comparator|Synchronous telepsychiatry|Control Arm: Synchronous telepsychiatry evaluation and consultation
16679807|NCT02084966|Experimental|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
16679808|NCT02084953|Experimental|ARM A: BMS-791325|BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days
16679809|NCT02084953|Active Comparator|ARM B: Moxifloxacin|Moxifloxacin 400mg tablet orally once on third day
16679810|NCT02084953|Placebo Comparator|ARM C: Placebo matching BMS-791325|Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days
16679811|NCT02084940||GnRH antagonist depot, Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
16679812|NCT02084927|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
16679813|NCT02084927|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
16679814|NCT02084914|Experimental|Group A|Endometrial scraching of uterine cavity by pipelle .
16679815|NCT02084914|Active Comparator|Group B|Uterine sound intoduced into uterine cavity without scratch .
16679816|NCT02084901|Experimental|Orsiro Arm|
16679817|NCT02084901|Active Comparator|BioMatrix or BioMatrix Flex Arm|
16679818|NCT02084875|Experimental|tofacitinib MR 11 mg Fed|tofacitinib modified release (MR) 11 mg tablet administered with food.
16679819|NCT02084875|Experimental|tofacitinib MR 11 mg Fasting|tofacitinib modified release (MR) 11 mg tablet administered without food.
16679820|NCT02084862|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
16679821|NCT02084862|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
16680297|NCT02081612|Active Comparator|Nutrition Education|Educational weight management group sessions alone
16679823|NCT02084849||Group 2|Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.
16679824|NCT02084836||Lean adolescents|
16679825|NCT02084823|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679826|NCT02084823|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679827|NCT02084823|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679828|NCT02084823|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16679829|NCT02084810|Active Comparator|NovoSeven®|
16679830|NCT02084810|Experimental|Eptacog alfa A 6 mg|
16679831|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
16679832|NCT02084784|Experimental|Indocyanine green & methylene blue,|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%
16679833|NCT02084771|Experimental|Oral Salt and Water|"Oral Salt and Water Loading:
~Participants randomized to this arm of the trial will receive 0.1 g/kg of salt (NaCl) and 12 mL/kg of water. Patients weighing more than 110 kg will receive the same amount as per a 110 kg patient. One third of the oral salt and water will be given before the CT and 2/3 post-CT as in the intravenous saline arm. Specifically, 0.03 g/kg of NaCl and 4 mL/kg of water in the one hour before CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken over 2 hours post-CT. The ingestion of the oral salt and water will be directly observed by the study nurse to ensure adherence to the protocol."
16679834|NCT02084771|Active Comparator|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
16679835|NCT02084758|Active Comparator|Nitrate supplementation|Sodium nitrate solution
16679836|NCT02084758|Placebo Comparator|Placebo supplementation|Sodium chloride solution
16679837|NCT02084745|Active Comparator|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
16679838|NCT02084745|Active Comparator|Implantation at post-Kpro at 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
16679839|NCT02084732|Experimental|Sorafenib|drug
16679840|NCT02084719|Experimental|Group A|Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
16679841|NCT02084719|Active Comparator|Group B|Patients will be tested only with the standard algorithm
16679842|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
16679843|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
16679844|NCT02084693||COMPREHENSIVE|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
16679845|NCT02084680|No Intervention|Control|Control group standard care
16679846|NCT02084680|Experimental|Community Health Workers|individual prenatal education
16679847|NCT02084654|Active Comparator|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
16679848|NCT02084654|Placebo Comparator|placebo|placebo in addition to weight loss
16679849|NCT02084641|Experimental|Insulin resistant and insulin sensitive|Both groups will be given the same intervention and then outcomes compared between groups
16679850|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
16679851|NCT02084615|Experimental|81mg aspirin|This arm will include perioperative 81 mg of aspirin.
16679852|NCT02084615|Experimental|325mg aspirin|Subjects will be taking 325mg of aspirin.
16679853|NCT02084602|Experimental|Artesunate/mefloquine|Orally administration of artesunate 4mg/Kg by three days Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
16679854|NCT02084589|Active Comparator|PCEA of continuous background infusion with demand dose|PCEA with background infusion of 5 ml/h and demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
16679855|NCT02084589|Active Comparator|PCEA with demand dose only|PCEA with demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
16679856|NCT02084576|Experimental|Nepafenac|One drop in the study eye 3 times daily for 30 days
16679857|NCT02084576|Active Comparator|Ketorolac|One drop in the study eye 4 times daily for 30 days
16679858|NCT02084563|Other|AML-Intensive Chemotherapy|"Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.
~Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:
~Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation
~Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
16679894|NCT02084342|Placebo Comparator|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.
~Normal saline (NS) 100ml IV for 20min, before incision."
16679957|NCT02083900|Experimental|Banana Leaf Dressing Group|The Banana Leaf Dressing site will receive a single layer of banana leaf dressing
16679859|NCT02084563|Other|AML-Non-intensive chemotherapy|"Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.
~Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
16679860|NCT02084563|No Intervention|Chronic Myeloid Disorders|"Patients with Chronic Myeloid Disorders:
~Myeloproliferative Neoplasms
~Myelodysplastic Syndromes
~Myeloproliferative/Myelodysplastic Neoplasms"
16679861|NCT02084550|Active Comparator|Vaminolac|Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
16679862|NCT02084550|Placebo Comparator|Saline|Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
16679863|NCT02084537|Active Comparator|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7 French (Fr) double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
16679864|NCT02084537|Active Comparator|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic approach. This includes laparoscopic cystogastrostomy with internal debridement.
16679865|NCT02084524|No Intervention|Nutritional evaluation|
16679866|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
16679867|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
16679868|NCT02084511|Experimental|Placebo reference|Placebo reference
16679869|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
16679870|NCT02084498|Active Comparator|ACC|Training in advanced carbohydrate counting
16679871|NCT02084498|Experimental|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
16679872|NCT02084485|Experimental|Arm A|
16679873|NCT02084485|Placebo Comparator|Arm B|
16679874|NCT02084472|Active Comparator|study 1: aqueous cream and baby oil|enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute
16679875|NCT02084472|Active Comparator|study 2: emulsifying ointment and cetomacrogol|patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution
16679876|NCT02084459|No Intervention|Control|Standard of care
16679877|NCT02084459|Experimental|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
16679878|NCT02084446|Active Comparator|Mycophenolate + Low Tacrolimus|"Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.
~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
16679879|NCT02084446|Experimental|Everolimus + Very Low Tacrolimus|"Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.
~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
16679880|NCT02084433|Active Comparator|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
16679881|NCT02084433|Experimental|intraosseous anaesthesia|"intraosseous anaesthesia using a computerized system (Quicksleeper) 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
16679882|NCT02084420|Experimental|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
16679883|NCT02084420|Active Comparator|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
16679884|NCT02084407|Active Comparator|DM1 subject with cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
16679885|NCT02084407|Active Comparator|DM1 subject without cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
16679886|NCT02084407|Active Comparator|Not DM1subject|Clinical examination, Skin biopsy, Blood and urine sampling
16679887|NCT02084394||no intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the concommittent ultrasound of the temporal artery. Deemed interventional by JHUIRB but no actual intervention done to subject.
16679888|NCT02084381|Experimental|MCO-Ci 400|MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
16679889|NCT02084381|Active Comparator|Revaclear 400|the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
16679890|NCT02084368|Experimental|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block guided by PNS.
16679891|NCT02084368|Placebo Comparator|combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group.
16679892|NCT02084355|Experimental|opioid rotation|"Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).
~oral oxycodone : convert to oral hydromorphone or fentanyl patch
~oral hydromorphone : convert to oral oxycodone or fentanyl patch
~fentanyl patch : convert to oral oxycodone or oral hydromorphone"
16679893|NCT02084355|Active Comparator|opioid dose escalation|"Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.
~oral oxycodone : maintain oral oxycodone and titrate the dose
~oral hydromorphone : maintain oral hydromorphone and titrate the dose
~fentanyl patch : maintain fentanyl patch and titrate the dose"
16680672|NCT02079155|Experimental|Arm II (R-LESS RP)|Patients undergo R-LESS RP.
16679895|NCT02084342|Experimental|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.
~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
16679896|NCT02084329|Experimental|Weighted Compression Vest|Weighted Compression Vest
16679897|NCT02084329|No Intervention|Control|
16679898|NCT02084316|Experimental|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
16679899|NCT02084316|Active Comparator|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.
~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.
~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
16679900|NCT02084303|Other|Ferumoxytol MRI|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI.
16679901|NCT02084290|Experimental|Shared Decision Making Program|Patients will have access to an educational decision making program and a risk prediction model, this web based program will be sent subjects in the intervention arm upon enrollment, they can access the program as many times as they wish.
16679902|NCT02084290|No Intervention|Control|Subjects enrolled at sites participating as control arms will access the same web-based surveys as the intervention group, and receive the same contacts from the study coordinator as the subjects enrolled at intervention sites.
16679903|NCT02084277|Experimental|Self-ligating brackets|Several self-ligating brackets are currently FDA-approved but have not been rigorously studied in this malocclusion patient population or in comparison to traditional brackets methods. Unlike conventional brackets, Self-ligating brackets (SLB) are bracket systems, without the wire ligature or elastic ligature, that have a tube-like device build into the bracket to close off the edgewise slot.
16679904|NCT02084277|Placebo Comparator|Conventional brackets|"The conventional brackets (CB) (edgewise appliance) retain the basic principle design of a rectangular wire in a rectangular slot. Archwire are tied to the bracket once placed in the slot with either elastometric ligation ties (O-rings) or steel ligation."
16679905|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
16679906|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
16679907|NCT02084251|Experimental|Exenatide analogue, Injection|PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
16679908|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
16679909|NCT02084225||Course participants|Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
16679910|NCT02084212|Other|Patients about to undergo epiretinal membrane surgery|
16679911|NCT02084199|Experimental|Part 1 - Severe renal impairment|Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
16679912|NCT02084199|Experimental|Part 1: Normal renal function|Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
16679913|NCT02084199|Experimental|Part 2 - Mild renal impairment|Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
16679914|NCT02084199|Experimental|Part 2 - Moderate renal impairment|Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
16679915|NCT02084199|Experimental|Part 2 - Normal renal function|Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
16679916|NCT02084186|Experimental|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
16679917|NCT02084186|Placebo Comparator|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
16679918|NCT02084173|Other|MET|Motivational Enhancement Therapy (MET)
16679919|NCT02084173|Other|MET + CRA|Motivational Enhancement Therapy (MET) with subsequent add-on The Community Reinforcement Approach (CRA)
16679920|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
16679921|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
16679922|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
16679923|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
16679924|NCT02084108|No Intervention|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
16679925|NCT02084108|Other|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
16679926|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
16679927|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
16679928|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
16679929|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
16679930|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
16679931|NCT02084069|Placebo Comparator|Control|Placebo
16679932|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
16679933|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
16679934|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
16679935|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
16679936|NCT02084043|Experimental|Breath-actuated vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.
16679937|NCT02084043|Experimental|Conventional vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.
16679938|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
16679939|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
16679940|NCT02084017|Active Comparator|Current Standard|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing applied under sterile conditions in the operating room following skin closure. Dressing changed post-operative day two and daily thereafter with daily inspection for infection by a physician.
16679941|NCT02084017|Experimental|Negative Pressure Wound Therapy|A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
16679942|NCT02084004|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
16679943|NCT02084004|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
16679944|NCT02084004|No Intervention|lifestyle counseling|
16679945|NCT02083991|Experimental|Steroid-free low TAC-arm|"Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.
~Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
16679946|NCT02083991|Active Comparator|Standard low-TAC arm|"Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.
~Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
16679947|NCT02083978||Bipolar Diagnosis|Individuals identified as having a Bipolar Diagnosis with a manic episode
16679948|NCT02083978||Control|Individuals identified as not having a major psychiatric diagnosis
16679949|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.
~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
16679950|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.
~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
16679951|NCT02083952|Experimental|swaddle blanket|
16679952|NCT02083939||Antibiotic Prophylaxis|This cohort will receive antibiotic prophylaxis prior to the hernia repair
16679953|NCT02083939||No Antibiotic Prophylaxis|This cohort will not receive antibiotic prophylaxis prior to the surgery
16679954|NCT02083926|Experimental|Ketamine infusion|A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
16679955|NCT02083926|Experimental|Saline infusion|A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
16679956|NCT02083913|Experimental|Supervised physical activity|
16679958|NCT02083900|Active Comparator|Hydrocolloid Dressing Arm|The donor under Hydrocolloid dressing was covered with hydrocolloid (DuoDERM CGF).
16679959|NCT02083887|Active Comparator|Group 1: ChAd63 ME-TRAP / MVA ME-TRAP at 16/24 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 infants aged 16 weeks at time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp (virus particles) intramuscular (IM) at 16 weeks and MVA ME-TRAP 1 x 10^8 pfu (plaque forming units) IM at 24 weeks.
16679960|NCT02083887|Active Comparator|Group 2: ChAd63 ME-TRAP / MVA ME-TRAP at 8/16 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 8 weeks at the time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 8 weeks and MVA ME-TRAP 1 x 10^8 pfu IM at 16 weeks
16679961|NCT02083887|Active Comparator|Group 3: ChAd63 ME-TRAP / MVA ME-TRAP at 1/8 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 1 week will be vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 1 week and MVA ME-TRAP 1 x 10^8 pfu IM at 8 weeks.
16679962|NCT02083887|No Intervention|Group 4: Control|20 healthy infants aged 16, 8 and 1 weeks will be enrolled into this group. (Five infants will be randomised to each of Groups 1 and 2 respectively while 10 infants aged 1 week will be randomised to Group 3). All twenty infants will receive EPI vaccinations only.
16679963|NCT02083874|Experimental|CBD|Open label CBD
16679964|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
16679965|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
16679966|NCT02083848|Other|7T MRI|All subjects are entered into a single arm.
16679967|NCT02083835||post-surgical patients|post-surgical patients > 18 years
16679968|NCT02083835||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
16679969|NCT02083822|Experimental|MRI assessment|
16679970|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
16679971|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
16679972|NCT02083796|Experimental|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
16679973|NCT02083796|Sham Comparator|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
16679974|NCT02083796|Active Comparator|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
16679975|NCT02083796|Sham Comparator|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
16679976|NCT02083783|Experimental|TRI102|Active, amphetamine extended-release oral suspension
16679977|NCT02083783|Placebo Comparator|Placebo|Placebo
16679978|NCT02083770|Experimental|Cancer Clinical Trials Education Program|Cancer Clinical Trials Education Program is offered to English- and Spanish-speaking Hispanics in the experimental arm. This program was designed to promote increased clinical trials literacy among Hispanic Americans. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among Hispanic Americans.
16679979|NCT02083770|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
16679980|NCT02083757||Resp|Fluid responsiveness is defined as a change of stroke volume stroke volume ≥ 10% after 250 ml rapid saline infusion in 10 minutes.
16679981|NCT02083757||Nonresp|Fluid responsiveness is defined as a change of stroke volume stroke volume < 10% after 250 ml rapid saline infusion in 10 minutes.
16679982|NCT02083744|Active Comparator|Control Group|Usual care group - patients will receive scales to take home and heart failure literature for self-monitoring of heart failure. Patients will complete final questionnaires
16679983|NCT02083744|Experimental|Psychoeducational Counseling|"1-on-1 psychoeducation session conducted by a bilingual research nurse at the clinic site or in the patient's home. Patients will receive a scale to measure weight, a diary to record weight and symptoms of heart failure, and telephone follow-up from the research nurse to reinforce the content of the education program every other week.
~Focus-groups - Perception of the intervention will be assessed with two focus groups."
16679984|NCT02083731|Experimental|MSCs|MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
16679985|NCT02083718|Experimental|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
16679986|NCT02083705|Experimental|SI+CC|"Chest compression will be superimposed by sustained inflations during CPR:
~CC+SI group Infants randomized in the SI group requiring CC, would receive CC at a rate of 90/min during an SI with a duration of 20sec (CC+SI). After 20 sec the SI will be interrupted for 1 sec and the next SI will be started for another 20sec13. Throughout this time CC is continued until ROSC. Every 45 sec (approximately 2 SIs) the clinical team would assess for changes in heart rate. CC+SI was continued until ROSC."
16679987|NCT02083705|Active Comparator|3:1 CPR|"CPR using 3:1 C:V ratio:
~3:1 C:V group Infants randomized into the 3:1 group requiring CC, would received CC using the current 3:1 C:V ratio recommend in the neonatal resuscitation guidelines16. Every 45 sec the clinical team would assess heart rate. 3:1 C:V CPR was continued until ROSC."
16679988|NCT02083692|Experimental|Metformin|
16679989|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
16679990|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
16679991|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
16679992|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
16679993|NCT02083666|Experimental|SOBI002|Single and repeated administration of different doses of test product
16679994|NCT02083666|Placebo Comparator|placebo|Single and repeated administration of placebo comparator
16679995|NCT02083653|Experimental|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
16679996|NCT02083653|Experimental|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
16679997|NCT02083653|Active Comparator|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
16679998|NCT02083640|Other|Treatment A (Reference)|
16679999|NCT02083640|Other|Treatment B (Test)|
16680000|NCT02083640|Other|Treatment C (Test)|
16680001|NCT02083627|Experimental|1:Single rosuvastatin,multiple fidaxomicin,single rosuvastatin|
16680002|NCT02083627|Experimental|2:Multiple fidaxomicin,single rosuvastatin,single rosuvastatin|
16680003|NCT02083614|Experimental|clamping|to clamp or release the catheter for 2 days before removal
16680004|NCT02083614|No Intervention|no clamping|
16680005|NCT02083601|Experimental|Psychological Support|The intervention group will participate in the 2-day, in-person Parent Forum and receive monthly phone calls from a mental health professional for 12 months.
16680006|NCT02083601|Other|No Psychological Support|This comparison group will attend the 2-day, in-person Parent Forum but will not receive long-term psychological support.
16680007|NCT02083588|Experimental|open - single arm|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
16680008|NCT02083575|Active Comparator|vitamin c|25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
16680009|NCT02083575|Other|iron chelator|Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
16680010|NCT02083549||Trauma 1 massively transfused|Trauma 1 massively transfused patients are identified as a Trauma level one patient by triage through guidelines from the Kessler Regional Trauma Center Trauma Triage Guidelines.
16680011|NCT02083536|Experimental|LDFWART + Docetaxel|"This study has 6 treatment cycles given at 3 weeks intervals ± 3 days. A cycle is defined as 1 treatment of morning Docetaxel and afternoon Low Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART). The first day of the first treatment is designated study day 1."
16680012|NCT02083523|Active Comparator|Motivational Interview|The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.
16680013|NCT02083523|Active Comparator|MI with Normative Feedback|The Motivational Interview with Normative Feedback, or MI + NF, condition/intervention included all procedures described for the MI condition. Additionally, in the MI + NF condition/intervention, the participants' days of marijuana and alcohol use were compared to two sets of norms ( age specific or level of care specific) available for treatment attending youth. Therapists used whichever norm provided a greater contrast with participants' use.
16680014|NCT02083510|Experimental|Colchicine|Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.
16680015|NCT02083497|Experimental|No banding|The volunteers who make up this group, held 18 kicks, 9 with the dominant leg and 9 with the non-dominant lower limb, without the intervention of any kind of bandage.
16680016|NCT02083497|Experimental|Group with Rigid Bandage|Volunteers carry out the same protocol described above, however, using rigid bandage. The bandage will be used for tape, Cremer brand and will be applied ankle support member of the individual, in order to limit the movement of the joint inversion.
16680017|NCT02083497|Experimental|Group with elastic bands|The protocol will be maintained, however, a brand elastic bandage Kinesio Sport applied to the lower support member of the individual, also in order to limit the movement of the joint inversion is used.
16680018|NCT02083471|Active Comparator|SOTI|Specific Oral Tolerance Induction with Egg or Cow's milk
16680019|NCT02083471|No Intervention|Food Allergy follow-up|
16680020|NCT02083458|Experimental|axillary vein catheterization|Catheterization of the axillary vein based on anatomical landmark.
16680021|NCT02083445|Placebo Comparator|Control group|Once a week there will be an attendance cognitive session (specific sessions designed to work on aspects related to body perception, movement, space) and the extraction of blood samples will be carried out to determine the progenitor cells on the same day of the active groups.
16680022|NCT02083445|Active Comparator|Exercise group|Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
16680023|NCT02083445|Active Comparator|Muscle electro-stimulation and IHH|Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.
16680024|NCT02083432|Active Comparator|5-weeks waiting list control|Half of the participants were randomly assigned to 5-weeks waiting list/Control group.The participants in the waiting list/Control Group are enrolled to the treatment Group (INtervention: 5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
16680025|NCT02083432|Experimental|5 session of CBT|Half of the participants were direct enrolled to 5 weeks(5 sessions) of cognitive behaviour therapy (CBT) performed by specially trained dentists. (Intervention: CBT)
16680026|NCT02083419||LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
16680027|NCT02083406|Experimental|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
16680028|NCT02083406|Experimental|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
16680029|NCT02083406|Experimental|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
16680030|NCT02083393||Patients with acute lung injury|Patients with sepsis induced acute lung injury
16680031|NCT02083393||Postsurgery patients|Postsurgery patients without acute lung injury and sepsis
16680032|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
16680033|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
16680034|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
16680035|NCT02083367||Hepatic Encephalopathy Group|Disease Group
16680036|NCT02083367||Control Group|Healthy Group
16680037|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
16680038|NCT02083341|Experimental|Muscle tension dysphonia - treatment|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
16680039|NCT02083341|Sham Comparator|Muscle tension dysphonia - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
16680040|NCT02083341|Experimental|Classically trained singers|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
16680041|NCT02083341|Sham Comparator|Classically trained singers - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
16680042|NCT02083328|Active Comparator|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
16680043|NCT02083328|Placebo Comparator|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
16680044|NCT02083315|Experimental|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
16680045|NCT02083315|Experimental|TRV130 3 mg|TRV130 3 mg IV x 1 dose
16680046|NCT02083315|Experimental|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
16680047|NCT02083315|Active Comparator|Morphine|Morphine 10 mg IV x 1 dose
16680048|NCT02083315|Placebo Comparator|Placebo|Dextrose 5% in water IV x 1 dose
16680049|NCT02083302|Experimental|Treatment1|The Treatment1 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2 and SCREAM Theater Dose 3.
16680050|NCT02083302|Experimental|Treatment2|The Treatment2 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2, SCREAM Theater Dose 3 and SCREAM Theater Dose 4.
16680051|NCT02083302|Other|Control|The control group received SCREAM Theater Dose 1.
16680052|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
16680053|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
16680054|NCT02083276|Experimental|Pivmecillinamhydrochlorid|Selexid 400 mg x 3 , 7 days
16680055|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
16680056|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
16680057|NCT02083250|Experimental|Treatment (vorinostat, chemotherapy, SCT)|"CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.
~TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0."
16680174|NCT02082444|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
16680058|NCT02083237|Active Comparator|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
16680059|NCT02083237|No Intervention|Waitlist Control|Due to the heavy demand for this clinical program, there is a naturally-occurring waitlist of approximately 3 months. Control participants are assessed during this period.
16680060|NCT02083224||Cancer patients|
16680061|NCT02083211|Experimental|mAb Nimotuzumab + chemotherapy|
16680062|NCT02083211|Placebo Comparator|placebo + chemotherapy|
16680063|NCT02083198||High Chloride|Patients receiving .9% sodium choride for resuscitation
16680064|NCT02083198||Low chloride|Patients receiving Plasmalyte for resuscitation
16680065|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
16680066|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
16680067|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
16680068|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
16680069|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
16680070|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
16680071|NCT02083159||Patients with NAFLD|
16680072|NCT02083146||Patients with CAD|Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.
16680073|NCT02083133||End Stage Renal Disease|GFR 15 ml/min or less or on Dialysis
16680074|NCT02083133||Chronic Kidney Disease Stage 4|GFR 15-30 ml/min
16680075|NCT02083133||Chronic Kidney Disease Stage -3|GFR 30-60 ml/min
16680076|NCT02083120|Experimental|nasal High Flow and Oxygen|overnight nasal High Flow (NHF) therapy+ individually titrated supplemental oxygen (2-6 L/min),total 35 L/min, 4 weeks at home
16680077|NCT02083120|Active Comparator|Long term Oxygen Therapy (LOT)|individually titrated supplemental oxygen (2-6 L/min), 4 weeks at home
16680078|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
16680079|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
16680080|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
16680081|NCT02083081|Experimental|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
16680082|NCT02083081|No Intervention|usual care|Usual care provided by health aides to pregnant women
16680083|NCT02083068|Experimental|Experimental|10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
16680084|NCT02083068|Placebo Comparator|Control|six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
16680085|NCT02083055|Experimental|dexmedetomidine|Intraoperative controlled hypotension by dexmedetomidine
16680086|NCT02083055|Active Comparator|nitroglycerin|Intraoperative controlled hypotension by nitroglycerin
16680087|NCT02083029|Experimental|Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
16680088|NCT02083029|Experimental|Non Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
16680089|NCT02083029|Experimental|Normal Volunteers|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
16680090|NCT02083016|Other|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
16680091|NCT02083016|Other|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
16680092|NCT02083003|Experimental|Polyamine low-diet|Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
16680093|NCT02083003|Active Comparator|Liberal alimentation|No specific alimentary diet
16680094|NCT02082990|Active Comparator|Face-to-Face Brief Intervention Group|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
16680095|NCT02082990|Experimental|Online Brief Intervention Group|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
16680096|NCT02082977|Experimental|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680097|NCT02082977|Experimental|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680098|NCT02082977|Experimental|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680099|NCT02082977|Experimental|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680100|NCT02082977|Experimental|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680101|NCT02082977|Experimental|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680102|NCT02082977|Experimental|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680103|NCT02082977|Experimental|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680104|NCT02082977|Experimental|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
16680105|NCT02082977|Experimental|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
16680106|NCT02082964|Experimental|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
16680107|NCT02082964|Experimental|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course.
16680108|NCT02082951|Experimental|Group 2: empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
16680109|NCT02082951|Experimental|Group 1: empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
16680110|NCT02082938|Experimental|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
16680111|NCT02082925|Experimental|COPD patient|
16680112|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
16680113|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
16680114|NCT02082899|Active Comparator|Active Comparator EBI-005 5 mg/mL|Administered 3 times per day
16680115|NCT02082899|Placebo Comparator|Placebo Comparator|Administered 3 times per day
16680116|NCT02082860|Experimental|Cohort A|rAAV2/5-PBGD vector dosage 1
16680117|NCT02082860|Experimental|Cohort B|rAAV2/5-PBGD vector dosage 2
16680118|NCT02082860|Experimental|Cohort C|rAAV2/5-PBGD vector dosage 3
16680119|NCT02082860|Experimental|Cohort D|rAAV2/5-PBGD vector dosage 4
16680120|NCT02082834|Experimental|EVAR|
16680121|NCT02082808|Experimental|Sequence 1|Participants will receive the study Treatment A for 5 days (DTG 50mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment B for 5 days (DCV 60mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
16680122|NCT02082808|Experimental|Sequence 2|Participants will receive the study Treatment B for 5 days (DCV 60mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment A for 5 days (DTG 50mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
16680123|NCT02082782|Experimental|irreversible electroporation (IRE)|Single arm study: percutaneous or open irreversible electropration of CRLM
16680124|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
16680125|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
16680126|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
16680127|NCT02082756|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
16680128|NCT02082756|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
16680129|NCT02082756|No Intervention|lifestyle counseling|
16680130|NCT02082743|Experimental|Outdoor activity|Outdoor activity in recess time
16680131|NCT02082743|No Intervention|Control|
16680132|NCT02082730|Active Comparator|Mid treatment Group|Patients who have completed 6 sessions at the Manchester CFS/ME Service for Children & Young People will be recruited. They would have had previous experience of using paper diaries.They will collect activity data using the ASARM system.
16680133|NCT02082730|Experimental|Start of Treatment Group|Newly presented patients, will collect activity data using the ASARM system.
16680134|NCT02082730|No Intervention|Audit group|"To provide comparative baseline data for general treatment response, we will audit pre-treatment and post-treatment clinical data on the regular gold standard clinical measures package, as these are the outcome measures routinely used in the clinic."
16680135|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
16680136|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
16680137|NCT02082704|Experimental|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
16680138|NCT02082704|Active Comparator|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
16680139|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg twice a day (BID). The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
16680140|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
16680141|NCT02082665|Experimental|Arm 1|On Day 1 subjects will simultaneously receive single dose of Rosuvastatin 10 mg tablet and Midazolam 3 mg syrup administered orally in the morning.
16680142|NCT02082652|Active Comparator|Control group (No ART)|Etonogestrel implant in participants not yet receiving ART (control group)
16680143|NCT02082652|Active Comparator|Nevirapine-based ART group|Etonogestrel implant in participants receiving nevirapine (NVP)-based ART
16680144|NCT02082652|Active Comparator|Efavirenz-based ART group|Etonogestrel implant in participants receiving efavirenz (EFV)-based ART
16680145|NCT02082639|Experimental|HPV Group|Subjects will receive two doses of HPV vaccine intramuscularly
16680146|NCT02082639|Experimental|HAV Group|Subjects will receive two doses of HAV vaccine intramuscularly
16680147|NCT02082639|Experimental|HPV+HAV Group|Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
16680148|NCT02082626|Experimental|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
16680149|NCT02082613|Experimental|Lord´s procedure|Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
16680150|NCT02082613|Active Comparator|Sclerotherapy|Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
16680151|NCT02082600|Experimental|Sleep deprivation|Exercise induced-muscle damage protocol followed by 60h of sleep deprivation (two nights) and one night of normal sleep (rebound).
16680152|NCT02082600|Experimental|Normal sleep|Exercise induced-muscle damage protocol followed by 3 nights of normal sleep
16680153|NCT02082587||QOL Assessment|
16680154|NCT02082574||patients|HIV infected for more than 5 years, aged over 50, treated with ARV
16680155|NCT02082574||control|non HIV (matched for age and gender)
16680156|NCT02082561|Experimental|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
16680157|NCT02082561|No Intervention|Waitlist|The waitlist control condition was comprised of patients randomly assigned to the waitlist condition (WL). Individuals in this condition were reassessed after five weeks and were then offered treatment, but were no longer followed.
16680158|NCT02082548|Experimental|Intervention|educational intervention arm
16680159|NCT02082548|No Intervention|control|Standard of care
16680160|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
16680161|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
16680162|NCT02082509||Traumatic Brain Injury (TBI)|Patient who have sustained a TBI over 1 month prior to enrollment, and endorse at least 1 post-concussive symptom at the time of enrollment.
16680163|NCT02082509||Healthy Controls (no TBI)|Subjects who match the TBI group's demographic characteristics, except that they have not sustained a TBI and they are otherwise physically and mentally healthy.
16680164|NCT02082496|Experimental|Control Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
16680165|NCT02082496|Experimental|Case Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
16680166|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
16680167|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
16680168|NCT02082470|Active Comparator|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
16680169|NCT02082470|Experimental|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
16680170|NCT02082457|Placebo Comparator|Placebo|Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.
16680171|NCT02082457|Experimental|YKP10811 10mg|Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.
16680172|NCT02082457|Experimental|YKP10811 20mg|One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.
16680173|NCT02082457|Experimental|YKP10811 40mg|Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.
16680178|NCT02082405|Experimental|Treatment (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC or IV over 3-5 seconds on days 1, 8, and 15; cyclophosphamide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
16680179|NCT02082392|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
16680180|NCT02082392|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
16680181|NCT02082392|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
16680182|NCT02082392|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
16680183|NCT02082379|Active Comparator|Term newborns 1-6 week old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
16680184|NCT02082379|Active Comparator|Infants 6-8 month old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
16680185|NCT02082366|Active Comparator|conventional irrigated ablation catheter|"TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter.
~Intervention: TCD monitoring of microembolic signal during procedure"
16680186|NCT02082366|Active Comparator|nMARQ circumferential irrigated catheter|"TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter.
~Intervention: TCD monitoring of microembolic signal during procedure"
16680187|NCT02082353||Retrospective CGD Cohort|Longitudinal analysis
16680188|NCT02082353||Prospective CGD Cohort|Longitudinal analysis
16680189|NCT02082353||HCT CGD Cohort|Cross-sectional analysis
16680190|NCT02082353||Conventional Non-Transplant CGD Cohort|Longitudinal analysis
16680191|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
16680192|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
16680193|NCT02082327|Experimental|0.3 mg/kg|IV infusion of migalastat HCl or placebo
16680194|NCT02082327|Experimental|1 mg/kg|IV infusion of migalastat HCl or placebo
16680195|NCT02082327|Experimental|10 mg/kg|IV infusion of migalastat HCl or placebo
16680196|NCT02082327|Experimental|150 mg IV|150 mg single IV infusion
16680197|NCT02082327|Experimental|150 mg oral|150 mg single oral dose
16680198|NCT02082301||Gestational diabetes|Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes
16680199|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
16680200|NCT02082275|Experimental|OB Nest|OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
16680201|NCT02082275|No Intervention|Traditional Prenatal care|Traditional prenatal visits in clinic with OB providers.
16680202|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
16680203|NCT02082249|Experimental|ABT-SLV187|up to 6 years
16680204|NCT02082236|Active Comparator|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
16680205|NCT02082236|Experimental|Treatment B|Single dose of SSM 30 mcg
16680206|NCT02082236|Experimental|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
16680207|NCT02082236|Experimental|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
16680208|NCT02082223|Experimental|Preoperative Rehabilitation|"Patient & caregiver input regarding 'single biggest concern right now' (modified BEACON buttons) will be elicited. Information gathered by the study team which includes a trained nursing coach and the patient/caregiver will together develop an individualized 'toolbox' of possible interventions to improve preoperative quality of life.
~Candidate interventions include, but not limited to: Participation in SMART program, caregiver participation in Caregivers study protocol MC1295 (IRB 13-002943), nutritional recommendations (deficiencies, immuno-nutrition), low impact resistance training/tai chi, referral to financial or counseling services, establishment of information sources & plans for concerns not frequently covered in clinical practice such as sleeplessness, spiritual assistance."
16680209|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
16680210|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
16680211|NCT02082197|Experimental|ABT-SLV176|ABT-SLV176 administered daily
16680212|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
16680213|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
16680214|NCT02082171|No Intervention|Control group|
16680216|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
16680217|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
16680218|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
16680219|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
16680220|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
16680221|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
16680222|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
16680223|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
16680224|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
16680225|NCT02082106||males/females|Participants should be capable of alpine skiing and cross country skiing.
16680226|NCT02082093|No Intervention|Traditional Care|
16680227|NCT02082093|Experimental|eNephro Application|"Telemedicine system which is a collaborative and expert system, consisting of:
~A dynamic shared medical record for the collection of administrative , medical, biological and clinical data for each patient. All health professionals can access the folder and fill in the support. It is the same for patients treated at home.
~A secure messaging for communication between health professionals and between patients and health professionals Expert systems analyzing data from each patient A management tool of therapeutic education
~These patients have a chronic renal failure moderate to end up being treated by ambulatory dialysis or kidney transplantation. The patients of each population will be randomly assigned in group 1 ie traditional care or in group 2 ie traditional care added by telemedicine system"
16680228|NCT02082080|Active Comparator|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
16680229|NCT02082080|No Intervention|Obese and overweight children|
16680230|NCT02082067|Experimental|Adductor canal|All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.
16680231|NCT02082067|Active Comparator|Femoral|All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.
16680232|NCT02082067|Placebo Comparator|Controls|No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.
16680233|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
16680234|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
16680235|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
16680236|NCT02082054|Active Comparator|PSE 120 mg, CM 8 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with M27 on scored side and plain on the other side"
16680237|NCT02082054|Experimental|Atropine 0.24 mg|Atropine 0.24 mg tablets dosed BID for 7.5 days
16680238|NCT02082041||Wounds on leg|
16680239|NCT02082028|Experimental|A (BGStar)|Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly.
16680240|NCT02082028|Active Comparator|B (traditional approach)|Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter.
16680241|NCT02082015|Experimental|true coil|Use the true coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
16680242|NCT02082015|Sham Comparator|sham coil|Use the sham coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: vertical to scalp
16680243|NCT02082002||MS-Group|MS-Group
16680244|NCT02082002||Healthy control|Healthy control
16680245|NCT02081989|Experimental|Denervation|Renal denervation
16680246|NCT02081989|No Intervention|No intervention|Control group - no intervention
16680247|NCT02081976|Active Comparator|Standard Care Group|Dental therapist providing standard periodontal treatment
16680248|NCT02081976|Experimental|Integrated Care Group|a combined treatment approach of Dental Therapist, Dental Hygienist, Cardiologist along with counselor
16680249|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
16680250|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
16680251|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
16680252|NCT02081937|Experimental|Anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.
16680253|NCT02081924|Active Comparator|Kisspeptin 0.1|Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
16680254|NCT02081924|Placebo Comparator|Saline|Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
16680255|NCT02081924|Active Comparator|Kisspeptin 0.3|Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
16680256|NCT02081924|Active Comparator|Kisspeptin 1.0|Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
16680257|NCT02081911|Experimental|High volume Adductor canal block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
16680258|NCT02081911|Experimental|Low volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
16680259|NCT02081911|Experimental|Femoral nerve block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
16680260|NCT02081898|No Intervention|control group|weight maintenance diet
16680261|NCT02081898|Experimental|low calorie diet (LCD) group|approximate 100 kcal/d calorie deficit
16680262|NCT02081885|Experimental|Tricalcium Phosphate / Chitosan|
16680263|NCT02081885|Active Comparator|Autologous Graft|
16680264|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
16680265|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
16680266|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
16680267|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
16680268|NCT02081833||Reminder group|the reminder group receives every 2 weeks a reminder to fill out the symptom diary (postcard or SMS)
16680269|NCT02081820||aneurysmal subarachnoid hemorrhage|observational, no intervention
16680270|NCT02081807||Dabigatran|
16680271|NCT02081807||Warfarin|
16680272|NCT02081794|Experimental|Arm I (Tailored education intervention)|Participants receive a tailored educational intervention on the risk of falls comprising one of four two-minute videos determined by which educational group the participant is placed in: high risk/high perception, high risk/low perception, low risk/high perception, or low risk/low perception. Participants also receive tailored printed educational information concerning hospital falls based on the participants' answers given on the Perceived Risk Survey and are tailored to the participants' perception of falls risk. Participants also complete an investigator-constructed satisfaction survey at 24 and 72 hours post-intervention.
16680273|NCT02081794|Active Comparator|Arm II (standard fall care)|Participants receive standard care by nurses comprising a falls risk assessment and verbal education and receive an educational instruction sheet on falls prevention.
16680274|NCT02081781||Probing, topical anesthesia|Nasolacrimal duct obstruction (NLDO) is a quite common condition among the infants. An imperforate membrane at the distal end of the nasolacrimal duct is the main cause of occlusion. Children with the signs of NLDO presenting with epiphora and/or mucous discharge were included in this study. Intervention with probing under topical anesthesia was performed on the same surgeon. And success rate was evaluated.
16680275|NCT02081768|Experimental|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
16680276|NCT02081755|Experimental|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
16680277|NCT02081755|Active Comparator|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
16680278|NCT02081729||high VZV ELISPOT results|high spot counts in ELISPOT
16680279|NCT02081729||low VZV ELISPOT results|low spot counts in ELISPOT
16680280|NCT02081716||high CMV ELISPOT results|high spot counts in ELISPOT
16680281|NCT02081716||low CMV ELISPOT results|low spot counts in ELISPOT
16680282|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
16680283|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
16680284|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
16680285|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
16680286|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
16680287|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
16680288|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
16680289|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
16680290|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
16680291|NCT02081664|Other|Lifestyle intervention|life-style oriented group program together with an individualized treatment program using therapies out of the spectrum of Complementary and Alternative Medicine (CAM)
16680292|NCT02081651|Experimental|Parmigiano Reggiano cheese|Children treated Parmigiano Reggiano cheese for 12 months
16680293|NCT02081651|No Intervention|Control subjects|Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
16680294|NCT02081638|Active Comparator|Elite Controller|Elite controllers not on ART
16680295|NCT02081638|Active Comparator|Treated Progressors|HIV infected on ART
16680296|NCT02081625|Experimental|NS-065/NCNP-01|
16680832|NCT02078206|No Intervention|Treatment as usual|
16680298|NCT02081612|Active Comparator|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
16680299|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
16680300|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
16680301|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
16680302|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
16680303|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
16680304|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
16680305|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
16680306|NCT02081560|Other|colistin pharmacokinetics|Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
16680307|NCT02081547||IPC status|presence of cancer cells.
16680308|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
16680309|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
16680310|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
16680311|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
16680312|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
16680313|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
16680314|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
16680315|NCT02081521|Experimental|Community behaviour change campaign|Participants will be exposed to the community behaviour change intervention.
16680316|NCT02081521|No Intervention|No community behaviour change campaign|No community intervention will take place in the control arm, although exposure to some intervention messaging (radio adverts) may take place.
16680317|NCT02081508|Experimental|Unfilled interference|Interference onset: delayed test at 540000 ms
16680318|NCT02081508|Experimental|Early interference|Interference onset: delayed test at 0 ms
16680319|NCT02081508|Experimental|Mid interference|Interference onset: delayed test at 360000 ms
16680320|NCT02081508|Experimental|Late interference|Interference onset: delayed test at 180000 ms
16680321|NCT02081495|Experimental|Sequence AB|Twenty-one participants will receive DOXIL/CAELYX reference product in Cycle 1 and DOXIL/CAELYX test product in Cycle 2. Each cycle will be separated by 28 days.
16680322|NCT02081495|Experimental|Sequence BA|Twenty-one participants will receive DOXIL/CAELYX test product in Cycle 1 and DOXIL/CAELYX reference product in Cycle 2. Each cycle will be separated by 28 days.
16680323|NCT02081482|Experimental|subjects with refractory chronic cluster headache|Adult subjects with refractory chronic cluster headache and ONS indication
16680324|NCT02081469|Other|Arm A:TDF for extend 24 weeks|Arm A:Continue TDF 300mg daily for extend 24 weeks after completion of chemotherapy
16680325|NCT02081469|Other|Arm B: TDF for extend 48 weeks|Arm B: Continue TDF 300mg daily for extend 48 weeks after completion of chemotherapy.
16680326|NCT02081456|Active Comparator|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
16680327|NCT02081456|Experimental|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
16680328|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
16680329|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
16680330|NCT02081430|Experimental|CT Manipulation|Prone cervicothoracic manipulation
16680331|NCT02081430|Active Comparator|Upper trapezius stretch|Passive sustained stretch to upper trapezius muscle
16680332|NCT02081430|No Intervention|Control|8 Minute wait
16680333|NCT02081417|Other|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
16680334|NCT02081417|Other|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
16680335|NCT02081404|Active Comparator|Esomeprazole|proton pump inhibitor
16680336|NCT02081404|Placebo Comparator|Placebo|placebo
16680373|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
16680374|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
16680337|NCT02081391|Experimental|Tapentadol immediate-release (IR)|"In the first 24 hours, tapentadol oral solution at a dose of 1.25 mg/kg body weight was given every 4 hours (±15 min) to participants aged 6 months to less than 18 years (maximum individual dose of tapentadol was 100 mg). Participants from 30 days to less than 6 months were dosed with 0.5 mg/kg body weight every 4 hours. Participants from birth to less than 30 days of age were dosed with 0.1 mg/kg body weight every 4 hours.
~After 24 hours and up to 72 hours, the dose could be reduced based on the investigator's judgment."
16680338|NCT02081391|Placebo Comparator|Placebo|Matching placebo oral solution was administered every 4 hours (±15 min) up to 72 hours.
16680344|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
16680345|NCT02081365|No Intervention|High Anxiety Wailist Control|
16680346|NCT02081352|Active Comparator|DermaPure™|DermaPure™ in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
16680347|NCT02081352|Sham Comparator|Standard care|Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
16680348|NCT02081339||Macular diseases|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
16680349|NCT02081326|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
16680350|NCT02081326|Placebo Comparator|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
16680351|NCT02081313|Active Comparator|Netherton syndrome|Patients with Netherton syndrome
16680352|NCT02081313|Active Comparator|Healthy controls|healthy controls
16680353|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
16680354|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
16680355|NCT02081287|Active Comparator|Lamotrigine|As adjunct to lithium therapy
16680356|NCT02081287|Experimental|IP6|As adjunct to lithium therapy
16680357|NCT02081274||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease between 2009 and 2013 in Samsung Medical Center
16680358|NCT02081261||Coronary artery bypass surgery|patients who underwent coronary artery bypass surgery between 2010 and 2012 in Samsung Medical Center
16680359|NCT02081248|Active Comparator|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
16680360|NCT02081248|Experimental|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
16680361|NCT02081235||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease during 2012 in Samsung Medical Center
16680362|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
16680363|NCT02081209|Experimental|Fat Reduction|
16680364|NCT02081196|Experimental|CoolSculpting of the Flank With Alternate Treatment Parameters|Each subject served as their own control with 1 flank treated with CoolSculpting; the contralateral flank was untreated.
16680365|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.
~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
16680366|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.
~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
16680367|NCT02081170|Experimental|autologous platelet concentrate|
16680368|NCT02081157||Breast Mastopexy with or without reduction using GalaFlex Mesh|Breast mastopexy with or without reduction, using GalaFLEX mesh
16680369|NCT02081144|No Intervention|Control Condition|Control or Standard Care condition. No intervention will be provided.
16680370|NCT02081144|Experimental|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
16680371|NCT02081131|Active Comparator|Laparoscopic Surgery|patients will be randomized to laparoscopic pancreatoduodenectomy group
16680372|NCT02081131|Active Comparator|Open Surgery|Patients will be randomized to Open pancreatoduodenectomy
16680375|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
16680376|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
16680377|NCT02081105|Other|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
16680378|NCT02081105|Other|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
16680379|NCT02081092||Pulmonary Alveolar Proteinosis (PAP)|Patients diagnosis with Pulmonary Alveolar Proteinosis.
16680380|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
16680381|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
16680382|NCT02081066|Other|patients with cardiovascular risk factors|
16680383|NCT02081053|Other|RF Ablation and Vertebral Augmentation|
16680384|NCT02081040||Infratentorial dysphagia patients|Infratentorial brain lesion patients with confirmed evidence of dysphagia
16680385|NCT02081040||Supratentorial dysphagia patients|Supratentorial brain lesions\ patients with confirmed evidence of dysphagia
16680386|NCT02081040||Brain lesion patients without dysphagia|Brain lesion patients with no evidence of dysphagia
16680387|NCT02081027|Experimental|Riluzole|The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
16680388|NCT02081027|Placebo Comparator|Placebo|Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
16680389|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
16680390|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
16680391|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
16680392|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
16680393|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
16680394|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
16680395|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
16680396|NCT02080975|Experimental|Data Collection During Atrial Flutter Ablation|
16680397|NCT02080962|Experimental|30 Gy in 5 fractions of 6 Gy|tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
16680398|NCT02080962|Experimental|40 Gy in 10 fractions of 4 Gy|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
16680399|NCT02080949|Experimental|HSRT - 4fx x 5 Gy|It'll be recruited 3 patients to the initial regimen of four fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered that the study was initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with the next dose level.
16680400|NCT02080923|Experimental|Brief Motivational Interview|Health-related counseling that takes place in as little as one hour or up to a few sessions.
16680401|NCT02080923|No Intervention|Standard Care|Participant will receive information about dating abuse in a handout and referrals to a national domestic violence hotline.
16680402|NCT02080910|Experimental|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
16680403|NCT02080910|No Intervention|Usual care|
16680404|NCT02080897||Palliative Surgery Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment
16680405|NCT02080897||Non-surgical Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery
16680406|NCT02080884||CLL patients on Mabthera (rituximab)|
16680407|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
16680408|NCT02080858|Experimental|Ticagrelor + Apixaban + ASA|180 mg Ticagrelor loading dose + apixaban 2.5 mg bid + 300 mg ASA loading dose (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg + 100 mg ASA od to reach steady state conditions within 4.5 days
16680409|NCT02080858|Active Comparator|Ticagrelor + Apixaban|180mg ticagrelor loading dose + apixaban 2.5 mg bid (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg to reach steady state conditions within 4.5 days
16680410|NCT02080845|Placebo Comparator|no caffeine & no theobromine|Drink 1
16680411|NCT02080845|Experimental|no caffeine & low theobromine|Drink 2
16680412|NCT02080845|Experimental|no caffeine & high theobromine|Drink 3
16680413|NCT02080845|Experimental|high caffeine & no theobromine|Drink 4
16680414|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
16680415|NCT02080832|Placebo Comparator|Placebo|
16680416|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
16680417|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
16680418|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
16680419|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
16680420|NCT02080806|Active Comparator|Mechanical insufflation exsufflation|Application of cough assist machine as part of the regular physiotherapy
16680421|NCT02080793|Other|Patients phase pilote|
16680422|NCT02080793|Other|Patients phase réelle|
16680477|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
16680423|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:
~- Single Dose, Diltiazem (Day 1)
~- Multiple Dose, Clarithromycin XL (Days 4-9)
~- Single Dose, Diltiazem (Day 8)"
16680424|NCT02080754|Placebo Comparator|sham arm|sham sellick maneuver
16680425|NCT02080754|Experimental|sellick arm|effective sellick maneuver
16680426|NCT02080741|Other|Type A behaviour profile|
16680427|NCT02080741|Other|Type B behaviour profile|
16680428|NCT02080728|Experimental|TAP-Bloc|
16680429|NCT02080728|Placebo Comparator|Control|
16680430|NCT02080715|Experimental|Tolcapone|Tasmar
16680431|NCT02080702||Monosyn|Construction of a gastrointestinal anastomoses
16680432|NCT02080689|Other|Salvage setting|The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)
16680433|NCT02080689|Other|Adjuvant setting|The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)
16680434|NCT02080663||Proximal row carpectomy|Proximal row carpectomy
16680435|NCT02080650|Other|Prostate cancer|Mesenchymal-marker based ferrofluid (c-MET)
16680436|NCT02080650|Other|Renal cell carcinoma|Mesenchymal-marker based ferrofluid (c-MET)
16680437|NCT02080650|Other|Bladder cancer|Mesenchymal-marker based ferrofluid (c-MET)
16680438|NCT02080650|Other|Gastric cancer|Mesenchymal-marker based ferrofluid (c-MET)
16680439|NCT02080650|Other|Colorectal cancer|Mesenchymal-marker based ferrofluid (c-MET)
16680440|NCT02080650|Other|Pancreatic cancer|Mesenchymal-marker based ferrofluid (c-MET)
16680441|NCT02080650|Other|Non-small cell lung cancer|Mesenchymal-marker based ferrofluid (c-MET)
16680442|NCT02080650|Other|Advanced MET amplified solid tumor|Mesenchymal-marker based ferrofluid (c-MET)
16680443|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
16680444|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
16680445|NCT02080624|Experimental|Rapamycin|Topical rapamycin applied once a day
16680446|NCT02080598|No Intervention|Controle|The volunteer do not smoke any cigarette during the study period
16680447|NCT02080598|Experimental|smoking|the volunteer smokes 2 cigarettes in 15 minutes
16680448|NCT02080585|No Intervention|Control group without advice|Control group receives no intervention or physical activity advice.
16680449|NCT02080585|Experimental|Computer-tailored physical activity advice|Subjects receive computer-tailored physical activity advice.
16680450|NCT02080572||Parkinson's Disease with DBS|Individuals with Parkinson's disease and deep brain stimulation will be recruited.
16680451|NCT02080559|Experimental|4CMenB - Test group|Administered at 2, 4 and 12 months of age
16680452|NCT02080559|Active Comparator|4CMenB - control group|Given at 5, 7 and 13 months of age
16680453|NCT02080546|Active Comparator|Cut/Coag|
16680454|NCT02080546|Experimental|V-mode|
16680455|NCT02080533|Experimental|Single|Slow-paced respiration therapy
16680456|NCT02080520|Active Comparator|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
16680457|NCT02080520|Placebo Comparator|Placebo|Oral placebo matched nattokinase daily
16680458|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
16680459|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
16680460|NCT02080494|No Intervention|Control|No tranexamic acid given
16680461|NCT02080494|Experimental|Tranexamic Acid|15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose
16680462|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
16680463|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
16680464|NCT02080468|Experimental|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide & EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
16680465|NCT02080468|Experimental|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide & EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
16680466|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)
~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
16680467|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)
~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
16680468|NCT02080442||Chronic Obstructive Pulmonary Disease|
16680469|NCT02080429|Active Comparator|Immediate Pushing|Patient's will begin to push when they are determined to be completely dilated.
16680470|NCT02080429|Experimental|Passive Descent|Patient's will wait 90 minutes prior to begin pushing
16680471|NCT02080416|Experimental|Nelfinavir|Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles
16680472|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
16680473|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
16680474|NCT02080390||Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
16680475|NCT02080377|Active Comparator|Current Standard Care|Insulin + Metformin
16680476|NCT02080377|Active Comparator|Treatment|Glibenclamide + Metformin
16680479|NCT02080351|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
16680480|NCT02080351|No Intervention|Usual care|Usual care in the emergency department
16680481|NCT02080338|Experimental|0.018 bracket slot system|Participants treated using 0.018-inch orthodontic bracket slot system
16680482|NCT02080338|Active Comparator|0.022 bracket slot system|Participants treated using 0.022-inch orthodontic bracket slot system
16680483|NCT02080325|Other|High Protein-Weight loss-Meat/High Protein-Weight loss Soy|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Meat with High Protein-Weight loss-Soy
16680484|NCT02080325|Other|High Protein-Weight loss-Soya/High Protein Weight loss-meat|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Soy with High Protein-Weight loss-Meat
16680485|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
16680486|NCT02080299|Active Comparator|Remote ischemic preconditioning (RIPC)|RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.
16680487|NCT02080299|Placebo Comparator|Placebo|Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.
16680488|NCT02080286|Active Comparator|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.
~They will undergo 5 consecutive daily sessions."
16680489|NCT02080286|Placebo Comparator|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.
~They will undergo 5 consecutive daily sessions."
16680490|NCT02080286|Placebo Comparator|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.
~They will undergo 5 consecutive daily sessions."
16680491|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
16680492|NCT02080273|Active Comparator|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
16680493|NCT02080273|Active Comparator|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
16680494|NCT02080260|Experimental|Single Arm|Oral Regorafenib
16680495|NCT02080247|Active Comparator|Intervention: Skin care regimen with Calmoseptine ointment|In this arm the patients with IAD will receive treatment with Calmoseptine Ointment for 6 days as a part of a structured skin regimen
16680496|NCT02080247|Active Comparator|Control: Skin care regimen with Destin ointment|In this arm , patient will receive treatment with Destin Maximum Strength 40% Zinc Oxide. Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
16680497|NCT02080234|Experimental|concurrent chemoradiotherapy with GELOX|"GELOX:
~gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
~IFRT
~IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
~the first cycle of chemotherapy was initiated on the same day of radiotherapy."
16680498|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
16680499|NCT02080208|Experimental|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
16680500|NCT02080208|No Intervention|Conventionnal|patients receiving oxygen via conventional way (low flow)
16680501|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
16680502|NCT02080182|Active Comparator|Acetylcysteine|Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
16680503|NCT02080182|Placebo Comparator|Placebo|Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
16680504|NCT02080169|Experimental|midazolam|Initiative dosage of midazolam is 0.05 mg/kg given intravenously, the maintenance dosage is 0.01-0.05 mg/kg/h, drug dosage is adjusted by target sedation level.
16680505|NCT02080169|Experimental|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min, the maintenance dosage is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level.
16680506|NCT02080169|Experimental|midazolam & dexmedetomidine|"Initiative dosage of midazolam is 0.05 mg/kg given intravenously, The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min(given or not according to patients' condition),.
~The maintenance dosage of midazolam is 0.01-0.05 mg/kg/h, the maintenance dosage of dexmedetomidine is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level."
16680507|NCT02080156|No Intervention|no-CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
16680508|NCT02080156|Experimental|CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
16680509|NCT02080143|Experimental|Air Activated Heat Patch|The experimental air activated heat patch will be worn by the subjects for 8 hours.
16680510|NCT02080143|Active Comparator|Marketed ThermaCare Air Activated Heat Patch|The marketed air activated heat patch will be worn by the subjects for 8 hours.
16680511|NCT02080130|Experimental|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
16680512|NCT02080130|Experimental|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
16680513|NCT02080130|Placebo Comparator|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
16680514|NCT02080117||patients who underwent kidney transplantation|patients who underwent living or deceased donor kidney transplantation between 2008 and 2013
16680515|NCT02080104|Active Comparator|intravenous 10 ıu oxytocin|group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery
16680516|NCT02080104|Experimental|intramusculer 10 ıu oxytocin|group which oxytocin administered intramusculary after vaginal delivery
16680517|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
16680518|NCT02080078|Experimental|Increasing dose of Theophylline|Patients will be put on the standard dose of 150 mg/day of erlotinib. Patients will be entered into the study on different dose levels of theophylline (100 mg/bid, 150 mg/bid, 200 mg/bid, or 200 mg/tid) for 28 days to find what is the lowest dose that effectively controls the diarrhea caused by erlotinib.
16680519|NCT02080078|Experimental|Increasing dose of erlotinib|Patients will be kept on a specified dose of theophylline while the dose of erlotinib increases in each group of patients enrolled (200 mg/qd, 225 mg/qd, or 250 mg/qd) for 28 days to determine what the maximum dose of erlotinib that can be given with theophylline and maintain a safety profile.
16680520|NCT02080065||liver transplantation|patients who underwent living donor liver transplantation during between 2007 and 2013
16680521|NCT02080052|Experimental|Robot-assisted prostate biopsy|
16680522|NCT02080039|Experimental|Electrical Stimulation|
16680523|NCT02080026|Experimental|CPS-immunization|"In this group a total of four CPS-immunizations will be performed, with bites from 15 Plasmodium infected mosquitoes per immunization, over a period of four months, during which volunteers will take chloroquine prophylaxis.
~14 weeks after the last immunization, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.
~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
16680524|NCT02080026|Other|Control|"This group will take chloroquine prophylaxis during the same period as the immunization group, but will not receive CPS-immunizations.
~10 weeks after stopping chloroquine prophylaxis, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.
~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
16680525|NCT02080013|Sham Comparator|ClosureFast group|Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux
16680526|NCT02080013|Sham Comparator|group 1|EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux
16680527|NCT02080000|Experimental|Optimised V-V timing delay|V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
16680528|NCT02080000|Active Comparator|Standard V-V timing delay|Standard settings
16680529|NCT02079987|Experimental|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
16680530|NCT02079987|Experimental|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
16680531|NCT02079974|Experimental|Pravastatin|Pravastatin sodium 20mg PO daily
16680532|NCT02079961|Experimental|Micronutrient-fortified yoghurt|"Micronutrient-fortified yoghurt + BCC
~All eligible children within the intervention arm will receive one fortified yoghurt per day, every day of the week, if the household satisfied to the contract of reliability in milk supply during the previous week, during the one year duration of the intervention."
16680533|NCT02079961|Active Comparator|Control|"BCC
~Children will not receive fortified yoghurt during the duration of the intervention"
16680534|NCT02079948|Active Comparator|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
16680535|NCT02079948|Placebo Comparator|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
16680536|NCT02079948|Experimental|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
16680537|NCT02079948|Experimental|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
16680538|NCT02079935|Experimental|Cognitive Behaviour Therapy|Treatment with small groups following a modified protocol first described by Fairburn 2008
16680539|NCT02079935|Experimental|Physical activity and dietary therapy|Treatment with guided physical activity and dietary therapy in small groups
16680540|NCT02079922|Experimental|Cohort 1|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16680541|NCT02079922|Experimental|Cohort 2|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16680542|NCT02079922|Experimental|Cohort 3|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16680543|NCT02079922|Experimental|Cohort 4|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16680544|NCT02079922|Experimental|Cohort 5|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16680545|NCT02079922|Experimental|Cohort 6|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
16680546|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
16680547|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
16680548|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
16680549|NCT02079896|Experimental|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
16680550|NCT02079896|Placebo Comparator|Control|Twice weekly doses of placebo, 9 total
16680551|NCT02079896|Experimental|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
16680552|NCT02079883||ocriplasmin|
16680553|NCT02079870|Experimental|Sema|Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
16680554|NCT02079870|Placebo Comparator|Placebo|
16680555|NCT02079857|Experimental|Standard|Fixed protocol
16680556|NCT02079857|Experimental|Individualized|Individualized protocol
16680557|NCT02079857|Sham Comparator|Control|Sham acupuncture/Placebo moxa
16680558|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
16680559|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
16680560|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
16680561|NCT02079831|Experimental|Higher protein and energy restriction|Participants in this arm will consume 30% of energy as protein with 25% energy restriction.
16680562|NCT02079831|Experimental|Lower protein and energy restriction|Participants in this arm will consume 15% of energy as protein with 25% energy restriction.
16680563|NCT02079818|Experimental|Penumbra Ruby Coil System|
16680564|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
16680565|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
16680566|NCT02079792|Active Comparator|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
16680567|NCT02079792|Experimental|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
16680568|NCT02079779|Experimental|Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of robotic-assisted therapy.
16680569|NCT02079779|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of classical rehabilitation.
16680570|NCT02079766|Experimental|High Risk of CTE|Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)
16680571|NCT02079766|Experimental|Control|Flortaucipir PET scans in former non-contact athletes
16680572|NCT02079753|Active Comparator|combined system|During the first visit, the technician installed a reservoir of liquid oxygen (Liberator 30, Caire) and a liquid Stroller oxygen pack (Caire) for patients using liquid oxygen, or a VisionAire5 (Airsep) stationary concentrator and an Inogen One G2 portable (Inogen) concentrator for patients using concentrators.
16680573|NCT02079753|Experimental|single system|Inogen One G2 portable concentrator (Inogen)
16680574|NCT02079740|Experimental|Treatment (trametinib, navitoclax)|Patients receive trametinib PO QD and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If unacceptable toxicity is observed, patients may receive trametinib PO QD on days 1-14.
16680575|NCT02079727|Experimental|Condrosulf (Chondroitin 4&6 sulfate)|1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days
16680576|NCT02079727|Placebo Comparator|Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule|1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days
16680577|NCT02079727|Active Comparator|Celebrex 200 mg capsule|1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days
16680578|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
16680579|NCT02079701|Experimental|23-valent pneumococcal vaccine|single dose, 23-valent pneumococcal vaccine, 0.5ml, intramuscular (IM)
16680580|NCT02079701|Placebo Comparator|placebo|0.5 ml injectible saline, IM
16680581|NCT02079688|Experimental|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.
~Comparison and random assignment of treatments to two distinct treatment areas (area 1, area 2).
~IMP SB011: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments) daily dosage: Approximately 10 mg hgd40 total dosage: Approximately 145 mg hgd40"
16680582|NCT02079688|Placebo Comparator|Multiple W/O/W formulation, active ingredient-free vehicle|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.
~Comparison and random assignment of treatments to two distinct treatment areas (Area 1, Area 2).
~Vehicle: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments)"
16680583|NCT02079675|Experimental|SKI3246 Low Dose|Intervention: Drug: SKI3246 Low Dose
16680584|NCT02079675|Experimental|SKI3246 High Dose|Intervention: Drug: SKI3246 High Dose
16680585|NCT02079675|Placebo Comparator|Placebo|Intervention: Drug: Placebo
16680586|NCT02079662|Experimental|Arm I (IO interventions)|Patients undergo up to 7 different IO intervention sessions per week during their 6-week course of radiotherapy for between 1 and 3 hours each session, in addition to, up to 6 aerobic training sessions per week and one grocery store trip during the course of the program. IO intervention programs consist of nutritional coaching, behavioral therapy, yoga and meditation practice, resistance training, and a weekly meal sharing and cooking class. Patients then have weekly meetings with the study psychologist on the computer for 6 months, followed by a monthly meeting on the computer from 6-12 months, and 2 hour meetings at all follow-up appointments during the first year after radiotherapy.
16680587|NCT02079662|Active Comparator|Arm II (standard of care)|Patients undergo standard of care.
16680588|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
16680589|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
16680590|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
16680591|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
16680592|NCT02079636|Experimental|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16680593|NCT02079636|Experimental|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16680594|NCT02079636|Experimental|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16680595|NCT02079636|Experimental|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16680596|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
16680597|NCT02079623||Pancreatic cancer|Patients with locally advanced pancreatic cancer.
16680598|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
16680599|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
16680600|NCT02079597||Healthy|Healthy individuals no infection
16680601|NCT02079597||SIRS|SIRS patients no included in an interventional study no peroperative infection
16680602|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
16680603|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
16680604|NCT02079571|Experimental|water+ Coconut water|forty subjects
16680607|NCT02079558|Experimental|Carbetocin|A standard 30 international units (IU) IV infusion of oxytocin during two hours
16680608|NCT02079545|Experimental|Group 1|18 participants will receive a single intravenous (IV) infusion of 100 mg sirukumab
16680609|NCT02079545|Experimental|Group 2|18 participants will receive a single subcutaneous (SC) injection of 50 mg sirukumab using a Pre-filled Syringe (PFS) fitted with the UltraSafe Passive™ Delivery System (PFS-U)
16680610|NCT02079545|Experimental|Group 3|18 participants will receive a single SC injection of 50 mg sirukumab using the SmartJect™ Autoinjector (PFS-AI)
16680611|NCT02079545|Experimental|Group 4|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-U
16680612|NCT02079545|Experimental|Group 5|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-AI
16680613|NCT02079532|Experimental|MabThera (Rituximab)|
16680614|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
16680615|NCT02079506|Experimental|Treatment A|
16680616|NCT02079506|Experimental|Treatment B|
16680617|NCT02079493||Total Knee Arthroplasty patients|TKA patients
16680618|NCT02079480|Experimental|Panel 1: BMS-986090 (0.5 mg) or Placebo|"BMS-986090 0.5 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
16680619|NCT02079480|Experimental|Panel 2: BMS-986090 (3 mg) or Placebo|"BMS-986090 3 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
16680620|NCT02079480|Experimental|Panel 3: BMS-986090 (10 mg) or Placebo|"BMS-986090 10 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
16680621|NCT02079480|Experimental|Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)|"BMS-986090 30 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
~And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once"
16680622|NCT02079480|Experimental|Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)|"BMS-986090 100 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
~And KLH 1 mg solution single intramuscular dose once"
16680623|NCT02079480|Experimental|Panel 6: BMS-986090 (100 mg) or Placebo|"BMS-986090 100 mg solution single dose intravenously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
16680624|NCT02079480|Experimental|Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)|"BMS-986090 300 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
~And KLH 1 mg solution single intramuscular dose once"
16680625|NCT02079480|Experimental|Panel 8: BMS-986090 (750 mg) or Placebo|"BMS-986090 750 mg solution single dose intravenously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
16680626|NCT02079480|Experimental|Panel 9: BMS-986090 (150 mg) or Placebo|"BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks
~OR
~Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks"
16680627|NCT02079467|Active Comparator|Standard rehabilitation|"Patients randomized to the control group will be managed with hip precautions immediately following surgery. They will weight bear on the operative joint as tolerated after surgery. They will be managed as per usual protocol post total hip arthroplasty. They will be transferred from the operative table with an abduction pillow between their legs and will be asked to keep this pillow between their legs while resting in bed and during sleep throughout their course in hospital. During physiotherapy treatments they will not flex the operative hip beyond 90 degrees, internally or externally rotate the operative hip more than 45 degrees, or actively adduct the operative hip past neutral."
16680628|NCT02079467|Experimental|Unrestricted rehabilitation|Patients randomized to the treatment group will have no restrictions in their post-operative rehabilitation. They will weight bear on the operative joint as tolerated after surgery. They will be asked to participate in activity as their level of comfort permits and will have no positional restrictions while in bed or completing activities of daily living.
16680629|NCT02079441||Infants, IBD mothers, anti TNF, pregnancy|Infants born to mother with IBD receiving ant- TNF medications during pregnancy
16680630|NCT02079441||infants, IBD mothers, pregnancy, medications|Infants born to mothers with IBD receiving non anti TNF medications during pregnancy
16680631|NCT02079428||Systolic heart failure, Diastolic heart failure|
16680632|NCT02079402|Active Comparator|Liberal (target-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.
~Fluid boluses may be given as long as hemodynamic variables improve (dynamic or static variable(s) of choice). A fluid bolus is to be followed by evaluation of effect 30 minutes after the intervention at the latest.
~'Variable(s) of choice' refers to the variable(s) used to assess hemodynamic improvement.
~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
16680633|NCT02079402|Experimental|Conservative (trigger-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.
~A fluid bolus of 250-500 ml may be given followed by evaluation of effect 30 minutes after the intervention at the latest if one of the following occurs:
~Plasma lactate concentration ≥ 4 mmol/l at point-of-care testing.
~Severe hypotension (MAP < 50mmHg).
~Mottling beyond edge of kneecap.
~Severe oliguria (only in the first 2 hours after randomisation). Severe oliguria defined as urine output ≤ 0.1 ml/kg/hour IBW last hour.
~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
16680634|NCT02079389|Active Comparator|Lap+Lus|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.
~In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a LUS examination of the primary tumor, liver and retroperitoneum.
~All the included patients are getting a CT scan of the abdomen after 3 months."
16680635|NCT02079389|No Intervention|laparoscopic examination (Lap)|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.
~In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection.
~All the included patients are getting a CT scan of the abdomen after 3 months."
16680636|NCT02079376|Experimental|Low blood TG patients|subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
16680637|NCT02079376|Experimental|High blood TG patients treated with blood TG lowering therapy|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
16680638|NCT02079376|Placebo Comparator|High blood TG patients|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
16680639|NCT02079363||Patients with pancreatic adenocarcinoma|"Exclusion criteria:
~No prior cancer. No anticoagulant treatment."
16680640|NCT02079363||Patients with chronic pancreatitis|"Exclusion criteria:
~No prior cancer. No anticoagulant treatment."
16680641|NCT02079363||Patients with acute pancreatitis|"Exclusion criteria:
~No prior cancer."
16680642|NCT02079363||Patients screened for but not having upper GI cancer|"Exclusion criteria:
~No prior cancer."
16680643|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
16680644|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
16680645|NCT02079337|Active Comparator|Deep NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during deep neuromuscular blockade and without neuromuscular blockade
16680646|NCT02079337|Placebo Comparator|No NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during no neuromuscular blockade and during deep neuromuscular blockade.
16680647|NCT02079324|Experimental|GX-051|GX-051 intratumoral injection
16680648|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
16680649|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
16680650|NCT02079298|Active Comparator|1|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole.
16680651|NCT02079298|Active Comparator|2|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen.
16680652|NCT02079298|Active Comparator|3|Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen.
16680653|NCT02079298|Placebo Comparator|4|Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen.
16680654|NCT02079285||EUS-FNA|Any patients who will undergo EUS-FNA for pancreas lesion during the study period
16680655|NCT02079272|Other|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.
~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
16680656|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
16680657|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
16680658|NCT02079233|Experimental|CLP 15 g QD|Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
16680659|NCT02079233|Experimental|CLP 7.5 g BID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner
16680660|NCT02079233|Experimental|CLP 5 g TID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner
16680661|NCT02079233|Experimental|CLP 3.75 g QID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
16680662|NCT02079220|Experimental|Arm A|"Arm A (every 2 week schedule) Dosage and dosage regimen for all study periods
~Capecitabine: will be administered 1,000 mg/m2 orally twice a day on Days 1 - 7 of each cycle, repeating every 14 days.
~Oxaliplatin: will be administered 85 mg/m2 IV on Day 1 of each cycle, repeating every 14 days.
~Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days."
16680663|NCT02079220|Experimental|Arm B|"Arm B (every 3 week schedule):
~Dosage and dosage regimen for all study periods
~Capecitabine: will be administered 850 mg/m2 orally twice a day on Days 1 - 14 of each cycle, repeating every 21 days.
~Oxaliplatin: will be administered 130 mg/m2 IV on Day 1 of each cycle, repeating every 21 days.
~Ziv-aflibercept: will be administered 6 mg/kg IV on Day 1 of each cycle, repeating every 21 days."
16680664|NCT02079207|Experimental|NBP606|Participants aged over 50 years are given a 0.5mL dose of 13-valent peumococcal conjugate vaccine administered on day 0.
16680665|NCT02079207|Active Comparator|Prodiax-23|Participants aged over 50 years are given a 0.5mL dose of 23-valent pneumococcal polysaccharide vaccine administered on day 0.
16680666|NCT02079194|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
16680667|NCT02079194|Experimental|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
16680668|NCT02079181|Experimental|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
16680669|NCT02079168|Experimental|Cohort 1|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.
16680670|NCT02079168|Experimental|Cohort 2|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
16680673|NCT02079142|Experimental|High Intensity Strategy: Train-the-trainer|One therapist from each counseling center randomized to this arm will be selected to become the trainer and will be trained to train their colleagues.
16680674|NCT02079142|Active Comparator|Low Intensity Strategy: Expert Consultation|The IPT expert from Washington University will travel to all counseling centers randomized to this condition and train all participating therapists on site and be available for monthly phone consultation for up to one year following training on site.
16680675|NCT02079116|Experimental|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.
~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
16680676|NCT02079116|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).
~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
16680677|NCT02079103|Experimental|Virtual reality|Virtual reality training using the YouGrabber® for patients with impaired arm motor function after stroke. The YouGrabber exercises focus on intensity, repetitions and motivating tasks and are adapted to the patient's motor abilities.
16680678|NCT02079103|Active Comparator|Conventional arm training|The patients receive supervised self-training exercises with focus on functional tasks adapted to their motor abilities.
16680679|NCT02079090|Active Comparator|Ketofol|Patient will receive 0.5 mg/kg Ketamine, and 2 minutes later receive 1 mg/kg Propofol.
16680680|NCT02079090|Experimental|Fentofol|Patient will receive 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol.
16680681|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
16680682|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
16680683|NCT02079064|Experimental|Desflurane|Desflurane at 1 MAC and
16680684|NCT02079064|Experimental|propofol|propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
16680685|NCT02079051|Experimental|High Intensity Weight Loss|High intensity medical weight loss
16680686|NCT02079051|Active Comparator|Moderate Intensity Weight Loss|Moderate intensity weight loss
16680687|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
16680688|NCT02079038|Active Comparator|Comparator Procedure|Comparator Surgical Procedure
16680689|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
16680690|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
16680691|NCT02079012|Experimental|Intervention group|"Receives:
~An information session
~A 10-week walking program (with documents, pedometer and three information sessions about motivation, a healthy diet and smoking cessation)
~A physical activity diary (which also functions as a tool to check protocol-compliance)
~Measurements"
16680692|NCT02079012|No Intervention|Control group|Only receives measurements.
16680693|NCT02078999||Control Grup|"Daily clinical data collection
~Quantitative tracheal aspirates (QTA) every 3 days
~Deep freeze serum samples for posterior analysis every day (two aliquots).
~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
16680694|NCT02078999||Patients with pulmonary infection|"Daily clinical data collection
~Quantitative tracheal aspirates (QTA) every 3 days
~Deep freeze serum samples for posterior analysis every day (two aliquots).
~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
16680695|NCT02078999||Patients with extrapulmonary infection|"Daily clinical data collection
~Quantitative tracheal aspirates (QTA) every 3 days
~Deep freeze serum samples for posterior analysis every day (two aliquots).
~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
16680696|NCT02078986|Experimental|Whole Body Electromyostimulation|
16680697|NCT02078986|Experimental|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks
16680698|NCT02078973|Active Comparator|15 mg tolvaptan|Oral administration of 15 mg tolvaptan on each examination day.
16680699|NCT02078973|Active Comparator|30 mg tolvaptan|Oral administration of 30 mg tolvaptan on each examination day.
16680700|NCT02078973|Active Comparator|45 mg tolvaptan|Oral administration of 45 mg tolvaptan on each examination day.
16680701|NCT02078973|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet
16680702|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
16680703|NCT02078947|Experimental|High Intensity Exercise|Patients perform interval- type endurance exercise at high intensity
16680704|NCT02078947|Active Comparator|Moderate Continuous Exercise|Patients perform endurance exercise at moderate intensity
16680705|NCT02078947|Sham Comparator|Usual Care|Patients receive advice on being physically active as well as usual care
16680706|NCT02078934|Experimental|Weight Loss|Patients with complex incisional/ventral hernias who are too obese to undergo hernia repair.
16680707|NCT02078921|Experimental|Treatment|Inorganic Nitrate
16680708|NCT02078921|Placebo Comparator|placebo|Placebo
16680709|NCT02078908|Active Comparator|40 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
16680710|NCT02078908|Active Comparator|120 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
16680711|NCT02078908|Active Comparator|240 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
16680712|NCT02078908|Placebo Comparator|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
16680713|NCT02078895|Experimental|Botox|The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
16680714|NCT02078895|No Intervention|Control|The control group will involve a ureteral stent placement with no injection.
16680715|NCT02078882|Experimental|Abatacept 125 mg weekly|Open label treatment with Abatacept
16680716|NCT02078869|Active Comparator|intramuscular Progesterone in oil|50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer
16680717|NCT02078869|Active Comparator|vaginal progesterone suppositories|200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer
16680718|NCT02078856|Experimental|A3384 Low dose|Administered twice daily for the duration of the study
16680719|NCT02078856|Experimental|A3384 High dose|Administered twice daily for the duration of the study
16680720|NCT02078856|Placebo Comparator|Placebo|Administered twice daily for the duration of the study
16680721|NCT02078843|Other|All patients|Subsequent performance of index test and standard test
16680722|NCT02078830|Placebo Comparator|3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
16680723|NCT02078830|Experimental|3M™ Tegaderm™ CHG Securement Dressing|- CHG activity at EVD entry site
16680724|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
16680725|NCT02078804|Experimental|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
16680726|NCT02078804|Experimental|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
16680727|NCT02078804|No Intervention|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
16680728|NCT02078791|Experimental|Botox infiltration|Botox infiltration in cervical region
16680729|NCT02078791|Experimental|Psychology therapy|Problem solving group therapy
16680730|NCT02078791|Experimental|Botox infiltration & psychology therapy|Botox infiltration in cervical region and problem solving group therapy.
16680731|NCT02078778|Experimental|Treatment|Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.
16680732|NCT02078765||hypertension|75 patients with hypertension and chronic kidney disease (CKD stage I-II)
16680733|NCT02078765||healthy subjects|75 healthy subjects
16680734|NCT02078752|Experimental|Part 1|
16680735|NCT02078739|Experimental|Yoga Program|Yoga Program twice per week for 8 weeks
16680736|NCT02078739|Active Comparator|Education|Education once per week for 8 weeks
16680737|NCT02078726|Active Comparator|Glucagon|1 mg glucagon given during colonoscopy
16680738|NCT02078726|Placebo Comparator|Placebo|1 mL normal saline
16680739|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
16680740|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
16680741|NCT02078700|Experimental|early palliative care programme|Patients will be proposed to be followed by the Palliative Care Team
16680742|NCT02078687|Active Comparator|Group 1, HM|This group received breastfeeding (human milk, HM) solely throughout the 4 month of intervention. Randomisation for group 1 or group 2. Mothers own milk.
16680743|NCT02078687|Active Comparator|Group 2, HMF|This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
16680744|NCT02078687|Active Comparator|Group 3, PF|This group received preterm formula (PF) throughout the intervention period of 4 month. This group was not randomised for ethical reasons. Enfalac Premature Formula, Mead Johnson Nutritionals
16680745|NCT02078674|Experimental|Group A|Placebo
16680746|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
16680747|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
16680748|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
16680749|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
16680750|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
16680751|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
16680752|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
16680753|NCT02078661|Active Comparator|PG101 0.25%|Topical application of drug
16680754|NCT02078661|Active Comparator|PG101 1.0%|Topical application of drug
16680755|NCT02078661|Placebo Comparator|Placebo|Topical application of placebo
16680756|NCT02078648|Experimental|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC
16680833|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
16680834|NCT02078180|Active Comparator|generic bupropion IR75|One oral dose of generic bupropion IR75
16680835|NCT02078180|Active Comparator|generic bupropion IR100|One oral dose of generic bupropion IR100
16680757|NCT02078635|Experimental|Portfolio Plus Diet|Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)
16680758|NCT02078635|Active Comparator|DASH-like (high fibre) diet|The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)
16680759|NCT02078622||COPD, Education and Case Management|Respiratory Therapist Education and Case Management
16680760|NCT02078609|Experimental|LGH447 monotherapy arm|LGH447 monotherapy in patients with AML or MDS
16680761|NCT02078609|Experimental|LGH447 + midostaurin combination arm|LGH447 + midostaurin in patients with AML
16680762|NCT02078596|Experimental|Divalproex|Divalproex at 10 mgs/lb
16680763|NCT02078596|Placebo Comparator|Sugar Pill|Equivalent 250 mg pills titrated to 10 mgs / lb over six weeks
16680764|NCT02078583|Experimental|Remifentanil，midazolam|Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
16680765|NCT02078583|Experimental|Fentanyl，midazolam|Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
16680766|NCT02078583|Placebo Comparator|Normal saline|Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
16680767|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
16680768|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
16680769|NCT02078544||Gynaecological cancer|
16680770|NCT02078531||Chemotherapy and anti-hormonal therapy|"cognitive assessment using CANTAB
~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
16680771|NCT02078531||chemotherapy only and healthy control group|"cognitive assessment using CANTAB
~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
16680772|NCT02078518||Multiple Myeloma|Questionnaires will be given to patients for completion.
16680773|NCT02078505|Experimental|PCOS after diet|Patients after 2 months of diet
16680774|NCT02078505|No Intervention|control|Ovulatory women
16680775|NCT02078492|Experimental|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
16680776|NCT02078492|Experimental|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
16680777|NCT02078492|Experimental|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
16680778|NCT02078479|Active Comparator|Real rTMS|The active group received Real rTMS over the hand area of motor cortex (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold) every day for ten consecutive days (5 days/week).
16680779|NCT02078479|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce the same of subjective sensation of rTMS
16680780|NCT02078466|No Intervention|Control group|Usual care
16680781|NCT02078466|Experimental|Assessment of functional ability|Assessment of functional ability and follow-up at home
16680782|NCT02078453|Active Comparator|Visual inspection|Dental treatment performed according to the caries diagnosis obtained with visual inspection performed alone
16680783|NCT02078453|Experimental|Radiographic examination|Dental treatment performed according to the caries diagnosis obtained with visual inspection and additional radiographic method.
16680784|NCT02078440|Other|Bromocriptine mesylate (Cycloset)|Bromocriptine mesylate (Cycloset)
16680785|NCT02078427||rAHF-PFM|Participants treated with rAHF-PFM alone
16680786|NCT02078427||rAHF-PEG|Participants treated with rAHF-PEG alone
16680787|NCT02078427||rAHF-PFM then rAHF-PEG|Participants treated with rAHF-PFM and subsequently switched to rAHF-PEG
16680788|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
16680789|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
16680790|NCT02078401||Neurofibromatosis type 1 children|
16680791|NCT02078388||Breast cancer,Doxorubicin|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had a pre-doxorubicin echocardiography done at NUHS will be enrolled. Study subjects will donate one sample of blood (20ml) for genetic and biomarker studies related to breast cancer and anthracyclines pharmacodynamics. An echocardiography will be performed to measure left ventricular ejection fraction, and compared with the subject's pre-doxorubicin echocardiography done at NUH. Correlative analysis will be performed between genetic variants and left ventricular ejection change.
16680792|NCT02078375|Placebo Comparator|Carbohydrate supplement|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a carbohydrate supplement to take twice daily (once after exercise).
16680793|NCT02078375|Experimental|Protein Supplementation|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a twice daily protein supplement (once after exercise).
16680794|NCT02078349|Experimental|Solid Tumors|"Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).
~One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities."
16680795|NCT02078336|Experimental|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
16684809|NCT02051972||Indicated for a VVI(R) pacemaker|
16680796|NCT02078336|Active Comparator|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment
~OR
~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment
~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment
~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment
~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
16680797|NCT02078323|Active Comparator|Linaclotide|Linaclotide 290micrograms q day 30 min before meal for a 10 week period
16680798|NCT02078323|Placebo Comparator|placebo|Placebo q day 30 min before meal for a 10 week period
16680799|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
16680800|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
16680801|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
16680802|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
16680803|NCT02078297||Scalp psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
16680804|NCT02078297||pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
16680805|NCT02078297||non-pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
16680806|NCT02078297||elbow psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
16680807|NCT02078297||leg psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
16680808|NCT02078297||Healthy subjects|
16680809|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
16680810|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
16680811|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
16680812|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
16680813|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
16680814|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
16680815|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
16680816|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
16680817|NCT02078271|Experimental|FBDG group|The group received Food Based Dietary Guidelines for feeding recommendation. Monthly-session with group of mothers involving interactive activities e.g. cooking session, cooking competition and games.
16680818|NCT02078271|Experimental|Stimulation group|The children received psychosocial stimulation from the mothers. Mothers were taught on psychosocial module which was developed using locally existing resources and was directed at improving four aspects of child development, namely gross motoric, fine motor, language and socio-emotional developments.
16680819|NCT02078271|Experimental|Combined (FBDG and Stimulation)|The group received both FBDG and psychosocial stimulation
16680820|NCT02078271|Other|Control|The group received standard health education messages from existing health care system.
16680821|NCT02078258|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a a variation of attention tasks to modify attentional biases, in which a probe always appears in the location of relatively positive stimuli after the two stimuli, one neutral and one emotional, were simultaneously presented.
~Participants complete 8 sessions (320 trials each with 20 minutes) over two weeks of neutral ABMT to shift attention toward neutral, in which a probe appeared in the location of neutral with 90% probability, and sadness-related with 10% probality. At a 9-week follow-up, participants completed 4 more sessions (480 trials each with 30 minutes)over two weeks of positive ABMT to shift attention toward positive words,in which a probe appeared in the location of 67% positive or 33% neutral."
16680822|NCT02078258|Active Comparator|Placebo control|The placebo ABMT was identical to the active ABMT, but shifted toward neutral (50%) or sad (50%) stimuli equally often (i.e., 50/50 training).
16680823|NCT02078245||Familial pancreatic cancer patients|Individual with ten fold higher risk to develop pancreatic cancer.
16680824|NCT02078232|Experimental|19G flex needle puncture|puncture of head of pancreas
16680825|NCT02078232|Active Comparator|22G needle puncture|puncture of head of pancreas
16680826|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
16680827|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
16680828|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
16680829|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
16680830|NCT02078219|Other|Allopurinol|Allopurinol 200mg
16680831|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
16680836|NCT02078180|Active Comparator|generic bupropion SR100|One oral dose of generic bupropion SR100
16680837|NCT02078180|Active Comparator|generic bupropion SR150|One oral dose of generic bupropion SR150
16680838|NCT02078180|Active Comparator|generic bupropion XL150|One oral dose of generic bupropion XL150
16680839|NCT02078180|Active Comparator|generic bupropion XL300|One oral dose of generic bupropion XL300
16680840|NCT02078154||Deep Venous Thrombosis (DVT)|DVT diagnosed by imaging technique with a low or moderate Wells score
16680841|NCT02078128|Experimental|oral beta-glucans|Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
16680842|NCT02078128|Placebo Comparator|oral sugar powder|control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
16680843|NCT02078115||chronic kidney disease, hypertension|20 <= age < 75 years 15 <= estimated glomerular filtration rate (GFR) < 90
16680844|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.
~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.
~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
16680845|NCT02078089|Other|Oxcarbazepine and Morphine|"Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.
~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days."
16680846|NCT02078076|Experimental|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
16680847|NCT02078063|Experimental|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
16680848|NCT02078063|Placebo Comparator|NaCL|10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
16680849|NCT02078050|Other|Phrenic nerves magnetic stimulations|
16680850|NCT02078037|Experimental|Arctic Sun cooling device|The Arctic Sun device pads will be placed on the patient as per manufacturer's instructions. Patients, who cannot tolerate placement of all the pads for any given reason, will still be included in the study if they can maintain normothermia (normal body temperature). The total normothermia time for the study is five days. After 5 days, the attending physician will make clinical decisions based on the patient needs.The temperature goal for this study is 36.5 degree Celsius, but normothermia for the purpose of this study will be defined as a temperature of 35.5 - 37.5 degree Celsius. A thermometer mounted urinary catheter will be used for temperature monitoring and feedback to the Arctic Sun.
16680851|NCT02078037|Active Comparator|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician) initiated at a temperature of 38.5 degrees Celsius
16680852|NCT02078024|Active Comparator|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
16680853|NCT02078024|Experimental|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
16680854|NCT02078024|Experimental|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
16680855|NCT02078024|Experimental|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
16680856|NCT02078024|Experimental|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
16680857|NCT02078011|Experimental|HIFU treatment|The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die
16680858|NCT02077998|Experimental|Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)|"PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.
~PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
16680859|NCT02077985|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
16680860|NCT02077985|Experimental|Sensory Adapted Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
16680861|NCT02077972|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
16680862|NCT02077959|Experimental|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16680863|NCT02077946||Liraglutide / Sitagliptin|
16680864|NCT02077933|Experimental|alpelisib and everolimus|alpelisib and everolimus administered once a day
16680865|NCT02077933|Experimental|alpelisib, everolimus and exemestane|alpelisib, everolimus and exemestane administered once a day
16680866|NCT02077933|Experimental|alpelisib and exemestane|alpelisib and exemestane administered once a day
16680867|NCT02077920|Experimental|Chlorhexidine before intubation|Group A: Oropharyngeal decontamination with chlorhexidine before intubation, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation, and every 6 hours after intubation.
16680868|NCT02077920|Experimental|Chlorhexidine after intubation|Group B: Oropharyngeal decontamination with chlorhexidine after intubation, n=48. Oral cleansing with chlorhexidine will be performed every 6 hours after endotracheal intubation.
16680908|NCT02077634|Active Comparator|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
16680909|NCT02077621|Experimental|PG2|"Treatment Group:
~PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
16680869|NCT02077920|Experimental|Subglottic secretion drainage|"Group C: Suctioning of subglottic secretions, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation and every 6 hours after intubation, and fiberoptic bronchoscopy-guided suctioning of subglottic secretions will be performed at 10:00 a.m. every day. The procedure will be as follows:
~Routine cleaning of the bronchoscope.
~Oral or nasal insertion of the bronchoscope (according to the decision of the attending physician based on the patient's condition). Rinsing of the subglottic region with 5-20 mL of chlorhexidine solution followed by suctioning. The rinsing procedure will be repeated 3-5 times.
~Routine cleaning of the bronchoscope. The patient will be monitored during all procedures."
16680870|NCT02077920|Experimental|0.9% sodium chloride injection|Group D: 0.9% sodium chloride injection, n=48. After endotracheal intubation, oral cleansing with normal saline will be performed every 6 hours.
16680871|NCT02077907|Active Comparator|Super Cereal Plus (SC+)|"800 kcal/d, 215 g/d
~Current protocol for treating MAM is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. In Sierra Leone, their FBF standard is Super Cereal Plus."
16680872|NCT02077907|Experimental|Super Cereal (SC) and oil and sugar|"200 g SC and 20 g fortified oil and 15 g sugar, per day
~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
16680873|NCT02077907|Experimental|Corn Soy Blend 14 (CSB14) and fortified oil|"978 kcal/day - 150 g CSB14 and 45 g oil, per day
~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
16680874|NCT02077907|Experimental|Plumpy'Sup|"500 kcal/d, 92 g/d
~Ready-to-Use Supplementary Food (RUSF)"
16680875|NCT02077894||Participants with retinal disease|Participants with retinal disease
16680876|NCT02077894||Unaffected family members|Members of the participant's family that do not have eye disease
16680877|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:
~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.
~Phase 2 portion:
~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
16680878|NCT02077868|Other|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
16680879|NCT02077868|Experimental|Treatment Arm B|MGN1703 treatment as maintenance therapy
16680880|NCT02077855||Toddlers fractures|
16680881|NCT02077842|Experimental|Nasal CPAP|The experimental group will receive nasal continuous positive airway pressure at 10cmH20 for one hour in the Post Anesthetic Care Unit.
16680882|NCT02077842|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
16680883|NCT02077829|Other|IMR therapists, IMR patients|"30 voluntary therapists from 9 mental health services will be trained and coached in IMR.
~40 patients from the 9 mental health services will receive Illness Management and Recovery from the therapists in training."
16680884|NCT02077816||Central venous catheter|Inpatients with CVC for medical care.
16680885|NCT02077803|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
16680886|NCT02077803|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
16680887|NCT02077803|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
16680888|NCT02077790|No Intervention|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
16680889|NCT02077777|Experimental|5-ASA|Mesalazine 800 mg orally t.i.d for 3 months
16680890|NCT02077777|No Intervention|No treatment|no treatment
16680891|NCT02077764||Controls, healthy individuals|controls
16680892|NCT02077764||Heart transplanted patients|Patients
16680893|NCT02077751|Experimental|Biotin labelled RBCs|Subjects receive biotin labelled autologous red blood cells.
16680894|NCT02077738|Experimental|HFCWO|HFCWO for 15 min twice a day
16680895|NCT02077738|Placebo Comparator|placebo|not to receive high-frequency chest wall oscillation (HFCWO)
16680896|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
16680897|NCT02077712|Active Comparator|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
16680898|NCT02077712|Active Comparator|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
16680899|NCT02077699|Experimental|1|Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks
16680900|NCT02077686|Experimental|Education - Diabetes and Travel|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Travel"
16680901|NCT02077686|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
16680902|NCT02077673||open surgery|25 patients undergoing open gastroesophageal resection
16680903|NCT02077673||robotic-assissted surgery|25 patients under-going robotic-assisted gastroesophageal surgery
16680904|NCT02077660|Placebo Comparator|4 daily placebo tea bags for 12 weeks|"All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin tea-bags. The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period)."
16680905|NCT02077660|Experimental|Four green tea bags per day for 12 weeks|After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).
16680906|NCT02077647||Conservative|Conservative treatment of osteoarthritis of the knee
16680907|NCT02077634|Active Comparator|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
16686531|NCT02039986||all subjects|all subjects enrolled in same cohort
16680910|NCT02077621|Placebo Comparator|Placebo|"Control group:
~Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
16680911|NCT02077608||Hyaluronan enriched transfer media|Embryos are incubated at least 10 minutes in hyaluronan enriched embryo transfer media before transfer
16680912|NCT02077608||Control group|Embryos are incubated in embryo transfer media containing low concentration of hyaluronan for at least 10 minutes before transfer
16680913|NCT02077595|Active Comparator|120Hz alternating current stimulation group|
16680914|NCT02077595|Active Comparator|5Hz alternating current stimulation group|
16680915|NCT02077595|Sham Comparator|sham alternating current stimulation group|
16680916|NCT02077569|Experimental|AZD5363 480mg|STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
16680917|NCT02077569|Placebo Comparator|Placebo|STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
16680918|NCT02077569|Experimental|AZD360mg|STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
16680919|NCT02077569|Experimental|AZD5363 240mg|STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
16680920|NCT02077556|Experimental|Everolimus|Everolimus/Tacrolimus/Methylprednisolone & Prednisolone
16680921|NCT02077556|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone
16680922|NCT02077543|Experimental|ProTool|Device: Brain Tissue Imprint - Medical Device (ProTool)
16680923|NCT02077517|Active Comparator|hand sewn anastomosis|Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing
16680924|NCT02077517|Active Comparator|stapled anastomosis|Patients with stapled anastomosis during Roux en Y Gastric Bypass performing
16680925|NCT02077504|Experimental|CONDUCTOME|MEG and MRI
16680926|NCT02077491|Active Comparator|Intervention|High-protein diet and resistance training
16680927|NCT02077491|No Intervention|Control|The control group recieves standard care during the study.
16680928|NCT02077478|Experimental|MCI|manually controlled infusion will be used
16680929|NCT02077478|Experimental|TCI|Target Controlled Infusion will be used
16680930|NCT02077465|Experimental|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
16680931|NCT02077465|Placebo Comparator|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
16680932|NCT02077452|Experimental|HMS5552 dose 1|HMS5552 25~400mg. Oral administration, twice per day.
16680933|NCT02077452|Experimental|HMS5552 dose 2|HMS5552 25~400mg. Oral administration, twice per day.
16680934|NCT02077452|Experimental|HMS5552 dose 3|HMS5552 25~400mg. Oral administration, twice per day.
16680935|NCT02077452|Experimental|HMS5552 dose 4|HMS5552 25~400mg. Oral administration, once per day.
16680936|NCT02077452|Experimental|HMS5552 dose 5|HMS5552 25~400mg. Oral administration, twice per day.
16680937|NCT02077439|Experimental|Hand Robotic Training|Hand Robotic Training
16680938|NCT02077439|Experimental|Hand and Arm Robotic Training|Hand and Arm Robotic Training
16680939|NCT02077439|Active Comparator|Conventional therapy|Conventional therapy
16680940|NCT02077426|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises
16680941|NCT02077413|Active Comparator|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
16680942|NCT02077413|Experimental|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
16680943|NCT02077413|Active Comparator|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
16680944|NCT02077413|Experimental|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
16680945|NCT02077400|No Intervention|no antibiotic|
16680946|NCT02077400|Active Comparator|Cephazolin|cefazoline
16680947|NCT02077387|Experimental|CHild Inhibitory Control Play (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
16680948|NCT02077387|Active Comparator|Attention control|Children will receive information regarding other healthy behaviors: brushing teeth, sunscreen use, being physically active
16680949|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
16680950|NCT02077374|Placebo Comparator|Placebo|Placebo BID
16680951|NCT02077361|Experimental|Open Label|"Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance. It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.
~It is the same vector used in the United Kingdom Phase I/II trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
16680952|NCT02077348|No Intervention|Insulin|"good glycemic control: 50 % of the subject's basal insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) and on the study-day. Basal period from 7.00 am to 12.00pm. The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.
~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
16680953|NCT02077348|Experimental|Insulin withdrawal|"10 % of the individual subject's regular insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) Basal period from 7.00 am to 12.00 pm (without insulin). The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.
~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
16680954|NCT02077348|Experimental|Norditropin (Growth Hormone)|"Same amount of insulin administered on the control day (good glycemic control) overnight and on the study day (hospitalized and fasting from 10 p.m.). On the study day, a bolus injection of 0,4 mg of growth hormone (Norditropin) will be administered at 7.05 am. Basal period from 7.00 am to 12.00 pm (good glycemic control).The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.
~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
16680955|NCT02077335|Experimental|HDR brachytherapy monotherapy|Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
16680956|NCT02077322|Experimental|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
16680957|NCT02077322|Active Comparator|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
16680958|NCT02077309|Active Comparator|Linagliptin|Patients will receive 5 mg linagliptin once daily for a period of 6 months.
16680959|NCT02077309|Placebo Comparator|Placebo|Patients will take placebo tablets once daily for a period of 6 months.
16680960|NCT02077296||Preoperative chemoradiotherapy|The group consists of patients aged ≥18 with a pathohistological diagnosis of locally advanced rectal adenocarcinoma (<15 cm from the anal verge). They are found eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery (stage 2 or 3 rectal cancer).
16680961|NCT02077283||Healthy people|This group contains healthy people only whose liver function and B ultrasound are normal.
16680962|NCT02077283||"group of liver depression and spleen deficiency pattern"|"In this group, patients are considered to be the pattern of liver depression and spleen deficiency. They mainly have the symptoms of loose stool, depression, fat tongue with white coating and teeth marks and soft or string pulse."
16680963|NCT02077283||"group of damp-heat in the interior pattern."|In this group ,NAFLD patients have symptoms with dry mouth, bitter mouth, heavy feeling in legs, yellow urine, reddish tongue with thick yellowish coating and slippery pulse.
16680964|NCT02077270|Experimental|electroacupuncture|patients in whom precolonoscopic electroacupuncture is preformed
16680965|NCT02077270|Placebo Comparator|Sham electroacupuncture|sham electroacupuncture
16680966|NCT02077270|Sham Comparator|No intervantion|no intervantion
16680967|NCT02077257|Other|Rosuvastatin 20mg|Rosuvastatin 20 mg/d
16680968|NCT02077257|Other|Rosuvastatin 10mg|Rosuvastatin 10 mg/d
16680969|NCT02077244|Experimental|Follow up talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
16680970|NCT02077244|No Intervention|No talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual
16680971|NCT02077244|No Intervention|Observation group|Patients with a score below 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual.
16680972|NCT02077231|Experimental|vitamin A palmitate eye gel|0.1% vitamin A palmitate; Sinqi, Shenyang, China
16680973|NCT02077231|Experimental|carbomer eye gel|0.2% Carbomer 940; Bausch & Lomb, Aschheim, Germany
16680974|NCT02077218|Experimental|Diagnostic (CT and blood biomarkers)|Patients undergo cardiac CT and collection of blood samples for analysis of hs-CRP via quantitative immunoturbidimetry and Lp-PLA2 via ELISA.
16680975|NCT02077205|Experimental|Manualised Cognitive Behavioral Therapy|Manualised Cognitive Behavioral Therapy in a Routine Care Setting
16680976|NCT02077192|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
16680977|NCT02077179|No Intervention|Standard of Care|Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
16680978|NCT02077179|Experimental|HIP Program|Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
16680979|NCT02077166|Experimental|Phase 1: Dose Level -1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
16680980|NCT02077166|Experimental|Phase 1: Dose Level 1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
16680981|NCT02077166|Experimental|Phase 1: Dose Level 1+|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
16680982|NCT02077166|Experimental|Phase 1: Dose Level 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
16680983|NCT02077166|Experimental|2Phase 1: Dose Level 3|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
16680984|NCT02077166|Experimental|Phase 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
16680985|NCT02077153|Experimental|Group Reminescence|In the experimental condition, everything begins ensuring the participants that all the memories shared will not be spread out of the group. Every session will deal with a theme, recalling specific autobiographic experiences; they will be suggested following a chronological order. Participants are encouraged to bring photos or objects related to past themes: at the end of each meeting the theme of the following is revealed. The researchers can also bring materials as cues for reminiscence.
16681022|NCT02076880|Experimental|Arm with caloric restriction|"Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.
~Intervention: caloric restriction"
16686681|NCT02039063|Experimental|4|E6011 15 mg/kg
16680986|NCT02077153|Active Comparator|Group discussion|In the control condition, every meeting will offer topics for discussion taken from newspaper and newscasts: personal opinions are promoted, and links with the daily life of participants are welcome (everyday activities, personal preferences). The main goal is to stimulate the social interaction and the communication, without dealing with personal events from the past nor private memories.
16680987|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
16680988|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
16680989|NCT02077114|Experimental|Ipilimumab|Patient who according to standard criteria are candidates to treatment with Ipilimumab
16680990|NCT02077114|Experimental|Vemurafenib|Patients who according to standard criteria are candidates to treatment with Vemurafenib
16680991|NCT02077101|Other|Quantitative study group|Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL [28, 29]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
16680992|NCT02077101|Other|Qualitative study group|"An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France.
~These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous .
~The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis."
16680993|NCT02077088|Experimental|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
16680994|NCT02077088|No Intervention|Only HA formula|only standard HA starter formula
16680995|NCT02077075|Active Comparator|Web-based weight loss program|Subjects will have access to a web-based weight loss program for an 8-week period.
16680996|NCT02077075|Experimental|On-line health coaching in addition to web-based program|Subjects will have access to the web-based wellness program and will also receive weekly personalized health coaching emails.
16680997|NCT02077062||study (hepatectomy) group|patients undergoing hepatectomy for malignant neoplasm
16680998|NCT02077062||control (non hepatectomy) group|patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
16680999|NCT02077049|Experimental|serious games self-training program|Serious games are played, using Kinect® and Fit Bit®. This program is performed during the 10 days of the intervention on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
16681000|NCT02077049|Active Comparator|Conventional self-training program|conventional physical exercises are performed during the 10 days of the intervention, on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
16681001|NCT02077036|Experimental|Active medical device|
16681002|NCT02077036|Placebo Comparator|Inactive medical device|
16681003|NCT02077023||Asymptomatic Carotid Artery Disease, AF|
16681004|NCT02077010|Experimental|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a jet nebulizer
16681005|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
16681006|NCT02076984|Other|Group A|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by titanium tacks
16681007|NCT02076984|Other|Group B|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by U shaped absorbable tacks
16681008|NCT02076958|Active Comparator|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
16681009|NCT02076958|Experimental|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
16681010|NCT02076945|Active Comparator|Healthy patients|Patients without diabetes and without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
16681011|NCT02076945|Experimental|Diabetic patients without neuropathy|Patients with diabetes but without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
16681012|NCT02076945|Experimental|Diabetic patients with neuropathy|Patients with diabetes and with peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus > 19.01 mm2)
16681013|NCT02076932|Active Comparator|Premenopausal women|The premenopausal women will be attending Spinning classes.
16681014|NCT02076932|Experimental|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
16681015|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
16681016|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
16681017|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
16681018|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
16681019|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
16681020|NCT02076893|Active Comparator|Tramadol/gabapentin/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled gabapentin 3 mg/kg [max 150 mg] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
16681021|NCT02076893|Placebo Comparator|Tramadol/placebo/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
16688317|NCT02028351||Maculopathy|No Intervention
16681023|NCT02076880|Experimental|Arm without caloric restriction|"Patients in this arm will not have a caloric restriction before surgery.
~Intervention: No caloric restriction"
16681024|NCT02076867|Experimental|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
16681025|NCT02076867|Active Comparator|Medical Care As Usual (MCAU)|
16681026|NCT02076854|Experimental|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
16681027|NCT02076854|No Intervention|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
16681028|NCT02076841||interferon beta-1a|30 μg intramuscularly once a week using an injection device (Avonex Pen).
16681029|NCT02076828|Experimental|Fe-OH-PM (Santafer® sp.)(Group II)|The patients in Group II were treated with Fe-OH-PM (Santafer® sp.), 6 mg/kg/day orally.
16681030|NCT02076828|Experimental|Fe-Zn (Ferro Zinc® sp.)(Group III)|The patients in Group III were treated with Fe-Zn (Ferro Zinc® sp.), 6 mg/kg/day orally
16681031|NCT02076828|Experimental|Fe-S (Ferro Sanol® sp.)(Group I)|The patients in Group I were treated with Ferro Sanol® sp., 6 mg/kg/day orally
16681032|NCT02076815|Experimental|Anagrelide retard|Anagrelide Retard prolonged-release formulation
16681033|NCT02076815|Active Comparator|Thromboreductin|Anagrelide immediate release formulation
16681034|NCT02076802||lifestyle counseling|physical exercises
16681035|NCT02076789||ICD generator replacement|Patients with standard indications to ICD generator replacement
16681036|NCT02076776|Active Comparator|Repetitive Task Practice (RTP)|This group focuses on RTP.
16681037|NCT02076776|Experimental|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
16681038|NCT02076776|Experimental|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
16681039|NCT02076763||Acute intermittent porphyria|Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).
16681040|NCT02076750|Experimental|Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
16681041|NCT02076750|Active Comparator|Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.
16681042|NCT02076737|Experimental|VEO|
16681043|NCT02076724|Experimental|Biological mesh (Strattice Firm)|Strattice Firm is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
16681044|NCT02076724|Experimental|Synthetic mesh (Prolene)|Prolene mesh is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
16681045|NCT02076711|Active Comparator|Active|Metoprololsuccinate
16681046|NCT02076711|Placebo Comparator|Placebo|Placebo
16681047|NCT02076698|Experimental|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
16681048|NCT02076698|Active Comparator|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
16681049|NCT02076685|Experimental|isoniazid rechalleng|When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
16681050|NCT02076672|Experimental|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
16681051|NCT02076659|Experimental|F8IL10 + MTX|"Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.
~An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.
~In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2."
16681052|NCT02076646|Experimental|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.
~L19-IL2 will be administered on days 1, 8 & 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
16681053|NCT02076646|Experimental|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
16681054|NCT02076646|Active Comparator|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
16681055|NCT02076633|Experimental|L19IL2 + L19TNF|One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF. Weekly administration for all combined leasions
16681056|NCT02076620|Experimental|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:
~cohort 1 --> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --> 17 μg/kg L19TNFα + doxorubicin."
16681057|NCT02076607||Conservative Treatment|Eleven patients underwent conservative treatment with Brace.
16681058|NCT02076607||Surgical Treatment|Fourteen patients who underwent surgical treatment (arthrodesis).
16681059|NCT02076594|Experimental|Docetaxel & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
16681189|NCT02075749|Experimental|Licorice|30 patients received licorice mucoadhesive films
16681060|NCT02076594|Experimental|Epirubicin & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)
16681061|NCT02076581||Stroke|Ten individuals with chronic stroke and limb spasticity will be recruited.
16681062|NCT02076581||Dystonia|Ten individuals with dystonic limbs and no spasticity will be recruited.
16681063|NCT02076581||Cerebral Palsy|Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited.
16681064|NCT02076581||Neurologically normal|Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited.
16681065|NCT02076568|Experimental|Education - Diabetes and Partnership|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Partnership"
16681066|NCT02076568|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
16681067|NCT02076555|Experimental|Education - Diabetes and Social Issues|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Social Issues"
16681068|NCT02076555|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
16681069|NCT02076542|Experimental|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
16681070|NCT02076542|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
16681071|NCT02076529|Experimental|Ramosetron 0.6mg|Ramosetron 0.6mg intravenous injection 30min before chemotherapy
16681072|NCT02076529|Experimental|Ramosetron 0.45mg|Ramosetron 0.45mg intravenous injection 30min before chemotherapy
16681073|NCT02076529|Active Comparator|Ramosetron 0.3mg|Ramosetron 0.3mg intravenous injection 30 min before chemotherapy
16681074|NCT02076516|Experimental|Drug-eluting stent: CORACTO®|Single arrm
16681075|NCT02076503|Experimental|PET-MR 18F-FACBC|
16681076|NCT02076490|Experimental|Software Supported Mirror Therapy|First experimental condition Physical/Occupational Therapy
16681077|NCT02076490|Experimental|Traditional mirror therapy|Second experimental condition Physical/Occupational Therapy
16681078|NCT02076490|Active Comparator|Sensomotor exercises without mirror|Control condition Physical/Occupational Therapy
16681079|NCT02076477|Experimental|Arm A|"Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.
~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
16681080|NCT02076477|Active Comparator|Arm B|"Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.
~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
16681081|NCT02076464|Experimental|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
16681082|NCT02076464|No Intervention|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
16681083|NCT02076451|Experimental|2 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
16681084|NCT02076451|Experimental|8 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
16681085|NCT02076451|Experimental|16 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
16681086|NCT02076451|Experimental|24 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
16681087|NCT02076438|Placebo Comparator|Placebo|Placebo capsules
16681088|NCT02076438|Experimental|Probiotics|Lactobacillus Rhamnosus GG 10 billion cfu BID
16681089|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
16681090|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
16681091|NCT02076412|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
16681092|NCT02076412|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
16681093|NCT02076399|Experimental|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
16681094|NCT02076399|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
16681095|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
16681096|NCT02076373|Experimental|recombinant human Erythropoietin (Epo)|"Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.
~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
16681097|NCT02076373|Placebo Comparator|Control|"Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.
~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
16681098|NCT02076360|Experimental|Preop Video|This arm will watch an instructional video in addition to their normal preoperative visit with the physician.
16681099|NCT02076360|No Intervention|No video|This arm will receive only the normal preoperative visit with the physician without the additional video
16681100|NCT02076347|Experimental|Office visit-based intervention|
16681101|NCT02076347|Experimental|Electronic message-based intervention|
16681102|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
16681103|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
16681104|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
16681105|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
16681106|NCT02076321|Other|Acetaminophen|control group
16681107|NCT02076321|Other|NSAID (Ibuprofen)|Study group
16681108|NCT02076308|Experimental|Electroacupuncture|Electroacupuncture and physical therapy
16681109|NCT02076308|Sham Comparator|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
16681110|NCT02076295||Parkinson's disease subjects|
16681111|NCT02076295||Normal control subjects|
16681112|NCT02076282||Healthy volunteers 1 MRI scan|"Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology.
~Healthy volunteers will receive 1 MRI scan without contrast agent."
16681113|NCT02076282||Patients with stage III NSCLC, 1 MRI scan|"Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available
~Patients will receive 1 MRI scan with contrast agent."
16681114|NCT02076269|Other|Arm 1|Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
16681115|NCT02076256|No Intervention|Control Group|
16681116|NCT02076256|Experimental|The helping relationships intervention program|The helping relationships intervention program will be implemented on the experimental group. And the control group will be provided with routine nursing care. Data will be collected at baseline, the sixth and the ninth month of the third year of study. Data will be analyzed using generalized estimating equation measures to evaluate the effect of the intervention program.
16681117|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
16681118|NCT02076230|Experimental|[14C] TH-302 (Label 1)|
16681119|NCT02076230|Experimental|[14C] TH-302 (Label 2)|
16681120|NCT02076217||unprotected intercourse 6-14 days prior to contraception|Women who initiate highly effective reversible contraception within 6-14 days of unprotected intercourse.
16681121|NCT02076204|Experimental|Home visiting|Home visiting group: Women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group. Home visiting for low-income, pregnant women - whereby individualized in-home services (including direct education, assessments, and referrals to community resources) are provided to families - has been identified by the Strong Start initiative as one promising method for reaching women who are vulnerable to poor birth outcomes.
16681122|NCT02076204|No Intervention|Non-Home Visiting|Control group: As described above, women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group.The home visiting program will provide control group families with referrals to other appropriate services in the community.
16681123|NCT02076191|Experimental|Myeloproliferative neoplasms|In phase I, increasing doses of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days. An initial dose of ruxolitinib of 10 mg orally twice daily is anticipated with planned, dose escalations of 15 mg orally twice daily, 25 mg orally twice daily and 50 mg orally twice daily. The dose can also be de-escalated to 5mg orally twice daily if dose limiting toxicities (DLTs) are observed at the initial 10mg dose. Patients will receive ruxolitinib as a single agent for the first 7 days followed by the administration of decitabine on day 8 for a total of 5 consecutive days. Patients will continue ruxolitinib at the assigned dose through the first cycle and may reduce the dose for specified toxicity beginning with the second cycle. Patients in Phase II will start at the recommended phase II dose (RPTD) of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days.
16681124|NCT02076178|Experimental|Arm 1|Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
16681125|NCT02076178|Experimental|Arm 2|Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
16681126|NCT02076165|Experimental|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
16681127|NCT02076165|Active Comparator|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
16681128|NCT02076152|Experimental|FMISO PET & MRI Group 1|"Bevacizumab:
~-- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).
~FMISO PET Scan
~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.
~The PET scan will be approximately 60-75 minutes.
~MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
16681186|NCT02075762|Active Comparator|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
16681398|NCT02074332|Experimental|Intervention|Physical activity guidance Health education
16681129|NCT02076152|Experimental|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:
~Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).
~CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).
~-FMISO PET Scan
~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.
~The PET scan will be approximately 60-75 minutes.
~- MRI
~Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
16681130|NCT02076139|Experimental|Nyaditum resae® 10e4|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
16681131|NCT02076139|Experimental|Nyaditum resae® 10e5|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
16681132|NCT02076139|Placebo Comparator|Placebo|The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
16681133|NCT02076126||Gastric aspirate|L/S ratio on the gastric aspirates are retrospectively compared with the possible development of RDS
16681134|NCT02076126||Hypopharyngeal secretion|L/S ratio on the hypopharyngeal secretions are retrospectively compared with the possible development of RDS
16681135|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
16681136|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
16681137|NCT02076100|Experimental|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
16681138|NCT02076100|Experimental|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
16681139|NCT02076100|Experimental|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
16681140|NCT02076087||Normal Weight (BMI: 18.5-24.9 kg/m²)|Liposuction/lipectomy
16681141|NCT02076087||Overweight (BMI: 25.0-29.9 kg/m²)|Liposuction/lipectomy
16681142|NCT02076087||Obese (BMI: >30.0kg/m²)|Liposuction/lipectomy
16681143|NCT02076074|Experimental|Treatment (HG-PBI)|Patients undergo single fraction high gradient-partial breast irradiation within 8 weeks after partial mastectomy.
16681144|NCT02076061||GOLD stage I|
16681145|NCT02076061||GOLD Stage II|
16681146|NCT02076061||GOLD Stage III|
16681147|NCT02076061||GOLD Stage IV|
16681148|NCT02076061||Smokers/ex-smokers w/o COPD|
16681149|NCT02076061||non-Smokers w/o COPD|
16681150|NCT02076048||Previous LCPUFA Supplementation|Children between the ages of 7 and 10 that were previously enrolled in a study of supplemented LCPUFA formula.
16681151|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
16681152|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.
~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
16681155|NCT02075996||Pomalidomide following lenalidomide|75 patients with pomalidomide directly following lenalidomide treatment
16681156|NCT02075996||Pomalidomide following other therapy|75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
16681157|NCT02075983|Experimental|Group 3 (IM+EP)|Group 3 will receive 12.0mg of vaccine over 12 weeks administered with EP using the Trigid Ichor device. We expect to see the greatest proportion of individuals making T cell and antigen specific antibody responses responses in this group. Depending on the magnitude of the effects, the differences between group 3 and the other groups may be statistically significant.
16681158|NCT02075983|Experimental|Group 2 (IM+TC)|Group 2 will also receive 13.2mg of vaccine over 12 weeks, with 12.0mg given IM and 1.2mg TC. We are interested in the impact of TC relative to ID vaccination on the ratio between HIV-specific T-cell responses, and whether or not CD8+ Tcells are favoured by this route.
16681159|NCT02075983|Active Comparator|Group 1 (IM+ID)|"Group 1 will serve as the reference arm and this group will receive a total dose of 13.2mg vaccine over 12 weeks with 12.0mg given IM and 1.2mg ID. This is 7.2mg more than has been given previously to healthy individuals and 6.2 mg more than given to those HIV-infected but similar doses of HIV DNA vaccines have been given in other trials with no serious consequences."
16681187|NCT02075762|Active Comparator|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
16681188|NCT02075749|Active Comparator|triamcinolone acetonide mucoadhesive|30 patients received triamcinolone acetonide mucoadhesive films
16681160|NCT02075970|Experimental|Epoetin Alpha study 1|"Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.
~Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder."
16681161|NCT02075970|Placebo Comparator|Epoetin Alpha study 2|"Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.
~Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.
~Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders."
16681162|NCT02075970|Experimental|Biotinylated red blood cells|Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
16681163|NCT02075944|Experimental|High intensity aerobic exercise|30 minutes of high intensity aerobic exercise 3 times a weeks for 9 weeks - incorporation interval training
16681164|NCT02075944|Experimental|Low intensity aerobic exercise|30 minutes of low intensity aerobic exercise 3 times a weeks for 9 weeks
16681165|NCT02075944|No Intervention|Control|No intervention. Participants are told not to make any changes in their everyday life
16681166|NCT02075931|Experimental|Physical Activity Feedback|The physical activity feedback intervention will involve real-time physical activity monitoring using a device to provide activity feedback directly to patients in combination with patient group meetings held monthly during the 12 week intervention for the purposes of mutual support in attaining physical activity goals.
16681167|NCT02075931|Active Comparator|Control|The control represents the current standard of care post total knee arthroplasty.
16681168|NCT02075905||Barrett's Esophagus-Low Grade Dysplasia|Subjects enrolled who have Barrett's Esophagus with low grade dysplasia. No research intervention is administered.
16681169|NCT02075905||Barrett's Esophagus-no dysplasia|Subjects enrolled with Barrett's Esophagus and no dysplasia. No research intervention is administered.
16681170|NCT02075892|Active Comparator|Mushroom Blend|4 grams daily; oral; 7 and 21 days
16681171|NCT02075892|Placebo Comparator|Placebo|4 grams maltodextrin, oral, 7 and 21 days
16681172|NCT02075879|Experimental|Nurse-led interviewing|Participants in experimental arm received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. They were additionally instructed to start walking or brisk walking at low duration and gradually progress to a maximum of 30 minutes daily per week. To facilitate exercise progression, the nurse case managers discussed exercise benefits, explored exercise barriers and developed mutual goals with patients. The nurse motivated them and checked the exercise behaviors to ensure adherence to the recommended exercise regime. The nurse case managers interviewed the patients weekly for six weeks and biweekly for another six weeks.
16681173|NCT02075879|Active Comparator|Brief group exercise|Participants received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. The in-center training was conducted by the researcher with a group of four-to six participants focusing on flexibility and strengthening exercise only.
16681174|NCT02075853||Bovine Xenograft|Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
16681175|NCT02075853||Iliac Crest Allograft|Patients in this group received an iliac crest cadaver allograft (bicortical or tricortical) in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so all future patients will receive the allograft during the procedure.
16681176|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
16681177|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
16681178|NCT02075827|Active Comparator|Problem-solving video game|Playing the video game 'Little Big Planet'
16681179|NCT02075827|Experimental|Competitive video game|Playing the video game 'Call of Duty'
16681180|NCT02075801||Defective amalgam restorations|"Treatment Groups:
~A. Sealing of amalgam margin defects: Defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Sealant, 3MESPE)was applied over the defective area. The sealant was polymerized with a photo curing unit (Curing-Light 2500, 3MESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
~B. Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr, Orange, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
~C. Control Group: The defective restorations did not receive any treatment."
16681181|NCT02075788|Placebo Comparator|Commercial white bread|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
16681182|NCT02075788|Experimental|Millet based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
16681183|NCT02075788|Active Comparator|Corn based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
16681184|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
16681185|NCT02075762|Active Comparator|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
16681190|NCT02075749|Placebo Comparator|Mucoadhesive film|30 patients received mucoadhesive films without any drug ingredients
16681191|NCT02075736|Experimental|KTP laser|device
16681192|NCT02075736|Active Comparator|TUR-P|device
16681193|NCT02075723|Experimental|Overfeeding + sleep restriction|overfeeding condition (130 % of energy requirements ) + 6 days of sleep restriction (4 hours per night)
16681194|NCT02075723|Experimental|Overfeeding + normal sleep duration|overfeeding condition (130 % of energy requirements ) + 6 days of normal sleep duration (8 hours per night)
16681195|NCT02075710|Experimental|High sugar/meal feed|Diet high in simple sugar fed as two large meals daily
16681196|NCT02075710|Experimental|High sugar/nibble|Diet high in simple sugar fed as 8 small meals daily
16681197|NCT02075710|Experimental|High fat/meal feed|Diet high in fat fed as two large meals daily
16681198|NCT02075710|Experimental|High fat/nibble|Diet high in fat fed as 8 small meals daily
16681199|NCT02075710|Experimental|High sugar/3 meals a day|Diet high in simple sugar fed as 3 meals a day
16681200|NCT02075710|Experimental|High fat/ 3 meals a day|Diet high in fat fed as 3 meals a day
16681201|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
16681202|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
16681203|NCT02075684|Other|In-office, Percutaneous Renal Biopsy|
16681204|NCT02075671|Experimental|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
16681205|NCT02075671|Sham Comparator|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
16681206|NCT02075671|Placebo Comparator|Vehicle Only|Entire face treated with vehicle substance only
16681207|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
16681208|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
16681209|NCT02075645|Other|team training|"Intervention: team training course. A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
16681210|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
16681211|NCT02075619|Experimental|Sequence 1|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 Fixed dose combination (FDC) formulation-1 tablet in Period 2 and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
16681212|NCT02075619|Experimental|Sequence 2|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2 and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
16681213|NCT02075619|Experimental|Sequence 3|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1, one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
16681214|NCT02075619|Experimental|Sequence 4|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
16681215|NCT02075619|Experimental|Sequence 5|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
16681216|NCT02075619|Experimental|Sequence 6|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one GSK3074477 FDC formulation-1 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
16681217|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
16681219|NCT02075580|Experimental|psychological support|Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion
16681220|NCT02075580|No Intervention|standard care|this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning
16681221|NCT02075567|Experimental|Therapy adaption T1DM|
16681222|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
16681223|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
16681224|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
16681225|NCT02075528|Experimental|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
16681226|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
16681227|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
16681228|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
16681229|NCT02075502|Experimental|Exercise therapy|Claudication, no peripheral revasc
16681230|NCT02075502|Placebo Comparator|Exercise advice|Claudication, no peripheral revasc
16681231|NCT02075502|Experimental|lower extremity ET, exercise therapy|
16681232|NCT02075502|Placebo Comparator|lower extremity ET, exercise advice|
16681233|NCT02075502|Experimental|Peripheral open intervention, exercise therapy|
16681234|NCT02075502|Placebo Comparator|Peripheral open intervention, exercise advice|
16681235|NCT02075489|Experimental|Acupressure|This group of patients will serve as the experimental group and receive acupressure treatment in addition to routine clinical care. Acupressure will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
16681236|NCT02075489|Active Comparator|Reiki|This group of participants will serve as control group and receive Reiki treatment in addition to routine clinical care. Reiki will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
16681237|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
16681238|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
16681239|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
16681240|NCT02075450|No Intervention|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
16681241|NCT02075450|Experimental|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
16681242|NCT02075450|Experimental|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
16681243|NCT02075450|Experimental|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
16681244|NCT02075437|Experimental|Functional Abdominal Pain (FAP)|To access (FAP) subjects will participate in: 10 therapy sessions; and the following treatments: 1) identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis: 2) adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children; and 3) incorporate caregivers as role models and facilitators based on attachment research.
16681245|NCT02075424|Experimental|salivery sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.
~Only one sampling will occur to doctors who are assigned to a single workstation.
~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call For each participant, a serie of control-samples will be taken during a day off and during a security break."
16681246|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
16681247|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
16681248|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
16681249|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
16681250|NCT02075385|Experimental|Speech pathology therapy|Pre, during and pos-treatment swallowing exercises.
16681251|NCT02075385|No Intervention|Control group|These patients will not receive speech pathology therapy.
16681252|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
16681253|NCT02075359||Preschoolers|Preschoolers, ages 3 to 5
16681254|NCT02075333|Active Comparator|Sucrose (50g)|A 381g blackcurrant drink (cordial and water) providing 50g of sucrose
16681255|NCT02075333|Placebo Comparator|Sucralose (0.92 g sugars)|A 381g blackcurrant drink (cordial and water) providing 0.92g of natural sugars
16681256|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
16681257|NCT02075307|Experimental|Blueberry Powder|The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
16681258|NCT02075307|Placebo Comparator|Placebo Powder|The placebo group will receive placebo powder in the same amounts for the same duration.
16681259|NCT02075294||youth|"<45years
~Adefovir dipivoxil or Entecavir
~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.
~Participants who received 0.5mg ETV more than 3 years will be recruited."
16681399|NCT02074332|No Intervention|Control|Receive no intervention
16681260|NCT02075294||middle age|"≥45years and<65years
~Adefovir dipivoxil or Entecavir
~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.
~Participants who received 0.5mg ETV more than 3 years will be recruited."
16681261|NCT02075294||elderly|"≥65 years
~Adefovir dipivoxil or Entecavir
~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.
~Participants who received 0.5mg ETV more than 3 years will be recruited."
16681262|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
16681263|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
16681264|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
16681265|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
16681266|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
16681267|NCT02075268|Other|10 mg, 30 mg|To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.
16681268|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
16681269|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
16681270|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
16681271|NCT02075242|Active Comparator|tacrolimus|Control group: Tacrolimus + Corticosteroid (dual oral therapy)
16681272|NCT02075242|Experimental|Mycophenolate Mofetil|Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)
16681273|NCT02075229||Group A|45 participants with AzBio baseline sentence scores between 41 - 50%
16681274|NCT02075229||Group B|45 participants with AzBio baseline sentence scores between 51 - 60%.
16681275|NCT02075216|Experimental|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection
~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.
~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
16681276|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
16681277|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
16681278|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
16681279|NCT02075190|Experimental|Treatment Group|Participants randomized to receive remediation training intervention delivered online (60 days of online training)
16681280|NCT02075190|Active Comparator|Control Group|Participants randomized to receive online gaming intervention (60 days of online play)
16681281|NCT02075164|Experimental|Fructose|Volunteers will be challenged with oral 150g Fructose per day for 56 days.
16681282|NCT02075164|Experimental|Glucose|Volunteers will be challenged with oral 167g Fructose per day for 56 days.
16681283|NCT02075164|No Intervention|NAFLD|Patients with confirmed simple fatty liver will be compared at baseline with other arms.
16681284|NCT02075164|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
16681285|NCT02075151|Other|Bronchial Thermoplasty|Bronchial thermoplasty
16681286|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
16681287|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
16681288|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
16681289|NCT02075112|Experimental|Soy isoflavone|Study treatment: Soy isoflavone in combination with radiation therapy & cisplatin
16681290|NCT02075099|Experimental|Isotonic drink|"Predonation hydratation with 500 ml of isotonic drink, to drinking in immediate predonation.
~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
16681291|NCT02075099|Experimental|mineral water|"Predonation hydratation with 500 ml of mineral water to drinking in immediate predonation whole blood.
~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
16681292|NCT02075099|Active Comparator|Advices|"Advices of drinking water or fruit juice glass(es) in immediate predonation whole blood.
~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
16681293|NCT02075086|Experimental|Chemotherapy treatment|Chemotherapy treatment with Xelox or Xeliri and bevacizumab
16681294|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
16681295|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
16681296|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
16681297|NCT02075060|Experimental|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
16681298|NCT02075060|Active Comparator|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
16681299|NCT02075047|Placebo Comparator|1|
16681300|NCT02075047|Experimental|ziprasidone|
16681301|NCT02075034|Experimental|560 mg morning/280 mg afternoon|Two 280 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule of rigosertib will be taken in the afternoon.
16681302|NCT02075034|Experimental|420 mg morning and afternon|One 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the afternoon.
16681303|NCT02075034|Experimental|280 mg TID|One 280 mg capsule of rigosertib will be taken in the morning, one 280 mg capsule of rigosertib will be taken at mid-day, and one 280 mg capsule of rigosertib will be taken in the afternoon.
16681304|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
16681305|NCT02075008|Experimental|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
16681306|NCT02074995|Experimental|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
16681307|NCT02074995|Experimental|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
16681308|NCT02074995|Placebo Comparator|Placebo Group 1B/1C, 2, 3, 4|
16681309|NCT02074982|Experimental|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
16681310|NCT02074982|Active Comparator|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
16681311|NCT02074969|Active Comparator|Gamma Nail 3|Gamma Nail 3 Stryker.
16681312|NCT02074969|Active Comparator|PFNA|PFNA Antirotation Synthes
16681313|NCT02074956|Experimental|Cohort 1 AERAS-404|"H4 Antigen at 5 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
16681314|NCT02074956|Experimental|Cohort 2 AERAS-404|"H4 Antigen at 15 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
16681315|NCT02074956|Experimental|Cohort 3 AERAS-404|"H4 Antigen at 50 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
16681316|NCT02074956|Experimental|Cohort 4 AERAS-404|"H4 Antigen at 150 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
16681317|NCT02074956|Experimental|Cohort 5 AERAS-404|"H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer
~2 doses at Study days 0 and 56"
16681318|NCT02074943|Experimental|PRP/Saline|Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
16681319|NCT02074930|Other|Single Arm|
16681320|NCT02074917|Experimental|AM anatomical ACL reconstruction|Femoral and tibial tunnels performed in anteromedial footprint of ACL reconstruction
16681321|NCT02074917|Experimental|CENTRAL anatomical ACL reconstruction|Femoral and tibial tunnels performed in the center of ACL footprint
16681322|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
16681323|NCT02074904|Placebo Comparator|Placebo|placebo
16681324|NCT02074891||Persons prescribed PrEP|adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
16681325|NCT02074878|Experimental|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200mg, twice daily and Sunitinib 25.0mg once daily
16681326|NCT02074878|Experimental|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
16681327|NCT02074878|Experimental|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
16681328|NCT02074865||newborns|
16681329|NCT02074852||Immediate catheter removal|The catheter was removed immediately after the CS
16681330|NCT02074852||Delayed catheter removal|The catheter was removed 12 hours postoperatively
16681331|NCT02074839|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
16681332|NCT02074826||Atrial fibrillation|"Genotyping of the AF associated variants
~Measurement of the amount of left atrial fibrosis"
16681333|NCT02074813|No Intervention|Standard|conventional pulmonary rehabilitation
16681334|NCT02074813|Experimental|Inspiratory muscle training|Inspiratory muscle training associated with a conventional pulmonary rehabilitation
16681335|NCT02074800|Experimental|Part 1|Participants will receive either 1.4 or 2.8 mg/kg of either Sp2/0-derived CNTO 328 or CHO-derived CNTO 328 or placebo.
16681336|NCT02074800|Experimental|Part 2|Participants will receive 1.4 mg/kg of either Sp2/0-derived or CHO-derived CNTO 328.
16681337|NCT02074787||Adult burn injuries|Adult patients with burns injuries attending the regional burns unit at Chelsea & Westminster hospital between 48 and 72 hours post burn will be invited to take part in the study at the time of presentation to the unit.
16681338|NCT02074774|Experimental|IntellO2|Automated control of FiO2
16681339|NCT02074774|Active Comparator|Manual|Manual control of FiO2
16681340|NCT02074761||SImmetry Implant|Subjects who are indicated for the SImmetry device and meet the inclusion/exclusion criteria will receive a SImmetry implant.
16681341|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
16681342|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
16681343|NCT02074735|Placebo Comparator|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
16681344|NCT02074735|Active Comparator|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
16681345|NCT02074722||Healthy Subjects|Healthy Subjects
16681346|NCT02074709|Active Comparator|TAP block|TAP block with plain bupivacaine
16681347|NCT02074709|Active Comparator|Wound infiltration|Wound infiltration with liposomal bupivacaine
16681369|NCT02074553|Experimental|Part 1 (Fasted): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16689587|NCT02019654||1|Mild or moderate TBI within the past 30 days
16681348|NCT02074683|Active Comparator|YEAR A PATHWAY|"Operative Procedure will occur after screening visit.
~Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
~Follow-up visits:
~Post op Visit 1 (2 weeks +/- 5 days)
~Post op study visit 2 (1 month)
~Post op study visit 3 (2 month)
~Post op study visit 4 (6 month)
~Post op study visit 5 (12 month) CROSSOVER to YEAR B PathWay
~Post op study visit 6 (18 months)
~Post op study visit 7 (24 months)"
16681349|NCT02074683|Active Comparator|Year B Pathway|"Observational visits at 6 and 12 months with fat grafting procedures during year 2.
~Study visit 1 (month 6)
~Study Visit 2 (month 12)
~Collection of subject's medication profile, vital signs (Temp, HR, Resp, BP), and weight to calculate BMI,
~Limited physical exam with a foot exam completed by the PI and /or the Coinvestigator
~Adverse Event Reporting
~Ultrasound
~Pedobarograph
~2D Photographs
~Foot Pain Assessment Questionnaire
~Medical chart review including review of records from SOC podiatrists
~Operative Visit Followed by Post op study visits 2-5 as described in Year A Pathway"
16681350|NCT02074670|Experimental|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
16681351|NCT02074657|Experimental|Activated natural killer cells|
16681352|NCT02074644|Experimental|Prostatic Arterial Embolization|Selective catheterization of the prostatic arteries followed by slow injection of Bead Block 300-500 or PVA 100+200 micra particles under fluoroscopic control.
16681353|NCT02074644|Sham Comparator|Sham procedure|Selective catheterization of the prostatic arteries followed by removal of the catheter with no particles injected.
16681354|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
16681355|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
16681356|NCT02074618|Experimental|Physical Exercise|The program of physical exercise was a resistance and aerobic training, initiated at low intensity and with a slow progressing according to the patient's tolerance. In aerobic exercise, for greater effectiveness of the training, the literature recommends moderate intensity, which corresponds with 50 to 70% of the maximum heart rate. Patients were instructed to keep the most constant as possible the speed during exercise on treadmill or cycle ergometer. For muscle strengthening exercises, the number of repetitions varied from 1 to 4 sets of 10 to 15 repetitions.
16681357|NCT02074605||Observation|Patients with melanoma who qualify for interferon treatment, but choose not to receive it.
16681358|NCT02074605||Interferon alpha|Patients who receive high dose interferon alpha for 4 weeks
16681359|NCT02074592|Experimental|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
16681360|NCT02074592|Active Comparator|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
16681361|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
16681362|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
16681363|NCT02074566|Other|2 times 1|PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute
16681364|NCT02074566|Other|2 times 2|PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes
16681365|NCT02074566|Other|2 times 3|PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes
16681366|NCT02074553|Experimental|Part 1 (Fasted): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation (four 150 mg capsules) orally in Part 1 of the study according to following treatment sequences. Treatment A (Reference Treatment: formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (Test Treatment: formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (Test Treatment: formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (Test Treatment: formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681367|NCT02074553|Experimental|Part 1 (Fasted): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681368|NCT02074553|Experimental|Part 1 (Fasted): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681396|NCT02074358|Experimental|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
16681397|NCT02074345|Experimental|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
16690026|NCT02016885|Placebo Comparator|Vehicle|Vehicle Topical Wipes
16681370|NCT02074553|Experimental|Part 2 (Fed): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment A (formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681371|NCT02074553|Experimental|Part 2 (Fed): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681372|NCT02074553|Experimental|Part 2 (Fed): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681373|NCT02074553|Experimental|Part 2 (Fed): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
16681374|NCT02074540||Diabetes Type II Patients|
16681375|NCT02074514|Experimental|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
16681376|NCT02074514|Experimental|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
16681377|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making."
16681378|NCT02074488|Experimental|Fall Prevention Exercises|Participant provided with Balancing Act exercise curriculum for completion at least fifteen minutes three times a week over a six month period.
16681379|NCT02074488|Other|Informational brochure|Participant receives an informational brochure and orientation to brochure contents.
16681380|NCT02074475||Control group|The control group of three sites for larger Adequacy of Anaesthesia study. Total 150 patients
16681381|NCT02074436|Experimental|Prophylactic EACA|Prophylactic EACA 1000 mg PO twice daily if platelets < 20 x 10⁹/L
16681382|NCT02074436|Active Comparator|Platelet transfusion|Platelet transfusion if platelet count is < 20 x 10⁹/L in the outpatient or < 10 x 10⁹/L in the inpatient setting
16681383|NCT02074423|Experimental|MealShape cinnamon extract|Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)
16681384|NCT02074423|Placebo Comparator|Placebo|Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)
16681385|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
16681386|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
16681387|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
16681388|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
16681389|NCT02074397|Experimental|Distant extrafascial injection|Injection away from the brachial plexus with the needle tip positioned in the middle scalene muscle
16681390|NCT02074397|Active Comparator|Subfascial injection|Injection within the brachial plexus, with the needle tip positioned between C5 and C6
16681391|NCT02074384|Other|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
16681392|NCT02074384|Other|Self Monitoring Blood Glucose|Participants will self test for two weeks.
16681393|NCT02074384|Other|Clinicians|Clinicians completing study visits.
16681394|NCT02074358|Experimental|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
16681395|NCT02074358|Experimental|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
16691342|NCT02008383|Experimental|Cabozantinib|60 mg Cabozantinib PO daily.
16681400|NCT02074319|Placebo Comparator|Placebo|Matching placebo for methotrexate
16681401|NCT02074319|Experimental|Methotrexate|Methotrexate 10 mg once a week orally
16681402|NCT02074306|Experimental|UROSHIELD®|Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
16681403|NCT02074306|Sham Comparator|SHAM UROSHIELD®|same as abouve but with Sham device.
16681404|NCT02074293|Experimental|Splenius|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681405|NCT02074293|Experimental|Scalene|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681406|NCT02074293|Experimental|Sterno-cleido-mastoid|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681407|NCT02074293|Experimental|Levator Scapulae|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681408|NCT02074293|Experimental|Semispinalis|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681409|NCT02074293|Experimental|Trapezius|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681410|NCT02074293|Experimental|Longissimus|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681411|NCT02074293|Experimental|Change from Baseline in Pain Frequency|Change from Baseline in Pain Frequency as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
16681412|NCT02074293|Experimental|Change from Baseline in Pain Intensity|Change from Baseline in Pain Intensity as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The severity on scales of 0(no pain) to 4(constant or extremely severe intensity).
16681413|NCT02074293|Experimental|Change from Baseline in CDSS|Change from Baseline in CDSS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The CDSS or Cervical Dystonia Severity Scale quantifies the severity of abnormal head positioning and was newly devised for this study. CDSS allots 1 point for each 5 degrees (or part thereof) of head deviation in each of the three planes of head movement (range of scores up to theoretical maximum of 54).
16681414|NCT02074293|Experimental|Percent of Patients with Improved PGAS|Percent of Patients with Improved PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
16681415|NCT02074293|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681416|NCT02074293|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681417|NCT02074293|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681418|NCT02074293|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681419|NCT02074293|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681420|NCT02074293|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681421|NCT02074293|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681422|NCT02074293|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681423|NCT02074293|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681424|NCT02074293|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681425|NCT02074293|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681426|NCT02074280|Experimental|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
16681427|NCT02074280|Experimental|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
16681428|NCT02074280|No Intervention|control|conventional treatment
16681429|NCT02074267|Experimental|Carbatin|Carbatin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
16681430|NCT02074267|Active Comparator|Neurontin|Neurontin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
16681431|NCT02074241||Positive Expression|Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.
16681432|NCT02074241||Negative Expression|Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.
16681433|NCT02074228|Experimental|Methylphenidate|Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks
16681434|NCT02074215|Experimental|Aerobic exercises|90-minute exercise sessions per week for 12 weeks
16681435|NCT02074215|Active Comparator|Stretch exercise|90-minute exercise sessions per week for 12 weeks
16681436|NCT02074202|Experimental|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
16681437|NCT02074202|Active Comparator|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
16681438|NCT02074189|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
16681439|NCT02074189|No Intervention|Control|No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
16681440|NCT02074163|Experimental|Glabella|"Glabella
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681441|NCT02074163|Experimental|Frontal|"Frontal
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681442|NCT02074163|Experimental|Temporal|"Temporal
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681443|NCT02074163|Experimental|Occipital|"Occipital
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681444|NCT02074163|Experimental|Paraspinal|"Paraspinal
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681445|NCT02074163|Experimental|Trapezius|"Trapezius
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681446|NCT02074163|Experimental|Change in frequency of headache days|Change in frequency of headache days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
16681447|NCT02074163|Experimental|Change in hrs of HA on HA days|Change in hrs of HA on HA days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
16681448|NCT02074163|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681449|NCT02074163|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681450|NCT02074163|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681451|NCT02074163|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681452|NCT02074163|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681453|NCT02074163|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681454|NCT02074163|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681455|NCT02074163|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681456|NCT02074163|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681457|NCT02074163|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681458|NCT02074163|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681459|NCT02074150|Experimental|Biceps Brachii|"Biceps Brachii (elbow flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681460|NCT02074150|Experimental|Flexor Carpi Radialis|"Flexor Carpi Radialis (wrist flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681461|NCT02074150|Experimental|Flexor carpi ulnaris|"Flexor carpi ulnaris (wrist flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681462|NCT02074150|Experimental|Flexor digitorum profundus|"Flexor digitorum profundus (finger flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681463|NCT02074150|Experimental|Flexor digitorum sublimis|"Flexor digitorum sublimis (finger flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681464|NCT02074150|Experimental|Adductor pollicis|"Adductor pollicis (thumb flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681465|NCT02074150|Experimental|Flexor pollicis longus|"Flexor pollicis longus (thumb flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
16681466|NCT02074150|Experimental|Change from Baseline in Elbow Ashworth|"Change from Baseline in Elbow Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
16681467|NCT02074150|Experimental|Change from Baseline in Wrist Ashworth|"Change from Baseline in Wrist Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
16681468|NCT02074150|Experimental|Change from Baseline in Finger Ashworth|"Change from Baseline in Finger Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
16681469|NCT02074150|Experimental|Change from Baseline in Thumb Ashworth|"Change from Baseline in Thumb Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
16681470|NCT02074150|Experimental|Change from Baseline in PGAS|Change from Baseline in PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
16681471|NCT02074150|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30
16681472|NCT02074150|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681473|NCT02074150|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681474|NCT02074150|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681475|NCT02074150|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681476|NCT02074150|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681477|NCT02074150|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681478|NCT02074150|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681479|NCT02074150|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681480|NCT02074150|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681481|NCT02074150|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
16681482|NCT02074137|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
16681483|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
16681484|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
16681485|NCT02074111||Intracranial atherosclerotic stroke|
16681486|NCT02074111||Moyamoya disease|
16681487|NCT02074111||Healthy controls|
16681488|NCT02074098|Experimental|a 65 cm bed height|1) Bed height : approximately 65cm (Lowest)
16681489|NCT02074098|Experimental|a 95cm bed height|2) Bed height : approximately 95cm (highest)
16681490|NCT02074072|Experimental|Direct laryngoscope|Macintosh laryngoscope
16681491|NCT02074072|Experimental|Videolaryngoscope-1|Glidescope
16681492|NCT02074072|Experimental|Videolaryngoscope-2|Airwayscope
16681493|NCT02074059|Experimental|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
16681494|NCT02074059|Experimental|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
16681495|NCT02074059|Experimental|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
16681496|NCT02074059|Experimental|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
16681497|NCT02074059|Experimental|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
16681498|NCT02074059|Active Comparator|nCPAP alone|nCPAP therapy alone
16681499|NCT02074046|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16681500|NCT02074046|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16681501|NCT02074046|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16681502|NCT02074046|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
16681503|NCT02074033||antibiotics for pneumonia|We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )
16681504|NCT02074020|Experimental|Blisibimod|
16681505|NCT02074020|Placebo Comparator|Placebo|
16681506|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops
~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
16681507|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops
~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
16681508|NCT02073994|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
16681509|NCT02073981||Parkinson Disease|
16681510|NCT02073968|Experimental|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.
~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.
~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC > 1500, and platelet count > 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
16681511|NCT02073955||Pakistani adults|"Men and women aged 40 and above, residing in Ibrahim Hyderi (periurban Pakistani community)
~Consenting to Interview about stroke symptoms"
16681512|NCT02073929|Active Comparator|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
16681513|NCT02073929|Placebo Comparator|Placebo|Placebo s.c. daily for 26 weeks
16681514|NCT02073916|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 with Laptinib followed by Abraxane
16681515|NCT02073903||LEP inpatients and their providers|This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
16681516|NCT02073890||traumatic subarachnoid haemorrhage|
16681517|NCT02073877||Controls - Holgers 0 & 1|
16681518|NCT02073877||Cases - Holgers >1 (active peri-implant dermatitis)|
16681519|NCT02073851|Experimental|TriGuard™HDH|Patients undergoing TAVR will be treated wIth experimental device TriGuard™HDH
16681520|NCT02073838|Experimental|Ribavirin, vismodegib, decitabine|Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
16681521|NCT02073838|Experimental|Ribavirin, vismodegib|Ribavirin 1400mg BID, vismodegib 150mg QD
16681522|NCT02073825|Experimental|Web Brief Intervention (WBI)|4-session WBI
16681523|NCT02073825|No Intervention|Delayed-WBI|4-session WBI after follow-up
16681524|NCT02073812|Experimental|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
16681525|NCT02073799||Photoselective vaporization of the prostate|Patients who underwent photoselective vaporization of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
16681526|NCT02073799||Holmium laser enucleation of the prostate|Patients who underwent holmium laser enucleation of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
16681527|NCT02073786|Active Comparator|Lightwand|Conventional lightwand intubation will performe for intubation
16681528|NCT02073786|Experimental|Optiscope|Rigid video stylet, manufactural named Optiscope, will perform for intubation
16681566|NCT02073487|Active Comparator|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
16681567|NCT02073474||Sativex® users|UK: All patients and who are prescribed Sativex®. Germany and Sweden: Patients who are prescribed Sativex® from selected specialist neurology centres.
16681568|NCT02073461|Experimental|CD1579 2.5%|Benzoyl Peroxide 2.5%
16681529|NCT02073773|Experimental|Virtual Reality based therapy, levodopa|"The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
16681530|NCT02073773|Active Comparator|occupational therapy, levodopa|"The control group will receive and additional half an hour per working day of standard occupational therapy.
~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
16681531|NCT02073760||Infection Prevention Experts|Adult caregivers of cardiac surgery patients (e.g. surgeons, nurses, infection preventionists) and administrators
16681532|NCT02073747|Placebo Comparator|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
16681533|NCT02073747|Active Comparator|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
16681534|NCT02073734|Experimental|Dexamethasone|Dexamethasone
16681535|NCT02073734|Placebo Comparator|Placebo|Sterile normal saline solution
16681536|NCT02073721|Experimental|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.
16681537|NCT02073721|Active Comparator|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor
16681538|NCT02073695|Other|Neutral Rotation Brace|Neutral Rotation Brace
16681539|NCT02073695|Other|Standard polysling (Current practice)|Standard polysling (Current practice)
16681540|NCT02073682|Experimental|Edoxaban group|After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
16681541|NCT02073682|Active Comparator|Dalteparin group|Participants receive Dalteparin treatment daily -solution for subcutaneous injection
16681542|NCT02073669|Other|Second generation immigrants from high TB incidence countries|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
16681543|NCT02073669|Other|Native Israelis|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
16681544|NCT02073656|Experimental|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
16681545|NCT02073656|Experimental|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
16681546|NCT02073630|Other|Healthy subjects|healthy subjects will receive either sham or active cerebellar stimulation
16681547|NCT02073630|Other|Dystonia|dystonic patients will receive either sham or active cerebellar stimulation
16681548|NCT02073617|Experimental|Real-time 3-dimensional DynaCT|Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
16681549|NCT02073604|Other|Healthy volunteers|Healthy volunteers
16681550|NCT02073604|Other|Congenital mirror movements|Patients presenting with congenital mirror movements
16681551|NCT02073591||Ceradan Regimen|Ceradan Cream and Ceradan Wash
16681552|NCT02073578|Other|Treatment|Peroral Endoscopic Myotomy (POEM)
16681553|NCT02073565|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
16681554|NCT02073565|Active Comparator|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
16681555|NCT02073552|Active Comparator|High volume|"Two 5 mg bisacodyl tablets It is a stimulant laxative with local action.
~Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate."
16681556|NCT02073552|Experimental|Low volume|"Two 5 mg bisacodyl tablets, taken in the same way as for the high volume group.
~Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid."
16681557|NCT02073539|Experimental|chest compression with 5cm feedback|We will feedback by one accelerometer (U-cpr). U-cpr is android based smartphone application.
16681558|NCT02073539|Experimental|chest compression with 6cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
16681559|NCT02073539|Experimental|chest compression with 7cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
16681560|NCT02073526||Anti-TNF|Inflammatory bowel patients age 18 and over treated with anti-TNF agents
16681561|NCT02073513|Experimental|kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied which controled the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.
~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
16681562|NCT02073513|Experimental|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
16681563|NCT02073513|No Intervention|Control Group (CG)|No application.
16681564|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
16681565|NCT02073487|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
16681569|NCT02073461|Experimental|CD1579 5%|Benzoyl Peroxide 5%
16681571|NCT02073448|Experimental|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
16681572|NCT02073448|Active Comparator|CD0271|Adapalene 01% Gel
16681573|NCT02073448|Active Comparator|CD1579|Benzoyl Peroxide 2.5% Gel
16681574|NCT02073435||Post-Implementation Group|Living Donor Liver Transplant patients with evidence based donor pain management solution.
16681575|NCT02073435||Pre-Implementation Group|Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
16681576|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
16681577|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
16681578|NCT02073396||Patients|Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.
16681579|NCT02073383|Experimental|Around Artery|"Intervention Name: Axillary brachial plexus block
~Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 ."
16681580|NCT02073383|Experimental|Two injections|Group 2: 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position .
16681581|NCT02073383|Active Comparator|Perineural|Group Perineural : 10 ml of bupivacaine 0.375 % will be injected around the median, ulnar and radial nerves .
16681582|NCT02073370||health subjects; outpatients aged over 65|The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
16681583|NCT02073357|Experimental|Light general anaesthesia (BIS = 50)|Light general anaesthesia
16681584|NCT02073357|Experimental|deep general anaesthesia (BIS = 35)|deep general anaesthesia
16681585|NCT02073344|Experimental|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
16681586|NCT02073344|Experimental|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
16681587|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
16681588|NCT02073318|Experimental|Balance training|
16681589|NCT02073318|Active Comparator|Control|Control group received 4 weeks upper extremities exercise in sitting position
16681590|NCT02073305||No sleep apnea|Subjects with no or light sleep apnea (AHI < 15/h)
16681591|NCT02073305||Sleep Apnea - untreated|"Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.
~Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol."
16681592|NCT02073305||Sleep Apnea - treated|Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.
16681593|NCT02073292|Experimental|c-RFA|cooled radiofrequency ablation
16681594|NCT02073292|Active Comparator|t-RFA|thermal radiofrequency ablation
16681595|NCT02073279|Experimental|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
16681596|NCT02073279|Placebo Comparator|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
16681597|NCT02073266|Active Comparator|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
16681598|NCT02073266|Active Comparator|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
16681599|NCT02073253|No Intervention|Without performing any operation (Phase Control)|
16681600|NCT02073253|Experimental|With ventilatory support through NIV (NIV Phase)|
16681601|NCT02073240||Enhanced TB IC Package|"Facilities randomized to the intervention group will receive the following:
~Skills-based training for TB IC focal points
~Audits and Feedback of performance data
~TB IC collaborative (including mentoring)
~Checklists"
16681602|NCT02073240||Usual Care Group|Usual Care group will receive available TB IC training/education alone.
16681603|NCT02073227|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
16681604|NCT02073227|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
16681605|NCT02073227|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
16681633|NCT02073071||Preterm/low birth weight infants|Preterm infant formula per standard of care
16681699|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
16681700|NCT02072551||Adult with neonatal diabetes|Adult with neonatal diabetes (before 1 year ) and need for insulin
16681606|NCT02073214|Experimental|Probiotic|"Single dose of probiotic, was administered enterally twice daily with food (in the morning and in the evening). The first dose of probiotic was administered within the first 48 hours after birth. The probiotic administration was continued for 6 weeks or until hospital discharge (whichever was earlier).
~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the probiotic. If the probiotic was discontinued for more than 7 days, the patient was withdrawn from the study."
16681607|NCT02073214|Placebo Comparator|Placebo|"Single dose of placebo was administered enterally twice daily with food (in the morning and in the evening). The first dose of placebo was administered within the first 48 hours after birth. The placebo administration was continued for 6 weeks or until hospital discharge (whichever was earlier).
~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the placebo. If the placebo was discontinued for more than 7 days, the patient was withdrawn from the study."
16681608|NCT02073201||High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
16681609|NCT02073201||Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
16681610|NCT02073201||Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
16681611|NCT02073188|Experimental|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
16681612|NCT02073188|Active Comparator|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
16681613|NCT02073175|Experimental|Postpartum with crying spells-Full dose|"Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.
~Intervention: Full dose dietary supplement Motherwell"
16681614|NCT02073175|Experimental|Day-5 postpartum - Full dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.
~Intervention: Full dose dietary supplement Motherwell"
16681615|NCT02073175|Experimental|Day-5 postpartum - Half dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.
~Intervention: Half dose dietary supplement Motherwell"
16681616|NCT02073175|Experimental|Day-5 postpartum - Quarter dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.
~Intervention: Quarter dose dietary supplement Motherwell"
16681617|NCT02073175|Other|Day-5 postpartum - Control|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.
~Intervention: Control protein to compare with Motherwell"
16681618|NCT02073162|Active Comparator|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
16681619|NCT02073162|Experimental|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
16681620|NCT02073149|Active Comparator|Low-dose iron as NaFeEDTA|Daily point-of-care fortification of (complementary) foods with 3 mg iron as NaFeEDTA.
16681621|NCT02073149|Active Comparator|Conventional dose iron as ferrous salt|Daily point-of-care fortification of (complementary) foods with 12.5 mg iron as encapsulated ferrous fumarate.
16681622|NCT02073149|Placebo Comparator|Placebo|Daily point-of-care fortification of (complementary) foods with placebo.
16681623|NCT02073136|Experimental|Phosphate modified diet|
16681624|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.
~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).
~Patients will continue until they experience disease progression or limiting toxicity."
16681625|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.
~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
16681626|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.
~Nivolumab administered intravenously at 240 mg every 2 weeks."
16681627|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
16681628|NCT02073097|Experimental|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):
~Rituximab IV over at least 90 minutes on day 2
~Carfilzomib IV over 30 minutes on days 1, and 2
~Cyclophosphamide IV over 30-60 minutes on day 3
~Doxorubicin hydrochloride IV over 3-5 minutes on day 3
~Vincristine sulfate IV over 1 minute on day 3
~Prednisone PO on days 3-7 any time
~Pegfilgrastim day 4
~Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
16681629|NCT02073084|Other|Sequence A|Sequence A
16681634|NCT02073045|Experimental|Supportive care (lymphedema education)|In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
16681635|NCT02073032||Head -Neck cancer patients, no intervention|
16681636|NCT02073019|Experimental|Cohort A|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
16681637|NCT02073019|Experimental|Cohort B|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
16681638|NCT02073019|Experimental|Cohort C|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
16681639|NCT02073006|Active Comparator|Natural Fibre Supplement|2 doses per day for 4 weeks
16681640|NCT02073006|Placebo Comparator|Placebo|2 doses per day for 4 weeks
16681641|NCT02072993|Experimental|AZD1979|Single ascending doses of oral solution AZD1979
16681642|NCT02072993|Placebo Comparator|Placebo|Placebo to match single ascending doses of oral solution AZD1979
16681643|NCT02072980|Other|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
16681644|NCT02072980|Other|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
16681645|NCT02072967||Ribomustin and rituximab|
16681646|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
16681647|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
16681648|NCT02072941|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
16681649|NCT02072941|No Intervention|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
16681650|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
16681651|NCT02072915|Experimental|Suction|Suction will be applied to patients undergoing EUS-FNA
16681652|NCT02072915|No Intervention|Without suction|No suction will be applied to patients undergoing EUS-FNA
16681653|NCT02072902||diabetes free|No intervention
16681654|NCT02072902||Diabetes prevalent|The exposure is diabetes morbidity present at study entery
16681655|NCT02072902||Diabetes incidence|The exposure is diabetes incidence during study follow up
16681656|NCT02072889|Experimental|Neck Angle Measures|Subjects will position his/her neck in order to measure distance between the internal jugular and the carotid artery to determine if there is a maximal distance to target prior to cannulation
16681657|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
16681658|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
16681659|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.
~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
16681660|NCT02072850||Myocardial infarction|Patients presenting with acute-ST elevation myocardial infarction referred for emergency invasive management by primary or rescue percutaneous coronary intervention.
16681661|NCT02072824|Experimental|Study Drug Level 1|
16681662|NCT02072824|Experimental|Study Drug Level 2|
16681663|NCT02072824|Placebo Comparator|Placebo|
16681664|NCT02072811|Other|Induction, DAC|"The first stage of treatment.
~First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
16681665|NCT02072811|Other|II early induction, CLAG|"Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16 day.
~Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day"
16681666|NCT02072811|Other|Consolidation, I HAM cycle|"I induction cycle starts after complete remission (CR).
~- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):
~If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation
~- After I consolidation, patients from Adverse risk group (ELN prognostic system):
~If compatible donor is present - immediate qualification for allogeneic HSCT.
~- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
16681697|NCT02072603|Active Comparator|Control Hospitals|Existing standard of EID care
16681698|NCT02072577|Experimental|Knowledge|Educational video.
16681667|NCT02072811|Other|II Consolidation HiDAraC|"Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.
~Patients form Very adverse risk receive Maintenance treatment:
~Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.
~Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
16681668|NCT02072811|Other|Consolidation, III HiDAraC cycle|"Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).
~Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
16681669|NCT02072798|Active Comparator|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
16681670|NCT02072798|Active Comparator|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
16681671|NCT02072785|Experimental|Vincristine Sulfate Liposome|"Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.
~Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
16681672|NCT02072785|Active Comparator|Vincristine Sulfate|"Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.
~Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
16681673|NCT02072772|Experimental|Positively Smoke Free group treatment|"Eight 90 minute group sessions (6-8 HIV-infected smokers per group) led by a pair of trained group leaders: a professional with psychology or social work training and a peer HIV-infected ex-smoker with tobacco treatment training.
~All subjects will be offered a 3 month supply of nicotine patches"
16681674|NCT02072772|Active Comparator|Standard care|Brief (<5 minutes) advice to quit Offer of nicotine patches Self-help brochure
16681675|NCT02072759|Experimental|Carnitine supplement|Carnitine supplement
16681676|NCT02072759|Placebo Comparator|Placebo|Placebo supplement
16681677|NCT02072759|No Intervention|Healthy control|Healthy control group
16681678|NCT02072746|Active Comparator|Zinc|zinc sulfate 220 mg daily
16681679|NCT02072746|Placebo Comparator|Placebo|Placebo study for comparison
16681680|NCT02072733|Other|geriatric assessment|"The intervention is individual and based on the Comprehensive Geriatric assessment (CGA) : collection of information on comorbidity, polypharmacy, physical, psychological and cognitive functions, nutrition as well as social status and support.
~The results of the CGA, the eventual medical changes and recommendations regarding e.g. initiation of nutritional supplementation, home-care referral or referral to e.g. physiotherapist will be forwarded to the general practitioner and to the oncologist in charge of the treatment"
16681681|NCT02072720|No Intervention|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
16681682|NCT02072720|Experimental|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
16681683|NCT02072707|Active Comparator|Epicardial VT ablation|Patients will underwent combined epicardial and endocardial mapping and ablation
16681684|NCT02072707|Active Comparator|Endocardial VT Ablation|Patients will underwent endocardial only VT mapping and ablation
16681685|NCT02072694|Experimental|75 grams of glucose plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water.
~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water."
16681686|NCT02072694|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge).
~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge)."
16681687|NCT02072681||Mild and Rapidly Improving Ischemic Stroke|"Patients 18 years or older with mild or rapidly improving acute ischemic stroke defined clinically. .Absence of non-ischemic conditions neuro-imaging (i.e. absence of hemorrhage or a mass on brain imaging that arrived to the hospital within 4.5 hours after the onset of stroke symptoms.
~All participants will have two follow up telephone calls: One at approximately 30 days after the stroke and one at approximately 90 days after the stroke to ask questions about how well participant can carry out usual duties after the stroke, how much assistance do he/she needs to perform your daily activities and how good or bad would he/she considers current health to be."
16681688|NCT02072668|Other|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
16681689|NCT02072668|Other|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
16681690|NCT02072655|No Intervention|without socio-asthetic care|
16681691|NCT02072655|Experimental|with socio-aesthetic cares|
16681692|NCT02072642|Active Comparator|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
16681693|NCT02072642|Placebo Comparator|Placebo light therapy (70 lux)|Placebo light therapy
16681694|NCT02072629|Experimental|Training of VHVs in iCCM|In these villages VHVs will be provided with iCCM training and equipped to support iCCM in their villages
16681695|NCT02072616|Experimental|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done after Pancreatic adenocarcinoma diagnosis
16681696|NCT02072603|Experimental|Intervention Hospitals|HITSystem implementation at hospital and its affiliated laboratory
16681701|NCT02072551||non diabetic adults with a relative with neonatal diabetes|
16681702|NCT02072538||Pre-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
16681703|NCT02072538||Post-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
16681704|NCT02072525|Experimental|Mtdap1 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
16681705|NCT02072525|Experimental|Mtdap2 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
16681706|NCT02072525|Experimental|Mtdap3 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
16681707|NCT02072525|Experimental|Pneum1 Group|Subjects will receive a dose of Pneumovax 23.
16681708|NCT02072525|Experimental|Pneum2 Group|Subjects will receive a dose of Pneumovax 23.
16681709|NCT02072525|Experimental|Pneum 3 Group|Subjects will receive a dose of Pneumovax 23.
16681710|NCT02072525|Experimental|Prev1 Group|Subjects will receive a dose of Prevnar 13.
16681711|NCT02072525|Experimental|Prev2 Group|Subjects will receive a dose of Prevnar 13.
16681712|NCT02072525|Experimental|Prev3 Group|Subjects will receive a dose of Prevnar 13.
16681713|NCT02072512|Active Comparator|Fulvestrant|Goserelin plus High Dose Fulvestrant
16681714|NCT02072512|Active Comparator|Anastrozole|Goserelin plus Anastrozole
16681715|NCT02072499|Experimental|KTP Green Light Prostatectomy|Device
16681716|NCT02072499|Active Comparator|Open prostatectomy|Surgical procedure
16681717|NCT02072486|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
16681718|NCT02072473||Unsuccessful right-sided AVNRT ablation|Patients with unsuccessful right-sided slow pathway ablation attempt, will be candidates for Coronary sinus / left-sided slow pathway ablation.
16681719|NCT02072460|Experimental|vestibular signals determination|vestibular signals determination by electromyography and electroencephalography associated to approaches from psychophysics
16681720|NCT02072447|Experimental|Microdose|
16681721|NCT02072434|Experimental|Edoxaban|Edoxaban oral tablet, 60 mg-once daily (QD), reduced to 30 mg based on protocol-defined parameters, for up to 49 days
16681722|NCT02072434|Active Comparator|Warfarin|"Participants naïve to anticoagulation, taking anticoagulants other than a Vitamin K antagonist (VKA) or taking a VKA but with a prothrombin time (PT) international normalized ratio (INR) of less than 2.0 receive enoxaparin until they reach a PT INR of at least 2.0, before taking warfarin.
~All participants in this arm receive warfarin oral tablet QD at their doctor's prescribed dose, for up to 49 days."
16681723|NCT02072421|Other|Non-SOS|
16681724|NCT02072408|Experimental|polypoidal choroidal vasculopathy without polyp|
16681725|NCT02072395|Experimental|Band/Plication|Treatment -- band/plication
16681726|NCT02072382|Experimental|Metformin|Metformin 850 mg twice a day for eight weeks versus Placebo
16681727|NCT02072369|Experimental|VAEDA Glove|Voice And EMG-Driven Actuated glove used during hand occupational therapy training
16681728|NCT02072369|Active Comparator|No-glove|hand occupational therapy sessions without assistive device
16681729|NCT02072356|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
16681730|NCT02072343|Experimental|Mainstream capnometer|
16681731|NCT02072343|Experimental|Microstream capnograph|
16681732|NCT02072330|Active Comparator|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
16681733|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
16681734|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
16681735|NCT02072330|Active Comparator|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
16681736|NCT02072330|Active Comparator|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
16681737|NCT02072317|Experimental|Paclitaxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
16681738|NCT02072317|Active Comparator|taxol|taxol 135 mg/m2, every three weeks for a cycle
16681739|NCT02072304|Experimental|web-based CBT|Web-based CBT group : The intervention is made up of 8 internet modules based on behavioral activation, cognitive behavioral therapy
16681740|NCT02072304|Active Comparator|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks
16681741|NCT02072291|Experimental|Nifedipine|Nifedipine 5mg single dose
16681742|NCT02072291|Placebo Comparator|Placebo|
16681743|NCT02072278|Experimental|Vortioxetine 10 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
16681744|NCT02072278|Experimental|Vortioxetine 20 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
16681745|NCT02072278|Active Comparator|Escitalopram 15 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
16681746|NCT02072278|Placebo Comparator|Placebo|capsules; 3 daily doses in each treatment period; orally
16681747|NCT02072265||Port-A implantation and chemotherapy|Patients scheduled for Port-A implantation and subsequent chemotherapy
16681748|NCT02072265||Port-A infection|Patients receiving Port-A removal due to infection
16681749|NCT02072252|Experimental|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
16681821|NCT02071810|Experimental|Placebo|Placebo, PLC
16682033|NCT02070354||Group 1|New clinic visit in GI Nutrition (prior to bariatric surgery).
16681750|NCT02072252|No Intervention|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
16681751|NCT02072239|Experimental|Device Applied|All participants will be treated with the Angioshield
16681752|NCT02072226|Active Comparator|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
16681753|NCT02072226|Experimental|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
16681754|NCT02072213|Experimental|GL2702 GLARS-NF1 , fasted|Tamsulsoin 0.4mg
16681755|NCT02072213|Active Comparator|Omix Ocas® , fasted|Tamsulsoin 0.4mg
16681756|NCT02072213|Experimental|GL2702 GLARS-NF1, after meal|Tamsulsoin 0.4mg
16681757|NCT02072213|Active Comparator|Omix Ocas®, after meal|Tamsulsoin 0.4mg
16681758|NCT02072200|Experimental|Modified release prednisone|Single arm / Lodotra
16681759|NCT02072187|Experimental|Active|"The vitamin D formula that will be used is Bio-D Mulsion 1000, produced by Biotics Research Corporation. This formula contains: Vitamin D (cholecalciferol), water and acacia gum and sesame oil.
~Participants will be provided with a dose of vitamin D at each visit beginning at the Baseline visit. The weekly dose of vitamin D will be 28 000IU (the equivalent of 4000IU daily) for a period of eight weeks. If baseline or week 4 serum vitamin D levels are measured as >100nmol/L, the dose will be reduced to 14 000IU (the equivalent of 2000IU daily). The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
16681760|NCT02072187|Placebo Comparator|Placebo|"The placebo formula, also produced by Biotics Research Corporation, will contain all of the non-medicinal ingredients but no vitamin D. It will be identical in appearance and taste.
~Participants will be provided with a dose of the placebo at each visit beginning at the Baseline visit. The weekly dose will be 28 drops or 14 drops if serum Vitamin D levels are >100nmol/L. The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
16681761|NCT02072174|Experimental|Anaferon for Children|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
16681762|NCT02072174|Placebo Comparator|Placebo|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
16681763|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
16681764|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
16681765|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
16681766|NCT02072148|Experimental|Low Risk Group I|"Group I:
~Complete resection (margins: tonsil >1mm, tongue >3mm, pT1-2, pN0-2B),
~No LVI, no PNI, <3 positive nodes.
~No ECS, No matted or Level >III,"
16681767|NCT02072148|Experimental|Intermediate Risk Group II|"Group II
~Complete resection (margins: tonsil <1mm, tongue <1mm, pT1-2, pN0-2B),
~+LVI, +PNI, <3 positive nodes. ≤1mm ECS."
16681768|NCT02072148|Experimental|High Risk Group IIIA|"3+ nodes, no ECS > 1mm
~Contralateral or supraclavicular nodes"
16681769|NCT02072148|Experimental|High Risk Group IIIB|"Incomplete surgical resection with + surgical margins
~≥ 1 mm ECS
~Matted nodes"
16681770|NCT02072135|Experimental|Exparel|Exparel 266mg
16681771|NCT02072122||women during fertility treatment|
16681772|NCT02072109||Bolus feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
16681773|NCT02072109||Continuous feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
16681774|NCT02072096|Experimental|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
16681775|NCT02072096|Active Comparator|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
16681776|NCT02072083|Active Comparator|dexmedetomidine|intranasal 1mcg/kg
16681777|NCT02072083|Active Comparator|ketamine|intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
16681778|NCT02072070|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
16681779|NCT02072070|Placebo Comparator|Placebo|Single intra-articular injection to the damaged knee joint
16681780|NCT02072057|Experimental|Ruxolitinib|Interventional arm
16681781|NCT02072044|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16681782|NCT02072031|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16681783|NCT02072031|Active Comparator|Sunitinib maleate|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
16681784|NCT02072018|Active Comparator|H-100|H-100, gel, daily, 6 months
16681785|NCT02072018|Placebo Comparator|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
16681786|NCT02072005||Regular cigarette smokers|
16681822|NCT02071797|Active Comparator|Arm A - Blanketroll lll|Cutaneous Cooling Blanket, Blanketroll lll, applied to cool patient to 32C. Standard care
16681823|NCT02071797|Active Comparator|Arm B - RhinoChill|Intra nasal cooling system, RhinoChill, to cool patient to 32C - Standard care
16682032|NCT02070367|Active Comparator|Usual treatment|Treatment as usual for condition Physiotherapy sessions
16681787|NCT02071979|Experimental|Autologous PRP Gel|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. The application of topical PRP gel may be used in chronic wounds possessing an open, moist wound bed according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical application) data.
16681788|NCT02071979|Experimental|Autologous PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Autologous PRP Injections may be used where chronic wounds possess a raised, hyperproliferative wound margin and/or plaque, according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare Autologous PRP for injections. For data analysis, the data from these patients will be classified as PRP Treatment Group (Direct Injection) data.
16681789|NCT02071979|Experimental|Autologous PRP Gel plus PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Some wounds may be suitable for both Autologous PRP Gel plus PRP Injections. Autologous PRP injections into, or to the periphery of, a moist wound bed in which no scarification or raised wound margin is apparent (where autologous PRP Gel can also be used) may further augment wound healing by addressing wound healing in multiple areas, following the treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical and Direct) data.
16681790|NCT02071979|No Intervention|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices. For data analysis, the data from these patients will be classified as Control (Standard of Care) Group data
16681791|NCT02071966|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
16681792|NCT02071966|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
16681793|NCT02071953|Experimental|Adhesive without acid pretreatment|Experimental adhesive w/out phosphoric acid in post. rest.
16681794|NCT02071953|Active Comparator|Adhesive with acid pretreatment|Experimental adhesive with phosphoric acid in post. rest.
16681795|NCT02071940|Experimental|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
16681796|NCT02071927|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
16681797|NCT02071927|Experimental|CB-Aza|CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity
16681798|NCT02071914|Experimental|CT-P27 10mg/kg|CT-P27 will be administrated once in IV infusion.
16681799|NCT02071914|Experimental|CT-P27 20mg/kg|CT-P27 will be administrated once in IV infusion.
16681800|NCT02071914|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
16681801|NCT02071901|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach >= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
16681802|NCT02071888|Experimental|CB-839|CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity
16681803|NCT02071888|Experimental|CB-839 and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity
16681804|NCT02071888|Experimental|CB-839, pomalidomide, and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity
16681805|NCT02071875||Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording
16681806|NCT02071862|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
16681807|NCT02071862|Experimental|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
16681808|NCT02071862|Experimental|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
16681809|NCT02071862|Experimental|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
16681810|NCT02071862|Experimental|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
16681811|NCT02071862|Experimental|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
16681812|NCT02071849|Experimental|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
16681813|NCT02071836|Experimental|Right Turns web application|Right Turns web application
16681814|NCT02071836|Active Comparator|Treatment as usual|Treatment as usual
16681815|NCT02071823|Experimental|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:
~Period 1: Fed Washout Period (7days) Period 2: Fasted"
16681816|NCT02071823|Experimental|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:
~Period 1: Fasted Washout Period (7days) Period 2: Fed"
16681817|NCT02071810|Experimental|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
16681818|NCT02071810|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
16681819|NCT02071810|Experimental|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
16681820|NCT02071810|Experimental|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
16681824|NCT02071771|Other|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
16681825|NCT02071771|Other|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
16681826|NCT02071758|Experimental|20 mcg LEISH-F3 + 5 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and low dose of SLA-SE adjuvant.
16681827|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of GLA-SE adjuvant.
16681828|NCT02071758|Experimental|5 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of GLA-SE adjuvant.
16681829|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of SLA-SE adjuvant.
16681830|NCT02071745||Navigation|
16681831|NCT02071732|Active Comparator|Real rTMS|Real rTMS is real continuous theta burst stimulation.
16681832|NCT02071732|Sham Comparator|Sham rTMS|Sham rTMS is sham continuous theta burst stimulation.
16681833|NCT02071719||Sunitinib|
16681834|NCT02071719||Sorafenib|
16681835|NCT02071719||Everolimus|
16681836|NCT02071719||Pazopanib|
16681837|NCT02071719||Axitinib|
16681838|NCT02071706|Other|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
16681839|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|123I-mIBG administration followed by nuclear imaging pre-ablation and post-ablation
16681840|NCT02071667||Subjects who require sinus surgery|
16681841|NCT02071654|Experimental|Venus P-valve transcatheter implantation|Single arm of percutaneous implantation of Venus-P valve for treating RVOT stenosis
16681842|NCT02071641|Experimental|Sunitinib|Patients will be treated in repeated 6-week cycles with 50 mg sunitinib orally daily for 4 weeks followed by 2 weeks off.
16681843|NCT02071615|Experimental|Methylphenidate and placebo|Placebo or Methylphenidate 20 mg tablet given once by mouth
16681844|NCT02071615|Experimental|modafinil and placebo|placebo or modafinil 200mg tablet given once by mouth
16681845|NCT02071615|Experimental|caffein and placebo|placebo or caffein 200mg tablet given once by mouth
16681846|NCT02071602|Placebo Comparator|Placebo|Placebo infused for up to 72 hours IV
16681847|NCT02071602|Active Comparator|CD-NP 5 ng/kg/min|CD-NP 5 ng/kg/min infused for up to 72 hours IV
16681848|NCT02071602|Placebo Comparator|CD-NP 10 ng/kg/min|CD-NP 10 ng/kg/min infused for up to 72 hours IV
16681849|NCT02071589|Experimental|Nifedipine oral solution|Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose
16681850|NCT02071589|Active Comparator|Nifedipine soft gelatine capsules|Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose
16681851|NCT02071576|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes
16681852|NCT02071563|Active Comparator|CSB14|Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).
16681853|NCT02071563|Active Comparator|RUSF1|Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product
16681854|NCT02071563|Active Comparator|SC+|Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour
16681855|NCT02071563|No Intervention|CSB+|Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.
16681856|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
16681857|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
16681858|NCT02071537|Experimental|Chloroquine with Carboplatin/Gemcitabine|Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
16681859|NCT02071524|Active Comparator|Cristalloid|group cristalloid (ringer lactate)
16681860|NCT02071524|Active Comparator|colloids|colloid: cristalloid in according to cardiac output
16681861|NCT02071511|Active Comparator|control group|Ablation of ventricular arrhythmias
16681862|NCT02071511|Sham Comparator|intervention group|Ablation of ventricular arrhythmias + renal denervation
16681863|NCT02071498|Experimental|Pillbox app named ALICE|pillbox app for elderly patients taking multiple medications. App was used during three months
16681864|NCT02071498|Active Comparator|oral and written information|oral and written information regarding the main risks related to their medications and the most common errors of patients
16681865|NCT02071485||No treatment|Subjects in this study will receive no treatment and rather will only be trained in using the motor imagination-based BCI system
16681866|NCT02071472|Experimental|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
16681867|NCT02071472|No Intervention|control|conventional anesthesiologist consultation for planned surgery patients
16681868|NCT02071459|Experimental|L-Threo DOPS|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS
16681869|NCT02071459|Placebo Comparator|placebo|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo
16681870|NCT02071433|Experimental|Saphenous nerve blockade|Experimental treatment 15 mL of levobupivacaine 0.5%
16681871|NCT02071433|Active Comparator|Femoral nerve blockade|Standard treatment 15 mL of levobupivacaine 0.5%
16681872|NCT02071420|Experimental|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
16681873|NCT02071420|Active Comparator|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
16681874|NCT02071407|Placebo Comparator|N1(traditional treatment group)|Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
16681875|NCT02071407|Experimental|N2(midazolam group)|Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
16681876|NCT02071394|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
16681877|NCT02071394|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
16681878|NCT02071381|Experimental|A|only DW330SR 45mg
16681879|NCT02071381|Experimental|B|only DW1030 75mg
16681880|NCT02071381|Experimental|C|DW330SR 45mg and DW1030 75mg
16681881|NCT02071368|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
16681882|NCT02071368|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]) formulation 1, under fed conditions.
16681883|NCT02071368|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]), formulation 2, under fed conditions.
16681884|NCT02071355|Experimental|Group 1|Participants will receive 100 mg TMC435 once daily for 7 days.
16681885|NCT02071355|Experimental|Group 2|Participants will receive 150 mg TMC435 once daily for 7 days.
16681886|NCT02071342||acute coronary syndrome|patients with acute myocardial infarction who are undergoing coronary angioplasty. MACE at 30 days and 1 year will be assessed . The acute recoil after implantation of bioabsorbable stents will also be assessed
16681887|NCT02071329|Experimental|Vaccine FP-01.1|Vaccine FP-01.1
16681888|NCT02071329|Placebo Comparator|Placebo|Placebo
16681889|NCT02071316|Active Comparator|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
16681890|NCT02071316|Placebo Comparator|Standard of care group, esomeprazole|* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
16681891|NCT02071303|Active Comparator|Tramadol|Women will receive Tramadol 100mg 1 hour before the procedure.
16681892|NCT02071303|Active Comparator|Celecoxib|Women will receive Celecoxib 200mg 1 hour before the procedure.
16681893|NCT02071303|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
16681894|NCT02071290|Sham Comparator|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
16681895|NCT02071290|Experimental|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
16681896|NCT02071277|Experimental|Pressure targeted modes|
16681897|NCT02071264|Other|HIV/STI intervention|This study implements a socio-behavioral intervention in Metro Manila, the Philippines, using a community-based participatory approach with 1-2 psychosocial and health education training workshops for the establishment managers and their workers, including street sex workers, focusing on HIV/AIDS risk reduction information, condom use, and condom negotiation skill-building. Participants participate in dream-building activities to explore personal goals and goals for their organization of peers. The interventions are directed at organizational behavior change and social influence modeling through training peers and managers. The participants receive information on STIs along with standard care, held on a day convenient to the participants and at a neutral location.
16681898|NCT02071251|Experimental|Prospective intervention|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
16681899|NCT02071238|Experimental|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
16681900|NCT02071238|No Intervention|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
16681901|NCT02071238|Experimental|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
16681902|NCT02071225|Experimental|Obinutuzmab + Bendamustine|Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
16681903|NCT02071212|Active Comparator|Clopidogrel|Loading dose 600 mg .Mainatinance dose 75 mg QD
16681904|NCT02071212|Experimental|Ticagrelor|Loading dose 180 mg . Maintenance 90 mg BID
16681905|NCT02071199|Experimental|Low dose 0.3X ACCS|20 microliters of 0.3X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
16681906|NCT02071199|Experimental|High dose 1X ACCS|20 microliters of 1X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
16681907|NCT02071199|Placebo Comparator|Normal saline|20 microliters of saline placebo per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
16681947|NCT02070939|Experimental|MAD cohorts 2-6 Experimental Arm|
16681948|NCT02070939|Placebo Comparator|MAD cohorts 2-6 Placebo Arm|
16681949|NCT02070939|Experimental|Japanese MAD cohort 7 Experimental arm|
16681950|NCT02070939|Placebo Comparator|Japanese MAD cohort 7 Placebo Arm|
16681951|NCT02070926||Perform coronary CT angiography|
16681952|NCT02070926||Do not perform coronary CT angiography|
16681908|NCT02071186|Experimental|Virtual Reality training|Subjects will be asked to walk on a treadmill while negotiating virtual obstacles. The VR system includes a camera based motion capture and a computer generated simulation. The camera is used to capture the movement of the participant's feet. These images are then transferred to the computer simulation and projected to the patient on a screen. The speed, orientation, size, frequency of appearance and shape of the targets are manipulated to increase task difficulty. The Virtual environment imposes a cognitive load requiring attention and response selection as well as processing of rich visual stimuli involving several perceptual processes. The system provides visual and auditory feedback of task performance to enhance motor learning.
16681909|NCT02071186|Experimental|Computerized Cognitive Remediation|"The AttenGo program will be used for neuro-cognitive remediation aimed at enhancing attention, concentration, working memory, and executive function. The program has shown to be effective in improving attention and executive function in children with ADHD. The training is composed of cognitive exercises that challenge subjects with problem solving, information processing, response inhibition and dividing attention. The users receive immediate feedback from the system when losing focus. The program is adaptive and progresses according to the subjects abilities."
16681910|NCT02071186|Active Comparator|Control group|Subjects in this group will be assessed based on the study protocol but will receive no treatment other than their standard of care which could include pharmacological or/ and non-pharmacological treatment.
16681911|NCT02071173|Experimental|Enrolled Patients|Subjects undergo an implant procedure to receive at least one investigational lead -- ACUITY X4 left ventricular (LV) CRT lead, RELIANCE 4-FRONT right ventricular (RV) ICD lead
16681912|NCT02071160|No Intervention|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
16681913|NCT02071160|No Intervention|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
16681914|NCT02071160|Experimental|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
16681915|NCT02071147|Other|Standard clinical intervention|Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
16681916|NCT02071147|Other|No Clinical Follow up|No routine follow-up appointment is made. Patients will be instructed to visit their optometrist between 6-8 weeks post-operative for review of the patient's glasses.
16681917|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
16681918|NCT02071121|Placebo Comparator|Placebo|Fasted participants will receive a single oral dose of placebo to BIIB061.
16681919|NCT02071121|Experimental|BIIB061 3 mg|Fasted participants will receive a single oral dose of BIIB061 3 mg.
16681920|NCT02071121|Experimental|BIIB061 10 mg|Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
16681921|NCT02071121|Experimental|BIIB061 30 mg|Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
16681922|NCT02071121|Experimental|BIIB061 60 mg|Fasted participants will receive a single oral dose of BIIB061 60 mg.
16681923|NCT02071121|Experimental|BIIB061 100 mg|Fasted participants will receive a single oral dose of BIIB061 100 mg.
16681924|NCT02071108|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
16681925|NCT02071095|Experimental|Arm A: Poly-ICLC|Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.
16681926|NCT02071095|Placebo Comparator|Arm B: Normal Saline|Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.
16681927|NCT02071082|Experimental|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
16681928|NCT02071082|Experimental|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
16681929|NCT02071069|Experimental|maintenance therapy|"Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks) .
~After 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or fluorouracil arm( leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
16681930|NCT02071056||history of visceral cancer|
16681931|NCT02071043|Experimental|XELOX|"XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:
~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
16681932|NCT02071030|Other|CBCT|Cone Beam CT
16681933|NCT02071030|Other|Panoramic radiograph|
16681934|NCT02071004|Other|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
16681935|NCT02071004|Experimental|DS-1040b|IV of 6 mg given once over 30 minutes
16681936|NCT02070991|Experimental|Macitentan|oral tablet, 10 mg once daily.
16681937|NCT02070991|Placebo Comparator|Placebo|Matching placebo, once daily.
16681938|NCT02070978|Experimental|Atacicept 75 mg|
16681939|NCT02070978|Experimental|Atacicept 150 mg|
16681940|NCT02070978|Experimental|Placebo/Atacicept 150 mg|
16681941|NCT02070965|Experimental|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
16681942|NCT02070965|Active Comparator|Comp01 Lotion|Comp01 Lotion, bid, 14 days
16681943|NCT02070965|Experimental|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
16681944|NCT02070952|Experimental|CyberKnife|CyberKnife Stereotactic Ablative Body Radiation Therapy
16681945|NCT02070939|Experimental|SAD cohorts 1-7 Experimental Arm|
16681946|NCT02070939|Placebo Comparator|SAD Cohorts 1-7 Placebo Arm|
16681953|NCT02070900|No Intervention|Standard of Care|Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines
16681954|NCT02070900|Experimental|POC Plus|Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines
16681955|NCT02070887||Entacapone|
16681956|NCT02070887||No Entacapone|
16681957|NCT02070874|Experimental|telehealth enhanced pain management|video-case conferences for providers PainTracker for patients
16681958|NCT02070874|No Intervention|usual care|usual care
16681959|NCT02070861|Experimental|Comparing cardiac output changes|"Explore the relationship between changes in cardiac output measured with eosophagal Doppler, the volume-clamp-method and exhaled CO2 during ventricular pacing and passive leg raise.
~Measurements with the volume-clamp-method were aborted due to technological difficulties."
16681960|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
16681961|NCT02070835|Experimental|ReCell®|ReCell® with skin graft
16681962|NCT02070835|Active Comparator|skin graft|split-thickness skin graft as control group
16681963|NCT02070822||TACE patients, for HCC|unresectable HCC patients
16681964|NCT02070809|Experimental|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
16681965|NCT02070809|Active Comparator|split-thickness skin graft method|This method is traditional split-thickness skin graft
16681966|NCT02070796|Experimental|Treatment A - B|Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours.
16681967|NCT02070796|Active Comparator|Treatment B - A|Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours.
16681968|NCT02070783|Experimental|ARA290|11-amino acid, linear peptide ARA290; intravenous injection with 2 mg ARA290 (single dosage).
16681969|NCT02070783|Placebo Comparator|Placebo|saline (NaCl 0.9%)
16681970|NCT02070770|Experimental|Very low calorie diet|
16681971|NCT02070770|Active Comparator|Standard weight loss diet|
16681972|NCT02070757|Experimental|Ceftolozane/tazobactam|Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
16681973|NCT02070757|Active Comparator|Meropenem|Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.
16681974|NCT02070744|Experimental|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
16681975|NCT02070744|Placebo Comparator|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
16681976|NCT02070744|Experimental|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
16681977|NCT02070744|Placebo Comparator|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
16681978|NCT02070744|Experimental|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
16681979|NCT02070731|No Intervention|unprotected TAVI|standard unprotected Transcatheter Aortic Valve Implantation
16681980|NCT02070731|Experimental|TAVI with the TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
16681981|NCT02070718|Placebo Comparator|Placebo|Cornstarch, National Formulary
16681982|NCT02070718|Experimental|Standard Dose Kappa Agonist|Pentazocine/Naloxone 50/0.5 mg
16681983|NCT02070718|Experimental|Half Dose Kappa Agonist|Pentazocine/Naloxone 25/0.25 mg
16681984|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
16681985|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
16681986|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection
16681987|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
16681988|NCT02070692|Experimental|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
16681989|NCT02070692|Placebo Comparator|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
16681990|NCT02070679|Placebo Comparator|Placebo|
16681991|NCT02070679|Active Comparator|Vit-E|600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
16681992|NCT02070666|Experimental|Protective ventilation arm|"Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)
~Plateau pressure less than 25 centimeter of water (cmH2O)
~Minimum PEEP of 5 cmH2O."
16681993|NCT02070666|Active Comparator|Control group|"Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)
~Plateau pressure less than 25 cmH2O
~Minimum PEEP of 5 cmH2O."
16681994|NCT02070653|Active Comparator|Ticagrelor|Ticagrelor 90 mg tablets twice daily for 12 months.
16681995|NCT02070653|Placebo Comparator|Placebo|Ticagrelor-placebo tablets twice daily for 12 months.
16682034|NCT02070354||Group 2|1 month prior to bariatric surgery
16681996|NCT02070640|Experimental|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
16681997|NCT02070627|Experimental|NIRF-C and IOC|Each enrolled subject will undergo injection with indocyanine green (ICG), intraoperative near infrared fluorescence cholangiography (NIRF-C) and standard of care intraoperative cholangiography.
16681998|NCT02070614||rs2242480 wild-type homozygote|*1/*1 Grouped by rs2242480 polymorphism genotyping
16681999|NCT02070614||rs2242480 mutant heterozygote|*1/*1G Grouped by rs2242480 polymorphism genotyping
16682000|NCT02070614||rs2242480 mutant homozygote|*1G/*1G Grouped by rs2242480 polymorphism genotyping
16682001|NCT02070588|Active Comparator|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
16682002|NCT02070588|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
16682003|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
16682004|NCT02070562||Community Group|Chinese lactating mothers from community maternal & child healthcare centre
16682005|NCT02070562||VIP Group|Chinese lactating mothers from VIP clinics (maternal care center)
16682006|NCT02070549|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16682007|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
16682008|NCT02070523|Experimental|PLD-contained VDCLD regimen|PLD 36 mg/m2 ivdrip over 60 minutes( d1、15),VCR 1.4mg/m iv(d1，8，15，22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip (d1～28).
16682009|NCT02070523|Active Comparator|DNR-contained VDCLD regimen|DNR 45 mg/m2 ivdrip over 60 minutes(d1～3),VCR 1.4mg/m2 iv(d1，d8，d15，d22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip(d1～28).
16682010|NCT02070510|Experimental|Victim and perpetrator compounds|Subjects receive two different victim compounds (lisinopril and warfarin) and two different perpetrator compounds (placebo semaglutide with carrier and oral semaglutide). Each dosing occasion is separated by a 7-day wash-out period.
16682011|NCT02070497|Experimental|case management_new|The patients with new-diagnosed lung cancer and accepting case management
16682012|NCT02070497|Experimental|case management_old|the patients with non-new-diagnosed lung cancer and with accepting case management
16682013|NCT02070497|No Intervention|control group|The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management
16682014|NCT02070484|Experimental|NuCel|Stemcell allograft
16682015|NCT02070484|Active Comparator|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
16682016|NCT02070471|Experimental|LC28-0126 Dose A|LC28-0126 Dose A
16682017|NCT02070471|Experimental|LC28-0126 Dose B|LC28-0126 Dose B
16682018|NCT02070471|Experimental|LC28-0126 Dose C|LC28-0126 Dose C
16682019|NCT02070471|Placebo Comparator|Placebo|Placebo
16682020|NCT02070458|Experimental|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
16682021|NCT02070445||Patients undergoing CABG|Patients will have no ventilation during CABG. There will be non-invasive assessments of the lung using ultrasound at different times during the perioperative period.The first assessment will be conducted before anesthesia induction (i.e. patients will be awake). A second assessment will be conducted after anesthesiology induction, but before the beginning of surgery. A third assessment will be conducted at the end of the surgery in the operating room. And two subsequent assessments will be conducted in ICU before and after extubation.
16682022|NCT02070432|Experimental|LUZ11 PDT|"Study consists of two phases, in each participant:
~Dose-finding phase with sequential periods in which single-ascending doses of LUZ11 will be titrated up to a dose that shows to be effective following photoirradiation of small spots of tumor surface.
~Final PDT session with the previously identified individual effective dose."
16682023|NCT02070419|Active Comparator|Arm I (TACE)|Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
16682024|NCT02070419|Experimental|Arm II (TACE+SBRT)|Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
16682025|NCT02070406|Experimental|Treatment (gene-modified T-cells, vaccine therapy, ipilimumab)|"CONDITIONING CHEMOTHERAPY REGIMEN: Patients receive cyclophosphamide IV on days -5 and -4 and fludarabine phosphate IV over 30 minutes daily on days -4 to -1.
~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV on day 0.
~IPILIMUMAB ADMINISTRATION: Patients receive ipilimumab IV over 90 minutes before the NY-ESO-1 TCR PBMC infusion on day 0 or after the infusion on day 1. Treatment repeats every 3 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity.
~NY-ESO-1(157-165) PEPTIDE PULSED DC ADMINISTRATION: Patients receive NY-ESO-1(157-165) peptide pulsed DC vaccine ID on days 1, 14, and 30.
~LOW DOSE IL-2 ADMINISTRATION: Patients receive aldesleukin (IL-2) SC BID on days 1-14."
16682026|NCT02070393|Experimental|Radiation Treatment using Protons|14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
16682027|NCT02070380|Experimental|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
16682028|NCT02070380|Experimental|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
16682029|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
16682030|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
16682031|NCT02070367|Experimental|Somatosensory rehabilitation|Weekly sessions with a certified (RSDC) somatosensory therapist using distal vibro-tactile counter-stimulation to anatomically related territories of the area of allodynia. Participants will also be provided with a structured home exercise program.
16682039|NCT02070341|Experimental|Split dose PEG|Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
16682040|NCT02070341|Experimental|Split dose Picosalax|Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.
16682041|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
16682042|NCT02070302|Active Comparator|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
16682043|NCT02070302|Placebo Comparator|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
16682044|NCT02070289|Experimental|Group 1: Cohort 1|
16682045|NCT02070289|Experimental|Group 1: Cohort 2|
16682046|NCT02070289|Experimental|Group 1: Cohort 3|
16682047|NCT02070289|Experimental|Group 2: Cohort 4|
16682048|NCT02070289|Experimental|Group 1 or 2: Cohort 5|
16682049|NCT02070289|Experimental|Group 1 or 2: Cohort 6|
16682050|NCT02070276|No Intervention|Standard Clinical Practice|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.
~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
16682051|NCT02070276|Experimental|Trans-thoracic echocardiography|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.
~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
16682052|NCT02070276|Experimental|Passive Leg Raising Test|"In addition to the arm A of the study, is performed a measurement of end-tidal CO2 (EtCO2) by trans-nasal canula with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver : an etCO2 increasing more than 12% from baseline was interpreted as fluid-responsive.
~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
16682053|NCT02070250|Experimental|From Cancer to Health (C2H-D)|Individuals participating in the From Cancer to Health (C2H-D) Stress Management Psychological Intervention
16682054|NCT02070237|Active Comparator|Enoxaparin Once Daily|This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
16682055|NCT02070237|Active Comparator|Enoxaparin Twice Daily|This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.
16682056|NCT02070224|Other|Knee osteoarthritis|
16682057|NCT02070211|Experimental|omega-3 PUFAs in add on to standard care|omega-3 PUFA supplementation as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
16682058|NCT02070211|Placebo Comparator|Placebo in add on to standard care|Placebo made by paraffin oil (not absorbed by the gastrointestinal tract) as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
16682059|NCT02070198|Experimental|Long acting FSH and GnrH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
16682060|NCT02070198|Experimental|daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
16682061|NCT02070198|Experimental|Triptorelin and recombinant FSH|Women in triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day until the day of HCG administration.
16682062|NCT02070185|Experimental|2 exposures|During the conditioning period, the children of this group was exposed only twice to the beverages
16682063|NCT02070185|Experimental|7 exposures|During the conditioning period, children of this group were exposed exposed 7 times to the beverages
16682064|NCT02070172||Cervicogenic Headache Group|This group of subjects is considered the symptomatic group. No intervention was provided in this study so there are no intervention groups.
16682065|NCT02070172||Healthy, Asymptomatic Group|Subjects in this group had no headache symptoms. Their neck motion was compared to subjects in the headache group. No intervention was provided to subjects in either group for this study.
16682066|NCT02070159|Active Comparator|Clopidogrel 600 mg|Patients administer conventional loading dose of clopidogrel 600 mg as active comparators.
16682067|NCT02070159|Experimental|Prasugrel 30 mg|Patients administer lower loading dose of prasugrel 30 mg.
16682068|NCT02070159|Active Comparator|Prasugrel 60 mg|Patients administer conventional loading dose of prasugrel 60 mg as active comparators.
16682069|NCT02070133|Experimental|Simvastatin|Patients with COPD will receive simvastatin 40 mg once a day for 12 weeks
16682070|NCT02070133|Placebo Comparator|Placebo|Patients with COPD will receive placebo once a day during 12 weeks
16682071|NCT02070120|Experimental|Chemoresection|4 once weekly outpatient intravesical instillations 40mg Mitomycin C
16682072|NCT02070120|Other|Surgical Management|Surgical management according to local practice
16682073|NCT02070107|Other|no arms|no arms, sponsor withdrew
16682074|NCT02070081|Experimental|Surgery|
16682075|NCT02070068|Experimental|Group 1|ICG administered 10 minutes prior to time of visualization
16682076|NCT02070068|Experimental|Group 2|ICG administered 45 min prior to time of visualization
16682077|NCT02070055||No treatment|No treatment
16682078|NCT02070042|Experimental|Omega- 3 Fatty Acid|The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
16682079|NCT02070042|Placebo Comparator|Placebo|Seagate® Extra Virgin Olive oil capsules
16682080|NCT02070029|Experimental|Acupuncture|"Acupuncture Therapy
~- twice weekly sessions for 5 weeks: 1st session 60 minutes with remaining 9 session approximately 45 minutes each. Physical exam at 1st session includes evaluation of peripheral pulses, head, neck, throat/tongue. No pelvic exam required."
16682081|NCT02070016|Experimental|TMS Parameter Condition 1 first|Application of Transcranial Magnetic Stimulation
16682082|NCT02070016|Experimental|TMS Parameter Condition 2 First|Application of Transcranial Magnetic Stimulation
16682083|NCT02070003|Experimental|Motivational Interviewing and Physician Guided Opioid Weaning|Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol.
16682084|NCT02070003|No Intervention|Usual Care|
16682085|NCT02069990|Active Comparator|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
16682086|NCT02069990|Experimental|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
16682087|NCT02069990|Experimental|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
16682088|NCT02069990|Active Comparator|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
16682089|NCT02069977|Experimental|Aripiprazole|"Dose level: 2, 5, 10, 15 mg/day
~Starting dose: 2 mg/day
~Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.
~Target dose: 5-15 mg/day
~Maximum dose: 15 mg/day
~Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
16682090|NCT02069964||Prospective hemi-neck RT|
16682091|NCT02069951|Experimental|Practice two procedures on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises.
~Participants randomised to the intervention group will practice two procedures on a simulator. First a procedural module A (a laparoscopic appendectomy) to a predefined proficiency level. Upon reaching proficiency for procedural module A the participants will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
16682092|NCT02069951|No Intervention|Practice one procedure on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises. Each exercise has to be passed twice within five consecutive attempts.
~Participants randomised to the control group will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
16682093|NCT02069938||Healthy Subjects|Noninvasive Brain Computer Interface Control
16682094|NCT02069925|Experimental|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
16682095|NCT02069925|Active Comparator|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
16682096|NCT02069912|Experimental|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
16682097|NCT02069899|Other|NI-0501 only in case is requested|NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.
16682098|NCT02069886|Experimental|deferasirox|single arm. all patients will receive deferasirox
16682099|NCT02069873|Experimental|16-Week Group Treatment|The 16-week treatment group will contain 3 blocks of treatment (exposure, cognitive, skills) with order randomized within the treatment. The first and last group session are considered inactive treatment sessions. The group treatment will be provided weekly.
16682100|NCT02069873|No Intervention|Wait List Control|The Wait List Control group will receive minimal attention, as they will meet bi-monthly for supportive sessions with the study psychologist. The study psychologist will not introduce any active treatment in the individual sessions.
16682101|NCT02069860|Experimental|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
16682281|NCT02068508||Pioglitazone|Pioglitazone 15 mg to 30 mg, orally, once daily
16692263|NCT02001922|No Intervention|Usual care|Usual COPD care
16682102|NCT02069847|Experimental|Esophageal stricture, Budesonide|Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR)
16682103|NCT02069847|No Intervention|Control group|Retrospective collect data for subjects who undergo endoscopic submucosal dissection or endoscopic mucosal resection
16682104|NCT02069834|Experimental|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
16682105|NCT02069834|Active Comparator|Arm 2 (control)|Continuation of existing HAART at the time of randomization
16682106|NCT02069821|Experimental|Group A|single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)
16682107|NCT02069821|Experimental|Group B|single administration : atorvastatin 40mg, qd, 7days(oral)
16682108|NCT02069808|Experimental|Group B: Follistim and Menopur|"Group B: N=25 subjects
~Cycle day 2 start Follistim 200 U/day up to 11 days duration.
~Cycle day 2 start Menopur (menotropins) 75 U/day up to 11 days duration.
~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.
~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.
~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
16682109|NCT02069808|Active Comparator|Group A: Follistim only|"Group A: N=25 subjects
~Cycle day 2 start Follistim 250 U/day up to 11 days duration.
~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.
~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.
~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
16682110|NCT02069795|Experimental|Voice recording|Subjects voices were recorded as they spoke specific words
16682111|NCT02069782|Experimental|Home visiting|Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.
16682112|NCT02069769|Experimental|communication with oncology team|oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
16682113|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
16682114|NCT02069743|Experimental|Intervention|The intervention group will use the study's mobile application during the 8-week study.
16682115|NCT02069743|No Intervention|Control|The control group will not use the study's mobile application during the study.
16682116|NCT02069730|Experimental|Unmatched Treatment (Selinexor)|"Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.
~If patients have a druggable aberration but there is no access to the relevant agent, then patients will receive selinexor"
16682117|NCT02069730|Experimental|Matched Therapy|"EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
~If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator."
16682118|NCT02069717||Not applicable-observational study|Not applicable-observational study
16682119|NCT02069704|Experimental|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
16682120|NCT02069704|Active Comparator|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
16682121|NCT02069691|Experimental|virtual reality-cycling training system|
16682122|NCT02069665|Experimental|Injection, medications and application|"Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd;
~Medications: according to TCM syndrome differentiations;
~Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough)
~Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm)
~External application: Fuxiong San"
16682123|NCT02069665|Active Comparator|Injection and medications|"Intravenous injection: Ribavirin Injection;
~Medications: symptomatic therapies
~Guaifenesin Syrup, for removing phlegm, relieving gasp-cough;
~Ibuprofen Suspension, and salbutamol in case of different symptoms"
16682124|NCT02069639||no treatment|
16682125|NCT02069626|Active Comparator|No wait|Usage of linear stapler without waiting of compression time
16682126|NCT02069626|Active Comparator|20 second wait|Usage of linear stapler with 20 second compression time
16682127|NCT02069626|Active Comparator|60 second wait|Usage of linear stapler with 60 second compression time
16682128|NCT02069613||Mild traumatic brain injury (mTBI)|Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).
16682129|NCT02069613||Control|Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI
16682130|NCT02069600|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
16682131|NCT02069600|No Intervention|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
16682132|NCT02069587|Experimental|Pomegranate|The women in this group will drink pomegranate juice
16682133|NCT02069574|Experimental|severe periodontitis group|non-surgical periodontal therapy
16682134|NCT02069574|Experimental|Moderate periodontitis group|non-surgical periodontal therapy
16682135|NCT02069574|No Intervention|healthy control|No treatment
16682136|NCT02069561|Experimental|Eicosapentaenoic Acid|Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days
16682245|NCT02068781|Active Comparator|Start with high-sodium diet|One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
16682137|NCT02069561|No Intervention|Normal controls|Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.
16682138|NCT02069548||Cervical dystonia|
16682139|NCT02069548||matched controlled subjects|matched in age (+/- 5 years) and gender
16682140|NCT02069535|Experimental|AVANZ Cupressus|AVANZ Cupressus
16682141|NCT02069522|Active Comparator|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
16682142|NCT02069522|Experimental|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
16682143|NCT02069509||Control research participants|diagnosis of FRDA genetically excluded
16682144|NCT02069509||FRDA patients|with genetically confirmed diagnosis of FRDA
16682145|NCT02069496||Subjects who receive Arepanrix®|Subjects who receive Arepanrix® as per routine practice
16682146|NCT02069483|Active Comparator|Motivational Interviewing|Subjects will engage in motivational interviewing and come up with messages to motivate quitting during the activity.
16682147|NCT02069483|Active Comparator|Tailored Feedback|Subjects will use reasons for quitting that they provided during the phone baseline for the text messages and audio recordings.
16682148|NCT02069470|Experimental|Continuing Medical Education|Continuing Medical Education
16682149|NCT02069470|No Intervention|Usual care|Usual care
16682150|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
16682151|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
16682152|NCT02069431|Experimental|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
16682153|NCT02069431|Placebo Comparator|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
16682154|NCT02069418|Experimental|Experimental arm|All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.
16682155|NCT02069405|Experimental|Music Group plus normal standard of care|Patients will listen to music prior and during the scan
16682156|NCT02069405|No Intervention|Control Group - Normal standard of care|
16682157|NCT02069392|Active Comparator|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
16682158|NCT02069392|Placebo Comparator|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
16682159|NCT02069379|No Intervention|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
16682160|NCT02069379|Experimental|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
16682161|NCT02069379|Placebo Comparator|Placebo|Placebo comparator to metformin treatment
16682162|NCT02069366|Placebo Comparator|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).
~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:
~PTSD-dronabinol (20)
~PTSD-placebo (20)
~TEC-dronabinol (20)
~TEC-placebo (20)
~HC-dronabinol (20)
~HC-placebo (20)"
16682163|NCT02069366|Active Comparator|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).
~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:
~PTSD-dronabinol (20)
~PTSD-placebo (20)
~TEC-dronabinol (20)
~TEC-placebo (20)
~HC-dronabinol (20)
~HC-placebo (20)"
16682164|NCT02069353|Experimental|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
16682165|NCT02069340|Experimental|Arm I (zoledronic acid over 15 minutes)|Patients receive zoledronic acid IV over 15 minutes on day 1.
16682166|NCT02069340|Experimental|Arm II (zoledronic acid over 30 minutes)|Patients receive zoledronic acid IV over 30 minutes on day 1.
16682167|NCT02069314|Experimental|Whey protein supplementation|50 grams of whey blended into frozen drink
16682168|NCT02069314|Experimental|Carbohydrate supplementation|50 grams of polycose blended into frozen drink
16682169|NCT02069301|Experimental|Integrated Depression/Microfinance Group|LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
16682170|NCT02069301|Other|Treatment as Usual|Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
16682171|NCT02069288|Experimental|1|Fludrocortisone
16682172|NCT02069288|Placebo Comparator|2|Placebo
16682173|NCT02069275|Experimental|Immediate mobilization|Immediate mobilization after coronary angiography or percutaneous coronary intervention
16682174|NCT02069275|Active Comparator|Two hours bedrest|Bedrest two hours after coronary angiography or percutaneous coronary intervention
16682246|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
16682175|NCT02069262|Experimental|angiography combination laparoscopy|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence. Those who developed rebleeding during the observation would be crossed over to the other investigation modality. Patients with negative findings on the initial assigned investigation but who developed rebleeding would undergo further investigation to localize the site of bleeding.
16682176|NCT02069262|Placebo Comparator|angiography alone|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
16682177|NCT02069249|Experimental|Healthy Nutrition Intervention|Healthy Nutrition Intervention (HNI)
16682178|NCT02069249|Experimental|Healthy Sleep Intervention|Healthy Sleep Intervention (HSI)
16682179|NCT02069249|No Intervention|Waiting list control|Waiting list control group
16682180|NCT02069236|No Intervention|G6PD Testing|All subjects receive G6PD test
16682181|NCT02069223|Active Comparator|Gastrectomy|Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.
16682182|NCT02069223|Active Comparator|BPD-DS|Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.
16682183|NCT02069223|Active Comparator|Gastrectomy+BPD-DS|Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.
16682184|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
16682185|NCT02069197|Active Comparator|Ketogenic diet, lifestyle counseling|ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction.
16682186|NCT02069197|Active Comparator|Orlistat, Lifestyle counseling|Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.
16682187|NCT02069197|Active Comparator|Standartized diet, Lifestyle counseling|Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.
16682188|NCT02069184|Experimental|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
16682189|NCT02069184|Experimental|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
16682190|NCT02069171||early ovarian cancer group|
16682191|NCT02069171||locally advanced cervical cancer group|
16682192|NCT02069171||primary endometrial cancer group|
16682193|NCT02069158|Experimental|PF-05212384, Carboplatin, Paclitaxel|starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC every 28 days Dose of Paclitaxel: 80 mg/m2 on days 1, 8 and 15
16682194|NCT02069145|Experimental|Drug: OMP-54F28, with Sorafenib|
16682195|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
16682196|NCT02069119|Experimental|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
16682197|NCT02069119|Placebo Comparator|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
16682198|NCT02069106|Experimental|Pro-Omega LDL|3 capsules 1000 mg BID for 8 weeks
16682199|NCT02069106|Placebo Comparator|Placebo|3 capsules BID for 8 weeks
16682200|NCT02069093|Experimental|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
16682201|NCT02069080|Experimental|1|All subjects are administered the study drug
16682202|NCT02069067||Advanced cancer patients with pain|
16682203|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
16682204|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
16682205|NCT02069054||Control|Healthy subjects
16682206|NCT02069041|Experimental|Ramucirumab + FOLFOX4|"8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles:
~FOLFOX4 every 2 weeks:
~85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2
~Participants may continue to receive treatment until discontinuation criteria are met."
16682207|NCT02069028||Low intensity intervention|human oriented interventions with less consideration to the system based act including, but not limited to, education, training, sepsis profile and posters with protocol algorithms.
16682208|NCT02069028||Intermediate intensity intervention|interventions that lie in between human oriented and system oriented Including, but not limited to, sepsis protocols, daily audits, feedback and clinical pathway
16682209|NCT02069028||High intensity intervention|system based interventions with less involvement of human effect including, but not limited to, electronic alert systems and sepsis response team.
16682210|NCT02069015|Experimental|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
16682211|NCT02069015|No Intervention|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
16682247|NCT02068755||Cardiac surgery|Patients who have undergone cardiac surgery
16682282|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
16692264|NCT02001909|Experimental|Regorafenib|
16682212|NCT02069002|Experimental|Cognitive-Behavioral Therapy (CBT)|"There will be ten (10) manualized session, fist 90 minutes and nine (9) 45-minute individual sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after the treatment. Sessions include psychoeducation about indoor air related symptoms and personal health behavior factors integrated on patients individual symptomatology, cognitive restructuring, behavioral experiments of patients health promoting behavior, imagery rescripting and relapse prevention.
~Intervention: Behavioral: Psychotherapy (CBT)"
16682213|NCT02069002|Experimental|Applied relaxation group therapy|"There will be seven (7) manualized session, first 120 minutes and six (6) 90-minute group sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after treatment. Sessions include information about indoor air related symptoms, behavioral training and experiments focusing on applied relaxation technique and relapse prevention.
~Intervention: Behavioral: group therapy (ART)
~NB: The Applied Relaxation group Therapy won´t be carried out due to slow and prolonged recruiting process (A steering group agreement 4/2015 and the Ethics Committee approval 5/2015 for the change of the study plan)."
16682214|NCT02069002|Experimental|Information session (psychoeducation)|"There will be one (1) manualized 90-minute individual session. The session includes information about indoor air related symptoms and factors affecting individual health behavior.
~Intervention: Information session (psychoeducation)"
16682215|NCT02068989||Stress Hyperglycemic Group|Repeat HbA1C in 1 year
16682216|NCT02068989||Euglycemic Group|Repeat HbA1C in 1 year
16682217|NCT02068976||Women with Primary Ovarian Insufficiency|
16682218|NCT02068963||Study Population|
16682219|NCT02068950|Other|Progressive resistance training|12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand).
16682220|NCT02068937|Active Comparator|Control Group|In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
16682221|NCT02068937|Experimental|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
16682222|NCT02068924|Experimental|slow freezing|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
16682223|NCT02068924|Other|vitrification|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
16682224|NCT02068911||Monitoring of ETCO2 and PTCO2|All neuromuscular patients
16682225|NCT02068898|Experimental|XS003 Dose-level 1|Capsule formulation
16682226|NCT02068898|Experimental|XS003 Dose-level 2|Capsule formulation
16682227|NCT02068898|Experimental|XS003 Dose-level 3|Capsule formulation
16682228|NCT02068898|Experimental|Tasigna|Marketed capsule
16682229|NCT02068885|Experimental|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
16682230|NCT02068885|Experimental|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
16682231|NCT02068885|Active Comparator|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
16682232|NCT02068872|Experimental|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
16682233|NCT02068859|Experimental|Diclofenac Cream 8%|Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.
16682234|NCT02068859|Active Comparator|Control|Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks
16682235|NCT02068846|Active Comparator|Ciprofloxacin|Active treatment twice daily for 28 days
16682236|NCT02068846|Placebo Comparator|Placebo|Placebo treatment twice daily for 28 days
16682237|NCT02068833||Gastrectomy|Subjects in this group will undergo a gastrectomy only.
16682238|NCT02068833||BPD-DS|Subjects in this group will undergo a BPD-DS surgery.
16682239|NCT02068820|Active Comparator|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
16682240|NCT02068820|Experimental|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
16682241|NCT02068807|Active Comparator|Lutein drops|oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
16682242|NCT02068807|Placebo Comparator|Glucose drops|oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
16682243|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16682244|NCT02068781|Active Comparator|Start with low-sodium diet|One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
16682248|NCT02068742|Experimental|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
16682249|NCT02068742|Active Comparator|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
16682250|NCT02068716||Adults with HAIs|"Adult cardiac surgery patients who develop infections in hospitals within 30 days post surgery.
~We will exclude patients presenting with endocarditis."
16682251|NCT02068703|Active Comparator|Intervention|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools (face mask, ear plugs and white noise machine) to improve sleep.
16682252|NCT02068703|Placebo Comparator|Inert Control|Same 10 min time exposure and tool delivery to subjects in this arm WITHOUT demonstration.
16682253|NCT02068690|Experimental|BI 425809 single rising dose|BI 425809 powder for oral solution (PfOS) in single rising doses
16682254|NCT02068690|Experimental|BI 425809 Crossover|Bioavailability of BI 425809 PfOS
16682255|NCT02068677|Other|sympathetic response|This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
16682256|NCT02068677|Other|no sympathetic response|This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
16682257|NCT02068664||Observational|prism adaptation treatment
16682258|NCT02068651|Experimental|Advance care planning programme|Participants in the experimental group will receive a structured advance care planning programme, namely Let Me Talk, delivered by a trained nurse facilitator. The programme will be conducted on individual basis through three one-hour home visits, once weekly. Family carers of the participants will be invited to all sessions.
16682259|NCT02068651|No Intervention|Usual care|Participants in the control group will receive three weekly home visits with basic health assessment and education provided by the trained nurse facilitator. If they request advance care planning information or assistance, an advance directive form, which is available on the Internet for public access, will be provided to them for their information.
16682260|NCT02068638|Experimental|IHE first, CONT second, CSII and MDI therapy|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
16682261|NCT02068638|Experimental|CONT first, IHE second,CSII and MDI therapy|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
16682262|NCT02068638|Experimental|GLU first, GLUFRU second, CSII and MDI therapy|GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
16682263|NCT02068638|Experimental|GLU-FRU first, GLU second, CSII therapy|GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
16682264|NCT02068625|Experimental|Treatment|Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
16682265|NCT02068625|Placebo Comparator|Control|Patients getting perioperative oral treatment with placebo for 7 days
16682266|NCT02068612|Experimental|MICT + IT|Moderate Intensity Continuous Training+Interval Training
16682267|NCT02068612|Active Comparator|LICT|Low Intensity Continuous Training
16682268|NCT02068599|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
16682269|NCT02068599|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
16682270|NCT02068599|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
16682271|NCT02068586|Experimental|Sunitinib|Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity
16682272|NCT02068586|Experimental|Valproic acid|Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity
16682273|NCT02068573|Active Comparator|Ventilation|Increased ventilation in the childs bedroom to at least 2-3 air changes pr hour.
16682274|NCT02068573|Placebo Comparator|Placebo ventilation|Ventilation system that recirculates the air in the childs bedroom
16682275|NCT02068560|Experimental|dDAVP infusion|During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).
16682276|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
16682277|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
16682278|NCT02068534||survivors from charcoal-burning suicide|survivors from charcoal-burning suicide and at least above 20 years old.
16682279|NCT02068521|Experimental|Treatment naive subjects with GHD|Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
16682280|NCT02068521|Experimental|Subjects who have completed a somavaratan study|All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.
16692265|NCT02001909|Experimental|Neomycin|
16682283|NCT02068482|Active Comparator|1a USDD|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
16682284|NCT02068482|No Intervention|1b USDD|Patients control, no drug
16682285|NCT02068482|No Intervention|Control group|Control Group, no disease, no drug
16682286|NCT02068456||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved Korean label.
16682287|NCT02068443|Active Comparator|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
16682288|NCT02068443|Experimental|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
16682289|NCT02068443|Active Comparator|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
16682290|NCT02068430|Experimental|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
16682291|NCT02068417|Active Comparator|Shock wave treatment|Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
16682292|NCT02068417|Placebo Comparator|Placebo Shock wave treatment|Shock waves are prohibited to enter the body by placebo stand-off.
16682293|NCT02068404|Other|Nifedipine|
16682294|NCT02068391|Experimental|Exercise|This group will perform the 'Exercise Program' for months 0 to 6, and will be unsupervised for months 7 to 12.
16682295|NCT02068391|Active Comparator|Stretching|This group will perform the 'Stretching Program' for months 0 to 6, and the 'Exercise Program' for months 7 to 12.
16682296|NCT02068378|Experimental|CMPE Optical Sensor Device|Single arm study
16682297|NCT02068365|Other|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
16682298|NCT02068352|Experimental|0.3% OPA-15406|BID 0.3% OPA-15406 Ointment, N = 40
16682299|NCT02068352|Experimental|1% OPA-15406|BID 1% OPA-15406 Ointment, N = 40
16682300|NCT02068352|Placebo Comparator|Placebo|BID 0% Vehicle Ointment, N = 40
16682301|NCT02068339|Placebo Comparator|Placebo|Placebo Comparator / Tid (total 0mg)
16682302|NCT02068339|Experimental|Oltipraz 1|Total 90mg, by mouth, tid
16682303|NCT02068339|Experimental|Oltipraz 2|Total 120mg, by mouth, tid
16682304|NCT02068326|Experimental|Mentalization Based Treatment|"the experimental intervention is a year-long manualized program that comprises four components:
~Five individual case-formulation sessions,
~MBT-I, an introductory pedagogical program for patients (three weekly sessions)
~MBT-G, MBT-program in groups (37 weekly sessions)
~MBT-P, a psychoeducation program for the patients' parents or parents substitutes (six sessions)."
16682305|NCT02068326|Active Comparator|Treatment As Usual|Participants randomized to the control group will receive Treatment As Usual (TAU). TAU is defined as comprising at least 12 monthly individual supportive sessions provided by non-MBT trained mental health professionals in the Department of Child and Adolescent Psychiatry in Region Zealand. Additional supportive sessions or other types of intervention may be offered to the patients according to the needs of the patients as evaluated by mental health professionals responsible for his/hers treatment. Hence, TAU may vary considerably in number and type of intervention across clinics and patients. All mental health services delivered during the treatment period to patients in the TAU group will be monitored and registered.
16682306|NCT02068313||Single cohort|
16682307|NCT02068287|Experimental|ESMOLOL|Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.
16682308|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
16682309|NCT02068261|Experimental|Cogmed working memory training|30-40 minutes of Cogmed computerized working memory training 3-5 days a week for 5-8 weeks. Every training session consists of a set of visual- and verbal working memory tasks that are trained on during the session.
16682310|NCT02068261|Active Comparator|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
16682311|NCT02068235|Experimental|Pilot Phase|Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).
16682312|NCT02068235|Experimental|Treatment A/Treatment B|"Subjects will receive Treatment A followed by Treatment B.
~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.
~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.
~There will be a washout period between doses of 12-15 days."
16682313|NCT02068235|Experimental|Treatment B/Treatment A|"Subjects will receive Treatment B followed by Treatment A.
~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.
~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.
~There will be a washout period between doses of 12-15 days."
16682314|NCT02068222|Experimental|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
16682315|NCT02068209|Active Comparator|Tramadol|Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
16682316|NCT02068209|Placebo Comparator|Placebo|Patients will receive a placebo 1 hour before the procedure.
16682556|NCT02066584||ECM Medium|An oocyte culture medium containing 0.5mM glucose (Irvine)
16682318|NCT02068183||World Trade Center exposed group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the World Trade Center exposed group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
16682319|NCT02068183||Unexposed comparison group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the unexposed comparison group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
16682320|NCT02068170||patients treated with a potentional QT-prolonging drug|
16682321|NCT02068157|Experimental|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
16682322|NCT02068144|Experimental|Cranberry Extract|Cranberry Extract in a 15.2oz beverage daily for 8 weeks
16682323|NCT02068144|Placebo Comparator|Placebo|Placebo 15.2oz beverage daily for 8 weeks
16682324|NCT02068131|Experimental|Novaferon+ xeloda|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).
~Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
16682327|NCT02068105|Experimental|ALKS 5461-A|
16682328|NCT02068105|Experimental|ALKS 5461-B|
16682329|NCT02068105|Experimental|ALKS 5461 Dose 1|
16682330|NCT02068105|Experimental|ALKS 5461 Dose 2|
16682331|NCT02068105|Experimental|ALKS 5461 Dose 3|
16682332|NCT02068105|Placebo Comparator|Placebo|
16682333|NCT02068092|Experimental|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
16682334|NCT02068079|Other|Vemurafenib and Trientine|
16682335|NCT02068053|Experimental|Arm A - BMS-986020|600 mg (approximately 80 micro Curie) of [14C] BMS-986020 Single Dose for 1 Day (Day 1) orally
16682336|NCT02068040|Experimental|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
16682337|NCT02068027|Experimental|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
16682338|NCT02068027|Placebo Comparator|Placebo|Placebo gel of identical appearance as active treatment
16682339|NCT02068001||RYGB|Food preference assessment in 100 patients at different timepoints, in a subset of 30 participants, also brain reward response to food cues will be assessed.
16682340|NCT02067988|Experimental|Treatment arm|Holmium-166 microspheres hepatic radioembolization, adjuvant to systemic 177Lu-dotatate.
16682341|NCT02067975|Other|Healthy Controls|All participants will receive both 6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3, and will also receive Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3. The order in which participants receive either placebo or tryptophan will be randomized (ie. placebo first study visit day tryptophan on second study day, or tryptophan on first study day and placebo on second study day)
16682342|NCT02067975|Other|Schizophrenia Related Disorders|All participants will receive both 6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3, and will also receive Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3. The order in which participants receive either placebo or tryptophan will be randomized (ie. placebo first study visit day tryptophan on second study day, or tryptophan on first study day and placebo on second study day)
16682343|NCT02067962|Other|Juvenile idiopathic arthritis.|Blood sample
16682344|NCT02067949|No Intervention|broad spectrum AB +fluids|Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES
16682345|NCT02067949|Active Comparator|simvastatin|50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)
16682346|NCT02067936|Active Comparator|Group A propofol + remifentanil|Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
16682347|NCT02067936|Active Comparator|Group B propofol + remifentanil|Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
16682348|NCT02067936|Active Comparator|Group C propofol + remifentanil|propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
16682349|NCT02067936|Active Comparator|group D propofol + remifentanil|propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
16682350|NCT02067923||Anti-CD3 mAb Plus Diabetes Standard of Care Group|This group of individuals received treatment in the original AbATE study.
16682351|NCT02067923||Diabetes Standard of Care Group|During the original AbATE study these individuals received standard care.
16682352|NCT02067910|Active Comparator|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
16682353|NCT02067910|Placebo Comparator|Placebo|First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
16682354|NCT02067897||Vandenbos procedure (skinfold excision)|Participants in this cohort will undergo with Vandenbos procedure (skinfold excision) for one or more ingrown toenails. This surgery will be formed as an day procedure under general anesthetic.
16682355|NCT02067884|Experimental|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
16682356|NCT02067871|Experimental|Electrical stimulation|"18-32 min of pulsed current.
~stimulation frequency of 80Hz (hertz).
~pulse duration of 200μs (microseconds).
~stimulation intensity fixed near to maximal tolerated."
16682357|NCT02067871|Experimental|Laser Therapy|"λ = 810 nm (nanometers)
~continuous wave
~200 mW (milliwatts) output power
~low-level laser therapy dose of 4-6J (Joules) per point
~six points at the knee joint"
16682358|NCT02067871|Experimental|Combined Treatment|"Electrical Stimulation:
~18-32 min of pulsed current,
~stimulation frequency of 80Hz (hertz).
~pulse duration of 200μs (microseconds).
~stimulation intensity fixed near to maximal tolerated.
~and
~Laser Therapy:
~λ = 810 nm (nanometers)
~continuous wave
~200 mW (milliwatts) output power
~low-level laser therapy dose of 4-6J (Joules) per point.
~six points at the knee joint."
16682359|NCT02067858|Other|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy
~Lesion dependent"
16682360|NCT02067845|Other|Pre-post test design|
16682361|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
16682362|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
16682363|NCT02067793|Placebo Comparator|Placebo|Placebo
16682364|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
16682365|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
16682366|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
16682367|NCT02067780|Experimental|The intervention (CRP-guided) group|500 mg (one tablet) of oral levofloxacin daily of levofloxacin for 7 days unless the serum CRP decrease by at least 50% from baseline value. Measurements of serum CRP were done at ED admission, at day-2, day-4 and day-6 and made available to the attending physicians.
16682368|NCT02067780|Experimental|The standard care (control) group|500 mg of levofloxacin per day for the first two days. Thereafter, oral tablet of placebo was prescribed according to CRP values as in CRP guided group to keep the blindness of the study.
16682369|NCT02067767|Experimental|Abacavir/Lamivudine/Dolutegravir|Patients switched from their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG.
16682370|NCT02067754||metastatic Cancer|metastatic gastrointestinal cancer, genitourinary cancer , rare cancer with treated any anti-cancer therapy
16682371|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
16682372|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
16682373|NCT02067728|Active Comparator|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
16682374|NCT02067728|Experimental|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
16682375|NCT02067715|Experimental|Sealed bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide. However, a customized tray will be placed over the bleaching agent during entire permanence of peroxide (45 minutes).
16682376|NCT02067715|Active Comparator|Conventional Bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
16682377|NCT02067702||Limb Cooling Assessment of ET Control|Healthy, volunteers with no known dermatological lesions, sensitivity to cold, or peripheral vascular disease.
16682378|NCT02067702||Limb Cooling Assessment of ET Experimental|Patients with known essential tremor for at least a year, and +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand.
16682379|NCT02067689|Experimental|Hemisphere Stimulation|Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
16682380|NCT02067689|Experimental|Temporal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
16682381|NCT02067689|Experimental|Frontal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the frontal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left frontal structures using 4x1 stimulation (e.g., 1mA left frontal, 1mA right frontal, sham; 2mA left frontal, 2mA right frontal, sham).
16682382|NCT02067689|Experimental|Parietal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the parietal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left parietal lobes using 4x1 stimulation (e.g., 1mA left parietal lobes, 1mA right parietal lobes, sham; 2mA parietal lobes, 2mA right parietal lobes, sham).
16682383|NCT02067689|Experimental|Supplementary Motor Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the Supplementary Motor Area at 1mA vs. 2mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left Supplementary Motor Area using 4x1 stimulation (e.g., 1mA left Supplementary Motor Area, 1mA right Supplementary Motor Area, sham; 2mA left Supplementary Motor Area, 2mA right Supplementary Motor Area, sham).
16682384|NCT02067689|Experimental|Brain Structure Interactions Group|This cohort will evaluate the interaction between frontal, parietal, temporal, and SMA regions in cognitive function. To accomplish this goal will require evaluation of change in cognitive and neurocognitive performance following transcranial direct current stimulation of different brain regions within the same subjects. For example, we will evaluate the contribution of frontal, SMA, and parietal regions by asking participants to undergo stimulation sessions at each of these sites, in addition to a sham session.
16682604|NCT02066298|Experimental|Mometasone then Tiotropium then Placebo|Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
16682385|NCT02067676|Experimental|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
16682386|NCT02067676|Experimental|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
16682387|NCT02067676|Experimental|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
16682388|NCT02067676|Experimental|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
16682389|NCT02067676|Experimental|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
16682390|NCT02067676|Experimental|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
16682391|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
16682392|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
16682393|NCT02067637||Exposed|Individuals with one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer.
16682394|NCT02067637||Unexposed|Healthy controls
16682395|NCT02067624|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the wrist extensor groups muscle for 9 sessions
16682396|NCT02067624|Sham Comparator|Sham Ultrasound therapy|The participants will receive a thirty minutes session of sham ultrasound therapy onto the wrist extensor groups muscle for 9 sessions
16682397|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
16682398|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
16682399|NCT02067598|Experimental|Scapular exercise|The participants will receive thirty minutes session of scapular exercise for 12 sessions
16682400|NCT02067598|No Intervention|Control|
16682401|NCT02067585|Experimental|LAGB|Standardized Lipid meals will be served to Laparoscopic adjustable gastric banding patients.
16682402|NCT02067585|Experimental|LRYGB|Standardized Lipid meals will be served to the Laparoscopic Rou-en-Y gastric bypass patients.
16682403|NCT02067585|Experimental|Non-surgical|Standardized Lipid meals will be served to the non-surgical obese patients
16682404|NCT02067572|Experimental|Salvia|Salvia mouthwash used 4 times per day for 4 days
16682405|NCT02067572|Active Comparator|Saline|Saline mouthwash used 4 times per day for 4 days.
16682406|NCT02067559|Experimental|ICU Diaries|A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Instructions will be provided to the patient's family at the time of randomization and will be available at the bedside for reference. Staff instructions will be posted at charting area for staff. During the patient's stay in ICU, the diary will never leave the unit. Under no circumstances will any part of an ICU diary be duplicated. Research staff will take a photograph of the patient after consent is obtained and the photograph will be mounted on the first page of the diary. Photographs will be taken with a Polaroid camera; therefore there will be no other record of the photograph.
16682407|NCT02067559|Experimental|Psychoeducation|The research nurse will provide a psychoeducational brochure to study participants at ICU discharge (if cognitive capacity is established) or 30 days after ICU discharge. If participants are not well enough 30 days post-discharge, they will be assessed every two weeks by research staff until the brochure is given to them. The brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions. The document will also be mailed to the participant's follow-up physician.
16682408|NCT02067559|Experimental|ICU Diary plus Psychoeducation|Participants will receive both ICU diary and psychoeducation interventions, with both documents provided at ICU-discharge, or 30 days post-discharge as above.
16682409|NCT02067559|No Intervention|Treatment as Usual|No additional intervention to usual ICU care will be given.
16682410|NCT02067546|Experimental|Experimental toilet seat|Experimental toilet seat for 1 month
16682411|NCT02067546|Sham Comparator|Standard toilet seat|Standard toilet seat for 1 month
16682412|NCT02067533|Experimental|flexion position|
16682413|NCT02067533|Experimental|extension position|
16682414|NCT02067520|Other|IT hydromorphone dose|dose response study
16682415|NCT02067507|No Intervention|Control|"LACDPH Site: CDC-developed small media in preferred language
~AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation
~Northeast Valley Health Corporation Site: Usual care"
16682416|NCT02067507|Experimental|Tailored education and referral|LACDPH Site: Tailored education and referral intervention administered at LACDPH Site
16682417|NCT02067507|Experimental|Staff training and patient reminders|Staff training and patient reminders administered at AltaMed Health Services Corporation Site
16682418|NCT02067507|Experimental|Clinic-level reminder systems|Clinic-level reminders administered at Northeast Valley Health Corporation Site
16682419|NCT02067494|Experimental|Myofascial Soft Tissue Release|"Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
~Myofascial release assisted the paravertebral fascia."
16682420|NCT02067494|Active Comparator|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
16682421|NCT02067481|Experimental|Single-arm weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (AP) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment.
16682422|NCT02067468|Experimental|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
16682423|NCT02067468|Active Comparator|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
16682424|NCT02067468|Active Comparator|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
16682425|NCT02067455|Other|LVAD patients|
16682426|NCT02067442|Active Comparator|oral acetaminophen|Patients in this arm of the study will receive oral acetaminophen and an IV placebo
16682427|NCT02067442|Active Comparator|intravenous acetaminophen|Patients in this arm of the study will receive IV acetaminophen and an oral placebo
16682428|NCT02067429|Experimental|Toric Intraocular lens|Toric intraocular lens implantation during standard cataract surgery
16682429|NCT02067429|Experimental|Limbal Relaxing Incisions|Limbal relaxing incisions during standard cataract surgery
16682430|NCT02067416|Active Comparator|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
16682431|NCT02067416|Active Comparator|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
16682432|NCT02067403|Experimental|Eadi optimized pressure-support|
16682433|NCT02067390||Vancomycin|Vancomycin
16682434|NCT02067390||Linezolid|Linezolid
16682435|NCT02067377|Placebo Comparator|inactive powder substance|inactive powder substance by mouth twice a day for 6 months
16682436|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medical food|SBI medical food 5 gr powder substance by mouth twice a day for 6 months
16682437|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medicalfood|SBI medical food 10 gr powder substance by mouth twice a day for 6 months
16682438|NCT02067364|Other|Fit & function test|CRT ShuntCheck sensors will be applied over the shunts of asymptomatic hydrocephalus patients. The device will be activated, cooling the skin under the sensor. Patients will change positions during the one hour procedure and data will be recorded. Data will be analyzed offline to identify product performance issues due to motion.
16682439|NCT02067351|Experimental|Mindfulness Intervention|Mindfulness intervention
16682440|NCT02067338|Placebo Comparator|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
16682441|NCT02067338|Active Comparator|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
16682442|NCT02067325|Experimental|Thai massage|The participants will receive thirty minutes session of Thai massage onto the trapezius muscle for 1 sessions
16682443|NCT02067325|Sham Comparator|Sham Microwave diathermy|The participants will receive thirty minutes session of Sham Microwave diathermy onto the trapezius muscle for 1 sessions
16682444|NCT02067312|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the trapezius muscle
16682445|NCT02067312|Sham Comparator|Sham Microwave diathermy|The participants will receive a thirty minutes session of Sham microwave diathermy onto the trapezius muscle
16682446|NCT02067299|Experimental|Cohort A|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of placebo (Period 1), JNJ-42847922 10 mg (Period 2), JNJ-42847922 20 mg (Period 3), and JNJ-42847922 40 mg (Period 4). Each treatment period and each subsequent treatment period will be separated by 1 week.
16682447|NCT02067299|Experimental|Cohort B|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 10 mg (Period 1), JNJ-42847922 40 mg (Period 2), placebo (Period 3), and JNJ-42847922 20 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
16682448|NCT02067299|Experimental|Cohort C|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 20 mg (Period 1), placebo (Period 2), JNJ-42847922 40 mg (Period 3), and JNJ-42847922 10 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
16682449|NCT02067299|Experimental|Cohort D|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 40 mg (Period 1), JNJ-42847922 20 mg (Period 2), JNJ-42847922 10 mg (Period 3), and placebo (Period 4). Each subsequent treatment period will be separated by 1 week.
16682450|NCT02067273|Experimental|TMS Intervention for 5 days|Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days
16682451|NCT02067273|Experimental|TMS Intervention for 1 day|Application of Transcranial Magnetic Stimulation (TMS) for 1 day
16682452|NCT02067260|Active Comparator|X5 HairLaser|
16682453|NCT02067260|Sham Comparator|X5 HairLaser Sham Device|
16682454|NCT02067247|Experimental|SOS forearm test|BeamMed Speed-of-Sound bone strength test at forearm
16682455|NCT02067234|Active Comparator|Routine Care/Education|Patient will be assessed by MD and provided education by nurse
16682456|NCT02067234|Experimental|Psychoeducation/Coping Prevention|Patient will be assessed by MD and will meet with psychologist to obtain psychoeducation about coping, behavioral strategies, and sleep hygiene
16682457|NCT02067221|Active Comparator|RIRS (retrograde intrarenal surgery)|Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
16682458|NCT02067221|Experimental|MPCNL (mini-perc)|"A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.
~Patients will be randomized and assigned to each group at the ratio 1:1"
16682459|NCT02067208|No Intervention|Waitlist Control|A waitlist control condition, where the participant receives no insole for 3 months. During this 3 month period, the participant will continue to be monitored for outcome variables.
16682652|NCT02066025||group_1|Women with positive biopsy for (ID, IL, DCIS) as patients.
16682460|NCT02067208|Experimental|Experimental wedged insole|Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
16682461|NCT02067195|Active Comparator|Guideline Hydration|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
16682462|NCT02067195|Active Comparator|Adequate Hydration|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
16682463|NCT02067182|Experimental|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.
~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:
~Patients aged 75 years or above
~Cr-Cl 30-50 ml/min
~Patients who receive concomitant verapamil
~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:
~Patients with moderate renal impairment
~Patients with gastritis, esophagitis or gastroesophageal reflux
~Other patients at increased risk of bleeding"
16682464|NCT02067182|No Intervention|No Oral Anticoagulation|
16682465|NCT02067169||CMV infection|allograft recipient with active CMV infection
16682466|NCT02067156|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
16682467|NCT02067143|Experimental|Study population|In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.
16682468|NCT02067130|Other|Fibroscan|Subjects enrolled will undergo Fibroscan. It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Fibroscan reading will be collected at the Gastroenterologist's (Dr. Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician. Anticipated timing of this procedure will be October to December 2013
16682469|NCT02067117|Experimental|influenza split vaccine|
16682470|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
16682471|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
16682472|NCT02067091|Active Comparator|BVS|Implantation of bioresorbable vascular scaffold in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
16682473|NCT02067091|Active Comparator|DES|Implantation of drug eluting stent in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
16682474|NCT02067078|Experimental|Combined saphenous nerve and obturator nerve block|
16682475|NCT02067078|Experimental|Saphenous nerve block|
16682476|NCT02067078|Active Comparator|Local infiltration analgesia|
16682477|NCT02067065|Experimental|Non-anesthesiologist propofol sedation|Bolus propofol sedation by non-anesthesiologist
16682478|NCT02067065|Active Comparator|Anesthesiologist administered propofol|Propofol sedation administered by an anesthesiologist
16682479|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
16682480|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
16682481|NCT02067039|Experimental|HIV self-testing|The intervention group of MSM (HIV negative or unaware of HIV status) will receive 4 rapid HIV test kits - 2 oral fluid tests (OraQuick), and 2 finger-stick blood tests (Sure Check). Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period, and men in the intervention arm will be allowed to order additional test kits to replenish the ones they use or give away. At month 12, all HIV-negative or those who are unaware of their HIV status participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a dried blood spot (DBS) specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
16682482|NCT02067039|No Intervention|Information only|All comparison group of MSM (HIV negative or unaware of HIV status) will take a baseline survey. Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period. At month 12, all HIV-negative and unaware of their HIV status comparison arm participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a DBS specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
16682483|NCT02067026|Experimental|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
16682484|NCT02067026|Placebo Comparator|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
16682485|NCT02067013|Active Comparator|Ranibizumab|Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
16682486|NCT02067013|Placebo Comparator|Control|Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).
16682487|NCT02067000||Obstructive Sleep Apnea|
16682488|NCT02066987|Experimental|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
16682489|NCT02066987|Experimental|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).
~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
16682490|NCT02066987|Active Comparator|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
16682491|NCT02066974||Hepatoma, Circulating tumor genome|Hepatoma requiring radiotherapy
16682492|NCT02066961||Cohort 1|Subjects with biochemical failure experience after primary treatment and have high-risk disease
16682493|NCT02066961||Cohort 2|Subjects with a medical diagnosis of castration-resistant prostate cancer
16682494|NCT02066961||Cohort 3|Subjects with an initial diagnosis of metastatic prostate cancer
16682495|NCT02066948|Active Comparator|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss&exercise e
16682496|NCT02066948|Active Comparator|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss&exercise
16682497|NCT02066935||kidney transplant patient|Kidney transplanted patients for at least one year
16682498|NCT02066922|Experimental|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
16682499|NCT02066922|Active Comparator|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
16682500|NCT02066909|Experimental|Cohort 1|Dosing in healthy Western subjects.
16682501|NCT02066909|Experimental|Cohort 2|Dosing in healthy Western subjects.
16682502|NCT02066909|Experimental|Cohort 3|Dosing in healthy Western subjects.
16682503|NCT02066909|Experimental|Cohort 4|Dosing in healthy Western subjects.
16682504|NCT02066909|Experimental|Cohort 5|Dosing in healthy Western subjects.
16682505|NCT02066909|Experimental|Cohort 6|Dosing in healthy Western subjects.
16682506|NCT02066909|Experimental|Cohort 7|Dosing in healthy Western subjects.
16682507|NCT02066909|Experimental|Optional Cohort 8|Dosing in healthy Western subjects. Cohort may not be conducted.
16682508|NCT02066909|Experimental|Cohort 9|Dosing in healthy Japanese subjects.
16682509|NCT02066896|Sham Comparator|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
16682510|NCT02066896|Active Comparator|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
16682511|NCT02066870|Experimental|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.
~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
16682512|NCT02066857|Active Comparator|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
16682513|NCT02066857|Active Comparator|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
16682514|NCT02066844|Active Comparator|Standard Manual Needle Injection|2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon
16682515|NCT02066844|Experimental|Navigator Injection|2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon
16682516|NCT02066831|Experimental|Telemedical Coaching|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal, which can be monitored by the participant and the coach. Health coaches which will have close phone contact to patients, supporting them to reduce weight and increase physical activity. In the first 12 weeks, patients will follow a formula diet (Almased) to achieve an initial weight reduction.
16682517|NCT02066831|Active Comparator|Telemedicine|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal which can be monitored by the participant.
16682518|NCT02066818|Active Comparator|Lidocaine Injection|Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
16682519|NCT02066818|Experimental|Lidocaine/tetracaine patch|Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
16682520|NCT02066805||Cohort 1|
16682605|NCT02066298|Experimental|Mometasone then Placebo then Tiotropium|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
16682521|NCT02066792|Experimental|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
16682522|NCT02066792|Active Comparator|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
16682523|NCT02066792|Placebo Comparator|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
16682524|NCT02066792|Active Comparator|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
16682525|NCT02066766||Subjects with diabetes mellitus (type 2)|
16682526|NCT02066753|Active Comparator|24 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.
16682527|NCT02066753|Experimental|48 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.
16682528|NCT02066740|Experimental|EverFlex™ stent with Entrust™ delivery system|
16682529|NCT02066727|Active Comparator|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
16682530|NCT02066727|Placebo Comparator|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
16682531|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
16682532|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
16682533|NCT02066701||Endoscopy Barrett's|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
16682534|NCT02066701||Endoscopy control|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
16682535|NCT02066688|Experimental|FA|Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm).
16682536|NCT02066688|Experimental|FA+Ca|Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm).
16682537|NCT02066688|Experimental|Ca|Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm).
16682538|NCT02066688|Placebo Comparator|blank control group|Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
16682539|NCT02066675|Experimental|Trabectedin|Trabectedin administered at the dose of 1.5 mg/mq-1.3 mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
16682540|NCT02066662|Experimental|Rivaroxaban|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing
16682541|NCT02066662|Active Comparator|Marcumar|Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
16682542|NCT02066649|Active Comparator|Carvedilol|Initiating patient on carvedilol after diagnosis of varices made on endoscopy
16682543|NCT02066649|Active Comparator|Variceal Band Ligation|performing variceal band ligation during endoscopy on patient after diagnosis of esophageal varices made on endoscopy
16682544|NCT02066649|Active Comparator|Combination Group (Carvedilol + Variceal band ligation)|once patient has confirmed large esophageal varices on endoscopy, he/she will be started on carvedilol (post-procedure) in addition to having variceal band ligation performed during endoscopy
16682545|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
16682546|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year (52 weeks).
~Discontinue treatment and at progression, retreatment allowed"
16682547|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
16682548|NCT02066610|Experimental|PN selenium and formula sodium selenate|Parenteral nutrition (PN) with selenium and sodium selenate supplementation of infant formula
16682549|NCT02066610|Experimental|PN selenium and formula sodium selenite|Parenteral nutrition (PN) with selenium and sodium selenite supplementation of infant formula
16682550|NCT02066610|Experimental|PN without selenium and formula sodium selenate|Parenteral nutrition (PN) without selenium and sodium selenate supplementation of infant formula
16682551|NCT02066610|Experimental|PN without selenium and formula sodium selenite|Parenteral nutrition (PN) without selenium and sodium selenite supplementation of infant formula
16682552|NCT02066597|Experimental|Intervention|
16682553|NCT02066584||Universal IVF Medium|An oocyte culture medium containing 5.55 Mm glucose (Origio, Medi-Cult)
16682554|NCT02066584||ISM1 Medium|An oocyte culture medium containing 1mM glucose ((Origio, MediCult)
16682555|NCT02066584||P1 Medium|An oocyte culture medium containing no glucose (Irvine)
16682557|NCT02066571|Other|droxidopa, then sugar pill|Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
16682558|NCT02066571|Other|sugar pill, then droxidopa|Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
16682559|NCT02066558|Active Comparator|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
16682560|NCT02066558|Placebo Comparator|placebo|Atmospheric air
16682561|NCT02066545|Placebo Comparator|Vehicle Gel|
16682562|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
16682563|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
16682564|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
16682565|NCT02066532|Experimental|Ruxolitinib/Trastuzumab|Jakafi (Ruxolitinib) and Trastuzumab (Herceptin) - 21 day cycle until disease progression
16682566|NCT02066519|Experimental|Physical exercise arm|Arm with physical exercise on rowing machine between M3 and M6
16682567|NCT02066519|No Intervention|Control arm|Arm with standard medical care without additional physical exercise
16682568|NCT02066506|Sham Comparator|asymptomatic group|patients with systemic right ventricle who are asymptomatic,
16682569|NCT02066506|Sham Comparator|symptomatic group|symptomatic group : patients with systemic right ventricle and heart failure signs and/or decrease exercise performance
16682570|NCT02066506|Sham Comparator|control|healthy subject matched with patients of asymptomatic group
16682571|NCT02066493||conservative management|neither surgical nor endovascular management
16682572|NCT02066493||endovascular management|endovascular management
16682573|NCT02066493||surgical management|surgical management
16682574|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
16682575|NCT02066467||Heart failure patients|"Subjects with art failure who receive stable optimal pharmacologic therapy
~Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
~Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
16682576|NCT02066454|Experimental|Apixaban|oral direct anti-Xa anticoagulant
16682577|NCT02066441|Experimental|Bio-D-Mulsion Forte®|Bio-D-Mulsion Forte® at a dosage level of 2 drops (4,000 IU) once daily for the 6-month treatment period.
16682578|NCT02066441|Placebo Comparator|Placebo|Placebo a dosage level of 2 drops once daily for the 6-month treatment period.
16682579|NCT02066428|Experimental|AERAS-404(50mcg H4/0nmol IC31) or Placebo|1 dose
16682580|NCT02066428|Experimental|AERAS404 (50mcgH4/100nmol IC31) or Placebo|1 dose
16682581|NCT02066428|Experimental|AERAS404 (50mcgH4/0nmol IC31) or Placebo|2 dose
16682582|NCT02066428|Experimental|AERAS404 (150mcgH4/0nmol IC31) or Placebo|1 dose
16682583|NCT02066428|Experimental|AERAS404 (50mcgH4/5000nmol IC31) or Placebo|1 dose
16682584|NCT02066428|Experimental|AERAS404 (50mcgH4/500nmol IC31) or Placebo|2 dose
16682585|NCT02066428|Experimental|AERAS404|2 dose placebo
16682586|NCT02066428|Experimental|AERAS404 (50mcg H4/100nmol IC31) or Placebo|2 dose
16682587|NCT02066415|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
16682588|NCT02066415|Experimental|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
16682589|NCT02066415|Placebo Comparator|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
16682590|NCT02066402|Experimental|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
16682591|NCT02066402|Active Comparator|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
16682592|NCT02066389|Placebo Comparator|Placebo|Participants received placebo capsules twice daily for 12 weeks.
16682593|NCT02066389|Experimental|Upadacitinib 3 mg BID|Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
16682594|NCT02066389|Experimental|Upadacitinib 6 mg BID|Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
16682595|NCT02066389|Experimental|Upadacitinib 12 mg BID|Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
16682596|NCT02066389|Experimental|Upadacitinib 18 mg BID|Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
16682597|NCT02066389|Experimental|Upadacitinib 24 mg QD|Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
16682598|NCT02066363|Active Comparator|Best nutritional Care|Best supportive nutritional care and dietician advise
16682599|NCT02066363|Experimental|Parenteral nutrition|Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.
16682600|NCT02066350|Experimental|Single pancreas transplantation|This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
16682601|NCT02066337|Placebo Comparator|placebo gel|scaling and root planing with placebo gel
16682602|NCT02066337|Active Comparator|Ozonated olive oil gel|scaling and root planing with Ozonated olive oil gel
16682603|NCT02066311|Experimental|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
16682606|NCT02066298|Experimental|Placebo then Mometasone then Tiotropium|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
16682607|NCT02066298|Experimental|Placebo then Tiotropium then Mometasone|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
16682608|NCT02066298|Experimental|Tiotropium then Placebo then Mometasone|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
16682609|NCT02066298|Experimental|Tiotropium then Mometasone then Placebo|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
16682610|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
16682611|NCT02066272||IBD patients|IBD patients who start or re-start anti-TNF therapy
16682612|NCT02066259||healthy_0|healthy, people with normal (negative) colonoscopy results.
16682613|NCT02066259||patient_1|people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ
16682614|NCT02066259||benign_2|people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia
16682615|NCT02066246|Sham Comparator|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
16682616|NCT02066246|Active Comparator|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
16682617|NCT02066233|Active Comparator|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
16682618|NCT02066233|Active Comparator|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
16682619|NCT02066220|Experimental|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
16682620|NCT02066220|Experimental|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.
~Total treatment duration is 48 weeks."
16682621|NCT02066207|Experimental|Fenofibrate|Subjects received Fenofibrate
16682622|NCT02066207|Experimental|Atorvastatin|Subjects received Atorvastatin
16682623|NCT02066207|Experimental|Fenofibrate and Atorvastatin|Subjects received Fenofibrate and Atorvastatin
16682624|NCT02066194|Active Comparator|Electroacupuncture|Patients randomized to the experimental group will receive EA at acupoints relevant to the treatment of abdominal pain and anxiety. Selection of these acupoints is based on a consensus between the acupuncturist of the study (Leung WW) and several professors of the Diploma Course of Clinical Acupuncture of the School of Professional and Continuing Education, University of Hong Kong.
16682625|NCT02066194|Placebo Comparator|Sham Acupuncture|Patients randomized to the control group will receive Sham acupuncture with sterile blunt-tip needles
16682626|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
16682627|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
16682628|NCT02066155|Experimental|Parish nurse|On-going support provided by parish nurse
16682629|NCT02066155|Experimental|Peer support|On-going support provided by a person with diabetes
16682630|NCT02066155|No Intervention|Control group|No on-going support provided
16682631|NCT02066142|Active Comparator|Tomosynthesis|Tomosynthesis will be compared to Ultrasound
16682632|NCT02066142|Other|Ultrasound|Ultrasound (sensitivity and specificity) will be compared to Tomosynthesis
16682633|NCT02066129|Active Comparator|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
16682634|NCT02066129|Active Comparator|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
16682635|NCT02066116|Experimental|Kinect-based Rehabilitation|
16682636|NCT02066116|Active Comparator|Self-exercises education|
16682637|NCT02066103|Experimental|Treatment|
16682638|NCT02066090|Experimental|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
16682639|NCT02066090|Sham Comparator|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
16682640|NCT02066077|Experimental|Bilateral temporal and propofol|During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
16682641|NCT02066077|Experimental|Bilateral temporal and etomidate|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
16682642|NCT02066077|Experimental|The right temporal and propofol|During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
16682643|NCT02066077|Experimental|The right temporal and etomidate|During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
16682644|NCT02066077|Experimental|Bilateral frontal and propofol|During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
16682645|NCT02066077|Experimental|Bilateral frontal and etomidate|During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
16682646|NCT02066077|Active Comparator|Standard-therapy Group|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
16682647|NCT02066064|Experimental|Group A|Subjects will undergo complete standard colonoscopy, followed by G-EYE(TM) Colonoscopy
16682648|NCT02066064|Active Comparator|Group B|Subject will undergo G-EYE(TM) colonoscopy followed by standard colonoscopy
16682649|NCT02066051|Experimental|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
16682650|NCT02066038|Experimental|A|Pemetrexed 500mg/m2+Carboplatin area under curve(AUC)=5, every 3 weeks, maximum 4 cycles, Erlotinib 150mg/d every cycle d2-15, and Erlotinib 150mg/d from the last cycle until disease progression
16682651|NCT02066025||group_0|Women with negative mammography (BIRADS 1-2), as negative controls.
16682653|NCT02066025||group_2|Women with positive mammography (BIRADS 3-4-5-6), and a negative biopsy diagnosis for breast cancer (ID, IL, DCIS) will be enrolled as benign (ADH, ALH, LCIS, fibroadenoma, fibrocystic changes (including sclerosing adenosis), Benign papillaoma, normal breast) as benigns.
16682654|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
16682655|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
16682656|NCT02066012||group T|group T composed of lean subjects
16682657|NCT02065986|Experimental|Arm A: Immediate offer of Truvada-PrEP|Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
16682658|NCT02065986|Other|Arm B: Deferred (12m) offer of Truvada-PrEP|Access to Truvada from 12 months after enrolment
16682659|NCT02065973|Active Comparator|Cohort 1 (Low Dose)|The group will receive the lowest dose of the vaccine
16682660|NCT02065973|Active Comparator|Cohort 2 (Mid Dose)|The Group will receive the middle dose of the vaccine
16682661|NCT02065973|Active Comparator|Cohort 3 (High Dose)|The Group will receive the highest dose of vaccine to be tested
16682662|NCT02065960|Experimental|Stereotactic body radiotherapy (SBRT)|Radiotherapy with SBRT to a dose of 40 Gy in 5 fractions delivered every other day over a period of 10-12 days, followed by breast conserving surgery.
16682663|NCT02065947|Active Comparator|general anesthesia|fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
16682664|NCT02065947|Experimental|paravertebral block|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
16682665|NCT02065921||COPD patients|establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.
16682666|NCT02065895|Experimental|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
16682667|NCT02065895|Experimental|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
16682668|NCT02065895|Experimental|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
16682669|NCT02065895|Experimental|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
16682670|NCT02065895|Experimental|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
16682671|NCT02065895|Experimental|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
16682672|NCT02065882|Experimental|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
16682673|NCT02065869|Experimental|BPX-501 T cells and rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).
~Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
16682674|NCT02065856|Experimental|AVANZ Salsola kali|Subcutaneous immunotherapy
16682675|NCT02065843|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
16682676|NCT02065843|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
16682677|NCT02065843|Active Comparator|Passiflora incarnata|100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.
16682678|NCT02065843|Active Comparator|midazolam|15 mg midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.
16682679|NCT02065830|Experimental|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.
~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
16682680|NCT02065817|Experimental|Tracer|
16682681|NCT02065804|Experimental|Active drug|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
16682682|NCT02065804|Placebo Comparator|Placebo|10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
16682683|NCT02065791|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
16682684|NCT02065791|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily
16682685|NCT02065778|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
16682686|NCT02065752|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
16682687|NCT02065752|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
16682688|NCT02065752|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
16682689|NCT02065739|Experimental|Period 1|Participants will receive a single 30-mg dose of JNJ-42165279 on Day 1.
16682690|NCT02065739|Experimental|Period 2|Participants will receive itraconazole 200 mg once a day from Day 4 to Day 10. A single oral 30-mg dose of JNJ-42165279 will be administered on Day 8 along with the dose of 200 mg itraconazole.
16682691|NCT02065726|Experimental|Whey protein|Nutritional counseling + 20 g (2 x 10 g) of whey proteins (Prother® - Spepharm Italy)
16682692|NCT02065726|Active Comparator|Nutritional counseling|Nutritional counseling
16682693|NCT02065713|Experimental|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.
~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
16682694|NCT02065713|Active Comparator|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
16682695|NCT02065700|Experimental|Filgotinib 200 mg once daily|Filgotinib 200 mg (2 x 100 mg) once daily (morning)
16682696|NCT02065700|Experimental|Filgotinib 100 mg twice daily|Filgotinib 100 mg twice daily (morning and evening)
16682697|NCT02065687|Experimental|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
16682698|NCT02065687|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
16682699|NCT02065648||Syngo NATIVE MRA|All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
16682700|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
16682701|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
16682702|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-SD|Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
16682703|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-HD|Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
16682704|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-SD|Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
16682705|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-HD|Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
16682706|NCT02065622|Experimental|Maintenance (Main Study): TDM Regimen|Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
16682707|NCT02065609|Experimental|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
16682708|NCT02065609|Experimental|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
16682709|NCT02065596|Experimental|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
16682710|NCT02065583||GI abdominal surgery patients|Patients recovering from gastrointestinal abdominal surgery.
16682711|NCT02065570|Experimental|Induction: Standard Induction Dose|Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.
16682712|NCT02065570|Experimental|Induction: Higher Induction Dose|Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.
16682713|NCT02065570|Experimental|Maintenance: Clinically Adjusted (CA) Regimen|Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.
16682714|NCT02065570|Experimental|Maintenance: Therapeutic Drug Monitoring (TDM) Regimen|At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.
16682715|NCT02065557|Experimental|Adalimumab Induction Standard Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
16682716|NCT02065557|Experimental|Adalimumab Induction High Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
16682717|NCT02065557|Experimental|Adalimumab Induction High Dose - Open Label|(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
16682718|NCT02065557|Placebo Comparator|Maintenance Placebo|(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
16682719|NCT02065557|Experimental|Adalimumab Maintenance Standard Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg [maximum dose of 40 mg] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
16682720|NCT02065557|Experimental|Adalimumab Maintenance High Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg [maximum dose of 40 mg] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
16682721|NCT02065544|Experimental|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
16682722|NCT02065531|Experimental|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
16682723|NCT02065531|Active Comparator|Mobilization with impulse technique|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
16682724|NCT02065518|Active Comparator|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment supervised by a physical therapist at the physical therapy clinics.
16682725|NCT02065518|Experimental|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
16682726|NCT02065518|Experimental|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a weighted vest to begin the strengthening component.
16682727|NCT02065518|Experimental|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
16682728|NCT02065505|Experimental|Pilates Group Solo|participate in this group 30 individuals who will be treated with the Pilates Method performing the exercises on the ground, using the Swiss ball and elastic bands. The exercises will aim to lengthen the musculature that are shortened due to the characteristic postural pattern of pathology (major and minor pectoral, shoulder adductors, biceps, wrist flexors, trunk side chain); strengthen the musculature that provide postural support (abdominal, middle trapezius, rhomboids, gluteus maximus, erector spinae and latissimus dorsi) and the upper limb musculature important for activities of daily living (triceps, biceps, internal rotators, external rotators and abductors of the shoulder).
16682729|NCT02065505|Experimental|Water Pilates Group|participate in this group 30 individuals who will be treated with the Pilates method, but doing the exercises in the therapy pool, with the aid of floats and weights. The protocol of stretches and exercises will work the same muscle groups than the G1, keeping the same decubitus whenever possible. The adaptations to the exercises are justified by the physical principles of water, which at one point may act for or against the activity being performed.
16682730|NCT02065492|Experimental|Standard Chelation & Amlodipine|"This arm will receive both chelation and amlodipine.
~Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day.
~Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.
~The dosage will depend on individual requirement, as determined by the treating hematologist."
16682731|NCT02065492|Active Comparator|Standard Chelation|"Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.
~The dosage will depend on individual requirement, as determined by the treating hematologist.
~This will serve as the control arm of the study without any additional intervention."
16682732|NCT02065479|Active Comparator|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
16682733|NCT02065479|Experimental|Prasugrel|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
16682734|NCT02065466|Experimental|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
16682735|NCT02065453|Other|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
16682736|NCT02065453|Other|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
16682737|NCT02065440|Active Comparator|Ebastine/Pseudoephedrine|administration of ebastine/pseudoephedrine 1cap/day for 1 week.
16682738|NCT02065440|Placebo Comparator|placebo|administration of placebo pill 1 cap/day for 1week
16682739|NCT02065427|Experimental|Social support|"Social support intervention
~Intervention is performed by the health professionals working at the primary health care team responsible for the patient, and consisits of the following components:
~a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support."
16682740|NCT02065427|No Intervention|Usual home health care|Caregivers and dependent patients: usual home health care, consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request
16682741|NCT02065414|Placebo Comparator|Neg Control Mouth Rinse W002194-0221-P|"Mouth rinse containing 5% Hydroalcohol
~Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse W002194-0221-P for 30 seconds and spit it out."
16682742|NCT02065414|Experimental|Experimental: Mouth Rinse 19668-012|Listerine Advance Gum Defense Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
16682743|NCT02065414|Active Comparator|Active Comparator Mouth Rinse 5000347078873|"Mouth rinse containing Chlorhexidine Corsodyl ®Mouthwash
~Twice each day, brush in usual manner with a fluoride-containing dentifrice, in the usual manner, rinse mouth with water, wait 5 minutes after brushing and then rinse with 10 ml of mouth rinse 5000347078873for 60 seconds and spit it out - do not swallow."
16682744|NCT02065401|Experimental|Deferitazole (disodium salt, granule)|
16682745|NCT02065401|Experimental|Deferitazole (disodium salt, tablet)|
16682746|NCT02065401|Experimental|Deferitazole (magnesium hydroxide salt)|
16682747|NCT02065388|Active Comparator|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
16682748|NCT02065388|Experimental|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
16682749|NCT02065388|Experimental|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
16682750|NCT02065375|Experimental|RTA 408 0.5% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 0.5% or Placebo) in the study eye for 14 days
16682751|NCT02065375|Experimental|RTA 408 1.0% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 1.0% or Placebo) in the study eye for 14 days
16682752|NCT02065362|Experimental|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f
16682753|NCT02065349|Placebo Comparator|Placebo|oral
16682754|NCT02065349|Active Comparator|ASP8477|oral
16682755|NCT02065336|Experimental|ARC-520 Cohort 1|a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
16682756|NCT02065336|Placebo Comparator|ARC-520 Cohort 2|a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
16682757|NCT02065336|Experimental|ARC-520 Cohort 3|a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
16682758|NCT02065336|Experimental|ARC-520 Cohort 4|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
16682759|NCT02065336|Experimental|ARC-520 Cohort 5|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection
16682760|NCT02065336|Experimental|Placebo Normal Saline Cohorts 1-5|a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection
16682761|NCT02065336|Experimental|ARC-520 Cohort 6|two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV
16682762|NCT02065336|Experimental|ARC-520 Cohort 7|a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)
16682763|NCT02065336|Experimental|ARC-520 Cohort 8|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every [Q]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4
16682764|NCT02065336|Experimental|ARC-520 Cohort 9|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6
16682765|NCT02065336|Experimental|ARC-520 Cohort 10|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7
16682766|NCT02065336|Experimental|ARC-520 Cohort 11|a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
16682767|NCT02065336|Experimental|ARC-520 Cohort 12|a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
16682768|NCT02065323|Active Comparator|ADT alone|Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
16682769|NCT02065323|Experimental|ADT plus Dovitinib|"Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
~Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons."
16682770|NCT02065310|No Intervention|Diabetes, Non-diabetes|
16682771|NCT02065297||Horton's disease|
16682772|NCT02065297||Infectious disease|
16682773|NCT02065297||Neoplasia|
16682774|NCT02065297||Control|
16682775|NCT02065284|Active Comparator|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
16682776|NCT02065284|Active Comparator|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
16682777|NCT02065284|Active Comparator|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
16682778|NCT02065271|Experimental|herbal supplements|500mg, 3 per day, 4weeks
16682779|NCT02065271|Placebo Comparator|placebo|500mg, 3 per day, 4 weeks
16682780|NCT02065258|Active Comparator|Breathing Exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions and will be part of the routine of breathing exercises the following exercises: I) Kapalabhati ; II) Uddhiyana ;III) Surya Bedhana
16682781|NCT02065258|Active Comparator|Aerobic Exercise|Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
16682782|NCT02065245|Experimental|Pilot phase - Group 1|Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
16682783|NCT02065245|Experimental|Pilot Phase - Group 2|Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
16682784|NCT02065245|Experimental|Pilot Phase - Group 3|Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
16682785|NCT02065245|Experimental|Randomized Phase - Group A|Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
16682786|NCT02065245|Experimental|Randomized phase - Group B|Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
16682787|NCT02065245|Experimental|Randomized Phase - Group C|Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.
16682788|NCT02065245|Experimental|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
16682789|NCT02065232||Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
16682790|NCT02065232||Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
16682791|NCT02065219|Experimental|Bupivacaine|injection, 25 mg, once, 5 min
16682792|NCT02065219|Placebo Comparator|Placebo|injection, 10 ml 0.9% sodium chloride, once, 5 min
16682793|NCT02065193||Beijing group|
16682794|NCT02065193||Guangdong group|
16682795|NCT02065193||Shenzhen group|
16682796|NCT02065193||Shanxi group|
16682797|NCT02065193||Liaoning group|
16682798|NCT02065193||Jilin group|
16682799|NCT02065193||Heilongjiang group|
16682800|NCT02065193||Jiangsu group|
16682801|NCT02065193||Zhejiang group|
16682802|NCT02065193||Fujian group|
16682803|NCT02065193||Henan group|
16682804|NCT02065193||Hubei group|
16682805|NCT02065193||Hunan group|
16682806|NCT02065193||'Shanxi group|
16682807|NCT02065180|Experimental|commercially available nutrition supplement|this group receives a commercially available nutritional supplement for a period of 2 months
16682808|NCT02065180|Placebo Comparator|control group|this group receives a placebo for a period of 2 months
16682809|NCT02065167|Experimental|Cultured autologous Mesenchymal Cells|"Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
~20x106 cells per cc in a single administration of 7cc"
16682810|NCT02065154|Experimental|Treatment|Cyclophosphamide (Cytoxan)
16682811|NCT02065141|Other|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day: stable isotope infusions with blood draws, sip feed"
16682910|NCT02064517|Placebo Comparator|Conventional technique|Apical MTA barrier
16682812|NCT02065141|Other|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.
~study day: stable isotope infusions with blood draws, sip feed"
16682813|NCT02065141|Other|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.
~study day: stable isotope infusions with blood draws, sip feed"
16682814|NCT02065128||Healthy Volunteers|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
16682815|NCT02065128||Irritable Larynx Syndrome Patients|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
16682816|NCT02065115|Experimental|Cryotherapy|Cryotherapy: 12 ounces of crushed ice place in a plastic bag applied to the radial artery puncture area for 3 minutes
16682817|NCT02065115|No Intervention|Control|Cryotherapy is not applied to the radial artery puncture area
16682818|NCT02065089|Experimental|playing the ipad quiz game|There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game)
16682819|NCT02065076|Active Comparator|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
16682820|NCT02065076|Placebo Comparator|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
16682821|NCT02065063|Experimental|Part 1|Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
16682822|NCT02065063|Experimental|Part 2|Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.
16682823|NCT02065063|Experimental|Part 3|Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
16682824|NCT02065050|No Intervention|Usual Care|Individuals in the usual care arm will not receive frequent contact by the study team. Individuals will be seen by a study team clinician 1 year after discharge to review diabetes management and obtain pertinent study related data.
16682825|NCT02065050|Experimental|Continued care|team-based care: Individuals in the continued care arm will be frequently contacted by the study team (consisting of endocrinologists, nurse practitioners, and health coaches) over the course of one year post-discharge. The team will monitor blood sugars and other health data, altering management as needed.
16682826|NCT02065037|Experimental|Warmed Carbon Dioxide Insufflation|warmed carbon dioxide insufflation used in colonoscopy
16682827|NCT02065037|Active Comparator|Room Temperature Air Insufflation|room temperature air insufflation used in colonoscopy
16682828|NCT02065024|Active Comparator|b-cryptoxanthin plus phytosterols|Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols
16682829|NCT02065024|Placebo Comparator|control|Fruit and milk based beverage not enriched
16682830|NCT02065011|Other|Long-term follow up|Long-term follow up of patients who received SAR421869 in a previous study TDU13600
16682831|NCT02064998|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
16682832|NCT02064998|Experimental|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
16682833|NCT02064998|No Intervention|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
16682834|NCT02064998|Experimental|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
16682835|NCT02064998|Experimental|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
16682836|NCT02064985|Experimental|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
16682837|NCT02064985|Experimental|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
16682838|NCT02064985|Experimental|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
16682911|NCT02064517|Experimental|Revascularisation pulpaire|hydroxide of calcium
16682990|NCT02063984|Experimental|Intensive Outpatient Treatment (IOP) + Contingency Management (CM) + Working Memory Training (WMT)|IOP + CM + WMT
16682991|NCT02063984|Active Comparator|IOP + CM|IOP + CM
16682839|NCT02064972||Patients undergoing allo-HSCT, who manifest GvHD.|Patients undergoing allo-HSCT, that manifest GvHD. Patients undergoing allo-HSCT will have CEC count performed at the following timepoints: T1 (baseline), T2 (pre-transplant), T3 (engraftment), T4 (GvHD onset) and T5 (post-GvHD). All patients will also be checked for CEC at day + 28.
16682840|NCT02064959|Experimental|Hypothermia|Hypothermia to 33°C
16682841|NCT02064959|Active Comparator|Normothermia|standard care - normothermia (37°C)
16682842|NCT02064946|Active Comparator|Vitamin D3|Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
16682843|NCT02064946|Placebo Comparator|Control|Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
16682844|NCT02064933||Retrospective Cohort (Longitudinal Analysis)|Participants with WAS treated at consortium centers since 1990 who have received transplant (Stratum A) or gene therapy (Stratum B)
16682845|NCT02064933||Prospective Cohort (Longitudinal Analysis)|Participants treated at consortium centers since 1990 who will receive transplant (Stratum A) or gene therapy (Stratum B)
16682846|NCT02064933||Cross-Sectional Cohort (Cross-sectional Analysis)|Living participants with WAS who have received transplant (Stratum A) or gene therapy (Stratum B) at Consortium Centers 1990-Present And >= 2 Years Post-Transplant
16682847|NCT02064920|Placebo Comparator|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
16682848|NCT02064920|Experimental|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
16682849|NCT02064907|Experimental|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
16682850|NCT02064907|Experimental|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
16682851|NCT02064894|Experimental|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
16682852|NCT02064894|Experimental|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
16682853|NCT02064894|Active Comparator|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
16682854|NCT02064881|Experimental|metformin glycinate|"620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.
~Total study dose: 1240mg every 12 hours."
16682855|NCT02064881|Active Comparator|metformin hydrochloride|"500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.
~Total study dose: 1000mg every 12 hours."
16682856|NCT02064868|Experimental|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
16682857|NCT02064868|Other|Standard of Care (SOC)|All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
16682858|NCT02064842|Experimental|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
16682859|NCT02064842|Experimental|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
16682860|NCT02064842|Experimental|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
16682861|NCT02064842|Experimental|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
16682862|NCT02064842|Experimental|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
16682863|NCT02064842|Experimental|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
16682980|NCT02064023|Experimental|insulin pump|subjects will use an insulin pump for the duration of the pregnancy. The intervention is that they will control their diabetes using an insulin pump
16682981|NCT02064023|Active Comparator|Multiple Daily Insulin injections|subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
16682864|NCT02064842|Experimental|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
16682865|NCT02064842|Experimental|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
16682866|NCT02064842|Experimental|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
16682867|NCT02064829|Active Comparator|Reference Drug - Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1
16682868|NCT02064829|Experimental|Test Drug - IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1
16682869|NCT02064816|Experimental|Rebif® Morning Administration|
16682870|NCT02064816|Experimental|Rebif® Evening Administration|
16682871|NCT02064803|Active Comparator|Control group: A|Gastro-entero anastomosis only
16682872|NCT02064803|Experimental|Experimental: B|Gastric partitioning Plus Gastro-entero anastomosis
16682873|NCT02064790||Group G - receiving gabapentin|Receiving gabapentin as standard of care. No intervention
16682874|NCT02064790||Group P - receiving pregabalin|Receiving pregabalin as standard of care No intervention
16682875|NCT02064790||Group Z - no neuropathic agent|Receiving only conservative treatment No drug treatment No intervention
16682876|NCT02064777|Experimental|Tacrolimus|
16682879|NCT02064751|Experimental|MultiPoint Pacing|CRT with MultiPoint Pacing
16682880|NCT02064738|No Intervention|Normal diet|Two weeks of unaltered diet
16682881|NCT02064738|Experimental|Low omega-6/high omega-3 diet|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
16682882|NCT02064725|Experimental|Sodium cridanimod|Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
16682883|NCT02064712|Active Comparator|Low CPAP Wean|NCPAP weaned to 5cm H2O for minimum of 24h, and if the neonate remains clinically stable as defined, wean in 1cm increments to 3cm H2O for minimum of 24h, at which time move to room air or 1L/min nasal cannula if supplemental O2 is required.
16682884|NCT02064712|Active Comparator|High CPAP Wean|NCPAP weaned to 5cm H2O for a minimum of 24h, and if the neonate remains clinically stable, move to room air or 1L/min nasal cannula if supplemental O2 is required.
16682885|NCT02064699||CMV infection|Renal transplant recipient immunized against the Cytomegalovirus
16682886|NCT02064686|No Intervention|TAE|
16682887|NCT02064673|Active Comparator|Curcumin|Curcumin 500 mg orally twice a day
16682888|NCT02064673|Placebo Comparator|sugar pill|placebo orally twice a day
16682889|NCT02064660|Experimental|single arm|A series of acupressure sessions within six months from the baseline
16682890|NCT02064647|Experimental|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool, uses a formula based on the patients Insulin Sensitivity Factor (ISF) to allow adjustments to meal time insulin boluses, based on CGM trend arrows.
16682891|NCT02064647|Active Comparator|10/20% bolus adjustment|10-20% increase/decrease of the total original recommended bolus dose (10% for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose calculated by the pump calculator (i.e. Bolus Wizard).
16682892|NCT02064647|No Intervention|No adjustment/ignore trend arrows|Subjects will ignore the CGM trend arrows, meal time bolus insulin as per Bolus Wizard
16682893|NCT02064634||Shinbaro (only)|
16682894|NCT02064634||Celecoxib (only)|
16682895|NCT02064634||Shinbaro + NSAIDs|
16682896|NCT02064634||Shinbaro + Celecoxib|
16682897|NCT02064621|Experimental|C(Candesartan 32mg)|Candesartan 32mg 1T, PO, QD for 9days
16682898|NCT02064621|Experimental|B(Candesartan 32mg/Amlodipine 10mg)|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
16682899|NCT02064608|Experimental|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
16682900|NCT02064595|Other|Intramedullary nail|Fractures treated with intramedullary reamed nail
16682901|NCT02064595|Active Comparator|External fixator|Tibial fractures treated with biplanar external fixation
16682902|NCT02064582|Other|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
16682903|NCT02064569|Experimental|GS010|
16682904|NCT02064556|Experimental|A(Amlodipine 10mg)|Amlodipine 10mg 1T, PO, QD for 9days
16682905|NCT02064556|Experimental|B(Amlodipine 10mg/Candesartan 32mg)|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
16682906|NCT02064543||ADPM and GAITRite|mobility assessments (ADPM, GAITRite) measuring gait parameters
16682907|NCT02064530|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
16682908|NCT02064530|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
16682909|NCT02064530|Sham Comparator|serum phsyologic|0,9% 21 ml serum physiologic
16682912|NCT02064504|Experimental|Sequence 1|Participants will receive the study treatment in the following order: ABFCED in each period (one per period). Where A=GSK961081 administered from DISKUS, B=GSK961081 Single strip (SS) administered from DPI, C=GSK961081 Dual Strip (DS) administered from DPI with a filled (lactose) second strip (DS configuration), D=GSK961081/fluticasone furoate (GSK961081/FF) administered from DPI (GSK961081 higher dose), E=FF DS administered from DPI with a filled (lactose) second strip (dual strip configuration), F=GSK961081/FF administered from DPI (GSK961081 lower dose).
16682913|NCT02064504|Experimental|Sequence 2|Participants will receive the study treatment in the following order: BCADFE in each period (one per period)
16682914|NCT02064504|Experimental|Sequence 3|Participants will receive the study treatment in the following order: CDBEAF in each period (one per period)
16682915|NCT02064504|Experimental|Sequence 4|Participants will receive the study treatment in the following order: DECFBA in each period (one per period)
16682916|NCT02064504|Experimental|Sequence 5|Participants will receive the study treatment in the following order: EFDACB in each period (one per period)
16682917|NCT02064504|Experimental|Sequence 6|Participants will receive the study treatment in the following order: FAEBDC in each period (one per period)
16682918|NCT02064491|Experimental|Erlotinib and Chemotherapy|Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance
16682919|NCT02064491|Active Comparator|Chemotherapy|Chemotherapy for four to six cycles
16682920|NCT02064478||Tissue preservation|Ponto implant installed using a tissue preservation surgical technique
16682921|NCT02064478||Tissue reduction|Ponto implant installed using a classical technique with skin thinning
16682922|NCT02064465|Experimental|Lamotrigine Dispersable/Chewable|lamotrigine dispersible/chewable tablet 100mg
16682923|NCT02064465|Experimental|Lamotrigine Compressed|lamotrigine compressed tablet 100mg
16682924|NCT02064452|Experimental|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
16682925|NCT02064452|Placebo Comparator|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
16682926|NCT02064439|Experimental|Arm 1|Rivaroxaban 10 mg once daily for 12 months
16682927|NCT02064439|Experimental|Arm 2|Rivaroxaban 20 mg once daily for 12 months
16682928|NCT02064439|Active Comparator|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
16682929|NCT02064426|Experimental|Molidustat (BAY85-3934)|
16682930|NCT02064426|Active Comparator|Epoetin alfa/beta|
16682931|NCT02064413|Experimental|ESS310|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
16682932|NCT02064400||Observational study group|Musculoskeletal ultrasound (all patients) and semi-structured patient interview (anticipated maximum 15 patients)
16682933|NCT02064387|Experimental|Schedule 1 Part 1|Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
16682934|NCT02064387|Experimental|Schedule 2 Part 1|Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
16682935|NCT02064387|Experimental|Schedule 1 Part 2|Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
16682936|NCT02064387|Experimental|Schedule 2 Part 2|Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
16682937|NCT02064374|Experimental|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
16682938|NCT02064374|Experimental|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
16682939|NCT02064361|Experimental|High intensity exercise|A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling
16682940|NCT02064348|Experimental|Arm 1: semaglutide + moxifloxacin placebo|Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
16682941|NCT02064348|Active Comparator|Arm 2A:|"Semaglutide placebo + moxifloxacin/moxifloxacin placebo:
~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
16682942|NCT02064348|Experimental|Arm 2B:|"Semaglutide placebo + moxifloxacin placebo/moxifloxacin:
~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
16682982|NCT02064010|Experimental|SNC-102, low dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
16682983|NCT02064010|Experimental|SNC-102, high dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
16682984|NCT02064010|Placebo Comparator|Placebo|Placebo tablet 4 week duration dosing
16682985|NCT02063997|Experimental|Arhalofenate 600 mg|
16682943|NCT02064335|Experimental|Intervention group|"Physical activity coaching: Participants will be coached by a professional physical activity coach through individual and group sessions.
~Intake: This talk (1 hour) is the start of the coaching. A physical activity plan will be set up, according to the needs and possibilities of the participant. Activities in leisure time and daily physical activity will be included.
~Group sessions: During 5 weeks and one time a week, the subjects will take part in the exercise lessons. About 5 subjects will be in one group and all sessions are supervised by a professional physical activity coach. Activities are walking, Nordic walking and conditional fitness.
~Evaluation: After the 5 weeks of group sessions, an evaluation moment will take place between each participant and the physical activity coach. The physical activity plan will be refined."
16682944|NCT02064335|No Intervention|Control group|The control group will operate as a waiting group. It means that in the first 6 months of the project, the subjects of the control group will only be measured and will not receive any intervention.
16682945|NCT02064322||SImmetry Implant|Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant.
16682946|NCT02064309|Experimental|Human islets in Beta-Air device|
16682947|NCT02064296|No Intervention|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
16682948|NCT02064296|Active Comparator|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
16682949|NCT02064296|Active Comparator|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
16682950|NCT02064283|Experimental|Diffusion MRI Assessment|Men with newly diagnosed metastatic disease initiating therapy with androgen deprivation, or men with hormone refractory prostate cancer initiating treatment with chemotherapy, will be assessed by diffusion MRI (Magnetic Resonance Imaging) at baseline, 2 weeks and again at 9-12 weeks.
16682951|NCT02064270|Active Comparator|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
16682952|NCT02064270|Active Comparator|Standard dressings|Standard postsurgical dressings
16682953|NCT02064257|Experimental|Intervention group|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
16682954|NCT02064257|No Intervention|Assessment-only group|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
16682955|NCT02064244||Acute renal failure in ICU|Ultrasound for measurement of Inferior Vena Cava size
16682956|NCT02064231|Experimental|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
16682957|NCT02064231|Experimental|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
16682958|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
16682959|NCT02064218||healthy subjects|healthy subjects
16682960|NCT02064205|Active Comparator|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
16682961|NCT02064205|Placebo Comparator|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
16682962|NCT02064192||ICD Group (n=1500)|First ICD device implantation (after baseline assessments) is not part of this observational study and is carried out in the responsibility of the treating physician, all ICD-devices will undergo unique standard programming to ensure comparability of ICD shock events between patients.
16682963|NCT02064192||Control Group (n=750)|Patients who fulfill inclusion criteria but do not receive an ICD device will be followed as part of the Control Group
16682964|NCT02064166|Experimental|Insulin|40 IU of intranasal insulin daily
16682965|NCT02064166|Placebo Comparator|Placebo|Placebo arm using intranasal normal saline
16682966|NCT02064153|Active Comparator|Cool dialysate|Recruited study subject undergoes cool dialysate (35.5ºC) session.
16682967|NCT02064153|Active Comparator|Warm dialysate|Recruited study subject undergoes warm dialysate (37ºC) session.
16682968|NCT02064140|Experimental|Neuromuscular blocking agent|
16682969|NCT02064127||Patients with abdominal pain|Adult patients admitted to the Emergency Department with a main complaint of abdominal pain
16682970|NCT02064114|Active Comparator|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
16682971|NCT02064114|Active Comparator|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
16682972|NCT02064101||Adolescent idiopathic scoliosis|Patients with adolescent idiopathic scoliosis undergoing spinal fusion
16682973|NCT02064088|Experimental|Small volume|Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine
16682974|NCT02064088|Experimental|High volume|Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine
16682975|NCT02064075|Active Comparator|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day.
16682976|NCT02064075|Active Comparator|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day.
16682977|NCT02064062|Experimental|Autologous Mesenchymal Stem Cells|
16682978|NCT02064049|Experimental|Hepatitis C treatment|All prisoners (in participating correctional centres) with hepatitis c, as identified during the hepatitis C surveillance phase of the study will be offered treatment for hepatitis C. The treatment course is sofosbuvir/velpatasvir 400/100mg for 12 weeks (1 tablet once daily).
16682979|NCT02064036|Experimental|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
16682986|NCT02063997|Experimental|Arhalofenate 800 mg|
16682992|NCT02063971|Experimental|Skin aging|Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day
16682993|NCT02063958|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period. Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. Dose escalation will not exceed a dose of 100 mg/m2 SNX-5422 qod even if the MTD has not been identified. Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.
16682994|NCT02063945|Active Comparator|Methylphenidate|"Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills."
16682995|NCT02063945|Active Comparator|Risperidone|Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.
16682996|NCT02063932||endomicroscopy|
16682997|NCT02063919||endomicroscopy|
16682998|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
16682999|NCT02063893||non-vaccine|
16683000|NCT02063893||giving low vaccine|
16683001|NCT02063893||giving middle vaccine|
16683002|NCT02063893||giving high vaccine|
16683003|NCT02063880|Experimental|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
16683004|NCT02063880|Active Comparator|Early ART|Initiation of HAART 7-14 days after enrollment.
16683005|NCT02063867|No Intervention|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
16683006|NCT02063867|Active Comparator|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
16683007|NCT02063854|Active Comparator|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683008|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683009|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683010|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683011|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683012|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683013|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
16683014|NCT02063841|Active Comparator|sterile identical sham drape|Sham drape and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
16683015|NCT02063841|Experimental|lead-free protective drape containing bismuth and antimony|lead-free protective drape containing bismuth and antimony (RADPAD®) hung around the fluoroscopy image intensifier to prevent scatter radiation, and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
16683016|NCT02063828|Experimental|Group A|Group A - Device Guided Breathing Low Dose
16683017|NCT02063828|Experimental|Group B|Group B - Device guided breathing high dose
16683018|NCT02063828|Sham Comparator|Group C|Group C - Usual Breathing Control Group
16683019|NCT02063815|Active Comparator|glass ionomer based fissure sealant|fissure sealant application
16683020|NCT02063815|Active Comparator|resin based fissure sealant|fissure sealant application
16683021|NCT02063802|Active Comparator|metformin and healthy habits program|1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
16683022|NCT02063802|Experimental|Conjugated Linoleic Acid and healthy habits|Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.
16683023|NCT02063802|Placebo Comparator|Placebo and healthy habits program|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.
16683024|NCT02063789|Experimental|Human immunoglobulin intravenous|Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.
16683025|NCT02063776||Children on HDF|
16683026|NCT02063776||Children on conventional HD|
16683027|NCT02063750|Experimental|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
16683028|NCT02063750|Active Comparator|Stretching group|Performed stretching exercises
16683029|NCT02063737|Sham Comparator|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
16683030|NCT02063737|Experimental|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
16683031|NCT02063724|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
16683032|NCT02063711|Experimental|Yoga Intervention|A 1-hour yoga session will take place with guided instruction provided by a registered yoga instructor. The class includes a warm up period of 5 minutes, which includes sitting with the eyes closed and slowly breathing through the nose. After which the participant will perform a series of yoga postures in coordination with her breathing for approximately 45 minutes. The last 10 minutes of class will encompass a semi-recumbent relaxation period. This is a one time intervention.
16683033|NCT02063711|No Intervention|Control group|In order to control for 1 hour worth of time, the participants in the control group will be given a 1 hour Power Point presentation on the benefits of exercise and yoga during pregnancy.
16683034|NCT02063698|Experimental|Arm I (auranofin)|Patients receive auranofin PO on day 2.
16683035|NCT02063698|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 2.
16683036|NCT02063685|Other|GROUP 1 - STANDARD|R-CHOP or R-bendamustine + Standard Maintenance
16683037|NCT02063685|Experimental|GROUP 2|FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
16683038|NCT02063685|Experimental|GROUP 1a|FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation
16683039|NCT02063685|Experimental|GROUP 1b|FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4
16683040|NCT02063672|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
16683041|NCT02063672|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
16683042|NCT02063659|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
16683043|NCT02063659|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
16683044|NCT02063659|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
16683045|NCT02063646|Placebo Comparator|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
16683046|NCT02063646|Experimental|Polyphenol-rich extract|"The test product is a food supplement named Neurophenol. It is presented as a hard-shell capsule containing polyphenol-rich extracts.
~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
16683047|NCT02063620|Active Comparator|ketamine HCL|%0.5 Lidocaine+Ketamine HCL 0.8 mg/kg, total 40ml, single dose administration, 30 minute duration, total 200mg lidocaine
16683048|NCT02063620|No Intervention|lidocaine+ serum physiologic|% 0.5 lidocaine+ serum physiologic, total 40ml, total 200 mg lidocaine, 30 minute duration, single dose administration,
16683049|NCT02063607|Active Comparator|Peginterferon alfa 2a|Peginterferon alfa 2a 180 mcg
16683050|NCT02063607|Experimental|Peginterferon Lambda|Peginterferon Lambda 60,120,180 and 240 mcg
16683051|NCT02063594|Placebo Comparator|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
16683052|NCT02063594|Experimental|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
16683053|NCT02063581|Experimental|Sequence 1: Tablet followed by Capsule|
16683055|NCT02063568|Active Comparator|Low dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
16683056|NCT02063568|Active Comparator|High dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
16683057|NCT02063555|Experimental|DAR-901|"Intradermal administration at 0, 2 and 4 months
~Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
16683058|NCT02063555|Active Comparator|BCG|Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
16683059|NCT02063555|Placebo Comparator|Sterile saline|Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
16683060|NCT02063529|Experimental|A (FOLFOXIRI + Cetuximab)|FOLFOXIRI + Cetuximab
16683061|NCT02063529|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
16683062|NCT02063516|Experimental|Guardian|Device: Guardian Laryngeal Mask
16683063|NCT02063516|Experimental|Proseal|Device:Proseal Laryngeal Mask Airway
16683064|NCT02063503|Experimental|Motor control therapy|physiotherapy
16683065|NCT02063503|Experimental|Isometric training therapy|physiotherapy
16683066|NCT02063503|Experimental|Combination therapy|physiotherapy
16683067|NCT02063490|Experimental|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)
~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
16683068|NCT02063490|No Intervention|Control arm|Standard care
16683069|NCT02063477|Placebo Comparator|Product one|150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)
16683070|NCT02063477|Active Comparator|Product two|150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)
16683072|NCT02063451|Other|Obese, Weight Loss, Very Low Calorie Diet|Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
16683073|NCT02063451|No Intervention|Lean, baseline measure|MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
16683074|NCT02063438|Active Comparator|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
16683075|NCT02063438|Active Comparator|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
16683076|NCT02063425|Active Comparator|Fluoxetine|
16683077|NCT02063425|Placebo Comparator|Placebo|
16683078|NCT02063412||XELOX|Capecitabine (Xeloda) 1000mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
16683079|NCT02063412||XP|Cisplatin (CDDP) 80 mg/m2 iv over 3 hrs d1 Capecitabine (Xeloda) 1000 mg/m2 po bid d1-14, Q3w
16683080|NCT02063412||FOLFOX|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and d2 5-FU 400mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d1 and d2 Q2w
16683081|NCT02063412||FP|Cisplatin (CDDP) 100 mg/m2 iv d1 5-FU 1000 mg/m2/d civi d1-5, Q4w
16683082|NCT02063386|Experimental|AZD1722|Single oral dose 15 mg of [14C]AZD1722
16683083|NCT02063373|Experimental|biomechanis knee OA and HA injection|Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks
16683084|NCT02063360|Experimental|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
16683085|NCT02063360|Experimental|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
16683086|NCT02063360|Experimental|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
16683087|NCT02063347||Coronary artery disease|With coronary artery disease
16683088|NCT02063347||No coronary artery disease|Without coronary artery disease
16683089|NCT02063334|Active Comparator|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
16683090|NCT02063334|Placebo Comparator|Placebo|Placebo in two doses during one day
16683091|NCT02063308|Experimental|Oxaloacetate (OAA)|100 mg OAA to be taken twice daily over the course of a month
16683092|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
16683093|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
16683094|NCT02063282||Clostridium difficile carriers|
16683095|NCT02063282||Clostridium difficile non carriers|
16683096|NCT02063269|Experimental|Rivastigmine|Rivastigmine
16683097|NCT02063256|Active Comparator|7 NUTS a day|the patients allocated to this arm will be instructed to supplement their diet with 7 nuts a day (whole shelled weight around 75 grams)
16683098|NCT02063256|Experimental|Diet modification|the patients allocated to this arm will be instructed to modify their diet allowing more intake of PUFA rich food avoiding saturated fat rich food
16683099|NCT02063243|Other|keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
16683100|NCT02063230|Experimental|Selumetinib HV|Healthy volunteers (HV)
16683101|NCT02063230|Experimental|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
16683102|NCT02063230|Experimental|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
16683103|NCT02063230|Experimental|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
16683104|NCT02063217|Experimental|Sleep Induction|7.5 grams of sodium oxybate
16683105|NCT02063217|Experimental|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
16683106|NCT02063217|No Intervention|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
16683107|NCT02063204|Experimental|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
16683108|NCT02063204|Experimental|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
16683109|NCT02063204|Experimental|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
16683110|NCT02063191||Atrial Fibrillation|Patients with atrial fibrillation during the EP study
16683111|NCT02063191||Bundle Branch Block|Patient with bundle branch block during the course of the EP study
16683112|NCT02063178|Experimental|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
16683113|NCT02063178|Active Comparator|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
16683114|NCT02063152||Entire Taiwan women|
16683115|NCT02063139|Experimental|Flutiform 50/5 ug (2 puffs bid) pMDI|Flutiform 50/5 ug (2 puffs bid) pMDI
16683116|NCT02063139|Active Comparator|Fluticasone 50 ug (2puffs bid) pMDI|Fluticasone 50 ug (2puffs bid) pMDI
16683117|NCT02063139|Other|Beclometasone Autohaler 50 ug (2 puffs bid)|Active control
16683118|NCT02063126|Active Comparator|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
16683119|NCT02063126|Placebo Comparator|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
16683120|NCT02063113|No Intervention|NA/NA|
16683121|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 100mg|
16683122|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 50mg|
16683123|NCT02063100|Experimental|Losartan potassium 50mg|
16683124|NCT02063100|Experimental|Shenyankangfu tablets|
16683125|NCT02063100|Experimental|Losartan potassium 100mg|
16683126|NCT02063087|Active Comparator|Decision Aid|Head CT Decision Aid
16683127|NCT02063087|No Intervention|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
16683128|NCT02063061|Sham Comparator|Sham treatment|Subject will answer standardized questionnaires. Sham treatment arm will receive initially 5 sham series and after they answer standardized questionnaires they will receive 5 series of active treatment. Afterwards patients will answer standardized questionnaires again.
16683129|NCT02063061|Active Comparator|ESWT treatment|Subject will answer standardized questionnaires. Subjects will receive 10 treatments with ESWT. Afterwards patients will answer standardized questionnaires again.
16683130|NCT02063048|No Intervention|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
16683131|NCT02063048|Experimental|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
16683132|NCT02063035|Experimental|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
16683133|NCT02063035|Placebo Comparator|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
16683134|NCT02063022|Active Comparator|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).
~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
16683240|NCT02062268||Urban area in South Jiangsu Province|health education & law enforcement
16692640|NCT01999517|Placebo Comparator|Placebo|IV Fluids
16683135|NCT02063022|Experimental|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
16683136|NCT02063009||patients scheduled for oncologic high-risk surgery|
16683137|NCT02062996|Experimental|ENT - full strength|Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
16683138|NCT02062996|Experimental|ENT - 1/2 strength|½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
16683139|NCT02062996|Experimental|DENTAL - Full strength 1.0 mL|Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).
16683140|NCT02062996|Experimental|DENTAL - Full strength 0.5 mL|Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).
16683141|NCT02062996|Experimental|DENTAL - ½ strength 0.5 mL|½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).
16683142|NCT02062983||Herceptin|The study will be carried in prospective manner enrolling all patients diagnosed with breast cancer and over expressed human epidermal growth factor receptor 2 (HER2) and they are requiring Trastuzumab Neu adjuvant/ adjuvant /metastatic therapy as per standard care.
16683143|NCT02062970|Experimental|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
16683144|NCT02062944|Experimental|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
16683145|NCT02062931|Experimental|Stem Cell Preparation and Injection|"Stem Cell Preparation and Injection:
~Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .
~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
16683146|NCT02062918|No Intervention|Control group|Patients in the control group did not use an abdominal belt.
16683147|NCT02062918|Experimental|Experimental group|Patients were instructed in how to use the abdominal belt for activities of physical effort that exacerbated lumbar pain as well as during moments of pain, and not to use it during rest. They should record the number of hours of belt use per day on spreadsheets distributed for this purpose.
16683148|NCT02062905|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
16683149|NCT02062905|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
16683150|NCT02062892|Experimental|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
16683151|NCT02062892|Active Comparator|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
16683152|NCT02062879|Experimental|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
16683153|NCT02062879|Active Comparator|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
16683154|NCT02062866|Active Comparator|Purse-String|Surgical wounds are healed via suturing.
16683155|NCT02062866|Active Comparator|Second Intent|Surgical wounds are allowed to heal without sutures.
16683156|NCT02062853|Experimental|Video Group|Subjects view educational video on the use of cream medication for the treatment of actinic keratoses.
16683157|NCT02062853|Active Comparator|Verbal Group|Subjects are given verbal instructions on the use of cream medication for the treatment of actinic keratoses.
16683158|NCT02062840|Experimental|High intensity whole-body infrared heating and Neuroimaging|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
16683159|NCT02062840|Sham Comparator|Low intensity whole-body infrared heating and|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH-control intervention where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
16683160|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
16683161|NCT02062801|Active Comparator|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
16683162|NCT02062801|Placebo Comparator|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
16683163|NCT02062788|Experimental|ORS group|Oral rehydration solution (ORS) treated group
16683164|NCT02062788|No Intervention|Non-ORS group|Oral rehydration solution (ORS) untreated group
16683165|NCT02062775|Active Comparator|Self-Fixating Hernia Mesh|Self-fixating polyester mesh will be used for laparoscopic inguinal hernia repair.
16683166|NCT02062775|Placebo Comparator|Non-Fixating Hernia Mesh|Non-fixating polyester mesh will be used for laparoscopic hernia repair.
16683167|NCT02062762|Experimental|Online-MBSR|8 week mindfulness based stress reduction online
16683168|NCT02062762|Active Comparator|Expressive Writing Online|Online distributed expressive writing intervention as active control
16683241|NCT02062268||urban area in Middle Jiangsu Province|health education & law enforcement
16692777|NCT01998646|Experimental|ASP4058 Tablet Dose Escalation Cohort|
16683169|NCT02062749|Experimental|Hyperthermic Intraperitoneal Chemotherapy|After cytoreductive surgery and lysis of adhesions, two large bore catheters are placed in the peritoneal cavity through the incision. Thirty minutes before HIPEC is begun, body temperature is cooled to 35°C. ). The catheters are connected to a perfusion circuit. Heated Oxaliplatin is added to the perfusate administered over 90 minutes. The starting dose of Oxaliplatin is 175 mg/m2.
16683170|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
16683171|NCT02062723||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
16683172|NCT02062710|Experimental|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).
~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
16683173|NCT02062710|Experimental|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).
~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
16683174|NCT02062710|Experimental|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
16683175|NCT02062710|Experimental|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).
~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
16683176|NCT02062710|Experimental|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
16683177|NCT02062710|Experimental|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
16683178|NCT02062697|Other|Ovarian Epithelial Cancer|"Lavage of the Cavum uteri and proximal fallopian tubes
~Liquid-PAP (Papanicolaou) smear"
16683179|NCT02062684|Experimental|Blisibimod|Blisibimod administered subcutaneously
16683180|NCT02062684|Placebo Comparator|Placebo|Placebo administered subcutaneously
16683181|NCT02062671|Experimental|immediate renal denervation|immediate renal denervation
16683182|NCT02062671|Active Comparator|delayed renal denervation|delayed renal denervation
16683183|NCT02062658|Experimental|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
16683184|NCT02062645|Experimental|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
16683185|NCT02062632|Experimental|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
16683186|NCT02062632|Placebo Comparator|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
16683187|NCT02062619|Experimental|Real tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.
~2mA anodal direct current stimulation applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
16683188|NCT02062619|Sham Comparator|Sham tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.
~Sham tDCS (periodical fade-in and fade-out stimulation routine) applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
16683189|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
16683190|NCT02062593|Active Comparator|Coronary angioplasty and optimum medical therapy|Percutaneous coronary intervention and optimal medical therapy
16683191|NCT02062593|Placebo Comparator|Sham procedure and optimum medical therapy|Placebo percutaneous coronary intervention and optimal medical therapy with risk factor modification and anti-anginal therapy
16683192|NCT02062580|Active Comparator|Delayed BCG|BCG delayed to 8 weeks of age
16683193|NCT02062580|Other|Early BCG|BCG at birth; standard of care
16683194|NCT02062567||Acute Achilles tendon rupture|
16683195|NCT02062541|Experimental|Funct. assessment+fast rehabilitation|Funct. assessment+fast rehabilitation
16683196|NCT02062541|Experimental|Funct. assessment+usual rehabilitation|Funct. assessment+usual rehabilitation
16683197|NCT02062541|Experimental|usual assessment+fast rehabilitation|usual assessment+fast rehabilitation
16683198|NCT02062541|No Intervention|usual assessment+usual rehabilitation|usual assessment+usual rehabilitation
16683199|NCT02062528|Experimental|omega-3 fatty acids|3 capsules each day during 8 weeks
16683200|NCT02062528|Placebo Comparator|placebo|3 capsules each day during 8 weeks
16683201|NCT02062515|Experimental|Icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
16683242|NCT02062268||urban area in North Jiangsu Province|health education & law enforcement
16683243|NCT02062268||rural area in South Jiangsu Province|health education & law enforcement
16683202|NCT02062502|Experimental|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
16683203|NCT02062502|Active Comparator|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
16683204|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
16683205|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
16683206|NCT02062476|Experimental|Treatment with Lactobacillus GG|extensively hydrolyzed casein formula containing LGG
16683207|NCT02062476|No Intervention|Children at diagnosis|
16683208|NCT02062463|Active Comparator|SPIROMAX|"Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.
~Participants receiving 800 mcg to 1000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 640 mcg and 18 mcg, respectively."
16683209|NCT02062463|Active Comparator|TURBOHALER|"Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.
~Participants receiving 1600 mcg to 2000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 1280 mcg and 36 mcg, respectively."
16683210|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
16683211|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
16683212|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
16683213|NCT02062424|Active Comparator|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
16683214|NCT02062424|Active Comparator|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
16683215|NCT02062424|No Intervention|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
16683216|NCT02062411|Experimental|CBT with booster sessions|Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol.
16683217|NCT02062411|Active Comparator|CBT only|Participants will only receive 12 cognitive-behavioral therapy sessions weekly.
16683218|NCT02062411|No Intervention|waiting|Participations will not be treated with CBT and keep waiting for 12 weeks for comparison.
16683219|NCT02062398|Experimental|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
16683220|NCT02062385|Experimental|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
16683221|NCT02062385|Placebo Comparator|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
16683222|NCT02062385|Experimental|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
16683223|NCT02062385|Placebo Comparator|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
16683224|NCT02062372|Experimental|Biopsy|Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies
16683225|NCT02062359|Experimental|All Participants|Patients will receive the standard National Cancer Institute (NCI) Surgery Branch non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of the anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ engineered peripheral blood lymphocyte (PBL) and aldesleukin
16683226|NCT02062346|Placebo Comparator|Placebo|Saline placebo
16683227|NCT02062346|Experimental|BQ123|Intravenous infusion of BQ123 1000nmol/min for 15min
16683228|NCT02062346|Experimental|BQ123/788|Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min
16683229|NCT02062346|No Intervention|Assessment of forearm vascular function|Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators
16683230|NCT02062333|Active Comparator|dexmedetomidine|0,4-0,8 µg./kg./h dexmedetomidine
16683231|NCT02062333|Active Comparator|esmolol|100- 300 µg./kg./min esmolol
16683232|NCT02062320||PRE-PCAPS|Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010
16683233|NCT02062320||POST-PCAPS|Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011.
16683234|NCT02062307||control patients|BMI and age matched healthy male subjects
16683235|NCT02062307||hypogonadism patients|unconfounded group of patients with hypogonadism
16683236|NCT02062294||Cohort|
16683237|NCT02062281|Active Comparator|23-valent Pneumococcal Polysaccharide vaccine|"0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.
~lot number: 20130106-1, duration:JAN,17,2015."
16683238|NCT02062281|Active Comparator|Trivalent Influenza Vaccine|"0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.
~lot number:20130713, duration:Jul,1,2014."
16683239|NCT02062281|Experimental|23vPPV+TIV|
16683244|NCT02062268||rural area in North Jiangsu Province|health education & law enforcement
16683245|NCT02062255|Active Comparator|Aspirin|Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.
16683246|NCT02062255|Active Comparator|Omega-3 Free Fatty Acids|Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
16683247|NCT02062255|Active Comparator|Aspirin & Omega-3 FFAs|Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.
16683248|NCT02062242|Experimental|Transvaginal electrical stimulation|Patients treated with transvaginal electrical stimulation.
16683249|NCT02062242|Experimental|Palpation|Patients treated with vaginal palpation.
16683250|NCT02062242|Experimental|Palpation with posterior pelvic tilt|Patients treated with vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles.
16683251|NCT02062242|Experimental|Control group|Patients receive verbal instructions related to the pelvic floor and its contraction.
16683252|NCT02062229||Halthy controls|Subjects not affected by any disease and with normal seminal fluid characteristics
16683253|NCT02062229||Oligospermia|Infertile subjects with oligospermia
16683254|NCT02062229||Varicocele|Infertile subjects with varicocele
16683255|NCT02062229||Asthenospermia|Infertile subjects with asthenospermia
16683256|NCT02062216||STEMI|Patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (PCI)
16683257|NCT02062216||STABLE ANGINA|Patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with Class I indication to elective percutaneous coronary intervention
16683258|NCT02062203|Experimental|AKB-6548 (therapeutic dose)|
16683259|NCT02062203|Experimental|AKB-6548 (supratherapeutic dose)|
16683260|NCT02062203|Placebo Comparator|Placebo|
16683261|NCT02062203|Active Comparator|Moxifloxacin|
16683262|NCT02062190|Active Comparator|resveratrol|
16683263|NCT02062190|Placebo Comparator|corn starch|"(10 patients) 100mg 2x/day
~1 month"
16683264|NCT02062177|Experimental|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
16683265|NCT02062177|Active Comparator|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
16683266|NCT02062164||bariatric surgery group|subjects who participate in the overall project and undergo bariatric surgery
16683267|NCT02062164||conservative care group|subjects who participate in the overall project and do not undergo bariatric surgery
16683268|NCT02062151|Experimental|NAS babies|Acupuncture for NAS
16683269|NCT02062138|Active Comparator|continuous passive motion (CPM)|
16683270|NCT02062138|Experimental|controlled active motion (CAM I)|
16683271|NCT02062138|Experimental|controlled active motion (CAM II)|
16683272|NCT02062112|No Intervention|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
16683273|NCT02062112|Active Comparator|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
16683274|NCT02062112|Active Comparator|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
16683275|NCT02062099|Experimental|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
16683276|NCT02062086|Other|Population 1|"(Community-dwelling older adults) will participate in the study for approximately 65 days.
~Population 1 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.
~The estimation of muscle mass will be made on 2 separate occasions in the community-dwelling elderly population in order to assess reproducibility of the method when tested approximately 60 days apart."
16683277|NCT02062086|Other|Population 2|"(Hip-fracture patients) will participate in the study for approximately 35 days during their in-hospital period, followed by 30 during their post-discharge period, so for a total period of at least 65 days.
~Population 2 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.
~In the hip fracture population, estimation of muscle mass by the D3 creatine method will be performed on up to 3 separate occasions to assess whether the method is sensitive enough to detect decreases in muscle mass that may occur during the recovery period after hip fracture."
16683278|NCT02062073|Active Comparator|Abametapir Lotion 0.74%|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
16683279|NCT02062073|Placebo Comparator|Vehicle Lotion|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
16683280|NCT02062073|Other|0.1% sodium lauryl sulfate|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
16683281|NCT02062073|Other|Saline 0.9%|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
16683282|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
16683283|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
16683284|NCT02062047|Experimental|FMSRP+CLX|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of chlorhexidine 2% gel, rinsing chlorhexidine 0.12% solution during 60 days
16683285|NCT02062047|Placebo Comparator|FMSRP + placebo group|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of placebo, rinsing placebo solution during 60 days
16683286|NCT02062047|Active Comparator|PMSRP group|Partial-mouth scaling and root planing in 4-6 sessions in a maximum of 2 weeks
16683287|NCT02062034|Experimental|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
16683288|NCT02062034|Experimental|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
16683289|NCT02062034|Placebo Comparator|Placebo|Placebo. 100mg daily oral intake for 24 weeks
16683290|NCT02062008|Other|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
16683291|NCT02061995|Experimental|PREOB® Intravenous Infusion|
16683292|NCT02061982|Experimental|Caffeine|Instant coffee with or without caffeine will be provided
16683293|NCT02061982|Placebo Comparator|Coffee without caffeine|Coffee without caffeine
16683294|NCT02061969|Active Comparator|Insulin glargine|Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
16683295|NCT02061969|Experimental|linagliptin|Oral linagliptin 5mg once daily added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
16683296|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
16683297|NCT02061930||single crowns supported by implants|single crowns supported by implants placed in the anterior maxilla region, periodontally healthy
16683298|NCT02061917|Experimental|Tobacco-Heating Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette
16683299|NCT02061917|Experimental|Snus (Smokeless Tobacco)|A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)
16683300|NCT02061917|Experimental|Tobacco-Burning Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette
16683301|NCT02061904|Other|Bone Mineral Density|"Bone mineral density measurement with intervention DEXA at the bone impaction graft site:
~DEXA: dual energy X-ray absorptiometry"
16683302|NCT02061904|Other|Hip function|"Hip Function/mobility development:
~Harris Hip Score"
16683303|NCT02061904|Other|pain experience|Pain experiences after surgery in the hip joint VAS-pain
16683304|NCT02061904|Other|General Patients Health condition|"Patients health condition monitoring: intervention SF12:
~Short Form Health Survey 12"
16683305|NCT02061904|Other|Intervention Satisfaction|Patients satisfaction development after the intervention VAS-satisfaction
16683306|NCT02061891|Active Comparator|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
16683307|NCT02061891|Experimental|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
16683308|NCT02061878|Experimental|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
16683309|NCT02061878|Placebo Comparator|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
16683310|NCT02061865|Experimental|Cohorts 1 - 4|Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4.
16683311|NCT02061852|Active Comparator|Physiotherapy|Traditional techniques
16683312|NCT02061852|Experimental|simeox|Medical device
16683313|NCT02061839|Experimental|Teinted sunscream|UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
16683314|NCT02061839|Active Comparator|Regular sunscream|UVA and UVB protection
16683315|NCT02061813|Experimental|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
16683316|NCT02061813|Placebo Comparator|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
16683317|NCT02061813|Other|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
16683318|NCT02061813|Other|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
16683319|NCT02061800|Active Comparator|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
16683320|NCT02061800|Experimental|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
16683321|NCT02061800|Experimental|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
16683322|NCT02061787||cardiopulmonary exercise testing|cardiopulmonary exercise testing
16683323|NCT02061774|Active Comparator|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
16683324|NCT02061774|Placebo Comparator|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
16683325|NCT02061761|Experimental|Part A - relatlimab (Dose escalation)|
16683326|NCT02061761|Experimental|Part C - relatlimab + nivolumab (Dose escalation)|
16683327|NCT02061761|Experimental|Part B - relatlimab (Cohort expansion)|
16683328|NCT02061761|Experimental|Part D - relatlimab + nivolumab (Cohort expansion)|
16683329|NCT02061748||dabigatran|
16683330|NCT02061748||warfarin|
16683331|NCT02061735||oral propranolol|Dosage of 1 mg/kg per day divided 2 times daily. Blood pressure, heart rate and oxygen saturation are monitored after propranolol initiation. Treatment is continued with a gradual increase to 2 mg/kg per day divided 2 times daily. Treatment is continued until the hemangioma no longer changes in the characteristics judged by the physicians, including, color, size, temperature and deformability.
16683332|NCT02061735||timolol maleate 0.5% gel|One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
16683333|NCT02061735||No treatment, observation only|No oral or topical treatment will be given as recommended by the treating physicians and elected by the parents. Patients will be evaluated periodically to determine what changes in treatment are warranted. If this occurs, the patients will be included in the appropriate study group.
16683334|NCT02061722|Experimental|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).
~The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.
~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
16683335|NCT02061709|Experimental|Ragweed-SPIRE 1|Ragweed SPIRE regimen 1 given 2 weeks apart
16683336|NCT02061709|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
16683337|NCT02061709|Experimental|Ragweed-SPIRE 3|Ragweed-SPIRE regimen 3 given 2 weeks apart
16683338|NCT02061709|Placebo Comparator|Placebo|Placebo given 2 weeks apart
16683339|NCT02061696|Active Comparator|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
16683340|NCT02061696|Active Comparator|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
16683341|NCT02061683|Experimental|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
16683342|NCT02061670|Experimental|Ragweed-SPIRE 1|Ragweed-SPIRE regimen 1 given 2 weeks apart
16683343|NCT02061670|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
16683344|NCT02061670|Placebo Comparator|Placebo|Placebo given 2 weeks apart
16683345|NCT02061657|Experimental|Myomectomy, rectal Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
16683346|NCT02061657|Active Comparator|Myomectomy, Placebo|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
16683347|NCT02061644|Experimental|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
16683348|NCT02061631|Experimental|Docetaxel, Cisplatin|"Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles.
~Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks.
~Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions."
16683349|NCT02061618|No Intervention|Usual Care|
16683350|NCT02061618|Experimental|Bollywood Dance Exercise|Participants in the Bollywood Dance Exercise group will take part in an 8-week dance intervention. The dance classes will take place 2 times per week, approximately 60 minutes per class, for 8 weeks total.
16683351|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
16683352|NCT02061592|Active Comparator|Etafilcon A Control Lens|etafilcon A
16683353|NCT02061592|Experimental|Etafilcon A Test Lens|etafilcon A
16683354|NCT02061579|Experimental|Once-Weekly Structured Contact|Participants in the Once Weekly Structured Contact group will take part in an 6-month exercise intervention and attend one structured group exercise session per week. They will engage in aerobic and resistance training for approximately 80 minutes per exercise session. Additionally, they will attend three exercise evaluations and six study visits.
16683395|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
16683355|NCT02061579|Experimental|Thrice-Weekly Structured Contact|Participants in the Thrice-Weekly Structured Contact group will take part in an 6-month exercise intervention and attend three structured group exercise sessions per week. In total, they will engage in aerobic and resistance training sessions for approximately 200 minutes per week. Additionally, they will attend three exercise evaluations and six study visits.
16683356|NCT02061579|No Intervention|Usual Care|Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
16683357|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
16683358|NCT02061566||Non acute kidney injury|Non acute kidney injury
16683359|NCT02061553|Sham Comparator|Motivation|1 in person session focused on importance of motivation followed by 8 wk SMS messages with self-selected motivational statements.
16683360|NCT02061553|Active Comparator|Intention|1 session of Behavioral Activation followed by 8 wk SMS messages in the form of BA- based implementation intentions.
16683361|NCT02061553|Experimental|BA-Tech|6 in person and 2 phone sessions of Behavioral Activation with EMA-based activity monitoring and SMS-assisted scheduling of value-based activities.
16683362|NCT02061540|Experimental|LUM001|LUM001 administered orally once each day
16683363|NCT02061527|Experimental|Breast reconstruction with ADM|Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.
16683364|NCT02061527|Active Comparator|Breast reconstruction without ADM|Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.
16683365|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
16683366|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
16683367|NCT02061501|Active Comparator|Speech therapy|Speech therapy (30 min per week) alone for the 6 first months. Then speech therapy (30 min per week) and optometric therapy (30 min per week) for the 6 last months.
16683368|NCT02061501|Experimental|Speech therapy and optometric therapy|Speech therapy (30 min per week) and optometric therapy (30 min per week) for 12 months.
16683369|NCT02061488|Active Comparator|open-loop night|
16683370|NCT02061488|Experimental|closed-loop night|
16683371|NCT02061475|Active Comparator|Lidocaine Patches|
16683372|NCT02061475|Placebo Comparator|Placebo Patches|
16683373|NCT02061462|No Intervention|Standard Group|Recipients of lungs procured from brain dead donors.
16683374|NCT02061462|Active Comparator|EVLP-DCD Group|Recipients of lungs procured from DCD donors, reconditioned/evaluated by EVLP
16683375|NCT02061449|Experimental|Initiating therapy with Romidepsin (Arm A)|Patients who are starting therapy with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
16683376|NCT02061449|Experimental|treatment with Romidepsin with SD or PR (Arm B)|Patients with stable disease on the treatment with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
16683377|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
16683378|NCT02061410|Experimental|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
16683379|NCT02061397|Experimental|simvastatin treatment arm|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
16683380|NCT02061384|Experimental|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
16683381|NCT02061384|Experimental|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
16683382|NCT02061371|Experimental|virtual therapy|Group 1 (G1) included 20 patients who will carry out the virtual therapy.
16683383|NCT02061371|Experimental|conventional physiotherapy|Group 2 (G2) included 20 patients who hold conventional physiotherapy.
16683384|NCT02061358|Experimental|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
16683385|NCT02061358|Experimental|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
16683386|NCT02061358|Experimental|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
16683387|NCT02061358|Experimental|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
16683388|NCT02061358|Experimental|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
16683389|NCT02061358|Experimental|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
16683390|NCT02061358|Experimental|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
16683391|NCT02061358|Experimental|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
16683392|NCT02061345||MCI|Prostate cancer patients having mild cognitive impairment (MCI) attributable to ADT with LHRHa
16683393|NCT02061345||Control|Prostate cancer patients on ADT with LHRHa not having mild cognitive impairment
16683394|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
16692778|NCT01998646|Experimental|ASP4058 Tablet - Fasting conditions|
16683396|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
16683397|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
16683398|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
16683399|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
16683400|NCT02061293|Experimental|Psilocybin|Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8. Psilocybin 25-40 mg/70 kg administered at 38 weeks.
16683401|NCT02061293|Active Comparator|Diphenhydramine|Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8. Psilocybin 25 mg/70 kg administered at 38 weeks.
16683402|NCT02061280|Experimental|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.
~Randomized to one of 3 study treatments:
~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
16683403|NCT02061280|Active Comparator|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.
~Randomized to one of 3 study treatments:
~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
16683404|NCT02061267|Experimental|Niacin Control|The subjects will receive a vitamin B3 supplement (2 g)
16683405|NCT02061267|Experimental|Niacin + SAT|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
16683406|NCT02061267|Experimental|Niacin + ROO|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
16683407|NCT02061267|Experimental|Niacin + O3|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
16683408|NCT02061254|Experimental|3 groups of subjects|"3 groups:
~group of 48 healthy volunteers (matched with venous insufficiency patients)
~group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)
~group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))
~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
16683409|NCT02061241||Patients|All included patients, having CRT implant procedure Will have both Pacing in vein at site of latest mechanical activation and Pacing in other suitable vein.
16683410|NCT02061228|No Intervention|Control arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
16683411|NCT02061228|Experimental|Induced endometrial injury arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
16683412|NCT02061215||recipients aged 20-40|CMV viral load
16683413|NCT02061215||recipients older than 60|CMV viral load
16683414|NCT02061202|Experimental|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
16683415|NCT02061202|Placebo Comparator|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
16683416|NCT02061189|Experimental|Swimming pool training group|"10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18 or M18 to M24 or M24 to M36, in defined and reproducible conditions.
~M0, M6, M12 and M18 or M0, M6, M12, M18 and M24 or M0, M6, M12, M18, M24 and M30 assessments: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis.
~M12 to M18 or M18 to M24 or M24 to M30: Physical exercise in a swimming pool (3 times per week).
~M24 or M30 or M36: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis."
16683417|NCT02061189|No Intervention|Control group|"20 patients with same assessments at M0, M6, M12 and M18, but:
~without swimming pool training.
~without M24 assessment."
16683418|NCT02061176|Experimental|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
16683419|NCT02061176|Active Comparator|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
16683420|NCT02061163|Experimental|Subjects with Crohn's disease|Contrast Enhanced Ultrasound Optison
16683421|NCT02061150||Asymptomatic newborns that had sepsis workup|Evaluation of medical records of asymptomatic newborns that had sepsis workup in the first 48 hours of life.
16683422|NCT02061137|Experimental|Rett syndrome, fingolimod (FTY720)|0.5 or 0.25mg Fingolimod daily
16683423|NCT02061124|Active Comparator|T2DM, sevelamer|Patients with type 2 diabetes treated with sevelamer
16683424|NCT02061124|Placebo Comparator|T2DM, placebo|Patients with type 2 diabetes treated with placebo
16683425|NCT02061124|Active Comparator|Healthy subjects, sevelamer|Healthy subjects treated with sevelamer
16683426|NCT02061124|Placebo Comparator|Healthy subjects, placebo|Healthy subjects treated with placebo
16683427|NCT02061111||Subclinical thyroid disease|26 pregnant women with subclinical hypothyroidism and/orTPO-antibodies, and their offspring.
16683428|NCT02061111||Healthy controls|51 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.
16683429|NCT02061098|Experimental|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.
~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
16683430|NCT02061098|Placebo Comparator|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.
~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
16683431|NCT02061085|Experimental|monotherapy treatment with Eribulin|Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
16683432|NCT02061072||Population pharmacokinetic estimation|Patients with severe or moderate hemophilia A or B, providing sparse data for population PK estimation
16683433|NCT02061059|Other|group 1|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements.
~group is assigned to standard: wears shoes produced with standard procedure"
16683434|NCT02061059|Other|group 2|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
16683435|NCT02061059|Other|group 3|"group is assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
~group is assigned to standard: wears shoes produced with standard procedure"
16683436|NCT02061059|Other|group 4|"group assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
16683437|NCT02061046||On CPAP therapy|OSA patients assessed before and after 8 weeks of CPAP therapy
16683438|NCT02061020|Experimental|Sequence 1|"THC containing cigarettes 10mg
~THC containing cigarettes 30mg
~Placebo"
16683439|NCT02061020|Experimental|Sequence 2|"THC containing cigarettes 30mg
~Placebo
~THC containing cigarettes 10mg"
16683440|NCT02061020|Experimental|Sequence 3|"Placebo
~THC containing cigarettes 10mg
~THC containing cigarettes 30mg"
16683441|NCT02061007|Experimental|Scans, Surgery and Follow-up|Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
16683442|NCT02060994||37-38 weeks|"Children who were born by elective Cesarean section after 37-38 gestational weeks.
~Intervention: No intervention."
16683443|NCT02060994||39 week or more|Children who were born by elective Cesarean section after 39 gestational weeks or more Intervention: No intervention.
16683444|NCT02060981|Active Comparator|Interview only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
16683445|NCT02060981|Placebo Comparator|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
16683446|NCT02060981|Experimental|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension, and to provide feedback regarding a new tool for helping patients learn more about their medications. Interview plus patients' index date for follow-up is the date of the scheduled interview.
16683447|NCT02060968||IRIS PREMIER Cohort|Promus PREMIER
16683448|NCT02060955|Experimental|Alecsat|"The experimental product is an autologous product based on the individual patients blood. Blood donation are performed in study weeks 0, 6, 11, 23 and 43.
~The patient receives treatment as bolus injection at study weeks 4, 9, 14, 26 and 46."
16683449|NCT02060955|Active Comparator|bevacizumab/irinotecan|Patients allocated to the comparator arm will be treated in accordance with standard practice in Denmark for relapsed glioblastoma multiforme, up to 16 treatment cycles with 4 weeks duration
16683450|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
16683451|NCT02060929|Experimental|Sequence 1|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
16683452|NCT02060929|Experimental|Sequence 2|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
16683453|NCT02060916|Experimental|PAZ320|Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.
16683454|NCT02060903|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
16683455|NCT02060903|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
16683456|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
16683457|NCT02060877||patients suspected of having lung cancer|observational study, there is no study intervention, only patient questionnaires
16683458|NCT02060864|Placebo Comparator|Placebo|2 Placebo pills
16683459|NCT02060864|Experimental|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
16683460|NCT02060864|Experimental|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
16683461|NCT02060851|Experimental|Vifor and EPO|intravenous iron and EPO
16683462|NCT02060851|Placebo Comparator|control|no intravenous iron or EPO
16683463|NCT02060851|Experimental|Vifor|intravenous iton but no EPO
16683464|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
16683465|NCT02060825||Regional saturation monitor|Patients undergoing surgical repair of hypoplastic left heart syndrome.
16683466|NCT02060812|Experimental|Group I, SSNB & ANB|21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
16683467|NCT02060812|Placebo Comparator|Group II, SSNB alone|The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
16683468|NCT02060786|Active Comparator|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
16683469|NCT02060786|Experimental|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
16683470|NCT02060760||UTROPIA study cohort|At least two cTnI data points available (including baseline) with blood samples available for hs-cTnI testing. No intervention.
16683471|NCT02060747|Experimental|Coordinator-based post fracture program|The intervention arm deals with the intervention of a nurse trained in the management of osteoporosis fractures assisted by a clinical research technician who will manage the logistics and reglementary aspects of the study (patient enrollment, quality and study proceedings).
16683472|NCT02060747|No Intervention|standard care|
16683473|NCT02060734|Experimental|lidocaine|The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.
16683474|NCT02060734|Active Comparator|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
16683476|NCT02060708|Other|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
16683477|NCT02060708|Other|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
16683478|NCT02060682||Navvus Catheter FFR|The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.
16683479|NCT02060669|Experimental|Arm 1|xeloda maintaenance
16683480|NCT02060669|No Intervention|Arm 2|best supprotive care
16683481|NCT02060656|Active Comparator|Control: R-GEM-P|Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
16683482|NCT02060656|Experimental|Experimental: LR-GEM|Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
16683483|NCT02060643||Cross-sectional hemi-neck RT|
16683484|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
16683485|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
16683486|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
16683487|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
16683488|NCT02060617|Experimental|Impairment-Based Group|The impairment-based intervention will be a multi-modal treatment approach utilizing manual therapy of the thoracolumbosacral spine and hips as well as motor control exercises. Patient education will also be provided.
16683489|NCT02060617|Active Comparator|Classification-Based Group|Patients in this group will be categorized into subgroups according to the Treatment-Based Classification (TBC) Algorithm and treated accordingly. Patient education will also be provided.
16683490|NCT02060604|Experimental|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
16683491|NCT02060604|Active Comparator|Ranibizumab Alone|3 monthly ranibizumab, then as needed
16683492|NCT02060591|Active Comparator|Exparel|
16683493|NCT02060591|Active Comparator|Marcaine|
16683494|NCT02060578|Other|Intervention|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
16683495|NCT02060565||Chronic liver disease|all patients with chronic liver disease followed using non-invasive methods
16683496|NCT02060552|Placebo Comparator|Febuxostat|Febuxostat 40mg once a day
16683497|NCT02060552|Experimental|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
16683498|NCT02060552|Experimental|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
16683499|NCT02060539|Experimental|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
16683500|NCT02060526|Active Comparator|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
16683501|NCT02060526|Active Comparator|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
16683502|NCT02060526|Placebo Comparator|Placebo|The comparator group will receive no treatment with rhHNS.
16683503|NCT02060500|Experimental|Cardiaplication|
16683504|NCT02060487|Experimental|Low dose|
16683505|NCT02060487|Experimental|Medium dose|
16683506|NCT02060487|Experimental|High dose|
16683507|NCT02060474|Experimental|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
16683508|NCT02060461|Experimental|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
16683509|NCT02060461|Experimental|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
16683510|NCT02060448|Experimental|2wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal self-injurious thoughts and behaviors, or SITBs, (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
16683511|NCT02060448|Experimental|2wk baseline + reappraisal (+ awareness)|"Participants will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs and behaviors (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
16683512|NCT02060448|Experimental|4wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
16683513|NCT02060448|Experimental|4wk baseline + reappraisal + (awareness)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
16683514|NCT02060435||EBER+ AMC|EBV+DLBCL patients in Asan Medical Center
16683515|NCT02060435||EBER+ SMC|EBV+DLBCL patients in Samsung Medical Center
16683516|NCT02060435||EBER- SMC|EBV-DLBCL patients in Samsung Medical Center
16683517|NCT02060422|Placebo Comparator|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
16683580|NCT02060019|Experimental|crestor 20mg(rosuvastatin 20mg)|1 tablet daily for 7days
16683581|NCT02060006|Placebo Comparator|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
16683518|NCT02060422|Experimental|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
16683519|NCT02060409||spliceosome|patient who have available data for spliceosome mutation status
16683520|NCT02060396|Experimental|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
16683521|NCT02060383|Experimental|Incretin based therapy (randomized group)|Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
16683522|NCT02060383|Experimental|Insulin (randomized group)|Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
16683523|NCT02060383|Other|Non-Randomized Arm|"This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.
~For the purpose of analysis, this non-randomized arm is further split into 3 groups:
~Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry
~Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment
~No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial"
16683524|NCT02060370|Experimental|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
16683525|NCT02060357|Active Comparator|Resolute Integrity Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
16683526|NCT02060357|Active Comparator|Promus Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
16683527|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
16683528|NCT02060331||Pelvic Organ Prolapse with Nocturia|Pelvic Organ Prolapse with Nocturia
16683529|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
16683530|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
16683531|NCT02060305|Experimental|Bevacizumab|Bevacizumab intra-articular injection; dose 20mg~40mg every 28 days for 4 times
16683532|NCT02060292||COPD|Stable, Non hypoxaemic, without history of vascular disease
16683533|NCT02060292||Healthy smokers|Age matched, smokers without COPD
16683534|NCT02060279|Experimental|Lifestyle intervention and carotenoid supplement|
16683535|NCT02060279|Experimental|Lifestyle intervention and placebo|
16683536|NCT02060266|Experimental|Semaglutide|
16683537|NCT02060253|Experimental|ganetespib, paclitaxel, and trastuzumab with pertuzumab|Patients receive trastuzumab intravenously (IV) over 30 minutes on days 1, 8, 15, and 22, pertuzumab IV over 30 minutes every 3 weeks (only in Part II of the study, starting day 1), paclitaxel IV over 1 hour on days 1, 8, 15, and 22, and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The MTD for ganetespib in combination with paclitaxel and trastuzumab is 150 mg/m2.
16683538|NCT02060240|Experimental|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
16683539|NCT02060240|No Intervention|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
16683540|NCT02060227|Active Comparator|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
16683541|NCT02060227|Active Comparator|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
16683542|NCT02060201|Other|Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting|Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods
16683543|NCT02060201|Other|Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
16683544|NCT02060201|Other|Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
16683545|NCT02060201|Other|Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting|Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods
16683546|NCT02060201|Other|Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
16683547|NCT02060201|Other|Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
16683582|NCT02060006|Experimental|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
16683554|NCT02060175|Experimental|1 CILOTAX arm|Cilotax drug-eluting stents implantation
16683555|NCT02060175|Active Comparator|2 DESyne arm|DESyne drug-eluting stents implantation
16683556|NCT02060162||HIV/HBV co-infected|150-200 patients in Zambia and 250-300 across all sites
16683557|NCT02060162||HIV mono-infected|700-750 patients in Zambia and 1600-1700 across all sites
16683558|NCT02060149|Sham Comparator|no nebulization|Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
16683559|NCT02060149|Active Comparator|nebulization with pH 7.4 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
16683560|NCT02060149|Experimental|nebulization with pH 7.8 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
16683561|NCT02060136||Study group|Men presenting to the urology clinic with lower urinary tract symptoms
16683562|NCT02060123|Experimental|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:
~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),
~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and
~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
16683563|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
16683564|NCT02060110||MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
16683565|NCT02060110||MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study
16683566|NCT02060097|Active Comparator|Cocoa flavanol beverage|flavanol 320mg/day
16683567|NCT02060097|Placebo Comparator|Placebo beverage|no flavanol
16683568|NCT02060084|Experimental|a control group|a control group : the same dose of luke warm water
16683569|NCT02060084|Experimental|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
16683570|NCT02060071|Other|Aortic setnsosi|blood test
16683571|NCT02060071|Other|controls|blood test
16683572|NCT02060058|Experimental|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.
~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.
~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
16683573|NCT02060058|Experimental|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.
~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
16683574|NCT02060058|Experimental|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.
~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
16683575|NCT02060045|Experimental|bundle implementation|The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
16683576|NCT02060032|Active Comparator|Atorvastatin|1.2% atorvastatin local drug delivery
16683577|NCT02060032|Sham Comparator|Simvastatin|1.2% simvastatin local drug delivery
16683578|NCT02060032|Placebo Comparator|Placebo|Placebo local drug delivery
16683579|NCT02060019|Experimental|exforge 10/160mg(amlodipine 10mg, valsartan160mg)|1 tablet daily for 10days
16683583|NCT02059993|Other|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
16683584|NCT02059993|No Intervention|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
16683585|NCT02059980|Experimental|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
16683586|NCT02059980|Placebo Comparator|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
16683587|NCT02059967|Experimental|Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)|Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
16683588|NCT02059954|Active Comparator|Vaginal hysterectomy|Vaginal hysterectomy
16683589|NCT02059954|Active Comparator|Total laparoscopic hysterectomy|Laparoscopic hysterectomy
16683590|NCT02059928|Experimental|Intraosseous device placement|Intraosseous device
16683591|NCT02059915|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16683592|NCT02059915|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16683593|NCT02059915|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16683594|NCT02059915|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16683595|NCT02059902|Placebo Comparator|Normal pain management|Normal saline (bolus followed by continuous infusion)
16683596|NCT02059902|Experimental|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
16683597|NCT02059889|Experimental|Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)|Patients undergo 15 imaging studies: 5 chest CT scans, 5 chest MRI scans, 5 PET scans. Each scan will be obtained before treatment begins, weeks 2 and 4 during radiation therapy, 3 months and 1 year following radiation therapy. THe chest CT obtained pre-treatment, at 3 months post treatment and 1 year post treatment are considered routine and would be obtained regardless of study participation. The pre-treatment PET scan is also considered routine. All other scans are being done for the purposes of this research.
16683598|NCT02059876|Experimental|carboplatin and paclitaxel ± trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer.
16683599|NCT02059863|Experimental|SPRING intervention clusters|"SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
~PLUS access to routine maternal and child health services"
16683600|NCT02059863|No Intervention|Control clusters|access to routine maternal and child health services
16683601|NCT02059850|Experimental|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
16683602|NCT02059837||Pterygium,recurrent|Consecutively recorded photographs of recurrent pterygium excision and following grafting were analyzed.
16683603|NCT02059824|Experimental|Eyelid|The selection of the laterality of the eyelid will be randomized
16683604|NCT02059811|Experimental|DASH Diet|"All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in to-go packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries."
16683605|NCT02059798||Decompression of cervical myelopathy|JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit
16683606|NCT02059785|Experimental|Pinocembrin for Injection|40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
16683607|NCT02059785|Placebo Comparator|placebo|60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
16683608|NCT02059772|Experimental|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
16683609|NCT02059772|Experimental|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
16683610|NCT02059759|Placebo Comparator|Placebo|"Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
~Intervention: Placebo"
16683611|NCT02059759|Experimental|1.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
~Intervention: 1.0 MIU IL-2 per day"
16683612|NCT02059759|Experimental|2.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
~Intervention: 2.0 MIU IL-2 per day"
16683613|NCT02059746||Vaginal birth|"Patients in the group give birth vaginally.
~Intervention: Questionnaires sent by mail"
16683614|NCT02059746||Cesaren section|"Patients in this group give birth via cesarean section.
~Intervention: Questionnaires sent by mail"
16683655|NCT02059512|Active Comparator|Group 1|Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.
16683656|NCT02059512|Placebo Comparator|Group 0|Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.
16683615|NCT02059733|Experimental|18F-DTBZ for Parkinson's Disease and parkinsonism|"This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.
~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
16683616|NCT02059720|Active Comparator|auto|patients receive autologous SCT
16683617|NCT02059720|Active Comparator|haplo|patients receive haplo-SCT
16683618|NCT02059707|Experimental|LAA exclusion procedure|LAA exclusion with the LARIAT RS Suture Delivery Device
16683619|NCT02059694|Experimental|Hyaluronidase|"Dilutions (Blocks):
~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
16683620|NCT02059694|Other|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
16683621|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
16683622|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
16683623|NCT02059655|Placebo Comparator|Eye drop solution|Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
16683624|NCT02059655|Active Comparator|Bimatoprost|1 drop daily of Bimatoprost 0.03%. Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
16683625|NCT02059642|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
16683626|NCT02059642|Experimental|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
16683627|NCT02059629||Group A: Eluna pacemaker family|Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.
16683628|NCT02059629||Group B: Sentus BP lead|Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).
16683629|NCT02059616|Experimental|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
16683630|NCT02059616|Experimental|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
16683631|NCT02059616|Experimental|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
16683632|NCT02059616|Experimental|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
16683633|NCT02059616|Experimental|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
16683634|NCT02059616|Experimental|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
16683635|NCT02059616|Experimental|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
16683636|NCT02059616|Experimental|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
16683637|NCT02059603|Experimental|Electroacupuncture|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the acupuncture needles.
16683638|NCT02059603|Active Comparator|Fast-track program|The design of this program is based on the consensus between our surgeons, anesthetists, physiotherapists, dietitians, and nurses, who have reviewed the relevant literature and made appropriate adjustments to suit the local situation.
16683639|NCT02059590|Experimental|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|single dose
16683640|NCT02059577|Experimental|Treatment Group|This group received a combination of nutritional treatments, added sequentially, including vitamins/minerals, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets.
16683641|NCT02059577|No Intervention|Non-Treatment Group|This group did not have any significant changes in their treatments for 12 months
16683642|NCT02059564|Experimental|Cohort A|The weekly treatment of the 6 mg HM11260C or placebo will be maintained
16683643|NCT02059564|Experimental|Cohort B|The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
16683644|NCT02059564|Experimental|Cohort C|The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
16683645|NCT02059551|Experimental|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\intervention section\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
16683646|NCT02059538|Other|Group 1|Metabolic syndrome
16683647|NCT02059538|Other|Group 2|Severly obese patients
16683648|NCT02059538|Other|Group 3|Type-2 diabetics patients
16683649|NCT02059538|Other|Group 4|Patients with first recent (< 2 weeks) acute coronary syndrome (ACS)
16683650|NCT02059538|Other|Group 5|Patients with stable chronic coronary artery disease without heart failure
16683651|NCT02059538|Other|Group 6|Patients with ischemic systolic heart failure (CHF)
16683652|NCT02059538|Other|Group 7|Patients with non-ischemic chronic heart failure
16683653|NCT02059538|Other|Group 8|Healthy volunteers
16683654|NCT02059525||syphilis infected|all patients with a new diagnosis of syphilis, receiving treatment at the Institute of Tropical Medicine
16683657|NCT02059512|Active Comparator|Group 2|Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.
16683658|NCT02059499|Experimental|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
16683659|NCT02059499|Experimental|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
16683660|NCT02059499|No Intervention|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
16683661|NCT02059486|Experimental|Teen Choice|The curriculum provides comprehensive sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress. The curriculum can be delivered in different formats that range in length from 6 to 12 weeks.
16683662|NCT02059486|No Intervention|Control|Business as usual school health curriuclum
16683663|NCT02059473|Experimental|Physiotherapy & Surgery|Mini-open rotator cuff repair
16683664|NCT02059473|Active Comparator|Physiotherapy|Structured physiotherapy
16683665|NCT02059460|Experimental|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
16683666|NCT02059460|Placebo Comparator|Control group|
16683667|NCT02059447|Experimental|Mindfulness Based Cognitive Therapy|An 8 week course of Mindfulness Based Cognitive therapy
16683668|NCT02059447|Active Comparator|Relaxation Therapy|An 8 week course of Relaxation Therapy.
16683669|NCT02059434|Experimental|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683670|NCT02059434|Experimental|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683671|NCT02059434|Experimental|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683672|NCT02059434|Experimental|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683673|NCT02059434|Experimental|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683674|NCT02059434|Experimental|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683675|NCT02059434|Placebo Comparator|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683676|NCT02059434|Experimental|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683677|NCT02059434|Experimental|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683678|NCT02059434|Active Comparator|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
16683679|NCT02059434|Active Comparator|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
16683680|NCT02059434|Placebo Comparator|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
16683681|NCT02059421|Experimental|Johrei Therapy|"3 sessions per week lasting 30 minutes.
~Daily report of bedtime and wake time.
~Baseline:
~Polysomnography
~Actigraphy
~Questionnaires
~Blood draw
~Urine collection
~2 weeks:
~Questionnaires
~Actigraphy download
~Sleep log reconciliation
~6 weeks:
~Polysomnography
~Actigraphy download
~sleep log reconciliation
~Questionnaires
~Blood draw
~Urine collection"
16683682|NCT02059421|Active Comparator|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"1 session per week for a total of 6 weeks with the option of 2 additional sessions.
~Daily report of bedtime and wake time.
~Baseline:
~Polysomnography
~Actigraphy
~Questionnaires
~Blood draw
~Urine collection
~2 weeks:
~Questionnaires
~Actigraphy download
~Sleep log reconciliation
~6 weeks:
~Polysomnography
~Actigraphy download
~sleep log reconciliation
~Questionnaires
~Blood draw
~Urine collection"
16683683|NCT02059408|No Intervention|Usual Care|The patients in this arm will receive normal primary care.
16683684|NCT02059408|Active Comparator|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm recommends using creatinine, cystatin C and albuminuria for detection and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
16683685|NCT02059408|Active Comparator|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment adds a pharmacist-led CKD management program and attempts to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
16683686|NCT02059395|Active Comparator|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
16683687|NCT02059395|Experimental|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
16683688|NCT02059382|Active Comparator|Control|ChiRunning training Weekly training log Blinded accelerometer
16683689|NCT02059382|Experimental|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
16683690|NCT02059369|Active Comparator|CFAE ablation|Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
16683691|NCT02059369|Active Comparator|CFAE + Lines|CFAE Ablation followed by linear lesions (anterior and Roof line)
16683692|NCT02059356||Non-cirrhotic patients with cognitive impairment|
16683693|NCT02059343||age less than or equal to 2 years|
16683694|NCT02059330|Experimental|Healthy Subjects of Japanese Descent|Enrolled Japanese subjects will receive four palbociclib single doses of differing dose amounts in fixed sequence over four treatment periods.
16683695|NCT02059330|Experimental|Healthy Non-Asian Subjects|Enrolled healthy non-Asian subjects will receive a single 125mg oral dose of palbociclib in a single treatment period.
16683754|NCT02058966|Placebo Comparator|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
16683696|NCT02059317||Group 1|"Six groups are created in order to randomized the order of interventions. In group 1, the order of interventions is as follows:
~Flexion-extension in the sagittal plane
~Rotation in a transverse plane
~Complex movement in three dimensions
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
16683697|NCT02059317||Group 2|"Six groups are created in order to randomized the order of interventions. In group 2, the order of interventions is as follows:
~Flexion-extension in the sagittal plane
~Complex movement in three dimensions
~Rotation in a transverse plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
16683698|NCT02059317||Group 3|"Six groups are created in order to randomized the order of interventions. In group 3, the order of interventions is as follows:
~Rotation in a transverse plane
~Flexion-extension in the sagittal plane
~Complex movement in three dimensions
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
16683699|NCT02059317||Group 4|"Six groups are created in order to randomized the order of interventions. In group 4, the order of interventions is as follows:
~Rotation in a transverse plane
~Complex movement in three dimensions
~Flexion-extension in the sagittal plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
16683700|NCT02059317||Group 5|"Six groups are created in order to randomized the order of interventions. In group 5, the order of interventions is as follows:
~Complex movement in three dimensions
~Flexion-extension in the sagittal plane
~Rotation in a transverse plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
16683701|NCT02059317||Group 6|"Six groups are created in order to randomized the order of interventions. In group 6, the order of interventions is as follows:
~Complex movement in three dimensions
~Rotation in a transverse plane
~Flexion-extension in the sagittal plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
16683702|NCT02059304|Other|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
16683703|NCT02059304|Other|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
16683704|NCT02059291|Experimental|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
16683705|NCT02059291|Placebo Comparator|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.
~150mg, participants were uptitrated to open-label canakinumab 300 mg."
16683706|NCT02059291|Experimental|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
16683707|NCT02059291|Placebo Comparator|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
16683708|NCT02059291|Experimental|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
16683709|NCT02059291|Placebo Comparator|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
16683710|NCT02059278|Experimental|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
16683711|NCT02059278|Experimental|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
16683712|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16683713|NCT02059252|Experimental|SmartMatrix scaffold|SmartMatrix dermal replacement scaffold
16683714|NCT02059239|Experimental|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
16683715|NCT02059239|Experimental|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
16683716|NCT02059226|Experimental|Internet-based CBT|Internet-based cognitive behavioural therapy
16683717|NCT02059226|Active Comparator|Internet-based resource page|Static webpage
16683718|NCT02059213|Active Comparator|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
16683719|NCT02059213|Experimental|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
16683720|NCT02059200|Experimental|MBCL + TAU|This cohort receives the Mindfulness Based Compassionate Living program in addition to treatment as usual.
16683721|NCT02059200|No Intervention|TAU|This cohort receives treatment as usual of any nature, e.g. psychotherapy, antidepressant medication etc.
16683722|NCT02059187|Experimental|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
16683723|NCT02059187|Active Comparator|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
16683724|NCT02059174|Experimental|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
16683725|NCT02059174|Experimental|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
16683726|NCT02059161|Experimental|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
16683727|NCT02059161|Active Comparator|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
16683728|NCT02059148|Experimental|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
16683729|NCT02059148|Experimental|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
16683730|NCT02059148|Experimental|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
16683731|NCT02059135|Active Comparator|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
16683732|NCT02059135|Placebo Comparator|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
16683733|NCT02059109|Experimental|Single|Staff will work alone to assemble the Belmont Rapid Infuser
16683734|NCT02059109|Experimental|Pair|Staff will work in pairs to assemble the Belmont Rapid Infuser
16683735|NCT02059096|Experimental|Repetitive transcranial magnetic stimulation (rTMS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation
16683736|NCT02059096|Other|Theta-Burst Stimulation (pcTBS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
16683737|NCT02059096|Other|repetitive Transcranial Magnetic Stimulation (rTMS)placebo|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
16683738|NCT02059083|Active Comparator|Cognitive behavioral therapy (CBT) alone|
16683739|NCT02059083|Experimental|Cognitive behavioral therapy plus HRV biofeedback|
16683740|NCT02059070|Experimental|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
16683741|NCT02059070|Experimental|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
16683742|NCT02059057|Experimental|LVRC System|
16683743|NCT02059044|Experimental|ISTOP-ADE|Interactive Voice Response System + Pharmacist
16683744|NCT02059044|No Intervention|Routine care|Routine care
16683745|NCT02059031|Experimental|Part A|In Part A, subjects will be randomized to receive two new formulations of GSK1265744 30 mg (New formulation 1 -micronized [B], New formulation 2un-micronized [C]) and the sodium salt reference formulation 30 mg (Reference formulation [A]) in one of six sequences; ABC, BCA, CAB, BAC, ACB, CBA in three treatment periods under fasting condition.
16683746|NCT02059031|Experimental|Part B|Fifteen eligible subjects completing the Part A of the study will enter in to Part B where they will receive either formulation B or C. The selected drug (B or C) will be administered under fed (moderate fat meal) condition in the fourth treatment period.
16683747|NCT02059018|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days
16683748|NCT02059018|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days
16683749|NCT02059005|Experimental|Specialized Community Disease Management|Specialized Community Disease Management
16683750|NCT02059005|Active Comparator|Treatment As Usual|Treatment as Usual: standard post-hospital discharge with medical monitoring.
16683751|NCT02058992||Ramelteon 8 mg administered orally once daily|
16683752|NCT02058979|Active Comparator|BOLUS INFUSION|Bolus infusion of antibiotics
16683753|NCT02058979|Experimental|CONTINUOUS INFUSION|Continuous infusion of antibiotics by way of infusion pump
16683755|NCT02058966|Experimental|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
16683756|NCT02058966|Experimental|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
16683757|NCT02058966|Experimental|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
16683758|NCT02058953||Craniotomy scheduled|"Patients who have scheduled craniotomy with melanoma brain metastases will have the following specimens collected:
~CNS tumor specimens, specifically the remaining portion from the resected melanoma CNS metastasis
~the remaining portion from the adjacent normal CNS tissue. No additional normal brain tissue will be collected for research purposes only, however the routinely collect peritumoral tissue will be retained.
~melanoma specimens from other extracranial, clinically palpable metastatic sites.
~CSF taken at around the time of the craniotomy procedure
~peripheral blood prior to craniotomy."
16683759|NCT02058953||Collection for non-craniotomy|"For those eligible patients who are not having a craniotomy:
~collection of CSF will be performed by lumbar puncture or from the patient's Ommaya reservoir, if present.
~collection of peripheral blood.
~NOTE: Only patients who have no absolute contraindications or up to two relative contraindications will be considered for lumbar puncture"
16683760|NCT02058940|Experimental|Exenatide|
16683761|NCT02058927||HIV-1 infected children|HIV-1-infected children initiating ART
16683762|NCT02058927||HIV-1 uninfected children|control group of HIV-1 uninfected children matched by age
16683763|NCT02058927||HIV-1 infected children revaccinated|nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers
16683764|NCT02058914|Experimental|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
16683765|NCT02058914|Active Comparator|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
16683766|NCT02058901|Experimental|Sunitinib high dose, weekly schedule|Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
16683767|NCT02058901|Experimental|Sunitinib high dose, biweekly schedule|When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
16683768|NCT02058875|Experimental|Treatment Group|Maximization of mycophenolicacid (MPA) derivative (to a total daily dosage of 1440mg of Myfortic®) and reduction of cyclosporine dosage (as defined by C2 monitoring) in 50 stable renal transplant patients previously on immunosuppressive therapy with cyclosporine, an MPA derivative and prednisone.
16683769|NCT02058875|Active Comparator|Control Group|25 patients continued on an mycophenolicacid (MPA) derivative, cyclosporine and prednisone.
16683770|NCT02058875|No Intervention|Observation Group|25 patients continued on an mycophenolic acid (MPA) derivative, tacrolimus, and prednisone will be followed during the same recruitment period as an additional comparison, as this is the other Calcineurin Inhibitor (CNI), which is used in kidney transplantation.
16683771|NCT02058849|Experimental|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
16683772|NCT02058849|Placebo Comparator|Placebo|Placebo
16683773|NCT02058836|Experimental|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
16683774|NCT02058836|Placebo Comparator|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
16683775|NCT02058823|Placebo Comparator|Arm 1: Real hypoxia and ¨Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 2.
16683776|NCT02058823|Placebo Comparator|Arm 2: Hypoxia placebo and Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the hypoxia placebo and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 1.
16683777|NCT02058823|Active Comparator|Arm 3: Hypoxia and Valsartan|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the Valsartan during the first two weeks and, after the wash-out, receive the treatment of the arm 4.
16683778|NCT02058823|Active Comparator|Arm 4: Hypoxia and Amlodipine|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the amlodipine during the first two weeks and, after the wash-out, receive the treatment of the arm 3.
16683779|NCT02058810|Other|Conventional nasal Oxygen|Conventional nasal Oxygen as needed
16683780|NCT02058810|Other|Nasal high flow|Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
16683781|NCT02058797|Experimental|Coherence Therapy|Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
16683782|NCT02058797|Active Comparator|Cognitive Behavioral Therapy|Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
16683783|NCT02058784|Experimental|Single-dose food effect in nonsmokers|Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
16683784|NCT02058784|Experimental|Single-dose food effect in smokers|Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
16683785|NCT02058771||Ischaemic cardiomyopathy|Patients with ischaemic cardiomyopathy attending for ICD implantation
16683786|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
16683787|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
16683788|NCT02058745|Active Comparator|CAU+ (Enhanced Care as Usual)|CAU+ (Enhanced Care as Usual) is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page for the 10 month duration of the study.
16683789|NCT02058745|Experimental|CAU+ and SmartCare|CAU+ (Enhanced Care as Usual) for eight weeks, followed by eight weeks of SmartCare. SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management.
16683790|NCT02058745|Experimental|CAU+ and Beating the Blues and SmartCare|CAU+ (Enhanced Care as Usual) and Beating the Blues concurrently for eight weeks, followed by SmartCare for eight weeks. Beating the Blues is an established, web-based, self-directed, cognitive behavioral therapy for managing depressive symptoms.
16683791|NCT02058732|Active Comparator|ALS patients receivng stem cells|Amyotrophic lateral sclerosis(ALS)subjects, who will be receiving stem cells, will undergo a brief clinical evaluation and questionnaire that will last approximately 20 to 30 min. Subjects will be asked to undergo magnetic resonance imaging(MRI)scans of the cervical spine and brain that will last approximately 60 minutes.
16683792|NCT02058732|Active Comparator|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis(ALS)patient who will not be receiving stem cells, will have an MRI that lasts approximately 60 minutes. This MRI will be repeated at three different time points. Subjects will have an initial MRI, then another at both 6 and 12 months after the initial magnetic resonance imaging(MRI)scan. Subjects will also complete a clinical examination which will take approximately 30 minutes for each MRI. The follow-up magnetic resonance imaging(MRI)scans done for ALS patients who do not receive stem cells are part of routine clinical studies and therefore subjects will not be billed.
16683793|NCT02058719||Cohort A1|HIV positive smokers
16683794|NCT02058719||Cohort A2|HIV positive non-smokers
16683795|NCT02058719||Cohort A3|HIV negative smokers
16683796|NCT02058719||Cohort A4|HIV negative non-smokers
16683797|NCT02058719||Cohort B1|HIV positive with COPD
16683798|NCT02058719||Cohort B2|HIV positive without COPD (non-COPD)
16683799|NCT02058719||Cohort B3|HIV negative with COPD
16683800|NCT02058706|Experimental|Arm A (enzalutamide and LHRH analogue therapy)|Patients receive enzalutamide orally PO QD and undergo orchiectomy or receive LHRH analogue therapy (leuprolide acetate, goserelin acetate, or any other FDA approved preparation). Treatment continues in the absence of disease progression or unacceptable toxicity.
16683801|NCT02058706|Active Comparator|Arm B (bicalutamide and LHRH analogue therapy)|Patients receive bicalutamide PO QD and undergo orchiectomy or receive LHRH analogue therapy as in Arm A. Treatment continues in the absence of disease progression or unacceptable toxicity.
16683802|NCT02058693|Placebo Comparator|Placebo Group|"Phase I (3 weeks) placebo adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).
~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
16683803|NCT02058693|Active Comparator|MSA group|"mixed salts amphetamine, adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).
~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
16683804|NCT02058680|Experimental|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.
~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
16683805|NCT02058667|Experimental|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
16683806|NCT02058654|Experimental|Creatine Group|Whey protein (30 g) and creatine supplement (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
16683807|NCT02058654|Placebo Comparator|Placebo Group|Whey protein (30 g) and bulking agent powder (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
16683808|NCT02058641|Experimental|Part A|Part A will consist of 2 sessions. In Session 1, 3 blisters will be induced by a challenging agent (cantharidin solution 0.2 %, with 5 microliter administered topically) in T2DM subjects on Day 1. Blisters will be harvested 48 (+/-2) hour (hr) post induction. In Session 2, the same subjects will be administered darapladib EC tablet 160 mg orally, once daily for 11 days. On Day 10, 3 blisters will be induced by cantharidin. Blisters will be harvested 48 (+/-2) hr post induction.
16683809|NCT02058641|Experimental|Part B|In Part B, healthy subjects will be enrolled and will follow the same dosing procedure as in Part A. The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A.
16683810|NCT02058628|Experimental|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
16683811|NCT02058628|Experimental|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
16683949|NCT02057731||III carriers|Carriers of GSD type III will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
16683812|NCT02058615|Experimental|Male Spouse Transition Toolkit|All participants in this group will be given access to the Male Spouse Transition Toolkit (MaTT). MaTT is a website based application that is designed to help male spouses of women with breast cancer to increase their awareness of the transitions and experiences they have as a husband and caregiver as well as to stay organized and seek help and resources as needed. To do so it consists of six sections: about me; common changes to expect; frequently asked questions; resources; calendar; and, important health information. These sections contain activities and exercises, as well as fillable templates (i.e., resources, calendar) that users can download at their convenience, from their home computer, tablet, or smart phone. They will be asked to use the MaTT for one month.
16683813|NCT02058615|No Intervention|Usual Care|Participants in this group will not receive access to the Male Spouse Transition Toolkit, and thus will not receive an intervention. Data collection for outcome variables will be the same as the participants in the experimental arm.
16683814|NCT02058602|Experimental|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
16683815|NCT02058589|Experimental|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
16683816|NCT02058589|Placebo Comparator|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
16683817|NCT02058576|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination) in period 2 orally once daily under fed condition.
16683818|NCT02058576|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fed condition.
16683819|NCT02058563|Experimental|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
16683820|NCT02058563|Active Comparator|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
16683821|NCT02058550|No Intervention|Arm I (no intervention)|Patients receive no additional reminders.
16683822|NCT02058550|Experimental|Arm II (email survey)|Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
16683823|NCT02058550|Experimental|Arm III (email surveys and phone calls)|Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
16683824|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
16683825|NCT02058524|Experimental|fecal microbiota transplantation|
16683826|NCT02058511|Experimental|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:
~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
16683827|NCT02058498|Experimental|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
16683828|NCT02058485|Active Comparator|Group HD|Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
16683829|NCT02058485|Sham Comparator|Group ND|Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
16683830|NCT02058485|Active Comparator|Group HM|Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
16683831|NCT02058485|Sham Comparator|Group NM|Midazolam was administered 0.025 mg. kg-1 in normotensive patient.
16683832|NCT02058472|Experimental|G3041|Amlodipine orotate 10mg/Olmesartan medoxomil 40mg
16683833|NCT02058472|Active Comparator|SEVIKAR®|Amlodipine besylate 10mg/Olmesartan medoxomil 40mg
16683834|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
16683835|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
16683836|NCT02058446|Experimental|Study group|Amlodipine/Valsartan Single-Pill Combination
16683837|NCT02058433|Experimental|pharmacokinetics group|Based on pharmacokinetics. Observe safety and efficacy. In first cycle a fixed Paclitaxel dose depends on BSA. In subsequent cycles the dosage of Paclitaxel will be adjusted depending on pharmacokinetics follow up .
16683838|NCT02058433|Active Comparator|Body surface area(BSA) group|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
16683839|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
16683840|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
16683841|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
16683842|NCT02058407|Experimental|Cohort 1- Part A|This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
16683869|NCT02058238||Arm 2: control-arm - non-robotic, open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
16683843|NCT02058407|Experimental|Cohort 2- Part A|This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
16683844|NCT02058407|Experimental|Cohort 3- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
16683845|NCT02058407|Experimental|Cohort 4- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.
16683846|NCT02058394||Cataract Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
16683847|NCT02058381|Experimental|Group 1 (alpelisib)|Alpelisib plus Tamoxifen and Goserelin (Group 1)
16683848|NCT02058381|Experimental|Group 2 (buparlisib)|Buparlisib plus Tamoxifen and Goserelin (Group 2)
16683849|NCT02058368|Experimental|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
16683850|NCT02058368|Experimental|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
16683851|NCT02058355|Experimental|Personalized Normative Feedback|This group receive the complete Personalized Normative Feedback (with normative information and a list of consequences)
16683852|NCT02058355|Experimental|Normative Feedback|This group receive a feedback only with normative informations (without a list of consequences)
16683853|NCT02058355|Experimental|Consequences List Feedback|This group receive a list of consequences without normative informations
16683854|NCT02058342|Experimental|Active Play at Home Intervention|Participant parents in the intervention arm will receive: 1) Active Play at Home curriculum and equipment, 2) Training session on Active Play at Home curriculum, 3) counseling on physical activity scheduling, identification of barriers, motivational strategies, 4) phone calls to check on compliance and issues with doing the program at home
16683855|NCT02058342|No Intervention|Wait-listed control|Participants will attend the baseline visit to do baseline measurements but will not receive any materials related to the Active Play at Home curriculum and will also not be contacted by phone during the control 24 weeks. After they serve as control group, they will be provided with the opportunity to receive the intervention.
16683856|NCT02058329|No Intervention|No intervention|Standard of care with no home visit
16683857|NCT02058329|Experimental|Home Visit|After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment
16683858|NCT02058316||Patients at risk for IPA|
16683859|NCT02058303|Experimental|Exparel forearm block|Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
16683860|NCT02058303|Active Comparator|Bupivacaine supraclavicular block|Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
16683861|NCT02058290|Active Comparator|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
16683862|NCT02058290|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
16683863|NCT02058277|Other|Healthy volunteers|Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order
16683864|NCT02058264|Experimental|Low Strength BBI-4000 and Vehicle|
16683865|NCT02058264|Experimental|High Strength BBI-4000 and Vehicle|
16683866|NCT02058251|Experimental|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
16683867|NCT02058251|Placebo Comparator|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
16683868|NCT02058238||Arm 1: Robotic-guided, Open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
16692779|NCT01998646|Experimental|ASP4058 Tablet - Fed conditions|
16683870|NCT02058238||Arm 3: robotic-guided, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
16683871|NCT02058238||Arm 4: control-arm - freehand, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
16683872|NCT02058225||Infant Group 1|This group consist of healthy, full-term babies whose mothers have no known medical conditions or complications during pregnancy.
16683873|NCT02058212|Placebo Comparator|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
16683874|NCT02058212|Active Comparator|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
16683875|NCT02058199|Experimental|normal subjects|A single dose of 10 mg of rivaroxaban will be administered
16683876|NCT02058199|Experimental|Obese non bypassed|A single dose of rivaroxaban will be administered
16683877|NCT02058199|Experimental|obese bypassed|A single dose of rivaroxaban will be administered
16683878|NCT02058199|Experimental|pre and post bypassed subject|A single dose of rivaroxaban will be administered prior to gastric bypass. Subjects will be restudied 12 to 24 weeks following bypass
16683879|NCT02058186|Active Comparator|Atopic dermatitis patients: Active|Atopic dermatitis patients: age 1-18 years old
16683880|NCT02058186|Placebo Comparator|Atopic dermatitis patients: Placebo|Atopic dermatitis patients: age 1-18 years old
16683881|NCT02058173|Experimental|chloroquine|150 mg chloroquine and lacebo , one tablet daily for 2 month
16683882|NCT02058173|Experimental|placebo|150 mg chloroquine and lacebo , one tablet daily for 2 month
16683883|NCT02058160|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
16683884|NCT02058160|Active Comparator|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
16683885|NCT02058147|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
16683886|NCT02058147|Active Comparator|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
16683887|NCT02058147|Active Comparator|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
16683888|NCT02058134|No Intervention|Control group|
16683889|NCT02058134|Experimental|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
16683890|NCT02058121|Experimental|Acceptance and Commitment Therapy|
16683891|NCT02058121|Active Comparator|Treatment as usual|
16683892|NCT02058108|Experimental|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
16683893|NCT02058108|Placebo Comparator|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
16683894|NCT02058095|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
16683895|NCT02058095|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
16683896|NCT02058082|Active Comparator|ejaculated sperm|Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm
16683897|NCT02058082|Active Comparator|testicular extracted sperm|Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm
16683898|NCT02058069|Experimental|Robotic Assisted Total Knee Arthroplasty|
16683899|NCT02058056|Experimental|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
16683900|NCT02058030|Other|3cm head elevation|Insertion of ProSeal laryngeal mask airway
16683901|NCT02058030|Active Comparator|6cm head elevation|Insertion of ProSeal laryngeal mask airway
16683902|NCT02058017|Experimental|Part I & Part II|"Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.
~Part II - This is a single-centre, open-label non-randomised phase II study evaluating OPB-51602 in stage III-IVB NPC conducted in the window period prior to definitive chemoradiotherapy. Eligible patients will receive OPB-51602 on a weekly basis (Day 1, 8, 15) at the recommended dose determined in part I for a total of 15 days prior to definitive chemoradiotherapy."
16683903|NCT02058004|Experimental|Cricoid pressure|Patients randomized to receive cricoid pressure during endotracheal intubation.
16683904|NCT02058004|No Intervention|No cricoid pressure|Patients randomized to receive no cricoid pressure during endotracheal intubation.
16683905|NCT02057991|No Intervention|Group I (standard of care)|Patients and caregivers receive standard of care.
16683906|NCT02057991|Experimental|Group II (educational video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
16683907|NCT02057991|Experimental|Group III (educational video, mindfulness exercise video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.
16683908|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
16683909|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
16683948|NCT02057731||Ib carriers|Carriers of GSD type Ib will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
16684053|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
16683910|NCT02057965|Active Comparator|Mesenchymal Stromal Cells + Everolimus|"Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.
~At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)"
16683911|NCT02057965|No Intervention|Everolimus + Tacrolimus|Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks).
16683912|NCT02057952|No Intervention|Usual Care Control|No intervention.
16683913|NCT02057952|Active Comparator|In Person Weight Management|Education and exercise in a community health center environment.
16683914|NCT02057952|Experimental|Video Conference Weight Management|Education and exercise delivered through video conference.
16683915|NCT02057939|Experimental|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
16683916|NCT02057926|Experimental|Tetracycline, Without Tetracycline|The study consist in two groups: test group (membrane treated with tetracycline) and control group (membrane no treated with tetracycline).
16683917|NCT02057913|Experimental|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
16683918|NCT02057900|Experimental|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
16683919|NCT02057887|Experimental|Cohort1|HM10660A SC once weekly
16683920|NCT02057887|Experimental|Cohort2|HM10660A SC once every 2 weeks
16683921|NCT02057887|Experimental|Cohort3|HM10660A SC once every 4 weeks
16683922|NCT02057887|Active Comparator|Cohort4|180 mcg Pegasys SC once weekly
16683923|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
16683924|NCT02057861||non-diabetic|non-diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded.
16683925|NCT02057861||diabetic|Diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded
16683926|NCT02057848|Active Comparator|low amount of carbohydrates|2 x 10 g carbohydrates (muesli bars)
16683927|NCT02057848|Active Comparator|high amount of carbohydrates|2 x 20 g carbohydrates (muesli bars)
16683928|NCT02057848|Other|Rapid-acting carbohydrates|30 g rapidly absorbable carboh. + 20 g muesli bar
16683929|NCT02057835|Experimental|BI 691751 low dose 1|BI 691751 low dose 1
16683930|NCT02057835|Experimental|BI 691751 low dose 2|BI 691751 low dose 2
16683931|NCT02057835|Experimental|BI 691751 middle dose|BI 691751 middle dose
16683932|NCT02057835|Experimental|BI 691751 high dose|BI 691751 high dose
16683933|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
16683934|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
16683935|NCT02057809||Parent-child dyad|Children with Developmental Disabilities and their parents
16683936|NCT02057809||Therapits|Therapists experienced in serving children with developmental disabilities
16683937|NCT02057796|Experimental|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"Arm1 Extensive TB screening:
~In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
16683938|NCT02057796|Experimental|Rifampin, isoniazid, pyrazinamide, ethambutol|"Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART
~In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
16683939|NCT02057783|Experimental|Physical activity|Obstructive sleep apnea and resistant hypertension controlled + physical activity
16683940|NCT02057783|No Intervention|Control Group|Obstructive sleep apnea and resistant hypertension controlled
16683941|NCT02057770|Experimental|Treatment (preparative regimen, transplant, cyclophosphamide)|"BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.
~OR
~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.
~AND
~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.
~AND
~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4."
16683942|NCT02057770|Experimental|CRS preventive regimen|The final ~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
16683943|NCT02057757|Experimental|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
16683944|NCT02057757|Placebo Comparator|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
16683945|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
16683946|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
16683947|NCT02057731||Ia carriers|Carriers of GSD type Ia will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
16683950|NCT02057731||0, VI, IX carriers|Carriers of GSD types 0, VI, and IX will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
16683951|NCT02057731||Noncarriers|Noncarriers of any type of GSD will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to ensure their noncarrier status. A questionnaire will also be filled out.
16683952|NCT02057718|Experimental|LUM001 (Maralixibat)|Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).
16683953|NCT02057692|Experimental|LUM001|LUM001 for oral administration
16683954|NCT02057692|Placebo Comparator|Placebo|Placebo administered orally once each day
16683955|NCT02057679|Active Comparator|Group A (Amoxicillin Clavulanic)|Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
16683956|NCT02057679|Placebo Comparator|Placebo|Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
16683957|NCT02057666|Experimental|Tasquinimod|One capsule (0.25, 0.50 or 1 mg), taken orally once a day with water and food (preferably the main evening meal).
16683958|NCT02057666|Placebo Comparator|Placebo|One capsule, taken orally once a day with water and food (preferably the main evening meal).
16683959|NCT02057653||Before GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record prior to the start of the training curriculum.
16683960|NCT02057653||After GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record after the training program took place
16683961|NCT02057640|Experimental|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
16683962|NCT02057627|Experimental|Perinatal Dyadic Psychotherapy|The Perinatal Dyadic Psychotherapy intervention consists of 8 home-based, nurse-delivered mother-infant sessions consisting of (a) a supportive, relationship-based, mother-infant psychotherapeutic component, and (b) a developmentally based infant-oriented component focused on promoting positive mother-infant interactions. The 8 sessions take place over three months with weekly 4 sessions (weeks 1 through 4) followed by 4 every other week sessions (weeks 5 through 8)
16683963|NCT02057627|Placebo Comparator|Standard care plus depression monitoring|Standard care plus depression monitoring by phone on a schedule comparable to the intervention groups' home visits. Eight phone calls will take place over three months with weekly 4 calls (weeks 1 through 4) followed by 4 every other week calls (weeks 5 through 8). Phone monitoring will include administration of the Edinburgh Postnatal Depression Scale.
16683964|NCT02057601|Experimental|Infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0ml and will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
16683965|NCT02057601|No Intervention|Non infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0 ml.
16683966|NCT02057588|Other|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
16683967|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.01%|Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
16683968|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.02%|Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
16683969|NCT02057575|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
16683970|NCT02057575|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
16683971|NCT02057562||Routine colonoscopy|Patients receiving routine colonoscopy (for a multitude of indications) at the study centers are eligible for participation
16683972|NCT02057549|Experimental|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
16683973|NCT02057549|Active Comparator|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
16683974|NCT02057536|Experimental|Arm A|8 week directed exercise program
16683975|NCT02057536|Active Comparator|Arm B|No directed exercise other than patients normal level of activity
16683976|NCT02057523|Experimental|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
16683977|NCT02057510||Patients receiving head and neck RT|No intervention
16683978|NCT02057497||Healthy volunteers|Considered generally healthy based on medical history and physical examination as per discretion of the investigator
16683979|NCT02057497||Type 1 Diabetes|T1DM diagnosed clinically prior to start of trial examinations
16683980|NCT02057497||Type 2 Diabetes|T2DM diagnosis prior to the start of trial examinations
16683981|NCT02057484||Organ transplant patients treated with Advagraf|To evaluate long-term graft survival in patients treated with Advagraf
16683982|NCT02057471|Experimental|Intravenous Ferric Carboxymaltose|All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
16683983|NCT02057458|Experimental|Acute Study: Sildenafil first, then Placebo|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
16683984|NCT02057458|Experimental|Acute Study: Placebo first, then Sildenafil|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
16684137|NCT02056535|Active Comparator|Intervention|Screened eligible, received baseline assessment and intervention
16683985|NCT02057458|Experimental|Sub-Chronic Study Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.
16683986|NCT02057445|Experimental|Recipient|EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
16683987|NCT02057445|Other|Donor|Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
16683988|NCT02057432|Experimental|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
16683989|NCT02057419||Contraceptive Method|"Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...
~Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period."
16683990|NCT02057419||Sexual Lubricant Method|3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
16683991|NCT02057406|Active Comparator|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
16683992|NCT02057406|Active Comparator|High EPA|Almost pure EPA 2 grams
16683993|NCT02057406|Placebo Comparator|Placebo|Matched placebo corn oil capsules
16683994|NCT02057393|Experimental|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
16683995|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
16683996|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
16683997|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
16683998|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
16683999|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
16684000|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
16684001|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
16684002|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
16684003|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
16684004|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
16684005|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
16684006|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
16684007|NCT02057367|Experimental|Scalp block with 0.5% plain marcaine|Anterior scalp block with 0.5% plain Marcaine 20 ml.
16684008|NCT02057367|Placebo Comparator|Scalp block with 0.9% normal saline|Anterior scalp block with 0.9% normal saline 20 ml.
16684009|NCT02057354|Active Comparator|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
16684010|NCT02057354|Experimental|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
16684011|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
16684012|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
16684013|NCT02057328|Active Comparator|NEBIVOLOL|Patients of the group of nebivolol will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients still classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range 12,5 mg hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
16684014|NCT02057328|Active Comparator|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisarta daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. The same procedure will be repeated at the end of the 6th month from the beginning of the study. Patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
16684015|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
16684016|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
16684017|NCT02057302|Placebo Comparator|Group B|There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper.
16684018|NCT02057302|Experimental|Group A|There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
16684019|NCT02057289|Experimental|Micafungin|"Subjects will be administered 5 mg/kg of micafungin intravenously as a ONE TIME dose.
~For patients undergoing Hematopoietic Stem Cell Transplant (HSCT), Micafungin will be given on during rest days (i.e. days when no chemotherapy is administered) and blood for pharmacokinetic measurements will be drawn over next 96 hours.
~Following this, further anti-fungal coverage will be at the discretion of the patient's attending physician. (I.e. other antifungal agent(s) or Micafungin at a standard clinical dose; repeat doses of 5mg/kg will NOT be administered.)"
16684020|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
16684021|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
16684022|NCT02057263|Experimental|Alendronate and Hepatitis B Vaccine|Participants in the experimental arm will receive 4 alendronate doses during their Hepatitis B vaccination course.
16684023|NCT02057263|Experimental|Sugar Pill and Hepatitis B Vaccine|Participants in the experimental arm will receive placebo doses during their Hepatitis B vaccination course.
16684024|NCT02057250|Experimental|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
16684025|NCT02057250|Experimental|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
16684026|NCT02057250|Experimental|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
16684027|NCT02057250|Experimental|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
16684028|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
16684029|NCT02057224|Experimental|Single arm|15 clinical patients undergoing renal denervation
16684030|NCT02057211|Placebo Comparator|sham transplantation of mesenchymal stem cells|control arm with sham transplantation
16684031|NCT02057211|Active Comparator|autologous mesenchymal stem cell transplantation|Active arm with transplantation of cells
16684032|NCT02057198|Active Comparator|Fidaxomicin|200 mg. 2 times a day for 10 days
16684033|NCT02057198|Active Comparator|Metronidazole|500 mg.orally 3 times daily for 10 days
16684034|NCT02057198|Active Comparator|Vancomycin|125 mg. orally 4 times a day for 10 days
16684035|NCT02057185||Study population|"Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.
~The study excludes non Italian speaking patients or unable to fully understand the study's forms."
16684036|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
16684037|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
16684038|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
16684039|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
16684040|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
16684041|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
16684042|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
16684043|NCT02057159|Experimental|NeuroVax|NeuroVax
16684044|NCT02057159|Placebo Comparator|IFA Placebo|IFA Placebo
16684045|NCT02057146|Experimental|Mother-baby endoscopy|Spyglass mother-baby endoscopy in conjunction with ERCP
16684046|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
16684047|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
16684048|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
16684049|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
16684050|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
16684051|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
16684052|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
16684054|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
16684055|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
16684056|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
16684057|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
16684058|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
16684059|NCT02057120|Active Comparator|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
16684060|NCT02057120|Placebo Comparator|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
16684061|NCT02057107|Other|SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel|Previously Treated With Cetuximab - Group A No Previous Cetuximab - Group C
16684062|NCT02057107|Other|SBRT + Cetuximab followed by Cetuximab|Previously Treated with Cetuximab - Group B No Previous Cetuximab - Group D
16684063|NCT02057094|Placebo Comparator|Control|Dining facility recovery feeding only, no supplemental protein consumed (an isoenergetic, carbohydrate supplement will be consumed by those assigned to the Control group)
16684064|NCT02057094|Active Comparator|Protein|"Consume dining facility food with:
~2, 20 g whey protein supplements daily (for ~27 days)
~1, 40 g casein protein supplement daily (for ~27 days)"
16684065|NCT02057094|Active Comparator|High-Protein|"Consume dining facility food with:
~2, 40 g whey protein supplements daily (~27 days)
~1, 50 g casein protein supplement daily (~27 days)"
16684066|NCT02057081|Experimental|Treatment|Intensive 14-session psychoeducational rehabilitation and skills-building intervention for couples.
16684067|NCT02057081|Active Comparator|Control|Didactic 14-session educational group intervention for families.
16684068|NCT02057068|Experimental|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention
~. Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.
~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.
~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).
~. SLEEP-E Dyads book
~. Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
16684069|NCT02057068|No Intervention|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
16684070|NCT02057055|Experimental|Soap 300000027003|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
16684071|NCT02057055|Experimental|Soap 300000029240|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
16684072|NCT02057042|Experimental|PS-cCBT|peer-assisted computerized CBT
16684073|NCT02057042|Active Comparator|EUC|Enhanced usual care
16684074|NCT02057029|Other|BCI Assay Results|The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER positive cancers and is provided through a CLIA certified commercial laboratory. It is an RT-PCR assay that can be performed on formalin fixed paraffin embedded sections of archived tissues. Participants will work in concert with a physician to determine future treatment options based on BCI results.
16684075|NCT02057003||DAA-based therapy against HCV|HIV/HCV-coinfected patients who start therapy against HCV including one or more DAA
16684076|NCT02056990||training advise|
16684077|NCT02056977|Experimental|Titration|Individualized PEEP titration by EIT
16684078|NCT02056977|Active Comparator|Control|PEEP stablished according to the routines at the institution (PEEP table according to the P/F ratio)
16684079|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
16684080|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
16684081|NCT02056951|Active Comparator|Multidisciplinary rehabilitation|The central objective of inpatient multidisciplinary orthopedic rehabilitation (MOR) is to improve functional health with the main focus on restoring and improving work ability. A MOR lasts on average 23 days with a total extent of therapy of 48 hours on average. MOR is provided by a multiprofessional team consisting of physicians, psychologists, sport therapists, physiotherapists, occupational therapists, masseurs, social workers, dieticians and nurses. The interventions are carried out mainly in open groups.
16684132|NCT02056561||TIVA (group T n: 15)|Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
16684133|NCT02056561||Sevoflurane (group S n: 15)|Group S were ventilated with 2% sevoflurane, 50% air and 50% O2 mix at 6 L/min flow.
16684134|NCT02056561||Desflurane (group D n: 15)|Group D cases were given 6% desflurane 50% air and 50% O2 mix at 6 L/min flow.
16684082|NCT02056951|Experimental|Interprofessional rehabilitation|The central objective of the interprofessional rehabilitation (PASTOR) is the development of active self-management of chronic non-specific low back pain. PASTOR is matched to the MOR with respect to the total duration and total extent of therapy, the included professions and the interventions dimensions (physical, psychological). The differences between PASTOR and MOR are characterized by, a) an integrative combination of profession related modules within a comprehensive and consistent treatment approach, b) an interprofessional and collaborative teamwork based on profession related modules, c) the use of standardized methods, media and materials by all professions in the therapeutic team d) a highly structured and detailed manual for the entire treatment process. The interventions are carried in fixed groups with eight to twelve participants.
16684083|NCT02056938|Experimental|ATG|"The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.
~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery)."
16684084|NCT02056938|Active Comparator|Basiliximab|The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).
16684085|NCT02056925|Experimental|Experimental|
16684086|NCT02056912|Other|Lipodystrophie Héréditaire|
16684087|NCT02056899|Experimental|Gabapentin|
16684088|NCT02056886|Experimental|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.
~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.
~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
16684089|NCT02056886|Other|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:
~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.
~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.
~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
16684090|NCT02056886|Other|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.
~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.
~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
16684091|NCT02056873|Experimental|Deep Brain Stimulation (DBS)|"Subjects' DBS surgical intervention requires implantation of a DBS system: two CM thalamic leads (one in each brain hemisphere), two ECOG strip leads (one in each brain hemisphere), and two neurostimulators implanted in the chest.
~The ECOG strip lead is implanted into the brain to provide an interface through which stimulation can be delivered or activity of the brain can be monitored by the device, or observed by a clinician using a programmer.
~Neurostimulator and leads system includes a programmer, which includes a wand and telemetry interface, and a patient remote control to check battery status and whether the device is on or off. The programmer is used to set up the device, including setup of stimulation and recording, as well as to retrieve data for subsequent review."
16684092|NCT02056860||Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
16684093|NCT02056860||Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
16684094|NCT02056860||Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
16684095|NCT02056860||Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
16684096|NCT02056860||Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
16684097|NCT02056847|Active Comparator|Pitavastatin calcium 4mg|Pitavastatin calcium (LIVALO®) 4mg, once a day
16684098|NCT02056847|Active Comparator|Pitavastatin calcium 2mg|Pitavastatin calcium (LIVALO®) 2mg, once a day
16684099|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
16684100|NCT02056808|Experimental|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
16684135|NCT02056535|No Intervention|Screened Only|Screened only and met criteria for eligibility for study
16684136|NCT02056535|No Intervention|Screened and Assessed|Screened as eligible for the study and received baseline assessment
16684101|NCT02056795|Experimental|Electroacupuncture|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
16684102|NCT02056795|Sham Comparator|Control|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
16684103|NCT02056782|Experimental|PGX-ODSH-2013-AML-1|See Intervention Description
16684104|NCT02056769|Experimental|CT Perfusion|All patients enrolled in the study
16684105|NCT02056756|Experimental|CBD|
16684106|NCT02056743|Experimental|Fermented-red ginseng|"At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.
~During 4~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
16684107|NCT02056743|Experimental|Red ginseng|"At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.
~During 4~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
16684108|NCT02056730|Experimental|Regpara|calcium sensing receptor agonist
16684109|NCT02056717|Experimental|Dexamethasone group|
16684110|NCT02056717|Placebo Comparator|Control group|
16684111|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
16684112|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
16684113|NCT02056691|Experimental|Exercise programme|Exercise programme Muscle biopsies
16684114|NCT02056678|Active Comparator|IV acetaminophen, OSA, laparoscopic cholecystectomy|IV acetaminophen 1000mg to be administered to obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy
16684115|NCT02056678|No Intervention|OSA, laparoscopic cholecystectomy, narcotics|No IV acetaminophen in obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy; patients will receive other modalities for pain control primarily including IV narcotics
16684116|NCT02056665|Experimental|MINOCYCLINE 8 weeks|"Duration of treatment: 8 weeks
~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.
~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.
~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
16684117|NCT02056665|Placebo Comparator|PLACEBO 8 weeks|Pill manufactured to mimic Minocycline 50 mg capsule
16684118|NCT02056665|Experimental|MINOCYCLINE 16 weeks|"Duration of treatment: 16 weeks
~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.
~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.
~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
16684119|NCT02056652|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
16684120|NCT02056652|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
16684121|NCT02056639|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
16684122|NCT02056639|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
16684123|NCT02056626|Active Comparator|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
16684124|NCT02056626|Active Comparator|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
16684125|NCT02056626|Active Comparator|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
16684126|NCT02056626|Active Comparator|arm 1|standard therapy, 25 mg twice daily (15 days)
16684127|NCT02056600|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
16684128|NCT02056600|Experimental|C|Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
16684129|NCT02056587|Experimental|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
16684130|NCT02056574|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
16684131|NCT02056574|Placebo Comparator|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
16684138|NCT02056522||Suspicious skin lesions.|No intervention is administered.
16684139|NCT02056509||Out of hospital cardiac arrest|Out of hospital cardiac arrest of non-traumatic cause
16684140|NCT02056509||Unexpected in-hospital cardiac arrest|Unexpected cardiac arrest during emergency department stay
16684141|NCT02056496|Experimental|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
16684142|NCT02056483|Experimental|Screening-based nurse navigation|Based on systematic screening for psychological and physical symptoms as well as health behavior a nurse navigator will refer to and monitor use of appropriate rehabilitation programs
16684143|NCT02056483|No Intervention|Usual care|Usual care
16684144|NCT02056470|Experimental|Freedom Total Knee Replacement|Freedom Total Knee
16684145|NCT02056457|Experimental|Responsible fatherhood or healthy marriage|
16684146|NCT02056457|Experimental|Control|
16684147|NCT02056444|Experimental|Topical tranexamic acid (TXA)|Single dose 1.5 grams topical TXA infiltrated into the surgical field at time of arthrotomy closure.
16684148|NCT02056444|Active Comparator|Intravenous TXA|Single 20 mg/kg dose of intravenous TXA administered prior to skin incision.
16684149|NCT02056431|Experimental|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
16684150|NCT02056431|No Intervention|IVR Control Group|Participants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) containing general messages regarding diabetic education.
16684151|NCT02056418|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
16684152|NCT02056418|Experimental|Corticosteroid|The patients receive treatment of corticosteroid only.
16684153|NCT02056418|No Intervention|Healthy control|healthy people applied with normal diet.
16684154|NCT02056405|Placebo Comparator|Placebo|Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
16684155|NCT02056405|Active Comparator|Mosapride|Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
16684156|NCT02056392|Experimental|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
16684157|NCT02056392|Active Comparator|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
16684158|NCT02056392|Placebo Comparator|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
16684159|NCT02056379|Active Comparator|Budesonide|2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.
16684160|NCT02056379|Active Comparator|Dexamethasone|This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.
16684161|NCT02056366|Active Comparator|α-lipoic acid|α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks
16684162|NCT02056366|No Intervention|No treatment group|No Intervention
16684163|NCT02056353|Active Comparator|Nurse-directed|Blood glucose control guided by paper protocol
16684164|NCT02056353|Experimental|LOGIC-Insulin|Blood glucose control guided by the LOGIC-Insulin algorithm
16684165|NCT02056340|Active Comparator|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
16684166|NCT02056340|Placebo Comparator|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
16684167|NCT02056327||Oral appliance with monitoring suite|Subjects will sleep with a standard oral appliance with the newly developed monitoring suite embedded within it for 1-2 nights while being monitored with standard in lab polysomnography or home sleep testing.
16684168|NCT02056314|Active Comparator|brochure|The participants will be given a brochure that describes problem gambling and recommends methods of staying in control of gambling such as coping skills.
16684169|NCT02056314|Experimental|electronic tutorial|The participants will be given an electronic tutorial that will explain how to stay in control of their gambling including information about coping skills, warning signs, and information about myths related to gambling.
16684170|NCT02056301|Active Comparator|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
16684171|NCT02056301|Active Comparator|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
16684172|NCT02056288|Active Comparator|Ultrasound Guided Supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
16684173|NCT02056288|Active Comparator|IV Opioids|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
16684174|NCT02056275|Experimental|ONS + dietary counseling|ONS/day + dietary counseling
16684175|NCT02056275|Active Comparator|Dietary counseling|Dietary counseling
16684176|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.
~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
16684177|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.
~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
16684178|NCT02056249||Healthy, lean subjects|Volunteers without anemia (hematocrit), diabetes (A1c), use of illicit drugs and antidepressants, or any other major health issues.
16684179|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1. Lorazepam 4 mg iv (initial dosage) titrated up to a maximum of 12 mg/24 hours OR midazolam 10 mg (initial dosage) up to 60 mg/24 hours (in steps of 5 mg/5 minutes) PLUS Fenytoine bolus i.v. 15-20 mg/kg in 30 minutes, followed by 150 mg 2 dd 1, adapted based on serum levels.
~Step 2. Propofol infusion with a maximum of 8 mg/kg/hour PLUS A second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.
~Step 3. Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages treatment should be guided by the EEG pattern."
16684180|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.
~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
16684181|NCT02056223|Experimental|paracetamol|Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.
16684182|NCT02056223|Active Comparator|Intravenous ibuprofen|Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.
16684183|NCT02056210|Experimental|Stem cell mobilization in diabetic patients|Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
16684184|NCT02056210|Experimental|Stem cell mobilization in non diabetic subjects|Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects
16684185|NCT02056197|Placebo Comparator|Placebo|Shortwave 30 minutes.
16684186|NCT02056197|Active Comparator|Stable|Stable surface exercises
16684187|NCT02056197|Experimental|Unstable|Unstable surface exercises
16684188|NCT02056184|Active Comparator|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
16684189|NCT02056184|Experimental|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
16684190|NCT02056171|Experimental|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
16684191|NCT02056171|Placebo Comparator|Placebo|A randomized group will receive placebo, and not quetiapine.
16684192|NCT02056158||HIV Negative Early COPD Smokers|HIV Negative Early COPD Smokers
16684193|NCT02056158||HIV Negative COPD Smokers|HIV Negative COPD Smokers
16684194|NCT02056158||HIV Negative Nonsmokers|HIV Negative Nonsmokers
16684195|NCT02056158||HIV Negative Smokers|HIV Negative Smokers
16684196|NCT02056158||HIV Positive Smokers|HIV Positive Smokers
16684197|NCT02056158||HIV Positive Nonsmokers|HIV Positive Nonsmokers
16684198|NCT02056158||HIV Positive COPD Smokers|HIV Positive COPD Smokers
16684199|NCT02056158||HIV Positive Early COPD Smokers|HIV Positive Early COPD Smokers
16684200|NCT02056145|Placebo Comparator|Group 1|Group 1 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.9% saline solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 30 ml saline solution 0.9%.
16684201|NCT02056145|Active Comparator|Group 2|Group 2 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 20 cc 0.25% bupivacaine solution en 10 cc saline solution 0.9%.
16684202|NCT02056145|Active Comparator|Group 3|Group 3 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.25% bupivacaine solution for lateral femoral cutaneous block, for a total of 30 cc of 0.25% bupivacaine solution.
16684203|NCT02056132||Cystic Fibrosis patients.|Patients with Cystic Fibrosis. Results of Exhaled Breath Condensate lab.
16684204|NCT02056132||Control Subjects|Individuals without Cystic Fibrosis or signs of current respiratory infection. Results of Exhaled Breath Condensate lab.
16684205|NCT02056119|Active Comparator|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:
~Physician order received for subject, randomization to jet nebulizer occurred.
~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).
~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.
~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
16684206|NCT02056119|Experimental|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.
~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.
~Aerosol treatment delivered per physician order.
~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
16684207|NCT02056106|Active Comparator|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
16684208|NCT02056106|Active Comparator|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
16684209|NCT02056093|Experimental|Intubated patients|Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.
16684243|NCT02055846|Experimental|prostate cancer|Realisation of blood sample, urinary sample and tumor biopsy
16692780|NCT01998646|Placebo Comparator|Placebo|
16684210|NCT02056067|Experimental|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
16684211|NCT02056067|Active Comparator|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
16684212|NCT02056054||Subjects with d-AIH|Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
16684213|NCT02056054||Subjects with Acute Rejection|Pediatric transplant patients with acute rejection will be enrolled at an outside center.
16684214|NCT02056054||Subjects with Chronic Rejection|Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
16684215|NCT02056054||Control Subjects|Healthy pediatric patients will be enrolled at the coordinating center (Yale).
16684216|NCT02056054||Subjects with Auto-immune Hepatitis|Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
16684217|NCT02056054||Subjects with Chronic Hepatitis C Virus|Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
16684218|NCT02056054||Adult Subjects with d-AIH|Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
16684219|NCT02056041||Hepatectomy for HCC|Patients submitted to surgery for HCC
16684220|NCT02056028||Bile leak after hepatic resection|
16684221|NCT02056015|Experimental|[68Ga]MLN6907|
16684222|NCT02056002|Active Comparator|Usual Care|"Standard CPAP educational training
~Educational Brochures
~Educational DVD videos mailed to participant"
16684223|NCT02056002|Experimental|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy
~Standard CPAP training
~Eight phone conversations with Peer Buddy over 3 months
~Subsequent 3 months use of phone system to contact Peer Buddy as needed
~One Month Visit:
~-Home visit to collect CPAP information
~Three Month Visit:
~Questionnaires
~Psycho Motor Vigilance Test (PVT) Video Game
~Collect CPAP information
~Measure weight
~Measure blood pressure
~Six Month Visit:
~Questionnaires
~PVT (Video game)
~Collect CPAP information
~Measure Weight
~Measure Blood Pressure
~Evaluate the program and Peer Buddy"
16684224|NCT02055989|Experimental|Dose-escalated radiotherapy level 1|
16684225|NCT02055989|Experimental|Sequential dose-escalated radiotherapy level 2|
16684226|NCT02055976|Experimental|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
16684227|NCT02055976|Experimental|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
16684228|NCT02055963|Experimental|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.
~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
16684229|NCT02055963|Placebo Comparator|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.
~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).
~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
16684230|NCT02055950||Kidney perfused by pulsatile machine|
16684231|NCT02055950||Kidney stored in refrigerated solution|
16684232|NCT02055937|Experimental|immediate implant breast reconstruction|immediate implant breast reconstruction
16684233|NCT02055924|Experimental|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
16684234|NCT02055911|Experimental|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
16684235|NCT02055898|Experimental|Placebo first, then sodium oxybate|Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights
16684236|NCT02055898|Experimental|Sodium oxybate first, then placebo|Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights
16684237|NCT02055885||Positive responders|Positive responders (R+): patients exhibiting an increase in the 6WT distance ≥ 10% and/or a decrease in dyspnea ≥ 10% (i.e., ≥ 1 point on the visual analogue scale).
16684238|NCT02055885||negative responders|Negative responders(R-): patients exhibiting a decrease in the distance ≥ 10% and/or an increase in dyspnea ≥ 10%.
16684239|NCT02055872|Experimental|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
16684240|NCT02055872|Placebo Comparator|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
16684241|NCT02055859|Other|single session radiosurgery|single session radiosurgery (gold standard)
16684242|NCT02055859|Experimental|multisession radiosurgery|multisession radiosurgery (3 fraction)
16684244|NCT02055833|Experimental|Intensive nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy) + n-3 polyunsaturated fatty acids-enriched oral nutritional supplements (1-2 bottles/day)
16684245|NCT02055833|Active Comparator|Nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy)
16684246|NCT02055820|Experimental|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
16684247|NCT02055820|Experimental|Venetoclax + R-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
16684248|NCT02055807|Experimental|PEEP and recruitment maneuvers|A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
16684249|NCT02055807|Active Comparator|ZEEP (Zero end-expiratory pressure)|No PEEP nor recruitment maneuvers will be used during surgery. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
16684250|NCT02055794|Active Comparator|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
16684251|NCT02055794|Active Comparator|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
16684252|NCT02055794|Active Comparator|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
16684253|NCT02055781|Experimental|Pacritinib, Once Daily|Pacritinib 400 mg taken orally, once daily
16684254|NCT02055781|Experimental|Pacritinib, Twice Daily|Pacritinib 200 mg taken orally, twice daily
16684255|NCT02055781|Active Comparator|Best Available Therapy|Best Available Therapy includes any physician-selected treatment for primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, such as approved JAK2 inhibitors, and may include any treatment received before study entry. Best Available Therapy may include ruxolitinib, other approved JAK2 inhibitors, hydroxyurea, glucocorticoids, erythropoietic agents, immunomodulatory agents, mercaptopurine, danazol, interferons, cytarabine, melphalan, or other agents and may also include no treatment and symptom-directed treatment without myelofibrosis-specific treatment.
16684256|NCT02055742||Specimen Collection|
16684257|NCT02055729||The study population|"The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.
~For a description of the study population, see the inclusion/exclusion criteria.
~Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample"
16684258|NCT02055716|Placebo Comparator|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
16684259|NCT02055716|Experimental|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
16684260|NCT02055703|Experimental|E2609|Experimental drug for Parts A, B, and C
16684261|NCT02055703|Active Comparator|itraconazole|Comparator drug for Part A1
16684262|NCT02055703|Active Comparator|rifampin|Comparator drug for Part A2
16684263|NCT02055703|Active Comparator|digoxin|Comparator drug for Part B
16684264|NCT02055703|Active Comparator|donepezil|Comparator drug for Part C
16684265|NCT02055690|Experimental|Phase Ib/II: Fosbretabulin & Pazopanib|"Phase Ib:
~Fosbretabulin and Pazopanib in combination. Fosbreatabulin dose will be in the range of 45mg/m2- 60 mg/m2 delivered by infusion every week for 3 weeks of a 4 week cycle until disease progression. Pazopanib will be either 600 mg or 800mg taken orally each day of 28 day cycle until disease progression.
~The phase II dose of both drugs will be determined by the Phase Ib component which is a dose finding exercise.
~Phase II:
~Fosbretabulin and Pazopanib in combination. Fosbretabulin 54mg/m2 delivered by infusion every week for 3 weeks of a 4 week for 28 day cycle until disease progression. Pazopanib 600mg taken orally each day for 28 day cycle until disease progression"
16684266|NCT02055690|Active Comparator|Phase II: Pazopanib|Pazopanib 800mg taken orally each day of 28 day cycle until disease progression
16684267|NCT02055664|Experimental|treatment|
16684268|NCT02055664|Placebo Comparator|control|
16684269|NCT02055651||Bayer Sao Paulo employees|Workers from Bayer in site Socorro who participate in the trial
16684270|NCT02055638|Experimental|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
16684271|NCT02055638|Placebo Comparator|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
16684272|NCT02055625|Experimental|Mesenchymal stromal cell treatment|Biological: Mesenchymal stromal cells
16684273|NCT02055586||Diagnostic (FLT-PET/MRI)|Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
16684333|NCT02055287|Experimental|LY03004- 37.5|LY03004 Dose Strength 37.5mg
16684334|NCT02055287|Experimental|LY03004 - 50|LY03004 Dose Strength 50mg
16684335|NCT02055274|Experimental|LY03003|4 Stable doses of LY03003 14, 28, 42 and 56 mg
16684274|NCT02055573|Experimental|Ready To Learn|1) The Ready to Learn (RTL) arm will receive a DVD in both Spanish and English and a bilingual booklet (both produced by Parents' action for Children) addressing the benefits of reading, talking and playing with young children, as well as a new children's board book.
16684275|NCT02055573|Experimental|All Babies Cry|2) The All Babies Cry (ABC) arm will receive a DVD in both, Spanish and English and a bilingual booklet (both produced by VIDA Health Communications, INC) explaining crying as part of normal infant behavior, highlighting signs of parental distress and providing strategies to sooth parents and their children
16684276|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
16684277|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
16684278|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and matching placebo (PBO) in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684279|NCT02055547|Experimental|Part 1 - Panel A - PBO > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684280|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684281|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > PBO > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, PBO in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684282|NCT02055547|Experimental|Part 1- Panel B- MK-8521 150μg > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684283|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > MK-8521 200μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684284|NCT02055547|Experimental|Part 1 - Panel B - PBO > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received PBO in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684285|NCT02055547|Experimental|Part 2 - Panel C - MK-8521 50μg > MK-8521 72μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 50μg Days 1 to 5 and MK-8521 72μg Days 6 to 10 in a single treatment period.
16684286|NCT02055547|Experimental|Part 2 - Panel D - MK-8521 100μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
16684287|NCT02055547|Experimental|Part 2 - Panel E - MK-8521 125μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
16684288|NCT02055547|Experimental|Part 2 - Panel F - MK-8521 72μg > MK-8521 125μg|Obese male participants of 45 to 65 years of age received a single dose of MK-8521 72μg Days 1 to 7 and MK-8521 125μg Days 8 to 14 in a single treatment period.
16684289|NCT02055547|Placebo Comparator|Part 2 - Panels C+D+E - Pooled Placebo|Healthy male participants of 18 to 45 years of age received PBO once daily for 10 days.
16684290|NCT02055547|Placebo Comparator|Part 2 - Panel F - Placebo|Obese male participants of 45 to 65 years of age received a single dose of PBO Days 1 to 14.
16684291|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > MK-8521 35μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, MK-8521 35μg (low dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684292|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > PBO > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, PBO MK-8521 in the second treatment period, and 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684293|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 125μg > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 125μg (high dose) in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684294|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 35μg > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 35μg (low dose) in the second treatment period, and MK-8521 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684295|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > PBO > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, PBO in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684296|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > MK-8521 125μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, MK-8521 125μg (high dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
16684336|NCT02055274|Active Comparator|Neupro|Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
16684297|NCT02055534|Experimental|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the Amyloidosis Center
16684298|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the Amyloidosis Center
16684299|NCT02055508|Experimental|Exercise Intervention Program (EIP)|"Inpatient periods: The combined resistance and endurance program consist of free weight and rubber band training for major upper and lower body muscle groups respectively of cycling/walking on an ergometer/treadmill 3x/week.
~Outpatient periods (3x/week at least two/one supervised training sessions): Supervised training sessions in the local outpatient training center will comprise of resistance exercise on machines and endurance training on an ergometer/treadmill. For non-supervised training session during the outpatient period participants will receive an exercise manual for individualized home-based exercising.
~In weekly phone calls, the advanced practice nurse will review adherence to the intervention and identify problems. Furthermore, the patients will also be asked the same questions as in the CMPC group."
16684300|NCT02055508|Active Comparator|Care-Management-Phone-Calls (CMPC)|"Patients in this arm will receive a weekly care-management-phone-call (CMPC), performed by an advanced practice nurse (APN). The CMPCs are based on a structured questionnaire, reflecting pain, shortness of breath, disturbed sleep, exhaustion and distress and potentially treatment related side effects (e.g. infections, polyneuropathy, etc.). In case of demanding management of symptoms or complaints (e.g. uncontrolled pain or breathlessness) the treating physician is contacted by the APN to facilitate improvement."
16684301|NCT02055482|Experimental|BAY85-3934|
16684302|NCT02055482|Active Comparator|Darbepoetin|
16684303|NCT02055456|Experimental|Nandrolone Decanoate|Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose
16684304|NCT02055443||Holter monitor group|12-lead holter monitor application
16684305|NCT02055430|Active Comparator|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
16684306|NCT02055430|Active Comparator|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
16684307|NCT02055417|Experimental|Personal Approaches to Treatment Choices for HIV|PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART.
16684308|NCT02055417|Active Comparator|Stress Reduction Skills Program|SRSP includes training in stress reduction skills such as relaxation, problem solving, and expressing negative feelings.
16684309|NCT02055404|Experimental|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
16684310|NCT02055404|Other|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
16684311|NCT02055391|Active Comparator|Behavioral Weight Loss|State of the art behavioral weight loss treatment
16684312|NCT02055391|Experimental|Enhanced Behavioral Weight Loss|Combines behavioral weight loss skills with skills specifically targeting emotional eating.
16684313|NCT02055378|Experimental|auricular acupoint stimulation|Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
16684314|NCT02055378|Active Comparator|Atropine|topical 0.125% atropine was given nightly during the study period.
16684315|NCT02055365|Experimental|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
16684316|NCT02055352|Experimental|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
16684317|NCT02055352|Active Comparator|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
16684318|NCT02055339|Experimental|Fisher & Paykel heated humidified high flow nasal cannula|For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization. When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm. The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
16684319|NCT02055339|Active Comparator|InfantFlow/RAM nasal continuous positive airway pressure|Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart. The nCPAP circuit will only be removed when it is time for oral feeds. The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations. The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
16684320|NCT02055326|Experimental|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
16684321|NCT02055326|Active Comparator|Health & Wellness|8 week program of health & wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
16684322|NCT02055300|Experimental|LY03005 - 20|LY03005 Dose Strength 20mg
16684323|NCT02055300|Experimental|LY03005 - 40|LY03005 Dose Strength 40mg
16684324|NCT02055300|Experimental|LY03005- 80|LY03005 Dose Strength 80mg
16684325|NCT02055300|Experimental|LY03005 - 120|LY03005 Dose Strength 120mg
16684326|NCT02055300|Experimental|LY03005 - 160|LY03005 Dose Strength 160 mg
16684327|NCT02055300|Experimental|LY03005 - 200|LY03005 Dose Strength 200mg
16684328|NCT02055300|Experimental|LY03005 - 120 - Fed|LY03005 120mg under Fed Conditions
16684329|NCT02055300|Active Comparator|Pristiq|Pristiq - 50mg
16684330|NCT02055300|Placebo Comparator|Placebo|Placebo
16684331|NCT02055287|Experimental|LY03004- 12.5|LY03004 dosage strength at 12.5mg
16684332|NCT02055287|Experimental|LY03004 - 25|LY03004 Dose Strength 25mg
16684337|NCT02055274|Active Comparator|Neupro PK|Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
16684338|NCT02055261|Other|OFF PPN DBS-ON PPN DBS|Patients randomly allocated to the order OFF Low frequency DBS of the pedunculopontine nucleus then ON Low frequency DBS of the pedunculopontine nucleus
16684339|NCT02055261|Other|ON PPN DBS - OFF PPN DBS|Patients randomly allocated to the order ON Low frequency DBS of the pedunculopontine nucleus then OFF Low frequency DBS of the pedunculopontine nucleus
16684341|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
16684342|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
16684343|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
16684344|NCT02055209||1|Adults only, all genders, US-born African American
16684345|NCT02055196|Experimental|Treatment (neuronal stem cells, irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells via intracerebral catheter on day 1 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16684346|NCT02055183||Participants treated with BAT®|Any patient of any age with a confirmed or suspected exposure to botulinum toxin who were treated with BAT®.
16684347|NCT02055170|Experimental|finasteride|finasteride 5mg po od from study entry to date of surgery
16684348|NCT02055157|Experimental|Cohort 1|Cohort 1: 2.5 ug/kg
16684349|NCT02055157|Experimental|Cohort 2|Cohort 2: 7.5 ug/kg,
16684350|NCT02055157|Experimental|Cohort 3|Cohort 3: 15 ug/Kg
16684351|NCT02055157|Experimental|Cohort 4|Cohort 4: 30 ug/kg
16684352|NCT02055144||Non squamous histology|patients with advanced, non-squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and pemetrexed. Maintenance with pemetrexed is allowed.
16684353|NCT02055144||Squamous histology|patients with advanced squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and gemcitabine
16684354|NCT02055131|Placebo Comparator|aspirn fixed dose|patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.
16684355|NCT02055131|Placebo Comparator|aspirin dose titrated with PFA-100|patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.
16684356|NCT02055131|No Intervention|placebo arm|in this group of patients we will just supervise thromboembolic events of the vascular access.
16684357|NCT02055118|Experimental|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
16684358|NCT02055118|Other|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
16684359|NCT02055105|Other|miRNA|
16684360|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 38 persons with their respective family members.
16684361|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 50 persons with their respective family members.
16684362|NCT02055092||LOD|Late onset dementia >= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
16684363|NCT02055079|Experimental|Sirolimus|Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.
16684364|NCT02055079|Placebo Comparator|Placebo|Fixed oral dose of placebo (blinded) once weekly for 24 months.
16684365|NCT02055066|Experimental|Arm 1|ARGX-111 0.3 mg/kg
16684366|NCT02055066|Experimental|Arm 2|ARGX-111 1.0 mg/kg
16684367|NCT02055066|Experimental|Arm 3|ARGX-111 3.0 mg/kg
16684368|NCT02055066|Experimental|Arm 4|ARGX-111 10 mg/kg
16684369|NCT02055053|Experimental|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
16684370|NCT02055053|Placebo Comparator|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
16684371|NCT02055027||Adherent Patients|Comparison between groups
16684372|NCT02055027||Non-adherent patients|Comparison between groups
16684373|NCT02055014|Active Comparator|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
16684374|NCT02055014|Experimental|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
16684375|NCT02055014|Experimental|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
16684376|NCT02054988|Experimental|caffeine|"three cups of coffee will be administered for 10 days (on chronic phase) and two cups of coffee will be consecutively administered for acute evaluation."
16684377|NCT02054988|Active Comparator|not caffeine|not caffeine will be administered for the duration of the study
16684378|NCT02054975|Experimental|vitamin D2 + vitamin D3|Vitamin D2 50,000 IU each week x 4 + vitamin D3 4,000 IU each day for 3 months
16684379|NCT02054975|Active Comparator|Vitamin D lower dose|800 IU vitamin D3 by mouth each day for 3 months
16684380|NCT02054962||Elderly|The investigators intend to asses the effect of fear of movement, PTSD symptoms, and physical activity on persistent pain and functional decline.
16684381|NCT02054949|Experimental|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
16684382|NCT02054936|Active Comparator|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
16693069|NCT01996644|Placebo Comparator|placebo|Placebo group plus exposure
16684383|NCT02054936|Active Comparator|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
16684384|NCT02054923|Experimental|Routine video recording group|Intervention: Procedure: Implementation of routine videorecording of colonoscopy withdrawal
16684385|NCT02054923|Active Comparator|Control group|Intervention: Behavioral: No routine videorecording (on demand videorecording possible)
16684386|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
16684387|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
16684388|NCT02054897|Experimental|Semaglutide 1.0 mg|
16684389|NCT02054897|Experimental|Semaglutide 0.5 mg|
16684390|NCT02054897|Placebo Comparator|Semaglutide placebo 1.0 mg|
16684391|NCT02054897|Placebo Comparator|Semaglutide placebo 0.5 mg|
16684392|NCT02054884|Experimental|Arm A: F16IL2 in combination with paclitaxel|
16684393|NCT02054884|Experimental|Arm B: Paclitaxel|
16684394|NCT02054871|Experimental|EGFR 30-60|"Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.
~Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles."
16684395|NCT02054871|Experimental|EGFR 60-90|Experimental: RIPC Remote preconditioning. EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
16684396|NCT02054871|No Intervention|EGRF 30-60|"No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.
~Patients randomised to this group will receive routine care."
16684397|NCT02054871|No Intervention|EGRF 60-90|No Intervention: Remote preconditioning control EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Patients randomised to this group will receive routine care.
16684398|NCT02054858|Experimental|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
16684399|NCT02054858|No Intervention|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
16684400|NCT02054845|Experimental|Body awareness therapy|The experimental treatment: BEWARE
16684401|NCT02054845|Active Comparator|Treatment as Usual|The new treatment is compared to this arm: Physical therapy
16684402|NCT02054832||Glycosade|A prospective cohort design will be used to assess the impact on sleep and continue to monitor safety of Glycosade.
16684403|NCT02054819|Other|Single arm study|"Induction chemotherapy and concurrent radiation to primary tumor Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
~Consolidation Radiation: therapy to metastatic sites At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites."
16684404|NCT02054806|Experimental|Pembrolizumab|Participants receive pembrolizumab 10 mg/kg, intravenously (IV), on Day 1 of every 2-week dosing cycle for up to 24 months
16684405|NCT02054780|Active Comparator|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
16684406|NCT02054780|Experimental|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
16684407|NCT02054767|Experimental|lidocaine|injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
16684408|NCT02054767|Experimental|mepivacaine|injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
16684409|NCT02054767|Experimental|articaine|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
16684410|NCT02054754|Experimental|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
16684411|NCT02054754|Experimental|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
16684412|NCT02054754|Experimental|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
16684413|NCT02054754|Experimental|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
16684414|NCT02054754|Experimental|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
16684415|NCT02054754|Placebo Comparator|Placebo|Single oral dose of matching placebo
16684416|NCT02054741|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
16684417|NCT02054741|No Intervention|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
16684418|NCT02054728|Experimental|RHC and IMT|
16684419|NCT02054715|Experimental|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
16684420|NCT02054715|Experimental|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
16684421|NCT02054702|Experimental|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
16684422|NCT02054702|Experimental|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
16684423|NCT02054689|Other|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
16684424|NCT02054676|Experimental|Classification assessment.|Random group of the partially edentulous individuals will be assessed according to prepared classification evaluation protocol during dental implant treatment period. Cone-beam computed tomography preoperative evaluation will be made during preoperative stage. Intraoperative edentulous jaw segment parameters evaluation, endosseous dental implant placement parameters assessment during intraoperative stage will be made. Dental implant position evaluation during early postoperative stage will be made. Medications will be prescribed. Late postoperative soft tissue evaluation of edentulous jaw segment will be made during final crown placement. Cone-beam computed tomography analysis results will be compared with subsequent stages assessment results to evaluate reliability of the classification.
16684425|NCT02054663|Experimental|Bolus|Patients randomized to this arm will receive a 600mg bolus dose of clopidogrel at the time of switching from ticagrelor to clopidogrel, followed by 75mg daily.
16684426|NCT02054663|Experimental|no bolus|Individuals randomized to this arm will receive 75mg of clopidogrel at the time of the transition followed by a daily dose of 75mg orally.
16684427|NCT02054650|Experimental|Osteopathic Manual Treatment (OMT)|The OMT protocol will be delivered following an examination for somatic dysfunction at each treatment session. The protocol will target the thoracic, lumbosacral, iliac, and pubic regions using the following techniques: high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue including stretching, kneading, and pressure; myofascial stretching and release; counterstrain; muscle energy; and other optional techniques as time permits and indicated. The intervention will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
16684428|NCT02054650|Sham Comparator|Sham OMT|Sham OMT will involve hand contact, active and passive range of motion, and sham techniques that simulate OMT (including optional OMT techniques), but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force. Sham OMT will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
16684429|NCT02054637|Experimental|Lanreotide|Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)
16684430|NCT02054624|Active Comparator|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
~Phase 1 will be 4 months of weight loss treatment
~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.
~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
16684431|NCT02054624|Active Comparator|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
~Phase 1 will be 4 months of weight loss treatment
~Phase 2 will be 12 months of follow-up contact by conference telephone call.
~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
16684432|NCT02054624|Active Comparator|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
~Phase 1 will be 4 months of weight loss treatment
~Phase 2 will be 12 months of follow-up contact by email.
~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
16684433|NCT02054611|Active Comparator|Educational Module First|Respondents will complete the online educational module first, followed by the evaluation
16684434|NCT02054611|Placebo Comparator|Evaluation First|Respondents will complete the the evaluation first, followed by the online educational module
16684435|NCT02054598|No Intervention|Control group|Usual care.
16684436|NCT02054598|Experimental|Intervention group|Decision aid and navigation
16684437|NCT02054585|Active Comparator|NaCl %0.9|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.
~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
16684438|NCT02054585|Experimental|NaCl 0.9% +5% dextrose|"Children will be included in each group in a randomized way using SAS program.
~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% glucose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
16684439|NCT02054572|Experimental|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
16684440|NCT02054559|Active Comparator|Total 6 cycles of R-CHOP|
16684441|NCT02054559|Experimental|Total 3 cycles of R-CHOP + RT|Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)
16684442|NCT02054533||IBD patients|patients with IBD undergoing intra-abdominal surgery
16684443|NCT02054520|Experimental|Arm 1A HyperAcute®-Melanoma (HAM) + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
16684444|NCT02054520|Active Comparator|Arm 2A Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
16684445|NCT02054520|Experimental|Arm 1B HyperAcute®-Melanoma (HAM) + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
16684446|NCT02054520|Active Comparator|Arm 2B Nivolumab alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
16684447|NCT02054520|Experimental|Arm 1C HyperAcute®-Melanoma (HAM) + pembrolizumab|Arm 1C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
16684448|NCT02054520|Active Comparator|Arm 2C Pembrolizumab alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
16684449|NCT02054507|No Intervention|Former premature infants|Cognitive and executive evaluation by Wechsler IV tests
16684450|NCT02054494||HIV patients with high CD4+ cell counts|HIV Infection, Chronic high CD4+ cell counts (>500 /μl), No known cardiac disease
16684451|NCT02054494||HIV patients with low CD4+ cell counts|HIV Infection, Chronic low CD4+ cell counts (<200 /μl), No known cardiac disease
16684452|NCT02054494||Control Group|No known cardiac disease.
16684453|NCT02054481|Experimental|Arm 1|BI 655066 s.c.
16684454|NCT02054481|Experimental|Arm 2|BI 655066 s.c.
16684455|NCT02054481|Experimental|Arm 3|BI 655066 s.c.
16684456|NCT02054481|Active Comparator|Arm 4|Ustekinumab s.c.
16684457|NCT02054468|Active Comparator|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
16684458|NCT02054468|Experimental|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
16684459|NCT02054455|Placebo Comparator|PPI and placebo|Patients will receive PPI and placebo for 3 days/week for 6 months
16684460|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for 6 months
16684461|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 1|Patients will receive placebo 3 days/week for the first three months and Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the following three months
16684462|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 2|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months
16684463|NCT02054442|Experimental|Arm A: MTX in combination with cetuximab|"The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.
~Premedication: H1-receptor antagonist and dexamethasone.
~The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.
~Premedication: ondansetron 8 mg.
~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
16684464|NCT02054442|Active Comparator|Arm B: MTX|"The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.
~Premedication: ondansetron 8 mg.
~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
16684465|NCT02054429|Experimental|Insulin|IIT arm subjects will receive an insulin aspart infusion at a minimal rate of 2 units/hr while maintaining blood glucose between 90-120mg/dl for 48 hrs
16684466|NCT02054429|No Intervention|Standard glycemic control|standard of care if not randomized to Insulin
16684467|NCT02054416|Active Comparator|Art Assist Device|The ArtAssist© (model AA1000) device is made by ACI Medical located in San Marcos, CA (http://acimedical.com/) and is cleared per FDA under K942530.The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
16684468|NCT02054416|Sham Comparator|Sham Device|"Sham devices look identical to the actual ArtAssist© devices, but provide low-pressure and differ only in number-coded tubing. The study sham intervention will consist of one hour of IPC with the sham ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the sham device has an internal device that stores the usage data) to evaluate subject compliance."
16684469|NCT02054403||angle closure|
16684545|NCT02053857|Active Comparator|RUTF|Standard RUTF at a dose of 175 kcal/kg/d
16684546|NCT02053857|Experimental|RUTF-P|RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d
16684470|NCT02054377|Experimental|Group A (face to face tai chi)|"8 x 1 hour taught individual classes of Tai Chi over 3 months provided by a Tai Chi instructor at the participant's home/convenient location. These focus on 8 core postures. This is in addition to participant's usual routine care. A DVD and booklet to aid home practise will be provided.
~Daily home Tai Chi practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).
~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
16684471|NCT02054377|Active Comparator|Group 2 (online tai chi)|"3 months usual routine care.
~8 x 1 hour taught individual classes of Tai Chi over 3 months provided over the internet by a Tai Chi instructor. A DVD and booklet to aid home practise will be provided.
~Daily Tai Chi home practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).
~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
16684472|NCT02054364|Experimental|FBT and CRT|Family-Based Treatment combined with Cognitive Remediation Therapy (15 sessions of each)
16684473|NCT02054364|Experimental|FBT and art therapy|Family-Based Treatment combined with art therapy (15 sessions of each)
16684474|NCT02054351|Experimental|IMAB027 administration|Monotherapy - different dose Levels.
16684475|NCT02054338|Experimental|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
16684476|NCT02054338|Active Comparator|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
16684477|NCT02054325|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
16684478|NCT02054325|Active Comparator|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
16684479|NCT02054312|Experimental|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
16684480|NCT02054312|Active Comparator|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
16684481|NCT02054299|Experimental|Drug application|6 treatment periods. On each period one of the following interventions
16684482|NCT02054286|Experimental|Group 1: THV01 (5.10E+6 TU) or Placebo|5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
16684483|NCT02054286|Experimental|Group 2: THV01 (5.10E+7 TU) or Placebo|5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
16684484|NCT02054286|Experimental|Group 3: THV01 (5.10E+8 TU) or Placebo|5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
16684485|NCT02054260|Experimental|Surgicel add therapy|
16684486|NCT02054247|Experimental|ultrasound|ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2
16684487|NCT02054247|Experimental|pulsed ultrasound|pulsed ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4
16684488|NCT02054247|Placebo Comparator|placebo ultrasound|placebo ultrasound : same ultrasound device as described above seemed to be working but without delivering any output
16684489|NCT02054221|Other|extended myectomy + MVreplacement|"Procedure: extended myoectomy, mitral valve surgery
~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy with full isscheniem subvalvular apparatus and mitral valve replacement.
~Evaluation results will be made myoectomy as TEE and direct tensiometer."
16684490|NCT02054221|Other|extended myectomy + MVrepair|"Procedure: extended myoectomy, mitral valve surgery
~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles and the mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
16684491|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
16684492|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
16684493|NCT02054208|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
16684494|NCT02054195|Experimental|IUD new technique|Training
16684495|NCT02054195|Experimental|No Training|No Training
16684496|NCT02054182|Active Comparator|Vitamin D|Vitamin D 2 500 IU daily from enrolment until hospital discharge
16684497|NCT02054182|Placebo Comparator|Placebo|Placebo
16684498|NCT02054169||pre-test group|All patients aged 65 or older presenting to the ED during the pre-test period
16684499|NCT02054169||post-test period|All patients aged 65 or older presenting to the ED in the post-test period
16684643|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
16684500|NCT02054156|Active Comparator|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
16684501|NCT02054156|Placebo Comparator|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
16684502|NCT02054143|Experimental|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) after the intubation occured until the patient was extubated.
16684503|NCT02054130|Placebo Comparator|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
16684504|NCT02054130|Experimental|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
16684505|NCT02054130|Experimental|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
16684506|NCT02054130|Experimental|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
16684507|NCT02054117||Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
16684508|NCT02054104|Experimental|1/Vaccine plus chemotherapy|H1299 cell lysates with iscomatrix vaccine with metronomic chemotherapy
16684509|NCT02054104|Experimental|2/Vaccine alone|H1299 cell lysates with iscomatrix adjuvant vaccine
16684510|NCT02054091|No Intervention|Control group|Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
16684511|NCT02054091|Experimental|Colostrum group|Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.
16684512|NCT02054078|Experimental|Bevacizumab|Bevacizumab200mg by intrapleural administration
16684513|NCT02054078|Active Comparator|Pulvis talci|Pulvis talci 4g by intrapleural administration
16684514|NCT02054065|No Intervention|Control|Normal care conditions, no computer-based physician alert.
16684515|NCT02054065|Experimental|CAUTI Decision Support|Decision support aimed at preventing Catheter Associated Urinary Tract Infections (CAUTIs)
16684516|NCT02054052|Experimental|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
16684517|NCT02054039|Experimental|Incentive spirometry (IS)|Group I
16684518|NCT02054039|Active Comparator|Breath stacking (BS)|Group II
16684519|NCT02054026|Experimental|Reducing the Risk|An eight-lesson (approximately eight-hour) version of Reducing the Risk
16684520|NCT02054026|No Intervention|Control|
16684521|NCT02054013|Experimental|Prostatic artery embolization|Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure with rapid recovery and low morbidity
16684522|NCT02054013|Other|Conventional monopolar transurethral prostatectomy|Standard treatment
16684523|NCT02054000|Active Comparator|Tirofiban group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
16684524|NCT02054000|Placebo Comparator|Placebo group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
16684525|NCT02053987|Experimental|Stroke rehabilitation|
16684526|NCT02053987|No Intervention|Control Group|This group will undergo rehabilitation as per the current stroke rehabilitation pathway.
16684527|NCT02053974|Active Comparator|Spironolactone|patients who randomized to spironolactone administered arm
16684528|NCT02053974|Placebo Comparator|Placebo|Patients who randomized to placebo administered arm
16684529|NCT02053961|Active Comparator|1Hz dTMS Real|This group will receive dTMS real treatment of 1Hz
16684530|NCT02053961|Sham Comparator|1HZ dTMS SHAM|This group will receive 1HZ dTMS SHAM treatment
16684531|NCT02053948|Experimental|Pursestring Wound Closure group|use Pursestring Wound Closure technique to close the stoma
16684532|NCT02053948|Experimental|Gunsight Skin Incision and Closure group|use Gunsight Skin Incision and Closure Technique to close the stoma
16684533|NCT02053935|Other|Dopamine|All patients will receive the same intervention.
16684534|NCT02053922|Active Comparator|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
16684535|NCT02053922|Active Comparator|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
16684536|NCT02053922|Active Comparator|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
16684537|NCT02053909|Active Comparator|Aspirin|One aspirin 81 mg capsule 2 times per day
16684538|NCT02053909|Active Comparator|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
16684539|NCT02053896||ISU302|15~60U/kg (once every 2 weeks for 6 months)
16684540|NCT02053883|Placebo Comparator|Placebo|Fibrin sealant only.
16684541|NCT02053883|Experimental|Cethrin (BA-210) - Low Dose|Low dose of Cethrin in a fibrin sealant.
16684542|NCT02053883|Experimental|Cethrin (BA-210) - High Dose|High dose of Cethrin in a fibrin sealant.
16684543|NCT02053870|Experimental|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
16684544|NCT02053870|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
16684547|NCT02053844|Experimental|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
16684548|NCT02053844|No Intervention|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
16684549|NCT02053818|Active Comparator|Remifentanil|Remifentanil the basic opioid drug in anesthesia
16684550|NCT02053818|Active Comparator|Sufentanil|Sufentanil the basic opioid drug in anesthesia
16684551|NCT02053805|Other|screening tests|The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.
16684552|NCT02053792|Experimental|rIX-FP|"Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.
~The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.
~For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.
~The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data."
16684553|NCT02053779|Experimental|GnRH-agonist|Experimental Arm: Triptorelin 0.1 mg
16684554|NCT02053779|No Intervention|Control Arm|Control Arm: No intervention
16684555|NCT02053766|Active Comparator|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
16684556|NCT02053766|Active Comparator|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
16684557|NCT02053766|Active Comparator|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
16684558|NCT02053753|Experimental|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
16684559|NCT02053753|Experimental|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
16684560|NCT02053740|Experimental|R-S-Y-R-T|We added R-S-Y-R-T (500 mg 3 times per day) for 6 months
16684561|NCT02053740|Other|Routine western medicine|We kept routine western medicine only (as control group)
16684562|NCT02053727|Active Comparator|Abatacept Arm|This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
16684563|NCT02053727|Placebo Comparator|Placebo Arm|This arm of study patients will receive matching placebo injections during the 24 week double blind period.
16684564|NCT02053714|Other|Self-management and education group|Self-management and education group - 8 weeks of group-based information and activities designed to improve diabetes self-management
16684565|NCT02053688|Active Comparator|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
16684566|NCT02053688|Active Comparator|Toric Soft Contact Lenses|commercial toric soft contact lenses
16684567|NCT02053675|Other|Vasopressin|
16684568|NCT02053662||Bladder Cancer Patients|Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
16684569|NCT02053649|Active Comparator|Usual Care|Usual Care will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
16684570|NCT02053649|Experimental|Triple Chronotherapy + Usual Care|triple chronotherapy (TC) will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
16684571|NCT02053636|Experimental|lucitanib|"Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.
~5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
16684572|NCT02053610|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
16684573|NCT02053610|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
16684574|NCT02053610|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
16684644|NCT02053038|Experimental|iFR|Treatment guided by iFR
16684575|NCT02053597|Experimental|doxorubicin and paclitaxel|All patients will receive four cycles of doxorubicin (A) (50 mg/m2) and paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
16684576|NCT02053584|Experimental|Dario BGMS|
16684577|NCT02053571|Experimental|TIPS with 3D overlay|
16684578|NCT02053558|Placebo Comparator|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
16684579|NCT02053558|Active Comparator|TAP BLOCK with ropivacaine|TAP block will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
16684580|NCT02053545|Experimental|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)
~Stratum 2 (Myeloid in remission): Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF
~Stratum 3 (Lymphoid in remission): Fractionated total body irradiation (fTBI), Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF"
16684581|NCT02053532||Positron emission tomography/magnetic resonance imaging|
16684582|NCT02053519|Active Comparator|Vigantol Oil, (Vitamin D3)|Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D). First dose at randomisation, 7 -28 days prior to commencing standard Hepatitis C treatment for Hepatitis C Genotypes 1 or 3 . Thereafter monthly with concurrent Hepatitis C treatment.
16684583|NCT02053519|Placebo Comparator|MyGliol Oil|Matched placebo. Subjects randomised to this arm will take 5 mls of active Placebo, (Mygliol oil), 7 - 28 days prior to commencing active Hepatitis C treatment and thereafter 5 mls monthly concurrent with Hepatitis C treatment for the duration of the study
16684584|NCT02053506|Experimental|Immune-enhancing nutritional beverage|This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.
16684585|NCT02053506|Experimental|Probiotics (BB-12)|This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).
16684586|NCT02053493|Active Comparator|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
16684587|NCT02053493|Placebo Comparator|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
16684588|NCT02053480||Pyruvate Kinase Deficiency|Patients of all ages with Pyruvate Kinase Deficiency
16684589|NCT02053467|Experimental|eConsult|Physicians randomized to the intervention will have access to the Champlain BASE eConsult service right away (pending completion of an orientation session)
16684590|NCT02053467|No Intervention|Control|Physicians randomized to the control group will use their standard referral practices for one year after randomization and only then will be given the option to use eConsult.
16684591|NCT02053454|Active Comparator|patisiran (ALN-TTR02)|
16684592|NCT02053454|Active Comparator|Sterile Normal Saline (0.9% NaCl)|
16684593|NCT02053428|Active Comparator|Gastrostomy - pull technique|Percutaneous image-guided gastrostomy using large-bore mushroom-retained catheters via the pull technique
16684594|NCT02053428|Active Comparator|Gastrostomy - push technique|Percutaneous image-guided gastrostomy using small-bore cope loop catheters via the push technique
16684595|NCT02053415|Experimental|Krill oil low dose|3 capsules krill oil per day, for 28 days
16684596|NCT02053415|Experimental|Krill oil high dose|9 capsules krill oil per day, for 28 days
16684597|NCT02053402|Placebo Comparator|Placebo|Placebo to be given daily for six months
16684598|NCT02053402|Active Comparator|Vitamin D|1200 IU of vitamin D, daily for six months
16684599|NCT02053389|Experimental|DVD Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) AND the DVD decision aid (Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer), which provides instruction and recommendations on how to participate in shared decision making with one's physician."
16684600|NCT02053389|Active Comparator|Written Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) alone."
16684601|NCT02053376|Experimental|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (120 mg) (160 mg for second and subsequent treatment cycles) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
16684602|NCT02053363|Experimental|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
16684603|NCT02053363|Active Comparator|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
16684604|NCT02053350|Experimental|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
16684605|NCT02053337|Experimental|Self adhesive foam dressing|Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
16684606|NCT02053337|Active Comparator|Comparator self adhesive foam dressing|Non Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
16684645|NCT02053038|Active Comparator|FFR|Treatment guided by FFR
16684646|NCT02053025|Active Comparator|mycoprotein|3 levels of mycoprotein will be consumed
16684647|NCT02053025|Active Comparator|control protein|3 levels of a control protein will be consumed
16684648|NCT02053012||PVT-192|
16684649|NCT02052999|Experimental|PAC-14028 cream 1%|PAC-14028 cream 1%, twice daily for 8 weeks
16684607|NCT02053324|Experimental|AvidinOX/ST2210|AvidinOX/ST2210 - vial containing 22.5 mg AvidinOX + vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to 15 % of the lesion volume followed by intravenous infusion of 177Lu-ST2210 Diagnostic dose : 10 ml, 250 MBq±10%177Lu, approximately 1 mg ST2210, 100 mg/mL ascorbic acid, followed by intravenous infusion of a therapeutic dose: 25 ml, escalating 177Lu dose starting at 5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210, 100 mg/ml ascorbic acid
16684608|NCT02053311|Active Comparator|Arm A: Orteronel|300mg orteronel twice daily and best supportive care until disease progression
16684609|NCT02053311|Active Comparator|Arm B: Placebo|Placebo twice daily and best supportive care until disease progression
16684610|NCT02053298|Experimental|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
16684611|NCT02053272|Active Comparator|2 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 2 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
16684612|NCT02053272|Active Comparator|5 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 5 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
16684613|NCT02053272|Active Comparator|15 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 15 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
16684614|NCT02053272|Placebo Comparator|Placebo|Licaps® size double zero (Size 00) hard gelatin capsules containing excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
16684615|NCT02053259|Experimental|Adaptive Goals with Immediate Reinforcement|Adaptive Physical Activity Goals, Immediate Financial Reinforcement
16684616|NCT02053259|Experimental|Adaptive Goals with Delayed Reinforcement|Adaptive Physical Activity Goals, Delayed Financial Reinforcement
16684617|NCT02053259|Experimental|Static Goals with Immediate Reinforcement|Static Physical Activity Goals, Immediate Financial Reinforcement
16684618|NCT02053259|Active Comparator|Static Goals with Delayed Reinforcement|Static Physical Activity Goals, Delayed Financial Reinforcement
16684619|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
16684620|NCT02053233|Experimental|Walkbot group|The Walkbot group received conventional physical therapy (session I for 40 min/day) companied with Walkbot training (session II for 30 min/day) 5 days a week for 4 weeks, 40 session in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks.
16684621|NCT02053233|Placebo Comparator|control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
16684622|NCT02053220|Experimental|Intra-tumoural cohort|
16684623|NCT02053220|Experimental|Intra-venous cohort|
16684624|NCT02053207|Experimental|Cog-Train Intervention|
16684625|NCT02053194|Experimental|Pharmacist-led educational intervention|Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
16684626|NCT02053194|No Intervention|Control|Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
16684627|NCT02053181|Experimental|Cadazolid|Single oral dose of 3000 mg.
16684628|NCT02053168|Other|Resorbable Mesh|Phasix Mesh
16684629|NCT02053155|Experimental|computer based patient education|The patients will complete a pre module and post module set of questions to determine whether their knowledge about peri operative smoking cessation increase smoking has changed. According to their willingness and eligibility, pharmacotherapy will be given.
16684630|NCT02053142|Experimental|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
16684631|NCT02053142|Active Comparator|Acyclovir|400 mg Acyclovir three times daily for 5 days
16684632|NCT02053142|Placebo Comparator|Placebo|Placebo three times daily for 5 days
16684633|NCT02053129|Other|HIV negative pregnant women|Pregnant women who are HIV negative attending their first ANC visit
16684634|NCT02053129|Other|HIV positive pregnant women|Pregnant women who are HIV positive accessing antenatal care.
16684635|NCT02053116|Experimental|PF-05175157|
16684636|NCT02053116|Placebo Comparator|Placebo|
16684637|NCT02053103|Experimental|PF-05175157|
16684638|NCT02053103|Placebo Comparator|Placebo|
16684639|NCT02053090|Active Comparator|Group Education with Stretching|"Group Education with Stretching will receive 10 small group educational classes at the Oregon Health & Science University (OHSU), based on the book Fibromyalgia (Biographies of Disease). Each chapter of Fibromyalgia covers different aspects of the disease and its treatment including global, economic, and risk statistics; a timeline of key events in the study of fibromyalgia; common symptoms and diagnostic indicators; natural history of fibromyalgia; pharmacologic and non-pharmacologic treatments; associated disorders and syndromes; and impact of fibromyalgia at home, in the workplace and in society at large. Participants will be informed that they should not start additional treatments until the end of the study and complementary and alternative treatments won't be covered until the last session. Participants will also receive a digital video disk (DVD) covering stretching appropriate for fibromyalgia patients and will be asked to incorporate the DVD over the next 10 weeks."
16684640|NCT02053090|Experimental|Group Acupuncture|20 treatments in 10 weeks will include individualized acupuncture in a group setting, dietary and lifestyle recommendations each based on the Traditional Chinese Medicine diagnosis (zhang fu) at the time of the visit.
16684641|NCT02053064|Experimental|SAF-301|
16684642|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
16684650|NCT02052999|Active Comparator|Rozex gel 0.75%|Rozex gel 0.75%, twice daily for 8 weeks
16684651|NCT02052999|Placebo Comparator|Vehicle|Vehicle, twice daily for 8 weeks
16684652|NCT02052986|Experimental|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
16684653|NCT02052973|Experimental|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
16684654|NCT02052960|Experimental|CetuGEX™ plus chemotherapy|720 mg weekly administration
16684655|NCT02052960|Active Comparator|Cetuximab plus chemotherapy|250 mg/m2 weekly administration
16684656|NCT02052947|Other|SPEC-DaTscan|SPEC-DaTscan
16684657|NCT02052934|Experimental|Cohort 1|Three sublingual (SL) doses of dMLT, 1 microgram (mcg), on Days 1, 15 and 29, 8 subjects
16684658|NCT02052934|Experimental|Cohort 2|Three SL doses of dMLT, 5 mcg, on Days 1, 15 and 29, 8 subjects
16684659|NCT02052934|Experimental|Cohort 3|Three SL doses of dMLT, 25 mcg, on Days 1, 15 and 29, 11 subjects
16684660|NCT02052934|Experimental|Cohort 4|Three SL doses of dMLT, 50 mcg, on Days 1, 15 and 29, 11 subjects
16684661|NCT02052934|Experimental|Cohort 5a|Three SL doses of dMLT,25 mcg on Days 1, 15 and 29, 13 subjects.
16684662|NCT02052934|Experimental|Cohort 5b|Three oral doses of dMLT, 25 mcg on Days 1, 15and 29, 13 subjects
16684663|NCT02052921|Active Comparator|Rectal resection|Surgical rectal resection
16684664|NCT02052921|Experimental|Observation|Conservative approach
16684665|NCT02052908|Experimental|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
16684666|NCT02052908|Experimental|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
16684667|NCT02052908|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
16684668|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
16684669|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
16684670|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
16684671|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.
~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
16684672|NCT02052869|Other|esophagus intubation|all patients will be intubated in the trachea first, with subsequent intubation in the esophagus. measurements will be performed on both tubes in a blinded manner.
16684673|NCT02052856||ACL Surgery|All English speaking patients 16 years and older having anterior cruciate ligament (ACL) surgery without any other surgery to knee or contralateral knee.
16684674|NCT02052843|Experimental|Steps to Success|Steps to Success enhanced home visits-including instruction for both young mothers and fathers on contraception, comprehensive sex education, and the importance of adequate birth spacing, and accompanied by group sessions on adulthood preparation topics.
16684675|NCT02052843|Active Comparator|Traditional Healthy Families|Traditional Healthy Families home visits which cover topics of parenting and child development
16684676|NCT02052830|Experimental|Wise Guys|A sexual health and male responsibility program for adolescent males
16684677|NCT02052830|No Intervention|Control|Business as usual sexual education in schools
16684678|NCT02052817|Active Comparator|Control|Debridement and standard of care in off-loading on control patients
16684679|NCT02052817|Experimental|Toad Brace|Debridement and fitting of Toad Brace
16684680|NCT02052791|Experimental|nusinersen|
16684681|NCT02052778|Experimental|Dose escalation|Phase 1 Dose escalation portion of futibatinib (TAS-120)
16684682|NCT02052778|Experimental|Dose expansion|Phase 1 Dose expansion portion for futibatinib (TAS-120)
16684683|NCT02052778|Experimental|Phase 2|Phase 2 portion for futibatinib (TAS-120)
16684684|NCT02052765|Experimental|ajmaline test|All patients underwent ajmaline test for ST shift recording
16684685|NCT02052752|Experimental|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
16684686|NCT02052752|Active Comparator|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
16684687|NCT02052752|Placebo Comparator|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
16684688|NCT02052739|Experimental|active drug|SAGE-547
16684689|NCT02052726|Experimental|Arm Label: Month 0, 1 and 3 Schedule|
16684690|NCT02052726|Experimental|Day 1, 8, and 30 Schedule|
16684691|NCT02052713|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
16684692|NCT02052713|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.
16684693|NCT02052687|Experimental|Part 1: LFX453/placebo|once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
16684694|NCT02052687|Experimental|Part 2 groupA: LFX453/placebo|once daily: LFX453 cream 1 / Placebo 1
16684695|NCT02052687|Experimental|Part 2 groupB: LFX453/placebo|once daily: LFX453 cream 2 / Placebo 2
16684696|NCT02052687|Experimental|Part 2 groupC: LFX453/LFX453|once daily: LFX453 cream 1 / LFX453 cream 2
16684697|NCT02052687|Other|Part 2 groupD: Imiquimod|once daily: imiquimod cream
16684698|NCT02052687|Experimental|Part 3: LFX453/placebo|twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
16684699|NCT02052674|Experimental|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
16684700|NCT02052674|Active Comparator|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
16684701|NCT02052661|Experimental|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
16684702|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.
~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
16684703|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
16684704|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.
~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
16684705|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
16684706|NCT02052635|Experimental|Ticagrelor|90 mg oral tablet
16684707|NCT02052635|Active Comparator|Clopidogrel|300 mg oral tablet
16684708|NCT02052609|Experimental|KHK4827 140mg SC|
16684709|NCT02052609|Experimental|KHK4827 210mg SC|
16684710|NCT02052596|Experimental|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
16684711|NCT02052596|Active Comparator|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
16684712|NCT02052583|Experimental|34°C|therapeutic hypothermia at 34 ° C
16684713|NCT02052583|Experimental|32°C|therapeutic hypothermia at 32 ° C
16684714|NCT02052570||Children post-HSCT|Children post-HSCT age 10-16 yrs of age who had allogeneic transplant who are within 5 years of transplant and returned to school in past 12-24 months after previously attending school pre-transplant
16684715|NCT02052570||Parents of children post-HSCT|Parents of children post-HSCT (children in focus group) will participate in focus group with other parents to discuss the challenges and successes of their child returning to school following HSCT.
16684716|NCT02052570||Teachers of children post-HSCT|Teachers of children post- HSCT (children in focus group) will participate in focus group with other teachers to discuss the challenges and successes of children returning to school post HSCT
16684717|NCT02052570||PBMT provider of child post-HSCT|PBMT provider of child-post HSCT (child in focus group) will participate in in focus group with other PBMT providers to discuss the successes and challenges of coordinating school reentry in child post-HSCT
16684718|NCT02052557|Active Comparator|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
16684719|NCT02052557|Active Comparator|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
16684720|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
16684721|NCT02052531|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, twice daily for 28 days
16684722|NCT02052531|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, twice daily for 28days
16684723|NCT02052531|Placebo Comparator|Vehicle|Vehicle, twice daily for 28days
16684724|NCT02052518|Experimental|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
16684725|NCT02052518|Placebo Comparator|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
16684726|NCT02052505|No Intervention|Usual care|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions.
16684727|NCT02052505|Experimental|Medication review|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions. Following this (usual care) a trained nurse will perform a medication review and discuss the observations with a physician.
16684728|NCT02052492|Experimental|Cohort A: EF-022 100 ng once weekly|Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks
16684729|NCT02052492|Experimental|Cohort B: EF-022 500 ng once weekly|Intra-Muscular injections of EF-022 500 ng once weekly for a period of 8 weeks
16684730|NCT02052492|Experimental|Cohort C: EF-022 1000 ng once weekly|Intra-Muscular injections of EF-022 1000 ng once weekly for a period of 8 weeks
16684804|NCT02052024|Active Comparator|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and will receive 1-3 injections per muscle at each visit.
16684731|NCT02052492|Experimental|Expanded Cohort|the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or 1000ng weekly treatment as detailed below: The first 18 patients will be assigned to alternating doses of either 100ng or 500ng in a sequential manner (each patient will be assigned to a single dose). A decision regarding adding a 1000ng dose cohort vs. continuing with the 100ng and 500ng doses will be based on a discussion of the interim analysis results.
16684732|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, Caucasian, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
16684733|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, African-American, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
16684734|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
16684735|NCT02052440|Experimental|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
16684736|NCT02052440|Placebo Comparator|Sugar Pill given three times daily|Placebo sugar bill
16684737|NCT02052427|Experimental|ADRCs|"Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:
~0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)
~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
16684738|NCT02052427|Placebo Comparator|Placebo|"Placebo - Physiological Solution
~Inactive substance (Lactated Ringers + autologous blood)
~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
16684739|NCT02052414|Experimental|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.
~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.
~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
16684740|NCT02052401|Experimental|Occupational Therapy Intervention|Post Discharge Domiciliary Intervention by Occupational Therapy (OT)
16684741|NCT02052401|No Intervention|Usual follow-up|Usual follow-up of post discharge elderly patients, including pharmacological, and non-pharmacological care.
16684742|NCT02052388|Experimental|Low Single Dose Brilacidin|0.6mg/kg Brilacidin IV (single dose)
16684743|NCT02052388|Experimental|High Single Dose Brilacidin|0.8mg/kg Brilacidin IV (single dose)
16684744|NCT02052388|Experimental|3-Day Regimen Brilacidin|0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 & 3
16684745|NCT02052388|Active Comparator|Standard dosing regimen Daptomycin|4mg/kg Daptomycin IV daily for 7 Days
16684746|NCT02052375|Experimental|ASP2408 low dosing frequency|
16684747|NCT02052375|Experimental|ASP2408 high dosing frequency|
16684748|NCT02052375|Experimental|Placebo low dosing frequency|
16684749|NCT02052375|Experimental|Placebo high dosing frequency|
16684750|NCT02052362|Experimental|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
16684751|NCT02052362|Experimental|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
16684752|NCT02052349|Experimental|Arm 1: ABT-333|A single centre, open-label, 4-treatment, 3-period, 4-sequence incomplete randomised, single dose crossover study in healthy subjects.
16684753|NCT02052336|Experimental|CJ-12420 200 mg + Clarithromycin 500mg|CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
16684754|NCT02052336|Active Comparator|CJ-12420 200mg|CJ-12420 200mg QD for 5 days
16684755|NCT02052336|Active Comparator|Clarithromycin 500mg|Clarithromycin 500mg BID for 5 days
16684756|NCT02052323|Experimental|artesunate/mefloquine (AS/MQ)|The antimalarial drug regimen being evaluated is: artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours; plus mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours; plus primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
16684757|NCT02052310|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight [≤70 kilograms (kg)] and high weight [>70 to 160 kg] participants will receive 70 and 100 milligrams [mg] roxadustat, respectively). Dose adjustment to achieve correction and subsequent maintenance of target hemoglobin (Hb) values (10-12 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg per administration (whichever is lower).
16684758|NCT02052310|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW, with starting doses and dose adjustment rules as per United States Package Insert (USPI) or summary of product characteristics (SmPC). Participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC) as per the country-specific product label (USPI or SmPC) or local standard of care (SOC).
16684759|NCT02052297|Other|Part A|In Part A, up to 6 healthy subjects will be enrolled in order to determine the human radiodosimetry following administration of the PET radioligand.
16684760|NCT02052297|Other|Part B|In Part B, up to 8 healthy subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in healthy subjects.
16684761|NCT02052297|Other|Part C|In Part C, up to 20 IPF subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in IPF subjects and, if appropriate, potentially quantify the test/re-test variability.
16684762|NCT02052284|No Intervention|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
16684805|NCT02052011|Experimental|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
16684806|NCT02052011|Placebo Comparator|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
16684807|NCT02051985|Experimental|Aerobic exercise training|
16684763|NCT02052284|Experimental|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
16684764|NCT02052271|Experimental|Essential tremor|cerebellar stimulation
16684765|NCT02052271|Placebo Comparator|Placebo arm|placebo stimulation
16684766|NCT02052258|Experimental|oxytocin|
16684767|NCT02052245||Subject delivering preterm baby|
16684768|NCT02052245||Subject delivering term baby|
16684769|NCT02052232|Active Comparator|Control|Control protein powder sachet
16684770|NCT02052232|Experimental|Experimental|Experimental protein powder sachet
16684771|NCT02052219|Experimental|Blisibimod|
16684772|NCT02052219|Placebo Comparator|Placebo|
16684773|NCT02052206|Experimental|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
16684774|NCT02052193|Experimental|Dabrafenib|Dabrafenib 150mg BID orally
16684775|NCT02052193|Active Comparator|Vemurafenib|Vemurafenib 960mg orally BID
16684776|NCT02052180|Experimental|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
16684777|NCT02052180|Active Comparator|Control|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
16684778|NCT02052167|Experimental|Methotrexate|
16684779|NCT02052154|Experimental|Prime-boost pneumococcal immunization|
16684780|NCT02052141|Experimental|500/1000|500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
16684781|NCT02052141|Experimental|1000/500|1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
16684782|NCT02052128|Experimental|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
16684783|NCT02052128|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
16684784|NCT02052128|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
16684785|NCT02052128|Experimental|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
16684786|NCT02052128|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
16684787|NCT02052128|Experimental|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
16684788|NCT02052115|Other|Exercise and weight loss|12 month exercise and weight loss intervention
16684789|NCT02052102|Active Comparator|No prior therapy, DIBH irradiation|Cohort 1 - No prior anthracycline-based chemotherapy or herceptin, deep inspiration breath hold breast radiation therapy
16684790|NCT02052102|Active Comparator|No prior therapy, FB technique|Cohort II - no prior Anthracycline based chemotherapy or Herceptin and (ii) to receive FB RT (not able to hold breath for at least 20 seconds or does not have a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
16684791|NCT02052102|Active Comparator|Prior therapy, DIBH irradiation|Cohort III - Prior Anthracycline-based chemotherapy or Herceptin, and (ii) eligible to receive DIBH RT. (Patient has a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
16684792|NCT02052089|Active Comparator|Physiotherapy|patients were educated to do stretching and eccentric strengthening exercise of wrist extensor muscles
16684793|NCT02052089|Experimental|extracorporeal shockwave therapy|patients were treated with 3 sessions of high-energy shock wave therapy ESWT (Evotron, Switech medical, Kreuzlingen, CH) in 2 weeks interval. Total energy flux density ranged from 0.1 to 0.14 mJ/mm2 (1500 impulses). Shockwave was targeted over lateral epicondyle where maximum tenderness was located.
16684794|NCT02052089|Experimental|Prolotherapy|injection of 20% dextrose (3cc mixed with 0.3cc of lidocaine) to ECRB tendon was done under ultrasound guidance
16684795|NCT02052089|Experimental|Platelet-rich plasma|3 cc of PRP (Harvest SmartPReP 2 APC 30 Process Kit, Harvest Technologies, Plymouth, MA) was injected into ECRB tendon under ultrasound guidance
16684796|NCT02052076|Experimental|Irregular meal pattern|Participants will be asked to consume a standard diet, spread over a different number of meals/snacks per day, for a 2week intervention period. Number of meals will range from 3 to 9 per day.
16684797|NCT02052076|Placebo Comparator|Regular Meal Pattern|Participants will be asked to consume a standard diet, spread over 6 of meals/snacks every day, for a 2week intervention period.
16684798|NCT02052063|Experimental|Surgery|Patient who undergone stapled transanal rectal resection for rectocele. Anal compliance will be evaluated before and starting the surgery using endoflip system
16684799|NCT02052050|Experimental|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
16684800|NCT02052050|No Intervention|control group|usual care
16684801|NCT02052037|Experimental|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
16684802|NCT02052037|Experimental|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.
~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained."
16684803|NCT02052024|Active Comparator|Botox|Treatment group will receive 100 units of BOTOX and will receive 1-3 injections per muscle at each visit.
16684810|NCT02051959|Active Comparator|Crossover 1a: anodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
16684811|NCT02051959|Active Comparator|Crossover 1b: sham + anodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
16684812|NCT02051959|Active Comparator|Crossover 2a: cathodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
16684813|NCT02051959|Active Comparator|Crossover 2b: sham + cathodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
16684814|NCT02051946|Active Comparator|Retroject device only|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid).
16684815|NCT02051946|Experimental|Retroject injection with ethacrynic acid injection|The next 3 patients, after the first 5 controls, will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein.
16684816|NCT02051946|Experimental|randomization to ethacrynic acid or balanced salt solution|The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
16684817|NCT02051933|Experimental|Botox|See Botox intervention description
16684818|NCT02051933|Placebo Comparator|Placebo|See Placebo Intervention Description
16684819|NCT02051907|Experimental|KAM1403 Gel|A group treated with KAM1403 for the study period.
16684820|NCT02051907|Sham Comparator|Aloevera Gel|A group treated with Aloevera Gel for the study period
16684821|NCT02051894||HIE Group|
16684822|NCT02051881|Other|Biopsies|Intestinal biopsies were taken in patients who underwent endoscopy.
16684823|NCT02051868|Active Comparator|Arm A|Cisplatin and 5-Fluorouracil
16684824|NCT02051868|Experimental|Arm B|Carboplatin plus Paclitaxel
16684825|NCT02051842|Experimental|Metadoxine|Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
16684826|NCT02051842|Placebo Comparator|Placebo tablet|Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
16684827|NCT02051829||All patients|Comparison of the four screening score
16684828|NCT02051816|Active Comparator|VL and AO|Video laryngoscopy and apneic oxygenation
16684829|NCT02051816|Active Comparator|DL and AO|Direct Laryngoscopy and apneic oxygenation
16684830|NCT02051816|Active Comparator|VL and no AO|Video Laryngoscopy and no apneic oxygenation
16684831|NCT02051816|Active Comparator|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
16684832|NCT02051803|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
16684833|NCT02051803|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
16684834|NCT02051790|Experimental|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
16684835|NCT02051777|Other|ONS 1 and DA|Oral Nutritional Supplement 1 and Dietary Advice
16684836|NCT02051777|Other|ONS 2 and DA|Oral Nutritional Supplement 2 and Dietary Advice
16684837|NCT02051777|Other|DA Alone|Dietary Advice Alone
16684838|NCT02051764|Experimental|Follow-up Flortaucipir PET Scan|
16684839|NCT02051751|Experimental|BYL719 and paclitaxel|All patients enrolled in the study will receive BYL719 once daily plus weekly paclitaxel
16684840|NCT02051738|Experimental|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
16684841|NCT02051738|Experimental|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
16684842|NCT02051725|Experimental|Active life-style intervention|"The active life-style intervention is designed as 12-week structured and progressive heavy-resistance power training combined with recommended everyday physical activity."
16684843|NCT02051725|No Intervention|Control|The control group is offered to enroll in the same active life-style intervention after the end of the 12-week control period. During the control period this group is asked to maintain the habitual life style.
16684844|NCT02051712|No Intervention|Usual care|Usual car accruing to guidelines
16685329|NCT02048410|Placebo Comparator|low saturated fats diet|low saturated fats diet
16684845|NCT02051712|Experimental|Individualized training|Individualized exercise training program in addition to usual care
16684846|NCT02051712|Experimental|Individualized training plus adherence measures|Individualized exercise training plus measures to increase adherence
16684847|NCT02051699||One-leg standing view|
16684848|NCT02051699||both-leg standing view|
16684849|NCT02051686|Active Comparator|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
16684850|NCT02051686|Placebo Comparator|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
16684851|NCT02051660|Experimental|Manualized CALM Intervention|
16684852|NCT02051660|Active Comparator|Non-manualized supportive intervention|
16684853|NCT02051634|Active Comparator|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
16684854|NCT02051634|Placebo Comparator|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
16684855|NCT02051621|Active Comparator|Cavo-tricuspid-isthmus-ablation|Ablation of atrial flutter
16684856|NCT02051621|Active Comparator|Pulmonary vein isolation|pulmonary vein isolation
16684857|NCT02051621|Active Comparator|Antiarrhythmic drug|"Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily
~cardioversion as needed"
16684858|NCT02051608|Experimental|Gantenerumab|Participants will receive gantenerumab as subcutaneous (SC) injection every 4 weeks (Q4W)
16684859|NCT02051608|Placebo Comparator|Placebo|Participants will receive placebo as SC injection Q4W
16684860|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
16684861|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.
~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
16684862|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.
~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
16684863|NCT02051569|Experimental|Tryptophan first|Tryptophan is given for the first 14 days, 6 times 500mg per day. Placebo is given 6 times per day for the second 14 days.
16684864|NCT02051569|Experimental|Tryptophan second|Placebo is given 6 times per day for the first 14 days. Tryptophan is given for the second 14 days, 6 times 500mg per day.
16684865|NCT02051556|Experimental|Best Side Improvement|Physical Therapy BSI (Best Side Improvement), aimed to potentiate the less affected body side.
16684866|NCT02051556|Experimental|Worse side improvement|Physical Therapy WSI (Worst Side Improvement), aimed to potentiate the most affected body side.
16684867|NCT02051556|Active Comparator|Standard treatment|Physical Therapy ST (Standard Treatment), aimed to potentiate both sides equally.
16684868|NCT02051543|Experimental|Brief Behavioral Treatment of Insomnia-Military Version|
16684869|NCT02051530|Experimental|tryptophan depletion first day|tryptophan depletion on the first day. on the other day participants receive placebo.
16684870|NCT02051530|Experimental|tryptophan depletion on day 2|tryptophan depletion on the second day. on the first day participants receive placebo.
16684871|NCT02051517||Vitrectomy|Subjects expected to have normal vitreous, undergoing vitrectomy surgery for medically indicated reasons.
16684872|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c <7% at the entrance in the study.
~Intervention:
~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
16684873|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c >8% at the entrance in the study.
~Intervention:
~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
16684874|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.
~Intervention:
~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
16684960|NCT02050893|Experimental|Propofol|Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4
16684875|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.
~Intervention:
~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
16684876|NCT02051491|Active Comparator|BP-NCPAP|Nasal BP-NCPAP will be delivered using the Infant Flow® SiPAP™ and either nasal prongs or mask interface. A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with transcutaneous carbon dioxide (TcCO2) monitor data (if available). Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm water (H2O) and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on fraction of inspired oxygen (FiO2) requirements.
16684877|NCT02051491|Experimental|NIHFV|NIHFV will be provided using the Drager VN500, using either nasal prong or mask interfaces.A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with TcCO2 monitor data (if available). Initial settings for NIHFV arm will be MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
16684878|NCT02051478|Experimental|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied.
16684879|NCT02051478|Active Comparator|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
16684880|NCT02051465|Experimental|LumenR Retractor|Endoscopic removal of polyp using modified overtube LumenR Retractor
16684881|NCT02051465|Active Comparator|Removal without overtube|Endoscopic removal of polyp without overtube
16684882|NCT02051452|Experimental|Methylphenidate|Methylphenidate
16684883|NCT02051452|Placebo Comparator|placebo|Saline
16684884|NCT02051439|Other|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava before balloon assisted Valsava. The second group performed balloon assisted Valsava before conventional Valsava for venous reflux examination by duplex scan.
16684885|NCT02051426|Experimental|D-serine|single P.O. administration of D-serine (2.1g)
16684886|NCT02051426|Placebo Comparator|Placebo|single P.O. administration of corn starch
16684887|NCT02051413|Other|Venlafaxine extended release|Venlafaxine extended-release, flexible dose
16684888|NCT02051400|Experimental|Intubation with the McGrath® MAC video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
16684889|NCT02051400|Experimental|Intubation with the GlidesScope® Ranger video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
16684890|NCT02051400|Experimental|Intubation with Macintosh laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
16684891|NCT02051387|Active Comparator|Cannabidiol|Cannabidiol capsule, 200 mg single dose
16684892|NCT02051387|Experimental|Cannabidiol CR|Cannabidiol tablet, various dosages
16684893|NCT02051387|Experimental|Amisulpride and Cannabidiol CR|Interaction between Amisulpride and Cannabidiol CR
16684894|NCT02051387|Experimental|Olanzapine and Cannabidiol CR|Interaction between Olanzapine and Cannabidiol CR
16684895|NCT02051387|Experimental|Quetiapine and Cannabidiol CR|Interaction between Quetiapine and Cannabidiol CR
16684896|NCT02051387|Experimental|Risperidone and Cannabidiol CR|Interaction between Risperidone and Cannabidiol CR
16684897|NCT02051387|Placebo Comparator|Cannabidiol CR and Placebo|Cannabidiol CR levels without interaction with antipsychotics
16684898|NCT02051374|Active Comparator|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
16684899|NCT02051374|Active Comparator|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
16684900|NCT02051361||Clopidogrel treated patients|Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin
16684901|NCT02051348|Placebo Comparator|Placebo|Placebo - 2 doses per day for 4 weeks
16684902|NCT02051348|Active Comparator|Pylopass|Probiotic - 2 doses per day for 4 weeks
16684903|NCT02051335|Experimental|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
16684961|NCT02050880||Normal eyes|Eyes without pathology.
16684904|NCT02051335|Experimental|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
16684905|NCT02051335|Experimental|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
16684906|NCT02051335|Experimental|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
16684907|NCT02051322|Experimental|Jet Nebulizer|Nebulization with a jet nebulizer and a classic mask
16684908|NCT02051322|Experimental|Trunk Mask Nebulizer|Nebulization with a je nebulizer and a trunk mask
16684909|NCT02051322|Experimental|Aerobika Nebulizer|Nebulization with an Aerobika
16684910|NCT02051309|Experimental|Guanfacine 6mg/day ER|Guanfacine 6mg/day extended release
16684911|NCT02051309|Placebo Comparator|Placebo|Placebo matching capsule
16684912|NCT02051296|Experimental|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
16684913|NCT02051296|Placebo Comparator|Placebo|PLacebo
16684914|NCT02051283||patients with HCC eligible for RFA|patients with HCC eligible for RFA
16684915|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
16684916|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
16684917|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
16684918|NCT02051244||Subjective memory loss|Subjects who report memory loss, that may or may not be confirmed by an informant, but have normal cognitive tests ( MMSE scores of 27 or above out of 30. SLUMS scores of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education).
16684919|NCT02051244||Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment - defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. MMSE score of 23-27 out of 30. SLUMS score of 16-19 for subjects with less than 8 years of education or 20-26 for those who have 12 or more years of education.
16684920|NCT02051244||Control|Subject who do not report memory loss and have normal cognitive tests. MMSE of 27 or above out of 30. SLUMS score of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education.
16684921|NCT02051231|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with oxytocin.
16684922|NCT02051231|Experimental|Oxytocin|Samples from each patient will be exposed to oxytocin and then allowed to rest for 30, 60 or 90 minutes.
16684925|NCT02051192|Experimental|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
16684926|NCT02051192|Active Comparator|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
16684927|NCT02051179||Replacement amalgam|Replacement The clinicians totally removed and replaced the defective restorations. After completing the cavity preparations, the tooth was restored with a new AM (Original D). Bonding agents and/or liners underneath the amalgam restorations were not used in this trial. Rubber dam isolation was used for all restorative treatments. .
16684962|NCT02050880||Glaucoma|Eyes with Glaucoma.
16684963|NCT02050880||Retinal|Eyes with Retinal Disease.
16684964|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
16684965|NCT02050854||Observation|Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole
16684966|NCT02050841|Experimental|Octaplas|Qualified patients will receive Octaplas as per protocol.
16684983|NCT02050763|No Intervention|Control arm|Control arm clusters (n=7) received standard of care HIV services alone.
16684928|NCT02051179||Repair Amalgam|The clinicians (PV and CM) used Carbide burs (330-010 Komet, Brasseler GmbH Co. Postfach 160.32631, Lemgo, Germany) to explore the defective margin, carious lesion or anatomic form of the restorations. Part of the restorative material adjacent to the defect was removed as an exploratory proceedure thus allowing a proper evaluation and subsequent diagnosis of the extent of the defect. Provided that the defect was limited and localized, the clinician then removed any defective tooth tissue. Mechanical retention was employed inside the existing AM restoration. Rubber dam isolation was used for this procedure. Repair of the restorations was carried out with a dispersed-phased amalgam (Original D, Wyckle Research Inc, Carson City, NV, USA).
16684929|NCT02051153|Experimental|Placebo|"Placebo: study participants received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
~Other Names: Placebo."
16684930|NCT02051153|Experimental|Modafinil|"Study participants received, in a double blind fashion, either a single dose (200 mg) of modafinil or a placebo pill identical to the drug.
~Other Names:
~Provigil"
16684931|NCT02051140|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry.
16684932|NCT02051140|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo.
16684933|NCT02051127|Experimental|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
16684934|NCT02051127|No Intervention|Control|Instructed to continue with their sedentary behavior for another 6 months.
16684935|NCT02051101|Other|Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
16684936|NCT02051088|Experimental|Revascularization with drug eluting technology|Revascularization with drug eluting technology
16684937|NCT02051088|Active Comparator|Revascularization without drug elution|Revascularization without drug elution technology
16684938|NCT02051075|Active Comparator|PXN only|Sperm activation with PXN before ICSI
16684939|NCT02051075|Experimental|PXN activation and oocyte activation|Sperm activation with PXN and oocyte activation
16684940|NCT02051062|Experimental|One 5 mL blood sample will be collected|A single 5 mL blood sample will be collected from pediatric patients treated with BAT®. The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
16684941|NCT02051049||Inborn errors of liver metabolism|
16684942|NCT02051036|Experimental|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
16684943|NCT02051036|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
16684944|NCT02051023|Experimental|FML 0.1% eyedrops|FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days
16684945|NCT02051023|Active Comparator|Liquifilm artificial tears eyedrops|Topical application 4 times a day in both eyes for 22 days
16684946|NCT02051010||Metastatic Breast Cancer|
16684947|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
16684948|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
16684949|NCT02050971|Active Comparator|Autologous cord blood transfusion|Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
16684950|NCT02050971|Sham Comparator|Standard treatment for neonatal anemia|Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development
16684951|NCT02050958|Experimental|OXP001|OXP001
16684952|NCT02050958|Active Comparator|Ibuprofen|Brufen
16684953|NCT02050945|Experimental|Patients with COPD|Patients with COPD are to be trained 3 times a week for 8 weeks
16684954|NCT02050945|Active Comparator|Control patients with COPD|Control patients with COPD are to be trained 3 times a week for 8 weeks
16684955|NCT02050932|Experimental|Iron absorption assessement|"60 mg Fe as FeSO4 with stable isotopic labels participants will receive at different times of the day (total of three dosages) and follow a standardized diet scheme.
~Subjects will act as their own controls during the study"
16684956|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
16684957|NCT02050906|Experimental|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.
~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
16684958|NCT02050906|Active Comparator|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
16684959|NCT02050893|Experimental|Midazolam|Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4
16693258|NCT01995253|Experimental|Free-living conditions|
16684967|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
16684968|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
16684969|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
16684970|NCT02050815|Experimental|MEK162|A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.
16684971|NCT02050802|Experimental|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684972|NCT02050802|Experimental|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684973|NCT02050802|Experimental|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684974|NCT02050802|Experimental|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684975|NCT02050802|Experimental|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684976|NCT02050802|Experimental|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684977|NCT02050802|Experimental|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684978|NCT02050802|Experimental|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
16684979|NCT02050789|No Intervention|Usual Care Arm|Programs will continue adhering to current ACGME requirements.
16684980|NCT02050789|Experimental|Intervention Arm|The intent of the intervention arm is to allow flexibility in surgical resident duty hours and improve continuity of care.
16684981|NCT02050776|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
16684982|NCT02050763|Experimental|Intervention arm|Intervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
16684984|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
16684985|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
16684986|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
16684987|NCT02050724|Experimental|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
16684988|NCT02050724|Experimental|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
16684989|NCT02050711|Other|Usual care|Patients will receive usual care from their general practitioners/pulmonologists.
16684990|NCT02050711|Experimental|Pulmonary rehabilitation|Patients will enrol in a 12-week PR program consisting on exercise training (3 times a week) and psychoeducation (once a week).
16684991|NCT02050698|Active Comparator|short leg walking cast|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed protected weightbearing in a short leg walking cast
16684992|NCT02050698|Experimental|hard-soled shoe|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed tolerable weightbearing in a hard-soled shoe
16684993|NCT02050685||All patients for PSG at SLBO|All patients incoming in the sleep study centre for a PSG. At the arrival the screening score will be recorder. AHI will be recorded next morning after analysis of the PSG.
16684994|NCT02050672|Active Comparator|untreated|Semen was prepared with routinely used media
16684995|NCT02050672|Experimental|myo-inositol|"routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.
~in particular the stock solution was prepared in order to add 15microliters per ml of medium"
16684996|NCT02050646|Experimental|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
16684997|NCT02050646|Experimental|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
16684998|NCT02050633||Severe cranial trauma|This is a cohort of adult patients who have suffered a severe TBI between 1 July 2005 and 1 May 2007.
16684999|NCT02050607|No Intervention|Control group|Control group
16685000|NCT02050607|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation from healthy lean donors
16685001|NCT02050594||Melanoma patients on Ipilimumab|All unresectable, recurrent or metastatic melanoma patients
16685002|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
16685003|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
16685004|NCT02050555|Placebo Comparator|Koji-extracted beverage|100ml/day for 12 weeks
16685005|NCT02050555|Experimental|Koji-extracted beverage fermented with LP28|100ml/day for 12 weeks. 1x10^11 cells (LP28)/day
16685006|NCT02050542|Other|Targeted biopsies guided by a fusion of MRI and ultrasound|After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
16685007|NCT02050542|Other|Systematic biopsies|The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
16685008|NCT02050529|Experimental|Labetalol|This group (Group A; Labetalol) receiveD intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20 mg wAS administered, and if required repeated in increments of 40 mg,80 mg,80 mg,80 mg every 10 minutes till SBP became <160 and DBP <110 mm Hg, upto a maximum cululative dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure were checked every 10 minutes.
16685009|NCT02050529|Active Comparator|Hydralazine|This group (Hydralazine;Group B) received intravenous Hydralazine and served control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure were checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg was still reached after 20 minutes, then second bolus was repeated. Similarly if after 20 minutes SBP was still ≥160 or DBP ≥110 mm Hg, then third dose was given. If SBP or DBP thresholds were still exceeded after 20 minutes then similarly 4th and 5th dose of 5 mg were given. Failure to reduce SBP<160 or DBP<110 after consecutive maximum 5 boluses(total 25 mg) was labeled as severe persistent hypertension.
16685010|NCT02050516|Active Comparator|single embryo culture|single embryo culture in single drops inside micro-well group culture dish
16685011|NCT02050516|Experimental|group embryo culture|group embryo culture in a single drop inside micro-well group culture dish
16685012|NCT02050503||intranasal transmucosal fentanyl pectin|intranasal transmucosal fentanyl in pectin (100, 200, 400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain
16685013|NCT02050490||Before group, no diary|
16685014|NCT02050490||After group, with symptom diary|
16685015|NCT02050477|Experimental|Laparoscopic Vertical Gastroplasty|
16685016|NCT02050464||Healthy controls|Healthy controls
16685017|NCT02050464||Alzheimer's disease|Patients with mild Alzheimer's disease
16685018|NCT02050464||Vascular dementia|Patients with vascular dementia
16685019|NCT02050464||Fronto-temporal dementia|Patients with fronto-temporal dementia
16685020|NCT02050464||Mild cognitive impairment|Patients with mild cognitive impairment
16685021|NCT02050451|Experimental|Nutrition Intervention|Ensure Plus®, consumed orally twice daily for 2 weeks before and 4 weeks after surgery
16685022|NCT02050451|Active Comparator|Control|Over the counter daily multivitamin for 2 weeks before and 4 weeks after surgery
16685023|NCT02050438||Knee Osteoarthritis patients with prostesis treatment|Patients operated previously of Knee Osteoarthritis with different prostesis designs according the Hospital guide
16685024|NCT02050425|Active Comparator|Therapeutic CPAP|Patients continue therapeutic continuous positive airway pressure (CPAP).
16685025|NCT02050425|Placebo Comparator|Subtherapeutic CPAP|Placebo-CPAP device delivering subtherapeutic pressure for two weeks.
16685026|NCT02050412|Other|Cat fur scratch test|
16685166|NCT02049424||transplanted patients|T-repleted haploidentical transplanted patients in Italy
16685027|NCT02050399|Active Comparator|Healthy subjects|15 men, 45 and 65 years old. After initial evaluation, clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise protocol will be performed.
16685028|NCT02050399|Experimental|Coronary disease with Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease and type 2 diabetes will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood), clinical autonomic tests and isometric exercise protocol will be performed.
16685029|NCT02050399|Experimental|Coronary disease without Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise will be performed.
16685030|NCT02050386||Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds.
16685031|NCT02050386||Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds.
16685032|NCT02050373|Experimental|Low-Level laser|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser (660nm, 40mW, 0.16 J, 4 J/cm2) was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
16685033|NCT02050373|No Intervention|Control|In the control group, patients receive only the preventive protocol bone marrow transplant industry, consisting of mouthwashes and sodium fluoride. For ethical reasons, individuals who present oral mucositis grade 2 (WHO) will receive LLLT.
16685034|NCT02050360|Experimental|Sildenafil 80 mg|Sildenafil 80 mg
16685035|NCT02050360|Experimental|Sildenafil 40 mg|Sildenafil 40 mg
16685036|NCT02050360|Placebo Comparator|Placebo|placebo
16685037|NCT02050347|Experimental|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
16685038|NCT02050347|Experimental|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
16685039|NCT02050347|Experimental|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
16685040|NCT02050347|Experimental|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
16685041|NCT02050334|Experimental|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
16685042|NCT02050334|Experimental|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
16685043|NCT02050321|Experimental|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
16685044|NCT02050308|Experimental|Internet-All Nations Breath of Life (I-ANBL)|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to quitting smoking (like: preparing to quit, dealing with cravings, and support systems, etc.) and topics relevant to American Indian culture (like traditional use of tobacco).
~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
16685045|NCT02050308|Active Comparator|Honoring the Gift of Heart Health|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to heart health (like: Assessing risk for heart disease, increasing fruit and vegetable consumption, physical activity, etc.).
~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
16685046|NCT02050295|Experimental|Nerve block washout|Patients will receive a washout infusion of saline through their perineural catheter to reverse their motor block while maintaining the sensory block.
16685047|NCT02050295|Sham Comparator|Sham washout|Patients will receive an infusion of saline run just enough to maintain catheter patency.
16685048|NCT02050282|No Intervention|Business as usual|Triage and treatment based on routine clinical assessment as usual
16685049|NCT02050282|Experimental|Supplementary NT-proBNP measurement|Triage and treatment based on routine clinical assessment supplemented with measurement of NT-proBNP
16685050|NCT02050269|Experimental|Iohexol|injection of 5 ml of iohexol
16685051|NCT02050256|Other|general practioner|
16685052|NCT02050243|Experimental|5ALA|All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
16685053|NCT02050230|Active Comparator|Fresh blood transfusion|One unit of blood stored for less than 14 days
16685054|NCT02050230|Experimental|Standard issue blood transfusion|One unit of blood stored under standard conditions
16685055|NCT02050217|Experimental|Noninvasive ventilation|Neurally Adjusted Ventilatory Assist versus Pressure Support flow triggered delivered by helmet
16685056|NCT02050204|Experimental|LEEF Industry only: Intervention|"Customized to the Leef (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
16685057|NCT02050204|No Intervention|LEEF Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
16685211|NCT02049151|Experimental|Tecemotide|
16685212|NCT02049151|Placebo Comparator|Placebo|
16685058|NCT02050204|Experimental|TOMO Industry only: Intervention|"Customized to the Tomo (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
16685059|NCT02050204|No Intervention|TOMO Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
16685060|NCT02050191|No Intervention|program feasibility|
16685061|NCT02050178|Experimental|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
16685062|NCT02050165|Experimental|KIND Bar|Daily inclusion of KIND Bars with almonds as a primary ingredient as part of the participant's usual diet, with diet counseling to adjust for the calories from the KIND Bars. KIND Bars that we will use in the study will include: Dark Chocolate Chili Almond; Cranberry Almond; Almond Walnut Macadamia; Pomegranate Blueberry Pistachio; Nut Delight; Fruit and Nut Delight; Almond and Apricot; Blueberry Pecan and Fiber.
16685063|NCT02050165|Experimental|Typical American Snack|Daily inclusion of conventional snacks (as part of the participant's usual diet, with diet counseling to adjust for the calories from the snacks. The snacks will consist of cookies considered to be conventional snack foods that are nutrient-dilute (i.e. relatively low in nutrients) and energy-dense (i.e., relatively high in kcal). Examples of conventional snack foods will include: Nabisco Snackwell Creme Sandwich 1.7 oz pack, Nabisco Newtons Fig 2 oz pack, Nabisco Cips Ahoy! Chocolate Chip 1.4 oz pack, and Nabisco Oreo Double Stuff Chocolate 1.3 oz pack.
16685064|NCT02050152|Placebo Comparator|0% nitrous oxide|Explicit and implicit memory will be tested in 0% nitrous oxide
16685065|NCT02050152|Active Comparator|30% nitrous oxide|Explicit and Implicit memory in 30% nitrous oxide
16685066|NCT02050152|Active Comparator|60% nitrous oxide|Explicit and Implicit memory with 60% nitrous oxide
16685067|NCT02050139|Experimental|L-cysteine (Biocysan®)|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
16685068|NCT02050139|Placebo Comparator|Placebo|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
16685069|NCT02050126|Experimental|Scar Revision|Caesarean Scar Revision using Lumenis UltraPulse Encore.
16685070|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft. custom made device or arch branch device.
16685071|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
16685072|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
16685073|NCT02050087|Active Comparator|3 weeks with simple sling|Early motion after arthroscopic rotator cuff repair.
16685074|NCT02050087|Active Comparator|6 weeks with neutral brace|Delayed motion after arthroscopic rotator cuff repair.
16685075|NCT02050074|Experimental|Colesevelam|
16685076|NCT02050074|Experimental|Metformin|
16685077|NCT02050074|Experimental|Placebo|
16685078|NCT02050074|Experimental|Colesevelam + exendin (9-39)|
16685079|NCT02050074|Experimental|Metformin + exendin (9-39)|
16685080|NCT02050074|Experimental|Placebo + + exendin (9-39)|
16685081|NCT02050061|Experimental|compression stocking|compression stocking (SIGVARISTM), daily for 3 months
16685082|NCT02050061|No Intervention|standard medical therapy|Usual care
16685083|NCT02050048|Experimental|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:
~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour
~LR fluid infusion during the procedure at 5 cc/kg/hr
~Post-procedure bolus of 20 cc/kg over 90 minutes"
16685084|NCT02050048|Active Comparator|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
16685085|NCT02050035|Experimental|CKD Aerobic Exercise Training|Chronic Kidney Disease participants randomly allocated to the CKD Exercise arm will receive 12 weeks of Aerobic Exercise Training three times per week.
16685086|NCT02050035|No Intervention|CKD Control|Chronic Kidney Disease participants allocated to the the CKD Control arm will receive their standard routine care over a 12 week period.
16685087|NCT02050035|No Intervention|Healthy Control|Healthy participants will act as comparators, they will undergo baseline testing only and will not receive an intervention.
16685088|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
16685089|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
16685090|NCT02050009|Experimental|Treatment (metformin hydrochloride, carboplatin, paclitaxel)|Patients receive metformin hydrochloride BID on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16685091|NCT02049996||Robotic-assisted prolapse repair|Subjects already scheduled for robotic-assisted prolapse repair in conjunction with vaginal hysterectomy
16685092|NCT02049996||Vaginal prolapse repair|Subjects already scheduled for vaginal prolapse repair in conjunction with vaginal hysterectomy.
16685093|NCT02049983|Experimental|Use of Levita Magnetics Grasper|
16685094|NCT02049970|Experimental|dexmedetomidine and bupivacaine|Bupivacaine 50 mg and dexmedetomidine 1 microgram/kg
16685095|NCT02049970|Experimental|Bupivacaine and placebo|Bupivacaine 100 mg and SF 10 ml
16685096|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane|Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).
16685097|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Fulvestrant|Sapanisertib 5 mg, unmilled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection, intramuscularly (IM), once on Day 1 of each cycle (Up to 57 cycles).
16685098|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Exemestane|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 8 cycles).
16685099|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Fulvestrant|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle up to 14 cycles plus fulvestrant 500 mg, injection, IM, once on Day 1 of each cycle (Up to 14 cycles).
16685100|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 4 mg + Exemestane|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 18 cycles).
16685101|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg + Exemestane (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 14 cycles) in everolimus sensitive participants.
16685102|NCT02049957|Experimental|Phase 2:Sapanisertib 4 mg+Fulvestrant (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 17 cycles) in everolimus sensitive participants.
16685103|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Exemestane (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus once daily in a 28-day cycle (Up to 12 cycles) in everolimus resistant participants.
16685104|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Fulvestrant (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 9 cycles) in everolimus resistant participants.
16685105|NCT02049944|Experimental|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
16685106|NCT02049931|Experimental|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
16685107|NCT02049931|Active Comparator|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
16685108|NCT02049931|Active Comparator|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
16685109|NCT02049905|Experimental|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
16685110|NCT02049905|Active Comparator|Investigator's Choice of Treatment|"These treatments include:
~Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;
~Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;
~Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;
~Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or
~Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
16685111|NCT02049892||Metal Ion|
16685112|NCT02049879|Experimental|Injection|Corticosteroids injection
16685113|NCT02049866|Experimental|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
16685114|NCT02049853|No Intervention|default group|"Patients with the randomization result default group receive standard diagnostics"
16685115|NCT02049853|Active Comparator|POCT group|"patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle"
16685116|NCT02049840|Experimental|Altis Single Incision Sling System|Altis Single Incision Sling System
16685117|NCT02049827|Experimental|Renal transplant|
16685118|NCT02049814|Experimental|Metformin + Voglibose 0.2 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
16685119|NCT02049814|Active Comparator|Metformin + Acarbose 50 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
16685120|NCT02049801|Experimental|Treatment (MEK inhibitor, MEK162, idarubicin, cytarabine)|"INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 PO BID on days -4 to -1 and days 5-18, cytarabine IV continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. Patients may receive a second course of induction at the discretion of the principal investigator.
~POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
16685121|NCT02049788|Active Comparator|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
16685122|NCT02049788|Experimental|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
16685123|NCT02049775|Experimental|NBI|
16685124|NCT02049762|Active Comparator|P2Y12 inhibitors and aspirin|ACS patients on novel P2Y12 inhibitors and aspirin
16685125|NCT02049762|Placebo Comparator|P2Y12 inhibitors and placebo|ACS patients on novel P2Y12 inhibitors and placebo
16685213|NCT02049138|Experimental|Open-label extension|All subjects will start treatment with ABT-494.
16685126|NCT02049749|No Intervention|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
16685127|NCT02049749|Experimental|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
16685128|NCT02049736|Experimental|Telbivudine|
16685129|NCT02049723||Patients with GERD|The knowledge level on GERD among Korean patients with gastroesophageal disease was evaluated by the method of multicenter survey
16685130|NCT02049710|Active Comparator|Sexual Behavior Intervention|
16685131|NCT02049710|Active Comparator|Driving behavior intervention|
16685132|NCT02049697|Experimental|14C-JNJ-39823277|
16685133|NCT02049684||Surgery|
16685134|NCT02049684||Physiotherapy|
16685135|NCT02049671||Growth Hormone Therapy|
16685136|NCT02049671||Control Group|
16685137|NCT02049658||Healthy volunteers|Healthy volunteers measured by currently used healthy screening procedures
16685138|NCT02049658||Suspected breast cancer subjects|Suspected breast cancer subjects without pathological examination yet but will have it soon
16685139|NCT02049658||Suspected lung cancer subjects|Suspected lung cancer subjects without pathological examination yet but will have it soon
16685140|NCT02049658||Suspected neurological tumor subjects|Suspected neurological tumor subjects without pathological examination yet but will have it soon
16685141|NCT02049658||Suspected patients with gynecological tumor|Suspected subjects with gynecological tumors without pathological examination yet but will have it soon
16685142|NCT02049645||faculty staff and their adult family members|faculties and their adult family members of the Third Xiang-Ya Hospital
16685143|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
16685144|NCT02049619|No Intervention|Control|Following endotracheal intubation, no pharyngeal pack was inserted into the hypopharynx.
16685145|NCT02049619|Experimental|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
16685146|NCT02049606|Experimental|LAYLA|Drug : LAYLA tablet/bid
16685147|NCT02049606|Active Comparator|CENATONE|Drug : CENATONE tablet/qd
16685148|NCT02049593|Experimental|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16685149|NCT02049593|Experimental|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16685150|NCT02049580|Experimental|RIC regimen|Thiotepa, Fludarabine, Cyclophosphamide pre- and post- transplantation.
16685151|NCT02049567|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
16685152|NCT02049554|No Intervention|Usual Care|
16685153|NCT02049554|Experimental|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
16685154|NCT02049541|Experimental|Treatment (PI3K inhibitor BKM120, rituximab)|Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.
16685155|NCT02049528|Experimental|3 mg CC-122 reference capsule formulation|3 mg CC-122 reference capsule given by mouth with 240 mL of room temp tap water
16685156|NCT02049528|Experimental|3 mg CC-122 test capsule formulation|3 mg CC-122 test capsule give by mouth with 240 mL of room temp tap water
16685157|NCT02049528|Experimental|3 mg CC-122 test capsule + high fat meal|3 mg CC-122 test capsule given by mouth with 240 mL of room temp tap water approximately 5 minutes after eating a high-fat meal
16685158|NCT02049515|Experimental|IPI-145|IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.
16685159|NCT02049515|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
16685160|NCT02049502|Experimental|fecal microbiota transplant|fecal microbiota transplant
16685161|NCT02049489|Experimental|ICT-121 DC vaccine|Autologous dendritic cells pulsed with peptide antigens
16685162|NCT02049476|Experimental|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
16685163|NCT02049450|Experimental|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
16685164|NCT02049437|Active Comparator|Arm A: TCZ, then placebo|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
16685165|NCT02049437|Placebo Comparator|Arm B: Placebo, then TCZ|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
16693500|NCT01993654||Primary Acquired Melanosis|
16685167|NCT02049411|Experimental|Ketamine group|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
16685168|NCT02049411|Sham Comparator|physiological solution|Control group: only physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
16685169|NCT02049398||Oral microbiome cohort|a cohort of 40 adults willing to provide oral samples approximately every two months forone year
16685170|NCT02049385|Experimental|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
16685171|NCT02049385|Experimental|Placebo|Subjects received a matched placebo for three weeks
16685172|NCT02049359|No Intervention|Control group|Care as usual; no bidirectional texting
16685173|NCT02049359|Experimental|Texting|Bidirectional texting weekly for 12 weeks
16685174|NCT02049346|Active Comparator|Epoetin alpha or beta (Epoetin group)|Patients in that arm were continued on the previous same dose and route of administration of Epoetin alpha/ beta (Epoetin group).
16685175|NCT02049346|Active Comparator|Darbepoetin alpha|subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol.
16685176|NCT02049346|Experimental|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous Methoxy polyethylene glycol-epoetin beta monthly.
16685177|NCT02049333|Active Comparator|Phacoemulsification|Cataract extraction alone
16685178|NCT02049333|Experimental|Phacoemulsification with Endoscopic Cycloplasty (ECPL)|Cataract extraction combined with endoscopic cycloplasty
16685179|NCT02049320||Remifentanil|Patients sedated using Remifentanil
16685180|NCT02049307|Active Comparator|Treatment|Losartan 100mg daily
16685181|NCT02049307|Placebo Comparator|Placebo|Matching placebo
16685182|NCT02049294|Active Comparator|Omalizumab (Xolair)|Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.
16685183|NCT02049294|Placebo Comparator|Placebo (Normal Saline)|0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab
16685184|NCT02049281|Experimental|Vintafolide|Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
16685185|NCT02049268|Experimental|Nicotine + Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
16685186|NCT02049268|Experimental|Placebo Nicotine + Alcohol|A placebo nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (placebo nicotine) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
16685187|NCT02049268|Experimental|Nicotine + Placebo Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink a placebo alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
16685188|NCT02049255|Placebo Comparator|Marcaine|Rachianesthesia with marcaine or chloroprocaine
16685189|NCT02049255|Active Comparator|Chloroprocaine|Rachianesthesia with marcaine or chloroprocaine
16685190|NCT02049242|Active Comparator|Triple tourniquet|
16685191|NCT02049242|Active Comparator|Single tourniquet|
16685192|NCT02049229|Experimental|OPTIMAX stent|Patients randomised to receive titanium-nitride-oxide coated OPTIMAX-stent
16685193|NCT02049229|Active Comparator|SYNERGY stent|Patients randomised to receive everolimus-eluting, biabsorabble polymer coated stent
16685194|NCT02049216|Sham Comparator|Sham tape|"Fixomull tape only
~Single piece of 10cm wide, 32cm long applied from inferior to tibial tuberosity, over patella and onto quadriceps muscle. Corners rounded. Tape to be applied with the knee in 90 degrees flexion.
~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
16685195|NCT02049216|Experimental|Flexible tape|"Flexible tape (rocktape brand) applied as follows:
~First piece of tape 10 cm wide and 32cm long (length of a standard goniometer). Split down centre 18cm from 1 end. Second piece of tape 5cm wide and 14cm long.
~Tape applied in 90 degrees knee flexion Applied with no tension in proximal and distal ends. 30% tension to un-split portion placed over quads. 50% tension to split portion placed either side of patella and crossing over at tibial tuberosity Additional piece of 5cm wide flexible tape applied with 80% tension over patella tendon, with no tension in 3cm from ends All tape corners rounded
~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
16685196|NCT02049203|Placebo Comparator|Placebo|Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days.
16685197|NCT02049203|Active Comparator|Ataciguat|Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days
16685198|NCT02049190|Experimental|onapristone 10 mg BID|onapristone 10 mg BID extended-release tablets
16685199|NCT02049190|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
16685200|NCT02049190|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
16685201|NCT02049190|Experimental|onapristone 40 mg BID|onapristone 40 mg BID extended-release tablets
16685202|NCT02049190|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release
16685203|NCT02049190|Experimental|onapristone 30 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg
16685204|NCT02049190|Experimental|onapristone 50 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg
16685205|NCT02049190|Experimental|Expansion cohort: onapristone 50 mg BID|Expansion cohort: onapristone 50 mg BID
16685206|NCT02049177||Head and Neck Cancer Cases|Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
16685207|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
16685208|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
16685209|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
16685210|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
16685214|NCT02049125||No AKI|Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL.
16685215|NCT02049125||AKI and Infection|Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL.
16685216|NCT02049125||AKI with No Infection|Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection.
16685217|NCT02049112|Experimental|Salivary equivalent|Single dose stick without any active substance
16685218|NCT02049112|Sham Comparator|Aequasyal|Multidose moisturizing oral spray without any active substance
16685219|NCT02049112|Sham Comparator|Biotene|Multidose moisturizing oral spray without any active substance
16685220|NCT02049086|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
16685221|NCT02049086|Active Comparator|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
16685222|NCT02049086|No Intervention|No Additional Referral|No intervention.
16685223|NCT02049073|Experimental|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
16685224|NCT02049073|Experimental|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
16685225|NCT02049073|No Intervention|Control|no medication
16685226|NCT02049060|Experimental|Tivantinib+carboplatino+pemetrexed|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
16685227|NCT02049047|Experimental|Everolimus|oral everolimus
16685228|NCT02049034|Placebo Comparator|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
16685229|NCT02049034|Experimental|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.
~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
16685230|NCT02049021|Experimental|Electroconvulsive Therapy|Patients in use of clozapine randomized to receive ECT treatment
16685231|NCT02049021|Sham Comparator|SHAM ECT|Patients receiving clozapine randomized to sham ECT (placebo)
16685232|NCT02049008|Experimental|Photodynamic Therapy|
16685233|NCT02049008|Sham Comparator|Sham Photodynamic Therapy|
16685234|NCT02048995||Bipolar Depressed|Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
16685235|NCT02048995||Healthy Comparator|Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
16685236|NCT02048982|Experimental|Guideline and Cost|The Choosing Wisely guideline and the cost of the test at our institution: $60.35 for a basic metabolic panel.
16685237|NCT02048982|Placebo Comparator|Guideline|"The Choosing Wisely guideline: Don't perform blood chemistry panels in asymptomatic, healthy adults."
16685238|NCT02048982|Active Comparator|Guideline and Victim|The Choosing Wisely Guideline and a clinical scenario with a patient as an identifiable victim who suffered harm from having an unnecessary test done
16685239|NCT02048982|Experimental|Guideline, Cost, and Victim|The Choosing Wisely guideline and a clinical scenario with a physician as an identifiable victim who suffered harm when he ordered an unnecessary test.
16685240|NCT02048969|Experimental|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil will be administered to the patient at a rate of 0.1 mg flumazenil per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
16685241|NCT02048969|Placebo Comparator|Saline|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
16685242|NCT02048956|Experimental|Hydrotherapy intervention|30 people will be recruited in order to the inclusion criteria for the study and they will receive an hydrotherapy intervention.
16685243|NCT02048956|Active Comparator|Control group|30 people will be recruited and included in this control group. The are not going to receive hydrotherapy treatment, only the treatment they receive as usual.
16685244|NCT02048943|Experimental|Treatment (dovitinib, gemcitabine, nab-paclitaxel)|Patients receive dovitinib lactate PO QD 5 days per week, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16685245|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
16685246|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
16685247|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
16685248|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
16685249|NCT02048917|Experimental|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
16685250|NCT02048917|Experimental|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
16685251|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
16685252|NCT02048917|Experimental|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
16685253|NCT02048917|Experimental|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
16685254|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
16685255|NCT02048917|Experimental|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
16685256|NCT02048917|Experimental|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
16685257|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
16685258|NCT02048917|Experimental|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
16685259|NCT02048917|Experimental|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
16685260|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
16685261|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
16685262|NCT02048891|Active Comparator|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
16685263|NCT02048891|Experimental|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
16685264|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:
~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.
~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
16685265|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:
~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.
~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
16685266|NCT02048865|Active Comparator|Apixaban|2.5 mg BID for 6 months
16685267|NCT02048865|Placebo Comparator|Placebo drug|2.5 mg BID for 6 months
16685268|NCT02048852|Experimental|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
16685269|NCT02048852|Experimental|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
16685270|NCT02048852|Active Comparator|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
16685271|NCT02048852|Experimental|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
16685272|NCT02048839||Radiel Intervention group and their children|Participated the Radiel- intervention study (2008-2011) in the Intervention group: Lifestyle counselling during and after pregnancy (up to 1 year post partum)
16685273|NCT02048839||Radiel Control Group with their children|Control group in the Radiel- intervention study.
16685274|NCT02048826|Experimental|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
16685275|NCT02048826|Experimental|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
16685276|NCT02048813|Experimental|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning course 2, patients also receive rituximab IV over 4 hours on day 1 (days 1 and 2 of course 2 only). Treatment repeats every 28 days for 7 courses. In the absence of disease progression, patients may continue ibrutinib PO QD.
16685277|NCT02048813|Experimental|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab as seen in Arm A and fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 courses.
16685278|NCT02048800||Treosulfan PK|Children with indication to HSCT receiving Treosulfan
16685279|NCT02048787|Experimental|Moderate renal impairment group|Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group
16685280|NCT02048787|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group
16685281|NCT02048787|Experimental|Matching healthy control group|Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
16685282|NCT02048774|Active Comparator|High Social Position|The investigators will randomly assign a participant to a higher social position.
16685283|NCT02048774|Experimental|Low Social Position|The investigators will randomly assign a participant to a lower social position.
16685284|NCT02048761|Placebo Comparator|Placebo Group|After debridement, placebo gel was applied into the periodontal pockets with a syringe and a blunt canula.
16685285|NCT02048761|Active Comparator|1% Metformin|After debridement, 1% Metformin gel was applied into the periodontal pockets with a syringe and a blunt canula.
16685286|NCT02048748|Experimental|Telemonitoring|Device: Weight and blood pressure device Device: Home telemonitoring device
16685287|NCT02048748|No Intervention|Control|Usual care
16685288|NCT02048722|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16685289|NCT02048709|Experimental|GDC-0919 Dose Escalation|GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle
16685290|NCT02048696|Experimental|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
16685291|NCT02048696|No Intervention|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
16685292|NCT02048683|Experimental|burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
16693501|NCT01993654||Malignant Melanoma|
16685293|NCT02048683|Other|non burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
16685294|NCT02048670|Experimental|Chronic Subjective Dizziness Syndrome Subjects|Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
16685295|NCT02048670|Active Comparator|Healthy Subjects|Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.
16685296|NCT02048657|Experimental|Foley group|The Foley Airway Stylet Tool was used to guide ProSeal LMA insertion
16685297|NCT02048657|Experimental|I-Tool group|the ProSeal LMA was inserted with a standard introducer-tool
16685298|NCT02048644|Placebo Comparator|placebo inhaler|matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
16685299|NCT02048644|Experimental|fostair|fostair 100mcg/6mcg 2pufss, twice a day.
16685300|NCT02048631||Oral Cancer Patients underwent Free Flap Reconstruction|
16685301|NCT02048618|Experimental|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
16685302|NCT02048618|Experimental|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
16685303|NCT02048618|Placebo Comparator|Placebo QD|2 placebo tablets in the morning
16685304|NCT02048605|Experimental|Psycho-social (CBT) based training|Psycho-social Training in Neurological Diseases - Parkinson's Disease ( Training according to Ellgring et al., 2006)
16685305|NCT02048605|Placebo Comparator|Unspecific group training|"Health Enhancement Program
~The validation of an active control intervention for Mindfulness Based Stress Reduction (MBSR) (MacCoon et al., 2012)"
16685306|NCT02048592|Active Comparator|Impact-Nutridrink|The first arm will be given immunonutrition -Impact- for 8 weeks, afterwards the patients will return to their previous nutrition support for another 8 weeks. We expect the improvement of oxidative stress parameters after 8 weeks of immunonutriton and return to baseline values when immunonutrition is stopped
16685307|NCT02048592|Active Comparator|Nutridrink-Impact|The second group will be given their previous nutrition support (Nutridrink) for 8 weeks, afterwards the patients will be switched to immunonutrition- Impact- for another 8 weeks. In this group of patients we do not expect any change of oxidative stress parameters after the first 8 weeks. The improvement is expected at the end of the second half of study.
16685308|NCT02048579|No Intervention|Treatment as Usual|
16685309|NCT02048579|Experimental|Behavior Therap + Motivational Interviewing|Supporting Teens' Academic Needs Daily Therapy program delivered to parents and teens
16685310|NCT02048566|Experimental|hTEEPM|Group hTEE protocolled monitoring (hTEEPM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration (see below) and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
16685311|NCT02048566|Experimental|hTEESM|Group hTEE standard monitoring (hTEESM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management in which case an hTEE assessment has to be performed. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
16685312|NCT02048566|Active Comparator|ControlPM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
16685313|NCT02048566|Active Comparator|ControlSM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
16685314|NCT02048553|Experimental|Tablet-guided|Guide-assisted ventriculostomy.
16685315|NCT02048553|Experimental|Freehand|standard ventriculostomy.
16685316|NCT02048540|Experimental|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
16685317|NCT02048540|Active Comparator|DOF|patients receive DOF pre and post surgery up to total 6 cycles
16685318|NCT02048527|Active Comparator|Global|In vitro embryo culture in single-step medium (Global)
16685319|NCT02048527|Active Comparator|Origio|In vitro embryo culture in sequential media (Origio)
16685320|NCT02048514|Experimental|Nellix Aneurysm Sealing|The Nellix® EndoVascular Aneurysm Sealing System
16685321|NCT02048501|Other|Weight Regain|The weight regain group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and regained at least 15% of the post-operative nadir weight.
16685322|NCT02048501|Other|Sustained Weight Loss (SWL)|The sustained weight loss group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and have regained less than 15% of the post-operative nadir weight.
16685323|NCT02048488|Experimental|Experimental Drug TSR-011|Experimental Drug TSR-011
16685324|NCT02048475|No Intervention|desflurane|inhalation concentration
16685325|NCT02048462||Cyclists|
16685326|NCT02048436||male female 18-45 years range of body types|18 male female subject mix that are 18-45 years of age and selected to represent a range of body types of varying physiques and body mass indexes
16685327|NCT02048423|Experimental|Ketamine|Drug
16685328|NCT02048410|Active Comparator|diet plus Lactobacillus paracasei B21060|low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
16685330|NCT02048397|Other|Pulmonary Rehabilitation (PRP)|Pulmonary Rehabilitation (PRP)
16685331|NCT02048397|Other|Pulmonary Rehabilitation plus oral nutritional supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
16685332|NCT02048384|Experimental|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
16685333|NCT02048384|Active Comparator|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
16685334|NCT02048371|Active Comparator|Cohort A: Liposarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
16685335|NCT02048371|Placebo Comparator|Cohort A: Liposarcoma, Placebo|"21 days on and 7 days off
~Placebo"
16685336|NCT02048371|Active Comparator|Cohort B: Osteosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
16685337|NCT02048371|Placebo Comparator|Cohort B: Osteosarcoma, placebo|"21 days on and 7 days off
~Placebo"
16685338|NCT02048371|Active Comparator|Cohort C: Ewing sarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
16685339|NCT02048371|Active Comparator|Cohort D: Rhabdomyosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
16685340|NCT02048371|Active Comparator|Cohort E: Mesenchymal Chondrosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
16685341|NCT02048358|Experimental|2B3-201 150mg|2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose
16685342|NCT02048358|Experimental|2B3-201 300mg|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose
16685343|NCT02048358|Experimental|2B3-201 450mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose
16685344|NCT02048358|Experimental|450mg 2B3-201|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
16685345|NCT02048358|Experimental|300mg 2B3-201|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose
16685346|NCT02048358|Experimental|2B3-201 450mg male volunteers|2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose
16685347|NCT02048358|Experimental|2B3-201 300mg or 450mg female volunteers|2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose
16685348|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 450 mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
16685349|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 dose tbd|2B3-201 (dose to be determined), once, IV infusion in 5% dextrose
16685350|NCT02048345|Experimental|Suspension, fasted state|Suspension Noxafil will be administered in the fasted state to the volunteers.
16685351|NCT02048345|Experimental|Suspension, with sugar (delay gastric emptying)|Suspension will be co-administered with glucose to delay the gastric emptying time
16685352|NCT02048345|Experimental|Solution, fasted state|A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
16685353|NCT02048345|Experimental|Solution, with sugar (delaying gastric emptying)|A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
16685354|NCT02048332|Experimental|Viral Specific VST Infusion|Viral reactivation or infection. VST Reinfusion required.
16685355|NCT02048319|Experimental|Experimental: Pasireotide LAR 60 mg|The subjects will be randomized (1:1) into two groups. Both groups will undergo aspiration sclerotherapy following the standard procedure. The intervention group will additionally receive two injections of 60 mg pasireotide long-acting release (LAR) intramuscularly: the first injection 14 days before and the second injection 14 days after the intervention.
16685356|NCT02048319|Placebo Comparator|Placebo|Patients in the placebo arm will receive two injections of saline solution corresponding to the scheme of the intervention group.
16685357|NCT02048306|Experimental|Family-based PR group|
16685358|NCT02048306|Active Comparator|Conventional PR group|
16685359|NCT02048293|Active Comparator|Group O|Remifentanyl innovative molecule = Ultiva®
16685360|NCT02048293|Active Comparator|Group A|Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.
16685361|NCT02048293|Active Comparator|Group B|Remifentanyl comparator B = Fada Remifentanilo
16685362|NCT02048280|Experimental|Intubated|NAVA level from 0.1 to 3
16685363|NCT02048267||Alcoholic|
16685364|NCT02048267||Non alcoholic|
16685365|NCT02048254|Experimental|brachytherapy|Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy
16685366|NCT02048254|Active Comparator|IMRT|IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times.
16685367|NCT02048241|Other|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
16685368|NCT02048241|Experimental|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
16685369|NCT02048228|Experimental|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for *2 carriers.CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
16685370|NCT02048228|Active Comparator|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
16685371|NCT02048215|Active Comparator|Ephedrine + Caffeine + diet|Ephedrine 20 mg + Caffeine 200 mg capsule t.i.d. for one month plus hypocaloric diet
16685372|NCT02048215|Placebo Comparator|Placebo + diet|Similarly-looking placebo capsule t.i.d. for one month plus hypocaloric diet
16685373|NCT02048202||premature neonate|premature neonate
16685374|NCT02048189|Other|Intensified multiple injections|
16685375|NCT02048189|Other|Pumps|
16685376|NCT02048176||Posterior Fossa Mutism|Patients with Posterior Fossa Mutism
16685377|NCT02048176||Non Posterior Fossa Mutism|Patients that did not develop Mutism
16685378|NCT02048163||Short infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.
16685379|NCT02048163||Prolonged infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.
16685380|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
16685381|NCT02048137|Active Comparator|Active transcranial direct current stimulation|
16685382|NCT02048137|Sham Comparator|Sham transcranial direct current stimulation|
16685383|NCT02048124|Active Comparator|25g standard needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
16685384|NCT02048124|Experimental|25d ProCor needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
16685385|NCT02048111|Experimental|IB1001|
16685386|NCT02048098|Active Comparator|Buccal misoprostol|400 µg buccal misoprostol per 3 hours
16685387|NCT02048098|Active Comparator|vaginal misoprostol|400 µg vaginal misoprostol per 3 hours
16685388|NCT02048085|Experimental|Ticagrelor|Ticagrelor Arm will be dosed with a loading dose of 180 mg followed by maintenance dose of 90 mg BID until discharge or up to 8 days.
16685389|NCT02048085|Active Comparator|Clopidogrel|Clopidogrel arm will be dose with a loading dose of 300 mg followed by maintenance dose of 75 mg everyday until discharge or up to 8 days.
16685390|NCT02048072|Experimental|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
16685391|NCT02048059|Experimental|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
16685392|NCT02048046||ECMO|
16685393|NCT02048033|Active Comparator|Arm with Apollo Endosurgery OverStitch technical|
16685394|NCT02048033|Placebo Comparator|Arm without Apollo Endosurgery OverStitch technical|
16685395|NCT02048020|Experimental|Treatment (paclitaxel, carboplatin, IMRT)|"INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity."
16685396|NCT02048007|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years
~Morbidity monitoring:
~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community.
~Anthropometry for all children aged 1 to 60 months per community.
~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint."
16685397|NCT02048007|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community
~Anthropometry for all children aged 1 to 60 months per community
~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint"
16685398|NCT02047994|Experimental|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
16685399|NCT02047994|No Intervention|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
16685431|NCT02047773|Active Comparator|Bacterial load guided duration|Antibiotics stopped early on day 8 or day 11 if the bacterial load when checked on day 7 and day 10 is less than 10^6cfu/ml.
16685432|NCT02047760||MS patients|All MS sub-types
16685400|NCT02047981|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
~In Niger during year 3, all communities will be offered azithroymcin."
16685401|NCT02047981|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
~In Niger during year 3, all communities will be offered azithroymcin."
16685402|NCT02047968|Experimental|wake therapy, light therapy and sleep time stabilisation|Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between. Light therapy for 30 minutes daily in the entire study period. Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
16685403|NCT02047968|No Intervention|treatment as usual|
16685404|NCT02047942|Active Comparator|Center-based cardiac rehabilitation|Patients randomized to the center-based training group will continue their training sessions at the outpatient clinics of UZ Leuven under direct supervision of physical therapists
16685405|NCT02047942|Experimental|Home-based training with telemonitoring guidance|Patients will receive an patient-tailored exercise prescription and will be asked to perform the exercise sessions in their home environment wearing heart rate monitors. Training data will be accessed by the research group on weekly basis in order to keep a record of frequency; duration and intensity of the sessions. Feedback will be given weekly to every patient.
16685406|NCT02047942|No Intervention|Control|
16685407|NCT02047929|Active Comparator|Facilitator-Led|This approach to dissemination allows clinics some freedom to tailor the Asthma Shared Decision Making (SDM) Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
16685408|NCT02047929|Active Comparator|Traditional|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will give an overview of the Asthma Shared Decision Making (SDM) Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
16685409|NCT02047929|No Intervention|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
16685410|NCT02047916||Normal Neonates > 33 weeks gestation|"Neonates >33 weeks gestational age
~Postnatal age <72 hours;
~Parental informed consent;
~Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
16685411|NCT02047903||Afatinib|
16685412|NCT02047890|Experimental|BAY1000394|Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
16685413|NCT02047877||Respiratory Illness|Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.
16685414|NCT02047864|Experimental|Creatine monohydrate|Creatine monohydrate to be given during a resistance training program
16685415|NCT02047864|Placebo Comparator|Sugar pill|Placebo to be given during a resistance training program
16685416|NCT02047851|Active Comparator|Acupuncture in active points|Patients in this group will receive real acupuncture
16685417|NCT02047851|Sham Comparator|Acupuncture in non-active points|Patients in this group will receive acupuncture, but in non-active points
16685418|NCT02047851|No Intervention|No treatment, just observation|Patients in this group will receive no treatment and will only be observed.
16685419|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
16685420|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
16685421|NCT02047825|Experimental|Experimental group|The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
16685422|NCT02047825|Active Comparator|Control group|Patients with multiple sclerosis not included in the intensive intervention. They receive the usual treatment of occupational and physical therapy.
16685423|NCT02047812||High volume hospitals|The hospitals in the upper tertile for procedural volume
16685424|NCT02047812||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
16685425|NCT02047812||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
16685426|NCT02047799|Active Comparator|Calcitriol|A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
16685427|NCT02047799|Placebo Comparator|Control|A daily dose of placebo (administered as 1 capsule )
16685428|NCT02047786||General Hospital Patients|Those patients undergoing appendicectomy in a general (non-specialised) surgical centre.
16685429|NCT02047786||Paediatric Hospital Patients|Those patients undergoing appendicectomy in specialised paediatric centres.
16685430|NCT02047773|Placebo Comparator|14 days Duration|14 days of antibiotics regardless of bacterial load.
16685433|NCT02047760||Controls|sex- and age-matched controls
16685434|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
16685435|NCT02047734|Experimental|Ozanimod 0.5 mg|Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
16685436|NCT02047734|Experimental|Ozanimod1 mg|Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
16685437|NCT02047734|Active Comparator|Interferon β-1a|interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.
16685438|NCT02047721|Experimental|Physical Intervention|A supervised exercise program
16685439|NCT02047721|Experimental|Nutritional Intervention|A supervised diet program
16685440|NCT02047695||Migraine with aura|Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls)
16685441|NCT02047682|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
16685442|NCT02047682|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
16685443|NCT02047669|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
16685444|NCT02047669|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
16685445|NCT02047656|Placebo Comparator|Placebo to LFF269 (Part 1)|Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
16685446|NCT02047656|Experimental|LFF269 (Part 1)|LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
16685447|NCT02047656|Experimental|LFF269 (Part 2)|LFF269 twice daily (b.i.d) for 5 days in patients with hypertension
16685448|NCT02047643|Experimental|On-algorithm first, then Off-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
16685449|NCT02047643|Experimental|Off-algorithm first, then On-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
16685450|NCT02047630|Experimental|Generic latanoprost|1 eye drop hs
16685451|NCT02047630|Active Comparator|Brand-name latanoprost|1 eye drop hs
16685452|NCT02047617|Active Comparator|the standard physiotherapy group|Physiotherapy rehabilitation techniques used in the management of this group include passive range of motion, active range of motion/bed exercises, sitting at edge of bed, sitting in armchair, active transfer from the bed to chair. Mobilization and rehabilitation program is progressively introduced after clinical stabilization with a goal of progressing to ambulation and pulmonary rehabilitation.
16685453|NCT02047617|Experimental|standing table group|The same program as standard physiotherapy group is applied, with daily sessions of standing table in supplement. Standing table was performed on a motorized tilt table (ref: table de verticalisation, Franco&fils). The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform, at 10° intervals from 30° to 80°.
16685454|NCT02047604|Experimental|Cohort A - SAN-300 0.5 mg/kg QW|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks
16685455|NCT02047604|Experimental|Cohort B - SAN-300 1.0 mg/kg QW|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks
16685456|NCT02047604|Experimental|Cohort C - SAN-300 2.0 mg/kg QOW|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks
16685457|NCT02047604|Experimental|Cohort D - SAN-300 4.0 mg/kg QOW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
16685458|NCT02047604|Experimental|Cohort E - SAN-300 4.0 mg/kg QW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
16685459|NCT02047604|Placebo Comparator|Placebo|Placebo dosing
16685460|NCT02047591||Relaxing-touch method|
16685461|NCT02047591||Usual care|
16685462|NCT02047578|Experimental|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
16685463|NCT02047565|Experimental|Part 1 - 60mg edoxaban|Treatment A: single oral dose of 60 mg edoxaban (1 × 60 mg tablet)
16685464|NCT02047565|Experimental|Part 1 - 180mg edoxaban|Treatment B: single oral dose of 180 mg edoxaban (3 × 60 mg tablet)
16685465|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 50 IU/kg Beriplex P/N|Dose cohort 1: 60 mg edoxaban + 50 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
16685466|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 20 IU/kg Beriplex P/N|Dose cohort 2: 60 mg edoxaban + 25 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
16685467|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 10 IU/kg Beriplex P/N|Dose cohort 3: 60 mg edoxaban + 10 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
16685468|NCT02047552|Active Comparator|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
16685469|NCT02047552|Active Comparator|Oxandrolone|Oxandrolone 10 mg PO q12 hours will be dosed for seven days.
16685470|NCT02047552|Experimental|Iron sucrose + oxandrolone|Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.
16685471|NCT02047552|Placebo Comparator|IV iron placebo and Oxandrolone placebo|100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo
16685472|NCT02047539|Experimental|1000 mg/day aspirin|1000 mg/day aspirin
16685473|NCT02047539|Placebo Comparator|sugar pill|sugar pill
16685474|NCT02047526||1|
16686482|NCT02040363|Active Comparator|COPD Patients ~90% VO2max|COPD Patients ~90% VO2max
16685475|NCT02047513|Experimental|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
16685476|NCT02047513|Experimental|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
16685477|NCT02047500|Experimental|TH-302 plus Nab-paclitaxel plus Gemcitabine|
16685479|NCT02047461|Experimental|ORGN001 (formerly ALXN1101)|daily IV infusions
16685480|NCT02047448|No Intervention|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
16685481|NCT02047448|Experimental|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
16685482|NCT02047435|Experimental|Information, event and workshops at a cartoon museum|
16685483|NCT02047435|Active Comparator|Information and event at a cartoon museum|
16685484|NCT02047422|Experimental|Add furosemide/no spironolactone|
16685485|NCT02047422|Experimental|Add metolazone/no spironolactone|
16685486|NCT02047422|Experimental|Add furosemid/spironolactone|
16685487|NCT02047422|Experimental|Add metolazone/spironolactone|
16685488|NCT02047396||Myocardial Infarction subjects|Subjects with first Myocardial Infarction presenting to one of the Mayo Clinic Hospitals in Rochester, Minnesota.
16685489|NCT02047383||respiratory infection|Hospitalized patients with a respiratory infection
16685490|NCT02047370|Experimental|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
16685491|NCT02047370|Placebo Comparator|Placebo group|Ultrasound disconnected in same position and with the same duration.
16685492|NCT02047357|Experimental|Intervention Arm|Learning Through Play Plus
16685493|NCT02047357|No Intervention|Control|This arm will receive no intervention
16685494|NCT02047344|Experimental|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
16685495|NCT02047331|Active Comparator|group PI|group PI were performed periarticular drug injection during surgery.
16685496|NCT02047331|Active Comparator|group FI|group FI were performed fascia iliaca block before surgery
16685497|NCT02047318|Experimental|LUM001|LUM001 administered orally up to twice each day
16685498|NCT02047305|Experimental|Radiofrequency ablation|To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN
16685499|NCT02047292|Active Comparator|THA28|THA Corail PinnacleCoC28
16685500|NCT02047292|Active Comparator|THA36|THA Corail DeltaMotion36
16685501|NCT02047292|Active Comparator|THA40|THA Corail DeltaMotion40
16685502|NCT02047279|Active Comparator|MVS + maze|"Procedure: Maze procedure, mitral valve surgery
~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.
~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
16685503|NCT02047279|Experimental|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction
~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.
~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
16685504|NCT02047266|Experimental|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.
~(MICS CABG group, n=50)"
16685505|NCT02047266|Active Comparator|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.
~(OPCABG group, n=50)"
16693502|NCT01993654||Normal|
16685506|NCT02047266|Active Comparator|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
16685507|NCT02047253|Experimental|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
16685508|NCT02047227|Experimental|Pergoveris®|
16685509|NCT02047227|Active Comparator|GONAL-f®|
16685510|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
16685511|NCT02047201|Experimental|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
16685512|NCT02047175|Experimental|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)
~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
16685513|NCT02047175|Experimental|B(Rosuvastatin)|"B(Rosuvastatin)
~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
16685514|NCT02047162|Experimental|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
16685515|NCT02047162|Placebo Comparator|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
16685516|NCT02047149|Experimental|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
16685517|NCT02047136|Experimental|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
16685518|NCT02047136|Active Comparator|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
16685519|NCT02047123|Experimental|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
16685520|NCT02047110|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.
16685521|NCT02047110|Experimental|Risankizumab 18 mg|Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks
16685522|NCT02047110|Experimental|Risankizumab 90 mg|Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
16685523|NCT02047110|Experimental|Risankizumab 180 mg|Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
16685524|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
16685525|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
16685526|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
16685527|NCT02047071|No Intervention|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
16685528|NCT02047071|Experimental|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
16685529|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
16685530|NCT02047045|Experimental|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
16685531|NCT02047045|Active Comparator|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
16685532|NCT02047032|Experimental|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
16685533|NCT02047032|Active Comparator|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
16685534|NCT02047019|Active Comparator|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
16685535|NCT02047019|Experimental|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
16685536|NCT02047019|Experimental|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
16685537|NCT02047006|Experimental|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:
~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.
~Effect of dialysis on levels of rivaroxaban:
~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
16685538|NCT02046993|Experimental|Smart phone based telemonitoring of HBP|". Patients do HBP monitoring
~. record their BP readings into the smart phone with downloaded application."
16685539|NCT02046993|Active Comparator|Enhanced usual care|". Patients to do HBP measurement
~. Record BP readings in their diary"
16685540|NCT02046980|Experimental|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
16685541|NCT02046980|Experimental|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
16685542|NCT02046980|Sham Comparator|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
16685543|NCT02046967|Active Comparator|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
16685544|NCT02046967|Active Comparator|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
16685545|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
16685546|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
16685547|NCT02046941|Experimental|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
16685548|NCT02046928|Experimental|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
16685549|NCT02046915|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|"Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle
~Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
~Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
16685550|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
16685551|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
16685552|NCT02046889|Experimental|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
16685553|NCT02046889|No Intervention|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
16685554|NCT02046876|Experimental|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
16685555|NCT02046863|Experimental|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
16685556|NCT02046850|Experimental|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
16685557|NCT02046850|Other|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
16685558|NCT02046850|Experimental|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
16685559|NCT02046837|Experimental|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
16685560|NCT02046837|Experimental|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
16685561|NCT02046837|Experimental|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
16685694|NCT02045927|Active Comparator|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
16685562|NCT02046824|Experimental|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
16685563|NCT02046824|Experimental|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
16685564|NCT02046824|Experimental|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
16685565|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
16685566|NCT02046811|Experimental|Patient activation and education|Patient activation and education (PAE)
16685567|NCT02046811|Experimental|PAE plus physician activation|PAE plus physician activation (PAE + MD)
16685568|NCT02046811|Experimental|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
16685569|NCT02046798|Experimental|14C labeled ASP3652|
16685570|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
16685571|NCT02046772|Experimental|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
16685572|NCT02046772|Active Comparator|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
16685573|NCT02046759|Experimental|Pharmacist-Intervention|
16685574|NCT02046759|Active Comparator|Routine Care|
16685575|NCT02046746|Experimental|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
16685576|NCT02046733|Experimental|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles
~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
16685577|NCT02046733|No Intervention|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
16685578|NCT02046720|Experimental|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
16685579|NCT02046707|Experimental|Patients with chronic heart failure|
16685580|NCT02046707|Other|Controls|
16685581|NCT02046694|Experimental|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
16685582|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
16685583|NCT02046668|Active Comparator|spironolactone|25mg spironolactone daily
16685584|NCT02046668|Placebo Comparator|Placebo|Matched Placebo
16685585|NCT02046655|Experimental|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.
~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.
~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.
~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
16685586|NCT02046655|Active Comparator|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.
~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.
~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
16685587|NCT02046642|Active Comparator|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
16685588|NCT02046642|Active Comparator|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
16685589|NCT02046629|Experimental|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
16685590|NCT02046616|Experimental|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
16685591|NCT02046603|Experimental|Tocilizumab Monotherapy|Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
16685592|NCT02046603|Experimental|Tocilizumab in Combination With Methotrexate or Other DMARDs|Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
16685695|NCT02045927|Other|Control Group|sedation monitoring with RASS score
16685696|NCT02045914|No Intervention|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
16685593|NCT02046590|Active Comparator|Deep Sedation|"Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.
~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure."
16685594|NCT02046590|Active Comparator|General Anaesthesia|"General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.
~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator."
16685595|NCT02046577|Experimental|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
16685596|NCT02046577|Experimental|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
16685597|NCT02046577|Placebo Comparator|Placebo|Oral placebo in liquid weekly during 6 months
16685598|NCT02046564|Experimental|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
16685599|NCT02046564|Placebo Comparator|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
16685600|NCT02046551|Placebo Comparator|Placebo|placebo
16685601|NCT02046551|Experimental|Atomoxetine|atomoxetine (40 mg/day)
16685602|NCT02046538|Experimental|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.
~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
16685603|NCT02046538|Active Comparator|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.
~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
16685604|NCT02046525|Experimental|Auto fecal microbitoa therapy|autologous fecal microbiota therapy
16685605|NCT02046525|Placebo Comparator|Saline enema|Saline enema
16685606|NCT02046512|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
16685607|NCT02046512|Placebo Comparator|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
16685608|NCT02046499|Active Comparator|Oxytocin arm|Oxytocin alone administered which is current standard of care
16685609|NCT02046499|Experimental|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
16685610|NCT02046486|Active Comparator|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
16685611|NCT02046486|Experimental|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
16685612|NCT02046473|Other|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
16685613|NCT02046460|Active Comparator|Oral Anticoagulation|Vitamin K-Antagonists, target INR 2.0-3.0
16685614|NCT02046460|Experimental|Antiplatelets|Acetylsalicylic acid, 300mg o.p.d.
16685615|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
16685616|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
16685617|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
16685697|NCT02045914|Experimental|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
16685814|NCT02045108|Experimental|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
16685618|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
16685619|NCT02046434|Experimental|Parkinson's Diesase|Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease
16685620|NCT02046434|Experimental|Control|Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate
16685621|NCT02046421|Experimental|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16685622|NCT02046408|Experimental|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
16685623|NCT02046408|No Intervention|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
16685624|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
16685625|NCT02046382|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
16685626|NCT02046382|Placebo Comparator|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
16685627|NCT02046369|Experimental|Luradisone|Luradisone 20- 80 mg administered once daily
16685628|NCT02046369|Placebo Comparator|Placebo|Placebo administered once daily
16685629|NCT02046356||Early-Stage HCC|Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA
16685630|NCT02046343|Experimental|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
16685631|NCT02046343|Placebo Comparator|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
16685632|NCT02046330|Experimental|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
16685633|NCT02046317|Experimental|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
16685634|NCT02046317|Active Comparator|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
16685635|NCT02046304|Experimental|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
16685636|NCT02046291|Experimental|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
16685637|NCT02046278|No Intervention|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
16685638|NCT02046278|Experimental|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
16685639|NCT02046265|Experimental|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
16685640|NCT02046265|Experimental|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
16685641|NCT02046265|Experimental|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
16685642|NCT02046265|Active Comparator|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
16685809|NCT02045134|Placebo Comparator|Placebo|Soluble corn flour not rich in anthocyanins
16685810|NCT02045134|Active Comparator|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
16685643|NCT02046239|Other|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
16685644|NCT02046239|Experimental|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
16685645|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
16685646|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
16685647|NCT02046213|Experimental|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
16685648|NCT02046200|Experimental|Ivermectin|Ivermectin 30 mg single dose
16685649|NCT02046200|Placebo Comparator|Sugar pill|Matched placebo, single dose
16685650|NCT02046187|Experimental|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
16685651|NCT02046174|Experimental|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
16685652|NCT02046174|No Intervention|Best Supportive Care Arm|patients who will receive, or continue receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
16685653|NCT02046161|Experimental|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
16685654|NCT02046161|Placebo Comparator|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
16685655|NCT02046148|Experimental|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
16685656|NCT02046148|Active Comparator|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
16685657|NCT02046135|Experimental|Sodium bicarbonate|At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains ~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
16685658|NCT02046135|Active Comparator|Sodium Chloride|At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.
16685659|NCT02046122|Experimental|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
16685660|NCT02046109|Experimental|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
16685661|NCT02046109|Active Comparator|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
16685662|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
16685663|NCT02046096|Experimental|Cook Celect® Vena Cava Filter|Cook Celect® Vena Cava Filter
16685664|NCT02046083|Experimental|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
16685665|NCT02046083|Placebo Comparator|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
16685666|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
16685811|NCT02045121|Experimental|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
16685815|NCT02045108|Experimental|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
16685667|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 400 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
16685668|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
16685669|NCT02046057|Experimental|PNB of SLN|Percutaneous core biopsy of sentinel node prior to standard sentinel node dissection
16685670|NCT02046044|Experimental|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
16685671|NCT02046044|Experimental|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
16685672|NCT02046031|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
16685673|NCT02046018|Active Comparator|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
16685674|NCT02046018|Active Comparator|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
16685675|NCT02046018|Active Comparator|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
16685676|NCT02046005|Active Comparator|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
16685677|NCT02046005|Experimental|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
16685678|NCT02046005|Experimental|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
16685679|NCT02045992|Experimental|Caffeine|Caffeine 500mg
16685680|NCT02045992|Placebo Comparator|Placebo|Lactose 500mg
16685681|NCT02045979|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
16685682|NCT02045979|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
16685683|NCT02045979|Active Comparator|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
16685684|NCT02045966|Experimental|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1
~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15
~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only
~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30
~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
16685685|NCT02045953|Experimental|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
16685686|NCT02045953|Experimental|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
16685687|NCT02045953|Experimental|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
16685688|NCT02045953|Experimental|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
16685689|NCT02045940|Experimental|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
16685690|NCT02045940|Experimental|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
16685691|NCT02045940|Experimental|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
16685692|NCT02045940|Experimental|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
16685693|NCT02045940|Experimental|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
16685816|NCT02045108|Sham Comparator|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
16685698|NCT02045901|Active Comparator|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
16685699|NCT02045901|Placebo Comparator|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
16685700|NCT02045888|Experimental|Low Dose ADRC|ADRCs prepared by investigational Celution Device
16685701|NCT02045888|Experimental|High Dose ADRC|ADRCs prepared by investigational Celution Device
16685702|NCT02045888|Placebo Comparator|Placebo|Placebo
16685703|NCT02045875|Experimental|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
16685704|NCT02045875|Active Comparator|Dulera Standard of Asthma Care|Dulera standard of asthma care
16685705|NCT02045862|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
16685706|NCT02045862|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
16685707|NCT02045862|Experimental|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
16685708|NCT02045849|Experimental|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
16685709|NCT02045849|Experimental|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
16685710|NCT02045849|Experimental|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
16685711|NCT02045836|Experimental|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
16685712|NCT02045836|Active Comparator|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
16685713|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
16685714|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
16685715|NCT02045823||Retina|clinical exam with results consistent with retina pathology
16685716|NCT02045810|Active Comparator|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
16685717|NCT02045810|Placebo Comparator|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
16685718|NCT02045797|Experimental|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily [BID]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
16685719|NCT02045797|Experimental|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
16685720|NCT02045797|Experimental|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
16685721|NCT02045784|Experimental|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
16685722|NCT02045784|Experimental|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
16685723|NCT02045784|Experimental|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
16685724|NCT02045784|Other|Breast milk|Unrestricted consumption during 4 days
16685725|NCT02045771|Other|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
16685812|NCT02045121|Active Comparator|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if >75% of visceral and parietal pleura in direct contact on chest x-ray.
16685726|NCT02045771|Experimental|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
16685727|NCT02045758|Experimental|TAP20-C|TAP20-C
16685728|NCT02045758|Active Comparator|Fingerstick|Fingerstick
16685729|NCT02045745|Experimental|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
16685730|NCT02045732|Experimental|Cohort 1|
16685731|NCT02045732|Experimental|PF-06342674 1.5 mg/kg|
16685732|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q2 Weeks)|
16685733|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q1 Week)|
16685734|NCT02045719|Experimental|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
16685735|NCT02045706|Experimental|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
16685736|NCT02045706|No Intervention|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
16685737|NCT02045693|Experimental|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1
~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
16685738|NCT02045693|Active Comparator|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1
~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
16685739|NCT02045680||deep block|deep block
16685740|NCT02045680||non deep block (historical control)|non deep block (historical control)
16685741|NCT02045667|Placebo Comparator|Placebo|Placebo tablets three times daily orally
16685742|NCT02045667|Active Comparator|Mexiletine|Mexiletine 200mg three times daily orally
16685743|NCT02045654||MDS patients|MDS patients who were treated with decitabine
16685744|NCT02045641|No Intervention|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
16685745|NCT02045641|Experimental|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion > 400ml OR b) pleural effusion< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
16685746|NCT02045628|Experimental|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
16685747|NCT02045628|No Intervention|Control|Those in the control group will receive usual care.
16685748|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
16685749|NCT02045615||New|Proposed technique for Wichita nail extraction
16685750|NCT02045602|Experimental|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
16685751|NCT02045602|Experimental|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
16685752|NCT02045602|Experimental|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
16685753|NCT02045589|Experimental|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
16685754|NCT02045576|Experimental|Sleep position trainer|Nightbalance
16685755|NCT02045576|Active Comparator|Oral Appliance Therapy|Somnodent
16685756|NCT02045563||Patients with type-1 diabetes|
16685757|NCT02045563||Patients with type-2 diabetes|
16685758|NCT02045563||Volontaires sains|
16685759|NCT02045550|Placebo Comparator|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
16685760|NCT02045550|Active Comparator|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
16685761|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
16685762|NCT02045524|Experimental|Injection location1|Single dose IM injection
16685763|NCT02045524|Experimental|Injection location 2|Single dose IM Injection
16685764|NCT02045511|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
16685765|NCT02045511|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
16685766|NCT02045498|Experimental|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
16685767|NCT02045498|No Intervention|conventional cpr|conventional cpr
16685768|NCT02045472|Experimental|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
16685769|NCT02045472|Placebo Comparator|Placebo|Placebo administered as a single infusion
16685813|NCT02045108|Experimental|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
16685770|NCT02045459|Experimental|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
16685771|NCT02045446|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
16685772|NCT02045446|Experimental|Stereotactic Body Radiation Therapy|consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
16685773|NCT02045433|Experimental|SABR Boost Therapy|
16685774|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
16685775|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
16685776|NCT02045394||Patients presenting with haemoptysis|
16685777|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
16685778|NCT02045368|Experimental|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
16685779|NCT02045355|Experimental|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
16685780|NCT02045355|No Intervention|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
16685781|NCT02045342|Experimental|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
16685782|NCT02045342|Placebo Comparator|Placebo|Ingest 500ml of placebo prior to metabolic measures.
16685783|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
16685784|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
16685785|NCT02045316||Normal pregnants|pregnants without obstetric complications
16685786|NCT02045303|Experimental|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
16685787|NCT02045290|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.
~The placebo product will contain the following components:
~Micosolle™, silica based excipient
~Silicified Micro Crystalline Cellulose, National Formulary
~Safflower Oil, United States Pharmacopeia
~K-30 Povidone Powder
~Magnesium Stearate, National Formulary (Vegetable source)
~Fumed Silica, National Formulary"
16685788|NCT02045290|Experimental|Metformin|Metformin 2000 mg per day
16685789|NCT02045277|Experimental|IDP-118 Lotion|halobetasol propionate [HP], tazarotene [Taz]
16685790|NCT02045277|Active Comparator|IDP-118 Monad HP Lotion|HP
16685791|NCT02045277|Active Comparator|IDP-118 Monad Taz Lotion|Taz
16685792|NCT02045277|Active Comparator|IDP-118 Vehicle Lotion|Vehicle
16685793|NCT02045264|Experimental|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
16685794|NCT02045251|Experimental|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
16685795|NCT02045238|Placebo Comparator|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
16685796|NCT02045238|Experimental|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
16685797|NCT02045225|Experimental|Cognitive behavioural therapy|Reduction of social anxiety & substance use in gay/bi men
16685798|NCT02045212|Experimental|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
16685799|NCT02045212|Placebo Comparator|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
16685800|NCT02045199|Experimental|V0111|
16685801|NCT02045199|Placebo Comparator|Placebo|
16685802|NCT02045186|Other|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
16685803|NCT02045173|Other|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
16685804|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
16685805|NCT02045147|Experimental|Grp 1 Low Cognition, Low Activation|Group 1: Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
16685806|NCT02045147|Experimental|Grp 2 Low Cognition, High Activation|Group 2: Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
16685807|NCT02045147|Experimental|Grp 3 Normal Cognition, Low Activation|Group 3: Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
16685808|NCT02045147|Experimental|Grp 4 Normal Cognition, High Activation|Group 4: Subjects will receive the least intensive intervention delivered by a RN coach.
16685817|NCT02045095|Experimental|Schedule A: MLN7243 1 mg|MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
16685818|NCT02045095|Experimental|Schedule A: MLN7243 2 mg|MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
16685819|NCT02045095|Experimental|Schedule A: MLN7243 4 mg|MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
16685820|NCT02045095|Experimental|Schedule A: MLN7243 8 mg|MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
16685821|NCT02045095|Experimental|Schedule A: MLN7243 12 mg|MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
16685822|NCT02045095|Experimental|Schedule A: MLN7243 18 mg|MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
16685823|NCT02045095|Experimental|Schedule A: MLN7243 Homozygous Mutant 4 mg|MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
16685824|NCT02045082|Experimental|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
16685825|NCT02045082|Experimental|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
16685826|NCT02045069|Experimental|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
16685827|NCT02045069|Experimental|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
16685828|NCT02045069|Placebo Comparator|Placebo|Placebo
16685829|NCT02045056|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
16685830|NCT02045056|Placebo Comparator|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
16685831|NCT02045043||Cardiomyopathy patients with ICDs|
16685832|NCT02045030|Experimental|aflibercept and FOLFIRI|aflibercept and FOLFIRI
16685833|NCT02045017|Experimental|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (> 75 years old)
16685834|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
16685835|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
16685836|NCT02044991|Active Comparator|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
16685837|NCT02044991|Placebo Comparator|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
16685838|NCT02044978|Active Comparator|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
16685839|NCT02044978|Placebo Comparator|control|Dental implant without coating Note: Both arms in each patient (2 implants)
16685840|NCT02044965|No Intervention|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
16685841|NCT02044965|Placebo Comparator|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
16685842|NCT02044965|Active Comparator|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
16685843|NCT02044952|Experimental|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
16685844|NCT02044939|Experimental|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
16685845|NCT02044939|No Intervention|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
16685846|NCT02044913|Experimental|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
16685847|NCT02044913|No Intervention|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
16685848|NCT02044887|Experimental|INTERVENTION|Participants will receive instructions to do physical activity with an adapted physical activity program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and caregivers.
16685849|NCT02044887|No Intervention|Control|The control group will receive regular care.
16685850|NCT02044874|Experimental|APD356 10 mg b.i.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
16685851|NCT02044874|Experimental|APD356 10 mg q.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
16685852|NCT02044874|Placebo Comparator|Placebo 10 mg b.i.d|Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
16685853|NCT02044861|Experimental|ACT-PFK-158|dose escalation
16685854|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
16685855|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
16685856|NCT02044835|Placebo Comparator|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
16685857|NCT02044835|Experimental|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
16685858|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
16685859|NCT02044809|Placebo Comparator|Placebo|
16685860|NCT02044809|Experimental|Cannabidiol 200mg Oral|
16685861|NCT02044809|Experimental|Cannabidiol 400mg Oral|
16685862|NCT02044809|Experimental|Cannabidiol 800mg Oral|
16685863|NCT02044796|Experimental|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.
~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
16685864|NCT02044783|Experimental|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
16685865|NCT02044783|No Intervention|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
16685866|NCT02044757|Experimental|SSB withdrawal|
16685867|NCT02044744|Experimental|Referral|Physical activity referral
16685868|NCT02044744|No Intervention|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
16685869|NCT02044731|Experimental|Family group sessions|Active and Healthy Families
16685870|NCT02044705|Experimental|Family group sessions|Active and Healthy Families
16685871|NCT02044705|No Intervention|Wait-list control|Controls may participate in Active and Healthy Families after the study
16685872|NCT02044679|Experimental|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
16685873|NCT02044679|Experimental|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
16685874|NCT02044679|Other|C = no change|No change
16685875|NCT02044666|Experimental|Treatment|
16685876|NCT02044653|Experimental|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
16685877|NCT02044653|Experimental|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
16685878|NCT02044653|Experimental|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
16685879|NCT02044653|Experimental|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
16685880|NCT02044653|Experimental|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
16685881|NCT02044653|Experimental|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
16685882|NCT02044653|Experimental|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
16685883|NCT02044653|Experimental|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
16685884|NCT02044653|Active Comparator|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
16685885|NCT02044653|Experimental|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
16685886|NCT02044653|Experimental|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
16685887|NCT02044653|Experimental|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
16685888|NCT02044653|Active Comparator|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
16685889|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
16685890|NCT02044627|Experimental|1 dose of [14C-ETC-1002]|
16685891|NCT02044614|Other|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
16685892|NCT02044601|Experimental|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.
~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
16685893|NCT02044601|Experimental|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.
~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
16685894|NCT02044588||HBsAg negative kidney allograft donor|
16685895|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
16685896|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
16693991|NCT01990482|Placebo Comparator|water group|water
16685897|NCT02044562|Experimental|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
16685898|NCT02044562|Placebo Comparator|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
16685899|NCT02044549|Active Comparator|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
16685900|NCT02044549|Active Comparator|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
16685901|NCT02044536||Faculty doctors|Experienced endoscopists (> 6000 cases). no intervention
16685902|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (< 4 months of endoscopy training) no intervention
16685903|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:
~Transient Elastography (Fibroscan)
~Acoustic Radiation Force Impulse (ARFI)
~Magnetic Resonance Elastography (MRE)"
16685904|NCT02044510|Experimental|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
16685905|NCT02044510|Placebo Comparator|Placebo|Inert placebo pill, matching active treatment pill.
16685906|NCT02044497|Experimental|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
16685907|NCT02044484|Experimental|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.
~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.
~Behavioral screening of patients at HIV primary care visits.
~Dissemination of palm cards with empowering messages at HIV primary care visits."
16685908|NCT02044484|No Intervention|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
16685909|NCT02044471|Experimental|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.
~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
16685910|NCT02044471|No Intervention|Control|standard care
16685911|NCT02044458|Active Comparator|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
16685912|NCT02044458|No Intervention|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
16685913|NCT02044445|Active Comparator|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
16685914|NCT02044445|Active Comparator|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
16685915|NCT02044432|Experimental|Ginger compress|
16685916|NCT02044432|No Intervention|Wait list|
16685917|NCT02044419|Experimental|lomitapide sprinkled in applesauce|Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
16685918|NCT02044419|Experimental|lomitapide sprinkled in mashed banana|Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
16685919|NCT02044419|Experimental|lomitapide (intact)|Intact capsule of 20 mg lomitapide
16685920|NCT02044406|Experimental|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
16685921|NCT02044406|Experimental|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
16685922|NCT02044393|Experimental|Reference|single dose BI 691751
16685923|NCT02044393|Experimental|Test|multiple doses of itraconazole + single dose BI 691751
16685924|NCT02044380|Experimental|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
16685925|NCT02044367|Experimental|Test 1 (Treatment A)|multiple dose of dabigatran
16685926|NCT02044367|Experimental|Test 2 (Treatment B)|multiple dose of dabigatran
16685927|NCT02044367|Experimental|Reference|multiple dose of dabigatran
16685928|NCT02044354|Other|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
16685929|NCT02044354|Other|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
16685930|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops
~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period
~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
16685931|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops
~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period
~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
16685932|NCT02044328|Experimental|Icotinib|Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
16685933|NCT02044315|Sham Comparator|Conventional|Conventional ICD programming
16685934|NCT02044315|Experimental|High-zone|High-zone ICD programming
16685999|NCT02043821|Other|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
16693992|NCT01990469|Experimental|Gemigliptin|Gemigliptin 50mg qd
16685935|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
16685936|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
16685937|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
16685938|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
16685939|NCT02044276|Experimental|lipegfilgrastim.|subcutaneous (SC) injection of 6 mg lipegfilgrastim
16685940|NCT02044276|Active Comparator|pegfilgrastim|SC injection of 6 mg pegfilgrastim
16685941|NCT02044263|Experimental|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
16685942|NCT02044263|Active Comparator|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
16685943|NCT02044250|Active Comparator|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
16685944|NCT02044250|Placebo Comparator|Aspirin|Antiplatelet monotherapy : Aspirin 100~200mg P.O. daily
16685945|NCT02044237|Experimental|Decoupling|specific technic to reduce hair pulling
16685946|NCT02044237|Active Comparator|progressive muscle relaxation|Progressive relaxation relaxation technic
16685947|NCT02044224|Experimental|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
16685948|NCT02044211|Active Comparator|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone
~Interventions:
~Behavioral:
~Counseling for heart failure self-care Counseling for depression
~Drug:
~Pharmacotherapy for heart failure Pharmacotherapy for depression"
16685949|NCT02044211|Active Comparator|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone
~Interventions:
~Behavioral:
~Counseling for heart failure self-care Usual care for depression
~Drug:
~Pharmacotherapy for heart failure
~Usual Care for depression"
16685950|NCT02044211|No Intervention|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
16685951|NCT02044211|No Intervention|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
16685952|NCT02044198|Active Comparator|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.
~Blood-stage controlled human malaria infection (CHMI) at day 70."
16685953|NCT02044198|No Intervention|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.
~Blood-stage controlled human malaria infection (CHMI) at day 70."
16685954|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
16685955|NCT02044185||control group|normal population with health screening
16685956|NCT02044172|Active Comparator|Radical prostatectomy|Radical prostatectomy
16685957|NCT02044172|Active Comparator|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
16685958|NCT02044172|Active Comparator|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
16685959|NCT02044159|Experimental|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
16685960|NCT02044159|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
16685961|NCT02044146|Experimental|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19*2 and CYP2C19*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (*2 or *3) and/or diabetes and/or (having age>65 AND BMI>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients >age 75 or wt < 60 kg, prasugrel will be reduced to 5mg daily."
16685962|NCT02044146|Active Comparator|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
16693993|NCT01990469|Placebo Comparator|Placebo|Gemigliptin placebo
16685963|NCT02044146|Other|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
16685964|NCT02044133|Other|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
16685965|NCT02044133|Other|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
16685966|NCT02044120|Experimental|niraparib and temozolomide|Niraparib (capsule) and temozolomide (capsule) will be taken together.
16685967|NCT02044120|Experimental|niraparib and irinotecan|Niraparib will be taken orally and irinotecan will be administered intravenously.
16685968|NCT02044120|Experimental|niraparib, irinotecan and temozolomide|Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.
16685969|NCT02044107|Experimental|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).
~The intervention consists of health center level co-packaging and visual counseling messages (zinc & ORS packaged at health center for diarrhea, and zinc & antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
16685970|NCT02044107|No Intervention|Control group|Current standard care at public health center (zinc & ORS for treatment of diarrhea and zinc & antibiotics for treatment of of pneumonia).
16685971|NCT02044094|Experimental|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
16685972|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
16685973|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
16685974|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
16685975|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
16685976|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
16685977|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:
~HDV antibodies
~if positive, HDV RNA"
16685978|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
16685979|NCT02044029||Age- and gender-matched controls|
16685980|NCT02044029||Patients with spinal muscular atrophy|
16685981|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
16685982|NCT02044003|Experimental|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
16685983|NCT02043990|Experimental|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
16685984|NCT02043977|Experimental|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
16685985|NCT02043964|Experimental|tears and cerebro-spinal fluid sampling|
16685986|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
16685987|NCT02043938|Experimental|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
16685988|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
16685989|NCT02043912||patients treated with haloperidol|
16685990|NCT02043899|Experimental|Single Arm Trial|This was a single arm trial, all patients were to undergo the same assessments and interventions.
16685991|NCT02043886|Active Comparator|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
16685992|NCT02043886|Placebo Comparator|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
16685993|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
16685994|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
16685995|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
16685997|NCT02043834|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
16685998|NCT02043834|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
16686000|NCT02043821|Experimental|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
16686001|NCT02043808||Dabigatran|
16686002|NCT02043808||Warfarin|
16686003|NCT02043795|Other|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
16686004|NCT02043782|Experimental|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
~First subjects are allocated to Coloplast Test; Secondly to either
~Own product (baseline)
~Competitor soft convex"
16686005|NCT02043782|Experimental|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
~First subjects are allocated to Competitor soft convex; Secondly to either
~Own product (baseline)
~Coloplast Test"
16686006|NCT02043782|Experimental|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
~First subjects are allocated to Own product; Secondly to either
~Coloplast Test
~Competitor soft convex"
16686007|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:
~review routinely collected information;
~conduct questionnaires with caregiver and child;
~conduct additional assessments of child;
~contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and
~conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
16686008|NCT02043756|Experimental|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
16686009|NCT02043756|Active Comparator|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
16686010|NCT02043743|Experimental|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
~Stem Cell Dose:
~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
16686011|NCT02043730|Experimental|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
16686012|NCT02043730|Active Comparator|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
16686013|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
16686014|NCT02043704|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
16686015|NCT02043704|Placebo Comparator|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
16686016|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
16686017|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
16686018|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
16686021|NCT02043665|Experimental|CVA21/pembrolizumab|CVA21/pembrolizumab
16686022|NCT02043652|Experimental|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
16686023|NCT02043626|Experimental|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
16686024|NCT02043626|No Intervention|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
16686025|NCT02043626|Experimental|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
16686026|NCT02043626|Experimental|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
16686027|NCT02043613|Active Comparator|Exercise in standard room|"Intervention: Exercise
~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
16686028|NCT02043613|Experimental|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings
~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
16686029|NCT02043613|No Intervention|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
16686030|NCT02043600|Experimental|Yoga|
16686031|NCT02043600|Active Comparator|Self-care|
16686032|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15
~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2
~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4
~1A-C repeat x1(2A-C) then 3rd Course B (3B)
~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)
~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1
~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)
~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
16686033|NCT02043574|Other|Stretching (Control)|Six months of stretching
16686034|NCT02043574|Experimental|Treadmill Exercise|Six months of treadmill training
16686035|NCT02043561|Sham Comparator|no urge|rectal balloon deflated
16686036|NCT02043561|Experimental|moderate urge|moderate urge induced by rectal balloon
16686037|NCT02043561|Experimental|high urge|high urge induced by rectal balloon
16686038|NCT02043548|Active Comparator|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
16686039|NCT02043548|Placebo Comparator|Group B: Placebo|Placebo arm - no active drug
16686040|NCT02043535|Other|Myocardial blood flow quantification|"The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels.
~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.
~Persantine stress myocardial PET perfusion imaging: as a standard for comparison."
16686041|NCT02043522|Experimental|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
16686042|NCT02043509|Experimental|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
16686043|NCT02043509|No Intervention|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
16686044|NCT02043496|Experimental|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
16686045|NCT02043496|Experimental|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
16686046|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
16686047|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
16686048|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); body composition by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.
16686049|NCT02043444|Experimental|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
16686050|NCT02043444|Active Comparator|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
16686051|NCT02043444|Placebo Comparator|normospermia|20 men with secretory azoospermia will have FDG PET-CT
16686052|NCT02043418||children VIH+|children infected with HIV
16686053|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
16686054|NCT02043405|Experimental|Exercise Training and Weight Loss Intervention|Combination weight loss/exercise training, on insulin sensitivity, muscle lipid composition and localization in skeletal muscle.
16686055|NCT02043405|Active Comparator|4 Month Weight Loss Only Intervention|Use exercise training and weight loss as separate interventions in obese subjects with and without pre-diabetes.
16686056|NCT02043392|Experimental|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
16686483|NCT02040363|Active Comparator|COPD patients ~60-65% VO2max|COPD patients ~60-65% VO2max
16686057|NCT02043379|Experimental|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
16686058|NCT02043379|Placebo Comparator|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
16686059|NCT02043366|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
16686060|NCT02043366|Active Comparator|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
16686061|NCT02043366|Active Comparator|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
16686062|NCT02043366|Active Comparator|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
16686063|NCT02043366|Active Comparator|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
16686064|NCT02043366|Sham Comparator|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
16686065|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
16686066|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
16686067|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
16686068|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
16686069|NCT02043340|Experimental|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
16686070|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
16686071|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
16686072|NCT02043314|Active Comparator|Isoniazida-LAQFA®|3 coated tablet of 100mg
16686073|NCT02043314|Experimental|Isoniazida|coated tablet of 300mg
16686074|NCT02043301|Active Comparator|Single 150 mg PF-04950615 dose administered to the abdomen|
16686075|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the upper arm|
16686076|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the thigh|
16686077|NCT02043288|Experimental|NC-6004 and Gemcitabine combination|NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
16686078|NCT02043288|Active Comparator|Gemcitabine monotherapy|Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
16686079|NCT02043275|Experimental|Leg training|Lower body resistance training only
16686080|NCT02043275|Active Comparator|Arm training|Upper body resistance training only
16686081|NCT02043262|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
16686082|NCT02043262|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
16686083|NCT02043249|No Intervention|CORD MILKING|WITHOUT MILKING
16686084|NCT02043236|Active Comparator|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
16686085|NCT02043236|Active Comparator|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
16686086|NCT02043236|No Intervention|Usual care|Control group gets usual care from their oncologist.
16686087|NCT02043223|Experimental|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
16686088|NCT02043223|Experimental|Late postpartum vitamin A suppl.|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
16686089|NCT02043223|Experimental|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
16686090|NCT02043223|Experimental|No postpartum vitamin A suppl.|Placebo supplementation, both at <3-day and 6-wk postpartum.
16686091|NCT02043210|Active Comparator|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
16686092|NCT02043210|Experimental|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
16694056|NCT01989936|Experimental|Eletriptan 80 mg|
16686093|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
16686094|NCT02043184|Active Comparator|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
16686095|NCT02043184|Experimental|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
16686096|NCT02043184|Experimental|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
16686097|NCT02043184|Experimental|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
16686098|NCT02043171|Placebo Comparator|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
16686099|NCT02043171|Placebo Comparator|Placebo Non-exercise|Placebo supplementation group without exercise
16686100|NCT02043171|Active Comparator|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
16686101|NCT02043171|Active Comparator|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
16686102|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
16686103|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
16686104|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
16686105|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
16686106|NCT02043132|Active Comparator|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
16686107|NCT02043132|Placebo Comparator|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
16686108|NCT02043119|Active Comparator|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
16686109|NCT02043119|No Intervention|Standard of Care|
16686110|NCT02043106|Experimental|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
16686111|NCT02043106|Active Comparator|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
16686112|NCT02043093|No Intervention|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
16686113|NCT02043093|Experimental|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
16686114|NCT02043080|No Intervention|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
16686115|NCT02043080|Experimental|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
16686116|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
16686117|NCT02043054|Experimental|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
16686118|NCT02043054|Active Comparator|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
16686119|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
16686120|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
16686121|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
16686122|NCT02043028|Experimental|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes
~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
16686123|NCT02043028|Experimental|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes
~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
16686124|NCT02043015|Other|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
16686125|NCT02043002|Experimental|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
16686126|NCT02042989|Experimental|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.
~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
16695445|NCT01980758|Experimental|Surgery|Laparoscopic Gastric Plication
16686127|NCT02042976|Experimental|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
16686128|NCT02042976|Active Comparator|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
16686129|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
16686130|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
16686131|NCT02042937|No Intervention|Control|No intervention
16686132|NCT02042937|Experimental|Exercise|Exercise to improve gluteus maximus recruitment
16686133|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
16686134|NCT02042911|Experimental|SyB L-0501|
16686135|NCT02042898|Active Comparator|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is <75 g/L (<7.5 g/dL;<4.7mmol/L) intraoperatively and/or postoperatively
16686136|NCT02042898|Active Comparator|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is <95 g/L (<9.5 g/dL<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or <85 g/L (< 8.5 g/dL;<5.3mmol/L) on the ward.
16686137|NCT02042885|Experimental|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
16686138|NCT02042885|Experimental|2: Regimen A Extension|2: OPB-111001, orally, once weekly
16686139|NCT02042885|Experimental|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
16686140|NCT02042885|Experimental|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
16686141|NCT02042872|Experimental|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
16686142|NCT02042872|No Intervention|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
16686143|NCT02042846|Experimental|SportWelding Fiji Anchor|
16686144|NCT02042833||Cohort|
16686145|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)
~Ophthalmic Examination:
~Tear Break Up Time (TBUT)
~Ocular Surface Disease Index (OSDI)
~Schirmer's II test
~Conjunctival staining with lissamine green
~Corneal staining with fluorescein
~Conjunctival redness assessment"
16686146|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)
~Ophthalmic Examination:
~TBUT
~OSDI
~Schirmer's II test
~Conjunctival staining with lissamine green
~Corneal staining with fluorescein
~Conjunctival redness assessment"
16686147|NCT02042807|Placebo Comparator|Placebo|placebo arm
16686148|NCT02042807|Active Comparator|MCS® 15 mg/day|MCS® soft capsule
16686149|NCT02042807|Active Comparator|MCS® 30 mg/day|MCS® soft capsule
16686150|NCT02042781|Experimental|PG545|Once weekly, one hour IV infusion of PG545.
16686151|NCT02042742|Experimental|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
16686152|NCT02042742|Placebo Comparator|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
16686153|NCT02042729|Experimental|E2022- Tape Formulation|
16686154|NCT02042729|Placebo Comparator|Matching Placebo E2022|Matching Placebo
16686155|NCT02042729|Active Comparator|E2022- New Formulation|
16686156|NCT02042729|Placebo Comparator|Placebo E2022- New Formulation|Matching Placebo
16686157|NCT02042716|Experimental|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
16686158|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
16686159|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
16686160|NCT02042703||cataracts|patients with cataracts
16686161|NCT02042690|Active Comparator|chemotherapy|"Drugs:
~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
16686162|NCT02042690|Experimental|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
16686163|NCT02042664|Experimental|treatment BYETTA|
16686164|NCT02042664|Active Comparator|metformine|
16686165|NCT02042651|Experimental|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
16686166|NCT02042651|Sham Comparator|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
16686167|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
16696395|NCT01974219||Healthy smokers|Healthy smokers
16686168|NCT02042625|Other|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
16686169|NCT02042612|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
16686170|NCT02042599|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
16686171|NCT02042586||Patients|
16686172|NCT02042586||Controls|
16686173|NCT02042573|Other|Depressive patients treated with rTMS|
16686174|NCT02042573|Other|Depressive patients treated with SSRI|
16686175|NCT02042573|Other|Controls|
16686176|NCT02042560||Patients with ITP|
16686177|NCT02042560||Controls|
16686178|NCT02042547||Patients about to undergo heart surgery|
16686179|NCT02042534|Experimental|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
16686180|NCT02042534|Active Comparator|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 [2.0 - 3.0].
16686181|NCT02042521|Experimental|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day
~Interventions: Dietary Supplement, Lactose Placebo"
16686182|NCT02042521|Experimental|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day
~Interventions: Dietary Supplement, Lactose Placebo"
16686183|NCT02042508|Experimental|Paraplegic patients|
16686184|NCT02042495|Experimental|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.
~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
16686185|NCT02042482|Experimental|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
16686186|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
16686187|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
16686188|NCT02042443|Experimental|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16686189|NCT02042443|Experimental|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
16686190|NCT02042430|Experimental|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
16686191|NCT02042417|Experimental|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
16686192|NCT02042404|Experimental|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
16686193|NCT02042391|Experimental|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
16686194|NCT02042391|Experimental|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
16686195|NCT02042391|Experimental|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
16686196|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
16686197|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
16686198|NCT02042352||pH test|VpH test gloves
16686199|NCT02042339|Experimental|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
16686200|NCT02042339|Placebo Comparator|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
16686333|NCT02041325|Placebo Comparator|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
16686201|NCT02042326|Experimental|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.
~The starting dose will be 2 mg per day, and will be adapted every week for one month.
~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
16686202|NCT02042313|Active Comparator|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
16686203|NCT02042313|Experimental|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
16686204|NCT02042300||IRIS-Xpedition/Alpine/Sierra Cohort|XIENCE Xpedition/Alpine/Sierra
16686205|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
16686206|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
16686207|NCT02042274|Experimental|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
16686208|NCT02042248|Experimental|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
16686209|NCT02042248|Experimental|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
16686210|NCT02042235|Experimental|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
16686211|NCT02042235|No Intervention|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk …).
16686212|NCT02042222|Active Comparator|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
16686213|NCT02042222|Active Comparator|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.
~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
16686214|NCT02042196|Experimental|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN
~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
16686215|NCT02042196|Experimental|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN
~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
16686216|NCT02042196|Experimental|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN
~No hormone modification."
16686217|NCT02042183|Experimental|Lubiprostone|Participants receive lubiprostone twice daily (BID) up to 12 weeks
16686218|NCT02042183|Placebo Comparator|Placebo|Participants receive placebo BID up to 12 weeks
16686219|NCT02042170|Experimental|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
16686220|NCT02042170|Experimental|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
16686221|NCT02042170|Active Comparator|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
16686222|NCT02042157|Experimental|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
16686223|NCT02042157|Placebo Comparator|Usual Toileting|This group will toilet as usual.
16686224|NCT02042157|Experimental|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
16686225|NCT02042157|Placebo Comparator|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
16686226|NCT02042144||Group 1|
16686227|NCT02042131|Active Comparator|Treatment As Usual (TAU)|"TAU includes the following intervention components:
~suicide risk assessment
~supportive listening
~provision of professional and crisis contact information
~referral to mental health treatment and community resources
~verbal contract for safety"
16686228|NCT02042131|Experimental|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:
~suicide risk assessment
~supportive listening
~identify personal warning signs
~identify self-management skills
~identify social support contacts
~provision of professional and crisis contact information
~referral to mental health treatment and community resources"
16686229|NCT02042131|Experimental|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:
~suicide risk assessment
~supportive listening
~identify personal warning signs
~identify self-management skills
~identify reasons for living
~identify social support contacts
~provision of professional and crisis contact information
~referral to mental health treatment and community resources"
16686230|NCT02042118|Experimental|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
16686231|NCT02042118|Active Comparator|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
16686232|NCT02042092|Active Comparator|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
16686233|NCT02042092|Active Comparator|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
16686234|NCT02042079|Experimental|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
16686235|NCT02042066|Experimental|Treated Group|This group will receive actual shockwave treatment
16686236|NCT02042053|Experimental|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
16686237|NCT02042027|Active Comparator|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
16686238|NCT02042027|Active Comparator|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
16686239|NCT02042014|Experimental|QTI571|Participants will receive QTI571 during 3 years.
16686240|NCT02042001|Experimental|Immediate Switch|Immediate switch to TDF/FTC/RPV
16686241|NCT02042001|Active Comparator|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
16686242|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
16686243|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
16686244|NCT02041975|Experimental|Prebiotic|Nutriose FB06 14g/day
16686245|NCT02041975|Placebo Comparator|Placebo|Maltodextrin
16686246|NCT02041962|Active Comparator|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
16686247|NCT02041962|Experimental|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
16686248|NCT02041936|Experimental|NanoKnife IRE System|
16686249|NCT02041923|Placebo Comparator|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
16686250|NCT02041923|Experimental|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
16686251|NCT02041910|Experimental|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
16686252|NCT02041910|Experimental|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
16686253|NCT02041897|Other|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
16686254|NCT02041884|Experimental|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
16686255|NCT02041884|Active Comparator|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
16686256|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
16686257|NCT02041871|Experimental|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
16686258|NCT02041871|Placebo Comparator|Placebo|Placebo
16686259|NCT02041858|No Intervention|Control|Control arm with organizational-based alarm parameter settings
16686260|NCT02041858|Experimental|Altered Alarm Settings|Altered set of alarm parameter settings.
16686261|NCT02041845|Active Comparator|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
16686262|NCT02041845|Experimental|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
16686334|NCT02041312||Gastric cancer|No intervention
16696396|NCT01974219||COPD smokers|COPD smokers
16686263|NCT02041832|Other|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
16686264|NCT02041832|Other|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
16686265|NCT02041819|Experimental|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
~Cisplatin: 75mg/m2,IV on days 1，22.
~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.
~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
16686266|NCT02041793|Active Comparator|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
16686267|NCT02041793|Active Comparator|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
16686268|NCT02041780|Experimental|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .
~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
16686269|NCT02041767|Experimental|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
16686270|NCT02041767|Experimental|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
16686271|NCT02041754|Active Comparator|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
16686272|NCT02041754|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
16686273|NCT02041741|Active Comparator|Weekly tips|Daily small and concrete happiness tips
16686274|NCT02041741|Active Comparator|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
16686275|NCT02041741|No Intervention|Wait-List Control|No intervention
16686276|NCT02041715|Experimental|TKM-100802 for Injection|
16686277|NCT02041715|Placebo Comparator|Placebo|
16686278|NCT02041702|Experimental|Cardiac MRI Scan Group|
16686279|NCT02041702|No Intervention|Control Group|
16686280|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.
~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
16686281|NCT02041676|Experimental|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
16686282|NCT02041676|Active Comparator|2: Usual surveillance|Usual surveillance of the non invasive ventilation
16686283|NCT02041663|Experimental|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
16686284|NCT02041650|Other|Patients with ACS treated medically|
16686285|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
16686286|NCT02041611|Other|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
16686287|NCT02041598|Experimental|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
16686288|NCT02041598|No Intervention|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
16686289|NCT02041585||Elder discharge cohort|There will be no intervention in this observational survey research.
16686290|NCT02041572|Other|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
16686291|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
16686292|NCT02041546|Active Comparator|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
16686293|NCT02041546|Active Comparator|Lung lavage with surfactant|Lung lavage with surfactant
16686294|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
16686295|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first
~Squamous subjects:
~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or
~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or
~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle
~Non-Squamous subjects:
~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle
~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle
~Optional crossover:
~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
16686296|NCT02041520|Experimental|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
16686297|NCT02041520|Placebo Comparator|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
16686298|NCT02041507|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
16686335|NCT02041299|Experimental|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.
16686299|NCT02041507|Experimental|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
16686300|NCT02041507|Experimental|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
16686301|NCT02041494|Active Comparator|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
16686302|NCT02041494|Active Comparator|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
16686303|NCT02041481|Experimental|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16686304|NCT02041481|Experimental|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16686305|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
16686306|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
16686307|NCT02041455|Experimental|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
16686308|NCT02041455|Experimental|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
16686309|NCT02041455|Active Comparator|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
16686310|NCT02041442|Experimental|All subjects|Electrical mapping of the urinary bladder
16686311|NCT02041429|Experimental|Phase I Dose Level 0: Paclitaxel + Ruxolitiniib 10 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 10 mg orally twice daily for 4 cycles
~1 cycle = 21 days
~Participants with stable disease or better will have the opportunity to continue on single agent 10 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
16686312|NCT02041429|Experimental|Phase I Dose Level 1: Paclitaxel + Ruxolitiniib 15 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 15 mg orally twice daily for 4 cycles
~1 cycle = 21 days
~Participants with stable disease or better will have the opportunity to continue on single agent 15 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
16686313|NCT02041429|Experimental|Phase I Dose Level 2: Paclitaxel + Ruxolitiniib 20 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 20 mg orally twice daily for 4 cycles
~1 cycle = 21 days
~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
16686314|NCT02041429|Experimental|Phase I Dose Level 3: Paclitaxel + Ruxolitiniib 25 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 25 mg orally twice daily for 4 cycles
~1 cycle = 21 days
~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
16686315|NCT02041416||Group 1|REDCap and paper pencil
16686316|NCT02041416||Group 2|REDCap twice
16686317|NCT02041416||Group 3|Support Screen and paper pencil
16686318|NCT02041416||Group 4|Support Screen twice
16686319|NCT02041403||Renal resistive Index|
16686320|NCT02041390|Experimental|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
16686321|NCT02041390|Active Comparator|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
16686322|NCT02041377|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes used the Karajishi TS Investigational Blood Glucose Monitoring System with no training. The criteria for the intended use population:
~At least 60% of subjects will be younger than age 65
~At least 10% of subjects will have type 1 diabetes"
16686323|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
16686324|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
16686325|NCT02041351|Experimental|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
16686326|NCT02041338|Experimental|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
16686327|NCT02041338|Active Comparator|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
16686328|NCT02041338|Experimental|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
16686329|NCT02041338|Active Comparator|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
16686330|NCT02041338|Experimental|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
16686331|NCT02041338|Active Comparator|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
16686332|NCT02041325|Experimental|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
16686336|NCT02041299|Active Comparator|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.
16686337|NCT02041286|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:
~At least 60% of subjects will be younger than age 65
~At least 10% of subjects will have type 1 diabetes"
16686338|NCT02041273|Experimental|Palbociclib given to healthy volunteers|
16686339|NCT02041260|Experimental|Open Label Cabozantimib|
16686340|NCT02041247|Active Comparator|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
16686341|NCT02041247|Placebo Comparator|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
16686342|NCT02041247|Active Comparator|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
16686343|NCT02041247|Active Comparator|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
16686344|NCT02041234|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
16686345|NCT02041234|Active Comparator|Best Medical Treatment|"Anti-diabetic medications provided (Mono- or Combination- therapy):
~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids & BP medications according to standard of care."
16686346|NCT02041221|Experimental|SPARC1316 Dose 1|Subjects will be administered with SPARC1316 dose 1
16686347|NCT02041221|Placebo Comparator|Placebo|The subjects will receive placebo.
16686348|NCT02041221|Experimental|SPARC1316 Dose 2|Subjects will be administered with SPARC1316 dose 2
16686349|NCT02041221|Experimental|SPARC1316 Dose 3|Subjects will be administered with SPARC1316 dose 3
16686350|NCT02041221|Experimental|SPARC1316 Dose 4|Subjects will be administered with SPARC1316 dose 4
16686351|NCT02041221|Experimental|SPARC1316 Dose 5|Subjects will be administered with SPARC1316 dose 5
16686352|NCT02041195|Active Comparator|RM-493 Once Daily|Once daily in the morning, equivalent PBO in evening.
16686353|NCT02041195|Active Comparator|RM-493 Split Dose|Split dose, one half in the morning and one half in the evening.
16686354|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
16686355|NCT02041182|Experimental|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
16686356|NCT02041182|Active Comparator|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
16686357|NCT02041169|Experimental|Subsequent walking performance|Subsequent walking performance
16686358|NCT02041156|Experimental|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
16686359|NCT02041156|Active Comparator|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
16686360|NCT02041143|Experimental|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
16686361|NCT02041143|Placebo Comparator|Placebo|Placebo (no protein)
16686362|NCT02041130|Experimental|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.
~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
16686363|NCT02041130|No Intervention|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
16686364|NCT02041117|Other|Rosuvastatin|
16686365|NCT02041104|Experimental|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
16686366|NCT02041104|Placebo Comparator|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
16686367|NCT02041091|Experimental|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
16686484|NCT02040363|Placebo Comparator|healthy volunteers|healthy volunteers
16686485|NCT02040350|Placebo Comparator|Placebo|Placebo was given to compare the effects
16686368|NCT02041091|Experimental|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
16686369|NCT02041078|Placebo Comparator|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
16686370|NCT02041078|Experimental|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
16686371|NCT02041065|Experimental|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
16686372|NCT02041065|Active Comparator|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
16686373|NCT02041052|Active Comparator|Conventional Whipple procedure|Conventional Whipple procedure
16686374|NCT02041052|Experimental|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
16686375|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
16686376|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
16686377|NCT02041026|Experimental|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
16686378|NCT02041013|No Intervention|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
16686379|NCT02041013|Experimental|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
16686380|NCT02040987|Experimental|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
16686381|NCT02040987|Experimental|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
16686382|NCT02040987|Placebo Comparator|Placebo|Placebo oral solution
16686383|NCT02040987|Active Comparator|Moxifloxacin|Moxifloxacin tablet
16686384|NCT02040961|Experimental|EtView|Use of ETVew double-lumen tube
16686385|NCT02040948|Experimental|Surgical patients|"Nexfin (Pulse Pressure Variation)
~Radical 7 (Pleth Variability Index)
~CardioQ (stroke volume)"
16686386|NCT02040935|Experimental|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
16686387|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
16686388|NCT02040909|Experimental|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
16686389|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
16686390|NCT02040883|Active Comparator|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
16686391|NCT02040883|Experimental|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
16686392|NCT02040870|Experimental|LDK378|daily dosing, 28-day cycle patients
16686393|NCT02040857|Experimental|Palbociclib With Adjuvant Endocrine Therapy|"Palbociclib 125 mg PO qd 21 days on, 7 days off
~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
16686394|NCT02040844|Other|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762].No further treatment received in CP007A
16686395|NCT02040844|Other|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762].No further treatment received in CP007A.
16686396|NCT02040844|Other|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]. No further treatment received in CP007A.
16686397|NCT02040831|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
16686398|NCT02040831|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
16686399|NCT02040818|Experimental|Antibiotic Lock Solution|
16686400|NCT02040818|Active Comparator|Guide-wire Exchange|
16686401|NCT02040805|Experimental|Group Cognitive-Behavioral Therapy|Sixteen sessions of group therapy facilitated by a psychologist.
16686402|NCT02040805|Experimental|Peer Facilitated Support Group|Fifteen sessions of peer-facilitated group support.
16686403|NCT02040792|Placebo Comparator|Placebo|Placebo
16686404|NCT02040792|Experimental|44 mcg|TD-4208
16686405|NCT02040792|Experimental|88 mcg|TD-4208
16686406|NCT02040792|Experimental|175 mcg|TD-4208
16686407|NCT02040792|Experimental|350 mcg|TD-4208
16686408|NCT02040779|Experimental|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
16686409|NCT02040779|Experimental|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
16686410|NCT02040779|Placebo Comparator|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
16686411|NCT02040766|Experimental|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).
~Placebo MDI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
16686439|NCT02040662|Experimental|Continuous Thoracic Paravertebral Block|"continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000
~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
16686412|NCT02040766|Experimental|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).
~Placebo MDI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
16686413|NCT02040766|Active Comparator|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).
~Placebo BAI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
16686414|NCT02040766|Active Comparator|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).
~Placebo BAI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
16686415|NCT02040766|Placebo Comparator|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
16686416|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
16686417|NCT02040740||Observation|Healthy early pubertal boys
16686418|NCT02040727|Active Comparator|Non-Resistance Trained|No Participation in Resistance Training
16686419|NCT02040727|Experimental|Resistance Trained|Participation in Resistance Training
16686434|NCT02040701||SDB group|
16686435|NCT02040701||Control group|
16686436|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
16686437|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
16686438|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
16686481|NCT02040376|Experimental|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
16686440|NCT02040662|Experimental|Continuous Thoracic Epidural Analgesia|"continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000
~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
16686441|NCT02040649|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
16686442|NCT02040649|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
16686443|NCT02040636|Experimental|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
16686444|NCT02040636|Active Comparator|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
16686445|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
16686446|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
16686447|NCT02040623|Placebo Comparator|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
16686448|NCT02040610|Active Comparator|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
16686449|NCT02040610|Active Comparator|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
16686451|NCT02040584|Experimental|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
16686452|NCT02040584|Active Comparator|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
16686453|NCT02040571|Experimental|Closed Loop|
16686454|NCT02040571|Active Comparator|Open Loop|
16686455|NCT02040558|Experimental|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
16686456|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
16686457|NCT02040532|Experimental|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
16686458|NCT02040519|Experimental|Evaluation by voiding diaries|
16686459|NCT02040506|Experimental|IGN523|IGN523
16686460|NCT02040493|Experimental|Intra-operative radiation therapy (IORT)|IORT
16686461|NCT02040480|Experimental|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
16686462|NCT02040480|Experimental|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
16686463|NCT02040480|Experimental|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
16686464|NCT02040480|Experimental|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
16686465|NCT02040480|Experimental|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
16686466|NCT02040480|Experimental|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
16686467|NCT02040454|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent
~Paclitaxel - single intravascular dose up to 20 mg"
16686468|NCT02040454|Sham Comparator|Standard Therapy Alone|heparin, angioplasty, stent
16686469|NCT02040441|Active Comparator|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
16686470|NCT02040441|Placebo Comparator|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
16686471|NCT02040441|Other|Observational|Low-risk pattern: Standard care
16686472|NCT02040428|Experimental|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
16686473|NCT02040428|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
16686474|NCT02040415|Experimental|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
16686475|NCT02040415|Active Comparator|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
16686476|NCT02040402|Active Comparator|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:
~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.
~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
16686477|NCT02040402|Active Comparator|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:
~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.
~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
16686478|NCT02040389|Active Comparator|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
16686479|NCT02040389|Active Comparator|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
16686480|NCT02040376|Experimental|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
16686486|NCT02040350|Active Comparator|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
16686487|NCT02040324|Active Comparator|Endotracheal Intubation|Clinical routine for longer lasting procedures
16686488|NCT02040324|Experimental|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
16686489|NCT02040311|Experimental|Topiramate 96 mg daily|
16686490|NCT02040311|Experimental|Topiramate 192 mg daily|
16686491|NCT02040311|Placebo Comparator|placebo|
16686494|NCT02040285|Active Comparator|Free laxative CTC|
16686495|NCT02040285|Experimental|Low-dose laxative bowel preparation for CTC|
16686496|NCT02040272|Experimental|Surgery|(Extended) pleurectomy decortication
16686497|NCT02040272|No Intervention|no surgery|no surgery
16686498|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
16686499|NCT02040246|Experimental|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
16686500|NCT02040246|Active Comparator|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
16686501|NCT02040233|Active Comparator|BAY1067197 (10 mg)|
16686502|NCT02040233|Active Comparator|BAY1067197|
16686503|NCT02040233|Placebo Comparator|Placebo (10 mg)|
16686504|NCT02040233|Placebo Comparator|Placebo|
16686505|NCT02040220||Group 1|Eylea treatment goup
16686506|NCT02040207|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
16686507|NCT02040194|Experimental|AM-101 injection|AM-101
16686508|NCT02040194|Placebo Comparator|Placebo injection|Placebo
16686509|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
16686510|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
16686511|NCT02040155|Experimental|Real time dosimetric monitoring of brachytherapy.|
16686512|NCT02040142|Experimental|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
16686513|NCT02040129|Experimental|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
16686514|NCT02040116|Other|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
16686515|NCT02040103|Experimental|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
16686516|NCT02040103|No Intervention|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
16686517|NCT02040090|Experimental|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
16686518|NCT02040090|Active Comparator|FDA approved HRIG product|Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB.
16686519|NCT02040077|Experimental|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
16686520|NCT02040077|Active Comparator|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
16686521|NCT02040077|Active Comparator|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
16686522|NCT02040064|Experimental|Treatment|"Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)
~Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)
~Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
16686523|NCT02040051|Active Comparator|GROUP A: Sound isolation / Music therapy|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit
~INTERVENTION: Second hour. Sound isolation
~INTERVENTION: Third hour. Music therapy
~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
16686524|NCT02040051|Active Comparator|GROUP B: Music therapy / Sound isolation|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit
~INTERVENTION: Second hour. Music therapy
~INTERVENTION: Third hour. Sound isolation
~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
16686525|NCT02040038|Experimental|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
16686526|NCT02040038|Active Comparator|Website|Participation in 2D website for DSMT/S for a period of 12 months.
16686527|NCT02040012|Active Comparator|AZP-531|subcut administration once or twice daily
16686528|NCT02040012|Placebo Comparator|Mannitol|subcut administration once or twice daily
16686529|NCT02039999|Experimental|Chronic cough|"Cough challenges to be administered include:
~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
16686530|NCT02039999|Active Comparator|Normal volunteer|"Cough challenges to be administered include:
~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
16686532|NCT02039973|Experimental|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
16686533|NCT02039973|Active Comparator|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
16686534|NCT02039960||DAWN cases including all prescription drugs|This group will consist of all DAWN cases where prescription drugs are mentioned.
16686535|NCT02039960||All bupropion cases (including use of other drugs)|This group will consist of all DAWN cases where bupropion is mentioned and is a subset of Group 1.
16686536|NCT02039960||Burpropion Only Cases|This group will consist of all DAWN cases where burpropion is specifically the only drug mentioned within the case report, and is a subset of Group 2.
16686537|NCT02039947|Experimental|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
16686538|NCT02039947|Experimental|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
16686539|NCT02039947|Experimental|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
16686540|NCT02039947|Experimental|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
16686541|NCT02039934|Experimental|high intensity interval training|
16686542|NCT02039908|Active Comparator|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
16686543|NCT02039908|Active Comparator|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
16686544|NCT02039895|Experimental|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
16686545|NCT02039882||Controls/Normals|control subjects without known cardiac disease, age ± 5 years and sex matched
16686546|NCT02039882||Acute Coronary Syndrome requiring Percutaneous Intervention|Subjects presenting to ER with Acute chest pain requiring cardiac catheterization
16686547|NCT02039882||Acute Coronary Syndrome, no intervention|Acute Coronary Syndrome, not requiring Percutaneous intervention
16686548|NCT02039869|Experimental|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
16686549|NCT02039869|Experimental|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
16686550|NCT02039856|Experimental|EBQI-Supported WH-PACT Implementation|Evidence-based Quality Improvement (EBQI) is a structured research-clinical partnership approach to facilitating implementation of new care models, including multilevel stakeholder engagement, quality improvement (QI) education/training, technical support, formative feedback, external practice facilitation, and national policy guidance.
16686551|NCT02039856|Active Comparator|Routine WH-PACT Implementation|National policy guidance
16686552|NCT02039843|Active Comparator|1|Emotional Support Dogs
16686553|NCT02039843|Active Comparator|2|Service Dogs
16686554|NCT02039830|Experimental|Group physiotherapy|12 weekly treatment visit + daily home exercise program
16686555|NCT02039830|Active Comparator|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
16686556|NCT02039817|Experimental|Healthy Volunteers|All subjects receive a single 50 mg oral dose of IDN-6556
16686557|NCT02039817|Experimental|Severe Renal Impairment|All subjects receive a single 50 mg oral dose of IDN-6556
16686558|NCT02039804|Experimental|Hyaluronic acid|Injectable hyaluronic acid.
16686559|NCT02039804|Active Comparator|Corticosteroids|Injectable corticosteroids.
16686560|NCT02039791|Experimental|Nimotuzumab plus chemoradiotherapy|
16686561|NCT02039778|Experimental|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.
~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy [IMPT] preferred) is an acceptable treatment modality.
~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
16686562|NCT02039765|Experimental|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
16686563|NCT02039752||Multivessel|from 1995
16686564|NCT02039739||Orsiro™ Drug Eluting Stent|
16686565|NCT02039726|Experimental|Quizartinib|Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.
16686602|NCT02039596|Experimental|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
16686919|NCT02037724|Experimental|iron rich food supplement (10 mg iron)|contains 10 mg of iron
16686566|NCT02039726|Active Comparator|Salvage chemotherapy|Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.
16686567|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
16686568|NCT02039700|Experimental|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of [14C]lesinurad
16686569|NCT02039687|Experimental|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
16686570|NCT02039687|Experimental|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
16686571|NCT02039687|Experimental|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
16686572|NCT02039687|Placebo Comparator|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
16686573|NCT02039674|Experimental|Part1 CohortA2 (Pembro2mg/kg+Paclitaxel [Pa]+Carboplatin [C])|Cohort A participants receive pembrolizumab (2 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (Aare Under the Curve [AUC] 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
16686574|NCT02039674|Experimental|Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B])|Cohort B2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
16686575|NCT02039674|Experimental|Part 1 Cohort C2 (Pembro 2mg/kg+Pemetrexed [Pe]+C)|Cohort C2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
16686576|NCT02039674|Experimental|Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
16686577|NCT02039674|Experimental|Part 1 Cohort E (Pembro 2mg/kg+Erlotinib)|Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral tablet once a day on every day of each 3-week cycle.
16686578|NCT02039674|Experimental|Part 1 Cohort F (Pembro 2mg/kg+Gefitinib)|Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via oral tablet once a day on every day of each 3-week cycle.
16686579|NCT02039674|Experimental|Part 2 Cohort G+ (Pembro 200mg+C+Pe)|Cohort G+ participants receive pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle.
16686580|NCT02039674|Experimental|Part 2 Cohort H (Pembro+I)|Cohort H participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle (at the recommended Phase II dose determined in Cohort D).
16686581|NCT02039674|Experimental|Part 1 Cohort A10 (Pembro+Paclitaxel [Pa]+Carboplatin [C])|Cohort A10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
16686582|NCT02039674|Experimental|Part 1 Cohort B10 (Pembro+Pa+C+Bevacizumab [B])|Cohort B10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
16686583|NCT02039674|Experimental|Part 1 Cohort C10 (Pembro 10mg/kg+Pemetrexed [Pe]+C)|Cohort C10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
16686584|NCT02039674|Experimental|Part 2 Cohort G- (Placebo+C+Pe)|Cohort G- participants receive placebo (normal saline solution) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS.
16686585|NCT02039674|Experimental|Part 1 Cohort D2 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D2 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
16686586|NCT02039674|Experimental|Part 1 Cohort D4 (Pembro 2mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
16686587|NCT02039661|Active Comparator|Lidocaine Spray|
16686588|NCT02039661|Placebo Comparator|Placebo|These patients received placebo spray.
16686589|NCT02039648|Active Comparator|Rumex acetosa L. extract|Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days
16686590|NCT02039648|Placebo Comparator|Placebo|Placebo mouthrinse, 10 ml, tid, 3 min, 7 days
16686591|NCT02039635|Experimental|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.
~Intervention: Dietary Supplement: Korean Red Ginseng"
16686592|NCT02039635|Placebo Comparator|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.
~Intervention: Other: Placebo"
16686593|NCT02039622||Patient under study condition|Patient under study condition
16686594|NCT02039609||Omnivores|No intervention, habitual diet
16686595|NCT02039609||Vegetarians|No intervention, habitual diet
16686596|NCT02039609||Vegans|No intervention, habitual diet
16686597|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
16686598|NCT02039596|Experimental|vegetarian breakfast|Diet: Vegetarian food items
16686599|NCT02039596|Experimental|Swedish Breakfast|Diet: Swedish food items
16686600|NCT02039596|Experimental|English breakfast|Diet: English food items
16686601|NCT02039596|Experimental|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
16686603|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
16686604|NCT02039570||haemorrhoids|The cohort contains only patients with symptomatic haemorrhoids - these patients will receive a transvaginal scan to examine their ovarian and internal iliac veins to ascertain whether there is any reflux
16686605|NCT02039557||NiCord®/CordIn™ transplanted|Anyone who signed the consent for this study received a NiCord®/CordIn™ infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
16686606|NCT02039544|Experimental|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
16686607|NCT02039544|Placebo Comparator|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
16686608|NCT02039531|Experimental|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.
~Procedure for the application of the treatment:
~1. Study Group or PRGF group
~Blood sample :
~Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.
~20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.
~Spinning of the sample:
~8 minutes at 1800 rpm .
~getting the blood fraction containing the PRGF
~activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.
~the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
16686609|NCT02039531|Active Comparator|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
16686610|NCT02039518|Experimental|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
16686611|NCT02039518|Other|observation group|observation
16686612|NCT02039505|Placebo Comparator|Induction Phase: Cohort 1, Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
16686613|NCT02039505|Experimental|Induction Phase: Cohort 1, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
16686614|NCT02039505|Experimental|Induction Phase: Cohort 2, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
16686615|NCT02039505|Experimental|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
16686616|NCT02039505|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
16686617|NCT02039505|Placebo Comparator|Maintenance Phase: Placebo continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
16686618|NCT02039505|Experimental|Open-Label Cohort: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
16686619|NCT02039492|Experimental|A|Denervation
16686620|NCT02039492|Active Comparator|B|Treatment with aldactone
16686621|NCT02039479|Placebo Comparator|TAU + Placebo|Treatment as Usual + Placebo
16686622|NCT02039479|Active Comparator|TAU + Lithium|Treatment as Usual + Lithium
16686623|NCT02039466|Active Comparator|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
16686624|NCT02039466|Active Comparator|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
16686625|NCT02039453|Experimental|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
16686626|NCT02039453|Active Comparator|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
16686627|NCT02039440|Other|Single arm|1 blood draw
16686628|NCT02039427|Placebo Comparator|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
16686629|NCT02039427|Active Comparator|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
16686630|NCT02039427|Active Comparator|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
16686631|NCT02039427|Active Comparator|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
16686632|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
16686633|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising >150min/week
16686634|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
16686635|NCT02039388|Other|High risk patients for breast and/or ovarian cancer|
16686636|NCT02039375|Experimental|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
16686637|NCT02039362|Other|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
16686638|NCT02039336|Experimental|Dacomitinib + PD-0325901|Dacomitinib: oral tablets PD-0325901: oral capsules
16686639|NCT02039323|Experimental|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
16686640|NCT02039310||≥ 65 years / opts for radical cystectomy|
16686641|NCT02039297|Other|No Intervention: Baseline arm|Pre and post design (same arm)
16686642|NCT02039284|Experimental|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
16686643|NCT02039284|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
16686644|NCT02039284|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
16686645|NCT02039284|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
16686646|NCT02039271|No Intervention|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
16686647|NCT02039271|Experimental|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
16686648|NCT02039258|Experimental|Sequence AB|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
16686649|NCT02039258|Experimental|Sequence BA|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
16686650|NCT02039245|Experimental|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
16686651|NCT02039232|Experimental|CarboFix Pedicle Screw System|
16686652|NCT02039219|Placebo Comparator|Placebo|Placebo
16686653|NCT02039219|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
16686654|NCT02039206|Experimental|Treatment|Deep TMS
16686655|NCT02039193|Experimental|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger & Grosse-Holtforth, 2008).
~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
16686656|NCT02039193|Experimental|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
16686657|NCT02039193|Experimental|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
16686658|NCT02039180|Experimental|AZD3293 oral solution|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
16686659|NCT02039180|Experimental|AZD3293 tablet formulation A|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
16686660|NCT02039180|Experimental|AZD3293 tablet formulation B|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
16686661|NCT02039167|Active Comparator|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
16686662|NCT02039167|No Intervention|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
16686663|NCT02039154|Experimental|Aerobic and strength training group|
16686664|NCT02039154|Active Comparator|Balance and flexibility group|
16686665|NCT02039141|Experimental|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
16686666|NCT02039141|No Intervention|Delayed ELSC Intervention Group|Control group (delayed intervention group)
16686667|NCT02039128|Experimental|Krill oil|1 gram per day in 12 weeks
16686668|NCT02039128|Active Comparator|Fish oil|1 gram per day in 12 weeks
16686669|NCT02039128|Placebo Comparator|Placebo|1 gram per day in 12 weeks
16686670|NCT02039115|Experimental|prednisone|Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
16686671|NCT02039115|Placebo Comparator|placebo|Placebo tablets will be taken in the same manner as the prednisone arm.
16686672|NCT02039102||Non-users of hormonal contraceptives|
16686673|NCT02039102||Users of hormonal contraceptives|
16686674|NCT02039089|Experimental|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
16686675|NCT02039089|Experimental|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
16686676|NCT02039089|Placebo Comparator|3|E2006-matched placebo tablets
16686677|NCT02039076|Experimental|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
16686678|NCT02039063|Experimental|1|E6011 2 mg/kg
16686679|NCT02039063|Experimental|2|E6011 5 mg/kg
16686680|NCT02039063|Experimental|3|E6011 10 mg/kg
16686682|NCT02039050|Active Comparator|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
16686683|NCT02039050|Experimental|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
16686684|NCT02039037|Active Comparator|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
16686685|NCT02039037|Active Comparator|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
16686686|NCT02039024|Experimental|18F- DTBZ for Parkinson's Disease|"This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.
~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
16686687|NCT02039011|Active Comparator|Indacaterol|
16686688|NCT02039011|Experimental|Indacaterol & tiotropium|
16686692|NCT02038985|Other|+ ICG Dye (Firefly)|Participants will receive ICG Dye
16686693|NCT02038972|Experimental|Autologous Stem Cells|A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
16686694|NCT02038959|No Intervention|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
16686695|NCT02038959|Experimental|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
16686696|NCT02038946|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
16686697|NCT02038933|Experimental|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
16686698|NCT02038920|Experimental|Induction Phase: Vedolizumab, 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
16686699|NCT02038920|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
16686700|NCT02038920|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
16686701|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
16686702|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo Continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
16686703|NCT02038920|Experimental|Open-Label: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
16686704|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
16686705|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
16686706|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
16686707|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
16686878|NCT02037984|Experimental|Infant V114: 2x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
16686708|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
16686709|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
16686710|NCT02038907|Experimental|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
16686711|NCT02038907|Experimental|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
16686712|NCT02038907|Experimental|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
16686713|NCT02038907|Experimental|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
16686714|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
16686715|NCT02038907|Experimental|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
16686716|NCT02038907|Experimental|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
16686717|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
16686718|NCT02038894|Active Comparator|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
16686719|NCT02038894|Active Comparator|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
16686720|NCT02038894|Active Comparator|Native Airway - no intubation|Anesthetic technique during (EGD)
16686721|NCT02038881|Experimental|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
16686722|NCT02038881|Experimental|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
16686723|NCT02038881|Experimental|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
16686724|NCT02038868|Experimental|ASP4901 group|After the main enrollment, patients will receive an oral dose of ASP4901 once daily for 4 weeks (double-blind treatment period).
16686725|NCT02038868|Placebo Comparator|Placebo group|After the main enrollment, patients will receive an oral dose of placebo once daily for 4 weeks (double-blind treatment period).
16686726|NCT02038868|Active Comparator|Tamsulosin group|After the main enrollment, patients will receive an oral dose of tamsulosin once daily for 4 weeks (double-blind treatment period).
16686727|NCT02038855|Active Comparator|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
16686728|NCT02038855|No Intervention|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
16686729|NCT02038842|Experimental|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
16686730|NCT02038842|Experimental|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
16686731|NCT02038842|Experimental|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
16686732|NCT02038842|Experimental|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
16686733|NCT02038829|Placebo Comparator|Placebo|Placebo bid
16686734|NCT02038829|Experimental|SUN-101 3 mcg|SUN-101 3 mcg bid
16686735|NCT02038829|Experimental|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
16686736|NCT02038829|Experimental|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
16686737|NCT02038829|Experimental|SUN-101 50 mcg|SUN-101 50 mcg bid
16686738|NCT02038829|Active Comparator|Aclidinium 400 mcg|Aclidinium 400 mcg bid
16686739|NCT02038816|Experimental|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
16686740|NCT02038816|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
16686741|NCT02038803||Adults- Cystic Fibrosis|Adults with cystic fibrosis who have respiratory colonization with Pseudomonas Aeruginosa. The actual study will involve instructing adult patients with CF on the use of a new form of Tobramycin for inhalation (powder) and then assessing this new form of TOBI podhaler vs the old TOBI solution related to patient preference on use, time involved in taking the new medication vs the old, and impact on their pulmonary function and subsequent exacerbation rate plus quality of life.
16686742|NCT02038790|Experimental|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
16686743|NCT02038790|Active Comparator|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
16686744|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
16686745|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
16686746|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
16686747|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
16686748|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
16686749|NCT02038777|Experimental|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
16686750|NCT02038764|Placebo Comparator|Placebo|Placebo
16686751|NCT02038764|Experimental|PF-06342674|
16686752|NCT02038751||Index proband|moderate to severe OSA (AHI>30 or AHI>15 needing CPAP intervention) age 20-99 y/o
16686753|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age >20 y/o
16686754|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age > 20 y/o
16686755|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age >20 y/o
16686756|NCT02038738|Experimental|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
16686757|NCT02038725||TIA in last 2 weeks|
16686758|NCT02038712|Experimental|Binge eating disorder (BED)|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who meet the current criteria for binge eating disorder (BED) in the fed condition and fasted condition.
16686759|NCT02038712|Experimental|Control|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who do not meet the current criteria for BED (Controls) in the fed condition and fasted condition.
16686760|NCT02038699|Experimental|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
16686761|NCT02038686|Active Comparator|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
16686762|NCT02038686|Active Comparator|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
16686763|NCT02038673|Experimental|Dose escalation part 0.5 mg QD|Oral
16686764|NCT02038673|Experimental|Dose escalation part 1.0 mg QD|Oral
16686765|NCT02038673|Experimental|Dose escalation part 2.0 mg QD|Oral
16686766|NCT02038673|Experimental|Dose escalation part 2.0 mg BID|Oral
16686767|NCT02038673|Experimental|Dose escalation part 4.0 mg BID|Oral
16686768|NCT02038673|Experimental|Dose escalation part 6.0 mg BID|Oral
16686769|NCT02038673|Experimental|Dose escalation part 10.0 mg BID|Oral
16686770|NCT02038673|Experimental|Dose escalation part 20.0 mg BID|Oral
16686771|NCT02038673|Experimental|Dose escalation part 16.0 mg BID|Oral
16686772|NCT02038673|Experimental|Expansion part Urothelial Carcinoma|Oral
16686773|NCT02038673|Experimental|Expansion part Hepatocellular Carcinoma|Oral
16686774|NCT02038673|Experimental|Expansion part Squamous Cell Lung Carcinoma|Oral
16686775|NCT02038660||Patients with coronary artery disease|
16686776|NCT02038647|Experimental|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
16686777|NCT02038647|Placebo Comparator|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).
16686778|NCT02038634|Active Comparator|Unguided injections|Corticosteroid injection (betamethasone) without ultrasound guidance.
16686779|NCT02038634|Active Comparator|Ultrasound-guided injections|Corticosteroid injections (betamethasone) under ultrasound guidance.
16686780|NCT02038621|Experimental|A|Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance.
16686781|NCT02038621|Placebo Comparator|B|Observation until progression
16686782|NCT02038608|Experimental|PET|
16686783|NCT02038595|Experimental|Healthy subjects|Healthy subjects (male, female)
16686784|NCT02038582|Active Comparator|POC CD4 & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and follow up with clinic accompaniment
16686785|NCT02038582|Active Comparator|POC CD4 & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and lay counselor follow up
16686786|NCT02038582|Active Comparator|POC CD4 & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and referral to clinic
16686787|NCT02038582|Active Comparator|CD4 Referral & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and follow up with clinic accompaniment
16686788|NCT02038582|Active Comparator|CD4 Referral & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and lay counselor follow up
16686789|NCT02038582|Active Comparator|CD4 Referral & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and referral to clinic
16686790|NCT02038582|Active Comparator|Circumcision - SMS Reminder|HIV negative uncircumcised males, randomized to SMS reminder for male circumcision
16686791|NCT02038582|Active Comparator|Circumcision - Lay Counselor|HIV negative uncircumcised males, randomized to lay counselor follow-up for male circumcision
16686792|NCT02038582|Active Comparator|Circumcision - Promotion|HIV negative uncircumcised males, randomized to promotion of male circumcision at the time of HIV testing
16686793|NCT02038582|Active Comparator|POC VL|HIV positive persons on ART, randomized to POC viral load testing
16686794|NCT02038582|Active Comparator|Laboratory based VL assay|HIV positive persons on ART, randomized to laboratory based viral load testing
16686795|NCT02038569|Experimental|LEO 80185 gel|
16686796|NCT02038556|Experimental|cognitive behaviorial therapy for insomnia group program|Behavioral
16686879|NCT02037984|Experimental|Infant V114: 2x:2x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
16696614|NCT01972737|Experimental|Ad5-hGCC-PADRE Vaccine|Active vaccine
16686797|NCT02038543|Experimental|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
16686798|NCT02038530||No Ultrasound|Low Clinical Pretest Probability and D-dimer < 1000 ug/L; Moderate Clinical Pretest Probability and D-dimer < 500 ug/L
16686799|NCT02038530||Ultrasound Required|Low Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; Moderate Clinical Pretest Probability and D-dimer 500 - 3000 ug/L; High Clinical Pretest Probability
16686800|NCT02038504||gastrointestinal fistula|
16686801|NCT02038491||regional anesthesia|patients undergoing regional anesthesia procedures
16686802|NCT02038478|Experimental|Transplantation Arm|"Transplantation
~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
16686803|NCT02038465|Other|patient|Complete questionary remembering the day
16686804|NCT02038465|Other|healthy volunteers|- Complete questionary, remembering the day
16686805|NCT02038452|Active Comparator|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
16686806|NCT02038452|Active Comparator|Wrist Splint|Wrist splint to be worn at night
16686807|NCT02038439|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, clinicians will be offered all 3 online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
16686808|NCT02038439|Experimental|Interventions A + B|"See Interventions Description. In this arm, clinicians will be offered the 2 following interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach"
16686809|NCT02038439|Experimental|Interventions A + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention C - Online Audit and Feedback"
16686810|NCT02038439|Experimental|Interventions B + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
16686811|NCT02038439|Experimental|Intervention A alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:
~* Intervention A - Online Clinical Questions Recorder"
16686812|NCT02038439|Experimental|Intervention B alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:
~* Intervention B - Online Evidence Retrieval Coach"
16686813|NCT02038439|Experimental|Intervention C alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:
~* Intervention C - Online Audit and Feedback"
16686814|NCT02038439|No Intervention|No intervention|In this arm, clinicians will be offered non of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
16686815|NCT02038426|Experimental|the patients with SpA|
16686816|NCT02038426|Experimental|sports subjects|
16686817|NCT02038426|Other|control subjects|
16686818|NCT02038413||NSCLC stage I|Consecutive patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All patients received respiratory gated CT (4DCT) scans. All were patients referred for primary radiotherapy or chemo radiation.
16686819|NCT02038400|Experimental|group A|KINETUBE medical Device
16686820|NCT02038400|Active Comparator|group B|insertion of tympanic ventilation tubes (tympanostomy)
16686821|NCT02038387|Experimental|Diet|
16686822|NCT02038374|Experimental|severe asthma atopic|
16686823|NCT02038374|Experimental|asthma non atopic|
16686824|NCT02038361|Experimental|blood sample|
16686825|NCT02038348|Other|PET with 18F-FDOPA|
16686826|NCT02038335||DMPA|Depot medroxyprogesterone acetate
16686827|NCT02038335||NET-EN|Norethisterone enantate
16686828|NCT02038335||MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
16686829|NCT02038335||LNG-I|Levonorgestrel subdermal implant
16686830|NCT02038335||ENG-I|Etonogestrel subdermal implant
16686831|NCT02038335||Cu-IUD|Copper IUD
16686832|NCT02038322|No Intervention|The Stork|Device - The Stork - complete kit (Conceptacle and Applicator)
16686833|NCT02038296|Experimental|Group 1|Group 1 received single-drug (doxorubicin)transarterial chemoembolization.
16686834|NCT02038296|Experimental|Group 2|Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization
16686835|NCT02038296|Experimental|Group 3|Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.
16686836|NCT02038283||Low-risk Colorectal Polyps|≤2 adenomas or 3-4 adenomas all of which are <1cm
16686837|NCT02038283||High-risk Colorectal Polyps|≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
16686838|NCT02038283||Stage I CRC|at least six months since diagnosis of Stage I CRC
16686839|NCT02038283||Stage II CRC|at least six months since diagnosis of Stage II CRC
16686840|NCT02038283||Stage III CRC|at least six months since diagnosis of Stage III CRC
16686841|NCT02038283||Stage IV CRC|at least six months since diagnosis of Stage IV CRC
16686842|NCT02038270||surgical patients|120 Adult patients, that are having a routine surgical procedure.
16686843|NCT02038257|Active Comparator|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
16686844|NCT02038257|Active Comparator|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
16686880|NCT02037984|Experimental|Infant V114: 0.5x:0.5x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
16686845|NCT02038257|Active Comparator|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
16686846|NCT02038257|Active Comparator|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
16686847|NCT02038244|Experimental|Integrative Medicine|
16686848|NCT02038231|Experimental|Parenting Mindfully Program|Mindfulness program for parents of adolescents provided for 2 hours once per week for 8 weeks.
16686849|NCT02038231|Active Comparator|Parent Education Program|Group for parents of adolescents providing handouts and brief education to parents on topics of adolescence, family relations, and risk behaviors. Group meets 3 times over the course of 8 weeks for about 15 minutes per meeting.
16686850|NCT02038218|Experimental|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:
~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;
~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.
~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
16686851|NCT02038192|Experimental|Living with Hope Program|"All participants in this group will receive the Living with Hope Program. It consists of viewing a 15 minute film on hope. Then for 5 minutes at the end of each day to write Stories of the Presentto work on over one month. Stories of the present is a directed journaling activity which includes writing challenges of the day, what was their hope that day and what would be their hope tomorrow."
16686852|NCT02038192|Experimental|Stories of the Present|Participants in this group will write Stories of the Present and not see the film.
16686853|NCT02038192|No Intervention|Usual Care|Participants in this group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
16686854|NCT02038179|Experimental|Allopurinol, Then Placebo|Participants will be asked to take 4 weeks of allopurinol (300 mg oral per day), then will crossover (after 2-4 week washout period) and take placebo for an additional 4 weeks.
16686855|NCT02038179|Experimental|Placebo, Then Allopurinol|Participants will be asked to take 4 weeks of placebo, then will crossover (after 2-4 week washout period) and take allopurinol (300 mg oral per day) for an additional 4 weeks.
16686856|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
16686857|NCT02038140|Other|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
16686858|NCT02038114|Experimental|Instructed to read pamphlets|This group will be instructed to read patient education pamphlets.
16686859|NCT02038101|Experimental|Education and Feedback Intervention|"This intervention includes the following components:
~Formal Rounds on AUC for TTE:
~Appropriate Use for TTE Application for Smartphone
~Individualized Feedback Reports provided by email"
16686860|NCT02038101|No Intervention|Control|Usual echocardiography ordering pratice.
16686861|NCT02038088||A|intravenous inhalational anesthesia
16686862|NCT02038088||B|intravenous anesthesia
16686863|NCT02038075|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
16686864|NCT02038075|Active Comparator|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
16686865|NCT02038062|Experimental|Sevoflurane|Sevoflurane Preconditioning
16686866|NCT02038062|No Intervention|No Sevoflurane|No Sevoflurane Preconditioning
16686867|NCT02038049|Experimental|VAY736|Intravenous infusion of VAY736
16686868|NCT02038049|Placebo Comparator|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
16686869|NCT02038036|Experimental|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
16686870|NCT02038036|Active Comparator|Best Available Therapy (BAT)|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
16686871|NCT02038023|Other|IV iron|Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.
16686872|NCT02038010|Experimental|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16686873|NCT02037997|Experimental|combination with Erlotinib|Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2
16686874|NCT02037997|Active Comparator|sequential chemotherapy for Erlotinib|docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd
16686875|NCT02037984|Experimental|Adult V114: 1x:1x:1x|Adults receive a single vaccination on Day 1.
16686876|NCT02037984|Experimental|Adult V114: 2x:2x:2x|Adults receive a single vaccination on Day 1.
16686877|NCT02037984|Experimental|Infant V114: 1x:1x:1x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
16686881|NCT02037984|Experimental|Infant V114: 1x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
16686882|NCT02037984|Active Comparator|Infant Prevnar 13®|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
16686883|NCT02037971|Experimental|Aerobic Exercise|Subjects will follow one defined exercise process, according their cardiopulmonary exercise test, during 16 weeks, two times per a week.
16686884|NCT02037971|Experimental|Control Group|A non-exercise group will receive regular educational information relating to their condition.
16686885|NCT02037958|Experimental|Laryngeal Mask Airway-Supreme|Patients who are randomly assigned to receive the LMA-Supreme
16686886|NCT02037958|Active Comparator|Endotracheal Tube|Patients who are randomly assigned to receive endotracheal intubation
16686887|NCT02037945|Experimental|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
16686888|NCT02037932|Experimental|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
16686889|NCT02037919|Experimental|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
16686890|NCT02037919|Active Comparator|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
16686891|NCT02037906|Experimental|Escalating Energy SWL|50 Patients
16686892|NCT02037906|Experimental|Constant Energy SWL|50 Patients
16686893|NCT02037906|Experimental|Reduction Energy SWL|50 Patients
16686894|NCT02037893|Experimental|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
16686895|NCT02037893|Active Comparator|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
16686896|NCT02037893|Active Comparator|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
16686897|NCT02037893|Placebo Comparator|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
16686898|NCT02037880||MPS IIIA/B Subjects|Cohort will be followed for one year to assess natural history of the disease.
16686899|NCT02037867||Patients|"Patients identified with one of the below chronic liver disease risk factors and undergoing community liver disease stratification using fibrosis biomarkers:
~Hazardous alcohol use (>14 units per week in females, >21 units per week in males, alcohol AUDIT score >=8 or read code relevant to alcohol abuse on GP system)
~Type 2 Diabetes
~Obesity
~Persistently raised serum ALT level, negative liver serology, and absence of above 2 risk factors"
16686900|NCT02037854|Placebo Comparator|Placebo|A nutrient formulation without the active ingredient
16686901|NCT02037854|Experimental|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
16686902|NCT02037841|Experimental|Nursing-driven Asthma protocol|Children randomized to the intervention group will have their β2-agonist medication weaned by the nurse, according to the steps outlined in the clinical pathway. The nurse will ensure that the patient's family is booked for asthma teaching, and will also remind the physicians to fill out an asthma action plan on discharge. Detailed information as to when to contact physicians in the event of an acute deterioration of the patient is included in the clinical pathway.
16686903|NCT02037841|No Intervention|Physician-driven asthma management|Patients in the control group will continue receiving the current standard of care, which consists of physicians weaning the β2-agonist medication when called to the bedside by the nurse or when deemed necessary by a physician
16686904|NCT02037828||Stable COPD in STEP1|no intervention
16686905|NCT02037828||Control in STEP 1|no intervention
16686906|NCT02037828||Case group in STEP 2|no intervention
16686907|NCT02037828||Control group in STEP2|no intervention
16686908|NCT02037815|Experimental|Mannitol|20% mannitol solution, 125 ml, IV infusion in 15 min
16686909|NCT02037815|Experimental|Hypertonic saline|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
16686910|NCT02037802|Active Comparator|caudal epidural catheterization group|30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
16686911|NCT02037802|Sham Comparator|control group|30 patients didn't receive caudal epidural analgesia
16686912|NCT02037776|Placebo Comparator|Rikkunshito Placebo|
16686913|NCT02037776|Active Comparator|Rikkunshito|
16686914|NCT02037750|Experimental|LINKS|Foster parent and child participate in 16-week intervention
16686915|NCT02037750|No Intervention|Services as Usual|Foster parent and child receive standard services through child welfare system
16686916|NCT02037737||RA patients on Abatacept IV|Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
16686917|NCT02037724|Other|supplement containing 60 mg iron sulfate|nutrient supplement containing 60 mg of iron as ferous sulfate
16686918|NCT02037724|Experimental|iron rich food supplement (60 mg iron)|contains 60 mg Iron
16686920|NCT02037724|Other|supplement containing 10 mg iron sulfate|nutrient supplement containing 10 mg of iron as ferous sulfate
16686921|NCT02037711|Active Comparator|Chirocaine group (levobupivacaine )|
16686922|NCT02037711|Sham Comparator|Control group|
16686923|NCT02037698|Experimental|Pre-PCI CT scan group|Pre-PCI CT scan
16686924|NCT02037698|No Intervention|Control group|Control
16686925|NCT02037685|Active Comparator|Usual care|Subjects randomized to usual care will receive a brochure once a year on the importance and impact of controlling cardiovascular risk factors, tips to improve statin adherence and smoking cessation strategies and public services. Subjects will also receive a letter every 6 months to remind about study participation along with educational material.
16686926|NCT02037685|Experimental|Motivational Interviewing (MINT)|"The MINT intervention will consist of 6 to 9 telephone encounters between a counselor trained in Motivational interviewing. All subjects in the MINT arm will be contacted every 3 months; however subjects who are not filling medication appropriately will receive additional calls.
~Each telephone encounter will last from 20 to 30 minutes and have a patient centered approach having the following basic structure and goals:
~Establishing a connection and reinforcing autonomy: .
~Empathizing with ambivalence and rolling with resistance.
~Coach the subject towards expressions of commitment."
16686927|NCT02037672|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
16686928|NCT02037672|Active Comparator|metformin and roflumilast|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os.
16686929|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
16686930|NCT02037646|Other|Qualitative fecal immunochemical test|"Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:
~>200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list <100 ng/dL - no colonoscopy
~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
16686931|NCT02037646|Other|Quantitative fecal immunochemical test|"Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:
~Positive - colonoscopy as per waiting list Negative - no colonoscopy
~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
16686932|NCT02037633|Active Comparator|Fascia iliaca compartment block|
16686933|NCT02037633|Active Comparator|Fentanyl|
16686934|NCT02037620|Experimental|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
16686935|NCT02037594|Experimental|Counseling + SOC Adherence|Sexual Health Counseling followed by Standard of Care Adherence Support
16686936|NCT02037594|Experimental|Counseling + Enhanced Adherence|Sexual Health Counseling followed by Enhanced Adherence Intervention
16686937|NCT02037594|Experimental|Information + SOC Adherence|PrEP Information followed by Standard of Care Adherence Support
16686938|NCT02037594|Experimental|Information + Enhanced Adherence|PrEP Information followed by Enhanced Adherence Intervention
16686939|NCT02037581|Experimental|Early detection and Integrated Care|"The intervention condition consisted of measures to improve early detection and treatment quality (Integrated Care).
~Interventions for the improvement of early detection. The measures for improved early detection aiming at reducing the duration of untreated psychosis included 4-year measures to improve mental health literacy, reduce stigma and improve service utilization.
~Measures to improve treatment quality should be achieved through extending the Hamburg model to a cross-age and interdisciplinary Integrated Care model for adolescent and young adult patients with psychotic disorders aged 12-29 years."
16686940|NCT02037581|Other|Standard Care|Historical control group with standard care parallelized regarding age, diagnosis and illness stage, which was treated in the period before the implementation of the intervention conditions. The control group consisted of n=105 patients with early psychosis between the ages of 12 and 29, who had been treated between January 2005 and December 2008. The central differences in comparison with the intervention conditions lie in the lack of measures for the improvement of early detection, the absence of the TACT team, as well as the regular referral to an established psychiatrist with in most cases regular contact frequency.
16686941|NCT02037568|No Intervention|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
16686942|NCT02037568|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
16686943|NCT02037555|Experimental|AT-III (Human)|"Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
~AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4"
16686944|NCT02037555|Placebo Comparator|Placebo|Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
16686945|NCT02037542|Experimental|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
16686946|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16686947|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16686948|NCT02037516|Active Comparator|Control Group|qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
16686949|NCT02037516|Active Comparator|Study Group|quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
16686950|NCT02037503|Placebo Comparator|Placebo for drug resistant depression|Patients will be treated for 21 days with daily oral placebo
16686951|NCT02037503|Experimental|Ketamine for suicidal ideation|Patients will be treated for 21 days with daily oral Ketamine
16686952|NCT02037503|Experimental|Ketamine for drug resistant depression|Patients will be treated for 21 days with daily oral Ketamine
16686953|NCT02037503|Placebo Comparator|Placebo in suicidal ideation|Patients will be treated for 21 days with daily oral placebo
16686954|NCT02037503|Experimental|Healthy Participants|Healthy participants that underwent a romantic relationship breakup will attend in tow experimental sessions, one with placebo and one with ketamine. Sessions will be separated within the range of 1 to 6 weeks
16686955|NCT02037490|Experimental|Grow2Gether Intervention|"Participants in the intervention group will:
~Participate in the Grow2Gether intervention
~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
16686956|NCT02037490|No Intervention|Control|"Participants in the control group will:
~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
16686957|NCT02037477|Experimental|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
16686958|NCT02037477|Experimental|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
16686959|NCT02037477|Experimental|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
16686960|NCT02037477|Experimental|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
16686961|NCT02037464|Experimental|Capsaicin Supplement|
16686962|NCT02037451|Experimental|intervention group|intervention group which receive auditory cueing while performing movement
16686963|NCT02037451|No Intervention|Control group|control group which performing movement after listen to required movement rhythm.
16686964|NCT02037438|Active Comparator|CONV Arm|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
16686965|NCT02037438|Experimental|PCCM ARM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
16686966|NCT02037425|Other|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
16686967|NCT02037412|Experimental|Ticagrelor Arm|Ticagrelor Arm
16686968|NCT02037412|Active Comparator|Clopidogrel Arm|Clopidogrel Arm
16686969|NCT02037399|Experimental|intravenous dexamethasone|To receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD
16686970|NCT02037399|Placebo Comparator|intravenous normal saline|To receive normal saline as placebo intravenous immediately after ESD
16686971|NCT02037386|Experimental|H-side branch stent|H-side branch stent group
16686972|NCT02037373||Octaplas™|Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
16686973|NCT02037373||Plasma|Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).
16686974|NCT02037360|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
16686975|NCT02037360|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
16686976|NCT02037347|Experimental|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
16686977|NCT02037334||Pregnancy|
16686978|NCT02037308|Placebo Comparator|Control white bread|
16686979|NCT02037308|Experimental|Beetroot bread|
16686980|NCT02037295|Experimental|OF_UF Vancomycin|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin
16686981|NCT02037295|Placebo Comparator|OF_UF Placebo|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo
16686982|NCT02037295|Experimental|UF_OF Vancomycin|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin
16686983|NCT02037295|Placebo Comparator|UF_OF Placebo|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo
16686984|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
16686985|NCT02037256|Experimental|A Treatment (bortezomib and filgrastim)|GROUP A: Bortezomib administered in the evening after comploetion of G-CSF collection or on day 6 of mobilization with G-CSF.
16686986|NCT02037256|Experimental|B Treatment (bortezomib and filgrastim)|GROUP B: Bortexomib administered on days 4 & day 7, before administration of filgrastim.
16686987|NCT02037243|Experimental|Water Treatment|Chlorine dispenser promotion and provision
16686988|NCT02037243|Experimental|Hand washing|Hand washing with soapy water promotion
16686989|NCT02037243|Experimental|Standard public health intervention|Health promotion using information about germs and disease
16686990|NCT02037243|Experimental|Disgust and shame intervention|Health promotion using disgust shame
16686991|NCT02037230|Experimental|MK-1775/ Gemcitabine/ Radiation Therapy|
16686992|NCT02037217|Experimental|ExAblate Treatment|
16687118|NCT02036515|Placebo Comparator|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
16686993|NCT02037204|Experimental|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
16686994|NCT02037191|Placebo Comparator|ARM A : METHOTREXATE|"Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).
~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):
~methotrexate alone or
~methotrexate associated with prednisone 0.3 mg/Kg/day"
16686995|NCT02037191|Placebo Comparator|ARM B : PLACEBO|"Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).
~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):
~methotrexate alone or
~methotrexate associated with prednisone 0.3 mg/Kg/day"
16686996|NCT02037178||The study population|"See inclusion/exclusion criteria.
~Intervention: First ultrasound reading
~Intervention: Second ultrasound interpretation"
16686997|NCT02037165|Experimental|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
16686998|NCT02037165|Experimental|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
16686999|NCT02037165|Experimental|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
16687000|NCT02037165|Experimental|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
16687001|NCT02037165|Experimental|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
16687002|NCT02037152|No Intervention|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
16687003|NCT02037152|Experimental|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
16687004|NCT02037139|Active Comparator|Control (screening)|screening only (standard care control)
16687005|NCT02037139|Active Comparator|Educational brochure|Screening + illustrated educational brochure
16687006|NCT02037139|Experimental|Education|Screening + illustrated educational brochure + an in-person educational intervention
16687007|NCT02037126|Experimental|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
16687008|NCT02037126|Active Comparator|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
16687009|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
16687010|NCT02037100||T2DM|Children 6-20 years old diagnosed with T2DM
16687011|NCT02037100||Obesity|
16687012|NCT02037087|Experimental|Good household prenatal practice (GHPP)|The GHPP arm receives SMS messages regarding knowledge on nutrition, labor, non-medical pain management, breastfeeding, and depression. This arm also receives messages delivered to the control group.
16687013|NCT02037087|Experimental|Care seeking (CS)|The CS arm receives SMS messages which include danger-sign recognition and reminders for government-subsidized projects. This arm also receives messages delivered to the control group.
16687014|NCT02037087|Experimental|Full bank of SMS|This arm receives the SMS messages delivered to the GHPP, CS and control group.
16687015|NCT02037087|No Intervention|Control|"Control group receives SMS messages regarding:
~Reminders of prenatal visits and certified skilled attendance of labor (status quo);
~Fetal development in different gestational stages.
~The three experimental groups receive the control messages as well."
16687016|NCT02037074|Experimental|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
16687017|NCT02037074|Experimental|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
16687018|NCT02037074|Experimental|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
16687019|NCT02037074|Placebo Comparator|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
16687020|NCT02037061|Placebo Comparator|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
16687021|NCT02037061|Active Comparator|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
16687022|NCT02037048|Active Comparator|Positive Pathologic Response|Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
16687023|NCT02037048|Experimental|Negative Pathologic Response|Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
16687024|NCT02037035|Experimental|Healthy|Healthy participants will receive ketamine in the scan
16687025|NCT02037035|Experimental|Depressed|Depressed participants will receive ketamine in the scan
16687026|NCT02037022|Experimental|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
16687027|NCT02037022|No Intervention|Delayed Treatment Group|Delayed Treatment Group (DTG)
16687028|NCT02037009|No Intervention|Usual surveillance|surveillance performed by a qualified nurse, present in the operating room during the whole anesthesia.
16687214|NCT02035878|Placebo Comparator|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
16687555|NCT02033577|Active Comparator|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb
16687029|NCT02037009|Experimental|centralised monitoring surveillance|1 anesthetic nurse is posted at a centralised monitoring station outside of the 3 operating rooms, while another one can intervene inside the 3 operating rooms whenever needed. Interphones allow communication between the monitoring station and the operating rooms.
16687030|NCT02036983|Active Comparator|Ultrasound guided bilateral TAP block|Ultrasound guided TAP Block with local anesthetic and dexamethasone.
16687031|NCT02036983|Active Comparator|Instillation of surgical site with local anesthestic.|Instillation of surgical site under direct visualization with local anesthetics and dexamethasone.
16687032|NCT02036983|Placebo Comparator|Control Group|Standard anesthetic technique
16687033|NCT02036970|Experimental|Part 1 Dose-Ranging Bardoxolone methyl 2.5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 2.5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
16687034|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
16687035|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 10 mg/Part 2: Open-Label|Participants received bardoxolone methyl 10 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
16687036|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 20 mg/Part 2: Open-Label|Participants received bardoxolone methyl 20 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
16687037|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone methyl 2.5 mg|Participants received bardoxolone methyl 2.5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
16687038|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone methyl 5 mg|Participants received bardoxolone methyl 5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
16687039|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants received bardoxolone methyl 10 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
16687040|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone methyl 20 mg|Participants received bardoxolone methyl 20 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
16687041|NCT02036970|Experimental|Part 1: Dose Titration: Bardoxolone methyl 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 started with bardoxolone methyl 5 mg once-daily from Day 1 and escalated to bardoxolone methyl 10 mg once-daily starting at Week 4 thru Week 16. Participants who continued to Part 2 continued to receive the same bardoxolone methyl dose once-daily in Part 2 (Week 16 and onwards)
16687042|NCT02036970|Placebo Comparator|Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 received Placebo once-daily from Day 1 thru Week 16. Participants who continued to Part 2 initially received bardoxolone methyl 5 mg once-daily from Week 16 thru Week 20 and bardoxolone methyl 10 mg from week 20 onwards
16687043|NCT02036957|Experimental|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption.
16687044|NCT02036957|Placebo Comparator|PLACEBO ARM|It be applicated in like manner that balm arm
16687045|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
16687046|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
16687047|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
16687048|NCT02036918|Active Comparator|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
16687049|NCT02036918|Experimental|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
16687050|NCT02036905|Experimental|Cervical and thoracic mobilization|Cervical and thoracic mobilization: described as a repetitive low-velocity oscillatory movement applied to a joint segment. It is graded 1-4 based on the size of the amplitude and where in range it is being applied. The mobilization technique chosen will be based on the examination and clinical reasoning process of the therapist. The cervical and thoracic mobilization will be applied to the most provocative level.
16687051|NCT02036905|Experimental|Cervical and thoracic manipulation|Cervical and thoracic manipulation: is defined as high-velocity low-amplitude thrust at end range of a particular spinal segment. The therapist performs this technique by taking up all available slack at a particular segment and applying a high-velocity thrust through the end-range restriction. The manipulation technique will be chosen based on the examination and clinical reasoning process of the therapist.
16687052|NCT02036892|Experimental|Lifestyle counseling with smartphones|Lifestyle counseling assisted by smartphones
16687053|NCT02036892|Active Comparator|Lifestyle counseling|Lifestyle counseling
16687054|NCT02036879|No Intervention|Main study|"The main study is an observational study.
~All women will be followed for one menstrual cycle (or approximately one month) observationally off of any hormone supplementation. They will have 3 study visits corresponding to their menstrual cycle phases (menses, ovulation, and luteal).
~Women participating in the main study may participate in the optional interventional sub-study.
~Men participating in this study will be followed for 1 month observationally. They will have 3 study visits that correlate with the female arm of this study."
16687055|NCT02036879|Experimental|Loestrin Optional Substudy|Women participating in the main study may participate in the optional sub-study. Following a negative urine pregnancy test, women will be started on once daily oral Loestrin (1.5 mg norethindrone + 0.03 mg ethyl estradiol). They will be followed for two months on this agent and have 2 additional study visits.
16687056|NCT02036866|Experimental|Physical Therapy Positive Expectation|The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
16687057|NCT02036866|Experimental|Physical Therapy Neutral Expectation|The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
16687058|NCT02036866|Experimental|Control- No Intervention|The patients in the control group will be reminded of their appointment in 1 week and instructed to maintain their usual activity level during that time.
16687059|NCT02036853|Experimental|Schedule A|Subjects previously treated with triheptanoin
16687060|NCT02036853|Experimental|Schedule B|Naïve to triheptanoin
16687061|NCT02036840||Penicillin allergy|
16687062|NCT02036827|Active Comparator|moderate NMB + standard pressure|Investigators will administrate rocuronium until moderate neuromuscular blockade (Train of Four >=1, Post-tetanic count>=8) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
16687063|NCT02036827|Active Comparator|deep NMB + standard pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
16687064|NCT02036827|Active Comparator|deep NMB + low pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 8 mmHg.
16687065|NCT02036814|Experimental|Group A who underwent to an inter-relational strategy|Group A who underwent to a health educational orientation program (inter-relational strategy)
16687066|NCT02036814|Experimental|Group B who underwent group orientation by the nurse|
16687067|NCT02036801||ARDS|Patients with ARDS (according to the Berlin Definition criteria) in mechanical ventilation
16687068|NCT02036801||Healthy control|Patients with healthy lung supported with mechanical ventilation for clinical purposes
16687069|NCT02036788||Postsurgical patients sedated and paralized|Patients admitted to ICU after surgery, treated with mechanical ventilation, sedated and paralized
16687070|NCT02036788||Postsurgical patients intubated and breathing spontaneously|
16687071|NCT02036775|Experimental|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
16687072|NCT02036775|Experimental|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
16687073|NCT02036775|Experimental|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
16687074|NCT02036775|Experimental|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
16687075|NCT02036775|Experimental|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
16687076|NCT02036775|Experimental|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
16687077|NCT02036762|Active Comparator|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
16687078|NCT02036762|Sham Comparator|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
16687079|NCT02036749|Active Comparator|quadratus lumborum block (nerve block)|quadratus lumborum block with ropivacaine
16687080|NCT02036749|Placebo Comparator|sham block|QL block with saline
16687081|NCT02036736|Experimental|Propofol|Intraoperative anesthetic strategy by Propofol versus Desflurane
16687082|NCT02036736|Experimental|Desflurane|Intraoperative anesthetic strategy by Desflurane versus Propofol
16687083|NCT02036723|Experimental|BCD-021|"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia.
~In this arm 72 patients will receive BCD-021 at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months."
16687084|NCT02036723|Active Comparator|Lucentis®|Lucentis® is ranibizumab drug produced by Novartis Pharmaceuticals Canada Inc. In this arm 36 patients will receive Lucentis® at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
16687085|NCT02036710||Cecum|Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
16687086|NCT02036710||Ileum|Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
16687087|NCT02036697|Experimental|Low Dose Spinal|"Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.
~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section."
16687088|NCT02036697|Active Comparator|Control Spinal Group|"Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.
~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section."
16687119|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 25mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg once every 2 weeks (Q2W) (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during Cycle 1 (28-day cycle).
16687554|NCT02033577|Experimental|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb
16687089|NCT02036684|No Intervention|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
16687090|NCT02036684|Experimental|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
16687091|NCT02036671|Experimental|EndoAVF|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
16687092|NCT02036658|Active Comparator|Cognitive Behavioral Group Therapy|Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg & Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, & Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg & Becker, 2002).
16687093|NCT02036658|Active Comparator|Mindfulness-Based Stress Reduction|MBSR will follow the standard curriculum outline compiled in 1993 by Jon Kabat-Zinn except that the one-day meditation retreat will be converted to four additional weekly group sessions between the standard class 6 and 7 so that there will be 12 weekly 2.5 hour sessions. This will be done to match the CBGT protocol in duration and time. The MBSR intervention will be delivered by a University of Massachusetts Center for Mindfulness certified MBSR instructor with more than 30 years of teaching experience. To support the practice, each participant will be given A Mindfulness-Based Stress Reduction Workbook (Stahl & Goldstein, 2010), which includes descriptions of mindfulness exercises together with pre-recorded audio files to support ongoing practice.
16687094|NCT02036658|No Intervention|Waitlist Control|This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
16687095|NCT02036645|Experimental|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
16687096|NCT02036645|Placebo Comparator|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
16687097|NCT02036645|Experimental|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
16687098|NCT02036645|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
16687099|NCT02036632|Other|Eye Patching|Intervention
16687100|NCT02036619||pregnant women without known diabetes|
16687101|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
16687102|NCT02036606||control|Questionary and neuropsychological tasks will be administered
16687103|NCT02036593|Experimental|Walk Your Heart to Health intervention|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.
~Walking group sessions conducted 3 times per week for 32 weeks."
16687104|NCT02036593|Other|Walk Your Heart to Health lagged|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.
~Walking group sessions conducted 3 times per week for 32 weeks."
16687105|NCT02036580|Experimental|Low Dose|Investigational product Tralokinumab
16687106|NCT02036580|Experimental|High Dose|Investigational product Tralokinumab
16687107|NCT02036580|Placebo Comparator|Placebo|Placebo
16687108|NCT02036567||surgical patients|no interventions, observational study
16687109|NCT02036567||laboring women|no interventions, observational study
16687110|NCT02036567||volunteers|pain induction by noxious heat stimulation, measurement of pain by device and documentation of pain reported by subjects
16687111|NCT02036554|Experimental|Tacrolimus plus Everolimus|Low dose Tacrolimus + Everolimus
16687112|NCT02036554|Active Comparator|Tacrolimus plus Mycophenolic acid|standard dose Tacrolimus + Mycophenolic acid
16687113|NCT02036541|Experimental|AqueSys XEN 45 Glaucoma Implant|
16687114|NCT02036528|Experimental|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
16687115|NCT02036528|Active Comparator|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
16687116|NCT02036515|Experimental|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
16687117|NCT02036515|Experimental|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
16687120|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 10 mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
16687121|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
16687122|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during Cycle 1 (28- day cycle).
16687123|NCT02036502|Experimental|Part 2:pembro 200 mg+len 10 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
16687124|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W weekly during each 28-day cycle.
16687125|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W weekly during each 28-day cycle.
16687126|NCT02036502|Experimental|Part 3:pembro 200 mg+carf 56 mg/m^2+dex 20 mg|Participants in Part 3 with relapsed or refractory multiple myeloma (rMM) received pembrolizumab 200 mg Q3W in combination with carfilzomib 56 mg/m^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg once or twice weekly (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
16687127|NCT02036489|Experimental|Induction and consolidation treatment|
16687128|NCT02036476|Experimental|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
16687129|NCT02036463|Active Comparator|Immediate Release Prednisone|During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
16687130|NCT02036463|Experimental|Delayed Release Prednisone|During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
16687131|NCT02036463|Placebo Comparator|Placebo-Delayed Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
16687132|NCT02036463|Placebo Comparator|Placebo-Immediate Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
16687133|NCT02036450|Experimental|ILR group|Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
16687134|NCT02036450|No Intervention|Control group|Followed according to standard care, i.e. by their general practitioner. Study visits are scheduled at inclusion and after 3 years. Furthermore, the participants are contacted by telephone after 1 and 2 years of follow-up, and endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
16687135|NCT02036437|Experimental|Cases|A dose of 20ug is required obtained by dissolving the 200ug tablet (Misotac® Sigma Pharmaceutical Industries) in 200 ml water (1ug per ml), the solution is shaked well before each administration. The solution will be orally administrated every two hours (max. 12 hrs) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy.
16687136|NCT02036437|Active Comparator|Control|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
16687137|NCT02036424|Active Comparator|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
16687138|NCT02036424|Active Comparator|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
16687139|NCT02036398|Active Comparator|Nephrostomy tube + double J stent|Standard therapy group with nephrostomy tube and double J stent left at the end of the PCNL
16687140|NCT02036398|Experimental|Double J stent without nephrostomy|Double J stent only left at the end of the procedure
16687141|NCT02036372|Experimental|BR (bolus regimen)|"Day before surgery: half evening dose long acting insulin
~Day of surgery:
~patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets
~patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets
~Measure blood glucose every 60 minutes, start 30 min prior to surgery
~Give bolus of insulin according to treatment algorithm"
16687142|NCT02036372|Experimental|LG (Liraglutide)|"Day before surgery: half dose of long acting and mealtime insulin from start liraglutide
~Day of surgery: withhold own insulin, stop oral glucose lowering tablets
~Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.
~In case of nausea graded higher than minimal, the patient will be excluded from the study
~Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.
~Measure glucose every 60 minutes, start 30 min prior to surgery
~Adjust according to bolus algorithm of BR group"
16697792|NCT01965080|Experimental|Exemestane|Exemestane 25 mg daily
16687143|NCT02036372|Active Comparator|GIK (glucose -insulin - potassium) infusion|"Day before surgery: half evening dose long acting insulin
~Day of surgery: stop oral glucose lowering tablets and withhold own insulin.
~GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.
~Calculate the insulin amount in the GIK infusion according to the formula:
~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg
~Measure blood glucose every 60 minutes, start 30 min prior to surgery
~Adjust glucose > 8 mmol/l according to treatment algorithm"
16687144|NCT02036359|Active Comparator|erlotinib|Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
16687145|NCT02036359|Active Comparator|Chemotherapy|"Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
~Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.
~Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.
~If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
16687146|NCT02036346|Experimental|Oral rehydration solution|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
16687147|NCT02036346|Experimental|No intervention|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
16687148|NCT02036346|Active Comparator|Colorectal resection without an ileostomy|Patients who have undergone colorectal resection surgery without an ileostomy creation
16687149|NCT02036333||Concussion Group|
16687150|NCT02036333||Control Group|
16687151|NCT02036320|Experimental|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
16687152|NCT02036320|Active Comparator|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
16687153|NCT02036307|Experimental|DHA-enriched|DHA-enriched supplement (DHA 3g + 600 mg EPA in 6 g of fish oil/day)
16687154|NCT02036307|Experimental|EPA-enriched|EPA-enriched supplement (EPA 2.4 g + DHA 600mg in 6 g of fish oil/day)
16687155|NCT02036294|Other|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
16687156|NCT02036294|Experimental|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
16687157|NCT02036281|Experimental|SP-SAP ARM|The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
16687158|NCT02036268|Active Comparator|Standard|Subjects will receive standard ostomy education.
16687159|NCT02036268|Experimental|Pre-Operative Education|In addition to standard ostomy education, subjects will receive additional education pre-operatively.
16687160|NCT02036268|Experimental|Two-week Post Operative Education|In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.
16687161|NCT02036255|Experimental|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
16687162|NCT02036255|Active Comparator|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
16687163|NCT02036242|Experimental|Sole local anesthetic|Epidural analgesia will be given with sole local anesthetic (0.125% ropivacaine) intermittently
16687164|NCT02036242|Active Comparator|Opioid plus local anesthetic|Epidural analgesia will be given with opioid (sufentanil) combined with local anesthetic (0.125% ropivacaine) intermittently
16687165|NCT02036229|Experimental|0.5% ivermectin cream|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
16687166|NCT02036229|Placebo Comparator|vehicle cream|Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
16687167|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
16687168|NCT02036203|Experimental|SCu300A IUB|
16687169|NCT02036203|Active Comparator|TCu380A|
16687170|NCT02036190||Control group|Former or current smokers without emphysema
16687171|NCT02036190||Emphysema|Current or former smokers with emphysema
16687172|NCT02036177|Experimental|SCu300A IUB|
16687173|NCT02036177|Active Comparator|T380A copper IUD|
16687174|NCT02036164|Active Comparator|Concurrent chemoradiation|"Radiation: Radiation Therapy
~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine
~Vaginal brachytherapy for 4-5 fractions
~Chemotherapy: Cisplatin
~- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy"
16687175|NCT02036164|Experimental|Concurretn chemoradiation plus adjuvant chemotherapy|"Radiation: Radiation Therapy
~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine
~Vaginal brachytherapy for 4-5 fractions
~Chemotherapy: Cisplatin, paclitaxel, carboplatin
~Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy
~Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT
~Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel"
16687213|NCT02035878|Active Comparator|Probiotics|400mg probiotic capsule taken once daily for ten weeks
16698269|NCT01961934|Experimental|Sodium Acetate C11 PET/CT Imaging|
16687176|NCT02036151|Experimental|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
16687177|NCT02036151|Active Comparator|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
16687178|NCT02036138|Active Comparator|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
16687179|NCT02036138|Experimental|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
16687180|NCT02036138|Experimental|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
16687181|NCT02036125|Experimental|Ultrasound guided injection|Ultrasound guided injection of 40 mg of methylprednisolone
16687182|NCT02036125|Active Comparator|Blind injection|Blind injection of 40 mg of methylprednisolone
16687183|NCT02036112|Experimental|Individual ELAPE|Patients will receive Individual ELAPE technique
16687184|NCT02036112|Experimental|Conventional ELAPE|Patients with advanced lower rectal cancer will receive conventional EALPE technique
16687185|NCT02036099|Experimental|Intervention|Participants in this arm will assess patients using the Driving in Mild Dementia Decision Tool.
16687186|NCT02036099|No Intervention|Control|Participants in this arm will assess patients using their usual care strategies.
16687187|NCT02036086|Experimental|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
16687188|NCT02036073|Experimental|EPO|In EPO group, the EPO was given by 500IU/kg every other day intravenously for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Center Configuration, melted configured with saline to 1ml/kg solution. For severe patients, they were started to treat with EPO when their vital signs, blood pressure were stable.
16687189|NCT02036060|Experimental|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
16687190|NCT02036060|Active Comparator|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
16687191|NCT02036047|Experimental|Exclusive cold polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using an exclusive cold polypectomy snare (Exacto cold snare). The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
16687192|NCT02036047|Active Comparator|regular polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using a regular polypectomy snare. The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
16687193|NCT02036034|Active Comparator|drape with forced air warmer|forced air warmer placed under the chin before draping, inflated after draping completed.
16687194|NCT02036034|Placebo Comparator|drape with warming blanket|warming blanket placed on torso of patient under the drape.
16687195|NCT02036021||PRE/non-PRE|children who develop or did not perioperative respiratory events between November 2012 and December 2013
16687196|NCT02036008|Other|Liver MRI with EcGd and with Gdfos|All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.
16687197|NCT02035995||Healthy volunteers|This group consisted of age matched non-pregnant healthy volunteers
16687198|NCT02035995||Healthy pregnant volunteers|This group consisted of age matched healthy pregnant volunteers
16687199|NCT02035982|Active Comparator|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
16687200|NCT02035982|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
16687201|NCT02035969|No Intervention|Conventional treatment (CT)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling and clinical follow up every three months. The caretaker of the child is responsible that the child will take the drugs and is provided with a pre-packed dosage form for easy remembering
16687202|NCT02035969|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counselling and clinical follow up every three months. In addition adherence support is provided according to the description under intervention.
16687203|NCT02035956|Experimental|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
16687204|NCT02035943|Active Comparator|Insulin separated|Seprated infusion of insulin
16687205|NCT02035943|Active Comparator|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
16687206|NCT02035930|Other|menstrual cycle,dexmedetomidine|
16687207|NCT02035917|Experimental|Locking plate|
16687208|NCT02035917|Active Comparator|Non-Locking plate|
16687209|NCT02035904|Experimental|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
16687210|NCT02035904|Placebo Comparator|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
16687211|NCT02035891|Active Comparator|colchicine|0.5mg/d colchicine
16687212|NCT02035891|Placebo Comparator|placebo|appearance is same as colchicine
16698270|NCT01961921|Experimental|ALN-TTR02 (patisiran)|
16687215|NCT02035865||Participants from former study 1|Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte'
16687216|NCT02035865||Participants from former study 2|Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148)
16687217|NCT02035852||Adult Gilomas|
16687218|NCT02035839|Other|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
16687219|NCT02035839|Other|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
16687220|NCT02035839|Other|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
16687221|NCT02035826|Active Comparator|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
16687222|NCT02035826|Active Comparator|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
16687223|NCT02035826|Active Comparator|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
16687224|NCT02035826|No Intervention|Arm 4|Control Arm
16687225|NCT02035813|Experimental|Ribociclib in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
16687226|NCT02035813|Experimental|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
16687227|NCT02035800|Experimental|Adalimumab (humira)|As standard of care.
16687228|NCT02035787|Experimental|Metformin|Metformin, 850 mg. twice daily.
16687229|NCT02035774|Active Comparator|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
16687230|NCT02035774|Placebo Comparator|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
16687231|NCT02035761||MSA Case|The screening evaluation will take less than 1 to 2 hours, and is usually conducted over the telephone. The visit for testing will take approximately 3 days, consisting (usually) of a day for clinical examinations and questionnaires and one day each for PET and MRI brain imaging and the third day for PET imaging of the heart and autonomic testing. If some checklists and questionnaires could not be completed conveniently in the time available, they may be finished over the telephone on a later day. At the completion of the 3-day evaluation, subjects are asked to return home and keep a log of their MSA symptoms and medication responses for 2 days. This will complete the active participation of MSA subjects in all aspects of the entire research program. The average time the subjects will be followed could be up to 1 week during which time the subjects are undergoing research related procedures.
16687232|NCT02035748|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
16687233|NCT02035735|Experimental|Videoendoscopy with WL and NBI|The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).
16687234|NCT02035722|No Intervention|Control group|AMD-related information is not given to patients randomized to the control group.
16687235|NCT02035722|Active Comparator|Video materials|Educational materials are presented in through a video (audio and visual)
16687236|NCT02035722|Active Comparator|Print materials|Educational materials are presented in the format of printed brochure (visual)
16687237|NCT02035709|Active Comparator|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
16687238|NCT02035709|Active Comparator|PCA|Intravenous Patient-Controlled Analgesia
16687239|NCT02035696|Experimental|TIVc-High Dose|Subjects (6 to <48 months old) received two doses of 0.75 mL of TIVc vaccine
16687240|NCT02035696|Experimental|TIVc-Full Dose|Subjects(6 to <48 months old) received two doses of 0.50 mL of TIVc vaccine
16687241|NCT02035696|Experimental|TIVc- Half Dose|Subjects (6 to <48 months old)received two doses of 0.25 mL of TIVc vaccine
16687242|NCT02035696|Active Comparator|TIVe|Subjects (6 to <48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to <36 months and IM/ 0.5 mL -for ages 36 to <48 months)
16687243|NCT02035683|Other|Advanced NSCLC patients undergoing first-line chemotherapy|single cohort
16687244|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
16687245|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.
~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
16687246|NCT02035657|Experimental|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
16687247|NCT02035644|Experimental|Jinlida granules|Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes
16687248|NCT02035644|Placebo Comparator|placebo granules|placebo prepared in indistinguishable granules
16687249|NCT02035631|Experimental|Intervention|Lifestyle intervention combining weight control, diet and physical activity
16687250|NCT02035631|Sham Comparator|Minimal intervention|Minimal diet intervention and minimal physical activity intervention
16687251|NCT02035618|Experimental|Exercises and manual therapy|
16687252|NCT02035618|Active Comparator|Exercises|
16687253|NCT02035605|Active Comparator|ALN-AT3SC|
16687254|NCT02035605|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16687255|NCT02035592|Active Comparator|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.
~Frequency: 26g per day.
~Total duration: 6-month."
16687256|NCT02035592|Active Comparator|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.
~Frequency: 26g per day.
~Total duration: 6-month."
16687257|NCT02035592|Placebo Comparator|Control|"Matched control powder; matched for appearance, taste and sugar content.
~Frequency: 26g per day.
~Total duration: 6-month."
16687258|NCT02035579|Experimental|Aerobic Training Intervention|Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
16687259|NCT02035579|Experimental|Stretching Intervention|Children in the stretching intervention will complete a series of full body stretches of the shoulders, arms, chest, back, legs, and feet 5-6 days per week and will return weekly to review the stretching program. The minimum duration of the stretching intervention will also be 6 weeks
16687262|NCT02035553|Placebo Comparator|Placebo|Placebo, two tablets, once daily by mouth
16687263|NCT02035553|Experimental|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
16687264|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
16687265|NCT02035527|Experimental|Treatment (sorafenib tosylate, docetaxel, and cisplatin)|Patients receive sorafenib tosylate PO BID on days 1-14 of course 0. Beginning in course 1, patients receive sorafenib tosylate PO BID on days 1-21, docetaxel IV over 1 hour on day 1, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.Correlative studies will be performed and a total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
16687266|NCT02035514|Experimental|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
16687267|NCT02035514|Experimental|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
16687268|NCT02035501|Active Comparator|L-Tyrosine|
16687269|NCT02035501|Placebo Comparator|Placebo|
16687270|NCT02035488|Experimental|Tobramycin|Patients with bronchiectasis
16687271|NCT02035475|Active Comparator|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
16687272|NCT02035475|Active Comparator|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
16687273|NCT02035449||McGrath MAC|McGrath MAC is a videolaryngscope
16687274|NCT02035436|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
16687275|NCT02035436|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
16687276|NCT02035423|Active Comparator|Male Guidance School|Non-Fortified Milk 120IU Milk 200IU Milk
16687277|NCT02035423|Active Comparator|Female Guidance|Non-fortified Milk 120IU Milk 200IU Milk
16687278|NCT02035423|Active Comparator|Male Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
16687279|NCT02035423|Active Comparator|Female Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
16687280|NCT02035410|Active Comparator|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
16687281|NCT02035410|No Intervention|Control group|No intervention group
16687282|NCT02035397|Experimental|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
16687283|NCT02035397|Placebo Comparator|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
16687284|NCT02035384||All patients|
16687285|NCT02035371|Experimental|FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
16687286|NCT02035371|Active Comparator|NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
16687287|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
16687288|NCT02035345|Experimental|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
~First hour - Administer 1 percent of total dose (5ml with tubing primed)
~Second hour - Administer 9 percent (45 mL)
~Third hour - Administer 90 percent (450 mL)"
16687289|NCT02035332|Experimental|Aurora Treatment Arm|Endometrial Ablation
16687290|NCT02035319||capillary malformation treated by laser|capillary malformation treated by laser
16687291|NCT02035306|Experimental|non-invasive Haemaglobin|Measuring haemaglobin using non-invasive co-oximetry device
16687292|NCT02035293|Other|PEP|No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
16687293|NCT02035280||Elderly suffering of spine deformity|Spinal deformity patients over the age of 60 years undergoing elective surgery and requiring fusion of at least 5 levels.
16687294|NCT02035267|Placebo Comparator|Placebo - Grade 1|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 1 (mild).
16687295|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 1|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 (mild).
16687296|NCT02035267|Placebo Comparator|Placebo - Grade 4|Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).
16687297|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 4|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants with CR SMFRS Grade 4 (extreme).
16687298|NCT02035254|Experimental|Intervention group|Web-based wellness program
16687299|NCT02035254|Other|Wait control group|Web-based wellness program after 3 month wait.
16687300|NCT02035241|Experimental|Spices 1|220 ml test drink containing spices 1, acute study / one time administration
16687301|NCT02035241|Experimental|Spices 2|220 ml test drink containing spices 2, acute study / one time administration
16687302|NCT02035241|Experimental|Spices 3|220 ml test drink containing spices 3, acute study / one time administration
16687303|NCT02035241|Experimental|Herbs 1|220 ml test drink containing herbs 1, acute study / one time administration
16687304|NCT02035241|Experimental|Herbs 2|220 ml test drink containing herbs 2, acute study / one time administration
16687305|NCT02035241|Placebo Comparator|Placebo|220 ml control drink, acute study / one time administration
16687306|NCT02035228|Experimental|Seated|"Patients breathing will be compared across a series of 9 trials in which unassisted breathing is compared to abdominal stimulation (SecondBreath) assisted breathing at various intensities. Each breathing trial will last for 2 minutes and will be conducted while the patient is seated. The following abdominal stimulation trials were included:
~Abdominal Stimulation - low / early Abdominal stimulation - low/late Abdominal Stimulation - low/full Abdominal stimulation - med/early Abdominal stimulation - med/late Abdominal Stimulation - med/full Abdominal Stimulation - high/early Abdominal Stimulation - high/late Abdominal Stimulation - high/full"
16687307|NCT02035228|Experimental|6 minute step test|"Patients will complete a 6 minute step test with and without abdominal stimulation (SecondBreath).
~Abdominal Stimulation - high/full"
16687308|NCT02035215|Experimental|Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g|Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
16687309|NCT02035215|Placebo Comparator|Atorvastatin 20mg, Placebo|Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
16687310|NCT02035202|Experimental|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
16687311|NCT02035202|Active Comparator|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
16687312|NCT02035202|No Intervention|Standard Care|Participants assigned to this condition will only participate in the assessments.
16687313|NCT02035176||Autistic children ages 6-11|Autistic children ages 6-11
16687314|NCT02035176||ADHD children ages 6-11|ADHD children ages 6-11
16687315|NCT02035176||Typical children ages 6-11|Typical children ages 6-11
16687316|NCT02035163|Active Comparator|Two sites cryoablation group|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
16687317|NCT02035163|No Intervention|Control group|No Intervention group
16687318|NCT02035150|Experimental|Oatmeal Breakfast|Participants will consume oatmeal breakfast daily for 4 weeks
16687319|NCT02035150|Experimental|Frosted Flakes|Participants will consume a frosted flakes breakfast daily for 4-weeks
16687320|NCT02035150|Placebo Comparator|No Breakfast|Participants will consume no breakfast for a 4-week period
16687321|NCT02035137|Active Comparator|Single-Agent 131I-MIBG|Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
16687322|NCT02035137|Active Comparator|131I-MIBG with Vincristine/Irinotecan|Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 31I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
16687323|NCT02035137|Active Comparator|131I-MIBG with Vorinostat|Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
16687324|NCT02035124|Experimental|BKM120 and Cabazitaxel|"BKM 120 orally once daily;
~Cabazitaxel 25 mg/m2 IV every 3 weeks"
16687325|NCT02035111|Experimental|Tianshu capsule|Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
16687326|NCT02035111|Placebo Comparator|Sugar pill|Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.
16687327|NCT02035098|Experimental|The Pac-IFicO programme|The Pac-IFicO programme is a complex interventions aimed at improving the quality of pain managementi in hospitalized patients.
16687328|NCT02035085|Experimental|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
16687329|NCT02035072|Experimental|Hypofractionated RT + Gem + Oxali|Hypofractionated radiotherapy + Gemcitabine + Oxaliplatin
16687330|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
16687331|NCT02035046|Other|study's population|
16687332|NCT02035033||low calcium supplement|low calcium supplement
16687333|NCT02035033||Calcium intake 500-1000 mg per day|Calcium intake 500-1000 mg per day
16687334|NCT02035033||Calcium intake above 1000 mg per day|Calcium intake above 1000 mg per day
16687335|NCT02035020|Experimental|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
16687336|NCT02035007|Experimental|LV-EF > 50%|PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]
16687337|NCT02034994|Experimental|Intervention group|Reduction of sugar sweetened beverages. cookies, sedentary activities and increasing physical activity
16687338|NCT02034994|No Intervention|Control group|No intervention
16687339|NCT02034981|Experimental|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
16687340|NCT02034968|Experimental|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.
~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle
~Cisplatin: 75mg/m2,IV on 21 day cycle"
16687341|NCT02034955|Experimental|Post-Operative adaptive radiotherapy|All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
16687342|NCT02034942|Experimental|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.
~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
16687343|NCT02034942|Active Comparator|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:
~Open the eyes to verbal commands.
~Follow the examiner's instructions with the eyes.
~Squeeze hands on request.
~Stick out the tongue on request.
~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
16687344|NCT02034929|Active Comparator|Endocuff-assisted colonoscopy|Endocuff-assisted colonoscopy
16687345|NCT02034929|Active Comparator|Standard colonoscopy|Standard Colonoscopy
16687346|NCT02034916|Experimental|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum
~Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
16687347|NCT02034903|No Intervention|Standard warming|Feeding warmed in water bath
16687348|NCT02034903|Experimental|Commercial warmer|Feedings warmed with a commercial warmer
16687349|NCT02034890|Experimental|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
16687350|NCT02034890|No Intervention|retrospective control patients|retrospective control patients
16687351|NCT02034877|Experimental|1|
16687352|NCT02034864|Experimental|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
16687353|NCT02034864|Sham Comparator|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
16687354|NCT02034851||Dexamethasone|Intervention group
16687355|NCT02034851||Control|Placebo group (physiological saline)
16687356|NCT02034838|Experimental|atazanavir 300mg boosted with ritonavir 100mg|"Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.
~Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive"
16687357|NCT02034825||Practicing urologic surgeons|"US board-certified
~Practicing urologic surgeons
~Performing at least 40 radical prostate surgeries annually
~Urologists will be excluded from participating in the study if:
~They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;
~They have spent less than 3 years in practice or perform less than 40 RP's per year
~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
16687358|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:
~Practicing, board-certified radiation oncologists
~Perform consultations on at least 80 patients with prostate cancer annually
~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
16687359|NCT02034799|Other|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
16687360|NCT02034799|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
16687361|NCT02034786|Experimental|Test|Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.
16687362|NCT02034786|Active Comparator|Control|Transdermal injection of hyaluronic acid only.
16687363|NCT02034773|Experimental|CC-220 0.3mg x 14 days|
16687364|NCT02034773|Experimental|CC-220 1mg x 28 days|
16687365|NCT02034773|Experimental|CC-220 0.3mg x 28 days|
16687366|NCT02034773|Experimental|CC-220 1mg x a total of 14 days|
16687367|NCT02034773|Experimental|Placebo|
16687368|NCT02034773|Experimental|CC-220 0.3mg (once every 3 days for 14 days)|
16687369|NCT02034773|Experimental|CC-220 1mg (once every 7 days for 28 days)|
16687370|NCT02034773|Experimental|CC-220 1mg (formulated and reference capsules)|
16687371|NCT02034760|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
16687419|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IM|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intramuscularly (IM)
16687372|NCT02034760|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
16687373|NCT02034760|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
16687374|NCT02034760|Active Comparator|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
16687375|NCT02034760|Placebo Comparator|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
16687376|NCT02034747|Experimental|Corticosteroid with the 50% reduced dose|oral
16687377|NCT02034747|Active Comparator|Corticosteroid with the maintained dose|oral
16687378|NCT02034734|Experimental|1: ASP3652|Multiple doses of ASP3652
16687379|NCT02034721|Experimental|Protein supplementation|60 grams protein before, during, after eccentric exercise
16687380|NCT02034721|Placebo Comparator|Placebo|60 grams placebo before, during, after eccentric exercise
16687381|NCT02034708|Experimental|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
16687382|NCT02034708|Experimental|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
16687383|NCT02034695||RAMP and Non-RAMP|
16687384|NCT02034682|Experimental|Volulyte 6%|"- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:
~Maize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da
~Na acetate trihydrate 4.63 gr
~Sodium Chloride 6.02 gr
~Potassium Chloride 0.3 gr
~MgCl 0.3 gr
~Sodium hydroxide-hydrochloric acid & H2O"
16687385|NCT02034682|Active Comparator|Geloplasma|"In 1000 ml:
~Modified fluid gelatin 30 gr
~Sodium Chloride 5.4 gr
~Potassium Chloride 0.37 gr
~MgCl 0.14 gr
~Sodium lactate 3.36 gr"
16687386|NCT02034669|Experimental|Treatment with ADSCs transplantation|4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous
16687387|NCT02034669|No Intervention|Treatment without ADSCs transplantation|Only intervention: laminectomy
16687388|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
16687389|NCT02034643|Other|patients with single-lumen tube|Patients who required intraoperative TEE and single-lumen tube; balloon pressure adjustment before TEE probe insertion
16687390|NCT02034643|Other|patients with double-lumen tube|Patients who required intraoperative TEE and double-lumen tube; balloon pressure adjustment before TEE probe insertion
16687391|NCT02034630|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
16687392|NCT02034617|No Intervention|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
16687393|NCT02034617|Experimental|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
16687394|NCT02034604|Experimental|Naftopidil Group|Naftopidil medication patients
16687395|NCT02034604|Active Comparator|Tamsulosin Goup|Tamsulosin medication patients
16687396|NCT02034591|Experimental|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
16687397|NCT02034591|Experimental|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
16687398|NCT02034591|Experimental|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
16687399|NCT02034578|Experimental|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
16687400|NCT02034578|Experimental|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
16687401|NCT02034578|Experimental|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
16687402|NCT02034565|Experimental|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
16687403|NCT02034565|Experimental|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
16687404|NCT02034552|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|
16687405|NCT02034552|Experimental|Radium-223 with abiraterone&prednisone|
16687406|NCT02034552|Experimental|Radium-223 with enzalutamide|
16687407|NCT02034539|Experimental|VADOplex treatment|best medical treatment in combination with intermittent pneumatic foot compression by the VADOplex system for 4 - 6 hours/day until total wound closure of the target lesion is achieved with a maximum treatment of 24 weeks
16687408|NCT02034539|No Intervention|conservative treatment|best medical treatment of the target lesion alone
16687409|NCT02034526|Placebo Comparator|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
16687410|NCT02034526|Experimental|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
16687411|NCT02034513|Experimental|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
16687412|NCT02034513|Active Comparator|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
16687413|NCT02034500|Experimental|S. sonnei 1790GAHB - 0.1 mcg - ID|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 0.1 mcg intradermally (ID)
16687414|NCT02034500|Experimental|S. sonnei 1790GAHB - 1 mcg - ID|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 1 mcg intradermally (ID)
16687415|NCT02034500|Experimental|S. sonnei 1790GAHB - 10 mcg - ID|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 10 mcg intradermally (ID)
16687416|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IN|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intranasally (IN)
16687417|NCT02034500|Experimental|S. sonnei 1790GAHB - 20 mcg - IN|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 20 mcg intranasally (IN)
16687418|NCT02034500|Experimental|S. sonnei 1790GAHB - 80 mcg - IN|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 80 mcg intranasally (IN)
16687547|NCT02033629|Active Comparator|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
16687420|NCT02034500|Placebo Comparator|Placebo - ID|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intradermally (ID). These were pooled in one Placebo group in the analyses
16687421|NCT02034500|Placebo Comparator|Placebo - IN|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intranasally (IN). These were pooled in one Placebo group in the analyses
16687422|NCT02034500|Placebo Comparator|Placebo - IM|2 subjects enrolled in COHORT C receiving 3 injections of Placebo intramuscularly (IM)
16687423|NCT02034487||Boys with delayed puberty|Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.
16687424|NCT02034474|Experimental|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
16687425|NCT02034474|Placebo Comparator|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
16687426|NCT02034461|Experimental|Acute surgical implantation|
16687427|NCT02034461|Experimental|Implantation of a Utah Electrode Array|Arm which has been amputated or has peripheral nerve trauma. Interventions include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about nerve stimulation.
16687428|NCT02034448||Acute Kidney Injury|CRRT intervention with adult patients with Acute Kidney Injury
16687429|NCT02034435|Active Comparator|Aim1-Low Sodium then High Sodium|"Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.
~Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made."
16687430|NCT02034435|Active Comparator|Aim 1-high salt diet then low salt diet|"Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.
~Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made."
16687431|NCT02034435|Active Comparator|Aim2- low salt diet and epleronone then amlodipine|Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.
16687432|NCT02034435|Active Comparator|aim2- low salt diet and amlodipine then epleronone|Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.
16687433|NCT02034422|Experimental|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
16687434|NCT02034422|Experimental|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
16687437|NCT02034396|Other|Blood draw|One blood draw at enrollment
16687438|NCT02034383|Experimental|Control|Diet will consist of a controlled diet without almonds for 3 weeks.
16687439|NCT02034383|Experimental|Whole Almonds|Diet will consist of a controlled diet with whole almonds for 3 weeks.
16687440|NCT02034383|Experimental|Roasted Whole Almonds|Diet will consist of a controlled diet with roasted whole almonds for 3 weeks.
16687441|NCT02034383|Experimental|Diced Almonds|Diet will consist of a controlled diet with diced almonds for 3 weeks.
16687442|NCT02034383|Experimental|Almond Butter|Diet will consist of a controlled diet with almond butter for 3 weeks.
16687443|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
16687444|NCT02034357|Other|Neurocognitive function|Neurocognitive function assessment (verbal learning and memory) as measured by CVLT and sleep evaluations in Parkinson's disease patients at baseline, and after 4 months and 1 year of CPAP treatment
16687445|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
16687446|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
16687447|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
16687448|NCT02034331|Active Comparator|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
16687449|NCT02034331|Active Comparator|Heat Application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
16687450|NCT02034331|Experimental|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
16687451|NCT02034331|Placebo Comparator|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
16687452|NCT02034292|Experimental|10mg MD|APD791 10mg Multiple dose and
16687453|NCT02034292|Experimental|20mg MD|APD791 20mg Multiple dose
16687454|NCT02034292|Experimental|40mg MD|APD791 40mg Multiple dose
16687455|NCT02034292|Experimental|60mg MD|APD791 60mg Multiple dose
16687456|NCT02034292|Placebo Comparator|Placebo MD|Placebo for Multiple dose group
16687457|NCT02034292|Experimental|120mg SD|APD791 120mg Single dose
16687458|NCT02034292|Experimental|240mg SD|APD791 240mg Single dose
16687459|NCT02034292|Experimental|320mg SD|APD791 320mg Single dose
16687460|NCT02034292|Placebo Comparator|Placebo SD|Placebo for Single dose
16687461|NCT02034279|Experimental|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
16687462|NCT02034279|No Intervention|No albumin|Only antibiotics
16687463|NCT02034266|Experimental|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
16687464|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
16687465|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
16687466|NCT02034227|Experimental|SG2000 - 15 µg/m2/day|Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
16687467|NCT02034227|Experimental|SG2000 - 30 µg/m2/day|Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
16687468|NCT02034214|Experimental|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
16687469|NCT02034214|Active Comparator|Education and health services alone|Life skills education Reproductive health services
16687470|NCT02034201|Active Comparator|Lisdexamfetamine|Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.
16687471|NCT02034201|Placebo Comparator|Placebo|Placebo will be administered orally daily through week 6 of the protocol.
16687472|NCT02034188|Experimental|Umbilical cord mesenchymal stem cells|
16687473|NCT02034175|Experimental|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
16687474|NCT02034175|Active Comparator|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
16687475|NCT02034162|Active Comparator|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
16687476|NCT02034162|Placebo Comparator|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
16687477|NCT02034149|Other|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
16687478|NCT02034149|Experimental|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
16687479|NCT02034149|Experimental|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
16687480|NCT02034136|Experimental|Ginsenoside|"Ginsenoside :
~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
16687481|NCT02034136|Placebo Comparator|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
16687482|NCT02034123|Experimental|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
16687483|NCT02034123|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
16687548|NCT02033629|Placebo Comparator|Ce 3 ng/ml|Remifentanil Ce 3 ng/ml
16687549|NCT02033616|Experimental|AVOVA-1|Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
16687484|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib will be administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib will be administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects will take their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
16687485|NCT02034097|Experimental|Cohort 1|Subjects with EGFRm NSCLC who have received clinical benefit (CR, PR, SD) for at least 4 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 milligram (mg) erlotinib once daily (OD) and 45 mg foretinib OD as a combination therapy until disease progression
16687486|NCT02034097|Experimental|Cohort 2|Subjects with EGFR/WT NSCLC who have received clinical benefit (CR, PR, SD) for at least 2 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 mg erlotinib OD and 45 mg foretinib OD as a combination therapy until disease progression.
16687487|NCT02034097|Experimental|Cohort 3|Subjects with NSCLC who are predicted to be sensitive to foretinib based on biomarkers identified with preclinical or clinical data will receive 60 mg foretinib OD as a monotherapy until disease progression
16687488|NCT02034084|Experimental|Right radial approach|Coronary diagnostic procedures performed through right radial approach
16687489|NCT02034084|Experimental|Left radial approach|Coronary diagnostic procedures performed through left radial approach
16687490|NCT02034071|Experimental|DCCR Open Label - DCCR Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to continue DCCR, at the same dose as they received on Day 69, in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
16687491|NCT02034071|Experimental|DCCR Open Label - Placebo Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to receive placebo equivalent to the DCCR dose received on Day 69 in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
16687492|NCT02034058|Other|Wingspan Stent System|Placement of the Wingspan Stent
16687493|NCT02034045|Active Comparator|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
16687494|NCT02034045|Experimental|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
16687495|NCT02034032|Active Comparator|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
16687496|NCT02034032|Active Comparator|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
16687497|NCT02034019|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
16687498|NCT02034019|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
16687499|NCT02034006|Experimental|Ranibizumab|Patients treated with a single ranibizumab 0.5 mg/0.05ml intravitreal injection
16687500|NCT02033993|Active Comparator|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
16687501|NCT02033993|Active Comparator|Arm 2|Paclitaxel - 175mg/m2: q21 days
16687502|NCT02033980|Other|colorectal lesions|All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
16687503|NCT02033967|Active Comparator|CVP|Central venous pressure-guided vasodilator-induced hypovolemia
16687504|NCT02033967|Experimental|SVV|stroke volume variation-guided vasodilator-induced hypovolemia
16687505|NCT02033941|Active Comparator|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
16687506|NCT02033941|Placebo Comparator|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
16687507|NCT02033928||Arm I: Transplant patients|
16687508|NCT02033928||Arm II: Plasma cell dyscrasia patients|
16687509|NCT02033915|Experimental|Interactive Discussion Group|The interactive discussion groups were held for six times (8-10 persons for each group). During the 50-60 minutes' discussion, the facilitators guided the participants to discuss a case vignette, focusing on the key issues of hospital suicide prevention, and to enhance their abilities of suicide risk identification and evaluation. Two research team members who served as facilitators led the group in a standardized manner.
16687510|NCT02033902||Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
16687511|NCT02033889|Experimental|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
16687550|NCT02033616|Placebo Comparator|MC|Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.
16687551|NCT02033603|Active Comparator|Femoral Nerve Block|Femoral Nerve block performed with 0.5% Ropivacaine 30mls (150mg)
16687552|NCT02033603|Active Comparator|Adductor Canal block|Adductor Canal block performed with 0.5% Ropivacaine 30mls (150mg)
16687553|NCT02033590|Experimental|SERI® Surgical Scaffold|
16687512|NCT02033889|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
16687513|NCT02033889|Placebo Comparator|Placebo/Glimepiride|Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
16687514|NCT02033876|Experimental|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
16687515|NCT02033876|Placebo Comparator|Placebo|matching placebo capsules to be taken twice daily
16687516|NCT02033863||Cohort A|Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
16687517|NCT02033863||Cohort B|Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
16687518|NCT02033850|Experimental|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.
~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
16687519|NCT02033850|No Intervention|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
16687520|NCT02033824|Other|Group 1 Control|Will receive only traditional craniectomy
16687521|NCT02033824|Experimental|Group 2 Treatment dHACM|Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
16687522|NCT02033798|Experimental|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
16687523|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
16687524|NCT02033759|Active Comparator|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
16687525|NCT02033759|Experimental|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
16687526|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm A|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed
16687527|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm B|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator treatment while receiving concurrent buprenorphine-naloxone as prescribed
16687528|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
16687529|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
16687530|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
16687531|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
16687532|NCT02033720||Asystole|Initial arrest rhythm is asystole.
16687533|NCT02033707|Experimental|Male volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
16687534|NCT02033707|Experimental|Female volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
16687535|NCT02033694||Participants With 2 Years Follow up|Participants with NIRS-IVUS imaging at baseline and assigned to follow up for Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) for 2 years
16687536|NCT02033681|Experimental|"One-per-mil Tumescent Solution"|
16687537|NCT02033681|Placebo Comparator|Saline Solution|
16687538|NCT02033668|Active Comparator|Arm A|Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion
16687539|NCT02033668|Experimental|Arm B|Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ
16687540|NCT02033668|Experimental|Arm C|Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg).
16687541|NCT02033668|Experimental|Arm D|Participants in this arm will receive single 200 mg dose of GSK933776 administered IM
16687542|NCT02033655|Experimental|Weight loss high protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60% of animal protein from pork.
16687543|NCT02033655|Active Comparator|Weight loss control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
16687544|NCT02033642|Experimental|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child.
16687545|NCT02033642|Experimental|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors at home.
16687546|NCT02033629|Active Comparator|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
16687556|NCT02033564|Active Comparator|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
16687557|NCT02033564|Active Comparator|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
16687558|NCT02033551|Experimental|Arm A - Veliparib Monotherapy|Subjects in this arm will be dosed with Veliparib continuous dosing.
16687559|NCT02033551|Experimental|Arm B - Veliparib in Combination with Carboplatin & Paclitaxel|Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.
16687560|NCT02033551|Experimental|Arm C Veliparib in Combination with Modified FOLFIRI|Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.
16687561|NCT02033538|Experimental|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
16687562|NCT02033525|Experimental|XCEL-M-ALPHA and standard rehabilitation|Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
16687563|NCT02033525|Active Comparator|standard rehabilitation|Standard rehabilitation program
16687564|NCT02033499|No Intervention|No testing|No testing
16687565|NCT02033499|Other|standard messaging|SMBG standard messaging
16687566|NCT02033499|Other|enhanced messaging|SMBG enhanced messaging
16687567|NCT02033486|Experimental|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
16687568|NCT02033473|Experimental|Apelin|An apelin clamp in which an apelin infusion will be administered prior to reference clamp
16687569|NCT02033473|Placebo Comparator|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp
16687570|NCT02033460|Experimental|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :
~In the fifth session we explained the patients to perform :
~Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.
~Five sets of isometric contraction of the neck extensors for 6-8 seconds
~Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.
~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :
~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
16687571|NCT02033460|Active Comparator|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:
~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
16687572|NCT02033460|Active Comparator|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
16687573|NCT02033447|Experimental|Magnetic Nanoparticle Injection|Patients undergoing radical cystoprostatectomy or prostatectomy
16687574|NCT02033434|Experimental|Intranasal Ketamine|All patients
16687575|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
16687576|NCT02033408|Experimental|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:
~PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)
~PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks
~PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks
~PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
16687577|NCT02033408|Active Comparator|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
16687578|NCT02033408|Other|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
16687579|NCT02033395||Participants exposed to tramautic event|
16687580|NCT02033382||Healthy Controls|Age and gender matched healthy controls
16687581|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
16687582|NCT02033369|Experimental|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
16687583|NCT02033369|No Intervention|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
16687584|NCT02033356|Experimental|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
16687585|NCT02033356|Experimental|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
16687586|NCT02033356|Experimental|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
16687587|NCT02033356|Experimental|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
16687588|NCT02033356|Experimental|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
16687757|NCT02032160|Experimental|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
16687589|NCT02033356|Experimental|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
16687590|NCT02033343|Experimental|Real-time tracking & beam adjustment|Prostate cancer radiotherapy using real-time tracking
16687591|NCT02033330|Active Comparator|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
16687592|NCT02033330|Active Comparator|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
16687593|NCT02033330|Experimental|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
16687594|NCT02033317|Experimental|patiromer|
16687595|NCT02033291||Cortical stroke or primary intracerebral hemorrhage patients:|patients who have a clear clinical presentation of either cortical stroke or primary intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI scans can be performed within 0-6 weeks of the vascular event and on two subsequent days as the vascular permeability may change significantly on the timescale of weeks.
16687596|NCT02033291||cSVD patients|patients who present with a transient ischemic attack (TIA) and cSVD related abnormalities on brain MRI. TIA patients are defined as patients with stroke like symptoms that last no longer than 24 hours. MRI abnormalities include extended white matter lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces. The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the first.
16687597|NCT02033278|Experimental|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
16687598|NCT02033278|Placebo Comparator|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
16687599|NCT02033265||Patients with BMI less than 30 kg/m2|Patients with BMI less than 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC.
16687600|NCT02033265||Patients with BMI 30 or above|Patients with BMI 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC
16687601|NCT02033252|Experimental|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
16687602|NCT02033252|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
16687603|NCT02033239|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
16687604|NCT02033239|Active Comparator|NovoRapid®|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
16687605|NCT02033226|Experimental|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
16687606|NCT02033226|Placebo Comparator|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
16687607|NCT02033213|Active Comparator|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
16687608|NCT02033213|Active Comparator|Liberal group|Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
16687609|NCT02033200|Experimental|Active|Stendra 200 mg
16687610|NCT02033200|Placebo Comparator|Placebo|placebo
16687611|NCT02033187|Experimental|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
16687612|NCT02033187|Active Comparator|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
16687613|NCT02033174|Other|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
16687614|NCT02033174|Other|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
16687615|NCT02033161|Experimental|Internet-delivered CBT|
16687616|NCT02033148|Experimental|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16687617|NCT02033135|Experimental|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.
16687618|NCT02033135|Active Comparator|Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.
16687619|NCT02033122|Active Comparator|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
16687620|NCT02033122|Sham Comparator|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
16687621|NCT02033109|Experimental|PC-1005|"4.00 g dosed once daily for 3 days (safety run-in)
~4.00 g dosed once daily for 14 days (main study)"
16687622|NCT02033109|Placebo Comparator|HEC gel|4.00 g dosed once daily for 14 days (main study only)
16687623|NCT02033096||Cohort 1: Stannsoporfin 1.5 mg/kg|Cohort 1: Received one 1.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
16687624|NCT02033096||Cohort 2: Stannsoporfin 3.0 mg/kg|Cohort 2: Received one 3.0 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
16687625|NCT02033096||Cohort 3: Stannsoporfin 4.5 mg/kg|Cohort 3: Received one 4.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
16687626|NCT02033096||Cohort 4: Placebo Control|Cohort 4: Received one sterile saline injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
16687627|NCT02033083|Active Comparator|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D&E procedure.
16687628|NCT02033083|Active Comparator|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D&E procedure.
16687629|NCT02033070||Non-Dysplastic IM, LGD, HGD|
16687630|NCT02033057|Experimental|Muscular electrostimulation.|The interventions is muscular electrostimulation.
16687631|NCT02033044|Experimental|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
16687632|NCT02033044|Active Comparator|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
16687633|NCT02033031|Active Comparator|Lucentis|PRN intravitreal injection of Lucentis
16687634|NCT02033031|Active Comparator|Avastin|PRN intravitreal injection of Lucentis
16687635|NCT02033018|Experimental|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
16687636|NCT02033005||Breastfed infants|>80% of feeds consisting of breast milk at both scanning points
16687637|NCT02033005||Formula-fed infants|>80% of feeds consisting of formula milk at both scanning points
16687638|NCT02033005||Mixed-fed infants|20%-80% of feeds consisting of breast milk.
16687639|NCT02032979|Experimental|FSHD patient|
16687640|NCT02032966|Experimental|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
16687641|NCT02032966|Active Comparator|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
16687642|NCT02032966|Other|syndesmotic injury|"Non-randomized / syndesmotic injury: patients who have a positive ligament stress test (signifying a syndesmotic injury) during surgery will require surgical treatment of both the tibia and the fibula and cannot be randomized to either arm (nonsurgical versus surgical). Patients in this arm will still be included in the study for the collection of clinical and functional outcomes."
16687643|NCT02032953|Experimental|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
16687644|NCT02032953|Experimental|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
16687645|NCT02032953|Placebo Comparator|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
16687646|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
16687647|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
16687648|NCT02032927|Active Comparator|Codeine/paracetamol|"The combination codeine/paracetamol,30 mg/500 mg,1 tablet every 8 hours, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
~At any stage of the study, patients treated with combination codeine/paracetamol in case of ineffectiveness (NRS> 4) despite maximal dosage (2 tablets every 8 hours) and/or side effect, will be subject to the opioid switch and will start equianalgesic therapy with oxycodone/naloxone combination."
16687649|NCT02032927|Active Comparator|Oxycodone/Naloxone|Combination oxycodone /naloxone, 5 mg/2.5 mg, 1 tablet/day, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
16687650|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
16687674|NCT02032745||Chemo-insensitive|Non-responders to chemotherapy (Probability for pathological negative nodal status)
16687651|NCT02032901|Experimental|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
16687652|NCT02032901|Experimental|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
16687653|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
16687654|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
16687655|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
16687656|NCT02032875|Experimental|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
16687657|NCT02032875|Experimental|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
16687658|NCT02032862|Experimental|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
16687659|NCT02032862|Placebo Comparator|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
16687660|NCT02032849|Active Comparator|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
16687661|NCT02032849|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
16687662|NCT02032836|Experimental|I-Neb - FOX|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion.
16687663|NCT02032836|Experimental|FOX - I-Neb|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion.
16687664|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
16687665|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
16687666|NCT02032810|Experimental|Dose Escalation|Dose Escalation of Panobinostat + Ipilimumab. Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
16687667|NCT02032797|Experimental|A: 7 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.
~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
16687668|NCT02032797|Placebo Comparator|B: 5 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.
~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
16687669|NCT02032784|Experimental|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
16687670|NCT02032784|Other|no octreotide|No Octreotide
16687671|NCT02032771|Experimental|M22 IPL and ResurFX|The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
16687672|NCT02032758|Experimental|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
16687673|NCT02032758|Other|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
16699333|NCT01954693|Placebo Comparator|Placebo|2x2.5mg daily
16687675|NCT02032745||Chemo-sensitive|Responders to chemotherapy (Probability for pathological negative nodal status)
16687676|NCT02032732||suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for suspected infection
16687677|NCT02032732||no suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for reason other than suspected infection
16687678|NCT02032719|Experimental|smartphone assisted lifestyle coaching|6 months of smartphone assisted lifestyle coaching
16687679|NCT02032719|Active Comparator|Lifestyle health coaching|6 months of lifestyle health coaching
16687680|NCT02032706|Experimental|Positional feedback|Deliver therapy when the supine position is detected
16687681|NCT02032693|Experimental|Everycell™|Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
16687682|NCT02032693|Placebo Comparator|Placebo|Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
16687683|NCT02032680|Experimental|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
16687684|NCT02032680|Active Comparator|In-persons Multi-Family Group Psycho-Education treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group Psycho-Education (MFG) that is the standard of care in the VA.
16687685|NCT02032680|Other|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG & DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
16687686|NCT02032667|Experimental|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
16687687|NCT02032667|No Intervention|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
16687688|NCT02032654|Active Comparator|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
16687689|NCT02032654|Experimental|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
16687690|NCT02032641|Experimental|Laser Treatment Side|"Each patient was randomized to have one of two scars treated with Laser Genesis. The treatment was administered by manually scanning the rapidly pulsed laser in an even, painting motion throughout the entire treatment zone. The eyebrow hairs were covered with white tape to prevent inadvertent alopecia. The laser handpiece was oriented perpendicular to the skin at all times, at a distance of 1-2 cm. Patients were instructed throughout to give verbal feedback regarding if the area was too hot as an additional safeguard against epidermal damage."
16687691|NCT02032641|No Intervention|Control side|Each patient had a scar which was randomized to not undergo treatments with Laser Genesis, and was used as a control. Patients were not allowed to undergo laser or any other scar treatments with the exception of sun protection for the control scar for the duration of the study.
16687692|NCT02032628|Experimental|High Intensity/Longer Duration|Exercise at higher intensity (~75% of VO2max) for 40 minute bouts 4 times per week
16687693|NCT02032628|Experimental|High Intensity/Lower Duration|Exercise at high intensity (~75% of VO2max) for 20 minute bouts 4 times per week
16687694|NCT02032628|Experimental|Lower Intensity/Higher Duration|Exercise at lower intensity (~55% of VO2max) for 40 minute bouts 4 times per week
16687695|NCT02032628|Experimental|Low Intensity/Low Duration|Exercise at lower intensity (~55% of VO2max) for 20 minute bouts 4 times per week
16687696|NCT02032615|Active Comparator|Education plus Gudness Nutritional Bar|Subjects will receive education about anemia and will consume Gudness Nutrition bars for 3 months
16687697|NCT02032615|Placebo Comparator|Education with no nutrition bar|Subjects will receive education about anemia but will not receive nutrition bar
16687698|NCT02032602|Active Comparator|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
16687699|NCT02032602|Experimental|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
16687700|NCT02032589|Experimental|Self-generation treatment|self-generation strategy treatment, embedded within practice of various activities
16687701|NCT02032589|Placebo Comparator|memory training|Treatment consists on traditional memory training
16687702|NCT02032576|Experimental|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
16687703|NCT02032563|Experimental|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before surgery
16687704|NCT02032550|Experimental|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
16687705|NCT02032550|No Intervention|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
16687706|NCT02032537|Active Comparator|Callmax cream|
16687707|NCT02032537|Placebo Comparator|Placebo|
16687708|NCT02032524|Experimental|Avalglucosidase alfa|administered intravenously every 2 weeks
16687709|NCT02032511||RAM Cannula Nasal Continuous Positive Airway Pressure|
16687710|NCT02032511||Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|
16687711|NCT02032498|Experimental|Indocyanine Green|superficial injections of Indocyanine Green in the breast
16687712|NCT02032485|Experimental|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery
16687713|NCT02032472|No Intervention|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
16687714|NCT02032472|Experimental|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
16687715|NCT02032459||Minority Women|Study data pulled from already collected data (N=1141 from the Camden Study of low income gravidae and minority gravidae (White, African-American and Hispanic) living in the northeastern United States (New Jersey).
16687716|NCT02032446|Experimental|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.
~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).
~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
16687717|NCT02032433|Active Comparator|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
16687718|NCT02032433|Active Comparator|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
16687719|NCT02032420|Experimental|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
16687720|NCT02032420|Active Comparator|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
16687721|NCT02032407|Experimental|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
16687722|NCT02032394|Experimental|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
16687723|NCT02032394|Experimental|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
16687724|NCT02032394|Active Comparator|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
16687725|NCT02032381|Other|allogeneic hematopoietic stem cell|The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
16687726|NCT02032368|Experimental|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
16687727|NCT02032368|No Intervention|Control group|Patients in Control group receive no management.
16687728|NCT02032355||hypotension|
16687729|NCT02032342|Active Comparator|Fuji Uni-blocker|Fuji Uni-blocker for selective lobar deflation
16687730|NCT02032342|Active Comparator|Cohen blocker|Cohen blocker for selective lobar deflation
16687731|NCT02032342|Active Comparator|Arndt® blocker|Arndt® blocker for selective lobar deflation
16687732|NCT02032342|Placebo Comparator|Endobronchial double lumen tube|Endobronchial double lumen tube for one lung ventilation
16687733|NCT02032329|Experimental|FastFES|Single Group Study - see Intervention Description
16687734|NCT02032316|Experimental|Interventional|Placement of ureteral stent following post-ureteroscopy
16687735|NCT02032303|Active Comparator|Ticagrelor|Patient randomized to Ticagrelor
16687736|NCT02032303|Active Comparator|Prasugrel|Patient randomized to Prasugrel
16687737|NCT02032290|Active Comparator|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
16687738|NCT02032290|Active Comparator|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
16687739|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
16687740|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
16687741|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
16687742|NCT02032264|Experimental|Comprehensive Chromosome Screening|Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos
16687743|NCT02032264|Placebo Comparator|No Comprehensive Chromosome Screening|The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.
16687744|NCT02032251|Experimental|ginger|The patients with infertility that underwent oral administration of ginger.
16687745|NCT02032251|Placebo Comparator|Placebo|The patients with infertility that receive placebo.
16687746|NCT02032238|Experimental|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
16687747|NCT02032238|No Intervention|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
16687748|NCT02032225||CADASIL|patients with CADASIL
16687749|NCT02032212|Experimental|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
16687750|NCT02032212|Experimental|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
16687751|NCT02032212|Experimental|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
16687752|NCT02032212|Experimental|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
16687753|NCT02032186|Experimental|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
16687754|NCT02032186|Placebo Comparator|Placebo|Placebo pills twice per day.
16687755|NCT02032173|Experimental|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
16687756|NCT02032160|Experimental|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
16687758|NCT02032147||NGF group|This group will be treated with NGF 18u daily for 60 days.
16687759|NCT02032147||control group|"this group will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
16687760|NCT02032134|Other|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
16687761|NCT02032121|Experimental|Intervention procedures|All the procedures will be completed for every subject
16687762|NCT02032108|Experimental|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.
~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
16687763|NCT02032095|Experimental|GB-0998|
16687764|NCT02032082|No Intervention|Ex vivo without CO|
16687765|NCT02032082|Experimental|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
16687766|NCT02032069||NHBD|Non Heart Beating Donors
16687767|NCT02032069||BDD|Brain death donors
16687768|NCT02032056|Experimental|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
16687769|NCT02032056|Experimental|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
16687770|NCT02032056|Placebo Comparator|Placebo|provided as powder in a sachet which can be added to food or drink.
16687771|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
16687772|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
16687773|NCT02032017|Experimental|Percutaneous assisted approach|In this technique, a second small incision (1 cm) at the anterior border of the femur is made. A canulla is placed underneath the muscle and used to pass the reamers in the direction of the acetabulum. There's no need to enlarge the skin incision or to release more muscle insertion to achieve good working access to the acetabulum. Two advantages can be defined: sparing of the gluteus medius muscle and safe access to the acetabulum to obtain perfect positioning of the implants.
16687774|NCT02032017|Active Comparator|Anterolateral approach|A standard transgluteal approach is used. This means a large part of the gluteus medius muscle is released to obtain good access to the acetabulum.
16687775|NCT02032004|Experimental|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
16687776|NCT02032004|Sham Comparator|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
16687777|NCT02031991|Experimental|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
16687778|NCT02031991|Active Comparator|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
16687779|NCT02031991|Active Comparator|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
16687780|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
16687781|NCT02031965|Experimental|Treatment (oncolytic HSV-1716)|Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
16687782|NCT02031952|Experimental|hepatectomy combined lymphadenectomy|hepatectomy combined lymphadenectomy
16687783|NCT02031952|Active Comparator|hepatectomy|hepatectomy alone
16687784|NCT02031939|Active Comparator|Standard chemoradiotherapy|Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )
16687785|NCT02031939|Experimental|induction and gap chemotherapy|induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + standard chemoradiotherapy (Capecitabine 2000mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)
16687786|NCT02031926|Experimental|Positive expiratory pressure|
16687787|NCT02031913||HBV without FL|Chronic hepatitis B without steatosis
16687788|NCT02031913||HBV with FL|Chronic hepatitis B patients with steatosis
16687789|NCT02031900||Undergoing EGD|
16687790|NCT02031887|Experimental|Infant starter formula with synbiotics|Infant starter formula with synbiotics
16687791|NCT02031887|Active Comparator|Infant formula without synbiotics|Infant formula without synbiotics
16687792|NCT02031874||Miami Cohort|Measured vaccine response to H1N1 in HIV perinatally infected children
16687793|NCT02031861|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
16687794|NCT02031861|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
16687795|NCT02031848|Active Comparator|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
16687796|NCT02031848|Active Comparator|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
16687841|NCT02031601|Other|TKI alone therapy|"Interventions:
~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]"
16687797|NCT02031835|Other|BWSTT (3 days a week for maximum of 20 minutes session)|BWSTT (20 minutes of treadmill training (velocity (≥0.1km/h) and body weight support (≤40% of patients weight) according to patients capability and comfort
16687798|NCT02031822|Active Comparator|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
16687799|NCT02031822|Active Comparator|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
16687800|NCT02031809||No additional unplanned major surgery|uneventfull intra-operative and postoperative course
16687801|NCT02031809||Additional unplanned major surgery|"Additional per-operative or post-operative unplanned major surgery such as unforeseen pneumonectomy, bilobectomy, lobectomy or additional segmentectomy, repair of major vessels or bronchi, bronchopleural fistula, unplanned surgery to other organs, within 30 days after the primary surgery.
~These do not include:
~Conversions without additional unplanned major surgery or suddne blood loss less than 500cc
~Conversions or additional resection for unforeseen oncologic reasons.
~Plasty, repair or sleeve resection of vessels after deliberate resection or transection for oncologic reasons"
16687802|NCT02031796|Experimental|CAVAREC images|CAVAREC images from x-ray angiography
16687803|NCT02031783|Experimental|mixture of glucose and fructose|mixture of glucose and fructose
16687804|NCT02031783|Active Comparator|Glucose|Single glucose
16687805|NCT02031770|Other|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
16687806|NCT02031770|Other|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
16687807|NCT02031757|Experimental|perturbation training|Standard physiotherapy augmented with perturbation training (BaMPer system).
16687808|NCT02031757|Active Comparator|balance exercise|standard physiotherapy augmented with balance exercises.
16687809|NCT02031744|Placebo Comparator|erlotinib [Tarceva] + placebo|
16687810|NCT02031744|Experimental|erlotinib [Tarceva] + onartuzumab [MetMAb]|
16687811|NCT02031731|Experimental|4 mg/kg Onartuzumab (MetMAb)|
16687812|NCT02031731|Experimental|15 mg/kg Onartuzumab (MetMAb)|
16687813|NCT02031731|Experimental|30 mg/kg Onartuzumab (MetMAb)|
16687814|NCT02031718|No Intervention|Online Education|
16687815|NCT02031718|Experimental|Online Education & Virtual Counseling|Online virtual counseling
16687816|NCT02031705|Active Comparator|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
16687817|NCT02031705|Placebo Comparator|control group|Control group was performed no additional cavotricuspid isthmus ablation.
16687818|NCT02031692|Active Comparator|Vitamin D and calcium supplement|
16687819|NCT02031692|No Intervention|Control|
16687820|NCT02031679|Experimental|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.
~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.
~The tablets should be swallowed whole with a glass of water."
16687821|NCT02031679|Placebo Comparator|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.
~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.
~The tablets should be swallowed whole with a glass of water."
16687822|NCT02031666|Active Comparator|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
16687823|NCT02031666|Experimental|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
16687824|NCT02031666|Experimental|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
16687825|NCT02031666|Experimental|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
16687826|NCT02031666|Experimental|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
16687827|NCT02031666|Experimental|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
16687828|NCT02031666|Experimental|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
16687829|NCT02031666|Experimental|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
16687830|NCT02031653||Study Group|
16687831|NCT02031640|Experimental|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
16687832|NCT02031640|Experimental|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
16687833|NCT02031640|Active Comparator|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
16687834|NCT02031640|Active Comparator|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
16687835|NCT02031640|Placebo Comparator|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
16687836|NCT02031627|Experimental|pneumatic compression - 1 hour per day|Pneumatic compression device - 12 consecutive days undergoing a 1 hour treatment regimen.
16687837|NCT02031627|Experimental|pneumatic compression - 2 hours per day|Pneumatic compression device - 5 consecutive days undergoing 1 hour treatment in the am and 1 hour of treatment in the pm.
16687838|NCT02031627|Experimental|pneumatic compression - 4 hours per day|Pneumatic compression device - 5 consecutive days undergoing treatment twice per day consisting of 2 consecutive 1 hour treatments in the am and the pm (4 hours total)
16687839|NCT02031614|Experimental|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
16687840|NCT02031601|Experimental|Combination therapy|"Interventions:
~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
16687842|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
16687843|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
16687844|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
16687845|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
16687846|NCT02031575|Experimental|Basic Treatment|Sends messages to participants about reproductive health.
16687847|NCT02031575|Experimental|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
16687848|NCT02031575|Placebo Comparator|Control|Sends messages to students about malaria prevention and control.
16687849|NCT02031562|Active Comparator|Chiropractic|Chiropractic
16687850|NCT02031562|Active Comparator|Physical therapy|Physical therapy
16687851|NCT02031549||SpermComet Assay|All study subjects will have their surplus sperm analyzed for DNA fragmentation with the SpermComet assay.
16687852|NCT02031536|Experimental|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16687853|NCT02031536|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16687854|NCT02031523|Active Comparator|Sanjie analgesic capsule|every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
16687855|NCT02031523|Placebo Comparator|placebo|every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
16687856|NCT02031510|Active Comparator|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
16687857|NCT02031510|Active Comparator|bupivacaine|transversus abdominis plane block with bupivacaine 0.25%
16687858|NCT02031510|Placebo Comparator|placebo|Transversus abdominis block with saline 0.9%
16687859|NCT02031497|Experimental|Drink with sweeteners|
16687860|NCT02031497|Active Comparator|Drink without sweeteners|
16687861|NCT02031471|Experimental|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
16687862|NCT02031458|Experimental|Atezolizumab|
16687863|NCT02031445|Placebo Comparator|Placebo|BID
16687864|NCT02031445|Experimental|MRX-6|BID
16687865|NCT02031432|Experimental|Cebranopadol|"Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.
~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day."
16687870|NCT02031406|No Intervention|Usual care|No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
16687871|NCT02031406|Experimental|Post-discharge pharmacist counseling|Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.
16687872|NCT02031393||singelton pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
16687873|NCT02031393||twin pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
16687874|NCT02031380|Experimental|Open angle glaucoma - iDropper device|Device
16687875|NCT02031367|Active Comparator|Corticosteroid|
16687876|NCT02031367|Experimental|Platelet Rich Plasma|
16687877|NCT02031354|Experimental|Lysine Chloride|
16687878|NCT02031341||Patients with type 2 diabetes mellitus|
16687879|NCT02031341||Normoglycemic individuals|Control group
16687880|NCT02031328|Experimental|Stereotactic Ablative Radiation|Stereotactic Ablative Radiation 26 Gy in 2 fractions, once weekly to prostate
16687881|NCT02031315||Resident of health areas of interest|Residents of 4 health areas will be monitored for sudden unexpected death within 72 months of follow up. Circumstances and past medical conditions will be checked.
16687882|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
16687883|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
16687884|NCT02031289|Active Comparator|Anemia|Hb < 120 g/L in women, Hb < 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
16687885|NCT02031289|Active Comparator|Iron deficiency|ferritin < 100 µg/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
16687886|NCT02031289|No Intervention|Natural comparison group|Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed
16688141|NCT02029534|Active Comparator|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
16687887|NCT02031276|Placebo Comparator|Double-blind Placebo IV|Participants randomized to receive double-blind placebo for risankizumab by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
16687888|NCT02031276|Experimental|Double-blind Risankizumab 200 mg IV|Participants randomized to receive double-blind risankizumab 200 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
16687889|NCT02031276|Experimental|Double-blind Risankizumab 600 mg IV|Participants randomized to receive double-blind risankizumab 600 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
16687890|NCT02031263|Experimental|thermoplasty group|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
16687891|NCT02031250|Active Comparator|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
16687892|NCT02031250|Experimental|Boost Arm|Boost radiation to hypoperfused volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
16687893|NCT02031237||Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.
~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
16687894|NCT02031237||Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.
~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
16687895|NCT02031237||Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.
~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
16687896|NCT02031224|Experimental|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
16687897|NCT02031224|Active Comparator|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).
~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
16687898|NCT02031211|Placebo Comparator|Placebo|0.4 ml/kg of normal saline will be administered subcutaneously.
16687899|NCT02031211|Experimental|Etanercept|Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.
16687900|NCT02031198|Experimental|AADvac1|"Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).
~Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above."
16687901|NCT02031185|No Intervention|Wait-list control|No intervention
16687902|NCT02031185|Experimental|FitBit only|Participants will use the FitBit device
16687903|NCT02031185|Experimental|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
16687904|NCT02031172||Subjects with Dry Eye Disease|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
16687905|NCT02031172||Subjects with Sjogren's Syndrome|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
16687906|NCT02031172||Healthy Controls|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
16687907|NCT02031146|Other|LP|Participants undergo lumbar puncture for CSF evaluation
16687908|NCT02031146|No Intervention|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
16687909|NCT02031107|Active Comparator|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
16687910|NCT02031107|Active Comparator|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
16688142|NCT02029534|Experimental|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
16687911|NCT02031107|Sham Comparator|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
16687912|NCT02031094||Major resection|Patients undergoing resection of >3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
16687913|NCT02031094||Minor resection|Patients undergoing resection of </= 3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
16687914|NCT02031081|Experimental|Treatment Period 1|A randomized assignment of prucalopride or placebo for a period of 28 days, crossover design
16687915|NCT02031081|Experimental|Treatment Period 2|A randomized assignment of either prucalopride or placebo for a period of 28 days, crossover design. Subjects who received active drug in Treatment Arm 1 will receive placebo and vice versa.
16687916|NCT02031068|Active Comparator|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:
~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms
~A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
16687917|NCT02031068|Experimental|Behavioral:Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:
~Sub-maximal aerobic training for up to 15 minutes
~Light coordination and sport-specific exercises for up to 10 minutes
~Visualization and imagery techniques
~Home program.
~A physiotherapist will supervise the rehabilitation."
16687918|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]FTD|
16687919|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]TPI|
16687920|NCT02031016|Active Comparator|Fentanyl|"fentanyl bolus injections on an as needed base, next to the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
16687921|NCT02031016|Active Comparator|Remifentanil|remifentanil, starting with 0.15 ug/Ideal Body Weight(IBW)(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
16687922|NCT02031003|Other|Control|Standard infant formula
16687923|NCT02031003|Experimental|Experimental 1|Standard infant formula containing a new fat blend
16687924|NCT02031003|Experimental|Experimental 2|Standard infant formula containing a new fat blend and fiber
16687925|NCT02031003|No Intervention|Human Milk (HM)|Non-randomized Human Milk group
16687926|NCT02030990|Experimental|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
16687927|NCT02030990|Experimental|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
16687928|NCT02030990|Active Comparator|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
16687929|NCT02030977|Active Comparator|Resveratrol|"Active Comparator: Resveratrol
~1 Resveratrol capsules for 12 weeks"
16687930|NCT02030977|Placebo Comparator|Placebo|one capsule per day
16687931|NCT02030964|Experimental|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). *Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
16687932|NCT02030938|Experimental|SERI® scaffold implanted breasts|
16687933|NCT02030925|Experimental|IW-3718|Twice a day
16687934|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
16687935|NCT02030912|Active Comparator|3 doses of amoxicillin daily for 7 days|Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
16687936|NCT02030912|Active Comparator|2 doses of minocycline daily for 5 days|Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
16687937|NCT02030912|Placebo Comparator|2 doses of placebo daily for 5 days|Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.
16687938|NCT02030899|Active Comparator|Cage|Cage filled with autologous bone
16687939|NCT02030899|Other|Plate|Plate augmentation after iliac bone graft
16687940|NCT02030886|Other|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
16687941|NCT02030873|Experimental|Virtual simulation training first|Participants in this arm receive virtual simulation training before dissection training.
16687942|NCT02030873|No Intervention|Dissection training first|Participants in this arm receive dissection training first and then virtual simulation training.
16687943|NCT02030860|Experimental|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
16687944|NCT02030860|Active Comparator|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
16687945|NCT02030847|Experimental|Arm1|"phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia."
16687946|NCT02030834|Experimental|Cohort A|murine CART19
16687947|NCT02030834|Experimental|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
16687948|NCT02030834|Experimental|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
16688143|NCT02029521|Experimental|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
16687949|NCT02030821|Active Comparator|Tranexamic Acid (TXA)|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.
~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
16687950|NCT02030821|Active Comparator|Epsilon-aminocaproic acid (Amicar)|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.
~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
16687951|NCT02030808|Placebo Comparator|Muscle Relaxants (MR) group|Cisatracurium will be administered
16687952|NCT02030808|Active Comparator|Non- Muscle Relaxants (NMR) group|No cisatracurium will be administered
16687953|NCT02030795|Active Comparator|Disconnection group|The single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse.
16687954|NCT02030795|Active Comparator|Bronchial Suction group|The suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
16687955|NCT02030782|Active Comparator|Usual Care|Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)
16687956|NCT02030782|Experimental|Quality Improvement for Depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
16687957|NCT02030769|Experimental|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
16687958|NCT02030769|Sham Comparator|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
16687959|NCT02030756|Active Comparator|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
16687960|NCT02030756|Sham Comparator|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
16687961|NCT02030743|Active Comparator|Visual training|Training in visual attention
16687962|NCT02030743|Placebo Comparator|Usual activity|Usual activity
16687963|NCT02030730|Experimental|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
16687964|NCT02030730|No Intervention|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
16687965|NCT02030717|Experimental|Spinal anesthesia|The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( < 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
16687966|NCT02030717|Active Comparator|Epidural anesthesia|Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.
16687967|NCT02030704||Atherosclerotic Plaque|
16687968|NCT02030691|Experimental|nCPAP - nHFPV|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
16687969|NCT02030691|Experimental|nHFPV - nCPAP|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
16687970|NCT02030678|Experimental|irinotecan Hydrochloride|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
16687971|NCT02030665|Active Comparator|Standardized MET plus CB (SMET-CB)|Motivational Enhancement plus Cognitive-Behavioral treatment
16687972|NCT02030665|Experimental|SMET+ CM (SMET-CB-CM)|Motivational Enhancement plus CB treatment plus contingency management
16687973|NCT02030665|Experimental|Individualized Assessment & Treatment (IATP)|Individualized Assessment and Treatment Program; Cognitive-Behavioral Treatment based on in-depth field monitoring of patient behavior
16687974|NCT02030665|Experimental|IATP + CM (IATP-CM).|Individualized Assessment and Treatment plus Contingency Management
16687975|NCT02030652|Experimental|SNIPPV Group|Synchronized nasal intermittent positive pressure using NAVA ( Intermittent nasal positive pressure positive ventilation.)
16687976|NCT02030652|Active Comparator|CPAP Group|Nasal CPAP group without intermittent ventilation.
16687977|NCT02030639|Experimental|[14C]-rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
16687978|NCT02030626|Experimental|active rTMS or active tDCS or placebo|Active rTMS (10 Hz) of the motor cortex followed by active tDCS (2 mA) of the motor cortex or conversely
16687979|NCT02030626|Placebo Comparator|Sham rTMS followed by tDCS (or conversely)|Placebo rTMD followed by placebo tDCS or conversely
16687980|NCT02030613|Other|Single arm: etanercept|Patients treated with etanercept for JIA
16688147|NCT02029508|Sham Comparator|Sham|The group using Reverse Epley maneuver for PSCC BPPV
16687981|NCT02030600|Experimental|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
16687982|NCT02030600|Active Comparator|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
16687983|NCT02030587|Experimental|Radiofrequency Ablation|Radiofrequency Ablation
16687984|NCT02030587|Active Comparator|Laparoscopic Adrenalectomy|Laparoscopic Adrenalectomy
16687985|NCT02030574|Experimental|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
16687986|NCT02030561|Experimental|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.
~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.
~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
16687987|NCT02030548||acute CABG|patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy
16687988|NCT02030535|Experimental|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
16687989|NCT02030535|Experimental|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
16687990|NCT02030535|Placebo Comparator|Placebo|patient will receive placebo
16687991|NCT02030522|Experimental|Prospective Treatment Cohort of ART|The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
16687992|NCT02030509||New diagnosed patients of head and neck cancer|New diagnosed patients of head and neck cancer
16687993|NCT02030509||Old diagnosed head and neck cancer patients|
16687994|NCT02030496|Active Comparator|Closed reduction and plaster|Closed reduction will be performed and after adequate reduction has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks.
16687995|NCT02030496|Active Comparator|open reduction and internal fixation|The intervention group will be treated with open reduction and internal fixation with a volar locking plate.
16687996|NCT02030483|Experimental|All Subjects|Palbociclib (PD 0332991) will be given at a prespecified dose by cohort orally on days 1-14 of a 28-day cycle. For cycle 1 only, PD 0332991 will start on Day 0. Lenalidomide (Revlimid®) will be given at a prespecified dose by cohort orally on days 8-21 of a 28-day cycle (or days 1-21 as defined by dose cohort level). Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 8, 15, and 22 of a 28-day cycle. For cycle 1 only, the dexamethasone will be omitted on Day 1.
16687997|NCT02030470|Other|fotosan|
16687998|NCT02030457|Experimental|Treatment A|Treatment A: beclomethasone dipropionate BAI, 160 mcg - a single administration of 4 inhalations (40 mcg/inhalation)
16687999|NCT02030457|Experimental|Treatment B|Treatment B: beclomethasone dipropionate BAI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
16688000|NCT02030457|Experimental|Treatment C|Treatment C: beclomethasone dipropionate MDI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
16688001|NCT02030444|No Intervention|Standard diagnostic work-up|All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
16688002|NCT02030444|Experimental|Extensive diagnostic work-up|All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
16688003|NCT02030431|Active Comparator|Cancellous screws|Patients in this group are having osteosynthesis with three screws
16688004|NCT02030431|Active Comparator|Dynaloc|Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)
16688005|NCT02030418|Experimental|Leadless Pacemaker|VVIR pacing
16688006|NCT02030405|Experimental|Ixazomib (MLN9708)|Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16688007|NCT02030392|Experimental|Intervention group|"IG participation in the cognitive-behavioral program Stop the pain with Happy Pingu. The program compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each)."
16688008|NCT02030392|Active Comparator|Active control group|CG participation in an information and education control group (physical well-being, health and gastrointestinal tract). The program of the control group compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each).
16688009|NCT02030379|Experimental|Online QPL-CT to Oncologist|Use the online QPL-CT to prioritize their questions and the prioritized list will be conveyed to their oncologist
16688010|NCT02030379|Experimental|Online QPL-CT|Use the online QPL-CT to prioritize their questions.
16688011|NCT02030379|Experimental|Pencil and Paper QPL-CT|Use pencil and paper QPL-CT to prioritize their questions
16688012|NCT02030366||TBI patients|
16688013|NCT02030366||Healthy Volunteers|
16688014|NCT02030353|Experimental|Self-regulation plus activity monitoring|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
16688015|NCT02030353|Experimental|Self-regulation|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
16688016|NCT02030353|No Intervention|Delayed intervention control|Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
16688017|NCT02030340||Testing Lower urinary tract dysfunction|All patients with lower urinary tract dysfunction where urodynamic diagnosis is required according to standards and (international) practice guidelines will have a synchronous double system (combination of air-charged and water filled) urodynamic test.
16688018|NCT02030327||No trauma|n=5 patients
16688019|NCT02030327||trauma without organ dysfunction|n=40 patients
16688020|NCT02030327||trauma with organ dysfunction|n=40 patients
16688021|NCT02030314|Experimental|chlorthalidone, resistant high blood pressure|if Furosemide dose is 40 mg per day, start Chlorthalidone 12.5 mg per day if Furosemide dose is 80 mg per day, start Chlorthalidone 25 mg per day
16688022|NCT02030301|Experimental|VCL-HB01, 0.25-mL dose|VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
16688023|NCT02030301|Placebo Comparator|PBS, 0.25-mL dose|PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
16688024|NCT02030301|Experimental|VCL-HB01, 0.5-mL dose|VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
16688025|NCT02030301|Placebo Comparator|PBS, 0.5-mL dose|PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
16688026|NCT02030301|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
16688027|NCT02030301|Experimental|VCL-HM01, 1-mL dose|VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
16688028|NCT02030301|Placebo Comparator|PBS, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses
16688029|NCT02030288|Experimental|Relational Agent plus Treatment as Usual|"Relational Agents are onscreen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
16688030|NCT02030288|No Intervention|Treatment as Usual|Patients are routinely screened yearly for unhealthy alcohol use. Providers are prompted to provide elements of a brief intervention if the patient scores 5 or above on the AUDIT-C. Providers are also prompted to refer patients if they meet certain criteria for specialty alcohol treatment.
16688031|NCT02030275|Experimental|RXI-109|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
16688032|NCT02030275|Placebo Comparator|Placebo|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
16688033|NCT02030262|Experimental|Air|The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.
16688034|NCT02030262|Active Comparator|Sulfur hexafluoride (SF6)|The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.
16688035|NCT02030249|Experimental|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
16688036|NCT02030249|Active Comparator|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
16688037|NCT02030236|Experimental|Cooling|
16688038|NCT02030223|Active Comparator|Transversus abdominis plane block with 20 ml ropivacaine 0,75%|Transversus abdominis plane block with 20 ml ropivacaine 0,75%
16688039|NCT02030223|Placebo Comparator|Transversus abdominis plane block with 20 ml saline|Transversus abdominis plane block with 20 ml saline
16688040|NCT02030210||cardiologists|
16688041|NCT02030210||study coordinators|
16688042|NCT02030210||registred nurses|
16688043|NCT02030197|Active Comparator|CRISP program|educational and socialization program
16688044|NCT02030197|Placebo Comparator|Control Group|no treatment control group
16688045|NCT02030184|Experimental|Topotecan and Rhenium Re 188 P2045|In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
16688046|NCT02030171|Active Comparator|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
16688047|NCT02030171|Active Comparator|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
16688048|NCT02030171|Active Comparator|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
16688049|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
16688050|NCT02030158||Usual resuscitation|Usual resuscitation
16688051|NCT02030145|Active Comparator|Classic Thoracic Lymphatic Pump|Subjects begin with Classic Thoracic Lymphatic Pump, then crossover to Compressive Thoracic Lymphatic Pump after 4-week washout period.
16688052|NCT02030145|Experimental|Compressive Thoracic Lymphatic Pump|Subjects begin with Compressive Thoracic Lymphatic Pump, then crossover to Classic Thoracic Lymphatic Pump after 4-week washout period.
16688144|NCT02029521|Placebo Comparator|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
16688053|NCT02030132|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
16688054|NCT02030132|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
16688055|NCT02030132|Experimental|Feedback 50th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the average team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
16688056|NCT02030132|Experimental|Feedback 75th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
16688057|NCT02030119|Active Comparator|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
16688058|NCT02030119|Experimental|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
16688059|NCT02030119|Experimental|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
16688060|NCT02030119|Experimental|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
16688061|NCT02030106||Prior Preterm Birth Patients|All obstetrical patients eligible for the study that have had a prior preterm birth.
16688062|NCT02030106||Term Birth Patients|All obstetrical patients eligible for the study that have not had a prior preterm birth.
16688063|NCT02030093||High-frequency telephone-based continuing care|High-frequency telephone-based continuing care
16688064|NCT02030093||Low-frequency telephone-based continuing care|Low-frequency telephone-based continuing care
16688065|NCT02030093||SMS group|SMS group
16688066|NCT02030093||Control group|Control group
16688067|NCT02030080|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
16688068|NCT02030080|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
16688069|NCT02030080|Experimental|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
16688070|NCT02030080|Experimental|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
16688071|NCT02030067|Experimental|RX-3117|All subjects will receive RX-3117.
16688072|NCT02030054|Active Comparator|atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
16688073|NCT02030054|Active Comparator|rosuvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin(20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
16688074|NCT02030041|Experimental|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.
~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
16688075|NCT02030041|Active Comparator|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.
~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
16688145|NCT02029508|Active Comparator|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
16688076|NCT02030041|Active Comparator|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
16688077|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
16688078|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
16688079|NCT02030002|Experimental|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
16688080|NCT02030002|Active Comparator|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
16688081|NCT02029989|Experimental|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
16688082|NCT02029989|Active Comparator|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
16688083|NCT02029976|Active Comparator|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
16688084|NCT02029976|Experimental|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting.
16688085|NCT02029963|Experimental|Cluster rTMS|Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
16688086|NCT02029963|Experimental|Taper rTMS|Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
16688087|NCT02029963|Experimental|Treatment as Usual|Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider
16688088|NCT02029950|Experimental|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
16688089|NCT02029937|Experimental|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
16688090|NCT02029937|No Intervention|Standard of care|No invention
16688091|NCT02029924|Experimental|BioChaperone insulin lispro|BioChaperone insulin lispro
16688092|NCT02029924|Active Comparator|Humalog®|Humalog®
16688093|NCT02029911|Experimental|Aurora Treatment Arm|Endometrial Ablation
16688094|NCT02029898|Active Comparator|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
16688095|NCT02029898|Placebo Comparator|Placebo|injectable solution 0.9% for the end of surgery
16688096|NCT02029885|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
16688097|NCT02029885|Sham Comparator|Sham Control|Blinded Sham Control Arm
16688098|NCT02029872|Active Comparator|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
16688099|NCT02029872|Active Comparator|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
16688100|NCT02029859|Experimental|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .
~Polygraphic examination between 30 and 36 weeks of amenorhea"
16688101|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
16688102|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
16688103|NCT02029833|Experimental|Regular Canola Oil|60% oleic acid
16688104|NCT02029833|Experimental|High Oleic Canola Oil|70% oleic acid
16688105|NCT02029833|Active Comparator|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, & flax oil
16688106|NCT02029820|Active Comparator|RenalGuard|Hydration with the device renalguard
16688107|NCT02029820|No Intervention|Saline|Hydration with saline 1ml/Kg/h for 12h
16688108|NCT02029807||Blood donors|Healthy adult volunteers donating blood
16688109|NCT02029794|Experimental|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
16688110|NCT02029794|Active Comparator|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
16688111|NCT02029781|Other|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
16688112|NCT02029768||Women with burn injury|
16688113|NCT02029768||Men with burn injury|
16688146|NCT02029508|Active Comparator|Semont maneuver|The group using Semont maneuver for PSCC BPPV
16688114|NCT02029755|Experimental|TAP block|postoperative analgesia with sono-guided transversus abdominis plane block and intravenous patient controlled analgesia (IV-PCA). Bilateral sono-guided TAP block will be performed after the induction of general anesthesia. 20 ml of 0.25% ropivacaine will be injected to the transversus abdominis plane under ultrasound guidance at each side (total 40 ml). IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
16688115|NCT02029755|Active Comparator|Local infiltration|postoperative analgesia with local anesthetics infiltration at surgical wound and intravenous patient controlled analgesia (IV-PCA). 20 ml of 0.5% ropivacaine will be injected at the surgical wound by the surgeon before the closure of wound. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
16688116|NCT02029755|Active Comparator|PCA only|postoperative analgesia with intravenous patient controlled analgesia. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
16688117|NCT02029742|Experimental|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
16688118|NCT02029742|Active Comparator|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
16688119|NCT02029729|Experimental|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
16688120|NCT02029716|Placebo Comparator|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
16688121|NCT02029716|Experimental|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, ~100 cm2 surface area)
16688122|NCT02029716|Experimental|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (~500 cm2 surface area)
16688123|NCT02029703|Sham Comparator|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
16688124|NCT02029703|Active Comparator|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
16688125|NCT02029690|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
16688126|NCT02029664|Experimental|Visual feedback distortion|Visual distortion increment based on the gait pattern
16688127|NCT02029651|Experimental|E-glove system|E-glove rehabilitation system for upper extremity
16688128|NCT02029651|Active Comparator|Conventional occupational therapy|conventional occupational therapy
16688129|NCT02029638|Experimental|RICG, BMT and high dose PT/Cy+SOC|"Reduced-intensity conditioning regimen (RICG), bone marrow transplantation (BMT), high dose post-transplant cyclophosphamide (PT/Cy) and Standard of Care (SOC).
~Participants will receive: ATG (pre-transplant), pre-medicated with acetaminophen, diphenhydramine; steroid taper of methylprednisolone; fludarabine (2-6 days before transplant), and low-dose cyclophosphamide (pre- transplant); total body irradiation the day before transplant. Participants will receive a living renal transplant followed by BMT. High-dose cyclophosphamide will be given on days 3 and 4 post-transplant with MESNA. Filgrastim will be given on day 5 post-transplant and continue until absolute neutrophil recovery. Standard immunosuppression of tacrolimus, MMF, and prednisone will begin on day 5 post-transplant and be given ≥26 weeks post-transplant. Eligible participants will be gradually withdrawn from medication over a period of 24-40 weeks."
16688130|NCT02029625|Experimental|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
16688131|NCT02029625|Active Comparator|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
16688132|NCT02029612|Other|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
16688133|NCT02029612|Other|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
16688134|NCT02029599|Experimental|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
16688135|NCT02029599|Experimental|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.
~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
16688136|NCT02029599|Placebo Comparator|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
16688137|NCT02029586|Experimental|MB12066|
16688138|NCT02029586|Placebo Comparator|Placebo|
16688139|NCT02029573|Experimental|Atorvastatin in Combination With Radiotherapy and Temozolomide|
16688140|NCT02029547|Experimental|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
16688148|NCT02029495|Experimental|210 mg brodalumab|Administered via subcutaneous injections
16688149|NCT02029495|Experimental|140 mg brodalumab|Administered via subcutaneous injection
16688150|NCT02029495|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
16688151|NCT02029482|Experimental|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
16688152|NCT02029482|Placebo Comparator|Placebo|Matching placebo tablets, once daily, for 18 days
16688153|NCT02029469|Experimental|HRA Device|Patients who will be treated with Ascension HRA device.
16688154|NCT02029456|Experimental|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
16688156|NCT02029430|Experimental|aldoxorubicin|Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.
16688157|NCT02029417|Experimental|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
16688158|NCT02029404|Active Comparator|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
16688159|NCT02029404|Active Comparator|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
16688160|NCT02029391|Active Comparator|Myofascial pain syndrome patients|Manual pressure release only
16688161|NCT02029391|Experimental|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
16688162|NCT02029378|Experimental|Eculizumab|Eculizumab, 900 mg intravenously once a week
16688163|NCT02029378|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
16688164|NCT02029365|Other|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
16688165|NCT02029365|Other|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
16688166|NCT02029352|Experimental|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
16688167|NCT02029352|Placebo Comparator|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
16688168|NCT02029339|Experimental|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
16688169|NCT02029339|Active Comparator|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
16688170|NCT02029313|Experimental|MKT-N2|Montelukast
16688171|NCT02029313|Active Comparator|Singulair|Montelukast sodium
16688172|NCT02029300|Other|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
16688173|NCT02029300|Other|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
16688174|NCT02029287|Experimental|Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
16688175|NCT02029287|Active Comparator|Subjects with CHF conventional clinic visit|Subjects with standardized treatment according to latest guidelines via conventional visit.
16688176|NCT02029274|Experimental|BAF312 0.5mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
16688177|NCT02029274|Experimental|BAF312 2mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
16688178|NCT02029274|Experimental|BAF312 10 mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
16688278|NCT02028598|Experimental|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
16688179|NCT02029274|Placebo Comparator|Placebo|During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
16688180|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
16688181|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
16688182|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
16688183|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
16688184|NCT02029235|Active Comparator|Acetaminophen/Ibuprofen (AIBU) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
16688185|NCT02029235|Active Comparator|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
16688186|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
16688187|NCT02029209|Experimental|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16688188|NCT02029209|Placebo Comparator|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
16688189|NCT02029196|Experimental|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
16688190|NCT02029196|Active Comparator|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
16688191|NCT02029183|Experimental|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
16688192|NCT02029170|Experimental|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
16688193|NCT02029170|Active Comparator|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
16688194|NCT02029157|Experimental|ARQ 197|Daily oral dose
16688195|NCT02029157|Placebo Comparator|Placebo|Daily oral dose
16688196|NCT02029131|Experimental|Exercise|
16688197|NCT02029131|No Intervention|Controls|
16688198|NCT02029118|Experimental|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
16688199|NCT02029118|Placebo Comparator|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
16688200|NCT02029118|Placebo Comparator|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
16688201|NCT02029118|Sham Comparator|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
16688202|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
16688203|NCT02029092||Orsiro|
16688204|NCT02029079|Experimental|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
16688205|NCT02029079|No Intervention|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
16688206|NCT02029066|Experimental|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
16688207|NCT02029053|Other|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
16688208|NCT02029040|Experimental|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
16688209|NCT02029040|Placebo Comparator|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
16688210|NCT02029027|Experimental|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
16688211|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
16688212|NCT02029014|Experimental|LAmbre closure system|
16688213|NCT02029001|Experimental|Arm A: Maintenance treatment|"Patients will continue targeted treatment matching the molecular alterations identified in their tumor
~for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion or a discontinuation criteria (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) is met for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib.
~until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) for durvalumab + tremelimumab"
16688279|NCT02028598|Experimental|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
16688280|NCT02028585|Active Comparator|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
16688214|NCT02029001|No Intervention|Arm B:Interruption of targeted treatment|"Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval).
~Treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib or until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met for durvalumab + tremelimumab.
~If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study."
16688215|NCT02028988|Experimental|Enzalutamide with External Beam Radiation|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingest enzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (24 weeks).
16688216|NCT02028975|Other|Patients with type 2 diabetes|
16688217|NCT02028975|Other|Obese patients without diabetes|
16688218|NCT02028975|Other|Healthy volunteers|
16688219|NCT02028962|Experimental|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
16688220|NCT02028962|No Intervention|Control|
16688221|NCT02028949|Experimental|Chemo-lipiodol|
16688222|NCT02028936|Experimental|Grape juice rich in polyphenols|
16688223|NCT02028936|Active Comparator|grape juice not enriched with polyphenols|
16688224|NCT02028923|Experimental|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
16688225|NCT02028923|Placebo Comparator|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
16688226|NCT02028910|Experimental|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.
~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
16688227|NCT02028910|Placebo Comparator|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.
~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
16688228|NCT02028897|Active Comparator|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
16688229|NCT02028897|Experimental|Alternative embryo culture|Embryo culture in system using small enclosed containers
16688230|NCT02028884|Experimental|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
16688231|NCT02028884|Placebo Comparator|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
16688232|NCT02028871|Active Comparator|Intranasal Insulin First|Intranasal Insulin First, Placebo Second
16688233|NCT02028871|Placebo Comparator|Placebo First|Placebo First, Intranasal Insulin Second
16688234|NCT02028845|Active Comparator|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
16688235|NCT02028845|Active Comparator|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
16688236|NCT02028832|Active Comparator|Usual care|Usual care provided to pediatric inpatients
16688237|NCT02028832|Experimental|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
16688238|NCT02028806|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
16688239|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
16688240|NCT02028780|Experimental|Idarucizumab single doses|different infusion durations
16688241|NCT02028780|Experimental|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
16688242|NCT02028767|Experimental|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
16688243|NCT02028767|Active Comparator|Separate tablets|Empagliflozin and Metformin tablets
16688281|NCT02028585|No Intervention|Control group|Control group maintained their usual diet without low-fat milk supplement.
16699688|NCT01952548|Placebo Comparator|Dose 1 Placebo|
16688244|NCT02028754|Experimental|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
16688245|NCT02028754|Active Comparator|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
16688246|NCT02028741|Experimental|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
16688247|NCT02028741|Sham Comparator|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
16688248|NCT02028728||Orsiro|
16688249|NCT02028715|Placebo Comparator|Experimental (Normal Saline)|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
16688250|NCT02028715|Active Comparator|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
16688251|NCT02028702|Active Comparator|Red Clover extract|150 ml/d Red Clover extract
16688252|NCT02028702|Placebo Comparator|Placebo|150 ml/d sweetened and coloured water
16688253|NCT02028689|Experimental|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg
~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
16688254|NCT02028689|Experimental|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg
~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
16688255|NCT02028676|Experimental|Clinically Driven Monitoring (CDM)|
16688256|NCT02028676|Active Comparator|Laboratory plus Clinical Monitoring (LCM)|
16688257|NCT02028676|Active Comparator|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
16688258|NCT02028676|Experimental|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
16688259|NCT02028676|Experimental|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
16688260|NCT02028676|Experimental|Once-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO
16688261|NCT02028676|Active Comparator|Twice-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
16688262|NCT02028676|Active Comparator|Continued cotrimoxazole prophylaxis|Once-daily doses 5-<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole >=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
16688263|NCT02028676|Experimental|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
16688264|NCT02028663|Experimental|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
16688265|NCT02028663|Experimental|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
16688266|NCT02028663|Experimental|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
16688267|NCT02028663|Active Comparator|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
16688268|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
16688269|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
16688270|NCT02028637|Experimental|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
16688271|NCT02028624|Experimental|Face-to-face|Patients received face-to-face nutrition counseling.
16688272|NCT02028624|Experimental|Telephone|Patients received telephone nutrition counseling.
16688273|NCT02028624|No Intervention|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
16688274|NCT02028598|Experimental|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
16688275|NCT02028598|Experimental|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
16688276|NCT02028598|Experimental|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
16688277|NCT02028598|Experimental|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
16688282|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure > 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
16688283|NCT02028559|Experimental|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
16688284|NCT02028559|No Intervention|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
16688285|NCT02028546|Experimental|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
16688286|NCT02028546|Experimental|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
16688287|NCT02028533|Active Comparator|Patients 1|Participants will receive intranasal oxytocin 40 International Units (IU).
16688288|NCT02028533|Placebo Comparator|Patients 2|Participants will receive 40 International Units of intranasal placebo.
16688289|NCT02028507|Experimental|Palbociclib plus Exemestane or Fulvestrant|"Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with
~Cohort 1: Exemestane 25 mg orally once daily.
~Cohort 2: Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle."
16688290|NCT02028507|Active Comparator|Capecitabine|Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
16688291|NCT02028494|Experimental|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
16688292|NCT02028494|Active Comparator|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
16688293|NCT02028481|Experimental|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
16688294|NCT02028468|Active Comparator|Anterolateral Approach|Patient Operated with Watson Jones Approach
16688295|NCT02028468|Active Comparator|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
16688296|NCT02028455|Experimental|Cohort 1|This cohort will determine the maximum tolerated dose of the Patient Derived CD19 specific CAR T cells also expressing an EGFRt and is restricted to patients with a prior history of allo-HCT
16688297|NCT02028455|Experimental|Cohort 2A|This cohort is for patient who have a history of allo-HCT with recurrence of disease post HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1.
16688298|NCT02028455|Experimental|Cohort 2B|This cohort is restricted to patients wtih no prior history of allo-HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1
16688299|NCT02028442|Experimental|Enadenotucirev|
16688300|NCT02028429|Experimental|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
16688301|NCT02028429|No Intervention|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
16688302|NCT02028416|Active Comparator|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
16688303|NCT02028416|Experimental|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
16688304|NCT02028403|Experimental|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
16688305|NCT02028403|Placebo Comparator|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
16688306|NCT02028403|Experimental|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
16688307|NCT02028403|Placebo Comparator|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
16688308|NCT02028403|Experimental|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
16688309|NCT02028403|Placebo Comparator|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
16688310|NCT02028403|Experimental|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
16688311|NCT02028403|Placebo Comparator|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
16688312|NCT02028390|Experimental|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
16688313|NCT02028377|Experimental|Imaging|PET/MRI
16688314|NCT02028364|Experimental|Everolimus given in conjunction with exemestane|Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.
16688315|NCT02028351||Normal|No Intervention
16688316|NCT02028351||Cataract|No intervention
16688318|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
16688319|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
16688320|NCT02028325|Experimental|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
16688321|NCT02028312|Active Comparator|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
16688322|NCT02028312|Placebo Comparator|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
16688323|NCT02028299|Experimental|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
16688324|NCT02028286|Experimental|CLS001|CLS001
16688325|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
16688326|NCT02028273||Actively using patients|Participants actively using cocaine.
16688327|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
16688328|NCT02028260|Active Comparator|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
16688329|NCT02028260|Placebo Comparator|Placebo|normal saline
16688330|NCT02028247|Experimental|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
16688331|NCT02028247|Active Comparator|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
16688332|NCT02028247|No Intervention|Waitlist condition|Participants randomized to the Waitlist condition will be asked to refrain from seeking out psychotherapy for anxiety as well as making psychiatric medication changes (if applicable) for a 16-week period.
16688333|NCT02028234|Active Comparator|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
16688334|NCT02028234|Active Comparator|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
16688335|NCT02028221|Placebo Comparator|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
16688336|NCT02028221|Experimental|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
16688337|NCT02028208|Experimental|Ammoniated mercury|Subjects will be patch tested with 4 experimental doses of ammoniated mercury, 0.013 mg/cm², 0.040 mg/cm², 0.12 mg/cm², and 0.36 mg/cm², a negative control and corresponding reference allergens, 1.0% ammoniated mercury in petrolatum and 0.5% elemental mercury in petrolatum. Patch tests will be worn for 48 hours.
16688338|NCT02028208|Experimental|Aluminum chloride and aluminum lactate|Subjects will be patch tested with 4 experimental doses of aluminum chloride, 0.040 mg/cm², 0.12 mg/cm², 0.36 mg/cm² and 0.72 mg/cm², 4 experimental doses of aluminum lactate 0.047 mg/cm², 0.14 mg/cm², 0.42 mg/cm² and 0.84 mg/cm², a negative control and corresponding reference allergens, 2.0% aluminum chloride in petrolatum and 12.0% aluminum lactate in petrolatum. Patch tests will be worn for 48 hours.
16688339|NCT02028208|Experimental|Sodium tetrachloropalladaate (Palladium)|Subjects will be patch tested with 5 experimental doses of sodium tetrachloropalladate 0.011 mg/cm², 0.033 mg/cm², 0.10 mg/cm², 0.30 mg/cm² and 0.60 mg/cm², a negative control and corresponding reference allergens, 3.0% sodium tetrachloropalladate in petrolatum and 1.0% palladium chloride 1.0% in petrolatum. Patch tests will be worn for 48 hours.
16688340|NCT02028195|Experimental|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
16688341|NCT02028195|No Intervention|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
16688342|NCT02028182|Experimental|Positive reactions, Concordance with reference allergen|Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
16688343|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
16688344|NCT02028156|Experimental|Partially Hydrolyzed Infant Formula|Fed ad lib.
16688372|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
16699689|NCT01952548|Placebo Comparator|Dose 2 Placebo|
16688345|NCT02028143|Experimental|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
16688346|NCT02028143|Active Comparator|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
16688347|NCT02028130|Experimental|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
16688348|NCT02028117|Experimental|Enadenotucirev|
16688349|NCT02028104|Experimental|stem cells|autologous bone marrow mononuclear cell transplantation
16688350|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
16688351|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
16688352|NCT02028078|Experimental|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
16688353|NCT02028065|Experimental|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
16688354|NCT02028065|Experimental|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
16688355|NCT02028065|Placebo Comparator|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
16688356|NCT02028052|Other|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
16688357|NCT02028052|Other|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
16688358|NCT02028039|Experimental|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
16688359|NCT02028026|Experimental|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
16688360|NCT02028026|Active Comparator|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
16688361|NCT02028000|Active Comparator|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
16688362|NCT02028000|Active Comparator|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
16688363|NCT02028000|Active Comparator|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
16688364|NCT02027987|Experimental|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
16688365|NCT02027987|Placebo Comparator|placebo|
16688366|NCT02027974|Active Comparator|Iconacy Hip System|Iconacy hip system prosthesis components
16688367|NCT02027974|Active Comparator|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
16688368|NCT02027961|Experimental|Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib|Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
16688369|NCT02027961|Experimental|Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib|Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
16688370|NCT02027961|Experimental|Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent)|Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
16688371|NCT02027961|Experimental|Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential)|Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
16688431|NCT02027545|Experimental|Decision Aid|Patients of primary care providers randomly assigned to the Decision Aid intervention (DA) that includes an individualized decision aid, provider education, and modified performance measure/reminder.
16688373|NCT02027935|Experimental|Treatment (T cells, chemo, aldesleukin, ipilimumab)|Beginning 48 to 72 hours prior to T cell infusion, patients receive cyclophosphamide IV over 30-60 minutes. Patients then receive autologous CD8+ melanoma-specific T cells IV over 30-60 minutes on day 0, aldesleukin SC BID on days 0-13 and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
16688374|NCT02027922|Experimental|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
16688375|NCT02027922|Active Comparator|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
16688376|NCT02027922|No Intervention|an oral hygiene tutorial|an oral hygiene tutorial
16688377|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
16688378|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
16688379|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
16688380|NCT02027896|Experimental|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
16688381|NCT02027896|No Intervention|Standard surgical care|Surgical hip fracture repair according to the standard timing.
16688382|NCT02027883|Active Comparator|Nominal Parameter|Nominal T shock setting
16688383|NCT02027883|Experimental|Experimental Parameter|Educated T shock setting
16688384|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
16688385|NCT02027857|No Intervention|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
16688386|NCT02027857|Experimental|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
16688387|NCT02027857|Other|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
16688388|NCT02027844|Experimental|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
16688389|NCT02027844|Active Comparator|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
16688390|NCT02027844|Experimental|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
16688391|NCT02027831|Experimental|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
16688392|NCT02027818|Experimental|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
16688393|NCT02027805|Experimental|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
16688394|NCT02027792|Experimental|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
16688395|NCT02027792|Active Comparator|Diclofenac gel|daily application of diclofenac gel 4 weeks application
16688396|NCT02027792|No Intervention|Usual care|no specific intervention
16688397|NCT02027779|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
16688398|NCT02027779|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
16688399|NCT02027766|Experimental|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
16688400|NCT02027766|No Intervention|Control|
16688401|NCT02027753|Experimental|Insulin glargine and Oral anti diabetic treatment(s)|"Insulin glargine: Lantus
~Add basal insulin: starting with 0.2 U/kg/day or 10 U/day
~Adjust insulin glargine dose according to Fasting blood glucose
~Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
16688402|NCT02027740|Experimental|almond|almonds are substituted for visible fat and carbohydrates
16688403|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
16688432|NCT02027545|Other|No Decision Aid|Patients of primary care providers will be randomly assigned to the pragmatic control (PC) that includes provider education and modified performance measure/reminder, but no decision aid.
16688433|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
16688498|NCT02027103|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
16688404|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.
~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
16688405|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.
~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
16688406|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.
~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.
~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
16688407|NCT02027701|Experimental|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
16688408|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
16688409|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
16688410|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
16688411|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
~Each arm corresponds to a different intervention order."
16688412|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
16688413|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
16688414|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
16688415|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
16688416|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
16688417|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
16688418|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
16688419|NCT02027623|Experimental|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
16688420|NCT02027623|Active Comparator|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
16688421|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
16688422|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
16688423|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
16688424|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
16688425|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
16688426|NCT02027584||preterm infant|gestational age at birth < 37 weeks
16688427|NCT02027584||term infant|gestational age at birth >36 weeks
16688428|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
16688429|NCT02027558|Experimental|Behavioral treatment|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
16688430|NCT02027558|Active Comparator|Active control|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
16688434|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
16699690|NCT01952548|Placebo Comparator|Dose 3 Placebo|
16688435|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
16688436|NCT02027493|Active Comparator|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had < 1 log decrease in HCV-RNA viremia
16688437|NCT02027493|Active Comparator|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
16688438|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.
~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
16688439|NCT02027467|Experimental|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
16688440|NCT02027467|Placebo Comparator|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
16688441|NCT02027454|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
16688442|NCT02027454|Experimental|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
16688443|NCT02027454|Experimental|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
16688444|NCT02027454|Experimental|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
16688445|NCT02027454|Experimental|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
16688446|NCT02027454|Experimental|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
16688447|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).
~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.
~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
16688448|NCT02027428|Experimental|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
16688449|NCT02027428|Other|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
16688450|NCT02027415|Experimental|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
16688451|NCT02027415|Experimental|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
16688452|NCT02027402|Experimental|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
16688453|NCT02027402|No Intervention|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
16688454|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
16688455|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
16688496|NCT02027116|Experimental|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
16688456|NCT02027376|Experimental|LDE225 (sonidegib) plus docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
16688457|NCT02027363|Experimental|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
16688458|NCT02027363|Experimental|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.
~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
16688459|NCT02027350|Experimental|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
16688460|NCT02027337|No Intervention|Control group|Healthy women that no use combined oral contraceptives
16688461|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
16688462|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
16688463|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
16688464|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
16688465|NCT02027337|Experimental|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
16688466|NCT02027337|Experimental|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
16688467|NCT02027324|Experimental|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
16688468|NCT02027324|Experimental|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
16688469|NCT02027311|Experimental|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
16688470|NCT02027311|Experimental|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
16688471|NCT02027298|Experimental|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
16688472|NCT02027285|Experimental|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
16688473|NCT02027285|Placebo Comparator|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
16688474|NCT02027272|Active Comparator|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
16688475|NCT02027272|Placebo Comparator|Placebo|Placebo, 2 doses, 12 hours apart
16688476|NCT02027259|Experimental|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
16688477|NCT02027259|No Intervention|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
16688478|NCT02027246|Experimental|Stem cell|Autologous bone marrow mononuclear cell transplantation
16688479|NCT02027233|Experimental|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
16688480|NCT02027220|Experimental|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
16688481|NCT02027207|Experimental|Shanchol|
16688482|NCT02027207|Placebo Comparator|Placebo|
16688483|NCT02027194|Experimental|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
16688484|NCT02027194|Active Comparator|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
16688485|NCT02027194|Placebo Comparator|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
16688486|NCT02027181|Experimental|device FreeO2|Automatic adjustment of oxygen
16688487|NCT02027181|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
16688488|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
16688489|NCT02027155|Active Comparator|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
16688490|NCT02027155|Placebo Comparator|Placebo (for AR09 solution)|Placebo; normal saline
16688491|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
16688492|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
16688493|NCT02027129|Other|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
16688494|NCT02027116|Experimental|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
16688495|NCT02027116|Experimental|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
16688497|NCT02027103|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
16688499|NCT02027090|Experimental|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
16688500|NCT02027090|Active Comparator|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
16688501|NCT02027077|Active Comparator|Control group|Control group
16688502|NCT02027077|Active Comparator|Lifestyle counseling|Behavioral intervention group
16688503|NCT02027064|Experimental|interferon|
16688504|NCT02027038|Experimental|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
16688505|NCT02027038|Active Comparator|Controls|healthy controls
16688506|NCT02027025|Active Comparator|SPARC 1103 low dose|The subjects will receive SPARC 1103 low dose
16688507|NCT02027025|Active Comparator|SPARC1103 high dose|The subjects will receive SPARC1103 high dose
16688508|NCT02027025|Placebo Comparator|SPARC Placebo|The subjects will receive SPARC Placebo
16688509|NCT02027012|Experimental|Renal denervation with Vessix system|
16688510|NCT02026986|Experimental|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
16688511|NCT02026986|No Intervention|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
16688512|NCT02026973|Experimental|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
16688513|NCT02026973|Experimental|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
16688514|NCT02026973|Experimental|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
16688515|NCT02026973|Experimental|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
16688516|NCT02026960|Experimental|Renal Cell Carcinoma Tumor Tissue|
16688517|NCT02026960|Experimental|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
16688518|NCT02026947|Placebo Comparator|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
16688519|NCT02026947|Experimental|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
16688520|NCT02026921|Experimental|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
16688521|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
16688522|NCT02026895|Experimental|Patient with infection by Staphylococcus lugdunensis|
16688523|NCT02026882|Other|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
16688524|NCT02026869|Active Comparator|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
16688525|NCT02026869|Active Comparator|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
16688526|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
16688527|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
16688528|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
16688529|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
16688530|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
16688531|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
16688532|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
16688533|NCT02026817|Experimental|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16688534|NCT02026817|Active Comparator|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16688535|NCT02026804||Prenatal mental disorders|
16688536|NCT02026791|Experimental|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
16688537|NCT02026791|Active Comparator|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
16688538|NCT02026778|Experimental|ondansetron-betahistine|ondansetron-betahistine group
16688539|NCT02026778|Placebo Comparator|ondansetron|ondansetron group
16688540|NCT02026765|Other|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
16688541|NCT02026765|Other|traditional lens|traditional Aspheric lens
16688542|NCT02026752||Study Population|
16688543|NCT02026739|Experimental|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
16688544|NCT02026739|Active Comparator|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
16688545|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
16688546|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
16688547|NCT02026713|Active Comparator|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
16688548|NCT02026700|Experimental|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
16688549|NCT02026687|Active Comparator|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
16688550|NCT02026687|Experimental|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
16688551|NCT02026674|Experimental|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
16688552|NCT02026661||those that did not receive ICSI or LAH|
16688553|NCT02026661||those that received ICSI only|
16688554|NCT02026661||those that received LAH only|
16688555|NCT02026661||those that received both ICSI and LAH|
16688556|NCT02026648||cases with cervical cancer|
16688557|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
16688558|NCT02026622|Other|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.
~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
16688559|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
16688560|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
16688561|NCT02026583|Experimental|Simvastatin|
16688562|NCT02026570|No Intervention|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
16688563|NCT02026570|Experimental|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
16688564|NCT02026570|Experimental|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
16688565|NCT02026544|Experimental|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
16688566|NCT02026531|Experimental|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
16688567|NCT02026518|Experimental|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
16688568|NCT02026518|Experimental|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
16688569|NCT02026518|Placebo Comparator|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
16688570|NCT02026518|Experimental|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
16688571|NCT02026505||Multiple Myeloma, Bortezomib|
16688572|NCT02026492|Other|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
16688573|NCT02026492|Other|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
16688574|NCT02026479|Experimental|regular treatment comparator|Ginaton
16688575|NCT02026479|Experimental|Dexamethasone Phosphate low dose|5mg
16688576|NCT02026479|Experimental|Dexamethasone Phosphate high dose|10mg
16688578|NCT02026453|No Intervention|Usual care|Physicians and nurses obtain admission medication history.
16688579|NCT02026453|Experimental|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
16688618|NCT02026180|Active Comparator|Micropuncture Access|Vascular access using micropuncture needle kit
16688580|NCT02026453|Experimental|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
16688581|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
16688582|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
16688583|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
16688584|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
16688585|NCT02026414|Experimental|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
16688586|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
16688587|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
16688588|NCT02026401|Placebo Comparator|Placebo|Placebo
16688589|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
16688590|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
16688591|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
16688592|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
16688593|NCT02026362|Other|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
16688594|NCT02026362|Experimental|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
16688595|NCT02026349|Active Comparator|favipiravir|
16688596|NCT02026349|Placebo Comparator|placebo|
16688597|NCT02026336|No Intervention|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
16688598|NCT02026323|Experimental|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
16688599|NCT02026323|Experimental|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI >23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
16688600|NCT02026310|Experimental|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
16688601|NCT02026310|Active Comparator|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
16688602|NCT02026297|Placebo Comparator|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
16688603|NCT02026297|Experimental|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
16688604|NCT02026284||Gravid women|A questionnaire was performed to gravid women
16688605|NCT02026271|Experimental|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
16688606|NCT02026258|Active Comparator|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
16688607|NCT02026258|Experimental|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
16688608|NCT02026245|Experimental|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.
~Intervention: Data gloves to perform movements"
16688609|NCT02026245|Experimental|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements
~Intervention: Data gloves to perform movements"
16688610|NCT02026232|Active Comparator|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
16688611|NCT02026232|Placebo Comparator|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
16688612|NCT02026219|Experimental|Clopidogrel|Clopidogrel 600mg loading
16688613|NCT02026219|Experimental|Ticagrelor|Ticagrelor 180mg loading
16688614|NCT02026206|Experimental|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
16688615|NCT02026206|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
16688616|NCT02026193|Experimental|oocyte vitrification|All retrieved mature oocytes will be vitrified.
16688617|NCT02026193|Active Comparator|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
16688619|NCT02026180|Active Comparator|Standard 18G vascular access needle|Vascular access using standard 18G needle
16688620|NCT02026167|No Intervention|Usual Care|No intervention, usual care
16688621|NCT02026167|Experimental|Intervention|Collaborative care with Health Care Assistant
16688622|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
16688623|NCT02026141|Experimental|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.
~Once the patient's spinal is performed, patient will receive the following:
~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr
~Infusion will be stopped after the last staple or suture is performed on the incision.
~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
16688624|NCT02026141|Placebo Comparator|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,
~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.
~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
16688625|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
16688626|NCT02026115|Active Comparator|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
16688627|NCT02026115|Experimental|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
16688628|NCT02026102|No Intervention|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
16688629|NCT02026102|Experimental|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
16688630|NCT02026089|No Intervention|Sero-positive for varicella at least 5 years prior|No treatment
16688631|NCT02026089|Active Comparator|Varicella vaccine|One dose varicella vaccine (Varivax).
16688632|NCT02026076|Experimental|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
16688633|NCT02026063|Experimental|250 mg Telotristat Etiprate|One telotristat etiprate (250 mg) tablet administered three times daily.
16688634|NCT02026063|Experimental|500 mg Telotristat Etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily.
16688635|NCT02026050|Active Comparator|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
16688636|NCT02026050|Active Comparator|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
16688637|NCT02026050|Placebo Comparator|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
16688638|NCT02026037|Experimental|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
16688639|NCT02026011|Experimental|Naltrexone|Naltrexone 50 mg/day
16688640|NCT02026011|Placebo Comparator|Sugar pill|Matched placebo
16688641|NCT02025998|Experimental|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
16688642|NCT02025998|Placebo Comparator|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
16688643|NCT02025985|Experimental|Part 1: Cohort A-Ovarian carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
16688644|NCT02025985|Experimental|Part 1: Cohort B-Endometrial carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
16688645|NCT02025985|Experimental|Part 1: Cohort C-Cervical carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
16688646|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
16688647|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
16688648|NCT02025972|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
16688649|NCT02025959|Experimental|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
16688650|NCT02025946||Total Ankle Arthroplasty|
16688651|NCT02025946||Tibiotalar Arthrodesis|
16688652|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
16688653|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
16688654|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
16688655|NCT02025920|Experimental|Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
16688656|NCT02025920|Experimental|Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
16688657|NCT02025920|Active Comparator|Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
16688658|NCT02025907|Experimental|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
16688659|NCT02025907|Placebo Comparator|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
16688660|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
16688661|NCT02025881|Experimental|Treatment|carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex
16688662|NCT02025868|Experimental|Adherence reinforcement before switch to 3rd-line ART|
16688663|NCT02025855|Experimental|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
16688664|NCT02025855|Placebo Comparator|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
16688665|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
16688666|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
16688667|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
16688668|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
16688669|NCT02025803|Experimental|TAS-114/capecitabine|See intervention description
16688670|NCT02025790|Experimental|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
16688671|NCT02025790|Active Comparator|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
16688672|NCT02025777|Experimental|capsule endoscopy and colonoscopy|
16688673|NCT02025751|Experimental|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
16688674|NCT02025751|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
16688675|NCT02025738|Active Comparator|MAGNET|magnet application over cardiac device
16688676|NCT02025738|Active Comparator|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
16688677|NCT02025738|Active Comparator|NO ACTION|no action is performed if patient meets inclusion criteria
16688678|NCT02025725|Experimental|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
16688679|NCT02025725|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
16688680|NCT02025712|Experimental|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
16688681|NCT02025699||LRTI|
16688682|NCT02025699||Sepsis|
16688683|NCT02025699||Non-Infectious disease group|
16688684|NCT02025686|Experimental|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
16688685|NCT02025673||Healthy Controls|Healthy subjects as control group.
16688686|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
16688687|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
16688688|NCT02025660|Experimental|Mw|
16688689|NCT02025660|Placebo Comparator|Saline; 0.3 ml x three days sc|
16688690|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
16688691|NCT02025634|Experimental|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
16688692|NCT02025634|Placebo Comparator|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
16688693|NCT02025621|Experimental|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
16688694|NCT02025621|Placebo Comparator|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
16688695|NCT02025608|Experimental|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
16688696|NCT02025608|Placebo Comparator|Placebo|Placebo, daily for 4 weeks
16688697|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
16688698|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
16688699|NCT02025582|Experimental|Kinesio tape|
16688700|NCT02025569|Experimental|Experimental group|Strain counterstrain intervention
16688701|NCT02025569|Sham Comparator|Control Group|Sham Strain Counterstrain intervention
16688702|NCT02025556|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
16688703|NCT02025556|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
16688704|NCT02025556|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
16688705|NCT02025543||Patient Group|Subjects with known or suspected iron overload will undergo serum ferritin measurement and an MRI scan.
16688706|NCT02025543||Control Group|Subjects with no known history of iron overload or liver disease will undergo an MRI scan.
16688707|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
16688708|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
16688709|NCT02025517|No Intervention|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
16688710|NCT02025517|Experimental|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
16688711|NCT02025504|Experimental|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
16688712|NCT02025504|Sham Comparator|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
16688713|NCT02025491|Experimental|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
16688714|NCT02025478|Experimental|Enteral Donor Breastmilk|"Donor breast milk will be pasteurized prior to use.
~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.
~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.
~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
16688715|NCT02025465|Experimental|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes
~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy))
~If rate inadequate the physician has option of:
~Further doses of metoprolol IV or PO
~Intravenous amiodarone
~IV diltiazem
~Observation"
16688716|NCT02025465|Active Comparator|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).
~If after 15 minutes
~The first dose is tolerated, and
~Ventricular rate is over 100 beats a minute AND
~Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy)
~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).
~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:
~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.
~If rate inadequate the physician has an option of:
~Metoprolol PO (by mouth) or IV (intravenous)
~Digoxin PO or IV
~Intravenous amiodarone
~Observation"
16688717|NCT02025452|Active Comparator|Rapid diagnostics and probiotic|
16688718|NCT02025452|Placebo Comparator|Rapid diagnostics and placebo|
16688719|NCT02025452|Experimental|Delayed diagnostics and probiotic|
16688720|NCT02025452|Placebo Comparator|Delayed diagnostics and placebo|
16688721|NCT02025439|Experimental|rTMS Alone followed by rTMS+AMA|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
16688722|NCT02025439|Experimental|AMA Alone followed by rTMS+AMA|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
16688723|NCT02025426|Active Comparator|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
16688724|NCT02025426|Active Comparator|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
16688725|NCT02025413|Other|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
16688726|NCT02025413|Other|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
16688727|NCT02025400|Active Comparator|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
16688728|NCT02025400|Experimental|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
16688729|NCT02025387|Experimental|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
16688730|NCT02025387|Sham Comparator|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
16688731|NCT02025374|Experimental|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
16688732|NCT02025374|Active Comparator|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
16688733|NCT02025361|Experimental|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
16688734|NCT02025361|Experimental|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
16688735|NCT02025348|Experimental|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
16688736|NCT02025348|Experimental|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
16688737|NCT02025348|Experimental|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
16688738|NCT02025348|Experimental|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
16688739|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
16688740|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
16688741|NCT02025322|No Intervention|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
16688742|NCT02025322|Experimental|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
16688743|NCT02025309|Active Comparator|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
16688744|NCT02025309|Placebo Comparator|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
16688745|NCT02025296|No Intervention|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
16688746|NCT02025296|Experimental|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
16688747|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
16688748|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
16688749|NCT02025270|Other|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
16688750|NCT02025257|Experimental|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
16688751|NCT02025257|No Intervention|Control|Patients are asked to live as usual.
16688752|NCT02025244|Active Comparator|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
16688753|NCT02025244|Active Comparator|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
16688754|NCT02025231|Experimental|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
16688755|NCT02025218|Experimental|Re-administration gefitinib|
16688756|NCT02025205|Experimental|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
16688757|NCT02025205|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
16688758|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with capecitabine|
16688759|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with trastuzumab|
16688760|NCT02025192|Experimental|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
16688761|NCT02025179|Experimental|Teriparatide and vibration|"Experimental: Teriparatide and vibration
~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
~Device: Vibration 10 min/day for 12 months"
16688762|NCT02025166|Active Comparator|Paracetamol|Pain treatment, aniline analgesics
16688763|NCT02025166|Active Comparator|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
16688764|NCT02025153|Other|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
16688765|NCT02025153|Other|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
16688766|NCT02025153|Other|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
16688767|NCT02025140|Active Comparator|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
16688768|NCT02025140|Experimental|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
16688769|NCT02025140|Experimental|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
16688770|NCT02025127|Experimental|Trophic feeding|Mechanically ventilated patients with septic shock > 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
16688771|NCT02025127|No Intervention|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
16688772|NCT02025114|Experimental|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
16688773|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
16688774|NCT02025088|Active Comparator|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
16688775|NCT02025088|Active Comparator|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
16688776|NCT02025075|Experimental|Deep Neuromuscular Block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
16688777|NCT02025075|Active Comparator|Moderate Neuromuscular block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
16688778|NCT02025062|No Intervention|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
16688779|NCT02025062|Experimental|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
16688780|NCT02025049|Experimental|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
16688781|NCT02025049|Placebo Comparator|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
16688848|NCT02024620|Active Comparator|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
16688782|NCT02025036|Experimental|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.
~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
16688783|NCT02025036|Active Comparator|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.
~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
16688784|NCT02025036|Experimental|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
16688785|NCT02025023|Active Comparator|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
16688786|NCT02025023|Active Comparator|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
16688787|NCT02025023|Active Comparator|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
16688788|NCT02025023|Active Comparator|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
16688789|NCT02025010|Experimental|abiraterone acetate|"Pre-treatment and progression tumor biopsies.
~Four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) taken orally on 28 day cycles.
~For participants who experience symptoms of persistent or severe hypertension or hypokalemia, prednisone 5 mg by mouth twice daily.
~For participations who tolerate AA monotherapy without the addition of prednisone to manage symptoms of persistent or severe mineralocorticoid excess, prednisone 5 mg by mouth twice daily will be added at PSA progression.
~Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess."
16688790|NCT02024997|Experimental|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
16688791|NCT02024984|Experimental|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
16688792|NCT02024984|Active Comparator|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
16688793|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
16688794|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
16688795|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
16688796|NCT02024932|Experimental|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
16688797|NCT02024932|Experimental|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
16688798|NCT02024932|Placebo Comparator|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
16688799|NCT02024932|Experimental|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
16688800|NCT02024932|Experimental|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
16688801|NCT02024932|Placebo Comparator|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
16688802|NCT02024919|Active Comparator|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
16688803|NCT02024919|Placebo Comparator|Saline|intracoronary saline 5 mL
16688804|NCT02024906|Experimental|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
16688805|NCT02024906|Active Comparator|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
16688806|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
16688807|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
16688808|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
16688809|NCT02024880|Experimental|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
16688810|NCT02024880|Active Comparator|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
16688811|NCT02024867|Active Comparator|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
16688812|NCT02024867|Experimental|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
16688813|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
16688814|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
16688815|NCT02024841|Experimental|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:
~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2
~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks
~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
16688816|NCT02024828|Experimental|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
16688817|NCT02024828|Experimental|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
16688818|NCT02024828|Experimental|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
16688819|NCT02024828|Experimental|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
16688820|NCT02024815|Experimental|External Beam radiotherapy|Single 8 Gy fraction
16688821|NCT02024815|Active Comparator|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
16688822|NCT02024789|Placebo Comparator|Placebo|
16688823|NCT02024789|Experimental|RG1662 120 mg bid|
16688824|NCT02024789|Experimental|RG1662 240 mg bid|
16688825|NCT02024776|Active Comparator|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
16688826|NCT02024776|No Intervention|No-intervention|Standard counseling and conventional pre-surgical measures
16688827|NCT02024763|Experimental|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
16688828|NCT02024763|No Intervention|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
16688829|NCT02024750|Experimental|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
16688830|NCT02024750|No Intervention|Usual Care|Patients and families obtain routine multidisciplinary diabetes care
16688831|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.
~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
16688832|NCT02024724|Active Comparator|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
16688833|NCT02024724|Active Comparator|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
16688834|NCT02024711|Experimental|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
16688835|NCT02024711|Active Comparator|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
16688836|NCT02024698|Active Comparator|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
16688837|NCT02024698|Active Comparator|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
16688838|NCT02024685|Active Comparator|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
16688839|NCT02024685|Experimental|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
16688840|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
16688841|NCT02024659|Experimental|budesonide|
16688842|NCT02024659|Placebo Comparator|placebo|
16688843|NCT02024646|Experimental|210 mg brodalumab|Administered via subcutaneous injections.
16688844|NCT02024646|Experimental|140 mg brodalumab|Administered via subcutaneous injection.
16688845|NCT02024646|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
16688846|NCT02024633|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
16688847|NCT02024620|Experimental|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
16688849|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
16688850|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
16688851|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
16688852|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
16688853|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
16688854|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
16688855|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
16688856|NCT02024594|Experimental|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
16688857|NCT02024594|Experimental|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
16688858|NCT02024594|No Intervention|control|No intervention
16688859|NCT02024581|Active Comparator|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
16688860|NCT02024581|Placebo Comparator|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
16688861|NCT02024568|Active Comparator|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.
~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.
~In case of poorly tolerated side effects a reduction to 50mg doses is available.
~Access to additional analgesic interventions is open as required for patient wellbeing."
16688862|NCT02024568|Placebo Comparator|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.
~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.
~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.
~Access to additional analgesic interventions is open as required for patient wellbeing."
16688863|NCT02024555|Active Comparator|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
16688864|NCT02024555|Placebo Comparator|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.
~The pill count will be the same as the comparator regimen."
16688865|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
16688866|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
16688867|NCT02024529|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL Intra-articular injection of Ampion
16688868|NCT02024529|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
16688869|NCT02024516|Experimental|50 gr concentrated pomegranate juice|
16688870|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
16688871|NCT02024503||Control group|Healthy Volunteers.
16688872|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
16688936|NCT02024048||Control|OCT
16688873|NCT02024477|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
16688874|NCT02024477|Active Comparator|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
16688875|NCT02024464|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent
16688876|NCT02024464|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
16688877|NCT02024451|Active Comparator|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.
~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
16688878|NCT02024451|No Intervention|radial shock wave& no treatment|No treatment: patients recieved no intervention.
16688879|NCT02024438|Other|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
16688880|NCT02024438|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
16688881|NCT02024425|Active Comparator|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
16688882|NCT02024425|Placebo Comparator|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
16688883|NCT02024412|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
16688884|NCT02024412|Placebo Comparator|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
16688885|NCT02024399|Other|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
16688886|NCT02024386|Experimental|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
16688887|NCT02024386|Experimental|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
16688888|NCT02024386|No Intervention|Control arm|No drug
16688889|NCT02024373|Experimental|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
16688890|NCT02024373|Placebo Comparator|placebo|placebo:20 mg (every evening orally) for 8 weeks
16688891|NCT02024360|Experimental|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
16688892|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
16688893|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
16688894|NCT02024334|Active Comparator|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
16688895|NCT02024334|Placebo Comparator|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
16688896|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
16688897|NCT02024308|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
16688898|NCT02024308|Active Comparator|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
16688899|NCT02024295|Experimental|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
16688900|NCT02024295|Active Comparator|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
16688901|NCT02024282|Other|usual care|
16688902|NCT02024282|Active Comparator|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.
~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.
~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.
~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
16688903|NCT02024282|Active Comparator|Brief intervention and parent leaflet|
16688904|NCT02024282|Active Comparator|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention & parent information leaflet intervention groups (factorial design)
16688905|NCT02024269|Experimental|Adipose Stem Cells|
16688906|NCT02024256|Active Comparator|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
16688907|NCT02024256|Sham Comparator|Water|Pads soaked with cold water
16688908|NCT02024243||miR210 and Punch Tissue Biopsy|Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
16688909|NCT02024230||Warfarin|The dose of warfarin can be controlled so that the PT-INR value will be 2.0-3.0 in those aged under 70 years and 1.6-2.6 in those aged 70 years or more.
16688937|NCT02024035||Tomotherapy|
16688938|NCT02024035||Arc'therapy Vmat|
16688910|NCT02024230||Rivaroxaban|A dose of 15 mg of rivaroxaban is orally administered to adults once a day. The dose can be reduced to 10 mg in patients with renal insufficiency (creatinine clearance: 30-49 mL/minute), patients at a high risk of hemorrhage (HAS-BLED score), old patients aged 75 years or more, and low body weight patients.
16688911|NCT02024217|Experimental|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
16688912|NCT02024204|Active Comparator|Uncontrolled LRS|Patients who have uncontrolled lower respiratory symptoms (ACT < 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
16688913|NCT02024204|Other|Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
16688914|NCT02024191|Experimental|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
16688915|NCT02024191|No Intervention|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
16688916|NCT02024178|Experimental|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
16688917|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
16688918|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
16688919|NCT02024152|Experimental|JDP-205 IV high dose|
16688920|NCT02024152|Experimental|JDP-205 IV low dose|
16688921|NCT02024152|Experimental|JDP-205 IM high dose|
16688922|NCT02024152|Active Comparator|Control|
16688923|NCT02024139|Experimental|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
16688924|NCT02024139|Placebo Comparator|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
16688925|NCT02024126|Experimental|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
16688926|NCT02024126|Active Comparator|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
16688927|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.
~Intervention: a fasted venous blood sample is taken before PET-scan"
16688928|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.
~Intervention: fasted venous blood sample"
16688929|NCT02024087|Experimental|Dalantercept 0.6 mg/kg plus sorafenib 400 mg|Cohort 1: Participants received dalantercept 0.6 mg/kg by subcutaneous (SC) injection once every 3 weeks plus sorafenib 400 mg orally (PO) once daily
16688930|NCT02024087|Experimental|Dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 2: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
16688931|NCT02024087|Experimental|Expansion cohort - dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 3: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
16688932|NCT02024074|Other|Sestamibi(Tc- MBI) scan of the breast|
16688933|NCT02024061|Experimental|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.
~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
16688934|NCT02024061|Active Comparator|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.
~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
16688935|NCT02024048||Pregnant|OCT
16688940|NCT02024022|Active Comparator|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:
~4L split polyethylene glycol solution
~split magnesium citrate/sodium picosulphate preparation regimen"
16688941|NCT02024022|Experimental|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
16688942|NCT02024009|Experimental|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
16688943|NCT02024009|Experimental|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
16688944|NCT02024009|Experimental|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then
~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
16688945|NCT02024009|Experimental|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then
~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
16688946|NCT02024009|Experimental|Arm E|"6 cycles of GEMABX*
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
16688947|NCT02023996|Experimental|PET Imaging With 89Zr-DFO-Trastuzumab|Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg [1]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics & determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts & blood draws. Subsequent patients will receive the antibody & will only undergo imaging at a single time point (based on the first 10 patients) & will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
16688948|NCT02023983|Experimental|Early discharge|
16688949|NCT02023983|Active Comparator|Standard discharge|
16688950|NCT02023970|Other|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
16688951|NCT02023970|Other|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
16688952|NCT02023970|Other|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
16688953|NCT02023957|Experimental|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
16688954|NCT02023957|No Intervention|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
16688955|NCT02023944|Other|Intervention|12-week course on memory and aging, consists of psychoeducation and skills training
16688956|NCT02023944|No Intervention|Control, No Intervention|"No Intervention, considered treatment as usual"
16688957|NCT02023931|Experimental|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
16688958|NCT02023918|Experimental|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
16688959|NCT02023905|Experimental|Arm 1|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is present, patients will be treated in Arm 1 with single-agent everolimus at 10 mg daily continuously. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
16688960|NCT02023905|Experimental|Arm 2|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is not present, patients will be treated in Arm 2 with combined everolimus and Temozolomide (TMZ). Everolimus will be given at 10 mg daily continuously, and Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression. In Arm 2, TMZ will be stopped after 12 cycles.
16688961|NCT02023905|Experimental|Arm 3|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If 1p/19q co-deletion is present, patients will be treated in Arm 3 with single-agent everolimus at 10 mg daily continuously. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
16688962|NCT02023892|Experimental|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
16699691|NCT01952548|Placebo Comparator|Dose 4 Placebo|
16688963|NCT02023892|Placebo Comparator|placebo|placebo 20mg tablet, single dose of 80mg by mouth
16688964|NCT02023879|Placebo Comparator|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.
~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
16688965|NCT02023879|Other|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.
~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
16688966|NCT02023879|Experimental|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.
~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
16688967|NCT02023866|Experimental|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
16688968|NCT02023853|Experimental|ultrasonic, erythritol, metronidazole gel|
16688969|NCT02023840|Active Comparator|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
16688970|NCT02023840|Placebo Comparator|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
16688971|NCT02023827|Experimental|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
16688972|NCT02023827|No Intervention|Standard care|Participants receive standard care from the probation officer
16688973|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
16688974|NCT02023801|Experimental|Aurora Treatment Arm|Endometrial Ablation
16688975|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
~Intervention: Biological: Pneumostem®"
16688976|NCT02023775||Patients implanted with Medtronic Melody valve|All patients that received a valve implantation were included in the registry.
16688977|NCT02023749|Active Comparator|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
16688978|NCT02023749|No Intervention|Control group|Control group maintained their usual diet without nut supplement
16688979|NCT02023736|Active Comparator|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
16688980|NCT02023736|Experimental|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
16688981|NCT02023723|Experimental|Energy Drink|16oz original flavor energy drink consume 2 -16oz energy drinks within 60 minutes
16688982|NCT02023723|Active Comparator|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
16688983|NCT02023710|Experimental|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
16688984|NCT02023710|Active Comparator|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
16688985|NCT02023697|Experimental|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
16688986|NCT02023697|Experimental|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
16688987|NCT02023697|Experimental|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
16688988|NCT02023684|Placebo Comparator|control|Irrigation will be carried out with saline
16688989|NCT02023684|Active Comparator|Lidocaine|Irrigation will be carried out with Lidocaine
16688990|NCT02023684|Active Comparator|Ropivacaine|Irrigation will be carried out with Ropivacaine
16688991|NCT02023658|Experimental|Systems analysis and improvement|pMTCT systems analysis and improvement
16688992|NCT02023658|No Intervention|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
16688993|NCT02023645|Experimental|Active supplement|10 mg lutein + 2 mg zeaxanthin
16688994|NCT02023645|Placebo Comparator|inert placebo|placebo for comparison
16688995|NCT02023632|Experimental|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
16688996|NCT02023632|Active Comparator|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
16688997|NCT02023632|Sham Comparator|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
16688998|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
16688999|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism >2.0 D
16689000|NCT02023606|Experimental|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.
16689001|NCT02023593|Experimental|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
16689002|NCT02023580|Experimental|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
16689003|NCT02023580|Active Comparator|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
16689004|NCT02023567|Experimental|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
16689005|NCT02023567|No Intervention|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
16689006|NCT02023554|Experimental|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
16689007|NCT02023554|Active Comparator|Theophylline alone|steady-state plasma concentration of theophylline alone
16689008|NCT02023541|Other|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
16689009|NCT02023541|Other|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
16689010|NCT02023515|Experimental|Stress Management|Approximately half of the participants will be randomized to a stress management arm. Participants will undergo Emotional Brain Training during a 90 minute session once per week for ten weeks in order to rewire the brain and improve stress management techniques.
16689011|NCT02023515|Active Comparator|standard behavioral weight loss|Half of participants will receive a standard behavioral weight loss program in 90 minute sessions once per week for 10 weeks
16689012|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
16689013|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
16689014|NCT02023489|Other|Type 2 Diabetes Mellitus|
16689015|NCT02023489|Other|Insulin sensitive volunteers|
16689016|NCT02023489|Other|prediabetic subjects|
16689017|NCT02023489|Other|familiar hypocalciuric hypercalcemic patients|
16689018|NCT02023489|Other|Type 1 diabetes mellitus|
16689019|NCT02023476|Experimental|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
16689020|NCT02023476|Active Comparator|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
16689021|NCT02023463|Experimental|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
16689022|NCT02023450|Experimental|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
16689023|NCT02023450|Experimental|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
16689024|NCT02023437|Experimental|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
16689025|NCT02023437|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
16689026|NCT02023424|Experimental|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
16689027|NCT02023411|Active Comparator|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.
16689028|NCT02023411|Placebo Comparator|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.
16689029|NCT02023398|Experimental|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
16689030|NCT02023398|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
16689031|NCT02023385|Experimental|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
16689032|NCT02023385|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
16689033|NCT02023372|Other|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
16689034|NCT02023359||Treatment|Everolimus and exemestane
16689035|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
16689036|NCT02023333|Experimental|Regorafenib|This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks).
16689037|NCT02023320|Experimental|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
16689038|NCT02023320|Experimental|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
16689039|NCT02023307|Experimental|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
16689040|NCT02023294|Active Comparator|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
16689041|NCT02023294|Experimental|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
16689042|NCT02023281|No Intervention|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
16689043|NCT02023281|Experimental|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
16689044|NCT02023268|Experimental|T2762|
16689045|NCT02023268|Active Comparator|Vismed®|
16689046|NCT02023255|Experimental|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
16689047|NCT02023255|Experimental|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
16689048|NCT02023255|Experimental|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
16689049|NCT02023255|Experimental|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
16689050|NCT02023255|Experimental|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
16689051|NCT02023255|Experimental|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
16689052|NCT02023255|Experimental|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
16689053|NCT02023255|Experimental|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
16689054|NCT02023242|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
16689055|NCT02023242|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
16689056|NCT02023229|Experimental|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
16689057|NCT02023229|Active Comparator|Diet|High-fiber high-protein diet
16689058|NCT02023203|Experimental|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
16689059|NCT02023203|Active Comparator|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
16689060|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
16689061|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
16689062|NCT02023164|Experimental|Test Drug|10 mg/mL, 1 mL
16689063|NCT02023164|Active Comparator|Control|50 mg/mL, 1 mL
16689064|NCT02023151|Other|Omalizumab|Active
16689065|NCT02023138|Active Comparator|Focus group|
16689066|NCT02023138|Experimental|Wiki|
16689067|NCT02023125|Experimental|Group 1: Treatment A first, then Treatment B|Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Each period will be separated by at least 10 days.
16689068|NCT02023125|Experimental|Group 1: Treatment B first, then Treatment A|Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Each period will be separated by at least 10 days.
16689106|NCT02022761|Experimental|80 mg Laninamivir octanoate|Dry Powder Inhaler
16689107|NCT02022761|Placebo Comparator|Matching placebo|Dry Powder Inhaler
16689108|NCT02022748|Experimental|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
16689069|NCT02023125|Experimental|Group 2: Alectinib Alone, Alectinib + Esomeprazole|Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
16689070|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
16689071|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
16689072|NCT02023099|Experimental|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis
16689073|NCT02023099|Placebo Comparator|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
16689074|NCT02023099|Experimental|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
16689075|NCT02023086||FABRY group|"contrast sensitivity measurement
~slit lamp assessment and intra-ocular pressure measurement
~ocular coherence tomography at the optic nerve head
~visual field testing
~OSOME (oxygen flow at the optic nerve head measurement)
~Tropicamide"
16689076|NCT02023086||CONTROL group|"contrast sensitivity measurement
~slit lamp assessment and intra-ocular pressure measurement
~ocular coherence tomography at the optic nerve head
~visual field testing
~oxygen flow at the optic nerve head measurement (OSOME)
~Under tropicamide"
16689077|NCT02023073||Healthy volunteers|
16689078|NCT02023047|Experimental|Once daily|Nifedipine 12 mg Once daily
16689079|NCT02023047|Experimental|Twice Daily|Nifedipine 12 mg twice daily
16689080|NCT02023034|Experimental|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
16689081|NCT02023034|Sham Comparator|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
16689082|NCT02023021|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
16689083|NCT02023008|Experimental|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
16689084|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
16689085|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
16689086|NCT02022982|Experimental|Palbociclib and PD-0325901|"Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.
~PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
16689087|NCT02022956|Experimental|Open-Label Lorcaserin (BELVIQ)|
16689088|NCT02022930|Experimental|Hydros|Hydros Joint Therapy
16689089|NCT02022930|Experimental|Hydros-TA|Hydros-TA Joint Therapy
16689090|NCT02022930|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide
16689091|NCT02022917|Experimental|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab 21 day cycles of carboplatin, paclitaxel, and bevacizumab
16689092|NCT02022904|Experimental|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
16689093|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
16689094|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
16689095|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
16689096|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
16689097|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
16689098|NCT02022852|Active Comparator|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
16689099|NCT02022852|Experimental|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
16689100|NCT02022826|Experimental|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
16689101|NCT02022813|No Intervention|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
16689102|NCT02022813|Experimental|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.
~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
16689103|NCT02022800|Other|PET 18FDOPA|PET 18FDOPA
16689104|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
16689105|NCT02022761|Experimental|40 mg Laninamivir octanoate|Dry Powder Inhaler
16689109|NCT02022748|Experimental|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
16689110|NCT02022748|Experimental|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
16689111|NCT02022735|Experimental|Bilateral stimulation|Participants will receive Deep Brain Stimulation Bilaterally.
16689112|NCT02022735|Experimental|Left stimulation|Participants will receive Deep Brain Stimulation on the left side only
16689113|NCT02022735|Experimental|Right stimulation|Participants will receive Deep Brain Stimulation on the right side only
16689114|NCT02022735|No Intervention|Off stimulation|Participants will receive no brain stimulation
16689115|NCT02022722|Active Comparator|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
16689116|NCT02022722|Active Comparator|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
16689117|NCT02022709|Active Comparator|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
16689118|NCT02022709|Active Comparator|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
16689119|NCT02022683|Experimental|Endoscopic Lung Volume Reduction|Patients are implanted with Zephyr Valves
16689120|NCT02022683|No Intervention|Standard of Care|Patients are given Standard Medical Care
16689121|NCT02022670|Placebo Comparator|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
16689122|NCT02022670|Experimental|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
16689123|NCT02022670|Experimental|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
16689124|NCT02022657|Active Comparator|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
16689125|NCT02022657|Active Comparator|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
16689126|NCT02022657|Active Comparator|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
16689127|NCT02022657|Active Comparator|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
16689128|NCT02022657|Active Comparator|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
16689129|NCT02022657|Active Comparator|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
16689138|NCT02022631|Experimental|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
16689139|NCT02022631|Active Comparator|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
16689140|NCT02022605|Experimental|Hands-on EMS training group|
16689141|NCT02022605|Active Comparator|Standard training group|
16689142|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
16689143|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
16689585|NCT02019667|Experimental|Placebo|Participants with SSADH Deficiency when on placebo for six months
16689144|NCT02022579|Experimental|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
16689145|NCT02022566||Supported self-management of osteoarthrits program|
16689146|NCT02022553|Experimental|rectal cancer, surgery|
16689147|NCT02022553|Active Comparator|rectal cancer, RACHEL, surgery|
16689148|NCT02022540|Experimental|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
16689149|NCT02022540|Experimental|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
16689150|NCT02022540|Experimental|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
16689151|NCT02022540|Experimental|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
16689152|NCT02022540|Experimental|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
16689153|NCT02022540|Experimental|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
16689154|NCT02022527|Experimental|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
16689155|NCT02022527|Active Comparator|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
16689156|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
16689157|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
16689158|NCT02022501|Experimental|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
16689159|NCT02022501|Experimental|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
16689160|NCT02022501|Experimental|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
16689161|NCT02022488|Active Comparator|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
16689162|NCT02022488|Active Comparator|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
16689163|NCT02022488|Placebo Comparator|midazolam|Midazolam 0.5mg/kg
16689164|NCT02022475|Active Comparator|Cholecalciferol|100 000 units vitamin D3 single dose
16689165|NCT02022475|Placebo Comparator|Placebo|similar appearance
16689166|NCT02022462|Experimental|Health Navigation|Up to 151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
16689167|NCT02022462|Other|Waitlist Control|Up to 146 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (n = 73, 6 month waitlist with treatment as usual then they will receive the intervention) or immediate intervention with the Bridge (n = 73). Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
16689168|NCT02022449|No Intervention|Control|participants only complete assessments
16689169|NCT02022449|Experimental|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
16689170|NCT02022436|Active Comparator|contrast ultrasound for patients with AAA|Contrast ultrasound
16689171|NCT02022436|Active Comparator|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
16689172|NCT02022423|Active Comparator|Telephone Counseling|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs
16689173|NCT02022423|Experimental|Internet-based walking program|Weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
16689174|NCT02022423|Experimental|Telephone counseling and Internet-based walking program|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs plus weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
16689175|NCT02022423|No Intervention|Usual Care|Subjects will continue with their health care as usual
16689176|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
16689177|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
16689178|NCT02022384||study patients|Blood sample and life quality questionnaires
16689179|NCT02022371|Experimental|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
16689180|NCT02022358|Active Comparator|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue
~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
16689254|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
16689181|NCT02022358|Experimental|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).
~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
16689182|NCT02022345|Active Comparator|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
16689183|NCT02022345|Active Comparator|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
16689184|NCT02022319|Other|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
16689185|NCT02022306|Placebo Comparator|SAD TD-6450|Single ascending dose (Part A)
16689186|NCT02022306|Placebo Comparator|MAD TD-6450|Multiple ascending dose (Part B)
16689187|NCT02022306|Active Comparator|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
16689188|NCT02022293|Active Comparator|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
16689189|NCT02022293|Placebo Comparator|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
16689190|NCT02022280|Experimental|Proton Pump Inhibitor|Lansoprazole (Prevacid)
16689191|NCT02022280|Placebo Comparator|Vitamin pill|
16689192|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
16689193|NCT02022267||control group|healthy children of employees of our hospital
16689194|NCT02022254|Experimental|Semaglutide administrations|
16689195|NCT02022241|Experimental|Repeated GnRHa|Patients were triggered with repeated GnRHa
16689196|NCT02022228|Experimental|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
16689197|NCT02022228|Experimental|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
16689198|NCT02022215|Experimental|ME1111 Solution, Low strength|
16689199|NCT02022215|Experimental|ME1111 Solution, High strength|
16689200|NCT02022215|Placebo Comparator|Matching Vehicle Solution|
16689201|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
16689202|NCT02022176|Active Comparator|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
16689203|NCT02022176|Placebo Comparator|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
16689204|NCT02022176|Active Comparator|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
16689205|NCT02022176|Placebo Comparator|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
16689206|NCT02022163|Experimental|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
16689207|NCT02022163|Experimental|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
16689208|NCT02022163|Experimental|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
16689209|NCT02022163|Experimental|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
16689210|NCT02022163|Placebo Comparator|Placebo|Placebo, 2 doses given 21 days apart
16689211|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
16689212|NCT02022137|Experimental|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
16689213|NCT02022137|Placebo Comparator|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
16689214|NCT02022137|Active Comparator|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
16689215|NCT02022124|Experimental|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
16689216|NCT02022124|No Intervention|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
16689217|NCT02022111|Active Comparator|Intervention Program of Care|"Patient Education and Behavioral Activation by a Care Coordinator;
~Supporting Self-Care;
~Psychiatrist and Diabetologist Reviews; and
~Decision-support Electronic Health Record System"
16689218|NCT02022111|Placebo Comparator|Control Arm|Participants randomized to the control arm will receive the existing standard of care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
16689429|NCT02020746|Active Comparator|EscharEx|Enzymatic debridement
16689221|NCT02022085|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;
~One implant magnet
~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
16689222|NCT02022072|Other|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
16689223|NCT02022059|Experimental|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
16689224|NCT02022059|Placebo Comparator|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
16689225|NCT02022046||2/study, control|Study group: children aged<18 years with chronic kidney disease Control group: children aged<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
16689226|NCT02022033|Experimental|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
16689227|NCT02022020||Group 1|
16689228|NCT02022007|Active Comparator|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
16689229|NCT02022007|Active Comparator|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
16689230|NCT02022007|Experimental|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)
~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
16689231|NCT02021994||Arm Automatic Electronic BPM|
16689232|NCT02021994||mercury sphygmomanometer|
16689233|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689234|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689235|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689236|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689237|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689238|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689239|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689240|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689241|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689242|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
16689243|NCT02021968|Experimental|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
16689244|NCT02021968|Placebo Comparator|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
16689245|NCT02021955|No Intervention|usual care|Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
16689246|NCT02021955|Experimental|guideline treatment recommendations|Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
16689247|NCT02021942|Experimental|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
16689248|NCT02021929|Experimental|Sorafenib|400 mg (2 capsules) taken by mouth once a day
16689249|NCT02021929|Placebo Comparator|Placebo|2 capsules taken by mouth once a day
16689250|NCT02021903|Experimental|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
16689251|NCT02021903|Placebo Comparator|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
16689252|NCT02021890|Experimental|ballroom and Latin dance program|two-hour dancing session twice a week
16689253|NCT02021890|Active Comparator|Self-selected physical activity|self-selected program of physical activity
16689255|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
16689256|NCT02021864|Experimental|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
16689257|NCT02021864|Active Comparator|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
16689258|NCT02021851|Active Comparator|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
16689259|NCT02021851|Placebo Comparator|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
16689260|NCT02021838||California|Lethality Assessment Program
16689261|NCT02021838||North Carolina|Lethality Assessment Program
16689262|NCT02021838||Ohio|Domestic Violence High Risk Team
16689263|NCT02021838||Illinois|Lethality Assessment Program
16689264|NCT02021838||Michigan|Lethality Assessment Program
16689265|NCT02021838||Tennessee|Lethality Assessment Program
16689266|NCT02021825|Other|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
16689267|NCT02021812|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
16689268|NCT02021799|No Intervention|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
16689269|NCT02021799|No Intervention|Nourished Pregnant Women|Pregnant women who are classified as healthy
16689270|NCT02021799|No Intervention|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
16689271|NCT02021799|Experimental|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
16689272|NCT02021799|Experimental|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
16689273|NCT02021786|Experimental|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
16689274|NCT02021786|No Intervention|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
16689275|NCT02021773|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
16689276|NCT02021773|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
16689277|NCT02021773|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
16689278|NCT02021760|Active Comparator|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if >180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
16689279|NCT02021760|Sham Comparator|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.
~Otheriwize normal primary PCI."
16689280|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
16689281|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine >30 ng/mL and urine cotinine >50 ng/mL
~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
16689282|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study
~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
16689283|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure
~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
16689284|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
16689285|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
16689430|NCT02020746|Placebo Comparator|Gel Vehicle|Control arm
16689431|NCT02020733|Other|balloon catheter|
16689432|NCT02020733|Other|metal cannula|
16689286|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
16689287|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
16689288|NCT02021695||Group I: Non-diabetic controls|"Group I: Non-diabetic controls Good overall health without history of Type II diabetes. Normal fasting glucose level (<100 mg/dL) and HbA1C < 5.7%
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
16689289|NCT02021695||Group II: Diabetic with HbA1C<7%|"Group II:
~HbA1C<7%
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
16689290|NCT02021695||Group III: Good controlled diabetics with 7 % <HbA1C < 10%|"Group III Good controlled diabetics with 7 % <HbA1C < 10%
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
16689291|NCT02021695||Group IV: Poorly controlled diabetics with HbA1C > 10%.|"Group IV:
~Poorly controlled diabetics with HbA1C > 10%.
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
16689292|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
16689293|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
16689294|NCT02021669|Experimental|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
16689295|NCT02021669|Placebo Comparator|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
16689296|NCT02021656|Experimental|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
16689297|NCT02021643|Experimental|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
16689298|NCT02021643|Experimental|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
16689299|NCT02021643|Experimental|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
16689300|NCT02021643|Experimental|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
16689301|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
16689302|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
16689303|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
16689304|NCT02021617|No Intervention|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
16689305|NCT02021604|Experimental|Pancreatic Imaging with Fluorodopa F 18|
16689306|NCT02021591|No Intervention|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
16689307|NCT02021591|Experimental|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
16689308|NCT02021578|Experimental|Family Cognitive Behavioral Prevention|A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.
16689309|NCT02021578|Active Comparator|Written Information|Families receive written materials about depression and the effects of parental depression on children.
16699692|NCT01952548|Placebo Comparator|Dose 5 Placebo|
16689310|NCT02021565|Experimental|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.
~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
16689311|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
16689312|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU >24 hours. All subjects will undergo blood sampling.
16689313|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).
~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
16689314|NCT02021526|Experimental|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
16689315|NCT02021526|Experimental|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
16689316|NCT02021513|Experimental|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
16689317|NCT02021513|Placebo Comparator|Placebo|Olive Oil
16689318|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
16689319|NCT02021474|Experimental|Histamine Dihydrochloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
16689320|NCT02021474|Placebo Comparator|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
16689321|NCT02021461|Experimental|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
16689322|NCT02021461|Experimental|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
16689323|NCT02021461|Experimental|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
16689324|NCT02021448|Other|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
16689325|NCT02021435|Experimental|Salt Substitute|salt substitute
16689326|NCT02021435|No Intervention|Control|Participants continue to buy salt at their own expense
16689327|NCT02021422|Other|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows
~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day
~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
16689328|NCT02021409|Experimental|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
16689329|NCT02021409|Experimental|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
16689330|NCT02021409|Experimental|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
16689331|NCT02021409|Active Comparator|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
16689332|NCT02021396|Experimental|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
16689333|NCT02021396|No Intervention|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
16689334|NCT02021383|Experimental|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
16689436|NCT02020694|Placebo Comparator|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.
~Hypocaloric diet"
16689335|NCT02021383|No Intervention|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
16689336|NCT02021383|Experimental|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
16689337|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
16689338|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
16689339|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
16689340|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
16689341|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
16689342|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
16689343|NCT02021357|Experimental|Hyperboloid associated with the exercise of proprioceptive|The proprioceptive treatment protocol if run in the use of exercises with hyperboloid based on studies of Biasotto-Gonzalez (2005), for each exercise will be held 6 sets of 6 reps. Between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain, and after that period you will be asked to volunteer the proprioceptive exercise of ´ ´ tongue on the hard palate ´ ´ Biasotto-Gonzalez-based (2005), which consists of the language supported in the hard palate, you must open and close the mouth, having as the principle language as a physical reference.
16689344|NCT02021357|Active Comparator|Hyperboloid|"The proprioceptive treatment protocol if run in the use of the hyperboloid, based on studies of Biasotto-Gonzalez (2005), but without the proprioceptive exercise of language in ´ ´ hard palate ´ ´.
~For each exercise will be held 6 series of 6 repetitions, and between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain."
16689345|NCT02021357|No Intervention|Control|The individuals in control group did not receive any type of intervention, being offered proprioceptive treatment after the study period.
16689346|NCT02021344|No Intervention|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
16689347|NCT02021344|Experimental|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
16689348|NCT02021344|Experimental|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
16689349|NCT02021344|No Intervention|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
16689350|NCT02021331|Active Comparator|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
16689351|NCT02021331|Experimental|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
16689352|NCT02021318|Experimental|Roxadustat|Participants received roxadustat orally according to the tiered weight-based approach, with starting dose of 70 mg (milligram) given thrice weekly (TIW) to participants weighing up to 70 kg (kilogram) and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL (gram per deciliter) and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat up to a maximum of 104 weeks.
16689353|NCT02021318|Active Comparator|Darbepoetin alfa|Participants received initial dose of darbepoetin alfa based upon the weight (either 0.45 μg/kg (microgram per kilogram), as a single subcutaneous or intravenous (IV) injection once weekly or 0.75 μg/kg, as a single subcutaneous injection once every 2 weeks) as per European Summary of Product Characteristics (EU SmPC) along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks.
16689354|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
16689355|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
16689356|NCT02021292|Experimental|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
16689357|NCT02021292|Placebo Comparator|Placebo|Matching placebo oral tablet, to be taken once daily.
16689358|NCT02021279|Experimental|MatriStem Pelvic Floor Matrix|surgical mesh device
16689359|NCT02021279|Active Comparator|Native Tissue Repair|suture repair
16689360|NCT02021253|Placebo Comparator|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:
~459 mg of corn starch
~6 mg of magnesium stearate
~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.
~Methods of administration: Oral.
~Duration of treatment: 14 days"
16689433|NCT02020720|Experimental|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
16689586|NCT02019667|Experimental|Study Drug|Participants with SSADH Deficiency receiving SGS-742 when on study drug for six months
16689361|NCT02021253|Active Comparator|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule
~Composition: One capsule of 560 mg contains Lactibiane tolerance:
~345 mg of corn starch
~114 mg premix lactic
~6 mg of magnesium stearate Excipients: magnesium stearate
~Method of administration: Oral
~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
16689362|NCT02021240|Active Comparator|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
16689363|NCT02021240|Active Comparator|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
16689364|NCT02021240|Placebo Comparator|Normal saline|Single dose of intravenous normal saline before incision
16689365|NCT02021227|No Intervention|Standard group|
16689366|NCT02021227|Other|Chair sitting group|
16689367|NCT02021214|Experimental|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose Placebo, single dose
16689368|NCT02021201|Experimental|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
16689369|NCT02021201|Experimental|2|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
16689370|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
16689371|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
16689372|NCT02021175|Experimental|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
16689373|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
16689374|NCT02021162||Gilenya|MS patients taking Gilenya
16689375|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
16689376|NCT02021149|Other|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
16689377|NCT02021149|Experimental|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
16689378|NCT02021149|Sham Comparator|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
16689379|NCT02021136|Experimental|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
16689380|NCT02021136|Active Comparator|Control|usual antalgic treatment + physical exercises recommendations.
16689381|NCT02021123|Experimental|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
16689382|NCT02021110|No Intervention|Control group|This group will receive standard care (no treatment)
16689383|NCT02021110|Experimental|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
16689384|NCT02021097|Experimental|LNG100 mcg/EE20 mcg|
16689385|NCT02021097|Active Comparator|LNG 150mcg/ EE 30mcg|
16689386|NCT02021084|Placebo Comparator|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
16689387|NCT02021084|Active Comparator|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
16689388|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
16689389|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
16689390|NCT02021058|Experimental|Experimental Formula|Experimental Formula
16689391|NCT02021058|Other|Standard Formula|Standard Control formula
16689392|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
16689393|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
16689394|NCT02021032|Experimental|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
16689395|NCT02021019|Experimental|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
16689396|NCT02021019|No Intervention|Usual Care|Usual care
16689435|NCT02020694|Experimental|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.
~Hypocaloric diet"
16689397|NCT02021006|Active Comparator|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.
~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
~Physicians can chose one the following schedules:
~nitrofurantoin 1.5-2 mg/kg per day
~Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
~cefixime 2 mg/kg per day
~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
16689398|NCT02021006|Experimental|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
16689399|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
16689400|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
16689401|NCT02020980||Post-stroke lower limb spasticity patients|
16689402|NCT02020967||Acromegaly patients|
16689403|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
16689404|NCT02020941|Experimental|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.
~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
16689405|NCT02020928|Experimental|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
16689406|NCT02020928|Sham Comparator|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
16689407|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
16689408|NCT02020889|Experimental|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
16689409|NCT02020889|Placebo Comparator|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
16689410|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
16689411|NCT02020863|Experimental|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
16689412|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
16689413|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
16689414|NCT02020824|Active Comparator|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.
~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
16689415|NCT02020824|Experimental|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.
~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
16689416|NCT02020824|Other|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.
~Imagery with functional MRI initial. Imagery with PET-scanner initial."
16689417|NCT02020811|Experimental|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
16689418|NCT02020798|Placebo Comparator|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
16689419|NCT02020798|Experimental|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
16689420|NCT02020785|Active Comparator|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
16689421|NCT02020785|Placebo Comparator|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
16689426|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
16689427|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
16689428|NCT02020759||ICU patients|Neurological monitoring with transcranial Doppler ultrasound
16689437|NCT02020681|Experimental|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
16689438|NCT02020681|Placebo Comparator|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
16689439|NCT02020668|Experimental|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
16689440|NCT02020668|Other|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
16689441|NCT02020655||10 healthy volunteers|Shear- force model
16689442|NCT02020642|Experimental|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
16689443|NCT02020642|No Intervention|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
16689444|NCT02020629|Experimental|Lixisenatide|Lixisenatide 20µg daily
16689445|NCT02020616|Experimental|LY3053102|Stage 1: Escalating dose (7 milligrams [mg] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
16689446|NCT02020616|Placebo Comparator|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
16689447|NCT02020616|Active Comparator|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
16689448|NCT02020616|Experimental|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
16689449|NCT02020603|Active Comparator|APC group|epinephrine injection plus argon plasma coagulation
16689450|NCT02020603|Active Comparator|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
16689451|NCT02020590|Experimental|ALLOB® Implantation|One arm: ALLOB® Implantation
16689452|NCT02020577|Experimental|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
16689453|NCT02020564|Experimental|Treatment Group|Computerized exercised will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16689454|NCT02020564|Placebo Comparator|Placebo control group|Computerized exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
16689455|NCT02020551|Placebo Comparator|saline spray application|Placebo group
16689456|NCT02020551|Experimental|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
16689457|NCT02020538|Placebo Comparator|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
16689458|NCT02020538|Active Comparator|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
16689459|NCT02020525|Experimental|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
16689460|NCT02020525|Active Comparator|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
16689461|NCT02020512|Experimental|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
16689462|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
16689463|NCT02020486|Experimental|Group A|Experimental
16689464|NCT02020486|Experimental|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
16689465|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
16689466|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
16689467|NCT02020460|Active Comparator|Subdural trial lead|SCS trial lead in the subdural space.
16689468|NCT02020460|Active Comparator|Epidural trial lead|SCS trial lead in the epidural space.
16689469|NCT02020434|Experimental|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
16689473|NCT02020408|Experimental|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
16689474|NCT02020395|Placebo Comparator|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
16689475|NCT02020395|Active Comparator|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
16689476|NCT02020382|Other|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
16689477|NCT02020382|Other|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
16689478|NCT02020382|Other|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
16689479|NCT02020382|Other|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
16689480|NCT02020382|Other|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
16689481|NCT02020382|Other|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
16689482|NCT02020369|Experimental|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
16689546|NCT02019927|Experimental|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
16689483|NCT02020369|Experimental|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
16689484|NCT02020356|Experimental|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
16689485|NCT02020356|Placebo Comparator|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
16689486|NCT02020343||Healthy|Not insulin resistant
16689487|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
16689488|NCT02020343||Type 2 diabetics|Type 2 diabetics
16689489|NCT02020330|Active Comparator|AL3days|Artemether-lumefantrine 3 days
16689490|NCT02020330|Experimental|AL5days|Artemether-lumefantrine 5 days
16689491|NCT02020317|Active Comparator|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
16689492|NCT02020317|No Intervention|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
16689493|NCT02020304|Experimental|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
16689494|NCT02020304|Active Comparator|refrigerated temperature|refrigerated temperature combined spinal epidural dose (~<43 degrees F)
16689495|NCT02020291|Experimental|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
16689496|NCT02020278|Experimental|Tolvaptan|"Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment.
~Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg."
16689497|NCT02020265|Experimental|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
16689498|NCT02020265|Sham Comparator|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
16689499|NCT02020265|Active Comparator|A\T NF|This group will train modulation of A\T ratio by EEG neurofeedback
16689500|NCT02020252||Touchscreen Participants|New lung, gastric and pancreatic cancer patients presenting to the University of Chicago outpatient oncology clinics, a large research institution located on Chicago's Southside, were identified for study accrual, using the electronic scheduling system.
16689501|NCT02020239|Experimental|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
16689502|NCT02020239|Experimental|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
16689503|NCT02020239|No Intervention|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
16689504|NCT02020226|Experimental|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
16689505|NCT02020213|Other|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
16689506|NCT02020200|Experimental|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
16689507|NCT02020187|Experimental|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
16689508|NCT02020187|No Intervention|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
16689509|NCT02020161|Experimental|ATRA-Idarubicin|
16689510|NCT02020135|Experimental|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
16689511|NCT02020122|Active Comparator|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
16689512|NCT02020122|Active Comparator|Pregabalin|PGB 150mg x twice a day x 2 days
16689513|NCT02020122|Placebo Comparator|Placebo|Non active placebo x twice a day x 2 days
16689514|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
16689515|NCT02020096|Experimental|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
16689516|NCT02020096|Active Comparator|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
16689517|NCT02020070|Experimental|Ipilimumab & Degarelix With Radical Prostatectomy|"Week 1: Degarelix SQ injection (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose) and Ipilimumab at 3 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose)
~Week 11, 14, 17 or after sufficient wound healing and recovery post RP:
~Ipilimumab 3 mg/kg IV Follow-up Twelve week intervals until Week 87."
16689518|NCT02020070|Experimental|Ipilimumab & Degarelix With Prior With Radical Prostatectomy|Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
16689519|NCT02020057|Active Comparator|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
16689520|NCT02020057|Experimental|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
16689521|NCT02020044|Other|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
16689522|NCT02020031|Experimental|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
16689523|NCT02020031|Active Comparator|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
16689524|NCT02020018|Experimental|Prospective group|Negative pressure wound therapy (Prevena Incision Management System) applied immediately postoperatively.
16689525|NCT02020018|Active Comparator|Retrospective arm|Conventional sterile dry wound dressing applied immediately postoperatively.
16689526|NCT02020005|Experimental|non-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
16689527|NCT02020005|Experimental|non-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
16689528|NCT02020005|Experimental|mint-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
16689529|NCT02020005|Experimental|mint-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
16689530|NCT02020005|Experimental|non-flavored nicotine inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
16689531|NCT02020005|Experimental|mint-flavored inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
16689532|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
16689533|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
16689534|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
16689535|NCT02019979|Experimental|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
16689536|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone
~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
16689537|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.
~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
16689538|NCT02019953|Other|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
16689539|NCT02019953|Other|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
16689540|NCT02019953|Other|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
16689541|NCT02019953|Other|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
16689542|NCT02019953|Other|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
16689543|NCT02019940|Experimental|Riluzole|Riluzole 50 mg orally twice per day
16689544|NCT02019927|Experimental|Non-arthritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
16689545|NCT02019927|Experimental|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
16689547|NCT02019927|Sham Comparator|Sham - Non-arthritic ischemic optic neuropathy|Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
16689548|NCT02019927|Sham Comparator|Sham - Multiple Sclerosis|Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
16689549|NCT02019927|Sham Comparator|Sham - Ocular Trauma|Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
16689550|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
16689551|NCT02019901|No Intervention|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
16689552|NCT02019901|Experimental|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
16689553|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
16689554|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
16689555|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
16689556|NCT02019875|Placebo Comparator|Water|200 mL of water once a day for 14 days
16689557|NCT02019875|Active Comparator|Rifampin|Rifampin 600 mg once a day for 14 days
16689558|NCT02019875|Active Comparator|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
16689559|NCT02019875|Active Comparator|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
16689560|NCT02019875|Active Comparator|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
16689561|NCT02019875|Active Comparator|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
16689562|NCT02019862||TRJ®|
16689563|NCT02019849||Plasmafit® Total Hip Arthroplasty|
16689564|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
16689565|NCT02019823|Active Comparator|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the *StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
16689566|NCT02019823|Experimental|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:
~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text
~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment
~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
16689567|NCT02019823|Experimental|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
16689568|NCT02019810|Active Comparator|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
16689569|NCT02019810|Experimental|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
16689570|NCT02019797|Experimental|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
16689571|NCT02019797|Active Comparator|Propofol|5-8 mg/kg/hr infusion during surgery.
16689572|NCT02019784|Active Comparator|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
16689573|NCT02019784|Placebo Comparator|Placebo|Placebo tablets - 550mg twice daily for 90 days
16689574|NCT02019758|Active Comparator|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
16689575|NCT02019758|Active Comparator|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
16689576|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
16689577|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
16689578|NCT02019719|Experimental|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
16689579|NCT02019719|Experimental|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
16689580|NCT02019719|Experimental|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
16689581|NCT02019719|Experimental|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
16689582|NCT02019719|Placebo Comparator|Placebo|Subjects will receive placebo once daily for 4 weeks
16689583|NCT02019706|Experimental|Imaging|All subjects will be imaged
16689584|NCT02019693|Experimental|1/Single arm|INC280 400 mg twice every day by mouth, continuously
16689588|NCT02019641|Experimental|AET|AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
16689589|NCT02019641|Active Comparator|No AET|control will not engage in AET.No AET (education only)
16689590|NCT02019628|Experimental|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
16689591|NCT02019628|Experimental|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
16689592|NCT02019615|Active Comparator|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
16689593|NCT02019615|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
16689594|NCT02019602|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.
~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
16689595|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
16689596|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
16689597|NCT02019589|Placebo Comparator|Placebo|Placebo
16689598|NCT02019576|Other|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
16689599|NCT02019563|Experimental|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
16689600|NCT02019563|Active Comparator|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
16689601|NCT02019550|Experimental|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
16689602|NCT02019550|Experimental|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
16689603|NCT02019537|Active Comparator|Steroid group|Triamcinolone injection group
16689604|NCT02019537|Experimental|PRP group|Allogeneic PRP injection group
16689605|NCT02019524|Experimental|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
16689606|NCT02019524|Experimental|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
16689607|NCT02019524|Experimental|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
16689608|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age >17 years
~none of the following contraindications for Methylprednisolone:
~Allergy against Methylprednisolone.
~Currently in systemic treatment with glucocorticoid
~Current gastric ulcer
~Insulin dependent diabetes mellitus
~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
16689636|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
16689637|NCT02019329|Placebo Comparator|Placebo + risperidone|
16689638|NCT02019329|Experimental|RO5545965 + risperidone|
16699693|NCT01952548|Placebo Comparator|Dose 6 Placebo|
16689609|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment
~age >17 years, Danish social security number
~and none of the following at time of surgery:
~systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.
~gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery
~Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
16689610|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.
16689611|NCT02019498|Experimental|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
16689612|NCT02019498|Active Comparator|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
16689613|NCT02019485|Experimental|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
16689614|NCT02019485|Experimental|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
16689615|NCT02019472|Experimental|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
16689616|NCT02019472|Experimental|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
16689617|NCT02019472|Experimental|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
16689618|NCT02019459|Active Comparator|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
16689619|NCT02019459|Experimental|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
16689620|NCT02019446|Experimental|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
16689621|NCT02019446|Active Comparator|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
16689622|NCT02019433||Structan®|
16689623|NCT02019420|Experimental|Tedizolid phosphate IV|Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
16689624|NCT02019420|Active Comparator|Linezolid IV|Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
16689625|NCT02019407|Experimental|CTI group|CTI(Cavo-Tricuspid Isthmus)
16689626|NCT02019407|Placebo Comparator|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
16689627|NCT02019394|Experimental|Lu AE58054|
16689628|NCT02019381|Other|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
16689629|NCT02019381|Other|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
16689630|NCT02019368|Placebo Comparator|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
16689631|NCT02019368|Experimental|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
16689632|NCT02019368|No Intervention|Non-smoker|Oxidative status in non-smoker
16689633|NCT02019355|Experimental|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
16689634|NCT02019355|Active Comparator|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
16689635|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
16689639|NCT02019316|Experimental|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
16689640|NCT02019316|Placebo Comparator|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
16689641|NCT02019303|Other|Abnormal lymph nodes|There is only one arm to this study and includes all eligible and consented patients with abnormal axillary lymph node on ultrasound.
16689642|NCT02019290|Experimental|bitopertin-Midazolam|
16689643|NCT02019277|Experimental|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
16689644|NCT02019264|Experimental|Lorcaserin hydrochloride (HCL)10 mg|APD356 10 mg twice daily
16689645|NCT02019264|Placebo Comparator|Placebo|Placebo twice daily
16689646|NCT02019251|Experimental|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
16689647|NCT02019238|Placebo Comparator|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
16689648|NCT02019238|Active Comparator|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
16689649|NCT02019225|Experimental|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
16689650|NCT02019225|No Intervention|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
16689651|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
16689652|NCT02019186|Experimental|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
16689653|NCT02019173|Experimental|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
16689654|NCT02019160|Experimental|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
16689655|NCT02019160|Active Comparator|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
16689656|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
16689657|NCT02019147||Healthy Term Neonates|Controls
16689658|NCT02019134|Active Comparator|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
16689659|NCT02019134|Experimental|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
16689660|NCT02019108|Experimental|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
16689661|NCT02019108|Active Comparator|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
16689662|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
16689663|NCT02019082|Active Comparator|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
16689664|NCT02019082|Placebo Comparator|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
16689665|NCT02019069|Experimental|Liposomal cytarabine-daunorubicin CPX-351|"1st INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV at a dose of 65 units/m2/day over 90 minutes on days 1, 3, and 5.
~2nd INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.
~CONSOLIDATION: Beginning on day 28, patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3."
16689666|NCT02019056|Placebo Comparator|Placebo|enteric coated capsule
16689667|NCT02019056|Experimental|MG 500mg|Metadoxine + garlic oil
16689668|NCT02019056|Experimental|MG 1000mg|Metadoxine + garlic oil
16689669|NCT02019056|Sham Comparator|Metadoxine 500mg|enteric coated capsule
16689670|NCT02019043|Experimental|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
16689671|NCT02019043|No Intervention|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
16689672|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
16689673|NCT02019017|Experimental|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
16699694|NCT01952548|Placebo Comparator|Dose 7 Placebo|
16689674|NCT02019017|Experimental|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
16689675|NCT02019004|Active Comparator|Onabotulinum Toxin A|One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.
16689676|NCT02019004|Active Comparator|Incobotulinum Toxin A|The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.
16689677|NCT02018991|Active Comparator|Everolimus-Eluting-Stent (EES)|Patients treated with EES
16689678|NCT02018991|Active Comparator|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
16689679|NCT02018991|Active Comparator|Biolimus-Eluting-Stent (BES)|Patients treated with BES
16689680|NCT02018978|Experimental|CTHP|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.
~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.
~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.
~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
16689681|NCT02018978|No Intervention|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
16689682|NCT02018965|Other|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
16689683|NCT02018965|Other|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
16689684|NCT02018952|Other|Ultrasonography assessment|
16689685|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
16689686|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
16689687|NCT02018939|Experimental|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
16689688|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle
~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
16689689|NCT02018900|Placebo Comparator|Placebo|Placebo
16689690|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
16689691|NCT02018887|Experimental|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
16689692|NCT02018887|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
16689693|NCT02018887|Experimental|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
16689694|NCT02018887|Placebo Comparator|Placebo (Part B)|Placebo administered orally for 14 days.
16689695|NCT02018887|Experimental|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
16689696|NCT02018887|Placebo Comparator|Placebo (Part C)|Placebo administered orally for 14 days.
16689697|NCT02018874|Experimental|LY2780301|
16689698|NCT02018861|Experimental|Parsaclisib|escalating doses given every day (QD)
16689699|NCT02018861|Experimental|Parsaclisib in combination with itacitinib (INCB039110)|Starting dose of parsaclisib determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD
16689700|NCT02018861|Experimental|Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide|Starting dose of parsaclisib determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.
16689701|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.
~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.
~Thus, the placebo training sessions are identical to the bias assessment sessions."
16689702|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.
~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.
~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
16689703|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
16689704|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
16689705|NCT02018835|Other|patients of an aortic bicuspidie|
16689706|NCT02018835|Other|patients of a syndrome of Marfan|
16689707|NCT02018835|Other|Healthy volunteers|
16689708|NCT02018822|Experimental|All Participants|Participants who needed at least two tooth restorations
16689709|NCT02018809|Experimental|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
16689710|NCT02018809|Experimental|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
16700495|NCT01947387||NPWT then Integra (on same admission)|
16689711|NCT02018809|Experimental|MAP Missed Doses|The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
16689712|NCT02018809|Other|Usual Care|Usual care with GlowCap.
16689713|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
16689714|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
16689715|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
16689716|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
16689717|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
16689718|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
16689719|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
16689720|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
16689721|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
16689722|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
16689723|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
16689724|NCT02018718|Other|Marathoners|
16689725|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
16689726|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
16689727|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
16689728|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
16689729|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
16689730|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
16689731|NCT02018666|Experimental|spontaneous NAVA mode|
16689732|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
16689733|NCT02018653|Experimental|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
16689734|NCT02018653|Placebo Comparator|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
16689735|NCT02018627|Experimental|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
16689736|NCT02018627|Active Comparator|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
16689737|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
16689738|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
16689739|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
16689740|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
16689741|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
16689742|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
16689806|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
16689807|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
16689808|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
16689743|NCT02018562|Experimental|Intervention|"The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.
~We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.
~i. SLP will also assess the duration of successful speech during each session
~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.
~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
16689744|NCT02018562|No Intervention|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
16689746|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
16689747|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
16689748|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
16689749|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
16689750|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
16689751|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
16689752|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
16689753|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
16689754|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals
~1 mg/kg, single dose IV administration of 3BNC117"
16689755|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
16689756|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
16689757|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
16689758|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
16689759|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
16689760|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART
~1 mg/kg, single dose IV administration of 3BNC117"
16689761|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
16689762|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
16689763|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
16689764|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
16689765|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
16689766|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
16689767|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
16689768|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
16689769|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.
~No interventions."
16689770|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
16689771|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
16689772|NCT02018458|Experimental|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
16689885|NCT02017808||OCT|Healthy controls
16689773|NCT02018458|Experimental|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
16689774|NCT02018445|Other|Accell Evo3 DBM & Local Autograft|Accell Evo3 DBM (posterolateral gutter symptomatic side) and Local Autograft (posterolateral gutter contralateral non-symptomatic side)
16689775|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
16689776|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
16689777|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;
~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;
~the activation step with an IV infusion of AlloStim on Day 28;
~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;
~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
16689778|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;
~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;
~the activation step with an IV infusion of AlloStim on Day 21;
~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.
~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
16689779|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;
~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;
~the activation step with an IV infusion of AlloStim on Day 21;
~the booster step with intravenous infusion of AlloStim on days 49 and 77.
~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
16689780|NCT02018406|Experimental|Intervention|Intervention Group
16689781|NCT02018406|Placebo Comparator|Control|Control Group
16689782|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
16689783|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
16689784|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
16689785|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
16689786|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
16689787|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
16689788|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
16689789|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
16689790|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
16689791|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
16689792|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
16689793|NCT02018315|Experimental|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
16689794|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
16689795|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
16689796|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
16689797|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
16689798|NCT02018263|Active Comparator|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
16689799|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
16689800|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
16689801|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
16689802|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
16689803|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
16689804|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
16689805|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
16689886|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
16689809|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
16689810|NCT02018224|Experimental|End-to-end suturation without augmentation|
16689811|NCT02018224|Experimental|End-to-end suturation with augmentation|
16689812|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
16689813|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
16689814|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
16689815|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
16689816|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
16689817|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
16689818|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
16689819|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
16689820|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
16689821|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
16689822|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
16689823|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
16689824|NCT02018107|Experimental|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
16689825|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
16689826|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
16689827|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
16689828|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
16689829|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
16689830|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
16689831|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
16689832|NCT02018055|Active Comparator|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
16689833|NCT02018055|Experimental|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
16689834|NCT02018042|Experimental|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
16689835|NCT02018029||cardiac resynchronisation therapy|
16689836|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
16689837|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
16689838|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
16689839|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
16689840|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
16689841|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
16689842|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
16689843|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
16689844|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
16689845|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
16689846|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
16689847|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
16689848|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
16689849|NCT02017964|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
16689850|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
16689851|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
16689852|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
16689853|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
16689854|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
16689855|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
16689856|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
16689857|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
16689858|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
16689859|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
16689860|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
16689861|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
16689862|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
16689863|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
16689864|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
16689865|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
16689866|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
16689867|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
16689868|NCT02017899|Experimental|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
16689869|NCT02017899|Experimental|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
16689870|NCT02017899|Experimental|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
16689871|NCT02017899|Experimental|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
16689872|NCT02017899|Experimental|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
16689873|NCT02017899|Placebo Comparator|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
16689874|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
16689875|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
16689876|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
16689877|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
16689878|NCT02017860|Experimental|Everolimus|Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.
16689879|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
16689880|NCT02017834|Experimental|harmonic scalpel|
16689881|NCT02017834|Active Comparator|standard technique|
16689882|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
16689883|NCT02017821|No Intervention|care as usual|
16689884|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
16689887|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
16689888|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
16689889|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
16689890|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
16689891|NCT02017769||Healthy controls|Healthy, gender and age matched controls
16689892|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
16689893|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
16689894|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
16689895|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
16689896|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
16689897|NCT02017717|Experimental|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab specified dose on specified days
16689898|NCT02017717|Experimental|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days
~Cohort 1b: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days"
16689899|NCT02017717|Active Comparator|Arm B: Bevacizumab|Cohort 2: Bevacizumab specified dose on specified days
16689900|NCT02017704|Active Comparator|IMRT and Capecitabine (potentially randomized to this arm)|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
~Followed by:
~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion
~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions
~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus
~Cycle length: 14 days (2 weeks)
~Duration of treatment: 12 cycles
~Then: Surgical Resection"
16689901|NCT02017704|Experimental|Endo-HDR (potentially randomized to this arm)|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
~Followed by:
~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion
~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions
~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus
~Cycle length: 14 days (2 weeks)
~Duration of treatment: 12 cycles
~Then: Surgical Resection"
16689902|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
16689903|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
16689904|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
16689905|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
16689906|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
16689907|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
16689908|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
16689909|NCT02017613|Experimental|Single arm|RP6530 administered orally
16689910|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
16689911|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
16689912|NCT02017574|Experimental|Implicit Group|Receives little feedback about task performance during learning
16689913|NCT02017574|Active Comparator|Control|Receives detailed feedback about task performance during learning
16689914|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
16689915|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
16689916|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
16689982|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
16690025|NCT02016885|Experimental|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
16689917|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
16689918|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
16689919|NCT02017535|Active Comparator|6 IPT-A Sessions|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) only.
~During the Continuation IPT-A sessions, the therapist will continue to emphasize the interpersonal strategies that were learned and practiced during the acute phase, and address any current interpersonal problems before they result in a recurrence of depressive symptoms. Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions."
16689920|NCT02017535|Active Comparator|6 IPT-A Sessions + Continue Current Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.
~Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions and will continue their acute phase fluoxetine dosing regimen and will meet with the psychiatrist on a monthly basis."
16689921|NCT02017535|Experimental|10 IPT-A Sessions + Begin Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.
~Adolescents who received only IPT-A during acute phase and who showed a partial response (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will begin treatment with fluoxetine during the continuation phase.The dosage schedule will be 10mg per day for the first week and 20mg per day for the following 5 weeks. If no treatment response is observed by the 6th week, the dosage can be increased to 40mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and biweekly thereafter. Pharmacotherapy sessions will include assessment of vital signs, adverse effects, safety, and symptomatic response."
16689922|NCT02017535|Experimental|10 IPT-A Sessions + Increase Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.
~Adolescents who received IPT-A and fluoxetine during the acute phase and were partial responders (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will have their fluoxetine dose increased to 60mg. Partial responders will meet with the psychiatrist biweekly for the first 2 months and monthly for the second 2 months."
16689923|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.
~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
16689924|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
16689925|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
16689926|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
16689927|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.
~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
16689930|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
16689931|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
16689932|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
16689933|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
16689934|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
16689935|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
16689936|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.
~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
16689937|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.
~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
16689983|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
16689938|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.
~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
16689939|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
16689940|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
16689941|NCT02017392|No Intervention|blank control|No intervention.
16689942|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
16689943|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
16689944|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
16689945|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
16689946|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
16689947|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
16689948|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
16689949|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
16689950|NCT02017327|Experimental|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
16689951|NCT02017327|Active Comparator|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
16689952|NCT02017327|Active Comparator|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
16689953|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
16689954|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
16689955|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
16689956|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
16689957|NCT02017314|Active Comparator|Group I|Patients with BMI <30
16689958|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
16689959|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
16689960|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
16689961|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
16689962|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
16689963|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
16689964|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
16689965|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
16689966|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
16689967|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
16689968|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
16689969|NCT02017223|Experimental|Knowme Device Wear|Participants wear KNOWME devices and use mobile phone interface for three days outside of school. This is a pre-post design with no control group
16689970|NCT02017210||Lean/normal weight|Individuals with body mass index (BMI)<25 kg/m^2 in the baseline study
16689971|NCT02017210||Overweight/Obese Insulin-Sensitive|Individuals with BMI>25kg/m^2 who were deemed insulin-sensitive by the hyperinsulinemic -euglycemic clamp (with M/I value above median for men and women separately)
16689972|NCT02017210||Overweight/Obese Insulin-Resistant|Individuals with BMI>25kg/m^2 who were deemed insulin-resistant by the hyperinsulinemic -euglycemic clamp (with M/I value under median for men and women separately)
16689973|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®
~Phase 2: Marevan®
~Phase 3: generic warfarin #1
~Phase 4: generic warfarin #2"
16689974|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1
~Phase 2: generic warfarin #1
~Phase 3: Marevan®
~Phase 4: generic warfarin #2"
16689975|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1
~Phase 2: generic warfarin #1
~Phase 3: generic warfarin #2
~Phase 4: Marevan®"
16689976|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®
~Phase 2: Marevan®
~Phase 3: generic warfarin #2
~Phase 4: generic warfarin #1"
16689977|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2
~Phase 2: generic warfarin #2
~Phase 3: Marevan®
~Phase 4: generic warfarin #1"
16689978|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2
~Phase 2: generic warfarin #2
~Phase 3: generic warfarin #1
~Phase 4: Marevan®"
16689979|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
16689980|NCT02017171|Experimental|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
16689981|NCT02017171|Placebo Comparator|Placebo|Oral placebo tablets
16689984|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
16689985|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
16689986|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
16689987|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
16689988|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
16689989|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
16689990|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
16689991|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
16689992|NCT02017093|Experimental|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
16689993|NCT02017093|Experimental|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
16689994|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
16689995|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
16689996|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
16689997|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
16689998|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
16689999|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
16690000|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
16690001|NCT02017015|Experimental|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
16690002|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
16690003|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
16690004|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
16690005|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
16690006|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
16690007|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
16690008|NCT02016963|Experimental|Raxibacumab arm|A maximum of 25 subjects (to include 3 evaluable female subjects) will receive a second dose of raxibacumab equal to that of the previous dose >= 4 months following the first dose.
16690009|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
16690010|NCT02016937||group g|general anesthesia, n: 21
16690011|NCT02016937||group S|spinal anesthesia, n: 21
16690012|NCT02016937||group E|epidural anesthesia, n: 21
16690013|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
16690018|NCT02016911|Experimental|Subjects with hepatic impairment|
16690019|NCT02016911|Active Comparator|Subjects with normal hepatic function|
16690020|NCT02016898|Experimental|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
16690021|NCT02016898|Experimental|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
16690022|NCT02016885|Experimental|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
16690023|NCT02016885|Experimental|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
16690024|NCT02016885|Experimental|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
16690027|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
16690028|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
16690029|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
16690030|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
16690031|NCT02016846|Placebo Comparator|Placebo|
16690032|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
16690033|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
16690034|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
16690035|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
16690036|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
16690037|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
16690038|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
16690039|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
16690040|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
16690041|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
16690042|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
16690043|NCT02016781|Active Comparator|Transplant|Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)
16690044|NCT02016781|Active Comparator|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
16690045|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
16690046|NCT02016755|Experimental|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
16690047|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
16690048|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
16690049|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
16690050|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
16690051|NCT02016729|Experimental|AMG 232|AMG 232 is an anti-cancer agent
16690052|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
16690053|NCT02016716|Experimental|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
16690054|NCT02016716|Experimental|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
16690055|NCT02016716|Experimental|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
16690056|NCT02016716|Placebo Comparator|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
16690057|NCT02016703|Experimental|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
16690058|NCT02016703|Experimental|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
16690059|NCT02016703|Experimental|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
16690060|NCT02016703|Experimental|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
16690061|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
16690062|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
16690100|NCT02016430|Experimental|MeLT Dietary intervention|Mediterranean Low-TMAO (MeLT) diet
16690101|NCT02016430|Experimental|TLC Dietary intervention|Therapeutic Lifestyle Changes (TLC) diet
16690063|NCT02016664|Experimental|Chronic pain patients on oral ketamine|"Days 1-7:
~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.
~Days 8-14:
~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
16690064|NCT02016651|Experimental|Right side position|Premature infants on mechanical ventilation are kept on their right side
16690065|NCT02016651|No Intervention|Supine position|Premature infants on mechanical ventilation are kept on their back
16690066|NCT02016638|Experimental|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:
~Obstetrics ward, AIIMS hospital"
16690067|NCT02016625|Experimental|1 Cyclosporine + Faldaprevir|
16690068|NCT02016625|Experimental|2 Tacrolimus + Faldaprevir|
16690069|NCT02016612|Active Comparator|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
16690070|NCT02016612|Active Comparator|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
16690071|NCT02016612|Active Comparator|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
16690072|NCT02016612|Active Comparator|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
16690073|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
16690074|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
16690075|NCT02016586|No Intervention|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
16690076|NCT02016586|Experimental|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
16690077|NCT02016573|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
16690078|NCT02016573|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
16690079|NCT02016560|Experimental|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
16690080|NCT02016560|Experimental|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
16690081|NCT02016560|Experimental|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
16690082|NCT02016560|Experimental|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
16690083|NCT02016547|Experimental|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
16690084|NCT02016547|Active Comparator|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
16690085|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
16690086|NCT02016521|Experimental|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
16690087|NCT02016521|Placebo Comparator|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
16690088|NCT02016508|Experimental|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
16690089|NCT02016495|Active Comparator|Magnesium + Lipoic Acid|
16690090|NCT02016495|Placebo Comparator|Placebo|
16690091|NCT02016482|Active Comparator|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
16690092|NCT02016482|Placebo Comparator|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
16690093|NCT02016469|Experimental|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
16690094|NCT02016469|Active Comparator|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
16690095|NCT02016469|Active Comparator|give pectin 20g/d|pure give pectin 20g/d for five days
16690096|NCT02016456|Experimental|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
16690097|NCT02016456|Active Comparator|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
16690098|NCT02016443|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
16690099|NCT02016443|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
16690102|NCT02016430|Experimental|MeLT dietary intervention with TMAO|Mediterranean Low TMAO diet with TMAO levels reported
16690103|NCT02016417|Experimental|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
16690104|NCT02016417|Active Comparator|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
16690105|NCT02016404|Active Comparator|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
16690106|NCT02016404|Placebo Comparator|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
16690107|NCT02016391|Experimental|Dexmedetomidine|
16690108|NCT02016378|Sham Comparator|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
16690109|NCT02016378|Active Comparator|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
16690110|NCT02016365|Experimental|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
16690111|NCT02016352|Experimental|patient|patient CSF extraction with hydrocephalus
16690112|NCT02016352|Other|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
16690113|NCT02016339|Active Comparator|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
16690114|NCT02016339|Active Comparator|Intensive care|"Standard group care plus:
~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
16690115|NCT02016326|Experimental|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
16690116|NCT02016326|Experimental|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
16690117|NCT02016326|Experimental|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
16690118|NCT02016313|Experimental|Immediate therapy|Physiotherapy protocol
16690119|NCT02016313|Placebo Comparator|waiting list|Physiotherapy protocol
16690120|NCT02016300|Experimental|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
16690121|NCT02016300|Active Comparator|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
16690122|NCT02016287|Experimental|sequential treatment|paclitaxel treatment and radiotherapy
16690123|NCT02016274|Experimental|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
16690124|NCT02016261|Experimental|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
16690125|NCT02016248|Experimental|Low Risk Cohort|"The low risk cohort will receive:
~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
16690126|NCT02016248|Experimental|High Risk Cohort|"The high risk cohort will receive:
~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
16690127|NCT02016235|Experimental|Dent Disease Intervention|Dent Disease subjects will receive 2 week supplementation with phosphorus
16690128|NCT02016235|Experimental|Kidney Stone subjects|Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
16690129|NCT02016235|Placebo Comparator|Dent Disease Observation|Dent disease subjects will not get phosphorus
16690130|NCT02016222|Experimental|Tears sampling|
16690131|NCT02016209|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
16690132|NCT02016196|Experimental|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
16690133|NCT02016196|Placebo Comparator|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
16690134|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil/Hydrochlorothiazide 4 mg/6.25 mg or 8 mg/6.25 mg combination tablets, orally, once daily for up to 12 months. This drug should not be used as a first-line drug for hypertension treatment. Participants received interventions as part of routine medical care.
16690135|NCT02016170|Experimental|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
16690136|NCT02016170|Experimental|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
16690137|NCT02016170|Active Comparator|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
16690138|NCT02016157|Experimental|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
16690139|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
16690140|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
16690141|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
16690142|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
16690143|NCT02016105|Experimental|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
16690144|NCT02016105|Active Comparator|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
16690145|NCT02016092||Patients with Parkinson's disease|
16690146|NCT02016092||Healthy Controls|
16690147|NCT02016079|Experimental|Omega-3|a fruit drink containing omega-3
16690148|NCT02016079|Placebo Comparator|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
16690149|NCT02016066|Experimental|CR6261|
16690150|NCT02016066|Placebo Comparator|Placebo|
16690151|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
16690152|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
16690153|NCT02016040|Active Comparator|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
16690154|NCT02016027|Experimental|Carica folia Arm|
16690155|NCT02016014|Experimental|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
16690156|NCT02016014|Active Comparator|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
16690157|NCT02016001|Experimental|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
16690158|NCT02016001|Experimental|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
16690159|NCT02015988|Experimental|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
16690160|NCT02015988|Active Comparator|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
16690161|NCT02015962|Experimental|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
16690162|NCT02015962|Experimental|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
16690163|NCT02015949|Active Comparator|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
16690164|NCT02015949|Placebo Comparator|Sugar pill|2 weeks of twice daily placebo
16690165|NCT02015936|Experimental|Prescriped Physical Activity|Physical fitness evaluation followed by prescribed physical activity and progress reporting.
16690166|NCT02015923|Experimental|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
16690167|NCT02015923|Active Comparator|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
16690168|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
16690169|NCT02015910|Placebo Comparator|Placebo|Placebo
16690170|NCT02015897|Active Comparator|Physical TherapyB|Group B
16690171|NCT02015897|Placebo Comparator|Physical TherapyA|Group A
16690172|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
16690173|NCT02015871|Experimental|Degarelix|
16690174|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
16690175|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
16690176|NCT02015845|Experimental|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
16690177|NCT02015845|Active Comparator|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
16690178|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
16690180|NCT02015806|Experimental|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
16690644|NCT02013024|Active Comparator|cryopreservation technique|slow freezing cryopreservation technique
16690181|NCT02015806|Experimental|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
16690182|NCT02015806|Experimental|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
16690183|NCT02015806|No Intervention|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
16690184|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
16690185|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
16690186|NCT02015806|No Intervention|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
16690187|NCT02015806|Experimental|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
16690188|NCT02015806|Experimental|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
16690189|NCT02015806|Experimental|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
16690190|NCT02015806|No Intervention|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
16690191|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
16690192|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
16690193|NCT02015806|No Intervention|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
16690194|NCT02015793|Experimental|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
16690195|NCT02015793|Experimental|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
16690196|NCT02015780|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
16690197|NCT02015780|Experimental|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
16690198|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
16690199|NCT02015754|Experimental|DEBIRI|
16690200|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
16690201|NCT02015728|Experimental|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
16690202|NCT02015728|Experimental|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
16690203|NCT02015728|Experimental|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
16690204|NCT02015728|Experimental|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
16690238|NCT02015520|Experimental|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
16690239|NCT02015520|Experimental|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
16690205|NCT02015715|Experimental|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
16690206|NCT02015715|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
16690207|NCT02015702|Experimental|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
16690208|NCT02015702|Active Comparator|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
16690209|NCT02015689|Experimental|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
16690210|NCT02015689|Active Comparator|CDC VIS|CDC Vaccine Information Statement (VIS)
16690211|NCT02015689|Experimental|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
16690212|NCT02015689|Experimental|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
16690213|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m^2, IV, and subsequently 80 mg/m^2, IV, and continued until disease progression.
16690214|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression.
16690215|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
16690216|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
16690217|NCT02015650|Active Comparator|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
16690218|NCT02015650|Active Comparator|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
16690219|NCT02015637|Experimental|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
16690220|NCT02015637|Active Comparator|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
16690221|NCT02015611|Placebo Comparator|Placebo|Matched bottle/pill placebo
16690222|NCT02015611|Experimental|Vitamin D|2,000 IU Vitamin D3 per day
16690223|NCT02015598|Experimental|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
16690224|NCT02015598|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
16690225|NCT02015585|Experimental|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
16690226|NCT02015585|Experimental|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
16690227|NCT02015585|Active Comparator|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
16690228|NCT02015572|Experimental|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
16690229|NCT02015572|Active Comparator|Usual care|Intervention from the patient's general physician.
16690230|NCT02015559|Experimental|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
16690231|NCT02015559|No Intervention|Arm II (no intervention)|Patients receive no intervention.
16690232|NCT02015546|Experimental|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
16690233|NCT02015546|Experimental|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
16690234|NCT02015546|Experimental|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
16690235|NCT02015533|Experimental|CR8020|
16690236|NCT02015533|Placebo Comparator|Placebo|
16690237|NCT02015520|Experimental|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
16690284|NCT02015260|Active Comparator|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
16690240|NCT02015520|Experimental|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
16690241|NCT02015507|Active Comparator|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
16690242|NCT02015507|Experimental|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
16690243|NCT02015494|Experimental|4 mcg VAX2012Q|4 mcg VAX2012Q
16690244|NCT02015494|Experimental|8 mcg VAX2012Q|8 mcg VAX2012Q
16690245|NCT02015494|Experimental|14 mcg VAX2012Q|14 mcg VAX2012Q
16690246|NCT02015494|Experimental|18 mcg VAX2012Q|18 mcg VAX2012Q
16690247|NCT02015494|Experimental|12 mcg VAX2012Q|12 mcg VAX2012Q
16690248|NCT02015494|Experimental|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
16690249|NCT02015494|Experimental|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
16690250|NCT02015481|Experimental|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
16690251|NCT02015468|Experimental|Early mobilization|
16690252|NCT02015468|Experimental|Late mobilization|
16690253|NCT02015455|Experimental|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
16690254|NCT02015455|No Intervention|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
16690255|NCT02015442|Experimental|High sucrose diet|High sucrose diet for 7 days
16690256|NCT02015442|Experimental|Low sucrose diet|Low sucrose diet for 7 days
16690257|NCT02015429|Active Comparator|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
16690258|NCT02015429|Experimental|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
16690259|NCT02015429|Experimental|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
16690260|NCT02015429|Experimental|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
16690261|NCT02015416|Experimental|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
16690262|NCT02015403|Experimental|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
16690263|NCT02015403|Active Comparator|Standard Care|
16690264|NCT02015390|Active Comparator|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
16690265|NCT02015390|Active Comparator|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
16690266|NCT02015377|Experimental|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
16690267|NCT02015377|Experimental|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
16690268|NCT02015364|Experimental|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
16690269|NCT02015364|No Intervention|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
16690270|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.
~Immunosuppression: cyclosporine and/or azathioprine"
16690271|NCT02015338||Typically Developing Children|Children with typical development (e.g. no presence of neurological disorders or diagnoses)
16690272|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
16690273|NCT02015325|No Intervention|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
16690274|NCT02015325|Experimental|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
16690275|NCT02015312|Experimental|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
16690276|NCT02015312|Placebo Comparator|Placebo|"capsules
~Dose:
~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
16690277|NCT02015299|Experimental|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
16690278|NCT02015299|Placebo Comparator|Placebo|Matching placebo + lifestyle advise
16690279|NCT02015286||Growth Disorders|
16690280|NCT02015273||Growth Disorders|
16690281|NCT02015260|Placebo Comparator|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
16690282|NCT02015260|Active Comparator|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
16690283|NCT02015260|Active Comparator|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
16690285|NCT02015247|Other|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
16690286|NCT02015234|Experimental|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
16690287|NCT02015221|Experimental|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
16690288|NCT02015221|Active Comparator|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
16690289|NCT02015208|Experimental|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
16690290|NCT02015195|Experimental|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690291|NCT02015195|Experimental|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690292|NCT02015195|Experimental|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690293|NCT02015195|Experimental|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690294|NCT02015195|Experimental|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690295|NCT02015195|Experimental|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690296|NCT02015195|Experimental|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
16690297|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
16690298|NCT02015169|Experimental|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs
~D1-D14 Capecitabine 850mg/m2 p.o bid
~D1 ~ Lapatinib 1250 mg qd dailiy"
16690299|NCT02015156|Experimental|PF-05280014|
16690300|NCT02015156|Active Comparator|Trastuzumab-US|
16690301|NCT02015143||Bipolar Disorder|
16690302|NCT02015143||Unipolar Disorder|
16690303|NCT02015130|Experimental|individual treatment|Individualized treatment
16690304|NCT02015130|No Intervention|control group|treatment according to current national guidelines
16690305|NCT02015117|Experimental|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
16690306|NCT02015117|Experimental|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
16690307|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) + PANVAC|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 10^8 pfu subcutaneous (SQ) at week 0 only; PANVAC-F 1 x 10^9 pfu SQ at weeks 3, 7, 11, and 15
16690308|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) Alone|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
16690309|NCT02015091|Experimental|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
16690310|NCT02015091|Experimental|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
16690311|NCT02015091|Experimental|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
16690312|NCT02015091|No Intervention|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
16690313|NCT02015078||African Americans|Targets are family members attending African American family reunions.
16690314|NCT02015065|Experimental|Vandetanib in Children|Children with measurable localized or metastatic wt-GIST
16690315|NCT02015065|Experimental|Vandetanib in Adults|Adults with measurable localized or metastatic wt-GIST
16690316|NCT02015039|Active Comparator|Botulinum Toxin Therapy Only|
16690317|NCT02015039|Experimental|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
16690320|NCT02015000|Experimental|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
16690321|NCT02014987|Experimental|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.
~The amount of running will be increased with 10 % per week."
16690322|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
16690323|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
16690324|NCT02014961|Active Comparator|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
16690325|NCT02014961|Placebo Comparator|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
16690326|NCT02014961|Other|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
16690327|NCT02014948|Experimental|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
16690645|NCT02013024|Active Comparator|vitrification cryopreservation technique|vitrification cryopreservation technique
16690328|NCT02014935|Experimental|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.
~The phases comprise:
~Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.
~Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.
~Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
16690329|NCT02014922|No Intervention|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
16690330|NCT02014922|Experimental|Treatment|"Participants in the study treatment group will receive all four products:
~TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn
~TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn
~TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD
~TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
16690331|NCT02014909|Experimental|KTN3379|KTN3379
16690332|NCT02014909|Experimental|Part II, Arm A|Combination of KTN3379 and cetuximab
16690333|NCT02014909|Experimental|Part II, Arm B|Combination of KTN3379 and erlotinib
16690334|NCT02014909|Experimental|Part II, Arm C|Combination of KTN3379 and vemurafenib
16690335|NCT02014909|Experimental|Part II, Arm D|Combination of KTN3379 and trastuzumab
16690336|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).
~Biomarker blood draw"
16690337|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).
~Biomarker blood draw"
16690338|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.
~Biomarker blood draw"
16690339|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.
~Biomarker blood draw"
16690340|NCT02014883|Experimental|GLUT1 DS|
16690341|NCT02014870|Experimental|Cohort 1|1:1000 dilution of neat virus
16690342|NCT02014870|Experimental|Cohort 2|1:100 dilution of neat virus
16690343|NCT02014870|Experimental|Cohort 3|1:10 dilution of neat virus
16690344|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
16690345|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
16690346|NCT02014844|Experimental|aldoxorubicin|Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
16690347|NCT02014831|Active Comparator|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
16690348|NCT02014831|Experimental|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
16690349|NCT02014818|Experimental|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
16690350|NCT02014818|Experimental|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
16690351|NCT02014805|Experimental|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
16690352|NCT02014805|No Intervention|observation|no treatment after radical resection for thymoma
16690353|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
16690354|NCT02014779|Experimental|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
16690355|NCT02014779|Active Comparator|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
16690356|NCT02014766|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
16690357|NCT02014766|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
16690358|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
16690359|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
16690419|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
16690685|NCT02012738|Other|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
16690360|NCT02014740|Experimental|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
16690361|NCT02014740|Active Comparator|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
16690362|NCT02014727|Experimental|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
16690363|NCT02014727|Experimental|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE
~AMA1-DiCo: 50µg
~GLA-SE 2.5 µg GLA per dose
~Route : Intramuscular Vaccination schedule : Do, W4, W26"
16690364|NCT02014727|Experimental|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE
~AMA1-DiCo: 50µg
~GLA-SE 2.5 µg GLA per dose
~Route : Intramuscular Vaccination schedule : Do, W4, W26"
16690365|NCT02014727|Placebo Comparator|Placebo|"Group B2 (18) : African volunteer : Placebo
~Placebo : isotonic saline solution
~Route : Intramuscular Vaccination schedule : Do, W4, W26"
16690366|NCT02014714|Active Comparator|Morphine|Intrathecal Morphine 0.1mg
16690367|NCT02014714|Active Comparator|Fentanyl|Intrathecal Fentanyl 40mcg
16690368|NCT02014701|Other|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
16690369|NCT02014688||American Indian or Alaskan Native Descent|
16690370|NCT02014688||Black or African American Descent|
16690371|NCT02014688||Asian Descent|
16690372|NCT02014688||Hispanic Descent|
16690373|NCT02014675||SD01 ICD lead|
16690374|NCT02014662|Other|Arm 1|Healthy subjects aged 18 to 35 years
16690375|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
16690376|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
16690377|NCT02014636|Experimental|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
16690378|NCT02014636|Experimental|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:
~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
16690379|NCT02014623|Active Comparator|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
16690380|NCT02014623|Other|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
16690381|NCT02014597|Experimental|Normal - No glaucoma|HOCD
16690382|NCT02014597|Experimental|Glaucoma|HOCD
16690383|NCT02014584|Experimental|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
16690384|NCT02014584|Placebo Comparator|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
16690385|NCT02014571|Experimental|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a [GT1a] and 2 HCV genotype 1b [GT1b]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
16690386|NCT02014571|Experimental|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
16690387|NCT02014571|Experimental|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
16690388|NCT02014571|Experimental|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
16690389|NCT02014558|Experimental|Gilteritinib 20 mg in Escalation Phase|Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690390|NCT02014558|Experimental|Gilteritinib 40 mg in Escalation Phase|Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690391|NCT02014558|Experimental|Gilteritinib 80 mg in Escalation Phase|Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690392|NCT02014558|Experimental|Gilteritinib 120 mg in Escalation Phase|Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690641|NCT02013050|Placebo Comparator|Placebo|Control
16690642|NCT02013050|Experimental|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
16690393|NCT02014558|Experimental|Gilteritinib 200 mg in Escalation Phase|Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690394|NCT02014558|Experimental|Gilteritinib 300 mg in Escalation Phase|Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690395|NCT02014558|Experimental|Gilteritinib 450 mg in Escalation Phase|Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
16690396|NCT02014558|Experimental|Gilteritinib 20 mg in Expansion Phase|Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
16690397|NCT02014558|Experimental|Gilteritinib 40 mg in Expansion Phase|Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
16690398|NCT02014558|Experimental|Gilteritinib 80 mg in Expansion Phase|Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
16690399|NCT02014558|Experimental|Gilteritinib 120 mg in Expansion Phase|Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
16690400|NCT02014558|Experimental|Gilteritinib 200 mg in Expansion Phase|Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
16690401|NCT02014558|Experimental|Gilteritinib 300 mg in Expansion Phase|Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
16690402|NCT02014545|Active Comparator|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
16690403|NCT02014545|Placebo Comparator|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
16690404|NCT02014532|Active Comparator|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
16690405|NCT02014532|Placebo Comparator|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
16690406|NCT02014519|Other|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
16690407|NCT02014506|Experimental|HAPLO|
16690408|NCT02014493|Active Comparator|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
16690409|NCT02014493|Active Comparator|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
16690410|NCT02014480|Experimental|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
16690411|NCT02014480|Experimental|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
16690412|NCT02014480|Experimental|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
16690413|NCT02014467|Experimental|Denosumab 60mg|injection
16690414|NCT02014467|Placebo Comparator|Placebo|injection
16690415|NCT02014454|Experimental|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.
~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
16690416|NCT02014441|Experimental|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.
~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
16690417|NCT02014428|Experimental|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
16690418|NCT02014428|Placebo Comparator|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
16690646|NCT02013011|Active Comparator|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
16690420|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
16690421|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
16690422|NCT02014402|Experimental|IG1202-A (Vascular)|
16690423|NCT02014402|Experimental|IG1202-B (Hepatic)|
16690424|NCT02014402|Experimental|IG1202-C (Soft Tissue)|
16690425|NCT02014402|Experimental|IG1202-D (Spinal)|
16690426|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
16690427|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
16690428|NCT02014376|Experimental|SD-101 Dermal Cream (6%)|SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
16690429|NCT02014376|Experimental|SD-101 Dermal Cream (3%)|SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
16690430|NCT02014376|Placebo Comparator|Vehicle (0%)|Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
16690431|NCT02014363|Experimental|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
16690432|NCT02014363|Experimental|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
16690433|NCT02014363|Active Comparator|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
16690434|NCT02014363|No Intervention|Lead-in phase|"Citalopram tablets:
~Standard dosing regime"
16690435|NCT02014350||DePuy Delta Xtend RTSA|
16690436|NCT02014337|Experimental|Mifepristone and Eribulin in combination|Single Arm
16690437|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
16690438|NCT02014311|Experimental|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with >50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
16690439|NCT02014311|Active Comparator|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis >50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
16690440|NCT02014298|Other|Control|One area assessed as a control area, compared to the laser-treated area
16690441|NCT02014298|Active Comparator|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
16690442|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
16690443|NCT02014272|Experimental|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
16690444|NCT02014272|Active Comparator|Reference|Individual references of rifampicin and isoniazid
16690445|NCT02014259|Experimental|Subjects with renal impairment|
16690446|NCT02014259|Active Comparator|Subjects with normal renal function|
16690447|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
16690448|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
16690449|NCT02014233|Experimental|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
16690450|NCT02014233|Placebo Comparator|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
16690451|NCT02014220|Experimental|Atlantic Western chips|deep fried potato chips
16690452|NCT02014220|Experimental|Dakota Pearl chips|deep fried potato chips
16690453|NCT02014220|Experimental|Andover Ontario chips|deep fried potato chips
16690454|NCT02014220|Experimental|white bread with margarine|energy control
16690455|NCT02014220|Experimental|white bread|control
16690456|NCT02014207|Experimental|golden crinkle|
16690457|NCT02014207|Experimental|high blanch|
16690458|NCT02014207|Experimental|low blanche|
16690459|NCT02014207|Experimental|high chill|
16690460|NCT02014207|Experimental|low chill|
16690461|NCT02014194|Placebo Comparator|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
16690462|NCT02014194|Active Comparator|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
16690463|NCT02014181|Experimental|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
16690464|NCT02014168|Experimental|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
16690465|NCT02014168|Placebo Comparator|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
16690466|NCT02014155|Experimental|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
16690729|NCT02012400|No Intervention|Control group|
16690467|NCT02014155|Experimental|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
16690468|NCT02014155|Experimental|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
16690469|NCT02014155|Experimental|COPD group not rehabilitation|
16690470|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
16690471|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
16690472|NCT02014129|Experimental|Cohort 1 - 100 mg Abemaciclib|100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
16690473|NCT02014129|Experimental|Cohort 2 - 150 mg Abemaciclib|150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
16690474|NCT02014129|Experimental|Cohort 3 - 200 mg Abemaciclib|200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
16690475|NCT02014116|Experimental|Cohort 1 Dose Escalation|LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16690476|NCT02014116|Experimental|Cohort 2 Dose Escalation|LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16690477|NCT02014116|Experimental|Cohort 3 Dose Escalation|LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16690478|NCT02014116|Experimental|Cohort 4 Dose Escalation|LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
16690479|NCT02014116|Experimental|Cohort 5 Dose Escalation|LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
16690480|NCT02014116|Experimental|Cohort 6 Dose Escalation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
16690481|NCT02014116|Experimental|Cohort A Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16690482|NCT02014116|Experimental|Cohort B Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16690483|NCT02014116|Experimental|Cohort C Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
16690484|NCT02014103|Other|Sequence 1|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
16690485|NCT02014103|Other|Sequence 2|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
16690486|NCT02014103|Other|Sequence 3|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
16690487|NCT02014090|Active Comparator|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
16690488|NCT02014090|Active Comparator|ECP|90 minutes of ECP
16690489|NCT02014077|Active Comparator|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
16690490|NCT02014077|Active Comparator|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
16690491|NCT02014064|Experimental|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety & efficacy of Atomoxetine
16690492|NCT02014064|Placebo Comparator|Placebo|"Control Group Schedule:
~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
16690493|NCT02014051|Experimental|SyB C-1101|
16690494|NCT02014025|Experimental|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
16690495|NCT02014025|Experimental|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
16690496|NCT02013999|Experimental|Virtual reality program|mobile device for virtual reality program
16690497|NCT02013999|Active Comparator|Control|standard occupuational therapy
16690498|NCT02013986|Experimental|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
16690499|NCT02013986|Active Comparator|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
16690500|NCT02013973|Experimental|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
16690501|NCT02013973|No Intervention|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
16690502|NCT02013960|Experimental|Laminaria|cytotec and laminaria
16690503|NCT02013960|Active Comparator|Cytotec|Cytotec only
16690504|NCT02013947|Other|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
16690505|NCT02013947|Other|low altitude group|2 weeks of exercise at 400 meters sea level
16690506|NCT02013934|Active Comparator|Probiotics|Dietary supplement
16690507|NCT02013934|Placebo Comparator|Placebo|Dietary supplement
16690508|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
16690509|NCT02013908|Active Comparator|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
16690510|NCT02013908|Experimental|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
16690511|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
16690512|NCT02013869|Experimental|Flow-I|Wash in of desflurane in an anaesthesia machine without below
16690513|NCT02013869|Active Comparator|Asys|Wash in of desflurane in conventional anaesthesia machine Asys
16690514|NCT02013856|Experimental|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
16690515|NCT02013856|Experimental|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
16690516|NCT02013856|Experimental|High Procyanidin|High procyanidin only
16690517|NCT02013856|Placebo Comparator|Placebo|No epicatechin and procyanidin
16690518|NCT02013843|Other|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
16690519|NCT02013830|Experimental|Avastin + Xeloda|
16690520|NCT02013817|Experimental|MabThera/Rituxan|
16690521|NCT02013804|Experimental|Dose arms|Dose Escalation
16690522|NCT02013791|Other|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
16690523|NCT02013791|Experimental|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
16690524|NCT02013791|Experimental|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
16690525|NCT02013791|Experimental|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
16690526|NCT02013791|Experimental|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
16690527|NCT02013791|Experimental|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
16690528|NCT02013791|Experimental|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
16690529|NCT02013791|Experimental|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
16690530|NCT02013791|Experimental|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
16690531|NCT02013778|Experimental|TACE + HCQ|Subjects will receive HCQ plus standard of care TACE.
16690532|NCT02013765|Experimental|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
16690533|NCT02013752|Active Comparator|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
16690534|NCT02013752|Other|Standard care|Standard care at delivery: Manual support of the perineum
16690535|NCT02013739||Patients with chronic heart failure|other
16690536|NCT02013739||Healthy volontiers|other
16690537|NCT02013726|Experimental|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
16690538|NCT02013713||Family Hypercholesterolemia in cardiology|
16690539|NCT02013700|Experimental|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
16690540|NCT02013700|Placebo Comparator|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
16690541|NCT02013700|Experimental|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
16690647|NCT02013011|Active Comparator|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
16690542|NCT02013700|Experimental|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
16690543|NCT02013687|Experimental|2 µg + Alhydrogel|vaccine
16690544|NCT02013687|Experimental|10 µg + Alhydrogel|vaccine
16690545|NCT02013687|Experimental|30 µg + Alhydrogel|vaccine
16690546|NCT02013687|Experimental|100 µg + Alhydrogel|vaccine
16690547|NCT02013674|Experimental|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
16690548|NCT02013674|Experimental|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
16690549|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
16690550|NCT02013648|Active Comparator|Standard arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day administered on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7.
~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.
~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.
~Follow-up period: There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
16690551|NCT02013648|Experimental|Investigational arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-7. Patients will receive dasatinib 100 mg QD on days 8-21. Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.
~Consolidation therapy (4 cycles). Treatment consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 iv over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21. Maintenance therapy: Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
16690552|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
16690553|NCT02013622|Experimental|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
16690554|NCT02013609|Experimental|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
16690555|NCT02013596|No Intervention|Control|Patients were given no TEAS
16690556|NCT02013596|Experimental|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
16690557|NCT02013596|Experimental|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
16690558|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
16690559|NCT02013570|Active Comparator|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
16690560|NCT02013570|Placebo Comparator|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
16690561|NCT02013557|Experimental|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
16690562|NCT02013557|No Intervention|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
16690563|NCT02013544|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
16690564|NCT02013544|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
16690565|NCT02013531|Experimental|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
16690566|NCT02013518|Experimental|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
16690567|NCT02013518|Other|Control group|Treatment as usual at the participating memory clinics
16690568|NCT02013505|No Intervention|Instructions printed on a paper.|There will be no intervention.
16690569|NCT02013505|Experimental|Paper and video instructions|.Instructions printed on paper and a educational video.
16690570|NCT02013492|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
16690571|NCT02013479|Experimental|SelenoPRECISE|SelenoPRECISE
16690572|NCT02013479|Placebo Comparator|Placebo|Placebo
16690573|NCT02013466|Other|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
16690648|NCT02012998|Experimental|HBVAXPRO Challenge dose|HBVAXPRO 5µg
16691343|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
16690574|NCT02013453|Active Comparator|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
16690575|NCT02013453|Active Comparator|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
16690576|NCT02013453|Experimental|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
16690577|NCT02013427|No Intervention|Observational|Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
16690578|NCT02013427|Active Comparator|Naproxen & Omeprazole|Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
16690579|NCT02013427|Placebo Comparator|Placebo Only|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
16690580|NCT02013414|Experimental|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
16690581|NCT02013388|Experimental|10 mg|single oral daily dose of 10 mg N91115 for 14 days
16690582|NCT02013388|Placebo Comparator|Placebo|single oral daily dose of placebo for 14 days
16690583|NCT02013388|Experimental|50 mg|single oral daily dose of 50 mg N91115 for 14 days
16690584|NCT02013388|Experimental|50 mg (single dose)|single oral dose of 50 mg N91115
16690585|NCT02013388|Experimental|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
16690586|NCT02013388|Experimental|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
16690587|NCT02013388|Experimental|500 mg|single oral daily dose of 500 mg N91115 for 14 days
16690588|NCT02013388|Placebo Comparator|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
16690589|NCT02013375|Experimental|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
16690590|NCT02013362|Experimental|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
16690591|NCT02013349|Other|DESyne Novolimus Eluting CSS|approved device continued access
16690592|NCT02013336|Experimental|MM-398 + cyclophosphamide|
16690593|NCT02013323|Active Comparator|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
16690594|NCT02013323|Placebo Comparator|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
16690595|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
16690596|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
16690597|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
16690598|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
16690599|NCT02013258|Active Comparator|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
16690600|NCT02013258|Placebo Comparator|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
16690601|NCT02013245|Experimental|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
16690602|NCT02013245|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
16690603|NCT02013245|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
16690604|NCT02013245|Active Comparator|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
16690605|NCT02013232|Placebo Comparator|placebo|risperidone plus placebo
16690606|NCT02013232|Experimental|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
16690607|NCT02013232|Experimental|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
16690608|NCT02013232|Experimental|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
16690609|NCT02013219|Experimental|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
16690610|NCT02013219|Experimental|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
16690643|NCT02013037|Experimental|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
16690611|NCT02013219|Experimental|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
16690612|NCT02013219|Experimental|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
16690613|NCT02013206|Experimental|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity.
16690614|NCT02013206|Experimental|Current/Former Smokers|Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
16690615|NCT02013193|Experimental|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
16690616|NCT02013193|Active Comparator|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
16690617|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
16690618|NCT02013180||control|benign prostatic diseases in pathologic evaluation
16690619|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.
~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.
~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
16690620|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.
~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
16690621|NCT02013154|Experimental|Part A: DKN-01 (Dose Escalation)|Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22
16690622|NCT02013154|Experimental|Part B: DKN-01 (Dose Confirmation)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
16690623|NCT02013154|Experimental|Part C: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
16690624|NCT02013154|Experimental|Part D: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
16690625|NCT02013154|Experimental|DKN-01 Monotherapy Substudy|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15
16690626|NCT02013154|Experimental|Part E: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
16690627|NCT02013154|Experimental|Part F DKN-01 (Dose Escalation+Expansion)|Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle
16690628|NCT02013141|Experimental|Telavancin|Telavancin 10 mg/kg IV administered over one hour one time.
16690629|NCT02013128|Experimental|Ublituximab + ibrutinib|Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose
16690630|NCT02013115|No Intervention|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
16690631|NCT02013115|Experimental|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
16690632|NCT02013102|Experimental|Arm Ⅰ|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks.
16690633|NCT02013102|Experimental|Arm Ⅱ|Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
16690634|NCT02013089|Experimental|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
16690635|NCT02013089|Experimental|Everolimus|Everolimus 10 mg orally once daily every day
16690636|NCT02013089|Experimental|Imatinib|Imatinib 400 mg tablet orally per day
16690637|NCT02013089|Experimental|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
16690638|NCT02013089|Experimental|Vandetanib|Vandetanib 300 mg orally once daily
16690639|NCT02013089|No Intervention|Control|No intervention was performed for patients without any gene alternation or without any available target agents
16690640|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:
~Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)
~2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
16690649|NCT02012985|Experimental|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
16690650|NCT02012985|Placebo Comparator|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
16690651|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
16690652|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
16690653|NCT02012959|Experimental|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.
~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter [mmol/L]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.
~Discontinued tolvaptan treatment immediately after randomization.
~All participants were observed up to 14 days post randomization."
16690654|NCT02012959|Experimental|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.
~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.
~Continued treatment for 2 additional days.
~All participants were observed up to 14 days post randomization."
16690655|NCT02012946|Active Comparator|dobutamine|patient receiving dobutamine
16690656|NCT02012946|Active Comparator|Levosimendan|patient receiving levosimendan
16690657|NCT02012920|Experimental|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
16690658|NCT02012920|Experimental|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
16690659|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
16690660|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
16690661|NCT02012881|Experimental|Physical activity intervention|60 minutes of physical activity on every school day
16690662|NCT02012881|Active Comparator|Control|Usual practice
16690663|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
16690664|NCT02012855|Experimental|Exercise only|90 minutes of exercise
16690665|NCT02012855|Experimental|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
16690666|NCT02012855|Experimental|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
16690667|NCT02012855|No Intervention|No exercise and no meal|No exercise and no meal
16690668|NCT02012842|Active Comparator|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
16690669|NCT02012842|Other|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
16690670|NCT02012829|No Intervention|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
16690671|NCT02012829|Active Comparator|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
16690672|NCT02012816|Other|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
16690673|NCT02012803|Experimental|Operative treatment|
16690674|NCT02012803|Active Comparator|conservative treatment|
16690675|NCT02012790|Experimental|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
16690676|NCT02012790|Experimental|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
16690677|NCT02012790|Active Comparator|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
16690678|NCT02012777|Active Comparator|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.
~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
16690679|NCT02012777|Active Comparator|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
16690680|NCT02012777|Active Comparator|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
16690681|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
16690682|NCT02012751|Experimental|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
16690683|NCT02012738|Active Comparator|Assignment to FORNET|17 participants were randomly assigned to FORNET
16690684|NCT02012738|Active Comparator|Assignment to CBT|14 participants were randomly assigned to CBT
16690686|NCT02012738|Other|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
16690687|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
16690688|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
16690689|NCT02012712|Experimental|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
16690690|NCT02012712|No Intervention|Usual care|Subjects received usual care (no invitation or access to the study PHR)
16690691|NCT02012686|Placebo Comparator|Control group|numerical rating scale of TENS non-applied group
16690692|NCT02012686|Active Comparator|TENS group|numerical rating scale of TENS applied group
16690693|NCT02012673|Experimental|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
16690694|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
16690695|NCT02012647|Active Comparator|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
16690696|NCT02012647|Placebo Comparator|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
16690697|NCT02012608|Active Comparator|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
16690698|NCT02012608|Placebo Comparator|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
16690699|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
16690700|NCT02012595||Healthy Controls|Healthy participants
16690701|NCT02012582|Experimental|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
16690702|NCT02012582|Experimental|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
16690703|NCT02012582|Experimental|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
16690704|NCT02012582|Placebo Comparator|Saline|0.9 % Sodium chloride infusion
16690705|NCT02012569|Experimental|TT.173|It is applied directly to the bleeding of the donor site
16690706|NCT02012569|Placebo Comparator|placebo|It is applied directly to the bleeding of the donor site
16690707|NCT02012556|Experimental|Tesamorelin|
16690708|NCT02012543|Experimental|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
16690709|NCT02012530|Active Comparator|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
16690710|NCT02012530|Active Comparator|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
16690711|NCT02012517|Active Comparator|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
16690712|NCT02012517|Experimental|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
16690713|NCT02012504||Western medicine|venlafaxine or escitalopram
16690714|NCT02012504||Chinese medcine|Shuganjieyu capsule
16690715|NCT02012491|Active Comparator|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
16690716|NCT02012491|Active Comparator|misoprostol|800 micrograms of vaginal misoprostol alone
16690717|NCT02012478|No Intervention|No intervention|baseline session - with surveys and HbA1C only
16690718|NCT02012478|Experimental|MI-informed SMS intervention|Baseline session with surveys & HbA1C MI baseline session Technology tutorial Intervention x 3 months
16690719|NCT02012465|Experimental|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):
~Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))
~Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.
~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
16690720|NCT02012452|Experimental|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
16690721|NCT02012452|Sham Comparator|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
16690722|NCT02012439|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
16690723|NCT02012439|Active Comparator|Cognitive therapy|Cognitive Therapy
16690724|NCT02012426|Experimental|Intervention Group|Participants enrolled in commercial weight management program
16690725|NCT02012426|Active Comparator|Control group|Participants enrolled in standard care weight management provision
16690726|NCT02012413|Active Comparator|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
16690727|NCT02012413|Placebo Comparator|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
16690728|NCT02012400|Experimental|Intervention group|
16690730|NCT02012387|Active Comparator|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
16690731|NCT02012387|Placebo Comparator|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
16690732|NCT02012387|Active Comparator|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
16690733|NCT02012374|Experimental|"Intensive Language Action Therapy (constrained)"|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. Spoken responses are explicitly modeled and encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
16690734|NCT02012374|Experimental|Unconstrained Intensive Language Action Therapy|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. All communicative responses are encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
16690735|NCT02012361|Active Comparator|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
16690736|NCT02012361|Active Comparator|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
16690737|NCT02012348|Placebo Comparator|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
16690738|NCT02012348|Experimental|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
16690739|NCT02012348|Active Comparator|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
16690740|NCT02012335|Placebo Comparator|ECT + saline|Brief pulse ECT with saline as placebo in each session
16690741|NCT02012335|Experimental|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
16690742|NCT02012322|Other|Placebo vs. Q10 100mg vs. Q10 300mg|
16690743|NCT02012322|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
16690744|NCT02012322|Other|Q10 100mg vs. Placebo vs. Q10 300mg|
16690745|NCT02012322|Other|Q10 100mg vs. Q10 300mg vs. Placebo|
16690746|NCT02012322|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
16690747|NCT02012322|Other|Q10 300mg vs. Q10 100mg vs. Placebo|
16690748|NCT02012309|Experimental|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
16690749|NCT02012309|Experimental|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
16690750|NCT02012296|Active Comparator|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
16690751|NCT02012296|Experimental|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
16690752|NCT02012283|Experimental|Vegetable Intake with Spices Added|Subjects consuming vegetables with mixed-spices added.
16690753|NCT02012283|Active Comparator|Vegetable Intake without Spices Added|Subjects consuming vegetables without spice.
16690754|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
16690755|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
16690756|NCT02012257|Experimental|Anterior Site|AMSA nerve block injection
16690757|NCT02012257|Experimental|Common Site|AMSA nerve block injection
16690758|NCT02012257|Experimental|Posterior Site|AMSA nerve block injection
16690759|NCT02012244|Experimental|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
16690760|NCT02012244|Experimental|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
16690761|NCT02012231|Experimental|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
16690762|NCT02012218|Experimental|ADT and Brexpiprazole|ADT and Brexpiprazole
16690763|NCT02012205|Experimental|wet cupping|patient will receive wet cupping
16690764|NCT02012205|No Intervention|control|not cupping
16690765|NCT02012192|Experimental|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
16690766|NCT02012192|Active Comparator|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
16690767|NCT02012179|Experimental|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
16690768|NCT02012179|No Intervention|Usual Care|General advice to limit dietary sodium as it is provided during routine clinic practice
16690769|NCT02012166|Experimental|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690770|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690771|NCT02012166|Experimental|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690772|NCT02012166|Experimental|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690773|NCT02012166|Experimental|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690774|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690775|NCT02012166|Experimental|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
16690776|NCT02012153|Experimental|Mesenchymal Stromal Cells|"A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.
~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
16690777|NCT02012140|Experimental|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
16690778|NCT02012127||Acromegalic patients|
16690779|NCT02012114|No Intervention|Cysteamine Bitartrate|Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
16690780|NCT02012101|Experimental|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
16690781|NCT02012101|Active Comparator|oxygen therapy|oxygen therapy is given during the whole experimental process
16690782|NCT02012088|Experimental|RCOMP|"R-COMP Regimen:
~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
16690783|NCT02012088|Active Comparator|RCHOP|"R-CHOP Regimen:
~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
16690784|NCT02012075|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
16690785|NCT02012075|Active Comparator|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
16690786|NCT02012062|Active Comparator|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
16690787|NCT02012062|Experimental|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
16690788|NCT02012049|Experimental|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
16690789|NCT02012049|Experimental|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
16690790|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
16690791|NCT02012023|Experimental|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
16690792|NCT02012023|Active Comparator|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
16690793|NCT02012010|Experimental|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
16690794|NCT02012010|Active Comparator|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
16690795|NCT02011997|Experimental|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
16690796|NCT02011997|Active Comparator|Lobectomy|Patients undergo cVATS lobectomy
16690797|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
16690798|NCT02011971|Active Comparator|Low dose|Vinpocetine 10 mg Healthy subjects
16690799|NCT02011971|Active Comparator|Mid-dose 1|Vinpocetine 20mg Healthy subjects
16690800|NCT02011971|Placebo Comparator|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
16690801|NCT02011971|Active Comparator|High Dose|Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
16690802|NCT02011958|Experimental|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11
~Miltefosine: orally taken every day during 28 days
~1 x 50 mg capsule per day if patient weights less or equal to 25 kg
~2 x 50 mg capsules per day if the patient weights more than 25 kg"
16690803|NCT02011958|Experimental|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
16690804|NCT02011945|Experimental|dasatinib Only|dasatinib 100 mg QD(CP) or 140 mg QD (AP)
16690805|NCT02011945|Experimental|Dose Level 1|Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
16690806|NCT02011945|Experimental|Dose Level 2|Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
16690807|NCT02011932||Healthy volunteers|
16690808|NCT02011932||Chronic hepatitis C|
16690809|NCT02011919|Other|Echopulse|Echopulse HIFU
16690810|NCT02011906|Active Comparator|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
16690811|NCT02011906|Active Comparator|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
16690812|NCT02011906|Placebo Comparator|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
16690813|NCT02011893|Experimental|Burst Stimulation|Burst Stimulation using the Prodigy system
16690814|NCT02011893|Active Comparator|Tonic Stimulation|Tonic Stimulation using the Prodigy system
16690815|NCT02011867|Experimental|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
16690816|NCT02011854|Experimental|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
16690817|NCT02011854|Other|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
16690818|NCT02011841|Experimental|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
16690819|NCT02011841|Active Comparator|Control group|Ciprofloxacin 500 mg/day orally for 6 months
16690820|NCT02011828|Experimental|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
16690821|NCT02011828|Experimental|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
16690822|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
16690823|NCT02011802|Active Comparator|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
16690824|NCT02011802|Experimental|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
16690825|NCT02011789|Experimental|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
16690826|NCT02011789|Active Comparator|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
16690827|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
16690828|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
16690829|NCT02011763|Experimental|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
16690830|NCT02011750|Experimental|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
16690831|NCT02011750|Placebo Comparator|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
16690832|NCT02011737|Active Comparator|Naftopidil|Naftopidil 75mg once daily
16690833|NCT02011737|Placebo Comparator|Placebo|Placebo once daily
16690834|NCT02011724|Experimental|Apligraf|
16690835|NCT02011711||Mirena|Women interested in beginning use of Mirena
16690836|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
16690837|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
16690838|NCT02011698|Experimental|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
16690839|NCT02011698|Active Comparator|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
16701244|NCT01942083|Experimental|OPB-111077|orally, once daily
16690840|NCT02011698|Experimental|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
16690841|NCT02011685|Active Comparator|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
16690842|NCT02011685|Experimental|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
16690843|NCT02011672|Experimental|nutrient-enriched milk|consumption of 250 ml three times per day
16690844|NCT02011672|Placebo Comparator|regular milk|consumption of 250 ml three times per day
16690845|NCT02011659|Active Comparator|Ramosetron|
16690846|NCT02011646|Experimental|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
16690847|NCT02011646|Active Comparator|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
16690848|NCT02011633|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16690849|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16690850|NCT02011633|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16690851|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16690852|NCT02011620|Active Comparator|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
16690853|NCT02011620|No Intervention|Standard care|Standard care - no intervention with nitrates
16690854|NCT02011594|Experimental|Arm A|Nimotuzumab
16690855|NCT02011594|Placebo Comparator|Arm B|Placebo (normal saline)
16690856|NCT02011568|Other|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
16690857|NCT02011568|Active Comparator|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
16690858|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
16690859|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
16690860|NCT02011529|Active Comparator|TEAMcare treatment of diabetes|
16690861|NCT02011529|No Intervention|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
16690862|NCT02011516|Placebo Comparator|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
16690863|NCT02011516|Active Comparator|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
16690864|NCT02011503|Experimental|dHACM|Application of multi-layer compression therapy with application of dHACM.
16690865|NCT02011503|Other|Control|Application of multi-layer compression therapy without application of dHACM.
16690866|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
16690867|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
16690868|NCT02011490|Experimental|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
16690869|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
16690870|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
16690871|NCT02011490|Experimental|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
16690872|NCT02011477|Experimental|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
16690918|NCT02011178|Other|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
16690873|NCT02011477|Placebo Comparator|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
16690874|NCT02011477|Active Comparator|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
16690875|NCT02011464|Experimental|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
16690876|NCT02011464|Placebo Comparator|Control|Saline infiltrated into posterior compartment
16690877|NCT02011451|Experimental|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
16690878|NCT02011451|Placebo Comparator|Sugar pill|Matched placebo capsules
16690879|NCT02011438|Experimental|UTalk Intervention|Active preventative intervention condition.
16690880|NCT02011438|No Intervention|Control|Education/Support Condition
16690881|NCT02011425|Experimental|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
16690882|NCT02011425|No Intervention|without mandibular advancement appliance|no therapy
16690883|NCT02011412||Intermountain Risk Score known|
16690884|NCT02011412||Intermountain Risk Score Unknown|
16690885|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
16690886|NCT02011373|Experimental|IFABOND|
16690887|NCT02011360|Other|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
16690888|NCT02011360|Other|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
16690889|NCT02011347|Experimental|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
16690890|NCT02011347|Experimental|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
16690891|NCT02011334|Experimental|RoActemra/Actemra|
16690892|NCT02011321|Experimental|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
16690893|NCT02011308|Active Comparator|Green Light Laser|
16690894|NCT02011308|Active Comparator|TURP|Transurethral Resection of the Prostate
16690895|NCT02011295|Other|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
16690896|NCT02011295|Other|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
16690897|NCT02011282|Experimental|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
16690898|NCT02011282|No Intervention|Control|Patients in this arm will receive the usual standard treatment
16690899|NCT02011269|Active Comparator|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
16690900|NCT02011269|Active Comparator|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
16690901|NCT02011269|Placebo Comparator|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
16690902|NCT02011256|Experimental|Implantable loop-recorder|
16690903|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
16690904|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
16690905|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
16690906|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
16690907|NCT02011230|No Intervention|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
16690908|NCT02011230|Experimental|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
16690909|NCT02011217|Experimental|Rye crisp bread A|
16690910|NCT02011217|Experimental|Rye crisp bread B|
16690911|NCT02011217|Experimental|Wheat crisp bread C|
16690912|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)
~Intervention: Electrical Impedance Myography (EIM)."
16690913|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
16690914|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
16690915|NCT02011191|Active Comparator|Biotin|10,000 micrograms biotin daily for 8 weeks
16690916|NCT02011191|Placebo Comparator|Sugar pill|
16690917|NCT02011178|Active Comparator|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
16701559|NCT01939964|Placebo Comparator|Placebo|sugar pill
16690919|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
16690920|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
16690921|NCT02011139|Active Comparator|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
16690922|NCT02011139|Active Comparator|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
16690923|NCT02011126|Experimental|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
16690924|NCT02011113|Experimental|Pomalidomide plus dexamethasone|
16690925|NCT02011100|Experimental|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
16690926|NCT02011100|Placebo Comparator|placebo|3 months placebo intake - taken twice a day (1-0-1)
16690927|NCT02011087|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
16690928|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
16690929|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
16690930|NCT02011022|Experimental|3g group|The dose of MTX is 3 g/m2
16690931|NCT02011022|Experimental|5g group|The dose of MTX is 5g/m2
16690932|NCT02011009|Experimental|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
16690933|NCT02010996|Experimental|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
16690934|NCT02010996|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
16690935|NCT02010983|Experimental|longstanding achalasia|
16690936|NCT02010970|Experimental|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
16690937|NCT02010970|Experimental|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
16690938|NCT02010970|Experimental|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
16690939|NCT02010957|Experimental|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
16690940|NCT02010944|Experimental|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
16690941|NCT02010944|Experimental|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
16690942|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
16690943|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
16690944|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
16690945|NCT02010918|Active Comparator|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
16690946|NCT02010905|Active Comparator|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
16690947|NCT02010905|Placebo Comparator|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
16690948|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
16690949|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
16690950|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
16690951|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
16690952|NCT02010866|Other|Counseling|in-person counseling through RFWP to distressed respondents on the ISP and patients who seek counseling without completing the ISP
16690953|NCT02010853|Experimental|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:
~During the acute phase within 24 hours
~In 72 hours
~In 3 months"
16690954|NCT02010853|Other|control|"each control will receive an evaluation in resting state IRMf during three successive visits:
~During the acute phase within 24 hours
~In 72 hours
~In 3 months"
16690955|NCT02010840|Experimental|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
16690956|NCT02010840|Active Comparator|Mother only|Only the women receives the psychoeducation program.
16690957|NCT02010840|No Intervention|Control group|Receives usual perinatal care services only
16690958|NCT02010827||Patients|Patients
16690959|NCT02010827||healthy controls|healthy controls
16690960|NCT02010814||PCOS|"Women fulfilling at least two of the three Rotterdam criteria for PCOS, including
~Irregular menstrual cycle
~Clinical/biochemical hyperandrogenemia
~Polycystic ovaries"
16690961|NCT02010801|Experimental|IRE for tumor before tumor resection|
16690962|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
16690963|NCT02010775|Active Comparator|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
16690964|NCT02010775|Active Comparator|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
16690965|NCT02010775|Active Comparator|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
16690966|NCT02010775|Active Comparator|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
16690967|NCT02010775|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
16690968|NCT02010762|Active Comparator|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
16690969|NCT02010762|Placebo Comparator|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
16690970|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
16690971|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
16690972|NCT02010736|Experimental|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
16690973|NCT02010723|Active Comparator|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
16690974|NCT02010723|Experimental|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
16690975|NCT02010710|Experimental|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
16690976|NCT02010710|No Intervention|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
16690977|NCT02010697|Experimental|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
16690978|NCT02010697|Experimental|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
16690979|NCT02010697|No Intervention|Usual care|one time mailing with a self-help quit kit
16690980|NCT02010684|No Intervention|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
16690981|NCT02010684|Experimental|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
16690982|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
16690983|NCT02010658|No Intervention|Memory|
16690984|NCT02010658|Experimental|Cognitive Aid|
16690985|NCT02010645|Experimental|Eltrombopag + Decitabine|"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
~Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle."
16690986|NCT02010632|Experimental|Generic clopidogrel product|Apolets® 75 mg tablet
16690987|NCT02010632|Active Comparator|Original clopidogrel product|Plavix® 75mg tablet
16690988|NCT02010619|Experimental|Cognitive behavior therapy|
16690989|NCT02010619|Active Comparator|Supportive therapy|
16690990|NCT02010606|Experimental|Cohort A: Patients with newly diagnosed glioblastoma|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
16690991|NCT02010606|Experimental|Cohort B: Patients with recurrent glioblastoma|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
16690992|NCT02010593|Experimental|Dapivirine Vaginal Ring|Safety study of a vaginal ring containing Dapivirine in a postmenopausal female population
16690993|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a flexible, platinum-catalyzed-cured matrix ring, identical to Dapivirine Ring-004, containing no active-drug
16690994|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
16690995|NCT02010567|Experimental|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
16690996|NCT02010567|Experimental|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
16690997|NCT02010554|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
16690998|NCT02010554|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
16690999|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
16691000|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
16691001|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
16691002|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
16691003|NCT02010515||Sinus rhythm, first ICD implantation|
16691004|NCT02010502|Active Comparator|Concentrated Beet Root Juice|500ml per day for 6 days
16691005|NCT02010502|Active Comparator|Beet root powder|500ml per day for 6 days
16691006|NCT02010502|Placebo Comparator|Placebo juice|Negligible nitrate
16691007|NCT02010489|No Intervention|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
16691008|NCT02010489|Other|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
16691009|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
16691010|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
16691011|NCT02010463|Other|Exercise Intervention|9-month exercise program involving four exercise education sessions
16691012|NCT02010450|Experimental|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
16691013|NCT02010450|Active Comparator|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
16691014|NCT02010437|Active Comparator|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.
~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.
~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
16691015|NCT02010437|Active Comparator|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
16691016|NCT02010437|Active Comparator|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
16691088|NCT02010047|Experimental|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
16691017|NCT02010424|Experimental|Individual culture|standard IVF protocol: half of the fertilized oocytes of the patient will be cultured individually in drops of 25 µl Cook cleavage medium till day 3 after fertilization and subsequently in drops of 25 µl Cook blastocyst medium till day 5 after fertilization
16691018|NCT02010424|Experimental|WOW|Half of the fertilized oocytes of the patient will be cultured in group in a WOW dish, each in a separate microwell but covered with one drop of 30 µl of Cook cleavage medium till day 3 after fertilization and subsequently all the embryos will be transferred to a new WOW dish (in the exactly the same position) covered with 30 µl of Cook blastocyst medium till day 5 after fertilization
16691019|NCT02010411|Active Comparator|Prolastin|Prolastin 250 mg nebulized BID, 10 days
16691020|NCT02010398|Active Comparator|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
16691021|NCT02010398|Active Comparator|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
16691022|NCT02010398|Experimental|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
16691023|NCT02010398|No Intervention|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
16691024|NCT02010385|Active Comparator|Octreotide|One subcutaneous injection - 1 mL
16691025|NCT02010385|Placebo Comparator|Saline|One subcutaneous injection - 1 mL
16691026|NCT02010372|Experimental|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
16691027|NCT02010372|Experimental|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
16691028|NCT02010372|No Intervention|Control|No intervention will be administered to this group.
16691029|NCT02010359|Experimental|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
16691030|NCT02010359|Placebo Comparator|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
16691031|NCT02010346|Experimental|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
16691032|NCT02010346|No Intervention|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
16691033|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
16691034|NCT02010320|Experimental|Computer dosed|Patients for which the computer model will calculate the individual doses
16691035|NCT02010320|Active Comparator|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
16691036|NCT02010307|Experimental|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
16691037|NCT02010307|Experimental|chronic periodontitis|25 patients with chronic periodontitis blood extraction
16691038|NCT02010307|Experimental|healthy|25 healthy periodontal patients blood extraction
16691039|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
16691040|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
16691041|NCT02010281|Experimental|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
16691042|NCT02010281|Placebo Comparator|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
16691043|NCT02010281|Experimental|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
16691044|NCT02010268|Experimental|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
16691045|NCT02010255|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
16691046|NCT02010255|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
16691047|NCT02010255|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
16691048|NCT02010255|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
16691049|NCT02010255|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
16691050|NCT02010255|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
16691051|NCT02010255|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
16691052|NCT02010255|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
16691089|NCT02010034|Other|Compassionate use|This lipid preparation is only being used for compassionate use.
16691053|NCT02010255|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
16691054|NCT02010255|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
16691055|NCT02010255|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
16691056|NCT02010255|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
16691057|NCT02010255|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
16691058|NCT02010255|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
16691059|NCT02010242|Experimental|GKT137831|GKT137831 100 mg capsules twice a day
16691060|NCT02010242|Placebo Comparator|Placebo|Placebo capsule twice a day
16691061|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
16691062|NCT02010216|Experimental|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
16691063|NCT02010203|Experimental|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
16691064|NCT02010203|Experimental|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
16691065|NCT02010203|Experimental|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
16691066|NCT02010203|Placebo Comparator|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
16691067|NCT02010203|Experimental|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
16691068|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
16691069|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
16691070|NCT02010164|Experimental|Old-CoQ10|
16691071|NCT02010164|No Intervention|Old|
16691072|NCT02010164|No Intervention|Young|Young less than 33 years old participants
16691073|NCT02010151|Experimental|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
16691074|NCT02010151|No Intervention|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
16691075|NCT02010138|Active Comparator|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
16691076|NCT02010138|Active Comparator|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
16691077|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.
~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
16691078|NCT02010112|Experimental|Initial Diagnosis Cohort|Subjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy
16691079|NCT02010099|Experimental|PP110 Gel|PP110 Gel
16691080|NCT02010099|Experimental|PP110 medicated wipes|PP110 Medicated wipes
16691081|NCT02010099|Active Comparator|Preparation-H cream|Preparation-H cream
16691082|NCT02010086|Experimental|Individual Cognitive Behavioral Therapy|
16691083|NCT02010086|Active Comparator|Standard Community Treatment|
16691084|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
16691085|NCT02010060|No Intervention|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
16691086|NCT02010060|Experimental|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
16691087|NCT02010060|Experimental|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
16691874|NCT02004743|Other|Intervention|Psychological management guidelines + patient education
16691090|NCT02010021|No Intervention|No drug treatment|Post-menopausal women with stage I-III breast cancer will have surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.
16691091|NCT02010021|Active Comparator|Letrozole-presurgical|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
16691092|NCT02010008|Experimental|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
16691093|NCT02010008|No Intervention|Comparison|Usual care
16691094|NCT02009995|Active Comparator|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
16691095|NCT02009995|Experimental|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.
~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
16691096|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
16691097|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
16691098|NCT02009956|Other|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
16691099|NCT02009943|Experimental|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
16691100|NCT02009943|Active Comparator|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:
~TSAT < 25%
~Serum iron concentration < 150 ug/mL
~Serum ferritin concentration < 1,500 ng/mL"
16691101|NCT02009943|No Intervention|Control|No iron supplementation
16691102|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
16691103|NCT02009891||Control|Control couples who will not use predictive model
16691104|NCT02009891||Predictive model|Couples who will use predictive model
16691105|NCT02009878|Other|tolvaptan 3.75 mg|tolvaptan 3.75 mg
16691106|NCT02009878|Other|tolvaptan 7.5 mg|tolvaptan 7.5 mg
16691107|NCT02009878|Other|tolvaptan 15 mg|tolvaptan 15 mg
16691108|NCT02009865|Experimental|Epanova 2 g/day|Arm 1
16691109|NCT02009865|Placebo Comparator|Olive Oil 2 g/day|Arm 2
16691110|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
16691111|NCT02009839|Experimental|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
16691112|NCT02009839|Placebo Comparator|Computer Games|14 weeks of interactive session with the therapist while playing computer games
16691113|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
16691114|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
16691115|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
16691116|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
16691117|NCT02009787|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
16691118|NCT02009787|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
16691119|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
16691120|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
16691121|NCT02009761|Experimental|BI 655064 subcutaneous|Escalating single dose as subcutaneous injection
16691122|NCT02009748|Active Comparator|Vitamin D supplementation|Colecalciferol 2.800 IU/day
16691123|NCT02009748|Placebo Comparator|Placebo|Vehicle (coconut oil)
16691124|NCT02009735|Experimental|virosensor|virus detection
16691232|NCT02009098|Active Comparator|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
16691125|NCT02009722|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
16691126|NCT02009722|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
16691127|NCT02009709|Active Comparator|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
16691128|NCT02009709|Active Comparator|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
16691129|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
16691130|NCT02009670|Experimental|13C inulin|13C inulin combined with an inulin load are administered orally
16691131|NCT02009670|Placebo Comparator|Placebo|A placebo is administered orally
16691132|NCT02009644|Experimental|Treovance|Subjects who receive the Treovance stent-graft
16691133|NCT02009631|Experimental|Sequence Group A|200 mg Veliparib
16691134|NCT02009631|Experimental|Sequence Group B|400 mg Veliparib
16691135|NCT02009631|Placebo Comparator|Sequence Group C|Placebo
16691136|NCT02009618|Placebo Comparator|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
16691137|NCT02009618|Experimental|Rifaximin|"Irritable bowel syndrome patients
~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
16691138|NCT02009605|Experimental|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
16691139|NCT02009592|Active Comparator|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
16691140|NCT02009592|Active Comparator|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
16691141|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
16691142|NCT02009579|Placebo Comparator|Comparator arm|Placebo
16691143|NCT02009566|Experimental|Abdominal radiographs with microfabricated tags|
16691144|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
16691145|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
16691146|NCT02009540|Placebo Comparator|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
16691147|NCT02009540|Active Comparator|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
16691148|NCT02009527|Experimental|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
16691149|NCT02009527|Placebo Comparator|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
16691150|NCT02009501|Active Comparator|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
16691151|NCT02009501|Active Comparator|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
16691152|NCT02009488|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
16691153|NCT02009488|Placebo Comparator|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
16691154|NCT02009475|Active Comparator|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
16691155|NCT02009475|Experimental|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
16691156|NCT02009462|Experimental|Artefill|Four treatment visits using Artefill dermal filler
16691157|NCT02009449|Experimental|Part A: Dose Escalation Cohort 1|Pegilodecakin (1 ug/kg) - Daily subcutaneous (SC) injections of pegilodecakin for up to 22 months
16691158|NCT02009449|Experimental|Part A: Dose Escalation Cohort 2|Pegilodecakin (2.5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
16691159|NCT02009449|Experimental|Part A: Dose Escalation Cohort 3|Pegilodecakin (5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
16691160|NCT02009449|Experimental|Part A: Dose Escalation Cohort 4|Pegilodecakin (10 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
16691161|NCT02009449|Experimental|Part A: Dose Escalation Cohort 5|Pegilodecakin (20 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
16691162|NCT02009449|Experimental|Part A: Dose Escalation Cohort 6|Pegilodecakin (40 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
16691163|NCT02009449|Experimental|Part A: Dose Expansion Cohort 1|at least 15 RCC participants will be dosed with pegilodecakin for up to 22 months
16691164|NCT02009449|Experimental|Part B: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
16691233|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
16691165|NCT02009449|Experimental|Part B: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
16691166|NCT02009449|Experimental|Part B: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
16691167|NCT02009449|Experimental|Part B: Dose Expansion Cohort|"Daily SC injection with pegilodecakin with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
16691168|NCT02009449|Experimental|Part C: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
16691169|NCT02009449|Experimental|Part C: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
16691170|NCT02009449|Experimental|Part C: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
16691171|NCT02009449|Experimental|Part C: Dose Expansion Cohort 1|"Daily SC injection with pegilodecakin with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
16691172|NCT02009449|Experimental|Part D: Dose Escalation Cohort 1|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).
~Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by
~• Gemcitabine 1000 mg/m2 IV."
16691173|NCT02009449|Experimental|Part E: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).
~• Capecitabine 1000 mg/m2 po BID"
16691174|NCT02009449|Experimental|Part F: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)
~• Paclitaxel 80 mg/ m2 IV"
16691175|NCT02009449|Experimental|Part G: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)
~• Pazopanib 800 mg po QD"
16691176|NCT02009449|Experimental|Part H: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
~• Pembrolizumab 2 mg/kg IV over 30 min"
16691177|NCT02009449|Experimental|Part I: Dose Escalation Cohort 1|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).
~• Nivolumab 3 mg/kg IV over 60 min"
16691178|NCT02009449|Experimental|Part H: Dose Escalation Cohort 2|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
~• Pembrolizumab 2 mg/kg IV over 30 min"
16691179|NCT02009449|Experimental|Part H: Dose Escalation Cohort 3|"Pegilodecakin (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
~• Pembrolizumab 2 mg/kg IV over 30 min"
16691180|NCT02009449|Experimental|Part J: Dose Escalation Cohort 1|Pegilodecakin (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
16691181|NCT02009436|Experimental|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
16691182|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
16691183|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
16691184|NCT02009410|Experimental|Creon|
16691185|NCT02009410|Placebo Comparator|Placebo|
16691186|NCT02009397|Experimental|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
16691188|NCT02009371|Experimental|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
16691189|NCT02009371|Placebo Comparator|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
16691190|NCT02009358|Experimental|Mental health promotion group|
16691191|NCT02009332|Experimental|Phase 1: ABI-009 100 mg/week|Phase 1, Cohort 1: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
16691192|NCT02009332|Experimental|Phase 1: ABI-009 200 mg/week|Phase 1, Cohort 2: ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
16691234|NCT02009072|Experimental|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
16691193|NCT02009332|Experimental|Phase 1: ABI-009 100 mg 2×/week|Phase 1, Cohort 2b: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, twice per week (total dose 200 mg per week) for 6 weeks
16691194|NCT02009332|Experimental|Phase 1: ABI-009 300 mg/week|Phase 1, Cohort 3: ABI-009 injectable suspension, 300 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
16691195|NCT02009332|Experimental|Phase 1: ABI-009 400 mg/week|Phase 1, Cohort 4: ABI-009 injectable suspension, 400 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
16691196|NCT02009332|Experimental|Phase 2: ABI-009 400 mg/week + Gemcitabine 2000 mg/week|ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 1 hour, once per week for 6 weeks; Gemcitabine, 2000 mg in 100 mL saline, administered intravesically after voiding of ABI-009 and retained for 1 hour, once per week for 6 weeks
16691197|NCT02009306|Experimental|PecFent and Epistatus|Medication administered by family / carer for symptoms
16691198|NCT02009306|Active Comparator|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
16691199|NCT02009306|Experimental|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:
~Epistatus administered PRN by family / carer for symptoms"
16691200|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
16691201|NCT02009280|Experimental|Propofol group|Propofol group
16691202|NCT02009280|Active Comparator|Sevoflurane group|Sevoflurane group
16691203|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
16691204|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
16691205|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
16691206|NCT02009254|Experimental|Mashed Potatoes (as produced)|
16691207|NCT02009254|Experimental|Mashed Potatoes (with no added butter during production)|
16691208|NCT02009254|Experimental|glucose control (50 g)|
16691209|NCT02009241|Active Comparator|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
16691210|NCT02009241|No Intervention|Control|
16691211|NCT02009228|Active Comparator|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
16691212|NCT02009228|Active Comparator|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
16691213|NCT02009215|Experimental|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
16691214|NCT02009215|No Intervention|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
16691215|NCT02009202|Active Comparator|picosulphate|Picosulphate is given orally
16691216|NCT02009202|Active Comparator|polyethylene glycol|Polyethylene glycol is given orally
16691217|NCT02009189|Placebo Comparator|Control|Saline flush
16691218|NCT02009189|Active Comparator|2% Taurolidine lock|Catheter lock with 2% Taurolidine
16691219|NCT02009189|Active Comparator|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
16691220|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
16691221|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
16691222|NCT02009163|Experimental|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
16691223|NCT02009163|Placebo Comparator|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
16691224|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
16691225|NCT02009137|Experimental|EVERA|EVERA- korean ESTES system, apply for 12 weeks
16691226|NCT02009137|Active Comparator|ESTES|ESTES apply for 12 weeks
16691227|NCT02009124|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
16691228|NCT02009124|No Intervention|Control|Stem cell therapy is not done for this group of spinal cord injury patients
16691229|NCT02009111|Experimental|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
16691230|NCT02009111|Other|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
16691231|NCT02009098|Active Comparator|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
16691235|NCT02009072|Experimental|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
16691236|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
16691237|NCT02009046|Experimental|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
16691238|NCT02009046|Active Comparator|Control Classroom Curriculum|Participants receive the control classroom curriculum.
16691239|NCT02009046|Experimental|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
16691240|NCT02009046|Active Comparator|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).
16691241|NCT02009033|Experimental|Ringer's lactate|Fluid therapy during operation
16691242|NCT02009007|Experimental|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
16691243|NCT02009007|Experimental|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
16691244|NCT02008994|Experimental|Genomic and Proteomic Profiling|"Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.
~Immunohistochemistry will look for specific markers of disease in your DNA.
~RNA sequencing will be used to help doctors and scientists understand how your genes are working.
~Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
16691245|NCT02008981|Active Comparator|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
16691246|NCT02008981|Active Comparator|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
16691247|NCT02008981|Active Comparator|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
16691248|NCT02008968|Active Comparator|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
16691249|NCT02008968|Active Comparator|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
16691250|NCT02008968|Placebo Comparator|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
16691251|NCT02008955|Experimental|lysine intake at different levels of intake|all subjects will receive all 7 of the lysine test levels, assigned in random order.
16691252|NCT02008942|Experimental|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
16691253|NCT02008942|Active Comparator|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
16691254|NCT02008929|Other|MG4101|Ex vivo expanded allogeneic NK cell
16691255|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
16691256|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
16691257|NCT02008916|Placebo Comparator|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
16691258|NCT02008903||EoE active disease|Inflammation as defined by >15 eos / HPF
16691259|NCT02008903||EoE remission|No inflammation in EoE patients after treatment
16691260|NCT02008903||normal control|No inflammation
16691261|NCT02008890|Experimental|Secukinumab 300mg|"Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.
~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.
~For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148."
16691262|NCT02008890|Experimental|Secukinumab 150mg|"Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.
~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.
~For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148."
16691263|NCT02008890|Placebo Comparator|Placebo|Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
16691264|NCT02008877|Experimental|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
16691265|NCT02008864|Placebo Comparator|Placebo|Wheat
16691266|NCT02008864|Active Comparator|Senna|Senna
16691267|NCT02008851|Experimental|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
16691268|NCT02008838|Active Comparator|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])
16691269|NCT02008838|Placebo Comparator|Placebo|250 mg Maltodexterin
16691270|NCT02008825|Experimental|ViSiGi|Utilization of ViSiGi calibration tube
16691271|NCT02008825|Active Comparator|Usual standard of care|Usual non suction Bougie
16691272|NCT02008812|Experimental|Ad sensor|virus detection
16691273|NCT02008799|Experimental|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
16691274|NCT02008786|Experimental|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
16691275|NCT02008786|Experimental|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
16691276|NCT02008773|Active Comparator|valacyclovir|3000mg daily oral 16 weeks
16691277|NCT02008773|Placebo Comparator|placebo|placebo 6 capsules daily oral 16 weeks
16691278|NCT02008760|Placebo Comparator|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
16691279|NCT02008760|Active Comparator|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
16691280|NCT02008747|Active Comparator|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.
~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
16691281|NCT02008747|No Intervention|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
16691282|NCT02008734|No Intervention|Control|
16691283|NCT02008734|Experimental|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
16691284|NCT02008721|Active Comparator|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
16691285|NCT02008721|Placebo Comparator|Placebo|Placebo
16691286|NCT02008708|Experimental|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
16691287|NCT02008708|Active Comparator|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
16691288|NCT02008695|Active Comparator|Youth microfinance only|Youth receive loan
16691289|NCT02008695|Active Comparator|youth and adult micro finance|youth and adult receive loan
16691290|NCT02008695|Active Comparator|adult microfinance|adults receive loan
16691291|NCT02008682|Experimental|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
16691292|NCT02008682|Active Comparator|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
16691293|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions
~Gustatory sensitivity test using Taste strips
~Blood sampling
~Questionnaires"
16691294|NCT02008656|Experimental|INCT|Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.
16691295|NCT02008656|Experimental|CNCT|Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.
16691296|NCT02008643|Experimental|children with food allergy|Chidren aged 8-18 year with food allergy
16691297|NCT02008643|Active Comparator|children with chronic diseases|
16691298|NCT02008643|Active Comparator|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient
~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
16691299|NCT02008630|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
16691300|NCT02008630|Experimental|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
16691301|NCT02008630|No Intervention|Control|Control group with treatment as usual
16691302|NCT02008617|Active Comparator|Study Drug|Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
16691303|NCT02008617|Sham Comparator|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
16691304|NCT02008604||Stroke patients|
16691305|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
16691306|NCT02008591|Active Comparator|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
16691307|NCT02008591|Active Comparator|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
16691308|NCT02008591|Active Comparator|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
16691309|NCT02008578|Experimental|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
16691310|NCT02008578|Placebo Comparator|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
16691311|NCT02008565|Placebo Comparator|Placebo - Exercise plus Biofeedback|"Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
16691340|NCT02008396|Experimental|75 mg to 125 mg MDMA with Psychotherapy|Participants will receive 75 to 125 mg during two psychotherapy sessions lasting approximately 7 hours; first session dose lower than second session dose.
16691312|NCT02008565|Experimental|Loperamide - Exercise plus Biofeedback|"Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
16691313|NCT02008565|Placebo Comparator|Placebo - Education Only|"Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
16691314|NCT02008565|Experimental|Loperamide - Education Only|"Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
16691315|NCT02008552|Other|Mediagene|Sampling blood
16691316|NCT02008539|Experimental|treatment arm|
16691317|NCT02008526|Experimental|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)
~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).
~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.
~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
16691318|NCT02008526|Experimental|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)
~Participants assigned to this group receive automatic text-messages.
~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.
~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
16691319|NCT02008526|No Intervention|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
16691320|NCT02008513|Active Comparator|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
16691321|NCT02008513|Active Comparator|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
16691322|NCT02008500|Placebo Comparator|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
16691323|NCT02008500|Active Comparator|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
16691324|NCT02008500|Sham Comparator|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
16691325|NCT02008487|Other|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
16691326|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 3 months|
16691327|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 3 months|
16691328|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 12 months|
16691329|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 12 months|
16691330|NCT02008461|Active Comparator|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
16691331|NCT02008461|Active Comparator|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.
~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
16691332|NCT02008448|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
16691333|NCT02008448|Active Comparator|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
16691334|NCT02008435|Experimental|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
16691335|NCT02008435|Active Comparator|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
16691336|NCT02008422|Experimental|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
16691337|NCT02008422|Active Comparator|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
16691338|NCT02008409|Experimental|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
16691339|NCT02008396|Placebo Comparator|Inactive Placebo with Psychotherapy|Subjects will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
16691341|NCT02008383|Experimental|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
16691346|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
16691347|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
16691348|NCT02008331|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
16691349|NCT02008331|Placebo Comparator|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
16691350|NCT02008318|Experimental|Phase (ph) 2: Galunisertib + BSC|Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
16691351|NCT02008318|Placebo Comparator|Ph 3: Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
16691352|NCT02008318|Experimental|Ph 3: Galunisertib + BSC|150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
16691353|NCT02008305|Experimental|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
16691354|NCT02008305|Active Comparator|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
16691356|NCT02008279|Experimental|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
16691357|NCT02008279|Experimental|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
16691358|NCT02008279|Experimental|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
16691359|NCT02008279|Experimental|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
16691360|NCT02008279|Experimental|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
16691361|NCT02008279|Experimental|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
16691362|NCT02008279|Experimental|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
16691363|NCT02008266||Patients with Rheumatoid Arthritis|
16691364|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
16691365|NCT02008240|Experimental|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
16691366|NCT02008240|Active Comparator|salpingectomy|Surgical removal of hydrosalpinx
16691367|NCT02008227|Experimental|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
16691368|NCT02008227|Active Comparator|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
16691369|NCT02008214|Experimental|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
16691370|NCT02008214|Placebo Comparator|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
16691371|NCT02008201|Experimental|Vitamin D dose 1|Vitamin D dose 1
16691372|NCT02008201|Experimental|Vitamin D dose 2|Vitamin D dose 2
16691373|NCT02008201|Experimental|Vitamin D dose 3|Vitamin D dose 3
16691374|NCT02008201|No Intervention|observational|No dose
16691375|NCT02008175|Experimental|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
16691376|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.
~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
16691377|NCT02008149|No Intervention|Standard of care group|SCI individuals receiving conventional rehab
16691378|NCT02008149|Experimental|FES-rowing group|Individuals with SCI participating in an FES-rowing program
16691379|NCT02008136|Experimental|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
16691380|NCT02008123|Experimental|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
16691381|NCT02008110|Experimental|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
16702643|NCT01932814||Aminoglycosides|have received aminoglycosides
16691382|NCT02008110|Active Comparator|Standard treatment strategy|Therapy is based on established european current guidelines
16691383|NCT02008097|Experimental|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
16691384|NCT02008097|Experimental|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
16691385|NCT02008097|Experimental|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
16691386|NCT02008097|Experimental|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
16691387|NCT02008097|Experimental|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
16691388|NCT02008097|Experimental|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
16691389|NCT02008084|Sham Comparator|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
16691390|NCT02008084|Experimental|TRIA-662|Following successful completion of the Baseline randomized to active drug
16691391|NCT02008084|Placebo Comparator|Placebo|Following successful completion of the Baseline randomized to placebo drug
16691392|NCT02008071|Experimental|Daily step goal financial incentive|
16691393|NCT02008071|Active Comparator|Control, Standard of Care|
16691394|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
16691395|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
16691396|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
16691397|NCT02008032|Experimental|All patients|Stationary Breast Tomosynthesis
16691398|NCT02008019|No Intervention|No treatment|No Everolimus treatment before surgery
16691399|NCT02008019|Experimental|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
16691400|NCT02008019|Experimental|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
16691401|NCT02008006|Experimental|BeEAM|"High Dose Chemotherapy (HDT) containing :
~Bendamustine
~Etoposide
~Cytarabine
~Melphalan
~HDT will be followed by an Autologous Stem Cell Transplantation"
16691402|NCT02007993|Active Comparator|Group 1|Treatment with a tongue scraper
16691403|NCT02007993|Experimental|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
16691404|NCT02007993|Experimental|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
16691405|NCT02007993|Experimental|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
16691406|NCT02007993|Experimental|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
16691407|NCT02007980||Patients with indwelling ureteral stent|Patients with existing indwelling ureteral stent, no additional treatment
16691408|NCT02007954|Experimental|DEBDOX|
16691409|NCT02007941|Experimental|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.
~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
16691410|NCT02007941|Active Comparator|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.
~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
16691411|NCT02007941|Experimental|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
16691412|NCT02007928|Other|rispéridone, aripiprazole, olanzapine...|"Study:
~We propose a prospective, interventional multicenter study.
~Method:
~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.
~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
16691413|NCT02007915|Experimental|Pamidronate Disodium|
16691414|NCT02007902||Very preterm babies|Observational model: cohort
16691415|NCT02007889|Active Comparator|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
16691416|NCT02007889|No Intervention|Control|control group received just antibiotic regimens without L-carnitine
16691447|NCT02007668|Experimental|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
16691448|NCT02007668|Placebo Comparator|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
16691449|NCT02007668|No Intervention|Control|This participants will not receive intervention
16691450|NCT02007655||Eliquis on Nonvalvular Atrial Fibrilliation patients|Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study
16691451|NCT02007642||No study treatment|
16692021|NCT02003768|Experimental|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
16691417|NCT02007876|Experimental|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.
~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.
~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
16691418|NCT02007876|No Intervention|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.
~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.
~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
16691419|NCT02007863|Experimental|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
16691420|NCT02007850|Placebo Comparator|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
16691421|NCT02007850|Active Comparator|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
16691422|NCT02007837|Experimental|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
16691423|NCT02007837|Placebo Comparator|Placebo|5mg folic acid, cellulose filler
16691424|NCT02007824|Experimental|ULSD-12D|ultrasound surgical device made by Ultech.
16691425|NCT02007824|Active Comparator|SONOCA-180|ultrasound surgical device made by Soering
16691426|NCT02007811|Experimental|allogeneic donor derived B-lymphocytes|
16691427|NCT02007798|Experimental|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
16691428|NCT02007798|Experimental|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
16691429|NCT02007798|Experimental|control group|P group: normal saline is infused intravenously
16691430|NCT02007785|Experimental|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
16691431|NCT02007772|Active Comparator|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
16691432|NCT02007772|Experimental|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
16691433|NCT02007759|Experimental|VitalStim|This group will be assigned to the active VitalStim unit.
16691434|NCT02007759|Sham Comparator|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
16691435|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
16691436|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
16691437|NCT02007733|Other|Single Arm|All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
16691438|NCT02007720|Placebo Comparator|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
16691439|NCT02007720|Experimental|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
16691440|NCT02007707|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
16691441|NCT02007707|Active Comparator|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
16691442|NCT02007694|Active Comparator|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
16691443|NCT02007694|Active Comparator|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
16691444|NCT02007694|Placebo Comparator|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
16691445|NCT02007681|Experimental|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
16691446|NCT02007681|No Intervention|Control|Regular free week with no changes performed
16692261|NCT02001935|Other|theophylline|
16691452|NCT02007629|Experimental|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
16691453|NCT02007616|Experimental|Non-action video game training|20 1-hour sessions of non-action video game training
16691454|NCT02007616|No Intervention|Control|Participants in the control group did not receive non-action video game training
16691455|NCT02007603|Experimental|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
16691456|NCT02007603|Experimental|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
16691457|NCT02007590|Experimental|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
16691458|NCT02007590|Sham Comparator|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
16691459|NCT02007590|No Intervention|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
16691460|NCT02007577|Active Comparator|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
16691461|NCT02007577|Placebo Comparator|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
16691462|NCT02007564|Experimental|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
16691463|NCT02007564|No Intervention|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
16691464|NCT02007551|Experimental|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
16691465|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
16691466|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
16691467|NCT02007525|Experimental|Yoga intervention|
16691468|NCT02007525|No Intervention|Wait list control|
16691469|NCT02007512|Experimental|Enzalutamide & exemestane|Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
16691470|NCT02007512|Active Comparator|Placebo & exemestane|Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.
16691471|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
16691472|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
16691473|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
16691474|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
16691475|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
16691476|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
16691477|NCT02007460|Experimental|Exercise leg|
16691478|NCT02007460|No Intervention|Control leg|
16691479|NCT02007447|Active Comparator|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
16691480|NCT02007447|Placebo Comparator|Placebo|Placebo - twice per day for 8 weeks
16691481|NCT02007434|Experimental|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
16691482|NCT02007434|Placebo Comparator|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
16691483|NCT02007434|Experimental|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
16691484|NCT02007434|Placebo Comparator|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
16691485|NCT02007434|Experimental|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
16691486|NCT02007434|Placebo Comparator|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
16691487|NCT02007434|Experimental|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
16691488|NCT02007434|Placebo Comparator|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
16691489|NCT02007421|Other|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.
~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
16691490|NCT02007421|Other|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.
~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
16691491|NCT02007408|Placebo Comparator|Placebo group|
16691492|NCT02007408|Active Comparator|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
16691493|NCT02007408|Active Comparator|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
16691494|NCT02007408|Active Comparator|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
16691495|NCT02007395||colonoscopy population|
16691496|NCT02007369|Experimental|WhatsApp|Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
16691497|NCT02007369|Experimental|Facebook|Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
16691498|NCT02007369|No Intervention|Control|Telephone follow ups and received a self-help book only
16691499|NCT02007356|Experimental|allogeneic HSCT|"The present study will evaluate and validate in a single-center, open-label, single arm fashion the safety and feasibility of direct infusions of donor-derived pathogen-specific IFN-γ positive T-cells in recipients of HSCT with post-transplant viral infection according to the previously clinically certified CCS® [3-6]. The Investigator will first generate and apply IFN-γ positive selected T-cells to recipients of HSCT with CMV, EBV or adenovirus as previously published. The Investigator aim is to include 6 patients from the University Hospital of Basel.
~With confirmed safety the investigator will in the future perform an efficacy study and extend this treat-ment for other clinically relevant pathogens including human herpesvirus (HHV)-6, HHV-8, polyomaviruses JC and BK and fungi including Aspergillus fumigatus and Candida albicans, to other immunosuppressed patients such as solid organ transplant (SOT) recipients."
16691500|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:
~meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);
~a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;
~receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);
~were admitted to the hospital during (part of) the infection episode.
~Date of entry into cohort: date of index culture of infection episode"
16691501|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.
~Date of cohort entry: date of index culture of matched infected patient"
16691502|NCT02007330|Experimental|Group L|Intravenous lidocaine infusion group
16691503|NCT02007330|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
16691504|NCT02007317|Experimental|Oshadi D and Oshadi R|Anti tumor agents
16691875|NCT02004730|Experimental|long single vessel disease|ABSORB implantation for long single vessel disease
16691505|NCT02007304|Experimental|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
16691506|NCT02007304|Placebo Comparator|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
16691507|NCT02007278|Active Comparator|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
16691508|NCT02007278|Active Comparator|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
16691509|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
16691510|NCT02007252|Experimental|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
16691511|NCT02007252|Placebo Comparator|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
16691512|NCT02007239|Experimental|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
16691513|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury >5 years)
16691514|NCT02007200|Experimental|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
16691515|NCT02007187|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
16691516|NCT02007187|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
16691517|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
16691518|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
16691519|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
16691520|NCT02007161|Active Comparator|Nutritional State|"Fed vs. Fasted State
~Diclofenac potassium 50 mg"
16691521|NCT02007161|Active Comparator|Use of a PPI|"Nexiam (esomeprazole) 40 mg
~Diclofenac potassium 50 mg"
16691522|NCT02007148|Experimental|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
16691523|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
16691524|NCT02007122|Experimental|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
16691525|NCT02007122|Experimental|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
16691526|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.
~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
16691527|NCT02007096|Experimental|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
16691528|NCT02007096|Placebo Comparator|Non Transabdominal Plane Block|Receiving placebo saline injection
16691529|NCT02007083|Active Comparator|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
16691530|NCT02007083|Active Comparator|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
16691600|NCT02006602|Experimental|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
16691531|NCT02007083|Active Comparator|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
16691532|NCT02007070|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
16691533|NCT02007057|Active Comparator|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
16691534|NCT02007057|Experimental|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
16691535|NCT02007044|Experimental|Arm I (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16691536|NCT02007044|Experimental|Arm II (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm I beginning on day 1 or 2. Patients also receive rituximab IV over 3-8 hours on days 1, 8, 15, and 22 of course 1 and day 1 of courses 2-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16691537|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
16691538|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
16691539|NCT02007018|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
16691540|NCT02007018|Active Comparator|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
16691541|NCT02007005|Experimental|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
16691542|NCT02006992|Active Comparator|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
16691543|NCT02006992|Experimental|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
16691544|NCT02006979|Experimental|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
16691545|NCT02006979|No Intervention|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
16691546|NCT02006966|Experimental|Group L|Intravenous lidocaine infusion group
16691547|NCT02006966|Active Comparator|Group C|Intravenous normal saline infusion - control group
16691548|NCT02006953|Active Comparator|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:
~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
16691549|NCT02006953|Active Comparator|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
16691550|NCT02006940|Experimental|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
16691551|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
16691552|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
16691553|NCT02006914||Placebo|HIV+ and insulin resistant
16691554|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
16691555|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
16691556|NCT02006888|Experimental|IBI-10090 low dose|IBI-10090 low dose
16691557|NCT02006888|Experimental|IBI-10090 med dose|IBI-10090 med dose
16691558|NCT02006888|Placebo Comparator|Placebo|Placebo
16691559|NCT02006875|Experimental|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
16691560|NCT02006875|Sham Comparator|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
16691561|NCT02006862||olanzapine, schizophrenia|
16691562|NCT02006849|Other|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
16691563|NCT02006849|Other|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
16691835|NCT02005042|No Intervention|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
16691564|NCT02006836|Other|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
16691565|NCT02006836|Other|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
16691566|NCT02006836|Other|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
16691567|NCT02006836|Other|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
16691568|NCT02006810|Experimental|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
16691569|NCT02006810|Other|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
16691570|NCT02006797|Experimental|intervention|patients with reconciliation procedure at discharge and included in the exchange process
16691571|NCT02006797|No Intervention|control|usual care
16691572|NCT02006771|Experimental|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
16691573|NCT02006771|Experimental|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
16691574|NCT02006771|Experimental|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
16691575|NCT02006771|Experimental|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
16691576|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
16691577|NCT02006745|Other|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
16691578|NCT02006745|Other|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
16691579|NCT02006732|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
16691580|NCT02006732|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
16691581|NCT02006732|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
16691582|NCT02006732|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
16691583|NCT02006719|Experimental|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
16691584|NCT02006719|Placebo Comparator|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
16691585|NCT02006706|Experimental|MabThera/Rituxan|
16691586|NCT02006693|Other|XEN® Gel Stent|The XEN®45 Gel Stent (XEN45 implant) was placed in the study eye as a standalone procedure.
16691587|NCT02006693|Other|XEN® Gel Stent with Cataract Surgery|The XEN® Gel Stent (XEN45 implant) with cataract surgery, occurred if the participant was diagnosed with a cataract.
16691588|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
16691589|NCT02006667|Experimental|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
16691590|NCT02006654|Placebo Comparator|Placebo|Placebo adjunct to base treatment with an AChEI
16691591|NCT02006654|Experimental|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
16691592|NCT02006641|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
16691593|NCT02006641|Experimental|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
16691594|NCT02006641|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
16691595|NCT02006628|Active Comparator|GWP42003 1000 milligrams (mg)/day|Participants received GWP42003 (100 mg/milliliter [mL]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
16691596|NCT02006628|Placebo Comparator|Placebo|Participants received placebo (0 mL cannabidiol [CBD]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
16691597|NCT02006615|Experimental|High frequency rTMS plus fNIRS|rTMS with neuroimage assessment of functional near infrared spectroscopy
16691598|NCT02006615|Sham Comparator|Sham rTMS|Sham stimulation
16691599|NCT02006615|Experimental|High frequency rTMS|High frequency rTMS to modulate brain areas
16691876|NCT02004730|Experimental|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
16691601|NCT02006602|Experimental|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
16691602|NCT02006589|Experimental|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
16691603|NCT02006589|Experimental|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
16691604|NCT02006576|Placebo Comparator|COPD, Placebo|Placebo three times daily
16691605|NCT02006576|No Intervention|Control subject|Control subjects, no intervention
16691606|NCT02006576|Experimental|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
16691607|NCT02006537|Experimental|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
16691608|NCT02006537|Experimental|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
16691609|NCT02006524|Active Comparator|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
16691610|NCT02006511|Experimental|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
16691611|NCT02006511|Active Comparator|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
16691612|NCT02006498|Experimental|Sillymarin|Active component study medication
16691613|NCT02006498|Placebo Comparator|Placebo|Placebo capsules
16691614|NCT02006485|Experimental|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
16691615|NCT02006485|Experimental|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
16691616|NCT02006485|Experimental|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 & 2
16691617|NCT02006472|Experimental|Pridopidine 45 mg|Twice daily
16691618|NCT02006472|Experimental|Pridopidine 67.5 mg|Twice daily
16691619|NCT02006472|Experimental|Pridopidine 90 mg|Twice daily
16691620|NCT02006472|Experimental|Pridopidine 112.5 mg|Twice daily
16691621|NCT02006472|Placebo Comparator|Placebo|Twice daily
16691622|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
16691623|NCT02006433|Experimental|Deep Brain Stimulation|"Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).
~Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156."
16691624|NCT02006420||ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
16691625|NCT02006420||Healthy Volunteers: ARFI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
16691626|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
16691627|NCT02006394|Experimental|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
16691628|NCT02006394|Placebo Comparator|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
16691629|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
16691630|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
16691631|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
16691632|NCT02006368|Experimental|Storage Age|
16691633|NCT02006355|Active Comparator|Continuous femoral nerve bloc|Continuous femoral nerve bloc
16691634|NCT02006355|Experimental|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
16691635|NCT02006342|Experimental|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
16691636|NCT02006342|Active Comparator|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
16691637|NCT02006329|Experimental|Intervention group - dietary consultation - Medit|
16691638|NCT02006329|No Intervention|Control group - dietary consultation - Mediterranean diet|
16691639|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
16691667|NCT02006134||ADULT VASCULITIS / COHORT 2|Adult patients in this cohort are those individuals that are participants in DCVAS and have any form of vasculitis. Clinical data and blood (DNA) collected at the time-of-diagnosis will be used for study.
16691640|NCT02006303|Active Comparator|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
16691641|NCT02006303|Active Comparator|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
16691642|NCT02006290|Experimental|1|
16691643|NCT02006290|Placebo Comparator|2|
16691644|NCT02006277|Experimental|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
16691645|NCT02006277|Experimental|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
16691646|NCT02006264|Active Comparator|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
16691647|NCT02006264|Placebo Comparator|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
16691648|NCT02006238|Experimental|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
16691649|NCT02006238|Placebo Comparator|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
16691650|NCT02006225|Experimental|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
16691651|NCT02006212|Other|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
16691652|NCT02006199|Experimental|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
16691653|NCT02006199|Experimental|meditation|8 weeks of mindfulness meditation
16691654|NCT02006186|Experimental|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
16691655|NCT02006186|No Intervention|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
16691656|NCT02006173|Placebo Comparator|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
16691657|NCT02006173|Active Comparator|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
16691658|NCT02006160|Active Comparator|treatment|dalfampridine
16691659|NCT02006160|Placebo Comparator|control|placebo
16691660|NCT02006147|Experimental|TLC399 (Group 1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
16691661|NCT02006147|Experimental|TLC399 (Group R1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
16691662|NCT02006147|Experimental|TLC399 (Group 2)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
16691663|NCT02006147|Experimental|TLC399 (Group 3)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
16691664|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
16691665|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA & serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
16691666|NCT02006134||ADULT VASCULITIS/ COHORT 1|Adult patients in this cohort are those at or near the time of diagnosis of GPA, MPA, EGPA or unclassified vasculitis that are participants in DCVAS. Clinical data and blood (RNA, DNA) will be collected at the time-of-diagnosis only.
16691977|NCT02004093|Experimental|Chemotherapy + Pertuzumab|
16691668|NCT02006134||HEALTHY CHILDREN / PEDIATRIC CONTROL|Participants in this cohort are otherwise healthy children with no history of inflammatory disease. Children will provide a one time donation of blood (RNA, serum) and urine.
16691669|NCT02006134||HEALTHY ADULTS / ADULT CONTROL|Participants in this cohort are otherwise healthy adults with no history of inflammatory disease. Adults will provide a one time donation urine and will provide blood (RNA, serum) as many as 4 times.
16691670|NCT02006121|Active Comparator|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
16691671|NCT02006121|Placebo Comparator|Placebo|Placebo: saline infusion
16691672|NCT02006108|Experimental|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg
~Interventions:
~Drug: Feraheme Procedure: MR Scan"
16691673|NCT02006095||Neuroimaging Correlates|
16691674|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 < 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
16691675|NCT02006069|Experimental|MPP ON|MPP ON: feature is enabled
16691676|NCT02006069|No Intervention|MPP OFF|MPP OFF: feature not enabled
16691677|NCT02006056|Experimental|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
16691678|NCT02006056|Experimental|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
16691679|NCT02006043|Experimental|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
16691680|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
16691681|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
16691682|NCT02006017|Experimental|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
16691683|NCT02006017|Experimental|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
16691684|NCT02005991|Experimental|PF-05212377 70 mg|
16691685|NCT02005991|Experimental|PF-05212377 20 mg|
16691686|NCT02005991|Experimental|PF-05212377 10 mg|
16691687|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
16691688|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
16691689|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
16691690|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
16691691|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
16691692|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
16691693|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
16691694|NCT02005939|Experimental|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
16691695|NCT02005939|Placebo Comparator|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
16691696|NCT02005926|Experimental|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness >3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
16691697|NCT02005900|Experimental|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
16691698|NCT02005900|Placebo Comparator|PLACEBO|
16691699|NCT02005887|Experimental|triptorelin + letrozole|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
16691700|NCT02005887|Experimental|degarelix + letrozole|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
16691701|NCT02005874||Dry eye|
16691702|NCT02005874||Non-dry eye|
16691836|NCT02005042|Experimental|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
16691837|NCT02005029|Placebo Comparator|Placebo|One time IV dose of placebo
16691838|NCT02005029|Experimental|Erythromycin|One time IV dose of 100 mg Erythromycin
16691978|NCT02004093|Active Comparator|Chemotherapy|
16691703|NCT02005861|Experimental|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.
~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.
~After that platelet gel will be loaded on the top of implant"
16691704|NCT02005848|Experimental|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
16691705|NCT02005848|Experimental|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
16691706|NCT02005848|Placebo Comparator|Placebo|Placebo
16691707|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic
~Routine standard clinical care based on the MoH guidelines
~Mentor mothers provide education and psychosocial support at facility
~Weekly support groups provided in clinic
~Phone call, SMS, or home visit for each missed appointment"
16691708|NCT02005835|Other|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):
~Routine standard clinical care based on the MoH guidelines
~Mentor mothers provide education and psychosocial support in community prior to each visit
~Monthly support groups in community
~Home visits for each missed appointment"
16691709|NCT02005835|No Intervention|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
16691710|NCT02005822|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
16691711|NCT02005822|No Intervention|Control|"Refusal control group:
~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.
~Historical control group:
~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
16691712|NCT02005809|Active Comparator|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
16691713|NCT02005809|No Intervention|without second look endoscopy|This group is not performed second look endoscopy after ESD
16691714|NCT02005796|Experimental|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
16691715|NCT02005796|Experimental|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
16691716|NCT02005796|Experimental|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
16691717|NCT02005783|Experimental|DBD arm|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally
16691718|NCT02005783|Other|EC/TC|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
16691719|NCT02005770|Experimental|Sevoflurane|General anesthesia using Sevoflurane
16691720|NCT02005770|Active Comparator|Propofol|General anesthesia using propofol TCI
16691721|NCT02005757|Experimental|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
16691722|NCT02005757|Active Comparator|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
16691723|NCT02005744|Experimental|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
16691724|NCT02005744|Experimental|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
16691725|NCT02005744|Experimental|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
16691726|NCT02005744|Experimental|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
16691727|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
16691728|NCT02005718|Experimental|Vitamin D|Cholecalciferol 300,000 twice
16691729|NCT02005705|Active Comparator|Outpatient|
16691730|NCT02005705|Active Comparator|Inpatient|
16691731|NCT02005692|Experimental|DynaSense sensor|
16691732|NCT02005679|Experimental|deaf persons with potential dementia|
16691733|NCT02005666|Experimental|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
16691734|NCT02005666|Active Comparator|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
16691735|NCT02005666|Placebo Comparator|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
16691736|NCT02005653|Experimental|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
16691737|NCT02005653|Experimental|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
16691738|NCT02005653|Experimental|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
16691739|NCT02005653|Active Comparator|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
16691740|NCT02005640||MSCT-based prothesis sizing|
16691741|NCT02005640||Echocardiographic-based prothesis sizing|
16691742|NCT02005627|Active Comparator|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
16691743|NCT02005627|Placebo Comparator|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
16691764|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
16691744|NCT02005614|Experimental|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).
~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.
~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
16691745|NCT02005601|Experimental|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
16691746|NCT02005601|Placebo Comparator|Control|Patients will receive 0mg of duloxetine
16691747|NCT02005588|Active Comparator|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
16691748|NCT02005588|Active Comparator|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
16691749|NCT02005575|Placebo Comparator|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
16691750|NCT02005575|Active Comparator|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
16691751|NCT02005562|Experimental|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours [q12h]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
16691752|NCT02005562|Active Comparator|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
16691753|NCT02005549|Experimental|Neoadjuvant Therapy|
16691754|NCT02005536|Experimental|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
16691755|NCT02005523|Experimental|RNS60|
16691756|NCT02005523|Placebo Comparator|Saline|
16691757|NCT02005510|Experimental|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
16691758|NCT02005510|Placebo Comparator|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
16691759|NCT02005497|Experimental|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
16691760|NCT02005497|Active Comparator|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
16691761|NCT02005497|No Intervention|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
16691762|NCT02005484|Experimental|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
16691763|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter squared (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
16691832|NCT02005068|Experimental|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
16691833|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
16691834|NCT02005042|No Intervention|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
16691979|NCT02004080||TBI admitted to ICU|Intensive Care treatment
16691765|NCT02005471|Experimental|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
16691766|NCT02005471|Experimental|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
16691767|NCT02005458|Experimental|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
16691768|NCT02005458|Experimental|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
16691769|NCT02005458|Experimental|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
16691770|NCT02005458|Active Comparator|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
16691771|NCT02005445|Experimental|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
16691772|NCT02005445|Sham Comparator|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
16691773|NCT02005432|Active Comparator|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
16691774|NCT02005432|Experimental|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
16691775|NCT02005432|Other|IVR arm|only IVR (intravitreal Ranibizumabe)
16691776|NCT02005419|Placebo Comparator|gemcitabine + placebo|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
16691777|NCT02005419|Experimental|gemcitabine + metformin|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
16691778|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
16691779|NCT02005393|Other|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
16691780|NCT02005380||Text-based Task|This group is required to do the text-based task
16691781|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
16691782|NCT02005367|No Intervention|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
16691783|NCT02005367|Experimental|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
16691784|NCT02005367|Experimental|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
16691785|NCT02005354|Active Comparator|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.
~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.
~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.
~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
16691786|NCT02005354|Placebo Comparator|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).
~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.
~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
16691787|NCT02005341|Active Comparator|Autograft bone|
16691788|NCT02005341|Experimental|nanOss with bone marrow aspirate|
16691789|NCT02005328|Experimental|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
16691790|NCT02005315|Experimental|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
16691791|NCT02005315|Experimental|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
16691792|NCT02005315|Experimental|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
16691793|NCT02005302|Experimental|Vitamin D2 Treatment|
16691794|NCT02005302|Active Comparator|1,25(OH)2 Vitamin D3|
16691795|NCT02005302|Experimental|low protein diet|
16691796|NCT02005302|Active Comparator|normal protein diet|
16691797|NCT02005289|Experimental|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
16702644|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
16691798|NCT02005289|Experimental|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
16691799|NCT02005276|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
16691800|NCT02005276|Experimental|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:
~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
16691801|NCT02005276|Experimental|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:
~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
16691802|NCT02005276|Experimental|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:
~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
16691803|NCT02005263|Experimental|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
16691804|NCT02005250||hyperthyroidism|61 pre- and postmenopausal women with hyperthyroidism
16691805|NCT02005250||hypothyroidism|32 pre- and postmenopausal women with hypothyroidism
16691806|NCT02005237|Experimental|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
16691807|NCT02005237|No Intervention|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
16691808|NCT02005224|Other|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
16691809|NCT02005211|Experimental|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
16691810|NCT02005211|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
16691811|NCT02005198||Survey|
16691812|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
16691813|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for < 30min before the age of 2.
16691814|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
16691815|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
16691816|NCT02005172|Other|Alivecor device and event monitor|Both the Alivecor device (experimental) and the standard of care (event monitor) will be provided to all patients for the duration of the study
16691817|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
16691818|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
16691819|NCT02005133||VEGF inhibitor naïve|
16691820|NCT02005133||VEGF inhibitor prior treated|
16691821|NCT02005120|Experimental|Arm A|Bevacizumab
16691822|NCT02005120|Experimental|Arm B|recombinant human endostatin
16691823|NCT02005107|Experimental|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
16691824|NCT02005107|Other|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
16691825|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
16691826|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
16691827|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
16691828|NCT02005081|Other|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
16691829|NCT02005081|Other|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
16691830|NCT02005068|Experimental|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
16691831|NCT02005068|Experimental|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
16691839|NCT02005016|Experimental|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
16691840|NCT02005003|Active Comparator|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
16691841|NCT02005003|Placebo Comparator|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
16691842|NCT02004990|Experimental|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
16691843|NCT02004977|Experimental|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
16691844|NCT02004977|No Intervention|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
16691845|NCT02004951|Other|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
16691846|NCT02004951|Other|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
16691847|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
16691848|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
16691849|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
16691850|NCT02004912|Experimental|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
16691851|NCT02004912|No Intervention|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
16691852|NCT02004899|Active Comparator|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
16691853|NCT02004899|Experimental|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
16691854|NCT02004899|Experimental|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
16691855|NCT02004886|Experimental|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
16691856|NCT02004886|Experimental|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
16691857|NCT02004886|Active Comparator|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
16691858|NCT02004886|Placebo Comparator|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
16691859|NCT02004873|Experimental|Micra Pacemaker Implant|
16691860|NCT02004860|Experimental|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
16691861|NCT02004860|Active Comparator|Mycoster Arm|2 applications per week for 6 months
16691862|NCT02004847|Experimental|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
16691863|NCT02004847|Experimental|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
16691864|NCT02004834|Active Comparator|0,5% levobupivacaine with 2% lidocaine|7,0 ml.of mixture 0,5% levobupivacaine with 2% lidocaine are given per level Th2,Th3,Th4 for ultrasound guided paravertebral blocks in breast surgery
16691865|NCT02004834|Active Comparator|0,5% levobupivacine|7,0 ml. 0,5% levobupivacaine are given per level Th2,Th3,Th4, given for ultrasound guided paravertebral blocks in breast surgery
16691866|NCT02004821|Experimental|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
16691867|NCT02004795|Experimental|BNCT+ IG-IMRT|single arm
16691868|NCT02004782|Active Comparator|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
16691869|NCT02004782|Placebo Comparator|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
16691870|NCT02004769|Experimental|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
16691871|NCT02004756|Experimental|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
16691872|NCT02004756|No Intervention|Healthy Controls|Healthy age-matched adolescents
16691873|NCT02004743|Other|Control|Treatment as Usual
16691877|NCT02004730|Experimental|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
16691878|NCT02004717|Experimental|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.
~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
16691879|NCT02004704|Experimental|GZ402665|GZ402665 administered intravenously once every 2 weeks for up to 9 years at the dose each patient was receiving at the end of their previous olipudase alfa study.
16691882|NCT02004678|Other|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either
~a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or
~a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
16691883|NCT02004678|Other|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either
~a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or
~a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
16691884|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
16691885|NCT02004652|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
16691886|NCT02004652|Placebo Comparator|Placebo|Vitamin C, 50mg, tablet
16691887|NCT02004639|Active Comparator|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
16691888|NCT02004639|No Intervention|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
16691889|NCT02004639|Active Comparator|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
16691890|NCT02004639|Sham Comparator|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
16691891|NCT02004626|Active Comparator|Collagenase|"Each gram of ointment contains :
~Collagenase ...0.6 U
~Vehicle qs ... 1 g
~Presentation:
~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .
~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
16691892|NCT02004626|Active Comparator|Kollagenase|"Each gram of ointment contains :
~Collagenase ... 0.6 U
~Vehicle qs ... 1 g
~Presentation
~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.
~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
16691893|NCT02004613|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.
16691894|NCT02004613|Placebo Comparator|Placebo|normal saline administration matching dexmedetomidine rate of infusion.
16691895|NCT02004600|Experimental|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
16691896|NCT02004587|Experimental|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
16691897|NCT02004587|Experimental|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
16691898|NCT02004587|Active Comparator|Healthy volunteers|Gemigliptin dosing in Healthy subjects
16691899|NCT02004574|Experimental|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
16691900|NCT02004574|Experimental|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
16691901|NCT02004574|Experimental|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
16691902|NCT02004561||Gastric Banding|Patients chose Gastric banding
16691903|NCT02004561||Gastric Bypass|Patients chose gastric bypass surgical operation
16691904|NCT02004548|Experimental|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
16691905|NCT02004535|Experimental|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
16691906|NCT02004522|Experimental|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules
16691907|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
16691908|NCT02004509|Active Comparator|anticoagulant|Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).
16691909|NCT02004509|No Intervention|Control|Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.
16691910|NCT02004496|No Intervention|Group A: no app|no use of an mobile application while treatment
16691911|NCT02004496|Active Comparator|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
16691912|NCT02004496|Active Comparator|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
16691913|NCT02004483|Experimental|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
16704834|NCT01918410|Placebo Comparator|Contact lens without alginic acid|
16691914|NCT02004470|No Intervention|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
16691915|NCT02004470|Experimental|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
16691916|NCT02004457|Experimental|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
16691917|NCT02004457|Placebo Comparator|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
16691918|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
16691919|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
16691920|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
16691921|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
16691922|NCT02004444||Untreated|10 untreated patients
16691923|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
16691924|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
16691925|NCT02004418|Experimental|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
16691926|NCT02004405|Experimental|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
16691927|NCT02004405|Active Comparator|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
16691928|NCT02004392|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
16691929|NCT02004392|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
16691930|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
16691931|NCT02004366|Experimental|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
16691932|NCT02004366|Active Comparator|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
16691933|NCT02004366|Experimental|Linagliptin on discharge|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
16691934|NCT02004366|Experimental|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
16691935|NCT02004366|Experimental|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
16691936|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
16691937|NCT02004340|Active Comparator|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
16691938|NCT02004340|Sham Comparator|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
16691939|NCT02004340|No Intervention|control|No transcutaneous stimulation is given
16691940|NCT02004327|Experimental|A Group|"1st administration - DW1029M300mg PO Once
~2nd administration - DW1029M600mg PO Once
~3rd administration - DW1029M1200mg PO Once"
16691941|NCT02004327|Experimental|B Group|"1st administration - DW1029M600mg PO Once
~2nd administration - DW1029M1200mg PO Once
~3rd administration - DW1029M300mg PO Once"
16691942|NCT02004327|Experimental|C Group|"1st administration - DW1029M1200mg PO Once
~2nd administration - DW1029M300mg PO Once
~3rd administration - DW1029M600mg PO Once"
16691943|NCT02004314|Other|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
16691944|NCT02004301|Experimental|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
16691945|NCT02004301|Experimental|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
16691946|NCT02004288|Experimental|Lactobacillus reuteri Protectis DSM17938|One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
16691947|NCT02004288|Placebo Comparator|Placebo|One chewable tablet twice per day with placebo per day
16691948|NCT02004275|Experimental|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
16691949|NCT02004275|Experimental|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16691950|NCT02004262|Experimental|Primary Cohort: Cy/GVAX + CRS-207|"200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
16691951|NCT02004262|Experimental|Primary Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.
~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
16691952|NCT02004262|Active Comparator|Primary Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.
~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
16691953|NCT02004262|Experimental|2nd-line Cohort: Cy/GVAX + CRS-207|"200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
16691954|NCT02004262|Experimental|2nd-line Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.
~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
16691955|NCT02004262|Active Comparator|2nd-line Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.
~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
16691956|NCT02004236|Experimental|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
16691957|NCT02004236|Experimental|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
16691958|NCT02004236|Placebo Comparator|tRNS with sham|This group receive 35 sessions with sham
16691959|NCT02004223|Experimental|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
16691960|NCT02004210|Experimental|The TARE group|transarterial radioembolization group
16691961|NCT02004210|Experimental|The TACE group|Transarterial chemoembolization group
16691962|NCT02004197|Experimental|Pylorex plus|Pylorex plus consisting of medicinal plants.
16691963|NCT02004197|Active Comparator|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
16691964|NCT02004184|Experimental|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
16691965|NCT02004184|Active Comparator|pemetrexed at progression|observation and pemetrexed therapy at disease progression
16691966|NCT02004171|Experimental|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
16691967|NCT02004171|Active Comparator|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
16691968|NCT02004158|Experimental|Positive psychology|Positive psychology intervention
16691969|NCT02004145|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
~Exercises:
~Gratitude for positive events
~Gratitude letter
~Performing acts of kindness
~Using personal strengths
~Enjoyable and meaningful activities:
~Repeating one of the previous exercises."
16691970|NCT02004145|Sham Comparator|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
~Exercises:
~Daily Events
~Health Events
~Morning and Evening Events
~Interactions with Others
~Leisure Time Activities
~Repeating one of the previous exercises."
16691971|NCT02004132|Experimental|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
16691972|NCT02004119|Placebo Comparator|Placebo|
16691973|NCT02004119|Experimental|KHK4577|
16691974|NCT02004106|Experimental|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (</= 6 mg) as a single intravenous (IV) infusion.
16691975|NCT02004106|Experimental|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
16691976|NCT02004106|Experimental|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
16691980|NCT02004067|Active Comparator|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
16691981|NCT02004067|Experimental|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
16691982|NCT02004054||optic neurotis|measure of pupil diameter
16691983|NCT02004041|Experimental|VLY-686 x mg|Single dose, X mg VLY-686, administered as X 50 mg VLY-686 oral capsule(s)
16691984|NCT02004041|Placebo Comparator|Placebo|Single dose, placebo, administered as X 50 mg oral capsule(s)
16691985|NCT02004028|Experimental|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
16691986|NCT02004015|Experimental|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
16691987|NCT02004015|Experimental|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
16691988|NCT02004015|Placebo Comparator|placebo|injection of placebo Injection in Intravenous bolus use
16691989|NCT02004002|Active Comparator|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
16691990|NCT02004002|Experimental|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
16691991|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
16691992|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
16691993|NCT02003976|Experimental|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
16691994|NCT02003976|Active Comparator|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
16691995|NCT02003963|Experimental|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
16691996|NCT02003963|No Intervention|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
16691997|NCT02003950|Other|Chocolate pre-restriction|
16691998|NCT02003950|Other|Chocolate Baseline|
16691999|NCT02003950|Other|Chocolate post-restriction|
16692000|NCT02003950|Other|Salty Snacks|
16692001|NCT02003950|Other|Sweet Non-Chocolate Snacks|
16692002|NCT02003950|Other|Dried Fruit|
16692003|NCT02003937|Experimental|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
16692004|NCT02003924|Sham Comparator|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
16692005|NCT02003924|Experimental|Enzalutamide|160 mg by mouth once daily
16692006|NCT02003911|Experimental|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)
~Once daily for 3 days"
16692007|NCT02003911|Placebo Comparator|Placebo suspension|"Same volume as active drug
~Once daily for 3 days"
16692008|NCT02003898|Experimental|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
16692009|NCT02003885|Experimental|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
16692010|NCT02003872|Experimental|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
16692011|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
16692012|NCT02003833|Experimental|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
16692013|NCT02003833|Placebo Comparator|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
16692014|NCT02003820|Experimental|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
16692015|NCT02003820|Experimental|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
16692016|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
16692017|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
16692018|NCT02003794|Experimental|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
16692019|NCT02003794|No Intervention|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
16692020|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
16692022|NCT02003768|Active Comparator|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
16692023|NCT02003755|Experimental|Spastic CP|continuous passive motion training
16692024|NCT02003742|Experimental|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
16692025|NCT02003742|Active Comparator|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
16692026|NCT02003729|Active Comparator|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
16692027|NCT02003729|No Intervention|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
16692028|NCT02003716||No treatment|
16692029|NCT02003703|Experimental|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
16692030|NCT02003703|Active Comparator|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
16692031|NCT02003690|Experimental|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
16692032|NCT02003690|Active Comparator|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
16692033|NCT02003677|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
16692034|NCT02003677|Active Comparator|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
16692035|NCT02003664|Active Comparator|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
16692036|NCT02003664|Placebo Comparator|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
16692037|NCT02003651|Experimental|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
16692038|NCT02003651|Placebo Comparator|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
16692039|NCT02003638|Experimental|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
16692040|NCT02003638|Placebo Comparator|Placebo|Placebo taken orally every day for 12 weeks
16692041|NCT02003625|Placebo Comparator|A. GCSF + Placebo|GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis [days -4, -3, -2, -1] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.
16692042|NCT02003625|Experimental|B. GCSF + meloxicam|"B. GCSF + meloxicam:
~Patients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected."
16692043|NCT02003612||All subjects|All subjects
16692044|NCT02003599|Placebo Comparator|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
~Both arm will use institutional skin care protocol."
16692045|NCT02003599|Experimental|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.
~Both arm will use institutional skin care protocol."
16692046|NCT02003586|Other|Plant-based ingredient to a starchy meal|Plant-based ingredient
16692047|NCT02003586|Other|Starchy meal alone|No plant-based ingredient
16692048|NCT02003573|Experimental|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
16692049|NCT02003560|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
16692050|NCT02003547|Experimental|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
16692051|NCT02003547|Experimental|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
16692052|NCT02003547|Experimental|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
16692053|NCT02003547|Placebo Comparator|Placebo|Topical Ocular Drop BID X 1 wk
16692054|NCT02003534|Experimental|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
16692055|NCT02003521||Intervension|Lung Flute
16692056|NCT02003508||Pre-school based vaccination program (not vaccine eligible)|Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
16692057|NCT02003508||Post-school based vaccination program (vaccine eligible)|Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
16692404|NCT02000973|Experimental|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
16692058|NCT02003495|Experimental|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.
~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.
~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.
~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
16692059|NCT02003495|Active Comparator|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
16692060|NCT02003495|Active Comparator|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
16692061|NCT02003495|Active Comparator|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
16692062|NCT02003495|Placebo Comparator|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
16692063|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
16692064|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
16692065|NCT02003469|Experimental|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
16692066|NCT02003456|Experimental|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
16692067|NCT02003443|Placebo Comparator|Sham Acupressure|Participants assigned to sham acupressure will receive similar instruction as those assigned to pain-relief acupressure, except that they will be taught to apply pressure to 10 acupoints that are unrelated to pain. That is, they will conduct self-administered acupressure 5 days/week for 8 weeks, as the pain-relief acupressure group does, but on 'sham' acupoints.
16692068|NCT02003443|No Intervention|Usual Care|Participants assigned to the UC group will receive no intervention.
16692069|NCT02003443|Experimental|Pain-Relief Acupressure|Participants assigned to pain-relief acupressure will be taught to apply physical pressure, using a wooden hand-held device designed for acupressure, to 10 acupoints on their body.That is, they will conduct self-administered acupressure 5 days/week for 8 weeks,on acupoints that are relevant to pain reduction.
16692070|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
16692071|NCT02003430||<65 years old|20 patients less than 65 years of age
16692072|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration > 3 months) for definitive treatment.
16692073|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
16692074|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
16692075|NCT02003391|Experimental|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
16692076|NCT02003391|Active Comparator|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
16692077|NCT02003378|Active Comparator|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
16692078|NCT02003378|Active Comparator|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
16692079|NCT02003365|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection
16692080|NCT02003365|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection
16692081|NCT02003365|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
16692082|NCT02003352|Experimental|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
16692083|NCT02003339|Experimental|RMIs|
16692084|NCT02003326|Other|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat <30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
16692085|NCT02003313|Experimental|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
16692086|NCT02003313|Active Comparator|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
16692087|NCT02003287|Experimental|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
16692088|NCT02003287|Active Comparator|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
16692089|NCT02003274|Other|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
16692090|NCT02003274|Other|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
16692091|NCT02003261|Experimental|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
16692092|NCT02003261|Other|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
16692093|NCT02003248|Experimental|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
16692094|NCT02003235|Experimental|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
16692095|NCT02003222|Experimental|Arm I (blinatumomab, chemotherapy)|See Detailed Description
16692096|NCT02003222|Active Comparator|Arm II (chemotherapy)|See Detailed Description
16692097|NCT02003209|Active Comparator|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.
~SURGERY: Patients undergo lumpectomy or mastectomy.
~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.
~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
16692098|NCT02003209|Experimental|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.
~SURGERY: Patients undergo lumpectomy or mastectomy.
~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.
~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
16692099|NCT02003183||Suspected CTE|A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, [F-18]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).
16692100|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
16692101|NCT02003157|Active Comparator|hypnosis|embryo transfer procedure with hypnosis
16692102|NCT02003157|Active Comparator|usual|embryo transfer usual procedure
16692103|NCT02003144|Experimental|Eculizumab|Eculizumab intravenous infusion every two weeks.
16692104|NCT02003131|Other|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
16692105|NCT02003131|Other|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
16692106|NCT02003118|Experimental|AKR 202|
16692107|NCT02003118|Placebo Comparator|Placebo|
16692108|NCT02003092|Experimental|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
16692109|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
16692110|NCT02003066|Experimental|Standard|
16692111|NCT02003066|Active Comparator|Conservative|
16692112|NCT02003053|Experimental|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
16692113|NCT02003053|Sham Comparator|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
16692114|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
16692115|NCT02003027|Experimental|BT injection|
16692116|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
16692117|NCT02003001|Experimental|BT injection|
16692118|NCT02002988|Experimental|BT injection|
16692119|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
16692120|NCT02002962|Active Comparator|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
16692121|NCT02002962|Active Comparator|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
16692122|NCT02002949|Experimental|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
16692123|NCT02002949|Active Comparator|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
16692124|NCT02002936|Experimental|SyB C-1101|
16692125|NCT02002923|Active Comparator|PVI only|
16692126|NCT02002923|Active Comparator|PVI+BT injection|
16692127|NCT02002897|Experimental|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
16692128|NCT02002897|Active Comparator|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
16705036|NCT01917058|Placebo Comparator|abatacept Subcutaneous vehicle|
16692129|NCT02002884|Experimental|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
16692130|NCT02002884|Experimental|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
16692131|NCT02002884|Experimental|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
16692132|NCT02002871|Experimental|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
16692133|NCT02002871|No Intervention|Control|contralateral untreated control plaque on the same patient.
16692134|NCT02002858|Experimental|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
16692135|NCT02002858|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
16692136|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
16692137|NCT02002832|Experimental|Lurasidone group|
16692138|NCT02002832|Active Comparator|Risperidone group|
16692139|NCT02002819|Experimental|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
16692140|NCT02002819|Experimental|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
16692141|NCT02002806|Experimental|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
16692142|NCT02002806|Placebo Comparator|Placebo Injection|Celiac plexus injection - placebo injection
16692143|NCT02002793|Other|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
16692144|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
16692145|NCT02002780|Experimental|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.
~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
16692146|NCT02002780|No Intervention|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
16692147|NCT02002767|Experimental|Participants with renal impairment|Participants with severe renal impairment will receive a single dose of velpatasvir.
16692148|NCT02002767|Active Comparator|Participants with normal renal function|Participants with normal renal function will receive a single dose of velpatasvir.
16692149|NCT02002754|Active Comparator|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
16692150|NCT02002754|Active Comparator|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
16692151|NCT02002741|Active Comparator|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses
~+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
16692152|NCT02002741|Placebo Comparator|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses
~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
16692153|NCT02002715|Active Comparator|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
16692154|NCT02002715|Active Comparator|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
16692155|NCT02002715|Active Comparator|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
16692156|NCT02002702|Experimental|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
16692157|NCT02002702|Experimental|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
16692158|NCT02002702|Placebo Comparator|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
16692159|NCT02002689|Experimental|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
16692160|NCT02002663|Experimental|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
16692161|NCT02002663|Placebo Comparator|saline|Continuous infusion of saline through intralesional catheter for 24 hs
16692162|NCT02002650|Experimental|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
16692163|NCT02002650|Active Comparator|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
16692164|NCT02002637|Experimental|Latella Knee Implant System|
16692165|NCT02002624|Active Comparator|Conventional|Conventional instrumentation
16692166|NCT02002624|Experimental|PSI|Patient specific instrumentation
16692405|NCT02000973|Experimental|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
16692167|NCT02002611|Experimental|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
16692168|NCT02002611|Experimental|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
16692169|NCT02002598|Experimental|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
16692170|NCT02002585|Experimental|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
16692171|NCT02002585|No Intervention|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
16692172|NCT02002572|Experimental|Mimic facial muscle from 3T MRI data|
16692173|NCT02002559||NBI Magnify Endoscopy|Detection of esphageal neoplasia through recognition of brownish discolored area via NBI and characterize the lesion using IPCL upon magnifying endoscopy
16692174|NCT02002559||Lugol Chromoendoscopy|Detection of esophageal neoplasia through recognition of discolored area
16692175|NCT02002546||ED chest pain presenting patients|
16692176|NCT02002533|Experimental|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
16692177|NCT02002533|Active Comparator|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
16692178|NCT02002520||case group|patients undergo third molar surgery
16692179|NCT02002520||control group|subjects do not require surgery
16692180|NCT02002507||park bench position|Comparing jugular venous flow in supine and park bench position in neurosurgical patients requiring their surgery in park bench position
16692181|NCT02002507||prone position|Comparing the jugular venous flow in the supine and prone position in patients requiring their surgery to be done in the prone position.
16692182|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:
~Bilateral internal jugular venous flow in supine and prone position
~Bilateral internal jugular venous flow in supine and park bench position
~Bilateral internal jugular venous flow in prone and park bench"
16692183|NCT02002481|No Intervention|Control|10 minutes ALS-CPR in a normal environment
16692184|NCT02002481|Experimental|Transport|10 minutes ALS-CPR during a transport
16692185|NCT02002468|Experimental|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
16692186|NCT02002468|Active Comparator|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
16692187|NCT02002455|Experimental|Multimodality imaging|PET/CT, PET/MRI, mpMRI
16692188|NCT02002442|Active Comparator|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
16692189|NCT02002442|Active Comparator|Essential oil|LISTERINE® ZERO™ Mouthwash
16692190|NCT02002442|Active Comparator|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
16692191|NCT02002442|Placebo Comparator|Saline|
16692192|NCT02002429|Experimental|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
16692193|NCT02002429|Active Comparator|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
16692194|NCT02002429|Sham Comparator|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
16692195|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
16692196|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
16692197|NCT02002403|Placebo Comparator|Placebo|
16692198|NCT02002403|Experimental|Optina Low Dose|Optina, 15 mg orally, twice daily
16692199|NCT02002403|Experimental|Optina - High Dose|Optina, 45 mg orally, twice daily
16692200|NCT02002390|Experimental|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
16692201|NCT02002390|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
16692202|NCT02002377|Experimental|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
16692203|NCT02002364|Active Comparator|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
16692204|NCT02002364|Active Comparator|Multiple use flexible optical scope|Multiple use flexible optical scope
16692205|NCT02002351||Pulmonary disease|
16692206|NCT02002338||Pterygium|Patients who were operated of pterygium
16692207|NCT02002325|Experimental|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
16692208|NCT02002325|Other|Standard Care|Standard treatment for acute stroke
16692209|NCT02002312|Experimental|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
16692210|NCT02002286|Experimental|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
16692211|NCT02002286|Other|cART control|Continue current cART regimen
16692212|NCT02002273|Experimental|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
16692213|NCT02002273|Experimental|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
16692214|NCT02002260|Active Comparator|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
16692215|NCT02002260|Active Comparator|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
16692216|NCT02002247|Placebo Comparator|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
16692217|NCT02002247|Active Comparator|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:
~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
16692218|NCT02002234|Other|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
16692219|NCT02002234|Other|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
16692220|NCT02002221|Experimental|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
16692221|NCT02002221|Placebo Comparator|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
16692222|NCT02002208|Experimental|OC000459 Tablets|50 mg orally once a day
16692223|NCT02002208|Placebo Comparator|Placebo Tablets|Orally once a day
16692224|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
16692225|NCT02002182|Experimental|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
16692226|NCT02002182|No Intervention|Control Group|Observational control group treated with standard of care therapy only
16692227|NCT02002169|Experimental|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
16692228|NCT02002169|Active Comparator|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
16692229|NCT02002156|Experimental|BCG at birth and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
16692230|NCT02002156|Experimental|BCG at 3 months old and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
16692231|NCT02002156|Experimental|Routine vaccines|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
16692262|NCT02001922|Experimental|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
16692232|NCT02002143|Active Comparator|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
16692233|NCT02002143|Experimental|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).
~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
16692237|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
16692238|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
16692239|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
16692240|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
16692241|NCT02002078|No Intervention|Methylprednisolone, caustic burns|
16692242|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
16692243|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
16692244|NCT02002052|Active Comparator|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
16692245|NCT02002052|Experimental|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
16692246|NCT02002039|Active Comparator|erythropoietin, perinatal asphyxia,|Treatment group
16692247|NCT02002039|Placebo Comparator|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
16692248|NCT02002026|Active Comparator|Ligation group|Uterine artery ligation will be done for patients in this group
16692249|NCT02002026|Placebo Comparator|Control group|Conventional CS
16692250|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
16692251|NCT02002000|Experimental|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
16692252|NCT02002000|Experimental|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
16692253|NCT02001987|Experimental|Tocilizumab|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
16692254|NCT02001974|Experimental|Group 1|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)
16692255|NCT02001974|Experimental|Group 2|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 100% increase to 800 mg t.i.d. if no toxicity in previous group (400 mg) three weeks on one week off (three to six patients)
16692256|NCT02001974|Experimental|Group 3|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 50% increase to 1200 mg t.i.d. if no toxicity in previous group (800 mg) three weeks on one week off (three to six patients).
16692257|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
16692258|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
16692259|NCT02001948|Active Comparator|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
16692260|NCT02001948|Active Comparator|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
16692266|NCT02001896|Experimental|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression
16692267|NCT02001896|Active Comparator|erlotinib along|Drug: erlotinib [Tarceva] 150mg/day po until disease progression
16692268|NCT02001883|Active Comparator|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
16692269|NCT02001883|Active Comparator|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
16692270|NCT02001870|Experimental|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
16692271|NCT02001870|Active Comparator|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
16692272|NCT02001857|Experimental|TachoSil|TachoSil
16692273|NCT02001857|No Intervention|No TachoSil|No TachoSil
16692274|NCT02001844|Placebo Comparator|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).
~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
16692275|NCT02001844|Experimental|Trial Group|"Trial Group:
~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.
~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
16692276|NCT02001831|Experimental|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):
~Carbohydrate 28.5 g
~Protein 8 g as Whey Protein Isolate
~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg
~Vitamin D3 10 μg
~Resveratrol 150 mg"
16692277|NCT02001831|Placebo Comparator|Control|"Placebo control
~Liquid nutrient support
~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
16692278|NCT02001818|Experimental|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).
~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
16692279|NCT02001805||Marathon runners|Very active runners that have been running > 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
16692280|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level < 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
16692281|NCT02001792|Sham Comparator|Controll group|Patients lying in a supine position during colonoscopy
16692282|NCT02001792|Active Comparator|Intervention|Patients lying in a left lateral position during colonoscopy
16692283|NCT02001779|Experimental|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
16692284|NCT02001779|Active Comparator|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
16692285|NCT02001766|Experimental|High intensity exercise|3 times per week in a total of 12 weeks
16692286|NCT02001766|Experimental|Low intensity exercise|3 times per week in a total of 12 weeks
16692287|NCT02001766|Experimental|Control|Normal lifestyle for 12 weeks
16692288|NCT02001753|Experimental|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
16692289|NCT02001753|Placebo Comparator|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
16692290|NCT02001753|No Intervention|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
16692291|NCT02001740|Placebo Comparator|lidocaine|frequency = once
16692292|NCT02001740|Experimental|Triamcinalone (steroid) and lidocaine|frequency = once
16692293|NCT02001727|Active Comparator|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
16692294|NCT02001727|Other|Control group|primarily unscreened group
16692295|NCT02001714|Experimental|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
16692296|NCT02001714|No Intervention|No Treatment|Subjects will not attend group behavioral treatment class.
16692297|NCT02001701|Experimental|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
16692298|NCT02001688|Experimental|Kamada-AAT for Inhalation, 80mg|Daily inhalation of Kamada-AAT for Inhalation, 80mg
16692299|NCT02001688|Placebo Comparator|Placebo|Placebo administered by inhalation daily
16692300|NCT02001688|Experimental|Kamada-AAT for Inhalation, 160mg|Daily inhalation of Kamada-AAT for Inhalation, 160mg
16692301|NCT02001675|Experimental|Volunteer healthy|
16692302|NCT02001662|Experimental|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is > 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.
~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
16692303|NCT02001662|Sham Comparator|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.
~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
16692304|NCT02001649|Other|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.
~Individuals will be genotyped at a total of 96 SNPs"
16692305|NCT02001649|Other|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
16692306|NCT02001636|Experimental|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.
~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
16692307|NCT02001636|Placebo Comparator|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.
~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
16692308|NCT02001623|Experimental|Tisotumab Vedotin (HuMax-TF-ADC)|All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
16692309|NCT02001610|Active Comparator|Hard shell gelatin capsules|"Comparison delivery vehicle in the form of gelatin capsule
~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
16692310|NCT02001610|Experimental|Acidophilus pearls|"Encapsulated using patented process
~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
16692311|NCT02001597||Surgery patients|
16692312|NCT02001584|Experimental|Healthy Volunteers|
16692313|NCT02001584|Experimental|Obese, Otherwise Healthy Volunteers|
16692314|NCT02001571|Experimental|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
16692315|NCT02001571|Experimental|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
16692316|NCT02001571|Experimental|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
16692317|NCT02001558|Experimental|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily.
16692318|NCT02001558|Active Comparator|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily.
16692319|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
16692320|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
16692321|NCT02001532||Healthy controls|Sex and age-matched healthy controls
16692322|NCT02001519|Experimental|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
16692323|NCT02001506|Active Comparator|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel
~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks
~Docetaxel 75 mg/m2, every 3 weeks"
16692324|NCT02001506|No Intervention|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel
~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks
~Docetaxel 75 mg/m2, every 3 weeks"
16692325|NCT02001480|Other|Echocardiography|"12 lead holter for 7 days
~CGM = continuous Glucose Monitoring"
16692326|NCT02001467|Active Comparator|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
16692327|NCT02001467|No Intervention|Control|No training is provided the control group participants.
16692328|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
16692329|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
16692330|NCT02001441||No treatment|
16692331|NCT02001428|Experimental|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
16692332|NCT02001428|No Intervention|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
16692333|NCT02001415|Active Comparator|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
16692334|NCT02001415|Active Comparator|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
16692335|NCT02001415|Active Comparator|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
16692336|NCT02001389|Experimental|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
16692337|NCT02001389|Experimental|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
16692338|NCT02001389|Experimental|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
16692339|NCT02001389|Experimental|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
16692340|NCT02001376|Experimental|Intensive exercise & home exercise|Intensive exercise group Home exercise group
16692341|NCT02001376|Experimental|Intensive exercise & control|Intensive exercise group Control group
16692342|NCT02001376|Experimental|Home exercise & control group|Home exercise Control group
16692343|NCT02001363|Experimental|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
16692344|NCT02001363|Placebo Comparator|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
16692345|NCT02001350||Resistant hypertension|
16692346|NCT02001324|Active Comparator|Paper-based data collection|Paper-based data collection
16692347|NCT02001324|Active Comparator|Web-based data collection|Web-based data collection
16692348|NCT02001311|Experimental|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
16692349|NCT02001298|Experimental|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
16692350|NCT02001298|Experimental|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
16692351|NCT02001285|Experimental|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
16692352|NCT02001285|Active Comparator|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
16692353|NCT02001272|Experimental|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
16692354|NCT02001272|Experimental|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
16692355|NCT02001272|Experimental|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
16692356|NCT02001259|Active Comparator|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
16692357|NCT02001259|Experimental|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
16692358|NCT02001246|Active Comparator|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
16692359|NCT02001246|Experimental|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
16692360|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
16692361|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
16692362|NCT02001220|Active Comparator|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
16692363|NCT02001220|Experimental|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
16692364|NCT02001207||MICU patients|
16692365|NCT02001194|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
16692366|NCT02001194|Experimental|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
16692406|NCT02000960|Experimental|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
16692407|NCT02000947|Experimental|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
16705155|NCT01916291|Experimental|Propess insertion|
16692367|NCT02001194|Experimental|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
16692368|NCT02001194|Experimental|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
16692369|NCT02001181|Experimental|Treatment group A|
16692370|NCT02001181|Placebo Comparator|Treatment B|
16692371|NCT02001168|Experimental|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
16692372|NCT02001168|Experimental|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
16692373|NCT02001168|Experimental|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
16692374|NCT02001168|Experimental|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
16692375|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
16692376|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
16692377|NCT02001142|Experimental|Exercise|
16692378|NCT02001142|No Intervention|Sedentary Control|
16692379|NCT02001129|Experimental|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
16692380|NCT02001129|Experimental|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
16692381|NCT02001129|Active Comparator|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
16692382|NCT02001116|Experimental|Pilot Hospitals|
16692383|NCT02001116|No Intervention|Control Hospitals|
16692384|NCT02001103|Active Comparator|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
16692385|NCT02001103|Active Comparator|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
16692386|NCT02001103|Placebo Comparator|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
16692387|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
16692388|NCT02001077|Active Comparator|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
16692389|NCT02001077|Active Comparator|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
16692390|NCT02001077|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
16692391|NCT02001064|Experimental|Care4Today v2.0 mobile application + electronic monitoring of adherence|"Care4Today v2.0 mobile application
~Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.
~Electronic monitoring of adherence:
~Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap."
16692392|NCT02001064|No Intervention|Electronic monitoring of adherence|Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap.
16692393|NCT02001051|Other|Operative Arm|operative arm
16692394|NCT02001051|Other|Delayed Operative Arm|delayed operative arm
16692395|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
16692396|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
16692397|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
16692398|NCT02001012|Active Comparator|Artemether-lumefantrine|"Artemether-lumefantrine.
~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet."
16692399|NCT02001012|Active Comparator|Chloroquine|"Chloroquine.
~1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.
~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
16692400|NCT02000999||Patients with bile duct strictures|
16692401|NCT02000986|Experimental|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
16692402|NCT02000973|Placebo Comparator|Normal saline|General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
16692403|NCT02000973|Experimental|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine 8ml
16692408|NCT02000947|Experimental|Arm A|Medi4736 and tremelimumab received by intravenous infusion
16692409|NCT02000947|Experimental|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
16692410|NCT02000947|Experimental|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
16692411|NCT02000934|Experimental|TAK-659 60 mg (Dose Escalation)|TAK-659 60 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 49 cycles).
16692412|NCT02000934|Experimental|TAK-659 80 mg (Dose Escalation)|TAK-659 80 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 4 cycles).
16692413|NCT02000934|Experimental|TAK-659 100 mg (Dose Escalation)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 32 cycles).
16692414|NCT02000934|Experimental|TAK-659 120 mg (Dose Escalation)|TAK-659 120 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 41 cycles).
16692415|NCT02000934|Experimental|TAK-659 CCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with chronic lymphocytic leukemia (CCL) (up to 6 cycles).
16692416|NCT02000934|Experimental|TAK-659 DLBCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with diffuse large B-cell lymphoma (DLBCL) (up to 49 cycles).
16692417|NCT02000934|Experimental|TAK-659 iNHL (Dose Expansion)|Single dose TAK-659 100 mg, tablet, orally in pharmacokinetic (PK) Run-in prior to Cycle 1 followed by TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with indolent non-hodgkin lymphoma (iNHL) (up to 32 cycles).
16692418|NCT02000934|Experimental|TAK-659 MCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with mantle cell lymphoma (MCL) (up to 6 cycles).
16692419|NCT02000934|Experimental|TAK-659 PTLD (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with post-transplant lymphoproliferative disorder (PTLD) (up to 1 cycle).
16692420|NCT02000921|Experimental|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
16692421|NCT02000921|Experimental|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
16692422|NCT02000921|Experimental|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
16692423|NCT02000908|Experimental|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
16692424|NCT02000908|Sham Comparator|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.
~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
16692425|NCT02000895||Preterm infants|>24 weeks <37 weeks gestational age
16692426|NCT02000895||Term infants|>37 weeks' gestational age
16692427|NCT02000895||Follow-up at 6 Years|Children enrolled from the birth cohort(s) to be followed at 6 to 10 years of age.
16692428|NCT02000882|Experimental|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.
~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
16692429|NCT02000869||wait-listed kidney transplant candidates|
16692430|NCT02000856|Active Comparator|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
16692431|NCT02000856|Placebo Comparator|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
16692432|NCT02000843|Other|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
16692433|NCT02000830||Placebo|Participants received placebo during the earlier study
16692434|NCT02000830||Stannsoporfin 3.0 mg/kg|Participants received Stannsoporfin 3.0 mg/kg during the earlier study
16692435|NCT02000830||Stannsoporfin 4.5 mg/kg|Participants received Stannsoporfin 4.5 mg/kg during the earlier study
16692436|NCT02000817|Experimental|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
16692437|NCT02000817|Experimental|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
16692438|NCT02000817|Experimental|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
16692439|NCT02000817|Experimental|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
16692440|NCT02000817|Placebo Comparator|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
16692441|NCT02000804|Experimental|darapladib 160mg|drug
16692442|NCT02000791|Experimental|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
16692443|NCT02000791|Active Comparator|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
16692444|NCT02000778|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
16692445|NCT02000765|Experimental|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing [14C]-GSK2140944 of approximately 22.5 microcurie [μCi] (approximately 0.8 megabecquerel [MBq]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing [14C]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
16692446|NCT02000752|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
16692447|NCT02000752|Sham Comparator|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
16692448|NCT02000739|Other|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.
~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
16692449|NCT02000726|Experimental|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
16692450|NCT02000713|Experimental|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
16692451|NCT02000713|Active Comparator|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
16692452|NCT02000700|Experimental|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
16692453|NCT02000700|Experimental|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
16692454|NCT02000674|Active Comparator|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
16692455|NCT02000674|Experimental|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
16692456|NCT02000661|Experimental|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
16692457|NCT02000661|Active Comparator|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
16692458|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
16692459|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
16692460|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
16692461|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
16692467|NCT02000596|Experimental|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
16692709|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
16692468|NCT02000596|Experimental|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
16692469|NCT02000596|Experimental|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
16692470|NCT02000583|Experimental|Aerobic Exercise Group|Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks
16692471|NCT02000583|Other|Control Group|Standard of Care exercise recommendations
16692472|NCT02000570|Experimental|sitting position|
16692473|NCT02000557||Class II Malocclusion|
16692474|NCT02000544|Other|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
16692475|NCT02000531|Experimental|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
16692476|NCT02000531|Active Comparator|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
16692477|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
16692478|NCT02000505|No Intervention|Control|5 minutes chest-compression-only CPR, without any support
16692479|NCT02000505|Experimental|PocketCPR|5 minutes chest-compression-only CPR, with support
16692480|NCT02000505|Experimental|Metronome|5 minutes chest-compression-only CPR, with support
16692481|NCT02000505|Experimental|110bpm Song|5 minutes chest-compression-only CPR, with support
16692482|NCT02000492|Experimental|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
16692483|NCT02000492|No Intervention|Control|
16692484|NCT02000479|Experimental|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
16692485|NCT02000479|No Intervention|Control|Continued usual care, habitual lifestyle
16692486|NCT02000466||Exposed cohort|
16692487|NCT02000453|Experimental|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
16692488|NCT02000440|Experimental|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
16692489|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.
~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
16692490|NCT02000414|Experimental|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
16692491|NCT02000401|Other|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
16692492|NCT02000388|Other|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
16692493|NCT02000388|Other|Standard of care|The intervention used will be standard of care
16692494|NCT02000375|Experimental|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
16692495|NCT02000362|Experimental|Treatment|"cohort 1. 5.0 x 10^7 stem cells after registration
~cohort 2. 1.0 x 10^8 stem cells after registration"
16692496|NCT02000349|Experimental|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*).
16692497|NCT02000349|Experimental|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
16692498|NCT02000336|Experimental|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
16692499|NCT02000336|Experimental|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
16692500|NCT02000336|Placebo Comparator|Placebo|daily oral tablet
16692501|NCT02000323|Active Comparator|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
~After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.
~Patients are targeted to receive calories for 25 kcal/kg/day."
16692502|NCT02000323|Active Comparator|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
~After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.
~Patients are targeted to receive calories for 25 kcal/kg/day."
16692503|NCT02000297|Active Comparator|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
16692504|NCT02000297|Experimental|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
16692505|NCT02000284||General ASD|150 general ASD children
16692506|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
16692507|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
16692508|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
16692509|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
16692510|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
16692511|NCT02000271|Other|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
16692512|NCT02000271|Experimental|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
16692513|NCT02000258|Other|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
16692514|NCT02000258|Other|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
16692515|NCT02000245|Active Comparator|verbal expression for compassion|verbal expression for compassion
16692516|NCT02000245|Active Comparator|verbal expression and touch|verbal expression and touch
16692517|NCT02000245|No Intervention|control|control
16692518|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
16692519|NCT02000219|Experimental|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.
~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
16692520|NCT02000206|Active Comparator|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:
~A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.
~Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
16692521|NCT02000206|Active Comparator|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:
~A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.
~Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
16692522|NCT02000193|Experimental|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.
~The treatment will continue until disease progression or intolerable adverse event"
16692523|NCT02000180|Experimental|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
16692524|NCT02000180|No Intervention|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
16692525|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
16692526|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
16692527|NCT02000154|Experimental|SyB L-1101|
16692528|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
16692529|NCT02000128|Experimental|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
16692530|NCT02000128|Other|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
16692531|NCT02000115|Experimental|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve and Portico delivery system.
~Status: ACTIVE, NOT ENROLLING."
16692532|NCT02000115|Active Comparator|Randomized IDE Cohort, CAV|"Any FDA approved, commercially-available transcatheter aortic valve (CAV).
~Status: ACTIVE, NOT ENROLLING."
16692533|NCT02000115|Experimental|Nested Valve-in-Valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve
~Status: ACTIVE, ENROLLING."
16692534|NCT02000115|Experimental|FlexNav Delivery System Study|"Portico transcatheter aortic valve and FlexNav delivery system
~Status: ACTIVE, NOT ENROLLING"
16692535|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
16692536|NCT02000089|Active Comparator|Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):
~> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and
~come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and
~have a first-degree relationship with at least one of the relatives with pancreatic cancer.
~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
16692710|NCT01999023|No Intervention|Observational group|No intervention
16692537|NCT02000089|Active Comparator|Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):
~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened.
~The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), age 40 years or older, regardless of family history of pancreas cancer."
16692538|NCT02000089|Active Comparator|Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):
~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and
~The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
16692539|NCT02000089|Active Comparator|Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
16692540|NCT02000089|Active Comparator|Peutz-Jeghers Syndrome|"At least 30 years old, and
~at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,
~known STK11 gene mutation carrier"
16692541|NCT02000089|Active Comparator|Negative control|"are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and
~have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
16692542|NCT02000089|Active Comparator|Chronic Pancreatitis|"are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,
~have no clinical or radiologic suspicion of pancreatic cancer"
16692543|NCT02000089|Active Comparator|Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
16692544|NCT02000089|Active Comparator|Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
16692545|NCT02000076|Experimental|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
16692546|NCT02000076|Experimental|Full sleep|Sleep with no restriction
16692547|NCT02000050|Experimental|Single Arm|"Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles
~Surgery
~Adjuvant therapy: FOLFOX4 8 cycles
~TME (Total Mesorectal Excision)"
16692548|NCT02000037|Active Comparator|Dietary care|Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).
16692549|NCT02000037|Experimental|IR reflexotherapy + dietary care|"Treatment is composed of :
~IR reflexotherapy sessions given by a trained professional ;
~dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille)."
16692550|NCT02000037|Experimental|IR Reflexotherapy|Treatment is composed of IR reflexotherapy sessions given by a trained professional.
16692551|NCT02000024|Experimental|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
16692552|NCT02000024|Active Comparator|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
16692553|NCT02000011|Other|standard strategy|
16692554|NCT02000011|Experimental|experimental strategy|
16692555|NCT01999998|Experimental|Pilot|
16692556|NCT01999985|Experimental|Dose Escalation and Dose Expansion|"Dose escalation followed by dose expansion. Escalation cohort: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.
~Expansion cohort:: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
16692557|NCT01999972|Experimental|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
16692558|NCT01999972|Experimental|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer [RCC] with no prior systemic therapy
16692559|NCT01999972|Experimental|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
16692560|NCT01999959|Experimental|Pertubation performed|Study group had pertubation and insemination
16692561|NCT01999959|No Intervention|Pertubation not performed|Study group had insemination only
16692562|NCT01999946|Experimental|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
16692563|NCT01999946|No Intervention|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
16692602|NCT01999738|Experimental|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).
~Intervention: EC1456 and EC20"
16705156|NCT01916278|Experimental|Emervel Lips Lidocaine|
16692564|NCT01999946|No Intervention|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
16692565|NCT01999933|Active Comparator|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
16692566|NCT01999933|Experimental|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
16692567|NCT01999933|Experimental|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
16692568|NCT01999920|Experimental|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
16692569|NCT01999920|Placebo Comparator|Placebo|Pill placebo.
16692570|NCT01999907|Placebo Comparator|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
16692571|NCT01999907|Active Comparator|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
16692572|NCT01999894|Experimental|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
16692573|NCT01999881|Experimental|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
16692574|NCT01999881|Active Comparator|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
16692575|NCT01999868|Experimental|UST, ABA/UST Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of abatacept (ABA) (125 mg) subcutaneous injections weekly from Week 12 to 39, in addition to ustekinumab placebo subcutaneous injections at Weeks 16 and 28.
16692576|NCT01999868|Active Comparator|UST, UST/ABA Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of ustekinumab (45 mg if <=100 kg or 90 mg if >100 kg at study entry) subcutaneous injections at Weeks 16 and 28, in addition to abatacept (ABA) placebo subcutaneous injections weekly from Week 12 to 39.
16692577|NCT01999855|Active Comparator|control group|"the Phonatory Maximum Time
~Vocal Handicap Index
~Scale GRBAS of Hirano
~Videolaryngoscopy"
16692578|NCT01999855|Experimental|Asthmatic patients|"The Phonatory Maximum Time
~Vocal Handicap Index
~Scale GRBAS of Hirano
~Videolaryngoscopy"
16692579|NCT01999842|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
16692580|NCT01999842|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
16692581|NCT01999842|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
16692582|NCT01999842|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
16692583|NCT01999842|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
16692584|NCT01999842|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
16692585|NCT01999829|Experimental|citrate of caffeine|
16692586|NCT01999829|Placebo Comparator|placebo|
16692587|NCT01999816|Experimental|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
16692588|NCT01999816|No Intervention|Control|Usual care
16692589|NCT01999803|Experimental|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
16692590|NCT01999803|Placebo Comparator|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
16692591|NCT01999790|Experimental|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
16692592|NCT01999790|Experimental|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
16692593|NCT01999777|Experimental|USL261|5 mg intranasal midazolam
16692594|NCT01999777|Placebo Comparator|Placebo|intranasal placebo
16692595|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
16692596|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
16692597|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
16692598|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
16692599|NCT01999738|Experimental|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).
~Intervention: EC1456 and EC20"
16692600|NCT01999738|Experimental|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).
~Intervention: EC1456 and EC20"
16692601|NCT01999738|Experimental|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).
~Intervention: EC1456 and EC20"
16692603|NCT01999738|Experimental|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.
~Intervention: EC1456 and EC20"
16692604|NCT01999738|Experimental|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.
~Intervention: EC1456 and EC20"
16692605|NCT01999738|Experimental|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).
~Intervention: EC1456 and EC20"
16692606|NCT01999725|Experimental|EDP-788|Single doses with dose escalation to continue in successive cohorts
16692607|NCT01999725|Placebo Comparator|Placebo|Single dose with matching placebo
16692608|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
16692609|NCT01999699|Experimental|HEPLISAV|
16692610|NCT01999686|Experimental|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
16692611|NCT01999686|Active Comparator|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
16692612|NCT01999686|Experimental|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
16692613|NCT01999673|Experimental|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
16692614|NCT01999673|Placebo Comparator|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
16692615|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
16692616|NCT01999647|Active Comparator|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
16692617|NCT01999647|Experimental|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
16692618|NCT01999634|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
16692619|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
16692620|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L
16692621|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
16692622|NCT01999595|Experimental|High frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation
~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
16692623|NCT01999595|Experimental|Low frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation
~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
16692624|NCT01999595|Experimental|High frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation
~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
16692625|NCT01999595|Experimental|Low frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation
~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
16692626|NCT01999595|Placebo Comparator|Control TENS|"TENS=transcutaneous electrical nerve stimulation
~Control TENS was the application of electrical stimulation via skin with no current"
16692627|NCT01999595|Sham Comparator|Sham TENS|"TENS=transcutaneous electrical nerve stimulation
~Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told that the TENS was turn-on whether you feel it or not"
16692628|NCT01999582|Experimental|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
16692629|NCT01999582|Experimental|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
16692630|NCT01999569|No Intervention|Control|Control cycle. No intervention.
16692631|NCT01999569|Experimental|Letrozole|5mg daily
16692632|NCT01999556||Patient|Specimen Collection
16692633|NCT01999556||Relative|Specimen Collection
16692634|NCT01999543|Other|Reference food format|reference food format with and without plant-based ingredient added
16692635|NCT01999543|Experimental|Food format one|Food format one with and without plant-based ingredient added
16692636|NCT01999543|Experimental|Food format two|Food format two with and without plant-based ingredient added
16692637|NCT01999543|Experimental|Food format three|Food format three with and without plant-based ingredient added
16692638|NCT01999530|Experimental|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
16692639|NCT01999517|Active Comparator|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
16692641|NCT01999504|Experimental|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
16692642|NCT01999504|Experimental|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
16692643|NCT01999504|Placebo Comparator|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
16692644|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
16692645|NCT01999465|Active Comparator|Standard NMES cohort|Patients who will apply standard NMES device.
16692646|NCT01999465|Sham Comparator|Sham NMES cohort|Patients who will apply sham NMES device.
16692647|NCT01999452|Experimental|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
16692648|NCT01999452|Experimental|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
16692649|NCT01999439|Experimental|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
16692650|NCT01999426|Experimental|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
16692651|NCT01999426|Active Comparator|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
16692652|NCT01999413|Experimental|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :
~Daunorubicin 60 mg/m²/day IV on D1, D2, and D3
~Cytarabine 200 mg/m²/day D1 to D7
~OMEGAVEN® 2 ml/kg D1 to D9,
~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours
~Induction cycle :
~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3
~- Cytarabine 200 mg/m²/day IV D1 to D7
~bone marrow aspirate at D15: If BM blasts are > 5% or if second induction course :
~Daunorubicin 35 mg/m²/day IV D17 and D18
~OMEGAVEN® 2 ml/kg
~Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19
~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).
~Consolidation will be administered at investigator's discretion"
16692653|NCT01999400|Experimental|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
16692654|NCT01999400|Experimental|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
16692655|NCT01999400|Experimental|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
16692656|NCT01999400|Experimental|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
16692657|NCT01999400|Experimental|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
16692658|NCT01999400|Experimental|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
16692659|NCT01999387||Completed OIT|Patients who completed OIT >6 months prior to enrollment
16692660|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
16692661|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
16692662|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
16692663|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
16692664|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
16692665|NCT01999335|Experimental|Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
16692711|NCT01999023|Experimental|Dietary supplement|Low protein formula formula (28.5 g) twice a day
16693608|NCT01992991|Experimental|Transcranial direct current stimulation|Anodal stimulation
16692666|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone: Expansion Phase|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
16692667|NCT01999322|Experimental|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
16692668|NCT01999322|Active Comparator|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
16692669|NCT01999309|Experimental|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
16692670|NCT01999309|Placebo Comparator|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
16692671|NCT01999296||Patients undergoing laparoscopic surgery|
16692672|NCT01999283|Active Comparator|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
16692673|NCT01999283|Active Comparator|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
16692674|NCT01999283|No Intervention|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
16692675|NCT01999270|Experimental|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
16692676|NCT01999257|No Intervention|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
16692677|NCT01999257|Active Comparator|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
16692678|NCT01999244|Experimental|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
16692679|NCT01999244|Experimental|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
16692680|NCT01999244|Experimental|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
16692681|NCT01999231|Experimental|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
16692682|NCT01999231|Experimental|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
16692683|NCT01999231|Experimental|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
16692684|NCT01999231|Experimental|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
16692685|NCT01999218|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
16692686|NCT01999218|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
16692687|NCT01999218|Active Comparator|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
16692688|NCT01999205|Experimental|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
16692689|NCT01999192|Experimental|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
16692690|NCT01999192|Experimental|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
16692691|NCT01999192|Experimental|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
16692692|NCT01999192|Placebo Comparator|Placebo|Placebo s.c. weekly
16692693|NCT01999179|Other|low-molecular-weight heparin or direct oral anticoagulant|"Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.
~Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants."
16692694|NCT01999166||Osteoarthritis|
16692695|NCT01999153|Experimental|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
16692696|NCT01999153|Placebo Comparator|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
16692697|NCT01999140||Primary prevention|
16692698|NCT01999114|Experimental|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr
16692699|NCT01999114|Experimental|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
16692700|NCT01999114|Active Comparator|Naltrexone|Naltrexone 50 mg tablets
16692701|NCT01999114|Placebo Comparator|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
16692702|NCT01999114|Active Comparator|Moxifloxacin|Moxifloxacin 400-mg tablets
16692703|NCT01999101|Experimental|Px-104|Px-104 capsules, 5 mg
16692704|NCT01999088|Experimental|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
16692705|NCT01999088|Placebo Comparator|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
16692706|NCT01999075|Placebo Comparator|Conventional Treatment|Conventional Treatment
16692707|NCT01999075|Active Comparator|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
16692708|NCT01999062|Experimental|IMRT + CT + MR scan|
16692712|NCT01999010|No Intervention|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
16692713|NCT01999010|Experimental|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
16692714|NCT01999010|Experimental|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
16692715|NCT01998997|Active Comparator|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
16692716|NCT01998997|Placebo Comparator|general health education|The placebo group will be given a brochure on good health habits
16692717|NCT01998984|Experimental|2 days placebo and 2 days drug|Placebo and drug
16692718|NCT01998984|Experimental|1 day placebo and 3 days drug|Placebo and drug
16692719|NCT01998984|Placebo Comparator|4 days placebo|Placebo
16692720|NCT01998984|Experimental|4 days drug|Drug
16692721|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
16692722|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
16692723|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
16692724|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
16692725|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
16692726|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
16692727|NCT01998958|Experimental|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
16692728|NCT01998958|Experimental|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
16692729|NCT01998958|Experimental|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
16692730|NCT01998958|Experimental|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
16692731|NCT01998958|Placebo Comparator|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
16692732|NCT01998945|Experimental|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
16692733|NCT01998945|Active Comparator|Relaxation Training (RT)|Participants will receive relaxation training
16692734|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
16692735|NCT01998919|Experimental|Tarceva + gemcitabine/platinum|
16692736|NCT01998919|Placebo Comparator|Placebo + gemcitabine/platinum|
16692737|NCT01998906|Experimental|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m^2), IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m^2, IV; methotrexate 40 mg/m^2, IV; and 5-fluorouracil 600 mg/m^2, IV, on Day 1 of Cycles 8 through 10.
16692738|NCT01998906|Active Comparator|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
16692774|NCT01998672|Placebo Comparator|Placebo|Oral drinking solution
16692775|NCT01998659|Active Comparator|Px-102|Px-102 drinking solution, single dose
16692776|NCT01998659|Placebo Comparator|Placebo|Placebo drinking solution, single dose
16692739|NCT01998906|Active Comparator|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
16692740|NCT01998893|Experimental|MabThera/Rituxan|
16692741|NCT01998880|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
16692742|NCT01998880|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
16692743|NCT01998880|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
16692744|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
16692745|NCT01998841|Experimental|Mutation Carriers: Crenezumab|"Study Period A: Participants will receive Crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
~Study Period B: Participants will be offered the opportunity to continue to receive blinded study drug until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
16692746|NCT01998841|Placebo Comparator|Mutation Carriers: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
~Study Period B: All mutation carriers entering Study Period B will, receive Crenezumab until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
16692747|NCT01998841|Placebo Comparator|Non-carriers of Mutation: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
~Study Period B: All non-mutation carriers entering Study Period B will continue to receive Placebo, until the results of the study are known and post trial access to Crenezumab is started or development of Crenezumab is discontinued."
16692748|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
16692749|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
16692750|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
16692751|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
16692752|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
16692753|NCT01998802|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
16692754|NCT01998802|Placebo Comparator|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
16692755|NCT01998789|Experimental|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.
~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
16692756|NCT01998789|Active Comparator|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.
~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
16692757|NCT01998776|Active Comparator|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
16692758|NCT01998776|Placebo Comparator|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
16692759|NCT01998763|Placebo Comparator|Placebo|5 placebo pills per day, 20 weeks
16692760|NCT01998763|Experimental|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
16692761|NCT01998750||Early-onset severe obesity|The study will enroll children and young adults up to 21 years of age with early onset severe obesity (BMI > 99th percentile noted at an age < 6 years of age).
16692762|NCT01998737||Women under osteoporosis suspicion|
16692763|NCT01998737||Healthy women|
16692764|NCT01998724|No Intervention|Standard Care|No intervention
16692765|NCT01998724|Experimental|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
16692766|NCT01998724|Experimental|Group Walking Exercise|24 week group walking intervention
16692767|NCT01998711|Experimental|Memory group|Memory training
16692768|NCT01998711|No Intervention|Control|Standard care
16692769|NCT01998698|Active Comparator|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
16692770|NCT01998698|Active Comparator|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
16692771|NCT01998685|Experimental|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
16692772|NCT01998685|Active Comparator|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
16692773|NCT01998672|Active Comparator|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
16692781|NCT01998633|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
16692782|NCT01998620|Experimental|Ademetionine 1|Ademetionine 2000mg
16692783|NCT01998620|Experimental|Ademetionine 2|Ademetionine 1000mg
16692784|NCT01998620|Active Comparator|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
16692785|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
16692786|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
16692787|NCT01998594|Active Comparator|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
16692788|NCT01998594|Experimental|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
16692789|NCT01998581|Experimental|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
16692790|NCT01998581|Active Comparator|Restylane-L®|Lips injected with Restylane-L®
16692791|NCT01998568||Corneal edema|Intraocular pressure measurement
16692792|NCT01998555|Other|CAD-CBT group therapy|CAD receive web-based CBT group therapy
16692793|NCT01998555|Other|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
16692794|NCT01998542|Experimental|AlloStim+CRCL|AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
16692795|NCT01998529|Experimental|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
16692796|NCT01998516||Schizophrenia Patients|
16692797|NCT01998516||Bipolar I Patients|
16692798|NCT01998516||Siblings of Schizophrenia Patients|
16692799|NCT01998516||Siblings of Bipolar I Patients|
16692800|NCT01998516||Healthy Controls|
16692801|NCT01998503|Active Comparator|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
16692802|NCT01998503|Experimental|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
16692803|NCT01998490|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
16692804|NCT01998490|Experimental|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
16692805|NCT01998490|No Intervention|Control|Control group with treatment as usual
16692806|NCT01998477|Experimental|TIVc|flu vaccine
16692807|NCT01998477|Active Comparator|TIV|flu vaccine
16692808|NCT01998464||Retinal Vasculitis Group|Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
16692809|NCT01998451|Experimental|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
16692810|NCT01998451|Other|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
16692811|NCT01998438|Experimental|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
16692812|NCT01998438|Experimental|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
16692813|NCT01998438|Experimental|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
16692814|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
16692815|NCT01998399|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
16692816|NCT01998399|Placebo Comparator|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
16692898|NCT01997853|Active Comparator|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
16692817|NCT01998386|Placebo Comparator|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
16692818|NCT01998386|Experimental|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
16692819|NCT01998386|Experimental|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
16692820|NCT01998386|Experimental|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
16692821|NCT01998373|Experimental|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
16692822|NCT01998373|No Intervention|control without education|this group did not receive an education
16692823|NCT01998360|Experimental|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
16692824|NCT01998360|Active Comparator|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
16692825|NCT01998347|Experimental|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.
~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
16692826|NCT01998347|Active Comparator|Cisplatin plus 5-fluorouracil|"Cisplatin:
~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.
~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
16692827|NCT01998334|Experimental|CVVH 6h|CVVH 6h for first three days
16692828|NCT01998334|Experimental|CVVH 10h|CVVH 10h for first three days
16692829|NCT01998334|Experimental|CVVHDF|CVVHDF 6h for first three days
16692830|NCT01998321|Experimental|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
16692831|NCT01998321|Experimental|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
16692832|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
16692833|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
16692834|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
16692835|NCT01998308||Group 4|50 knees will have single injection of Monovisc
16692836|NCT01998295|Active Comparator|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days
~Dosage:
~tablet for body weight between 5-14.9 Kilograms.
~tablets for body weight between 15-24.9 Kilograms.
~tablets for body weight between 25-34.9 Kilograms."
16692837|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
16692838|NCT01998282||Control|Traditional water management practices and cooking stoves
16692839|NCT01998269||Adult patients with diabetes and hypertension|
16692840|NCT01998256|Sham Comparator|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
16692841|NCT01998256|Active Comparator|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
16692842|NCT01998243|Experimental|IGB group A|the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
16692843|NCT01998243|Placebo Comparator|control group B|the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
16692844|NCT01998230|Experimental|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
16692845|NCT01998230|No Intervention|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
16692846|NCT01998217|Active Comparator|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
16692847|NCT01998217|Experimental|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
16692848|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
16692849|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
16692850|NCT01998191|Active Comparator|Implicit Case note review (nurse)|"Notes to be reviewed using the implicit method by a nurse
~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
16692851|NCT01998191|Active Comparator|Implicit Case note review (MDT)|"Notes to be reviewed using the implicit method by an expert physician and nurse team.
~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
16692852|NCT01998191|Active Comparator|Implicit Case note review (physician)|"Notes to be reviewed using the implicit method by an expert physician
~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
16692853|NCT01998165|Experimental|Remifentanil (0.25 µg/kg/min)|
16692854|NCT01998152|Experimental|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
16692855|NCT01998152|No Intervention|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
16692856|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
16692857|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
16692858|NCT01998126|Experimental|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
16692859|NCT01998126|Experimental|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
16692860|NCT01998126|Experimental|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
16692861|NCT01998126|Experimental|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
16692862|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
16692863|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
16692864|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
16692865|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
16692866|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
16692867|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
16692868|NCT01998100|Experimental|Prolonged Exposure + Exercise|
16692869|NCT01998100|Active Comparator|Prolonged Exposure Alone|
16692870|NCT01998087|Experimental|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
16692871|NCT01998087|Active Comparator|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
16692872|NCT01998087|No Intervention|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
16692873|NCT01998074|Experimental|Study formula|
16692874|NCT01998061|Experimental|Arm A|TKI alone until rapid progression
16692875|NCT01998061|Experimental|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
16692876|NCT01998048|Active Comparator|Latarjet|60 patients treated with open Latarjet operation
16692877|NCT01998048|Active Comparator|Bankart|60 patients treated with arthroscopic Bankart operation
16692878|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
16692879|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
16692880|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
16692881|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
16692882|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
16692883|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
16692884|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
16692885|NCT01998009|Other|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
16692886|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
16692887|NCT01997983|Experimental|TC-3 Gel with Botox|open label observational study
16692888|NCT01997970|Experimental|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
16692889|NCT01997970|Experimental|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
16692890|NCT01997957|Experimental|TACE+HAIC-OXA+S-1|
16692891|NCT01997957|No Intervention|TACE+HAIC-OXA|
16692892|NCT01997944|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
16692893|NCT01997944|Active Comparator|Pegasys|Peginteferon 180 mcg multiple dose S.C.
16692894|NCT01997905|Experimental|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
16692895|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
16692896|NCT01997879|Experimental|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
16692897|NCT01997866|Other|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model
~Polysomnogram Sleep Study"
16692899|NCT01997853|Placebo Comparator|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
16692900|NCT01997840|Experimental|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
16692901|NCT01997827|Active Comparator|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
16692902|NCT01997827|Experimental|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
16692903|NCT01997814|Active Comparator|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
16692904|NCT01997814|Placebo Comparator|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
16692905|NCT01997801|Placebo Comparator|C group|In C group, NS infusion will be done intraoperatively.
16692906|NCT01997801|Experimental|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
16692907|NCT01997788|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
16692908|NCT01997788|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
16692909|NCT01997775|Experimental|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
16692910|NCT01997762|Placebo Comparator|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
16692911|NCT01997762|Experimental|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
16692912|NCT01997749|Experimental|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
16692913|NCT01997749|Active Comparator|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
16692914|NCT01997736|Experimental|Ablation|
16692915|NCT01997723|Experimental|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
16692916|NCT01997710|Experimental|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
16692917|NCT01997710|Active Comparator|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
16692918|NCT01997697|Experimental|Patients with obesity|behavior change program among patients with obesity
16692919|NCT01997684|Experimental|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.
~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.
~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.
~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
16692920|NCT01997684|Active Comparator|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
16692921|NCT01997671|Experimental|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
16692922|NCT01997671|No Intervention|Control group|Routine clinical practice
16692923|NCT01997658|Experimental|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
16692924|NCT01997658|Placebo Comparator|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
16692925|NCT01997645|Active Comparator|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.
~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
16692926|NCT01997645|Active Comparator|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.
~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
16692927|NCT01997632|Active Comparator|control vaccine: Imovax Polio®|
16692928|NCT01997632|Experimental|investigational vaccine|
16692929|NCT01997606|Experimental|Purotex|use of Purotex treated bedding covers
16692930|NCT01997606|Placebo Comparator|Placebo|no use of Purotex treated bedding covers
16692931|NCT01997593|Experimental|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
16692932|NCT01997580|Experimental|Escitalopram|depressed patients receiving escitalopram treatment
16692933|NCT01997580|No Intervention|Control|healthy controls matched for age, gender, and BMI
16693006|NCT01997021|Experimental|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
16692934|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
16692935|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
16692936|NCT01997554|Experimental|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
16692937|NCT01997554|Experimental|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
16692938|NCT01997554|Experimental|more than 60 years old|Group of patients more than 60 years old at recruitment.
16692939|NCT01997541||plain tube|
16692940|NCT01997541||reinforced tube|
16692941|NCT01997528|Experimental|Extracorporeal CO2 elimination by ILA Activve(R)|
16692942|NCT01997515|Active Comparator|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
16692943|NCT01997515|Placebo Comparator|Group P (Placebo)|Group P (placebo) will receive the same amount of saline.
16692944|NCT01997489|Experimental|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
16692945|NCT01997476|Experimental|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.
~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
16692946|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
16692947|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
16692948|NCT01997450||Q/LAIV|FluMist Quadrivalent
16692949|NCT01997450||Inactivated Influenza Vaccine|Inactivated Influenza Vaccine
16692950|NCT01997437|Other|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
16692951|NCT01997411|Experimental|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
16692952|NCT01997411|Active Comparator|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
16692953|NCT01997385|Active Comparator|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
16692954|NCT01997385|Experimental|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
16692955|NCT01997372|Experimental|high dose ATG,low dose ATG|
16692956|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
16692957|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
16692958|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
16692959|NCT01997333|Active Comparator|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
16692960|NCT01997333|Experimental|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
16692961|NCT01997320|Experimental|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
16692962|NCT01997320|Active Comparator|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
16692963|NCT01997307||Stratification by gender and age, including 4 age categories|>=55-64 years
16692964|NCT01997307||Age >=65 to 74|
16692965|NCT01997307||Age >=75 to 84|
16692966|NCT01997307||Age >=85|
16692967|NCT01997294|Active Comparator|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
16692968|NCT01997294|Placebo Comparator|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
16692969|NCT01997281|Experimental|DF-cereal|"dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
~amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)
~one serving (40g) of steamed egg is added for dinner and breakfast"
16692970|NCT01997281|Other|conventional cereal|"conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
~amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)
~one serving (40g) of steamed egg is added for dinner and breakfast"
16692971|NCT01997268|Placebo Comparator|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
16692972|NCT01997268|Experimental|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
16692973|NCT01997268|Experimental|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
16692974|NCT01997268|Experimental|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
16692975|NCT01997255|Experimental|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
16692976|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
16692977|NCT01997229|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
16692978|NCT01997229|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
16692979|NCT01997216|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
16692980|NCT01997216|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
16692981|NCT01997203|Experimental|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.
~Dose of vitamin D 15,000 IU/week"
16692982|NCT01997203|No Intervention|HCV without Vit D|
16692983|NCT01997190|Experimental|Study Arm|AdV-tk + valacyclovir
16692984|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
16692985|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
16692986|NCT01997164|Experimental|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
16692987|NCT01997164|Experimental|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
16692988|NCT01997151|Experimental|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
16692989|NCT01997151|No Intervention|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
16692990|NCT01997138|Experimental|Anakinra|Anakinra 100 mg in 2 ml saline IA
16692991|NCT01997138|Placebo Comparator|Placebo|Saline 2 ml IA
16692992|NCT01997125|Experimental|Open Label|Neural bridge system implant and external stimulator
16692993|NCT01997112|Active Comparator|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
16692994|NCT01997112|Placebo Comparator|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
16692995|NCT01997099||Library Creation|Individuals responsible for creating the drug library
16692996|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
16692997|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
16692998|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
16692999|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
16693000|NCT01997086|Active Comparator|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
16693001|NCT01997086|Active Comparator|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
16693002|NCT01997060|Experimental|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (~-700KCal/day). Education within nutrition, exercise and healthy living in general.
16693003|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
16693004|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
16693005|NCT01997021|Experimental|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
16705157|NCT01916278|Experimental|Juvéderm Volbella with Lidocaine|
16693007|NCT01997021|Experimental|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
16693008|NCT01997021|Experimental|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
16693009|NCT01997021|Experimental|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
16693010|NCT01997021|Experimental|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
16693011|NCT01997008|Experimental|Intervention|"Participants receive a five week intervention providing the following activities:
~EMA:
~Ecological Momentary Assessment (EMA) of Emotion throughout the day.
~Intervention:
~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.
~Gratitude: Participants identify one more more things that make them feel grateful.
~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.
~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.
~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.
~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
16693012|NCT01997008|No Intervention|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.
~EMA detail:
~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
16693013|NCT01996995|Experimental|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
16693014|NCT01996995|Sham Comparator|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
16693015|NCT01996982|Experimental|Device|CCS Device application
16693016|NCT01996969|Other|Regorafenib|This study is a single arm study with biomarker analysis
16693017|NCT01996956|Other|Volume loading|
16693018|NCT01996943|Placebo Comparator|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
16693019|NCT01996943|Active Comparator|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
16693020|NCT01996930|Active Comparator|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.
~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
16693021|NCT01996930|Active Comparator|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
16693022|NCT01996917|Active Comparator|Prineo closure|One breast will have skin closure with Prineo.
16693023|NCT01996917|No Intervention|Standard Suture|One breast will be closed in the standard fashion with suture.
16693024|NCT01996904|Experimental|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
16693025|NCT01996904|Active Comparator|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
16693026|NCT01996891|Other|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
16693027|NCT01996891|Other|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
16693028|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
16693029|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
16693030|NCT01996865|Experimental|Arm A: Lenalidomide + rituximab followed by lenalidomide|Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but < 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by a Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
16693068|NCT01996644|Experimental|Setraline|250 mg DCS (setraline) versus placebo plus exposure
16693031|NCT01996865|Active Comparator|Arm B: Lenalidomide + rituximab followed by rituximab|Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but < 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
16693032|NCT01996852|Active Comparator|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
16693033|NCT01996852|Experimental|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
16693034|NCT01996852|No Intervention|Usual Care (UC)|Study participants will not receive any study intervention, but will continue with standard care.
16693035|NCT01996839|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
16693036|NCT01996839|Active Comparator|Vehicle (BID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
16693037|NCT01996839|Experimental|Loteprednol Etabonate Gel (TID)|Loteprednol Gel 0.38% administered three times daily (TID).
16693038|NCT01996839|Active Comparator|Vehicle (TID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).
16693039|NCT01996826|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.
~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
16693040|NCT01996826|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.
~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
16693041|NCT01996813|Experimental|Prospective Case|Patients with a BMI of 30 kg/m^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
16693042|NCT01996813|No Intervention|Historical Control|Patients with a BMI of 30 kg/m^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
16693043|NCT01996800|Experimental|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
16693044|NCT01996800|Active Comparator|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
16693045|NCT01996787|Active Comparator|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
16693046|NCT01996787|Active Comparator|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
16693047|NCT01996774||Child, peanut/ nut allergy, no treatment|
16693048|NCT01996774||Child, peanut/nut allergy, tolerance|
16693049|NCT01996774||Non allergic child, without atopia|
16693050|NCT01996761|Experimental|Study Group 1|Study Group 1: 30ml Cerebrolysin
16693051|NCT01996761|Placebo Comparator|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
16693052|NCT01996748|Experimental|DF277|Two administrations daily for 7 days
16693053|NCT01996748|Placebo Comparator|Placebo|Two administrations daily for 7 days
16693054|NCT01996735|Active Comparator|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
16693055|NCT01996735|Placebo Comparator|Placebo|Placebo single dose
16693056|NCT01996709|Experimental|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
16693057|NCT01996709|Active Comparator|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
16693058|NCT01996696|Experimental|Metformin|Metformin 500 mg PO TID x 30-36 months
16693059|NCT01996696|Placebo Comparator|Placebo|Identical placebo TID x 30-36 months
16693060|NCT01996683|Active Comparator|iron chelation|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
16693061|NCT01996683|Placebo Comparator|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
16693062|NCT01996670||<2h group|
16693063|NCT01996670||2-4h group|
16693064|NCT01996670||>4h group|
16693065|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
16693066|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
16693067|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
16693070|NCT01996618|Experimental|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
16693071|NCT01996618|Placebo Comparator|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
16693072|NCT01996605|Experimental|Oxytocin 15 mcg|Oxytocin 15 mcg injected spinally
16693073|NCT01996605|Experimental|Oxytocin 150 mcg|Oxytocin 150 mcg injected spinally
16693074|NCT01996605|Active Comparator|Placebo|Preservative free normal saline injected spinally
16693075|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
16693076|NCT01996579|Experimental|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
16693077|NCT01996579|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
16693078|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
16693079|NCT01996540|Experimental|Interventional arm|Interventional arm
16693080|NCT01996540|No Intervention|Standard arm|Standard arm
16693081|NCT01996527|Experimental|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
16693082|NCT01996514|Experimental|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
16693083|NCT01996514|Experimental|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
16693084|NCT01996514|Experimental|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
16693085|NCT01996514|Experimental|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
16693086|NCT01996501|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
16693087|NCT01996488|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
16693088|NCT01996475|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
16693089|NCT01996462|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
16693090|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
16693091|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
16693095|NCT01996423|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
16693096|NCT01996423|Placebo Comparator|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
16693097|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
16693117|NCT01996319|Active Comparator|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
16693098|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
16693099|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
16693100|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
16693101|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
16693102|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
16693103|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
16693104|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
16693105|NCT01996397|Other|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
16693106|NCT01996384|Experimental|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
16693107|NCT01996384|Active Comparator|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
16693108|NCT01996371|Other|Group 1|Unilateral pedicle screws
16693109|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
16693110|NCT01996371|Other|Group 3|Bilateral pedicle screws
16693111|NCT01996358|Active Comparator|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
16693112|NCT01996358|Active Comparator|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
16693113|NCT01996358|Active Comparator|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
16693114|NCT01996345|Experimental|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
16693115|NCT01996345|No Intervention|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
16693116|NCT01996332|Experimental|Tarceva Arm|
16693118|NCT01996319|Active Comparator|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
16693119|NCT01996306|Active Comparator|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
16693120|NCT01996306|Experimental|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
16693121|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
16693122|NCT01996280|Placebo Comparator|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
16693123|NCT01996280|Experimental|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
16693126|NCT01996254|Experimental|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
16693127|NCT01996254|Sham Comparator|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
16693128|NCT01996241|Experimental|Intervention Village Clusters|Receive multi-level, structural and norms-based intervention
16693129|NCT01996241|No Intervention|Control Village Clusters|No multi-level, structural and norms-based intervention
16693130|NCT01996228|Experimental|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
16693131|NCT01996215||AMD controls|
16693132|NCT01996215||AMD cases|
16693133|NCT01996202|Other|Resected Melanoma|Subjects with resected melanoma.
16693134|NCT01996202|Other|Unresected Melanoma|Subjects with unresected melanoma.
16693135|NCT01996189|Experimental|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
16693136|NCT01996189|Active Comparator|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
16693137|NCT01996176|Experimental|Intervention group|Intervention group
16693138|NCT01996176|Placebo Comparator|Intervention control|Control group
16693139|NCT01996163||Male|
16693140|NCT01996163||Female|
16693141|NCT01996150|Experimental|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
16693142|NCT01996137|Experimental|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
16693143|NCT01996124|Experimental|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
16693144|NCT01996124|Placebo Comparator|Placebo|Placebo Breezehaler
16693145|NCT01996111|Experimental|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
16693146|NCT01996111|Experimental|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
16693147|NCT01996111|Experimental|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
16693148|NCT01996111|Placebo Comparator|• Group 1|• Injection of 1.0 cc of 0.9% Saline
16693149|NCT01996098|Experimental|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
16693150|NCT01996098|Experimental|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
16693151|NCT01996098|No Intervention|Chemotherapy alone|No intervention
16693152|NCT01996085|Experimental|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.
~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
16693153|NCT01996085|Active Comparator|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).
~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
16693154|NCT01996072|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
16693155|NCT01996059|Experimental|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
16693156|NCT01996059|Active Comparator|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
16693157|NCT01996046||Bone mets|Patients will undergo an [18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
16693158|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
16693159|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
16693160|NCT01995994||RT-CGM|
16693161|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
16693162|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
16693163|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
16693164|NCT01995955|Experimental|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
16693165|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
16693166|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
16693167|NCT01995929||neurogenic dysphagia|Patients suffering from neurogenic dysphagia due to several reasons (e.g. Parkinson´s disease).
16693168|NCT01995916|Experimental|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
16693169|NCT01995916|Active Comparator|Social Support Group|Social Support Group Intervention
16693170|NCT01995903|Experimental|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
16693171|NCT01995903|Active Comparator|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
16693172|NCT01995890|Experimental|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
16693173|NCT01995890|No Intervention|control|No intervention in the control arm
16693174|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
16693175|NCT01995864|Experimental|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
16693176|NCT01995864|No Intervention|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
16693177|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
16693178|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
16693179|NCT01995838|Experimental|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
16693180|NCT01995838|Placebo Comparator|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
16693181|NCT01995825|Experimental|Brand lamotrigine then Generic lamotrigine|Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.
16693182|NCT01995825|Experimental|Generic lamotrigine then Brand lamotrigine|Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.
16693183|NCT01995812|Experimental|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
16693184|NCT01995812|No Intervention|Control group|
16693185|NCT01995799|Experimental|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
16693186|NCT01995799|Experimental|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
16693187|NCT01995799|Experimental|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
16693188|NCT01995786|No Intervention|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
16693189|NCT01995786|Experimental|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) < SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
16693190|NCT01995773||Healthy Controls|Healthy control women
16693191|NCT01995721|Experimental|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
16693192|NCT01995708|Experimental|Arm 1 Vaccine|This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical & Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10^6 LCs per dose (i.e., combination of 3x10^6 CT7 mRNA-electroporated LCs + 3x10^6 MAGE-A3 mRNA-electroporated LCs + 3x10^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
16693193|NCT01995708|Active Comparator|Arm 2 control|Patients receive standard of care treatment after autologous stem cell transplant
16693194|NCT01995695|Experimental|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
16693195|NCT01995695|Experimental|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
16693196|NCT01995669|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
16693197|NCT01995656|Placebo Comparator|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
16693198|NCT01995656|Experimental|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
16693199|NCT01995656|Placebo Comparator|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
16693200|NCT01995656|Experimental|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
16693201|NCT01995656|Placebo Comparator|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
16693202|NCT01995656|Experimental|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
16693203|NCT01995643|Active Comparator|Active Capsule|Grape Seed Extract Capsule: 300 mg
16693204|NCT01995643|Placebo Comparator|Placebo Capsule|Placebo Capsule: Maltodextrin
16693205|NCT01995630|Experimental|Hypermetropic, spherical IOL|AMO Sensar AR40e
16693206|NCT01995630|Experimental|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
16693207|NCT01995630|Active Comparator|Emmetropic, spherical IOL|AMO Sensar AR40e
16693208|NCT01995630|Active Comparator|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
16693209|NCT01995617|Experimental|Low Dose (Cohort 1)|
16693210|NCT01995617|Experimental|Mid Dose (Cohort 2)|
16693211|NCT01995617|Experimental|High Dose (Cohort 3)|
16693212|NCT01995604|Experimental|dHACM|UltraPulse laser therapy with application of dHACM
16693213|NCT01995604|Placebo Comparator|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
16693214|NCT01995578|Experimental|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
16693215|NCT01995552|Other|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
16693216|NCT01995539|Experimental|iPro2 Use|All subjects wearing iPro2, having therapy regimens, and having baseline and EOS A1C tests
16693217|NCT01995526|Experimental|Insulin Peglispro|Single subcutaneous dose of 1.3 Units per kilogram (U/kg) insulin peglispro on Day 1.
16693218|NCT01995513|Experimental|Enzalutamide & Abiraterone/prednisone|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
16693219|NCT01995513|Active Comparator|Enzalutamide placebo & Abiraterone/prednisone|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
16693220|NCT01995500|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:
~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent
~Delivery System - Rapid Exchange (RX) Coronary System
~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®
~Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
16693221|NCT01995500|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:
~Endeavor Resolute Stent - a premounted cobalt alloy based stent
~Delivery system - Rapid Exchange (RX) Coronary System
~Polymer system
~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
16693222|NCT01995487|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:
~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent
~Delivery System - Rapid Exchange (RX) Coronary System
~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®
~Ridaforolimus drug - CAS Registry Number: 572924-54-0
~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
16693223|NCT01995487|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:
~Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent
~Delivery system (Rapid Exchange [RX] Coronary System)
~Polymer system
~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
16693224|NCT01995474|Experimental|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
16693225|NCT01995474|Active Comparator|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
16693226|NCT01995461|Experimental|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
16693227|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
16693228|NCT01995435|Experimental|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
16693229|NCT01995435|Experimental|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
16693230|NCT01995422|Experimental|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
16693231|NCT01995396|Active Comparator|APE with intersphincteric dissection|Abdominoperineal excision with intersphincteric dissection and a stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
16693232|NCT01995396|Active Comparator|Hartmann´s procedure|Hartmann´s operation and stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
16693233|NCT01995383|Placebo Comparator|Part 1: Placebo (PL)|
16693234|NCT01995383|Experimental|Part 1: Single Ascending Doses (SAD) of RO6836191|
16693235|NCT01995383|Placebo Comparator|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
16693236|NCT01995383|Placebo Comparator|Part 2: PL: NS followed by LS diet|
16693237|NCT01995383|Experimental|Part 2: RO6836191: LS followed by NS diet|
16693238|NCT01995383|Experimental|Part 2: RO6836191: NS followed by LS diet|
16693239|NCT01995370|Active Comparator|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.
~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
16693240|NCT01995370|Experimental|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).
~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
16693241|NCT01995357|Experimental|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
16693242|NCT01995357|Experimental|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
16693243|NCT01995357|Experimental|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
16693244|NCT01995357|Experimental|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
16693245|NCT01995357|Experimental|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
16693246|NCT01995357|Experimental|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
16693247|NCT01995344|Active Comparator|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
16693248|NCT01995344|Active Comparator|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
16693249|NCT01995331|Other|moderate-dose cyclophosphomide|
16693250|NCT01995318|Placebo Comparator|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
16693251|NCT01995318|Other|Kinesiotaping|Application of anti-edema kinesiotaping
16693252|NCT01995292|Experimental|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
16693253|NCT01995292|Experimental|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
16693254|NCT01995279|Experimental|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
16693255|NCT01995279|Placebo Comparator|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
16693256|NCT01995266|Experimental|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and
~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
16693257|NCT01995253|Experimental|Controlled conditions|
16693259|NCT01995240|Experimental|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.
16693260|NCT01995240|Experimental|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.
16693261|NCT01995227|Experimental|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
16693262|NCT01995214|Experimental|P|Anesthesia maintenance with propofol+remifentanil
16693263|NCT01995214|Experimental|S|Anesthesia maintenance with sevoflurane+remifentanil
16693264|NCT01995201|Experimental|Part 1: All patients|
16693265|NCT01995201|Experimental|Part 2 A: Sustained clinical remission|
16693266|NCT01995201|Experimental|Part 2 B: Low disease activity|
16693267|NCT01995188|Experimental|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
16693268|NCT01995188|Experimental|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
16693269|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
16693270|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
16693272|NCT01995162|Experimental|Free-living conditions|
16693273|NCT01995149|Experimental|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
16693274|NCT01995136|Experimental|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
16693275|NCT01995123|Experimental|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
16693276|NCT01995123|Active Comparator|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
16693277|NCT01995110|Experimental|normal weight subjects|
16693278|NCT01995110|Experimental|obese subjects|
16693279|NCT01995097|Experimental|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
16693280|NCT01995097|Active Comparator|Support Messages Only|support text messages through 35th week of pregnancy
16693281|NCT01995084|Experimental|Optimization|Patients undergo a [F-18]HX4 PET/CT scan 2,3 and 4h after [F-18]HX4 injection.
16693282|NCT01995084|Experimental|Reproducibility|Patients undergo two [F-18]HX4 PET/CT scans 3.5h after [F-18]HX4 injection within a 10-day time frame.
16693283|NCT01995071|Experimental|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily [QD]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693284|NCT01995071|Experimental|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693285|NCT01995071|Experimental|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693286|NCT01995071|Experimental|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693287|NCT01995071|Experimental|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693288|NCT01995071|Experimental|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693427|NCT01994135|Experimental|Test food dose 1|Test food dose 1 response will be compared to reference test food
16693289|NCT01995071|Experimental|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693290|NCT01995071|Experimental|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693291|NCT01995071|Experimental|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693292|NCT01995071|Experimental|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693293|NCT01995071|Experimental|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693294|NCT01995071|Experimental|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16693295|NCT01995058|Experimental|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
16693296|NCT01995058|Experimental|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
16693297|NCT01995058|Experimental|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
16693298|NCT01995058|Active Comparator|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
16693299|NCT01995045|Experimental|Bupivicaine & Triamcinolone|Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
16693300|NCT01995045|Active Comparator|Bupivicaine|Retrobulbar anesthesia with Bupivicaine Hydrochloride
16693301|NCT01995032|Experimental|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
16693302|NCT01995032|Placebo Comparator|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
16693303|NCT01995019|Placebo Comparator|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
16693304|NCT01995019|Experimental|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
16693305|NCT01995006|Experimental|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
16693306|NCT01995006|Active Comparator|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
16693307|NCT01994993|Active Comparator|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
16693308|NCT01994993|Active Comparator|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
16693309|NCT01994993|Active Comparator|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
16693310|NCT01994993|Active Comparator|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
16693311|NCT01994993|Active Comparator|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
16693312|NCT01994980|Active Comparator|Default 4 days antibiotic therapy|Default 4 days antibiotic therapy
16693313|NCT01994980|No Intervention|Default 8 days antibiotic therapy|Default 8 days antibiotic therapy
16693314|NCT01994967|Experimental|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride
~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
16693315|NCT01994967|Active Comparator|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride
~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
16693316|NCT01994954|No Intervention|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
16693317|NCT01994954|Experimental|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.
~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
16693318|NCT01994941|Experimental|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.
~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
16693347|NCT01994733|Experimental|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
16693389|NCT01994460|Experimental|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
16693390|NCT01994447|No Intervention|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
16693319|NCT01994941|Active Comparator|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).
~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
16693320|NCT01994928|Active Comparator|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
16693321|NCT01994928|Experimental|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
16693322|NCT01994915|Experimental|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
16693323|NCT01994915|No Intervention|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
16693324|NCT01994902|Experimental|First Coloplast test product|"The subjects test:
~test period 1: Coloplast test product test period 2: SenSura Convex Light"
16693325|NCT01994902|Experimental|First SenSura Convex Light|"The subjects test:
~test period 1: SenSura Convex Light test period 2: Coloplast test product"
16693326|NCT01994889|Experimental|Tafamidis - 20 mg|Active Treatment-Low dose
16693327|NCT01994889|Experimental|Tafamidis - 80 mg|Active Treatment-High Dose
16693328|NCT01994889|Placebo Comparator|Placebo|Placebo control
16693329|NCT01994876|Experimental|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement
~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
16693330|NCT01994876|Experimental|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements
~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
16693331|NCT01994863|Experimental|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.
~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.
~The three Standard Care products were tested in a 1:1:1 randomisation."
16693332|NCT01994863|Experimental|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.
~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.
~The three Standard Care products were tested in a 1:1:1 randomisation."
16693333|NCT01994850|Experimental|Phase I/II|"Total of six 21-day cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP). Cycle 1 rituximab dose divided between Days 1 and 2 to prevent severe infusion reactions in rituximab naïve patients; brentuximab vedotin and cytotoxic chemotherapy administered on Day 2. Cycles 2 through 6 brentuximab vedotin and R-CHP administered on Day 1. Prednisone (or steroid equivalent) administered Days 1-5 of each cycle (prior to rituximab infusion).
~Cycle 1:
~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 100 mg/m2 IV; Day 2: Rituximab 275 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg or 1.2 mg/kg (Phase I data established a MTD of 1.8 mg/kg brentuximab vedotin)
~Cycles 2-6:
~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 375 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg"
16693334|NCT01994837|Experimental|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
16693335|NCT01994824|Experimental|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.
~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
16693336|NCT01994785|Active Comparator|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
16693337|NCT01994785|Active Comparator|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
16693338|NCT01994785|Active Comparator|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
16693339|NCT01994785|Active Comparator|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
16693340|NCT01994772|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
16693341|NCT01994772|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
16693342|NCT01994759|Active Comparator|Training|strengthening and stretching exercises.
16693343|NCT01994759|Active Comparator|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
16693344|NCT01994759|Active Comparator|Training and Glucocorticosteroid injections|A combination treatment of the two above.
16693345|NCT01994746|Experimental|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
16693346|NCT01994746|Active Comparator|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular [IM]).
16693388|NCT01994460|Experimental|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
16693348|NCT01994733|Active Comparator|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
16693349|NCT01994720|Experimental|ticagrelor|
16693350|NCT01994720|Active Comparator|Acetylsalicylic acid (ASA)|
16693351|NCT01994707|Active Comparator|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
16693352|NCT01994707|Placebo Comparator|Placebo|Deflated cuff on arm for 30 minutes.
16693353|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
16693354|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
16693355|NCT01994681||Pancreatic Cancer|
16693356|NCT01994681||Healthy|
16693357|NCT01994668|Experimental|Lorazepam|
16693358|NCT01994668|Placebo Comparator|Placebo|
16693359|NCT01994655|Experimental|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
16693360|NCT01994642|Active Comparator|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
16693361|NCT01994642|Placebo Comparator|Placebo|Placebo Sterile Otic Suspension
16693362|NCT01994642|Experimental|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
16693363|NCT01994629|Experimental|MenACWY-CRM|MenACWY-CRM
16693364|NCT01994629|Active Comparator|MenACWY-TT|MenACWY-TT
16693365|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
16693366|NCT01994603|Experimental|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
16693367|NCT01994603|Experimental|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
16693368|NCT01994590|Experimental|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.
~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.
~Participant to take 5 mg oral prednisone, twice daily."
16693369|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
16693370|NCT01994538|Active Comparator|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
16693371|NCT01994538|Placebo Comparator|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
16693372|NCT01994525|Experimental|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.
~Challenge occurs 3 weeks after final immunization."
16693373|NCT01994525|Placebo Comparator|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.
~Challenge occurs 3 weeks after final immunization."
16693374|NCT01994525|Other|Cohort 1: Nonimmunized|"No protective intervention given.
~Challenge occurs directly after screening."
16693375|NCT01994525|Experimental|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.
~Challenge occurs 3 weeks after final immunization."
16693376|NCT01994525|Placebo Comparator|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.
~Challenge occurs 3 weeks after final immunization."
16693377|NCT01994525|Other|Cohort 2: Nonimmunized|"No protective intervention given.
~Challenge occurs directly after screening."
16693378|NCT01994525|Experimental|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort
~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.
~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
16693379|NCT01994512|Experimental|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
16693380|NCT01994512|Experimental|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
16693381|NCT01994499|Experimental|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
16693382|NCT01994499|Active Comparator|Medical pleural drainage|Medical drainage
16693383|NCT01994486|Experimental|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
16693384|NCT01994473|Experimental|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
16693385|NCT01994473|Placebo Comparator|Placebo|An oral of matched placebo
16693386|NCT01994473|Experimental|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
16693387|NCT01994460|Active Comparator|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
16693391|NCT01994447|Experimental|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
16693392|NCT01994434|Other|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
16693393|NCT01994421|Sham Comparator|Kinesiotape|
16693394|NCT01994408|Experimental|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
16693395|NCT01994395|Experimental|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
16693396|NCT01994395|Active Comparator|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
16693397|NCT01994382|Experimental|cerdulatinib (PRT062070)|Intervention: Drug: cerdulatinib (PRT062070) or cerdulatinib (PRT062070) plus rituximab
16693398|NCT01994369|Experimental|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
16693399|NCT01994356|Active Comparator|Usual contraceptive counseling|subjects received usual contraceptive counseling
16693400|NCT01994356|Experimental|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
16693401|NCT01994343|Experimental|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
16693402|NCT01994343|No Intervention|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
16693403|NCT01994330|Experimental|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
16693404|NCT01994330|Placebo Comparator|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
16693405|NCT01994317|Active Comparator|Standard sedation dose|IV sedation dose calculated using current standard of care
16693406|NCT01994317|Experimental|Algorithm|IV sedation dose calculated by study algorithm
16693407|NCT01994304|No Intervention|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
16693408|NCT01994304|Active Comparator|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
16693409|NCT01994291|Active Comparator|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
16693410|NCT01994291|Experimental|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
16693411|NCT01994278|Experimental|Tooth brush|Periclean is a soft rubber gentle toothbrush
16693412|NCT01994265|Active Comparator|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
16693413|NCT01994265|Active Comparator|Dabigatran|Dabigatran 150 mg twice daily
16693414|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
16693415|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
16693416|NCT01994239|Active Comparator|Radiation|"Pelvic radiotherapy
~46 Gy in 23 fractions of 2 Gy.
~prostate only-boost up to 66 Gy"
16693417|NCT01994239|Experimental|Radiation and Degarelix|"Radiotherapy:
~46 Gy in 23 fractions of 2 Gy.
~prostate only-boost up to 66 Gy
~Associated with hormonal therapy by degarelix:
~beginning in parallel to radiotherapy for 6 months
~First dose of 240 mg
~Maintenance dose of 80 mg"
16693418|NCT01994226|Active Comparator|Low-dose colchicine|500 mcg every eight hours for four days
16693419|NCT01994226|Active Comparator|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
16693420|NCT01994213|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
16693421|NCT01994200|Experimental|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
16693422|NCT01994200|Other|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
16693423|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
16693424|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
16693425|NCT01994148|Experimental|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
16693426|NCT01994135|Active Comparator|Reference food|The reference food is white bread
16693428|NCT01994135|Experimental|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
16693429|NCT01994122||People who have dropped out of school|
16693430|NCT01994122||College students (control group)|
16693431|NCT01994109|Active Comparator|MYOBLOC 2500 U|Subjects will receive specified dose of MYOBLOC
16693432|NCT01994109|Active Comparator|MYOBLOC 3500 U|Subjects will receive specified dose of MYOBLOC
16693433|NCT01994109|Placebo Comparator|Placebo|Subjects will receive volume matched Placebo
16693434|NCT01994096|Experimental|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
16693435|NCT01994083|Placebo Comparator|Placebo|Placebo
16693436|NCT01994083|Experimental|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
16693437|NCT01994070|Active Comparator|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
16693438|NCT01994070|Active Comparator|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
16693439|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.
~resistant patients were defined as patients reached PD after first month administration and first three months administration"
16693440|NCT01994044|Active Comparator|Multimodal rehabilitation|
16693441|NCT01994044|Active Comparator|Cervical fusion|
16693442|NCT01994031|Experimental|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
16693443|NCT01994031|Experimental|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
16693444|NCT01994031|Experimental|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
16693445|NCT01994031|Experimental|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
16693446|NCT01994031|Experimental|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
16693447|NCT01994031|Active Comparator|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
16693448|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
16693449|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
16693450|NCT01994005|Placebo Comparator|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
16693451|NCT01994005|Active Comparator|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
16693452|NCT01993979|Other|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
16693453|NCT01993979|Experimental|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
16693454|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
16693455|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
16693456|NCT01993966||non-tumoral|specimens come from non-tumoral patients
16693457|NCT01993953|Active Comparator|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
16693458|NCT01993953|Active Comparator|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
16693459|NCT01993953|Active Comparator|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
16693460|NCT01993953|No Intervention|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
16693461|NCT01993940|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
16693462|NCT01993940|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
16693463|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
16693464|NCT01993901|Experimental|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
16693498|NCT01993654||Nevus|
16693499|NCT01993654||Racial Melanosis|
16693465|NCT01993901|No Intervention|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
16693466|NCT01993888|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
16693467|NCT01993888|Other|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
16693468|NCT01993875|Experimental|Lubiprostone|
16693469|NCT01993875|Placebo Comparator|Placebo|
16693470|NCT01993862|No Intervention|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
16693471|NCT01993862|Active Comparator|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
16693472|NCT01993849|Active Comparator|N-Acetylcysteine (NAC)|Oral N-acetylcysteine 1200 mg twice daily dosing for 8 weeks
16693473|NCT01993849|Placebo Comparator|Placebo|Oral placebo (matched in appearance to active treatment) twice daily dosing for 8 weeks
16693474|NCT01993836|Active Comparator|Total Intravenous Anesthesia with Propofol|Patients in this arm will receive general anesthesia with propofol as the primary amnestic agent.
16693475|NCT01993836|Active Comparator|General anesthesia with Isoflurane|Patients in this arm will undergo general anesthesia with isoflurane as the primary amnestic agent.
16693476|NCT01993823|Experimental|G238|Five drops into the ear canal twice daily for 14 days
16693477|NCT01993823|Active Comparator|Clotrimazole|Five drops into the ear canal twice daily for 14 days
16693478|NCT01993810|Active Comparator|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* IV over 1 hour and carboplatin* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.
~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
16693479|NCT01993810|Experimental|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* and carboplatin*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.
~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
16693480|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
16693481|NCT01993784|Experimental|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
16693482|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
16693483|NCT01993758|Active Comparator|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
16693484|NCT01993758|Experimental|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
16693485|NCT01993745||Study group|ECMO Patients survived
16693486|NCT01993745||Control|ECMO Patient died
16693487|NCT01993732|Experimental|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
16693492|NCT01993693|Experimental|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
16693493|NCT01993693|Placebo Comparator|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
16693494|NCT01993680|Experimental|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
16693495|NCT01993680|Active Comparator|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
16693496|NCT01993667|Active Comparator|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
16693497|NCT01993667|Experimental|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
16693503|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
16693504|NCT01993628|Experimental|Alzheimer's disease (AD)|Rey figure test and MRI
16693505|NCT01993628|Experimental|Lewy body's dementia (LBD)|Rey figure test and MRI
16693506|NCT01993615|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetabular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
16693507|NCT01993615|Active Comparator|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
16693508|NCT01993602|No Intervention|Control group|no intervention was performed in this group during postoperative period,
16693509|NCT01993602|Active Comparator|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
16693510|NCT01993602|Active Comparator|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
16693511|NCT01993602|Active Comparator|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
16693512|NCT01993602|Active Comparator|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
16693513|NCT01993589|No Intervention|Control group|Control group
16693514|NCT01993589|Active Comparator|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
16693515|NCT01993589|Active Comparator|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
16693516|NCT01993589|Active Comparator|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
16693517|NCT01993589|Active Comparator|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
16693518|NCT01993589|Active Comparator|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
16693519|NCT01993576|Experimental|indocyanine green|Indocyanine green is injected intravenously.
16693520|NCT01993563|Experimental|Graded Motor Imagery|
16693521|NCT01993563|Active Comparator|Standard treatment|
16693522|NCT01993550|Experimental|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
16693523|NCT01993550|Active Comparator|Education|Overview of resources for psychosocial support and health information
16693524|NCT01993537|No Intervention|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
16693525|NCT01993537|No Intervention|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
16693526|NCT01993537|No Intervention|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
16693527|NCT01993537|Experimental|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
16693528|NCT01993524|Experimental|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
16693529|NCT01993524|Placebo Comparator|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
16693530|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L
16693531|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L
16693532|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L
16693533|NCT01993498|Other|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
16693534|NCT01993472|Experimental|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
16693535|NCT01993472|Active Comparator|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
16693536|NCT01993459|Experimental|Midazolam intravenous|3mg/ml midazolam given intravenously
16693537|NCT01993459|Placebo Comparator|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
16693538|NCT01993446|Experimental|DRM02|DRM02 Topical Gel, 0.25%
16693539|NCT01993446|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
16693540|NCT01993433|Experimental|DRM02|DRM02 Topical Gel, 0.25%
16693541|NCT01993433|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
16693542|NCT01993420|Experimental|DRM02|DRM02 Topical Gel, 0.25%
16693543|NCT01993420|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
16693544|NCT01993407|Experimental|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
16693609|NCT01992991|Sham Comparator|Sham stimulation|30 sek of Transcranial direct current stimulation
16693545|NCT01993407|Placebo Comparator|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
16693546|NCT01993394|Experimental|ventilation|hypergravity gas mixture
16693547|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
16693548|NCT01993368|Other|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
16693549|NCT01993368|Other|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
16693550|NCT01993368|Other|controls|necessitating an extraction of wisdom teeth
16693551|NCT01993355|Active Comparator|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
16693552|NCT01993355|Experimental|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
16693553|NCT01993355|Experimental|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
16693554|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
16693555|NCT01993329|Experimental|Gefapixant 50/ Gefapixant 300/ Placebo|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
16693556|NCT01993329|Experimental|Gefapixant 50/ Placebo/ Gefapixant 300|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
16693557|NCT01993329|Experimental|Gefapixant 300/ Gefapixant 50/ Placebo|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
16693558|NCT01993329|Experimental|Gefapixant 300/ Placebo/ Gefapixant 50|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
16693559|NCT01993329|Experimental|Placebo/ Gefapixant 50/ Gefapixant 300|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
16693560|NCT01993329|Experimental|Placebo/ Gefapixant 300/ Gefapixant 50|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
16693561|NCT01993316|Experimental|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
16693562|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
16693563|NCT01993290|Active Comparator|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
16693564|NCT01993290|Active Comparator|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
16693565|NCT01993290|Active Comparator|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
16693566|NCT01993277|Active Comparator|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
16693567|NCT01993277|Active Comparator|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
16693568|NCT01993277|Active Comparator|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
16693569|NCT01993277|Active Comparator|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
16693570|NCT01993251|Active Comparator|melatonin 0.5mg|
16693571|NCT01993251|Active Comparator|melatonin 2mg|
16693572|NCT01993251|Active Comparator|melatonin 6mg|
16693573|NCT01993251|Placebo Comparator|placebo|
16693574|NCT01993238|Experimental|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
16693575|NCT01993225|Placebo Comparator|Placebo|Placebo Gel and Placebo capsules
16693576|NCT01993225|Experimental|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
16693577|NCT01993225|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
16693578|NCT01993212|Placebo Comparator|Placebo|Androxal Placebo and Gel Placebo
16693579|NCT01993212|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
16693580|NCT01993212|Experimental|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
16693581|NCT01993199|Active Comparator|deep biopsy|
16693610|NCT01992978|Experimental|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
16693582|NCT01993186|Experimental|UX007|"Participants randomized to receive UX007 enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.
~Following completion of the Week 8 study visit, participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
16693583|NCT01993186|Placebo Comparator|Placebo|"Participants randomized to receive placebo enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.
~Following completion of the Week 8 study visit, placebo participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
16693584|NCT01993173|Experimental|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
16693585|NCT01993173|Active Comparator|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
16693586|NCT01993160|Experimental|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
16693587|NCT01993147|Other|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
16693588|NCT01993134|Experimental|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
16693589|NCT01993134|Active Comparator|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
16693590|NCT01993121|Experimental|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
16693591|NCT01993108|Experimental|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
16693592|NCT01993108|Experimental|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
16693593|NCT01993095|Experimental|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
16693594|NCT01993095|Active Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
16693595|NCT01993082|Experimental|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.
~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
16693596|NCT01993082|No Intervention|Activity Maintenance Group|Participants randomized into the waitlist control group receive no aerobic training. Wait-list control participants will receive monthly check-in phone calls to establish that they have not significantly increased activity engagement. Participants in this group will receive a free gym membership at the end of the study, monthly phone calls with a fitness coach support provider for 6 months, and 2 coaching text messages per week.
16693597|NCT01993069|Experimental|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
16693598|NCT01993056|Experimental|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
16693599|NCT01993056|Placebo Comparator|control|the control group follows its regular training routine
16693600|NCT01993030|Experimental|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
16693601|NCT01993030|Active Comparator|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
16693602|NCT01993017|Experimental|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
16693603|NCT01993017|Active Comparator|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
16693604|NCT01993017|Placebo Comparator|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
16693605|NCT01993004||Healthy subjects|Self-explanatory
16693606|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
16693607|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
16705787|NCT01911871||thalassemia|patients affected with thalassemia
16693611|NCT01992978|Active Comparator|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
16693612|NCT01992965|Experimental|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:
~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
16693613|NCT01992965|Active Comparator|Conventional Group|"Conventional Group：
~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
16693614|NCT01992952|Experimental|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
16693615|NCT01992952|Active Comparator|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
16693616|NCT01992939|Active Comparator|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
16693617|NCT01992939|Active Comparator|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
16693618|NCT01992926|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
16693619|NCT01992926|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
16693620|NCT01992913|Experimental|iCBT|integrated CBT with computerized cognitive remediation
16693621|NCT01992913|Other|UC|usual care
16693622|NCT01992900|Experimental|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
16693623|NCT01992900|Active Comparator|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
16693624|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
16693625|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
16693626|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
16693627|NCT01992874|Experimental|Pimasertib Capsule/Pimasertib Tablet|
16693628|NCT01992874|Experimental|Pimasertib Tablet/Pimasertib Capsule|
16693629|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
16693630|NCT01992848|Experimental|All participants|"Venous blood sampling 4-day food diary
~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
16693631|NCT01992835|Placebo Comparator|measurement of mediators in biological fluids|
16693632|NCT01992835|Experimental|Grass pollen allergen extract|
16693633|NCT01992822|Experimental|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
16693634|NCT01992809|Active Comparator|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
16693635|NCT01992809|Placebo Comparator|placebo mineral oil|placebo mineral oil 3 ml/day
16693636|NCT01992796|Experimental|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).
~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.
~Route of administration : oral by nasogastric tube.
~Medication permitted and not permitted during the trial:
~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
16693637|NCT01992796|Placebo Comparator|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
16693638|NCT01992783|Experimental|Hi-maize resistant starch|13.5 g/day
16693639|NCT01992783|Placebo Comparator|Maltodextrin|13.5 g/day
16693640|NCT01992770|Experimental|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring >90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
16693641|NCT01992770|Active Comparator|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
16693642|NCT01992757||Cardiac surgery with cardiopulmary bypass|
16693643|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
16693644|NCT01992731|Active Comparator|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).
~vs."
16693645|NCT01992731|Active Comparator|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.
~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
16693646|NCT01992718|Active Comparator|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
16693647|NCT01992718|Active Comparator|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
16693648|NCT01992705|Other|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:
~Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.
~Stereotactic Body Radiotherapy (SBRT):
~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
16693649|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
16693650|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
16693651|NCT01992679|No Intervention|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
16693652|NCT01992679|Experimental|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
16693653|NCT01992666|Experimental|Blood sampling|
16693654|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
16693655|NCT01992653|Experimental|Polatuzumab Vedotin (1.0mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
16693656|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
16693657|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
16693658|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
16693659|NCT01992653|Experimental|Polatuzumab Vedotin (2.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
16693660|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
16693661|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
16693662|NCT01992627|Experimental|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
16693663|NCT01992614|Experimental|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
16693664|NCT01992614|Experimental|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
16693665|NCT01992614|Experimental|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
16693666|NCT01992601|Experimental|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
16693667|NCT01992601|Experimental|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
16693668|NCT01992601|Experimental|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
16693669|NCT01992601|Experimental|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
16693670|NCT01992588|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
16693671|NCT01992588|Experimental|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
16693672|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
16693673|NCT01992562|Experimental|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
16693674|NCT01992562|Placebo Comparator|Placebo|1ml of normal saline bolus intrathecal injection
16693675|NCT01992549|Experimental|Human-cl rhFVIII|
16693676|NCT01992536|Experimental|Ia: MenABCWY+OMV|Investigational
16693677|NCT01992536|Placebo Comparator|Ib: Placebo|Saline
16693678|NCT01992536|Experimental|IIa: MenABCWY+¼OMV|Investigational
16693679|NCT01992536|Placebo Comparator|IIb: Placebo|Saline
16693680|NCT01992536|Experimental|IIIa: MenABCWY+OMV|Investigational
16693681|NCT01992536|Experimental|IIIb: MenABCWY+¼OMV|Investigational
16693682|NCT01992536|Experimental|IVa: MenABCWY+OMV|Investigational
16693683|NCT01992536|Experimental|IVb: MenABCWY+¼OMV|Investigational
16693684|NCT01992536|Placebo Comparator|IVc: Placebo|Saline
16693685|NCT01992523|Experimental|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
16693686|NCT01992523|Active Comparator|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
16693687|NCT01992510||silicone oil fiiled eye|those with a condition
16693688|NCT01992510||fellow eye|the contralateral eye in the same patient
16693689|NCT01992497|Placebo Comparator|Formula + placebo|
16693690|NCT01992497|Experimental|Formula + probiotic|Formula + probiotic
16693691|NCT01992497|Experimental|Breastfed + probiotic|Breastfed + probiotic
16693692|NCT01992497|Placebo Comparator|Breastfed + placebo|
16693693|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
16693694|NCT01992445||Suicidal|
16693695|NCT01992445||Other mental health|
16693696|NCT01992445||Control (non suicidal, non mental health)|
16693697|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
16693698|NCT01992406||Transrectal hybrid-NOTES anterior resection|
16693699|NCT01992393|Experimental|TIME|This arm will receive the TIME intervention.
16693700|NCT01992393|No Intervention|Treatment as Usual (TAU)|This arm will receive treatment as usual.
16693701|NCT01992380|Experimental|Healthy Volunteer Subjects|Healthy males or females 50 years or older with no evidence of cognitive impairment
16693702|NCT01992380|Experimental|MCI subjects|Subjects 50 years or older with mild cognitive impairment (MCI)
16693703|NCT01992380|Experimental|Probable AD Subjects|Subjects 50 years or older with probable Alzheimer's Disease (AD)
16693704|NCT01992367|Placebo Comparator|Placebo|placebo arm
16693705|NCT01992367|Other|ASLAN003|Active drug
16693706|NCT01992354|Experimental|Single Arm|Evaluation of PET MR device for image assessment and device performance
16693707|NCT01992341|Experimental|AMG 386 15mg/kg and paclitaxel 80mg/m2|
16693708|NCT01992328|Experimental|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
16693709|NCT01992315|Experimental|Adipose-Derived ECM|
16693710|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
16693711|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
16693712|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
16693713|NCT01992276|Experimental|CR8020|Investigational monoclonal antibody against influenza A viruses
16693714|NCT01992276|Experimental|CR6261|Investigational monoclonal antibody against influenza A viruses
16693715|NCT01992276|Placebo Comparator|Placebo|Dextrose: 5% in water
16693716|NCT01992263|Experimental|Vitamin D (600 IU)|
16693717|NCT01992263|Experimental|Vitamin D (2000 IU)|
16693718|NCT01992263|Experimental|Vitamin D (4000 IU)|
16693719|NCT01992263|Placebo Comparator|Placebo|
16693720|NCT01992250|Other|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
16693721|NCT01992250|Other|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
16693722|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
16693723|NCT01992224|Experimental|early mechanical ventilation|"Fulfillment of three or more criteria below:
~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation
~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
16693724|NCT01992224|Experimental|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
16693725|NCT01992211|Experimental|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
16693726|NCT01992211|Experimental|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
16693727|NCT01992211|Experimental|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
16693728|NCT01992211|Experimental|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
16693798|NCT01991743|Active Comparator|Group 7.5|Administration of 7.5mg bupivacaine.
16693729|NCT01992211|Experimental|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
16693730|NCT01992211|Experimental|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
16693731|NCT01992198|Experimental|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
16693732|NCT01992198|Active Comparator|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
16693733|NCT01992185|Active Comparator|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
16693734|NCT01992185|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
16693735|NCT01992172|Active Comparator|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
16693736|NCT01992172|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
16693737|NCT01992159|Placebo Comparator|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
16693738|NCT01992159|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
16693739|NCT01992159|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
16693740|NCT01992159|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
16693741|NCT01992146|Placebo Comparator|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
16693742|NCT01992146|Experimental|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
16693743|NCT01992133|Experimental|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
16693744|NCT01992133|Placebo Comparator|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
16693745|NCT01992120|Experimental|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:
~Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient
~Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)
~Subjects will take a written test focusing on early recognition and management of sepsis
~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient
~In the second visit:
~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios
~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis
~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
16693746|NCT01992120|Placebo Comparator|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:
~Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient
~Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios
~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis
~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient
~In the second visit:
~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios
~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis
~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
16693747|NCT01992107|Experimental|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
16693748|NCT01992107|Active Comparator|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
16693749|NCT01992107|Active Comparator|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
16693750|NCT01992094|Experimental|QIVc|Influenza vaccine
16693751|NCT01992094|Active Comparator|TIV1c|Influenza vaccine
16693752|NCT01992094|Active Comparator|TIV2c|Influenza vaccine
16693753|NCT01992081|Experimental|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
16693754|NCT01992081|Other|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
16693755|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:
~Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment
~Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
16693756|NCT01992055|Experimental|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
16705790|NCT01911858|Experimental|Askina Calgitrol Paste|
16693757|NCT01992055|Active Comparator|Education & relaxation training|Education and relaxation training control group
16693758|NCT01992042|Experimental|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
16693759|NCT01992029||ALS Patients|
16693760|NCT01992029||Control patients suffering from neuropathy|
16693761|NCT01992029||Control patients suffering from myopathy|
16693762|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
16693763|NCT01992016|Experimental|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
16693764|NCT01992016|Experimental|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
16693765|NCT01992003||Patients undergoing spine surgery|
16693766|NCT01991990|Placebo Comparator|Placebo|
16693767|NCT01991990|Experimental|RoActemra/Actemra|
16693768|NCT01991977|Experimental|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
16693769|NCT01991964|Experimental|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
16693770|NCT01991964|Other|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
16693771|NCT01991951|Experimental|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
16693772|NCT01991951|Active Comparator|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
16693773|NCT01991938|Experimental|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
16693774|NCT01991925||quality of life, quality of care|
16693775|NCT01991912|Experimental|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
16693776|NCT01991899|Experimental|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
16693777|NCT01991899|Active Comparator|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
16693778|NCT01991886|Experimental|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
16693779|NCT01991873|Experimental|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:
~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15
~Re-induction upon progression:
~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.
~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
16693780|NCT01991873|Experimental|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:
~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15
~Re-induction upon progression:
~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.
~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
16693781|NCT01991860|Experimental|APD421|APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
16693782|NCT01991860|Placebo Comparator|Placebo|Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia
16693783|NCT01991847|Experimental|Physical activity|Physical activity
16693784|NCT01991834|Placebo Comparator|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
16693785|NCT01991834|Active Comparator|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
16693786|NCT01991821|Experimental|APD421|IV APD421 single dose
16693787|NCT01991821|Placebo Comparator|Placebo|IV placebo single dose
16693788|NCT01991808|Experimental|DCE-MRI|
16693789|NCT01991795|Experimental|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
16693790|NCT01991795|Placebo Comparator|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
16693791|NCT01991782|No Intervention|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
16693792|NCT01991782|Experimental|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
16693793|NCT01991769|Experimental|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
16693794|NCT01991769|Active Comparator|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
16693795|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
16693796|NCT01991743|Active Comparator|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
16693797|NCT01991743|Active Comparator|Group 5|Administration of 5 mg bupivacaine.
16707383|NCT01900782|Experimental|Dosing Regimen 2|Subcutaneous injection
16693799|NCT01991743|Active Comparator|Group 10|Administration of 10 mg bupivacaine.
16693800|NCT01991717|Experimental|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
16693801|NCT01991717|Other|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
16693802|NCT01991691|Experimental|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
16693803|NCT01991678|Experimental|normal hepatic function|12 Patients will receive a 90-minute IV infusion
16693804|NCT01991678|Experimental|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
16693805|NCT01991678|Experimental|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
16693806|NCT01991665|Other|Group A|Digital examination before instrumental delivery to determine fetal head station and position
16693807|NCT01991665|Other|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
16693808|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).
~One group of patients."
16693809|NCT01991639|No Intervention|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
16693810|NCT01991639|Experimental|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
16693811|NCT01991626|Other|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
16693812|NCT01991626|Other|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
16693813|NCT01991626|Other|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
16693814|NCT01991626|Other|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
16693815|NCT01991626|Other|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
16693816|NCT01991626|Other|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
16693817|NCT01991626|Other|phytase|Maize meal containing micronutrient powder and phytase
16693818|NCT01991626|Other|MNP-control|maize meal containing micronutrient powder (MNP)
16693819|NCT01991626|Other|FePP control|Maize meal containing FePP
16693820|NCT01991626|Other|FeSO4 control|Maize meal containing FeSO4
16693821|NCT01991613|Experimental|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
16693822|NCT01991613|No Intervention|Control group|Study subjects will receive standard of care nutrition
16693823|NCT01991600|Active Comparator|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
16693824|NCT01991600|Experimental|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
16693825|NCT01991587|Experimental|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
16693826|NCT01991587|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
16693827|NCT01991587|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
16693828|NCT01991587|Placebo Comparator|Placebo|A single dose of Placebo
16693829|NCT01991574|Placebo Comparator|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
16693830|NCT01991574|Active Comparator|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
16693831|NCT01991574|Experimental|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
16693832|NCT01991561|Experimental|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
16693833|NCT01991561|Experimental|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
16693834|NCT01991561|Experimental|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
16693835|NCT01991561|Experimental|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
16693836|NCT01991561|Experimental|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
16693837|NCT01991561|Placebo Comparator|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
16693838|NCT01991548|Other|Diabetic participants with study devices|
16693839|NCT01991522|Experimental|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
16693840|NCT01991522|Active Comparator|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
16693841|NCT01991509|Experimental|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
16693842|NCT01991509|Experimental|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
16693843|NCT01991509|Placebo Comparator|Placebo IV|Placebo Administered Intravenously
16693844|NCT01991509|Placebo Comparator|Placebo SC|Placebo Administered Subcutaneously
16693845|NCT01991509|Experimental|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
16693846|NCT01991509|Experimental|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
16693847|NCT01991483|Experimental|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
16693848|NCT01991483|Experimental|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
16693849|NCT01991483|Placebo Comparator|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
16693850|NCT01991483|Placebo Comparator|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
16693851|NCT01991470|Experimental|Enlite sensors|Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.
16693852|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI)
16693853|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.
~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
16693854|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
16693855|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
16693856|NCT01991405|Sham Comparator|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
16693857|NCT01991392|Active Comparator|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
16693858|NCT01991392|Experimental|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
16693859|NCT01991379|Experimental|MEK162 in Combination With Imatinib Mesylate|Pts will be treated with the combination therapy of MEK162 & imatinib. The phase Ib portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the standard 3+3 escalation doses. Phase Ib expansion cohort, pts will receive the RP2D: imatinib 400 mg once daily (standard of care first line imatinib dose) & MEK162 at the RP2D twice daily. The phase II portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the RP2D. The MEK162 RP2D was originally determined based on the phase Ib escalation data & it was established as 45 mg BID. After the completion of the phase Ib dose expansion & initiation of phase II, the MEK162 RP2D was reduced to 30 mg BID30 for better long term tolerability. Patient's will now begin MEK162 at the revised RP2D of 30 mg BID. 1 cycle is 28 days. If no progression of the tumor is seen, pts will continue on therapy. Pts who have progression of disease will proceed directly to second line therapy as per standard of care.
16693860|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
16693861|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
16693862|NCT01991366||No Eptifibatide|Receive no eptifibatide
16693863|NCT01991353|Experimental|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
16693864|NCT01991353|Active Comparator|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
16693865|NCT01991340||Cohort|
16693866|NCT01991327|Experimental|Androxal|Androxal 25 mg capsules once a day for 7 days
16693867|NCT01991327|Active Comparator|Placebo Androxal|
16693868|NCT01991314|Experimental|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
16693869|NCT01991301|Experimental|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
16693870|NCT01991288|Experimental|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
16693871|NCT01991288|Active Comparator|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
16693872|NCT01991275|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
16693873|NCT01991275|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
16693874|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
16693875|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
16693876|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
16693877|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
16693878|NCT01991249|Experimental|blood sample|
16693879|NCT01991236|Experimental|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
16693880|NCT01991236|Other|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
16693881|NCT01991223|Placebo Comparator|Placebo group|NS infusion will be done during surgery.
16693882|NCT01991223|Experimental|Dex group|DEX infusion will be done during surgery.
16693883|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
16693884|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
16693885|NCT01991197|Experimental|Sitagliptin|"Double blind phase (week 0-16):
~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.
~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.
~Open-label phase (week 16-32):
~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
16693886|NCT01991197|Active Comparator|Gliclazide|"Double-blind phase (week 0-16):
~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.
~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.
~Open-label phase (week 16-32):
~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
16693887|NCT01991184|Experimental|Dose-escalation|
16693888|NCT01991171|Experimental|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
16693889|NCT01991171|Placebo Comparator|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
16693890|NCT01991171|No Intervention|Control Group|This participants will not receive intervention
16693891|NCT01991158|Experimental|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
16693892|NCT01991145|Experimental|UCB and EPO|UCB + EPO + Rehabilitation
16693893|NCT01991145|Active Comparator|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
16693894|NCT01991145|Active Comparator|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
16693895|NCT01991145|Placebo Comparator|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
16693896|NCT01991132|Other|MediView 2.0 software|
16693897|NCT01991119|Active Comparator|Propafenone|Propafenone group
16693898|NCT01991119|Active Comparator|Dronedarone|Dronedarone group
16693899|NCT01991106|Experimental|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
16693900|NCT01991106|Experimental|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
16693901|NCT01991106|Active Comparator|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
16693902|NCT01991106|No Intervention|non-obese children|100 healthy non-obese children aged 7-16 (controls)
16693903|NCT01991080|Active Comparator|Wheatgerm juice|patients will drink Wheatgerm juice
16693904|NCT01991080|Active Comparator|Biofeedback|The patients will undergo biofeedback relaxation therapy
16693905|NCT01991067|Active Comparator|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
16693906|NCT01991067|Active Comparator|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
16693907|NCT01991054|Experimental|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
16693908|NCT01991054|Placebo Comparator|placebo group|placebo group, 15 ml per month for 6 months
16693909|NCT01991041||Rufinamide|
16693910|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
16693911|NCT01991028|Experimental|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
16693912|NCT01991028|Active Comparator|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
16693987|NCT01990508|Sham Comparator|Control|Monthly letters with generic nutrition information only
16693988|NCT01990495|Active Comparator|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
16693913|NCT01991002|Other|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.
~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
16693914|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
16693915|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
16693916|NCT01990950|Experimental|Zenith® Fenestrated AAA Endovascular Graft|
16693917|NCT01990937|Active Comparator|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
16693918|NCT01990937|Placebo Comparator|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
16693919|NCT01990924|Experimental|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
16693920|NCT01990924|Active Comparator|15 FPS|Conventional rate fluoroscopy at 15 FPS
16693921|NCT01990911|Experimental|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
16693922|NCT01990911|Sham Comparator|Medical therapy|This group will not receive renal sympathetic denervation
16693923|NCT01990898|Experimental|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
16693924|NCT01990885|Experimental|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
16693925|NCT01990885|Experimental|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
16693926|NCT01990885|Experimental|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
16693927|NCT01990885|Experimental|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
16693928|NCT01990885|Experimental|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
16693929|NCT01990872|Placebo Comparator|Placebo in high calcium group|Placebo + habitual dietary calcium intake (>1000 mg/d)
16693930|NCT01990872|Active Comparator|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake <700 mg/d
16693931|NCT01990872|Placebo Comparator|Placebo in low/moderate calcium group|Placebo + habitual calcium intake <700 mg/d
16693932|NCT01990872|Active Comparator|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (>1000 mg/d)
16693933|NCT01990859|Experimental|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
16693934|NCT01990846|Experimental|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
16693935|NCT01990846|Experimental|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
16693936|NCT01990846|Placebo Comparator|Placebo|Single Dose administration Placebo for Flufirvitide-3
16693937|NCT01990846|Experimental|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
16693938|NCT01990846|Experimental|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
16693939|NCT01990846|Placebo Comparator|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
16693940|NCT01990820|Active Comparator|Adenoidectomy without balloon dilation|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
16693941|NCT01990820|Experimental|Adenoidectomy with balloon dilation|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
16693942|NCT01990807|Active Comparator|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
16693943|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
16693944|NCT01990781|Experimental|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
16693945|NCT01990781|Active Comparator|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
16693946|NCT01990781|Active Comparator|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
16693947|NCT01990781|Placebo Comparator|N: normal saline|N: normal saline (placebo): 2 ml
16693948|NCT01990768|Experimental|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
16693949|NCT01990768|Experimental|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
16693950|NCT01990768|Placebo Comparator|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
16693951|NCT01990755|Active Comparator|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.
~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
16693989|NCT01990495|Active Comparator|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
16693990|NCT01990482|Experimental|coffee|coffee
16693952|NCT01990755|Active Comparator|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.
~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
16693953|NCT01990755|Active Comparator|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.
~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
16693954|NCT01990742|Experimental|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
16693955|NCT01990742|No Intervention|Standard care|Usual care will be provided to residents in the control homes.
16693956|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
16693957|NCT01990716|Other|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
16693958|NCT01990716|Other|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
16693959|NCT01990703|Experimental|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
16693960|NCT01990703|Active Comparator|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
16693961|NCT01990690|Active Comparator|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
16693962|NCT01990690|Placebo Comparator|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
~Group 2 was given a placebo once daily for two weeks."
16693963|NCT01990677|Active Comparator|25mg Eplerenone- Chronic CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
16693964|NCT01990677|Placebo Comparator|Placebo- Chronic CSCR Diagnosis|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
16693965|NCT01990677|Active Comparator|25mg Eplerenone- Acute CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
16693966|NCT01990677|Active Comparator|Placebo- Acute CSCR Diagnosis.|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
16693967|NCT01990664|Experimental|senofilcon A|Contact lenses to be worn in a daily wear modality
16693968|NCT01990664|Experimental|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
16693969|NCT01990638||DM group|
16693970|NCT01990638||non-DM group|
16693971|NCT01990625|Experimental|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
16693972|NCT01990625|No Intervention|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
16693973|NCT01990612|No Intervention|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
16693974|NCT01990612|Other|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
16693975|NCT01990599|Other|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
16693976|NCT01990573|Experimental|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
16693977|NCT01990573|Experimental|methadone HCl 0.4 mg/kg|0.4mg/kg IV methadon HCl
16693978|NCT01990573|Active Comparator|control group|control no methadone, standard of care opioids.
16693979|NCT01990560|Experimental|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
16693980|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
16693981|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
16693982|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
16693983|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
16693984|NCT01990534|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
16693985|NCT01990521|Experimental|MS3TMRI / TRUS Guided Biopsy|
16693986|NCT01990508|Experimental|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
16693994|NCT01990456|Experimental|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
16693995|NCT01990456|Experimental|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
16693996|NCT01990443|Experimental|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
16693997|NCT01990443|Experimental|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
16693998|NCT01990430|Experimental|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.
~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
16693999|NCT01990430|No Intervention|Control|Patients will be asked to maintain their usual life style, without special changes
16694000|NCT01990417|Experimental|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
16694001|NCT01990404|Active Comparator|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
16694002|NCT01990404|Placebo Comparator|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
16694003|NCT01990391|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
16694004|NCT01990391|Experimental|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
16694005|NCT01990352|Experimental|Pegylated liposomal doxorubicin|
16694006|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
16694007|NCT01990326|Experimental|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
16694008|NCT01990326|Placebo Comparator|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
16694009|NCT01990313|Experimental|Activa PC+S|
16694010|NCT01990300||Alogliptin/Pioglitazone combination tablets|Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
16694011|NCT01990287|Experimental|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
16694012|NCT01990287|Active Comparator|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
16694013|NCT01990274|Experimental|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
16694014|NCT01990274|Active Comparator|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
16694015|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
16694016|NCT01990248||Cohort|
16694017|NCT01990235|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
16694018|NCT01990235|No Intervention|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
16694019|NCT01990209|Experimental|Orteronel|The planned dose of orteronel is 300mg orally (PO) twice daily (BID), for a total daily dose of 600mg.
16694020|NCT01990196|Active Comparator|AR inhibition only|"AR inhibition only Group 1: degarelix + enzalutamide
~Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy."
16694021|NCT01990196|Active Comparator|AR inhibition plus MEK inhibition|"AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide
~In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks."
16694022|NCT01990196|Active Comparator|AR inhibition plus SRC inhibition|"AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide
~In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks."
16694023|NCT01990183|Experimental|CareToy|CareToy intervention
16694024|NCT01990183|Other|Standard Care|Standard Care
16694025|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (>0.5s) SVR confirmed with duplex ultrasound.
16694026|NCT01990157|Experimental|TAB08|Multiple TAB08 administrations as intravenous infusions.
16694027|NCT01990144|Experimental|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
16694028|NCT01990131|Experimental|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
16694029|NCT01990131|Placebo Comparator|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
16694030|NCT01990118|Active Comparator|Neoral|Patients who continued to be treated with the drug Neoral.
16694031|NCT01990118|Experimental|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
16694032|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
16694033|NCT01990092|Experimental|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
16694034|NCT01990092|Placebo Comparator|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
16694035|NCT01990079|Experimental|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
16694036|NCT01990079|Active Comparator|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
16694037|NCT01990066|Experimental|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
16694038|NCT01990066|No Intervention|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
16694039|NCT01990053|Experimental|Beating the Blues|Beating the Blues plus helper support.
16694040|NCT01990053|No Intervention|Waitlist Condition|Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
16694041|NCT01990040||Teduglutide treated|SBS participants who have been treated with teduglutide.
16694042|NCT01990040||Non-teduglutide treated|SBS participants who have not been treated with teduglutide.
16694043|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.
~No intervention will be undertaken."
16694044|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.
~No intervention will be undertaken."
16694045|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
16694046|NCT01990001|Experimental|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
16694047|NCT01990001|No Intervention|Control|Members in the control group were not enrolled in the reminder system
16694048|NCT01989988|Active Comparator|LRYGB|20 subjects Randomized will undergo LRYGB surgery
16694049|NCT01989988|Active Comparator|SADJB|20 subjects will undergo SADJB surgery
16694050|NCT01989988|Active Comparator|LMGB|20 subjects will undergo LMGB surgery
16694051|NCT01989962|Experimental|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
16694052|NCT01989962|Sham Comparator|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
16694053|NCT01989949|Experimental|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
16694054|NCT01989936|Placebo Comparator|Placebo|
16694055|NCT01989936|Experimental|Eletriptan 40 mg|
16694057|NCT01989923|Active Comparator|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
16694058|NCT01989923|Active Comparator|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
16694059|NCT01989910|Active Comparator|Raltegravir|Raltegravir 400mg oral twice daily
16694060|NCT01989910|Active Comparator|Efavirenz|Efavirenz 600mg oral at bedtime
16694062|NCT01989884|Experimental|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
16694063|NCT01989871|No Intervention|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
16694064|NCT01989871|Experimental|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
16694065|NCT01989858|Experimental|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
16694066|NCT01989858|Active Comparator|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
16694067|NCT01989858|Experimental|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
16694068|NCT01989858|Active Comparator|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
16694069|NCT01989845|Experimental|oral rivaroxaban in cancer-associated VTE|
16694070|NCT01989832||Biological and clinical Data collected|
16694071|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
16694072|NCT01989819||control group|A skin biopsy will be performed in control group
16694073|NCT01989819||non auto-immune small fiber neuropathies|
16694074|NCT01989806|Active Comparator|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
16694075|NCT01989806|Placebo Comparator|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
16694076|NCT01989793|Active Comparator|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
16694077|NCT01989793|Placebo Comparator|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
16694078|NCT01989780|Active Comparator|Arm A|weekly paclitaxel + bevacizumab
16694079|NCT01989780|Experimental|Arm B|"weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice)* + bevacizumab then back to weekly paclitaxel + bevacizumab
~* Letrozole, Anastrozole, Exemestane, Fulvestrant, Goserelin, leuprorelin or LHRH Analogs + Aromatase inhibitors."
16694080|NCT01989767|Active Comparator|control|Rehabilitation as usual
16694081|NCT01989767|Experimental|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
16694082|NCT01989754|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
16694083|NCT01989754|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) once daily.
16694084|NCT01989741|Other|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
16694085|NCT01989728|Active Comparator|care as usual|
16694086|NCT01989728|Experimental|psychiatric examination and feedback|
16694087|NCT01989715|Experimental|adult patients waiting for orthognathic surgery|
16694088|NCT01989702|Active Comparator|Fermented blueberry product|
16694089|NCT01989702|Placebo Comparator|Placebo|
16694090|NCT01989702|Active Comparator|Probiotic bacteria|
16694091|NCT01989689|Experimental|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
16694092|NCT01989689|Active Comparator|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
16694093|NCT01989676|Experimental|PF-05280014|
16694094|NCT01989676|Active Comparator|Herceptin®|
16694095|NCT01989663|Experimental|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
16694096|NCT01989663|Placebo Comparator|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
16694097|NCT01989663|Experimental|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
16694188|NCT01989091|Active Comparator|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
16694098|NCT01989663|Experimental|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
16694099|NCT01989663|Placebo Comparator|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
16694100|NCT01989650|Active Comparator|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
16694101|NCT01989650|No Intervention|No break|No break will be provided
16694102|NCT01989637|Experimental|Strawberry Meal|40 g freeze-dried strawberries included in test meal
16694103|NCT01989637|Placebo Comparator|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
16694104|NCT01989624||Pancreatic Adenocarcinoma|
16694105|NCT01989611|Other|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
16694106|NCT01989598|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
16694109|NCT01989572|Experimental|Arm I (sargramostim, peptide vaccine)|Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
16694110|NCT01989572|Experimental|Arm II (sargramostim placebo, peptide vaccine)|Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
16694111|NCT01989572|Experimental|Arm III (sargramostim, peptide placebo)|Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
16694112|NCT01989572|Placebo Comparator|Arm IV (placebo, peptide placebo)|Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
16694113|NCT01989572|Experimental|Arm V (sargramostim)|Patients receive sargramostim SC on days 1-14.
16694114|NCT01989572|Placebo Comparator|Arm VI (sargramostim placebo)|Patients receive sargramostim placebo SC on days 1-14.
16694115|NCT01989559|Experimental|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
16694116|NCT01989546|Experimental|1/Talazoparib (BMN 673)|Single agent
16694117|NCT01989533|Placebo Comparator|A|Placebo controlled (blinded)
16694118|NCT01989533|Active Comparator|B|Intranasal Randomized
16694119|NCT01989533|Experimental|C|Oral Open label
16694120|NCT01989533|Experimental|D|Intranasal Open Label
16694121|NCT01989520|Experimental|Treatment A|Phase IIb formulation
16694122|NCT01989520|Experimental|Treatment B|Putative phase III formulation
16694123|NCT01989520|Experimental|Treatment C|Slow dissolution variant 1
16694124|NCT01989520|Experimental|Treatment D|Slow dissolution variant 2
16694125|NCT01989520|Experimental|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
16694126|NCT01989507|Experimental|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
16694127|NCT01989507|Active Comparator|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
16694128|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
16694129|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
16694130|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
16694131|NCT01989468|Experimental|Secukinumab (AIN457) 150 mg s.c.|1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
16694132|NCT01989468|Experimental|Secukinumab (AIN457) 300 mg s.c.|2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
16694133|NCT01989468|Placebo Comparator|Placebo|Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
16694134|NCT01989455|Experimental|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.
~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.
~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
16694135|NCT01989455|Experimental|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.
~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.
~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
16694136|NCT01989455|Experimental|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.
~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
16694137|NCT01989455|Experimental|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.
~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.
~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
16707384|NCT01900769|Experimental|Blood Volume Dilution|
16694138|NCT01989442|Experimental|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
16694139|NCT01989442|Active Comparator|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
16694140|NCT01989429|Active Comparator|Daivonex|topical application
16694141|NCT01989429|Placebo Comparator|vehicle|topical application
16694142|NCT01989429|Experimental|M518101|topical application
16694143|NCT01989416|Placebo Comparator|Soap bathing|ICU patients will be bathing with soap at least once daily
16694144|NCT01989416|Experimental|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
16694145|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
16694146|NCT01989351||VAS<4|
16694147|NCT01989351||VAS>4|
16694148|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
16694149|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.
~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.
~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
16694150|NCT01989325|Experimental|Carfilzomib|"Single agent arm.
~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
16694151|NCT01989312|Active Comparator|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
16694152|NCT01989312|Active Comparator|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
16694153|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
16694154|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility >50% or IVC diameter less than or equal to 12mm
16694155|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility <50% or IVC diameter >12mm
16694156|NCT01989260|Other|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
16694157|NCT01989247|Experimental|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
16694158|NCT01989247|No Intervention|Control group|
16694159|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
16694160|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
16694161|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
16694162|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
16694163|NCT01989221|Other|Placebo followed by Sancuso|Placebo at baseline for one week followed by Sancuso® (granisetron transdermal system) 3.1 mg/24 hours for two weeks
16694164|NCT01989208|Placebo Comparator|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
16694165|NCT01989208|Experimental|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
16694166|NCT01989195|Experimental|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
16694167|NCT01989182|Experimental|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
16694168|NCT01989182|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
16694169|NCT01989169|Active Comparator|Midazolam|Administered as a single oral 6 mg dose on Day 1.
16694170|NCT01989169|Experimental|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
16694171|NCT01989156|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
16694172|NCT01989156|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
16694173|NCT01989156|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
16694174|NCT01989143|Experimental|SAD Cohorts 1-8 Experimental Arm|
16694175|NCT01989143|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
16694176|NCT01989143|Experimental|MAD Cohorts 9-11 Experimental Arm|
16694177|NCT01989143|Placebo Comparator|MAD Cohorts 9-11 Placebo Arm|
16694178|NCT01989143|Experimental|MAD Cohort 12 Experimental Arm|
16694179|NCT01989143|Placebo Comparator|MAD Cohort 12 Placebo Arm|
16694180|NCT01989130|Experimental|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
16694181|NCT01989130|Active Comparator|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
16694182|NCT01989117||Osteopathy|
16694183|NCT01989117||No osteopathy|
16694184|NCT01989104||Children|6-12 years of age
16694185|NCT01989104||Adolescents|13-17 years of age
16694186|NCT01989104||Young adults|18-20 years of age
16694187|NCT01989091|Experimental|B-Lock (IMD)|Investigational Medical Device (IMD)
16694189|NCT01989078|Experimental|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
16694190|NCT01989065|Active Comparator|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
16694191|NCT01989065|Experimental|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
16694192|NCT01989052|Experimental|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
16694193|NCT01989052|Experimental|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
16694194|NCT01989052|Experimental|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
16694195|NCT01989052|Experimental|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
16694196|NCT01989026|Active Comparator|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
16694197|NCT01989026|No Intervention|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
16694198|NCT01989013|Other|biweekly intervention|biweekly intervention
16694199|NCT01989000|Active Comparator|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
16694200|NCT01989000|Active Comparator|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
16694201|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
16694202|NCT01988974|Experimental|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
16694203|NCT01988974|Active Comparator|Attention control condition|2) participation in the healthy sleep program
16694204|NCT01988961|Experimental|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
16694205|NCT01988948|Other|student cohort|"Various biological sampling
~blood sampling,
~oral, vulvar, vaginal and anal sampling for women,
~oral and genital sampling for men"
16694206|NCT01988935|Experimental|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
16694207|NCT01988935|Active Comparator|Smoking Cessation|Smoking cessation intervention
16694208|NCT01988922|Experimental|Ketamine arm- *1/*1|1.*1/*1- oral racemic ketamine 0.4 mg/kg
16694209|NCT01988922|Experimental|Ketamine arm - *1/*6|2. *1/*6- oral racemic ketamine 0.4 mg/kg
16694210|NCT01988922|Experimental|Ketamine arm - *6/*6|3. *6/*6- oral racemic ketamine 0.4 mg/kg
16694211|NCT01988909|Experimental|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
16694212|NCT01988896|Experimental|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days [14-day run-in period + 28-day concomitant dosing period]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
16694213|NCT01988896|Experimental|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
16694214|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
16694215|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
16694216|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
16694217|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
16694218|NCT01988870|Experimental|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
16694219|NCT01988857|Experimental|dTpa Group|
16694220|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
16694253|NCT01988571|Active Comparator|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
16694254|NCT01988571|Placebo Comparator|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
16709588|NCT01886443|Experimental|Combined drug approach, safety study|
16694221|NCT01988831|Placebo Comparator|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.
~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.
~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
16694222|NCT01988831|Experimental|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.
~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.
~One long acting pill a day until an evidence of disease progression or the end of the study."
16694223|NCT01988818|Active Comparator|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
16694224|NCT01988818|Experimental|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
16694225|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
16694226|NCT01988792|Active Comparator|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
16694227|NCT01988792|Active Comparator|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
16694228|NCT01988779|Active Comparator|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
16694229|NCT01988779|Active Comparator|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
16694230|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
16694231|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
16694232|NCT01988753||Subjects with Liver Fibrosis|"Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.
~Biomarker Analysis
~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.
~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
16694233|NCT01988714|Experimental|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
16694234|NCT01988714|Placebo Comparator|(CG) plus evidence-based SE|(CG) plus evidence-based SE
16694235|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
16694236|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
16694237|NCT01988688|Experimental|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
16694238|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
16694239|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
16694240|NCT01988662|Experimental|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
16694241|NCT01988662|Active Comparator|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
16694242|NCT01988649|Active Comparator|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
16694243|NCT01988649|Placebo Comparator|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
16694244|NCT01988636|Experimental|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
16694245|NCT01988636|Active Comparator|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
16694246|NCT01988636|Placebo Comparator|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
16694247|NCT01988623|Experimental|Pivotal Response Treatment (PRT)|
16694248|NCT01988610|Experimental|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
16694249|NCT01988597||Dry Eyes|
16694250|NCT01988584|Active Comparator|Umbilical Cord Blood (UCB) Arm|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
16694251|NCT01988584|Active Comparator|Bone Marrow Stem Cells (BMMNC's)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
16694252|NCT01988584|Placebo Comparator|Placebo (inactive substance) Group|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
16712768|NCT01865019||volume controlled|volume ontrolled ventilation
16694255|NCT01988558|Experimental|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
16694256|NCT01988558|Placebo Comparator|Placebo Group|
16694257|NCT01988545|Active Comparator|GLP-1|1,5 nmol/kg,GLP-1 sc injection
16694258|NCT01988545|Active Comparator|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
16694259|NCT01988545|Active Comparator|Exendin-4|Exendin-4 ;10 ug,sc injection
16694260|NCT01988545|Placebo Comparator|isotonic saline|2 ml of isotonic saline, sc injection
16694261|NCT01988532||Adult PWH|
16694262|NCT01988519|Active Comparator|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
16694263|NCT01988519|Active Comparator|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
16694264|NCT01988506|Experimental|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
16694265|NCT01988493|Experimental|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
16694266|NCT01988493|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
16694267|NCT01988493|Experimental|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
16694268|NCT01988493|Experimental|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
16694269|NCT01988493|Experimental|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
16694270|NCT01988480|Experimental|Image-guided surgery|Image-guided implant placement
16694271|NCT01988480|Sham Comparator|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
16694272|NCT01988467|Experimental|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:
~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.
~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.
~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
16694273|NCT01988467|Experimental|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:
~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.
~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.
~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
16694274|NCT01988428|No Intervention|standard care|"standard care
~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
16694275|NCT01988428|Experimental|Antibiotics|"ceftriaxone 2000 mg (after taking bloodcultures)
~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
16694276|NCT01988415|Other|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).
16694277|NCT01988402|Active Comparator|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
16694278|NCT01988402|Placebo Comparator|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
16694279|NCT01988389|Experimental|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
16694280|NCT01988389|Other|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
16694281|NCT01988376|Experimental|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
16694282|NCT01988376|Active Comparator|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
16694283|NCT01988363|Other|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
16694284|NCT01988350||Non-smokers|
16694285|NCT01988350||Smokers|
16694286|NCT01988337|Experimental|Resin infiltration|"One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
16694287|NCT01988337|Sham Comparator|Mock treatment|"A second proximal caries lesion of each patient (split mouth design) will recieve a placebo treatment to mimic resin infiltration."
16694288|NCT01988324|Experimental|FES/FDHT-PET|
16694289|NCT01988311|Experimental|Drug Only|psilocybin dose manipulation as described in the protocol
16694290|NCT01988311|No Intervention|Cognitive/Behavioral Tasks Only|
16694291|NCT01988311|No Intervention|Imaging Only|
16694292|NCT01988298|Experimental|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
16694293|NCT01988298|Active Comparator|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
16694294|NCT01988285||Dysphagia and GERD controls|"The cross-sectional arm will consist of patients who are having a clinically indicated endoscopy for reflux and/or dysphagia.
~Cross-sectional participants will have specimens collected and complete a questionnaire."
16712769|NCT01865019||pressure controlled|pressure controlled ventilation
16694295|NCT01988285||Prospective Longitudinal EoE Cases|"The prospective longitudinal group will be subjects who have a positive EoE diagnosis during initial endoscopy. This prospective group will be followed up at their clinically indicated endoscopy after their standard of care clinical therapy of swallowed steroids.
~Prospective longitudinal participants will have specimens collected and complete questionnaires s prior to their standard of care clinical therapy of swallowed steroids and at their clinically indicated follow up upper endoscopy."
16694296|NCT01988259|Active Comparator|Bilateral approach for laminoplasty|Open approach for laminoplasty
16694297|NCT01988259|Active Comparator|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
16694298|NCT01988259|Active Comparator|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
16694299|NCT01988259|Active Comparator|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
16694300|NCT01988246|Sham Comparator|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
16694301|NCT01988246|Active Comparator|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
16694302|NCT01988233|Experimental|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
16694303|NCT01988233|Experimental|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
16694304|NCT01988220|Experimental|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
16694305|NCT01988220|Active Comparator|repeated exposure to sensory input|
16694306|NCT01988207|Experimental|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
16694307|NCT01988207|Active Comparator|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
16694308|NCT01988194|No Intervention|Usual care|Participants will receive usual care in the hospital.
16694309|NCT01988194|Experimental|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
16694310|NCT01988181|Active Comparator|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
16694311|NCT01988181|Experimental|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
16694312|NCT01988168|Experimental|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
16694313|NCT01988168|Active Comparator|Staples closure|Closure of skin with stainless-steel surgical staples.
16694314|NCT01988155|Active Comparator|Eccentric Exericse|
16694315|NCT01988155|Experimental|Astym|
16694316|NCT01988142|Experimental|SCI|
16694317|NCT01988129|Experimental|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
16694318|NCT01988129|No Intervention|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.
~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
16694319|NCT01988116|Experimental|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
16694320|NCT01988116|Placebo Comparator|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
16694321|NCT01988103|Experimental|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
16694322|NCT01988103|Experimental|Apremilast 30mg|Apremilast 30 mg tablets orally BID
16694323|NCT01988103|Placebo Comparator|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
16694324|NCT01988090|Experimental|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
16694325|NCT01988090|Active Comparator|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
16694326|NCT01988077|Other|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
16694327|NCT01988064|Experimental|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
16712770|NCT01865006||Ligasure LF1212|
16694328|NCT01988064|Experimental|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
16694329|NCT01988038||No treatment|
16694330|NCT01988012|Experimental|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
16694331|NCT01987999|Experimental|Acetogenins|Acetogenins twice (BID) per day for 12 months
16694332|NCT01987986|Experimental|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
16694333|NCT01987986|Experimental|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
16694334|NCT01987986|Experimental|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
16694335|NCT01987986|Placebo Comparator|Placebo|"Placebo
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
16694336|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
16694337|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
16694338|NCT01987960|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
16694339|NCT01987960|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
16694340|NCT01987947|Placebo Comparator|Placebo|
16694341|NCT01987947|Active Comparator|Quilizumab|
16694342|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
16694343|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
16694344|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
16694345|NCT01987908|Experimental|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
16694346|NCT01987908|Placebo Comparator|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
16694347|NCT01987908|Experimental|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
16694348|NCT01987908|Placebo Comparator|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
16694349|NCT01987895|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
16694350|NCT01987895|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
16694351|NCT01987882||"A. Natural History or Watchful Waiting"|
16694352|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
16694353|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
16694354|NCT01987882||D. Hip Reconstructive Surgery|
16694355|NCT01987882||E. Salvage Hip Surgery|
16694356|NCT01987856|Active Comparator|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
16694357|NCT01987856|Placebo Comparator|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
16694358|NCT01987843|Experimental|MT-1303-Low|MT-1303-Low Dose
16694359|NCT01987843|Experimental|MT-1303-Middle|MT-1303-Middle Dose
16694360|NCT01987843|Experimental|MT-1303-High|MT-1303-High Dose
16694361|NCT01987843|Placebo Comparator|Placebo|Placebo
16694362|NCT01987830|Other|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.
~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
16694363|NCT01987817|Experimental|AR101 powder provided in capsules|Study product provided in pull-apart peanut protein capsules
16694364|NCT01987817|Placebo Comparator|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
16694365|NCT01987804|Experimental|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
16694366|NCT01987804|Experimental|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
16694367|NCT01987804|Placebo Comparator|Placebo|N=16 patients are administrated placebo vaginally
16694395|NCT01987622|Active Comparator|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
16694368|NCT01987778|Experimental|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
16694369|NCT01987778|No Intervention|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
16694370|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
16694371|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
16694372|NCT01987739|Experimental|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
16694373|NCT01987739|Experimental|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
16694374|NCT01987739|Experimental|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
16694375|NCT01987739|Experimental|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
16694376|NCT01987739|Experimental|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
16694377|NCT01987739|Experimental|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
16694379|NCT01987713|Experimental|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
16694380|NCT01987700|Active Comparator|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
16694381|NCT01987700|Active Comparator|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
16694382|NCT01987700|Active Comparator|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
16694383|NCT01987700|Active Comparator|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
16694384|NCT01987687|Active Comparator|Rest|Breakfast followed by a rest period prior to OGTT.
16694385|NCT01987687|Experimental|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
16694386|NCT01987687|Experimental|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
16694387|NCT01987674|Experimental|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
16694388|NCT01987674|Placebo Comparator|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
16694389|NCT01987661|Active Comparator|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
16694390|NCT01987661|Experimental|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
16694391|NCT01987648||All study participants|Included are all patients who 18 years or older, who get an elective craniotomy (no biopsy, no awake surgery, no re-operation) and who are treated at the Department of Neurosurgery
16694392|NCT01987635|Experimental|MEMO 3D anuloplasty ring|MEMO 3D anuloplasty ring
16694393|NCT01987635|Active Comparator|rigid ring|rigid ring
16694394|NCT01987622|Experimental|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
16694396|NCT01987609|Experimental|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
16712771|NCT01865006||Ultracision|
16694397|NCT01987609|Placebo Comparator|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
16694398|NCT01987596|Experimental|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
16694399|NCT01987596|Experimental|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
16694400|NCT01987583|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.
~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
16694401|NCT01987583|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
16694402|NCT01987570|Experimental|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
16694403|NCT01987570|Placebo Comparator|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
16694404|NCT01987557|Experimental|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
16694405|NCT01987557|Experimental|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
16694406|NCT01987557|Placebo Comparator|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
16694407|NCT01987544|Active Comparator|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
16694408|NCT01987544|Experimental|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
16694409|NCT01987531|Experimental|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
16694410|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
16694411|NCT01987505|Experimental|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
16694412|NCT01987492|Experimental|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
16694413|NCT01987492|Experimental|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
16694414|NCT01987492|Placebo Comparator|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
16694415|NCT01987479|Experimental|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
16694416|NCT01987466||Post cardiac arrest patient|
16694417|NCT01987453|Experimental|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
16694418|NCT01987453|Experimental|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
16694419|NCT01987453|Experimental|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
16694420|NCT01987440|Experimental|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
16694421|NCT01987440|Placebo Comparator|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
16694422|NCT01987427|Experimental|A|lorcaserin + phentermine placebo
16694423|NCT01987427|Experimental|B|lorcaserin + phentermine-HCl + phentermine placebo
16694424|NCT01987427|Experimental|C|lorcaserin + phentermine-HCl
16694425|NCT01987414|Experimental|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
16694426|NCT01987414|Active Comparator|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
16694427|NCT01987401||Iraq and Afghanistan Era Veterans|Veterans who served during the Iraq and Afghanistan Era
16694428|NCT01987388|Experimental|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
16694429|NCT01987388|Experimental|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
16694430|NCT01987388|Experimental|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
16694431|NCT01987388|Experimental|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
16694432|NCT01987375|Experimental|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
16694433|NCT01987362|Experimental|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
16694434|NCT01987362|Experimental|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
16694435|NCT01987349|Other|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
16694436|NCT01987349|Other|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
16694437|NCT01987349|Other|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
16694438|NCT01987349|Other|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
16694439|NCT01987349|Other|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
16694440|NCT01987349|Other|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
16694441|NCT01987349|Other|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
16694442|NCT01987323|Experimental|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
16694443|NCT01987310|Active Comparator|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
16694444|NCT01987310|No Intervention|usual care|follow up group with no intervention
16694445|NCT01987310|Active Comparator|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
16694446|NCT01987297|Experimental|ATRA+Arsenic|All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation. High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
16694447|NCT01987297|Active Comparator|ATRA+chemo|All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation. High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
16694448|NCT01987284|Experimental|SER100|SER100 10 mg s.c. twice daily
16694449|NCT01987284|Placebo Comparator|Placebo|Placebo administered s.c. twice daily
16694450|NCT01987271|Experimental|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
16694451|NCT01987271|No Intervention|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
16694452|NCT01987258|No Intervention|Control|No exercise (control experiment)
16694453|NCT01987258|Experimental|Interval Walking|A one hour interval walking exercise bout
16694454|NCT01987258|Experimental|Continuous walking|A one hour continuous walking exercise bout
16694455|NCT01987232|Experimental|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
16694456|NCT01987219|Active Comparator|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
16694457|NCT01987219|Active Comparator|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
16694458|NCT01987219|Placebo Comparator|Placebo|Placebo Saline solution 3 cc NA
16694481|NCT01987024|Experimental|groupB- actim partus|
16694482|NCT01987011|Experimental|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
16694483|NCT01987011|Placebo Comparator|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
16694484|NCT01986998|Active Comparator|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
16694485|NCT01986998|Active Comparator|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
16694486|NCT01986985|Other|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
16694487|NCT01986972|Active Comparator|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
16694459|NCT01987206|Active Comparator|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.
~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
16694460|NCT01987206|Experimental|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.
~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
16694461|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
16694462|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
16694463|NCT01987167|Experimental|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
16694464|NCT01987154|Active Comparator|Marketed cow milk-based premature infant formula|
16694465|NCT01987154|Experimental|Marketed extensively hydrolyzed casein infant formula|
16694466|NCT01987141|Experimental|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
16694467|NCT01987141|No Intervention|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
16694468|NCT01987128|Experimental|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
16694469|NCT01987128|Active Comparator|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
16694470|NCT01987115|Experimental|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
16694471|NCT01987115|Active Comparator|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
16694472|NCT01987102|Experimental|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)
~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
16694473|NCT01987102|Experimental|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)
~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5mg/m2 or 30mg/m2*)
~*Dose will depend on outcome from Cohort 1"
16694474|NCT01987089|Experimental|CBT-I|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician. Session 1 serves as an orientation. No active treatment is delivered at this time. Sessions 2 & 3 are used to deliver the three main components of the intervention which are Sleep Restriction (SRT), Stimulus Control, and Sleep Hygiene. All but two of the remaining sessions are dedicated to the titration of total sleep time and to ensuring patient adherence. One session (session 5) entails the delivery of a specific form of cognitive therapy. The final session (session 8) is used to engage in a relapse-prevention didactic, i.e., to review first, how insomnia becomes chronic and second, the strategies that are likely to abort an extended episode of insomnia.
16694475|NCT01987089|Placebo Comparator|QDT|"This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate conditioned arousal, occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime."
16694476|NCT01987076|Active Comparator|Corticosteroids per os: Prednisone + Emollient|
16694477|NCT01987076|Experimental|Topical corticosteroid: Clobetasol + Emollient|
16694478|NCT01987063||pregnant woman with twins|pregnant woman with twins
16694479|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
16694480|NCT01987024|Active Comparator|group A-usual procedure|
16694488|NCT01986972|Experimental|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
16694489|NCT01986959|Experimental|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
16694490|NCT01986959|Other|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
16694491|NCT01986946|Experimental|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
16694492|NCT01986946|Experimental|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
16694493|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
16694494|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
16694495|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
16694496|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
16694497|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
16694498|NCT01986920|Active Comparator|A-101 25%|Low dose group
16694499|NCT01986920|Active Comparator|A-101 32.5%|Mid Dose Group
16694500|NCT01986920|Active Comparator|A-101 40%|High Dose Group
16694501|NCT01986920|Placebo Comparator|A-101 Vehicle|Placebo group
16694502|NCT01986907|Experimental|Ranibizumab|Administered as an Intravitreal injection
16694503|NCT01986894|Placebo Comparator|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
16694504|NCT01986894|Experimental|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
16694505|NCT01986894|Experimental|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
16694506|NCT01986894|Active Comparator|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
16694507|NCT01986881|Experimental|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
16694508|NCT01986881|Experimental|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
16694509|NCT01986881|Placebo Comparator|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years
16694510|NCT01986868|Other|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
16694511|NCT01986855|Experimental|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
16694512|NCT01986855|Experimental|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
16694513|NCT01986855|Placebo Comparator|Placebo|Matching placebo
16694514|NCT01986842|Experimental|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
16694515|NCT01986842|Experimental|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
16694516|NCT01986829|Experimental|Treatment (ablation)|"Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.
~Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
16694517|NCT01986803|Experimental|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
16694518|NCT01986803|Active Comparator|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
16694519|NCT01986790|Experimental|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
16694520|NCT01986790|Experimental|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
16694521|NCT01986790|Experimental|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
16694522|NCT01986777|Active Comparator|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
16694523|NCT01986777|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
16694524|NCT01986764|Active Comparator|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
16694525|NCT01986764|Active Comparator|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
16694526|NCT01986764|Placebo Comparator|Placebo|
16694527|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
16694528|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
16694529|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
16694530|NCT01986725|Active Comparator|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
16694531|NCT01986725|Active Comparator|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
16694532|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
16694533|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
16694534|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
16694535|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
16694536|NCT01986686|No Intervention|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
16694537|NCT01986686|Active Comparator|Surgery|The surgery group will be offered colon resection.
16694538|NCT01986673|Experimental|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
16694539|NCT01986673|Active Comparator|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
16694540|NCT01986660|Experimental|Ibuprofen Cream (SST-0225)|
16694541|NCT01986647|Experimental|On the Move Exercise - exercise leader|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
16694542|NCT01986647|Active Comparator|Standard program - exercise leader|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
16694543|NCT01986647|Active Comparator|On the Move - staff activity personnel|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
16694544|NCT01986647|Active Comparator|Standard - staff activity personnel|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel
16694545|NCT01986634|Other|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
16694546|NCT01986621||Patients undergoing elective PCI|
16694547|NCT01986608|Experimental|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
16694548|NCT01986608|Experimental|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
16694549|NCT01986608|Experimental|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
16694550|NCT01986582|Active Comparator|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning & evening, for 8 days.
16694551|NCT01986582|Placebo Comparator|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning & evening, for 8 days.
16694552|NCT01986569|Experimental|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
16694553|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
16694554|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
16694555|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
16694556|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
16694557|NCT01986543|Experimental|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
16694558|NCT01986543|Experimental|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
16694559|NCT01986543|Active Comparator|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
16694560|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
16694561|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
16694562|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
16694563|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
16694564|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
16694565|NCT01986517|Experimental|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
16694566|NCT01986517|Experimental|No feedback|Therapists assigned to this group will receive no feedback
16694567|NCT01986491|Experimental|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
16694635|NCT01986127|Experimental|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
16694636|NCT01986127|Placebo Comparator|saline|5 ml of saline
16712772|NCT01865006||Conventional|
16694568|NCT01986491|Experimental|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
16694569|NCT01986491|Experimental|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
16694570|NCT01986491|Experimental|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
16694571|NCT01986491|Experimental|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
16694572|NCT01986491|Experimental|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
16694573|NCT01986491|Experimental|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
16694574|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
16694575|NCT01986465|Experimental|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
16694576|NCT01986465|Placebo Comparator|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
16694577|NCT01986452|Active Comparator|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
16694578|NCT01986452|Experimental|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
16694579|NCT01986426|Experimental|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.
~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.
~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
16694580|NCT01986426|Experimental|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:
~Once daily on 2 consecutive days week 1-3."
16694581|NCT01986426|Experimental|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
16694582|NCT01986426|Experimental|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
16694583|NCT01986413|Active Comparator|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
16694584|NCT01986413|Experimental|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
16694585|NCT01986400|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
16694586|NCT01986400|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
16694587|NCT01986387|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
16694588|NCT01986387|No Intervention|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
16694589|NCT01986374|Experimental|HCG is introduced with small catheter.|phase 1 non randomized pilot
16694590|NCT01986361|Experimental|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
16694591|NCT01986361|Placebo Comparator|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
16712890|NCT01864213|Experimental|Ametop cream|
16694592|NCT01986348|Experimental|Arm A: Selinexor 60 mg and Surgery|Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.
16694593|NCT01986348|Experimental|Arm B: Selinexor 50 mg/m^2|Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
16694594|NCT01986348|Experimental|Arm C: Selinexor 60 mg|Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
16694595|NCT01986348|Experimental|Arm D: Selinexor 80 mg|Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
16694596|NCT01986335|Experimental|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
16694597|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
16694598|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
16694599|NCT01986322|Experimental|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.
~DTP/HB/Hib component:
~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
16694600|NCT01986322|Active Comparator|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age
~DTP/HB component:
~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal
~Hib component:
~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
16694601|NCT01986309|Active Comparator|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
16694602|NCT01986309|Placebo Comparator|Group P|Normal saline solution administered under the same regimen
16694603|NCT01986296|Experimental|ExAblate Treatment|
16694604|NCT01986283|Placebo Comparator|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
16694605|NCT01986283|Experimental|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
16694606|NCT01986283|Experimental|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
16694607|NCT01986283|Active Comparator|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
16694608|NCT01986270|Placebo Comparator|Placebo|
16694609|NCT01986270|Experimental|Eletriptan 40 mg|
16694610|NCT01986270|Experimental|Eletriptan 80 mg|
16694611|NCT01986270|Experimental|Sumatriptan 25 mg|
16694612|NCT01986270|Experimental|Sumatriptan 50 mg|
16694613|NCT01986257|Experimental|Emotion Regulation Group Therapy (ERGT).|
16694614|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
16694615|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
16694616|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
16694617|NCT01986231|Experimental|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
16694618|NCT01986218|Experimental|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
16694619|NCT01986218|Experimental|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
16694620|NCT01986218|Experimental|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
16694621|NCT01986218|Experimental|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
16694622|NCT01986205|Experimental|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
16694623|NCT01986205|Placebo Comparator|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
16694624|NCT01986192|Experimental|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
16694625|NCT01986192|Active Comparator|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
16694626|NCT01986179|Active Comparator|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
16694627|NCT01986179|Experimental|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
16694628|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
16694629|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
16694630|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
16694631|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
16694632|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
16694633|NCT01986140|Experimental|PAXMAN Orbis Scalp Cooler|Scalp Cooling
16694634|NCT01986140|Other|Control No treatment|Control
16694637|NCT01986114|Experimental|SM-13496 20-120mg|once daily orally SM-13496 20-120 mg flexibly dosed
16694638|NCT01986101|Placebo Comparator|Placebo|once daily orally
16694639|NCT01986101|Experimental|SM-13496 20 - 60 mg/day|once daily orally
16694640|NCT01986101|Experimental|SM-13496 80 - 120 mg/day|once daily orally
16694641|NCT01986088|Placebo Comparator|Placebo|
16694642|NCT01986088|Experimental|Eletriptan 40 mg|
16694643|NCT01986088|Experimental|Eletriptan 80 mg|
16694644|NCT01986088|Experimental|Sumatriptan 50 mg|
16694645|NCT01986088|Experimental|Sumatriptan 100 mg|
16694646|NCT01986075|Active Comparator|Computer-assisted Therapy alone|Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week when receiving Behavioral: Computer assisted therapy alone.
16694647|NCT01986075|Experimental|Computer-assisted CBT + Adderall-XR|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
16694648|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
16694649|NCT01986062|Experimental|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
16694650|NCT01986062|Placebo Comparator|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
16694651|NCT01986049|Experimental|Bupivicaine 0.5%|Drug Bupivacaine 0.5%
16694652|NCT01986049|Experimental|Bupivicaine 0.25%|Drug Bupivacaine 0.25%
16694653|NCT01986049|Placebo Comparator|Normal Saline|Saline Normal
16694654|NCT01986036|Sham Comparator|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
16694655|NCT01986036|Active Comparator|PROTEIN|High-protein breakfast.
16694656|NCT01986036|Active Comparator|CALCIUM|High-calcium breakfast.
16694657|NCT01986036|Experimental|PRO-CAL|High-protein and calcium breakfast.
16694658|NCT01986023|Experimental|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
16694659|NCT01986023|No Intervention|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
16694660|NCT01986010|Experimental|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694661|NCT01986010|Experimental|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694662|NCT01986010|Experimental|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694663|NCT01986010|Experimental|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694664|NCT01986010|Experimental|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694665|NCT01986010|Experimental|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
16694666|NCT01986010|Experimental|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694667|NCT01986010|Experimental|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
16694668|NCT01986010|Experimental|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694669|NCT01986010|Experimental|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
16694670|NCT01986010|Experimental|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
16694671|NCT01986010|Placebo Comparator|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
16694672|NCT01986010|Placebo Comparator|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
16694673|NCT01986010|Experimental|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
16694674|NCT01986010|Experimental|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
16694675|NCT01986010|Placebo Comparator|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
16694676|NCT01986010|Placebo Comparator|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
16713185|NCT01862068||Atherosclerotic patients|
16694677|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent
~Any tumor site
~Stage I-IV, M0
~Treated with radiotherapy alone or in combination with systemic therapy
~Definitive radiotherapy or postoperative radiotherapy
~Interventions:
~Radiation alone
~Radiation in combination with systemic therapy"
16694678|NCT01985971|Experimental|EF5|
16694679|NCT01985958|Experimental|Single arm|In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.
16694680|NCT01985945|Other|Yoga|
16694681|NCT01985945|No Intervention|Without Yoga|
16694682|NCT01985932|Other|Functional MRI|Subjects in this arm receive functional MRI during radiation therapy treatment planning.
16694683|NCT01985919||Bone marrow aspirate/biopsy and blood specimens|Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases
16694684|NCT01985906|Experimental|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone < 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.
~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
16694685|NCT01985893|Other|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
16694686|NCT01985893|Other|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
16694687|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
16694688|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
16694689|NCT01985880||Control|Control
16694690|NCT01985867|Experimental|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10^8 colony forming units (CFU), twice daily, orally for 4 weeks
16694691|NCT01985867|Placebo Comparator|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
16694692|NCT01985854|Active Comparator|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
16694693|NCT01985854|Experimental|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
16694694|NCT01985841|Experimental|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -> Bevacizumab plus Docetaxel
16694695|NCT01985828|Experimental|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy
~OR
~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
16694696|NCT01985828|Experimental|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
16694697|NCT01985815|Experimental|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
16694698|NCT01985815|Experimental|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
16694699|NCT01985802|Other|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
16694700|NCT01985789|Active Comparator|diphenhydramine|50mg dose given as two 25mg capsules
16694701|NCT01985789|Active Comparator|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
16694702|NCT01985789|Active Comparator|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
16694703|NCT01985789|Placebo Comparator|placebo|given as 2 placebo capsules
16694704|NCT01985776|Active Comparator|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
16694705|NCT01985776|Active Comparator|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
16694706|NCT01985776|No Intervention|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
16694707|NCT01985776|No Intervention|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
16694708|NCT01985763|Experimental|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.
16694709|NCT01985750|Placebo Comparator|Drug: d-cycloserine or placebo|"Other Names:
~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception
~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
16694710|NCT01985750|Active Comparator|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo
~Other Names:
~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception
~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
16694711|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
16694712|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
16694713|NCT01985724|Active Comparator|A|FEC -> TXT
16694714|NCT01985724|Experimental|B|Docetaxel/Cyclophosphamide (TC)
16695446|NCT01980745|Active Comparator|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
16694715|NCT01985711|Experimental|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
16694716|NCT01985711|Other|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
16694717|NCT01985698|Experimental|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
16694718|NCT01985698|Active Comparator|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
16694719|NCT01985685|Experimental|Thiamine|200mg intravenous thiamine in 50ml 5% dextrose, single dose
16694720|NCT01985685|Placebo Comparator|Placebo|50ml intravenous 5% dextrose, single dose
16694721|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
16694722|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
16694723|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
16694724|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
16694725|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
16694726|NCT01985646|Experimental|surgery treatment|one stage pull through left-colectomy
16694727|NCT01985646|Experimental|conservative treatment|anal dilation, colonic lavage, oral probiotic
16694728|NCT01985633|Experimental|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
16694729|NCT01985633|Active Comparator|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
16694730|NCT01985620|Active Comparator|study group|Educational intervention with the parents
16694731|NCT01985620|No Intervention|control group|
16694732|NCT01985607|Experimental|Thickened|
16694733|NCT01985607|Active Comparator|Control|
16694734|NCT01985594|Active Comparator|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
16694735|NCT01985594|Placebo Comparator|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
16694736|NCT01985581|Experimental|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
16694737|NCT01985581|Placebo Comparator|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
16694738|NCT01985568|Active Comparator|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
16694739|NCT01985568|Experimental|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
16694740|NCT01985555|Experimental|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
16694741|NCT01985542|Active Comparator|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
16694742|NCT01985542|No Intervention|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
16694743|NCT01985529|Experimental|Exercise|Enrollment in pulmonary rehabilitation
16694744|NCT01985529|No Intervention|Control|
16694745|NCT01985516|Experimental|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
16694746|NCT01985516|Active Comparator|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
16694747|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
16694748|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
16694749|NCT01985490|Experimental|epiretinal membrane|
16694777|NCT01985334|Experimental|C2 (indacaterol/glycopyrronium)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
16694778|NCT01985334|Experimental|D1 (any LAMA or LABA and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
16694823|NCT01985035|Experimental|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
16694750|NCT01985477|Experimental|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.
~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.
~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
16694751|NCT01985477|Experimental|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.
~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
16694752|NCT01985464|Experimental|Umbilical cord mesenchymal stem cells|
16694753|NCT01985451|Experimental|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
16694754|NCT01985438|Active Comparator|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
16694755|NCT01985438|Active Comparator|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
16694756|NCT01985425|Experimental|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
16694757|NCT01985425|Placebo Comparator|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
16694758|NCT01985412||Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
16694759|NCT01985412||Pediatric Heart Transplant Recipients|Patients <18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
16694760|NCT01985412||Adult Lung Transplant Recipients|Patients >18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
16694761|NCT01985412||Pediatric Lung Transplant Recipients|Patients <18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
16694762|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
16694763|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
16694764|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
16694765|NCT01985386|Experimental|GDS (gastric delivery system), meal|GDS capsule with meal
16694766|NCT01985386|Active Comparator|Ferrous sulfate, meal|Ferrous sulfate with meal
16694767|NCT01985373|Experimental|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
16694770|NCT01985347|Active Comparator|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
16694771|NCT01985347|No Intervention|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression & normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
16694772|NCT01985334|Experimental|A1 (any SABA and/or SAMA)|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
16694773|NCT01985334|Experimental|A2 (glycopyrronium)|Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
16694774|NCT01985334|Experimental|B1 (any LAMA or LABA and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
16694775|NCT01985334|Experimental|B2 (glycopyrronium and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
16694776|NCT01985334|Experimental|C1 (any LABA and ICS)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
16694779|NCT01985334|Experimental|D2 (indacaterol/glycopyrronium and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
16694780|NCT01985321|Experimental|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
16694781|NCT01985321|Placebo Comparator|Placebo/Ethanol|36 applications over a 96 hour period
16694782|NCT01985308|Experimental|MRT-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
16694783|NCT01985308|Sham Comparator|MRT-SHAM|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
16694784|NCT01985295|Other|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --
~(starting) 400 mg 3
~600 mg 3
~(maximum) 800 mg 3"
16694785|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
16694786|NCT01985269|Active Comparator|Home visits|Minimal physical examination at home Drug adherence/pill counts
16694787|NCT01985269|No Intervention|Control|Normal standard of care
16694788|NCT01985256|Experimental|Single Arm|Toca 511 vector/Toca FC
16694789|NCT01985243|Experimental|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
16694790|NCT01985243|Experimental|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
16694791|NCT01985243|No Intervention|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
16694792|NCT01985243|No Intervention|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
16694793|NCT01985230|Experimental|ReActiv8 Implant|
16694794|NCT01985204|Placebo Comparator|Placebo|Placebo tablet
16694795|NCT01985204|Experimental|Intervention|Iodine tablet
16694796|NCT01985191|Experimental|Arm 1|SAR405838 and pimasertib in escalating doses
16694797|NCT01985178|Experimental|Omega-3 Fatty Acid Supplement|
16694798|NCT01985165|Experimental|Imrecoxib|0.1g,BID,po
16694799|NCT01985152|Experimental|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
16694800|NCT01985152|Experimental|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
16694801|NCT01985152|Experimental|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
16694802|NCT01985152|Experimental|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
16694803|NCT01985152|Experimental|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
16694804|NCT01985152|Experimental|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
16694805|NCT01985152|Experimental|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
16694806|NCT01985152|Placebo Comparator|Placebo|Placebo-matching tablets, orally
16694807|NCT01985139|Experimental|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
16694808|NCT01985139|Experimental|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
16694809|NCT01985126|Experimental|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
16694810|NCT01985126|Experimental|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
16694811|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
16694812|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
16694813|NCT01985100|Experimental|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
16694815|NCT01985074|Experimental|Case-management intervention|Receiving nurse-managed intervention
16694816|NCT01985074|No Intervention|Control arm|Control group not receiving any intervention
16694817|NCT01985061|Active Comparator|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
16694818|NCT01985061|Experimental|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
16694819|NCT01985061|Active Comparator|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
16694820|NCT01985035|Experimental|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
16694821|NCT01985035|Experimental|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
16694822|NCT01985035|Experimental|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
16694901|NCT01984502|Experimental|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
16694824|NCT01985022|Experimental|PII with IES|The treatment condition that this group receives is PII with IES for 9 months.
16694825|NCT01985022|Experimental|IES|The treatment condition that this group receives is IES for 9 months.
16694826|NCT01985009|Other|Fibroscan®|Single arm study. See intervention item for détails..
16694827|NCT01984996|Experimental|Freedom ProFlor Inguinal Hernia Implant|
16694828|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
16694829|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
16694830|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
16694831|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
16694832|NCT01984983|Placebo Comparator|Placebo: 0.9% saline|0.9% saline
16694833|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
16694834|NCT01984957|Other|disease (ALS, SMA or SBMA)|muscle biopsy
16694835|NCT01984944|Other|Autistic Patient|"50 adults
~25 childs"
16694836|NCT01984944|Other|Controls|"50 adults
~25 childs"
16694837|NCT01984931|Experimental|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
16694838|NCT01984931|Active Comparator|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
16694839|NCT01984918|Active Comparator|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
16694840|NCT01984918|No Intervention|Non-SMS reminder|No text message reminder via Short Message Service (SMS) will be sent
16694841|NCT01984892|Experimental|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
16694842|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
16694843|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).
~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
16694844|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
16694845|NCT01984840|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
16694846|NCT01984840|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
16694847|NCT01984827|Experimental|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
16694848|NCT01984827|Experimental|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
16694849|NCT01984827|Placebo Comparator|Placebo|Placebo
16694850|NCT01984814|Experimental|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
16694851|NCT01984814|No Intervention|Control|No cell transplantation was done
16694852|NCT01984801|Experimental|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
16694853|NCT01984801|Experimental|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
16694854|NCT01984801|Experimental|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
16694855|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
16694856|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
16694857|NCT01984775|Experimental|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
16694858|NCT01984775|Experimental|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
16694859|NCT01984775|Experimental|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
16694860|NCT01984775|Placebo Comparator|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
16694861|NCT01984775|Active Comparator|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
16694862|NCT01984775|Active Comparator|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
16694863|NCT01984762|Active Comparator|RYGBP|Roux-en-Y gastric bypass
16694864|NCT01984762|Active Comparator|SG|sleeve gastrectomy
16694865|NCT01984749|Experimental|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
16694866|NCT01984749|No Intervention|Non-febuxostat treatment group|No febuxostat treatment
16694867|NCT01984736|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
16694868|NCT01984723|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
16694869|NCT01984710|Experimental|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
16694870|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
16694871|NCT01984697|Experimental|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
16694872|NCT01984697|Experimental|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
16694873|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
16694874|NCT01984697|Active Comparator|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
16694875|NCT01984684|Experimental|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
16694876|NCT01984684|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
16694877|NCT01984671|Experimental|Mobile Pain Coping Skills Training|Pain coping skills training
16694878|NCT01984671|No Intervention|Standard Care Control|
16694879|NCT01984658|Experimental|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
16694880|NCT01984645|Experimental|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
16694881|NCT01984645|No Intervention|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
16694882|NCT01984632|Experimental|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
16694883|NCT01984632|Active Comparator|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
16694884|NCT01984619||Blunt Tip Cannula|
16694885|NCT01984606|Experimental|Empagliflozin|Empagliflozin once daily
16694886|NCT01984606|Active Comparator|Sitagliptin|Sitagliptin once daily
16694887|NCT01984593|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
16694888|NCT01984593|Active Comparator|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
16694889|NCT01984580|Experimental|Zinc|
16694890|NCT01984580|Placebo Comparator|sodium|
16694891|NCT01984567|Experimental|Vitamin E|
16694892|NCT01984567|Experimental|Lipoic acid|
16694893|NCT01984567|Placebo Comparator|Control|
16694894|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
16694895|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
16694896|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
16694897|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
16694898|NCT01984541|Experimental|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
16694899|NCT01984528|Experimental|Prick Test|Alternaria alternata allergen extract Positve control Negative control
16694900|NCT01984515|Experimental|Team Red Primary Care|Eligible patients will receive the Referral Management System in primary care
16695447|NCT01980745|Placebo Comparator|sugar pill|sugar pill
16694902|NCT01984489|Placebo Comparator|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
16694903|NCT01984489|Experimental|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
16694904|NCT01984489|Experimental|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
16694905|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
16694906|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
16694907|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
16694908|NCT01984463|Active Comparator|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
16694909|NCT01984463|Experimental|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
16694910|NCT01984450|Active Comparator|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
16694911|NCT01984450|Active Comparator|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
16694912|NCT01984424|Other|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
16694913|NCT01984424|Other|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
16694914|NCT01984424|Active Comparator|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
16694915|NCT01984424|Experimental|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
16694916|NCT01984424|Experimental|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
16694917|NCT01984411|Experimental|Radial Technical|Radial technical is the procedure for catheterization
16694918|NCT01984411|Active Comparator|Femoral Technical|Vascular Access for cardiac catheterization
16694919|NCT01984398|Experimental|12.5 mg Androxal (formulations A and B)|12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
16694920|NCT01984398|Experimental|25 mg Androxal (formulations A and B)|25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
16694921|NCT01984385||Patients with a hip fracture|
16694922|NCT01984372||Tresiba® users|
16694923|NCT01984359|Other|Single arm|Biosamples will be obtained at multiple time-points for all participants
16694924|NCT01984346|Experimental|Convergent Procedure|Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
16694925|NCT01984346|Active Comparator|Standalone Endocardial Catheter Ablation|Endocardial Catheter Ablation Treatment
16694926|NCT01984333|Experimental|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
16694927|NCT01984333|No Intervention|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
16694974|NCT01984047|Experimental|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
16695448|NCT01980719||Healthy, Age-Matched|
16694928|NCT01984320|Active Comparator|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
16694929|NCT01984320|Active Comparator|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
16694930|NCT01984320|Active Comparator|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
16694931|NCT01984294|Experimental|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
16694932|NCT01984294|Experimental|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
16694933|NCT01984294|Experimental|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
16694934|NCT01984281|Experimental|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
16694935|NCT01984281|No Intervention|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
16694936|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
16694937|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
16694938|NCT01984255|Active Comparator|A- Bavituximab plus Ipilimumab|Arm A-Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
16694939|NCT01984255|Experimental|Arm B Ipilimumab|Arm B-Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
16694940|NCT01984242|Experimental|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
16694941|NCT01984242|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union [EU] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
16694942|NCT01984242|Active Comparator|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
16694943|NCT01984229|Experimental|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
16694944|NCT01984229|Experimental|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
16694945|NCT01984216|Experimental|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
16694946|NCT01984216|Active Comparator|Billroth II|Billroth II for the gastrojejunostomy reconstruction
16694947|NCT01984203|Experimental|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.
~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
16694948|NCT01984203|Active Comparator|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.
~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
16694949|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
16694950|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
16694951|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
16694952|NCT01984164|Active Comparator|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
16694953|NCT01984164|Active Comparator|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
16694954|NCT01984138|Experimental|Estring|ESTRING
16694955|NCT01984138|Active Comparator|REPLENS|Replens
16694956|NCT01984125|Experimental|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
16694957|NCT01984125|No Intervention|Control|
16694958|NCT01984112|Experimental|Intramedullary Locked Nail|
16694959|NCT01984112|Active Comparator|Locked Plate|
16694960|NCT01984099|Active Comparator|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
16694961|NCT01984099|Placebo Comparator|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
16694962|NCT01984086|Experimental|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
16694963|NCT01984086|Experimental|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
16694964|NCT01984073|Active Comparator|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
16694965|NCT01984073|Active Comparator|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
16694966|NCT01984073|Placebo Comparator|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
16694967|NCT01984060|Other|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.
~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
16694968|NCT01984060|No Intervention|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
16694969|NCT01984047|Experimental|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
16694970|NCT01984047|Experimental|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
16694971|NCT01984047|Experimental|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
16694972|NCT01984047|Experimental|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
16694973|NCT01984047|Experimental|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
16695449|NCT01980719||Fatigued|
16694975|NCT01984034|Experimental|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
16694976|NCT01984034|Active Comparator|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
16694977|NCT01984021|Experimental|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
16694978|NCT01984021|Placebo Comparator|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
16694979|NCT01984008|Experimental|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
16694980|NCT01984008|Active Comparator|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
16694981|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
16694982|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
16694983|NCT01983969|Experimental|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
16694984|NCT01983956|Experimental|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
16694985|NCT01983956|No Intervention|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
16694986|NCT01983943|Experimental|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
16694987|NCT01983943|Placebo Comparator|Placebo|Placebo 40mg will be taken once per day for 6 months.
16694988|NCT01983930|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
16694989|NCT01983930|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 20 minute meditation
16694990|NCT01983917|Other|Use of the Diabetes Application|
16694991|NCT01983904|Experimental|Long Pulse Width|deep brain stimulation with short & long pulse width
16694992|NCT01983904|Experimental|Short Pulse Width|deep brain stimulation with short & long pulse width
16694993|NCT01983891|Experimental|Intervention|6-week nutrition education and cooking course
16694994|NCT01983878|Experimental|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
16694995|NCT01983865|Other|Exposure to birch pollen|
16694996|NCT01983852||1|Children during End of Life Care
16694997|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
16694998|NCT01983826|Experimental|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
16694999|NCT01983826|Placebo Comparator|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
16695000|NCT01983813|Experimental|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
16695001|NCT01983813|Other|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
16695002|NCT01983800|Active Comparator|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
16695003|NCT01983800|Active Comparator|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
16695004|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
16695005|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
16695006|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
16695007|NCT01983761|Experimental|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment
~Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)
~Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000
~Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000
~Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000
~Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg
~Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg
~Day6 Rest
~Day7 Rest
~Day8 Cord blood infusions"
16695008|NCT01983761|Experimental|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment
~Day0 Admit, hydration
~Day1 Fludarabine 40 mg/m2 IV
~Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg
~Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg
~Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV
~Day5 Rest Day6 Cord blood infusions"
16695009|NCT01983748|Experimental|A|Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA
16695010|NCT01983748|No Intervention|B|Control, Standard of care, which is clinical control every 3 months
16695011|NCT01983735|Experimental|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
16695012|NCT01983735|Active Comparator|S-Amlodipine 2.5, 5mg|
16695013|NCT01983709|Experimental|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.
~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
16695014|NCT01983696|Experimental|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
16695015|NCT01983696|No Intervention|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
16695016|NCT01983683|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
16695017|NCT01983683|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
16695018|NCT01983670|Experimental|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
16695019|NCT01983670|Experimental|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
16695020|NCT01983670|No Intervention|health group 2|health subjects controlled group
16695021|NCT01983670|No Intervention|SCA group 2|SCA subjects controlled group
16695022|NCT01983657|Experimental|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
16695023|NCT01983657|Experimental|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
16695024|NCT01983657|Experimental|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
16695025|NCT01983657|Active Comparator|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~When the treatment is ineffective, and anti-GM-CSF antibody titers level <1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
16695026|NCT01983644|Experimental|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
16695027|NCT01983644|Active Comparator|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
16695028|NCT01983631|Experimental|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
16695029|NCT01983631|No Intervention|Non-WBV group|Stage 1 : Controlled group
16695030|NCT01983631|Experimental|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
16695031|NCT01983631|No Intervention|non-training group|Stage 2: Controlled group
16695032|NCT01983618|Placebo Comparator|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
16695033|NCT01983618|Experimental|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
16695034|NCT01983605|Experimental|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
16695035|NCT01983592|Active Comparator|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
16695067|NCT01983423|No Intervention|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
16695450|NCT01980719||Not Fatigued|
16695036|NCT01983592|Placebo Comparator|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
16695037|NCT01983579|Experimental|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
16695038|NCT01983579|Experimental|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
16695039|NCT01983579|Experimental|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
16695040|NCT01983566|Active Comparator|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
16695041|NCT01983566|Experimental|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
16695042|NCT01983566|Experimental|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
16695043|NCT01983566|Experimental|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
16695044|NCT01983553||CYD Dengue Vaccine Group|Participants who received 3 injections of 0.5 milliliter (mL) CYD dengue vaccine, 1 injection each at 0, 6, and 12 months, subcutaneously in study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
16695045|NCT01983553||Control Group|Participants who received either 0.5 mL Rabies vaccine (Verorab®) or placebo control, subcutaneously as a first injection on Day 0, placebo for second and third injections at 6 and 12 months, respectively in the study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
16695046|NCT01983540|Experimental|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
16695047|NCT01983540|Experimental|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
16695048|NCT01983540|Active Comparator|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
16695049|NCT01983527|Experimental|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
16695050|NCT01983527|Active Comparator|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
16695051|NCT01983527|Active Comparator|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
16695052|NCT01983514|Active Comparator|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
16695053|NCT01983514|Placebo Comparator|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
16695054|NCT01983514|Experimental|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
16695055|NCT01983514|Experimental|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
16695056|NCT01983501|Experimental|Tucatinib (ONT-380) in combination with T-DM1|
16695057|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
16695058|NCT01983475|Placebo Comparator|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
16695059|NCT01983475|Experimental|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
16695060|NCT01983462|Experimental|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
16695061|NCT01983462|Active Comparator|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
16695062|NCT01983462|Placebo Comparator|Placebo|Placebo
16695063|NCT01983449|Experimental|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
16695064|NCT01983436|Experimental|Manual Lymphatic Drainage|"9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.
~4 more sessions (one every two days)."
16695065|NCT01983436|No Intervention|Control|No session of manual lymphatic drainage
16695066|NCT01983423|Experimental|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
16695531|NCT01980108|Experimental|400mL|400mL of water will be given to the patient prior to scanning
16695068|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
16695069|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
16695070|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
16695071|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
16695072|NCT01983397|Experimental|Resistance training|Resistance training
16695073|NCT01983397|Experimental|Multicomponent training|Multicomponent training
16695074|NCT01983397|No Intervention|Control Group|The Control Group did not realize any intervention.
16695075|NCT01983384|Placebo Comparator|Anesthetic Depth: standard care|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive routine anesthetic management not guided by the processed electroencephalogram
16695076|NCT01983384|Experimental|Anesthetic Depth: interventional|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive anesthetic management guided by the processed electroencephalogram (processed EEG-guided anesthetic depth)
16695077|NCT01983371|Experimental|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
16695078|NCT01983358|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
16695079|NCT01983358|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
16695082|NCT01983332||occupational therapists|Occupational Therapists
16695083|NCT01983319|Experimental|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
16695084|NCT01983319|Sham Comparator|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
16695085|NCT01983319|No Intervention|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
16695086|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
16695087|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
16695088|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
16695089|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
16695090|NCT01983293|Experimental|QLV based implant strategy|QLV represents the pacing site with the largest amount of dyssynchrony as measured by the left ventricular electrical delay. The QLV based implant strategy finds the left ventricle vein branch and left ventricular lead cathode with the longest QLV measurement and places the lead at this location and programs the device using this lead cathode.
16695091|NCT01983293|Placebo Comparator|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach.
16695092|NCT01983280|Experimental|Healing Touch|
16695093|NCT01983267|Active Comparator|cannabis|Patient using cannabis during chemotherapy treatment
16695094|NCT01983267|No Intervention|control|Patients under chemotherapy treatment
16695095|NCT01983254|Experimental|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
16695096|NCT01983254|Active Comparator|education program|6 week access to a web-based, critical illness-specific education program
16695097|NCT01983241|Experimental|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
16695098|NCT01983241|Experimental|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
16695099|NCT01983241|Placebo Comparator|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
16695100|NCT01983228|No Intervention|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
16695101|NCT01983228|Experimental|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
16695102|NCT01983215|Experimental|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
16695103|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
16695104|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
16695105|NCT01983189|Experimental|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
16695106|NCT01983163|Active Comparator|ketogenic diet|ketogenic diet (2.5 to 4:1)
16695107|NCT01983163|Active Comparator|Modifid Atkin's diet|Modified Atkin's Diet
16695108|NCT01983150|Experimental|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
16695109|NCT01983150|Active Comparator|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
16695110|NCT01983124|Experimental|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
16695111|NCT01983111|Experimental|buprenorphine|Patch
16695112|NCT01983111|Active Comparator|tramadol/acetaminophen|Oral tablet
16695113|NCT01983085|Other|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
16695114|NCT01983085|Other|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
16695115|NCT01983072|Active Comparator|Infant starter formula|standard infant formula
16695116|NCT01983072|Experimental|Infant starter formula + prebiotics + probiotics|infant formula
16695117|NCT01983072|Other|Breastfeeding group|reference group
16695118|NCT01983059||Patients with Liver Venous Thrombosis|
16695119|NCT01983046|Placebo Comparator|placebo|placebo
16695120|NCT01983046|Active Comparator|high acetate ratio|high acetate ratio
16695121|NCT01983046|Active Comparator|high butyrate ratio|high butyrate ratio
16695122|NCT01983046|Active Comparator|high propionate ratio|high propionate ratio
16695123|NCT01983033|Experimental|active treatment condition (ATC)|training protocol 'drop it'
16695124|NCT01983033|Other|waiting list control|no treatment other than treatment as usual
16695125|NCT01983020|Experimental|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
16695126|NCT01983020|Experimental|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
16695127|NCT01983020|Experimental|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
16695128|NCT01983020|Placebo Comparator|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
16695129|NCT01983007|Experimental|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
16695130|NCT01983007|Experimental|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
16695131|NCT01982994|Experimental|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
16695132|NCT01982994|No Intervention|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
16695133|NCT01982981|No Intervention|control|The control group only be assessed
16695134|NCT01982981|Experimental|water provision|The experimental group get water every 15 days
16695137|NCT01982955|Experimental|Phase 1b: Tepotinib 300 milligram (mg)|Participants received Tepotinib 300 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
16695138|NCT01982955|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
16695139|NCT01982955|Experimental|Phase 2: Tepotinib and Gefitinib|Participants randomized to receive Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
16695140|NCT01982955|Experimental|Phase 2: Pemetrexed and Cisplatin/Carboplatin|Participants randomized to receive 500 milligram per square meter (mg/m^2) of Pemetrexed as intravenous infusion over 10 minutes in combination with Cisplatin (75 mg/m2 as an intravenous infusion over 2 hours) or Carboplatin (intravenously at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator) on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment or up to 6 cycles if or 4 cycles followed by Premetrexed maintenance monotherapy.
16695141|NCT01982955|Experimental|Phase 2: Single-arm Cohort (MET+ T790M positive)|Participants with MET+ T790M positive Non-small Cell Lung Cancer (NSCLC) received a Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
16695142|NCT01982942|Experimental|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
16695143|NCT01982942|Placebo Comparator|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
16695144|NCT01982929|Sham Comparator|Sham block & Oral Meds|Definition intervention. Sham procedure. Blocks mimicked the TAP blocks, but neither needle nor injectate was used. Patients had bilateral ultrasound scans over the lateral aspect of the abdomen. To mimic the injection of medicine, a blunt needleless syringe was firmly pressed on either side of the abdomen. An adhesive bandage was applied over the injection or sham injection sites.
16695145|NCT01982929|Experimental|TAP block & Oral Meds|Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
16695146|NCT01982916|Experimental|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
16695147|NCT01982916|Placebo Comparator|Placebo|Placebo by bid for 4 weeks
16695148|NCT01982916|Active Comparator|Active comparator|Active Comparator and Placebo by bid for 4 weeks
16695149|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
16713186|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
16695150|NCT01982890||Normal human controls|"Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.
~Subjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
16695151|NCT01982877|Experimental|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
16695152|NCT01982877|Experimental|Educational Control|ICU educational component
16695153|NCT01982864|Experimental|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
16695154|NCT01982851|Active Comparator|Group E|Epidural de novo technique
16695155|NCT01982851|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
16695156|NCT01982851|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
16695157|NCT01982838|Active Comparator|Group E|Epidural de novo technique
16695158|NCT01982838|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
16695159|NCT01982838|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
16695160|NCT01982825|Experimental|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
16695161|NCT01982825|Active Comparator|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
16695162|NCT01982812|Experimental|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
16695163|NCT01982812|Active Comparator|Standard AED|Standard AED regimen
16695164|NCT01982799|Experimental|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
16695165|NCT01982799|Experimental|Endodontic Tx plus local anesthetic|local anesthetic
16695166|NCT01982786|Active Comparator|Arm 1|IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
16695167|NCT01982786|Active Comparator|Arm 2|"IGRT 37.5 Gy in 15 fractions
~+ HDR brachytherapy boost 15 Gy"
16695168|NCT01982773|Experimental|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
16695169|NCT01982773|Active Comparator|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
16695170|NCT01982760|Experimental|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
16695171|NCT01982760|No Intervention|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
16695172|NCT01982747|Other|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
16695173|NCT01982747|Other|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
16695174|NCT01982734|Active Comparator|Native curcumin|80 mg curcumin as native powder
16695175|NCT01982734|Experimental|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
16695176|NCT01982734|Experimental|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
16695177|NCT01982734|Experimental|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
16695178|NCT01982721|Experimental|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
16695179|NCT01982721|No Intervention|Healthy volunteers|
16695180|NCT01982695|Active Comparator|Lisinopril|
16695181|NCT01982695|Active Comparator|Losartan|
16695182|NCT01982682|Experimental|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
16695183|NCT01982669||Different degree of spicy food intake|
16695184|NCT01982656|Experimental|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
16695185|NCT01982656|Placebo Comparator|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
16695186|NCT01982643|Experimental|naltrexone plus bupropion|extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)
16695187|NCT01982630|Experimental|Part I - MK-8521 64/120 μg/day|Participants will receive once daily subcutaneous MK-8521 (starting dose 64 μg/day Days 1 to 7 escalated to 120 μg/day for Days 8 to 14).
16695188|NCT01982630|Experimental|Part I - MK-8521 34/72 μg/day|Participants will receive once daily subcutaneous MK-8521(starting dose 34 μg/day Days 1 to 7 escalated to 72 μg/day for Days 8 to 14).
16695189|NCT01982630|Active Comparator|Part I - Liraglutide 0.6/1.2/1.8 mg/day|Participants will receive once daily subcutaneous liraglutide (starting dose 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, escalated to 1.8 mg for Days 8 to 14).
16695190|NCT01982630|Placebo Comparator|Part I - Placebo|Participants receive a dose of placebo that will match the administration volume of MK-8521.
16695191|NCT01982630|Experimental|Part II - MK-8521 300 ug/day - T2DM Participants|For T2DM participants, MK-8521 titrated to 300 ug/day. Starting at 64 ug and increasing to 120 ug on Day 8 and to 180 ug on Day 15 and increasing to 240 ug on Day 20 and to 300 ug on Day 25. The total number of dosing days will be 29.
16695192|NCT01982630|Active Comparator|Part II - Liraglutide 1.8 mg/day - T2DM Participants|Liraglutide titrated to 1.8 mg/day for 29 days. Starting at 0.6 mg and increasing to 1.2 mg on Day 8 and to 1.8 mg on Day 15.
16695193|NCT01982630|Placebo Comparator|Part II - Placebo - T2DM Participants|Participants receive a dose of placebo that will match the administration volume of MK-8521 across the 29 days.
16695194|NCT01982630|Experimental|Part II - MK-8521 120 ug/day - Non-Diabetic Participants|For non-diabetic overweight/obese participants MK-8521 titrated to 120 ug/day. The total dosing days will be 14 days, starting at 64 ug and increasing to 120 ug on Day 8.
16695195|NCT01982617|Experimental|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
16695196|NCT01982617|Experimental|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
16695197|NCT01982604|Experimental|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:
~TI-Inhalation Powder A TI-Inhalation Powder B
~*30 units (10 units + 20 units)"
16695198|NCT01982604|Experimental|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:
~TI-Inhalation Powder B TI-Inhalation Powder A
~*30 units (10 units + 20 units)"
16695199|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
16695200|NCT01982578|Experimental|Product: Genistein|60 mg of genistein BID for 360 days. Intervention: Product: Genistein
16695201|NCT01982578|Placebo Comparator|Product: Placebo|1 placebo capsule BID for 360 days. Intervention: Product: Placebo
16695202|NCT01982565|Experimental|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
16695203|NCT01982565|Active Comparator|Control Arm|Standard of Care
16695204|NCT01982539|Experimental|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
16695205|NCT01982526||Endmetrioma surgery|
16695206|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.
~These patients will be examined in 4 positions with the ultrasound."
16695207|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
16695208|NCT01982487|No Intervention|Arm A (no treatment)|Patients receive no treatment.
16695209|NCT01982487|Experimental|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
16695210|NCT01982487|Experimental|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
16695211|NCT01982487|Experimental|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
16695212|NCT01982474|Experimental|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
16695213|NCT01982474|Placebo Comparator|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
16695214|NCT01982474|No Intervention|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
16695215|NCT01982461|Experimental|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
16695216|NCT01982461|Active Comparator|Crestor®|One Crestor® tablet 10mg taken once daily.
16695217|NCT01982448|Experimental|Arm A: Cisplatin|Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
16695218|NCT01982448|Experimental|Arm B: Paclitaxel|Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
16695219|NCT01982435|Other|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
16695220|NCT01982435|Other|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
16695221|NCT01982422|Experimental|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
16713564|NCT01859585|No Intervention|No medication|No medication
16695222|NCT01982422|Placebo Comparator|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
16695223|NCT01982409|Experimental|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
16695224|NCT01982396|Active Comparator|Twice daily|
16695225|NCT01982396|Experimental|Once daily|
16695226|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
16695227|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
16695228|NCT01982357||premature infant|Laser Speckle Imaging and Diffuse Optical Spectroscopy
16695229|NCT01982344|Experimental|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
16695230|NCT01982344|No Intervention|usual care (G1)|The one group perform traditional PD procedure (G1)
16695231|NCT01982331|Experimental|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
16695232|NCT01982331|Placebo Comparator|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
16695233|NCT01982318|Active Comparator|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
16695234|NCT01982318|Placebo Comparator|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
16695235|NCT01982305|Experimental|Simulator|One training session with the simulator.
16695236|NCT01982305|Active Comparator|Cadaver|One training session with a cadaver.
16695237|NCT01982292|Experimental|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
16695238|NCT01982292|Placebo Comparator|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
16695239|NCT01982266|Experimental|GRADION™ Hip Total Cartilage Replacement (TCR)™|
16695240|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
16695241|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
16695242|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
16695243|NCT01982240|Active Comparator|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
16695244|NCT01982240|Active Comparator|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
16695245|NCT01982240|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
16695246|NCT01982240|Other|Bisacodyl|Rescue medication
16695247|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
16695248|NCT01982214|Sham Comparator|sedentary|No intervention
16695249|NCT01982214|Experimental|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
16695250|NCT01982201|Experimental|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
16695251|NCT01982201|Experimental|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
16695252|NCT01982188||Single incision sling|
16695253|NCT01982175|Experimental|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
16695254|NCT01982162||Cohort A|severe school aged asthma cohort
16695255|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
16695256|NCT01982162||Cohort C|Severe pre school wheeze cohort
16695257|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
16695258|NCT01982149||Group 1|Non-smokers (n=20)
16695259|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
16695260|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
16695261|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
16695262|NCT01982123|Experimental|SPECT/CT Mid-& Post-RT|Investigational 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment.
16695263|NCT01982110|Experimental|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
16695264|NCT01982110|Active Comparator|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
16695265|NCT01982097||Group 1|
16695266|NCT01982071|Experimental|Treatment group|Intravenous (IV)
16695300|NCT01981850|Experimental|Stage 2: Cohort 3 10mg /kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
16695301|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
16695267|NCT01982058|Experimental|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
16695268|NCT01982058|Active Comparator|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
16695269|NCT01982058|Other|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
16695270|NCT01982045|Experimental|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
16695271|NCT01982045|Active Comparator|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
16695272|NCT01982032|Active Comparator|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
16695273|NCT01982032|Active Comparator|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
16695274|NCT01982019|Other|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
16695275|NCT01982019|Other|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
16695276|NCT01982019|Other|healthy volonteers|Meal test taking and hormones measure including 26RFa
16695277|NCT01982006|Active Comparator|Phaco|Cataract surgery by phacoemulsification
16695278|NCT01982006|Experimental|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
16695279|NCT01981993||patients at ICU with sepsis|
16695280|NCT01981980|Experimental|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
16695281|NCT01981980|Experimental|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
16695282|NCT01981967|Experimental|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
16695283|NCT01981967|Active Comparator|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
16695284|NCT01981954|Experimental|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
16695285|NCT01981941|Experimental|Treatment group|Oral
16695286|NCT01981928|Experimental|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
16695287|NCT01981928|Placebo Comparator|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
16695288|NCT01981915|Experimental|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
16695289|NCT01981915|Experimental|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
16695290|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
16695291|NCT01981889|Other|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
16695292|NCT01981863|Experimental|Epsilonaminocaproic acid|One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo
16695293|NCT01981863|Placebo Comparator|Placebo, Antifibrinolytic activity|Placebo: same IV volume as experimental arm
16695294|NCT01981850|Experimental|Stage 1: Cohort 1 Weekly|Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
16695295|NCT01981850|Experimental|Stage 1: Cohort 1 Every 4 Weeks|Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
16695296|NCT01981850|Experimental|Stage 1: Cohort 2 Weekly|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
16695297|NCT01981850|Experimental|Stage 1: Cohort 2 Every 4 Weeks|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
16695298|NCT01981850|Experimental|Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
16695299|NCT01981850|Experimental|Stage 2: Cohort 2 3mg/kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
16695302|NCT01981811|Active Comparator|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
16695303|NCT01981798|Active Comparator|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
16695304|NCT01981798|No Intervention|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
16695305|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
16695306|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
16695307|NCT01981772|Experimental|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
16695308|NCT01981772|Active Comparator|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
16695309|NCT01981759|Placebo Comparator|Placebo|Participants receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
16695310|NCT01981759|Experimental|D-Cycloserine|Participants will receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
16695311|NCT01981746|Experimental|30 ml|30 ml ropivacaine 0.1%, single bolus
16695312|NCT01981746|Experimental|10 ml|10 ml 0.1% ropivacaine, single bolus
16695313|NCT01981733|Experimental|Device|
16695314|NCT01981720|Experimental|1.0 mg/kg|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
16695315|NCT01981707|Experimental|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
16695316|NCT01981694|Experimental|Single ascending doses|
16695317|NCT01981694|Experimental|Measurement of eye blink rate|
16695318|NCT01981681|Experimental|Cohort 1 Experimental Arm|
16695319|NCT01981681|Experimental|Cohort 2 Experimental Arm|
16695320|NCT01981681|Experimental|Cohort 3 Experimental Arm|
16695321|NCT01981681|Placebo Comparator|Cohort 3 Placebo Arm|
16695322|NCT01981681|Experimental|Cohort 4 Experimental Arm|
16695323|NCT01981681|Placebo Comparator|Cohort 4 Placebo Arm|
16695324|NCT01981668|Experimental|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
16695325|NCT01981655|Experimental|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
16695326|NCT01981655|Active Comparator|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
16695327|NCT01981642|Experimental|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
16695328|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
16695329|NCT01981616|Experimental|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
16695330|NCT01981616|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
16695331|NCT01981603|Experimental|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
16695332|NCT01981603|No Intervention|usual care|usual care
16695333|NCT01981590|Experimental|All enrolled patients|All enrolled patients that underwent a scheduled cardiac catheterization involving an atrial fibrillation (AF) ablation procedure as per clinical practice
16695334|NCT01981577||Patients with Parkinson's Disease|
16695335|NCT01981577||Healthy volunteers|
16695336|NCT01981564|Experimental|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
16695337|NCT01981564|Active Comparator|Standard Asthma Education Control group|Standard asthma education during nurse home visits
16695338|NCT01981551|Experimental|PF-03084014 in Desmoid Tumors/Aggressive Fibromatosis|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
16695340|NCT01981525|Experimental|Arm 1|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
16695341|NCT01981499|Experimental|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
16695342|NCT01981499|Placebo Comparator|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
16695343|NCT01981499|Experimental|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
16695344|NCT01981499|Experimental|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
16695345|NCT01981499|Experimental|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
16695346|NCT01981499|Experimental|Arm B4|Placebo control
16695347|NCT01981486|Placebo Comparator|Placebo|Placebo tablets
16695348|NCT01981486|Experimental|PF-05180999|Modified-release tablets of PF-05180999
16695349|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
16695350|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
16695351|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
16695352|NCT01981460|No Intervention|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
16695353|NCT01981460|Experimental|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
16695354|NCT01981447|Active Comparator|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
16695355|NCT01981447|Active Comparator|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
16695356|NCT01981434|Active Comparator|Video game based obesity education|This is the intervention group. They will be given the opportunity to play an interactive educational video game for teaching health and nutrition.
16695357|NCT01981434|No Intervention|No intervention|This is the control group that will receive only printed information about health and nutrition and will not be given the opportunity to play the educational video game.
16695358|NCT01981421||Liver fibrosis|patients who had chronic liver disease
16695359|NCT01981408|Experimental|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
16695360|NCT01981395|Experimental|Treatment regimn 1|150 mg Fenobam Orally - once
16695361|NCT01981395|Placebo Comparator|Treatment Regimen 2|Placebo orally - once
16695362|NCT01981382||Incident cases|Persistent nonspecific low back pain
16695363|NCT01981382||Controls|Acute low back pain that resolves in <6 months
16695364|NCT01981369|Active Comparator|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
16695365|NCT01981369|Experimental|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
16695366|NCT01981356|Experimental|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
16695367|NCT01981356|Active Comparator|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
16695368|NCT01981343|Experimental|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
16695369|NCT01981343|Placebo Comparator|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
16695370|NCT01981330|Experimental|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
16695371|NCT01981317|Experimental|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.
~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
16695372|NCT01981317|Active Comparator|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
16695373|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
16695374|NCT01981291|Active Comparator|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
16695375|NCT01981291|Experimental|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
16695376|NCT01981278|Experimental|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
16695377|NCT01981278|Experimental|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
16695378|NCT01981265||Hand osteoarthritis|
16695379|NCT01981252|Experimental|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
16695380|NCT01981239|Experimental|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
16695381|NCT01981239|Active Comparator|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
16695382|NCT01981226|Experimental|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
16695383|NCT01981200|Experimental|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
16695384|NCT01981187|Experimental|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
16695385|NCT01981174|Active Comparator|30-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
16695386|NCT01981174|Active Comparator|32-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
16695387|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
16695388|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
16695389|NCT01981148||Healthy patients|Healthy patients
16695390|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
16695391|NCT01981135|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16695392|NCT01981135|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
16695393|NCT01981122|Experimental|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
16695394|NCT01981122|Experimental|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
16695395|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
16695396|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
16695397|NCT01981083|Experimental|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
16695398|NCT01981083|Active Comparator|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
16695399|NCT01981070|Other|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
16695400|NCT01981070|Active Comparator|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
16695401|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
16695402|NCT01981057||Individual|individually prescribed parenteral receipt
16695403|NCT01981044|Experimental|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
16695404|NCT01981031|Experimental|A|Drug: BioChaperone® Combo
16695405|NCT01981031|Active Comparator|B|Drug: Humalog® Mix25
16695406|NCT01981018|Experimental|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
16695407|NCT01981005|Experimental|RO5424802|
16695408|NCT01980992|Active Comparator|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
16695409|NCT01980992|Placebo Comparator|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
16695410|NCT01980979|Experimental|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
16695411|NCT01980966|Experimental|MHAA4549A|
16695412|NCT01980966|Placebo Comparator|Placebo|
16695413|NCT01980966|Active Comparator|Tamiflu|
16695414|NCT01980953|Experimental|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
16695415|NCT01980953|Experimental|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
16695416|NCT01980953|Experimental|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
16695417|NCT01980953|Experimental|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
16695418|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
16695419|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
16695420|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
16695421|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
16695422|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
16695423|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
16695424|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
16695425|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
16695426|NCT01980927|Experimental|NUCCA atlas correction|NUCCA atlas correction for migraine patients
16695427|NCT01980914|Experimental|Type 2 diabetes group|Patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin. All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %.
16695428|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
16695429|NCT01980888|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
16695430|NCT01980888|Placebo Comparator|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
16695431|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
16695432|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
16695433|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
16695434|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
16695435|NCT01980849|Experimental|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
16695436|NCT01980849|Active Comparator|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
16695437|NCT01980836|Active Comparator|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
16695438|NCT01980836|Active Comparator|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
16695439|NCT01980823|Experimental|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
16695440|NCT01980810|Experimental|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
16695441|NCT01980797||Bicuspid aortic valve disease|"Group/Cohort Label - Bicuspid aortic valve
~Group/Cohort Description -
~Patients diagnosed with bicuspid aortic valve
~All ages ≥8 years
~Able to provide fully informed consent"
16695442|NCT01980797||Tricuspid aortic valve control patients|"Group/Cohort Label - Tricuspid aortic valve control patients
~Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched.
~Patients not diagnosed with bicuspid aortic valve
~All ages ≥8 years
~Able to provide fully informed consent"
16695451|NCT01980706|Placebo Comparator|Placebo|Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
16695452|NCT01980706|Active Comparator|30 Mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
16695453|NCT01980706|Active Comparator|90 mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
16695454|NCT01980693|Other|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
16695455|NCT01980680|Experimental|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
16695456|NCT01980680|Active Comparator|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
16695457|NCT01980667|Experimental|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
16695458|NCT01980654|Experimental|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
16695459|NCT01980654|Experimental|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
16695460|NCT01980641|No Intervention|Control group|Assessment of each participant's home and his or her performance of ADL.
16695461|NCT01980641|Experimental|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
16695462|NCT01980641|Experimental|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
16695463|NCT01980641|No Intervention|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
16695464|NCT01980628|Experimental|ibrutinib|ibrutinib capsules: 560 mg once daily
16695465|NCT01980615|Experimental|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
16695466|NCT01980615|Experimental|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
16695467|NCT01980615|Experimental|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
16695468|NCT01980615|Active Comparator|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
16695469|NCT01980615|Active Comparator|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
16695470|NCT01980615|Active Comparator|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
16695471|NCT01980602|Experimental|Supervised Exercise Program|
16695472|NCT01980589|Experimental|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
16695473|NCT01980576||Pre-operative pain measurement|Patients with low back pain
16695474|NCT01980563|Active Comparator|ultrasound|
16695475|NCT01980563|Active Comparator|combined monitoring|
16695476|NCT01980550|Experimental|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
16695477|NCT01980537|Experimental|Stereotaxis|Magnetic wire navigation
16695478|NCT01980537|Active Comparator|Conventional|Conventional wire navigation
16695479|NCT01980524|Experimental|acipimox+|250 mg at 0 and 180 minutes (one day)
16695480|NCT01980524|Placebo Comparator|Placebo|1 Tablet at 0 and 180 minutes (one day)
16695481|NCT01980498|Experimental|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:
~Fentanyl pectin nasal spray (FPNS)
~Physician choice-Usual Care (PC-UC)"
16695482|NCT01980498|Active Comparator|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:
~Fentanyl pectin nasal spray (FPNS)
~Physician choice-Usual Care (PC-UC)"
16695483|NCT01980485|Active Comparator|Feedback on lung age and exhaled carbon monoxide|
16695484|NCT01980485|Sham Comparator|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
16695485|NCT01980472|Experimental|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
16695486|NCT01980459|Experimental|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
16695487|NCT01980446|Other|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
16695488|NCT01980433|Experimental|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
16695489|NCT01980433|Sham Comparator|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
16695490|NCT01980420|Other|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
16695491|NCT01980407|Experimental|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
16695492|NCT01980394|Other|prospective cohort study|
16695493|NCT01980381|Experimental|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
16695494|NCT01980381|No Intervention|Control group|Treatment as usual, with focus on the present everyday occupations
16695495|NCT01980368|Experimental|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
16695496|NCT01980368|Active Comparator|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
16695497|NCT01980355|Experimental|Tranexamic Acid|1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.
16695498|NCT01980355|Placebo Comparator|Placebo|Placebo given over 15 minutes into the vein once prior to surgery.
16695499|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
16695500|NCT01980329|Experimental|Maraviroc|single oral administration of 300 mg maraviroc
16695501|NCT01980316|Experimental|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
16695502|NCT01980316|Experimental|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
16695503|NCT01980303|Experimental|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
16695504|NCT01980303|Experimental|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
16695505|NCT01980303|Experimental|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
16695506|NCT01980303|Experimental|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
16695507|NCT01980303|Experimental|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
16695508|NCT01980303|Experimental|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
16695509|NCT01980277|Experimental|LY2780301 + paclitaxel|"The following dose-levels will be investigated:
~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week
~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week
~Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week
~A dose reduction could be explored:
~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
16695510|NCT01980264|Experimental|Diagnostic imaging|Harmonic Generation Microscopy
16695511|NCT01980238|Experimental|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
16695512|NCT01980238|Active Comparator|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
16695513|NCT01980225|Experimental|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
16695514|NCT01980225|No Intervention|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
16695515|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
16695516|NCT01980199|Experimental|Fexinidazole|"600mg tablets
~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
16695517|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
16695518|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
16695519|NCT01980173|Experimental|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.
~Intervention: Bakri balloon"
16695520|NCT01980173|Active Comparator|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.
~Intervention: Routine Care"
16695521|NCT01980160|Active Comparator|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
16695522|NCT01980160|Sham Comparator|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
16695523|NCT01980147|Experimental|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
16695524|NCT01980147|No Intervention|Comparison|Naturalistic comparison arm: No intervention offered, no intervention prohibited.
16695525|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
16695526|NCT01980108|No Intervention|empty stomach|No fluid will be given to the patient prior to scanning.
16695527|NCT01980108|Experimental|50mL|50mL of water will be given to the patient prior to scanning
16695528|NCT01980108|Experimental|100mL|100mL of water will be given to the patient prior to scanning
16695529|NCT01980108|Experimental|200mL|200mL of water will be given to the patient prior to scanning
16695530|NCT01980108|Experimental|300mL|300mL of water will be given to the patient prior to scanning
16695532|NCT01980095|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
16695533|NCT01980095|Placebo Comparator|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
16695534|NCT01980082|Active Comparator|Cefazolin|"Cefazolin
~1 gram/2 gram if body mass index > 40 - one time dose, 30-60 min prior to incision."
16695535|NCT01980082|Placebo Comparator|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
16695536|NCT01980069|Experimental|Neostigmine arm|Neostigmine arm
16695537|NCT01980069|Active Comparator|Sugammadex arm|Sugammadex arm
16695538|NCT01980056|Experimental|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
16695539|NCT01980043|Other|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
16695540|NCT01980030|Experimental|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
16695541|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
16695542|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
16695543|NCT01980004|Experimental|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
16695544|NCT01980004|Experimental|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
16695545|NCT01979991|Experimental|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
16695546|NCT01979978|Experimental|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
16695547|NCT01979978|No Intervention|Control|This group received standard school curriculum.
16695548|NCT01979965|Active Comparator|Active drug|Ranolazine therapy for three months
16695549|NCT01979965|Placebo Comparator|Sugar Pill|sugar pill therapy for three months
16695550|NCT01979952|Experimental|Nintedanib|150 mg twice daily
16695551|NCT01979952|Placebo Comparator|Placebo|twice daily dosing
16695552|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
16695553|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
16695554|NCT01979926|Experimental|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
16695555|NCT01979926|Experimental|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
16695556|NCT01979926|Placebo Comparator|Placebo|Sugar pill
16695557|NCT01979913|Experimental|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
16695558|NCT01979900|Experimental|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
16695559|NCT01979900|Placebo Comparator|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
16695560|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
16695561|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
16695562|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
16695563|NCT01979874|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
16695564|NCT01979874|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
16695565|NCT01979861|Experimental|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
16695566|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
16695567|NCT01979835|Experimental|GF|Women who have a GyneFix Viz inserted
16695568|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:
~Patient aged ≥ 18 years;
~diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1
~Patient is in stable clinical condition and
~the previous specific PH medication has been retained unchanged during the past 3 weeks"
16695569|NCT01979809|Sham Comparator|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
16695570|NCT01979809|Active Comparator|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
16695571|NCT01979809|Active Comparator|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
16695572|NCT01979796|Experimental|Ecig 24 mg nicotine|Ecig 24 mg nicotine
16695573|NCT01979796|Sham Comparator|Ecig 0 mg nicotine|Ecig 0 mg nicotine
16695574|NCT01979796|Placebo Comparator|Nicotine free inhalator|Nicotine free inhalator
16695575|NCT01979783||LBP|group of subjects with low back pain
16695576|NCT01979783||nonLBP|group without low back pain
16695657|NCT01979341|Active Comparator|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
16695577|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
16695578|NCT01979757|Active Comparator|Centrifugation|Patients recieved fatgraft processed by Centrifugation
16695579|NCT01979757|Active Comparator|Puregraft|Patients recieved fatgraft processed by Puregraft
16695580|NCT01979744|Experimental|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
16695581|NCT01979744|Active Comparator|Resolute Integrity - Angio|Resolute Integrity - Angio arm
16695582|NCT01979744|Active Comparator|Promus - Angio|Promus - Angio arm
16695583|NCT01979744|Active Comparator|Promus - IVUS|Promus - IVUS arm
16695584|NCT01979731|Experimental|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
16695585|NCT01979731|Active Comparator|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
16695586|NCT01979718|Experimental|Full term intervention|"random selection
~composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
16695587|NCT01979718|Active Comparator|Half term intervention|"random selection
~composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
16695588|NCT01979692|Experimental|One arm ; CLM use in TTNB|"to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions
~to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.
~the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
16695589|NCT01979679|Active Comparator|Lurasidone 80 mg per day|Lurasidone 80 mg per day
16695590|NCT01979679|Active Comparator|Lurasidone 120 mg per day|Lurasidone 120 mg per day
16695591|NCT01979679|Active Comparator|Lurasidone 160 mg per day|Lurasidone 160 mg per day
16695592|NCT01979666|Experimental|study group|the patients that will get a nitrate patch
16695593|NCT01979666|Placebo Comparator|control group|the patients that will get the placebo patch
16695594|NCT01979653|Experimental|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
16695595|NCT01979653|Experimental|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
16695596|NCT01979640|Experimental|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
16695597|NCT01979640|Experimental|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
16695598|NCT01979640|Experimental|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
16695599|NCT01979627|Experimental|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
16695600|NCT01979627|Other|transradial approach group|patients in transradial group received interventional procedure through radial artery
16695601|NCT01979614|Experimental|Serelaxin|Serelaxin was administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
16695602|NCT01979614|Placebo Comparator|Placebo|Placebo was administered by intravenous infusion for 48 hours
16695603|NCT01979601|Experimental|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
16695604|NCT01979601|Experimental|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
16695605|NCT01979601|Experimental|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
16695606|NCT01979601|Experimental|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
16695607|NCT01979601|Experimental|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
16695608|NCT01979601|Experimental|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
16695609|NCT01979601|Experimental|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
16695610|NCT01979601|Experimental|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
16695611|NCT01979601|Experimental|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
16695612|NCT01979601|Experimental|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
16695613|NCT01979601|Placebo Comparator|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
16695614|NCT01979601|Placebo Comparator|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
16695615|NCT01979588|Placebo Comparator|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
16695616|NCT01979588|Active Comparator|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
16695617|NCT01979562||100 runners|Male runners between 18-60 years.
16695618|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
16695619|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
16695620|NCT01979536|Experimental|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.
~COURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
16695621|NCT01979536|Experimental|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.
~COURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
16695622|NCT01979523|Experimental|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
16695623|NCT01979523|Experimental|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16695624|NCT01979510|Experimental|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
16695625|NCT01979510|Experimental|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
16695626|NCT01979497|Active Comparator|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
16695627|NCT01979497|Active Comparator|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
16695628|NCT01979484|Experimental|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
16695629|NCT01979484|Experimental|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
16695630|NCT01979471|Other|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
16695631|NCT01979471|No Intervention|Usual Care|"Patients randomized to the usual care group will receive:
~Usual pharmacy care with no specific interventions for 3 months
~At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
16695632|NCT01979458|Experimental|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
16695633|NCT01979445|Experimental|Prasugrel 30 Min After Cangrelor|Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours [hrs] after initiation of cangrelor infusion).
16695634|NCT01979445|Experimental|Clopidogrel Within 5 Min After Cangrelor|Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion).
16695635|NCT01979445|Experimental|Clopidogrel 1.5 Hrs During Cangrelor|Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1.
16695636|NCT01979445|Experimental|Clopidogrel 1 Hr During Cangrelor|Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.
16695637|NCT01979432|Other|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
16695638|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
16695639|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
16695640|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
16695641|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
16695642|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
16695643|NCT01979406|Active Comparator|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
16695644|NCT01979406|Experimental|Ad4-PA-1|"Given at 10^9, 10^10 and 10^11 vp
~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
16695645|NCT01979406|Experimental|Ad4-PA-2|"Given at 10^9, 10^10 and 10^11 vp
~Ad4-PA at Days 1, 15 and 29"
16695646|NCT01979406|Experimental|Ad4-PA-3|"Ad4 given at 10^9, 10^10 and 10^11 vp
~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
16695647|NCT01979406|Experimental|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles
~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
16695648|NCT01979406|Experimental|Ad4 PA-GPI-2|"Given at 10^9, 10^10 and 10^11 viral particles
~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
16695649|NCT01979406|Experimental|Ad4-PA-GPI -3|"Given at 10^9, 10^10 and 10^11 viral particles
~Ad4-PA-GPI at Days 1, 15 and 29"
16695650|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
16695651|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
16695652|NCT01979380|Experimental|KD101|
16695653|NCT01979380|Placebo Comparator|placebo|
16695654|NCT01979367|Experimental|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
16695655|NCT01979354|Active Comparator|Spinal morphine|0.15 mg spinal morphine
16695656|NCT01979354|No Intervention|Control|No spinal morphine
16695658|NCT01979341|Active Comparator|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
16695659|NCT01979341|Active Comparator|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
16695660|NCT01979328|Experimental|Study arm|geko neuromuscular electrostimulation
16695661|NCT01979315||patients with LBP|
16695662|NCT01979315||healthy individulas|
16695663|NCT01979302|Experimental|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
16695664|NCT01979302|Other|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
16695665|NCT01979289|Experimental|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
16695666|NCT01979289|Active Comparator|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
16695667|NCT01979276|Experimental|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
16695668|NCT01979263|Active Comparator|Attention Bias Modification|Attention Bias Modification computer task
16695669|NCT01979263|Placebo Comparator|Placebo Computer Task|Placebo computer task
16695670|NCT01979250|No Intervention|Normal corneas|Normal corneas from patients that undergo cataract surgery.
16695671|NCT01979250|Other|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
16695672|NCT01979237|Experimental|SPASO method, FARES method|Reduction method: SPASO method, FARES method
16695673|NCT01979224|No Intervention|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
16695674|NCT01979211|Experimental|Cetuximab and Radiation|Cetuximab 400 mg/m2 IV over 120 minutes loading dose > 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions
16695675|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
16695676|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
16695677|NCT01979185|Active Comparator|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
16695678|NCT01979185|Experimental|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
16695679|NCT01979159|Experimental|Combined Aphasia-ApraxiaTreatment|Administration of Combined Aphasia and Apraxia of Speech Treatment )(CAAST) to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
16695680|NCT01979146|Experimental|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
16695681|NCT01979146|No Intervention|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
16695682|NCT01979133|Experimental|icariin|Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
16695683|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
16695684|NCT01979107|Experimental|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
16695685|NCT01979107|No Intervention|Control group|The participants will be treated as usual by the general practitioner.
16695686|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
16695687|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
16695688|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
16695689|NCT01979055|Experimental|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
16695690|NCT01979055|Placebo Comparator|Control group|3 telephone calls to assess any additional questions regarding asthma
16695691|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
16695692|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
16695693|NCT01979029|Experimental|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
16695694|NCT01979029|Experimental|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
16695988|NCT01977053|Experimental|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
16695695|NCT01979016|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
16695696|NCT01979016|Experimental|Dupilumab 200 mg qw|Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
16695697|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
16695698|NCT01978990||Diabetes Management System , blood glucose|
16695699|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
16695700|NCT01978964|Experimental|ONT-10 Vaccine|
16695701|NCT01978951|Experimental|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
16695702|NCT01978951|Active Comparator|Conventional CKD care|standard guidelines of CKD treatment
16695703|NCT01978938|Experimental|Eravacycline|Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
16695704|NCT01978938|Active Comparator|Levofloxacin|Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
16695705|NCT01978925|Experimental|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
16695706|NCT01978925|No Intervention|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
16695707|NCT01978912|Experimental|Cohort 1|one time 5 μg/disc dose of KTP-001 by intradiscal injection
16695708|NCT01978912|Experimental|Cohort 2|one time 15 μg/disc dose of KTP-001 by intradiscal injection
16695709|NCT01978912|Experimental|Cohort 3|one time 50 μg/disc dose of KTP-001 by intradiscal injection
16695710|NCT01978912|Experimental|Cohort 4|one time 150 μg/disc dose of KTP-001 by intradiscal injection
16695711|NCT01978899|Active Comparator|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group
~The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.
~Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
16695712|NCT01978899|Active Comparator|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
16695713|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
16695714|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
16695715|NCT01978873|Experimental|Arm A:|"Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)
~Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
16695716|NCT01978873|Active Comparator|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
16695717|NCT01978860|Experimental|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
16695718|NCT01978821|Experimental|stem cell|autologous bone marrow mononuclear cell transplantation
16695719|NCT01978795|Experimental|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
16695720|NCT01978795|Active Comparator|Control|
16695721|NCT01978782|Active Comparator|raltegravir alone|raltegravir 400 mg BID for 5 days
16695722|NCT01978782|Active Comparator|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
16695723|NCT01978782|Experimental|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
16695724|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
16695725|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
16695726|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
16695727|NCT01978743|Experimental|Raltegravir|Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
16696019|NCT01976845|Active Comparator|Midazolam|Midazolam 2 mg IV (2 ml)
16695728|NCT01978730|Experimental|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
16695729|NCT01978730|Experimental|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
16695730|NCT01978730|Placebo Comparator|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
16695731|NCT01978717|Experimental|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
16695732|NCT01978717|Experimental|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
16695733|NCT01978704|Experimental|Glycaemic load|
16695734|NCT01978704|Active Comparator|Carbohydrates content|
16695735|NCT01978691|Active Comparator|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
16695736|NCT01978691|Active Comparator|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
16695737|NCT01978691|Active Comparator|Synbiotic|B. lactis 420 (10^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
16695738|NCT01978691|Placebo Comparator|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
16695739|NCT01978678||Pulmicort|ICS and LABA - based on ACQ and FeNO
16695740|NCT01978665|Placebo Comparator|prednisone and Solumedrol|placebo arm versus prednisone
16695741|NCT01978665|Placebo Comparator|solumedrol|placebo versus solu medrol
16695742|NCT01978665|Other|placebo|measurement of fitness
16695743|NCT01978652|Experimental|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
16695744|NCT01978652|Experimental|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
16695745|NCT01978626|Experimental|Smart phone Apps|"1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder
~2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others
~3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
16695746|NCT01978626|Active Comparator|Control|"1st year: traditional paper-pencil diary
~2nd year: no social persuasion is given beyond sessions
~3rd year: Tai-chi teaching by Digital Video Disc only"
16695747|NCT01978613|Experimental|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
16695748|NCT01978613|Experimental|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
16695749|NCT01978613|Experimental|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
16695750|NCT01978613|Experimental|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
16695751|NCT01978613|Experimental|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
16695752|NCT01978600|Experimental|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
16695753|NCT01978600|Active Comparator|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
16695754|NCT01978587|Experimental|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
16695755|NCT01978587|Experimental|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
16695756|NCT01978574|Active Comparator|Documentary videos|In the placebo control condition, participants watch daily videos.
16695757|NCT01978574|Experimental|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
16695758|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
16695759|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
16695760|NCT01978561|Placebo Comparator|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
16695761|NCT01978548|Experimental|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
16695762|NCT01978548|Experimental|JNJ-54861911 50 mg|
16695763|NCT01978548|Placebo Comparator|Placebo|Patients will receive matching placebo.
16695764|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
16695765|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
16695766|NCT01978522|Experimental|NICOLA Participants|All participants enrolled in the NICOLA cohort
16695767|NCT01978509|Active Comparator|Low volume prep (Prepopik)|Low volume prep for colonoscopy (Prepopik)
16695768|NCT01978509|Active Comparator|Moderate volume prep (Moviprep)|Moderate volume prep for colonoscopy (Moviprep)
16695769|NCT01978509|Active Comparator|High volume prep (Golytely)|High volume prep for colonoscopy (Golytely)
16695770|NCT01978496|Placebo Comparator|Placebo|
16695771|NCT01978496|Experimental|Eletriptan 20 mg|
16695772|NCT01978496|Experimental|Eletriptan 40 mg|
16695773|NCT01978496|Experimental|Eletriptan 80 mg|
16695774|NCT01978483|Other|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
16695886|NCT01977794|Experimental|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
16695775|NCT01978483|Experimental|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
16695776|NCT01978483|Placebo Comparator|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
16695777|NCT01978470|Experimental|Active|Trigeminal nerve stimulation
16695778|NCT01978457|Experimental|cocaine hydrochloride|cocaine hydrochloride
16695779|NCT01978457|Experimental|propranolol|propranolol
16695780|NCT01978457|Placebo Comparator|placebo|placebo
16695781|NCT01978444|Experimental|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
16695782|NCT01978444|Active Comparator|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
16695783|NCT01978431|Experimental|Stimulant|Cocaine and Methylphenidate
16695784|NCT01978431|Placebo Comparator|Placebo|methylphenidate
16695785|NCT01978418|Placebo Comparator|Placebo|Placebo is administered once, at 30-60 minutes of age
16695786|NCT01978418|Active Comparator|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
16695787|NCT01978405|Experimental|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
16695788|NCT01978405|Placebo Comparator|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
16695789|NCT01978392|Experimental|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
16695790|NCT01978392|No Intervention|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
16695791|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
16695792|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
16695793|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
16695794|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
16695795|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
16695796|NCT01978353|Experimental|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
16695797|NCT01978353|Active Comparator|Psychoeducation|Participants receive information about memory functioning and aging
16695798|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
16695799|NCT01978327|Experimental|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
16695800|NCT01978327|Placebo Comparator|Placebo|Matching placebo
16695801|NCT01978327|Experimental|simvastatin|for drug-drug interaction
16695802|NCT01978327|Experimental|simvastatin co-dosed with GSK2647544|for drug-drug interaction
16695803|NCT01978314|Experimental|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
16695804|NCT01978314|Experimental|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
16695805|NCT01978314|Experimental|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
16695806|NCT01978314|Experimental|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
16695807|NCT01978314|Experimental|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
16695808|NCT01978301|Active Comparator|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
16695809|NCT01978301|Placebo Comparator|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
16695810|NCT01978301|No Intervention|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
16695811|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
16695812|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
16695813|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
16695814|NCT01978275|Experimental|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
16695815|NCT01978275|Active Comparator|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
16695816|NCT01978262|Other|healthy woman|All women are to receive the quadrivalent influenza vaccine
16695817|NCT01978249|Experimental|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
16695818|NCT01978249|Active Comparator|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
16695819|NCT01978236|Experimental|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
16695820|NCT01978236|Experimental|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
16695821|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
16695822|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
16695823|NCT01978210|Experimental|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
16695824|NCT01978210|Active Comparator|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
16695825|NCT01978184|Experimental|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
16695826|NCT01978184|Experimental|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
16695827|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
16695828|NCT01978158|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
16695829|NCT01978158|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
16695830|NCT01978158|Active Comparator|Normoxia|Subjects wil be breathing room air (21%)
16695831|NCT01978145|Experimental|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
16695832|NCT01978145|Experimental|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
16695833|NCT01978132|Active Comparator|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).
~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
16695834|NCT01978132|Placebo Comparator|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
16695835|NCT01978119|Experimental|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
16695836|NCT01978119|Experimental|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
16695837|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
16695838|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
16695839|NCT01978093|Experimental|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
16695840|NCT01978093|Active Comparator|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
16695841|NCT01978080|Experimental|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
16695842|NCT01978080|Active Comparator|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
16695843|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
16696020|NCT01976845|Placebo Comparator|Saline|Saline 2 ml
16695844|NCT01978054|Experimental|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
16695845|NCT01978054|No Intervention|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
16695846|NCT01978041|Experimental|Meal prepared with non fluoridated water (<0.1 ppm F)|
16695847|NCT01978041|Experimental|Meal prepared with fluoridated water (1 ppm F)|
16695848|NCT01978041|Experimental|Non fluoridated water (<0.1 ppm F)|
16695849|NCT01978041|Experimental|Fluoridated water (1 ppm F)|
16695850|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
16695851|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
16695852|NCT01978028|Active Comparator|ferric carboxymaltose|ferric carboxymaltose
16695853|NCT01978028|Placebo Comparator|placebo|placebo
16695854|NCT01978015|Experimental|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
16695855|NCT01978015|Experimental|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
16695856|NCT01978015|Placebo Comparator|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
16695857|NCT01978015|Experimental|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
16695858|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
16695859|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
16695860|NCT01977989|No Intervention|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
16695861|NCT01977989|Active Comparator|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
16695862|NCT01977976|Experimental|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
16695863|NCT01977976|No Intervention|Control group|No intervention prior to scheduled IVF
16695864|NCT01977963||Agranulocytosis|
16695865|NCT01977937|Experimental|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
16695866|NCT01977937|Placebo Comparator|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
16695867|NCT01977924|Experimental|polyphenols|600 mg polyphenols (grape extract)
16695868|NCT01977924|Placebo Comparator|Placebo|microcrystalline cellulose
16695869|NCT01977911|Experimental|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:
~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
16695870|NCT01977898|Experimental|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
16695871|NCT01977898|Placebo Comparator|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
16695872|NCT01977885|Experimental|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
16695873|NCT01977872|Experimental|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
16695874|NCT01977872|No Intervention|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
16695875|NCT01977859|Placebo Comparator|Saline|Saline infusion
16695876|NCT01977859|Active Comparator|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
16695877|NCT01977859|Active Comparator|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
16695878|NCT01977859|Active Comparator|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
16695879|NCT01977859|Active Comparator|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
16695880|NCT01977833|Experimental|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
16695881|NCT01977833|Active Comparator|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
16695882|NCT01977820|Experimental|Sapropterin|
16695883|NCT01977820|Placebo Comparator|Placebo|
16695884|NCT01977807|Experimental|Myopia|Myopia Lasik treatment of virgin eyes.
16695885|NCT01977807|Experimental|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
16695887|NCT01977794|Experimental|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
16695888|NCT01977781|Experimental|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
16695889|NCT01977781|Active Comparator|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
16695890|NCT01977768|Experimental|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
16695891|NCT01977768|Placebo Comparator|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
16695892|NCT01977755|Active Comparator|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
16695893|NCT01977755|Active Comparator|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
16695894|NCT01977755|Placebo Comparator|Placebo|bolus injection, followed by infused over 6 hours
16695895|NCT01977742|Active Comparator|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
16695896|NCT01977742|Active Comparator|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.
~The cardiac vagal index will be measured at every 8 weeks."
16695897|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
16695898|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
16695899|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
16695900|NCT01977703|Active Comparator|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
16695901|NCT01977703|Experimental|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
16695902|NCT01977690|No Intervention|Standard Management|Patients wore no brace.
16695903|NCT01977690|Experimental|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
16695904|NCT01977677|Experimental|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
16695905|NCT01977664||oocyte maturation failure|no intervention
16695906|NCT01977651|Experimental|Enzalutamide 160 mg|Participants received 160 mg of enzalutamide orally once a day, for 4 months. At the end of the 4-month treatment period, participants who were assessed as deriving benefit from enzalutamide treatment continued in the extension period. The total study drug treatment duration for the extended period depended on individual clinical benefit. If a participant experienced a Grade 3 or higher toxicity that was attributed to enzalutamide and could not be ameliorated by the use of adequate medical intervention, treatment with enzalutamide was allowed to be interrupted for 1 week or until the toxicity grade improved to Grade 2 or lower severity. Subsequently, enzalutamide was restarted at the original dose 160 mg per day or a reduced dose 120 or 80 mg per day in consultation with the medical monitor.
16695907|NCT01977638|Experimental|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
16695908|NCT01977625|Active Comparator|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
16695909|NCT01977625|Placebo Comparator|Sugar Pill|Placebo pill, capsules
16695910|NCT01977612|Active Comparator|Stainless Steel Staples|Skin closure with stainless steel staples
16695911|NCT01977612|Experimental|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
16695912|NCT01977599|No Intervention|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
16695987|NCT01977053|No Intervention|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
16695913|NCT01977599|Experimental|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
16695914|NCT01977586|Experimental|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
16695915|NCT01977573|Experimental|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
16695916|NCT01977573|Other|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
16695917|NCT01977560|Other|Standard Care|This arm will receive standard care for Type 2 diabetes: exercise and diet counseling according to the American Diabetes Association recommendations.
16695918|NCT01977560|Experimental|Optimum Lifestyle intervention|This arm will be participate in weekly visits with a dietitian and 4 weekly supervised exercise sessions. They will be advised to follow a high-protein, low-carbohydrate diet.
16695919|NCT01977547|Active Comparator|Short storage|Red blood cells storage duration of equal to or less than 7 days.
16695920|NCT01977547|Active Comparator|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
16695921|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
16695922|NCT01977521|Experimental|Treatment|transcranial direct current stimulation (2mA)
16695923|NCT01977521|Sham Comparator|Sham|Sham stimulation
16695924|NCT01977508||haemodialysis vascular access using ePTFE grafts|
16695925|NCT01977495|Active Comparator|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
16695926|NCT01977495|Active Comparator|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
16695927|NCT01977482|Experimental|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
16695928|NCT01977482|Experimental|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
16695929|NCT01977482|Experimental|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
16695930|NCT01977482|Experimental|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
16695931|NCT01977482|Experimental|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
16695932|NCT01977482|Active Comparator|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
16695933|NCT01977469|Experimental|Low intensity resistance training|Low intensity resistance training + aerobic training
16695934|NCT01977469|Experimental|High intensity resistance training|High intensity resistance training + aerobic training
16695935|NCT01977456|Experimental|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
16695936|NCT01977443|Active Comparator|APD-209 Eye drops|APD-209 Eye drops
16695937|NCT01977443|Placebo Comparator|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
16695938|NCT01977430|Experimental|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
16695939|NCT01977430|No Intervention|Control Arm|
16695940|NCT01977417|Experimental|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
16695941|NCT01977417|Placebo Comparator|Placebo|Placebo capsule twice per day
16695942|NCT01977378|Experimental|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
16695943|NCT01977378|Active Comparator|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
16695944|NCT01977365|Experimental|Growth promotion based on child centered approach|
16695945|NCT01977365|No Intervention|Control|
16695946|NCT01977352|Active Comparator|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
16695947|NCT01977352|Experimental|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
16695948|NCT01977339|Experimental|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
16695949|NCT01977339|Active Comparator|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
16695950|NCT01977326|Experimental|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
16695951|NCT01977326|Active Comparator|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
16695952|NCT01977313||All study participants|All study participants
16695953|NCT01977300|Placebo Comparator|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
16695954|NCT01977300|Experimental|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
16695955|NCT01977300|Active Comparator|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
16695956|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
16695957|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
16695958|NCT01977274|Experimental|gynecological cancer|blood and tumor samples
16695959|NCT01977261|Experimental|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
16695960|NCT01977261|Active Comparator|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
16695961|NCT01977248|Experimental|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
16695962|NCT01977235|Experimental|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
16695963|NCT01977235|Active Comparator|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
16695964|NCT01977222|Experimental|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
16695965|NCT01977209|Experimental|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
16695966|NCT01977209|Placebo Comparator|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
16695967|NCT01977196|Experimental|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
16695968|NCT01977183|Experimental|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
16695969|NCT01977183|Placebo Comparator|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
16695970|NCT01977183|Experimental|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
16695971|NCT01977183|Placebo Comparator|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
16695972|NCT01977170|Experimental|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:
~PRP-T 10ug NaCl 0.85%
~Frequency: 1 injection"
16695973|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
16695974|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
16695975|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
16695976|NCT01977131|Experimental|stromal cells modified HGF|
16695977|NCT01977118|Experimental|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
16695978|NCT01977118|Placebo Comparator|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
16695979|NCT01977105|Experimental|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
16695980|NCT01977092|Experimental|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
16695981|NCT01977092|Other|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
16695982|NCT01977079|Other|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.
~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
16695983|NCT01977079|Other|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.
~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
16695984|NCT01977066|Experimental|Six months supervised exercise training|
16695985|NCT01977066|Experimental|Six months home-based exercise training|
16695986|NCT01977066|No Intervention|Control group|
16695989|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
16695990|NCT01977027|Other|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:
~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.
~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
16695991|NCT01977027|Other|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:
~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.
~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.
~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.
~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
16695992|NCT01977014||Patient with LenusPro pump|
16695993|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
16695994|NCT01976988|Active Comparator|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
16695995|NCT01976988|Experimental|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
16695996|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
16695997|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
16695998|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
16695999|NCT01976949|Active Comparator|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
16696000|NCT01976949|Active Comparator|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
16696001|NCT01976936|Experimental|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
16696002|NCT01976936|Active Comparator|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
16696003|NCT01976936|Placebo Comparator|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
16696004|NCT01976923|Active Comparator|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
16696005|NCT01976923|Sham Comparator|Control arm|Small-gauge pars plana vitrectomy
16696006|NCT01976910|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.
~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
~The MTD will be where 2 DLTs are noted and the study is discontinued."
16696007|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.
~Intervention: Knee flexion measurement 1
~Intervention: Knee flexion measurement 2
~Intervention: Heel - interface pressure measurements"
16696008|NCT01976884||Severe sepsis|Patients with severe sepsis
16696009|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
16696010|NCT01976884||Tumor|Patients with pancreatic cancer
16696011|NCT01976884||Volunteer|
16696012|NCT01976871|Experimental|Oral Dopamine Agonist to Rotigotine|During the study, we will switch patients who are not satisfied with their current oral dopamine agonist to rotigotine. Cross-titration will allow determination of the lowest effective dose of rotigotine. We will use as initial guidance the equivalence determined from the Parkinson's Disease trials, in which 1 mg rotigotine was shown to be approximately equivalent to 1-1.5 mg ropinirole or 0.25 -0.375 mg pramipexole. Tolerability, adverse events, and RLS symptom control will be evaluated. These data will provide clinicians with practical guidance to optimize RLS treatment while minimizing adverse events.
16696013|NCT01976858|Experimental|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
16696014|NCT01976858|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
16696015|NCT01976858|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
16696016|NCT01976858|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
16696017|NCT01976858|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
16696018|NCT01976845|Experimental|Propofol|Propofol 20 mg IV (2 ml)
16696021|NCT01976832|Experimental|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
16696022|NCT01976832|Active Comparator|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.
~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
16696023|NCT01976819|Experimental|TW speaking valve/HME|Use of the TW speaking valve/HME
16696024|NCT01976806|Experimental|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
16696025|NCT01976806|Active Comparator|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
16696026|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
16696027|NCT01976780|Active Comparator|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
16696028|NCT01976780|Active Comparator|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and > 34 kg: 4 tablets) given twice a day for 3 days.
16696029|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
16696030|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
16696031|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
16696032|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 > 80% predicted
16696033|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
16696034|NCT01976741|Experimental|Rogaratinib total dose escalation|Participants with any type of solid tumor received escalating doses of Rogaratinib oral solution or tablet. The actual dose-escalation cohorts were 100 mg (50 mg BID), 200 mg (100 mg BID), 400 mg (200 mg BID), 800 mg (400 mg BID), 1200 mg (600 mg BID), and 1600 mg (800 mg BID). The participants in the 100 mg and 200 mg dose-escalation cohorts received oral solution and the participants in all the subsequent dose-escalation cohorts received tablet. And as an exception, on C1D-3 in the 200 mg dose-escalation cohort, the participants received tablet instead of oral solution.
16696035|NCT01976741|Experimental|Rogaratinib dose expansion (All Comers)|"Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.
~(1600 mg/day) in 21-days cycles."
16696036|NCT01976741|Experimental|Rogaratinib dose expansion (BC)|Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
16696037|NCT01976741|Experimental|Rogaratinib dose expansion (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
16696038|NCT01976741|Experimental|Rogaratinib dose expansion (sqNSCLC)|Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
16696039|NCT01976728|Experimental|LutrePulse 10 µg/pulse|Gonadorelin acetate 10 µg/pulse
16696040|NCT01976728|Experimental|LutrePulse 15 µg/pulse|Gonadorelin acetate 15 µg/pulse
16696041|NCT01976728|Experimental|LutrePulse 20 µg/pulse|Gonadorelin acetate 20 µg/pulse
16696042|NCT01976728|Placebo Comparator|Placebo|Placebo
16696043|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
16696044|NCT01976702|Experimental|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
16696045|NCT01976702|Active Comparator|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
16696046|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
16696047|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
16696048|NCT01976676|Experimental|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
16696049|NCT01976676|Active Comparator|folic acid|1 mg Folic acid per day
16696050|NCT01976663|Experimental|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
16696051|NCT01976663|Active Comparator|Control NLFs|Nasolabial folds treated with Control.
16696052|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
16696053|NCT01976637|Experimental|no compression|no compression stockings worn during a 3 weeks period
16696054|NCT01976637|Active Comparator|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
16696055|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
16696056|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
16696057|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
16696058|NCT01976585|Experimental|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
16696059|NCT01976572|Placebo Comparator|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
16696060|NCT01976572|Active Comparator|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
16696061|NCT01976572|Active Comparator|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
16696062|NCT01976572|Active Comparator|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
16696063|NCT01976559|Experimental|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
16696064|NCT01976546||airway|Patients with one or more predictors of diffucult airway
16696065|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
16696066|NCT01976520|Experimental|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
16696067|NCT01976507|Experimental|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
16696068|NCT01976494|Experimental|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
16696069|NCT01976494|Active Comparator|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
16696070|NCT01976481|Experimental|Sunbed|sunbed exposure
16696071|NCT01976481|No Intervention|Observation|only observation of subjects recruited after randomization
16696072|NCT01976468||SCC metastasis|organ transplant recipients
16696073|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
16696074|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
16696075|NCT01976429|Other|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
16696076|NCT01976429|Other|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
16696077|NCT01976416|Experimental|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
16696078|NCT01976416|Placebo Comparator|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
16696079|NCT01976403|Experimental|Pain booklet|
16696080|NCT01976403|No Intervention|standard care|
16696081|NCT01976390|Active Comparator|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
16696082|NCT01976390|Active Comparator|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
16696083|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
16696084|NCT01976364|Experimental|Tofacitinib|
16696085|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
16696086|NCT01976338|Experimental|Ranibizumab 0.5 mg|PRN Intravitreal injection
16696087|NCT01976338|Sham Comparator|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
16696088|NCT01976325|No Intervention|Standard Care|This arm will receive no intervention; only standard medical care.
16696089|NCT01976325|Experimental|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
16696090|NCT01976312|Experimental|Ranibizumab 0.5 mg|PRN intravitreal injection
16696091|NCT01976312|Sham Comparator|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
16696092|NCT01976299|Experimental|Active Treatment|Standard of Care with the AVERT system
16696093|NCT01976299|No Intervention|Standard of Care|
16696094|NCT01976286|Active Comparator|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
16717078|NCT01835678|Placebo Comparator|Placebo|Placebo
16696095|NCT01976286|Active Comparator|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
16696096|NCT01976273|Active Comparator|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
16696097|NCT01976273|Active Comparator|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
16696098|NCT01976260|Active Comparator|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
16696099|NCT01976260|Active Comparator|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
16696100|NCT01976247|Active Comparator|Noninvasive Cryolipolysis Device|The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
16696101|NCT01976247|Active Comparator|High Intensity Focused Ultrasound Device|The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
16696102|NCT01976234|Active Comparator|Fresh group|Fresh group will receive RBC stored for less than 14 days
16696103|NCT01976234|Active Comparator|Old group|Old group will receive RBC stored for 14 days or more
16696104|NCT01976221||Prioritization|Team-based multifaceted interactive training
16696105|NCT01976208|Experimental|Omalizumab|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
16696106|NCT01976208|Placebo Comparator|placebo|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
16696107|NCT01976195|Experimental|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
16696108|NCT01976195|Active Comparator|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
16696109|NCT01976182|Active Comparator|METHOTREXATE|"In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take
~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.
~Non responders at Month 4 will be randomized and treated either by:
~Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;
~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
16696110|NCT01976182|Active Comparator|CYCLOPHOSPHAMIDE|"In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.
~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);
~Non responders at Month 4 will be randomized and treated either by:
~Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;
~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
16696111|NCT01976169|Experimental|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.
~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
16696112|NCT01976156|Experimental|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
16696113|NCT01976156|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
16696114|NCT01976143|Experimental|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
16696115|NCT01976130|Experimental|bronchoscopy|Procedure
16696116|NCT01976117|Experimental|enose|
16696117|NCT01976104|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
16696118|NCT01976104|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
16696119|NCT01976104|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
16696120|NCT01976104|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
16696121|NCT01976091|Experimental|Cohort 1A|Two (n=2) adult LGMD2D wheelchair-dependent subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via single-limb perfusion at the low dose. Subjects will receive a dose of 1 x 10 12th vg/kg in a single limb with delivery to the whole limb.
16696341|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
16696122|NCT01976091|Experimental|Cohort 1B|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via bilateral whole limb perfusion at low dose of 1 x 10 12th vg/kg.
16696123|NCT01976091|Experimental|Cohort 2|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA bilateral whole limb perfusion at high dose.Subjects will receive a total dose of 3 x 10 12th vg/kg per limb delivered to both extremities
16696124|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
16696125|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
16696126|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
16696127|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
16696128|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
16696129|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
16696130|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
16696131|NCT01976039|Other|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
16696132|NCT01976039|Experimental|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
16696133|NCT01976026|Experimental|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.
~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
16696134|NCT01976026|Active Comparator|Best standard therapy|"May be any of the following:
~Conservative management when no surgical or endovascular treatment is considered possible or reasonable
~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques
~Parent vessel occlusion, with or without bypass
~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).
~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.
~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
16696135|NCT01976013|Other|Coaguchek|infants will receive sequential coagulation checks
16696136|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
16696137|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
16696138|NCT01975987|Experimental|Intubation with the Bonfils fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia
~Glottic visualization will be evaluated by direct laryngoscopy.
~The endotracheal tube will be loaded onto the scope
~Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position
~Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.
~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
16696139|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
16696140|NCT01975961|Experimental|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).
~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
16696141|NCT01975961|Active Comparator|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).
~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
16696142|NCT01975948|Experimental|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
16696143|NCT01975948|Active Comparator|Treatment as Usual: Physicians|Those administering treatment as usual for depression
16696144|NCT01975948|Experimental|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
16696145|NCT01975948|Active Comparator|Treatment as Usual: Patients|Those receiving treatment as usual for depression
16696146|NCT01975935|Placebo Comparator|Placebo|Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
16696147|NCT01975935|Experimental|Amlexanox|Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
16696148|NCT01975922|Experimental|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.
~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
16696149|NCT01975922|No Intervention|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
16696150|NCT01975909|Active Comparator|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
16696151|NCT01975909|Sham Comparator|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
16696152|NCT01975896|Experimental|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
16696153|NCT01975896|No Intervention|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
16696154|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
16696155|NCT01975870|Experimental|intervention group|use of application on smartphone for lifestyle counseling
16696156|NCT01975870|No Intervention|control group|no use of application on smartphone
16696157|NCT01975857|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
16696158|NCT01975857|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
16696159|NCT01975844|Experimental|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:
~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.
~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
16696160|NCT01975831|Experimental|Escalation: 0.3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (0.3 mg/kg every 2 weeks [Q2W] for 13 cycles) and tremelimumab (3 mg/kg every 4 weeks [Q4W] for 6 cycles, then every 12 weeks [Q12W]). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696161|NCT01975831|Experimental|Escalation: 1 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (1 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696162|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696163|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 1 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 12 or 13 cycles) and tremelimumab (1 mg/kg Q4W for 6 cycles, then Q12W or Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696164|NCT01975831|Experimental|Expansion: Ovarian Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696165|NCT01975831|Experimental|Expansion: Colorectal Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696166|NCT01975831|Experimental|Expansion: Non-triple Negative Breast Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696167|NCT01975831|Experimental|Expansion: Renal Cell Carcinoma|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696168|NCT01975831|Experimental|Expansion: Cervical Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
16696169|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
16696170|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
16696171|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
16696172|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
16696173|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
16696174|NCT01975805|Experimental|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
16696175|NCT01975805|Experimental|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
16696176|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
16696177|NCT01975779|Experimental|Cohort A1: Lu AE58054 or placebo|
16696178|NCT01975779|Experimental|Cohort A2: Lu AE58054 or placebo|
16696179|NCT01975779|Experimental|Cohort B1: Lu AE58054|
16696180|NCT01975766|Experimental|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
16696181|NCT01975753|Active Comparator|Intravenous morphine|one bolus of intravenous morphine
16696182|NCT01975753|Experimental|nebulized morphine|"one nebulized bolus of morphine"
16696183|NCT01975753|Active Comparator|fentanyl|"one nebulized bolus of fentanyl"
16696184|NCT01975740|Experimental|Manual diaphragm release technique|
16696185|NCT01975740|Other|Sham manual diaphragm release technique|
16696186|NCT01975727|Placebo Comparator|Injection of Placebo|Intravenous Saline 0.9% 10 ml
16696187|NCT01975727|Active Comparator|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
16696188|NCT01975727|Active Comparator|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
16696189|NCT01975727|Active Comparator|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
16696190|NCT01975714|Experimental|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.
~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
16696191|NCT01975714|Experimental|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.
~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
16696192|NCT01975701|Experimental|BGJ398X|To estimate anti-tumor efficacy of BGJ398
16696193|NCT01975688|Experimental|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
16696194|NCT01975688|Experimental|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
16696195|NCT01975688|Experimental|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
16696196|NCT01975688|Experimental|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
16696197|NCT01975675|Experimental|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
16696198|NCT01975675|Experimental|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
16696199|NCT01975675|Experimental|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
16696200|NCT01975675|Experimental|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
16696201|NCT01975662|Experimental|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.
~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.
~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
16696202|NCT01975662|Active Comparator|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
16696203|NCT01975649|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
16696204|NCT01975649|Placebo Comparator|Placebo|patients will use placebo for 120 days
16696391|NCT01974245|Active Comparator|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
16696205|NCT01975636|Experimental|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
16696206|NCT01975623|Experimental|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
16696207|NCT01975610|Experimental|CC-292 375mg|Treatment
16696208|NCT01975610|Placebo Comparator|Placebo|Control
16696209|NCT01975597||Bone marrow aspirates and biopsy|
16696210|NCT01975584|Experimental|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
16696211|NCT01975571|Experimental|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.
~Intervention: These patients will receive a Hybrid L24 cochlear implant."
16696212|NCT01975571|Experimental|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold >90 dB HL at 1500 Hz and profound loss at higher frequencies.
~Intervention: These patients will receive a Hybrid L24 cochlear implant."
16696213|NCT01975571|Experimental|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.
~Intervention: These patients will receive a Hybrid S12 cochlear implant."
16696214|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
16696215|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
16696216|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
16696217|NCT01975545|Active Comparator|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
16696218|NCT01975545|Experimental|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
16696219|NCT01975519|Experimental|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.
16696220|NCT01975506||head start practitioners|
16696221|NCT01975493||Amoxicillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
16696222|NCT01975493||Ampicillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
16696223|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
16696224|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
16696225|NCT01975493||Flucloxacillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
16696226|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
16696227|NCT01975480|Experimental|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
16696228|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
16696229|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
16696230|NCT01975454|Active Comparator|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
16696231|NCT01975454|Experimental|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
16696232|NCT01975441|Active Comparator|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
16696233|NCT01975441|Experimental|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
16696234|NCT01975441|Experimental|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
16696235|NCT01975428|Other|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
16696236|NCT01975428|Active Comparator|DM Pgm + device|"Disease management (DM) program plus a device corresponding to an individual's disease(s):
~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.
~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.
~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
16696342|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
16696237|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
16696238|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
16696239|NCT01975389|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
16696240|NCT01975389|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
16696241|NCT01975376|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
16696242|NCT01975376|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
16696243|NCT01975363|Experimental|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
16696244|NCT01975363|Experimental|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
16696245|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
16696246|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
16696247|NCT01975337|Experimental|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
16696248|NCT01975337|Active Comparator|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
16696249|NCT01975324|Experimental|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
16696250|NCT01975324|Placebo Comparator|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
16696251|NCT01975311|Experimental|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
16696252|NCT01975311|Placebo Comparator|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
16696253|NCT01975298|Experimental|Laquinimod 0.6 mg|
16696254|NCT01975298|Experimental|Laquinimod 1.2 mg|
16696255|NCT01975298|Active Comparator|Avonex®|
16696256|NCT01975285|Active Comparator|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
16696257|NCT01975285|Placebo Comparator|Saline group|Saline 1 ml per 20cc
16696258|NCT01975272|Active Comparator|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
16696259|NCT01975272|Active Comparator|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
16696260|NCT01975272|Placebo Comparator|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
16696261|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:
~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
16696262|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.
~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
16696263|NCT01975246|Experimental|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
16696264|NCT01975246|Active Comparator|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
16696265|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
16696266|NCT01975220|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
16696267|NCT01975220|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
16696268|NCT01975220|Experimental|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
16696269|NCT01975207|No Intervention|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
16696343|NCT01974583||the control group C|Group C were covered with paraffin gauze
16696344|NCT01974570|Experimental|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
16696392|NCT01974232||Romiplostim group|
16696270|NCT01975207|Experimental|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.
~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
16696271|NCT01975207|Experimental|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
16696272|NCT01975207|Experimental|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
16696273|NCT01975194|Experimental|Rosuvastatin|Patients that receive rosuvastatin
16696274|NCT01975168|Experimental|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
16696275|NCT01975168|Sham Comparator|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
16696276|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
16696277|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
16696278|NCT01975142|Experimental|TDM-1|
16696279|NCT01975129|Experimental|Vagitocin (Oxytocin)|
16696280|NCT01975116|Experimental|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
16696281|NCT01975103|Experimental|Topcon Endpoint management|Active laser treatment
16696282|NCT01975103|Sham Comparator|Control|Powerless (sham) laser treatment
16696284|NCT01975077|Experimental|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
16696285|NCT01975077|Experimental|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
16696286|NCT01975064|Active Comparator|Propofol|Propofol for maintenance of anesthesia
16696287|NCT01975064|Active Comparator|Sevoflurane|Sevoflurane for maintenance of anesthesia
16696288|NCT01975051|Experimental|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
16696289|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
16696290|NCT01975025|Experimental|All study participants|Short daily dialysis for 2 weeks
16696291|NCT01975012|Experimental|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
16696292|NCT01975012|Experimental|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
16696293|NCT01974986|Placebo Comparator|Placebo|Water with flavoring and non-nutritive sweetener.
16696294|NCT01974986|Experimental|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
16696295|NCT01974986|Experimental|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
16696296|NCT01974973|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
16696297|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
16696298|NCT01974934|Experimental|Desvenlafaxine Succinate|
16696299|NCT01974921|Experimental|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
16696300|NCT01974908|Experimental|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
16696301|NCT01974895|Experimental|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
16696302|NCT01974895|Active Comparator|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
16696303|NCT01974882|Experimental|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
16696304|NCT01974882|No Intervention|Control|No adjunctive therapy following abdominal surgery.
16696305|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
16696306|NCT01974869||Inflammatory bowel diseases-2|Controls
16696307|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
16696308|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
16696309|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients receiving augmentation therapy in the home through Coram
16696310|NCT01974817|Experimental|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
16696345|NCT01974570|Placebo Comparator|Placebo|Participants are provided in double blinded fashion to Placebo
16696393|NCT01974232||Eltrombopag group|
16696394|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
16696311|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
16696312|NCT01974791|Experimental|GET Living Treatment|
16696313|NCT01974778|Experimental|Active|Meal
16696314|NCT01974778|Placebo Comparator|Control|Water
16696315|NCT01974765|Experimental|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.
~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
16696316|NCT01974752|Experimental|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
16696317|NCT01974752|Placebo Comparator|placebo twice daily|placebo twice daily in combination with dacarbazine.
16696318|NCT01974739|Active Comparator|hydrochloorthiazide|once a day 25 mg
16696319|NCT01974739|Placebo Comparator|placebo|once a day placebo
16696320|NCT01974726|Other|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
16696321|NCT01974726|Other|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
16696322|NCT01974726|Other|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
16696323|NCT01974726|Other|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
16696324|NCT01974700|Active Comparator|Levetiracetam|
16696325|NCT01974700|No Intervention|No anti-epileptic treatment|
16696326|NCT01974687|Experimental|Group A: Healthy|Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.
16696327|NCT01974687|Experimental|Group B: GT1 HCV-infected, treatment naive on Day 1|HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.
16696328|NCT01974687|Experimental|Group C: GT1 HCV-infected on Days 1-7|HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
16696329|NCT01974687|Experimental|Group D: GT2 through GT6 HCV-infected on Days 1-7|HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
16696330|NCT01974687|Experimental|Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment|HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
16696331|NCT01974687|Experimental|Group F: GT1 HCV-infected on Days 1-7, + Itraconazole|HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.
16696332|NCT01974674|Experimental|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
16696333|NCT01974661|Experimental|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
16696334|NCT01974648|Active Comparator|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
16696335|NCT01974648|Experimental|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
16696336|NCT01974635|Experimental|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
16696337|NCT01974622|Experimental|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
16696338|NCT01974609|Experimental|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
16696339|NCT01974609|Active Comparator|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
16696340|NCT01974596|Experimental|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
16717079|NCT01835665|Experimental|Nimodipine|
16696346|NCT01974544|Experimental|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
16696347|NCT01974544|Experimental|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
16696348|NCT01974544|Experimental|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
16696349|NCT01974531||Preterm birth/ Timely birth|
16696350|NCT01974531||Women/men|
16696351|NCT01974518|Active Comparator|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
16696352|NCT01974518|Active Comparator|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
16696353|NCT01974505|Experimental|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
16696354|NCT01974492|Active Comparator|Upper leg vein|Upper leg vein harvesting
16696355|NCT01974492|Active Comparator|Lower leg vein|Lower leg vein harvesting
16696356|NCT01974479|Experimental|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10^7 CD56+ cells/kg, and up to 1 x 10^8 CD56+ cells/Kg
16696357|NCT01974466|Active Comparator|Goal A|"controled fluid therapy: 5~10ml/kg/hr fulfillment of two or more of four criteria:
~heart rate <120 beats/min,
~mean arterial blood pressure 65-85 mm Hg,
~urine output ≥1 ml/kg /h
~Hematocrit ≤35%."
16696358|NCT01974466|Other|Goal B|"controled fluid therapy: 5~10ml/kg/hr fulfillment of all of the following criteria:
~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
16696359|NCT01974453||Right transradial|Procedures performed through right transradial approach
16696360|NCT01974453||Left transradial|Procedures performed through left transradial approach
16696361|NCT01974453||Femoral|Procedures performed through transfemoral approach
16696362|NCT01974440|Placebo Comparator|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab [BR] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for 6 cycles + placebo.
16696363|NCT01974440|Experimental|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
16696364|NCT01974414|Active Comparator|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
16696365|NCT01974414|No Intervention|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
16696366|NCT01974401|Active Comparator|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
16696367|NCT01974401|No Intervention|control group|patients in this group received routine oral health care protocols.
16696368|NCT01974388|Active Comparator|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
16696369|NCT01974388|Active Comparator|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
16696370|NCT01974375|Experimental|micafungin|micafungin sodium IV (Mycamine®)
16696371|NCT01974375|Active Comparator|Fluconazole|Fluconazole IV (use same brand in each hospital)
16696372|NCT01974362||Cad/Cam Monolithic Zirconia|Patients that have a full-mouth (maxilla and mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
16696373|NCT01974362||Zirconia-Feldspathic|Patients that have a full-mouth (maxilla and mandible) implant supported rehabilitation restored with zirconia substructure and feldspathic veneered biomaterial
16696374|NCT01974349|Experimental|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
16696375|NCT01974349|Experimental|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
16696376|NCT01974336|Experimental|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
16696377|NCT01974336|Experimental|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
16696378|NCT01974323|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
16696379|NCT01974323|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
16696380|NCT01974310|Active Comparator|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
16696381|NCT01974310|Experimental|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
16696382|NCT01974297|Active Comparator|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
16696383|NCT01974297|Experimental|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
16696384|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
16696385|NCT01974271||Cohort|
16696386|NCT01974258|Experimental|Dose-expansion: onartuzumab + cobimetinib|
16696387|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib|
16696388|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
16696389|NCT01974258|Experimental|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
16696390|NCT01974245|Placebo Comparator|Placebo|100 drops/week for 12 weeks
16696397|NCT01974206|Experimental|ASP0113|One (1) mL of 5 mg/mL ASP0113 will be administered to the subjects at the clinical site via injection
16696398|NCT01974206|Placebo Comparator|Placebo|One (1) mL of 5 mg/mL placebo will be administered to the subjects at the clinical site via injection
16696399|NCT01974193|Experimental|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
16696400|NCT01974193|No Intervention|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
16696401|NCT01974167|Experimental|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
16696402|NCT01974167|Active Comparator|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
16696403|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
16696404|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
16696405|NCT01974141|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
16696406|NCT01974141|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
16696407|NCT01974115|Active Comparator|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
16696408|NCT01974102|Active Comparator|lifestyle|Attentional control group will receive weekly meeting to view relaxing video and facilitate discussion along with counseling on nutrition and physical activity for 8 weeks.
16696409|NCT01974102|Experimental|therapy|Active group will receive weekly mindfulness based parenting stress reduction (PMH) plus nutrition and physical activity counseling for 8 weeks.
16696410|NCT01974089||Pneumonia and dysphagia|Patients with community aquired pneumonia and oropharyngea dysphagia
16696411|NCT01974089||Pneumonia|Patients with community aquired pneumonia
16696412|NCT01974076|Active Comparator|Active tDCS|
16696413|NCT01974076|Sham Comparator|Sham tDCS|
16696414|NCT01974063||A. Nonsmokers|Subjects have smoked <100 cigarettes or <10 shisha pipes per lifetime and whose urine nicotine <2 ng/mL and/or urine cotinine <5 ng/mL, at entry into the study.
16696415|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine >30 ng/mL and/or urine cotinine >50 ng/ml.
16696416|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking >4 pipes/wk and carboxyhemoglobin >2.5.
16696417|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
16696418|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
16696419|NCT01974050|Other|Text message monitoring|Use of text messaging to monitor post-vaccination
16696420|NCT01974037|Active Comparator|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
16696421|NCT01974037|Experimental|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
16696422|NCT01974037|Experimental|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
16696423|NCT01974037|No Intervention|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
16696424|NCT01974037|No Intervention|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
16696425|NCT01974037|Experimental|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
16696426|NCT01974037|Experimental|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
16696427|NCT01974037|Experimental|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
16696428|NCT01974024|Experimental|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
16696429|NCT01974024|Active Comparator|Dexamethasone|Dexamethasone was re-administered in the cycle.
16696430|NCT01974011|Experimental|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
16696431|NCT01974011|Active Comparator|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:
~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
16696432|NCT01973998|Experimental|Roflumilast|500 ug tablet daily for 180 days
16696433|NCT01973998|Placebo Comparator|Placebo|Placebo 1 tablet daily x 180 days
16696530|NCT01973309|Experimental|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
16696434|NCT01973972|Experimental|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
16696435|NCT01973972|Active Comparator|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
16696436|NCT01973946|No Intervention|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
16696437|NCT01973946|Experimental|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.
~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
16696438|NCT01973933|Experimental|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
16696439|NCT01973920|Experimental|Oshadi Icp|Oshadi Icp oral insulin,
16696440|NCT01973907|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
16696441|NCT01973907|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
16696442|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.
~Blood and urine sampling will follow this schedule:
~24h: blood (3ml)
~48h: blood (3ml) and urine
~End of infusion: blood (3ml)
~6h after end of infusion: blood (3ml) and urine.
~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.
~Then all frozen samples will be analyzed to get Midazolam concentrations."
16696443|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
16696444|NCT01973868|Experimental|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.
~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.
~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.
~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
16696445|NCT01973855|Experimental|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
16696446|NCT01973855|Placebo Comparator|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
16696447|NCT01973842|Active Comparator|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
16696448|NCT01973842|Active Comparator|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
16696449|NCT01973842|Active Comparator|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
16696450|NCT01973829|Other|Baseline arm|baseline data (50 patients or 3 months per center)
16696451|NCT01973816|Experimental|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
16696452|NCT01973816|Active Comparator|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
16696453|NCT01973790|Experimental|Z-338|100mg TID
16696454|NCT01973777|Experimental|IUB|There is one arm of women who will have IUBs inserted
16696455|NCT01973764|Other|Ultrasound guided arm|
16696456|NCT01973764|Other|Landmark-based arm|
16696457|NCT01973751|No Intervention|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
16696574|NCT01973010|Experimental|Massage|To treat low back pain with massage
16696458|NCT01973751|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
16696459|NCT01973751|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
16696460|NCT01973725|Experimental|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
16696461|NCT01973712|Experimental|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
16696462|NCT01973712|Experimental|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
16696463|NCT01973699|Placebo Comparator|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
16696464|NCT01973699|Experimental|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
16696465|NCT01973686|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
16696466|NCT01973686|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
16696467|NCT01973686|No Intervention|Control|Receives no intervention
16696468|NCT01973673|Active Comparator|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
16696469|NCT01973673|No Intervention|Usual care|Usual clinical care to be provided by oncologists.
16696470|NCT01973660|Experimental|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
16696471|NCT01973660|Experimental|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
16696472|NCT01973647|Experimental|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
16696473|NCT01973647|Experimental|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
16696474|NCT01973647|Experimental|COPD Education (COPD-ED)|Six weekly sessions of COPD education
16696475|NCT01973647|Placebo Comparator|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
16696476|NCT01973634|Active Comparator|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
16696477|NCT01973634|Experimental|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
16696478|NCT01973634|Active Comparator|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
16696479|NCT01973634|Experimental|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
16696480|NCT01973608|Experimental|MSB0010445 Low Dose Cohort 0.3 mg/kg|
16696481|NCT01973608|Experimental|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
16696482|NCT01973608|Experimental|MSB0010445 High Dose Cohort 1.8 mg/kg|
16696483|NCT01973608|Experimental|MSB0010445 High Dose Cohort 2.4 mg/kg|
16696484|NCT01973595|Experimental|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
16696485|NCT01973595|Other|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
16696486|NCT01973569|Experimental|Denosumab 6 months|denosumab administered subcutaneously every 6 months
16696487|NCT01973569|Experimental|Denosumab 3 months|denosumab administered subcutaneously every 3 months
16696488|NCT01973569|Placebo Comparator|placebo|placebo administered subcutaneously to match denosumab
16696489|NCT01973556|Experimental|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
16696490|NCT01973556|No Intervention|Usual Care|
16696491|NCT01973543|Experimental|VY-AADC01 Dose 1|7.5 x 10^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
16696492|NCT01973543|Experimental|VY-AADC01 Dose 2|1.5 x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
16696493|NCT01973543|Experimental|VY-AADC01 Dose 3|4.7x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
16696494|NCT01973530|Active Comparator|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
16696575|NCT01973010|Active Comparator|Ibuprofen|Medicine control group
16696691|NCT01972269|Active Comparator|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696495|NCT01973530|Other|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
16696496|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
16696497|NCT01973504|Experimental|MP4OX 500-mL|500-mL dose of MP4OX
16696498|NCT01973504|Experimental|MP4OX 750-mL|750-mL dose of MP4OX
16696499|NCT01973504|Sham Comparator|Control|Standard crystalloid Keep Vein Open (KVO) infusion
16696500|NCT01973491|Experimental|ATX-MS-1467|
16696501|NCT01973478|Experimental|DBS|"The medical device includes:
~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)
~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.
~The target is the Accumbens nucleus.
~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.
~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
16696502|NCT01973478|Sham Comparator|SHAM|"The medical device includes:
~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)
~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.
~The target is the Accumbens nucleus.
~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.
~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
16696503|NCT01973465|Experimental|Fecal Microbiota Therapy|
16696504|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
16696505|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
16696506|NCT01973439|Other|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
16696507|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
16696508|NCT01973413|Experimental|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
16696509|NCT01973413|Placebo Comparator|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
16696510|NCT01973400|Experimental|Tocotrienol|200 mg, twice a day, 12 months
16696511|NCT01973400|Placebo Comparator|Placebo|200 mg, twice a day, 12 months
16696512|NCT01973387|Experimental|Treatment Arm A|
16696513|NCT01973387|Experimental|Treatment Arm B|
16696514|NCT01973374|No Intervention|Routine Care|
16696515|NCT01973374|Experimental|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
16696516|NCT01973361|Experimental|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
16696517|NCT01973361|Active Comparator|Best Practice wound care|Participants receiving best practice wound care alone
16696518|NCT01973348|Experimental|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
16696519|NCT01973348|Active Comparator|2-hour eye patching|2-hour eye patching for moderate amblyopia
16696520|NCT01973348|Experimental|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
16696521|NCT01973348|Active Comparator|6-hour eye patching|6-hour eye patching for severe amblyopia
16696522|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).
~See interventions for more details."
16696523|NCT01973335|Experimental|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.
~See interventions for more details."
16696524|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.
~See interventions for more details."
16696525|NCT01973335|Active Comparator|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.
~See interventions for more details."
16696526|NCT01973322|Experimental|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
16696527|NCT01973322|Experimental|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
16696528|NCT01973322|Experimental|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
16696529|NCT01973322|Experimental|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
16696531|NCT01973296|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
16696532|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
16696533|NCT01973283|Experimental|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
16696534|NCT01973270|Experimental|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
16696535|NCT01973270|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
16696536|NCT01973270|No Intervention|Treatment as Usual|Treatment as Usual
16696537|NCT01973257|Experimental|select from the option menu|select from the option menu
16696538|NCT01973244|Experimental|NNC0195-0092 (somapacitan)|
16696539|NCT01973244|Active Comparator|Norditropin®|
16696540|NCT01973231|Experimental|Metformin + liraglutide 1.8 mg|
16696541|NCT01973231|Active Comparator|Metformin + lixisenatide 20 microg|
16696542|NCT01973218|Experimental|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
16696543|NCT01973218|Active Comparator|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
16696544|NCT01973205|Placebo Comparator|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
16696545|NCT01973205|Experimental|Acetaminophen 250 mg and aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
16696546|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
16696547|NCT01973166|Experimental|Picosecond Q-switched Laser Treatment|Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
16696548|NCT01973166|Active Comparator|Nanosecond Q-switched Laser Treatment|Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
16696549|NCT01973153|Active Comparator|Brief Motivational Counseling (BMC)|
16696550|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|
16696551|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Home Visits (BMC+Home)|
16696552|NCT01973140|Other|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
16696553|NCT01973127|Experimental|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.
~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
16696554|NCT01973127|Sham Comparator|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.
~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
16696555|NCT01973114|Experimental|Group 1|One intratympanic injection of latanoprost (Day1)
16696556|NCT01973114|Placebo Comparator|Group 2|One intratympanic injection of placebo
16696557|NCT01973114|Experimental|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
16696558|NCT01973114|Placebo Comparator|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
16696559|NCT01973101|Experimental|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
16696560|NCT01973101|Active Comparator|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
16696561|NCT01973088||non-urate calculus|
16696562|NCT01973088||non-calculus|
16696563|NCT01973088||urate calculus|
16696564|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
16696565|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
16696566|NCT01973062|Experimental|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
16696567|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
16696568|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Ribavirin 200mg tablet orally twice a day for 12 weeks"
16696569|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
16696570|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
16696571|NCT01973036|Active Comparator|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
16696572|NCT01973036|Experimental|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
16696573|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
16696576|NCT01972997|Experimental|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
16696577|NCT01972984|Experimental|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
16696578|NCT01972971|Other|pharmacist care|
16696579|NCT01972958|Experimental|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
16696580|NCT01972958|No Intervention|usual care|control group with usual care
16696581|NCT01972945|Experimental|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
16696582|NCT01972945|Active Comparator|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
16696583|NCT01972932|Placebo Comparator|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
16696584|NCT01972932|Active Comparator|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
16696585|NCT01972919|Experimental|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
16696586|NCT01972906|Experimental|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
16696587|NCT01972906|Active Comparator|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
16696588|NCT01972893|Experimental|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
16696589|NCT01972893|Placebo Comparator|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
16696590|NCT01972880|Experimental|tablet-1|
16696591|NCT01972880|Active Comparator|tablet-2|
16696592|NCT01972867|Experimental|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
16696593|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
16696594|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
16696595|NCT01972841|Experimental|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
16696596|NCT01972841|Experimental|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
16696597|NCT01972841|Placebo Comparator|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
16696598|NCT01972841|Active Comparator|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
16696599|NCT01972841|Active Comparator|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
16696600|NCT01972841|Active Comparator|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
16696601|NCT01972828|Experimental|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
16696602|NCT01972828|Active Comparator|CONTROL|
16696603|NCT01972789|Experimental|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
16696604|NCT01972789|Experimental|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF >200 um on OCT.
16696605|NCT01972776|Experimental|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
16696606|NCT01972776|Experimental|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
16696607|NCT01972776|Experimental|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
16696608|NCT01972776|Placebo Comparator|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
16696609|NCT01972776|Experimental|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
16696610|NCT01972776|Placebo Comparator|Placebo Part 2|Participants received matching placebo for 8 weeks.
16696611|NCT01972763|Active Comparator|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
16696612|NCT01972763|Active Comparator|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
16696613|NCT01972750|Experimental|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
16696615|NCT01972724|Experimental|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
16696616|NCT01972724|Experimental|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
16696617|NCT01972724|Experimental|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
16696618|NCT01972711|Experimental|SEP-363856|Single-dose SEP-363856 50 mg
16696619|NCT01972711|Active Comparator|Amisulpride|Single-dose Amisulpride 400 mg.
16696620|NCT01972711|Placebo Comparator|Placebo|Matched placebo
16696621|NCT01972698|Experimental|Self-directed and simulation-assisted training|
16696622|NCT01972698|Active Comparator|Traditional apprenticeship training|
16696623|NCT01972685|Other|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
16696624|NCT01972672|Experimental|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
16696625|NCT01972659|Active Comparator|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
16696626|NCT01972659|Experimental|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
16696627|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
16696628|NCT01972633|Active Comparator|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
16696629|NCT01972633|Active Comparator|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
16696630|NCT01972620|Active Comparator|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
16696631|NCT01972620|No Intervention|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
16696632|NCT01972607|No Intervention|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
16696633|NCT01972607|Experimental|EXERCISE|This group will receive the treatment with aerobic exercise training
16696634|NCT01972594|No Intervention|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
16696635|NCT01972594|Experimental|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
16696636|NCT01972581|Experimental|Reaction Time Training|
16696637|NCT01972581|No Intervention|Control|
16696638|NCT01972568|Experimental|Atacicept 75 mg|
16696639|NCT01972568|Experimental|Atacicept 150 mg|
16696640|NCT01972568|Placebo Comparator|Placebo|
16696641|NCT01972555|Experimental|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
16696642|NCT01972555|Active Comparator|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
16696643|NCT01972542|Active Comparator|Type 2 DM|"Intervention : Oral fat tolerance test
~well or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
16696644|NCT01972542|Active Comparator|Prediabetes|"Intervention : Oral fat tolerance test
~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
16696645|NCT01972542|Sham Comparator|Normal glucose tolerance|"Intervention : Oral fat tolerance test
~No impaired fasting glucose and impaired glucose tolerance"
16696646|NCT01972529|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
16696647|NCT01972529|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
16696648|NCT01972529|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
16696649|NCT01972529|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
16696650|NCT01972516|Experimental|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
16696651|NCT01972516|No Intervention|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
16696652|NCT01972503|Experimental|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
16696653|NCT01972503|Active Comparator|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
16696654|NCT01972490|Experimental|ARM A|patients received avastin in combination with mFOLFOX6
16696655|NCT01972490|Active Comparator|ARM B|Patients received mFOLFOX6 alone
16696656|NCT01972477|Experimental|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
16696657|NCT01972477|Experimental|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
16696658|NCT01972477|Placebo Comparator|Placebo|Placebo once daily, taken every day along the study period
16696659|NCT01972464|Placebo Comparator|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
16696660|NCT01972464|Experimental|Progesterone|In this group women will receive oral micronized progesterone twice a day.
16696661|NCT01972451|Placebo Comparator|Colonoscopy without enhanced dye|no enhanced dye
16696662|NCT01972451|Active Comparator|Colonoscopy with enhanced dye|enhanced dye
16696663|NCT01972438|Experimental|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
16696664|NCT01972438|Placebo Comparator|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
16696665|NCT01972425|Experimental|Biomarker-based diagnostic|Analyse sample on arrival
16696666|NCT01972425|No Intervention|Routine use of antibiotics|Do not analyse the sample on arrival
16696667|NCT01972412|Other|Telephone support|Intervention type: Telephone support for four months.
16696668|NCT01972399|Experimental|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
16696669|NCT01972399|Active Comparator|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
16696670|NCT01972386||Spectrum Image Analysis|
16696671|NCT01972373|Experimental|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
16696672|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
16696673|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
16696674|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
16696675|NCT01972347|Experimental|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
16696676|NCT01972334|Experimental|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
16696677|NCT01972334|Placebo Comparator|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
16696678|NCT01972321|Experimental|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
16696679|NCT01972321|Experimental|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
16696680|NCT01972321|Active Comparator|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
16696681|NCT01972308|Experimental|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
16696682|NCT01972308|Other|usual care|Patient receives asthma care as usual from their asthma provider
16696683|NCT01972269|Active Comparator|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696684|NCT01972269|Active Comparator|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696685|NCT01972269|Active Comparator|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696686|NCT01972269|Active Comparator|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696687|NCT01972269|Active Comparator|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696688|NCT01972269|Active Comparator|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696689|NCT01972269|Active Comparator|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696690|NCT01972269|Active Comparator|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696692|NCT01972269|Active Comparator|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696693|NCT01972269|Active Comparator|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696694|NCT01972269|Active Comparator|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
16696695|NCT01972269|Active Comparator|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
16696696|NCT01972269|Active Comparator|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
16696697|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
16696698|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
16696699|NCT01972243||venous thromboembolism|
16696700|NCT01972230|Experimental|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.
~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
16696701|NCT01972230|Active Comparator|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
16696704|NCT01972204|Experimental|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
16696705|NCT01972204|Sham Comparator|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
16696706|NCT01972191||Group 1|Group 1 : Bare eye marking group
16696707|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
16696708|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
16696709|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
16696710|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
16696711|NCT01972165|Experimental|Group I|Mini-incision carpal tunnel release group
16696712|NCT01972165|Active Comparator|Group II|Endoscopic carpal tunnel release group
16696713|NCT01972152|Experimental|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
16696714|NCT01972152|Experimental|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
16696715|NCT01972152|Active Comparator|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
16696716|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
16696717|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
16696718|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
16696719|NCT01972113|Placebo Comparator|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
16696720|NCT01972113|Active Comparator|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
16696721|NCT01972113|Active Comparator|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
16696722|NCT01972100|Active Comparator|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
16696723|NCT01972100|Active Comparator|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
16696724|NCT01972087|No Intervention|Control|Participants randomized to the control arm receive no telephone simulation training.
16696725|NCT01972087|Experimental|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
16696726|NCT01972074|Experimental|Memantine|"Participants in the placebo arm will receive placebo (no active ingredients) in capsule form twice daily. It will be administered twice daily for 12 weeks. Participants will undergo neuroimaging before and after the 12-week treatment phase.
~Placebo: Capsule"
16696727|NCT01972074|Placebo Comparator|Placebo|"Participants in the memantine arm will receive memantine in capsule form twice daily. It will be administered twice daily for 12 weeks (including a 4-week titration phase to a maximum dose of 20 mg per day). Participants will undergo neuroimaging before and after the 12-week treatment phase.
~Memantine: Capsule"
16696728|NCT01972074|No Intervention|Control Group|Healthy controls will undergo neuroimaging twice (12 weeks apart) and will receive no intervention during the 12-week window.
16696729|NCT01972061|Experimental|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
16696730|NCT01972061|Active Comparator|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
16696731|NCT01972061|Active Comparator|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
16696732|NCT01972061|Active Comparator|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
16696733|NCT01972048|Active Comparator|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
16696734|NCT01972048|Experimental|Intervention group|Participants will receive the mMammogram intervention.
16696735|NCT01972035|Experimental|ValAcyclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValA or ValG in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
16696780|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
16696736|NCT01972035|Active Comparator|ValGanciclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValG or ValA in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
16696737|NCT01972022|Experimental|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
16696738|NCT01972022|Active Comparator|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
16696739|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
16696740|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
16696741|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
16696742|NCT01971983|Experimental|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
16696743|NCT01971983|Experimental|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
16696744|NCT01971983|Sham Comparator|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
16696745|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
16696746|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
16696747|NCT01971957||Sjogren-Larsson syndrome|There are no cohorts for this study.
16696748|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
16696749|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
16696750|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
16696751|NCT01971931||Patients undergoing TKR.|
16696752|NCT01971918|Experimental|early switch|"early switch of monoclonal antibodies anti-TNF
~anti drug antibodies dosage"
16696753|NCT01971918|Experimental|therapeutic intensification|"therapeutic intensification of monoclonal antibodies anti-TNF
~anti drug antibodies dosage"
16696754|NCT01971905||Oben label|There is no intervention on this descriptive study
16696755|NCT01971892|Experimental|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
16696756|NCT01971892|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
16696757|NCT01971879|Sham Comparator|Control|
16696758|NCT01971879|Active Comparator|Remote preconditioning|
16696759|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
16696760|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
16696761|NCT01971840|Experimental|MOVI-KIDS Program|Intervention group
16696762|NCT01971840|No Intervention|Control|No intervention
16696763|NCT01971827|No Intervention|Control|No intervention
16696764|NCT01971827|Experimental|MOVI-KIDS Program|Intervention group
16696765|NCT01971814|Experimental|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
16696766|NCT01971801|Active Comparator|Vitamin D|Vitamin D3, 50,000 IU, weekly
16696767|NCT01971801|Placebo Comparator|Placebo|Placebo comparator, weekly
16696768|NCT01971788|Experimental|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
16696769|NCT01971788|Active Comparator|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
16696770|NCT01971775|Active Comparator|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
16696771|NCT01971775|Active Comparator|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
16696772|NCT01971762||Patients diagnosed bacteremia by S. aureus|
16696773|NCT01971749||Unprotected left main coronary artery stenosis patients|
16696774|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
16696775|NCT01971723|Active Comparator|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
16696776|NCT01971723|Placebo Comparator|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
16696777|NCT01971710|Other|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
16696778|NCT01971710|Other|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
16696779|NCT01971710|Other|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
16696781|NCT01971671||Chinese lactating mother|no intervention.
16696782|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:
~Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12
~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
16696783|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:
~Induction therapy : 4 cycles of VCD (21 days)
~Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15
~Velcade® and Dexamethasone identical treatment to Arm A
~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
16696784|NCT01971645|Experimental|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
16696785|NCT01971645|Placebo Comparator|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
16696786|NCT01971645|Active Comparator|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
16696787|NCT01971632|Active Comparator|Oxycodone/Naloxone|
16696788|NCT01971632|Placebo Comparator|Placebo oxycodone/naloxone|
16696789|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
16696790|NCT01971606|Experimental|Rosuvastatin group|Rosuvastatin group
16696791|NCT01971606|Placebo Comparator|Placebo group|Placebo group
16696792|NCT01971593|Other|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
16696793|NCT01971593|Other|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
16696794|NCT01971580|Other|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
16696795|NCT01971580|Other|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
16696796|NCT01971567|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
16696797|NCT01971567|Placebo Comparator|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
16696798|NCT01971554|Experimental|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
16696799|NCT01971554|Experimental|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
16696800|NCT01971554|Experimental|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
16696801|NCT01971554|Placebo Comparator|Placebo|Placebo, oral, QD for Days 1 to 14
16696802|NCT01971541|Experimental|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
16696803|NCT01971541|Active Comparator|Cognitive Processing Therapy|A group-administered PTSD treatment program.
16696804|NCT01971528|No Intervention|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
16696805|NCT01971528|No Intervention|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
16696806|NCT01971528|No Intervention|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
16696807|NCT01971528|No Intervention|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
16696808|NCT01971528|Experimental|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
16696809|NCT01971528|No Intervention|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
16696810|NCT01971515|Experimental|MSC2363318A|
16696811|NCT01971515|Experimental|MSC2363318A plus Trastuzumab|
16696812|NCT01971515|Experimental|MSC2363318A plus Tamoxifen|
16696813|NCT01971502|Experimental|BI 1060469 single rising dose part|single rising doses given as tablet
16696814|NCT01971502|Experimental|BI 1060469 food effect part|given as tablet fasted and fed
16696815|NCT01971489|Experimental|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16696816|NCT01971476|Experimental|All patients|Volasertib will be administered as intravenous infusion
16696817|NCT01971463|Experimental|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
16696818|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
16696819|NCT01971437|Experimental|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
16696820|NCT01971437|Placebo Comparator|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
16696821|NCT01971424|Experimental|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
16696822|NCT01971424|No Intervention|Controls|The control group was educated by a trained dietician to follow a healthy diet.
16696823|NCT01971411||Community dwelling elderly black females|
16696824|NCT01971398|Experimental|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
16696825|NCT01971398|Experimental|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
16696826|NCT01971398|Active Comparator|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
16696827|NCT01971385|Active Comparator|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
16696828|NCT01971385|Placebo Comparator|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
16696829|NCT01971359||Retrospective|
16696830|NCT01971346|Other|Etanercept|100 mg Etanercept injections per week for 3 months.
16696831|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:
~pulse pressure variation
~stroke volume variation
~plethysmographic variation index"
16696832|NCT01971320|Experimental|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks
~Urostim I stimulation will be done during meals for 6 weeks"
16696833|NCT01971320|Placebo Comparator|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks
~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
16696834|NCT01971307|Experimental|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
16696835|NCT01971307|No Intervention|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
16696836|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
16696837|NCT01971281|Experimental|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
16696838|NCT01971281|Experimental|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
16696839|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
16696840|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
16696841|NCT01971255|Experimental|High Titer (HAI > or = 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of ≥1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
16696842|NCT01971255|Experimental|Low Titer (HAI < 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of <1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
16696843|NCT01971242|Active Comparator|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
16696844|NCT01971242|Placebo Comparator|Placebo|Placebo, 2mg administered subcutaneously once weekly
16696845|NCT01971229|Sham Comparator|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
16696846|NCT01971229|Active Comparator|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
16696847|NCT01971216|No Intervention|Control|Breastfeeding mothers who are not randomised to relaxation intervention
16696848|NCT01971216|Experimental|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
16696849|NCT01971203|Experimental|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
16696850|NCT01971203|Placebo Comparator|placebo plus CBT|treatment group receiving placebo pill plus CBT
16696851|NCT01971190|Sham Comparator|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
16696852|NCT01971190|Active Comparator|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
16696853|NCT01971177|Experimental|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
16696854|NCT01971177|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
16696855|NCT01971164|Experimental|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
16696856|NCT01971164|Experimental|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
16696857|NCT01971164|Experimental|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
16696858|NCT01971164|Experimental|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
16696859|NCT01971151|Experimental|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
16696860|NCT01971151|Experimental|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
16696904|NCT01970839|Other|Tourniquet, pain, nerve injury, sensory nerve function|
16696861|NCT01971151|Active Comparator|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
16696862|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
16696863|NCT01971125||No treatment|"Patients with:
~diabetes mellitus type 2
~absence of heart disease previously reported
~age >45 years
~Informed Consent
~Patients without:
~presence of heart disease previously reported
~diabetes type 1
~serious systemic disease, with an expected lifetime lower than 2 years
~no willingness to participate to the screening
~inadequate compliance to study procedure
~participation to other study"
16696864|NCT01971112|Experimental|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
16696865|NCT01971112|Placebo Comparator|Placebo|
16696866|NCT01971099|Placebo Comparator|Placebo|patients will use placebo for 120 days
16696867|NCT01971099|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
16696868|NCT01971086||acute rhinitis|
16696869|NCT01971073|Experimental|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.
~Intervention: Device: transcranial direct current stimulation"
16696870|NCT01971073|Sham Comparator|Sham tDCS|Sham tDCS
16696871|NCT01971060|Experimental|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
16696872|NCT01971047|Active Comparator|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
16696873|NCT01971047|Active Comparator|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
16696874|NCT01971034|Experimental|Paclitaxel and Metformin|
16696875|NCT01971021|Active Comparator|PICC-line|PICC line insertion.
16696876|NCT01971021|Active Comparator|PORT|Subcutaneous venous port insertion
16696877|NCT01971008|Placebo Comparator|Placebo binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours"
16696878|NCT01971008|Active Comparator|Elastic abdominal binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours"
16696879|NCT01970995|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
16696880|NCT01970995|Active Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
16696881|NCT01970995|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
16696882|NCT01970982|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
16696883|NCT01970982|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
16696884|NCT01970982|Active Comparator|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
16696885|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
16696886|NCT01970943|No Intervention|No Intervention|PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
16696887|NCT01970943|Placebo Comparator|Saline Injection (Placebo)|PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
16696888|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
16696889|NCT01970917|Other|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
16696890|NCT01970917|Other|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
16696891|NCT01970904|Experimental|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
16696892|NCT01970904|Experimental|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
16696893|NCT01970904|Experimental|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
16696894|NCT01970891|Experimental|Freezing of Gait amelioration|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait amelioration
16696895|NCT01970878|Experimental|GFF MDI (PT003)|
16696896|NCT01970878|Experimental|GP MDI (PT001)|
16696897|NCT01970878|Experimental|FF MDI (PT005)|
16696898|NCT01970878|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
16696899|NCT01970865|Experimental|PF-06463922|
16696900|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
16696901|NCT01970852|Experimental|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
16696902|NCT01970852|No Intervention|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
16696903|NCT01970852|Experimental|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
16696905|NCT01970826|Experimental|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
16696906|NCT01970826|Active Comparator|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.
~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.
~It will be evaluated the duration of surgery."
16696907|NCT01970826|Experimental|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.
~It will be evaluated the duration of surgery."
16696908|NCT01970826|Active Comparator|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
16696909|NCT01970826|Experimental|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
16696910|NCT01970826|Active Comparator|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
16696911|NCT01970813|Active Comparator|Study group|acupuncture and bee venom acupuncture point injection
16696912|NCT01970813|Sham Comparator|Control group|sham acupuncture and normal saline injections
16696913|NCT01970813|No Intervention|Waiting group|no additional intervention
16696914|NCT01970800|Experimental|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
16696915|NCT01970787|Experimental|RFA|Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
16696916|NCT01970774|Experimental|MTM and PGx|Participants attend two MTM sessions and have PGx testing
16696917|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
16696918|NCT01970748|Placebo Comparator|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
16696919|NCT01970748|Active Comparator|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
16696920|NCT01970735|Experimental|FSHD patient|
16696921|NCT01970722|Experimental|Treatment (surgery, HIPEC cisplatin)|"Patients undergo surgery and receive hyperthermic cisplatin IP over 60 minutes.
~Beginning at least 3 weeks after surgery, patients may receive carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or gemcitabine hydrochloride IP or IV at the discretion of the medical and gynecologic oncologists."
16696922|NCT01970696||Ovarian Stromal Tumors|
16696923|NCT01970696||Testicular Stromal Tumors|
16696924|NCT01970696||Ovarian Small Cell Carcinoma|
16696925|NCT01970683|Experimental|VSL #3|probiotics given orally BID
16696926|NCT01970683|Other|placebo|Near-identically appearing placebo
16696927|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
16696928|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
16696929|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have >=4 brain metastases will be treated with gamma knife radiosurgery.
16696930|NCT01970631|No Intervention|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
16696931|NCT01970631|Active Comparator|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
16696932|NCT01970631|Active Comparator|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
16696933|NCT01970631|Active Comparator|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
16696934|NCT01970618|Experimental|Part A: single dose escalation (healthy subjects)|
16696935|NCT01970618|Experimental|Part B: 7 day repeat dose (healthy subjects)|
16696936|NCT01970618|Experimental|Part C: 14 day repeat dose (COPD patients)|
16696937|NCT01970605||Patients with PAOD or aneurysms|"Patients
~in Fontaine class > IIa,
~in need of aneurysm repair,
~with defined cardiovascular risk factors or
~graft infections.
~Surgical reconstruction with defined Silver Graft vascular prosthesis."
16696938|NCT01970592|Experimental|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
16696939|NCT01970579|Experimental|Paclitaxel coated balloon|
16696940|NCT01970579|Active Comparator|uncoated PTA catheter|
16696941|NCT01970566|Experimental|IE-MCR|Intense Exercise/Moderate Calorie Restriction
16696942|NCT01970566|Active Comparator|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
16696943|NCT01970566|Active Comparator|CBT|cognitive behavioral therapy
16696944|NCT01970553|Experimental|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):
~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,
~immediately followed by:
~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
16696945|NCT01970540|Experimental|lurbinectedin (PM01183) / doxorubicin|
16696946|NCT01970527|Experimental|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16696947|NCT01970514|Experimental|ARO Spinal System|ARO Spinal System
16696948|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)
~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
16696949|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)
~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
16696950|NCT01970488|Experimental|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
16696951|NCT01970488|Active Comparator|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
16696952|NCT01970475|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
16696953|NCT01970475|Active Comparator|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
16696954|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
16696955|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
16696956|NCT01970449|Experimental|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
16696957|NCT01970449|Placebo Comparator|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
16696958|NCT01970449|Experimental|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
16696959|NCT01970449|Placebo Comparator|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
16696960|NCT01970449|Experimental|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
16696961|NCT01970449|Placebo Comparator|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
16696962|NCT01970436|Experimental|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
16696963|NCT01970436|No Intervention|Usual Prenatal Care|Usual, in-person prenatal care.
16696964|NCT01970423|Other|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
16696965|NCT01970423|Other|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
16696966|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
16696967|NCT01970397|Experimental|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
16696968|NCT01970397|Experimental|Belotero Balance®|Perioral Lines treated with Belotero Balance®
16696969|NCT01970384|Experimental|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
16697008|NCT01970176|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
16697009|NCT01970176|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
16696970|NCT01970384|Sham Comparator|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
16696971|NCT01970371|Experimental|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received 15 milligram per killogram (mg/kg) plazomicin therapy (plus meropenem or tigecycline) as a 30-minute intravenous (IV) infusion once daily for 7 to 14 days.
16696972|NCT01970371|Active Comparator|Colistin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received a 5 mg/kg IV loading dose (300 mg maximum) colistin (plus meropenem or tigecycline) followed by a 5 mg/kg/d maintenance dose divided into every 8 hours (q8h) or every 12 hours (q12h) for 7 to 14 days.
16696973|NCT01970371|Experimental|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
16696974|NCT01970358|Experimental|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)
~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162
~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
16696975|NCT01970345|Experimental|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.
~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
16696976|NCT01970345|Placebo Comparator|Placebo|Placebo
16696977|NCT01970332|No Intervention|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
16696978|NCT01970332|Experimental|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
16696979|NCT01970332|Experimental|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
16696980|NCT01970319||Diabetic with nephropathy|
16696981|NCT01970319||Diabetics without nephropathy|
16696982|NCT01970306|Experimental|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
16696983|NCT01970293|Other|Introduction to AA volunteer|
16696984|NCT01970293|No Intervention|AA materials offered|
16696985|NCT01970280|Active Comparator|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
16696986|NCT01970280|No Intervention|Observation|
16696987|NCT01970267|Active Comparator|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
16696988|NCT01970267|Sham Comparator|Not Treated|
16696989|NCT01970254||Screening (hepatitis B screening)|Patients with unknown HBV infection status undergo 3 HBV screening tests (HBsAg, anti-HBc, and anti-HBs) before chemotherapy. Patients with known HBV infection status undergo either HBsAg or anti-HBc screening tests if there is no evidence of HBV testing in the last 3 months. All patients complete HBV risk assessment survey.
16696990|NCT01970241|Experimental|NPH with steroid dose|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).
~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
16696991|NCT01970241|Active Comparator|Control - Background and correction insulin|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
16696992|NCT01970228|Active Comparator|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
16696993|NCT01970228|Active Comparator|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
16696994|NCT01970228|Active Comparator|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
16696995|NCT01970215|Placebo Comparator|Group 1|TA-8995 0mg (placebo) & placebo statin
16696996|NCT01970215|Experimental|Group 2|TA-8995 1mg & placebo statin
16696997|NCT01970215|Experimental|Group 3|TA-8995 2.5mg & placebo statin
16696998|NCT01970215|Experimental|Group 4|TA-8995 5mg & placebo statin
16696999|NCT01970215|Experimental|Group 5|TA-8995 10mg & placebo statin
16697000|NCT01970215|Active Comparator|Group 6|TA-8995 0mg (placebo) & atorvastatin 20mg
16697001|NCT01970215|Active Comparator|Group 7|TA-8995 10mg & atorvastatin 20mg
16697002|NCT01970215|Active Comparator|Group 8|TA-8995 0mg (placebo) & rosuvastatin 10mg
16697003|NCT01970215|Active Comparator|Group 9|TA-8995 10mg & rosuvastatin 10mg
16697004|NCT01970202|Active Comparator|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
16697005|NCT01970202|Active Comparator|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
16697006|NCT01970202|Other|Control|no treatment
16697007|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. < 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
16697010|NCT01970163|Experimental|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
16697011|NCT01970163|Placebo Comparator|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
16697012|NCT01970163|Active Comparator|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
16697013|NCT01970150|Experimental|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
16697014|NCT01970137|Experimental|KPS-0373|
16697015|NCT01970124|Experimental|KPS-0373|
16697016|NCT01970111|Experimental|KPS-0373|
16697017|NCT01970098|Experimental|KPS-0373|
16697018|NCT01970098|Placebo Comparator|Placebo|
16697019|NCT01970072|Experimental|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
16697020|NCT01970072|Experimental|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
16697021|NCT01970072|Experimental|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
16697022|NCT01970072|Experimental|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
16697023|NCT01970072|Experimental|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
16697024|NCT01970072|Experimental|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
16697025|NCT01970072|Experimental|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
16697026|NCT01970072|Experimental|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
16697027|NCT01970072|Experimental|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
16697028|NCT01970072|Experimental|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
16697029|NCT01970072|Active Comparator|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
16697030|NCT01970059|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
16697031|NCT01970059|Active Comparator|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
16697032|NCT01970046|Placebo Comparator|Placebo/Metformin|
16697033|NCT01970046|Experimental|SP2086 (50mg b.i.d)/Metformin|
16697034|NCT01970046|Experimental|SP2086 (50mg q.d.)/Metformin|
16697035|NCT01970033|Placebo Comparator|Placebo|
16697036|NCT01970033|Experimental|SP2086 50 mg b.i.d|
16697037|NCT01970033|Experimental|SP2086 100 mg q.d.|
16697038|NCT01970020|Experimental|JNJ-38518168|
16697039|NCT01970007|Experimental|Zilver Vena Venous Self-Expanding Stent|
16697040|NCT01969994|Experimental|Controlled dietary background & (-)-[2-14C]epicatechin intake|
16697041|NCT01969981||PICC placement|
16697042|NCT01969968|Other|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
16697043|NCT01969968|Other|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
16697044|NCT01969968|Other|non obese|non obese patients
16697045|NCT01969955|Experimental|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
16697046|NCT01969942|Experimental|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
16697047|NCT01969942|Experimental|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
16697048|NCT01969929|Active Comparator|20G|20G vitrectomy with scleral and conjunctival sutures for closure
16697049|NCT01969929|Active Comparator|23G|23G transconjunctival sutureless vitrectomy
16697050|NCT01969916|Other|Regadenoson|
16697051|NCT01969903|Experimental|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
16697052|NCT01969903|Experimental|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
16697053|NCT01969903|Experimental|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
16697054|NCT01969890|Experimental|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
16697055|NCT01969890|No Intervention|standard therapy|Standard therapy
16697056|NCT01969877|Experimental|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
16697057|NCT01969877|Experimental|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
16697058|NCT01969877|Experimental|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
16697059|NCT01969877|Experimental|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
16697060|NCT01969864|Experimental|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
16697061|NCT01969864|Experimental|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
16697062|NCT01969864|Placebo Comparator|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
16697063|NCT01969851|Experimental|Lacosamide|
16697064|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
16697065|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
16697066|NCT01969825|Experimental|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
16697067|NCT01969825|No Intervention|No massage|Normal protocol for semen collection prior to intrauterine insemination.
16697068|NCT01969812|Experimental|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
16697069|NCT01969812|Active Comparator|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
16697070|NCT01969799|Experimental|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
16697071|NCT01969799|Placebo Comparator|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
16697072|NCT01969786|Experimental|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
16697073|NCT01969786|No Intervention|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
16697074|NCT01969773|Experimental|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
16697075|NCT01969773|Placebo Comparator|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
16697076|NCT01969760|No Intervention|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
16697077|NCT01969760|Experimental|Healthy Families DC Program|Healthy Families DC Program
16697078|NCT01969747|Experimental|Empagliflozin low|Empagliflozin low once daily
16697079|NCT01969747|Experimental|Empagliflozin medium|Empagliflozin medium once daily
16697080|NCT01969747|Experimental|Empagliflozin high|Empagliflozin high once daily
16697081|NCT01969747|Placebo Comparator|Placebo|Placebo once daily
16697082|NCT01969734|Experimental|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
16697083|NCT01969721|Experimental|T+O FDC dosage 1|Low dose
16697084|NCT01969721|Experimental|T+O FDC dosage 2|High dose
16697085|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 1|Low dose
16697086|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 2|High dose
16697087|NCT01969708|Active Comparator|aflibercept|2.0 mg aflibercept every 4 weeks
16697088|NCT01969708|Active Comparator|bevacizumab|1.25 mg bevacizumab every 4 weeks
16697089|NCT01969695|Experimental|ABT-199|ABT-199 monotherapy
16697090|NCT01969682|Experimental|Arm A (ABT-199 and rifampin)|
16697091|NCT01969669|Experimental|Arm A (ABT-199 and ketoconazole)|
16697092|NCT01969656|Placebo Comparator|Placebo|
16697093|NCT01969656|Active Comparator|Calcitriol|
16697094|NCT01969656|Experimental|50 ng 2MD|
16697095|NCT01969656|Experimental|110 ng 2MD|
16697096|NCT01969656|Experimental|170 ng 2MD|
16697097|NCT01969656|Experimental|220 ng 2MD|
16697098|NCT01969656|Experimental|440 ng 2MD|
16697102|NCT01969630|Active Comparator|PEB|PEB angioplasty plus provisional nitinol stent implantation
16697103|NCT01969630|Experimental|PES|Systematic PES angioplasty
16697104|NCT01969617|Experimental|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
16697105|NCT01969617|Placebo Comparator|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
16697106|NCT01969604|Experimental|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
16697107|NCT01969604|No Intervention|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
16697108|NCT01969591|Experimental|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
16697109|NCT01969591|Other|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
16697110|NCT01969578|Active Comparator|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel
~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
16697378|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
16697111|NCT01969578|Experimental|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin
~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
16697112|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
16697113|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
16697114|NCT01969539|Experimental|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
16697115|NCT01969539|Experimental|Combivent Respimat - ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R via ventilator adapter
16697116|NCT01969526|Experimental|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
16697117|NCT01969526|No Intervention|No intervention|Usual care
16697118|NCT01969513|Experimental|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
16697119|NCT01969513|Sham Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
16697120|NCT01969500|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
16697121|NCT01969500|Experimental|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
16697122|NCT01969487|Experimental|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
16697123|NCT01969487|No Intervention|No preoperative warm-up|
16697124|NCT01969474|Experimental|Cannabis|Treatment with a Cannabis capsule
16697125|NCT01969474|Placebo Comparator|Placebo|Placebo
16697126|NCT01969461|Experimental|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
16697127|NCT01969461|Active Comparator|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
16697128|NCT01969448|Active Comparator|Inframammary Fold Incision Cohort|"Inframammary fold incision which is in the crease under the breast.
~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)
~Intraoperatively prior to mastectomy
~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)
~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
16697129|NCT01969448|Active Comparator|Lateral Radial Incision Cohort|"Lateral radial incision
~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)
~Intraoperatively prior to mastectomy
~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)
~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
16697130|NCT01969448|Other|Non-Randomized Cohort|"Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.
~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)
~Intraoperatively prior to mastectomy
~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)
~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
16697131|NCT01969435|Experimental|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"Day -7, carmustine intravenous (IV) infusion
~Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day
~Day -2, melphalan HCl (propylene glycol-free)(IV) infusion
~Day 0, stem cell transplant."
16697132|NCT01969422||observation group|observation
16697133|NCT01969409|Placebo Comparator|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
16697134|NCT01969409|Experimental|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
16697135|NCT01969396|Experimental|SonoBiopsy Catheter|
16697136|NCT01969396|Active Comparator|Endometrial biopsy catheter|
16697137|NCT01969383|Experimental|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
16719390|NCT01819922|Experimental|PF-05175157|
16697138|NCT01969370|Experimental|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
16697139|NCT01969370|No Intervention|Control|No option to request non-medically actionable incidental information
16697140|NCT01969357|Placebo Comparator|Placebo|
16697141|NCT01969357|Experimental|50 mg SP2086|
16697142|NCT01969357|Experimental|100 mg SP2086|
16697143|NCT01969357|Experimental|200 mg SP2086|
16697144|NCT01969357|Active Comparator|100 mg Sitagliptin|
16697145|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
16697146|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
16697147|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
16697148|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
16697149|NCT01969331|Placebo Comparator|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.
~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
16697150|NCT01969331|Active Comparator|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
16697151|NCT01969318|Placebo Comparator|Placebo/Metformin|
16697152|NCT01969318|Experimental|SP2086 (50mg q.d)/Metformin|
16697153|NCT01969318|Experimental|SP2086 (100mg q.d.)/Metformin|
16697154|NCT01969305|Experimental|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
16697155|NCT01969305|Experimental|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
16697156|NCT01969292|Experimental|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
16697157|NCT01969292|Sham Comparator|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
16697158|NCT01969292|No Intervention|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
16697159|NCT01969266|Experimental|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
16697160|NCT01969240|Active Comparator|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
16697161|NCT01969240|No Intervention|Usual Care|Patients randomized to the usual care arm (no decision aid used)
16697162|NCT01969227|Experimental|Cohort|Adult mechanically ventilated patients who are deemed eligible for a spontaneous breathing trial and are candidates to receive subanesthetic ketamine by the primary critical care team.
16697163|NCT01969214|Experimental|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally
~1 tablet, 3 times a day"
16697164|NCT01969201|Experimental|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
16697165|NCT01969201|Active Comparator|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
16697166|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
16697167|NCT01969175|Experimental|Intervention Diet|
16697168|NCT01969175|Placebo Comparator|Control|
16697169|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
16697170|NCT01969149|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.
~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .
~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
16697171|NCT01969149|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.
~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.
~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
16697172|NCT01969136|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
16697173|NCT01969136|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
16697174|NCT01969136|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
16697175|NCT01969123|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
16697176|NCT01969123|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
16697177|NCT01969123|Placebo Comparator|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
16697178|NCT01969110|Active Comparator|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
16697179|NCT01969110|Active Comparator|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
16697180|NCT01969097|Experimental|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
16697181|NCT01969097|Active Comparator|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
16697182|NCT01969097|Sham Comparator|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
16697183|NCT01969084|Experimental|Linagliptin|Subjects given Linagliptin
16697184|NCT01969084|Placebo Comparator|Sugar pill|Subjects given sugar pill/placebo
16697185|NCT01969071|Active Comparator|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
16697186|NCT01969071|Active Comparator|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
16697187|NCT01969058|Active Comparator|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
16697188|NCT01969058|No Intervention|No study treatment Arm|No Isotretinoin treatment
16697189|NCT01969045|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
16697190|NCT01969045|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
16697191|NCT01969032|Experimental|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
16697192|NCT01969019|Active Comparator|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
16697193|NCT01969019|Active Comparator|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
16697194|NCT01969006|Experimental|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
16697195|NCT01969006|Placebo Comparator|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
16697196|NCT01968993|Experimental|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
16697197|NCT01968980|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
16697198|NCT01968980|Placebo Comparator|Placebo|
16697199|NCT01968967|Experimental|Bococizumab (PF-04950615; RN316)|
16697200|NCT01968967|Placebo Comparator|Placebo|
16697201|NCT01968954|Experimental|Bococizumab (PF-04950615;RN316)|
16697202|NCT01968954|Placebo Comparator|Placebo|
16697203|NCT01968941|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT)
16697204|NCT01968941|Active Comparator|Conventional Radiotherapy|Conventional Radiotherapy (CRT)
16697205|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
16697206|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
16697207|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
16697208|NCT01968915|Experimental|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
16697209|NCT01968902|Active Comparator|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
16697210|NCT01968902|Placebo Comparator|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
16697211|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
16697212|NCT01968876|No Intervention|Standard Care|The control group will not use the medication adherence app
16697213|NCT01968876|Experimental|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
16697214|NCT01968850|No Intervention|no bone anti-resorptive therapy|(standard of care)
16697215|NCT01968850|Experimental|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
16697216|NCT01968850|Experimental|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
16697217|NCT01968837|No Intervention|Cervical cancer screening|
16697218|NCT01968824|No Intervention|General Anesthesia|general anesthesia only
16697219|NCT01968824|Experimental|Brachial Plexus Nerve Block|brachial plexus nerve block
16697220|NCT01968811|Experimental|Avance foam, abdominal dressing kit|
16697221|NCT01968798|Active Comparator|Aspirin|100 mg enteric-coated aspirin
16697222|NCT01968798|Placebo Comparator|Placebo|Placebo
16697223|NCT01968785|Active Comparator|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
16697224|NCT01968785|Active Comparator|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
16697441|NCT01967381|Experimental|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
16697225|NCT01968772|Other|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
16697226|NCT01968759|Active Comparator|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
16697227|NCT01968759|Experimental|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
16697228|NCT01968746||ED patients with suspected infection|
16697229|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
16697230|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
16697231|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
16697232|NCT01968707|Active Comparator|ChloraPrep Hi-Lite Orange|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697233|NCT01968707|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697234|NCT01968707|Experimental|3M CHG/IPA Prep Tint 10.5 mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697235|NCT01968707|Experimental|3M CHG/IPA Prep Tint 26-mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697236|NCT01968694|Experimental|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
16697237|NCT01968694|Placebo Comparator|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
16697238|NCT01968681|Experimental|Alexandrite laser treatment|
16697239|NCT01968668|Experimental|BAY94-8862 (1.25 mg)|
16697240|NCT01968668|Experimental|BAY94-8862 (2.5 mg)|
16697241|NCT01968668|Experimental|BAY94-8862 (5 mg )|
16697242|NCT01968668|Experimental|BAY94-8862 (7.5 mg)|
16697243|NCT01968668|Experimental|BAY94-8862 (10 mg)|
16697244|NCT01968668|Placebo Comparator|Placebo|
16697245|NCT01968668|Experimental|BAY 94-8862 (15 mg)|
16697246|NCT01968668|Experimental|BAY 94-8862 (20 mg)|
16697247|NCT01968642|Experimental|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
16697248|NCT01968642|No Intervention|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
16697249|NCT01968629|Experimental|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
16697250|NCT01968616|Other|Intravitreal Lucentis 0.5mg|One arm
16697251|NCT01968590|Active Comparator|cholecalciferol 600 IU|cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
16697252|NCT01968590|Active Comparator|cholecalciferol 4,000 IU|Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
16697253|NCT01968577|Experimental|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
16697254|NCT01968577|No Intervention|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
16697255|NCT01968564|Experimental|High-dose curcumin pill|
16697256|NCT01968564|Experimental|Low-dose curcumin pill|
16697257|NCT01968564|Placebo Comparator|Placebo pill|
16697258|NCT01968551|Experimental|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.
~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
16697259|NCT01968551|Experimental|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
16697260|NCT01968551|Active Comparator|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
16697261|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
16697262|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
16697263|NCT01968525|Experimental|Group A|the hemoglobin is >12g/L in patients from group A.
16697264|NCT01968525|Experimental|Group B|Hb 9-12g/L
16697265|NCT01968525|Experimental|Group C|Hb<9g/L
16697266|NCT01968512|Experimental|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
16697267|NCT01968512|Sham Comparator|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
16697268|NCT01968499||All recruited patients|Patients who receive stent implantation and aged >18 years.
16697269|NCT01968486|Experimental|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
16719391|NCT01819922|Placebo Comparator|Placebo|
16697270|NCT01968486|Experimental|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
16697271|NCT01968486|Experimental|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
16697272|NCT01968473|Experimental|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
16697273|NCT01968460|Experimental|P2B001 Treatment A|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
16697274|NCT01968460|Experimental|P2B001 Treatment B|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
16697275|NCT01968460|Placebo Comparator|Placebo|Placebo once daily for 12 weeks.
16697276|NCT01968447|Experimental|hypocapnia|arterial pCO2 of 3.5 kPa
16697277|NCT01968447|Active Comparator|normocapnia|arterial PCO2 of 6.5-7.0 kPa
16697278|NCT01968434|Experimental|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.
~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
16697279|NCT01968434|Active Comparator|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
16697280|NCT01968421|Experimental|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
16697281|NCT01968421|Placebo Comparator|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
16697282|NCT01968408|Active Comparator|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)
~ARM I: Rotavirus vaccinated patients
~ARM II: Non-rotavirus vaccinated patients"
16697283|NCT01968408|Placebo Comparator|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded
~for the duration of hospitalization"
16697284|NCT01968395|Other|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
16697285|NCT01968382|Experimental|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
16697286|NCT01968382|Experimental|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
16697287|NCT01968382|Placebo Comparator|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
16697288|NCT01968369|Active Comparator|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
16697289|NCT01968369|Placebo Comparator|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
16697290|NCT01968356|Experimental|3M CHG/IPA Prep Colorless|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697291|NCT01968356|Experimental|3M CHG/IPA Prep Tint|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697292|NCT01968356|Active Comparator|ChloraPrep Hi-Lite Orange|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697293|NCT01968356|Placebo Comparator|Normal Saline|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
16697294|NCT01968343|Experimental|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
16697295|NCT01968343|Active Comparator|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
16697296|NCT01968330|Experimental|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
16697297|NCT01968330|No Intervention|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
16697298|NCT01968317|Experimental|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16697299|NCT01968317|Experimental|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
16697300|NCT01968304|No Intervention|Iron status follow up|
16697301|NCT01968291|Experimental|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
16697302|NCT01968291|No Intervention|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
16697303|NCT01968278|Experimental|Baked milk group|BM (baked milk)
16697304|NCT01968278|No Intervention|Control|IgE-cow's milk allergic patients not treated with OIT
16697305|NCT01968265|Placebo Comparator|Placebo|
16697306|NCT01968265|Active Comparator|ISIS-GCCRRx|
16697442|NCT01967381|Experimental|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
16697307|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
16697308|NCT01968239|Experimental|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
16697309|NCT01968239|Active Comparator|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
16697310|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
16697311|NCT01968213|Experimental|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
16697312|NCT01968213|Placebo Comparator|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
16697313|NCT01968200|Experimental|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
16697314|NCT01968200|Experimental|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
16697315|NCT01968187|Experimental|FE 992097|
16697316|NCT01968187|Placebo Comparator|Placebo|
16697317|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
16697318|NCT01968161|Other|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
16697319|NCT01968135|Placebo Comparator|Sugar Pill|Placebo Sugar Pill
16697320|NCT01968135|Experimental|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
16697321|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of <140mmHg (or <130mmHg in the diabetes patients); and LDL <70mg/dl (1.81mmol/L) or drop by 50%.
16697322|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
16697323|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
16697324|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
16697325|NCT01968096|No Intervention|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
16697326|NCT01968096|No Intervention|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
16697327|NCT01968096|No Intervention|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
16697328|NCT01968096|Experimental|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
16697329|NCT01968096|Experimental|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
16697330|NCT01968096|No Intervention|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
16697331|NCT01968083|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
16697332|NCT01968083|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
16697333|NCT01968070|Experimental|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
16697334|NCT01968070|Placebo Comparator|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
16697335|NCT01968070|Experimental|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
16697336|NCT01968070|Placebo Comparator|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
16697337|NCT01968070|Active Comparator|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
16697338|NCT01968057|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
16697339|NCT01968057|Experimental|Baricitinib + Ciclosporin|Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4
16697340|NCT01968044|Experimental|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
16697341|NCT01968044|Other|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
16697342|NCT01968031|Experimental|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:
~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
16697343|NCT01968031|Experimental|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:
~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
16697377|NCT01967810|Experimental|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
16697344|NCT01968031|Placebo Comparator|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:
~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
16697345|NCT01968018|Experimental|Tramadol HCI + acetaminophen|
16697346|NCT01968005|Placebo Comparator|Placebo|Therapy with placebo
16697347|NCT01968005|Experimental|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
16697348|NCT01967992|Active Comparator|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
16697349|NCT01967992|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.
~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
16697350|NCT01967979|Experimental|Cohort 1 (Itraconazole DDI)|
16697351|NCT01967979|Experimental|Cohort 2 (Fluoxetine DDI)|
16697352|NCT01967966|Experimental|Bioavailability|
16697353|NCT01967966|Experimental|Elimination & PK|
16697354|NCT01967953|No Intervention|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.
~Events: lung procurement, cold storage on ice, transplantation."
16697355|NCT01967953|Experimental|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).
~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
16697356|NCT01967940|Experimental|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
16697357|NCT01967940|Experimental|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
16697358|NCT01967940|Placebo Comparator|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
16697359|NCT01967940|Experimental|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a > 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
16697360|NCT01967927|Experimental|GRID 18F-MISO|
16697361|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
16697362|NCT01967901|Active Comparator|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.
~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
16697363|NCT01967901|Active Comparator|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
16697364|NCT01967901|Active Comparator|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
16697365|NCT01967901|Active Comparator|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
16697368|NCT01967875|Active Comparator|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
16697369|NCT01967875|Experimental|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
16697370|NCT01967875|Active Comparator|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
16697371|NCT01967862|Experimental|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
16697372|NCT01967849|Other|Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
16697373|NCT01967849|Other|Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
16697374|NCT01967836|Other|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
16697375|NCT01967823|Experimental|1/Cyclophosphamide & Fludarabine + Anti-ESO murine TCR transduced PBL + HD Aldesleukin|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine T-cell receptor (TCR) transduced PBL + high-dose (HD) aldesleukin
16697376|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
16719440|NCT01819545||Mild cognitive impairment|no intervention
16697379|NCT01967797|Experimental|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
16697380|NCT01967797|No Intervention|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
16697381|NCT01967784|Experimental|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
16697382|NCT01967771|Experimental|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
16697383|NCT01967758|Experimental|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
16697384|NCT01967758|Experimental|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
16697385|NCT01967758|Experimental|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
16697386|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
16697387|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
16697388|NCT01967732|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of CC)."
16697389|NCT01967732|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of CC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
16697390|NCT01967732|Active Comparator|THS 2.2 then NNS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NNS)"
16697391|NCT01967732|Active Comparator|NNS then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NNS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
16697392|NCT01967719|Active Comparator|mTHS 2.2 then mCC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mCC)."
16697393|NCT01967719|Active Comparator|mCC then mTHS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mCC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
16697394|NCT01967719|Active Comparator|mTHS 2.2 then NNS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NNS)"
16697395|NCT01967719|Active Comparator|NNS then mTHS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NNS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
16697396|NCT01967706|Active Comparator|mTHS then mCC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mCC)."
16697397|NCT01967706|Active Comparator|mCC then mTHS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mCC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS)."
16697398|NCT01967706|Active Comparator|mTHS then NRT|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NRT)"
16697399|NCT01967706|Active Comparator|NRT then mTHS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NRT)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS)."
16697400|NCT01967680|Active Comparator|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
16697443|NCT01967368|Experimental|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
16697444|NCT01967368|Active Comparator|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
16697445|NCT01967355|Experimental|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
16719441|NCT01819545||Normal aging|no intervention
16697401|NCT01967680|Experimental|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.
~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.
~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
16697402|NCT01967667|Experimental|Liposomal glutathione|dose steps
16697403|NCT01967667|Placebo Comparator|Placebo|dose steps
16697404|NCT01967654|Experimental|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
16697405|NCT01967654|Experimental|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
16697406|NCT01967641|Experimental|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
16697407|NCT01967628|Experimental|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
16697408|NCT01967628|Placebo Comparator|Sugar capsule|Placebo comparator made of sugar in a capsule
16697409|NCT01967589|Experimental|DC (dosing condition)|Escalation design.
16697410|NCT01967589|Experimental|Oral A|Escalation design. Planned end-dose is 5 mg.
16697411|NCT01967589|Experimental|Oral B|Escalation design. Planned end-dose is 10 mg.
16697412|NCT01967589|Experimental|Oral C|Escalation design. Planned end-dose is 20 mg.
16697413|NCT01967576|Experimental|1/Arm 1-Axitinib|Axitinib 5 mg twice a day on a 28-day cycle
16697414|NCT01967563||overweight and class I obese adult male volunteers|Adult Male Subjects (18-50) will be recruited in order to determine the effects on energy expenditure of transitioning from an energyand macronutrient-balanced standard baseline diet (50% carbohydrate, 35% fat, 15% protein) to a eucaloric ketogenic diet (5% carbohydrate, 80% fat, 15% protein).
16697415|NCT01967550|Experimental|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
16697416|NCT01967550|Placebo Comparator|Placebo|Vehicle control
16697417|NCT01967537|Experimental|68Gallium DOTATATE imaging|68Gallium DOTATATE imaging
16697418|NCT01967524|Experimental|botulinum toxin A + ropivacaïne|
16697419|NCT01967524|Active Comparator|Ropivacaïne|
16697420|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
16697421|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
16697422|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
16697423|NCT01967511||Healthy control subjects|
16697424|NCT01967498|Experimental|montelukast|this arm will receive montelukast as the active intervention of the study
16697425|NCT01967498|Placebo Comparator|placebo|
16697426|NCT01967485|Experimental|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
16697427|NCT01967485|Active Comparator|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
16697428|NCT01967472|Active Comparator|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.
~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
16697429|NCT01967472|Active Comparator|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.
~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
16697430|NCT01967459|Active Comparator|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
16697431|NCT01967459|Active Comparator|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
16697432|NCT01967433|Experimental|Diphenhydramine|Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
16697433|NCT01967433|Placebo Comparator|Placebo|0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
16697434|NCT01967420|Experimental|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
16697435|NCT01967420|Active Comparator|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
16697436|NCT01967407|Experimental|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
16697437|NCT01967394|Experimental|Intervention County|Use of internet based social marketing intervention
16697438|NCT01967394|Placebo Comparator|Control County|No use of social media
16697439|NCT01967381|Placebo Comparator|Arm 1|Subjects will be maintained on oral placebo.
16697440|NCT01967381|Experimental|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
16697446|NCT01967342|Experimental|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
16697447|NCT01967342|Experimental|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
16697448|NCT01967342|Active Comparator|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
16697449|NCT01967329|Active Comparator|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
~One of two treatments randomly assigned to treatment naive participants in Aklavik"
16697450|NCT01967329|Active Comparator|Sequential, treatment naive|"Sequential Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
16697451|NCT01967329|Active Comparator|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:
~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson"
16697452|NCT01967329|Active Comparator|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
16697453|NCT01967329|Active Comparator|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:
~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
16697454|NCT01967329|Active Comparator|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
16697455|NCT01967329|Active Comparator|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:
~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
16697456|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
16697457|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
16697458|NCT01967290|Experimental|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
16697459|NCT01967290|Active Comparator|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
16697460|NCT01967277|Placebo Comparator|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
16697461|NCT01967277|Active Comparator|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
16697462|NCT01967264|Experimental|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
16697463|NCT01967264|Experimental|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
16697464|NCT01967264|Experimental|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
16697465|NCT01967264|Placebo Comparator|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
16697466|NCT01967251|Experimental|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
16697467|NCT01967251|Experimental|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
16697468|NCT01967251|Experimental|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
16697469|NCT01967251|Placebo Comparator|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
16697470|NCT01967238|Active Comparator|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
16697471|NCT01967238|Active Comparator|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
16697472|NCT01967238|Active Comparator|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
16697473|NCT01967225|Experimental|Tedizolid Phosphate (Sivextro, BAY1192631)|Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
16697474|NCT01967225|Active Comparator|Linezolid|Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
16697475|NCT01967212|Experimental|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
16697476|NCT01967212|Active Comparator|Swallow training without biofeedback|
16697477|NCT01967199|Active Comparator|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
16697478|NCT01967199|Experimental|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
16697479|NCT01967186|Experimental|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
16697480|NCT01967186|Experimental|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
16697481|NCT01967186|Experimental|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
16697482|NCT01967186|Active Comparator|Kidney transplantation only|Subject that only undergoes kidney transplantation
16697483|NCT01967173|Experimental|Crossover sequence 1|Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
16697484|NCT01967173|Experimental|Crossover sequence 2|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
16697485|NCT01967173|Experimental|Crossover sequence 3|Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
16697486|NCT01967173|Experimental|Crossover sequence 4|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
16697487|NCT01967173|Experimental|Crossover sequence 5|Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
16697488|NCT01967173|Experimental|Crossover sequence 6|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
16697489|NCT01967173|Experimental|Crossover sequence 7|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
16697490|NCT01967173|Experimental|Crossover sequence 8|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
16697491|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
16697492|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
16697493|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
16697494|NCT01967147|Experimental|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
16697495|NCT01967147|Active Comparator|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
16697496|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Neg|LTBI Negative 3 Doses
16697497|NCT01967134|Experimental|H56:IC31 (15 ug H56) LTBI Pos|LTBI Positive 3 Doses
16697498|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Pos|LTBI Positive 3 Doses
16697499|NCT01967121|Experimental|'Compex unit's Active Recovery® program'|The Compex electrical stimulation system utilized in this study is intended for external application with electrodes to create a muscular contraction and help enhance recovery after eccentric muscular activity.
16697500|NCT01967121|Other|Ice application|A randomized pre and post-test research design will be used to compare three interventions (control, ice, compex) to alleviate the physical symptoms of delayed-onset muscle soreness (DOMS).
16697501|NCT01967121|No Intervention|Control|This is a control group where subjects will not perform an intervention.
16697502|NCT01967108|Experimental|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
16697503|NCT01967108|No Intervention|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
16697504|NCT01967095|Experimental|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.
~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
16697505|NCT01967082|Experimental|Prevention (focus group, APPSPIRE app, survey)|Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
16697506|NCT01967069|Active Comparator|DFD01 Spray|DFD01 Spray twice daily
16697507|NCT01967069|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily
16697508|NCT01967043|Experimental|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle
~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
16697793|NCT01965067|Active Comparator|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
16697509|NCT01967043|Experimental|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel
~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
16697510|NCT01967030||Women with recent GDM pregnancy|The study cohort includes women who had gestational diabetes mellitus (GDM) in their index pregnancy for study enrollment. There are two pre-defined groups: 1) women who breastfeed intensively during the first 4 months postpartum, and 2) women who mostly fed formula during the first 4 months postpartum. The study enrolled women into these pre-defined groups, but some women transitioned into mixed feeding groups after enrollment.
16697511|NCT01967017|Experimental|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
16697512|NCT01967017|Placebo Comparator|Placebo|paracervical block using 15 mL of bacteriostatic saline
16697513|NCT01967004|Experimental|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
16697514|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
16697515|NCT01966978|Active Comparator|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
16697516|NCT01966978|Active Comparator|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
16697517|NCT01966965|Experimental|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
16697518|NCT01966965|Active Comparator|NEDAX|FOLLOWING THE LEAFLET TREATMENT
16697519|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
16697520|NCT01966939||Surgery|Craniotomy or Craniectomy
16697521|NCT01966939||Control|age, gender and teeth condition matched
16697522|NCT01966926|Experimental|Daily Weight Tracking|weighing frequency instructions and tips
16697523|NCT01966926|Experimental|Weekly Weight Tracking|weighing frequency instructions and tips
16697524|NCT01966913|Experimental|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:
~A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.
~The ICE chemotherapy regimen:
~Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,
~Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,
~Ifosfamide, 2400 mg/m²/d,
~For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
16697525|NCT01966900|Active Comparator|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF
~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
16697526|NCT01966900|Active Comparator|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF
~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
16697527|NCT01966887|Experimental|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
16697528|NCT01966887|Placebo Comparator|Placebo; single intracoronary infusion|Placebo comparator
16697529|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
16697530|NCT01966861|No Intervention|usual care|Weaning as protcolised by the units' daily practice (SBT)
16697531|NCT01966861|Experimental|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
16697532|NCT01966848|Active Comparator|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
16697533|NCT01966848|Active Comparator|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
16697534|NCT01966835|Experimental|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
16697535|NCT01966835|No Intervention|control group|no exercise intervention
16697536|NCT01966822|Experimental|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
16697537|NCT01966822|Active Comparator|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
16697538|NCT01966809|Experimental|Photofrin photodynamic therapy.|Photofrin photodynamic therapy. Drug - 2.5 mg/kg, light - 240 mJ/cm2.
16697539|NCT01966796||PSI II|PSI less than 70 or equal to 70
16697540|NCT01966796||PSI III|PSI 70-90
16697541|NCT01966796||PSI IV|PSI 90-130
16697542|NCT01966796||PSI V|PSI more than 130
16697543|NCT01966783|Experimental|Budesonide dosage 1|Budesonide 2 mg suppository
16697544|NCT01966783|Experimental|Budesonide dosage 2|Budesonide 4 mg suppository
16697545|NCT01966783|Active Comparator|Mesalazine|Mesalazine 1g suppository
16697546|NCT01966783|Experimental|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
16697547|NCT01966770|Active Comparator|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
16697548|NCT01966770|Active Comparator|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
16721852|NCT01803217|Experimental|mode switch to atrial pacing|
16697549|NCT01966770|Active Comparator|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
16697550|NCT01966770|Active Comparator|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
16697551|NCT01966770|Active Comparator|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
16697552|NCT01966770|Active Comparator|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
16697553|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
16697554|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
16697555|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
16697556|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
16697557|NCT01966731|Experimental|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
16697558|NCT01966718|Experimental|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
16697559|NCT01966705|Experimental|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
16697560|NCT01966705|Experimental|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
16697561|NCT01966705|Experimental|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
16697562|NCT01966705|No Intervention|Waiting-list condition|No intervention: 12 weeks
16697563|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 1|"Fluticasone Propionate Drug formulation 1 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.
~See Formulation Development in Detailed Description for details regarding differences in formulations"
16697564|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 2|"Fluticasone Propionate Drug formulation 2 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.
~See Formulation Development in Detailed Description for details regarding differences in formulations"
16697565|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3|"Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.
~See Formulation Development in Detailed Description for details regarding differences in formulations"
16697566|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3*|Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose. * (The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
16697567|NCT01966679|Active Comparator|Double-blind (active versus placebo)|AZD7325 versus placebo
16697568|NCT01966679|Placebo Comparator|Placebo|
16697569|NCT01966666|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
16697570|NCT01966666|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
16697571|NCT01966666|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
16697572|NCT01966666|Placebo Comparator|Placebo|
16697573|NCT01966653|Active Comparator|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
16697574|NCT01966653|Active Comparator|fosfomycin|A single 3g dose of oral fosfomycin will be given.
16697575|NCT01966640|Experimental|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
16697576|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
16697577|NCT01966614|Experimental|PRX302|PRX302 injection
16697578|NCT01966614|Placebo Comparator|Placebo|Placebo (Vehicle-only injection)
16697579|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
16697580|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
16697581|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
16697582|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
16697583|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
16697584|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
16697585|NCT01966575|Experimental|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
16697586|NCT01966575|No Intervention|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
16697587|NCT01966562|Experimental|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
16697588|NCT01966562|Active Comparator|MC TRAINING|MULTICOMPONENT TRAINING
16697589|NCT01966562|No Intervention|CG|Control group
16697590|NCT01966549|Experimental|CNTO 6785|
16697591|NCT01966549|Placebo Comparator|Placebo|
16697592|NCT01966536|Experimental|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
16697593|NCT01966523|Experimental|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
16697594|NCT01966523|Other|Usual Care|Residents will receive usual care for infections
16697595|NCT01966510|Experimental|Cord blood transplantation|Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
16697596|NCT01966497||Core study therapy|"idarubicin for both induction and consolidation courses
~if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
16697597|NCT01966484|Active Comparator|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
16697598|NCT01966484|Active Comparator|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
16697599|NCT01966471|Active Comparator|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
16697600|NCT01966471|Experimental|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
16697601|NCT01966458|Experimental|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
16697602|NCT01966458|Active Comparator|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
16697603|NCT01966445|Experimental|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
16697604|NCT01966445|Experimental|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
16697605|NCT01966432|Other|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:
~Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.
~Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.
~Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
16697606|NCT01966419|Active Comparator|Ornithine phenylacetate|Participants receive ornithine phenylacetate for up to 5 days via continuous IV infusion in addition to standard of care (SOC)
16697607|NCT01966419|Placebo Comparator|Placebo|Participants receive matching placebo up to 5 days via continuous IV infusion in addition to SOC
16697608|NCT01966406|Experimental|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
16697609|NCT01966406|Active Comparator|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
16697610|NCT01966393|Active Comparator|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
16697611|NCT01966393|Active Comparator|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
16697612|NCT01966393|Active Comparator|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
16697613|NCT01966380|Experimental|Device, dressing|Intervention: Device, Leia dressing
16697614|NCT01966380|Active Comparator|Dressing , device|Intervention: Device: Hydroactive surgical dressing
16697615|NCT01966367|Experimental|CliniMACS PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMACS (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
16697616|NCT01966354|Experimental|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach
~Long axis, in-plane needle:
~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
16697617|NCT01966354|Experimental|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach
~Short axis, out-of-plane needle:
~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
16697618|NCT01966354|Experimental|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach
~Oblique axis, in-plane needle:
~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
16697794|NCT01965067|Experimental|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
16697619|NCT01966341|Active Comparator|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
16697620|NCT01966341|Experimental|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
16697621|NCT01966328|Experimental|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
16697622|NCT01966328|Active Comparator|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
16697623|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.
~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
16697624|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.
~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
16697625|NCT01966302|Experimental|Beraprost open label|Compassionate use access to open label BPS-314d-MR
16697626|NCT01966289|Experimental|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
16697627|NCT01966289|Experimental|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
16697628|NCT01966289|Experimental|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
16697629|NCT01966289|Experimental|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
16697630|NCT01966276|Experimental|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.
~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
16697631|NCT01966276|Placebo Comparator|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
16697632|NCT01966263|Active Comparator|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
16697633|NCT01966263|Active Comparator|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.
~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
16697634|NCT01966250|Experimental|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
16697635|NCT01966250|Active Comparator|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
16697636|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
16697637|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
16697638|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.
~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
16697639|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.
~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
16697786|NCT01965132||Biologic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab)
16697640|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.
~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
16697641|NCT01966198|Experimental|all patients|tilt
16697642|NCT01966185|No Intervention|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
16697643|NCT01966185|Experimental|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
16697644|NCT01966172|Experimental|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
16697645|NCT01966172|Active Comparator|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
16697646|NCT01966159|Experimental|SYNERGY Investigational Device|SYNERGY Stent System
16697647|NCT01966159|Active Comparator|PE Plus Investigational Device|PE Plus Stent System
16697648|NCT01966146|Experimental|TAVI|Echocardiography after TAVI
16697649|NCT01966146|Experimental|MitraClip|Echocardiography after MitraClip procedure
16697650|NCT01966133|No Intervention|Control|no interventions were assigned
16697651|NCT01966133|Active Comparator|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
16697652|NCT01966120|Active Comparator|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
16697653|NCT01966120|Placebo Comparator|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
16697654|NCT01966107|Experimental|Aclidinium Bromide|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
16697655|NCT01966107|Placebo Comparator|Placebo|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
16697656|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
16697657|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
16697658|NCT01966081|Other|Cases|
16697659|NCT01966081|Other|controls|
16697660|NCT01966068|Experimental|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
16697661|NCT01966055|Experimental|Solithromycin|
16697662|NCT01966042|Experimental|Stem Cell Therapy|"All subjects enrolled in the study underwent:
~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
16697663|NCT01966029|Experimental|Treatment|All patients receive treatment with BMN 110
16697664|NCT01966016|Experimental|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
16697665|NCT01966016|Experimental|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
16697666|NCT01966003|Experimental|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
16697667|NCT01966003|Active Comparator|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
16697668|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
16697669|NCT01965977|Experimental|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
16697670|NCT01965951|Experimental|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
16697671|NCT01965951|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
16697672|NCT01965938|Active Comparator|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
16697673|NCT01965938|Other|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
16697674|NCT01965925|Experimental|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
16697675|NCT01965925|Placebo Comparator|Placebo|Subjects will take placebo upon waking once per day.
16697676|NCT01965912|Experimental|Kuvan®|
16697677|NCT01965899|Experimental|Insertable Cardiac Monitor Implant|
16697678|NCT01965886|Active Comparator|Medial approach|Medial parapatellar approach (classic approach)
16697679|NCT01965886|Experimental|Keblish approach|Lateral parapatellar approach (Keblish approach)
16698036|NCT01963351||Locally advanced and metastatic nsclc|non squamous
16697680|NCT01965873|Experimental|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
16697681|NCT01965873|No Intervention|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
16697682|NCT01965860|Experimental|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
16697683|NCT01965860|No Intervention|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
16697684|NCT01965860|Experimental|E-LEARNING|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire, no simulation.
16697685|NCT01965847|Active Comparator|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
16697686|NCT01965847|Experimental|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
16697687|NCT01965834|Experimental|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
16697688|NCT01965821|Other|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
16697689|NCT01965821|Other|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
16697690|NCT01965808|Experimental|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
16697691|NCT01965808|Experimental|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
16697692|NCT01965795|Placebo Comparator|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.
~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
16697693|NCT01965795|Experimental|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.
~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
16697694|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
16697695|NCT01965769|Experimental|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
16697696|NCT01965769|No Intervention|gastric residual evaluation|Infants will receive routine gastric residual evaluation
16697697|NCT01965756|Experimental|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
16697698|NCT01965756|Experimental|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
16697699|NCT01965743|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
16697700|NCT01965730|Active Comparator|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
16697701|NCT01965730|Experimental|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
16697787|NCT01965119|Experimental|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
16697788|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
16697704|NCT01965691|Experimental|Protein intake|Protein intake- Dietary supplement
16697705|NCT01965678|Experimental|OMT|
16697706|NCT01965665|Experimental|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
16697707|NCT01965652|Experimental|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
16697708|NCT01965652|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
16697709|NCT01965639|Experimental|High Risk group|Extension of Care
16697710|NCT01965626|Active Comparator|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days
~HD-DXM (orally at 40 mg daily for 4d )"
16697711|NCT01965626|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
16697712|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
16697713|NCT01965600|Experimental|Cohort 1|
16697714|NCT01965600|Experimental|Cohort 2|
16697715|NCT01965587|Active Comparator|novasure mirena IUS combined|novasure mirena IUS combined therapy
16697716|NCT01965587|Active Comparator|novasure alone|Sole treatment with Novasure
16697717|NCT01965574|Experimental|Single arm|
16697718|NCT01965561|Experimental|CRoC|Use of Combat Ready Clamp (CRoC)
16697719|NCT01965561|Experimental|AAJT|Use of Abdominal Aortic and Junctional Tourniquet
16697720|NCT01965561|Experimental|JETT|Junctional Emergency Treatment Tool
16697721|NCT01965561|Experimental|SJT|SAM Junctional Tourniquet
16697722|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
16697723|NCT01965535|Experimental|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
16697724|NCT01965535|Experimental|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
16697725|NCT01965522|Experimental|Melatonin and Vitamin D|
16697726|NCT01965522|Experimental|Placebo and Vitamin D|
16697727|NCT01965522|Experimental|Melatonin and Placebo|
16697728|NCT01965522|Placebo Comparator|Placebo and Placebo|
16697729|NCT01965509|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
16697730|NCT01965509|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
16697731|NCT01965509|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
16697732|NCT01965496|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
16697733|NCT01965496|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
16697734|NCT01965496|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
16697735|NCT01965483|Experimental|Weekly radiation|once-weekly breast irradiation
16697736|NCT01965470|Experimental|Combination Prevention|"Scale-up of HTC services during 2 annual HTC campaigns, with a target of >90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.
~Scale-up of universal ART for all HIV-infected adults, with a target of >93% of HIV positive adults receiving ART.
~Scale-up of retention in care and adherence interventions, with a target of ensuring that >95% of HIV-infected adults are virally suppressed with HIV-1 RNA <400 copies per ML..
~Scale-up of linkage to MC services, with a target of ensuring >60% of HIV-negative men are circumcised.
~Rapid strengthening of PMTCT services, with a target of >90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery."
16697737|NCT01965470|Active Comparator|Enhanced Care|Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
16697738|NCT01965431|Experimental|BI 207127 + Faldaprevir|Tablets/capsules
16697739|NCT01965431|Active Comparator|Moxifloxacin (Avalox®)|Tablets
16697740|NCT01965431|Experimental|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
16697741|NCT01965418|Active Comparator|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
16697742|NCT01965418|Placebo Comparator|placebo|placebo of Fufang Biejia Ruangan Tablet
16697743|NCT01965405|Experimental|Phase 1: Standard of Care (A)|Brief counseling and bupropion
16697744|NCT01965405|Experimental|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
16697745|NCT01965405|Experimental|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
16697746|NCT01965405|Experimental|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
16697747|NCT01965405|Experimental|Phase 2b: Responders (A)|Bupropion, no additional treatment.
16697748|NCT01965405|Experimental|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
16697749|NCT01965392|Experimental|healtn education|one group received an educational program
16697750|NCT01965379|Active Comparator|Intervention|Restriction on food containing phosphorus additives.
16697751|NCT01965379|Placebo Comparator|Control|Standard care.
16697752|NCT01965366|Active Comparator|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
16697753|NCT01965366|Placebo Comparator|Placebo + VRE|Placebo + virtual reality exposure therapy
16697789|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
16697790|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
16721853|NCT01803217|Active Comparator|atrioventricular hysteresis function|
16697754|NCT01965353|Experimental|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
~Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.
~Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.
~Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.
~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
16697755|NCT01965340|Experimental|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
16697756|NCT01965340|No Intervention|Patients treated as usual|
16697757|NCT01965327|Experimental|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
16697758|NCT01965314|Placebo Comparator|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
16697759|NCT01965314|Active Comparator|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
16697760|NCT01965301|Experimental|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
16697761|NCT01965301|Active Comparator|Diphenhydramine|Single oral dose of diphenhydramine 50mg
16697762|NCT01965301|Placebo Comparator|Placebo|Single oral dose
16697763|NCT01965288|Experimental|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
16697764|NCT01965288|Active Comparator|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
16697765|NCT01965275|Experimental|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
16697766|NCT01965262|Active Comparator|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
16697767|NCT01965262|Active Comparator|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
16697768|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval > 10mm; Lateral > 10mm
16697769|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval < 5 mm; Lateral 5 - 8 mm
16697770|NCT01965236|Experimental|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
16697771|NCT01965236|Experimental|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
16697772|NCT01965223|Experimental|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
16697773|NCT01965223|Experimental|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
16697774|NCT01965210|Experimental|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
16697775|NCT01965210|Experimental|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
16697776|NCT01965210|Experimental|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
16697777|NCT01965210|Experimental|Large non-supplemented rye|Large portion of rye porridge without supplements.
16697778|NCT01965210|Experimental|Small non-supplemented rye|Small portion of rye porridge without supplements.
16697779|NCT01965210|Active Comparator|Refined wheat bread|Refined wheat bread.
16697780|NCT01965184|Experimental|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
16697781|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
16697782|NCT01965158|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
16697783|NCT01965158|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
16697784|NCT01965145|Experimental|Gevokizumab|Solution for subcutaneous injection, Dose 1
16697785|NCT01965145|Placebo Comparator|Placebo|Solution for subcutaneous injection, placebo
16697791|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
16697795|NCT01965054|Experimental|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
16697796|NCT01965054|No Intervention|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
16697797|NCT01965041|Experimental|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
16697798|NCT01965028|Experimental|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
16697799|NCT01965015|Experimental|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
16697800|NCT01965002|Experimental|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
16697801|NCT01964989|Experimental|aQIV|flu vaccine
16697802|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
16697803|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
16697804|NCT01964963||Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
16697805|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
16697806|NCT01964937|Experimental|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.
~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
16697807|NCT01964937|Experimental|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.
~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
16697808|NCT01964937|Experimental|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.
~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
16697809|NCT01964937|Experimental|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.
~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
16697810|NCT01964937|Experimental|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
16697811|NCT01964924|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.
~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16697812|NCT01964911|Experimental|Ropivacaïne|
16697813|NCT01964898|Experimental|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
16697814|NCT01964898|Active Comparator|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
16697815|NCT01964885|Active Comparator|IQP-AS-105|One tablet daily
16697816|NCT01964885|Placebo Comparator|Placebo|One tablet daily
16697817|NCT01964872|Experimental|JNJ-38877618|
16697818|NCT01964872|Placebo Comparator|Placebo|
16697819|NCT01964859|Experimental|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
16697820|NCT01964846|Experimental|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
16698131|NCT01962792|Experimental|Phase 1 - Dose Finding|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
16697821|NCT01964846|Placebo Comparator|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
16697822|NCT01964833|Sham Comparator|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
16697823|NCT01964833|Experimental|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
16697824|NCT01964820|Experimental|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
16697825|NCT01964820|No Intervention|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
16697826|NCT01964807|Experimental|Cigarette smokers|Will smoke 1 cigarette, National Institute of Drug Abuse (NIDA) test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with <0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
16697827|NCT01964807|Experimental|Nonsmokers|Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.
16697828|NCT01964807|Experimental|Smokeless tobacco users|Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.
16697829|NCT01964807|Experimental|e-cigarette users|Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
16697830|NCT01964781|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
16697831|NCT01964781|Experimental|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
16697832|NCT01964781|Experimental|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
16697833|NCT01964781|Experimental|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
16697834|NCT01964781|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
16697835|NCT01964781|Placebo Comparator|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
16697836|NCT01964755|Experimental|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:
~Chemotherapy: Up to 6 cycles, 21 days each:
~Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;
~Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;
~Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;
~Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;
~Antiviral-Based Therapy
~Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;
~Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
16697837|NCT01964742|Experimental|HIV-HCV co-infected patients|
16697838|NCT01964729|Sham Comparator|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
16697839|NCT01964729|Experimental|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
16697840|NCT01964716|Experimental|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
16697841|NCT01964716|Active Comparator|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
16697842|NCT01964703|Placebo Comparator|control|
16697843|NCT01964703|Active Comparator|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
16697844|NCT01964703|Active Comparator|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
16697845|NCT01964677|Experimental|MR-HIFU of painful bone metastases|
16697846|NCT01964664|Experimental|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
16697847|NCT01964664|Active Comparator|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
16697848|NCT01964651|Experimental|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
16697849|NCT01964651|Experimental|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
16697850|NCT01964651|Experimental|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
16697851|NCT01964651|Experimental|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
16697852|NCT01964638|Other|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
16697853|NCT01964625|Experimental|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
16697854|NCT01964599|Other|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
16697855|NCT01964599|Other|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
16697856|NCT01964599|Other|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
16697857|NCT01964586|Active Comparator|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
16697858|NCT01964586|Active Comparator|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
16697859|NCT01964573|Experimental|Rotigotine group|
16697860|NCT01964573|Placebo Comparator|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
16697861|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:
~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg
~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg
~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg
~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
16697862|NCT01964547|Active Comparator|Sativex|"Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
~Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability."
16697863|NCT01964547|Placebo Comparator|Placebo|Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
16697864|NCT01964534|Active Comparator|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
16697865|NCT01964534|Experimental|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
16697866|NCT01964521|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
16697867|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
16697868|NCT01964495|Active Comparator|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
16697869|NCT01964495|Experimental|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
16697870|NCT01964495|Experimental|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
16697871|NCT01964482|Experimental|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
16697872|NCT01964482|No Intervention|Usual care|Usual care
16697873|NCT01964469|Placebo Comparator|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
16697874|NCT01964469|Experimental|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
16697875|NCT01964469|No Intervention|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
16697876|NCT01964456|Active Comparator|Patients|Patients suffering of anorexia
16697877|NCT01964456|Placebo Comparator|Control|Subjects controls (not suffering of anorexia)
16697878|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
16697879|NCT01964430|Experimental|nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2|Participants received nab-Paclitaxel 125 mg/m^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
16697880|NCT01964430|Active Comparator|Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
16697881|NCT01964417|Active Comparator|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
16697882|NCT01964417|Active Comparator|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
16697883|NCT01964404|Experimental|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
16697884|NCT01964404|Experimental|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
16697885|NCT01964404|Placebo Comparator|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
16697886|NCT01964391|Experimental|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (>) 2 centimeters (cm) in diameter.
16697887|NCT01964378|Experimental|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
16697888|NCT01964378|Active Comparator|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
16697889|NCT01964365|Experimental|Rosuvastatin|multiple dose of Rosuvastatin 20mg
16697890|NCT01964365|Experimental|Fenofibric acid|multiple dose of Fenofibric acid 135mg
16697891|NCT01964365|Experimental|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
16697892|NCT01964352|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
16697893|NCT01964352|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
16697894|NCT01964352|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
16697895|NCT01964352|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
16697896|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
16697897|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
16697898|NCT01964326|Experimental|Atorvastatin calcium 10 mg|
16697899|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
16697900|NCT01964300|Experimental|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
16697901|NCT01964287|Experimental|Gembrax followed by Folfirinox|"Gembrax:
~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest
~Folfirinox:
~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
16697902|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
16697903|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
16697904|NCT01964248|Experimental|Lidocaïne/prilocaïne|"Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base
~Single dose: 2 grams (one tube of cream)
~Cream applied 2 hours before blood sample"
16697905|NCT01964248|Placebo Comparator|Placebo|"Single dose: 2 grams (one tube of cream)
~Cream applied 2 hours before blood sample"
16697906|NCT01964235|Experimental|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
16697907|NCT01964235|Placebo Comparator|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
16697908|NCT01964222|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
16697909|NCT01964222|No Intervention|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
16697910|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
16697911|NCT01964196|Experimental|ASP1517 low dose group|Oral
16697912|NCT01964196|Experimental|ASP1517 middle dose group|Oral
16697913|NCT01964196|Experimental|ASP1517 high dose group|Oral
16697914|NCT01964196|Placebo Comparator|Placebo group|Oral
16697915|NCT01964183|Experimental|treatment group|
16697916|NCT01964170|Experimental|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
16697917|NCT01964170|Active Comparator|Goserelin|part 1 for 1 year treatment
16697918|NCT01964157|Experimental|LDK378 arm|
16697919|NCT01964144|Experimental|Dovitinib arm|
16697920|NCT01964131|Experimental|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
16697921|NCT01964131|Other|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
16697922|NCT01964118|Other|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
16698132|NCT01962792|Experimental|Phase 2b - Main Study|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
16697923|NCT01964118|Experimental|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
16697924|NCT01964105|Experimental|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
16697925|NCT01964105|No Intervention|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).
~Goal: 50 patients"
16697926|NCT01964105|Other|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.
~Goal: 50 Patients"
16697927|NCT01964092|Experimental|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
16697928|NCT01964092|Active Comparator|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
16697929|NCT01964079|Active Comparator|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
16697930|NCT01964079|Active Comparator|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
16697931|NCT01964066|Experimental|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
16697932|NCT01964066|Active Comparator|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
16697933|NCT01964053|Experimental|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
16697934|NCT01964053|Active Comparator|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
16697935|NCT01964040|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
16697936|NCT01964040|Experimental|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
16697937|NCT01964040|Active Comparator|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
16697938|NCT01964027|Experimental|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
16697939|NCT01964014|Experimental|advagraf|The same capacity advagaf + sirolimus
16697940|NCT01964001|Placebo Comparator|Placebo|starch
16697941|NCT01964001|Experimental|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
16697942|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
16697943|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
16697944|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
16697945|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
16697946|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
16697947|NCT01963936|Experimental|Supreme LMA|
16697948|NCT01963936|Active Comparator|Facial mask|
16697949|NCT01963923|Experimental|Rehabilitation Group|The rehabilitation group must complete at least 16 sessions of the Pulmonary Rehabilitation Program
16697950|NCT01963923|No Intervention|Control Group|The control group must complete only the outcome measures and continue with their clinical routine as specified by their physicians.
16697951|NCT01963910|Active Comparator|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
16698133|NCT01962792|Experimental|Phase 2b - Sub-study|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
16697952|NCT01963910|Placebo Comparator|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
16697953|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
16697954|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
16697955|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
16697956|NCT01963871|Experimental|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
16697957|NCT01963858|Experimental|Functional relaxation|Functional relaxation
16697958|NCT01963858|Active Comparator|No relaxation|No relaxation
16697959|NCT01963845|Placebo Comparator|Placebo|Placebo
16697960|NCT01963845|Experimental|Active drug|Sitagliptin 100 mg
16697961|NCT01963832|Experimental|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
16697962|NCT01963832|Experimental|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
16697963|NCT01963832|Experimental|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
16697964|NCT01963832|Experimental|Usual care and placebo|Usual physical care combined with placebo
16697965|NCT01963819|No Intervention|Control|Standard treatment
16697966|NCT01963819|Experimental|Intervention|Endometrial biopsy before standard treatment
16697967|NCT01963806|Experimental|Smartphone-supplemented iCBT with therapist support|n = 50
16697968|NCT01963806|Experimental|Smartphone-supplemented iCBT without therapist support|n = 50
16697969|NCT01963806|Active Comparator|Active waiting list control group with delayed treatment|n = 50
16697970|NCT01963793|Other|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
16697971|NCT01963793|Other|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
16697972|NCT01963780|Experimental|OCS Lung Tx.|
16697973|NCT01963767|Experimental|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
16697974|NCT01963767|Placebo Comparator|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
16697975|NCT01963754|Experimental|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
16697976|NCT01963754|Active Comparator|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
16697977|NCT01963741|Experimental|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
16697978|NCT01963741|Experimental|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
16697979|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
16697980|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
16697981|NCT01963715|Experimental|EGFR+ Solid Tumor|EGFR+ Solid Tumor
16697982|NCT01963702|Experimental|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
16697983|NCT01963702|Active Comparator|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
16697984|NCT01963689|Placebo Comparator|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
16697985|NCT01963689|Experimental|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
16697986|NCT01963689|Experimental|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
16697987|NCT01963676|Experimental|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
16697988|NCT01963676|Sham Comparator|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
16697989|NCT01963663|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
16697990|NCT01963663|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
16697991|NCT01963650||No treatment|
16697992|NCT01963637|Experimental|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
16697993|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
16697994|NCT01963611|Experimental|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
16697995|NCT01963611|Experimental|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
16697996|NCT01963611|Experimental|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
16697997|NCT01963611|Experimental|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
16697998|NCT01963611|Active Comparator|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
16697999|NCT01963598|Experimental|Group 1|Dosing regimen 1
16698000|NCT01963598|Experimental|Group 2|Dosing regimen 2
16698001|NCT01963598|Experimental|Group 3|Dosing regimen 3
16698002|NCT01963598|Experimental|Group 4|Dosing regimen 4
16698003|NCT01963585||Negative metacholine|Healthy control
16698004|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
16698005|NCT01963572|Experimental|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
16698006|NCT01963572|No Intervention|general care group (CG)|CG raises any health-related question, they can be answered.
16698007|NCT01963559|Other|Diabetic patients with MPP|
16698008|NCT01963559|Other|Diabetic patients without MPP|
16698009|NCT01963546|Other|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
16698010|NCT01963546|Other|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
16698011|NCT01963546|Other|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
16698012|NCT01963546|Experimental|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.
~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
16698013|NCT01963507|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
16698014|NCT01963507|No Intervention|Control|
16698015|NCT01963494|Experimental|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
16698016|NCT01963494|Active Comparator|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
16698017|NCT01963494|Active Comparator|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
16698018|NCT01963481|Experimental|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:
~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
16698019|NCT01963468|Experimental|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.
~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
16698020|NCT01963468|No Intervention|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
16698021|NCT01963455|Experimental|MDCs transplant|The women who have stress urinary incontinency.
16698022|NCT01963442|Active Comparator|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
16698023|NCT01963442|Placebo Comparator|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
16698024|NCT01963429|Experimental|A(radiofrequency ablation )|radiofrequency ablation
16698025|NCT01963429|Experimental|B(Proton)|hypofractionated proton beam therapy
16698026|NCT01963416|Placebo Comparator|Control|macro- and micro-nutrient matched control (240 ml)
16698027|NCT01963416|Experimental|Orange juice|commercial orange juice (240 ml)
16698028|NCT01963416|Experimental|whole orange|whole orange fruit (240 ml)
16698029|NCT01963416|Experimental|processed whole orange|processed whole orange (240 ml)
16698030|NCT01963403|Active Comparator|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
16698031|NCT01963403|Placebo Comparator|Placebo|Placebo
16698032|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
16698033|NCT01963377|Experimental|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
16698034|NCT01963377|Experimental|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
16698035|NCT01963364|Experimental|Intervention group|All healthy volunteers
16698037|NCT01963338|Experimental|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
16698038|NCT01963338|Experimental|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
16698039|NCT01963325|Experimental|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
16698040|NCT01963312|Experimental|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
16698041|NCT01963312|Active Comparator|Transurethral Resection|Surgery to remove part of the prostate gland
16698042|NCT01963299|Active Comparator|Ropivacaine alone group|
16698043|NCT01963299|Experimental|Ropivacaine/Clonidine group|
16698044|NCT01963286|Other|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
16698045|NCT01963273|Experimental|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
16698046|NCT01963260|Experimental|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
16698047|NCT01963260|Experimental|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
16698048|NCT01963260|Experimental|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
16698049|NCT01963260|Experimental|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
16698050|NCT01963260|Experimental|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
16698051|NCT01963260|Placebo Comparator|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
16698052|NCT01963260|Experimental|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
16698053|NCT01963260|Experimental|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
16698054|NCT01963260|Placebo Comparator|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
16698055|NCT01963260|Placebo Comparator|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
16698056|NCT01963247||Healthy Athletes|
16698057|NCT01963247||Concussed Athletes|
16698058|NCT01963234|Experimental|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
16698059|NCT01963221|Other|fluodeoxyglucose (18f)|
16698060|NCT01963208|Experimental|ganaxolone|active
16698061|NCT01963208|Placebo Comparator|Placebo|placebo, non-active
16698062|NCT01963195|Experimental|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
16698063|NCT01963182|Experimental|irinotecan dose based on genetic polymorphism of UGT1A1|
16698064|NCT01963169|Experimental|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
16698065|NCT01963169|Experimental|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
16698066|NCT01963169|No Intervention|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
16698067|NCT01963156|Experimental|Prescription synchronization|
16698068|NCT01963156|No Intervention|Control|
16698069|NCT01963143|Experimental|Treatment Sequence 1 - Adults|Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
16698070|NCT01963143|Experimental|Treatment Sequence 2 - Adults|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
16698071|NCT01963143|Experimental|Pediatrics|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
16698072|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
16698073|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
16698074|NCT01963117|Experimental|Combined hypertermia and RT|Combined hypertermia and radiothearpy
16698075|NCT01963104|Experimental|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
16698076|NCT01963104|Experimental|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
16698077|NCT01963104|Experimental|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
16698078|NCT01963104|Experimental|No screening test|This group of subjects will not receive a screening test.
16698079|NCT01963104|Experimental|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
16698080|NCT01963104|Experimental|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
16698081|NCT01963104|Experimental|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
16698082|NCT01963104|Experimental|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
16698083|NCT01963104|Experimental|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
16698084|NCT01963104|Experimental|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
16698085|NCT01963091|Experimental|oxytocin|
16698086|NCT01963091|Placebo Comparator|placebo|
16698087|NCT01963078|Placebo Comparator|PTSD placebo Day 1, Oxytocin Day 2|Participants PTSD will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
16698088|NCT01963078|Experimental|PTSD Oxytocin Day 1, Placebo Day 2|Participants with PTSD will self-administer 24 IUs of OT nasal spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
16698089|NCT01963078|Placebo Comparator|Resilient Placebo Day 1, Oxytocin Day 2|Resilient controls will self-administer matching placebo spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
16698090|NCT01963078|Experimental|Resilient Oxytocin Day 1, Placebo Day 2|Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
16698091|NCT01963065||Moderately pre-term infants and their mothers|cohort of moderately pre-term infants and their mothers
16698092|NCT01963052|Experimental|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Additional subjects may be enrolled for expansion of these dose levels to further evaluate the safety and efficacy, as recommended by a data review team (DRT).
16698093|NCT01963052|Experimental|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
16698094|NCT01963052|Experimental|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
16698095|NCT01963052|Experimental|Part A: AGS15E Dose Expansion|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
16698096|NCT01963039|Active Comparator|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
16698097|NCT01963039|Sham Comparator|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
16698098|NCT01963026|Experimental|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
16698099|NCT01963013|Experimental|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
16698100|NCT01963013|Active Comparator|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
16698101|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
16698102|NCT01962987|Experimental|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
16698103|NCT01962987|Active Comparator|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
16698104|NCT01962987|Placebo Comparator|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
16698105|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
16698106|NCT01962961|Experimental|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
16698107|NCT01962961|Experimental|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
16698108|NCT01962961|Placebo Comparator|Placebo|Matching placebo pills given twice daily for 8 weeks
16698109|NCT01962948|Experimental|Treatment (paclitaxel, ganetespib)|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16698110|NCT01962935|Experimental|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
16698111|NCT01962935|Placebo Comparator|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
16698112|NCT01962935|Active Comparator|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
16698113|NCT01962922|Active Comparator|LCP-Tacro|Envarsus XR
16698114|NCT01962922|Active Comparator|Tacrolimus - IR|Tacrolimus
16698115|NCT01962909|Experimental|PTP-01|single IV bolus dose 24 hours prior to surgery
16698116|NCT01962896|Experimental|Erlotinib + sirolimus|
16698117|NCT01962883|No Intervention|Control group|Osteopathic evaluation Cognitive and Physical Rest
16698118|NCT01962883|Experimental|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
16698119|NCT01962870|Placebo Comparator|Placebo|Placebo Nasal Spray
16698120|NCT01962870|Active Comparator|Vasopressin|Vasopressin Nasal Spray
16698121|NCT01962857|Experimental|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
16698122|NCT01962857|No Intervention|Control|No intervention - participants maintain usual lifestyle
16698123|NCT01962844|Other|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
16698124|NCT01962844|Experimental|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
16698125|NCT01962831|Experimental|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
16698126|NCT01962831|Experimental|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
16698127|NCT01962818|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
16698128|NCT01962818|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
16698129|NCT01962805|Experimental|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
16698130|NCT01962805|Experimental|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
16723527|NCT01791725|Experimental|ELND005 QD|ELND005 250 mg QD
16698134|NCT01962779|Experimental|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
16698135|NCT01962779|No Intervention|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
16698136|NCT01962766|Active Comparator|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
16698137|NCT01962766|Experimental|instructions|instructions to modify their tongue position (1 session)
16698138|NCT01962753|Experimental|18FAV45|
16698139|NCT01962740|Active Comparator|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
16698140|NCT01962740|Active Comparator|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
16698141|NCT01962740|Active Comparator|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
16698142|NCT01962714|Experimental|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
16698143|NCT01962714|Active Comparator|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
16698144|NCT01962701||OCT-group|OCT prior to C-section
16698145|NCT01962701||None-OCT-group|No OCT prior to C-section
16698146|NCT01962688|Experimental|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
16698147|NCT01962688|Sham Comparator|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
16698148|NCT01962688|Experimental|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
16698149|NCT01962688|Sham Comparator|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
16698150|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
16698151|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
16698152|NCT01962662|Experimental|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
16698153|NCT01962662|Experimental|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
16698154|NCT01962662|Other|control group|U/E exercise
16698155|NCT01962649|Experimental|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
16698157|NCT01962623|Active Comparator|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
16698158|NCT01962623|Other|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
16698159|NCT01962610|Experimental|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
16698160|NCT01962610|No Intervention|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
16698161|NCT01962597|Active Comparator|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
16698162|NCT01962597|Active Comparator|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
16698163|NCT01962597|Experimental|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
16698164|NCT01962584||SAM|patients with suspected acute myocarditis
16698165|NCT01962584||HC|Healthy controls
16698166|NCT01962571|Experimental|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
16698167|NCT01962571|Placebo Comparator|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
16698168|NCT01962558|Experimental|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
16698228|NCT01962181|Placebo Comparator|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
16698169|NCT01962558|Sham Comparator|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
16698170|NCT01962545|Experimental|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
16698171|NCT01962545|No Intervention|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
16698172|NCT01962532|Experimental|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which <33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
16698173|NCT01962532|Experimental|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
16698174|NCT01962532|Experimental|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
16698175|NCT01962519|Experimental|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
16698176|NCT01962519|No Intervention|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
16698177|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
16698178|NCT01962493|Active Comparator|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
16698179|NCT01962493|Other|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
16698180|NCT01962480|Active Comparator|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
16698181|NCT01962480|No Intervention|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
16698182|NCT01962467|Experimental|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
16698183|NCT01962454|Experimental|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
16698184|NCT01962454|Placebo Comparator|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
16698185|NCT01962441|Experimental|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
16698186|NCT01962441|Experimental|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
16698187|NCT01962441|Experimental|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
16698188|NCT01962441|Experimental|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
16698189|NCT01962428|Experimental|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
16698190|NCT01962428|Active Comparator|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
16698191|NCT01962415|Experimental|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
16698192|NCT01962415|Experimental|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
16698193|NCT01962402|Experimental|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
16698194|NCT01962389|Experimental|Winsor Laser Catheter|
16698226|NCT01962194|Experimental|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
16698227|NCT01962181|Active Comparator|Ritalin|Ritalin treatment at different doses
16698195|NCT01962376|Active Comparator|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
~placebo:Physiological saline"
16698196|NCT01962376|Experimental|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
16698197|NCT01962363|Experimental|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
16698198|NCT01962350|Experimental|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation
~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
16698199|NCT01962350|Experimental|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation
~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
16698200|NCT01962337|Experimental|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
16698201|NCT01962337|Experimental|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
16698202|NCT01962337|Experimental|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
16698203|NCT01962324|Experimental|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
16698204|NCT01962311|Experimental|All patients|lumbar puncture
16698205|NCT01962298|Placebo Comparator|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
16698206|NCT01962298|Active Comparator|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
16698207|NCT01962298|Active Comparator|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
16698208|NCT01962298|Active Comparator|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
16698209|NCT01962298|Active Comparator|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
16698210|NCT01962285|Experimental|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.
~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.
~32 channel-EEg and BIS continuous monitoring"
16698211|NCT01962272|Experimental|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
16698212|NCT01962272|Active Comparator|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.
~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
16698213|NCT01962259|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
16698214|NCT01962259|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
16698215|NCT01962259|Experimental|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
16698216|NCT01962259|No Intervention|Control|Receives no intervention.
16698217|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
16698218|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
16698219|NCT01962233|Experimental|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
16698220|NCT01962220|No Intervention|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.
~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
16698221|NCT01962220|Experimental|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
16698222|NCT01962207|Experimental|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
16698223|NCT01962207|Experimental|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
16698224|NCT01962207|Experimental|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
16698225|NCT01962207|Experimental|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
16698229|NCT01962168||Evolution® Biliary Stent - Uncovered|
16698230|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
16698231|NCT01962142||Exacerbated asthma patients|
16698232|NCT01962129||Patients affected by a syndrome OFD|
16698233|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
16698234|NCT01962116|Placebo Comparator|Heparin lock|
16698235|NCT01962116|Experimental|Citrate lock|
16698236|NCT01962103|Experimental|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
16698237|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 120 mg/m^2|nab-paclitaxel 120 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
16698238|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 150 mg/m^2|nab-paclitaxel 150 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
16698239|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 180 mg/m^2|nab-paclitaxel 180 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
16698240|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 210 mg/m^2|nab-paclitaxel 210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
16698241|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 240 mg/m^2|nab-paclitaxel 240 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
16698242|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 270 mg/m^2|nab-paclitaxel 270 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
16698243|NCT01962103|Experimental|Phase 2: Ewing's Sarcoma|Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
16698244|NCT01962103|Experimental|Phase 2: Neuroblastoma|Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
16698245|NCT01962103|Experimental|Phase 2: Rhabdomyosarcoma|Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
16698246|NCT01962090|Experimental|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
16698247|NCT01962090|Experimental|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
16698248|NCT01962077|Experimental|MedCem MTA pulpotomies|
16698249|NCT01962064|Experimental|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
16698250|NCT01962064|Experimental|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
16698251|NCT01962064|Experimental|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
16698252|NCT01962064|Experimental|Young|cognitive assessment and Brain imaging examination MRI of young subjects
16698253|NCT01962051||Delivery system Entry|
16698254|NCT01962038|Active Comparator|Combined Aerobic and Resistance Exercise/Cognitive Training|
16698255|NCT01962038|Active Comparator|Stretching Exercises/Cognitive Training|
16698256|NCT01962025|Active Comparator|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
16698257|NCT01962025|No Intervention|Step Ladder Group|Patients will use step ladder needling technique
16698258|NCT01962012|Experimental|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
16698259|NCT01962012|Sham Comparator|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
16698260|NCT01961999|Active Comparator|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
16698261|NCT01961999|Active Comparator|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:
~persistent and refractory oliguria (<0,5 ml/Kg/h >12h), despite therapy
~refractory extravascular fluid overload
~azotemia > 40mmol/L or 240 mg/dL
~metabolic acidosis (pH<7,2)
~hyperkaliemia (k+>6 mmol/L)"
16698262|NCT01961986|Active Comparator|TSR: traditional subscap release|"TSR - traditional subscapularis release approach
~Subscapularis tendon release technique TSR"
16698263|NCT01961986|Experimental|TSR: rotator cuff sparing|Rotator cuff sparing technique TSR
16698264|NCT01961973|Active Comparator|Cultured chondrocytes|"Cultured chondrocytes:
~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
16698265|NCT01961973|Active Comparator|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
16698266|NCT01961960|Experimental|ASP7374 group|
16698267|NCT01961947|Experimental|ASP7374 group|
16698268|NCT01961947|Active Comparator|TIV group|
16698271|NCT01961908|Experimental|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
16698272|NCT01961895|Active Comparator|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
16698273|NCT01961895|Experimental|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.
~Rescue bolus 5 ml and 30 minutes lockout"
16698274|NCT01961882|Experimental|OCV-501 arm|
16698275|NCT01961882|Placebo Comparator|Placebo arm|
16698276|NCT01961869|Experimental|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
16698277|NCT01961869|Experimental|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
16698278|NCT01961869|Experimental|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
16698279|NCT01961869|Experimental|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
16698280|NCT01961869|Experimental|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
16698281|NCT01961869|Experimental|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
16698282|NCT01961856|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose
16698283|NCT01961856|Experimental|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
16698284|NCT01961843|Experimental|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
16698285|NCT01961830|Experimental|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
16698286|NCT01961817|Other|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.
~The second visualization then will be performed with the conventional method."
16698287|NCT01961817|Other|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.
~The second visualization then will be performed with the retromolar method."
16698288|NCT01961804|Other|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
16698289|NCT01961804|Experimental|Preventive reversion|Realise a preventive reversion before performing any CT scan.
16698290|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
16698291|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
16698292|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
16698293|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
16698294|NCT01961765|Experimental|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
16698295|NCT01961752|Placebo Comparator|Control group|
16698296|NCT01961752|Experimental|Bupivacaine only group|
16698297|NCT01961752|Active Comparator|Bupivacaine with triamcinolone group|
16698298|NCT01961739|Experimental|2% lidocaine|topical application, two times per day for 15 consecutive days
16698299|NCT01961739|Placebo Comparator|placebo|vaseline base applied topically, two times per day for 15 consecutive days
16698300|NCT01961726|Placebo Comparator|Placebo|
16698301|NCT01961726|Experimental|30 mg dose of JVS-100|
16698302|NCT01961726|Experimental|45 mg dose of JVS-100|
16698303|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
16698304|NCT01961700|Experimental|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
16698305|NCT01961700|No Intervention|Control group|No physiotherapy.
16698306|NCT01961687|Other|Resorbable Mesh|Phasix Mesh
16698307|NCT01961674|Experimental|Capsinoid arm|On capsinoids
16698308|NCT01961674|Placebo Comparator|Placebo arm|Placebo
16698309|NCT01961661|Experimental|probiotic|Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day
16698310|NCT01961661|Placebo Comparator|placebo|maltodextrins
16698311|NCT01961648|Active Comparator|Dead space|Participant will sleep connected to a mask with added dead space half of the night
16698312|NCT01961648|Sham Comparator|room air|Participant will sleep connected to a mask open to rrom air, half of the night
16698313|NCT01961635|Experimental|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
16698314|NCT01961635|Experimental|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
16698315|NCT01961635|Experimental|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
16698316|NCT01961622|Experimental|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
16698317|NCT01961622|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
16698388|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
16698389|NCT01961050|Experimental|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
16698318|NCT01961609|Experimental|Secukinumab (AIN457) 300 mg|Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.
16698319|NCT01961609|Experimental|Secukinumab (AIN457) 150 mg|Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg.
16698320|NCT01961596|Experimental|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
~After 2 days the measurements will be repeated with the other application."
16698321|NCT01961596|Placebo Comparator|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
~After 2 days the measurements will be repeated with the other application."
16698322|NCT01961583|Experimental|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
16698323|NCT01961557|Experimental|Feasibility Arm|All participants will be evaluated using the different configurations of the EA-KAFO (see Table 1 in the protocol), which includes the configuration that contains the Active Motorized KAFO and the configuration that contains the Powerwalk Knee Exoskeleton. Each subject will serve as their own control to assess the effect of each configuration of the EA-KAFO interventions.
16698324|NCT01961544|Experimental|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
16698325|NCT01961531|Experimental|Accuboost APBI|28Gy delivered in 5 daily fractions
16698326|NCT01961505|Experimental|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
16698327|NCT01961505|Placebo Comparator|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
16698328|NCT01961492|Active Comparator|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
16698329|NCT01961492|No Intervention|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
16698330|NCT01961479|Experimental|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
16698331|NCT01961479|Other|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
16698332|NCT01961466||Diabetic patients|
16698333|NCT01961453|Active Comparator|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
16698334|NCT01961453|Placebo Comparator|Placebo capsule|One capsule of placebo administered once daily at 8 AM
16698335|NCT01961427|Active Comparator|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
16698336|NCT01961427|Active Comparator|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
16698337|NCT01961427|Active Comparator|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
16698338|NCT01961427|Active Comparator|sodium nitrate (0mmol)|Ingestion of water as a placebo
16698339|NCT01961427|Active Comparator|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
16698340|NCT01961427|Active Comparator|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
16698341|NCT01961427|Active Comparator|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
16698342|NCT01961414|Experimental|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
16698343|NCT01961401|Experimental|High intensity exercise|High intensity, short duration exercise on bike
16698344|NCT01961401|Experimental|Moderate exercise|Moderate intensity exercise training on bike
16698345|NCT01961401|No Intervention|No exercise|No exercise, resting in the lab
16698346|NCT01961388||Group 1|Acarbose_BAY G5421
16698347|NCT01961388||Group 2|Metformin
16698349|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
16698350|NCT01961349|Placebo Comparator|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
16698351|NCT01961349|Active Comparator|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
16698352|NCT01961349|Active Comparator|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
16698390|NCT01961050|Other|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
16698391|NCT01961037|Experimental|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
16698353|NCT01961336|Experimental|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
16698354|NCT01961336|No Intervention|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
16698355|NCT01961323|Experimental|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
16698356|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.
~Intervention: Plasma analysis for bacterial translocation
~Intervention: Stool analysis"
16698357|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.
~Intervention: Plasma analysis for bacterial translocation
~Intervention: Stool analysis"
16698358|NCT01961297|Experimental|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
16698359|NCT01961284|Active Comparator|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
16698360|NCT01961284|Active Comparator|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
16698361|NCT01961271|Experimental|Buprenorphine transdermal patch|Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
16698362|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
16698363|NCT01961245|Active Comparator|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
16698364|NCT01961245|No Intervention|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
16698365|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
16698366|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
16698367|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
16698368|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
16698369|NCT01961219|Active Comparator|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
16698370|NCT01961219|Active Comparator|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
16698371|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
16698372|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
16698373|NCT01961193|Experimental|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
16698374|NCT01961193|Experimental|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
16698375|NCT01961193|No Intervention|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
16698376|NCT01961180|Active Comparator|active comparator|Drug: Cipralex
16698377|NCT01961180|Placebo Comparator|placebo comparator|Drug: Placebo
16698378|NCT01961167|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
16698379|NCT01961154|Other|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
16698380|NCT01961128|Experimental|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
16698381|NCT01961115|Experimental|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
16698382|NCT01961089|Experimental|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
16698383|NCT01961089|Active Comparator|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
16698384|NCT01961089|Experimental|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
16698385|NCT01961076|Experimental|uncooked corn starch|Patients receive uncooked corn starch before bed-time
16698386|NCT01961076|Experimental|modified corn starch|Patients receive modified corn starch before bed-time
16698387|NCT01961076|Experimental|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
16698392|NCT01961024||Type 2 diabetic men|
16698393|NCT01961024||Age- and weight-matched controls|
16698394|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
16698395|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
16698396|NCT01960998|Experimental|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
16698397|NCT01960998|Active Comparator|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
16698398|NCT01960985|Experimental|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
16698399|NCT01960985|Experimental|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
16698400|NCT01960972|Experimental|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.
~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
16698401|NCT01960946|Active Comparator|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
16698402|NCT01960946|Placebo Comparator|Placebo|Matched placebo 5 grams by mouth three times a day
16698403|NCT01960933|Active Comparator|Culprit lesion revascularization|Only the culprit lesion is treated whereas other study lesions are left un-treated.
16698404|NCT01960933|Active Comparator|Full revascularization|Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically >50% and FFR <0.80 are treated in a separate procedure within the index hospitalization. Stenoses > 90% are treated without prior FFR.
16698405|NCT01960920|Active Comparator|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
16698406|NCT01960920|Experimental|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
16698407|NCT01960907|No Intervention|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
~They will follow their usual care path as provided by their local NHS"
16698408|NCT01960907|Experimental|Interventional|"Patients will receive a system form monitoring their health status.
~The system is composed by:
~a touch-screen pc for the administration of daily questionnaires
~RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern
~a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.
~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
16698409|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
16698410|NCT01960868|Experimental|patients|
16698411|NCT01960868|Other|control group|
16698412|NCT01960855|Placebo Comparator|Placebo BID|Placebo twice daily (BID) for 12 weeks.
16698413|NCT01960855|Experimental|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
16698414|NCT01960855|Experimental|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
16698415|NCT01960855|Experimental|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
16698416|NCT01960855|Experimental|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
16698417|NCT01960842|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.
~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
16698418|NCT01960829|Experimental|Everolimus|
16698419|NCT01960816|Experimental|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
16698464|NCT01960582|Experimental|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
16698465|NCT01960582|No Intervention|Ordinary practice|Ordinary practice, not structured
16698466|NCT01960569|Active Comparator|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
16698420|NCT01960803|Experimental|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
16698421|NCT01960790||Participants who received Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
16698422|NCT01960777|Experimental|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
16698423|NCT01960777|Active Comparator|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
16698424|NCT01960764|Experimental|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
16698425|NCT01960764|Placebo Comparator|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
16698426|NCT01960751|Other|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
16698427|NCT01960738|Experimental|Intervention|The intervention group received a pre-dive checklist and a post-dive log
16698428|NCT01960738|No Intervention|Control|The control group received the post-dive log only.
16698429|NCT01960725|Active Comparator|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
16698430|NCT01960725|Experimental|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
16698431|NCT01960712|No Intervention|Continued external drainage|Continued external drainage alone.
16698432|NCT01960712|Active Comparator|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
16698433|NCT01960699||CPC < 3|Good neurological outcome
16698434|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
16698435|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
16698436|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
16698437|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
16698438|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
16698439|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
16698440|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
16698441|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
16698442|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
16698443|NCT01960673|Experimental|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.
~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
16698444|NCT01960673|Experimental|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.
~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
16698445|NCT01960673|Experimental|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.
~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.
~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
16698446|NCT01960673|Experimental|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
16698447|NCT01960660|Experimental|Investigational Product|Omega-3 fatty acids in the form of triglycerides
16698448|NCT01960660|Active Comparator|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
16698449|NCT01960660|Active Comparator|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
16698450|NCT01960660|Active Comparator|Comparator Product 3|Omega-3 fatty acids from salmon oil.
16698451|NCT01960647|Other|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
16698452|NCT01960647|Active Comparator|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
16698453|NCT01960621|Experimental|2|
16698454|NCT01960608||low sodium group|24_hours_urine_sodium < 100 mEq/L
16698455|NCT01960608||mid sodium group|24_hours_urine_sodium >= 100 mEq/L and < 200 mEq/L
16698456|NCT01960608||high sodium group|24_hours_urine_sodium >= 200 mEq/L
16698457|NCT01960608||low income group|the income 25% below the quartile
16698458|NCT01960608||low mid income group|the income 25% - 50% below the quartile
16698459|NCT01960608||mid income group|the income 50% - 75% below the quartile
16698460|NCT01960608||high income group|the income 75% over the quartile
16698461|NCT01960595|Experimental|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
16698462|NCT01960595|Active Comparator|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
16698463|NCT01960595|Active Comparator|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
16699085|NCT01956305|Experimental|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
16698467|NCT01960569|Placebo Comparator|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
16698468|NCT01960556||Simulation|Simulation Training part of education
16698469|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
16698470|NCT01960543|Active Comparator|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%
~Doses:
~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
16698471|NCT01960543|Active Comparator|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:
~Doses:
~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
16698472|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
16698473|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
16698474|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
16698475|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
16698476|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
16698477|NCT01960517|Experimental|Catheter placed|
16698478|NCT01960504|Experimental|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
16698479|NCT01960491|Experimental|Device Closure of Atrial Septal Defect|
16698480|NCT01960478|Other|bood test|
16698481|NCT01960465|Experimental|African Americans|138 Self identified African American
16698482|NCT01960465|Active Comparator|non African Americans|53 Caucasians and 29 Other race (non African-Americans) Veterans.
16698483|NCT01960452||Primary insomnia|
16698484|NCT01960452||Healthy sleeping controls|
16698485|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
16698486|NCT01960426|Active Comparator|Empiric Dose Intensification|Intensify treatment with the existing drug
16698487|NCT01960426|Active Comparator|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
16698488|NCT01960413|Experimental|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
16698489|NCT01960413|Placebo Comparator|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
16698490|NCT01960400|Active Comparator|GMI + tDCS|Graded motor imagery (GMI) + tDCS
16698491|NCT01960400|Placebo Comparator|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
16698492|NCT01960387|Experimental|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
16698493|NCT01960374|Experimental|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
16698494|NCT01960374|Experimental|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
16698495|NCT01960361|Experimental|ICE dental implant|Subjects implanted with ICE implant
16698496|NCT01960348|Active Comparator|patisiran (ALN-TTR02)|
16698497|NCT01960348|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
16698498|NCT01960335|Active Comparator|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
16698499|NCT01960335|Experimental|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
16698500|NCT01960335|Experimental|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
16698501|NCT01960322|Experimental|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
16698502|NCT01960309|Experimental|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
16698503|NCT01960309|Experimental|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
16698504|NCT01960309|Experimental|3. TnI elevation|TnI>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
16698505|NCT01960309|Experimental|4. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb<5.1. Intervention: minimal invasive cardiac imaging
16698506|NCT01960309|Experimental|5. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb>5.0. Intervention: minimal invasive cardiac imaging
16698507|NCT01960309|Active Comparator|Control|TnI <0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
16698508|NCT01960296|Experimental|Clopidogrel|Continue home dose of clopidogrel into surgery
16698509|NCT01960296|Active Comparator|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
16698510|NCT01960283|Active Comparator|Group I|"The group I will receive the intervention :
~Methotrexate + anti-H1"
16698511|NCT01960283|Placebo Comparator|Group II|The intervention in group II will include : placebo + anti-H1
16698512|NCT01960270|Experimental|Alone controlateral stimulation|"Device: INTERSTIM II
~Stimulator II activated
~Stimulator I not activated
~Measure of efficacy on bladder hyperactivity"
16698513|NCT01960270|Experimental|2 sides-stimulation|"Device: INTERSTIM II
~Stimulator I and II activated
~Measure of efficacy on bladder hyperactivity"
16698514|NCT01960257|Experimental|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
16698515|NCT01960257|Active Comparator|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
16698516|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
16698517|NCT01960231||pancreas specific MODY-2|
16698518|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
16698519|NCT01960205|Experimental|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
16698520|NCT01960205|Active Comparator|Lifestyle intervention|Lifestyle intervention for 6 months
16698521|NCT01960205|Active Comparator|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
16698522|NCT01960205|Experimental|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
16698523|NCT01960192|Experimental|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
16698524|NCT01960192|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
16698525|NCT01960179|Experimental|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
16698526|NCT01960166|Experimental|Active distraction|Child will use Ipad as active distraction
16698527|NCT01960166|Experimental|Passive Distraction|Child will watch movie as passive distraction (control)
16698528|NCT01960153|Experimental|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
16698529|NCT01960153|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
16698530|NCT01960140|Experimental|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
16698531|NCT01960140|Experimental|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
16698532|NCT01960127|Experimental|Aerobic Exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
16698533|NCT01960127|Placebo Comparator|Usual Care Group|These patients will continue with their normal daily activity ad will not be provided with supervised aerobic exercise training during the study period.
16698534|NCT01960114|Experimental|Acetaminophen ER|
16698535|NCT01960114|Placebo Comparator|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
16698536|NCT01960101|Experimental|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
16698537|NCT01960101|Other|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
16698538|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
16698539|NCT01960075|Active Comparator|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
16698540|NCT01960075|Active Comparator|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
16698541|NCT01960075|Active Comparator|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
16698542|NCT01960062|No Intervention|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
16723528|NCT01791725|Placebo Comparator|Placebo|Placebo BID
16698543|NCT01960062|Experimental|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
16698544|NCT01960049|Placebo Comparator|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
16698545|NCT01960049|Active Comparator|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
16698546|NCT01960036|No Intervention|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
16698547|NCT01960036|Experimental|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
16698548|NCT01960036|Active Comparator|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
16698550|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
16698551|NCT01960010|Placebo Comparator|Vehicle|Vehicle
16698552|NCT01959997|Active Comparator|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
16698553|NCT01959997|Active Comparator|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.
~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
16698554|NCT01959984|Experimental|100g Standard Noodles|100g Standard Noodles
16698555|NCT01959984|Experimental|75g Oral Glucose|75g Oral Glucose
16698556|NCT01959971|Experimental|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
16698557|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
16698558|NCT01959945|Experimental|Study Group 1, Flublok|Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
16698559|NCT01959945|Active Comparator|Study Group 2, Fluarix|Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
16698560|NCT01959945|Experimental|Study Group 3, Flublok|Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
16698561|NCT01959945|Active Comparator|Study Group 4, Fluarix|Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
16698562|NCT01959932|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
16698563|NCT01959932|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
16698564|NCT01959932|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
16698565|NCT01959919||Arm 1: Device|
16698566|NCT01959906||R0|Complete resection
16698567|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
16698568|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
16698569|NCT01959880|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
16698570|NCT01959880|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.
~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
16698571|NCT01959880|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
16698572|NCT01959880|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
16698573|NCT01959867|Experimental|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
16698574|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
16698575|NCT01959854|Active Comparator|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
16698576|NCT01959854|Experimental|xanthan gum|1 drop in each eye four times a day for 30 days
16698577|NCT01959841|Experimental|ASP2151(200 mg)|once daily
16698578|NCT01959841|Experimental|ASP2151(400mg)|once daily
16698579|NCT01959841|Experimental|valaciclovir|1000 mg three times daily
16698624|NCT01959529|Active Comparator|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
16699086|NCT01956305|Experimental|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
16698580|NCT01959828|Experimental|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).
~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).
~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
16698581|NCT01959815||Scleroderma and diagnosed PAH|
16698582|NCT01959815||"Low risk scleroderma"|
16698583|NCT01959815||Healthy volunteers|
16698584|NCT01959815||"High risk scleroderma"|
16698585|NCT01959802|Other|Vitrectomy|Vitrectomy for macular pseudo hole
16698586|NCT01959789||Control|Standard treatment
16698587|NCT01959789||2 days|bleaching treatments made in 2 days
16698588|NCT01959776|Other|Vitrectomy|
16698589|NCT01959763|Experimental|weight loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits
16698590|NCT01959763|Experimental|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method
16698591|NCT01959763|Experimental|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
16698592|NCT01959750|Experimental|Intervention Group|
16698593|NCT01959750|No Intervention|Control Group|
16698594|NCT01959737|No Intervention|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
16698595|NCT01959737|Experimental|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
16698596|NCT01959724|Other|Vitrectomy|Vitreous surgery to treat macular detachment
16698597|NCT01959711|Experimental|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
16698598|NCT01959711|Active Comparator|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
16698599|NCT01959698|Experimental|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
16698600|NCT01959685|Experimental|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
16698601|NCT01959672|Experimental|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.
~IMMUNOTHERAPY: Patients with CA125 level >= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.
~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
16698602|NCT01959659||Cohort|
16698603|NCT01959646|Placebo Comparator|Placebo|Placebo Group
16698604|NCT01959646|Experimental|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
16698605|NCT01959633|Experimental|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
16698606|NCT01959620|No Intervention|Assessment only|Participants will receive assessment only.
16698607|NCT01959620|Experimental|1-session exposure intervention|Participants will receive one session of exposure therapy.
16698608|NCT01959620|Experimental|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
16698609|NCT01959607|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of CC)."
16698610|NCT01959607|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of CC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
16698611|NCT01959607|Active Comparator|THS 2.2 then NRT|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NRT gum [Nicorette® 2mg])."
16698612|NCT01959607|Active Comparator|NRT then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NRT gum [Nicorette® 2mg])
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
16698613|NCT01959594|Experimental|Cohort 1|
16698614|NCT01959594|Experimental|Cohort 2|
16698615|NCT01959594|Experimental|Cohort 3|
16698616|NCT01959594|Experimental|Optional Cohort 4|
16698617|NCT01959594|Experimental|Optional Cohort 5|
16698618|NCT01959581|Other|Movement enhancing device|Guided play while wearing a movement assisting device
16698619|NCT01959568|Experimental|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
16698620|NCT01959568|Active Comparator|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
16698621|NCT01959555||Retrospective collection of data|
16698622|NCT01959542|Experimental|MRIs and PSA Blood Test|"Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI
~Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI
~Visit 3 (on last day of EBRT): PSA blood test
~Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
16698623|NCT01959529|Experimental|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
16698625|NCT01959516|Experimental|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
16698626|NCT01959516|Experimental|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
16698627|NCT01959503|Experimental|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
16698628|NCT01959503|Active Comparator|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
16698629|NCT01959490|Experimental|Cohort 1P (HER2 positive)|Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
16698630|NCT01959490|Experimental|Cohort 1T (HER2 positive)|Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
16698631|NCT01959490|Experimental|Cohort II (HER2 negative)|Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
16698632|NCT01959477|Experimental|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
16698633|NCT01959464|Experimental|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.
~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
16698634|NCT01959464|Placebo Comparator|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
16698635|NCT01959451|Active Comparator|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
16698636|NCT01959451|Experimental|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
16698637|NCT01959438|Experimental|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
16698638|NCT01959425|Experimental|Off OAT Group (Test)|Discontinuation of OAT Therapy
16698639|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
16698640|NCT01959412|Experimental|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
16698641|NCT01959412|Experimental|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
16698642|NCT01959412|Experimental|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
16698643|NCT01959412|Experimental|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
16698644|NCT01959412|Experimental|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
16698645|NCT01959412|Experimental|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
16698646|NCT01959399|Experimental|ASP015K + rosuvastatin|
16698647|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
16698648|NCT01959373|Experimental|patients|
16698649|NCT01959373|Experimental|healthy volunteers|
16698650|NCT01959360|Active Comparator|direct lateral|
16698651|NCT01959360|Experimental|minimal invasive|
16698652|NCT01959360|Experimental|modified minimal invasive|
16698653|NCT01959347|Sham Comparator|Miduretheral Sling (Control)|Miduretheral Sling (Control)
16698654|NCT01959347|Experimental|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
16698655|NCT01959334|Active Comparator|Glucagon IM|Glucagon dose of 1 milligram (mg) administered intramuscularly (IM).
16698656|NCT01959334|Experimental|Nasal Glucagon (NG|Nasal Glucagon (NG) doses of 3 mg administered intra-nasally.
16698657|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
16698658|NCT01959295|Experimental|ASP2151|
16698659|NCT01959295|Placebo Comparator|ASP2151 placebo|
16698660|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
16698661|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
16698662|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
16698663|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
16698664|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
16698665|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
16698666|NCT01959256|Experimental|Learning|Visual perceptual learning (VPL) group
16698667|NCT01959256|No Intervention|Control|Control group
16698668|NCT01959243|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
16698669|NCT01959243|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
16698670|NCT01959230|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
16698671|NCT01959230|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
16698672|NCT01959217|Experimental|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
16698673|NCT01959204|Other|Active|Open label pharmacokinetic study of oxycodone.
16698674|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
16698675|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
16698676|NCT01959178|Experimental|LD127025 MF|Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
16698677|NCT01959178|Active Comparator|Air Optix Aqua MF|Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
16698678|NCT01959165|Experimental|MEDI7183 dose 1|Double blinded
16698679|NCT01959165|Experimental|MEDI7183 dose 2|Double blinded
16698680|NCT01959165|Experimental|MEDI7183 dose 3|Double blinded
16698681|NCT01959165|Placebo Comparator|Placebo|Double blinded
16698682|NCT01959152|Experimental|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
16698683|NCT01959139|Active Comparator|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16698684|NCT01959139|Experimental|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
16698685|NCT01959139|Experimental|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours
16698686|NCT01959126|Experimental|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
16698687|NCT01959113|Experimental|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
16698688|NCT01959113|Placebo Comparator|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
16698689|NCT01959100|Experimental|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
16698690|NCT01959100|Placebo Comparator|Placebo|250 mg x 3/week during a meal for a period of 2 years.
16698691|NCT01959087|Experimental|1: Single port surgery|Surgery with single port
16698692|NCT01959087|Active Comparator|2: Multiport surgery|Surgery with multiport
16698693|NCT01959074|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
16698694|NCT01959074|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics
16698695|NCT01959061|Experimental|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
16698696|NCT01959048|Experimental|fecal microbiota transplant|fecal microbiota transplantation
16698697|NCT01959035|Experimental|Aripiprazole once-monthly|
16698698|NCT01959022|Experimental|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
16698699|NCT01959009|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min
~Ti = 1s
~Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
16698700|NCT01959009|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min
~Ti = 1s
~Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
16698701|NCT01958996|Experimental|idarubicin|
16698702|NCT01958983|Experimental|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
16698703|NCT01958983|No Intervention|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
16698704|NCT01958970|Experimental|PINTA 745|
16698705|NCT01958970|Placebo Comparator|Placebo|
16698706|NCT01958957|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
16699087|NCT01956305|Experimental|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
16698707|NCT01958944|Experimental|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday & Saturday) in which no treatment under this study will be provided.
16698708|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
16698709|NCT01958918|Experimental|Ranibizumab|1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
16698710|NCT01958918|Active Comparator|Aflibercept|1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
16698711|NCT01958905|Experimental|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
16698712|NCT01958892||TURP|
16698713|NCT01958892||TUERP|
16698714|NCT01958879|Experimental|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
16698715|NCT01958879|Placebo Comparator|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
16698716|NCT01958866|Active Comparator|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
16698717|NCT01958866|Experimental|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
16698718|NCT01958866|Placebo Comparator|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
16698719|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
16698720|NCT01958840|Experimental|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
16698721|NCT01958840|Active Comparator|Supportive Counseling|Supportive Counseling Condition - 10 sessions
16698722|NCT01958827|Experimental|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
16698723|NCT01958814|Experimental|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
16698724|NCT01958814|Experimental|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
16698725|NCT01958801|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
16698726|NCT01958801|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
16698727|NCT01958788|Experimental|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
16698728|NCT01958775|Experimental|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
16698729|NCT01958775|Placebo Comparator|Placebo|placebo
16698730|NCT01958762|Other|Screening for cancers in the oral cavity|
16698731|NCT01958749|No Intervention|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.
~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
16698732|NCT01958749|Experimental|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -
~10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation
~Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)
~Supernatant removed and collected into syringe
~Injected onto surface of fat graft
~Rest added to piece of gelfoam
~Place gelfoam + PRP on the TM perforation"
16698733|NCT01958736|Experimental|Experimental|Ballistic Strength Training
16698734|NCT01958736|Active Comparator|Control|Usual care Physiotherapy
16698735|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
16698736|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
16698737|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
16698738|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
16698739|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
16724325|NCT01786031|Experimental|experimental|metastasis biopsy
16698740|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
16698741|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
16698742|NCT01958671|Experimental|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
16698743|NCT01958671|Experimental|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
16698744|NCT01958671|Other|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
16698745|NCT01958645|Experimental|A|MEDI8111
16698746|NCT01958645|Placebo Comparator|B|Placebo for MEDI8111
16698747|NCT01958632||N|nerve suture
16698748|NCT01958632||NT|nerve transplantation
16698749|NCT01958632||VM|vein-in-muscle conduit
16698750|NCT01958619|Experimental|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
16698751|NCT01958619|Experimental|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
16698752|NCT01958619|Experimental|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
16698753|NCT01958619|Experimental|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
16698754|NCT01958606|Experimental|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
16698755|NCT01958606|Active Comparator|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
16698756|NCT01958593|Placebo Comparator|Comparator|Participants will receive placebo during each of two experimental sessions.
16698757|NCT01958593|Experimental|3,4-methylenedioxymethamphetamine|Participants will receive full-dose MDMA during each of two experimental sessions.
16698758|NCT01958580|Experimental|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
16698759|NCT01958567|Experimental|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
16698760|NCT01958567|Experimental|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
16698761|NCT01958554|Experimental|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
16698762|NCT01958554|No Intervention|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
16698763|NCT01958541|Experimental|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
16698764|NCT01958541|Active Comparator|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
16698765|NCT01958528||Cohort 1 Progressors|
16698766|NCT01958528||Cohort 2 - Non-Progressors|
16698767|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
16698768|NCT01958502|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
16698769|NCT01958489|Experimental|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
16698770|NCT01958489|Experimental|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.
16698771|NCT01958476|Active Comparator|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
16699132|NCT01955980|Active Comparator|Budes; Treatment B|Budes Nasal Spray 50 µg budesonide/pump
16698772|NCT01958476|Active Comparator|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
16698773|NCT01958463|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
16698774|NCT01958450|Experimental|Er:YAG laser|acne scar treatment using Er:YAG laser
16698775|NCT01958450|Active Comparator|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
16698776|NCT01958437|Experimental|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
16698777|NCT01958437|Active Comparator|MCI ACTIVE tDCS|Group receives active brain stimulation
16698778|NCT01958437|Sham Comparator|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
16698779|NCT01958437|Sham Comparator|MCI SHAM tDCS|Group receives sham brain stimulation
16698780|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome
16698781|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome
16698782|NCT01958411||18FDG-PET/CT|
16698783|NCT01958398|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback.
16698784|NCT01958398|Experimental|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
16698785|NCT01958398|No Intervention|Control|Untreated control group
16698786|NCT01958385|Active Comparator|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
16698787|NCT01958385|Sham Comparator|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
16698788|NCT01958372|Experimental|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
16698789|NCT01958372|Experimental|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
16698790|NCT01958359|Experimental|Short IVR|IVR-based alcohol diary with feedback
16698791|NCT01958359|Experimental|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
16698792|NCT01958359|No Intervention|Control|Untreated control group
16698793|NCT01958346|Sham Comparator|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
16698794|NCT01958346|Experimental|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
16698795|NCT01958333|Experimental|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
16698796|NCT01958333|Experimental|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
16698797|NCT01958333|Experimental|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
16698798|NCT01958320|Experimental|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.
~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
16698799|NCT01958320|Active Comparator|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)
~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
16698800|NCT01958307|Experimental|Intervention|Lifestyle intervention
16698801|NCT01958307|No Intervention|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
16698802|NCT01958294|Other|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
16698803|NCT01958281|Experimental|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
16698804|NCT01958281|Experimental|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
16698805|NCT01958281|Experimental|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
16698806|NCT01958255|Other|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
16698807|NCT01958242|No Intervention|Preoperative blood harvesting|
16698808|NCT01958229||CHB patients without cirrhosis|
16699133|NCT01955967|Other|Lidocaine|
16698809|NCT01958216|Other|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
16698810|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
16698811|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
16698812|NCT01958177|Other|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
16698813|NCT01958164|Experimental|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
16698814|NCT01958164|Sham Comparator|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
16698815|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.
~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
16698816|NCT01958138|Experimental|propofol with Isoflurane|Propofol with Isoflurane, Group-I is the intervention arm with combination of two drugs such as low dose propofol and Isoflurane MAC awake.
16698817|NCT01958138|Active Comparator|alone isoflurane|The group-II is the control arm of study by using the only Isoflurane 1.2 MAC
16698818|NCT01958125|Active Comparator|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
16698819|NCT01958125|Placebo Comparator|inactive gammacore|same as the active treatment, but without the therapy treatment provided
16698820|NCT01958112|Experimental|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
16698821|NCT01958099|Other|Injury Prevention Specialist|
16698822|NCT01958099|Experimental|Kiosk Intervention|
16698823|NCT01958086|Experimental|Neural Communication System|The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
16698824|NCT01958073|Experimental|Conjugated Estrogen Vaginal Cream|Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
16698825|NCT01958073|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
16698826|NCT01958073|Placebo Comparator|Placebo|Per vagina
16698827|NCT01958060|Experimental|BI 1034020 intravenous part|single rising doses
16698828|NCT01958060|Experimental|BI 1034020 subcutaneous part|single rising doses
16698829|NCT01958047|Experimental|ASP3652|One single dose
16698830|NCT01958034|Experimental|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
16698831|NCT01958034|No Intervention|Control|No dietary supplement with bilberry extract
16698834|NCT01958008|Experimental|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
16698835|NCT01958008|Experimental|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
16698836|NCT01958008|Experimental|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
16698837|NCT01957995|Experimental|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
16698838|NCT01957995|Experimental|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
16698839|NCT01957995|Experimental|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
16698840|NCT01957995|Experimental|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
16698841|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
16698842|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
16698843|NCT01957956|Experimental|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.
~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.
~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.
~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.
~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16698844|NCT01957943|Placebo Comparator|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
16698845|NCT01957943|Active Comparator|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
16698846|NCT01957943|Active Comparator|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
16698847|NCT01957930|Experimental|Intensified insulin treatment|Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
16698848|NCT01957930|Active Comparator|Standard treatment|Mixed Insulin (2-3 times a day)
16698849|NCT01957930|No Intervention|Healthy controls|These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-
16698850|NCT01957917|Experimental|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
16698851|NCT01957917|Experimental|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
16698852|NCT01957917|Active Comparator|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
16698853|NCT01957904|Other|ArterX Surgical Sealant|
16698854|NCT01957878|Experimental|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
16698855|NCT01957878|Placebo Comparator|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
16698856|NCT01957865|Experimental|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
16698857|NCT01957865|Experimental|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
16698858|NCT01957865|No Intervention|control|Real-time adherence monitoring only (no SMS)
16698859|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
16698860|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
16698861|NCT01957839|No Intervention|pretreatment group|doppler evaluation at pretreatment period
16698862|NCT01957839|Experimental|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
16698863|NCT01957826|Placebo Comparator|placebo comparator|transendocardial injection of placebo solution
16698864|NCT01957826|Experimental|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
16698865|NCT01957813|Other|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
16698866|NCT01957813|Experimental|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
16698867|NCT01957800|Experimental|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
16698868|NCT01957800|Active Comparator|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
16698869|NCT01957787|Experimental|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. Tumors in both lungs are to be treated at an appropriate interval, determined on an individual basis. Treatment of bilateral index tumors in a single treatment session will not be performed. All participants will receive cryoablation of up to 6 metastatic lung tumors. Treatment of all study index tumors are to be completed within an 8-week window.
16698870|NCT01957774|Experimental|THR-18|
16698871|NCT01957774|Placebo Comparator|Placebo|matching placebo; look-alike with no active ingredients
16698872|NCT01957761||Clostridium difficile infection|
16698873|NCT01957748|No Intervention|Standard of Care (SoC)|Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services.
16698874|NCT01957748|Active Comparator|SoC + ALERT Intervention|Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study.
16698875|NCT01957735|Experimental|BP31510 monotherapy|"Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.
~first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.
~second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
16698876|NCT01957735|Active Comparator|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:
~Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;
~5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR
~Docetaxel IV once weekly at a starting dose of 20 mg/m2.
~Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
16698877|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
16725404|NCT01778855|Active Comparator|Normothermia|IV t-PA and normothermia
16698878|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
16698879|NCT01957709|Experimental|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.
16698880|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
16698881|NCT01957683|Experimental|Single Arm|
16698882|NCT01957670|Experimental|Treatment with Lacrima medical device|
16698883|NCT01957657|Experimental|Healthy volunteers group 1|Healthy volunteers with normal renal function
16698884|NCT01957657|Experimental|Renal function group 2|Patients with mild renal impairment
16698885|NCT01957657|Experimental|Renal function group 3|Patients with moderate renal impairment
16698886|NCT01957657|Experimental|Renal function group 4|Patients with severe renal impairment
16698887|NCT01957644|Experimental|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
16698888|NCT01957644|Experimental|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
16698889|NCT01957644|Experimental|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
16698890|NCT01957631|Active Comparator|Corticosteroid injection|Corticosteroid injection
16698891|NCT01957631|Experimental|Platelet rich plasma injection|Platelet rich plasma injection
16698892|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
16698893|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
16698894|NCT01957605||prone position|Patient scheduled for surgery in the prone position
16698895|NCT01957592||Subjects with diabetes mellitus (type 2)|
16698896|NCT01957579|Experimental|MEDI-551|
16698897|NCT01957566|Experimental|APS|
16698898|NCT01957553|Experimental|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
16698899|NCT01957553|Experimental|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
16698900|NCT01957540|Experimental|Ticagrelor|Ticagrelor 90mg bid for 15 days
16698901|NCT01957540|Active Comparator|Prasugrel|Prasugrel 10mg od for 15 days
16698902|NCT01957527||Ticagrelor discontinuation|
16698903|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
16698904|NCT01957501||Major Depressive Disorder Participants|
16698905|NCT01957501||Bipolar Disorder Participants:|
16698906|NCT01957501||Healthy Control Participants|
16698907|NCT01957488|Experimental|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects are first allocated to test Coloplast Test product 1 and secondly test either:
~Coloplast Test product 1 and thereafter Coloplast SenSura
~Coloplast Sensura and thereafter Coloplast Test product 2"
16698908|NCT01957488|Experimental|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects are first allocated to test Coloplast Test product 2 and secondly test either:
~Coloplast Test product 1 and thereafter Coloplast SenSura
~Coloplast Sensura and thereafter Coloplast Test product 1"
16698909|NCT01957488|Experimental|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects are first allocated to test Coloplast SenSura and secondly test either:
~Coloplast Test product 2 and thereafter Coloplast Test product 1
~Coloplast Test product 1 and thereafter Coloplast Test product 2"
16698910|NCT01957475|Experimental|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
16698911|NCT01957475|Experimental|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
16698912|NCT01957462|Experimental|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
16698913|NCT01957462|Experimental|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
16698914|NCT01957449|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
16698915|NCT01957449|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
16698916|NCT01957436|Active Comparator|Arm A|androgen deprivation therapy + docetaxel
16698917|NCT01957436|Experimental|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
16698918|NCT01957436|Experimental|Arm C|Arm A + radiotherapy
16698919|NCT01957436|Experimental|Arm D|Arm B + radiotherapy
16698920|NCT01957423|Experimental|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
16698921|NCT01957423|Active Comparator|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
16698922|NCT01957410|Experimental|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
16698923|NCT01957410|Placebo Comparator|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
16699134|NCT01955954|Experimental|Canary Breathing System|Treatment with Canary Breathing System
16698924|NCT01957397|Experimental|Coloplast Test 1|"The subjects are randomised to two arms
~In both arms the subjects start measuring the performance of own product to collect baseline data.
~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2
~Finally the all subject test Coloplast Test 3"
16698925|NCT01957397|Experimental|Coloplast Test 2|"The subjects are randomised to two arms
~In both arms the subjects start measuring the performance of own product to collect baseline data.
~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1
~Finally the all subject test Coloplast Test 3"
16698926|NCT01957384|Experimental|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:
~Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)
~Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
16698927|NCT01957384|Experimental|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:
~Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)
~Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
16698928|NCT01957384|Experimental|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:
~Coloplast Test product 1 and thereafter Coloplast Test product 2
~Coloplast Test product 2 and thereafter Coloplast Test product 1"
16698929|NCT01957371|Experimental|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
16698930|NCT01957358|Experimental|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
16698931|NCT01957345|Other|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
16698932|NCT01957345|Other|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
16698933|NCT01957345|Other|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
16698934|NCT01957332|Experimental|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
16698935|NCT01957319|Active Comparator|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
16698936|NCT01957319|Placebo Comparator|placebo|sugar pill
16698937|NCT01957306|Experimental|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
16698938|NCT01957293|Experimental|Salbutamol|
16698939|NCT01957293|Placebo Comparator|Sugar Syrup|
16698940|NCT01957280|Experimental|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
16698941|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
16698942|NCT01957267||Normal Group|Volunteers with healthy eyes
16698943|NCT01957254||Severe Sepsis|Patient with severe sepsis
16698944|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
16698945|NCT01957228|Experimental|bone biopsies|
16698946|NCT01957215|Experimental|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
16698947|NCT01957215|Placebo Comparator|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
16698948|NCT01957202|Experimental|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
16698949|NCT01957189|Experimental|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
16698950|NCT01957176|Experimental|Cohort A|Cohort A consists of subjects who had completed their treatment with eltrombopag (ELT) during their participation in a parent study for Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 50 to 300 mg once daily (OD) for subjects of non- East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e. Japanese, Chinese, Taiwanese, Thai and Korean) will be 25 to 150 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
16698951|NCT01957176|Experimental|Cohort B|Cohort B consists of adult subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
16698982|NCT01957033|Experimental|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
16698983|NCT01957033|Experimental|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
16698984|NCT01957033|Experimental|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
16698952|NCT01957176|Experimental|Cohort C|Cohort C consists of pediatric subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
16698953|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
16698954|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
16698955|NCT01957163|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
16698956|NCT01957150|Experimental|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
16698957|NCT01957150|Experimental|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
16698958|NCT01957137|Other|Continuous|The device parameter will be continuous.
16698959|NCT01957137|Other|Cycling Parameter #1|The device parameter will be cyclic program #1.
16698960|NCT01957137|Other|Cycling Parameter #2|The device parameter will be cyclic program #2.
16698961|NCT01957137|Other|Cycling Parameter #3|The device parameter will be cyclic program #3.
16698962|NCT01957137|Other|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
16698963|NCT01957124|Experimental|PRF application|
16698964|NCT01957111||Individuals with insomnia|
16698965|NCT01957111||Good sleepers|
16698966|NCT01957098|Placebo Comparator|0% pentose|Pure sucrose without pentoses added.
16698967|NCT01957098|Active Comparator|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
16698968|NCT01957098|Active Comparator|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
16698969|NCT01957098|Active Comparator|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
16698970|NCT01957085||Hospitalized Patients|Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.
16698971|NCT01957072|Experimental|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
16698972|NCT01957072|Other|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
16698973|NCT01957059|Experimental|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
16698974|NCT01957059|Experimental|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
16698975|NCT01957059|Experimental|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.
~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).
~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate)."
16698976|NCT01957059|Experimental|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
16698977|NCT01957046|Other|Oral Laxative|
16698978|NCT01957033|Experimental|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
16698979|NCT01957033|Experimental|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
16698980|NCT01957033|Experimental|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
16698981|NCT01957033|Experimental|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
16698985|NCT01957033|Experimental|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
16698986|NCT01957033|Experimental|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
16698987|NCT01957007|Experimental|Docetaxel|Drug: Docetaxel - administered intravenously
16698988|NCT01957007|Experimental|vantictumab|Drug: vantictumab - administered intravenously
16698989|NCT01956994|Experimental|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
16698990|NCT01956994|Active Comparator|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
16698991|NCT01956981|Placebo Comparator|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
16698992|NCT01956981|Active Comparator|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
16698993|NCT01956955|Active Comparator|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
16698994|NCT01956955|Active Comparator|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
16698995|NCT01956942|Experimental|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
16698996|NCT01956942|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
16698997|NCT01956929|Experimental|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
16698998|NCT01956929|Placebo Comparator|Placebo|2 weeks of Placebo (lactulose pills)
16698999|NCT01956916|Experimental|Probiotics|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
16699000|NCT01956916|Placebo Comparator|Placebo|Capsules containing maltodextrin
16699001|NCT01956903|Experimental|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
16699002|NCT01956890|Other|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
16699003|NCT01956877||Healthy volunteers|
16699004|NCT01956864|Experimental|Dose VD 1|Vitamin D
16699005|NCT01956864|Experimental|Dose VD 2|Vitamin D
16699006|NCT01956864|Experimental|Dose VD 3|Vitamin D
16699007|NCT01956864|Experimental|Dose VD 4|Vitamin D
16699008|NCT01956864|Experimental|Dose VD 5|Vitamin D
16699009|NCT01956864|Experimental|VD 6 Month Treatment|Vitamin D
16699010|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
16699011|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
16699012|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
16699013|NCT01956838|Experimental|Umami|intraduodenal infusion of umami
16699014|NCT01956838|Experimental|sweet|intraduodenal infusion of sweet tastant
16699015|NCT01956838|Experimental|bitter|intraduodenal infusion of bitter tastant
16699016|NCT01956838|Experimental|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
16699017|NCT01956838|Placebo Comparator|placebo|intraduodenal infusion of placebo (tap water)
16699018|NCT01956825|Placebo Comparator|water|just water
16699019|NCT01956825|Experimental|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
16699020|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
16699021|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
16699022|NCT01956786|Active Comparator|Amlodipine|5mg amlodipine,once daily for 8 weeks
16699023|NCT01956786|Experimental|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
16699024|NCT01956786|Experimental|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
16699025|NCT01956773|Experimental|MeTree - Patient|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients as clinical decision support.
16699026|NCT01956773|Experimental|MeTree - Provider|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to providers as clinical decision support.
16699052|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
16725405|NCT01778855|Active Comparator|Hypothermia|IV t-PA and hypothermia
16699027|NCT01956760|Experimental|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
16699028|NCT01956760|Placebo Comparator|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
16699029|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
16699030|NCT01956734|Experimental|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.
~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
16699031|NCT01956721|Experimental|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
16699032|NCT01956721|Experimental|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
16699033|NCT01956721|Other|Healthy Volunteers|Healthy Volunteers with no heart failure
16699036|NCT01956695|Experimental|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.
~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
16699037|NCT01956682|Active Comparator|Infant formula|HA formula + starch + L. reuteri
16699038|NCT01956682|Placebo Comparator|Standard Formula|Standard Infant Formula
16699039|NCT01956669|Experimental|Pazopanib|All subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m^2/dose or as a powder in suspension at a dose of 225 mg/m^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m^2/dose was not tolerated (>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
16699040|NCT01956656|Placebo Comparator|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
16699041|NCT01956656|Placebo Comparator|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
16699042|NCT01956643|Experimental|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.
~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
16699043|NCT01956643|Placebo Comparator|Control|Routine care during NPO
16699044|NCT01956630|Experimental|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
16699045|NCT01956630|Active Comparator|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
16699046|NCT01956617|Other|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
16699047|NCT01956604|Experimental|Clonidine|"Clonidine administered orally:
~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
16699048|NCT01956604|Placebo Comparator|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):
~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
16699049|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
16699050|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
16699051|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
16699053|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
16699054|NCT01956578|Experimental|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
16699055|NCT01956565|Experimental|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
16699056|NCT01956565|No Intervention|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
16699057|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
16699058|NCT01956526|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
16699059|NCT01956526|Experimental|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
16699060|NCT01956526|No Intervention|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
16699061|NCT01956500|Experimental|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
16699062|NCT01956500|Placebo Comparator|Placebo|Placebo (3 capsules per day for 8 weeks)
16699063|NCT01956487|Other|Propafenone|Open label comparison of 2 formulations
16699064|NCT01956474|Other|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
16699065|NCT01956448|Experimental|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
16699066|NCT01956448|Experimental|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
16699067|NCT01956435|Other|Excimer Light Treatment Right Leg, Control Left Leg|Excimer light treatment will be performed on the right leg of every subject, no treatment on the left or control leg of the subject.
16699068|NCT01956435|Other|Excimer Light Treatment Left Leg, Control Right Leg|Excimer light treatment will be performed on the left leg of every subject, no treatment on the right or control leg of the subject.
16699069|NCT01956422|Experimental|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
16699070|NCT01956422|Active Comparator|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
16699071|NCT01956409|Experimental|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
16699072|NCT01956396|Experimental|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
16699073|NCT01956383|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
16699074|NCT01956370|Experimental|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
16699075|NCT01956370|Active Comparator|Surgical|Adult male surgical circumcision
16699076|NCT01956357|Experimental|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.
~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
16699077|NCT01956357|Experimental|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.
~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
16699078|NCT01956344|Experimental|Immediate Treatment|Cognitive-behavioral therapy
16699079|NCT01956344|No Intervention|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
16699080|NCT01956344|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
16699081|NCT01956318|Experimental|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
16699082|NCT01956318|No Intervention|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
16699083|NCT01956305|Experimental|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
16699084|NCT01956305|Experimental|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
16699088|NCT01956305|Experimental|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
16699089|NCT01956305|Placebo Comparator|Placebo|placebo to match DS-7309
16699090|NCT01956292||Intraparenchimal cerebral haemorrhage|
16699091|NCT01956279|Experimental|Pregnenolone (Arm 1)|Pregnenolone
16699092|NCT01956279|Placebo Comparator|Placebo (Arm 2)|Placebo
16699093|NCT01956266|Experimental|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
16699094|NCT01956240|Experimental|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
16699095|NCT01956240|Experimental|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
16699096|NCT01956227|Experimental|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
16699097|NCT01956227|Experimental|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
16699098|NCT01956227|Experimental|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
16699099|NCT01956227|No Intervention|Control|Participants will not receive any treatment.
16699100|NCT01956214|Experimental|FES exercise|Participants will receive FES
16699101|NCT01956214|Sham Comparator|Mock FES exercise|participant will receive Mock FES
16699102|NCT01956201|Experimental|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
16699103|NCT01956201|Active Comparator|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
16699104|NCT01956188|Experimental|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
16699105|NCT01956188|Placebo Comparator|Placebo|Soy oil (3000 mg/d)
16699106|NCT01956175|Experimental|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
16699107|NCT01956175|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
16699108|NCT01956162|Experimental|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
16699109|NCT01956162|Active Comparator|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
16699110|NCT01956149|Experimental|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
16699111|NCT01956136|Experimental|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
16699112|NCT01956136|Experimental|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
16699113|NCT01956123|Experimental|A|Follitropin Delta (FE 999049) (COS cycle 2)
16699114|NCT01956123|Active Comparator|B|Follitropin Alfa (GONAL-F) (COS cycle 2)
16699115|NCT01956123|Experimental|C|Follitropin Delta (FE 999049) (COS cycle 3)
16699116|NCT01956123|Active Comparator|D|Follitropin Alfa (GONAL-F) (COS cycle 3)
16699117|NCT01956110|Experimental|A|Follitropin Delta (FE 999049)
16699118|NCT01956110|Active Comparator|B|Follitropin Alfa (GONAL-F)
16699119|NCT01956097|Experimental|HX106 590mg|HX106 590mg/day
16699120|NCT01956097|Experimental|HX106 1180mg|HX106 1180mg/day
16699121|NCT01956097|Placebo Comparator|Placebo|Placebo
16699122|NCT01956084|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
16699123|NCT01956084|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
16699124|NCT01956071|Experimental|WAPD|Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.
16699125|NCT01956058|Experimental|brachytherapy remedial|
16699126|NCT01956045||Decision making|
16699127|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.
~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
16699128|NCT01956019|Experimental|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
16699129|NCT01956006|Experimental|MIlrinone|ER milrinone
16699130|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
16699131|NCT01955980|Experimental|Buparid; Treatment A|Buparid 1mg budesonide/2 ml nebulizer solution
16699135|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
16699136|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
16699137|NCT01955928|Experimental|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
16699138|NCT01955928|No Intervention|Waiting-list|Waiting-list
16699139|NCT01955915||Choroidal Tumor Group|15 patients diagnosed with small posterior choroidal tumors will be considered and evaluated for enrollment into this study
16699140|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
16699141|NCT01955889|Experimental|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
16699142|NCT01955889|Active Comparator|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
16699143|NCT01955876||Group 1|
16699144|NCT01955863|Active Comparator|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
16699145|NCT01955863|Experimental|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
16699146|NCT01955863|Experimental|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
16699147|NCT01955850|Experimental|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
16699148|NCT01955850|Experimental|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
16699149|NCT01955850|No Intervention|Waiting-list|Waiting-list
16699150|NCT01955837|Experimental|TAS-102|
16699151|NCT01955837|Placebo Comparator|Placebo|
16699152|NCT01955824|Experimental|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
16699153|NCT01955824|Active Comparator|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
16699154|NCT01955811|Other|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
16699155|NCT01955798|Experimental|Trocar|Pyramidal tip reusable 11mm trocar
16699156|NCT01955798|Active Comparator|Veress needle|Veress needle
16699157|NCT01955785|Active Comparator|PC ventilation|Intervention with pressure controlled ventilator
16699158|NCT01955785|Active Comparator|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
16699159|NCT01955772|Experimental|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.
~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
16699160|NCT01955772|Other|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.
~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
16699161|NCT01955759|Experimental|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
16699162|NCT01955759|Experimental|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
16699163|NCT01955759|Placebo Comparator|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
16699164|NCT01955746||Type 1 DM|
16699165|NCT01955733|Experimental|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
16699166|NCT01955720|Experimental|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
16699167|NCT01955720|Experimental|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
16699168|NCT01955720|Experimental|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
16699169|NCT01955720|Experimental|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
16699170|NCT01955707|Experimental|natalizumab|300 mg single intravenous (IV) injection
16699171|NCT01955707|Placebo Comparator|Placebo|A single IV dose of placebo
16699172|NCT01955694|Experimental|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
16699173|NCT01955694|Experimental|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
16699174|NCT01955694|Active Comparator|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium
16699175|NCT01955694|Experimental|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
16699176|NCT01955694|Experimental|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
16699177|NCT01955694|Experimental|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
16699178|NCT01955668|Experimental|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
16699179|NCT01955655|Active Comparator|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
16699180|NCT01955655|Placebo Comparator|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
16699181|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
16699182|NCT01955629|Experimental|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m^2 q3w and Capecitabine 850 mg/m^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
16699183|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
16699184|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
16699185|NCT01955603|Experimental|Dose level 1|
16699186|NCT01955603|Experimental|Dose level 2|
16699187|NCT01955603|Experimental|Dose level 3|
16699188|NCT01955590|Experimental|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
16699189|NCT01955590|Active Comparator|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
16699190|NCT01955590|Active Comparator|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
16699191|NCT01955577|Experimental|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
16699192|NCT01955577|Placebo Comparator|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
16699193|NCT01955564|Experimental|Cohort 1|NW-3509a - 1mg or placebo
16699194|NCT01955564|Experimental|Cohort 2|NW-3509a 2mg or placebo
16699195|NCT01955564|Experimental|Cohort 3|NW-3509a 5mg or placebo
16699196|NCT01955564|Experimental|Cohort 4|NW-3509a 10 mg or placebo
16699197|NCT01955564|Experimental|Cohort 5|NW-3509a 20 mg or placebo
16699198|NCT01955564|Experimental|Cohort 6|NW-3509a 30 mg or placebo
16699199|NCT01955551|Experimental|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
16699200|NCT01955551|Active Comparator|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
16699201|NCT01955538|Active Comparator|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
16699202|NCT01955538|Experimental|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
16699203|NCT01955538|Experimental|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
16699204|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
16699205|NCT01955512|Placebo Comparator|Placebo|Arm given placebo
16699206|NCT01955512|Experimental|Clopidogrel|Group given clopidogrel
16699207|NCT01955499|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16699208|NCT01955486|Experimental|flight simulation|flight simulation in pressure chamber
16699209|NCT01955473|Experimental|Sym004|
16699210|NCT01955460|Experimental|Treatment (chemotherapy, autologous T-cell immunotherapy)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
16699211|NCT01955447|Placebo Comparator|Reference|no added plant-based ingredients
16699212|NCT01955447|Active Comparator|Low level plant-based ingredients|Low level addition of plant-based ingredients
16699213|NCT01955447|Active Comparator|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
16699214|NCT01955447|Active Comparator|High level plant-based ingredients|High level addition of plant-based ingredients
16699215|NCT01955434|Experimental|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16699216|NCT01955421|Experimental|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
16699217|NCT01955421|Experimental|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
16699218|NCT01955408||Overactive bladder after Synergo|
16699219|NCT01955395|Active Comparator|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
16699220|NCT01955395|Active Comparator|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
16699221|NCT01955382|Experimental|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
16699222|NCT01955382|Placebo Comparator|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
16699223|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
16699224|NCT01955356|Experimental|Scratching|induced endometrial injury
16699225|NCT01955356|No Intervention|No scratching|None intervention
16699226|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
16699227|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
16699228|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
16699229|NCT01955317|Experimental|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
16699230|NCT01955317|Active Comparator|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
16699231|NCT01955304|Experimental|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
16699232|NCT01955304|Experimental|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
16699233|NCT01955291|Experimental|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
16699234|NCT01955291|Other|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
16699235|NCT01955278|Experimental|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
16699236|NCT01955265|Experimental|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
16699237|NCT01955265|Active Comparator|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
16727889|NCT01761695||CML BC|Diagnosed as CML with blast crisis
16699238|NCT01955252|Experimental|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.
~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.
~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
16699239|NCT01955239|Active Comparator|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
16699240|NCT01955239|Experimental|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
16699241|NCT01955226|Experimental|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
16699242|NCT01955226|Active Comparator|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
16699243|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
16699244|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
16699245|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
16699246|NCT01955200|Experimental|CLOP-150|clopidogrel 150mg once daily
16699247|NCT01955200|Experimental|CLOP+CILOST|clopidogrel 75mg once daily plus cilostazol 100mg twice daily
16699248|NCT01955200|Experimental|TICAG|ticagrelor 90mg twice daily
16699249|NCT01955200|Active Comparator|CON(conventional DAPT)|clopidogrel 75mg once daily
16699250|NCT01955200|Active Comparator|Non-HOPR|clopidogrel 75mg once daily
16699251|NCT01955187|Experimental|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
16699252|NCT01955187|Active Comparator|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
16699253|NCT01955174|Experimental|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
16699254|NCT01955174|Sham Comparator|No injection|No injection of botulinum toxin
16699255|NCT01955161|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
16699256|NCT01955161|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
16699257|NCT01955161|Experimental|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
16699258|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
16699259|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
16699260|NCT01955148||Twin Pregnancy|Current twin pregnancy
16699261|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
16699262|NCT01955135|Active Comparator|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
16699263|NCT01955135|Active Comparator|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
16699264|NCT01955122|Other|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:
~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
16699265|NCT01955122|Other|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:
~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
16699266|NCT01955109|Experimental|Viaskin Peanut 250 mcg|
16699267|NCT01955096|Experimental|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
16699268|NCT01955096|Other|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
16699269|NCT01955083|Experimental|Pillar implant|"Arm 1- Pillar implant (Study group):
~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
16699270|NCT01955083|Active Comparator|Radiofrequency|"Arm 2- Radiofrequency (control group):
~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
16699271|NCT01955070|Experimental|Implementation|Multimedia Presentation for Ketamine sedation
16699272|NCT01955070|Experimental|Intervention|Multimedia Presentation for Ketamine sedation
16699273|NCT01955070|No Intervention|Control|Patients that received the standard consent with signed consent form
16699274|NCT01955057||Smokers with lung cancer|
16699275|NCT01955044|Experimental|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
16699276|NCT01955044|Experimental|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
16699277|NCT01955044|Placebo Comparator|placebo|"the placebo is a drop that will be administered to ELBW infants."
16699278|NCT01955031|Experimental|Telemonitoring|Patient with type 2 diabetes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
16699279|NCT01955031|Sham Comparator|Usual care|patient randomized in this group have a usual care
16699280|NCT01955018|Experimental|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
16699281|NCT01955018|Other|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
16699282|NCT01955005|Experimental|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
16699283|NCT01955005|Active Comparator|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
16699284|NCT01954992|Experimental|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
16699285|NCT01954992|Active Comparator|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
16699286|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
16699287|NCT01954966|Active Comparator|Progesterone 200 mg capsules|Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.
16699288|NCT01954966|Placebo Comparator|Progesterone 200 mg look-alike capsules|Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.
16699289|NCT01954953||no intervention|
16699290|NCT01954940|Experimental|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
16699291|NCT01954940|No Intervention|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
16699292|NCT01954927|Active Comparator|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
16699293|NCT01954927|Placebo Comparator|Placebo|Patients will be randomized to receive one dose of placebo.
16699294|NCT01954914|Experimental|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
16699295|NCT01954901|Experimental|Standard treatment plus Hyperbaric Oxygen|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
16699296|NCT01954901|Placebo Comparator|Standard treatment with Hyperbaric Room Air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
16699297|NCT01954888|Active Comparator|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
16699298|NCT01954888|Active Comparator|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
16699299|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
16699300|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
16699301|NCT01954875||healthy controls|healthy subjects as controls
16699302|NCT01954862|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
16699303|NCT01954862|Experimental|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
16699304|NCT01954862|Experimental|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
16699305|NCT01954862|Experimental|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
16699331|NCT01954706|Active Comparator|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
16699332|NCT01954693|Experimental|Everolimus (RAD001)|2x2.5mg daily
16699306|NCT01954862|Experimental|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
16699307|NCT01954862|Experimental|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
16699308|NCT01954849|Experimental|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
16699309|NCT01954849|Placebo Comparator|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
16699310|NCT01954836|Experimental|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
16699311|NCT01954836|Active Comparator|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
16699312|NCT01954823|Experimental|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
16699313|NCT01954823|No Intervention|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
16699314|NCT01954810|No Intervention|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
16699315|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
16699316|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
16699317|NCT01954784|Experimental|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.
~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.
~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.
~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16699318|NCT01954771|Active Comparator|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
16699319|NCT01954771|Active Comparator|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
16699320|NCT01954771|Active Comparator|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
16699321|NCT01954758|Experimental|Personalized embryo transfer (pET)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and an endometrial biopsy in a substituted cycle after 5 days (around 120 hours) of progesterone administration. The ERA test will determine the window of implantation (WOI) for each patient and will recommend the best time for embryo transfer thereby increasing the chances of a successful outcome. In some specific cases (≤ 10%) a second biopsy will be required to help the bioinformatic predictor to ensure the most appropriated moment for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, following the ERA result, a personalized embryo transfer (pET) will be carried out following the same conditions in which the ERA test was obtained, using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage)
16699322|NCT01954758|Active Comparator|Frozen embryo transfer (FET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), a frozen embryo transfer (FET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
16699323|NCT01954758|Active Comparator|Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
16699324|NCT01954745|Experimental|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
16699325|NCT01954732|No Intervention|Group I (observation)|Patients undergo observation.
16699326|NCT01954732|Experimental|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
16699327|NCT01954732|Experimental|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
16699328|NCT01954719|Experimental|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
16699329|NCT01954719|No Intervention|control group|cervix not dilated after surgery
16699330|NCT01954706|Experimental|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
16699334|NCT01954680|Experimental|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
16699335|NCT01954680|Experimental|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
16699336|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
16699337|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to < 25 and/or WHtR ≥0.4 to <0.5)
16699338|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to < 25 and/ or WHtR ≥0.4 to <0.5)
16699339|NCT01954654|Experimental|Accelerated treatment|
16699340|NCT01954654|Active Comparator|Standard treatment|
16699341|NCT01954641|Experimental|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
16699342|NCT01954641|Active Comparator|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
16699343|NCT01954628|Experimental|AQX-1125|1 x AQX-1125 capsule daily
16699344|NCT01954628|Placebo Comparator|Placebo|1 x Placebo capsule daily
16699345|NCT01954615|Experimental|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
16699346|NCT01954615|Experimental|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
16699347|NCT01954615|Experimental|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
16699348|NCT01954615|Experimental|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
16699349|NCT01954615|Experimental|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
16699350|NCT01954615|Experimental|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
16699351|NCT01954615|Experimental|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
16699352|NCT01954602|Active Comparator|Touch group|Sphincterotome assisted guide-wire cannulation
16699353|NCT01954602|Experimental|No touch group|Guide-wire cannulation
16699354|NCT01954589|Experimental|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
16699355|NCT01954589|Experimental|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
16699356|NCT01954589|Experimental|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
16699357|NCT01954589|Experimental|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.
~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant & 2 subjects received placebo"
16699358|NCT01954589|Experimental|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
16699359|NCT01954589|Experimental|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
16699360|NCT01954589|Experimental|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
16699361|NCT01954576|Experimental|NovoTTF therapy|Patients undergo NovoTFF therapy at least 18 hours daily for 6 months (bevacizumab-naive) or 4 months (bevacizumab-refractory). Treatment may continue for up to 2 years in patients experiencing CR, PR, or SD.
16699362|NCT01954563|Experimental|Group 1|Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
16699363|NCT01954563|Experimental|Group 2|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28.
16699364|NCT01954563|Experimental|Group 3|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
16699365|NCT01954550|Experimental|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
16699366|NCT01954550|Sham Comparator|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
16699367|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
16699368|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
16699369|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
16699370|NCT01954524|Experimental|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
16699371|NCT01954511|No Intervention|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
16699372|NCT01954498|Experimental|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
16699373|NCT01954498|Active Comparator|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
16699374|NCT01954485|Experimental|LaserLok abutment|Laser microtexturing dental implant abutment
16699375|NCT01954485|Active Comparator|3inOne abutment|Standard dental implant abutment
16699376|NCT01954472|Experimental|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
16699377|NCT01954472|Active Comparator|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
16699378|NCT01954459|Active Comparator|Sensor alone|Glucose sensor site will not have Insupatch
16699379|NCT01954459|Experimental|Sensor with Insupatch|Glucose sensor site with Insupatch
16699380|NCT01954446|Experimental|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
16699381|NCT01954446|Experimental|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
16699382|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
16699383|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
16699384|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
16699385|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
16699386|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
16699387|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
16699388|NCT01954420|Other|Attention Control|"Standard care + cancer education
~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
16699389|NCT01954420|Experimental|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention
~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
16699390|NCT01954407|No Intervention|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
16699391|NCT01954407|Experimental|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
16699392|NCT01954407|Experimental|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
16699393|NCT01954394|Experimental|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
16699394|NCT01954381|Other|control|
16699395|NCT01954381|Experimental|patient|
16699396|NCT01954368|Placebo Comparator|Intranasal placebo|Patients receiving intranasal placebo at ED admission
16699397|NCT01954368|Experimental|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
16699398|NCT01954355|Experimental|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)
~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
16699399|NCT01954342||Pregnant|Obese pregnant women
16699400|NCT01954329||Patients suspected of TIA by the GP|
16699401|NCT01954316|Experimental|CFI-400945 fumarate Schedule A|CFI-400945 fumarate tablets daily dosing expansion at 64mg
16699402|NCT01954316|Experimental|CFI-400945 fumarate Schedule B|CFI-400945 fumarate tablets intermittent dosing schedule, 2 days on/5 days off. Escalation at following levels: 96mg, 128mg
16699403|NCT01954316|Experimental|CFI-400945 fumarate Schedule C|CFI-400945 fumarate tablets intermittent dosing schedule, 1 day on/6 days off. Escalation will start at MTD of Schedule B
16699404|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is <14 ng/L) and troponin negative (if hsTnT on first presentation is >=14 ng/l)."
16699405|NCT01954303||Progress of CHD|
16699406|NCT01954290|Active Comparator|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.
~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.
~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
16699407|NCT01954290|Experimental|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
16699408|NCT01954277|Experimental|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
16699409|NCT01954277|Sham Comparator|Placebo Sham|All patients will receive 10 placebo sham sessions.
16699410|NCT01954264|Other|Overall Study Group|Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy.
16699411|NCT01954251|Experimental|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
16699412|NCT01954251|Active Comparator|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
16699413|NCT01954238|Active Comparator|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
16699414|NCT01954238|Placebo Comparator|Placebo|GCC-4401C matching placebo capsule
16699415|NCT01954238|Experimental|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
16699416|NCT01954225|Other|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
16699417|NCT01954212|Experimental|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
16699418|NCT01954212|No Intervention|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.
~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
16699419|NCT01954199|Experimental|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
16699420|NCT01954199|No Intervention|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living
~Upon trial completion, treatment will be offered."
16699421|NCT01954186|Experimental|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
16699422|NCT01954186|Active Comparator|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
16699423|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
16699424|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
16699425|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
16699426|NCT01954147|Experimental|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
16699427|NCT01954147|Experimental|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
16699428|NCT01954147|Experimental|GLP-1|Liraglutide
16699429|NCT01954147|Active Comparator|Control|Standard Medical Treatment
16699430|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
16699431|NCT01954121|Experimental|Levetiracetam|Levetiracetam 1000 mg/day
16699432|NCT01954121|Active Comparator|Carbamazepine|Carbamazepine 400 mg/day
16699433|NCT01954108|Other|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
16699434|NCT01954108|Active Comparator|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
16699492|NCT01953770|Active Comparator|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
16728572|NCT01756924|Active Comparator|Standard of Care|
16699435|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups.
16699436|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
16699437|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
16699438|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
16699439|NCT01954082|Experimental|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
16699440|NCT01954082|Placebo Comparator|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
16699441|NCT01954069|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
16699442|NCT01954056|Active Comparator|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
16699443|NCT01954056|Placebo Comparator|Placebo|Saline placebo
16699444|NCT01954043|Experimental|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
16699445|NCT01954030|Experimental|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
16699446|NCT01954030|Experimental|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
16699447|NCT01954030|Experimental|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
16699448|NCT01954017|Experimental|STP206|Biological
16699449|NCT01954017|Placebo Comparator|Control|Sterile water
16699450|NCT01953991|Active Comparator|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
16699451|NCT01953991|Active Comparator|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
16699452|NCT01953978|Active Comparator|Dexamethasone|"Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
16699453|NCT01953978|Placebo Comparator|Placebo|"Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
16699454|NCT01953952|Experimental|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
16699455|NCT01953952|Active Comparator|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
16699456|NCT01953939|Experimental|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
16699457|NCT01953926|Experimental|Neratinib monotherapy|Neratinib monotherapy in HER2 mutated cancers including cervical, salivary gland, and lung cancers containing EGFR exon 18 mutations.
16699458|NCT01953926|Experimental|Neratinib and Trastuzumab|Neratinib and Trastuzumab in HER2 mutated (TNBC, HR-negative) breast cancers.
16699459|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Randomized)|Neratinib, Fulvestrant and Trastuzumab or Fulvestrant and Trastuzumab or Fulvestrant alone in HER2 mutated (HR-positive with prior CDK4/6i) breast cancers.
16699460|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Non-Randomized)|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated (HR-positive with CDK4/6i naïve) breast cancers.
16699461|NCT01953913|Experimental|Afatinib|Patient will receive afatinib once daily
16699493|NCT01953770|Experimental|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
16699695|NCT01952535|Experimental|HMS5552 dose 1|A single dose of HMS5552 tablets (5~50mg) taken orally.
16699462|NCT01953900|Experimental|GD2 T cells plus VZV vaccine|In this study we will be administering from 1 x 10^6 to 1 x 10^9 transduced autologous VZV-specific CTLs, derived from VZV-specific memory T cells, so there will be no risk of alloreactivity. 6.1.1 Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m2/day followed by Fludarabine 30 mg/m2/day.
16699463|NCT01953887|Experimental|1 combination tablet EC905|
16699464|NCT01953887|Experimental|2: solifenacin|
16699465|NCT01953887|Experimental|3: tamsulosin|
16699466|NCT01953874|Experimental|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
16699467|NCT01953874|Active Comparator|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
16699468|NCT01953861|Experimental|1: fasted|EC905 + fasted
16699469|NCT01953861|Experimental|2: low-fat breakfast|EC905 + low-fat breakfast
16699470|NCT01953861|Experimental|3: high-fat breakfast|EC905 + high-fat breakfast
16699471|NCT01953848|Experimental|1: Low dose EC905|
16699472|NCT01953848|Experimental|2: High dose EC905|
16699473|NCT01953835|Experimental|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
16699474|NCT01953835|Experimental|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
16699475|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
16699476|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
16699477|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
16699478|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
16699479|NCT01953809|Experimental|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
16699480|NCT01953809|Experimental|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
16699481|NCT01953809|Experimental|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
16699482|NCT01953809|Experimental|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
16699483|NCT01953796|Experimental|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle >10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
16699484|NCT01953796|Active Comparator|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
16699485|NCT01953783|Experimental|IXAZOMIB|"Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.
~Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity."
16699486|NCT01953770|Active Comparator|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
16699487|NCT01953770|Experimental|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
16699488|NCT01953770|Experimental|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
16699489|NCT01953770|Active Comparator|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
16699490|NCT01953770|Experimental|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
16699491|NCT01953770|Active Comparator|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
16699494|NCT01953770|Experimental|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
16699495|NCT01953757|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
16699496|NCT01953757|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
16699497|NCT01953744|Experimental|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
16699498|NCT01953744|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
16699499|NCT01953731|Experimental|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
16699500|NCT01953705|Experimental|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
16699501|NCT01953705|Placebo Comparator|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
16699502|NCT01953692|Experimental|Cohort 1: Myelodysplastic Syndrome (MDS)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
16699503|NCT01953692|Experimental|Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
16699504|NCT01953692|Experimental|Cohort 3: Relapsed/Refractory (R/R) Hodgkin lymphoma (HL)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
16699505|NCT01953692|Experimental|Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
16699506|NCT01953692|Experimental|Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
16699507|NCT01953692|Experimental|Cohort 4C: R/R Follicular Lymphoma (FL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
16699508|NCT01953692|Experimental|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
16699509|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 20 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles.
16699510|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 25 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.
16699511|NCT01953679|Active Comparator|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
16699512|NCT01953679|Active Comparator|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
16699513|NCT01953666|Experimental|Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
16699514|NCT01953666|Active Comparator|Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
16699515|NCT01953666|No Intervention|No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
16699516|NCT01953653|Other|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
16699517|NCT01953653|Other|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
16699518|NCT01953640||Ancillary-correlative (gene expression with CYP-17 inhibition)|Laboratory Biomarker Analysis: Tissue, blood, and urine samples are collected at baseline and after 12-14 weeks of treatment and assessed for circulating tumor cells, genome-wide SNP, and exome sequencing. Subjects will also receive a Quality-of-Life Assessment.
16699519|NCT01953627|Experimental|Surgical procedure with the system Kymerax|
16699520|NCT01953614|Sham Comparator|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
16699521|NCT01953614|Active Comparator|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
16699522|NCT01953614|No Intervention|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
16699523|NCT01953601|Experimental|Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)|[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
16699524|NCT01953601|Experimental|Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)|[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
16699525|NCT01953601|Placebo Comparator|Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)|[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
16699526|NCT01953588|Active Comparator|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
16699527|NCT01953588|Active Comparator|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
16699528|NCT01953588|Active Comparator|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
16699529|NCT01953575|Experimental|Active Eosinophilic Esophagitis|Subjects with an eosinophil count greater than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
16699530|NCT01953575|Experimental|Inactive Eosinophilic Esophagitis|Subjects with an eosinophil count less than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
16699531|NCT01953575|Placebo Comparator|Control group|Subjects are those undergoing clinically indicated upper endoscopy for nonesophageal symptoms in whom a normal-appearing esophagus was found at the time of endoscopy
16699532|NCT01953562||Intubated infants|
16699533|NCT01953549|Experimental|physical fitness training|aerobic physical fitness training
16699534|NCT01953549|Active Comparator|relaxation|non-aerobic training
16699535|NCT01953536|Experimental|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
16699536|NCT01953536|Experimental|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
16699537|NCT01953536|Active Comparator|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
16699538|NCT01953523|Experimental|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
16699539|NCT01953510|Active Comparator|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
16699540|NCT01953510|Experimental|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
16699541|NCT01953510|Experimental|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
16699542|NCT01953510|Experimental|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
16699543|NCT01953510|Experimental|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
16699544|NCT01953510|No Intervention|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
16699545|NCT01953510|No Intervention|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
16699546|NCT01953497|Placebo Comparator|Placebo|Placebo
16699547|NCT01953497|Active Comparator|URC102|URC102
16699548|NCT01953484|Experimental|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
16699549|NCT01953484|Experimental|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
16699550|NCT01953484|Experimental|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
16699551|NCT01953471||Allergic rhinitis|
16699552|NCT01953458||hepatitis C and/or B|
16699553|NCT01953445|Experimental|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
16699554|NCT01953432|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
16699555|NCT01953432|Placebo Comparator|Placebo|Matched placebo daily dosing.
16699556|NCT01953419|Experimental|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
16699557|NCT01953406|Experimental|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
16699558|NCT01953380|Active Comparator|extended information|Extended information on specific allergy
16699559|NCT01953380|No Intervention|Information according to clin. routine|Information according to clinical routine
16699560|NCT01953367|Experimental|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
16699561|NCT01953367|Active Comparator|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
16699562|NCT01953354|Experimental|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
16699563|NCT01953354|Placebo Comparator|Placebo|Six doses of TSO placebo orally over a ten-week period
16699564|NCT01953341|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 .
16699565|NCT01953341|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo.
16699566|NCT01953328|Placebo Comparator|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
16699567|NCT01953328|Placebo Comparator|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
16699568|NCT01953328|Experimental|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
16699569|NCT01953328|Experimental|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
16699605|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
16728573|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
16699570|NCT01953328|Placebo Comparator|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
16699571|NCT01953328|Other|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
16699572|NCT01953328|Experimental|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
16699573|NCT01953328|Experimental|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
16699574|NCT01953315|Experimental|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
16699575|NCT01953302|Experimental|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
16699576|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
16699577|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
16699578|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
16699579|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
16699580|NCT01953237|Active Comparator|Control|Individuals randomized to the control condition will be provided with a smartphone free of charge with unlimited use of the phone's voice and internet capabilities. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period. All participants will be contacted by research staff to trouble-shoot problems with the smartphone at the end of the first week, but will receive no additional contact from research staff until the end of the trial.
16699581|NCT01953237|Experimental|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
16699582|NCT01953224|Experimental|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
16699583|NCT01953224|No Intervention|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
16699584|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
16699585|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
16699586|NCT01953185|Experimental|Manual diaphragm release technique|
16699587|NCT01953185|Sham Comparator|Control group|
16699588|NCT01953172|Placebo Comparator|Placebo capsules|Placebo capsules
16699589|NCT01953172|Experimental|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
16699590|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
16699591|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
16699592|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged < 38 years without endometriosis where more than > 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
16699593|NCT01953133|No Intervention|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.
~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
16699594|NCT01953133|Experimental|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
16699595|NCT01953120|Experimental|Belatacept|Survival and rejection in patients switched to belatacept.
16699596|NCT01953107|Experimental|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
16699597|NCT01953107|Placebo Comparator|Placebo + Vitamin C|300 mg of Placebo
16699598|NCT01953094|Other|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
16699599|NCT01953094|Other|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
16699600|NCT01953081|Experimental|TD-8954|TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
16699601|NCT01953081|Active Comparator|Metoclopramide|Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline
16699602|NCT01953055|Experimental|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
16699603|NCT01953042|No Intervention|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
16699604|NCT01953042|Active Comparator|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
16699607|NCT01953003|Experimental|Arm A : iv vinflunine plus Capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
16699608|NCT01953003|Active Comparator|capecitabineArm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
16699609|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.
~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
16699610|NCT01952977|Active Comparator|MCT|MCT oil (20 g) was included in the test breakfast
16699611|NCT01952977|Placebo Comparator|LCT|Corn oil (20 g) was included in the test breakfast
16699612|NCT01952964|Experimental|JUC spray dressing|
16699613|NCT01952951|Experimental|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
16699614|NCT01952951|Active Comparator|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
16699615|NCT01952938||LINK SL|Patients
16699616|NCT01952938||EnduRo|Patients
16699617|NCT01952925|Experimental|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
16699618|NCT01952912|Active Comparator|PkEP|
16699619|NCT01952912|Active Comparator|OP|
16699620|NCT01952899||Albert Schweitzer Hospital|
16699621|NCT01952899||Erasmus MC Academic Hospital|
16699622|NCT01952899||Ikazia Hospital|
16699623|NCT01952899||IJsselland Hospital|
16699624|NCT01952899||Maasstad Hospital|
16699625|NCT01952899||Sint Franciscus Gasthuis Hospital|
16699626|NCT01952886|Experimental|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
16699627|NCT01952886|Active Comparator|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
16699628|NCT01952873|Active Comparator|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
16699629|NCT01952873|Experimental|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
16699630|NCT01952860|Experimental|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
16699631|NCT01952847|Placebo Comparator|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
16699632|NCT01952847|Experimental|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
16699633|NCT01952847|Placebo Comparator|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
16699634|NCT01952847|Experimental|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
16699635|NCT01952834|Experimental|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
16699636|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
16699637|NCT01952808|Experimental|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
16699638|NCT01952808|No Intervention|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
16699639|NCT01952795|Active Comparator|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
16699640|NCT01952795|No Intervention|No intervention|Usual diet and exercise
16699641|NCT01952782|Experimental|Naloxone, Kisspeptin, GnRH|"The study will involve 3 visits:
~Outpatient screening visit
~Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)
~Outpatient follow-up visit"
16699687|NCT01952548|Experimental|Dose 7 Active|
16699642|NCT01952769|Experimental|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
16699643|NCT01952756|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
16699644|NCT01952756|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
16699645|NCT01952743|Active Comparator|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
16699646|NCT01952743|Experimental|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
16699647|NCT01952730|Experimental|Experimental Treatment Arm|GVAX, up to 6 vaccinations, administered via injection
16699648|NCT01952704|Experimental|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
16699649|NCT01952704|Placebo Comparator|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
16699650|NCT01952691|Experimental|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
16699651|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
16699652|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
16699653|NCT01952665|Active Comparator|comfilcon A|Daily wear soft contact lens comfilcon A
16699654|NCT01952665|Active Comparator|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
16699655|NCT01952652|Active Comparator|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
16699656|NCT01952652|Active Comparator|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
16699657|NCT01952639|Experimental|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
16699658|NCT01952639|Experimental|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
16699659|NCT01952639|Active Comparator|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
16699660|NCT01952639|Active Comparator|30 g of casein|Subjects will consume 30 g of casein protein type and amount
16699661|NCT01952639|Experimental|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
16699662|NCT01952626|Active Comparator|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
16699663|NCT01952626|Experimental|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
16699664|NCT01952613|Experimental|Stroke - FES|Stroke population currently prescribed a FES orthotic device (< week)
16699665|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
16699666|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
16699667|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
16699668|NCT01952587|Other|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
16699669|NCT01952587|Other|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
16699670|NCT01952574|Placebo Comparator|Placebo|"Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.
~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
16699671|NCT01952574|Experimental|Erenumab 7 mg QM|"Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.
~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
16699672|NCT01952574|Experimental|Erenumab 21 mg QM|"Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.
~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
16699673|NCT01952574|Experimental|Erenumab 70 mg QM|"Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.
~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
16699674|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg PFS|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
16699675|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg AI/Pen|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
16699676|NCT01952561|Experimental|2 weeks|
16699677|NCT01952561|Experimental|1 week|
16699678|NCT01952561|Experimental|4 weeks|
16699679|NCT01952561|Experimental|8 weeks|
16699680|NCT01952561|Experimental|12 weeks|
16699681|NCT01952548|Experimental|Dose 1 Active|
16699682|NCT01952548|Experimental|Dose 2 Active|
16699683|NCT01952548|Experimental|Dose 3 Active|
16699684|NCT01952548|Experimental|Dose 4 Active|
16699685|NCT01952548|Experimental|Dose 5 Active|
16699686|NCT01952548|Experimental|Dose 6 Active|
16699696|NCT01952535|Experimental|HMS5552 dose 2|A single dose of HMS5552 tablets (5~50mg) taken orally.
16699697|NCT01952535|Experimental|HMS5552 dose 3|A single dose of HMS5552 tablets (5~50mg) taken orally.
16699698|NCT01952535|Experimental|HMS5552 dose 4|A single dose of HMS5552 tablets (5~50mg) taken orally.
16699699|NCT01952535|Experimental|HMS5552 dose 5|A single dose of HMS5552 tablets (5~50mg) taken orally.
16699700|NCT01952535|Experimental|HMS5552 dose 6|A single dose of HMS5552 tablets (5~50mg) taken orally.
16699701|NCT01952522|Experimental|Weighted brace|
16699702|NCT01952522|Placebo Comparator|non weighted brace|
16699703|NCT01952509||Cohort|
16699704|NCT01952496|Other|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months."
16699705|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level <20ng/ml)
16699706|NCT01952483||Vitamin D normal|Serum level >35 ng/ml
16699707|NCT01952470|Experimental|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa.
16699708|NCT01952470|Active Comparator|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
16699709|NCT01952457|Experimental|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
16699710|NCT01952457|Active Comparator|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
16699711|NCT01952444|Experimental|Group 1 ETI-204 and Ciprofloxacin|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1, immediately followed by an IV dose of ciprofloxacin 400 mg infused over 60 minutes, followed by oral doses of ciprofloxacin (750 mg every 12 hours) from Day 2 to Day 8 and a final dose on the morning of Day 9.
16699712|NCT01952444|Other|Group 2 ETI-204 Alone|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1.
16699713|NCT01952431|Experimental|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
16699714|NCT01952431|Active Comparator|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
16699715|NCT01952418|No Intervention|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
16699716|NCT01952418|Active Comparator|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
16699717|NCT01952405|Experimental|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
16699718|NCT01952405|Placebo Comparator|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
16699719|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
16699720|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
16699721|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
16699722|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
16699723|NCT01952353|Experimental|Preoperation TACE arm|In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist
16699724|NCT01952353|Active Comparator|Resection arm|Liver resection Plus Thrombectomy
16699725|NCT01952340|Experimental|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
16699726|NCT01952340|Placebo Comparator|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
16699727|NCT01952327|Other|plueurapump|Implantation of pleurapump system
16699728|NCT01952314|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics.
16699729|NCT01952314|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
16699730|NCT01952301|Active Comparator|xenogeneic collagen matrix|Xenogeneic collagen matrix device placed on treatment wound bed site
16699731|NCT01952301|Active Comparator|Free Gingival Graft|Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed
16699734|NCT01952262||critically ill ICU patients|critically ill intensive care unit patients
16699735|NCT01952249|Experimental|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
16699736|NCT01952249|Experimental|Taxol|demcizumab combined with weekly paclitaxel
16699737|NCT01952236|Experimental|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
16699738|NCT01952236|Active Comparator|Web Only|A best-practices Web-based smoking cessation program.
16699739|NCT01952223|Experimental|ADT + pelvic RT|"ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen
~Pelvic RT (by IMRT or IGRT protocol):
~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
16699740|NCT01952223|Experimental|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles
~Prostate-only RT (IMRT or IGRT):
~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
16699741|NCT01952223|Experimental|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles
~Pelvic RT (IMRT or IGRT):
~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
16699742|NCT01952223|Active Comparator|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen
~Prostate-only RT (IMRt or IGRT):
~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
16699743|NCT01952210|Experimental|nutrition consultation and exercise program|individual nutritional consultation and exercise
16699744|NCT01952210|Active Comparator|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
16699745|NCT01952197|Experimental|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
16699746|NCT01952184|Active Comparator|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
16699747|NCT01952184|Experimental|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
16699749|NCT01952145|Experimental|Insulin degludec/liraglutide OD plus metformin|
16699750|NCT01952145|Active Comparator|Insulin glargine OD plus metformin|
16699751|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
16699752|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
16699753|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
16699754|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
16699755|NCT01952119|No Intervention|Routine Care|Routine care, no intervention
16699756|NCT01952119|Active Comparator|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
16699757|NCT01952106|Experimental|distraction|use the computer game to distract children's pain and anxiety during venepuncture
16699758|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
16699759|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
16699760|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
16699761|NCT01952093||Term control group|Healthy term infants
16699762|NCT01952080|Experimental|teduglutide|Open label teduglutide, subcutaneously injected.
16699763|NCT01952080|No Intervention|Standard of Care|
16699764|NCT01952067|Experimental|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
16699765|NCT01952067|Active Comparator|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
16699766|NCT01952054|Experimental|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
16699767|NCT01952041|Experimental|Device: Smartphone|Participants in the smartphone intervention arm received treatment as usual in addition to receiving a smartphone with the study application. The study application identified relapse risk and prompted the clinical team to provide enhanced services.
16699768|NCT01952041|Active Comparator|Treatment as Usual|Treatment as usual included outpatient case management, linkage to services and medication monitoring.
16699769|NCT01952015|Experimental|AIN457|"All subjects were assigned to receive 150 mg secukinumab (AIN457) by subcutaneous injections. AIN457 was administered at baseline, weeks 1, 2, 3, 4. Prior to receiving the week 8 dose, all subjects were assigned to the following treatment group based on clinical components of their Clinical Global Impression (CGI) evaluation at week 8.
~No up-titration group received 1 injection of 150 mg AIN457 at weeks 8, 12, and each visit from week 16 until week 48.
~Up-titration group received 2 injections of 150 mg AIN457 at weeks 8, 9, 12 and each visit from week 16 until week 48.
~Subjects who received 150 mg AIN457 can be up-titrated to 300 mg AIN 457 at any visit starting at week 16 based on clinical components of their CGI evaluation and investigator's discretion."
16699770|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
16700309|NCT01948635|Experimental|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
16699771|NCT01951989|Experimental|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.
~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
16699772|NCT01951976|Experimental|Intervention Condition|"Questionnaires and yoga classes.
~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
16699773|NCT01951963|Experimental|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
16699774|NCT01951963|Active Comparator|Morphine|Morphine, single dose, 0.05 mg/kg, IV
16699775|NCT01951950|Active Comparator|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
16699776|NCT01951950|Active Comparator|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
16699777|NCT01951937|Active Comparator|Fish Meals|3 Fish meals per week for 4 months
16699778|NCT01951937|Placebo Comparator|Placebo|Habitual diet
16699779|NCT01951924|Experimental|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
16699780|NCT01951924|Experimental|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
16699781|NCT01951911|Active Comparator|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
16699782|NCT01951911|Placebo Comparator|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
16699783|NCT01951898|Active Comparator|Montelukast|
16699784|NCT01951898|Sham Comparator|Vitamin B6|
16699785|NCT01951885|Active Comparator|Group A (tacrolimus, methotrexate)|Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.
16699786|NCT01951885|Experimental|Group B (tacrolimus, methotrexate, mycophenolate mofetil)|Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).
16699787|NCT01951872|Experimental|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
16699788|NCT01951872|Experimental|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
16699789|NCT01951859|Experimental|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
16699790|NCT01951859|Placebo Comparator|Placebo Cream|
16699791|NCT01951846|Experimental|BIBF 1120|
16699792|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
16699793|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.
~No treatment, observational"
16699794|NCT01951820|Active Comparator|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
16699795|NCT01951820|Experimental|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
16699796|NCT01951807|Experimental|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
16699797|NCT01951807|Experimental|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
16699798|NCT01951807|No Intervention|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
16699799|NCT01951781|Other|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
16699800|NCT01951768|Experimental|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
16699801|NCT01951768|Active Comparator|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
16699802|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
16699803|NCT01951742|Experimental|Dose 1|lowest dose
16699804|NCT01951742|Experimental|Dose 2|second lowest dose
16699805|NCT01951742|Experimental|Dose 3|mid-level dose
16699806|NCT01951742|Experimental|Dose 4|second highest dose
16699807|NCT01951742|Experimental|Dose 5|highest dose
16699808|NCT01951729|Experimental|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
16699809|NCT01951716|Experimental|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
16699810|NCT01951716|Experimental|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
16699811|NCT01951703|Active Comparator|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
16699812|NCT01951703|Experimental|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
16699813|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
16699814|NCT01951677|Active Comparator|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
16699815|NCT01951677|Experimental|HBsAg + Advax-1(TM)|HBsAg + Advax-1
16699816|NCT01951677|Experimental|HBsAg + Advax-2(TM)|HBsAg + Advax-2
16699817|NCT01951677|Experimental|HBsAg + Advax-3(TM)|HBsAg + Advax-3
16699818|NCT01951677|Active Comparator|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
16699819|NCT01951677|Experimental|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
16699820|NCT01951677|Experimental|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
16699821|NCT01951677|Experimental|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
16699822|NCT01951677|Active Comparator|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
16699823|NCT01951677|Experimental|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
16699824|NCT01951677|Experimental|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
16699825|NCT01951677|Experimental|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
16699826|NCT01951664|Experimental|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
16699827|NCT01951664|Active Comparator|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
16699828|NCT01951651|Experimental|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
16699829|NCT01951651|Experimental|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
16699830|NCT01951638|Experimental|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
16699831|NCT01951638|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
16699832|NCT01951638|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
16699833|NCT01951638|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
16699834|NCT01951638|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
16699835|NCT01951625|Experimental|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
16699836|NCT01951625|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
16699837|NCT01951625|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
16699838|NCT01951625|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
16699839|NCT01951625|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
16699840|NCT01951612|Experimental|Executive Function Training Program|Participants in this group will receive the novel intervention training.
16699841|NCT01951612|Active Comparator|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
16699842|NCT01951599|Experimental|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
16699843|NCT01951599|Experimental|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
16699844|NCT01951599|Experimental|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
16699845|NCT01951599|Experimental|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
16699846|NCT01951599|Experimental|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
16699849|NCT01951573|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
16699850|NCT01951573|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
16699851|NCT01951560|Experimental|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
16699852|NCT01951560|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
16699853|NCT01951547|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
16699854|NCT01951547|Active Comparator|Oral hygiene instructions|Oral hygiene instructions given at baseline
16700310|NCT01948635|Active Comparator|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
16699855|NCT01951534|Experimental|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
16699856|NCT01951534|Other|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
16699857|NCT01951521|Experimental|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
16699858|NCT01951521|No Intervention|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
16699859|NCT01951508|Other|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
16699860|NCT01951482|Experimental|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
16699861|NCT01951482|Active Comparator|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
16699862|NCT01951469|Experimental|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
16699863|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
16699864|NCT01951456|Experimental|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
16699865|NCT01951456|Active Comparator|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
16699866|NCT01951443|Experimental|Ginseng|Encapsulated 400mg Rg3-KRG extract
16699867|NCT01951443|Placebo Comparator|Wheat Bran|400mg Wheat Bran capsule
16699868|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
16699869|NCT01951417|Experimental|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
16699870|NCT01951404|Active Comparator|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
16699871|NCT01951404|Placebo Comparator|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
16699872|NCT01951391|Other|Control Soap vs. Benzalkonium Chloride Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with benzalkonium chloride soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The benzalkonium chloride forearm will be swabbed at baseline and 6 hours.
16699873|NCT01951391|Other|Control Soap vs. Triclocarban Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
16699874|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
16699875|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
16699876|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
16699877|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
16699878|NCT01951352|Experimental|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
16699879|NCT01951339|Experimental|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
16699880|NCT01951339|Active Comparator|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
16699881|NCT01951326|Active Comparator|RHB-104|5 RHB-104 capsules administered orally BID
16699882|NCT01951326|Placebo Comparator|Placebo|5 placebo capsules administered orally BID
16699883|NCT01951313|Experimental|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
16699884|NCT01951300|Other|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
16699885|NCT01951287|Experimental|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
16699886|NCT01951287|Experimental|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
16700570|NCT01946932|Active Comparator|Cardiac Arrest 33°|survivors with temperature treatment 33°
16699887|NCT01951287|Experimental|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
16699888|NCT01951287|Experimental|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
16699889|NCT01951287|Experimental|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
16699890|NCT01951287|Experimental|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
16699891|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
16699892|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
16699893|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
16699894|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
16699895|NCT01951261|Active Comparator|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
16699896|NCT01951261|No Intervention|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (daily visits).
16699897|NCT01951248|Experimental|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
16699898|NCT01951235|Experimental|Imeglimin (Dose 1)|
16699899|NCT01951235|Experimental|Imeglimin (Dose 2)|
16699900|NCT01951235|Experimental|Imeglimin (Dose 3)|
16699901|NCT01951235|Experimental|Imeglimin (Dose 4)|
16699902|NCT01951235|Placebo Comparator|Placebo|
16699903|NCT01951222|Experimental|V0162 dose1|
16699904|NCT01951222|Experimental|V0162 dose2|
16699905|NCT01951222|Placebo Comparator|placebo|Placebo
16699906|NCT01951209|Experimental|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
16699907|NCT01951209|Experimental|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
16699908|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
16699909|NCT01951196||Healthy subjects|75 healthy subjects.
16699910|NCT01951183|Placebo Comparator|Placebo|
16699911|NCT01951183|Experimental|RO6811135|
16699912|NCT01951170|Experimental|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
16699913|NCT01951157|Active Comparator|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
16699914|NCT01951157|Experimental|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
16699915|NCT01951157|Experimental|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
16699916|NCT01951144|Experimental|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
16699917|NCT01951144|Experimental|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
16699918|NCT01951144|Experimental|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
16699919|NCT01951144|Experimental|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
16699920|NCT01951118|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
16699921|NCT01951105|No Intervention|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
16699922|NCT01951105|Active Comparator|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.
~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
16699923|NCT01951105|Placebo Comparator|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
16699924|NCT01951092|Experimental|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
16699925|NCT01951079|Experimental|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
16699926|NCT01951066|Experimental|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
16699927|NCT01951066|Experimental|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
16699928|NCT01951053|Experimental|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
16699929|NCT01951053|Experimental|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
16699930|NCT01951053|Experimental|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
16699931|NCT01951053|Experimental|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
16699932|NCT01951053|Experimental|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
16699933|NCT01951053|Experimental|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
16699934|NCT01951040||Oxytocin|Oxytocin was administered during labor
16699935|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
16699936|NCT01951027|Experimental|Cohort 1|GX-G3 12.5 μg/kg or Placebo
16699937|NCT01951027|Experimental|Cohort 2|GX-G3 25 μg/kg or Placebo
16699938|NCT01951027|Experimental|Cohort 3|GX-G3 50 μg/kg or Placebo
16699939|NCT01951027|Experimental|Cohort 4|GX-G3 100 μg/kg or Placebo
16699940|NCT01951014|Experimental|Teen Social Media Education|See description under intervention description
16699941|NCT01951014|No Intervention|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
16699942|NCT01951001|Active Comparator|group 1|Fixed-dose Prasugrel of 10 mg/d
16699943|NCT01951001|Active Comparator|group 2|Fixed-dose Prasugrel of 5 mg/d
16699944|NCT01951001|Active Comparator|group 3|"Phenotype-based prasugrel dose
~If patients show PRU < 85, prasugrel dose will be reduced by 5 mg/d.
~If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d."
16699945|NCT01950988|Other|Children|
16699946|NCT01950988|Other|Adults|
16699947|NCT01950988|Other|Elderly people|
16699948|NCT01950975|Other|Parents|2 parents of child
16699949|NCT01950975|Other|infant|
16699950|NCT01950962|Other|slight periodontal disease|
16699951|NCT01950962|Other|moderate periodontal disease|
16699952|NCT01950962|Other|severe periodontal disease|
16699953|NCT01950949|Experimental|change respiratory parameters, volume expanding|
16699954|NCT01950936|Experimental|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is <0.15 ng/ml and dis-encouraged whenever Procalcitonin is <0.25 ng/ml
16699955|NCT01950936|No Intervention|Control - Standard of Care|Antibiotics are administered according to current guidelines
16699956|NCT01950923|Experimental|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
16699957|NCT01950923|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
16699958|NCT01950910||subjects w/ non-motor neurodegenerative disease|subjects with ALS or with non-motor neurodegenerative disease
16699959|NCT01950910||subjects w/out motorneuron degenerative dis|subjects without motorneuron degenerative disease
16699960|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
16699961|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
16699962|NCT01950884|Experimental|Ezetimibe|Ezetimibe tablets plus lifestyle
16699963|NCT01950884|Active Comparator|lifestyle|lifestyle
16699964|NCT01950871|Other|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
16699965|NCT01950858|Experimental|Biological|6 weeks of HBO treatment as well as non weight bearing
16699966|NCT01950858|Active Comparator|Control|non weight bearing
16699967|NCT01950845|Experimental|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
16699968|NCT01950845|Sham Comparator|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
16699969|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
16699970|NCT01950832||Control|60 healthy volunteers
16699971|NCT01950819|Experimental|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
16699972|NCT01950819|Active Comparator|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
16699973|NCT01950806|Active Comparator|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
16699974|NCT01950806|Placebo Comparator|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
16699975|NCT01950793|Active Comparator|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
~One injection only"
16701057|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
16699976|NCT01950793|Experimental|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
~One injection only"
16699977|NCT01950780|Experimental|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
16699978|NCT01950754|Other|depressive patients|
16699979|NCT01950754|Other|nondepressed controls|
16699980|NCT01950741|Experimental|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
16699981|NCT01950728|No Intervention|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
16699982|NCT01950728|Active Comparator|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
16699983|NCT01950728|Active Comparator|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
16699984|NCT01950728|Active Comparator|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
16699985|NCT01950715|Other|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
16699986|NCT01950702|Active Comparator|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.
~Patient's head were fixed at neutral position during all intubation period."
16699987|NCT01950702|Experimental|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
16699990|NCT01950676|No Intervention|Control|Individuals in the control group will not use the smart phone application
16699991|NCT01950676|Experimental|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
16699992|NCT01950663|Experimental|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
16699993|NCT01950650||Patients with diabetes|
16699994|NCT01950650||Physicians|
16699995|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
16699996|NCT01950637||Healthcare professionals (HCPs)|
16699997|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
16699998|NCT01950611|Experimental|Bortezomib in treatment|
16699999|NCT01950598|Active Comparator|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
16700000|NCT01950598|Experimental|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
16700002|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
16700003|NCT01950546|Experimental|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
16700004|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
16700005|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
16700006|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
16700007|NCT01950520|Experimental|Cohort 2|Interventions, in random order, will be administered during one of the six one-day stays
16700008|NCT01950520|Experimental|Cohort 3|Interventions, in random order, will be administered during one of the four overnight inpatient stays
16700009|NCT01950520|Experimental|Low Temperature 1st|Low temperature before 27c (Cohort 1 only)
16700010|NCT01950520|Experimental|Low Temperature 2nd|Low temperature after 27c (Cohort 1 only)
16700011|NCT01950507|Experimental|Cohort 1|subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
16700012|NCT01950507|Experimental|Cohort 2|subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
16700013|NCT01950507|Experimental|Cohort 3|subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.
16700014|NCT01950494|Experimental|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
16700015|NCT01950494|Placebo Comparator|Blinded emollient therapy|Blinded emollient therapy
16700016|NCT01950481|Experimental|Normal Hepatic Function|Subjects with normal hepatic function
16700017|NCT01950481|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment
16700018|NCT01950481|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
16700019|NCT01950481|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment
16700020|NCT01950468|Experimental|NAV5001|
16700021|NCT01950468|Active Comparator|DaTscan|
16700022|NCT01950455|Experimental|NAV5001|
16700023|NCT01950416|Experimental|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
16700024|NCT01950416|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
16700025|NCT01950403|Experimental|Arm I (linaclotide acetate)|Participants receive linaclotide acetate PO QD on days 1-7.
16700026|NCT01950403|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO QD on days 1-7.
16700027|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
16700028|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
16700029|NCT01950377||Healthy Adults|Healthy adults healthy adults - male and female
16700030|NCT01950364|Experimental|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
16700031|NCT01950364|Experimental|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
16700032|NCT01950351|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
16700033|NCT01950338|Experimental|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
16700034|NCT01950338|No Intervention|Control group|The control group will not receive any intervention.
16700035|NCT01950325|Experimental|Group 1|1mg/kg IV
16700036|NCT01950325|Experimental|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)[only portion of the study that is randomized]
16700037|NCT01950325|Experimental|Group 4|20 mg/kg IV
16700038|NCT01950325|Experimental|Group 5|40 mg/kg IV
16700039|NCT01950312|Experimental|gevokizumab|Solution for subcutaneous injection
16700040|NCT01950299|Experimental|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
16700041|NCT01950299|Experimental|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
16700042|NCT01950299|Placebo Comparator|Placebo|Placebo for 14 days
16700043|NCT01950273|Experimental|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
16700044|NCT01950273|Active Comparator|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
16700045|NCT01950260|Experimental|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
16700046|NCT01950260|Placebo Comparator|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
16700047|NCT01950247|Experimental|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
16700048|NCT01950247|Active Comparator|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
16700049|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
16700050|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
16700051|NCT01950221|Experimental|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
16700052|NCT01950221|Placebo Comparator|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
16700053|NCT01950208||knee pain|patients suffering from knee injury
16700054|NCT01950195|Experimental|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.
~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.
~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
16700055|NCT01950195|Experimental|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.
~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.
~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
16700056|NCT01950182|Active Comparator|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
16700057|NCT01950182|Experimental|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
16701058|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
16700058|NCT01950169|Active Comparator|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
16700059|NCT01950169|Active Comparator|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
16700060|NCT01950169|Active Comparator|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
16700061|NCT01950156|Experimental|Vaccine|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
16700062|NCT01950143|Active Comparator|Standard broccoli soup|26 volunteers
16700063|NCT01950143|Experimental|Beneforte broccoli soup|26 volunteers
16700064|NCT01950143|Experimental|Beneforte extra broccoli soup|26 volunteers
16700065|NCT01950130|Experimental|IABP group|Preoperative IABP insertion
16700066|NCT01950130|No Intervention|Control group|Preoperative conservative treatment
16700067|NCT01950117|Active Comparator|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
16700068|NCT01950117|Experimental|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
16700069|NCT01950104|Active Comparator|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
16700070|NCT01950104|Experimental|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
16700071|NCT01950091|Experimental|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
16700072|NCT01950091|Active Comparator|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
16700073|NCT01950091|No Intervention|Usual care control group|No contact; Control group
16700074|NCT01950078||surgical patients|grouped by receiving surgery
16700075|NCT01950078||Healthy volunteers group|grouped by healthy college students
16700076|NCT01950065|Experimental|Immediate Treatment with iovera|Immediate treatment with iovera
16700077|NCT01950065|Active Comparator|Delayed Treatment with iovera|Delayed Treatment with iovera
16700078|NCT01950052|No Intervention|Control group|No special diet, patients will continue with a normal diet
16700079|NCT01950052|Experimental|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
16700080|NCT01950039|Active Comparator|Betaine|
16700081|NCT01950039|Placebo Comparator|Placebo|
16700082|NCT01950026|Experimental|white|cryotherapy application
16700083|NCT01950026|Experimental|black|cryotherapy application
16700084|NCT01950026|Experimental|Brown|cryotherapy application
16700085|NCT01950026|Experimental|asian|cryotherapy application
16700086|NCT01950013|No Intervention|Passive Control|Hearing aid alone
16700087|NCT01950013|Experimental|Training|Auditory Training Program. Hearing aid plus auditory training
16700088|NCT01950013|Sham Comparator|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
16700089|NCT01950000|Placebo Comparator|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
16700090|NCT01950000|Experimental|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.
~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).
~Pharmaceutical form:
~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
16700091|NCT01949987|Active Comparator|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
16700092|NCT01949987|Experimental|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
16700093|NCT01949974|Experimental|Integral Attention Program (PAI)|"The key points of the PAI are:
~To assess and manage pain and other symptoms resulting from disease progression.
~To evaluate the information needs that may arise and to address them.
~To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.
~To provide guidance in decision-making while respecting patient autonomy.
~To establish a plan of care and treatment, adapted to the evolution and needs of the patient.
~To promote continuity of care."
16700094|NCT01949974|Active Comparator|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
16700095|NCT01949961|Active Comparator|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
16700194|NCT01949337|Experimental|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
16700096|NCT01949961|Placebo Comparator|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
16700097|NCT01949948|Active Comparator|Tenecteplase|0.4 mg/kg single bolus intravenously
16700098|NCT01949948|Active Comparator|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
16700099|NCT01949935|Placebo Comparator|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
16700100|NCT01949935|Experimental|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
16700101|NCT01949922|Experimental|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
16700102|NCT01949909|Experimental|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
16700103|NCT01949909|Experimental|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
16700104|NCT01949909|Placebo Comparator|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
16700105|NCT01949909|Experimental|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
16700106|NCT01949909|Experimental|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
16700107|NCT01949909|Experimental|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
16700108|NCT01949909|Experimental|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
16700109|NCT01949896|Other|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.
~Pro-inflammatory cytokine response will be monitored at 3 times points."
16700110|NCT01949896|Other|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.
~Pro-inflammatory cytokine response will be monitored at 3 times points."
16700111|NCT01949883|Experimental|CPI-0610|
16700112|NCT01949870|Other|Selumetinib|25mg/day, 50mg/day and 75mg/day
16700113|NCT01949857|Experimental|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-15 years \6.50 lgCCID50/ml in adults aged 16 up to 65 years old
16700114|NCT01949857|Experimental|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
16700115|NCT01949857|Experimental|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
16700116|NCT01949857|Experimental|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
16700117|NCT01949844|Other|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:
~Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,
~Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.
~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
16700118|NCT01949831|No Intervention|Control|Usual care
16700119|NCT01949831|Experimental|Functional assessment|Assessment of functional ability in combination with follow-up at home
16700120|NCT01949818|Experimental|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
16700121|NCT01949818|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
16700122|NCT01949805|Active Comparator|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
16700123|NCT01949805|Experimental|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
16700124|NCT01949792|Active Comparator|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
16700125|NCT01949792|Active Comparator|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
16700126|NCT01949779||TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
16700127|NCT01949753|Experimental|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
16700128|NCT01949753|Placebo Comparator|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
16700129|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
16700311|NCT01948622|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
16700130|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.
~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
16700131|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
16700132|NCT01949714||Incidentaloma patients|Incidentaloma patients
16700133|NCT01949701|Experimental|Vaccine|HLA-A*0201restricted URLC10 peptides
16700134|NCT01949688|Experimental|HLA-A*2402 restricted peptides|HLA-A*2402 restricted peptides with adjuvant
16700135|NCT01949688|Experimental|HLA-A*0201 restricted peptides|HLA-A*0201 restricted peptides with adjuvant
16700136|NCT01949675|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
16700137|NCT01949675|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
16700138|NCT01949675|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
16700139|NCT01949662|Experimental|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
16700140|NCT01949662|Active Comparator|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
16700141|NCT01949649|Active Comparator|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
16700142|NCT01949649|Active Comparator|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
16700143|NCT01949649|Active Comparator|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
16700144|NCT01949649|Active Comparator|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
16700145|NCT01949636||lean adolescents|
16700146|NCT01949623||RP patients|Retinitis Pigmentosa patients
16700147|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
16700148|NCT01949610|Experimental|14C-JNJ26489112|
16700149|NCT01949597||Patients with symptomatic endometriosis|
16700150|NCT01949571|Experimental|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
16700151|NCT01949558|No Intervention|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
16700152|NCT01949558|Experimental|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
16700153|NCT01949545|Experimental|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
16700154|NCT01949545|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin > 1-1.5 x ULN or AST > ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
16700155|NCT01949545|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin > 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
16700156|NCT01949545|Experimental|Severe Hepatic Impairment|(Bilirubin > 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin > 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
16700257|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
16700157|NCT01949532|Experimental|Normal Renal Function|Participants with normal renal function (creatinine clearance [CrCl] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
16700158|NCT01949532|Experimental|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
16700159|NCT01949519|Experimental|Docetaxel and Lycopene|
16700160|NCT01949506|Other|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with > 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for >5 fraction treatment schedules.
16700161|NCT01949493|Other|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
16700162|NCT01949493|Experimental|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
16700163|NCT01949480|Active Comparator|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
16700164|NCT01949480|Experimental|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
16700165|NCT01949467|Other|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
16700166|NCT01949467|Other|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
16700167|NCT01949467|Other|TFPD|20 patients with treated Ferroportin Disease (TFPD)
16700168|NCT01949467|Other|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
16700169|NCT01949467|Other|HV|20 Healthy volunteers (HV) patients
16700170|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
16700171|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt bid x4 weeks|
16700172|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
16700173|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x4 weeks|
16700174|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
16700175|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x8 weeks|
16700176|NCT01949441|Experimental|ToleroMune HDM|
16700177|NCT01949441|Placebo Comparator|Placebo|
16700178|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
16700179|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
16700180|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio <70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
16700181|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
16700182|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
16700183|NCT01949389|Experimental|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
16700184|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
16700185|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
16700186|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
16700187|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
16700188|NCT01949376||Controls|healthy, cognitively normal subjects
16700189|NCT01949363|Experimental|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
16700190|NCT01949363|Experimental|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
16700191|NCT01949350|Active Comparator|Carbohydrate|CHO loaded test:
16700192|NCT01949350|Active Comparator|Carbohydrate protein|CHO-P loaded test:
16700193|NCT01949350|Active Comparator|Water|Starved as for surgery
16700195|NCT01949337|Experimental|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
16700196|NCT01949324|Experimental|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
16700197|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
16700198|NCT01949311|Experimental|Dupilumab|Participants will receive repeat doses of dupilumab
16700199|NCT01949298|Experimental|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
16700200|NCT01949298|Active Comparator|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
16700201|NCT01949285|Sham Comparator|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.
~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
16700202|NCT01949285|Active Comparator|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.
~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
16700203|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
16700204|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
16700205|NCT01949246||CRT patients|Patients undergoing CRT device implantation
16700206|NCT01949246||Healthy patients|Healthy controls
16700207|NCT01949233|Experimental|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
16700208|NCT01949233|Experimental|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
16700209|NCT01949233|Experimental|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
16700210|NCT01949233|Placebo Comparator|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
16700211|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
16700212|NCT01949207|Experimental|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
16700213|NCT01949207|Experimental|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
16700214|NCT01949194|Experimental|Regorafenib|Single-agent regorafenib
16700215|NCT01949181|Experimental|Pulmonary cancer|
16700216|NCT01949168|Active Comparator|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
16700217|NCT01949168|Active Comparator|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
16700218|NCT01949168|Active Comparator|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
16700219|NCT01949155|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:
~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
16700220|NCT01949155|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:
~One sham injection into each ear during surgery."
16700221|NCT01949142|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:
~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
16700222|NCT01949142|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:
~One sham injection into each ear during surgery."
16700223|NCT01949129|Experimental|Flu/Thio/Treo|"Fludarabine/Thiotepa/Treosulfan is for conditioning before HSCT from MSD or MD. ATG Thymo or Grafalon is used for patients who receive stem cells from unrelated donors.
~Fludarabine/Thiotepa/Treosulfan with either ATG Thymo or Grafalon is also used for HSCT from MMD with in vitro T-Cell Depletion (TCD) or with CD34+ selection.
~Fludarabine/Thiotepa/Treosulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
16700224|NCT01949129|Active Comparator|TBI/VP16|"TBI (Total Body Irradiation) / VP16 is used for conditioning for HSCT with MSD or MD graft with patients who are older than 48 months at the time of conditioning.
~TBI/VP16 is also used with Post TX-Cyclophosphamide for MMD-graft without in vitro T-Cell Depletion.
~TBI/VP16 with either ATG Thymo or Grafalon is used for MMD-HSCT with in vitro T-Cell Depletion or with CD34+ selection."
16700225|NCT01949129|Experimental|Flu/Thio/ivBu|"Fludarabine/Thiotepa/iV Busulfan is used for conditioning before HSCT from MSD or MD.
~Fludarabine/Thiotepa/iBu with either ATG Thymo or Grafalon is also used for HSCT from MMD-HSCT with T-Cell Depletion (TCD) or haplo with CD34+ selection.
~Fludarabine/Thiotepa/iV Busulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
16700226|NCT01949116|Experimental|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
16700227|NCT01949116|Placebo Comparator|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
16700228|NCT01949103|Experimental|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
16700229|NCT01949103|Experimental|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
16700230|NCT01949103|Experimental|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
16700231|NCT01949103|Experimental|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
16700232|NCT01949103|Experimental|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
16700233|NCT01949103|Experimental|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
16700234|NCT01949090|Experimental|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
16700235|NCT01949090|Experimental|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
16700236|NCT01949090|Experimental|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
16700237|NCT01949090|Experimental|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
16700238|NCT01949090|Placebo Comparator|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
16700239|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
16700240|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
16700241|NCT01949064|Active Comparator|Michigan-type occlusal splint|Occlusal splint, Michigan-type
16700242|NCT01949064|Active Comparator|Grindcare|Biofeedback device
16700243|NCT01949051|Experimental|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
16700244|NCT01949038|Placebo Comparator|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
16700245|NCT01949038|Placebo Comparator|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
16700246|NCT01949038|Active Comparator|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
16700247|NCT01949038|Active Comparator|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
16700248|NCT01949025|Experimental|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
16700249|NCT01949025|No Intervention|Control group|
16700250|NCT01949012|No Intervention|Control|Standard monitoring
16700251|NCT01949012|Experimental|Capnography|Standard monitoring and capnography
16700252|NCT01948999|Active Comparator|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
16700253|NCT01948999|Sham Comparator|SHAM ECT|Anesthesia and concomitant muscular paralysis
16700254|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Normal Renal Function)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
16700255|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
16700256|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
16700308|NCT01948648|Active Comparator|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
16700258|NCT01948986|Experimental|Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)|Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
16700259|NCT01948973|Active Comparator|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
16700260|NCT01948973|Active Comparator|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
16700261|NCT01948960|No Intervention|standard care|everolimus dose is continued independently of everolimus AUC
16700262|NCT01948960|Active Comparator|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
16700263|NCT01948947|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
16700264|NCT01948947|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
16700265|NCT01948934|Experimental|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
16700266|NCT01948921|Placebo Comparator|placebo|1 ml normal saline will be given 5 minutes before EGD
16700267|NCT01948921|Active Comparator|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
16700268|NCT01948908|Experimental|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
16700269|NCT01948908|Experimental|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
16700270|NCT01948908|Experimental|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
16700271|NCT01948895|Experimental|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
16700272|NCT01948882|Experimental|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
16700273|NCT01948869|Experimental|Phoenix II|Application over 29 days twice daily
16700274|NCT01948869|Active Comparator|Phoenix I|Application over 29 days twice daily
16700275|NCT01948869|No Intervention|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
16700276|NCT01948856|Experimental|J022X ST|
16700277|NCT01948856|Placebo Comparator|Placebo|
16700278|NCT01948843|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
16700279|NCT01948830|Active Comparator|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
16700280|NCT01948830|Active Comparator|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
16700281|NCT01948817|Experimental|Deferasirox|Deferasirox 20mg/kg taken BID
16700282|NCT01948804|Experimental|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
16700283|NCT01948791|Experimental|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
16700284|NCT01948778|Experimental|oXiris™ filter|oXiris™ filter
16700285|NCT01948778|Experimental|Toraymyxin Filter|Toraymyxin Filter
16700286|NCT01948778|Other|Standard of Care|Standard of Care CRRT if necessary
16700287|NCT01948765|Active Comparator|Xenon and propofol|
16700288|NCT01948765|Placebo Comparator|propofol|
16700289|NCT01948752|No Intervention|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
16700290|NCT01948752|Experimental|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
16700291|NCT01948752|Experimental|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
16700292|NCT01948752|Experimental|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
16700293|NCT01948739|Experimental|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
16700294|NCT01948726|Experimental|Hypofractionation with SIB|
16700295|NCT01948713|Experimental|Group 1|Strengthening of pelvic floor muscles.
16700296|NCT01948713|Experimental|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
16700297|NCT01948700|Other|Brief Intervention|Motivational Interviewing (MI)
16700298|NCT01948700|Other|Standard Intervention|Education
16700299|NCT01948687||1. the control group|healthy adult volunteers
16700300|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
16700301|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
16700302|NCT01948674|Experimental|computerized tasks- adaptive|
16700303|NCT01948674|Active Comparator|computerized tasks - nonadaptive|
16700304|NCT01948661|Experimental|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
16700305|NCT01948661|Placebo Comparator|placeboA + placeboB|placeboA + placeboB per day for four weeks
16700306|NCT01948648|Active Comparator|Colesevelam|3.75g/day for 6 weeks
16700307|NCT01948648|Active Comparator|Fish Oil|1g/day for 6 weeks
16700312|NCT01948622|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
16700313|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
16700314|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
16700315|NCT01948596|Experimental|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
16700316|NCT01948583|Active Comparator|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).
~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
16700317|NCT01948583|Active Comparator|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).
~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
16700318|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
16700319|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
16700320|NCT01948557|Other|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
16700321|NCT01948544||chronic obstructive pulmonary disease|"More than 12 million adults are diagnosed with COPD
~COPD is the 4th leading cause of death in the U.S.
~Breathing difficulty is the major reason patients seek medical attention
~COPD patients requiring hospitalization were associated with higher costs
~Oximetry is an important tool for assessing need for Long-term oxygen therapy
~LTOT has been proven to improve survival and quality of life
~Patients will be provided a lightweight portable oxygen concentrator to:
~support increased activity
~improve quality of life
~increase functional capacity"
16700322|NCT01948531|Experimental|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
16700323|NCT01948518|Experimental|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
16700324|NCT01948505|Active Comparator|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
16700325|NCT01948505|Placebo Comparator|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
16700326|NCT01948492|Experimental|protein|varying protein intake in random order from deficient to excess
16700327|NCT01948479|Experimental|Insole optimised with inshoe analysis|
16700328|NCT01948479|Active Comparator|Routine insole provision|
16700329|NCT01948466|Experimental|Commercials|Schools Administered Commercials
16700330|NCT01948466|No Intervention|Control|Schools not Administered Commercials
16700331|NCT01948453|Active Comparator|Garlic|daily consumption of two odor controlled garlic tablets
16700332|NCT01948453|Placebo Comparator|Placebo|daily consumption of placebo
16700333|NCT01948440|Experimental|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
16700334|NCT01948440|No Intervention|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
16700335|NCT01948414|Other|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
16700336|NCT01948414|Other|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
16700337|NCT01948414|Other|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
16700338|NCT01948401|Experimental|Controlled asthma|
16700339|NCT01948401|Experimental|Uncontrolled asthma with additional OCS|
16700340|NCT01948401|Experimental|Uncontrolled asthma without additional OCS|
16700341|NCT01948388|Active Comparator|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
16700342|NCT01948388|Active Comparator|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
16700343|NCT01948375|Experimental|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
16700344|NCT01948375|Experimental|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
16700345|NCT01948362|Active Comparator|Sulforadex|Active compound
16700346|NCT01948362|Experimental|alpha Cyclodextrin|Placebo control arm
16700347|NCT01948349|No Intervention|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique [31], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
16701059|NCT01943318||Autoimmune|Autoimmune Cirrhosis
16700348|NCT01948349|Experimental|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
16700349|NCT01948349|Experimental|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
16700350|NCT01948349|Experimental|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
16700351|NCT01948336|Placebo Comparator|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
16700352|NCT01948336|Active Comparator|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
16700353|NCT01948323|Other|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info
~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
16700354|NCT01948323|No Intervention|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
16700355|NCT01948310|Active Comparator|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
16700356|NCT01948310|Placebo Comparator|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
16700357|NCT01948297|Experimental|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
16700358|NCT01948297|Experimental|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
16700359|NCT01948284|Active Comparator|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
16700360|NCT01948284|Active Comparator|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
16700361|NCT01948271|Experimental|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
16700362|NCT01948258|Other|Clearblue Advanced Fertility Monitor|Use of Clearblue Fertility Monitor
16700363|NCT01948245|Active Comparator|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.
~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
16700364|NCT01948245|Placebo Comparator|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.
~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
16700365|NCT01948232|Experimental|Perindopril|
16700366|NCT01948219|Experimental|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
16700367|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(>=150ms) QRS duration
16700368|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(<150ms) QRS duration
16700369|NCT01948193|Experimental|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
16700485|NCT01947413|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
16700370|NCT01948180|Experimental|baltaleucel-T|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.
~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
16700371|NCT01948167|Experimental|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
16700372|NCT01948167|Experimental|Coping with Stress|Coping with Stress
16700373|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
16700374|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
16700375|NCT01948141|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16700376|NCT01948128|Experimental|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
16700377|NCT01948128|Placebo Comparator|Placebo|Placebo taken daily by mouth
16700378|NCT01948115|Placebo Comparator|Medical air|
16700379|NCT01948115|Experimental|equimolar mixture of oxygen and nitrous oxide|
16700380|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
16700381|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
16700382|NCT01948089|Experimental|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
16700383|NCT01948089|Experimental|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
16700384|NCT01948076|Placebo Comparator|resident without GE vscan|baseline physical exam use
16700385|NCT01948076|Active Comparator|resident with GE vscan|residents with augmentation of physical exam by ultrasound
16700386|NCT01948063|Placebo Comparator|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
16700387|NCT01948063|Experimental|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
16700388|NCT01948050|Experimental|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
16700389|NCT01948050|Sham Comparator|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
16700390|NCT01948037|Active Comparator|hydrotherapy|
16700391|NCT01948037|Other|hot spring|30-minutes/per day;4weeks
16700392|NCT01948024|Active Comparator|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
16700393|NCT01948024|Experimental|Test Arm - Asenapine|10 mg BID sublingual tablet
16700394|NCT01948011|Experimental|Racecadotril 10mg suspension|single oral dose
16700395|NCT01948011|Experimental|Racecadotril 30mg suspension|single oral dose
16700396|NCT01948011|Experimental|Racecadotril 60mg suspension|single oral dose
16700397|NCT01948011|Active Comparator|Racecadotril 60mg granules|single oral dose
16700398|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
16700399|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
16700400|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
16700401|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
16700402|NCT01947972|Other|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
16700405|NCT01947946|Experimental|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
16700406|NCT01947946|Experimental|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
16700407|NCT01947946|Placebo Comparator|Placebo|A (Dummy) injection
16700408|NCT01947933|Placebo Comparator|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
16700409|NCT01947933|Experimental|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
16700410|NCT01947933|Experimental|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
16700411|NCT01947920|Experimental|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
16700412|NCT01947920|Experimental|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
16700486|NCT01947400||Hospitalists|AIDET Training
16700487|NCT01947387||Integra|
16700413|NCT01947920|Experimental|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
16700414|NCT01947907|Experimental|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
16700415|NCT01947907|Experimental|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
16700416|NCT01947907|Experimental|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
16700417|NCT01947907|Active Comparator|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
16700418|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
16700419|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
16700420|NCT01947855|Experimental|Empagliflozin low dose|Empagliflozin low dose tablet once daily
16700421|NCT01947855|Experimental|Empagliflozin high dose|Empagliflozin high dose tablet once daily
16700422|NCT01947855|Placebo Comparator|Placebo|Placebo tablet once daily
16700423|NCT01947842|Experimental|Smartphone App|The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.
16700424|NCT01947842|No Intervention|Counseling Alone|This arm will receive only counseling from the pharmacist with no other intervention.
16700425|NCT01947829||Chronic Hemodialysis|
16700426|NCT01947816||Humira|Humira 40 mg (marketed product) eow for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration, for up to 52 weeks.
16700427|NCT01947803|Experimental|Paliperidone Palmitate|
16700428|NCT01947790|Experimental|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
16700429|NCT01947790|Active Comparator|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
16700430|NCT01947764|No Intervention|Usual Care|"The Usual Care components for the control clinics will include the following:
~All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training
~Chart materials to guide and document disclosure counseling and visits
~The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.
~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
16700431|NCT01947764|Experimental|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:
~Modified materials to guide disclosure sessions
~Videotaped narratives for parental counseling
~Dedicated disclosure counselors to initiate and conduct the disclosure process
~Post-disclosure support groups for children
~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
16700432|NCT01947751|Active Comparator|CVC exchange|The CVC will be removed immediately.
16700433|NCT01947751|Experimental|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
16700434|NCT01947738|Experimental|VBY-891|VBY-891
16700435|NCT01947738|Placebo Comparator|Placebo|Capsules containing excipient but no active drug
16700436|NCT01947712|Placebo Comparator|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
16700437|NCT01947712|Active Comparator|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
16700438|NCT01947699|Experimental|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
16700439|NCT01947699|Experimental|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
16700440|NCT01947699|Experimental|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
16700441|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
16700442|NCT01947673|Experimental|Modified Mindfulness Based Stress Reduction (MBSR) Program|After individual instruction, participants in this arm will perform meditation by following a series of mindfulness meditation (MM) recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using a digital audio (MP3) player at home on non-dialysis days, and asked to keep a log of these sessions.
16700443|NCT01947673|Placebo Comparator|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
16700444|NCT01947660|Experimental|Continuous regional anesthesia|
16700445|NCT01947660|Active Comparator|Systemic analgesia|
16700446|NCT01947647|Experimental|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
16700488|NCT01947387||Integra + NPWT (short-inpatient use only)|
16700489|NCT01947387||Integra + NPWT (long-all other durations)|
16700490|NCT01947387||Integra + STSG|
16700491|NCT01947387||Integra + Dermoinductive Agent|
16700447|NCT01947647|Active Comparator|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
16700448|NCT01947634|Experimental|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
16700449|NCT01947595|Active Comparator|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~A+B or A+C or B+C or A+B+C"
16700450|NCT01947595|Active Comparator|hight risk non responder, normal lifestyle intervention|"high risk non-responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~A+B or A+C or B+C or A+B+C"
16700451|NCT01947595|Active Comparator|Responder, normal lifestyle intervention|"Responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~No A, only B or C"
16700452|NCT01947595|Active Comparator|Responder, single lifestyle advice (control group)|"Responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~No A, only B or C"
16700453|NCT01947582|Other|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
16700454|NCT01947569|Experimental|iDC recipients|iDC cells modified by in vitro engineering.
16700455|NCT01947569|Active Comparator|Control DC recipients|DC cells which have not been modified.
16700456|NCT01947569|Placebo Comparator|Placebo recipients|Saline injections.
16700457|NCT01947556|Other|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
16700458|NCT01947556|Other|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
16700459|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
16700460|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
16700461|NCT01947530|Active Comparator|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
16700462|NCT01947530|Active Comparator|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
16700463|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
16700464|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
16700465|NCT01947504|Experimental|education and support intervention|education and support intervention
16700466|NCT01947504|No Intervention|waiting list|waiting list and regular medical follow-up
16700467|NCT01947491|Experimental|DFD01 Spray|DFD01 Spray twice daily for 28 days
16700468|NCT01947491|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily for 28 days
16700469|NCT01947491|Active Comparator|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
16700470|NCT01947491|Placebo Comparator|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
16700471|NCT01947478|Experimental|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
16700472|NCT01947478|Active Comparator|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
16700473|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
16700474|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
16700475|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
16700476|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
16700477|NCT01947452|Experimental|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
16700478|NCT01947452|Experimental|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
16700479|NCT01947439|Experimental|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
16700480|NCT01947439|Active Comparator|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
16700481|NCT01947426|Experimental|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
16700482|NCT01947426|Placebo Comparator|Control (milk without DHA)|Mothers comsuming placebo and their neonates
16700483|NCT01947413|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
16700484|NCT01947413|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
16700492|NCT01947387||Free Flap|
16700496|NCT01947374|Experimental|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
16700497|NCT01947374|Experimental|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
16700498|NCT01947348|Experimental|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
16700499|NCT01947335|No Intervention|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
16700500|NCT01947335|Active Comparator|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
16700501|NCT01947322|Experimental|Allogenic NK cells infusion|
16700502|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
16700503|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
16700504|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
16700505|NCT01947283|Experimental|Intervention Patients & Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.
~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.
~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers.
~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
16700506|NCT01947283|Experimental|Intervention Patients, Control Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.
~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.
~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
16700507|NCT01947283|No Intervention|Control Patients, Intervention Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.
~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.
~Control patients will receive a pamphlet called Managing Your Mental Health Care. For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
16700508|NCT01947283|No Intervention|Control Patients & Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.
~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.
~Control patients will receive a pamphlet called Managing Your Mental Health Care."
16700509|NCT01947283|No Intervention|Non-Randomized Controlled Trial Patients|Participants in this arm are patients who did not participate in the Randomized Controlled Trial. One to two patients will be recruited for each enrolled provider (Control and Intervention). One clinical session per patient will be audio recorded. These clinical recordings will be used to provide feedback only for Intervention providers during part 1 of the DECIDE-PC intervention.
16700510|NCT01947283|No Intervention|Control Providers|Participants in this arm are providers who were randomized to the Control group. Control providers will not receive the DECIDE-PC intervention.
16700511|NCT01947283|Experimental|Intervention Providers|Participants in this arm are providers who were randomized to the Intervention group. Intervention providers will receive the DECIDE-PC intervention. The DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.
16700512|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
16700513|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
16700514|NCT01947257|Other|ventilated patients|
16700515|NCT01947244|Experimental|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
16700516|NCT01947244|Active Comparator|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
16700517|NCT01947231|Experimental|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
16700518|NCT01947231|Active Comparator|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
16700519|NCT01947218|Experimental|smoking COPD|
16700520|NCT01947218|Experimental|smoking without COPD|
16700521|NCT01947218|Other|No Smoking Control|
16700522|NCT01947218|Experimental|severe asthma|
16700523|NCT01947205|Active Comparator|paracetamol|Duration
16700524|NCT01947205|Active Comparator|without drug|Control group
16700525|NCT01947205|Active Comparator|dexketoprofen trometamol|Study group
16700526|NCT01947205|Active Comparator|two puff xylocain administration on cervical surface|Study group
16700527|NCT01947205|Active Comparator|paracervical block with ultracaine|study group
16700528|NCT01947192|Experimental|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
16700529|NCT01947192|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching.
16700530|NCT01947179|No Intervention|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
16700531|NCT01947179|Experimental|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
16700532|NCT01947153|Experimental|Fixed dose combination|Linagliptin/Metformin
16700533|NCT01947153|Experimental|Free combination|Linagliptin and Metformin
16700534|NCT01947140|Experimental|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
16700535|NCT01947140|Experimental|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
16700536|NCT01947140|Experimental|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
16700537|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
16700538|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
16700539|NCT01947114|Active Comparator|Group Propofol|
16700540|NCT01947114|Active Comparator|Group Ketamine|
16700541|NCT01947101|Experimental|Ulcerative Colitis|Fecal Microbiota Transplant
16700542|NCT01947088|Experimental|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
16700543|NCT01947088|Active Comparator|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
16700544|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
16700545|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
16700546|NCT01947062|Active Comparator|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
16700547|NCT01947062|Experimental|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
16700548|NCT01947049|No Intervention|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
16700549|NCT01947049|Experimental|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
16700550|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
16700551|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
16700552|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
16700553|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
16700554|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
16700555|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
16700556|NCT01947023|Experimental|Treatment (lapatinib, dabrafenib)|"Patients receive dabrafenib* PO BID on days 1-28 and lapatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib."
16700557|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
16700558|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
16700559|NCT01947010|Active Comparator|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
16700560|NCT01946997||Group 1: Non Diabetic|Normal retina
16700561|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
16700562|NCT01946984|Active Comparator|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
16700563|NCT01946984|Placebo Comparator|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
16700564|NCT01946971|Experimental|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
16700565|NCT01946971|Experimental|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
16700566|NCT01946958|Experimental|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
16700567|NCT01946958|Experimental|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
16700568|NCT01946945|No Intervention|Control - Standard ART treatment|
16700569|NCT01946945|Experimental|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
16700571|NCT01946932|Active Comparator|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
16700572|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
16700573|NCT01946906|No Intervention|No treatment|patient receive no active treatment
16700574|NCT01946906|Experimental|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
16700575|NCT01946893|Experimental|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
16700576|NCT01946893|Active Comparator|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
16700577|NCT01946880|Experimental|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
16700578|NCT01946880|Active Comparator|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
16700579|NCT01946867|Experimental|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
16700580|NCT01946854|Other|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
16700581|NCT01946854|Active Comparator|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
16700582|NCT01946841|Experimental|RealDiet®Renal enteral nutrition|
16700583|NCT01946828|Experimental|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
16700584|NCT01946815|Experimental|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
16700585|NCT01946802||Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
16700586|NCT01946789|Experimental|ALT-803|
16700587|NCT01946776|Other|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
16700588|NCT01946763|No Intervention|safety of Anesthesia|No pre operative education
16700589|NCT01946763|Experimental|Behavioral : pre operative education|Behavioral pre operative education
16700590|NCT01946750|Experimental|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
16700591|NCT01946750|Other|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
16700592|NCT01946737|Active Comparator|Invasive coronary angiography (ICA)|Routine diagnostic ICA
16700593|NCT01946737|Experimental|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
16700594|NCT01946711|Experimental|Buparid; Treatment A|Buparid 1 mg budesonide/2 ml nebuliser solution
16700595|NCT01946711|Active Comparator|Budes; Treatment B|Budes® Nasal Spray 50 µg budesonide/pump
16700596|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
16700597|NCT01946672|Experimental|isotopic intraoperative detection|Lower-limb drainage isotopic intraoperative detection
16700598|NCT01946659|Experimental|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
16700599|NCT01946659|Other|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
16700600|NCT01946646|Experimental|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
16700601|NCT01946633|Experimental|Esophagogastroduodenoscopy（ECG）|n=15
16700602|NCT01946620|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
16700603|NCT01946620|Experimental|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
16700604|NCT01946620|Active Comparator|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
16700605|NCT01946607|Active Comparator|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
16700606|NCT01946607|Placebo Comparator|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
16700607|NCT01946594|Active Comparator|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:
~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
16700608|NCT01946594|Placebo Comparator|Placebo Arm|"Placebo Suspension:
~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
16700609|NCT01946581||Cataract Surgery|
16700610|NCT01946568|Experimental|Single dose Dalbavancin|
16700645|NCT01946308|Experimental|conformational positioner & mattress|conformational positioner & mattress, five hours on each
16700646|NCT01946295|Experimental|Famotidine|Famotidine 100mg x 2 orally
16700647|NCT01946295|Placebo Comparator|Placebo|Placebo control
16700681|NCT01946035|Experimental|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
16700682|NCT01946022|Active Comparator|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
16700611|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
16700612|NCT01946542|Placebo Comparator|placebo|placebo drink, single dose, taste and color-matched to experimental drink
16700613|NCT01946542|Experimental|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
16700614|NCT01946529|Active Comparator|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
16700615|NCT01946529|Active Comparator|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
16700616|NCT01946503||Short bowel syndrome|Patients followed in a clinic for short bowel syndrome
16700617|NCT01946503||Healthy controls|Patients seen in a general pediatric clinic without chronic or acute diseases
16700618|NCT01946490||Radiotherapy in 2001|
16700619|NCT01946490||Radiotherapy in 2004|
16700620|NCT01946490||Radiotherapy in 2006|
16700621|NCT01946490||Radiotherapy in 2010|
16700622|NCT01946477|Experimental|Pomalidomide + dexamethasone|Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
16700623|NCT01946477|Experimental|Pomalidomide + Dexamethasone + Daratumumab|"Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/ day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:
~Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2
~Days 1 and 15 for Cycle 3 through Cycle 6
~Day 1 for Cycle 7 and each cycle thereafter until disease progression"
16700624|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
16700625|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
16700626|NCT01946451||Idiophatic ERMs|
16700627|NCT01946451||Secondary ERMs|
16700628|NCT01946438|Experimental|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
16700629|NCT01946438|Experimental|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
16700630|NCT01946438|Experimental|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
16700631|NCT01946438|Experimental|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
16700632|NCT01946425|Experimental|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to < 36 months of age at enrollment
16700633|NCT01946425|Experimental|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to < 9 years of age at enrollment
16700634|NCT01946412|No Intervention|Observational Arm|
16700635|NCT01946412|Experimental|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:
~50 mg q12h for subjects 2 to <6 years of age and <14 kg,
~75 mg q12h for subjects 2 to <6 years of age and ≥ 14 kg, or
~150 mg q12h for subjects ≥ 6 years of age."
16700636|NCT01946399|Other|Ozurdex implant|Intravitreal injection of Ozurdex implant
16700637|NCT01946386|Experimental|LEO 90100|
16700638|NCT01946373|Experimental|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
16700639|NCT01946373|Experimental|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
16700640|NCT01946360|No Intervention|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
16700641|NCT01946347|Experimental|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
16700642|NCT01946347|Active Comparator|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
16700643|NCT01946334|Experimental|patients|
16700644|NCT01946321|Other|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
16700747|NCT01945567|Experimental|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
16700648|NCT01946282|Active Comparator|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.
~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.
~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
16700649|NCT01946282|Active Comparator|FIT plus $5 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.
~Intervention: FIT kits and invitation letter with a $5 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.
~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
16700650|NCT01946282|Active Comparator|FIT plus $10 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.
~Intervention: FIT kits and invitation letter with a $10 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.
~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
16700651|NCT01946269|Active Comparator|Standard group|
16700652|NCT01946269|Active Comparator|Goal-directed therapy (GDT) protocol|
16700653|NCT01946256|Active Comparator|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
16700654|NCT01946256|Placebo Comparator|Erythromycin|Erythromycin 500mg four times in a day for 1 week
16700655|NCT01946243|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
16700656|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
16700657|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
16700658|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
16700659|NCT01946191|Experimental|Coaching Group|"24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts
~Online self-monitoring
~Real-time updates to primary care physicians"
16700660|NCT01946191|Active Comparator|Tracking Group|-Online self-monitoring
16700661|NCT01946178|Experimental|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
16700662|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
16700663|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
16700664|NCT01946152|Experimental|Treatment (pomalidomide, dexamethasone, filgrastim-sndz)|"INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16700665|NCT01946139|Experimental|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
16700666|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
16700667|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
16700668|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
16700669|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
16700670|NCT01946100|Other|Multifocal Lung Adenocarcinoma|
16700671|NCT01946087|Experimental|RIPC group|
16700672|NCT01946087|Placebo Comparator|Control group|
16700673|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
16700674|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
16700675|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
16700676|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
16700677|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
16700678|NCT01946061|Experimental|Treatment group|
16700679|NCT01946048|Experimental|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
16700680|NCT01946035|Placebo Comparator|Placebo|Participants will take 1 capsule placebo each evening
16701060|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
16700683|NCT01946022|Active Comparator|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
16700684|NCT01946009|Experimental|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
16700685|NCT01945996|Active Comparator|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
16700686|NCT01945996|Experimental|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
16700687|NCT01945983|Active Comparator|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
16700688|NCT01945983|Placebo Comparator|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
16700689|NCT01945970|Experimental|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
16700690|NCT01945970|Active Comparator|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
16700691|NCT01945970|Placebo Comparator|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
16700692|NCT01945957|Experimental|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
16700693|NCT01945957|Experimental|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
16700694|NCT01945944|Placebo Comparator|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
16700695|NCT01945944|Experimental|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
16700696|NCT01945931|Experimental|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
16700697|NCT01945931|No Intervention|Control|Health workers in the control clusters will not have access to the Safe Delivery App
16700698|NCT01945918|Active Comparator|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
16700699|NCT01945918|Active Comparator|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
16700700|NCT01945918|Experimental|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
16700701|NCT01945905|Experimental|Extramural|Extramural medication delivery and supervision
16700702|NCT01945905|Active Comparator|Intramural|Intramural medication delivery and supervision
16700703|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.
~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
16700704|NCT01945879|Experimental|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
16700705|NCT01945866|Active Comparator|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
16700706|NCT01945866|Experimental|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
16700707|NCT01945853|Experimental|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
16700708|NCT01945840|Active Comparator|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
16701061|NCT01943318||Toxic|Medication related cirrhosis
16700709|NCT01945840|Experimental|Gut hormone infusion|"Infusion of three gut hormones (GLP-1, PYY and oxyntomodulin) subcutaneously for 4 weeks as below:
~Combination of GLP-1/OXM/PYY (GOP)
~Single GLP-1
~Single OXM
~Single PYY
~Combination of GLP-1 and OXM
~Combination of GLP-1 and PYY
~Combination of OXM and PYY"
16700710|NCT01945840|Placebo Comparator|Placebo infusion|Saline infusion given subcutaneously for 4 weeks.
16700711|NCT01945840|Active Comparator|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks.
16700712|NCT01945827||DeltaMaxx treated Patients|
16700713|NCT01945814|Experimental|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
16700714|NCT01945814|Experimental|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
16700715|NCT01945801|Active Comparator|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
16700716|NCT01945801|Placebo Comparator|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
16700717|NCT01945801|Active Comparator|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
16700718|NCT01945788|Active Comparator|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
16700719|NCT01945788|Experimental|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
16700720|NCT01945775|Experimental|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
16700721|NCT01945775|Active Comparator|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
16700722|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
16700723|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
16700724|NCT01945749|Experimental|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
16700725|NCT01945749|Active Comparator|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
16700726|NCT01945736||Cohort 1|> or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.
16700727|NCT01945736||Cohort 2|2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
16700728|NCT01945736||Cohort 3|6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
16700729|NCT01945723||Healthy volunteers|Healthy volunteers
16700730|NCT01945710|Experimental|Eribulin-LF Schedule 1|"Schedule 1: Eribulin-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2.
~Schedule 1a: Eribulin-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
16700731|NCT01945710|Experimental|Eribulin-LF Schedule 2|Schedule 2: Eribulin-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
16700732|NCT01945697||normal oral mucosa|
16700733|NCT01945697||oral precancerous lesion or oral cancer|
16700734|NCT01945684|Experimental|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
16700735|NCT01945684|Active Comparator|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
16700736|NCT01945645|Experimental|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
16700737|NCT01945632|No Intervention|no treatment|Control group with no treatment.
16700738|NCT01945632|Experimental|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
16700739|NCT01945632|Experimental|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
16700740|NCT01945632|Experimental|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
16700741|NCT01945606|Experimental|Placebo and BAY1067197|Patients will get both treatment 1 and 2
16700742|NCT01945593|Experimental|Fixed BAX855 prophylaxis|45-80 IU/kg twice weekly to once per week.
16700743|NCT01945593|Experimental|Pharmacokinetic (PK)-tailored BAX 855 prophylaxis|PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level
16700744|NCT01945580|Active Comparator|Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
16700745|NCT01945580|Active Comparator|Control|Prolapse Repair with Native Tissue Only
16700746|NCT01945567|Experimental|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
16700748|NCT01945567|Experimental|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
16700749|NCT01945554|Experimental|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
16700750|NCT01945554|Experimental|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
16700751|NCT01945541|No Intervention|standard fluid management|postoperative BMC measurements
16700752|NCT01945541|Active Comparator|body composition monitoring preoperative|pre and postoperative BCM measurements
16700753|NCT01945528|Experimental|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
16700754|NCT01945528|Active Comparator|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
16700755|NCT01945515|Experimental|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
16700756|NCT01945515|Sham Comparator|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
16700757|NCT01945502||nasal packing with dry packs|
16700758|NCT01945502||nasal packing with wet packs|
16700759|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
16700760|NCT01945502||no nasal packing|
16700761|NCT01945489|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
16700762|NCT01945489|Other|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
16700763|NCT01945476|Experimental|midazolam|midazolam group
16700764|NCT01945476|Active Comparator|normal saline|control group
16700765|NCT01945450|Active Comparator|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
16700766|NCT01945450|No Intervention|No treatment|No antibiotics
16700767|NCT01945437|Placebo Comparator|Control|Control group receive same volume of normal saline as in the magnesium group
16700768|NCT01945437|Experimental|magnesium|This group receive magnesium sulfate perioperatively.
16700769|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
16700770|NCT01945411|Experimental|Experimental|the length between incisor and mandible angle
16700771|NCT01945411|Active Comparator|Active comparator|the length between mouth corner-mandible angle
16700772|NCT01945398|Experimental|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
16700773|NCT01945398|Placebo Comparator|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
16700774|NCT01945385|Experimental|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
16700775|NCT01945385|No Intervention|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
16700776|NCT01945372|Experimental|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
16700777|NCT01945372|Sham Comparator|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
16700778|NCT01945359||Relapsing Remitting MS (RRMS)|
16700779|NCT01945346|Experimental|PRX167700|
16700780|NCT01945346|Placebo Comparator|Placebo|
16700781|NCT01945333|Active Comparator|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
16700782|NCT01945333|Active Comparator|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
16700783|NCT01945333|Active Comparator|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
16700784|NCT01945333|Active Comparator|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
16700785|NCT01945320||HD-BCM|"Patients at National Taiwan University Hospital
~Patients who have received HD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years"
16700786|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
16700787|NCT01945294|Experimental|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
16700788|NCT01945294|Experimental|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
16700831|NCT01944969|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
16700832|NCT01944943|Experimental|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
16700833|NCT01944930|Experimental|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
16700789|NCT01945294|Experimental|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
16700790|NCT01945281|Experimental|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
16700791|NCT01945281|Active Comparator|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
16700792|NCT01945268|Experimental|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
16700793|NCT01945268|Placebo Comparator|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
16700794|NCT01945255||HD-ABI|"Patients at National Taiwan University Hospital (NTUH)
~Patients who have received PD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years"
16700795|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
16700796|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
16700797|NCT01945216||Alogliptin 25mg, tablets, orally, once daily, up to 36 months|
16700798|NCT01945203||PD-ABI|"Patients at National Taiwan University Hospital (NTUH)
~Patients who have received PD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years."
16700799|NCT01945190|Experimental|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
16700800|NCT01945190|Experimental|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
16700801|NCT01945177|No Intervention|white light endoscopy|white light endoscopy
16700802|NCT01945177|Active Comparator|narrow band imaging|narrow band imaging
16700803|NCT01945151|Experimental|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
16700804|NCT01945138|No Intervention|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
16700805|NCT01945138|Experimental|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
16700806|NCT01945125|No Intervention|THW Group|Patients under THW stimulation for RIT
16700807|NCT01945125|Other|rhTSH Group|Patients under rhTSH stimulation for RIT
16700808|NCT01945112|Experimental|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
16700809|NCT01945099|Active Comparator|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
16700810|NCT01945099|Experimental|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
16700811|NCT01945099|Experimental|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
16700812|NCT01945086|Experimental|Ustekinumab 45 mg|
16700813|NCT01945086|Experimental|Ustekinumab 90 mg|
16700814|NCT01945086|Placebo Comparator|Placebo|
16700815|NCT01945073|No Intervention|Control (RC)|Routine clinical care with no intervention
16700816|NCT01945073|Experimental|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
16700817|NCT01945073|Experimental|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
16700818|NCT01945060|Experimental|heart rate Control to Range System (hrCTR) using DiAs Platform|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
16700819|NCT01945060|Placebo Comparator|DiAs Control-to-Range System not informed for heart rate|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
16700820|NCT01945047|Experimental|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
16700821|NCT01945047|Active Comparator|Midazolam|In phase 1 patients will be randomized to receive active placebo
16700822|NCT01945034|Experimental|Topical IBU twice daily|
16700823|NCT01945034|Placebo Comparator|Placebo twice daily|
16700824|NCT01945034|Experimental|Topical IBU three times daily|
16700825|NCT01945034|Placebo Comparator|Placebo three times daily|
16700826|NCT01945021|Experimental|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
16700827|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
16700828|NCT01944995|Experimental|group B|
16700829|NCT01944995|Experimental|group A|
16700830|NCT01944982|Experimental|Activated natural killer cells|Activated natural killer cells
16700834|NCT01944930|Experimental|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
16700835|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
16700836|NCT01944904|Placebo Comparator|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
16700837|NCT01944904|Active Comparator|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
16700838|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
16700839|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
16700840|NCT01944865|Experimental|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
16700841|NCT01944865|Experimental|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
16700842|NCT01944852|Experimental|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
16700843|NCT01944852|Active Comparator|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
16700844|NCT01944839|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
16700845|NCT01944839|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
16700846|NCT01944826||Tako-Tsubo And Cancer Registry|
16700847|NCT01944813|Experimental|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
16700848|NCT01944813|No Intervention|No intervention: usual care|No intervention just usual care
16700849|NCT01944800|Experimental|Ticagrelor|
16700850|NCT01944800|Active Comparator|Prasugrel|
16700851|NCT01944787|Active Comparator|Routine|IV Hydration at 125 cc hour
16700852|NCT01944787|Experimental|Intervention|IV Hydration at 250 cc hour
16700853|NCT01944774|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
16700854|NCT01944774|Experimental|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
16700855|NCT01944774|Active Comparator|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
16700856|NCT01944761|Experimental|Immediate Group|The 15 patients in this group will be randomized to start the 12 week exercise intervention without delay (immediate condition).
16700857|NCT01944761|Experimental|Delayed Intervention|The 15 patients in this group will be randomized to start the intervention after the first group has completed the exercise intervention (delayed condition)
16700858|NCT01944748|Experimental|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
16700859|NCT01944748|No Intervention|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
16700860|NCT01944735|Experimental|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
16700861|NCT01944735|Placebo Comparator|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
16700862|NCT01944722|Experimental|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
16700863|NCT01944696|Active Comparator|continuous (uninterrupted) phototherapy|standard phototherapy
16700864|NCT01944696|Experimental|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
16700865|NCT01944683|Experimental|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.
~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
16700866|NCT01944683|Placebo Comparator|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.
~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
16700867|NCT01944670|Experimental|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
16700868|NCT01944657|Active Comparator|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
16700869|NCT01944657|Active Comparator|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
16700870|NCT01944644|Active Comparator|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
16700871|NCT01944644|Sham Comparator|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
16700872|NCT01944631|Placebo Comparator|Placebo|Nasal spray 4 times a day over 4 to 10 days
16700873|NCT01944631|Experimental|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
16700874|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
16700875|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
16700876|NCT01944592|Experimental|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination with GTA's
16700877|NCT01944592|Active Comparator|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination on manikins.
16700878|NCT01944579|Experimental|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
16700879|NCT01944579|Experimental|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
16700880|NCT01944566|Experimental|heavy armpit odour|subjects with heavy armpit odour
16700881|NCT01944553|Experimental|prospective|Single Arm
16700882|NCT01944540|Active Comparator|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
16700883|NCT01944540|Experimental|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
16700884|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
16700885|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
16700886|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
16700887|NCT01944501|Active Comparator|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
16700888|NCT01944501|Placebo Comparator|Sham TMS|Patients receiving sham transcranial magnetic stimulation
16700889|NCT01944501|Active Comparator|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
16700890|NCT01944501|Placebo Comparator|Sham TDCS|Patients receiving sham transcranial direct current stimulation
16700891|NCT01944488|Experimental|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
16700892|NCT01944462|Experimental|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
16700893|NCT01944449|Experimental|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
16700894|NCT01944449|Experimental|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
16700895|NCT01944449|Active Comparator|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
16700896|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:
~Must be taking a stable parkinsonian medication
~Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.
~Response to cholinesterase inhibitor over a period of six months will be monitored."
16700897|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:
~Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.
~Response to cholinesterase inhibitor over a period of six months will be monitored."
16700898|NCT01944423|Experimental|PSRT_DCS|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
16700899|NCT01944423|Placebo Comparator|PSRT_PBO|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill placebo dose one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
16700900|NCT01944410|Experimental|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
16700901|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
16700902|NCT01944384|Experimental|aldactone|aldactone 25 mg for 6 months
16700903|NCT01944384|No Intervention|without aldactone|
16700904|NCT01944371|Experimental|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
16700905|NCT01944371|Experimental|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
16700906|NCT01944371|Experimental|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
16700907|NCT01944358||Taiwan AIDS study group|
16700960|NCT01944033|Active Comparator|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
16701062|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
16700908|NCT01944332|Experimental|gamete treatment- oocytes and sperm|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The injected oocytes will be then exposed to the previously mentioned activating agents for the purpose of inducing embryo development. The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI.
16700909|NCT01944319|Active Comparator|Control group|The participants in control group will accept routine meropenem therapy
16700910|NCT01944319|Experimental|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
16700911|NCT01944306||Low birth-weight, obese|
16700912|NCT01944306||Low birth-weight, normal body weight|
16700913|NCT01944306||Normal birth-weight, obese|
16700914|NCT01944306||Normal birth-weight, normal body weight|
16700915|NCT01944293|Experimental|Ketamine|0.5 mg/kg, I.V. (in the vein)
16700916|NCT01944293|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
16700917|NCT01944280|Experimental|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
16700918|NCT01944280|No Intervention|control|usual care
16700919|NCT01944267|Active Comparator|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
~Prepared surgical area will be measured apico-coronally and mesio-distally."
16700920|NCT01944267|Active Comparator|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.
~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
~No vertical incision made. Gingiva coronal to horizontal incision remains intact.
~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
16700921|NCT01944267|Active Comparator|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.
~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
16700922|NCT01944254|Active Comparator|random to respiration|Cardiac output measurement at random to respiration
16700923|NCT01944254|Experimental|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
16700924|NCT01944254|Experimental|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
16700925|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
16700926|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
16700927|NCT01944228|Experimental|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
16700928|NCT01944228|Sham Comparator|Sham stimulation|Catheter placed in the IJV without stimulation
16700929|NCT01944215|Active Comparator|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
16700930|NCT01944215|Active Comparator|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
16700961|NCT01944033|Experimental|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
16729123|NCT01753128|Active Comparator|imipramine|
16700931|NCT01944215|Active Comparator|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At ~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
16700932|NCT01944215|Active Comparator|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
16700933|NCT01944202|Experimental|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
16700934|NCT01944202|No Intervention|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
16700935|NCT01944189|Experimental|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.
~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
16700936|NCT01944189|Experimental|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.
~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
16700937|NCT01944176|Experimental|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
16700938|NCT01944176|Placebo Comparator|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
16700939|NCT01944163|No Intervention|Usual care|GP provide care as usual to their CLBP patients.
16700940|NCT01944163|Other|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
16700941|NCT01944150|Active Comparator|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
16700942|NCT01944150|Experimental|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
16700943|NCT01944137|No Intervention|Standard Care|Participant will receive standard cancer care
16700944|NCT01944137|Experimental|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
16700945|NCT01944124|Experimental|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
16700946|NCT01944124|Active Comparator|Exercise Prescription|Received a tailored exercise prescription only.
16700947|NCT01944111|Experimental|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
16700948|NCT01944098|Experimental|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
16700949|NCT01944098|Active Comparator|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
16700950|NCT01944085|Active Comparator|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
16700951|NCT01944085|Active Comparator|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
16700952|NCT01944085|Placebo Comparator|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
16700953|NCT01944072|Other|60%|aerobic exercise training intensity of 60%Wmax
16700954|NCT01944072|Other|80%|aerobic exercise training intensity of 80%Wmax
16700955|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.
~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
16700956|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.
~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
16700957|NCT01944046|Placebo Comparator|DB Placebo Nasal Spray|Placebo treatment during weeks 0-24 double blind phase
16700958|NCT01944046|Active Comparator|DB Oxytocin Nasal Spray|DB Oxytocin- quadruply masked treatment with intranasal oxytocin during weeks 0-24 of study during double blind phase of study
16700959|NCT01944046|Active Comparator|open label intranasal oxytocin|non masked treatment with intranasal oxytocin from weeks 24-48 in those participants who completed first 24 weeks of double blind treatment
16701245|NCT01942070|Experimental|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
16700962|NCT01944020|Experimental|CPAP|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
16700963|NCT01944020|No Intervention|Control|Control will be no use of CPAP for 2 months
16700964|NCT01944007|Experimental|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
16700965|NCT01944007|Experimental|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
16700966|NCT01944007|Experimental|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
16700967|NCT01944007|Experimental|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
16700968|NCT01943994|Experimental|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
16700969|NCT01943994|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
16700970|NCT01943981||Optimal/inappropriate exercise response|
16700971|NCT01943968|Other|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
16700972|NCT01943955|Experimental|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
16700973|NCT01943942|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
16700974|NCT01943942|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
16700975|NCT01943916|Experimental|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
16700976|NCT01943916|Experimental|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
16700977|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
16700978|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
16700979|NCT01943890|Experimental|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
16700980|NCT01943877|Experimental|Propolis|
16700981|NCT01943877|Sham Comparator|scaling and root planing|
16700982|NCT01943864|Experimental|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
16700983|NCT01943864|Experimental|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
16700984|NCT01943864|Experimental|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
16700985|NCT01943851|Experimental|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
16700986|NCT01943851|Experimental|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
16700987|NCT01943851|Experimental|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
16700988|NCT01943838|Experimental|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
16700989|NCT01943825|Experimental|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
16700990|NCT01943825|Experimental|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
16700991|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
16701024|NCT01943565|Active Comparator|Hydromorphone 25mcg|The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
16700992|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
16700993|NCT01943812|Experimental|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
16700994|NCT01943812|Active Comparator|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
16700995|NCT01943799|Experimental|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
16700996|NCT01943799|Experimental|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
16700997|NCT01943799|Experimental|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
16700998|NCT01943799|Experimental|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
16700999|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
16701000|NCT01943773|Experimental|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
16701001|NCT01943773|Experimental|No Prehabilitation|The control group will undergo routine pre-operative management.
16701002|NCT01943760|Active Comparator|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
16701003|NCT01943760|Experimental|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
16701004|NCT01943734|Experimental|Lifestyle counseling|Information passed on anthropometric assessment
16701005|NCT01943721|Experimental|VISION5 Product|VISION5 Product in both eyes
16701006|NCT01943708|Active Comparator|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
16701007|NCT01943708|Experimental|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
16701008|NCT01943695|Experimental|Aerobic Training During Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training an intensity of at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
16701009|NCT01943695|Experimental|Aerobic Training After Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training at an intensity 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
16701010|NCT01943695|Experimental|Continuous Aerobic Training|The ultimate goal is for participants to complete 3 exercise sessions week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
16701011|NCT01943695|Experimental|General Physical Activity Group|Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress, and answer questions.
16701012|NCT01943682|Experimental|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
16701013|NCT01943669|Experimental|ReWalk™ device|Self-controlled group; single cohort.
16701014|NCT01943656|Experimental|Tobii™ Eyegaze System|Single arm, open label study.
16701015|NCT01943643|Experimental|CT angiography, coronary bifurcations|
16701016|NCT01943630|Active Comparator|AS101|Topical 15% AS101 gel, once a day (overnight)
16701017|NCT01943630|Placebo Comparator|Vehicle|Vehicle, Once a day topical application (Overnight)
16701018|NCT01943617|Active Comparator|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
16701019|NCT01943617|Experimental|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
16701020|NCT01943604|Experimental|Experimental|"Nutella Breakfast
~Waffle Breakfast"
16701021|NCT01943591|Experimental|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
16701022|NCT01943591|Active Comparator|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
16701023|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
16701025|NCT01943565|Active Comparator|Hydromorphone 50mcg|The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
16701026|NCT01943565|Active Comparator|Hydromorphone 100mcg|The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
16701027|NCT01943552|Experimental|ipratropium|500 mcg four times a day
16701028|NCT01943552|Placebo Comparator|placebo|
16701029|NCT01943539|Experimental|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
16701030|NCT01943513|Experimental|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
16701031|NCT01943513|Placebo Comparator|Placebo|Participants receive intravenous (IV) infusions of placebo
16701032|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
16701033|NCT01943487|Experimental|1: verapamil + EC905|
16701034|NCT01943474|Experimental|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
16701035|NCT01943474|Active Comparator|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
16701036|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 3 mg/kg|
16701037|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 10 mg/kg|
16701038|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 20 mg/kg|
16701039|NCT01943461|Experimental|Expansion Cohort: Avelumab 10 mg/kg|
16701040|NCT01943435|Active Comparator|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.
~NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol
~Adjunctive analgesics: acetaminophen, tramadol, or gabapentin
~Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine
~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
16701041|NCT01943435|Active Comparator|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
16701042|NCT01943435|Active Comparator|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.
~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
16701043|NCT01943422|Experimental|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)
~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)
~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
16701044|NCT01943422|Experimental|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)
~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)
~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
16701045|NCT01943422|Experimental|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)
~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)
~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
16701046|NCT01943409|Active Comparator|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
16701047|NCT01943409|Experimental|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
16701048|NCT01943396|Experimental|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
16701049|NCT01943396|No Intervention|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
16701050|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
16701051|NCT01943370|Experimental|Early saline irrigation|Initiation of early saline irrigation
16701052|NCT01943370|Active Comparator|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
16701053|NCT01943357|Experimental|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
16701054|NCT01943344|Experimental|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
16701055|NCT01943331||patients admitted to ICU|
16701056|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis
~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
16701063|NCT01943305|Experimental|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
16701064|NCT01943305|Experimental|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
16701065|NCT01943292|Experimental|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
16701066|NCT01943279|Active Comparator|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
16701067|NCT01943279|Experimental|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
16701068|NCT01943266|Experimental|protein intake|protein intake randomly fed from deficient to excess
16701069|NCT01943253|Active Comparator|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
16701070|NCT01943253|Active Comparator|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
16701071|NCT01943240|Experimental|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
16701072|NCT01943240|Active Comparator|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
16701073|NCT01943227||6ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 6ml/kg Tidal volume.
~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
16701074|NCT01943227||9ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 9ml/kg Tidal volume.
~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
16701075|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
16701076|NCT01943201|Experimental|new bedsheet|new bedsheet
16701077|NCT01943201|Placebo Comparator|conventional bedsheet|conventional bedsheet
16701078|NCT01943188|Experimental|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.
~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.
~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
16701079|NCT01943175||Genetic High Risk|
16701080|NCT01943175||Healthy Control|
16701081|NCT01943162|Experimental|SMART-CPT|CPT with additional elements of cognitive rehabilitation
16701082|NCT01943162|Active Comparator|CPT|Standard Cognitive Processing Therapy
16701083|NCT01943136|Experimental|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
16701084|NCT01943136|Active Comparator|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
16701085|NCT01943123|Experimental|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
16701086|NCT01943123|Placebo Comparator|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
16701087|NCT01943110|Experimental|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:
~Upper deltoid with the side-load ID adapter
~Upper deltoid with the AD ID adapter
~Suprascapular (behind the shoulder) with the side-load ID adapter
~Suprascapular with the AD ID adapter
~Forearm with the side-load ID adapter
~Forearm with the AD ID adapter"
16701088|NCT01943084|Experimental|Norditropin®|
16701089|NCT01943084|Active Comparator|Genotropin®|
16701090|NCT01943071|Experimental|Day care for patients with dementia|Day care for patients with dementia
16701091|NCT01943071|No Intervention|Care as usual|Care as usual
16701092|NCT01943058|Experimental|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
16701093|NCT01943058|Experimental|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
16701094|NCT01943045|Experimental|NGM282 Dose 1|NGM Dose 1
16701095|NCT01943045|Experimental|NGM282 Dose 2|NGM Dose 2
16701096|NCT01943045|Experimental|NGM282 Dose 3|NGM Dose 3
16701097|NCT01943045|Placebo Comparator|Placebo|Placebo
16729549|NCT01750229|Experimental|3030 Hz|Frequency Setting - 3030 Hz
16701098|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
16701099|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
16701100|NCT01943019|Experimental|Linagliptin|Linagliptin daily
16701101|NCT01943006|Experimental|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate
~Twice daily"
16701102|NCT01943006|Placebo Comparator|Placebo|"Patients treated with placebo cream without active substance
~Twice daily"
16701103|NCT01942993|Experimental|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
16701104|NCT01942980|Other|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
16701105|NCT01942980|Other|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
16701106|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
16701107|NCT01942954|Experimental|Mobile health cognitive stimulation|Experimental group
16701108|NCT01942954|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
16701109|NCT01942941|Experimental|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
16701110|NCT01942928|Active Comparator|Usual NHS care|
16701111|NCT01942928|Active Comparator|Usual NHS Care plus Osteopathic Manipulative Therapy|
16701112|NCT01942915|Experimental|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
16701113|NCT01942902|Experimental|Continuous Glucose Monitoring System|
16701114|NCT01942889|Active Comparator|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
16701115|NCT01942889|Placebo Comparator|Placebo|Placebo
16701116|NCT01942876|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
16701117|NCT01942876|Sham Comparator|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
16701118|NCT01942863|Experimental|water exchange single balloon enteroscopy|
16701119|NCT01942863|Active Comparator|CO2 insufflation single balloon enteroscopy|
16701120|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
16701121|NCT01942837|Experimental|Enzalutamide|Participants will be treated with four 40 mg capsules (160 mg) once daily of enzalutamide taken orally. All participants without orchiectomy will be maintained on LHRH agonist/antagonist therapy. Participants will be evaluated clinically and with laboratory studies on day 1 of every 28 day cycle. Participants will maintain a drug diary from time of initiation of study treatment to time of discontinuation from the study (Appendix C).
16701122|NCT01942824|Experimental|Intervention|Text Message
16701123|NCT01942824|No Intervention|Usual Care|
16701124|NCT01942811|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
16701125|NCT01942811|No Intervention|Control|Usual care and a health education booklet and video on cancer prevention
16701126|NCT01942798|Active Comparator|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).
~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
16701127|NCT01942798|Experimental|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).
~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.
~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
16701166|NCT01942564||Control Subjects|"Age 18 years or older
~Have not had a previous head injury
~Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
16701128|NCT01942785|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
16701129|NCT01942772|Experimental|experimental test of healthy subjects|wearing experiment，motion experiment
16701130|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
16701131|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
16701132|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)
~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups"
16701133|NCT01942759||Oestrogen receptor status|Negative Positive
16701134|NCT01942759||Progesterone receptor status|Negative Positive
16701135|NCT01942759||HER-2 neu status|Negative Positive
16701136|NCT01942746|Active Comparator|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
16701137|NCT01942746|Active Comparator|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
16701138|NCT01942746|Placebo Comparator|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
16701139|NCT01942746|No Intervention|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
16701140|NCT01942733|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
16701141|NCT01942720|Other|Capsule endoscopy|
16701142|NCT01942707|Active Comparator|Abdominoplasty without Scarpa´s Facia|Anchor-line abdominoplasty where the Scarpa's Fascia will be removed.
16701143|NCT01942707|Experimental|abdominoplasty with Scarpa's Fascia|Anchor-line abdominoplasty where the Scarpa's Fascia will be preserved.
16701144|NCT01942694|Placebo Comparator|Placebo|One pill daily
16701145|NCT01942694|Active Comparator|Vitamin D (Cholecalciferol)|One vitamin D pill daily
16701146|NCT01942681|Other|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
16701147|NCT01942668|Experimental|Treatment 1|Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
16701148|NCT01942668|Experimental|Treatment 2|Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
16701149|NCT01942668|Experimental|Treatment 3|Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
16701150|NCT01942668|Experimental|Treatment 4|Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
16701151|NCT01942668|Placebo Comparator|Placebo|Two Placebo softgel capsules taken orally once a day for twelve months.
16701152|NCT01942655|Experimental|Patients with recto-colic biopsies prescribed|45 patients
16701153|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.
~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
16701154|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.
~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
16701155|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.
~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
16701156|NCT01942616|Experimental|Condition 1|"Each study arm contains different scenarios presented to the participant.
~Condition 1 is a Perpetrator Positive scenario.
~The content of the Condition 1 group is as follows:
~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
16701157|NCT01942616|Experimental|Condition 2|"Each study arm contains different scenarios presented to the participant.
~Condition 2 is a Perpetrator Negative scenario.
~The content of the Condition 2 group is as follows:
~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
16701158|NCT01942616|Placebo Comparator|Condition 3|"Each study arm contains different scenarios presented to the participant.
~The content of the Condition 3 group is as follows:
~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
16701159|NCT01942603||Observation|
16701160|NCT01942603||Complete Lymfnode Dissection|
16701161|NCT01942590|Experimental|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
16701162|NCT01942590|Placebo Comparator|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
16701163|NCT01942577|No Intervention|No treatment|
16701164|NCT01942577|Active Comparator|NoSting|
16701165|NCT01942564||Case Subjects|"Age 18 years or older
~Had a head injury that occurred at least 6 months prior to entering study
~Have found lights more bothersome since injury"
16701167|NCT01942551|Experimental|tadalafil, dutasteride|
16701168|NCT01942551|Experimental|dutasteride, tadalafil|
16701169|NCT01942538|Experimental|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
16701170|NCT01942538|Sham Comparator|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
16701171|NCT01942538|Sham Comparator|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
16701172|NCT01942538|Experimental|rTMS|real rTMS for 3 weeks but without clinical improvement
16701173|NCT01942538|Sham Comparator|sham|sham treatment for 3 weeks without clinical improvement
16701174|NCT01942525||Intrauterine growth restriction|birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
16701175|NCT01942525||Appropriate for gestation age|control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
16701176|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
16701177|NCT01942499|Other|Community Exercise Group|Community-based exercise program for one year
16701178|NCT01942499|No Intervention|Usual Care|
16701179|NCT01942486|Experimental|Investigational Coating|
16701180|NCT01942473|Experimental|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
16701181|NCT01942473|Placebo Comparator|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
16701182|NCT01942460|Experimental|Ferumoxytol|
16701183|NCT01942447|Experimental|FMT|FMT
16701184|NCT01942447|Active Comparator|Standard|Vancomycin
16701185|NCT01942421|Experimental|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
16701186|NCT01942408|No Intervention|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
16701187|NCT01942408|Active Comparator|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
16701188|NCT01942395|Active Comparator|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
16701189|NCT01942395|Active Comparator|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
16701190|NCT01942395|No Intervention|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
16701191|NCT01942382|Experimental|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
16701192|NCT01942382|Experimental|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
16701193|NCT01942382|Experimental|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
16701194|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
16701195|NCT01942356|Experimental|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
16701196|NCT01942356|Active Comparator|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
16701197|NCT01942356|Active Comparator|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
16701198|NCT01942343|Active Comparator|Arm 1 : Droperidol 1,25 mg|
16701199|NCT01942343|Active Comparator|Arm 2 : Droperidol 0,625 mg|
16701200|NCT01942343|Active Comparator|Arm 3 : Odansetron 4 mg|
16701201|NCT01942330|No Intervention|Traditional Laparoscopic-Assisted Colectomy|
16701202|NCT01942330|Experimental|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
16701203|NCT01942317|Experimental|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
16701204|NCT01942317|No Intervention|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
16701205|NCT01942304|Active Comparator|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
16701206|NCT01942304|Experimental|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
16701207|NCT01942291|Experimental|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
16701208|NCT01942291|Experimental|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
16701209|NCT01942278|No Intervention|Usual Care|Care is delivered according to baseline standard practice
16701210|NCT01942278|Experimental|BHOMA|Care is delivered according to the BHOMA intervention
16701211|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
16701212|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
16701213|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
16701214|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
16701215|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
16701216|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
16701217|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
16701218|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
16701219|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
16701220|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
16701221|NCT01942239|Active Comparator|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
16701222|NCT01942239|No Intervention|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
16701223|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
16701224|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
16701225|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
16701226|NCT01942187|Active Comparator|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
16701227|NCT01942187|Active Comparator|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
16701228|NCT01942174|Other|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.
~Interventions : biological/vaccine and drug"
16701229|NCT01942174|Experimental|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.
~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination
~Interventions : biological/vaccine and drug"
16701230|NCT01942161|Experimental|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
16701231|NCT01942161|Experimental|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
16701232|NCT01942161|Experimental|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
16701233|NCT01942148|Experimental|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
16701236|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
16701237|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
16701238|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
16701239|NCT01942109|Active Comparator|Furosemide|This group will receive furosemide as a diuretic treatment
16701240|NCT01942109|Experimental|Torasemide|This group will receive torasemide as a diuretic treatment
16701241|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
16701242|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
16701243|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
16701246|NCT01942070|Active Comparator|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
16701247|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
16701248|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
16701249|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
16701250|NCT01942044|Experimental|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
16701251|NCT01942044|Active Comparator|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
16701252|NCT01942044|Active Comparator|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
16701253|NCT01942031|Experimental|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
16701254|NCT01942031|No Intervention|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
16701255|NCT01942018|Experimental|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
16701256|NCT01941992|Experimental|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
16701257|NCT01941992|Placebo Comparator|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
16701258|NCT01941979|Experimental|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)
~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
16701259|NCT01941979|No Intervention|Observation|
16701260|NCT01941966|Experimental|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
16701261|NCT01941953|Experimental|Metformin and Flourouracil|
16701262|NCT01941940|Experimental|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
16701263|NCT01941927|Experimental|Trametinib, GSK2141795|"Trametinib (GSK1120212)
~Oral
~2 mg
~Daily
~Number of Cycles: until progression or unacceptable toxicity develops
~GSK2141795
~Oral
~25 mg
~Daily
~Number of Cycles: until progression or unacceptable toxicity develops"
16701264|NCT01941914|Experimental|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.
~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
16701265|NCT01941901|Experimental|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.
~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
16701266|NCT01941901|Active Comparator|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.
~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
16701267|NCT01941888|Experimental|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
16701268|NCT01941888|Active Comparator|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged< 70 - 0.03 mg/kg if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
16701269|NCT01941875|No Intervention|No Luteal Support|Control group: No luteal phase support or medication will be used
16701270|NCT01941875|Experimental|Luteal Vaginal Progesterone|Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
16701271|NCT01941862|Experimental|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
16701272|NCT01941862|Experimental|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
16701273|NCT01941862|Experimental|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
16701274|NCT01941862|No Intervention|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
16701275|NCT01941849|Experimental|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.
~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
16701276|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
16701277|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
16701278|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
16701279|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
16701280|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
16701866|NCT01938040|Placebo Comparator|Sugar water|100mL of normal saline to be administered over 5 minutes
16701281|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
16701282|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
16701283|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
16701284|NCT01941810|Experimental|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
16701285|NCT01941797|Experimental|Peri-implant mucosa|
16701286|NCT01941797|Active Comparator|periodontal mucosa|
16701287|NCT01941784|Experimental|Supportive care (health education program)|See Detailed Description.
16701288|NCT01941771|Active Comparator|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
16701289|NCT01941771|Experimental|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
16701290|NCT01941758|Experimental|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
16701291|NCT01941745|Placebo Comparator|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
16701292|NCT01941745|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
16701293|NCT01941745|Experimental|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
16701294|NCT01941732|Experimental|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
16701295|NCT01941719|Experimental|enhanced foot care education|Importance of daily foot self-care was reinforced at based by viewing personal barefoot plantar pressure in gait
16701296|NCT01941719|Active Comparator|Standard Foot Care Education|
16701297|NCT01941706|Experimental|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
16701298|NCT01941706|Experimental|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
16701299|NCT01941693|Experimental|Integrated care|"Integrated care:
~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
16701300|NCT01941693|Active Comparator|Usual care|Usual care
16701301|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
16701302|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
~CHOP-21 Day1 = day 21 (3 cycles)
~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.
~day 2-Day 5 Prednisone
~1mg/kg/day PO."
16701303|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
16701304|NCT01941667|Experimental|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level
~Daily messages requesting weight, intake, pulse ox and pulse are automated
~Virtual home visits occur twice weekly where the investigators see the infant and families."
16701305|NCT01941667|Placebo Comparator|Usual Care|Infants will have usual care as defined by cardiology.
16701306|NCT01941654|Experimental|preemptive local ablative therapy|
16701307|NCT01941641|Experimental|neoadjuvant FOLFOXIRI|
16701308|NCT01941628|Experimental|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
16701309|NCT01941628|Active Comparator|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
16701310|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
16701311|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
16701312|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
16701313|NCT01941589|Active Comparator|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
16701314|NCT01941589|Active Comparator|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
16701315|NCT01941589|Active Comparator|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
16701316|NCT01941589|Active Comparator|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
16701422|NCT01940900|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
16729550|NCT01750229|Experimental|5882 Hz|Frequency Setting - 5882 Hz
16701317|NCT01941576|Experimental|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
16701318|NCT01941576|Placebo Comparator|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
16701319|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
16701320|NCT01941563|Sham Comparator|Control|Sham injection
16701321|NCT01941550|Other|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.
~For max. 6 times at all."
16701322|NCT01941537|Experimental|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
16701323|NCT01941537|Placebo Comparator|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
16701324|NCT01941524|Active Comparator|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
16701325|NCT01941524|Active Comparator|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
16701326|NCT01941511|Experimental|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
16701327|NCT01941498|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
16701328|NCT01941485|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
16701329|NCT01941472|Experimental|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
16701330|NCT01941459||1 Custodiol|Custodiol
16701331|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
16701332|NCT01941446|Experimental|pre-generated treatment scheme|Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet
16701333|NCT01941446|Placebo Comparator|Pre-generated tratment scheme|Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet
16701334|NCT01941446|Placebo Comparator|Moxifloxacin|Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet
16701335|NCT01941433|Experimental|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
16701336|NCT01941433|Other|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
16701337|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
16701338|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
16701339|NCT01941407|Experimental|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
16701340|NCT01941394|Experimental|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
16701341|NCT01941394|No Intervention|Without MSC|Without MSC infusion
16701342|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
16701343|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
16701344|NCT01941368|No Intervention|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
16701345|NCT01941368|Placebo Comparator|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
16701346|NCT01941368|Active Comparator|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
16701347|NCT01941355|Experimental|Exercise training, psycho-educative|
16701348|NCT01941355|Experimental|Psycho-educative component|
16701349|NCT01941355|Experimental|Exercise training component|
16701350|NCT01941355|No Intervention|Usual care|
16701351|NCT01941342|Active Comparator|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
16701352|NCT01941342|Experimental|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:
~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
16701353|NCT01941342|Experimental|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:
~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
16701354|NCT01941342|Experimental|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:
~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
16701355|NCT01941329|Experimental|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
16701356|NCT01941329|Active Comparator|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.
~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
16701357|NCT01941316|Experimental|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m2 of carfilzomib and 125 mg/m2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.
~Stratification for phase II component:
~Platinum sensitive disease: initial response to platinum-based chemotherapy with progression > 90 days after last treatment.
~Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
16701358|NCT01941303||Advanced stage non-small cell lung cancer patients|
16701359|NCT01941290||Orsiro|
16701360|NCT01941277|Experimental|Intensive Exercise Group|Behavioral
16701361|NCT01941277|Experimental|Current Recommendations Exercise Group|Behavioral
16701362|NCT01941264|Active Comparator|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
16701363|NCT01941264|No Intervention|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
16701364|NCT01941251|Active Comparator|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
16701365|NCT01941251|Sham Comparator|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
16701366|NCT01941238||Insulin pump|
16701367|NCT01941238||MDI|
16701368|NCT01941225|Placebo Comparator|Placebo|Nebulized normal saline. Single administration
16701369|NCT01941225|Experimental|Inhaled iloprost 5.0 mcg|Single administration
16701370|NCT01941212|Active Comparator|Music therapy and Behavioral therapy|Music and behavioral therapy
16701371|NCT01941212|Active Comparator|Music only|Music therapy without behavioral therapy
16701372|NCT01941212|No Intervention|Control|Patients will not listen to music neither will get music therapy
16701373|NCT01941199|Experimental|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
16701374|NCT01941199|Experimental|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
16701375|NCT01941199|Experimental|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
16701376|NCT01941199|Experimental|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
16701377|NCT01941199|Experimental|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
16701378|NCT01941199|Experimental|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
16701379|NCT01941186|Experimental|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
16701380|NCT01941186|No Intervention|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
16701381|NCT01941173|Experimental|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
16701382|NCT01941160|Experimental|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
16701383|NCT01941160|Placebo Comparator|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
16701384|NCT01941147|Experimental|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
16701385|NCT01941134|Experimental|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.
~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
16701386|NCT01941121|Experimental|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
16701387|NCT01941108|No Intervention|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
16701423|NCT01940887|Experimental|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
16701424|NCT01940887|Active Comparator|Sham + bevacizumab or aflibercept|E10030 sham injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
16701388|NCT01941108|Experimental|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
16701389|NCT01941095|Experimental|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
16701390|NCT01941082|Experimental|Part A: RO6867461|Single doses
16701391|NCT01941082|Experimental|Part B: RO6867461|Multiple doses
16701392|NCT01941069|Active Comparator|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
16701393|NCT01941069|Active Comparator|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
16701394|NCT01941056|Experimental|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
16701395|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
16701396|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
16701397|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
16701398|NCT01941030|Experimental|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
16701399|NCT01941030|Active Comparator|Balloon Angioplasty|Balloon Angioplasty (BA) alone
16701400|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
16701401|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
16701402|NCT01941004|Experimental|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
16701403|NCT01941004|Placebo Comparator|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
16701404|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
16701405|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
16701406|NCT01940978|Placebo Comparator|Control|Methylphenidate ER QD placebo BID
16701407|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
16701408|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
16701409|NCT01940965|Experimental|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
16701410|NCT01940965|Experimental|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
16701411|NCT01940965|Experimental|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
16701412|NCT01940965|Experimental|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
16701413|NCT01940952|Active Comparator|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
16701414|NCT01940952|Placebo Comparator|Placebo|Placebo + Donepezil 5mg or 10mg
16701415|NCT01940952|Active Comparator|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
16701416|NCT01940939|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an inter-train interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
16701417|NCT01940939|Sham Comparator|Sham rTMS|Sham rTMS stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.Intervention: Device: Repetitive Transcranial Magnetic Stimulation
16701418|NCT01940926|Experimental|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
16701419|NCT01940913|Active Comparator|Probiotics|
16701420|NCT01940913|Placebo Comparator|Placebo|
16701421|NCT01940900|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
16701427|NCT01940848|Experimental|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
16701428|NCT01940848|Placebo Comparator|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
16701429|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
16701430|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
16701431|NCT01940822|Experimental|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
16701432|NCT01940822|Experimental|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
16701433|NCT01940809|Experimental|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16701434|NCT01940809|Experimental|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
16701435|NCT01940809|Experimental|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16701436|NCT01940809|Experimental|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
16701437|NCT01940809|Experimental|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16701438|NCT01940809|Experimental|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
16701439|NCT01940809|Experimental|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
16701440|NCT01940809|Experimental|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
16701441|NCT01940796|Experimental|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing > 100 kg. The dose for participants weighing > 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
16701442|NCT01940783|Other|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
16701443|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
16701444|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
16701445|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
16701446|NCT01940744|Experimental|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
16701447|NCT01940744|Active Comparator|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
16701448|NCT01940731|Experimental|Colistimethate sodium|
16701449|NCT01940718|Experimental|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
16701450|NCT01940705|Active Comparator|Standard of care (SoC)|standard of care hearing-aid orientation as provided by clinical audiologist
16701451|NCT01940705|Experimental|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
16701452|NCT01940705|Experimental|SoC plus hearing aid DVD|SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
16701453|NCT01940705|Experimental|Soc plus teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids
16729551|NCT01750216||Cohort|
16701454|NCT01940692|Active Comparator|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
16701455|NCT01940692|Experimental|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
16701456|NCT01940679|Experimental|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
16701457|NCT01940679|Experimental|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
16701458|NCT01940679|Experimental|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
16701459|NCT01940679|Experimental|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
16701460|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
16701461|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) >=2.39
16701462|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) >=2.99
16701463|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) >=6.53
16701464|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)>=181.55
16701465|NCT01940653|Other|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
16701466|NCT01940653|Active Comparator|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
16701467|NCT01940640|Experimental|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
16701468|NCT01940640|Active Comparator|Control|follow on capsules without probiotics
16701469|NCT01940627|Experimental|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
16701470|NCT01940627|Placebo Comparator|Control|Firemen consuming placebo capsules during two weeks
16701471|NCT01940601|Experimental|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
16701472|NCT01940601|Experimental|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
16701473|NCT01940601|Active Comparator|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
16701474|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
16701475|NCT01940575|Active Comparator|Restylane®|Inject Restylane® on right or left nasolabial fold
16701476|NCT01940575|Experimental|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
16701477|NCT01940562|Experimental|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.
~Starting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.
~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
16701478|NCT01940549|Sham Comparator|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
16701479|NCT01940549|Active Comparator|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
16701480|NCT01940536|Active Comparator|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
16701481|NCT01940536|Placebo Comparator|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
16701482|NCT01940523|Active Comparator|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
16701483|NCT01940523|Active Comparator|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
16701484|NCT01940510|Experimental|Healthy subjects|
16701485|NCT01940497|Experimental|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
16701486|NCT01940497|Experimental|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
16701487|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
16701488|NCT01940471|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
16701489|NCT01940471|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
16701490|NCT01940471|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
16701491|NCT01940445|Experimental|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
16701492|NCT01940445|Experimental|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
16701493|NCT01940432|Experimental|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
16701494|NCT01940432|Experimental|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
16701495|NCT01940419|Active Comparator|Tranexamic Acid|1g Tranexamic acid iv just before surgery
16701496|NCT01940419|Placebo Comparator|Placebo|sterile sodium chloride 9mg/ml iv
16701497|NCT01940406|Experimental|Stimulation procedure|Stimulation procedure
16701498|NCT01940393|Active Comparator|Cetirizine|Cetirizine
16701499|NCT01940393|Active Comparator|Desloratadine|desloratadine
16701500|NCT01940393|Active Comparator|Fexofenadine|Fexofenadine
16701501|NCT01940393|Active Comparator|Ebastine|ebastine
16701502|NCT01940393|Active Comparator|Bilastine|bilastine
16701503|NCT01940367|Active Comparator|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
16701504|NCT01940367|Active Comparator|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
16701505|NCT01940354|Experimental|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
16701506|NCT01940354|Active Comparator|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
16701507|NCT01940341|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
16701508|NCT01940341|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
16701509|NCT01940341|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
16701510|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
16701511|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
16701512|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
16701513|NCT01940315|Active Comparator|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
16701514|NCT01940315|Placebo Comparator|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
16701515|NCT01940302|Experimental|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
16701516|NCT01940302|No Intervention|Control|Received only oral hypoglycemic agents.
16701517|NCT01940289|Active Comparator|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
16701518|NCT01940289|Active Comparator|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
16701519|NCT01940276|Experimental|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
16701520|NCT01940263|Placebo Comparator|Placebo|placebo 320 mg daily for twelve weeks
16701521|NCT01940263|Experimental|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
16701522|NCT01940250|Placebo Comparator|Sterile water|"Sterile water will be packaged identically to the active comparator.
~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
16701560|NCT01939951|Active Comparator|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
16701561|NCT01939951|Placebo Comparator|Placebo|sugar pill
16701562|NCT01939938|Experimental|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
16701563|NCT01939925|Experimental|New plain language summary format|New plain language summary format of a Cochrane systematic review
16701523|NCT01940250|Active Comparator|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.
~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:
~If the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins
~If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated
~If the systolic BP decrease rapidly more than 25% over 15 minutes
~If the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
16701524|NCT01940237|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
16701525|NCT01940224|Active Comparator|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
16701526|NCT01940224|Placebo Comparator|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
16701527|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
16701528|NCT01940172|Experimental|Birinapant with Conatumumab|
16701529|NCT01940159|Active Comparator|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
16701530|NCT01940159|Placebo Comparator|Placebo|Matched placebo.
16701531|NCT01940146|Placebo Comparator|SPARC Placebo|
16701532|NCT01940146|Experimental|SPARC1310 I|
16701533|NCT01940146|Experimental|SPARC1310 II|
16701534|NCT01940146|Experimental|SPARC1310 III|
16701535|NCT01940133|Experimental|PQR309|Different dose evaluation
16701536|NCT01940120|Experimental|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
16701537|NCT01940107|Other|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
16701538|NCT01940107|Experimental|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
16701539|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
16701540|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
16701541|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:
~documented ventricular arrhythmia or
~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
~high risk for ventricular arrhythmia (LVEF ≤ 35%) or
~intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)
~who are not admitted for cardiac surgery"
16701542|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:
~documented ventricular arrhythmia or
~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
~high risk for ventricular arrhythmia (LVEF ≤ 35%)
~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
16701543|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:
~Coronary artery bypass graft surgery and who do not have prior myocardial infarction
~Aortic valve replacement"
16701544|NCT01940068|Experimental|New Thickened Amino acid based formula|
16701545|NCT01940068|Active Comparator|Amino acid based formula|
16701546|NCT01940055|Experimental|Experimental group|Dual Task Treadmill Walking Exercise Program
16701547|NCT01940055|Active Comparator|Control group|Dual task recumbent cycling exercise program
16701548|NCT01940042|Experimental|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
16701549|NCT01940042|No Intervention|clasical group|no additional action will be taken after the operation
16701550|NCT01940016|Experimental|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
16701551|NCT01940016|Active Comparator|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
16701552|NCT01940003|No Intervention|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
16701553|NCT01940003|Experimental|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
16701554|NCT01939990|Active Comparator|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
16701555|NCT01939990|Placebo Comparator|Placebo|Group B will be given Placebo.
16701556|NCT01939977|Experimental|Paricalcitol|Paricalcitol oral capsules.
16701557|NCT01939977|Active Comparator|Calcifediol|Calcifediol oral drops.
16701558|NCT01939964|Active Comparator|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
16701564|NCT01939925|Active Comparator|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
16701565|NCT01939912|Experimental|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
16701566|NCT01939899|Experimental|IXAZOMIB|Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
16701567|NCT01939886|Experimental|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
16701568|NCT01939886|Active Comparator|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
16701569|NCT01939873|Experimental|KRISTELLER|Uterine fundal pressure
16701570|NCT01939873|No Intervention|Control group|
16701571|NCT01939860|No Intervention|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
16701572|NCT01939860|Experimental|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
16701573|NCT01939847|Experimental|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
16701574|NCT01939847|No Intervention|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
16701575|NCT01939834|Experimental|AAA Control|"Subjects will use their home insulin pump along with a continuous glucose monitor (CGM) receiver. A CGM will be worn for 7 days prior to the study admission. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.
~Subjects will be asked to provide the study team their insulin pump data on Day 2 or 3 to ensure accuracy of data collection. Subjects will be asked to submit insulin pump, glucometer, and CGM data 1-2 days prior to their admission and again the evening prior to the study admission at a Research House.
~During the Experimental Admission, the AAA system will be tested using the DiAs platform. Subjects will participate in 45 minutes of exercise during the 40 hour admission (n=36). A subset (n=5-7) will continue with 5 nights of consecutive closed loop control (23:00-07:00)."
16701576|NCT01939834|Active Comparator|CGM + insulin pump at home|"The experimental and control admissions (40hr admissions) are exactly the same except for the study admission. During the Control Admission, subjects will use their home insulin pump along with a continuous glucose monitor receiver without running any specialized mathematical equations.
~The active comparator for subjects participating in 5 consecutive nights of closed loop control will be the sensor-augmented pump therapy at home."
16701577|NCT01939821|Experimental|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
16701578|NCT01939821|Active Comparator|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
16701579|NCT01939821|No Intervention|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
16701580|NCT01939808|Other|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
16701581|NCT01939808|Other|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
16701582|NCT01939795|No Intervention|Healthy People|Control group
16701583|NCT01939795|Experimental|Untrained CRT|Untrained CRT patients
16701584|NCT01939795|Experimental|Exercise trained + CRT|Exercise-trained CRT patients
16701661|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
16701662|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
16701867|NCT01938027|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
16701585|NCT01939782|Experimental|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:
~No Breakfast (NoB): fasting until lunch at 12:00
~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
16701586|NCT01939782|Active Comparator|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:
~No Breakfast (NoB): fasting until lunch at 12:00
~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
16701587|NCT01939756|Experimental|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
16701588|NCT01939743|Experimental|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
16701589|NCT01939743|Other|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
16701590|NCT01939730|Experimental|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
16701591|NCT01939717|Other|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
16701592|NCT01939717|No Intervention|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
16701593|NCT01939704|No Intervention|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
16701594|NCT01939704|No Intervention|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
16701595|NCT01939704|Experimental|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
16701596|NCT01939704|Experimental|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
16701597|NCT01939691|Experimental|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
16701598|NCT01939691|Experimental|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
16701599|NCT01939691|Experimental|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
16701600|NCT01939665|Experimental|Irreversible electroporation|Single arm study: Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma
16701601|NCT01939652|Active Comparator|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
16701602|NCT01939652|Experimental|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
16701603|NCT01939639|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
16701604|NCT01939639|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
16701605|NCT01939626|Experimental|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
16701606|NCT01939626|Other|Control|Embryos cultured in two Culture media for 5 Days.
16701607|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
16701608|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
16701609|NCT01939600|Experimental|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
16701610|NCT01939587|Experimental|PBF-680 5 mg|5 mg of PBF-680
16701611|NCT01939587|Experimental|PBF-680 20 mg|20 mg of PBF-680
16701612|NCT01939587|Placebo Comparator|Placebo|Placebo
16701613|NCT01939574|Experimental|Chemoradiation & Adjuvant Therapy:|"Concurrent chemoradiation Therapy:
~Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.
~Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.
~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.
~Adjuvant Therapy:
~Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.
~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
16701614|NCT01939561|Active Comparator|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
16701615|NCT01939561|Placebo Comparator|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
16701616|NCT01939548|Experimental|PF-02545920 (5mg)|
16701617|NCT01939548|Placebo Comparator|Placebo|
16701618|NCT01939548|Experimental|PF-02545920 (15mg)|
16701619|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
16701620|NCT01939522|Experimental|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
16701621|NCT01939509|Experimental|Atenolol-Bisoprolol|
16701622|NCT01939496|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
16701623|NCT01939496|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
16701624|NCT01939496|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
16701625|NCT01939483|Experimental|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
~This arm also includes laboratory biomarker analysis as an intervention."
16701626|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
16701627|NCT01939457|Experimental|misoprostol|400 mcg misoprostol sublingually
16701628|NCT01939444|Experimental|naloxone intranasal|2.0 mg by the nasal route
16701629|NCT01939444|Active Comparator|naloxone intravenous|1.0 mg intravenous
16701630|NCT01939431||Advanced|advanced stage podoconiosis
16701631|NCT01939431||Control|non-podoconiosis controls
16701632|NCT01939431||Early|early stage podoconiosis
16701633|NCT01939418|Experimental|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
16701634|NCT01939405|No Intervention|standard physical activity counseling|
16701635|NCT01939405|Experimental|built environment use counseling|personalized counseling on active use of the built environment
16701636|NCT01939392|Experimental|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
16701637|NCT01939392|No Intervention|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
16701638|NCT01939379|Active Comparator|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
16701639|NCT01939379|Active Comparator|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
16701640|NCT01939366|Experimental|Cebranopadol 300 µg|
16701641|NCT01939366|Experimental|Cebranopadol 600 µg|
16701642|NCT01939366|Active Comparator|Pregabalin|
16701643|NCT01939366|Placebo Comparator|Matching Placebo|
16701644|NCT01939366|Experimental|Cebranopadol 100 µg|
16701647|NCT01939327|Experimental|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
16701648|NCT01939314|Active Comparator|Bupivacaine|Bupivicaine .03ml to each nare
16701649|NCT01939314|Placebo Comparator|Normal Saline|normal saline .03 ml to each nare
16701650|NCT01939301|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide
16701651|NCT01939301|Placebo Comparator|Placebo|Oxygen
16701652|NCT01939288|Experimental|Group 1|Half of recruited subjects (n=5)
16701653|NCT01939288|Experimental|Group 2|Other half of recruited subjects (n=5)
16701654|NCT01939275|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)|Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
16701655|NCT01939262|Experimental|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
16701656|NCT01939262|Placebo Comparator|Control|Subjects maintained their existing diet without modification.
16701657|NCT01939249|Active Comparator|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
16701658|NCT01939249|Experimental|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
16701659|NCT01939236|Experimental|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
16701660|NCT01939236|Placebo Comparator|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
16701663|NCT01939210|Experimental|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
16701664|NCT01939210|Active Comparator|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
16701665|NCT01939197|Experimental|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
16701666|NCT01939197|Experimental|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
16701667|NCT01939197|Experimental|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
16701668|NCT01939197|Experimental|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
16701669|NCT01939197|Experimental|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
16701670|NCT01939197|Experimental|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
16701671|NCT01939197|Experimental|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
16701672|NCT01939197|Experimental|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
16701673|NCT01939197|Experimental|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
16701674|NCT01939197|Experimental|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
16701675|NCT01939197|Experimental|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
16701676|NCT01939197|Experimental|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
16701677|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
16701678|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
16701679|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
16701680|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
16701681|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
16701682|NCT01939171|Placebo Comparator|Non treated|Cadaver donor is cared and treated as usual protocol
16701683|NCT01939171|Experimental|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
16701684|NCT01939158|Experimental|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
16701685|NCT01939158|Experimental|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
16701686|NCT01939158|Experimental|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
16701687|NCT01939158|Active Comparator|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
16701688|NCT01939145|Active Comparator|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
16701689|NCT01939145|Active Comparator|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
16701690|NCT01939132|Experimental|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
16701691|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
16701692|NCT01939106|Other|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
16701693|NCT01939093|Experimental|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
16701694|NCT01939093|Active Comparator|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
16701695|NCT01939080|Active Comparator|Medical supervision|Exercise training with supervised sessions Classics training
16701696|NCT01939080|Active Comparator|No medical supervision|Exercise training without supervised sessions Classics training
16701697|NCT01939067|Other|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).
~Escalation of the ventilatory support per protocol and the attending physician."
16701698|NCT01939067|Other|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).
~Escalation of the ventilatory support per protocol and the attending physician."
16701699|NCT01939054|Experimental|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
16701700|NCT01939054|Active Comparator|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
16701790|NCT01938482|Experimental|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
16701701|NCT01939041|Experimental|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
16701702|NCT01939041|Experimental|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
16701703|NCT01939041|Active Comparator|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
16701704|NCT01939028|Experimental|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
16701705|NCT01939015|Active Comparator|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
16701706|NCT01939015|Experimental|three dimensional titanium miniplate|3D curved strut miniplate* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
16701707|NCT01939002|Experimental|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
16701708|NCT01939002|Experimental|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
16701709|NCT01938989|Other|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
16701710|NCT01938989|Other|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
16701711|NCT01938976|Experimental|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
16701712|NCT01938976|Experimental|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
16701713|NCT01938963|No Intervention|Care as usual|
16701714|NCT01938963|Experimental|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
16701715|NCT01938950|Active Comparator|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
16701716|NCT01938950|Active Comparator|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
16701717|NCT01938950|Active Comparator|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
16701718|NCT01938937|Experimental|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
16701719|NCT01938937|Sham Comparator|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
16701720|NCT01938924|No Intervention|No intervention|No intervention
16701721|NCT01938924|Active Comparator|GekoTM|geko applied to bypass limb
16701940|NCT01937494|Experimental|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
16701722|NCT01938911|Experimental|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701723|NCT01938911|Experimental|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701724|NCT01938911|Experimental|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701725|NCT01938911|Placebo Comparator|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701726|NCT01938911|Experimental|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701727|NCT01938911|Experimental|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701728|NCT01938911|Experimental|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701729|NCT01938911|Placebo Comparator|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
16701730|NCT01938898|Other|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
16701731|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
16701732|NCT01938859|Experimental|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
16701733|NCT01938859|Experimental|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
16701734|NCT01938859|Active Comparator|Lithium monotherpy|Lithium monotherapy
16701735|NCT01938846|Experimental|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
16701736|NCT01938846|Experimental|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
16701737|NCT01938846|Experimental|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
16701738|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16701739|NCT01938820|Active Comparator|Entecavir Therapy|"Entecavir monotherapy:
~entecavir, 0.5mg, qd, oral, for 2 years."
16701740|NCT01938820|Experimental|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
16701741|NCT01938807|Experimental|Intervention|The intervention group receives the CareCoach mobile application
16701742|NCT01938807|Active Comparator|Control|The control group receives standard care.
16701743|NCT01938781|Active Comparator|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
16701744|NCT01938781|Experimental|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
16701745|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
16701746|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
16701747|NCT01938755|Experimental|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
16701748|NCT01938755|Experimental|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
16701749|NCT01938755|Experimental|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
16701750|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
16701751|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
16701752|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
16701753|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
16701754|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
16701755|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
16701756|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
16701791|NCT01938482|Experimental|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
16701792|NCT01938469|Other|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
16701793|NCT01938469|Other|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
16701757|NCT01938729|Experimental|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.
~Level 1: Systemic gemcitabine 650mg/m^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
16701758|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
16701759|NCT01938690|Sham Comparator|Sham stimulation|Sham stimulation on the scalp of unaffected brain
16701760|NCT01938690|Experimental|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
16701761|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
16701762|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
16701763|NCT01938664|Experimental|Candesartan w Cognitive Behavior Therapy|Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
16701764|NCT01938664|Placebo Comparator|Placebo w Cognitive Behavior Therapy|Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
16701765|NCT01938651|Experimental|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
16701766|NCT01938638|Experimental|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
16701767|NCT01938638|Experimental|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
16701768|NCT01938625|Experimental|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
16701769|NCT01938625|Experimental|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
16701770|NCT01938612|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
16701771|NCT01938612|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
16701772|NCT01938612|Experimental|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
16701773|NCT01938612|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
16701774|NCT01938612|Experimental|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
16701775|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
16701776|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
16701777|NCT01938586||Surgical excision|
16701778|NCT01938573|Experimental|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
16701779|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
16701780|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
16701781|NCT01938547|Experimental|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).
~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
16701782|NCT01938534|Experimental|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice
~for 10 days"
16701783|NCT01938534|Active Comparator|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
16701784|NCT01938521|Experimental|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
16701785|NCT01938521|Placebo Comparator|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
16701786|NCT01938508|Experimental|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
16701787|NCT01938508|Experimental|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
16701788|NCT01938495|Experimental|NeuRx® Diaphragm Pacing System™ (DPS)|Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
16701789|NCT01938495|No Intervention|Standard of Care|patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
16729705|NCT01749150|Experimental|without cirrhosis|
16701794|NCT01938456|Experimental|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
16701795|NCT01938443|Experimental|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
16701796|NCT01938443|Experimental|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
16701797|NCT01938430|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
16701798|NCT01938430|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
16701799|NCT01938430|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
16701800|NCT01938430|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
16701801|NCT01938430|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
16701802|NCT01938430|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
16701803|NCT01938430|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
16701804|NCT01938430|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
16701805|NCT01938430|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
16701806|NCT01938430|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
16701807|NCT01938430|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
16701808|NCT01938430|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
16701809|NCT01938430|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
16701810|NCT01938430|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
16701811|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
16701812|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
16701813|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
16701814|NCT01938391|Other|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
16701815|NCT01938378|Other|Pediatric patients undergoing TPE|octaplas™
16701816|NCT01938365||Diabetes|
16701817|NCT01938365||Normal glucose regulation|
16701818|NCT01938352|Experimental|CR8020|CR8020 administered as a single 2-hour intravenous infusion
16701819|NCT01938352|Placebo Comparator|Placebo|Placebo administered as a single 2-hour intravenous infusion
16701820|NCT01938339|Experimental|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
16701821|NCT01938326|Active Comparator|TLDG|No mini-laparotomy in the epigastrium Reconstruction by the uncut Roux-en Y gastrojejunostomy
16701822|NCT01938326|Active Comparator|SIDG|SIDG : pure single incision laparoscopic distal gastrectomy Reconstruction by the uncut Roux-en Y gastrojejunostomy
16701823|NCT01938313|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
16701824|NCT01938313|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
16701825|NCT01938300|Experimental|Magnesium|"Magnesium sulfate infusion during a operation period.
~Infusion regimen:
~Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes
~Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
16701826|NCT01938300|Placebo Comparator|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
16701827|NCT01938287|Experimental|SENSIMED Triggerfish|
16701828|NCT01938274|Experimental|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
16701829|NCT01938274|No Intervention|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
16701830|NCT01938261|Experimental|Paracetamol effect on ductus|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
16701831|NCT01938261|Experimental|Paracetamol effect on pain|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
16701832|NCT01938248|Active Comparator|Control|Aspirin 81 mg once daily
16701833|NCT01938248|Experimental|Intervention|Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
16701834|NCT01938235|Experimental|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)
~*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.
~If the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.
~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
16701835|NCT01938235|Placebo Comparator|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.
16701836|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval < 0,5 cm and lateral 0,5-0,8 cm
16701837|NCT01938209|Experimental|seated general thoracic spine manipulation|seated general thoracic spine manipulation
16701838|NCT01938209|Experimental|supine specific thoracic spine manipulation|Specific supine manipulation
16701839|NCT01938196|Experimental|KWA-0711 Dose1|
16701840|NCT01938196|Experimental|KWA-0711 Dose2|
16701841|NCT01938196|Experimental|KWA-0711 Dose3|
16701842|NCT01938196|Experimental|KWA-0711 Dose4|
16701843|NCT01938196|Placebo Comparator|Placebo|
16701844|NCT01938183|Placebo Comparator|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
16701845|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
16701846|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
16701847|NCT01938170|Experimental|FluMist|Subjects receiving vaccine at home
16701848|NCT01938157|Experimental|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
16701849|NCT01938144|Experimental|Treatment A|IBU 200 mg/ PE 10 mg
16701850|NCT01938144|Experimental|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
16701851|NCT01938144|Active Comparator|Treatment C|Acetaminophen 500 mg
16701852|NCT01938131|Placebo Comparator|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
16701853|NCT01938131|Experimental|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
16701854|NCT01938118|Experimental|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
16701855|NCT01938118|Active Comparator|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
16701856|NCT01938105|Experimental|Nimotuzumab+chemoradiotherapy|
16701857|NCT01938092|Active Comparator|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
16701858|NCT01938092|Placebo Comparator|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
16701859|NCT01938079|Active Comparator|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
16701860|NCT01938079|Experimental|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
16701861|NCT01938066|Active Comparator|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
16701862|NCT01938066|Sham Comparator|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
16701863|NCT01938053|Other|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
16701864|NCT01938053|Other|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
16701865|NCT01938040|Active Comparator|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
16701868|NCT01938001|Experimental|Rituximab and Lenalidomide|Participants received rituximab 375 mg/m^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but < 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
16701869|NCT01938001|Active Comparator|Rituximab and Placebo|Participants received riituximab 375 mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
16701870|NCT01937988|Experimental|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
16701871|NCT01937988|No Intervention|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
16701872|NCT01937975|Experimental|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
16701873|NCT01937975|Experimental|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
16701874|NCT01937975|Experimental|Healthy Participants|Healthy participants (estimated glomerular filtration rate >=80 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
16701875|NCT01937949|Other|Endovascular|"The study will include patients treated by endovascular aortic repair of juxtarenal, suprarenal and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft. The graft includes combinations of scallops, holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
~Other names:
~Endovascular stent Stent-graft"
16701876|NCT01937936|Experimental|CBT|Cognitive Behavioral Therapy (CBT)
16701877|NCT01937936|Active Comparator|Education|Health Education
16701878|NCT01937910|Experimental|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
16701879|NCT01937910|Active Comparator|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
16701880|NCT01937897|Experimental|Left-Sided Massage|Unilateral massage on the left side of the body.
16701881|NCT01937897|Active Comparator|Right-Sided Massage|Unilateral massage on the right side of the body.
16701882|NCT01937897|Sham Comparator|Bi-Lateral Massage|Traditional massage on the back of the body.
16701883|NCT01937884|Experimental|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
16701884|NCT01937884|Active Comparator|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
16701885|NCT01937871|Placebo Comparator|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
16701886|NCT01937871|Experimental|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
16701887|NCT01937871|Other|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
16701888|NCT01937858||Normal renal function|
16701889|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
16701890|NCT01937858||End stage renal disease on hemodialysis|
16701891|NCT01937832|Active Comparator|Ertapenem|
16701892|NCT01937832|Experimental|Faropenem|
16701893|NCT01937819|Experimental|SMART arm|Using SMARTPHONE application for self judging bowel preparation
16701894|NCT01937819|No Intervention|Conventional arm|Non-using SMARTPHONE application for bowel preparation
16701895|NCT01937806|Experimental|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
16701896|NCT01937806|Active Comparator|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
16701897|NCT01937793|Active Comparator|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
16701898|NCT01937793|Active Comparator|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
16701899|NCT01937767|Active Comparator|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
16701900|NCT01937767|Experimental|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
16701901|NCT01937767|Experimental|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
16701902|NCT01937754|Active Comparator|Nitric Oxide supplement|
16701903|NCT01937754|Placebo Comparator|Placebo|
16701904|NCT01937728|Active Comparator|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
16701941|NCT01937481|Experimental|Nutrition and Physical Activity|The Food Friends programs
16701942|NCT01937481|No Intervention|Control|Control group
16701905|NCT01937728|Experimental|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.
~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
16701906|NCT01937728|Experimental|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
16701907|NCT01937728|Active Comparator|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
16701908|NCT01937728|Experimental|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
16701909|NCT01937728|Experimental|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.
~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
16701910|NCT01937715|Experimental|Arm A|PF-05212384 plus FOLFIRI
16701911|NCT01937715|Active Comparator|Arm B|Bevacizumab plus FOLFIRI
16701912|NCT01937702|Experimental|Anti-diabetes medication|Insulin
16701913|NCT01937689|Experimental|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
16701914|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
16701915|NCT01937663|Experimental|KWA-0711 Dose1|
16701916|NCT01937663|Experimental|KWA-0711 Dose2|
16701917|NCT01937663|Experimental|KWA-0711 Dose3|
16701918|NCT01937663|Experimental|KWA-0711 Dose4|
16701919|NCT01937650|Active Comparator|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
16701920|NCT01937650|Placebo Comparator|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
16701921|NCT01937637|Other|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.
~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
16701922|NCT01937624||Diagnostic ultrasound and radiographic imaging|- The diagnostic musculoskeletal ultrasound and x-rays will both be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
16701923|NCT01937611|Experimental|Dexmedetomidine|dexmedetomidine 1μg•kg-1
16701924|NCT01937611|Active Comparator|midazolam|midazolam 0.03 mg•kg-1
16701925|NCT01937598|Experimental|Sitagliptin, then Placebo|
16701926|NCT01937598|Experimental|Placebo, then Sitagliptin|
16701927|NCT01937585|Active Comparator|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
16701928|NCT01937585|Experimental|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
16701929|NCT01937572|Experimental|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
16701930|NCT01937572|Other|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
16701931|NCT01937559|Experimental|Topical Tranexamic acid (TXA)|Tranexamic acid (TXA) applied topically
16701932|NCT01937559|Placebo Comparator|Saline|Normal saline
16701933|NCT01937559|Active Comparator|Tranexamic acid (TXA)|Tranexamic acid (TXA) administered intravenously
16701934|NCT01937546|Active Comparator|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
16701935|NCT01937546|Experimental|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
16701936|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
16701937|NCT01937520|Experimental|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
16701938|NCT01937520|Placebo Comparator|device|no acupuncture will be done on this group of subjects
16701939|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
16701943|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
16701944|NCT01937455|Experimental|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
16701945|NCT01937455|Experimental|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
16701946|NCT01937455|Experimental|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
16701947|NCT01937455|Experimental|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
16701948|NCT01937442|Experimental|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
16701949|NCT01937429|Experimental|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
16701950|NCT01937429|Active Comparator|Standard colonoscopy|Standard colonoscopy with insufflation of air
16701951|NCT01937416|Experimental|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
16701952|NCT01937390||LAMA/LABA Patients|
16701953|NCT01937364|Placebo Comparator|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
16701954|NCT01937364|Active Comparator|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
16701955|NCT01937351|Experimental|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
16701956|NCT01937338|Experimental|AZD7624|
16701957|NCT01937338|Placebo Comparator|Placebo|
16701958|NCT01937325|Active Comparator|Ivacaftor|150mg orally twice daily
16701959|NCT01937325|Placebo Comparator|Placebo|Matching placebo
16701960|NCT01937312|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
16701961|NCT01937312|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
16701962|NCT01937299|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
16701963|NCT01937299|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
16701964|NCT01937260|Experimental|Brodalumab 140mg SC|open label, all subjects receive brodulamab
16701965|NCT01937260|Experimental|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
16701966|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
16701967|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
16701968|NCT01937234|Active Comparator|Metoclopramide|Intravenous injection of 10mg metoclopramide
16701969|NCT01937234|Placebo Comparator|Placebo|Intravenous injection of 0.9% sodium chloride
16701970|NCT01937221||mild cognitive impairment|
16701971|NCT01937221||mild to moderate cognitive impairment|
16701972|NCT01937221||normal or control group|
16701973|NCT01937208|Experimental|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
16701974|NCT01937208|Active Comparator|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
16701975|NCT01937195|Experimental|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
16701976|NCT01937182|Active Comparator|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
16701977|NCT01937182|Placebo Comparator|Placebo|Intervention Drug: Placebo
16701978|NCT01937169|Experimental|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.
~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
16702009|NCT01936948|Active Comparator|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
16702010|NCT01936948|No Intervention|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
16729760|NCT01748825|Experimental|ARM 7 AZD1775 300 mg Twice Daily|
16701979|NCT01937169|Placebo Comparator|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.
~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
16701980|NCT01937169|Sham Comparator|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.
~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
16701981|NCT01937156|Experimental|SP-01|
16701982|NCT01937156|Active Comparator|Granisetron Hydrochloride Tablet|
16701983|NCT01937143|Placebo Comparator|Control|General information about infant immunizations at birth of a newborn infant
16701984|NCT01937143|Active Comparator|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
16701985|NCT01937143|Active Comparator|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
16701986|NCT01937130|Experimental|IDN-6556 5 mg|Dosed twice daily
16701987|NCT01937130|Experimental|IDN-6556 25 mg|Dosed twice daily
16701988|NCT01937130|Experimental|IDN-6556 50 mg|Dosed twice daily
16701989|NCT01937130|Placebo Comparator|Placebo|Dosed twice daily
16701990|NCT01937117|Experimental|Trastuzumab and Pertuzumab|Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
16701991|NCT01937104|Experimental|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60
~Drug: Remifentanil Adjuvant continuous administration
~- adjust effect site concentration to maintain changes of vital sign below 20%
~Device: Ultrasonographic measurement of ONSD
~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
~Trendelenburg position - 30 degree"
16701992|NCT01937104|Experimental|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60
~Drug: Remifentanil Adjuvant continuous administration
~- adjust effect site concentration to maintain changes of vital sign below 20%
~Device: Ultrasonographic measurement of ONSD
~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
~Reverse Trendelenburg position - 30 degree"
16701993|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of > 48 weeks.
16701994|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
16701995|NCT01937078|Active Comparator|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
16701996|NCT01937065||No treatment|
16701997|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
16701998|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
16701999|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
16702000|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
16702001|NCT01937026|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
16702002|NCT01937026|Experimental|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
16702003|NCT01937013|Experimental|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
16702004|NCT01937013|Placebo Comparator|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
16702005|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:
~Carboplatin* on day 1
~*If a patient is allergic to carboplatin, then give
~Cisplatin** on day 1
~**If a patient is allergic to cisplatin and carboplatin, then give
~Oxaliplatin on day 1
~Gemcitabine on day 1 only
~Bevacizumab on day 1"
16702006|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8
~Bevacizumab on day 1"
16702007|NCT01936961|Experimental|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
16702008|NCT01936948|Active Comparator|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
16729761|NCT01748825|Experimental|ARM 8 AZD1775 400 mg Once Daily|
16702011|NCT01936948|No Intervention|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
16702012|NCT01936935|Experimental|Low-fat dairy|3 servings/d of low-fat dairy
16702013|NCT01936935|Placebo Comparator|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
16702014|NCT01936922|Experimental|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
16702015|NCT01936909|Experimental|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
16702016|NCT01936909|Experimental|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
16702017|NCT01936909|Placebo Comparator|Placebo|Placebo injections daily for 12 weeks
16702018|NCT01936896|Experimental|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
16702019|NCT01936883|Active Comparator|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
16702020|NCT01936883|Active Comparator|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
16702021|NCT01936870||Fesoterodine (Toviaz)|
16702022|NCT01936857|Experimental|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
16702023|NCT01936857|Active Comparator|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
16702024|NCT01936844|Experimental|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
16702025|NCT01936844|Placebo Comparator|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
16702029|NCT01936805|Active Comparator|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
16702030|NCT01936805|Placebo Comparator|Control|A loading dose of placebo was administrated 24 h before the PCI.
16702031|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
16702032|NCT01936792||Controls|Controls with no premorbid health conditions
16702033|NCT01936779|Active Comparator|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
16702034|NCT01936779|Placebo Comparator|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
16702035|NCT01936753|Experimental|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
16702036|NCT01936753|No Intervention|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
16702037|NCT01936740|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
16702038|NCT01936740|Other|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
16702039|NCT01936727|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
16702040|NCT01936727|Other|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
16702041|NCT01936714|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
16702075|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
16702076|NCT01936480|Placebo Comparator|Placebo Group|Healthy volunteers with QT genotype score in the highest or lowest quintile
16702042|NCT01936714|Other|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
16702043|NCT01936701|Other|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
16702044|NCT01936701|Other|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
16702045|NCT01936688|Experimental|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
16702046|NCT01936688|Experimental|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
16702047|NCT01936688|Placebo Comparator|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
16702048|NCT01936688|Active Comparator|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
16702049|NCT01936675|No Intervention|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
16702050|NCT01936675|Active Comparator|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
16702051|NCT01936662|Experimental|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
16702052|NCT01936662|Active Comparator|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
16702053|NCT01936649|Experimental|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
16702054|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.
~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
16702055|NCT01936623|Experimental|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
16702056|NCT01936623|Other|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
16702057|NCT01936610|Experimental|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
16702058|NCT01936610|Experimental|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
16702059|NCT01936597|Active Comparator|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
16702060|NCT01936597|Experimental|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
16702061|NCT01936597|Experimental|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
16702062|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
16702063|NCT01936584||TEP repair|TEP repair for inguinal hernia
16702064|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
16702065|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
16702066|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
16702067|NCT01936545|Experimental|propofol|The anesthesia was maintained with propofol during liver transplantation.
16702068|NCT01936545|Active Comparator|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
16702069|NCT01936532|Experimental|assessment of treatment lenalidomide, dexamethasone,MLN9708|
16702070|NCT01936519|Active Comparator|Calcineurin Inhibitor with Mycophenolic Acid|Calcineurin inhibitor immunosuppression with mycophenolic acid
16702071|NCT01936519|Experimental|Everolimus with Mycophenolic Acid|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
16702072|NCT01936506|Experimental|Cognitive Training A|emotional memory training exercise
16702073|NCT01936506|Active Comparator|Cognitive Training B|memory training exercise
16702074|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
16702077|NCT01936467|Experimental|Standard suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the standard suction FNA technique: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
16702078|NCT01936467|Experimental|Capillary suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the capillary suction FNA technique: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
16702079|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
16702080|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
16702081|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
16702082|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
16702083|NCT01936441|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.
~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
16702084|NCT01936441|Placebo Comparator|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
16702085|NCT01936428|Other|interview|
16702086|NCT01936415|Experimental|Regenerex|One of the two prosthesis investegated
16702087|NCT01936415|Active Comparator|Vanguard|
16702088|NCT01936402|Experimental|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.
~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
16702089|NCT01936402|Experimental|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.
~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
16702090|NCT01936389|Experimental|0.5%|0.5% Rho-Kinase Inhibitor
16702091|NCT01936389|Experimental|0.7%|0.7% Rho-Kinase Inhibitor
16702092|NCT01936376||head & neck cancer patients, cisplatin treatment|
16702093|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
16702094|NCT01936363|Experimental|Pimasertib (once daily) plus SAR245409|
16702095|NCT01936363|Experimental|Pimasertib (twice daily) plus SAR245409 placebo|
16702096|NCT01936350|Experimental|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
16702097|NCT01936350|Placebo Comparator|Placebo|12 patients will be in this group, they will take placebo
16702098|NCT01936337|Active Comparator|DLX105 Hydrogel|
16702099|NCT01936337|Placebo Comparator|Placebo Hydrogel|
16702100|NCT01936324|Experimental|Phase 1|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
16702101|NCT01936324|Experimental|Phase 2a|Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
16702102|NCT01936311|No Intervention|Control Group|This group will receive usual care.
16702103|NCT01936311|Experimental|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
16702104|NCT01936298|Experimental|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
16702105|NCT01936298|Experimental|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
16702106|NCT01936285|Placebo Comparator|Control group|Patients taking placebo
16702107|NCT01936285|Experimental|Colchicine|Active treatment group
16702108|NCT01936272|Active Comparator|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
16702109|NCT01936272|Active Comparator|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
16702110|NCT01936259|Active Comparator|Comprehensive Mini Humeral Stem|"The Comprehensive® Shoulder System with mini stem component, which will be the control device for this clinical investigation and was 510(k) cleared under K060692 on May 30, 2006.
~The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments."
16702241|NCT01935479|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
16702111|NCT01936259|Experimental|Comprehensive Nano Humeral Component|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
16702112|NCT01936246|Experimental|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
16702113|NCT01936246|No Intervention|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
16702114|NCT01936233|Experimental|Aspirin AND Lamivudine|
16702115|NCT01936233|Active Comparator|Lamivudine|
16702116|NCT01936220|Experimental|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
16702117|NCT01936220|Experimental|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
16702118|NCT01936220|Active Comparator|Treatment as usual|Discontinuity of care, relapse prevention as usual
16702119|NCT01936207||One Group|
16702120|NCT01936194|Experimental|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
16702121|NCT01936194|Other|High Olive Oil|infants receiving capsule without DHA and EPA.
16702122|NCT01936194|Experimental|DHA+EPA|infants receiving capsule containing DHA and EPA.
16702123|NCT01936181|Experimental|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
16702124|NCT01936181|Active Comparator|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
16702125|NCT01936181|Experimental|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
16702126|NCT01936181|Active Comparator|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
16702127|NCT01936168|Active Comparator|RFA|Radiofrequency Ablation (RFA)
16702128|NCT01936168|Experimental|MOCA|Mechanochemical Endovenous Ablation (MOCA)
16702129|NCT01936155|Experimental|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
16702130|NCT01936142|No Intervention|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
16702131|NCT01936142|Experimental|RenalGuard|Use of the RenalGuard system during CRT implantation
16702132|NCT01936129|Active Comparator|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
16702133|NCT01936129|Placebo Comparator|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
16702134|NCT01936116|Experimental|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
16702135|NCT01936116|Active Comparator|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
16702136|NCT01936103|Active Comparator|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
16702137|NCT01936103|Experimental|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
16702138|NCT01936090|Experimental|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.
~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
16702139|NCT01936077|Experimental|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
16702140|NCT01936064|Active Comparator|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
16702141|NCT01936064|Active Comparator|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
16702142|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
16702143|NCT01936038|Placebo Comparator|Control Group|CPAP
16702144|NCT01936038|Experimental|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
16702145|NCT01936025|Active Comparator|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
16702146|NCT01936025|Experimental|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
16702147|NCT01936025|Experimental|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
16702148|NCT01936025|Experimental|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
16702149|NCT01936025|Experimental|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
16702150|NCT01936025|Experimental|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
16702151|NCT01936025|Experimental|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
16702152|NCT01936025|Placebo Comparator|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
16702242|NCT01935479|Active Comparator|MN-10-T SD|Single administration of teriparatide acetate
16731076|NCT01740505|Experimental|Timing and Coordination|
16702153|NCT01936012|Experimental|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
16702154|NCT01936012|Active Comparator|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
16702155|NCT01935999|Other|One piece closed pouch|One piece closed pouch
16702156|NCT01935986|Experimental|probiotic|dietary supplement
16702157|NCT01935986|Placebo Comparator|placebo|dietary supplement without probiotic
16702158|NCT01935973|Active Comparator|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
16702159|NCT01935973|Experimental|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16702160|NCT01935960|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
16702161|NCT01935960|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
16702162|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
16702163|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
16702164|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
16702165|NCT01935934|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16702166|NCT01935921|Experimental|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
16702167|NCT01935908|No Intervention|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
16702168|NCT01935908|Active Comparator|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
16702169|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
16702170|NCT01935882|Active Comparator|Artemether-Lumefantrine|Artemether-Lumefantrine combination
16702171|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
16702172|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
16702173|NCT01935869|Experimental|LEO 90100|
16702174|NCT01935869|Placebo Comparator|Vehicle|
16702175|NCT01935869|Other|Petrolatum ointment|
16702176|NCT01935856|Experimental|KHK7580|
16702177|NCT01935843|Experimental|Anti-tumor responses of CART-HER-2|
16702178|NCT01935830|Experimental|LAAM arm|"[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)
~Efavirenz, oral capsules, 600 mg
~Ritonavir, oral capsules, 100 mg"
16702179|NCT01935817|Active Comparator|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
16702180|NCT01935817|Placebo Comparator|sugar pill|one placebo pill per day for 12 months
16702181|NCT01935804|Experimental|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
16702182|NCT01935804|Active Comparator|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
16702183|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.
~Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of gelofusine without a cooling vest."
16702184|NCT01935791|Experimental|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min without a cooling vest.
16702243|NCT01935479|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
16702185|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.
~No brown adipose tissue (BAT) identified on visit 1, therefore no visit 2."
16702186|NCT01935791|Experimental|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.
~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius. Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
16702187|NCT01935791|Experimental|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius.
~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.
~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius."
16702188|NCT01935791|Experimental|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.
~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.
~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius."
16702189|NCT01935791|Experimental|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.
~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.
~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius."
16702190|NCT01935791|Experimental|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.
~Visit 2 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.
~Visit 3- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
16702191|NCT01935791|Experimental|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|"Visit 1 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.
~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.
~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius"
16702192|NCT01935778|Active Comparator|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
16702193|NCT01935778|Experimental|Docetaxel and capecitabine and oxaliplatin|"Docetaxel 60 mg/m² will be intravenously infused over at least 1 hour on Day 1 every 3 weeks.
~Oxaliplatin 100 mg/m² will be intravenously infused over at least 2 hours on Day 1 every 3 weeks.
~Capecitabine 800 mg/m² will be orally administered twice daily from Day 1 evening to Day 15 morning every 3 weeks. (Total 1,600 mg/m² daily)"
16702194|NCT01935765|Experimental|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
16702195|NCT01935765|Experimental|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
16702196|NCT01935752|Other|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples & vascular echotracking
16702197|NCT01935752|Other|healthy volunteer|healthy volunteer:blood samples & vascular echotracking
16702198|NCT01935752|Other|hypertensive patients|hypertensive patients:blood samples & vascular echotracking
16702199|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
16702200|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
16702201|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
16702202|NCT01935713|Experimental|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
16702203|NCT01935713|Experimental|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
16702204|NCT01935713|Experimental|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
16702205|NCT01935700|Experimental|colchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
16702206|NCT01935687|Experimental|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
16702207|NCT01935674|Experimental|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
16702208|NCT01935674|Experimental|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
16702209|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
16702210|NCT01935635|Experimental|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
16702211|NCT01935635|Experimental|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
16702212|NCT01935635|Experimental|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
16702213|NCT01935635|No Intervention|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
16702214|NCT01935635|No Intervention|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
16702215|NCT01935635|No Intervention|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
16702216|NCT01935622|Experimental|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
16702217|NCT01935622|Experimental|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
16702218|NCT01935622|Placebo Comparator|Placebo|Placebo
16702219|NCT01935609|Experimental|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
16702220|NCT01935609|No Intervention|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
16702221|NCT01935596|Active Comparator|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
16702222|NCT01935596|Active Comparator|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
16702223|NCT01935583|Experimental|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
16702224|NCT01935583|No Intervention|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
16702225|NCT01935570|Experimental|Magnesium|
16702226|NCT01935557|Active Comparator|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
16702227|NCT01935557|Active Comparator|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
16702228|NCT01935544|Experimental|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
16702229|NCT01935544|Other|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
16702230|NCT01935531|Experimental|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
16702231|NCT01935518|Experimental|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
16702232|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
16702233|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
16702234|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
16702235|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
16702236|NCT01935492|Active Comparator|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
16702237|NCT01935492|Active Comparator|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
16702238|NCT01935479|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
16702239|NCT01935479|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
16702240|NCT01935479|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
16731077|NCT01740505|Experimental|Aerobic Walking|
16702244|NCT01935479|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
16702245|NCT01935479|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
16702246|NCT01935479|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
16702247|NCT01935479|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
16702248|NCT01935479|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
16702249|NCT01935466||Pioglitazone|Ever users of Pioglitazone
16702250|NCT01935466||Other drugs|Never users of pioglitazone
16702251|NCT01935453|Experimental|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
16702252|NCT01935440|Active Comparator|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
16702253|NCT01935440|Experimental|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
16702254|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
16702255|NCT01935414|Experimental|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
16702256|NCT01935414|Active Comparator|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
16702257|NCT01935401||Women with Bulimia Nervosa|"fNIR
~- Functional near-infrared spectroscopy measured-brain activity"
16702258|NCT01935401||Healthy Controls|"fNIR
~- Functional near-infrared spectroscopy measured-brain activity"
16702259|NCT01935388|Experimental|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
16702260|NCT01935388|No Intervention|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
16702261|NCT01935375|Experimental|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
16702262|NCT01935375|Active Comparator|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
16702263|NCT01935362|Placebo Comparator|placebo|Placebo administered to participant
16702264|NCT01935362|Active Comparator|Citrus supplement|Citrus supplement administered to participant
16702265|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
16702266|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16702267|NCT01935323|Experimental|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
16702268|NCT01935323|Active Comparator|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
16702269|NCT01935310|Experimental|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
16702270|NCT01935297|Active Comparator|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
16702271|NCT01935297|No Intervention|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
16702272|NCT01935284||Healthy Volunteers|
16702273|NCT01935271|Experimental|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
16702274|NCT01935271|Placebo Comparator|Placebo|Sugar-based placebo drink mix
16702275|NCT01935258|Experimental|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
16702276|NCT01935258|Other|care as usual|Usual care of the general practitioner
16702277|NCT01935245|Experimental|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
16702278|NCT01935245|Active Comparator|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
16702279|NCT01935232||Men|140 Men
16702280|NCT01935232||Female|500 Female
16702281|NCT01935219|Experimental|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
16702282|NCT01935219|Active Comparator|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
16702283|NCT01935219|Placebo Comparator|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
16702284|NCT01935206|Placebo Comparator|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
16702285|NCT01935206|Experimental|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
16702286|NCT01935193|Experimental|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
16702287|NCT01935180|No Intervention|Standard colonoscopy|
16702288|NCT01935180|Active Comparator|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
16702289|NCT01935167|Experimental|A Group|DW1029M 600mg for 24 weeks
16702290|NCT01935167|Experimental|B Group|DW1029M 1200mg for 24 weeks
16702291|NCT01935167|Placebo Comparator|C Group|Placebo for 24 weeks
16702292|NCT01935154|Placebo Comparator|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
16702293|NCT01935154|Experimental|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
16702294|NCT01935141|Experimental|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
16702295|NCT01935141|Active Comparator|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
16702296|NCT01935128|Experimental|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
16702297|NCT01935115|Active Comparator|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
16702298|NCT01935115|Experimental|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
16702299|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
16702300|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
16702301|NCT01935089|Experimental|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
16702302|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
16702303|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
16702304|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
16702305|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
16702306|NCT01935063|Experimental|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
16702307|NCT01935063|Active Comparator|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, & Steege, 2003).
16702308|NCT01935050|Experimental|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
16702309|NCT01935024|No Intervention|Normal Activity level|
16702310|NCT01935024|Active Comparator|Personalized Exercise Regimen|
16702311|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
16702312|NCT01934998||SCA6 and control|SCA6 and control
16702313|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
16702314|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
16702315|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
16702316|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
16702317|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
16702318|NCT01934972|Experimental|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
16702319|NCT01934972|Active Comparator|CR + placebo|Cognitive Remediation and placebo
16702320|NCT01934959|Experimental|Probiotics|
16702321|NCT01934946|Experimental|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
16731078|NCT01740505|Active Comparator|Stretching and Relaxation|
16702322|NCT01934946|Placebo Comparator|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
16702323|NCT01934933|Active Comparator|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
16702324|NCT01934933|Active Comparator|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
16702325|NCT01934933|Active Comparator|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
16702326|NCT01934907|Experimental|washed RBC|Packed RBCs are Washed and then, transfused.
16702327|NCT01934907|No Intervention|pack RBC|Packed RBCs are transfused.
16702328|NCT01934894|Experimental|cabazitaxel and lapatinib combination|"Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)
~Lapatinib PO once daily (dose to be determined)
~Treatment cycles will be repeated every 3 weeks."
16702329|NCT01934881|Experimental|group I|Voltage adjustment only
16702330|NCT01934881|Experimental|group II|Combined parameters adjustment
16702331|NCT01934868|Experimental|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.
~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
16702332|NCT01934868|Active Comparator|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
16702333|NCT01934842|Experimental|TAP20-C|TAP20-C
16702334|NCT01934842|Active Comparator|SAFE-T-FILL|SAFE-T-FILL
16702335|NCT01934829|Experimental|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
16702336|NCT01934829|Placebo Comparator|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
16702337|NCT01934816|Experimental|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
16702338|NCT01934816|Placebo Comparator|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
16702339|NCT01934816|Active Comparator|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
16702340|NCT01934803|Active Comparator|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
16702341|NCT01934803|Placebo Comparator|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
16702342|NCT01934790|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
16702343|NCT01934777|Experimental|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
16702344|NCT01934777|Placebo Comparator|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
16702345|NCT01934764||autoimmune disease|
16702346|NCT01934751|Other|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
16702347|NCT01934751|Other|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
16702348|NCT01934738|Experimental|Group 1: Cohort 1|
16702349|NCT01934738|Experimental|Group 1: Cohort 2|
16702350|NCT01934738|Experimental|Group 1: Cohort 3|
16702351|NCT01934738|Experimental|Group 2: Cohort 4|
16702352|NCT01934738|Experimental|Group 1: Cohort 5|
16702353|NCT01934738|Experimental|Group 2: Cohort 6|
16702354|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
16702355|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
16702356|NCT01934712|Experimental|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
16702357|NCT01934712|Active Comparator|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
16702358|NCT01934699|Active Comparator|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
16702359|NCT01934699|Experimental|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
16702360|NCT01934686||Subjects with diabetes mellitus (type 2)|
16702361|NCT01934673||Subjects with diabetes (type 2)|
16702362|NCT01934660||Group 1|Healthy volunteers
16702363|NCT01934660||Group 2|Subjects diagnosed with diabetes
16702364|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
16702365|NCT01934647|Experimental|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
16702366|NCT01934647|Experimental|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
16702367|NCT01934647|Experimental|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
16702368|NCT01934634|Experimental|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
16702369|NCT01934621|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
16702370|NCT01934621|Placebo Comparator|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
16702371|NCT01934608|Experimental|Refill synch|Participants in this group will have their medication refill schedule synchronized.
16702372|NCT01934608|No Intervention|Control|Participants in this arm will receive usual care
16702373|NCT01934595|Experimental|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
16702374|NCT01934595|Active Comparator|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
16702375|NCT01934582|Experimental|Open label extension|
16702376|NCT01934569|Experimental|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
16702377|NCT01934556|Active Comparator|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
16702378|NCT01934556|Active Comparator|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
16702379|NCT01934556|Active Comparator|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
16702380|NCT01934543|Experimental|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
16702381|NCT01934543|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
16702382|NCT01934530|Active Comparator|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
16702383|NCT01934530|Experimental|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
16702384|NCT01934504||Tolerant AAV|Tolerant participants with AAV
16702385|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
16702386|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
16702387|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
16702388|NCT01934491|Experimental|Cognitive Training A|emotional memory training exercise
16702389|NCT01934491|Active Comparator|Cognitive Training B|memory training exercise
16702390|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
16702391|NCT01934452||Complete Remission|Complete remission arm in mRCC patients treated with sunitinib.
16731350|NCT01738698|Placebo Comparator|Placebo|
16702392|NCT01934452||Non Complete Remission|Non complete remission arm in mRCC patients treated with sunitinib.
16702393|NCT01934439|Experimental|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
16702394|NCT01934426||Admission High Risk|Admission High Risk
16702395|NCT01934413|Active Comparator|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
16702396|NCT01934413|Other|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
16702397|NCT01934374|Experimental|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
16702398|NCT01934374|No Intervention|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
16702399|NCT01934361|Experimental|Lomustine+ buparlisib (Phase Ib)|
16702400|NCT01934361|Experimental|carboplatin+ buparlisib (Phase Ib)|
16702401|NCT01934361|Experimental|lomustine+ buparlisib (Phase II)|
16702402|NCT01934361|Placebo Comparator|lumustine + placebo (Phase II)|
16702403|NCT01934361|Experimental|carboplatin+ buparlisib (Phase II)|
16702404|NCT01934348|Experimental|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
16702405|NCT01934348|Active Comparator|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
16702406|NCT01934335|Experimental|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
16702407|NCT01934335|Placebo Comparator|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
16702408|NCT01934322|Experimental|Case Management|"Furnish specific assistance and to provide referrals for the patients:
~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.
~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.
~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.
~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
16702409|NCT01934322|No Intervention|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
16702410|NCT01934309|Experimental|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
16702411|NCT01934309|No Intervention|No TB reminders|Only receive existing reminders; no TB reminders
16702412|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
16702413|NCT01934283|No Intervention|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
16702414|NCT01934270|Experimental|Anaerobic Test|
16702415|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
16702416|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
16702417|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
16702418|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
16702419|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
16702420|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
16702421|NCT01934231|Experimental|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
16702422|NCT01934218|Active Comparator|Gel-One|3 mL, a single intra-articular injection of Gel-One
16702423|NCT01934218|Placebo Comparator|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
16702424|NCT01934205|Experimental|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
16702425|NCT01934205|Experimental|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
16702426|NCT01934205|Experimental|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
16702427|NCT01934205|Experimental|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
16702428|NCT01934205|Experimental|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702429|NCT01934205|Experimental|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702430|NCT01934205|Experimental|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702431|NCT01934205|Experimental|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702432|NCT01934205|Experimental|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702433|NCT01934205|Experimental|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702434|NCT01934205|Experimental|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702435|NCT01934205|Experimental|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
16702436|NCT01934192|Experimental|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
16702437|NCT01934192|Placebo Comparator|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
16702438|NCT01934192|Experimental|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
16702439|NCT01934192|Active Comparator|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
16702440|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
16702441|NCT01934166|Experimental|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
16702442|NCT01934153|Experimental|Cohort A|Single dose of topical [14C]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
16702443|NCT01934153|Experimental|Cohort B|Single dose of topical [14C]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
16702444|NCT01934153|Experimental|Cohort C|Single dose of topical [14C]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
16702445|NCT01934153|Experimental|Cohort D|Single dose of topical [14C]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
16702446|NCT01934140|Experimental|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
16702447|NCT01934140|Active Comparator|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
16702448|NCT01934127|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
16702449|NCT01934127|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
16702450|NCT01934127|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
16702451|NCT01934127|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
16702452|NCT01934127|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
16702453|NCT01934127|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
16702454|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
16702455|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
16702456|NCT01934101|Experimental|CHR-5154|CHR-5154
16702457|NCT01934101|Placebo Comparator|Placebo|Placebo
16702458|NCT01934088|Experimental|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
16702459|NCT01934088|Active Comparator|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
16702460|NCT01934075|Experimental|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
16702461|NCT01934075|No Intervention|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
16702462|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
16702463|NCT01934049|Active Comparator|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
16702464|NCT01934049|Placebo Comparator|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
16702465|NCT01934036|Experimental|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
16702466|NCT01934036|Placebo Comparator|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
16702467|NCT01934023|Active Comparator|Varenicline|FDA approved smoking cessation medication
16702468|NCT01934023|Placebo Comparator|Placebo Sugar Pill|sugar pill
16702469|NCT01934010|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
16702470|NCT01933997|Experimental|MG01CI 1400 mg|
16702471|NCT01933984|Experimental|Individualized dosing|"Ventilator support
~Determining personal target airway resistance
~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
~Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
16702472|NCT01933984|Active Comparator|Fixed dosing|"Ventilator support
~Determining personal target airway resistance
~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
~No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
16702473|NCT01933971|Other|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.
~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.
~The sites, where the injections are to be performed, are planned as follows:
~st injection: upper part of the upper arm, posterior surface
~nd injection: upper part of the thigh
~rd injection: abdomen with the exception of the umbilical area
~th injection: upper part of the contra-lateral upper arm, posterior surface
~th injection: upper part of the contra-lateral thigh
~th injection: abdomen with the exception of the umbilical area
~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
16702474|NCT01933971|Other|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.
~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.
~The sites, where the injections are to be performed, are planned as follows:
~st injection: upper part of the upper arm, posterior surface
~nd injection: upper part of the thigh
~rd injection: abdomen with the exception of the umbilical area
~th injection: upper part of the contra-lateral upper arm, posterior surface
~th injection: upper part of the contra-lateral thigh
~th injection: abdomen with the exception of the umbilical area
~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
16702475|NCT01933971|Other|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.
~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.
~The sites, where the injections are to be performed, are planned as follows:
~st injection: upper part of the upper arm, posterior surface
~nd injection: upper part of the thigh
~rd injection: abdomen with the exception of the umbilical area
~th injection: upper part of the contra-lateral upper arm, posterior surface
~th injection: upper part of the contra-lateral thigh."
16702477|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
16702478|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
16702479|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
16702480|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
16702481|NCT01933919|Placebo Comparator|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.
~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
16702482|NCT01933919|Experimental|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.
~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
16702483|NCT01933906|Experimental|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.
~Maximum treatment duration will not expand 18 months."
16702484|NCT01933880|Experimental|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
16702485|NCT01933880|Active Comparator|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
16702486|NCT01933867|Experimental|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
16702487|NCT01933867|Active Comparator|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
16702488|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
16702489|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
16702490|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
16702491|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
16702492|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
16702493|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
16702494|NCT01933828|Active Comparator|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
16702495|NCT01933828|Active Comparator|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
16702496|NCT01933828|Other|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
16702497|NCT01933815|Experimental|TPI 287 + bevacizumab|"All subjects in phase 1 & subjects randomized to the TPI 287 + bevacizumab arm in phase 2 will be administered a 1-hour IV infusion of TPI 287 once every 3 weeks (Days 1 & 22 of 42-day cycle) & a 30-90 minute IV infusion of bevacizumab once every 2 weeks (Days 1, 15, & 29).
~In phase 1, the dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6, while the dose of bevacizumab remains constant (10 mg/kg). The first 5 dose levels will be 140, 150, 160, 170, & 180 mg/m2. Dose levels beyond 180 mg/m2 will be increased in increments of 20 mg/m2. Three subjects will be treated at a dose level halfway between the dose level that exceeds the MTD and the dose level immediately prior to further refine the MTD.
~In phase 2, the dose of TPI 287 will be the MTD determined in phase 1, & the dose of bevacizumab will be the same as phase 1 (10 mg/kg).
~Subjects may continue on treatment unless they meet one or more of the protocol discontinuation criteria."
16702498|NCT01933815|Active Comparator|Bevacizumab|"All subjects randomized to the bevacizumab alone arm in phase 2 will be administered bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of a 42-day cycle). The dose of bevacizumab will be 10 mg/kg.
~Subjects will be withdrawn from the study if they meet one or more of the discontinuation criteria outlined in the protocol; however, treatment with bevacizumab may continue under the FDA approved labeling for bevacizumab at the discretion of the subject's doctor.
~All subjects in phase 1 will be administered TPI 287 in combination with bevacizumab (i.e., there will be no bevacizumab alone arm during phase 1)."
16702499|NCT01933802|Experimental|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
16702500|NCT01933789|Experimental|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
16702501|NCT01933789|No Intervention|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
16702502|NCT01933776|Experimental|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
16702503|NCT01933776|Experimental|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
16702504|NCT01933763|Experimental|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
16702505|NCT01933763|Experimental|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
16702506|NCT01933750|No Intervention|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
16702507|NCT01933750|Experimental|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
16702508|NCT01933737|Experimental|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
16702509|NCT01933737|Experimental|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
16702510|NCT01933724|Experimental|5 mg prednisone|Subjects will be randomized to 5 mg per day of prednisone for a 6 month period.
16702511|NCT01933724|Experimental|0 mg prednisone|Subjects will be randomized to 0 mg per day of prednisone dose for a 6 month period.
16702512|NCT01933711|Experimental|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
16702513|NCT01933711|No Intervention|Observation|observational arm, no intervention
16702514|NCT01933698|Active Comparator|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
16702515|NCT01933698|Active Comparator|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
16702516|NCT01933685|Experimental|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
16702517|NCT01933685|Placebo Comparator|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
16702518|NCT01933672|Experimental|PF-04937319 once-daily|
16702519|NCT01933672|Experimental|PF-04937319 split-dose|
16702520|NCT01933672|Active Comparator|Sitagliptin once-daily|
16702521|NCT01933659|Experimental|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
16702522|NCT01933659|Placebo Comparator|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
16702523|NCT01933646||Cohort 1|
16702524|NCT01933633|Experimental|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
16702525|NCT01933633|No Intervention|Control|Standard care
16702526|NCT01933620||Patient|Patients who might become colonized or infected with a multi drug-resistant organism
16702527|NCT01933607|Other|TOPS System|Post Marketing Study
16702528|NCT01933594|Experimental|Cohort 1-Arm 1A (Romidepsin)|Participants in Cohort 1, Arm 1A received Romidepsin intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702529|NCT01933594|Placebo Comparator|Cohort 1-Arm 1B (Placebo for Romidepsin)|Participants in Cohort 1, Arm 1B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702530|NCT01933594|Experimental|Cohort 2-Arm 2A (Romidepsin)|Participants in Cohort 2, Arm 2A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702531|NCT01933594|Placebo Comparator|Cohort 2-Arm 2B (Placebo for Romidepsin)|Participants in Cohort 2, Arm 2B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702532|NCT01933594|Experimental|Cohort 3-Arm 3A (Romidepsin)|Participants in Cohort 3, Arm 3A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702533|NCT01933594|Placebo Comparator|Cohort 3-Arm 3B (Placebo for Romidepsin)|Participants in Cohort 3, Arm 3B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702534|NCT01933594|Experimental|Cohort 4-Arm 4A (Romidepsin)|Participants in Cohort 4, Arm 4A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702535|NCT01933594|Placebo Comparator|Cohort 4-Arm 4B (Placebo for Romidepsin)|Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
16702536|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
16702537|NCT01933568|Experimental|Radiation|combined CFRT and SABR with concurrent cisplatin
16702538|NCT01933555|Experimental|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
16731351|NCT01738685|Other|Control.|Nutritional Education.
16702539|NCT01933555|No Intervention|Control group|Standard care, which was routine check ups and care provided by health care professionals.
16702540|NCT01933542|Active Comparator|Chlorzoxazone|"Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
16702541|NCT01933542|Placebo Comparator|Placebo|"Oral administration of two placebo tablets
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
16702542|NCT01933529|Experimental|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
16702543|NCT01933529|Placebo Comparator|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
16702544|NCT01933516|Experimental|GP2013|
16702545|NCT01933503|Experimental|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
16702546|NCT01933503|Experimental|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
16702547|NCT01933503|Experimental|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
16702548|NCT01933490|Other|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
16702549|NCT01933490|Active Comparator|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
16702550|NCT01933490|Active Comparator|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
16702551|NCT01933477|No Intervention|Local Standard of Care|Arm A: Referral of post-partum women from the antenatal clinic to general adult ART services at approximately 4-8 weeks postpartum (the local current standard of care in this setting)
16702552|NCT01933477|Active Comparator|MCH-focused ART services|Arm B: Continued receipt of MCH-focused ART services based at the antenatal clinic throughout the period of breastfeeding. Post-partum women will only be referred to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined.
16702553|NCT01933464|Experimental|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
16702554|NCT01933464|Placebo Comparator|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
16702555|NCT01933451|Experimental|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
16702556|NCT01933451|Other|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
16702557|NCT01933438|Experimental|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
16702558|NCT01933438|Active Comparator|Control|Standard treatment
16702559|NCT01933425|Active Comparator|Deep neuromuscular block followed by no neuromuscular block|"Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.
~Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade"
16702560|NCT01933425|Placebo Comparator|No neuromuscular block followed by deep neuromuscular block|"No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.
~Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade."
16702561|NCT01933412|Experimental|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
16702562|NCT01933412|Active Comparator|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
16702563|NCT01933399|Other|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
16702564|NCT01933399|Experimental|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
16702565|NCT01933399|Experimental|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
16702566|NCT01933386|Other|SoundBite|SoundBite will be used for the first 30 days
16702567|NCT01933386|Other|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
16702568|NCT01933373|Active Comparator|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
16702569|NCT01933373|Experimental|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
16702570|NCT01933360|Active Comparator|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
16702571|NCT01933360|Active Comparator|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
16702572|NCT01933360|Active Comparator|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
16702573|NCT01933360|Active Comparator|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
16702574|NCT01933347|Experimental|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
16702575|NCT01933334|Experimental|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day [mg/day]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
16702641|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
16702645|NCT01932801|No Intervention|Assessment-only|Assessment-only control condition
16702576|NCT01933334|Experimental|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
16702577|NCT01933321|Experimental|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
16702578|NCT01933308|Experimental|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
16702579|NCT01933308|Experimental|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
16702580|NCT01933308|Experimental|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. [33] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
16702581|NCT01933295|Active Comparator|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
16702582|NCT01933295|Experimental|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
16702583|NCT01933295|Experimental|Sleep Restriction Therapy|Brief sleep restriction therapy.
16702584|NCT01933282|Experimental|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
16702585|NCT01933269|Experimental|FACBC|
16702586|NCT01933256|Experimental|600mg HIP2B|600mg HIP2B
16702587|NCT01933256|Placebo Comparator|Placebo|Placebo
16702588|NCT01933256|Experimental|400mg HIP2B|400mg HIP2B
16702589|NCT01933243|Experimental|Fish oil|Fish oil for 12 weeks
16702590|NCT01933243|Placebo Comparator|Placebo pill|Placebo pills for 12 weeks
16702591|NCT01933230|Other|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
16702592|NCT01933217|Experimental|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
16702593|NCT01933217|Placebo Comparator|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
16702594|NCT01933204|Experimental|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
16702595|NCT01933204|Active Comparator|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
16702596|NCT01933191|Experimental|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
16702597|NCT01933191|Placebo Comparator|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
16702598|NCT01933178|Other|Cirrus AS-OCT|
16702599|NCT01933165|Other|LipiView|
16702600|NCT01933152||Group 1|
16702601|NCT01933139|Experimental|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
16702602|NCT01933139|No Intervention|Control|standard physician interaction (control arm)
16702603|NCT01933126|Experimental|HCG administration|Intrauterine HCG injection
16702604|NCT01933126|Placebo Comparator|Placebo|G2 Medium
16702642|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
16702605|NCT01933113|Experimental|DBS of the Lateral Hypothalamic Area|"Single Arm: Deep Brain Stimulation of LHA for maximum RMR On days 1-4, subjects stayed in the inpatient unit to have metabolic weight, temperature, and resting metabolic rate (RMR) measured at different settings.
~Metabolic testing RMR measurement: A clear plastic hood was placed over the head and chest Oxygen intake and carbon dioxide out-put were measured to determine how many calories were burned during the next 15-30 minutes. Each hour for the next seven hours, DBS settings were changed and the above process was repeated. On Day 4, a DXA scan was performed to assess body composition. Primary endpoint is the determination of optimal settings"
16702606|NCT01933100|Experimental|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
16702607|NCT01933100|Experimental|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
16702608|NCT01933100|Experimental|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
16702609|NCT01933087|No Intervention|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
16702610|NCT01933087|Experimental|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
16702611|NCT01933061|Experimental|Abraxane 150 mg/m² Intravenous (IV)|
16702612|NCT01933061|Experimental|CC-486 orally plus Abraxane IV|
16702613|NCT01933048|Other|Healthcare Worker Administration|FluMist administered by a Healthcare Worker
16702614|NCT01933048|Experimental|Self-Administration|FluMist self-administered by subject
16702615|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
16702616|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population.
16702617|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
16702618|NCT01933022|Other|Single Arm: Eligard|Single Arm
16702619|NCT01932996|Active Comparator|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
16702620|NCT01932996|Placebo Comparator|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
16702621|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
16702622|NCT01932970|Experimental|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
16702623|NCT01932957|Other|Laparotomy arm|Standard treatment
16702624|NCT01932957|Experimental|Laparoscopy arm|Treatment by laparoscopy
16702625|NCT01932944||No treatment|
16702626|NCT01932931|Active Comparator|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
16702627|NCT01932931|Placebo Comparator|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
16702628|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
16702629|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
16702630|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
16702631|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
16702632|NCT01932905|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
16702633|NCT01932905|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
16702634|NCT01932905|Active Comparator|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
16702635|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
16702636|NCT01932879|Experimental|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
16702637|NCT01932879|Other|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
16702638|NCT01932866|Active Comparator|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
16702639|NCT01932866|Experimental|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
16702640|NCT01932853||Hemodialysis patients|Patients > 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
16702646|NCT01932801|Active Comparator|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
16702647|NCT01932801|Experimental|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
16702648|NCT01932801|Placebo Comparator|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
16702649|NCT01932788|Active Comparator|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
16702650|NCT01932788|Placebo Comparator|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
16702651|NCT01932775|Experimental|GlucoTab System|
16702652|NCT01932762|Experimental|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
16702653|NCT01932762|Experimental|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
16702654|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
16702655|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
16702656|NCT01932749|Active Comparator|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:
~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
16702657|NCT01932749|Active Comparator|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:
~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
16702658|NCT01932736|Experimental|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
16702659|NCT01932723|Experimental|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
16702660|NCT01932710|Experimental|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
16702661|NCT01932697|Experimental|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
16702662|NCT01932684|Experimental|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
16702663|NCT01932684|No Intervention|Control Group|
16702664|NCT01932684|Experimental|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
16702665|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
16702666|NCT01932658|Experimental|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
16702667|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
16702668|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
16702669|NCT01932632|No Intervention|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
16702670|NCT01932632|Experimental|Medication Minimization|"Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)
~Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
16702671|NCT01932606|Experimental|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
16702672|NCT01932606|Placebo Comparator|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
16702673|NCT01932593|Experimental|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
16702674|NCT01932593|Placebo Comparator|Placebo|
16702752|NCT01931995|Active Comparator|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
16702675|NCT01932580|Other|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.
~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
16702676|NCT01932567|Experimental|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
16702677|NCT01932567|Experimental|Incentive spirometry|Use of incentive spirometry during 3 minutes
16702678|NCT01932567|Experimental|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
16702679|NCT01932554|Experimental|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.
~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
16702680|NCT01932554|Placebo Comparator|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.
~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
16702681|NCT01932541|Experimental|Latuda (Lurasidone)|
16702682|NCT01932528|Experimental|500 mg LX606|All subjects will receive a single oral 500 mg dose of [14C]-LX1606.
16702683|NCT01932515|No Intervention|Screening|
16702684|NCT01932502|Experimental|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
16702685|NCT01932489|Other|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
16702686|NCT01932476|Experimental|Celiac Disease Alone Gluten Challenge|
16702687|NCT01932476|Sham Comparator|Celiac Disease Alone Sham Challenge|
16702688|NCT01932476|Experimental|Celiac Disease and T1D Gluten Challenge|
16702689|NCT01932476|Sham Comparator|Celiac Disease and T1D Sham Challenge|
16702690|NCT01932463|Experimental|ExAb;ate MRgFUS|
16702691|NCT01932450|Experimental|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
16702692|NCT01932450|Active Comparator|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
16702693|NCT01932437|Experimental|Cohort 1|"3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.
~1 subject will receive an IM dose of ETI-204-placebo in an identical fashion."
16702694|NCT01932437|Experimental|Cohort 2|"6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
16702695|NCT01932437|Experimental|Cohort 3|"6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
16702696|NCT01932437|Experimental|Cohort 4|"6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
16702697|NCT01932437|Experimental|Cohort 5|"6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
16702698|NCT01932424|Experimental|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
16702699|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
16702700|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
16702701|NCT01932385|Experimental|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
16702702|NCT01932385|Active Comparator|Best Supportive Care|treatment mainly on nutrition and symptoms control
16702703|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
16702704|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
16702705|NCT01932359|Active Comparator|rapidly absorbable suture (Vicryl Rapide)|
16702706|NCT01932359|Active Comparator|non-absorbable suture (Ethilon)|
16702707|NCT01932333|Experimental|Cohort 1|
16702708|NCT01932333|Experimental|Cohort 2|
16702709|NCT01932320|Experimental|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
16702753|NCT01931995|Active Comparator|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
16731352|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
16702710|NCT01932320|Experimental|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
16702711|NCT01932320|Experimental|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
16702712|NCT01932307|Experimental|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
16702713|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
16702714|NCT01932281|Experimental|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
16702715|NCT01932281|Placebo Comparator|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
16702716|NCT01932268|Experimental|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
16702717|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
16702718|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
16702719|NCT01932242|Experimental|Sequence A|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 14 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 120.
16702720|NCT01932242|Experimental|Sequence B|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 120 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 14.
16702721|NCT01932229|Experimental|Afatinib treatment|
16702722|NCT01932216|Active Comparator|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
16702723|NCT01932216|Active Comparator|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
16702724|NCT01932203|Active Comparator|aspirin|aspirin 100mg by mouth once a day for 104 weeks
16702725|NCT01932203|Experimental|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
16702726|NCT01932190|Experimental|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
16702727|NCT01932190|Experimental|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
16702728|NCT01932177|Active Comparator|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
16702729|NCT01932177|Active Comparator|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
16702730|NCT01932177|Experimental|Schedule C|Everolimus and sorafenib in alternance
16702731|NCT01932177|Experimental|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
16702732|NCT01932164|Experimental|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
16702733|NCT01932151|Other|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
16702734|NCT01932138|Experimental|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
16702735|NCT01932138|Other|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
16702736|NCT01932125|Experimental|Cohort|
16702737|NCT01932112|Other|adenosine arm|single arm study
16702738|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
16702739|NCT01932086|Experimental|White rice|
16702740|NCT01932086|Experimental|Brown rice|
16702741|NCT01932086|Experimental|Black rice|
16702742|NCT01932086|Active Comparator|Bread|
16702743|NCT01932086|Active Comparator|Glucose solution|
16702744|NCT01932073|No Intervention|Control Group|Receives institutional skin care protocol
16702745|NCT01932073|Experimental|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
16702746|NCT01932060|Experimental|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
16702747|NCT01932060|Active Comparator|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
16702748|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
16702749|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
16702750|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
16702751|NCT01932021|Experimental|adipose tissue grafting|
16702754|NCT01931982|Active Comparator|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
16702755|NCT01931982|No Intervention|No treatment|
16702756|NCT01931969||IJVC intervention|
16702757|NCT01931956|Experimental|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
16702758|NCT01931956|Experimental|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
16702759|NCT01931956|Experimental|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
16702760|NCT01931956|Experimental|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
16702761|NCT01931943|Experimental|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
16702762|NCT01931930|Experimental|Perilla extract|Experimental arm: Perilla extract
16702763|NCT01931930|Placebo Comparator|Maltodextrin|Placebo arm: Maltodextrin
16702764|NCT01931917|Experimental|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
16702765|NCT01931917|Active Comparator|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
16702766|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
16702767|NCT01931891||prreclampsia|
16702768|NCT01931878|Placebo Comparator|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
16702769|NCT01931878|Active Comparator|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
16702770|NCT01931865|Experimental|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
16702771|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
16702772|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
16702773|NCT01931839|Experimental|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
16702774|NCT01931839|Experimental|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
16702775|NCT01931839|Experimental|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
16702776|NCT01931839|Experimental|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
16702777|NCT01931839|No Intervention|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
16702778|NCT01931839|Experimental|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
16702779|NCT01931839|Experimental|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
16702780|NCT01931826|Active Comparator|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
16702781|NCT01931826|Active Comparator|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
16702782|NCT01931813||Infants likely to present febrile convulsions|
16702783|NCT01931800||Presenting patients a pneumonia pneumococcique|
16702784|NCT01931800||Patients presenting a bacteremia pneumococcique|
16702785|NCT01931800||Patients affected by pneumococcique meningitis|
16702786|NCT01931787|Experimental|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16702787|NCT01931774||Acne Patients|
16702788|NCT01931774||Control Subjects|From General Population
16702789|NCT01931761|Experimental|[C14] selumetinib 75mg single dose|[C14] selumetinib 75mg single dose
16702790|NCT01931748|Experimental|UNCNT|6 times/ 12 days
16702791|NCT01931748|Active Comparator|MELSMON|6 times/ 12 days
16702792|NCT01931735|Experimental|Randomized Meniscectomy|This group will have a partial meniscectomy
16702793|NCT01931735|Active Comparator|Randomized Lavage|This group will have arthroscopy and lavage
16702794|NCT01931735|Other|Standard of Care Meniscectomy Pre-Amend|Pre-Amendment: surgeons determined standard of care option, meniscectomy, best benefited the patient. Therefore, the patient was not randomized.
16702795|NCT01931735|Other|Standard of Care Meniscectomy Post-Amend|Post Amendment: patients received a meniscectomy as a standard of care and were observed for 24-months post-operative.
16702796|NCT01931722|Active Comparator|Branched chain amino acid|Branched chain amino acid as food supplement
16702797|NCT01931722|Active Comparator|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
16702798|NCT01931709|Experimental|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
16702799|NCT01931696|Experimental|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
16702800|NCT01931696|Sham Comparator|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
16702801|NCT01931683|Experimental|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
16702802|NCT01931670|Placebo Comparator|Placebo|Placebo twice daily (BID) for the 6-month Treatment Period
16702803|NCT01931670|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
16702804|NCT01931670|Experimental|Elagolix 200 mg BID|Elagolix 200 mg BID for the 6-month Treatment Period
16702805|NCT01931657|Experimental|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
16702806|NCT01931657|Placebo Comparator|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
16702807|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
16702808|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
16702809|NCT01931631|Experimental|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
16702810|NCT01931631|Active Comparator|ADA diet|American Diabetes Association diet
16702811|NCT01931618|Active Comparator|Usual care|"Receives two interventions:
~Online screening and feedback.
~Online booklet."
16702812|NCT01931618|Experimental|Extended follow-up|"Receives two interventions:
~Online screening and feedback.
~Online multi session follow-up."
16702813|NCT01931605|Experimental|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
16702814|NCT01931592|Active Comparator|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
16702815|NCT01931592|Placebo Comparator|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
16702816|NCT01931579|Experimental|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
16702817|NCT01931566|Placebo Comparator|Low Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.
16702818|NCT01931566|Placebo Comparator|High Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
16702819|NCT01931566|Experimental|High Risk Pioglitazone|Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
16702820|NCT01931553|Experimental|Standardized attending morning rounds|"Pre-rounds discretion
~Pre-rounds huddle
~Bedside RN integration
~Patient-centered rounding
~Real-time order writing"
16702821|NCT01931553|No Intervention|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
16702822|NCT01931540|Experimental|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
16702823|NCT01931540|No Intervention|11 non-frail controls (9 LM)|Studied only at baseline
16702824|NCT01931540|Experimental|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
16702825|NCT01931527|No Intervention|Obese subjects with normal uric acid|Subjects with a body mass index = or > 30 kg/m² with normal uric acid (= or < 5 mg/dL)
16702826|NCT01931527|Experimental|Obese subjects with high uric acid|"Subjects with a body mass index = or > 30 kg/m² with high uric acid (>6 mg/dL)
~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
16702827|NCT01931488|Other|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
16702828|NCT01931475|Experimental|Duloxetine|"Double Blind Treatment Phase:
~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
~Extension Treatment Phase:
~60 mg duloxetine administered by mouth QD for 13 weeks.
~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
16702829|NCT01931475|Placebo Comparator|Placebo|"Double Blind Treatment Phase:
~Placebo administered by mouth once a day (QD) for 13 weeks.
~Extension Treatment Phase:
~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
16702830|NCT01931462|Experimental|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
16702831|NCT01931449|Experimental|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
16702832|NCT01931449|Active Comparator|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
16702833|NCT01931436|Experimental|Qing'E pill|Administered twice a day, and each 9 g
16702834|NCT01931423|Placebo Comparator|Drainage Group|early placental drainage plus cord traction
16702835|NCT01931423|No Intervention|Controlled Group|spontaneous removal placenta
16702836|NCT01931410|Placebo Comparator|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
16702837|NCT01931410|Placebo Comparator|rectal|rectal 600 mgr misoprostol will be administered
16702838|NCT01931410|No Intervention|synpitan|
16702839|NCT01931384|Experimental|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
16702840|NCT01931384|Placebo Comparator|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
16702841|NCT01931371|Active Comparator|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
16702842|NCT01931371|Active Comparator|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
16702843|NCT01931358|Experimental|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
16702844|NCT01931358|Placebo Comparator|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
16702845|NCT01931358|Experimental|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
16702846|NCT01931358|Placebo Comparator|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
16702847|NCT01931358|Experimental|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
16702848|NCT01931358|Placebo Comparator|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
16702849|NCT01931358|Experimental|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
16702850|NCT01931358|Placebo Comparator|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
16702851|NCT01931345|Experimental|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
16702852|NCT01931345|Active Comparator|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
16702853|NCT01931332|Active Comparator|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
16702854|NCT01931332|Active Comparator|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
16702855|NCT01931319|Experimental|Intravenous Baclofen|Three single doses were evaluated using three cohorts (N=12 per cohort). Subjects received single doses of baclofen: 7.5, 11.5 or 15mg 10-minute intravenous infusion administered over 10 minutes by an infusion pump and 10, 15, or 20mg taken orally with a 48-hour washout phase between oral and intravenous arms of the study. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
16702856|NCT01931293|Experimental|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
16702857|NCT01931280|Experimental|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
16702858|NCT01931280|No Intervention|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
16702859|NCT01931267|Experimental|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
16702860|NCT01931267|Active Comparator|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
16702861|NCT01931241|Experimental|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
16702862|NCT01931241|Experimental|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
16702863|NCT01931241|Experimental|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
16702864|NCT01931241|Experimental|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 & 3
16702865|NCT01931241|Experimental|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
16702866|NCT01931228|Experimental|MI-E plus manually assisted coughing|
16702867|NCT01931228|Experimental|Manually assisted coughing only|
16702868|NCT01931215|Active Comparator|morphine group|spinal anesthesia with intrathecal morphine
16702869|NCT01931215|Experimental|TAP group|TAP-block with ropivacaine and clonidine
16702870|NCT01931202|Placebo Comparator|Double Blind-Placebo|Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.
16702871|NCT01931202|Active Comparator|Double Blind-Escitalopram|Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.
16702872|NCT01931202|Active Comparator|Open Treatment with Escitalopram|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
16702873|NCT01931189|Experimental|NI-071|
16702874|NCT01931189|Active Comparator|Infliximab|
16702875|NCT01931176|Experimental|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
16702876|NCT01931176|Placebo Comparator|Placebo|Participants will receive a single injection of placebo at study entry.
16702877|NCT01931163|Experimental|Everolimus|Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily
16702878|NCT01931150|Experimental|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
16702879|NCT01931150|Experimental|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
16702880|NCT01931137|Experimental|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
16702881|NCT01931137|Experimental|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
16702882|NCT01931137|Experimental|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
16702883|NCT01931124|Experimental|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
16702884|NCT01931124|Experimental|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
16702885|NCT01931111||Norwegian Elderly Population|
16702886|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
16702887|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
16702888|NCT01931072|Experimental|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
16702889|NCT01931072|Active Comparator|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
16702890|NCT01931072|No Intervention|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
16702891|NCT01931059|Experimental|Risperidone then Placebo|This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
16702930|NCT01930747|Experimental|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
16702892|NCT01931059|Experimental|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day
16702893|NCT01931046|Experimental|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
16702894|NCT01931046|Experimental|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
16702895|NCT01931033|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
16702896|NCT01931020|Active Comparator|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
16702897|NCT01931020|Experimental|Glucose|1ml of 25% glucose will be administered prior to heel lance
16702898|NCT01931007|Experimental|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
16702899|NCT01931007|Placebo Comparator|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
16702900|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
16702901|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
16702902|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
16702903|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
16702904|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
16702905|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
16702906|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
16702907|NCT01930955|Active Comparator|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
16702908|NCT01930955|No Intervention|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
16702909|NCT01930942|Experimental|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
16702910|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
16702911|NCT01930916|Other|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
16702912|NCT01930890|Experimental|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
16702913|NCT01930890|Experimental|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
16702914|NCT01930877|Active Comparator|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
16702915|NCT01930877|Placebo Comparator|Placebo|Normal saline placebo infusion
16702916|NCT01930864|Experimental|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
16702917|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
16702918|NCT01930838||Controls|Matched on age, sex and body mass index
16702919|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
16702920|NCT01930812|Experimental|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
16702921|NCT01930799|Other|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
16702922|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
16702923|NCT01930773|Experimental|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
16702924|NCT01930773|Experimental|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
16702925|NCT01930773|No Intervention|Conventional Arm|Regular approach for performing elective PCI.
16702926|NCT01930760|Experimental|Educational Intervention Group|
16702927|NCT01930760|Experimental|Behavioural Intervention Group|
16702928|NCT01930747|Experimental|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
16702929|NCT01930747|Experimental|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
16702931|NCT01930734|Placebo Comparator|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.
~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
16702932|NCT01930734|Experimental|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
16702933|NCT01930721|Experimental|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
16702934|NCT01930721|Experimental|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
16702935|NCT01930708|Experimental|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
16702936|NCT01930682|Experimental|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
16702937|NCT01930682|Other|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
16702938|NCT01930669|Other|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
16702939|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
16702940|NCT01930643|Experimental|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
16702941|NCT01930643|No Intervention|Control|Patients with routine passive rehabilitation program.
16702942|NCT01930630|Experimental|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
16702943|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
16702944|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
16702945|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
16702946|NCT01930604|Active Comparator|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
16702947|NCT01930604|Placebo Comparator|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
16702948|NCT01930604|Active Comparator|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
16702949|NCT01930604|Placebo Comparator|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
16702950|NCT01930604|Active Comparator|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
16702951|NCT01930604|Placebo Comparator|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
16702952|NCT01930604|Active Comparator|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
16702953|NCT01930604|Placebo Comparator|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
16702954|NCT01930604|Active Comparator|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
16702955|NCT01930604|Placebo Comparator|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
16702956|NCT01930591|Active Comparator|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
16702957|NCT01930591|Experimental|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
16702958|NCT01930578|Experimental|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
16702959|NCT01930578|Experimental|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
16702960|NCT01930578|Experimental|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
16702961|NCT01930565|Experimental|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
16702962|NCT01930565|Active Comparator|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
16702963|NCT01930552|Experimental|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
16702964|NCT01930539|Experimental|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
16703850|NCT01924832|Experimental|BG00012 Part 1|BG00012 120 mg delivered to varying locations of the GI tract
16702965|NCT01930539|No Intervention|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
16702966|NCT01930526|Experimental|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
16702967|NCT01930500|Experimental|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
16702968|NCT01930500|Experimental|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
16702969|NCT01930500|No Intervention|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
16702970|NCT01930487|Experimental|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
16702971|NCT01930487|Experimental|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
16702972|NCT01930461|Experimental|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
16702973|NCT01930461|Experimental|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
16702974|NCT01930461|Experimental|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
16702975|NCT01930461|Placebo Comparator|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
16702976|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
16702977|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
16702978|NCT01930435|Experimental|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
16702979|NCT01930422|Experimental|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
16702980|NCT01930422|Sham Comparator|Placebo tDCS|Sham procedure
16702981|NCT01930409|Active Comparator|Education Only|"A 1 hour education session in the acute setting
~A toolkit with education, exercise and self management instructions for after hip fracture"
16702982|NCT01930409|Experimental|Education + Telephone Follow-up|"A 1 hour education session in the acute setting
~A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
16702983|NCT01930396|Experimental|Tinzaparin|
16702984|NCT01930396|Active Comparator|Unfractionated Heparin|
16702985|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
16702986|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
16702987|NCT01930383||Arm C|patients who receive systemic therapy
16702988|NCT01930370|Experimental|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
16702989|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
16702990|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
16702991|NCT01930344|Active Comparator|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
16702992|NCT01930344|Placebo Comparator|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
16702993|NCT01930331|Experimental|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
16702994|NCT01930331|Active Comparator|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
16702995|NCT01930318|Placebo Comparator|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
16702996|NCT01930318|Placebo Comparator|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
16702997|NCT01930318|Experimental|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
16702998|NCT01930318|Experimental|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
16702999|NCT01930292|Experimental|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
16703000|NCT01930292|Experimental|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
16703001|NCT01930292|Experimental|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
16703002|NCT01930292|Experimental|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
16703003|NCT01930279||surface markers on T cells as assessed by FACS|
16703004|NCT01930266|No Intervention|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
16703005|NCT01930266|Active Comparator|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
16703006|NCT01930266|Experimental|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
16703007|NCT01930240|Placebo Comparator|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
16703008|NCT01930240|Experimental|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
16703009|NCT01930240|Experimental|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
16703010|NCT01930227|Experimental|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
16703011|NCT01930227|Sham Comparator|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
16703012|NCT01930227|No Intervention|Control|No stimulation was given
16703013|NCT01930214||None/mild calcification|Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
16703014|NCT01930214||Moderate Calcification|Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
16703015|NCT01930214||Severe calcification|Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
16703016|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
16703017|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
16703018|NCT01930188|Experimental|Semaglutide 0.5 mg + sitagliptin placebo|
16703019|NCT01930188|Experimental|Semaglutide 1.0 mg + sitagliptin placebo|
16703020|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
16703021|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
16703022|NCT01930175|Placebo Comparator|Placebo|single dose iv of Placebo
16703023|NCT01930175|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
16703024|NCT01930175|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg initiated following a safety review of patients receiving VAY736 3 mg/kg or placebo.
16703025|NCT01930162|Experimental|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
16703026|NCT01930149|Experimental|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
16703027|NCT01930149|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
16703028|NCT01930136|Experimental|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
16703029|NCT01930136|Active Comparator|Ad libitum health diet|
16703030|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
16703031|NCT01930123|Placebo Comparator|Health controls|15 healthy controls for comparison with NALFD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
16703032|NCT01930110|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
16703033|NCT01930110|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
16703034|NCT01930097|Active Comparator|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.
~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
16703035|NCT01930097|Active Comparator|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
16703036|NCT01930097|Active Comparator|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
16703037|NCT01930084|Experimental|Combination intervention + incentives|"Point of care CD4+ after HIV diagnosis
~Accelerated ART initiation
~SMS appointment reminders
~Non-cash financial incentives (FI)"
16703038|NCT01930084|Experimental|Combination intervention strategy(CIS)|"Point of care (POC) CD4+ after HIV diagnosis
~Accelerated ART initiation
~SMS appointment reminders"
16703039|NCT01930084|No Intervention|Standard of care (SOC)|Standard of care, no intervention
16703040|NCT01930071|Experimental|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
16703041|NCT01930058|Experimental|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
16703042|NCT01930058|Experimental|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
16703043|NCT01930058|Experimental|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
16703104|NCT01929590|Active Comparator|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
16703105|NCT01929590|Active Comparator|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
16703106|NCT01929590|Experimental|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
16703044|NCT01930045|Experimental|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
16703045|NCT01930045|Experimental|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
16703046|NCT01930045|Experimental|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
16703047|NCT01930045|Experimental|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
16703048|NCT01930045|Experimental|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
16703049|NCT01930045|Experimental|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
16703050|NCT01930032||All subjects|
16703051|NCT01930019|Experimental|OE|OE - obese patients (BMI>40) in which etomidate was used,
16703052|NCT01930019|Other|NE|NE - patients with normal body mass (BMI<25), in which etomidate was used,
16703053|NCT01930019|Experimental|OT|OT - obese patients in which thiopental was used,
16703054|NCT01930019|Other|NT|NT - patients with normal body mass, in which thiopental was used
16703055|NCT01930006|Experimental|MGCD265|
16703056|NCT01929993|Experimental|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
16703057|NCT01929993|Active Comparator|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
16703058|NCT01929980|Experimental|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
16703059|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
16703060|NCT01929954|Experimental|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
16703061|NCT01929954|Active Comparator|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
16703062|NCT01929941|Experimental|Group 1 INCB047986|
16703063|NCT01929941|Experimental|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
16703064|NCT01929928||Surgical Patients|
16703065|NCT01929915|Active Comparator|Epidural patient controlled analgesia|Epidural patient controlled analgesia
16703066|NCT01929915|Sham Comparator|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
16703067|NCT01929902||Surgical Patients|
16703107|NCT01929577|Experimental|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
16703108|NCT01929577|Experimental|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
16703109|NCT01929577|Experimental|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
16703851|NCT01924832|Experimental|BG00012 Part 2|BG00012 240 mg delivered to varying locations of the GI tract
16703068|NCT01929889|Experimental|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
16703069|NCT01929876|Experimental|Cobimetinib + Itraconazole|
16703070|NCT01929863|Experimental|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
16703071|NCT01929863|Experimental|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
16703072|NCT01929850|Active Comparator|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
16703073|NCT01929850|Other|Control|Weight Watchers Program for morbidly obese patients.
16703074|NCT01929837|Experimental|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
16703075|NCT01929837|Sham Comparator|sham E-field navigated rTMS|Sham electrical field navigated rTMS
16703076|NCT01929837|Experimental|non-navigated rTMS|non-navigated rTMS
16703077|NCT01929837|Experimental|Experimental, Navigated rTMS|Navigated rTMS,
16703078|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
16703079|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
16703080|NCT01929798|Experimental|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
16703081|NCT01929798|No Intervention|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
16703082|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
16703083|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
16703084|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
16703085|NCT01929759|Other|Drug switching|Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
16703086|NCT01929746|Experimental|BIIB019, 75 mg|BIIB019 delivered via Subcutaneous Injection
16703087|NCT01929746|Experimental|BIIB019, 150 mg|BIIB019 delivered via Subcutaneous Injection
16703088|NCT01929720|Experimental|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
16703089|NCT01929720|Active Comparator|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
16703090|NCT01929707|Experimental|LY3050258|Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.
16703091|NCT01929707|Placebo Comparator|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
16703092|NCT01929694|Active Comparator|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
16703093|NCT01929694|Placebo Comparator|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
16703094|NCT01929681|Experimental|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment
~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
16703095|NCT01929681|Sham Comparator|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment
~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
16703096|NCT01929668|Active Comparator|polyethylene glycol|4L polyethylene glycol
16703097|NCT01929668|Experimental|polyethylene glycol with ascorbic acid|2L polyethylene glycol and ascorbic acid
16703098|NCT01929655|Experimental|Radium-223 dichloride|
16703099|NCT01929642|Experimental|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
16703100|NCT01929629|Placebo Comparator|Placebo fasting|Single or multiple dosing placebo
16703101|NCT01929629|Experimental|Active fed condition|AZD0914 given as single dose
16703102|NCT01929616|Experimental|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
16703103|NCT01929603|Experimental|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
16703110|NCT01929564|Active Comparator|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
16703111|NCT01929564|Placebo Comparator|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
16703112|NCT01929551|Other|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
16703113|NCT01929551|Other|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
16703114|NCT01929551|Other|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
16703115|NCT01929551|Other|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
16703116|NCT01929551|Other|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
16703117|NCT01929551|Other|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
16703118|NCT01929551|Other|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
16703119|NCT01929538|Active Comparator|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
16703120|NCT01929538|Active Comparator|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
16703121|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
16703122|NCT01929512|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16703123|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16703124|NCT01929512|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16703125|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
16703126|NCT01929499|Experimental|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.
~For CapeOx regimen:
~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.
~For mFolfox6 regimen:
~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
16703127|NCT01929499|Experimental|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
16703128|NCT01929499|No Intervention|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
16703129|NCT01929486|Experimental|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|<Phase Ia> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
16703130|NCT01929486|Experimental|<Phase Ib> Mogamulizumab of the tolerated dose|<Phase Ib> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
16703131|NCT01929486|Experimental|<Phase Ib> Mogamulizumab 0.1mg/kg|<Phase Ib> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
16703132|NCT01929460|Other|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
~Ciprofloxacin 500mg by mouth twice a day for three days."
16703133|NCT01929460|Placebo Comparator|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
~Oral Placebo, one cap twice a day for three days."
16703134|NCT01929434|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
16703135|NCT01929434|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
16703136|NCT01929434|Experimental|stem cell injection|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
16703137|NCT01929421|Experimental|Gemcitabine/ s-1|
16703138|NCT01929395|Active Comparator|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
16703139|NCT01929395|Active Comparator|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
16703140|NCT01929382|Active Comparator|Actimmune (interferon gamma 1b)|Subjects > 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
16704305|NCT01921946|Other|Part A|Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)
16703141|NCT01929382|Experimental|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
16703142|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
16703143|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
16703144|NCT01929356|Experimental|chest physiotherapy|session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
16703145|NCT01929343|Experimental|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg(milligrams per kilogram) initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
16703146|NCT01929343|Active Comparator|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
16703147|NCT01929343|Placebo Comparator|saline|Saline will be administered at same volume of lidocaine in active arms.
16703148|NCT01929330|Experimental|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
16703149|NCT01929330|Experimental|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
16703150|NCT01929317|Experimental|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
16703151|NCT01929317|Experimental|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
16703152|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
16703153|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
16703154|NCT01929291||Boostrix Group|Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.
16703155|NCT01929278|Experimental|CT Gel patch|CT Gel is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1% and tretinoin 0.025%) in a modified vehicle. The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
16703156|NCT01929278|Placebo Comparator|Vehicle gel patch|The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
16703157|NCT01929278|Experimental|Blank patch|Blank patches did not contain CT Gel or vehicle gel.
16703158|NCT01929265|Experimental|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)
~1 arm for all patients"
16703159|NCT01929252|Active Comparator|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
16703160|NCT01929252|Active Comparator|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
16703161|NCT01929239|Experimental|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
16703162|NCT01929226|Experimental|ETI-204|A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
16703163|NCT01929226|Placebo Comparator|Placebo for ETI-204|A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
16703164|NCT01929213|Experimental|Udenafil|
16703165|NCT01929213|Experimental|Bosentan|
16703166|NCT01929213|Experimental|Udenafil/Bosentan|
16703167|NCT01929200|Experimental|1-year treatment with icotinib|Patients will receive 1-year treatment with icotinib after operation.
16703168|NCT01929200|Experimental|2-year treatment with icotinib|Patients will receive 2-year treatment with icotinib after operation.
16704306|NCT01921946|Other|Part B|Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)
16703169|NCT01929187|Active Comparator|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
16703170|NCT01929187|Active Comparator|amorolfine 5% nail lacquer|5% amorolfine
16703171|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
16703172|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
16703173|NCT01929161|Experimental|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
16703174|NCT01929161|Placebo Comparator|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
16703175|NCT01929161|Experimental|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
16703176|NCT01929161|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
16703177|NCT01929148|Experimental|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
16703178|NCT01929148|Active Comparator|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
16703179|NCT01929135|Experimental|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
16703180|NCT01929135|Placebo Comparator|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
16703181|NCT01929122|Placebo Comparator|Placebo-Control|Randomized participants consume 1 meal and 1 snack per day that does not include either rice bran or navy bean powder for 28 days.
16703182|NCT01929122|Experimental|Cooked Navy Bean Powder|Randomized participants consume 1 meal and 1 snack per day containing cooked navy bean powder (35 g/day) for 28 days.
16703183|NCT01929122|Experimental|Rice Bran|Randomized participants consume 1 meal and 1 snack per day containing rice bran (30 g/day) for 28 days.
16703184|NCT01929109|Experimental|LY2409021 Control|Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
16703185|NCT01929109|Experimental|LY2409021 Mild Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
16703186|NCT01929109|Experimental|LY2409021 Moderate Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
16703187|NCT01929109|Experimental|LY2409021 Severe Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
16703188|NCT01929109|Experimental|LY2409021 End Stage Renal Disease|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.
16703189|NCT01929096|Experimental|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
16703190|NCT01929096|Experimental|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
16703191|NCT01929096|Experimental|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
16703192|NCT01929096|Active Comparator|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
16703193|NCT01929083|Experimental|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
16703194|NCT01929083|Placebo Comparator|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
16703195|NCT01929070|Experimental|Group 1|"R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state
~R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet
~T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state
~T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet
~R1 -> T2 -> R2 -> T1"
16703196|NCT01929070|Experimental|Group 2|R2 -> R1 -> T1 -> T2
16703197|NCT01929070|Experimental|Group 3|T1 -> R2 -> T2 -> R1
16703198|NCT01929070|Experimental|Group 4|T2 -> T1 -> R1 -> R2
16703199|NCT01929057||Acne patients|This group consists of patients who have at least moderate to severe acne on their back
16703200|NCT01929057||Healthy Controls|This group contains participants who do not have any active acne lesions on their back
16703201|NCT01929044|Experimental|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
16703202|NCT01929044|Active Comparator|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
16703203|NCT01929031|Other|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
16703204|NCT01929031|Other|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
16703205|NCT01929031|Other|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
16703206|NCT01929031|Other|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
16703248|NCT01928823|Placebo Comparator|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
16703207|NCT01929031|Other|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
16703208|NCT01929031|Other|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
16703209|NCT01929018|Experimental|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
16703210|NCT01929018|No Intervention|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
16703211|NCT01929005|No Intervention|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
16703212|NCT01929005|Experimental|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
16703213|NCT01928992||3D|Subjects that undergo 3D mammography
16703214|NCT01928992||2D|Subjects that undergo 2D mammography
16703215|NCT01928979||Group 1|
16703216|NCT01928966|Active Comparator|Group I - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four weeks of study: receive 1.5 ounces of pumpkin seeds per day for consumption; Third four weeks of the study: consume their perceived normal diet.
16703217|NCT01928966|Active Comparator|Group II - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four week period: consume perceived normal diet; Third four week period: receive 1.5 ounces of pumpkin seeds per day for consumption.
16703218|NCT01928940|Experimental|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
16703219|NCT01928927|Experimental|Arm A: Telmisartan|
16703220|NCT01928927|No Intervention|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
16703221|NCT01928914|Placebo Comparator|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
16703222|NCT01928914|Experimental|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
16703223|NCT01928914|Active Comparator|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
16703224|NCT01928914|Experimental|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
16703225|NCT01928914|Experimental|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
16703226|NCT01928901|Experimental|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
16703227|NCT01928901|Experimental|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
16703228|NCT01928901|Placebo Comparator|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
16703229|NCT01928901|Placebo Comparator|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
16703230|NCT01928888|Experimental|Arm HFP|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo
16703231|NCT01928888|Experimental|Arm HPF|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine
16703232|NCT01928888|Experimental|Arm FHP|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo
16703233|NCT01928888|Experimental|Arm FPH|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid
16703234|NCT01928888|Experimental|Arm PHF|1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine
16703235|NCT01928888|Experimental|Arm PFH|1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid
16703236|NCT01928875|Experimental|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
16703237|NCT01928875|Active Comparator|Routine (Standard) Anesthesia Monitoring|
16703238|NCT01928862|Experimental|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
16703239|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
16703240|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
16703241|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
16703242|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
16703243|NCT01928849|Placebo Comparator|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
16703244|NCT01928849|Experimental|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
16703245|NCT01928836||Non-suspected lung cancer group|"Aged 40 to 75 years;
~Male smoker (≥400 cig/year), female smoker or non-smoker;
~Visible lung nodule lesion in the chest (based on local CT result);
~Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
16703246|NCT01928836||Suspected lung cancer group|"Aged 40 to 75 years;
~Male smoker (≥400 cig/year), female smoker or non-smoker;
~Visible lung cancer lesion in the chest (based on local CT result);
~With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
16703247|NCT01928823|Experimental|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
16703249|NCT01928810|Experimental|70% VO2max|"Cognitive Behavioural Therapy (CBT)
~+ aerobic exercise (30 minutes, 70% VO2max) prior to 5 in-vivo exposure sessions"
16703250|NCT01928810|Active Comparator|30% VO2max|"Cognitive Behavioural Therapy (CBT)
~+ placebo exercise (30 minutes, 30% VO2max) prior to 5 in-vivo exposure sessions"
16703251|NCT01928797|No Intervention|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
16703252|NCT01928797|Experimental|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
16703253|NCT01928784|Experimental|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
16703254|NCT01928784|Experimental|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
16703255|NCT01928771|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
16703256|NCT01928771|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
16703257|NCT01928771|Placebo Comparator|Placebo|Placebo administered subcutaneously
16703258|NCT01928758|Experimental|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
16703259|NCT01928758|Placebo Comparator|Usual Nicotine Content Cigarettes|Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)
16703260|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
16703261|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
16703262|NCT01928732|Active Comparator|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
16703263|NCT01928732|Active Comparator|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
16703264|NCT01928719|Experimental|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg per cigarette) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
16703265|NCT01928719|Placebo Comparator|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes with a usual nicotine content (about 11.6 mg per cigarette)
16703266|NCT01928706|Experimental|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
16703267|NCT01928706|Active Comparator|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
16703268|NCT01928693|Active Comparator|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
16703269|NCT01928693|Active Comparator|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
16703270|NCT01928693|Active Comparator|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
16703271|NCT01928680|Experimental|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.
~This is a single arm phase II clinical trial."
16703272|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
16703273|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
16703274|NCT01928654|Experimental|Micropulse laser treatment|Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern
16703275|NCT01928654|Active Comparator|Laser modified ETDRS|Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.
16703276|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
16703277|NCT01928628|Active Comparator|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
16703278|NCT01928628|Experimental|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
16703279|NCT01928628|Experimental|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
16703280|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
16703317|NCT01928446|Experimental|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
16704542|NCT01920295|Experimental|Cryoballoon ablation|Cryoballoon ablation
16703281|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
16703282|NCT01928602|Experimental|Expressive Aphasia Group A|"Behavioral: TherAppy Language App
~Behavioral: Mind-Games"
16703283|NCT01928602|Experimental|Expressive Aphasia Group B|"Behavioral: Mind-Games
~Behavioral: TherAppy Language App"
16703284|NCT01928589|Active Comparator|PBI|270 cGy (centigray) x 15
16703285|NCT01928589|Experimental|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
16703286|NCT01928576|Experimental|Arm C|Nivolumab 3mg/kg every 2 weeks until progression
16703287|NCT01928576|Experimental|Arm D|"Anti-PD-1/PD-L1 treatment naïve patients only
~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15
~Followed by:
~Nivolumab 3mg/kg every 2 weeks until progression
~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
16703288|NCT01928576|Experimental|Arm E|"Patients must have had refractory (Arm E=less than 24 weeks from first dose of anti-PD-1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.
~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15
~Followed by:
~Nivolumab 3mg/kg every 2 weeks until progression
~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
16703289|NCT01928576|Experimental|Arm F|"Patients must have had recurrent (Arm F=more than 24 weeks from first dose of anti-PD1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.
~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15
~Followed by:
~Nivolumab 3mg/kg every 2 weeks until progression
~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
16703290|NCT01928563|Experimental|Dapoxetine|Dapoxetine is administered
16703291|NCT01928563|Experimental|Udenafil|Udenafil is administered
16703292|NCT01928563|Experimental|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
16703293|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
16703294|NCT01928537|Experimental|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
16703295|NCT01928524|Experimental|DOS2W Dose level 1A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
16703296|NCT01928524|Experimental|DOS2W Dose level 2A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
16703297|NCT01928524|Experimental|DOS2W Dose level 3A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
16703298|NCT01928524|Experimental|DOS2W Dose level 4A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
16703299|NCT01928524|Experimental|DOS3W Dose level 1B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
16703300|NCT01928524|Experimental|DOS3W Dose level 2B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
16703301|NCT01928524|Experimental|DOS3W Dose level 3B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
16703302|NCT01928511|Active Comparator|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
16703303|NCT01928511|Experimental|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
16703304|NCT01928511|Experimental|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
16703305|NCT01928498|Experimental|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon Angioplasty
16703306|NCT01928498|Active Comparator|Conventional uncoated balloon|Percutaneous Transluminal Angioplasty (PTA)
16703307|NCT01928485|Active Comparator|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
16703308|NCT01928485|Experimental|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
16703309|NCT01928472|Experimental|Group A|H7N9c low dose with adjuvant
16703310|NCT01928472|Experimental|Group B|H7N9c medium dose with adjuvant
16703311|NCT01928472|Experimental|Group C|H7N9c high dose with adjuvant
16703312|NCT01928472|Experimental|Group D|H7N9c high dose without adjuvant
16703313|NCT01928459|Experimental|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
16703314|NCT01928459|Experimental|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
16703315|NCT01928459|Experimental|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
16703316|NCT01928459|Experimental|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
16703318|NCT01928446|Placebo Comparator|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
16703319|NCT01928433|Experimental|Finafloxacin 5 days|"Intervention:
~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
16703320|NCT01928433|Experimental|Finafloxacin 10 days|"Intervention:
~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
16703321|NCT01928433|Active Comparator|Ciprofloxacin 10 days|"Intervention:
~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
16703322|NCT01928420|Experimental|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
16703323|NCT01928420|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
16703324|NCT01928407|Experimental|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
16703325|NCT01928407|Experimental|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
16703332|NCT01928381|Placebo Comparator|placebo capsules|Capsules to match pregabalin and AZD5213
16703333|NCT01928381|Experimental|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
16703334|NCT01928381|Active Comparator|pregabalin|pregabalin capsules
16703335|NCT01928368|Active Comparator|Experimental Arm|
16703336|NCT01928368|Placebo Comparator|Placebo Arm|
16703337|NCT01928355||metabolically healthy|
16703338|NCT01928355||Unhealthy|
16703339|NCT01928342|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
16703340|NCT01928342|Placebo Comparator|Placebo|Capsule without coenzyme A.
16703341|NCT01928329|Placebo Comparator|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
16703342|NCT01928329|Experimental|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
16703343|NCT01928316|Experimental|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
16703344|NCT01928316|Experimental|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
16703345|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
16703346|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
16703347|NCT01928290|Experimental|Arm A: FOLFIRINOX (HER2-negative)|"Irinotecan 180 mg/m2 IV on Days 1 & 15.
~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.
~Leucovorin 400 mg/m2 IV on Days 1 & 15.
~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
16703348|NCT01928290|Experimental|Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.
~Irinotecan 180 mg/m2 IV on Days 1 & 15.
~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.
~Leucovorin 400 mg/m2 IV on Days 1 & 15.
~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
16703349|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
16703350|NCT01928264|Experimental|Physical activity|Physical activity group program over 12 weeks; 1 hour sessions, 2 times a week
16703351|NCT01928264|No Intervention|Leisure time activities|Predominantly sedentary leisure time group activities, like playing board games, doing handicrafts, etc.; 12 weeks, 1 hour sessions, 2 times a week
16703352|NCT01928251|Experimental|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level < 4 ppm, saliva cotinine level < 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
16732351|NCT01732211|Placebo Comparator|Placebo|
16703353|NCT01928251|Experimental|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
16703354|NCT01928251|No Intervention|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
16703355|NCT01928238|Experimental|Arm 1|"Patients will have two 20-minute noninvasive periods :
~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
16703356|NCT01928238|Experimental|Arm 2|"Patients will have two 20-minute noninvasive periods :
~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
16703357|NCT01928225|Experimental|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
16703358|NCT01928225|Placebo Comparator|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
16703359|NCT01928212||healthy control|Sex- and agematched healthy subjects
16703360|NCT01928212||Parkinson group|Patients with Parkinson's disease
16703361|NCT01928199|Active Comparator|Sitagliptin|"Sitaglipitin tablets will be administered orally for 3 months from randomization
~Initial dose will be 100mg/daily, adjusted per renal function:
~Creatinine clearance > or = 50mL/min: 100mg/day Creatinine clearance > or = 30 and <50mL/min: 50mg/day Creatinine clearance <30 mL/min or on dialysis: 25mg/day"
16703362|NCT01928199|Placebo Comparator|Placebo|Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator
16703363|NCT01928186|Experimental|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
16703364|NCT01928173|Active Comparator|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
16703365|NCT01928173|Active Comparator|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
16703366|NCT01928160|Experimental|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16703367|NCT01928160|Experimental|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16703368|NCT01928147|Experimental|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
16703369|NCT01928147|Experimental|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
16703370|NCT01928147|Experimental|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
16703371|NCT01928134|Experimental|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
16703372|NCT01928134|Active Comparator|B|Vit K2+CaCO3
16703373|NCT01928121|Experimental|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
16703374|NCT01928121|No Intervention|Usual care|
16703375|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
16703376|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
16703377|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
16703378|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
16703379|NCT01928043|Experimental|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
16703380|NCT01928030|Experimental|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
16703381|NCT01928017||Hematooncology patients|No intervention
16703382|NCT01928004|Experimental|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
16703383|NCT01928004|Active Comparator|denture reline|conventional reline of mandibular complete denture
16703384|NCT01927991|Experimental|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
16703385|NCT01927991|Active Comparator|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
16703386|NCT01927978||esophageal cancer, 18F-FDG PET|
16704543|NCT01920295|Active Comparator|Cryoballoon after medical therapy|Cryoballoon ablation
16703387|NCT01927965|Experimental|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
16703388|NCT01927952|Active Comparator|Kirschner wire|surgical fixation using a Kirschner wire
16703389|NCT01927952|Active Comparator|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
16703390|NCT01927952|Active Comparator|Stryker Smart-Toe implant|surgical fixation utilizing the Stryker Smart-Toe implant
16703391|NCT01927939||Histological proven breast cancer with bone lesion|
16703392|NCT01927926|Experimental|Whey-protein & polydextrose snack|Whey-protein & polydextrose snack bar.
16703393|NCT01927926|Placebo Comparator|Control snack|Control snack bar containing minimal protein and not polydextrose.
16703394|NCT01927913|Experimental|SPD602|
16703395|NCT01927913|Active Comparator|Deferasirox|
16703396|NCT01927900|Active Comparator|HMO1|HMO diluted in water
16703397|NCT01927900|Placebo Comparator|Glucose|Glucose diluted in water
16703398|NCT01927900|Active Comparator|HMO2|HMO diluted in water
16703399|NCT01927900|Active Comparator|HMO3|HMO diluted in water
16703400|NCT01927900|Active Comparator|HMO4|HMO diluted in water
16703401|NCT01927900|Active Comparator|HMO5|HMO diluted in water
16703402|NCT01927900|Active Comparator|HMO6|HMO diluted in water
16703403|NCT01927900|Active Comparator|HMO7|HMO diluted in water
16703404|NCT01927900|Active Comparator|HMO8|HMO diluted in water
16703405|NCT01927900|Active Comparator|HMO9|HMO diluted in water
16703406|NCT01927887|Experimental|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
16703407|NCT01927874|Active Comparator|Infiltration, analgesic effect|10ml 0.5% bupivacaine each side Block Injection of local anesthetic at pudendal nerve
16703408|NCT01927874|Active Comparator|Spinal block|10 mg of hyperbaric 0.5% bupivacaine Injection of anesthetic at subarachnoidal space
16703409|NCT01927861|Experimental|0.033 mg/kg/day|
16703410|NCT01927861|Experimental|0.066 mg/kg/day|
16703411|NCT01927848|Experimental|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
16703412|NCT01927848|Placebo Comparator|Placebo|Dosage: 3 capsules once daily with meals
16703413|NCT01927835|Experimental|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
16703414|NCT01927835|Experimental|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
16703415|NCT01927835|Experimental|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
16703416|NCT01927835|Experimental|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
16703417|NCT01927835|Placebo Comparator|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
16703418|NCT01927835|Placebo Comparator|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
16703419|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
16703420|NCT01927783||Group 1|Healthy Volunteer
16703421|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
16703422|NCT01927783||Group 3|Focus Group
16703423|NCT01927783||Group 4|Focus Group- Mobile App
16703424|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
16703425|NCT01927783||Group 6|Community Organization Survey focus Group
16703426|NCT01927770||WES/WGS|Eligible adults (or parents of eligible children) consenting to enroll in an NIH study thatincludes WES/WGS.
16703427|NCT01927757|Experimental|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
16703428|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
16704544|NCT01920295|Experimental|Cryoballoon as first-line therapy|Cryoballoon ablation
16703429|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
16703430|NCT01927731|Experimental|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
16703431|NCT01927731|Experimental|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
16703432|NCT01927718|Experimental|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.
~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
16703433|NCT01927705|Experimental|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10^7 stem cells after registration.
~FURESTEM-AD Inj. 2. 5.0 x 10^7 stem cells after registration."
16703434|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
16703435|NCT01927679|Other|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
16703436|NCT01927679|Other|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
16703437|NCT01927666|Experimental|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
16703438|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:
~memory complaint
~normal general cognition
~normal activities of daily living
~not demented"
16703439|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:
~relatively focal executive dysfunction
~Within reference range on tests of memory, language and visuospatial skills
~normal general cognition
~normal activities of daily living
~not demented"
16703440|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:
~Age and gender matched healthy subjects without significant neuropsychiatric disorder
~Able to understand and provide signed informed consent"
16703441|NCT01927640|Experimental|Dexmedetomidine and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion
16703442|NCT01927640|Placebo Comparator|Normal saline and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)
16703443|NCT01927627|Experimental|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
16703444|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT <0.5mm (10 patients) and those with MIT >0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
16703445|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
16703446|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
16703447|NCT01927588|Experimental|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
16703448|NCT01927588|Active Comparator|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
16703449|NCT01927575|Active Comparator|Standard X-Ray + CT|Standard X-Ray + CT arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
16703450|NCT01927575|Active Comparator|Standard X-Ray + MRI|Standard X-Ray + MRI arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
16703451|NCT01927575|Experimental|Tomo|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
16703452|NCT01927562|Experimental|Duodenal Treatment|The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
16703453|NCT01927549|Active Comparator|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter >2 mm with high grade stenoses (>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
16703488|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
16703489|NCT01927328|No Intervention|Control|Standard Care as determined by the clinical team
16703454|NCT01927549|Active Comparator|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
16703455|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
16703456|NCT01927523|No Intervention|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
16703457|NCT01927523|Experimental|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
16703458|NCT01927523|Experimental|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
16703459|NCT01927523|Experimental|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
16703460|NCT01927510|Experimental|early mobilisation|intervention of early mobilisation
16703461|NCT01927510|No Intervention|Control|Standard care
16703462|NCT01927497|Experimental|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
16703463|NCT01927497|Active Comparator|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
16703464|NCT01927484|Experimental|methotrexate|25mg oral methotrexate tablets
16703465|NCT01927484|Placebo Comparator|placebo|25 mg/week placebo tablets
16703466|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
16703467|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
16703468|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
16703469|NCT01927458|Experimental|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
16703470|NCT01927445|No Intervention|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
16703471|NCT01927445|Experimental|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
16703472|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
16703473|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
16703474|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
16703475|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
16703476|NCT01927406|Experimental|Prostaglandin Analog vs Timolol|In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
16703477|NCT01927406|Experimental|Prostaglandin Analog|In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
16703478|NCT01927393|Experimental|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
16703479|NCT01927393|Active Comparator|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
16703480|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
16703481|NCT01927367|Other|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
16703482|NCT01927367|No Intervention|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
16703483|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
16703484|NCT01927341|Experimental|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
16703485|NCT01927341|Experimental|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
16703486|NCT01927341|Experimental|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
16703487|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
16733599|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
16703490|NCT01927328|Active Comparator|Iron isomaltoside 1000|Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
16703491|NCT01927315|Experimental|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
16703492|NCT01927315|Placebo Comparator|Placebo|Placebo oral tablets daily for 12 weeks
16703493|NCT01927302|Experimental|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
16703494|NCT01927302|Experimental|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
16703495|NCT01927302|Experimental|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
16703496|NCT01927289|Active Comparator|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
16703497|NCT01927289|Active Comparator|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
16703498|NCT01927276|Placebo Comparator|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
16703499|NCT01927276|Active Comparator|Wheat Flour|Wheat Flour 10 grams daily
16703500|NCT01927263|Experimental|NI-071|
16703501|NCT01927263|Active Comparator|Infliximab|
16703502|NCT01927250|Experimental|Okada Health and Wellness program|12,166 Japanese volunteers with/without illness, who were interested in practicing Okada Health and Wellness program for 3 consecutive months.
16703503|NCT01927237|Experimental|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
16703504|NCT01927237|Experimental|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
16703505|NCT01927224|Experimental|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
16703506|NCT01927224|Experimental|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
16703507|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
16703508|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
16703509|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
16703510|NCT01927198|Placebo Comparator|Placebo|Placebo group
16703511|NCT01927185|Active Comparator|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
16703512|NCT01927185|Active Comparator|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
16703513|NCT01927172|Other|AirSonea|Use of AirSonea to detect wheeze sounds.
16703514|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
16703515|NCT01927159|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
16703516|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
16703517|NCT01927159|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
16703518|NCT01927159|Placebo Comparator|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
16703519|NCT01927146||Resectable gastric cancer|No intervention
16703520|NCT01927133||FIBROFRANCE Project|
16703521|NCT01927120|Experimental|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
16703522|NCT01927107|Active Comparator|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
16703523|NCT01927107|Active Comparator|Control|Standard diet therapy
16703524|NCT01927094|Active Comparator|Probiotic|"Saccharomyces boulardii 1 x 250 mg per day for 5 days, PO or Lactobacillus GG 1 x 10(9) CFU per day for 5 days or
~Lactobacillus reuteri 1 x 10(8) CFU per day for 5 days"
16703525|NCT01927094|Active Comparator|Control|ORS-ad libitum
16703526|NCT01927081|Active Comparator|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
16703527|NCT01927081|Active Comparator|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
16704545|NCT01920295|Active Comparator|Cryoballoon after failed drug therapy|Cryoballoon ablation
16703528|NCT01927068|Experimental|Global Cohort 1|All subjects to be treated with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTX PTA) Balloon Catheter in Cohort 1.
16703529|NCT01927068|Experimental|Global ISR Cohort 2|"For Cohort 2, the same device was commercially available, and subjects were to be treated with the CE Marked, renamed device Stellarex 0.035 OTW drug-coated angioplasty balloon (Stellarex 035 DCB)"
16703530|NCT01927055|Active Comparator|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
16703531|NCT01927055|Placebo Comparator|Placebo|Placebo
16703532|NCT01927042|Experimental|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
16703533|NCT01927042|Active Comparator|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
16703534|NCT01927029|Experimental|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
16703535|NCT01927029|Placebo Comparator|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
16703536|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
16703537|NCT01927003|Experimental|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
16703538|NCT01926977|Active Comparator|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
16703539|NCT01926977|Active Comparator|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
16703540|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
16703541|NCT01926951|Experimental|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
16703542|NCT01926938||adults at risk|Latino adults with family history of type 2 diabetes
16703543|NCT01926938||controls|Latino adults without family history of type 2 diabetes and normal glucose tolerance
16703544|NCT01926925||1|Overweight Hispanic children/adolescents
16703545|NCT01926925||2|Lean Hispanic children/adolescents
16703546|NCT01926912||Participants with schizophrenia|
16703547|NCT01926899|Experimental|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
16703548|NCT01926886|Experimental|Trastuzumab|Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
16703549|NCT01926886|No Intervention|Health Care Professionals|Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
16703550|NCT01926873||Healthy volunteers|
16703551|NCT01926860|Experimental|Study group - Prevenar®13 and Hepatitis A vaccines|Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0
16703552|NCT01926860|Active Comparator|Pneumococcal conjugate vaccine -Control group - Prevenar®13|PCV -Control group (group 2) - Prevenar®13: one vaccine injection administered on Day 0
16703553|NCT01926860|Active Comparator|HepA -Control group - Hepatitis A vaccine|HepA -Control group (group 3) - Hepatitis A vaccine: one vaccine injection administered on Day 0
16703554|NCT01926847|Experimental|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
16703555|NCT01926847|Experimental|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
16703556|NCT01926834|Experimental|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
16703557|NCT01926834|Placebo Comparator|placebo|normal saline, 500ml,i.v.,qd, for 7 days
16703558|NCT01926834|No Intervention|health volunteers|health volunteers, no drug to be given.
16703559|NCT01926821|Experimental|sonifilan|Group who get sonifilan
16703560|NCT01926821|No Intervention|control|No Sonifilan administered
16703561|NCT01926808||Vitamin D supplementation|
16703562|NCT01926795|Active Comparator|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
16703563|NCT01926795|Experimental|No immobilization|No cast or splint will be applied to the injured extremity
16703564|NCT01926795|Other|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
16703565|NCT01926782|Placebo Comparator|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
16703566|NCT01926782|Experimental|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
16703567|NCT01926782|Experimental|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
16703568|NCT01926769|Experimental|FOLFOX6+Metformin/FOFIRI+Metformin|
16703569|NCT01926756|Other|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
16703668|NCT01926106|Active Comparator|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
16703570|NCT01926756|Active Comparator|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
16703571|NCT01926743|Experimental|NIR with ICG group|
16703572|NCT01926730|No Intervention|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
16703573|NCT01926730|Experimental|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
16703574|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
16703575|NCT01926717||Pancreaticoduodenectomy|
16703576|NCT01926704||healthy, young subjects|
16703577|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
16703578|NCT01926678|Experimental|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
16703579|NCT01926678|Active Comparator|Light touch therapy|Light touch therapy once per week for 6 weeks
16703580|NCT01926678|Other|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
16703581|NCT01926665|Experimental|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
16703582|NCT01926652|Experimental|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
16703583|NCT01926652|Experimental|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
16703584|NCT01926639|Experimental|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
16703585|NCT01926626|Experimental|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
16703586|NCT01926613|Active Comparator|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
16703587|NCT01926613|Experimental|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
16703588|NCT01926600||PO|administrated by per oral
16703589|NCT01926600||IV|Administrated by intravenous
16703590|NCT01926600||SL|administrated by sublingual
16703591|NCT01926587|Experimental|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
16703592|NCT01926574|Experimental|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
16703593|NCT01926574|Experimental|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
16703594|NCT01926574|Active Comparator|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
16703595|NCT01926574|No Intervention|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
16703596|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
16703597|NCT01926548|Experimental|CJ Imatinib 200mg|1 tablet(200mg) a day,PO,QD
16703598|NCT01926548|Active Comparator|Gleevec 100mg|2 tablet(100mg) a day,PO,QD
16703599|NCT01926535|Experimental|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
16703775|NCT01925300|Experimental|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd|Single administration : 6 days, per oral
16703600|NCT01926535|Active Comparator|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
16703601|NCT01926522|Experimental|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
16703602|NCT01926522|Active Comparator|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
16703603|NCT01926509|Experimental|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
16703604|NCT01926509|Experimental|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28).
16703605|NCT01926509|Experimental|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
16703606|NCT01926509|Placebo Comparator|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
16703607|NCT01926496|Experimental|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
16703608|NCT01926496|Active Comparator|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
16703609|NCT01926483|Experimental|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
16703610|NCT01926470|Experimental|anteroposterior approach group|anteroposterior approach group
16703611|NCT01926470|Active Comparator|oblique approach group|oblique approach group
16703612|NCT01926457|Experimental|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation
~diabetes education
~blood glucose monitoring
~medications as needed per California Diabetes and Pregnancy established protocol
~growth ultrasounds
~antenatal testing"
16703613|NCT01926457|Active Comparator|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation
~diabetes education
~blood glucose monitoring
~medications as needed per California Diabetes and Pregnancy established protocol
~growth ultrasounds
~antenatal testing"
16703614|NCT01926444|Experimental|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
16703615|NCT01926444|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
16703616|NCT01926444|Experimental|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
16703617|NCT01926444|Placebo Comparator|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
16703618|NCT01926431|Experimental|Exercise|60 minutes of high intensity treadmill running
16703619|NCT01926431|Experimental|Rest|60 minutes of seated rest (control trial)
16703620|NCT01926418|No Intervention|Control|The control group receives the TPB questionnaires but receives no intervention
16703621|NCT01926418|Experimental|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
16703622|NCT01926418|Experimental|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
16703623|NCT01926405|Other|Subjects with narcolepsy or with idiopathic hypersomnia|
16703624|NCT01926405|Other|Control patients with no sleeping disorder|
16703625|NCT01926392|Experimental|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
16703626|NCT01926392|Active Comparator|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
16703627|NCT01926379|Experimental|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
16703628|NCT01926379|Other|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
16703629|NCT01926366|Experimental|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
16703630|NCT01926366|Placebo Comparator|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
16703776|NCT01925300|Experimental|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd|Single administration : 6 days, per oral
16703631|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
16703632|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
16703633|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
16703634|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
16703635|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
16703636|NCT01926327|Active Comparator|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
16703637|NCT01926327|Placebo Comparator|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
16703638|NCT01926314|Experimental|device|Patients in this group will be offered pelvic floor muscle rehabilitation program using PHENIX Neuromuscular Stimulation Therapy System device. The participants will start therapy once a week 42 days after delivery, and last 8 weeks.
16703639|NCT01926314|Active Comparator|usual home care without device|Patients in this group will receive usual home care without device.
16703640|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
16703641|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
16703642|NCT01926288|Other|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
16703643|NCT01926288|Other|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
16703644|NCT01926275|Experimental|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
16703645|NCT01926275|Active Comparator|NPPV|noninvasive positive pressure ventilation
16703646|NCT01926275|Active Comparator|IMT|inspiratory muscle training
16703647|NCT01926275|Placebo Comparator|LTOT|Long time oxygen therapy
16703648|NCT01926262|Experimental|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
16703649|NCT01926262|No Intervention|Reference group|No Specific Strength Training
16703650|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.
~300 participants with an isolated cognitive complaint and an age of 60 years or more."
16703651|NCT01926236|Active Comparator|Arm A: Active symptom control (ASC)|Active Symptom Control
16703652|NCT01926236|Experimental|Arm B: ASC with OxMdG chemotherapy|Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU)
16703653|NCT01926223|Experimental|Home visiting Group|
16703654|NCT01926223|No Intervention|Control Group|
16703655|NCT01926210|Experimental|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
16703656|NCT01926210|Active Comparator|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
16703657|NCT01926197|Active Comparator|mFFX|mFOLFIRINOX
16703658|NCT01926197|Experimental|mFFX+SBRT|mFOLFIRINOX + SBRT
16703659|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
16703660|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
16703661|NCT01926171|Experimental|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
16703662|NCT01926158|Experimental|Denosumab|Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery
16703663|NCT01926158|Placebo Comparator|Placebo|Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery
16703664|NCT01926132|Experimental|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
16703665|NCT01926132|Active Comparator|Normal Saline 150ml|Normal Saline 150ml, covered bottle
16703666|NCT01926119|Experimental|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
16703667|NCT01926106|Experimental|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
16703669|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
16703670|NCT01926080|No Intervention|Standard Bereavement Care|Those randomized to control group (no DVD) Standard Bereavement Care Arm receive the bereavement materials given to families as standard-practice of care in the NICU at SLCH following the death of an infant
16703671|NCT01926054|Active Comparator|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
16703672|NCT01926054|Active Comparator|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
16703673|NCT01926041|Experimental|Intervention|A 16-week FIT2 program that combines smoking cessation therapy with individualized behavior coaching in diet and physical activity for PCWG restriction.
16703674|NCT01926041|No Intervention|Control|Usual care
16703675|NCT01926028|Experimental|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
16703676|NCT01926028|Experimental|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
16703677|NCT01926028|Placebo Comparator|Placebo|Placebo: aluminum hydroxide adjuvant
16703678|NCT01926015|Experimental|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
16703679|NCT01926015|Active Comparator|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
16703680|NCT01926002|Experimental|Low-Dose MK-8351|Low-dose MK-8351 administered as single inhaled dose.
16703681|NCT01926002|Experimental|High-Dose MK-8351|High-dose MK-8351 administered as a single inhaled dose.
16703682|NCT01926002|Placebo Comparator|Placebo to MK-8351|Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
16703683|NCT01925989|Experimental|Insulin Peglispro/Insulin Glargine|Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
16703684|NCT01925989|Active Comparator|Insulin Glargine/Insulin Peglispro|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin. Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen.
16703685|NCT01925989|No Intervention|Control|Control Arm. Untreated healthy participants.
16703686|NCT01925976|Other|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
16703687|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
16703688|NCT01925950|Placebo Comparator|Placebo|Control
16703689|NCT01925950|Experimental|orBec|Investigational drug
16703690|NCT01925937|Experimental|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
16703691|NCT01925937|Active Comparator|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
16703692|NCT01925924|Experimental|Resin-modified glass ionomer cement|Resin-modified glass ionomer cement is used to attach the fixed orthodontic brackets (brace) to the teeth.
16703693|NCT01925924|Active Comparator|Composite resin|Composite resin is used to attach fixed orthodontic brackets (brace)to the teeth.
16703694|NCT01925898|Experimental|Ketamine|Oral ketamine
16703695|NCT01925898|Active Comparator|Midazolam|Oral Midazolam
16703696|NCT01925885|Active Comparator|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
16703697|NCT01925885|Experimental|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
16703698|NCT01925859|Experimental|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
16703699|NCT01925833|Experimental|Both insertion and withdrawal|
16703700|NCT01925833|Active Comparator|Only withdrawal|
16703701|NCT01925820|Experimental|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
16703702|NCT01925820|Active Comparator|Arm 2|Entecavir daily for 144 weeks.
16703703|NCT01925820|Active Comparator|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
16703704|NCT01925807|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
16703705|NCT01925794|Experimental|COBRA PzF Stent|
16703706|NCT01925781|Experimental|e-Cigarette|STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
16703707|NCT01925781|Active Comparator|Nicotine polacrilex|Nicotine Replacement gum
16703777|NCT01925300|Experimental|Concor 5mg 2T and Crestor 20 mg 1Tab, qd|Combination administration : 6 days, per oral
16703778|NCT01925287|Active Comparator|Native curcumin powder|500 mg curcumin as native powder
16703708|NCT01925768|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
16703709|NCT01925768|Placebo Comparator|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
16703710|NCT01925755||Group 1|
16703711|NCT01925742|Experimental|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
16703712|NCT01925742|Experimental|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
16703713|NCT01925729|Experimental|ragweed|ragweed -- 1000PNU intranasal spray
16703714|NCT01925729|Experimental|histamine|5 mg intranasal spray
16703715|NCT01925729|Experimental|pseudoephedrine|pseudoephedrine -- 60 mg orally
16703716|NCT01925729|Experimental|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
16703717|NCT01925716|Experimental|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
16703718|NCT01925716|Experimental|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
16703719|NCT01925703|Experimental|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
16703720|NCT01925690|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
16703721|NCT01925690|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
16703722|NCT01925677|Experimental|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
16703723|NCT01925664|Experimental|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
16703724|NCT01925664|No Intervention|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
16703725|NCT01925651|Other|Low Risk - No bolus|No Bolus
16703726|NCT01925651|Other|Low- Risk Alternate Bolus|Alternate Bolus
16703727|NCT01925651|Other|High Risk - Alternate Bolus|Alternate Bolus
16703728|NCT01925651|Other|High Risk - Continuous bolus|Continuous bolus
16703729|NCT01925638|Experimental|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
16703730|NCT01925625|No Intervention|Control|participants monitored for 10 years for lung cancer incidence.
16703731|NCT01925625|Active Comparator|Early CDT Lung Test|Early CDT lung blood test
16703732|NCT01925612|Experimental|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
16703733|NCT01925612|Experimental|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
16703734|NCT01925612|Experimental|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone
~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
16703779|NCT01925287|Experimental|Micronized curcumin powder|500 mg curcumin as micronized powder
16703780|NCT01925287|Experimental|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
16703781|NCT01925274|Experimental|Arm A|PF-05212384 plus Irinotecan
16703782|NCT01925274|Active Comparator|Arm B|Cetuximab plus Irinotecan
16703735|NCT01925612|Active Comparator|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
16703736|NCT01925612|Experimental|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone
~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.
~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
16703737|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:
~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.
~Part 2:
~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.
~Part 3:
~Adjuvant Bevacizumab and Optune"
16703738|NCT01925560|Experimental|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
16703739|NCT01925560|Experimental|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
16703740|NCT01925560|Experimental|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
16703741|NCT01925547|Experimental|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
16703742|NCT01925547|Placebo Comparator|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
16703743|NCT01925534|Experimental|Optiflow|High-flow humidified nasal oxygen delivery system
16703744|NCT01925534|Active Comparator|Oxygen therapy|Standard oxygen therapy
16703745|NCT01925521|Experimental|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
16703746|NCT01925521|Placebo Comparator|Part1 : Placebo of OPS-2071|Single dose, Placebo
16703747|NCT01925521|Experimental|Part2 : OPS-2071|Multiple dose
16703748|NCT01925521|Placebo Comparator|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
16703749|NCT01925495|Experimental|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
16703750|NCT01925482|Other|Group 1 -- no history of otitis media|no history of otitis media
16703751|NCT01925482|Other|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
16703752|NCT01925469|Experimental|Benzocaine|Benzocaine spray (14%), an FDA approved drug, will be used to assess whether this provides additional pain relief at time of hysterosalpingogram.
16703753|NCT01925469|Placebo Comparator|Saline spray|A saline placebo spray will be used in the placebo group.
16703754|NCT01925456|Other|Toviaz|Patients willingness to take Toviaz 4mg and 8mg
16703755|NCT01925443|Experimental|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
16703756|NCT01925443|No Intervention|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
16703757|NCT01925443|Experimental|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
16703758|NCT01925430||Comparative product|A device which monitors sleep/wake states
16703759|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
16703760|NCT01925417|Experimental|RBX2660 (microbiota suspension)|enema-based delivery of RBX2660
16703761|NCT01925404|Experimental|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
16703762|NCT01925404|Experimental|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
16703763|NCT01925404|Experimental|Combined arm|We will offer free classes and the frequent user program at the park
16703764|NCT01925404|No Intervention|Control|Business as usual, no special physical activity programs offered
16703765|NCT01925391|Active Comparator|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
16703766|NCT01925391|Active Comparator|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
16703767|NCT01925378|Experimental|Nelfinavir|This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia
16703768|NCT01925365|Experimental|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
16703769|NCT01925365|Placebo Comparator|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
16703770|NCT01925352|Experimental|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
16703771|NCT01925339|Experimental|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
16703772|NCT01925339|Experimental|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
16703773|NCT01925313|Experimental|CJ-30044|
16703774|NCT01925313|Active Comparator|TALION TAB. 10mg|
16703783|NCT01925261|Placebo Comparator|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
16703784|NCT01925261|Placebo Comparator|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
16703785|NCT01925261|Placebo Comparator|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
16703786|NCT01925261|Placebo Comparator|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
16703787|NCT01925261|Placebo Comparator|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
16703788|NCT01925248|Active Comparator|Whey protein group|Patients will be randomized to receive whey protein
16703789|NCT01925248|Placebo Comparator|Placebo group|Patients will be randomized to receive placebo
16703790|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
16703791|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
16703792|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
16703793|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
16703794|NCT01925222||Control-vaccinated infant|
16703795|NCT01925222||PCV-vaccinated child, catch-up schedule|
16703796|NCT01925222||Control-vaccinated child, catch-up schedule|
16703797|NCT01925209|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
16703798|NCT01925209|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
16703799|NCT01925209|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
16703800|NCT01925209|Placebo Comparator|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
16703801|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
16703802|NCT01925183|Experimental|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
16703803|NCT01925183|Experimental|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
16703804|NCT01925170|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
16703805|NCT01925157|Experimental|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
16703806|NCT01925157|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
16703807|NCT01925157|Experimental|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
16703808|NCT01925157|Placebo Comparator|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
16703809|NCT01925144|Experimental|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
16703810|NCT01925144|Experimental|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
16703811|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin)|Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16703812|NCT01925118|Experimental|High-dose IL-2|
16703813|NCT01925105|Experimental|Optimization of treatment|Optimization of treatment of diseases and symptoms
16703814|NCT01925105|Placebo Comparator|Control|Treatment as usual
16703815|NCT01925092|Experimental|mifepristone|Daily doses of mifepristone over 84 days.
16703816|NCT01925079|Experimental|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
16703817|NCT01925079|Sham Comparator|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
16703818|NCT01925066|Experimental|Aerosolized Vancomycin|
16703819|NCT01925053|Placebo Comparator|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
16703820|NCT01925053|Active Comparator|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
16704703|NCT01919229|Active Comparator|Letrozole|Letrozole 2.5 mg alone once daily
16703821|NCT01925040|Experimental|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
16703822|NCT01925040|Active Comparator|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
16703823|NCT01925027|Experimental|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
16703824|NCT01925014|Experimental|Low-dose CT|Diagnostic CT with low-dose radiation
16703825|NCT01925014|Active Comparator|Standard-dose CT|Diagnostic CT with standard-dose radiation
16703826|NCT01925001|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
16703827|NCT01925001|Active Comparator|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
16703828|NCT01924988|Experimental|Prostatic Embolization|Therapeutic occlusion of the prostate arteries
16703829|NCT01924975|Active Comparator|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
16703830|NCT01924975|Active Comparator|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
16703831|NCT01924962|No Intervention|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
16703832|NCT01924962|Active Comparator|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
16703833|NCT01924949|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
16703834|NCT01924936|Placebo Comparator|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
16703835|NCT01924936|Experimental|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
16703836|NCT01924936|Experimental|Email + DBT program & Coach|"Caring Email + DBT online program & Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
16703837|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
16703838|NCT01924910|Placebo Comparator|Placebo Pill|Received identical pills that do not contain vitamin D. Blood levels of 25(OH)D determined at 10 days, 3 months, and 1 year following placebo dose.
16703839|NCT01924910|Active Comparator|Vitamin D|250,000 IU cholecalciferol as single, oral dose. Blood levels 25(OH)D measured at 10 days, 3 months, and 1 year following dose.
16703840|NCT01924897|Experimental|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.
~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
16703841|NCT01924897|No Intervention|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
16703842|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
16703843|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
16703844|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
16703845|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
16703846|NCT01924871|Active Comparator|Desflurane group|1.5 MAC desflurane until extubation
16703847|NCT01924871|Active Comparator|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
16703848|NCT01924858|Experimental|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of [18F] GSK2647544 and a dynamic PET scan. [18F]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of [18F]GSK2647544
16703849|NCT01924845|Experimental|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
16703852|NCT01924819|Experimental|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).
~OR epirubicin + oxaliplatin + capecitabine OR 3 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel
~5 weeks preoperative chemoradiotherapy.
~Gastric resection.
~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).
~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
16703853|NCT01924819|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).
~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel
~Gastric resection.
~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine) OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
16703854|NCT01924806|Active Comparator|WoundWand™ Debridement Device|Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
16703855|NCT01924806|Active Comparator|Standard of Care sharp debridement|Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
16703856|NCT01924793|Experimental|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.
~Dry Powder Inhaled Dose:
~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
16703857|NCT01924793|Experimental|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.
~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
16703858|NCT01924780|Active Comparator|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
16703859|NCT01924780|Active Comparator|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
16703860|NCT01924780|Sham Comparator|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
16703861|NCT01924767|Experimental|BI 10773 (dose group 3)|multiple doses as tablet
16703862|NCT01924767|Experimental|BI 10773 (dose group 4)|multiple doses as tablet
16703863|NCT01924767|Experimental|BI 10773 (dose group 1)|multiple doses as tablet
16703864|NCT01924767|Experimental|BI 10773 (dose group 2)|multiple doses as tablet
16703865|NCT01924754||Standard intramuscular injection (NS-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe (NS-IM)
16703866|NCT01924754||PharmaJet needle-free Stratis device (JI-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device (JI-IM)
16703867|NCT01924754||PharmaJet needle-free Tropis device (JI-ID)|HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device (JI-ID)
16703868|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
16703869|NCT01924728|Active Comparator|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
16703870|NCT01924728|Sham Comparator|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
16703871|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
16703872|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
16703873|NCT01924702|Active Comparator|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
16703874|NCT01924702|Sham Comparator|sham tDCS|Intensive language therapy with Sham-tDCS
16703875|NCT01924689|Experimental|Clostridium novyi-NT spores|
16703876|NCT01924676|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16703877|NCT01924676|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16703878|NCT01924676|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
16703879|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM|
16703880|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
16703881|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM|
16703882|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
16703883|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM|
16703884|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
16703965|NCT01924130|Experimental|One Healthy Breakfast Program|Classroom feeding, nutrition education lessons, social marketing, and parent outreach.
16703966|NCT01924130|No Intervention|Control|Only receive assessments.
16703885|NCT01924637|Experimental|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
16703886|NCT01924637|Active Comparator|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
16703887|NCT01924624|Experimental|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
16703888|NCT01924624|Active Comparator|Control|No adjuvant Thalidomide treatment after curative hepatic resection
16703889|NCT01924611|Active Comparator|Control Group|Atraumatic Restorative Technique using cotton rolls.
16703890|NCT01924611|Experimental|Experimental Group|Atraumatic Restorative Technique using rubber dam.
16703891|NCT01924598|Experimental|DBS surgery|
16703892|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
16703893|NCT01924572|No Intervention|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
16703894|NCT01924572|Experimental|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
16703895|NCT01924572|Experimental|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
16703896|NCT01924572|Experimental|cord milking|provider milks the cord 5 times from placenta to infant
16703897|NCT01924559|Active Comparator|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
16703898|NCT01924559|Active Comparator|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
16703899|NCT01924559|Experimental|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
16703900|NCT01924559|Active Comparator|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
16703901|NCT01924559|Active Comparator|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
16703902|NCT01924559|Active Comparator|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
16703903|NCT01924546|Experimental|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
16703904|NCT01924546|No Intervention|Control|No additional water provided during the day. Additional water provided at the end of the school day.
16703905|NCT01924533|Experimental|Olaparib+ paclitaxel|olaparib + paclitaxel
16703906|NCT01924533|Placebo Comparator|Placebo+paclitaxel|placebo+ paclitaxel
16703907|NCT01924520|Experimental|Group 1 (FK949E lower dose)|Oral
16703908|NCT01924520|Experimental|Group 2 (FK949E middle dose)|Oral
16703909|NCT01924520|Experimental|Group 3 (FK949E higher dose)|Oral
16703910|NCT01924507|Experimental|CPAP|Patients with apnea will be treated with CPAP during the night.
16703911|NCT01924507|No Intervention|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
16703912|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
16703913|NCT01924481|Experimental|low theobromine & low caffeine|Drink 1
16703914|NCT01924481|Experimental|low theobromine & high caffeine|Drink 2
16703915|NCT01924481|Experimental|high theobromine & low caffeine|Drink 3
16703916|NCT01924481|Active Comparator|no theobromine & high caffeine|Drink 4
16703917|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
16703918|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
16703919|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
16703920|NCT01924429|Experimental|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
16703921|NCT01924429|Experimental|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
16703922|NCT01924416|Experimental|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
16703923|NCT01924416|Active Comparator|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
16703924|NCT01924403|Experimental|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
16703925|NCT01924403|Experimental|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
16703926|NCT01924403|Experimental|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
16703927|NCT01924390|Active Comparator|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
16703928|NCT01924390|Experimental|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
16703929|NCT01924377|Other|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
16703930|NCT01924377|Experimental|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
16703931|NCT01924364|Experimental|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
16703967|NCT01924117|No Intervention|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
16703932|NCT01924364|Sham Comparator|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
16703933|NCT01924351|Other|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
16703934|NCT01924338|Experimental|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
16703935|NCT01924338|Experimental|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
16703936|NCT01924338|Experimental|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
16703937|NCT01924338|Experimental|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
16703938|NCT01924325|Active Comparator|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
16703939|NCT01924325|Experimental|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
16703940|NCT01924325|Experimental|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
16703941|NCT01924312|Placebo Comparator|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
16703942|NCT01924312|Experimental|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
16703943|NCT01924299|Experimental|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.
~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
16703944|NCT01924299|Experimental|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.
~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
16703945|NCT01924286|Experimental|Prednisone|Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
16703946|NCT01924286|Placebo Comparator|Placebo|Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
16703947|NCT01924273|Other|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
16703948|NCT01924260|Experimental|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16703949|NCT01924247|Other|Interventional Arm|Interventional Arm
16703950|NCT01924247|Other|Control Arm|Control Arm: Standard treatment by family physician
16703951|NCT01924234|Active Comparator|morphine|Volunteers are given morphine injection
16703952|NCT01924234|Active Comparator|remifentanil|Volunteers are given remifentanil infusion
16703953|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
16703954|NCT01924208|Active Comparator|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
16703955|NCT01924208|Active Comparator|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
16703956|NCT01924208|Active Comparator|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
16703957|NCT01924208|No Intervention|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
16703958|NCT01924195|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
16703959|NCT01924195|Placebo Comparator|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
16703960|NCT01924182|Other|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
16703961|NCT01924182|Other|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
16703962|NCT01924169|Experimental|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
16703963|NCT01924156|Experimental|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
16703964|NCT01924143|Experimental|TD-9855|
16703968|NCT01924104|Active Comparator|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
16703969|NCT01924104|Active Comparator|Low dose aspirin|Low dose aspirin, 75mg/day, orally
16703970|NCT01924104|Active Comparator|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
16703971|NCT01924104|Placebo Comparator|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
16703972|NCT01924091|Experimental|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.
~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
16703973|NCT01924091|Experimental|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
16703974|NCT01924078|Experimental|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
16703975|NCT01924065|Active Comparator|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
16703976|NCT01924065|Active Comparator|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
16703977|NCT01924052|Active Comparator|Migraine patients with high genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
16703978|NCT01924052|Active Comparator|Migraine patients with low genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
16703979|NCT01924039|Experimental|Brief Motivational Enhancement Therapy|
16703980|NCT01924039|Other|treatment as usual|
16703981|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
16703982|NCT01924026||Unaffected Siblings|With normal Phe levels
16703983|NCT01924013|Placebo Comparator|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)
~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
16703984|NCT01924013|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
16703985|NCT01924013|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
16703986|NCT01924013|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
16703987|NCT01924013|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
16703988|NCT01924000|Experimental|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
16703989|NCT01924000|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
16703990|NCT01923987|Experimental|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
16703991|NCT01923974|Placebo Comparator|Placebo|IV formulation
16703992|NCT01923974|Active Comparator|Melatonin 10 mg|IV formulation, Melatonin 10 mg
16703993|NCT01923974|Active Comparator|Melatonin 100 mg|IV formulation, Melatonin 100 mg
16703994|NCT01923961|Experimental|HDF NaCl, Then HD, Then Standard Pre-HDF|Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
16703995|NCT01923961|Experimental|HD, Then Standard Pre-HDF, Then HDF NaCl|Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
16703996|NCT01923961|Experimental|Standard Pre-HDF, Then HDF NaCl, Then HD|Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
16703997|NCT01923948|Active Comparator|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
16703998|NCT01923948|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose
16703999|NCT01923935|Experimental|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)"
16704000|NCT01923922|Other|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
16704001|NCT01923909|Active Comparator|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
16704044|NCT01923649|Experimental|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
16733600|NCT01724060||Gastric banding|Patients due for gastric banding
16704002|NCT01923909|Experimental|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
16704003|NCT01923896|Experimental|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
16704004|NCT01923896|Active Comparator|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
16704005|NCT01923883|Active Comparator|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
16704006|NCT01923883|Experimental|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
16704007|NCT01923870|Experimental|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m^2 with moderate hepatic impairment (Child-Pugh Class B)
16704008|NCT01923870|Experimental|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m^2
16704009|NCT01923857|Experimental|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
16704010|NCT01923857|Experimental|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
16704011|NCT01923857|Experimental|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
16704012|NCT01923857|Experimental|Severe renal impairment|
16704013|NCT01923844|Experimental|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
16704014|NCT01923844|Experimental|beractant|preterm infants who received beractant for respiratory distress syndrome
16704015|NCT01923844|No Intervention|Control|Preterm infants without respiratory distress syndrome
16704016|NCT01923831|Experimental|Magnesium group|
16704017|NCT01923831|Active Comparator|Dexamethasone group|
16704018|NCT01923818|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo rivaroxaban from day 1 to day 30
16704019|NCT01923818|Experimental|Rivaroxaban 5mg|Receiving a 5-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
16704020|NCT01923818|Experimental|rivaroxaban 10mg|Receiving a 10-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
16704021|NCT01923805|Experimental|Treatment Group|Vitagel
16704022|NCT01923805|No Intervention|Control|Standard of care for surgical hemostasis.
16704023|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
16704024|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
16704025|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
16704026|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
16704027|NCT01923766|Experimental|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
16704028|NCT01923753|Experimental|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):
~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
16704029|NCT01923753|Active Comparator|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):
~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
16704030|NCT01923753|Sham Comparator|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):
~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
16704031|NCT01923740|Experimental|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
16704032|NCT01923740|Active Comparator|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
16704033|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
16704034|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
16704035|NCT01923701|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
16704036|NCT01923701|No Intervention|Monitoring|This group receives standard care only.
16704037|NCT01923688|Experimental|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
16704038|NCT01923688|No Intervention|control-no intervention|
16704039|NCT01923675|Experimental|color blocking tint|Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
16704040|NCT01923675|Other|holographic diffuser|Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
16704041|NCT01923675|Other|diffuser & color blocking tint|Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
16704042|NCT01923675|Other|holographic diffuser and neutral tint|Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
16704043|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
16704610|NCT01919879|Experimental|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
16704045|NCT01923649|Placebo Comparator|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
16704046|NCT01923636|Other|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
16704047|NCT01923623|Experimental|Block|Popliteal and saphenous Block with Ropivacaine
16704048|NCT01923623|Placebo Comparator|NaCl|
16704049|NCT01923610|Experimental|Main|MVA HIV-B
16704050|NCT01923597|Active Comparator|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
16704051|NCT01923597|Placebo Comparator|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
16704052|NCT01923584|Active Comparator|EPI-743 400mg|EPI-743 at a dose of 400 mg three times daily
16704053|NCT01923584|Active Comparator|EPI-743 200mg|EPI-743 at a dose of 200 mg three times daily
16704054|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
16704055|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
16704056|NCT01923558|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
16704057|NCT01923558|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
16704058|NCT01923545|Experimental|DA-3031 3.6mg|PEG-G-CSF
16704059|NCT01923545|Experimental|DA-3031 6mg|PEG-G-CSF
16704060|NCT01923545|Active Comparator|Leucostim®|G-CSF
16704061|NCT01923519|Experimental|allergic rhinitis|
16704062|NCT01923519|Experimental|allergic rhinitis and asthma|
16704063|NCT01923519|Experimental|witnesses|
16704064|NCT01923506|Experimental|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
16704065|NCT01923493|Active Comparator|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
16704066|NCT01923493|Experimental|tuina|tuina treatment
16704067|NCT01923480|Experimental|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
16704068|NCT01923480|Experimental|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
16704069|NCT01923480|Experimental|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
16704070|NCT01923467|Experimental|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
16704071|NCT01923454|Experimental|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.
~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.
~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
16704072|NCT01923441||Highschool athletes|
16704073|NCT01923441||midschool athletes|
16704074|NCT01923428|Experimental|5 mg BID|AZD1722
16704075|NCT01923428|Experimental|20 mg BID|AZD1722
16704076|NCT01923428|Experimental|50 mg BID|AZD1722
16704077|NCT01923428|Placebo Comparator|Placebo|
16704078|NCT01923415||Group 1: SLE|>=10 participants with systemic lupus erythematosus (SLE)
16704079|NCT01923415||Group 2: DLE|>=10 participants with discoid lupus erythematosus (DLE)
16704080|NCT01923415||Group 3: SCLE|>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
16704081|NCT01923402||Exclusive cigarette smokers|
16704082|NCT01923402||Exclusive moist snuff consumers|
16704083|NCT01923402||Non-tobacco consumers|
16704084|NCT01923389|Placebo Comparator|Placebo|
16704085|NCT01923389|Experimental|100 mg PF-05231023|
16704086|NCT01923376|Other|Lactulose|per standard of care
16704087|NCT01923376|Active Comparator|polyethylene glycol 3350 (Golytely)|
16704088|NCT01923363|Experimental|Standard Dose to High Dose Piperacillin/Tazobactam|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
16704089|NCT01923350|Experimental|Weight Reduction Intervention|
16704090|NCT01923350|Active Comparator|Weight Reduction Control Arm|
16704091|NCT01923350|Active Comparator|Tested for diabetes|
16704092|NCT01923350|Active Comparator|Not tested for diabetes|
16704093|NCT01923337|Experimental|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16704094|NCT01923324|Experimental|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
16704095|NCT01923324|Active Comparator|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
16704611|NCT01919879|Active Comparator|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
16704096|NCT01923311|Experimental|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.
~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
16704097|NCT01923311|Experimental|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA > 1,000 copies/mL can continue after Week 48.
~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
16704098|NCT01923311|Experimental|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.
~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
16704099|NCT01923311|Experimental|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.
~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
16704100|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
16704101|NCT01923285|Experimental|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
16704102|NCT01923285|Active Comparator|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
16704103|NCT01923272|Sham Comparator|Sham Device|inactive AlphaCore device
16704104|NCT01923272|Active Comparator|AlphaCore|Active AlphaCore device
16704105|NCT01923259|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
16704106|NCT01923259|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
16704107|NCT01923246|Experimental|Single WEB intervention|Web intervention recieved once.
16704108|NCT01923246|Experimental|Repeated WEB intervention|Web intervention recieved twice.
16704109|NCT01923246|Experimental|Single IVR intervention|IVR intervention recieved once
16704110|NCT01923246|Experimental|Repeated IVR intervention|IVR intervention recieved twice
16704111|NCT01923246|No Intervention|Control group|Untreated Control Group.
16704112|NCT01923233|Experimental|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
16704113|NCT01923220|Experimental|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
16704114|NCT01923220|Sham Comparator|Aloe Vera Jel|To be applied topically
16704115|NCT01923207|Experimental|DX-2930|DX-2930 administered by subcutaneous route
16704116|NCT01923207|Placebo Comparator|placebo|inactive formulation of DX-2930
16704117|NCT01923194|Experimental|Test Group|
16704118|NCT01923194|Active Comparator|Comparator Group|
16704119|NCT01923181|Experimental|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704120|NCT01923181|Experimental|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704121|NCT01923181|Experimental|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704704|NCT01919229|Experimental|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
16704122|NCT01923181|Experimental|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704123|NCT01923181|Experimental|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.
~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
16704124|NCT01923181|Experimental|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704125|NCT01923181|Experimental|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.
~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
16704126|NCT01923181|Placebo Comparator|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704127|NCT01923181|Active Comparator|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
16704128|NCT01923168|Experimental|Alpelisib + Letrozole|Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
16704129|NCT01923168|Experimental|Buparlisib + Letrozole|Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
16704130|NCT01923168|Placebo Comparator|Placebo + Letrozole|Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
16704131|NCT01923155|Active Comparator|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
16704132|NCT01923155|Active Comparator|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
16704133|NCT01923142|Experimental|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
16704134|NCT01923142|Placebo Comparator|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
16704135|NCT01923129|Experimental|24 hour postop catheter removal|group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
16704136|NCT01923129|No Intervention|72 hour postoperative catheter removal|catheter removed on postoperative day 3 (72 hours postoperatively)
16704137|NCT01923116|Experimental|HPV-16 vaccine|
16704138|NCT01923090|Experimental|Finasteride|Finasteride treatment 5mg for 3 weeks
16704139|NCT01923090|Experimental|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
16704140|NCT01923077|Placebo Comparator|Conventional|Conventional treatment with simvastatin
16704141|NCT01923077|Active Comparator|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
16704142|NCT01923064|Active Comparator|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
16704143|NCT01923064|Experimental|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
16704144|NCT01923038|Active Comparator|Patients ventilated with zero end expiratory pressure (ZEEP)|patients undergoing gynecologic laparoscopic surgery ventilated at zero end expiratory pressure
16704145|NCT01923038|Active Comparator|Patients ventilated with positive end expiratory pressure|patients undergoing gynecologic laparoscopic surgery ventilated at PEEP
16704146|NCT01923038|Active Comparator|recruitment plus PEEP|patients undergoing gynecologic laparoscopic surgery undergoing recruitment plus PEEP
16704147|NCT01923025|Experimental|RO5545965|
16704148|NCT01923012|Experimental|Vitamin K2|
16704149|NCT01922999|Active Comparator|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
16704150|NCT01922999|Active Comparator|Melatonin|comparison of melatonin 1mg or melatonin 3mg
16704151|NCT01922986|Experimental|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
16704152|NCT01922986|Sham Comparator|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
16704153|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
16704154|NCT01922960|Other|micro-imaging|"Sublingual or subconjunctival micro-imaging of the microcirculation taken for 3 minute intervals at certain timepoints.
~Timepoints for burn/trauma subjects: Day0, Day1,Day2,Day6 & Day7 Timepoints for general surgery population: post-induction, prior to resection, after resection,& closing of surgical wound."
16704155|NCT01922947|Active Comparator|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
16704156|NCT01922947|Sham Comparator|Health Counseling|
16704157|NCT01922934|Experimental|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
16704158|NCT01922934|No Intervention|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
16704159|NCT01922921|Active Comparator|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
16704160|NCT01922921|Experimental|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
16704161|NCT01922908|Active Comparator|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
16704162|NCT01922908|Placebo Comparator|SHAM infusion|Infusion of normal saline placebo
16704163|NCT01922895|Placebo Comparator|Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
16704164|NCT01922895|Active Comparator|Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
16704165|NCT01922882|Experimental|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:
~family engagement, personal preparation, disclosure practice using intervention materials
~health promotion training and a mother-child visit
~play-for-communication and custody care planning"
16704166|NCT01922882|No Intervention|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.
~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.
~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
16704167|NCT01922869|Experimental|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
16704168|NCT01922856|Experimental|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.
~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
16704169|NCT01922856|Experimental|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
16704170|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
16704171|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
16704172|NCT01922830|Experimental|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).
~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
16704173|NCT01922830|Placebo Comparator|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).
~The placebo supplementation is identical-looking to the Bio-25 supplement."
16704174|NCT01922817|Active Comparator|Saxagliptin|5mg once daily in addition to insulin therapy
16704175|NCT01922817|Placebo Comparator|Placebo|Crossover Placebo once daily
16704176|NCT01922804|Experimental|K2 vitamin|K2 vitamin 375 microgram a day for 3 years
16704177|NCT01922804|Placebo Comparator|placebo|1 tablet a day for 3 years
16704178|NCT01922791|Active Comparator|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
16704179|NCT01922791|Active Comparator|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
16704180|NCT01922791|Active Comparator|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
16704181|NCT01922791|Placebo Comparator|Placebo|Comparison of probiotics, fish oil and their combination to placebo
16704182|NCT01922778|Experimental|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.
~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
16704183|NCT01922765|Experimental|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
16704184|NCT01922765|Experimental|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
16704185|NCT01922765|Experimental|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
16704186|NCT01922765|Experimental|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
16704187|NCT01922752|Experimental|CEP-37440|
16704232|NCT01922388||Early Motor Complication|This group is composed of PD patients with motor complications of 3 years or less. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
16733601|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
16704188|NCT01922739|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
16704189|NCT01922713|Placebo Comparator|white maize|white maize and a corn oil capsule
16704190|NCT01922713|Experimental|orange maize|orange maize and a corn oil capsule
16704191|NCT01922713|Active Comparator|vitamin A|white maize and a vitamin A capsule
16704192|NCT01922687|Experimental|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
16704193|NCT01922687|Active Comparator|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
16704194|NCT01922674|No Intervention|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
16704195|NCT01922674|Active Comparator|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
16704196|NCT01922661|Experimental|Cohort 1|Dose 1 of REGN1908-1909 or placebo
16704197|NCT01922661|Experimental|Cohort 2|Dose 2 of REGN1908-1909 or placebo
16704198|NCT01922661|Experimental|Cohort 3|Dose 3 of REGN1908-1909 or placebo
16704199|NCT01922648||2-4 months|Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
16704200|NCT01922648||6 - 12 months|Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
16704201|NCT01922648||3 - 6 years|Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
16704202|NCT01922635|Other|1|
16704203|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
16704204|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
16704205|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
16704206|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
16704207|NCT01922596|Experimental|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
16704208|NCT01922596|Experimental|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
16704209|NCT01922583|Experimental|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
16704210|NCT01922570|Experimental|Dietary supplements:parenteral nutrition|supplemental parenteral nutrition and enteral nutrition in case of failure (intake below 60% of energy needs) of enteral nutrition by day 3 after admission in the ICU or enteral nutrition only.
16704211|NCT01922557||NICOM|
16704212|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
16704213|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
16704214|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
16704215|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
16704216|NCT01922518|Active Comparator|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
16704217|NCT01922518|Active Comparator|Apex pacing group|Put RV lead around the apex
16704218|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
16704219|NCT01922492|Experimental|Autologous islet transplantation|Autologous islet transplantation arm: autologous islet transplantation
16704220|NCT01922492|Active Comparator|Oral anti-diabetic drugs|Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
16704221|NCT01922479|Experimental|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
16704222|NCT01922479|Active Comparator|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
16704223|NCT01922466|Experimental|Bee Venom Acupuncture|
16704224|NCT01922466|Experimental|Loxoprofen|
16704225|NCT01922466|Experimental|EWCT : Bee Venom Acupucture and Loxoprofen|
16704226|NCT01922453|Experimental|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
16704227|NCT01922453|No Intervention|no music and sound|
16704228|NCT01922440||Chronic Hypoparathyroidism|A rare disease with a duration of longer than 6 months characterized by insufficient parathyroid hormone (PTH) secretion, which can result in hypocalcemia, hyperphosphatemia, and associated clinical findings.
16704229|NCT01922414|Active Comparator|Laser|Patients will undergo Laser lithotripsy
16704230|NCT01922414|Active Comparator|Ultrasonic|Patients will undergo ultrasonic lithotripsy
16704231|NCT01922401|Experimental|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
16733603|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
16704233|NCT01922388||Late Motor Complication|This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
16704234|NCT01922375|Experimental|Naftopidil dose 2|PO administration
16704235|NCT01922375|Placebo Comparator|Placebo|PO administration
16704236|NCT01922375|Experimental|Naftopidil dose 1|PO administration
16704237|NCT01922362|Experimental|Negative pressure drainage system|Negative pressure drainage system
16704238|NCT01922362|Active Comparator|Indirect wet dressing group|Indirect wet dressing
16704239|NCT01922349|Placebo Comparator|Placebo (Multiple dose)|Placebo
16704240|NCT01922349|Experimental|Dose 1, Single dose|Low dose
16704241|NCT01922349|Experimental|Dose 2, Single dose|Medium dose
16704242|NCT01922349|Experimental|Dose 3, Single dose|High dose
16704243|NCT01922349|Experimental|Dose 4, Multiple dose|Low dose
16704244|NCT01922349|Experimental|Dose 5, Multiple dose|Medium dose
16704245|NCT01922349|Experimental|Dose 6, Multiple dose|High dose
16704246|NCT01922349|Placebo Comparator|Placebo (Single dose)|Placebo
16704247|NCT01922336|Experimental|SB2|SB2 (Study drug)
16704248|NCT01922336|Active Comparator|EU Remicade|EU sourced Remicade (Reference drug)
16704249|NCT01922336|Active Comparator|US Remicade|US sourced Remicade (Reference drug)
16704250|NCT01922310|Other|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
16704251|NCT01922297|Experimental|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
16704252|NCT01922297|Other|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
16704253|NCT01922284|Experimental|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.
~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
16704254|NCT01922284|Active Comparator|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.
~At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
16704255|NCT01922271|Experimental|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
16704256|NCT01922271|Experimental|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
16704257|NCT01922258|Placebo Comparator|Placebo|Matching Placebo Once-Daily
16704258|NCT01922258|Experimental|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
16704259|NCT01922245|Experimental|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
16704260|NCT01922219|Other|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
16704261|NCT01922206|No Intervention|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
16704262|NCT01922206|Experimental|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
16704263|NCT01922193|Experimental|Test Group|
16704264|NCT01922193|Active Comparator|Control Group|
16704265|NCT01922180||COPD Exacerbation|COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
16704266|NCT01922167|Experimental|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
16704267|NCT01922167|Placebo Comparator|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
16704268|NCT01922154|Experimental|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
16704303|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
16704304|NCT01921959||Partners of no intervention women|Partners of women randomized to control
16704269|NCT01922141|Experimental|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
16704270|NCT01922141|Experimental|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
16704271|NCT01922141|Active Comparator|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
16704272|NCT01922128|Active Comparator|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
16704273|NCT01922128|Placebo Comparator|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
16704274|NCT01922115|Active Comparator|TROSPIUM CHLORIDE|Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).
16704275|NCT01922115|Placebo Comparator|PLACEBO|Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).
16704276|NCT01922102|Experimental|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
16704277|NCT01922102|Experimental|Group II|0.5 mg ranibizumab driven by disease activity criteria
16704278|NCT01922102|Active Comparator|Group III|verteporfin PDT
16704279|NCT01922089|Experimental|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
16704280|NCT01922089|Experimental|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
16704281|NCT01922076|Experimental|Treatment (adavosertib, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive adavosertib PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
16704282|NCT01922063|Experimental|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
16704283|NCT01922063|Sham Comparator|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
16704284|NCT01922063|No Intervention|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
16704285|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
16704286|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
16704287|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
16704288|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
16704289|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
16704290|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
16704291|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
16704292|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
16704293|NCT01922037|Experimental|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
16704294|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
16704295|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
16704296|NCT01922011|Experimental|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to <18 years (7 mg/kg); age 7 years to < 12 years (9 mg/kg); age 24 months to <7 years (12 mg/kg); age 12 months to <24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
16704297|NCT01922011|Active Comparator|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
16704298|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
16704299|NCT01921985|Active Comparator|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
16704300|NCT01921985|Placebo Comparator|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
16704301|NCT01921972|Active Comparator|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
16704302|NCT01921972|Experimental|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
16704307|NCT01921933|Experimental|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
16704308|NCT01921920|Active Comparator|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
16704309|NCT01921920|Active Comparator|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
16704310|NCT01921920|Active Comparator|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
16704311|NCT01921920|Active Comparator|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
16704312|NCT01921907|Experimental|Active|topical treatment
16704313|NCT01921907|Placebo Comparator|Placebo|topical treatment
16704314|NCT01921894|Experimental|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
16704315|NCT01921894|Experimental|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
16704316|NCT01921894|Active Comparator|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
16704317|NCT01921881|Experimental|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:
~Without taking any St John's wort
~After 3 weeks pretreatment with St John's wort
~Minimum 6 weeks after last St John's wort ingestion"
16704318|NCT01921868|Experimental|Acetyl-L-Carnitine|Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
16704319|NCT01921855|Experimental|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
16704320|NCT01921855|Experimental|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
16704321|NCT01921855|Experimental|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
16704322|NCT01921855|Experimental|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
16704323|NCT01921842|Experimental|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
16704324|NCT01921842|Other|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
16704325|NCT01921829|No Intervention|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
16704326|NCT01921829|Experimental|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is < 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is > 5 L/day, diuretic regimen will be reduced.
16704327|NCT01921816|Other|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
16704328|NCT01921803|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
16704329|NCT01921803|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
16704330|NCT01921790|Experimental|Avastin+ GemAOD|Avastin+ GemAOD means Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone
16704331|NCT01921777|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
16704332|NCT01921777|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
16704333|NCT01921764|Experimental|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
16704334|NCT01921764|Active Comparator|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
16704335|NCT01921751|Experimental|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
16704336|NCT01921751|Experimental|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
16704337|NCT01921751|Active Comparator|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity [randomized to this arm after 3rd cycle and no progression]
16704338|NCT01921738|Experimental|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
16704339|NCT01921738|Experimental|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
16704340|NCT01921738|Placebo Comparator|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
16704341|NCT01921738|Placebo Comparator|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
16704669|NCT01919450|Active Comparator|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
16704342|NCT01921725|Experimental|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
16704343|NCT01921712|Experimental|PUR0200 low dose|PUR0200 low dose, single dose inhalation
16704344|NCT01921712|Experimental|PUR0200 mid dose|PUR0200 mid dose, single dose inhalation
16704345|NCT01921712|Experimental|PUR0200 high dose|PUR0200 high dose, single dose inhalation
16704346|NCT01921712|Placebo Comparator|Placebo|PUR0200 matched placebo, single dose, inhalation
16704347|NCT01921712|Active Comparator|Active Comparator|Active Comparator, single dose, inhalation
16704348|NCT01921699|Other|irrelevant|
16704349|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week
~AND, At least one of the following:
~Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)
~Abnormal pH index (pH less than 4 for greater than 6% of study)
~Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
16704350|NCT01921686||Eosinophilic Esophagitis (EoE)|"History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)
~Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy
~Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
16704351|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
16704352|NCT01921673|Experimental|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off
~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
16704353|NCT01921647|Experimental|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
16704354|NCT01921647|Experimental|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
16704355|NCT01921647|Experimental|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
16704356|NCT01921647|Active Comparator|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
16704357|NCT01921634|Other|Standard analysis|Standard pathological analysis currently used.
16704358|NCT01921634|Other|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
16704359|NCT01921621|No Intervention|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
16704360|NCT01921621|Active Comparator|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
16704361|NCT01921621|Experimental|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
16704362|NCT01921608|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
16704363|NCT01921595|Experimental|Valanced salt colloid group|
16704364|NCT01921595|Active Comparator|Valanced salt crystalloid group|
16704365|NCT01921582|Experimental|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)
~Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.
~Dosage form: tablet
~Dosage frequency: daily
~Duration: 12 weeks total"
16704366|NCT01921582|Active Comparator|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy
~12 individual 50-minute appointments over the course of up to 14 weeks
~According to Fairburn, Marcus, and Wilson (1993)"
16704367|NCT01921569|Experimental|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
16704368|NCT01921569|Placebo Comparator|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
16704369|NCT01921556|Active Comparator|QualiCCare education|"QualiCCareeducation is a training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
16704370|NCT01921556|No Intervention|usual care|The practices randomized to the control group apply care as usual
16704371|NCT01921543|Experimental|CI/BNST stimulation on|
16704372|NCT01921543|Experimental|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
16704373|NCT01921543|Experimental|ITP stimulation on|
16704374|NCT01921543|Experimental|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
16704375|NCT01921530|Active Comparator|Interbody Fusion|
16704376|NCT01921530|Active Comparator|Posterolateral Fusion|
16704377|NCT01921517|Experimental|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
16704378|NCT01921517|Placebo Comparator|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
16704379|NCT01921504|Experimental|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
16704380|NCT01921504|No Intervention|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
16704381|NCT01921491|Other|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
16704382|NCT01921491|Active Comparator|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
16704383|NCT01921491|Experimental|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
16704384|NCT01921478||Cohort|
16704385|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
16704386|NCT01921452|Experimental|POC TSH Kits + Third Generation TSH Kit|
16704387|NCT01921439|Active Comparator|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
16704388|NCT01921439|No Intervention|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
16704389|NCT01921426|Experimental|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
16704390|NCT01921400||HCV-infected mothers|in situ hybridization
16704391|NCT01921400||Uninfected mothers|in situ hybridization
16704392|NCT01921387|Experimental|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
16704393|NCT01921374|Experimental|sleep parameters|To assess the sleep parameters.
16704394|NCT01921374|Other|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
16704395|NCT01921374|Experimental|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
16704396|NCT01921374|Experimental|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
16704397|NCT01921374|Experimental|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
16704398|NCT01921361|Active Comparator|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
16704399|NCT01921361|Active Comparator|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
16704400|NCT01921361|Placebo Comparator|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
16704401|NCT01921348|Experimental|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
16704402|NCT01921348|Sham Comparator|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
16704403|NCT01921335|Active Comparator|ARRY-380 Twice Daily Dosage|ARRY-380 will be 450mg orally twice-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg.ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
16704404|NCT01921335|Active Comparator|ARRY-380 Once Daily|ARRY-380 will be 750mg orally once-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg. ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
16704405|NCT01921322|Experimental|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
16704406|NCT01921322|Active Comparator|MDI|Multiple daily insulin injections used for treatment
16704407|NCT01921309|Experimental|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
16704408|NCT01921309|Active Comparator|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
16704409|NCT01921296|Experimental|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
16704410|NCT01921283|Experimental|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
16704411|NCT01921283|Active Comparator|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
16704412|NCT01921270|Experimental|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
16704413|NCT01921257|Experimental|Treatment|Cat-PAD and Placebo
16704414|NCT01921244|No Intervention|Usual Care|"Approximately 120 families will be asked to participate as usual care subjects and will complete surveys before and immediately after their visit, and approximately 3 months after the visit. These families will not receive the decision aid nor will their provider have been trained how to use the decision aid. All participating providers will have up to 10 usual care patients enrolled at baseline prior to allocation. During the trial, the control group [usual care providers] will have up to 10 additional patients enrolled for ongoing usual care data collection. After the trial is complete, the control group providers will cross over to the intervention arm."
16704415|NCT01921244|Experimental|Intervention|Approximately 80 families/patients with regularly scheduled clinic follow-up visits in the Division of Developmental and Behavioral Pediatrics (DDBP) at Cincinnati Childrens with providers trained on shared decision making will receive the decision aid prior to their index visit and complete surveys before and immediately after their visit, and approximately 3 months later.
16704416|NCT01921231|Experimental|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
16704417|NCT01921231|Active Comparator|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
16704418|NCT01921218|Experimental|Treatment|Belatacept (Nulojix) IV
16704419|NCT01921218|Active Comparator|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
16704420|NCT01921205|Experimental|Lacosamide|
16704421|NCT01921205|Placebo Comparator|Placebo|
16704422|NCT01921192|Active Comparator|Folic Acid, vit B6 and B12|
16704423|NCT01921192|Placebo Comparator|Sugar pill|
16704424|NCT01921179|Experimental|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
16704425|NCT01921179|Active Comparator|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
16704426|NCT01921166|Active Comparator|clomiphene plus gonadotropins|clomiphene plus gonadotropins
16704427|NCT01921166|Active Comparator|Leuprolide flare|Leuprolide flare
16704428|NCT01921153|Experimental|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
16704429|NCT01921153|Experimental|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
16704430|NCT01921140|Other|Fasted|Olaparib tablets following no breakfast
16704431|NCT01921140|Other|High-fat meal|Olaparib tablets after high-fat breakfast
16704432|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
16704433|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
16704434|NCT01921114|Active Comparator|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
16704435|NCT01921114|Active Comparator|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
16704436|NCT01921101|Other|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
16704437|NCT01921101|Other|control|participants will not receive intensive nutritional support from hospital admission to discharge
16704438|NCT01921088|Experimental|Contingent|Contingent RT-fMRI-NF of brain activity in the target region of interest
16704439|NCT01921088|Sham Comparator|Non-contingent|Sham RT-fMRI-NF of brain activity of previously recorded subject
16704440|NCT01921075||Volunteers|young (age<30), healthy, lean (BMI<25) volunteers
16704441|NCT01921062|No Intervention|Control|Patients allocated to the control group only receive standard treatment.
16704442|NCT01921062|Experimental|Motor imagery|Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.
16704443|NCT01921036|Experimental|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
16704444|NCT01921036|Active Comparator|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
16704445|NCT01921010|Active Comparator|Niaspan|Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
16704446|NCT01921010|Placebo Comparator|Control|patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
16704447|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
16704448|NCT01920984|Experimental|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
16704449|NCT01920984|No Intervention|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
16704568|NCT01920152|Active Comparator|Hyaluronic Acid Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
16704450|NCT01920971|Active Comparator|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
16704451|NCT01920971|Placebo Comparator|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
16704452|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
16704453|NCT01920945|Experimental|OnabotulinumtoxinA|
16704454|NCT01920932|Experimental|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
16704455|NCT01920919|Experimental|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
16704456|NCT01920919|Placebo Comparator|Placebo|Placebo tablet, for 180 days
16704457|NCT01920906|Experimental|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
16704458|NCT01920893|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
16704459|NCT01920893|Experimental|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
16704460|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
16704461|NCT01920880||Healthy controls|Healthy controls
16704462|NCT01920867|Active Comparator|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
16704463|NCT01920867|Active Comparator|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
16704464|NCT01920867|Active Comparator|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
16704465|NCT01920854|Experimental|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
16704466|NCT01920854|Placebo Comparator|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
16704467|NCT01920841|Experimental|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
16704468|NCT01920841|Experimental|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
16704469|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
16704470|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
16704471|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
16704472|NCT01920802|Experimental|olanzapine|5mg BID olanzapine for up to 4 weeks
16704473|NCT01920802|Experimental|iloperidone|6mg BID iloperidone up to 4 weeks
16704474|NCT01920802|Placebo Comparator|placebo|BID placebo up to 4 weeks
16704475|NCT01920789|Experimental|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
16704476|NCT01920789|Active Comparator|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
16704477|NCT01920776|Experimental|Rutine treatment group, Ultrasound group|
16704478|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
16704479|NCT01920750|Experimental|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
16704480|NCT01920750|Experimental|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
16704481|NCT01920737|Experimental|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:
~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
16704482|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores < -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and stunting (HAZ < -2 SD).
16704483|NCT01920711|Experimental|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
16704484|NCT01920711|Active Comparator|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
16704485|NCT01920698|Experimental|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
16704486|NCT01920698|Other|Control|Patients randomized to the Control group will receive optimal therapy alone
16704487|NCT01920685|Experimental|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
16704488|NCT01920685|Other|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
16704489|NCT01920672|Experimental|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
16704490|NCT01920672|Active Comparator|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
16704491|NCT01920659|Experimental|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
16704492|NCT01920659|Experimental|REHIT|6 weeks of HIT, 3 times a week (20sec)
16704493|NCT01920659|No Intervention|control|control
16704494|NCT01920646|Experimental|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.
~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
16704495|NCT01920646|No Intervention|Control|normal school meal as daily meal (5 days/weeks) for 3 months
16704496|NCT01920633||People with Down syndrome|
16704497|NCT01920620|Experimental|Intervention Arm|Inpatient weight loss counseling Motivational interviewing and troubleshooting via phone
16704498|NCT01920620|No Intervention|Usual Care Arm|Participants in the usual care group were not provided with any specific instructions regarding weight loss, diet or exercise prior to discharge. Follow-up phone calls for usual care subject were used only to obtain weight and assess for changes in medications or health condition.
16704499|NCT01920607|Active Comparator|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
16704500|NCT01920607|Experimental|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
16704501|NCT01920594|Experimental|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
16704502|NCT01920594|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
16704503|NCT01920581||volunteers|
16704504|NCT01920568|Experimental|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
16704505|NCT01920568|Experimental|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
16704506|NCT01920555|Active Comparator|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
16704507|NCT01920555|Active Comparator|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
16704508|NCT01920555|Active Comparator|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
16704509|NCT01920555|Active Comparator|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
16704510|NCT01920555|Placebo Comparator|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
16704511|NCT01920542|Experimental|no dexmedetomidine|no administration of dexmedetomidine
16704512|NCT01920542|Active Comparator|dexmedetomidine|administration of 0.5ug/kg dexmedetomidine for 10 min and infusion of 0.5ug/kg/h of dexmedetomidine until weaning of cardiopulmonary bypass
16704513|NCT01920529|Experimental|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
16704569|NCT01920139|Other|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
16704514|NCT01920529|Placebo Comparator|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
16704515|NCT01920516||Melphalan|"Day +1:
~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg
~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).
~Day +30: The above procedure is repeated.
~Day +90: In case of response, a third administration following the above procedures will be repeated."
16704516|NCT01920503||doxorubicin|"Day +1:
~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.
~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
16704517|NCT01920490|Experimental|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
16704518|NCT01920490|Active Comparator|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
16704519|NCT01920477|Experimental|Ofatumumab|Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
16704520|NCT01920477|Placebo Comparator|Placebo|Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
16704521|NCT01920451|Experimental|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
16704522|NCT01920451|No Intervention|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
16704523|NCT01920438|Experimental|PEG|Percutaneous Endoscopic Gastrostomy
16704524|NCT01920438|Experimental|RIG|Radiologically-guided Insertion of Gastrostomy
16704525|NCT01920425|Other|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
16704526|NCT01920425|Other|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
16704527|NCT01920412|Experimental|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
16704528|NCT01920399|Placebo Comparator|Placebo|IV infusions of 0.9% normal saline
16704529|NCT01920399|Experimental|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
16704530|NCT01920386|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|1tab PO within 5hours from teeth extraction
16704531|NCT01920386|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|1tab PO within 5hours from teeth extraction and then 1tab more after 6hours
16704532|NCT01920373|Active Comparator|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
16704533|NCT01920373|Experimental|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
16704534|NCT01920360|Experimental|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
16704535|NCT01920360|Experimental|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
16704536|NCT01920360|Experimental|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
16704537|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
16704538|NCT01920334|Experimental|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
16704539|NCT01920334|Placebo Comparator|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
16704540|NCT01920321|Experimental|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
16704541|NCT01920308||5 mm Bard LifeStent Vascular Stent|"The study population will be comprised of subjects who present with moderate lifestyle-limiting claudication to mild tissue loss (Rutherford Category 2-5) that are candidates for PTA and stenting.
~Subjects with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be considered for enrollment. The reference vessel diameter will be appropriate for treatment with available stent diameter of 5.0 mm (by visual estimate)."
16704546|NCT01920282|Active Comparator|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
16704547|NCT01920282|Active Comparator|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
16704548|NCT01920282|Experimental|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
16704549|NCT01920269|Active Comparator|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra-ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
16704550|NCT01920269|Active Comparator|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
16704551|NCT01920269|Active Comparator|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
16704552|NCT01920256|Experimental|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
16704553|NCT01920256|Active Comparator|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
16704554|NCT01920243|Experimental|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
16704555|NCT01920243|No Intervention|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
16704556|NCT01920243|Experimental|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
16704557|NCT01920243|No Intervention|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
16704558|NCT01920230|Experimental|Mindfulness-ACT-intervention|Group meetings face-to-face and web-based program using principles of mindfulness and ACT.
16704559|NCT01920230|Experimental|Control|Control group, no intervention.
16704560|NCT01920217||normal control|
16704561|NCT01920217||Sepsis group|
16704562|NCT01920204|Experimental|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
16704563|NCT01920191|Experimental|IMA 950 and Poly ICLC|
16704564|NCT01920178|Active Comparator|PinPointe Foot Laser|Active laser
16704565|NCT01920178|Sham Comparator|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
16704566|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
16704567|NCT01920152|Experimental|Autologous PRP Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
16704570|NCT01920126|Experimental|Sodium bicarbonate group|Sodium bicarbonate group
16704571|NCT01920126|Placebo Comparator|Saline group|Saline group
16704572|NCT01920113|Experimental|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
16704573|NCT01920113|Active Comparator|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
16704574|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
16704575|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
16704576|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
16704577|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).
~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
16704578|NCT01920087|Experimental|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
16704579|NCT01920087|Placebo Comparator|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
16704580|NCT01920074|Experimental|Rectiv|
16704581|NCT01920061|Experimental|Arm A|
16704582|NCT01920061|Experimental|Arm B|
16704583|NCT01920061|Experimental|Arm C|
16704584|NCT01920061|Experimental|Expansion Arm 1|
16704585|NCT01920061|Experimental|Expansion Arm 2|
16704586|NCT01920048|Experimental|Percutaneous Coronary Intervention and Optimal Medical Therapy|
16704587|NCT01920048|Active Comparator|Optimal Medical Therapy alone|
16704588|NCT01920035|Experimental|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
16704589|NCT01920035|No Intervention|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
16704590|NCT01920022|Experimental|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
16704591|NCT01920022|Active Comparator|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
16704592|NCT01920009|Active Comparator|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
16704593|NCT01920009|No Intervention|Controlgroup|patients in this group will receive usual care by pharmacists
16704594|NCT01919996|Experimental|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
16704595|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
16704596|NCT01919970|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
16704597|NCT01919970|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
16704598|NCT01919957|No Intervention|memory outcome|
16704599|NCT01919944|Experimental|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
16704600|NCT01919944|Experimental|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
16704601|NCT01919944|Experimental|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
16704602|NCT01919944|Placebo Comparator|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
16704603|NCT01919931||Candida Infection|Patients infected with Candida albicans
16704604|NCT01919931||No infection|Patients with no Candida albicans infection
16704605|NCT01919918|Other|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
16704606|NCT01919918|Other|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
16704607|NCT01919905|Active Comparator|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
16704608|NCT01919905|Placebo Comparator|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
16704609|NCT01919892|Experimental|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
16705037|NCT01917045|Experimental|low body fat percentage|body fat percentage less than 30%
16704612|NCT01919866|Experimental|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
16704613|NCT01919853|Experimental|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
16704614|NCT01919853|Active Comparator|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
16704615|NCT01919840|Active Comparator|Group C|• conventional protocol, volume replacement with massive bleeding.
16704616|NCT01919840|Experimental|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
16704617|NCT01919827|Experimental|MSC endobronchial infusion|
16704618|NCT01919814|Active Comparator|Appethyl™, then Placebo|Participants receive Appethyl™ liquid once four hours after breakfast. After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
16704619|NCT01919814|Placebo Comparator|Placebo, then Appethyl™|Participants receive the placebo drink once four hours after breakfast. After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
16704620|NCT01919801|Experimental|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
16704621|NCT01919801|Placebo Comparator|Placebo|Placebo will be administered as a single subcutaneous injection
16704622|NCT01919788|Placebo Comparator|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.
~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
16704623|NCT01919788|Experimental|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
16704624|NCT01919788|Experimental|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.
~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
16704625|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).
~Acinetobacter baumannii
~Staphylococcus aureus
~Klebsiella pneumonia
~Pseudomonas aeruginosa
~Enterococcus faecalis
~Enterococcus faecium"
16704626|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
16704627|NCT01919749|Other|treatment|recommended treatment
16704628|NCT01919736|Active Comparator|Moderate gait retraining|a moderate 7 degree toe-in modification
16704629|NCT01919736|Active Comparator|Mild gait retraining|A 2 degree toe-in gait retraining
16704630|NCT01919723|Active Comparator|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
16704631|NCT01919723|Active Comparator|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
16704632|NCT01919710|Experimental|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
16704633|NCT01919697|Experimental|Plecanatide 3.0 mg|Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
16704634|NCT01919697|Experimental|Plecanatide 6.0 mg|Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
16704635|NCT01919684|Active Comparator|Active|LGD-6972
16704636|NCT01919684|Placebo Comparator|Placebo (Captisol®)|Vehicle Control (Captisol®)
16704637|NCT01919671|Experimental|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
16704638|NCT01919671|Placebo Comparator|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
16704639|NCT01919658|Active Comparator|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
16704640|NCT01919658|Active Comparator|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
16704641|NCT01919645|Experimental|Combined Training Group|"Combined Training - (strength + aerobics).
~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.
~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
16704642|NCT01919645|Placebo Comparator|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
16704670|NCT01919450|Active Comparator|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
16704643|NCT01919632|Experimental|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
16704644|NCT01919619|Experimental|Treatment (lenalidomide and ipilimumab)|Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
16704645|NCT01919606|Experimental|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
16704646|NCT01919606|Experimental|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
16704647|NCT01919593|Experimental|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
16704648|NCT01919593|Active Comparator|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
16704649|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.
~Subjects must:
~Should have a blood exam (20ml) before the surgery.
~Site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
16704650|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
16704651|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
16704652|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.
~Subjects must:
~Should have a blood exam (20ml) before the surgery.
~Site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
16704653|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
16704654|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
16704655|NCT01919554|Placebo Comparator|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
16704656|NCT01919554|Experimental|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
16704657|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
16704658|NCT01919528|Experimental|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
16704659|NCT01919515|Other|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
16704660|NCT01919502|Other|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
16704661|NCT01919489|Experimental|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
16704662|NCT01919489|Active Comparator|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
16704663|NCT01919476|Active Comparator|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
16704664|NCT01919476|Experimental|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
16704665|NCT01919463|No Intervention|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
16704666|NCT01919463|Experimental|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
16704667|NCT01919463|Experimental|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
16704668|NCT01919450|Active Comparator|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
16704702|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
16704671|NCT01919450|Active Comparator|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
16704672|NCT01919437|Experimental|Web-Enabled Cognitive Neuropsychological Evaluation System|
16704673|NCT01919424|Active Comparator|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
16704674|NCT01919424|Active Comparator|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse*II BAN nebulizer will be used to perform a methacholine challenge
16704675|NCT01919411|Experimental|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
16704676|NCT01919411|Placebo Comparator|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
16704677|NCT01919398|Experimental|LY2940680|"Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.
~Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met."
16704678|NCT01919385|Experimental|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
16704679|NCT01919372|Active Comparator|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
16704680|NCT01919372|Experimental|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
16704681|NCT01919359|Experimental|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
16704682|NCT01919359|Placebo Comparator|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2
~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
16704683|NCT01919346|Experimental|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
16704684|NCT01919346|Placebo Comparator|Normal Saline|Administered at same volume and time as Experimental arm
16704685|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
16704686|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
16704687|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
16704688|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
16704689|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
16704690|NCT01919307|Experimental|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
16704691|NCT01919294|Experimental|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
16704692|NCT01919281|Experimental|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
16704693|NCT01919281|Experimental|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
16704694|NCT01919281|No Intervention|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
16704695|NCT01919268|Experimental|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
16704696|NCT01919268|Active Comparator|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
16704697|NCT01919255|Active Comparator|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior]
16704698|NCT01919255|Active Comparator|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior]
16704699|NCT01919255|Active Comparator|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
16704700|NCT01919255|Active Comparator|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
16704701|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
16733604|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
16704705|NCT01919229|Experimental|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
16704706|NCT01919216|Active Comparator|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
16704707|NCT01919216|Placebo Comparator|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
16704708|NCT01919203|Experimental|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
16704709|NCT01919190|Active Comparator|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
16704710|NCT01919190|Sham Comparator|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
16704711|NCT01919177|Active Comparator|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
16704712|NCT01919177|Placebo Comparator|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
16704713|NCT01919164|Placebo Comparator|Placebo|Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
16704714|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles|Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
16704715|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg- 4 Cycles|Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
16704716|NCT01919164|Experimental|Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
16704717|NCT01919164|Placebo Comparator|Sprifermin (AS902330) 100 mcg- 4 Cycles|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
16704718|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
16704719|NCT01919138||severe sepsis, septic shock|
16704720|NCT01919125|Experimental|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
16704721|NCT01919125|Experimental|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
16704722|NCT01919125|Experimental|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
16704723|NCT01919112|Experimental|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
16704724|NCT01919112|Active Comparator|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
16704725|NCT01919112|Sham Comparator|Sham Stimulation|Twice daily swallowing exercises only
16704726|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
16704727|NCT01919086|Experimental|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
16704728|NCT01919073|Experimental|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
16704729|NCT01919073|Active Comparator|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
16704730|NCT01919060||lesions in colon|
16704731|NCT01919060||lesions in extra-colon|
16704732|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
16704766|NCT01918774|Other|Cognitive behavior therapy for work success|Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
16704733|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
16704734|NCT01919008|Experimental|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet
~Days 3 to 6: Three FK949E low dose tablets
~Days 7 to 10: One FK949E high dose tablet"
16704735|NCT01919008|Experimental|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet
~Days 3 to 6: One FK949E high dose tablet
~Days 7 to 10: Three FK949E low dose tablets"
16704736|NCT01918995|Experimental|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
16704737|NCT01918995|Experimental|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
16704738|NCT01918995|Experimental|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
16704739|NCT01918995|Placebo Comparator|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
16704740|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm >30mm and < 50mm
16704741|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
16704742|NCT01918956|Active Comparator|conventional regimen of PURETHAL Birch|"Initial treatment:
~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).
~Maintenance treatment:
~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
16704743|NCT01918956|Experimental|rush regimen of PURETHAL Birch|"Initial treatment:
~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)
~Maintenance treatment:
~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
16704744|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
16704745|NCT01918930|Experimental|MGA271|MGA271 (administered in main study CP-MGA271-01)
16704746|NCT01918917|Active Comparator|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
16704747|NCT01918917|Active Comparator|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
16704748|NCT01918904|Experimental|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
16704749|NCT01918904|Placebo Comparator|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
16704750|NCT01918891|No Intervention|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
16704751|NCT01918891|Experimental|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
16704752|NCT01918891|Experimental|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
16704753|NCT01918878|Experimental|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
16704754|NCT01918865|Experimental|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
16704755|NCT01918865|Placebo Comparator|Placebo|Weekly Dosing for 26 Weeks
16704756|NCT01918852|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
16704757|NCT01918852|Experimental|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
16704758|NCT01918839|Experimental|VINCI Plus|One side has been treated with VINCI Plus
16704759|NCT01918839|Active Comparator|Restylane-L|One side has been treated with Restylane-L
16704760|NCT01918826|Active Comparator|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
16704761|NCT01918826|Placebo Comparator|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
16704762|NCT01918813|Experimental|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
16704763|NCT01918800|Experimental|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
16704764|NCT01918800|Active Comparator|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
16704765|NCT01918787|Experimental|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
16704767|NCT01918761|Experimental|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 (i.v) q21d Dacomitinib 45mg/ orally (continuous)
16704832|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
16704768|NCT01918748|Experimental|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.
~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
16704769|NCT01918735|Experimental|Group/dose level 1a|25 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
16704770|NCT01918735|Placebo Comparator|Group/dose level 1b|Matching placebo for Group/dose level 1a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
16704771|NCT01918735|Experimental|Group/dose level 2a|75 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
16704772|NCT01918735|Placebo Comparator|Group/dose level 2b|Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
16704773|NCT01918735|Experimental|Group/dose level 3a|200 mg GWP42006 oral solution (single dose) followed by an intravenous administration of 5 mg GWP42006 after the oral dose
16704774|NCT01918735|Placebo Comparator|Group/dose level 3b|Matching placebo for Group/dose level 3a
16704775|NCT01918735|Experimental|Group/dose level 4a|400 mg GWP42006 oral solution
16704776|NCT01918735|Placebo Comparator|Group/dose level 4b|Matching placebo for Group/dose level 4a
16704777|NCT01918735|Experimental|GWP42006 1, 2, or 3 times daily|Subjects will receive the selected dose of GWP42006 once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
16704778|NCT01918735|Placebo Comparator|Placebo 1, 2, or 3 times daily|Subjects will receive placebo once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
16704779|NCT01918722|Experimental|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
16704780|NCT01918722|Active Comparator|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
16704781|NCT01918722|Placebo Comparator|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
16704782|NCT01918709|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
16704783|NCT01918709|Experimental|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
16704784|NCT01918709|Experimental|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
16704785|NCT01918696|Experimental|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
16704786|NCT01918696|Active Comparator|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel [write the feeling you decided on], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
16704787|NCT01918696|Placebo Comparator|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
16704788|NCT01918683|Other|A -Tace alone|A - TACE alone (control group, current practice and treatment)
16704789|NCT01918683|Experimental|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
16704790|NCT01918670||Pasteur|
16704791|NCT01918670||Grenoble|
16704792|NCT01918670||Nantes|
16704793|NCT01918670||Parly|
16704794|NCT01918670||Rennes|
16704795|NCT01918670||Rouen|
16704830|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
16704796|NCT01918657|Active Comparator|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded.
16704797|NCT01918657|Placebo Comparator|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
16704798|NCT01918644|Experimental|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
16704799|NCT01918631|Active Comparator|Entecavir|Entecavir 0.5mg QD for 48 weeks
16704800|NCT01918631|Active Comparator|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
16704801|NCT01918618||Levosimendan|study group
16704802|NCT01918618||No Levosimendan|Control group
16704803|NCT01918605|Experimental|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
16704804|NCT01918605|Active Comparator|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
16704805|NCT01918592|Experimental|MRI/PET|
16704806|NCT01918579|Experimental|CRP intervention|Patients will be tested by rapid POC CRP test
16704807|NCT01918579|No Intervention|Control|Patients will not be tested by rapid POC CRP test
16704808|NCT01918566|Placebo Comparator|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
16704809|NCT01918566|Active Comparator|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
16704810|NCT01918566|Active Comparator|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
16704811|NCT01918566|Active Comparator|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
16704812|NCT01918566|Active Comparator|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
16704813|NCT01918566|Sham Comparator|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
16704814|NCT01918553|Experimental|Subject in the study ALIENOR|
16704815|NCT01918540|Active Comparator|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
16704816|NCT01918540|Active Comparator|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
16704817|NCT01918527|Other|A, Conventional treatment|Operation + 4 or 8 cycles of adjuvant chemotherapy, if indicated.
16704818|NCT01918527|Other|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
16704819|NCT01918501|Experimental|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
16704820|NCT01918488|Experimental|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
16704821|NCT01918488|Experimental|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
16704822|NCT01918475|Active Comparator|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
16704823|NCT01918475|Active Comparator|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
16704824|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
16704825|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
16704826|NCT01918449|No Intervention|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
16704827|NCT01918449|Experimental|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
16704828|NCT01918436|Experimental|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.
~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.
~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
16704829|NCT01918436|Active Comparator|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
16704831|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
16704833|NCT01918410|Active Comparator|Contact Lens with alginic acid|
16704835|NCT01918397|Active Comparator|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
16704836|NCT01918397|Experimental|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
16704837|NCT01918397|Experimental|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
16704838|NCT01918397|Experimental|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
16704839|NCT01918384|Experimental|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
16704840|NCT01918384|Placebo Comparator|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
16704841|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
16704842|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
16704843|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
16704844|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
16704845|NCT01918358|Experimental|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
16704846|NCT01918345|No Intervention|Standard Care (Control)|This group will receive a one-on-one counseling session during one visit with a Certified Diabetes Educator (CDE), who will provide standard advice on diabetes prevention and healthy lifestyle. They will receive a booklet on exercise and healthy diet as per current Canadian guidelines for healthy eating. This group will also receive a check-in telephone call from the Study Coordinator, half-way through the study. This group will not receive motivational interviewing, health coaching on low GI diet and/or exercise, or additional telephone follow-up.
16704847|NCT01918345|Experimental|Diet & Physical Activity Program with Health Coach|Participants assigned to this arm will receive a combination of the home-based physical activity program with health coach and the home-based low-GI diet program with health coach, as described in the respective individual arms. The Health Coach for this group will be a CDE.
16704848|NCT01918345|Experimental|Physical Activity Program with Health Coach|Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
16704849|NCT01918345|Experimental|Diet Program with Health Coach|Participants will be counseled to follow recommendations for Canadians on healthy eating (Canada's Food Guide and Space on Your Plate. Low GI education will be layered on top of Canada's Food Guide recommendations. The goal for participants in the diet group is to lower their dietary GI by 8-10 units. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their dietary and low GI goals. The health coach for this group will be a CDE.
16704850|NCT01918332|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
16704851|NCT01918332|Active Comparator|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
16704852|NCT01918332|Active Comparator|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
16704853|NCT01918332|Placebo Comparator|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
16704854|NCT01918319|Experimental|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
16704855|NCT01918319|No Intervention|Control|
16704856|NCT01918306|Experimental|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.
~Cohort 1, 3 of 3 patients received:
~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.
~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.
~If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.
~If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II
~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
16704857|NCT01918306|Experimental|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.
~Determination of the maximally tolerated dose (MTD) of GDC-0941."
16704858|NCT01918306|Active Comparator|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.
~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.
~Arm 1 Cisplatin Only Patient received:
~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
16704926|NCT01917890|Experimental|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
16704927|NCT01917890|Placebo Comparator|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
16704859|NCT01918306|Experimental|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.
~Arm 2 Cisplatin + GDC-0941 Patients received:
~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).
~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
16704860|NCT01918306|Experimental|2PHIICO|"Arm 2: Crossover post-progression
~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.
~Patient received:
~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).
~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
16704861|NCT01918293|Experimental|SMART arm|Using smartphone application for control of asthma
16704862|NCT01918293|No Intervention|conventional arm|non-using smartphone application for control asthma
16704863|NCT01918280|Experimental|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
16704864|NCT01918280|Other|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
16704865|NCT01918267||Cohort|
16704866|NCT01918254|Experimental|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
16704867|NCT01918254|Experimental|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
16704868|NCT01918254|Experimental|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
16704869|NCT01918241|Experimental|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
16704870|NCT01918241|Experimental|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
16704871|NCT01918241|Experimental|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
16704872|NCT01918241|Experimental|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10^9/L, but at least 7 days.
16704873|NCT01918228|Experimental|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
16704874|NCT01918228|No Intervention|Control group|No intervention will be provided by the study team.
16704875|NCT01918215|Other|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
16704876|NCT01918215|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
16704877|NCT01918202|Experimental|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
16704878|NCT01918202|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
16704879|NCT01918202|Experimental|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
16704880|NCT01918189|Experimental|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
16704881|NCT01918176|Experimental|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
16704882|NCT01918163|No Intervention|No Pills|Patients in this group will not receive Pomegranate pills.
16704883|NCT01918163|Active Comparator|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
16704884|NCT01918150|Experimental|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
16704885|NCT01918150|Active Comparator|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
16704886|NCT01918137|Experimental|chocolate bar|
16704887|NCT01918137|Experimental|porridge|
16704928|NCT01917877|Experimental|study group|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
16704929|NCT01917877|Active Comparator|control|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
16705034|NCT01917071|Experimental|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
16704888|NCT01918124|Experimental|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:
~Radiotherapy:
~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
~Cisplatin:
~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.
~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
16704889|NCT01918111|Experimental|RD group|Renal denervation group
16704890|NCT01918111|Active Comparator|Control group|Control group
16704891|NCT01918098|Experimental|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
16704892|NCT01918098|Active Comparator|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
16704893|NCT01918085|Other|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
16704894|NCT01918085|Other|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
16704895|NCT01918072||Stepped wedge participants|"Designated Women's Health Providers with one or more episodes of care for women patients during each period of the intervention.
~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
16704896|NCT01918072||Electronic consultation survey participants|"Designated Women's Health Providers who completed surveys about use of electronic consultations.
~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
16704897|NCT01918072||Quality assessment participants|Primary care providers delivering women's health care for one or more of the following conditions: abnormal uterine bleeding; menopausal symptoms; urinary incontinence.
16704898|NCT01918059|Experimental|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
16704899|NCT01918059|Experimental|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
16704900|NCT01918059|Experimental|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
16704901|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
16704902|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
16704903|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
16704904|NCT01918020|Experimental|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
16704905|NCT01918020|Other|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
16704906|NCT01918007|Active Comparator|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
16704907|NCT01918007|No Intervention|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
16704908|NCT01917994|Experimental|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
16704909|NCT01917994|Active Comparator|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
16704910|NCT01917981|Experimental|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
16704911|NCT01917968|Active Comparator|Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
16704912|NCT01917968|Active Comparator|Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
16704913|NCT01917942|Active Comparator|Standard of Care|Standard of Care
16704914|NCT01917942|Experimental|Humidification|Humidification
16704916|NCT01917916|Experimental|BI 655064 dose group 1|subject to receive BI 655064 dose group 1 single dose
16704917|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 1|subject to receive placebo
16704918|NCT01917916|Experimental|BI 655064 dose group 2|subject to receive BI 655064 dose group 2 single dose
16704919|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 2|subject to receive a placebo
16704920|NCT01917916|Experimental|BI 655064 dose group 4|Subject to receive BI 655064 dose group 4 single dose
16704921|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 4|Subject to receive placebo
16704922|NCT01917916|Experimental|BI 655064 dose group 3|Subject to receive BI 655064 dose group 3 single dose
16704923|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 3|Subject to receive placebo
16704924|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
16704925|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
16704930|NCT01917864|Experimental|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
16704931|NCT01917838|Experimental|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:
~Greater quality of the Design and Do process rated by therapists, parents, and independent coders.
~Greater quantity and quality of HW assignments rated by therapists and parents.
~Greater quality of the Review process as rated by therapists, parents, and independent coders.
~Greater satisfaction with treatment as rated by the parent, target child, and therapists."
16704932|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
16704933|NCT01917812|Placebo Comparator|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
16704934|NCT01917812|Experimental|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.
~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.
~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
16704935|NCT01917812|Experimental|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.
~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.
~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
16704936|NCT01917799|Experimental|Aspirin|75mg tab of aspirin once daily
16704937|NCT01917799|Active Comparator|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
16704938|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
16704939|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
16704940|NCT01917773|Experimental|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
16704941|NCT01917747|Active Comparator|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
16704942|NCT01917747|Experimental|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
16704943|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ < - 3 and/or MUAC < 115 mm.
16704944|NCT01917721|Experimental|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
16704945|NCT01917721|Active Comparator|Placebo|The comparative arm of the study will receive standard care and placebo for Kawasaki disease, but not doxycycline
16704946|NCT01917708|Experimental|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
16704947|NCT01917695|Active Comparator|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
16704948|NCT01917695|Experimental|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
16704949|NCT01917695|Experimental|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
16704950|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
16704951|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
16704952|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
16704953|NCT01917669||Diabetic Patients|These patients will have good glucose control.
16704954|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
16704955|NCT01917656|Experimental|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
16704956|NCT01917656|Active Comparator|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
16704957|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
16704958|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
16704959|NCT01917630|Experimental|ALV003|
16704960|NCT01917630|Placebo Comparator|Placebo|
16704961|NCT01917617|Experimental|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1
~Short hydration via oral rehydration solution (OS-1)
~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
16704962|NCT01917617|Active Comparator|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin
~Other Names:
~Gemcitabine； gemzer Cisplatin； Cispulan
~Standard hydration via intravenous infusion
~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
16704963|NCT01917604|Experimental|open exposure and control|● surgically uncover the canine tooth and bone removal exposing the largest diameter of the ectopic canine crown make a window in the palatal soft tissue and bond bracket after 10 days
16704964|NCT01917604|Experimental|closed exposure and control|raising a flap in the area of impacted canine,bonding an attachment and resuturing the flap
16704965|NCT01917591|Active Comparator|MariGen Wound|Fish derived extra cellular matrix
16704966|NCT01917591|Active Comparator|Oasis Sheet|Pig intestine derived extra cellular matrix
16704967|NCT01917578|Experimental|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
16704968|NCT01917578|Experimental|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
16704969|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
16704970|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
16704971|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
16704972|NCT01917552|Experimental|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
16704973|NCT01917552|No Intervention|observation|
16704974|NCT01917539|Sham Comparator|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
16704975|NCT01917539|Experimental|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
16704976|NCT01917526|Active Comparator|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
16704977|NCT01917526|Active Comparator|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
16704978|NCT01917513|Experimental|G-EYE™ colonoscopy|G-EYE™ colonoscopy
16704979|NCT01917513|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
16704980|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
16704981|NCT01917474|Experimental|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content < 20% of the total daily energy intake with the following composition:
~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
16704982|NCT01917474|Active Comparator|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:
~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
16704983|NCT01917448|Sham Comparator|Control|The skin will be injected with local anesthetic without spinal block
16704984|NCT01917448|Active Comparator|Spinal morphine|0.15 mg spinal morphine
16704985|NCT01917435|Experimental|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
16704986|NCT01917435|Experimental|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
16704987|NCT01917409|Experimental|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
16704988|NCT01917409|Experimental|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
16704989|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
16704990|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
16704991|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
16704992|NCT01917357|Experimental|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:
~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
16704993|NCT01917357|Active Comparator|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:
~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
16704994|NCT01917344|Other|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
16704997|NCT01917318|Experimental|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
16704998|NCT01917318|Experimental|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
16704999|NCT01917305|Experimental|platform-switched implant|platform-switched implant
16705000|NCT01917305|Active Comparator|platform-matched implant|platform-matched implant
16705001|NCT01917292|Other|Periodontal care|
16705002|NCT01917292|Experimental|One-Stage Full-Mouth Disinfection|
16705003|NCT01917279|Active Comparator|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.
16705004|NCT01917279|Experimental|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
16705005|NCT01917266||Concordant|
16705006|NCT01917266||Discordant|
16705007|NCT01917253|Experimental|standard length catheter|Standard Device for peripheral vein cannulation
16705008|NCT01917253|Experimental|Long catheter|Standard Device for peripheral vein cannulation
16705009|NCT01917240|Experimental|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
16705010|NCT01917240|Placebo Comparator|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
16705011|NCT01917227|Experimental|Video|
16705012|NCT01917214||Non-Interventional Study|
16705013|NCT01917201|Other|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
16705014|NCT01917201|Other|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
16705015|NCT01917188|Active Comparator|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
16705016|NCT01917188|Other|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
16705017|NCT01917188|No Intervention|Usual care|Patients will receive usual care by bedside nurse.
16705018|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
16705019|NCT01917162|Other|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
16705020|NCT01917162|Other|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
16705021|NCT01917149|Experimental|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
16705022|NCT01917149|Experimental|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
16705023|NCT01917149|Experimental|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
16705024|NCT01917149|Experimental|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
16705025|NCT01917149|Experimental|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
16705026|NCT01917136|Experimental|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
16705027|NCT01917123|Active Comparator|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
16705028|NCT01917123|Placebo Comparator|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
16705029|NCT01917110|Experimental|omafilcon A|Contact Lens Group
16705030|NCT01917110|Active Comparator|Spectacle Group|Prescription at Baseline
16705031|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
16705032|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
16705033|NCT01917084|Experimental|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
16705035|NCT01917058|Active Comparator|abatacept|
16705038|NCT01917045|Experimental|heigh body fat percentage|body fat percentage more than 30%
16705039|NCT01917032|Active Comparator|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
16705040|NCT01917032|Placebo Comparator|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
16705041|NCT01917019|Placebo Comparator|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
16705042|NCT01917019|Experimental|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
16705043|NCT01917019|Experimental|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
16705044|NCT01917019|Experimental|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
16705045|NCT01917006|Experimental|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
16705046|NCT01917006|Experimental|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1. Participants were eligible for another treatment after 12 weeks.
16705047|NCT01917006|Experimental|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
16705048|NCT01917006|Experimental|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
16705049|NCT01917006|Experimental|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
16705050|NCT01917006|Experimental|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
16705051|NCT01917006|Placebo Comparator|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
16705052|NCT01916993|Experimental|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
16705053|NCT01916993|Experimental|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
16705054|NCT01916993|Experimental|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
16705055|NCT01916993|Experimental|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
16705056|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
16705057|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
16705058|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
16705059|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
16705060|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
16705061|NCT01916954|Active Comparator|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
16705062|NCT01916954|Experimental|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
16705063|NCT01916941|Active Comparator|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
16705064|NCT01916941|Placebo Comparator|Placebo|Placebo X 6 weeks
16705065|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
16705066|NCT01916915|Experimental|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
16705067|NCT01916915|Experimental|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
16705068|NCT01916915|Placebo Comparator|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
16705069|NCT01916902|Active Comparator|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
16705070|NCT01916902|Active Comparator|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
16705071|NCT01916889|Experimental|RACY test|"4-question RACY delirium screening tool"
16705072|NCT01916876|No Intervention|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
16705073|NCT01916876|Other|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.
~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.
~Integrated Medical Follow-up package"
16705074|NCT01916863|Experimental|LX4211|400 mg of LX4211
16705075|NCT01916863|Active Comparator|Canagliflozin|300 mg canagliflozin
16705076|NCT01916863|Placebo Comparator|Placebo|LX4211 placebo
16705077|NCT01916850|Experimental|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
16705078|NCT01916850|Experimental|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
16705079|NCT01916850|Placebo Comparator|Placebo|Identical placebo administered once daily for 10 consecutive days
16705080|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
16705153|NCT01916317|Active Comparator|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
16705081|NCT01916824|Experimental|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
16705082|NCT01916824|No Intervention|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
16705083|NCT01916798|Active Comparator|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
16705084|NCT01916798|No Intervention|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
16705085|NCT01916785|Experimental|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
16705086|NCT01916785|Active Comparator|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
16705087|NCT01916785|Active Comparator|B|Arm B : Dasatinib standard dose with Cmin < 3nM analysed on blood after 7-10 days dasatinib 100mg intake
16705088|NCT01916772||cherubism patients|no interventions
16705089|NCT01916759|Other|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
16705090|NCT01916759|Other|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
16705091|NCT01916759|Other|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
16705092|NCT01916746|Experimental|transvaginal resection of pregnancy tissue|
16705093|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
16705094|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
16705095|NCT01916720|Experimental|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
16705096|NCT01916720|Experimental|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
16705097|NCT01916720|Placebo Comparator|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
16705098|NCT01916707|Active Comparator|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
16705099|NCT01916707|Experimental|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
16705100|NCT01916694|Experimental|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
16705101|NCT01916694|Active Comparator|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
16705102|NCT01916681|Experimental|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
16705103|NCT01916681|Experimental|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
16705104|NCT01916681|Experimental|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
16705105|NCT01916681|Experimental|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
16705106|NCT01916655|Placebo Comparator|Usual Care|standard and typical PAP (Positive Airway Pressure) educational and support protocol
16705107|NCT01916655|Experimental|Self-Management Care|Individualized self-management educational and support protocol
16705108|NCT01916655|Experimental|Self-Management Mobile Care|Individualized self-management educational and support protocol delivered in part by mobile health tool
16705109|NCT01916642|Placebo Comparator|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
16705110|NCT01916642|Active Comparator|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
16705111|NCT01916642|Active Comparator|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
16705112|NCT01916642|Active Comparator|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
16705113|NCT01916642|Active Comparator|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
16705114|NCT01916629|Active Comparator|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
16705115|NCT01916629|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
16705116|NCT01916603|Experimental|Normative intervention|Normative intervention on diet & physical & breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
16705117|NCT01916603|No Intervention|Routine care|Routine antenatal care according to national guidelines
16705154|NCT01916304|Experimental|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
16705118|NCT01916590|Active Comparator|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
16705119|NCT01916590|Placebo Comparator|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
16705120|NCT01916577|Active Comparator|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
16705121|NCT01916577|Experimental|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
16705122|NCT01916564|Active Comparator|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
16705123|NCT01916564|Active Comparator|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
16705124|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
16705125|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
16705126|NCT01916525|Experimental|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
16705127|NCT01916525|No Intervention|Control|A conventional post-acute care group treated according to finnish guidelines.
16705128|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
16705129|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
16705130|NCT01916486|Experimental|Exercise training|Twice-weekly for the 6-month duration.
16705131|NCT01916486|Experimental|Complex mental and social activities|Twice-weekly for the 6-month duration.
16705132|NCT01916486|Active Comparator|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
16705133|NCT01916473|Active Comparator|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
16705134|NCT01916473|Experimental|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
16705135|NCT01916460|Experimental|Gastroparetic patient 19G|Endoscopic Ultrasound Fine Needle Aspiration of the gastric wall prior to surgical placement of gastric neurostimulator with 19-gauge fine core needle used for aspiration
16705136|NCT01916447|Experimental|TAS-102 and CPT-11 with or without Bevacizumab|
16705137|NCT01916434|Experimental|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
16705138|NCT01916434|Experimental|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
16705139|NCT01916434|Placebo Comparator|No salmon|The placebo group will continue to consume their habitual diet
16705140|NCT01916421|Active Comparator|EZ Shot|
16705141|NCT01916421|Active Comparator|Expect™|
16705142|NCT01916421|Active Comparator|EchoTip® Ultra|
16705143|NCT01916408|Active Comparator|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
16705144|NCT01916408|Placebo Comparator|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
16705145|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
16705146|NCT01916382|Experimental|Nitisinone|Homogentisic acid lowering drug intervention
16705147|NCT01916382|No Intervention|No treatment|comparrator
16705148|NCT01916369|Experimental|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
16705149|NCT01916356|Experimental|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
16705150|NCT01916343|Experimental|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
16705151|NCT01916343|No Intervention|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
16705152|NCT01916317|No Intervention|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
16705158|NCT01916265|Experimental|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
16705159|NCT01916265|Experimental|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
16705160|NCT01916265|Experimental|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
16705161|NCT01916252|Active Comparator|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
16705162|NCT01916252|Active Comparator|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
16705163|NCT01916239|Experimental|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
16705164|NCT01916239|Experimental|Pomegranate extract formulation-1|New pomegranate extract formulation-1
16705165|NCT01916239|Experimental|Pomegranate extract formulation-2|New pomegranate extract formulation-2
16705166|NCT01916226|Experimental|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
16705167|NCT01916226|Placebo Comparator|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
16705168|NCT01916226|Experimental|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
16705169|NCT01916226|Placebo Comparator|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
16705170|NCT01916213|Active Comparator|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
16705171|NCT01916213|Active Comparator|ICSI|
16705172|NCT01916200|Experimental|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
16705173|NCT01916200|No Intervention|Blank group|IBS regular treatment group
16705174|NCT01916187|Experimental|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
16705175|NCT01916174|Experimental|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
16705176|NCT01916174|Experimental|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
16705177|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
16705178|NCT01916135|Experimental|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of [18F]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
16705179|NCT01916122|Experimental|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.
~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
16705180|NCT01916109|Experimental|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
16705181|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
16705182|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
16705183|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
16705184|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
16705185|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
16705186|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
16705187|NCT01916070||patients with syncope|
16705188|NCT01916070||patients with near syncope|
16705189|NCT01916057|Experimental|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
16705190|NCT01916044|Experimental|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
16705191|NCT01916044|No Intervention|control|no measure of Uterine Segment Ultrasound
16705192|NCT01916031|Experimental|Education|Upper Respiratory Infection education in Fall
16705193|NCT01916031|No Intervention|Standard Curriculum|
16705194|NCT01916018|Other|hypothyroid group|Clinical exams radiologic exams Blood sample
16705195|NCT01916005|Experimental|endocarditis|
16705196|NCT01915992|Other|Volunteer healthy|
16705197|NCT01915992|Active Comparator|leukemia patient's|
16705198|NCT01915979|Experimental|Plasma rich in growth factors (PRGF)|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
16705199|NCT01915979|Active Comparator|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
16705200|NCT01915966|Experimental|Cardamom, ginger and orange juice gelatin|Dietary Supplement
16705201|NCT01915966|Active Comparator|Camomile infusion with lemon juice|Dietary Supplement
16705202|NCT01915953||anemia|Measuring Hb valuse on anemia patients
16705203|NCT01915940|Experimental|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
16705204|NCT01915940|Active Comparator|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
16705205|NCT01915927|Other|1|Only 1 arm: treatment with MSC-AFP
16705206|NCT01915914|Experimental|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
16705207|NCT01915914|Active Comparator|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
16705208|NCT01915901|Experimental|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
16705209|NCT01915901|Experimental|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
16705210|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
16705211|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
16705212|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
16705213|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
16705214|NCT01915875|Experimental|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
16705215|NCT01915849|Experimental|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
16705216|NCT01915849|Experimental|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
16705217|NCT01915849|Experimental|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
16705218|NCT01915849|Experimental|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
16705219|NCT01915836|Experimental|Alpha game testers and questionaires|"This a video game designed to help smokers quit & remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.
~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes & will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video &/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
16705220|NCT01915823|Active Comparator|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray
~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
16705221|NCT01915823|Placebo Comparator|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
16705222|NCT01915810|Experimental|Arm I (pre-quit physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning 2 weeks before the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise activity per week for 5 weeks.
16705223|NCT01915810|Experimental|Arm II (quit day physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning on the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise per week for 5 weeks.
16705224|NCT01915810|Active Comparator|Arm III (no physical activity)|Participants quit smoking on an assigned date and receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks.
16705303|NCT01915186|Experimental|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
16705225|NCT01915797||Patient having a cancer and abnormal development|Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
16705226|NCT01915784|Experimental|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
16705227|NCT01915784|Experimental|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
16705228|NCT01915771|Experimental|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
16705229|NCT01915758|Experimental|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
16705230|NCT01915758|Placebo Comparator|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
16705231|NCT01915745|No Intervention|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
16705232|NCT01915745|Experimental|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
16705233|NCT01915732|Experimental|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
16705234|NCT01915732|Active Comparator|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
16705235|NCT01915719|Experimental|Early non invasive ventilation|Early non invasive ventilation
16705236|NCT01915719|Active Comparator|Oxygen therapy only|Oxygen therapy only
16705237|NCT01915706|No Intervention|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
16705238|NCT01915706|Experimental|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
16705239|NCT01915693|No Intervention|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
16705240|NCT01915693|Experimental|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
16705241|NCT01915680||Glaucoma|
16705242|NCT01915680||Control|
16705243|NCT01915667|Experimental|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
16705244|NCT01915667|Experimental|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
16705245|NCT01915667|Active Comparator|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
16705246|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
16705247|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
16705248|NCT01915641|Active Comparator|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
16705249|NCT01915641|Sham Comparator|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
16705250|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
16705251|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.
~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
16705252|NCT01915602|Experimental|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
16705253|NCT01915589|Experimental|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
16705254|NCT01915576|Experimental|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
16705255|NCT01915576|Experimental|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
16705256|NCT01915576|Experimental|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
16705257|NCT01915563|No Intervention|SBT and extubation|After a SBT patients will be extubated as usual
16705258|NCT01915563|Experimental|SBT and rest 60 min before extubation|After SBT patients will be reconnected to mechanical ventilation during 60 min before extubation
16705259|NCT01915550|Active Comparator|metformin|metformin was added without raising the insulin dose
16705260|NCT01915550|Active Comparator|Raising Insulin|insulin dose is raised
16705261|NCT01915537|Experimental|Infliximab group|Infliximab with MTX treatment
16705262|NCT01915537|Active Comparator|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
16705263|NCT01915524|Experimental|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.
~local radiation (4x5 Gy)"
16705264|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry
16705265|NCT01915511||Subjects with a non-IPF ILD diagnosis|Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype
16705266|NCT01915498|Experimental|enasidenib|enasidenib administered orally. Multiple doses will be administered to determine the RP2D.
16705267|NCT01915485|Experimental|Lu 177|progressive metastatic medullary thyroid cancer
16705268|NCT01915472|Experimental|IMMU 130|
16705269|NCT01915459|Experimental|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
16705270|NCT01915459|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
16705271|NCT01915433|Experimental|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
16705272|NCT01915433|Experimental|Wahls Diet|Wahls Diet (modified paleolithic diet)
16705273|NCT01915433|No Intervention|Usual Care|Control - usual care only.
16705274|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
16705275|NCT01915381|Active Comparator|Control group|follow up detraining effect of multimodal intervention
16705276|NCT01915381|Experimental|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
16705277|NCT01915368|Active Comparator|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
16705278|NCT01915368|Experimental|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
16705279|NCT01915368|Experimental|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
16705280|NCT01915355|Experimental|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
16705281|NCT01915342|Experimental|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.
~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
16705282|NCT01915329|Experimental|Verum-RSS|RSS Stimulation with high frequency electric pulses
16705283|NCT01915329|Sham Comparator|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
16705284|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
16705285|NCT01915303|Experimental|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
16705286|NCT01915290||1600 elderly participants|Norwegian elderly population
16705287|NCT01915277|Experimental|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
16705288|NCT01915277|Experimental|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
16705289|NCT01915277|Experimental|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
16705290|NCT01915277|Experimental|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
16705291|NCT01915277|Experimental|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
16705292|NCT01915277|Experimental|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
16705293|NCT01915277|Experimental|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
16705294|NCT01915277|Experimental|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
16705295|NCT01915277|Experimental|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
16705296|NCT01915277|Experimental|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
16705297|NCT01915264||Group 1|
16705298|NCT01915225||1/ Cohort 1|Subjects with or without solid tumors in whom diagnostic, preventative, or therapeutic intervention is being performed
16705301|NCT01915199|Experimental|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
16705302|NCT01915199|No Intervention|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
16705418|NCT01914432|Active Comparator|Rosuvastatin|PO, Once Daily, 8 weeks
16705304|NCT01915186|Placebo Comparator|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
16705305|NCT01915173|Experimental|Supplement + Expanded Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
16705306|NCT01915173|Placebo Comparator|Placebo + Standard Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
16705307|NCT01915173|Experimental|Supplement + Standard Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
16705308|NCT01915173|Placebo Comparator|Placebo + Expanded Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
16705309|NCT01915160|Active Comparator|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
16705310|NCT01915160|Experimental|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
16705311|NCT01915147|Experimental|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
16705312|NCT01915147|Experimental|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
16705313|NCT01915134|Experimental|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
16705314|NCT01915134|Active Comparator|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
16705315|NCT01915121|Active Comparator|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
16705316|NCT01915121|Placebo Comparator|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
16705317|NCT01915108|No Intervention|group R0|remifentanil Ce of 0 ng/ml
16705318|NCT01915108|Active Comparator|group R0.5|remifentanil Ce of 0.5 ng/ml
16705319|NCT01915108|Active Comparator|group R1.0|remifentanil Ce of 1.0 ng/ml
16705320|NCT01915108|Active Comparator|group R1.5|remifentanil Ce of 1.5 ng/ml
16705321|NCT01915095|Active Comparator|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
16705322|NCT01915095|Active Comparator|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
16705323|NCT01915095|Active Comparator|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
16705324|NCT01915082|Experimental|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).
~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
16705325|NCT01915082|Placebo Comparator|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).
~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
16705326|NCT01915069|Experimental|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
16705327|NCT01915056|No Intervention|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
16705328|NCT01915056|Experimental|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
16705329|NCT01915043|Active Comparator|health education for lymphedema prevention|health education for lymphedema prevention
16705330|NCT01915043|Experimental|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
16705331|NCT01915030|Experimental|High protein diet|High protein diet during caloric restriction
16705332|NCT01915030|Placebo Comparator|Standard protein diet|Standard protein diet during caloric restriction
16705333|NCT01915017|Experimental|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
16705334|NCT01915017|Experimental|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
16705335|NCT01915017|Experimental|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
16705336|NCT01915017|Active Comparator|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
16705337|NCT01915004|Other|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
16705338|NCT01915004|Experimental|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
16705419|NCT01914432|Active Comparator|Telmisartan|PO, Once Daily, 8 weeks
16705420|NCT01914432|Placebo Comparator|Placebo|PO, Once Daily, 8 weeks
16733875|NCT01722266|Active Comparator|Liraglutide 1.2mg|Daily injections
16705339|NCT01914991|Active Comparator|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
16705340|NCT01914991|Experimental|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
16705341|NCT01914978|Experimental|Handbook|Food allergy handbook for parents
16705342|NCT01914978|Placebo Comparator|Treatment as usual|Food allergy treatment as usual
16705343|NCT01914965|Active Comparator|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
16705344|NCT01914965|Placebo Comparator|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
16705345|NCT01914952|Active Comparator|CaHMB Capsule|
16705346|NCT01914952|Active Comparator|HMB free acid gelcap|
16705347|NCT01914952|Active Comparator|HMB free acid in water|
16705348|NCT01914952|Active Comparator|CaHMB powder in water|
16705349|NCT01914952|Active Comparator|HMB free acid (oral not in gelcap or water)|
16705350|NCT01914939|Experimental|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
16705351|NCT01914939|Active Comparator|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
16705352|NCT01914939|Experimental|Oxytocin|Intranasal administration of 24 IU of oxytocin
16705353|NCT01914939|Placebo Comparator|placebo drug|Intranasal placebo drug
16705354|NCT01914926|Active Comparator|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
16705355|NCT01914926|Active Comparator|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
16705356|NCT01914913|Other|BMMNCs|BMMNCs
16705357|NCT01914900|Experimental|induction TPF chemotherapy|
16705358|NCT01914887|Experimental|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
16705359|NCT01914874|Experimental|Mindfulness Meditation|12 weekly sessions in group format
16705360|NCT01914874|No Intervention|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
16705361|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
16705362|NCT01914848|Active Comparator|Control Group|A routine care discharge planning with the social service
16705363|NCT01914848|Experimental|Advance Care Planning ACP|"Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
~--------------------------------------------------------------------------------"
16705364|NCT01914835|Experimental|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
16705365|NCT01914822|Experimental|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
16705366|NCT01914822|Placebo Comparator|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
16705367|NCT01914809|Experimental|group with a preeclampsia before 34 SA|
16705368|NCT01914809|Other|group with a normal pregnancy|
16705369|NCT01914796|Placebo Comparator|Single ascending doses|
16705370|NCT01914796|Placebo Comparator|Measurement of eye blink rate|
16705371|NCT01914783|Experimental|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
16705372|NCT01914783|Active Comparator|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
16705421|NCT01914419|Active Comparator|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
16705422|NCT01914419|Active Comparator|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
16705373|NCT01914783|Placebo Comparator|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
16705374|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
16705375|NCT01914757|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
16705376|NCT01914757|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
16705377|NCT01914757|Placebo Comparator|Placebo|Placebo administered subcutaneously
16705378|NCT01914744|Experimental|entecavir|entecavir 0.5 mg/day PO
16705379|NCT01914744|Active Comparator|lamivudine|lamivudine 100 mg/day PO
16705380|NCT01914731|Experimental|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
16705381|NCT01914718|Experimental|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
16705382|NCT01914705|Active Comparator|Landmark Procedure|Using Landmarks to guide SCVC placement
16705383|NCT01914705|Active Comparator|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
16705384|NCT01914692|Experimental|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
16705385|NCT01914692|Placebo Comparator|Blank group|Use the normal saline instead of somatostatin.
16705386|NCT01914679|Experimental|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
16705387|NCT01914666|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
16705388|NCT01914653|Experimental|Pre-radiated|
16705389|NCT01914653|Experimental|Not radiated|
16705390|NCT01914653|Experimental|Post-radiated|
16705391|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
16705392|NCT01914627|Experimental|Loion|
16705393|NCT01914627|Active Comparator|SA-Gel|
16705394|NCT01914614||Working Poor Survivors|Low Wage workers
16705395|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
16705396|NCT01914601|Active Comparator|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
16705397|NCT01914601|Active Comparator|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
16705398|NCT01914588|Experimental|Telemonitoring + Standard care|
16705399|NCT01914588|Active Comparator|Standard care|
16705400|NCT01914575|Experimental|Dipole Density Mapping|
16705401|NCT01914562|Experimental|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
16705402|NCT01914562|Experimental|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
16705403|NCT01914562|Experimental|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
16705404|NCT01914562|Experimental|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
16705405|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
16705406|NCT01914523|Placebo Comparator|Macintosh|tracheal intubation will be performed using a Macintosh
16705407|NCT01914523|Active Comparator|King Vision|tracheal intubation will be performed using a King Vision
16705408|NCT01914523|Active Comparator|Glidescope|tracheal intubation will be performed using a Glidescope
16705409|NCT01914523|Active Comparator|AirTraq|tracheal intubation will be performed using a AirTraq
16705410|NCT01914510|Experimental|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
16705411|NCT01914497|Experimental|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
16705412|NCT01914484|Experimental|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.
~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
16705413|NCT01914471|No Intervention|Control|These schools did not receive the intervention.
16705414|NCT01914471|Experimental|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
16705415|NCT01914458|Experimental|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
16705416|NCT01914445|Experimental|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
16705417|NCT01914432|Experimental|YH16410|PO, Once Daily, 8 weeks
16705423|NCT01914419|Active Comparator|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
16705424|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
16705425|NCT01914406|Active Comparator|continuous moderate training|Continued exercise 45 min.
16705426|NCT01914393|Experimental|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
16705427|NCT01914380||Group 1|
16705428|NCT01914367|Active Comparator|Cervarix group|One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.
16705429|NCT01914367|Active Comparator|Gardasil Group|One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.
16705430|NCT01914341|Experimental|Music|pentatonic live music
16705431|NCT01914341|No Intervention|control|no intervention
16705432|NCT01914315|Experimental|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
16705433|NCT01914315|Active Comparator|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
16705434|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
16705435|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
16705436|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
16705437|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
16705438|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
16705439|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
16705440|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
16705441|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
16705442|NCT01914289|Experimental|Resection|To observe prognosis of resection of icc
16705443|NCT01914289|Active Comparator|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
16705444|NCT01914263|Experimental|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10^9 CIK cells.
16705445|NCT01914263|No Intervention|Control|The eligible patients are followed up for 30 days without any treatment.
16705446|NCT01914250|Active Comparator|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
16705447|NCT01914237|Experimental|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
16705448|NCT01914224|Experimental|Group 1|dietary education of low sodium and high potassium consumption
16705449|NCT01914224|Active Comparator|Group 2|dietary education of low sodium consumption only
16705450|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
16705451|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
16705452|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
16705453|NCT01914185|No Intervention|Comparison Schools|Regular health promotion activities
16705454|NCT01914185|Experimental|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
16705455|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
16705456|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
16705457|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
16705458|NCT01914159|Experimental|Ranibizumab|
16705459|NCT01914146|Other|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
16705460|NCT01914146|Other|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
16705461|NCT01914133|No Intervention|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
16705462|NCT01914133|Placebo Comparator|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
16705463|NCT01914133|Active Comparator|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
16705464|NCT01914107|Experimental|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
16705465|NCT01914107|Experimental|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group
~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
16705466|NCT01914094|No Intervention|Standard care|Received current standard care.
16705467|NCT01914094|Experimental|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
16705468|NCT01914081|Active Comparator|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
16705469|NCT01914081|Placebo Comparator|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
16705470|NCT01914068|No Intervention|Control|No in hospital exercise training and no exercise advice.
16705471|NCT01914068|Active Comparator|Exercise Intervention|In hospital exercise training
16705472|NCT01914055|Active Comparator|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
16705473|NCT01914055|Experimental|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
16705474|NCT01914042|Experimental|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
16705475|NCT01914042|Active Comparator|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
16705476|NCT01914016|Other|prolonged walk|
16705477|NCT01914003||CSID Mutations|Individual has one or more known CSID mutations.
16705478|NCT01914003||Control|Individual does not have any known CSID mutations.
16705479|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:
~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
16705480|NCT01913990|Experimental|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:
~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of >16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
16705481|NCT01913977|Experimental|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
16705482|NCT01913964|Experimental|Acetyl-L-carnitine|2 g daily for 12 months
16705483|NCT01913964|Placebo Comparator|placebo|
16705484|NCT01913951|Experimental|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16705485|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
16705486|NCT01913925|Active Comparator|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
16705487|NCT01913925|Placebo Comparator|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
16705488|NCT01913912|Active Comparator|Lisdexamfetamine dimesylate (LDX)|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the optimal dose of LDX will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking LDX at the DRUG unit.
16705489|NCT01913912|Placebo Comparator|Sugar pill|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
16705490|NCT01913899|Experimental|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
16705491|NCT01913899|Active Comparator|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
16705492|NCT01913886|Experimental|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
16733876|NCT01722266|Active Comparator|Liraglutide 0.6 mg|Daily injection
16705493|NCT01913873|Experimental|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values > 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
16705494|NCT01913860|No Intervention|Control|Control group will receive usual care
16705495|NCT01913860|Active Comparator|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
16705496|NCT01913860|Active Comparator|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
16705497|NCT01913847|Experimental|Sildenafil|Sildenafil 20 mg
16705498|NCT01913847|Placebo Comparator|Placebo|Placebo
16705499|NCT01913834|Active Comparator|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
16705500|NCT01913834|Experimental|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
16705501|NCT01913834|Experimental|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
16705502|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
16705503|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
16705504|NCT01913808|Experimental|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit [mg] = 2.4 x patient's weight [kg] x (target Hb [13 g/dL] - current Hb [g/dL]) + 500 [mg iron stores]
16705505|NCT01913808|Active Comparator|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
16705506|NCT01913795|Active Comparator|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
16705507|NCT01913795|Placebo Comparator|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
16705508|NCT01913795|Placebo Comparator|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
16705509|NCT01913795|Sham Comparator|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
16705510|NCT01913782||patients with low back pain|"Patients with disc herniation or radiculitis who are over 18 years of age.
~Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.
~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
16705511|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
16705512|NCT01913756|Experimental|Gouda-type cheese|80 g/day Gouda-type cheese
16705513|NCT01913756|No Intervention|Low cheese intake|
16705514|NCT01913756|Experimental|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
16705515|NCT01913743||MINDSETS|overweight/obese
16705516|NCT01913730|No Intervention|No prolonged therapy is scheduled|
16705517|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
16705518|NCT01913717|Experimental|External beam radiotherapy|External beam radiotherapy
16705519|NCT01913704|Placebo Comparator|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.
~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
16705520|NCT01913704|Active Comparator|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.
~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
16705521|NCT01913678|Active Comparator|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
16705522|NCT01913678|Active Comparator|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
16705523|NCT01913678|Placebo Comparator|Complete diet|The participants will be given all dietary items in their diet.
16705524|NCT01913665|Active Comparator|B.Lactis|children with functional constipation
16705525|NCT01913665|Active Comparator|Inulin|children with functional constipation
16705526|NCT01913665|Active Comparator|B.Lactis+ınulin|children with functional constipation
16705527|NCT01913665|Placebo Comparator|plasebo|children with functional constipation
16705528|NCT01913652|Experimental|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.
~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
16735761|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
16705529|NCT01913639|Experimental|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
16705530|NCT01913626|Experimental|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
16705531|NCT01913613|Experimental|Treatment|Treatment with the IASD device
16705532|NCT01913600|Other|Resolute Integrity|Resolute Integrity Stent
16705533|NCT01913587|Experimental|Acupuncture & Nerve block|Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
16705534|NCT01913587|Active Comparator|Nerve block|Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
16705535|NCT01913574|Experimental|Acupuncture & NCPB|The NCPB will be administered once at the start of the trial and the acupuncture will be performed 3 times per week for 2 weeks (6 times in total).
16705536|NCT01913574|Active Comparator|NCPB|The NCPB alone will be applied to the patients in this group, once at the start of the trial.
16705537|NCT01913561|Experimental|Master Caution Garment|"each patient will be connected simultaneously with two devices:
~ECG gel electrodes
~Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
16705538|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
16705539|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
16705540|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
16705541|NCT01913535|Active Comparator|Low Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
16705542|NCT01913535|Active Comparator|High Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
16705543|NCT01913535|Other|Placebo/Low-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
16705544|NCT01913535|Other|Placebo/High-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
16705545|NCT01913535|Placebo Comparator|Placebo/Placebo Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
16705546|NCT01913522|Experimental|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
16705547|NCT01913522|Active Comparator|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
16705548|NCT01913522|Experimental|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
16705549|NCT01913509|Experimental|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
16705550|NCT01913509|Active Comparator|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
16705551|NCT01913496|Placebo Comparator|Standard care|standard care ,without the web application ebalance
16705552|NCT01913496|Active Comparator|ebalance|using the ebalance application for 14 weeks
16705553|NCT01913483|Experimental|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram [kg]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate [eGFR] <30 milliliters/minute [mL/min]).
16705554|NCT01913483|Active Comparator|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
16705555|NCT01913470|Experimental|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
16705556|NCT01913470|Experimental|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
16705557|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
16705558|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
16705559|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
16705560|NCT01913444|Experimental|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
16705561|NCT01913431|Experimental|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
16705562|NCT01913431|Experimental|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
16705563|NCT01913418|Active Comparator|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
16705564|NCT01913418|Placebo Comparator|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
16705565|NCT01913405|Experimental|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.
~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
16705566|NCT01913392||morbidly obese, chronic renal disease|adult patients (> 18 years) who have stage 4 or 5 chronic renal disease (CrCl < 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI > 40 kg/m2, or BMI > 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
16705567|NCT01913379|Experimental|1: MDV3100|
16705568|NCT01913379|Experimental|2: MDV3100 and gemfibrozil|
16705569|NCT01913379|Experimental|3: MDV3100 and itraconazole|
16705570|NCT01913366|Experimental|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
16705571|NCT01913366|Experimental|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
16705572|NCT01913353|Experimental|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
16705573|NCT01913353|Active Comparator|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
16705574|NCT01913340|Active Comparator|Erythropoietin|1000 U/kg/dose x 5 doses
16705575|NCT01913340|Placebo Comparator|Normal saline|
16705576|NCT01913327|Experimental|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
16705577|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
16705578|NCT01913314|Experimental|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) [^14C] labeled drug
16705579|NCT01913301|Experimental|Alagebrium|
16705580|NCT01913288|Experimental|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
16705581|NCT01913288|Sham Comparator|Hospital Sounds|Exposure to standard hospital sounds; routine care.
16705582|NCT01913275|Active Comparator|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
16705583|NCT01913275|Active Comparator|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
16705584|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
16705585|NCT01913249|Experimental|Intervention|Seton through fistula 6 months prior to LIFT
16705586|NCT01913249|Active Comparator|Control|Seton through fistula 3 weeks prior to LIFT surgery
16705587|NCT01913236|Experimental|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
16705588|NCT01913236|No Intervention|Control|Treatment as usual provided by general practitioners to elderly patients with depression
16705589|NCT01913223|Experimental|submucosal dissection by dissector water jet|
16705590|NCT01913197|Experimental|Pre-implant MRI images and planning|
16705591|NCT01913184|Active Comparator|Continuous nebulization|Continuous nebulization with AKITA
16705592|NCT01913184|Experimental|Discontinuous nebulization|Discontinuous nebulization with AKITA
16705593|NCT01913171|Active Comparator|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
16705594|NCT01913171|Active Comparator|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
16736366|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
16705595|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
16705596|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
16705597|NCT01913145|Experimental|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
16705598|NCT01913132|No Intervention|Standard wound dressing OPEN|Standard wound dressing
16705599|NCT01913132|Experimental|PICO dressing OPEN|Negative pressure wound therapy with PICO (Smith & Nephew)
16705600|NCT01913132|No Intervention|Standard dressing EVAR|Standard wound dressing
16705601|NCT01913132|Experimental|PICO dressing EVAR|Negative pressure wound therapy with PICO (Smith & Nephew)
16705602|NCT01913119|Experimental|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.
~Dose and administration: 4-hour infusion of 14 mg/m2"
16705603|NCT01913106|Experimental|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
16705604|NCT01913093||Leukemia survivors with neurocognitive deficit|"Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as case."
16705605|NCT01913093||Leukemia survivors without neurocognitive deficit|Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.
16705606|NCT01913080|Active Comparator|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
16705607|NCT01913080|No Intervention|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
16705608|NCT01913067|Experimental|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
16705609|NCT01913054|Active Comparator|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
16705610|NCT01913054|Experimental|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
16705611|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
16705612|NCT01913028|Experimental|MEDI9929|Solution of MEDI9929, SC
16705613|NCT01913028|Placebo Comparator|Placebo|Placebo solution for MEDI9929, SC
16705614|NCT01913015|Experimental|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
16705615|NCT01913015|Experimental|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
16705616|NCT01913002|Experimental|Treatment A|LX4211 800 mg
16705617|NCT01913002|Experimental|Treatment B|LX4211 2000 mg
16705618|NCT01913002|Active Comparator|Treatment C|moxifloxacin 400 mg
16705619|NCT01913002|Placebo Comparator|Treatment D|Placebo
16705620|NCT01912989|Experimental|Lifestyle counseling|NOURISH+ plus motivational interviewing
16705621|NCT01912976|Experimental|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
16705622|NCT01912976|Active Comparator|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
16705623|NCT01912963|Experimental|Phase I: Dose Level 1 (D1)|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1
~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1
~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (D1)
~Cycle duration=21 days
~The Phase I run-in potentially evaluates 2 dose levels of eribulin in combination with pertuzumab and trastuzumab. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
16705652|NCT01912742|Experimental|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
16705788|NCT01911871||sickle cell disease|patients affected with sickle cell disease
16705624|NCT01912963|Experimental|Phase II Cohort A: Without Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1
~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1
~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)
~Cycle duration=21 days
~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
16705625|NCT01912963|Experimental|Phase II Cohort B: With Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1
~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1
~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)
~Cycle duration=21 days
~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
16705626|NCT01912950|Experimental|Prowave LX IPL|"Prowave LX IPL, short pulse setting and snowflake mode On"
16705627|NCT01912950|No Intervention|No Treatment|No treatment administered.
16705628|NCT01912937|Experimental|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
16705629|NCT01912898||1|
16705630|NCT01912885|Placebo Comparator|Group TENS 0-1|Electrodes will be fixated to one leg and sessions will be held once a week.
16705631|NCT01912885|Experimental|Group TENS 1-1|Electrical stimulation of the posterior tibial nerve of one leg once a week.
16705632|NCT01912885|Experimental|Group TENS 1-2|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
16705633|NCT01912885|Experimental|Group TENS 2-1|Electrical stimulation of the posterior tibial nerve of two legs once a week.
16705634|NCT01912885|Experimental|Group TENS 2-2|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
16705635|NCT01912872|Experimental|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
16705636|NCT01912872|Active Comparator|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
16705637|NCT01912859|Experimental|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
16705638|NCT01912859|No Intervention|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
16705639|NCT01912846|Sham Comparator|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.
~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
16705640|NCT01912846|Experimental|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
16705641|NCT01912820|Experimental|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
16705642|NCT01912820|Placebo Comparator|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
16705645|NCT01912794|Experimental|Sensory Conditions|
16705646|NCT01912781|Experimental|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
16705647|NCT01912781|Active Comparator|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
16705648|NCT01912768|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
16705649|NCT01912768|Active Comparator|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
16705650|NCT01912755|Experimental|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
16705651|NCT01912755|Active Comparator|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
16705685|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
16705789|NCT01911871||myelodysplasia|patients affected with myelodysplasia
16705653|NCT01912742|Experimental|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
16705654|NCT01912729|Experimental|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
16705655|NCT01912729|Experimental|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
16705656|NCT01912729|No Intervention|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
16705657|NCT01912716|Experimental|high-dose indomethacin|200mg rectal indomethacin
16705658|NCT01912716|Active Comparator|standard dose indomethacin|100mg rectal indomethacin
16705659|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
16705660|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
16705661|NCT01912690|Placebo Comparator|standard of care|
16705662|NCT01912690|Active Comparator|aerobic training only|
16705663|NCT01912690|Active Comparator|Aerobic and strength training|
16705664|NCT01912677|Active Comparator|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
16705665|NCT01912677|Experimental|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
16705666|NCT01912677|Experimental|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
16705667|NCT01912651|No Intervention|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
16705668|NCT01912651|Experimental|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
16705669|NCT01912638|Experimental|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
16705670|NCT01912638|Active Comparator|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
16705671|NCT01912625|Experimental|Treatment (trametinib, chemotherapy, radiation therapy)|"CONCURRENT CHEMOTHERAPY: Patients undergo IMRT or 3D-CRT QD 5 days a week for 6 weeks. Patients receive trametinib PO QD and carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiation proceed to consolidation chemotherapy.
~CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and 22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
16705672|NCT01912612|Experimental|Arm 1 (Patients with pain, duloxetine)|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
16705673|NCT01912612|No Intervention|Arm 2 (Patients without pain -- control)|Patient reported pain and symptoms assessment for comparison at baseline.
16705674|NCT01912599|Active Comparator|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
16705675|NCT01912599|Active Comparator|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
16705676|NCT01912586|No Intervention|Arm A|Patients receive no interventions for ED after laparoscopic surgery
16705677|NCT01912586|Experimental|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
16705678|NCT01912586|Experimental|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
16705679|NCT01912573|Experimental|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
16705680|NCT01912573|Active Comparator|Standard of Care (TAU)|Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose.
16705681|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
16705682|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
16705683|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
16705684|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
16705686|NCT01912534|Active Comparator|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
16705687|NCT01912534|Placebo Comparator|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
16705688|NCT01912521|Experimental|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
16705689|NCT01912521|No Intervention|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
16705690|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
16705691|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
16705692|NCT01912495|Experimental|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
16705693|NCT01912482|Experimental|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
16705694|NCT01912482|Active Comparator|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
16705695|NCT01912482|No Intervention|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
16705696|NCT01912469|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
16705697|NCT01912469|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
16705698|NCT01912456|Experimental|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
16705699|NCT01912456|Experimental|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
16705700|NCT01912456|Experimental|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
16705701|NCT01912456|Experimental|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
16705702|NCT01912443||Bevacizumab Plus Chemotherapy|
16705703|NCT01912430|Experimental|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
16705704|NCT01912430|Experimental|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
16705705|NCT01912417|Experimental|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
16705706|NCT01912417|No Intervention|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
16705707|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
16705708|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
16705709|NCT01912391|Experimental|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
16705710|NCT01912391|Placebo Comparator|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
16705711|NCT01912378|Experimental|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
16705712|NCT01912378|Placebo Comparator|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
16705713|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast & collar/cuff for 3 weeks
16705714|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint & collar/cuff for 3 weeks
16705715|NCT01912352|Experimental|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
16705716|NCT01912339|Experimental|Treatment|Treatment: Rezūm System
16705717|NCT01912339|Other|Control|Control: Rigid Cystoscopy
16705718|NCT01912326|Active Comparator|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
16705719|NCT01912326|Active Comparator|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
16705720|NCT01912313|Experimental|Rectal biopsy|
16705721|NCT01912300|Experimental|Lean adolescents|
16705722|NCT01912300|Experimental|Obese adolescents|
16705723|NCT01912287|Experimental|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
16705724|NCT01912287|Active Comparator|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available [88]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
16705725|NCT01912287|Sham Comparator|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
16705726|NCT01912274|Experimental|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
16705727|NCT01912261|Active Comparator|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
16705728|NCT01912261|Placebo Comparator|Placebo|one capsule orally daily
16705729|NCT01912248||Heart failure|strength training
16705730|NCT01912248||Heart Transplant recipients|strength training
16705731|NCT01912248||patients with ischemic heart disease|strength training
16705732|NCT01912235|Active Comparator|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
16705733|NCT01912235|Active Comparator|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine &15N proline to measure arginine and proline flux
16705734|NCT01912235|Active Comparator|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
16705735|NCT01912222|Experimental|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.
~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
16705736|NCT01912222|Experimental|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.
~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
16705737|NCT01912222|Experimental|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.
~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
16705738|NCT01912209|Experimental|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
16705739|NCT01912209|No Intervention|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
16705740|NCT01912196|Experimental|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).
~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
16705741|NCT01912196|Placebo Comparator|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).
~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
16705742|NCT01912183|Active Comparator|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
16705743|NCT01912183|Experimental|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
16705744|NCT01912170|Experimental|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
16705745|NCT01912170|Experimental|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
16705746|NCT01912170|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
16705747|NCT01912157|Placebo Comparator|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
16705748|NCT01912157|Active Comparator|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
16705749|NCT01912144|Other|coffee|Coffee beverage
16705750|NCT01912131|Experimental|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
16705751|NCT01912131|Active Comparator|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
16705752|NCT01912131|Experimental|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
16705753|NCT01912131|Experimental|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences.
16705754|NCT01912118|Experimental|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
16705755|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
16705756|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
16705757|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
16705758|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
16705759|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
16705760|NCT01912118|Experimental|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
16705761|NCT01912118|Experimental|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
16705762|NCT01912105|Experimental|treatment|Airway Medix Closed Suction System
16705763|NCT01912105|Active Comparator|control|standard closed suctioning systems
16705764|NCT01912092|Experimental|Askina Calgitrol Paste|
16705765|NCT01912066|Experimental|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
16705766|NCT01912066|Active Comparator|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
16705767|NCT01912053|Experimental|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
16705768|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
16705769|NCT01912027|Experimental|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
16705770|NCT01912027|Active Comparator|Open Latarjet technique|Open Latarjet technique
16705771|NCT01912014|Experimental|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
16705772|NCT01912001|Other|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
16705773|NCT01911988||Colon&Rectal Stage II /Stage III|
16705774|NCT01911975|Placebo Comparator|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
16705775|NCT01911975|Experimental|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
16705776|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
16705777|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
16705778|NCT01911949|Experimental|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
16705779|NCT01911949|Placebo Comparator|Placebo femoral nerve block|Sterile normal saline solution
16705780|NCT01911936|Experimental|LJM716|
16705781|NCT01911923|Active Comparator|No CPAP/PEEP and 100 % oxygen|This is the control group
16705782|NCT01911923|Experimental|CPAP/PEEP and 30 % oxygen|This is the intervention group
16705783|NCT01911910|No Intervention|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
16705784|NCT01911910|Experimental|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
16705785|NCT01911897|Experimental|MobiusHD|MobiusHD
16705786|NCT01911884|Other|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
16705791|NCT01911845|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
16705792|NCT01911832|Experimental|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
16705793|NCT01911832|Experimental|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
16705794|NCT01911819|Experimental|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
16705795|NCT01911819|Experimental|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
16705796|NCT01911819|Experimental|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
16705797|NCT01911806|Experimental|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks & back care pillow use during the day for 2 weeks
16705798|NCT01911806|Active Comparator|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
16705799|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
16705800|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
16705801|NCT01911780|Experimental|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
16705802|NCT01911780|Active Comparator|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
16705806|NCT01911754|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
16705807|NCT01911741|Experimental|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
16705808|NCT01911741|Experimental|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
16705809|NCT01911741|Experimental|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
16705810|NCT01911728|Experimental|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
16705811|NCT01911715|Experimental|Single Oral MDV3100 dose|
16705812|NCT01911702|Active Comparator|Conventional Group|In this group patients receive volemic standard treatment (conventional)
16705813|NCT01911702|Active Comparator|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
16705814|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
16705815|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
16705816|NCT01911676|Experimental|PF-03463275 Active Dose #1|Active dose between 40mg
16705817|NCT01911676|Experimental|PF-03463275 Active Dose #2|Active dose between 60mg
16705818|NCT01911676|Placebo Comparator|Placebo|Placebo- no active dose of PF-03463275.
16705819|NCT01911663|Experimental|KRG|500 mg Korea red ginseng (KRG)
16705820|NCT01911663|Placebo Comparator|Placebo|500 mg placebo (corn starch)
16705821|NCT01911650|Experimental|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
16705822|NCT01911650|Other|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
16705823|NCT01911637|Experimental|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
16705824|NCT01911637|Placebo Comparator|Placebo|Placebo
16705825|NCT01911624|Experimental|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
16705826|NCT01911624|Active Comparator|enoxaparin|enoxaparin 40 mg od, sc
16705827|NCT01911611|Placebo Comparator|Placebo|
16705828|NCT01911611|Experimental|RO6870868|
16705868|NCT01911390|Active Comparator|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
16705899|NCT01911195|Active Comparator|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
16705829|NCT01911598|Experimental|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
16705830|NCT01911598|Experimental|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
16705831|NCT01911585|Active Comparator|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
16705832|NCT01911585|Experimental|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
16705833|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
16705834|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
16705835|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
16705836|NCT01911546|Experimental|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
16705837|NCT01911533|Experimental|extracorporeal CO2|
16705838|NCT01911520|Experimental|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
16705839|NCT01911520|Experimental|BMI < 50, TBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
16705840|NCT01911520|Experimental|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
16705841|NCT01911520|Experimental|BMI < 50, IBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
16705842|NCT01911520|Experimental|BMI > 50, TBW, 2mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
16705843|NCT01911520|Experimental|BMI > 50, TBW, 4mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
16705844|NCT01911520|Experimental|BMI >50, IBW, 2 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
16705845|NCT01911520|Experimental|BMI >50, IBW, 4 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
16705846|NCT01911507|Experimental|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16705847|NCT01911494|Experimental|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
16705848|NCT01911494|No Intervention|Control|Current standard of antenatal care
16705849|NCT01911481|Experimental|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
16705850|NCT01911481|No Intervention|control|
16705851|NCT01911468|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
16705852|NCT01911468|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
16705853|NCT01911468|Active Comparator|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
16705854|NCT01911455|Active Comparator|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
16705855|NCT01911455|Placebo Comparator|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
16705856|NCT01911442|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
16705857|NCT01911442|Experimental|Lurasidone 60 mg|Lurasidone 60 mg once daily
16705858|NCT01911442|Placebo Comparator|Placebo|Placebo once daily
16705859|NCT01911429|Experimental|Lurasidone 40 mg|Lurasidone 40 mg once daily
16705860|NCT01911429|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
16705861|NCT01911429|Placebo Comparator|Placebo|Placebo 40 or 80 mg once daily
16705862|NCT01911416|Experimental|All participants|All participants on study
16705863|NCT01911403|Active Comparator|Angio-Seal|Closure procedure by Angio-Seal
16705864|NCT01911403|Active Comparator|Manual compression|Closure procedure by manual compression
16705865|NCT01911390|Placebo Comparator|Control Arm|No bean or rice bran additive in smoothie or muffin.
16705866|NCT01911390|Active Comparator|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
16705867|NCT01911390|Active Comparator|Rice bran|15 grams rice bran/day in smoothie or muffin.
16705869|NCT01911377|Active Comparator|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.
~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
16705870|NCT01911377|Placebo Comparator|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
16705874|NCT01911351|No Intervention|standard management|Patients randomized to this arm will receive standard management alone for their minor procedure.
16705875|NCT01911351|Experimental|Nitrous Oxide|Patients randomized to this arm will receive nitrous oxide plus standard management for their minor procedure.
16705876|NCT01911338|Experimental|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
16705877|NCT01911338|Active Comparator|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
16705878|NCT01911325|Experimental|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
16705879|NCT01911325|Experimental|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
16705880|NCT01911325|Placebo Comparator|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
16705881|NCT01911312|Experimental|Intervention|
16705882|NCT01911312|Active Comparator|Body Temperature Control|Stimulation performed with body temperature control
16705883|NCT01911299|Experimental|Choline|Liquid glycerophosphocholine (GPC) supplement
16705884|NCT01911299|Placebo Comparator|Placebo|Liquid placebo supplement
16705885|NCT01911286||Standard group|Apnea test according to the recommendation
16705886|NCT01911286||CPAP group|Apnea test with CPAP connection
16705887|NCT01911273|Experimental|PF 03446962 plus best supportive care (BSC)|
16705888|NCT01911273|Placebo Comparator|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
16705889|NCT01911260|Active Comparator|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
16705890|NCT01911260|Placebo Comparator|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
16705891|NCT01911260|Placebo Comparator|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
16705892|NCT01911260|Active Comparator|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
16705893|NCT01911247|Experimental|Arm 1|
16705894|NCT01911234|Experimental|TNF-Kinoid|TNF Kinoid + ISA51
16705895|NCT01911234|Placebo Comparator|Placebo|Placebo + ISA51
16705896|NCT01911221|Experimental|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
16705897|NCT01911208|Experimental|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
16705898|NCT01911208|Experimental|Control|Clinical sites can use which ever recruitment methods they prefer.
16706124|NCT01909622|Active Comparator|Vitamin D-unfortified milk|Unfortified skim milk
16705900|NCT01911195|Experimental|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
16705901|NCT01911182|Experimental|Inhalation of low concentration of CO2|
16705902|NCT01911182|Active Comparator|caffeine only|
16705903|NCT01911169|Experimental|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
16705904|NCT01911169|Active Comparator|Vitamin D 400|cholecalciferol 400 IU daily by mouth
16705905|NCT01911156|Other|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
16705906|NCT01911156|Other|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
16705907|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.
~Patients undergo cardiac surgery and are over 18 years of age.
~Patients need bypass machine for their cardiac surgery and traditional CO measurement.
~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
16705908|NCT01911104|Experimental|Exercise|10 weeks of aerobic exercise
16705909|NCT01911104|No Intervention|Active Control|Young athletes as a trained control
16705910|NCT01911091|Experimental|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
16705911|NCT01911091|No Intervention|Group 2 - Athlete exercise|Athletes are not given any intervention
16705912|NCT01911091|No Intervention|Group 3 - Obese No Exercise|The Obese group will not receive intervention
16705913|NCT01911078|Other|Renal Denervation Group|Subjects receiving renal denervation procedure.
16705914|NCT01911078|No Intervention|Control Group|"Subjects not receiving renal denervation procedure.
~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
16705915|NCT01911065|Experimental|Zostavax™ vaccine group|Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
16705916|NCT01911065|No Intervention|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
16705917|NCT01911052|Experimental|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
16705918|NCT01911052|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
16705919|NCT01911052|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
16705920|NCT01911039|Experimental|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
16705921|NCT01911026|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
16705922|NCT01911026|No Intervention|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
16705923|NCT01911013|Active Comparator|Cage and Plate|anterior cervical discectomy and fusion surgery at one segment is performed using cervical cage and plate system
16705924|NCT01911013|Experimental|Cage alone|anterior cervical discectomy and fusion surgery at one segment is performed using only cervical cage without plate
16705925|NCT01911000|Experimental|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
16705926|NCT01910987|Experimental|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
16705927|NCT01910987|Other|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
16705928|NCT01910974|Experimental|endoscopic sub-mucosal dissection|
16705929|NCT01910961|Experimental|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
16705930|NCT01910961|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
16705931|NCT01910948|Experimental|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
16705932|NCT01910935|Experimental|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
16705933|NCT01910935|No Intervention|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
16705934|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
16705935|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
16705936|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
16705937|NCT01910909|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
16705938|NCT01910896|Experimental|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
16705939|NCT01910896|No Intervention|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
16705940|NCT01910883|Experimental|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
16705941|NCT01910883|Experimental|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
16705942|NCT01910883|Experimental|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
16705943|NCT01910883|Experimental|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
16705944|NCT01910883|Experimental|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
16705945|NCT01910883|Experimental|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
16705946|NCT01910870|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
16705947|NCT01910857|Experimental|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
16705948|NCT01910857|No Intervention|Control|Standard care
16705949|NCT01910844|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
16705950|NCT01910831|Experimental|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
16705951|NCT01910831|Placebo Comparator|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
16705952|NCT01910818|Experimental|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
16705953|NCT01910818|Experimental|No Treatment|This is the area receiving no treatment.
16705954|NCT01910805|Experimental|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
16705955|NCT01910805|No Intervention|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
16705956|NCT01910792|Active Comparator|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
16705957|NCT01910792|Active Comparator|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
16705958|NCT01910779|Active Comparator|100 joule arm|100 joule as first biphasic shock energy
16705959|NCT01910779|Active Comparator|120 joule arm|120 joule as first biphasic shock energy
16705960|NCT01910766|Experimental|Coenzyme Q10/CC group|"Intervention:
~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
16705961|NCT01910766|Active Comparator|CC alone group|"Intervention:
~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
16705962|NCT01910753|Experimental|APA|Patient with neck cancer and accepting the physical activity program .
16705963|NCT01910740|Experimental|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
16705964|NCT01910740|Active Comparator|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
16705965|NCT01910727|Experimental|Together on Diabetes-Hopkins|
16705966|NCT01910714|Active Comparator|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
16705967|NCT01910714|Experimental|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
16705968|NCT01910701|Experimental|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
16705969|NCT01910688|Experimental|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
16737239|NCT01700660||Control|Patients operated without VIO.
16705970|NCT01910675|Experimental|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
16705971|NCT01910675|Active Comparator|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
16705972|NCT01910662|Experimental|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
16705973|NCT01910662|Experimental|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
16705974|NCT01910662|Experimental|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
16705975|NCT01910662|Experimental|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
16705976|NCT01910662|Experimental|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
16705977|NCT01910662|Experimental|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
16705978|NCT01910649|Experimental|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
16705979|NCT01910636|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
16705980|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
16705981|NCT01910610|Experimental|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
16705982|NCT01910610|Experimental|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
16705983|NCT01910597|Experimental|SBG|
16705984|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
16705985|NCT01910571|Experimental|P7435|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.
~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
16705986|NCT01910571|Placebo Comparator|Placebo|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.
~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
16705987|NCT01910558|Active Comparator|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
16705988|NCT01910558|Experimental|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
16705989|NCT01910558|Placebo Comparator|Digestible Starch|Supplementation with six grams of digestible starch
16705990|NCT01910545|Experimental|OTS167IV|single arm
16705991|NCT01910532|Experimental|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
16705992|NCT01910519|Experimental|H5N1 vaccine plus AS03 adjuvant|"H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant
~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
16705993|NCT01910519|Experimental|H5N1 vaccine without adjuvant|"H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant
~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
16705994|NCT01910506|Experimental|RDEA3170|
16705995|NCT01910493|Active Comparator|ART no SMS reminders|control group
16705996|NCT01910493|Active Comparator|PMTCT no SMS reminders|control group
16705997|NCT01910493|Experimental|SMS reminders to PMTCT cohort|experimental group
16705998|NCT01910493|Experimental|SMS reminders to ART cohort|experimental group
16705999|NCT01910480|Experimental|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
16706000|NCT01910467|Experimental|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
16706001|NCT01910467|Other|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
16706002|NCT01910454|Experimental|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
16706003|NCT01910454|Active Comparator|Task Specific Training (TST)|
16706004|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
16706005|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
16706006|NCT01910428|Experimental|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
16706007|NCT01910415|Experimental|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.
~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
16706008|NCT01910415|Experimental|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.
~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
16706009|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
16706010|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
16706011|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
16706012|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
16706013|NCT01910376||Control cohort|Nursing home residents without cancer
16706014|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
16706015|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
16706016|NCT01910363|Experimental|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
16706017|NCT01910363|Active Comparator|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
16706018|NCT01910350|Experimental|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
16706019|NCT01910350|Active Comparator|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
16706020|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
16706021|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
16706022|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
16706023|NCT01910324|Experimental|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
16706024|NCT01910324|Other|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
16706025|NCT01910311|Experimental|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
16706026|NCT01910311|Experimental|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
16706027|NCT01910298|Active Comparator|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).
16706028|NCT01910298|Active Comparator|Two Stage Breast Reconstruction|Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.
16706029|NCT01910285|Experimental|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
16706694|NCT01905709|Experimental|All patients|150-500 ml of human fecal matter
16706030|NCT01910285|Active Comparator|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
16706031|NCT01910259|Experimental|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
16706032|NCT01910259|Experimental|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
16706033|NCT01910259|Experimental|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
16706034|NCT01910259|Placebo Comparator|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
16706035|NCT01910246|Experimental|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
16706036|NCT01910233||adult patients with acute dyspnea in ED|
16706037|NCT01910220|Placebo Comparator|Group 1|placebo
16706038|NCT01910220|Experimental|Group 2|REGN1033 (SAR391786)
16706039|NCT01910220|Placebo Comparator|Group 3|placebo + exercise regimen
16706040|NCT01910220|Experimental|Group 4|REGN1033 (SAR391786) + exercise regimen
16706041|NCT01910194|Other|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
16706042|NCT01910194|Other|Lantus|4 weeks Lantus plus another 4 weeks combination
16706043|NCT01910181|Experimental|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
16706044|NCT01910181|Experimental|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
16706045|NCT01910168||Cohort|
16706046|NCT01910155|Experimental|Test|Ciprofloxacin/Dexamethasone
16706047|NCT01910155|Active Comparator|Reference|Ciprodex (R)
16706048|NCT01910155|Placebo Comparator|Placebo|Placebo
16706049|NCT01910142|Active Comparator|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
16706050|NCT01910142|Placebo Comparator|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
16706051|NCT01910129|Active Comparator|gammaCore|Active stimulation treatment
16706052|NCT01910129|Placebo Comparator|sham gammaCore|Inactive stimulation treatment
16706053|NCT01910116|Placebo Comparator|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
16706054|NCT01910116|Active Comparator|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
16706055|NCT01910090|Experimental|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
16706056|NCT01910090|Active Comparator|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
16706057|NCT01910077|Experimental|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
16706058|NCT01910077|Active Comparator|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
16706059|NCT01910064|Experimental|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
16706060|NCT01910051||Generally healthy|Generally healthy
16706061|NCT01910051||Type 2 diabetes mellitus|Type 2 diabetes mellitus
16706062|NCT01910038|Experimental|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
16706063|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
16706064|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
16706065|NCT01909999|Experimental|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
16706066|NCT01909999|Active Comparator|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
16706067|NCT01909986|Experimental|E1|[14C]-ONO-4053
16706068|NCT01909973|Experimental|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
16706069|NCT01909973|No Intervention|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
16706070|NCT01909960|Experimental|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
16706071|NCT01909960|Experimental|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
16706072|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
16706073|NCT01909934|Experimental|Brentuximab vedotin|1.8 mg/kg IV infusion
16706074|NCT01909908|Experimental|ECM in Saline|
16706075|NCT01909908|Active Comparator|Blood Products|
16706076|NCT01909908|Experimental|ECM in Blood Products|
16706077|NCT01909895|Experimental|Anger induction|The participant will be asked to undergo a validated anger induction task.
16706078|NCT01909895|Experimental|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
16706079|NCT01909895|Experimental|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
16706080|NCT01909895|Other|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
16706081|NCT01909882|Other|Family member's massage therapy|Family member's massage therapy
16706166|NCT01909336|Active Comparator|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
16706082|NCT01909869|Experimental|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
16706083|NCT01909856|Experimental|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
16706084|NCT01909856|Experimental|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
16706085|NCT01909843|Experimental|ALX-0171 Oral inhalation|
16706086|NCT01909830|Experimental|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.
~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
16706087|NCT01909817||Routine coronary angiogram patients|
16706088|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
16706089|NCT01909804|Experimental|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
16706090|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
16706091|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
16706092|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
16706093|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
16706094|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
16706095|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
16706096|NCT01909804|Experimental|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
16706097|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
16706098|NCT01909804|Experimental|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
16706099|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
16706100|NCT01909791|Experimental|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
16706101|NCT01909791|Active Comparator|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
16706102|NCT01909791|Experimental|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
16706103|NCT01909778|Experimental|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
16706104|NCT01909765|Active Comparator|Dorsal slite|Skin and mucosa insicion made together
16706105|NCT01909765|Experimental|Double incision|Skin and mucosa incision made separately
16706106|NCT01909752|Experimental|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
16706107|NCT01909752|Experimental|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
16706108|NCT01909752|Experimental|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
16706109|NCT01909739|Experimental|Statin group|
16706110|NCT01909739|Placebo Comparator|Placebo group|
16706111|NCT01909726||Interactive media|ScreenPlay
16706112|NCT01909726||Passive media|Silent nature video
16706113|NCT01909726||No media|Standard care
16706114|NCT01909713|Experimental|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
16706115|NCT01909700|Experimental|Single Incision Mesh|intervention: single incision mesh implantation
16706116|NCT01909674|Experimental|Oronasal Mask|Initial administration of oronasal CPAP mask
16706117|NCT01909674|Experimental|Nasal Mask|Initial administration of nasal CPAP mask
16706118|NCT01909661|Experimental|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
16706119|NCT01909661|Experimental|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
16706120|NCT01909648|Other|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
16706121|NCT01909635|Experimental|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
16706122|NCT01909635|Experimental|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
16706123|NCT01909622|Experimental|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
16706125|NCT01909609|Sham Comparator|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
16706126|NCT01909609|Experimental|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
16706127|NCT01909596|Experimental|Knee osteoarthritis patients|Without orthoses 6° lateral wedge insoles 10° lateral wedge insoles Neutral customized foot orthoses 6° lateral customized foot orthoses 7° lateral customized foot orthoses 8° lateral customized foot orthoses 9° lateral customized foot orthoses 10° lateral customized foot orthoses Orthotist integrated lateral customized foot orthoses Orthotist lateral customized foot orthoses
16706128|NCT01909583|Active Comparator|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
16706129|NCT01909583|Placebo Comparator|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
16706130|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
16706131|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
16706132|NCT01909557|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
16706133|NCT01909557|Placebo Comparator|placebo|
16706134|NCT01909544|Experimental|Oxygen|
16706135|NCT01909544|Sham Comparator|Room air|
16706136|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
16706137|NCT01909505||Normal Males|Males with normal levels of serum testosterone
16706138|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
16706139|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
16706140|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
16706141|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
16706142|NCT01909479|Experimental|MOD-4023|
16706143|NCT01909479|Placebo Comparator|Placebo|
16706144|NCT01909466|Other|Gluteal Injection|
16706145|NCT01909466|Other|Deltoid Injection|
16706150|NCT01909440|Experimental|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
16706151|NCT01909440|Experimental|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
16706152|NCT01909440|Experimental|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
16706153|NCT01909440|Active Comparator|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
16706154|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
16706155|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
16706156|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
16706157|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
16706158|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
16706159|NCT01909414|Experimental|Arm A: GEO-D03 DNA and MVA/HIV62B vaccines|At study entry and Week 8, participants will receive the GEO-D03 DNA vaccine administered as 1 mL intramuscularly (IM) in either deltoid. At Weeks 16 and 24, they will receive the MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
16706160|NCT01909414|Placebo Comparator|Arm B: Placebo for GEO-D03 and MVA/HIV62B|At study entry and Week 8, participants will receive the placebo for GEO-D03 DNA vaccine administered as 1 mL IM in either deltoid. At Weeks 16 and 24, they will receive the placebo for MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
16706161|NCT01909388|Experimental|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
16706162|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
16706163|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer
16706164|NCT01909349|No Intervention|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (>8 weeks after signing up)
16706165|NCT01909349|Experimental|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit & vegetable intake
16708007|NCT01896544|Active Comparator|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
16706167|NCT01909336|Active Comparator|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
16706168|NCT01909336|Active Comparator|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
16706169|NCT01909323|Placebo Comparator|sugary dessert cream|
16706170|NCT01909323|Experimental|maltitol alone|
16706171|NCT01909323|Experimental|maltitol 85% / FOS 15%|
16706172|NCT01909323|Experimental|maltitol 68% / FOS 32%|
16706173|NCT01909323|Experimental|maltitol 50% / FOS 50%|
16706174|NCT01909323|Experimental|FOS alone|
16706175|NCT01909310|Active Comparator|with head support|patients are ventilated with their heads positioned on a support
16706176|NCT01909310|Sham Comparator|without head support|patients are ventilated without head support
16706177|NCT01909297|Active Comparator|ProSeal LMA|Supraglottic airway device
16706178|NCT01909297|Active Comparator|suprema LMA|Supraglottic airway device
16706179|NCT01909297|Active Comparator|I-gel LMA|Supraglottic airway device
16706180|NCT01909284|Experimental|Acupuncture & Epidural nerve block|acupuncture plus epidural block
16706181|NCT01909284|Active Comparator|Epidural nerve block|epidural block alone
16706182|NCT01909271|Experimental|Intervention Group|Participants will receive education through a novel program called Stroke Education Film Viewing.
16706183|NCT01909271|Other|Usual Care Group|Participants will receive education through Stroke Education Pamphlet Exposure.
16706184|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.
~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
16706185|NCT01909245|Experimental|Single Arm Study|Allogenic Human Islet Cell Transplant with immunosuppression
16706186|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
16706187|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
16706188|NCT01909219|Active Comparator|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
16706189|NCT01909219|Active Comparator|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
16706190|NCT01909193|Experimental|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
16706191|NCT01909193|Experimental|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
16706192|NCT01909180|Experimental|Cardiac|Revolution CT Cardiac Imaging Scan
16706193|NCT01909180|Experimental|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
16706194|NCT01909180|Experimental|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
16706195|NCT01909167|Active Comparator|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
16706196|NCT01909167|Active Comparator|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
16706197|NCT01909154|Experimental|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
16706198|NCT01909141|Active Comparator|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
16706199|NCT01909141|Active Comparator|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
16706200|NCT01909128|Experimental|fermented milk|
16706201|NCT01909128|Experimental|fermented rice|
16706202|NCT01909128|Placebo Comparator|placebo|
16706203|NCT01909115|Active Comparator|1000 IU of Vitamin D Daily|Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
16706204|NCT01909115|Experimental|4000 IU of Vitamin D Daily|Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
16706205|NCT01909102|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
16706206|NCT01909102|Active Comparator|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
16706207|NCT01909089|Experimental|Chloroprocaine|Up-down sequential allocation.
16706208|NCT01909076|Active Comparator|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
16706209|NCT01909076|Experimental|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
16706210|NCT01909063|Experimental|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
16706211|NCT01909063|Experimental|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice
~Vitamin D, Vitamin E, and Vitamin A"
16706212|NCT01909063|Placebo Comparator|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice
~Control, 700 mg Calcium"
16706213|NCT01909050||refractory celiac disease|
16706214|NCT01909050||well-controlled celiac disease|
16706215|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
16706216|NCT01909050||gluten-sensitivity|
16706217|NCT01909050||disorders other than celiac disease.|
16706218|NCT01909037|Experimental|Flexofytol (bio-optimized curcumin)|
16706219|NCT01909024|Experimental|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
16706220|NCT01909024|Active Comparator|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
16706221|NCT01909011|Experimental|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
16706222|NCT01909011|Sham Comparator|Sham CES|The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.
16706223|NCT01908998|Active Comparator|Sandal|
16706224|NCT01908972|Active Comparator|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
16706225|NCT01908972|Experimental|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
16706226|NCT01908959|Experimental|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
16706227|NCT01908959|No Intervention|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
16706228|NCT01908946|Experimental|SMS Reminders|SMS reminders
16706229|NCT01908946|No Intervention|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
16706230|NCT01908933|Experimental|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
16706231|NCT01908920|Other|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
16706232|NCT01908920|Other|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
16706233|NCT01908920|Other|CONTROL|No intervention
16706234|NCT01908907|Active Comparator|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
16706235|NCT01908907|Placebo Comparator|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
16706236|NCT01908894|Experimental|BIOD-123|SC administration of 0.20 U/kg
16706237|NCT01908894|Experimental|BIOD-125|SC administration of 0.20 U/kg
16706238|NCT01908894|Active Comparator|Humalog|SC administration of 0.20 U/kg
16706239|NCT01908881|Active Comparator|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
16706240|NCT01908881|Experimental|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
16706241|NCT01908868|Experimental|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
16706242|NCT01908868|Active Comparator|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
16706243|NCT01908855|Experimental|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
16706244|NCT01908855|Active Comparator|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
16706245|NCT01908842|Active Comparator|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
16706246|NCT01908842|Experimental|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
16706247|NCT01908829|Experimental|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
16706248|NCT01908829|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
16706249|NCT01908829|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
16706250|NCT01908816|Experimental|ranibizumab|0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
16706251|NCT01908803|Experimental|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
16706252|NCT01908803|Active Comparator|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
16706253|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
16706255|NCT01908764|Experimental|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
16706256|NCT01908764|Experimental|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
16706257|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
16706258|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
16706259|NCT01908751|Experimental|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
16706260|NCT01908751|Experimental|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
16706261|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
16706262|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
16706263|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
16706264|NCT01908725|Experimental|Lamazym|1 mg Lamazym/kg body weight
16706265|NCT01908712|Experimental|Lamazym|1 mg Lamazym/kg body weight
16706266|NCT01908699|Experimental|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
16706267|NCT01908699|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
16706268|NCT01908686|Active Comparator|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
16706269|NCT01908686|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
16706270|NCT01908673|Active Comparator|HRV biofeedback|heart rate variability biofeedback
16706271|NCT01908673|Active Comparator|ASTM|Automatic Self Transcedental Meditation
16706272|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
16706273|NCT01908647|Experimental|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
16706274|NCT01908647|Experimental|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
16706275|NCT01908647|Experimental|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
16706276|NCT01908647|Sham Comparator|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
16706277|NCT01908634|Active Comparator|Milk-based Strawberry Beverage no meal|Milk-based Strawberry beverage without meal
16706278|NCT01908634|Experimental|Water-based Strawberry Beverage no meal|Water-based Strawberry beverage without meal
16706279|NCT01908634|Active Comparator|Milk-based strawberry Beverage with meal|Milk-based Strawberry beverage with meal
16706280|NCT01908634|Experimental|Water-based strawberry Beverage with meal|Water-based Strawberry beverage with meal
16706281|NCT01908621|Active Comparator|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
16706282|NCT01908621|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
16706283|NCT01908595|Experimental|M518101|Proper quantity twice daily
16706284|NCT01908582|Experimental|Evacetrapib|"Period 1:
~130 milligram (mg) evacetrapib administered orally, once on Day 1"
16706285|NCT01908582|Experimental|Evacetrapib + Rifampin|"Period 2:
~Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)
~Evacetrapib: 130 mg administered orally once on Day 16"
16706286|NCT01908569|Active Comparator|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
16706287|NCT01908569|Experimental|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
16706288|NCT01908556|Experimental|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
16706289|NCT01908543|Experimental|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet
~This is a single arm study. Individuals in this arm will
~have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods
~receive a single tablet of ferrous sulphate 200mg
~fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months
~have a second blood sample later that day (20 mls of blood
~Total number of participants in arm = 100"
16706290|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 1|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
16706291|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 2|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
16706292|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 3 and 4|The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
16706293|NCT01908517|Experimental|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
16706294|NCT01908504|Other|PET-CT|
16706295|NCT01908491|Active Comparator|IV PCA|hydromorphone with ketorolac
16706296|NCT01908491|Experimental|Continuous wound infusion|ON-Q Painbuster with ropivacaine
16706297|NCT01908478|Experimental|Combination: veliparib, gemcitabine, and IMRT|
16706298|NCT01908465|Active Comparator|Ebastine|Ebastine
16706299|NCT01908465|Placebo Comparator|placebo|Placebo
16706300|NCT01908452|Experimental|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
16706301|NCT01908452|Placebo Comparator|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
16706302|NCT01908439|Experimental|Whole-body vibration|A new method for muscle reflex latency measurement
16706303|NCT01908426|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
16706304|NCT01908426|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo tablet once daily
16706305|NCT01908413|Experimental|CUDC-427|
16706306|NCT01908400|Other|BMMNCs|Intravenous transfer of (BMMNCs)
16706307|NCT01908387|Experimental|Oral azacitidine|
16706308|NCT01908374|Active Comparator|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
16706309|NCT01908374|Experimental|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids [(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)]
16706452|NCT01907399|Other|obese patients|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
16706310|NCT01908361|Experimental|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
16706311|NCT01908361|Experimental|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
16706312|NCT01908361|Active Comparator|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
16706313|NCT01908348|Experimental|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
16706314|NCT01908335|Experimental|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
16706315|NCT01908335|Experimental|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
16706316|NCT01908335|Experimental|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
16706317|NCT01908335|Active Comparator|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
16706318|NCT01908322||Group 1|
16706319|NCT01908309|Active Comparator|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
16706320|NCT01908309|Active Comparator|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
16706321|NCT01908296|Experimental|FK949E group|receiving FK949E with and without fluvoxamine
16706322|NCT01908283|Experimental|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
16706323|NCT01908283|Experimental|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
16706324|NCT01908270|Experimental|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
16706325|NCT01908270|Other|Usual care|Patients continue usual care by their practitioner
16706326|NCT01908257|Experimental|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)
~Day 5: Ranitidine 150 mg twice daily (bid)
~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.
~Day 7: Ranitidine 150 mg (bid)"
16706327|NCT01908257|Experimental|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)
~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad
~Day 3: Ranitidine 150 mg (bid)
~Day 7: Lesinurad 400 mg (qd)"
16706328|NCT01908244|No Intervention|Control|No pentatonic music
16706329|NCT01908244|Experimental|Music|
16706330|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
16706331|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
16706332|NCT01908205|Experimental|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
16706333|NCT01908205|Placebo Comparator|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
16706334|NCT01908192|Experimental|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
16706335|NCT01908192|Placebo Comparator|Placebo|The control treatment is placebo.
16706336|NCT01908166|Experimental|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
16706337|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
16706338|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
16706339|NCT01908140|Experimental|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
16706340|NCT01908140|Active Comparator|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
16706341|NCT01908127|Active Comparator|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.
~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
16706342|NCT01908127|Experimental|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
16706343|NCT01908114|No Intervention|Group A|Routine Polio Program activities will be carried out with out any active intervention
16706344|NCT01908114|Experimental|Group B|"Expanded intervention with following components
~Community support groups for both male and female at village/community level
~Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations
~Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)
~Delivery of interventions & commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
16706345|NCT01908114|Experimental|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
16706346|NCT01908101|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16706347|NCT01908088|Experimental|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
16706348|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
16706349|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
16706350|NCT01908062|Active Comparator|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
16706351|NCT01908062|Experimental|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
16706352|NCT01908049|Experimental|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
16706353|NCT01908049|Placebo Comparator|Placebo|No active substance is given.
16706354|NCT01908023|Experimental|exercise|
16706355|NCT01908010|Experimental|Group 1, low dose|ABT-354
16706356|NCT01908010|Experimental|Group 2, high dose|ABT-354
16706357|NCT01907997|Experimental|Group L|Intravenous lidocaine infusion group
16706358|NCT01907997|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
16706359|NCT01907984|Experimental|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
16706360|NCT01907984|Active Comparator|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
16706361|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
16706362|NCT01907945|Experimental|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
16706363|NCT01907945|Active Comparator|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
16706364|NCT01907932|Experimental|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents
~Each resident will complete questionaire:
~Adequacy of image quality
~What is best view obtained
~Greatest Longitudinal Measure
~Diagnosis
~Diagnostic Certainty
~Time to Complete exam"
16706365|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
16706366|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:
~Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.
~Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.
~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
16706367|NCT01907906|Experimental|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
16706368|NCT01907906|Experimental|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
16706369|NCT01907893|Experimental|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
16706370|NCT01907893|No Intervention|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
16706371|NCT01907880|Active Comparator|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
16706372|NCT01907880|Active Comparator|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
16706373|NCT01907867|Experimental|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.
~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).
~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
16706554|NCT01906788|Experimental|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
16706374|NCT01907867|Experimental|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.
~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).
~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.
~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
16706375|NCT01907867|Experimental|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.
~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).
~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.
~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
16706376|NCT01907854|Experimental|Liraglutide + metformin + sitagliptin placebo|
16706377|NCT01907854|Experimental|Sitagliptin + metformin + liraglutide placebo|
16706378|NCT01907841|Experimental|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
16706379|NCT01907841|Placebo Comparator|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
16706380|NCT01907828|Experimental|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
16706381|NCT01907828|Active Comparator|Cardiac ablation|Cardiac ablation
16706382|NCT01907815|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16706383|NCT01907802|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16706384|NCT01907789|Experimental|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
16706385|NCT01907789|Experimental|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
16706386|NCT01907789|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
16706387|NCT01907776|Experimental|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
16706388|NCT01907776|Placebo Comparator|Placebo|ME1100 placebo inhalation solution
16706389|NCT01907763|Experimental|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
16706390|NCT01907763|Experimental|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
16706391|NCT01907763|Placebo Comparator|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
16706392|NCT01907750|Active Comparator|Transanastomotic tube|use of transanastomotic tube.
16706393|NCT01907750|Active Comparator|Transcystic tube|use of transcystic tube to drain bile duct
16706394|NCT01907737|Active Comparator|Active tDCS and active PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
16706395|NCT01907737|Other|Active tDCS and sham PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
16706396|NCT01907737|Other|Sham tDCS and active PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
16706397|NCT01907737|Sham Comparator|Sham tDCS and sham PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
16706398|NCT01907724|Experimental|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
16706399|NCT01907724|Experimental|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
16706400|NCT01907711|Sham Comparator|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
16706448|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
16706449|NCT01907425|Other|Pre-natal Patient|
16706450|NCT01907412|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
16706451|NCT01907412|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
16706401|NCT01907711|Active Comparator|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
16706402|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
16706403|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
16706404|NCT01907685|Experimental|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
16706405|NCT01907672|Experimental|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
16706406|NCT01907672|No Intervention|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
16706407|NCT01907659|No Intervention|Standard of care|Standard of care for respiratory infections
16706408|NCT01907659|Experimental|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
16706409|NCT01907646|Experimental|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
16706410|NCT01907646|Experimental|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
16706411|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
16706412|NCT01907620|Other|Normal pregnancy|women pregnant
16706413|NCT01907620|Other|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
16706414|NCT01907607|Experimental|PD-0332991|"Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib.
~PD-0332991 is formulated as gelatin capsules of 100 mg and 25 mg respectively."
16706415|NCT01907594|Active Comparator|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
16706416|NCT01907594|Placebo Comparator|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
16706417|NCT01907581|Other|Patients admitted to an ICU|
16706418|NCT01907568||Patients with schizophrenia|With and without hallucinations
16706419|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
16706420|NCT01907568||Patients with hearing impairment|With and without hallucinations
16706421|NCT01907568||Patients with visual loss|With and without hallucinations
16706422|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
16706423|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
16706424|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
16706425|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
16706426|NCT01907568||Patients with delirium|With and without hallucinations
16706427|NCT01907568||Healthy participants|With and without hallucinations
16706428|NCT01907568||Patients with mood disorder|With and without hallucinations
16706429|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
16706430|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
16706431|NCT01907555||Patients presenting neutropenia|
16706432|NCT01907542|Active Comparator|Monocryl suture skin closure|Monocryl skin suture
16706433|NCT01907542|Active Comparator|Stapled skin closure|stapled skin closure
16706434|NCT01907529|Experimental|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
16706435|NCT01907529|Active Comparator|Chemo only|docetaxel, epirubicin and cyclophosphamide
16706436|NCT01907516|Active Comparator|Cell phone-internet first|Cell phone-internet home glucose reporting system first
16706437|NCT01907516|Placebo Comparator|Voicemail first|Voicemail home blood glucose reporting first
16706438|NCT01907503|Other|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
16706439|NCT01907503|Other|Healthy volunteer|Healthy volunteer
16706440|NCT01907490|Experimental|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
16706441|NCT01907477|Other|neutropenic patients|
16706442|NCT01907464|Experimental|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
16706443|NCT01907464|Active Comparator|controls subjects|This arm is composed of healthy volunteers
16706444|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
16706445|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
16706446|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
16706447|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
16706631|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
16706453|NCT01907399|Other|obese patients with type 2 diabetes|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
16706454|NCT01907399|Other|healthy volunteers|free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L
16706455|NCT01907386|Other|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).
~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.
~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).
~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
16706456|NCT01907373|Active Comparator|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
16706457|NCT01907373|Experimental|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
16706460|NCT01907347||ICU patients|
16706461|NCT01907334|Active Comparator|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
16706462|NCT01907334|Active Comparator|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
16706463|NCT01907321|Experimental|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
16706464|NCT01907321|Placebo Comparator|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
16706465|NCT01907308|Experimental|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
16706466|NCT01907295||Patients|Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH
16706467|NCT01907295||Relatives and controls|Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals
16706468|NCT01907282|Experimental|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
16706469|NCT01907282|Active Comparator|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
16706470|NCT01907269|Experimental|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
16706471|NCT01907269|No Intervention|Usual care|
16706472|NCT01907256|Active Comparator|group A|stair step incisions
16706473|NCT01907256|Active Comparator|Group B|inverted V incision
16706474|NCT01907243|Active Comparator|spreader flap|Usage of spreader flap of upper lateral cartilage
16706475|NCT01907243|No Intervention|Control group|performing of rhinoplasty without spreader flap
16706476|NCT01907230|Experimental|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
16706477|NCT01907230|No Intervention|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
16706478|NCT01907217|Active Comparator|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
16706479|NCT01907217|Experimental|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
16706480|NCT01907204|Active Comparator|Oral|Oral drug (methylprednisolone) administration
16706481|NCT01907204|Experimental|Metered dose inhaler|
16706482|NCT01907204|Experimental|Nebulized|
16706483|NCT01907191|Experimental|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine
16706484|NCT01907191|Active Comparator|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint)
16706485|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
16706486|NCT01907165|Experimental|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
16706487|NCT01907165|Experimental|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
16706488|NCT01907152|Experimental|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
16706489|NCT01907152|No Intervention|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
16706490|NCT01907139|Experimental|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
16706491|NCT01907139|Experimental|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
16706492|NCT01907139|Active Comparator|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
16706493|NCT01907139|Experimental|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
16706494|NCT01907126|Experimental|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
16706495|NCT01907126|Placebo Comparator|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
16706496|NCT01907113|Experimental|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
16706497|NCT01907113|Experimental|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
16706498|NCT01907113|Experimental|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
16706499|NCT01907113|Experimental|BI 10773 / Group 5|Single Dose Administration (kidney failure)
16706500|NCT01907113|Experimental|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
16706501|NCT01907100|Placebo Comparator|Placebo + pemetrexed/cisplatin|Placebo controlled arm
16706502|NCT01907100|Experimental|Nintedanib 200mg + pemetrexed/cisplatin|Experimental arm
16706503|NCT01907087|Experimental|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
16706504|NCT01907074|Experimental|Cholates Compound|
16706505|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
16706506|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
16706507|NCT01907061|Active Comparator|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
16706508|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
16706509|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
16706510|NCT01907035|Experimental|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
16706511|NCT01907035|Active Comparator|Usual care|Family practice attention without the psychologist support
16706552|NCT01906801|Active Comparator|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
16706553|NCT01906788|Active Comparator|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
16706632|NCT01906229||ARDS+SIRS|
16706512|NCT01907022|Experimental|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
16706513|NCT01907009|Experimental|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.
~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.
~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).
~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.
~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
16706514|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
16706515|NCT01906996||four corner fusion|patients were treated with a four corner fusion
16706516|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
16706517|NCT01906970|Experimental|ClampArt|ClampArt
16706518|NCT01906957|Experimental|Elderly healthy subjects|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
16706519|NCT01906957|Experimental|Patients with metabolic syndrome|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
16706520|NCT01906957|Experimental|coronary patients|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
16706521|NCT01906957|Experimental|heart failure patients|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
16706522|NCT01906944|Active Comparator|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
16706523|NCT01906944|Active Comparator|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
16706524|NCT01906931|Experimental|Portable Oxygen Concentrator first|
16706525|NCT01906931|Active Comparator|Portable oxygen cylinder first|
16706526|NCT01906918|Experimental|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
16706527|NCT01906918|Placebo Comparator|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
16706528|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation|Active TMS (1)
16706529|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 2|Active TMS (2)
16706530|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 3|Active TMS (3)
16706531|NCT01906892|Experimental|1a|6 weeks of group drumming workshops
16706532|NCT01906892|Experimental|1b|6 weeks of group drumming workshops
16706533|NCT01906892|Experimental|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
16706534|NCT01906892|Active Comparator|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
16706535|NCT01906892|Active Comparator|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
16706536|NCT01906892|Active Comparator|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
16706537|NCT01906892|Experimental|3a|10 weeks of participatory group drumming workshops
16706538|NCT01906892|Active Comparator|3b|10 weeks of engagement with other non-musical social activities
16706539|NCT01906879|Active Comparator|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
16706540|NCT01906879|Experimental|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
16706541|NCT01906879|Experimental|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
16706542|NCT01906866|Active Comparator|Circadin 2/5/10 mg|
16706543|NCT01906866|Placebo Comparator|Placebo|Placebo arm
16706544|NCT01906853|No Intervention|No BCG|No BCG
16706545|NCT01906853|Experimental|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
16706546|NCT01906840|Experimental|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
16706547|NCT01906840|Placebo Comparator|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
16706548|NCT01906827||pregnant with ICP|pregnant with ICP
16706549|NCT01906814|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
16706550|NCT01906814|Active Comparator|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
16706551|NCT01906801|Experimental|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
16706692|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
16706555|NCT01906788|Experimental|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
16706556|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
16706557|NCT01906762|Experimental|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
16706558|NCT01906762|Experimental|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient's weight(averagely 70 kg), about 7 mg Morphine was used.
16706559|NCT01906749|Placebo Comparator|Placebo|Placebo
16706560|NCT01906749|Active Comparator|Colchicine|Colchicine 0.5mg once daily for 24 months
16706561|NCT01906710|Placebo Comparator|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
16706562|NCT01906710|Active Comparator|integrated medicines management|"integrated medicines management consists of
~patient centred medication reconciliation
~intermediate medication review
~discharge counseling
~transfer of information to primary care"
16706563|NCT01906697|Active Comparator|group B|middle turbinate resection
16706564|NCT01906697|Active Comparator|group C|middle turbinate medialization
16706565|NCT01906697|Active Comparator|group A|middle turbinate Radio Frequency (RF) turbinoplasty
16706566|NCT01906684|Experimental|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
16706567|NCT01906671|Experimental|Puri-Nethol|Tablet formulation of 6-mercaptopurine
16706568|NCT01906671|Experimental|Xaluprine|Oral liquid formulation of 6-mercaptopurine
16706569|NCT01906658|Experimental|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
16706570|NCT01906658|Experimental|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
16706571|NCT01906658|Experimental|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
16706572|NCT01906658|Experimental|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
16706573|NCT01906645|No Intervention|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
16706574|NCT01906645|Experimental|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
16706575|NCT01906632|Other|gene expression profile|
16706576|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
16706577|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
16706578|NCT01906606|Experimental|Parenting Program|12 session community-based parenting program
16706579|NCT01906606|No Intervention|Control Group|received visual aids on nutrition
16706580|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
16706581|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
16706582|NCT01906580|Experimental|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
16706583|NCT01906580|Experimental|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
16706584|NCT01906580|Experimental|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
16706585|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:
~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart
~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart
~• Pulmonary edema or cyanosis
~• Oliguria (< 400 mL in 24 h)
~• Persistent headaches
~• Epigastric pain and/or impaired liver function
~• Thrombocytopenia
~• Oligohydramnios, decreased fetal growth, or placental abruption"
16706586|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
16706587|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
16706588|NCT01906554|Experimental|Egg Dose|
16706589|NCT01906541|Experimental|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
16706590|NCT01906528|Experimental|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
16706591|NCT01906515|No Intervention|Control Group|Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
16706592|NCT01906515|Experimental|SpHb Group.|Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care
16706593|NCT01906502|Experimental|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
16706594|NCT01906489|Experimental|AKB-6548|
16706595|NCT01906489|Placebo Comparator|Placebo|
16706596|NCT01906476|Experimental|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
16706597|NCT01906476|Active Comparator|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
16706598|NCT01906450|Experimental|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
16706599|NCT01906450|Placebo Comparator|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
16706600|NCT01906450|No Intervention|baselline screening only|Dental prophylaxis is offered
16706601|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
16706602|NCT01906424|Other|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
16706603|NCT01906424|Active Comparator|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
16706604|NCT01906424|Active Comparator|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
16706605|NCT01906411||subjecst with different BMI|
16706606|NCT01906398|Other|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1
16706607|NCT01906385|Experimental|Rhenium Liposome Treatment|
16706608|NCT01906372|Experimental|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
16706609|NCT01906359|Experimental|Dietary fat - PO|Native palm olein (IV56)
16706610|NCT01906359|Experimental|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
16706611|NCT01906359|Experimental|Dietary fat - HOS|High oleic sunflower oil
16706612|NCT01906346|Experimental|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
16706613|NCT01906346|Experimental|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
16706614|NCT01906346|Experimental|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
16706615|NCT01906333|Experimental|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
16706616|NCT01906333|Experimental|Exercise & Fasted|2 hour exercise while staying fasted
16706617|NCT01906320|Experimental|Training group|
16706618|NCT01906320|No Intervention|Control Group|
16706619|NCT01906307|Experimental|LJPC-501|LJPC-501, continuous infusion
16706620|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
16706621|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
16706622|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
16706623|NCT01906268|Experimental|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor
~Attention Bias Modification Treatment (ABMT) - active"
16706624|NCT01906268|Sham Comparator|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor
~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
16706625|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender, pregnancy) who are participating in observational or clinical studies on FTC/TDF for PrEP
16706626|NCT01906242|Placebo Comparator|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
16706627|NCT01906242|Active Comparator|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
16706628|NCT01906242|Active Comparator|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
16706629|NCT01906242|Active Comparator|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
16706630|NCT01906229||Acute respiratory distress syndrome (ARDS)|
16706633|NCT01906216|Active Comparator|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
16706634|NCT01906216|Experimental|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
16706635|NCT01906203|Experimental|ultramarathon|
16706636|NCT01906190|Experimental|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
16706637|NCT01906164|Experimental|ALS-008176|
16706638|NCT01906164|Placebo Comparator|Placebo|
16706639|NCT01906151|Other|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
16706640|NCT01906138|Other|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
16706641|NCT01906125|Experimental|Palbociclib given to Healthy Volunteers|
16706642|NCT01906112|No Intervention|Controlled|No surgery for primary breast tumor.
16706643|NCT01906112|Experimental|Study|Surgery for primary breast tumor.
16706644|NCT01906099|Experimental|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
16706645|NCT01906099|Active Comparator|healthy dietary recommendations|no nutritional intervention
16706646|NCT01906086|Experimental|legume consumption|legume consumption, 4 servings per week, for 6 weeks
16706647|NCT01906086|Active Comparator|healthy dietary recommendations|no nutritional intervention
16706648|NCT01906073|Experimental|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
16706649|NCT01906073|Active Comparator|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
16706650|NCT01906060|Experimental|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
16706651|NCT01906034|Experimental|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
16706652|NCT01906034|Experimental|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
16706653|NCT01906034|No Intervention|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
16706654|NCT01906021|Experimental|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
16706655|NCT01906008|Experimental|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
16706656|NCT01906008|Placebo Comparator|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
16706657|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
16706658|NCT01905982|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
16706693|NCT01905722|Experimental|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
16706659|NCT01905982|Experimental|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
16706660|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
16706661|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
16706662|NCT01905956|Active Comparator|IQP-AK-102|2 capsules per dose, three times daily
16706663|NCT01905956|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily
16706664|NCT01905943|Experimental|Obinutuzumab|Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
16706665|NCT01905930|Experimental|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
16706666|NCT01905930|Active Comparator|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
16706667|NCT01905917|No Intervention|Control|Usual care
16706668|NCT01905917|Experimental|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
16706669|NCT01905904|Active Comparator|sevorane|Sevorane 4% concentration during anesthesia induction
16706670|NCT01905904|Active Comparator|sevorane %7|Sevorane 7% concentration during anesthesia induction
16706671|NCT01905891|Other|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
16706672|NCT01905891|Other|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
16706673|NCT01905878|Experimental|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
16706674|NCT01905878|Experimental|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
16706676|NCT01905826||Patient Relatives|Blood relatives of enrolled patients.
16706677|NCT01905826||Patients|Patients with known mutations in GATA2 or those with clinical and laboratory characteristics strongly consistent with GATA2 deficiency.
16706678|NCT01905813|Experimental|INCB040093|
16706679|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
16706680|NCT01905800|Active Comparator|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
16706681|NCT01905800|Experimental|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
16706682|NCT01905800|Placebo Comparator|Placebo treatment|Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
16706683|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
16706684|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
16706685|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
16706686|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
16706687|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
16706688|NCT01905748|Experimental|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
16706689|NCT01905748|Experimental|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
16706690|NCT01905735|Placebo Comparator|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
16706691|NCT01905735|Active Comparator|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
16706695|NCT01905696|Experimental|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
16706696|NCT01905683|Experimental|16-20 Units per kg body weight incobotulinumtoxinA|
16706697|NCT01905670|Experimental|Implant|Implant of the WiCS-LV system
16706698|NCT01905657|Experimental|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
16706699|NCT01905657|Experimental|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
16706700|NCT01905657|Active Comparator|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years.
16706701|NCT01905644|Experimental|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.
~Intervention: Perineal ultrasound"
16706702|NCT01905644|No Intervention|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
16706703|NCT01905631|No Intervention|Untreated Control Group|Subjects will apply nothing for the entire three days of the trial. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
16706704|NCT01905631|Active Comparator|Treatment Group (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
16706705|NCT01905618|Experimental|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
16706706|NCT01905618|No Intervention|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
16706707|NCT01905605|Experimental|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
16706708|NCT01905605|Placebo Comparator|placebo supplementation|Placebo to be administered BID for 8 weeks
16706709|NCT01905592|Active Comparator|Physician's choice|Physician may select from 4 active comparators
16706710|NCT01905592|Experimental|niraparib|Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
16706711|NCT01905579|Experimental|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
16706712|NCT01905579|Experimental|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
16706713|NCT01905566|Active Comparator|Clopidogrel|clopidogrel: 75mg once a day
16706714|NCT01905566|Experimental|Ticagrelor|ticagrelor: 90mg twice a day
16706715|NCT01905553|Experimental|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
16706716|NCT01905553|Experimental|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
16706717|NCT01905540|Experimental|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
16706718|NCT01905540|Experimental|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
16706719|NCT01905540|Experimental|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
16706720|NCT01905540|Experimental|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
16706721|NCT01905527||Standard Services of Group A (Group A1)|
16706722|NCT01905527||Customized Services of Group A (Group A2)|
16706723|NCT01905527||Group B|
16706724|NCT01905514|No Intervention|control|using Medication event monitoring system
16706725|NCT01905514|Active Comparator|internet mobile application|using both mobile internet application and medication event monitoring system
16706726|NCT01905501|Active Comparator|Total intravenous anesthesia|Total intravenous anaesthesia
16706727|NCT01905501|Experimental|Balanced anesthesia|
16706728|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
16706729|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
16706730|NCT01905488||Group S|patients who showed IJVVI in supine position
16706731|NCT01905475|Experimental|POL6326|POL6326 intravenous infusion
16706732|NCT01905475|Placebo Comparator|Placebo|Placebo intravenous infusion
16706733|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
16706734|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
16706735|NCT01905449|Experimental|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
16706736|NCT01905449|Experimental|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
16706737|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
16706738|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
16706739|NCT01905423||Paga (annual MDA)|"This group includes eligible residents of the village of Paga. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
~Paga received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
16706740|NCT01905423||Lewomada (annual MDA)|"This group includes eligible residents of the village of Lewomada. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
~Lewomada received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
16706741|NCT01905423||Pruda (semiannual MDA)|"This group includes eligible residents of the village of Pruda. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.
~Pruda received a total of five rounds of MDA over a period of 24 months (once every 6 months)."
16706742|NCT01905423||Pekalongan (annual MDA)|"This group includes the villages of Banyurip Ageng and Jenggot. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
16706743|NCT01905423||Pekalongan (semiannual MDA)|"This group includes the villages of Kertoharjo and Pabean. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.
~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
16706744|NCT01905410|Experimental|single treatment - VVZ-149 Injection|"single ascending dose escalation
~0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts
~4 hours IV infusion"
16706745|NCT01905410|Placebo Comparator|single treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort
~4 hours IV infusion"
16706746|NCT01905410|Experimental|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.
~high and low dosage
~4 hours IV infusion x 2 times/day x 3 days"
16706747|NCT01905410|Placebo Comparator|multiple treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort
~4 hours IV infusion x 2 times/day x 3 days"
16706748|NCT01905397|Active Comparator|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
16706749|NCT01905397|Active Comparator|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
16706750|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
16706751|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
16706752|NCT01905371|Experimental|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:
~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
16706753|NCT01905371|Placebo Comparator|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:
~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
16706754|NCT01905345|Experimental|Endurance and Resistance Training|Endurance and resistance exercise
16706755|NCT01905345|Experimental|Resistance Training|resistance exercise (12wk)
16706756|NCT01905345|Experimental|Resistance and resistance Training|resistance exercise (24 wk)
16706757|NCT01905332|Experimental|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
16706758|NCT01905332|Active Comparator|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
16706759|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
16706760|NCT01905306|Experimental|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
16706761|NCT01905306|Experimental|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
16706762|NCT01905293|Experimental|100% portion size|100% portion size condition
16706763|NCT01905293|Experimental|150% portion size|150% portion size condition
16706764|NCT01905293|Experimental|200% portion size|200% portion size condition
16706765|NCT01905280|Experimental|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
16706766|NCT01905280|Active Comparator|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
16706767|NCT01905267|Experimental|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
16706768|NCT01905267|No Intervention|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
16706769|NCT01905254|Other|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
16706805|NCT01905007|Active Comparator|Defibrillation testing|Defibrillation testing at initial ICD implantation
16706806|NCT01905007|No Intervention|No defibrillation testing|No defibrillation testing at initial ICD implantation
16706770|NCT01905241|Experimental|Anatomic TSA using RTI|During Anatomic Total Shoulder Arthroplasty (TSA), the surgeon will have use of the SmartBone and the bone cement mold made from the SmartBone (the RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
16706771|NCT01905228|Experimental|CBL0137|"Dose Level 9: 150 mg/m2, IV
~Dose Level 10: 180 mg/m2, IV
~Dose Level 11: 240 mg/m2, IV
~Dose Level 12: 320 mg/m2, IV
~Dose Level 13: 400 mg/m2, IV
~Dose Level 14: 540 mg/m2, IV
~Dose Level 15: 700 mg/m2, IV
~Dose Level 16: 920 mg/m2, IV
~Dose Level 17: 1200 mg/m2, IV
~Dose Level 18: 1600 mg/m2, IV
~Dose Level 19: 2100 mg/m2, IV
~Dose Level 20: 2700 mg/m2, IV"
16706772|NCT01905215|Experimental|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
16706773|NCT01905215|Experimental|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
16706774|NCT01905215|Experimental|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
16706775|NCT01905215|Experimental|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
16706776|NCT01905215|Experimental|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
16706777|NCT01905215|Experimental|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
16706778|NCT01905215|Placebo Comparator|Group Placebo 1|Subjects in this group will receive a single dose of placebo
16706779|NCT01905215|Placebo Comparator|Group Placebo 2|Subjects in this group will receive a single dose of placebo
16706780|NCT01905202|Experimental|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
16706781|NCT01905189|Experimental|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
16706782|NCT01905176|Experimental|Predischarge educational intervention|In person education on heart failure topics before discharge
16706783|NCT01905176|Experimental|Telephone educational intervention|Telephone support and education post-discharge
16706784|NCT01905176|Experimental|Combination|Pre-discharge in person education and post-discharge telephone education and support
16706785|NCT01905176|No Intervention|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
16706786|NCT01905163|Experimental|laparoscopic management|Tumor Debulking Surgery by laparoscopy
16706787|NCT01905150|Experimental|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
16706788|NCT01905150|Active Comparator|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
16706789|NCT01905137|Active Comparator|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
16706790|NCT01905137|Placebo Comparator|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
16706791|NCT01905124|Experimental|Drug: CF101|CF101 1 mg q12 hours
16706792|NCT01905124|Placebo Comparator|Placebo tablets of CF101|Placebo tablets q12 hours
16706793|NCT01905111|Experimental|BI 853520|BI 853520 once daily in a dose escalation schedule
16706794|NCT01905098|Experimental|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.
~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
16706795|NCT01905098|Active Comparator|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.
~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
16706796|NCT01905072|Experimental|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
16706797|NCT01905072|No Intervention|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
16706798|NCT01905059|Active Comparator|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)
~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
16706799|NCT01905059|Active Comparator|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
16706800|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
16706801|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
16706802|NCT01905020|Active Comparator|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
16706803|NCT01905020|Active Comparator|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
16706804|NCT01905020|Active Comparator|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
16737420|NCT01699230|No Intervention|Control group|
16706809|NCT01904981|Experimental|Atenolol|Atenolol group
16706810|NCT01904981|Experimental|Valsartan|Valsartan group
16706811|NCT01904968||Colon cancers in patients living the Cote D'or area|
16706812|NCT01904929|Experimental|Reconditioning in the effort|
16706813|NCT01904916|Other|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
16706814|NCT01904903|Other|HER2 therapies, cardiac medications|"Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses
~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:
~Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.
~Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.
~Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks."
16706815|NCT01904890|Experimental|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
16706816|NCT01904890|Active Comparator|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
16706817|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
16706818|NCT01904877||Phase II: 367 HIV positive MSM|"Linking to care:
~Providing enhanced HIV care."
16706819|NCT01904864|Active Comparator|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
16706820|NCT01904864|Active Comparator|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
16706821|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
16706822|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
16706823|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
16706824|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
16706825|NCT01904812|Other|Lupus erythematosus|
16706826|NCT01904799|Other|Cognitive Assessment|
16706827|NCT01904786|Experimental|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
16706828|NCT01904786|Placebo Comparator|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
16706829|NCT01904773|Placebo Comparator|Placebo|
16706830|NCT01904773|Experimental|low dose AZD5213|
16706831|NCT01904773|Experimental|high dose AZD5213|
16706832|NCT01904760|Experimental|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
16706833|NCT01904760|Placebo Comparator|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
16706834|NCT01904747|Experimental|Palbociclib given to healthy volunteers|
16706835|NCT01904734|Active Comparator|No previous male hormone treatment|Clomiphene
16706836|NCT01904734|Active Comparator|Previously treated with testosterone|Clomiphene
16706837|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
16706838|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
16706839|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
16706840|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
16706841|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
16706842|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
16706843|NCT01904721|Placebo Comparator|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
16706844|NCT01904708|No Intervention|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
16706871|NCT01904526|Experimental|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
16708008|NCT01896544|Placebo Comparator|Placebo|Oral suspension of placebo cholecalciferol
16706845|NCT01904708|Active Comparator|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
16706846|NCT01904695|Experimental|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker & Herbs for 8 weeks
16706847|NCT01904695|Active Comparator|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
16706848|NCT01904682|Experimental|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
16706849|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive <3 months.
16706850|NCT01904656|Experimental|Arm I|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
16706851|NCT01904656|Active Comparator|Arm II|"Participants are exposed to a Healthy Eating Peaches!- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
16706852|NCT01904643|Experimental|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.
~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.
~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.
~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
16706853|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
16706854|NCT01904617|Experimental|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
16706855|NCT01904617|Experimental|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
16706856|NCT01904617|Experimental|NS at 250mL/hr|Normal saline at 250mL/hr
16706857|NCT01904604|Placebo Comparator|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
16706858|NCT01904604|Experimental|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
16706859|NCT01904604|Experimental|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
16706860|NCT01904591|Experimental|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
16706861|NCT01904578|Experimental|true acupressure|Massage the effective pressure points as a self-care method at home [ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
16706862|NCT01904578|Sham Comparator|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
16706863|NCT01904578|No Intervention|control|The control group only received the weekly control of blood pressure and speech communication .
16706864|NCT01904565|Experimental|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
16706865|NCT01904552|Experimental|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
16706866|NCT01904552|Experimental|normal periapex (NP)|clinical pulp vitality periapical index score of 1
16706867|NCT01904539|Experimental|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
16706868|NCT01904539|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
16706869|NCT01904539|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
16706870|NCT01904539|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
16706872|NCT01904513|Experimental|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at ~10^10 CFU/day
16706873|NCT01904513|Other|Milk|Daily consumption of pasteurized whole milk
16706874|NCT01904500|Other|Cefazolin 2 grams|
16706875|NCT01904500|Active Comparator|Cefazolin 3 grams|
16706876|NCT01904487|Experimental|PET scans|Both alcoholics and healthy controls will undergo two [11C]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
16706877|NCT01904474|Experimental|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).
~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
16706878|NCT01904474|Active Comparator|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
16706879|NCT01904461|Experimental|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
16706880|NCT01904461|Active Comparator|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
16706881|NCT01904448|Experimental|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
16706882|NCT01904422|Experimental|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
16706883|NCT01904422|Experimental|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
16706884|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
16706885|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
16706886|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
16706887|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
16706888|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
16706889|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
16706890|NCT01904396|Experimental|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
16706891|NCT01904383||Trazenta|
16706892|NCT01904357|Active Comparator|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
16706893|NCT01904357|Active Comparator|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
16706894|NCT01904344|Other|Sensor testing and validation|
16706895|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
16706896|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
16706897|NCT01904318|Experimental|IDP-73152 mesylate 40 mg|
16706898|NCT01904318|Experimental|IDP-73152 mesylate 80 mg|
16706899|NCT01904318|Experimental|IDP-73152 mesylate 160 mg|
16706900|NCT01904318|Experimental|IDP-73152 mesylate 320 mg|
16706901|NCT01904318|Experimental|IDP-73152 mesylate 640 mg|
16706902|NCT01904318|Experimental|IDP-73152 mesylate 1280 mg|
16706903|NCT01904318|Placebo Comparator|Placebo|
16706904|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
16706905|NCT01904292|Experimental|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with <30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
16706906|NCT01904279|Experimental|TCZ SC 162 mg Q3W|Participants with body weight less than (<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
16706907|NCT01904279|Experimental|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
16706908|NCT01904266|Sham Comparator|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
16706909|NCT01904266|Experimental|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
16706910|NCT01904253|Experimental|TAS-102|
16706911|NCT01904253|Active Comparator|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
16706912|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
16706913|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
16706914|NCT01904227|Experimental|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.
~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.
~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
16706915|NCT01904227|Active Comparator|Outpatient DBT|Control condition: Standard outpatient DBT
16706916|NCT01904214|Experimental|severe renal impairmnt|
16706917|NCT01904214|Experimental|moderate renal impairment|
16706918|NCT01904214|Experimental|mild renal impairment|
16706919|NCT01904214|Experimental|healthy subjects|
16706920|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
16706921|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
16706922|NCT01904162|Experimental|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
16706923|NCT01904162|Experimental|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
16706924|NCT01904162|Experimental|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
16706925|NCT01904162|Experimental|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
16706926|NCT01904149|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
16706927|NCT01904149|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
16706928|NCT01904149|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
16706929|NCT01904149|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
16706930|NCT01904149|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
16706931|NCT01904149|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
16706932|NCT01904136|Experimental|Treatment (NK cells, allogeneic stem cell transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.
~NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.
~TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.
~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90."
16706933|NCT01904123|Experimental|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16706934|NCT01904110|Experimental|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
16706935|NCT01904110|Active Comparator|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
16706936|NCT01904097|Sham Comparator|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
16706937|NCT01904097|Experimental|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
16706938|NCT01904084|Active Comparator|Volar locked plating|One group with distal radius fracture is operated with Locking plate
16706939|NCT01904084|Active Comparator|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
16706940|NCT01904071|Experimental|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
16706941|NCT01904071|Experimental|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
16707016|NCT01903499|Active Comparator|Bean patty|Bean Patty
16707017|NCT01903499|Active Comparator|Beef patty|Beef patty
16706942|NCT01904071|Active Comparator|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
16706943|NCT01904058|Experimental|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
16706944|NCT01904058|Placebo Comparator|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
16706945|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
16706946|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
16706947|NCT01904006|Experimental|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
16706948|NCT01904006|Active Comparator|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
16706949|NCT01903993|Active Comparator|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
16706950|NCT01903993|Experimental|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
16706951|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
16706952|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
16706953|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
16706954|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
16706955|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
16706956|NCT01903941|Experimental|Training|Aerobic
16706957|NCT01903941|Placebo Comparator|Control|Not exercise
16706958|NCT01903928|Experimental|ASP0113 group|Participants receive 1 mL of ASP0113 intramuscularly 5 times, on days -14 to -3, 14 to 40, 60 ± 5, 90 ± 10, and 180 ± 10, counting from the transplantation (stem cell transfusion) day (day 0)
16706959|NCT01903915||Patients|Schizophrenia group
16706960|NCT01903915||Control|Healthy control group
16706961|NCT01903902|Experimental|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter > 2.25 mm and ≤ 2.75 mm)
16706962|NCT01903889|Active Comparator|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
16706963|NCT01903889|Experimental|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
16706964|NCT01903876|Placebo Comparator|General Health promotion|A 3-hour general mental health web-based program.
16706965|NCT01903876|Experimental|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
16706966|NCT01903863|Experimental|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
16706967|NCT01903863|Active Comparator|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
16706968|NCT01903850|Experimental|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
16706969|NCT01903837|Experimental|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
16706970|NCT01903837|Experimental|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
16706971|NCT01903837|Experimental|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
16706972|NCT01903837|Placebo Comparator|Placebo|Olanzapine + placebo tablets taken once daily
16706973|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
16706974|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
16706975|NCT01903824|Experimental|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
16706976|NCT01903811|Experimental|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
16706977|NCT01903811|Experimental|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
16706978|NCT01903798|Active Comparator|Prednisolone (Lille <0.45)|At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.
16707054|NCT01903252|Experimental|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
16706979|NCT01903798|Experimental|Prednisolone, rilonacept (Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).
16706980|NCT01903798|Active Comparator|Prednisolone (Lille >0.45)|Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.
16706981|NCT01903798|Experimental|Prednisolone, mycophenolate(Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.
16706982|NCT01903785|Experimental|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
16706983|NCT01903785|Placebo Comparator|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
16706984|NCT01903772|Experimental|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
16706985|NCT01903772|Sham Comparator|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
16706986|NCT01903759|Other|Patients with spontaneous rupture of the fetal membranes|
16706987|NCT01903746||Patients in septic shock|
16706988|NCT01903720|Experimental|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
16706989|NCT01903707|Experimental|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
16706990|NCT01903707|Placebo Comparator|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
16706991|NCT01903694|Active Comparator|sorafenib|800 mg of sorafenib twice daily orally.
16706992|NCT01903694|Experimental|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
16706993|NCT01903681|Active Comparator|Circadin 10 mg|Second arm higher dose
16706994|NCT01903681|Active Comparator|Circadin 2 mg|First arm lower dose
16706995|NCT01903655|Other|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
16706996|NCT01903655|Other|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
16706997|NCT01903655|Other|control group|patient with no depressive disorder during the study period and no psychiatric history
16706998|NCT01903642|Other|Patients with inflammatory syndrome|
16706999|NCT01903629|Experimental|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
16707000|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
16707001|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
16707002|NCT01903590|Active Comparator|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
16707003|NCT01903590|Experimental|Transobturator tape surgery|Randomized 50 patients undergoing TOT
16707004|NCT01903577|Experimental|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.
~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
16707005|NCT01903577|Experimental|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.
~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
16707006|NCT01903577|Experimental|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.
~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
16707007|NCT01903564||normal|pregnant women with uncomplicated pregnancies
16707008|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
16707009|NCT01903551|Experimental|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
16707010|NCT01903551|No Intervention|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
16707011|NCT01903538|Experimental|Cathodal transcranial direct current stimulation|
16707012|NCT01903538|Sham Comparator|Sham transcranial direct current stimulation|
16707013|NCT01903525|Placebo Comparator|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
16707014|NCT01903525|Experimental|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
16707015|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
16707018|NCT01903486|Other|Prednisone|Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
16707019|NCT01903473|Experimental|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
16707020|NCT01903473|Active Comparator|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
16707021|NCT01903460|Experimental|LUM001|LUM001 administered orally once each day
16707022|NCT01903460|Placebo Comparator|Placebo|Placebo administered orally once each day
16707023|NCT01903447|Active Comparator|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
16707024|NCT01903447|Active Comparator|CBT|12 weeks of individual cognitive behavioral therapy
16707025|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to 2 of 3 periods
16707026|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to 2 of 3 periods
16707027|NCT01903421|Active Comparator|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
16707028|NCT01903421|Active Comparator|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
16707029|NCT01903408|Other|Arm 1: Boost to prostate|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up
16707030|NCT01903408|Other|Arm 2: Boost to prostate and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) & pelvic lymph node mets (61.2 Gy) in 34 Fx
16707031|NCT01903408|Other|Arm 3: Boost to prostate bed|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published
16707032|NCT01903408|Other|Arm 4: Boost to prostate bed and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) & lymph node metastases (61.2 Gy) in 34 Fx
16707033|NCT01903408|Other|Arm 5: Boost to lymph node metastases|Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx
16707034|NCT01903395|Experimental|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
16707035|NCT01903395|No Intervention|Usual Care|Usual print media, offered standardly by the recruiting centres.
16707036|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
16707037|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery >16 years of age.
16707038|NCT01903356||Patients with T2DM|
16707039|NCT01903343||Healthy Volunteers|Single group of healthy male medical students at Ninewells Hospital & Medical School, Dundee.
16707040|NCT01903330|Experimental|(ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab/bevacizumab biosimilar|"ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10 mg/kg every 2 weeks.
~The treatment will be repeated every 28 days until progression of disease or intolerance."
16707041|NCT01903330|Placebo Comparator|(Placebo Injection/Placebo Pill) +Bevacizumab/bevacizumab biosimilar|"The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab or approved bevacizumab biosimilar just as the active treatment group above.
~The treatment will be repeated every 28 days until progression of disease or intolerance."
16707042|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
16707043|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
16707044|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
16707045|NCT01903304|Experimental|olive oil|intervention with olive oil for 3 months
16707046|NCT01903304|Placebo Comparator|Placebo|Intervention with placebo for 3 months
16707047|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
16707048|NCT01903278|Experimental|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
16707049|NCT01903278|Active Comparator|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
16707050|NCT01903278|Experimental|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
16707051|NCT01903278|Active Comparator|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
16707052|NCT01903265|Experimental|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
16707053|NCT01903265|Placebo Comparator|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
16737562|NCT01698112|Experimental|Flaxseed High Dose|
16707055|NCT01903252|Active Comparator|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
16707056|NCT01903239|Other|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
16707057|NCT01903226|Experimental|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
16707058|NCT01903226|Experimental|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
16707059|NCT01903226|No Intervention|controll|Patients in this group will perform no (additional) training.
16707060|NCT01903213||Kiklin group|Oral
16707061|NCT01903200|Experimental|FK949E Fed Group|FK949E is administered after breakfast
16707062|NCT01903200|Experimental|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
16707063|NCT01903187|Experimental|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
16707064|NCT01903187|Active Comparator|Sham procedure|Sham procedure
16707065|NCT01903174|Experimental|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
16707066|NCT01903161|Experimental|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
16707067|NCT01903161|Placebo Comparator|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
16707068|NCT01903135|Other|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
16707069|NCT01903135|Other|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
16707070|NCT01903135|Other|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
16707071|NCT01903122|Active Comparator|Cevimeline|Single Dose 30 mg Capsule
16707072|NCT01903122|Active Comparator|Evoxac|Single dose 30 mg capsule
16707073|NCT01903109|Active Comparator|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
16707074|NCT01903109|Active Comparator|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
16707075|NCT01903096|Experimental|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
16707076|NCT01903096|Active Comparator|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
16707077|NCT01903083|Experimental|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
16707078|NCT01903070|Experimental|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
16707079|NCT01903070|Experimental|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
16707080|NCT01903057|Experimental|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8
~Placebo has same appearance and dosing as azithromycin."
16707081|NCT01903057|Placebo Comparator|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8
~Placebo has same appearance and dosing as azithromycin."
16707082|NCT01903044|Experimental|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
16707083|NCT01903031|Experimental|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
16707084|NCT01903031|Experimental|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
16707085|NCT01903031|Experimental|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
16707086|NCT01903018|Experimental|P276-00|
16707087|NCT01903005|Experimental|Open-label BNX sublingual tablets|Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.
16707088|NCT01902992|Experimental|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
16707137|NCT01902550|Experimental|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
16707303|NCT01901328|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
16707089|NCT01902992|Placebo Comparator|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
16707090|NCT01902979|Experimental|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
16707091|NCT01902979|No Intervention|Usual Care|
16707092|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
16707093|NCT01902953|Experimental|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
16707094|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
16707095|NCT01902927|Experimental|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
16707096|NCT01902914|Experimental|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
16707097|NCT01902914|Active Comparator|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
16707098|NCT01902901|Active Comparator|Usual care|Requested carrier status testing.
16707099|NCT01902901|Experimental|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
16707100|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
16707101|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
16707102|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
16707103|NCT01902862|Experimental|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
16707104|NCT01902849||Group 1 - TIVA-TCI|"include 35 patients with colorectal cancer undergoing surgery
~anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.
~for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.
~for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).
~intervention:blood sampling for IL measurement"
16707105|NCT01902849||Group II- ISOFLURANE|"include 35 patients with colorectal cancer undergoing surgery
~anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml
~maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)
~intervention:blood sampling for IL measurement"
16707106|NCT01902836|Experimental|Conventional Treatment plus DLE|"Conventional treatment plus DLE
~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;
~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
16707107|NCT01902836|Placebo Comparator|Conventional treatment plus placebo|"Conventional treatment plus placebo:
~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
16707108|NCT01902823|No Intervention|No Nurse Navigator Services|
16707109|NCT01902823|Experimental|Services from a Nurse Navigator|
16707110|NCT01902810|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization
16707111|NCT01902810|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization
16707138|NCT01902550|Experimental|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter [ml] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
16707139|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
16707140|NCT01902524|Experimental|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
16707141|NCT01902511|Experimental|G-CSF + Erythropoietin|
16707112|NCT01902797|Experimental|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
16707113|NCT01902784|Experimental|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).
~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
16707114|NCT01902784|No Intervention|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
16707115|NCT01902771|Experimental|DC Vaccine + Lysate|"Leukapheresis: Baseline, post-surgery;
~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;
~Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;
~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
16707116|NCT01902758|Experimental|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
16707117|NCT01902758|Placebo Comparator|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
16707118|NCT01902745|Active Comparator|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.
~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
16707119|NCT01902745|Active Comparator|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.
~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
16707120|NCT01902732|Other|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
16707121|NCT01902719|Experimental|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
16707122|NCT01902719|Experimental|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
16707123|NCT01902719|Experimental|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
16707124|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.
~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
16707125|NCT01902680|Experimental|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
16707126|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
16707127|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
16707128|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
16707129|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
16707130|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
16707131|NCT01902641|Active Comparator|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
16707132|NCT01902641|Active Comparator|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
16707133|NCT01902641|Active Comparator|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
16707134|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
16707135|NCT01902615||Cohort|
16707136|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
16707143|NCT01902498|Experimental|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
16707144|NCT01902498|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
16707145|NCT01902498|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
16707146|NCT01902485|Active Comparator|Quickstart|Immediate start
16707147|NCT01902485|Active Comparator|Afterstart|Delayed start
16707148|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
16707149|NCT01902459|Active Comparator|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component.
16707150|NCT01902459|Other|Standard of Care|Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat.
16707151|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
16707152|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
16707153|NCT01902433|Experimental|Astym|A form of soft tissue mobilization using instruments
16707154|NCT01902433|Active Comparator|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
16707155|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
16707156|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
16707157|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.
~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
16707158|NCT01902394|Experimental|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
16707159|NCT01902394|Placebo Comparator|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
16707160|NCT01902394|No Intervention|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
16707161|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16707162|NCT01902368|Other|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
16707163|NCT01902368|No Intervention|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
16707164|NCT01902355|Experimental|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
16707165|NCT01902355|Active Comparator|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
16707166|NCT01902342|Experimental|CES1 gene variant group|Oseltamivir 75 mg 1 cap
16707167|NCT01902342|Experimental|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
16707168|NCT01902329|Experimental|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
16707169|NCT01902329|Experimental|SGN-CD33A Monotherapy|SGN-CD33A
16707170|NCT01902303|Placebo Comparator|Matching Placebo|Matching Placebo
16707171|NCT01902303|Experimental|BTL-TML-HSV|Experimental Product
16707172|NCT01902290|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injections until week 24.
16707173|NCT01902290|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injections until week 24.
16707174|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
16707175|NCT01902264|Experimental|EE20/DRSP/L-5-MTHF|
16707176|NCT01902251|Experimental|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
16707177|NCT01902251|Active Comparator|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
16707178|NCT01902238|Experimental|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
16707179|NCT01902225|Experimental|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours
~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
16707180|NCT01902212|Experimental|Oral Nutritional Supplement|2 servings a day
16707181|NCT01902199|Active Comparator|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
16707182|NCT01902199|Placebo Comparator|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
16707183|NCT01902186|Experimental|raltegravir|raltegravir and atazanavir and ritonavir
16707184|NCT01902186|Active Comparator|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
16707304|NCT01901328|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
16707185|NCT01902173|Experimental|Treatment (uprosertib, dabrafenib, trametinib)|"Dabrafenib mesylate and uprosertib: Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib: Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16707186|NCT01902160|Experimental|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
16707187|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
16707188|NCT01902134|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
16707189|NCT01902134|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
16707190|NCT01902134|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
16707191|NCT01902134|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
16707192|NCT01902134|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
16707193|NCT01902134|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
16707194|NCT01902121|Experimental|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
16707195|NCT01902121|Experimental|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
16707196|NCT01902108|Experimental|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
16707197|NCT01902108|Active Comparator|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
16707198|NCT01902095|Experimental|Tooth powder (test) arm|Experimental arm: tooth powder
16707199|NCT01902095|Active Comparator|Tooth Paste (control)|Tooth Paste
16707200|NCT01902082|Experimental|Mesenchymal stem cell arm|Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
16707201|NCT01902082|Placebo Comparator|Placebo|Patients received one dose of normal saline.
16707202|NCT01902069|Experimental|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
16707203|NCT01902069|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
16707204|NCT01902056|Active Comparator|one layer allograft|One layer allograft as a positive control
16707205|NCT01902056|Experimental|Two layer allograft|Two layer allograft as the test group.
16707206|NCT01902030||Proven/Probable IA Patients|Case Population
16707207|NCT01902030||possible/No IA Patients|Control population
16707208|NCT01902017|Experimental|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
16707209|NCT01902017|Experimental|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
16707210|NCT01902017|Placebo Comparator|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
16707211|NCT01902017|Placebo Comparator|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
16707212|NCT01902004|Active Comparator|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
16707213|NCT01902004|Active Comparator|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
16707214|NCT01901991|Experimental|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).
~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
16707215|NCT01901991|Active Comparator|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).
~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
16707216|NCT01901978|Experimental|Weight Loss|Caloric restrictive diet
16707217|NCT01901965|Experimental|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
16707218|NCT01901965|Experimental|eccentric training|unilateral eccentric resistance exercises
16707219|NCT01901965|Sham Comparator|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
16707220|NCT01901952|Active Comparator|Standard of care|
16707221|NCT01901952|Experimental|Intensive education and support|
16707222|NCT01901939|Experimental|exercise|daily bedside tailored low intensity pedaling exercise
16707223|NCT01901926|Active Comparator|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.
~Checkup will be repeated at 3, 6 & 9 month interval along with HbA1C levels"
16707224|NCT01901926|No Intervention|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
16707225|NCT01901913|Experimental|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
16707226|NCT01901913|Active Comparator|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
16707227|NCT01901887|Experimental|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months
~Other names: none"
16707228|NCT01901887|Placebo Comparator|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months
~Other names: none"
16707229|NCT01901874|Experimental|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
16707230|NCT01901861|Active Comparator|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
16707231|NCT01901861|Placebo Comparator|Placebo|Placebo is given before meal ingestion
16707232|NCT01901848|Experimental|CPT+ICSC|This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
16707233|NCT01901848|Active Comparator|ICSC only|This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
16707234|NCT01901835|Experimental|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
16707235|NCT01901835|Experimental|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
16707236|NCT01901822|Active Comparator|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
16707237|NCT01901822|Experimental|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
16707238|NCT01901809|Active Comparator|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
16707239|NCT01901809|Active Comparator|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
16707240|NCT01901809|Active Comparator|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
16707241|NCT01901809|Active Comparator|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
16707242|NCT01901796|Experimental|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
16707243|NCT01901796|No Intervention|Usual care|Usual prenatal care
16707244|NCT01901783|Active Comparator|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
16707245|NCT01901783|Experimental|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
16707246|NCT01901770|Experimental|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
16707247|NCT01901770|Active Comparator|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
16707248|NCT01901757|Experimental|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
16707249|NCT01901757|Experimental|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
16707250|NCT01901744|Experimental|Patients undergoing cataract surgery|
16707251|NCT01901731|Experimental|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
16707252|NCT01901731|Active Comparator|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
16707253|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
16707254|NCT01901705|Active Comparator|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
16707255|NCT01901705|Placebo Comparator|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
16707256|NCT01901692|Experimental|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
16707257|NCT01901692|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
16707258|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
16707259|NCT01901666|Experimental|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
16707305|NCT01901315|Experimental|Online consultation|Monthly video consultations with psychiatrist
16707306|NCT01901315|Experimental|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
16707260|NCT01901653|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
16707261|NCT01901640|Experimental|DA-8159|Udenafil(The study had one arm.)
16707262|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
16707263|NCT01901614|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
16707264|NCT01901614|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
16707265|NCT01901601|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
16707266|NCT01901601|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
16707267|NCT01901588|Experimental|Dexmedetomidine|dexmedetomidine/precedex
16707268|NCT01901588|Placebo Comparator|Placebo|patients receive saline solution.
16707269|NCT01901575|Experimental|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
16707270|NCT01901562|Experimental|Ductoscopic papillomectomy|Ductoscopic papillomectomy to treat pathological nipple discharge
16707271|NCT01901549|Active Comparator|PCI+Renal denervation|
16707272|NCT01901549|Active Comparator|PCI alone|
16707273|NCT01901536|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
16707274|NCT01901536|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
16707275|NCT01901523|Experimental|Provision of information|Reporting of discrepancy to journal
16707276|NCT01901510|Active Comparator|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
16707277|NCT01901510|Other|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
16707278|NCT01901497|Experimental|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
16707279|NCT01901497|Experimental|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
16707280|NCT01901497|Experimental|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
16707281|NCT01901484|Active Comparator|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
16707282|NCT01901484|Active Comparator|Praziquantel|double dose
16707283|NCT01901471|Experimental|CsA Group|
16707284|NCT01901471|Placebo Comparator|Placebo group|
16707285|NCT01901458|Experimental|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
16707286|NCT01901458|Active Comparator|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
16707287|NCT01901445|Experimental|Educational action group|
16707288|NCT01901445|No Intervention|Control group|
16707289|NCT01901432|Experimental|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:
~50 mg b.i.d.,
~100 mg b.i.d.;
~150 mg b.i.d.,
~200 mg b.i.d.;
~150 mg t.i.d.;
~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.
~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.
~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
16707290|NCT01901419|Experimental|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
16707291|NCT01901419|Active Comparator|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
16707292|NCT01901406||ERM|idiopathic epiretinal membrane patients
16707293|NCT01901393|Experimental|IV ibuprofen|800mg ibuprofen
16707294|NCT01901393|Active Comparator|ketorolac|30mg ketorolac
16707295|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
16707296|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
16707297|NCT01901367|Experimental|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
16707298|NCT01901367|No Intervention|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
16707299|NCT01901354|Active Comparator|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of <30 cm H2O, and a goal respiratory rate of 6-35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end-expiratory pressure is set as per the ARDSNet Positive end-expiratory pressure table
16707300|NCT01901354|Active Comparator|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.
~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5-0.8 seconds to achieve an end expiratory flow 25-50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%-70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at <5 cm H20."
16707301|NCT01901341|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
16707302|NCT01901341|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
16707307|NCT01901302|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
16707308|NCT01901302|Placebo Comparator|Placebo|Placebo BID for a 12-week treatment period
16707309|NCT01901289|Experimental|Drug-Eluting Stent|
16707310|NCT01901276|Experimental|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
16707311|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)
~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
16707312|NCT01901250|Experimental|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
16707313|NCT01901250|Placebo Comparator|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
16707314|NCT01901237|Other|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
16707315|NCT01901224|Experimental|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
16707316|NCT01901224|Placebo Comparator|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
16707317|NCT01901211|Experimental|Exergaming|In this arm, the participants will participate in the exergaming intervention.
16707318|NCT01901211|No Intervention|Comparison Arm|In this arm of the study, participants will engage in their typical physical activity routines for the ten week duration. Participants will receive a call from the RA each week. The RA will ask the child to report on all the physical and social activities that they engaged in for that week.
16707319|NCT01901198|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
16707320|NCT01901198|Active Comparator|Pegasys|Peginterferon 180 mcg single dose S.C.
16707321|NCT01901185|Experimental|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
16707322|NCT01901172|Experimental|Extension|
16707323|NCT01901172|Experimental|Part 1: Drug-drug interaction|
16707324|NCT01901172|Experimental|Part 2: Relative bioavailability|
16707325|NCT01901172|Experimental|Part 3: Food effect|
16707326|NCT01901159|Experimental|RO4995819 capsule|
16707327|NCT01901159|Experimental|RO4995819 tablet|
16707328|NCT01901146|Experimental|ABP 980|"Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
~After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
16707329|NCT01901146|Active Comparator|Trastuzumab|"Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
~After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
16707330|NCT01901133|Experimental|A: Mild hepatic impairment subjects + control|
16707331|NCT01901133|Experimental|B: Moderate hepatic impairment subjects + control|
16707332|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
16707333|NCT01901107||Kiklin group|
16707334|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.
~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
16707335|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
16707336|NCT01901081|Experimental|Prosthetic Training with IMES prosthesis|
16707337|NCT01901068||MonoMax|Elective primary laparotomy
16707338|NCT01901055|Experimental|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
16707339|NCT01901055|Placebo Comparator|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
16707340|NCT01901042|Experimental|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
16707341|NCT01901042|Placebo Comparator|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
16707342|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
16707343|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
16707344|NCT01901016|Experimental|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
16707345|NCT01901016|Experimental|Schultz's autogenic training|Schultz's autogenic training
16707346|NCT01901016|No Intervention|control|The CG continued to receive their standard care. After data collection at the six-month follow-up, the CG participants were invited to attend one of two relaxation interventions.
16707347|NCT01901003|Placebo Comparator|placebo group|placebo
16707348|NCT01901003|Active Comparator|no premedication group|no premedication
16707349|NCT01901003|Experimental|Lorazepam group|lorazepam
16707350|NCT01900990|Experimental|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
16707351|NCT01900990|No Intervention|Conventional weaning|Patients in this group were weaned by conventional stratiges.
16707352|NCT01900977|Active Comparator|Arm A Universal Testing w/Immediate ART|
16707353|NCT01900977|Active Comparator|Arm B ART according to National Guidelines|
16707354|NCT01900977|Other|Standard of Care|"Includes:
~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
16707355|NCT01900964|Active Comparator|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
16707356|NCT01900964|Experimental|Collagen membrane|A resorbable collagen membrane will be used in the test group.
16707357|NCT01900951|Experimental|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
16707358|NCT01900938|Active Comparator|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
16707359|NCT01900938|Active Comparator|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
16707360|NCT01900925|Active Comparator|Low back treatment only (pragmatic)|"advise to stay active,
~discourage bed rest,
~appropriate medication use,
~reassurance.
~Short term use of manipulation/medication,
~supervised exercise,
~cognitive behavioral therapy,
~multidisciplinary treatment,
~termination of use of modalities."
16707361|NCT01900925|Experimental|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
16707362|NCT01900912|Experimental|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
16707363|NCT01900912|No Intervention|Rural communities|No intervention will be delivered (n=61 communities)
16707364|NCT01900899|Experimental|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
16707365|NCT01900899|Active Comparator|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
16707366|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
16707367|NCT01900873|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
16707368|NCT01900873|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
16707369|NCT01900860|Active Comparator|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
16707370|NCT01900860|Active Comparator|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
16707371|NCT01900860|Active Comparator|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
16707372|NCT01900847|Active Comparator|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
16707373|NCT01900847|Experimental|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
16707374|NCT01900834||All participants|
16707375|NCT01900821||Women|All women having mammograms
16707376|NCT01900808||Patients with chronic liver disease|
16707377|NCT01900795|Experimental|V117957|
16707378|NCT01900795|Active Comparator|Ibuprofen|
16707379|NCT01900795|Placebo Comparator|Placebo|
16707380|NCT01900782|Experimental|Dosing Regimen 1|Subcutaneous injection
16707381|NCT01900782|Active Comparator|Active Comparator|Subcutaneous injection
16707382|NCT01900782|Placebo Comparator|Placebo|Subcutaneous injection
16707385|NCT01900756|Active Comparator|Behavioral|"Pre-appointment phone text
~In-clinic educational video
~Patient report card
~Post-clinic phone text
~Outpatient stroke registry"
16707386|NCT01900756|No Intervention|Standard care|Routine and customary management.
16707387|NCT01900743|Experimental|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
16707388|NCT01900743|Placebo Comparator|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
16707389|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
16707390|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
16707391|NCT01900717|Active Comparator|chimiotherapy alone|"LV5FU2 simplified,
~5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,
~fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
16707392|NCT01900717|Experimental|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"LV5FU2 simplified,
~FOLFOX 4 simplified,
~FOLFIRI modified.
~Bevacizumab 5 mg/kg/ 2 weeks"
16707393|NCT01900704|Experimental|SER120 750 ng|SER120 750 ng
16707394|NCT01900704|Experimental|SER120 1500 ng|SER120 1500 ng
16707395|NCT01900704|Placebo Comparator|Placebo|Placebo
16707396|NCT01900691|Experimental|Evolution® Esophageal Stent|
16707397|NCT01900678|Experimental|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
16707398|NCT01900665|Experimental|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
16707399|NCT01900665|Placebo Comparator|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
16707400|NCT01900652|Experimental|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
16707401|NCT01900652|Experimental|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
16707402|NCT01900639|Active Comparator|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
16707403|NCT01900639|Experimental|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
16707404|NCT01900626|Active Comparator|single epidural catheter|
16707405|NCT01900626|Active Comparator|double epidural catheter|
16707406|NCT01900613|Experimental|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
16707407|NCT01900613|Active Comparator|Comparison|Comparison community of San Joaquin
16707408|NCT01900600|Placebo Comparator|Placebo|Placebo
16707409|NCT01900600|Active Comparator|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
16707410|NCT01900600|Active Comparator|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
16707411|NCT01900600|Active Comparator|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
16707412|NCT01900587|Experimental|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
16707413|NCT01900587|Experimental|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
16707415|NCT01900561|Experimental|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
16707468|NCT01900236|Experimental|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
16707469|NCT01900223||Shoulder prosthesis bearer|
16707416|NCT01900561|No Intervention|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
16707417|NCT01900548|Experimental|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
16707418|NCT01900548|Experimental|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
16707419|NCT01900548|Placebo Comparator|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
16707420|NCT01900522|Experimental|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
16707421|NCT01900522|Experimental|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
16707422|NCT01900509|Experimental|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.
~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
16707423|NCT01900496|Experimental|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:
~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.
~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a ~ 1 year total course of therapy."
16707424|NCT01900483||pre bariatric surgery|
16707425|NCT01900483||post bariatric surgery|
16707426|NCT01900470|Experimental|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
16707427|NCT01900470|No Intervention|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
16707428|NCT01900457|Active Comparator|Volunteer healthy|healthy volunteers
16707429|NCT01900457|Experimental|patients|vestibular defective patients
16707430|NCT01900444|Experimental|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
16707431|NCT01900431|Placebo Comparator|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
16707432|NCT01900431|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
16707433|NCT01900418|Active Comparator|Walking|Walk with Ease
16707434|NCT01900418|No Intervention|Wait list control|Wait list control receiving the active intervention 6 weeks later.
16707435|NCT01900405||Dexmedetomidine|All children undergoing
16707436|NCT01900392|No Intervention|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, & 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
16707437|NCT01900392|Experimental|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.
~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
16707438|NCT01900392|Experimental|Lottery|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.
~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
16707439|NCT01900379|Experimental|OSA/CPAP|OSA patients intervention : CPAP treatment
16707440|NCT01900379|Sham Comparator|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
16707441|NCT01900379|No Intervention|control group|Patients without any apnea syndrome
16707442|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
16707443|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
16707444|NCT01900353|Active Comparator|horizontal brushing method|brushing methods
16707445|NCT01900353|Active Comparator|Vertical brushing method|brushing methods
16707446|NCT01900340|Placebo Comparator|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
16707447|NCT01900340|Active Comparator|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
16707448|NCT01900340|Placebo Comparator|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
16707449|NCT01900340|Active Comparator|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
16707450|NCT01900327|Experimental|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
16707451|NCT01900327|Active Comparator|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
16707452|NCT01900314|Active Comparator|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
16707453|NCT01900314|Sham Comparator|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
16707454|NCT01900301|Experimental|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
16707455|NCT01900301|Placebo Comparator|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
16707456|NCT01900301|Experimental|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
16707457|NCT01900301|Experimental|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
16707458|NCT01900288|Experimental|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).
~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
16707459|NCT01900288|Placebo Comparator|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.
~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
16707460|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS > 15). Septic shock is defined by sepsis with hypotension requiring >4 hours of vasopressor support over previous 24 hours.
16707461|NCT01900262|Experimental|Strengthening|Novice recreational runners from the Calgary area.
16707462|NCT01900262|Experimental|Balance Training|Novice recreational runners from the Calgary area.
16707463|NCT01900262|Experimental|Stretching|Novice recreational runners from the Calgary area.
16707464|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
16707465|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
16707466|NCT01900249|Placebo Comparator|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
16707467|NCT01900236|No Intervention|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
16707540|NCT01899729|Placebo Comparator|Placebo|Saline (placebo) q wk x 12 wks
16707541|NCT01899729|Experimental|IMO-8400 Regimen 4|IMO_8400 at 0.6 mg/kg q wk x 12 wks
16707470|NCT01900210|Experimental|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
16707471|NCT01900210|No Intervention|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
16707472|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
16707473|NCT01900184|Experimental|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
16707474|NCT01900184|Experimental|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
16707475|NCT01900184|Experimental|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
16707476|NCT01900184|Placebo Comparator|Placebo|The placebo will be administered in solution with 200 mL of purified water.
16707477|NCT01900171|Experimental|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707478|NCT01900171|Experimental|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707479|NCT01900171|Experimental|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707480|NCT01900171|Experimental|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707481|NCT01900171|Experimental|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707482|NCT01900171|Experimental|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707483|NCT01900171|Experimental|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707484|NCT01900171|Experimental|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707485|NCT01900171|Placebo Comparator|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
16707486|NCT01900158|Experimental|Phase I|Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.
16707488|NCT01900106|Experimental|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
16707489|NCT01900106|Active Comparator|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
16707490|NCT01900093|Experimental|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
16707491|NCT01900080|Experimental|Same-Day ART Group|"Same-Day HIV testing and ART initiation:
~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
16707492|NCT01900080|Active Comparator|Standard ART Group|"Standard ART Initiation:
~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
16707493|NCT01900080|Experimental|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count >500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
16707494|NCT01900080|Active Comparator|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
16707495|NCT01900067|Active Comparator|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
16707496|NCT01900067|No Intervention|Control|no active warming, standard of care
16707497|NCT01900054|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
16707498|NCT01900041|Experimental|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
16707499|NCT01900041|Other|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
16707500|NCT01900028|Experimental|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
16707501|NCT01900015|Active Comparator|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
16707502|NCT01900015|Active Comparator|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
16707503|NCT01900002|Experimental|Treatment (sorafenib tosylate, TheraSphere)|Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16707542|NCT01899716|Experimental|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
16707543|NCT01899716|No Intervention|Control|
16707504|NCT01899989|Experimental|A) >5cm,Chemo eligible (closed to accrual)|Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
16707505|NCT01899989|Experimental|B) 3-5cm OR Chemo ineligible|Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in < 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in < 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
16707506|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
16707507|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
16707508|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
16707509|NCT01899924|Experimental|Event Related Potentials|
16707510|NCT01899911|Experimental|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
16707511|NCT01899898|Experimental|Simplified Modified Atkins Diet|
16707512|NCT01899898|Active Comparator|Antiepileptic drugs alone|
16707513|NCT01899885|No Intervention|historic control group|Standard treatment in the historic control group
16707514|NCT01899885|Active Comparator|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:
~Intervention before, during and after abdominal surgery.
~Focus on fast track with multimodal standardized intervention:
~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)
~GDT-LiDCO fluid management pre-, per- and postoperative
~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score
~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
16707515|NCT01899872|Experimental|Patients with type 1 diabetes|Patients with type 1 diabetes
16707516|NCT01899859|Active Comparator|Cohort 1|Patient receives dose of GR-MD-02 or placebo
16707517|NCT01899859|Active Comparator|Cohort 2|Patient receives dose of GR-MD-02 or Placebo
16707518|NCT01899859|Active Comparator|Cohort 3|Patient receives dose of GR-MD-02 or placebo
16707519|NCT01899846|Experimental|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
16707520|NCT01899846|Experimental|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
16707521|NCT01899846|Experimental|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
16707522|NCT01899833|Experimental|99mTc-EC-DG, Diagnostic|99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose
16707523|NCT01899820|Active Comparator|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
16707524|NCT01899820|Experimental|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
16707525|NCT01899807|Other|Single Arm|
16707526|NCT01899794|Active Comparator|TVT-O|mid-urethral sling
16707527|NCT01899794|Active Comparator|Oxytrol|medication
16707528|NCT01899781|Experimental|with antibiotic and without antibiotic|
16707529|NCT01899768|Experimental|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
16707530|NCT01899768|Experimental|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
16707531|NCT01899768|Experimental|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
16707532|NCT01899755|Experimental|GSK2800528 Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
16707533|NCT01899755|Placebo Comparator|Placebo Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
16707534|NCT01899755|Active Comparator|Adalimumab Arm|In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection
16707535|NCT01899742|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
16707536|NCT01899742|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
16707537|NCT01899729|Experimental|IMO-8400 Regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
16707538|NCT01899729|Experimental|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
16707539|NCT01899729|Experimental|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
16707544|NCT01899703|Experimental|GSK2330672|Subject will receive GSK2330672 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either (i) GSK2330672 followed by placebo; OR (ii) placebo followed by GSK2330672.
16707545|NCT01899703|Experimental|Placebo|Subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either GSK2330672 followed by placebo; OR placebo followed by GSK2330672.
16707546|NCT01899690|Experimental|antibiotic|7 days of preventive antibiotics after surgery
16707547|NCT01899690|No Intervention|No antibiotic|No preventive postoperative antibiotics
16707548|NCT01899677|Experimental|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
16707549|NCT01899677|Placebo Comparator|distilled water|2 x 0.5 cc distilled water will be given during 30 days
16707550|NCT01899664|Other|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
16707551|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
16707552|NCT01899638|Experimental|UMEC/VI 125/25 mcg|Combination in high dose
16707553|NCT01899638|Experimental|UMEC/VI 62.5/25 mcg|Combination in low dose
16707554|NCT01899638|Experimental|UMEC 125 mcg|LAMA mono in high dose
16707555|NCT01899638|Experimental|UMEC 62.5 mcg|LAMA mono in low dose
16707556|NCT01899638|Experimental|VI 25 mcg|LABA mono
16707557|NCT01899625|Active Comparator|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
16707558|NCT01899625|Active Comparator|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
16707559|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
16707560|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
16707561|NCT01899599|Experimental|PankoMab-GEX|1700mg, i.v., q3w
16707562|NCT01899599|Placebo Comparator|Placebo|matching placebo
16707563|NCT01899586|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
16707564|NCT01899586|Experimental|Aerobic Exercise (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
16707565|NCT01899573|Experimental|Treatment|
16707566|NCT01899560|Other|Unique arm|Experimental and comparator
16707567|NCT01899547|Experimental|Arm I|Patients undergo laparoscopic-assisted rectal resection.
16707568|NCT01899547|Active Comparator|Arm II|Patients undergo conventional open rectal resection.
16707569|NCT01899534|No Intervention|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
16707570|NCT01899534|Experimental|E-screening|Women will complete mental health screening on a tablet
16707571|NCT01899521|Placebo Comparator|Placebo zinc and placebo SAMe|Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
16707572|NCT01899521|Active Comparator|Active zinc and placebo SAMe|Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
16707573|NCT01899521|Active Comparator|Placebo zinc and active SAMe|Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
16707574|NCT01899521|Active Comparator|Active zinc and active SAMe|Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
16707575|NCT01899508|Experimental|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
16707576|NCT01899495|Experimental|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
16707577|NCT01899482|Experimental|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
16707578|NCT01899482|Active Comparator|Control|One educational session in group.
16707579|NCT01899469|Experimental|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
16707580|NCT01899469|Experimental|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
16707581|NCT01899469|Experimental|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
16707582|NCT01899456|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
16707583|NCT01899456|Experimental|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
16708009|NCT01896544|Active Comparator|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
16707584|NCT01899443||Total hip and knee replacement patients|This study will select up to 20 high volume (>275 cases annually) public and private hospitals across Australia. A random sample of c.2200 patients with diagnosis of osteoarthritis undergoing primary total hip or knee replacement surgery will be recruited.
16707585|NCT01899430|Active Comparator|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
16707586|NCT01899430|Experimental|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
16707587|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
16707588|NCT01899417||Standard Knee Replacements|knee joint replacement
16707589|NCT01899404|Experimental|18-FDG PET/CT, DWI, DCE-MRI|
16707590|NCT01899378|Experimental|daily probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month
16707591|NCT01899378|Experimental|weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month
16707592|NCT01899378|Experimental|bi-weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month
16707593|NCT01899378|No Intervention|control|
16707594|NCT01899365||Multifaceted|"brief structured interview with the physician about pneumococcal risk and vaccination,
~information sheet delivered to patients with explanation about risk and benefit of APV,
~letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,
~3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner."
16707595|NCT01899365||Control|"information sheet delivered to patients with explanation about the aim of the study,
~brief interview with the physician about study."
16707596|NCT01899352|Other|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
16707597|NCT01899339||pulmonary embolism|patients with submassive pulmonary embolism
16707598|NCT01899326|Experimental|Treatment (desipramine, filgrastim)|Patients receive desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection begins on day 6.
16707599|NCT01899313|Experimental|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
16707600|NCT01899313|Placebo Comparator|Placebo Texts|Placebo texts will be given instead of interventional texts
16707601|NCT01899300|Experimental|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
16707602|NCT01899287|Experimental|education in skin care|"The experimental intervention consists of:
~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.
~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
16707603|NCT01899287|No Intervention|no intervention|The control group will not have access to the group education, the profession specific information and the social guidance or the telephone hotline.
16707604|NCT01899274|Experimental|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
16707605|NCT01899274|No Intervention|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
16707606|NCT01899261|Experimental|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
16707607|NCT01899248||Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
16707608|NCT01899248||Desflurane|Performing liver transplantation under general anesthesia using desflurane
16707609|NCT01899235|Active Comparator|Stent|drug eluting stent (Resolute)
16707610|NCT01899235|Experimental|drug eluting balloon|drug eluting balloon (Elutax)
16707611|NCT01899222||fundus imaging|retinal photograph obtained at visit
16707612|NCT01899209|Experimental|Group A|STARR
16707613|NCT01899209|Experimental|Group B|Laparoscopic ventral Rectopexy
16707614|NCT01899196|Other|no Arm|
16707615|NCT01899170|Sham Comparator|Sham-DBS|Only patients. Inactive deep brain stimulation for the initial three months following implantation.
16707616|NCT01899170|Active Comparator|Active DBS|Only patients. Active deep brain stimulation for the initial three months following surgery.
16707617|NCT01899170|Experimental|TMS and PET imaging|This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.
16707618|NCT01899157||Survey|"Thai naive HIV-infected patients
~Thai HIV-infected patient reciering highly active antiretroviral therapy"
16707619|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
16707620|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
16707621|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
16707622|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
16707623|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
16707624|NCT01899131|Other|platform-switch tapered internal implants|2 platform-switch tapered internal implants placed in 10 participants.clinical and radiographic assessment in 6,12,24, month post implant insertion
16707625|NCT01899118|Experimental|Nimotuzumab plus chemoradiotherapy|
16707626|NCT01899105|Experimental|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
16707627|NCT01899105|Experimental|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
16707628|NCT01899092|Experimental|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
16707629|NCT01899066|Experimental|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.
~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
16707630|NCT01899066|Active Comparator|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
16707631|NCT01899053|Experimental|Dose Escalation Treatment Arm A|TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
16707632|NCT01899053|Experimental|Dose Escalation Treatment Arm B|TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
16707633|NCT01899053|Experimental|Dose Escalation Treatment Arm C|TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
16707634|NCT01899053|Experimental|Drug-Drug Interaction (DDI) Expansion Cohort|TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
16707635|NCT01899040|Active Comparator|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
16707636|NCT01899040|Placebo Comparator|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
16707637|NCT01899027|Active Comparator|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
16707638|NCT01899027|Placebo Comparator|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
16707639|NCT01899001|Experimental|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
16707640|NCT01899001|Other|Nutrition Counseling|16 weeks of Nutrition Counseling alone
16707641|NCT01898975||500ml fluid loading|All enrolled patients
16707642|NCT01898962|Experimental|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
16707643|NCT01898949|Experimental|Cold Exposure|
16707644|NCT01898936|Experimental|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.
~The laser settings will be as follows:
~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
16707645|NCT01898936|Sham Comparator|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
16707646|NCT01898923|Experimental|ON101 Cream|ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
16707647|NCT01898923|Other|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
16707648|NCT01898910|Active Comparator|PVI+renal denervation+OMT|
16707649|NCT01898910|Active Comparator|PVI+GP ablation+OMT|
16707650|NCT01898897|Active Comparator|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.
~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
16707651|NCT01898897|Experimental|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
16707652|NCT01898884|Experimental|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
16707653|NCT01898884|Experimental|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
16707654|NCT01898871|Experimental|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
16707655|NCT01898871|Active Comparator|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
16707656|NCT01898858||HYPOXIA|
16707657|NCT01898858||HYPERCAPNIA|
16707658|NCT01898858||HYPOXIA + HYPERCAPNIA|
16707659|NCT01898845|Experimental|LEE011|LEE011
16707660|NCT01898819|Experimental|dexmedetomidine|dexmedetomidine infusion from beginning of the anesthesia to just before returning to horizontal position
16707661|NCT01898819|Placebo Comparator|saline|Saline infusion from same time period.
16707662|NCT01898806|Experimental|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
16707663|NCT01898806|Experimental|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
16707664|NCT01898806|Experimental|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
16707665|NCT01898806|Placebo Comparator|Placebo|"Intralesional Saline (Placebo):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
16707666|NCT01898793|Experimental|Phase I: 0.5 x 10^6/kg CIML NK cells (Dose Levels 1-3)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
16707667|NCT01898793|Experimental|Lead-in Cohort & Phase II (ALT-803): Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
~Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
16707668|NCT01898793|Experimental|Pediatric Cohort: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
~Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses"
16707669|NCT01898793|Experimental|Phase II (IL-2): Maximum NK cell/number kg|The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
16707670|NCT01898780|Experimental|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
16707671|NCT01898780|Experimental|interrupted suture|pancreaticojejunostomy with interrupted suture
16707672|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of >70% predicted.
16707673|NCT01898754|Experimental|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
16707674|NCT01898754|No Intervention|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
16707675|NCT01898741|Experimental|irradiation|24 Gy in 3 fractions
16707676|NCT01898728|Active Comparator|Liquid preoperative medications|Liquid preoperative medications
16707677|NCT01898728|Active Comparator|Gel preoperative medications|Gel preoperative medications
16707678|NCT01898715|Experimental|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
16707679|NCT01898702|Experimental|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
16707680|NCT01898702|Placebo Comparator|No intervention|Don't participate in a scheduled and standardized expert patients programme course
16707681|NCT01898689|Experimental|RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
16707682|NCT01898689|Active Comparator|RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.
16707683|NCT01898676|Active Comparator|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
16707684|NCT01898676|Active Comparator|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
16707685|NCT01898663|Experimental|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DCs + CIK cells
16707686|NCT01898650|Experimental|craniofacial abnormalities|Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.
16707687|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
16707688|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
16707689|NCT01898624||Betanis group|mirabegron treated group
16707690|NCT01898611|Active Comparator|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
16707691|NCT01898611|Placebo Comparator|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
16707692|NCT01898598|Placebo Comparator|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
16707693|NCT01898598|Experimental|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
16707694|NCT01898585|Experimental|Zelboraf Arm|
16707695|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
16707696|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
16707697|NCT01898559|Experimental|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black & Mild little cigars.
~Other: Switch to smoking only little cigars"
16707698|NCT01898559|Experimental|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.
~Other: Switch to smoking only little cigars"
16707699|NCT01898546|Experimental|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
16707700|NCT01898546|Active Comparator|Primary angioplasty|Primary angioplasty alone
16707701|NCT01898520|Active Comparator|Sativex|Oromucosal spray containing delta-9-tetrahydrocannabinol (THC) (27 mg/mL):cannabidiol (CBD) (25 mg/mL). Each 100 μL spray to the sub-lingual or oral mucosa delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
16707702|NCT01898520|Placebo Comparator|Placebo|Oromucosal spray containing ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum number of daily sprays was 12.
16707703|NCT01898507|Experimental|Low nicotine cigarettes|"Participants will smoke their own brand cigarettes during a baseline 5 day period, followed by a 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
~Other: Low nicotine cigarettes"
16707704|NCT01898494|Experimental|Arm A (TOS)|Patients undergo transoral surgical resection of the oropharyngeal tumor.
16707705|NCT01898494|Experimental|Arm B (TOS, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose IMRT QD five days a week for 5 weeks.
16707706|NCT01898494|Experimental|Arm C (TOS, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.
16707707|NCT01898494|Experimental|Arm D (TOS, standard-dose IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
16707708|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
16707709|NCT01898468|Active Comparator|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
16707710|NCT01898468|Active Comparator|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
16707711|NCT01898455|Experimental|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
16707712|NCT01898442|Active Comparator|Ticagrelor 180|Standard ticagrelor 180mg loading dose
16707713|NCT01898442|Experimental|Ticagrelor 270mg|High ticagrelor 270mg loading dose
16707714|NCT01898442|Experimental|Ticagrelor 360mg|High ticagrelor 360mg loading dose
16707715|NCT01898429|Active Comparator|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
16707716|NCT01898429|Active Comparator|Right-sided SCC DBS|Active stimulation of the right-sided electrode
16707717|NCT01898416|Experimental|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
16707718|NCT01898403|Experimental|Sentinel Lymph Node (SLN) Detection|All patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution for detection of melanoma in lymph nodes. In addition, lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) will be conducted for all participants with the same objective.
16707719|NCT01898390|Experimental|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
16707720|NCT01898390|No Intervention|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
16707721|NCT01898377|Experimental|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd
~Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)
~Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
16707722|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
16707723|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
16707724|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
16707725|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
16707726|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
16707727|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
16707728|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.
~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.
~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
16707729|NCT01898338|Experimental|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
16707730|NCT01898338|Active Comparator|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
16707731|NCT01898325|Other|Naïve GD patients|"Naïve GD patients
~Intervention: device - Fibroscan"
16707732|NCT01898325|Other|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
16707733|NCT01898325|Other|Healthy control|Healthy control Intervention: device - Fibroscan
16707734|NCT01898325|Other|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
16707735|NCT01898312|Experimental|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
16707736|NCT01898312|Placebo Comparator|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
16707737|NCT01898299|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
16707738|NCT01898299|Sham Comparator|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
16707739|NCT01898286|Experimental|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
16707740|NCT01898273|Experimental|Single|I-124-CLR1404, open-label
16707741|NCT01898260|Other|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
16707742|NCT01898260|Other|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
16707743|NCT01898247|No Intervention|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
16707744|NCT01898247|Experimental|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
16707745|NCT01898234|Experimental|Revaclear|
16707746|NCT01898234|Experimental|Helixone high flux|
16707747|NCT01898234|Experimental|Xevonta|
16707748|NCT01898234|Experimental|Helixone low flux|
16707749|NCT01898221|Active Comparator|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
16707750|NCT01898221|Active Comparator|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
16707751|NCT01898208|Experimental|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
16707752|NCT01898208|Experimental|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
16707753|NCT01898208|Experimental|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
16707754|NCT01898195|Active Comparator|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
16707755|NCT01898195|Experimental|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
16707756|NCT01898195|Experimental|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
16708113|NCT01895803||smoking woman 18-60 years old|
16707757|NCT01898182|Experimental|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
16707758|NCT01898169|Experimental|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
16707759|NCT01898156|Experimental|BIW-8962|"Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur
~Phase 2 - Recommended dose determined in Phase 1"
16707760|NCT01898143|Other|Whole body vibration in COPD|Patients with COPD GOLD III or IV
16707761|NCT01898143|Other|Whole body vibration in ILD|PAtients with interstitial lung disease
16707762|NCT01898130|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16707767|NCT01898104|Active Comparator|SCRT|short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.
16707768|NCT01898104|Active Comparator|V-SCRT|Valproic acid (V) + short course radiotherapy
16707769|NCT01898104|Active Comparator|C-SCRT|capecitabine (C) + short course radiotherapy
16707770|NCT01898104|Active Comparator|VC-SCRT|valproic acid + capecitabine + short course radiotherapy
16707771|NCT01898091|Experimental|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
16707772|NCT01898091|Placebo Comparator|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
16707773|NCT01898078|Experimental|Alisertib 50 mg Fed + Fasted|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
16707774|NCT01898078|Experimental|Alisertib 50 mg Fasted + Fed|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
16707775|NCT01898065|Experimental|PET imaging, 18 F-miso|Single Arm study
16707776|NCT01898052|Experimental|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
16707777|NCT01898052|Active Comparator|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
16707778|NCT01898039|Experimental|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.
~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
16707779|NCT01898026|Experimental|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
16707780|NCT01898026|Other|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
16707781|NCT01898013|Active Comparator|Pregnenolone|"Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:
~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued."
16707782|NCT01898013|Placebo Comparator|Placebo|"Placebo will be administered exactly the same as the active comparator (pregnenolone) and will consist of the following schedule:
~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): placebo PO, BID x 1 week, Visit 4 (week 2): placebo PO, BID x 1 week, Visit 5 (week 3): placebo PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered in the exact manner as active study medication and then discontinued."
16707783|NCT01897987|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
16707784|NCT01897987|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
16707785|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
16737563|NCT01698112|Experimental|Flaxseed Low Dose|
16707786|NCT01897961|Other|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
16707787|NCT01897961|Other|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
16707788|NCT01897961|Other|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
16707789|NCT01897948|Experimental|Milk-based beverage with DHA at mid-level|
16707790|NCT01897948|Experimental|Milk-based beverage with DHA at high level|
16707791|NCT01897948|Active Comparator|Milk-based beverage without DHA|
16707792|NCT01897922|Active Comparator|Marketed routine infant formula|
16707793|NCT01897922|Experimental|Infant formula containing a probiotic source|
16707794|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
16707795|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
16707796|NCT01897909||HIV negative|HIV negative blood donors
16707797|NCT01897896|Experimental|Rollover Cohort: SD-809 ER|Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
16707798|NCT01897896|Experimental|Switch Cohort: SD-809 ER|Participants who were receiving an approved dosing regimen of tetrabenazine for at least 8 weeks prior to screening, will be converted overnight from their existing tetrabenazine regimen to SD-809 ER regimen to achieve targeted steady-state area under the curve (AUC) of total (alpha+beta)- Dihydrotetrabenazine (HTBZ) metabolites that is predicted to be comparable to that of participant's prior tetrabenazine regimen. Participants will remain on initial dose of SD-809 ER through Week 1. Dose adjustment will be continued through Week 4 to optimize the dose. Dose of SD-809 ER can be adjusted weekly (upward or downward) in increments of 6 mg per day (6 mg/day or 12 mg/day after a total daily dose of 48 mg is reached), based on chorea control and treatment regimen tolerability. Long-term treatment with SD-809 ER at a stable dose (although further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
16707799|NCT01897883||One Group|Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
16707800|NCT01897870|Experimental|HomeCoMe-program group|the arm receiving the pharmacist home visit
16707801|NCT01897857|Experimental|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
16707802|NCT01897857|Active Comparator|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
16707803|NCT01897844|Experimental|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
16707804|NCT01897844|Experimental|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
16707805|NCT01897844|Experimental|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
16707806|NCT01897831|Experimental|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
16707807|NCT01897818|Experimental|ALS patients|
16707808|NCT01897805|Experimental|Heart-protecting Musk Pill|Patients will get standard treatment for coronary artery disease plus 2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months
16707809|NCT01897805|Placebo Comparator|Placebo|Patients will get standard treatment for coronary artery disease plus 2 placebo pills each time, three times a day by mouth for 24 months
16707810|NCT01897792|Experimental|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
16707811|NCT01897792|Placebo Comparator|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
16707812|NCT01897779|Experimental|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
16707813|NCT01897779|Experimental|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
16707814|NCT01897779|Placebo Comparator|Normal Saline|Single and multiple dose of normal saline
16707815|NCT01897779|Experimental|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
16707816|NCT01897766||Somatropin|Patients administered Somatropin.
16707817|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
16707818|NCT01897727|Active Comparator|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP > 140/90 mm Hg throughout the 3 month study.
16707819|NCT01897727|Sham Comparator|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP < 140/90 mm Hg throughout the study.
16707820|NCT01897714|Experimental|Phase I: Melflufen 15 mg + Dexamethasone|Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
16707821|NCT01897714|Experimental|Phase I: Melflufen 25 mg + Dexamethasone|IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
16707934|NCT01897077|Experimental|Peanut Allergic|Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
16707822|NCT01897714|Experimental|Phase I: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
16707823|NCT01897714|Experimental|Phase I: Melflufen 55 mg + Dexamethasone|IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
16707824|NCT01897714|Experimental|Phase I + II: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
16707825|NCT01897714|Experimental|Phase II: Melflufen 40 mg (Single Agent)|IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
16707826|NCT01897701|Experimental|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
16707827|NCT01897701|Experimental|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
16707828|NCT01897701|Experimental|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & 21
16707829|NCT01897701|Experimental|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & Day 21
16707830|NCT01897701|Experimental|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
16707831|NCT01897701|Experimental|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
16707832|NCT01897701|Experimental|Group G|Placebo; IM; Day 0 & 21
16707833|NCT01897688|Experimental|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
16707834|NCT01897675|Active Comparator|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
16707835|NCT01897675|Experimental|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
16707836|NCT01897662|Experimental|NUTRIOSE|Group of volunteers fed with NUTRIOSE
16707837|NCT01897662|Active Comparator|GLUCIDEX|Group of volunteers fed with GLUCIDEX
16707838|NCT01897649|Experimental|NUTRIOSE|group of volunteers fed with NUTRIOSE
16707839|NCT01897649|Active Comparator|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
16707840|NCT01897636|Experimental|EUS-guided fine-needle injection of DCs vaccinations|
16707841|NCT01897623|Other|ultrasound of aorta|
16707842|NCT01897610|No Intervention|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
16707843|NCT01897610|Experimental|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
16707844|NCT01897597|Experimental|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
16707845|NCT01897597|Experimental|BI 144807 PfoS Treatment C|high dose of BI 144807
16707846|NCT01897597|Experimental|BI 144807 Tab Treatment B|intermediate dose of BI 144807
16707847|NCT01897597|Experimental|BI 144807 Tab Treatment D|high dose of BI 144807
16707848|NCT01897597|Experimental|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
16707849|NCT01897597|Experimental|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
16707850|NCT01897597|Experimental|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
16707851|NCT01897584|Experimental|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
16707852|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 1|This portion comprises dose escalation and dose expansion to establish the recommended Phase 2 dose (RP2D) when tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as well as the drug-drug interaction (DDI) potential of tazemetostat are evaluated. CLOSED TO ENROLLMENT
16707853|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 2|This portion is restricted to subjects with DLBCL or FL for the determination of efficacy and safety of tazemetostat monotherapy and tazemetostat in combination with prednisolone as defined by histology, cell of origin and EZH2 mutation status.
16707854|NCT01897558|Active Comparator|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
16707855|NCT01897558|Active Comparator|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
16707856|NCT01897545|Active Comparator|PV isolation|
16707857|NCT01897545|Active Comparator|PV isolation+renal denervation|
16707858|NCT01897532|Experimental|Linagliptin|
16707859|NCT01897532|Placebo Comparator|Placebo|
16707860|NCT01897519|Experimental|Arm 1 lower dose ABT-719|
16707861|NCT01897519|Experimental|Arm 2 intermediate dose ABT-719|
16707862|NCT01897519|Experimental|Arm 3 high dose ABT-719|
16707863|NCT01897519|Placebo Comparator|Arm 4 Placebo|
16707864|NCT01897493|Active Comparator|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
16707865|NCT01897493|Experimental|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
16707866|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.
~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
16708150|NCT01895582||Non active TB-infected patients (other diagnosis)|same symptoms than two others groups but an other diagnosis
16707867|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.
~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
16707868|NCT01897467|Placebo Comparator|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
16707869|NCT01897467|Experimental|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.
~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
16707870|NCT01897454|Experimental|Treatment (FOLFIRINOX, IMRT, and gemcitabine hydrochloride)|"CHEMOTHERAPY REGIMEN: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on day 1, and fluorouracil IV over 46 hours on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving disease progression proceed to chemoradiotherapy.
~CHEMORADIOTHERAPY REGIMEN: Beginning 4-6 weeks after completion of chemotherapy, patients undergo IMRT on 5 consecutive days per week for a total of 28 fractions and receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity."
16707871|NCT01897441|Experimental|Stratum A (HER2-positive disease)|Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks
16707872|NCT01897441|Experimental|Stratum B (paclitaxel followed by AC)|Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.
16707873|NCT01897441|Experimental|Stratum C (AC followed by paclitaxel)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
16707874|NCT01897428|Active Comparator|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
16707875|NCT01897428|Experimental|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
16707876|NCT01897415|Experimental|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
16707877|NCT01897402|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
16707878|NCT01897402|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
16707879|NCT01897389|Experimental|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
16707880|NCT01897389|Experimental|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
16707881|NCT01897389|Experimental|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
16707882|NCT01897389|Experimental|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
16707883|NCT01897389|Experimental|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
16707884|NCT01897389|Experimental|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
16707885|NCT01897389|Experimental|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
16707886|NCT01897389|Experimental|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
16707887|NCT01897376|Other|Pfannenstiel incision|
16707888|NCT01897376|Other|vertical skin incision|
16707889|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
16707890|NCT01897350||CMR following ST segment myocardial infarction|
16707891|NCT01897337|Experimental|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
16707892|NCT01897337|Placebo Comparator|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
16707893|NCT01897324|Experimental|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
16707894|NCT01897324|Experimental|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
16707895|NCT01897324|Experimental|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
16707935|NCT01897077|Active Comparator|Healthy Volunteers|Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
16708149|NCT01895582||Non active TB-infected patients (already met TB)|some of elders have already met M tuberculosis before active antibiotherapy exists
16707896|NCT01897324|Experimental|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
16707897|NCT01897311|Experimental|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
16707898|NCT01897311|Experimental|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
16707899|NCT01897311|Placebo Comparator|Placebo with TENS off|TENS application when off
16707900|NCT01897298|Experimental|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
16707901|NCT01897298|No Intervention|Usual care|Patients will continue their usual care
16707902|NCT01897285|Experimental|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
16707903|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
16707904|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
16707905|NCT01897259|Active Comparator|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
16707906|NCT01897259|Active Comparator|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
16707907|NCT01897259|Placebo Comparator|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
16707908|NCT01897259|Active Comparator|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
16707909|NCT01897246|Active Comparator|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
16707910|NCT01897246|Active Comparator|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
16707911|NCT01897233|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.
~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.
~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
16707912|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
16707913|NCT01897207|Experimental|Dendritic cell application|
16707914|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
16707915|NCT01897181|Active Comparator|Hearing aids|Patients who agree to use hearing aids
16707916|NCT01897181|No Intervention|No hearing aids|Patients who did not agree to use hearing aids
16707917|NCT01897168||No grouping|
16707918|NCT01897155|Other|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
16707919|NCT01897155|Other|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
16707920|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 1|
16707921|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 2|
16707922|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 3|
16707923|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 4|
16707924|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 5|
16707925|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 6|
16707926|NCT01897129||Early pregnancy|Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
16707927|NCT01897129||Chorionic villous sampling|Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
16707928|NCT01897129||Spontaneous abortion|Women with miscarriage at a gestational age up to 22 weeks
16707929|NCT01897129||Preterm birth|Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
16707930|NCT01897129||Vaginal delivery at term|Women with spontaneous vaginal delivery at term (week 37+0-)
16707931|NCT01897129||Elective ceaserean section at term|Women undergoing elective cesarean section at term (week 37+0-)
16707932|NCT01897090|Experimental|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
16707933|NCT01897090|Active Comparator|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
16707936|NCT01897064|Experimental|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
16707937|NCT01897064|Active Comparator|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
16707938|NCT01897051|Experimental|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
16707939|NCT01897051|Placebo Comparator|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
16707940|NCT01897038|Experimental|Cohort 1 (Onartuzumab)|
16707941|NCT01897038|Experimental|Cohorts 2/3 (Onartuzumab + Sorafenib)|
16707942|NCT01897025|Active Comparator|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.
~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.
~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
16707943|NCT01897025|Sham Comparator|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:
~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.
~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
16707944|NCT01897012|Experimental|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
16707950|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)
~Subgroups:
~receiving immunosuppressant therapy
~not on immunosuppressant therapy"
16707951|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.
~Subgroups:
~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
16707952|NCT01896973|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
16707953|NCT01896960|Active Comparator|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
16707954|NCT01896960|Active Comparator|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
16707955|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
16707956|NCT01896934|Experimental|Sertraline|50-200mg daily
16707958|NCT01896908|Experimental|Intervention|Sodium restriction (1.6g sodium daily - 4g salt) combined with 800 ml of fluid intake
16707959|NCT01896908|No Intervention|Control|Normal sodium diet (4g sodium daily - 10g salt) and free fluid intake
16707960|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
16707961|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
16707962|NCT01896895|Placebo Comparator|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.
~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
16707963|NCT01896882|Experimental|Intervention|Nutritional education on sodium restriction diet.
16707964|NCT01896882|No Intervention|Control|Standard treatment.
16707965|NCT01896869|Experimental|Ipilimumab + Vaccine (Arm A)|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
16707966|NCT01896869|Experimental|FOLFIRINOX (Arm B)|Administered every 14 days (one cycle)
16707967|NCT01896856|Experimental|Phase 1: Dose Escalation|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.
~Various doses of SGI-110 are tested to determine the maximum tolerated dose in combination with irinotecan."
16707968|NCT01896856|Experimental|Phase 2: Arm A SGI-110 + irinotecan|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.
~Growth factor support (filgrastim and peg-filgrastim) is given during cycle 1 with option to give additional growth factor support at subsequent cycles per clinician judgement."
16707969|NCT01896856|Active Comparator|Phase 2: Arm B regorafenib or TAS-102|"Subjects received either regorafenib or TAS-102 based on physician and patient preference. Subjects that had received one of these standard of care drugs (regorafenib or TAS-102) prior to enrollment received the other on study.
~Regorafenib taken daily from days 1-21 of each 28-day cycle or TAS-102 taken twice daily on days 1-5 and 8-12 of each 28-day cycle.
~Subjects who had disease progression on Arm B were given the option to receive Arm A study drugs after a 14 day wash-out period."
16707970|NCT01896830|Experimental|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
16707971|NCT01896830|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
16707972|NCT01896791|Active Comparator|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
16707973|NCT01896791|Placebo Comparator|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
16707974|NCT01896778|Experimental|Arm I (B-WARM for 30 minutes)|Patients undergo B-WARM at 39 degrees C for 30 minutes.
16707975|NCT01896778|Experimental|Arm II (B-WARM for 2 hours)|Patients undergo B-WARM at 39 degrees C for 2 hours.
16707976|NCT01896765|Experimental|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
16707977|NCT01896765|Other|Usual care|Standard care with respect to medical and interventional therapy.
16707978|NCT01896739|Experimental|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
16707979|NCT01896739|Active Comparator|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
16707980|NCT01896739|Experimental|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
16707981|NCT01896739|Active Comparator|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
16707982|NCT01896726|Experimental|Baricitinib + Microgynon|Microgynon [30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
16707983|NCT01896713|Other|Diagnostic: Single Arm|Imaging (MS3TMRI)
16707984|NCT01896700|Experimental|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.
~Other name: Ritalin"
16707985|NCT01896700|Placebo Comparator|Placebo|Placebo pill, bid for 6 weeks
16707986|NCT01896687|Experimental|Scrambler therapy|Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
16707987|NCT01896687|Sham Comparator|Sham Scrambler treatment|Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days
16707988|NCT01896661|Experimental|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
16707989|NCT01896661|Active Comparator|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
16707990|NCT01896648||Type 2 diabetic women|
16707991|NCT01896635|Active Comparator|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
16707992|NCT01896635|Placebo Comparator|Placebo arm|Placebo infusions
16707993|NCT01896622|Experimental|A|Ritonavir
16707994|NCT01896622|Experimental|B|Cobicistat
16707995|NCT01896609|Experimental|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:
~Reiferon Retard® 160 µg /week subcutaneous injection.
~Ribavirin in a dose of 13 mg/kg/day orally"
16707996|NCT01896609|Experimental|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;
~Reiferon Retard® 160 µg /week subcutaneous injection
~Ribavirin in a dose of 13 mg/kg/day orally
~Xerovirinc® 500mg twice daily orally."
16707997|NCT01896609|Experimental|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:
~Bon-One ® 0.5 µg daily orally
~Reiferon Retard® 160 µg /week subcutaneous injection
~Ribavirin in a dose of 13 mg/kg/day orally
~Xerovirinc® 500mg twice daily orally."
16707998|NCT01896596|Active Comparator|Menjugate|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menjugate (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
16707999|NCT01896596|Active Comparator|Menitorix|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menitorix (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
16708000|NCT01896596|Active Comparator|NeisVac-C|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with NeisVac-C(at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
16708001|NCT01896583|Experimental|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
16708002|NCT01896583|Placebo Comparator|Placebo|oral
16708003|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
16708004|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
16708005|NCT01896557|Experimental|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
16708006|NCT01896557|Experimental|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
16708010|NCT01896531|Experimental|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
16708011|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
16708012|NCT01896518|No Intervention|Counseling|
16708013|NCT01896518|Experimental|Nicotine lozenge|Participants will receive nicotine lozenge to use as needed for 12 weeks.
16708014|NCT01896518|Experimental|Tobacco lozenge|Participants will receive tobacco lozenge to use as needed for 12 weeks.
16708015|NCT01896505|Experimental|Arm 1 - Treatment A, B, C, D|"There are 4 treatment formulations of KCP-330:
~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation
~In Arm 1, the following order will be utilized:
~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C Week 4, day 1: Treatment D
~(Note that recruitment has been completed for this arm)"
16708016|NCT01896505|Experimental|Arm 2 - Treatment B, A, D, C|"There are 4 treatment formulations of KCP-330:
~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation
~In Arm 2, the following order will be utilized:
~Week 1, day 1: Treatment B Week 2, day 1: Treatment A Week 3, day 1: Treatment D Week 4, day 1: Treatment C
~(Note that recruitment has been completed for this arm)"
16708017|NCT01896505|Experimental|Arm 3|"To evaluate tumor response in sarcoma patients (RECIST v1.1 criteria) on KCP-330.
~(Note that recruitment has been completed for this arm)"
16708018|NCT01896505|Experimental|Arm 4 - Treatment A, B, C|"There are 3 treatment formulations of KCP-330:
~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg
~In Arm 4, the following order will be utilized:
~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C"
16708019|NCT01896505|Experimental|Arm 5 - Treatment C, A, B|"There are 3 treatment formulations of KCP-330:
~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg
~In Arm 5, the following order will be utilized:
~Week 1, day 1: Treatment C Week 2, day 1: Treatment A Week 3, day 1: Treatment B"
16708020|NCT01896505|Experimental|Arm 6 - Treatment B, C, A|"There are 3 treatment formulations of KCP-330:
~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg
~In Arm 6, the following order will be utilized:
~Week 1, day 1: Treatment B Week 2, day 1: Treatment C Week 3, day 1: Treatment A"
16708021|NCT01896492|Active Comparator|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
16708022|NCT01896492|Placebo Comparator|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
16708023|NCT01896492|No Intervention|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
16708024|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
16708025|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
16708026|NCT01896466|Active Comparator|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
16708027|NCT01896466|Active Comparator|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
16708028|NCT01896466|Active Comparator|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
16708029|NCT01896466|Sham Comparator|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
16708030|NCT01896466|Experimental|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
16708031|NCT01896466|Active Comparator|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
16708032|NCT01896453|Active Comparator|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
16708033|NCT01896453|Experimental|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
16708034|NCT01896453|Experimental|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
16708035|NCT01896453|Sham Comparator|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
16708036|NCT01896440|Active Comparator|Group A - standard ondansetron dose first|Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.
16708037|NCT01896440|Active Comparator|Group B - high dose ondansetron first|Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.
16708038|NCT01896427|Active Comparator|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
16708039|NCT01896427|Active Comparator|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
16708040|NCT01896414|Experimental|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
16708041|NCT01896414|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
16708042|NCT01896401|Experimental|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
16708043|NCT01896388|Active Comparator|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
16708044|NCT01896388|Placebo Comparator|Placebo|Oral Administration of Placebo (After breakfast, After supper)
16708045|NCT01896349|Experimental|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.
~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
16708046|NCT01896349|Active Comparator|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.
~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
16708047|NCT01896336|Experimental|5mg sublingual Zolpidem hemitartrate|1 QD
16708048|NCT01896336|Active Comparator|10 mg oral Zolpidem hemitartrate|1 QD.
16708049|NCT01896323|Experimental|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
16708050|NCT01896323|Active Comparator|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
16708051|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
16708052|NCT01896297|Other|dabigatran etexilate|75mg BID by oral
16708053|NCT01896284|Experimental|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
16708054|NCT01896271|Experimental|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
16708055|NCT01896258||Regional emergency centers|
16708056|NCT01896258||Local emergency centers|
16708057|NCT01896245|Active Comparator|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
16708058|NCT01896245|Active Comparator|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
16708059|NCT01896245|Active Comparator|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
16708060|NCT01896232|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
16708061|NCT01896232|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
16708062|NCT01896219|Active Comparator|Gesture performed under control tomodensitometric (CT)|Conventional
16708063|NCT01896219|Experimental|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
16708064|NCT01896206|Experimental|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
16708065|NCT01896193|Experimental|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
16708066|NCT01896193|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
16708067|NCT01896180|Experimental|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
16708068|NCT01896180|Active Comparator|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
16708069|NCT01896167|Active Comparator|Hypoxia|Inhalation of air with 8-12% oxygen content
16708070|NCT01896167|Placebo Comparator|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
16708071|NCT01896154|Experimental|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
16708072|NCT01896154|Experimental|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
16708073|NCT01896154|Experimental|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
16708074|NCT01896154|Experimental|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
16708075|NCT01896154|Experimental|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
16708076|NCT01896154|Placebo Comparator|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
16708077|NCT01896128|Experimental|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
16708078|NCT01896128|Placebo Comparator|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
16708079|NCT01896115|Experimental|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
16708080|NCT01896115|Experimental|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
16708081|NCT01896115|Experimental|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
16708082|NCT01896115|Experimental|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
16708083|NCT01896102|Experimental|Lenti-D Drug Product|
16708084|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
16708085|NCT01896063|Experimental|Electroacupuncture preconditioning|
16708086|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
16708087|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
16708088|NCT01896037|Experimental|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
16708089|NCT01896024|Active Comparator|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
16708090|NCT01896024|Experimental|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
16708091|NCT01896011|Active Comparator|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
16708092|NCT01896011|Placebo Comparator|Placebo|Placebo injection pen identical to active drug injection pen
16708093|NCT01895985|Experimental|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
16708094|NCT01895972|Experimental|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
16708095|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
16708096|NCT01895946|Experimental|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
16708097|NCT01895946|Experimental|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
16708098|NCT01895933|Active Comparator|Active / control|One side has been treated with SurgiShield
16708099|NCT01895933|No Intervention|No intervention|One side has no intervention
16708100|NCT01895920|Experimental|HIV infection|20 HIV infected subjects
16708101|NCT01895907||Special Olympic athletes|
16708102|NCT01895894|Experimental|Mycophenolate mofetil|
16708103|NCT01895894|No Intervention|Control|
16708104|NCT01895881|Experimental|Estradiol Daily|1 mg Estradiol daily for 180 days.
16708105|NCT01895881|Placebo Comparator|Placebo|Placebo for 180 days.
16708106|NCT01895868|Active Comparator|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
16708107|NCT01895868|No Intervention|Control|Clinical training alone.
16708108|NCT01895855|Experimental|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU
16708109|NCT01895855|Placebo Comparator|Placebo|Biological: Placebo physiological saline
16708110|NCT01895842|Experimental|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.
~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
16708111|NCT01895829|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.
~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
16708112|NCT01895816|Experimental|fertility coated tablet|700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
16708114|NCT01895790|Experimental|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
16708115|NCT01895777|Experimental|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
16708116|NCT01895777|Active Comparator|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
16708117|NCT01895764|Active Comparator|Adalimumab|adalimumab 40mg every 2 weeks
16708118|NCT01895764|Experimental|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
16708119|NCT01895751|No Intervention|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:
~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.
~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
16708120|NCT01895751|Active Comparator|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
16708121|NCT01895738|Experimental|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
16708122|NCT01895738|No Intervention|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
16708123|NCT01895712||Orsiro|
16708124|NCT01895699|Experimental|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
16708125|NCT01895699|Placebo Comparator|Placebo group|
16708126|NCT01895699|Other|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
16708127|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
16708128|NCT01895686||Narrow angle|patients diagnosed with narrow angles
16708129|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
16708130|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
16708131|NCT01895660|Experimental|Group with continuous constraint and daily therapy|
16708132|NCT01895660|Experimental|Group with continuous constrainit and 3 days a week therapy|
16708133|NCT01895660|Experimental|Group with part-time constraint and daily therapy|
16708134|NCT01895660|Experimental|Group with part-time constraint and 3 days a week therapy|
16708135|NCT01895660|Active Comparator|Usual and customary treatment group|
16708136|NCT01895647|Experimental|Biceps stimulation|EMS
16708137|NCT01895647|Experimental|Quadriceps stimulation|EMS
16708138|NCT01895647|No Intervention|Control|Control group without electric muscle stimulation
16708139|NCT01895634|Experimental|Treatment|Intervention Device: Rev-01
16708140|NCT01895621|Experimental|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
16708141|NCT01895621|Placebo Comparator|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
16708142|NCT01895608|Experimental|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
16708143|NCT01895608|Active Comparator|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
16708144|NCT01895608|Experimental|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
16708145|NCT01895608|Active Comparator|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
16708146|NCT01895595|Experimental|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
16708147|NCT01895595|Active Comparator|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
16708148|NCT01895582||Active TB-infected patients|TB-infected patients with bacteriological and histological evidences
16737564|NCT01698112|No Intervention|Flaxseed control|
16708151|NCT01895569|Experimental|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
16708152|NCT01895556|Experimental|Information|Information about male circumcision and HIV risk
16708153|NCT01895556|Placebo Comparator|Control|Control
16708154|NCT01895543|Experimental|EBX10|Elobixibat 10 mg
16708155|NCT01895530|No Intervention|Control group|Conventional treatment with no probiotic supplementation
16708156|NCT01895530|Experimental|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
16708157|NCT01895517|Active Comparator|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
16708158|NCT01895517|Experimental|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
16708159|NCT01895504|Experimental|ColoAssist|Screening colonoscopy with a new colonoscope with gradual stiffness
16708160|NCT01895504|Active Comparator|MEI|Screening colonoscopy with colonoscopes compatible with and guided by MEI
16708161|NCT01895491|Experimental|CohortⅠ|VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle
16708162|NCT01895491|Experimental|CohortⅡ|VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle
16708163|NCT01895491|Experimental|CohortⅢ|VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle
16708164|NCT01895478|Experimental|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
16708165|NCT01895478|No Intervention|Control|Control attendings were not given the PACCI-ED use intervention.
16708166|NCT01895465|Experimental|A slitted diaper|An ordinary pediatric urine collection bag used in the ED that will be used together with the slitted diaper
16708167|NCT01895452|Experimental|ALKS 9072, Low Dose|
16708168|NCT01895452|Experimental|ALKS 9072, High Dose|
16708169|NCT01895439|Experimental|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
16708170|NCT01895413|Experimental|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
16708171|NCT01895400|Active Comparator|Renexin|Renexin 1T bid for 12 weeks
16708172|NCT01895400|Placebo Comparator|Placebo|Placebo 1T bid for 12 weeks
16708173|NCT01895387|Experimental|Whole grains and legumes|
16708174|NCT01895387|Placebo Comparator|Refined rice|
16708175|NCT01895374|Experimental|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
16708176|NCT01895374|Active Comparator|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
16708177|NCT01895361|Experimental|High-dose SelG1 (Selg1 5.0 mg/kg)|IV Infusion, once every 4 weeks through Week 50
16708178|NCT01895361|Experimental|Low-dose SelG1 (Selg1 2.5 mg/kg)|IV Infusion, once every 4 weeks through Week 50
16708179|NCT01895361|Placebo Comparator|Placebo|IV Infusion, once every 4 weeks through Week 50
16708180|NCT01895348|Active Comparator|propofol only|
16708181|NCT01895348|Active Comparator|propofol-remifentanil|
16708182|NCT01895348|Active Comparator|dexmedetomidine-remifentanil|
16708183|NCT01895335|Experimental|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
16708184|NCT01895322|Experimental|OPC-41061|
16708185|NCT01895309|Experimental|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
16708186|NCT01895309|Active Comparator|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
16708187|NCT01895296|Experimental|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
16708188|NCT01895296|Placebo Comparator|Placebo|saline s.c. t.i.d.
16708189|NCT01895283|Experimental|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
16708190|NCT01895270|Experimental|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
16708191|NCT01895270|Placebo Comparator|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
16708192|NCT01895257|Active Comparator|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
16708193|NCT01895257|Active Comparator|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
16708194|NCT01895244|Experimental|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
16708195|NCT01895244|Experimental|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
16708196|NCT01895231|Experimental|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
16708197|NCT01895231|Placebo Comparator|Placebo|0.9 % saline Infusion over 15 min
16708198|NCT01895218|Experimental|Iron isomaltoside 1000 (Monofer®)|
16708199|NCT01895218|Active Comparator|Standard medical Care|
16708200|NCT01895205|Experimental|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
16708201|NCT01895205|Active Comparator|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:
~Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC
~Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
16708202|NCT01895192|Other|Fertile men|Assessment of sperm morphology by high magnification with interference contrast microscopy.
16708203|NCT01895179|Experimental|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
16708204|NCT01895179|Placebo Comparator|Grazing|Participants will eat meals spread out over the course of the day.
16708205|NCT01895166|Experimental|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
16708206|NCT01895166|Active Comparator|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
16708207|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
16708208|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
16708209|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
16708210|NCT01895140|Experimental|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
16708211|NCT01895140|Other|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
16708212|NCT01895127|Active Comparator|Standard of Care|"Plasmapheresis (PP) x 3, at 40-60 cc/kg.
~Immunoglobulin (IVIg), to be administered after each PP"
16708213|NCT01895127|Experimental|Soliris (eculizumab)|"1200 mg first dose (Time: Screening/Week 0, after Biopsy Proven AMR)
~900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)
~1200 mg week 5
~Week 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
16708214|NCT01895101|Placebo Comparator|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
16708215|NCT01895101|No Intervention|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
~In this arm the subjects receives as in standard care no pericardial lavage."
16708216|NCT01895101|Experimental|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
16708217|NCT01895088|Experimental|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
16708218|NCT01895075|Experimental|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
16708219|NCT01895075|Placebo Comparator|Normal saline|Normal saline inhalation 2ml tid
16708220|NCT01895062|Experimental|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
16708221|NCT01895062|No Intervention|no intervention|Routine care is administered without the application of cNEP.
16708222|NCT01895049|Active Comparator|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
16708223|NCT01895049|Experimental|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
16708224|NCT01895036|Experimental|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
16708225|NCT01895023|Experimental|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
16708226|NCT01895023|Active Comparator|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
16708227|NCT01895023|Placebo Comparator|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
16708228|NCT01895010|Experimental|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
16708229|NCT01895010|Active Comparator|tropisetron|treated with tropisetron 6mg before TACE
16708230|NCT01894997|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.
~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
16708231|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
16708232|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
16739474|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
16708233|NCT01894971|Experimental|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
16708234|NCT01894958|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
16708235|NCT01894958|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
16708236|NCT01894945||Patients with suspected lymphoma.|
16708237|NCT01894932|Experimental|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
16708238|NCT01894932|Experimental|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
16708239|NCT01894932|Experimental|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
16708240|NCT01894932|Experimental|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
16708241|NCT01894932|No Intervention|normal|normal, no intervention.
16708242|NCT01894932|No Intervention|Drug treatment remission patient|Drug treatment remission patient
16708243|NCT01894919|Experimental|2H3H511_V|In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
16708244|NCT01894919|No Intervention|2H3H511_NV|In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
16708245|NCT01894919|Experimental|3H5_11_V|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
16708246|NCT01894919|No Intervention|3H5_11_NV|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
16708247|NCT01894919|Experimental|68_11_V|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
16708248|NCT01894919|No Intervention|68_11_NV|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
16708249|NCT01894919|Experimental|02_2_5_V|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
16708250|NCT01894919|No Intervention|02_2_5_NV|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
16708251|NCT01894919|Experimental|02_6_10_V|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
16708252|NCT01894919|No Intervention|02_6_10_NV|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
16708253|NCT01894919|Experimental|NAIVE 123|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
16708254|NCT01894919|Experimental|NAIVE_4A|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
16708255|NCT01894919|Experimental|NAIVE_4B|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
16708256|NCT01894906|Placebo Comparator|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
16708257|NCT01894906|Experimental|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
16708258|NCT01894893||Breastfeeding mothers|
16708259|NCT01894880|Active Comparator|early SSC|Early SSC: bonding straight after birth
16708260|NCT01894880|Other|late SSC|late SSC: bonding after termination of operation
16708261|NCT01894867|Experimental|magnesium|will get magnesium for 6 weeks
16708262|NCT01894867|Placebo Comparator|placebo|will get placebo for 6 weeks
16708263|NCT01894854|No Intervention|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
16708264|NCT01894854|Active Comparator|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
16708265|NCT01894841|Experimental|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
16708266|NCT01894841|Other|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
16708267|NCT01894828|Active Comparator|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
16708268|NCT01894828|No Intervention|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
16708269|NCT01894815|Experimental|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
16708270|NCT01894815|Active Comparator|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
16708271|NCT01894815|Placebo Comparator|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.
~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
16708272|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
16708273|NCT01894789|Experimental|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
16708274|NCT01894789|Active Comparator|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
16708275|NCT01894776|Experimental|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin
~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily
~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
16708276|NCT01894763|Active Comparator|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
16708277|NCT01894763|Active Comparator|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
16708278|NCT01894750|Experimental|skill bulding Intevention|group-based skill building self-care program
16708279|NCT01894750|No Intervention|usual care|
16708280|NCT01894737|Placebo Comparator|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
16708281|NCT01894737|Experimental|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
16708282|NCT01894724|Experimental|NeuroSave Device|Targeted Hypothermia with NeuroSave Device
16708283|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
16708284|NCT01894685|Experimental|Mesalazine|Mesalazine, 3 grams once daily for six months
16708285|NCT01894685|Placebo Comparator|Placebo|Placebo, 3 grams, once daily for six months
16708286|NCT01894672|Experimental|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
16708287|NCT01894659|No Intervention|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
16708288|NCT01894659|Experimental|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
16708289|NCT01894659|Experimental|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
16708290|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
16708291|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
16708292|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
16708293|NCT01894633|Experimental|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
16708294|NCT01894633|Placebo Comparator|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
16708295|NCT01894620|Placebo Comparator|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
16708296|NCT01894620|Active Comparator|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
16708297|NCT01894607|Experimental|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.
~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.
~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
16708298|NCT01894594|Experimental|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
16708299|NCT01894581|Experimental|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
16708300|NCT01894581|Active Comparator|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
16708301|NCT01894568|Experimental|Insulin Peglispro|Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
16708302|NCT01894568|Active Comparator|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.
16708303|NCT01894555|Experimental|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
16708304|NCT01894542|Experimental|Cod protein from presscake|
16708305|NCT01894542|Experimental|Cod protein from presscake + stickwater|
16739780|NCT01683097|No Intervention|Control|Questionnaire
16708306|NCT01894542|Placebo Comparator|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
16708307|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
16708308|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
16708309|NCT01894516|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
16708310|NCT01894516|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
16708311|NCT01894516|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
16708312|NCT01894516|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
16708313|NCT01894503|Experimental|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
16708314|NCT01894490||Jejunostomy|Patients who received a jejunostomy
16708315|NCT01894490||Nasojejunal catheter|Patients who received a nasojejunal catheter
16708316|NCT01894477|Experimental|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate
~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
16708317|NCT01894477|Experimental|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI
~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
16708318|NCT01894464|Experimental|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
16708319|NCT01894464|No Intervention|Control Group|
16708320|NCT01894451|Experimental|89Zr-bevacizumab-PET/CT Scan|"89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.
~The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.
~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
16708321|NCT01894438|No Intervention|Control Group|This arm will receive written general advice for a healthy lifestyle.
16708322|NCT01894438|Experimental|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
16708323|NCT01894438|Experimental|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
16708324|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.
~Intervention: HPV screening for women Intervention: HPV screening for men"
16708325|NCT01894412|Experimental|HD 203|prefilled syringe
16708326|NCT01894412|Active Comparator|Enbrel|prefilled syringe
16708327|NCT01894399|Experimental|Cohort 1|100 mg HM61713 single dose in Korean
16708328|NCT01894399|Experimental|Cohort 2|200 mg HM61713 single dose in Korean
16708329|NCT01894399|Experimental|Cohort 3|300 mg HM61713 single dose in Korean
16708330|NCT01894399|Experimental|Cohort 4|200 mg HM61713 single dose in Japanese
16708331|NCT01894399|Experimental|Cohort 5|300 mg HM61713 single dose in Japanese
16708332|NCT01894399|Experimental|Cohort 6|200 mg HM61713 single dose in Caucasian
16708333|NCT01894399|Experimental|Cohort 7|300 mg HM61713 single dose in Caucasian
16708334|NCT01894386|Experimental|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
16708335|NCT01894386|Experimental|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
16708336|NCT01894386|Experimental|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
16708337|NCT01894386|Experimental|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
16708338|NCT01894373|Experimental|CIK, psoriasis|
16708339|NCT01894360|Experimental|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
16708340|NCT01894360|Experimental|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
16708380|NCT01894100|Experimental|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
16708410|NCT01893892|Placebo Comparator|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
16708341|NCT01894347||Colistin inhalative|"Adult ICU patients with
~invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection
~indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital
~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
16708342|NCT01894334|No Intervention|Control group|no intervention
16708343|NCT01894334|Experimental|Tranexamic acid group|tranexamic acid ，intravenous 30mg/kg/d，Preoperative
16708344|NCT01894334|Experimental|Edaravone group|edaravone, iv, 1mg/kg/d,Preoperative
16708345|NCT01894334|Experimental|Ulinastatin group|Ulinastatin ,iv，20,000 U /kg/d，Preoperative
16708346|NCT01894308|Active Comparator|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
16708347|NCT01894308|Active Comparator|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
16708348|NCT01894295|Experimental|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
16708349|NCT01894295|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram
16708350|NCT01894282|Active Comparator|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
16708351|NCT01894282|Experimental|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
16708352|NCT01894269|Experimental|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
16708353|NCT01894269|No Intervention|Control|No anti-viral therapy after TACE.
16708354|NCT01894256|Other|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
16708355|NCT01894256|Other|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
16708356|NCT01894256|Other|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
16708357|NCT01894243|Other|Normal hepatic function|"Patients with:
~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
16708358|NCT01894243|Other|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
16708359|NCT01894243|Other|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
16708360|NCT01894230|Experimental|Genotype results plus usual care|SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.
16708361|NCT01894230|Active Comparator|Usual care only|SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
16708362|NCT01894217|Experimental|Genetic testing|Genetic testing and reporting for SLCO1B1*5 allele
16708363|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
16708364|NCT01894191|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
16708365|NCT01894191|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
16708366|NCT01894191|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
16708367|NCT01894178|Active Comparator|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
16708368|NCT01894178|Active Comparator|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
16708369|NCT01894165|Experimental|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
16708370|NCT01894165|Placebo Comparator|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
16708371|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
16708372|NCT01894139|Experimental|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
16708373|NCT01894139|Active Comparator|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI ~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
16708374|NCT01894126|Experimental|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
16708375|NCT01894126|Experimental|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
16708376|NCT01894126|No Intervention|Control|
16708377|NCT01894113|Active Comparator|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
16708378|NCT01894113|Active Comparator|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
16708379|NCT01894100|Other|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
16708577|NCT01892826|No Intervention|LH pic|
16708381|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
16708382|NCT01894087|No Intervention|Enhanced usual care - Cohort 1|
16708383|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
16708384|NCT01894087|No Intervention|Enhanced usual care - Cohort 2|
16708385|NCT01894074|Placebo Comparator|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
16708386|NCT01894074|Active Comparator|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
16708387|NCT01894061|Experimental|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
16708388|NCT01894048|Experimental|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
16708389|NCT01894035||Group 1|
16708390|NCT01894022|Experimental|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
16708391|NCT01894009|Active Comparator|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
16708392|NCT01894009|Sham Comparator|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
16708393|NCT01893996|Experimental|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
16708394|NCT01893996|Placebo Comparator|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
16708395|NCT01893983|Experimental|Motivational Coaching|Telephone based Motivational Coaching sessions
16708396|NCT01893983|No Intervention|Referral alone|This is the current standard of care
16708397|NCT01893970|Experimental|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
16708398|NCT01893970|Active Comparator|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
16708399|NCT01893957|Experimental|Healthy|Healthy women undergoing high voltage electrical stimulation
16708400|NCT01893957|Experimental|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
16708401|NCT01893944|Experimental|Virtual Reality|- Participate in this group 20 women to be treated by means of games Xbox 360 ®, attributed to this, custom applications using virtual and augmented reality to be developed.
16708402|NCT01893944|Experimental|Vibration therapy|- participate in this group 20 women who will undergo 15 minutes of continuous vibration by vibration of the upper mantle, with a frequency of 40 Hz, 3 function and intensity tolerable, keeping the limb supported and raised to 120 °.
16708403|NCT01893944|Active Comparator|control group|- participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises, dissociation girdle, active and active-assisted exercises for groups flexors, extensors, abductors and adductors of the upper limbs, which will be three series 10 repetitions for each exercise.
16708404|NCT01893931|Placebo Comparator|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
16708405|NCT01893931|Active Comparator|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
16708406|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history > 20 pack/years
16708407|NCT01893905|Experimental|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
16708408|NCT01893905|Placebo Comparator|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
16708409|NCT01893892|Experimental|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
16708761|NCT01891500|Placebo Comparator|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
16708411|NCT01893879|Experimental|(RS)2-(3-benzoylphenyl)-propionic acid|"Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
~Laboratory biomarker analysis will be performed."
16708412|NCT01893879|Placebo Comparator|placebo for study drug|"Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
~Laboratory biomarker analysis will be performed."
16708413|NCT01893866|Experimental|A|
16708414|NCT01893866|Experimental|B|
16708415|NCT01893853|Other|Water|Electrolyte- and mineral-free water with exercise intervention
16708416|NCT01893853|Placebo Comparator|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
16708417|NCT01893853|Experimental|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
16708418|NCT01893840|Experimental|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
16708419|NCT01893827|Active Comparator|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
16708420|NCT01893827|Active Comparator|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
16708421|NCT01893814|Active Comparator|Probiotics|
16708422|NCT01893814|Placebo Comparator|Control|
16708423|NCT01893801|Experimental|nab-paclitaxel+Cisplatin+gemcitabine|This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.
16708424|NCT01893788|Active Comparator|Aliskiren|Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.
16708425|NCT01893788|Active Comparator|Eplerenone|Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers
16708426|NCT01893775|Experimental|1|Hu-Mik-Beta-1 every 3 weeks
16708427|NCT01893762|Experimental|16 rowers|Adult rowers, aged between 18 and 25, training >6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
16708428|NCT01893749|Experimental|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.
~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
16708429|NCT01893749|No Intervention|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.
~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
16708430|NCT01893736|No Intervention|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
16708431|NCT01893736|Experimental|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
16708432|NCT01893736|Experimental|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
16708433|NCT01893723|Experimental|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
16708434|NCT01893723|Other|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
16708435|NCT01893710||Control|'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
16708436|NCT01893710||chronic kidney disease|Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
16708437|NCT01893710||Peritoneal dialysis|Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
16708438|NCT01893710||Post PD and with functioning graft|Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
16708439|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
16708440|NCT01893684|Experimental|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
16708441|NCT01893684|Experimental|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams.
16708898|NCT01890603|Experimental|Care Coordination Arm|
16708442|NCT01893684|Experimental|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
16708443|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
16708444|NCT01893658|Active Comparator|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone
~Standard clinical therapy with prednisone.
~Day 1-14: 60 mg/day 14 days (2 weeks)
~Day 15-28: 40 mg/day (2 weeks)
~Day 29-35: 30 mg/day (1 week)
~Day 36-42: 20 mg/day (1 week)
~Day 43-49: 10 mg/day (1 week)
~Day 50-56: 5 mg/day (1 week)
~Subjects will stop taking prednisone on day 57
~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
16708445|NCT01893658|Active Comparator|Prednisone|"Standard clinical therapy with prednisone.
~Day 1-14: 60 mg/day 14 days (2 weeks)
~Day 15-28: 40 mg/day (2 weeks)
~Day 29-35: 30 mg/day (1 week)
~Day 36-42: 20 mg/day (1 week)
~Day 43-49: 10 mg/day (1 week)
~Day 50-56: 5 mg/day (1 week)
~Subjects will stop taking prednisone on day 57
~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
16708446|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
16708447|NCT01893632|Experimental|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
16708448|NCT01893632|Placebo Comparator|Placebo|Capsules filled with riboflavin.
16708449|NCT01893606|Placebo Comparator|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
16708450|NCT01893606|Experimental|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
16708451|NCT01893593|Other|Control|Usual care
16708452|NCT01893593|Active Comparator|Intervention|Multifaceted intervention to improve clinical systems
16708453|NCT01893580|Experimental|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
16708454|NCT01893580|Experimental|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
16708455|NCT01893580|Experimental|3. Experimental|Exercise in a team initiated two weeks after surgery.
16708456|NCT01893580|Other|4. Usual care|Exercise in a team initiated six weeks after surgery.
16708457|NCT01893567|Experimental|Clobex spray|
16708458|NCT01893554|Experimental|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
16708459|NCT01893554|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
16708460|NCT01893554|Experimental|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
16708461|NCT01893554|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
16708462|NCT01893554|Experimental|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
16708463|NCT01893554|Placebo Comparator|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
16708464|NCT01893554|Experimental|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
16708465|NCT01893554|Placebo Comparator|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
16708466|NCT01893541|Active Comparator|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
16708467|NCT01893541|Active Comparator|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
16708468|NCT01893528|Experimental|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
16708899|NCT01890603|Active Comparator|Quality Measure Improvement|
16708469|NCT01893528|Experimental|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
16708470|NCT01893528|Experimental|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
16708471|NCT01893515|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
16708472|NCT01893515|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
16708473|NCT01893502|Active Comparator|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
16708474|NCT01893502|Active Comparator|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
16708475|NCT01893489|Active Comparator|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
16708476|NCT01893489|Sham Comparator|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
16708477|NCT01893476|No Intervention|control|In this arm, practitioners will provide usual care for COPD patients.
16708478|NCT01893476|Other|adherence to guideline|Implementation educational programme: guideline adherences. The results of this trial will be directly applicable to primary care settings. Should the interventions delivered at the level of the GP practice be found to be effective in improving patients' quality of life then the findings would have a wider application.
16708479|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
16708480|NCT01893450|Active Comparator|methimazole|methimazole 30 mg daily during one year
16708481|NCT01893450|Active Comparator|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
16708482|NCT01893450|Active Comparator|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
16708483|NCT01893437|Experimental|Single oral dose group|
16708484|NCT01893424|Active Comparator|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
16708485|NCT01893424|Experimental|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
16708486|NCT01893411|Experimental|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
16708487|NCT01893411|Experimental|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
16708488|NCT01893411|Experimental|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
16708489|NCT01893398|Experimental|rehabilitation (MST) program|The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
16708490|NCT01893398|No Intervention|Usual care program|Usual care PWA program
16708491|NCT01893385|Experimental|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
16708492|NCT01893385|Other|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
16708493|NCT01893372|Experimental|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
16708494|NCT01893372|Experimental|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
16708495|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
16708496|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
16708497|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
16708498|NCT01893346|Experimental|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
16708499|NCT01893333|Experimental|Nerve sparing radical hysterectomy group|"sparing hypogastric nerve
~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
16708500|NCT01893333|Active Comparator|Radical hysterectomy group|Conventional radical hysterectomy
16708578|NCT01892813|Experimental|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
16708728|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
16708501|NCT01893320|Experimental|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).
~Following the phase I portion, patients in phase II receive the following induction:
~Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.
~Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
16708502|NCT01893307|Experimental|Intensity-Modulated X-Ray Therapy (IMRT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
~Treating physician evaluate each patient for possible chemotherapy.
~Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
~Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy."
16708503|NCT01893307|Experimental|Intensity-Modulated Proton Beam Therapy (IMPT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
~Treating physician evaluate each patient for possible chemotherapy.
~Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
~Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy."
16708504|NCT01893294|Experimental|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
16708505|NCT01893281|Experimental|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
16708506|NCT01893268||Cohort|
16708507|NCT01893255||Cohort|
16708508|NCT01893242|Experimental|Aleglitazar Arm|
16708509|NCT01893242|Placebo Comparator|Placebo Arm|
16708510|NCT01893229|Experimental|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
16708511|NCT01893229|Experimental|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
16708512|NCT01893229|Experimental|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
16708513|NCT01893229|Experimental|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
16708514|NCT01893229|Experimental|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg-160mmg/d; duration: 6 weeks
16708515|NCT01893229|Experimental|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg-2000mg/d;serum Li level: 0.6mmol-1.2mmol/L; duration: 6 weeks
16708516|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
16708517|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
16708518|NCT01893203|Other|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
16708519|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
16708520|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
16708521|NCT01893177|Experimental|Elderly subjects aged over 60 years|
16708522|NCT01893177|Experimental|Adults from 18 to 60 years old inclusive|
16708523|NCT01893164|Experimental|moderate cubital tunnel syndrome|Sensory,Intermittent paresthesias; vibratory perception normal or decreasedMotor,Measurable weakness in pinch or grip strengthTests,Elbow flexion test or Tinel's sign is positive; finger crossing may be abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
16708524|NCT01893164|Experimental|severe cubital tunnel syndrome|Sensory,Persistent paresthesias; vibratory perception decreased; abnormal two-point discrimination(static >6 mm, moving >4 mm)Motor,Measurable weakness in pinch and grip plus muscle atrophyTests,Positive elbow flexion test or positive Tinel's sign may be present; finger crossing usually abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
16708525|NCT01893151|Experimental|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
16708526|NCT01893151|Placebo Comparator|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
16708527|NCT01893138|Experimental|Roll-in: AMDC for USR|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
16708528|NCT01893138|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
16708529|NCT01893138|Experimental|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
16708530|NCT01893138|Placebo Comparator|Roll in: Placebo|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
16708531|NCT01893125|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
16708532|NCT01893125|Placebo Comparator|Placebo|Placebo 1 cap tid 21 days
16708533|NCT01893112|Experimental|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
16708727|NCT01891773|No Intervention|Usual Care|Daily medication to be taken at home.
16708534|NCT01893112|Other|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
16708535|NCT01893099|Experimental|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
16708536|NCT01893099|Experimental|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
16708537|NCT01893099|Experimental|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
16708538|NCT01893099|Experimental|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
16708539|NCT01893086|Active Comparator|LH alone|LH, laparoscopic hysterectomy
16708540|NCT01893086|Experimental|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
16708541|NCT01893073|Active Comparator|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
16708542|NCT01893073|No Intervention|Waiting group|
16708543|NCT01893060|Experimental|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
16708544|NCT01893060|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
16708545|NCT01893060|Experimental|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
16708546|NCT01893060|Sham Comparator|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
16708547|NCT01893047|No Intervention|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
16708548|NCT01893047|Experimental|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
16708549|NCT01893047|Experimental|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
16708550|NCT01893034|Active Comparator|Conservative treatment|Physiotherapy and activity modification
16708551|NCT01893034|Active Comparator|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
16708552|NCT01893021||Postpartum Malawian women|
16708553|NCT01893008|Experimental|Usual care + Inspiratory Muscle Training (IMT)|
16708554|NCT01893008|No Intervention|Usual care (no IMT)|
16708555|NCT01892995|Experimental|Ketamine|active arm
16708556|NCT01892995|Sham Comparator|Diphenhydramine|sham arm
16708557|NCT01892995|Placebo Comparator|Saline|placebo
16708558|NCT01892982|Experimental|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
16708559|NCT01892982|No Intervention|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
16708560|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
16708561|NCT01892956||Healthy volunteers|
16708562|NCT01892956||Newly diagnosed T2DM|Newly diagnosed T2DM, who have not started yet medical treatment with glucose lowering medications
16708563|NCT01892943||Patients with LHON|
16708564|NCT01892930|Experimental|Treatment (SBRT, nephrectomy)|Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.
16708565|NCT01892904|Experimental|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
16708566|NCT01892904|Active Comparator|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
16708567|NCT01892891|Experimental|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
16708568|NCT01892891|Placebo Comparator|Placebo comparator|Placebo
16708569|NCT01892878|Other|Single Arm Study|All patients will receive treatment
16708570|NCT01892865|Active Comparator|Historical means method|Operative time will be predicted using historical service means. Schedule will be constructed using this time
16708571|NCT01892865|Experimental|Predictive Modeling System (PMS)|Operative time will be predicted using a regression model. Schedule will be constructed using this time
16708572|NCT01892852|Experimental|Acupuncture|Acupuncture treatment
16708573|NCT01892852|No Intervention|Control|No other active treatment or sham acupuncture for this symptoms
16708574|NCT01892839|Experimental|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
16708575|NCT01892839|Active Comparator|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
16708576|NCT01892826|Experimental|hCG group|
16708579|NCT01892813|Active Comparator|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
16708580|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
16708581|NCT01892787|Experimental|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
16708582|NCT01892787|Active Comparator|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
16708583|NCT01892761||TCL/MMF Group|
16708584|NCT01892761||CyA/MMF Group|
16708585|NCT01892748|Active Comparator|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
16708586|NCT01892748|Placebo Comparator|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
16708587|NCT01892722|Experimental|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
16708588|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
16708589|NCT01892722|Experimental|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2)
16708590|NCT01892709|Experimental|Hydromorphone|"All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, Do you want more pain medicine? This question will be asked 30 minutes after they answered no or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers yes. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period."
16708591|NCT01892696|Other|mechanically ventilated patients|"patients admitted to a 18-bed medical surgical intensive care unit of the military hospital of Tunisia and were mechanically ventilated fully adapted to their ventilator and in sinus rhythm.
~intervention:varying inspiratory flow waveforms"
16708592|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
16708593|NCT01892670|Experimental|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.
~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
16708594|NCT01892670|Experimental|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.
~Device: Terumo IMUFLEX WB-SP collection bag system"
16708595|NCT01892670|Experimental|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.
~Device: Terumo IMUFLEX WB-SP collection bag system"
16708596|NCT01892670|Experimental|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.
~Device: Terumo IMUFLEX WB-SP collection bag system"
16708597|NCT01892670|Experimental|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).
~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
16708598|NCT01892670|Experimental|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).
~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
16708599|NCT01892657|Experimental|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
16708600|NCT01892644|Active Comparator|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
16708601|NCT01892644|Active Comparator|Venesection HC|10 patients with hemochromatosis treated with venesection
16708602|NCT01892644|Active Comparator|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
16708603|NCT01892644|No Intervention|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
16708604|NCT01892631|Other|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
16708605|NCT01892631|Experimental|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
16708606|NCT01892618|Active Comparator|Pneumovax|Pneumovax, 1x 0.5 ml injection
16708607|NCT01892618|Experimental|Prevenar 13|Prevenar 13, 1x 0.5 ml injection
16708608|NCT01892605|Experimental|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
16708609|NCT01892592|No Intervention|Usual Care|No Interventions
16708610|NCT01892592|No Intervention|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
16708611|NCT01892592|Experimental|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
16708612|NCT01892579|Experimental|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
16708729|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
16708613|NCT01892579|Active Comparator|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
16708614|NCT01892566|No Intervention|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
16708615|NCT01892566|Experimental|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
16708616|NCT01892553|Experimental|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
16708617|NCT01892553|Experimental|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
16708618|NCT01892540|Experimental|Cohort 1: Standard positioning device|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
16708619|NCT01892540|Experimental|Cohort 2: New positioning device|
16708620|NCT01892540|Experimental|Cohort 3: Current positioning device until new is available|
16708621|NCT01892527|Experimental|Tivantinib plus Cetuximab|Single arm
16708622|NCT01892514|Experimental|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
16708623|NCT01892514|Experimental|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
16708624|NCT01892501|Other|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
16708625|NCT01892488|Placebo Comparator|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
16708626|NCT01892488|Experimental|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
16708627|NCT01892475|Experimental|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
16708628|NCT01892475|Experimental|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
16708629|NCT01892449|Experimental|prolonged I:E ratio (1:1) group|
16708630|NCT01892449|Active Comparator|conventional I:E ratio (1:2) group|
16708631|NCT01892436|Experimental|Secukinumab 75mg|Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
16708632|NCT01892436|Experimental|Secukinumab 150mg|Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
16708633|NCT01892436|Experimental|Placebo - AIN457A 75mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
16708634|NCT01892436|Experimental|Placebo - AIN457 150mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
16708635|NCT01892423|Experimental|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
16708636|NCT01892410|Experimental|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
16708637|NCT01892397|Experimental|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
16708638|NCT01892384|Experimental|BI 409306 dose 1|low dose, once daily
16708639|NCT01892384|Experimental|BI 409306 dose 2|medium dose, once daily
16708640|NCT01892384|Experimental|BI 409306 dose 3|high dose, once daily
16708641|NCT01892384|Placebo Comparator|Placebo|placebo, once daily
16740615|NCT01677806|Active Comparator|Conservative therapy|
16708642|NCT01892371|Experimental|Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16708643|NCT01892371|Experimental|Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16708644|NCT01892358|Active Comparator|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
16708645|NCT01892358|Placebo Comparator|Assessment-Only|Participants in this arm will receive treatment-as-usual
16708646|NCT01892345|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction Period: Participants received eculizumab (900 milligrams [mg]) via intravenous (IV) infusion once a week (every 7 ± 2 days) for 4 weeks followed by eculizumab 1200 mg for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received eculizumab (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
16708647|NCT01892345|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (900 mg) via IV infusion once a week (every 7 ± 2 days) for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received matching placebo (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
16708648|NCT01892332|Other|lidocaine with fentanyl 75ug|
16708649|NCT01892319||All patients|
16708650|NCT01892306|Experimental|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
16708651|NCT01892306|Active Comparator|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
16708652|NCT01892293|Experimental|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
16708653|NCT01892280|Experimental|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
16708654|NCT01892280|Experimental|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
16708655|NCT01892280|Experimental|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
16708656|NCT01892280|No Intervention|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
16708657|NCT01892267|Experimental|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
16708658|NCT01892267|Active Comparator|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
16708659|NCT01892254|Experimental|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
16708660|NCT01892254|Placebo Comparator|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
16708661|NCT01892241|Experimental|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
16708662|NCT01892241|Active Comparator|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
16708663|NCT01892241|No Intervention|Control group|Those in group C didn't accept any antiviral regiment .
16708664|NCT01892228|Experimental|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
16708665|NCT01892215|Experimental|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
16708666|NCT01892215|Experimental|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
16708667|NCT01892189|Experimental|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
16708668|NCT01892189|Experimental|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
16708669|NCT01892189|Experimental|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
16708760|NCT01891500|Experimental|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
16708670|NCT01892189|Experimental|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
16708671|NCT01892189|Experimental|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period"
16708672|NCT01892189|Experimental|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
16708673|NCT01892189|Experimental|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:
~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period"
16708674|NCT01892189|Experimental|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
16708675|NCT01892189|Experimental|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period
16708676|NCT01892176|Experimental|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
16708677|NCT01892163|Active Comparator|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
16708678|NCT01892163|Experimental|Ozurdex fixed dosing|
16708679|NCT01892150|Experimental|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
16708680|NCT01892137|Other|Open label active|
16708681|NCT01892124|Experimental|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
16708682|NCT01892124|Experimental|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
16708683|NCT01892111|Experimental|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
16708684|NCT01892111|No Intervention|no intervention|IVF/ICSI procedure.
16708685|NCT01892098|Active Comparator|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
16708686|NCT01892098|Placebo Comparator|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
16708687|NCT01892085|Experimental|Early initiation|Initiation of breast milk expression <1 hour following delivery.
16708688|NCT01892085|Experimental|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
16708689|NCT01892085|Other|Late initiation|Initiation of milk expression >3-6 hours following delivery.
16708690|NCT01892072||HCC patients|Hepatocellular carcinoma patients treated by surgical treatment
16708691|NCT01892059|Experimental|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
16708692|NCT01892059|Active Comparator|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
16708693|NCT01892046|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
16708694|NCT01892033|Experimental|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
16708695|NCT01892020|Experimental|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
16708696|NCT01892020|Experimental|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
16708697|NCT01892007|Experimental|Cogmed RM (adaptive)|Online training intervention: An adaptive version of Cogmed RM working memory training. Task difficulty (number of to-be-remembered items) increases based on individual performance, in order to maintain average daily performance levels of approximately 60% of trials correct. Participants complete 35-45 minutes of active training per day, 5 days a week for 5 weeks.
16708698|NCT01892007|Placebo Comparator|Cogmed RM (non-adaptive, placebo)|Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
16708699|NCT01891994|Experimental|Eltrombopag|Administration of eltrombopag at a dose of 150mg/day for 6 months
16708700|NCT01891981|Experimental|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.
~Phase II Starting Dose: Maximum tolerated dose from Phase I."
16708701|NCT01891968|Experimental|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
16708702|NCT01891955|Active Comparator|Diet A|Healthy diet with grains and dairy
16708703|NCT01891955|Active Comparator|Diet B|Healthy diet without grains and dairy
16708704|NCT01891942|Experimental|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
16708705|NCT01891942|Experimental|normal subjects|Fifteen healthy men with normal lung function
16708706|NCT01891929|Experimental|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
16708707|NCT01891929|Active Comparator|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
16708708|NCT01891916|No Intervention|extensively hydrolysed casein formula|extensively hydrolysed casein formula
16708709|NCT01891916|Active Comparator|Extensively hydrolyzed casein formula + LGG|Extensively hydrolized formula plus LGG
16708710|NCT01891890|Active Comparator|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
16708711|NCT01891890|Active Comparator|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
16708712|NCT01891890|Active Comparator|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
16708713|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
16708714|NCT01891864|Experimental|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
16708715|NCT01891864|Active Comparator|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
16708716|NCT01891851|Experimental|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
16708717|NCT01891838|Active Comparator|Volume controlled ventilation|Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
16708718|NCT01891838|Experimental|Pressure-controlled ventilation|initial pressure of 15 cm H2O, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Pressure is modified to maintain a tidal volume of 7 mL/kg of ideal body weight and frequency ventilation is modified to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg
16708719|NCT01891825|Active Comparator|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
16708720|NCT01891825|Active Comparator|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
16708721|NCT01891812|Experimental|Nitrous oxide 50%|Nitrous oxide 50% administered for 15 minutes.
16708722|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
16708723|NCT01891786|No Intervention|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
16708724|NCT01891786|Active Comparator|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
16708725|NCT01891786|Active Comparator|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
16708726|NCT01891773|Experimental|School-based therapy|Daily dose of medication to be provided in the school setting.
16708730|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
16708731|NCT01891734|Experimental|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
16708732|NCT01891734|Active Comparator|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
16708733|NCT01891721|Experimental|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
16708734|NCT01891721|Experimental|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
16708735|NCT01891721|Active Comparator|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
16708736|NCT01891695|Experimental|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
16708737|NCT01891682||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
16708738|NCT01891669|Experimental|Part 1|
16708739|NCT01891656|Experimental|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
16708740|NCT01891656|No Intervention|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
16708741|NCT01891656|Experimental|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
16708742|NCT01891643|Experimental|Arm 1: Lenalidomide + Dexamethasone|"Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug
~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
16708743|NCT01891643|Experimental|Arm 2: Lenalidomide + Dexamethasone + Elotuzumab|"Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)
~Dexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15(cycles 3-18); Day 1 (cycle 19 & beyond)]
~Dexamethasone 40 mg tablets by mouth once daily [Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 & beyond)]
~Dexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18); Day 1 (cycle 19 & beyond)]
~Elotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18)]
~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 & beyond)
~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
16708744|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
16708745|NCT01891617|Experimental|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
16708746|NCT01891617|Experimental|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
16708747|NCT01891617|Experimental|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
16708748|NCT01891617|Experimental|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
16708749|NCT01891591||obese female subjects|16 obese female subjects with BMI > 40 kg/m2 on a waiting list for bariatric surgery
16708750|NCT01891565|Experimental|Activity Feedback|Feedback
16708751|NCT01891565|No Intervention|No Feedback|
16708752|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
16708753|NCT01891552||DEBIRI|only DEBIRI treatment
16708754|NCT01891539||doxorubicin|"Day +1:
~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.
~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
16708755|NCT01891526||Hepatic patients|patients with hepatic insufficiency
16708756|NCT01891526||Healthy Controls|Healthy adults
16708757|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
16708758|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
16708759|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
16708762|NCT01891500|Active Comparator|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
16708763|NCT01891487|Active Comparator|Track A|Those on active study medication
16708764|NCT01891487|Placebo Comparator|Track B|Those on placebo.
16708765|NCT01891474|Experimental|U-health care|voice inception technique based U-healthcare service
16708766|NCT01891474|No Intervention|control|conventional treatment
16708767|NCT01891461|Experimental|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
16708768|NCT01891461|No Intervention|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
16708769|NCT01891448|Experimental|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
16708770|NCT01891448|Other|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
16708771|NCT01891435|Active Comparator|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
16708772|NCT01891435|Active Comparator|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
16708773|NCT01891435|Active Comparator|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
16708774|NCT01891409|Other|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
16708775|NCT01891396|Placebo Comparator|Saline|Single injection of 0.9% saline supplied as a 4 mL unit dose in a 5mL glass syringe
16708776|NCT01891396|Experimental|Hyaluronic Acid and TH|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 mL unit dose in a 5 mL glass syringe
16708777|NCT01891396|Active Comparator|Hyaluronic Acid|Single injection of sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe
16708778|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
16708779|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
16708780|NCT01891357|Experimental|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
16708781|NCT01891344|Experimental|Ovarian cancer|rucaparib
16708782|NCT01891331|Experimental|VT-1161 300mg QD|
16708783|NCT01891331|Experimental|VT-1161 600mg QD|
16708784|NCT01891331|Experimental|VT-1161 600mg BID|
16708785|NCT01891331|Active Comparator|Fluconazole 150mg|
16708786|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
16708787|NCT01891305|Experimental|VT-1161 200/50mg|
16708788|NCT01891305|Experimental|VT-1161 600/150mg|
16708789|NCT01891305|Experimental|VT-1161 1200/300mg|
16708790|NCT01891305|Placebo Comparator|Matching placebo|
16708791|NCT01891292|No Intervention|Control|
16708792|NCT01891292|Active Comparator|Enalapril|
16708793|NCT01891292|Active Comparator|N-Acetylcysteine|
16708794|NCT01891279|Experimental|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
16708795|NCT01891279|Experimental|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
16708796|NCT01891266|Experimental|Non-tourniquet assisted TKA|
16708797|NCT01891266|Other|Tourniquet assisted TKA|
16708798|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
16708799|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
16708800|NCT01891227|Experimental|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
16708801|NCT01891214||Ulcerative Colitis and Crohn's Disease|
16708802|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
16708803|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
16708804|NCT01891175|Experimental|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
16708805|NCT01891175|Active Comparator|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
16708806|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
16740616|NCT01677793||Child and adolescent population|
16708807|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
16708808|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
16708809|NCT01891136|Experimental|Peanut protein|Subjects to receive varying amounts of peanut protein as peanut oral immunotherapy.
16708810|NCT01891123|Placebo Comparator|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
16708811|NCT01891123|Active Comparator|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
16708812|NCT01891110|Experimental|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
16708813|NCT01891110|Experimental|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
16708814|NCT01891110|Experimental|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
16708815|NCT01891097|Active Comparator|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
16708816|NCT01891097|Experimental|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
16708817|NCT01891097|No Intervention|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
16708818|NCT01891084|Active Comparator|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.
~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
16708819|NCT01891084|Placebo Comparator|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.
~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
16708820|NCT01891071|Experimental|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
16708821|NCT01891071|No Intervention|Standard care|Standard care
16708822|NCT01891058|Active Comparator|drug-shock vs shock only|For ED patients with RAFF, Investigators will compare conversion to normal sinus rhythm between the two strategies of i) attempted pharmacological cardioversion with intravenous procainamide followed by DC cardioversion if necessary (Drug-Shock), and ii) DC cardioversion alone (Shock Only).
16708823|NCT01891058|No Intervention|pad positions|For ED RAFF patients undergoing DC cardioversion, Investigators will compare conversion to normal sinus rhythm between the i) antero-posterior and ii) antero-lateral pad positions.
16708824|NCT01891045|No Intervention|Control|Patients merely monitored on background variables to function as a baseline of comparison
16708825|NCT01891045|Active Comparator|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
16708826|NCT01891045|Experimental|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
16708827|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
16708828|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
16708829|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
16708830|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
16708831|NCT01891006|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
16708832|NCT01891006|Other|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
16708833|NCT01890993||Liraglutide|
16708834|NCT01890993||DPP-4|
16708835|NCT01890967|Experimental|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
16708836|NCT01890967|Experimental|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
16708837|NCT01890967|Experimental|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
16708838|NCT01890967|Experimental|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
16708839|NCT01890967|Experimental|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
16708840|NCT01890967|Placebo Comparator|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
16708841|NCT01890954|Active Comparator|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
16708842|NCT01890954|No Intervention|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admisssion
16708843|NCT01890941|Experimental|KCT-0809 Lower Dose|
16708844|NCT01890941|Experimental|KCT-0809 Higher Dose|
16708845|NCT01890941|Placebo Comparator|Placebo|
16708846|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
16708847|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
16708848|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
16708849|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
16708850|NCT01890902|Experimental|Impracor (Ketoprofen 10% Cream)|Topical Cream over a period of 14 days
16708851|NCT01890902|Placebo Comparator|Placebo Cream:|Topical Cream over a period of 14 days
16708852|NCT01890889|Active Comparator|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
16708853|NCT01890889|Active Comparator|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
16708854|NCT01890889|Placebo Comparator|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
16708855|NCT01890876|Active Comparator|Low altitude|Walking uphill Walking downhill
16708856|NCT01890876|Active Comparator|High altitude|Walking uphill Walking downhill
16708857|NCT01890863|Experimental|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
16708858|NCT01890863|Experimental|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
16708859|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
16708860|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
16708861|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
16708862|NCT01890837|Placebo Comparator|Placebo|Placebo TID
16708863|NCT01890824||Breast Cancer Patients|Breast cancer patients to be studied before and after chemotherapy
16708864|NCT01890824||Healthy Female Controls|Healthy female controls will be compared to breast cancer patients before and after chemotherapy and to healthy male controls
16708865|NCT01890824||Healthy Male Controls|Healthy male controls will be compared to healthy female controls to determine gender differences
16708866|NCT01890811|Experimental|Boost High Protein|Boost high protein with added spirulina
16708867|NCT01890798|Experimental|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
16708868|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
16708869|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
16708870|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
16708871|NCT01890772|Active Comparator|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
16708872|NCT01890772|Active Comparator|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
16708873|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
16708874|NCT01890746|Experimental|Eltrombopag arm|Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
16708875|NCT01890746|Placebo Comparator|Placebo arm|Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
16708876|NCT01890733|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
16708877|NCT01890733|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
16708878|NCT01890720|Experimental|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
16708879|NCT01890720|Active Comparator|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
16708880|NCT01890707|Active Comparator|Deep Sedation|Deep sedation
16708881|NCT01890707|Other|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
16708882|NCT01890694|Placebo Comparator|Placebo|"Subjects will receive placebo once daily.
~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
16708883|NCT01890694|Experimental|Tolvaptan|"Subjects will receive Tolvaptan once daily.
~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
16708884|NCT01890681|Active Comparator|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:
~center and family self-assessment,
~center intervention materials delivered several times over the 6-month period, and;
~parent handouts
~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
16708885|NCT01890681|Experimental|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:
~center and family self-assessment;
~targeted technical assistance by Baby NAP SACC consultant for providers and parents;
~training workshops for child care providers; and
~parent outreach and support."
16708886|NCT01890668|Experimental|Osteopathic Manipulative Treatment|Randomization and first OMT will take place at discharge (Day 3); second osteopathic therapy will be performed by the same osteopath practitioner at Day10.
16708887|NCT01890668|Placebo Comparator|Control group|Control group consists in classical medical and paramedical breastfeeding support. OMT on the newborn will be realized by osteopath dissimulated behind a screen. Placebo OMT consists to mimic, without the knowledge of parents, osteopathic techniques on a dolly.
16708888|NCT01890655|Experimental|MT-1303-Low|MT-1303-Low Dose
16708889|NCT01890655|Experimental|MT-1303-Middle|MT-1303-Middle Dose
16708890|NCT01890655|Experimental|MT-1303-High|MT-1303-High Dose
16708891|NCT01890642|Sham Comparator|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if > age 1 yr or sucrose if < 1 yr
16708892|NCT01890642|Other|Pain Ease|This group will receive Pain Ease Spray only if > 1 yr or sucrose only if child < 1 yr
16708893|NCT01890642|Experimental|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if > 1 yr and will receive sucrose is < 1 yr
16708894|NCT01890629|Experimental|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
16708895|NCT01890629|Active Comparator|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
16708896|NCT01890629|Active Comparator|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
16708897|NCT01890616||Motility|This arm will ingest the SmartPill.
16708900|NCT01890590|Experimental|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
16708901|NCT01890577||Study population|Single cohort of dialysis patients
16708902|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
16708903|NCT01890551|Other|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
16708904|NCT01890551|Other|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
16708905|NCT01890538|Active Comparator|Piracetam|2 g intravenous piracetam
16708906|NCT01890538|Active Comparator|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
16708907|NCT01890525||PROMISE study patients|
16708908|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
16708909|NCT01890499|Experimental|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.
~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
16708910|NCT01890499|Active Comparator|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
16708911|NCT01890473|Experimental|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
16708912|NCT01890473|Experimental|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
16708913|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
16708914|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
16708915|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
16708916|NCT01890434|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
16708917|NCT01890421|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
16708918|NCT01890408|Experimental|ropivacaine|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
16708919|NCT01890408|Placebo Comparator|placebo|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
16708920|NCT01890395|Other|blood collection|procedure: Blood draws as the intervention
16708921|NCT01890382|Placebo Comparator|Control|alanine as placebo to leucine (same dosage); corn starch as placebo to protein and/or creatine (same dosage)
16708922|NCT01890382|Experimental|whey protein|
16708923|NCT01890382|Experimental|soy protein|
16708924|NCT01890382|Experimental|leucine supplementation|
16708925|NCT01890382|Experimental|whey plus creatine|
16708926|NCT01890382|Experimental|creatine|
16708927|NCT01890369|Experimental|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
16708928|NCT01890369|Experimental|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
16708929|NCT01890369|Experimental|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
16708930|NCT01890369|Experimental|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
16708931|NCT01890356|Experimental|Transcranial electrical stimulation|
16708932|NCT01890343|Experimental|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
16708933|NCT01890343|Experimental|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
16708934|NCT01890343|Experimental|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
16708935|NCT01890330|Experimental|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
16708936|NCT01890330|Active Comparator|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
16708937|NCT01890317|Experimental|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
16708938|NCT01890317|No Intervention|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
16708939|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
16708940|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
16741749|NCT01670188|No Intervention|Non-SCD group|Standard care
16708941|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
16708942|NCT01890278|Active Comparator|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
16708943|NCT01890278|Active Comparator|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
16708944|NCT01890265|Experimental|Pamrevlumab|Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.
16708945|NCT01890265|Placebo Comparator|Placebo|Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.
16708946|NCT01890265|Active Comparator|Sub-Study: Pamrevlumab+Pirfenidone or Nintedanib|"Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.
~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
16708947|NCT01890265|Placebo Comparator|Sub-Study: Placebo+Pirfenidone or Nintedanib|"Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.
~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
16708948|NCT01890252|Experimental|Hyper CL|Hyper osmotic contact lens
16708949|NCT01890252|Experimental|Hyper CL + Saline solution|combined treatment of hyper osmotic contact lens+ hypertonic solution
16708950|NCT01890252|Active Comparator|saline solution|hypertonic solution
16708951|NCT01890239|Experimental|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
16708952|NCT01890239|No Intervention|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
16708953|NCT01890226|No Intervention|Control|
16708954|NCT01890226|Experimental|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
16708955|NCT01890213|Experimental|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
16708956|NCT01890200|Experimental|TCM-700C (low dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
16708957|NCT01890200|Experimental|TCM-700C (high dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
16708958|NCT01890200|Placebo Comparator|Placebo|placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
16708959|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
16708960|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
16708961|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
16708962|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
16708963|NCT01890148|Experimental|1|oral BD administration of 45 mg AZD5069
16708964|NCT01890135|Active Comparator|endothelin receptor antogonist|10 mg of zibotentan
16708965|NCT01890135|Placebo Comparator|placebo|matched placebo
16708966|NCT01890122|Active Comparator|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
16708967|NCT01890122|Active Comparator|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
16708968|NCT01890122|Experimental|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
16708969|NCT01890122|Placebo Comparator|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
16708970|NCT01890109|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
16708971|NCT01890109|Experimental|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
16708972|NCT01890096|Experimental|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
16708973|NCT01890096|Experimental|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
16708974|NCT01890083|Active Comparator|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
16708975|NCT01890083|Experimental|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
16708976|NCT01890070|Placebo Comparator|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fiber)
~Three weeks of washout to avoid additive effects on treatments to follow."
16708995|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
16708977|NCT01890070|Experimental|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
~Three weeks of washout to avoid additive effects on treatments to follow."
16708978|NCT01890070|Experimental|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.
~Three weeks of washout to avoid additive effects on treatments to follow."
16708979|NCT01890070|Experimental|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.
~Three weeks of washout to avoid additive effects on treatments to follow."
16708980|NCT01890070|Experimental|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
16708981|NCT01890070|Experimental|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
16708982|NCT01890070|Experimental|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100g of Italian organic Olive Oil
~Three weeks of washout to avoid additive effects on treatments to follow."
16708983|NCT01890070|Placebo Comparator|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)
~Three weeks of washout to avoid additive effects on treatments to follow."
16708984|NCT01890070|Experimental|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.
~Three weeks of washout to avoid additive effects on treatments to follow."
16708985|NCT01890070|Experimental|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine
~Three weeks of washout to avoid additive effects on treatments to follow."
16708986|NCT01890070|Experimental|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.
~Three weeks of washout to avoid additive effects on treatments to follow."
16708987|NCT01890070|Experimental|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
16708988|NCT01890070|Experimental|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
16708989|NCT01890070|Experimental|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil
~Three weeks of washout to avoid additive effects on treatment following."
16708990|NCT01890070|Placebo Comparator|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)
~Three weeks of washout to avoid additive effects on treatments to follow."
16708991|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
~Three weeks of washout to avoid additive effects on treatments to follow."
16708992|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine
~Three weeks of washout to avoid additive effects on treatments to follow."
16708993|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts
~Three weeks of washout to avoid additive effects on treatments to follow."
16708994|NCT01890070|Experimental|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
16709051|NCT01889797|Active Comparator|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
16743087|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
16708996|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil
~Three weeks of washout to avoid additive effects on treatments to follow."
16708997|NCT01890070|Placebo Comparator|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)
~Three weeks of washout to avoid additive effects on treatments to follow."
16708998|NCT01890070|Experimental|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
16708999|NCT01890070|Experimental|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine
~Three weeks of washout to avoid additive effects on treatments to follow."
16709000|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts
~Three weeks of washout to avoid additive effects on treatments to follow."
16709001|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
16709002|NCT01890070|Experimental|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
16709003|NCT01890070|Experimental|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil
~This is followed by a 3 week wash out period, to neutralize any additive effects."
16709004|NCT01890057|Experimental|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
16709005|NCT01890057|Experimental|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
16709006|NCT01890044||Moderate to highest risk for VTE|Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
16709007|NCT01890031|No Intervention|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
16709008|NCT01890031|Other|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
16709009|NCT01890031|Other|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
16709010|NCT01890031|Other|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
16709011|NCT01890031|Other|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
16709012|NCT01890018|Active Comparator|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:
~Arm 1. Control group no modifications
~Electronic Pill Bottle tracking"
16709013|NCT01890018|Experimental|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:
~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps
~Electronic Pill Bottle tracking; Adherence Messaging"
16709014|NCT01890018|Experimental|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:
~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient
~Electronic Pill Bottle tracking; Social Influence"
16709015|NCT01890018|Experimental|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:
~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps
~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
16709016|NCT01890005|Experimental|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
16709017|NCT01890005|Placebo Comparator|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
16709018|NCT01889992|Active Comparator|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
16709019|NCT01889992|Experimental|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
~Sirolimus dosage is based on blood levels."
16709052|NCT01889797|Experimental|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
16709211|NCT01888835|Active Comparator|Mirtazapine|mirtazapine 30 mg orally per day
16709212|NCT01888835|Placebo Comparator|Placebo|placebo (30 mg) orally per day
16709020|NCT01889992|Active Comparator|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
16709021|NCT01889992|Active Comparator|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.
~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
16709022|NCT01889992|Active Comparator|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
16709023|NCT01889992|Experimental|MTor Immunosuppression|"Sirolimus
~Sirolimus dosage is based on blood levels.
~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
16709024|NCT01889992|Experimental|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
16709025|NCT01889979|Experimental|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
16709026|NCT01889979|Placebo Comparator|Placebo|2 mL of a sterile solution SC
16709027|NCT01889966|Experimental|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
16709028|NCT01889953|Other|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
16709029|NCT01889940|No Intervention|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.
~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.
~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
16709030|NCT01889940|Other|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
16709031|NCT01889927|No Intervention|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
16709032|NCT01889927|Active Comparator|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
16709033|NCT01889914|Experimental|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.
~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
16709034|NCT01889914|Experimental|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).
~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
16709035|NCT01889888|Experimental|ADRC injection|
16709036|NCT01889875|No Intervention|Control group|
16709037|NCT01889875|Active Comparator|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
16709038|NCT01889875|Active Comparator|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
16709039|NCT01889862|Active Comparator|BMN165 20mg/day|BMN165 20mg/day self-administered daily
16709040|NCT01889862|Placebo Comparator|20 mg/day Placebo|20 mg/day Placebo self-administered daily
16709041|NCT01889862|Active Comparator|BMN165 40mg/day|BMN165 40mg/day self-administered daily
16709042|NCT01889862|Placebo Comparator|40 mg/day Placebo|40 mg/day Placebo self-administered daily
16709043|NCT01889849|Experimental|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
16709044|NCT01889849|Active Comparator|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
16709045|NCT01889836|Experimental|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
16709046|NCT01889836|Active Comparator|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
16709047|NCT01889823|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
16709048|NCT01889823|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
16709049|NCT01889810|Active Comparator|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
16709050|NCT01889810|Placebo Comparator|Placebo|Placebo group
16709053|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
16709054|NCT01889784|Other|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
16709055|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
16709056|NCT01889784|Other|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
16709057|NCT01889771|Experimental|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
16709058|NCT01889771|Experimental|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
16709059|NCT01889758|Active Comparator|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
16709060|NCT01889758|Active Comparator|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
16709061|NCT01889758|Active Comparator|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
16709062|NCT01889732||ROTEM|
16709063|NCT01889719|Experimental|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
16709064|NCT01889719|Active Comparator|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
16709065|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
16709066|NCT01889693||chronic stable angina|patients with chronic stable angina
16709067|NCT01889693||control|control subjects without coronary artery disease
16709068|NCT01889680|Active Comparator|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
16709069|NCT01889680|Experimental|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
16709070|NCT01889667|Experimental|ORMD-0801 Dose # 1|Oral Insulin Formulation
16709071|NCT01889667|Experimental|ORMD-0801 Dose # 2|Oral Insulin Formulation
16709072|NCT01889667|Placebo Comparator|Placebo|Oil Capsules
16709073|NCT01889654||patient|
16709074|NCT01889654||healthy volunteers|
16709075|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
16709076|NCT01889641||healthy volunteers|Subjects controls
16709077|NCT01889628|Other|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
16709078|NCT01889628|Other|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
16709079|NCT01889628|Other|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
16709080|NCT01889615||Suspected ovarian cancer|dual time PET/CT
16709081|NCT01889602|Experimental|Topiramate 100mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
16709082|NCT01889602|Experimental|Topiramate 150mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 150mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
16709083|NCT01889602|Experimental|Topiramate 200mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 200mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
16709084|NCT01889589||NYC adults|
16709085|NCT01889576|Experimental|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of >= 1,9 mg/dL).
16709086|NCT01889576|No Intervention|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
16709209|NCT01888848|Experimental|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
16709087|NCT01889563|Experimental|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
16709088|NCT01889563|No Intervention|No Physical Exercise Training Program|No Physical Exercise Training Program
16709089|NCT01889550|Active Comparator|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
16709090|NCT01889550|Placebo Comparator|Access to the website www.ouh.dk|Access to the usual information from the hospital website
16709091|NCT01889537|Experimental|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
16709092|NCT01889537|Experimental|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
16709093|NCT01889524|Active Comparator|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
16709094|NCT01889524|Experimental|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
16709095|NCT01889511|Experimental|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
16709096|NCT01889511|No Intervention|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
16709097|NCT01889498|No Intervention|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
16709098|NCT01889498|Active Comparator|Acetazolamide|Treatment arm
16709099|NCT01889472|Active Comparator|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
16709100|NCT01889472|Experimental|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
16709101|NCT01889459||PCI for CTO|
16709102|NCT01889446|Placebo Comparator|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
16709103|NCT01889446|Placebo Comparator|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
16709104|NCT01889433|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
16709105|NCT01889433|Active Comparator|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight ≥75 kg)
16709106|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
16709107|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
16709108|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
16709109|NCT01889394|Active Comparator|limberg flap|primary wound closure using a limberg flap
16709110|NCT01889394|Active Comparator|secondary wound healing|secondary wound healing
16709111|NCT01889381|Experimental|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
16709112|NCT01889368|Active Comparator|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
16709113|NCT01889368|Placebo Comparator|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
16709114|NCT01889355|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
16709115|NCT01889342|Experimental|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
16709116|NCT01889342|Active Comparator|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark & Wells, 1995) and PTSD (Foa, 2007).
16709117|NCT01889329|Experimental|RUTF-1|Made from local food ingredients
16709118|NCT01889329|Experimental|RUTF-2|Made from local food ingredients
16709119|NCT01889329|Active Comparator|Plumpynut|Made from peanut
16709210|NCT01888848|Placebo Comparator|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
16709253|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
16709120|NCT01889316|Other|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).
~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
16709121|NCT01889303|Active Comparator|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.
~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
16709122|NCT01889303|Experimental|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles
~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
16709123|NCT01889290|Experimental|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
16709124|NCT01889277|Experimental|MT-3995-Low|MT-3995-Low Dose
16709125|NCT01889277|Experimental|MT-3995-High|MT-3995-High Dose
16709126|NCT01889277|Placebo Comparator|Placebo|Placebo
16709127|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
16709128|NCT01889251|Experimental|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
16709129|NCT01889251|Sham Comparator|Sham injection|Single sham injection to the study eye at baseline
16709131|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
16709132|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
16709133|NCT01889225||Framingham Heart study|
16709134|NCT01889225||Framingham Offspring cohort|
16709135|NCT01889225||Atherosclerosis Risk In Communities|
16709136|NCT01889225||Charleston Heart study|
16709137|NCT01889225||Cardiovascular Health study|
16709138|NCT01889225||Rancho Bernardo study|
16709139|NCT01889225||Nurses' Health I study|
16709140|NCT01889225||Panel Study Income Dynamics|
16709141|NCT01889225||MRFIT Referred Care|
16709142|NCT01889225||HDFP Referral Care|
16709143|NCT01889225||Alameda County Health and Ways of Living Study|
16709144|NCT01889225||Nurses' Health II study|
16709145|NCT01889225||Tecumseh County Health study|
16709146|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
16709147|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
16709148|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
16709149|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
16709150|NCT01889212|Experimental|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
16709151|NCT01889199|Placebo Comparator|Sugar pill|Placebo intervention
16709152|NCT01889199|Experimental|Flutamide|Flutamide 125 mg orally daily for six 28-day cycles.
16709153|NCT01889186|Experimental|Single arm|Single arm
16709154|NCT01889173|Experimental|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
16709155|NCT01889173|Experimental|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
16709156|NCT01889173|Experimental|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
16709157|NCT01889173|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
16709158|NCT01889160|Experimental|Part A Active|AZD4721 Solution
16709159|NCT01889160|Placebo Comparator|Part A Placebo|Placebo for AZD4721
16709160|NCT01889160|Experimental|Part B solution|AZD4721 Solution
16709161|NCT01889160|Active Comparator|Part B Suspension|AZD4721 Suspension
16709162|NCT01889147|Active Comparator|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
16709163|NCT01889147|Placebo Comparator|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
16709164|NCT01889147|Active Comparator|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
16709165|NCT01889134|Experimental|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
16709166|NCT01889134|Active Comparator|Parathyroidectomy|Selective parathyroidectomy
16709167|NCT01889134|No Intervention|Control group|No intervention
16709168|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
16709169|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
16709170|NCT01889108|No Intervention|Control|Usual care
16709171|NCT01889108|Experimental|Intervention group|Intervention with SPEEDI
16709172|NCT01889095|Experimental|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
16709173|NCT01889095|Active Comparator|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
16709174|NCT01889082|Active Comparator|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
16709175|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
16743217|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
16709176|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). *New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
16709177|NCT01889069|Experimental|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
16709178|NCT01889056|Experimental|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
16709179|NCT01889056|Placebo Comparator|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
16709180|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
16709181|NCT01889004|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
16709182|NCT01889004|Experimental|Propofol|Intravenous propofol using target controlled infusion
16709183|NCT01888991|No Intervention|water with resting condition|
16709184|NCT01888991|Experimental|glucose with resting condition|
16709185|NCT01888991|Experimental|water with exercise condition|
16709186|NCT01888991|Experimental|glucose with exercise condition|
16709187|NCT01888978|Experimental|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
16709188|NCT01888978|Experimental|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
16709189|NCT01888978|Experimental|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
16709190|NCT01888978|Experimental|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
16709191|NCT01888978|Experimental|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
16709192|NCT01888978|Experimental|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
16709193|NCT01888978|Experimental|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
16709194|NCT01888965|Experimental|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
16709195|NCT01888952|Experimental|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).
~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.
~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
16709196|NCT01888913||Adult Women|Adult Women aged 18-50
16709197|NCT01888900|Experimental|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
16709198|NCT01888900|Experimental|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
16709199|NCT01888887|Experimental|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
16709200|NCT01888874|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
16709201|NCT01888874|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
16709202|NCT01888874|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
16709203|NCT01888874|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
16709204|NCT01888874|Experimental|GLPG0634 25 mg BID|Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
16709205|NCT01888874|Experimental|GLPG0634 50 mg BID|Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
16709206|NCT01888874|Experimental|GLPG0634 100 mg BID|Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.
16709207|NCT01888861|Experimental|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
16709208|NCT01888861|Placebo Comparator|placebo|the patients in this arm were received 900mg placebo through NG tube.
16743218|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
16709213|NCT01888822|Placebo Comparator|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
16709214|NCT01888822|Active Comparator|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
16709215|NCT01888822|Active Comparator|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
16709216|NCT01888809|Experimental|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
16709217|NCT01888809|Active Comparator|Screening and referral|Annual screening and referral for services as needed
16709218|NCT01888796|Active Comparator|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
16709219|NCT01888796|Placebo Comparator|Placebo|Placebo (tablets) once daily for 6 month
16709220|NCT01888783|Experimental|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
16709221|NCT01888783|Active Comparator|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
16709222|NCT01888783|Active Comparator|Healthy Controls|Healthy adult persons.
16709223|NCT01888770||Normotensive Term|Infants born at term (>37 weeks) to Normotensive pregnancies
16709224|NCT01888770||Term Preeclampsia|Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
16709225|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at <37 weeks gestation
16709226|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at <37 weeks completed gestation
16709227|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
16709228|NCT01888757|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
16709229|NCT01888757|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
16709230|NCT01888744|Active Comparator|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH ≤ 10 IU/l and progesterone < 1,5ng/ml)
16709231|NCT01888744|Active Comparator|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
16709232|NCT01888731|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
16709233|NCT01888731|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
16709234|NCT01888718|Experimental|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
16709235|NCT01888718|Active Comparator|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
16709236|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
16709237|NCT01888705||NE|Smokers wiht normal spirometry.
16709238|NCT01888705||LV|Patients with COPD level I, mild.
16709239|NCT01888705||MOD|Patients with COPD level II, moderate.
16709240|NCT01888705||GV|Patients with COPD level III, severe.
16709241|NCT01888705||MGV|Patients with COPD level IV, very severe.
16709242|NCT01888679|Experimental|head movement|head movement in extension, flexion, right and left rotation
16709243|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
16709244|NCT01888666||slow palatal expansion (SPE)|
16709245|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
16709246|NCT01888653|Active Comparator|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
16709247|NCT01888640|Active Comparator|ActiveTENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
16709248|NCT01888640|Placebo Comparator|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
16709249|NCT01888640|No Intervention|No TENS (Standard Care)|Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
16709250|NCT01888627|Experimental|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
16709251|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
16709252|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
16709254|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
16709255|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
16709256|NCT01888575||Drug|PPI continuous use; No PPI use
16709257|NCT01888562|Experimental|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
16709258|NCT01888549|Experimental|arm1-High dose PPI|
16709259|NCT01888549|Active Comparator|arm2-standard dose PPI|
16709260|NCT01888549|Placebo Comparator|arm3-placebo|Esomeprazole placebo
16709261|NCT01888536|Experimental|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
16709262|NCT01888536|Active Comparator|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
16709263|NCT01888536|Active Comparator|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
16709264|NCT01888523|Experimental|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
16709265|NCT01888523|Experimental|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
16709266|NCT01888510|Experimental|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
16709267|NCT01888497|Experimental|Arm A|
16709268|NCT01888497|Experimental|Arm B|
16709269|NCT01888497|Active Comparator|Arm C|
16709270|NCT01888497|Placebo Comparator|Arm D|
16709271|NCT01888484|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
16709272|NCT01888471|Other|Cases Group|"Cases Group will be defined as:
~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:
~EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.
~LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
16709273|NCT01888471|Other|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
16709274|NCT01888458|Experimental|Micafungine|
16709275|NCT01888445|Experimental|ASP1517 Low dose group|Participants received an oral dose of ASP1517 three times a week.
16709276|NCT01888445|Experimental|ASP1517 Middle dose group|Participants received an oral dose of ASP1517 three times a week.
16709277|NCT01888445|Experimental|ASP1517 High dose group|Participants received an oral dose of ASP1517 three times a week.
16709278|NCT01888445|Active Comparator|Darbepoetin group|Participants received Darbepoetin alfa intravenously once a week.
16709279|NCT01888432|Experimental|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
16709280|NCT01888432|Active Comparator|Standard tacrolimus|Standard tacrolimus ± corticosteroids
16709281|NCT01888419|No Intervention|No active treatment|Clinical follow-up, no active intervention.
16709282|NCT01888419|Experimental|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
16709283|NCT01888406|Experimental|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
16709284|NCT01888406|Other|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
16709285|NCT01888393|Experimental|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
16709286|NCT01888393|Experimental|Group B|Approximately 12 healthy subjects (male and female)
16709287|NCT01888380|Experimental|Foetuses|"still birth and termination of pregnancies
~intervention: minimally invasive, virtual autopsy"
16709288|NCT01888380|Experimental|Newborns|"who died of natural- and non-natural cause
~intervention: minimally invasive, virtual autopsy"
16709289|NCT01888380|Experimental|Children and adolescents|"who died of natural- and non-natural cause
~intervention: minimally invasive, virtual autopsy"
16709290|NCT01888367|Experimental|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
16709291|NCT01888367|Placebo Comparator|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
16709292|NCT01888367|No Intervention|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
16709293|NCT01888354|Experimental|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
16709294|NCT01888354|Experimental|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
16709295|NCT01888341|Experimental|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
16709296|NCT01888341|Active Comparator|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
16709297|NCT01888328|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
16709298|NCT01888328|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
16709299|NCT01888315|Experimental|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:
~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
16709300|NCT01888315|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
16709347|NCT01887990|Placebo Comparator|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
16709974|NCT01883700|Experimental|High-GI, High-GL Meal|Instant Mashed Potatoes
16709301|NCT01888302|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
16709302|NCT01888289|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
16709303|NCT01888289|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
16709304|NCT01888276|Other|healthy volunteers|evaluation of word generation and of motivation
16709305|NCT01888276|Other|compulsive gamblers|evaluation of word generation and of motivation
16709306|NCT01888263|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
16709307|NCT01888263|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
16709308|NCT01888250|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
16709309|NCT01888250|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
16709310|NCT01888237|Active Comparator|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
16709311|NCT01888237|Experimental|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
16709312|NCT01888224|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
16709313|NCT01888224|Active Comparator|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
16709314|NCT01888211|Experimental|Omega 3 fatty acid supplementation|Omacor 2 grams daily
16709315|NCT01888211|Placebo Comparator|Olive Oil|Olive Oil capsule 2 grams daily
16709316|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
16709317|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
16709318|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
16709319|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
16709320|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
16709321|NCT01888172|Experimental|Weight Watchers Online|
16709322|NCT01888172|Experimental|Weight Watchers Online + ActiveLink|
16709323|NCT01888172|Active Comparator|Internet Delivered Eating and Activity Program|
16709324|NCT01888159|Active Comparator|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
16709325|NCT01888159|Active Comparator|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
16709326|NCT01888146|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
16709327|NCT01888146|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
16709328|NCT01888133|Experimental|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
16709329|NCT01888133|Experimental|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
16709330|NCT01888120||Severe Chronic Pain|
16709331|NCT01888107|Experimental|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
16709332|NCT01888094|Experimental|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
16709333|NCT01888094|Other|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
16709334|NCT01888081|Experimental|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
16709335|NCT01888068||No treatment|
16709336|NCT01888055|Experimental|transcranial direct current stimulation|
16709337|NCT01888055|Placebo Comparator|sham stimulation|
16709338|NCT01888042|Experimental|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
16709339|NCT01888029|Experimental|transcranial direct current stimulation|
16709340|NCT01888029|Placebo Comparator|sham stimulation|
16709341|NCT01888016|Experimental|fascial manipulation|
16709342|NCT01888016|Active Comparator|standard treatment|
16709343|NCT01888003|Active Comparator|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
16709344|NCT01888003|Other|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
16709345|NCT01888003|Other|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
16709346|NCT01887990|Active Comparator|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
16709348|NCT01887990|Active Comparator|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
16709349|NCT01887990|Placebo Comparator|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
16709350|NCT01887977|Experimental|Computational modeling|
16709351|NCT01887964|Other|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
16709352|NCT01887964|Other|Community-2|Received RS4 flour first and then control flour
16709353|NCT01887951|Active Comparator|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
16709354|NCT01887951|Experimental|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
16709355|NCT01887938|Experimental|Cohort 1|Participants will receive 10 milligram (mg) of HGT-1110 (Recombinant human arylsulfatase A) intrathecal (IT) injection every-other-week (EOW).
16709356|NCT01887938|Experimental|Cohort 2|Participants will receive 30 mg of HGT-1110 IT injection EOW.
16709357|NCT01887938|Experimental|Cohort 3|Participants will receive 100 mg of HGT-1110 IT injection EOW.
16709358|NCT01887938|Experimental|Cohort 4|Participants will receive 100 mg of HGT-1110 IT injection once weekly for 12 weeks followed by 150 mg EOW.
16709359|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
16709360|NCT01887912|Experimental|C. difficile Vaccine Group|Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
16709361|NCT01887912|Placebo Comparator|Placebo Group|Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
16709362|NCT01887899|Experimental|transcranial direct current stimulation|
16709363|NCT01887899|Placebo Comparator|sham stimulation|
16709364|NCT01887886|Experimental|Onartuzumab + Erlotinib|
16709365|NCT01887886|Active Comparator|Placebo + Erlotinib|
16709366|NCT01887873|Other|Hyaluronan Thiomer i.o. implantable device|active treatment
16709367|NCT01887860|Experimental|Cetaphil Daily Facial Moisturizer SPF50|All subjects receive Cetaphil Daily Facial Moisturizer SPF 50
16709368|NCT01887847|Experimental|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
16709369|NCT01887847|Active Comparator|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
16709370|NCT01887834|Placebo Comparator|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules
~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
16709371|NCT01887834|Active Comparator|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules
~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:
~Lactobacillus gasseri KS-13 1.2
~Bifidobacterium bifidum G9-1 0.15
~Bifidobacterium longum MM-2 0.15
~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
16709372|NCT01887821|Active Comparator|Chloroquine|25mg base/kg for 3 days
16709373|NCT01887821|Active Comparator|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
16709374|NCT01887808|Experimental|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
16709375|NCT01887795|Experimental|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
16709376|NCT01887795|Experimental|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
16709377|NCT01887782|Experimental|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
16709378|NCT01887782|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
16709379|NCT01887769||Lung cancer patient at diagnosis|
16709380|NCT01887756|Experimental|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
16709381|NCT01887743|Experimental|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
16709382|NCT01887730|Active Comparator|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
16709383|NCT01887730|Placebo Comparator|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
16709384|NCT01887730|Active Comparator|Arm 3|Hand cleaning with alcohol-containing hand rub
16709406|NCT01887548|Active Comparator|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
16709445|NCT01887327|Experimental|Stannsoporfin 4.5 mg/kg|Participants receive stannsoporfin (4.5 mg/kg) and phototherapy
16709446|NCT01887314|Experimental|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
16709385|NCT01887717|Experimental|TheraSphere|Participants will receive TheraSphere at a dose consistent with the approved product label to the treated lobe of the liver. TheraSphere will be administered through the hepatic artery. The target dose will be 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% will be permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere will be permitted if a treatable progression is detected during follow-up evaluations. Any re-treatment will take place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants can receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations will be permitted.
16709386|NCT01887717|Active Comparator|Sorafenib|Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
16709387|NCT01887704|Experimental|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.
~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.
~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
16709388|NCT01887704|Active Comparator|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.
~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
16709389|NCT01887691|Experimental|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
16709390|NCT01887678|Experimental|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
16709391|NCT01887678|Placebo Comparator|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
16709392|NCT01887665|Experimental|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
16709393|NCT01887652|Active Comparator|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
16709394|NCT01887652|Active Comparator|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
16709395|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
16709396|NCT01887626|Experimental|A|Ticagrelor 90 mg as a whole tablet
16709397|NCT01887626|Experimental|B|Ticagrelor 90 mg tablet crushed and suspended in water
16709398|NCT01887626|Experimental|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
16709399|NCT01887613||Regnite group|Patients who receive Regnite
16709400|NCT01887600|Experimental|Roxadustat|Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.
16709401|NCT01887600|Placebo Comparator|Placebo|Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.
16709402|NCT01887587|Experimental|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
~Dexamethasone- 10 mg/m2 orally or IV on days 1-14
~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
~MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.
~For patients without central nervous system (CNS) involvement:
~Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
~Methotrexate 12 mg administered intrathecally on day 8
~For patients with CNS involvement:
~-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
16709403|NCT01887574|Experimental|Open|
16709404|NCT01887561|No Intervention|treatment|
16709405|NCT01887548|Experimental|Active CD|Patients whose CDAI score >150 points would be enrolled in this group.
16709407|NCT01887535|Experimental|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
16709408|NCT01887535|Experimental|Cohort 2: JNJ-54861911 10 mg|
16709409|NCT01887535|Experimental|Cohort 3: JNJ-54861911 30 mg|
16709410|NCT01887535|Experimental|Cohort 4: JNJ-54861911 80 mg|
16709411|NCT01887535|Experimental|Cohort 5: JNJ-54861911 25 mg|
16709412|NCT01887535|Placebo Comparator|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
16709413|NCT01887522|Experimental|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:
~Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
16709414|NCT01887522|Active Comparator|Control Vinblastine only|"Control Vinblastine only arm:
~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
~Each 28-day cycle is repeated on Day 29/Day 1.
~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.
~Vinblastine will be temporarily stopped in case of neutropenia <1 x109/L or thrombopenia <75 x 109/L. It could be re-started at a reduced dose after complete recovery.
~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
16709415|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
16709416|NCT01887483|Active Comparator|Vetal Laban active|Vetal Laban with L. acidophilus
16709417|NCT01887483|Placebo Comparator|Placebo|Vetal Laban -like product without L. acidophilus
16709418|NCT01887470|Experimental|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
16709419|NCT01887470|Experimental|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
16709420|NCT01887470|Experimental|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
16709421|NCT01887470|Experimental|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
16709422|NCT01887457|Experimental|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
16709423|NCT01887444|Experimental|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
16709424|NCT01887444|Placebo Comparator|Placebo|Other: Placebo
16709425|NCT01887431|Experimental|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
16709426|NCT01887431|Active Comparator|Conventional therapy|3-month routine clinic visits
16709427|NCT01887418|Experimental|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
16709428|NCT01887418|Experimental|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
16709429|NCT01887418|Active Comparator|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
16709430|NCT01887405|Active Comparator|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
16709431|NCT01887405|Active Comparator|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
16709432|NCT01887392|Experimental|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
16709433|NCT01887392|Experimental|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
16709434|NCT01887379|Experimental|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
16709435|NCT01887379|Experimental|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
16709436|NCT01887366|Experimental|TV-1380 150 mg|
16709437|NCT01887366|Experimental|TV-1380 300 mg|
16709438|NCT01887366|Placebo Comparator|Placebo|
16709439|NCT01887353|Active Comparator|Ranolazine|
16709440|NCT01887353|Placebo Comparator|Placebo|
16709441|NCT01887340|Experimental|Cohort 1|"PET-TDM
~carboplatine: Dose (mg) = AUC x (GFR + 25)
~GFR : glomérulaire filtration (ml/min)
~AUC : area under curve (mg/ml x min)"
16709442|NCT01887340|Experimental|Cohort 2|"PET-TDM
~ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)
~carboplatine: Dose (mg) = AUC x (GFR + 25)
~GFR : glomérulaire filtration (ml/min)
~AUC : area under curve (mg/ml x min)"
16709443|NCT01887327|Placebo Comparator|Placebo|Participants receive placebo and phototherapy
16709444|NCT01887327|Experimental|Stannsoporfin 3.0 mg/kg|Participants receive stannsoporfin (3.0 mg/kg) and phototherapy
16709447|NCT01887314|Placebo Comparator|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
16709448|NCT01887301|Active Comparator|Group 1: mild hepatic impairment|Mild hepatic impairment: eight patients of Child-Pugh Grade A (Score 5-6). All patients received Sativex treatment.
16709449|NCT01887301|Active Comparator|Group 2: Moderate hepatic impairment|Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
16709450|NCT01887301|Experimental|Group 3: Pugh Grade B (Score 7-9).|Severe hepatic impairment: eight patients of Child-Pugh Grade C (Score 10-15). All patients received Sativex treatment.
16709451|NCT01887301|Active Comparator|Group 4: Control group|Control Group: eight healthy subjects matched with respect to age (±10 years), weight (±10% body mass index [BMI]) and sex to the severe or most severe evaluable patients. All patients received Sativex treatment.
16709452|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle
~(1 cycle - 4 weeks)"
16709453|NCT01887275|Experimental|medical ozone therapy with humares|
16709454|NCT01887275|Active Comparator|conventional interferon-α|
16709455|NCT01887262|Experimental|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
16709456|NCT01887262|Active Comparator|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
16709457|NCT01887249|Experimental|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
16709458|NCT01887249|Active Comparator|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
16709459|NCT01887249|No Intervention|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
16709460|NCT01887236|Active Comparator|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
16709461|NCT01887236|Active Comparator|Stability Ball|A physical activity program that is based on the Stability Ball
16709462|NCT01887223|Experimental|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
16709463|NCT01887223|Active Comparator|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
16709464|NCT01887210|Experimental|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
16709465|NCT01887210|Active Comparator|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
16709466|NCT01887197|Experimental|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
16709467|NCT01887197|Experimental|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
16709468|NCT01887184|Placebo Comparator|Normal Saline|Normal saline was given intranasally
16709469|NCT01887184|Active Comparator|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
16709470|NCT01887171|Experimental|Tacrolimus + HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
16709471|NCT01887171|No Intervention|HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
16709472|NCT01887158|Active Comparator|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
16709473|NCT01887158|Active Comparator|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
16709474|NCT01887145|Active Comparator|Open surgery|Open surgery is Open carpal tunnel release
16709475|NCT01887145|Experimental|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
16709476|NCT01887132|Experimental|Open-Label Donepezil|
16709477|NCT01887132|Experimental|Donepezil - Blinded|
16709478|NCT01887132|Placebo Comparator|Placebo|
16709479|NCT01887119|Active Comparator|Eplerenone|Eplerenone 50 mg 1dd during four weeks
16709480|NCT01887119|Placebo Comparator|Placebo|Eplerenone-matched placebo
16709583|NCT01886482|No Intervention|no intervention|control diet
16709481|NCT01887106|Experimental|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
16709482|NCT01887106|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
16709483|NCT01887106|Experimental|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
16709484|NCT01887106|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
16709485|NCT01887093|Experimental|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
16709486|NCT01887093|Experimental|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
16709487|NCT01887093|No Intervention|No walking|The control group was requested to maintain their usual level of physical activity.
16709488|NCT01887080|Experimental|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
16709489|NCT01887080|Experimental|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
16709490|NCT01887080|Other|Cardiovascular Risk Factors|Education about risk factors
16709491|NCT01887067|Experimental|Renal denervation therapy|
16709492|NCT01887054|Active Comparator|Training Group|"There are 2 study visits. Subjects in this group will complete the following:
~Visit 1
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments
~Taught how to complete a visual problem-solving task (Tower of Hanoi)
~Given a diary to record training at home.
~In-home
~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1
~Visit 2
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments"
16709493|NCT01887054|Placebo Comparator|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:
~Visit 1
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments
~Visit 2
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments"
16709494|NCT01887041|Active Comparator|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
16709495|NCT01887041|Active Comparator|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.
~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
16709496|NCT01887028|Experimental|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
16709497|NCT01887028|Other|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
16709498|NCT01887028|Other|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
16709499|NCT01887028|Other|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
16709500|NCT01887015|Experimental|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
16709501|NCT01887015|Other|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
16709502|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
16709503|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
16709504|NCT01886989|Experimental|Cocoa|Cocoa polyphenols (960mg)
16709505|NCT01886989|Placebo Comparator|Placebo|Placebo powder (109mg polyphenols) in water
16709506|NCT01886976|Experimental|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
16709507|NCT01886963|Active Comparator|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
16709508|NCT01886963|Experimental|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
16709584|NCT01886469|Experimental|Adolescents (12-17yrs)|
16709509|NCT01886937|Experimental|37.5 mg Phentermine daily for 7 days|"In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.
~Other names for phentermine:
~adipex ionamin"
16709510|NCT01886937|Placebo Comparator|Placebo (for phentermine 37.5mg)|In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
16709511|NCT01886924|Experimental|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
16709512|NCT01886924|Active Comparator|Nutrition Control|Computer delivered nutrition education
16709513|NCT01886911|Active Comparator|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
16709514|NCT01886911|Experimental|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
16709515|NCT01886911|Experimental|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
16709516|NCT01886911|Active Comparator|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
16709517|NCT01886898|Placebo Comparator|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
16709518|NCT01886898|Experimental|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
16709519|NCT01886898|Experimental|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
16709520|NCT01886898|Other|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
16709521|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
16709522|NCT01886872|Active Comparator|Arm I (rituximab, bendamustine hydrochloride)|Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
16709523|NCT01886872|Experimental|Arm II (ibrutinib)|Patients receive ibrutinib PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16709524|NCT01886872|Experimental|Arm III (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16709525|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
16709526|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.
~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
16709527|NCT01886820|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
16709528|NCT01886807|Other|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
16709529|NCT01886807|Other|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
16709530|NCT01886807|Experimental|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
16709531|NCT01886794|Experimental|Postmenopausal, topical vaginal cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to estrogen cream.
16709532|NCT01886794|No Intervention|Pre-menopausal, no topical vaginal cream|Pre-menopausal, no topical vaginal cream. These women will be examined at different stages in their menstrual cycle in order to compare characteristics of the cycle at high and lower estrogen timepoints.
16709533|NCT01886794|Placebo Comparator|Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to placebo.
16709534|NCT01886781|Experimental|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
16709535|NCT01886781|Placebo Comparator|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
16709536|NCT01886781|No Intervention|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
16709537|NCT01886781|No Intervention|Wash out period|Wash out period of two weeks, no treatment.
16709538|NCT01886768|Experimental|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
16709585|NCT01886469|Experimental|Children (6-11 yrs)|
16709586|NCT01886456|Experimental|PLT|patients treated with patterned laser trabeculoplasty
16709587|NCT01886456|Active Comparator|SLT|patients treated with selective laser trabeculoplasty
16709539|NCT01886768|Active Comparator|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
16709540|NCT01886755|Experimental|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
16709541|NCT01886755|Placebo Comparator|Placebo Comparator|Standard oral rehydration solution
16709542|NCT01886742|Active Comparator|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
16709543|NCT01886742|Experimental|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
16709544|NCT01886729|Active Comparator|tDCS simultaneously with hyperbaric oxygen therapy|
16709545|NCT01886729|Active Comparator|tDCS 3 weeks after start tinnitus|
16709546|NCT01886716|Experimental|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
16709547|NCT01886716|Experimental|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
16709548|NCT01886716|Experimental|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
16709549|NCT01886716|Placebo Comparator|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
16709550|NCT01886703|Experimental|Walking Intervention|Pedometer Walking Program
16709551|NCT01886690|Experimental|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
16709552|NCT01886690|Active Comparator|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
16709553|NCT01886677|Experimental|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
16709554|NCT01886677|Other|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
16709555|NCT01886664|Active Comparator|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
16709556|NCT01886664|Experimental|Desflurane|Performing liver transplantation under general anesthesia using desflurane
16709557|NCT01886638|Experimental|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
16709558|NCT01886625|Experimental|Sympathicotomy|unilateral single-port VATS sympathicotomy
16709559|NCT01886612|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.
~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
16709560|NCT01886599|Experimental|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
16709561|NCT01886599|Experimental|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
16709562|NCT01886599|Experimental|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
16709563|NCT01886599|Experimental|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
16709564|NCT01886599|Experimental|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
16709565|NCT01886586|Active Comparator|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
16709566|NCT01886586|Active Comparator|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
16709567|NCT01886586|Active Comparator|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
16709568|NCT01886573|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
16709569|NCT01886560|Placebo Comparator|Placebo|Adding eatable flour into the pills
16709570|NCT01886560|Experimental|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
16709571|NCT01886547||New patient presented with prostate disease|prostate disease identified
16709572|NCT01886534|Experimental|Enhanced Caregiver Support with Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©
~Standardized education sessions
~Heart Failure Diuretic Decision Support Tool for Patient Self Management©
~Digital talking scale"
16709573|NCT01886534|Other|Usual Care with Caregiver|Usual care
16709574|NCT01886534|Experimental|Enhanced Support without Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©
~Standardized education sessions
~Heart Failure Diuretic Decision Support Tool for Patient Self Management©
~Digital talking scale"
16709575|NCT01886534|Other|Usual Care without Caregiver|Usual Care
16709576|NCT01886521|Experimental|Lumbar drain group|Lumbar drain
16709577|NCT01886521|Active Comparator|Ventricular drain|Ventricular drain
16709578|NCT01886508|Experimental|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
16709579|NCT01886508|Active Comparator|RH|patients in Arm RH undergo radical hysterectomy (RH)
16709580|NCT01886495|Active Comparator|nutrition intervention|high protein diet
16709581|NCT01886495|No Intervention|control diet|
16709582|NCT01886482|Active Comparator|nutrition intervention|high protein diet
16709589|NCT01886430|Experimental|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
16709590|NCT01886430|Placebo Comparator|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
16709591|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
16709592|NCT01886391|Experimental|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
16709593|NCT01886378|Experimental|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
16709594|NCT01886365|Active Comparator|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
16709595|NCT01886365|Active Comparator|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
16709596|NCT01886365|Other|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
16709597|NCT01886352|Active Comparator|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
16709598|NCT01886352|Experimental|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
16709599|NCT01886352|Experimental|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
16709600|NCT01886339||Healthy population|
16709601|NCT01886326|Experimental|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
16709602|NCT01886326|Experimental|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
16709603|NCT01886326|Experimental|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
16709604|NCT01886326|Experimental|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
16709605|NCT01886326|Experimental|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
16709606|NCT01886326|Experimental|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
16709607|NCT01886313|Active Comparator|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
16709608|NCT01886313|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
16709609|NCT01886300||Cohort|
16709610|NCT01886287|Experimental|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
16709611|NCT01886274|Experimental|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
16709612|NCT01886274|Sham Comparator|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
16709613|NCT01886274|No Intervention|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
16709614|NCT01886248|Experimental|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
~Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
16709615|NCT01886235|Experimental|Diagnosis (intravital microscopy)|Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma.
16709616|NCT01886222|Experimental|Long-term mild hypothermia|Focused intervention
16709617|NCT01886222|Other|Normothermia|Standard management
16709618|NCT01886209|Experimental|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
16709619|NCT01886209|Experimental|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
16709620|NCT01886196|Experimental|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
16709621|NCT01886196|Placebo Comparator|placebo|placebo after exercise training sessions(3 times per week for 9 months)
16709622|NCT01886196|Experimental|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
16709623|NCT01886196|Sham Comparator|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
16709624|NCT01886183|Experimental|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
16709625|NCT01886183|Active Comparator|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
16709838|NCT01884623|Experimental|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
16709626|NCT01886170|No Intervention|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
16709627|NCT01886170|Experimental|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
16709628|NCT01886170|Experimental|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
16709629|NCT01886157|Active Comparator|Corticosteroid injection|Standard corticosteroid injection.
16709630|NCT01886157|Experimental|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
16709631|NCT01886144||Knee OA|People with knee OA of one knee
16709632|NCT01886131|Experimental|Synchronised video-polysomnography|
16709633|NCT01886118|Experimental|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
16709634|NCT01886118|Active Comparator|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
16709635|NCT01886105|Experimental|SmEDTMP/Autologous Stem Cell Infusion/RT|"DAY 1 Tracer dose 153Sm-EDTMP administration (1 mCi/kg) SPECT/High-resolution CT at 4 hours. SPECT/CT (low resolution) at 24 and 48 hrs
~DAY 7 Individualized treatment dose 153Sm-EDTMP administration (max 30 mCi/kg) SPECT scans at 4, 24 and 48 hours
~DAY 21 (2 weeks following treatment dose) Auto-Stem cell infusion
~DAY 40 (approx. two weeks after stem cell rescue) Initiate EBT upon count recovery
~1 MONTH following completion of all therapy Response assessment with repeat imaging (CT/MRI, Tc-99m bone scan) 18F-MISO/FDG PET"
16709636|NCT01886092|Active Comparator|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
16709637|NCT01886092|Active Comparator|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
16709638|NCT01886092|Active Comparator|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
16709639|NCT01886092|Sham Comparator|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
16709640|NCT01886079|Experimental|Dexmedetomidine group|
16709641|NCT01886079|Placebo Comparator|Saline group|
16709642|NCT01886066|Experimental|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
16709643|NCT01886053|Active Comparator|Ertapenem|
16709644|NCT01886053|Experimental|Faropenem（low-dose group)|
16709645|NCT01886053|Experimental|Faropenem（high dose group）|
16709646|NCT01886040||cases with endometrial cancer|
16709647|NCT01886027|Experimental|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
16709648|NCT01886027|Active Comparator|Relaxation|Relaxation training will teach patients different relaxation training skills.
16709649|NCT01886027|No Intervention|Wait-list control|Standard medical care until the 3-month follow-up is completed
16709650|NCT01886014|Experimental|oxytocin|application of intranasal oxytocin 40IE
16709651|NCT01886014|Placebo Comparator|placebo|"application of intranasal saline
~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
16709652|NCT01886001|Experimental|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
16709653|NCT01886001|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
16709654|NCT01886001|Experimental|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
16709655|NCT01886001|Sham Comparator|Control (no application)|Control arm, no product is applied, which is standard of care.
16709656|NCT01885988|Active Comparator|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
16709657|NCT01885988|Placebo Comparator|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
16709658|NCT01885962|No Intervention|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
16709659|NCT01885962|Experimental|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
16709661|NCT01885936|Experimental|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
16709662|NCT01885936|Placebo Comparator|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
16709692|NCT01885715|Placebo Comparator|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709839|NCT01884623|Active Comparator|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
16709975|NCT01883700|Experimental|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
16709663|NCT01885923|Active Comparator|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
16709664|NCT01885923|No Intervention|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
16709665|NCT01885910|Experimental|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
16709666|NCT01885897|Experimental|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
16709667|NCT01885884|Experimental|Supportive Care Intervention|Monthly (minimum) patient & caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
16709668|NCT01885884|No Intervention|Usual Care|Participants will receive standard oncology care from their oncology providers.
16709669|NCT01885871|Experimental|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
16709670|NCT01885858|Other|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
16709671|NCT01885858|Other|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
16709672|NCT01885845|Experimental|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
16709673|NCT01885845|Experimental|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
16709674|NCT01885832|Experimental|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
16709675|NCT01885819|Experimental|Treatment|Autologous stromal vascular fraction cells
16709676|NCT01885806|Experimental|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:
~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
16709677|NCT01885806|Sham Comparator|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
16709678|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
16709679|NCT01885780|Experimental|Astigmatic keratotomy|
16709680|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
16709681|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
16709682|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
16709683|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area < 55cm2/m2 for men and < 39 cm2/m2 for women
16709684|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
16709685|NCT01885741|Experimental|IPBS|
16709686|NCT01885728|Active Comparator|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
16709687|NCT01885728|No Intervention|No nutritional supplement|No specific nutritional requirements have to be met in this group.
16709688|NCT01885715|Placebo Comparator|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709689|NCT01885715|Active Comparator|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
16709690|NCT01885715|Active Comparator|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709691|NCT01885715|Active Comparator|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709758|NCT01885273|Experimental|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
16709903|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
16709693|NCT01885715|Active Comparator|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709694|NCT01885715|Active Comparator|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709695|NCT01885715|Active Comparator|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
16709696|NCT01885702|Experimental|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
16709697|NCT01885702|Experimental|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
16709698|NCT01885689|Experimental|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.
~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
16709699|NCT01885676|Experimental|PRGF-Endoret|
16709700|NCT01885676|Placebo Comparator|Saline Solution|
16709701|NCT01885663|Experimental|Umbilical cord blood therapy|Umbilical cord blood therapy
16709702|NCT01885650|Experimental|Normal airway clearance|The patients usual airway clearance technique
16709703|NCT01885650|Experimental|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
16709704|NCT01885637|No Intervention|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
16709705|NCT01885637|Other|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
16709706|NCT01885624|Experimental|TAB08|Single TAB08 i.v. infusion
16709707|NCT01885611|Active Comparator|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)
~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
16709708|NCT01885611|Experimental|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)
~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
16709709|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
16709710|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
16709711|NCT01885572|Other|TiLOOP Bra|Treatment with TiLOOP Bra
16709712|NCT01885559|Placebo Comparator|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
16709713|NCT01885559|Active Comparator|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
16709714|NCT01885546|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
16709715|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
16709716|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
16709717|NCT01885533||Post-radiodione medication|watchful monitoring
16709718|NCT01885520|Experimental|fasting condition|eperisone SR administrated under fasting condition
16709719|NCT01885520|Active Comparator|Fed condition|eperisone SR administrated under fed condition
16709720|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
16709721|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:
~the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)
~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
16709722|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
16709723|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
16709724|NCT01885494||Control group|Untreated control group
16709725|NCT01885481|Active Comparator|ESI-1|epidural steroid injection using dexamethasone
16709726|NCT01885481|Experimental|ESI-2|epidural steroid injection using betamethasone
16709727|NCT01885455|Active Comparator|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
16709728|NCT01885455|Experimental|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.
~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).
~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
16709729|NCT01885442|Experimental|In-bed leg cycle ergometry|
16709730|NCT01885429|Experimental|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
16709731|NCT01885429|Experimental|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
16709732|NCT01885429|Experimental|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
16709733|NCT01885429|Experimental|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
16709734|NCT01885429|Experimental|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
16709735|NCT01885416|Active Comparator|high fat meal without dairy products|high fat meal without dairy products
16709736|NCT01885416|Experimental|high fat meal with additional milk|high fat meal with additional milk
16709737|NCT01885416|Experimental|dairy product meal|dairy product meal
16709738|NCT01885403|Experimental|Respiratory Parameters Measurements|
16709739|NCT01885390|Experimental|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
16709740|NCT01885377|Experimental|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
16709741|NCT01885377|Active Comparator|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
16709742|NCT01885364|Placebo Comparator|Placebo & propofol|Pretreatment with normal saline before injection of propofol
16709743|NCT01885364|Experimental|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
16709744|NCT01885364|Experimental|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
16709745|NCT01885364|Active Comparator|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
16709746|NCT01885351|Experimental|Phase II: MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.
~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
16709747|NCT01885351|Experimental|Phase II: MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3 test-specific barriers/concerns in real time.
~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers"
16709748|NCT01885351|No Intervention|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
16709749|NCT01885338|Experimental|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
16709750|NCT01885338|Placebo Comparator|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
16709751|NCT01885325|Experimental|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
16709752|NCT01885325|No Intervention|Control|The preschools in the control group did not receive the intervention
16709753|NCT01885312|Active Comparator|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
16709754|NCT01885312|Other|Ecological Momentary Assessment|Mobile Assessment only
16709755|NCT01885312|Experimental|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
16709756|NCT01885312|Active Comparator|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
16709757|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
16709972|NCT01883700|Experimental|Low-GI, High-GL Meal|Boiled Pasta
16709759|NCT01885273|Active Comparator|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
16709760|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
16709761|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
16709762|NCT01885260|Placebo Comparator|Placebo|Placebo
16709763|NCT01885234|Experimental|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
16709764|NCT01885234|Placebo Comparator|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
16709765|NCT01885221|Experimental|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
16709766|NCT01885221|No Intervention|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
16709767|NCT01885208|Experimental|Semaglutide 1.0 mg|
16709768|NCT01885208|Active Comparator|Exenatide ER 2.0 mg|
16709769|NCT01885195|Experimental|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
16709770|NCT01885182|Experimental|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
16709771|NCT01885182|Active Comparator|Oxycodone|5mg, 10mg, 20mg or 40mg
16709772|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
16709773|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
16709774|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
16709775|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
16709776|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
16709777|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
16709778|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
16709779|NCT01885130|Experimental|Cetaphil Daily Advance Ultra Hydrating Lotion|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
16709780|NCT01885117|Experimental|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
16709781|NCT01885117|Experimental|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
16709782|NCT01885104|Experimental|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
16709783|NCT01885104|Placebo Comparator|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
16709784|NCT01885091|Experimental|Kinerase|
16709785|NCT01885078|Experimental|Baricitinib 4 mg|"Baricitinib 4 milligrams (mg) administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.
~Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
16709786|NCT01885078|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.
~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
16709787|NCT01885065|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
16709788|NCT01885052|Placebo Comparator|1|Receives weekly assessment messages ONLY
16709789|NCT01885052|Active Comparator|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
16709790|NCT01885052|Active Comparator|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
16709791|NCT01885026|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use, and Internet-based treatment for depression or anxiety
16709792|NCT01885026|Experimental|Control|Assessment only of alcohol and drug use and Internet-based treatment for depression or anxiety
16709793|NCT01885013|Experimental|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.
~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
16709794|NCT01885013|Active Comparator|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
16709795|NCT01885000|Experimental|Brimonidine tartrate 0.5% gel|Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
16709796|NCT01885000|Placebo Comparator|Vehicle|Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.
16709797|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
16709798|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
16709799|NCT01884961|Experimental|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.
~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.
~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
16709800|NCT01884948|Active Comparator|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
16709801|NCT01884948|Placebo Comparator|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
16709802|NCT01884935|Experimental|Natalizumab|300 mg intravenously (IV) every 4 weeks
16709803|NCT01884922|Experimental|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested
~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
16709804|NCT01884909|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
16709805|NCT01884909|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
16709806|NCT01884896|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
16709807|NCT01884896|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
16709808|NCT01884883|Other|Internal unicompartmental knee brace|
16709809|NCT01884870|Other|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
16709810|NCT01884857|Active Comparator|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
16709811|NCT01884857|Experimental|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
16709812|NCT01884844|Experimental|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
16709813|NCT01884844|Placebo Comparator|Placebo|methylcellulose po qday for 12weeks
16709814|NCT01884831|Experimental|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
16709815|NCT01884818|Experimental|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
16709816|NCT01884818|Sham Comparator|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
16709817|NCT01884805|Other|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
16709818|NCT01884792|Placebo Comparator|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
16709819|NCT01884792|Experimental|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
16709820|NCT01884792|Placebo Comparator|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
16709821|NCT01884792|Experimental|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
16709822|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
16709823|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
16709824|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
16709825|NCT01884740|Experimental|SIACI of Erbitux and Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 m/m2) and Bevacizumab (15 mg/kg)
16709826|NCT01884727|Active Comparator|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
16709827|NCT01884727|Placebo Comparator|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
16709828|NCT01884714|Experimental|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
16709829|NCT01884701|Experimental|Intervention|Intervention
16709830|NCT01884688|Experimental|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
16709831|NCT01884675|Experimental|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
16709832|NCT01884675|Placebo Comparator|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
16709833|NCT01884662|Experimental|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
16709834|NCT01884662|Active Comparator|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
16709835|NCT01884649||Group of Hashimoto thyroiditis patients|
16709836|NCT01884649||Healty control group|
16709837|NCT01884636|Experimental|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
16743219|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
16709840|NCT01884597|Active Comparator|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
16709841|NCT01884597|Active Comparator|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
16709842|NCT01884597|Active Comparator|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
16709843|NCT01884584|Experimental|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
16709844|NCT01884571|Experimental|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
16709845|NCT01884558|Experimental|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
16709846|NCT01884545|Active Comparator|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
16709847|NCT01884545|Experimental|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
16709848|NCT01884545|Experimental|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
16709849|NCT01884545|Experimental|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
16709850|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16709851|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16709852|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16709853|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16709854|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16709855|NCT01884519|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
16709856|NCT01884519|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
16709857|NCT01884506|Experimental|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
16709858|NCT01884506|Experimental|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
16709859|NCT01884493|Experimental|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
16709860|NCT01884493|Sham Comparator|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
16709861|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
16709862|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
16709863|NCT01884467|Experimental|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
16709864|NCT01884467|Placebo Comparator|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
16709865|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
16709866|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
16709867|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
16709868|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index <5/h.
16709869|NCT01884441|Experimental|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
16709870|NCT01884428|Experimental|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
16709871|NCT01884415|Experimental|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
16709872|NCT01884415|Active Comparator|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
16743220|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
16709873|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
16709874|NCT01884389|Experimental|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
16709875|NCT01884389|No Intervention|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
16709876|NCT01884376|Experimental|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
16709877|NCT01884363|Experimental|Walnuts|This group will receive one ounce of walnuts per day
16709878|NCT01884363|No Intervention|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
16709879|NCT01884350|Experimental|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
16709880|NCT01884350|Experimental|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
16709881|NCT01884337|Experimental|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
16709882|NCT01884324|No Intervention|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
16709883|NCT01884324|Experimental|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
16709884|NCT01884311|Experimental|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
16709885|NCT01884298|Experimental|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
16709886|NCT01884285|Experimental|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
16709887|NCT01884285|Experimental|Part C2: AZD8186/abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
16709888|NCT01884285|Experimental|Part D1: AZD8186 and AZD2014|Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
16709889|NCT01884285|Experimental|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
16709890|NCT01884285|Experimental|Part D2: AZD8186/ AZD2014|Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
16709891|NCT01884285|Experimental|Part C1: AZD8186 & abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
16709892|NCT01884272|Experimental|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
16709893|NCT01884272|Active Comparator|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
16709894|NCT01884259|Active Comparator|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).
~Active comparator is 5-fluorouracil for first three cycles."
16709895|NCT01884259|Experimental|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).
~Experimental: cetuximab for the first three cycles."
16709896|NCT01884246|Experimental|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
16709897|NCT01884246|Active Comparator|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
16709898|NCT01884233|Experimental|Text Messaging CBT|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
16709899|NCT01884233|Active Comparator|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
16709900|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
16709901|NCT01884207||orbital tumors|
16709902|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
16743484|NCT01658072|Experimental|Peri-Articular Injection|
16709904|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
16709905|NCT01884181||Healthy Controls|"The healthy control subjects without a clinically significant neuropsychiatric disorders.
~Able to understand and provide signed informed consent.
~Age range and gender matched with Patients with Huntington Disease Group."
16709906|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
16709907|NCT01884155|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
16709908|NCT01884142|No Intervention|Heart Failure Untrained Group|Control Group
16709909|NCT01884142|Experimental|Heart Failure Exercise-trained Group|Aerobic Exercise Training
16709910|NCT01884116|Active Comparator|NSAID patch group|administer the NSAID patch
16709911|NCT01884116|Experimental|NSAID patch + transcutaneous electric nerve stimulation group|
16709912|NCT01884116|Experimental|NSAID patch + heating pad group|
16709913|NCT01884116|Experimental|NSAID patch + topical capsaicin group|
16709914|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
16709915|NCT01884090|Experimental|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
16709916|NCT01884090|Active Comparator|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
16709917|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
16709918|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
16709919|NCT01884064|Experimental|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
16709920|NCT01884064|Placebo Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
16709921|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
16709922|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
16709923|NCT01884038|Experimental|1|
16709924|NCT01884038|Placebo Comparator|2|
16709925|NCT01884025|Experimental|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
16709926|NCT01884025|Sham Comparator|Health and Humor Class|Equally engaging attention control condition
16709927|NCT01884012|Experimental|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
16709928|NCT01884012|Sham Comparator|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
16709929|NCT01883999|Experimental|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
16709930|NCT01883986|Experimental|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
16709931|NCT01883986|No Intervention|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
16709932|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
16709933|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
16709934|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
16709935|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
16709936|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
16709937|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
16709938|NCT01883947|Experimental|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
16709939|NCT01883947|Sham Comparator|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
16709940|NCT01883934|Experimental|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
16709941|NCT01883934|Active Comparator|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
16709942|NCT01883921||Immunoglobulin Therapy|
16709973|NCT01883700|Experimental|Low-GI, High GL Meal|Boiled Chickpeas with Oil
16709943|NCT01883908|Experimental|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
16709944|NCT01883908|Active Comparator|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
16709945|NCT01883895|Other|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.
~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.
~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.
~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
16709946|NCT01883882|Experimental|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
16709947|NCT01883882|No Intervention|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
16709948|NCT01883869|Experimental|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
16709949|NCT01883869|Placebo Comparator|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
16709950|NCT01883856|Active Comparator|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
16709951|NCT01883856|Experimental|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
16709952|NCT01883843|Experimental|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.
~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
16709953|NCT01883843|Active Comparator|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
16709954|NCT01883830|Experimental|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
16709955|NCT01883830|Active Comparator|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
16709956|NCT01883817|Placebo Comparator|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
16709957|NCT01883817|Experimental|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
16709958|NCT01883804|Experimental|Study group|All participants selected to continue with Methyldopa administration.
16709959|NCT01883791|Experimental|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
16709960|NCT01883791|Other|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
16709961|NCT01883778||Emergency Department Patients|
16709962|NCT01883778||Emergency Medicine Physicians|
16709963|NCT01883765|Experimental|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
16709964|NCT01883765|Sham Comparator|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
16709965|NCT01883765|Active Comparator|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
16709966|NCT01883752|No Intervention|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
16709967|NCT01883752|Experimental|Goal-directed Therapy group|Goal-direct therapy
16709968|NCT01883739|Experimental|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
16709969|NCT01883726|Experimental|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
16709970|NCT01883726|Experimental|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap [3]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
16709971|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
16709976|NCT01883687|Experimental|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
16709977|NCT01883687|No Intervention|No septoplasty|patient will only receive Le Fort I osteotomy
16709978|NCT01883674|Experimental|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
16709979|NCT01883674|Experimental|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
16709980|NCT01883674|Placebo Comparator|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
16709981|NCT01883661|Other|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
16709982|NCT01883648|Experimental|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
16709983|NCT01883648|Placebo Comparator|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
16709984|NCT01883635|Active Comparator|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
16709985|NCT01883635|Experimental|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
16709986|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
16709987|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
16709988|NCT01883622||Healthy|Healthy pregnant women
16709989|NCT01883609|Active Comparator|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
16709990|NCT01883609|Active Comparator|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
16709991|NCT01883609|No Intervention|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
16709992|NCT01883609|No Intervention|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
16709993|NCT01883596|Experimental|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
16709994|NCT01883596|Placebo Comparator|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
16709995|NCT01883583|Experimental|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
16709996|NCT01883570|Experimental|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
16709997|NCT01883570|Active Comparator|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
16709998|NCT01883544|Experimental|ALXN1007|Infusion of ALXN1007
16709999|NCT01883544|Placebo Comparator|placebo|Infusion placebo
16710000|NCT01883531|Placebo Comparator|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
16710001|NCT01883531|Active Comparator|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
16710002|NCT01883518|Experimental|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
16710003|NCT01883505|Experimental|ND0612|levodopa and carbidopa solution
16710004|NCT01883505|Placebo Comparator|Placebo|Saline
16710005|NCT01883492|Experimental|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).
~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.
~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
16710006|NCT01883492|Active Comparator|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).
~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.
~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
16710007|NCT01883479|Experimental|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
16710008|NCT01883479|Experimental|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
16710009|NCT01883479|No Intervention|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
16710010|NCT01883466|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
16710011|NCT01883466|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
16710012|NCT01883453|Placebo Comparator|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
16710013|NCT01883453|Active Comparator|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
16710014|NCT01883440|Placebo Comparator|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
16710015|NCT01883440|Active Comparator|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
16710016|NCT01883427|Placebo Comparator|Placebo: Saline+glucose nasal spray|Subjects received nasal spray containing both saline+glucose twice daily for 3 months
16710017|NCT01883427|Active Comparator|Nasal spray with glucose oxidase+glucose|Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
16710018|NCT01883414|Active Comparator|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
16710019|NCT01883414|Active Comparator|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
16710020|NCT01883401|Experimental|High dose strawberry|50g freeze-dried strawberries/day
16710021|NCT01883401|Experimental|Low-dose strawberry|25g freeze-dried strawberries/day
16710022|NCT01883401|Other|Fiber/calorie control (high dose)|Dietary fiber (8g)
16710023|NCT01883401|Other|Fiber/calorie control (low dose)|Dietary fiber (4g)
16710024|NCT01883375|Experimental|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
16710025|NCT01883375|Experimental|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
16710026|NCT01883362|Experimental|Standard of Care with Midostaurin|Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
16710027|NCT01883362|Active Comparator|Standard of Care|Patients received standard of care alone in the post SCT setting
16710028|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation
16710029|NCT01883349||Control Arm|Subjects without kidney disease
16710030|NCT01883323|Experimental|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
16710031|NCT01883310|Active Comparator|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
16710032|NCT01883310|Experimental|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
16710033|NCT01883297|Experimental|Re-Stimulated Tumor-Infiltrating Lymphocytes and interleukin-2|Cyclophosphamide will be given prior to Re-Stimulated Tumor-Infiltrating Lymphocytes, and interleukin-2.
16710034|NCT01883284|Experimental|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
16710035|NCT01883284|Other|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
16710036|NCT01883271|Experimental|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
16710037|NCT01883271|Experimental|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
16710038|NCT01883271|No Intervention|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
16710039|NCT01883271|No Intervention|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
16710040|NCT01883258|Experimental|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
16710041|NCT01883258|Experimental|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
16710042|NCT01883258|No Intervention|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
16710043|NCT01883258|No Intervention|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
16710044|NCT01883245|Active Comparator|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
16710045|NCT01883245|Experimental|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.
~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
16710046|NCT01883232|Active Comparator|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
16710047|NCT01883232|Experimental|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
16710048|NCT01883219|Experimental|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
16710085|NCT01882946|Experimental|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
16710049|NCT01883193|Experimental|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
16710050|NCT01883193|Experimental|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
16710051|NCT01883193|No Intervention|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
16710052|NCT01883180|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
16710053|NCT01883180|Experimental|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
16710054|NCT01883167|Experimental|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.
~Days 15-21: RDEA3170 10 mg or placebo qd."
16710055|NCT01883167|Experimental|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.
~Days 15-21: febuxostat 40 mg qd."
16710056|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
16710057|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
16710058|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
16710059|NCT01883154||IVF pregnancies|
16710060|NCT01883141|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure
16710061|NCT01883128|Experimental|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
16710062|NCT01883128|Experimental|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
16710063|NCT01883128|Experimental|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
16710064|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
16710065|NCT01883102|Experimental|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
16710066|NCT01883102|Placebo Comparator|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
16710067|NCT01883089|Other|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
16710068|NCT01883076|Experimental|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
16710069|NCT01883063|Experimental|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
16710070|NCT01883063|Active Comparator|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
16710071|NCT01883050|Other|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
16710072|NCT01883050|No Intervention|No Intervention|No Intervention
16710073|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
16710074|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
16710075|NCT01883024|Other|Type 1 diabetes|
16710076|NCT01883011|Experimental|Piracetam|"IV infusion 12 g piracetam in 60 ml
~IV Ampoules 3 g piracetam in 15 ml
~Oral solution 33 % piracetam (bottle of 125 ml)
~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
16710077|NCT01883011|Placebo Comparator|Placebo|"IV infusion 12 g placebo in 60 ml
~IV Ampoules 3 g placebo in 15 ml
~Oral solution 33% placebo (bottle of 125 ml)
~Oral tablets 1200 mg placebo (blisters of 10 tablets)
~All IV forms were identical in presentation, size and color to allow a double blind design.
~All oral forms were identical in shape, size, color and taste to allow a double blind design."
16710078|NCT01882998|Experimental|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
16710079|NCT01882998|Experimental|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
16710080|NCT01882985|Experimental|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
16710081|NCT01882972|Experimental|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
16710082|NCT01882972|Placebo Comparator|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
16710083|NCT01882959||Placebo|
16710084|NCT01882959||Intervention|Radiofrequncy Denervation
16710086|NCT01882933|Experimental|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
16710087|NCT01882933|Other|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
16710088|NCT01882920|Experimental|Goal directed therapy intravenous restricitve fluid protocol|
16710089|NCT01882920|Active Comparator|Control arm|
16710090|NCT01882907|Experimental|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
16710091|NCT01882907|Active Comparator|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
16710092|NCT01882894|Experimental|Custom PFO orthosis|This is a custom made orthosis
16710093|NCT01882894|Placebo Comparator|Faux foot orthosis|Foam insert without arch support
16710094|NCT01882881|Active Comparator|Healthy American Control Diet|
16710095|NCT01882881|Experimental|Dark Chocolate/Cocoa Diet|
16710096|NCT01882881|Experimental|Almond Diet|
16710097|NCT01882881|Experimental|Dark Chocolate/Cocoa + Almond Diet|
16710098|NCT01882868|Experimental|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m^2 (2 hours) and irinotecan 180 mg/m^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m^2.
16710099|NCT01882842|Experimental|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
16710100|NCT01882842|No Intervention|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
16710101|NCT01882829|Experimental|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
16710102|NCT01882816|Experimental|IMRT and doxorubicin|All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.
16710103|NCT01882803|Experimental|Duvelisib|
16710104|NCT01882777|No Intervention|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
16710105|NCT01882777|Active Comparator|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
16710106|NCT01882764|Experimental|HMPL-004 1800 mg/day|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of HMPL-004 (600 mg TID; total dose 1800 mg/day) daily, for 52 weeks.
~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
16710107|NCT01882764|Placebo Comparator|Placebo|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of Placebo tablets TID, daily, for 52 weeks.
~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
16710108|NCT01882751||ConforMIS|Patients with ConforMIS implants
16710109|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
16710110|NCT01882725|Experimental|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
16710111|NCT01882712|Experimental|CD07805/47 Gel 0.5%|active arm
16710112|NCT01882712|Placebo Comparator|CD07805/47 Gel Placebo|Comparator arm
16710113|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
16710114|NCT01882686|Experimental|Classification Based Cognitive Functional Therapy|
16710115|NCT01882673|Experimental|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
16710116|NCT01882673|Active Comparator|Nutrition Control|Computer delivered nutrition education
16710117|NCT01882660|Experimental|Decitabine treatment|Treatment with decitabine
16710118|NCT01882647|Experimental|Active Arm|Topical lotion, applied twice daily
16710119|NCT01882647|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
16710120|NCT01882634|Experimental|Ultrasound arm|
16710121|NCT01882621|Active Comparator|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
16710122|NCT01882621|Placebo Comparator|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
16710123|NCT01882608|No Intervention|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
16710124|NCT01882608|Experimental|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
16710125|NCT01882595|Experimental|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
16710126|NCT01882595|Active Comparator|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
16710127|NCT01882569||Back surgery|
16710372|NCT01881035|Experimental|Renal nerve denervation|Renal nerve denervation
16710128|NCT01882556|Experimental|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
16710129|NCT01882556|Placebo Comparator|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
16710130|NCT01882543|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
16710131|NCT01882543|Placebo Comparator|Placebo|1 x placebo capsule daily
16710132|NCT01882530|Placebo Comparator|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710133|NCT01882530|Experimental|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710134|NCT01882530|Experimental|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710135|NCT01882530|Experimental|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710136|NCT01882530|Experimental|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710137|NCT01882530|Experimental|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710138|NCT01882530|Experimental|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710139|NCT01882530|Experimental|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
16710140|NCT01882517|Active Comparator|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
16710141|NCT01882517|Placebo Comparator|Placebo yogurt|Dietary Supplement: Placebo yogurt
16710142|NCT01882504|Experimental|gevokizumab|Solution for subcutaneous injection
16710143|NCT01882491|Placebo Comparator|Placebo|
16710144|NCT01882491|Experimental|gevokizumab|
16710146|NCT01882465|Other|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
16710147|NCT01882465|Other|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
16710148|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
16710149|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
16710150|NCT01882465|Other|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
16710151|NCT01882465|Other|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
16710152|NCT01882452|Experimental|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
16710153|NCT01882452|Active Comparator|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
16710154|NCT01882439|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
16710155|NCT01882439|Experimental|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
16710156|NCT01882439|Placebo Comparator|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
16710157|NCT01882439|Placebo Comparator|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
16710158|NCT01882426|Active Comparator|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
16710159|NCT01882426|Placebo Comparator|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
16710160|NCT01882413||Patients with Planned Cataract Removal|Patients with planned cataract removal surgery are evaluated for the presence of inflammatory dry eye disease. No treatment is administered.
16710161|NCT01882400|Experimental|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
16710254|NCT01881776|Active Comparator|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
16710162|NCT01882387|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
16710163|NCT01882374|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
16710164|NCT01882361|Active Comparator|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
16710165|NCT01882361|Placebo Comparator|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
16710166|NCT01882348|No Intervention|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.
~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.
~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
16710167|NCT01882348|Experimental|Intervention|The Intervention Group will receive the CEASE Intervention
16710168|NCT01882335|Experimental|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
16710169|NCT01882335|No Intervention|Control|No peer support for exclusive breastfeeding
16710170|NCT01882322|Experimental|Advagraf conversion group|Oral
16710171|NCT01882322|Active Comparator|Prograf maintenance group|Oral
16710172|NCT01882296|Experimental|AGSPT_10|tablet, 10mg, QD, 7days
16710173|NCT01882296|Experimental|AGSPT_20|tablet, 20mg, QD, 7days
16710174|NCT01882296|Experimental|AGSPT_40|tablet, 20mg x 2, QD, 7days
16710175|NCT01882296|Active Comparator|Pantoprazole_20|tablet, 20mg, QD, 7days
16710176|NCT01882296|Active Comparator|Pantoprazole_40|tablet, 40mg, QD, 7days
16710177|NCT01882283|Experimental|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
16710178|NCT01882283|Placebo Comparator|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
16710179|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
16710180|NCT01882257|No Intervention|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
16710181|NCT01882257|Experimental|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
16710182|NCT01882257|Experimental|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
16710183|NCT01882244|Experimental|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
16710184|NCT01882244|Active Comparator|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
16710185|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
16710186|NCT01882218|Active Comparator|Standard treatment|Standard liver surgery and post-operative treatment
16710187|NCT01882218|Experimental|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
16710188|NCT01882205|Active Comparator|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
16710189|NCT01882205|Experimental|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
16710190|NCT01882205|Active Comparator|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
16710191|NCT01882205|Experimental|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
16710192|NCT01882205|Active Comparator|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
16710193|NCT01882205|Experimental|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
16710194|NCT01882192|Experimental|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
16710195|NCT01882192|No Intervention|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
16710196|NCT01882179|Placebo Comparator|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
16710579|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
16710197|NCT01882179|Active Comparator|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible
~In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
16710198|NCT01882166|Experimental|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
16710199|NCT01882166|Experimental|puregon|subcutaneous 150 IE Puregon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
16710200|NCT01882153|Experimental|Developmentally Based Intervention|
16710201|NCT01882153|Experimental|Behaviorally Based Intervention|
16710202|NCT01882140|Experimental|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
16710203|NCT01882140|Placebo Comparator|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
16710204|NCT01882127|Active Comparator|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
16710205|NCT01882127|Experimental|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
16710206|NCT01882101|Experimental|Posterior tibial nerve stimulation|
16710207|NCT01882101|Experimental|Biofeedback|
16710208|NCT01882088|Experimental|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
16710209|NCT01882075|Active Comparator|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
16710210|NCT01882075|Experimental|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
16710211|NCT01882062|Experimental|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
16710212|NCT01882049|Experimental|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
16710213|NCT01882036|Active Comparator|Gastric Bypass w/ matched hypocaloric diet|
16710214|NCT01882036|Active Comparator|Hypocaloric Diet|
16710215|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders.
16710216|NCT01882023||Healthy Controls|Age- and gender matched healthy controls.
16710217|NCT01882010|Sham Comparator|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
16710218|NCT01882010|Placebo Comparator|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
16710219|NCT01882010|Experimental|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
16710220|NCT01881997|Placebo Comparator|Normal Saline|IM normal saline
16710221|NCT01881997|Experimental|Fentanyl|IM Fentanyl
16710222|NCT01881984|Experimental|Ravicti|Open Label Study
16710223|NCT01881971|Placebo Comparator|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
16710224|NCT01881971|Experimental|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
16710225|NCT01881958|Experimental|DiaPep277®|
16710226|NCT01881945|Experimental|Physiological measurments|
16710227|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
16710228|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
16710229|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
16710230|NCT01881919|Experimental|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
16710231|NCT01881919|Placebo Comparator|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
16710371|NCT01881048|Experimental|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
16710232|NCT01881906|Other|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
16710233|NCT01881906|Other|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
16710234|NCT01881893|No Intervention|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
16710235|NCT01881893|Experimental|ACHD-CARE Program|"Group based psychosocial intervention.
~Educational: congenital heart disease information
~Behavioral: cognitive behavioral therapy
~Behavioral: social interactions and communication skills"
16710236|NCT01881880|Other|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
16710237|NCT01881867|No Intervention|Cohort I (no therapy)|Patients receive no treatment (observation) after completion of standard sipuleucel-T therapy.
16710238|NCT01881867|Experimental|Cohort II (glycosylated recombinant human interleukin-7)|Patients receive glycosylated recombinant human interleukin-7 SC every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
16710239|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
16710240|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
16710241|NCT01881841|No Intervention|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
16710242|NCT01881841|Experimental|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
16710243|NCT01881828|Experimental|Metformin|Metformin 2000 mg per day
16710244|NCT01881828|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.
~The placebo product will contain the following components:
~Micosolle™, silica based excipient
~Silicified Micro Crystalline Cellulose, National Formulary
~Safflower Oil, United States Pharmacopeia
~K-30 Povidone Powder
~Magnesium Stearate, National Formulary (Vegetable source)
~Fumed Silica, National Formulary"
16710245|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
16710246|NCT01881802||morphine or heroin dependence patients|
16710247|NCT01881802||normal control group|
16710248|NCT01881789|Experimental|Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
16710249|NCT01881789|Experimental|Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 180 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
16710250|NCT01881789|Experimental|Oprozomib 210 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
16710251|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
16710252|NCT01881789|Experimental|Oprozomib 240 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
16710253|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Cyclophosphamide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with oral cyclophosphamide 300 mg/m² on days 1, 8, and 15 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 8 cycles, whichever occurred first. After completing 8 cycles of treatment, participants with stable disease or better were to continue on oprozomib with dexamethasone premedication for a total of 24 cycles or until progression of disease or unacceptable toxicity. After completing 24 cycles of treatment, participants without evidence of disease progression could have continued on oprozomib with or without dexamethasone pretreatment.
16710255|NCT01881776|Active Comparator|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
16710256|NCT01881776|No Intervention|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
16710257|NCT01881763|Experimental|Ketamine|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
16710258|NCT01881763|Active Comparator|Methohexital|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
16710259|NCT01881750|Experimental|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
16710260|NCT01881750|Placebo Comparator|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
16710261|NCT01881737|Experimental|Pregnenolone|Pregnenolone up to 500 mg per day
16710262|NCT01881724|No Intervention|Usual Care|
16710263|NCT01881724|Experimental|sleep education program|
16710264|NCT01881711|Experimental|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
16710265|NCT01881711|Active Comparator|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
16710266|NCT01881711|Experimental|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
16710267|NCT01881711|Active Comparator|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
16710268|NCT01881711|Experimental|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
16710269|NCT01881711|Active Comparator|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
16710270|NCT01881672||Coma patients in ICU under mechanical ventilation|
16710271|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
16710272|NCT01881646|Experimental|Positron emission tomography (PET)|Positron emission tomography (PET) using [11C]PBR28
16710273|NCT01881633|Experimental|ISU302|15 U/kg I.V. injection
16710274|NCT01881633|Experimental|ISU302 30 U/kg|Drug ISU302 I.V. injection
16710275|NCT01881633|Experimental|ISU302 60 U/kg|Drug ISU302 I.V. injection
16710276|NCT01881633|Placebo Comparator|Placebo|ISU302 Placebo I.V. injection
16710277|NCT01881620|Experimental|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
16710278|NCT01881607|No Intervention|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
16710279|NCT01881607|Experimental|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
16710280|NCT01881594|Active Comparator|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
16710281|NCT01881594|Experimental|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
16710282|NCT01881581|Experimental|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
16710283|NCT01881581|Experimental|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
16710284|NCT01881581|Experimental|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
16710285|NCT01881581|Experimental|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
16710286|NCT01881581|Experimental|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
16710287|NCT01881581|Experimental|High dose MVA or Placebo|300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
16710288|NCT01881581|Experimental|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
16710327|NCT01881295|Placebo Comparator|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
16710289|NCT01881581|Experimental|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
16710290|NCT01881568|Experimental|Experimental|"Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:
~50mL by irrigation before wound closure
~50mL by intraarticular administration (Drenofast) after wound closure.
~Intravenous administration of Normal saline (0.9% sodium chloride) as follow:
~100mL before tourniquet realised
~100mL 3 hours after surgery"
16710291|NCT01881568|Active Comparator|Comparator|"Topical administration of Normal saline (0.9% sodium chloride) as follow:
~50mL by irrigation before wound closure
~50mL by intraarticular administration (Drenofast) after wound closure
~Intravenous administration of two dosis of Tranexamic Acid as follow:
~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised
~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
16710292|NCT01881555|Other|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.
~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
16710293|NCT01881555|Other|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
16710294|NCT01881529||Limited Scleroderma|
16710295|NCT01881529||Diffuse Scleroderma|
16710296|NCT01881516|Active Comparator|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
16710297|NCT01881516|Sham Comparator|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
16710298|NCT01881503|Other|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
16710299|NCT01881490|Active Comparator|Group 1|120 Children with Crohn's disease undergoing MRE & colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
16710300|NCT01881490|Active Comparator|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
16710301|NCT01881477|Experimental|kinetics modalities|passive movements active movements assisted movements resisted movements
16710302|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
16710303|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
16710304|NCT01881425|Experimental|InnFocus MicroShunt|InnFocus MicroShunt
16710305|NCT01881425|Active Comparator|Trabeculectomy|glaucoma surgery to reduce IOP
16710306|NCT01881412|Experimental|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
16710307|NCT01881412|Placebo Comparator|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
16710308|NCT01881399|Experimental|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:
~Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)
~Virtual cholangiography (enhanced-reality) superimposed on fluorescence images
~Conventional IOC (intraoperative cholangiography)"
16710309|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
16710310|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
16710311|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
16710312|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
16710313|NCT01881373|Experimental|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
16710314|NCT01881373|Other|Delayed Optimized CHL program|Comparison community that participated in community engagement process and received delayed optimized program.
16710315|NCT01881373|No Intervention|Temporal|Communities assessed for temporal trends in anthropometry.
16710316|NCT01881360|Experimental|Gluten-free diet|
16710317|NCT01881360|Active Comparator|Hypocaloric diet|
16710318|NCT01881347|Experimental|Active First|Active resveratrol first, placebo second
16710319|NCT01881347|Experimental|Placebo first|Placebo first, active resveratrol second
16710320|NCT01881321|Experimental|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
16710321|NCT01881321|No Intervention|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
16710322|NCT01881308|Active Comparator|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
16710323|NCT01881308|Experimental|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
16710324|NCT01881308|Active Comparator|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
16710325|NCT01881308|Experimental|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
16710326|NCT01881308|Other|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
16744779|NCT01649531|Active Comparator|Control group|2 Implants
16710328|NCT01881295|Experimental|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
16710329|NCT01881295|Experimental|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
16710330|NCT01881295|Experimental|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
16710331|NCT01881295|Experimental|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
16710332|NCT01881295|Experimental|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
16710333|NCT01881295|Experimental|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
16710334|NCT01881295|Experimental|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
16710335|NCT01881295|Experimental|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
16710336|NCT01881282|Experimental|Carraghenates Cream|
16710337|NCT01881282|Active Comparator|Mayinglong Musk Hemorrhoid Ointment|
16710338|NCT01881269||No treatment|No treatment, prospective observational
16710339|NCT01881243||Adult patients resuscitated from cardiac arrest|
16710340|NCT01881230|Experimental|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
16710341|NCT01881230|Experimental|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
16710342|NCT01881230|Active Comparator|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
16710343|NCT01881217|Experimental|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
16710344|NCT01881217|Experimental|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
16710345|NCT01881217|Experimental|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
16710346|NCT01881204|Experimental|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
16710347|NCT01881204|Experimental|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
16710348|NCT01881204|Placebo Comparator|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
16710349|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
16710350|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
16710351|NCT01881178|Active Comparator|Apricot|Supplement: Apricot Juice
16710352|NCT01881178|Experimental|Nopalea|Supplement: Nopalea
16710353|NCT01881165|Experimental|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
16710354|NCT01881165|Placebo Comparator|Placebo|A capsule containing control formulation
16710355|NCT01881152|Experimental|Intervention|Educational campaign
16710356|NCT01881152|Other|Control|Usual care
16710357|NCT01881139|Experimental|experimental 1|men with exercise training for 3 months
16710358|NCT01881126|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
16710359|NCT01881126|Active Comparator|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
16710360|NCT01881113|Experimental|AC-170 0.24%|
16710361|NCT01881113|Placebo Comparator|AC-170 0%|
16710362|NCT01881100|Experimental|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
16710363|NCT01881100|Active Comparator|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
16710364|NCT01881087|Experimental|Levo-7.5 mg|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 7.5 mg. Single Dose.
16710365|NCT01881087|Experimental|Levo-9.37|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 9.37 mg. Single Dose.
16710366|NCT01881087|Active Comparator|Levo-11.25|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 11.25 mg. Single Dose.
16710367|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
16710368|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
16710369|NCT01881048|No Intervention|Arm I|Patients undergo observation.
16710370|NCT01881048|Experimental|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
16710373|NCT01881022|Experimental|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
16710374|NCT01881009|Experimental|Inpatient overnight|Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
16710375|NCT01881009|Experimental|Summer Camp Session|Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.
16710376|NCT01880996|Experimental|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
16710377|NCT01880996|No Intervention|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
16710378|NCT01880970|Active Comparator|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
16710379|NCT01880970|Placebo Comparator|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
16710380|NCT01880970|No Intervention|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
16710381|NCT01880957|Other|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
16710382|NCT01880957|Other|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
16710383|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
16710384|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
16710385|NCT01880931|Experimental|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
16710386|NCT01880931|Experimental|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
16710387|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
16710388|NCT01880905|Experimental|female undergoing gynecological surgery|
16710389|NCT01880892|Experimental|Post cricopharyngeal myotomy|There is only one arm to the study. This is patients who have undergone cricopharyngeal myotomy for Zenker's diverticulum. Their levels of laryngopharyngeal reflux will be measured using the Restech Dx-pH device.
16710390|NCT01880879|Experimental|helios stent|the group with helios stent implanted
16710391|NCT01880866|Experimental|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
16710392|NCT01880853|Experimental|group 1|screening with mammography alone
16710393|NCT01880853|Experimental|group 2|screening with ultrasonography alone
16710394|NCT01880853|Experimental|group 3|screening with both mammography and ultrasound
16710395|NCT01880840|Active Comparator|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
16710396|NCT01880840|Active Comparator|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
16710400|NCT01880814|Experimental|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
16710401|NCT01880814|Experimental|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
16710402|NCT01880788||CNV secondary to CSC|
16710403|NCT01880788||CSC without CNV|
16710404|NCT01880788||CNV secondary to advanced AMD|
16710405|NCT01880775|Experimental|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
16710406|NCT01880775|Active Comparator|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
16710407|NCT01880749|Experimental|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
16710408|NCT01880736|Experimental|IDeg OD Flexible Dose|
16710409|NCT01880736|Experimental|IDeg OD Fixed Dose|
16710410|NCT01880736|Experimental|IDeg OD Simple|
16710411|NCT01880736|Experimental|IDeg OD Stepwise|
16710412|NCT01880723|Experimental|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
16710413|NCT01880723|Placebo Comparator|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
16710414|NCT01880710|Active Comparator|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
16710415|NCT01880710|Experimental|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
16745301|NCT01645150|No Intervention|Control group|No intervention
16710416|NCT01880697|Experimental|TIVc (≥18 to ≤ 60 years) + TIVc (≥ 61 years)|Subjects in each age cohort received one dose of the cell-derived trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVc) formulation 2013/2014 Northern Hemisphere
16710417|NCT01880684||Passive Leg Rising|
16710418|NCT01880671|Experimental|Migraine Medical Device|
16710419|NCT01880671|Placebo Comparator|Inactive Migraine Medical Device|
16710420|NCT01880658|Experimental|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
16710421|NCT01880645|Other|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
16710422|NCT01880632|Experimental|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
16710423|NCT01880619|Placebo Comparator|Group A|Patients in this group will receive placebo
16710424|NCT01880619|Active Comparator|Group B|Patients in this group will receive Tamsulosin
16710425|NCT01880619|Active Comparator|Group C|Patients in this group will receive Solifenacin
16710426|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
16710427|NCT01880593|Experimental|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
16710428|NCT01880593|Placebo Comparator|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
16710429|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
16710430|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
16710431|NCT01880567|Experimental|Treatment (ibrutinib, rituximab)|Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16710432|NCT01880554|Other|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
16710433|NCT01880541|Experimental|hypnosedation|hypnosedation
16710434|NCT01880541|Other|general anesthesia|general anesthesia
16710435|NCT01880528|Experimental|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
16710436|NCT01880528|Placebo Comparator|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
16710437|NCT01880515|Experimental|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
16710438|NCT01880515|No Intervention|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
16710439|NCT01880502|Experimental|Belviq 10mg|
16710440|NCT01880502|Experimental|Belviq 20mg|
16710441|NCT01880502|Placebo Comparator|Placebo|
16710442|NCT01880489|Experimental|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
16710443|NCT01880489|No Intervention|Wait List Control Condition|
16710444|NCT01880476|Experimental|Home visits and group program|
16710445|NCT01880463|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day
~Fish oil placebo"
16710446|NCT01880463|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
16710447|NCT01880463|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo
~fish oil placebo"
16710448|NCT01880463|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
16710449|NCT01880450|Experimental|Project Prepared|
16710450|NCT01880450|Active Comparator|TEEN-Teen Education & Employment Network|
16710451|NCT01880437|Experimental|Vismodegib|
16710452|NCT01880424|Placebo Comparator|controlled arm|
16710453|NCT01880424|Experimental|treatment arm|
16710454|NCT01880411|Experimental|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
16710455|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
16710478|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
16710456|NCT01880385|Experimental|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
16710457|NCT01880372|Experimental|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
16710458|NCT01880372|No Intervention|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
16710459|NCT01880359|Placebo Comparator|Radiotherapy+ Cisplatin+ Placebo|Accelerated radiotherapy (Therapeutic Planning Target Volume (PTV): 70 Gray (Gy), 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) Patients will receive placebo (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only).
16710460|NCT01880359|Experimental|Radiotherapy+ Cisplatin+ Nimorazole|"Accelerated radiotherapy (Therapeutic PTV: 70 Gy, 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) .
~Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only)."
16710461|NCT01880346|Active Comparator|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
16710462|NCT01880346|Active Comparator|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
16710463|NCT01880333|Experimental|Children on Modified Atkin Diet|
16710464|NCT01880320|Experimental|CD0271 0.3% /CD1579 2.5% Gel|active arm
16710465|NCT01880320|Active Comparator|CD0271 0.1% / CD1579 2.5%|Comparator arm
16710466|NCT01880320|Placebo Comparator|Topical Gel Vehicle|Placebo arm
16710467|NCT01880307|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
16710468|NCT01880307|Active Comparator|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
16710469|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
16710470|NCT01880281|Active Comparator|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.
~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
16710471|NCT01880281|Active Comparator|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.
~The investigational's day, they will receive 1g of bicarbonate."
16710472|NCT01880268|Experimental|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
16710473|NCT01880268|Experimental|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
16710474|NCT01880255|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
16710475|NCT01880255|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
16710476|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with
~Diabetes (all types)
~Small vessels (≤2.75 mm)
~Chronic total occlusion (CTO)
~Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
16710477|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
16710516|NCT01879930|Active Comparator|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
16710479|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
16710480|NCT01880216|Active Comparator|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
16710481|NCT01880216|Experimental|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
16710482|NCT01880203|Experimental|aspiration for Molecular Cytogenetic Analysis.|
16710483|NCT01880190|Active Comparator|Ringer's Lactate|Crystalloid solution
16710484|NCT01880190|Active Comparator|HES 130/0.4 and Ringer's Lactate|Colloid solution
16710485|NCT01880177||Current smokers|Current smokers (>10 pk yrs.)
16710486|NCT01880177||Ex-smokers|Ex-smokers with a history of >10 pk yrs
16710487|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
16710488|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
16710489|NCT01880151|Experimental|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
16710490|NCT01880151|Experimental|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
16710491|NCT01880151|Experimental|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
16710492|NCT01880138|Experimental|watching animated cartoon|
16710493|NCT01880138|Placebo Comparator|not watching animated cartoon|
16710494|NCT01880125|Other|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
16710495|NCT01880125|Other|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
16710496|NCT01880112|Experimental|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
16710497|NCT01880112|Active Comparator|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
16710498|NCT01880099|Placebo Comparator|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
16710499|NCT01880099|Active Comparator|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
16710500|NCT01880099|Active Comparator|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
16710501|NCT01880086|Experimental|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
16710502|NCT01880086|Placebo Comparator|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
16710503|NCT01880073|Experimental|FemVue device|FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.
16710504|NCT01880060|Experimental|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
16710505|NCT01880060|Experimental|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
16710506|NCT01880047|Active Comparator|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
16710507|NCT01880047|Placebo Comparator|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
16710508|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
16710509|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
16710510|NCT01879982||Wellness Wearable System & Smartphone|
16710511|NCT01879969|Experimental|asymmetric patients, classic procedure|random selected
16710512|NCT01879969|Experimental|asymmetric patients, computer assisted|random selected
16710513|NCT01879956|Active Comparator|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
16710514|NCT01879956|Placebo Comparator|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
16710515|NCT01879943|Experimental|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.
~Interventions:
~Device: PillCam COLON 2 on D0
~Procedure: Standard colonoscopy on D1"
16710517|NCT01879930|Placebo Comparator|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
16710518|NCT01879917|Active Comparator|Liraglutide|1.8 mg
16710519|NCT01879917|Placebo Comparator|Saline|
16710520|NCT01879904|Experimental|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
16710521|NCT01879891|Other|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.
~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
16710522|NCT01879891|Other|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
16710523|NCT01879878|Experimental|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
16710524|NCT01879878|Placebo Comparator|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
16710525|NCT01879865|Other|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
16710526|NCT01879865|Other|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
16710527|NCT01879852|Active Comparator|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
16710528|NCT01879852|Experimental|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
16710529|NCT01879839|No Intervention|Control Group|Patients who don't follow a special diet.
16710530|NCT01879839|Other|Diet Group|Patients who subsist on a special diet.
16710531|NCT01879826|Sham Comparator|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
16710532|NCT01879826|Experimental|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
16710533|NCT01879813|Active Comparator|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
16710534|NCT01879813|Placebo Comparator|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
16710535|NCT01879800|No Intervention|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
16710536|NCT01879800|Experimental|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
16710537|NCT01879787|Experimental|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
16710538|NCT01879787|Experimental|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
16710539|NCT01879787|Experimental|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
16710540|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
16710541|NCT01879787|Experimental|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
16710578|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
16710542|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
16710543|NCT01879787|No Intervention|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
16710544|NCT01879774|Other|Patients with hyponatremia|Neuropsychological and motoric tests are conducted in patients with hyponatremia.
16710545|NCT01879774|Other|Patients with normal serum sodium|Neuropsychological and motoric tests are conducted in patients with normal serum sodium.
16710546|NCT01879761||Immunosuppressed|"Immunosuppressed includes patients with any one of the following:
~a diagnosis of a hematological malignancy
~a diagnosis of HIV
~myelosuppressive chemotherapy in the previous 90 days
~immune-modulating medications in the previous 90 days"
16710547|NCT01879761||Non-Immunosuppressed|Subject does not fit immunosuppressed criteria
16710548|NCT01879748|Experimental|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
16710549|NCT01879748|Placebo Comparator|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
16710550|NCT01879735|Experimental|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
16710551|NCT01879735|Experimental|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
16710552|NCT01879722|Experimental|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
16710553|NCT01879722|Experimental|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
16710554|NCT01879722|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
16710555|NCT01879722|Experimental|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
16710556|NCT01879722|Experimental|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
16710557|NCT01879722|Placebo Comparator|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
16710558|NCT01879709|Experimental|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
16710559|NCT01879709|Placebo Comparator|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
16710560|NCT01879709|Active Comparator|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
16710561|NCT01879696|Experimental|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
16710562|NCT01879696|No Intervention|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
16710563|NCT01879683|Experimental|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
16710564|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
16710565|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
16710566|NCT01879657|Experimental|68Ga-DOTATATE PET scans|"Will perform 68Ga-DOTATATE PET scans on subjects. The same anatomic areas will be imaged with 68Ga-DOTATATE PET and 111In-penteoctreotide Scintigraphy to ensure relevant comparison of lesion detection.
~The images from 68Ga-DOTATATE PET/CT will be reported by an experienced nuclear medicine physician who will be unaware of the results of the previous 111Inpenteoctreotide study. Areas of abnormal focal uptake will be documented. These areas of abnormal uptake will be compared with cross-sectional imaging (CT or MRI)to confirm the presence of lesions. The images from 111In- penteoctreotide Scintigraphy will be reported independently by another experienced nuclear medicine physician."
16710567|NCT01879644|Active Comparator|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
16710568|NCT01879644|Active Comparator|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
16710569|NCT01879644|Active Comparator|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
16710570|NCT01879644|Active Comparator|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
16710571|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
16710572|NCT01879618|Experimental|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
16710573|NCT01879605|Experimental|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
16710574|NCT01879605|Active Comparator|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
16710575|NCT01879605|No Intervention|Control grup|No intervention
16710576|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
16710577|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
16710580|NCT01879579|Experimental|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
16710581|NCT01879579|No Intervention|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
16710582|NCT01879553|Experimental|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
16710583|NCT01879553|Experimental|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
16710584|NCT01879540|Experimental|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
16710585|NCT01879527|Active Comparator|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
16710586|NCT01879527|Placebo Comparator|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
16710587|NCT01879514|Experimental|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
16710588|NCT01879514|Placebo Comparator|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
16710589|NCT01879501|Experimental|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
16710590|NCT01879501|No Intervention|Usual Care|Usual care delivered at the Singapore National Eye Centre
16710591|NCT01879488|Active Comparator|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
16710592|NCT01879488|Active Comparator|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
16710593|NCT01879475|Experimental|032-11|032-11 topical haemostat.
16710594|NCT01879475|Active Comparator|Floseal (R)|Floseal(R) topical haemostat
16710595|NCT01879462|Experimental|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
16710596|NCT01879462|Experimental|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
16710597|NCT01879462|Experimental|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
16710598|NCT01879462|Experimental|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
16710599|NCT01879462|Experimental|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
16710600|NCT01879462|Experimental|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
16710601|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)
~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.
~The measure of outcome is composite and includes several changes:
~Changes in:
~cell death (% from tested cells)
~cell cycle (% cells in G1, G2 and S phases)
~cell migration (% closure in Scratch test)
~cell invasion (% cells passing through membrane in Transwell assay)
~RNA repertoire (Fold change)
~miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
16710602|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
16710603|NCT01879423|Experimental|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
16710604|NCT01879423|Experimental|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
16710605|NCT01879410|Experimental|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
16710606|NCT01879410|Active Comparator|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
16710607|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
16710608|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
16710609|NCT01879384|Experimental|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
16710610|NCT01879371|Active Comparator|Ibuprofen (Brufen®)|film-coated tablet
16710611|NCT01879371|Active Comparator|Ibuprofen (Nurofen Immedia®)|film-coated tablet
16710612|NCT01879371|Experimental|Ibuprofen+caffeine|fixed-dose-combination (FDC)
16710613|NCT01879358|Active Comparator|ORSIRO stent|ORSIRO stent group
16710614|NCT01879358|Active Comparator|NOBORI stent|NOBORI stent group
16710615|NCT01879345|Experimental|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
16710616|NCT01879345|Experimental|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
16710617|NCT01879345|Placebo Comparator|Placebo|placebo tablets
16710618|NCT01879332|Placebo Comparator|Placebo|Matching placebo tablets for oral administration
16710619|NCT01879332|Experimental|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
16710620|NCT01879332|Experimental|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
16710621|NCT01879319|Experimental|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
16710622|NCT01879319|Experimental|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
16710623|NCT01879293|Experimental|Metformin group|In this group, metformin 0.5 three times daily for one year.
16710624|NCT01879293|Placebo Comparator|Placebo group|In this group, placebo will be given twice daily for one year.
16710625|NCT01879280|Experimental|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
16710626|NCT01879280|Active Comparator|traditional pterional craniotomy|traditional pterional craniotomy
16710627|NCT01879267|Other|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
16710628|NCT01879267|Other|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
16710629|NCT01879254||DBS for OCD|
16710630|NCT01879241|Experimental|Rasagiline|"Rasagiline
~1 mg/day; 18 months"
16710631|NCT01879241|Placebo Comparator|Placebo|once daily, 18 months
16710632|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.
16710633|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be taken orally each morning for 6 months.
16710634|NCT01879215|Active Comparator|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
16710635|NCT01879215|Active Comparator|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
16710636|NCT01879202|Active Comparator|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
16710637|NCT01879202|Placebo Comparator|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
16710638|NCT01879189|Experimental|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
16710639|NCT01879189|No Intervention|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
16710640|NCT01879176|Experimental|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
16710641|NCT01879176|No Intervention|Control|No filter will be installed on the CPB machine.
16710642|NCT01879163|Experimental|Group A|The first six volunteers will receive an intradermal injection of 1x10^7 pfu MVA85A-IMX313 (non-randomised).
16710643|NCT01879163|Active Comparator|Group B|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
16710644|NCT01879163|Active Comparator|Group C|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
16710684|NCT01878890|Experimental|Efavirenz: 2200 mg|Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.
16710645|NCT01879150|Experimental|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.
~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.
~Subjects will be followed-up for 50 weeks post-procedure."
16710646|NCT01879137||healthy adults|
16710647|NCT01879137||Patients with a polyuria-polydipsia syndrome|
16710648|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
16710649|NCT01879111|Experimental|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
16710650|NCT01879111|No Intervention|state-of-art depression screening|
16710651|NCT01879098|Placebo Comparator|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
16710652|NCT01879098|Experimental|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16710653|NCT01879098|Experimental|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16710654|NCT01879098|Experimental|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
16710655|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
16710656|NCT01879059|Experimental|Exercise|5 days of inactivity followed by a 1 day return to physical activity
16710657|NCT01879046|Experimental|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
16710658|NCT01879033|Active Comparator|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
16710659|NCT01879033|Placebo Comparator|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
16710660|NCT01879020|Experimental|TA-8995 1 mg|
16710661|NCT01879020|Experimental|TA-8995 2.5 mg|
16710662|NCT01879020|Experimental|TA-8995 5 mg|
16710663|NCT01879020|Experimental|TA-8995 10 mg|
16710664|NCT01879020|Experimental|TA-8995 25 mg|
16710665|NCT01879020|Placebo Comparator|Placebo (TA-8995 1mg)|
16710666|NCT01879020|Placebo Comparator|Placebo (TA-8995 2.5mg)|
16710667|NCT01879020|Placebo Comparator|Placebo (TA-8995 5mg)|
16710668|NCT01879020|Placebo Comparator|Placebo (TA-8995 10mg)|
16710669|NCT01879020|Placebo Comparator|Placebo (TA-8995 25mg)|
16710670|NCT01879007|Experimental|group 1|received one intravenous administration and one oral medication with interval of 1 week,
16710671|NCT01879007|Experimental|group 2|received one oral administration and one intravenous medication with interval of 1 week
16710672|NCT01878994|Placebo Comparator|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
16710673|NCT01878994|Experimental|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
16710674|NCT01878968|Experimental|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
16710675|NCT01878968|Experimental|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
16710676|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
16710677|NCT01878942|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
16710678|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held
~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
16710679|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up
~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
16710680|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
16710681|NCT01878890|Experimental|Efavirenz: 600 mg|Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.
16710682|NCT01878890|Experimental|Efavirenz: 1200 mg|Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.
16710683|NCT01878890|Experimental|Efavirenz: 1800 mg|Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.
16710685|NCT01878864|Experimental|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
16710686|NCT01878864|Active Comparator|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
16710687|NCT01878851||pulpotomy|
16710688|NCT01878838|Active Comparator|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
16710689|NCT01878838|Active Comparator|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
16710690|NCT01878825|Experimental|Fluviral 18-60 Years Group|Subjects aged between 18 and 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
16710691|NCT01878825|Experimental|Fluviral >60 Years Group|Subjects aged > 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm
16710692|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
16710693|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Elderly Group|Subjects >60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
16710694|NCT01878799|Experimental|HIV|Subjects with HIV and HCV
16710695|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
16710696|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
16710697|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
16710698|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
16710699|NCT01878747|Experimental|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
16710700|NCT01878747|No Intervention|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
16710701|NCT01878734|No Intervention|Control|This arm will act as a control and will not receive Micronutrient Powders
16710702|NCT01878734|Experimental|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
16710708|NCT01878708|Experimental|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
16710709|NCT01878695|Experimental|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.
~600mg n-acetylcysteine orally twice daily except on day of infusion"
16710710|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
16710711|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
16710712|NCT01878656|Active Comparator|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
16710713|NCT01878656|Active Comparator|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
16710714|NCT01878643|Placebo Comparator|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
16710715|NCT01878643|Experimental|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
16710716|NCT01878630|Experimental|Remote Patient Management|intervention group
16710717|NCT01878630|Active Comparator|Usual Care|control group
16710718|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
16710719|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
16710720|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
16710755|NCT01878435|No Intervention|Control|
16710756|NCT01878435|Experimental|SMS reminder and Travel subsidy 2|
16710798|NCT01878188|Experimental|twice-weekly treatments of BC-819 and BCG|6 twice-weekly treatments of BC-819/PEI and BCG
16710721|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
16710722|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
16710723|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
16710724|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
16710725|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
16710726|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
16710727|NCT01878591||Women in active second stage of labour|Ultrasound examinations
16710728|NCT01878578|Experimental|Eslicarbazepine acetate|ESL 600 mg tablets
16710729|NCT01878578|Active Comparator|phenytoin|Hidantina® 100 mg tablets
16710730|NCT01878578|Placebo Comparator|Placebo|Placebo tablets
16710731|NCT01878565|Experimental|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
16710732|NCT01878565|Other|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
16710733|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
16710734|NCT01878539|Experimental|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
16710735|NCT01878526|Experimental|Omeprazole plus alginic acid and placebo of domperidone|
16710736|NCT01878526|Experimental|Omeprazole plus domperidone and placebo of alginic acid|
16710737|NCT01878513|Experimental|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
16710738|NCT01878513|Experimental|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
16710739|NCT01878513|Experimental|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
16710740|NCT01878500|Experimental|Intraoperative stereotactic imaging|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure.
16710741|NCT01878487|Other|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
16710742|NCT01878474|Experimental|Single ascending dose in Caucasian men|
16710743|NCT01878474|Experimental|Age-effect in Caucasian men|
16710744|NCT01878474|Experimental|Gender-effect in Caucasian women|
16710745|NCT01878474|Experimental|Single ascending dose in Japanese men|
16710746|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Caucasian men|
16710747|NCT01878474|Placebo Comparator|Placebo: Age-effect in Caucasian men|
16710748|NCT01878474|Placebo Comparator|Placeo: Gender-effect in Caucasian women|
16710749|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Japanese men|
16710750|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
16710751|NCT01878461|Experimental|M518101|Proper quantity twice a day
16710752|NCT01878448|Experimental|Anlotinib|
16710753|NCT01878435|Experimental|SMS reminder|
16710754|NCT01878435|Experimental|SMS reminder and Travel subsidy|
16710757|NCT01878422|Experimental|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus
~FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min
~Day 1,2:
~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours
~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours
~Day 1,2:
~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
16710758|NCT01878422|Experimental|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
16710759|NCT01878422|Experimental|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
16710760|NCT01878422|Experimental|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
16710761|NCT01878422|Experimental|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
16710762|NCT01878422|Experimental|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
16710763|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
16710764|NCT01878409||Healthy Subjects|Healthy Subjects
16710765|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
16710766|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
16710767|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
16710768|NCT01878370|Experimental|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
16710769|NCT01878370|Experimental|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
16710770|NCT01878357|Experimental|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
16710771|NCT01878357|Experimental|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
16710772|NCT01878357|No Intervention|Arm 3|Without MST
16710773|NCT01878344|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
16710774|NCT01878344|Placebo Comparator|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
16710775|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
16710776|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
16710777|NCT01878318|Experimental|RoActemra/Actemra|
16710778|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
16710779|NCT01878292|Placebo Comparator|Placebo|Dose-matched placebo tablets, once per day, oral administration
16710780|NCT01878292|Experimental|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
16710781|NCT01878292|Experimental|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
16710782|NCT01878279||HIV negative|
16710783|NCT01878279||HIV positive|HIV positive children in care
16710784|NCT01878266|Experimental|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
16710785|NCT01878266|Experimental|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
16710786|NCT01878266|Other|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
16710787|NCT01878253|Experimental|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
16710788|NCT01878240|Active Comparator|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
16710789|NCT01878240|Experimental|Coil embolization during EVAR|coil embolization during Endovascular repair
16710790|NCT01878227|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
16710791|NCT01878227|Active Comparator|Fenofibrate 200mg|Fenofibrate 200mg per day
16710792|NCT01878214|Experimental|Intervention group|Targeted messaging
16710793|NCT01878214|Active Comparator|Control group|Standard messaging
16710794|NCT01878201|Experimental|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
16710795|NCT01878201|Active Comparator|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
16710796|NCT01878188|Experimental|BC-819/PEI and BCG alternating|4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG
16710797|NCT01878188|Experimental|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG
16710799|NCT01878175|Experimental|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
16710800|NCT01878162|Experimental|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
16710801|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
16710802|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
16710803|NCT01878136|Active Comparator|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)
~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
16710804|NCT01878136|Placebo Comparator|Placebo|"Placebo
~Dose 1 mL sterile saline"
16710805|NCT01878123|Experimental|AMP-110|Escalating doses of AMP-110
16710806|NCT01878123|Placebo Comparator|Placebo|
16710807|NCT01878110|Experimental|COMB|
16710808|NCT01878097|Experimental|Green Dot Bystander Training|Green Dot intervention
16710809|NCT01878097|Active Comparator|Control|Awareness Eduation
16710810|NCT01878084|Other|all study participants|"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)
~The extraction sockets will be allocated either to the control : Extraction socket will be left empty
~or
~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"
16710811|NCT01878071||Single group cross sectional|
16710812|NCT01878058|Other|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
16710814|NCT01878006|Experimental|Morphine|Morphine injection 10 mg/70kg
16710815|NCT01878006|Placebo Comparator|Placebo|Saline injection
16710816|NCT01877967|Experimental|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
16710817|NCT01877967|Placebo Comparator|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
16710818|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
16710819|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
16710820|NCT01877941|Active Comparator|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
16710821|NCT01877928|Experimental|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
16710822|NCT01877928|Active Comparator|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
16710823|NCT01877915|Experimental|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
16710824|NCT01877915|Placebo Comparator|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
16710825|NCT01877902||Pemetrexed 500 mg/m 2|
16710826|NCT01877889|Experimental|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
16710827|NCT01877889|Experimental|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
16710828|NCT01877889|Experimental|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
16710829|NCT01877876||Patient undergoing spine surgery|
16710830|NCT01877863|Experimental|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
16710831|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses
16710832|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
16710833|NCT01877837|Experimental|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.
~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.
~Day Treatment
~-22 Alemtuzumab 3mg IV (test dose)
~-21 Alemtuzumab 10mg IV
~-20 Alemtuzumab 15mg IV
~-19 Alemtuzumab 20mg IV
~-8 Fludarabine 30mg/m2 IV
~-7 Fludarabine 30mg/m2 IV
~-6 Fludarabine 30mg/m2 IV
~-5 Fludarabine 30mg/m2 IV
~-4 Fludarabine 30mg/m2 IV
~-3 Melphalan 140mg/m2 IV
~-2 Rest Day
~-1 Rest Day
~0 Stem Cell Infusion"
16710877|NCT01877577|Active Comparator|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
16710834|NCT01877824|Experimental|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
16710835|NCT01877824|No Intervention|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
16710836|NCT01877811|Experimental|RXDX-105|
16710837|NCT01877798|Experimental|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
16710838|NCT01877798|Experimental|ScvO2|ScvO2 directed group
16710839|NCT01877785|Experimental|MHAA4549A Arm|
16710840|NCT01877785|Placebo Comparator|Placebo Arm|
16710841|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
16710842|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair.
16710843|NCT01877759|Other|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
16710844|NCT01877746|Experimental|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
16710845|NCT01877746|Experimental|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
16710846|NCT01877746|Other|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
16710847|NCT01877733|Experimental|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
16710848|NCT01877733|No Intervention|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
16710849|NCT01877720|Experimental|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
16710850|NCT01877720|Experimental|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
16710851|NCT01877707|Other|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
16710852|NCT01877694|Experimental|Auriclosene Solution 0.3%|Dosed QID for 4 Days
16710853|NCT01877694|Placebo Comparator|Auriclosene Vehicle|Dosed QID for 4 days
16710854|NCT01877681|Experimental|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
16710855|NCT01877681|Active Comparator|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
16710856|NCT01877668|Experimental|Tofacitinib 5 mgBID x 12 months|
16710857|NCT01877668|Experimental|Tofacitinib 10 mg BID x 12 months|
16710858|NCT01877668|Active Comparator|Adalimumab 40 mg q2 weeks x 12 months|
16710859|NCT01877668|Placebo Comparator|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
16710860|NCT01877668|Placebo Comparator|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
16710863|NCT01877642|Other|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
16710864|NCT01877642|Other|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
16710865|NCT01877642|Other|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
16710866|NCT01877642|Other|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
16710867|NCT01877642|Other|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
16710868|NCT01877642|Other|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
16710869|NCT01877642|Other|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
16710870|NCT01877629|Experimental|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
16710871|NCT01877629|Experimental|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
16710872|NCT01877616|Other|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
16710873|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
16710874|NCT01877590|Placebo Comparator|placebo group|An identical placebo daily
16710875|NCT01877590|Experimental|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
16710876|NCT01877577|Active Comparator|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
16710878|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
16710879|NCT01877564|No Intervention|Group 2 - No treatment|
16710880|NCT01877551|Active Comparator|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
16710881|NCT01877551|Placebo Comparator|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
16710882|NCT01877538||[11C]donepezil PET|[11C]donepezil is a radiopharmaceutical. It is evaluated whether the binding of [11C]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
16710883|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
16710884|NCT01877512|Active Comparator|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
16710885|NCT01877512|Active Comparator|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
16710886|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
16710887|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
16710888|NCT01877473|Active Comparator|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
16710889|NCT01877473|Active Comparator|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
16710890|NCT01877460|Experimental|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
16710891|NCT01877460|Experimental|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
16710892|NCT01877460|Experimental|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
16710893|NCT01877460|Experimental|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
16710894|NCT01877447|Experimental|cathodal F4|"Transcranial Direct Current Stimulation
~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
16710895|NCT01877447|Experimental|Anodal F3|"Transcranial Direct Current Stimulation'
~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
16710896|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
16710897|NCT01877421|Experimental|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
16710898|NCT01877421|Experimental|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
16710899|NCT01877421|Experimental|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
16710900|NCT01877421|Experimental|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
16710901|NCT01877421|Experimental|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
16710902|NCT01877421|Experimental|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
16710903|NCT01877421|Experimental|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
16710904|NCT01877421|Experimental|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
16710905|NCT01877421|Experimental|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
16710906|NCT01877421|Placebo Comparator|Placebo|Placebo
16710907|NCT01877408|Active Comparator|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
16710908|NCT01877408|Experimental|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
16710909|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
16710910|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
16710911|NCT01877382|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules.
16710912|NCT01877382|Experimental|Part 2, Milademetan Alone|Participants with advanced melanoma and diffuse large B cell lymphoma (DLBCL) receive milademetan alone with different dose schedules.
16710913|NCT01877356|Experimental|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
16710914|NCT01877356|Experimental|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
16710992|NCT01876758|No Intervention|Treatment as Usual|No memory training or puzzle games, just the study evaluations
16710993|NCT01876745||NovoSeven® (activated recombinant factor VII)|
16710915|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
16710916|NCT01877330|Active Comparator|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
16710917|NCT01877330|Active Comparator|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
16710918|NCT01877317|Experimental|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
16710919|NCT01877304|Experimental|AKITA with program central deposition|Nebulization for central deposition
16710920|NCT01877304|Active Comparator|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
16710921|NCT01877291||Nonsmokers|Young healthy nonsmokers
16710922|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history <2.5 pack years"
16710923|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history ≥ 2.5 pack-years"
16710924|NCT01877278|Active Comparator|active|Group wearing the active device emitting pulsed electromagnetic fileds
16710925|NCT01877278|Placebo Comparator|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
16710926|NCT01877265|Experimental|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SC) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of 1 of 3 treatment periods
16710927|NCT01877265|Experimental|LY2605541 - Source 2|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1of 3 treatment periods
16710928|NCT01877265|Experimental|LY2605541 - Source 3|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1 of 3 treatment periods
16710929|NCT01877252||Endovascular treatment|Angioplasty +/- stent
16710930|NCT01877252||Open treatment|Bypass (vein or prosthetic)
16710931|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
16710932|NCT01877252||Conservative treatment|no vascular intervention
16710933|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
16710934|NCT01877226|Experimental|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
16710935|NCT01877213|Experimental|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
16710936|NCT01877213|No Intervention|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
16710937|NCT01877200||Subjects with diabetes (type 2)|
16710938|NCT01877187|Other|Lipiodol|Lipiodol, 10cc per TACE.
16710939|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
16710940|NCT01877161|Experimental|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
16710941|NCT01877161|Sham Comparator|Control group|Repetitive magnetic stimulation (Sham)
16710942|NCT01877161|Experimental|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
16710943|NCT01877148|Experimental|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
16710944|NCT01877148|Sham Comparator|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
16710945|NCT01877135||Anal AIN3|patients > 18 years, with anal AIN3, without history of anal carcinoma
16710946|NCT01877122|Experimental|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
16710947|NCT01877122|Active Comparator|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
16710948|NCT01877109||Lymphoma|Lymphoma patients
16710949|NCT01877096|Experimental|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
16710950|NCT01877096|Active Comparator|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
16710951|NCT01877083|Experimental|Lenvatinib|
16710952|NCT01877070||early stage prostate patients & their partners/close allies|
16710953|NCT01877057|Experimental|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
16710954|NCT01877044|Placebo Comparator|Placebo|Maltodextrin
16710955|NCT01877044|Experimental|NAXUS 7.5 grams|Arabinoxylan
16710956|NCT01877044|Experimental|NAXUS 15.0 grams|Arabinoxylan
16710957|NCT01877031|Active Comparator|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
16710958|NCT01877031|Experimental|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
16710959|NCT01877018|Experimental|electronic reminder|Electronic reminder introduced into primary care medical health record.
16710960|NCT01877018|No Intervention|Usual care|Usual care control group
16710961|NCT01877005|Experimental|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.
~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
16711105|NCT01876017|Other|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
16710962|NCT01876992|Experimental|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.
~For children <50kg:
~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.
~For children ≥50kg:
~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.
~For adults:
~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
16710963|NCT01876992|No Intervention|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.
~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
16710964|NCT01876979|Active Comparator|IMF Screws|Use of IMF screws as a means to wire the jaws.
16710965|NCT01876979|Active Comparator|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
16710966|NCT01876966|Experimental|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
16710967|NCT01876966|Experimental|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
16710968|NCT01876953|Experimental|Dasatinib 100mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
16710969|NCT01876953|Experimental|Dasatinib 140mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
16710970|NCT01876940|Active Comparator|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
16710971|NCT01876940|Experimental|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
16710972|NCT01876927|Experimental|Arm A|"DOX 4 cycles - Surgery - Follow-up
~DOX:
~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.
~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
16710973|NCT01876927|Experimental|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up
~DOX:
~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.
~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.
~Each cycle will be repeated every 3 weeks."
16710974|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
16710975|NCT01876901|Experimental|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|Patients treated with 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) in centers who routinely performing this intervention.
16710976|NCT01876901|Experimental|Colo-anal anastomosis (CAA)|Patients operated with colo-anal anastomosis (CAA) in centers who routinely performing this intervention.
16710977|NCT01876875|Experimental|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
16710978|NCT01876875|Active Comparator|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
16710979|NCT01876862|Experimental|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.
~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
16710980|NCT01876849|Experimental|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
16710981|NCT01876836|Experimental|i-gel|i-gel placed after induction
16710982|NCT01876836|Active Comparator|C-LMA|C-LMA placed after induction
16710983|NCT01876823|Experimental|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
16710984|NCT01876810|Experimental|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
16710985|NCT01876810|Placebo Comparator|Placebo pill|One lactose pill twice a day for two weeks.
16710986|NCT01876797|Other|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
16710987|NCT01876784|Experimental|Vandetanib|Vandetanib 300 mg tablet, orally once daily until disease progression or death.
16710988|NCT01876784|Placebo Comparator|Placebo|Placebo matched to vandetanib tablet, orally once daily until disease progression or death.
16710989|NCT01876771|Experimental|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) [177]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.
~Nominal maintenance stage dose of 75 mCi (2.78 GBq) [177]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
16710990|NCT01876758|Experimental|Cognitive Intervention: Memory Training|Memory training before and after ECT
16710991|NCT01876758|Active Comparator|Comparable general mental stimulation|Puzzle games before and after ECT
16746827|NCT01634503|Experimental|2mg of GX-188E by electroporation|
16710994|NCT01876732|Experimental|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
16710995|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
16710996|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
16710997|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
16710998|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
16710999|NCT01876706|Experimental|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
16711000|NCT01876693|No Intervention|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
16711001|NCT01876693|Experimental|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
16711002|NCT01876680|Experimental|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
16711003|NCT01876680|Experimental|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
16711004|NCT01876667|Active Comparator|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
16711005|NCT01876667|Placebo Comparator|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
16711006|NCT01876654|Experimental|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
16711007|NCT01876654|No Intervention|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
16711008|NCT01876641|Experimental|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
16711009|NCT01876628|Placebo Comparator|Flucloxacillin and placebo|Intravenous or oral Flucloxacillin with an oral placebo
16711010|NCT01876628|Active Comparator|Flucloxacillin and Clindamycin|Intravenous or oral Flucloxacillin with oral Clindamycin
16711011|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
16711012|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
16711013|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
16711014|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
16711015|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
16711016|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
16711017|NCT01876602|Experimental|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
16711018|NCT01876602|Active Comparator|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
16711019|NCT01876589|Active Comparator|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
16711020|NCT01876589|Active Comparator|Xience Prime|Participant will receive a Xience Prime stent
16711021|NCT01876576|Active Comparator|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
16711022|NCT01876576|Active Comparator|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
16711023|NCT01876563|Active Comparator|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
16711024|NCT01876563|Placebo Comparator|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
16711025|NCT01876550|Experimental|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
16711026|NCT01876550|Active Comparator|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
16711027|NCT01876550|Placebo Comparator|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
16711028|NCT01876537|Active Comparator|Usual surgery|
16711029|NCT01876537|Active Comparator|Hardware wound healing|
16711030|NCT01876524|Experimental|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
16711106|NCT01876004|Experimental|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
16711107|NCT01876004|Placebo Comparator|Placebo|Prescribed Placebo intramuscularly.
16711031|NCT01876524|Experimental|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
16711032|NCT01876524|Sham Comparator|Sham Group|75 patients will be receive tRNS sham 35 sessions.
16711033|NCT01876511|Experimental|Cohort A: MSI Positive Colorectal Cancer|
16711034|NCT01876511|Experimental|Cohort B: MSI Negative Colorectal Cancer|
16711035|NCT01876511|Experimental|Cohort C: MSI Positive Non-Colorectal Cancer|
16711036|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
16711037|NCT01876485|Experimental|Arm 1: Empowering Patients in Chronic Care (EPIC)|Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
16711038|NCT01876485|Active Comparator|Arm 2: Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
16711039|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
16711040|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
16711041|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
16711042|NCT01876459|Other|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
16711043|NCT01876459|Other|"Lewy Body Disease arm"|Patient with Lewy Body Disease
16711044|NCT01876446|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
16711045|NCT01876433|Active Comparator|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
16711046|NCT01876433|Placebo Comparator|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
16711047|NCT01876420|Experimental|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
16711048|NCT01876407|Experimental|Low energy laser|Administration of a low energy laser for oral mucositis.
16711049|NCT01876407|Placebo Comparator|Placebo|
16711050|NCT01876394|Experimental|Coconut oil|
16711051|NCT01876394|Experimental|Canola oil|
16711052|NCT01876394|Experimental|Grapeseed oil|
16711053|NCT01876394|Experimental|Chia oil|
16711054|NCT01876394|Placebo Comparator|Butter|
16711055|NCT01876381|Experimental|OPC-41061|
16711056|NCT01876368|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
16711057|NCT01876368|Active Comparator|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
16711058|NCT01876355|Experimental|Clonidine|
16711059|NCT01876355|Placebo Comparator|Sodium chloride|
16711060|NCT01876342|Experimental|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
16711061|NCT01876342|Active Comparator|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
16711062|NCT01876329||Rheumatoid Arthritis|Patients with seropositive or seronegative Rheumatoid Arthritis
16711063|NCT01876329||Autoimmune Thyroid Disease (AITD)|Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.
16711064|NCT01876329||Control|Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses
16711065|NCT01876316|Active Comparator|Moxifloxacin|single oral administration of 400mg of moxifloxacin
16711066|NCT01876316|Placebo Comparator|Placebo|single oral administration of 400mg of placebo
16711067|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
16711068|NCT01876290|Experimental|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
16711069|NCT01876290|Placebo Comparator|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
16711070|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
16711071|NCT01876264|Experimental|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
16711072|NCT01876264|Active Comparator|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
16711073|NCT01876251|Experimental|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2
16711074|NCT01876238|Experimental|T-PAT Intervention|Prognosis discussion intervention with study team.
16711075|NCT01876238|Active Comparator|Control: Standard Care|Usual care appointment
16711076|NCT01876225|No Intervention|No coughing|Cervical punch biopsy without forced coughing intervention
16711077|NCT01876225|Experimental|coughing|Forced coughing during cervical punch biopsy
16711108|NCT01875991|Experimental|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
16746828|NCT01634503|Experimental|4mg of GX-188E by electroporation|
16711078|NCT01876212|Experimental|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).
~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.
~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
16711079|NCT01876212|Experimental|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.
~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.
~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
16711080|NCT01876199|Experimental|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
16711081|NCT01876199|No Intervention|standard follow-up|2-week follow-up appointment with no reminders
16711082|NCT01876186|Experimental|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
16711083|NCT01876186|Active Comparator|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
16711084|NCT01876173|Experimental|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
16711085|NCT01876173|No Intervention|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
16711086|NCT01876160|Experimental|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
16711087|NCT01876160|Experimental|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
16711088|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
16711089|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
16711090|NCT01876134||Elective cardiac surgery|
16711091|NCT01876121||Celecox group|
16711092|NCT01876108|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
16711093|NCT01876108|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
16711094|NCT01876095|Experimental|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:
~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
16711095|NCT01876095|No Intervention|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
16711096|NCT01876082|Experimental|PAZOPANIB|"Pazopanib
~800 mg per day
~oral administration
~at least 1 hour before or 2 hours after a meal,
~until disease progression or for 12 months maximum"
16711097|NCT01876082|Active Comparator|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
16711098|NCT01876069|Active Comparator|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
16711099|NCT01876069|Active Comparator|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
16711100|NCT01876056|Experimental|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
16711101|NCT01876056|No Intervention|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
16711102|NCT01876043|Experimental|plitidepsin|plitidepsin
16711103|NCT01876030|Experimental|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
16711104|NCT01876030|No Intervention|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
16711109|NCT01875991|Experimental|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
16711110|NCT01875978|Active Comparator|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
16711111|NCT01875952|Other|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
16711112|NCT01875939|Other|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
16711113|NCT01875939|Other|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
16711114|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Single Dose (SD)|
16711115|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
16711116|NCT01875926|Experimental|ALX-0171 Intravenous (IV)|
16711117|NCT01875913|Experimental|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
16711118|NCT01875913|Experimental|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
16711119|NCT01875900|Active Comparator|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
16711120|NCT01875900|Experimental|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
16711121|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
16711122|NCT01875874|Experimental|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
16711123|NCT01875861|Experimental|Intervention|Evidence-Based Quality Improvement plus external facilitation to promote uptake of quality improvement tools and improvement strategies available as part of a national initiative (the MIAMI Project) to disseminate recommendations, tools, and improvement strategies relevant to metabolic monitoring and management.
16711124|NCT01875861|No Intervention|Comparison|"Usual care, in the context of the MIAMI Project."
16711125|NCT01875848|Experimental|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
16711126|NCT01875848|Active Comparator|opioid dose escalation|increase of up to 25% of current opioid dose
16711127|NCT01875835|Active Comparator|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
16711128|NCT01875835|Active Comparator|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
16711129|NCT01875822|Experimental|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
16711130|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
16711131|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
16711132|NCT01875796|Experimental|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
16711133|NCT01875796|Active Comparator|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
16711134|NCT01875783|Experimental|OCT imaging|All study participants will undergo optical coherence tomography imaging and will be referred to a retina specialist for further standard care evaluation and management if they are identified as having diabetic macular edema or the scan quality is not sufficient to evaluate macular status.
16711135|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
16711136|NCT01875757|Experimental|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
16711137|NCT01875757|Active Comparator|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
16711138|NCT01875744|Experimental|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
16711139|NCT01875744|Active Comparator|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
16711140|NCT01875731|Experimental|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
16711141|NCT01875731|Active Comparator|Guideline|Strategy based on enforced guideline guided antibiotic use
16711142|NCT01875718|Active Comparator|UC1010 low dose|
16711143|NCT01875718|Active Comparator|UC1010 high dose|
16711144|NCT01875718|Placebo Comparator|Vehicle|
16711145|NCT01875705|Experimental|Stage I-Dose Escalation|
16711146|NCT01875705|Experimental|Stage II-Cohort-Expansion|
16711147|NCT01875679|Active Comparator|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
16711186|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
16711148|NCT01875679|Experimental|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
16711149|NCT01875666|Active Comparator|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
16711150|NCT01875666|Active Comparator|pertuzumab|single dose infusion of pertuzumab (840 mg)
16711151|NCT01875666|Active Comparator|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
16711152|NCT01875666|Active Comparator|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
16711153|NCT01875653|Active Comparator|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:
~Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.
~Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.
~Mode of Administration: Subcutaneous (SC) injections."
16711154|NCT01875653|Experimental|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:
~Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.
~Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.
~Mode of Administration: Subcutaneous (SC) injections."
16711155|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
16711156|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
16711157|NCT01875627|Placebo Comparator|Carbohydrate Noodles|0g Konjac Noodles
16711158|NCT01875627|Experimental|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
16711159|NCT01875627|Experimental|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
16711160|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
16711161|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
16711165|NCT01875575|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
16711166|NCT01875575|Active Comparator|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
16711167|NCT01875575|Placebo Comparator|Placebo|intragastric tap water
16711168|NCT01875562|Experimental|Qishe Pill|
16711169|NCT01875549|Active Comparator|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
16711170|NCT01875549|Active Comparator|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
16711171|NCT01875536|Experimental|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
16711172|NCT01875536|Sham Comparator|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
16711173|NCT01875523|Experimental|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
16711174|NCT01875523|Experimental|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
16711175|NCT01875523|Experimental|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
16711176|NCT01875523|Experimental|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
16711177|NCT01875510|Active Comparator|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
16711178|NCT01875510|Placebo Comparator|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
16711179|NCT01875497|Experimental|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
16711180|NCT01875484||High miR-126 group|
16711181|NCT01875484||Moderate miR-126 group|
16711182|NCT01875484||Low miR-126 group|
16711183|NCT01875471|Active Comparator|delefilcon A|Spherical daily disposable soft contact lens
16711184|NCT01875471|Experimental|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
16711185|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
16711187|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
16711188|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
16711189|NCT01875445|Placebo Comparator|Placebo|Matched dosage of inositol daily.
16711190|NCT01875445|Active Comparator|Inositol|Powder form, 2g TID up to 6g TID
16711191|NCT01875419|Experimental|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
16711192|NCT01875419|Sham Comparator|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
16711193|NCT01875406|Experimental|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
16711194|NCT01875393|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
16711195|NCT01875380|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
16711196|NCT01875367|Experimental|Arm A: T-IV + T-SC vial + T-SC device|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
16711197|NCT01875367|Experimental|Arm B: T-IV + T-SC device + T-SC vial|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
16711198|NCT01875354|Placebo Comparator|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
16711199|NCT01875354|Experimental|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
16711200|NCT01875341|Active Comparator|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas & hypopneas are prevented during all sleep stages.
16711201|NCT01875341|Sham Comparator|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
16711202|NCT01875328|Experimental|Telemedicine|Telemedicine group
16711203|NCT01875328|Active Comparator|Clinic|Clinic group
16711204|NCT01875289|Experimental|Ropivacain|Local anaesthesia
16711205|NCT01875289|Placebo Comparator|NaCl 0.9%|Saline
16711206|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
16711207|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
16711208|NCT01875263|Experimental|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
16711209|NCT01875263|Active Comparator|Control|Cloxacillin 2g / 4 hrs iv 14 days
16711210|NCT01875250|Experimental|Arm A - Enzalutamide for 3 months|Enzalutamide for 3 months
16711211|NCT01875250|Experimental|Arm B - Enzalutamide for 3 months + PSA-TRICOM|Enzalutamide 3 months + PSA-TRICOM (Prostvac-V/F) on weeks 1, 3, 5, 9,13,17 and 21
16711212|NCT01875237|Experimental|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
16711213|NCT01875224|Experimental|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
16711214|NCT01875224|Active Comparator|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
16711215|NCT01875198|Experimental|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
16711216|NCT01875198|Active Comparator|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
16711217|NCT01875185|Experimental|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
16711218|NCT01875172|Experimental|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
16711219|NCT01875172|Placebo Comparator|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
16711220|NCT01875159|Experimental|Caffeine|Caffeine citrate 6 mg/kg/day
16711329|NCT01874483|Experimental|BI 187004 dose 7|multiple dose given over 14 days
16747818|NCT01627613|Placebo Comparator|saline solution|Placebo group
16711221|NCT01875159|No Intervention|Active Comparator: no caffeine|Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.
16711222|NCT01875146|Active Comparator|4x4 min HIT|Conventional 4x4 min high-intensity interval training
16711223|NCT01875146|Experimental|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
16711224|NCT01875146|Experimental|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
16711225|NCT01875146|Active Comparator|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
16711226|NCT01875133|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
16711227|NCT01875133|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
16711228|NCT01875133|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
16711229|NCT01875133|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
16711230|NCT01875120||Female patients with increased risk to experience PONV.|
16711231|NCT01875107|Experimental|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
16711232|NCT01875094|Experimental|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
16711233|NCT01875094|No Intervention|Usual Care|
16711234|NCT01875081|No Intervention|Control group|Best Supportive care
16711235|NCT01875081|Experimental|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
16711236|NCT01875081|Experimental|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
16711237|NCT01875068|Experimental|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
16711238|NCT01875068|Other|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
16711239|NCT01875055|Experimental|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
16711240|NCT01875055|Active Comparator|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
16711241|NCT01875042|Experimental|TENS|Transcutaneous Electrical Nerve Stimulation
16711242|NCT01875042|Sham Comparator|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
16711243|NCT01875029|Sham Comparator|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
16711244|NCT01875029|Experimental|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.
~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
16711245|NCT01875003|Experimental|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms [mcg] of fluticasone propionate dry powder inhaler [DPI] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
16711246|NCT01875003|Experimental|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
16711247|NCT01875003|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
16711248|NCT01874990|Experimental|women with a history of severe preeclampsia|women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago
16711249|NCT01874990|Experimental|control|women with no history of pregnancy-related hypertensive complications
16711250|NCT01874977|Experimental|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
16711251|NCT01874977|Experimental|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
16711252|NCT01874977|Other|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
16711253|NCT01874964|Experimental|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
16711254|NCT01874964|Active Comparator|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
16711255|NCT01874951|Placebo Comparator|Placebo|In this arm, patients will receive placebo for three weeks.
16711256|NCT01874951|Experimental|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
16711257|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
16711258|NCT01874899||Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
16711259|NCT01874899||Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
16711260|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
16711261|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
16711262|NCT01874873|Experimental|Anlotinib|
16711263|NCT01874860|Experimental|Extensive treatment group|"Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening.
~For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use.
~For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended.
~For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment."
16711264|NCT01874860|Experimental|Standard care group|Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
16711265|NCT01874847|Experimental|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
16711266|NCT01874847|Placebo Comparator|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
16711267|NCT01874847|Experimental|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
16711268|NCT01874834|Placebo Comparator|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
16711269|NCT01874834|Experimental|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
16711270|NCT01874834|Experimental|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
16711271|NCT01874834|Experimental|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
16711272|NCT01874821|Experimental|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
16711273|NCT01874821|Other|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
16711274|NCT01874808||Healthy|Healthy
16711275|NCT01874808||ALS with postural instability|ALS with postural instability
16711276|NCT01874808||ALS without postural instability|ALS without postural instability
16711277|NCT01874795|Experimental|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
16711278|NCT01874795|Sham Comparator|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
16711279|NCT01874782|Experimental|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
16711280|NCT01874769||Blood collection and skin biopsies|
16711281|NCT01874756|Experimental|LY500307 150mg|LY500307 150mg
16711282|NCT01874756|Placebo Comparator|placebo|placebo 6 pills of inactive drug
16711283|NCT01874756|Experimental|LY500307 75mg|LY500307 75mg
16711284|NCT01874756|Experimental|LY500307 25mg|LY500307 25mg
16711285|NCT01874743|Experimental|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
16711330|NCT01874470|Placebo Comparator|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
16711331|NCT01874470|Experimental|renal denervation|Allegro Renal Denervation System (AngioCare)
16711286|NCT01874730|Other|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
16711287|NCT01874730|Active Comparator|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
16711288|NCT01874717|Experimental|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
16711289|NCT01874717|Other|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
16711290|NCT01874704|Other|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
16711291|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
16711292|NCT01874678|Experimental|TS-1/Cisplatin|single arm
16711293|NCT01874665|Experimental|Cohort A|Participants with KIT exon 11-mutant GIST.
16711294|NCT01874665|Experimental|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
16711295|NCT01874652|Experimental|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
16711296|NCT01874639|Experimental|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
16711297|NCT01874639|Other|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
~- Test group: hepatectomy with Aquamantys®"
16711298|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
16711299|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
16711300|NCT01874613|Experimental|Skull bone reconstruction|Patients with skull bone defect
16711301|NCT01874613|Experimental|Orbital floor defect|Patients with orbital floor defect
16711302|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
16711303|NCT01874587|No Intervention|standard radiotherapy|single pre-treatment planning before radiotherapy
16711304|NCT01874587|Experimental|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
16711305|NCT01874574|Experimental|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
16711306|NCT01874574|Active Comparator|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
16711307|NCT01874561|Experimental|Group 1|"Group 1: investigational product (custirsen) will receive:
~320 mg of custirsen + 5 mg of dexamethasone on day 1
~480 mg of custirsen + 5 mg of dexamethasone on day 3
~640 mg of custirsen + 3 mg of dexamethasone on day 5
~640 mg of custirsen on day 7 under fasting conditions"
16711308|NCT01874561|Placebo Comparator|Group 2|"Group 2: placebo (normal saline) will receive:
~placebo + 5 mg of dexamethasone on day 1
~placebo + 5 mg of dexamethasone on day 3
~placebo + 3 mg of dexamethasone on day 5
~placebo on day 7 under fasting conditions"
16711309|NCT01874561|Active Comparator|Group 3|"Group 3: positive control (moxifloxacin) will receive:
~placebo + 5 mg of dexamethasone on day 1
~placebo + 5 mg of dexamethasone on day 3
~placebo + 3 mg of dexamethasone on day 5
~400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
16711310|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
16711311|NCT01874548||Cervical cancer|"1st year: 30 surgical candidates with cervical cancer tissue collected during operation.
~2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.
~3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
16711312|NCT01874535|Active Comparator|GERD Los Angeles A and B-4 week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group
16711313|NCT01874535|Active Comparator|GERD Los Angeles A and B-8-week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group
16711314|NCT01874522|Experimental|TAS-102 tablets|
16711315|NCT01874522|Experimental|TAS-102 oral solution|
16711316|NCT01874509|Active Comparator|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
16711317|NCT01874509|Experimental|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
16711318|NCT01874496|Experimental|GDS, meal|GDS, meal
16711319|NCT01874496|Experimental|GDS, no meal|GDS, no meal
16711320|NCT01874496|Active Comparator|control, no meal|control, no meal
16711321|NCT01874496|Active Comparator|control, meal|control, meal
16711322|NCT01874483|Experimental|BI 187004 dose 1|multiple dose given over 14 days
16711323|NCT01874483|Experimental|BI 187004 dose 2|multiple dose given over 14 days
16711324|NCT01874483|Experimental|BI 187004 dose 3|multiple dose given over 14 days
16711325|NCT01874483|Experimental|BI 187004 dose 4|multiple dose given over 14 days
16711326|NCT01874483|Experimental|BI 187004 dose 5|multiple dose given over 14 days
16711327|NCT01874483|Experimental|BI 187004 dose 6|multiple dose given over 14 days
16711328|NCT01874483|Placebo Comparator|Placebo|placebo
16711332|NCT01874444|Experimental|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
16711333|NCT01874444|Experimental|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
16711334|NCT01874444|Experimental|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
16711335|NCT01874444|Sham Comparator|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
16711336|NCT01874431|Experimental|Finerenone (BAY94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
16711337|NCT01874431|Experimental|Finerenone (BAY94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
16711338|NCT01874431|Experimental|Finerenone (BAY94-8862)(5 mg)|5 mg dose oral once daily for 90 days
16711339|NCT01874431|Experimental|Finerenone (BAY94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
16711340|NCT01874431|Experimental|Finerenone (BAY94-8862) (10 mg)|10 mg dose oral once daily for 90 days
16711341|NCT01874431|Experimental|Finerenone (BAY94-8862) (15 mg)|15 mg dose oral once daily for 90 days
16711342|NCT01874431|Experimental|Finerenone (BAY94-8862)(20 mg)|20 mg dose oral once daily for 90 days
16711343|NCT01874431|Placebo Comparator|Placebo|Placebo oral dose once daily for 90 days
16711344|NCT01874418|Other|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
16711345|NCT01874392|Experimental|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
16711346|NCT01874379|Experimental|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
16711347|NCT01874379|Active Comparator|Standard of Care|This group will serve as the control arm
16711348|NCT01874379|Experimental|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
16711349|NCT01874366|Experimental|P11187|"Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort
~Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts
~Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
16711350|NCT01874366|Placebo Comparator|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
16711353|NCT01874340|Experimental|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
16711354|NCT01874340|Placebo Comparator|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
16711355|NCT01874340|Experimental|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
16711356|NCT01874340|Experimental|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
16711357|NCT01874327|Active Comparator|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
16711358|NCT01874327|Active Comparator|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
16711359|NCT01874314|Experimental|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
16711360|NCT01874314|Active Comparator|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
16711361|NCT01874314|Placebo Comparator|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
16711362|NCT01874314|Experimental|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
16711363|NCT01874301|Experimental|High quantity probiotic food product|
16711364|NCT01874301|Experimental|Low quantity probiotic food product|
16711365|NCT01874301|Placebo Comparator|Placebo|
16711366|NCT01874288|Experimental|DI-Leu16-IL2 0.5 mg/m^2|Participants will receive DI-Leu16-IL2 0.5 mg/m^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
16711367|NCT01874288|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
16711368|NCT01874288|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
16711369|NCT01874288|Experimental|DI-Leu16-IL2 4.0 mg/m^2|Participants will receive DI-Leu16-IL2 4.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
16711370|NCT01874288|Experimental|DI-Leu16-IL2 6.0 mg/m^2|Participants will receive DI-Leu16-IL2 6.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
16711371|NCT01874275|Experimental|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
16711372|NCT01874275|Placebo Comparator|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
16711373|NCT01874262|Experimental|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
16711374|NCT01874262|Placebo Comparator|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
16711375|NCT01874249|Experimental|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
16711376|NCT01874249|Experimental|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
16711377|NCT01874249|Experimental|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
16711378|NCT01874249|Experimental|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
16711379|NCT01874249|No Intervention|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
16711380|NCT01874236|Active Comparator|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
16711381|NCT01874236|Active Comparator|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
16711382|NCT01874236|Active Comparator|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
16711383|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
16711384|NCT01874210||Hemodialysis|Hemodialysis patients
16711385|NCT01874210||Control|"Household contacts on the same diet
~Healthy unrelated controls"
16711386|NCT01874197|Other|B -TEVAR|Implantation of the B-TEVAR device
16711387|NCT01874184|Experimental|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
16711388|NCT01874184|No Intervention|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
16711389|NCT01874171|Active Comparator|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
16711390|NCT01874171|Experimental|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
16711391|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
16711392|NCT01874145|Active Comparator|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
16711393|NCT01874145|Experimental|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.
~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
16711394|NCT01874132|Experimental|Aerobic exercise training|Dose response
16711395|NCT01874132|Experimental|Aerobic and resistance exercise training|Dose response
16711396|NCT01874132|No Intervention|Control|Non-exercising control group
16711397|NCT01874119|Experimental|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
16711398|NCT01874119|Placebo Comparator|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
16711399|NCT01874106|Experimental|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
16711400|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
16711401|NCT01874093|Experimental|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
16711402|NCT01874093|Sham Comparator|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
16711403|NCT01874080|Experimental|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
16711404|NCT01874080|Experimental|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
16711405|NCT01874080|Experimental|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
16711406|NCT01874080|Experimental|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
16711407|NCT01874067||Arthritis glove|Early inflammatory, rheumatoid or hand osteoarthritis with hand/wrist swelling and pain
16711408|NCT01874054|Experimental|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
16711409|NCT01874041|Experimental|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
16711772|NCT01871597|Experimental|Intervention Group|Intervention - Pulmonary Artery Energy Seal
16711410|NCT01874041|Experimental|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
16711411|NCT01874041|No Intervention|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
16711412|NCT01874028|Experimental|Trientine dihydrochloride|
16711413|NCT01874015|Active Comparator|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
16711414|NCT01874015|Active Comparator|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
16711415|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
16711416|NCT01873989|Experimental|Testosterone replacement|Testosterone replacement for hypogonadism.
16711417|NCT01873989|Other|Waitlist control|This arm involves watchful waiting.
16711418|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
16711419|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
16711420|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
16711421|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
16711422|NCT01873950|Experimental|Ranolazine 1500mg|Ranolazine
16711423|NCT01873950|Experimental|Dofetilide 500mcg|Dofetilide
16711424|NCT01873950|Experimental|Verapamil HCl 120 mg|Verapamil
16711425|NCT01873950|Experimental|Quinidine sulfate 400mg|Quinidine sulfate
16711426|NCT01873950|Placebo Comparator|Placebo|Placebo
16711427|NCT01873937|Experimental|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
16711428|NCT01873937|Experimental|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
16711429|NCT01873937|Active Comparator|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
16711430|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
16711431|NCT01873898|Experimental|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
16711432|NCT01873885|Experimental|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
16711433|NCT01873885|Experimental|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
16711434|NCT01873885|Experimental|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
16711435|NCT01873872|Active Comparator|Theralac probiotic|
16711436|NCT01873872|Active Comparator|Culturelle probiotic|
16711437|NCT01873872|Placebo Comparator|Placebo|
16711438|NCT01873859|Active Comparator|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
16711439|NCT01873859|No Intervention|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
16711440|NCT01873846|Experimental|Silicone Hydrogel Contact Lens|Contact lenses to be worn in each eye on a daily wear basis for 2 weeks. Participants will be provided with Bausch + Lomb Biotrue® multi-purpose solution and contact lens cases for daily rinsing, cleaning, disinfecting, and storing their lenses.
16711441|NCT01873833|Experimental|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16711442|NCT01873820|Experimental|Calcium ascorbate -> ascorbic acid|
16711443|NCT01873820|Experimental|Ascorbic acid -> calcium ascorbate|
16711444|NCT01873807|Experimental|IDA-Etoposide Intensified Conditioning|
16711445|NCT01873807|Active Comparator|Non-IDA Conditioning|
16711446|NCT01873794|Active Comparator|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
16711447|NCT01873794|Active Comparator|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
16711448|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
16711449|NCT01873768|Active Comparator|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
16711450|NCT01873768|Active Comparator|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
16711451|NCT01873755|Experimental|asthma physical activity intervention|two schools will receive intervention
16711452|NCT01873742|Experimental|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
16711453|NCT01873742|Experimental|Treatment as usual|This condition will not include the use of the STIC feedback system.
16711454|NCT01873729|Experimental|Naltrexone|Naltrexone
16711455|NCT01873716|Experimental|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
16711456|NCT01873716|No Intervention|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
16711457|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.
~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
16711458|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.
~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
16711459|NCT01873690|Placebo Comparator|Placebo|Placebo
16711460|NCT01873690|Active Comparator|Ciprofloxacin|Ciprofloxacin
16711461|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
16711462|NCT01873677|Experimental|M518101|Proper quantity twice a day
16711463|NCT01873664|Experimental|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
16711464|NCT01873651|Experimental|Delta III|Implantation of a Delta III Prosthesis
16711465|NCT01873638|Other|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
16711466|NCT01873638|Other|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
16711467|NCT01873625|Placebo Comparator|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
16711468|NCT01873625|Active Comparator|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
16711469|NCT01873612|Experimental|Sedation with dexmedetomidine|Sedation with dexmedetomidine
16711470|NCT01873612|Experimental|Sedation with propofol|Sedation with propofol
16711471|NCT01873599|Experimental|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
16711472|NCT01873599|No Intervention|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
16711473|NCT01873586|Experimental|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
16711474|NCT01873586|Active Comparator|Local autograft|Local autograft (posterolateral gutter at the contralateral side)
16711475|NCT01873573|Active Comparator|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
16711476|NCT01873573|Active Comparator|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
16711477|NCT01873560||FFRpost|High FFRpost group and low FFRpost group were defined according to the optimal cut-off value for predicting clinical outcome.
16711478|NCT01873547|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
16711479|NCT01873547|Experimental|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
16711480|NCT01873547|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
16711481|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
16711482|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
16711483|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
16711484|NCT01873521|Active Comparator|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
16711485|NCT01873521|Active Comparator|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
16711486|NCT01873508|Experimental|Fast release MR capsule|
16711487|NCT01873508|Experimental|Slow release MR capsule|
16711488|NCT01873508|Experimental|Target release MR capsule|
16711489|NCT01873495|Experimental|Omacetaxine: Consolidation/Maintenance|
16711490|NCT01873482|Experimental|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
16711491|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
16711492|NCT01873456|Experimental|Multifactorial nutritional intervention|dietician, resistance type exercise, dysphagia assessment and treatment
16711493|NCT01873456|No Intervention|usual care|usual care
16711494|NCT01873443|Experimental|Rituximab, MTX, folic acid|
16711495|NCT01873430|Active Comparator|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
16711496|NCT01873430|Active Comparator|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
16711497|NCT01873430|Active Comparator|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
16711498|NCT01873430|Placebo Comparator|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
16711499|NCT01873430|No Intervention|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
16711500|NCT01873417|Experimental|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
16711501|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
16711502|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
16711503|NCT01873391|Active Comparator|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
16711504|NCT01873391|Active Comparator|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
16711505|NCT01873378|Experimental|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
16711506|NCT01873378|No Intervention|No pharmacological treatment|
16711507|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
16711508|NCT01873352|Active Comparator|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
16711509|NCT01873352|Active Comparator|CA (control)|Catheter ablation of atrial fibrillation (control group)
16711510|NCT01873339|Experimental|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
16711511|NCT01873326|Experimental|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)* Mesna** 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)*
~**Additional mesna may be given at the discretion of the investigator
~*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
16711512|NCT01873326|Active Comparator|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)
~*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
16711513|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
16711514|NCT01873300|Experimental|treatment group|Patients undergoing POEM procedure
16711515|NCT01873274|Active Comparator|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
16711516|NCT01873274|Active Comparator|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
16711517|NCT01873274|Active Comparator|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
16711518|NCT01873248|Experimental|Diagnostics with PET|68Ga-DOTATATE PET scans will be performed on subjects
16711519|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
16711520|NCT01873222|Experimental|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI
~Assessment by OFDI at a 8-month follow-up"
16711521|NCT01873222|Active Comparator|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI
~Assessment by OFDI at a 8-month follow-up"
16711522|NCT01873196|Experimental|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
16711523|NCT01873196|No Intervention|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
16711524|NCT01873196|Experimental|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
16711525|NCT01873196|No Intervention|Control-No repackaged CSB|
16711526|NCT01873183|Experimental|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.
~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
16711527|NCT01873183|No Intervention|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
16711528|NCT01873170||Combined Oral Contraceptive pills|Levonorgestrel/ethinyl estradiol 0.15mg/30mcg daily oral tabs x21 then 7 inert tabs
16711529|NCT01873170||depot medroxyprogesterone acetate|150mg DMPA intramuscular injection once every 3 months
16711530|NCT01873170||Levonorgestrel-intrauterine device|52mg levonorgestrel intrauterine device
16711531|NCT01873170||Copper intrauterine device|Copper T380A intrauterine device
16711532|NCT01873170||Etonogestrel contraceptive implant|68mg etonogestrel subdermal implant
16711533|NCT01873170||Control|Low risk of pregnancy due to sterilization, heterosexual abstinence, or consistent condom use
16711534|NCT01873157|Placebo Comparator|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.
~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
16711535|NCT01873157|Active Comparator|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.
~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
16711536|NCT01873144|Active Comparator|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
16711568|NCT01872962|Active Comparator|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
16711537|NCT01873144|Experimental|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
16711538|NCT01873131|Experimental|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
16711539|NCT01873131|No Intervention|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
16711540|NCT01873131|Experimental|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
16711541|NCT01873118|No Intervention|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
16711542|NCT01873118|Experimental|implementation unit|"3 implementation protocols implemented sequentially:
~RN-RHDS: implementation of discharge readiness assessment by the discharging nurse
~RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness
~RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
16711543|NCT01873105|Experimental|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
16711544|NCT01873105|No Intervention|Control pre-intervention|Usual care control before implementation of the health team communication intervention
16711545|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
16711546|NCT01873079|Active Comparator|Esomeprazole|esomeprazole 40mg bd for 10 days
16711547|NCT01873079|Sham Comparator|Standard care|No other study drug or placebo will be given
16711548|NCT01873066|Experimental|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
16711549|NCT01873066|Active Comparator|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
16711550|NCT01873053|Experimental|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
16711551|NCT01873053|Experimental|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
16711552|NCT01873053|Placebo Comparator|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
16711553|NCT01873040|Experimental|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
16711554|NCT01873040|Experimental|Information Pages|Participants will have website access to vaccine information pages.
16711555|NCT01873040|No Intervention|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
16711556|NCT01873027|Experimental|OFDI-guided PCI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI
~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
16711557|NCT01873027|Active Comparator|IVUS-guided PCI|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI
~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
16711558|NCT01873014|Experimental|high Iodine intake|
16711559|NCT01873014|Active Comparator|low Iodine intake|
16711560|NCT01873001|Experimental|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
16711561|NCT01872988|Active Comparator|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
16711562|NCT01872988|Placebo Comparator|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
16711563|NCT01872975|Active Comparator|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
16711564|NCT01872975|No Intervention|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
16711565|NCT01872975|Experimental|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
16711566|NCT01872975|Experimental|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
16711567|NCT01872962|Experimental|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
16711569|NCT01872936|Other|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
16711570|NCT01872936|Other|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
16711571|NCT01872923|Experimental|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
16711572|NCT01872910|Placebo Comparator|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.
~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.
~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
16711573|NCT01872910|Experimental|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.
~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.
~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
16711574|NCT01872910|Active Comparator|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).
~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.
~Celecoxib was not administered in Part B.
~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
16711575|NCT01872897|Active Comparator|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
16711576|NCT01872897|Placebo Comparator|Placebo tablets|Single dose of 4 Placebo tablets
16711577|NCT01872884|Experimental|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
16711578|NCT01872884|Placebo Comparator|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
16711579|NCT01872871|Placebo Comparator|local anasthetic drops|topical anaesthetic drop with placebo
16711580|NCT01872871|Active Comparator|Paracetamol|Topical anaesthetic drop with Paracetamol
16711581|NCT01872858|Active Comparator|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
16711582|NCT01872858|Experimental|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
16711583|NCT01872845|Active Comparator|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
16711584|NCT01872845|Experimental|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
16711585|NCT01872832|Experimental|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
16711586|NCT01872832|Experimental|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
16711587|NCT01872832|Experimental|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
16711588|NCT01872832|Experimental|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
16711589|NCT01872819|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
16711590|NCT01872806|Experimental|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
16711591|NCT01872780|Active Comparator|rosiglitazone|avandia
16711592|NCT01872780|Active Comparator|genetic polymorphism|avandia CYP2C8 genotype
16711593|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
16711594|NCT01872754|Active Comparator|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
16711595|NCT01872754|Experimental|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
16711596|NCT01872741|Active Comparator|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
16711597|NCT01872741|Active Comparator|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
16711598|NCT01872728|Placebo Comparator|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
16711599|NCT01872728|Active Comparator|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
16711600|NCT01872715|Experimental|Oracea|"Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.
~Oral dose for 12 weeks"
16711601|NCT01872702|Experimental|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
16711703|NCT01872026|Experimental|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
16711602|NCT01872702|No Intervention|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
16711603|NCT01872689|Placebo Comparator|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
16711604|NCT01872689|Experimental|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
16711605|NCT01872689|Placebo Comparator|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
16711606|NCT01872689|Experimental|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
16711607|NCT01872676|Experimental|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
16711608|NCT01872676|Sham Comparator|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
16711609|NCT01872663|Experimental|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
16711610|NCT01872663|Experimental|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
16711611|NCT01872663|Experimental|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
16711612|NCT01872663|Experimental|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
16711613|NCT01872663|Experimental|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
16711614|NCT01872663|Experimental|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
16711615|NCT01872663|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
16711616|NCT01872650|No Intervention|Control|No placement of an adhesion barrier
16711617|NCT01872650|Experimental|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
16711618|NCT01872637|Experimental|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
16711619|NCT01872637|Active Comparator|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
16711704|NCT01872013|Experimental|low dose ASP7991|
16711705|NCT01872013|Experimental|middle dose ASP7991|
16711706|NCT01872013|Experimental|high dose ASP7991|
16711620|NCT01872624|Active Comparator|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
16711621|NCT01872624|Placebo Comparator|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
16711622|NCT01872611|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
16711623|NCT01872611|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
16711624|NCT01872598|Experimental|Masitinib escalating dose|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
16711625|NCT01872598|Experimental|Masitinib fixed dose (4.5 mg/kg/day)|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
16711626|NCT01872598|Experimental|Masitinib fixed dose (3.0 mg/kg/day)|Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
16711627|NCT01872598|Placebo Comparator|Placebo (escalating dose)|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
16711628|NCT01872598|Placebo Comparator|Placebo (fixed dose)|Participants receive fixed dose placebo, given orally twice daily
16711629|NCT01872585|Experimental|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
16711630|NCT01872572|Other|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
16711631|NCT01872572|Other|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
16711632|NCT01872572|Other|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
16711633|NCT01872572|Other|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
16711634|NCT01872572|Other|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:
~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration
~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
16711635|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
16711636|NCT01872546|Experimental|Adalimumab|
16711637|NCT01872533|Experimental|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
16711638|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
16711639|NCT01872507|Active Comparator|biofeedback training|usual treatment+12 treatment of biofeedback training
16711640|NCT01872507|No Intervention|control|usual treatment
16711641|NCT01872494|Experimental|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
16711642|NCT01872494|Active Comparator|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
16711643|NCT01872481|Placebo Comparator|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
16711644|NCT01872481|Experimental|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
16711645|NCT01872468|No Intervention|Control|There is not intervention in this group.
16711646|NCT01872468|Active Comparator|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
16711647|NCT01872455|Active Comparator|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
16711648|NCT01872455|Experimental|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
16711649|NCT01872442|Experimental|Dasatinib|Dasatinib,Bristol Myers Squibb
16711650|NCT01872442|Experimental|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
16711651|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
16711652|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
16711653|NCT01872416|Experimental|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
16711654|NCT01872403|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
16711655|NCT01872390|Experimental|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
16711656|NCT01872390|Other|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
16711707|NCT01872013|Placebo Comparator|Placebo|
16711708|NCT01872000|Experimental|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
16711657|NCT01872377|Experimental|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
16711658|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
16711659|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.
~ENT consists of:
~Daily conditioning exercise: 35-40 minutes
~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.
~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
16711660|NCT01872338|Active Comparator|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
16711661|NCT01872338|Other|Treatment As Usual|VA standard care for suicide prevention
16711662|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
16711663|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
16711664|NCT01872312|Other|treatment|Loading IBV® Valve System
16711665|NCT01872299||Control|Healthy control subjects
16711666|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
16711667|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
16711668|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
16711669|NCT01872286|Experimental|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
16711670|NCT01872286|Experimental|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
16711675|NCT01872234|Experimental|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
16711676|NCT01872234|No Intervention|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
16711677|NCT01872221|Experimental|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
16711678|NCT01872208|Experimental|HAVG graft|HAVG graft implantation to study participants.
16711679|NCT01872195|Experimental|* Before checklists|The comprehensive patient safety checklist system
16711680|NCT01872195|Experimental|* After checklists|Without the comprehensive patient safety checklist system
16711681|NCT01872182|Experimental|Test arm|ALS-L1023 300mg in two tablets
16711682|NCT01872182|Placebo Comparator|Comparator arm|placebo in two tablets
16711683|NCT01872169|Other|Disordered eating screening questionnaire|
16711684|NCT01872156|Experimental|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
16711685|NCT01872156|Other|Control Group|The group control will act according to usual management.
16711686|NCT01872143|Experimental|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
16711687|NCT01872117|Experimental|Applications of shortwave diathermy|
16711688|NCT01872117|Experimental|Applications of microwave diathermy|
16711689|NCT01872104|No Intervention|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
16711690|NCT01872104|Experimental|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
16711691|NCT01872091|Experimental|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
16711692|NCT01872091|Experimental|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
16711693|NCT01872078|Experimental|AZD4901 20 mg once a day|AZD4901 20 mg once a day
16711694|NCT01872078|Experimental|AZD4901 20mg twice a day|AZD4901 20mg twice a day
16711695|NCT01872078|Experimental|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
16711696|NCT01872078|Experimental|Placebo to match AZD4901|
16711697|NCT01872065|Experimental|ARC-520|Single dose, intravenous administration of ARC-520.
16711698|NCT01872065|Placebo Comparator|Normal Saline|Single dose, intravenous administration of Normal Saline
16711699|NCT01872052|Experimental|Acutus Medical System|
16711700|NCT01872039|Active Comparator|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
16711701|NCT01872039|Experimental|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
16711702|NCT01872026|Experimental|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
16711709|NCT01872000|Active Comparator|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
16711710|NCT01871987|Experimental|fasted group|receiving FK949E in fasted condition
16711711|NCT01871987|Experimental|low fat group|receiving FK949E after low fat meal
16711712|NCT01871987|Experimental|high fat group|receiving FK949E after high fat meal
16711713|NCT01871974|Experimental|low-dose group FK949E|oral
16711714|NCT01871974|Experimental|high-dose group FK949E|oral
16711715|NCT01871961|Experimental|Methotrexate|
16711716|NCT01871948|No Intervention|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
16711717|NCT01871948|Experimental|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
16711718|NCT01871935|Active Comparator|Remifentanil|Anaesthesia with remifentanil/propofol
16711719|NCT01871935|Active Comparator|Sufentanil|Anaesthesia with sufentanil/propofol
16711720|NCT01871922|Placebo Comparator|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
16711721|NCT01871922|Active Comparator|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
16711722|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
16711723|NCT01871896|Experimental|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
16711724|NCT01871883|Experimental|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
16711725|NCT01871883|Active Comparator|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
16711726|NCT01871870|Experimental|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
16711727|NCT01871857|Active Comparator|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
16711728|NCT01871857|Experimental|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
16711729|NCT01871844|Experimental|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
16711730|NCT01871844|Experimental|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
16711731|NCT01871844|Experimental|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
16711732|NCT01871844|Active Comparator|octreotide 50 mcg tid|octreotide 50 mcg tid
16711733|NCT01871818|Experimental|Combined program|"Combined program with physiotherapy, endurance training and resistance training.
~120 patients will receive this combined program"
16711734|NCT01871818|Active Comparator|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
16711735|NCT01871805|Experimental|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
16711736|NCT01871805|Experimental|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
16711737|NCT01871792|Experimental|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
16711738|NCT01871792|Placebo Comparator|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
16711739|NCT01871779|Experimental|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
16711740|NCT01871779|Experimental|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
16711741|NCT01871766|Experimental|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
16711742|NCT01871766|Experimental|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
16711769|NCT01871610|Experimental|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
16711770|NCT01871610|Experimental|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
16711771|NCT01871610|Experimental|Normal control|People aged 30 or older without mTBI or AD
16748544|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
16711743|NCT01871766|Experimental|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
16711744|NCT01871766|Experimental|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
16711745|NCT01871753|Experimental|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
16711746|NCT01871753|No Intervention|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
16711747|NCT01871740|Experimental|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
16711748|NCT01871740|Active Comparator|Enalapril maleate|Enalapril maleate 10 mg per day is given
16711750|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
16711751|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
16711752|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
16711753|NCT01871701|Experimental|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
16711754|NCT01871701|Experimental|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
16711755|NCT01871701|Experimental|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
16711756|NCT01871701|Placebo Comparator|Placebo|Water intake
16711757|NCT01871688|Other|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
16711758|NCT01871675|Experimental|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.
~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
16711759|NCT01871675|Experimental|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.
~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
16711760|NCT01871662|Active Comparator|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
16711761|NCT01871662|Experimental|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
16711762|NCT01871662|Experimental|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
16711763|NCT01871649|Active Comparator|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
16711764|NCT01871649|Experimental|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
16711765|NCT01871636|Active Comparator|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
16711766|NCT01871636|Active Comparator|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
16711767|NCT01871623|Experimental|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
16711768|NCT01871623|Active Comparator|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
16711773|NCT01871584|Experimental|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
16711774|NCT01871584|Active Comparator|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
16711776|NCT01871558|Active Comparator|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
16711777|NCT01871558|Experimental|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
16711778|NCT01871545|Experimental|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
16711779|NCT01871545|No Intervention|Healthy Controls|
16711780|NCT01871532|Experimental|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
16711781|NCT01871532|Active Comparator|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
16711782|NCT01871519|Other|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
16711783|NCT01871506|Experimental|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
16711784|NCT01871506|Experimental|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
~Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
~Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant."
16711785|NCT01871493|Experimental|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
16711786|NCT01871493|Active Comparator|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
16711787|NCT01871493|Experimental|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
16711788|NCT01871493|Experimental|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
16711789|NCT01871493|Active Comparator|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
16711790|NCT01871493|Experimental|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
16711791|NCT01871493|Experimental|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
16711792|NCT01871493|Experimental|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
16711793|NCT01871480|Experimental|Group A|Gefitinib combination with CIK cell immunotherapy
16711794|NCT01871480|Active Comparator|Group B|Gefitinib alone
16711795|NCT01871467|Experimental|Sargramostim administration|Subjects will receive sargramostim.
16711796|NCT01871454|Experimental|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
16711797|NCT01871441|Experimental|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
16711798|NCT01871428|Experimental|Aleglitazar|
16711799|NCT01871428|Placebo Comparator|Placebo|
16711800|NCT01871415|Experimental|Aleglitazar + metformin|
16711801|NCT01871415|Active Comparator|Placebo + metformin|
16711802|NCT01871402|Experimental|Active Arm|Topical lotion, applied twice daily
16711803|NCT01871402|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
16711804|NCT01871389||cholecalciferol|
16711805|NCT01871389||usual treatment|
16711806|NCT01871376|Active Comparator|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.
~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
16711807|NCT01871376|Active Comparator|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.
~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
16711842|NCT01871038||Rotavirus Positive Cases|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
16711808|NCT01871363|Experimental|preoperative chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
~bevacizumab: at dose 5 mg/kg on days -1, 15,31.
~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
16711809|NCT01871350|Experimental|Protein and Fish Oil|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil
~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
16711810|NCT01871350|Experimental|Protein|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil
~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
16711811|NCT01871350|Placebo Comparator|Placebo|"Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil
~High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil"
16711812|NCT01871337|Experimental|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
16711813|NCT01871324|Experimental|Lifestyle counseling|
16711814|NCT01871311|Experimental|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
16711815|NCT01871298|Other|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
16711816|NCT01871298|No Intervention|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
16711817|NCT01871285|Experimental|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
16711818|NCT01871285|Experimental|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
16711819|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
16711820|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
16711821|NCT01871220|Active Comparator|Divergent Abutment|Divergent Transition Profile
16711822|NCT01871220|Experimental|Concave Abutment|Concave Transition Profile
16711823|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
16711824|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
16711825|NCT01871194||Rivaroxaban|This is a non-interventional study
16711826|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
16711827|NCT01871181|Experimental|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
16711828|NCT01871181|Active Comparator|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
16711829|NCT01871168|Sham Comparator|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
16711830|NCT01871168|Experimental|TAP block|Patients receive a continuous TAP block
16711831|NCT01871155|Experimental|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
16711832|NCT01871155|No Intervention|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
16711833|NCT01871142|Experimental|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
16711834|NCT01871129|Placebo Comparator|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
16711835|NCT01871129|Active Comparator|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
16711836|NCT01871116|Experimental|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
16711837|NCT01871116|Active Comparator|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
16711838|NCT01871103|Other|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
16711839|NCT01871090|Active Comparator|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
16711840|NCT01871090|No Intervention|Interrogation with programmer|Interrogation with programmer according to usual standard of care
16711841|NCT01871077|Experimental|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
16711925|NCT01870557||Diabetes Mellitus type 1|n=100
16711843|NCT01871038||Rotavirus Negative Controls|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
16711844|NCT01871025|Experimental|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 30 days to discharge.
16711845|NCT01871025|Other|Usual care|Usual care in COPD
16711846|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
16711847|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
16711848|NCT01870999|Experimental|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
16711849|NCT01870999|Experimental|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
16711850|NCT01870999|Experimental|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
16711851|NCT01870986|Experimental|A|PF-06410293
16711852|NCT01870986|Active Comparator|B|Adalimumab-EU
16711853|NCT01870986|Active Comparator|C|Adalimumab-US
16711854|NCT01870973|Experimental|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
16711855|NCT01870973|Active Comparator|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
16711856|NCT01870960|Other|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
16711857|NCT01870960|Other|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
16711858|NCT01870947|Experimental|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
16711859|NCT01870947|Experimental|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
16711860|NCT01870934||Telemedicine, Diabetes, foot ulcer|
16711861|NCT01870921|Experimental|Ticargrelor|90 mg/tablet, 1 tablet bid
16711862|NCT01870908||tacrolimus + biological agents|
16711863|NCT01870895|Experimental|YM060 group|
16711864|NCT01870895|Placebo Comparator|Placebo group|
16711865|NCT01870882|Active Comparator|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
16711866|NCT01870882|Sham Comparator|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
16711867|NCT01870869|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
16711868|NCT01870869|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
16711869|NCT01870869|Experimental|Revision-Augmentation|Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
16711870|NCT01870869|Experimental|Revision-Reconstruction|Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
16711871|NCT01870856|Experimental|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
16711872|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
16711873|NCT01870856|Experimental|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
16711874|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
16711875|NCT01870843|Experimental|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
16711876|NCT01870830|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
16711877|NCT01870830|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
16711878|NCT01870830|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
16711879|NCT01870830|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
16711880|NCT01870817|Active Comparator|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
16711881|NCT01870817|No Intervention|Control|Standard care
16711882|NCT01870804|Active Comparator|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance < 30 ml/min)
16711883|NCT01870804|Active Comparator|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
16711884|NCT01870791|Experimental|Omegaven|Omegaven in combination with EOX chemotherapy
16711926|NCT01870557||Diabetes Mellitus type 2|n=100
16711885|NCT01870778|Experimental|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
16711886|NCT01870778|Placebo Comparator|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
16711887|NCT01870765|Active Comparator|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
16711888|NCT01870765|Experimental|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
16711889|NCT01870752|Other|Transplantation of previously cryopreserved ovarian tissue|Surgical transplantation of previously collected cryopreserved ovarian cortical tissue.
16711890|NCT01870739|Experimental|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.
~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
16711891|NCT01870739|Active Comparator|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.
~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
16711892|NCT01870726|Experimental|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
16711893|NCT01870726|Experimental|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
16711894|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
16711895|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
16711896|NCT01870700|Experimental|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
16711897|NCT01870700|Placebo Comparator|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
16711898|NCT01870687|Experimental|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
16711899|NCT01870687|Placebo Comparator|Placebo|2 tablets in the morning, oral, 3 months treatment
16711900|NCT01870674|Experimental|YH12852|"<SAD cohort>
~Experimental: YH12852 1mg/single dose, qd
~Experimental: YH12852 3mg/single dose, qd
~Experimental: YH12852 10mg/single dose, qd
~<FSD cohort>
~Experimental: YH12852 0.5mg/single dose, qd
~Experimental: YH12852 1mg/single dose, qd
~Experimental: YH12852 2mg/single dose, qd
~Experimental: YH12852 3mg/single dose, qd
~<MAD cohort>
~Experimental: YH12852 0.5mg/repeat dose, qd
~Experimental: YH12852 1mg/repeat dose, qd
~Experimental: YH12852 2mg/repeat dose, qd
~Experimental: YH12852 3mg/repeat dose, qd
~Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
16711901|NCT01870674|Active Comparator|Prucalopride|<each cohort> Prucalopride succinate 1.321mg
16711902|NCT01870674|Placebo Comparator|Placebo|<each cohort> Matching Placebo
16711903|NCT01870661|Experimental|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
16711904|NCT01870661|Active Comparator|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
16711905|NCT01870648|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron
~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
16711906|NCT01870648|Placebo Comparator|Placebo (sugar pill)|
16711907|NCT01870635|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron
~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
16711908|NCT01870635|Placebo Comparator|Placebo (sugar pill)|
16711909|NCT01870622|Active Comparator|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
16711910|NCT01870622|Experimental|Flow waves|Flow waves will be used to confirm correct tube placement
16711911|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
16711912|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
16711913|NCT01870596|Experimental|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
16711914|NCT01870596|Active Comparator|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
16711915|NCT01870583|Active Comparator|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
16711916|NCT01870583|Active Comparator|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
16711917|NCT01870583|Active Comparator|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
16711918|NCT01870570|Other|Reference Glucose|Glucose Standard (50g of Glucose)
16711919|NCT01870570|Experimental|Food Product A: Corn Flakes|Corn Flakes
16711920|NCT01870570|Experimental|Food Product B: Ginger Bread|Ginger Bread
16711921|NCT01870570|Experimental|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
16711922|NCT01870570|Experimental|Food Product D: Crackers Nature|Crackers Nature
16711923|NCT01870570|Experimental|Food Product E: Breakfast Biscuit|Breakfast Biscuit
16711924|NCT01870570|Experimental|Food Product F: White Bread|White Bread
16711927|NCT01870544|Experimental|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2*10^10 organisms. The LGG is contained in capsules (1*10^10 organisms per capsule), and two capsules will be taken per day.
16711928|NCT01870544|Placebo Comparator|Placebo|Placebo to be taken orally for 44 days.
16711929|NCT01870518|Active Comparator|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
16711930|NCT01870518|Active Comparator|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
16711931|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
16711932|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
16711933|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
16711934|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
16711935|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
16711936|NCT01870479|Experimental|Live music|Patient preferred live music during chemotherapy session.
16711937|NCT01870479|Active Comparator|Taped music|Patient preferred taped music during chemotherapy
16711938|NCT01870479|No Intervention|Control|Usual care during chemotherapy
16711939|NCT01870466|Experimental|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
16711940|NCT01870466|Experimental|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
16711941|NCT01870466|Experimental|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
16711942|NCT01870466|Experimental|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
16711943|NCT01870466|Experimental|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
16711944|NCT01870466|Experimental|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
16711945|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
16711946|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
16711947|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
16711948|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
16711949|NCT01870440|Experimental|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
16711950|NCT01870427|Experimental|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
16711951|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm.
16711952|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
16711953|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
16711954|NCT01870388|Experimental|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
16711955|NCT01870388|Experimental|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
16711956|NCT01870388|Experimental|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
16711957|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
16711958|NCT01870375||MPS II|Hunter syndrome patients
16711959|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
16711960|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
16711961|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
16711962|NCT01870362|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
16711963|NCT01870362|Placebo Comparator|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
16711964|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
16711965|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
16711966|NCT01870336|Experimental|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
16711967|NCT01870336|Experimental|Knee brace|OdrA Knee brace (alone)
16711968|NCT01870336|Experimental|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
16712059|NCT01869842|Experimental|non DM, OCT group|
16711969|NCT01870323|Experimental|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
16711970|NCT01870323|Active Comparator|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
16711971|NCT01870310|No Intervention|Standard medical therapy|
16711972|NCT01870310|Experimental|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
16711973|NCT01870297|Experimental|LY3025876|Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
16711974|NCT01870297|Placebo Comparator|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
16711975|NCT01870297|Experimental|LY3025876 + Liraglutide|Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
16711976|NCT01870297|Placebo Comparator|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
16711977|NCT01870284|Experimental|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
16711978|NCT01870284|Experimental|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
16711979|NCT01870284|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
16711980|NCT01870284|Active Comparator|Adalimumab|Administered by 40 mg SC injection
16711981|NCT01870271|Experimental|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
16711982|NCT01870258|Placebo Comparator|those without MI in 2 weeks|patient without MI in 2 weeks
16711983|NCT01870258|Active Comparator|patient with MI|group with MI in 2 weeks
16711984|NCT01870245|Experimental|ACHN-975|
16711985|NCT01870245|Placebo Comparator|Placebo|
16711986|NCT01870232|Experimental|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
16711987|NCT01870219|Active Comparator|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
16711988|NCT01870219|Active Comparator|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
16711989|NCT01870206|Experimental|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
16711990|NCT01870206|Active Comparator|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
16711991|NCT01870193|Active Comparator|Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
16711992|NCT01870193|Active Comparator|Elderly active|Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months
16711993|NCT01870193|Placebo Comparator|Elderly placebo|Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
16711994|NCT01870180|Experimental|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
16711995|NCT01870180|Placebo Comparator|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
16711996|NCT01870167|Placebo Comparator|placebo|Placebo
16711997|NCT01870167|Experimental|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
16711998|NCT01870154|Experimental|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
16711999|NCT01870154|Active Comparator|Control group|Usual care
16712000|NCT01870141|Experimental|Psychological Intervention|Cognitive Behavioural Intervention
16712001|NCT01870141|No Intervention|Current standard of care|
16712002|NCT01870128|Active Comparator|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
16712003|NCT01870128|Active Comparator|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
16712004|NCT01870128|Experimental|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
16712005|NCT01870115|Placebo Comparator|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
16712006|NCT01870115|Active Comparator|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
16712007|NCT01870102|Active Comparator|Pelubiprofen IR (Pelubiprofen 30 mg)|
16712008|NCT01870102|Experimental|Pelubiprofen SR (Pelubiprofen 45 mg)|
16712009|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
16712010|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
16712011|NCT01870089|Experimental|Study group|
16712012|NCT01870076|Experimental|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
16712013|NCT01870076|Sham Comparator|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
16712014|NCT01870076|Active Comparator|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
16712015|NCT01870076|No Intervention|Control, No Presence|No Presence in the room one hour prior to bed.
16712016|NCT01870063||open heart surgery|
16712017|NCT01870050|Active Comparator|dapsone gel - verum|dapsone gel - verum
16712018|NCT01870050|Placebo Comparator|dapsone gel - vehicle only|
16712019|NCT01870037|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.
16712020|NCT01870037|Experimental|hMaxi-K 16000 µg|Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
16712021|NCT01870037|Experimental|hMaxi-K 24000 µg|Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
16712022|NCT01870024|Active Comparator|1: Lorazepam + Placebo|[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
16712023|NCT01870024|Active Comparator|2: Clonazepam + Placebo|[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
16712024|NCT01870024|Active Comparator|3: Clonazepam + Fosphenytoin|[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
16712025|NCT01870011|Experimental|Desflurane balanced anesthesia group|
16712026|NCT01870011|Active Comparator|Propofol total intravenous anesthesia group|
16712027|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
16712028|NCT01869998||High risk group 1 (B)|(B)Vortex depth<0.45 with anticoagulation
16712029|NCT01869998||High risk group 2 (C)|(C)Vortex depth <0.45 without anticoagulation
16712030|NCT01869985|Experimental|HCP1104|HCP1104
16712031|NCT01869985|Active Comparator|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
16712032|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have >1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
16712033|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
16712034|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
16712035|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
16712036|NCT01869959|Placebo Comparator|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
16712037|NCT01869959|Experimental|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
16712038|NCT01869959|Experimental|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
16712039|NCT01869959|Experimental|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
16712040|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
16712041|NCT01869933|Experimental|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
16712042|NCT01869933|Experimental|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
16712043|NCT01869920|Experimental|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
16712044|NCT01869920|Other|Controll group|Usual care
16712045|NCT01869907|Placebo Comparator|Placebo|Placebo, once daily
16712046|NCT01869907|Active Comparator|Amitriptyline|Amitriptyline 25mg, once daily
16712047|NCT01869907|Active Comparator|Minocycline|Minocycline 100mg, once daily
16712048|NCT01869894|Active Comparator|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
16712049|NCT01869894|Active Comparator|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
16712050|NCT01869894|Active Comparator|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
16712051|NCT01869881|Active Comparator|Sarpogrelate|
16712052|NCT01869881|Placebo Comparator|Placebo|
16712053|NCT01869868||Depression, ECT|
16712054|NCT01869855|Active Comparator|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
16712055|NCT01869855|Active Comparator|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
16712056|NCT01869842|Active Comparator|DM, angio group|
16712057|NCT01869842|Experimental|DM, OCT group|
16712058|NCT01869842|Active Comparator|non DM, angio group|
16712060|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis
16712061|NCT01869816||Acute coronary syndrome (ACS)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
16712062|NCT01869816||Stable angina pectoris (SAP)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
16712063|NCT01869816||Control|Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
16712064|NCT01869790|Experimental|Meal challenge|Different fat types
16712065|NCT01869777|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
16712066|NCT01869764|Experimental|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
16712067|NCT01869764|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
16712068|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
16712069|NCT01869738|Experimental|MGuard Prime|MGuard Prime stent
16712070|NCT01869738|Active Comparator|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
16712071|NCT01869725|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
16712072|NCT01869712|Experimental|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
16712073|NCT01869712|Experimental|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
16712074|NCT01869712|Active Comparator|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
16712075|NCT01869712|Active Comparator|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
16712076|NCT01869699|Placebo Comparator|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
16712077|NCT01869699|Experimental|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
16712078|NCT01869686|Experimental|Denosumab|single subcutaneous injection
16712079|NCT01869673|Active Comparator|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
16712080|NCT01869673|Experimental|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
16712081|NCT01869660|Experimental|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
16712082|NCT01869660|No Intervention|Usual Care|Patients with no special program about decision making.
16712083|NCT01869647|Active Comparator|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
16712084|NCT01869647|Active Comparator|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
16712085|NCT01869647|Active Comparator|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
16712114|NCT01869452|Other|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
16749090|NCT01618591|Experimental|Acute Watery Diarrhea|
16712086|NCT01869634|Active Comparator|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
16712087|NCT01869634|No Intervention|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
16712088|NCT01869621|Experimental|Metformin|6 days treatment with metformin
16712089|NCT01869608|Experimental|postpartum screening|Oral glucose tolerance test 2 days post-partum
16712090|NCT01869582|Experimental|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
16712091|NCT01869582|Experimental|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
16712092|NCT01869582|Experimental|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
16712093|NCT01869582|Experimental|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
16712094|NCT01869569|Active Comparator|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
16712095|NCT01869569|Placebo Comparator|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
16712096|NCT01869556|Active Comparator|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
16712097|NCT01869556|Active Comparator|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
16712098|NCT01869556|Active Comparator|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
16712099|NCT01869543|Experimental|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
16712100|NCT01869543|Experimental|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
16712101|NCT01869543|Experimental|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
16712102|NCT01869543|Experimental|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
16712103|NCT01869530||Healthy children|
16712104|NCT01869517|Active Comparator|Intrastromal corneal continuous ring (Myoring)|
16712105|NCT01869517|Active Comparator|Intrastromal corneal ring segments (Keraring)|
16712106|NCT01869504|Experimental|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
16712107|NCT01869491|Active Comparator|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
16712108|NCT01869491|Placebo Comparator|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
16712109|NCT01869478|Active Comparator|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
16712110|NCT01869478|Active Comparator|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
16712111|NCT01869465|Active Comparator|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
16712112|NCT01869465|Experimental|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
16712113|NCT01869452|Other|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
16749091|NCT01618591|Experimental|Acute Dysentery/Febrile|
16712115|NCT01869452|Other|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
16712116|NCT01869439|Experimental|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
16712117|NCT01869426|Active Comparator|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
16712118|NCT01869426|Placebo Comparator|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
16712119|NCT01869413|Experimental|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
16712120|NCT01869413|Placebo Comparator|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
16712121|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
16712122|NCT01869387|No Intervention|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
16712123|NCT01869387|Experimental|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
16712124|NCT01869374|Experimental|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
16712125|NCT01869374|Active Comparator|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
16712126|NCT01869361|Placebo Comparator|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
16712127|NCT01869361|Active Comparator|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
16712128|NCT01869348|No Intervention|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
16712129|NCT01869348|Experimental|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
16712130|NCT01869335|Active Comparator|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
16712131|NCT01869335|Active Comparator|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
16712132|NCT01869322|Experimental|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
16712133|NCT01869322|Active Comparator|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
16712134|NCT01869309|No Intervention|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
16712135|NCT01869309|Active Comparator|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
16712136|NCT01869296|Active Comparator|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
16712137|NCT01869296|Experimental|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
16712138|NCT01869283|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
16712139|NCT01869283|Experimental|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
16712140|NCT01869283|Experimental|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
16712141|NCT01869283|No Intervention|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
16712142|NCT01869257|Active Comparator|control|regular suture not coated with triclosan
16712143|NCT01869257|Experimental|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
16712144|NCT01869244||hand resting splint|Patients with hand resting splint treatment
16712145|NCT01869231|Experimental|major surgery|colic surgery
16712146|NCT01869231|Experimental|minor surgery|appendectomy; cholecystectomy
16712147|NCT01869231|Experimental|ileostomy and colostomy|ileostomy colostomy
16712148|NCT01869231|Experimental|other surgery|all of others abdominal surgical intervention
16712149|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
16712150|NCT01869205|Experimental|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
16712151|NCT01869192|Active Comparator|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
16712152|NCT01869192|Active Comparator|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
16712153|NCT01869179|Experimental|Community of Voices choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
16712154|NCT01869179|Experimental|Wait-list control group|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
16712155|NCT01869166|Experimental|anti-tumor response of CART-EGFR|
16712156|NCT01869153||Preterm infants|Preterm infants born at either <32 weeks gestation or < 1750g birth weight
16712157|NCT01869140|Sham Comparator|sham spinal manual therapy|activator set to zero
16712158|NCT01869140|Experimental|percussive spinal manual therapy|activator set to the maximum force
16712159|NCT01869140|Experimental|Firm thoracic spinal manual therapy|Firm thoracic manipulation
16712160|NCT01869127|No Intervention|Control|Standard care
16712161|NCT01869127|Experimental|Shoes|Shoes
16712162|NCT01869114|Experimental|High risk Myleodysplastic Syndrome (MDS)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16712163|NCT01869114|Experimental|Acute Myeloid Leukemia (AML)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16712164|NCT01869114|Experimental|MDS or AML with prior Azacitadine therapy|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
16712165|NCT01869088|Active Comparator|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
16712166|NCT01869088|Experimental|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
16712167|NCT01869075|Experimental|AMI - Knowledge Translation toolkit|AMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
16712168|NCT01869075|No Intervention|AMI - Usual Care|Usual care
16712169|NCT01869075|Experimental|MGS - Knowledge Translation Toolkit|Knowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
16712170|NCT01869075|No Intervention|MGS - Usual Care|Usual Care
16712171|NCT01869075|Experimental|HFS - Knowledge Translation Toolkit|Knowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
16712172|NCT01869075|No Intervention|HFS - Usual Care|Usual Care
16712173|NCT01869062|Other|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
16712174|NCT01869062|Other|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
16712175|NCT01869049||ITP patients accepted splenectomy|
16712176|NCT01869049||Trauma with spleen rupture underwent splenectomy|
16712177|NCT01869036|Active Comparator|caudal anesthesia|
16712178|NCT01869036|Active Comparator|caudal anesthesia supplemented with morphine|
16712179|NCT01869023|Other|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
16712180|NCT01869010||HIV Tenofovir|
16712181|NCT01869010||HIV No tenofovir|
16712182|NCT01869010||Seronegative controls|
16712183|NCT01868997|Placebo Comparator|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
16712184|NCT01868997|Experimental|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
16712185|NCT01868984|Sham Comparator|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
16712186|NCT01868984|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
16712891|NCT01864200|Experimental|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
16712187|NCT01868971|Other|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
16712188|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
16712189|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
16712190|NCT01868945|Experimental|5 µg/day Hy.D Calcifediol|
16712191|NCT01868945|Experimental|10 µg/day Hy.D Calcifediol|
16712192|NCT01868945|Experimental|15 µg/day Hy.D Calcifediol|
16712193|NCT01868945|Active Comparator|20 µg/day vitamin D3|
16712194|NCT01868932|Experimental|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
16712195|NCT01868932|Active Comparator|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
16712196|NCT01868919|Experimental|Positive Parenting Program|Level 3 or 4 of Triple P
16712197|NCT01868906|Other|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
16712198|NCT01868906|Other|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
16712199|NCT01868893|Experimental|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
16712200|NCT01868880|Experimental|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
16712201|NCT01868880|Active Comparator|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
16712202|NCT01868867|Experimental|Intervention|Receives on line training and text messaging for treatment
16712203|NCT01868867|No Intervention|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
16712204|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
16712205|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
16712206|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
16712207|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
16712208|NCT01868841|Active Comparator|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
16712209|NCT01868841|Active Comparator|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
16712210|NCT01868828|Experimental|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)
~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)
~Drug: Dexamethasone(40mg, orally, on days 1-4)
~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
~Not suitable for transplant patients will continue accept treatment for 8 cycles."
16712211|NCT01868828|Experimental|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)
~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)
~Drug: Dexamethasone(40mg, orally, on days 1-4)
~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
~Not suitable for transplant patients will continue accept treatment for 8 cycles."
16712212|NCT01868802|Experimental|Ketamine treated|
16712213|NCT01868802|Placebo Comparator|Control, placebo treated|
16712214|NCT01868789|Experimental|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
16712215|NCT01868789|Active Comparator|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
16712216|NCT01868776|Experimental|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
16712217|NCT01868776|Active Comparator|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
16712218|NCT01868763|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks.
16712219|NCT01868763|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
16712220|NCT01868763|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
16712221|NCT01868750|Active Comparator|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
16712222|NCT01868750|Placebo Comparator|Control|Placebo pill taken twice daily for 7 days prior to surgery
16712223|NCT01868737|Experimental|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
16712224|NCT01868737|Placebo Comparator|HIV- exposed infants|MCT oil
16712225|NCT01868737|Placebo Comparator|HIV-unexposed infants|MCT oil
16712226|NCT01868737|Experimental|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
16712227|NCT01868711|Active Comparator|*Cognitive behavior therapy|Depressed patients will receive 12 virtual sessions of cognitive behavior therapy (CBT) for depression. CBT Includes behavior activation, correcting distorted thoughts, and other tools to reduce symptoms.
16712228|NCT01868711|Other|Supportive psychotherapy|Supportive psychotherapy aims to strengthen the patient's ability to cope effectively with various life stressors. Specifically, in our study, supportive psychotherapy will be geared towards reducing or alleviating symptoms of depression. The sessions will be administered virtually.
16712229|NCT01868698|Experimental|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
16712230|NCT01868698|Experimental|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
16712231|NCT01868698|Experimental|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
16712232|NCT01868685|Placebo Comparator|Placebo|
16712233|NCT01868685|Experimental|BYM338|
16712234|NCT01868672|No Intervention|Control|Participant receives usual care.
16712235|NCT01868672|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
16712236|NCT01868659|Experimental|Diagnostic checklist|Diagnostic checklist used before patient discharged
16712237|NCT01868659|Placebo Comparator|Usual care|No diagnostic checklist used during patient encounter
16712238|NCT01868646|Experimental|Subetta|
16712239|NCT01868646|Placebo Comparator|Placebo|
16712240|NCT01868633|Active Comparator|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
16712241|NCT01868633|Placebo Comparator|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
16712242|NCT01868620|Experimental|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
16712243|NCT01868620|Active Comparator|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
16712244|NCT01868607||Adult lung function|
16712245|NCT01868594|Experimental|Subetta group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
16712246|NCT01868594|Placebo Comparator|Placebo group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
16712247|NCT01868581|Experimental|insulin degludec|
16712248|NCT01868581|Experimental|IDegAsp|
16712249|NCT01868568|Experimental|IDegAsp 30 + placebo|
16712250|NCT01868568|Experimental|Insulin aspart + insulin degludec - low concentration 1|
16712251|NCT01868568|Experimental|IDegAsp 40 + placebo|
16712252|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration 1|
16712253|NCT01868568|Experimental|IDegAsp 45 + placebo|
16712254|NCT01868568|Experimental|Insulin aspart + insulin degludec|
16712255|NCT01868568|Experimental|IDegAsp 55 + placebo|
16712256|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration|
16712257|NCT01868568|Active Comparator|BIAsp 30 + placebo|
16712258|NCT01868555|Experimental|IDegAsp 30|
16712259|NCT01868555|Experimental|IDegAsp 45|
16712260|NCT01868555|Experimental|insulin degludec (B)|
16712261|NCT01868555|Experimental|insulin degludec (E)|
16712262|NCT01868542|Experimental|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : >6.1 mmol/L (>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, < 4.4 mmol/L (<80 mg/dL) -3U insulin detemir.
16712263|NCT01868542|Experimental|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : >10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, <3.1 mmol/L (<56 mg/dL) -4U insulin detemir.
16712264|NCT01868529|Experimental|Low dose|
16712265|NCT01868529|Experimental|Medium dose|
16712266|NCT01868529|Experimental|High dose|
16712267|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
16712268|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
16712269|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
16712270|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
16712271|NCT01868503|Experimental|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
16712272|NCT01868490|Experimental|drug|single-group studies
16712273|NCT01868477|Experimental|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
16712274|NCT01868477|Experimental|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
16712275|NCT01868464|Experimental|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10^6 cfu
16712276|NCT01868464|Experimental|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10^6 colony forming units (cfu)
16712277|NCT01868464|Experimental|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10^6 cfu
16712278|NCT01868464|Experimental|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10^6 cfu
16712279|NCT01868451|Experimental|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
16712280|NCT01868451|Experimental|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
16712281|NCT01868451|Experimental|Cohort 3|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
16712282|NCT01868451|Experimental|Cohort 4|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin & AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 & 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin & AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin & AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck & diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
16712283|NCT01868438|Active Comparator|Pyronaridine-artesunate granules (Period 1)|"In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.
~In second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
16712284|NCT01868438|Active Comparator|Pyronaridine-artesunate tablets (Period1)|"In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.
~In second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
16712285|NCT01868425|Experimental|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
16712286|NCT01868425|Placebo Comparator|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
16712287|NCT01868412|Experimental|Resin & honey|Abilar 10% resin salve
16712288|NCT01868412|Active Comparator|Resin vs. honey|Activon Tube 25 g
16712289|NCT01868399||Suspected dengue fever subjects|No any intervention
16712290|NCT01868399||Community Healty Residents|No intervention
16712291|NCT01868386|Experimental|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
16712292|NCT01868386|Experimental|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
16712293|NCT01868386|Experimental|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
16712294|NCT01868386|Experimental|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
16712295|NCT01868373|Other|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
16712892|NCT01864200|Placebo Comparator|Saline placebo|Saline placebo
16712296|NCT01868360|Experimental|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.
~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
16712297|NCT01868360|Placebo Comparator|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
16712298|NCT01868347|Active Comparator|control|PEEP after pneumoperitoneum and trendelenburg
16712299|NCT01868347|Experimental|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
16712300|NCT01868334|Experimental|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation
~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
16712301|NCT01868334|No Intervention|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
16712302|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
16712303|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
16712304|NCT01868295|Experimental|Sleeping with denture|Sleeping with denture at night
16712305|NCT01868295|No Intervention|Sleeping without denture|Sleeping without denture at night
16712306|NCT01868282|Experimental|Group 1|Hamstrings block
16712307|NCT01868282|Active Comparator|Group 2|Obturator block
16712308|NCT01868282|Sham Comparator|Group 3|Control group
16712309|NCT01868269|Other|Dexamethasone Cyclophosphamide Rituximab|
16712310|NCT01868256|Experimental|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in < 72 hours
16712311|NCT01868256|Active Comparator|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
16712312|NCT01868243|Experimental|Dabigatran|Dabigatran 110 mg BID
16712313|NCT01868243|Active Comparator|Warfarin|Warfarin adjusted-dose
16712314|NCT01868230|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
16712315|NCT01868230|No Intervention|Standard of Care|
16712316|NCT01868191|Placebo Comparator|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
16712317|NCT01868191|Experimental|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
16712318|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
16712319|NCT01868165||Cohort of older adults taking antihypertensives|Adults aged 80 and over treated with antihypertensive drugs
16712320|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
16712321|NCT01868126|Experimental|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
16712322|NCT01868126|Experimental|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
16712323|NCT01868126|Experimental|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
16712324|NCT01868126|Experimental|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
16712325|NCT01868126|Active Comparator|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
16712326|NCT01868126|Placebo Comparator|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
16712327|NCT01868113|Active Comparator|Inhaled fluticasone propionate|Inhaled corticosteroid
16712328|NCT01868113|Placebo Comparator|Inhaler propellant|Placebo
16712329|NCT01868100|No Intervention|self-completion questionnaire|
16712330|NCT01868087|Experimental|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
16712331|NCT01868087|Placebo Comparator|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
16712332|NCT01868074|No Intervention|Usual|Participants who are not randomized to the fitted insole intervention
16712333|NCT01868074|Experimental|Insole|Participants randomized to use of a custom-molded insole during pregnancy
16712334|NCT01868061|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
16712335|NCT01868061|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
16712336|NCT01868061|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
16712337|NCT01868048|Experimental|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.
~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
16712371|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
16712372|NCT01867840||arthritis|
16712338|NCT01868048|Placebo Comparator|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
16712339|NCT01868035|Experimental|Single Arm|tositumomab and iodine I-131 tositumomab
16712340|NCT01868022|Experimental|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
16712341|NCT01868022|Experimental|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
16712342|NCT01868022|Experimental|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
16712343|NCT01868009|Experimental|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
16712344|NCT01868009|Experimental|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
16712345|NCT01867996|Experimental|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
16712346|NCT01867983|Active Comparator|Control|Behavioral: Smoking cessation
16712347|NCT01867983|Experimental|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
16712348|NCT01867983|Experimental|Sequential|Behavioral: Weight gain prevention and smoking cessation
16712349|NCT01867970|Experimental|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
16712350|NCT01867970|Experimental|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
16712351|NCT01867970|No Intervention|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
16712352|NCT01867957|Experimental|Low-dose GC1109|
16712353|NCT01867957|Placebo Comparator|Low-dose Placebo|
16712354|NCT01867957|Experimental|High-dose GC1109|
16712355|NCT01867957|Placebo Comparator|High-dose Placebo|
16712356|NCT01867944|Experimental|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
16712357|NCT01867944|Active Comparator|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
16712358|NCT01867931||Erosive Esophagitis|
16712359|NCT01867931||Non-erosive Reflux Disease|
16712360|NCT01867931||Heatlhy volunteers|
16712361|NCT01867918|Experimental|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
16712362|NCT01867918|Placebo Comparator|Cheomotherapy|Standard chemotherapy
16712363|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
16712364|NCT01867892|Experimental|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
16712365|NCT01867892|Active Comparator|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
16712366|NCT01867879|Experimental|TAS-102|
16712367|NCT01867879|Placebo Comparator|Placebo|
16712368|NCT01867866|Experimental|TAS-102|
16712369|NCT01867866|Experimental|FTD (Trifluridine)|
16712370|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
16713717|NCT01858597||gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
16712373|NCT01867827|Experimental|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
16712374|NCT01867827|Active Comparator|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
16712375|NCT01867814|Experimental|Pneumoperitoneum|Patients undergoing laparoscopic surgery
16712376|NCT01867788||Parkinson's disease subjects|
16712377|NCT01867788||Healthy Control subjects|
16712378|NCT01867775|Active Comparator|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
16712379|NCT01867775|Placebo Comparator|Placebo|Placebo 15 mg, once a day at night for 14 days
16712380|NCT01867762|Experimental|JNJ 49095397|
16712381|NCT01867762|Placebo Comparator|Placebo|
16712382|NCT01867749|Experimental|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
16712383|NCT01867749|Active Comparator|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
16712384|NCT01867736|Experimental|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
16712385|NCT01867736|Active Comparator|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
16712386|NCT01867723|Experimental|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
16712387|NCT01867723|No Intervention|Control group|Control group get usual care
16712388|NCT01867710|Experimental|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
16712389|NCT01867710|Experimental|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
16712390|NCT01867710|Experimental|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
16712391|NCT01867710|Experimental|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
16712392|NCT01867697|Active Comparator|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
16712393|NCT01867697|Experimental|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
16712394|NCT01867684|No Intervention|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
16712395|NCT01867684|Experimental|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
16712396|NCT01867671|Experimental|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
16712397|NCT01867671|Placebo Comparator|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
16712398|NCT01867658|Experimental|Progel® Pleural Air Leak Sealant|
16712399|NCT01867645|Active Comparator|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
16712400|NCT01867645|Placebo Comparator|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
16712401|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
16712402|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
16712403|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.
~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
16712404|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.
~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
16712405|NCT01867593|Experimental|C-11 methionine PET|C-11 methionine PET pre and post radiation
16712406|NCT01867580|Experimental|V.A.C.Ulta with Prontosan instillation|Treatment Arm
16712407|NCT01867580|Active Comparator|V.A.C.Ulta without instillation|Control Arm
16712408|NCT01867567|Experimental|6 Hours|Removal of bandage after 6 hours
16712409|NCT01867567|Active Comparator|24 hours|removal of bandage after 24 hours
16712410|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
16712411|NCT01867528|Experimental|Laparoscopic adhesiolysis|
16712412|NCT01867528|Active Comparator|Open adhesiolysis|
16712413|NCT01867515|Active Comparator|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.
~age between 18 and 35
~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
16712414|NCT01867515|Active Comparator|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below
~age 18 to 65 Acoustic distortion of speech"
16712415|NCT01867515|Active Comparator|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.
~age between 36 and 65
~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
16712416|NCT01867502|Other|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.
~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
16712417|NCT01867502|Other|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.
~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
16712418|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
16712419|NCT01867476||Healthy Normals|
16712420|NCT01867463|Experimental|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
16712421|NCT01867463|Experimental|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
16712422|NCT01867463|Experimental|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
16712423|NCT01867450||Biomarker Cross-section|Cross-sectional biomarker study in Chinese diesel workers
16712424|NCT01867437|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
16712425|NCT01867437|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
16712426|NCT01867424|Active Comparator|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
16712427|NCT01867424|Active Comparator|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
16712428|NCT01867411||ex-smokers|former smokers who have quit
16712429|NCT01867411||never smokers|never smoked
16712430|NCT01867411||non-treatment seeking smokers|smokers not interested in quitting smoking
16712431|NCT01867411||Treatment seeking smokers|smokers interested in quitting smoking
16712432|NCT01867333|Experimental|1|Enzaluatmide alone
16712433|NCT01867333|Experimental|2|Enzaluatmide with PSA-TRICOM
16712434|NCT01867320|Experimental|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
16712435|NCT01867307|Experimental|Healthy Controls|healthy controls
16712436|NCT01867307|Experimental|Patients|patients with type 2 diabetes mellitus
16712437|NCT01867294|Experimental|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
16712438|NCT01867294|Experimental|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
16712439|NCT01867294|Placebo Comparator|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
16712440|NCT01867294|Active Comparator|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
16712441|NCT01867281|Active Comparator|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
16712442|NCT01867281|Placebo Comparator|Control: placebo|Participants will receive placebo
16712443|NCT01867268|Experimental|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
16712444|NCT01867268|No Intervention|Control|control group without any intervention
16712445|NCT01867268|Experimental|Prone positioning|Positioning the patient following surgery for 10 days
16712446|NCT01867268|Experimental|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
16712447|NCT01867255|Other|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
16712448|NCT01867242|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
16712449|NCT01867242|Experimental|Complete Substitution|Use snus in place of cigarettes
16712450|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes)|Use snus and cigarettes how ever you like
16712451|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
16712452|NCT01867216|Placebo Comparator|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
16712453|NCT01867216|Experimental|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
16712454|NCT01867203||Statin users|
16712455|NCT01867190|Other|ASCT01|ASCT01 (Autologous Stem Cell Transplantation)
16712456|NCT01867177|Other|HIV testing|Identification of HIV infection among recently infected adults
16712457|NCT01867177|Experimental|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
16712458|NCT01867177|Active Comparator|standard of care|Standard of HIV care; standard of linkage to HIV care
16712459|NCT01867164|Experimental|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
16713718|NCT01858597||control|Those healthy pregnant women
16712460|NCT01867164|Experimental|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
16712461|NCT01867151|Experimental|Gluten free diet|BMS patients following a GFD
16712462|NCT01867151|Sham Comparator|Normal Diet|Patients with BMS maintaing a normal diet
16712463|NCT01867138|Experimental|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
16712464|NCT01867138|Active Comparator|Vancomycin|Initial empirical treatment with vancomycin and amikacin
16712465|NCT01867125|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams [mg]) every 4 weeks for 104 weeks.
16712466|NCT01867125|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
16712467|NCT01867125|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
16712468|NCT01867112|Active Comparator|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
16712469|NCT01867112|Active Comparator|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
16712470|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
16712471|NCT01867086|Experimental|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
16712472|NCT01867073||Advanced solid tumours|
16712473|NCT01867060|Other|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
16712474|NCT01867047|Experimental|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
16712475|NCT01867047|Experimental|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)
16712476|NCT01867034|Active Comparator|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
16712477|NCT01867034|Active Comparator|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
16712478|NCT01867021|Experimental|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
16712479|NCT01867021|Active Comparator|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
16712480|NCT01867008|Experimental|Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor|
16712481|NCT01866995|Experimental|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
16712482|NCT01866995|Active Comparator|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
16712483|NCT01866995|Experimental|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
16712484|NCT01866982|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
16712485|NCT01866982|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
16712486|NCT01866969|Experimental|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
16712487|NCT01866943|Placebo Comparator|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
16712488|NCT01866943|Experimental|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
16712489|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks
~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks
~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
16712490|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks
~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks
~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
16712491|NCT01866917|Experimental|TAP|Patients will receive Ropivicaine 0.5% 20cc injectate from a study labeled syringe
16712492|NCT01866917|Placebo Comparator|Saline|Patients will receive Normal saline 20cc injectate from a study labeled syringe
16712675|NCT01865591|Experimental|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
16712493|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
16712494|NCT01866891|Experimental|single arm|
16712495|NCT01866878|Experimental|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.
~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.
~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
16712496|NCT01866878|Experimental|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
16712497|NCT01866878|No Intervention|A control group|
16712498|NCT01866839|Experimental|CD34+ cell positively selected graft stem cell recipient|Recipients received a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg total), fludarabine (125 mg/m2 total) and total body irradiation (1200 cGy with lung shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS® system. Older subjects will receive a lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
16712499|NCT01866826|Experimental|HIV Infected Subjects|Human immunodeficiency virus (HIV) infected subjects with viral suppression on antiretroviral (ART). Double-blinded/placebo controlled trial with cross-over design. Rifaximin
16712500|NCT01866826|Placebo Comparator|HIV Infected Subjects Placebo|HIV infected subjects with viral suppression on ART. Double-blinded/placebo controlled trial with cross-over design. Placebo
16712501|NCT01866813|No Intervention|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
16712502|NCT01866813|Experimental|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
16712503|NCT01866800|Active Comparator|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
16712504|NCT01866800|Placebo Comparator|Conventional Treatment|Saline and N-Acetylcysteine
16712505|NCT01866787||Study cohort|
16712506|NCT01866774|Experimental|Fecal calprotectin level|Fecal calprotectin level
16712507|NCT01866774|No Intervention|Symptom questionnaire|
16712508|NCT01866761||Periodontitis, Lifestyle-related disease|
16712509|NCT01866748|Experimental|Part A (single dose)|
16712510|NCT01866748|Experimental|Part B (multiple dose)|
16712511|NCT01866735|No Intervention|Usual Care|
16712512|NCT01866735|Experimental|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):
~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
16712513|NCT01866722|Active Comparator|Usual Care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
16712514|NCT01866722|Active Comparator|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
16712515|NCT01866722|Active Comparator|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
16712516|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
16712517|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
16712518|NCT01866696|Experimental|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
16712519|NCT01866683|Experimental|Group 1|1 month respiratory training
16712520|NCT01866683|Experimental|Group 2|1 month waiting period
16712521|NCT01866670|Experimental|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation
~Each patient will participate individually in three sequential meetings (A1, A2 and A3).
~In the experimental group, it will be developed the support spiritual intervention in all three meetings.
~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
16712522|NCT01866670|Active Comparator|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).
~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
16712523|NCT01866657|Experimental|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
16712524|NCT01866657|No Intervention|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
16712525|NCT01866644|Experimental|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
16712526|NCT01866644|Placebo Comparator|Saline|With usual technique
16712527|NCT01866631||No treatment|
16712528|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
16712529|NCT01866605|Placebo Comparator|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
16712530|NCT01866605|Active Comparator|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
16712531|NCT01866605|Active Comparator|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
16712532|NCT01866592|Other|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
16712533|NCT01866579||ethambutol optic neuropathy|
16712534|NCT01866566|Placebo Comparator|HBV-3|one dose HBV
16712535|NCT01866566|Placebo Comparator|HBV-6|one dose HBV
16712536|NCT01866566|Experimental|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
16712537|NCT01866566|Experimental|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
16712538|NCT01866553|Experimental|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
16712539|NCT01866540|Experimental|Fluenz vaccine|LAIV vaccine
16712540|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
16712541|NCT01866514|Experimental|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
16712542|NCT01866501|Experimental|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
16712543|NCT01866488|Experimental|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
16712544|NCT01866488|Placebo Comparator|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
16712545|NCT01866475|Active Comparator|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
16712546|NCT01866475|Active Comparator|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
16712547|NCT01866475|Active Comparator|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
16712548|NCT01866475|Active Comparator|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
16712549|NCT01866462|Experimental|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
16712550|NCT01866462|Placebo Comparator|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
16712551|NCT01866449|Experimental|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
16712552|NCT01866436|Experimental|Multimedia group|The multimedia group is the interventional arm of the study
16712553|NCT01866436|Experimental|Study Day Group|The study day group are the control arm of the study
16712554|NCT01866423|Experimental|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16712555|NCT01866410|Experimental|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16712556|NCT01866397|Experimental|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
16712557|NCT01866384|Other|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
16712558|NCT01866384|Experimental|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
16712559|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
16712676|NCT01865578|Experimental|tDCS|Transcranial direct current stimulation
16712560|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
16712561|NCT01866358|Placebo Comparator|Umbilical vein infusion|using umbilical vein infusion for resucitation
16712562|NCT01866358|Experimental|Intraosseous infusion|using intraosseous infusion for resucitation
16712563|NCT01866345|Active Comparator|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
16712564|NCT01866345|Experimental|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
16712565|NCT01866332|Active Comparator|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
16712566|NCT01866332|Experimental|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.
~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
16712567|NCT01866319|Experimental|Ipilimumab|Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
16712568|NCT01866319|Experimental|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
16712569|NCT01866319|Active Comparator|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.
16712570|NCT01866306|Experimental|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712571|NCT01866306|Experimental|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712572|NCT01866306|Experimental|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712573|NCT01866306|Experimental|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712574|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712575|NCT01866306|Experimental|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712576|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
16712577|NCT01866293|Experimental|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
16712578|NCT01866280|Experimental|Normal sleep Normal meals|Normal sleep/Normal meal times
16712579|NCT01866280|Experimental|Normal sleep Late meals|Normal sleep/Late meal times
16712580|NCT01866280|Experimental|Late sleep Late meals|Late sleep/Late meal times
16712581|NCT01866280|Experimental|Late sleep Normal meals|Late sleep/Normal meal times
16712582|NCT01866267|Other|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
16712583|NCT01866254|Experimental|Hydromorphone|100 mg, intrathecal administration
16712584|NCT01866254|Active Comparator|Morphine|200 mg, intrathecal administration
16712585|NCT01866241|Experimental|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
16712586|NCT01866241|Placebo Comparator|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
16712587|NCT01866228|No Intervention|No Consultation Recording|Participant does not receive consultation recording
16712588|NCT01866228|Experimental|Consultation Recording|Participant receives consultation recording
16712589|NCT01866215|Experimental|Study1a|exercice performed 90 min before 13C fructose meal ingestion
16712590|NCT01866215|Experimental|study 1b|exercise performed 90 min after 13C fructose meal ingestion
16712591|NCT01866215|No Intervention|study 1c|no exercise
16712592|NCT01866215|Experimental|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
16712593|NCT01866215|Active Comparator|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
16712594|NCT01866189|Experimental|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
16712595|NCT01866176|Experimental|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren & Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
16712596|NCT01866163|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
16712597|NCT01866163|Placebo Comparator|Vehicle|Aerosol foam vehicle
16712598|NCT01866150||Cohort|
16712599|NCT01866137||no treatment|no treatment
16712677|NCT01865578|Sham Comparator|sham stimulation|sham stimulation
16713911|NCT01857232|Experimental|Low dose APD403|OND + APD403 followed by oral APD403 low dose
16712600|NCT01866124|Experimental|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.
~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
16712601|NCT01866124|No Intervention|Comparison group|
16712602|NCT01866111|Placebo Comparator|Placebo|Placebo
16712603|NCT01866111|Experimental|YKP3089 Low Dose|YKP3089 Low Dose
16712604|NCT01866111|Experimental|YKP3089 Medium Dose|YKP3089 Medium Dose
16712605|NCT01866111|Experimental|YKP3089 High Dose|YKP3089 High Dose
16712606|NCT01866098|Experimental|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
16712607|NCT01866098|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 52 weeks
16712608|NCT01866098|Experimental|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
16712609|NCT01866085|Active Comparator|AdVance|sling procedure
16712610|NCT01866085|Active Comparator|ARGUS|sling procedure
16712611|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
16712612|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
16712613|NCT01866059|Experimental|Calcium silicate cement|Biodentine
16712614|NCT01866059|Active Comparator|Glass Ionomer Cement|Fuji IX
16712615|NCT01866059|Active Comparator|Resin Modified Glass Ionomer Cement|Fuji II LC
16712616|NCT01866046|Experimental|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
16712617|NCT01866033|Experimental|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
16712618|NCT01866007|Experimental|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
16712619|NCT01866007|Experimental|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
16712620|NCT01866007|Experimental|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
16712621|NCT01866007|Experimental|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
16712622|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
16712623|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
16712624|NCT01865981||Brugada|Patients suffering from Brugada syndrome
16712625|NCT01865968|Experimental|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
16712626|NCT01865968|Active Comparator|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
16712627|NCT01865968|Experimental|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
16712628|NCT01865955|No Intervention|Palpation|Palpation will be used to determine placement of the spinal needle.
16712629|NCT01865955|Experimental|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
16712630|NCT01865942|Active Comparator|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
16712631|NCT01865942|Active Comparator|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
16712632|NCT01865929|Active Comparator|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
16712633|NCT01865929|Active Comparator|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
16712634|NCT01865916|Active Comparator|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
16712635|NCT01865916|Experimental|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
16712636|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
16712637|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
16712638|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
16712639|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
16712640|NCT01865864||1|Compliant with CPAP
16712641|NCT01865864||2|noncompliant with CPAP
16712642|NCT01865851|Active Comparator|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
16712643|NCT01865851|Active Comparator|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
16712644|NCT01865838|Active Comparator|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
16712645|NCT01865838|No Intervention|Control|Patients in this arm does NOT receive Seprafilm during surgery.
16712765|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
16712646|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.
~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
16712647|NCT01865812|Experimental|OCA: 10 mg|obeticholic acid, oral administration, 10 mg, 8 weeks
16712648|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
16712649|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
16712650|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
16712651|NCT01865773|Experimental|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
16712652|NCT01865760|Experimental|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
16712653|NCT01865760|Active Comparator|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
16712654|NCT01865760|Other|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
16712655|NCT01865747|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
16712656|NCT01865747|Active Comparator|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
16712657|NCT01865734|Experimental|Early Physical Therapy|Physical therapy after initial podiatry visit
16712658|NCT01865734|Active Comparator|Usual Podiatric Care|Usual care provided by podiatry
16712659|NCT01865721|Active Comparator|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
16712660|NCT01865721|Active Comparator|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
16712661|NCT01865708|Other|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
16712662|NCT01865695|Placebo Comparator|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
16712663|NCT01865695|Active Comparator|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
16712664|NCT01865669|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
16712665|NCT01865669|Experimental|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
16712666|NCT01865656|Other|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:
~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
16712667|NCT01865656|No Intervention|Control Arm|
16712668|NCT01865643|Other|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
16712669|NCT01865643|Experimental|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
16712670|NCT01865630|Experimental|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
16712671|NCT01865617|Experimental|Treatment (anti-CD19-CAR autologous T cells)|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
~DOSE DENSE EXPANSION COHORT: An additional cohort will receive a second anti-CD19-CAR lentiviral vector-transduced autologous T cell infusion without additional lymphodepleting chemotherapy 10-21 days after the first infusion if adequate CD19 CAR-T cells can be produced and appropriate criteria are met."
16712672|NCT01865604|Experimental|Anodal tDCS|anaodal transcranial direct current stimulation
16712673|NCT01865604|Active Comparator|Cathodal tDCS|cathodal transcranial direct current stimulation
16712674|NCT01865604|Sham Comparator|Sham tDCS|no stimulation
16712678|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at
~EC junction requiring total gastrectomy,
~Duodenum requiring Whipple operation;
~Large GIST requiring multiviceral resection;
~Rectum: requiring APR."
16712679|NCT01865552|Experimental|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
16712680|NCT01865552|Experimental|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
16712681|NCT01865552|Experimental|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
16712682|NCT01865552|Experimental|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
16712683|NCT01865552|Other|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
16712684|NCT01865552|Other|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
16712685|NCT01865539|Active Comparator|Custom Foot Orthotic|Custom foot orthotic
16712686|NCT01865539|Sham Comparator|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
16712687|NCT01865526|Active Comparator|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
16712688|NCT01865526|Experimental|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
16712689|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 4mg|
16712690|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 8 mg|
16712691|NCT01865500|Active Comparator|Budesonide 4 mg & Budesonide 8 mg|
16712692|NCT01865487|Placebo Comparator|2-Dose Placebo|Placebo QFT Neg and Pos, 2 Doses, days 0,56
16712693|NCT01865487|Experimental|2-Dose 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56
16712694|NCT01865487|Experimental|2-Dose 15/500 H56ug/IC31nmol|15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
16712695|NCT01865487|Experimental|2-Dose 50/500 H56ug/IC31nmol|50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
16712696|NCT01865487|Placebo Comparator|3-Dose, Placebo|Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112
16712697|NCT01865487|Experimental|3-Dose, 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112
16712698|NCT01865474|Experimental|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
16712699|NCT01865474|Experimental|Treatment II|Placebo tablet of DLBS1033, thrice daily
16712700|NCT01865448|Active Comparator|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
16712701|NCT01865448|Placebo Comparator|Control|Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
16712702|NCT01865435|Experimental|new borns|
16712703|NCT01865422|Experimental|chronic cough|
16712704|NCT01865409|Active Comparator|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
16712705|NCT01865396|Experimental|early palliative care|Interventional palliative care, after diagnosis and once a month.
16712706|NCT01865396|Active Comparator|Standard care|Patients will receive the standard oncologic care.
16712707|NCT01865383|Experimental|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
16712708|NCT01865383|No Intervention|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
16712709|NCT01865370|Experimental|Kochujang Pills|
16712710|NCT01865370|Placebo Comparator|Placebo|
16712711|NCT01865357|Experimental|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
16712712|NCT01865357|Experimental|Control|healthy subject
16712713|NCT01865344||Heart surgery|Pain monitoring at different time periods
16712714|NCT01865331|Experimental|Low dose, insulin degludec|
16712715|NCT01865331|Experimental|Medium dose, insulin degludec|
16712716|NCT01865331|Experimental|High dose, insulin degludec|
16712717|NCT01865331|Experimental|IDegAsp 50|
16712718|NCT01865318|Experimental|Part 1 (Once-daily dosing regimen, high concentration)|
16712719|NCT01865318|Experimental|Part 2 (Twice-daily dosing regimen, high concentration)|
16712720|NCT01865318|Experimental|Part 3 (Once-daily dosing regimen, low concentration)|
16712721|NCT01865305|Experimental|Trial part 1|
16712722|NCT01865305|Experimental|Trial part 2|
16712723|NCT01865292|Experimental|Insulin degludec|
16712724|NCT01865292|Active Comparator|Insulin glargine|
16712725|NCT01865279|Experimental|Trial part 1|
16712726|NCT01865279|Active Comparator|Trial part 2|
16712727|NCT01865266|Experimental|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):
~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
16712766|NCT01865045||no treatment|no treatment
16712767|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
16712728|NCT01865266|Experimental|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):
~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
16712729|NCT01865266|Placebo Comparator|CG|"The compare group(CG):
~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
16712730|NCT01865253|Experimental|Renal Denervation|Renal Denervation treatment
16712731|NCT01865240|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
16712732|NCT01865240|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
16712733|NCT01865227|Active Comparator|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
16712734|NCT01865227|No Intervention|Standard treatment|
16712735|NCT01865201|Experimental|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
16712736|NCT01865201|Experimental|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
16712737|NCT01865188|Experimental|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
16712738|NCT01865188|Experimental|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
16712739|NCT01865188|Active Comparator|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
16712740|NCT01865188|Active Comparator|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
16712741|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
16712742|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
16712743|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
16712744|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
16712745|NCT01865188|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
16712746|NCT01865175|Active Comparator|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
16712747|NCT01865175|Experimental|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
16712748|NCT01865162|Experimental|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
16712749|NCT01865149||both optic nerve sheath diameter|
16712750|NCT01865136|Other|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
16712751|NCT01865136|No Intervention|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
16712752|NCT01865123|Experimental|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
16712753|NCT01865123|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
16712754|NCT01865123|Placebo Comparator|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
16712755|NCT01865110|Experimental|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
16712756|NCT01865110|Active Comparator|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
16712757|NCT01865110|Experimental|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
16712758|NCT01865110|Active Comparator|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
16712759|NCT01865097|Experimental|Relaxation guided imagery|
16712760|NCT01865097|Active Comparator|Relaxing music|
16712761|NCT01865084|Experimental|Placebo|Placebo taken orally once daily.
16712762|NCT01865084|Experimental|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
16712763|NCT01865084|Experimental|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
16712764|NCT01865071|Experimental|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
16712773|NCT01864993|Experimental|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
16712774|NCT01864993|Experimental|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
16712775|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
16712776|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
16712777|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
16712778|NCT01864967||control|did not receive carbon dioxide
16712779|NCT01864954|Experimental|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
16712780|NCT01864954|Active Comparator|Basic Static Web|Static website access only, only introductory call.
16712781|NCT01864941|Active Comparator|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
16712782|NCT01864941|Sham Comparator|Catheter Venography Only|Patients will undergo catheter venography only.
16712784|NCT01864915|Experimental|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
16712785|NCT01864915|Experimental|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
16712786|NCT01864915|Experimental|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
16712787|NCT01864902|Experimental|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
16712788|NCT01864889|Experimental|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
16712789|NCT01864876|Experimental|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
16712790|NCT01864876|Experimental|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
16712791|NCT01864876|Experimental|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
16712792|NCT01864863|Experimental|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
16712793|NCT01864863|Experimental|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
16712794|NCT01864850|Active Comparator|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
16712795|NCT01864850|Experimental|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
16712796|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
16712797|NCT01864824|Experimental|methyl donor|"Methyl donor is made up of:
~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
16712798|NCT01864824|Placebo Comparator|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
16712799|NCT01864811|Experimental|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
16712800|NCT01864811|Experimental|baby-massage|The infants will receive baby massage
16712801|NCT01864798|Experimental|Denosumab|
16712802|NCT01864785|Other|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
16712803|NCT01864785|Other|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
16712804|NCT01864772|Experimental|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)
~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
16712805|NCT01864759|Experimental|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
16712806|NCT01864746|Experimental|Palbociclib|Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
16712807|NCT01864746|Placebo Comparator|Placebo|Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles
16712808|NCT01864733|Experimental|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:
~Physical rehabilitation including endurance and resistance exercises two to three times a week.
~Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.
~n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.
~Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
16712809|NCT01864733|Other|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
16712810|NCT01864720|Active Comparator|Professionally Administered CBT-I (Standard Care)|Patients assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
16712884|NCT01864252|Experimental|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
16712893|NCT01864187|Experimental|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
16712811|NCT01864720|Experimental|Stepped Care CBT-I|Patients having an ISI score > 7 but < 15 (approximately 100 patients), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score > 14 (approximately 100 patients) will receive six weekly sessions of CBT-I administered individually by a professional.
16712812|NCT01864707|Experimental|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
16712813|NCT01864707|Experimental|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
16712814|NCT01864707|Active Comparator|usual care|usual care without additional treatment
16712815|NCT01864694|Experimental|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
16712816|NCT01864694|Experimental|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
16712817|NCT01864694|Experimental|Control|Assessment-only control group
16712818|NCT01864681|Experimental|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
16712819|NCT01864681|Placebo Comparator|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
16712820|NCT01864655|Experimental|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
16712821|NCT01864655|Experimental|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
16712822|NCT01864655|Experimental|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
16712823|NCT01864655|Placebo Comparator|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
16712824|NCT01864642|Experimental|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
16712825|NCT01864629|Other|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
16712826|NCT01864629|No Intervention|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
16712827|NCT01864616|Experimental|Group 3|Vitamin D3, 10,000 IU daily
16712828|NCT01864616|Experimental|Group 2|Vitamin D3 2,000 IU daily
16712829|NCT01864616|Experimental|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
16712830|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery
~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
16712831|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: universal test & treat|"Intervention arm first phase: baseline community-based HIV and multi-disease testing
~Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery"
16712832|NCT01864590|Experimental|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
16712833|NCT01864590|Active Comparator|Double Sylo Bag - Mesh Protocol|Open Abdomen
16712834|NCT01864577|Experimental|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
16712835|NCT01864577|Active Comparator|With water seal|Patients al left on water seal only
16712836|NCT01864564|No Intervention|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.
~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
16712837|NCT01864564|Experimental|Early Screening|"Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.
~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
16712838|NCT01864551|Active Comparator|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
16712839|NCT01864551|Active Comparator|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
16712840|NCT01864538|Experimental|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
16712841|NCT01864525|Placebo Comparator|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
16712842|NCT01864525|Experimental|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
16712843|NCT01864512||ITP patients receiving eltrombopag therapy|
16712844|NCT01864499|Experimental|Tumor Resection|
16712845|NCT01864499|Active Comparator|Biopsy Brain Tumor|
16712846|NCT01864486|Experimental|Intelligent Retinal Implant System|
16712847|NCT01864473|Other|Kshar Sutra|
16712885|NCT01864252|Experimental|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
16712886|NCT01864239|Experimental|Patient-centred tailored intervention|Medicines Advice Service
16712887|NCT01864239|No Intervention|Control|Usual care
16712848|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
16712849|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
16712850|NCT01864447|Experimental|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of >3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.
~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
16712851|NCT01864447|No Intervention|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
16712852|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
16712853|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
16712854|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
16712855|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
16712856|NCT01864408|Other|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
16712857|NCT01864408|Experimental|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
16712858|NCT01864395|Experimental|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
16712859|NCT01864395|Experimental|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
16712860|NCT01864395|Experimental|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
16712861|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
16712862|NCT01864382|Experimental|Core stability|Core stability.5 days a week during 5 weeks
16712863|NCT01864369|Active Comparator|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
16712864|NCT01864369|Experimental|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
16712865|NCT01864356|Experimental|NT100 Dose 1|NT100 Dose 1
16712866|NCT01864356|Experimental|NT100 Dose 2|NT100 Dose 2
16712867|NCT01864356|Placebo Comparator|Placebo|Placebo
16712868|NCT01864343|Experimental|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
16712869|NCT01864330|Experimental|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
16712870|NCT01864330|Active Comparator|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
16712871|NCT01864330|Active Comparator|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
16712872|NCT01864317|Experimental|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
16712873|NCT01864317|Experimental|Normal Tension Glaucoma|30 patients with normal tension glaucoma
16712874|NCT01864317|Experimental|Ocular Hypertension|30 patients with ocular hypertension
16712875|NCT01864317|Other|Healthy subjects|30 healthy control subjects
16712876|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
16712877|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
16712878|NCT01864291|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
16712879|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
16712880|NCT01864265|Active Comparator|Certolizumab Pegol|
16712881|NCT01864265|Placebo Comparator|Placebo|
16712882|NCT01864252|Sham Comparator|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
16712883|NCT01864252|Active Comparator|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
16712888|NCT01864226|Placebo Comparator|Placebo|
16712889|NCT01864226|Experimental|RO5545965|
16712894|NCT01864174|Active Comparator|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks
~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
16712895|NCT01864174|Active Comparator|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks
~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
16712896|NCT01864161|Experimental|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
16712897|NCT01864161|Active Comparator|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
16712898|NCT01864148|Experimental|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.
~Avonex once-weekly intramuscular (IM) injection up to Week 84."
16712899|NCT01864148|Experimental|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
16712900|NCT01864148|Experimental|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
16712901|NCT01864148|Experimental|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
16712902|NCT01864148|Placebo Comparator|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
16712903|NCT01864135|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
16712904|NCT01864109|Experimental|Patients with localized disease|"Patients with localized disease will receive six cycles of the combination as maintenance therapy following standard chemotherapy.
~Cycles 4-6 will include:
~Ifosfamide 2,800 mg/m2/day on days 1-5
~Etoposide 100 mg/m2/day on days 1-5
~Cycle 7 will include :
~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day
~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day
~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)
~Cycles 8-13 will include:
~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously
~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously"
16712905|NCT01864109|Experimental|Patients with metastatic disease|"Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.
~Cycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:
~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously
~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously
~Cycles 6, 9, and 12 will include:
~Ifosfamide 2,800 mg/m2/day on days 1-5
~Etoposide 100 mg/m2/day on days 1-5
~Cycle 15 will include:
~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day
~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day
~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)"
16712906|NCT01864096|Experimental|Metformin|
16712907|NCT01864096|Placebo Comparator|Placebo|
16712908|NCT01864083|Experimental|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
16712909|NCT01864083|Experimental|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
16712910|NCT01864070|Experimental|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.
~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.
~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
16712911|NCT01864057|Active Comparator|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
16712912|NCT01864057|No Intervention|American mothers|Baseline blood and breast milk sample collection
16712913|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16712914|NCT01864005|Experimental|Ticagrelor|
16712915|NCT01864005|Active Comparator|clopidogrel|
16712916|NCT01863979||Acute Atrial Fibrillation|
16712917|NCT01863966|Experimental|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
16712918|NCT01863966|Active Comparator|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
16712919|NCT01863953|Experimental|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
16712920|NCT01863953|Active Comparator|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
16712921|NCT01863953|Active Comparator|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
16712992|NCT01863459|Placebo Comparator|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.
~Placebo is taken once per day for 8 weeks"
16750089|NCT01611792|Experimental|Stabilization|
16712922|NCT01863940|Experimental|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
16712923|NCT01863940|No Intervention|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
16712924|NCT01863927|Experimental|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
16712925|NCT01863914|Placebo Comparator|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
16712926|NCT01863914|Active Comparator|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
16712927|NCT01863901|Experimental|Treatment with the Cryo-Touch III Device|
16712928|NCT01863888|Experimental|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
16712929|NCT01863888|No Intervention|Reference population|Untreated healthy subjects
16712930|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
16712931|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
16712932|NCT01863862|Experimental|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
16712933|NCT01863849|Experimental|Age group 1: adults (18-59 years)|"Intervention: Vaccination with Fluval AB suspension for injection.
~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
16712934|NCT01863849|Experimental|Age group 2: elderly (> 60 years)|"Intervention: Vaccination with Fluval AB suspension for injection.
~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
16712935|NCT01863836|Experimental|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
16712936|NCT01863836|Active Comparator|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
16712937|NCT01863823|Other|Amoxicillin and Tetracyclines|drug treatment
16712938|NCT01863823|Other|Mouth washing|Mouth washing
16712939|NCT01863810|Experimental|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
16712940|NCT01863810|Active Comparator|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
16712941|NCT01863797|Active Comparator|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.
~When the participants reached the active phase they were monitored according to the clinical guidelines."
16712942|NCT01863797|Experimental|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
16712943|NCT01863784|Experimental|JNJ-38518168|
16712944|NCT01863771|Experimental|Golimumab|
16712945|NCT01863771|Placebo Comparator|Placebo|
16712946|NCT01863758|Experimental|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
16712947|NCT01863745|Experimental|nilotinib|16 patients who are currently enrolled in a Novartis- sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study receiving nilotinib and has fulfilled all their requirements in the parent study will be enrolled.
16712948|NCT01863732|Experimental|Secukinumab (AIN457) 75mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
16712949|NCT01863732|Experimental|Secukinumab (AIN457) 75 to 150mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
16712950|NCT01863732|Experimental|Secukinumab (AIN457) 150mg Grp2|Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
16712951|NCT01863732|Experimental|Pbo in Core then AIN457 75mg Grp1|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed.Secukinumab in PFS for s.c. self-administration Q4W
16712952|NCT01863732|Experimental|Pbo in Core then AIN457 75 to 150mg Grp1|Participants were on Placebo in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
16712953|NCT01863732|Experimental|Pbo in Core then AIN457 150mg Grp2|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
16712954|NCT01863719|Experimental|Cohort 1|9 Subjects
16712955|NCT01863719|Experimental|Cohort 2|9 Subjects
16712956|NCT01863719|Experimental|Cohort 3|9 Subjects
16712957|NCT01863719|Experimental|Cohort 4|12 Subjects
16712958|NCT01863706|Experimental|Misoprostol|400µg oral misoprostol
16712959|NCT01863706|Active Comparator|Oxytocin|20 IU oxytocin
16712960|NCT01863693||Cohort|
16712961|NCT01863680|Experimental|COL-1620|
16712962|NCT01863667|Experimental|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
16712963|NCT01863667|Active Comparator|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
16712964|NCT01863654|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
16712965|NCT01863654|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
16712966|NCT01863641|Experimental|treatment group|Patients will receive calcitriol at a fixed dose daily.
16712967|NCT01863641|Active Comparator|control group|Patients will receive placebo daily.
16712968|NCT01863628|Placebo Comparator|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
16712969|NCT01863628|Experimental|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
16712970|NCT01863615|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
16712971|NCT01863615|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
16712972|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
16712973|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
16712974|NCT01863576|Active Comparator|Omega-3|This group is receiving omega-3 supplement.
16712975|NCT01863576|Placebo Comparator|Oil Corn|This group is receiving the placebo comparator.
16712976|NCT01863563|Experimental|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
16712977|NCT01863550|Experimental|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
16712978|NCT01863550|Experimental|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
16712979|NCT01863550|Experimental|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
16712980|NCT01863550|Experimental|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
16712981|NCT01863537|Experimental|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
16712982|NCT01863537|Active Comparator|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
16712983|NCT01863511|Active Comparator|usual care|IV loop diuretics
16712984|NCT01863511|Active Comparator|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
16712985|NCT01863511|Active Comparator|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
16712986|NCT01863498|Active Comparator|PCA pain control|Patients will have PCA for pain control
16712987|NCT01863498|Active Comparator|Epidural pain control|Patients will have an epidural for pain control
16712988|NCT01863485|Experimental|CM082|CM082 tablet
16712989|NCT01863472|Active Comparator|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
16712990|NCT01863472|Active Comparator|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
16712991|NCT01863459|Experimental|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.
~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
16712993|NCT01863446|Experimental|Lighting1|Ocular light exposure of a red wavelength light for one or two nights
16712994|NCT01863446|Experimental|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
16712995|NCT01863446|Experimental|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
16712996|NCT01863446|Experimental|Lighting4|Ocular light exposure to a red wavelength light on day1 and to a blue-green wavelength light on day 2
16712997|NCT01863433|Experimental|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
16712998|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5<95%, V10<88%,V20<80%,V30<65%, V40<45%.
16712999|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5<90%, V10<80%,V20<70%,V30<55%, V40<35%.
16713000|NCT01863407|Experimental|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
16713001|NCT01863407|Placebo Comparator|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
16713002|NCT01863394|Active Comparator|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.
~CHWs will screen children 06-59 months in their village once a month"
16713003|NCT01863394|Experimental|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village
~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns
~Mothers will be asked to check their child's MUAC and look for pedal oedema
~whenever the child does not seem to be in 'good health' to the mother
~whenever the mother feels that the child is 'unwell' or 'sick'
~whenever it seems to the mother that her child has lost weight
~whenever the mother thinks that it is necessary to do so"
16713004|NCT01863381|Experimental|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
16713005|NCT01863368|Experimental|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
16713006|NCT01863368|Active Comparator|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
16713007|NCT01863355|Experimental|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
16713008|NCT01863355|Active Comparator|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
16713009|NCT01863355|Active Comparator|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
16713010|NCT01863342||CSI score < 40|CSI cutoff value<40
16713011|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
16713012|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
16713013|NCT01863316|Experimental|1) I gel group|using supraglottic airway I gel
16713014|NCT01863316|Active Comparator|2) LMA Supreme group|using supraglottic airway LMA Supreme
16713015|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
16713016|NCT01863277|Active Comparator|Melatonin|Melatonin 14mg/daily given over 14 days
16713017|NCT01863277|Placebo Comparator|sugar pill|sugar pill given over 14 days
16713018|NCT01863264|Experimental|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.
~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
16713019|NCT01863251|Experimental|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
16713020|NCT01863251|Placebo Comparator|Placebo|Placebo inactive medication
16713021|NCT01863238||Ivacaftor Treated|
16713022|NCT01863225|Experimental|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
16713023|NCT01863225|Experimental|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
16713024|NCT01863225|Experimental|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
16713025|NCT01863225|Experimental|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
16713026|NCT01863212|Experimental|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
16750090|NCT01611792|Active Comparator|Strengthening and Conditioning|
16713027|NCT01863212|Experimental|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
16713028|NCT01863199|Active Comparator|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
16713029|NCT01863199|Active Comparator|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
16713030|NCT01863199|Experimental|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
16713031|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
16713032|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
16713033|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
16713034|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
16713035|NCT01863173|Active Comparator|metoprolol|patient or intervention group
16713036|NCT01863173|Active Comparator|placebo group|control group
16713037|NCT01863160|Other|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
16713038|NCT01863160|Other|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
16713039|NCT01863147|Experimental|Sitagliptin|Sitagliptin 0.1 daily for 1 year
16713040|NCT01863147|Active Comparator|acarbose|acarbose 150mg daily for 1 year
16713041|NCT01863134|Experimental|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
16713042|NCT01863134|Placebo Comparator|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
16713043|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
16713044|NCT01863108|Experimental|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
16713045|NCT01863095|Experimental|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
16713046|NCT01863095|Active Comparator|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
16713047|NCT01863082|Experimental|exercise|the patients will be submitted to an exercise protocol
16713048|NCT01863056|Experimental|Sit-Stand Desk|Cross-over trial: so one group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self in period 2) and the other group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self in period 1).
16713049|NCT01863056|No Intervention|Control|Used normal work desk which only allows working sitting down
16713050|NCT01863043|Active Comparator|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
16713051|NCT01863043|Experimental|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
16713052|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
16713053|NCT01863017|Sham Comparator|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
16713054|NCT01863017|Experimental|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
16713055|NCT01863004|Experimental|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.
~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
16713056|NCT01862991|Placebo Comparator|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
16713057|NCT01862991|Active Comparator|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
16713107|NCT01862614|Experimental|Buffered Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc buffered 4% articaine.
16713058|NCT01862991|Experimental|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
16713059|NCT01862978|Experimental|Heparin|Patient receiving Heparin
16713060|NCT01862978|Experimental|Nadroparin|Patient receiving nadroparin
16713061|NCT01862978|Placebo Comparator|Placebo|Patients receiving placebo
16713062|NCT01862965|Experimental|PredEver|Prednisone and Everolimus
16713063|NCT01862952|Active Comparator|antiepileptic treatment as used in daily clinical practice|Antiepileptic treatment as used in daily clinical practice.
16713064|NCT01862952|No Intervention|No medication|
16713065|NCT01862939|Experimental|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
16713066|NCT01862939|Experimental|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
16713067|NCT01862939|Placebo Comparator|part 2 placebo|placebo to match part 2 DS-7309
16713068|NCT01862926|Experimental|Rituximab|1g given at baseline and two weeks.
16713069|NCT01862926|Active Comparator|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
16713070|NCT01862913|Experimental|Computer-assisted CBT|"Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.
~Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
16713071|NCT01862913|Active Comparator|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
16713072|NCT01862900|Experimental|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
16713073|NCT01862900|Experimental|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
16713074|NCT01862900|Experimental|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
16713075|NCT01862887|Experimental|PH-797804|Subjects will receive a single 24 mg dose in the fed state
16713076|NCT01862887|Experimental|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
16713077|NCT01862887|Experimental|Placebo|Subjects will receive a single placebo dose
16713078|NCT01862874|Experimental|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
16713079|NCT01862874|Placebo Comparator|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
16713080|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
16713081|NCT01862835|Experimental|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
16713082|NCT01862835|Experimental|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
16713083|NCT01862835|Experimental|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
16713084|NCT01862835|Experimental|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
16713085|NCT01862822|Experimental|upright position|Upright position during urine bag collection
16713086|NCT01862822|No Intervention|usual position|
16713087|NCT01862809||cases|smokers
16713088|NCT01862809||controls|non-smokers
16713089|NCT01862796|Experimental|Obese underfeeding (UF)|Obese randomized to received a 35% calorie reduced diet
16713090|NCT01862796|Experimental|Obese weight maintaining (WMEN)|Randomized to receive a weight-maintaining diet
16713091|NCT01862796|Experimental|Lean weight maintaining (WMEN)|Normal weight individuals receiving a weight-maintaining energy needs diet
16713092|NCT01862731||1/Control Volunteers|Healthy controls
16713093|NCT01862731||2/Volunteers with Pain|Subjects with Chronic Idiopathic Patellofemoral Pain
16713094|NCT01862718|Experimental|1|Ablation plus radiation
16713095|NCT01862705|Experimental|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
16713096|NCT01862705|Sham Comparator|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
16713097|NCT01862692|Active Comparator|Developmental Awareness Skils|
16713098|NCT01862692|Experimental|Baby-Net condition|
16713099|NCT01862679|Experimental|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
16713100|NCT01862679|Experimental|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
16713101|NCT01862653|Experimental|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
16713102|NCT01862653|No Intervention|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
16713103|NCT01862640|Placebo Comparator|Placebo|Matching placebo once daily
16713104|NCT01862640|Experimental|Brexpiprazole 1 mg|Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
16713105|NCT01862640|Experimental|Brexpiprazole 2 mg|Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
16713106|NCT01862627||Macular retinoschisis and detachment|
16713108|NCT01862614|Active Comparator|Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc 4% articaine (unbuffered).
16713109|NCT01862601|Experimental|JetTouch injections|
16713110|NCT01862562|Active Comparator|Open surgery|Conventional procedure
16713111|NCT01862562|Experimental|Laparoscopic surgery|Minimum invasive procedure
16713112|NCT01862549|Experimental|DBT for children|Dialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
16713113|NCT01862549|Active Comparator|Treatment as Usual|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
16713114|NCT01862536|Placebo Comparator|Placebo|Placebo tablet
16713115|NCT01862536|Experimental|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
16713116|NCT01862523|Placebo Comparator|diluent|diluent
16713117|NCT01862523|Experimental|capsaicin|capsaicin
16713118|NCT01862523|No Intervention|control healthy volunteers|control healthy volunteers
16713119|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.
~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
16713120|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.
~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
16713121|NCT01862484|Experimental|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
16713122|NCT01862484|Sham Comparator|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
16713123|NCT01862471|Experimental|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.
~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
16713124|NCT01862458|Active Comparator|tPA alone|tPA alone used to treat empyema
16713125|NCT01862458|Experimental|tPA plus dornase|tPA plus dornase used to treat empyema
16713126|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
16713127|NCT01862432|Experimental|immediate skin-to-skin|
16713128|NCT01862432|No Intervention|control|
16713129|NCT01862419|Experimental|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
16713130|NCT01862419|No Intervention|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
16713131|NCT01862406|Experimental|Generic Label|Purportedly generic version of the analgesic presented
16713132|NCT01862406|Active Comparator|Brand-name Label|actual brand-name analgesic presented
16713133|NCT01862393|Experimental|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
16713134|NCT01862393|Experimental|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
16713135|NCT01862393|Experimental|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
16713136|NCT01862380|Experimental|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
16713137|NCT01862380|Experimental|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
16713138|NCT01862367||rFXIII|
16713139|NCT01862354|Active Comparator|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
16713140|NCT01862354|Active Comparator|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
16713141|NCT01862341|Experimental|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
16713142|NCT01862328|Experimental|MLN4924 and Docetaxel (Arm 1)|
16713143|NCT01862328|Experimental|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
16713144|NCT01862328|Experimental|MLN4924 + Gemcitabine (Arm 3)|
16713179|NCT01862081|Experimental|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
16713180|NCT01862081|Experimental|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
16713181|NCT01862081|Experimental|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
16713145|NCT01862315|Experimental|No prior chemo or responded/stable with prior chemo|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day30} pump flow rate) on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
16713146|NCT01862315|Experimental|patients who have failed systemic therapy|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day 30}/ pump flow rate) on day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
16713147|NCT01862315|Experimental|pts who have had prior oxaliplatin & have existing neuropathy|All patients receive will receive gemcitabine alone with HAI FUDR/Dex Gemcitabine (800 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
16713148|NCT01862302|Active Comparator|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
16713149|NCT01862302|Placebo Comparator|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
16713150|NCT01862289|Experimental|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
16713151|NCT01862263|Experimental|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
16713152|NCT01862263|Placebo Comparator|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
16713153|NCT01862250|Experimental|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
16713154|NCT01862237|Experimental|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
16713155|NCT01862237|Experimental|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
16713156|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
16713157|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
16713158|NCT01862211|Experimental|members of family of children with a DA1AT|
16713159|NCT01862211|Experimental|children with a DA1AT|
16713160|NCT01862198|Experimental|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
16713161|NCT01862185|Experimental|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
16713162|NCT01862185|No Intervention|control|patients whom do not checked semi-quantitative procalcitonin examination
16713163|NCT01862172|Other|additional MRI|
16713164|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
16713165|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
16713166|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
16713167|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
16713168|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
16713169|NCT01862120|Experimental|interleukin-2|Dose D1 of interleukin-2
16713170|NCT01862120|Experimental|Dose D2 of interleukin-2|Dose D2 of interleukin-2
16713171|NCT01862120|Experimental|Dose D3 of interleukin-2|Dose D3 of interleukin-2
16713172|NCT01862120|Placebo Comparator|placebo|placebo
16713173|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
16713174|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
16713175|NCT01862081|Experimental|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
16713176|NCT01862081|Experimental|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
16713177|NCT01862081|Experimental|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
16713178|NCT01862081|Experimental|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
16713182|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
16713183|NCT01862068||MPA patients|
16713187|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
16713188|NCT01862042|Other|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
16713189|NCT01862029|Experimental|Roflumilast|
16713190|NCT01862016|Active Comparator|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
16713191|NCT01862016|Experimental|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
16713192|NCT01862003|Experimental|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
16713193|NCT01861990|Experimental|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
16713194|NCT01861977|Experimental|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
16713195|NCT01861977|Active Comparator|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
16713196|NCT01861964|Placebo Comparator|Sugar Pill|
16713197|NCT01861964|Active Comparator|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
16713198|NCT01861964|Active Comparator|Xylooligosarcharide 1.4g|
16713199|NCT01861951|Experimental|Pazopanib|"Pazopanib 800 mg, p.o., daily
~Duration of treatment:
~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
16713200|NCT01861951|Active Comparator|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.
~Duration of treatment:
~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
16713201|NCT01861938|Experimental|Melanoma vaccine|
16713202|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
16713203|NCT01861925||Large regular astigmatism|Astigmatism of > 1.5 diopters, regular astigmatism.
16713204|NCT01861925||Large irregular astigmatism|Astigmatism of > 1.5 diopters, irregular astigmatism.
16713205|NCT01861912|Active Comparator|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
16713206|NCT01861912|Experimental|Arsenic trioxide TACE+IV|"Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
~Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
16713207|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
16713208|NCT01861886|Experimental|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
16713209|NCT01861873|Other|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
16713210|NCT01861860|Experimental|New OPERA Criteria|TAXUS™ Element long stent
16713211|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
16713212|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
16713213|NCT01861821|Active Comparator|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
16713214|NCT01861821|Active Comparator|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
16713215|NCT01861808|Other|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
16713216|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
16713217|NCT01861782|Experimental|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
16713218|NCT01861782|Experimental|Sulfur Pool & Medicinal Mud|Sulfur Pool & Medicinal Mud
16713219|NCT01861769|Experimental|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
16713289|NCT01861366|Active Comparator|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
16713220|NCT01861769|Experimental|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
16713221|NCT01861769|No Intervention|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
16713222|NCT01861756|Experimental|Diabetes Medication Choice Decision Aid|
16713223|NCT01861756|No Intervention|Standard care|
16713224|NCT01861743|Experimental|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
16713225|NCT01861743|Active Comparator|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
16713226|NCT01861730|Experimental|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
16713227|NCT01861730|Experimental|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
16713228|NCT01861730|Experimental|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
16713229|NCT01861730|Experimental|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
16713230|NCT01861730|Experimental|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
16713231|NCT01861730|Experimental|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
16713232|NCT01861730|Experimental|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
16713233|NCT01861717|Experimental|Somatuline Depot Subcutaneous (SC)|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
16713234|NCT01861704|Active Comparator|Lyric|Silver Lyric device
16713235|NCT01861704|Active Comparator|Lyric2|Lyric2 (Barracuda) device
16713236|NCT01861691|Active Comparator|Open surgery|Open colectomy
16713237|NCT01861691|Experimental|Laparoscopic surgery|Laparoscopic colectomy
16713238|NCT01861678|Active Comparator|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
16713239|NCT01861678|Experimental|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
16713240|NCT01861665|Active Comparator|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
16713241|NCT01861665|Active Comparator|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
16713242|NCT01861652|Experimental|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
16713243|NCT01861639|Experimental|ineffective rTMS - Active TBS - fMRI|
16713244|NCT01861639|Experimental|Effective rTMS - Active TBS - fMRI|
16713245|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - fMRI|
16713246|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - fMRI|
16713247|NCT01861639|Experimental|ineffective rTMS - Active TBS - EEG|
16713248|NCT01861639|Experimental|Effective rTMS - Active TBS - EEG|
16713249|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - EEG|
16713250|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - EEG|
16713251|NCT01861626|Other|sequence 1 : Test drug - Reference|
16713252|NCT01861626|Other|Sequence 2 : Reference - Test drug|
16713253|NCT01861613|Experimental|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
16713254|NCT01861600|Experimental|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
16713255|NCT01861600|Active Comparator|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
16713256|NCT01861600|Experimental|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
16713257|NCT01861600|Other|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
16713258|NCT01861600|Experimental|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
16713259|NCT01861587|Experimental|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
16713260|NCT01861587|Experimental|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
16713261|NCT01861574|Experimental|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
16713262|NCT01861574|Sham Comparator|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
16713263|NCT01861574|Sham Comparator|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
16713264|NCT01861574|Sham Comparator|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
16713265|NCT01861561|Experimental|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
16750091|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
16713266|NCT01861561|Active Comparator|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
16713267|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
16713268|NCT01861535|Experimental|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
16713269|NCT01861535|Active Comparator|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
16713270|NCT01861522|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
16713271|NCT01861522|Placebo Comparator|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
16713272|NCT01861509|Experimental|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
16713273|NCT01861496|Experimental|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
16713274|NCT01861470||Preterm infants|all <32 weeks
16713275|NCT01861457|Experimental|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
16713276|NCT01861457|Placebo Comparator|Phosphate-buffered saline|Placebo
16713277|NCT01861444||Cohort|
16713278|NCT01861431|Active Comparator|HIVSRR|4 sessions of HIV sexual risk reduction
16713279|NCT01861431|Experimental|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
16713280|NCT01861418|Placebo Comparator|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
16713281|NCT01861418|Experimental|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
16713282|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
16713283|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
16713284|NCT01861392|Active Comparator|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
16713285|NCT01861392|Active Comparator|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
16713286|NCT01861379|Experimental|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
16713287|NCT01861379|Placebo Comparator|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
16713288|NCT01861366|Experimental|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
16713390|NCT01860729|Experimental|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
16713391|NCT01860729|Placebo Comparator|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
16713290|NCT01861353|Experimental|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.
~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
16713291|NCT01861353|Placebo Comparator|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.
~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
16713292|NCT01861340|Experimental|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
16713293|NCT01861327|Experimental|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
16713294|NCT01861327|Active Comparator|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
16713295|NCT01861327|Experimental|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
16713296|NCT01861327|Active Comparator|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
16713297|NCT01861327|Experimental|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
16713298|NCT01861327|Active Comparator|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
16713299|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.
~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.
~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.
~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
16713300|NCT01861301|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
16713301|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).
~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD
~Inclusion of pediatric patients, <15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
16713302|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it's compliance in sleep apnea patients with ischaemic stroke.
16713303|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
16713304|NCT01861262|Experimental|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
16713305|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
16713306|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
16713307|NCT01861223|Experimental|afatinib + nimotuzumab|
16713308|NCT01861210|Experimental|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
16713309|NCT01861210|Active Comparator|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
16713310|NCT01861197|Experimental|Dovitinib monotherapy|
16713311|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
16713312|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
16713313|NCT01861171|Placebo Comparator|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
16713314|NCT01861171|Active Comparator|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
16713315|NCT01861158|Experimental|Parenting Wisely|Immediate access to the online Parenting Wisely program
16713316|NCT01861158|Active Comparator|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
16713317|NCT01861158|No Intervention|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
16713318|NCT01861145|Active Comparator|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
16713392|NCT01860716|Placebo Comparator|Solution for infusion|Solution for infusion administrated via nasogastric tube
16713319|NCT01861145|Experimental|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.
~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
16713320|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
16713321|NCT01861119|Experimental|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
16713322|NCT01861119|Active Comparator|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
16713323|NCT01861119|No Intervention|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
16713330|NCT01861080||incident hypertensives|"Inclusion Criteria:
~age≧30years
~primary incident hypertension
~signed informed consent"
16713331|NCT01861067|Experimental|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
16713332|NCT01861067|Active Comparator|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
16713333|NCT01861054|Experimental|Treated patients - Total|Patients eligible will be treated with Reparixin as add-in monotherapy
16713334|NCT01861041|Experimental|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
16713335|NCT01861041|Active Comparator|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
16713336|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
16713337|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
16713338|NCT01861015|Experimental|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine ([1/2] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
16713339|NCT01861015|Active Comparator|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
16713340|NCT01861002|Experimental|AML Arm|"Participants with Acute Myeloid Leukemia (AML)
~Intervention:
~Azacytidine (Dose Level 1 @ 75 mg/m2/day)
~Fludarabine 30 mg/m2/dose
~Cytarabine 2000 mg/m2/dose
~Intrathecal (IT) Cytarabine"
16713341|NCT01861002|Experimental|ALL Arm|"Patients with Acute Lymphocytic Leukemia
~Intervention:
~Azacytidine (Dose Level 1 @ 75 mg/m2/day)
~Fludarabine 30 mg/m2/dose
~Cytarabine 2000 mg/m2/dose
~Intrathecal Methotrexate (IT MTX)"
16713342|NCT01860989|Experimental|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
16713343|NCT01860989|Experimental|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
16713344|NCT01860989|Experimental|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
16713345|NCT01860989|Experimental|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
16713346|NCT01860976|Experimental|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
16713347|NCT01860976|Placebo Comparator|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
16713348|NCT01860963|Active Comparator|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
16713349|NCT01860963|Active Comparator|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
16713350|NCT01860963|Active Comparator|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
16713351|NCT01860950|Active Comparator|anodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder (Brand Phoresor-II Auto) . BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
16713352|NCT01860950|Active Comparator|anodal tDCS plus pain-education|"Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder.
~Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing."
16713353|NCT01860950|Experimental|cathodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC. BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
16713354|NCT01860950|Experimental|cathodal tDCS plus pain-education|Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode attached to the right shoulder and the cathode electrode was placed over the left DLPFC. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
16713355|NCT01860950|Sham Comparator|sham tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session.
16713356|NCT01860950|Sham Comparator|sham tDCS plus pain-education|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
16713357|NCT01860937|Experimental|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
16713358|NCT01860937|Experimental|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion & did not experience any non-hematologic grade 4 toxicities.
16713359|NCT01860924|Active Comparator|health education|health education control
16713360|NCT01860924|Experimental|exercise|vigorous supervised exercise
16713361|NCT01860911|Experimental|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
16713362|NCT01860911|Experimental|Insulin-Resistant|One group consists of insulin resistant volunteers.
16713363|NCT01860898|Other|Skin Biopsy|
16713364|NCT01860885||Patients requiring naloxone for respiratory depression|
16713365|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
16713366|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
16713367|NCT01860872||Combined Group|MRI Quality & Image Relatedness
16713368|NCT01860859|Other|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
16713369|NCT01860859|Other|Locked single layer closure|As reported in Williams Obstetrics textbook
16713370|NCT01860859|Other|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
16713371|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
16713372|NCT01860833|Active Comparator|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
16713373|NCT01860833|Active Comparator|diclofenac 150 mg/day|diclofenac 75 mg bid
16713374|NCT01860833|Active Comparator|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
16713375|NCT01860833|Active Comparator|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
16713376|NCT01860833|Active Comparator|celecoxib 200 mg/day|celecoxib 200 mg once day
16713377|NCT01860833|Active Comparator|celecoxib 400 mg/day|celecoxib 200 mg bid
16713380|NCT01860807|Experimental|Ibudilast|Ibudilast 50 mg twice daily
16713381|NCT01860807|Placebo Comparator|Placebo|matching placebo twice daily
16713382|NCT01860794|Other|Mesencephalic Neuronal Precursor Cells|
16713383|NCT01860781|Experimental|paliperidone palmitate|paliperidone palmitate
16713384|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
16713385|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
16713386|NCT01860755|Experimental|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
16713387|NCT01860755|Active Comparator|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
16713388|NCT01860742|Active Comparator|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
16713389|NCT01860742|Active Comparator|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
16713393|NCT01860716|Experimental|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
16713394|NCT01860703|Experimental|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
16713395|NCT01860703|Experimental|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
16713396|NCT01860703|Experimental|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
16713397|NCT01860703|Experimental|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
16713398|NCT01860690|Experimental|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
16713399|NCT01860677|Active Comparator|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
16713400|NCT01860677|Placebo Comparator|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
16713401|NCT01860664|Experimental|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
16713402|NCT01860664|Placebo Comparator|Placebo|mineral oil and white petrolatum
16713403|NCT01860651|Active Comparator|Web-monitoring|"There is two arms for intervention:
~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
16713404|NCT01860651|No Intervention|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.
~Patients in treatment with biologicals: retrospective routine treatment algorithm"
16713405|NCT01860638|Experimental|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
16713406|NCT01860638|Placebo Comparator|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
16713407|NCT01860625|Experimental|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠
~placebo : 3 people, 12.5㎠"
16713408|NCT01860625|Experimental|2(25㎠)|"drug : 9 people, 87.5mg/25㎠
~placebo : 3 people, 25㎠"
16713409|NCT01860625|Experimental|3(50㎠)|"drug : 9 people, 175mg/50㎠
~placebo : 3 people, 50㎠"
16713410|NCT01860612|Experimental|PMA Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
16713411|NCT01860612|Experimental|Compassionate Use Cohort|Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
16713412|NCT01860612|Experimental|Continued Access Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the Continued Access cohort, after enrollment in the PMA cohort is complete.The fellow eye can be treated 1 month after the primary eye.
16713413|NCT01860599|Other|Prediabetes with exercise|150 minutes of moderate exercise per week
16713414|NCT01860599|Other|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
16713415|NCT01860586|Experimental|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
16713416|NCT01860573|Active Comparator|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
16713417|NCT01860573|Experimental|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
16713418|NCT01860560|Experimental|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
16713419|NCT01860560|Experimental|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
16713420|NCT01860547|Experimental|bilberry|
16713421|NCT01860547|Experimental|sea buckthorn berry|
16713422|NCT01860547|Experimental|sea buckthorn phenolic extract|
16713423|NCT01860547|Experimental|sea buckthorn oil|
16713460|NCT01860287|Experimental|buprenorphine (0.4 mg) group|Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
16713461|NCT01860274|Experimental|External Mesh|
16713508|NCT01859988|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
16713424|NCT01860534|Experimental|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
16713425|NCT01860534|No Intervention|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
16713426|NCT01860521|Active Comparator|Programmed Intermittent Epidural Bolus|
16713427|NCT01860521|Active Comparator|Continuous Epidural Infusion|
16713428|NCT01860508|Experimental|pemetrexed|
16713429|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
16713430|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
16713431|NCT01860482|Experimental|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
16713432|NCT01860469|Active Comparator|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
16713433|NCT01860469|Experimental|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
16713434|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
16713435|NCT01860443|Experimental|Telepsychiatry collaborative program|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.
~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).
~Supervision of primary care professionals through an internet site run by a team of specialists.
~Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
16713436|NCT01860443|Active Comparator|Usual care|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.
~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
16713437|NCT01860417|Experimental|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
16713438|NCT01860417|Active Comparator|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
16713439|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
16713440|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
16713441|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
16713442|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
16713443|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
16713444|NCT01860391|Experimental|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.
~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
16713445|NCT01860378|Active Comparator|No Video: Full price & $5 off|Participants will not view the pertussis video
16713446|NCT01860378|Experimental|Video: Full price & $5 off|Participants will watch a brief (~ 1 minute) video about Tdap vaccination
16713447|NCT01860365|Experimental|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
16713448|NCT01860365|Active Comparator|Conventional supportive care|Patients receiving conventional supportive care
16713449|NCT01860352|Other|Fish Oil|
16713450|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
16713451|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
16713452|NCT01860326|Experimental|Alisporivir|Single 200 mg oral dose
16713453|NCT01860313|Experimental|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
16713454|NCT01860313|Experimental|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
16713455|NCT01860313|No Intervention|Waiting List group|This group was used as control group and did not receive any intervention.
16713456|NCT01860300|Experimental|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
16713457|NCT01860300|Placebo Comparator|Placebo|Placebo
16713458|NCT01860287|Placebo Comparator|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
16713459|NCT01860287|Experimental|buprenorphine (0.2 mg) group|Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
16713462|NCT01860261|Experimental|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
16713463|NCT01860261|No Intervention|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
16713464|NCT01860248|Experimental|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
16713465|NCT01860248|Placebo Comparator|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
16713466|NCT01860235|Experimental|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
16713467|NCT01860235|Active Comparator|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
16713468|NCT01860235|Active Comparator|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
16713469|NCT01860235|Placebo Comparator|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
16713470|NCT01860222|Active Comparator|SR|
16713471|NCT01860222|Experimental|PLAT|
16713472|NCT01860209|Experimental|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
16713473|NCT01860209|Experimental|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
16713474|NCT01860196|Active Comparator|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
16713475|NCT01860196|Active Comparator|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
16713478|NCT01860170|Active Comparator|Cohort 1-Bortezomib (Velcade®)|Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
16713479|NCT01860170|Active Comparator|Cohort 2-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
16713480|NCT01860170|Active Comparator|Cohort 3-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
16713481|NCT01860157|Sham Comparator|Sham H1 Coil|deep rTMS sham treatment
16713482|NCT01860157|Active Comparator|Active H1|deep rTMS active treatment
16713483|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
16713484|NCT01860131|Active Comparator|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
16713485|NCT01860131|Active Comparator|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
16713486|NCT01860131|No Intervention|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.
~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.
~This is minimal intervention and considered the control arm."
16713487|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
16713488|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
16713489|NCT01860105|Active Comparator|75mg MDCO-157|iv
16713490|NCT01860105|Active Comparator|150mg MDCO-157|iv
16713491|NCT01860105|Active Comparator|300mg MDCO-157|iv
16713492|NCT01860105|Active Comparator|300mg PLAVIX|oral
16713493|NCT01860092||Argus II Retinal Prosthesis|Patients implanted with the Argus II Retinal Prosthesis
16713494|NCT01860079|Active Comparator|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
16713495|NCT01860079|No Intervention|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
16713496|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
16713497|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
16713498|NCT01860053|Experimental|behavioral intervention|
16713499|NCT01860053|No Intervention|no treatment control|
16713500|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
16713501|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
16713502|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
16713503|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
16713504|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
16713505|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
16713506|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
16713507|NCT01859988|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
16713754|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
16713755|NCT01858350|No Intervention|No intervention|
16713509|NCT01859988|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
16713510|NCT01859988|Experimental|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
16713511|NCT01859988|Experimental|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
16713512|NCT01859988|Experimental|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
16713513|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
16713514|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
16713515|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
16713516|NCT01859949|Experimental|Genotropin (somatropin)|
16713517|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
16713518|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
16713519|NCT01859923|Experimental|Group 1: 12 to 17 Years of Age|Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
16713520|NCT01859923|Experimental|Group 2: 6 to 11 Years of Age|Participants 6 to 11 years old (inclusive) received adult formulation delamanid 50 mg (1x50 mg tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
16713521|NCT01859923|Experimental|Group 3: 3 to 5 Years of Age|Participants 3 to 5 years old (inclusive) received 25 mg pediatric formulation of delamanid (DPF - suspension prepared using dispersible tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
16713522|NCT01859923|Experimental|Group 4: Birth to 2 Years of Age|"Participants from birth to 2 years old (inclusive) received DPF (suspension prepared using dispersible tablet) for 182 days plus OBR. Participants continued to receive OBR up to Day 365. The DPF dose was based on the participant's body weight during the baseline visit:
~Participants >10 kilograms (kg) received DPF 10 mg BID plus OBR
~Participants >8 kg and ≤10 kg received DPF 5 mg BID plus OBR
~Participants ≥5.5 kg and ≤8 kg received DPF 5 mg once per day (QD) plus OBR
~Delamanid dose was adjusted as needed for Group 4 participants based on the weight measurement at specified study visits [Visits 5 (Day 28), 7 (Day 56), 9 (Day 84), 11 (Day 126) and 12 (Day 154)]."
16713523|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
16713524|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
16713525|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
16713526|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
16713527|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
16713528|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
16713529|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
16713530|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
16713531|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
16713532|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
16713533|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
16713560|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
16713534|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
16713535|NCT01859819|Experimental|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH <2 X ULN.
~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
16713536|NCT01859819|Experimental|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (> 25% Bone marrow blasts) without CNS involvement.
~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
16713537|NCT01859819|Experimental|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:
~Any L3 blasts in CSF
~Cranial nerve palsy (if not explained by extracranial tumor)
~Clinical spinal cord compression
~Isolated intracerebral mass
~Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
16713538|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
16713539|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
16713540|NCT01859793|Placebo Comparator|Matching Placebo|Matching Placebo for Sitagliptin
16713541|NCT01859793|Active Comparator|Sitagliptin|100mg pill, PO administered once daily.
16713542|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.
~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
16713543|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
16713544|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
16713545|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
16713546|NCT01859741|Experimental|OMP-59R5 Combination with Etoposide and Cisplatin|
16713547|NCT01859741|Experimental|Etoposide and Cisplatin plus Placebo|
16713548|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
16713549|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
16713550|NCT01859715|Active Comparator|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
16713551|NCT01859715|Active Comparator|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
16713552|NCT01859715|Active Comparator|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
16713553|NCT01859702|Experimental|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
16713554|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
16713555|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
16713556|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
16713557|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
16713558|NCT01859650||NSCLC patients undergoing RT|
16713559|NCT01859637|Experimental|Zarzio®/Filgrastim HEXAL®|Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
16713561|NCT01859611|Experimental|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
16713562|NCT01859585|Experimental|Parecoxib|Parecoxib
16713563|NCT01859585|Experimental|Ketorolac|Ketorolac
16713565|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
16713566|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
16713567|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
16713568|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
16713569|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
16713570|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
16713571|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
16713572|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
16713573|NCT01859507|Experimental|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
16713574|NCT01859494|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
16713575|NCT01859481|Placebo Comparator|Placebo|
16713576|NCT01859481|Experimental|Eletriptan HBr 40 mg|
16713577|NCT01859481|Experimental|Eletriptan HBr 80 mg|
16713578|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
16713579|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
16713580|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
16713581|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
16713582|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
16713583|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
16713584|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
16713585|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
16713586|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
16713587|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
16713588|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
16713589|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
16713590|NCT01859416|No Intervention|Control|Usual nutritional care
16713591|NCT01859403|Placebo Comparator|Usual Care|Usual care for veterans as part of the MOVE! program
16713592|NCT01859403|Active Comparator|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
16713593|NCT01859390|Experimental|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
16713594|NCT01859390|Active Comparator|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
16713595|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
16713596|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
16713597|NCT01859351|Experimental|WX-037|PI3K inhibitor
16713598|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
16713599|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
16713600|NCT01859325|Experimental|Vaccine|HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 g (1500 g of the HIV-1 gag/pol plasmid and 1500 g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500 g each) will be mixed and combined with 1000 g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000 g (500 g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.
16713601|NCT01859325|Placebo Comparator|Placebo|Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.
16713602|NCT01859312|Experimental|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
16713603|NCT01859299||Affected|Participants with various types of uveitis
16713604|NCT01859299||Healthy controls|Participants without uveitis
16713605|NCT01859286||regular sign out process|
16713606|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
16713607|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
16713608|NCT01859260|No Intervention|Control|
16713609|NCT01859260|Experimental|Intervention|CPAP/autopap
16713610|NCT01859247|Active Comparator|Dorsal Premotor rTMS|0.2 Hz rTMS for 15 minutes
16713611|NCT01859247|Active Comparator|Primary motor cortex rTMS|0.2 Hz rTMS for 15 minutes
16713612|NCT01859247|Active Comparator|Supplemental Motor Area rTMS|0.2 Hz rTMS for 15 minutes
16713613|NCT01859247|Active Comparator|Anterior Cingulate rTMS|0.2 Hz rTMS for 15 minutes
16713614|NCT01859247|Sham Comparator|Sham rTMS|0.2 Hz rTMS for 15 minutes
16713615|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
16713616|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
16713617|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
16713618|NCT01859195||Focus Group Stage|~20-24 participants, to comprise 3-6 focus groups
16713619|NCT01859195||Cognitive Interview Stage|~12-16 participants in individual cognitive interviews
16713620|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16713621|NCT01859169||Control Group|Group that be administrated biliary drainage only
16713622|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
16713623|NCT01859156||Carbon Monoxide Exposure|
16713624|NCT01859143|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
16713625|NCT01859143|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
16713627|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
16713628|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
16713629|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
16713630|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
16713631|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
16713632|NCT01859091|Experimental|Fat Reduction|
16713633|NCT01859078|Experimental|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.
~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
16713634|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
16713635|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
16713636|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
16713637|NCT01859052|Other|low-fat diet|Obese Migraineurs
16713638|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
16713639|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
16713640|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.
~Phase I will be followed by an expansion Phase Ib."
16713641|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.
~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
16713756|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
16713642|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.
~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
16713643|NCT01859013|Experimental|Topiramate|Four (4) weeks of meal replacement therapy, followed by 28-weeks of topiramate therapy. Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks.
16713644|NCT01859013|Placebo Comparator|Sugar Pill|Four (4) weeks of meal replacement therapy, followed by 28-weeks of placebo (sugar pill) therapy.
16713645|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
16713646|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
16713647|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
16713648|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
16713649|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
16713650|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
16713651|NCT01858948|Experimental|Quitiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) for 24 weeks
16713652|NCT01858948|Placebo Comparator|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
16713653|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
16713654|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
16713655|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
16713656|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
16713657|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
16713658|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
16713659|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
16713660|NCT01858935|Placebo Comparator|Placebo|
16713661|NCT01858922|Experimental|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
16713662|NCT01858922|Experimental|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.
~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
16713663|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
16713664|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
16713665|NCT01858896|Active Comparator|Glucagon-Like Peptide -1 (GLP-1) infusion|Infusion of GLP-1 during experimental period
16713666|NCT01858896|Placebo Comparator|Saline Infusion|Saline infusion during experimental period
16713667|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
16713668|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
16713669|NCT01858857||Geriatric psychiatric in patients|
16713670|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
16713671|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
16713672|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
16713673|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
16713674|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
16713675|NCT01858818||healthy 18 year old males|
16713676|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
16713677|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
16713678|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
16713757|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
16713912|NCT01857232|Experimental|Mid dose APD403|OND + APD403 followed by oral APD403 mid dose
16713679|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.
~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
16713680|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
16713681|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
16713682|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
16713683|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
16713684|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
16713685|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
16713686|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
16713687|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
16713688|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
16713689|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
16713690|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
16713691|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
16713692|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
16713693|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
16713694|NCT01858753|Experimental|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
16713695|NCT01858753|Placebo Comparator|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
16713696|NCT01858740|Experimental|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.
~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
16713697|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
16713698|NCT01858727|No Intervention|control group|do not active heating group
16713699|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy
~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:
~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
16713700|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
16713701|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
16713702|NCT01858701|Other|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
16713703|NCT01858701|Other|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
16713704|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
16713705|NCT01858675|Experimental|Biomarkers, total blood volume|
16713706|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
16713707|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
16713708|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
16713709|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
16713710|NCT01858636||Angio-Seal VIP Vascular Closure|
16713711|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
16713712|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
16713713|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
16713714|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
16713715|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
16713716|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
16750222|NCT01610778|Placebo Comparator|Placebo|
16713719|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.
~dosage:
~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional
~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
16713720|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
16713721|NCT01858584|No Intervention|control group|
16713722|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.
~Cycle A
~Daily oral Thalidomide (at 3mg/kg)
~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
~Daily oral Etoposide (50 mg/m2/d)
~Cycle B
~Daily oral Thalidomide (at 3mg/kg)
~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
16713723|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)
~Capsules of same size and color as used in metronomic therapy Best supportive care
~Management of pain as per WHO standard for pain management"
16713724|NCT01858558|Experimental|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
16713725|NCT01858558|Active Comparator|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
16713726|NCT01858545|Experimental|Experimental|MatriStem MicroMatrix and MatriStem Wound Matrix
16713727|NCT01858545|Active Comparator|Comparator|Cellular Dermal Replacement Tissue
16713728|NCT01858532|Active Comparator|Atrasentan|0.75 mg atrasentan once daily by mouth for up to 52 months
16713729|NCT01858532|Placebo Comparator|Placebo|Placebo once daily by mouth for up to 52 months
16713730|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
16713731|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
16713732|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
16713733|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
16713734|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
16713735|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
16713736|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
16713737|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
16713738|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
16713739|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
16713740|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
16713741|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
16713742|NCT01858441|Other|Abiraterone Acetate|
16713743|NCT01858428|Active Comparator|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
16713744|NCT01858428|Experimental|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
16713745|NCT01858415|Experimental|Single arm|
16713746|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
16713747|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
16713748|NCT01858389|Experimental|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
16713749|NCT01858389|Experimental|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
16713750|NCT01858376|Other|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
16713751|NCT01858363|Experimental|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
16713752|NCT01858363|Placebo Comparator|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
16713753|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
16713910|NCT01857232|Placebo Comparator|Placebo|OND + APD403 followed by oral PLACEBO
16713758|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
16713759|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
16713760|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
16713761|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
16713762|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
16713763|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
16713764|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
16713765|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
16713766|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
16713767|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
16713768|NCT01858285||Epilepsy, genetics|
16713769|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
16713770|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
16713771|NCT01858259||azathioprine|Patients receiving azathioprine
16713772|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
16713773|NCT01858259||methotrexate|Patients receiving methotrexate
16713774|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
16713775|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
16713776|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
16713777|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
16713778|NCT01858233|No Intervention|Routine care|standard dietary counseling
16713779|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
16713780|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.
~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
16713781|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
16713782|NCT01858194|Experimental|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
16713783|NCT01858194|Placebo Comparator|VT ablation alone|No further therapy in addition to VT ablation
16713784|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
16713785|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
16713786|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
16713790|NCT01858155|Experimental|Melatonin|
16713791|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
16713792|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
16713793|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
16713794|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
16713795|NCT01858116|Experimental|[68Ga]ABY-025|
16713796|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
16750223|NCT01610778|Experimental|Supplement|
16713797|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
16713798|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
16713799|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
16713800|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
16713801|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
16713802|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
16713803|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
16713804|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
16713805|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
16713806|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
16713807|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
16713808|NCT01858012||HCV infection|patients with hepatitis C infection
16713809|NCT01858012||non-HCV infection|healthy controls
16713810|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
16713811|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
16713812|NCT01857986|Experimental|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
16713813|NCT01857986|Active Comparator|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
16713814|NCT01857973|Experimental|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
16713815|NCT01857960||Adolescents|Acne survey among Mexican adolescents
16713816|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
16713817|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.
~Cells for infusion are prepared using the CliniMACS System."
16713818|NCT01857921|Active Comparator|Pravastatin group|
16713819|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
16713820|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
16713821|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
16713822|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
16713823|NCT01857882|Experimental|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
16713824|NCT01857882|No Intervention|Standard Care|Routine pre-consultation education
16713825|NCT01857869|Experimental|GSK257049-0,1,7M Group|Subjects receiving 2 doses of GSK257049 vaccine given at 0 and 1 months and followed 6 months later (At Month 7) by another dose of GSK257049 vaccine.
16713826|NCT01857869|Experimental|GSK257049-0,1,2M Group|Subjects receiving 3 doses of GSK257049 vaccine given one month apart (0,1 and 2 months).
16713827|NCT01857869|Experimental|Infectivity Control Group|Volunteers who did not receive any immunization but underwent sporozoite challenge
16713830|NCT01857843|Experimental|ZES group|
16713831|NCT01857843|Active Comparator|EES group|
16713832|NCT01857843|Experimental|Vytorin group|
16713833|NCT01857843|Active Comparator|Mevalotin group|
16713834|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
16713835|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
16713836|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
16713837|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
16713838|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
16713839|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
16713840|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
16713841|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
16713842|NCT01857791|Experimental|multidisciplinary, behavior modification|
16713843|NCT01857778||Lactating Women|
16713844|NCT01857765|Active Comparator|Standard of Care|
16713845|NCT01857765|Experimental|Rehabilitation|
16713846|NCT01857752|Experimental|temozolomide|
16713847|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
16713848|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
16713849|NCT01857713|Active Comparator|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
16713850|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
16713851|NCT01857700|Placebo Comparator|Standard of Care|
16713852|NCT01857687||patients with coronary artery stenosis|
16713853|NCT01857661|Other|control|hearing aid without an integrated sound generator
16713854|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
16713855|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
16713856|NCT01857648|No Intervention|Control|Control group.
16713857|NCT01857622|Experimental|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
16713858|NCT01857622|Experimental|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
16713859|NCT01857622|Experimental|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
16713860|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
16713861|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
16713862|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
16713863|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
16713864|NCT01857583|Experimental|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
16713865|NCT01857583|Experimental|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
16713866|NCT01857583|Active Comparator|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
16713867|NCT01857583|Experimental|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
16713868|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
16713869|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
16713870|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
16713871|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
16713872|NCT01857531|Experimental|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:
~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.
~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.
~Post-Quit Period:
~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.
~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
16713873|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
16713874|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
16713875|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
16713876|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
16713877|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
16713878|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
16713879|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
16713880|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].
~The first dose will be administered under direct supervision."
16713881|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
16713882|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
16713883|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
16713884|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
16713885|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
16713886|NCT01857401||Observational study|Blood draw only, observational study
16713887|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
16713888|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
16713889|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
16713890|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
16713891|NCT01857362|Active Comparator|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
16713892|NCT01857362|Experimental|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
16713893|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
16713894|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
16713895|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
16713896|NCT01857323|Experimental|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
16713897|NCT01857310|Experimental|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
16713898|NCT01857310|Placebo Comparator|Placebo|Matching placebo, taken orally daily for 6 months.
16713899|NCT01857297|Experimental|Adults (aged 18 to 59 years)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
16713900|NCT01857297|Experimental|Older Adults (aged 60 years or older)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
16713901|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
16713902|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
16713903|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
16713904|NCT01857258|Experimental|Green Tea|Participants will be provided a confection containing green tea concentrate
16713905|NCT01857258|Active Comparator|Control|Participants will be provided a confection devoid of green tea concentrate
16713906|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
16713907|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
16713908|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
16713909|NCT01857232|Other|Control|OND + DEX + FOS followed by oral DEX
16713913|NCT01857232|Experimental|High dose APD403|OND + APD403 followed by oral APD403 high dose
16713914|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.
~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
16713915|NCT01857206|Experimental|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
16713916|NCT01857206|Active Comparator|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
16713917|NCT01857193|Experimental|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
16713918|NCT01857193|Experimental|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
16713919|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
16713920|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
16713921|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
16713922|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
16713923|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
16713924|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
16713925|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
16713926|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
16713927|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
16713928|NCT01857141|Experimental|dexmedetomidine|
16713929|NCT01857141|Placebo Comparator|normal saline|
16713930|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
16713931|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
16713932|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:
~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.
~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.
~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).
~Treatment schedule for maintenance until progression or intolerance:
~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
16713933|NCT01857102|Active Comparator|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
16713934|NCT01857102|Experimental|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
16713935|NCT01857089|Experimental|Pressure Measurement|
16713936|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
16713937|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
16713938|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
16713939|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
16713940|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
16713941|NCT01857037|Other|Single arm|Single arm
16713942|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
16713943|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
16714021|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
16713944|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion
~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER
~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)
~Duration: Until end of surgery"
16713945|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion
~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER
~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)
~Duration: Until end of surgery"
16713946|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.
~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
16713947|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
16713948|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
16713949|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
16713950|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
16713951|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
16713952|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
16713953|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
16713954|NCT01856933|Experimental|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
16713955|NCT01856920|Experimental|A|GI-6207 for 1 year
16713956|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
16713957|NCT01856907|Experimental|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
16713958|NCT01856907|Placebo Comparator|Placebo pill|1 pill/BID for 16 weeks
16713959|NCT01856907|Active Comparator|Metformin|1000 mg BID
16713960|NCT01856881|Active Comparator|AMG 876|
16713961|NCT01856881|Placebo Comparator|Placebo|
16713962|NCT01856868|Experimental|Treatment with Epicatechin|Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
16713963|NCT01856855|Experimental|Stereotactic Body Radiation Therapy with Integrated Boost|
16713964|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
16713965|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
16713966|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
16713967|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
16713968|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
16713969|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
16713970|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
16713971|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
16713972|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
16713973|NCT01856790|Experimental|Closed Loop Insulin Delivery|"Each participant recruited into the study will undergo two inpatient closed loop admissions.
~The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.
~Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
~Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy."
16713974|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
16713975|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
16713976|NCT01856764|Experimental|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
16713977|NCT01856764|Placebo Comparator|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
16713978|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
16713979|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
16713980|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
16714184|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
16713981|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing
~Hemodynamic measurements for CRT device programming"
16713982|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing
~CRT device programming without hemodynamics"
16713983|NCT01856712|Active Comparator|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
16713984|NCT01856712|Experimental|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
16713985|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
16713986|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
16713987|NCT01856686|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
16713988|NCT01856686|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
16713989|NCT01856673|Experimental|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
16713990|NCT01856673|Experimental|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
16713991|NCT01856673|Other|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
16713992|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
16713993|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
16713994|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
16713995|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
16713996|NCT01856647||psoriatic lean|9 psoriatic lean
16713997|NCT01856647||psoriatic obese|9 psoriatic obese
16713998|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
16713999|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
16714000|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
16714001|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:
~Patient's > 10 kg will receive DPF 10 mg BID + OBR
~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR
~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
16714002|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
16714003|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
16714004|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
16714005|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
16714006|NCT01856595|Experimental|PF-06291874|
16714007|NCT01856595|Placebo Comparator|Placebo|
16714008|NCT01856582|Experimental|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
16714009|NCT01856569||observational|
16714010|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
16714011|NCT01856556|Placebo Comparator|Placebo|Saline
16714012|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
16714013|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
16714014|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
16714015|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
16714016|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
16714017|NCT01856543|Placebo Comparator|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
16714018|NCT01856543|Experimental|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
16714019|NCT01856530|Experimental|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
16714020|NCT01856530|Placebo Comparator|Placebo|Matched placebo nasal spray
16714022|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
16714023|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;
~Suspected but without known prior history of CAD
~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)
~Glomerular filtration rate >60 ml/min
~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
16714024|NCT01856491|Other|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
16714027|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
16714028|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
16714029|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
16714030|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
16714031|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
16714032|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
16714033|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
16714034|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
16714035|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
16714036|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
16714037|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
16714038|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
16714039|NCT01856374|Active Comparator|Cypher group|
16714040|NCT01856374|Experimental|Xience group|
16714041|NCT01856374|Active Comparator|Pravastatin group|
16714042|NCT01856374|Experimental|Atorvastatin group|
16714043|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
16714044|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
16714045|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
16714046|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
16714047|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
16714048|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
16714049|NCT01856309|Experimental|Sirukumab 100 mg|
16714050|NCT01856309|Experimental|Sirukumab 50 mg / placebo|
16714051|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
16714052|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
16714053|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
16714054|NCT01856270|Experimental|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
16714055|NCT01856270|Experimental|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
16714056|NCT01856257|Active Comparator|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
16714057|NCT01856257|Experimental|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
16714058|NCT01856257|Experimental|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.
~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
16714059|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
16714060|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
16714061|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
16714089|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
16714090|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
16714062|NCT01856218|Experimental|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.
~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
16714063|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
16714064|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
16714065|NCT01856192|Experimental|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16714066|NCT01856192|Active Comparator|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
16714067|NCT01856179|Experimental|Echium oil young|"BMI<25,
~age 20-30"
16714068|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
16714069|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
16714070|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
16714071|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
16714072|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
16714073|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
16714074|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
16714075|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
16714076|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
16714077|NCT01856127|Experimental|Vilazodone|Vilazodone
16714078|NCT01856127|Active Comparator|Sertraline|Sertraline
16714079|NCT01856114|Experimental|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
16714080|NCT01856114|Placebo Comparator|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
16714081|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.
~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
16714082|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
16714083|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
16714084|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
16714085|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:
~Class 1a/1c antiarrhythmics
~Sotalol
~Amiodarone"
16714086|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
16714087|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
16714088|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
16714216|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
16714091|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
16714092|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
16714093|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
16714094|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
16714095|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
16714096|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
16714097|NCT01855971|Active Comparator|Fragile X syndrome experimental group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).
~Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).
~Treatment period: 3 months (from month 1 to month 4)
~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
16714098|NCT01855971|Placebo Comparator|Fragile X syndrome control group|"Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).
~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
16714099|NCT01855958|Experimental|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
16714100|NCT01855958|Sham Comparator|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
16714101|NCT01855945|Experimental|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
16714102|NCT01855945|Experimental|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
16714103|NCT01855945|Experimental|Group C|15 µg H3N2c unadjuvanted
16714104|NCT01855932|Experimental|Technology Supported|
16714105|NCT01855919|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
16714106|NCT01855919|Placebo Comparator|Placebo|Placebo administered orally once every day for 15 weeks.
16714107|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
16714108|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
16714109|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
16714110|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
16714111|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
16714112|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
16714113|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
16714114|NCT01855867|Other|Stribild|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
16714115|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
16714116|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
16714117|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
16714118|NCT01855828|Experimental|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
16714119|NCT01855789|Experimental|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score </=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
16714217|NCT01855113||braces|those with braces for orthodontic correction.
16714120|NCT01855789|Experimental|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
16714121|NCT01855789|Active Comparator|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
16714122|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
16714123|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
16714124|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:
~$0 SGD for less than 50,000 steps during the week
~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)
~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
16714125|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
16714126|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
16714127|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
16714128|NCT01855750|Placebo Comparator|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
16714129|NCT01855750|Experimental|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
16714130|NCT01855737||Warfarin Using Group|
16714131|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.
~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.
~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
16714132|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
16714133|NCT01855698||All patients registered|
16714134|NCT01855685|Experimental|Open label|X vivo gene therapy
16714135|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
16714136|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
16714137|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
16714138|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
16714139|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
16714140|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
16714141|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
16714142|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
16714143|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
16714144|NCT01855607|Experimental|topical menthol|topical menthol cream to hands and feet
16714145|NCT01855607|Placebo Comparator|placebo cream|topical cream without menthol
16714146|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
16714147|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
16714148|NCT01855581||sedation group|Children requiring sedation for MRI/CT
16714149|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
16714183|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
16714218|NCT01855100||Rivaroxaban|
16714150|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
16714151|NCT01855555||sedation group|Children requiring sedation for MRI/CT
16714152|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
16714153|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
16714154|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
16714155|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
16714156|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
16714157|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
16714158|NCT01855503||Metastatic Breast Cancer|
16714159|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
16714160|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
16714161|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
16714162|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
16714163|NCT01855451|Active Comparator|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
16714164|NCT01855451|Active Comparator|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
16714165|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
16714166|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
16714167|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
16714168|NCT01855425|Other|Investigational CBCT|Radiation
16714169|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
16714170|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
16714171|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
16714172|NCT01855399|Experimental|Peer Coaching + Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
16714173|NCT01855399|Active Comparator|Peer Coaching Alone|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
16714174|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
16714175|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
16714176|NCT01855373|Other|Placebo|No active ingredient
16714177|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
16714178|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
16714179|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
16714180|NCT01855360|Experimental|TUDCA and Doxycycline|INTERVENTION: Patients meeting study criteria were prescribed TUDCA taken orally, 250 mg three times daily. and doxycycline taken orally, 100 mg twice daily.
16714181|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
16714182|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
16714286|NCT01854645|Experimental|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
16714185|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
16714186|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
16714187|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
16714188|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
16714189|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
16714190|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
16714191|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
16714192|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
16714193|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
16714194|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
16714195|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
16714196|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
16714197|NCT01855243|Active Comparator|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG > 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
16714198|NCT01855243|Active Comparator|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG > 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
16714199|NCT01855243|Active Comparator|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG > 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
16714200|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
16714201|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
16714202|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
16714203|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
16714204|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
16714205|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
16714206|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
16714207|NCT01855191||Standard|
16714208|NCT01855191||Standard + saliva collection|
16714209|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
16714210|NCT01855165|No Intervention|General advice|
16714211|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
16714212|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
16714213|NCT01855139||Rivaroxaban|
16714214|NCT01855126|Experimental|Blue light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two blue Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the blue light mask was worn nightly for 8 weeks. There will be a two week washout period between each intervention
16714215|NCT01855126|Placebo Comparator|Red light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two red Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the red light mask was worn nightly for 8 weeks, with a two week washout period between each intervention
16714219|NCT01855074|Experimental|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
16714220|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.
~Side studies include:
~pharmacogenetics
~pharmacokinetics of SN-38
~carboxylesterase activity in the index lesion
~midazolam clearance test (only in Rotterdam patients)"
16714221|NCT01855048|Experimental|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
16714222|NCT01855048|Placebo Comparator|INT200-Placebo|Placebo
16714223|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
16714224|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
16714225|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
16714226|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
16714227|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
16714228|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
16714229|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
16714230|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
16714231|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
16714232|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
16714233|NCT01854970|Experimental|Patient|
16714234|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
16714235|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
16714236|NCT01854944|Experimental|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:
~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
16714237|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
16714238|NCT01854918|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product [all-IP] period.
16714239|NCT01854918|Experimental|Evolocumab + Standard of Care|Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
16714240|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
16714241|NCT01854892|Experimental|Manipulation|Spinal manipulation
16714242|NCT01854892|Experimental|Mobilization|Spinal mobilization
16714243|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
16714244|NCT01854879|Experimental|Nucleus 6|
16714245|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
16714246|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
16714247|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
16714248|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
16714249|NCT01854827|Experimental|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
16714250|NCT01854814|Experimental|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
16714251|NCT01854814|Active Comparator|losartan|maximus tolerated labeled dose of losartan
16714252|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
16714253|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
16714254|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
16714284|NCT01854645|Experimental|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
16714285|NCT01854645|Experimental|GP MDI|Glycopyrronium (GP) MDI (PT001)
16714255|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
16714256|NCT01854775|Experimental|Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg|HIV-infected, ARV treatment-naive adolescents (12 to < 18 years of age weighing ≥ 35 kg) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
16714257|NCT01854775|Experimental|Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg|Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
16714258|NCT01854775|Experimental|Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg|Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
16714259|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
16714260|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
16714261|NCT01854749|Experimental|S1 combined with cisplatin|
16714262|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
16714263|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
16714264|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
16714265|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
16714266|NCT01854710|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
16714267|NCT01854710|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
16714268|NCT01854710|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
16714269|NCT01854710|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
16714270|NCT01854710|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
16714271|NCT01854710|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
16714272|NCT01854697|Experimental|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals [DAAs] with RBV in GT1a)
16714273|NCT01854697|Active Comparator|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
16714274|NCT01854697|Experimental|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
16714275|NCT01854697|Experimental|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
16714276|NCT01854697|Active Comparator|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
16714277|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
16714278|NCT01854671|No Intervention|standard care|
16714279|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
16714280|NCT01854658|Experimental|FF MDI (PT005)|FF MDI administered as two puffs BID
16714281|NCT01854658|Experimental|GP MDI (PT001)|GP MDI administered as two puffs BID
16714282|NCT01854658|Experimental|GFF MDI (PT003)|GFF MDI administered as two puffs BID
16714283|NCT01854658|Placebo Comparator|Placebo MDI|Inhaled placebo administered as two puffs BID
16714287|NCT01854645|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
16714288|NCT01854645|Placebo Comparator|Placebo|Placebo MDI
16714289|NCT01854632|Experimental|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
16714290|NCT01854632|Placebo Comparator|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
16714291|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
16714292|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
16714293|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
16714294|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
16714295|NCT01854593|Active Comparator|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
16714296|NCT01854593|Sham Comparator|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
16714297|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
16714298|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
16714299|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
16714300|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
16714303|NCT01854541||Radiotherapy|All patients receiving radiotherapy
16714304|NCT01854528|Experimental|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 [150 mg/ 100 mg/ 25 mg once daily] and ABT-333 [250 mg twice daily]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
16714305|NCT01854528|Active Comparator|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously [SC] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
16714306|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
16714307|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
16714308|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
16714309|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.
~The child was given multi-faceted counseling for good oral health habits."
16714310|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
16714311|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
16714312|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
16714313|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
16714314|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
16714315|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
16714316|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
16714317|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
16714318|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
16714319|NCT01854450|Other|control|usual obstetrical care
16714320|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
16714321|NCT01854437||placebo|placebo 1 tab TDS
16714322|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
16714323|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
16714324|NCT01854398|Experimental|CPAP group|
16714325|NCT01854398|Sham Comparator|sham-CPAP group|
16714326|NCT01854385|Experimental|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
16714364|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
16750301|NCT01610323|Other|Control group|Standard care
16714327|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).
~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
16714328|NCT01854359|Other|Active treatment|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
16714329|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
16714330|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
16714331|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
16714332|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
16714333|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
16714334|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
16714335|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
16714336|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
16714337|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
16714338|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
16714339|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
16714340|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
16714341|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
16714342|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
16714343|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
16714344|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
16714345|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
16714346|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
16714347|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
16714348|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
16714349|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
16714350|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.
~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
16714351|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
16714352|NCT01854177|Active Comparator|Aprepitant|Aprepitant 125 mg
16714353|NCT01854177|Placebo Comparator|Placebo|Inert capsule
16714354|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
16714355|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
16714356|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
16714357|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
16714358|NCT01854138|No Intervention|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
16714359|NCT01854138|Experimental|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
16714360|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
16714361|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
16714362|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
16714363|NCT01854112||T-cell lymphoma|
16714365|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
16714366|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
16714367|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
16714368|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
16714369|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
16714370|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
16714371|NCT01854047|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16714372|NCT01854047|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16714373|NCT01854047|Experimental|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16714374|NCT01854047|Experimental|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16714375|NCT01854047|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
16714376|NCT01854034|Experimental|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
16714377|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
16714378|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
16714379|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
16714380|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
16714381|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
16714382|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
16714383|NCT01853995|No Intervention|Untreated Class II Control Group|control group
16714384|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
16714385|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
16714386|NCT01853969||Patients who have carpal tunnel release surgery|
16714387|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
16714388|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
16714389|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
16714390|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
16714391|NCT01853930|Other|Laboratory training|Patients will be trained in the laboratory with feedback by a rehabilitation therapist
16714392|NCT01853930|Other|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
16714393|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
16714394|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
16714395|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
16714396|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
16714397|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
16714398|NCT01853878|Experimental|GSK2302032A Group|The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
16714399|NCT01853878|Placebo Comparator|Placebo group|The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
16714400|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
16714401|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
16714402|NCT01853852|Experimental|50 mg|GR181413A/AT1001
16714403|NCT01853852|Experimental|150 mg|GR181413A/AT1001
16714404|NCT01853852|Experimental|450 mg|GR181413A/AT1001
16714405|NCT01853852|Placebo Comparator|Placebo|placebo
16714406|NCT01853826|Experimental|afatinib|Patients will receive afatinib once daily
16714407|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
16714408|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
16714409|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
16714410|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
16714411|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
16714412|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
16714413|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
16714414|NCT01853774|Experimental|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
16714415|NCT01853774|No Intervention|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
16714416|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
16714417|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
16714418|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
16714419|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
16714420|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
16714421|NCT01853748|Active Comparator|Study Drug|T-DM1 every three weeks by IV for 17 treatments (total of 51 weeks)
16714422|NCT01853748|Active Comparator|Standard of Care|Paclitaxel and Trastuzumab once per week by IV for 12 weeks. Beginning week 13, Trastuzumab only by IV injection every three weeks for 13 treatments
16714423|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
16714424|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
16714425|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
16714426|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
16714427|NCT01853722|Experimental|DCN01|
16714428|NCT01853722|Placebo Comparator|Unisol|
16714429|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:
~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
16714430|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:
~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
16714431|NCT01853696|Active Comparator|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
16714432|NCT01853696|Active Comparator|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
16714433|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
16714434|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
16714435|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:
~These patients will have chemotherapy during the time of radiation treatment"
16714436|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:
~These patients will have chemotherapy prior to other radiation treatment."
16714437|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
16714438|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
16714439|NCT01853644|Experimental|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
16714440|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell ALL|"3 daily doses of cyclophosphamide together with fludarabine with be administered finishing at least 24 hours before T cell infusion.
~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
16714441|NCT01853631|Experimental|CD19 CAR T Cells for Bcell ALL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
16714442|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell NHL/CLL|"3 daily doses of cyclophosphamide together with fludarabine will be administered finishing at least 24 hours before T cell infusion.
~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
16714443|NCT01853631|Experimental|CD19 CAR T Cells for Bcell NHL/CLL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
16714444|NCT01853618|Experimental|Pilot 1/Arm A1-Tremelimumab + RFA or TACE|Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
16714445|NCT01853618|Experimental|2/Arm A2 - Tremelimumab + RFA or TACE|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
16714446|NCT01853618|Experimental|3/Arm B - Tremelimumab + TACE|Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
16714447|NCT01853618|Experimental|4/Arm C (never opened)|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
16714448|NCT01853618|Experimental|5/Arm D - Tremelimumab + Cryoablation|Tremelimumab + Cryoablation
16714449|NCT01853618|Experimental|6/Arm E - Tremelimumab + RFA|Tremelimumab + Radiofrequency Ablation (RFA)
16714450|NCT01853605|Experimental|Augmentation|Women undergoing breast augmentation.
16714451|NCT01853605|Experimental|Reconstruction|Women undergoing breast reconstruction.
16714452|NCT01853605|Experimental|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
16714453|NCT01853605|Experimental|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
16714454|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
16714455|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
16714456|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
16714457|NCT01853553|Experimental|Spironolactone|Active arm
16714458|NCT01853553|Placebo Comparator|Sugar Pill|Placebo
16714459|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
16714460|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
16714461|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
16714462|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
16714463|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
16714464|NCT01853475|Experimental|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
16714465|NCT01853475|Experimental|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
16714466|NCT01853475|Active Comparator|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
16714467|NCT01853462|Experimental|Proprioceptive Neuromuscular Facilitation (PNF)|Supervised PNF training
16714468|NCT01853462|Experimental|Balance|Supervised balance training
16714469|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
16714470|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
16714471|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
16714472|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
16714473|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
16714474|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
16714475|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
16714476|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
16714477|NCT01853397|Experimental|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
16714478|NCT01853397|Experimental|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
16714516|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
16714479|NCT01853397|Experimental|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
16714480|NCT01853397|Active Comparator|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
16714481|NCT01853384|Experimental|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
16714482|NCT01853384|Placebo Comparator|HP802-247 Vehicle plus compression therapy|fibrinogen solution & thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
16714483|NCT01853371|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.
~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
16714484|NCT01853371|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
16714485|NCT01853358|Experimental|NK Cell infusion|"Cell collection
~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation
~NK Cell selection
~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)
~NK Cell ex-vivo activation
~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)
~NK Cell infusion (60 to 90 days after transplantation)"
16714486|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
16714487|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
16714488|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
16714489|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
16714490|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
16714491|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
16714492|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
16714493|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
16714494|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
16714495|NCT01853280|Experimental|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
16714496|NCT01853280|Placebo Comparator|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
16714497|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
16714498|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
16714499|NCT01853254|Experimental|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
16714500|NCT01853241||Single balloon|Single Balloon Enteroscopy
16714501|NCT01853241||Spirus|Spirus Enteroscopy
16714502|NCT01853228|Experimental|Decitabine and cytarabine|
16714503|NCT01853215|Experimental|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
16714504|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
16714505|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
16714506|NCT01853189|Other|OMT + Usual Care|
16714507|NCT01853189|Other|Usual Care|
16714508|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
16714509|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
16714510|NCT01853163|Other|Gadolinium contrast agent|Patients who have received Gadolinium contrast agents in the past
16714511|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
16714512|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
16714513|NCT01853137|Experimental|FLMGM Treatment Group|
16714514|NCT01853137|No Intervention|Untreated Class II Control Group|
16714515|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
16714517|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
16714518|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
16714519|NCT01853085||Patients with POAG or OHT|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
16714520|NCT01853072|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
16714521|NCT01853072|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
16714522|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
16714523|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
16714524|NCT01853046|Experimental|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
16714525|NCT01853046|Experimental|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
16714526|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
16714527|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
16714528|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
16714529|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
16714530|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
16714531|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
16714532|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
16714533|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
16714534|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
16714535|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
16714536|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
16714537|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
16714538|NCT01852981|No Intervention|Control|Control group.
16714539|NCT01852968||Patients with type 1 diabetes|"Hippocampal neurochemistry and metabolism will examined in Patients with type 1 diabetes using magnetic resonance spectroscopy.
~Patients with type 1 diabetes will also undergo neurocognitive testing to assess hippocampal function"
16714540|NCT01852968||healthy controls|"Hippocampal neurochemistry and metabolism will be examined in healthy controls using magnetic resonance spectroscopy.
~Healthy controls will also undergo neurocognitive testing to assess hippocampal function"
16714541|NCT01852955|Active Comparator|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
16714542|NCT01852955|Placebo Comparator|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
16714543|NCT01852942|Experimental|Losartan|
16714544|NCT01852942|Placebo Comparator|Sugar Pill|
16714545|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
16714546|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
16714547|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
16714548|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
16714549|NCT01852903|Experimental|calcium ascorbate|
16714550|NCT01852903|Active Comparator|ascorbic acid|
16714551|NCT01852903|Placebo Comparator|placebo|
16714552|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
16714553|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
16714554|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
16714555|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
16714556|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
16714557|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
16714558|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
16714559|NCT01852851|Active Comparator|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
16714560|NCT01852851|No Intervention|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
16714561|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
16714562|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
16714563|NCT01852825|Experimental|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
16714564|NCT01852825|Placebo Comparator|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
16714565|NCT01852825|Experimental|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
16714566|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
16714567|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
16714568|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
16714569|NCT01852799|Experimental|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.
~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
16714570|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
16714571|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
16714572|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
16714573|NCT01852760||UC in Remission|Patients with UC in remission
16714574|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
16714575|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
16714576|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
16714577|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
16714578|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
16714579|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
16714613|NCT01852513|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
16714614|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
16714615|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
16714580|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
16714581|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
16714582|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
16714583|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
16714584|NCT01852682|Experimental|PA21|
16714585|NCT01852669|Experimental|Inversion, Hydration, ESWL|ESWL with hydration and inversion
16714586|NCT01852669|Active Comparator|ESWL, Hydration|ESWL with hydration
16714587|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
16714588|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
16714589|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
16714590|NCT01852643|Active Comparator|Spreader graft|
16714591|NCT01852643|Active Comparator|Lateral crural overlay|
16714592|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
16714593|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
16714594|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
16714595|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
16714596|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714597|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714598|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714599|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714600|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714601|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714602|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
16714603|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
16714604|NCT01852591|Experimental|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
16714605|NCT01852578|Experimental|1|
16714606|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
16714607|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
16714608|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
16714609|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
16714610|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
16714611|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
16714612|NCT01852513|Active Comparator|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
16714616|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
16714617|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
16714618|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
16714619|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
16714620|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
16714621|NCT01852448||Patients with Cystic Fibrosis|Blood or Saliva Sample Collection and Glucose -potentiated arginine (GPA) stimulation tests will be completed for all enrolled patients.
16714622|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
16714623|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
16714624|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
16714625|NCT01852422||Pelvic prolapse|
16714626|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
16714627|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
16714628|NCT01852383|Experimental|Duloxetine|"A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.
~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.
~Administration was as a single a.m. dose."
16714629|NCT01852370|Experimental|BOLT+BMT|All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
16714630|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
16714631|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
16714632|NCT01852344|Other|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
16714633|NCT01852344|Other|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
16714634|NCT01852344|Other|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
16714635|NCT01852344|Other|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
16714636|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
16714637|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
16714638|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
16714639|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
16714640|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
16714641|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
16714642|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
16714643|NCT01852292|Experimental|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m^2 weekly.
16714644|NCT01852292|Placebo Comparator|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m^2 weekly.
16714645|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
16714646|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
16714647|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
16714648|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
16714677|NCT01852084|Experimental|enVista control lens|Spherical control lens
16714678|NCT01852071|Experimental|Gene Therapy|Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
16714714|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
16714649|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
16714650|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
16714651|NCT01852240||erectile dysfunction|"Inclusion criteria:
~male patients with ED defined by an IIEF-5 score of ≤ 21
~age between 18-45a
~Exclusion criteria:
~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)
~pure psychogenic (non-organic) ED with good spontaneous / nightly erections
~periodontal treatment within the last 3 months
~antibiotic intake within the last 3 months"
16714652|NCT01852214|Active Comparator|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
16714653|NCT01852214|Active Comparator|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
16714654|NCT01852201|No Intervention|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:
~General medical management according to AHA/ASA guidelines
~Admission to monitored or intensive care unit for at least 24 hours
~Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient
~Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician
~Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines
~Follow-up imaging study required in any patient with neurologic deterioration"
16714655|NCT01852201|Experimental|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
16714656|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
16714657|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
16714658|NCT01852175|Active Comparator|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
16714659|NCT01852175|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
16714660|NCT01852162|Experimental|Dabigatran|Dabigatran 150mg
16714661|NCT01852162|Placebo Comparator|Placebo|Placebo
16714662|NCT01852149|Experimental|MPAS Implant|MPAS Implant
16714663|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
16714664|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
16714665|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
16714666|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
16714667|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
16714668|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
16714669|NCT01852110|Placebo Comparator|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
16714670|NCT01852110|Experimental|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
16714671|NCT01852110|Experimental|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
16714672|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
16714673|NCT01852110|Placebo Comparator|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
16714674|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
16714675|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
16714676|NCT01852084|Experimental|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
16714679|NCT01852058|Experimental|OnabotulinumtoxinA 50 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
16714680|NCT01852058|Experimental|OnabotulinumtoxinA 100 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
16714681|NCT01852058|Experimental|OnabotulinumtoxinA 200 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
16714682|NCT01852045|Experimental|OnabotulinumtoxinA 50 U|OnabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 (NCT01852058) if qualified.
16714683|NCT01852045|Experimental|OnabotulinumtoxinA 100 U|OnabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
16714684|NCT01852045|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
16714685|NCT01852032|Experimental|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
16714686|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
16714687|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
16714688|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
16714689|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
16714690|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
16714691|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
16714692|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
16714693|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
16714694|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
16714695|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
16714696|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
16714697|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
16714698|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
16714699|NCT01851954|Experimental|clarithromycin|Population PK
16714700|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
16714701|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
16714702|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
16714703|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
16714704|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
16714705|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
16714706|NCT01851889||CF-LVAD pump speed.|
16714707|NCT01851876|Experimental|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
16714708|NCT01851876|No Intervention|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
16714709|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
16714710|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
16714711|NCT01851863|Active Comparator|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
16714712|NCT01851863|Active Comparator|proton pump inhibitor|Prescribe Omeprazole.
16714713|NCT01851850|Experimental|Drug|
16714715|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
16714716|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
16714717|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
16714718|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
16714719|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
16714720|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
16714721|NCT01851772|Experimental|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.
~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
16714722|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
16714723|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
16714724|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.
~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.
~Biomarker blood draws will be drawn at different time points.
~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
16714725|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).
~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.
~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
16714726|NCT01851720|Active Comparator|Control group / Standard of Care|"IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
~(Bolus dose can be titrated up in 25 mcg increments if necessary)
~Maximum dose of 100 mcg/hr"
16714727|NCT01851720|Active Comparator|Low dose IV fentanyl PCA|"Initially: 10 mcg demand dose every 12 minutes
~No initial bolus and no continuous infusion
~Demand dose increased 10 mcg every 12 minutes if necessary
~Maximum dose of 100 mcg/hr"
16714728|NCT01851707|Experimental|IPI-145, low dose BID|
16714729|NCT01851707|Experimental|IPI-145, medium dose BID|
16714730|NCT01851707|Experimental|IPI-145, high dose BID|
16714731|NCT01851707|Placebo Comparator|Placebo BID|
16714732|NCT01851694|Experimental|GLP-1|The incretin, Glucagon-Like-peptide-1 (GLP-1) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins. (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
16714733|NCT01851694|Experimental|GIP|The incretin, Glucose-dependent Insulinotropic Polypeptide (GIP) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
16714734|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
16714735|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
16714736|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
16714737|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
16714738|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
16714739|NCT01851655|Experimental|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
16714783|NCT01851382||Cohort 1|Healthy volunteers.
16714740|NCT01851655|Active Comparator|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
16714741|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
16714742|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
16714743|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
16714744|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
16714745|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
16714746|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
16714747|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
16714748|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
16714749|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
16714750|NCT01851603|Placebo Comparator|Sugar pill|Placebo
16714751|NCT01851590|Experimental|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
16714752|NCT01851590|Active Comparator|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
16714753|NCT01851590|Active Comparator|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
16714754|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
16714755|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
16714756|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
16714757|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
16714758|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
16714759|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
16714760|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
16714761|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
16714762|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
16714763|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
16714764|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
16714765|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
16714766|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
16714767|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
16714768|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
16714769|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
16714770|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
16714771|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
16714772|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
16714773|NCT01851447||Fragile Sarcolemmal Muscular Dystrophy|patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
16714774|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
16714775|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
16714776|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
16714777|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
16714778|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
16714779|NCT01851395||1/Thoracic malignancies|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma.
16714780|NCT01851395||2/Genitourinary malignancies|Patients with genitourinary malignancies
16714781|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
16714782|NCT01851395||4/Ovarian|Patients with ovarian cancer
16714785|NCT01851343|Experimental|1|All patients will receive the same treatment
16714786|NCT01851330|Experimental|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
16714787|NCT01851330|Experimental|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
16714788|NCT01851330|Experimental|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
16714789|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
16714790|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
16714791|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
16714792|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
16714793|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
16714794|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
16714795|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
16714796|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
16714797|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
16714798|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
16714799|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
16714800|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
16714801|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
16714802|NCT01851252|Experimental|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
16714803|NCT01851239||medical ICU inpatients|
16714804|NCT01851239||surgical ICU inpatients|
16714805|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
16714806|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
16714807|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
16714808|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
16714809|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
16714810|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
16714811|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
16714812|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days
~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
16714813|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
16714814|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
16714815|NCT01851148|Other|usual care|triptans treatment only
16714816|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
16714817|NCT01851135|Experimental|Patients with NF1|
16714818|NCT01851135|Other|Healthy controls|
16714819|NCT01851122|Placebo Comparator|Placebo|
16714820|NCT01851122|Experimental|l-theanine|
16714821|NCT01851109|No Intervention|Control|
16714822|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
16714823|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
16714824|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
16714825|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
16714826|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
16714827|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
16714828|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
16714829|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
16714830|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
16714831|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
16714832|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
16714833|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
16714834|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
16714835|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
16714836|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
16714837|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
16714838|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
16714839|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
16714840|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
16714841|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
16714842|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
16714843|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
16714844|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
16714845|NCT01850966||Iguratimod|
16714846|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
16714847|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
16714848|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
16714849|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
16714850|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
16714851|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
16714852|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
16714853|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
16714854|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
16714855|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
16714856|NCT01850888|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
16714857|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
16714858|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
16714859|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
16714860|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
16714861|NCT01850849|Experimental|LEO 39652 cream|Active drug
16714862|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
16714863|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
16714864|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
16714865|NCT01850823|Placebo Comparator|placebo|Placebo
16714866|NCT01850823|Active Comparator|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
16714867|NCT01850823|Experimental|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
16714868|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
16714869|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
16714870|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
16714871|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
16714872|NCT01850784|Active Comparator|Standard formula|Standard formula
16751438|NCT01602367|Experimental|Arm4: Placebo|
16714873|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
16714874|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
16714875|NCT01850758|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
16714876|NCT01850758|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
16714877|NCT01850745||Control|Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program
16714878|NCT01850745||Validation cohort|Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
16714879|NCT01850745||Pilot cohort|Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
16714880|NCT01850732|Other|ultrasound of aorta|
16714881|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
16714882|NCT01850719|Active Comparator|Physical Therapy|
16714883|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
16714884|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
16714885|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
16714886|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
16714887|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
16714888|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
16714889|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
16714890|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
16714891|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
16714892|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
16714893|NCT01850641|Experimental|PA21|
16714894|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
16714895|NCT01850615|Experimental|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
16714896|NCT01850615|Active Comparator|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
16714897|NCT01850602|Experimental|PA21|
16714898|NCT01850602|Active Comparator|Sevelamer hydrochloride|
16714899|NCT01850589|Other|Conservative Therapy|"Conservative therapy:
~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.
~Counseling consists of:
~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.
~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
16714900|NCT01850589|Other|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:
~One hour group counseling sessions, focusing on patient education and behavior modification.
~Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.
~Counseling including information on nutrition, exercise, and chemical dependency.
~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
16714901|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
16714902|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
16714903|NCT01850563|Other|HBO feasibility|
16714904|NCT01850550|No Intervention|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
16714905|NCT01850550|Experimental|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
16714906|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
16714907|NCT01850524|Active Comparator|IXAZOMIB|"IXAZOMIB 4.0 mg capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40 mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.
~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
16714908|NCT01850524|Placebo Comparator|Placebo|"IXAZOMIB matching-placebo capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.
~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib placebo-matching capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
16715064|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
16714909|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
16714910|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
16714911|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
16714912|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
16714913|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
16714914|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
16714915|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
16714916|NCT01850459||IQ-Matched Control Subjects|
16714917|NCT01850459||Age-Matched Neurotypical Controls|
16714918|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
16714919|NCT01850446|Experimental|Ergoferon|The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
16714920|NCT01850446|Active Comparator|Oseltamivir (Tamiflu)|"The treatment period is 5 days.
~1 capsule (75 mg) twice a day during the meal or regardless of meal."
16714921|NCT01850433|Experimental|Internet CBT|
16714922|NCT01850420|Experimental|IMC-1|Experimental intervention
16714923|NCT01850420|Placebo Comparator|Matching placebo|
16714924|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
16714925|NCT01850394|Placebo Comparator|Control group|physiologic saline 25 ml
16714926|NCT01850394|Active Comparator|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
16714927|NCT01850394|Active Comparator|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
16714928|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
16714929|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
16714930|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
16714931|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
16714932|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
16714933|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
16714934|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
16714935|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
16714936|NCT01850303|Other|Surveillance|
16714937|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
16714938|NCT01850290||Dopamine Imaging|
16714939|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.
~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
16714940|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.
~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
16714941|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
16714942|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
16714943|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
16714944|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
16714945|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.
~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
16715209|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
16714946|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.
~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
16714947|NCT01850225|Experimental|Device implantation|Implantation of device
16714948|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
16714949|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
16714950|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
16714951|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
16714952|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
16714953|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
16714954|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
16714955|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
16714956|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
16714957|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
16714958|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
16714959|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
16714960|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
16714961|NCT01850147|Experimental|Sunitinib|
16714962|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
16714963|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
16714964|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
16714965|NCT01850108|Experimental|Non-Myeloablative Conditioning and Bone Marrow Transplantation|
16714966|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
16714967|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
16714968|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
16714969|NCT01850082|Other|Endoscopic Vein Harvest (EVH)|An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
16714970|NCT01850082|Other|Open Vein Harvest (OVH)|"Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as bridging technique) along the course of the vein."
16714971|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
16714972|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
16714973|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
16714974|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
16714975|NCT01850030|Experimental|Dydrogesterone 30 mg|
16714976|NCT01850030|Experimental|Micronized Progesterone 600 mg|
16714977|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.
~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
16714978|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.
~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
16714979|NCT01850004|Experimental|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
16714980|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
16714981|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
16715210|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
16714982|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
16714983|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
16714984|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
16714985|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
16714986|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
16714987|NCT01849939|Experimental|Fludarabin|
16714988|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
16714989|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
16714990|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
16714991|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
16714992|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
16714993|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
16714994|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
16714995|NCT01849887|Placebo Comparator|Placebo|Placebo
16714996|NCT01849874|Experimental|MEK162|
16714997|NCT01849874|Active Comparator|Physician's choice chemotherapy|
16714998|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).
~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.
~Variables considered in this study:
~TSH and FT4
~Questionnaire of Quality of life for older adults (WHOQOL-OLD)
~Mini-Mental State Examination
~Geriatric Depression Scale
~Cardiopulmonary exercise testing - cardiopulmonary capacity"
16714999|NCT01849848|Experimental|SyB L-0501|
16715000|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
16715001|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
16715002|NCT01849822|Experimental|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
16715003|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
16715004|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
16715005|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
16715006|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.
~After collection, participants will receive dexamethasone x 4 days every 14 days.
~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.
~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.
~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)
~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
16715007|NCT01849770|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
16715008|NCT01849770|Active Comparator|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
16715009|NCT01849770|Placebo Comparator|Placebo|Placebo, by mouth per day for 12 weeks.
16715010|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
16715011|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
16715012|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
16715013|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
16715014|NCT01849731|Experimental|Intervention A|Face-to face intervention
16715015|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
16715016|NCT01849731|No Intervention|Control Group|
16715017|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.
~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.
~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
16715018|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.
~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.
~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.
~10 x ½ an hour of individual psychotherapy."
16715019|NCT01849705||All subjects|No intervention
16715020|NCT01849692|Experimental|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
16751645|NCT01601028|Placebo Comparator|Placebo|Placebo
16715021|NCT01849692|Experimental|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
16715022|NCT01849692|Experimental|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
16715023|NCT01849692|Experimental|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
16715024|NCT01849692|Active Comparator|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
16715025|NCT01849679||Post-Extubation Subjects|
16715026|NCT01849666|Active Comparator|A: phenprocoumon single dose|
16715027|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
16715028|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
16715029|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
16715030|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
16715031|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
16715032|NCT01849627|Experimental|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
16715033|NCT01849627|Experimental|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
16715034|NCT01849614||Patient group|Women with left-sided breast cancer
16715035|NCT01849601|Experimental|PTA catheter|
16715036|NCT01849588|Experimental|Treatment Arm|Sorafenib taken orally twice per day
16715037|NCT01849575|Active Comparator|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
16715038|NCT01849575|No Intervention|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
16715039|NCT01849562|Active Comparator|Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg|Sovaprevir 200 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
16715040|NCT01849562|Active Comparator|Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg|Sovaprevir 400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
16715041|NCT01849562|Placebo Comparator|Placebo|Placebo for Sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based RBV QD for 12 weeks
16715042|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
16715043|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
16715044|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
16715045|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
16715046|NCT01849523|No Intervention|Standard care|Standard care
16715047|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
16715048|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
16715049|NCT01849497|Experimental|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
16715050|NCT01849497|Experimental|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
16715051|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
16715052|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
16715053|NCT01849471||patients with prostate cancer|questionnaires
16715054|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
16715055|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
16715056|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
16715057|NCT01849432||Control|Healthy Controls
16715058|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
16715059|NCT01849432||Panic Disorder|Participants with Panic Disorder
16715060|NCT01849432||Specific Phobia|Participants who have specific phobias
16715061|NCT01849419|Experimental|Single group|Healthy volunteers received all drug conditions (MDMA, oxytocin, and placebo) using a within-subjects design.
16715062|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
16715063|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
16751874|NCT01599377|Experimental|Cohort 1|
16715065|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
16715066|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
16715067|NCT01849367|Experimental|Active tDCS (1)|
16715068|NCT01849367|Active Comparator|Active tDCS (2)|
16715069|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
16715070|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
16715071|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
16715072|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
16715073|NCT01849328||Breast Cancer|
16715074|NCT01849328||Healthy|
16715075|NCT01849315|Placebo Comparator|Control|Sedentary intervention
16715076|NCT01849315|Active Comparator|AKIDS II|Physically active group
16715077|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715078|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715079|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715080|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715081|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715082|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715083|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
16715084|NCT01849289|Experimental|Insulin Degludec|
16715085|NCT01849289|Experimental|Insulin Glargine|
16715086|NCT01849276|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
16715087|NCT01849263|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
16715088|NCT01849250|Experimental|Arm I (docosahexaenoic acid)|Patients receive docosahexaenoic acid PO BID for 12 weeks.
16715089|NCT01849250|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 weeks.
16715090|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
16715091|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
16715092|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
16715093|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
16715094|NCT01849211|Other|neuromuscular block|
16715095|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
16715096|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
16715097|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
16715098|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
16715099|NCT01849172|Experimental|electroacupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
16715100|NCT01849172|Sham Comparator|sham electroacupuncture|Sham electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).Specially constructed EA apparatus were used with no skin penetration, electricity output, or de qi requirement for needle manipulation One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
16715101|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
16715102|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
16715211|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
16751875|NCT01599377|Experimental|Cohort 2|
16715103|NCT01849146|Experimental|Arm I (adavosertib, temozolomide, radiation)|"INITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.
~MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
16715104|NCT01849146|Experimental|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
16715105|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
16715106|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
16715107|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
16715108|NCT01849107|Experimental|Plasma citrulline|
16715109|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).
~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
16715110|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
16715111|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
16715112|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
16715113|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
16715114|NCT01849068|Experimental|Ezetimibe|
16715115|NCT01849068|Placebo Comparator|Placebo|
16715116|NCT01849055|Placebo Comparator|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
16715117|NCT01849055|Experimental|LY3023703|Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
16715118|NCT01849055|Active Comparator|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
16715119|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
16715120|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
16715121|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
16715122|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
16715123|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
16715124|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
16715125|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
16715126|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
16715127|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
16715128|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
16715129|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:
~Day 1: 20 mg (loading dose)
~Day 2: 40 mg (loading dose)
~Days 3-7: 6 mg (maintenance dose) once daily
~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
16715130|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:
~Day 1: 50 mg (loading dose)
~Day 2-3: 10 mg once daily
~Days 4-7: 20 mg once daily"
16715131|NCT01848990|Experimental|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
16715132|NCT01848990|Experimental|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
16715133|NCT01848990|Active Comparator|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
16715134|NCT01848977|Experimental|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.
~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
16715167|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
16715212|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
16715135|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.
~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.
~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
16715136|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed.Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain UNMCs standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
16715137|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound.2.The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants ( subcostal position x2 and lateral position x2)
16715138|NCT01848938|Active Comparator|Smartphone treatment|Smartphone treatment with PFMT.
16715139|NCT01848938|No Intervention|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
16715140|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
16715141|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
16715142|NCT01848912||Bone Marrow Transplant Patients|
16715143|NCT01848899|Experimental|Ioxaglate Arm|
16715144|NCT01848899|Experimental|Iodixanol arm|
16715145|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
16715146|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
16715147|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
16715148|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
16715149|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
16715150|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
16715151|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
16715152|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
16715153|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
16715154|NCT01848847|Experimental|Full Bladder|Hysteroscopy conducted under full bladder.
16715155|NCT01848847|Experimental|Empty Bladder|Hysteroscopy conducted under empty bladder.
16715156|NCT01848834|Experimental|Cohort A: Triple Negative Breast Cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
16715157|NCT01848834|Experimental|Cohort B: Head & Neck Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
16715158|NCT01848834|Experimental|Cohort C: Urothelial Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
16715159|NCT01848834|Experimental|Cohort D: Gastric Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
16715160|NCT01848834|Experimental|Cohort B2: Head & Neck Cancer Expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
16715161|NCT01848821|Other|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
16715162|NCT01848821|Other|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
16715163|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
16715164|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
16715165|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
16715166|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
16715208|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
16715168|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
16715169|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
16715170|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
16715171|NCT01848756|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
16715172|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
16715173|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
16715174|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
16715175|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
16715176|NCT01848717|Experimental|Lift thread|
16715177|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
16715178|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
16715179|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
16715180|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
16715181|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
16715182|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
16715183|NCT01848652|Experimental|MYOCET|
16715184|NCT01848639|Active Comparator|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
16715185|NCT01848639|Placebo Comparator|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
16715186|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
16715187|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
16715188|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
16715189|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
16715190|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
16715191|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
16715192|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
16715193|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.
~Deliver the following information in the orde of the items below:
~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection
~Briefly additional tests:
~Radio show
~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
16715194|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
16715195|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
16715196|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
16715197|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
16715198|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
16715199|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
16715200|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
16715201|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
16715202|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
16715203|NCT01848483|Experimental|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
16715204|NCT01848483|Other|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
16715205|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
16715206|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
16715207|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
16753746|NCT01586845|Experimental|Voclosporin|Voclosporin
16715213|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, PTZ+C; Cycles 3 & 4: HDMTX 12 h, C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
16715214|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, C; Cycles 3 & 4: HDMTX 12 h, PTZ + C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
16715215|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, PTZ+C; Cycles 3 & 4: HDMTX 4 h, C|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
16715216|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, C; Cycles 3 & 4: HDMTX 4 h, C + PTZ|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
16715217|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
16715218|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
16715219|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
16715220|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
16715221|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:
~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises
~FD:
~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
16715222|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:
~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
16715223|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
16715224|NCT01848366|Experimental|Biowave Treatment|Twelve weekly treatments
16715225|NCT01848353|Active Comparator|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
16715226|NCT01848353|Active Comparator|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
16715227|NCT01848353|Active Comparator|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
16715228|NCT01848353|Experimental|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
16715229|NCT01848353|Experimental|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
16715230|NCT01848353|Experimental|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
16715231|NCT01848353|No Intervention|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
16715232|NCT01848353|No Intervention|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
16715233|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
16715234|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
16715235|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
16715236|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
16715237|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
16753747|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
16715238|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
16715239|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
16715240|NCT01848288|Experimental|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
16715241|NCT01848288|Active Comparator|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
16715242|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
16715243|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
16715244|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
16715245|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
16715246|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
16715247|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
16715248|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
16715249|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
16715250|NCT01848223||late menopause|
16715251|NCT01848210|Experimental|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
16715252|NCT01848210|Placebo Comparator|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
16715253|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
16715254|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
16715255|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning
16715256|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
16715257|NCT01848171|No Intervention|blank|No intervention
16715258|NCT01848158|Experimental|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
16715259|NCT01848158|Sham Comparator|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
16715260|NCT01848145|Experimental|Ofatumumab|Rapid Infusion of Ofatumumab
16715261|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.
~Rituximab: intravenous, 375 mg/m2, day 1
~Cyclophosphamide: intravenous, 750 mg/m2, day 1
~Doxorubicin: intravenous, 50 mg/m2, day 1
~Vincristine: intravenous, 1,4 mg/m2, day 1
~Prednisone: oral, 100 mg, days 1-5"
16715262|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days
~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15
~Rituximab: intravenous, 375 mg/m2, day 1
~Cyclophosphamide: intravenous, 750 mg/m2, day 1
~Doxorubicin: intravenous, 50 mg/m2, day 1
~Prednisone: oral, 100 mg, days 1-5"
16715263|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
16715264|NCT01848119|Placebo Comparator|Placebo|lactose capsules
16715265|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
16715266|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
16715267|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation
~sputum collection"
16715268|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
16715269|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
16715270|NCT01848067|Experimental|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16715271|NCT01848054|Experimental|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets
~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
16715272|NCT01848054|Active Comparator|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets
~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
16715273|NCT01848041|Experimental|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
16715274|NCT01848041|Experimental|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
16754074|NCT01584713|Experimental|Adipose derived Stem Cells|
16715275|NCT01848041|Placebo Comparator|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
16715276|NCT01848028||Fumaric acid ester|Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed
16715277|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
16715278|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
16715279|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
16715280|NCT01848028||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
16715281|NCT01848028||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
16715282|NCT01848028||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
16715283|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
16715284|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
16715285|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
16715286|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
16715287|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
16715288|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
16715289|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
16715290|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
16715291|NCT01848015||CTCs positive|
16715292|NCT01848002|Experimental|rFXIII|
16715293|NCT01848002|Placebo Comparator|Placebo|
16715294|NCT01847989|Experimental|rFXIII|
16715295|NCT01847989|Placebo Comparator|Placebo|
16715296|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
16715297|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
16715298|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
16715299|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
16715300|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
16715301|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
16715302|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
16715303|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
16715304|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
16715305|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
16715306|NCT01847937||Hereditary axonal neuropathic|
16715307|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
16715308|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
16715309|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
16715310|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
16715311|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
16715312|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
16715313|NCT01847898|Experimental|Balloon Kyphoplasty|
16715314|NCT01847885|Experimental|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
16715315|NCT01847885|Sham Comparator|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
16715316|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
16715317|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
16715318|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
16715319|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
16715320|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
16715321|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
16715322|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
16715323|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
16715324|NCT01847859|Experimental|Ultrasound performed by nurses|Focused examination of the pleural and pericardial cavity. Cardiologists perform reference ultrasound examinations.
16715325|NCT01847846|Experimental|Prototype mask|Participants will be randomised to trial the new prototype mask for 4 and 8 weeks. The prototype mask will be used in conjunction with the participant's home CPAP machine. The participant's will be instructed to use the prototype mask every night until the completion of the trial. No changes will be made to the participant's prescribed CPAP settings.
16715326|NCT01847833||Patients with brain tumors|
16715327|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
16715328|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
16715329|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
16715330|NCT01847807|No Intervention|MS control|
16715331|NCT01847794|Experimental|chemotheropy|
16715332|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
16715333|NCT01847781|Active Comparator|Healthy controls|Prevenar13
16715334|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.
~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
16715335|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.
~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
16715336|NCT01847755|Experimental|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
16715337|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
16715338|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
16715339|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
16715340|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
16715341|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
16715342|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
16715343|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
16715344|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
16715345|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
16715346|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
16715347|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)
~Carboplatin AUC 6 i.v. first day
~Paclitaxel 175 mg/m2 i.v. first day
~Surgery
~Post-Operative treatment
~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):
~Carboplatin AUC 6 i.v. first day
~Paclitaxel 175 mg/m2 i.v. first day
~Bevacizumab 15 mg/Kg i.v. first day1
~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
16715348|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.
~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.
~c) Postoperative treatment
~Both arms:
~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):
~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.
~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
16715349|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
16715350|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
16715351|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
16715352|NCT01847651|Active Comparator|LOLA|"Other Names:
~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA
~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
16715353|NCT01847651|Placebo Comparator|Placebo|
16715354|NCT01847638|Active Comparator|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
16715355|NCT01847638|Active Comparator|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
16715356|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
16715357|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
16715358|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
16715359|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
16715360|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
16715445|NCT01847027|Active Comparator|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
16715361|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
16715362|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
16715363|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
16715364|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1
~Multiple dose administration: Dose 1"
16715365|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2
~Multiple dose administration: Dose 2"
16715366|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3
~Multiple dose administration: Dose 3"
16715367|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4
~Multiple dose administration: Dose 4"
16715368|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
16715369|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
16715370|NCT01847560||Dabigatran|
16715371|NCT01847560||Warfarin or other New Oral Anticoagulant (NOAC)|
16715372|NCT01847547||Dabigatran|
16715373|NCT01847547||Warfarin|
16715374|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
16715375|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision
~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.
~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.
~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
16715376|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
16715377|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
16715378|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
16715379|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
16715380|NCT01847482|Experimental|Therapeutic Hypothermia|
16715381|NCT01847469|Experimental|Zonisamide|Participants in this arm will receive zonisamide for 12 weeks.
16715382|NCT01847469|Placebo Comparator|Placebo|Participants in this arm will receive placebo medication for 12 weeks.
16715383|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
16715384|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
16715385|NCT01847443|Experimental|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
16715386|NCT01847443|Experimental|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
16715387|NCT01847443|Active Comparator|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
16715388|NCT01847443|Active Comparator|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
16715389|NCT01847430|Experimental|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
16715390|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.
~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
16715391|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
16715392|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
16715393|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
16715394|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
16715395|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
16715396|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
16715397|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
16715398|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
16715399|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
16715400|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
16715401|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
16715402|NCT01847313|Active Comparator|Liraglutide|Liraglutide 0.6 mg daily
16715403|NCT01847313|No Intervention|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
16715404|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
16715405|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
16715406|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
16715409|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
16715410|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
16715411|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
16715412|NCT01847248||Severe sepsis|Patients with severe sepsis
16715413|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
16715414|NCT01847248||Control|Healthy volunteers
16715415|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
16715416|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
16715417|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
16715418|NCT01847209|Experimental|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
16715419|NCT01847196|Experimental|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
16715420|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
16715421|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
16715422|NCT01847170|Experimental|Fecal Microbial Transplantation|
16715423|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.
~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
16715424|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.
~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
16715425|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
16715426|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
16715427|NCT01847131|Active Comparator|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
16715428|NCT01847131|Placebo Comparator|placebo|placebo nasal spray 2 sprays in each nostril twice daily
16715429|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
16715430|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
16715431|NCT01847092|Active Comparator|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
16715432|NCT01847092|Placebo Comparator|Placebo|Placebo capsule BID PO for 12 Weeks
16715433|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
16715434|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
16715435|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
16715436|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
16715437|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
16715438|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
16715439|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
16715440|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
16715441|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
16715442|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
16715443|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
16715444|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
16715446|NCT01847027|Placebo Comparator|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:
~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
16715447|NCT01847014|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
16715448|NCT01847001|Experimental|Propranolol + Neoadjuvant Chemotherapy|"Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.
~Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and
~Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).
~If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.
~After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.
~DOT imaging will be done at 4 additional time points, including beo."
16715449|NCT01846988|Active Comparator|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
16715450|NCT01846988|Active Comparator|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
16715451|NCT01846988|Active Comparator|APAP pressurized comparison|randomization periods for 6-8 weeks. An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.
16715452|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
16715453|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
16715454|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
16715455|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
16715456|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
16715457|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
16715458|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.
~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
16715459|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
16715460|NCT01846923|Experimental|PCV13|
16715461|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
16715462|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
16715463|NCT01846871|Experimental|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
16715464|NCT01846858||CO2 Laser|
16715465|NCT01846858||Monopolar energy|
16715466|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
16715467|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
16715468|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
16715469|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).
~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.
~Fatigue will be assessed with the FIS and 6 Minute Walk Test.
~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
16715470|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
16715471|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
16715576|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
16715472|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
16715473|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
16715474|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
16715475|NCT01846754||Hemodialysis patients|
16715476|NCT01846741|Other|Model 106 VNS Therapy System|
16715477|NCT01846728|Experimental|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
16715478|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
16715479|NCT01846702|Placebo Comparator|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
16715480|NCT01846702|Experimental|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
16715481|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
16715482|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
16715483|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
16715484|NCT01846663|Experimental|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
16715485|NCT01846663|Placebo Comparator|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
16715486|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
16715487|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
16715488|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
16715489|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
16715490|NCT01846624|Experimental|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.
~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed up for up to 1 year."
16715491|NCT01846611|Experimental|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
16715492|NCT01846611|Active Comparator|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
16715493|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
16715494|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
16715495|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
~E.coli Endotoxin Day 7 - 2 ng/kg"
16715496|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication
~E.coli Endotoxin Day 7 - 2 ng/kg"
16715497|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
~E.coli Endotoxin Day 7 - 2 ng/kg"
16715498|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
16715499|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
16715500|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
16715501|NCT01846507|Experimental|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
16715502|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
16715503|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
16715504|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000
~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
16715505|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo
~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
16715506|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000
~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
16715507|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo
~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
16715508|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
16715509|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
16715577|NCT01846013|Experimental|Stand|
16715578|NCT01846013|Experimental|Move|
16715510|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
16715511|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
16715512|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh A|Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
16715513|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh B|Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
16715514|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh C|Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
16715515|NCT01846455|Experimental|HCV Without Hepatic Impairment|Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
16715516|NCT01846455|Active Comparator|No Hepatic Disease or Impairment|Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
16715517|NCT01846442|Placebo Comparator|Placebo|
16715518|NCT01846442|Experimental|0.25% DHEA|
16715519|NCT01846442|Experimental|0.5% DHEA|
16715520|NCT01846442|Experimental|1.0% DHEA|
16715521|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
16715522|NCT01846416|Experimental|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
16715523|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
16715524|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
16715525|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
16715526|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
16715527|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
16715528|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
16715529|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
16715530|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
16715531|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
16715532|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
16715533|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
16715534|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
16715535|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
16715536|NCT01846312||All participants|
16715537|NCT01846299|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
16715538|NCT01846299|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
16715539|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
16715540|NCT01846273|Experimental|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
16715541|NCT01846273|Active Comparator|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
16715542|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
16715543|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
16715544|NCT01846234||MS patients|MS patients
16715545|NCT01846221|Experimental|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
16715579|NCT01846013|Experimental|Stand and Move|
16715580|NCT01846013|No Intervention|General Wellness|
16715546|NCT01846221|Experimental|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
16715547|NCT01846208|Experimental|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
16715548|NCT01846208|Experimental|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
16715549|NCT01846208|Experimental|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
16715550|NCT01846195|Sham Comparator|no blood draw|CM 1500 with no blood draw
16715551|NCT01846195|Active Comparator|blood draw|CM 1500 with blood draw
16715552|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks and placebo in PM
16715553|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks and placebo in AM
16715554|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
16715555|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
16715556|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
16715557|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
16715558|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
16715559|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC
~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.
~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
16715560|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.
~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
16715561|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.
~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
16715562|NCT01846130|No Intervention|Control|Control bed rest group
16715563|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
16715564|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
16715565|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
16715566|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
16715567|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
16715568|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
16715569|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
16715570|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
16715571|NCT01846104|Experimental|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
16715572|NCT01846091|Experimental|Treatment (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.
16715573|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
16715574|NCT01846039|Experimental|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
16715575|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule
~1 capsule per week"
16715581|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
16715582|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
16715583|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
16715584|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
16715585|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
16715586|NCT01845987|Placebo Comparator|Placebo|
16715587|NCT01845987|Experimental|CNTO 1959|
16715588|NCT01845974|Experimental|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
16715589|NCT01845974|Active Comparator|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
16715590|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
16715591|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
16715592|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
16715593|NCT01845922|Experimental|Low sodium diet|Low sodium diet
16715594|NCT01845922|No Intervention|Control|Standard diet regime
16715595|NCT01845909||young adults - Central region of Portugal|
16715596|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
16715597|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
16715598|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
16715599|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
16715600|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
16715601|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
16715602|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
16715603|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
16715604|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
16715605|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
16715606|NCT01845831|Experimental|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
16715607|NCT01845831|Active Comparator|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
16715608|NCT01845831|Experimental|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
16715609|NCT01845831|Experimental|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
16715610|NCT01845831|Experimental|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
16715611|NCT01845818||Ankylosing Spondylitis and Psoriatic Arthritis|Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
16715612|NCT01845805|Experimental|Arm A: CC-486|"CC-486 (oral azacitidine), 300 mg total (three 100mg tablets), taken daily on days 1-21 (of a 28 day cycle); indefinite cycles until visible tumor recurrence, then first line chemotherapy"
16715613|NCT01845805|Active Comparator|Arm B: observation|"Observation, indefinite until visible tumor recurrence, then first line chemotherapy"
16715614|NCT01845792|Experimental|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
16715615|NCT01845792|Active Comparator|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
16715616|NCT01845779|Experimental|patients in complete response|
16715617|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
16715618|NCT01845766|No Intervention|control arm|
16715619|NCT01845753||All colorectal cancer patients|
16715620|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
16715621|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
16715622|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
16715623|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
16715624|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
16715625|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
16715626|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
16715627|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
16715628|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
16715629|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
16715630|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
16715631|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
16715632|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
16715633|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
16715634|NCT01845649|Active Comparator|Active|Estradiol Vaginal Gel (0.03 mg estradiol / g )
16715635|NCT01845649|Sham Comparator|Vehicle|Vehicle Vaginal Gel
16715636|NCT01845636|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
16715637|NCT01845623|Experimental|Treatment A|
16715638|NCT01845623|Experimental|Treatment B|
16715639|NCT01845623|Placebo Comparator|Treatment C|
16715640|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
16715641|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
16715642|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
16715643|NCT01845597||MAKOplasty® medial UKA|Patients who have received a MAKOplasty® robotically guided unilateral knee arthroplasty (UKA) and received a medial MCK onlay implant.
16715644|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
16715645|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
16715646|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
16715647|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
16715648|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
16715649|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
16715650|NCT01845532|Experimental|TPI group|
16715651|NCT01845532|Active Comparator|ELMA group|
16715652|NCT01845532|No Intervention|None group|
16715653|NCT01845519|Experimental|Tailored Group|
16715654|NCT01845519|Active Comparator|Targeted Group|
16715655|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
16715656|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
16715657|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
16715658|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
16715659|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
16715660|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
16715661|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
16715662|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
16715663|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
16715664|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
16715665|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
16715666|NCT01845441|Experimental|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
16715667|NCT01845441|Active Comparator|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
16715668|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
16715669|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
16715670|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
16715671|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
16715672|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
16715673|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
16715674|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
16715675|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
16715676|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
16715677|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
16715678|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis
~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.
~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.
~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
16715679|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
16715680|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
16715681|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
16715682|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
16715683|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
16715684|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
16715685|NCT01845311|Experimental|ReZolve2 Treatment Group|
16715767|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
16715686|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
16715687|NCT01845285||aortic valve disease|aortic valve replacement
16715688|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).
~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
16715689|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).
~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
16715690|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
16715691|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
16715692|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
16715693|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
16715694|NCT01845233||Non invasive ventilation|
16715695|NCT01845220|Active Comparator|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
16715696|NCT01845220|Placebo Comparator|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
16715697|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
16715698|NCT01845194|Experimental|Drug application|"Two treatment periods:
~Treatment period 1:
~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application
~Treatment period 2:
~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.
~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
16715699|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
16715700|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
16715701|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
16715702|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
16715703|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
16715704|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
16715705|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
16715706|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
16715707|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
16715708|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
16715709|NCT01845155|Experimental|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
16715710|NCT01845155|Active Comparator|Counselling|Counselling
16715711|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
16715712|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
16715713|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
16715714|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
16715715|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
16715716|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
16715717|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
16715718|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
16715719|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
16715720|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
16715721|NCT01845077|Experimental|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
16715722|NCT01845077|Active Comparator|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
16715723|NCT01845077|Experimental|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
16715724|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
16715725|NCT01845077|Experimental|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
16715726|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
16715727|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
16715728|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
16715729|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
16715730|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
16715731|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
16715732|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
16715733|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
16715734|NCT01845051||Migraine group|Patients diagnosed with migraine
16715735|NCT01845051||Healthy group|Healthy subjects with no migraine as control
16715736|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
16715737|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
16715738|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
16715739|NCT01845025|Experimental|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
16715740|NCT01845025|Active Comparator|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
16715741|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
16715742|NCT01844999|Other|Usual patient education + standard educational websites|
16715743|NCT01844999|Experimental|Usual patient education + P3P decision support website|
16715744|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
16715745|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
16715746|NCT01844973|Placebo Comparator|Vehicle|
16715747|NCT01844973|Active Comparator|M518101|
16715748|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
16715749|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
16715750|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
16715751|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
16715752|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
16715753|NCT01844908|Experimental|Electroacupuncture|
16715754|NCT01844895|Experimental|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months
~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
16715755|NCT01844882||Chronic Kidney Disease|
16715756|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.
~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
16715757|NCT01844856|Experimental|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
16715758|NCT01844856|Active Comparator|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
16715759|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
16715760|NCT01844830|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
16715761|NCT01844830|Placebo Comparator|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
16715762|NCT01844817|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
16715763|NCT01844817|Placebo Comparator|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
16715764|NCT01844804|Experimental|A = PF-06438179|
16715765|NCT01844804|Active Comparator|B = Infliximab-EU|
16715766|NCT01844804|Active Comparator|C = Infliximab-US|
16715902|NCT01843972|Experimental|BI 691751 dose 4 (part I)|single dose given as oral solution
16715768|NCT01844778|Active Comparator|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
16715769|NCT01844778|Active Comparator|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
16715770|NCT01844778|Active Comparator|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
16715771|NCT01844765|Experimental|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
16715772|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatinib or dasatinib
16715773|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.
16715774|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
16715775|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
16715776|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
16715777|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
16715778|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
16715779|NCT01844726|Experimental|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
16715780|NCT01844726|Placebo Comparator|Placebo|Single IV administration of placebo
16715781|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
16715782|NCT01844713|No Intervention|Control|Distribution of general skin care information
16715783|NCT01844700|Active Comparator|Ziprasidone|(20-160mg/d, bid) for 12 weeks
16715784|NCT01844700|Active Comparator|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
16715785|NCT01844687|Other|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
16715786|NCT01844687|Other|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
16715787|NCT01844687|Other|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
16715788|NCT01844687|Other|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
16715789|NCT01844687|Other|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
16715790|NCT01844687|Other|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
16715791|NCT01844687|Other|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
16715792|NCT01844687|Other|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
16715793|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
16715794|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
16715795|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
16715796|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
16715797|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
16715798|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
16715799|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
16715800|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
16715801|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
16715802|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
16715803|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
16715804|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
16715805|NCT01844583|Experimental|Esomeprazole 40 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.
~Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.
~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
16715806|NCT01844583|Experimental|Rifampin 600 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.
~Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.
~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
16715807|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
16715808|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
16715809|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
16715810|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
16715811|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
16715812|NCT01844544||patients after femur neck fracture|
16715813|NCT01844531|Experimental|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
16715814|NCT01844531|Active Comparator|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
16715815|NCT01844531|Experimental|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
16715816|NCT01844531|Active Comparator|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
16715817|NCT01844518|Experimental|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months
~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
16715818|NCT01844505|Experimental|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
16715819|NCT01844505|Experimental|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
16715820|NCT01844505|Experimental|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
16715821|NCT01844492|Active Comparator|ICU Usual Care Control|described below
16715822|NCT01844492|Experimental|The PARTNER Intervention|described below
16715823|NCT01844479|Active Comparator|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.
~The industry standard diabetic innersole will be used as the active comparator"
16715824|NCT01844479|Experimental|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
16715825|NCT01844466|Experimental|stroke patients|
16715826|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
16715827|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
16715828|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
16715829|NCT01844440|Experimental|HRM|
16715830|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
16715831|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
16715832|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
16715833|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
16715834|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
16715835|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
16715836|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
16715837|NCT01844388|Experimental|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
16715838|NCT01844388|Active Comparator|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
16715839|NCT01844375|Experimental|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
16715840|NCT01844375|Active Comparator|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
16715841|NCT01844362|Experimental|Uterine transplantation|Patients undergo transplantation of the uterus from live donor.
16715842|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
16715843|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
16715844|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
16715845|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
16715846|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
16715847|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
16715848|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
16715849|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
16715850|NCT01844297|Other|TDF+3TC+EFV|
16715851|NCT01844284|Experimental|Absorb™ BVS|Subjects receiving Absorb™ BVS
16715852|NCT01844284|Active Comparator|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
16715853|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
16715854|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
16715855|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
16715856|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
16715857|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
16715858|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
16715859|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.
~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.
~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.
~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
16715860|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
16715861|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.
~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.
~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
16715862|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.
~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.
~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
16715863|NCT01844232|Experimental|Arbaclofen Extended Release (ER) Tablets|Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day
16715864|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
16715865|NCT01844206|Active Comparator|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
16715866|NCT01844206|Placebo Comparator|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
16715867|NCT01844193|No Intervention|Standard Therapy|This arm of the study will follow the standard therapy course after total knee arthroplasty.
16715868|NCT01844193|Experimental|Standard Therapy + NMES|This arm will follow the standard course of therapy but also incorporate daily neuromuscular electrical stimulation into the daily therapy regimen after total knee arthroplasty through use of the Compex Rehab device.
16715869|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
16715870|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
16715871|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
16715872|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951
~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
16715873|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:
~The TENS device used: FDA K071951
~TENS is calibrated to allow for maximum range in the specifications.
~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.
~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.
~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
16715874|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
16715875|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
16715876|NCT01844128||overweight women with infertility|
16715877|NCT01844115|Placebo Comparator|Placebo|Dose-matched placebo tablets, oral administration
16715878|NCT01844115|Experimental|Vilazodone|Vilazodone tablets, oral administration
16715879|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
16715880|NCT01844076|Experimental|Phase I Level -2|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.
~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg once per day (days 1-21) for a 21 day cycle"
16715881|NCT01844076|Experimental|Phase I Level -1|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.
~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
16715882|NCT01844076|Experimental|Phase I Level 0|Group 3: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 200 mg twice a day (days 1-21) for a 21 day cycle
16715883|NCT01844076|Experimental|Phase II|"Phase II will use the treatment outlined in phase I, using the recommended phase II dose (RP2D) derived from Phase I.
~Patients will receive capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
16715884|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
16715885|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
16715886|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
16715887|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
16715888|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
16715889|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
16715890|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
16715891|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
16715892|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
16715893|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
16715894|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
16715895|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
16715896|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
16715897|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
16715898|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
16715899|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
16715900|NCT01843972|Experimental|BI 691751 dose 2 (part I)|single dose given as oral solution
16715901|NCT01843972|Experimental|BI 691751 dose 3 (part I)|single dose given as oral solution
16715903|NCT01843972|Experimental|BI 691751 dose 5 (part I)|single dose given as oral solution
16715904|NCT01843972|Experimental|BI 691751 dose 6 (part I)|single dose given as oral solution
16715905|NCT01843972|Experimental|BI 691751 dose 7 (part I)|single dose given as oral solution
16715906|NCT01843972|Experimental|BI 691751dose 1 (part I)|single dose given as oral solution
16715907|NCT01843972|Placebo Comparator|Placebo (part I)|placebo solution
16715908|NCT01843972|Experimental|BI 691751 tablet (part II)|single dose given as 1 tablet
16715909|NCT01843972|Active Comparator|BI 691751 solution (part II)|single dose given as oral solution
16715910|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.
~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes
~Group 2:
~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes
~Group 3:
~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes
~Group 4:
~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM
~Group 5:
~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM
~Group 6:
~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM
~Group 7:
~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
16715911|NCT01843933|No Intervention|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
16715912|NCT01843933|Active Comparator|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
16715913|NCT01843920|Active Comparator|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
16715914|NCT01843920|Experimental|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
16715915|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
16715916|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
16715917|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
16715918|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
16715919|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
16715920|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
16715921|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
16715922|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.
~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:
~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.
~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.
~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.
~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
16715923|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
16715924|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
16715925|NCT01843842|Experimental|Ergoferon (5 ml 3 times a day)|
16715926|NCT01843842|Placebo Comparator|Placebo (5 ml 3 times a day)|
16715927|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)
~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions
~then surgery.
~All drugs will be sourced from local stock"
16715928|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)
~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*
~then surgery.
~All drugs will be sourced from local stock"
16716073|NCT01842633|Experimental|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
16715929|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
16715930|NCT01843803|Experimental|patient inventory tool|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
16715931|NCT01843803|Active Comparator|attention control|prior to the encounter, the patient will view a brief video containing general health information.
16715932|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
16715933|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
16715934|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
16715935|NCT01843777|Active Comparator|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
16715936|NCT01843777|Experimental|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
16715937|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
16715938|NCT01843751|Active Comparator|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
16715939|NCT01843751|Experimental|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
16715940|NCT01843738|Experimental|All participants|
16715941|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
16715942|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
16715943|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
16715944|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
16715945|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
16715946|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
16715947|NCT01843673|Experimental|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
16715948|NCT01843660|Experimental|Tramadol Hydrochloride (HCl)-Paracetamol|
16715949|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
16715950|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
16715951|NCT01843634|Experimental|ODSH|
16715952|NCT01843621|Experimental|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
16715953|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.
~They cannot change physical activity and nutritional habits."
16715954|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.
~They have to present an attendance above or equal to 80%."
16715955|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
16715956|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
16715957|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
16715958|NCT01843556|Experimental|E2022 Tape Formulation|
16715959|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
16715960|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
16715961|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
16715962|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
16715963|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
16715964|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
16715965|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
16715966|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
16715967|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
16715968|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
16715969|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
16715970|NCT01843465||Cryoablation of atrial fibrillation|
16715971|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.
~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.
~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.
~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29
~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29
~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
16715972|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.
~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.
~popularize and educate the asthma action plan
~run a emergency call system for acute exacerbation
~educate the proper techniques using inhalers
~correct the deficiency of magnesium (magnesium 500mg per day)"
16715973|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
16715974|NCT01843413|Experimental|Treatment (SRS)|Patients undergo SRS guided by CT and MRI.
16715975|NCT01843400||Group 1|
16715976|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
16715977|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
16715980|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
16715981|NCT01843348|Active Comparator|TAC+MPA|
16715982|NCT01843348|Experimental|TAC+Certican|
16715983|NCT01843348|Experimental|CycA+Certican|
16715984|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
16715985|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
16715986|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
16715987|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
16715988|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
16715989|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
16715990|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
16715991|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
16715992|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
16715993|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
16715994|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
16715995|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
16715996|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
16715997|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
16715998|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
16716034|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
16715999|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
16716000|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
16716001|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.
~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
16716002|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
16716003|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
16716004|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
16716005|NCT01843205|Placebo Comparator|Placebo|Subjects will be maintained on placebo.
16716006|NCT01843205|Experimental|Buspirone|Subjects will be maintained on buspirone.
16716007|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
16716008|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
16716009|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
16716010|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
16716011|NCT01843153|Other|intermittent|injection of ropivacaine on demand
16716012|NCT01843153|Other|continuous|continuous ropivacaine infusion
16716013|NCT01843140||Young female cancer survivors|
16716014|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
16716015|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
16716016|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
16716017|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
16716018|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
16716019|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
16716020|NCT01843101|Other|Keratoconus|5 patients with keratoconus
16716021|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
16716022|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
16716023|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
16716024|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
16716025|NCT01843062|Experimental|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
16716026|NCT01843062|Placebo Comparator|Placebo|Placebo plus Radioactive Iodine Therapy
16716027|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:
~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.
~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.
~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.
~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.
~Chemotherapy:
~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.
~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
16716028|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
16716029|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
16716030|NCT01843023|Experimental|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [Vivitrol®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
16716031|NCT01843023|Active Comparator|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
16716032|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
16716033|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
16716116|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
16716035|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
16716036|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
16716037|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
16716038|NCT01842958|Active Comparator|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
16716039|NCT01842958|Experimental|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
16716040|NCT01842945|No Intervention|Wait-list control|
16716041|NCT01842945|Experimental|Treatment with therapist contact|
16716042|NCT01842945|Experimental|Treatment without therapist contact|
16716043|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
16716044|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
16716045|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
16716046|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
16716047|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
16716048|NCT01842906|Experimental|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
16716049|NCT01842906|Sham Comparator|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
16716050|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
16716051|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
16716052|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
16716053|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
16716054|NCT01842841|Experimental|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
16716055|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
16716056|NCT01842828|Other|Standard care|Standard care for smoking cessation
16716057|NCT01842815|Experimental|755nm Alexandrite Laser Single Pass (Right Side).|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The right side will be treated once within the same visit.
16716058|NCT01842815|Experimental|755nm Alexandrite Laser Double Pass (Left Side)|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The left side of the tattoo will be treated twice within the same visit 20 minutes apart.
16716059|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
16716060|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
16716061|NCT01842789|Other|Acessa Procedure w/o TAG|Acessa Procedure without the use of Targeting Animation Guidance
16716062|NCT01842789|Other|Acessa Procedure with TAG|Acessa Procedure with Targeting Animation Guidance
16716063|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
16716064|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
16716065|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
16716066|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
16716067|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
16716068|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
16716069|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
16716070|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
16716071|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
16716072|NCT01842646|Experimental|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
16716117|NCT01842256|Active Comparator|Atorvastatin 40mg|
16716074|NCT01842633|Active Comparator|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
16716075|NCT01842633|Placebo Comparator|Placebo Caplets|Four placebo caplets to be administered
16716076|NCT01842620|Experimental|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
16716077|NCT01842620|Active Comparator|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
16716078|NCT01842607|Experimental|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
16716079|NCT01842594|Experimental|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
16716080|NCT01842581|Experimental|Rifaximin 550 mg BID|Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
16716081|NCT01842581|Experimental|Rifaximin 550 mg BID + Lactulose|Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
16716082|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
16716083|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.
~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
16716084|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
16716085|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
16716086|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
16716087|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
16716088|NCT01842516|Placebo Comparator|Placebo|Placebo
16716089|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
16716090|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
16716091|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
16716092|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
16716093|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
16716094|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
16716095|NCT01842438|Experimental|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
16716096|NCT01842438|No Intervention|Control|This group will not receive the intervention during the life-span of the project
16716097|NCT01842412||claudication|
16716098|NCT01842412||healthy|
16716099|NCT01842399|Placebo Comparator|Experimental 1|2x/day orally
16716100|NCT01842399|Experimental|Experimental 2|75 mg, 2x/day, orally
16716101|NCT01842399|Experimental|Experimental 3|150 mg, 2x/day, orally
16716102|NCT01842386|Experimental|Rituximab|Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
16716103|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
16716104|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
16716105|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
16716106|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
16716107|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
16716108|NCT01842334|Experimental|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
16716109|NCT01842334|Placebo Comparator|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
16716110|NCT01842321|Experimental|Abiraterone Acetate|
16716111|NCT01842308|Experimental|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.
~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
16716112|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
16716113|NCT01842282|Experimental|Amlexanox|
16716114|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
16716115|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
16716118|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
16716119|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
16716120|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
16716121|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
16716122|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
16716123|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
16716124|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
16716125|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
16716126|NCT01842191|Experimental|Fish oil|
16716127|NCT01842191|Placebo Comparator|Placebo|
16716128|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.
~Endometrial Injury
~Done between 18-24 days prior to embryo transfer cycle.
~Using transfer catheter.
~Introduction of the same to the uterine fundus.
~Systematic scrapping of the four uterine walls, lengthwise.
~Performed by a skilled doctor.
~Subsequent ultrasound control"
16716129|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
16716130|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
16716131|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
16716132|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
16716133|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
16716134|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
16716135|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
16716136|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
16716137|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
16716138|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
16716139|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
16716140|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
16716141|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
16716142|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
16716143|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
16716144|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
16716145|NCT01842061|Experimental|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
16716146|NCT01842061|Active Comparator|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
16716147|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
16716148|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
16716149|NCT01842035|Experimental|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
~--------------------------------------------------------------------------------"
16716150|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
16716151|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
16716152|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
16716153|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
16716154|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
16716155|NCT01841996|Experimental|ME1111 solution|
16716156|NCT01841996|Placebo Comparator|Vehicle Solution|
16716157|NCT01841983|Experimental|Intervention|Be Well Work Well
16716158|NCT01841983|No Intervention|Control|No intervention
16716159|NCT01841970|Other|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
16716160|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
16716161|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
16716162|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
16716163|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
16716164|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
16716165|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
16716166|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
16716167|NCT01841892|No Intervention|Usual Care Control|
16716168|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
16716169|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
16716170|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
16716171|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
16716172|NCT01841866|Placebo Comparator|awake|LMA removal
16716173|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
16716174|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
16716175|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
16716176|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
16716177|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
16716178|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
16716179|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
16716180|NCT01841814|Experimental|lymphoma|
16716181|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
16716182|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
16716183|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
16716184|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
16716185|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
16716186|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
16716187|NCT01841762|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
16716188|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
16716189|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16716190|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.
16716191|NCT01841723|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16716192|NCT01841710||Women|
16716193|NCT01841697|Experimental|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
16716194|NCT01841697|Active Comparator|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
16716195|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
16716196|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
16716197|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
16716198|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
16716199|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
16716200|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
16716201|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
16716202|NCT01841645|Other|CLA depletion-repletion|
16716203|NCT01841632|Experimental|MultiStem|"Dose escalation
~Cohort 1
~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)
~Cohort 2
~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)
~Cohort 3
~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)
~Cohort 4
~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
16716204|NCT01841619|Active Comparator|IVIg as a monotherapy|IVIg will be used as a first line treatment. Topical treatment will be stopped at the beginning of IVIg therapy.
16716205|NCT01841606|Experimental|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
16716206|NCT01841606|Placebo Comparator|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
16716207|NCT01841593|Experimental|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
16716208|NCT01841593|Experimental|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
16716209|NCT01841567|Other|dressing|
16716210|NCT01841554|Experimental|Single|
16716211|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.
~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
16716212|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
16716213|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
16716214|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
16716215|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
16716216|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
16716217|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
16716218|NCT01841489|Experimental|Sequence 1|
16716219|NCT01841489|Experimental|Sequence 2|
16716220|NCT01841489|Experimental|Sequence 3|
16716221|NCT01841489|Experimental|Sequence 4|
16716222|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
16716223|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-
~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
16716226|NCT01841437||iStent|
16716227|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
16716228|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
16716229|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
16716230|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
16716231|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
16717080|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
16716232|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
16716233|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
16716234|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.
~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.
~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
16716235|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
16716236|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
16716237|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
16716238|NCT01841359|Other|Pramlintide (Symlin)|"Participants in this study will be asked to complete 4 study visits. Study visit 1 will be for screening. Eligible individuals who provide informed consent will be asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms. At study visit 2, a baseline mixed meal tolerance test will be performed. Glucose, hormonal responses, and satiety will be assessed. Glucose and symptom log will be reviewed. Pramlintide will be prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During treatment, the participants will keep a record of all hypoglycemic symptoms and blood glucose measurements at those times.
~Study visit 3 will occur at week 4 of treatment and focus on evaluation of symptoms and side effects. Participants will again complete a food and glucose diary for 3 days. During study visit 4 (week 8 of treatment), participants will undergo a repeat mixed meal tolerance test."
16716239|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
16716240|NCT01841333|Experimental|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
16716241|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
16716242|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
16716243|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
16716244|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
16716245|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
16716246|NCT01841281|Active Comparator|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.
~All subjects will receive L-arginine and placebo in this cross-over design study."
16716247|NCT01841281|Active Comparator|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.
~All subjects will receive L-arginine and placebo in this cross-over design study."
16716248|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
16716249|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
16716250|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
16716251|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
16716252|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
16716253|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
16716254|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
16716255|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
16716256|NCT01841216|Experimental|Low Back Pain|Lower Body Exercises with and without resistance
16716257|NCT01841216|Experimental|Healthy|Lower Body Exercises with and without resistance
16716258|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
16716259|NCT01841190||PROCALCITONIN|
16716260|NCT01841190||DELTA SOFA|
16716261|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
16716262|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
16716263|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
16716457|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
16716264|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
16716265|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
16716266|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
16716267|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
16716268|NCT01841151|No Intervention|Waiting-list|Treatment as usual only
16716269|NCT01841125|Experimental|escitalopram|escitalopram 15mg
16716270|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
16716271|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
16716272|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
16716273|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
16716274|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
16716275|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
16716276|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
16716277|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
16716278|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
16716279|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
16716280|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
16716281|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
16716282|NCT01841073|Experimental|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
16716283|NCT01841073|Placebo Comparator|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
16716284|NCT01841060|Experimental|Radiofrequency ablathermy|Percutaneous radiofrequency ablation (RFA)
16716285|NCT01841047|Other|Radiotherapy|Evaluation of the combination of radiotherapy with helical tomotherapy (54 Gy) followed by surgery in retro-peritoneal liposarcomas.
16716286|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
16716287|NCT01841021|Experimental|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
16716288|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
16716289|NCT01841008|Placebo Comparator|Group Placebo|
16716290|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
16716291|NCT01840982|Experimental|Giant embryonic brown rice|
16716292|NCT01840982|Experimental|Giant embryonic rice|
16716293|NCT01840982|Active Comparator|White rice|
16716294|NCT01840982|Active Comparator|Glucose solution|
16716295|NCT01840969||CAOD group|Single arm study group
16716296|NCT01840956|Experimental|HAVG|Surgical placement of HAVG
16716297|NCT01840943|Experimental|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
16716298|NCT01840943|Active Comparator|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
16716299|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
16716300|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
16716301|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
16716302|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
16716303|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
16716304|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
16716305|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
16716306|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
16716307|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
16716308|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
16716309|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
16716310|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
16716311|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
16716312|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
16716458|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
16716313|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
16716314|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
16716315|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
16716316|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
16716317|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
16716318|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
16716319|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
16716320|NCT01840761|Placebo Comparator|Placebo|
16716321|NCT01840748||no vasodilator|patients receiving no vasodilator
16716322|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
16716323|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
16716324|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
16716325|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
16716326|NCT01840722|No Intervention|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
16716327|NCT01840722|Experimental|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
16716328|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
16716329|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
16716330|NCT01840696|Experimental|Regadenoson|
16716331|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
16716332|NCT01840644||all participants|Walking on treadmill, different velocities and incline
16716333|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
16716334|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
16716335|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5
~Will initiate Nasal Continuous positive airway pressure (CPAP)"
16716336|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
16716337|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
16716338|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5
~Will initiate Nasal Continuous positive airway pressure (CPAP)"
16716339|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
16716340|NCT01840605|Experimental|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
16716341|NCT01840605|Active Comparator|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
16716342|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
16716343|NCT01840579|Experimental|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
16716344|NCT01840579|Experimental|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
16716345|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
16716346|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin Area Under The Curve (AUC) 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
16716347|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
16716348|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
16716459|NCT01839877|Experimental|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
16716349|NCT01840579|Experimental|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
16716350|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
16716351|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
16716352|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
16716353|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
16716354|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
16716355|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
16716356|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
16716359|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
16716360|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
16716361|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
16716362|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
16716363|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
16716364|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
16716365|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
16716366|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
16716367|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
16716368|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
16716369|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
16716370|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
16716371|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
16716372|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
16716373|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
16716374|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
16716375|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
16716376|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
16716377|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
16716378|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
16716379|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.
~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
16716380|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
16716381|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.
~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
16716382|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
16716383|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
16716384|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
16716385|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
16716386|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
16716387|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
16716388|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
16716389|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
16716390|NCT01840410|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
16716391|NCT01840410|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
16716392|NCT01840397||Spine surgery|Patients undergoing spine surgery
16716393|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
16716394|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
16716395|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
16716396|NCT01840371|Experimental|Propofol based group|
16716397|NCT01840371|Active Comparator|Fentanyl based group|
16716398|NCT01840358|Other|Patients starting pump therapy|
16716399|NCT01840345|Experimental|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
16716400|NCT01840332|Experimental|L-thyroxin|this is one arm study
16716401|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
16716402|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
16716403|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
16716404|NCT01840293||Primary Breast Cancer|
16716405|NCT01840293||Recurrent/Metastatic Breast Cancer|
16716406|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
16716407|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
16716408|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
16716409|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
16716410|NCT01840241|Experimental|BIVON group|
16716411|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
16716412|NCT01840228|Active Comparator|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
16716413|NCT01840228|Placebo Comparator|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
16716414|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
16716415|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
16716416|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
16716417|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
16716418|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
16716419|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
16716420|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
16716421|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
16716422|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
16716423|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
16716424|NCT01840163|Other|CanSORT Online Tool|Comprehensive decision tool
16716425|NCT01840163|Other|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
16716426|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
16716427|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
16716428|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
16716429|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
16716430|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
16716431|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
16716432|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
16716433|NCT01840085|Experimental|0.03% DSC127 topical gel|
16716434|NCT01840072|Experimental|Active antihypertensive treatment|Active antihypertensive treatment
16716435|NCT01840072|No Intervention|Usual care|Discontinue all home BP medications.
16716436|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
16716437|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
16716438|NCT01840046|Experimental|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:
~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.
~The dosage is as follows:
~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
16716439|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
16716440|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
16716441|NCT01840020||Gastric bypass|patients recruited from Central Norway
16716442|NCT01840020||Gastric sleeve|patients recruited from Central Norway
16716443|NCT01840007|Experimental|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.
~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
16716444|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).
~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).
~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
16716445|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
16716446|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
16716447|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
16716448|NCT01839955|Experimental|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
16716449|NCT01839955|Experimental|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
16716450|NCT01839942||no gap closure|no hernia gap closure
16716451|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure
~extracorporal suturing of gap"
16716452|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
16716453|NCT01839929|Experimental|Prograf/Advagraf|conversion from Prograf to Advagraf
16716454|NCT01839916|Experimental|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
16716455|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
16716456|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
16717081|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
16716460|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
16716461|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
16716462|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
16716463|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
16716464|NCT01839838|Experimental|APBI with protons|
16716465|NCT01839825|Experimental|QuietCare|QuieCare system installed
16716466|NCT01839825|No Intervention|control|no system installed
16716467|NCT01839812|Other|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
16716468|NCT01839799|Experimental|Arm 1 - FOLFIRINOX|"FOLFIRINOX:
~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles over 8 weeks
~Chemoradiation:
~Radiation to begin no sooner than 28 days from last day of chemotherapy.
~On Day 1(+ 2days to accommodate scheduling difficulties):
~Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.
~FOLFIRINOX:
~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated"
16716469|NCT01839799|Experimental|Arm 2 - Gemcitabine / Abraxane|"Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles over 8 weeks
~Chemoradiation:
~Radiation to begin no sooner than 28 days from last day of chemotherapy. On Day 1 (+ 2days to accommodate scheduling difficulties) Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.
~Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles, if tolerated"
16716470|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
16716471|NCT01839773|Experimental|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
16716472|NCT01839773|Active Comparator|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
16716473|NCT01839760||Inpatient cohort|Patients admitted to general wards
16716474|NCT01839760||ICU cohort|Patients admitted to ICU
16716475|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
16716476|NCT01839734|Experimental|Arm A|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
16716477|NCT01839734|No Intervention|Arm B|No intervention
16716478|NCT01839721|Active Comparator|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
16716479|NCT01839721|Active Comparator|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
16716480|NCT01839721|Placebo Comparator|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
16716481|NCT01839708|Experimental|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
16716482|NCT01839708|No Intervention|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
16716484|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
16716485|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
16716486|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
16716487|NCT01839656|Experimental|Nusinersen 6 mg|
16716488|NCT01839656|Experimental|Nusinersen 12 mg|
16716489|NCT01839643|Experimental|2.4 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
16716490|NCT01839643|Experimental|3.0 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
16716491|NCT01839630||Group 1|
16716492|NCT01839617|Active Comparator|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
16716493|NCT01839617|Active Comparator|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
16716494|NCT01839604|Experimental|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
16716495|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
16716496|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
16716497|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
16716498|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
16716499|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
16716500|NCT01839539|No Intervention|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
16716501|NCT01839539|Experimental|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
16716502|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
16716503|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
16754075|NCT01584700|Other|Renal Artery Denervation|Ontervention
16716504|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
16716505|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
16716506|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
16716507|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
16716508|NCT01839487|Experimental|Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m^2) NAB and 1000 mg/m^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.
16716509|NCT01839487|Active Comparator|Run-in Phase - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
16716510|NCT01839487|Experimental|Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.
16716511|NCT01839487|Active Comparator|Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
16716512|NCT01839487|Experimental|Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).
16716513|NCT01839487|Active Comparator|Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.
16716514|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
16716515|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
16716516|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.
~Intervention: Post-partum oral glucose tolerance test"
16716517|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.
~Intervention: Post-partum oral glucose tolerance test"
16716518|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
16716519|NCT01839422|Experimental|Controls|Memory assessment. Brain imaging examination MRI.
16716520|NCT01839422|Experimental|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
16716521|NCT01839422|Experimental|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
16716522|NCT01839409|No Intervention|control|Control without vestibular stimulation
16716523|NCT01839409|No Intervention|Bilateral areflexia|Patient with vestibular bilateral areflexia
16716524|NCT01839409|No Intervention|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
16716525|NCT01839409|Experimental|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
16716605|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
16716528|NCT01839383|Active Comparator|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
16716529|NCT01839383|Active Comparator|DCa1.5|using dialysate calcium concentration 1.5mmol/L
16716530|NCT01839383|Active Comparator|DCa1.75|using dialysate calcium concentration 1.75mmol/L
16716531|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
16716532|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
16716533|NCT01839357|Experimental|Rivaroxaban|
16716534|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
16716535|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
16716536|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
16716537|NCT01839331|Experimental|Low Dose Ampion|4 mL Ampion
16716538|NCT01839331|Placebo Comparator|Placebo|4 mL placebo
16716539|NCT01839331|Experimental|High Dose Ampion|10 mL Ampion
16716540|NCT01839331|Placebo Comparator|10 mL Placebo|10 ml Placebo
16716541|NCT01839318|Experimental|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
16716542|NCT01839318|Active Comparator|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
16716543|NCT01839318|Active Comparator|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
16716544|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
16716545|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
16716546|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
16716547|NCT01839279|Experimental|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
16716548|NCT01839279|Placebo Comparator|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
16716549|NCT01839279|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
16716550|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
16716551|NCT01839253|Experimental|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
16716552|NCT01839253|Active Comparator|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
16716553|NCT01839253|Placebo Comparator|control|none of antihypertensive agents
16716554|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.
~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.
~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
16716555|NCT01839227|Experimental|regional cerebral oxygen saturation|
16716556|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
16716557|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
16716558|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
16716559|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
16716560|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
16716561|NCT01839188|Experimental|PR5I (V1); Pediacel® (V2); PR5I (V3)|[Vaccination 1]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. [Vaccination 2]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. [Vaccination 3]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.
16716562|NCT01839175|Experimental|Group 1|
16716563|NCT01839175|Active Comparator|Group 2|
16716564|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
16716565|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
16716566|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
16716567|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
16716568|NCT01839149|Experimental|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
16716569|NCT01839149|Placebo Comparator|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
16717238|NCT01834495|Active Comparator|Self expandable stent|same to Balloon expandable stent
16716570|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
16716571|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
16716572|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
16716573|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
16716574|NCT01839110|Active Comparator|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
16716575|NCT01839110|Placebo Comparator|Placebo|Placebo by mouth twice per day
16716576|NCT01839110|No Intervention|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF >=45%) will undergo same procedures in the observational arm but will not receive an intervention.
16716577|NCT01839097|Experimental|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.
~Enrollment will begin with the enrollment of patients into Cohort 3.
~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
16716578|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
16716579|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
16716580|NCT01839071|Other|biopsy of fat tissue|
16716581|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
16716582|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
16716583|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
16716584|NCT01839032|Experimental|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
16716585|NCT01839019|Placebo Comparator|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
16716586|NCT01839019|Experimental|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
16716587|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
16716588|NCT01838993|Active Comparator|Lidocaine|Inhalation of lidocaine before intubation
16716589|NCT01838993|Placebo Comparator|Control|Normal saline inhalation before intubation
16716590|NCT01838980|Experimental|Colonoscopy|
16716591|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
16716592|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
16716593|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
16716594|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
16716595|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
16716596|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
16716597|NCT01838954|Active Comparator|Short-wave diathermy|Short-wave diathermy device turned on
16716598|NCT01838954|Placebo Comparator|control|Short-wave diathermy device turned off
16716599|NCT01838941|Experimental|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
16716600|NCT01838928|Experimental|Bupivacaine|
16716601|NCT01838915|Experimental|Dietary Supplement: Prebiotics+Glutamine|
16716602|NCT01838915|Placebo Comparator|Placebo|
16716603|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
16716604|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
16716606|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
16716607|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
16716608|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
16716609|NCT01838876|Experimental|Cariprazine + ADT|Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
16716610|NCT01838863|Experimental|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
16716611|NCT01838863|Active Comparator|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
16716612|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
16716613|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
16716614|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
16716615|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
16716616|NCT01838798||Study population|"See in inclusion/exclusion criteria.
~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
16716617|NCT01838785|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
16716618|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.
~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
16716619|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
16716620|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
16716621|NCT01838746||PCI|Patients undergoing PCI
16716622|NCT01838746||CABG|Patients undergoing CABG
16716623|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
16716624|NCT01838720|Experimental|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
16716625|NCT01838720|Active Comparator|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
16716626|NCT01838707|Active Comparator|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
16716627|NCT01838707|Active Comparator|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
16716628|NCT01838707|Active Comparator|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
16716629|NCT01838694|Placebo Comparator|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
16716630|NCT01838694|Experimental|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
16716631|NCT01838681|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
16716632|NCT01838681|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
16716633|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
16716634|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
16716746|NCT01837927|Active Comparator|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
16716635|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
16716636|NCT01838655|Experimental|Nitisinone|Oral administration of nitisinone
16716637|NCT01838642|Active Comparator|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
16716638|NCT01838642|Active Comparator|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
16716639|NCT01838629||thyroid nodule|
16716640|NCT01838616|Experimental|Tapentadol Prolonged Release (PR)|
16716641|NCT01838616|Active Comparator|Oxycodone/Naloxone Prolonged Release|
16716642|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
16716643|NCT01838590|Experimental|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
16716644|NCT01838590|Experimental|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
16716645|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.
~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.
~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
16716646|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.
~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.
~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
16716647|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
16716648|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
16716649|NCT01838551|Experimental|Levoketoconazole DL0|Levoketoconazole Tablets Dose Level 0 Once Daily
16716650|NCT01838551|Experimental|Levoketoconazole DL1|Levoketoconazole Tablets Dose Level 1 Twice Daily
16716651|NCT01838551|Experimental|Levoketoconazole DL2|Levoketoconazole Tablets Dose Level 1 Twice Daily
16716652|NCT01838551|Experimental|Levoketoconazole DL3|Levoketoconazole Tablets Dose Level 3 Twice Daily
16716653|NCT01838551|Experimental|Levoketoconazole DL4|Levoketoconazole Tablets Dose Level 4 Twice Daily
16716654|NCT01838551|Experimental|Levoketoconazole DL5|Levoketoconazole Tablets Dose Level 5 Twice Daily
16716655|NCT01838551|Experimental|Levoketoconazole DL6|Levoketoconazole Tablets Dose Level 6 Twice Daily
16716656|NCT01838551|Experimental|Levoketoconazole DL7|Levoketoconazole Tablets Dose Level 7 Twice Daily
16716657|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
16716658|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
16716659|NCT01838525||SIRS, SEPSIS|
16716660|NCT01838525||sepsis, severe sepsis, septic shock|
16716661|NCT01838525||health, SIRS, Sepsis|
16716665|NCT01838499|Experimental|MEDI8968|
16716666|NCT01838499|Placebo Comparator|Saline|
16716667|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
16716668|NCT01838473|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
16716669|NCT01838473|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
16716670|NCT01838473|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
16716671|NCT01838473|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
16716672|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
16716673|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
16716674|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
16716675|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
16716676|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
16717789|NCT01830699|Placebo Comparator|Corticosteroid|80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once
16716677|NCT01838447|No Intervention|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
16716678|NCT01838447|Experimental|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
16716679|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
16716680|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
16716681|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
16716682|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
16716683|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
16716684|NCT01838395|Experimental|BL-8040 + Ara-C|"Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (monotherapy period) over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (combined period) over 5 days. During the combined period, BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated."
16716685|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
16716686|NCT01838369|Experimental|BI-505|
16716687|NCT01838356||No treatment.|
16716688|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
16716689|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
16716690|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
16716691|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
16716692|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients without Diabetes|
16716693|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients with Diabetes|
16716694|NCT01838304|Active Comparator|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
16716695|NCT01838304|Experimental|Probability ramp control|Propofol titrated to deep sedation using PRC software.
16716696|NCT01838291||Patients on Ferriprox therapy <1 month|
16716697|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
16716698|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
16716699|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
16716700|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
16716701|NCT01838252|Sham Comparator|Saline|
16716702|NCT01838239|Experimental|Fish oil|
16716703|NCT01838226|Experimental|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
16716704|NCT01838226|No Intervention|Treatment as usual control|Usual VA care
16716705|NCT01838200|Experimental|Cohort 1, Group 1 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
16716706|NCT01838200|Experimental|Cohort 1, Group 2 (BCG 0.8-3.2 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
16716747|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
16716748|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
16716707|NCT01838200|Experimental|Cohort 1, Group 3 (BCG 4.0-16.0 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
16716708|NCT01838200|Experimental|Cohort 2 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration ≥10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
16716709|NCT01838174|Experimental|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
16716710|NCT01838174|Active Comparator|IV methylprednisolone (steroids)|3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
16716711|NCT01838161|Active Comparator|Part I|Interview questions will focus on reticence to vaccinate children.
16716712|NCT01838161|Experimental|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.
~a pretest survey
~the video vignette
~and a post-test survey measuring intention to receive appropriate adolescent vaccines"
16716713|NCT01838161|Experimental|Part III|"enhanced video educational intervention (video vignettes + standard of care vaccine event)
~standard of care vaccination event"
16716714|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
16716715|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
16716716|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
16716717|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
16716718|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
16716719|NCT01838109|No Intervention|Control group|no intervention total 87 patients
16716720|NCT01838096|Experimental|THA|
16716721|NCT01838083|Experimental|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
16716722|NCT01838083|Experimental|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
16716723|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
16716724|NCT01838057||painPREMIER cohort|
16716725|NCT01838057||Control cohort|
16716726|NCT01838044|Experimental|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
16716727|NCT01838044|Other|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
16716728|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
16716729|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
16716730|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
16716731|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
16716732|NCT01838005|No Intervention|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
16716733|NCT01838005|Experimental|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
16716734|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
16716735|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
16716736|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
16716737|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
16716738|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
16716739|NCT01837966|Active Comparator|Lavender oil|Lavender oil aromatherapy
16716740|NCT01837966|Placebo Comparator|Placebo|Placebo -- unscented oil aromatherapy
16716741|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
16716742|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
16716743|NCT01837940|Placebo Comparator|Placebo|
16716744|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
16716745|NCT01837927|Experimental|NVA237|NVA237 inhaled via the Breezhaler® device once daily
16754170|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
16716749|NCT01837901|Sham Comparator|Sham|OkuStim is used to determine the phosphene threshold, device is turned on but no stimulation is performed.
16716750|NCT01837901|Experimental|150%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.
16716751|NCT01837901|Experimental|200%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.
16716752|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
16716753|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
16716754|NCT01837875|No Intervention|Control|Mailed informational literature
16716755|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
16716756|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
16716757|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
16716758|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.
16716759|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
16716760|NCT01837823|Experimental|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
16716761|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
16716762|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
16716763|NCT01837797|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
16716764|NCT01837797|Experimental|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
16716765|NCT01837797|Experimental|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
16716766|NCT01837784||Elderly patients|
16716767|NCT01837784||Patients with diabetes mellitus|
16716768|NCT01837784||Patients with heart failure|
16716769|NCT01837784||Patients with resistant hypertension|
16716770|NCT01837771|Active Comparator|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
16716771|NCT01837771|No Intervention|No intervention|
16716772|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
16716773|NCT01837745|Active Comparator|Ablation group|"Administration of 1.1 GBq of I131 is given after the second intramuscular injections of rhTSH (0.9 mg). A whole body scan (WBS) is performed 2 to 5 days after the administration or I131 with determination of the neck uptake.
~Follow-up consists in:
~10 (+/- 2 months) after randomization: neck ultrasound + a serum Tg measurement after rhTSH stimulation
~2 years (+/- 2 months) after randomization: serum Tg measurement under LT4 treatment (Tg/LT4)
~3 years (+/- 2 months) after randomization: neck ultrasound and a serum Tg/LT4
~4 years (+/- 2 months) after randomization: a serum Tg/LT4
~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
16716774|NCT01837745|Experimental|Follow up group|Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
16716775|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
16716776|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
16716777|NCT01837719|Experimental|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
16716778|NCT01837719|Experimental|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
16716779|NCT01837719|Experimental|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
16716780|NCT01837719|Experimental|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
16716781|NCT01837719|Experimental|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
16716782|NCT01837706||Emergency Room Patients|
16716783|NCT01837693|No Intervention|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
16716784|NCT01837693|Experimental|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
16754465|NCT01582165|Active Comparator|Angina. IMR. Statin.|
16716785|NCT01837680|Active Comparator|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
16716786|NCT01837680|Active Comparator|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
16716787|NCT01837667|Experimental|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
16716788|NCT01837654|Experimental|Plantarflexion - 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
16716789|NCT01837654|Experimental|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
16716790|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
16716791|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
16716792|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
16716793|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
16716794|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
16716795|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
16716796|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
16716797|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
16716798|NCT01837628|Active Comparator|Lidocaine gel|Intraurethral Lidocaine gel 2%
16716799|NCT01837628|Experimental|Paraffin Oil|Intraurethral injection
16716800|NCT01837615|Experimental|Photopill treatment|
16716801|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
16716802|NCT01837589|Other|QCT and DXA|All the patients will have both QCT and DXA
16716803|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
16716804|NCT01837550|Active Comparator|Control group|no professional support
16716805|NCT01837550|Experimental|Intervention group|Professional support via Internet
16716806|NCT01837537||no treatment|no treatment, prospective observational
16716807|NCT01837524|Experimental|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
16716808|NCT01837524|Active Comparator|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
16716809|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
16716810|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
16716811|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
16716812|NCT01837485|Experimental|Lactol|
16716813|NCT01837485|Placebo Comparator|Placebo|
16716814|NCT01837472|Experimental|Probiotic|
16716815|NCT01837472|Placebo Comparator|Placebo|
16716816|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) <1
16716817|NCT01837459||Obese-SDB|Obese and with AHI>1
16716818|NCT01837459||Lean-Normal|Non-obese with AHI<1
16716819|NCT01837459||Lean-SDB|Non-obese with AHI>1
16716820|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
16716821|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
16716822|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
16716823|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
16716824|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
16716825|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
16716826|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
16716827|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
16716828|NCT01837394|Active Comparator|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
16716829|NCT01837394|Placebo Comparator|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
16716830|NCT01837381|Other|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
16716831|NCT01837355|Placebo Comparator|Placebo|placebo once daily for 12 weeks
16716832|NCT01837355|Experimental|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
16716833|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
16716834|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
16716835|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.
~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
16716836|NCT01837316|Experimental|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
16716837|NCT01837316|Placebo Comparator|Placebo|A single dose inhalation of matching placebo in the morning
16716838|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
16716839|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
16716840|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
16716841|NCT01837277|Experimental|Dolutegravir|Intervention: Patients will receive ART regimen based on investigational drug Dolutegravir 50 mg QD + TDF 300 mg QD+ 3TC 150 mg BID
16716842|NCT01837277|Active Comparator|Efavirenz|Intervention: Patients who received ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year, befor the use of DTG as SOC for first-line therapy (historic controls)
16716843|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
16716844|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
16716845|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
16716846|NCT01837238|Experimental|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
16716847|NCT01837238|Placebo Comparator|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
16716848|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
16716849|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
16716850|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
16716851|NCT01837225||Intermediate Dose Contrast Agent|Patients in the intermediate dose arm will receive 20 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
16716852|NCT01837199|Experimental|Smoking|Metronidazole plus Amoxicillin
16716853|NCT01837199|Experimental|Non-Smoking|Metronidazole plus Amoxicillin
16716854|NCT01837186||EFP|Empyema following pneumonectomy
16716855|NCT01837186||nEFP|No empyema following pneumonectomy
16716856|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
16716857|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
16717036|NCT01835977|Active Comparator|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
16716858|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.
~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
16716859|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
16716860|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
16716861|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
16716862|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo a repeat CT-PET scan 3 months after the operation.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
16716863|NCT01837147|Experimental|Web-based Tracking Group|Technology-Based Physical Activity Promotion
16716864|NCT01837147|Active Comparator|Pedometer Group|Participants assigned to this group will receive a pedometer.
16716865|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
16716866|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
16716867|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
16716868|NCT01837121|Other|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
16716869|NCT01837121|No Intervention|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
16716870|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
16716871|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
16716872|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
16716873|NCT01837082|Active Comparator|Iron|ferric carboxymaltose
16716874|NCT01837082|Placebo Comparator|Placebo|Sodium chloride 0.9%
16716875|NCT01837069|Active Comparator|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
16716876|NCT01837069|No Intervention|Control|Standard of care
16716877|NCT01837043|Experimental|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
16716878|NCT01837043|Active Comparator|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
16716879|NCT01837030|Other|Oral Iron|
16716880|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
16716881|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
16716882|NCT01837017|No Intervention|Control|Wait-list control.
16716883|NCT01837004|Experimental|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
16716884|NCT01836991|Other|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
16716885|NCT01836991|Experimental|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
16716886|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
16716887|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
16716952|NCT01836471|Experimental|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
16716888|NCT01836965|Experimental|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
16716889|NCT01836952||Infants|Infant born via vaginal delivery
16716890|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
16716891|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
16716892|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
16716893|NCT01836926|Active Comparator|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers
~intervention:
~Trocar Placement and Exposure
~Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels
~Taking Down the Splenic Flexure
~rectal dissection till the levator ani muscle and resection of thye lateral ligaments
~then the peranal phase as in the laparotomy approach."
16716894|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
16716895|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
16716896|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
16716897|NCT01836887|Placebo Comparator|Intervention 1|Very low polyphenol fruit based drink (control)
16716898|NCT01836887|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - low
16716899|NCT01836887|Active Comparator|Invervention 3|Polyphenol-enriched fruit-based drink - high
16716900|NCT01836874||Topiramate|
16716901|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
16716902|NCT01836848|Experimental|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
16716903|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
16716904|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
16716905|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
16716906|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
16716907|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
16716908|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
16716909|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
16716910|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
16716911|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
16716912|NCT01836796|Placebo Comparator|Placebo|
16716913|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
16716914|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
16716915|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
16716916|NCT01836757|Experimental|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
16716917|NCT01836757|Placebo Comparator|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
16716918|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
16716919|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
16716920|NCT01836731|Experimental|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
16716953|NCT01836471|Placebo Comparator|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
16717076|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
16716921|NCT01836731|Experimental|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
16716922|NCT01836731|No Intervention|Control|"The control group is not enrolled in the CBEHPP.
~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
16716923|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
16716924|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
16716925|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
16716926|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
16716927|NCT01836692|Experimental|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
16716928|NCT01836679|Experimental|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
16716929|NCT01836679|Placebo Comparator|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
16716930|NCT01836653|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
16716931|NCT01836653|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
16716932|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
16716933|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
16716934|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
16716935|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
16716936|NCT01836601|No Intervention|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
16716937|NCT01836601|Experimental|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
16716938|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.
~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
16716939|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.
~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
16716940|NCT01836575|Experimental|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle] + Antiemetic therapy at investigator's discretion.
16716941|NCT01836575|Active Comparator|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
16716942|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
16716943|NCT01836549|Experimental|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.
~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
16716944|NCT01836536|Other|BEVACIZUMAB|BEVACIZUMAB standard of care
16716945|NCT01836523|Experimental|Liraglutide 0.6 mg + insulin|
16716946|NCT01836523|Experimental|Liraglutide 1.2 mg + insulin|
16716947|NCT01836523|Experimental|Liraglutide 1.8 mg + insulin|
16716948|NCT01836523|Placebo Comparator|Liraglutide placebo 0.6 mg + insulin|
16716949|NCT01836523|Placebo Comparator|Liraglutide placebo 1.2 mg + insulin|
16716950|NCT01836523|Placebo Comparator|Liraglutide placebo 1.8 mg + insulin|
16716951|NCT01836484||Surgically staged endometrial and cervical carcinoma|
16716954|NCT01836471|Experimental|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
16716955|NCT01836471|Active Comparator|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
16716956|NCT01836471|Placebo Comparator|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
16716957|NCT01836458|Experimental|Dose 1: 30 mg|Single dose of KAE609 30 mg
16716958|NCT01836458|Experimental|Dose 2: 20 mg|Single dose of KAE609 20 mg
16716959|NCT01836458|Experimental|Dose 3: 10 mg|Single dose of KAE609 10 mg
16716960|NCT01836458|Experimental|Dose 4: 15 mg|Single dose of KAE609 15 mg
16716961|NCT01836445|Experimental|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
16716962|NCT01836445|Active Comparator|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
16716963|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy
~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.
~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.
~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.
~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.
~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
16716964|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57
~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest
~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy
~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine
~Ineligible for surgical resection & stable disease = continue FOLFIRINOX
~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
16716965|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy
~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.
~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.
~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.
~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.
~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
16716966|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone
~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71
~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days
~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy
~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine
~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest
~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
16716967|NCT01836419|Experimental|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
16716968|NCT01836419|Active Comparator|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
16716969|NCT01836406|Experimental|Keromin Group|
16716970|NCT01836406|Placebo Comparator|Placebo Group|
16716971|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
16716999|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 2)|Part A, Period 1. Participants will receive a single 20-mg oral dose of LY2409021 on Day 1.
16716972|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
16716973|NCT01836380|Experimental|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
16716974|NCT01836367|Experimental|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
16716975|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
16716976|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
16716977|NCT01836341|Experimental|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*
~*afatinib dose levels: 20mg daily, 30mg daily & 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
16716978|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.
~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.
~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.
~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
16716979|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.
~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.
~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.
~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
16716980|NCT01836315||Obese|Defined by a BMI >35 kg/M2
16716981|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
16716982|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
16716983|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
16716984|NCT01836289|Experimental|High-dose Cyclophosphamide|High-dose Cyclophosphamide
16716985|NCT01836276|Experimental|African American (AA) Smokers|AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
16716986|NCT01836276|Active Comparator|White Smokers|White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
16716987|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
16716988|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
16716989|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
16716990|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
16716991|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
16716992|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
16716993|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
16716994|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
16716995|NCT01836211|Experimental|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
16716996|NCT01836211|Active Comparator|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
16716997|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 1)|Part A, Period 1. Participants will receive a single 20-milligram (mg) oral dose of LY2409021 on Day 1.
16716998|NCT01836198|Experimental|LY2409021+Gemfibrozil (Part A, Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 mg gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20-mg oral dose of LY2409021 on Day 4.
16717000|NCT01836198|Experimental|LY2409021+Ketoconazole (Part A, Cohort 2)|Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
16717001|NCT01836198|Experimental|LY2409021+Clarithromycin (Part B)|Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
16717002|NCT01836185|Experimental|Evacetrapib (Healthy)|Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function
16717003|NCT01836185|Experimental|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
16717004|NCT01836185|Experimental|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
16717005|NCT01836185|Experimental|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
16717006|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
16717007|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
16717008|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
16717009|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
16717010|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
16717011|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
16717012|NCT01836146|Experimental|Renal Artery Ablation|
16717013|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
16717014|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
16717015|NCT01836120|Active Comparator|Docetaxel|
16717016|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
16717017|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
16717018|NCT01836081|Experimental|fluid responsiveness|
16717019|NCT01836068|Experimental|Enfuvirtide monotherapy|Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.
16717020|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
16717021|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
16717022|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
16717023|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
16717024|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
16717025|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
16717026|NCT01836029|Experimental|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.
~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.
~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.
~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
16717027|NCT01836029|Active Comparator|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.
~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.
~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.
~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
16717028|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
16717029|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
16717030|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
16717031|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
16717032|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
16717033|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
16717034|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
16717035|NCT01835977|Active Comparator|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
16717077|NCT01835678|Active Comparator|Linagliptin|Linagliptin
16717037|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
16717038|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
16717039|NCT01835951|Other|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
16717040|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:
~Dose level (DL) 1 = 50 mg / day,
~Dose level (DL) 2 = 100 mg / day, and
~Dose level (DL) 3 = 150 mg / day .
~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
16717041|NCT01835938|Placebo Comparator|placebo|
16717042|NCT01835925||Tissue specmien|
16717043|NCT01835912|Placebo Comparator|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
16717044|NCT01835912|Experimental|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
16717045|NCT01835912|Placebo Comparator|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
16717046|NCT01835912|Experimental|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
16717047|NCT01835899|Experimental|Placebo to BI 1015550|placebo
16717048|NCT01835899|Experimental|BI 1015550 low dose 1|powder for oral solution
16717049|NCT01835899|Experimental|BI 1015550 low dose 2|powder for oral solution
16717050|NCT01835899|Experimental|BI 1015550 medium dose 1|powder for oral solution
16717051|NCT01835899|Experimental|BI 1015550 medium dose 2|powder for oral solution
16717052|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
16717053|NCT01835873|Active Comparator|Lactated Ringer's|Crystalloid solution - 1000 ml preload
16717054|NCT01835873|Active Comparator|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
16717055|NCT01835860|Other|Embolization|Prostate artery embolization
16717056|NCT01835847|Experimental|A single-arm study|
16717057|NCT01835834|Experimental|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm** thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width [mm] / area [mm2])** of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm* wall thickness. The core is veneered with dental porcelain at the dental laboratory.
~Intended use and indications:
~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.
~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
16717058|NCT01835821|Experimental|prosthesis|"NobelProcera™ Crown shaded zirconia:
~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
16717059|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
16717060|NCT01835795|Active Comparator|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
16717061|NCT01835795|Placebo Comparator|Placebo|Swiss DolorClast® CLASSIC placebo applicator
16717062|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
16717063|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
16717064|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
16717065|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
16717066|NCT01835756|Active Comparator|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
16717067|NCT01835756|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
16717068|NCT01835743|Active Comparator|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
16717069|NCT01835743|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
16717070|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
16717071|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
16717072|NCT01835717||Cognitively normal individuals|
16717073|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
16717074|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
16717075|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
16717082|NCT01835639|Experimental|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
16717083|NCT01835626|Experimental|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
16717084|NCT01835613|Other|Tocilizumab|"Biomarkers Measures
~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
16717085|NCT01835600|Active Comparator|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
16717086|NCT01835600|Placebo Comparator|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
16717087|NCT01835587|Experimental|CC-486|Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
16717088|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
16717089|NCT01835561|Experimental|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
16717090|NCT01835561|Experimental|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
16717091|NCT01835548|Experimental|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
16717092|NCT01835548|Placebo Comparator|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
16717093|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
16717094|NCT01835509|Experimental|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
16717095|NCT01835509|No Intervention|Control, Newsletters|
16717096|NCT01835496|No Intervention|Ferriprox|single 1500 mg dose of Ferriprox
16717097|NCT01835470|Experimental|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
16717098|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
16717099|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
16717100|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
16717101|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
16717102|NCT01835431|Experimental|Insulin degludec/insulin aspart|
16717103|NCT01835431|Active Comparator|Insulin detemir|
16717104|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
16717105|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
16717106|NCT01835405|Active Comparator|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
16717107|NCT01835405|Active Comparator|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
16717108|NCT01835405|Active Comparator|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
16717109|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
16717110|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
16717111|NCT01835379|Experimental|Oasis|Oasis
16717112|NCT01835379|Other|Standard|Standard Care
16717113|NCT01835353|Experimental|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
16717114|NCT01835353|Active Comparator|Prasugrel 60mg loading dose|
16717115|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
16717116|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
16717117|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
16717118|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
16717119|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
16717193|NCT01834781|Placebo Comparator|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
16717194|NCT01834768|Experimental|A|Eplerenone
16717120|NCT01835288|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16717121|NCT01835275|Experimental|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
16717122|NCT01835275|Active Comparator|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
16717123|NCT01835275|No Intervention|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
16717124|NCT01835262|Active Comparator|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
16717125|NCT01835262|Experimental|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
16717126|NCT01835249|Experimental|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP <120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP <120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
16717127|NCT01835249|Active Comparator|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP <130 mmHg @ 1 visit; <135 mmHg @ 2 consecutive visits.
16717128|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
16717129|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
16717130|NCT01835223|Experimental|Treatment (tivozanib - 1 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16717131|NCT01835223|Experimental|Treatment (tivozanib - 1.5 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16717132|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
16717133|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
16717134|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
16717135|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
16717136|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
16717137|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
16717138|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
16717139|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
16717140|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
16717141|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
16717142|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
16717143|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16717144|NCT01835158|Active Comparator|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16717145|NCT01835158|Active Comparator|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
16717146|NCT01835145|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
16717147|NCT01835145|Experimental|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
16717148|NCT01835132|Experimental|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
16717149|NCT01835119|Experimental|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.
~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
16717150|NCT01835119|No Intervention|control group|no gum
16717151|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
16717152|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
16717153|NCT01835093|Experimental|A single-arm study|
16717154|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
16717155|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
16717156|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
16717157|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
16717191|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT
~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
16717159|NCT01835041|Experimental|Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
16717160|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:
~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
16717161|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:
~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
16717162|NCT01835015|Experimental|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
16717163|NCT01835015|Experimental|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
16717164|NCT01835015|Experimental|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
16717165|NCT01835015|Experimental|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
16717166|NCT01835015|Experimental|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
16717167|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
16717168|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
16717169|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
16717170|NCT01834963|Experimental|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks
~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
16717171|NCT01834963|Experimental|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks
~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
16717172|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
16717173|NCT01834924|Active Comparator|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
16717174|NCT01834924|No Intervention|Control|Standard provider medication counseling
16717175|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
16717176|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
16717177|NCT01834885|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
16717178|NCT01834885|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
16717179|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
16717180|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
16717181|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
16717182|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
16717183|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
16717184|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
16717185|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
16717186|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
16717187|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
16717188|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
16717189|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
16717190|NCT01834807||Cohort|
16717192|NCT01834781|Active Comparator|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
16717195|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
16717196|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
16717197|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
16717198|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
16717199|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
16717200|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
16717201|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
16717202|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
16717203|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
16717204|NCT01834729|Experimental|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.
~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
16717205|NCT01834729|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
16717206|NCT01834716|Experimental|Aerobics exercise|Participants in this group will be randomized to aerobics exercise (the equivalent of walking briskly for 50 minutes three times per week).
16717207|NCT01834716|Experimental|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics (attending classes of toning and stretching a minimum of three times per week) exercise group.
16717208|NCT01834703|Active Comparator|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
16717209|NCT01834703|Active Comparator|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
16717210|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
16717211|NCT01834677||Healthy Human|
16717212|NCT01834677||Depressed Human|
16717213|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
16717214|NCT01834677||Human Diagnosed with Parkinson's Disease|
16717215|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
16717216|NCT01834651|Experimental|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
16717217|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
16717218|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
16717219|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
16717220|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
16717221|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
16717222|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
16717223|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
16717224|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:
~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
16717225|NCT01834586|Other|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.
~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
16717226|NCT01834573|Active Comparator|Intervention|Patients of the intervention arm receive a 10 week exercise program
16717227|NCT01834573|No Intervention|Control|Patients of the control arm do not participate in exercise
16717228|NCT01834547|Experimental|Methylphenidate|Methylphenidate
16717229|NCT01834547|Experimental|modafinil|modafinil
16717230|NCT01834547|Experimental|caffeine|caffeine
16717231|NCT01834547|Placebo Comparator|placebo|placebo
16717232|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
16717233|NCT01834534|No Intervention|Usual care|Usual medical care.
16717234|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
16717235|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
16717236|NCT01834508|Other|Treatment group|
16717237|NCT01834495|Experimental|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
16754466|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
16717239|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
16717240|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
16717241|NCT01834469|Other|ICG NIR imaging|see Summary and description iv injection of ICG
16717242|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.
~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
16717243|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.
~The control group will continue to receive usual care as they did before they enrolled in this study"
16717244|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
16717245|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
16717246|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
16717247|NCT01834430|Experimental|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
16717248|NCT01834430|No Intervention|parenteral nutrient group|
16717249|NCT01834404|Experimental|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
16717250|NCT01834404|Placebo Comparator|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
16717251|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
16717252|NCT01834378|No Intervention|No intervention|
16717253|NCT01834378|Experimental|Low intensity intervention|
16717254|NCT01834378|Experimental|High intensity intervention|
16717255|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
16717256|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
16717257|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
16717258|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
16717259|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
16717260|NCT01834339|Active Comparator|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
16717261|NCT01834339|Experimental|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
16717262|NCT01834326|Active Comparator|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
16717263|NCT01834326|Experimental|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
16717264|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
16717265|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
16717266|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
16717267|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
16718438|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
16717268|NCT01834274|Experimental|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
16717269|NCT01834274|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
16717270|NCT01834261|Active Comparator|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
16717271|NCT01834261|Placebo Comparator|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
16717272|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16717273|NCT01834235|Active Comparator|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
16717274|NCT01834235|Experimental|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
16717275|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
16717276|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
16717277|NCT01834183|Experimental|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
16717278|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
16717279|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
16717280|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
16717281|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
16717282|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
16717283|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
16717284|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
16717285|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
16717286|NCT01834144|Active Comparator|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
16717287|NCT01834144|Active Comparator|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
16717288|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
16717289|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.
~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.
~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
16717290|NCT01834105|Experimental|Liuwei Dihuang Pills|
16717291|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
16717292|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
16717293|NCT01834079|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
16717294|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
16717295|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
16717296|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
16717297|NCT01834027|Experimental|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
16717298|NCT01834027|Active Comparator|No music|The patients in this group with have headphones but no music will be played.
16717299|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
16717300|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
16717301|NCT01834001||1/Untreated prostate cancer|Patients with untreated prostate cancer
16717302|NCT01834001||2/Radiotherapy treated prostate cancer|Patients with prostate cancer who have already received definitive radiotherapy and have experienced biochemical failure
16717303|NCT01833988|Experimental|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
16717304|NCT01833988|Active Comparator|Usual Care|Usual Care
16717305|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
16717306|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
16717343|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
16718476|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
16717307|NCT01833949|Active Comparator|ULOD arm (N=49)|"Unilateral laparoscopic drilling
~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:
~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
16717308|NCT01833949|Active Comparator|BLOD arm (N=47)|"Bilateral laparoscopic drilling
~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).
~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
16717309|NCT01833936|Active Comparator|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
16717310|NCT01833936|Sham Comparator|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
16717311|NCT01833923|Experimental|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
16717312|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
16717313|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
16717314|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
16717315|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
16717316|NCT01833897|Experimental|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
16717317|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
16717318|NCT01833871|Experimental|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
16717319|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
16717320|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
16717321|NCT01833845|Experimental|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
16717322|NCT01833832|Experimental|Cytoreductive surgery followed by HIPEC|Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
16717323|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
16717324|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
16717325|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
16717326|NCT01833793||Group 1|
16717327|NCT01833780||GBS carriage status|
16717328|NCT01833780||GBS status during labor|
16717329|NCT01833767|Experimental|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
16717330|NCT01833754|Experimental|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
16717331|NCT01833754|Experimental|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
16717332|NCT01833754|Experimental|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
16717333|NCT01833741|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
16717334|NCT01833728|Experimental|nefopam-propacetamol combination group|
16717335|NCT01833728|Active Comparator|propacetamol alone group|
16717336|NCT01833715|Active Comparator|Morphine|morphine group 0.08 mg / kg, to start surgery
16717337|NCT01833715|Experimental|Methadone|methadone group 0.08 mg / kg, to start surgery
16717338|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
16717339|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
16717340|NCT01833689|Placebo Comparator|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
16717341|NCT01833689|Active Comparator|food consumption: product|The test food will provide 50g of available carbohydrate
16717342|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
16754712|NCT01580527|Experimental|Early enteral nutrition|
16717344|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
16717345|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
16717346|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
16717347|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
16717348|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
16717349|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
16717350|NCT01833637|No Intervention|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
16717351|NCT01833637|Active Comparator|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
16717352|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
16717353|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
16717354|NCT01833611|Experimental|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
16717355|NCT01833611|Placebo Comparator|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
16717356|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
16717357|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
16717358|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
16717359|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
16717360|NCT01833559|Other|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
16717361|NCT01833559|Other|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
16717362|NCT01833559|Other|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
16717363|NCT01833546|Experimental|Evofosfamide 240 mg|
16717364|NCT01833546|Experimental|Evofosfamide 340 mg|
16717365|NCT01833546|Experimental|Evofosfamide 480 mg|
16717366|NCT01833546|Experimental|Evofosfamide 340 mg + Gemcitabine|
16717367|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
16717368|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
16717369|NCT01833520|Experimental|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.
~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
16717370|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
16717371|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
16717372|NCT01833494|Experimental|PA21|
16717373|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
16717374|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
16717375|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
16718477|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
16717376|NCT01833455|Placebo Comparator|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
16717377|NCT01833455|Placebo Comparator|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
16717378|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
16717379|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
16717380|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
16717381|NCT01833403|Other|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
16717382|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
16717383|NCT01833377|Experimental|caraway sample|caraway sample
16717384|NCT01833377|Active Comparator|Placebo|
16717385|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
16717386|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
16717387|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
16717388|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
16717389|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
16717390|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
16717391|NCT01833312|No Intervention|Control|Best medical treatment
16717392|NCT01833299|Active Comparator|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
16717393|NCT01833299|Experimental|TACE+sorafinib|TACE+sorafinib
16717394|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
16717395|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
16717396|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
16717397|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
16717398|NCT01833260|No Intervention|Without music|
16717399|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
16717400|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
16717401|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
16717402|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
16717403|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
16717404|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
16717405|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
16717406|NCT01833169|Experimental|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
16717407|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
16717441|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
16754803|NCT01579825|No Intervention|Control|
16717408|NCT01833143|Experimental|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
16717409|NCT01833130|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
16717410|NCT01833130|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
16717411|NCT01833117|Experimental|FID 119515A|FID 119515A, 1 drop instilled in the study eye, single dose
16717412|NCT01833117|Active Comparator|Blink|Blink® Tears, 1 drop instilled in the study eye, single dose
16717413|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
16717414|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
16717415|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
16717416|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
16717417|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
16717418|NCT01833091|Experimental|intervention|creat light period 12 hours with cover on incubator
16717419|NCT01833091|No Intervention|control|
16717420|NCT01833078|Other|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
16717421|NCT01833065|Experimental|EBX 10|Elobixibat 10 mg/day
16717422|NCT01833065|Experimental|EBX 5|Elobixibat 5 mg/day
16717423|NCT01833065|Placebo Comparator|PLCBO|Placebo
16717424|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
16717425|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
16717426|NCT01833026|Experimental|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.
~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
16717427|NCT01833026|Placebo Comparator|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.
~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
16717428|NCT01833013|Other|endometriosis cohort|females suffer from endometriosis
16717429|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
16717430|NCT01832987|Experimental|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
16717431|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
16717432|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
16717433|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
16717434|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
16717435|NCT01832961|Experimental|flutter valve exercises|30 minutes of breathing exercises with flutter device
16717436|NCT01832961|Sham Comparator|flutter-sham exercises|30 minutes of breathing exercise with flutter-sham device
16717437|NCT01832948|Experimental|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
16717438|NCT01832935|Active Comparator|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
16717439|NCT01832935|Active Comparator|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
16717440|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
16717857|NCT01830205|Experimental|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
16717442|NCT01832909|Experimental|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
16717443|NCT01832909|Experimental|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
16717444|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:
~Single dose of ecallantide subcutaneous dosing:
~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.
~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
16717445|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
16717446|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.
~Amblyopia:
~VA <20/40 and 2 logMAR lines difference in normal eye
~Mild amblyopia (>20/40)
~Moderate amblyopia (20/40 and <20/100)
~Severe amblyopia (≥20/100 or worse)
~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.
~Strabismus:
~Constant: >2 PD at near and or distance.
~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.
~Amblyogenic factor categorization:
~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.
~'hypermetropia' (≥3.5 D),
~'myopia' (≥-4.0 D),
~'astigmatism' (≥1.5 D).
~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
16717447|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
16717448|NCT01832870|Experimental|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
16717449|NCT01832857|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
16717450|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
16717451|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
16717452|NCT01832831||Continent Men|
16717453|NCT01832831||Incontinent Men|
16717454|NCT01832818|Experimental|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
16717455|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
16717456|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
16717457|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
16717458|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
16717459|NCT01832766|Active Comparator|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
16717460|NCT01832766|Placebo Comparator|sugar pill|one capsule given by mouth at 8:00 a.m.
16717461|NCT01832753|Placebo Comparator|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.
~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
16717462|NCT01832753|No Intervention|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.
~Subjects that have TSH >10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
16717463|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
16717464|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
16717465|NCT01832727|Experimental|Cohort 180 mg 5/14 Schedule (Phase 1b)|Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717466|NCT01832727|Experimental|Cohort 210 mg 5/14 Schedule (Phase 1b)|"Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
~This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
16717606|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
16717467|NCT01832727|Experimental|Cohort 150/180 mg 5/14 Schedule (Phase 1b)|Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward. Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717468|NCT01832727|Experimental|Cohort 210 mg 2/7 Schedule (Phase 1b)|"Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
~This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
16717469|NCT01832727|Experimental|Cohort 240 mg 2/7 Schedule (Phase 1b)|Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717470|NCT01832727|Experimental|Cohort 270 mg 2/7 Schedule (Phase 1b)|Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717471|NCT01832727|Experimental|Cohort 300 mg 2/7 Schedule (Phase 1b)|Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717472|NCT01832727|Experimental|Cohort 330 mg 2/7 Schedule (Phase 1b)|Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717473|NCT01832727|Experimental|Phase 2 300 mg 2/7 Schedule|The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
16717474|NCT01832714||mTBI|Subjects who undergo an mTBI event
16717475|NCT01832714||Control|Subjects who do not undergo an mTBI
16717476|NCT01832701|Experimental|coffee|4 cups of soluble coffee per day (2.5g per cup)
16717477|NCT01832701|Placebo Comparator|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
16717478|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
16717479|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
16717480|NCT01832675|Active Comparator|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
16717481|NCT01832675|Active Comparator|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
16717482|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
16717483|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
16717484|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
16717485|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
16717486|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
16717487|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
16717488|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
16717489|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
16717490|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
16717491|NCT01832623|Experimental|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
16717492|NCT01832610||HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
16717493|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
16717494|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
16717495|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
16717496|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
16717497|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
16717498|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
16717499|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
16754804|NCT01579812|Experimental|Metformin|
16717500|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
16717501|NCT01832532|Experimental|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
16717502|NCT01832532|No Intervention|Control group|Control group
16717503|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
16717504|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
16717505|NCT01832506|Experimental|MSC2156119J|
16717506|NCT01832493|Experimental|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
16717507|NCT01832480|Active Comparator|MTZ 2 g|Single dose MTZ
16717508|NCT01832480|Experimental|MTZ 500 mg twice daily x 7 days|Multi dose MTZ
16717509|NCT01832467|Experimental|cetuximab-containing chemotherapy|"Cetuximab may be given at either one of the following schedules at the investigator's discretion:
~2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.
~Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.
~Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.
~Regimens to be combined with biweekly cetuximab:
~Irinotecan at 2-weekly schedule.
~FOLFIRI (as inpatient or via ambulatory pump).
~FOLFOX (as inpatient or via ambulatory pump)."
16717510|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
16717511|NCT01832441|Other|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
16717512|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
16717513|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
16717514|NCT01832402|Experimental|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
16717515|NCT01832402|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
16717516|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
16717517|NCT01832389|No Intervention|Group C|control group
16717518|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
16717519|NCT01832363|Experimental|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
16717520|NCT01832363|Active Comparator|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
16717521|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
16717522|NCT01832337|Experimental|precondition|
16717523|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
16717524|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
16717525|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup not receiving topical ketorolac."
16717526|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup not receiving topical ketorolac."
16717527|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
16717528|NCT01832285|Experimental|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
16717529|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
16717530|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
16717531|NCT01832259|Placebo Comparator|Placebo arm|Participants receiving placebo
16717532|NCT01832259|Experimental|Pazopanib arm|Participants receiving Pazopanib
16717533|NCT01832233|Experimental|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
16717534|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
16717535|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
16717536|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
16717537|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
16717538|NCT01832207|Active Comparator|MTS|Motor threshold of stimulation
16717539|NCT01832207|Active Comparator|STS|Sensorial threshold of stimulation
16717540|NCT01832207|Sham Comparator|Placebo|
16717541|NCT01832194|Experimental|Botox|"Botox:
~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
16717542|NCT01832181||Metformin|
16717543|NCT01832181||Control|
16717544|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
16717545|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
16717546|NCT01832155|Experimental|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
16717547|NCT01832155|Other|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
16717548|NCT01832129|Active Comparator|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
16717549|NCT01832129|Experimental|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
16717550|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
16717551|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
16717552|NCT01832090|Experimental|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
16717553|NCT01832090|Active Comparator|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
16717554|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
16717555|NCT01832077||grader|grade fundus pictures in ZOC
16717556|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
16717557|NCT01832051|Experimental|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
16717558|NCT01832038|Experimental|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
16717559|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
16717560|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
16717561|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
16717562|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
16717563|NCT01832012|No Intervention|No intervention|Group 2
16717564|NCT01831999|Experimental|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
16717565|NCT01831999|No Intervention|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
16717566|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
16717567|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
16717568|NCT01831973|Experimental|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
16717569|NCT01831960|Experimental|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
16717570|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
16717571|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
16717572|NCT01831934|Experimental|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
16717573|NCT01831934|Experimental|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
16717638|NCT01831531|Experimental|S-1|"Patients will receive chemoradiation with S-1.
~Interventions:
~Drug: S-1 Radiation: Radiation therapy"
16717574|NCT01831921|Experimental|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
16717575|NCT01831921|Active Comparator|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
16717576|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
16717577|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
16717578|NCT01831895|Experimental|MobiusHD™|MobiusHD™
16717579|NCT01831882||Major Depressive Disorder|
16717580|NCT01831882||Healthy Control|
16717581|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
16717582|NCT01831869|No Intervention|blank|no intervention
16717583|NCT01831856|Experimental|F373280|
16717584|NCT01831856|Placebo Comparator|Placebo|
16717585|NCT01831843|Placebo Comparator|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
16717586|NCT01831843|Experimental|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
16717587|NCT01831843|Experimental|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
16717588|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
16717589|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
16717590|NCT01831817|Experimental|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
16717591|NCT01831817|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
16717592|NCT01831817|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
16717593|NCT01831817|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
16717594|NCT01831804|Experimental|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
16717595|NCT01831804|Experimental|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
16717596|NCT01831804|Experimental|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
16717597|NCT01831804|Experimental|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
16717598|NCT01831804|Experimental|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
16717599|NCT01831804|Experimental|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
16717600|NCT01831804|Experimental|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
16717601|NCT01831791|Experimental|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
16717602|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
16717603|NCT01831765|Experimental|Meal time FIAsp and insulin detemir|
16717604|NCT01831765|Active Comparator|Meal time insulin aspart and insulin detemir|
16717605|NCT01831765|Experimental|Post meal FIAsp and insulin detemir|
16717639|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
16717607|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
16717608|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
16717609|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
16717610|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
16717611|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
16717612|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
16717613|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
16717614|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
16717615|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
16717616|NCT01831726|Experimental|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
16717617|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
16717618|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
16717619|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
16717620|NCT01831687|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
16717621|NCT01831687|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
16717622|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
16717623|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
16717624|NCT01831661|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
16717625|NCT01831661|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
16717626|NCT01831648|Experimental|Volonteers|Blood sample
16717627|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.
~Exclusion Criteria
~younger than 18 years old.
~where the clinician/General Practitioner (GP) does not provide consent.
~incapable of giving informed consent.
~physically or cognitively incapable of completing the questionnaire.
~too ill to participate."
16717628|NCT01831635||General Practice Control|"For each MPN case one GP control will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.
~The following patient groups will be excluded. Those:
~younger than 18 years old.
~where the clinician/GP does not provide consent.
~incapable of giving informed consent.
~physically or cognitively incapable of completing the questionnaire.
~too ill to participate. The WHO performance evaluation scale will be used at the stage of participant identification. Only those scoring 0-3 will be considered eligible for inclusion in the study. Those scoring 3 are described as Symptomatic >50% in bed but not bedbound."
16717629|NCT01831635||Non-blood relative or family control|Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.
16717630|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.
~Day 1:
~Patient arrives having abstained medication for minimum 20 hours.*
~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*
~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment.*
~Day 2:
~Patient arrives having abstained medication for a minimum of 20 hours.*
~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*
~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment.*"
16717631|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.
~Day 1:
~Patient arrives having abstained medication for minimum 20 hours.*
~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*
~CRF 2, Adult ASRS and WAIS subtests.
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*
~Day 2 (after 14 - 40 days):
~Patient arrives having abstained medication for a minimum of 20 hours.*
~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*
~CRF 3, ASRS and EHI.
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment.*"
16717632|NCT01831596|Experimental|ciSNaP|
16717633|NCT01831583|Experimental|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
16717634|NCT01831583|Experimental|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
16717635|NCT01831570|Other|symptomatic and radiographic hand osteoarthritis|Patients above 35-years old with symptomatic and radiographic hand osteoarthritis
16717636|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
16717637|NCT01831544|Experimental|MVAD® Pump|Implant of HeartWare MVAD® System
16717640|NCT01831505|Experimental|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
16717641|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
16717642|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
16717643|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
16717644|NCT01831466|Experimental|Treatment Group A|
16717645|NCT01831466|Experimental|Treatment Group B|
16717646|NCT01831466|Placebo Comparator|Treatment Group C|
16717647|NCT01831466|Experimental|Treatment Group D|
16717648|NCT01831466|Experimental|Treatment Group E|
16717649|NCT01831466|Placebo Comparator|Treatment Group F|
16717650|NCT01831453|Placebo Comparator|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
16717651|NCT01831453|Active Comparator|experimental|omega-3 1 gram three times daily for 6 months
16717652|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
16717653|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
16717654|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)|Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.
16717655|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (SAD)|Participants will receive andecaliximab 1.0 mg/kg on Day 1.
16717656|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (SAD)|Participants will receive andecaliximab 2.5 mg/kg on Day 1.
16717657|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (SAD)|Participants will receive andecaliximab 5.0 mg/kg on Day 1.
16717658|NCT01831427|Placebo Comparator|Placebo Pooled (SAD)|Participants will receive placebo on Day 1.
16717659|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)|Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.
16717660|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (MAD)|Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
16717661|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (MAD)|Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
16717662|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (MAD)|Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
16717663|NCT01831427|Experimental|Andecaliximab 150 mg SC (Adaptive MAD)|Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
16717664|NCT01831427|Placebo Comparator|Placebo Pooled (MAD)|Participants will receive placebo on Days 1, 15, and 29.
16717665|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
16717666|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
16717667|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
16717668|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
16717669|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
16717670|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
16717671|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
16717672|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
16717673|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
16717674|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
16717675|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
16717676|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
16717677|NCT01831375|Experimental|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
16717678|NCT01831375|Other|Get Connected|Attention control group
16717679|NCT01831362|Experimental|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
16717680|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
16717681|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
16717682|NCT01831336||Orsiro DES|
16717858|NCT01830205|Experimental|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
16717683|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
16717684|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
16717685|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
16717686|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
16717687|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
16717688|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
16717689|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
16717690|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
16717691|NCT01831297||syncope|
16717692|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
16717693|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
16717694|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
16717695|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
16717696|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
16717697|NCT01831258|Experimental|SensAwake On|The comfort feature 'SensAwake' will be turned on
16717698|NCT01831258|Active Comparator|SensAwake Off|The comfort feature 'SensAwake' will be turned off
16717699|NCT01831232|Experimental|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
16717700|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
16717701|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
16717702|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
16717703|NCT01831206|No Intervention|standard treatment|Standard treatment alone
16717704|NCT01831193|Active Comparator|Diabetic|
16717705|NCT01831193|Active Comparator|Non-diabetic|
16717706|NCT01831180||Premenopausal women 19-25 yrs|
16717707|NCT01831180||Postmenopausal 60 yrs +|
16717708|NCT01831167|Experimental|dynamic light|dynamic light
16717709|NCT01831167|No Intervention|reference|normal light
16717710|NCT01831154|Experimental|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
16717711|NCT01831154|Experimental|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
16717712|NCT01831154|Experimental|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
16717713|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
16717714|NCT01831128||Control|No ASV treatment
16717715|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
16717716|NCT01831102||Mexican American|Mexican American ancestry
16717717|NCT01831089|Experimental|Treatment|PM01183 + paclitaxel +/- bevacizumab
16717790|NCT01830686|Experimental|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
16717718|NCT01831076|Active Comparator|Treatment (exemestane, surgery)|Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
16717719|NCT01831076|Experimental|treatment (exemestane, tamoxifen, surgery)|Patients receive exemestane plus tamoxifen orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
16717720|NCT01831063|No Intervention|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
16717721|NCT01831063|Experimental|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
16717722|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
16717723|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
16717724|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
16717725|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
16717726|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
16717727|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
16717728|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
16717729|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
16717730|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
16717731|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
16717732|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
16717733|NCT01831024|Experimental|Treatment Group|Dignicap System
16717734|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
16717735|NCT01831011|Experimental|mildronate|infusion of mildronate
16717736|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
16717737|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
16717738|NCT01830998||control, MCI|control and MCI group.Glycaemic control
16717739|NCT01830998||control and MCI|treatment and without treatment
16717740|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
16717741|NCT01830985|Experimental|Single Arm VX-509|
16717742|NCT01830972|Experimental|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:
~Part I: participants continued on 6 g/day SA-ER for 12 weeks
~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day [QID]) for 36 months
~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)
~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
16717743|NCT01830972|Experimental|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:
~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months
~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)
~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
16717744|NCT01830959|Experimental|Roflumilast|Roflumilast
16717745|NCT01830959|Placebo Comparator|Placebo|Placebo
16717746|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
16717747|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
16717748|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
16717784|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
~Intervention: Multi-port hysterectomy"
16717785|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of > 7.2 mg/dl) and/or gout.
16717786|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
16717787|NCT01830712||Chart review|
16717788|NCT01830699|Active Comparator|Rilonacept|160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
16717749|NCT01830933|Experimental|BreastCARE Intervention|"Intervention Clinic Patients: The RA will welcome the patient upon arrival at the clinic and again explain study procedures and field any questions. The RA will have the patient sign the HIPAA authorization form and then demonstrate how to enter information and answer questions on the tablet-PC and the patient will indicate their consent electronically before beginning the assessment.
~Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patietns before she meets with her doctor."
16717750|NCT01830933|No Intervention|BreastCARE Comparison|"Patients will be randomized into the intervention or comparison groups at the time of recruitment. Block-randomization will be used to assign patients to intervention or comparison groups.
~Comparison Clinic Patients. Contact and baseline interview procedures will be the same for patients from the comparison clinics, however there will be no computer assessment at the time of their clinic visit. An RA will meet the patient 10 minutes prior to her appointment time to obtain written HIPAA authorization."
16717751|NCT01830920|Placebo Comparator|Placebo|An identical appearing placebo will be administered.
16717752|NCT01830920|Experimental|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
16717753|NCT01830920|Experimental|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
16717754|NCT01830920|Experimental|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
16717755|NCT01830920|Experimental|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses ~80% of the pre-surgery dose.
16717756|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
16717757|NCT01830907|Active Comparator|Parenteral|
16717758|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
16717759|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
16717760|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
16717761|NCT01830881|Placebo Comparator|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
16717762|NCT01830881|Active Comparator|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
16717763|NCT01830868||Zonisamide tablets|
16717764|NCT01830855|Experimental|rLP2086 lot 1|
16717765|NCT01830855|Experimental|rLP2086 lot 2|
16717766|NCT01830855|Experimental|rLP2086 lot 3|
16717767|NCT01830855|Active Comparator|Control|Havrix (HAV) and Saline
16717768|NCT01830842|Placebo Comparator|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
16717769|NCT01830842|Other|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
16717770|NCT01830829|Experimental|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
16717771|NCT01830829|Placebo Comparator|Placebo|Placebo
16717772|NCT01830816|Experimental|Normal Renal Function: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
16717773|NCT01830816|Experimental|Severe Renal Impairment: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
16717774|NCT01830816|Experimental|End-stage Renal Disease: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
16717775|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
16717776|NCT01830790|Active Comparator|Healthy Controls|Healthy individuals >65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
16717777|NCT01830790|Experimental|AMD patients|Age-related macular degeneration (AMD) patients >65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
16717778|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
16717779|NCT01830764|Other|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
16717780|NCT01830764|Other|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
16717781|NCT01830751|Experimental|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
16717782|NCT01830751|Sham Comparator|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
16717783|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
~Intervention: Single-port, peri-umbilical hysterectomy"
16717791|NCT01830686|Active Comparator|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
16717792|NCT01830686|Placebo Comparator|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
16717793|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
16717794|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
16717795|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
16717796|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
16717797|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
16717798|NCT01830647||Cohort|
16717799|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
16717800|NCT01830621|Active Comparator|BBI608|BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care
16717801|NCT01830621|Placebo Comparator|Placebo|Placebo two times daily + Best Supportive Care
16717802|NCT01830608||300 patients with AMD|
16717803|NCT01830595|Active Comparator|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
16717804|NCT01830595|Placebo Comparator|Placebo|Matched placebo will be administered by mouth twice daily
16717805|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
16717806|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
16717807|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
16717808|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
16717809|NCT01830569|Experimental|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
16717810|NCT01830569|Other|Control group|The regular Evidence Linker will be available in this group.
16717811|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
16717812|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
16717813|NCT01830543|Experimental|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
16717814|NCT01830543|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
16717815|NCT01830543|Experimental|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
16717816|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
16717817|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
16717818|NCT01830517|Experimental|amlodipine camsylate|amlodipine camsylate 5mg
16717819|NCT01830517|Active Comparator|losartan potassium|losartan potassium 50mg
16717820|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
16717821|NCT01830491|Experimental|Clopidogrel napadisilate|aspirin 100mg
16717822|NCT01830491|Active Comparator|clopidogrel bisulfate|aspirin 100mg
16717823|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
16717824|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
16717825|NCT01830452|Experimental|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
16717826|NCT01830452|Active Comparator|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
16754805|NCT01579799|Active Comparator|Dose 0.5|
16717827|NCT01830439|Experimental|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
16717828|NCT01830439|Experimental|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
16717829|NCT01830439|Experimental|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
16717830|NCT01830439|Experimental|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
16717831|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
16717832|NCT01830400||Eslicarbazepine Acetate tablets|
16717833|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
16717834|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
16717835|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
16717836|NCT01830361|Experimental|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
16717837|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
16717838|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
16717839|NCT01830335|Experimental|Drug|Indomethacin 1.2 mg kg 1 dose
16717840|NCT01830335|Placebo Comparator|Placebo|flour capsule
16717841|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
16717842|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
16717843|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
16717844|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
16717845|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
16717846|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
16717847|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
16717848|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
16717849|NCT01830283|Active Comparator|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
16717850|NCT01830283|Experimental|2 dose varicella vaccine|The provider never get the varicella vaccine
16717851|NCT01830270|Experimental|PET regimen|
16717852|NCT01830257|Experimental|sending message|The investigators would send the tip to the children's guardian
16717853|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.
~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
16717854|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
16717855|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:
~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation
~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,
~250 mg/m2 in patients aged >80 years."
16717856|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
16754806|NCT01579799|Active Comparator|Dose 7.5|
16717859|NCT01830205|Experimental|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
16717860|NCT01830205|Experimental|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
16717861|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
16717862|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
16717863|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
16717864|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
16717865|NCT01830140|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
16717866|NCT01830140|Active Comparator|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
16717867|NCT01830127|Experimental|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
16717868|NCT01830127|Experimental|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
16717869|NCT01830114|Experimental|Web app evaluation group|
16717870|NCT01830101|Experimental|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
16717871|NCT01830101|Experimental|TMZ alone|TMZ alone
16717872|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
16717873|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
16717874|NCT01830075|No Intervention|Control group|The control group receives care as usual.
16717875|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
16717876|NCT01830062|Experimental|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
16717877|NCT01830049||Group I|Older males with ED
16717878|NCT01830049||Group II|Older males with normal erectile function
16717879|NCT01830049||Gourp III|Young males with normal rectile function
16717880|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
16717881|NCT01830023||cardiac ultrasound examination|
16717882|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
16717883|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
16717884|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
16717885|NCT01829997|Experimental|nanOss Bioactive 3D BVF|Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
16717886|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
16717887|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
16717888|NCT01829971|Experimental|MRX34|Single agent MRX34
16717889|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
16717890|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
16717891|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
16754807|NCT01579799|Active Comparator|Dose 3|
16717892|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
16717893|NCT01829919|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.
16717894|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
16717895|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
16717896|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
16717897|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
16717898|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
16717899|NCT01829867|Experimental|sNN0031|
16717900|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
16717901|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
16717902|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
16717903|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
16717904|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
16717905|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
16717906|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
16717907|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
16717908|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
16717909|NCT01829776|Experimental|education|Educational intervention
16717910|NCT01829763|Experimental|botox|
16717911|NCT01829750|Sham Comparator|Control|"(Stage 1) No active intervention after standard surgical treatment
~(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1."
16717912|NCT01829750|Active Comparator|Cardiac progenitor cell infusion|(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells
16717915|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
16717916|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
16717917|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
16717918|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
16717919|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
16717920|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
16717921|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
16717922|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
16717923|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
16717924|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
16717925|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
16717926|NCT01829607|Placebo Comparator|Placebo|
16717927|NCT01829594|Experimental|Case Management|
16717928|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
16717929|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and once weekly at weeks 13, 21, 29, and 37.
16717930|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
16717931|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
16717932|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
16717933|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
16717934|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
16717935|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
16717936|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
16717937|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
16717938|NCT01829516|Experimental|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
16717939|NCT01829516|Placebo Comparator|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.
~NOTE: This is a cross-over design and subjects will participate in both arms."
16717940|NCT01829503|Experimental|decitabine and cytarabine|
16717941|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
16717942|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
16717943|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
16717944|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
16717945|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
16717946|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
16717947|NCT01829464|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
16717948|NCT01829464|Experimental|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
16717949|NCT01829464|Experimental|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
16717950|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
16717951|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
16717952|NCT01829438|No Intervention|Without music|6MWT without music
16717953|NCT01829438|Experimental|With fast music|6MWT with a fast music
16717954|NCT01829438|Experimental|With slow music|6MWT with a slow music
16717955|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
16717956|NCT01829425|Active Comparator|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
16717957|NCT01829425|Active Comparator|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
16717958|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:
~Patients at first-line treatment for MM:
~Within 15 days before the start of the treatment
~Within one month after the end of the first-line treatment
~Six (6) months after the end of the first-line treatment
~Patients at relapse after disease response (CR or PR) lasting at least 6 months
~At relapse
~Within 15 days after the end of the treatment of relapse
~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
16717959|NCT01829399|Experimental|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
16717960|NCT01829399|Sham Comparator|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
16717961|NCT01829386||Non heme iron levels on MRI|"Intervention: MRI scans To develop a reliable MR based measurement of Non-heme iron in brain tissue of patients with hemorrhagic stroke : on day 3, 14 and 30 after stroke to assess the non heme iron levels on MRI.
~To evaluate the role of iron chelators following a hemorrhagic stroke/parenchymal hemorrhage."
16717962|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
16717963|NCT01829360|Experimental|Standard then Alternative: High Dose|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose (dose 9 x dose frequency 4)
16717964|NCT01829360|Experimental|Alternative: High Dose then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose (dose 9 x dose frequency 4) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
16717965|NCT01829360|Experimental|Alternative: High Dose Frequency then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
16717966|NCT01829360|Experimental|Standard then Alternative: High Dose Frequency|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9)
16717967|NCT01829347|Experimental|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
16754808|NCT01579799|Active Comparator|Dose 1.2|
16717968|NCT01829347|Other|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
16717969|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
16717970|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
16717971|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
16717972|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
16717973|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
16717974|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
16717975|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
16717976|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
16717977|NCT01829295|Experimental|Methotrexate|oral methotrexate
16717978|NCT01829295|Experimental|Mycophenolate Mofetil|oral mycophenolate mofetil
16717979|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:
~Provide HIV and STI test results
~First Interview
~Attend 8 sessions - 1 session per week
~Second interview occurs immediately following the 8th session with HIV and STI tests
~Third interview occurs 3 months after the 8th session with HIV and STI tests"
16717980|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.
~Provide HIV and STI test results
~First Interview
~No sessions for 8 weeks
~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled
~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.
~Attend 8 sessions - 1 session per week
~Fourth interview occurs immediately after the 8th session with HIV and STI tests
~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
16717981|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
16717982|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
16717983|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
16717984|NCT01829243|Experimental|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
16717985|NCT01829243|Placebo Comparator|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
16717986|NCT01829230|Experimental|Test lens C|Test lens C from previous study
16717987|NCT01829230|Active Comparator|Test lens A|Test lens A from previous study
16717988|NCT01829217|Experimental|Sunitinib|42 day cycle, taken orally every day for the first 28 days followed by 14 days off
16717989|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
16717990|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
16717991|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
16717992|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
16717993|NCT01829191|Experimental|Test Lens A|Test lenses will be worn in a daily wear modality
16717994|NCT01829191|Experimental|Test Lens C|Test lenses will be worn in a daily wear modality
16717995|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
16717996|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
16717997|NCT01829165|Experimental|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
16717998|NCT01829165|Sham Comparator|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.
~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
16717999|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
16718000|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
16718001|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
16718002|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
16718003|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
16718004|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
16718005|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
16718006|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
16718007|NCT01829113|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
16718008|NCT01829113|Placebo Comparator|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
16718009|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
16718010|NCT01829100|No Intervention|waitlist|15-week waitlist
16718011|NCT01829087|Experimental|Botox injection|
16718012|NCT01829087|Placebo Comparator|Control|
16718013|NCT01829061||No Treatment|
16718014|NCT01829048|Experimental|PF-02545920|
16718015|NCT01829048|Placebo Comparator|Placebo|
16718016|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
16718017|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
16718018|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
16718019|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
16718020|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.
~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
16718021|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
16718022|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
16718023|NCT01828983|Experimental|Telephone support groups|Telephone support groups, each with participants and a trained group leader. Each hour-long telephone group will meet bi-monthly for six months for a total of 12 meetings. Groups are structured with education, skills building, and support. Participants will receive and use a Spouse Workbook with information and activities.
16718024|NCT01828983|Active Comparator|Education webinars|Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
16718025|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
16718026|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
16718027|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
16718028|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
16718029|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
16718030|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
16718031|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
16718032|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
16718033|NCT01828918|Other|early recurrence|find the postoperative early relapse out
16718034|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
16718035|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
16718036|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
16718037|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
16718038|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
16718039|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
16718040|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
16718041|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
16718042|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
16718043|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
16718044|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
16718045|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
16718046|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
16718047|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
16718048|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
16718049|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
16718050|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
16718051|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
16718052|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
16718053|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
16718054|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
16718055|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
16718056|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718057|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718058|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718059|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718060|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718061|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718062|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718063|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
16718064|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
16718065|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
16718066|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
16718067|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
16718068|NCT01828762|Experimental|DC-TC+GM-CSF|
16718069|NCT01828749||CT abdomen and pelvis|blunt trauma patients without suspected fractures of the pelvis, hip or lumbar spine in two age groups: ages 3-17 years and 18-60 years
16718070|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV
~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
16718071|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV
~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
16718072|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
16718073|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
16718074|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
16718075|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
16718076|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:
~Fixed low dose nadroparin, or;
~Fixed low dose enoxaparin, or;
~Fixed low dose dalteparin, or;
~Fixed low dose tinzaparin."
16718077|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.
~Intermediate dose nadroparin, or;
~Intermediate dose enoxaparin, or;
~Intermediate dose dalteparin, or;
~Intermediate dose tinzaparin."
16718078|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
16718079|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
16718080|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
16718081|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
16718082|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
16718083|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
16718084|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
16718085|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
16718086|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
16718087|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
16718088|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
16718089|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
16718090|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
16718091|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
16718092|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
16718093|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment
~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
16718094|NCT01828593|Placebo Comparator|Placebo|Matching Placebo
16718095|NCT01828593|Active Comparator|SBI 2.5 g|Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
16718096|NCT01828593|Active Comparator|SBI 5.0g|Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
16718097|NCT01828580|Experimental|AutoLap|
16718098|NCT01828567|Experimental|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
16718099|NCT01828567|No Intervention|Control|Usual care
16718135|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
16755578|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
16718100|NCT01828554|Experimental|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.
~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.
~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
16718101|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
16718102|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
16718103|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
16718104|NCT01828515|Experimental|Vilazodone and Hydrocortisone, then Placebo and Hydrocortisone|Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment. After a 23 day medication washout the procedure will be repeated using placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment.
16718105|NCT01828515|Experimental|Placebo and Hydrocortisone, then Vilazodone and Hydrocortisone|Placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment. After a 23 day medication washout the procedure will be repeated using Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment.
16718106|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
16718107|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
16718108|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
16718109|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
16718110|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
16718111|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
16718112|NCT01828476|Experimental|ARM A|Abiraterone with ABT-263
16718113|NCT01828476|Experimental|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
16718114|NCT01828463|No Intervention|no treatment|comparrator
16718115|NCT01828463|Experimental|Nitisinone 1mg|interventional
16718116|NCT01828463|Experimental|Nitisinone 2mg|interventional
16718117|NCT01828463|Experimental|Nitisinone 4mg|interventional
16718118|NCT01828463|Experimental|Nitisinone 8mg|interventional
16718119|NCT01828437|Experimental|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
16718120|NCT01828437|Active Comparator|Prednisolone|allocated patients receive prednisolone alone
16718121|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
16718122|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
16718123|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
16718124|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.
~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
16718125|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
16718126|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
16718127|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
16718128|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
16718129|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
16718130|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
16718131|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled
~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
16718132|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
16718133|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
16718134|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
16718136|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
16718137|NCT01828281|Active Comparator|Therapeutic CPAP|Therapeutic CPAP
16718138|NCT01828281|Sham Comparator|control|subtherapeutic CPAP using 4 cm water
16718139|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
16718140|NCT01828255|Experimental|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
16718141|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
16718142|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
16718143|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
16718144|NCT01828229|Experimental|inactivity|Inactivity for two weeks
16718145|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
16718146|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
16718147|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
16718148|NCT01828216|Active Comparator|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest & abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer & supplemented by oronasal airflow thermistor, & finger pulse oximetry.
16718149|NCT01828216|Active Comparator|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
16718150|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
16718151|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
16718152|NCT01828190|Experimental|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
16718153|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
16718154|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
16718155|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
16718156|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
16718157|NCT01828164|Experimental|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
16718158|NCT01828164|Sham Comparator|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
16718159|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
16718160|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.
~After 5 days they switch their supplement."
16718161|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.
~After 5 days they switch their supplement"
16718162|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.
~After 5 days they switch their supplement"
16718163|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
16718164|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
16718167|NCT01828099|Experimental|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
16718168|NCT01828099|Active Comparator|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg